<SEC-DOCUMENT>0001193125-21-313597.txt : 20211029
<SEC-HEADER>0001193125-21-313597.hdr.sgml : 20211029
<ACCEPTANCE-DATETIME>20211029173032
ACCESSION NUMBER:		0001193125-21-313597
CONFORMED SUBMISSION TYPE:	S-1
PUBLIC DOCUMENT COUNT:		159
FILED AS OF DATE:		20211029
DATE AS OF CHANGE:		20211029

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			Roivant Sciences Ltd.
		CENTRAL INDEX KEY:			0001635088
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		IRS NUMBER:				981173944
		STATE OF INCORPORATION:			D0
		FISCAL YEAR END:			0331

	FILING VALUES:
		FORM TYPE:		S-1
		SEC ACT:		1933 Act
		SEC FILE NUMBER:	333-260619
		FILM NUMBER:		211364462

	BUSINESS ADDRESS:	
		STREET 1:		CLARENDON HOUSE, 2 CHURCH STREET
		CITY:			HAMILTON HM11
		STATE:			D0
		ZIP:			HM11
		BUSINESS PHONE:		441-295-5950

	MAIL ADDRESS:	
		STREET 1:		CLARENDON HOUSE
		STREET 2:		2 CHURCH STREET
		CITY:			HAMILTON
		STATE:			D0
		ZIP:			HM11
</SEC-HEADER>
<DOCUMENT>
<TYPE>S-1
<SEQUENCE>1
<FILENAME>d164680ds1.htm
<DESCRIPTION>FORM S-1
<TEXT>
<XBRL>
<?xml version="1.0" encoding="utf-8" ?>
<html xmlns:roiv="http://roivant.com/20210630" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:dei="http://xbrl.sec.gov/dei/2021" xmlns:iso4217="http://www.xbrl.org/2003/iso4217" xmlns:deprecated="http://www.xbrl.org/2009/arcrole/deprecated" xmlns:country="http://xbrl.sec.gov/country/2021" xmlns:currency="http://xbrl.sec.gov/currency/2021" xmlns:exch="http://xbrl.sec.gov/exch/2021" xmlns:naics="http://xbrl.sec.gov/naics/2021" xmlns:sic="http://xbrl.sec.gov/sic/2021" xmlns:stpr="http://xbrl.sec.gov/stpr/2021" xmlns:us-gaap="http://fasb.org/us-gaap/2021-01-31" xmlns:xl="http://www.xbrl.org/2003/XLink" xmlns:utr="http://www.xbrl.org/2009/utr" xmlns:srt="http://fasb.org/srt/2021-01-31" xmlns:ix="http://www.xbrl.org/2013/inlineXBRL" xmlns:ixt="http://www.xbrl.org/inlineXBRL/transformation/2015-02-26" xmlns:xbrll="http://www.xbrl.org/2003/linkbase" xmlns:ixt-sec="http://www.sec.gov/inlineXBRL/transformation/2015-08-31" xmlns="http://www.w3.org/1999/xhtml">
<head>
<title>Form S-1</title>
<meta content="text/html; charset=UTF-8" http-equiv="Content-Type"/>
</head>
<body style=""><div style='display: none'><ix:header><ix:hidden><ix:nonNumeric name="dei:AmendmentFlag" contextRef="P04_01_2021To06_30_2021">false</ix:nonNumeric><ix:nonNumeric name="dei:EntityRegistrantName" id="hidden28317344" contextRef="P04_01_2021To06_30_2021">Roivant Sciences Ltd.</ix:nonNumeric><ix:nonFraction name="us-gaap:DebtInstrumentMeasurementInput" id="hidden28229201" contextRef="PAsOn06_30_2021_MaximumMembersrtRangeAxis_MeasurementInputDiscountRateMemberusgaapMeasurementInputTypeAxis" unitRef="Unit_pure" decimals="2">0.12</ix:nonFraction><ix:nonFraction name="us-gaap:DebtInstrumentMeasurementInput" id="hidden28229202" contextRef="PAsOn06_30_2021_MeasurementInputDiscountRateMemberusgaapMeasurementInputTypeAxis_MinimumMembersrtRangeAxis" unitRef="Unit_pure" decimals="2">0.11</ix:nonFraction><ix:nonNumeric name="dei:EntityCentralIndexKey" contextRef="P04_01_2021To06_30_2021">0001635088</ix:nonNumeric><ix:nonNumeric name="us-gaap:DebtInstrumentTerm" id="hidden28230199" contextRef="P05_14_2021To05_14_2021_CreditFacilityMemberusgaapDebtInstrumentAxis_DermavantSciencesLtdMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis_SubsequentEventMemberusgaapSubsequentEventTypeAxis">P5Y</ix:nonNumeric><ix:nonFraction name="us-gaap:CommonStockParOrStatedValuePerShare" id="hidden28228642" contextRef="PAsOn06_30_2021" unitRef="Unit_USD_per_Share" decimals="INF">0.0000001</ix:nonFraction><ix:nonFraction name="us-gaap:CommonStockParOrStatedValuePerShare" contextRef="PAsOn03_31_2021" unitRef="Unit_USD_per_Share" decimals="INF">0.0000001</ix:nonFraction><ix:footnote id="FN_95030" xml:lang="en-US">Primarily Greater China, United States state and local and United Kingdom activity</ix:footnote ><ix:footnote id="FN_95032" xml:lang="en-US">Primarily related to operations in Switzerland, the United Kingdom, and other jurisdictions with statutory tax rates different than the Bermuda rate. </ix:footnote ><ix:footnote id="FN_95031" xml:lang="en-US">Primarily Greater China and United Kingdom activity</ix:footnote ></ix:hidden><ix:references><link:schemaRef xlink:type="simple" xlink:href="roiv-20210630.xsd" /><link:linkbaseRef xlink:type="simple" xlink:href="roiv-20210630_pre.xml" xlink:role="http://www.xbrl.org/2003/role/presentationLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:link="http://www.xbrl.org/2003/linkbase" /><link:linkbaseRef xlink:type="simple" xlink:href="roiv-20210630_def.xml" xlink:role="http://www.xbrl.org/2003/role/definitionLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:link="http://www.xbrl.org/2003/linkbase" /><link:linkbaseRef xlink:type="simple" xlink:href="roiv-20210630_lab.xml" xlink:role="http://www.xbrl.org/2003/role/labelLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:link="http://www.xbrl.org/2003/linkbase" /><link:linkbaseRef xlink:type="simple" xlink:href="roiv-20210630_cal.xml" xlink:role="http://www.xbrl.org/2003/role/calculationLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:link="http://www.xbrl.org/2003/linkbase" /></ix:references><ix:resources><xbrli:context id="P04_01_2020To03_31_2021" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001635088</xbrli:identifier> </xbrli:entity> <xbrli:period> <xbrli:startDate>2020-04-01</xbrli:startDate> <xbrli:endDate>2021-03-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P04_01_2019To03_31_2020" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001635088</xbrli:identifier> </xbrli:entity> <xbrli:period> <xbrli:startDate>2019-04-01</xbrli:startDate> <xbrli:endDate>2020-03-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P04_01_2020To06_30_2020" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001635088</xbrli:identifier> </xbrli:entity> <xbrli:period> <xbrli:startDate>2020-04-01</xbrli:startDate> <xbrli:endDate>2020-06-30</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P04_01_2021To06_30_2021" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001635088</xbrli:identifier> </xbrli:entity> <xbrli:period> <xbrli:startDate>2021-04-01</xbrli:startDate> <xbrli:endDate>2021-06-30</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn03_31_2021" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001635088</xbrli:identifier> </xbrli:entity> <xbrli:period> <xbrli:instant>2021-03-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn03_31_2020" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001635088</xbrli:identifier> </xbrli:entity> <xbrli:period> <xbrli:instant>2020-03-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn06_30_2021" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001635088</xbrli:identifier> </xbrli:entity> <xbrli:period> <xbrli:instant>2021-06-30</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2021To03_31_2021" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001635088</xbrli:identifier> </xbrli:entity> <xbrli:period> <xbrli:startDate>2021-01-01</xbrli:startDate> <xbrli:endDate>2021-03-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn05_31_2019" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001635088</xbrli:identifier> </xbrli:entity> <xbrli:period> <xbrli:instant>2019-05-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2020To01_31_2020" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001635088</xbrli:identifier> </xbrli:entity> <xbrli:period> <xbrli:startDate>2020-01-01</xbrli:startDate> <xbrli:endDate>2020-01-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P05_01_2021To05_01_2021" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001635088</xbrli:identifier> </xbrli:entity> <xbrli:period> <xbrli:startDate>2021-05-01</xbrli:startDate> <xbrli:endDate>2021-05-01</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P05_01_2021To05_31_2021" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001635088</xbrli:identifier> </xbrli:entity> <xbrli:period> <xbrli:startDate>2021-05-01</xbrli:startDate> <xbrli:endDate>2021-05-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn09_30_2020" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001635088</xbrli:identifier> </xbrli:entity> <xbrli:period> <xbrli:instant>2020-09-30</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn05_31_2021" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001635088</xbrli:identifier> </xbrli:entity> <xbrli:period> <xbrli:instant>2021-05-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn05_01_2021" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001635088</xbrli:identifier> </xbrli:entity> <xbrli:period> <xbrli:instant>2021-05-01</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn07_31_2020" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001635088</xbrli:identifier> </xbrli:entity> <xbrli:period> <xbrli:instant>2020-07-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn07_31_2021" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001635088</xbrli:identifier> </xbrli:entity> <xbrli:period> <xbrli:instant>2021-07-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn04_30_2020" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001635088</xbrli:identifier> </xbrli:entity> <xbrli:period> <xbrli:instant>2020-04-30</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn03_31_2019" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001635088</xbrli:identifier> </xbrli:entity> <xbrli:period> <xbrli:instant>2019-03-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn06_30_2020" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001635088</xbrli:identifier> </xbrli:entity> <xbrli:period> <xbrli:instant>2020-06-30</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2021To03_31_2021_ArbutusBiopharmaCorporationMemberdeiLegalEntityAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001635088</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="dei:LegalEntityAxis" >roiv:ArbutusBiopharmaCorporationMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2021-01-01</xbrli:startDate> <xbrli:endDate>2021-03-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P05_01_2018To06_30_2020_GenevantSciencesLtdMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001635088</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis" >roiv:GenevantSciencesLtdMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2018-05-01</xbrli:startDate> <xbrli:endDate>2020-06-30</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P08_25_2020To09_30_2020_ImmunovantSciencesLtdMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis_RestrictedStockMemberusgaapAwardTypeAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001635088</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis" >roiv:ImmunovantSciencesLtdMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis" >us-gaap:RestrictedStockMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2020-08-25</xbrli:startDate> <xbrli:endDate>2020-09-30</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P08_25_2020To09_30_2020_CommonStockMemberusgaapStatementEquityComponentsAxis_ImmunovantINCMemberusgaapBusinessAcquisitionAxis_UnderwrittenPublicOfferingMemberusgaapSubsidiarySaleOfStockAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001635088</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis" >roiv:ImmunovantINCMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis" >us-gaap:CommonStockMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis" >roiv:UnderwrittenPublicOfferingMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2020-08-25</xbrli:startDate> <xbrli:endDate>2020-09-30</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P08_25_2020To09_30_2020_CommonStockMemberusgaapStatementEquityComponentsAxis_UnderwrittenPublicOfferingMemberusgaapSubsidiarySaleOfStockAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001635088</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis" >roiv:UnderwrittenPublicOfferingMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis" >us-gaap:CommonStockMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2020-08-25</xbrli:startDate> <xbrli:endDate>2020-09-30</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P04_01_2019To03_31_2020_SumitovantMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001635088</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis" >roiv:SumitovantMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2019-04-01</xbrli:startDate> <xbrli:endDate>2020-03-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P04_01_2019To03_31_2020_EmployeeStockOptionMemberusgaapAwardTypeAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001635088</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis" >us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2019-04-01</xbrli:startDate> <xbrli:endDate>2020-03-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P04_01_2019To03_31_2020_MaximumMembersrtRangeAxis_MeasurementInputExpectedTermMemberusgaapMeasurementInputTypeAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001635088</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="srt:RangeAxis" >srt:MaximumMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis" >us-gaap:MeasurementInputExpectedTermMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2019-04-01</xbrli:startDate> <xbrli:endDate>2020-03-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P04_01_2019To03_31_2020_MeasurementInputExpectedTermMemberusgaapMeasurementInputTypeAxis_MinimumMembersrtRangeAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001635088</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="srt:RangeAxis" >srt:MinimumMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis" >us-gaap:MeasurementInputExpectedTermMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2019-04-01</xbrli:startDate> <xbrli:endDate>2020-03-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P04_01_2019To03_31_2020_SumitomoMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001635088</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis" >roiv:SumitomoMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2019-04-01</xbrli:startDate> <xbrli:endDate>2020-03-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P04_01_2019To03_31_2020_FairValueInputsLevel3MemberusgaapFairValueByFairValueHierarchyLevelAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001635088</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis" >us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2019-04-01</xbrli:startDate> <xbrli:endDate>2020-03-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P04_01_2019To03_31_2020_ResearchAndDevelopmentExpenseMemberusgaapIncomeStatementLocationAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001635088</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis" >us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2019-04-01</xbrli:startDate> <xbrli:endDate>2020-03-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P04_01_2019To03_31_2020_GeneralAndAdministrativeExpenseMemberusgaapIncomeStatementLocationAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001635088</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis" >us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2019-04-01</xbrli:startDate> <xbrli:endDate>2020-03-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P04_01_2019To03_31_2020_TwoThousandFifteenEquityIncentivePlanMemberusgaapPlanNameAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001635088</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis" >roiv:TwoThousandFifteenEquityIncentivePlanMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2019-04-01</xbrli:startDate> <xbrli:endDate>2020-03-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P04_01_2019To03_31_2020_SubsidiaryEquityIncentivePlanMemberusgaapPlanNameAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001635088</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis" >roiv:SubsidiaryEquityIncentivePlanMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2019-04-01</xbrli:startDate> <xbrli:endDate>2020-03-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P04_01_2019To03_31_2020_LiabilityInstrumentsMeasuredAtFairValueMemberusgaapBalanceSheetLocationAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001635088</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis" >roiv:LiabilityInstrumentsMeasuredAtFairValueMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2019-04-01</xbrli:startDate> <xbrli:endDate>2020-03-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P04_01_2019To03_31_2020_USsrtStatementGeographicalAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001635088</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis" >country:US</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2019-04-01</xbrli:startDate> <xbrli:endDate>2020-03-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P04_01_2019To03_31_2020_CHsrtStatementGeographicalAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001635088</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis" >country:CH</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2019-04-01</xbrli:startDate> <xbrli:endDate>2020-03-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P04_01_2019To03_31_2020_BMsrtStatementGeographicalAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001635088</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis" >country:BM</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2019-04-01</xbrli:startDate> <xbrli:endDate>2020-03-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P04_01_2019To03_31_2020_OtherMembersrtStatementGeographicalAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001635088</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis" >roiv:OtherMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2019-04-01</xbrli:startDate> <xbrli:endDate>2020-03-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P04_01_2019To03_31_2020_DermavantSciencesLtdMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001635088</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis" >roiv:DermavantSciencesLtdMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2019-04-01</xbrli:startDate> <xbrli:endDate>2020-03-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P04_01_2019To03_31_2020_ArbutusBiopharmaCorporationMemberdeiLegalEntityAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001635088</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="dei:LegalEntityAxis" >roiv:ArbutusBiopharmaCorporationMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2019-04-01</xbrli:startDate> <xbrli:endDate>2020-03-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P04_01_2019To03_31_2020_SioGeneTherapiesIncMemberdeiLegalEntityAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001635088</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="dei:LegalEntityAxis" >roiv:SioGeneTherapiesIncMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2019-04-01</xbrli:startDate> <xbrli:endDate>2020-03-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P04_01_2019To03_31_2020_PerformanceOptionsMemberusgaapAwardTypeAxis_TwoThousandFifteenEquityIncentivePlanMemberusgaapPlanNameAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001635088</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis" >roiv:PerformanceOptionsMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis" >roiv:TwoThousandFifteenEquityIncentivePlanMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2019-04-01</xbrli:startDate> <xbrli:endDate>2020-03-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P04_01_2019To03_31_2020_RedeemableNoncontrollingInterestMemberusgaapStatementClassOfStockAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001635088</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis" >roiv:RedeemableNoncontrollingInterestMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2019-04-01</xbrli:startDate> <xbrli:endDate>2020-03-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P04_01_2019To03_31_2020_AdditionalPaidInCapitalMemberusgaapStatementEquityComponentsAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001635088</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis" >us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2019-04-01</xbrli:startDate> <xbrli:endDate>2020-03-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P04_01_2019To03_31_2020_EmployeeStockOptionMemberusgaapAwardTypeAxis_TwoThousandFifteenEquityIncentivePlanMemberusgaapPlanNameAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001635088</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis" >us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis" >roiv:TwoThousandFifteenEquityIncentivePlanMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2019-04-01</xbrli:startDate> <xbrli:endDate>2020-03-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P04_01_2019To03_31_2020_NoncontrollingInterestMemberusgaapStatementEquityComponentsAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001635088</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis" >us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2019-04-01</xbrli:startDate> <xbrli:endDate>2020-03-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P04_01_2019To03_31_2020_CommonStockMemberusgaapStatementEquityComponentsAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001635088</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis" >us-gaap:CommonStockMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2019-04-01</xbrli:startDate> <xbrli:endDate>2020-03-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P04_01_2019To03_31_2020_AccumulatedOtherComprehensiveIncomeMemberusgaapStatementEquityComponentsAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001635088</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis" >us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2019-04-01</xbrli:startDate> <xbrli:endDate>2020-03-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P04_01_2019To03_31_2020_RetainedEarningsMemberusgaapStatementEquityComponentsAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001635088</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis" >us-gaap:RetainedEarningsMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2019-04-01</xbrli:startDate> <xbrli:endDate>2020-03-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P04_01_2020To03_31_2021_ProteovantSciencesIncMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001635088</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis" >roiv:ProteovantSciencesIncMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2020-04-01</xbrli:startDate> <xbrli:endDate>2021-03-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P04_01_2020To03_31_2021_SoftwareDevelopmentMemberusgaapPropertyPlantAndEquipmentByTypeAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001635088</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis" >us-gaap:SoftwareDevelopmentMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2020-04-01</xbrli:startDate> <xbrli:endDate>2021-03-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P04_01_2020To03_31_2021_FurnitureAndFixturesMemberusgaapPropertyPlantAndEquipmentByTypeAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001635088</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis" >us-gaap:FurnitureAndFixturesMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2020-04-01</xbrli:startDate> <xbrli:endDate>2021-03-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P04_01_2020To03_31_2021_EquipmentMemberusgaapPropertyPlantAndEquipmentByTypeAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001635088</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis" >us-gaap:EquipmentMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2020-04-01</xbrli:startDate> <xbrli:endDate>2021-03-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P04_01_2020To03_31_2021_ComputerEquipmentMemberusgaapPropertyPlantAndEquipmentByTypeAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001635088</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis" >us-gaap:ComputerEquipmentMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2020-04-01</xbrli:startDate> <xbrli:endDate>2021-03-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P04_01_2020To03_31_2021_SumitovantMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001635088</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis" >roiv:SumitovantMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2020-04-01</xbrli:startDate> <xbrli:endDate>2021-03-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P04_01_2020To03_31_2021_EmployeeStockOptionMemberusgaapAwardTypeAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001635088</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis" >us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2020-04-01</xbrli:startDate> <xbrli:endDate>2021-03-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P04_01_2020To03_31_2021_PerformanceOptionsMemberusgaapAwardTypeAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001635088</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis" >roiv:PerformanceOptionsMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2020-04-01</xbrli:startDate> <xbrli:endDate>2021-03-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P04_01_2020To03_31_2021_MaximumMembersrtRangeAxis_MeasurementInputExpectedTermMemberusgaapMeasurementInputTypeAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001635088</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="srt:RangeAxis" >srt:MaximumMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis" >us-gaap:MeasurementInputExpectedTermMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2020-04-01</xbrli:startDate> <xbrli:endDate>2021-03-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P04_01_2020To03_31_2021_MeasurementInputExpectedTermMemberusgaapMeasurementInputTypeAxis_MinimumMembersrtRangeAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001635088</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis" >us-gaap:MeasurementInputExpectedTermMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="srt:RangeAxis" >srt:MinimumMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2020-04-01</xbrli:startDate> <xbrli:endDate>2021-03-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P04_01_2020To03_31_2021_SumitomoMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001635088</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis" >roiv:SumitomoMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2020-04-01</xbrli:startDate> <xbrli:endDate>2021-03-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P04_01_2020To03_31_2021_LeaseholdImprovementsMemberusgaapPropertyPlantAndEquipmentByTypeAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001635088</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis" >us-gaap:LeaseholdImprovementsMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2020-04-01</xbrli:startDate> <xbrli:endDate>2021-03-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P04_01_2020To03_31_2021_CommonStockAwardsMemberusgaapAwardTypeAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001635088</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis" >roiv:CommonStockAwardsMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2020-04-01</xbrli:startDate> <xbrli:endDate>2021-03-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P04_01_2020To03_31_2021_PerformanceRestrictedStockUnitsMemberusgaapAwardTypeAxis_PerformanceRestrictedStockUnitsPlanMemberusgaapPlanNameAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001635088</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis" >roiv:PerformanceRestrictedStockUnitsMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis" >roiv:PerformanceRestrictedStockUnitsPlanMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2020-04-01</xbrli:startDate> <xbrli:endDate>2021-03-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P04_01_2020To03_31_2021_CappedValueAppreciationRightsMemberusgaapAwardTypeAxis_TwoThousandFifteenEquityIncentivePlanMemberusgaapPlanNameAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001635088</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis" >roiv:CappedValueAppreciationRightsMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis" >roiv:TwoThousandFifteenEquityIncentivePlanMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2020-04-01</xbrli:startDate> <xbrli:endDate>2021-03-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P04_01_2020To03_31_2021_PerformanceOptionsMemberusgaapAwardTypeAxis_TwoThousandFifteenEquityIncentivePlanMemberusgaapPlanNameAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001635088</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis" >roiv:PerformanceOptionsMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis" >roiv:TwoThousandFifteenEquityIncentivePlanMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2020-04-01</xbrli:startDate> <xbrli:endDate>2021-03-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P04_01_2020To03_31_2021_RestrictedStockUnitsRSUMemberusgaapAwardTypeAxis_TwoThousandFifteenEquityIncentivePlanMemberusgaapPlanNameAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001635088</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis" >us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis" >roiv:TwoThousandFifteenEquityIncentivePlanMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2020-04-01</xbrli:startDate> <xbrli:endDate>2021-03-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P04_01_2020To03_31_2021_EmployeeStockOptionMemberusgaapAwardTypeAxis_TwoThousandFifteenEquityIncentivePlanMemberusgaapPlanNameAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001635088</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis" >us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis" >roiv:TwoThousandFifteenEquityIncentivePlanMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2020-04-01</xbrli:startDate> <xbrli:endDate>2021-03-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P04_01_2020To03_31_2021_FairValueInputsLevel3MemberusgaapFairValueByFairValueHierarchyLevelAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001635088</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis" >us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2020-04-01</xbrli:startDate> <xbrli:endDate>2021-03-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P04_01_2020To03_31_2021_ResearchAndDevelopmentExpenseMemberusgaapIncomeStatementLocationAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001635088</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis" >us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2020-04-01</xbrli:startDate> <xbrli:endDate>2021-03-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P04_01_2020To03_31_2021_GeneralAndAdministrativeExpenseMemberusgaapIncomeStatementLocationAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001635088</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis" >us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2020-04-01</xbrli:startDate> <xbrli:endDate>2021-03-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P04_01_2020To03_31_2021_ArbutusBiopharmaCorporationMemberdeiLegalEntityAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001635088</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="dei:LegalEntityAxis" >roiv:ArbutusBiopharmaCorporationMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2020-04-01</xbrli:startDate> <xbrli:endDate>2021-03-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P04_01_2020To03_31_2021_CappedValueAppreciationRightsMemberusgaapAwardTypeAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001635088</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis" >roiv:CappedValueAppreciationRightsMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2020-04-01</xbrli:startDate> <xbrli:endDate>2021-03-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P04_01_2020To03_31_2021_PerformanceRestrictedStockUnitsMemberusgaapAwardTypeAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001635088</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis" >roiv:PerformanceRestrictedStockUnitsMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2020-04-01</xbrli:startDate> <xbrli:endDate>2021-03-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P04_01_2020To03_31_2021_RestrictedStockUnitsRSUMemberusgaapAwardTypeAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001635088</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis" >us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2020-04-01</xbrli:startDate> <xbrli:endDate>2021-03-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P04_01_2020To03_31_2021_TwoThousandFifteenEquityIncentivePlanMemberusgaapPlanNameAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001635088</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis" >roiv:TwoThousandFifteenEquityIncentivePlanMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2020-04-01</xbrli:startDate> <xbrli:endDate>2021-03-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P04_01_2020To03_31_2021_SubsidiaryEquityIncentivePlanMemberusgaapPlanNameAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001635088</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis" >roiv:SubsidiaryEquityIncentivePlanMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2020-04-01</xbrli:startDate> <xbrli:endDate>2021-03-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P04_01_2020To03_31_2021_LiabilityInstrumentsMeasuredAtFairValueMemberusgaapBalanceSheetLocationAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001635088</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis" >roiv:LiabilityInstrumentsMeasuredAtFairValueMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2020-04-01</xbrli:startDate> <xbrli:endDate>2021-03-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P04_01_2020To03_31_2021_USsrtStatementGeographicalAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001635088</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis" >country:US</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2020-04-01</xbrli:startDate> <xbrli:endDate>2021-03-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P04_01_2020To03_31_2021_CHsrtStatementGeographicalAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001635088</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis" >country:CH</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2020-04-01</xbrli:startDate> <xbrli:endDate>2021-03-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P04_01_2020To03_31_2021_BMsrtStatementGeographicalAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001635088</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis" >country:BM</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2020-04-01</xbrli:startDate> <xbrli:endDate>2021-03-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P04_01_2020To03_31_2021_OtherMembersrtStatementGeographicalAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001635088</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis" >roiv:OtherMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2020-04-01</xbrli:startDate> <xbrli:endDate>2021-03-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P04_01_2020To03_31_2021_MinimumMembersrtRangeAxis_StateAndLocalJurisdictionMemberusgaapIncomeTaxAuthorityAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001635088</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis" >us-gaap:StateAndLocalJurisdictionMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="srt:RangeAxis" >srt:MinimumMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2020-04-01</xbrli:startDate> <xbrli:endDate>2021-03-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P04_01_2020To03_31_2021_MaximumMembersrtRangeAxis_StateAndLocalJurisdictionMemberusgaapIncomeTaxAuthorityAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001635088</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis" >us-gaap:StateAndLocalJurisdictionMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="srt:RangeAxis" >srt:MaximumMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2020-04-01</xbrli:startDate> <xbrli:endDate>2021-03-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P04_01_2020To03_31_2021_RoivantEquityRepurchaseMemberusgaapShareRepurchaseProgramAxis_SumitomoTransactionAgreementMemberusgaapTypeOfArrangementAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001635088</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis" >roiv:SumitomoTransactionAgreementMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:ShareRepurchaseProgramAxis" >roiv:RoivantEquityRepurchaseMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2020-04-01</xbrli:startDate> <xbrli:endDate>2021-03-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P04_01_2020To03_31_2021_MinimumMembersrtRangeAxis_USsrtStatementGeographicalAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001635088</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis" >country:US</xbrldi:explicitMember> <xbrldi:explicitMember dimension="srt:RangeAxis" >srt:MinimumMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2020-04-01</xbrli:startDate> <xbrli:endDate>2021-03-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P04_01_2020To03_31_2021_MaximumMembersrtRangeAxis_USsrtStatementGeographicalAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001635088</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis" >country:US</xbrldi:explicitMember> <xbrldi:explicitMember dimension="srt:RangeAxis" >srt:MaximumMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2020-04-01</xbrli:startDate> <xbrli:endDate>2021-03-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P04_01_2020To03_31_2021_PerformanceRestrictedStockUnitsPlanMemberusgaapPlanNameAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001635088</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis" >roiv:PerformanceRestrictedStockUnitsPlanMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2020-04-01</xbrli:startDate> <xbrli:endDate>2021-03-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P04_01_2020To03_31_2021_SioGeneTherapiesIncMemberdeiLegalEntityAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001635088</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="dei:LegalEntityAxis" >roiv:SioGeneTherapiesIncMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2020-04-01</xbrli:startDate> <xbrli:endDate>2021-03-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P04_01_2020To03_31_2021_ImmunovantINCMemberusgaapBusinessAcquisitionAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001635088</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis" >roiv:ImmunovantINCMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2020-04-01</xbrli:startDate> <xbrli:endDate>2021-03-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P04_01_2020To03_31_2021_DatavantHoldingsIncMemberdeiLegalEntityAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001635088</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="dei:LegalEntityAxis" >roiv:DatavantHoldingsIncMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2020-04-01</xbrli:startDate> <xbrli:endDate>2021-03-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P04_01_2020To03_31_2021_AdditionalPaidInCapitalMemberusgaapStatementEquityComponentsAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001635088</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis" >us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2020-04-01</xbrli:startDate> <xbrli:endDate>2021-03-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P04_01_2020To03_31_2021_SubscriptionsReceivablesMemberusgaapStatementEquityComponentsAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001635088</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis" >roiv:SubscriptionsReceivablesMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2020-04-01</xbrli:startDate> <xbrli:endDate>2021-03-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P04_01_2020To03_31_2021_NoncontrollingInterestMemberusgaapStatementEquityComponentsAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001635088</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis" >us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2020-04-01</xbrli:startDate> <xbrli:endDate>2021-03-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P04_01_2020To03_31_2021_GenevantSciencesLtdMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001635088</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis" >roiv:GenevantSciencesLtdMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2020-04-01</xbrli:startDate> <xbrli:endDate>2021-03-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P04_01_2020To03_31_2021_ConvertibleNotesPayableMemberusgaapShortTermDebtTypeAxis_ImmunovantSciencesLtdMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001635088</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis" >roiv:ImmunovantSciencesLtdMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:ShortTermDebtTypeAxis" >us-gaap:ConvertibleNotesPayableMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2020-04-01</xbrli:startDate> <xbrli:endDate>2021-03-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P04_01_2020To03_31_2021_ConvertibleNotesPayableMemberusgaapShortTermDebtTypeAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001635088</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:ShortTermDebtTypeAxis" >us-gaap:ConvertibleNotesPayableMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2020-04-01</xbrli:startDate> <xbrli:endDate>2021-03-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P04_01_2020To03_31_2021_ConvertibleNotesPayableMemberusgaapShortTermDebtTypeAxis_ImmunovantINCMemberusgaapBusinessAcquisitionAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001635088</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis" >roiv:ImmunovantINCMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:ShortTermDebtTypeAxis" >us-gaap:ConvertibleNotesPayableMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2020-04-01</xbrli:startDate> <xbrli:endDate>2021-03-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P04_01_2020To03_31_2021_SiliconTherapeuticsMemberusgaapBusinessAcquisitionAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001635088</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis" >roiv:SiliconTherapeuticsMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2020-04-01</xbrli:startDate> <xbrli:endDate>2021-03-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P04_01_2020To03_31_2021_RedeemableNoncontrollingInterestMemberusgaapStatementClassOfStockAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001635088</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis" >roiv:RedeemableNoncontrollingInterestMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2020-04-01</xbrli:startDate> <xbrli:endDate>2021-03-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P04_01_2020To03_31_2021_CommonStockMemberusgaapStatementEquityComponentsAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001635088</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis" >us-gaap:CommonStockMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2020-04-01</xbrli:startDate> <xbrli:endDate>2021-03-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P04_01_2020To03_31_2021_AccumulatedOtherComprehensiveIncomeMemberusgaapStatementEquityComponentsAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001635088</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis" >us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2020-04-01</xbrli:startDate> <xbrli:endDate>2021-03-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P04_01_2020To03_31_2021_RetainedEarningsMemberusgaapStatementEquityComponentsAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001635088</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis" >us-gaap:RetainedEarningsMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2020-04-01</xbrli:startDate> <xbrli:endDate>2021-03-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P04_01_2020To03_31_2021_ImmunovantINCMemberusgaapBusinessAcquisitionAxis_WarrantMemberusgaapStatementEquityComponentsAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001635088</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis" >roiv:ImmunovantINCMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis" >us-gaap:WarrantMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2020-04-01</xbrli:startDate> <xbrli:endDate>2021-03-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P03_01_2020To03_31_2020_CytovantScienceHkLtdMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis_SeriesA1PreferredStockMemberusgaapStatementClassOfStockAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001635088</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis" >roiv:CytovantScienceHkLtdMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis" >roiv:SeriesA1PreferredStockMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2020-03-01</xbrli:startDate> <xbrli:endDate>2020-03-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P03_01_2021To03_31_2021_SiliconTherapeuticsMemberusgaapBusinessAcquisitionAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001635088</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis" >roiv:SiliconTherapeuticsMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2021-03-01</xbrli:startDate> <xbrli:endDate>2021-03-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P03_01_2021To03_31_2021_SinovantIncMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001635088</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis" >roiv:SinovantIncMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2021-03-01</xbrli:startDate> <xbrli:endDate>2021-03-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P03_01_2021To03_31_2021_FirstTrancheMemberusgaapRestructuringPlanAxis_SiliconTherapeuticsMemberusgaapBusinessAcquisitionAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001635088</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis" >roiv:SiliconTherapeuticsMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:RestructuringPlanAxis" >roiv:FirstTrancheMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2021-03-01</xbrli:startDate> <xbrli:endDate>2021-03-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P03_01_2021To03_31_2021_SecondTrancheMemberusgaapRestructuringPlanAxis_SiliconTherapeuticsMemberusgaapBusinessAcquisitionAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001635088</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis" >roiv:SiliconTherapeuticsMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:RestructuringPlanAxis" >roiv:SecondTrancheMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2021-03-01</xbrli:startDate> <xbrli:endDate>2021-03-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P12_01_2020To12_31_2020_ProteovantSciencesIncMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001635088</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis" >roiv:ProteovantSciencesIncMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2020-12-01</xbrli:startDate> <xbrli:endDate>2020-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P12_01_2019To12_31_2019_SumitomoMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001635088</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis" >roiv:SumitomoMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2019-12-01</xbrli:startDate> <xbrli:endDate>2019-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P08_01_2019To08_31_2019_DermavantSciencesLtdMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001635088</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis" >roiv:DermavantSciencesLtdMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2019-08-01</xbrli:startDate> <xbrli:endDate>2019-08-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P05_01_2020To05_31_2020_ImmunovantSciencesLtdMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis_RestrictedStockMemberusgaapAwardTypeAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001635088</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis" >roiv:ImmunovantSciencesLtdMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis" >us-gaap:RestrictedStockMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2020-05-01</xbrli:startDate> <xbrli:endDate>2020-05-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P05_01_2012To05_31_2012_DermavantSciencesLtdMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001635088</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis" >roiv:DermavantSciencesLtdMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2012-05-01</xbrli:startDate> <xbrli:endDate>2012-05-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P07_01_2021To07_31_2021_DatavantMemberusgaapBusinessAcquisitionAxis_SubsequentEventMemberusgaapSubsequentEventTypeAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001635088</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis" >roiv:DatavantMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis" >us-gaap:SubsequentEventMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2021-07-01</xbrli:startDate> <xbrli:endDate>2021-07-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2021To01_31_2021_ProteovantSciencesIncMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001635088</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis" >roiv:ProteovantSciencesIncMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2021-01-01</xbrli:startDate> <xbrli:endDate>2021-01-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P07_01_2020To07_31_2020_GenevantSciencesLtdMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001635088</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis" >roiv:GenevantSciencesLtdMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2020-07-01</xbrli:startDate> <xbrli:endDate>2020-07-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2020To01_31_2020_DermavantSciencesLtdMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001635088</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis" >roiv:DermavantSciencesLtdMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2020-01-01</xbrli:startDate> <xbrli:endDate>2020-01-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2020To01_31_2020_SinovantIncMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001635088</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis" >roiv:SinovantIncMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2020-01-01</xbrli:startDate> <xbrli:endDate>2020-01-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P04_01_2018To04_30_2018_GenevantSciencesLtdMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001635088</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis" >roiv:GenevantSciencesLtdMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2018-04-01</xbrli:startDate> <xbrli:endDate>2018-04-30</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P11_01_2020To11_30_2020_AffivantSciencesMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001635088</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis" >roiv:AffivantSciencesMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2020-11-01</xbrli:startDate> <xbrli:endDate>2020-11-30</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P11_01_2020To11_30_2020_FirstProductTargetsEachOfCertainSpecifiedAdditionalMoleculartargetsMemberROIVMilestoneEventsAxis_MaximumMembersrtRangeAxis_ProteovantSciencesIncMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001635088</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="roiv:MilestoneEventsAxis" >roiv:FirstProductTargetsEachOfCertainSpecifiedAdditionalMoleculartargetsMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="srt:RangeAxis" >srt:MaximumMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis" >roiv:ProteovantSciencesIncMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2020-11-01</xbrli:startDate> <xbrli:endDate>2020-11-30</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P11_01_2020To11_30_2020_FirstProductFirstProductForEachMolecularTargetCoveredByIntellectualPropertyMemberROIVMilestoneEventsAxis_MaximumMembersrtRangeAxis_ProteovantSciencesIncMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001635088</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis" >roiv:ProteovantSciencesIncMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="roiv:MilestoneEventsAxis" >roiv:FirstProductFirstProductForEachMolecularTargetCoveredByIntellectualPropertyMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="srt:RangeAxis" >srt:MaximumMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2020-11-01</xbrli:startDate> <xbrli:endDate>2020-11-30</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P11_01_2020To11_30_2020_AffivantSciencesMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis_MaximumMembersrtRangeAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001635088</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis" >roiv:AffivantSciencesMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="srt:RangeAxis" >srt:MaximumMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2020-11-01</xbrli:startDate> <xbrli:endDate>2020-11-30</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P11_01_2020To11_30_2020_FirstProductTargetsTargetingEachOfTwoSpecifiedInitialTargetsMemberROIVMilestoneEventsAxis_MaximumMembersrtRangeAxis_ProteovantSciencesIncMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001635088</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis" >roiv:ProteovantSciencesIncMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="roiv:MilestoneEventsAxis" >roiv:FirstProductTargetsTargetingEachOfTwoSpecifiedInitialTargetsMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="srt:RangeAxis" >srt:MaximumMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2020-11-01</xbrli:startDate> <xbrli:endDate>2020-11-30</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P11_01_2020To11_30_2020_ProteovantSciencesIncMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001635088</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis" >roiv:ProteovantSciencesIncMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2020-11-01</xbrli:startDate> <xbrli:endDate>2020-11-30</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P09_01_2019To09_30_2019_CommonStockMemberusgaapStatementEquityComponentsAxis_HealthSciencesMemberusgaapBusinessAcquisitionAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001635088</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis" >roiv:HealthSciencesMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis" >us-gaap:CommonStockMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2019-09-01</xbrli:startDate> <xbrli:endDate>2019-09-30</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P09_01_2019To09_30_2019_HealthSciencesMemberusgaapBusinessAcquisitionAxis_SeriesA1PreferredStockMemberusgaapStatementClassOfStockAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001635088</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis" >roiv:HealthSciencesMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis" >roiv:SeriesA1PreferredStockMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2019-09-01</xbrli:startDate> <xbrli:endDate>2019-09-30</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P09_01_2019To09_30_2019_HealthSciencesMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis_ImmunovantINCMemberusgaapBusinessAcquisitionAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001635088</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis" >roiv:HealthSciencesMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis" >roiv:ImmunovantINCMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2019-09-01</xbrli:startDate> <xbrli:endDate>2019-09-30</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P04_01_2020To04_30_2020_CommonStockMemberusgaapStatementEquityComponentsAxis_ImmunovantINCMemberusgaapBusinessAcquisitionAxis_UnderwrittenPublicOfferingMemberusgaapSubsidiarySaleOfStockAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001635088</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis" >roiv:ImmunovantINCMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis" >us-gaap:CommonStockMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis" >roiv:UnderwrittenPublicOfferingMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2020-04-01</xbrli:startDate> <xbrli:endDate>2020-04-30</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P04_01_2020To04_30_2020_CommonStockMemberusgaapStatementEquityComponentsAxis_UnderwrittenPublicOfferingMemberusgaapSubsidiarySaleOfStockAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001635088</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis" >roiv:UnderwrittenPublicOfferingMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis" >us-gaap:CommonStockMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2020-04-01</xbrli:startDate> <xbrli:endDate>2020-04-30</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P04_01_2020To12_31_2020_ArbutusBiopharmaCorporationMemberdeiLegalEntityAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001635088</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="dei:LegalEntityAxis" >roiv:ArbutusBiopharmaCorporationMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2020-04-01</xbrli:startDate> <xbrli:endDate>2020-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P12_27_2019To12_27_2019_SumitomoMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001635088</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis" >roiv:SumitomoMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2019-12-27</xbrli:startDate> <xbrli:endDate>2019-12-27</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P12_26_2019To12_26_2019_RoivantEquityRepurchaseMemberusgaapShareRepurchaseProgramAxis_SumitomoTransactionAgreementMemberusgaapTypeOfArrangementAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001635088</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis" >roiv:SumitomoTransactionAgreementMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:ShareRepurchaseProgramAxis" >roiv:RoivantEquityRepurchaseMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2019-12-26</xbrli:startDate> <xbrli:endDate>2019-12-26</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P09_29_2017To09_29_2017_ArbutusBiopharmaCorporationMemberdeiLegalEntityAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001635088</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="dei:LegalEntityAxis" >roiv:ArbutusBiopharmaCorporationMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2017-09-29</xbrli:startDate> <xbrli:endDate>2017-09-29</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P05_01_2021To05_01_2021_SubsequentEventMemberusgaapSubsequentEventTypeAxis_SumitomoPharmaceuticalsCoLtdMemberusgaapBusinessAcquisitionAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001635088</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis" >roiv:SumitomoPharmaceuticalsCoLtdMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis" >us-gaap:SubsequentEventMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2021-05-01</xbrli:startDate> <xbrli:endDate>2021-05-01</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P07_31_2020To07_31_2020_GenevantSciencesLtdMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001635088</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis" >roiv:GenevantSciencesLtdMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2020-07-31</xbrli:startDate> <xbrli:endDate>2020-07-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P07_31_2020To07_31_2020_ArbutusBiopharmaCorporationMemberdeiLegalEntityAxis_GenevantSciencesLtdMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001635088</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis" >roiv:GenevantSciencesLtdMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="dei:LegalEntityAxis" >roiv:ArbutusBiopharmaCorporationMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2020-07-31</xbrli:startDate> <xbrli:endDate>2020-07-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn03_31_2020_FairValueInputsLevel1MemberusgaapFairValueByFairValueHierarchyLevelAxis_FairValueMeasurementsRecurringMemberusgaapFairValueByMeasurementFrequencyAxis_MoneyMarketFundsMemberusgaapFairValueByAssetClassAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001635088</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis" >us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis" >us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis" >us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2020-03-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn03_31_2020_FairValueMeasurementsRecurringMemberusgaapFairValueByMeasurementFrequencyAxis_MoneyMarketFundsMemberusgaapFairValueByAssetClassAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001635088</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis" >us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis" >us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2020-03-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn03_31_2020_CytovantScienceHkLtdMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis_SeriesA1PreferredStockMemberusgaapStatementClassOfStockAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001635088</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis" >roiv:CytovantScienceHkLtdMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis" >roiv:SeriesA1PreferredStockMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2020-03-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn03_31_2020_CommonStockMemberusgaapFairValueByAssetClassAxis_FairValueInputsLevel1MemberusgaapFairValueByFairValueHierarchyLevelAxis_FairValueMeasurementsRecurringMemberusgaapFairValueByMeasurementFrequencyAxis_SioGeneTherapiesIncMemberdeiLegalEntityAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001635088</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis" >us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember> <xbrldi:explicitMember dimension="dei:LegalEntityAxis" >roiv:SioGeneTherapiesIncMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis" >us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis" >us-gaap:CommonStockMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2020-03-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn03_31_2020_CommonStockMemberusgaapFairValueByAssetClassAxis_FairValueMeasurementsRecurringMemberusgaapFairValueByMeasurementFrequencyAxis_SioGeneTherapiesIncMemberdeiLegalEntityAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001635088</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="dei:LegalEntityAxis" >roiv:SioGeneTherapiesIncMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis" >us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis" >us-gaap:CommonStockMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2020-03-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn03_31_2020_ArbutusBiopharmaCorporationMemberdeiLegalEntityAxis_CommonStockMemberusgaapFairValueByAssetClassAxis_FairValueInputsLevel1MemberusgaapFairValueByFairValueHierarchyLevelAxis_FairValueMeasurementsRecurringMemberusgaapFairValueByMeasurementFrequencyAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001635088</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis" >us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember> <xbrldi:explicitMember dimension="dei:LegalEntityAxis" >roiv:ArbutusBiopharmaCorporationMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis" >us-gaap:CommonStockMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis" >us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2020-03-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn03_31_2020_ArbutusBiopharmaCorporationMemberdeiLegalEntityAxis_CommonStockMemberusgaapFairValueByAssetClassAxis_FairValueMeasurementsRecurringMemberusgaapFairValueByMeasurementFrequencyAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001635088</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="dei:LegalEntityAxis" >roiv:ArbutusBiopharmaCorporationMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis" >us-gaap:CommonStockMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis" >us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2020-03-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn03_31_2020_ArbutusBiopharmaCorporationMemberdeiLegalEntityAxis_ConvertiblePreferredStockMemberusgaapFairValueByAssetClassAxis_FairValueInputsLevel2MemberusgaapFairValueByFairValueHierarchyLevelAxis_FairValueMeasurementsRecurringMemberusgaapFairValueByMeasurementFrequencyAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001635088</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis" >us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis" >us-gaap:ConvertiblePreferredStockMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="dei:LegalEntityAxis" >roiv:ArbutusBiopharmaCorporationMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis" >us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2020-03-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn03_31_2020_ArbutusBiopharmaCorporationMemberdeiLegalEntityAxis_ConvertiblePreferredStockMemberusgaapFairValueByAssetClassAxis_FairValueMeasurementsRecurringMemberusgaapFairValueByMeasurementFrequencyAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001635088</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis" >us-gaap:ConvertiblePreferredStockMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="dei:LegalEntityAxis" >roiv:ArbutusBiopharmaCorporationMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis" >us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2020-03-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn03_31_2020_FairValueInputsLevel1MemberusgaapFairValueByFairValueHierarchyLevelAxis_FairValueMeasurementsRecurringMemberusgaapFairValueByMeasurementFrequencyAxis_OtherInvestmentCompaniesMemberusgaapFairValueByAssetClassAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001635088</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis" >us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis" >us-gaap:OtherInvestmentCompaniesMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis" >us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2020-03-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn03_31_2020_FairValueMeasurementsRecurringMemberusgaapFairValueByMeasurementFrequencyAxis_OtherInvestmentCompaniesMemberusgaapFairValueByAssetClassAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001635088</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis" >us-gaap:OtherInvestmentCompaniesMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis" >us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2020-03-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn03_31_2020_MaximumMembersrtRangeAxis_MeasurementInputOptionVolatilityMemberusgaapMeasurementInputTypeAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001635088</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="srt:RangeAxis" >srt:MaximumMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis" >us-gaap:MeasurementInputOptionVolatilityMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2020-03-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn03_31_2020_MeasurementInputOptionVolatilityMemberusgaapMeasurementInputTypeAxis_MinimumMembersrtRangeAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001635088</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="srt:RangeAxis" >srt:MinimumMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis" >us-gaap:MeasurementInputOptionVolatilityMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2020-03-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn03_31_2020_MaximumMembersrtRangeAxis_MeasurementInputRiskFreeInterestRateMemberusgaapMeasurementInputTypeAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001635088</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="srt:RangeAxis" >srt:MaximumMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis" >us-gaap:MeasurementInputRiskFreeInterestRateMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2020-03-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn03_31_2020_MeasurementInputRiskFreeInterestRateMemberusgaapMeasurementInputTypeAxis_MinimumMembersrtRangeAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001635088</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="srt:RangeAxis" >srt:MinimumMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis" >us-gaap:MeasurementInputRiskFreeInterestRateMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2020-03-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn03_31_2020_FairValueInputsLevel1MemberusgaapFairValueByFairValueHierarchyLevelAxis_FairValueMeasurementsRecurringMemberusgaapFairValueByMeasurementFrequencyAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001635088</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis" >us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis" >us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2020-03-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn03_31_2020_FairValueInputsLevel2MemberusgaapFairValueByFairValueHierarchyLevelAxis_FairValueMeasurementsRecurringMemberusgaapFairValueByMeasurementFrequencyAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001635088</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis" >us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis" >us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2020-03-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn03_31_2020_FairValueMeasurementsRecurringMemberusgaapFairValueByMeasurementFrequencyAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001635088</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis" >us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2020-03-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn03_31_2020_FairValueInputsLevel3MemberusgaapFairValueByFairValueHierarchyLevelAxis_FairValueMeasurementsRecurringMemberusgaapFairValueByMeasurementFrequencyAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001635088</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis" >us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis" >us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2020-03-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn03_31_2020_ResearchAndDevelopmentExpenseMemberusgaapIncomeStatementLocationAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001635088</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis" >us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2020-03-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn03_31_2020_EmployeeRelatedExpensesMemberusgaapIncomeStatementLocationAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001635088</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis" >roiv:EmployeeRelatedExpensesMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2020-03-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn03_31_2020_ProfessionalServicesExpensesMemberusgaapIncomeStatementLocationAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001635088</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis" >roiv:ProfessionalServicesExpensesMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2020-03-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn03_31_2020_OtherGeneralAndAdministrativeExpensesMemberusgaapIncomeStatementLocationAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001635088</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis" >roiv:OtherGeneralAndAdministrativeExpensesMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2020-03-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn03_31_2020_ArbutusBiopharmaCorporationMemberdeiLegalEntityAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001635088</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="dei:LegalEntityAxis" >roiv:ArbutusBiopharmaCorporationMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2020-03-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn03_31_2020_SioGeneTherapiesIncMemberdeiLegalEntityAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001635088</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="dei:LegalEntityAxis" >roiv:SioGeneTherapiesIncMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2020-03-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn03_31_2020_OtherInvestmentCompaniesMemberusgaapInvestmentTypeAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001635088</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis" >us-gaap:OtherInvestmentCompaniesMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2020-03-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn03_31_2020_NovaquestMemberusgaapTypeOfArrangementAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001635088</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis" >roiv:NovaquestMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2020-03-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn03_31_2020_EmployeeMembersrtTitleOfIndividualAxis_SumitomoMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001635088</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis" >roiv:SumitomoMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis" >roiv:EmployeeMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2020-03-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn03_31_2021_FairValueMeasurementsRecurringMemberusgaapFairValueByMeasurementFrequencyAxis_MoneyMarketFundsMemberusgaapFairValueByAssetClassAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001635088</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis" >us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis" >us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2021-03-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn03_31_2021_FairValueInputsLevel1MemberusgaapFairValueByFairValueHierarchyLevelAxis_FairValueMeasurementsRecurringMemberusgaapFairValueByMeasurementFrequencyAxis_MoneyMarketFundsMemberusgaapFairValueByAssetClassAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001635088</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis" >us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis" >us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis" >us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2021-03-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn03_31_2021_PerformanceRestrictedStockUnitsPlanMemberusgaapPlanNameAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001635088</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis" >roiv:PerformanceRestrictedStockUnitsPlanMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2021-03-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn03_31_2021_TwoThousandFifteenEquityIncentivePlanMemberusgaapPlanNameAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001635088</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis" >roiv:TwoThousandFifteenEquityIncentivePlanMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2021-03-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn03_31_2021_SpecialReserveMemberusgaapAwardTypeAxis_TwoThousandFifteenEquityIncentivePlanMemberusgaapPlanNameAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001635088</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis" >roiv:TwoThousandFifteenEquityIncentivePlanMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis" >roiv:SpecialReserveMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2021-03-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn03_31_2021_FairValueMeasurementsRecurringMemberusgaapFairValueByMeasurementFrequencyAxis_OtherInvestmentCompaniesMemberusgaapFairValueByAssetClassAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001635088</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis" >us-gaap:OtherInvestmentCompaniesMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis" >us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2021-03-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn03_31_2021_FairValueInputsLevel1MemberusgaapFairValueByFairValueHierarchyLevelAxis_FairValueMeasurementsRecurringMemberusgaapFairValueByMeasurementFrequencyAxis_OtherInvestmentCompaniesMemberusgaapFairValueByAssetClassAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001635088</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis" >us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis" >us-gaap:OtherInvestmentCompaniesMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis" >us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2021-03-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn03_31_2021_ArbutusBiopharmaCorporationMemberdeiLegalEntityAxis_ConvertiblePreferredStockMemberusgaapFairValueByAssetClassAxis_FairValueMeasurementsRecurringMemberusgaapFairValueByMeasurementFrequencyAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001635088</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="dei:LegalEntityAxis" >roiv:ArbutusBiopharmaCorporationMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis" >us-gaap:ConvertiblePreferredStockMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis" >us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2021-03-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn03_31_2021_ArbutusBiopharmaCorporationMemberdeiLegalEntityAxis_ConvertiblePreferredStockMemberusgaapFairValueByAssetClassAxis_FairValueInputsLevel2MemberusgaapFairValueByFairValueHierarchyLevelAxis_FairValueMeasurementsRecurringMemberusgaapFairValueByMeasurementFrequencyAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001635088</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis" >us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember> <xbrldi:explicitMember dimension="dei:LegalEntityAxis" >roiv:ArbutusBiopharmaCorporationMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis" >us-gaap:ConvertiblePreferredStockMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis" >us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2021-03-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn03_31_2021_ArbutusBiopharmaCorporationMemberdeiLegalEntityAxis_CommonStockMemberusgaapFairValueByAssetClassAxis_FairValueMeasurementsRecurringMemberusgaapFairValueByMeasurementFrequencyAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001635088</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="dei:LegalEntityAxis" >roiv:ArbutusBiopharmaCorporationMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis" >us-gaap:CommonStockMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis" >us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2021-03-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn03_31_2021_ArbutusBiopharmaCorporationMemberdeiLegalEntityAxis_CommonStockMemberusgaapFairValueByAssetClassAxis_FairValueInputsLevel1MemberusgaapFairValueByFairValueHierarchyLevelAxis_FairValueMeasurementsRecurringMemberusgaapFairValueByMeasurementFrequencyAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001635088</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis" >us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember> <xbrldi:explicitMember dimension="dei:LegalEntityAxis" >roiv:ArbutusBiopharmaCorporationMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis" >us-gaap:CommonStockMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis" >us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2021-03-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn03_31_2021_CommonStockMemberusgaapFairValueByAssetClassAxis_FairValueMeasurementsRecurringMemberusgaapFairValueByMeasurementFrequencyAxis_SioGeneTherapiesIncMemberdeiLegalEntityAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001635088</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis" >us-gaap:CommonStockMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="dei:LegalEntityAxis" >roiv:SioGeneTherapiesIncMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis" >us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2021-03-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn03_31_2021_CommonStockMemberusgaapFairValueByAssetClassAxis_FairValueInputsLevel1MemberusgaapFairValueByFairValueHierarchyLevelAxis_FairValueMeasurementsRecurringMemberusgaapFairValueByMeasurementFrequencyAxis_SioGeneTherapiesIncMemberdeiLegalEntityAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001635088</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis" >us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis" >us-gaap:CommonStockMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="dei:LegalEntityAxis" >roiv:SioGeneTherapiesIncMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis" >us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2021-03-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn03_31_2021_MaximumMembersrtRangeAxis_MeasurementInputOptionVolatilityMemberusgaapMeasurementInputTypeAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001635088</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="srt:RangeAxis" >srt:MaximumMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis" >us-gaap:MeasurementInputOptionVolatilityMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2021-03-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn03_31_2021_MeasurementInputOptionVolatilityMemberusgaapMeasurementInputTypeAxis_MinimumMembersrtRangeAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001635088</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="srt:RangeAxis" >srt:MinimumMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis" >us-gaap:MeasurementInputOptionVolatilityMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2021-03-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn03_31_2021_MeasurementInputRiskFreeInterestRateMemberusgaapMeasurementInputTypeAxis_MinimumMembersrtRangeAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001635088</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis" >us-gaap:MeasurementInputRiskFreeInterestRateMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="srt:RangeAxis" >srt:MinimumMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2021-03-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn03_31_2021_MaximumMembersrtRangeAxis_MeasurementInputRiskFreeInterestRateMemberusgaapMeasurementInputTypeAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001635088</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis" >us-gaap:MeasurementInputRiskFreeInterestRateMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="srt:RangeAxis" >srt:MaximumMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2021-03-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn03_31_2021_FairValueMeasurementsRecurringMemberusgaapFairValueByMeasurementFrequencyAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001635088</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis" >us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2021-03-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn03_31_2021_FairValueInputsLevel2MemberusgaapFairValueByFairValueHierarchyLevelAxis_FairValueMeasurementsRecurringMemberusgaapFairValueByMeasurementFrequencyAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001635088</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis" >us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis" >us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2021-03-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn03_31_2021_FairValueInputsLevel1MemberusgaapFairValueByFairValueHierarchyLevelAxis_FairValueMeasurementsRecurringMemberusgaapFairValueByMeasurementFrequencyAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001635088</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis" >us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis" >us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2021-03-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn03_31_2021_CHsrtStatementGeographicalAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001635088</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis" >country:CH</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2021-03-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn03_31_2021_USsrtStatementGeographicalAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001635088</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis" >country:US</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2021-03-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn03_31_2021_GBsrtStatementGeographicalAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001635088</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis" >country:GB</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2021-03-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn03_31_2021_TaxAuthorityInOtherJurisdictionsMembersrtStatementGeographicalAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001635088</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis" >roiv:TaxAuthorityInOtherJurisdictionsMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2021-03-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn03_31_2021_StateAndLocalJurisdictionMemberusgaapIncomeTaxAuthorityAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001635088</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis" >us-gaap:StateAndLocalJurisdictionMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2021-03-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn03_31_2021_MeasurementInputDiscountRateMemberusgaapMeasurementInputTypeAxis_MinimumMembersrtRangeAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001635088</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="srt:RangeAxis" >srt:MinimumMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis" >us-gaap:MeasurementInputDiscountRateMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2021-03-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn03_31_2021_MaximumMembersrtRangeAxis_MeasurementInputDiscountRateMemberusgaapMeasurementInputTypeAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001635088</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="srt:RangeAxis" >srt:MaximumMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis" >us-gaap:MeasurementInputDiscountRateMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2021-03-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn03_31_2021_FairValueInputsLevel3MemberusgaapFairValueByFairValueHierarchyLevelAxis_FairValueMeasurementsRecurringMemberusgaapFairValueByMeasurementFrequencyAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001635088</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis" >us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis" >us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2021-03-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn03_31_2021_ArbutusBiopharmaCorporationMemberdeiLegalEntityAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001635088</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="dei:LegalEntityAxis" >roiv:ArbutusBiopharmaCorporationMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2021-03-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn03_31_2021_ResearchAndDevelopmentExpenseMemberusgaapIncomeStatementLocationAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001635088</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis" >us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2021-03-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn03_31_2021_EmployeeRelatedExpensesMemberusgaapIncomeStatementLocationAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001635088</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis" >roiv:EmployeeRelatedExpensesMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2021-03-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn03_31_2021_ProfessionalServicesExpensesMemberusgaapIncomeStatementLocationAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001635088</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis" >roiv:ProfessionalServicesExpensesMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2021-03-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn03_31_2021_OtherGeneralAndAdministrativeExpensesMemberusgaapIncomeStatementLocationAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001635088</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis" >roiv:OtherGeneralAndAdministrativeExpensesMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2021-03-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn03_31_2021_EmployeeStockOptionMemberusgaapAwardTypeAxis_TwoThousandFifteenEquityIncentivePlanMemberusgaapPlanNameAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001635088</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis" >us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis" >roiv:TwoThousandFifteenEquityIncentivePlanMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2021-03-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn03_31_2021_PerformanceOptionsMemberusgaapAwardTypeAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001635088</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis" >roiv:PerformanceOptionsMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2021-03-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn03_31_2021_SumitomoMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001635088</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis" >roiv:SumitomoMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2021-03-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn03_31_2021_NovaquestMemberusgaapTypeOfArrangementAxis_RegulatoryMilestoneMemberusgaapTransactionTypeAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001635088</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis" >roiv:NovaquestMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:TransactionTypeAxis" >roiv:RegulatoryMilestoneMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2021-03-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn03_31_2021_CommercialMilestoneMemberusgaapTransactionTypeAxis_NovaquestMemberusgaapTypeOfArrangementAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001635088</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis" >roiv:NovaquestMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:TransactionTypeAxis" >roiv:CommercialMilestoneMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2021-03-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn03_31_2021_RestrictedStockUnitsRSUMemberusgaapAwardTypeAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001635088</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis" >us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2021-03-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn03_31_2021_ImmunovantINCMemberusgaapBusinessAcquisitionAxis_WarrantMemberusgaapStatementEquityComponentsAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001635088</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis" >roiv:ImmunovantINCMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis" >us-gaap:WarrantMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2021-03-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn03_31_2021_OtherInvestmentCompaniesMemberusgaapInvestmentTypeAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001635088</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis" >us-gaap:OtherInvestmentCompaniesMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2021-03-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn03_31_2021_SioGeneTherapiesIncMemberdeiLegalEntityAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001635088</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="dei:LegalEntityAxis" >roiv:SioGeneTherapiesIncMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2021-03-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn03_31_2021_DatavantHoldingsIncMemberdeiLegalEntityAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001635088</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="dei:LegalEntityAxis" >roiv:DatavantHoldingsIncMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2021-03-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn03_31_2021_DermavantSciencesLtdMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis_RevisionOfPriorPeriodReclassificationAdjustmentMembersrtRestatementAxis_SubsequentEventMemberusgaapSubsequentEventTypeAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001635088</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis" >roiv:DermavantSciencesLtdMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis" >us-gaap:SubsequentEventMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="srt:RestatementAxis" >srt:RevisionOfPriorPeriodReclassificationAdjustmentMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2021-03-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn03_31_2021_CappedValueAppreciationRightsMemberusgaapAwardTypeAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001635088</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis" >roiv:CappedValueAppreciationRightsMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2021-03-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn03_31_2021_PerformanceRestrictedStockUnitsMemberusgaapAwardTypeAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001635088</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis" >roiv:PerformanceRestrictedStockUnitsMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2021-03-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn03_31_2021_CommonStockAwardsMemberusgaapAwardTypeAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001635088</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis" >roiv:CommonStockAwardsMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2021-03-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn03_31_2021_GenevantSciencesLtdMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001635088</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis" >roiv:GenevantSciencesLtdMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2021-03-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn03_31_2021_ConvertibleNotesPayableMemberusgaapShortTermDebtTypeAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001635088</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:ShortTermDebtTypeAxis" >us-gaap:ConvertibleNotesPayableMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2021-03-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn03_31_2021_ProteovantSciencesIncMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001635088</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis" >roiv:ProteovantSciencesIncMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2021-03-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn03_31_2021_SiliconTherapeuticsMemberusgaapBusinessAcquisitionAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001635088</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis" >roiv:SiliconTherapeuticsMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2021-03-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn03_31_2021_NovaquestMemberusgaapTypeOfArrangementAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001635088</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis" >roiv:NovaquestMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2021-03-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn03_31_2021_EmployeeMembersrtTitleOfIndividualAxis_SumitomoMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001635088</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis" >roiv:SumitomoMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis" >roiv:EmployeeMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2021-03-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2020_ArbutusBiopharmaCorporationMemberdeiLegalEntityAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001635088</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="dei:LegalEntityAxis" >roiv:ArbutusBiopharmaCorporationMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2020-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2020_ProteovantSciencesIncMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001635088</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis" >roiv:ProteovantSciencesIncMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2020-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn11_30_2020_ProteovantSciencesIncMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001635088</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis" >roiv:ProteovantSciencesIncMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2020-11-30</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2019_SumitomoMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001635088</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis" >roiv:SumitomoMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2019-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2019_MaximumMembersrtRangeAxis_SumitomoMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001635088</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis" >roiv:SumitomoMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="srt:RangeAxis" >srt:MaximumMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2019-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2019_EmployeeMembersrtTitleOfIndividualAxis_SumitomoMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001635088</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis" >roiv:EmployeeMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis" >roiv:SumitomoMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2019-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_27_2019_SumitomoMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001635088</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis" >roiv:SumitomoMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2019-12-27</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_26_2019_RoivantEquityRepurchaseMemberusgaapShareRepurchaseProgramAxis_SumitomoTransactionAgreementMemberusgaapTypeOfArrangementAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001635088</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis" >roiv:SumitomoTransactionAgreementMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:ShareRepurchaseProgramAxis" >roiv:RoivantEquityRepurchaseMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2019-12-26</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn09_30_2020_CommonStockMemberusgaapStatementEquityComponentsAxis_ImmunovantINCMemberusgaapBusinessAcquisitionAxis_UnderwrittenPublicOfferingMemberusgaapSubsidiarySaleOfStockAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001635088</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis" >us-gaap:CommonStockMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis" >roiv:ImmunovantINCMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis" >roiv:UnderwrittenPublicOfferingMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2020-09-30</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn09_30_2020_ImmunovantSciencesLtdMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001635088</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis" >roiv:ImmunovantSciencesLtdMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2020-09-30</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn09_30_2019_HealthSciencesMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis_ImmunovantINCMemberusgaapBusinessAcquisitionAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001635088</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis" >roiv:HealthSciencesMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis" >roiv:ImmunovantINCMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2019-09-30</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn09_30_2019_HealthSciencesMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001635088</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis" >roiv:HealthSciencesMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2019-09-30</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn09_30_2019_CommonStockMemberusgaapStatementEquityComponentsAxis_HealthSciencesMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001635088</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis" >roiv:HealthSciencesMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis" >us-gaap:CommonStockMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2019-09-30</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn08_31_2018_NovaquestMemberusgaapTypeOfArrangementAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001635088</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis" >roiv:NovaquestMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2018-08-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn08_31_2018_CommercialMilestoneMemberusgaapTransactionTypeAxis_NovaquestMemberusgaapTypeOfArrangementAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001635088</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis" >roiv:NovaquestMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:TransactionTypeAxis" >roiv:CommercialMilestoneMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2018-08-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn08_31_2018_NovaquestMemberusgaapTypeOfArrangementAxis_RegulatoryMilestoneMemberusgaapTransactionTypeAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001635088</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis" >roiv:NovaquestMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:TransactionTypeAxis" >roiv:RegulatoryMilestoneMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2018-08-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn05_31_2020_ImmunovantINCMemberusgaapBusinessAcquisitionAxis_WarrantMemberusgaapStatementEquityComponentsAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001635088</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis" >roiv:ImmunovantINCMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis" >us-gaap:WarrantMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2020-05-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn05_31_2020_ImmunovantSciencesLtdMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001635088</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis" >roiv:ImmunovantSciencesLtdMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2020-05-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn05_31_2019_PrimeRateMemberusgaapVariableRateAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001635088</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:VariableRateAxis" >us-gaap:PrimeRateMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2019-05-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn05_31_2012_DermavantSciencesLtdMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001635088</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis" >roiv:DermavantSciencesLtdMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2012-05-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn05_14_2021_DermavantSciencesLtdMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis_RevenueInterestPurchaseAndSaleAgreementMemberusgaapTypeOfArrangementAxis_SubsequentEventMemberusgaapSubsequentEventTypeAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001635088</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis" >roiv:DermavantSciencesLtdMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis" >us-gaap:SubsequentEventMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis" >roiv:RevenueInterestPurchaseAndSaleAgreementMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2021-05-14</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn05_14_2021_CreditFacilityMemberusgaapDebtInstrumentAxis_DermavantSciencesLtdMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis_SubsequentEventMemberusgaapSubsequentEventTypeAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001635088</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis" >roiv:DermavantSciencesLtdMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis" >us-gaap:SubsequentEventMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis" >roiv:CreditFacilityMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2021-05-14</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn05_14_2021_DermavantSciencesLtdMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis_SubsequentEventMemberusgaapSubsequentEventTypeAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001635088</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis" >roiv:DermavantSciencesLtdMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis" >us-gaap:SubsequentEventMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2021-05-14</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn01_31_2021_ProteovantSciencesIncMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001635088</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis" >roiv:ProteovantSciencesIncMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2021-01-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn07_31_2020_GenevantSciencesLtdMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001635088</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis" >roiv:GenevantSciencesLtdMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2020-07-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn07_31_2020_DatavantHoldingsIncMemberdeiLegalEntityAxis_SeriesBPreferredStockMemberusgaapStatementClassOfStockAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001635088</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="dei:LegalEntityAxis" >roiv:DatavantHoldingsIncMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis" >us-gaap:SeriesBPreferredStockMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2020-07-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn07_31_2020_SeriesBPreferredStockMemberusgaapStatementClassOfStockAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001635088</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis" >us-gaap:SeriesBPreferredStockMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2020-07-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn04_30_2020_CommonStockMemberusgaapStatementEquityComponentsAxis_ImmunovantINCMemberusgaapBusinessAcquisitionAxis_UnderwrittenPublicOfferingMemberusgaapSubsidiarySaleOfStockAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001635088</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis" >us-gaap:CommonStockMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis" >roiv:ImmunovantINCMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis" >roiv:UnderwrittenPublicOfferingMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2020-04-30</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn04_30_2020_DatavantHoldingsIncMemberdeiLegalEntityAxis_SeriesBPreferredStockMemberusgaapStatementClassOfStockAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001635088</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="dei:LegalEntityAxis" >roiv:DatavantHoldingsIncMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis" >us-gaap:SeriesBPreferredStockMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2020-04-30</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn02_29_2020_MaximumMembersrtRangeAxis_RoivantEquityRepurchaseMemberusgaapShareRepurchaseProgramAxis_SumitomoTransactionAgreementMemberusgaapTypeOfArrangementAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001635088</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="srt:RangeAxis" >srt:MaximumMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis" >roiv:SumitomoTransactionAgreementMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:ShareRepurchaseProgramAxis" >roiv:RoivantEquityRepurchaseMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2020-02-29</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn01_31_2020_SinovantIncMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001635088</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis" >roiv:SinovantIncMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2020-01-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn10_31_2018_NovaquestMemberusgaapTypeOfArrangementAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001635088</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis" >roiv:NovaquestMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2018-10-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn06_30_2021_FairValueMeasurementsRecurringMemberusgaapFairValueByMeasurementFrequencyAxis_MoneyMarketFundsMemberusgaapFairValueByAssetClassAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001635088</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis" >us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis" >us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2021-06-30</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn06_30_2021_FairValueInputsLevel1MemberusgaapFairValueByFairValueHierarchyLevelAxis_FairValueMeasurementsRecurringMemberusgaapFairValueByMeasurementFrequencyAxis_MoneyMarketFundsMemberusgaapFairValueByAssetClassAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001635088</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis" >us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis" >us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis" >us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2021-06-30</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn06_30_2021_TwoThousandFifteenEquityIncentivePlanMemberusgaapPlanNameAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001635088</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis" >roiv:TwoThousandFifteenEquityIncentivePlanMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2021-06-30</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn06_30_2021_PerformanceRestrictedStockUnitsPlanMemberusgaapPlanNameAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001635088</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis" >roiv:PerformanceRestrictedStockUnitsPlanMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2021-06-30</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn06_30_2021_FairValueMeasurementsRecurringMemberusgaapFairValueByMeasurementFrequencyAxis_OtherInvestmentCompaniesMemberusgaapFairValueByAssetClassAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001635088</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis" >us-gaap:OtherInvestmentCompaniesMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis" >us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2021-06-30</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn06_30_2021_FairValueInputsLevel1MemberusgaapFairValueByFairValueHierarchyLevelAxis_FairValueMeasurementsRecurringMemberusgaapFairValueByMeasurementFrequencyAxis_OtherInvestmentCompaniesMemberusgaapFairValueByAssetClassAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001635088</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis" >us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis" >us-gaap:OtherInvestmentCompaniesMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis" >us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2021-06-30</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn06_30_2021_ArbutusBiopharmaCorporationMemberdeiLegalEntityAxis_ConvertiblePreferredStockMemberusgaapFairValueByAssetClassAxis_FairValueMeasurementsRecurringMemberusgaapFairValueByMeasurementFrequencyAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001635088</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="dei:LegalEntityAxis" >roiv:ArbutusBiopharmaCorporationMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis" >us-gaap:ConvertiblePreferredStockMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis" >us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2021-06-30</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn06_30_2021_ArbutusBiopharmaCorporationMemberdeiLegalEntityAxis_ConvertiblePreferredStockMemberusgaapFairValueByAssetClassAxis_FairValueInputsLevel2MemberusgaapFairValueByFairValueHierarchyLevelAxis_FairValueMeasurementsRecurringMemberusgaapFairValueByMeasurementFrequencyAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001635088</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis" >us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember> <xbrldi:explicitMember dimension="dei:LegalEntityAxis" >roiv:ArbutusBiopharmaCorporationMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis" >us-gaap:ConvertiblePreferredStockMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis" >us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2021-06-30</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn06_30_2021_ArbutusBiopharmaCorporationMemberdeiLegalEntityAxis_CommonStockMemberusgaapFairValueByAssetClassAxis_FairValueMeasurementsRecurringMemberusgaapFairValueByMeasurementFrequencyAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001635088</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="dei:LegalEntityAxis" >roiv:ArbutusBiopharmaCorporationMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis" >us-gaap:CommonStockMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis" >us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2021-06-30</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn06_30_2021_ArbutusBiopharmaCorporationMemberdeiLegalEntityAxis_CommonStockMemberusgaapFairValueByAssetClassAxis_FairValueInputsLevel1MemberusgaapFairValueByFairValueHierarchyLevelAxis_FairValueMeasurementsRecurringMemberusgaapFairValueByMeasurementFrequencyAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001635088</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis" >us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember> <xbrldi:explicitMember dimension="dei:LegalEntityAxis" >roiv:ArbutusBiopharmaCorporationMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis" >us-gaap:CommonStockMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis" >us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2021-06-30</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn06_30_2021_CommonStockMemberusgaapFairValueByAssetClassAxis_FairValueMeasurementsRecurringMemberusgaapFairValueByMeasurementFrequencyAxis_SioGeneTherapiesIncMemberdeiLegalEntityAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001635088</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis" >us-gaap:CommonStockMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="dei:LegalEntityAxis" >roiv:SioGeneTherapiesIncMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis" >us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2021-06-30</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn06_30_2021_CommonStockMemberusgaapFairValueByAssetClassAxis_FairValueInputsLevel1MemberusgaapFairValueByFairValueHierarchyLevelAxis_FairValueMeasurementsRecurringMemberusgaapFairValueByMeasurementFrequencyAxis_SioGeneTherapiesIncMemberdeiLegalEntityAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001635088</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis" >us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis" >us-gaap:CommonStockMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="dei:LegalEntityAxis" >roiv:SioGeneTherapiesIncMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis" >us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2021-06-30</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn06_30_2021_SpecialReserveMemberusgaapAwardTypeAxis_TwoThousandFifteenEquityIncentivePlanMemberusgaapPlanNameAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001635088</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis" >roiv:SpecialReserveMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis" >roiv:TwoThousandFifteenEquityIncentivePlanMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2021-06-30</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn06_30_2021_FairValueMeasurementsRecurringMemberusgaapFairValueByMeasurementFrequencyAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001635088</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis" >us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2021-06-30</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn06_30_2021_FairValueInputsLevel2MemberusgaapFairValueByFairValueHierarchyLevelAxis_FairValueMeasurementsRecurringMemberusgaapFairValueByMeasurementFrequencyAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001635088</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis" >us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis" >us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2021-06-30</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn06_30_2021_FairValueInputsLevel1MemberusgaapFairValueByFairValueHierarchyLevelAxis_FairValueMeasurementsRecurringMemberusgaapFairValueByMeasurementFrequencyAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001635088</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis" >us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis" >us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2021-06-30</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn06_30_2021_MaximumMembersrtRangeAxis_MeasurementInputDiscountRateMemberusgaapMeasurementInputTypeAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001635088</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="srt:RangeAxis" >srt:MaximumMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis" >us-gaap:MeasurementInputDiscountRateMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2021-06-30</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn06_30_2021_MeasurementInputDiscountRateMemberusgaapMeasurementInputTypeAxis_MinimumMembersrtRangeAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001635088</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="srt:RangeAxis" >srt:MinimumMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis" >us-gaap:MeasurementInputDiscountRateMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2021-06-30</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn06_30_2021_FairValueInputsLevel3MemberusgaapFairValueByFairValueHierarchyLevelAxis_FairValueMeasurementsRecurringMemberusgaapFairValueByMeasurementFrequencyAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001635088</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis" >us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis" >us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2021-06-30</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn06_30_2021_ArbutusBiopharmaCorporationMemberdeiLegalEntityAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001635088</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="dei:LegalEntityAxis" >roiv:ArbutusBiopharmaCorporationMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2021-06-30</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn06_30_2021_ResearchAndDevelopmentExpenseMemberusgaapIncomeStatementLocationAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001635088</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis" >us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2021-06-30</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn06_30_2021_EmployeeRelatedExpensesMemberusgaapIncomeStatementLocationAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001635088</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis" >roiv:EmployeeRelatedExpensesMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2021-06-30</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn06_30_2021_ProfessionalServicesExpensesMemberusgaapIncomeStatementLocationAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001635088</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis" >roiv:ProfessionalServicesExpensesMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2021-06-30</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn06_30_2021_OtherGeneralAndAdministrativeExpensesMemberusgaapIncomeStatementLocationAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001635088</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis" >roiv:OtherGeneralAndAdministrativeExpensesMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2021-06-30</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn06_30_2021_SioGeneTherapiesIncMemberdeiLegalEntityAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001635088</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="dei:LegalEntityAxis" >roiv:SioGeneTherapiesIncMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2021-06-30</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn06_30_2021_DatavantHoldingsIncMemberdeiLegalEntityAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001635088</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="dei:LegalEntityAxis" >roiv:DatavantHoldingsIncMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2021-06-30</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn06_30_2021_OtherInvestmentCompaniesMemberusgaapInvestmentTypeAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001635088</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis" >us-gaap:OtherInvestmentCompaniesMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2021-06-30</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn06_30_2021_NovaquestMemberusgaapTypeOfArrangementAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001635088</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis" >roiv:NovaquestMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2021-06-30</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn06_30_2021_EmployeeMembersrtTitleOfIndividualAxis_SumitomoMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001635088</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis" >roiv:SumitomoMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis" >roiv:EmployeeMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2021-06-30</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="P04_01_2021To06_30_2021_PerformanceOptionsMemberusgaapAwardTypeAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001635088</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis" >roiv:PerformanceOptionsMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2021-04-01</xbrli:startDate> <xbrli:endDate>2021-06-30</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P04_01_2021To06_30_2021_CommonStockAwardsMemberusgaapAwardTypeAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001635088</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis" >roiv:CommonStockAwardsMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2021-04-01</xbrli:startDate> <xbrli:endDate>2021-06-30</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P04_01_2021To06_30_2021_PerformanceRestrictedStockUnitsMemberusgaapAwardTypeAxis_PerformanceRestrictedStockUnitsPlanMemberusgaapPlanNameAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001635088</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis" >roiv:PerformanceRestrictedStockUnitsPlanMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis" >roiv:PerformanceRestrictedStockUnitsMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2021-04-01</xbrli:startDate> <xbrli:endDate>2021-06-30</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P04_01_2021To06_30_2021_CappedValueAppreciationRightsMemberusgaapAwardTypeAxis_TwoThousandFifteenEquityIncentivePlanMemberusgaapPlanNameAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001635088</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis" >roiv:TwoThousandFifteenEquityIncentivePlanMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis" >roiv:CappedValueAppreciationRightsMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2021-04-01</xbrli:startDate> <xbrli:endDate>2021-06-30</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P04_01_2021To06_30_2021_PerformanceOptionsMemberusgaapAwardTypeAxis_TwoThousandFifteenEquityIncentivePlanMemberusgaapPlanNameAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001635088</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis" >roiv:TwoThousandFifteenEquityIncentivePlanMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis" >roiv:PerformanceOptionsMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2021-04-01</xbrli:startDate> <xbrli:endDate>2021-06-30</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P04_01_2021To06_30_2021_RestrictedStockUnitsRSUMemberusgaapAwardTypeAxis_TwoThousandFifteenEquityIncentivePlanMemberusgaapPlanNameAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001635088</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis" >us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis" >roiv:TwoThousandFifteenEquityIncentivePlanMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2021-04-01</xbrli:startDate> <xbrli:endDate>2021-06-30</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P04_01_2021To06_30_2021_EmployeeStockOptionMemberusgaapAwardTypeAxis_TwoThousandFifteenEquityIncentivePlanMemberusgaapPlanNameAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001635088</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis" >us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis" >roiv:TwoThousandFifteenEquityIncentivePlanMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2021-04-01</xbrli:startDate> <xbrli:endDate>2021-06-30</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P04_01_2021To06_30_2021_FairValueInputsLevel3MemberusgaapFairValueByFairValueHierarchyLevelAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001635088</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis" >us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2021-04-01</xbrli:startDate> <xbrli:endDate>2021-06-30</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P04_01_2021To06_30_2021_ResearchAndDevelopmentExpenseMemberusgaapIncomeStatementLocationAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001635088</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis" >us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2021-04-01</xbrli:startDate> <xbrli:endDate>2021-06-30</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P04_01_2021To06_30_2021_GeneralAndAdministrativeExpenseMemberusgaapIncomeStatementLocationAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001635088</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis" >us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2021-04-01</xbrli:startDate> <xbrli:endDate>2021-06-30</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P04_01_2021To06_30_2021_ArbutusBiopharmaCorporationMemberdeiLegalEntityAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001635088</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="dei:LegalEntityAxis" >roiv:ArbutusBiopharmaCorporationMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2021-04-01</xbrli:startDate> <xbrli:endDate>2021-06-30</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P04_01_2021To06_30_2021_PerformanceRestrictedStockUnitsMemberusgaapAwardTypeAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001635088</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis" >roiv:PerformanceRestrictedStockUnitsMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2021-04-01</xbrli:startDate> <xbrli:endDate>2021-06-30</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P04_01_2021To06_30_2021_CappedValueAppreciationRightsMemberusgaapAwardTypeAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001635088</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis" >roiv:CappedValueAppreciationRightsMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2021-04-01</xbrli:startDate> <xbrli:endDate>2021-06-30</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P04_01_2021To06_30_2021_SubsidiaryEquityIncentivePlanMemberusgaapPlanNameAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001635088</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis" >roiv:SubsidiaryEquityIncentivePlanMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2021-04-01</xbrli:startDate> <xbrli:endDate>2021-06-30</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P04_01_2021To06_30_2021_PerformanceRestrictedStockUnitsPlanMemberusgaapPlanNameAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001635088</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis" >roiv:PerformanceRestrictedStockUnitsPlanMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2021-04-01</xbrli:startDate> <xbrli:endDate>2021-06-30</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P04_01_2021To06_30_2021_SioGeneTherapiesIncMemberdeiLegalEntityAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001635088</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="dei:LegalEntityAxis" >roiv:SioGeneTherapiesIncMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2021-04-01</xbrli:startDate> <xbrli:endDate>2021-06-30</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P04_01_2021To06_30_2021_AdditionalPaidInCapitalMemberusgaapStatementEquityComponentsAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001635088</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis" >us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2021-04-01</xbrli:startDate> <xbrli:endDate>2021-06-30</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P04_01_2021To06_30_2021_NoncontrollingInterestMemberusgaapStatementEquityComponentsAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001635088</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis" >us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2021-04-01</xbrli:startDate> <xbrli:endDate>2021-06-30</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P04_01_2021To06_30_2021_AccumulatedOtherComprehensiveIncomeMemberusgaapStatementEquityComponentsAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001635088</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis" >us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2021-04-01</xbrli:startDate> <xbrli:endDate>2021-06-30</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P04_01_2021To06_30_2021_RetainedEarningsMemberusgaapStatementEquityComponentsAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001635088</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis" >us-gaap:RetainedEarningsMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2021-04-01</xbrli:startDate> <xbrli:endDate>2021-06-30</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P04_01_2021To06_30_2021_TransitionServicesAndStrategicCooperationAgreementMemberROIVAgreementAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001635088</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="roiv:AgreementAxis" >roiv:TransitionServicesAndStrategicCooperationAgreementMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2021-04-01</xbrli:startDate> <xbrli:endDate>2021-06-30</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P04_01_2021To06_30_2021_SumitomoMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001635088</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis" >roiv:SumitomoMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2021-04-01</xbrli:startDate> <xbrli:endDate>2021-06-30</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P04_01_2021To06_30_2021_AssetPurchaseAgreementMemberROIVAgreementAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001635088</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="roiv:AgreementAxis" >roiv:AssetPurchaseAgreementMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2021-04-01</xbrli:startDate> <xbrli:endDate>2021-06-30</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P04_01_2020To06_30_2020_FairValueInputsLevel3MemberusgaapFairValueByFairValueHierarchyLevelAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001635088</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis" >us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2020-04-01</xbrli:startDate> <xbrli:endDate>2020-06-30</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P04_01_2020To06_30_2020_ResearchAndDevelopmentExpenseMemberusgaapIncomeStatementLocationAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001635088</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis" >us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2020-04-01</xbrli:startDate> <xbrli:endDate>2020-06-30</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P04_01_2020To06_30_2020_GeneralAndAdministrativeExpenseMemberusgaapIncomeStatementLocationAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001635088</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis" >us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2020-04-01</xbrli:startDate> <xbrli:endDate>2020-06-30</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P04_01_2020To06_30_2020_EmployeeStockOptionMemberusgaapAwardTypeAxis_TwoThousandFifteenEquityIncentivePlanMemberusgaapPlanNameAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001635088</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis" >roiv:TwoThousandFifteenEquityIncentivePlanMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis" >us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2020-04-01</xbrli:startDate> <xbrli:endDate>2020-06-30</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P04_01_2020To06_30_2020_PerformanceOptionsMemberusgaapAwardTypeAxis_TwoThousandFifteenEquityIncentivePlanMemberusgaapPlanNameAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001635088</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis" >roiv:PerformanceOptionsMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis" >roiv:TwoThousandFifteenEquityIncentivePlanMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2020-04-01</xbrli:startDate> <xbrli:endDate>2020-06-30</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P04_01_2020To06_30_2020_SubsidiaryEquityIncentivePlanMemberusgaapPlanNameAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001635088</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis" >roiv:SubsidiaryEquityIncentivePlanMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2020-04-01</xbrli:startDate> <xbrli:endDate>2020-06-30</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P04_01_2020To06_30_2020_RestrictedStockUnitsRSUMemberusgaapAwardTypeAxis_TwoThousandFifteenEquityIncentivePlanMemberusgaapPlanNameAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001635088</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis" >us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis" >roiv:TwoThousandFifteenEquityIncentivePlanMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2020-04-01</xbrli:startDate> <xbrli:endDate>2020-06-30</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P04_01_2020To06_30_2020_CappedValueAppreciationRightsMemberusgaapAwardTypeAxis_TwoThousandFifteenEquityIncentivePlanMemberusgaapPlanNameAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001635088</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis" >roiv:CappedValueAppreciationRightsMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis" >roiv:TwoThousandFifteenEquityIncentivePlanMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2020-04-01</xbrli:startDate> <xbrli:endDate>2020-06-30</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P04_01_2020To06_30_2020_PerformanceRestrictedStockUnitsMemberusgaapAwardTypeAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001635088</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis" >roiv:PerformanceRestrictedStockUnitsMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2020-04-01</xbrli:startDate> <xbrli:endDate>2020-06-30</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P04_01_2020To06_30_2020_SioGeneTherapiesIncMemberdeiLegalEntityAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001635088</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="dei:LegalEntityAxis" >roiv:SioGeneTherapiesIncMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2020-04-01</xbrli:startDate> <xbrli:endDate>2020-06-30</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P04_01_2020To06_30_2020_ArbutusBiopharmaCorporationMemberdeiLegalEntityAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001635088</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="dei:LegalEntityAxis" >roiv:ArbutusBiopharmaCorporationMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2020-04-01</xbrli:startDate> <xbrli:endDate>2020-06-30</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P04_01_2020To06_30_2020_DatavantHoldingsIncMemberdeiLegalEntityAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001635088</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="dei:LegalEntityAxis" >roiv:DatavantHoldingsIncMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2020-04-01</xbrli:startDate> <xbrli:endDate>2020-06-30</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P04_01_2020To06_30_2020_AdditionalPaidInCapitalMemberusgaapStatementEquityComponentsAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001635088</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis" >us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2020-04-01</xbrli:startDate> <xbrli:endDate>2020-06-30</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P04_01_2020To06_30_2020_NoncontrollingInterestMemberusgaapStatementEquityComponentsAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001635088</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis" >us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2020-04-01</xbrli:startDate> <xbrli:endDate>2020-06-30</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P04_01_2020To06_30_2020_AccumulatedOtherComprehensiveIncomeMemberusgaapStatementEquityComponentsAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001635088</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis" >us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2020-04-01</xbrli:startDate> <xbrli:endDate>2020-06-30</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P04_01_2020To06_30_2020_RetainedEarningsMemberusgaapStatementEquityComponentsAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001635088</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis" >us-gaap:RetainedEarningsMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2020-04-01</xbrli:startDate> <xbrli:endDate>2020-06-30</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P04_01_2020To06_30_2020_TransitionServicesAndStrategicCooperationAgreementMemberROIVAgreementAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001635088</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="roiv:AgreementAxis" >roiv:TransitionServicesAndStrategicCooperationAgreementMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2020-04-01</xbrli:startDate> <xbrli:endDate>2020-06-30</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn06_30_2020_EmployeeMembersrtTitleOfIndividualAxis_SumitomoMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001635088</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis" >roiv:SumitomoMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis" >roiv:EmployeeMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2020-06-30</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn07_31_2021_ProteovantSciencesIncMemberusgaapBusinessAcquisitionAxis_SubsequentEventMemberusgaapSubsequentEventTypeAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001635088</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis" >roiv:ProteovantSciencesIncMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis" >us-gaap:SubsequentEventMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2021-07-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="P05_01_2021To05_31_2021_RevenueInterestPurchaseAndSaleAgreementMemberusgaapFinancialInstrumentAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001635088</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis" >roiv:RevenueInterestPurchaseAndSaleAgreementMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2021-05-01</xbrli:startDate> <xbrli:endDate>2021-05-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn05_31_2021_AssetPurchaseAgreementMemberROIVAgreementAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001635088</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="roiv:AgreementAxis" >roiv:AssetPurchaseAgreementMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2021-05-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn09_29_2017_ArbutusBiopharmaCorporationMemberdeiLegalEntityAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001635088</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="dei:LegalEntityAxis" >roiv:ArbutusBiopharmaCorporationMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2017-09-29</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="P03_31_2021To03_31_2021_SumitomoMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001635088</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis" >roiv:SumitomoMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2021-03-31</xbrli:startDate> <xbrli:endDate>2021-03-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P05_14_2021To05_14_2021_CreditFacilityMemberusgaapDebtInstrumentAxis_DermavantSciencesLtdMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis_SubsequentEventMemberusgaapSubsequentEventTypeAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001635088</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis" >roiv:DermavantSciencesLtdMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis" >us-gaap:SubsequentEventMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis" >roiv:CreditFacilityMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2021-05-14</xbrli:startDate> <xbrli:endDate>2021-05-14</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn03_31_2019_FairValueInputsLevel3MemberusgaapFairValueByFairValueHierarchyLevelAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001635088</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis" >us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2019-03-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn03_31_2019_RedeemableNoncontrollingInterestMemberusgaapStatementClassOfStockAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001635088</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis" >roiv:RedeemableNoncontrollingInterestMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2019-03-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn03_31_2019_CommonStockMemberusgaapStatementEquityComponentsAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001635088</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis" >us-gaap:CommonStockMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2019-03-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn03_31_2019_AdditionalPaidInCapitalMemberusgaapStatementEquityComponentsAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001635088</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis" >us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2019-03-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn03_31_2019_SubscriptionsReceivablesMemberusgaapStatementEquityComponentsAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001635088</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis" >roiv:SubscriptionsReceivablesMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2019-03-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn03_31_2019_AccumulatedOtherComprehensiveIncomeMemberusgaapStatementEquityComponentsAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001635088</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis" >us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2019-03-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn03_31_2019_RetainedEarningsMemberusgaapStatementEquityComponentsAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001635088</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis" >us-gaap:RetainedEarningsMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2019-03-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn03_31_2019_NoncontrollingInterestMemberusgaapStatementEquityComponentsAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001635088</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis" >us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2019-03-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn03_31_2020_RedeemableNoncontrollingInterestMemberusgaapStatementClassOfStockAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001635088</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis" >roiv:RedeemableNoncontrollingInterestMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2020-03-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn03_31_2020_CommonStockMemberusgaapStatementEquityComponentsAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001635088</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis" >us-gaap:CommonStockMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2020-03-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn03_31_2020_AdditionalPaidInCapitalMemberusgaapStatementEquityComponentsAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001635088</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis" >us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2020-03-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn03_31_2020_SubscriptionsReceivablesMemberusgaapStatementEquityComponentsAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001635088</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis" >roiv:SubscriptionsReceivablesMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2020-03-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn03_31_2020_AccumulatedOtherComprehensiveIncomeMemberusgaapStatementEquityComponentsAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001635088</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis" >us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2020-03-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn03_31_2020_RetainedEarningsMemberusgaapStatementEquityComponentsAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001635088</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis" >us-gaap:RetainedEarningsMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2020-03-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn03_31_2020_NoncontrollingInterestMemberusgaapStatementEquityComponentsAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001635088</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis" >us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2020-03-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn03_31_2020_FairValueInputsLevel3MemberusgaapFairValueByFairValueHierarchyLevelAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001635088</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis" >us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2020-03-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn03_31_2020_EmployeeStockOptionMemberusgaapAwardTypeAxis_TwoThousandFifteenEquityIncentivePlanMemberusgaapPlanNameAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001635088</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis" >us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis" >roiv:TwoThousandFifteenEquityIncentivePlanMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2020-03-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn03_31_2020_RestrictedStockUnitsRSUMemberusgaapAwardTypeAxis_TwoThousandFifteenEquityIncentivePlanMemberusgaapPlanNameAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001635088</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis" >us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis" >roiv:TwoThousandFifteenEquityIncentivePlanMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2020-03-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn03_31_2020_PerformanceOptionsMemberusgaapAwardTypeAxis_TwoThousandFifteenEquityIncentivePlanMemberusgaapPlanNameAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001635088</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis" >roiv:PerformanceOptionsMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis" >roiv:TwoThousandFifteenEquityIncentivePlanMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2020-03-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn03_31_2020_CappedValueAppreciationRightsMemberusgaapAwardTypeAxis_TwoThousandFifteenEquityIncentivePlanMemberusgaapPlanNameAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001635088</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis" >roiv:CappedValueAppreciationRightsMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis" >roiv:TwoThousandFifteenEquityIncentivePlanMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2020-03-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn03_31_2020_PerformanceRestrictedStockUnitsMemberusgaapAwardTypeAxis_PerformanceRestrictedStockUnitsPlanMemberusgaapPlanNameAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001635088</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis" >roiv:PerformanceRestrictedStockUnitsMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis" >roiv:PerformanceRestrictedStockUnitsPlanMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2020-03-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn03_31_2020_CommonStockAwardsMemberusgaapAwardTypeAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001635088</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis" >roiv:CommonStockAwardsMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2020-03-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn03_31_2021_PerformanceRestrictedStockUnitsMemberusgaapAwardTypeAxis_PerformanceRestrictedStockUnitsPlanMemberusgaapPlanNameAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001635088</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis" >roiv:PerformanceRestrictedStockUnitsMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis" >roiv:PerformanceRestrictedStockUnitsPlanMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2021-03-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn03_31_2021_CappedValueAppreciationRightsMemberusgaapAwardTypeAxis_TwoThousandFifteenEquityIncentivePlanMemberusgaapPlanNameAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001635088</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis" >roiv:CappedValueAppreciationRightsMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis" >roiv:TwoThousandFifteenEquityIncentivePlanMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2021-03-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn03_31_2021_PerformanceOptionsMemberusgaapAwardTypeAxis_TwoThousandFifteenEquityIncentivePlanMemberusgaapPlanNameAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001635088</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis" >roiv:PerformanceOptionsMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis" >roiv:TwoThousandFifteenEquityIncentivePlanMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2021-03-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn03_31_2021_RestrictedStockUnitsRSUMemberusgaapAwardTypeAxis_TwoThousandFifteenEquityIncentivePlanMemberusgaapPlanNameAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001635088</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis" >us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis" >roiv:TwoThousandFifteenEquityIncentivePlanMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2021-03-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn03_31_2021_RedeemableNoncontrollingInterestMemberusgaapStatementClassOfStockAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001635088</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis" >roiv:RedeemableNoncontrollingInterestMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2021-03-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn03_31_2021_CommonStockMemberusgaapStatementEquityComponentsAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001635088</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis" >us-gaap:CommonStockMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2021-03-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn03_31_2021_AdditionalPaidInCapitalMemberusgaapStatementEquityComponentsAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001635088</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis" >us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2021-03-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn03_31_2021_SubscriptionsReceivablesMemberusgaapStatementEquityComponentsAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001635088</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis" >roiv:SubscriptionsReceivablesMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2021-03-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn03_31_2021_AccumulatedOtherComprehensiveIncomeMemberusgaapStatementEquityComponentsAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001635088</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis" >us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2021-03-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn03_31_2021_RetainedEarningsMemberusgaapStatementEquityComponentsAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001635088</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis" >us-gaap:RetainedEarningsMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2021-03-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn03_31_2021_NoncontrollingInterestMemberusgaapStatementEquityComponentsAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001635088</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis" >us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2021-03-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn03_31_2021_FairValueInputsLevel3MemberusgaapFairValueByFairValueHierarchyLevelAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001635088</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis" >us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2021-03-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn06_30_2021_PerformanceRestrictedStockUnitsMemberusgaapAwardTypeAxis_PerformanceRestrictedStockUnitsPlanMemberusgaapPlanNameAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001635088</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis" >roiv:PerformanceRestrictedStockUnitsMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis" >roiv:PerformanceRestrictedStockUnitsPlanMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2021-06-30</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn06_30_2021_CappedValueAppreciationRightsMemberusgaapAwardTypeAxis_TwoThousandFifteenEquityIncentivePlanMemberusgaapPlanNameAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001635088</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis" >roiv:TwoThousandFifteenEquityIncentivePlanMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis" >roiv:CappedValueAppreciationRightsMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2021-06-30</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn06_30_2021_PerformanceOptionsMemberusgaapAwardTypeAxis_TwoThousandFifteenEquityIncentivePlanMemberusgaapPlanNameAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001635088</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis" >roiv:TwoThousandFifteenEquityIncentivePlanMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis" >roiv:PerformanceOptionsMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2021-06-30</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn06_30_2021_RestrictedStockUnitsRSUMemberusgaapAwardTypeAxis_TwoThousandFifteenEquityIncentivePlanMemberusgaapPlanNameAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001635088</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis" >us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis" >roiv:TwoThousandFifteenEquityIncentivePlanMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2021-06-30</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn06_30_2021_EmployeeStockOptionMemberusgaapAwardTypeAxis_TwoThousandFifteenEquityIncentivePlanMemberusgaapPlanNameAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001635088</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis" >us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis" >roiv:TwoThousandFifteenEquityIncentivePlanMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2021-06-30</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn06_30_2021_CommonStockAwardsMemberusgaapAwardTypeAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001635088</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis" >roiv:CommonStockAwardsMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2021-06-30</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn06_30_2021_RedeemableNoncontrollingInterestMemberusgaapStatementClassOfStockAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001635088</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis" >roiv:RedeemableNoncontrollingInterestMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2021-06-30</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn06_30_2021_CommonStockMemberusgaapStatementEquityComponentsAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001635088</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis" >us-gaap:CommonStockMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2021-06-30</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn06_30_2021_AdditionalPaidInCapitalMemberusgaapStatementEquityComponentsAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001635088</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis" >us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2021-06-30</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn06_30_2021_SubscriptionsReceivablesMemberusgaapStatementEquityComponentsAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001635088</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis" >roiv:SubscriptionsReceivablesMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2021-06-30</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn06_30_2021_AccumulatedOtherComprehensiveIncomeMemberusgaapStatementEquityComponentsAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001635088</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis" >us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2021-06-30</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn06_30_2021_RetainedEarningsMemberusgaapStatementEquityComponentsAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001635088</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis" >us-gaap:RetainedEarningsMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2021-06-30</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn06_30_2021_NoncontrollingInterestMemberusgaapStatementEquityComponentsAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001635088</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis" >us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2021-06-30</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn06_30_2021_FairValueInputsLevel3MemberusgaapFairValueByFairValueHierarchyLevelAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001635088</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis" >us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2021-06-30</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn06_30_2020_RedeemableNoncontrollingInterestMemberusgaapStatementClassOfStockAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001635088</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis" >roiv:RedeemableNoncontrollingInterestMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2020-06-30</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn06_30_2020_CommonStockMemberusgaapStatementEquityComponentsAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001635088</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis" >us-gaap:CommonStockMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2020-06-30</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn06_30_2020_AdditionalPaidInCapitalMemberusgaapStatementEquityComponentsAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001635088</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis" >us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2020-06-30</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn06_30_2020_SubscriptionsReceivablesMemberusgaapStatementEquityComponentsAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001635088</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis" >roiv:SubscriptionsReceivablesMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2020-06-30</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn06_30_2020_AccumulatedOtherComprehensiveIncomeMemberusgaapStatementEquityComponentsAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001635088</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis" >us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2020-06-30</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn06_30_2020_RetainedEarningsMemberusgaapStatementEquityComponentsAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001635088</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis" >us-gaap:RetainedEarningsMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2020-06-30</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn06_30_2020_NoncontrollingInterestMemberusgaapStatementEquityComponentsAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001635088</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis" >us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2020-06-30</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn06_30_2020_FairValueInputsLevel3MemberusgaapFairValueByFairValueHierarchyLevelAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001635088</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis" >us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2020-06-30</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:unit id="Unit_USD" > <xbrli:measure>iso4217:USD</xbrli:measure> </xbrli:unit><xbrli:unit id="Unit_shares" > <xbrli:measure>xbrli:shares</xbrli:measure> </xbrli:unit><xbrli:unit id="Unit_EUR" > <xbrli:measure>iso4217:EUR</xbrli:measure> </xbrli:unit><xbrli:unit id="Unit_pure" > <xbrli:measure>xbrli:pure</xbrli:measure> </xbrli:unit><xbrli:unit id="Unit_Year" > <xbrli:measure>utr:Year</xbrli:measure> </xbrli:unit><xbrli:unit id="Unit_CAD" > <xbrli:measure>iso4217:CAD</xbrli:measure> </xbrli:unit><xbrli:unit id="Unit_Day" > <xbrli:measure>utr:Day</xbrli:measure> </xbrli:unit><xbrli:unit id="Unit_Segment" > <xbrli:measure>roiv:Segment</xbrli:measure> </xbrli:unit><xbrli:unit id="Unit_USD_per_Share" > <xbrli:divide> <xbrli:unitNumerator> <xbrli:measure>iso4217:USD</xbrli:measure> </xbrli:unitNumerator> <xbrli:unitDenominator> <xbrli:measure>xbrli:shares</xbrli:measure> </xbrli:unitDenominator> </xbrli:divide> </xbrli:unit><ix:relationship fromRefs="Fact_28229485" toRefs="FN_95030"/><ix:relationship fromRefs="Fact_28229486" toRefs="FN_95030"/><ix:relationship fromRefs="Fact_28229520" toRefs="FN_95032"/><ix:relationship fromRefs="Fact_28229521" toRefs="FN_95032"/><ix:relationship fromRefs="Fact_28229522" toRefs="FN_95032"/><ix:relationship fromRefs="Fact_28229523" toRefs="FN_95032"/><ix:relationship fromRefs="Fact_28229787" toRefs="FN_95031"/><ix:relationship fromRefs="Fact_28229788" toRefs="FN_95031"/></ix:resources></ix:header></div><div style="font-size: 13.28px; margin-top: 0pt; margin-bottom: 1.67em;;font-weight: bold;"><a href="#toc">Table of Contents</a></div> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">As filed with the Securities and Exchange Commission on October 29, 2021 </div></div></div></div> </div> </div> <div style="text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;">Registration <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">No.&#160;333-&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</div> </div></div> <div style="font-size: 2pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 2pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="line-height: 1pt; margin-top: 0pt; margin-bottom: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="line-height: 3pt; margin-top: 0pt; margin-bottom: 2pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 12pt; margin-top: 2pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">SECURITIES AND EXCHANGE COMMISSION </div></div></div> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Washington, D.C. 20549 </div></div></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center;"> <div style="margin: 0pt auto 2pt; width: 21%; text-align: center; line-height: 6pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </div> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;">FORM <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"><ix:nonNumeric name="dei:DocumentType" contextRef="P04_01_2021To06_30_2021">S-1</ix:nonNumeric></div> </div></div> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">REGISTRATION STATEMENT </div></div></div> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">UNDER </div></div></div></div> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">THE SECURITIES ACT OF 1933 </div></div></div></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center;"> <div style="margin: 0pt auto 2pt; width: 21%; text-align: center; line-height: 6pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </div> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 18pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 18pt; letter-spacing: 0px; top: 0px;;display:inline;"><span style="-sec-ix-hidden:hidden28317344">ROIVANT SCIENCES LTD.</span> </div></div></div> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">(Exact Name of Registrant as Specified in Its Charter) </div></div></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 8pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="font-size: 0px;">
<td style="width: 34%;"></td>
<td style="vertical-align: bottom;"></td>
<td style="width: 32%;"></td>
<td style="width: 1%; vertical-align: bottom;"></td>
<td style="width: 32%;"></td> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: top;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Bermuda</div></div></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: top;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2834</div></div></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: top;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">98-1173944</div></div></div></td> </tr>
<tr style="font-family: Times New Roman; font-size: 7pt; page-break-inside: avoid;">
<td style="vertical-align: top;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(State or Other Jurisdiction of<br/> Incorporation or Organization)</div></div></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: top;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(Primary Standard Industrial<br/> Classification Code Number)</div></div></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: top;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(I.R.S. Employer<br/> Identification Number)</div></div></td> </tr> </table> <div style="clear: both; max-height: 0px;"></div> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">Suite 1, 3rd Floor </div></div></div> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">11-12</div> St. James&#8217;s Square </div></div> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">London SW1Y 4LB </div></div></div> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">United Kingdom </div></div></div> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">+44 207 400 3347 </div></div></div> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 7pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 7pt; letter-spacing: 0px; top: 0px;;display:inline;">(Address, Including Zip Code, and Telephone Number, Including Area Code, of Registrant&#8217;s Principal Executive Offices) </div></div></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center;"> <div style="margin: 0pt auto 2pt; width: 21%; text-align: center; line-height: 6pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </div> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">Corporation Service Company </div></div></div> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">251 Little Falls Drive </div></div></div> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">Wilmington, Delaware 19808 </div></div></div> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;">(800) <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">927-9801</div> </div></div> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 7pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 7pt; letter-spacing: 0px; top: 0px;;display:inline;">(Name, Address, Including Zip Code, and Telephone Number, Including Area Code, of Agent For Service) </div></div></div> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Copy to: </div></div></div></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 8pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="font-size: 0px;">
<td style="width: 99%; font-family: &quot;Times New Roman&quot;;"></td> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: top;;text-align:center;"> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">Derek J. Dostal<br/> Davis Polk&#160;&amp; Wardwell LLP</div></div></div> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">450 Lexington Avenue</div></div></div> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">New York, New York 10017</div></div></div> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 1pt; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">(212)&#160;450-4000</div></div></div> </td> </tr> </table> <div style="clear: both; max-height: 0px;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center;"> <div style="margin: 0pt auto 2pt; width: 21%; text-align: center; line-height: 6pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Approximate date of commencement of proposed sale to the public</div></div>: From time to time after the effective date of this registration statement. </div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 8pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">If any of the securities being registered on this form are to be offered on a delayed or continuous basis pursuant to Rule 415 under the Securities Act of 1933, check the following box.&#160;&#160;&#9746; </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 8pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">If this form is filed to register additional securities for an offering pursuant to Rule 462(b) under the Securities Act, check the following box and list the Securities Act registration statement number of the earlier effective registration statement for the same offering.&#160;&#160;&#9744; </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 8pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">If this form is a post-effective amendment filed pursuant to Rule 462(c) under the Securities Act, check the following box and list the Securities Act registration statement number of the earlier effective registration statement for the same offering.&#160;&#160;&#9744; </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 8pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">If this form is a post-effective amendment filed pursuant to Rule 462(d) under the Securities Act, check the following box and list the Securities Act registration statement number of the earlier effective registration statement for the same offering.&#160;&#160;&#9744; </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 8pt; margin-top: 6pt; margin-bottom: 0pt;">Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-accelerated</div> filer, a smaller reporting company, or an emerging growth company. See the definitions of &#8220;large accelerated filer,&#8221; &#8220;accelerated filer,&#8221; &#8220;smaller reporting company&#8221; and &#8220;emerging growth company&#8221; in Rule <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">12b-2</div> of the Exchange Act. </div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 8pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="font-size: 0px;">
<td style="width: 13%;"></td>
<td style="width: 1%; vertical-align: bottom;"></td>
<td style="width: 66%;"></td>
<td style="width: 1%; vertical-align: bottom;"></td>
<td style="width: 17%;"></td>
<td style="width: 1%; vertical-align: bottom;"></td>
<td style="width: 1%;"></td> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom;">Large&#160;accelerated&#160;filer</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#9744;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">Accelerated&#160;filer</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#9744;</td> </tr>
<tr style="font-size: 1pt;">
<td style="height: 6pt;">&#160;</td>
<td colspan="2" style="height: 6pt;">&#160;</td>
<td colspan="2" style="height: 6pt;">&#160;</td>
<td colspan="2" style="height: 6pt;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"><ix:nonNumeric name="dei:EntityFilerCategory" contextRef="P04_01_2021To06_30_2021" format="ixt-sec:entityfilercategoryen">Non-accelerated filer</ix:nonNumeric></div></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#9744; (Do not check if a smaller reporting company)</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">Smaller&#160;reporting&#160;company</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"><ix:nonNumeric name="dei:EntitySmallBusiness" contextRef="P04_01_2021To06_30_2021" format="ixt:booleantrue">&#9746;</ix:nonNumeric></td> </tr>
<tr style="font-size: 1pt;">
<td style="height: 6pt;">&#160;</td>
<td colspan="2" style="height: 6pt;">&#160;</td>
<td colspan="2" style="height: 6pt;">&#160;</td>
<td colspan="2" style="height: 6pt;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">Emerging&#160;growth&#160;company</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"><ix:nonNumeric name="dei:EntityEmergingGrowthCompany" contextRef="P04_01_2021To06_30_2021" format="ixt:booleantrue">&#9746;</ix:nonNumeric></td> </tr> </table> <div style="clear: both; max-height: 0px;"></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 8pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section&#160;7(a)(2)(B) of the Securities Act.&#160;&#160;<ix:nonNumeric name="dei:EntityExTransitionPeriod" contextRef="P04_01_2021To06_30_2021" format="ixt:booleantrue">&#9746;</ix:nonNumeric> </div></div> <div style="text-align: center;"> <div style="margin: 0pt auto 2pt; width: 21%; text-align: center; line-height: 6pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 6pt; margin-bottom: 0pt; text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">CALCULATION OF REGISTRATION FEE </div></div></div></div> <div style="font-size: 2pt; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-size: 2pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 8pt; border-collapse: collapse; border-spacing: 0px; text-indent: 0px;">
<tr style="font-size: 0px;">
<td style="width: 44%;"></td>
<td style="width: 1%; vertical-align: bottom;"></td>
<td style="width: 13%;"></td>
<td style="width: 1%; vertical-align: bottom;"></td>
<td style="width: 13%;"></td>
<td style="width: 1%; vertical-align: bottom;"></td>
<td style="width: 13%;"></td>
<td style="width: 1%; vertical-align: bottom;"></td>
<td style="width: 13%;"></td> </tr>
<tr style="font-size: 1px;">
<td colspan="9" style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div> </td> </tr>
<tr style="font-family: Times New Roman; font-size: 6pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; border-top-color: rgb(0, 0, 0); border-top-width: 0.75pt; border-top-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Title of Each Class<br/> of Securities to be Registered</div></div></div></td>
<td style="vertical-align: bottom; border-top-color: rgb(0, 0, 0); border-left-color: rgb(0, 0, 0); border-top-width: 0.75pt; border-left-width: 0.75pt; border-top-style: solid; border-left-style: solid;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; border-top-color: rgb(0, 0, 0); border-top-width: 0.75pt; border-top-style: solid; white-space: nowrap;;text-align:center;"> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">Amount to be</div></div></div></div> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 6pt; margin-top: 0pt; margin-bottom: 1pt; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">Registered(1)</div></div></div></div> </td>
<td style="vertical-align: bottom; border-top-color: rgb(0, 0, 0); border-left-color: rgb(0, 0, 0); border-top-width: 0.75pt; border-left-width: 0.75pt; border-top-style: solid; border-left-style: solid;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; border-top-color: rgb(0, 0, 0); border-top-width: 0.75pt; border-top-style: solid; white-space: nowrap;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Proposed Maximum<br/> Offering Price Per Share(2)</div></div></div></td>
<td style="vertical-align: bottom; border-top-color: rgb(0, 0, 0); border-left-color: rgb(0, 0, 0); border-top-width: 0.75pt; border-left-width: 0.75pt; border-top-style: solid; border-left-style: solid;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; border-top-color: rgb(0, 0, 0); border-top-width: 0.75pt; border-top-style: solid; white-space: nowrap;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Proposed Maximum<br/> Aggregate Offering Price(2)</div></div></div></td>
<td style="vertical-align: bottom; border-top-color: rgb(0, 0, 0); border-left-color: rgb(0, 0, 0); border-top-width: 0.75pt; border-left-width: 0.75pt; border-top-style: solid; border-left-style: solid;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; border-top-color: rgb(0, 0, 0); border-top-width: 0.75pt; border-top-style: solid; white-space: nowrap;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Amount of<br/> Registration Fee</div></div></div></td> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: top; border-top-color: rgb(0, 0, 0); border-top-width: 0.75pt; border-top-style: solid;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">Primary Offering</div></div></div></div> </td>
<td style="vertical-align: bottom; border-top-color: rgb(0, 0, 0); border-left-color: rgb(0, 0, 0); border-top-width: 0.75pt; border-left-width: 0.75pt; border-top-style: solid; border-left-style: solid;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; border-top: 0.75pt solid rgb(0, 0, 0); font-size: x-small;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-size: x-small; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom; border-top-color: rgb(0, 0, 0); border-left-color: rgb(0, 0, 0); border-top-width: 0.75pt; border-left-width: 0.75pt; border-top-style: solid; border-left-style: solid;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; border-top: 0.75pt solid rgb(0, 0, 0); font-size: x-small;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-size: x-small; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom; border-top-color: rgb(0, 0, 0); border-left-color: rgb(0, 0, 0); border-top-width: 0.75pt; border-left-width: 0.75pt; border-top-style: solid; border-left-style: solid;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; border-top: 0.75pt solid rgb(0, 0, 0); font-size: x-small;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-size: x-small; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom; border-top-color: rgb(0, 0, 0); border-left-color: rgb(0, 0, 0); border-top-width: 0.75pt; border-left-width: 0.75pt; border-top-style: solid; border-left-style: solid;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; border-top: 0.75pt solid rgb(0, 0, 0); font-size: x-small;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-size: x-small; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: top; border-top: 0.75pt solid rgb(0, 0, 0); font-size: 8pt;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">Common Shares, par value $0.0000000341740141 per share (the &#8220;Common Shares&#8221;)</div></div></div> </td>
<td style="vertical-align: bottom; border-top-color: rgb(0, 0, 0); border-left-color: rgb(0, 0, 0); border-top-width: 0.75pt; border-left-width: 0.75pt; border-top-style: solid; border-left-style: solid;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; border-top-color: rgb(0, 0, 0); border-top-width: 0.75pt; border-top-style: solid; white-space: nowrap;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">30,750,261(3)</div></td>
<td style="vertical-align: bottom; border-top-color: rgb(0, 0, 0); border-left-color: rgb(0, 0, 0); border-top-width: 0.75pt; border-left-width: 0.75pt; border-top-style: solid; border-left-style: solid;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; border-top-color: rgb(0, 0, 0); border-top-width: 0.75pt; border-top-style: solid; white-space: nowrap;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">$6.68</div></td>
<td style="vertical-align: bottom; border-top-color: rgb(0, 0, 0); border-left-color: rgb(0, 0, 0); border-top-width: 0.75pt; border-left-width: 0.75pt; border-top-style: solid; border-left-style: solid;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; border-top-color: rgb(0, 0, 0); border-top-width: 0.75pt; border-top-style: solid; white-space: nowrap;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">$205,257,992.18</div></td>
<td style="vertical-align: bottom; border-top-color: rgb(0, 0, 0); border-left-color: rgb(0, 0, 0); border-top-width: 0.75pt; border-left-width: 0.75pt; border-top-style: solid; border-left-style: solid;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; border-top-color: rgb(0, 0, 0); border-top-width: 0.75pt; border-top-style: solid; white-space: nowrap;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">$19,027.42</div></td> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: top; border-top-color: rgb(0, 0, 0); border-top-width: 0.75pt; border-top-style: solid;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">Secondary Offering</div></div></div></div> </td>
<td style="vertical-align: bottom; border-top-color: rgb(0, 0, 0); border-left-color: rgb(0, 0, 0); border-top-width: 0.75pt; border-left-width: 0.75pt; border-top-style: solid; border-left-style: solid;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; border-top: 0.75pt solid rgb(0, 0, 0); font-size: x-small;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-size: x-small; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom; border-top-color: rgb(0, 0, 0); border-left-color: rgb(0, 0, 0); border-top-width: 0.75pt; border-left-width: 0.75pt; border-top-style: solid; border-left-style: solid;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; border-top: 0.75pt solid rgb(0, 0, 0); font-size: x-small;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-size: x-small; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom; border-top-color: rgb(0, 0, 0); border-left-color: rgb(0, 0, 0); border-top-width: 0.75pt; border-left-width: 0.75pt; border-top-style: solid; border-left-style: solid;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; border-top: 0.75pt solid rgb(0, 0, 0); font-size: x-small;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-size: x-small; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom; border-top-color: rgb(0, 0, 0); border-left-color: rgb(0, 0, 0); border-top-width: 0.75pt; border-left-width: 0.75pt; border-top-style: solid; border-left-style: solid;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; border-top: 0.75pt solid rgb(0, 0, 0); font-size: x-small;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-size: x-small; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: top; border-top: 0.75pt solid rgb(0, 0, 0); font-size: 8pt;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">Common Shares</div></div></div> </td>
<td style="vertical-align: bottom; border-top-color: rgb(0, 0, 0); border-left-color: rgb(0, 0, 0); border-top-width: 0.75pt; border-left-width: 0.75pt; border-top-style: solid; border-left-style: solid;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; border-top-color: rgb(0, 0, 0); border-top-width: 0.75pt; border-top-style: solid; white-space: nowrap;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">595,134,445(4)</div></td>
<td style="vertical-align: bottom; border-top-color: rgb(0, 0, 0); border-left-color: rgb(0, 0, 0); border-top-width: 0.75pt; border-left-width: 0.75pt; border-top-style: solid; border-left-style: solid;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; border-top-color: rgb(0, 0, 0); border-top-width: 0.75pt; border-top-style: solid; white-space: nowrap;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">$6.68</div></td>
<td style="vertical-align: bottom; border-top-color: rgb(0, 0, 0); border-left-color: rgb(0, 0, 0); border-top-width: 0.75pt; border-left-width: 0.75pt; border-top-style: solid; border-left-style: solid;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; border-top-color: rgb(0, 0, 0); border-top-width: 0.75pt; border-top-style: solid; white-space: nowrap;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">$3,972,522,420.38</div></td>
<td style="vertical-align: bottom; border-top-color: rgb(0, 0, 0); border-left-color: rgb(0, 0, 0); border-top-width: 0.75pt; border-left-width: 0.75pt; border-top-style: solid; border-left-style: solid;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; border-top-color: rgb(0, 0, 0); border-top-width: 0.75pt; border-top-style: solid; white-space: nowrap;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">$368,252.83</div></td> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: top; border-top: 0.75pt solid rgb(0, 0, 0); font-size: 8pt;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">Warrants to purchase Common Shares</div></div></div> </td>
<td style="vertical-align: bottom; border-top-color: rgb(0, 0, 0); border-left-color: rgb(0, 0, 0); border-top-width: 0.75pt; border-left-width: 0.75pt; border-top-style: solid; border-left-style: solid;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; border-top-color: rgb(0, 0, 0); border-top-width: 0.75pt; border-top-style: solid; white-space: nowrap;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">10,214,365(5)</div></td>
<td style="vertical-align: bottom; border-top-color: rgb(0, 0, 0); border-left-color: rgb(0, 0, 0); border-top-width: 0.75pt; border-left-width: 0.75pt; border-top-style: solid; border-left-style: solid;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; border-top-color: rgb(0, 0, 0); border-top-width: 0.75pt; border-top-style: solid; white-space: nowrap;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">$ &#8212;&#160;&#160;</div></td>
<td style="vertical-align: bottom; border-top-color: rgb(0, 0, 0); border-left-color: rgb(0, 0, 0); border-top-width: 0.75pt; border-left-width: 0.75pt; border-top-style: solid; border-left-style: solid;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; border-top-color: rgb(0, 0, 0); border-top-width: 0.75pt; border-top-style: solid; white-space: nowrap;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">$ &#8212;&#160;&#160;</div></td>
<td style="vertical-align: bottom; border-top-color: rgb(0, 0, 0); border-left-color: rgb(0, 0, 0); border-top-width: 0.75pt; border-left-width: 0.75pt; border-top-style: solid; border-left-style: solid;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; border-top-color: rgb(0, 0, 0); border-top-width: 0.75pt; border-top-style: solid; white-space: nowrap;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">$ &#8212;&#160;&#160;(6)</div></td> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: top; border-top-color: rgb(0, 0, 0); border-top-width: 0.75pt; border-top-style: solid;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">Total</div></div></div></div> </td>
<td style="vertical-align: bottom; border-top-color: rgb(0, 0, 0); border-left-color: rgb(0, 0, 0); border-top-width: 0.75pt; border-left-width: 0.75pt; border-top-style: solid; border-left-style: solid;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; border-top: 0.75pt solid rgb(0, 0, 0); font-size: x-small;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-size: x-small; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom; border-top-color: rgb(0, 0, 0); border-left-color: rgb(0, 0, 0); border-top-width: 0.75pt; border-left-width: 0.75pt; border-top-style: solid; border-left-style: solid;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; border-top: 0.75pt solid rgb(0, 0, 0); font-size: x-small;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-size: x-small; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom; border-top-color: rgb(0, 0, 0); border-left-color: rgb(0, 0, 0); border-top-width: 0.75pt; border-left-width: 0.75pt; border-top-style: solid; border-left-style: solid;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; border-top-color: rgb(0, 0, 0); border-top-width: 0.75pt; border-top-style: solid; white-space: nowrap;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">$4,177,780,412.56</div></td>
<td style="vertical-align: bottom; border-top-color: rgb(0, 0, 0); border-left-color: rgb(0, 0, 0); border-top-width: 0.75pt; border-left-width: 0.75pt; border-top-style: solid; border-left-style: solid;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; border-top-color: rgb(0, 0, 0); border-top-width: 0.75pt; border-top-style: solid; white-space: nowrap;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">$387,280.25</div></td> </tr>
<tr style="font-size: 1px;">
<td colspan="9" style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div> </td> </tr>
<tr style="font-size: 1px;">
<td colspan="9" style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div> </td> </tr> </table> <div style="clear: both; max-height: 0px; text-indent: 0px;"></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 8pt; border-collapse: collapse; border-spacing: 0px; text-indent: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 4%; vertical-align: top;;text-align:left;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">(1)</div></td>
<td style="vertical-align: top; font-size: 8pt;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">Pursuant to Rule 416 under the Securities Act of 1933, as amended (the &#8220;Securities Act&#8221;), the registrant is also registering an indeterminate number of additional Common Shares that may become issuable as a result of any stock dividend, stock split, recapitalization or other similar transaction. </div></div></div> </td> </tr> </table> <div style="clear: both; max-height: 0px; text-indent: 0px;"></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 8pt; border-collapse: collapse; border-spacing: 0px; text-indent: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 4%; vertical-align: top;;text-align:left;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">(2)</div></td>
<td style="vertical-align: top; font-size: 8pt;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">Estimated solely for the purpose of calculating the registration fee in accordance with Rule 457(c) and Rule 457(g) under the Securities Act, based on the average of the high and low prices of the Common Shares on October&#160;22, 2021 as reported on The Nasdaq Global Market, which was approximately $6.68 per share. </div></div></div> </td> </tr> </table> <div style="clear: both; max-height: 0px; text-indent: 0px;"></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 8pt; border-collapse: collapse; border-spacing: 0px; text-indent: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 4%; vertical-align: top;;text-align:left;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">(3)</div></td>
<td style="vertical-align: top; font-size: 8pt;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">Consists of the primary issuance of (i) 20,535,896 Common Shares that may be issued upon exercise of the Registrant&#8217;s outstanding public warrants (the &#8220;Public Warrants&#8221;) and (ii) 10,214,365 Common Shares that may be issued upon exercise of the Registrant&#8217;s outstanding private warrants (the &#8220;Private Placement Warrants&#8221; and, collectively with the Public Warrants, the &#8220;Warrants&#8221;) following the public resale of the Private Placement Warrants. The Private Placement Warrants were sold simultaneously with the closing of the initial public offering of MAAC at a price of $1.00 to the MAAC Sponsor. </div></div></div> </td> </tr> </table> <div style="clear: both; max-height: 0px; text-indent: 0px;"></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 8pt; border-collapse: collapse; border-spacing: 0px; text-indent: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 4%; vertical-align: top;;text-align:left;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">(4)</div></td>
<td style="vertical-align: top; font-size: 8pt;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">Consists of 595,134,445 Common Shares registered for resale by the Holders (as defined below), consisting of (i) 22,000,000 Common Shares issued in connection with the PIPE Financing (as defined below), (ii) 10,214,365 Common Shares issuable upon exercise of the Private Placement Warrants and (iii) 562,920,080 issued and outstanding Common Shares held by the Holders (including Common Shares underlying vested restricted share awards). </div></div></div> </td> </tr> </table> <div style="clear: both; max-height: 0px; text-indent: 0px;"></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 8pt; border-collapse: collapse; border-spacing: 0px; text-indent: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 4%; vertical-align: top;;text-align:left;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">(5)</div></td>
<td style="vertical-align: top; font-size: 8pt;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">Consists of the 10,214,365 outstanding Private Placement Warrants sold simultaneously with the closing of the initial public offering of MAAC at a price of $1.00 to the MAAC Sponsor. </div></div></div> </td> </tr> </table> <div style="clear: both; max-height: 0px; text-indent: 0px;"></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 8pt; border-collapse: collapse; border-spacing: 0px; text-indent: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 4%; vertical-align: top;;text-align:left;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">(6)</div></td>
<td style="vertical-align: top; font-size: 8pt;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">No separate fee due in accordance with Rule 457(i). </div></div></div> </td> </tr> </table> <div style="clear: both; max-height: 0px; text-indent: 0px;"></div> <div style="text-indent: 4%; font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">The Registrant hereby amends this Registration Statement on such date or dates as may be necessary to delay its effective date until the Registrant shall file a further amendment which specifically states that this Registration Statement shall thereafter become effective in accordance with Section&#160;8(a) of the Securities Act of 1933 or until the Registration Statement shall become effective on such date as the Commission, acting pursuant to said Section&#160;8(a), may determine. </div></div></div></div> </div> </div> <div style="font-size: 4pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 4pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="line-height: 1pt; margin-top: 0pt; margin-bottom: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="line-height: 3pt; margin-top: 0pt; margin-bottom: 2pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;;font-weight: bold;"><a href="#toc">Table of Contents</a></div> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"> <div style="font-family: Arial Narrow; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="color: rgb(235, 0, 41); letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">The information in this preliminary prospectus is not complete and may be changed. Neither we nor the selling securityholders may sell these securities until the registration statement filed with the Securities and Exchange Commission is effective. This preliminary prospectus is not an offer to sell these securities and is not soliciting an offer to buy these securities in any jurisdiction where the offer or sale is not permitted. </div></div></div></div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="color: rgb(235, 0, 41); letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">PRELIMINARY PROSPECTUS </div></div></div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="color: rgb(235, 0, 41); letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">SUBJECT TO COMPLETION, DATED OCTOBER 29, 2021 </div></div></div></div> <div style="text-align: center; margin-top: 0pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="color: red; letter-spacing: 0px; top: 0px;;display:inline;">
<img alt="" src="g164680g30a01.jpg" style="width: 388px; height: 93px;"/></div> </div></div> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 18pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 18pt; letter-spacing: 0px; top: 0px;;display:inline;">595,134,445 Common Shares </div></div></div> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 17pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 17pt; letter-spacing: 0px; top: 0px;;display:inline;">30,750,261 Common Shares Issuable Upon Exercise of Warrants </div></div></div> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 18pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 18pt; letter-spacing: 0px; top: 0px;;display:inline;">10,214,365 Private Placement Warrants </div></div></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center;"> <div style="margin: 0pt auto 2pt; width: 21%; text-align: center; line-height: 6pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">This prospectus relates to the issuance by us of up to (i) 20,535,896 common shares, $0.0000000341740141 par value per share (the &#8220;Common Shares&#8221;), that are issuable by us upon the exercise of the outstanding public warrants (the &#8220;Public Warrants&#8221;), which were previously registered, and (ii) 10,214,365 Common Shares that are issuable by us upon the exercise of the private warrants (the &#8220;Private Placement Warrants&#8221; and, collectively with the Public Warrants, the &#8220;Warrants&#8221;) originally issued in a private placement to Patient Square Capital LLC (the &#8220;MAAC Sponsor&#8221;). </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">This prospectus also relates to the potential offer and sale from time to time by the securityholders named in this prospectus or their permitted transferees (the &#8220;Holders&#8221;) of (i)&#160;up to 595,134,445 of our Common Shares, consisting of (x) 22,000,000 Common Shares issued in the PIPE Financing (as defined herein), (y) up to 10,214,365 Common Shares issuable upon exercise of the Private Placement Warrants and (z) 562,920,080 issued and outstanding Common Shares held by certain Holders (including Common Shares underlying vested restricted share awards), and (ii)&#160;the Private Placement Warrants. We will not receive any proceeds from the sale of Common Shares or Private Placement Warrants by the Holders pursuant to this prospectus. </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The Holders may offer, sell or distribute all or a portion of the securities hereby registered publicly or through private transactions at prevailing market prices or at negotiated prices. We will not receive any of the proceeds from such sales of the Common Shares or Warrants, except with respect to amounts received by us upon the exercise of the Warrants. We will bear all costs, expenses and fees in connection with the registration of these securities, including with regard to compliance with state securities or &#8220;blue sky&#8221; laws. The Holders will bear all commissions and discounts, if any, attributable to their sale of Common Shares or Warrants. See &#8220;Plan of Distribution.&#8221; </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Our Common Shares and Public Warrants are listed on The Nasdaq Global Market under the symbols &#8220;ROIV&#8221; and &#8220;ROIVW,&#8221; respectively. On October 28, 2021, the last reported sale price of our Common Shares was $7.96 per Common Share and the last reported sale price of our Warrants was $1.41 per Warrant. </div></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center;"> <div style="margin: 0pt auto 2pt; width: 21%; text-align: center; line-height: 6pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </div> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"> <div style="text-indent: 5%; font-family: &quot;Times New Roman&quot;; font-size: 12pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">We are an &#8220;emerging growth company&#8221; under federal securities laws and are subject to reduced public company reporting requirements. Investing in our securities involves a high degree of risk. You should review carefully the risks and uncertainties described under the heading &#8220;<a href="#rom164680_5">Risk Factors</a>&#8221; beginning on page 6 of this prospectus, and under similar headings in any amendment or supplements to this prospectus. </div></div></div></div> <div style="text-indent: 4%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Neither the Securities and Exchange Commission nor any state securities commission has approved or disapproved of these securities or passed upon the adequacy or accuracy of this prospectus. Any representation to the contrary is a criminal offense. </div></div></div></div> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt; text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The date of this prospectus is &#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;, 2021. </div></div></div> </div> </div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;;font-weight: bold;"><a href="#toc" style="text-indent: 0px;">Table of Contents</a></div> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"> <div id="toc" style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="text-decoration: underline; letter-spacing: 0px; top: 0px;;display:inline;">TABLE OF CONTENTS</div> </div></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="font-size: 0px;">
<td style="width: 95%;"></td>
<td style="width: 2%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Page</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"><a href="#rom164680_1">About This Prospectus</a></div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">ii</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"><a href="#rom164680_2">Frequently Used Terms</a></div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">iii</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"><a href="#rom164680_3">Cautionary Note Regarding Forward-Looking Statements</a></div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">v</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"><a href="#rom164680_4">Summary of the Prospectus</a></div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">1</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"><a href="#rom164680_5">Risk Factors</a></div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">6</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"><a href="#rom164680_6">Use of Proceeds</a></div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">88</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"><a href="#rom164680_7">Determination of Offering Price</a></div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">89</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"><a href="#rom164680_8">Market Information for Common Stock and Dividend Policy</a></div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">90</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"><a href="#rom164680_9">Unaudited Pro Forma Condensed Combined Financial Information</a></div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">91</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"><a href="#rom164680_10">Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations</a></div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">101</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"><a href="#rom164680_11">Business</a></div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">127</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"><a href="#rom164680_12">Management</a></div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">253</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"><a href="#rom164680_13">Executive and Director Compensation</a></div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">259</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"><a href="#rom164680_14">Certain Relationships and Related Party Transactions</a></div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">275</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"><a href="#rom164680_15">Principal Securityholders</a></div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">281</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"><a href="#rom164680_16">Selling Holders</a></div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">284</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"><a href="#rom164680_17">Description of Securities</a></div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">291</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"><a href="#rom164680_18">Plan of Distribution</a></div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">305</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"><a href="#rom164680_19">Securities Act Restrictions on Resale of Securities</a></div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">308</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"><a href="#rom164680_20">Material United States Tax Considerations</a></div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">310</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"><a href="#rom164680_20a">Material United Kingdom Tax Considerations</a></div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">318</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"><a href="#rom164680_21">Legal Matters</a></div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">320</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"><a href="#rom164680_22">Experts</a></div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">321</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"><a href="#rom164680_23">Where You Can Find More Information</a></div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">322</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"><a href="#rom164680_24">Index To Consolidated Financial Statements</a></div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">F-1</div></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">i </div></div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;;font-weight: bold;"><a href="#toc">Table of Contents</a></div> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"> <div id="rom164680_1" style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">ABOUT THIS PROSPECTUS </div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">This prospectus is part of a registration statement on Form <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">S-1</div> that we filed with the Securities and Exchange Commission (the &#8220;SEC&#8221;) using the &#8220;shelf&#8221; registration process. Under this shelf registration process, the Holders may, from time to time, sell the securities offered by them described in this prospectus. We will not receive any proceeds from the sale by such Holders of the securities offered by them described in this prospectus. This prospectus also relates to the issuance by us of the shares of Common Shares issuable upon the exercise of any Warrants. We will receive proceeds from any exercise of the Warrants for cash. </div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Neither we nor the Holders have authorized anyone to provide you with any information other than that provided in this prospectus, as well as any information incorporated by reference into this prospectus and any applicable prospectus supplement. Neither we nor the Holders can provide any assurance as to the reliability of any other information that others may give you. Neither we nor the Holders are making an offer of these securities in any jurisdiction where the offer is not permitted. You should not assume that the information in this prospectus, any applicable prospectus supplement or any documents incorporated by reference is accurate as of any date other than the date of the applicable document. Since the respective dates of this prospectus and the documents incorporated by reference into this prospectus, our business, financial condition, results of operations and prospects may have changed. </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">We may also provide a prospectus supplement or post-effective amendment to the registration statement to add information to, or update or change information contained in, this prospectus. You should read both this prospectus and any applicable prospectus supplement or post-effective amendment to the registration statement together with the additional information to which we refer you in the sections of this prospectus entitled &#8220;<div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Where You Can Find More Information</div></div>.&#8221; </div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Unless the context indicates otherwise, references in this prospectus to the &#8220;Company,&#8221; &#8220;Roivant,&#8221; &#8220;we,&#8221; &#8220;us,&#8221; &#8220;our&#8221; and similar terms refer to Roivant Sciences Ltd., a Bermuda exempted limited company, and its consolidated subsidiaries. Note that references in this prospectus to Roivant&#8217;s development pipeline, product candidate pipeline or discovery stage pipeline may omit certain programs, product candidates or assets that are not material to Roivant individually or in the aggregate. </div></div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">ii </div></div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;;font-weight: bold;"><a href="#toc">Table of Contents</a></div> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"> <div id="rom164680_2" style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">FREQUENTLY USED TERMS </div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#8220;Business Combination&#8221; means the transactions contemplated by the Business Combination Agreement, pursuant to which Merger Sub merged with and into MAAC, with MAAC surviving the merger. </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#8220;Business Combination Agreement&#8221; means the business combination agreement, dated as of May&#160;1, 2021, as amended, by and among Roivant, MAAC and Merger Sub. </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#8220;Common Shares&#8221; means each Common Share of Roivant, par value $0.0000000341740141 per share. </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#8220;Effective Time&#8221; means the effective time of the closing of the Business Combination. </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#8220;MAAC&#8221; means (x)&#160;prior to the Business Combination, Montes Archimedes Acquisition Corp., a Delaware corporation and (y)&#160;from and after the Business Combination, Roivant Rhine Holdings, Inc. </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#8220;MAAC Class&#160;A Shares&#8221; means each share of Class&#160;A common stock of MAAC, par value $0.0001 per share. </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#8220;MAAC Class&#160;B Shares&#8221; means each share of Class&#160;B common stock of MAAC, par value $0.0001 per share. </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#8220;MAAC Shares&#8221; means, collectively, the MAAC Class&#160;A Shares and the MAAC Class&#160;B Shares. </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#8220;MAAC Sponsor&#8221; means Patient Square Capital LLC. </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#8220;MAAC Warrant&#8221; means each whole warrant of MAAC entitling the holder to purchase one MAAC Class&#160;A Share per warrant at a price of $11.50 per share. </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#8220;Merger Sub&#8221; means Rhine Merger Sub, Inc., a Delaware corporation. </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#8220;Myovant Top-Up Shares&#8221; means common shares of Myovant Sciences Ltd. (&#8220;Myovant&#8221;) subject to the Share Return Agreement, dated as of December 27, 2019, between Roivant and Sumitomo Dainippon Pharma Co., Ltd. For more information, see Roivant&#8217;s Schedule 13D with respect to Myovant filed with the SEC on December 31, 2019. </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#8220;PIPE Financing&#8221; means the sale and issuance to the PIPE Investors of an aggregate of 22,000,000 MAAC Class&#160;A Shares at a purchase price of $10.00 per share, for aggregate gross proceeds of $220,000,000. </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#8220;PIPE Investors&#8221; means those certain institutional and accredited investors that entered into the Subscription Agreements in connection with the PIPE Financing. </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#8220;Private Placement Warrants&#8221; means the 10,214,365 warrants sold simultaneously with the closing of the initial public offering (including through exercise of the over-allotment option) of MAAC at a price of $1.00 to the MAAC Sponsor and then converted into warrants to purchase Common Shares in connection with the closing of the Business Combination. </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#8220;Public Warrants&#8221; means the 20,535,912 warrants sold simultaneously with the closing of the initial public offering of MAAC and then converted into warrants to purchase Common Shares in connection with the closing of the Business Combination. After giving effect to rounding to eliminate fractional warrants in connection with the closing of the Business Combination, there were 20,535,896 Public Warrants outstanding as of September&#160;30, 2021. </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#8220;Public Vants&#8221; means Arbutus Biopharma Corp., Immunovant, Inc. and Sio Gene Therapies, Inc. </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#8220;Sponsor Support Agreement&#8221; means the agreement, dated as of May&#160;1, 2021, as amended by Amendment No.&#160;1, dated as of June&#160;9, 2021 and Amendment No.&#160;2, dated as of September&#160;30, 2021, pursuant to which the MAAC Sponsor agreed to undertake certain actions in support of the Business Combination, including, but not limited to, delivering a voting proxy pursuant to which the MAAC Sponsor voted in favor of the proposals presented for approval herein. </div></div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">iii </div></div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;;font-weight: bold;"><a href="#toc">Table of Contents</a></div> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#8220;Subscription Agreements&#8221; means the subscription agreements entered into by the PIPE Investors providing for the purchase by the PIPE Investors at the Effective Time of an aggregate of 22,000,000 MAAC Class&#160;A Shares at a price per share of $10.00. </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#8220;Roivant&#8221; means Roivant Sciences Ltd., a Bermuda exempted limited company, together with its consolidated subsidiaries, as context requires. </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#8220;Warrants&#8221; means, collectively, the Private Placement Warrants and the Public Warrants. </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#8220;Transactions&#8221; means the Business Combination and the other transactions contemplated by the Business Combination Agreement. </div></div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">iv </div></div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;;font-weight: bold;"><a href="#toc">Table of Contents</a></div> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"> <div id="rom164680_3" style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">CAUTIONARY NOTE REGARDING FORWARD-LOOKING STATEMENTS </div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">This prospectus may contain &#8220;forward-looking statements&#8221; within the meaning of Section&#160;27A of the Securities Act and Section&#160;21E of the Exchange Act. Our forward-looking statements include, but are not limited to, statements regarding our or our management team&#8217;s expectations, hopes, beliefs, intentions or strategies regarding the future, and statements that are not historical facts. In addition, any statements that refer to projections, forecasts or other characterizations of future events or circumstances, including any underlying assumptions, are forward-looking statements. The words &#8220;anticipate,&#8221; &#8220;believe,&#8221; &#8220;continue,&#8221; &#8220;could,&#8221; &#8220;estimate,&#8221; &#8220;expect,&#8221; &#8220;intends,&#8221; &#8220;may,&#8221; &#8220;might,&#8221; &#8220;plan,&#8221; &#8220;possible,&#8221; &#8220;potential,&#8221; &#8220;predict,&#8221; &#8220;project,&#8221; &#8220;should,&#8221; &#8220;would&#8221; and similar expressions may identify forward-looking statements, but the absence of these words does not mean that a statement is not forward-looking. </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The forward-looking statements contained in this prospectus are based on our current expectations and beliefs concerning future developments and their potential effects on us taking into account information currently available to us. There can be no assurance that future developments affecting us will be those that we have anticipated. Should one or more of these risks or uncertainties materialize, they could cause our actual results to differ materially from the forward-looking statements. Some factors that could cause actual results to differ include, but are not limited to risk associated with: </div></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 4%;">&#160;</td>
<td style="width: 4%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">our limited operating history and risks involved in biopharmaceutical product development; </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 4%;">&#160;</td>
<td style="width: 4%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">the fact that we will likely incur significant operating losses for the foreseeable future; </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 4%;">&#160;</td>
<td style="width: 4%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;">the impact of public health outbreaks, epidemics or pandemics (such as the <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">COVID-19</div> pandemic) on our business (including our clinical trials and <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">pre-clinical</div> studies), operations and financial condition and results; </div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 4%;">&#160;</td>
<td style="width: 4%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;">our ability to acquire, <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">in-license</div> or discover new product candidates; </div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 4%;">&#160;</td>
<td style="width: 4%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">our Vant structure and the potential that we may fail to capitalize on certain development opportunities; </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 4%;">&#160;</td>
<td style="width: 4%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;">clinical trials and <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">pre-clinical</div> studies, which are very expensive, time-consuming, difficult to design and implement and involve uncertain outcomes; </div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 4%;">&#160;</td>
<td style="width: 4%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">the unproven nature of our approach to the discovery and development of product candidates from our targeted protein degradation platform; </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 4%;">&#160;</td>
<td style="width: 4%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">the novelty, complexity and difficulty of manufacturing certain of our product candidates, including any manufacturing problems that result in delays in development or commercialization of our product candidates; </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 4%;">&#160;</td>
<td style="width: 4%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">difficulties we may face in enrolling and retaining patients in clinical trials and/or clinical development activities; </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 4%;">&#160;</td>
<td style="width: 4%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">the results of our clinical trials not supporting our proposed claims for a product candidate; </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 4%;">&#160;</td>
<td style="width: 4%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;">changes in interim, <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">top-line</div> and/or preliminary data from our clinical trials changing as more data becoming available or being delayed due to audit and verification process; </div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 4%;">&#160;</td>
<td style="width: 4%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">changes in product manufacturing or formulation that could lead to the incurrence of costs or delays; </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 4%;">&#160;</td>
<td style="width: 4%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">the failure of any third party we contract with to conduct, supervise and monitor our clinical trials to perform in a satisfactory manner or to comply with applicable requirements; </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 4%;">&#160;</td>
<td style="width: 4%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">the fact that obtaining approvals for new drugs is a lengthy, extensive, expensive and unpredictable process that may end with our inability to obtain regulatory approval by the FDA or other regulatory agencies in other jurisdictions; </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 4%;">&#160;</td>
<td style="width: 4%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">the failure of our clinical trials to demonstrate substantial evidence of the safety and efficacy of product candidates, including, but not limited to, scenarios in which our product candidates may cause adverse </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">v </div></div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;;font-weight: bold;"><a href="#toc">Table of Contents</a></div> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;">
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 9%;">&#160;</td>
<td style="vertical-align: top;"> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">effects that could delay regulatory approval, discontinue clinical trials, limit the scope of approval or generally result in negative media coverage of us; </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 4%;">&#160;</td>
<td style="width: 4%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">our inability to obtain regulatory approval for a product candidate in certain jurisdictions, even if we are able to obtain approval in certain other jurisdictions; </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 4%;">&#160;</td>
<td style="width: 4%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">our ability to effectively manage growth and to attract and retain key personnel; </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 4%;">&#160;</td>
<td style="width: 4%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">any business, legal, regulatory, political, operational, financial and economic risks associated with conducting business globally; </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 4%;">&#160;</td>
<td style="width: 4%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">our ability to obtain and maintain patent and other intellectual property protection for our technology and product candidates; </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 4%;">&#160;</td>
<td style="width: 4%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">the inadequacy of patent terms and their scope to protect our competitive position; </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 4%;">&#160;</td>
<td style="width: 4%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;">the failure to issue (or the threatening of their breadth or strength of protection) or provide meaningful exclusivity for our product candidates or any future product candidate of our patent applications that we hold or have <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">in-licensed;</div> </div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 4%;">&#160;</td>
<td style="width: 4%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">the fact that we do not currently and may not in the future own or license any issued composition of matter patents covering certain of our product candidates and our inability to be certain that any of our other issued patents will provide adequate protection for such product candidates; </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 4%;">&#160;</td>
<td style="width: 4%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">the fact that our largest shareholders (and certain members of our management team) own a significant percentage of our stock and will be able to exert significant control over matters subject to shareholder approval; </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 4%;">&#160;</td>
<td style="width: 4%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">the outcome of any legal proceedings that may be instituted against us in connection with the Business Combination and related transactions; </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 4%;">&#160;</td>
<td style="width: 4%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">changes in applicable laws or regulations; </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 4%;">&#160;</td>
<td style="width: 4%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">the possibility that we may be adversely affected by other economic, business and/or competitive factors; and </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 4%;">&#160;</td>
<td style="width: 4%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">other risks and uncertainties, including those described under the heading &#8220;Risk Factors.&#8221; </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">These risks are not exhaustive. New risk factors emerge from time to time and it is not possible for our management to predict all risk factors, nor can we assess the impact of all factors on our business or the extent to which any factor, or combination of factors, may cause actual results to differ materially from those contained in any forward-looking statements. In addition, statements that &#8220;we believe&#8221; and similar statements reflect our beliefs and opinions on the relevant subject. These statements are based upon information available to us as of the date of this prospectus, and while we believe such information forms a reasonable basis for such statements, such information may be limited or incomplete, and our statements should not be read to indicate that we have conducted an exhaustive inquiry into, or review of, all potentially available relevant information. These statements are inherently uncertain and investors are cautioned not to unduly rely upon these statements. Except as required by law, we undertake no obligation to update any forward-looking statements to reflect events or circumstances after the date of such statements. </div></div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">vi </div></div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;;font-weight: bold;"><a href="#toc" style="text-indent: 0px;">Table of Contents</a></div> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"> <div style="border: 1pt solid rgb(0, 0, 0); margin-right: 0px; margin-left: 0px; max-width: 100%;"> <div style="width: 97%; margin-top: 1.5%; margin-right: -1.25%; margin-left: 1.5%;"> <div id="rom164680_4" style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">SUMMARY OF THE PROSPECTUS </div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">This summary highlights selected information appearing elsewhere in this prospectus or the documents incorporated by reference herein. Because it is a summary, it may not contain all of the information that may be important to you. To understand this offering fully, you should read this entire prospectus, the registration statement of which this prospectus is a part and the documents incorporated by reference herein carefully, including the information set forth under the heading &#8220;Risk Factors&#8221; and our financial statements. </div></div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Overview of the Company </div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">We are building the next-generation &#8220;big pharma&#8221; company, organized to harness modern technologies and the entrepreneurial spirit of nimble biotechnology companies at scale. Our mission is to improve the delivery of healthcare to patients by treating every inefficiency as an opportunity. </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">We are a diverse team of experienced drug developers, scientists, physicians, company builders, data scientists and engineers, biopharma investors, physicists and business development professionals dedicated to improving the lives of patients. At Roivant, we combine our team&#8217;s extensive experience and multi-disciplinary expertise with innovative technologies to identify and advance potentially transformative medicines. </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">We deploy a hypothesis-driven approach to identify novel or clinically-validated targets and biological pathways in areas of high unmet medical need. We then seek to acquire, <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">in-license</div> or discover promising drug candidates against those targets or pathways. Our small molecule discovery engine is powered by a unique combination of leading computational physics and machine learning capabilities for <div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">in silico</div></div> drug design. </div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">We develop drug candidates in subsidiary companies we call &#8220;Vants&#8221; with a distinct approach to sourcing talent, aligning incentives and deploying technology. Each of our Vant teams is built with deep relevant expertise to promote successful execution of our development strategy. Our Vants continue to benefit from the support of the Roivant platform and technologies that are built to address inefficiencies in the drug discovery, development and commercialization process. </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Our agile Vant model has allowed us to rapidly add capabilities in diverse therapeutic areas, including immunology, dermatology, hematology and oncology, and modalities, including biologics, topicals, gene therapies and bifunctional small molecules. We currently have 14 Vants and, together, we are advancing a deep and diversified pipeline of over 30 drug candidates. We have launched and taken public multiple Vants, resulting in an aggregate ownership stake of approximately $940&#160;million in the Public Vants (inclusive of the value of the Myovant Top-Up Shares) as of September&#160;30, 2021. The Vant model also enables a modular approach to the monetization of therapies we advance through development, allowing us to pursue commercialization of some products independently, while selectively establishing partnerships for other Vants or divesting of the Vants entirely. </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Since our founding in 2014, we have: </div></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 9%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">conducted nine international Phase 3 trials, the last eight of which have been successful; </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 9%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">consummated a $3&#160;billion upfront partnership with Sumitomo Dainippon Pharma (&#8220;Sumitomo&#8221;); </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 9%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">developed four drugs that received FDA approval after their transfer to Sumitomo; </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 9%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">built a pipeline of over 30 drug candidates ranging from early discovery to registration; </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 9%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;">launched Roivant Discovery, our small molecule discovery engine comprising advanced computational physics and machine learning capabilities, integrated with an <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">in-house</div> wet lab facility; and </div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 9%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">created innovative software tools to optimize each stage of the drug discovery, development and commercialization process. </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> </div> <div style="clear: both;"><br/></div> </div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">1 </div></div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;;font-weight: bold;"><a href="#toc">Table of Contents</a></div> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"> <div style="border: 1pt solid rgb(0, 0, 0); margin-right: 0px; margin-left: 0px; max-width: 100%;"> <div style="margin: 1.5% -1.25% 1.5% 1.5%; width: 97%;"> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">On October&#160;9, 2020, MAAC completed its initial public offering of MAAC Units, consisting of one MAAC Class&#160;A Share and <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">one-half</div> of one MAAC Warrant, with each unit consisting of one share of MAAC&#8217;s Class&#160;A common stock and <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">one-half</div> of one MAAC Warrant, with each whole MAAC Warrant entitling the holder thereof to purchase one share of MAAC&#8217;s Class&#160;A common stock at a price of $11.50 per share. On September&#160;30, 2021, Merger Sub merged with and into MAAC, with MAAC continuing as the surviving company. As a result of such merger and the other Transactions, MAAC became a direct, wholly-owned subsidiary of Roivant under the name &#8220;Roivant Rhine Holdings, Inc.&#8221; </div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">Roivant&#8217;s principal executive office is located at Suite 1, 3rd Floor, <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">11-12</div> St. James&#8217;s Square, London SW1Y 4LB, United Kingdom. </div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Summary Risk Factors </div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">An investment in our Common Shares involves substantial risk. The occurrence of one or more of the events or circumstances described in the section of this prospectus entitled &#8220;Risk Factors,&#8221; alone or in combination with other events or circumstances, may have a material adverse effect on our business, cash flows, financial condition and results of operations. Important factors and risks that could cause actual results to differ materially from those in the forward-looking statements include, among others, the following: </div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt; margin-left: 4%;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Risks Related to Our Business and Industry </div></div></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 9%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Our limited operating history and the inherent uncertainties and risks involved in biopharmaceutical product development may make it difficult for us to execute on our business model and for you to assess our future viability. </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 9%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">We will likely incur significant operating losses for the foreseeable future and may never achieve or maintain profitability. </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 9%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;">The ongoing global pandemic resulting from the outbreak of the novel strain of coronavirus, <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">SARS-CoV-2,</div></div> which causes <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">COVID-19,</div> could adversely impact our business, including our clinical trials and <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">pre-clinical</div> studies. </div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 9%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;">We may not be successful in our efforts to acquire, <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">in-license</div> or discover new product candidates. </div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 9%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Because we have multiple programs and product candidates in our development pipeline and are pursuing a variety of target indications and treatment approaches, we may expend our limited resources to pursue a particular product candidate and fail to capitalize on development opportunities or product candidates that may be more profitable or for which there is a greater likelihood of success. </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 9%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">We face risks associated with the Vant structure. </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 9%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;">Clinical trials and <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">pre-clinical</div> studies are very expensive, time-consuming, difficult to design and implement and involve uncertain outcomes. We may encounter substantial delays in clinical trials, or may not be able to conduct or complete clinical trials or <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">pre-clinical</div> studies on the expected timelines, if at all. </div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 9%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Our approach to the discovery and development of product candidates from our targeted protein degradation platform is unproven, which makes it difficult to predict the time, cost of development and likelihood of successfully developing any product candidates from this platform. </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 9%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;">We may not be successful in our efforts to acquire, <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">in-license</div> or discover new product candidates. </div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 9%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Certain of our product candidates, including our gene therapy product candidates, are novel, complex and difficult to manufacture. </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> </div> </div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">2 </div></div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;;font-weight: bold;"><a href="#toc">Table of Contents</a></div> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"> <div style="border: 1pt solid rgb(0, 0, 0); margin-right: 0px; margin-left: 0px; max-width: 100%;"> <div style="margin: 1.5% -1.25% 1.5% 1.5%; width: 97%;">
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 9%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Obtaining approval of a new drug is an extensive, lengthy, expensive and inherently uncertain process, and the FDA or another regulator may delay, limit or deny approval. </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 9%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Our clinical trials may fail to demonstrate substantial evidence of the safety and efficacy of product candidates that we may identify and pursue for their intended uses, which would prevent, delay or limit the scope of regulatory approval and commercialization. </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 9%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Our product candidates may cause adverse effects or have other properties that could delay or prevent their regulatory approval, cause us to suspend or discontinue clinical trials, abandon further development or limit the scope of any approved label or market acceptance. </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 9%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">We depend on the knowledge and skills of our senior leaders, and may not be able to manage our business effectively if we are unable to attract and retain key personnel. </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 9%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Changes in funding for, or disruptions to the operations of, the FDA, the SEC and other government agencies could hinder their ability to hire and retain key leadership and other personnel, prevent new products and services from being developed or commercialized in a timely manner or otherwise prevent those agencies from performing normal functions on which the operation of our business may rely, which could negatively impact our business. </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 9%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">We will need to expand our organization and may experience difficulties in managing this growth, which could disrupt operations. </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 9%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">If we are unable to obtain and maintain patent and other intellectual property protection for our technology and product candidates or if the scope of the intellectual property protection obtained is not sufficiently broad, we may not be able to compete effectively in our markets. </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 9%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;">If the patent applications we hold or have <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">in-licensed</div> with respect to our product candidates fail to issue, if their breadth or strength of protection is threatened, or if they fail to provide meaningful exclusivity for our product candidates or any future product candidate, it could dissuade companies from collaborating with us to develop product candidates, and threaten our ability to commercialize, future drugs. </div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 9%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Patent terms and their scope may be inadequate to protect our competitive position on current and future product candidates for an adequate amount of time. </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt; margin-left: 4%;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Risks Related to Our Securities, Our Jurisdiction of Incorporation and Certain Tax Matters </div></div></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 9%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The listing of our securities on Nasdaq did not benefit from the process undertaken in connection with an underwritten initial public offering. </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 9%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">If our performance does not meet market expectations, the price of our securities may decline. </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 9%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">We have and will continue to incur increased costs as a result of operating as a public company and our management has and will continue to devote a substantial amount of time to new compliance initiatives. </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 9%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Our failure to timely and effectively implement controls and procedures required by Section&#160;404(a) of the Sarbanes-Oxley Act that will be applicable to us after the Business Combination is consummated could have a material adverse effect on our business. </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 9%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;">Anti-takeover provisions in our memorandum of association, <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">bye-laws</div> and Bermuda law could delay or prevent a change in control, limit the price investors may be willing to pay in the future for our Common Shares and could entrench management. </div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 9%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Our largest shareholders and certain members of our management own a significant percentage of our Common Shares and will be able to exert significant control over matters subject to shareholder approval. </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> </div> </div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">3 </div></div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;;font-weight: bold;"><a href="#toc">Table of Contents</a></div> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"> <div style="border: 1pt solid rgb(0, 0, 0); margin-right: 0px; margin-left: 0px; max-width: 100%;"> <div style="width: 97%; margin-top: 1.5%; margin-right: -1.25%; margin-left: 1.5%;"> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">THE OFFERING </div></div></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="vertical-align: top;">
<td style="width: 38%;"> <div style="text-indent: -2%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 1pt; margin-left: 2%; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Issuer </div></div> </td>
<td>Roivant Sciences Ltd. </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 10pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Issuance of Common Shares </div></div></div> <div style="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="vertical-align: top;">
<td style="width: 38%;"> <div style="text-indent: -2%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 1pt; margin-left: 7%; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Common Shares offered by the Company </div></div> </td>
<td>Up to 30,750,261 Common Shares, consisting of (i) 20,535,896 Common Shares issuable upon exercise of the Public Warrants and (ii) 10,214,365 Common Shares issuable upon the exercise of the Private Placement Warrants. </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="vertical-align: top;">
<td style="width: 38%;"> <div style="text-indent: -2%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 1pt; margin-left: 7%; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Common Shares outstanding prior to exercise of all Warrants </div></div> </td>
<td>684,789,169 Common Shares (as of September&#160;30, 2021) (including Common Shares underlying vested restricted share awards). </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="vertical-align: top;">
<td style="width: 38%;"> <div style="text-indent: -2%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 1pt; margin-left: 7%; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Common Shares outstanding assuming exercise of all Warrants </div></div> </td>
<td>715,539,430 Common Shares (based on the number of Common Shares outstanding as of September&#160;30, 2021) (including Common Shares underlying vested restricted share awards). </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="vertical-align: top;">
<td style="width: 38%;"> <div style="text-indent: -2%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 1pt; margin-left: 7%; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Use of Proceeds </div></div> </td>
<td>We will receive up to an aggregate of approximately $353.6&#160;million from the exercise of the Warrants, assuming the exercise in full of all of the Warrants for cash. We expect to use any such net proceeds from the exercise of the Warrants for general corporate purposes. See &#8220;Use of Proceeds.&#8221; </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 10pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Resale of Common Shares and Warrants </div></div></div> <div style="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="vertical-align: top;">
<td style="width: 38%;"> <div style="text-indent: -2%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 1pt; margin-left: 7%; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Common Shares offered by the Holders </div></div> </td>
<td>Up to 595,134,445 Common Shares, consisting of (i) 22,000,000 Common Shares issued in the PIPE Financing, (ii)&#160;up to 10,214,365 Common Shares issuable upon exercise of the Private Placement Warrants and (iii) 562,920,080 issued and outstanding Common Shares held by certain Holders (including Common Shares underlying vested restricted share awards). </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="vertical-align: top;">
<td style="width: 38%;"> <div style="text-indent: -2%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 1pt; margin-left: 7%; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Warrants offered by the Holders </div></div> </td>
<td>Up to 10,214,365 Private Placement Warrants. </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="vertical-align: top;">
<td style="width: 38%;"> <div style="text-indent: -2%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 1pt; margin-left: 7%; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Redemption </div></div> </td>
<td>The Warrants are redeemable in certain circumstances. See the section entitled &#8220;Description of Securities&#8212;Warrants&#8221; for further discussion. </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="vertical-align: top;">
<td style="width: 38%;"> <div style="text-indent: -2%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 1pt; margin-left: 7%; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Use of Proceeds </div></div> </td>
<td>We will not receive any proceeds from any sale of Common Shares by the Holders. See &#8220;Use of Proceeds.&#8221; </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="vertical-align: top;">
<td style="width: 38%;"> <div style="text-indent: -2%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 1pt; margin-left: 7%; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Redemption </div></div> </td>
<td>The Warrants are redeemable in certain circumstances. See &#8220;Description of Securities&#8212;Redeemable Warrants&#8221; for further discussion. </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="vertical-align: top;">
<td style="width: 38%;"> <div style="text-indent: -2%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 1pt; margin-left: 7%; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Market for Common Shares and Warrants </div></div> </td>
<td>The Common Shares and Public Warrants are currently traded on The Nasdaq Global Market under the symbols &#8220;ROIV&#8221; and &#8220;ROIVW,&#8221; respectively. </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> </div> <div style="clear: both;"><br/></div> </div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">4 </div></div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;;font-weight: bold;"><a href="#toc">Table of Contents</a></div> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"> <div style="border: 1pt solid rgb(0, 0, 0); margin-right: 0px; margin-left: 0px; max-width: 100%;"> <div style="margin: 1.5% -1.25% 1.5% 1.5%; width: 97%;">
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="vertical-align: top;">
<td style="width: 38%;"> <div style="text-indent: -2%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 1pt; margin-left: 2%; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Risk Factors </div></div> </td>
<td>See &#8220;<div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Risk Factors</div></div>&#8221; and other information included in this prospectus for a discussion of factors you should consider before investing in our securities. </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">For additional information concerning the offering, see &#8220;Plan of Distribution.&#8221; </div></div> </div> </div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">5 </div></div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;;font-weight: bold;"><a href="#toc">Table of Contents</a></div> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"> <div id="rom164680_5" style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">RISK FACTORS </div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Our business involves a high degree of risk. You should carefully consider the risks described below, together with the other information contained in this prospectus, including our condensed consolidated financial statements and the related notes appearing elsewhere in this prospectus, as well as the risks, uncertainties and other information set forth in the reports and other materials filed or furnished by us and our majority-controlled subsidiary, Immunovant, Inc. (&#8220;Immunovant&#8221;), with the SEC. We cannot assure you that any of the events discussed in the risk factors below will not occur. These risks could have a material and adverse impact on our business, prospects, results of operations, financial condition and cash flows. If any such events were to happen, the trading shares of our Common Shares could decline, and you could lose all or part of your investment. </div></div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Risks Related to Our Business and Industry </div></div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Risks Related to Our Financial Position and Strategy </div></div></div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Our limited operating history and the inherent uncertainties and risks involved in biopharmaceutical product development may make it difficult for us to execute on our business model and for you to assess our future viability. We have never generated product revenue from the commercialization of our drug product candidates, and there is no guarantee that we will do so in the future. </div></div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">We are a biopharmaceutical and healthcare technology company with a limited operating history upon which you can evaluate our business and prospects. We were formed in April 2014, and our operations to date have been limited to acquiring or <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">in-licensing</div> product candidates or developing technologies for the discovery, development, and commercialization of product candidates, starting or acquiring subsidiary businesses, which we refer to as the Vants, in which to house those product candidates or technologies, and hiring management teams to operate the Vants and oversee the development of our product candidates and technologies. </div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Our ability to execute on our business model and generate revenues depends on a number of factors including our ability to: </div></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 4%;">&#160;</td>
<td style="width: 4%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;">identify new acquisition or <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">in-licensing</div> opportunities; </div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 4%;">&#160;</td>
<td style="width: 4%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;">successfully identify new product candidates through our computational discovery and targeted protein degradation platforms and advance those product candidates into <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">pre-clinical</div> studies and clinical trials; </div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 4%;">&#160;</td>
<td style="width: 4%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;">successfully complete ongoing <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">pre-clinical</div> studies and clinical trials and obtain regulatory approvals for our current and future product candidates; </div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 4%;">&#160;</td>
<td style="width: 4%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">successfully market our healthcare technology products and services; </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 4%;">&#160;</td>
<td style="width: 4%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">raise additional funds when needed and on terms acceptable to us; </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 4%;">&#160;</td>
<td style="width: 4%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">attract and retain experienced management and advisory teams; </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 4%;">&#160;</td>
<td style="width: 4%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;">add operational, financial and management information systems and personnel, including personnel to support clinical, <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">pre-clinical</div> manufacturing and planned future commercialization efforts and operations; </div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 4%;">&#160;</td>
<td style="width: 4%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">launch commercial sales of product candidates, whether alone or in collaboration with others, including establishing sales, marketing and distribution systems; </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 4%;">&#160;</td>
<td style="width: 4%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">initiate and continue relationships with third-party suppliers and manufacturers and have commercial quantities of product candidates manufactured at acceptable cost and quality levels and in compliance with the U.S. Food and Drug Administration (the &#8220;FDA&#8221;) and other regulatory requirements; </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 4%;">&#160;</td>
<td style="width: 4%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">set acceptable prices for product candidates and obtain coverage and adequate reimbursement from third-party payors; </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">6 </div></div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;;font-weight: bold;"><a href="#toc">Table of Contents</a></div> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;">
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 4%;">&#160;</td>
<td style="width: 4%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">achieve market acceptance of product candidates in the medical community and with third-party payors and consumers; and </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 4%;">&#160;</td>
<td style="width: 4%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">maintain, expand and protect our intellectual property portfolio. </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">If we cannot successfully execute any one of the foregoing, our business may not succeed and the price of our Common Shares may be negatively impacted. </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">Biopharmaceutical product development, which represents the core of our business model, is a highly speculative undertaking and involves a significant degree of risk. Our product candidates will require substantial development time &#8211; including extensive clinical, and in some cases <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">pre-clinical,</div> research and development &#8211; and resources before we would be able to apply for or receive applicable regulatory approvals and begin generating revenue from product sales. </div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">We have not yet demonstrated an ability to successfully acquire regulatory clearance or approval, develop or manufacture a commercial scale product, or arrange for a third-party to do so on our behalf, or conduct sales and marketing activities necessary for successful biopharmaceutical product commercialization. We have generated minimal revenues to date, and no revenues from the commercialization of our drug product candidates. Consequently, we have limited operations upon which to evaluate our business and predictions about our future success or viability may not be as accurate as they could be if we had a longer operating history or a history of successfully developing and commercializing biopharmaceutical product candidates. </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">Because of the numerous risks and uncertainties associated with biopharmaceutical product development, we are unable to predict the timing or amount of increased expenses, or when we will be able to generate any meaningful revenue or achieve or maintain profitability, if ever. Our expenses could increase beyond expectations if we are required by the FDA or comparable <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-U.S.</div> regulatory authorities to perform studies or clinical trials in addition to those that are currently anticipated or to otherwise provide data beyond that which we currently believe is necessary to support an application for marketing approval or to continue clinical development, or if there are any delays in any of our or our future collaborators&#8217; clinical trials or the development of our product candidates that we may identify. Even if a product is approved for commercial sale, we could incur significant costs associated with the commercial launch of any such product. </div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">We may never be able to develop or commercialize a marketable drug or achieve profitability. Revenue from the sale of any product candidate for which regulatory approval is obtained will be dependent, in part, upon the size of the markets in the territories for which we gain regulatory approval, the accepted price for the product, the ability to obtain reimbursement at any price, the strength and term of patent exclusivity for the product, the competitive landscape of the product market, and whether we own the commercial rights for that territory. Even if we achieve profitability in the future, we may not be able to sustain profitability in subsequent periods. Our failure to achieve sustained profitability would depress the value of our company and could impair our ability to raise capital, expand our business, expand our pipeline, market our product candidates, if approved, and pursue or continue our operations. Our prior losses, combined with expected future losses, have had and will continue to have an adverse effect on our shareholders&#8217; equity and working capital. </div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">We will likely incur significant operating losses for the foreseeable future and may never achieve or maintain profitability. </div></div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Investment in biopharmaceutical product development is highly speculative because it entails substantial upfront capital expenditures and significant risk that a product candidate will fail to gain regulatory approval or become commercially viable. None of our current product candidates has received marketing approval anywhere in the world and we have not generated any product revenues from the commercial sale of our biopharmaceutical products. We cannot estimate with precision the extent of our future losses. We may never generate product revenue from the commercial sales of our product candidates or achieve profitability. </div></div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">7 </div></div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;;font-weight: bold;"><a href="#toc">Table of Contents</a></div> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">We expect to continue to incur substantial operating losses through the projected commercialization of our product candidates. Our ability to generate product revenue and achieve profitability is dependent on the ability to complete the development of our product candidates, obtain necessary regulatory approvals and manufacture and successfully market product candidates alone or in collaboration with others. </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">If we do successfully obtain regulatory approval to market product candidates, our revenue will be dependent upon, in part and among other things, the size of the markets in the territories for which we gain regulatory approval, the number of competitors in such markets, the accepted price for product candidates and whether we own the commercial rights for those territories. If the indication approved by regulatory authorities is narrower than expected, or the treatment population is narrowed by competition, physician choice or treatment guidelines, we may not generate significant revenue from sales of our product candidates, even if approved. We cannot assure you that we will be profitable even if we successfully commercialize our product candidates. </div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">The ongoing global pandemic resulting from the outbreak of the novel strain of coronavirus, <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">SARS-CoV-2,</div></div> which causes <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">COVID-19,</div> could adversely impact our business, including our clinical trials and <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">pre-clinical</div> studies. </div></div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;">Public health crises such as pandemics or similar outbreaks could adversely impact our business. In December 2019, a novel strain of coronavirus, <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">SARS-CoV-2,</div></div> which causes <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">COVID-19,</div> emerged. <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">COVID-19</div> has since spread globally, including to the countries in which we and our other business partners conduct business. Governments in affected regions have implemented, and may continue to implement or <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">re-implement,</div> safety precautions, including quarantines, travel restrictions, business closures, cancellations of public gatherings and other measures they deem necessary. Like many other organizations and individuals, we and our employees have taken additional steps to avoid or reduce infection, including limiting travel and implementing remote work arrangements. We will continue to actively monitor the situation and may take further actions that could alter our business operations as may be required by national, state or local authorities, or that we determine are in the best interests of our employees and shareholders. </div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">As a result of the <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">COVID-19</div> pandemic and policy responses to it, in April and May 2020 we initially observed a decrease in both patient screening and patient enrollment in certain of our ongoing clinical trials. Patient screening and the number of patients eligible for enrollment in our clinical trials has since returned to expected levels. However, some of our development programs have been delayed. Together with our investigators and clinical sites, we continue to assess the impact of the coronavirus pandemic on enrollment and the ability to maintain patients enrolled in our clinical trials and the corresponding impact on the timing of the completion of our ongoing clinical trials. We have experienced, or may in the future experience, disruptions as a result of <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">COVID-19</div> or future pandemics that severely impact our business, clinical trials and <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">pre-clinical</div> studies, including: </div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">delays or difficulties in enrolling patients in our clinical trials, and the consequences of such delays or difficulties, including terminating clinical trials prematurely; </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">delays or difficulties in clinical site initiation, including difficulties in recruiting clinical site investigators and clinical site staff; </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;">delays or disruptions in <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-clinical</div> experiments due to unforeseen circumstances at contract research organizations (&#8220;CROs&#8221;), and vendors along their supply chain; </div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;">increased rates of patients withdrawing from our clinical trials following enrollment as a result of contracting <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">COVID-19,</div> being forced to quarantine or not accepting home health visits; </div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">diversion of healthcare resources away from the conduct of clinical trials, including the diversion of hospitals serving as our clinical trial sites and hospital staff supporting the conduct of our clinical trials; </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">interruption of key clinical trial activities, such as clinical trial site data monitoring, due to limitations on travel imposed or recommended by federal or state governments, employers and others or </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">8 </div></div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;;font-weight: bold;"><a href="#toc">Table of Contents</a></div> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;">
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 9%;">&#160;</td>
<td style="vertical-align: top;"> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;">interruption of clinical trial subject visits and study procedures (particularly any procedures that may be deemed <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-essential),</div> which may impact the integrity of subject data and clinical study endpoints; </div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;">interruption or delays in the operations of the FDA and comparable <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-U.S.</div> regulatory agencies, which may impact review and approval timelines; </div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">interruption of, or delays in receiving, supplies of our product candidates from our contract manufacturing organizations due to staffing shortages, production slowdowns or stoppages and disruptions in delivery systems; </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;">limitations on employee resources that would otherwise be focused on the conduct of our clinical trials and <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">pre-clinical</div> studies, including because of sickness of employees or their families, the desire of employees to avoid contact with large groups of people, an increased reliance on working from home or mass transit disruptions; </div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">other disruptions to our business generally, including from the transition to remote working for the majority of our employees and the implementation of new health and safety requirements for our employees; and </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">waiver or suspension of patent or other intellectual property rights. </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">These and other factors arising from the <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">COVID-19</div> pandemic, including risks relating to the emergence of the delta variant and other new variants, the efficacy and availability of vaccines and rates of vaccination, the pandemic worsening in countries that are already afflicted with <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">COVID-19</div> or the <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">COVID-19</div> pandemic continuing to spread to additional countries or returning to countries where the pandemic has been partially contained, could further adversely impact our ability to conduct clinical trials and our business generally, and could have a material adverse impact on our operations and financial condition and results. </div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">We are continuing to monitor potential delays or other impacts on our business, our clinical trials, healthcare systems and the global economy as a whole. These effects could have a material impact on our business, operations and financial results. </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">To the extent the <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">COVID-19</div> pandemic adversely affects our business, operations and financial results, it may also have the effect of heightening many of the other risks described elsewhere, such as those relating to our clinical development operations, the supply chain for our ongoing and planned clinical trials and our ability to seek and receive regulatory approvals for our product candidates. </div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">We may not be successful in our efforts to acquire, <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">in-license</div> or discover new product candidates. </div></div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;">The success of our business is highly dependent on our ability to successfully identify new product candidates, whether through acquisitions or <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">in-licensing</div> transactions, or through our internal discovery capabilities. Our acquisition and <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">in-licensing</div> efforts focus on identifying assets in development by third parties across a diverse range of therapeutic areas that, in our view, are underutilized or undervalued. Our strategy often entails designing <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">low-cost</div> studies that result in quick <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">&#8220;go/no-go&#8221;</div> decisions when deciding whether or how to proceed with future development for a given asset, once acquired. We may decide to proceed with the development of a drug candidate on this basis and later determine that the more costly and time intensive trials do not support the initial value the product was thought to hold. Even if a product candidate does prove to be valuable, its value may be less than anticipated at the time of investment. We may also face competition for attractive investment opportunities. A number of entities compete with us for such opportunities, many of which have considerably greater financial and technical resources. If we are unable to identify a sufficient number of such product candidates, or if the product candidates that we identify do not prove to be as valuable as anticipated, we will not be able to generate returns and implement our investment strategy and our business and results of operations may suffer materially. </div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Our drug discovery efforts are centered on our targeted protein degradation platform and our computational discovery technology. As a company we have relatively limited experience in drug discovery generally, with </div></div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">9 </div></div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;;font-weight: bold;"><a href="#toc">Table of Contents</a></div> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">targeted protein degradation as an approach to target inhibition and with computational discovery as a technology. Our future success depends, in part, on our ability to successfully use targeted protein degradation and computational discovery technology to identify promising new product candidates. </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Very few small molecule product candidates using targeted protein degradation, such as the product candidates which may be generated by our targeted protein degradation platform, have been tested in humans and none has been approved in the United States or Europe. The data underlying the feasibility of developing therapeutic products based on protein degradation technology is both preliminary and limited. We have not yet succeeded and may not succeed in advancing any product candidates developed using our targeted protein degradation platform into clinical trials, demonstrating the efficacy and safety of such product candidates or obtain marketing approval thereafter. As a result, it is difficult to predict the time and cost of protein degrader product candidate development and we cannot predict whether the application of our targeted protein degradation platform will result in the development and marketing approval of any products. Any problems we experience in the future related to this platform or any of our related development programs may cause significant delays or unanticipated costs or may prevent the development of a commercially viable product. Any of these factors may prevent us from completing our preclinical studies or any clinical trials that we may initiate or commercializing any internally discovered product candidates we may develop on a timely or profitable basis, if at all. </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Although we believe that our computational discovery platform has the potential to identify more promising molecules than traditional research methods and to accelerate drug discovery efforts, our focus on using our platform technology to discover and design molecules with therapeutic potential may not result in the discovery and development of commercially viable products for us. Computational discovery is a relatively new approach to drug development. As an organization, we have not yet developed any product candidates using this technology that have advanced into clinical trials and we may fail to identify potential product candidates for clinical development. Even if we are able to advance product candidates identified through our computational discovery platform into clinical trials, those trials may not be successful in demonstrating the efficacy and safety of such product candidates and, as a result, we may not be able to obtain regulatory approvals for those product candidates. </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">Any such failure to <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">in-license</div> or acquire new product candidates from third parties, or to discover new product candidates using our targeted protein degradation or computational discovery platforms would have a material adverse effect on our business, financial condition, results of operations and prospects. </div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Because we have multiple programs and product candidates in our development pipeline and are pursuing a variety of target indications and treatment approaches, we may expend our limited resources to pursue a particular product candidate and fail to capitalize on development opportunities or product candidates that may be more profitable or for which there is a greater likelihood of success. </div></div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">We have limited financial and management resources. As a result, we may forego or delay pursuit of opportunities with potential target indications or product candidates that later prove to have greater commercial potential than our current and planned development programs and product candidates. Our resource allocation decisions may cause us to fail to capitalize on viable commercial product candidates or profitable market opportunities. Our spending on current and future research and development programs and other future product candidates for specific indications may not yield any commercially viable future product candidates. If we do not accurately evaluate the commercial potential or target market for a particular product candidate, we may be required to relinquish valuable rights to that product candidate through collaboration, licensing or other royalty arrangements in cases in which it would have been more advantageous for us to retain sole development and commercialization rights to such future product candidates. </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">Additionally, we may pursue additional <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">in-licenses</div> or acquisitions of product candidates or programs, which entails additional risk to us. Identifying, selecting and acquiring promising product candidates requires substantial technical, financial and human resources expertise. Efforts to do so may not result in the actual </div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">10 </div></div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;;font-weight: bold;"><a href="#toc" style="text-indent: 0px;">Table of Contents</a></div> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">acquisition or license of a successful product candidate, potentially resulting in a diversion of our management&#8217;s time and the expenditure of our resources with no resulting benefit. For example, if we are unable to identify programs that ultimately result in approved products, we may spend material amounts of our capital and other resources evaluating, acquiring and developing products that ultimately do not provide a return on our investment. </div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">We face risks associated with the Vant structure. </div></div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">We develop our product candidates in the Vants, which operate similarly to independent biopharmaceutical companies. While we believe that there are significant competitive advantages to this structure, as compared to traditional pharmaceutical companies or smaller biopharma companies, the Vant structure also poses certain risks for our business. </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">Operating the Vants independently, rather than under a centralized, consolidated management team, may result in increased costs at the Vants, as certain functions or processes, including clinical and <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-clinical</div> personnel, business development, finance, accounting, human resources and legal functions, are replicated across the Vants. There may also be certain <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">start-up</div> costs, associated with the establishment of a new Vant or integration of a newly acquired business into a Vant, which are greater under the Vant model than they would be under a centralized model. The use of the Vant model may also entail increased costs for us, including the time and expenses associated with hiring Vant CEOs and management teams, overseeing Vant equity incentive arrangements and managing compliance-related risks, including the internal controls, reporting systems and procedures necessary for us to operate as a public company. We may also be exposed to increased &#8220;key employee&#8221; risks, in the event a Vant CEO were to depart, including the loss of other senior Vant personnel, potentially resulting in significant delays to the development programs at the Vant. These increased expenses, complexities and other challenges may make using and scaling the Vant model more challenging and costly than it would be for a traditional pharmaceutical company to both operate and expand the number of product candidates under development, which could have a material adverse effect on our consolidated business, financial condition, results of operations or prospects. This decentralized model could also make compliance with applicable laws and regulations more challenging to monitor and may expose us to increased costs that could, in turn, harm our business, financial condition, results of operations or prospects. </div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">In addition, a single or limited number of the Vants may, now or in the future, comprise a large proportion of our value. Similarly, a large proportion of our consolidated revenues may in the future be derived from one or a small number of Vants. Any adverse development at those Vants, including the termination of a key license agreement or other loss of the intellectual property underlying a product candidate or the failure of a clinical trial for a product candidate under development at the Vant, could have a material adverse effect on our consolidated business, financial condition, results of operations or prospects. </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">We manage the Vants in part through our designees who serve on the Vant boards of directors. In their capacities as directors, those individuals owe fiduciary duties to the Vants and their shareholders under applicable law, which may at times require them to take actions that are not directly in our interest. To the extent any such actions have an adverse effect on the value of our ownership interest in the Vant, it could further adversely impact our consolidated business, financial condition, results of operations or prospects. </div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Our business may suffer reputational harm due to failures of our product candidates. </div></div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The failure of any of our product candidates could have a lasting negative impact on our reputation, which could, in turn, impact our ability to successfully enter into future licensing arrangements or other transactions with potential counterparties, raise future capital or attract key personnel to join us. As a result, our business and prospects would be materially harmed and our results of operations and financial condition would likely suffer materially. </div></div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">11 </div></div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;;font-weight: bold;"><a href="#toc">Table of Contents</a></div> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">We face risks associated with potential future payments related to our product candidates. </div></div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;">Our model for asset <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">in-licensing</div> transactions typically involves a low upfront payment combined with milestone and royalty payments contingent upon the achievement of certain future development and commercial events. These arrangements generally involve a payment or payments upon certain regulatory milestones, including regulatory approval, and then upon achieving specified levels of sales, with ongoing royalty payments which can extend for up to the life of a product. These payments may become due before a product is generating revenues, in which case we may not have sufficient funds available to meet our obligations. If this were to occur, we would default on our payment obligations and could face penalties, delays in development or reputational damage. Even if a product is commercialized and generating revenue, payments could become due that are so large that the investment is not profitable or is less profitable than anticipated. For example, this could occur if at the time of the initial investment, we overestimated the value of the product and agreed to a payment schedule using these inflated estimates. If we are unable to make milestone and royalty payments related to our product candidates when due, our business and prospects could suffer. </div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Our investment strategy and future growth relies on a number of assumptions, some or all which may not be realized. </div></div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Our investment strategy and plans for future growth rely on a number of assumptions, including, in the case of our biopharmaceutical product candidates, assumptions related to adoption of a particular therapy, incidence of an indication, use of a product candidate versus competitor therapies and size of patient populations. Some or all of these assumptions may be incorrect. We cannot accurately predict whether our product candidates will achieve significant market acceptance in line with these assumptions or whether there will be a market for our product candidates that reaches that which is anticipated. If any of these assumptions are incorrect or overstated, our results and future prospects will be materially and adversely affected. </div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">If we enter into acquisitions or strategic partnerships, this may increase our capital requirements, dilute our shareholders, cause us to incur debt or assume contingent liabilities and subject us to other risks. </div></div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">We may engage in various acquisitions and strategic partnerships in the future, including licensing or acquiring new product candidates, intellectual property rights, technologies or businesses. Any acquisition or strategic partnership may entail numerous risks, including: </div></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 4%;">&#160;</td>
<td style="width: 4%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">increased operating expenses and cash requirements; </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 4%;">&#160;</td>
<td style="width: 4%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">the assumption of indebtedness or contingent liabilities; </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 4%;">&#160;</td>
<td style="width: 4%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">the issuance of our or our subsidiaries&#8217; equity securities which would result in dilution to our shareholders; </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 4%;">&#160;</td>
<td style="width: 4%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">assimilation of operations, intellectual property, products and product candidates of an acquired company, including difficulties associated with integrating new personnel; </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 4%;">&#160;</td>
<td style="width: 4%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">the diversion of our management&#8217;s attention from our existing product programs and initiatives in pursuing such an acquisition or strategic partnership; </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 4%;">&#160;</td>
<td style="width: 4%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">retention of key employees, the loss of key personnel and uncertainties in our ability to maintain key business relationships; </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 4%;">&#160;</td>
<td style="width: 4%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">risks and uncertainties associated with the other party to such a transaction, including the prospects of that party and their existing products or product candidates, intellectual property, and regulatory approvals; and </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 4%;">&#160;</td>
<td style="width: 4%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">our inability to generate revenue from acquired intellectual property, technology and/or products sufficient to meet our objectives or even to offset the associated transaction and maintenance costs. </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">12 </div></div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;;font-weight: bold;"><a href="#toc">Table of Contents</a></div> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">In addition, if we undertake such a transaction, we may issue dilutive securities, assume or incur debt obligations, incur large <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">one-time</div> expenses and acquire intangible assets that could result in significant future amortization expense. </div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">We face risks associated with our ongoing strategic alliance with Sumitomo Dainippon Pharma Co., Ltd. (&#8220;Sumitomo&#8221;), as well as other acquisitions, partnerships, alliances or strategic transactions we may undertake in the future. </div></div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">In December 2019, we and Sumitomo completed various transactions in connection with the formation of a strategic alliance between the companies, including (i)&#160;Sumitomo indirectly acquiring from us our controlling equity interests in five affiliates, (ii)&#160;our granting Sumitomo options to purchase, subject to certain exceptions, our existing equity interests in six other privately-held affiliates of ours, (iii)&#160;our granting Sumitomo access to key elements of our proprietary technology platforms and (iv)&#160;issuing our Common Shares to Sumitomo. In exchange, Sumitomo made a $3.0&#160;billion upfront cash payment to us upon the closing of the transactions. </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">We face a number of risks in connection with our transactions with Sumitomo, including, but not limited to: </div></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 4%;">&#160;</td>
<td style="width: 4%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">diversion of management time and focus away from operating our business; </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 4%;">&#160;</td>
<td style="width: 4%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">reliance on certain employees of the alliance with Sumitomo who will continue to provide key services for us, including information technology services; </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 4%;">&#160;</td>
<td style="width: 4%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">changes in relationships with strategic partners as a result of product acquisitions or strategic positioning resulting from these transactions; </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 4%;">&#160;</td>
<td style="width: 4%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">risks arising from technological and data platforms shared between us and the alliance with Sumitomo, such as DrugOme<div style="font-size: 85%; vertical-align: top;;display:inline;;font-size:9.4px">&#174;</div>, including data or other security breaches at Sumitomo or its affiliates that could, in turn, impact us, or disputes over ownership of intellectual property between us and the alliance with Sumitomo, which could impact our access to those platforms; </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 4%;">&#160;</td>
<td style="width: 4%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-competition</div> obligations arising from the formation of the alliance with Sumitomo; </div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 4%;">&#160;</td>
<td style="width: 4%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">coordination of research and development efforts; and </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 4%;">&#160;</td>
<td style="width: 4%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">litigation or other claims, including claims from terminated employees, customers, former shareholders or other third parties. </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">We may also face similar risks in connection with any other mergers, acquisitions, divestitures or strategic alliances that we have undertaken in the past or may undertake in the future, including our acquisition of Oncopia Therapeutics, which closed in November 2020, and of Silicon Therapeutics, which closed in March 2021. If we acquire businesses with promising technologies, we may not be able to realize the benefits of acquiring such businesses, including any anticipated synergies between the acquired business and our existing business, if we are unable to successfully integrate them with our existing operations, technology and company culture. </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">In addition, any such mergers, acquisitions, divestitures or strategic alliances may be complex, time consuming and expensive to execute and may be subject to regulatory requirements that could impact our business. There can be no guarantee that we will be able to successfully consummate such acquisitions or other transactions, which could result in a significant diversion of management and other employee time, as well as substantial <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">out-of-pocket</div></div> costs. </div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">If any acquisitions or other transactions are not completed for any reason, we may incur significant costs and the market price of our Common Shares may decline. In addition, even if an acquisition is consummated, the integration of the acquired business, product or other assets into our Company may be complex and time-consuming, and we may not achieve the anticipated benefits, cost-savings or growth opportunities we expect. Potential difficulties that may be encountered in the integration process include the following: integrating </div></div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">13 </div></div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;;font-weight: bold;"><a href="#toc">Table of Contents</a></div> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">personnel, operations and systems; coordinating geographically dispersed organizations; distracting management and employees from current operations; maintaining the existing business relationships of the acquired company; and managing inefficiencies associated with integrating the operations of the Company and the acquired business, product or other assets. For biopharmaceutical businesses we have acquired or may acquire in the future, or alliances or joint ventures in the biopharmaceutical industry, we may encounter numerous difficulties in developing, manufacturing and marketing any new drugs related to such businesses, which may delay or prevent us from realizing the expected benefits or enhancing our business. We cannot assure you that, following any such acquisition, alliance or partnership, we will achieve the expected synergies to justify the transaction. </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Our failure to address these risks or other problems encountered in connection with the strategic alliance with Sumitomo, or other past or future acquisitions, partnerships or strategic alliances could cause us to fail to realize the anticipated benefits of these transactions, incur unanticipated liabilities and harm our business generally. There is also a risk that current or future acquisitions will result in the shareholder litigation, incurrence of debt, contingent liabilities, amortization expenses or incremental operating expenses, any of which could harm our financial condition or results of operations. </div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">If we obtain a controlling interest in additional companies in the future, it could adversely affect our operating results and the value of our Common Shares, thereby disrupting our business. </div></div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">As part of our strategy, we expect to form and invest in additional wholly-owned and majority-owned subsidiaries. Investments in our existing and any future subsidiaries involve numerous risks, including, but not necessarily limited to, risks related to: </div></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 4%;">&#160;</td>
<td style="width: 4%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">conducting research and development activities in new therapeutic areas or treatment approaches in which we have little to no experience; </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 4%;">&#160;</td>
<td style="width: 4%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">diversion of financial and managerial resources from existing operations; </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 4%;">&#160;</td>
<td style="width: 4%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">actual or potential conflicts among new and existing Vants to the extent they have overlapping or competing areas of focus or pipeline products; </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 4%;">&#160;</td>
<td style="width: 4%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;">successfully negotiating a proposed acquisition, <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">in-license</div> or investment in a timely manner and at a price or on terms and conditions favorable to us; </div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 4%;">&#160;</td>
<td style="width: 4%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">successfully combining and integrating a potential acquisition into our existing business to fully realize the benefits of such acquisition; </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 4%;">&#160;</td>
<td style="width: 4%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;">the impact of regulatory reviews on a proposed acquisition, <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">in-license</div> or investment; and </div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 4%;">&#160;</td>
<td style="width: 4%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;">the outcome of any legal proceedings that may be instituted with respect to the proposed acquisition, <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">in-license</div> or investment. </div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">If we fail to properly evaluate potential acquisitions, <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">in-licenses,</div> investments or other transactions associated with the creation of new research and development programs or the maintenance of existing ones, we might not achieve the anticipated benefits of any such transaction, we might incur costs in excess of what we anticipate, and management resources and attention might be diverted from other necessary or valuable activities. </div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">We will require additional capital to fund our operations, and if we fail to obtain necessary financing, we may not be able to complete the development and commercialization of our product candidates. </div></div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">We expect to spend substantial capital to complete the development of, seek regulatory approvals for and commercialize our biopharmaceutical product candidates, as well as to advance the development of our healthcare technologies. Because the length of time and activities associated with successful development of our biopharmaceutical product candidates is highly uncertain, and due to the inherent challenges and uncertainties associated with the development of novel healthcare technologies, we are unable to estimate with certainty the actual funds we will require to execute on our strategy. </div></div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">14 </div></div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;;font-weight: bold;"><a href="#toc">Table of Contents</a></div> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Our future funding requirements, both near- and long-term, will depend on many factors, including, but not limited to: </div></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 4%;">&#160;</td>
<td style="width: 4%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">with respect to our biopharmaceutical product candidates: </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 9%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">the cost and timing of newly launched product candidates or Vants; </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 9%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;">the initiation, timing, progress, costs and results of <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">pre-clinical</div> studies and clinical trials for our product candidates; </div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 9%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;">the outcome, timing and cost of meeting regulatory requirements established by the FDA and other comparable <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-U.S.</div> regulatory authorities globally; </div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 9%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">the cost of filing, prosecuting, defending and enforcing our patent claims and other intellectual property rights; </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 9%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">the cost of defending potential intellectual property disputes, including patent infringement actions brought by third parties against us or any of our current or future product candidates; </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 9%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;">the cost and timing of completion of <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">pre-clinical,</div> clinical and commercial manufacturing activities; </div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 9%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">the cost of establishing sales, marketing and distribution capabilities for our product candidates in regions where we choose to commercialize our product candidates on our own; </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 9%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">the initiation, progress, timing and results of our commercialization of our product candidate, if approved for commercial sale; and </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 9%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">other costs associated with preparing the commercial launch of our product candidates; </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 4%;">&#160;</td>
<td style="width: 4%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">for our healthcare and drug discovery technologies: </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 9%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">the costs related to hiring and retaining employees with the expertise necessary to manage these technologies; </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 9%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">investments in wet labs, computational resources and other facilities; and </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 9%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">the costs needed to update, maintain and improve these technologies and the infrastructure underlying these technologies, including with respect to data protection and cybersecurity. </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">We cannot be certain that additional capital will be available on acceptable terms, or at all. If we are unable to raise additional capital in sufficient amounts or on terms acceptable to us, we may have to significantly delay, scale back or discontinue the development or commercialization of any product candidate, delay the launch or expansion of a given healthcare technology product or potentially discontinue our operations altogether. In addition, attempting to secure additional capital may divert the time and attention of our management from <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">day-to-day</div></div> activities and harm our business. Because of the numerous risks and uncertainties associated with our business, we are unable to estimate the amounts of increased capital outlays, operating expenditures and capital requirements associated with our current product development programs and technology products. </div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">We expect that significant additional capital will be needed in the future to continue our planned operations, including with respect to fulfilling our and the Vants&#8217; human resources needs, which may be costly. Until such time, if ever, that we can generate substantial revenues, we expect to continue to finance our cash needs through a combination of equity offerings, debt financings, strategic alliances and license and development agreements or other collaborations both at our parent and at certain affiliates. To the extent that we raise additional capital by issuing equity securities at the parent or subsidiary level, our existing shareholders&#8217; ownership, or our ownership in our subsidiaries, may experience substantial dilution, and the terms of these securities may include liquidation or other preferences that could harm the rights of a common shareholder. Additionally, any agreements for future debt or preferred equity financings, if available, may involve covenants limiting or restricting our ability to take specific actions, such as incurring additional debt, making capital expenditures or declaring dividends. If we raise </div></div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">15 </div></div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;;font-weight: bold;"><a href="#toc">Table of Contents</a></div> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">additional funds through collaborations, strategic alliances or marketing, distribution or licensing arrangements with third parties, we may have to relinquish valuable rights to our product candidates, future revenue streams, research programs or technologies, or grant licenses on terms that may not be favorable to us. The foregoing restrictions associated with potential sources of additional capital may make it more difficult for us to raise additional capital or to pursue business opportunities, including potential acquisitions. If we are unable to obtain adequate financing or financing on terms satisfactory to us, if and when we require it, our ability to grow or support our business and to respond to business challenges could be significantly limited. </div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Risks Related to the Development of Our Product Candidates </div></div></div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Clinical trials and <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">pre-clinical</div> studies are very expensive, time-consuming, difficult to design and implement and involve uncertain outcomes. We may encounter substantial delays in clinical trials, or may not be able to conduct or complete clinical trials or <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">pre-clinical</div> studies on the expected timelines, if at all. </div></div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;">Our biopharmaceutical product candidates are in clinical development or <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">pre-clinical</div> studies and will require, as applicable, extensive clinical testing before a New Drug Application (&#8220;NDA&#8221;) or other similar application for regulatory approval, such as a Biologics License Application (&#8220;BLA&#8221;) or an application for marketing authorization in the European Union (&#8220;EU&#8221;) or United Kingdom (&#8220;UK&#8221;), may be submitted, or extensive <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">pre-clinical</div> testing before an Investigational New Drug application (&#8220;IND&#8221;) or an application for authorization for the conduct of a clinical trial in the EU or UK may be submitted. We cannot provide you any assurance that we will submit an IND, NDA or other similar application for regulatory approval for our product candidates within projected timeframes or whether any such application will be approved by the relevant regulatory authorities. </div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">Clinical trials and <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">pre-clinical</div> studies are very expensive, time-consuming and difficult to design and implement, in part because they are subject to rigorous regulatory requirements. For instance, the FDA, an institutional review board (&#8220;IRB&#8221;), an Ethics Committee (&#8220;EC&#8221;) or other regulatory authorities may not agree with the proposed analysis plans or trial design for the clinical trials of our product candidates, and during any such review, may identify unexpected efficacy or safety concerns, which may delay the effective date of an IND or approval of an NDA or similar application. The FDA, the European Medicines Agency (&#8220;EMA&#8221;) or the European Commission or other relevant regulatory authority may also find that the benefits of any product candidate in any applicable indication do not outweigh its risks in a manner sufficient to grant regulatory approval. </div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">The FDA or other regulatory authorities may also not agree with the scope of our proposed investigational plan. For example, they may find that our proposed development program is not sufficient to support a marketing authorization application, or that the proposed indication is considered to be too broad. Moreover, the FDA or other regulatory authorities may also refuse or impose certain restrictions on our reliance on data supporting our marketing authorization application should such data originate from studies outside of the relevant jurisdiction or be affected by regulatory <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-compliance,</div> including issues of data integrity. In each case, this could delay the clinical development and authorization timeline for a given product candidate. </div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">Failures can occur at any stage of clinical trials or <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">pre-clinical</div> studies, and we could encounter problems that cause us to abandon or repeat clinical trials or <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">pre-clinical</div> studies. In addition, results from clinical trials or <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">pre-clinical</div> studies may require further evaluation, delaying the next stage of development or submission of an IND or an NDA or similar application. Further, product candidates in later stages of clinical trials may fail to show the desired safety and efficacy traits despite having progressed through nonclinical studies and initial clinical trials, and such product candidates may exhibit safety signals in later stage clinical trials that they did not exhibit in <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">pre-clinical</div> or early-stage clinical trials. A number of companies in the biopharmaceutical industry have suffered significant setbacks in, or the discontinuation of, advanced clinical trials due to lack of efficacy or adverse safety profiles, notwithstanding promising results in earlier trials or studies. Likewise, the results of early clinical trials or <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">pre-clinical</div> studies of our product candidates may not be predictive of the results of planned development programs, and there can be no assurance that the results of studies conducted by collaborators or other third parties will be viewed favorably or are indicative of our own future trial results. </div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">16 </div></div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;;font-weight: bold;"><a href="#toc">Table of Contents</a></div> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">The commencement and completion of <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">pre-clinical</div> studies and clinical trials may be delayed by several factors, including: </div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">failure to obtain regulatory authorization to commence a trial or reaching consensus with regulatory authorities regarding the design or implementation of our studies; </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;">other regulatory issues, including the receipt of any inspectional observations on FDA&#8217;s <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">Form-483,</div> Warning or Untitled Letters, clinical holds, or complete response letters or similar communications/objections by other regulatory authorities; </div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">unforeseen safety issues, or subjects experience severe or unexpected adverse events; </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">occurrence of serious adverse events in trials of the same class of agents conducted by other sponsors; </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">lack of effectiveness during clinical trials; </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">resolving any dosing issues, including those raised by the FDA or other regulatory authorities; </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">inability to reach agreement on acceptable terms with prospective CROs and clinical trial sites, the terms of which can be subject to extensive negotiation and may vary significantly among different CROs and trial sites; </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">slower than expected rates of patient recruitment or failure to recruit suitable patients to participate in a trial; </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">failure to add a sufficient number of clinical trial sites; </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">unanticipated impact from changes in or modifications to protocols or clinical trial design, including those that may be required by the FDA or other regulatory authorities; </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">inability or unwillingness of clinical investigators or study participants to follow our clinical and other applicable protocols or applicable regulatory requirements; </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">an IRB or EC refusing to approve, suspending, or terminating the trial at an investigational site, precluding enrollment of additional subjects, or withdrawing their approval of the trial; </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">premature discontinuation of study participants from clinical trials or missing data; </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">failure to manufacture or release sufficient quantities of our product candidate or failure to obtain sufficient quantities of active comparator medications for our clinical trials, if applicable, that in each case meet our quality standards, for use in clinical trials; </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">inability to monitor patients adequately during or after treatment; or </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">inappropriate unblinding of trial results. </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">In addition, disruptions caused by the <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">COVID-19</div> pandemic increase the likelihood that we encounter such difficulties or delays in initiating, enrolling, conducting or completing our planned and ongoing clinical trials.&#160;Further, we, the FDA or other regulatory authorities may suspend our clinical trials in an entire country at any time, or an IRB/EC may suspend our clinical trial sites within any country, if it appears that we or our collaborators are failing to conduct a trial in accordance with applicable regulatory requirements, including Good Clinical Practice (&#8220;GCP&#8221;) regulations, that we are exposing participants to unacceptable health risks, or if the FDA or other regulatory authority finds deficiencies in our IND or equivalent applications for other countries or in the manner in which clinical trials are conducted. Therefore, we cannot predict with any certainty the schedule for commencement and completion of future clinical trials. </div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">If we experience delays in the commencement or completion of our clinical trials, or if we terminate a clinical trial prior to completion, the commercial prospects of our product candidates could be harmed, and our ability to generate product revenue from any of our product candidates, if approved, may be delayed. In addition, any delays in our clinical trials could increase our costs, cause a decline in our share price, slow down the </div></div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">17 </div></div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;;font-weight: bold;"><a href="#toc">Table of Contents</a></div> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">approval process, and jeopardize our ability to commence product sales and generate revenue. Any of these occurrences may harm our business, financial condition and results of operations. In addition, many of the factors that cause or lead to a termination or suspension of, or delay in the commencement or completion of clinical trials may also ultimately lead to the denial of regulatory approval of our product candidates. We may make formulation or manufacturing changes to our product candidates, in which case we may need to conduct additional <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">pre-clinical</div> or clinical studies to bridge our modified product candidates to earlier versions. Any delays to our clinical trials that occur as a result could shorten any period during which we may have the exclusive right to commercialize our product candidates and our competitors may be able to bring product candidates to market before we do, and the commercial viability of our product candidates could be significantly reduced. </div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Moreover, principal investigators for our clinical trials may serve as scientific advisors or consultants to us from time to time and receive compensation in connection with such services. Under certain circumstances, we may be required to report some of these relationships to the FDA or other regulatory authorities. The FDA or other regulatory authorities may conclude that a financial relationship between us and a principal investigator has created a conflict of interest or otherwise affected the integrity of the study. The FDA or other regulatory authority may therefore question the integrity of the data generated at the applicable clinical trial site and the utility of the clinical trial itself may be jeopardized. This could result in a delay in approval, or rejection, of our marketing and authorization applications by the FDA or other regulatory authority, as the case may be, and may ultimately lead to the denial of marketing approval of any of our product candidates. </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">In addition, for our product candidates in clinical development, prior to our acquisition of the rights to those product candidates we had no involvement with or control over the <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">pre-clinical</div> or clinical development of those product candidates. We are therefore dependent on our licensing and other transaction partners having conducted such research and development in accordance with the applicable protocol and legal, regulatory and scientific standards, having accurately reported the results of all clinical trials and other research they conducted prior to our acquisition of the rights to product candidates, having correctly collected and interpreted the data from these trials and other research and having supplied us with complete information, data sets and reports required to adequately demonstrate the results reported through the date of our acquisition of these product candidates. Problems associated with the pre-acquisition development of our product candidates could result in increased costs and delays in the development of our product candidates, which could harm our ability to generate any future revenue from sales of product candidates, if approved. </div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Our approach to the discovery and development of product candidates from our targeted protein degradation platform is unproven, which makes it difficult to predict the time, cost of development and likelihood of successfully developing any product candidates from this platform. </div></div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Treating diseases using targeted protein degradation is a new treatment approach. Our future success depends in part on the successful development of this novel therapeutic approach. Very few small molecule product candidates using targeted protein degradation have been tested in humans. None have been approved in the United States or Europe, and the data underlying the feasibility of developing these types of therapeutic products is both preliminary and limited. If any adverse learnings are made by other developers of chimeric targeting molecules, development of these product candidates could be materially impacted, which could in turn adversely impact our financial condition and future growth. </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The scientific research that forms the basis of our efforts to develop our degrader product candidates is ongoing and the scientific evidence to support the feasibility of developing these treatments is both preliminary and limited. In addition, we may be unable to replicate the scientific evidence supporting our protein degrader candidates observed by our academic collaborators in commercial laboratories. </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Further, certain cancer patients have shown inherent primary resistance to approved drugs that inhibit disease-causing proteins and other patients have developed acquired secondary resistance to these inhibitors. </div></div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">18 </div></div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;;font-weight: bold;"><a href="#toc">Table of Contents</a></div> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Although we believe our product candidates may have the ability to degrade the specific mutations that confer resistance to currently marketed inhibitors of disease-causing enzymes, any inherent primary or acquired secondary resistance to our product candidates in patients, or if the research proves to be contradicted, would prevent or diminish their clinical benefit. </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">We have not yet completed <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">IND-enabling</div> work for, or initiated a clinical trial of, any product candidate associated with our targeted protein degradation platform and we have not yet assessed the safety of any of these product candidates in humans. Although some of our product candidates have produced observable results in animal studies, there is a limited safety data set for their effects in animals. In addition, these product candidates may not demonstrate the same chemical and pharmacological properties in humans and may interact with human biological systems in unforeseen, ineffective or harmful ways. As a result, there could be adverse effects from treatment with any of our current or future product candidates that we cannot predict at this time. </div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">Additionally, the regulatory approval process for novel product candidates such as those associated with our targeted protein degradation platform is uncertain and can be more expensive and take longer than for other, better-known or extensively studied classes of product candidates. Although other companies are also developing therapeutics based on targeted protein degradation, no product candidates of this type have been approved in the United States or Europe. As a result, it is difficult for us to predict the time and cost of developing our product candidates and we cannot predict whether any of these product candidates will receive marketing approval or achieve commercial acceptance. Any development problems we experience in the future related to our targeted protein degradation platform or any of our related research programs may cause significant delays or unanticipated costs or may prevent the development of a commercially viable product. Any of these factors may prevent us from completing our <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">pre-clinical</div> studies or any clinical trials that we may initiate, as well as from commercializing any product candidates we may develop on a timely or profitable basis, if at all. </div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Certain of our product candidates, including our gene therapy product candidates, are novel, complex and difficult to manufacture. We could experience manufacturing problems that result in delays in our development or commercialization programs or otherwise harm our business. </div></div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The manufacturing processes our contract manufacturing organizations (&#8220;CMOs&#8221;) use to produce our product candidates are complex, novel and have not necessarily been validated for commercial use. Several factors could cause production interruptions, including equipment malfunctions, facility contamination, raw material shortages or contamination, natural disasters, disruption in utility services, human error or disruptions in the operations of our suppliers. </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">Our gene therapy product candidates may require processing steps that are more complex than those required for most small molecule drugs. Moreover, unlike small molecules, the physical and chemical properties of biologics generally cannot be fully characterized. As a result, assays of the finished product may not be sufficient to ensure that the product is consistent from <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">lot-to-lot</div></div> or will perform in the intended manner. Accordingly, our CMOs must employ multiple steps to control the manufacturing process to assure that the process is reproducible and the product candidate is made strictly and consistently in compliance with the process. Problems with the manufacturing process, even minor deviations from the normal process, could result in product defects or manufacturing failures that result in lot failures, product recalls, product liability claims or insufficient inventory to conduct clinical trials or supply commercial markets. We may encounter problems achieving adequate quantities and quality of clinical-grade materials that meet the FDA, the EU or other applicable standards or specifications with consistent and acceptable production yields and costs. </div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">In addition, the FDA, the EMA and other comparable regulatory authorities may require us to submit samples of any lot of any approved product together with the protocols showing the results of applicable tests at any time. Under some circumstances, the FDA, the EMA or other comparable regulatory authorities may require that we not distribute a lot until the agency authorizes its release. Slight deviations in the manufacturing process, including those affecting quality attributes and stability, may </div></div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">19 </div></div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;;font-weight: bold;"><a href="#toc">Table of Contents</a></div> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">result in unacceptable changes in the product that could result in lot failures or product recalls. Lot failures or product recalls could cause us to delay product launches or clinical trials, which could be costly to us and otherwise harm our business, financial condition, results of operations and prospects. </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Our CMOs also may encounter problems hiring and retaining the experienced scientific, quality assurance, quality-control and manufacturing personnel needed to operate our manufacturing processes, which could result in delays in production or difficulties in maintaining compliance with applicable regulatory requirements. Any problems in our CMOs&#8217; manufacturing process or facilities could result in delays in planned clinical trials and increased costs, and could make us a less attractive collaborator for potential partners, including larger biotechnology companies and academic research institutions, which could limit access to additional attractive development programs. Problems in our manufacturing process could restrict our ability to meet potential future market demand for products. </div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">We may encounter difficulties enrolling and retaining patients in clinical trials, and clinical development activities could thereby be delayed or otherwise adversely affected. </div></div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">We may encounter delays or difficulties in enrolling, or be unable to enroll, a sufficient number of patients to complete any of our clinical trials for our product candidates on current timelines, or at all, and even once enrolled we may be unable to retain a sufficient number of patients to complete any of our clinical trials for these product candidates. Enrollment in our clinical trials may also be slower than we anticipate, or be stopped, leading to delays in the development timelines for our product candidates. </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">Patient enrollment and retention in clinical trials depends on many factors, including the size of the patient population, the nature of the trial protocol, our ability to recruit clinical trial investigators with the appropriate competencies and experience, delays in enrollment due to travel or quarantine policies, or other factors, related to <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">COVID-19,</div> the existing body of safety and efficacy data with respect to the study drug, the number and nature of competing treatments and ongoing clinical trials of competing drugs for the same indication, the proximity of patients to clinical sites, the eligibility criteria for the trial and the proportion of patients screened that meets those criteria, our ability to obtain and maintain patient consents, our ability to successfully complete prerequisite studies before enrolling certain patient populations. For certain of our product candidates, including IMVT-1401, which targets certain rare autoimmune indications, there are limited patient pools from which to draw in order to complete our clinical trials in a timely and cost-effective manner. In addition, for certain of our early-stage development programs, there may be a limited number of sites where it is feasible to run clinical trials, making such programs particularly susceptible to delays caused by issues at those sites. </div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">Furthermore, any negative results or new safety signals we may report in clinical trials of our product candidates may make it difficult or impossible to recruit and retain patients in other clinical trials we are conducting or to resume enrolling patients once a paused clinical trial has been resumed. For example, in February 2021, our subsidiary, Immunovant, voluntarily paused dosing in its clinical trials for IMVT-1401 globally due to elevated total cholesterol and <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">low-density</div> lipoprotein (&#8220;LDL&#8221;) levels observed in some patients treated with IMVT-1401, resulting in a delay in Immunovant&#8217;s development of IMVT-1401. In future trials of IMVT-1401, it may be more difficult for Immunovant to recruit and retain patients for such clinical trials. Similarly, negative results reported by our competitors about their drug candidates may negatively affect patient recruitment in our clinical trials. Also, marketing authorization of competitors in this same class of drugs may impair our ability to enroll patients into our clinical trials, delaying or potentially preventing us from completing recruitment of one or more of our trials. </div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Delays or failures in planned patient enrollment or retention may result in increased costs, program delays or both, which could have a harmful effect on our ability to develop our product candidates, or could render further development impossible. In addition, we expect to rely on CROs and clinical trial sites to ensure proper and timely conduct of our future clinical trials, and, while we intend to enter into agreements governing their services, we will be limited in our ability to compel their actual performance. </div></div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">20 </div></div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;;font-weight: bold;"><a href="#toc" style="text-indent: 0px;">Table of Contents</a></div> <div> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">The results of our clinical trials may not support our proposed claims for our product candidates, or regulatory approvals on a timely basis or at all, and the results of earlier studies and trials may not be predictive of future trial results. </div></div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;">Success in <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">pre-clinical</div> testing and early clinical trials does not ensure that later clinical trials will be successful, and we cannot be sure that the results of later clinical trials will replicate the results of prior <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">pre-clinical</div> testing and clinical trials. In particular, we cannot assure you that the reductions in IgG antibodies that we have observed to date in our clinical trials of IMVT-1401 will be observed in any future clinical trials. Likewise, promising results in interim analyses or other preliminary analyses do not ensure that the clinical trial as a whole will be successful. A number of companies in the pharmaceutical industry, including biotechnology companies, have suffered significant setbacks in, or the discontinuation of, clinical trials, even after promising results in earlier <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">pre-clinical</div> studies or clinical trials. These setbacks have been caused by, among other things, <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">pre-clinical</div> findings made while clinical trials were underway and safety or efficacy observations made in clinical trials, including previously unreported adverse events. In February 2021, our subsidiary, Immunovant, voluntarily paused dosing in its clinical trials for IMVT-1401 globally due to elevated total cholesterol and LDL levels observed in patients treated with IMVT-1401, resulting in a delay in Immunovant&#8217;s development of IMVT-1401. Immunovant is progressing discussions with the FDA and is planning to progress discussions with other regulatory authorities, with the intent to continue development of IMVT-1401. While the ASCEND <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">GO-2</div> trial was terminated and the efficacy results, based on approximately half the anticipated number of subjects who had reached the week 13 primary efficacy analysis at the time of the termination of the trial, were inconclusive, further discussions with external experts are ongoing to determine whether a specific population can be identified to optimize the clinical performance of IMVT-1401. Based on these analyses, Immunovant intends to initiate discussions with regulatory authorities before the end of the calendar year 2021 and reinstate its program in Thyroid Eye Disease based on regulatory alignment. Failure to successfully complete clinical trials of IMVT-1401 and to demonstrate the efficacy and safety necessary to obtain regulatory approval to market IMVT-1401 would significantly harm our business. </div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">The results of <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">pre-clinical</div> studies and early clinical trials of our product candidates may not be predictive of the results of later-stage clinical trials. Product candidates in later stages of clinical trials may fail to show the desired safety and efficacy traits despite having progressed through <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">pre-clinical</div> and initial clinical trials. A future failure of a clinical trial to meet its <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">pre-specified</div> endpoints would likely cause us to abandon our product candidates. Any delay in, or termination of, our clinical trials will delay the submission of an NDA or other similar applications to the FDA or other relevant comparable <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-U.S.</div> regulatory authorities and, ultimately, our ability to commercialize our product candidates, if approved, and generate product revenues. Even if our clinical trials are completed as planned, we cannot be certain that their results will support our claims for differentiation or the effectiveness or safety of our product candidates. The FDA has substantial discretion in the review and approval process and may disagree that our data support the differentiated claims we propose. In addition, only a small percentage of product candidates under development result in the submission of an NDA or other similar application to the FDA and other comparable <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-U.S.</div> regulatory authorities and even fewer are approved for commercialization. </div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Interim, <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">top-line</div> or preliminary data from our clinical trials that we announce or publish from time to time may change as more patient data become available and are subject to audit and verification procedures that could result in material changes in the final data. </div></div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;">From time to time, we may publicly disclose preliminary or <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">top-line</div> data from our clinical trials, which is based on a preliminary analysis of then-available <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">top-line</div> data, and the results and related findings and conclusions are subject to change following a full analysis of all data related to the particular trial. We also make assumptions, estimations, calculations and conclusions as part of our analyses of data, and we may not have received or had the opportunity to fully and carefully evaluate all data. As a result, the preliminary and <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">top-line</div> results that we report may differ from future results of the same trials, or different conclusions or considerations may qualify such results, once additional data have been received and fully evaluated. <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">Top-line</div> data also remain </div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">21 </div></div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;;font-weight: bold;"><a href="#toc">Table of Contents</a></div> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">subject to audit and verification procedures that may result in the final data being materially different from the <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">top-line</div> data we previously published. As a result, preliminary and <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">top-line</div> data should be viewed with caution until the final data are available. From time to time, we may also disclose interim data from our clinical trials. Interim data from clinical trials that we may complete are subject to the risk that one or more of the clinical outcomes may materially change as patient enrollment continues and more patient data become available. Adverse differences between preliminary, <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">top-line</div> or interim data and final data could significantly harm our business prospects. Further, disclosure of preliminary or interim data by us or by our competitors could result in increased volatility in the price of our shares. </div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">Further, others, including regulatory agencies, may not accept or agree with our assumptions, estimates, calculations, conclusions or analyses or may interpret or weigh the importance of data differently, which could impact the value of the particular program, the approvability or commercialization of the particular product candidate or product and our business in general. In addition, the information we choose to publicly disclose regarding a particular study or clinical trial is based on what is typically extensive information, and you or others may not agree with what we determine is the material or otherwise appropriate information to include in our disclosure, and any information we determine not to disclose may ultimately be deemed significant with respect to future decisions, conclusions, views, activities or otherwise regarding a particular product, product candidate or our business. If the <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">top-line</div> data that we report differ from actual results, or if others, including regulatory authorities, disagree with the conclusions reached, our ability to obtain approval for and commercialize product candidates, our business, operating results, prospects or financial condition may be harmed. </div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Changes in methods of product manufacturing or formulation may result in additional costs or delay. </div></div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;">As product candidates proceed through <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">pre-clinical</div> studies to pivotal clinical trials towards potential approval and commercialization, it is common that various aspects of the development program, such as manufacturing methods and formulation, are altered along the way in an effort to optimize processes and results. Such changes carry the risk that they will not achieve these intended objectives. Any of these changes could cause product candidates to perform differently and affect the results of planned clinical trials or other future clinical trials conducted with the altered materials. Such changes may also require additional testing, FDA notification or FDA approval. Similar requirements apply in other jurisdictions. This could delay completion of clinical trials, require the conduct of bridging clinical trials or the repetition of one or more clinical trials, increase clinical trial costs, delay approval of our product candidates and jeopardize our ability to commence sales and generate revenues. </div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">We rely on third parties to conduct, supervise and monitor our clinical trials, and if those third parties perform in an unsatisfactory manner or fail to comply with applicable requirements, it may harm our business. </div></div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;">We rely on CROs and clinical trial sites to ensure the proper and timely conduct of our clinical trials, and we expect to have limited influence over their actual performance. In addition, we rely upon CROs to monitor and manage data for our clinical programs, as well as the execution of future <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-clinical</div> studies. We expect to control only certain aspects of our CROs&#8217; activities. Nevertheless, we will be responsible for ensuring that each of our studies is conducted in accordance with the applicable protocol, legal, regulatory and scientific standards and that clinical trial sites meet applicable protocol and regulatory requirements, and our reliance on the CROs does not relieve us of our regulatory responsibilities. </div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">We and our CROs will be required to comply with the Good Laboratory Practices (&#8220;GLPs&#8221;) and GCPs, which are regulations and guidelines enforced by the FDA and other comparable <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-U.S.</div> regulatory authorities, which also require compliance with the International Council for Harmonization of Technical Requirements for Pharmaceuticals for Human Use (&#8220;ICH&#8221;) guidelines for any of our product candidates that are in <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">pre-clinical</div> and clinical development. The regulatory authorities enforce GCP regulations through periodic inspections of trial sponsors, principal investigators and clinical trial sites. Although we may rely on CROs to conduct our <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">GLP-compliant</div> nonclinical studies and <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">GCP-compliant</div> clinical trials, we remain responsible for ensuring that </div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">22 </div></div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;;font-weight: bold;"><a href="#toc">Table of Contents</a></div> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">each of our GLP nonclinical studies and GCP clinical trials is conducted in accordance with its investigational plan and protocol and applicable laws and regulations, and our expected reliance on the CROs does not relieve us of our regulatory responsibilities. If we or our CROs fail to comply with GCPs, the clinical data generated in our clinical trials may be deemed unreliable and the FDA or comparable <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-U.S.</div> regulatory authorities may reject our marketing applications and require us to perform additional clinical trials before approving our marketing applications. Accordingly, if our CROs fail to comply with these regulations or other applicable laws, regulations or standards, or fail to recruit a sufficient number of subjects, we may be required to repeat clinical trials, which would delay the regulatory approval process. Failure by any future CROs to properly execute study protocols in accordance with applicable law could also create product liability and healthcare regulatory risks for us as sponsors of those studies. </div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Our CROs will not be our employees, and we will not control whether or not they devote sufficient time and resources to our future clinical and nonclinical programs. These CROs may also have relationships with other commercial entities, including our competitors, for whom they may also be conducting clinical trials, or other drug development activities which could harm our competitive position. We face the risk of potential unauthorized disclosure or infringement, misappropriation or other violation of our intellectual property by CROs, which may reduce our trade secret and intellectual property protection and allow our potential competitors to access and exploit our proprietary technology. If our CROs do not successfully carry out their contractual duties or obligations, fail to meet expected deadlines, or if the quality or accuracy of the clinical data they obtain is compromised due to the failure to adhere to our clinical protocols or regulatory requirements or for any other reasons, our clinical trials may be extended, delayed or terminated, and we may not be able to obtain regulatory approval for, or successfully commercialize any product candidate that we develop. As a result, our financial results and the commercial prospects for any product candidate that we develop would be harmed, our costs could increase, and our ability to generate revenues could be delayed. </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">If our relationships with these CROs terminate, we may not be able to enter into arrangements with alternative CROs or do so on commercially reasonable terms or in a timely manner. Switching or adding additional CROs involves substantial cost and requires management time and focus. In addition, there is a natural transition period when a new CRO commences work. As a result, delays occur, which can adversely impact our ability to meet our desired clinical development timelines. Though we intend to carefully manage our relationships with the CROs, there can be no assurance that we will not encounter challenges or delays in the future or that these delays or challenges will not have an adverse impact on our business, financial condition and prospects. </div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">We do not have our own manufacturing capabilities and will rely on third parties to produce clinical supplies and commercial supplies of our product candidates and any future product candidate. </div></div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">We do not own or operate, and do not expect to own or operate, facilities for product manufacturing, storage and distribution, or testing. We will rely on third parties to produce clinical and commercial supplies of our product candidates and any future product candidate. </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">Third-party vendors may be difficult to identify for our product process and formulation development and manufacturing due to special capabilities required, and they may not be able to meet our quality standards. In addition, certain of our third-party manufacturers and suppliers may encounter delays in providing their services as a result of supply chain constraints. If any third-party manufacturers or third parties in the supply chain for materials used in the production of our product candidates or any future product candidates are adversely impacted by supply chain constraints, our supply chain may be disrupted, limiting our ability to manufacture product candidates for our <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">pre-clinical</div> studies, clinical trials, research and development operations and commercialization. Any significant delay in the supply of a product candidate, or the raw material components thereof, for an ongoing clinical trial due to the need to replace a third-party manufacturer could considerably delay completion of our clinical trials, product testing and potential regulatory approval of our product candidate. If our manufacturers or we are unable to purchase these raw materials after regulatory approval has been </div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">23 </div></div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;;font-weight: bold;"><a href="#toc">Table of Contents</a></div> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">obtained for our product candidates, the commercial launch of our product candidates would be delayed or there would be a shortage in supply, which would impair our ability to generate revenue from the sale of our product candidates. Moreover, as a result of projected supply constraints for certain materials used in the production of our product candidates, we have in the past and may in the future reserve manufacturing capacity in advance of receiving required efficacy or safety results from our clinical trials, which may involves committing substantial financial resources to current or future potential product candidates that may never be approved or achieve commercialization at scale or at all. In addition, legislative, executive and regulatory proposals are pending to, among other things, prevent drug shortages and reduce the dependency of the United States on foreign supply chains and manufacturing. While we are still assessing these developments, they could impact our selection and utilization of CMOs, vendors and other suppliers and could have a material adverse impact on our business, financial condition and results of operations. </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">The facilities used by our contract manufacturers to manufacture our product candidates must be approved by the FDA pursuant to inspections that will be conducted after we submit an NDA or other similar application to the FDA. Such facilities must also register with the FDA. Similar requirements apply in other jurisdictions. We do not control the manufacturing process of, and are completely dependent on, our contract manufacturing partners for compliance with Current Good Manufacturing Practice (&#8220;cGMP&#8221;) requirements for the manufacture of drug product candidates. If our contract manufacturers cannot successfully manufacture material that conforms to our specifications and the strict regulatory requirements of the FDA or comparable <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-U.S.</div> regulatory authorities, we will not be able to secure or maintain regulatory approval for our product candidates. In addition, we have limited control over the ability of our contract manufacturers to maintain adequate quality control, quality assurance and qualified personnel. If the FDA or comparable <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-U.S.</div> regulatory authorities do not approve these facilities for the manufacture of our product candidates or if they withdraw any such approval in the future, we may need to find alternative manufacturing facilities, which would significantly impact our ability to develop, obtain regulatory approval for or market our product candidates, if approved. </div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Further, our reliance on third-party manufacturers entails risks to which we would not be subject if we manufactured product candidates ourselves, including: </div></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">inability to meet our product specifications and quality requirements consistently; </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">delay or inability to procure or expand sufficient manufacturing capacity; </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;">manufacturing and product quality issues related to <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">scale-up</div> of manufacturing; </div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;">costs and validation of new equipment and facilities required for <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">scale-up;</div> </div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">failure to comply with applicable laws, regulations and standards, including cGMP and similar standards; </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">deficient or improper record-keeping; </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">inability to negotiate manufacturing agreements with third parties under commercially reasonable terms; </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">termination or nonrenewal of manufacturing agreements with third parties in a manner or at a time that is costly or damaging to us; </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">reliance on a limited number of sources, and in some cases, single sources for product components, such that if we are unable to secure a sufficient supply of these product components, we will be unable to manufacture and sell our product candidates in a timely fashion, in sufficient quantities or under acceptable terms; </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">lack of qualified backup suppliers for those components that are currently purchased from a sole or single source supplier; </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">operations of our third-party manufacturers or suppliers could be disrupted by conditions unrelated to our business or operations, including the bankruptcy of the manufacturer or supplier or other regulatory sanctions related to the manufacturer of another company&#8217;s product candidates; </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">24 </div></div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;;font-weight: bold;"><a href="#toc">Table of Contents</a></div> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;">
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">carrier disruptions or increased costs that are beyond our control; and </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">failure to deliver our product candidates under specified storage conditions and in a timely manner. </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Any of these events could lead to clinical trial delays, cost overruns, delay or failure to obtain regulatory approval or impact our ability to successfully commercialize our product candidates as well as potential product liability litigation, product recalls or product withdrawals. Some of these events could be the basis for FDA or other regulatory authority action, including injunction, recall, seizure, total or partial suspension of production, or suspension or revocation of manufacturing/import authorizations and GMP certificates. </div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">If the contract manufacturing facilities on which we rely do not continue to meet regulatory requirements or are unable to meet our requirements, including providing an adequate supply, our business will be harmed. </div></div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;">All entities involved in the preparation of product candidates for clinical trials or commercial sale, including our existing CMOs for all of our product candidates, are subject to extensive regulation. Components of a finished therapeutic product approved for commercial sale or used in late-stage clinical trials must be manufactured in accordance with cGMP, or similar regulatory requirements outside the United States. These regulations govern manufacturing processes and procedures, including recordkeeping, and the implementation and operation of quality systems to control and assure the quality of investigational products and products approved for sale. Poor control of production processes can lead to the introduction of contaminants or to inadvertent changes in the properties or stability of our product candidates. Our failure, or the failure of third-party manufacturers, to comply with applicable regulations could result in the issuance of inspectional observations on FDA&#8217;s <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">Form-483,</div> Warning or Untitled Letters, similar communications/objections by other authorities, public safety alerts identifying our company or products and sanctions being imposed on us, including clinical holds, import alerts, fines, injunctions, civil penalties, delays, suspension or withdrawal of approvals, license revocation, suspension of production, seizures or recalls of product candidates or marketed drugs, operating restrictions and criminal prosecutions, any of which could significantly and adversely affect clinical or commercial supplies of our product candidates. </div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">We and/or our CMOs must supply all necessary documentation in support of an NDA or similar regulatory application on a timely basis, and must adhere to regulations enforced by the FDA and other regulatory agencies through their facilities inspection program. Some of our CMOs have never produced a commercially approved pharmaceutical product and therefore have not obtained the requisite regulatory authority approvals to do so. The facilities and quality systems of some or all of our third-party contractors must pass a <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">pre-approval</div> inspection for compliance with the applicable regulations as a condition of regulatory approval of our product candidates or any of our other potential products. In addition, the regulatory authorities may, at any time, audit or inspect a manufacturing facility involved with the preparation of our product candidates or our other potential products or the associated quality systems for compliance with the regulations applicable to the activities being conducted. Although we oversee the CMOs, we cannot control the manufacturing process of, and are completely dependent on, our CMO partners for compliance with the regulatory requirements. If these facilities do not pass a <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">pre-approval</div> plant inspection, regulatory approval of the products may not be granted or may be substantially delayed until any violations are corrected to the satisfaction of the regulatory authority, if ever. </div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The regulatory authorities also may, at any time following approval of a product for sale, inspect the manufacturing facilities of our third-party contractors. If any such inspection or audit identifies a failure to comply with applicable regulations or if a violation of our product specifications or applicable regulations occurs independent of such an inspection or audit, we or the relevant regulatory authority may require remedial measures that may be costly and/or time consuming for us or a third party to implement, and that may include the temporary or permanent suspension of a clinical trial or commercial sales or the temporary or permanent closure of a facility. Any such remedial measures imposed upon us or third parties with whom we contract could materially harm our business. </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Additionally, if supply from one approved manufacturer is interrupted, an alternative manufacturer would need to be qualified through a supplemental NDA or similar regulatory filing, which could result in further delay. </div></div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">25 </div></div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;;font-weight: bold;"><a href="#toc">Table of Contents</a></div> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">The regulatory agencies may also require additional studies if a new manufacturer is relied upon for commercial production. In some cases, the technical skills required to manufacture our product candidates may be unique or proprietary to the original CMO and we may have difficulty, or there may be contractual restrictions prohibiting us from, transferring such skills to a <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">back-up</div> or alternate supplier, or we may be unable to transfer such skills at all. In addition, if we are required to change CMOs for any reason, we will be required to verify that the new CMO maintains facilities and procedures that comply with quality standards and with all applicable regulations. We will also need to verify, such as through a manufacturing comparability study, that any new manufacturing process will produce our product candidate according to the specifications previously submitted to the FDA or another regulatory authority. The delays associated with the verification of a new CMO could negatively affect our ability to develop product candidates or commercialize our products in a timely manner or within budget. In addition, changes in manufacturers often involve changes in manufacturing procedures and processes, which could require that we conduct bridging studies between our prior clinical supply used in our clinical trials and that of any new manufacturer. We may be unsuccessful in demonstrating the comparability of clinical supplies, which could require the conduct of additional clinical trials. Accordingly, switching manufacturers may involve substantial costs and is likely to result in a delay in our desired clinical and commercial timelines. </div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">These factors could cause us to incur higher costs and could cause the delay or termination of clinical trials, regulatory submissions, required approvals, or commercialization of our product candidates. Furthermore, if our suppliers fail to meet contractual requirements and we are unable to secure one or more replacement suppliers capable of production at a substantially equivalent cost, our clinical trials may be delayed or we could lose potential revenue. </div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">If malignancies arise in patients treated with our gene therapy product candidates, including <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">ARU-1801,</div> under development at Aruvant Sciences (&#8220;Aruvant&#8221;) or if there are other safety events that require us to halt or delay clinical development of <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">ARU-1801</div> or other gene therapies, the development of those therapies would be delayed and the commercial potential of those therapies would be materially and negatively impacted. </div></div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;">A potentially significant risk in any gene therapy product candidate using viral vectors is that the vector will insert in or near cancer-causing oncogenes leading to uncontrolled clonal proliferation of mature cancer cells in the patient, known as insertional oncogenesis, which can lead to certain forms of cancer. In early 2021, a company developing a gene therapy for the treatment of sickle cell disease announced that one of its patients has developed acute myelogenous leukemia following treatment.&#160;While Aruvant has not experienced any similar safety events to date, any such events arising in patients treated with <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">ARU-1801</div> could result in delays to the clinical development timeline, the suspension of clinical development altogether or, following approval by the FDA and/or other relevant regulatory authorities, if received, the product being removed from the market or its market opportunity being significantly reduced. In addition, the sickle cell disease population has an elevated underlying risk of malignancy. As a result, if patients treated with <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">ARU-1801</div> develop a malignancy, it may be difficult for us to determine the underlying cause of the malignancy and the link, if any, to <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">ARU-1801,</div> potentially causing further delays to our clinical development timeline. Any of the foregoing issues arising in relation to <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">ARU-1801</div> or other gene therapy product candidates could lead to adverse publicity and have a material adverse effect on our business and the price of our Common Shares. </div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Risks Related to Regulatory Approval and Commercialization of Our Product Candidates </div></div></div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Obtaining approval of a new drug is an extensive, lengthy, expensive and inherently uncertain process, and the FDA or another regulator may delay, limit or deny approval. If we are unable to obtain regulatory approval in one or more jurisdictions for any product candidates, our business will be substantially harmed. </div></div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;">We cannot commercialize a product until the appropriate regulatory authorities have reviewed and approved the product candidate. Approval by the FDA and comparable <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-U.S.</div> regulatory authorities is lengthy and unpredictable, and depends upon numerous factors, including substantial discretion of the regulatory authorities. Approval policies, regulations, or the type and amount of <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-clinical</div> or clinical data necessary to gain approval </div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">26 </div></div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;;font-weight: bold;"><a href="#toc">Table of Contents</a></div> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">may change during the course of a product candidate&#8217;s development and may vary among jurisdictions, which may cause delays in the approval or the decision not to approve an application. To date, we have not obtained regulatory approval for any product candidates, and it is possible that our current product candidates and any other product candidates which we may seek to develop in the future will not ever obtain regulatory approval. We cannot be certain that any of our product candidates will receive regulatory approval or be successfully commercialized even if we receive regulatory approval. </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">Obtaining marketing approval of a new drug is an extensive, lengthy, expensive and inherently uncertain process and the FDA or other <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-U.S.</div> regulatory authorities may delay, limit or deny approval of a product candidate for many reasons, including: </div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">we may not be able to demonstrate that a product candidate is safe and effective as a treatment for the targeted indications, and in the case of our product candidates regulated as biological products, that the product candidate is safe, pure, and potent for use in its targeted indication, to the satisfaction of the FDA or other relevant regulatory authorities; </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;">the FDA or other relevant regulatory authorities may require additional <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">pre-approval</div> studies or clinical trials, which would increase costs and prolong development timelines; </div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">the results of clinical trials may not meet the level of statistical or clinical significance required by the FDA or other relevant regulatory authorities for marketing approval; </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;">the FDA or other relevant regulatory authorities may disagree with the number, design, size, conduct or implementation of clinical trials, including the design of proposed <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">pre-clinical</div> and early clinical trials of any future product candidates; </div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">the CROs that we retain to conduct clinical trials may take actions outside of our control, or otherwise commit errors or breaches of protocols, that adversely impact the clinical trials and ability to obtain marketing approvals; </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;">the FDA or other relevant regulatory authorities may not find the data from nonclinical, <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">pre-clinical</div> studies or clinical trials sufficient to demonstrate that the clinical and other benefits of a product candidate outweigh its safety risks; </div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;">the FDA or other relevant regulatory authorities may disagree with an interpretation of data or significance of results from nonclinical, <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">pre-clinical</div> studies or clinical trials or may require additional studies; </div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">the FDA or other relevant regulatory authorities may not accept data generated at clinical trial sites; </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;">if an NDA, BLA or a similar application is reviewed by an advisory committee, the FDA or other relevant regulatory authority, as the case may be, may have difficulties scheduling an advisory committee meeting in a timely manner or the advisory committee may recommend against approval of our application or may recommend that the FDA or other relevant regulatory authority, as the case may be, require, as a condition of approval, additional nonclinical, <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">pre-clinical</div> studies or clinical trials, limitations on approved labeling or distribution and use restrictions; </div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">the FDA or other relevant regulatory authorities may require development of a risk evaluation and mitigation strategy (&#8220;REMS&#8221;) or its equivalent, as a condition of approval; </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">the FDA or other relevant regulatory authorities may require additional post-marketing studies and/or patient registries for product candidates; </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">the FDA or other relevant regulatory authorities may find the chemistry, manufacturing and controls data insufficient to support the quality of our product candidate; </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">the FDA or other relevant regulatory authorities may identify deficiencies in the manufacturing processes or facilities of third-party manufacturers; or </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">27 </div></div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;;font-weight: bold;"><a href="#toc">Table of Contents</a></div> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;">
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">the FDA or other relevant regulatory authorities may change their approval policies or adopt new regulations. </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">Our future success depends significantly on our ability to successfully complete clinical trials for our product candidates, obtain regulatory approval and then successfully commercialize those product candidates. Any inability to successfully initiate, conduct or complete clinical trials could result in additional costs to us or impair our ability to generate revenue. In addition, if we make manufacturing or formulation changes to our product candidates, we may be required to or we may elect to conduct additional <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-clinical</div> studies or clinical trials to bridge data obtained from our modified product candidates to data obtained from <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-clinical</div> and clinical research conducted using earlier versions of these product candidates. Clinical trial delays could also shorten any periods during which our products have patent protection and may allow our competitors to bring products to market before we do, which could impair our ability to successfully commercialize product candidates and may harm our business and results of operations. </div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Delays in the initiation, conduct or completion of any clinical trial of our product candidates will increase our costs, slow down the product candidate development and approval process and delay or potentially jeopardize our ability to receive regulatory approvals, commence product sales and generate revenue. In addition, many of the factors that cause, or lead to, a delay in the commencement or completion of clinical trials may also ultimately lead to the denial of regulatory approval of our product candidates. Any of these events could have a material adverse effect on our business, prospects, financial condition and results of operations and have a negative impact on the price of our Common Shares. </div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Our clinical trials may fail to demonstrate substantial evidence of the safety and efficacy of product candidates that we may identify and pursue for their intended uses, which would prevent, delay or limit the scope of regulatory approval and commercialization. </div></div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;">Before obtaining regulatory approvals for the commercial sale of any of our product candidates, we must demonstrate through lengthy, complex and expensive <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-clinical</div> studies, <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">pre-clinical</div> studies and clinical trials that the applicable product candidate is both safe and effective for use in each target indication, and in the case of our product candidates regulated as biological products, that the product candidate is safe, pure, and potent for use in its targeted indication. Each product candidate must demonstrate an adequate risk versus benefit profile in its intended patient population and for its intended use. </div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Clinical testing is expensive and can take many years to complete, and its outcome is inherently uncertain. Failure can occur at any time during the clinical development process. Most product candidates that begin clinical trials are never approved by regulatory authorities for commercialization. We have limited experience in designing clinical trials and may be unable to design and execute a clinical trial to support marketing approval. </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">We cannot be certain that our current clinical trials or any other future clinical trials will be successful. Additionally, any safety concerns observed in any one of our clinical trials in our targeted indications could limit the prospects for regulatory approval of our product candidates in those and other indications, which could have a material adverse effect on our business, financial condition and results of operations. In addition, even if such clinical trials are successfully completed, we cannot guarantee that the FDA or comparable <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-U.S.</div> regulatory authorities will interpret the results as we do, and more trials could be required before we submit our product candidates for approval. Moreover, results acceptable to support approval in one jurisdiction may be deemed inadequate by another regulatory authority to support regulatory approval in that other jurisdiction. To the extent that the results of the trials are not satisfactory to the FDA or comparable <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-U.S.</div> regulatory authorities for support of a marketing application, we may be required to expend significant resources, which may not be available to us, to conduct additional trials in support of potential approval of our product candidates. Even if regulatory approval is secured for a product candidate, the terms of such approval may limit the scope and use of the specific product candidate, which may also limit its commercial potential. </div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">28 </div></div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;;font-weight: bold;"><a href="#toc">Table of Contents</a></div> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Our product candidates may cause adverse effects or have other properties that could delay or prevent their regulatory approval, cause us to suspend or discontinue clinical trials, abandon further development or limit the scope of any approved label or market acceptance. </div></div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Adverse events caused by our product candidates could cause us, other reviewing entities, clinical trial sites or regulatory authorities to interrupt, delay or halt clinical trials and could result in the denial of regulatory approval. If an unacceptable frequency or severity of adverse events or new safety signals are reported in our clinical trials for our product candidates or any future product candidates, our ability to obtain regulatory approval for such product candidates may be negatively impacted. Treatment-related side effects arising from, or those perceived to arise from, our product candidates or those from other companies targeting similar diseases, could also affect patient recruitment or the ability of enrolled patients to complete the trial or result in potential product liability claims. In addition, these side effects may not be appropriately recognized or managed by the treating medical staff. For example, in February 2021, our subsidiary Immunovant voluntarily paused dosing in its ongoing trials for IMVT-1401 globally due to elevated total cholesterol and LDL levels observed in patients treated with IMVT-1401, resulting in a delay in Immunovant&#8217;s development of IMVT-1401. Any of these occurrences may harm our business, financial condition and prospects. </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Furthermore, if any of our product candidates are approved and then cause serious or unexpected side effects, a number of potentially significant negative consequences could result, including: </div></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">regulatory authorities may withdraw, suspend, vary, or limit their approval of the product or require a REMS (or equivalent outside the United States) to impose restrictions on its distribution or other risk management measures; </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">regulatory authorities may require that we recall a product; </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">additional restrictions being imposed on the marketing or manufacturing processes of product candidates or any components thereof; </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">regulatory authorities may require the addition of labeling statements, such as warnings or contraindications, require other labeling changes of a product or require field alerts or other communications to physicians, pharmacies or the public; </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">we may be required to change the way a product is administered or to conduct additional clinical trials, change the labeling of a product or conduct additional post-marketing studies or surveillance; </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;">we may be required to repeat <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">pre-clinical</div> studies or clinical trials or terminate programs for a product candidate, even if other studies or trials related to the program are ongoing or have been successfully completed; </div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">we could be sued and held liable for harm caused to patients; </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">we could elect to discontinue the sale of our products; </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">our product candidates may become less competitive; and </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">our reputation may suffer. </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Any of these events could prevent us from achieving or maintaining market acceptance of the affected product candidate and could substantially increase the costs of commercializing our product candidates and have a negative impact on the price of our Common Shares. </div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">The regulatory approval processes of the FDA and comparable <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-U.S.</div> regulatory authorities are lengthy, time consuming and inherently unpredictable, and even if we obtain approval for a product candidate in one country or jurisdiction, we may never obtain approval for or commercialize it in any other jurisdiction, which would limit our ability to realize our full market potential. </div></div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Prior to obtaining approval to commercialize a product candidate in any jurisdiction, we or our collaborators must demonstrate with substantial evidence from well-controlled clinical trials, and to the satisfaction of the FDA </div></div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">29 </div></div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;;font-weight: bold;"><a href="#toc">Table of Contents</a></div> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">or comparable <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-U.S.</div> regulatory agencies, that such product candidate is safe and effective and, as applicable, pure and potent for its intended use. Results from <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-clinical</div> studies and clinical trials can be interpreted in different ways. Even if we believe the nonclinical or clinical data for a product candidate are promising, such data may not be sufficient to support approval by the FDA and other regulatory authorities. In order to market any products in any particular jurisdiction, we must establish and comply with numerous and varying regulatory requirements on a <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">country-by-country</div></div> basis regarding safety and efficacy. Approval by the FDA does not ensure approval by regulatory authorities in any other country or jurisdiction outside the United States. In addition, clinical trials conducted in one country may not be accepted by regulatory authorities in other countries, and regulatory approval in one country does not guarantee regulatory approval in any other country. Approval processes vary among countries and can involve additional product testing and validation, as well as additional administrative review periods. Seeking regulatory approval could result in difficulties and costs for us and require additional nonclinical studies or clinical trials, which could be costly and time consuming. Regulatory requirements can vary widely from country to country and could delay or prevent the introduction of our products in those countries. We do not have any product candidates approved for sale in any jurisdiction, including in international markets, and we do not have experience in obtaining regulatory approval. If we fail to comply with regulatory requirements in international markets or to obtain and maintain required approvals, or if regulatory approvals in international markets are delayed, our target market will be reduced and our ability to realize the full market potential of any product we develop will be unrealized. </div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Our failure to maintain or continuously improve our quality management program could have an adverse effect upon our business, subject us to regulatory actions, cause a loss of patient confidence in us or our products, among other negative consequences. </div></div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Quality management plays an essential role in contract manufacturing of drugs or drug products, conducting clinical trials, preventing defects, improving our product candidates and services and assuring the safety and efficacy of our product candidates. Our goal is to maintain a robust quality management program which includes the following broad pillars of quality: </div></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">monitoring and assuring regulatory compliance for clinical trials, manufacturing and testing of good applicable practice (&#8220;GxP&#8221;) (e.g., GCP, GLP and GMP regulated) products; </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">monitoring and providing oversight of all GxP suppliers (e.g., contract development manufacturing organizations and CROs); </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">establishing and maintaining an integrated, robust quality management system for clinical, manufacturing, supply chain and distribution operations; and </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">cultivating a proactive, preventative quality culture and employee and supplier training to ensure quality. </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Our future success depends on our ability to maintain and continuously improve our quality management program. A quality or safety issue may result in adverse inspection reports, warning letters, monetary sanctions, injunction to halt manufacture and distribution of drugs or drug products, civil or criminal sanctions, costly litigation, refusal of a government to grant approvals and licenses, restrictions on operations or withdrawal, suspension or variation of existing approvals and licenses. An inability to address a quality or safety issue in an effective and timely manner may also cause negative publicity, or a loss of patient confidence in us or our future products, which may result in difficulty in successfully launching product candidates and the loss of potential future sales, which could have an adverse effect on our business, financial condition, and results of operations. </div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Even if we obtain FDA approval for a product candidate in the United States, we may never obtain approval for or commercialize our product candidates in any other jurisdiction, which would limit our ability to realize the drug candidate&#8217;s full market potential. </div></div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">In order to market any products outside of the United States, we must establish and comply with numerous and varying regulatory requirements of other countries regarding safety and effectiveness. Clinical trials </div></div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">30 </div></div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;;font-weight: bold;"><a href="#toc" style="text-indent: 0px;">Table of Contents</a></div> </div> <div> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">conducted in one country may not be accepted by regulatory authorities in other countries, and regulatory approval in one country does not mean that regulatory approval will be obtained in any other country. Approval processes vary among countries and can involve additional product testing and validation and additional or different administrative review periods from those in the United States, including additional <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">pre-clinical</div> studies or clinical trials, as clinical trials conducted in one jurisdiction may not be accepted by regulatory authorities in other jurisdictions. In many jurisdictions outside the United States, a product candidate must be approved for reimbursement before it can be sold in that jurisdiction. In some cases, the price that we intend to charge for our products is also subject to approval. </div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Seeking regulatory approval outside of the United States could result in difficulties and costs and require additional nonclinical studies or clinical trials which could be costly and time-consuming. Regulatory requirements can vary widely from country to country and could delay or prevent the introduction of our product candidates in those countries. The regulatory approval outside of the United States process may include all of the risks associated with obtaining FDA approval. We do not have any product candidates approved for sale in any jurisdiction, including international markets, and we do not have experience in obtaining regulatory approval in international markets. If we fail to comply with regulatory requirements in international markets or to obtain and maintain required approvals, or if regulatory approval in international markets is delayed, our target market will be reduced and our ability to realize the full market potential of our products will be harmed. </div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Even if we obtain regulatory approval for our product candidates, we will still face extensive ongoing quality and regulatory obligations and continued regulatory review, which may result in significant additional expense, and our product may face future development and quality or regulatory compliance difficulties. </div></div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Any product candidate for which we obtain marketing approval will be subject to extensive and ongoing regulatory requirements, including for manufacturing processes, post-approval clinical data, labeling, packaging, distribution, adverse event reporting, storage, recordkeeping, traceability, conduct of potential post-market studies and post-market submission requirements, export, import, advertising and promotional activities for such product, among other things, will be subject to extensive and ongoing requirements of and review by the FDA and other regulatory authorities. These requirements include submissions of safety and other post-marketing information and reports, establishment of registration and drug listing requirements, continued compliance with current cGMP, requirements relating to manufacturing, quality control, quality assurance and corresponding maintenance of records and documents, requirements regarding the distribution of samples to physicians, prior notification/review and/or approval of advertising and promotional materials by the competent authorities, recordkeeping and GCP requirements for any clinical trials that we conduct post-approval. Even if marketing approval of a product candidate is granted, the approval may be subject to limitations on the indicated uses for which the product may be marketed or to the conditions of approval, including any requirement to implement a REMS. If a product candidate receives marketing approval, the accompanying label may limit the approved use of the drug or the FDA or other regulatory authorities may require that contraindications, warnings or precautions, including in some cases, a boxed warning, be included in the product labeling, which could limit sales of the product. </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">The FDA and other relevant regulatory authorities may also impose requirements for costly post-marketing studies or clinical trials and surveillance to monitor the safety or efficacy of a product. Failure to complete such post-marketing requirements in accordance with the timelines and conditions set forth by the FDA and other relevant regulatory authorities could significantly increase costs or delay, limit or ultimately restrict the commercialization of such product. The FDA and other relevant regulatory authorities closely regulates the post-approval marketing and promotion of drugs to ensure drugs are marketed only for the approved indications and in accordance with the provisions of the approved labeling and that promotional and advertising materials and communications are truthful and <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-misleading.</div> Although the FDA and other regulatory agencies do not regulate a physician&#8217;s choice of drug treatment made in the physician&#8217;s independent medical judgment, regulatory authorities impose stringent restrictions on manufacturers&#8217; communications and if we do not market our product candidates for their approved indications or in a manner which regulators believe to be truthful and <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-misleading,</div> we may be subject to enforcement action. Moreover, in the EU we will be prohibited from promoting prescription-only medicinal products to members of </div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">31 </div></div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;;font-weight: bold;"><a href="#toc">Table of Contents</a></div> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">individuals who are not healthcare professionals. Violations of the Federal Food, Drug, and Cosmetic Act in the United States and other comparable regulations in other jurisdictions relating to the promotion of prescription drugs may lead to enforcement actions and investigations by the FDA, Department of Justice, State Attorneys General and other comparable <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-U.S.</div> regulatory agencies alleging violations of United States federal and state health care fraud and abuse laws, as well as state consumer protection laws and comparable laws in other jurisdictions. </div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">In addition, later discovery of previously unknown adverse events or other problems with our product candidates, manufacturers or manufacturing processes, or failure to comply with regulatory requirements, may negatively impact our business and the price of our Common Shares and may yield various results, including: </div></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">restrictions on the manufacture such product candidates; </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">restrictions on the labeling or marketing of such product candidates, including a &#8220;black box&#8221; warning or contraindication on the product label or communications containing warnings or other safety information about the product; </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">restrictions on product distribution or use; </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">requirements to conduct post-marketing studies or clinical trials, or any regulatory holds on our clinical trials; </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">requirement of a REMS (or equivalent outside the United States); </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Warning or Untitled Letters or similar communications from other relevant regulatory authorities; </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">withdrawal of the product candidates from the market; </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">refusal to approve pending applications or supplements to approved applications that we submit; </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">recall of product candidates; </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">fines, restitution or disgorgement of profits or revenues; </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">suspension, variation or withdrawal of marketing approvals; </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">refusal to permit the import or export of our product candidates; </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">product seizure; or </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">lawsuits, injunctions or the imposition of civil or criminal penalties. </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">Non-compliance</div> by us or any current or future collaborator with regulatory requirements, including safety monitoring or pharmacovigilance can also result in significant financial penalties. </div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Breakthrough Therapy Designation, Fast Track Designation, Regenerative Medicine Advanced Therapy Designation or orphan drug designation by the FDA or other relevant regulatory authorities, even if granted for any product candidate, may not lead to a faster development, regulatory review or approval process, and does not necessarily increase the likelihood that any product candidate will receive marketing approval in the United States or other jurisdictions. </div></div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;">We have sought, or may in the future seek, Breakthrough Therapy Designation, Fast Track Designation, Regenerative Medicine Advanced Therapy Designation or orphan drug designation for certain of our product candidates. <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">ARU-1801,</div> a gene therapy in development by Aruvant for the treatment of sickle cell disease, has received orphan drug designation and rare pediatric disease designation by the FDA, as well as priority review and orphan designation by the EMA. In addition, two gene therapies under development by Sio Gene Therapies, <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">AXO-AAV-GM1,</div></div> in development for the treatment of GM1 gangliosidosis, and <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">AXO-AAV-GM2,</div></div> in development for the treatment of GM2 gangliosidosis, also known as <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">Tay-Sachs</div> and Sandhoff diseases, have received rare pediatric disease designation and orphan drug designation (in the case of <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">AXO-AAV-GM1)</div></div> and rare pediatric disease designation (in the case of <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">AXO-AAV-GM2)</div></div> from the FDA. </div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">A breakthrough therapy is defined as a therapy that is intended, alone or in combination with one or more other therapies, to treat a serious or life-threatening disease or condition, and preliminary clinical evidence </div></div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">32 </div></div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;;font-weight: bold;"><a href="#toc">Table of Contents</a></div> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">indicates that the therapy may demonstrate substantial improvement over existing therapies on one or more clinically significant endpoints, such as substantial treatment effects observed early in clinical development. For therapies that have been designated as breakthrough therapies, interaction and communication between the FDA and the sponsor of the trial can help to identify the most efficient path for clinical development while minimizing the number of patients placed in potentially less efficacious control regimens. Therapies designated as breakthrough therapies by the FDA may also be eligible for priority review and accelerated approval. Designation as a breakthrough therapy is within the discretion of the FDA. Accordingly, even if we believe a product candidate meets the criteria for designation as a breakthrough therapy, the FDA may disagree and instead determine not to make such designation. In any event, the receipt of a Breakthrough Therapy Designation for a product candidate may not result in a faster development process, review or approval compared to therapies considered for approval under conventional FDA procedures and does not assure ultimate approval by the FDA. In addition, even if a product candidate qualifies as a breakthrough therapy, the FDA may later decide that such product candidate no longer meets the conditions for qualification or decide that the time period for FDA review or approval will not be shortened. </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">If a therapy is intended for the treatment of a serious or life-threatening condition and the therapy demonstrates the potential to address unmet medical needs for this condition, the therapy sponsor may apply for Fast Track Designation. The FDA has broad discretion whether or not to grant this designation, so even if we believe a particular product candidate is eligible for this designation, we cannot assure you that the FDA would decide to grant it. Even if we do receive Fast Track Designation, we may not necessarily experience a faster development process, review or approval compared to conventional FDA procedures. The FDA may withdraw Fast Track Designation if we believe that the designation is no longer supported by data from our clinical development program. Fast Track Designation alone does not guarantee qualification for the FDA&#8217;s priority review procedures. </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">Regulatory authorities in some jurisdictions, including the United States and the European Economic Area (the &#8220;EEA&#8221;), may designate drugs and biologics for relatively small patient populations as orphan drugs. In the United States, the FDA may designate a drug or biologic as an orphan drug if it is intended to treat a rare disease or condition, which is defined as a disease or condition that affects fewer than 200,000 individuals annually in the United States or for which there is no reasonable expectation that costs of research and development of the drug for the disease or condition can be recovered by sales of the drug in the United States. Generally, if a product with an orphan drug designation subsequently receives the first marketing approval for the indication for which it has such designation, the product is entitled to a period of marketing exclusivity, which precludes the FDA from approving another marketing application for the same drug or biologic for the same orphan indication for that time period. In the United States, in order for a product to receive orphan drug exclusivity, FDA must not have previously approved a drug considered the same drug for the same orphan indication, or the subsequent drug must be shown to be clinically superior to such a previously approved sane drug. The applicable period is seven years in the United States. A similar data exclusivity scheme exists in the EEA, the European Commission, on the basis of a scientific opinion by the EMA&#8217;s Committee for Orphan Medicinal Products, or COMP, grants orphan drug designation to promote the development of products that are intended for the diagnosis, prevention, or treatment of a life-threatening or chronically debilitating condition affecting not more than five in 10,000 persons in the EU. Additionally, designation is granted for products intended for the diagnosis, prevention, or treatment of a life-threatening, seriously debilitating or serious and chronic condition when, without incentives, it is unlikely that sales of the drug in the EU would be sufficient to justify the necessary investment in developing the drug or biological product. In any event, orphan designation is granted only if there is no satisfactory method of diagnosis, prevention, or treatment, or, if such a method exists, the medicine must be of significant benefit to those affected by the condition. Orphan designation in the EU entitles a party to financial incentives such as reduction of fees or fee waivers and ten years of market exclusivity following drug or biological product approval. This orphan market exclusivity period prevents the European Commission and the competent authorities of the EU Member States from accepting an application or granting marketing authorization for any similar medicinal product intended for the same orphan indication. The orphan market exclusivity applies in parallel to the &#8220;normal&#8221; data and market exclusivity in the EEA, whereby no company can make reference to (rely on) the innovator drug company&#8217;s <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">pre-clinical</div> and clinical data in order to obtain a marketing authorization </div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">33 </div></div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;;font-weight: bold;"><a href="#toc">Table of Contents</a></div> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">for eight years from the date of the first approval of the innovator drug in the EEA and no generic drug can be marketed for ten years from the first approval of the innovator drug in the EEA; the innovator drug may qualify for an extra year&#8217;s protection. This additional one year of marketing exclusivity may be obtained where the innovator company is granted a marketing authorization for a significant new indication for the relevant medicinal product. In such a situation, the generic company can only market their product after 11 years from the first grant of the innovator company&#8217;s marketing authorization for the product in the EEA. </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Orphan drug exclusivity may be lost if the FDA or EMA determines that the request for designation was materially defective or if the manufacturer is unable to assure sufficient quantity of the drug or biologic to meet the needs of patients with the rare disease or condition. In the EEA, orphan drug designation, and the related benefits, may be lost if it is established before the market authorization is granted that the designation criteria are no longer met. </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px; text-indent: 0px;;display:inline;">Moreover, the ten year orphan market exclusivity in the EEA may be reduced to six years if the orphan drug designation criteria are no longer met at the end of the fifth year since grant of the approval, including where it is shown that the product is sufficiently profitable not to justify maintenance of market exclusivity. </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">If we obtain orphan drug exclusivity for a product, that exclusivity may not effectively protect the product from competition because different drugs can be approved for the same condition. Even after an orphan drug is approved, the FDA or the EMA can subsequently approve the same drug for a different condition or the same condition if the FDA or the EMA concludes that the later drug is clinically superior in that it is shown to be safer, more effective or makes a major contribution to patient care. In the EEA, a marketing authorization may also be granted, for the same therapeutic indication, to a competitor with a similar medicinal product during the exclusivity period if we are unable to supply sufficient quantities of the medicinal product for which we received marketing authorization. Upcoming legislative reforms in the EU may result in a reduction of market exclusivity periods for orphan medicinal products and/or imposition of additional requirements for grant of such exclusivity. </div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Certain of our gene therapy product candidates are based on novel technologies and the regulatory landscape that governs these product candidates we may develop is rigorous, complex, uncertain and subject to change, which makes it difficult to predict the time and cost of developing the product candidates and subsequently obtaining regulatory approval. </div></div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The clinical study requirements of the FDA, the EMA and other regulatory agencies and the criteria these regulators use to determine the safety and efficacy of a product candidate vary substantially according to the type, complexity, novelty and intended use and market of the potential product candidates. The regulatory approval process for novel product candidates such as our gene therapies can be more expensive and take longer than for other, better known or more extensively studied pharmaceutical or other product candidates. Currently, a limited number of gene therapy products have been approved by the FDA, the EMA and the European Commission. Given the few precedents of approved gene therapy products, it is difficult to determine how long it will take or how much it will cost to obtain regulatory approvals for our product candidates in the United States, the EU or other jurisdictions. Approvals by the EMA and the European Commission may not be indicative of what the FDA may require for approval. </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Regulatory requirements governing the development of gene therapy products have changed frequently and may continue to change in the future. The FDA has established the Office of Tissues and Advanced Therapies within the Center for Biologics Evaluation and Research (the &#8220;CBER&#8221;), to consolidate the review of gene therapy and related products, and to advise the CBER on its review. The FDA can put an IND on clinical hold if the information in an IND is not sufficient to assess the risks in pediatric patients. In addition to FDA oversight and oversight by IRBs, under guidelines promulgated by the National Institutes of Health (&#8220;NIH&#8221;) gene therapy clinical trials funded by NIH are also subject to review and oversight by an institutional biosafety committee (&#8220;IBC&#8221;), a local institutional committee that reviews and oversees research utilizing recombinant or synthetic nucleic acid molecules at that institution. Before a clinical study can begin at any institution, that institution&#8217;s IRB, and, where applicable, its IBC assesses the safety of the research and identifies any potential risk to public </div></div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">34 </div></div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;;font-weight: bold;"><a href="#toc">Table of Contents</a></div> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">health or the environment. While the NIH guidelines are not mandatory unless the research in question is being conducted at or sponsored by institutions receiving NIH funding of recombinant or synthetic nucleic acid molecule research, many companies and other institutions not otherwise subject to the NIH Guidelines voluntarily follow them. Moreover, serious adverse events or developments in clinical trials of gene therapy product candidates conducted by others may cause the FDA or other regulatory bodies to initiate a clinical hold on our clinical trials or otherwise change the requirements for approval of any of our product candidates. Although the FDA decides whether individual gene therapy protocols may proceed, the review process and determinations of other reviewing bodies can impede or delay the initiation of a clinical trial, even if the FDA has reviewed the trial and approved its initiation. </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">Adverse developments in <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">pre-clinical</div> studies or clinical trials conducted by others in the field of gene therapy and gene regulation products may cause the FDA, the EMA and other regulatory bodies to revise the requirements for approval of any product candidates we may develop or limit the use of products utilizing gene regulation technologies, either of which could harm our business. In addition, the clinical trial requirements of the FDA, the EMA and other regulatory authorities and the criteria these regulators use to determine the safety and efficacy of a product candidate vary substantially according to the type, complexity, novelty, and intended use and market of the potential products. The regulatory approval process for novel product candidates such as our gene therapies can be more expensive and take longer than for other, better known, or more extensively studied pharmaceutical or other product candidates. In addition, because of the evolving regulatory landscape for novel product candidates such as our gene therapies, there is a heightened risk relating to changes in regulatory requirements, such as the required trial size, the size of safety databases and duration of clinical <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">follow-up</div> required for approval, which could develop in a manner that adversely impacts our business, financial condition and results of operations. </div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Further, as we are developing novel potential treatments for diseases in which there is little clinical experience with new endpoints and methodologies, there is heightened risk that the FDA, the EMA or other regulatory bodies may not consider the clinical trial endpoints to provide clinically meaningful results, and the resulting clinical data and results may be more difficult to analyze. The prospectively designed natural history studies with the same endpoints as our corresponding clinical trials may not be accepted by the FDA, EMA or other regulatory authorities. Regulatory agencies administering existing or future regulations or legislation may not allow production and marketing of products utilizing gene regulation technology in a timely manner or under technically or commercially feasible conditions. In addition, regulatory action or private litigation could result in expenses, delays, or other impediments to our research programs or the commercialization of resulting products. </div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Even if our product candidates receive marketing approval, they may fail to achieve market acceptance by physicians, patients, third-party payors or others in the medical community necessary for commercial success. </div></div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The commercial success of our product candidates will depend upon their degree of market acceptance by physicians, patients, third-party payors and others in the medical community. Even if any product candidates we may develop receive marketing approval, they may nonetheless fail to gain sufficient market acceptance by physicians, patients, healthcare payors and others in the medical community. The degree of market acceptance for any product candidates we may develop, if approved for commercial sale, will depend on a number of factors, including: </div></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">the efficacy and safety of such product candidates as demonstrated in pivotal clinical trials and published in peer-reviewed journals; </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">the potential and perceived advantages compared to alternative treatments, including any similar generic treatments; </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">the ability to offer these products for sale at competitive prices; </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;">the ability to offer appropriate patient financial assistance programs, such as commercial insurance <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">co-pay</div> assistance; </div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">35 </div></div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;;font-weight: bold;"><a href="#toc">Table of Contents</a></div> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;">
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">convenience and ease of dosing and administration compared to alternative treatments; </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;">the clinical indications for which the product candidate is approved by FDA or comparable <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-U.S.</div> regulatory agencies; </div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;">product labeling or product insert requirements of the FDA or other comparable <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-U.S.</div> regulatory authorities, including any limitations, contraindications or warnings contained in a product&#8217;s approved labeling; </div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">restrictions on how the product is dispensed or distributed; </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">the timing of market introduction of competitive products; </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">publicity concerning these products or competing products and treatments; </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">the strength of marketing and distribution support; </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">favorable third-party coverage and sufficient reimbursement; and </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">the prevalence and severity of any side effects or AEs. </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Sales of medical products also depend on the willingness of physicians to prescribe the treatment, which is likely to be based on a determination by these physicians that the products are safe, therapeutically effective and cost effective. In addition, the inclusion or exclusion of products from treatment guidelines established by various physician groups and the viewpoints of influential physicians can affect the willingness of other physicians to prescribe such products. </div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">If approved, our product candidates regulated as biologics may face competition from biosimilars approved through an abbreviated regulatory pathway. </div></div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;">The Patient Protection and Affordable Care Act, as amended by the Health Care and Education Reconciliation Act of 2010 (the &#8220;ACA&#8221;), includes a subtitle called the Biologics Price Competition and Innovation Act of 2009 (the &#8220;BPCIA&#8221;), which created an abbreviated approval pathway under section 351(k) of the Public Health Service Act (&#8220;PHSA&#8221;) for biological products that are biosimilar to or interchangeable with <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">an&#160;FDA-licensed&#160;reference</div> biological product. Under the BPCIA, a section 351(k) application for a biosimilar or interchangeable product may not be submitted to the FDA until four years following the date that the reference product was first licensed by the FDA. In addition, the approval of a biosimilar or interchangeable product may not be made effective by the FDA until 12 years from the date on which the reference product was first licensed. During <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">this&#160;12-year&#160;period</div> of exclusivity, another company may still market a competing version of the reference product if the FDA approves a full BLA for the competing product submitted under section 351(a) of the PHSA containing the competing sponsor&#8217;s own <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">pre-clinical</div> data and data from adequate and well-controlled clinical trials to demonstrate the safety, purity, and potency of the other company&#8217;s product. The law is complex and is still being interpreted and implemented by the FDA and the FDA only approved the first interchangeable biosimilar in July 2021. As a result, its ultimate impact, implementation, and meaning are subject to uncertainty. In addition, the Further Consolidated Appropriations Act, 2020, which incorporated the framework from the Creating and Restoring Equal Access To Equivalent Samples legislation, purports to promote competition in the market for drugs and biological products by facilitating the timely entry of lower-cost generic and biosimilar versions of those drugs and biological products, including by allowing generic drug, 505(b)(2) NDA or biosimilar developers to obtain access to branded drug and biological product samples. While the full impact of these provisions is unclear at this time, its provisions do have the potential to facilitate the development and future approval of biosimilar versions of our products, introducing biosimilar competition that could have a material adverse impact on our business, financial condition and results of operations. </div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Whether approval of a biological product qualifies for reference product exclusivity turns on whether FDA consider the approval a &#8220;first licensure.&#8221; Not every licensure of a biological product is considered a &#8220;first licensure&#8221; that gives rise to its own exclusivity period. We believe that our product candidates approved as a </div></div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">36 </div></div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;;font-weight: bold;"><a href="#toc">Table of Contents</a></div> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">biological product under a BLA should qualify for <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">the&#160;12-year&#160;period</div> of exclusivity. However, there is a risk that this exclusivity could be shortened due to congressional action or otherwise. Other aspects of the BPCIA, some of which may impact the BPCIA exclusivity provisions, have also been the subject of recent litigation. Moreover, the extent to which a biosimilar, once licensed, will be substituted for any one of our reference products in a way that is similar to traditional generic substitution <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">for&#160;non-biological&#160;products</div> is not yet clear, and will depend on a number of marketplace and regulatory factors that are still developing. If competitors are able to obtain marketing approval for biosimilars referencing our products, our products may become subject to competition from such biosimilars, with the attendant competitive pressure and consequences. </div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">If, in the future, we are unable to establish sales, marketing and distribution capabilities or enter into agreements with third parties to sell, market and distribute any product candidates we may develop, we may not be successful in commercializing those product candidates if and when they are approved. </div></div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;">We do not currently have any infrastructure for the sales, marketing or distribution of any product, and the cost of establishing and maintaining such an organization may exceed the cost-effectiveness of doing so. In order to market any product that may be approved, we must build our sales, distribution, marketing, compliance, managerial and other <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-technical</div> capabilities or make arrangements with third parties to perform these services. To achieve commercial success for any product for which we obtain marketing approval, we will need a sales and marketing organization or outsource these functions to third parties. In the future, we may choose to build a focused sales, marketing, and commercial support infrastructure to market and sell our product candidates, if and when they are approved. We may also elect to enter into collaborations or strategic partnerships with third parties to engage in commercialization activities with respect to selected product candidates, indications or geographic territories, including territories outside the United States, although there is no guarantee we will be able to enter into these arrangements even if the intent is to do so. </div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">There are risks involved with both establishing our own commercial capabilities and entering into arrangements with third parties to perform these services. For example, recruiting and training a sales force or reimbursement specialists is expensive and time consuming and could delay any product launch. If the commercial launch of a product candidate for which we recruit a sales force and establish marketing and other commercialization capabilities is delayed or does not occur for any reason, we would have prematurely or unnecessarily incurred these commercialization expenses. This may be costly, and our investment would be lost if we cannot retain or reposition commercialization personnel. </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Factors that may inhibit our efforts to commercialize any approved product on our own include: </div></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">the inability to recruit and retain adequate numbers of effective sales, marketing, reimbursement, customer service, medical affairs, and other support personnel; </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">the inability of sales personnel to obtain access to physicians or persuade adequate numbers of physicians to prescribe any future approved products; </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">the inability of reimbursement professionals to negotiate arrangements for formulary access, reimbursement, and other acceptance by payors; </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">the inability to price products at a sufficient price point to ensure an adequate and attractive level of profitability; </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">restricted or closed distribution channels that make it difficult to distribute our products to segments of the patient population; </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">the lack of complementary products to be offered by sales personnel, which may put us at a competitive disadvantage relative to companies with more extensive product lines; and </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">unforeseen costs and expenses associated with creating an independent commercialization organization. </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">37 </div></div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;;font-weight: bold;"><a href="#toc">Table of Contents</a></div> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">If we are unable to build our own sales force or negotiate a collaborative relationship for the commercialization of any product candidate, we may be forced to delay potential commercialization or reduce the scope of our sales or marketing activities. If we elect to increase our expenditures to fund commercialization activities ourselves, we will need to obtain additional capital, which may not be available to us on acceptable terms, or at all. If we do not have sufficient funds, we will not be able to bring any product candidate to market or generate product revenue. We could enter into arrangements with collaborative partners at an earlier stage than otherwise would be ideal and we may be required to relinquish certain rights to our product candidate or otherwise agree to terms unfavorable to us, any of which may have an adverse effect on our business, operating results and prospects. </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">If we enter into arrangements with third parties to perform sales, marketing, commercial support, and distribution services, our product revenue or the profitability of product revenue may be lower than if we were to market and sell any products we may develop internally. In addition, we may not be successful in entering into arrangements with third parties to commercialize our product candidates or may be unable to do so on terms that are favorable to us or them. We may have little control over such third parties, and any of them may fail to devote the necessary resources and attention to sell and market our products effectively or may expose us to legal and regulatory risk by not adhering to regulatory requirements and restrictions governing the sale and promotion of prescription drug products, including those restricting <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">off-label</div> promotion. If we do not establish commercialization capabilities successfully, either on our own or in collaboration with third parties, we will not be successful in commercializing our product candidates, if approved. </div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Our current and future relationships with investigators, health care professionals, consultants, third-party payors, patient support, charitable organizations, customers, and others are subject to applicable healthcare regulatory laws, which could expose us to penalties and other risks. </div></div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Our business operations and current and potential future arrangements with investigators, healthcare professionals, consultants, third-party payors, patient support, charitable organizations, customers, and others, expose us to broadly applicable fraud and abuse and other healthcare laws and regulations. These laws regulate the business or financial arrangements and relationships through which we conduct our operations, including how we research, market, sell and distribute our product candidates for which we obtain marketing approval. Such laws include, without limitation: </div></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">the federal Anti-Kickback Statute, which is a criminal law that prohibits, among other things, persons and entities from knowingly and willfully soliciting, offering, receiving or providing remuneration, directly or indirectly, in cash or in kind, to induce or reward, or in return for, either the referral of an individual for, or the purchase, lease, order or recommendation of, any good, facility, item or service, for which payment may be made, in whole or in part, under a federal healthcare program (such as Medicare and Medicaid). The term &#8220;remuneration&#8221; has been broadly interpreted by the federal government to include anything of value. Although there are a number of statutory exceptions and regulatory safe harbors protecting certain activities from prosecution, the exceptions and safe harbors are drawn narrowly, and arrangements may be subject to scrutiny or penalty if they do not fully satisfy all elements of an available exception or safe harbor. Practices that involve remuneration that may be alleged to be intended to induce prescribing, purchases or recommendations may be subject to scrutiny if they do not qualify for an exception or safe harbor. A person or entity does not need to have actual knowledge of the federal Anti-Kickback Statute or specific intent to violate it to have committed a violation; in addition, the government may assert that a claim including items or services resulting from a violation of the federal Anti-Kickback Statute constitutes a false or fraudulent claim for purposes of the False Claims Act. Violations of the federal Anti-Kickback Statute may result in civil monetary penalties up to $100,000 for each violation. Civil penalties for such conduct can further be assessed under the federal False Claims Act. Violations can also result in criminal penalties, including criminal fines and imprisonment of up to 10 years. Similarly, violations can result in exclusion from participation in government healthcare programs, including Medicare and Medicaid; </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">38 </div></div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;;font-weight: bold;"><a href="#toc">Table of Contents</a></div> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;">
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">the federal false claims laws, including the False Claims Act, which imposes civil penalties, including through civil whistleblower or qui tam actions, against individuals or entities for knowingly presenting, or causing to be presented, to the federal government, claims for payment that are false or fraudulent; knowingly making, using or causing to be made or used, a false record or statement material to a false or fraudulent claim; or knowingly making or causing to be made, a false statement to avoid, decrease or conceal an obligation to pay money to the federal government. When an entity is determined to have violated the federal civil False Claims Act, the government may impose civil fines and penalties currently ranging from $11,665 to $23,331 for each false claim or statement for penalties assessed after June&#160;19, 2020, with respect to violations occurring after November&#160;2, 2015, plus treble damages, and exclude the entity from participation in Medicare, Medicaid and other federal healthcare programs; </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">the federal health care fraud statute (established by Health Insurance Portability and Accountability Act of 1996 (&#8220;HIPAA&#8221;)), which imposes criminal and civil liability for, among other things, knowingly and willfully executing, or attempting to execute, a scheme to defraud any healthcare benefit program or making false or fraudulent statements relating to healthcare matters; similar to the federal Anti-Kickback Statute, a person or entity does not need to have actual knowledge of the statute or specific intent to violate it to have committed a violation; </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">the Administrative Simplification provisions of HIPAA, as amended by the Health Information Technology for Economic and Clinical Health Act (&#8220;HITECH&#8221;), and their implementing regulations, which impose obligations, including mandatory contractual terms, with respect to safeguarding the privacy, security, and transmission of individually identifiable health information on health plans, health care clearing houses, and most healthcare providers and their business associates, defined as independent contractors or agents of covered entities that create, receive or obtain protected health information in connection with providing a service for or on behalf of a covered entity; </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">various privacy, cybersecurity and data protection laws, rules and regulations at the international, federal, state and local level impose obligations with respect to safeguarding the privacy, security, and cross-border transmission of personal data and health information; </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">the federal Civil Monetary Penalties Law, which authorizes the imposition of substantial civil monetary penalties against an entity that engages in activities including, among others (1)&#160;knowingly presenting, or causing to be presented, a claim for services not provided as claimed or that is otherwise false or fraudulent in any way; (2)&#160;arranging for or contracting with an individual or entity that is excluded from participation in federal health care programs to provide items or services reimbursable by a federal health care program; (3)&#160;violations of the federal Anti-Kickback Statute; or (4)&#160;failing to report and return a known overpayment; </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">the federal Physician Payments Sunshine Act, which requires certain manufacturers of drugs, devices, biologics, and medical supplies for which payment is available under Medicare, Medicaid or the Children&#8217;s Health Insurance Program (with certain exceptions) to report annually to the government information related to payments or other &#8220;transfers of value&#8221; made to physicians, certain other healthcare providers, and teaching hospitals, and requires applicable manufacturers and group purchasing organizations to report annually to the government ownership and investment interests held by the physicians described above and their immediate family members and payments or other &#8220;transfers of value&#8221; to such physician owners (covered manufacturers are required to submit reports to the government by the 90th day of each calendar year); and </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;">analogous state and EU and foreign national laws and regulations, such as state anti-kickback and false claims laws, which may apply to our business practices, including but not limited to, research, distribution, sales, and marketing arrangements and claims involving healthcare items or services reimbursed by <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-governmental</div> third-party payors, including private insurers, or otherwise restrict payments that may be made to healthcare providers and other potential referral sources; state laws that require pharmaceutical companies to comply with the pharmaceutical industry&#8217;s voluntary compliance guidelines and the relevant compliance guidance promulgated by the federal government, and state </div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">39 </div></div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;;font-weight: bold;"><a href="#toc">Table of Contents</a></div> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;">
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 9%;">&#160;</td>
<td style="vertical-align: top;"> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">laws that require drug manufacturers to report information related to payments and other transfers of value to physicians and other healthcare providers or marketing expenditures; and several recently passed state laws that require disclosures related to state agencies and/or commercial purchasers with respect to certain price increases that exceed a certain level as identified in the relevant statutes, some of which contain ambiguous requirements that government officials have not yet clarified; and EU and foreign national laws prohibiting promotion of prescription-only medicinal products to individuals other than healthcare professionals, governing strictly all aspects of interactions with healthcare professionals and healthcare organizations and requiring public disclosure of transfers of value made to a broad range of stakeholders, including healthcare professionals, healthcare organizations, medical students, physicians associations, patient organizations and editors of specialized press. </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Efforts to ensure that our current and future business arrangements with third parties will comply with applicable healthcare laws and regulations will involve substantial costs. It is possible that governmental authorities will conclude that our business practices do not comply with current or future statutes, regulations, agency guidance or case law involving applicable healthcare laws. If our operations are found to be in violation of any of these or any other applicable health regulatory laws that may apply to us, we may be subject to significant penalties, including the imposition of significant civil, criminal and administrative penalties, damages, monetary fines, disgorgement, individual imprisonment, possible exclusion from participation in Medicare, Medicaid and other federal healthcare programs, contractual damages, reputational harm, diminished profits and future earnings, additional reporting requirements and oversight if we become subject to a corporate integrity agreement or similar agreement and curtailment or restructuring of our operations, any of which could adversely affect our ability to operate our business and our results of operations. Even the mere issuance of a subpoena, civil investigative demand or the fact of an investigation alone, regardless of the merit, may result in negative publicity, a drop in our share price and other harm to our business, financial condition and our results of operations. Defending against any such actions can be costly, time-consuming and may require significant financial and personnel resources. Therefore, even if we are successful in defending against any such actions that may be brought against us, our business may be impaired. </div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Healthcare legislative measures aimed at reducing healthcare costs may have a material adverse effect on our business and results of operations. </div></div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The United States and many other jurisdictions have enacted or proposed legislative and regulatory changes affecting the healthcare system that could prevent or delay marketing approval of our product candidates or any future product candidates, restrict or regulate post-approval activities and affect our ability to profitably sell any product for which we obtain marketing approval. Changes in regulations, statutes or the interpretation of existing regulations could impact our business in the future by requiring, for example: (i)&#160;changes to our manufacturing arrangements; (ii)&#160;additions or modifications to product labeling; (iii)&#160;the recall or discontinuation of our products; or (iv)&#160;additional record-keeping requirements. If any such changes were to be imposed, they could adversely affect the operation of our business. </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">In the United States, there have been and continue to be a number of legislative initiatives to contain healthcare costs, including costs for pharmaceuticals. For example, in March 2010, the ACA was passed, which substantially changed the way healthcare is financed by both governmental and private insurers, and significantly impacted the U.S. pharmaceutical industry. The ACA, among other things, subjects biological products to potential competition by lower-cost biosimilars, addresses a new methodology by which rebates owed by manufacturers under the Medicaid Drug Rebate Program are calculated for drugs that are inhaled, infused, instilled, implanted or injected, increases the minimum Medicaid rebates owed by manufacturers under the Medicaid Drug Rebate Program and extends the rebate program to individuals enrolled in Medicaid managed care organizations, establishes annual fees and taxes on manufacturers of certain branded prescription drugs, and creates a new Medicare Part D coverage gap discount program, in which manufacturers must agree to offer 70% </div></div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">40 </div></div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;;font-weight: bold;"><a href="#toc" style="text-indent: 0px;">Table of Contents</a></div> </div> <div> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">point-of-sale</div></div> discounts off negotiated prices of applicable brand drugs to eligible beneficiaries during their coverage gap period, as a condition for the manufacturer&#8217;s outpatient drugs to be covered under Medicare Part D. </div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Since its enactment, there have been numerous judicial, administrative, executive, and legislative challenges to certain aspects of the ACA, and we expect there will be additional challenges and amendments to the ACA in the future, with unpredictable and uncertain results. Congress has introduced several pieces of legislation aimed at significantly revising or repealing the ACA. The law appears likely to continue the downward pressure on pharmaceutical pricing, especially under the Medicare program, and may also increase our regulatory burdens and operating costs. </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">In addition, other legislative changes have been proposed and adopted in the United States since the ACA was enacted. In August 2011, the Budget Control Act of 2011, among other things, created measures for spending reductions by Congress. A Joint Select Committee on Deficit Reduction, tasked with recommending a targeted deficit reduction of at least $1.2 trillion for the years 2013 through 2021, was unable to reach required goals, thereby triggering the legislation&#8217;s automatic reduction to several government programs. This includes aggregate reductions of Medicare payments to providers of 2% per fiscal year, which went into effect in 2013, and, due to subsequent legislative amendments, will remain in effect through 2029 unless additional Congressional action is taken. Pursuant to the CARES Act and subsequent legislation, these reductions were suspended from May&#160;1, 2020 through December&#160;31, 2021 due to the <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">COVID-19</div> pandemic. As the legislation currently stands, the reductions will go back into effect as of January 2022 and will remain in effect through 2030 unless additional Congressional action is taken. The American Taxpayer Relief Act of 2012 further reduced Medicare payments to several providers, including hospitals and cancer treatment centers, and increased the statute of limitations period for the government to recover overpayments to providers from three to five years. </div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">There has been increasing legislative and enforcement interest in the United States with respect to drug pricing practices. Specifically, there have been several recent U.S. Congressional inquiries and proposed federal and state legislation designed to, among other things, bring more transparency to drug pricing, reduce the cost of prescription drugs under Medicare, and reform government program reimbursement methodologies for drugs. Current Congressional proposals include direct price negotiation by Medicare in Medicare Parts B and D, international reference pricing for certain Medicare drugs, and inflationary rebates on Part B and Part D drugs whose prices increase above a certain amount, and Part D drug benefit redesign. At the federal level, the former Trump administration released a &#8220;Blueprint&#8221; to lower drug prices and reduce out of pocket costs of drugs that contains additional proposals to increase manufacturer competition, increase the negotiating power of certain federal healthcare programs, incentivize manufacturers to lower the list price of their products and reduce the out of pocket costs of drug products paid by consumers. The U.S. Department of Health and Human Services (&#8220;HHS&#8221;) implemented several of these provisions to date. In May 2019, Centers for Medicare and Medicaid Services (the &#8220;CMS&#8221;), issued a final rule to allow Medicare Advantage Plans the option of using step therapy, a type of prior authorization, for Part B drugs beginning January&#160;1, 2020. Additionally, on November&#160;20, 2020, HHS finalized a regulation removing safe harbor protection for price reductions from pharmaceutical manufacturers to plan sponsors under Part D, either directly or through pharmacy benefit managers, unless the price reduction is required by law. The rule also creates a new safe harbor for price reductions reflected at the <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">point-of-sale,</div></div> as well as a safe harbor for certain fixed fee arrangements between pharmacy benefit managers and manufacturers. These modifications to the safe harbors are being challenged in court and HHS has delayed their implementation until January&#160;1, 2023; however, the rule may be repealed through legislative action before such time. In July 2021, President Biden issued an executive order pertaining to drug pricing, which expressed support for legislation allowing direct negotiation in Medicare Part D and inflationary rebates, and directed various executive branch agencies to take actions to lower drug prices and promote generic competition. Several pending legislative efforts, including President Biden&#8217;s larger Build Back Better legislative agenda, incorporate these drug pricing reforms in addition to policies aimed at redesigning the Medicare Part D benefit and adopting drug price transparency measures. </div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">41 </div></div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;;font-weight: bold;"><a href="#toc">Table of Contents</a></div> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Recent federal legislation and actions by state and local governments in the United States may permit reimportation of drugs from foreign countries into the United States, including foreign countries where the drugs are sold at lower prices than in the United States, which could materially adversely affect our operating results. </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Moreover, upcoming legislative and policy changes in the EU, some of which may materialize as early as 2022, are aimed at increasing accessibility and affordability of medicinal products, as well as at increased cooperation between the EU Member States. Such initiatives may further impact the price and reimbursement status of our products in the future. </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">There have been, and likely will continue to be, legislative and regulatory proposals at the national and state levels in jurisdictions around the world directed at containing or lowering the cost of healthcare, including prescription drugs. The implementation of cost containment measures or other healthcare reforms may prevent us from being able to generate revenue, attain profitability, or commercialize our product. Such reforms could have an adverse effect on anticipated revenue from product candidates that we may successfully develop and for which we may obtain regulatory approval and may affect our overall financial condition and ability to develop product candidates. We cannot predict the initiatives that may be adopted in the future. The continuing efforts of the government, insurance companies, managed care organizations and other payors of healthcare services to contain or reduce costs of healthcare and/or impose price controls may adversely affect: </div></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">the demand for our product candidates, if approved; </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">our ability to receive or set a price that we believe is fair for our products; </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">our ability to generate revenue and achieve or maintain profitability; </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">the amount of taxes that we are required to pay; and </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">the availability of capital. </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">We expect that healthcare reform measures that may be adopted in the future, may result in additional reductions in Medicare and other healthcare funding, more rigorous coverage criteria, lower reimbursement and new payment methodologies. This could lower the price that we receive for any approved product. Any denial in coverage or reduction in reimbursement from Medicare or other government-funded programs may result in a similar denial or reduction in payments from private payors, which may prevent us from being able to generate sufficient revenue, attain profitability or commercialize our product candidates, if approved. </div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Coverage and adequate reimbursement may not be available for our product candidates, which could make it difficult for us to sell our product candidates profitably. </div></div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Market acceptance and sales of any approved product candidates that we develop will depend in part on the extent to which coverage and adequate reimbursement for these product candidates and related treatments will be available from third-party payors, including government health administration authorities and private health insurers. The target patient populations for our drugs are often relatively small, as a result of which the pricing and reimbursement of our product candidates, if approved, must be adequate to support commercial infrastructure. If we are unable to obtain adequate levels of reimbursement, our ability to successfully market and sell our product candidates will be adversely affected. The manner and level at which reimbursement is provided for services related to our product candidates (e.g., for administration of our product to patients) is also important. Inadequate reimbursement for such services may lead to physician resistance and adversely affect our ability to market or sell our product candidates. There is no assurance that our product candidates, if approved, would achieve adequate coverage and reimbursement levels. </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">In the United States, no uniform policy of coverage and reimbursement for product candidates exists among third-party payors. Third-party payors decide which drugs they will pay for and establish reimbursement levels. Third-party payors often rely upon Medicare coverage policy and payment limitations in setting their own coverage and reimbursement policies. However, decisions regarding the extent of coverage and amount of </div></div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">42 </div></div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;;font-weight: bold;"><a href="#toc">Table of Contents</a></div> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">reimbursement to be provided for any product candidates that we develop will be made on a <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">plan-by-plan</div></div> basis. One payor&#8217;s determination to provide coverage for a product does not assure that other payors will also provide coverage, and adequate reimbursement, for the product. Additionally, a third-party payor&#8217;s decision to provide coverage for a drug does not imply that an adequate reimbursement rate will be approved. Each plan determines whether or not it will provide coverage for a drug, what amount it will pay the manufacturer for the drug, on what tier of its formulary the drug will be placed and whether to require step therapy. The position of a drug on a formulary generally determines the <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">co-payment</div> that a patient will need to make to obtain the drug and can strongly influence the adoption of a drug by patients and physicians. Patients who are prescribed treatments for their conditions and providers prescribing such services generally rely on third-party payors to reimburse all or part of the associated healthcare costs. Patients are unlikely to use our product candidates unless coverage is provided and reimbursement is adequate to cover a significant portion of the cost of the product candidates. Further, from time to time, typically on an annual basis, payment rates are updated and revised by third-party payors. Such updates could impact the demand for our product candidates, to the extent that patients who are prescribed our product candidates, if approved, are not separately reimbursed for the cost of the product. </div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The process for determining whether a third-party payor will provide coverage for a product may be separate from the process for setting the price of a product or for establishing the reimbursement rate that such a payor will pay for the product. Even if we obtain adequate levels of reimbursement, third-party payors, such as government or private healthcare insurers, carefully review and increasingly question the coverage of, and challenge the prices charged for, product candidates. A primary trend in the U.S. healthcare industry and elsewhere is cost containment. Increasingly, third-party payors are requiring that pharmaceutical companies provide them with predetermined discounts from list prices and are challenging the prices for product candidates. We may also be required to conduct expensive pharmacoeconomic studies to justify the coverage and the amount of reimbursement for particular medications. We cannot be sure that coverage and reimbursement will be available for any product that we commercialize and, if reimbursement is available, what the level of reimbursement will be. Inadequate coverage and reimbursement may impact the demand for, or the price of, any product for which we obtain marketing approval. If coverage and adequate reimbursement are not available, or are available only to limited levels, we may not be able to successfully commercialize any product candidates that we develop. </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Additionally, there have been a number of legislative and regulatory proposals to change the healthcare system in the United States and in some other jurisdictions that could affect our ability to sell any future drugs profitably. These legislative and regulatory changes may negatively impact the reimbursement for any future drugs, following approval. There can be no assurance that our candidates, if approved, will be considered medically reasonable and necessary, that they will be considered cost-effective by third-party payors, that coverage or an adequate level of reimbursement will be available, or that reimbursement policies and practices in the United States and in other countries where our product candidates are sold will not harm our ability to sell our product candidates profitably, if they are approved for sale. </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">In the EU, similar political, economic and regulatory developments may affect our ability to profitably commercialize our product candidates, if approved. In addition to continuing pressure on prices and cost containment measures, legislative developments in the EU or the EU Member State may harm our ability to sell our product candidates profitably, if they are approved for sale. The delivery of healthcare in the EU, including the establishment and operation of health services and the pricing and reimbursement of medicines, is almost exclusively a matter for national EU Member States law. National governments and health service providers have different priorities and approaches to the delivery of health care and the pricing and reimbursement of products in that context. The healthcare budgetary constraints in most countries have resulted in restrictions on the pricing and reimbursement of medicines. In markets outside of the United States and EU, reimbursement and healthcare payment systems vary significantly by country, and many countries have instituted price ceilings on specific products and therapies. All of this could affect our ability to commercialize our product candidates, if approved. </div></div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">43 </div></div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;;font-weight: bold;"><a href="#toc">Table of Contents</a></div> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Recent federal legislation and actions by state and local governments may permit reimportation of drugs from foreign countries into the United States, including foreign countries where the drugs are sold at lower prices than in the United States, which could materially adversely affect our operating results. </div></div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;">We may face competition in the United States for our product candidates, if approved, from therapies sourced from foreign countries that have placed price controls on pharmaceutical products. In the United States, the Medicare Modernization Act (&#8220;MMA&#8221;) contains provisions that may change U.S. importation laws and expand pharmacists&#8217; and wholesalers&#8217; ability to import cheaper versions of an approved drug and competing products from Canada, where there are government price controls. These changes to U.S. importation laws will not take effect unless and until the Secretary of the HHS certifies that the changes will pose no additional risk to the public&#8217;s health and safety and will result in a significant reduction in the cost of products to consumers. On September&#160;23, 2020, the Secretary of HHS made such certification to Congress, and on October&#160;1, 2020, the FDA published a final rule that allows for the importation of certain prescription drugs from Canada. Under the final rule, States and Indian Tribes, and in certain future circumstances pharmacists and wholesalers, may submit importation program proposals to the FDA for review and authorization. Since the issuance of the final rule, on November&#160;23, 2020, several industry groups filed federal lawsuits in the U.S. District Court for the District of Columbia, requesting injunctive relief to prevent implementation of the rule. Further, authorities in Canada have passed rules designed to safeguard the Canadian drug supply from shortages. On September&#160;25, 2020, CMS stated drugs imported by States under this rule will not be eligible for federal rebates under Section&#160;1927 of the Social Security Act and manufacturers would not report these drugs for &#8220;best price&#8221; or Average Manufacturer Price purposes. Since these drugs are not considered covered outpatient drugs, CMS further stated it will not publish a National Average Drug Acquisition Cost for these drugs. Separately, the FDA also issued a final guidance document outlining a pathway for manufacturers to obtain an additional National Drug Code (&#8220;NDC&#8221;), for an <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">FDA-approved</div> drug that was originally intended to be marketed in a foreign country and that was authorized for sale in that foreign country. In addition, the July 2021 executive order pertaining to drug pricing directs the FDA to support and work with States and Indian Tribes to develop importation plans to import prescription drugs from Canada under the MMA and final rule. If implemented, importation of drugs from Canada may materially and adversely affect the price we receive for any of our product candidates. The regulatory and market implications of the final rule and guidance are unknown at this time. Proponents of drug reimportation may attempt to pass legislation that would directly allow reimportation under certain circumstances. Legislation or regulations allowing the reimportation of drugs, if enacted, could decrease the price we receive for any products that we may develop and adversely affect our future revenues and prospects for profitability. </div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Other Risks Related to Our Business and Industry </div></div></div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">We depend on the knowledge and skills of our senior leaders, and may not be able to manage our business effectively if we are unable to attract and retain key personnel. </div></div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;">We have benefited substantially from the leadership, performance and vision of our senior leaders, in particular, our founder and Executive Chairman, Vivek Ramaswamy, our Chief Executive Officer, Matthew Gline, and other senior executives of ours and of the Vants. We rely greatly on the investment experience and medical and scientific expertise of our senior leadership team to identify product candidates and guide future investments and opportunities, as well as the drug development expertise of our and the Vants&#8217; senior leadership to guide the <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">pre-clinical</div> and clinical development of our product candidates. Our success will depend on our ability to retain our current management team. In addition, while we expect to engage in an orderly transition process as we integrate newly appointed officers and managers, we face a variety of risks and uncertainties relation to management transition, including diversion of management attention from business concerns, failure to retain other key personnel or loss of institutional knowledge. Competition for senior leadership in the healthcare investment industry is intense, and we cannot guarantee that we will be able to retain key personnel of ours or of the Vants. </div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Our senior leaders and key employees may terminate their positions with us at any time. Due to the small number of employees at some of the Vants, the loss of key employee may have a larger impact on our business. </div></div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">44 </div></div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;;font-weight: bold;"><a href="#toc">Table of Contents</a></div> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">In particular, we rely on a limited number of employees in certain key jurisdictions, including the United Kingdom (the &#8220;U.K.&#8221;), Switzerland and Bermuda. If we lose one or more members of our or the Vants&#8217; senior leadership teams or other key employees, our ability to successfully implement our business strategies could be adversely impacted. Replacing these individuals may be difficult, cause disruption and may take an extended period of time due to the limited number of individuals in our industry with the breadth of skills and experience required to develop, gain regulatory approval of, and commercialize product candidates successfully. Competition to hire from this limited pool is intense, and we may be unable to hire, train, retain or motivate additional key personnel. We do not maintain &#8220;key person&#8221; insurance for any members of our senior leadership team or other employees. </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">To encourage valuable employees to remain at our company, in addition to salary and cash incentives, we have provided certain equity awards that vest over time. The value to employees of equity awards that vest over time may be significantly affected by movements in our share price that are beyond our control and may at any time be insufficient to counteract more lucrative offers from other companies. Despite our efforts to retain invaluable employees, members of our management, scientific and development teams may terminate their employment with us at any time. Although we have employment agreements with our key employees, certain of these employment agreements provide for <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">at-will</div> employment, which means that any of our employees could leave our employment at any time. Our success also depends on our ability to continue to attract, retain and motivate high skilled junior, <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">mid-level</div> and senior managers as well as junior, <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">mid-level</div> and senior scientific and medical personnel. </div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Changes in funding for, or disruptions to the operations of, the FDA, the SEC and other government agencies could hinder their ability to hire and retain key leadership and other personnel, prevent new products and services from being developed or commercialized in a timely manner or otherwise prevent those agencies from performing normal functions on which the operation of our business may rely, which could negatively impact our business. </div></div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;">The ability of the FDA to review and approve new products or take action with respect to other regulatory matters can be affected by a variety of factors, including government budget and funding levels, ability to hire and retain key personnel and accept payment of user fees, the availability of personnel and other resources in light of governmental &#8220;stay at home&#8221; orders in response to the <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">COVID-19</div> pandemic, and statutory, regulatory and policy changes. Average review times at the agency have fluctuated in recent years as a result. In addition, government funding of the SEC and other government agencies on which our operations may rely, including those that fund research and development activities is subject to the political process, which is inherently fluid and unpredictable. </div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">Disruptions at the FDA and other agencies may also slow the time necessary for new drugs to be reviewed and/or approved, or for other actions to be taken, by relevant government agencies, which would adversely affect our business. For example, over the last several years, including for 35 days beginning on December&#160;22, 2018, the U.S. government has shut down several times and certain regulatory agencies, such as the FDA and the SEC, have had to furlough critical FDA, SEC and other government employees and stop critical activities. Since March 2020, foreign and domestic inspections by the FDA have largely been on hold due to impacts of the <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">COVID-19</div> pandemic, with the FDA announcing plans in July 2020 to resume prioritized domestic inspections. In April 2021, the FDA issued guidance describing how it will request and conduct voluntary remote interactive evaluations of manufacturing and outsourcing facilities as well as facilities involved in <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-clinical</div> and clinical research. With respect to <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">pre-approval</div> inspections, the FDA has been using other tools and approaches where possible, including requesting existing inspection reports from other foreign regulatory partners, requesting information from applicants, and requesting records and other information directly from facilities and other inspected entities. Should the FDA determine that an inspection is necessary for approval of a marketing application and an inspection cannot be completed during the review cycle due to restrictions on travel and there are other identified deficiencies, the FDA has stated that it generally intends to issue a complete response letter. Further, if there is inadequate information to make a determination on the acceptability of a facility without other </div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">45 </div></div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;;font-weight: bold;"><a href="#toc">Table of Contents</a></div> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">identified deficiencies, the FDA may defer action on the application until an inspection can be completed. In 2020, several companies announced receipt of complete response letters due to the FDA&#8217;s inability to complete required inspections for their applications. Regulatory authorities outside the United States may adopt similar restrictions or other policy measures in response to the <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">COVID-19</div> pandemic and may experience delays in their regulatory activities. Additionally, as of June&#160;23, 2020, the FDA noted it is continuing to ensure timely reviews of applications for medical products during the <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">COVID-19</div> pandemic in line with its user fee performance goals. On July&#160;16, 2020, the FDA noted that it is continuing to expedite oncology product development with its staff teleworking full-time. However, the FDA may not be able to continue its current pace and approval timelines could be extended, including where a <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">pre-approval</div> inspection or an inspection of clinical sites is required and due to the <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">COVID-19</div> pandemic and travel restrictions the FDA is unable to complete such required inspections during the review period. If a prolonged government shutdown or disruption to the operations of the FDA occurs, it could significantly impact the ability of the FDA to timely review and process our regulatory submissions, which could have a material adverse effect on our business. Similarly, a prolonged government shutdown or disruption to the operations of the USPTO could prevent the timely review of our patent applications, which could delay the issuance of any U.S. patents to which we might otherwise be entitled. Future government shutdowns and similar events could impact our ability to access the public markets and obtain necessary capital in order to properly capitalize and continue our operations. </div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">We will need to expand our organization and may experience difficulties in managing this growth, which could disrupt operations. </div></div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;">In connection with our continued growth and the Business Combination, we expect to hire, either directly or through our current or future affiliates, additional employees for our managerial, finance and accounting, clinical, scientific and engineering, regulatory, operational, manufacturing, sales and marketing teams. We may have difficulties in connection with identifying, hiring, integrating and retaining new personnel. Future growth would impose significant additional responsibilities on management, including the need to identify, recruit, maintain, motivate and integrate additional employees, consultants and contractors. Also, management may need to divert a disproportionate amount of its attention away from our <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">day-to-day</div></div> activities and devote a substantial amount of time to managing these growth activities. We may not be able to effectively manage the expansion of operations across our entities, which may result in weaknesses in infrastructure, give rise to operational mistakes, loss of business opportunities, loss of employees and reduced productivity among remaining employees. Our future growth could require significant capital expenditures and may divert financial resources from other projects, such as the development of product candidates. If our management is unable to effectively manage our growth, our expenses may increase more than expected, our ability to generate and/or grow revenues could be reduced, and we may not be able to implement our business strategy. Our future financial performance and ability to commercialize product candidates and new technologies and compete effectively will partly depend on our ability to effectively manage any future growth. </div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Many of the other pharmaceutical and healthcare technology companies that we compete against for qualified personnel and consultants have greater financial and other resources, different risk profiles and a longer operating history in the industry than us. They also may provide more diverse opportunities and better chances for career advancement. Some of these opportunities may be more appealing to high-quality candidates and consultants than what we have to offer. If we are unable to continue to attract and retain high-quality personnel and consultants, the rate and success at which we can discover and develop product candidates and our business will be harmed. </div></div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">46 </div></div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;;font-weight: bold;"><a href="#toc">Table of Contents</a></div> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Our international operations may expose us to business, legal, regulatory, political, operational, financial and economic risks associated with conducting business globally. </div></div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Part of our business strategy involves potential expansion internationally with third-party collaborators to seek regulatory approval for our product candidates globally. Doing business internationally involves a number of risks, including but not limited to: </div></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">multiple conflicting and changing laws and regulations such as tax laws, export and import restrictions, employment laws, anti-bribery and anti-corruption laws, regulatory requirements and other governmental approvals, permits and licenses; </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">failure by us or our collaborators to obtain appropriate licenses or regulatory approvals for the sale or use of our product candidate, if approved, in various countries; </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">difficulties in managing operations in different jurisdictions; </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;">complexities associated with managing multiple payor-reimbursement regimes or <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">self-pay</div> systems; </div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">financial risks, such as longer payment cycles, difficulty enforcing contracts and collecting accounts receivable and exposure to currency exchange rate fluctuations; </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">varying protection for intellectual property rights; </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">natural disasters, political and economic instability, including wars, terrorism and political unrest, outbreak of disease, boycotts, curtailment of trade and other business restrictions; and </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">failure to comply with the United States Foreign Corrupt Practices Act (the &#8220;FCPA&#8221;), including its books and records provisions and its anti-bribery provisions, the United Kingdom Bribery Act 2010 (the &#8220;U.K. Bribery Act&#8221;), and similar anti-bribery and anti-corruption laws in other jurisdictions, for example by failing to maintain accurate information and control over sales or distributors&#8217; activities. </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Any of these risks, if encountered, could significantly harm our future international expansion and operations and, consequently, negatively impact our financial condition, results of operations and cash flows. </div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Unfavorable global economic conditions could adversely affect our business, financial condition or results of operations. </div></div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Our ability to invest in and expand our business and meet our financial obligations, to attract and retain third-party contractors and collaboration partners and to raise additional capital depends on our operating and financial performance, which, in turn, is subject to numerous factors, including the prevailing economic and political conditions and financial, business and other factors beyond our control, such as the rate of unemployment, the number of uninsured persons in the United States, political influences and inflationary pressures. For example, an overall decrease in or loss of insurance coverage among individuals in the United States as a result of unemployment, underemployment or the repeal of certain provisions of the ACA may decrease the demand for healthcare services and pharmaceuticals. If fewer patients are seeking medical care because they do not have insurance coverage, we may experience difficulties in any eventual commercialization of our product candidates and our business, results of operations, financial condition and cash flows could be adversely affected. </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">In addition, our results of operations could be adversely affected by general conditions in the global economy and in the global financial markets upon which pharmaceutical and biopharmaceutical companies such as us are dependent for sources of capital. In the past, global financial crises have caused extreme volatility and disruptions in the capital and credit markets. A severe or prolonged economic downturn could result in a variety of risks to our business, including a reduced ability to raise additional capital when needed on acceptable terms, if at all, and weakened demand for our product candidates. A weak or declining economy could also strain our suppliers, possibly resulting in supply disruption. Any of the foregoing could harm our business and we cannot anticipate all of the ways in which the current economic climate and financial market conditions could adversely impact our business. </div></div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">47 </div></div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;;font-weight: bold;"><a href="#toc">Table of Contents</a></div> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">We face significant competition in an environment of rapid technological and scientific change, and there is a possibility that our competitors may achieve regulatory approval before us or develop therapies that are safer, more advanced or more effective than ours, which may negatively impact our ability to successfully market or commercialize any product candidates we may develop and ultimately harm our financial condition. </div></div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The development and commercialization of new drug products is highly competitive. We may face competition with respect to any product candidates that we seek to develop or commercialize in the future from major pharmaceutical companies, specialty pharmaceutical companies and biotechnology companies worldwide. Potential competitors also include academic institutions, government agencies and other public and private research organizations that conduct research, seek patent protection, and establish collaborative arrangements for research, development, manufacturing, and commercialization. </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">There are a number of large pharmaceutical and biotechnology companies that are currently pursuing the development and commercialization of products for the treatment of the indications that we are pursuing, including, but not limited to: </div></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Roflumilast, a PDE4 inhibitor, a potential competitor to tapinarof, in development by Dermavant Sciences (&#8220;Dermavant&#8221;) for the topical treatment of psoriasis and atopic dermatitis; </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Ruxolitinib, a topical Janus kinase inhibitor, a potential competitor to tapinarof, in development by Dermavant for the topical treatment of atopic dermatitis; </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;">Teprotumumab, an insulin-like growth <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">factor-1</div> receptor inhibitor, a potential competitor to IMVT-1401, in development by Immunovant for the treatment of thyroid eye disease; </div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Efgartigimod, an anti-FcRn antibody fragment, and nipocalimab, an anti-FcRn antibody, both potential competitors to IMVT-1401, in development by Immunovant for the treatment of myasthenia gravis; and </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;">CTX001, a gene-editing therapy, and LentiGlobin, a gene therapy delivering a modified form of adult hemoglobin, both potential competitors to <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">ARU-1801,</div> in development by Aruvant for the treatment of sickle cell disease. </div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">If any of these or other competitors, including competitors for our other product candidates, receive FDA approval before we do, our product candidates would not be the first treatment on the market, and our market share may be limited. In addition to competition from other companies targeting our target indications, any products we may develop may also face competition from other types of therapies. </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">Many of our current or potential competitors, either alone or with their strategic partners, have significantly greater financial resources and expertise in research and development, manufacturing, <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">pre-clinical</div> testing, conducting clinical trials, obtaining regulatory approvals and marketing approved products than we do. </div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Mergers and acquisitions in the pharmaceutical and biotechnology industries may result in even more resources being concentrated among a smaller number of our competitors. Smaller or early-stage companies may also prove to be significant competitors, particularly through collaborative arrangements with large and established companies. These competitors also compete with us in recruiting and retaining qualified scientific and management personnel and establishing clinical trial sites and patient registration for clinical trials, as well as in acquiring technologies complementary to, or necessary for, our programs. Our commercial opportunity could be reduced or eliminated if our competitors develop and commercialize products that are safer, more effective, have fewer or less severe side effects, are more convenient, or are less expensive than any products that we may develop. Furthermore, currently approved products could be discovered to have application for treatment of our targeted disease indications or similar indications, which could give such products significant regulatory and market timing advantages over our product candidates. Our competitors also may obtain FDA or other regulatory approval for their products more rapidly than we may obtain approval for ours and may obtain orphan product exclusivity from the FDA for indications that we are targeting, which could result in our competitors establishing </div></div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">48 </div></div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;;font-weight: bold;"><a href="#toc">Table of Contents</a></div> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">a strong market position before we are able to enter the market. Additionally, products or technologies developed by our competitors may render our potential product candidates uneconomical or obsolete and we may not be successful in marketing any product candidates we may develop against competitors. </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">In addition, we could face litigation or other proceedings with respect to the scope, ownership, validity and/or enforceability of our patents relating to our competitors&#8217; products and our competitors may allege that our products infringe, misappropriate or otherwise violate their intellectual property. The availability of our competitors&#8217; products could limit the demand, and the price we are able to charge, for any products that we may develop and commercialize. </div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">The markets in which our healthcare technology Vants participate are competitive, and if we do not compete effectively, our business and operating results could be adversely affected. </div></div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The overall market for healthcare technologies and software is global, rapidly evolving, competitive and subject to changing technology and shifting customer focus. Our healthcare technology Vants, including Datavant, a healthcare data infrastructure company, Lokavant, a clinical trial technology company, and Alyvant, a salesforce technology company, face competition from well-established providers of these solutions, certain of which may have long-standing relationships with many of our current and potential customers, including large biopharmaceutical companies. We also face competition from solutions that biopharmaceutical companies develop internally and from smaller companies that offer products and services directed at more specific markets than we target, enabling these smaller competitors to focus a greater proportion of their efforts and resources on these markets, as well as a large number of companies that have been founded with the goal of applying machine learning technologies to drug discovery. </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Many of our competitors are able to devote greater resources to the development, promotion, and sale of their software solutions and services. Third parties with greater available resources and the ability to initiate or withstand substantial price competition could acquire our current or potential competitors. Our competitors may also establish cooperative relationships among themselves or with third parties that may further enhance their product offerings or resources. If our competitors&#8217; products, services or technologies become more accepted than our solutions, if our competitors are successful in bringing their products or services to market earlier than ours, if our competitors are able to respond more quickly and effectively to new or changing opportunities, technologies, or customer requirements, or if their products or services are more technologically capable than ours, then the business and prospects of these Vants could be adversely affected. </div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">We and our subsidiaries are subject to litigation and investigation risks which could adversely affect their business, results of operations and financial condition and could cause the market value of our Common Shares to decline. Insurance coverage may not be available for, or adequate to cover, all potential exposure for litigation and other business risks. </div></div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;">We and our subsidiaries are from time to time subject to various litigation matters and claims, including regulatory proceedings, administrative proceedings, securities litigation and other lawsuits, and governmental investigations. In addition, we and our subsidiaries may receive requests for information from governmental agencies in connection with their regulatory or investigatory authority or from private third parties pursuant to subpoena. These proceedings may be complex and prolonged, and may occupy the resources of us and our subsidiaries&#8217; management and employees. These proceedings are also costly to prosecute and defend and may involve substantial awards or damages payable by us or our subsidiaries if not favorably resolved. We and our subsidiaries may be required to pay substantial amounts or grant certain rights on unfavorable terms in order to settle such proceedings. We also face risks relating to litigation arising from judgments made by us and the Vants as to the materiality of any developments in our businesses, including with respect to <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">pre-clinical</div> and clinical data, and the resulting disclosure (or lack thereof) may give rise to securities litigation. </div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">We maintain insurance policies for litigation and various business risks, but such policies may not be adequate to compensate us for potential losses. In addition, such insurance may not be available to us in the </div></div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">49 </div></div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;;font-weight: bold;"><a href="#toc">Table of Contents</a></div> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">future on economically reasonable terms, or at all. Further, our insurance may not cover all claims made against us and defending a suit, regardless of its merit, could be costly and divert management&#8217;s attention. Because of the uncertain nature of litigation, investigations and insurance coverage decisions, it is not possible to predict the outcome of these matters, which could have a material adverse effect on the business, results of operations, and financial condition of us and our subsidiaries, as applicable, could impact the ability to consummate a transaction that is challenged or otherwise subject to such litigation and could cause the market value of our Common Shares to decline. </div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Negative public opinion and increased regulatory scrutiny of gene therapy and genetic research may damage public perception of our gene therapy product candidates and any future products or adversely affect our ability to conduct our business or obtain and maintain marketing approvals for our product candidates. </div></div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Public perception may be influenced by claims that gene therapy, including gene editing technologies, is unsafe or unethical, and research activities and adverse events in the field, even if not ultimately attributable to us or our product candidates, could result in increased governmental regulation, unfavorable public perception, challenges in recruiting patients to participate in our clinical studies, potential regulatory delays in the testing or approval of our potential products, stricter labeling requirements for those product candidates that are approved and a decrease in demand for any such product. More restrictive government regulations or negative public opinion would have a negative effect on our business or financial condition and may delay or impair the development and commercialization of our product candidates or demand for any approved products. </div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">We may not hold a controlling stake in certain of our subsidiaries and thus may not be able to direct our business or the development of our product candidates. </div></div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">For certain of the Vants, including Arbutus, Datavant and Sio Gene Therapies, we hold less than a majority ownership interest or are otherwise limited in our ability to direct or control the business and the development of the product candidates or technologies at the Vant. In addition, for certain other Vants, including Immunovant, we may in the future come to hold less than a majority ownership interest in the Vant. Furthermore, even if we own a majority ownership interest in a Vant, we may not necessarily be able to control the outcome of certain corporate actions. If the business or development of a product candidate at one of these Vants were to face challenges, we would be adversely affected as a result and would be limited in our ability to cause or influence the Vant in question to take appropriate remediative actions. </div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Our business and operations would suffer in the event of system failures, cyber-attacks or a deficiency in our cyber-security. </div></div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Our computer systems, as well as those of various third parties on which we presently rely, or may rely on in the future, including our CROs and other contractors, consultants and law and accounting firms, may sustain damage from computer viruses, unauthorized access, data breaches, phishing attacks, cybercriminals, natural disasters (including hurricanes and earthquakes), terrorism, war and telecommunication and electrical failures. Such information technology systems are additionally vulnerable to security breaches from inadvertent or intentional actions by our employees, third-party vendors, contractors, consultants, business partners, and/or other third parties. Any of the foregoing may compromise our system infrastructure, or that of our third-party vendors and other contractors and consultants, or lead to data leakage. The risks of a security breach or disruption, particularly through cyber-attacks or cyber intrusion, including by computer hackers, sovereign governments and cyber terrorists, have generally increased over time, along with the number, intensity and sophistication of attempted attacks and intrusions from around the world. </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">We generally require our third-party providers to implement effective security measures and to identify and correct for any such failures, deficiencies or breaches. Although we seek to supervise such third parties&#8217; security measures, our ability to do so is limited. If the information technology systems of our third-party vendors and other contractors and consultants become subject to disruptions or security breaches, we may have insufficient </div></div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">50 </div></div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;;font-weight: bold;"><a href="#toc" style="text-indent: 0px;">Table of Contents</a></div> </div> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">recourse against such third parties and we may have to expend significant resources to mitigate the impact of such an event, and to develop and implement protections to prevent future events of this nature from occurring. </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">We cannot to anticipate all possible types of security threats and we cannot guarantee that our data protection efforts and our investment in information technology will prevent significant breakdowns, data leakages, security breaches in our systems, or those of our third-party vendors and other contractors and consultants, or other cyber incidents that could have a material adverse effect upon our reputation, business, operations, or financial condition. If any of the aforementioned security events were to occur, it could result in a material disruption of our drug development programs and business operations. For example, the loss of nonclinical or clinical trial data from completed, ongoing or planned trials could result in delays in our regulatory approval efforts and significantly increase our costs to recover or reproduce the data. In addition, we rely on third parties to supply components for and to manufacture our product candidates and to conduct clinical trials, and similar events relating to their computer systems could also have a material adverse effect on our business. To the extent that any disruption or security breach were to result in a loss of or damage to our data or applications, or inappropriate disclosure of personal, confidential or proprietary information, we could incur liability and reputational damage and the further development of any product candidate could be delayed. The costs related to significant security breaches or disruptions could be material and exceed the limits of the cybersecurity insurance we maintain against such risks. </div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">We are subject to stringent privacy laws, information security laws, regulations, policies and contractual obligations related to data privacy and security and changes in such laws, regulations, policies and contractual obligations could adversely affect our business, including in particular our healthcare technology businesses. </div></div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">We are subject to data privacy and protection laws and regulations that apply to the collection, transmission, storage and use of personally-identifying information, which among other things, impose certain requirements relating to the privacy, security and transmission of personal information. The legislative and regulatory landscape for privacy and data protection continues to evolve in jurisdictions worldwide, and there has been an increasing focus on privacy and data protection issues. Failure to comply with these laws and regulations could result in enforcement actions against us, including possible fines, imprisonment of company officials and public censure, claims for damages by affected individuals, damage to our reputation and loss of goodwill, any of which could have a material adverse effect on our business, financial condition, results of operations or prospects. </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">There are numerous U.S. federal and state laws and regulations related to the privacy and security of personal information. At the federal level, regulations promulgated pursuant to HIPAA establish privacy and security standards for &#8220;covered entities&#8221; (group health plans and most healthcare providers) that limit the use and disclosure of individually identifiable health information those entities receive or create (&#8220;protected health information&#8221;), and require the implementation of administrative, physical and technological safeguards to protect the security, confidentiality, integrity and availability of electronic protected health information. While we generally are not subject to HIPAA in our business, we do business with various entities that are subject to HIPAA and we have to expend resources to understand their obligations, adjust contractual relationships in light of those obligations, or change business practices. Congress has considered expanding the scope of the HIPAA privacy and security regulations and we may in the future become subject to them ourselves, which would require additional expenditures and create additional risks. </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">In addition, many states in which we operate have laws that protect the privacy and security of personal information. Certain state laws may be more stringent or broader in scope, or offer greater individual rights, with respect to personal information than federal, international or other state laws, and such laws may differ from each other, which may complicate compliance efforts. For example, the California Confidentiality of Medical Information Act (the &#8220;CMIA&#8221;), a statute similar to HIPAA that expressly applies to pharmaceutical companies and companies that provide technologies for processing personal health information, imposes stringent data privacy and security requirements and obligations with respect to the personal health information of California </div></div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">51 </div></div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;;font-weight: bold;"><a href="#toc">Table of Contents</a></div> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">residents. Among other things, the CMIA requires that a pharmaceutical company obtain a signed, written authorization from a patient or company employee in order to disclose his or her personal health information, with limited exceptions, and requires security measures to protect the information. The CMIA authorizes administrative fines and civil penalties of up to $25,000 for willful violations and up to $250,000 if the violation is for purposes of financial gain, as well as criminal fines. In addition, the California Consumer Privacy Act of 2018 (the &#8220;CCPA&#8221;), which went into effect on January&#160;1, 2020, requires covered businesses to provide substantial disclosures to California residents and honor such residents&#8217; data protection and privacy rights, including the right to <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">opt-out</div> of certain sales of personal information. The CCPA provides for civil penalties for violations, as well as a private right of action for certain data breaches that result in the compromise of highly sensitive personal information, which may increase the likelihood of, and risks associated with, data breach litigation. The CCPA has been amended several times, including by the California Privacy Rights Act (the &#8220;CPRA&#8221;), a ballot initiative that passed in November 2020 which, among other things, created a new state agency vested with authority to implement and enforce the CCPA and the CPRA. Effective in most material aspects starting on January&#160;1, 2023, the CPRA will expand California residents&#8217; rights with respect to certain sensitive personal information and give California residents&#8217; a right to opt out of the sharing of certain personal information for targeted online advertising. Virginia and Colorado also recently enacted CCPA/CPRA-like laws, the Virginia Consumer Data Privacy Act (the &#8220;VDCPA&#8221;) and the Colorado Privacy Act (&#8220;CPA&#8221;), to provide their respective residents with similar rights. New legislation enacted in various other states will continue to shape the data privacy environment nationally. Certain state laws may be more stringent or broader in scope, or offer greater individual rights, with respect to confidential, sensitive and personal information than federal, international or other state laws, and such laws may differ from each other, which may complicate compliance efforts. The effects on our business of the CMIA, CCPA, CPRA, VDCPA, CPA and other similar state laws and general consumer protection authorities are potentially significant, and may require us to modify our data processing practices and policies and to incur substantial costs and expenses in an effort to comply. </div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">Outside of the United States, laws, regulations and standards in many jurisdictions apply broadly to the collection, use, retention, security, disclosure, transfer and other processing of personal information. For example, in EEA, the collection and use of personal data is governed by the provisions of the General Data Protection Regulation (the &#8220;GDPR&#8221;). The GDPR came into effect in May 2018, superseding the European Union Data Protection Directive, and imposing more stringent data privacy and security requirements on companies in relation to the processing of personal data. The GDPR, together with national legislation, regulations and guidelines of the EU member states governing the processing of personal data, impose strict obligations on controllers, including <div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">inter alia</div></div>: (i)&#160;accountability and transparency requirements, and enhanced requirements for obtaining valid consent; (ii)&#160;obligations to consider data protection as any new products or services are developed and to limit the amount of personal data processed; (iii)&#160;obligations to comply with data protection rights of data subjects; and (iv)&#160;reporting of certain personal data breaches to the supervisory authority without undue delay (and no later than 72 hours where feasible). The GDPR also prohibits the transfer of personal data from the EEA to countries outside of the EEA unless made to a country deemed to have adequate data privacy laws by the European Commission or a data transfer mechanism has been put in place. Until recently, one such data transfer mechanism was the <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">EU-US</div> Privacy Shield, but the Privacy Shield was invalidated for international transfers of personal data in July 2020 by the Court of Justice of the European Union (&#8220;CJEU&#8221;). The CJEU upheld the validity of standard contractual clauses (&#8220;SCCs&#8221;) as a legal mechanism to transfer personal data but companies relying on SCCs will, subject to additional guidance from regulators in the EEA and the U.K., need to evaluate and implement supplementary measures that provide privacy protections additional to those provided under SCCs. It remains to be seen whether SCCs will remain available and whether additional means for lawful data transfers will become available. The GDPR authorizes fines for certain violations of up to 4% of global annual revenue or &#8364;20&#160;million, whichever is greater. Such fines are in addition to any civil litigation claims by customers and data subjects. European data protection authorities may interpret the GDPR and national laws differently and impose additional requirements, which contributes to the complexity of processing personal data in or from the EEA. In June 2021, the CJEU issued a ruling that expanded the scope of the &#8220;one stop shop&#8221; under the GDPR. According to the ruling, the competent authorities of EU Member States may, under certain strict conditions, bring claims to their national courts against a company for breaches of the GDPR, including unlawful cross-</div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">52 </div></div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;;font-weight: bold;"><a href="#toc">Table of Contents</a></div> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">border processing activities, even such company does not have an establishment in the EU member state in question and the competent authority bringing the claim is not the lead supervisory authority. </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">Further, as of January&#160;1, 2021, and the expiry of transitional arrangements agreed to between the United Kingdom and EU (<div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">i.e</div></div>., following the United Kingdom&#8217;s exit from the EU &#8211; otherwise known as Brexit), data processing in the United Kingdom is governed by a United Kingdom version of the GDPR (combining the GDPR and the Data Protection Act 2018), exposing us to two parallel regimes, each of which potentially authorizes similar fines and other potentially divergent enforcement actions for certain violations. With respect to transfers of personal data from the EEA to the United Kingdom, on June&#160;28, 2021 the European Commission issued an adequacy decision in respect of the United Kingdom&#8217;s data protection framework, enabling data transfers from EU member states to the United Kingdom to continue without requiring organizations to put in place contractual or other measures in order to lawfully transfer personal data between the territories. While it is intended to last for at least four years, the European Commission may unilaterally revoke the adequacy decision at any point, and if this occurs it could lead to additional costs and increase our overall risk exposure. Moreover, other countries have also passed or are considering passing laws requiring local data residency or restricting the international transfer of data. </div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">If we or our third party service providers are unable to properly protect the privacy and security of personal information, or other sensitive data we process in our business, we could be found to have breached our contracts. Further, if we fail to comply with applicable privacy laws, we could face civil and criminal penalties. Enforcement activity from state Attorneys General and agencies such as the California Privacy Protection Agency, the Federal Trade Commission, EU Data Protection Authorities and other regulatory authorities in relation to privacy and cybersecurity matters can result in financial liability and reputational harm, and responses to such enforcement activity can consume significant internal resources. In the United States, the threat of class action lawsuits based on data security breaches or alleged unfair practices adds a further layer of risk. We cannot be sure how these privacy laws and regulations will be interpreted, enforced or applied to our operations. In addition to the risks associated with enforcement activities and potential contractual liabilities, our ongoing efforts to comply with evolving laws and regulations at the federal and state level may be costly and require ongoing modifications to our policies, procedures and systems. </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Data privacy remains an evolving landscape at both the domestic and international level, with new regulations coming into effect. It is possible that these laws may be interpreted and applied in a manner that is inconsistent with our practices and our efforts to comply with the evolving data protection rules may be unsuccessful. Significant resources are needed to understand and comply with this changing landscape. Failure to comply with federal, state and international laws regarding privacy and security of personal information could expose us to penalties under such laws. Any such failure to comply with data protection and privacy laws could result in government-imposed fines or orders requiring that we change our practices or unwind certain lines of business, claims for damages or other liabilities, regulatory investigations and enforcement action, litigation and significant costs for remediation, any of which could adversely affect our business. Even if we are not determined to have violated these laws, government investigations into these issues typically require the expenditure of significant resources and generate negative publicity, which could harm our business, financial condition, results of operations or prospects. </div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Our or our affiliates&#8217; employees, independent contractors, principal investigators, consultants, commercial collaborators, service providers and other vendors or potential collaborators may engage in misconduct or other improper activities, including noncompliance with regulatory standards and requirements, which could harm our results of operations. </div></div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">We are exposed to the risk that our or our affiliates&#8217; employees and contractors, including principal investigators, CROs, CMOs, consultants, commercial collaborators, service providers and other vendors may engage in misconduct or other illegal activity. Misconduct by these parties could include intentional, reckless or negligent conduct or other unauthorized activities that violate the laws and regulations of the FDA and other </div></div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">53 </div></div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;;font-weight: bold;"><a href="#toc">Table of Contents</a></div> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">similar regulatory bodies, including those laws that require the reporting of true, complete and accurate information to such regulatory bodies; manufacturing and the FDA&#8217;s GCP, GLP and GMP standards; federal, state and foreign healthcare fraud and abuse laws and data privacy; or laws that require the true, complete and accurate reporting of financial information or data. In particular, sales, marketing and other business arrangements in the healthcare industry are subject to extensive laws intended to prevent fraud, kickbacks, self-dealing, bribery, corruption, antitrust violations and other abusive practices. These laws may restrict or prohibit a wide range of business activities, including research, manufacturing, distribution, pricing, discounting, marketing and promotion, sales commission, customer incentive programs and other business arrangements. Activities subject to these laws also involve the improper use or misrepresentation of information obtained in the course of clinical trials, creating fraudulent data in our nonclinical studies or clinical trials or illegal misappropriation of drug product, which could result in regulatory sanctions and serious harm to our reputation. It is not always possible to identify and deter employee or third-party misconduct, and the precautions we take to detect and prevent this activity may not be effective in controlling unknown or unmanaged risks or losses or in protecting us from governmental investigations or other actions or lawsuits stemming from a failure to comply with such laws or regulations. </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Additionally, we are subject to the risk that a person, including any person who may have engaged in any fraud or misconduct, or government agency could allege such fraud or other misconduct, even if none occurred. Furthermore, we rely on our CROs and clinical trial sites to adequately report data from our ongoing clinical trials. Moreover, in some instances, our licensing partners conduct clinical trials with respect to product candidates in different territories and we rely on any such partners to share data from their ongoing clinical trials as required under our agreements with such partners. For example, any failure by such parties to adequately report safety signals to us in a timely manner from any such trials may also affect the approvability of our product candidates or cause delays and disruptions for the approval of our product candidates, if at all. If our or our affiliates&#8217; employees, independent contractors, principal investigators, consultants, commercial collaborators, service providers or other vendors are alleged or found to be in violation of any such regulatory standards or requirements, or become subject to a corporate integrity agreement or similar agreement and curtailment of our operations, it could have a significant impact on our business and financial results, including the imposition of significant civil, criminal and administrative penalties, damages, monetary fines, suspension or delay in our clinical trials, possible exclusion from participation in Medicare, Medicaid and other federal healthcare programs, FDA debarment, contractual damages, reputational harm, diminished profits and future earnings, and additional reporting requirements and oversight, any of which could harm our ability to operate our business and our results of operations. </div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Potential product liability lawsuits against us could cause us to incur substantial liabilities and limit commercialization of any product candidates that we may develop. </div></div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The use of existing product candidates in clinical trials and the sale of any product candidates for which we obtain marketing approval exposes us to the risk of product liability claims. Product liability claims might be brought against us by consumers, health care providers, other pharmaceutical companies or others taking or otherwise coming into contact with our product candidates. On occasion, large judgments have been awarded in class action lawsuits where drugs have had unanticipated harmful effects. If we cannot successfully defend against product liability claims, it could incur substantial liability and costs. In addition, regardless of merit or eventual outcome, product liability claims may result in: </div></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">impairment of our business reputation and significant negative media attention; </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">delay or termination of clinical trials, or withdrawal of participants from our clinical trials; </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">significant costs to defend the related litigation; </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">distraction of management&#8217;s attention from our primary business; </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">substantial monetary awards to patients or other claimants; </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">inability to commercialize existing product candidates or any future product candidate, if approved; </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">54 </div></div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;;font-weight: bold;"><a href="#toc">Table of Contents</a></div> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;">
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">product recalls, withdrawals or labeling, marketing or promotional restrictions; </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">decreased demand for existing product candidates or any future product candidate, if approved; and </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">loss of revenue. </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The product liability insurance we currently carry, and any additional product liability insurance coverage we acquire in the future, may not be sufficient to reimburse us for any expenses or losses we may suffer. Moreover, insurance coverage is becoming increasingly expensive and in the future we may not be able to maintain insurance coverage at a reasonable cost or in sufficient amounts to protect us against losses due to liability. If we obtain marketing approval for product candidates, we intend to acquire insurance coverage to include the sale of commercial product candidates; however, it may be unable to obtain product liability insurance on commercially reasonable terms or in adequate amounts. A successful product liability claim or series of claims brought against us could adversely affect our results of operations and business, including preventing or limiting the commercialization of any product candidates, if approved, that we develop. </div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">If we fail to comply with environmental, health and safety laws and regulations, we could become subject to fines or penalties or incur costs that could harm our business. </div></div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">We are subject to numerous environmental, health and safety laws and regulations, including those governing laboratory procedures and the handling, use, storage, treatment and disposal of hazardous materials and wastes. Certain of our operations may involve the use of hazardous and flammable materials, including chemicals and biological materials, and may also produce hazardous waste products. We generally contract with third parties for the disposal of these materials and wastes. We cannot eliminate the risk of contamination or injury from these materials. In the event of contamination or injury resulting from our use of hazardous materials, we could be held liable for any resulting damages, and any liability could exceed our resources. We also could incur significant costs associated with civil or criminal fines and penalties for failure to comply with such laws and regulations. </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Although we maintain workers&#8217; compensation insurance to cover us for costs and expenses we may incur due to injuries to our employees resulting from the use of hazardous materials, this insurance may not provide adequate coverage against potential liabilities. We do not maintain insurance for environmental liability or toxic tort claims that may be asserted against us in connection with our storage or disposal of biological, hazardous or radioactive materials. </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">In addition, we may incur substantial costs in order to comply with current or future environmental, health and safety laws and regulations. These current or future laws and regulations may impair our research, development or production efforts. Our failure to comply with these laws and regulations also may result in substantial fines, penalties or other sanctions. </div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">We or the third parties upon whom we depend may be adversely affected by earthquakes, outbreak of disease&#160;or other natural disasters and our business continuity and disaster recovery plans may not adequately protect us from a serious disaster. </div></div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Earthquakes or other natural disasters could severely disrupt our operations, and have a material adverse effect on our business, results of operations, financial condition and prospects. If a natural disaster, power outage or other event occurred that prevented us from using all or a significant portion of our offices, that damaged critical infrastructure, such as the manufacturing facilities of our third-party CMOs, or that otherwise disrupted operations, it may be difficult or, in certain cases, impossible for us to continue our business for a substantial period of time. The disaster recovery and business continuity plans we have in place currently are limited and are unlikely to prove adequate in the event of a serious disaster or similar event. We may incur substantial expenses as a result of the limited nature of our disaster recovery and business continuity plans, which, particularly when taken together with our lack of earthquake insurance, could have a material adverse effect on our business. </div></div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">55 </div></div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;;font-weight: bold;"><a href="#toc">Table of Contents</a></div> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">The increasing use of social media platforms presents new risks and challenges. </div></div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Social media is increasingly being used to communicate about our research, product candidates, investigational medicines and the diseases our product candidates and investigational medicines are being developed to treat. Social media practices in the biopharmaceutical industry continue to evolve and regulations relating to such use are not always clear. This evolution creates uncertainty and risk of noncompliance with regulations applicable to our business, resulting in potential regulatory actions against us. For example, patients may use social media channels to comment on their experience in an ongoing blinded clinical study or to report an alleged adverse event. When such disclosures occur, there is a risk that we fail to monitor and comply with applicable adverse event reporting obligations or we may not be able to defend our business or the public&#8217;s legitimate interests in the face of the political and market pressures generated by social media due to restrictions on what we may say about our development candidates and investigational medicines. There is also a risk of inappropriate disclosure of sensitive information or negative or inaccurate posts or comments about us on any social networking website. Furthermore, our employees, affiliates and/or business partners may use social media for their personal use, and their activities on social media or in other forums could result in adverse publicity for us. Any negative publicity as a result of social media posts, whether or not such claims are accurate, could adversely impact us. If any of these events were to occur or we otherwise fail to comply with applicable regulations, we could incur liability, face regulatory actions, or incur other harm to our business. The use of social media also creates additional risks in the EEA and the UK where promotion of prescription-only medicines to patients and the general public is strictly prohibited. Social media content that is generated, shared or liked by our company or our directors, employees, staff or other representatives may potentially be perceived or construed as constituting prohibited promotion of prescription-only medicinal products and trigger enforcement and penalties. This is an area of increased scrutiny in both the EEA and the UK. </div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">The United Kingdom&#8217;s withdrawal from the European Union may adversely impact our ability to obtain regulatory approvals of our product candidates in the European Union and may require us to incur additional expenses in order to develop, manufacture and commercialize our product candidates in the European Union. </div></div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Our headquarters are located in the United Kingdom. The United Kingdom formally exited the EU, commonly referred to as Brexit, on January&#160;31, 2020. Under the terms of its departure, the United Kingdom entered a transition period (the &#8220;Transition Period&#8221;), during which it continued to follow all EU rules. The Transition Period ended on December&#160;31, 2020. On December&#160;30, 2020, the United Kingdom and European Union signed the Trade and Cooperation Agreement, which includes an agreement on free trade between the two parties. </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">There is considerable uncertainty resulting from a lack of precedent and the complexity of the United Kingdom and the EU&#8217;s intertwined legal regimes as to how Brexit (following the Transition Period) will impact the life sciences industry in Europe, including our company, including with respect to ongoing or future clinical trials. The impact will largely depend on the model and means by which the United Kingdom&#8217;s relationship with the EU is governed post-Brexit and the extent to which the United Kingdom chooses to diverge from the EU regulatory framework. For example, following the Transition Period, Great Britain will no longer be covered by the centralized procedures for obtaining <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">EU-wide</div> marketing authorizations and our products will therefore require a separate marketing authorization to allow us to market such products in Great Britain. It is unclear as to whether the relevant authorities in the EU and the United Kingdom are adequately prepared for the additional administrative burden caused by Brexit. Any delay in obtaining, or an inability to obtain, any marketing approvals, as a result of Brexit or otherwise, would prevent us from or delay us commercializing our product candidates in the United Kingdom and/or the EEA and restrict our ability to generate revenue and achieve and sustain profitability. In the short term, following the expiry of the Transition Period there is a risk of disrupted import and export processes due to a lack of administrative processing capacity by the respective United Kingdom and EU customs agencies that may delay time-sensitive shipments and may negatively impact our product supply chain. Further, under current plans, orphan designation in the United Kingdom (or Great Britain, depending on whether there is a prior centralized marketing authorization in the EEA) following Brexit is to be based on the prevalence of the condition in Great Britain as opposed to the current position where prevalence in </div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">56 </div></div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;;font-weight: bold;"><a href="#toc">Table of Contents</a></div> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">the EU is the determinant. It is therefore possible that conditions that are currently designated as orphan conditions in the United Kingdom will no longer be and that conditions are not currently designated as orphan conditions in the European Union will be designated as such in the United Kingdom. </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">If any of these outcomes occur, we may be forced to restrict or delay efforts to seek regulatory approval in the United Kingdom and/or EEA for our product candidates, which could significantly and materially harm our business. There is a degree of uncertainty regarding the overall impact that Brexit will have on (i)&#160;the marketing of pharmaceutical products, (ii)&#160;the process to obtain regulatory approval in the United Kingdom for product candidates or (iii)&#160;the award of exclusivities that are normally part of the EU legal framework (for instance Supplementary Protection Certificates, Pediatric Extensions or Orphan exclusivity). </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Brexit may also result in a reduction of funding to the EMA once the United Kingdom no longer makes financial contributions to European institutions, such as the EMA. If funding to the EMA is so reduced, it could create delays in the EMA issuing regulatory approvals for our product candidates and, accordingly, have a material adverse effect on our business, financial condition, results of operations or prospects. </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">In addition, we may be required to pay taxes or duties or be subjected to other hurdles in connection with the importation of our product candidates into the EU, or we may incur expenses in establishing a manufacturing facility in the EU in order to circumvent such hurdles. If any of these outcomes occur, we may be forced to restrict or delay efforts to seek regulatory approval in the United Kingdom or the EU for our product candidates, or incur significant additional expenses to operate our business, which could significantly and materially harm or delay our ability to generate revenues or achieve profitability of our business. </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">As a result of Brexit, other EU Member States may seek to conduct referenda with respect to their continuing membership with the EU. Given these possibilities and others we may not anticipate, as well as the absence of comparable precedent, it is unclear what financial, regulatory and legal implications the withdrawal of the United Kingdom from the EU will have and how such withdrawal will affect us, and the full extent to which our business could be adversely affected. </div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Risks Related to Our Intellectual Property </div></div></div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">If we are unable to obtain and maintain patent and other intellectual property protection for our technology and product candidates or if the scope of the intellectual property protection obtained is not sufficiently broad, we may not be able to compete effectively in our markets. </div></div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;">We rely, and will continue to rely, upon a combination of patents, trademarks, trade secret protection and confidentiality agreements with employees, consultants, collaborators, advisors and other third parties to protect the intellectual property related to our brand, current and future drug development programs and product candidates. Our success depends in large part on our ability to obtain and maintain patent protection in the United States and other countries with respect to our product candidates and any future product candidates. We seek to protect our proprietary position by <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">in-licensing</div> or acquiring intellectual property and filing patent applications in the United States and abroad related to our current and future development programs and product candidates, defending our intellectual property rights against third-party challenges and enforcing our intellectual property rights to prevent third-party infringement. The patent prosecution process is expensive and time-consuming, and we may not be able to file and prosecute all necessary or desirable patent applications at a reasonable cost or in a timely manner. Furthermore, there is always a risk that our licensed or owned issued patents and any pending and future patent applications may not protect our product candidates, in whole or in part, and may not effectively prevent others from commercializing competitive product candidates, or that an alteration to our product candidates or processes may provide sufficient basis for a competitor to avoid infringing our patent claims. The risks associated with patent rights generally apply to patent rights that we <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">in-license</div> now or in the future, as well as patent rights that we may own now or in the future. </div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">It is also possible that we will fail to identify patentable aspects of our research and development output before it is too late to obtain patent protection. Although we enter into <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-disclosure</div> and confidentiality </div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">57 </div></div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;;font-weight: bold;"><a href="#toc">Table of Contents</a></div> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">agreements with parties who have access to confidential or patentable aspects of their research and development output, such as employees, corporate collaborators, outside scientific collaborators, CROs, contract manufacturers, consultants, advisors and other third parties, any of these parties may breach the agreements and disclose such output before a patent application is filed, thereby jeopardizing our ability to obtain patent protection. In addition, while we have <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">pre-publication</div> review procedures in effect, premature or inadvertent publication of potentially patentable subject matter could preclude our ability to obtain patent protection. We may choose not to seek patent protection for certain innovations or product candidates and may choose not to pursue patent protection in certain jurisdictions, and under the laws of certain jurisdictions, patents or other intellectual property rights may be unavailable or limited in scope and, in any event, any patent protection we obtain may be limited. As a result, product candidates may not be protected by patents in all jurisdictions. We generally apply for patents in those countries where we intend to make, have made, use, offer for sale, or sell product candidates and where we assess the risk of infringement to justify the cost of seeking patent protection. However, we do not seek protection in all countries where we intend to sell product candidates and we may not accurately predict all the countries where patent protection would ultimately be desirable. If we fail to timely file a patent application in any such country or major market, we may be precluded from doing so at a later date. The patent applications that we own or <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">in-license</div> may fail to result in issued patents with claims that cover product candidates in the United States or in other countries. We may also inadvertently make statements to regulatory agencies during the regulatory approval process that may be inconsistent with positions that have been taken during prosecution of our patents, which may result in such patents being narrowed, invalidated or held unenforceable in enforcement and other adversarial proceedings. </div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">The patent applications that we own or <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">in-license</div> may fail to result in issued patents with claims that cover our product candidates or any future product candidate in the United States or in other countries. Our pending patent applications at the Patent Cooperation Treaty (the &#8220;PCT&#8221;) are not eligible to become issued patents until, among other things, we file a national stage patent application within 30 months in the countries in which we seek patent protection. If we do not timely file any national stage patent applications, we may lose our priority date with respect to our PCT patent applications and any patent protection on the inventions disclosed in such PCT patent applications. We cannot guarantee any current or future patents will provide us with any meaningful protection or competitive advantage. For example, any issued patents might not cover the pharmaceutical composition of the product candidate that is ultimately commercialized. There is no assurance that all of the potentially relevant prior art relating to our patents and patent applications has been found, which can prevent a patent from issuing from a pending patent application or be used to invalidate an issued patent. The examination process may require us to narrow our claims, which may limit the scope of patent protection that we may ultimately obtain. Even if patents do successfully issue and even if such patents cover our product candidates or any future product candidate, third parties may challenge their validity, enforceability or scope, which may result in such patents being narrowly construed, invalidated, or held unenforceable, any of which could limit our ability to prevent competitors and other third parties from developing and marketing similar product candidates or limit the length of terms of patent protection we may have for our product candidates and technologies. Other companies may also design around technologies we have patented, licensed or developed. In addition, the issuance of a patent does not give us the right to practice the patented invention. Third parties may have blocking patents that could prevent us from marketing product candidates or practicing our own patented technology or impose a substantial royalty burden to do so. Any successful opposition to these patents or any other patents owned by or licensed to us could deprive us of rights necessary for the successful commercialization of any product candidates that we may develop. Further, if we encounter delays in regulatory approvals, the period of time during which we could market a product candidate under patent protection could be reduced. If any of our patents are challenged, invalidated, circumvented by third parties or otherwise limited or expire prior to the commercialization of our product candidates, and if we do not own or have exclusive rights to other enforceable patents protecting our product candidates or other technologies, competitors and other third parties could market product candidates and use processes that are substantially similar to, or superior to, ours and our business would suffer. </div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">58 </div></div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;;font-weight: bold;"><a href="#toc">Table of Contents</a></div> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">If the patent applications we hold or have <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">in-licensed</div> with respect to our product candidates fail to issue, if their breadth or strength of protection is threatened, or if they fail to provide meaningful exclusivity for our product candidates or any future product candidate, it could dissuade companies from collaborating with us to develop product candidates, and threaten our ability to commercialize, future drugs. Any such outcome could have a materially adverse effect on our business. Our pending patent applications cannot be enforced against third parties practicing the technology claimed in such applications unless and until a patent issues from such applications. </div></div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The patent position of biotechnology and pharmaceutical companies generally is highly uncertain, involves complex legal and factual questions and has in recent years been the subject of much litigation. The standards that the U.S. Patent and Trademark Office (the &#8220;USPTO&#8221;) and its counterparts in other countries use to grant patents are not always applied predictably or uniformly. In addition, the laws of countries other than the United States may not protect our rights to the same extent as the laws of the United States, and many companies have encountered significant problems in protecting and defending such rights in such jurisdictions. For example, European patent law restricts the patentability of methods of treatment of the human body more than United States law does. </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Other parties have developed technologies that may be related or competitive to our own technologies and such parties may have filed or may file patent applications, or may have received or may receive patents, claiming inventions that may overlap or conflict with those claimed in our own or licensed patent applications or issued patents. Furthermore, publications of discoveries in scientific literature often lag behind the actual discoveries, and patent applications in the United States and other jurisdictions are typically not published until 18 months after filing, or in some cases not at all. Therefore, we cannot know with certainty whether we or our licensors were the first to make the inventions claimed in our owned or licensed patents or pending patent applications, or that we or our licensors were the first to file for patent protection of such inventions. As a result, the issuance, scope, validity, enforceability and commercial value of our patent rights are highly uncertain. Our pending and future patent applications may not result in patents being issued which protect our technology or product candidates, in whole or in part, or which effectively prevent others from commercializing competitive technologies and product candidates. Changes in either the patent laws or interpretation of the patent laws in the United States and other countries may diminish the value of our patents or narrow the scope of our patent protection. </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">Patent reform legislation in the United States, including the Leahy-Smith America Invents Act (&#8220;the Leahy-Smith Act&#8221;), could increase those uncertainties and costs surrounding the prosecution of our patent applications and the enforcement or defense of our issued patents. The Leahy-Smith Act was signed into law on September&#160;16, 2011 and includes a number of significant changes to U.S. patent law. These include provisions that affect the way patent applications are prosecuted, redefine prior art and provide more efficient and cost-effective avenues for competitors to challenge the validity of patents. These include allowing third-party submission of prior art to the USPTO during patent prosecution and additional procedures to challenge the validity of a patent by USPTO administered post-grant proceedings, including post-grant review, <div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">inter partes</div></div> review, and derivation proceedings. After March&#160;15, 2013, under the Leahy-Smith Act, the United States transitioned to a first inventor to file system in which, assuming that the other statutory requirements are met, the first inventor to file a patent application will be entitled to the patent on an invention regardless of whether a third party was the first to invent the claimed invention. The Leahy-Smith Act and its implementation could increase the uncertainties and costs surrounding the prosecution of our patent applications, our ability to obtain future patents, and the enforcement or defense of our issued patents, all of which could harm our business, financial condition, results of operations and prospects. </div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">The issuance of a patent is not conclusive as to its inventorship, scope, validity or enforceability, and our owned and licensed patents may be challenged in the courts or patent offices in the United States and abroad. We are currently and may in the future be subject to third-party <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">pre-issuance</div> submissions of prior art to the USPTO or its equivalents and we or our licensors have in the past, and may in the future, become involved in opposition, derivation, reexamination, <div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">inter partes</div></div> review, post-grant review or interference proceedings in the U.S. or in </div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">59 </div></div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;;font-weight: bold;"><a href="#toc">Table of Contents</a></div> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">other jurisdictions challenging our patent rights or the patent rights of others. A third party may also claim that our owned or licensed patent rights are invalid or unenforceable in a litigation. For example, three U.S. patents (U.S. Patent Nos. 8,058,069, 9,364,435 and 9,404,127) relating to lipid nanoparticle molar ratios and the aggregation of lipid nanoparticles that Genevant Sciences (&#8220;Genevant&#8221;) exclusively licenses from Arbutus Biopharma Corp. (&#8220;Arbutus&#8221;) were the subject of <div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">inter partes </div></div>review proceedings brought by Moderna Therapeutics, Inc. (&#8220;Moderna&#8221;) before the Patent Trial and Appeal Board of the USPTO (&#8220;PTAB&#8221;). The PTAB upheld all claims of U.S. Patent No.&#160;8,058,069, invalidated some of the claims of U.S. Patent No.&#160;9,364,435 and invalidated all claims of U.S. Patent No.&#160;9,404,127. The United States Court of Appeals for the Federal Circuit (the &#8220;Federal Circuit&#8221;) heard oral arguments with respect to U.S. Patent Nos. 8,058,069 and 9,364,435 in October 2021 and decisions are pending. The Federal Circuit vacated and remanded the PTAB&#8217;s decision on U.S. Patent No.&#160;9,494,127. The PTAB&#8217;s decision with respect to U.S. Patent No.&#160;9,494,127 had been held in administrative abeyance pending a review following a recent Supreme Court ruling in an unrelated case. The matter is now pending before the Federal Circuit and at the briefing stage. Additionally, one European patent (EU patent no. EP2279254) relating to lipid nanoparticle molar ratios that Genevant exclusively licenses from Arbutus is the subject of an opposition proceeding brought by Merck Sharp&#160;&amp; Dohme Corporation and Moderna at the European Patent Office Opposition Division. The outcome following legal assertions of invalidity and unenforceability is unpredictable. An adverse determination in any such submission, proceeding or litigation could reduce the scope of, or invalidate, our patent rights, allow third parties to commercialize our technology or product candidates and compete directly with us, without payment to us, result in our inability to manufacture or commercialize product candidates without infringing third-party patent rights or result in our breach of agreements pursuant to which we license such rights to our collaborators or licensees. In addition, if the breadth or strength of protection provided by our patents and patent applications is threatened, it could dissuade companies from collaborating with us to license, develop or commercialize current or future product candidates. Such challenges may result in loss of exclusivity or freedom to operate or in patent claims being narrowed, invalidated or held unenforceable, in whole or in part, which could limit our ability to stop others from using or commercializing similar or identical technology and product candidates, or limit the duration of the patent protection of our technology and product candidates. Such challenges also may result in substantial cost and require significant time from our scientists and management, even if the eventual outcome is favorable to us. Any of the foregoing could have a material adverse effect on our business, financial condition, results of operations and prospects. </div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">Even if they are unchallenged, our owned and licensed patents and pending patent applications, if issued, may not provide us with any meaningful protection or prevent competitors from designing around our patent claims to circumvent our owned or licensed patents by developing similar or alternative technologies or therapeutics in a <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-infringing</div> manner. For example, a third party may develop a competitive product that provides benefits similar to one or more of our product candidates but that falls outside the scope of our patent protection. Moreover, patents have a limited lifespan. In the United States, the natural expiration of a patent is generally 20 years after it is filed. Various extensions may be available; however the life of a patent, and the protection it affords, are limited. Without patent protection for our current or future product candidates, it may be open to competition from generic versions of such product candidates. Given the amount of time required for the development, testing and regulatory review of new product candidates, patents protecting such candidates might expire before or shortly after such candidates are commercialized. As a result, our owned and licensed patent portfolio may not provide us with sufficient rights to exclude others from commercializing product candidates similar or identical to our own and, which could have a material adverse effect on our business, financial condition, results of operations and prospects. </div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Patent terms and their scope may be inadequate to protect our competitive position on current and future product candidates for an adequate amount of time. </div></div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;">Patents have a limited lifespan. In the United States, if all maintenance fees are timely paid, the natural expiration of a patent is generally 20 years from its earliest U.S. <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-provisional</div> filing date. In certain instances, the patent term may be adjusted to add additional days to compensate for delays incurred by the USPTO in </div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">60 </div></div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;;font-weight: bold;"><a href="#toc" style="text-indent: 0px;">Table of Contents</a></div> <div> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">issuing the patent. Also, the patent term may be extended for a period of time to compensate for at least a portion of the time a product candidate was undergoing FDA regulatory review. However, the life of a patent, and the protection it affords, are limited. Even if patents covering product candidates are obtained, once the patent life has expired, we may be open to competition from competitive product candidates, including generics or biosimilars. Given the amount of time required for the development, testing and regulatory review of new product candidates, patents protecting such candidates might expire before or shortly after such candidates are commercialized. For example, the patent covering the use of tapinarof as an active ingredient to treat psoriasis and atopic dermatitis, but not limited to any formulation, expired in December 2020. As a result, our owned and licensed patent portfolio may not provide us with sufficient rights to exclude others from commercializing product candidates similar or identical to ours. </div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">We do not currently and may not in the future own or license any issued composition of matter patents covering certain of our product candidates, including tapinarof, and we cannot be certain that any of our other issued patents will provide adequate protection for such product candidates. </div></div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">Composition-of-matter</div></div> patents on the active pharmaceutical ingredient (&#8220;API&#8221;) in prescription drug products are generally considered to be the strongest form of intellectual property protection for drug products because those types of patents provide protection without regard to any particular method of use or manufacture or formulation of the API used. While we generally seek composition of matter patents for our product candidates, such patents may not be available for all of our product candidates. For example, we do not own or <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">in-license</div> any issued composition of matter patents in the United States or any other jurisdiction with respect to tapinarof. Instead, we rely on an issued U.S. patent claiming topical formulations of tapinarof, including the formulation studied in Phase 3, and an issued U.S. patent covering methods of using the patented topical formulations to treat inflammatory diseases, including psoriasis and atopic dermatitis. The formulation and <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">method-of-use</div></div> patents have natural expiration dates in 2036. We additionally rely on a drug substance (&#8220;DS&#8221;) patent covering the high purity commercial crystal form of the DS, the commercial DS synthesis and several novel intermediates that are formed in the synthesis, which has a natural expiration date in 2038. </div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">Method-of-use</div></div> patents protect the use of a product for the specified method and formulation patents cover formulations of the API. These types of patents do not prevent a competitor or other third party from developing or marketing an identical product for an indication that is outside the scope of the patented method or from developing a different formulation that is outside the scope of the patented formulation. Moreover, with respect to <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">method-of-use</div></div> patents, even if competitors or other third parties do not actively promote their product for our targeted indications or uses for which we may obtain patents, physicians may recommend that patients use these products <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">off-label,</div> or patients may do so themselves. Although <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">off-label</div> use may infringe or contribute to the infringement of <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">method-of-use</div></div> patents, the practice is common, and this type of infringement is difficult to prevent or prosecute. </div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">Our owned and licensed patents and pending patent applications, if issued, may not adequately protect our intellectual property or prevent competitors or others from designing around our patent claims to circumvent our owned or licensed patents by developing similar or alternative technologies or therapeutics in a <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-infringing</div> manner. If the breadth or strength of protection provided by the patents and patent applications we own or license with respect to our product candidates is not sufficient to impede such competition or is otherwise threatened, it could dissuade companies from collaborating with us to develop, and threaten our ability to commercialize, our product candidates. Any of the foregoing could have a material adverse effect on our business, financial condition, results of operations and prospects. </div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">If we do not obtain protection under the Hatch-Waxman Amendments by extending the patent term, our business may be harmed. </div></div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Our commercial success will largely depend on our ability to obtain and maintain patent and other intellectual property in the United States and other countries with respect to our proprietary technology, product </div></div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">61 </div></div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;;font-weight: bold;"><a href="#toc">Table of Contents</a></div> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">candidates and our target indications. Given the amount of time required for the development, testing and regulatory review of new product candidates, patents protecting our product candidates might expire before or shortly after such candidate begins to be commercialized. We expect to seek extensions of patent terms in the United States and, if available, in other countries where we are prosecuting patents. </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Depending upon the timing, duration and specifics of FDA marketing approval of product candidates, one or more of our U.S. patents may be eligible for a limited patent term extension (&#8220;PTE&#8221;) under the Drug Price Competition and Patent Term Restoration Act of 1984, referred to as the Hatch-Waxman Amendments. The Hatch-Waxman Amendments permit a patent restoration term of up to five years beyond the normal expiration of the patent as compensation for patent term lost during development and the FDA regulatory review process, which is limited to the approved indication (and potentially additional indications approved during the period of extension) covered by the patent. This extension cannot extend the remaining term of a patent beyond a total of 14 years from the date of product approval and is limited to only one patent that covers the approved product, the approved use of the product, or a method of manufacturing the product. However, the applicable authorities, including the FDA and the USPTO in the United States, and any equivalent regulatory authority in other countries, may not agree with our assessment of whether such extensions are available, and may refuse to grant extensions to our patents, or may grant more limited extensions than we request. We may not be granted an extension because of, for example, failing to apply within applicable deadlines, failing to apply prior to expiration of relevant patents or otherwise failing to satisfy applicable requirements. Moreover, the applicable time-period or the scope of patent protection afforded could be less than we request. Even if we are able to obtain an extension, the patent term may still expire before or shortly after we receive FDA marketing approval. </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">If we are unable to extend the expiration date of our existing patents or obtain new patents with longer expiry dates, our competitors may be able to take advantage of our investment in development and clinical trials by referencing our clinical and <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">pre-clinical</div> data to obtain approval of competing product candidates following our patent expiration and launch their product earlier than might otherwise be the case. </div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Obtaining and maintaining our patent protection depends on compliance with various procedural, document submission, fee payment and other requirements imposed by governmental patent agencies, and our patent protection could be reduced or eliminated as a result of <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-compliance</div> with these requirements. </div></div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;">Periodic maintenance fees on any issued patent are due to be paid to the USPTO and other patent agencies in other jurisdictions in several stages over the lifetime of the patent. The USPTO and various national or international patent agencies require compliance with a number of procedural, documentary, fee payment and other similar provisions during the patent application process. In certain circumstances, we rely on our licensing partners to pay these fees due to U.S. and <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-U.S.</div> patent agencies and to take the necessary action to comply with these requirements with respect to our licensed intellectual property. While an inadvertent lapse can in many cases be cured by payment of a late fee or by other means in accordance with the applicable rules, there are situations in which noncompliance can result in abandonment or lapse of the patent or patent application, resulting in partial or complete loss of patent rights in the relevant jurisdiction. <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">Non-compliance</div> events that could result in abandonment or lapse of patent rights include, but are not limited to, failure to timely file national and regional stage patent applications based on our international patent applications, failure to respond to official actions within prescribed time limits, <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-payment</div> of fees and failure to properly legalize and submit formal documents. If we or our licensors fail to maintain the patents and patent applications covering our product candidates or any future product candidate, our competitors might be able to enter the market earlier than anticipated, which would have an adverse effect on our business. </div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">62 </div></div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;;font-weight: bold;"><a href="#toc">Table of Contents</a></div> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">We rely on certain <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">in-licensed</div> patents and other intellectual property rights in connection with our development of certain product candidates and, if we fail to comply with our obligations under our existing and any future intellectual property licenses with third parties, we could lose license rights that are important to our business. </div></div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Our ability to develop and commercialize product candidates is dependent on licenses to patent rights and other intellectual property granted to it by third parties. Further, development and commercialization of our current product candidates, and development of any future product candidates, may require us to enter into additional license or collaboration agreements. </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Our current license agreements impose, and future agreements may impose, various development, diligence, commercialization and other obligations on us and require us to meet development timelines, or to exercise commercially reasonable efforts to develop and commercialize licensed products, in order to maintain the licenses. If we fail to comply with our obligations under these licenses, our licensors may have the right to terminate these license agreements, in which event we may not be able to market our product candidates. Termination of any of our license agreements or reduction or elimination of our licensed rights may also result in our having to negotiate new or reinstated licenses with less favorable terms. Additionally, certain provisions in our intellectual property agreements may be susceptible to multiple interpretations. The resolution of any contract interpretation disagreement that may arise could affect the scope of our rights to the relevant intellectual property or technology, or affect financial or other obligations under the relevant agreement, either of which could harm our business, financial condition, results of operations and prospects. For example, disputes may arise with respect to our current or future licensing agreement include disputes relating to: </div></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">the scope of rights granted under the license agreement and other interpretation-related issues; </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">our financial or other obligations under the license agreement; </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">the extent to which our technology and product candidates infringe on intellectual property of the licensor that is not subject to the licensing agreement; </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">the sublicensing of patent and other rights; </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">our diligence obligations under the license agreements and what activities satisfy those diligence obligations; </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;">the inventorship or ownership of inventions and <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">know-how</div> resulting from the joint creation or use of intellectual property by our licensors and us and our partners; and </div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">the priority of invention of patented technology. </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">If disputes over intellectual property that we have licensed prevent or impair our ability to maintain our current licensing arrangements on acceptable terms, we may be unable to successfully develop and commercialize our product candidates. If our licenses are terminated, we may lose our rights to develop and market our technology and product candidates, lose patent protection for our product candidates and technology, experience significant delays in the development and commercialization of our product candidates, or incur liability for damages. In addition, we may need to obtain additional licenses from our licensors and, in connection with obtaining such licenses, we may agree to amend our existing licenses in a manner that may be more favorable to the licensors, including by agreeing to terms that could enable third parties, including our competitors, to receive licenses to a portion of the intellectual property that is subject to our existing licenses and to compete with our product candidates. </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Furthermore, if our licenses are terminated, or if the underlying patents fail to provide the intended exclusivity, competitors or other third parties would have the freedom to seek regulatory approval of, and to market, products identical or competitive to ours and we may be required to cease our development and commercialization of certain of our product candidates. Moreover, if disputes over intellectual property that we license prevent or impair our ability to maintain other licensing arrangements on commercially acceptable terms, </div></div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">63 </div></div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;;font-weight: bold;"><a href="#toc">Table of Contents</a></div> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">we may be unable to successfully develop and commercialize the affected product candidates. In addition, certain of these license agreements, may not be assignable by us without the consent of the respective licensor, which may have an adverse effect on our ability to engage in certain transactions. Any of the foregoing could have a material adverse effect on our business, financial condition, results of operations and prospects. </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">In addition, in some circumstances, we may not have the right to control the preparation, filing and prosecution of patent applications, or to maintain or enforce the patents, covering technology that it licenses from third parties. For example, pursuant to the license agreement we have with the&#160;Cincinnati Children&#8217;s Hospital Medical Center (&#8220;CCHMC&#8221;), CCHMC controls such activities for certain patents licensed to ASG under such agreement, subject to ASG&#8217;s right to review and comment. Therefore, we cannot be certain that these or other patents will be prosecuted, maintained and enforced in a manner consistent with the best interests of our business. Additionally, we may not have sufficient ability to provide input into the patent prosecution, maintenance and defense process with respect to such patents, and our licensors may fail to take the steps that we believe are necessary or desirable in order to obtain, maintain, defend and enforce the licensed patents. If our current or future licensors or collaboration partners fail to obtain, maintain, defend, protect or enforce any patents or patent applications licensed to us, our rights to such patents and patent applications may be reduced or eliminated and our right to develop and commercialize product candidates that are the subject of such licensed rights could be adversely affected. </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Furthermore, certain of our current and future licenses may not provide us with exclusive rights to use the licensed intellectual property and technology, or may not provide us with rights to use such intellectual property and technology in all relevant fields of use and in all territories in which we may wish to develop or commercialize our technology and product candidates in the future. The intellectual property portfolio licensed to us by our licensors at least in some respects, may therefore be used by such licensors or licensed to third parties, and such third parties may have certain enforcement rights with respect to such intellectual property. For example, Immunovant does not have rights to develop, manufacture, use or commercialize IMVT-1401 or file or enforce patents relating to these assets in territories other than the United States, Canada, Mexico, the EU, the U.K., Switzerland, the Middle East, North Africa and Latin America, as such rights in other jurisdictions have been retained by HanAll Biopharma Co., Ltd. (&#8220;HanAll&#8221;) or licensed by HanAll to third parties. Additionally, Dermavant does not have the right to develop, manufacture, use or commercialize tapinarof in China, including Hong Kong, Macau or Taiwan, as such rights were retained by Welichem Biotech Inc. Patents licensed to us could be put at risk of being invalidated or interpreted narrowly in litigation filed by or against our licensors or another licensee or in administrative proceedings brought by or against our licensors or another licensee in response to such litigation or for other reasons. As a result, we may not be able to prevent competitors or other third parties from developing and commercializing competitive products, including in territories covered by our licenses. </div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Third party claims or litigation alleging infringement, misappropriation or other violations of third-party patents or other proprietary rights or seeking to invalidate our patents or other proprietary rights, may delay or prevent the development and commercialization of our product candidates and any future product candidate. </div></div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;">Our commercial success depends in part on our avoidance of infringement, misappropriation and other violations of the patents and proprietary rights of third parties. However, our research, development and commercialization activities may be subject to claims that we infringe, misappropriate or otherwise violate patents or other intellectual property rights owned or controlled by third parties. Our competitors or other third parties may assert infringement claims against us, alleging that our product candidates are covered by their patents. We cannot be certain that we do not infringe existing patents or that we will not infringe patents that may be granted in the future. There is a substantial amount of litigation, both within and outside the United States, involving patent and other intellectual property rights in the biotechnology and pharmaceutical industries, including patent infringement lawsuits, interferences, derivation and administrative law proceedings,<div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;"> inter partes</div></div> review, and post-grant review before the USPTO, as well as oppositions and similar processes in other </div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">64 </div></div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;;font-weight: bold;"><a href="#toc">Table of Contents</a></div> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">jurisdictions. Numerous U.S. and <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-U.S.</div> issued patents and pending patent applications, which are owned by third parties, exist in the fields in which we and our collaborators are developing product candidates. As the biotechnology and pharmaceutical industries expand and more patents are issued, and as we gain greater visibility, the risk increases that our product candidates or other business activities may be subject to claims of infringement of the patent and other proprietary rights of third parties. Third parties may assert that we are infringing their patents or employing their proprietary technology without authorization. There may be third-party patents or patent applications with claims to materials, formulations, methods of manufacture or methods for treatment related to the use or manufacture of our product candidates. For example, we are aware of third-party patents and patent applications that, if issued as patents, could be construed in a manner that negatively impacts the commercialization of <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">ARU-1801.</div> If any such patents were held by a court of competent jurisdiction to cover <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">ARU-1801,</div> we may be required to cease development or commercialization of <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">ARU-1801</div> unless we obtain a license under the applicable patents, or until such patents expire. Such a license may not be available on commercially reasonable terms, may only be available on a <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-exclusive</div> basis or may not be available at all. We could also be required to pay damages, which could be significant, including treble damages and attorneys&#8217; fees if we are found to have willfully infringed such patents. </div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">Additionally, because patent applications can take many years to issue, there may be currently pending patent applications which may later result in issued patents that our product candidates may infringe. In addition, third parties may obtain patents in the future and claim that use of our technologies infringes upon these patents. If any third-party patents were held by a court of competent jurisdiction to cover any of our product candidates, the holders of any such patents may be able to block our ability to commercialize such product candidate unless we obtained a license under the applicable patents, or until such patents expire. Similarly, if any third-party patent were held by a court of competent jurisdiction to cover aspects of our formulations, processes for manufacture or methods of use, including combination therapy, the holders of any such patent may be able to block our ability to develop and commercialize the applicable product candidate unless we obtained a license or until such patent expires. In either case, such a license may not be available on commercially reasonable terms or at all. Claims that we have misappropriated the confidential information or trade secrets of third parties could have a similar negative impact on our business. In addition, we may be subject to claims that we are infringing other intellectual property rights, such as trademarks or copyrights, or misappropriating the trade secrets of others, and to the extent that our employees, consultants or contractors use intellectual property or proprietary information owned by others in their work for us, disputes may arise as to the rights in related or resulting <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">know-how</div> and inventions, which could be time-consuming and divert the attention of senior management. </div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Parties making claims against us may obtain injunctive or other equitable relief, which could effectively block our ability to further develop and commercialize one or more of our product candidates. Defense of these claims, regardless of their merit, would involve substantial litigation expense and would be a substantial diversion of employee resources from our business. In the event of a successful infringement or other intellectual property claim against it, we may have to pay substantial damages, including treble damages and attorneys&#8217; fees for willful infringement, obtain one or more licenses from third parties, pay royalties or redesign our affected product candidates, which may be impossible or require substantial time and monetary expenditure. We cannot predict whether any such license would be available at all or whether it would be available on commercially reasonable terms. Furthermore, even in the absence of litigation, we may need to obtain licenses from third parties to advance our research or allow commercialization of our product candidates, and we have done so from time to time. We may fail to obtain any of these licenses at a reasonable cost or on reasonable terms, if at all. In that event, we would be unable to further develop and commercialize one or more of our product candidates, which could harm our business significantly. We cannot provide any assurances that third-party patents do not exist which might be enforced against our product candidates, resulting in either an injunction prohibiting our sales, or, with respect to our sales, an obligation on our part to pay royalties and/or other forms of compensation to third parties. </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Some of our competitors may be able to sustain the costs of complex intellectual property litigation more effectively than we can because the competitors have substantially greater resources. In addition, intellectual </div></div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">65 </div></div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;;font-weight: bold;"><a href="#toc">Table of Contents</a></div> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">property litigation, regardless of its outcome, may cause negative publicity, adversely impact prospective customers, cause product shipment delays, or prohibit us from manufacturing, marketing or otherwise commercializing our product candidates, services, and technology. Any uncertainties resulting from the initiation and continuation of any litigation could adversely impact our ability to raise additional funds or otherwise harm our business, results of operation, financial condition or cash flows. </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Furthermore, because of the substantial amount of discovery required in connection with intellectual property litigation, there is a risk that some of our confidential information could be compromised by disclosure during this type of litigation. There could also be public announcements of the results of hearings, motions or other interim proceedings or developments, which could adversely impact the price of our Common Shares. </div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">We may not identify relevant third-party patents or may incorrectly interpret the relevance, scope or expiration of a third-party patent, which might harm our ability to develop and market our product candidates. </div></div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">We cannot guarantee that any of our or our licensors&#8217; patent searches or analyses, including the identification of relevant patents, the scope of patent claims or the expiration of relevant patents, are complete or thorough, nor can we be certain that we have identified each and every third-party patent and pending application in the United States and abroad that is or may be relevant to or necessary for the commercialization of product candidates in any jurisdiction. Patent applications in the United States and elsewhere are not published until approximately 18 months after the earliest filing for which priority is claimed, with such earliest filing date being commonly referred to as the priority date. In addition, U.S. patent applications filed before November&#160;29, 2000 and certain U.S. patent applications filed after that date that will not be filed outside the United States remain confidential until patents issue. Therefore, patent applications covering our product candidates could have been filed by others without our knowledge. Additionally, pending patent applications that have been published can, subject to certain limitations, be later amended in a manner that could cover our product candidates, any future product candidates, or the use thereof, provided such pending patent applications result in issued patents. Our ability to develop and market our product candidate or any future product candidates can be adversely affected in jurisdictions where such patents are issued. </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The scope of a patent claim is determined by an interpretation of the law, the written disclosure in a patent and the patent&#8217;s prosecution history. Our interpretation of the relevance or the scope of a patent or a pending application may be incorrect, which may negatively impact our ability to market our product candidates. We may incorrectly determine that our product candidates are not covered by a third-party patent or may incorrectly predict whether a third party&#8217;s pending application will issue with claims of relevant scope. Our determination of the expiration date of any patent in the United States or abroad that we consider relevant may be incorrect and we may incorrectly conclude that a third-party patent is invalid or unenforceable. Our failure to identify and correctly interpret relevant patents may negatively impact our ability to develop and market our product candidates or any future product candidates, if approved. </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">If we fail to identify and correctly interpret relevant patents, we may be subject to infringement claims. We cannot guarantee that we will be able to successfully settle or otherwise resolve such infringement claims. If we fail in any such dispute, in addition to being forced to pay damages, we may be temporarily or permanently prohibited from commercializing any of our product candidates that are held to be infringing. We might, if possible, also be forced to redesign product candidates or services so that we no longer infringe the third-party intellectual property rights. Any of these events, even if we were ultimately to prevail, could require us to divert substantial financial and management resources that we would otherwise be able to devote to our business. </div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">We may be involved in lawsuits to protect or enforce our patents, the patents of our licensors or our other intellectual property rights, which could be expensive, time consuming and unsuccessful. </div></div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Competitors may infringe, misappropriate or otherwise violate our patents, the patents of our licensors or our other intellectual property rights. To counter infringement or unauthorized use, we may be required to file </div></div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">66 </div></div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;;font-weight: bold;"><a href="#toc">Table of Contents</a></div> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">and prosecute legal claims against one or more third parties, which can be expensive and time-consuming, even if ultimately successful. In addition, in an infringement proceeding, a court may decide that a patent of ours or our licensors is not valid or is unenforceable, or may refuse to stop the other party from using the technology at issue on the grounds that our patents do not cover the technology in question. The standards that courts use to interpret patents are not always applied predictably or uniformly and can change, particularly as new technologies develop. As a result, we cannot predict with certainty how much protection, if any, will be given to our patents if we attempt to enforce them and they are challenged in court. Further, even if we prevail against an infringer in U.S. district court, there is always the risk that the infringer will file an appeal and the district court judgment will be overturned at the appeals court and/or that an adverse decision will be issued by the appeals court relating to the validity or enforceability of our patents. An adverse result in any litigation or defense proceedings could put one or more of our patents at risk of being invalidated or interpreted narrowly in a manner insufficient to achieve our business objectives, or could put our patent applications at risk of not issuing. The initiation of a claim against a third party may also cause the third party to bring counter claims against us such as claims asserting that our patents are invalid or unenforceable. In patent litigation in the United States, defendant counterclaims alleging invalidity or unenforceability are commonplace. Grounds for a validity challenge could be an alleged failure to meet any of several statutory requirements, including lack of novelty, obviousness, <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-enablement</div> or lack of written description or <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-statutory</div> subject matter. Grounds for an unenforceability assertion could be an allegation that someone connected with prosecution of the patent withheld relevant material information from the USPTO, or made a materially misleading statement, during prosecution. Third parties may also raise similar validity claims before the USPTO in post-grant proceedings such as ex parte reexaminations, <div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">inter partes</div></div> review, or post-grant review, or oppositions or similar proceedings outside the United States, in parallel with litigation or even outside the context of litigation. The outcome following legal assertions of invalidity and unenforceability is unpredictable. We cannot be certain that there is no invalidating prior art, of which we and the patent examiner were unaware during prosecution. For the patents and patent applications that we have licensed, we may have limited or no right to participate in the defense of any licensed patents against challenge by a third party. If a defendant were to prevail on a legal assertion of invalidity or unenforceability, we would lose at least part, and perhaps all, of any future patent protection on our current or future product candidates. Such a loss of patent protection could harm our business. Additionally, any adverse outcome could allow third parties to commercialize our products and compete directly with us, without payment to us, or result in our inability to manufacture or commercialize products without infringing third-party patent rights. </div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Even if we establish infringement, the court may decide not to grant an injunction against further infringing activity and instead award only monetary damages, which may or may not be an adequate remedy. We may not be able to detect or prevent, alone or with our licensors, misappropriation of our intellectual property rights, particularly in countries where the laws may not protect those rights as fully as in the United States. Our business could be harmed if in litigation the prevailing party does not offer us a license on commercially reasonable terms. Any litigation or other proceedings to enforce our intellectual property rights may fail, and even if successful, may result in substantial costs and distract our management and other employees. </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Furthermore, because of the substantial amount of discovery required in connection with intellectual property litigation, there is a risk that some of our confidential information could be compromised by disclosure during this type of litigation. There could also be public announcements of the results of hearings, motions or other interim proceedings or developments. If securities analysts or investors perceive these results to be negative, it could have an adverse effect on the price of our Common Shares. </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">We may not have sufficient financial or other resources to adequately conduct such litigation or proceedings. Some of our competitors or other third parties may be able to sustain the costs of such litigation or proceedings more effectively than we can because of their greater financial resources and more mature and developed intellectual property portfolios. Because of the expense and uncertainty of litigation, we may conclude that even if a third party is infringing our issued patent, any patents that may be issued as a result of our pending or future patent applications or other intellectual property rights, the risk-adjusted cost of bringing and enforcing such a claim or action may be too high or not in the best interest of our company or our shareholders. In such </div></div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">67 </div></div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;;font-weight: bold;"><a href="#toc">Table of Contents</a></div> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">cases, we may decide that the more prudent course of action is to simply monitor the situation or initiate or seek some other <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-litigious</div> action or solution. </div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Because many of the patents we own are owned by our subsidiaries, and in certain cases by subsidiaries that are not or will not be directly commercializing products, we may not be in a position to obtain a permanent injunction against a third party that is found to infringe our patents. </div></div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Many patents that we own are assigned to our subsidiaries or to their respective subsidiaries. For example, any patents that Immunovant owns are assigned to its wholly-owned subsidiary Immunovant Sciences GmbH and any patents that Dermavant owns are assigned to its wholly-owned subsidiary Dermavant Sciences GmbH. If a third party is found to be infringing such patents, we and our direct subsidiaries may not be able to permanently enjoin the third party from making, using, offering for sale or selling the infringing product or activity for the remaining life of such patent in the United States or other jurisdictions when the patent is assigned to a subsidiary, which is not the entity that is or would be commercializing a potentially competitive product or service. In such a circumstance, such third party may be able to compete with us or our subsidiaries, which could have a material adverse effect on our competitive position, business, financial condition, results of operations, and prospects. </div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Changes in U.S. patent law or the patent law of other countries or jurisdictions could diminish the value of patents in general, thereby impairing our ability to protect our product candidates. </div></div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">As is the case with other biopharmaceutical companies, our success is heavily dependent on intellectual property. Obtaining and enforcing patents in the biopharmaceutical industry involves both technological and legal complexity and is therefore costly, time consuming and inherently uncertain. Changes in either the patent laws or interpretation of the patent laws in the United States or USPTO rules and regulations could increase the uncertainties and costs. </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">The United States has recently enacted and implemented wide-ranging patent reform legislation. In addition, patent reform legislation may pass in the future that could lead to additional uncertainties and increased costs surrounding the prosecution, enforcement and defense of our patents and pending patent applications. The U.S. Supreme Court has ruled on several patent cases in recent years, either narrowing the scope of patent protection available in certain circumstances or weakening the rights of patent owners in certain situations. In addition to increasing uncertainty with regard to our ability to obtain patents in the future, this combination of events has created uncertainty with respect to the value of patents, once obtained. For example, the Biden administration recently indicated its support for a proposal at the World Trade Organization to waive patent rights with respect to <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">COVID-19</div> vaccines. Any waiver of our patent or other intellectual property protection by the U.S. and other foreign governments, including with respect to Genevant&#8217;s licensed lipid nanoparticle (&#8220;LNP&#8221;) delivery technology as used in connection with Messenger RNA vaccine delivery, could have a material adverse effect on our competitive position, business, financial condition, results of operations and prospects. </div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">Depending on actions by the U.S. Congress, the federal courts, and the USPTO, the laws and regulations governing patents could change in unpredictable ways that would weaken our ability to obtain new patents or to enforce patents that we have licensed or that we might obtain in the future. Similarly, changes in patent law and regulations in other countries or jurisdictions or changes in the governmental bodies that enforce them or changes in how the relevant governmental authority enforces patent laws or regulations may weaken our ability to obtain new patents or to enforce patents that we have licensed or that we may obtain in the future. We cannot predict future changes in the interpretation of patent laws or changes to patent laws that might be enacted into law by United States and <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-U.S.</div> legislative bodies. Those changes may materially affect our patents or patent applications and our ability to obtain additional patent protection in the future. </div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">In addition, the United States federal government retains certain rights in inventions produced with its financial assistance under the Bayh-Dole Act. The federal government retains a &#8220;nonexclusive, nontransferable, </div></div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">68 </div></div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;;font-weight: bold;"><a href="#toc">Table of Contents</a></div> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">irrevocable, <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">paid-up</div> license&#8221; for its own benefit. The Bayh-Dole Act also provides federal agencies with <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">&#8220;march-in</div> rights.&#8221; <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">March-in</div> rights allow the government, in specified circumstances, to require the contractor or successors in title to the patent to grant a &#8220;nonexclusive, partially exclusive, or exclusive license&#8221; to a &#8220;responsible applicant or applicants.&#8221; For example, the research resulting in certain of our <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">in-licensed</div> patent rights and technology for certain product candidates was funded in part by the U.S. federal government. As a result, the federal government may have certain rights to such patent rights and technology, which include <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">march-in</div> rights. If the federal government decides to exercise these rights, it is not required to engage us as its contractor in connection with doing so. The federal government&#8217;s rights may also permit it to disclose our confidential information to third parties and to exercise <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">march-in</div> rights to use or allow third parties to use our licensed technology. The federal government can exercise its <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">march-in</div> rights if it determines that action is necessary because we fail to achieve practical application of the government-funded technology, or because action is necessary to alleviate health or safety needs, to meet requirements of federal regulations, or to give preference to U.S. industry. Further, the recipient of U.S. government funding is required to comply with certain other requirements, including timely disclosing the inventions claimed in such patent rights to the U.S. government and timely electing title to such inventions. The U.S. government has the right to take title to such intellectual property rights if we, or the applicable licensor, fail to disclose the invention to the government and fail to file an application to register the intellectual property within specified time limits. Intellectual property generated under a government funded program is also subject to certain reporting requirements, compliance with which may require us or the applicable licensor to expend substantial resources. In addition, our rights in such inventions may be subject to certain requirements to manufacture product candidates embodying such inventions in the United States. We cannot be certain that our current or future licensors will comply with the disclosure or reporting requirements of the Bayh-Dole Act at all times, or be able to rectify any lapse in compliance with these requirements. Any exercise by the government of any of the foregoing rights or by any third party of its reserved rights could have a material adverse effect on our competitive position, business, financial condition, results of operations, and prospects. </div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">The validity, scope and enforceability of any patents listed in the Orange Book that cover our product candidates or patents that cover our biologic product candidates can be challenged by third parties. </div></div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;">If one of our product candidates is approved by the FDA and if a third party files an application under Section&#160;505(b)(2) or an abbreviated new drug application (&#8220;ANDA&#8221;) under Section&#160;505(j) for a generic product containing any of our product candidates, including tapinarof (which, following the natural expiration of our method of use patent family, will be protected only by our formulation patent), and relies in whole or in part on studies conducted by or for us, the third party will be required to certify to the FDA that either: (1)&#160;there is no patent information listed in the Orange Book with respect to our NDA for the applicable approved product candidate; (2)&#160;the patents listed in the Orange Book have expired; (3)&#160;the listed patents have not expired, but will expire on a particular date and approval is sought after patent expiration; or (4)&#160;the listed patents are invalid or will not be infringed by the manufacture, use or sale of the third party&#8217;s generic product. A certification under 21 CFR &#167;&#160;314.94(a)(12)(i)(A)(4) that the new product will not infringe the Orange Book-listed patents for the applicable approved product candidate, or that such patents are invalid, is called a paragraph IV certification. If the third party submits a paragraph IV certification to the FDA, a notice of the paragraph IV certification must also be sent to us once the third party&#8217;s ANDA is accepted for filing by the FDA. We may then initiate a lawsuit to defend the patents identified in the notice. The filing of a patent infringement lawsuit within 45 days of receipt of the notice automatically prevents the FDA from approving the third party&#8217;s ANDA until the earliest of 30 months or the date on which the patent expires, the lawsuit is settled, or the court reaches a decision in the infringement lawsuit in favor of the third party. If we do not file a patent infringement lawsuit within the required <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">45-day</div> period, the third party&#8217;s ANDA will not be subject to the <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">30-month</div> stay of FDA approval. </div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Moreover, a third party may challenge the current patents, or patents that may issue in the future, within our portfolio, which could result in the invalidation of some or all of the patents that might otherwise be eligible for listing in the Orange Book for one of our products. If a third party successfully challenges all of the patents that </div></div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">69 </div></div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;;font-weight: bold;"><a href="#toc">Table of Contents</a></div> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">might otherwise be eligible for listing in the Orange Book for one of our products before an ANDA or 505(b)(2) NDA is filed we will be unable to obtain a <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">30-month</div> stay of FDA approval of a 505(b)(2) or ANDA. </div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">For example, our three issued U.S. patents covering tapinarof may not provide adequate protection from competitive products developed by 505(b)(1) NDA, 505(b)(2) NDA or 505(j) ANDA applicants containing paragraph IV certifications if such applicants are able to design around the three patents. One or more competitors may circumvent these patents by filing a marketing application with the FDA under Sections 505(b)(2) or 505(j) of the Federal Food, Drug and Cosmetic Act containing a paragraph IV certification for a competitive product containing the active moiety in tapinarof and successfully challenging the validity of the three patents or successfully designing around the three patents. Any successful challenge against the three patents and/or designing around one or more of the patents could result in a generic version of tapinarof being commercialized before the expiration of the three patents. If the three patents are successfully challenged or designed around, our business, results of operations, financial condition and prospects would be harmed. </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">For biologics, the BPCIA provides a mechanism for one or more third parties to seek FDA approval to manufacture or sell a biosimilar or interchangeable versions of brand name biological product candidates. Due to the large size and complexity of biological product candidates, as compared to small molecules, a biosimilar must be &#8220;highly similar&#8221; to the reference product with &#8220;no clinically meaningful differences between the two.&#8221; The BPCIA does not require reference product sponsors to list patents in the FDA&#8217;s Orange Book and does not include an automatic <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">30-month</div> stay of FDA approval upon the timely filing of a lawsuit. The BPCIA, however, does require a formal <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">pre-litigation</div> process which includes the exchange of information between a biosimilar applicant and a reference biologic sponsor that includes the identification of relevant patents and each parties&#8217; basis for infringement and invalidity. After the exchange of this information, we may then initiate a lawsuit within 30 days to defend the patents identified in the exchange. If the biosimilar applicant successfully challenges the asserted patent claims, it could result in the invalidation of, or render unenforceable, some or all of the relevant patent claims or result in a finding of <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-infringement.</div> </div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">If we are unsuccessful in enforcing our patents against generics or biosimilars, our products could face competition prior to the expiration of the patents which cover such products, which could have a material adverse effect on our business, financial condition, results of operations and prospects. Furthermore, any such litigation or other proceedings to enforce or defend intellectual property rights are often very complex in nature, may be very expensive and time-consuming, may divert management&#8217;s attention from our core business, and may result in unfavorable results that could limit our ability to prevent third parties from competing with product candidates. </div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">We may not be able to protect our intellectual property rights throughout the world. </div></div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Filing, prosecuting and defending patents on product candidates in all countries throughout the world would be prohibitively expensive, and our intellectual property rights in some countries outside the United States can be less extensive than those in the United States. The requirements for patentability may differ in certain countries, particularly developing countries, and the breadth of patent claims allowed can be inconsistent. In addition, the laws of some countries do not protect intellectual property rights to the same extent as laws of the United States. </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Consequently, we may not be able to prevent third parties from practicing our inventions in all countries outside the United States, or from selling or importing product candidates made using our inventions in and into the United States or other jurisdictions. Competitors may use our technologies in jurisdictions where we have not obtained patent protection to develop their own product candidates and may also export infringing product candidates to territories where we have patent protection, but enforcement is not as strong as that in the United States. These product candidates may compete with our product candidates and our patents or other intellectual property rights may not be effective or sufficient to prevent them from competing. </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">We do not have patent rights in all countries in which a market may exist. Moreover, in jurisdictions where we do have patent rights, proceedings to enforce such rights could result in substantial costs and divert our efforts </div></div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">70 </div></div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;;font-weight: bold;"><a href="#toc" style="text-indent: 0px;">Table of Contents</a></div> </div> <div> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">and attention from other aspects of our business, could put our patents at risk of being invalidated or interpreted narrowly, and our patent applications at risk of not issuing. Additionally, such proceedings could provoke third parties to assert claims against us. We may not prevail in any lawsuits that we initiate and the damages or other remedies awarded, if any, may not be commercially meaningful. Thus, we may not be able to stop a competitor from marketing and selling in other countries product candidates and services that are the same as or similar to our product candidates and services, and our competitive position would be harmed. </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Many companies have encountered significant problems in protecting and defending intellectual property rights in other jurisdictions. The legal systems of certain countries, particularly certain developing countries, do not favor the enforcement of patents, trade secrets, and other intellectual property protection, particularly those relating to biotechnology product candidates, which could make it difficult for us to stop the infringement of our patents or marketing of competing product candidates in violation of our proprietary rights generally. Proceedings to enforce our patent rights in other jurisdictions, whether or not successful, could result in substantial costs and divert our efforts and attention from other aspects of our business, could put our patents at risk of being invalidated or interpreted narrowly and our patent applications at risk of not issuing and could provoke third parties to assert claims against us. We may not prevail in any lawsuits that we initiate and the damages or other remedies awarded, if any, may not be commercially meaningful. Accordingly, our efforts to enforce our intellectual property rights around the world may be inadequate to obtain a significant commercial advantage from the intellectual property that we develop or license. </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Many countries, including European Union countries, India, Japan and China, have compulsory licensing laws under which a patent owner may be compelled under specified circumstances to grant licenses to third parties. In addition, many countries limit the enforceability of patents against government agencies or government contractors. In those countries, we may have limited remedies, which could materially diminish the value of those patents. This could limit our potential revenue opportunities. Accordingly, our efforts to enforce our intellectual property rights around the world may be inadequate to obtain a significant commercial advantage from the intellectual property that we develop or license. </div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">If we are unable to protect the confidentiality of any trade secrets, our business and competitive position would be harmed. </div></div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;">In addition to seeking patents for any product candidates, we may rely on trade secrets, including unpatented software, <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">know-how,</div> technology and other proprietary information, to maintain our competitive position. We seek to protect this software and information, in part, by entering into <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-disclosure</div> and confidentiality agreements with parties who have access to them, such as our employees, corporate collaborators, outside scientific collaborators, contract manufacturers, consultants, advisors and other third parties. We also enter into confidentiality and invention or patent assignment agreements with our employees and consultants. </div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Because we rely and expect to continue to rely on third parties to manufacture our product candidates and future product candidates, and we collaborate and expect to continue to collaborate with third parties on the development of current and future product candidates, we must, at times, share trade secrets with them. We also conduct joint research and development programs that may require us to share trade secrets under the terms of our research and development partnerships or similar agreements. We seek to protect our proprietary technology in part by entering into confidentiality agreements and, if applicable, material transfer agreements, consulting agreements or other similar agreements with our advisors, employees, third-party contractors and consultants prior to beginning research or disclosing proprietary information. These agreements typically limit the rights of the third parties to use or disclose our confidential information, including our trade secrets. Despite the contractual provisions employed when working with third parties, the need to share trade secrets and other confidential information increases the risk that such trade secrets become known by our competitors, are inadvertently incorporated into the technology of others, or are disclosed or used in violation of these agreements. Any disclosure, either intentional or unintentional, by our employees, the employees of third parties with whom we share facilities or third-party consultants and vendors that we engage to perform research, clinical </div></div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">71 </div></div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;;font-weight: bold;"><a href="#toc">Table of Contents</a></div> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">trials or manufacturing activities, or misappropriation by third parties (such as through a cybersecurity breach) of our trade secrets or proprietary information could enable competitors to duplicate or surpass our technological achievements, thus eroding our competitive position in the market. Further, adequate remedies may not exist in the event of unauthorized use or disclosure. Given that our proprietary position is based, in part, on our <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">know-how</div> and trade secrets, a competitor&#8217;s discovery of our trade secrets or other unauthorized use or disclosure would impair our competitive position and may have an adverse effect on our business and results of operations. </div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">In addition, these agreements typically restrict the ability of our advisors, employees, third-party contractors and consultants to publish data potentially relating to our trade secrets, although our agreements may contain certain limited publication rights. Policing unauthorized use of our or our licensors&#8217; intellectual property is difficult, expensive and time-consuming, and we may be unable to determine the extent of any unauthorized use. Moreover, enforcing a claim that a party illegally disclosed or misappropriated a trade secret is difficult, expensive and time-consuming, and the outcome is unpredictable. In addition, some courts inside and outside the United States are less willing or unwilling to protect trade secrets. Despite our efforts to protect our trade secrets, our competitors and other third parties may discover our trade secrets, including our proprietary software, either through breach of our agreements with third parties, independent development or publication of information by any of our third-party collaborators. A competitor&#8217;s or other third party&#8217;s discovery of our trade secrets, including our proprietary software, would impair our competitive position and have an adverse impact on our business. </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">We cannot guarantee that we have entered into <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-disclosure,</div> confidentiality agreements, material transfer agreements or consulting agreements with each party that may have or have had access to our trade secrets or proprietary software, technology and processes. Despite these efforts, any of these parties may breach the agreements and disclose our proprietary information, including our trade secrets and proprietary software, and we may not be able to obtain adequate remedies for such breaches. Monitoring unauthorized uses and disclosures of our intellectual property is difficult, and we do not know whether the steps we have taken to protect our intellectual property will be effective. In addition, we may not be able to obtain adequate remedies for any such breaches. Enforcing a claim that a party illegally disclosed or misappropriated a trade secret is difficult, expensive and time-consuming, and the outcome is unpredictable. In addition, some courts inside and outside the United States are less willing or unwilling to protect trade secrets. If any of our trade secrets, including our proprietary software, were to be lawfully obtained or independently developed by a competitor or other third party, we would have no right to prevent them, or those to whom they communicate it, from using that technology or information to compete with us. If any of our trade secrets, including our proprietary software, were to be disclosed to or independently developed by a competitor or other third party, our competitive position would be harmed. </div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Certain software utilized in our computational drug discovery efforts may include third party open source software. Any failure to comply with the terms of one or more open source software licenses could adversely affect our business, subject us to litigation, or create potential liability. </div></div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Certain software utilized in our computational drug discovery efforts may include third party open source software and we expect to continue to incorporate open source software in the future. The use of open source software involves a number of risks, many of which cannot be eliminated and could negatively affect our business. For example, we cannot ensure that we have effectively monitored our use of open source software or that we are in compliance with the terms of the applicable open source licenses or our current policies and procedures. There have been claims against companies that use open source software asserting that the use of such open source software infringes the claimants&#8217; intellectual property rights. As a result, we could be subject to suits by third parties claiming infringement on such third parties&#8217; intellectual property rights. Litigation could be costly for us to defend, have a negative effect on our business, financial condition and results of operations, or require us to devote additional research and development resources to modify our computational drug discovery platform. </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Use of open source software may entail greater risks than use of third-party commercial software, as open source licensors generally do not provide warranties, controls on the origin of the software or other contractual </div></div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">72 </div></div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;;font-weight: bold;"><a href="#toc">Table of Contents</a></div> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">protections regarding infringement claims or the quality of the code, including with respect to security vulnerabilities. In addition, certain open source licenses require that source code for software programs that interact with such open source software be made available to the public at no cost and that any modifications or derivative works to such open source software continue to be licensed under the same terms as the open source software license. The terms of various open source licenses have not been interpreted by courts in the relevant jurisdictions, and there is a risk that such licenses could be construed in a manner that imposes unanticipated conditions or restrictions on our ability to market our solutions. By the terms of certain open source licenses, if portions of our proprietary software are determined to be subject to an open source license or if we combine our proprietary software with open source software in a certain manner, we could be required to release the source code of our proprietary software and to make our proprietary software available under open source licenses, each of which could reduce or eliminate the effectiveness of our computational discovery efforts. We may also face claims alleging noncompliance with open source license terms or misappropriation or other violation of open source technology. Any of these events could create liability for us and damage our reputation, which could have a material adverse effect on our competitive position, business, financial condition, results of operations and prospects. </div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">We may be subject to claims that our employees, consultants or independent contractors have wrongfully used or disclosed confidential information of their former employers or other third parties. </div></div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">We employ individuals who were previously employed at universities or other software, biotechnology or pharmaceutical companies, including our licensors, competitors or potential competitors. Although we seek to protect our ownership of intellectual property rights by ensuring that our agreements with our employees, collaborators and other third parties with whom we do business include provisions requiring such parties to not use the confidential information of their former employer, we may be subject to claims that we or our employees, consultants, independent contractors or other third parties have inadvertently or otherwise used or disclosed confidential information of our employees&#8217; former employers or other third parties. We may also be subject to claims that former employers or other third parties have an ownership interest in our owned or licensed patents or patent applications. Litigation may be necessary to defend against these claims. There is no guarantee of success in defending these claims, and if we fail in defending any such claims, in addition to paying monetary damages, we may lose valuable intellectual property rights, such as exclusive ownership of, or right to use, valuable intellectual property, which could limit our ability to stop others from using or commercializing similar technology and therapeutics, without payment to us, could limit the duration of the patent protection covering our technology and product candidates and could result in our inability to develop, manufacture or commercialize our product candidates without infringing third-party patent rights. Such intellectual property rights could be awarded to a third party, and we could be required to obtain a license from such third party to commercialize our current or future product candidates. Such a license may not be available on commercially reasonable terms or at all. Even if we are successful, litigation could result in substantial cost and be a distraction to our management and other employees. Moreover, any such litigation or the threat thereof may harm our reputation, our ability to form strategic alliances or sublicense our rights to collaborators, engage with scientific advisors or hire employees or consultants, each of which would harm our business, results of operations and financial condition. </div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">We may be subject to claims challenging the inventorship or ownership of our patents and other intellectual property. </div></div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;">We rely on a combination of internally developed and <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">in-licensed</div> intellectual property rights and we or our licensors may be subject to claims that former employees, collaborators or other third parties have an interest in our owned or <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">in-licensed</div> patents, trade secrets, or other intellectual property as an inventor or <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">co-inventor.</div> For example, we or our licensors may have inventorship disputes arise from conflicting obligations of employees, consultants or other third parties who are involved in developing product candidates. Litigation may be necessary to defend against these and other claims challenging inventorship or our or our licensors&#8217; ownership of our owned or <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">in-licensed</div> patents, trade secrets or other intellectual property. If we or our licensors fail in defending any such claims, in addition to paying monetary damages, we may lose valuable intellectual property rights, such </div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">73 </div></div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;;font-weight: bold;"><a href="#toc">Table of Contents</a></div> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">as exclusive ownership of, or right to use, intellectual property that is important to product candidates. Even if we are successful in defending against such claims, litigation could result in substantial costs and be a distraction to management and other employees. Any of the foregoing could harm our business, financial condition, results of operations and prospects. </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">In addition, while it is our policy to require our employees, contractors and other third parties who may be involved in the development of intellectual property to execute agreements assigning such intellectual property to us, we may be unsuccessful in executing such an agreement with each party who in fact develops intellectual property that we regard as our own. Our invention assignment agreements may not be self-executing or may be breached, and we may not have adequate remedies for any such breach. Additionally, we may be forced to bring claims against third parties, or defend claims they may bring against us, to determine the ownership of what we regard as our intellectual property. Furthermore, individuals executing agreements with us may have preexisting or competing obligations to a third party, such as an academic institution, and thus an agreement with us may be ineffective in perfecting ownership of inventions developed by that individual. </div></div> <div style="text-indent: 4%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Intellectual property litigation could cause us to spend substantial resources and distract our personnel from their normal responsibilities, and have a harmful effect on the success of our business. </div></div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Even if resolved in our favor, litigation or other legal proceedings relating to intellectual property claims may cause us to incur significant expenses, and could distract our technical and management personnel from their normal responsibilities. In addition, there could be public announcements of the results of hearings, motions or other interim proceedings or developments, and if securities analysts or investors perceive these results to be negative, it could adversely impact the price of our Common Shares. Such litigation or proceedings could substantially increase our operating losses and reduce the resources available for development activities or any future sales, marketing or distribution activities. We may not have sufficient financial or other resources to conduct such litigation or proceedings adequately. Some of our competitors may be able to sustain the costs of such litigation or proceedings more effectively than we can because of their greater financial resources. </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">Accordingly, despite our efforts, we may not be able to prevent third parties from infringing upon or misappropriating our intellectual property. In addition, the uncertainties associated with litigation could compromise our ability to raise the funds necessary to continue our clinical trials and internal research programs, or <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">in-license</div> needed technology or other future product candidates. Uncertainties resulting from the initiation and continuation of patent litigation or other proceedings could compromise our ability to compete in the marketplace, including compromising our ability to raise the funds necessary to continue our clinical trials, continue our research programs, license necessary technology from third parties, or enter into development collaborations that would help us commercialize product candidates, if approved. Any of the foregoing could harm our business, financial condition, results of operations and prospects. </div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">We may not be successful in obtaining necessary intellectual property rights to future product candidates through acquisitions and <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">in-licenses.</div> </div></div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;">A third party may hold intellectual property, including patent rights, that are important or necessary to the development of our product candidates. Accordingly, we may seek to acquire or <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">in-license</div> patented or proprietary technologies to develop such product candidates or to grow our product offerings and technology portfolio. However, we may be unable to acquire or <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">in-license</div> intellectual property rights relating to, or necessary for, any such product candidate or technology from third parties on commercially reasonable terms or at all. Even if we are able to <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">in-license</div> any such necessary intellectual property, it could be on <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-exclusive</div> terms, thereby giving our competitors and other third parties access to the same intellectual property licensed to us, and it could require us to make substantial licensing and royalty payments. In that event, we may be unable to develop or commercialize such product candidates or technology. We may also be unable to identify product candidates or technology that we believe are an appropriate strategic fit for our company and protect intellectual property relating to, or necessary for, such product candidate and technology. </div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">74 </div></div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;;font-weight: bold;"><a href="#toc">Table of Contents</a></div> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">The <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">in-licensing</div> and acquisition of third-party intellectual property rights for any future product candidate is a competitive area, and a number of more established companies are also pursuing strategies to <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">in-license</div> or acquire third-party intellectual property rights for product candidates that we may consider attractive or necessary. These established companies may have a competitive advantage over us due to their size, cash resources and greater clinical development and commercialization capabilities. Furthermore, companies that perceive us to be a competitor may be unwilling to assign or license rights to us. If we are unable to successfully obtain rights to additional technologies or product candidates, our business, financial condition, results of operations and prospects for growth could suffer. </div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">In addition, we expect that competition for the <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">in-licensing</div> or acquisition of third-party intellectual property rights for any future product candidate and technologies that are attractive to us may increase in the future, which may mean fewer suitable opportunities for us as well as higher acquisition or licensing costs. We may be unable to <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">in-license</div> or acquire the third-party intellectual property rights for product candidates or technology on terms that would allow us to make an appropriate return on our investment. </div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Any trademarks we have obtained or may obtain may be infringed or successfully challenged, resulting in harm to our business. </div></div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">We rely on trademarks as one means to distinguish product candidates that are approved for marketing from the product candidates of our competitors. Our current and future trademark applications in the United States and in other jurisdictions may not be allowed or may subsequently be opposed, challenged, infringed, circumvented, declared generic or determined to be infringing other marks. Additionally, once we select new trademarks and apply to register them, our trademark applications may not be approved. Third parties have in the past opposed, are currently opposing and may in the future oppose or attempt to cancel our trademark applications or trademarks, or otherwise challenge our use of the trademarks. In the event that our trademarks are successfully challenged, we could be forced to rebrand product candidates, which could result in loss of brand recognition and could require us to devote resources to advertising and marketing new brands. Our competitors may infringe our trademarks and we may not have adequate resources to enforce our trademarks. If we attempt to enforce our trademarks and assert trademark infringement claims, a court may determine that the marks we have asserted are invalid or unenforceable, or that the party against whom we have asserted trademark infringement has superior rights to the marks in question. In this case, we could ultimately be forced to cease use of such trademarks. </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">We may not be able to protect our rights to these trademarks and trade names, which we need to build name recognition among potential partners or customers in our markets of interest. At times, competitors may adopt trade names or trademarks similar to ours, thereby impeding our ability to build brand identity and possibly leading to market confusion. In addition, there could be potential trade name or trademark infringement claims brought by owners of other registered trademarks or trademarks that incorporate variations of our registered or unregistered trademarks or trade names. Over the long term, if we are unable to establish name recognition based on our trademarks and trade names, then we may not be able to compete effectively and our business may be adversely affected. Our efforts to enforce or protect our proprietary rights related to trademarks, trade secrets, domain names, copyrights or other intellectual property may be ineffective and could result in substantial costs and diversion of resources. Any of the foregoing could have a material adverse effect on our business, financial condition, results of operations and prospects. </div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Intellectual property rights do not necessarily address all potential threats to our competitive advantage. </div></div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;">Once granted, patents may remain open to invalidity challenges including opposition, interference, <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">re-examination,</div> post-grant review, <div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">inter partes</div></div> review, nullification or derivation action in court or before patent offices or similar proceedings for a given period after allowance or grant, during which time third parties can raise objections against such grant. In the course of such proceedings, which may continue for a protracted period of time, the patent owner may be compelled to limit the scope of the allowed or granted claims thus attacked, or may lose the allowed or granted claims altogether. </div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">75 </div></div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;;font-weight: bold;"><a href="#toc">Table of Contents</a></div> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">In addition, the degree of future protection afforded by our intellectual property rights is uncertain because intellectual property rights have limitations, and may not adequately protect our business, provide a barrier to entry against our competitors or potential competitors, or permit us to maintain our competitive advantage. </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Moreover, if a third party has intellectual property rights that cover the practice of our technology, we may not be able to fully exercise or extract value from our intellectual property rights. The following examples are illustrative: </div></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">others may be able to make formulations or compositions that are the same as or similar to product candidates, but that are not covered by the claims of the patents that we own; </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">others may be able to make product candidates that are similar to product candidates that we intend to commercialize that are not covered by the patents that we exclusively licensed and have the right to enforce; </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">we, our licensor or any collaborators might not have been the first to make or reduce to practice the inventions covered by the issued patents or pending patent applications that we own or have exclusively licensed; </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">we or our licensor or any collaborators might not have been the first to file patent applications covering certain of our inventions; </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">others may independently develop similar or alternative technologies or duplicate any of our technologies without infringing our intellectual property rights; </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">it is possible that our pending patent applications will not lead to issued patents; </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">issued patents that we own or have exclusively licensed may not provide us with any competitive advantages, or may be held invalid or unenforceable as a result of legal challenges; </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">our competitors might conduct research and development activities in the United States and other countries that provide a safe harbor from patent infringement claims for certain research and development activities, as well as in countries where we do not have patent rights, and then use the information learned from such activities to develop competitive product candidates for sale in our major commercial markets; and we may not develop additional proprietary technologies that are patentable; </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">third parties performing manufacturing or testing for us using our product candidates or technologies could use the intellectual property of others without obtaining a proper license; </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">parties may assert an ownership interest in our intellectual property and, if successful, such disputes may preclude us from exercising exclusive rights over that intellectual property; </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;">we may not develop or <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">in-license</div> additional proprietary technologies that are patentable; </div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">we may not be able to obtain and maintain necessary licenses on commercially reasonable terms, or at all; </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">the patents of others may harm our business; and </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;">we may choose not to file a patent application in order to maintain certain trade secrets or <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">know-how,</div> and a third party may subsequently file a patent application covering such intellectual property. </div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Should any of these events occur, they could significantly harm our business and results of operations. </div></div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">76 </div></div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;;font-weight: bold;"><a href="#toc">Table of Contents</a></div> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Risks Related to our Securities, our Jurisdiction of Incorporation and Certain Tax Matters </div></div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">The listing of our securities on Nasdaq did not benefit from the process undertaken in connection with an underwritten initial public offering. </div></div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Our Common Shares and our Warrants are listed on Nasdaq under the symbols &#8220;ROIV&#8221; and &#8220;ROIVW,&#8221; respectively. Unlike an underwritten initial public offering of our securities, the initial listing of our securities as a result of the Business Combination did not benefit from the following: </div></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">the book-building process undertaken by underwriters that helps to inform efficient price discovery with respect to opening trades of newly listed securities; </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">underwriter support to help stabilize, maintain or affect the public price of the new issue immediately after listing; and </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">underwriter due diligence review of the offering and potential liability for material misstatements or omissions of fact in a prospectus used in connection with the securities being offered or for statements made by its securities analysts or other personnel. </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The lack of such a process in connection with the listing of our securities could result in diminished investor demand, inefficiencies in pricing and a more volatile public price for our securities in the near future than in connection with an underwritten initial public offering. </div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">If our performance does not meet market expectations, the price of our securities may decline. </div></div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">If our performance does not meet market expectations, the price of our Common Shares may decline. In addition, even if an active market for our Common Shares develops and continues, the trading price of our Common Shares could be volatile and subject to wide fluctuations in response to various factors, some of which are beyond our control. Prior to the Business Combination, there was not a public market for our Common Shares, and trading in our Common Shares was not active. Any of the factors listed below could have a material adverse effect on the price of our Common Shares. </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Factors affecting the trading price of our Common Shares may include: </div></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">actual or anticipated fluctuations in our quarterly and annual financial results or the quarterly and annual financial results of companies perceived to be similar to it; </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">changes in the market&#8217;s expectations about operating results; </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">our operating results failing to meet market expectations in a particular period; </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">a Vant&#8217;s operating results failing to meet market expectations in a particular period, which could impact the market prices of shares of a public Vant or the valuation of a private Vant, and in turn adversely impact the trading price of our Common Shares; </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;">the results of clinical trials or <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">pre-clinical</div> studies conducted by us and the Vants; </div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">changes in financial estimates and recommendations by securities analysts concerning us, the Vants or the biopharmaceutical industry and market in general; </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">operating and stock price performance of other companies that investors deem comparable to us; </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">changes in laws and regulations affecting our and the Vants&#8217; businesses; </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">commencement of, or involvement in, litigation involving MAAC or us; </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">changes in our capital structure, such as future issuances of securities or the incurrence of debt; </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;">the volume of our Common Shares available for public sale, which may be limited due to, among other reasons, the extent of redemptions by MAAC stockholders in connection with the consummation of the Business Consummation and the relatively limited free float of our Common Shares, particularly prior to the expiration of the <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">lock-up</div> provisions described elsewhere in this prospectus; </div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">77 </div></div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;;font-weight: bold;"><a href="#toc">Table of Contents</a></div> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;">
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">any significant change in our board of directors or management; </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">sales of substantial amounts of our Common Shares directors, executive officers or significant shareholders or the perception that such sales could occur; and </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">general economic and political conditions such as recessions, interest rates, fuel prices, international currency fluctuations and acts of war or terrorism. </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Broad market and industry factors may depress the market price of our Common Shares irrespective of our or the Vants&#8217; operating performance. The stock market in general has experienced price and volume fluctuations that have often been unrelated or disproportionate to the operating performance of the particular companies affected. The trading prices and valuations of these stocks, and of our securities, may not be predictable. A loss of investor confidence in the market for companies engaging in digital payments or the stocks of other companies which investors perceive to be similar to us could depress our stock price regardless of our business, prospects, financial conditions or results of operations. A decline in the market price of our Common Shares also could adversely affect our ability to issue additional securities and our ability to obtain additional financing in the future. </div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Our warrant agreement designates the courts of the State of New York or the United States District Court for the Southern District of New York as the sole and exclusive forum for certain types of actions and proceedings that may be initiated by holders of our Warrants, which could limit the ability of warrant holders to obtain a favorable judicial forum for disputes with our company. </div></div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Our warrant agreement provides that, subject to applicable law, (i)&#160;any action, proceeding or claim against us arising out of or relating in any way to the warrant agreement, including under the Securities Act, will be brought and enforced in the courts of the State of New York or the United States District Court for the Southern District of New York, and (ii)&#160;that we irrevocably submit to such jurisdiction, which jurisdiction shall be the exclusive forum for any such action, proceeding or claim. We waive any objection to such exclusive jurisdiction and that such courts represent an inconvenient forum. </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Notwithstanding the foregoing, these provisions of the warrant agreement do not apply to suits brought to enforce any liability or duty created by the Exchange Act or any other claim for which the federal district courts of the United States of America are the sole and exclusive forum. Any person or entity purchasing or otherwise acquiring any interest in any of our Warrants shall be deemed to have notice of and to have consented to the forum provisions in our warrant agreement. If any action, the subject matter of which is within the scope the forum provisions of the warrant agreement, is filed in a court other than a court of the State of New York or the United States District Court for the Southern District of New York (a &#8220;foreign action&#8221;) in the name of any holder of our Warrants, such holder shall be deemed to have consented to: (x)&#160;the personal jurisdiction of the state and federal courts located in the State of New York in connection with any action brought in any such court to enforce the forum provisions (an &#8220;enforcement action&#8221;) and (y)&#160;having service of process made upon such warrant holder in any such enforcement action by service upon such warrant holder&#8217;s counsel in the foreign action as agent for such warrant holder. </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">This <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">choice-of-forum</div></div> provision may limit a warrant holder&#8217;s ability to bring a claim in a judicial forum that it finds favorable for disputes with our company, which may discourage such lawsuits. Warrant holders who do bring a claim in a court of the State of New York or the United States District Court for the Southern District of New York could face additional litigation costs in pursuing any such claim, particularly if they do not reside in or near the State of New York. Alternatively, if a court were to find this provision of our warrant agreement inapplicable or unenforceable with respect to one or more of the specified types of actions or proceedings, we may incur additional costs associated with resolving such matters in other jurisdictions, which could materially and adversely affect our business, financial condition and results of operations and result in a diversion of the time and resources of our management and board of directors. </div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">78 </div></div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;;font-weight: bold;"><a href="#toc">Table of Contents</a></div> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">We may amend the terms of the Warrants in a manner that may be adverse to holders of Public Warrants with the approval by the holders of at least 50% of the then outstanding Public Warrants. As a result, the exercise price of your Warrants could be increased, the exercise period could be shortened and the number of shares purchasable upon exercise of a warrant could be decreased, all without your approval. </div></div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Our Warrants were initially issued by MAAC in registered form under a warrant agreement between Continental Stock Transfer&#160;&amp; Trust Company (&#8220;CST&#8221;), as warrant agent, and us but American Stock Transfer&#160;&amp; Trust Company has assumed CST&#8217;s responsibilities as warrant agent under the warrant agreement. </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The warrant agreement provides that the terms of the Warrants may be amended without the consent of any holder for the purpose of (i)&#160;curing any ambiguity or correct any mistake or defective provision (ii)&#160;amending the provisions relating to cash dividends on common stock as contemplated by and in accordance with the warrant agreement or (iii)&#160;adding or changing any provisions with respect to matters or questions arising under the warrant agreement as the parties to the warrant agreement may deem necessary or desirable and that the parties deem to not adversely affect the rights of the registered holders of the Warrants, provided that the approval by the holders of at least 50% of the then-outstanding Public Warrants is required to make any change that adversely affects the interests of the registered holders of Public Warrants. Accordingly, we may amend the terms of the Public Warrants in a manner adverse to a holder if holders of at least 50% of the then outstanding Public Warrants approve of such amendment. Although our ability to amend the terms of the Public Warrants with the consent of at least 50% of the then outstanding Public Warrants is unlimited, examples of such amendments could be amendments to, among other things, increase the exercise price of the Warrants, convert the Warrants into cash, shorten the exercise period or decrease the number of our Common Shares purchasable upon exercise of a warrant. </div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">We have and will continue to incur increased costs as a result of operating as a public company and our management has and will continue to devote a substantial amount of time to new compliance initiatives. </div></div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">As a public company, we have and will continue to incur significant legal, accounting and other expenses that we did not incur as a private company, and these expenses may increase even more after we are no longer an emerging growth company, as defined in Section&#160;2(a) of the Securities Act. In addition, we expect to record incremental share-based compensation expense in connection with the consummation of the Business Combination. </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">As a public company, we are subject to the reporting requirements of the Exchange Act, the Sarbanes-Oxley Act and the Dodd-Frank Act, as well as rules adopted, and to be adopted, by the SEC and the Nasdaq. Our management and other personnel have and will continue to devote a substantial amount of time to these compliance initiatives. Moreover, these rules and regulations have substantially increased our legal and financial compliance costs and made some activities more time-consuming and costly. For example, these rules and regulations have made it more difficult and more expensive for us to obtain director and officer liability insurance and forced us to accept reduced policy limits. We cannot predict or estimate the amount or timing of additional costs we have and will continue to incur to respond to these requirements. The impact of these requirements could also make it more difficult for us to attract and retain qualified persons to serve on our board of directors, our board committees or as executive officers. </div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Our failure to timely and effectively implement controls and procedures required by Section&#160;404(a) of the Sarbanes-Oxley Act that will be applicable to us after the Business Combination is consummated could have a material adverse effect on our business. </div></div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">As a public company, we are required to provide management&#8217;s attestation on internal controls as required under Section&#160;404(a) of the Sarbanes-Oxley&#160;Act. The standards required for a public company under Section&#160;404(a) of the Sarbanes-Oxley&#160;Act are significantly more stringent than those required of us as a privately-held&#160;company. Management is implementing controls and procedures that it expects will adequately respond to the increased regulatory compliance and reporting requirements applicable after the Business </div></div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">79 </div></div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;;font-weight: bold;"><a href="#toc">Table of Contents</a></div> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Combination. If we are not successful in implementing the additional requirements of Section&#160;404(a) in a timely manner or with adequate compliance, we may not be able to assess whether our internal controls over financial reporting are effective, which may subject us to adverse regulatory consequences and could harm investor confidence and the market price of our securities. </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Failure to properly implement internal controls on a timely basis may lead to the identification of one or more material weaknesses or control deficiencies in the future, which may prevent us from being able to report our financial results accurately on a timely basis or help prevent fraud, and could cause our reported financial results to be materially misstated and result in the loss of investor confidence or delisting and cause the market price of our Common Shares to decline. If we have material weaknesses in the future, it could affect the financial results that we report or create a perception that those financial results do not fairly state our financial position or results of operations. Either of those events could have an adverse effect on the value of our Common Shares. </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Further, even if we conclude that our internal control over financial reporting provides reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with U.S. GAAP, because of its inherent limitations, internal control over financial reporting may not prevent or detect fraud or misstatements. Failure to implement required new or improved controls, or difficulties encountered in their implementation, could harm our results of operations or cause us to fail to meet our future reporting obligations. </div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">We may redeem your unexpired Warrants prior to their exercise at a time that is disadvantageous to you, thereby making your Warrants worthless. </div></div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;">We have the ability to redeem outstanding Warrants at any time after they become exercisable and prior to their expiration, at a price of $0.01 per warrant, provided that the last reported sales price of our Common Shares is equal to or exceeds $18.00 per share (as adjusted for share sub divisions, share capitalizations, rights issuances, subdivisions, reorganizations, recapitalizations and the like) for any 20 trading days within a 30 <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">trading-day</div> period ending on the third trading day prior to the date they send the notice of redemption to the warrant holders. If and when the Warrants become redeemable by us, we may not exercise our redemption right if the issuance of shares upon exercise of the Warrants is not exempt from registration or qualification under applicable state blue sky laws or if we are unable to effect such registration or qualification. We will use our best efforts to register or qualify such shares under the blue sky laws of the state of residence in those states in which the Warrants were offered by us. Redemption of the outstanding Warrants could force an investor to (i)&#160;to exercise their Warrants and pay the exercise price therefor at a time when it may be disadvantageous for an investor to do so, (ii)&#160;for an investor to sell their Warrants at the then-current market price when they might otherwise wish to hold their Warrants or (iii)&#160;to accept the nominal redemption price which, at the time the outstanding Warrants are called for redemption, is likely to be substantially less than the market value of an investors Warrants. </div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">In addition, we may redeem an investor&#8217;s Warrants at any time after they become exercisable and prior to their expiration at a price of $0.10 per warrant upon a minimum of 30 days&#8217; prior written notice of redemption provided that holders will be able to exercise their Warrants prior to redemption for a number of Common Shares determined based on the redemption date and the fair market value of our Common Shares. The value received upon exercise of the Warrants (1)&#160;may be less than the value the holders would have received if they had exercised their Warrants at a later time where the underlying share price is higher and (2)&#160;may not compensate the holders for the value of the Warrants, including because the number of shares received is capped at 0.361 Common Shares per warrant (subject to adjustment) irrespective of the remaining life of the Warrants. None of the Private Placement Warrants will be redeemable by us so long as they are held by the MAAC Sponsor or its permitted transferees. </div></div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">80 </div></div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;;font-weight: bold;"><a href="#toc" style="text-indent: 0px;">Table of Contents</a></div> </div> <div> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Our management will have the ability to require holders of our Warrants to exercise such Warrants on a cashless basis, which will cause holders to receive fewer Common Shares upon their exercise of the Warrants than they would have received had they been able to exercise their Warrants for cash. </div></div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">If we call the Public Warrants for redemption after the redemption criteria have been satisfied, our management will have the option to require any holder that wishes to exercise their warrant (including any Warrants held by the MAAC Sponsor, MAAC&#8217;s former officers or directors, other purchasers of MAAC&#8217;s founders&#8217; units, or their permitted transferees) to do so on a &#8220;cashless basis.&#8221; If our management chooses to require holders to exercise their Warrants on a cashless basis, the number of Common Shares received by a holder upon exercise will be fewer than it would have been had such holder exercised his warrant for cash. This will have the effect of reducing the potential &#8220;upside&#8221; of the holder&#8217;s investment in our company. </div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Changes in laws or regulations, or a failure to comply with any laws and regulations, may adversely affect our business, investments and results of operations. </div></div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">We are subject to laws and regulations enacted by national, regional and local governments. In particular, we will be required to comply with certain SEC and other legal requirements. Compliance with, and monitoring of, applicable laws and regulations may be difficult, time consuming and costly. Those laws and regulations and their interpretation and application may also change from time to time and those changes could have a material adverse effect on our business, investments and results of operations. In addition, a failure to comply with applicable laws or regulations, as interpreted and applied, could have a material adverse effect on our business and results of operations. </div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Anti-takeover provisions in our memorandum of association and <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">bye-laws</div> and under Bermuda law could delay or prevent a change in control, limit the price investors may be willing to pay in the future for our Common Shares and could entrench management. </div></div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;">Our memorandum of association and <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">bye-laws</div> contain provisions that could make it more difficult for a third-party to acquire us without the consent of our board of directors. These provisions provide for: </div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">a classified board of directors with staggered three-year terms; </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">the ability of our board of directors to determine the powers, preferences and rights of preference shares and to cause us to issue the preference shares without shareholder approval; </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">the ability of our board of directors to prevent the transfer of capital stock, or the exercise of rights with respect to our capital stock, if the effect of such transfer or exercise of rights would result in a shareholder holding more than 9.9% of the total issued and outstanding shares of our capital stock on a fully diluted basis; and </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">requiring advance notice for shareholder proposals and nominations and placing limitations on convening shareholder meetings. </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">These provisions may make more difficult the removal of management and may discourage transactions that otherwise could involve payment of a premium over prevailing market prices for our securities. These provisions could also discourage proxy contests and make it more difficult for you and other shareholders to elect directors of your choosing and cause us to take corporate actions other than those you desire, any of which could harm our share price. </div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Our largest shareholders and certain members of our management own a significant percentage of our Common Shares and are able to exert significant control over matters subject to shareholder approval. </div></div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Our founder and certain of our largest shareholders hold a significant percentage of our Common Shares. As a result, these holders have the ability to substantially influence us and exert significant control through this ownership position and, in the case of certain holders, service on our board of directors. For example, these </div></div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">81 </div></div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;;font-weight: bold;"><a href="#toc">Table of Contents</a></div> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">holders may be able to control elections of directors, issuance of equity, including to our employees under equity incentive plans, amendments of our organizational documents, or approval of any merger, amalgamation, sale of assets or other major corporate transaction. These holders&#8217; interests may not always coincide with our corporate interests or the interests of other shareholders, and it may exercise its voting and other rights in a manner with which you may not agree or that may not be in the best interests of our other shareholders. So long as these holders continue to own a significant amount of our equity, they will continue to be able to strongly influence and effectively control our decisions. </div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Future sales and issuances of our or the Vants&#8217; equity securities or rights to purchase equity securities, including pursuant to our or the Vants&#8217; equity incentive and other compensatory plans, will result in additional dilution of the percentage ownership of our shareholders and could cause our share price to fall. </div></div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">We and the Vants will need additional capital in the future to continue our planned operations. To the extent we raise additional capital by issuing equity securities, including in our subsidiaries, our shareholders may experience substantial dilution. We or the Vants may sell Common Shares, convertible securities or other equity securities in one or more transactions at prices and in a manner we determine from time to time. If we sell Common Shares, convertible securities or other equity securities in more than one transaction, investors may be materially diluted by subsequent sales. In addition, new investors could gain rights superior to our existing shareholders. </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Pursuant to our 2021 Equity Incentive Plan (the &#8220;2021 EIP&#8221;), we are authorized to grant options and other share-based awards to our employees, directors and consultants. The aggregate number of shares initially reserved for issuance under the 2021 EIP will be increased annually on the first day of each fiscal year during the term of the plan in an amount equal to the lesser of (i) 5% of the number of our Common Shares outstanding as of the day of the immediately preceding fiscal year and (ii)&#160;such number of our Common Shares as determined by our board of directors in its discretion. As a result of this annual increase, or if our board of directors elects in the future to make any additional increase in the number of shares available for future grant under the 2021 EIP, and if our shareholders approve of any such additional increase, our shareholders may experience additional dilution, and our share price may fall. </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Issuance of options and other share-based awards pursuant to equity incentive plans at the Vants may indirectly have a similar effect of diluting your ownership in us since a portion of the value of our Common Shares is tied to the value of the Vants, which would be diluted in the event of a grant of options or other similar equity grants to the employees of the Vants. </div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">If securities analysts publish negative evaluations of our shares, the price of our Common Shares could decline. </div></div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The trading market for our securities will be influenced by the research and reports that industry or securities analysts may publish about us, our business, market or competitors. If any of the analysts who may cover us change their recommendation regarding our Common Shares adversely, or provide more favorable relative recommendations about its competitors, the price of our Common Shares would likely decline. If any analyst who may cover us were to cease coverage or fail to regularly publish reports, we could lose visibility in the financial markets, which in turn could cause our share price or trading volume to decline. </div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Our founder and certain of our largest shareholders will own a substantial portion of our Common Shares. As a result, there may be&#160;limited&#160;liquidity&#160;for our Common Shares. </div></div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;">Our founder and certain of our largest shareholders hold a significant percentage of our Common Shares. Such shareholders are subject to certain <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">lock-up</div> arrangements and as a result there may initially be limited liquidity in the trading market for our Common Shares. In addition, even once the applicable <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">lock-up</div> periods expire, the liquidity for our Common Shares may remain limited given the substantial holdings of such </div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">82 </div></div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;;font-weight: bold;"><a href="#toc">Table of Contents</a></div> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">shareholders, which could make the price of our Common Shares more volatile and may make it more difficult for investors to buy or sell large amounts of our Common Shares. </div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Because there are no current plans to pay cash dividends on our Common Shares for the foreseeable future, you may not receive any return on investment unless you sell our Common Shares for a price greater than that which you paid for it. </div></div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Our may retain future earnings, if any, for future operations, expansion and debt repayment and has no current plans to pay any cash dividends for the foreseeable future. Any decision to declare and pay dividends as a public company in the future will be made at the discretion of our board of directors and will depend on, among other things, our results of operations, financial condition, cash requirements, contractual restrictions, applicable law and other factors that our board of directors may deem relevant. In addition, our ability to pay dividends may be limited by covenants of any existing and future outstanding indebtedness we or our subsidiaries incur. As a result, you may not receive any return on an investment in our Common Shares unless you sell your shares of for a price greater than that which you paid for them. </div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">We are an exempted company limited by shares incorporated under the laws of Bermuda and it may be difficult for you to enforce judgments against us or our directors and executive officers. </div></div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;">We are an exempted company limited by shares incorporated under the laws of Bermuda. As a result, the rights of our shareholders are governed by Bermuda law and our memorandum of association and <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">bye-laws.</div> The rights of shareholders under Bermuda law may differ from the rights of shareholders of companies incorporated in another jurisdiction. It may be difficult for investors to enforce in the U.S. judgments obtained in U.S. courts against us based on the civil liability provisions of the U.S. securities laws. It is doubtful whether courts in Bermuda will enforce judgments obtained in other jurisdictions, including the U.S., against us or our directors or officers under the securities laws of those jurisdictions or entertain actions in Bermuda against us or our directors or officers under the securities laws of other jurisdictions. </div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Bermuda law differs from the laws in effect in the U.S. and may afford less protection to our shareholders. </div></div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;">We are incorporated under the laws of Bermuda. As a result, our corporate affairs are governed by the Bermuda Companies Act 1981, as amended, (the &#8220;Companies Act&#8221;) which differs in some material respects from laws typically applicable to U.S. corporations and shareholders, including the provisions relating to interested directors, amalgamations, mergers and acquisitions, takeovers, shareholder lawsuits and indemnification of directors. Generally, the duties of directors and officers of a Bermuda company are owed to the company only. Shareholders of Bermuda companies typically do not have rights to take action against directors or officers of the company and may only do so in limited circumstances. Shareholder class actions are not available under Bermuda law. The circumstances in which shareholder derivative actions may be available under Bermuda law are substantially more proscribed and less clear than they would be to shareholders of U.S. corporations. The Bermuda courts, however, would ordinarily be expected to permit a shareholder to commence an action in the name of a company to remedy a wrong to the company where the act complained of is alleged to be beyond the corporate power of the company or illegal or would result in the violation of the company&#8217;s memorandum of association or <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">bye-laws.</div> Furthermore, consideration would be given by a Bermuda court to acts that are alleged to constitute a fraud against the minority shareholders or, for instance, where an act requires the approval of a greater percentage of the company&#8217;s shareholders than those who actually approved it. </div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">When the affairs of a company are being conducted in a manner that is oppressive or prejudicial to the interests of some shareholders, one or more shareholders may apply to the Supreme Court of Bermuda, which may make such order as it sees fit, including an order regulating the conduct of the company&#8217;s affairs in the future or ordering the purchase of the shares of any shareholders by other shareholders or by the company. Additionally, under our <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">bye-laws</div> and as permitted by Bermuda law, each shareholder will waive any claim or right of action against our directors or officers for any action taken by directors or officers in the performance of </div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">83 </div></div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;;font-weight: bold;"><a href="#toc">Table of Contents</a></div> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">their duties, except for actions involving fraud or dishonesty. In addition, the rights of our shareholders and the fiduciary responsibilities of our directors under Bermuda law are not as clearly established as under statutes or judicial precedent in existence in jurisdictions in the U.S., particularly the State of Delaware. Therefore, our shareholders may have more difficulty protecting their interests than would shareholders of a corporation incorporated in a jurisdiction within the U.S. </div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">There are regulatory limitations on the ownership and transfer of our Common Shares. </div></div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;">Common shares may be offered or sold in Bermuda only in compliance with the provisions of the Companies Act and the Bermuda Investment Business Act 2003, which regulates the sale of securities in Bermuda. In addition, the Bermuda Monetary Authority must approve all issues and transfers of shares of a Bermuda exempted company. However, the Bermuda Monetary Authority has, pursuant to its statement of June&#160;1, 2005, given its general permission under the Exchange Control Act 1972 and related regulations for the issue and free transfer of our Common Shares to and among persons who are <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-residents</div> of Bermuda for exchange control purposes as long as the shares are listed on an appointed stock exchange, which includes Nasdaq. Additionally, we have sought and have obtained a specific permission from the Bermuda Monetary Authority for the issue and transfer of our Common Shares up to the amount of our authorized capital from time to time, and options, warrants, depository receipts, rights, loan notes, debt instruments and our other securities to persons resident and <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-resident</div> for exchange control purposes with the need for prior approval of such issue or transfer. The general permission or the specific permission would cease to apply if we were to cease to be listed on the Nasdaq or another appointed stock exchange. </div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">We may become subject to unanticipated tax liabilities and higher effective tax rates. </div></div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">We are incorporated under the laws of Bermuda. We are centrally managed and controlled in the U.K., and under current U.K. tax law, a company which is centrally managed and controlled in the U.K. is regarded as resident in the U.K. for taxation purposes. Accordingly, we expect to be subject to U.K. taxation on our income and gains, and subject to U.K.&#8217;s controlled foreign company rules, except where an exemption applies. We may be treated as a dual resident company for U.K. tax purposes. As a result, our right to claim certain reliefs from U.K. tax may be restricted, and changes in law or practice in the U.K. could result in the imposition of further restrictions on our right to claim U.K. tax reliefs. We may also become subject to income, withholding or other taxes in certain jurisdictions by reason of our activities and operations, and it is also possible that taxing authorities in any such jurisdictions could assert that we are subject to greater taxation than we currently anticipate. Any such additional tax liability could materially adversely affect our results of operations. </div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">The intended tax effects of our corporate structure and intercompany arrangements depend on the application of the tax laws of various jurisdictions and on how we operate our business. </div></div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;">We are incorporated under the laws of Bermuda. We currently have subsidiaries in the U.S., U.K., Switzerland, China and certain other jurisdictions. If we succeed in growing our business, we expect to conduct increased operations through our subsidiaries in various countries and tax jurisdictions, in part through intercompany service agreements between our subsidiaries and us. In that case, our corporate structure and intercompany transactions, including the manner in which we develop and use our intellectual property, will be organized so that we can achieve our business objectives in a <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">tax-efficient</div> manner and in compliance with applicable transfer pricing rules and regulations. If two or more affiliated companies are located in different countries or tax jurisdictions, the tax laws and regulations of each country generally will require that transfer prices be the same as those between unrelated companies dealing at arm&#8217;s length and that appropriate documentation be maintained to support the transfer prices. While we believe that we operate in compliance with applicable transfer pricing laws and intend to continue to do so, our transfer pricing procedures are not binding on applicable taxing authorities. If taxing authorities in any of these countries were to successfully challenge our transfer prices as not reflecting arm&#8217;s length transactions, they could require it to adjust its transfer prices and thereby reallocate its income to reflect these revised transfer prices, which could result in a higher tax liability to </div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">84 </div></div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;;font-weight: bold;"><a href="#toc">Table of Contents</a></div> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">us. In addition, if the country from which the income is reallocated does not agree with the reallocation, both countries could tax the same income, resulting in double taxation. If taxing authorities were to allocate income to a higher tax jurisdiction, subject our income to double taxation or assess interest and penalties, it would increase its consolidated tax liability, which could adversely affect our financial condition, results of operations and cash flows. </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Significant judgment is required in evaluating our tax positions and determining our provision for income taxes. During the ordinary course of business, there are many transactions and calculations for which the ultimate tax determination is uncertain. For example, our effective tax rates could be adversely affected by changes in foreign currency exchange rates or by changes in the relevant tax, accounting, and other laws, regulations, principles, and interpretations. As we intend to operate in numerous countries and taxing jurisdictions, the application of tax laws can be subject to diverging and sometimes conflicting interpretations by tax authorities of these jurisdictions. It is not uncommon for taxing authorities in different countries to have conflicting views, for instance, with respect to, among other things, the manner in which the arm&#8217;s length standard is applied for transfer pricing purposes, or with respect to the valuation of intellectual property. </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">In addition, tax laws are dynamic and subject to change as new laws are passed and new interpretations of the law are issued or applied. We continue to assess the impact of such changes in tax laws and interpretations on our business and may determine that changes to our structure, practice, tax positions or the manner in which we conduct our business are necessary in light of such changes and developments in the tax laws of other jurisdictions in which we operate. Such changes may nevertheless be ineffective in avoiding an increase in our consolidated tax liability, which could adversely affect our financial condition, results of operations and cash flows. </div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Changes in our effective tax rate may reduce our net income in future periods. </div></div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;">Our tax position could be adversely impacted by changes in tax rates, tax laws, tax practice, tax treaties or tax regulations or changes in the interpretation thereof by the tax authorities in Europe (including the U.K. and Switzerland), the U.S., Bermuda, China and other jurisdictions, as well as being affected by certain changes currently proposed by the Organization for Economic <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">Co-operation</div> and Development and their action plan on Base Erosion and Profit Shifting. Such changes may become more likely as a result of recent economic trends in the jurisdictions in which we operate, particularly if such trends continue. If such a situation were to arise, it could adversely impact our tax position and our effective tax rate. Failure to manage the risks associated with such changes, or misinterpretation of the laws providing such changes, could result in costly audits, interest, penalties, and reputational damage, which could adversely affect our business, results of our operations, and our financial condition. </div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Our actual effective tax rate may vary from our expectation and that variance may be material. A number of factors may increase our future effective tax rates, including: (1)&#160;the jurisdictions in which profits are determined to be earned and taxed; (2)&#160;the resolution of issues arising from any future tax audits with various tax authorities; (3)&#160;changes in the valuation of our deferred tax assets and liabilities; (4)&#160;increases in expenses not deductible for tax purposes, including transaction costs and impairments of goodwill in connection with acquisitions; (5)&#160;changes in the taxation of stock-based compensation; (6)&#160;changes in tax laws or the interpretation of such tax laws, and changes in U.S. generally accepted accounting principles; and (7)&#160;challenges to the transfer pricing policies related to our structure. </div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">The IRS may not agree that we should be treated as a <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-U.S.</div> corporation for U.S. federal income tax purposes. </div></div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Under current U.S. federal income tax law, a corporation generally will be considered to be a U.S. corporation for U.S. federal income tax purposes only if it is created or organized in the United States or under the law of the United States or of any State. Accordingly, under generally applicable U.S. federal income tax </div></div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">85 </div></div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;;font-weight: bold;"><a href="#toc">Table of Contents</a></div> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">rules, we, while we were not created or organized in the United States or under the law of the United States or of any State but is instead a Bermuda incorporated entity and tax resident of the U.K., would generally be classified as a <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-U.S.</div> corporation. Section&#160;7874 of the Code and the Treasury regulations promulgated thereunder, however, contain specific rules that may cause a <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-U.S.</div> corporation to be treated as a U.S. corporation for U.S. federal income tax purposes. If it were determined that we are treated as a U.S. corporation for U.S. federal income tax purposes under Section&#160;7874 of the Code and the Treasury regulations promulgated thereunder, we would be liable for U.S. federal income tax on our income just like any other U.S. corporation and certain distributions made by us to our shareholders that are not &#8220;U.S. Holders&#8221; of us would be subject to U.S. withholding tax. We believe that we should not be treated as a U.S. corporation for U.S. federal income tax purposes under Section&#160;7874 of the Code. However, the interpretation of Treasury regulations relating to the required ownership of us is subject to uncertainty and there is limited guidance regarding their application. Accordingly, there can be no assurance that the IRS will not take a contrary position to those described above or that a court will not agree with a contrary position of the IRS in the event of litigation. You are urged to consult your tax advisor to determine the tax consequences if the classification of us as a <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-U.S.</div> corporation is not respected. </div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">U.S. holders that own 10% or more of the combined voting power or value of our Common Shares may suffer adverse tax consequences because we and our <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-U.S.</div> subsidiaries may be characterized as &#8220;controlled foreign corporations&#8221; (&#8220;CFCs&#8221;), under Section&#160;957(a) of the Code. </div></div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;">A <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-U.S.</div> corporation is considered a CFC if more than 50% of (1)&#160;the total combined voting power of all classes of stock of such corporation entitled to vote, or (2)&#160;the total value of the stock of such corporation, is owned, or is considered as owned by applying certain constructive ownership rules, by U.S. shareholders (U.S. persons who own stock representing 10% or more of the combined voting power or value of all outstanding stock of such <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-U.S.</div> corporation) on any day during the taxable year of such <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-U.S.</div> corporation. Certain U.S. shareholders of a CFC generally are required to include currently in gross income such shareholders&#8217; share of the CFC&#8217;s &#8220;Subpart F income,&#8221; a portion of the CFC&#8217;s earnings to the extent the CFC holds certain U.S. property, and a portion of the CFC&#8217;s &#8220;global intangible <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">low-taxed</div> income&#8221; (as defined under Section&#160;951A of the Code). Such U.S. shareholders are subject to current U.S. federal income tax with respect to such items, even if the CFC has not made an actual distribution to such shareholders. &#8220;Subpart F income&#8221; includes, among other things, certain passive income (such as income from dividends, interests, royalties, rents and annuities or gain from the sale of property that produces such types of income) and certain sales and services income arising in connection with transactions between the CFC and a person related to the CFC. &#8220;Global intangible <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">low-taxed</div> income&#8221; may include most of the remainder of a CFC&#8217;s income over a deemed return on its tangible assets. </div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">We believe that we will not be classified as a CFC in the current taxable year. However, it is possible that our <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-U.S.</div> subsidiaries could be classified as CFCs in the current taxable year. For U.S. holders who hold 10% or more of the combined voting power or value of our Common Shares, this may result in adverse U.S. federal income tax consequences, such as current U.S. taxation of Subpart F income (regardless of whether we make any distributions), taxation of amounts treated as global intangible <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">low-taxed</div> income under Section&#160;951A of the Code with respect to such shareholder, and being subject to certain reporting requirements with the IRS. Any such U.S. holder who is an individual generally would not be allowed certain tax deductions or foreign tax credits that would be allowed to a U.S. corporation. If you are a U.S. holder who holds 10% or more of the combined voting power or value of our Common Shares, you should consult your own tax advisors regarding the U.S. tax consequences of acquiring, owning, or disposing of our Common Shares. </div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">U.S. holders of our Common Shares may suffer adverse tax consequences if we are characterized as a passive foreign investment company. </div></div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Generally, if, for any taxable year, at least 75% of our gross income is passive income, or at least 50% of the average quarterly value of our assets is attributable to assets that produce passive income or are held for the production of passive income, including cash, we would be characterized as a passive foreign investment </div></div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">86 </div></div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;;font-weight: bold;"><a href="#toc">Table of Contents</a></div> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">company (a &#8220;PFIC&#8221;) for U.S. federal income tax purposes. For purposes of these tests, passive income generally includes dividends, interest, gains from the sale or exchange of investment property and rents and royalties other than rents and royalties which are received from unrelated parties in connection with the active conduct of a trade or business. Additionally, a look-through rule generally applies with respect to 25% or more owned subsidiaries. If we are characterized as a PFIC, U.S. holders of our Common Shares may suffer adverse tax consequences, including having gains realized on the sale of our Common Shares treated as ordinary income rather than capital gain, the loss of the preferential tax rate applicable to dividends received on our Common Shares by individuals who are U.S. holders, and having interest charges apply to certain distributions by us and the proceeds of sales or other dispositions of our Common Shares that result in a gain to the U.S. holder. In addition, special information reporting may be required. </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Our status as a PFIC will depend on the nature and composition of our income and the nature, composition and value of our assets from time to time. The 50% passive asset test described above is generally based on the fair market value of each asset. If we are a CFC (determined by disregarding certain downward attribution rules) and not publicly traded for the relevant taxable year, however, the test shall be applied based on the adjusted basis of our assets. </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">Recently adopted Treasury regulations (the &#8220;New Regulations&#8221;), modify certain of the rules described above. Such modifications include, for example, permitting asset value to be determined more frequently than on a quarterly basis and treating a <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-U.S.</div> corporation as publicly traded for a taxable year if the stock of such corporation is publicly traded, other than in de minimis quantities, for at least twenty trading days during such taxable year. </div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">The New Regulations generally apply to taxable years of shareholders beginning on or after January&#160;14, 2021. A shareholder, however, may choose to apply such rules for any open taxable year beginning before January&#160;14, 2021, provided that, with respect to a <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-U.S.</div> corporation being tested for PFIC status, the shareholder consistently applies certain of the provisions of the New Regulations and certain other Treasury regulations for such year and all subsequent years. Investors who are U.S. holders should consult their own tax advisors regarding the impact and applicability of the New Regulations. </div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">Because our Common Shares should be considered to be &#8220;publicly traded&#8221; for the current taxable year that ends on March&#160;31, 2022, we should apply the 50% passive asset test using the fair market value of our assets. This determination, however, is subject to uncertainty. In addition, our status may also depend, in part, on how quickly we utilize our cash <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">on-hand</div> and cash from future financings in our business. </div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Based on the foregoing, with respect to the taxable year that ended on March&#160;31, 2021, we believe that we were not a PFIC (based in part on our belief that we were not classified as a CFC in the taxable year that ended on March&#160;31, 2021) and presently do not anticipate that we will be a PFIC based upon the expected value of our assets, including any goodwill and intangible property, and the expected nature and composition of our income and assets. However, our status as a PFIC is a fact-intensive determination made on an annual basis, and we cannot provide any assurances regarding our PFIC status for the current or future taxable years. Our U.S. counsel expresses no opinion with respect to our PFIC status for the current or future taxable years. We will determine our PFIC status for each taxable year and make such determination available to U.S. holders. </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">We have implemented structures and arrangements intended to mitigate the possibility that we will be classified as a PFIC. There can be no assurance that the IRS will not successfully challenge these structures and arrangements, which may result in an adverse impact on the determination of whether we are classified as a PFIC in the current and future taxable years. In addition, recently finalized U.S. Treasury regulations, of which we are continuing to assess the impact, may also adversely affect the treatment of these structures and arrangements with respect to our PFIC status. </div></div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">87 </div></div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;;font-weight: bold;"><a href="#toc">Table of Contents</a></div> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"> <div id="rom164680_6" style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">USE OF PROCEEDS </div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Any sales of Common Shares or Warrants by the Holders pursuant to this prospectus will be solely for the Holders&#8217; respective accounts. The Company will not receive any proceeds from any such sales. </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The Company will receive up to an aggregate of approximately $353.6&#160;million from the exercise of the Warrants, assuming the exercise in full of all of the Warrants for cash. The Company expects to use any such net proceeds from the exercise of the Warrants for general corporate purposes. The Company will have broad discretion over the use of proceeds from the exercise of the Warrants. There is no assurance that the holders of the Warrants will elect to exercise any or all of such Warrants. </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The Holders will pay any underwriting fees, discounts and selling commissions incurred by such Holders in connection with any sale of their Common Shares. The Company will bear all other costs, fees and expenses incurred in effecting the registration of the Common Shares covered by this prospectus, including, without limitation, all registration and filing fees, Nasdaq listing fees and fees and expenses of counsel and independent registered public accountants. </div></div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">88 </div></div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;;font-weight: bold;"><a href="#toc">Table of Contents</a></div> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"> <div id="rom164680_7" style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">DETERMINATION OF OFFERING PRICE </div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The offering price of the Common Shares underlying the Warrants offered hereby is determined by reference to the exercise price of the Warrants of $11.50 per share. The Public Warrants are listed on The Nasdaq Global Market under the symbol &#8220;ROIVW.&#8221; </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">We cannot currently determine the price or prices at which Common Shares may be sold by the Holders under this prospectus. </div></div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">89 </div></div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;;font-weight: bold;"><a href="#toc">Table of Contents</a></div> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"> <div id="rom164680_8" style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">MARKET INFORMATION FOR COMMON STOCK AND DIVIDEND POLICY </div></div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Market Information </div></div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"></div> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The Common Shares and Public Warrants are currently listed on The Nasdaq Global Market under the symbols &#8220;ROIV&#8221; and &#8220;ROIVW,&#8221; respectively. Prior to the consummation of the Merger, MAAC Class&#160;A Shares and MAAC Warrants were listed on Nasdaq under the symbols &#8220;MAAC&#8221; and &#8220;MAACW,&#8221; respectively. As of As of October&#160;26, 2021, there were 219&#160;holders of record of our Common Shares and one holder of record of our Public Warrants. </div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt; text-indent: 0px;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Dividend Policy </div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">We have not declared or paid any dividends on our Common Shares or the Warrants to date. We anticipate that we will retain all of our future earnings, if any, for use in the operation and expansion of our business and do not anticipate paying cash dividends in the foreseeable future. Any decision to declare and pay dividends in the future will be made at the sole discretion of our board of directors and will depend on, among other things, our results of operations, cash requirements, financial condition, contractual restrictions and other factors that our board of directors may deem relevant. </div></div> </div> </div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"> </div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">90 </div></div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;;font-weight: bold;"><a href="#toc" style="text-indent: 0px;">Table of Contents</a></div> </div> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"> <div id="rom164680_9" style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">UNAUDITED PRO FORMA CONDENSED COMBINED FINANCIAL INFORMATION </div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The following unaudited pro forma condensed combined balance sheet of Roivant as of June&#160;30, 2021 and the unaudited pro forma condensed combined statements of operations of Roivant for the year ended March&#160;31, 2021 and the three months ended June&#160;30, 2021 are based on the historical financial statements of MAAC and Roivant after giving effect to the Business Combination and PIPE Financing, as outlined below. </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">The unaudited pro forma condensed combined financial information has been prepared in accordance with Article 11 of Regulation <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">S-X,</div> Pro Forma Financial Information, as amended by Release <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">No.&#160;33-10786</div> &#8220;Amendments to Financial Disclosures about Acquired and Disposed Businesses.&#8221; The unaudited pro forma condensed combined statements of operations for the year ended March&#160;31, 2021 and the three months ended June&#160;30, 2021 give pro forma effect to the Business Combination and PIPE Financing as if they were completed on April&#160;1, 2020. The unaudited pro forma condensed combined balance sheet as of June&#160;30, 2021 gives pro forma effect to the Business Combination and PIPE Financing as if they were completed on June&#160;30, 2021. </div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">The unaudited pro forma condensed combined financial information is based on and should be read in conjunction with the audited historical financial statements of Roivant for the year ended March&#160;31, 2021, and the unaudited historical financial statements of Roivant as of and for the three months ended June&#160;30, 2021; and the audited historical financial statements of MAAC for the period from July&#160;6, 2020 (inception) through December&#160;31, 2020, and the unaudited historical financial statements of MAAC as of and for the three and six months ended June&#160;30, 2021 and the notes thereto; as well as the disclosures contained in the section titled &#8220;Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations,&#8221; and the equivalent disclosure in MAAC&#8217;s Annual Report on Form <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">10-K</div> for the year ended December&#160;31, 2020 and its Quarterly Report on Form <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">10-Q</div> for the three and six months ended June&#160;30, 2021, as filed with the SEC. </div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The unaudited pro forma condensed combined financial information has been presented for illustrative purposes only and does not necessarily reflect what Roivant&#8217;s financial condition or results of operations would have been had the Business Combination and PIPE Financing occurred on the dates indicated. Further, the unaudited pro forma condensed combined financial information also may not be useful in predicting the future financial condition and results of operations of Roivant. The actual financial position and results of operations may differ significantly from the pro forma amounts reflected herein due to a variety of factors. The unaudited pro forma transaction accounting adjustments represent management&#8217;s estimates based on information available as of the date of this unaudited pro forma condensed combined financial information and are subject to change as additional information becomes available and analyses are performed. </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">On September&#160;30, 2021, Roivant completed its previously announced Business Combination with MAAC through the merger of Roivant&#8217;s wholly owned subsidiary, Merger Sub, with MAAC, with MAAC surviving the Business Combination as a wholly owned subsidiary of Roivant. </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Prior to the Business Combination, MAAC&#8217;s stockholders had the right to elect to redeem all or a portion of their MAAC Class&#160;A Shares for a per share price calculated in accordance with MAAC&#8217;s governing documents. The unaudited pro forma condensed combined financial statements presented herein reflect the actual redemption of 38,400,312 MAAC Class&#160;A Shares by MAAC&#8217;s stockholders (the &#8220;Redemptions&#8221;).&#160;The Business Combination Agreement provided that the obligation of Roivant to consummate the Business Combination was conditioned on, among other things, the aggregate proceeds available for release to MAAC from MAAC&#8217;s Trust Account being equal to or greater than $210.0&#160;million at the time of Closing (the &#8220;Minimum Cash Condition&#8221;). As a result of the Redemptions, the proceeds available for release to MAAC from MAAC&#8217;s Trust Account were less than $210.0&#160;million and the Minimum Cash Condition was not satisfied. Roivant agreed to waive the Minimum Cash Condition and the Business Combination closed on September&#160;30, 2021. </div></div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">91 </div></div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;;font-weight: bold;"><a href="#toc">Table of Contents</a></div> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">ROIVANT SCIENCES LTD. </div></div></div> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">UNAUDITED PRO FORMA CONDENSED </div></div></div> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">COMBINED BALANCE SHEET </div></div></div> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">AS OF JUNE&#160;30, 2021 </div></div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">(in thousands) </div></div></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 9pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="font-size: 0px;">
<td style="width: 60%;"></td>
<td style="width: 1%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td>
<td style="width: 1%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td>
<td style="width: 1%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td>
<td style="width: 1%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td>
<td style="width: 1%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Roivant<br/>(Historical)</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">MAAC<br/>(Historical)</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Transaction<br/>Accounting<br/>Adjustments</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Note&#160;3</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Pro Forma</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Assets</div></div></div> </td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td> </tr>
<tr style="font-family: Times New Roman; font-size: 9pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; letter-spacing: 0px; top: 0px;;display:inline;">Current Assets:</div></div> </td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td> </tr>
<tr style="font-family: Times New Roman; font-size: 9pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; letter-spacing: 0px; top: 0px;;display:inline;">Cash and cash equivalents</div></div> </td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">1,996,733</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">1,173</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">193,821</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(a),(b)</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">2,191,727</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 9pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; letter-spacing: 0px; top: 0px;;display:inline;">Restricted cash</div></div> </td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">2,711</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">2,711</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 9pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; letter-spacing: 0px; top: 0px;;display:inline;">Other current assets</div></div> </td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">58,165</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">128</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">58,293</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 9pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; letter-spacing: 0px; top: 0px;;display:inline;">Due from underwriters</div></div> </td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 9pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 5em; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; letter-spacing: 0px; top: 0px;;display:inline;">Total current assets</div></div></div> </td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2,057,609</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">1,301</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">193,821</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2,252,731</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 9pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; letter-spacing: 0px; top: 0px;;display:inline;">Property and equipment, net</div></div> </td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">15,550</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">15,550</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 9pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;">Operating lease <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">right-of-use</div></div> assets</div> </td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">65,163</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">65,163</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 9pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; letter-spacing: 0px; top: 0px;;display:inline;">Restricted cash, net of current portion</div></div> </td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">8,933</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">8,933</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 9pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; letter-spacing: 0px; top: 0px;;display:inline;">Cash and Marketable Securities held in Trust Account</div></div> </td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">410,798</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(410,798</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(c)</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 9pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; letter-spacing: 0px; top: 0px;;display:inline;">Investments measured at fair value</div></div> </td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">180,359</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">180,359</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 9pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; letter-spacing: 0px; top: 0px;;display:inline;">Long-term investment</div></div> </td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">100,563</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">100,563</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 9pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; letter-spacing: 0px; top: 0px;;display:inline;">Other assets</div></div> </td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">26,520</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(5,623</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(b)</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">20,897</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 9pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 5em; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; letter-spacing: 0px; top: 0px;;display:inline;">Total Assets</div></div></div> </td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">$</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2,454,697</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">$</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">412,099</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">$</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(222,600</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">)&#160;</div></div></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">$</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2,644,196</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 9pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; letter-spacing: 0px; top: 0px;;display:inline;">Liabilities, Redeemable Noncontrolling Interest and Shareholders&#8217; Equity</div></div></div> </td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td> </tr>
<tr style="font-family: Times New Roman; font-size: 9pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; letter-spacing: 0px; top: 0px;;display:inline;">Accounts payable</div></div> </td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">15,014</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">3,257</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">18,271</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 9pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; letter-spacing: 0px; top: 0px;;display:inline;">Accrued expenses</div></div> </td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">73,788</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">5,615</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">79,403</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 9pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; letter-spacing: 0px; top: 0px;;display:inline;">Operating lease liabilities</div></div> </td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">12,055</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">12,055</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 9pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; letter-spacing: 0px; top: 0px;;display:inline;">Deferred consideration liability</div></div> </td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">100,000</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">100,000</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 9pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; letter-spacing: 0px; top: 0px;;display:inline;">Other current liabilities</div></div> </td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">8,301</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">105</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">8,406</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 9pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 5em; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; letter-spacing: 0px; top: 0px;;display:inline;">Total Current Liabilities</div></div></div> </td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">209,158</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">8,977</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#8212;&#160;&#160;</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">218,135</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 9pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; letter-spacing: 0px; top: 0px;;display:inline;">Liability instruments measured at fair value</div></div> </td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">5,906</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">47,355</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">18,953</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(d)</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">72,214</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 9pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; letter-spacing: 0px; top: 0px;;display:inline;">Operating lease liability, noncurrent</div></div> </td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">65,263</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">65,263</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 9pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; letter-spacing: 0px; top: 0px;;display:inline;">Deferred underwriting commissions</div></div> </td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">14,375</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(14,375</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(b)</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 9pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; letter-spacing: 0px; top: 0px;;display:inline;">Long-term debt</div></div> </td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">186,350</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">186,350</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 9pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; letter-spacing: 0px; top: 0px;;display:inline;">Other liabilities</div></div> </td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">8,188</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">8,188</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 9pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; letter-spacing: 0px; top: 0px;;display:inline;">Total Liabilities</div></div></div> </td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">474,865</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">70,707</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">4,578</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">550,150</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 9pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; letter-spacing: 0px; top: 0px;;display:inline;">Class&#160;A common stock subject to possible redemption</div></div> </td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">336,392</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(336,392</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(e)</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 9pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; letter-spacing: 0px; top: 0px;;display:inline;">Redeemable noncontrolling interest</div></div> </td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">22,491</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">22,491</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 9pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; letter-spacing: 0px; top: 0px;;display:inline;">Shareholders&#8217; Equity:</div></div> </td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td> </tr>
<tr style="font-family: Times New Roman; font-size: 9pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; letter-spacing: 0px; top: 0px;;display:inline;">Preferred stock</div></div> </td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 9pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; letter-spacing: 0px; top: 0px;;display:inline;">Class&#160;A common stock</div></div> </td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">1</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(1</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(e)</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 9pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; letter-spacing: 0px; top: 0px;;display:inline;">Class&#160;B common stock</div></div> </td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">1</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(1</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(e)</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 9pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;">Additional <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">paid-in</div> capital</div> </td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">3,824,974</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">23,136</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">475,316</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(e)</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">4,323,426</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 9pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; letter-spacing: 0px; top: 0px;;display:inline;">Subscription receivable</div></div> </td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(100,000</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(100,000</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 9pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; letter-spacing: 0px; top: 0px;;display:inline;">Retained earnings (accumulated deficit)</div></div> </td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(2,000,645</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(18,138</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(366,100</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(e)</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(2,384,883</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 9pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; letter-spacing: 0px; top: 0px;;display:inline;">Accumulated other comprehensive (loss) income</div></div> </td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(1,207</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(1,207</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 9pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; letter-spacing: 0px; top: 0px;;display:inline;">Noncontrolling interests</div></div> </td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">234,219</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">234,219</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 9pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 5em; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; letter-spacing: 0px; top: 0px;;display:inline;">Total Shareholders&#8217; Equity (Deficit)</div></div></div> </td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">1,957,341</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">5,000</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">109,214</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2,071,555</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 9pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 5em; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; letter-spacing: 0px; top: 0px;;display:inline;">Total liabilities, redeemable noncontrolling interest and shareholders&#8217; equity</div></div></div> </td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">$</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2,454,697</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">$</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">412,099</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">$</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(222,600</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">)&#160;</div></div></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">$</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2,644,196</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">See accompanying notes to unaudited pro forma condensed combined financial information. </div></div></div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">92 </div></div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;;font-weight: bold;"><a href="#toc">Table of Contents</a></div> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">ROIVANT SCIENCES LTD. </div></div></div> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">UNAUDITED PRO FORMA CONDENSED COMBINED </div></div></div> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">STATEMENT OF OPERATIONS </div></div></div> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">FOR THE THREE MONTHS ENDED JUNE&#160;30, 2021 </div></div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">(in thousands, except share and per share amounts) </div></div></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="font-size: 0px;">
<td style="width: 49%;"></td>
<td style="width: 4%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td>
<td style="width: 4%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td>
<td style="width: 4%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td>
<td style="width: 4%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td>
<td style="width: 4%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(A)</div></div><br/><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Roivant<br/>(Historical)</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(B)</div></div><br/><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">MAAC<br/>(Historical)</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Transaction<br/>Accounting<br/>Adjustments</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Note&#160;3</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Pro Forma</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Revenue, net</div></div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">7,735</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">7,735</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Operating expenses:</div></div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Cost of revenues</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">742</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">742</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Research and development</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">78,626</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">4,127</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(f</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">82,753</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">General and administrative</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">82,754</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">5,141</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">14,143</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(f</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">102,038</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Administrative expenses - related party</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">30</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">30</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Total operating expenses</div></div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">162,122</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">5,171</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">18,270</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">185,563</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Loss from operations</div></div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(154,387</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">)&#160;</div></div></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(5,171</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">)&#160;</div></div></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(18,270</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">)&#160;</div></div></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(177,828</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">)&#160;</div></div></td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Change in fair value of investments</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">8,619</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">8,619</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Change in fair value of debt and liability instruments</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">4,585</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">21,218</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">25,803</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Gain on termination of Sumitomo Options</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(66,472</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(66,472</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Gain on deconsolidation of subsidiary</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Financing costs - derivative warrant liability</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Unrealized gain on marketable securities held in trust account</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Other (income) expense, net</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(134</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(7</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">7</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(g</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(134</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Loss before income taxes</div></div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(100,985</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">)&#160;</div></div></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(26,382</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">)&#160;</div></div></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(18,277</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">)&#160;</div></div></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(145,644</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">)&#160;</div></div></td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Income tax expense</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">93</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">93</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Net loss</div></div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(101,078</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">)&#160;</div></div></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(26,382</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">)&#160;</div></div></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(18,277</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">)&#160;</div></div></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(145,737</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">)&#160;</div></div></td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Net loss attributable to noncontrolling interests</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(18,895</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(18,895</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Net loss attributable to Roivant Sciences Ltd.</div></div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">$</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(82,183</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">)&#160;</div></div></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">$</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(26,382</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">)&#160;</div></div></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">$</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(18,277</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">)&#160;</div></div></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">$</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(126,842</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">)&#160;</div></div></td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Earnings per Share</div></div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Weighted average shares outstanding, basic and diluted</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">222,081,975</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">691,559,504</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Basic and diluted net loss per share</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(0.37</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(i</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(0.18</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">See accompanying notes to unaudited pro forma condensed combined financial information. </div></div></div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">93 </div></div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;;font-weight: bold;"><a href="#toc">Table of Contents</a></div> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">ROIVANT SCIENCES LTD. </div></div></div> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">UNAUDITED PRO FORMA CONDENSED COMBINED </div></div></div> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">STATEMENT OF OPERATIONS </div></div></div> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">FOR THE YEAR ENDED MARCH&#160;31, 2021 </div></div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">(in thousands, except share and per share amounts) </div></div></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="font-size: 0px;">
<td style="width: 48%;"></td>
<td style="width: 4%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td>
<td style="width: 4%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td>
<td style="width: 4%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td>
<td style="width: 4%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td>
<td style="width: 4%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(A)</div></div><br/><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Roivant<br/>(Historical)</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(B)</div></div><br/><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">MAAC<br/>(Historical)</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Transaction<br/>Accounting<br/>Adjustments</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Note&#160;3</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Pro Forma</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Revenue, net</div></div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">23,795</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">23,795</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Operating expenses:</div></div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Cost of revenues</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">2,057</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">2,057</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Research and development</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">832,758</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">53,675</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(f</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">886,433</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">General and administrative</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">259,878</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">4,411</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">448,454</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(f</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">712,743</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Administrative expenses - related party</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">58</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">58</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Total operating expenses</div></div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">1,094,693</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">4,469</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">502,129</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">1,601,291</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Loss from operations</div></div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(1,070,898</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">)&#160;</div></div></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(4,469</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">)&#160;</div></div></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(502,129</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">)&#160;</div></div></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(1,577,496</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">)&#160;</div></div></td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Change in fair value of investments</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(95,533</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(95,533</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Change in fair value of debt and liability instruments</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">29,845</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(19,372</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">10,473</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Gain on deconsolidation of subsidiary and consolidation of unconsolidated entity</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(115,364</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(115,364</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Financing costs - derivative warrant liability</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">6,800</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">6,800</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Unrealized gain on marketable securities held in trust account</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(6</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">6</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(g</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Other (income) expense</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">8,701</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(172</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">13,637</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(g</td>
<td style="vertical-align: bottom; white-space: nowrap;">),(h)&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">22,166</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Net Income (Loss) from continuing operations before income taxes</div></div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(898,547</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">)&#160;</div></div></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">8,281</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(515,772</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">)&#160;</div></div></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(1,406,038</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">)&#160;</div></div></td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Income tax expense</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">1,686</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">36</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(36</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(g</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">1,686</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Income (loss) from continuing operations, net of tax</div></div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(900,233</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">)&#160;</div></div></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">8,245</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(515,736</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">)&#160;</div></div></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(1,407,724</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">)&#160;</div></div></td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Net loss attributable to noncontrolling interests</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(90,999</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(90,999</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Net Income (loss) from continuing operations attributable to Roivant Sciences Ltd.</div></div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">$</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(809,234</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">)&#160;</div></div></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">$</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">8,245</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">$</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(515,736</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">)&#160;</div></div></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">$</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(1,316,725</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">)&#160;</div></div></td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Earnings per Share</div></div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Weighted average shares outstanding, basic and diluted</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">215,312,273</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">687,292,597</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Basic and diluted net loss per share</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(3.76</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(i</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(1.92</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">See accompanying notes to unaudited pro forma condensed combined financial information. </div></div></div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">94 </div></div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;;font-weight: bold;"><a href="#toc">Table of Contents</a></div> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">ROIVANT SCIENCES LTD. </div></div></div> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">NOTES TO UNAUDITED PRO FORMA CONDENSED COMBINED FINANCIAL INFORMATION </div></div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">(in thousands, except share and per share amounts) </div></div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Note 1&#8212;Description of the Business Combination </div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">On September&#160;30, 2021, Roivant completed its previously announced Business Combination with MAAC through the merger of Roivant&#8217;s wholly owned subsidiary, Merger Sub, with MAAC, with MAAC surviving the Business Combination as a wholly owned subsidiary of Roivant. </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">Upon the Closing of the Business Combination, the following transactions occurred: (i)&#160;Roivant&#8217;s <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">bye-laws</div> were amended and restated, each outstanding Common Share of Roivant was subdivided (and in the case of certain <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-voting</div> shares of Roivant, converted) into a number of Common Shares based on a fixed exchange ratio of 2.9262:1 (the &#8220;Roivant Exchange Ratio&#8221;), and each outstanding equity award of Roivant was subdivided and adjusted into a number comparable equity awards of Roivant based on the Roivant Exchange Ratio (the steps contemplated by this clause (i), collectively, the <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">&#8220;Pre-Closing</div> Steps&#8221;); and (ii)&#160;Merger Sub merged with and into MAAC, with MAAC surviving the Merger. </div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">At the Effective Time (a)&#160;each outstanding MAAC Class&#160;A Share and MAAC Class&#160;B Share (other than treasury shares and any shares held by the MAAC Sponsor, any affiliate of the MAAC Sponsor or any MAAC Independent Director or its transferee) was automatically canceled and extinguished and converted into one Common Share, (b)&#160;each outstanding MAAC Class&#160;B Share held by the MAAC Sponsor, any affiliate of the MAAC Sponsor or any MAAC Independent Director or its transferee was automatically canceled and extinguished and converted into a number of Common Shares based on the MAAC Sponsor Exchange Ratio, with a portion of such Common Shares issued to the MAAC Sponsor, any affiliate of the MAAC Sponsor or any MAAC Independent Director or its transferee by virtue of the Merger being subject to the vesting and other terms and conditions set forth in the Sponsor Support Agreement (as more fully described below), and (c)&#160;each outstanding warrant to purchase MAAC Class&#160;A Shares was converted automatically into the right to acquire Common Shares on the terms and subject to the conditions set forth in the MAAC Warrant Agreement. The MAAC Sponsor Exchange Ratio was 0.75. </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">Concurrently with the execution of the Business Combination Agreement, MAAC, the MAAC Sponsor, Roivant and each of the MAAC Insiders, entered into the Sponsor Support Agreement, which was subsequently amended on June&#160;9, 2021, to reflect the MAAC Independent Directors and Roivant entering into respective <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">Lock-Up</div> Agreements, and further amended on September&#160;30, 2021. </div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">Pursuant to the Sponsor Support Agreement, among other things, (a)&#160;2,033,591 Common Shares issued to the MAAC Sponsor and 10,000 Common Shares issued to each MAAC Independent Director, each in respect of its MAAC Class&#160;B Shares, are subject to the vesting conditions described below and the other restrictions set forth in the Sponsor Support Agreement with respect to the $15 <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">Earn-Out</div> Shares and (b) 1,016,796 Common Shares issued to the MAAC Sponsor and 5,000 Common Shares issued to each MAAC Independent Director, each in respect of its MAAC Class&#160;B Shares, will be subject to the vesting conditions described below and the other restrictions set forth in the Sponsor Support Agreement with respect to the $20 <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">Earn-Out</div> Shares. The remaining number of Common Shares issued to the MAAC Sponsor and each MAAC Independent Director are not subject to the vesting conditions described below (the &#8220;Retained Shares&#8221;). </div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">The $15 <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">Earn-Out</div> Shares will vest if the closing price of the Common Shares is greater than or equal to $15.00 over any twenty out of thirty trading day period during the period commencing on the earlier of (a)&#160;the date on which the registration statement of which this prospectus forms a part is declared effective or (b)&#160;November&#160;15, 2021, and ending no later than the fifth anniversary of the Closing Date (the &#8220;Vesting Period&#8221;), and the $20 <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">Earn-Out</div> Shares will vest if the closing price of the Common Shares is greater than or equal to $20.00 over any twenty out of thirty trading day period during the Vesting Period. The Vesting Period will, if a </div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">95 </div></div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;;font-weight: bold;"><a href="#toc">Table of Contents</a></div> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">definitive purchase agreement with respect to a Sale (as defined in the Sponsor Support Agreement) is entered into on or prior to the end of such period, be extended to the earlier of one day after the consummation of such Sale and the termination of such definitive transaction agreement, and if a Sale occurs during such Vesting Period, then all of the <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">Earn-Out</div> Shares unvested as of such time will automatically vest immediately prior to the consummation of such Sale. If any <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">Earn-Out</div> Shares have not vested on or prior to the end of such Vesting Period, then such <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">Earn-Out</div> Shares will be forfeited. </div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Note 2&#8212;Basis of Presentation </div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The historical financial information of MAAC and Roivant has been adjusted in the unaudited pro forma condensed combined financial information to reflect transaction accounting adjustments related to the Business Combination and PIPE Financing in accordance with U.S. GAAP. </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The Business Combination is a capital transaction in substance whereby MAAC will be treated as the acquired company for financial reporting purposes. This determination was primarily based on the following: </div></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 9%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">Pre-Business</div> Combination Roivant stockholders own the majority of the issued and outstanding Common Shares of Roivant following the Business Combination. </div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 9%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The executive officers of Roivant prior to the Business Combination continue to manage Roivant following the Business Combination. </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 9%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The majority of the board of directors of Roivant is comprised of the individuals who served on the board of directors of Roivant prior to the Business Combination. </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 9%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Roivant&#8217;s operations prior to the Business Combination will continue to be the operations of Roivant following the Business Combination. </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Accordingly, because MAAC does not represent a business for accounting purposes and its primary asset represents cash and cash equivalents, the Business Combination will be treated similar to an equity contribution in exchange for the issuance of Common Shares. The net assets of MAAC will be stated at historical cost, with no goodwill or other intangible assets recorded. </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Roivant and MAAC have different fiscal years. As Roivant&#8217;s fiscal year ends on March&#160;31 and MAAC&#8217;s fiscal year ends on December&#160;31, the unaudited pro forma condensed combined statement of operations for the fiscal year ended March&#160;31, 2021 was prepared using the following information: </div></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 9%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The historical results of Roivant for its fiscal year ended March&#160;31, 2021. </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 9%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The historical results of MAAC for the period ended March&#160;31, 2021, which were derived by adding MAAC&#8217;s unaudited condensed statement of operations for the six months ended June&#160;30, 2021 and MAAC&#8217;s audited statement of operations for the period from July&#160;6, 2020 (inception) through December&#160;31, 2020, and then subtracting MAAC&#8217;s unaudited condensed statement of operations for the three months ended June&#160;30, 2021. </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Note 3&#8212;Pro Forma Adjustments </div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Adjustments to the Unaudited Pro Forma Condensed Combined Balance Sheet as of June&#160;30, 2021. </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The transaction accounting adjustments included in the unaudited pro forma condensed combined balance sheet as of June&#160;30, 2021 are as follows: </div></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 4%; vertical-align: top;;text-align:left;">3(a)</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Cash and cash equivalents. </div></div>Represents the impact of the Business Combination and PIPE Financing on the cash and cash equivalents balance of Roivant. </div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">96 </div></div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;;font-weight: bold;"><a href="#toc">Table of Contents</a></div> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">The table below reflects the pro forma adjustments related to cash and cash equivalents of Roivant <div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">(in thousands)</div></div>: </div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 76%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="font-size: 0px;">
<td style="width: 75%;"></td>
<td style="width: 6%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td>
<td style="width: 6%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Note</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Cash balance of Roivant prior to Business Combination</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">1,996,733</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Cash balance of MAAC prior to Business Combination</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">1,173</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Total pre Business Combination</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">1,997,906</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">MAAC Cash and Marketable Securities in Trust</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(1</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">410,798</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">PIPE</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(2</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">220,000</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Payment to redeeming MAAC Class&#160;A stockholders</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(3</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(384,040</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Payment of deferred underwriting commissions</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(4</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(14,375</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Payment of transaction costs</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(5</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(38,562</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Total Business Combination adjustments</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">193,821</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Post Business Combination cash and cash equivalents</div></div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">$</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2,191,727</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 4%; vertical-align: top;;text-align:left;">(1)</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;">Represents the amount of the restricted cash and marketable securities held in the Trust Account that becomes available in connection with the Business Combination (see Note 3(c) <div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Trust Account</div></div>). </div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 4%; vertical-align: top;;text-align:left;">(2)</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;">Represents the issuance of 22,000,000 Common Shares at a price of $10.00 per share in connection with the PIPE Financing (see Note 3(e)(5) <div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Impact on equity</div></div>). </div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 4%; vertical-align: top;;text-align:left;">(3)</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;">Represents the amount paid to MAAC public stockholders who exercised redemption rights, including accrued interest (see Note 3(e)(6) <div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Impact on equity</div></div>). </div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 4%; vertical-align: top;;text-align:left;">(4)</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;">Represents payment of deferred underwriting fees payable by MAAC (see Note 3(b)(1) <div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Transaction costs</div></div>). </div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 4%; vertical-align: top;;text-align:left;">(5)</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;">Represents payment of other transaction costs (see Note 3(b)(2) <div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Transaction costs</div></div>). </div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">3(b) <div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Transaction costs</div></div>. </div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 4%; vertical-align: top;;text-align:left;">(1)</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;">Payment of deferred underwriting commissions incurred by MAAC in the amount of $14.4&#160;million (See Note 3(a)(4) <div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Cash and cash equivalents</div></div>). The unaudited pro forma condensed combined balance sheet reflects payment of these costs as a reduction of cash, with a corresponding decrease in deferred underwriting fee payable. </div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 4%; vertical-align: top;;text-align:left;">(2)</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;">Represents the recognition of $44.2&#160;million of transaction costs. Of the $44.2&#160;million, $5.6&#160;million was capitalized within other assets on Roivant&#8217;s balance sheet as of June&#160;30, 2021. An additional approximately $38.6&#160;million of incremental transaction expenses are estimated to be incurred through the Business Combination and PIPE Financing (see Note 3(a)(5) <div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Cash and cash equivalents</div></div>). The unaudited pro forma condensed combined balance sheet reflects costs allocated to the <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">Earn-Out</div> Shares and warrants, which will be liability classified subsequent to the Business Combination, as a reduction of cash and other assets, with a corresponding charge to accumulated deficit. The remaining costs are reflected as a reduction of cash and other assets, with a corresponding decrease in additional <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">paid-in</div> capital (see Note 3(e)(10) <div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Impact on equity</div></div>). </div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 4%; vertical-align: top;;text-align:left;">3(c)</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Trust Account</div></div>. Represents the release of the restricted cash and marketable securities held in the Trust Account upon consummation of the Business Combination to fund the Closing of the Business Combination (See Note 3(a)(1) <div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Cash and cash equivalents</div></div>). </div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 4%; vertical-align: top;;text-align:left;">3(d)</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">Earn-Out</div> Shares. </div></div>Represents recognition of the estimated fair values of the <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">Earn-Out</div> Shares as derivatives that will not qualify for equity classification. These amounts are classified as liabilities in the unaudited pro forma condensed combined balance sheet. The estimated fair values of the <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">Earn-Out</div> Shares were determined using a Monte Carlo simulation valuation model using a distribution of potential outcomes based on certain underlying assumptions such as stock price, volatility and risk-free interest rates. Following the Business Combination, these liabilities will be remeasured to fair value at each reporting date and subsequent changes in the fair value will be recognized in Roivant&#8217;s consolidated statement of operations. See Note 1 &#8220;Description of the Business Combination&#8221; for more information. </div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">97 </div></div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;;font-weight: bold;"><a href="#toc">Table of Contents</a></div> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 4%;">3(e) <div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Impact on equity. </div></div>The following table represents the impact of the Business Combination and PIPE Financing on the number of Common Shares and represents the total equity section impact of redemptions by MAAC&#8217;s stockholders: </div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt; margin-left: 4%;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">(in thousands, except share amounts) </div></div></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 7pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="font-size: 0px;">
<td style="width: 17%;"></td>
<td style="width: 1%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td>
<td style="width: 1%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td>
<td style="width: 1%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td>
<td style="width: 1%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td>
<td style="width: 1%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td>
<td style="width: 1%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td>
<td style="width: 1%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td>
<td style="width: 1%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td>
<td style="width: 1%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td>
<td style="width: 1%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td>
<td style="width: 1%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td>
<td style="width: 1%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td>
<td style="width: 1%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td>
<td style="width: 1%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td>
<td style="width: 1%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td>
<td style="width: 1%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td> </tr>
<tr style="font-family: Times New Roman; font-size: 6pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td colspan="2" style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td rowspan="2" style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td colspan="6" rowspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Roivant/Combined<br/>Company Common<br/>Shares</div></div></td>
<td rowspan="2" style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td colspan="10" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">MAAC Common Stock</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td colspan="2" style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td colspan="2" style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td colspan="2" style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td colspan="2" style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td colspan="2" style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td colspan="2" style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td colspan="2" style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td rowspan="2" style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td colspan="2" rowspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Roivant/Combined<br/>Company&#160;Temporary</div></div><br/><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Equity</div></div></td>
<td rowspan="2" style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td colspan="6" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">MAAC Temporary<br/>Equity</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 6pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td colspan="2" style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td colspan="6" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Class&#160;A</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Class&#160;B</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td colspan="2" style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td colspan="2" style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td colspan="2" style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td colspan="2" style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td colspan="2" style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td colspan="2" style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td colspan="2" style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td colspan="6" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Class&#160;A Common Stock</div></div><br/><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">subject to possible<br/>redemption</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 6pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Note&#160;3</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Shares</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Par<br/>Value</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Shares</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Amount</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Shares</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Amount</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Additional<br/><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">paid-in</div><br/>capital</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Subscription<br/>receivable</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Accumulated<br/>deficit</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Accumulated<br/>other<br/>comprehensive<br/>loss</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Noncontrolling<br/>interests</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Total<br/>stockholders&#8217;<br/>equity</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Redeemable</div></div><br/><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">non- controlling<br/>interest</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Shares</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Amount</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 7pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 7pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 7pt; letter-spacing: 0px; top: 0px;;display:inline;">Roivant equity as of June&#160;30, 2021 - pre Business Combination</div></div> </td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">222,669,799</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">3,824,974</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(100,000</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(2,000,645</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(1,207</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">234,219</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">1,957,341</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">22,491</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">$&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 7pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 7pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 7pt; letter-spacing: 0px; top: 0px;;display:inline;">MAAC equity as of June&#160;30, 2021 - pre Business Combination</div></div> </td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">7,432,583</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">1</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">10,267,956</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">1</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">23,136</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(18,138</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">5,000</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">33,639,240</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">336,392</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 7pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 7pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 7pt; letter-spacing: 0px; top: 0px;;display:inline;">Total equity balance pre Business Combination</div></div> </td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">222,669,799</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">7,432,583</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">1</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">10,267,956</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">1</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">3,848,110</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(100,000</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(2,018,783</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(1,207</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">234,219</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">1,962,341</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">22,491</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">33,639,240</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">336,392</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 7pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 7pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 7pt; letter-spacing: 0px; top: 0px;;display:inline;">Subdivision of Roivant shares</div></div> </td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(1</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">652,416,691</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 7pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 7pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 7pt; letter-spacing: 0px; top: 0px;;display:inline;">Transaction Accounting Adjustments:</div></div> </td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td> </tr>
<tr style="font-family: Times New Roman; font-size: 7pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 7pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 7pt; letter-spacing: 0px; top: 0px;;display:inline;">Reclassification of MAAC Class&#160;A common stock to Common Shares</div></div> </td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(2</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">33,639,240</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">336,392</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">336,392</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(33,639,240</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(336,392</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 7pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 7pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 7pt; letter-spacing: 0px; top: 0px;;display:inline;">Reclassification of MAAC Class&#160;A common stock to Common Shares</div></div> </td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(2</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">7,432,583</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(7,432,583</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(1</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">1</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 7pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 7pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 7pt; letter-spacing: 0px; top: 0px;;display:inline;">Reclassification of MAAC Class&#160;B common stock to Common Shares</div></div> </td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(3</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">10,267,956</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(10,267,956</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(1</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">1</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 7pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 7pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;">Reclassification to MAAC Sponsor <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">Earn-Out</div> Shares</div> </td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(4</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(3,080,387</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 7pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 7pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 7pt; letter-spacing: 0px; top: 0px;;display:inline;">PIPE Investment</div></div> </td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(5</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">22,000,000</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">220,000</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">220,000</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 7pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 7pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 7pt; letter-spacing: 0px; top: 0px;;display:inline;">Redemption of MAAC Class&#160;A common stock</div></div> </td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(6</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(38,400,312</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(384,040</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(384,040</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 7pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 7pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 7pt; letter-spacing: 0px; top: 0px;;display:inline;">Forfeited MAAC Class&#160;B common stock</div></div> </td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(7</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(2,566,989</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 7pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 7pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;">Recognition of <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">Earn-Out</div> Shares as a liability</div> </td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(8</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(18,953</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(18,953</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 7pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 7pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 7pt; letter-spacing: 0px; top: 0px;;display:inline;">Liquidity vesting of certain stock-based awards at Close of the Business Combination</div></div> </td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(9</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">3,026,722</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">370,773</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(370,773</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 7pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 7pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 7pt; letter-spacing: 0px; top: 0px;;display:inline;">Payment of incremental transaction costs</div></div> </td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(10</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(30,720</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(13,465</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(44,185</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 7pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 7pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 7pt; letter-spacing: 0px; top: 0px;;display:inline;">Elimination of the historical accumulated deficit of MAAC</div></div> </td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(11</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(18,138</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">18,138</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 7pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 7pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 7pt; letter-spacing: 0px; top: 0px;;display:inline;">Total Transaction Accounting Adjustments</div></div> </td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">32,318,813</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(7,432,583</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(1</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(10,267,956</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(1</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">475,316</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(366,100</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">109,214</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(33,639,240</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(336,392</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 7pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 7pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 7pt; letter-spacing: 0px; top: 0px;;display:inline;">Post-Business Combination</div></div></div> </td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">684,735,504</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">$</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#8212;&#160;&#160;</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#8212;&#160;&#160;</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">$</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#8212;&#160;&#160;</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#8212;&#160;&#160;</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">$</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#8212;&#160;&#160;</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">$</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">4,323,426</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">$</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(100,000</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">)&#160;</div></div></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">$</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(2,384,883</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">)&#160;</div></div></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">$</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(1,207</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">)&#160;</div></div></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">$</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">234,219</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">$</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2,071,555</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">$</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">22,491</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#8212;&#160;&#160;</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">$&#8212;&#160;&#160;</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">98 </div></div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;;font-weight: bold;"><a href="#toc">Table of Contents</a></div> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;">
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 4%; vertical-align: top;;text-align:left;">(1)</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;">Represents the total number of Common Shares held by Roivant&#8217;s <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">pre-Business</div> Combination Shareholders immediately after the Closing, which is equal to the number Common Shares outstanding as of September&#160;30, 2021, prior to the consummation of the Business Combination, multiplied by the Roivant Exchange Ratio, subject to adjustment as set forth in the Business Combination Agreement. </div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 4%; vertical-align: top;;text-align:left;">(2)</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Represents the conversion of all MAAC Class&#160;A Shares of capital stock into post-Closing Common Shares. </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 4%; vertical-align: top;;text-align:left;">(3)</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Represents the conversion of all MAAC Class&#160;B Shares of capital stock into post-Closing Common Shares. </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 4%; vertical-align: top;;text-align:left;">(4)</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;">Represents the conversion of a portion of the MAAC Class&#160;B Shares into <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">Earn-Out</div> Shares (See Note 1 &#8211; Description of the Business Combination). </div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 4%; vertical-align: top;;text-align:left;">(5)</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;">Represents the issuance of 22,000,000 Common Shares at a price of $10.00 per share in connection with the PIPE Financing (see Note 3(a)(2) <div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Cash and cash equivalents</div></div>). </div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 4%; vertical-align: top;;text-align:left;">(6)</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;">Represents the redemption of MAAC Class&#160;A Shares (see Note 3(a)(3) <div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Cash and cash equivalents</div></div>). </div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 4%; vertical-align: top;;text-align:left;">(7)</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;">Represents the forfeiture of Retained Shares and <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">Earn-Out</div> Shares based on the MAAC Sponsor Exchange Ratio of 0.75 (See Note 1 &#8211; Description of the Business Combination). </div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 4%; vertical-align: top;;text-align:left;">(8)</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;">Represents the recognition of the estimated fair value of the <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">Earn-Out</div> Shares as a liability (see Note 3(d) <div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">Earn-Out</div> Shares</div></div>). </div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 4%; vertical-align: top;;text-align:left;">(9)</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;">Represents the estimated <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">catch-up</div> expense related to prior service for certain Roivant share-based compensation awards, which contain a performance condition tied to achievement of a liquidity event (see Note 3(f) <div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Share-based compensation</div></div>). </div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 4%; vertical-align: top;;text-align:left;">(10)</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;">Represents payment of estimated other transaction costs (see Note 3(b)(2) <div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Transaction costs</div></div>). </div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 4%; vertical-align: top;;text-align:left;">(11)</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Represents the elimination of the historical accumulated deficit of MAAC. </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Adjustments to the Unaudited Pro Forma Condensed Combined Statements of Operations for the three months ended June&#160;30, 2021 and the year ended March&#160;31, 2021 </div></div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The unaudited pro forma condensed combined statement of operations for the three months ended June&#160;30, 2021 is derived from the following historical financial information: </div></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 4%;">&#160;</td>
<td style="width: 5%; vertical-align: top;;text-align:left;">(A)</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The unaudited consolidated statement of operations of Roivant for the three months ended June&#160;30, 2021. </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 4%;">&#160;</td>
<td style="width: 5%; vertical-align: top;;text-align:left;">(B)</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The unaudited condensed statement of operations of MAAC for the three months ended June&#160;30, 2021. </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The unaudited pro forma condensed combined statement of operations for the year ended March&#160;31, 2021 is derived from the following historical financial information: </div></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 4%;">&#160;</td>
<td style="width: 5%; vertical-align: top;;text-align:left;">(A)</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The audited consolidated statement of operations of Roivant for the year ended March&#160;31, 2021. </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 4%;">&#160;</td>
<td style="width: 5%; vertical-align: top;;text-align:left;">(B)</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The sum of MAAC&#8217;s unaudited condensed statement of operations for the six months ended June&#160;30, 2021 and MAAC&#8217;s audited statement of operations for the period from July&#160;6, 2020 (inception) through December&#160;31, 2020, less MAAC&#8217;s unaudited condensed statement of operations for the three months ended June&#160;30, 2021. </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The transaction accounting adjustments included in the unaudited pro forma condensed combined statements of operations for the three months ended June&#160;30, 2021 and the year ended March&#160;31, 2021 are as follows: </div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt; margin-left: 4%;">3(f)<div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;"> Share-based compensation.</div></div> Certain Roivant restricted stock units, performance options, and capped value appreciation rights (&#8220;CVARs&#8221;) granted prior to the Business Combination are subject to (i)&#160;service-vesting conditions and (ii)&#160;a performance condition tied to the achievement of a liquidity event. Historically, Roivant did not record share-based compensation expense related to these awards as the liquidity event requirement had not been met and was deemed not probable of being met. Upon consummation of the Business Combination, the liquidity event requirement was met, resulting in the recognition of a <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">one-time</div> <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">catch-up</div> expense relating to cumulative service rendered between the grant date of the respective awards and completion of the Business Combination. As such, this adjustment reflects, using the accelerated </div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">99 </div></div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;;font-weight: bold;"><a href="#toc">Table of Contents</a></div> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 4%;">attribution method, the estimated <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">catch-up</div> expense and estimated expense to be recognized in the period following the Business Combination related to these awards, assuming that the Business Combination had been consummated on April&#160;1, 2020. Any remaining expense will be recognized over the awards&#8217; applicable requisite service period. For the year ended March&#160;31, 2021, pro forma share-based compensation expense reflects an estimated total of $502.1&#160;million, consisting of an estimated $370.8&#160;million of <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">catch-up</div> expense relating to prior service and an estimated $131.3&#160;million of expense to be recognized in the twelve months following the Closing. Of this amount, $448.4&#160;million is presented in general and administrative expenses and $53.7&#160;million is presented in research and development expenses. For the three months ended June&#160;30, 2021, pro forma share-based compensation expense reflects an estimated total of $18.3&#160;million to be recognized in the following three months. Of this amount, $14.2&#160;million is presented in general and administrative expenses and $4.1&#160;million is presented in research and development expenses. The income tax effects, to be reflected at the statutory tax rate for pro forma financial presentation purposes, have been offset by a valuation allowance as Roivant expects to incur continuing losses. </div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt; margin-left: 4%;">3(g)<div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;"> Interest income and unrealized gain. </div></div>Represents an adjustment to eliminate interest income and unrealized gains/losses on marketable securities held in the Trust Account as of the beginning of the period. The associated income tax expense was eliminated as a result of the elimination of the Trust Account income. </div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt; margin-left: 4%;">3(h)<div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;"> Transaction costs allocated to <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">Earn-Out</div> Shares and warrants.</div></div> Represents expenses allocated to the Earnout Shares and warrants, which will be liability classified subsequent to the Business Combination. These costs are reflected in the unaudited pro forma condensed combined statements of operations for the year ended March&#160;31, 2021 within other (income) expense. </div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt; margin-left: 4%;">3(i) <div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Net loss per share.</div></div> Represents pro forma net loss per share based on pro forma net loss and, for the year ended March&#160;31, 2021, pro forma weighted-average shares outstanding of 687,292,597, and for the three months ended June&#160;30, 2021, pro forma weighted average shares outstanding of 691,559,504 after giving effect to the pro forma adjustments for such periods. There is no difference between basic and diluted pro forma net loss per share as the inclusion of all potential Common Shares outstanding would have been anti-dilutive. </div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">100 </div></div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;;font-weight: bold;"><a href="#toc" style="text-indent: 0px;">Table of Contents</a></div> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"> <div id="rom164680_10" style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">MANAGEMENT&#8217;S DISCUSSION AND ANALYSIS OF </div></div></div> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">FINANCIAL CONDITION AND RESULTS OF OPERATIONS </div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">The following discussion and analysis of Roivant&#8217;s financial condition and results of operations should be read in conjunction with Roivant&#8217;s (1)&#160;unaudited condensed consolidated financial statements and notes to those statements included elsewhere in this prospectus and (2)&#160;audited consolidated financial statements and notes to those statements included elsewhere in this prospectus. Certain information contained in the discussion and analysis set forth below includes forward-looking statements that involve risks and uncertainties. Roivant&#8217;s actual results may differ materially from those anticipated in these forward-looking statements as a result of many factors. Please see &#8220;Cautionary Statement Regarding Forward-Looking Statements&#8221; and &#8220;Risk Factors.&#8221; Our fiscal year ends on March&#160;31 and our fiscal quarters end on June&#160;30, September&#160;30 and December 31. </div></div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Overview </div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">We are building the next-generation &#8220;big pharma&#8221; company, organized to harness modern technologies and the entrepreneurial spirit of nimble biotechnology companies at scale. Our mission is to improve the delivery of healthcare to patients by treating every inefficiency as an opportunity. </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">We are a diverse team of experienced drug developers, scientists, physicians, company builders, data scientists and engineers, biopharma investors, physicists and business development professionals dedicated to improving the lives of patients. At Roivant, we combine our team&#8217;s extensive experience and multi-disciplinary expertise with innovative technologies to identify and advance potentially transformative medicines. </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">We deploy a hypothesis-driven approach to identify novel or clinically-validated targets and biological pathways in areas of high unmet medical need. We then seek to acquire, <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">in-license</div> or discover promising drug candidates against those targets or pathways. Our small molecule discovery engine is powered by a unique combination of leading computational physics and machine learning (&#8220;ML&#8221;) capabilities for in silico drug design. </div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">We develop drug candidates in subsidiary companies we call &#8220;Vants&#8221; with a distinct approach to sourcing talent, aligning incentives and deploying technology. Each of our Vant teams is built with deep relevant expertise to promote successful execution of our development strategy. Our Vants continue to benefit from the support of our platform and technologies that are built to address inefficiencies in the drug discovery, development and commercialization process. </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Our agile Vant model has allowed us to rapidly add capabilities in diverse therapeutic areas, including immunology, dermatology, hematology and oncology, and modalities, including biologics, topicals, gene therapies and bifunctional small molecules. We currently have 14 Vants and, together, we are advancing a deep and diversified pipeline of over 30 drug candidates. We have launched and taken public multiple Vants, resulting in an aggregate ownership stake of approximately $940&#160;million in the Public Vants (inclusive of the value of the Myovant Top-Up Shares) as of September&#160;30, 2021. The Vant model also enables a modular approach to the monetization of therapies we advance through development, allowing us to pursue commercialization of some products independently, while selectively establishing partnerships for other Vants or divesting of the Vants entirely. </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Since our founding in 2014, we have: </div></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 10%;">&#160;</td>
<td style="width: 2%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">conducted nine international Phase 3 trials, the last eight of which have been successful; </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 10%;">&#160;</td>
<td style="width: 2%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">consummated a $3&#160;billion upfront partnership with Sumitomo; </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 10%;">&#160;</td>
<td style="width: 2%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">developed four drugs that received FDA approval after their transfer to Sumitomo; </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 10%;">&#160;</td>
<td style="width: 2%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">built a pipeline of over 30 drug candidates ranging from early discovery to registration; </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">101 </div></div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;;font-weight: bold;"><a href="#toc">Table of Contents</a></div> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;">
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 10%;">&#160;</td>
<td style="width: 2%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;">launched Roivant Discovery, our small molecule discovery engine comprising advanced computational physics and machine learning capabilities, integrated with an <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">in-house</div> wet lab facility; and </div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 10%;">&#160;</td>
<td style="width: 2%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">created innovative software tools to optimize each stage of the drug discovery, development and commercialization process. </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The following table summarizes our development-stage product candidate pipeline. In addition to the development-stage product candidates, we have active drug discovery projects in targets across oncology, immunology and neurology. </div></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="font-size: 0px;">
<td style="width: 18%; font-family: &quot;Times New Roman&quot;;"></td>
<td style="width: 1%; vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="width: 34%; font-family: &quot;Times New Roman&quot;;"></td>
<td style="width: 2%; vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="width: 13%; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="width: 12%; font-family: &quot;Times New Roman&quot;;"></td>
<td style="width: 1%; vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="width: 12%; font-family: &quot;Times New Roman&quot;;"></td> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; white-space: nowrap; padding-bottom: 1pt;"> <div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt; border-bottom: 1pt solid rgb(0, 0, 0); display: table-cell; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">Product Candidate</div></div></div> </td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid; white-space: nowrap;;text-align:center;"> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 1pt; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">Indication</div></div></div> </td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;&#160;</td>
<td style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid; white-space: nowrap;;text-align:center;"> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 1pt; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">Vant</div></div></div> </td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;&#160;</td>
<td style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid; white-space: nowrap;;text-align:center;"> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 1pt; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">Modality</div></div></div> </td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;&#160;</td>
<td style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid; white-space: nowrap;;text-align:center;"> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 1pt; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">Phase</div></div></div> </td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;">Tapinarof</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: top;">Psoriasis</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: top;">Dermavant</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: top;">Topical</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: top;;text-align:center;">Registration</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;">Tapinarof</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: top;">Atopic Dermatitis</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: top;">Dermavant</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: top;">Topical</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: top;;text-align:center;">Phase 3</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;">Cerdulatinib</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: top;">Vitiligo</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: top;">Dermavant</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: top;">Topical</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: top;;text-align:center;">Phase 2</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;">IMVT-1401</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: top;">Myasthenia Gravis</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: top;">Immunovant</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: top;">Biologic</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: top;;text-align:center;">Phase 2</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;">IMVT-1401</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: top;">Warm&#160;Autoimmune&#160;Hemolytic&#160;Anemia</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: top;">Immunovant</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: top;">Biologic</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: top;;text-align:center;">Phase 2</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;">IMVT-1401</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: top;">Thyroid Eye Disease</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: top;">Immunovant</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: top;">Biologic</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: top;;text-align:center;">Phase 2</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">ARU-1801</div></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: top;">Sickle Cell Disease</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: top;">Aruvant</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: top;">Gene&#160;Therapy</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: top;;text-align:center;">Phase 2</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;">Namilumab</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: top;">Sarcoidosis</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: top;">Kinevant</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: top;">Biologic</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: top;;text-align:center;">Phase 1</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;">LSVT-1701</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: top;">Staph Aureus Bacteremia</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: top;">Lysovant</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: top;">Biologic</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: top;;text-align:center;">Phase 1</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;">Cerdulatinib</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: top;">Atopic Dermatitis</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: top;">Dermavant</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: top;">Topical</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: top;;text-align:center;">Phase 1</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">DMVT-504</div></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: top;">Hyperhidrosis</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: top;">Dermavant</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: top;">Small&#160;Molecule</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: top;;text-align:center;">Phase 1</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">DMVT-503</div></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: top;">Acne</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: top;">Dermavant</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: top;">Topical</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: top;;text-align:center;">Preclinical</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">ARU-2801</div></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: top;">Hypophosphatasia</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: top;">Aruvant</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: top;">Gene&#160;Therapy</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: top;;text-align:center;">Preclinical</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;">AFM32</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: top;">Solid Tumors</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: top;">Affivant</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: top;">Biologic</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: top;;text-align:center;">Preclinical</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">CVT-TCR-01</div></div></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: top;">Oncologic&#160;Malignancies</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: top;">Cytovant</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: top;">Cell Therapy</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: top;;text-align:center;">Preclinical</td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Note: All drugs in current pipeline are investigational and subject to health authority approval. </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;">Our small molecule discovery engine powers<div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">&#160;in silico</div></div>&#160;drug discovery, and includes the following key components: </div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;">A quantum mechanics-based molecular dynamics software platform to predict the interactions, energies and conformational behavior of targets and generate novel drug candidates; </div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">A supercomputing cluster composed of over 600 graphics processing units; </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">A suite of degrader-specific ML tools; </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">A wet lab fully equipped for synthetic chemistry, crystallography, biophysics, biochemistry and biology.</div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">102 </div></div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;;font-weight: bold;"><a href="#toc">Table of Contents</a></div> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The following table summarizes our ownership of certain subsidiary companies and certain affiliates as of June&#160;30, 2021. </div></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 76%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="font-size: 0px;">
<td style="width: 73%;"></td>
<td style="width: 12%; vertical-align: bottom;"></td>
<td></td>
<td style="width: 11%; vertical-align: bottom;"></td>
<td></td> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td colspan="3" style="vertical-align: bottom;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Roivant Ownership</div></div></td> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; white-space: nowrap; padding-bottom: 1pt;"> <div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt; border-bottom: 1pt solid rgb(0, 0, 0); display: table-cell; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">Vant</div></div></div> </td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;&#160;</td>
<td style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Basic<div style="font-size: 85%; vertical-align: top;;display:inline;;font-size:7.5px">1</div></div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Fully&#160;Diluted<div style="font-size: 85%; vertical-align: top;;display:inline;;font-size:7.5px">2</div></div></div></td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Dermavant</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:center;">100%</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:center;">84%</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Immunovant<div style="font-size: 85%; vertical-align: top;;display:inline;;font-size:9.4px">3</div></div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:center;">58%<div style="font-size: 85%; vertical-align: top;;display:inline;;font-size:9.4px">4</div></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:center;">53%<div style="font-size: 85%; vertical-align: top;;display:inline;;font-size:9.4px">4</div></td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Aruvant</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:center;">88%</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:center;">79%</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Proteovant</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:center;">60%</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:center;">60%</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Lysovant</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:center;">100%</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:center;">99%</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Kinevant</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:center;">88%</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:center;">88%</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Affivant</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:center;">100%</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:center;">100%</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Cytovant</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:center;">72%</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:center;">68%</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Arbutus</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:center;">32%<div style="font-size: 85%; vertical-align: top;;display:inline;;font-size:9.4px">4</div></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:center;">29%<div style="font-size: 85%; vertical-align: top;;display:inline;;font-size:9.4px">4</div></td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Sio Gene Therapies</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:center;">27%<div style="font-size: 85%; vertical-align: top;;display:inline;;font-size:9.4px">4</div></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:center;">24%<div style="font-size: 85%; vertical-align: top;;display:inline;;font-size:9.4px">4</div></td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Genevant</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:center;">83%</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:center;">69%</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Lokavant</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:center;">90%</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:center;">85%</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Datavant<div style="font-size: 85%; vertical-align: top;;display:inline;;font-size:9.4px">5</div></div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:center;">52%</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:center;">48%</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Alyvant</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:center;">97%</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:center;">95%</td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Note: Excludes early-stage pipeline of protein degraders and inhibitors being developed through our small molecule discovery engine. All drugs in current pipeline are investigational and subject to health authority approval. Ownership figures as of June&#160;30, 2021. Arbutus basic and fully diluted ownership includes the conversion of preferred shares held by Roivant into common shares, which was completed on October&#160;18, 2021. Roivant ownership in Cytovant includes both direct and indirect ownership. </div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 4%; vertical-align: top;;text-align:left;">1.</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Basic refers to Roivant&#8217;s percentage ownership of the issued and outstanding shares of the entity. </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 4%; vertical-align: top;;text-align:left;">2.</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Fully diluted refers to Roivant&#8217;s percentage ownership of all outstanding equity interests, whether vested or unvested, of the entity. </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 4%; vertical-align: top;;text-align:left;">3.</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">In August 2021, Roivant purchased from Immunovant 17,021,276 shares of Immunovant common stock at a price of $11.75 per share, for an aggregate purchase price of $200.0&#160;million. Following this transaction, Roivant beneficially owns 73,398,664 shares of Immunovant common stock, representing a basic ownership interest of approximately 63.8%. </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 4%; vertical-align: top;;text-align:left;">4.</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Denotes entities that are publicly traded. </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 4%; vertical-align: top;;text-align:left;">5.</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">In June 2021, Datavant entered into a definitive merger agreement to combine with Ciox Health. The transaction closed in July 2021. Following the closing of the merger, Roivant has a minority equity ownership in the combined entity. </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">Through continued investment in our model, we believe we are well-positioned to advance our current pipeline through regulatory approval and commercialization, expand our pipeline through novel drug discovery <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">and&#160;in-licensing&#160;and</div> acquisition transactions, and execute on our vision of transforming the delivery of healthcare to patients. </div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">103 </div></div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;;font-weight: bold;"><a href="#toc">Table of Contents</a></div> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">We have a robust calendar of potential near-term catalysts, including the items set forth below. In addition, we plan to <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">in-license</div> multiple potentially category-leading drugs per year. </div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="font-size: 0px;">
<td style="width: 13%; font-family: &quot;Times New Roman&quot;;"></td>
<td style="width: 1%; vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="width: 66%; font-family: &quot;Times New Roman&quot;;"></td>
<td style="width: 3%; vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="width: 15%; font-family: &quot;Times New Roman&quot;;"></td> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid; white-space: nowrap;"> <div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 1pt; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">Vant</div></div></div> </td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;&#160;</td>
<td style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;"> <div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 1pt; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">Catalyst</div></div></div> </td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;&#160;</td>
<td style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;"> <div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 1pt; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">Expected Timing</div></div></div> </td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;">Dermavant</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: top;">Tapinarof NDA filing in psoriasis</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: top;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">Mid-2021</div> &#10003;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: top;">Tapinarof Phase 3 initiation in atopic dermatitis</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: top;">2H 2021 &#10003;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: top;">FDA approval decision on tapinarof for psoriasis</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: top;">2Q 2022</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: top;">Topline data from tapinarof Phase 3 trials in atopic dermatitis</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: top;">1H 2023</td> </tr>
<tr style="font-size: 1pt;">
<td style="height: 12pt;"></td>
<td colspan="2" style="height: 12pt;"></td>
<td colspan="2" style="height: 12pt;"></td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;">Immunovant</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: top;">Initiate pivotal trial in MG</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: top;">Early 2022</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: top;">Reinitiate program in TED</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: top;"> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 1pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">TBA</div></div> </td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: top;">Reinitiate program in WAIHA</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: top;"> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 1pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">TBA</div></div> </td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: top;">Announce at least two new indications for IMVT-1401</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: top;">2H 2022</td> </tr>
<tr style="font-size: 1pt;">
<td style="height: 12pt; font-family: &quot;Times New Roman&quot;;"></td>
<td colspan="2" style="height: 12pt; font-family: &quot;Times New Roman&quot;;"></td>
<td colspan="2" style="height: 12pt; font-family: &quot;Times New Roman&quot;;"></td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;">Aruvant</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: top;">First patient dosed with updated <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">ARU-1801</div> manufacturing process</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: top;">2H 2021 &#10003;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: top;">Additional clinical data from <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">ARU-1801</div> Phase 1/2</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: top;">2H 2021 &#10003;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: top;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">ARU-1801</div> Phase 3 initiation</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: top;">1H 2023</td> </tr>
<tr style="font-size: 1pt;">
<td style="height: 12pt;"></td>
<td colspan="2" style="height: 12pt;"></td>
<td colspan="2" style="height: 12pt;"></td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;">Kinevant</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: top;">Namilumab Phase 2 initiation in sarcoidosis</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: top;">1H 2022</td> </tr>
<tr style="font-size: 1pt;">
<td style="height: 12pt;"></td>
<td colspan="2" style="height: 12pt;"></td>
<td colspan="2" style="height: 12pt;"></td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;">Lysovant</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: top;">LSVT-1701 MAD initiation</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: top;">1H 2022</td> </tr>
<tr style="font-size: 1pt;">
<td style="height: 12pt;"></td>
<td colspan="2" style="height: 12pt;"></td>
<td colspan="2" style="height: 12pt;"></td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;">Proteovant</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: top;">Phase 1 initiation for first degrader candidate</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: top;">2022</td> </tr>
<tr style="font-size: 1pt;">
<td style="height: 12pt;"></td>
<td colspan="2" style="height: 12pt;"></td>
<td colspan="2" style="height: 12pt;"></td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;">Roivant / Proteovant</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: top;">Multiple additional degrader candidates entering IND-enabling studies each year </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: top;">Starting 2022</td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Note: References are to calendar years. All catalyst timings are based on current expectations and, where applicable, contingent on FDA feedback, and may be subject to change. </div></div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Recent Developments </div></div></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 4%;">&#160;</td>
<td style="width: 4%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Datavant:</div></div> In June 2021, Datavant and Ciox Health entered into a definitive agreement to merge the two companies. The combined entity, named Datavant, is the nation&#8217;s largest health data ecosystem, enabling patients, providers, payers, health data analytics companies, patient-facing applications, government agencies and life science companies to securely exchange their patient-level data. The merger closed on July&#160;27, 2021. At closing, Roivant received approximately $320&#160;million in cash and a minority equity ownership in the combined entity. </div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 4%;">&#160;</td>
<td style="width: 4%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Aruvant: </div></div>In June 2021, Aruvant announced data published on <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">ARU-2801,</div> an investigational gene therapy, that showed improved survival out to 18 months in hypophosphatasia mice. </div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 4%;">&#160;</td>
<td style="width: 4%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Immunovant: </div></div>In August 2021, Roivant made a $200&#160;million investment in Immunovant. Following this transaction, Roivant owns 73,398,664 shares of Immunovant common stock, representing approximately a 63.8% ownership interest. </div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 4%;">&#160;</td>
<td style="width: 4%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Dermavant: </div></div>In August 2021, the FDA accepted for filing Dermavant&#8217;s NDA for tapinarof for the treatment of plaque psoriasis in adult patients. The FDA has assigned a PDUFA target action date in the second quarter of calendar year 2022. In September 2021, Dermavant dosed the first patient in a Phase 3 trial of tapinarof for the treatment of atopic dermatitis. </div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 4%;">&#160;</td>
<td style="width: 4%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Genevant: </div></div>In August 2021, Genevant entered into a global collaboration and license agreement with Takeda for the development and commercialization of novel nonviral gene therapies for up to two rare liver diseases. Genevant will be eligible for up to $303&#160;million in upfront and potential milestone payments, plus royalties on product sales. This is the second collaboration between Genevant and Takeda. </div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">104 </div></div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;;font-weight: bold;"><a href="#toc">Table of Contents</a></div> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Business Combination </div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">On May&#160;1, 2021, we entered into a Business Combination Agreement (the &#8220;Business Combination Agreement&#8221;) with Montes Archimedes Acquisition Corporation (&#8220;MAAC&#8221;) and Rhine Merger Sub, Inc. (&#8220;Merger Sub&#8221;). MAAC was incorporated in Delaware on July&#160;6, 2020 and was formed as a blank check company for the purpose of effecting a merger, share exchange, asset acquisition, stock purchase, recapitalization, reorganization or similar business combination with one or more businesses. Pursuant to the Business Combination Agreement, and assuming a favorable vote by MAAC&#8217;s stockholders at a special meeting of MAAC&#8217;s stockholders convened for purposes of approving the transactions contemplated by the Business Combination Agreement (the &#8220;Business Combination&#8221;), and the satisfaction or waiver of all other closing conditions pursuant to the Business Combination Agreement, Merger Sub will merge with and into MAAC, with MAAC surviving the merger as our wholly owned subsidiary. </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">For financial accounting and reporting purposes, MAAC will be treated as the acquired company. Accordingly, because MAAC does not represent a business for accounting purposes and its primary asset represents cash and cash equivalents, the Business Combination will be treated as an equity contribution in exchange for the issuance of Roivant shares. The net assets of MAAC will be stated at historical cost, with no goodwill or other intangible assets recorded. We will be deemed both the accounting predecessor and the successor SEC registrant, which means that our financial statements for previous periods will be disclosed in our future periodic reports filed with the SEC. </div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;">Impact of <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">COVID-19</div> </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;">We have been actively monitoring the impact of the <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">COVID-19</div> pandemic on our employees and our business. Based on guidance issued by federal, state and local authorities, we transitioned to a remote work model for our employees in March 2020 and our workforce continues to primarily work remotely. </div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">The <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">COVID-19</div> pandemic has had a variable impact on our clinical trials by disrupting certain study sites. In the conduct of our business activities, we continue to take actions designed to protect the safety and well-being of our patients and employees. Although some of our clinical development timelines have been impacted by delays related to the <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">COVID-19</div> pandemic, we have not experienced material financial impacts on our business and operations as a result of the <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">COVID-19</div> pandemic. However, the impact on our future results will largely depend on future developments related to <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">COVID-19,</div> which are highly uncertain and cannot be predicted with confidence, such as the emergence of new variants, the ultimate duration and spread of the outbreak, the continuing impact of the <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">COVID-19</div> pandemic on financial markets and the global economy, travel restrictions and social distancing in the United States and other countries, business closures or business disruptions and the effectiveness of actions taken in the United States and other countries to contain, treat, and prevent the disease, including the availability and effectiveness of vaccines. </div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">For additional information about risks and uncertainties related to the <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">COVID-19</div> pandemic that may impact our business, financial condition and results of operations, see the section titled &#8220;Risk Factors&#8221; included elsewhere in this prospectus. </div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Components of Results of Operations </div></div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt; margin-left: 2%;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Revenue, net </div></div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">We have not generated any revenues to date from the sale of our product candidates and do not anticipate generating any revenues from the sale of product candidates unless and until we successfully complete development and obtain regulatory approval to market our product candidates. Our revenue to date primarily includes the recognition of upfront payments received in connection with license agreements. Revenue is also generated by subscription and service-based fees. Our revenue recognized from inception to date has not been significant. </div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt; margin-left: 2%;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Cost of revenues </div></div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Our cost of revenues primarily relates to subscription and service-based revenue recognized for the use of technology developed and consists primarily of employee, hosting, and third-party data costs. Our cost of revenues has not been significant to date. </div></div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">105 </div></div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;;font-weight: bold;"><a href="#toc">Table of Contents</a></div> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 2%;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Research and development expenses </div></div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Research and development expenses consist mainly of costs incurred in connection with the discovery and development of our product candidates. Research and development expenses primarily include the following: </div></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 4%;">&#160;</td>
<td style="width: 4%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Program-specific costs, including: </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 10%;">&#160;</td>
<td style="width: 2%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">direct third-party costs, which include expenses incurred under agreements with contract research organizations (&#8220;CROs&#8221;) and contract manufacturing organizations (&#8220;CMOs&#8221;), the cost of consultants who assist with the development of our product candidates on a program-specific basis, investigator grants, sponsored research, manufacturing costs in connection with producing materials for use in conducting nonclinical and clinical studies, and any other third-party expenses directly attributable to the development of our product candidates; and </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 10%;">&#160;</td>
<td style="width: 2%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">payments made in connection with asset acquisitions and license agreements upon the achievement of development milestones. </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;">Consideration for the purchase of <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">in-process</div> research and development (&#8220;IPR&amp;D&#8221;) through asset acquisitions and license agreements, including: </div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 10%;">&#160;</td>
<td style="width: 2%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">cash upfront payments; </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 10%;">&#160;</td>
<td style="width: 2%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">shares and other liability instruments issued; and </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 10%;">&#160;</td>
<td style="width: 2%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">fair value of future contingent consideration payments. </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Unallocated internal costs, including: </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 10%;">&#160;</td>
<td style="width: 2%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">employee-related expenses, such as salaries, share-based compensation, and benefits, for research and development personnel; and </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 10%;">&#160;</td>
<td style="width: 2%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">other expenses, including consulting costs, that are not allocated to a specific program. </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">Research and development activities, including asset acquisitions and license agreements, will continue to be central to our business model. We anticipate that our research and development expenses will increase for the foreseeable future as we advance our product candidates through <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">pre-clinical</div> studies and clinical trials, as well as acquire new product candidates. Research and development expenses will also be driven by the number of small molecules from our discovery engine that we advance through preclinical studies and clinical trials. In addition, we expect our research and development expenses to increase in the future, including as a result of our small molecule discovery engine through which we utilize our computational platform for in silico design of novel drug candidates. We expect higher employee-related expenses, including higher share-based compensation expenses, as well as higher consulting costs as we hire additional resources to support increasing development activity. </div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">The duration, costs and timing of <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">pre-clinical</div> studies and clinical trials of our product candidates will depend on a variety of factors that include, but are not limited to, the following: </div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">the scope, rate of progress, expense and results of our preclinical development activities, any future clinical trials of our product candidates, and other research and development activities that we may conduct; </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">the number and scope of preclinical and clinical programs we decide to pursue; </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">the uncertainties in clinical trial design and patient enrollment or drop out or discontinuation rates; </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">the number of doses that patients receive; </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">the countries in which the trials are conducted; </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">our ability to secure and leverage adequate CRO support for the conduct of clinical trials; </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">106 </div></div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;;font-weight: bold;"><a href="#toc">Table of Contents</a></div> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;">
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">our ability to establish an appropriate safety and efficacy profile for our product candidates; </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">the timing, receipt and terms of any approvals from applicable regulatory authorities; </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">the potential additional safety monitoring or other studies requested by regulatory agencies; </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">the significant and changing government regulation and regulatory guidance; </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">our ability to establish clinical and commercial manufacturing capabilities, or make arrangements with third-party manufacturers in order to ensure that we or our third-party manufacturers are able to make product successfully; </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;">the impact of any business interruptions to our operations due to the <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">COVID-19</div> pandemic; and </div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">our ability to maintain a continued acceptable safety profile of our product candidates following approval, if any, of our product candidates. </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">In addition, the probability of success for our product candidates will depend on numerous factors, including competition, manufacturing capability and commercial viability. </div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt; margin-left: 2%;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">General and administrative expenses </div></div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;">General and administrative expenses consist primarily of employee-related expenses for general and administrative personnel, including those responsible for the identification and acquisition or <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">in-license</div> of new drug candidates as well as for overseeing Vant operations and facilitating the use of our platform and technologies at Vants. General and administrative expenses also consist of legal and accounting fees, consulting services and other operating costs relating to corporate matters and daily operations. General and administrative expenses also include costs incurred relating to the identification, acquisition or <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">in-license</div> and technology transfer of promising drug candidates along with costs incurred relating to the integration of new technologies. </div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">We anticipate that our general and administrative expenses will increase in the future to support our continued research and development activities, potential commercialization efforts, and increased costs associated with being a public company. These increases will likely include additional costs related to the hiring of new personnel, including higher share-based compensation expenses, and fees to outside consultants, as well as other expenses. As a public company, we anticipate incurring expenses related to maintaining compliance with the rules and regulations promulgated by the SEC, the applicable Nasdaq listing rules and the requirements of the Sarbanes-Oxley Act of 2002, as amended (the &#8220;Sarbanes-Oxley Act&#8221;). If any of our current or future product candidates receives regulatory approval in the U.S. or another jurisdiction, we expect that we would incur significantly increased expenses associated with building a sales and marketing team. </div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt; margin-left: 2%;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Change in fair value of investments </div></div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Change in fair value of investments includes the unrealized loss (gain) on equity investments in publicly-traded companies, including Sio Gene Therapies Inc. (&#8220;Sio&#8221;) and Arbutus Biopharma Corporation (&#8220;Arbutus&#8221;). We have elected the fair value option to account for these investments. </div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt; margin-left: 2%;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Change in fair value of debt and liability instruments </div></div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;">Change in fair value of debt and liability instruments primarily includes the unrealized loss relating to the measurement and recognition of fair value on a recurring basis of certain liabilities, including debt issued by a wholly-owned subsidiary of Dermavant to NovaQuest <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">Co-Investment</div> Fund VIII, L.P. (the &#8220;NovaQuest Facility&#8221;), and other liability instruments, including options granted to Sumitomo Dainippon Pharma Co., Ltd. (&#8220;Sumitomo&#8221;) to purchase our ownership interests in certain subsidiaries (the &#8220;Sumitomo Options&#8221;) before the termination of those options in June 2021. </div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">107 </div></div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;;font-weight: bold;"><a href="#toc">Table of Contents</a></div> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 2%;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Gain on termination of Sumitomo Options </div></div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;">Gain on termination of Sumitomo Options resulted from the completion of transactions contemplated by an Asset Purchase Agreement entered into with Sumitomo and its subsidiary Sumitomo Pharmaceuticals (Suzhou) Co., Ltd. (&#8220;SPC&#8221;) in May 2021. The transactions contemplated by the Asset Purchase Agreement closed in June 2021. Pursuant to the Asset Purchase Agreement: (i)&#160;Sumitomo terminated all of its existing options to acquire our ownership interest in certain subsidiaries; (ii)&#160;we transferred and assigned to SPC all of our intellectual property, development and commercialization rights for (a)&#160;lefamulin in Mainland China, Taiwan, Hong Kong, and Macau (collectively &#8220;Greater China&#8221;), (b) vibegron in Mainland China, (c)&#160;rodatristat ethyl in Greater China and South Korea and <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">(d)&#160;RVT-802</div> in Greater China and South Korea; (iii)&#160;Sumitomo agreed to pay us $5.0&#160;million in cash; and (iv)&#160;Sumitomo entered into an agreement with us to pursue future collaborations with Genevant. The Company received the cash payment, net of certain withholding taxes, in August 2021. </div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt; margin-left: 2%;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Other (income) expense, net </div></div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Other (income) expense, net consists of losses from our equity method investment, interest income on our cash and cash equivalents, interest expense resulting from interest accrued on long-term debt and the amortization of debt discount and issuance costs, and other miscellaneous income. </div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt; margin-left: 2%;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Income tax expense </div></div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Income tax expense is recorded for the jurisdictions in which we do business. Deferred tax assets and liabilities are recognized for the future tax consequences attributable to differences between the financial statement carrying amounts of existing assets and liabilities and the respective tax bases. Deferred tax assets and liabilities are measured using enacted tax rates expected to apply to taxable income in the years in which those temporary differences are expected to be recovered or settled. The effect on deferred tax assets and liabilities of a change in tax rates is recognized in income in the period that includes the enactment date. A valuation allowance is recorded when, after consideration of all positive and negative evidence, it is not more likely than not that our deferred tax assets will be realizable. When uncertain tax positions exist, we recognize the tax benefit of tax positions to the extent that the benefit will more likely than not be realized. The determination as to whether the tax benefit will more likely than not be realized is based upon the technical merits of the tax position as well as consideration of the available facts and circumstances. </div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt; margin-left: 2%;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Net loss attributable to noncontrolling interests </div></div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Net loss attributable to noncontrolling interests consists of the portion of net loss of those consolidated entities that is not allocated to us. Changes in the amount of net loss attributable to noncontrolling interests are directly impacted by the net loss of our consolidated entities and changes in ownership percentages. </div></div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">108 </div></div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;;font-weight: bold;"><a href="#toc">Table of Contents</a></div> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Results of Operations </div></div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Comparison of the three months ended June&#160;30, 2021 and 2020 </div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The following table sets forth our results of operations for the three months ended June&#160;30, 2021 and 2020: </div></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 84%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="font-size: 0px;">
<td style="width: 62%;"></td>
<td style="width: 5%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td>
<td style="width: 5%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td>
<td style="width: 5%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;&#160;</td>
<td colspan="6" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Three&#160;Months&#160;Ended<br/>June&#160;30,</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2021</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2020</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Change</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td colspan="10" style="vertical-align: bottom;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">(in thousands)</div></div></div></div></td>
<td style="vertical-align: bottom;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Revenue, net</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">7,735</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">1,576</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">6,159</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Operating expenses:</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Cost of revenues</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">742</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">180</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">562</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Research and development</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">78,626</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">58,734</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">19,892</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">General and administrative</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">82,754</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">57,115</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">25,639</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 5em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Total operating expenses</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">162,122</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">116,029</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">46,093</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Loss from operations</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(154,387</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(114,453</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(39,934</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Change in fair value of investments</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">8,619</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(41,148</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">49,767</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Change in fair value of debt and liability instruments</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">4,585</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">17,125</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(12,540</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Gain on termination of Sumitomo Options</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(66,472</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(66,472</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Gain on deconsolidation of subsidiary</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(86,516</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">86,516</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Other (income) expense, net</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(134</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">2,842</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(2,976</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Loss before income taxes</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(100,985</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(6,756</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(94,229</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Income tax expense</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">93</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">1,221</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(1,128</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Net loss</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(101,078</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(7,977</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(93,101</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Net loss attributable to noncontrolling interests</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(18,895</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(4,734</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(14,161</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Net loss attributable to Roivant Sciences Ltd.</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(82,183</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(3,243</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(78,940</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt; margin-left: 2%;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Variance analysis for three months ended June&#160;30, 2021 and 2020 </div></div></div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt; margin-left: 2%;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Revenue, net </div></div></div></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 84%; font-family: &quot;Times New Roman&quot;; font-size: 8pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="font-size: 0px;">
<td style="width: 70%;"></td>
<td style="width: 4%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td>
<td style="width: 4%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td>
<td style="width: 4%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;&#160;</td>
<td colspan="6" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Three&#160;Months&#160;Ended<br/>June&#160;30,</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2021</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2020</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Change</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td colspan="10" style="vertical-align: bottom;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">(in thousands)</div></div></div></div></td>
<td style="vertical-align: bottom;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Revenue, net</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">7,735</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">1,576</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">6,159</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Revenue, net increased by $6.2&#160;million to $7.7&#160;million for the three months ended June&#160;30, 2021 compared to $1.6&#160;million for the three months ended June&#160;30, 2020, primarily due to the recognition of upfront payments received in connection with license agreements. Revenue generated was not significant in either period presented. </div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt; margin-left: 2%;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Cost of revenues </div></div></div></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 84%; font-family: &quot;Times New Roman&quot;; font-size: 8pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="font-size: 0px;">
<td style="width: 69%;"></td>
<td style="width: 6%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td>
<td style="width: 6%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td>
<td style="width: 7%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;&#160;</td>
<td colspan="6" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Three&#160;Months&#160;Ended<br/>June&#160;30,</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;&#160;&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2021</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2020</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;&#160;&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Change</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td colspan="10" style="vertical-align: bottom;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">(in thousands)</div></div></div></div></td>
<td style="vertical-align: bottom;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Cost of revenues</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">742</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">180</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">562</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">109 </div></div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;;font-weight: bold;"><a href="#toc">Table of Contents</a></div> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Cost of revenues increased by $0.6&#160;million to $0.7&#160;million for the three months ended June&#160;30, 2021 compared to $0.2&#160;million for the three months ended June&#160;30, 2020. Cost of revenues was not significant in either period presented and reflects primarily the cost of revenues generated by subscription and service-based fees. </div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt; margin-left: 2%;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Research and development expenses </div></div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">For the three months ended June&#160;30, 2021 and 2020, our research and development expenses consisted of the following: </div></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 84%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="font-size: 0px;">
<td style="width: 64%;"></td>
<td style="width: 5%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td>
<td style="width: 5%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td>
<td style="width: 5%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;&#160;</td>
<td colspan="6" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Three Months Ended<br/>June&#160;30,</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2021</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2020</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Change</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td colspan="10" style="vertical-align: bottom;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">(in thousands)</div></div></div></div></td>
<td style="vertical-align: bottom;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Program-specific costs:</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">IMVT-1401 (Immunovant, Inc.)</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">13,688</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">14,393</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(705</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Tapinarof (Dermavant Sciences Ltd.)</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">9,757</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">8,414</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">1,343</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">ARU-1801</div> (Aruvant Sciences Ltd.)</div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">2,389</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">3,353</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(964</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Gimsilumab (Kinevant Sciences Ltd.)</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">2,069</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">12,325</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(10,256</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Other program-specific costs</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">20,112</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">9,097</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">11,015</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 5em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Total program-specific costs</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">48,015</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">47,582</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">433</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Unallocated internal costs:</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Share-based compensation</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">1,615</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">1,119</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">496</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Personnel-related expenses</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">22,092</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">8,767</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">13,325</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Other expenses</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">6,904</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">1,266</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">5,638</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Total research and development expenses</div></div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">78,626</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">58,734</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">19,892</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">Research and development expenses increased by $19.9&#160;million to $78.6&#160;million for the three months ended June&#160;30, 2021 compared to $58.7&#160;million for the three months ended June&#160;30, 2020, primarily due to an increase of $13.3&#160;million in personnel-related expenses. This increase in personnel-related expenses is partially driven by additional headcount to support drug discovery efforts using our computational discovery technology and targeted protein degradation platform, following the acquisition of Silicon Therapeutics (&#8220;SiTX&#8221;) in March 2021 and Oncopia Therapeutics, Inc. (&#8220;Oncopia&#8221;) in November 2020. Additionally, program-specific costs for Dermavant&#8217;s tapinarof program increased by $1.3&#160;million and other program-specific costs increased by $11.0&#160;million, partially offset by a decrease of $10.3&#160;million for Kinevant Sciences Ltd.&#8217;s (&#8220;Kinevant&#8221;) gimsilumab program as a result of higher costs during the three months ended June&#160;30, 2020 related to our study in <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">COVID-19</div> Associated ARDS. </div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt; margin-left: 2%;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">General and administrative expenses </div></div></div></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 84%; font-family: &quot;Times New Roman&quot;; font-size: 8pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="font-size: 0px;">
<td style="width: 67%;"></td>
<td style="width: 4%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td>
<td style="width: 4%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td>
<td style="width: 4%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;&#160;</td>
<td colspan="6" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Three Months Ended<br/>June&#160;30,</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2021</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2020</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Change</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td colspan="10" style="vertical-align: bottom;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">(in thousands)</div></div></div></div></td>
<td style="vertical-align: bottom;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">General and administrative</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">82,754</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">57,115</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">25,639</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">General and administrative expenses increased by $25.6&#160;million to $82.8&#160;million for the three months ended June&#160;30, 2021 compared to $57.1&#160;million for the three months ended June&#160;30, 2020. The increase was primarily due to increases in professional and transaction fees of $8.3&#160;million, in part as a result of increased business activity as we prepare to operate as a public company,&#160;personnel-related expenses of $6.7&#160;million and share-based compensation expense of $4.5&#160;million. </div></div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">110 </div></div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;;font-weight: bold;"><a href="#toc" style="text-indent: 0px;">Table of Contents</a></div> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 2%;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Change in fair value of investments </div></div></div></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 84%; font-family: &quot;Times New Roman&quot;; font-size: 8pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="font-size: 0px;">
<td style="width: 67%;"></td>
<td style="width: 4%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td>
<td style="width: 4%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td>
<td style="width: 4%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;&#160;</td>
<td colspan="6" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Three Months Ended<br/>June&#160;30,</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2021</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2020</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Change</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td colspan="10" style="vertical-align: bottom;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">(in thousands)</div></div></div></div></td>
<td style="vertical-align: bottom;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Change in fair value of investments</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">8,619</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(41,148</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">49,767</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Change in fair value of investments was an unrealized loss of $8.6&#160;million and unrealized gain of $41.1&#160;million for the three months ended June&#160;30, 2021 and 2020, respectively. The change of $49.8&#160;million was primarily driven by changes in the public share prices of Arbutus and Sio. </div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt; margin-left: 2%;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Change in fair value of debt and liability instruments </div></div></div></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 84%; font-family: &quot;Times New Roman&quot;; font-size: 8pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="font-size: 0px;">
<td style="width: 67%;"></td>
<td style="width: 4%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td>
<td style="width: 4%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td>
<td style="width: 4%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;&#160;</td>
<td colspan="6" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Three Months Ended<br/>June&#160;30,</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2021</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2020</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Change</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td colspan="10" style="vertical-align: bottom;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">(in thousands)</div></div></div></div></td>
<td style="vertical-align: bottom;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Change in fair value of debt and liability instruments</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">4,585</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">17,125</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(12,540</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Change in fair value of debt and liability instruments was an unrealized loss of $4.6&#160;million and $17.1&#160;million for the three months ended June&#160;30, 2021 and 2020, respectively. Change in fair value of debt and liability instruments for the three months ended June&#160;30, 2021 primarily consisted of an unrealized loss of $5.1&#160;million relating to the NovaQuest facility, which was largely due to the passage of time. Change in fair value of debt and liability instruments for the three months ended June&#160;30, 2020 primarily consisted of an unrealized loss of $17.9&#160;million relating to the NovaQuest Facility, which was largely due to a decrease in the discount rate. </div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt; margin-left: 2%;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Gain on termination of Sumitomo Options </div></div></div></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 84%; font-family: &quot;Times New Roman&quot;; font-size: 8pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="font-size: 0px;">
<td style="width: 68%;"></td>
<td style="width: 4%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td>
<td style="width: 4%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td>
<td style="width: 4%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;&#160;</td>
<td colspan="6" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Three&#160;Months&#160;Ended<br/>June&#160;30,</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2021</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2020</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Change</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td colspan="10" style="vertical-align: bottom;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">(in thousands)</div></div></div></div></td>
<td style="vertical-align: bottom;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Gain on termination of Sumitomo Options</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(66,472</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(66,472</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Gain on termination of Sumitomo Options was $66.5&#160;million for the three months ended June&#160;30, 2021 due to the completion of transactions contemplated by the Asset Purchase Agreement entered into with Sumitomo and SPC. See &#8220;Components of Results of Operations-Gain on termination of Sumitomo Options&#8221; above for additional information. </div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt; margin-left: 2%;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Gain on deconsolidation of subsidiary </div></div></div></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 84%; font-family: &quot;Times New Roman&quot;; font-size: 8pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="font-size: 0px;">
<td style="width: 69%;"></td>
<td style="width: 4%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td>
<td style="width: 4%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td>
<td style="width: 4%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;&#160;</td>
<td colspan="6" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Three&#160;Months&#160;Ended<br/>June&#160;30,</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2021</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2020</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Change</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td colspan="10" style="vertical-align: bottom;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">(in thousands)</div></div></div></div></td>
<td style="vertical-align: bottom;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Gain on deconsolidation of subsidiary</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(86,516</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">86,516</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Gain on deconsolidation of subsidiary was $86.5&#160;million for the three months ended June&#160;30, 2020 related to a gain of $86.5&#160;million on the deconsolidation of Datavant in April 2020. </div></div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">111 </div></div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;;font-weight: bold;"><a href="#toc">Table of Contents</a></div> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 2%;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Other (income) expense, net </div></div></div></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 84%; font-family: &quot;Times New Roman&quot;; font-size: 8pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="font-size: 0px;">
<td style="width: 70%;"></td>
<td style="width: 4%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td>
<td style="width: 4%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td>
<td style="width: 4%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;&#160;</td>
<td colspan="6" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Three&#160;Months&#160;Ended<br/>June&#160;30,</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2021</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2020</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Change</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td colspan="10" style="vertical-align: bottom;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">(in thousands)</div></div></div></div></td>
<td style="vertical-align: bottom;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Other (income) expense, net</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(134</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">2,842</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(2,976</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Other (income) expense, net consisted of $0.1&#160;million of other income, net and $2.8&#160;million of other expense, net for the three months ended June&#160;30, 2021 and 2020, respectively. The change in other (income) expense, net was primarily driven by losses from our equity method investment in Genevant of $3.8&#160;million incurred through June 2020 until we consolidated Genevant, partially offset by higher interest expense of $1.7&#160;million for the three months ended June&#160;30, 2021 as compared to the three months ended June&#160;30, 2020. </div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt; margin-left: 2%;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Income tax expense </div></div></div></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 84%; font-family: &quot;Times New Roman&quot;; font-size: 8pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="font-size: 0px;">
<td style="width: 70%;"></td>
<td style="width: 5%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td>
<td style="width: 5%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td>
<td style="width: 5%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;&#160;</td>
<td colspan="6" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Three&#160;Months&#160;Ended<br/>June&#160;30,</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2021</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2020</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Change</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td colspan="10" style="vertical-align: bottom;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">(in thousands)</div></div></div></div></td>
<td style="vertical-align: bottom;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Income tax expense</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">93</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">1,221</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(1,128</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Income tax expense decreased by $1.1&#160;million to $93&#160;thousand for the three months ended June&#160;30, 2021, compared to $1.2&#160;million for the three months ended June&#160;30, 2020. Income tax expense was not significant in either period presented and reflects the income tax expense computed in jurisdictions in which we operate. </div></div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">112 </div></div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;;font-weight: bold;"><a href="#toc">Table of Contents</a></div> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 4%;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Comparison of the years ended March&#160;31, 2021 and 2020 </div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The following table sets forth our results of operations for the years ended March&#160;31, 2021 and 2020: </div></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 84%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="font-size: 0px;">
<td style="width: 55%;"></td>
<td style="width: 5%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td>
<td style="width: 5%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td>
<td style="width: 5%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;&#160;</td>
<td colspan="6" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Years&#160;Ended&#160;March&#160;31,</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2021</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2020</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Change</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td colspan="10" style="vertical-align: bottom;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">(in thousands)</div></div></div></div></td>
<td style="vertical-align: bottom;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Revenue, net</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">23,795</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">67,689</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(43,894</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Operating expenses:</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Cost of revenues</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">2,057</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">1,131</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">926</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Research and development</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">832,758</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">263,217</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">569,541</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">General and administrative</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">259,878</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">335,766</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(75,888</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 5em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Total operating expenses</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">1,094,693</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">600,114</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">494,579</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Loss from operations</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(1,070,898</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(532,425</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(538,473</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Change in fair value of investments</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(95,533</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">136,005</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(231,538</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Change in fair value of debt and liability instruments</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">29,845</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(13,722</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">43,567</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Gain on deconsolidation of subsidiary and consolidation of unconsolidated entity</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(115,364</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(107,344</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(8,020</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Other expense, net</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">8,701</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">13,622</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(4,921</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Loss from continuing operations before income taxes</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(898,547</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(560,986</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(337,561</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Income tax expense</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">1,686</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">7,124</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(5,438</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Loss from continuing operations, net of tax</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(900,233</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(568,110</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(332,123</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Income from discontinued operations, net of tax</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">1,578,426</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(1,578,426</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Net (loss) income</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(900,233</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">1,010,316</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(1,910,549</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Net loss attributable to noncontrolling interests</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(90,999</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(190,193</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">99,194</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Net (loss) income attributable to Roivant Sciences Ltd.</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(809,234</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">1,200,509</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(2,009,743</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt; margin-left: 4%;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Variance analysis for years ended March&#160;31, 2021 and 2020 </div></div></div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt; margin-left: 4%;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Revenue, net </div></div></div></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 84%; font-family: &quot;Times New Roman&quot;; font-size: 8pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="font-size: 0px;">
<td style="width: 66%;"></td>
<td style="width: 4%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td>
<td style="width: 4%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td>
<td style="width: 4%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;&#160;</td>
<td colspan="6" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Years&#160;Ended&#160;March&#160;31,</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2021</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2020</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Change</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td colspan="10" style="vertical-align: bottom;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">(in thousands)</div></div></div></div></td>
<td style="vertical-align: bottom;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Revenue, net</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">23,795</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">67,689</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(43,894</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Revenue, net decreased by $43.9&#160;million to $23.8&#160;million for the year ended March&#160;31, 2021 compared to $67.7&#160;million for the year ended March&#160;31, 2020. The decrease was primarily driven by a nonrefundable, upfront payment of $60.0&#160;million received by Dermavant during the year ended March&#160;31, 2020 from Japan Tobacco Inc., parent company of Torii Pharmaceutical Co., Ltd., for the exclusive rights to develop, register, and market tapinarof in Japan, partially offset by $19.8&#160;million of revenue generated by Genevant during the year ended March&#160;31, 2021 following consolidation in July 2020. Revenue generated by subscription and service-based fees was not significant in either period presented. </div></div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">113 </div></div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;;font-weight: bold;"><a href="#toc">Table of Contents</a></div> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 4%;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Cost of revenues </div></div></div></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 84%; font-family: &quot;Times New Roman&quot;; font-size: 8pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="font-size: 0px;">
<td style="width: 69%;"></td>
<td style="width: 5%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td>
<td style="width: 5%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td>
<td style="width: 5%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;&#160;</td>
<td colspan="6" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Years&#160;Ended&#160;March&#160;31,</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2021</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2020</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Change</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td colspan="10" style="vertical-align: bottom;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">(in thousands)</div></div></div></div></td>
<td style="vertical-align: bottom;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Cost of revenues</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">2,057</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">1,131</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">926</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Cost of revenues increased by $0.9&#160;million to $2.1&#160;million for the year ended March&#160;31, 2021 compared to $1.1&#160;million for the year ended March&#160;31, 2020. Cost of revenues was not significant in either period presented and reflects cost of revenues generated by subscription and service-based fees. </div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt; margin-left: 4%;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Research and development expenses </div></div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">For the years ended March&#160;31, 2021 and 2020, our research and development expenses consisted of the following: </div></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 84%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="font-size: 0px;">
<td style="width: 61%;"></td>
<td style="width: 5%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td>
<td style="width: 5%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td>
<td style="width: 5%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;&#160;</td>
<td colspan="6" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Years Ended March&#160;31,</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2021</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2020</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Change</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td colspan="10" style="vertical-align: bottom;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">(in thousands)</div></div></div></div></td>
<td style="vertical-align: bottom;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Program-specific costs:</div></div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">IMVT-1401 (Immunovant, Inc.)</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">49,236</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">39,230</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">10,006</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Tapinarof (Dermavant Sciences Ltd.)</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">34,002</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">69,394</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(35,392</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">ARU-1801</div> (Aruvant Sciences Ltd.)</div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">24,347</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">11,064</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">13,283</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Gimsilumab (Kinevant Sciences Ltd.)</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">21,969</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">7,288</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">14,681</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">RVT-1601</div> (Respivant Sciences Ltd.)</div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">6,784</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">16,935</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(10,151</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">AXO-LENTI-PD</div></div> (Sio Gene Therapies, Inc.)</div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">21,219</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(21,219</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Other program-specific costs</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">29,790</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">32,402</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(2,612</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Total program-specific costs</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">166,128</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">197,532</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(31,404</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Consideration for the purchase of IPR&amp;D through asset acquisitions and license agreements</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">591,916</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">10,250</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">581,666</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Unallocated internal costs:</div></div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Share-based compensation</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">22,637</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">7,738</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">14,899</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Personnel-related expenses</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">45,646</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">33,865</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">11,781</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Other expenses</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">6,431</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">13,832</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(7,401</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Total research and development expenses</div></div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">832,758</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">263,217</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">569,541</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Research and development expenses increased by $569.5&#160;million to $832.8&#160;million for the year ended March&#160;31, 2021 compared to $263.2&#160;million for the year ended March&#160;31, 2020 primarily due to an increase of $581.7&#160;million in consideration for the purchase of IPR&amp;D through asset acquisitions and license agreements, partially offset by a decrease in program-specific costs of $31.4&#160;million. </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">The increase of $581.7&#160;million in consideration for the purchase of IPR&amp;D was primarily due to multiple asset acquisitions and license agreements entered into during the year ended March&#160;31, 2021, including consideration of $399.6&#160;million attributed to IPR&amp;D relating to the acquisition of the business of SiTX; consideration of $116.5&#160;million relating to the stock purchase agreement to acquire Oncopia; $41.4&#160;million attributed to IPR&amp;D as part of the consolidation of Genevant, which was previously accounted for as an equity method investment; and consideration relating to the licensing and strategic collaboration agreement with Affimed N.V. (&#8220;Affimed&#8221;), pursuant to which Affimed received consideration that included $40.0&#160;million in upfront cash and <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">pre-paid</div> research and development funding and $20.0&#160;million of our Common Shares. During the year ended March&#160;31, 2020, we made a <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">one-time</div> upfront payment of $10.0&#160;million related to our multi-program license and collaboration agreement with Medigene AG. </div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">114 </div></div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;;font-weight: bold;"><a href="#toc">Table of Contents</a></div> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">The decrease of $31.4&#160;million in program-specific costs was mainly due to a decrease of $35.4&#160;million relating to Dermavant&#8217;s tapinarof program primarily as a result of the completion of two pivotal Phase 3 clinical trials, PSOARING 1 AND PSOARING 2, and a <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">one-time</div> milestone payment of C$30.0&#160;million (approximately $23 million) made upon the achievement of a development milestone during the year ended March&#160;31, 2020; decrease of $21.2&#160;million relating to Sio&#8217;s <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">AXO-LENTI-PD</div></div> program as a result of the deconsolidation of Sio in February 2020; and decrease of $10.2&#160;million for Respivant Sciences Ltd.&#8217;s (&#8220;Respivant&#8221;) <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">RVT-1601</div> program as a result of its termination. These decreases were partially offset by increases of $14.7&#160;million for Kinevant&#8217;s gimsilumab program, including $3.0&#160;million resulting from the achievement of development milestones, $13.3&#160;million for Aruvant&#8217;s <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">ARU-1801</div> program, and $10.0&#160;million for Immunovant&#8217;s IMVT-1401 program. These increases in program-specific costs were primarily due to increases in clinical development costs. </div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt; margin-left: 4%;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">General and administrative expenses </div></div></div></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 84%; font-family: &quot;Times New Roman&quot;; font-size: 8pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="font-size: 0px;">
<td style="width: 64%;"></td>
<td style="width: 4%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td>
<td style="width: 4%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td>
<td style="width: 4%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;&#160;</td>
<td colspan="6" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Years Ended March&#160;31,</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2021</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2020</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Change</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td colspan="10" style="vertical-align: bottom;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">(in thousands)</div></div></div></div></td>
<td style="vertical-align: bottom;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">General and administrative</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">259,878</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">335,766</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(75,888</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">General and administrative expenses decreased by $75.9&#160;million to $259.9&#160;million for the year ended March&#160;31, 2021 compared to $335.8&#160;million for the year ended March&#160;31, 2020. The decrease was primarily due to decreases in personnel-related expenses of $38.5&#160;million and professional and transaction fees of $27.9&#160;million. The decrease in personnel-related expenses is partially driven by the deconsolidation of Sio in February 2020 and Datavant in April 2020. </div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt; margin-left: 4%;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Change in fair value of investments </div></div></div></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 84%; font-family: &quot;Times New Roman&quot;; font-size: 8pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="font-size: 0px;">
<td style="width: 63%;"></td>
<td style="width: 4%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td>
<td style="width: 4%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td>
<td style="width: 4%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;&#160;</td>
<td colspan="6" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Years Ended March&#160;31,</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2021</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2020</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Change</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td colspan="10" style="vertical-align: bottom;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">(in thousands)</div></div></div></div></td>
<td style="vertical-align: bottom;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Change in fair value of investments</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(95,533</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">136,005</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(231,538</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Change in fair value of investments was an unrealized gain of $95.5&#160;million and unrealized loss of $136.0&#160;million for the years ended March&#160;31, 2021 and 2020, respectively. The change of $231.5&#160;million was primarily driven by changes in the share prices of Arbutus and Sio. </div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt; margin-left: 4%;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Change in fair value of debt and liability instruments </div></div></div></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 84%; font-family: &quot;Times New Roman&quot;; font-size: 8pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="font-size: 0px;">
<td style="width: 66%;"></td>
<td style="width: 4%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td>
<td style="width: 4%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td>
<td style="width: 4%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;&#160;</td>
<td colspan="6" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Years Ended March&#160;31,</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2021</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2020</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Change</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td colspan="10" style="vertical-align: bottom;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">(in thousands)</div></div></div></div></td>
<td style="vertical-align: bottom;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Change in fair value of debt and liability instruments</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">29,845</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(13,722</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">43,567</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Change in fair value of debt and liability instruments was an unrealized loss of $29.8&#160;million and unrealized gain of $13.7&#160;million for the years ended March&#160;31, 2021 and 2020, respectively. Change in fair value of debt and liability instruments for the year ended March&#160;31, 2021 primarily consisted of an unrealized loss of $61.0&#160;million relating to the NovaQuest Facility, partially offset by an unrealized gain of $33.5&#160;million relating to the Sumitomo Options. Change in fair value of debt and liability instruments for the year ended March&#160;31, 2020 primarily consisted of an unrealized gain of $9.9&#160;million relating to the NovaQuest Facility and an unrealized gain of $3.2&#160;million relating to the Sumitomo Options. Changes in the fair value of the NovaQuest Facility primarily resulted from updates to the estimated timing of amounts payable to NovaQuest and discount rates. </div></div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">115 </div></div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;;font-weight: bold;"><a href="#toc">Table of Contents</a></div> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 4%;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Gain on deconsolidation of subsidiary and consolidation of unconsolidated entity </div></div></div></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 84%; font-family: &quot;Times New Roman&quot;; font-size: 8pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="font-size: 0px;">
<td style="width: 63%;"></td>
<td style="width: 4%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td>
<td style="width: 4%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td>
<td style="width: 4%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;&#160;</td>
<td colspan="6" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Years Ended March&#160;31,</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2021</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2020</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Change</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td colspan="10" style="vertical-align: bottom;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(in thousands)</div></div></td>
<td style="vertical-align: bottom;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Gain on deconsolidation of subsidiary and consolidation of unconsolidated entity</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(115,364</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(107,344</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(8,020</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Gain on deconsolidation of subsidiary and consolidation of unconsolidated entity was $115.4&#160;million and $107.3&#160;million for the years ended March&#160;31, 2021 and 2020, respectively. Gain on deconsolidation of subsidiary and consolidation of unconsolidated entity for the year ended March&#160;31, 2021 primarily related to a gain of $86.5&#160;million on the deconsolidation of Datavant in April 2020 and a gain of $28.8&#160;million resulting from the remeasurement of our previously held interest in Genevant upon its consolidation in July 2020. Gain on deconsolidation of subsidiary was $107.3&#160;million for the year ended March&#160;31, 2020 due to the deconsolidation Sio in February 2020. </div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt; margin-left: 4%;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Other expense, net </div></div></div></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 84%; font-family: &quot;Times New Roman&quot;; font-size: 8pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="font-size: 0px;">
<td style="width: 68%;"></td>
<td style="width: 4%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td>
<td style="width: 4%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td>
<td style="width: 4%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;&#160;</td>
<td colspan="6" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Years&#160;Ended&#160;March&#160;31,</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2021</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2020</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Change</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td colspan="10" style="vertical-align: bottom;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">(in thousands)</div></div></div></div></td>
<td style="vertical-align: bottom;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Other expense, net</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">8,701</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">13,622</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(4,921</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Other expense, net was $8.7&#160;million and $13.6&#160;million for the years ended March&#160;31, 2021 and 2020, respectively. The change in other expense, net was primarily driven by reduced losses from our equity method investment in Genevant of $17.6&#160;million incurred through July 2020 until we consolidated Genevant and lower interest expense of $4.9&#160;million, partially offset by lower interest income of $16.6&#160;million for the year ended March&#160;31, 2021 as compared to the year ended March&#160;31, 2020. </div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt; margin-left: 4%;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Income tax expense </div></div></div></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 84%; font-family: &quot;Times New Roman&quot;; font-size: 8pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="font-size: 0px;">
<td style="width: 69%;"></td>
<td style="width: 4%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td>
<td style="width: 4%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td>
<td style="width: 4%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;&#160;</td>
<td colspan="6" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Years&#160;Ended&#160;March&#160;31,</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2021</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2020</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Change</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td colspan="10" style="vertical-align: bottom;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(in thousands)</div></div></td>
<td style="vertical-align: bottom;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Income tax expense</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">1,686</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">7,124</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(5,438</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Income tax expense decreased by $5.4&#160;million to $1.7&#160;million for the year ended March&#160;31, 2021, compared to $7.1&#160;million for the year ended March&#160;31, 2020. Income tax expense was not significant in either period presented and reflects the income tax expense computed in jurisdictions in which we operate. </div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Income from discontinued operations, net of tax </div></div></div></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 84%; font-family: &quot;Times New Roman&quot;; font-size: 8pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="font-size: 0px;">
<td style="width: 63%;"></td>
<td style="width: 4%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td>
<td style="width: 4%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td>
<td style="width: 4%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;&#160;</td>
<td colspan="6" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Years Ended<br/>March&#160;31,</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2021</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2020</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Change</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td colspan="6" style="vertical-align: bottom;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">(in thousands)</div></div></div></div></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Income from discontinued operations, net of tax</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;"></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">1,578,426</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(1,578,426</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Income from discontinued operations, net of tax was $1,578.4&#160;million for the year ended March&#160;31, 2020 and consisted of a $1,985.9&#160;million gain on sale of business resulting from the Sumitomo Transaction, partially offset by the net losses of the entities for which we transferred our entire ownership interest to Sumitomo. Refer to Note 5, &#8220;Sumitomo Transaction Agreement&#8221; of our consolidated financial statements included elsewhere in this prospectus for additional information. </div></div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">116 </div></div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;;font-weight: bold;"><a href="#toc">Table of Contents</a></div> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Liquidity and Capital Resources </div></div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt; margin-left: 2%;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Overview </div></div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">For the three months ended June&#160;30, 2021 and 2020, we incurred net losses of $101.1&#160;million and $8.0&#160;million, respectively. As of June&#160;30, 2021, we had cash and cash equivalents of approximately $2.0&#160;billion and our accumulated deficit was approximately $2.0&#160;billion. We have not generated any revenues to date from the sale of our product candidates. Our revenue, primarily generated through license agreements as well as from subscription and service-based fees, has not been significant to date. Our operations to date have been financed primarily through the sale of equity securities, sale of subsidiary interests, debt financings and revenue generated from licensing and collaboration arrangements. </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">In May 2021, Dermavant and certain of its subsidiaries entered in a $40.0&#160;million senior secured credit facility with XYQ Luxco S.A.R.L (&#8220;XYQ Luxco&#8221;), as lender, and U.S. Bank National Association, as collateral agent. </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">For the years ended March&#160;31, 2021 and 2020, we incurred losses from continuing operations of $900.2&#160;million and $568.1&#160;million, respectively. As of March&#160;31, 2021, we had cash and cash equivalents of approximately $2.1&#160;billion and our accumulated deficit was approximately $1.9&#160;billion. We have not generated any revenues to date from the sale of our product candidates. Our revenue, primarily generated through license agreements as well as from subscription and service-based fees, has not been significant to date. Our operations to date have been financed primarily through the sale of equity securities, sale of subsidiary interests, debt financings and revenue generated from licensing and collaboration arrangements. </div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt; margin-left: 2%;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Sources of Liquidity </div></div></div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt; margin-left: 2%;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;"><div style="text-decoration: underline; letter-spacing: 0px; top: 0px;;display:inline;">Roivant Equity Financing Transactions </div> </div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Since inception, we have completed multiple equity financing transactions, including the following financing transaction completed during the year ended March&#160;31, 2020. </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">In December 2019, in connection with the Sumitomo Transaction, we raised net proceeds of approximately $999.2&#160;million in connection with the sale of our Common Shares to Sumitomo. </div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt; margin-left: 2%;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;"><div style="text-decoration: underline; letter-spacing: 0px; top: 0px;;display:inline;">Sumitomo Transaction </div> </div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">In December 2019, we closed the Sumitomo Transaction, including the transfer of our ownership interest in five Vants &#8211; Myovant Sciences Ltd., Urovant Sciences Ltd., Enzyvant Therapeutics Ltd., Altavant Sciences Ltd., and Spirovant Sciences Ltd. &#8211; to Sumitovant Biopharma Ltd. (&#8220;Sumitovant&#8221;), a wholly-owned subsidiary of Sumitomo. In addition, in connection with the Sumitomo Transaction, we (i)&#160;granted Sumitomo options to purchase all, or in the case of Dermavant, 75%, of our ownership interests in six other subsidiaries (Dermavant, Genevant, Lysovant, Metavant, Cytovant and Sinovant), and (ii)&#160;(a)&#160;transferred the proprietary technology platform DrugOme to Sumitomo (for which Roivant retains a perpetual royalty free license for internal use) and (b)&#160;licensed the Digital Innovation technology platform to Sumitomo (for which both parties retain ongoing access). In exchange for these components of the Sumitomo Transaction, we received approximately $1.9&#160;billion in cash, which was in addition to the $999.2&#160;million from the sale of our Common Shares to Sumitomo as discussed above. </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">In June 2021, we completed a transaction with Sumitomo pursuant to which Sumitomo terminated its existing options to acquire our equity interests in certain of our subsidiaries. </div></div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">117 </div></div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;;font-weight: bold;"><a href="#toc">Table of Contents</a></div> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"> <div style="text-indent: 2%; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;"><div style="text-decoration: underline; letter-spacing: 0px; top: 0px;;display:inline;">Consolidated Vant Equity Financing Transactions </div></div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Since inception, we have completed multiple Vant equity financing transactions, including the following financing transactions completed during the years ended March&#160;31, 2021 and 2020: </div></div> <div style="text-indent: 2%; font-family: Times New Roman; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Immunovant </div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">During the years ended March&#160;31, 2021 and 2020, Immunovant issued shares of common stock for an aggregate net proceeds of $384.9&#160;million (including an aggregate of $27.5&#160;million of shares of common stock purchased by us) in private financings, underwritten public offerings, and warrant exercises. </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Additionally, in December 2019, Immunovant Sciences Ltd. (&#8220;ISL&#8221;) completed a business combination with Health Sciences Acquisition Corporation (&#8220;HSAC&#8221;), a special purpose acquisition company, pursuant to which HSAC acquired 100% of the outstanding shares of ISL (the &#8220;HSAC Transaction&#8221;). Following the HSAC Transaction, ISL became a wholly owned subsidiary of HSAC, which was renamed &#8220;Immunovant, Inc.&#8221; HSAC was treated as the &#8220;acquired&#8221; company for accounting purposes. Immunovant received $111.0&#160;million in cash as a result of the HSAC Transaction, consisting of the funds held in HSAC&#8217;s trust account. The proceeds included $5.1&#160;million related to common shares purchased by us. </div></div> <div style="text-indent: 2%; font-family: Times New Roman; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Proteovant </div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">In December 2020, following Proteovant Sciences, Inc&#8217;s (&#8220;Proteovant&#8221;) acquisition of Oncopia in November 2020, SK, Inc. (formerly known as SK Holdings Co., Ltd.) (&#8220;SK&#8221;) entered into a subscription agreement (the &#8220;SK Subscription Agreement&#8221;) pursuant to which SK agreed to make a $200.0&#160;million equity investment in Proteovant, representing an ownership interest of 40.0% on the closing date. In January 2021, in accordance with the terms of the SK Subscription Agreement, SK made the first payment of $100.0&#160;million to Proteovant. A second $100.0&#160;million payment is expected to be made by SK to Proteovant on or about July&#160;12, 2021, the date six months from the closing date. </div></div> <div style="text-indent: 2%; font-family: Times New Roman; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;"><div style="text-decoration: underline; letter-spacing: 0px; top: 0px;;display:inline;">Consolidated Vant Debt Financings </div></div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Since inception, we have completed multiple Vant debt financings, including the following debt financing completed during the year ended March&#160;31, 2020: </div></div> <div style="text-indent: 2%; font-family: Times New Roman; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Dermavant </div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">In May 2019, Dermavant entered into a loan and security agreement (the &#8220;Hercules Loan Agreement&#8221;) with Hercules, pursuant to which Dermavant borrowed an aggregate of $20.0&#160;million. In May 2021, all amounts outstanding under the Hercules Loan Agreement were repaid using the proceeds from the $40.0&#160;million senior secured credit facility entered into by Dermavant in May 2021, and Dermavant terminated the Hercules Loan Agreement. </div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt; margin-left: 2%;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Funding Requirements </div></div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">We expect to continue to incur significant and increasing operating losses at least for the foreseeable future. We do not expect to generate product revenue until we successfully complete development and obtain regulatory approval for any of our current or future product candidates, which may never occur. Our operating results, including our net losses, may fluctuate significantly from <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">quarter-to-quarter</div></div> and <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">year-to-year,</div></div> depending on the timing of our planned clinical trials, our expenditures on other research and development activities and our <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">pre-commercialization</div> efforts. We anticipate that our expenses will increase substantially as we: </div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 4%;">&#160;</td>
<td style="width: 4%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">fund preclinical studies and clinical trials for our product candidates, which we are pursuing or may choose to pursue in the future; </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">118 </div></div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;;font-weight: bold;"><a href="#toc">Table of Contents</a></div> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;">
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 4%;">&#160;</td>
<td style="width: 4%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">fund the manufacturing of drug substance and drug product of our product candidates in development; </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 4%;">&#160;</td>
<td style="width: 4%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">seek to identify, acquire, develop and commercialize additional product candidates; </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 4%;">&#160;</td>
<td style="width: 4%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">invest in activities related to the discovery of novel drugs and advancement of our internal programs; </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 4%;">&#160;</td>
<td style="width: 4%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">integrate acquired technologies into a comprehensive regulatory and product development strategy; </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 4%;">&#160;</td>
<td style="width: 4%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">maintain, expand and protect our intellectual property portfolio; </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 4%;">&#160;</td>
<td style="width: 4%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">hire scientific, clinical, quality control and administrative personnel; </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 4%;">&#160;</td>
<td style="width: 4%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">add operational, financial and management information systems and personnel, including personnel to support our drug development efforts; </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 4%;">&#160;</td>
<td style="width: 4%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">achieve milestones under our agreements with third parties that will require us to make substantial payments to those parties; </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 4%;">&#160;</td>
<td style="width: 4%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">seek regulatory approvals for any product candidates that successfully complete clinical trials; </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 4%;">&#160;</td>
<td style="width: 4%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">ultimately establish a sales, marketing and distribution infrastructure and scale up external manufacturing capabilities to commercialize any drug candidates for which we may obtain regulatory approval; and </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 4%;">&#160;</td>
<td style="width: 4%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">begin to operate as a public company. </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">We expect to continue to finance our cash needs through a combination of our cash on hand and future equity offerings, debt financings, sales of subsidiaries, and collaborations, strategic alliances or marketing, distribution, licensing or similar arrangements with third parties. To the extent that we raise additional capital through the sale of equity or convertible debt securities, your ownership interest will be diluted, and the terms of these securities may include liquidation or other preferences that adversely affect your rights as a common shareholder. Any agreements for future debt or preferred equity financings, if available, may involve covenants limiting or restricting our ability to take specific actions, such as incurring additional debt, making capital expenditures or declaring dividends. </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">If we raise additional funds through collaborations, strategic alliances or marketing, distribution, licensing or similar arrangements with third parties, we may be required to relinquish valuable rights to our technologies, future revenue streams, research programs or product candidates or to grant licenses on terms that may not be favorable to us. Adequate additional funding may not be available to us on acceptable terms, or at all. If we are unable to raise capital in sufficient amounts or on terms acceptable to us, we may have to significantly delay, scale back or discontinue the development or commercialization of our product candidates, grant rights to develop and market product candidates that we would otherwise prefer to develop and market ourselves or potentially discontinue operations. </div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt; margin-left: 2%;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Cash Flows </div></div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The following table sets forth a summary of our cash flows for the three months ended June&#160;30, 2021 and 2020: </div></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 76%; font-family: &quot;Times New Roman&quot;; font-size: 8pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="font-size: 0px;">
<td style="width: 70%;"></td>
<td style="width: 5%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td>
<td style="width: 5%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;&#160;</td>
<td colspan="6" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Three&#160;Months&#160;Ended&#160;June&#160;30,</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2021</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2020</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td colspan="6" style="vertical-align: bottom;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">(in thousands)</div></div></div></div></td>
<td style="vertical-align: bottom;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Net cash used in operating activities</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(141,170</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(111,167</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Net cash used in investing activities</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(2,339</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(25,641</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Net cash provided by financing activities</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">10,210</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">181,130</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">119 </div></div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;;font-weight: bold;"><a href="#toc">Table of Contents</a></div> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The following table sets forth a summary of our cash flows for the years ended March&#160;31, 2021 and 2020: </div></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 76%; font-family: &quot;Times New Roman&quot;; font-size: 8pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="font-size: 0px;">
<td style="width: 69%;"></td>
<td style="width: 5%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td>
<td style="width: 5%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;&#160;</td>
<td colspan="6" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Years Ended March&#160;31,</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2021</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2020</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td colspan="6" style="vertical-align: bottom;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">(in thousands)</div></div></div></div></td>
<td style="vertical-align: bottom;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Net cash used in operating activities</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(552,138</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(758,750</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Net cash (used in) provided by investing activities</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(31,702</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">1,694,790</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Net cash provided by financing activities</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">456,264</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">214,081</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The cash flows from discontinued operations have not been segregated and are included in the statements of cash flows for the year ended March&#160;31, 2020. Refer to Note 6, &#8220;Discontinued Operations&#8221; of our financial statements included elsewhere in this prospectus for further information regarding our discontinued operations. </div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt; margin-left: 2%;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Operating Activities </div></div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;">Cash flow from operating activities represents the cash receipts and disbursements related to all of our activities other than investing and financing activities. Cash flow from operating activities is derived from adjusting our net loss (income) for <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-cash</div> items and changes in working capital. </div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">For the three months ended June&#160;30, 2021, cash used in operating activities increased by $30.0&#160;million to $141.2&#160;million compared to the three months ended June&#160;30, 2020. This increase was primarily driven by an increase in cash required to fund operations, particularly as a result of recent asset acquisitions including SiTX in March 2021, Oncopia in November 2020, Affimed in November 2020, and Genevant in July 2020. </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">For the year ended March&#160;31, 2021, cash used in operating activities decreased by $206.6&#160;million to $552.1&#160;million compared to the year ended March&#160;31, 2020. This decrease was primarily driven by the reduction in cash required to fund the operations of Vants sold to Sumitomo in December 2019, partially offset by an increase in upfront cash consideration for IPR&amp;D relating to asset acquisitions and license agreements. </div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt; margin-left: 2%;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Investing Activities </div></div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Cash flow from investing activities includes cash used for acquisitions, net of cash acquired; cash provided by dispositions, net of cash disposed; capital expenditures; and purchases of equity securities and other investments. Cash flow from investing activities also includes cash provided by sale of business. </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">For the three months ended June&#160;30, 2021, cash used in investing activities decreased by $23.3&#160;million to $2.3&#160;million compared to the three months ended June&#160;30, 2020. This decrease in cash used in investing activities is primarily attributed to cash disposed upon deconsolidation of Datavant in April 2020 and investments made in unconsolidated entities during the three months ended June&#160;30, 2020. </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">For the year ended March&#160;31, 2021, cash flow from investing activities changed by $1,726.5&#160;million to net cash used in investing activities of $31.7&#160;million from net cash provided by investing activities of $1,694.8&#160;million for the year ended March&#160;31, 2020. This change in cash flow from investing activities is primarily attributed to proceeds from the sale of business, net of cash disposed, in December 2019, resulting from the Sumitomo Transaction. </div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt; margin-left: 2%;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Financing Activities </div></div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">For the three months ended June&#160;30, 2021, cash provided by financing activities decreased by $170.9&#160;million to $10.2&#160;million compared to the three months ended June&#160;30, 2020. This change was primarily driven by net proceeds from the issuance of equity at our majority-owned subsidiary Immunovant, Inc. during the three months ended June&#160;30, 2020. During the three months ended June&#160;30, 2021, proceeds were generated by the </div></div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">120 </div></div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;;font-weight: bold;"><a href="#toc" style="text-indent: 0px;">Table of Contents</a></div> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">senior secured credit facility entered into by Dermavant and certain of its subsidiaries with XYQ Luxco, as lender, and U.S. Bank National Association, as collateral agent, partially offset by cash used to repay all amounts outstanding under a previously existing loan and security agreement with Hercules Capital, Inc. </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">For the year ended March&#160;31, 2021, cash provided by financing activities increased by $242.2&#160;million to $456.3&#160;million compared to the year ended March&#160;31, 2020. This change was primarily driven by higher net proceeds from the issuance of subsidiary equity, resulting from the issuance of Immunovant common stock upon completing two underwritten public offerings and warrant exercises and the issuance of Proteovant common stock to SK, during the year ended March&#160;31, 2021 as compared to net proceeds from the issuance of subsidiary equity during the year ended March&#160;31, 2020. During the year ended March&#160;31, 2020, proceeds were also generated from the issuance of our Common Shares and the Sumitomo Options pursuant to the Sumitomo Transaction as well as from subsidiary debt financings. However, these proceeds were largely offset by cash used to repurchase certain of our Common Shares and equity awards along with cash used to purchase subsidiary equity and repay certain subsidiary long-term debt and convertible debt during the year ended March&#160;31, 2020. </div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt; margin-left: 2%;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Outlook </div></div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">We expect our existing cash and cash equivalents will be sufficient to fund our committed operating expenses and capital expenditure requirements for at least the next twelve months based on current operating plans and financial forecasts. However, we have based this estimate on assumptions that may prove to be wrong, which may require us to use our capital resources sooner than expected. See &#8220;Cautionary Note Regarding Forward-Looking Statements&#8221; and &#8220;Risk Factors&#8221; in this prospectus. </div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Contractual Obligations and Commitments </div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">We have certain payment obligations under various asset acquisition and license agreements. Under these agreements we are required to make milestone payments upon successful completion and achievement of certain development, regulatory and commercial milestones. The payment obligations under the asset acquisition and license agreements are contingent upon future events such as our achievement of specified development, regulatory and commercial milestones, and we will be required to make milestone payments and royalty payments in connection with the sale of products developed under these agreements. The achievement and timing of these future milestone payments are not probable or reasonably estimable, and therefore such amounts have not been included on our consolidated balance sheet as of June&#160;30, 2021. </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">We enter into agreements in the normal course of business with CROs and other vendors for clinical trials and with vendors for preclinical studies and other services and products for operating purposes, which are generally cancelable upon written notice. </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Our contractual obligations also include operating lease liabilities, primarily relating to real estate leases. Refer to Note 13, &#8220;Leases&#8221; of our audited financial statements included elsewhere in this prospectus for further information regarding our leases. </div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt; margin-left: 2%;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Loan and Security Agreement between Dermavant and Hercules </div></div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">In May 2019, Dermavant entered into the Hercules Loan Agreement with Hercules as agent and lender, under which Dermavant, borrowed an aggregate of $20.0&#160;million (the &#8220;2019 Term Loan&#8221;). The 2019 Term Loan was fully drawn in May 2019. In May 2021, Dermavant repaid all amounts outstanding under the Hercules Loan Agreement using the proceeds from the $40.0&#160;million Credit Facility entered into by Dermavant and certain of its subsidiaries in May 2021, and Dermavant terminated the Hercules Loan Agreement. See &#8220;Dermavant Senior Secured Credit Facility&#8221; below for additional information. </div></div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">121 </div></div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;;font-weight: bold;"><a href="#toc">Table of Contents</a></div> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 2%;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Funding Agreement between Dermavant and NovaQuest </div></div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;">In July 2018, as a result of Dermavant&#8217;s acquisition of tapinarof from GlaxoSmithKline Intellectual Property Development Ltd. and Glaxo Group Limited (collectively &#8220;GSK&#8221;), Dermavant entered into the NovaQuest Facility, pursuant to which Dermavant is required to make milestone and other quarterly interest payments to NovaQuest <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">Co-Investment</div> Fund VIII, L.P. (&#8220;NovaQuest&#8221;) upon the achievement of certain regulatory and commercial milestones for tapinarof in either psoriasis or atopic dermatitis in the United States, the European Union and Japan. These obligations terminate upon marketing approval revocation or withdrawal of tapinarof for health and safety reasons by either (x)&#160;the U.S. Food and Drug Administration (the &#8220;FDA&#8221;) or (y)&#160;Dermavant, Dermavant&#8217;s affiliates, or any sublicensee. The aggregate maximum amount of regulatory milestone payments Dermavant could be required to make under the NovaQuest Facility is $440.6&#160;million and the maximum aggregate amount of commercial milestone payments Dermavant could be required to make under the NovaQuest Facility is $141.0&#160;million. In some circumstances, Dermavant may be able to offset certain of the regulatory milestone payments with up to $88.1&#160;million of the commercial milestone payments. Dermavant is also required to make significant payments to NovaQuest if development of tapinarof is terminated or if Dermavant terminates development of tapinarof for one indication and receives approval for the other. NovaQuest is not obligated to refund to Dermavant any payments previously made under the NovaQuest Facility. </div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt; margin-left: 2%;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Dermavant Senior Secured Credit Facility </div></div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">In May 2021, DSL, Dermavant Holdings Limited, Dermavant Sciences IRL Limited and DSG, as borrowers and certain other subsidiaries of DSL, as initial guarantors, entered into a $40.0&#160;million senior secured credit facility (the &#8220;Credit Facility&#8221;) with XYQ Luxco, as lender, and U.S. Bank National Association, as collateral agent. The Credit Facility has a five-year maturity and bears an interest rate of 10.0% per annum. Interest is payable quarterly in arrears on the last day of each calendar quarter through the maturity date. A lump sum principal payment is due on the maturity date. </div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt; margin-left: 2%;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Acquisition of Silicon Therapeutics </div></div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">In March 2021, we completed the acquisition of the business of SiTX for consideration of approximately $450.0&#160;million, with additional cash payments payable subject to the satisfaction of certain regulatory and commercial milestones. A remaining balance of approximately $100.0&#160;million is payable to former SiTX equity holders on the earlier of (x)&#160;approximately 30 to 60 days following the public listing of our Common Shares, in either cash or our Common Shares (at our election), and (y) 12 months following the closing of the acquisition, in cash. For accounting purposes, the fair value of consideration transferred was $402.4&#160;million. </div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt; margin-left: 2%;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Palantir Master Subscription Agreement </div></div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">In May 2021, we entered into a master subscription agreement with Palantir Technologies Inc. (&#8220;Palantir&#8221;) for access to Palantir&#8217;s proprietary software for a five-year period. The remaining minimum payments for this software subscription are $39.0&#160;million. </div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">Off-Balance</div> Sheet Arrangements </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;">We did not have any material <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">off-balance</div> sheet arrangements, as defined under SEC rules, during the periods presented. </div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Critical Accounting Policies and Significant Judgments and Estimates </div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Our management&#8217;s discussion and analysis of our financial condition and results of operations is based on our financial statements, which have been prepared in accordance with U.S. generally accepted accounting principles (&#8220;U.S. GAAP&#8221;). The preparation of these financial statements requires us to make estimates, </div></div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">122 </div></div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;;font-weight: bold;"><a href="#toc">Table of Contents</a></div> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">judgments and assumptions that affect the reported amounts of assets and liabilities, and disclosures of contingencies as of the dates of the financial statements, and the reported amounts of revenues and expenses during the reporting periods. In accordance with U.S. GAAP, we evaluate our estimates and judgments on an ongoing basis. We base our estimates on historical experience and on various other factors that we believe are reasonable under the circumstances, the results of which form the basis for making judgments about the carrying value of assets and liabilities that are not readily apparent from other sources. Actual results may differ from these estimates under different assumptions or conditions. On an ongoing basis, we evaluate our judgments and estimates in light of changes in circumstances, facts, or experience. Changes in estimates and assumptions are reflected in reported results in the period in which they become known. Any references to applicable accounting guidance is meant to refer to the authoritative U.S. GAAP as found in the Accounting Standards Codification (the &#8220;ASC&#8221;), and Accounting Standards Updates (&#8220;ASU&#8221;), issued by the Financial Accounting Standards Board (the &#8220;FASB&#8221;). The consolidated financial statements include the accounts of Roivant and our subsidiaries in which we have a controlling financial interest, most often through a majority voting interest. </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">We define our critical accounting policies as those under U.S. GAAP that require us to make subjective estimates and judgments about matters that are uncertain and are likely to have a material impact on our financial condition and results of operations, as well as the specific manner in which we apply those principles. </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">While our significant accounting policies are described in more detail in Note 2, &#8220;Summary of Significant Accounting Policies&#8221; in our consolidated financial statements included elsewhere in this prospectus, we believe that the following accounting policies are those most critical to the judgments and estimates used in the preparation of our financial statements. </div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt; margin-left: 2%;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Research and Development Expenses </div></div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Research and development expenses consist primarily of costs incurred in connection with the discovery and development of our product candidates. We expense research and development costs as incurred. </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">We accrue expense for preclinical studies and clinical trial activities performed by vendors based upon estimates of the proportion of work completed. We determine such estimates by reviewing contracts, vendor agreements and purchase orders, and through discussions with our internal personnel and external service providers as to the progress or stage of completion and the agreed-upon fee to be paid for such services. However, actual costs and timing of preclinical studies and clinical trials are highly uncertain, subject to risks, and may change depending upon a number of factors, including our clinical development plan. </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">We make estimates of our accrued expenses as of each balance sheet date in our financial statements based on facts and circumstances known at that time. If the actual timing of the performance of services or the level of effort varies from the estimate, the accrual is adjusted accordingly. Nonrefundable advance payments for goods and services are deferred and recognized as expense in the period that the related goods are consumed or services are performed. </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">We evaluate license agreements and asset acquisitions for IPR&amp;D projects to determine if it meets the definition of a business and thus should be accounted for as a business combination. If the IPR&amp;D does not meet the definition of a business and the assets have not reached technological feasibility and therefore have no alternative future use, we expense payments made under such license agreements as research and development expense. </div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt; margin-left: 2%;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Share-Based Compensation </div></div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">We recognize compensation costs related to share-based awards granted to employees, directors, and consultants based on the estimated fair value of the awards on the date of grant. The grant date fair value of the stock-based awards is recognized over the requisite service period, which is generally the vesting period of the </div></div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">123 </div></div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;;font-weight: bold;"><a href="#toc">Table of Contents</a></div> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">respective awards. We may grant awards with graded-vesting features. When such awards have only service vesting requirements, we elected to record share-based compensation expense on a straight-line basis. If awards with graded-vesting features contain performance or market conditions, then we record share-based compensation expense using the accelerated attribution method. </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">We estimate the fair value of stock options using the Black-Scholes option-pricing model, which requires assumptions, including the fair value of our Common Shares prior to our initial public offering, volatility, the expected term of our stock options, the risk-free interest rate for a period that approximates the expected term of our stock options, and our expected dividend yield. Certain assumptions used in our Black-Scholes option-pricing model represent management&#8217;s best estimates and involve a number of variables, uncertainties and assumptions and the application of management&#8217;s judgment, as they are inherently subjective. If any assumptions change, our stock-based compensation expense could be materially different in the future. </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">These subjective assumptions are estimated as follows: </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Fair value of common share</div></div>&#8212;As a privately held company, we estimate the fair value of the shares of common stock underlying our share-based awards on each grant date. To determine the fair value of our Common Shares underlying option grants, we considered, among other things, valuations of our common share prepared by an unrelated third-party valuation firm in accordance with the guidance provided by the American Institute of Certified Public Accountants Practice Guide, Valuation of Privately-Held-Company Equity Securities Issued as Compensation. The estimation of the fair value of the Common Shares considered factors including the following: </div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">the prices of our Common Shares sold to investors in arm&#8217;s length transactions; </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">the estimated present value of our future cash flows; </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">our business, financial condition and results of operations; </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">our forecasted operating performance; </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">the illiquid nature of our Common Shares; </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">industry information such as market size and growth; </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">market capitalization of comparable companies and the estimated value of transactions such companies have engaged in; and </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">macroeconomic conditions. </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">We apply similar methodology to estimate the fair value of the shares of common stock underlying share-based awards at our privately held Vants. Now that our Common Shares are publicly traded, we will determine the fair value of each common share underlying share-based awards based on the closing price of our Common Shares as reported by the Nasdaq on the date of grant and therefore it will not be necessary to determine the fair value of the new stock-based award pursuant to the methodology described above. </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Expected term</div></div>&#8212;We have generally elected to use the &#8220;simplified method&#8221; for estimating the expected term of options, whereby the expected term equals the arithmetic average of the vesting term and the original contractual term of the option (generally 10 years). </div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Expected volatility</div></div>&#8212;As a privately held company, we do not have any trading history for our common share; accordingly, the expected volatility was estimated based on the average volatility for comparable publicly traded biotechnology companies over a period equal to the expected term of the stock option grants. The comparable companies were chosen based on their similar size, stage in the life cycle or area of specialty. We apply similar methodology to estimate the expected volatility at our privately held Vants. </div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Risk-free interest rate</div></div>&#8212;The risk-free rate assumption is based on the U.S. Treasury instruments with maturities similar to the expected term of our stock options at the time of the grant. </div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">124 </div></div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;;font-weight: bold;"><a href="#toc">Table of Contents</a></div> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Expected dividend yield</div></div>&#8212;We have not issued any dividends in our history and do not expect to issue dividends over the life of the options; therefore, we have estimated the dividend yield to be zero. </div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Recently Adopted Accounting Pronouncements </div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">A description of recently issued accounting pronouncements that may potentially impact our financial position and results of operations is disclosed in Note 2, &#8220;Summary of Significant Accounting Policies&#8221; in our consolidated financial statements included elsewhere in this prospectus. </div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">JOBS Act </div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">In April 2012, the Jumpstart Our Business Startups Act of 2012 (the &#8220;JOBS Act&#8221;) was enacted. Section&#160;107(b) of the JOBS Act provides that an emerging growth company can take advantage of an extended transition period for complying with new or revised accounting standards. Thus, an emerging growth company can delay the adoption of certain accounting standards until those standards would otherwise apply to private companies. We have elected not to avail ourselves of this extended transition period, and, as a result, we will adopt new or revised accounting standards on the relevant dates on which adoption of such standards is required for other public companies. </div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Quantitative and Qualitative Disclosures about Market Risk </div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Under SEC rules and regulations, because we are considered to be a &#8220;smaller reporting company,&#8221; we are not required to provide the information required by this item in this report. </div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Implications of Being an Emerging Growth Company and Smaller Reporting Company </div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">We are an &#8220;emerging growth company&#8221; within the meaning of the JOBS Act. As an emerging growth company, we may take advantage of certain exemptions from various public company reporting requirements, including the requirement that our internal control over financial reporting be audited by our independent registered public accounting firm pursuant to Section&#160;404 of the Sarbanes-Oxley Act, certain requirements related to the disclosure of executive compensation in this prospectus and in our periodic reports and proxy statements, and the requirement that we hold a nonbinding advisory vote on executive compensation and any golden parachute payments. We have also taken advantage of the ability to provide reduced disclosure of financial information in this prospectus, such as being permitted to include only two years of audited financial information and two years of selected financial information in addition to any required unaudited interim financial statements, with correspondingly reduced &#8220;Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations&#8221; disclosure. We may take advantage of these exemptions until we are no longer an emerging growth company. Section&#160;107 of the JOBS Act provides that an &#8220;emerging growth company&#8221; can take advantage of the extended transition period provided in Section&#160;7(a)(2)(B) of the Securities Act, for complying with new or revised accounting standards. In other words, an &#8220;emerging growth company&#8221; can delay the adoption of certain accounting standards until those standards would otherwise apply to private companies. We have elected not to avail ourselves of this extended transition period, and, as a result, we will adopt new or revised accounting standards on the relevant dates on which adoption of such standards is required for other public companies. However, because we have taken advantage of certain reduced reporting requirements, the information contained herein may be different from the information you receive from other public companies in which you hold shares. </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">We will remain an emerging growth company until the earlier of (1)&#160;the last day of the fiscal year (a)&#160;following the fifth anniversary of the date of the first sale of Roivant Common Shares pursuant to an effective registration statement or (b)&#160;in which we have total annual gross revenue of at least $1.07&#160;billion (as adjusted for inflation pursuant to SEC rules from time to time), and (2)&#160;the date on which (x)&#160;we are deemed to be a large accelerated filer, which means the market value of Roivant Common Shares that are held by <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-affiliates</div> exceeds $700&#160;million as of the prior September 30th, or (y)&#160;the date on which we have issued more than $1.0&#160;billion in nonconvertible debt during the prior three-year period. </div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">125 </div></div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;;font-weight: bold;"><a href="#toc">Table of Contents</a></div> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Additionally, we are a &#8220;smaller reporting company&#8221; as defined in Item 10(f)(1) of Regulation <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">S-K.</div> Smaller reporting companies may take advantage of certain reduced disclosure obligations, including, among other things, providing only two years of audited financial statements. We will remain a smaller reporting company until the last day of the fiscal year in which (i)&#160;the market value of our Common Shares held by <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-affiliates</div> exceeds $250&#160;million as of the end of that year&#8217;s second fiscal quarter, or (ii)&#160;our annual revenues exceeded $100&#160;million during such completed fiscal year and the market value of our Common Shares held by <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-affiliates</div> exceeds $700&#160;million as of the end of that year&#8217;s second fiscal quarter. To the extent we take advantage of such reduced disclosure obligations, it may also make comparison of our financial statements with other public companies more difficult. </div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">126 </div></div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;;font-weight: bold;"><a href="#toc">Table of Contents</a></div> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"> <div id="rom164680_11" style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">BUSINESS </div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">References to &#8220;Roivant,&#8221; &#8220;the Company,&#8221; &#8220;we,&#8221; &#8220;us&#8221; or &#8220;our&#8221; in the following section refer to Roivant Sciences Ltd. and its subsidiaries, unless the context otherwise requires. </div></div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Overview </div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">We are building the next-generation &#8220;big pharma&#8221; company, organized to harness modern technologies and the entrepreneurial spirit of nimble biotechnology companies at scale. Our mission is to improve the delivery of healthcare to patients by treating every inefficiency as an opportunity. </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">We are a diverse team of experienced drug developers, scientists, physicians, company builders, data scientists and engineers, biopharma investors, physicists and business development professionals dedicated to improving the lives of patients. At Roivant, we combine our team&#8217;s extensive experience and multi-disciplinary expertise with innovative technologies to identify and advance potentially transformative medicines. </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">We deploy a hypothesis-driven approach to identify novel or clinically-validated targets and biological pathways in areas of high unmet medical need. We then seek to acquire, <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">in-license</div> or discover promising drug candidates against those targets or pathways. Our small molecule discovery engine is powered by a unique combination of leading computational physics and machine learning (&#8220;ML&#8221;) capabilities for <div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">in silico</div></div> drug design. </div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">We develop drug candidates in subsidiary companies we call &#8220;Vants&#8221; with a distinct approach to sourcing talent, aligning incentives and deploying technology. Each of our Vant teams is built with deep relevant expertise to promote successful execution of our development strategy. Our Vants continue to benefit from the support of the Roivant platform and technologies that are built to address inefficiencies in the drug discovery, development and commercialization process. </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Our agile Vant model has allowed us to rapidly add capabilities in diverse therapeutic areas, including immunology, dermatology, hematology and oncology, and modalities, including biologics, topicals, gene therapies and bifunctional small molecules. We currently have 14 Vants and, together, we are advancing a deep and diversified pipeline of over 30 drug candidates. We have launched and taken public multiple Vants, resulting in an aggregate ownership stake of approximately $940&#160;million in the Public Vants (inclusive of the value of the Myovant Top-Up Shares) as of September&#160;30, 2021. The Vant model also enables a modular approach to the monetization of therapies we advance through development, allowing us to pursue commercialization of some products independently, while selectively establishing partnerships for other Vants or divesting of the Vants entirely. </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Since our founding in 2014, we have: </div></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 13%;">&#160;</td>
<td style="width: 4%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 2%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">conducted nine international Phase 3 trials, the last eight of which have been successful; </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 13%;">&#160;</td>
<td style="width: 4%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 2%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">consummated a $3&#160;billion upfront partnership with Sumitomo (see &#8220;&#8212;Platform Recognition&#8221;); </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 13%;">&#160;</td>
<td style="width: 4%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 2%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">developed four drugs that received FDA approval after their transfer to Sumitomo; </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 13%;">&#160;</td>
<td style="width: 4%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 2%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">built a pipeline of over 30 drug candidates ranging from early discovery to registration; </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 13%;">&#160;</td>
<td style="width: 4%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 2%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;">launched Roivant Discovery, our small molecule discovery engine, consisting of a collection of advanced computational physics capabilities, integrated with an <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">in-house</div> wet lab facility; and </div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 13%;">&#160;</td>
<td style="width: 4%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 2%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">created innovative software tools to optimize each stage of the drug discovery, development and commercialization process. </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">127 </div></div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;;font-weight: bold;"><a href="#toc">Table of Contents</a></div> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Today, we have 14 Vants. We plan to create additional Vants based on the outputs of the Roivant platform, including our <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">in-licensing</div> efforts and our small molecule discovery engine, Roivant Discovery. The following table summarizes our Vants: </div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 8pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="font-size: 0px;">
<td style="width: 8%;"></td>
<td style="width: 1%; vertical-align: bottom;"></td>
<td></td>
<td style="width: 1%; vertical-align: bottom;"></td>
<td></td>
<td style="width: 1%; vertical-align: bottom;"></td>
<td style="width: 14%;"></td>
<td style="width: 1%; vertical-align: bottom;"></td>
<td style="width: 19%;"></td>
<td style="width: 1%; vertical-align: bottom;"></td>
<td style="width: 7%;"></td>
<td style="width: 1%; vertical-align: bottom;"></td>
<td style="width: 16%;"></td>
<td style="width: 1%; vertical-align: bottom;"></td>
<td style="width: 25%;"></td> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;&#160;</td>
<td colspan="3" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Roivant<br/>Ownership at</div></div><br/><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">June&#160;30, 2021</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; white-space: nowrap; padding-bottom: 1pt;"> <div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt; border-bottom: 1pt solid rgb(0, 0, 0); display: table-cell; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">Vant</div></div></div> </td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;&#160;</td>
<td style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Basic</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;&#160;</td>
<td style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Diluted</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 1pt; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">Description</div></div></div> </td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 1pt; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">Lead&#160;Program&#160;/&#160;Mechanism</div></div></div> </td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 1pt; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">Modality</div></div></div> </td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 1pt; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">Indication(s)&#160;/Phase</div></div></div> </td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 1pt; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">Upcoming&#160;Milestones</div></div></div> </td> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: top;">Dermavant</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: top;">100%</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: top;">84%</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: top;">Developing treatments for unmet needs in immuno-dermatology</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: top;">Tapinarof / Therapeutic aryl hydrocarbon receptor modulating agent</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: top;">Topical</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: top;"> <div style="text-indent: -1.5em; font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 2em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#8226;&#8195;&#8202;Psoriasis&#160;/Registration</div></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 1pt; margin-left: 2em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">Atopic dermatitis / Phase&#160;3</div></div> </td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: top;"> <div style="text-indent: -1.5em; font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 2em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#8226;&#8195;&#8202;Q2 &#8216;22: FDA approval decision on Tapinarof for psoriasis</div></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 1pt; margin-left: 2em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">1H &#8216;23: Topline Phase 3 data in atopic dermatitis</div></div> </td> </tr>
<tr style="font-size: 1pt;">
<td style="height: 6pt; font-family: &quot;Times New Roman&quot;;"></td>
<td colspan="2" style="height: 6pt; font-family: &quot;Times New Roman&quot;;"></td>
<td colspan="2" style="height: 6pt; font-family: &quot;Times New Roman&quot;;"></td>
<td colspan="2" style="height: 6pt; font-family: &quot;Times New Roman&quot;;"></td>
<td colspan="2" style="height: 6pt; font-family: &quot;Times New Roman&quot;;"></td>
<td colspan="2" style="height: 6pt; font-family: &quot;Times New Roman&quot;;"></td>
<td colspan="2" style="height: 6pt; font-family: &quot;Times New Roman&quot;;"></td>
<td colspan="2" style="height: 6pt; font-family: &quot;Times New Roman&quot;;"></td> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: top;">Immunovant</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: top;">58%*</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: top;">53%*</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: top;">Developing an anti-FcRn monoclonal antibody for <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">IgG-mediated</div> autoimmune diseases</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: top;">IMVT-1401 / Anti-FcRn monoclonal antibody</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: top;">Biologic</td>
<td rowspan="2" style="vertical-align: bottom;">&#160;</td>
<td rowspan="2" style="vertical-align: top;"> <div style="text-indent: -1.5em; font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 2em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#8226;&#8195;&#8202;Myasthenia gravis, thyroid eye disease, and warm autoimmune hemolytic anemia / Phase&#160;2</div></div> </td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: top;"> <div style="text-indent: -1.5em; font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 2em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#8226;&#8195;&#8202;Early 2022: Initiate pivotal trial in MG</div></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-indent: -1.5em; font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 1pt; margin-left: 2em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#8226;&#8195;&#8202;TBA: Reinitiate program in TED</div></div> </td> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: top; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: top; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: top; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: top; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: top; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: top; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: top;"> <div style="text-indent: -1.5em; font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 2em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#8226;&#8195;&#8202;TBA: Reinitiate program in WAIHA</div></div> </td> </tr>
<tr style="font-size: 1pt;">
<td style="height: 6pt; font-family: &quot;Times New Roman&quot;;"></td>
<td colspan="2" style="height: 6pt; font-family: &quot;Times New Roman&quot;;"></td>
<td colspan="2" style="height: 6pt; font-family: &quot;Times New Roman&quot;;"></td>
<td colspan="2" style="height: 6pt; font-family: &quot;Times New Roman&quot;;"></td>
<td colspan="2" style="height: 6pt; font-family: &quot;Times New Roman&quot;;"></td>
<td colspan="2" style="height: 6pt; font-family: &quot;Times New Roman&quot;;"></td>
<td colspan="2" style="height: 6pt; font-family: &quot;Times New Roman&quot;;"></td>
<td colspan="2" style="height: 6pt; font-family: &quot;Times New Roman&quot;;"></td> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: top; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: top; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: top; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: top; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: top; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: top; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: top; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: top;"> <div style="text-indent: -1.5em; font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 2em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#8226;&#8195;&#8202;2H &#8216;22: Announce at least two new indications for IMVT-1401 </div></div> </td> </tr>
<tr style="font-size: 1pt;">
<td style="height: 6pt; font-family: &quot;Times New Roman&quot;;"></td>
<td colspan="2" style="height: 6pt; font-family: &quot;Times New Roman&quot;;"></td>
<td colspan="2" style="height: 6pt; font-family: &quot;Times New Roman&quot;;"></td>
<td colspan="2" style="height: 6pt; font-family: &quot;Times New Roman&quot;;"></td>
<td colspan="2" style="height: 6pt; font-family: &quot;Times New Roman&quot;;"></td>
<td colspan="2" style="height: 6pt; font-family: &quot;Times New Roman&quot;;"></td>
<td colspan="2" style="height: 6pt; font-family: &quot;Times New Roman&quot;;"></td>
<td colspan="2" style="height: 6pt; font-family: &quot;Times New Roman&quot;;"></td> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: top;">Aruvant</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: top;">88%</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: top;">79%</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: top;">Developing transformative gene therapies for severe blood disorders</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: top;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">ARU-1801</div> / Ex vivo lentiviral gene therapy delivering a novel, highly potent variant of fetal hemoglobin (HbF)</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: top;">Gene&#160;therapy</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: top;"> <div style="text-indent: -1.5em; font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 2em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#8226;&#8195;&#8202;Sickle cell disease / Phase 1/2</div></div> </td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: top;"> <div style="text-indent: -1.5em; font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 2em; line-height: normal;">&#8226;&#8195;&#8202;2H &#8216;21: Ongoing new patient and follow up data from additional <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">ARU-1801</div> Phase 1/2 patients</div> </td> </tr>
<tr style="font-size: 1pt;">
<td style="height: 6pt; font-family: &quot;Times New Roman&quot;;"></td>
<td colspan="2" style="height: 6pt; font-family: &quot;Times New Roman&quot;;"></td>
<td colspan="2" style="height: 6pt; font-family: &quot;Times New Roman&quot;;"></td>
<td colspan="2" style="height: 6pt; font-family: &quot;Times New Roman&quot;;"></td>
<td colspan="2" style="height: 6pt; font-family: &quot;Times New Roman&quot;;"></td>
<td colspan="2" style="height: 6pt; font-family: &quot;Times New Roman&quot;;"></td>
<td colspan="2" style="height: 6pt; font-family: &quot;Times New Roman&quot;;"></td>
<td colspan="2" style="height: 6pt; font-family: &quot;Times New Roman&quot;;"></td> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: top; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: top; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: top; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: top; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: top; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: top; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: top; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: top;"> <div style="text-indent: -1.5em; font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 2em; line-height: normal;">&#8226;&#8195;&#8202;1H &#8216;23: <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">ARU-1801</div> Phase 3 initiation</div> </td> </tr>
<tr style="font-size: 1pt;">
<td style="height: 6pt; font-family: &quot;Times New Roman&quot;;"></td>
<td colspan="2" style="height: 6pt; font-family: &quot;Times New Roman&quot;;"></td>
<td colspan="2" style="height: 6pt; font-family: &quot;Times New Roman&quot;;"></td>
<td colspan="2" style="height: 6pt; font-family: &quot;Times New Roman&quot;;"></td>
<td colspan="2" style="height: 6pt; font-family: &quot;Times New Roman&quot;;"></td>
<td colspan="2" style="height: 6pt; font-family: &quot;Times New Roman&quot;;"></td>
<td colspan="2" style="height: 6pt; font-family: &quot;Times New Roman&quot;;"></td>
<td colspan="2" style="height: 6pt; font-family: &quot;Times New Roman&quot;;"></td> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: top;">Proteovant</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: top;">60%</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: top;">60%</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: top;">Developing heterobifunctional protein degraders for oncology, neurology, and immunology, with exclusive access to VantAI</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: top;">AR Degrader</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: top;">Small Molecule</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: top;"> <div style="text-indent: -1.5em; font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 2em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#8226;&#8195;&#8202;Prostate cancer / Preclinical</div></div> </td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: top;"> <div style="text-indent: -1.5em; font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 2em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#8226;&#8195;&#8202;2022: AR degrader Phase 1 initiation</div></div> </td> </tr>
<tr style="font-size: 1pt;">
<td style="height: 6pt; font-family: &quot;Times New Roman&quot;;"></td>
<td colspan="2" style="height: 6pt; font-family: &quot;Times New Roman&quot;;"></td>
<td colspan="2" style="height: 6pt; font-family: &quot;Times New Roman&quot;;"></td>
<td colspan="2" style="height: 6pt; font-family: &quot;Times New Roman&quot;;"></td>
<td colspan="2" style="height: 6pt; font-family: &quot;Times New Roman&quot;;"></td>
<td colspan="2" style="height: 6pt; font-family: &quot;Times New Roman&quot;;"></td>
<td colspan="2" style="height: 6pt; font-family: &quot;Times New Roman&quot;;"></td>
<td colspan="2" style="height: 6pt; font-family: &quot;Times New Roman&quot;;"></td> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: top;">Lysovant</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: top;">100%</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: top;">99%</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: top;">Developing a novel endolysin for <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">hard-to-treat</div></div> Staph aureus infection</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: top;">LSVT-1701 / Endolysin</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: top;">Biologic</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: top;"> <div style="text-indent: -1.5em; font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 2em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#8226;&#8195;&#8202;Staph aureus bacteremia and infective endocarditis / Phase 1</div></div> </td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: top;"> <div style="text-indent: -1.5em; font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 2em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#8226;&#8195;&#8202;1H &#8216;22: LSVT-1701 MAD initiation</div></div> </td> </tr>
<tr style="font-size: 1pt;">
<td style="height: 6pt; font-family: &quot;Times New Roman&quot;;"></td>
<td colspan="2" style="height: 6pt; font-family: &quot;Times New Roman&quot;;"></td>
<td colspan="2" style="height: 6pt; font-family: &quot;Times New Roman&quot;;"></td>
<td colspan="2" style="height: 6pt; font-family: &quot;Times New Roman&quot;;"></td>
<td colspan="2" style="height: 6pt; font-family: &quot;Times New Roman&quot;;"></td>
<td colspan="2" style="height: 6pt; font-family: &quot;Times New Roman&quot;;"></td>
<td colspan="2" style="height: 6pt; font-family: &quot;Times New Roman&quot;;"></td>
<td colspan="2" style="height: 6pt; font-family: &quot;Times New Roman&quot;;"></td> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: top; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: top;">88% </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: top;">88%</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: top;">Developing an <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">anti-GM-CSF</div></div> monoclonal antibody for autoimmune diseases</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: top;">Namilumab / <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">Anti-GM-CSF</div></div> monoclonal antibody </td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: top;">Biologic </td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: top;"> <div style="text-indent: -1.5em; font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 2em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#8226;&#8195;&#8202;Sarcoidosis / Phase 1 </div></div> </td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: top;"> <div style="text-indent: -1.5em; font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 2em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#8226;&#8195;&#8202;1H &#8216;22: Namilumab Phase 2 initiation</div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">128 </div></div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;;font-weight: bold;"><a href="#toc">Table of Contents</a></div> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;">
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 8pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="font-size: 0px;">
<td style="width: 8%;"></td>
<td style="width: 1%; vertical-align: bottom;"></td>
<td></td>
<td style="width: 1%; vertical-align: bottom;"></td>
<td></td>
<td style="width: 1%; vertical-align: bottom;"></td>
<td style="width: 14%;"></td>
<td style="width: 1%; vertical-align: bottom;"></td>
<td style="width: 19%;"></td>
<td style="width: 1%; vertical-align: bottom;"></td>
<td style="width: 5%;"></td>
<td style="width: 1%; vertical-align: bottom;"></td>
<td style="width: 16%;"></td>
<td style="width: 1%; vertical-align: bottom;"></td>
<td style="width: 25%;"></td> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;&#160;</td>
<td colspan="3" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Roivant<br/>Ownership at</div></div><br/><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">June&#160;30, 2021</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; white-space: nowrap; padding-bottom: 1pt;"> <div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt; border-bottom: 1pt solid rgb(0, 0, 0); display: table-cell; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">Vant</div></div></div> </td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;&#160;</td>
<td style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Basic</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;&#160;</td>
<td style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Diluted</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 1pt; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">Description</div></div></div> </td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 1pt; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">Lead&#160;Program&#160;/&#160;Mechanism</div></div></div> </td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 1pt; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">Modality</div></div></div> </td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 1pt; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">Indication(s)&#160;/Phase</div></div></div> </td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 1pt; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">Upcoming&#160;Milestones</div></div></div> </td> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: top;">Affivant</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: top;">100%</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: top;">100%</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: top;">Developing bispecific antibodies for oncology indications with unmet medical need</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: top;">AFM32 / Bispecific antibody</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: top;">Biologic</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: top;"> <div style="text-indent: -1.5em; font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 2em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#8226;&#8195;&#8202;Solid Tumors / Preclinical</div></div> </td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: top;"> <div style="text-indent: -1.5em; font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 2em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#8226;&#8195;&#8202;1H &#8216;23: File IND</div></div> </td> </tr>
<tr style="font-size: 1pt;">
<td style="height: 12pt; font-family: &quot;Times New Roman&quot;;"></td>
<td colspan="2" style="height: 12pt; font-family: &quot;Times New Roman&quot;;"></td>
<td colspan="2" style="height: 12pt; font-family: &quot;Times New Roman&quot;;"></td>
<td colspan="2" style="height: 12pt; font-family: &quot;Times New Roman&quot;;"></td>
<td colspan="2" style="height: 12pt; font-family: &quot;Times New Roman&quot;;"></td>
<td colspan="2" style="height: 12pt; font-family: &quot;Times New Roman&quot;;"></td>
<td colspan="2" style="height: 12pt; font-family: &quot;Times New Roman&quot;;"></td>
<td colspan="2" style="height: 12pt; font-family: &quot;Times New Roman&quot;;"></td> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: top;">Cytovant</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: top;">72%</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: top;">68%</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: top;">Developing cellular medicines uniquely suited to Asian patients</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: top;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">CVT-TCR-01</div></div> / <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">TCR-T</div> targeting <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">NY-ESO-1</div></div></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: top;">Cell therapy</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: top;"> <div style="text-indent: -1.5em; font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 2em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#8226;&#8195;&#8202;Oncologic malignancies / Preclinical</div></div> </td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: top;"> <div style="text-indent: -1.5em; font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 2em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#8226;&#8195;&#8202;2H &#8216;21: Initiation of CMC activities</div></div> </td> </tr>
<tr style="font-size: 1pt;">
<td style="height: 12pt; font-family: &quot;Times New Roman&quot;;"></td>
<td colspan="2" style="height: 12pt; font-family: &quot;Times New Roman&quot;;"></td>
<td colspan="2" style="height: 12pt; font-family: &quot;Times New Roman&quot;;"></td>
<td colspan="2" style="height: 12pt; font-family: &quot;Times New Roman&quot;;"></td>
<td colspan="2" style="height: 12pt; font-family: &quot;Times New Roman&quot;;"></td>
<td colspan="2" style="height: 12pt; font-family: &quot;Times New Roman&quot;;"></td>
<td colspan="2" style="height: 12pt; font-family: &quot;Times New Roman&quot;;"></td>
<td colspan="2" style="height: 12pt; font-family: &quot;Times New Roman&quot;;"></td> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: top;">Arbutus</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: top;">32%*</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: top;">29%*</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: top;">Developing a potential cure for chronic HBV infection</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: top;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">AB-729</div> / RNAi inhibiting HBV replication</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: top;">RNA therapy</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: top;"> <div style="text-indent: -1.5em; font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 2em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#8226;&#8195;&#8202;Hepatitis B / Phase 2</div></div> </td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: top;"> <div style="text-indent: -1.5em; font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 2em; line-height: normal;">&#8226;&#8195;&#8202;2H &#8216;21: Additional data from <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">AB-729</div> trial</div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-indent: -1.5em; font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 2em; line-height: normal;">&#8226;&#8195;&#8202;2H &#8216;21: Initial data from Phase 1a/b <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">AB-836</div> trial</div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-indent: -1.5em; font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 1pt; margin-left: 2em; line-height: normal;">&#8226;&#8195;&#8202;2H &#8216;21 and 1H &#8216;22: Initiation of <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">AB-729</div> Phase 2 combination trials</div> </td> </tr>
<tr style="font-size: 1pt;">
<td style="height: 12pt; font-family: &quot;Times New Roman&quot;;"></td>
<td colspan="2" style="height: 12pt; font-family: &quot;Times New Roman&quot;;"></td>
<td colspan="2" style="height: 12pt; font-family: &quot;Times New Roman&quot;;"></td>
<td colspan="2" style="height: 12pt; font-family: &quot;Times New Roman&quot;;"></td>
<td colspan="2" style="height: 12pt; font-family: &quot;Times New Roman&quot;;"></td>
<td colspan="2" style="height: 12pt; font-family: &quot;Times New Roman&quot;;"></td>
<td colspan="2" style="height: 12pt; font-family: &quot;Times New Roman&quot;;"></td>
<td colspan="2" style="height: 12pt; font-family: &quot;Times New Roman&quot;;"></td> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: top;">Sio Gene Therapies</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: top;">27%*</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: top;">24%*</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: top;">Developing gene therapies for neurodegenerative diseases</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: top;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">AXO-AAV-GM1</div></div> / In vivo AAV9 gene therapy</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: top;">Gene therapy</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: top;"> <div style="text-indent: -1.5em; font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 2em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#8226;&#8195;&#8202;GM1 gangliosidosis / Phase 1/2</div></div> </td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: top;"> <div style="text-indent: -1.5em; font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 2em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#8226;&#8195;&#8202;1H &#8216;22: Data update from ongoing Phase 1/2 trial</div></div> </td> </tr>
<tr style="font-size: 1pt;">
<td style="height: 12pt; font-family: &quot;Times New Roman&quot;;"></td>
<td colspan="2" style="height: 12pt; font-family: &quot;Times New Roman&quot;;"></td>
<td colspan="2" style="height: 12pt; font-family: &quot;Times New Roman&quot;;"></td>
<td colspan="2" style="height: 12pt; font-family: &quot;Times New Roman&quot;;"></td>
<td colspan="2" style="height: 12pt; font-family: &quot;Times New Roman&quot;;"></td>
<td colspan="2" style="height: 12pt; font-family: &quot;Times New Roman&quot;;"></td>
<td colspan="2" style="height: 12pt; font-family: &quot;Times New Roman&quot;;"></td>
<td colspan="2" style="height: 12pt; font-family: &quot;Times New Roman&quot;;"></td> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: top;">Genevant</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: top;">83%</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: top;">69%</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: top;">Advancing delivery of nucleic acid therapeutics</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: top;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: top;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: top;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: top;">&#8212;&#160;&#160;</td> </tr>
<tr style="font-size: 1pt;">
<td style="height: 12pt;"></td>
<td colspan="2" style="height: 12pt;"></td>
<td colspan="2" style="height: 12pt;"></td>
<td colspan="2" style="height: 12pt;"></td>
<td colspan="2" style="height: 12pt;"></td>
<td colspan="2" style="height: 12pt;"></td>
<td colspan="2" style="height: 12pt;"></td>
<td colspan="2" style="height: 12pt;"></td> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: top;">Lokavant</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: top;">90%</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: top;">85%</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: top;">Optimizing trial operations with an <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">end-to-end</div></div> risk monitoring solution</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: top;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: top;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: top;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: top;">&#8212;&#160;&#160;</td> </tr>
<tr style="font-size: 1pt;">
<td style="height: 12pt;"></td>
<td colspan="2" style="height: 12pt;"></td>
<td colspan="2" style="height: 12pt;"></td>
<td colspan="2" style="height: 12pt;"></td>
<td colspan="2" style="height: 12pt;"></td>
<td colspan="2" style="height: 12pt;"></td>
<td colspan="2" style="height: 12pt;"></td>
<td colspan="2" style="height: 12pt;"></td> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: top;">Datavant**</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: top;">52%</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: top;">48%</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: top;">Connecting patient-level health data through privacy-first, HIPAA-compliant tokens</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: top;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: top;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: top;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: top;">&#8212;&#160;&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: top;">Alyvant</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: top;">97%</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: top;">95%</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: top;">Leveraging data and artificial intelligence to connect patients to therapies</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: top;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: top;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: top;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: top;">&#8212;&#160;&#160;</td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Note: Excludes early-stage pipeline of protein degraders and inhibitors being developed through our small molecule discovery engine. All drugs in current pipeline are investigational and subject to health authority approval. Where applicable, upcoming milestones are contingent on FDA feedback. </div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Ownership figures as of June&#160;30, 2021. Arbutus basic and fully diluted ownership includes the conversion of preferred shares held by Roivant into Common Shares, which was completed on October&#160;18, 2021. Roivant ownership in Cytovant includes both direct and indirect ownership. </div></div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">129 </div></div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;;font-weight: bold;"><a href="#toc">Table of Contents</a></div> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;">
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 4%; vertical-align: top;;text-align:left;">*</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Denotes entities that are publicly traded. </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 4%; vertical-align: top;;text-align:left;">**</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">In June 2021, Datavant entered into a definitive merger agreement to combine with Ciox Health. The transaction closed in July 2021. Following the closing of the merger, Roivant has a minority equity ownership in the combined entity. For more information, see &#8220;Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations&#8211;Recent Developments.&#8221; </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The following table summarizes our development-stage product candidate pipeline. </div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Development Pipeline </div></div></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="font-size: 0px;">
<td style="width: 20%; font-family: &quot;Times New Roman&quot;;"></td>
<td style="width: 1%; vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="width: 39%; font-family: &quot;Times New Roman&quot;;"></td>
<td style="width: 1%; vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="width: 12%; font-family: &quot;Times New Roman&quot;;"></td>
<td style="width: 1%; vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="width: 14%; font-family: &quot;Times New Roman&quot;;"></td>
<td style="width: 1%; vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="width: 11%; font-family: &quot;Times New Roman&quot;;"></td> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; white-space: nowrap; padding-bottom: 1pt;"> <div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt; border-bottom: 1pt solid rgb(0, 0, 0); display: table-cell; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">Product Candidate</div></div></div> </td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 1pt; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">Indication</div></div></div> </td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 1pt; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">Vant</div></div></div> </td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 1pt; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">Modality</div></div></div> </td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 1pt; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">Phase</div></div></div> </td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;">Tapinarof</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: top;">Psoriasis</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: top;">Dermavant</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: top;">Topical</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: top;">Registration</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;">Tapinarof</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: top;">Atopic Dermatitis</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: top;">Dermavant</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: top;">Topical</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: top;">Phase 3</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;">Cerdulatinib</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: top;">Vitiligo</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: top;">Dermavant</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: top;">Topical</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: top;">Phase 2</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;">IMVT-1401</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: top;">Myasthenia Gravis</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: top;">Immunovant</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: top;">Biologic</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: top;">Phase 2</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;">IMVT-1401</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: top;">Warm Autoimmune Hemolytic Anemia</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: top;">Immunovant</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: top;">Biologic</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: top;">Phase 2</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;">IMVT-1401</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: top;">Thyroid Eye Disease</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: top;">Immunovant</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: top;">Biologic</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: top;">Phase 2</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">ARU-1801</div></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: top;">Sickle Cell Disease</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: top;">Aruvant</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: top;">Gene Therapy</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: top;">Phase 2</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;">Namilumab</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: top;">Sarcoidosis</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: top;">Kinevant</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: top;">Biologic</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: top;">Phase 1</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;">LSVT-1701</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: top;">Staph Aureus Bacteremia</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: top;">Lysovant</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: top;">Biologic</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: top;">Phase 1</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;">Cerdulatinib</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: top;">Atopic Dermatitis</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: top;">Dermavant</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: top;">Topical</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: top;">Phase 1</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">DMVT-504</div></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: top;">Hyperhidrosis</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: top;">Dermavant</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: top;">Small&#160;Molecule</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: top;">Phase 1</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">DMVT-503</div></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: top;">Acne</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: top;">Dermavant</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: top;">Topical</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: top;">Preclinical</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">ARU-2801</div></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: top;">Hypophosphatasia</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: top;">Aruvant</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: top;">Gene&#160;Therapy</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: top;">Preclinical</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;">AFM32</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: top;">Solid Tumors</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: top;">Affivant</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: top;">Biologic</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: top;">Preclinical</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">CVT-TCR-01</div></div></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: top;">Oncologic&#160;Malignancies</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: top;">Cytovant</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: top;">Cell Therapy</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: top;">Preclinical</td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-family: Times New Roman; font-size: 8pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">Note: All drugs in current pipeline are investigational and subject to health authority approval. </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">As part of our mission to redefine &#8220;big pharma,&#8221; we aim to develop transformative medicines faster for diseases for which there are no approved therapies or the current standard of care treatment has significant limitations or drawbacks. We believe we are uniquely positioned to accomplish this by: </div></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;">Relentlessly pursuing opportunities to <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">in-license</div> or acquire drugs that we believe can deliver successful outcomes on accelerated timelines; </div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Designing creative deal structures to balance risk and the potential for future value creation; </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Using our computational drug discovery technologies to design and identify compounds with the greatest probability of success early in the discovery process; </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Creating nimble, entrepreneurial Vants that operate similar to independent biotechnology companies where each management team, comprised of world-class drug developers and clinical operators, is solely focused on their respective Vant&#8217;s mission; </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Incentivizing employees with equity in their Vants, which encourages focus and calculated risk-taking; </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Providing operational support from our centralized functions to accelerate Vant formation and operational maturation; </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Developing proprietary computational technologies that leverage our unique position at the intersection of biopharma and technology; </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">130 </div></div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;;font-weight: bold;"><a href="#toc" style="text-indent: 0px;">Table of Contents</a></div> <div> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;">
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Providing Vants with access to our team of scientific experts, physicians and technologists to help optimize their clinical development and commercial strategies; and </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Leveraging our business development engine and vast network of industry relationships for the identification of value-creating collaborations and synergistic partnerships. </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">Through continued investment in our model, we believe we are well-positioned to advance our current pipeline through regulatory approval and commercialization, expand our pipeline through novel drug discovery and <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">in-licensing</div> and acquisition transactions, and execute on our vision of transforming the delivery of healthcare to patients. </div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Our Process </div></div></div> <div style="text-align: center; margin-top: 0pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="color: red; letter-spacing: 0px; top: 0px;;display:inline;">
<img alt="" src="g164680g00y02.jpg" style="width: 605px; height: 265px;"/></div> </div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Discover </div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;">We focus on developing potentially transformative medicines that address areas of significant unmet medical need. We take a hypothesis-driven approach, focusing on compelling pathways, targets and drug classes that we believe lack established leaders, and we proactively pursue or discover drugs that align with our hypotheses. We focus on building diversification and varied risk profiles into our pipeline and are agnostic to therapeutic area, stage of development and drug modality. We leverage internally developed technologies as well as a multi-disciplinary team with diverse backgrounds to evaluate the universe of targets and biological pathways that we deem compelling. Once we have built conviction around a specific target or biological pathway, we look for assets to <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">in-license</div> or acquire, and/or design novel drugs through our small molecule discovery engine. </div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">Our ability to rapidly identify and execute <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">in-licensing</div> opportunities is underpinned by our diverse business development team, which consists of former investment professionals and experienced R&amp;D and data scientists. A suite of tools that we built <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">in-house</div> supports our business development team by bringing a computationally driven approach to the identification of <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">in-licensing</div> opportunities as well as supporting our R&amp;D decision-making across all stages of the drug discovery and development process. Our track record in R&amp;D and our ability to implement creative deal structures ensures that we are a favored development partner and are able to acquire assets on attractive terms with shared risk and aligned incentives. We have been successful <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">in-licensing</div> drugs from global pharmaceutical companies, small biotech startups and academic centers around the world, and we are proud of our deep network of academic and industry partners. Our goal is to add multiple potentially category-creating or category-leading drugs to our pipeline each year through this <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">in-licensing</div> strategy, a pace which is consistent with our track record over the past several years. </div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">131 </div></div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;;font-weight: bold;"><a href="#toc">Table of Contents</a></div> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">As a complement to our <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">in-licensing</div> strategy, we also apply our hypothesis-driven approach to our small molecule discovery engine, ensuring we direct our efforts toward high value pathways, targets and drug classes. Our discovery engine is defined by the distinctive combination of capabilities in computational physics and ML. Through the acquisition of Silicon Therapeutics, we have world-leading capabilities in computational physics for drug design. Silicon Therapeutics has built an advanced computational physics platform integrated with a proprietary supercomputing cluster and a <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">wet-lab</div> facility equipped for generating a broad range of experimental data. We have also built a ML platform, VantAI, tailored to the <div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">in silico</div></div> design and optimization of novel protein degraders in development at Proteovant. We believe the unique combination of both computational physics and ML capabilities will position us as the leader in computational drug discovery and establish a sustainable source of future small molecule drug candidates. </div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Our discovery engine has broad capabilities across multiple categories of small molecules and an initial special focus on targeted protein degradation, a therapeutic approach with broad potential applicability to diseases associated with protein overactivity and with no incumbent leader. Our capabilities in targeted protein degradation include a long-term partnership with a leading academic lab, the ability to optimize our degraders using both computational physics and ML and our well-established clinical development capabilities. Based on promising early-stage preclinical data for our first computationally-designed degrader candidates, we believe that our computational approach can generate candidates that achieve real-world degradation against relevant targets. </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">We anticipate that our discovery engine will expand our clinical-stage pipeline by generating candidates to advance through the launch of potential new Vants, or to integrate with existing Vants if there is appropriate therapeutic area overlap, in either case taking advantage of Roivant&#8217;s established clinical development capabilities. </div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Develop </div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">We believe the Vant model accelerates successful execution due to three key factors: nimble teams, incentive alignment and robust governance. We build Vant teams with deep, relevant expertise to promote successful execution of development strategy. By keeping Vant teams focused and generally small, we strive to eliminate excessive bureaucracy, thereby facilitating rapid decision-making and ultimately accelerating outcomes. Vants are built as entrepreneurial biotech companies, where each Vant leader is compensated with significant upside potential in the form of Vant equity. By aligning employee incentives with successful Vant outcomes, we encourage Vant leaders to take calculated risks and implement strategies that we believe differentiate the speed and creativity of development capabilities from legacy large pharmaceutical companies, where drug developers may face asymmetric downside in the event of failure and where upside equity, if granted, is diluted by many diverse projects. Vants are also supported through a robust governance structure that is centralized at Roivant. Our governance team ensures accountability for execution at Vants and allows us to capture synergies through shared technology and certain future shared commercial functions, while at the same time providing access to a broad range of Roivant resources when Vants face critical strategic questions. </div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Commercialize or monetize </div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The Vant model is designed to maximize the value of each drug that we successfully develop and generate returns for shareholders through the independent commercialization of products, partnerships with pharmaceutical and biotechnology companies or the selective sale of Vants. Our primary objective is to launch commercial products ourselves, but we may sell or partner Vants or specific drugs based on the facts and circumstances, including, without limitation, the strategic rationale and financial return potential. </div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Our Technologies </div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Our platform leverages technologies that are designed to optimize each stage of the drug discovery, development and commercialization process. </div></div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">132 </div></div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;;font-weight: bold;"><a href="#toc">Table of Contents</a></div> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Our small molecule discovery engine at Roivant Discovery powers <div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">in silico</div></div> drug discovery through the combination of two distinct approaches to computational drug design: the physics approach and the ML approach. The physics approach applies quantum mechanics and statistical thermodynamics to model the behavior of and interactions between molecules in a biological system. This includes molecular dynamics simulations, which predict how potential drug molecules bind to and modulate therapeutic protein targets. ML approaches for drug design, meanwhile, use pattern-recognition algorithms to discern mathematical relationships from empirical observations of small molecules and extrapolate to predict chemical, biological and physical properties of novel compounds. ML techniques are very efficient in terms of computing power consumed compared to physics-based approaches and can be scaled to large datasets without the need for extensive computational resources. To effectively build a leadership position in computational drug discovery, we deliberately built and assembled capabilities in both computational physics and ML, creating a combined platform that we believe to be significantly differentiated from others. </div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"></div> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The key components of our small molecule discovery engine include: </div></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0px;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px; text-indent: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">A quantum mechanics-based molecular dynamics software platform to predict the interactions, energies and conformational behavior of targets and generate novel drug candidates.</div></div></div></div> We can simulate hundreds of molecules per day and make predictions for drug design, enabling the optimization of properties such as binding affinity, selectivity, membrane permeability and solubility. We also have a suite of molecular dynamics and simulation tools to generate additional insights regarding individual atomic contributions to binding properties and conformational dynamics. </div> </td> </tr> </table> <div style="clear: both; max-height: 0pt; text-indent: 0px;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0px;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px; text-indent: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">A supercomputing cluster composed of over 600 graphics processing units</div></div></div></div><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">. </div></div>Our supercomputing cluster allows us to run molecular simulations at biologically meaningful timescales predicting not only affinity but also how biomolecules will respond at an atomic level to perturbations such as mutation, phosphorylation, protonation, or the addition or removal of a ligand and functionally important structural changes in proteins. </div> </td> </tr> </table> <div style="clear: both; max-height: 0pt; text-indent: 0px;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0px;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px; text-indent: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">A suite of degrader-specific ML tools.</div></div></div></div> We have developed a novel protein contact-first workflow that utilizes information about known protein-protein interactions to build new degraders that can effectively stabilize <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">target-E3</div> interfaces; a degron knowledge graph, which we believe to be industry-leading, to map the ubiquitin proteasome system; and a unique model, based on millions of carefully curated protein stability datapoints, to predict degradation. </div> </td> </tr> </table> <div style="clear: both; max-height: 0pt; text-indent: 0px;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0px;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px; text-indent: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">A wet lab fully equipped for synthetic chemistry, crystallography, biophysics, biochemistry and biology</div></div></div></div><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">.</div></div> Our <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">in-house</div> laboratories are tightly integrated with our computational physics platform to directly augment simulations with biophysical data as well as validate simulation predictions. Certain experimental techniques enable more accurate and efficient simulations on targets where we lack crystal structures. Combined with homology modeling and <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">X-ray</div> crystallography, this allows for the simultaneous design of chemical matter against a target while refining atomistic structural models and solving high-resolution crystal structures. </div> </td> </tr> </table> <div style="clear: both; max-height: 0pt; text-indent: 0px;"></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">Our computational physics capabilities, which we obtained through the acquisition of Silicon Therapeutics, allow us to predict how molecules will interact by using principles of quantum physics to computationally model the forces and energies of the atomic and <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">sub-atomic</div> particles that comprise the molecule system. Based on internal and published benchmarks, we believe that the speed and accuracy of binding free energy calculations made by our programs are on par with the best commercially available tool, Schr&#246;dinger&#8217;s FEP+, and superior to open-source methods. Further, we believe our ability to rapidly validate and constrain simulations with experimental data generated <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">in-house</div> creates a sustainable advantage compared to competitors. These capabilities power <div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">in silico</div></div> assays that allow us to potentially predict binding affinity of a ligand and protein, predict conformational dynamics of a protein as it shifts from active to inactive state, and identify binding sites on a protein. </div> </div> </div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">VantAI combines cutting-edge ML techniques with deep systems biology expertise to power the discovery of novel protein degraders. VantAI&#8217;s distinctive degrader platform includes a novel &#8220;protein contact-first&#8221; </div></div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">133 </div></div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;;font-weight: bold;"><a href="#toc">Table of Contents</a></div> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">workflow that uses graph representations of known protein-protein interactions to design new degraders that can effectively stabilize <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">target-E3</div> interfaces; an industry-leading ubiquitin proteasome system map allowing for the identification of degron motifs; and complex models for protein degradation and prediction of key chemical properties, trained on over five years of proprietary degrader-specific experimental data and millions of carefully curated protein stability datapoints. Our VantAI-designed degrader candidates have produced promising early-stage preclinical data that suggests our computational approach can generate candidates that achieve real-world degradation against multiple relevant targets. The use of VantAI&#8217;s computational technology on compounds for the inducement of protein degradation will be dedicated exclusively to Proteovant until at least early 2026, other than certain <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">pre-specified</div> work on designated targets being conducted for third parties. </div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">We believe that our small molecule discovery engine may allow us to replace experimental assays with <div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">in silico</div></div> assays, resulting in decreased time and costs, ultimately accelerating the <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">hit-to-lead</div></div> and lead optimization stages of the drug discovery process. Further, we expect to increase our likelihood of identifying novel binding pockets on previously &#8220;undruggable&#8221; targets. We plan to direct our expanding capabilities in computational drug discovery towards targets selected with the same &#8220;investment lens&#8221; we use for our <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">in-licensing</div> strategy, and we expect it to produce candidates for continued clinical development within our existing clinical trial infrastructure. </div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">The hypothesis generation for both our internal discovery engine and <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">in-licensing</div> strategies is supported by a tool we developed <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">in-house</div> called DrugOme, which we sold as part of the Sumitomo Transaction but retain a perpetual license to. DrugOme is a comprehensive map of targets and drug candidates in development that enables differentiated analysis of development strategies and potential business development opportunities. DrugOme employs natural language processing to extract, ingest and harmonize data across diverse structured and unstructured sources to construct a centralized database that captures available data regarding clinical trials, company financials, prescriptions and intellectual property. This database informs R&amp;D decision-making across all stages of the drug discovery and development process. DrugOme supports our business development by rapidly defining the competitive and therapeutic landscape for a specific asset, predicting clinical trial costs, identifying trends in treatment patterns, optimizing clinical trial site and investigator selection and providing other customized analyses. We believe our computational approach to identifying assets for <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">in-licensing</div> and the creative drug development strategies that accompany those assets are key advantages unique to the Roivant platform. </div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">As we have developed drugs in clinical trials, we have built technologies to improve the process of running such trials. We have aggregated many of these at our subsidiary Lokavant. Lokavant&#8217;s software integrates real-time data from ongoing clinical trials and monitors risks related to time, cost and quality. Its proprietary data model serves as a &#8220;common language&#8221; for trial operational data and ensures that all trial data sources are ingested, harmonized and aggregated into a central database, allowing the trial sponsor to access operational trial data in near-real time. This approach is a substantial departure from traditional operations which typically share different types of trial data asynchronously and on multi-week delays. Algorithms trained on a proprietary dataset of operational metadata from over 1,300 trials are designed to identify the most important risks with sufficient time to empower researchers to implement interventions to mitigate those risks and deliver trial results on budget and on time. In addition to being deployed in Roivant trials, Parexel, a leading global contract research organization (&#8220;CRO&#8221;), is using Lokavant&#8217;s software as its remote monitoring platform, and we intend to grow Lokavant&#8217;s customer base with other CROs and trial sponsors. </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">In designing development and commercialization strategies for our pipeline of drugs, we also identified significant shortcomings with commercially available patient data. Today, healthcare data is siloed across multiple fragmented data sources, limiting the ability to generate a comprehensive understanding of patient health. Datavant, a company which we founded and in which we maintain a <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-controlling</div> interest, is working to address this problem. Datavant recently merged with Ciox Health, LLC (as described below). The combined company seeks to power every exchange of health data, unlocking a massive ecosystem of companies using linked, longitudinal data to improve patient outcomes. Datavant linking technology enables the advanced use of real-world evidence, patient finding, outcomes research, and commercial analytics. Datavant&#8217;s customers and partners include Janssen/J&amp;J and other top 20 pharmaceutical companies, ZS, Medidata, Cigna, Parexel, Symphony Health, Komodo Health and the NIH. We can also use Datavant&#8217;s technology to better understand the real-world health outcomes of subjects who participate in our trials beyond the duration of the trials themselves. </div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">134 </div></div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;;font-weight: bold;"><a href="#toc">Table of Contents</a></div> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">In June 2021, Datavant entered into a definitive merger agreement with CIOX Health, LLC. (&#8220;Ciox Health&#8221;), a leader in clinical data exchange. The combined entity, named Datavant, is the nation&#8217;s largest health data ecosystem, enabling patients, providers, payers, health data analytics companies, patient-facing applications, government agencies, and life science companies to securely exchange their patient-level data. The merger closed in July 2021. At closing, Roivant received approximately $320&#160;million in cash and a minority equity ownership interest in the combined entity. </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">We have begun to build technology to support our transition from a development-stage biopharmaceutical company into a commercial one. Alyvant is an early-stage technology product for physician and patient segmentation, targeting and engagement. Alyvant generates dynamic call plans uniquely prioritized on likelihood to prescribe by integrating patient and payor data with physician behavioral characteristics and presents those call plans through a salesforce app that drives adherence to call plans and reprioritizes physician outreach based on feedback from the field. In a 2019 pilot <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">co-promotion</div> of three products, Alyvant increased total prescriptions by 223% compared to the same period in the prior year and generated a &gt;2x increase in the number of activated prescribers. As we deliver products to market, we expect to expand the suite of technology tools available to accelerate and optimize commercialization. </div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">We will continue to execute against our goal of building the next-generation pharmaceutical company by fully integrating modern technologies at each stage of the drug discovery, development and commercialization process. We believe that there is significant opportunity to address inefficiencies within these processes, and we expect to build technologies where we find commercially available tools nonexistent or insufficient for our needs. </div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Unique Features of the Roivant Platform </div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Our model allows each Vant to rapidly scale given full access to shared technologies that address inefficiencies in the drug discovery, development and commercialization process. </div></div> <div style="text-align: center; margin-top: 0pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="color: red; letter-spacing: 0px; top: 0px;;display:inline;">
<img alt="" src="g164680g00y03.jpg"/></div> </div></div> <div style="font-family: Times New Roman; font-size: 8pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">Note: All trademarks are property of their respective owners. </div></div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">135 </div></div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;;font-weight: bold;"><a href="#toc">Table of Contents</a></div> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">We aim to redefine &#8220;big pharma&#8221; by rapidly developing and commercializing transformative medicines in areas of high unmet medical need where there are no approved therapies or there are significant limitations associated with current standards of care. We believe our platform is uniquely positioned to accomplish this by: </div></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Leveraging complementary approaches to identify or discover promising drug candidates:</div></div></div></div> We assembled our current late-stage product candidate pipeline by relentlessly pursuing opportunities to <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">in-license</div> or acquire programs where we believe we can deliver successful outcomes on accelerated timelines. In addition, our computational drug discovery engine allows us to design, optimize and validate our own novel product candidates, providing us with another avenue to pursue compelling targets or pathways and further expand our pipeline. </div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Creating nimble, entrepreneurial Vants</div></div></div></div><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">:</div></div> Vants generally operate similar to independent biotechnology companies where each management team is focused on their respective mission and are economically incentivized to maximize value through Vant-specific equity grants. Each of our Vant teams is built with deep relevant expertise to ensure successful execution of their specific development strategy. The Vant model is designed to facilitate rapid decision making and calculated risk taking, by empowering, aligning and incentivizing Vant teams around the specific outcomes of their product candidates. </div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Developing and deploying proprietary technologies:</div></div></div></div><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"> </div></div>We believe we are able to develop transformative medicines faster by building and applying computational tools to drug discovery, development and commercialization. We occupy a unique position at the intersection of biopharma and technology, having built our capabilities in parallel, optimizing each for synergy with the other, in contrast to big pharma who have added software tools to legacy workflows or technology startups that lack experience developing drugs. Vants have access to, and are supported by, these technologies. </div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Allocating capital to maximize R&amp;D efficiency:</div></div></div></div><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"> </div></div>We apply an objective, rigorous decision framework across the drug development process designed to ensure resources and capital are continuously directed towards programs we believe have a higher probability of success and away from those that fail to meet our internal hurdles. We centralize capital allocation decisions at the Roivant level, while distributing operational decisions to the Vants, allowing us to strategically deploy capital in high growth areas, regardless of potentially competing operational priorities. </div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Maintaining a diversified pipeline with various risk profiles:</div></div></div></div><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"> </div></div>We have built a pipeline of over 30 drugs across different therapeutic areas, phases of development, modalities and geographies. This approach limits our exposure to several concentrated scientific and biological risks and allows us to pursue multiple innovative hypotheses across our portfolio as we seek to develop therapies for patient populations with high unmet need. </div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Designing creative <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">&#8220;win-win&#8221;</div> deal structures:</div></div></div></div> We structure our partnerships to balance risk and the potential for future value creation. We ensure that a significant proportion of near-term expenses go toward development, allowing us to stage our investment and align incentives as well as limit losses in the event of a setback. Our scale and track record of developing product candidates assures partners that we are uniquely capable of maximizing value for patients and investors. </div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Providing operating leverage through centralized support functions:</div></div></div></div><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"> </div></div>Our model allows us to accelerate Vant formation and maturation by centralizing and sharing certain support functions across various Vants. Vants also benefit from access to our vast network of scientific experts, physicians and technologists to help optimize their clinical development and plans for commercialization. </div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Platform Recognition </div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">In December 2019, we entered into a $3&#160;billion upfront partnership with Sumitomo. There were four key components of this transaction: </div></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Sumitomo acquired 100% of Roivant&#8217;s ownership interest in five Vants: Urovant, Myovant, Enzyvant, Altavant and Spirovant. </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">136 </div></div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;;font-weight: bold;"><a href="#toc">Table of Contents</a></div> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;">
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Sumitomo acquired options to purchase Roivant&#8217;s ownership interest in six additional Vants (the &#8220;Option Vants&#8221;), in each case at a purchase price calculated by reference to a specified multiple. In June 2021, Sumitomo and Roivant completed a transaction which included the termination of Sumitomo&#8217;s outstanding options to acquire Roivant&#8217;s ownership interest in the Option Vants. See the section titled &#8220;Recent Events&#8212;Option Vants Transaction&#8221; for additional information. </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Roivant and Sumitomo agreed to share access to two technology platforms: DrugOme and Digital Innovation, an approach to integrating technologists into business operations. </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Sumitomo acquired 26,952,143 Roivant Common Shares at a per share price of $37.10 (or 78,867,360 shares of Roivant acquired at a per share price of $12.68 after giving effect to the share subdivision completed in connection with the Business Combination). </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Our Growth Strategies </div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">We believe we are on our way to building the next generation &#8220;big pharma&#8221; company by leveraging our unique platform to transform the delivery of healthcare to patients. To support this goal and mission, we are executing on 5 key pillars of growth: </div></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Deliver successes across our current pipeline:</div></div></div></div> Our current pipeline is comprised of multiple potentially transformative drug candidates across all stages of development, modalities and therapeutic areas. Our ability to successfully develop promising drug candidates has been evidenced through four FDA approvals from Vants sold to Sumitomo. We will continue to advance our diverse pipeline through to late-stage development and ultimately, if successful, regulatory approval, expanding our track record of pipeline successes to date. </div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">We have a robust calendar of potential near-term catalysts, including the items set forth below. In addition, we plan to <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">in-license</div> multiple potentially category-leading drugs per year.</div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="font-size: 0px;">
<td style="width: 13%; font-family: &quot;Times New Roman&quot;;"></td>
<td style="width: 2%; vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="width: 57%; font-family: &quot;Times New Roman&quot;;"></td>
<td style="width: 2%; vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="width: 28%; font-family: &quot;Times New Roman&quot;;"></td> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; white-space: nowrap; padding-bottom: 1pt;"> <div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt; border-bottom: 1pt solid rgb(0, 0, 0); display: table-cell; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">Vant</div></div></div> </td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;&#160;</td>
<td style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 1pt; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">Catalyst</div></div></div> </td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;&#160;</td>
<td style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 1pt; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">Expected Timing</div></div></div> </td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;">Dermavant</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: top;">Tapinarof NDA filing in psoriasis</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: top;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">Mid-2021</div> &#10003;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: top;">Tapinarof Phase 3 initiation in atopic dermatitis</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: top;">2H 2021 &#10003;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: top;">FDA approval decision on tapinarof for psoriasis</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: top;">2Q 2022</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: top;">Topline data from tapinarof Phase 3 trials in atopic dermatitis</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: top;">1H 2023</td> </tr>
<tr style="font-size: 1pt;">
<td style="height: 6pt;">&#160;</td>
<td colspan="2" style="height: 6pt;">&#160;</td>
<td colspan="2" style="height: 6pt;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;">Immunovant</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: top;">Initiate pivotal trial in MG</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: top;">Early 2022</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: top;">Reinitiate program program in TED</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: top;"> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 1pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">TBA</div></div> </td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: top;">Reinitiate program program in WAIHA</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: top;"> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 1pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">TBA</div></div> </td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: top;">Announce at least two new indications for IMVT-1401</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: top;">2H 2022</td> </tr>
<tr style="font-size: 1pt;">
<td style="height: 6pt; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td colspan="2" style="height: 6pt; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td colspan="2" style="height: 6pt; font-family: &quot;Times New Roman&quot;;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;">Aruvant</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: top;">First patient dosed with updated <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">ARU-1801</div> manufacturing process</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: top;">2H 2021 &#10003;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: top;">Additional clinical data from <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">ARU-1801</div> Phase 1/2</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: top;">2H 2021 &#10003;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: top;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">ARU-1801</div> Phase 3 initiation</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: top;">1H 2023</td> </tr>
<tr style="font-size: 1pt;">
<td style="height: 6pt;">&#160;</td>
<td colspan="2" style="height: 6pt;">&#160;</td>
<td colspan="2" style="height: 6pt;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;">Kinevant</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: top;">Namilumab Phase 2 initiation in sarcoidosis</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: top;">1H 2022</td> </tr>
<tr style="font-size: 1pt;">
<td style="height: 6pt;">&#160;</td>
<td colspan="2" style="height: 6pt;">&#160;</td>
<td colspan="2" style="height: 6pt;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;">Lysovant</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: top;">LSVT-1701 MAD initiation</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: top;">1H 2022</td> </tr>
<tr style="font-size: 1pt;">
<td style="height: 6pt;">&#160;</td>
<td colspan="2" style="height: 6pt;">&#160;</td>
<td colspan="2" style="height: 6pt;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;">Proteovant</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: top;">Phase 1 initiation for first degrader candidate</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: top;">2022</td> </tr>
<tr style="font-size: 1pt;">
<td style="height: 6pt;">&#160;</td>
<td colspan="2" style="height: 6pt;">&#160;</td>
<td colspan="2" style="height: 6pt;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; text-indent: 0px;">Roivant / Proteovant</td>
<td style="vertical-align: bottom; text-indent: 0px;">&#160;&#160;</td>
<td style="vertical-align: top; text-indent: 0px;">Multiple additional degrader candidates entering IND-enabling studies each year </td>
<td style="vertical-align: bottom; text-indent: 0px;">&#160;&#160;</td>
<td style="vertical-align: top; text-indent: 0px;">Starting 2022</td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Note: References are to calendar years. All catalyst timings are based on current expectations and, where applicable, contingent on FDA feedback, and may be subject to change. </div></div></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Expand our pipeline through acquisitions or <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">in-licensing</div> transactions:</div></div></div></div> We intend to continue to expand our existing pipeline through acquiring or <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">in-licensing</div> additional transformative drug candidates. Our goal is to add multiple potentially category-creating or category-leading drugs to our pipeline each year on average via this <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">in-licensing</div> strategy, a pace which is consistent with our track </div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">137 </div></div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;;font-weight: bold;"><a href="#toc">Table of Contents</a></div> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;">
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 9%;">&#160;</td>
<td style="vertical-align: top;"> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">record over the past several years. We will continue to manage our pipeline like a portfolio and build diversified risk profiles across therapeutic area, target, modality and stage of development. </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Expand our pipeline through drug discovery:</div></div></div></div> In parallel with our <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">in-licensing</div> strategy, we intend to expand our pipeline through computational discovery of novel drug candidates. Thus far, we have focused our discovery efforts towards novel protein degraders. We plan to initiate a Phase 1 trial for our first degrader candidate in 2022 and rapidly build upon our early pipeline of degraders. We expect that the significant investments we have made in our small molecule discovery engine will allow us to generate novel drug candidates internally and initiate multiple <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">IND-enabling</div> studies each year starting in 2022. </div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Power our entire platform by technology:</div></div></div></div> We have built leading capabilities in computational drug discovery with our distinctive combination of ML and computational physics platforms. Our investment in computational discovery bolsters our existing technology platform that seeks to address inefficiencies across each stage of the drug discovery, development and commercialization process. We expect to continue to make strategic investments in technology to power the entire Roivant platform, ultimately accelerating the delivery of transformative medicines to patients. </div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Commercialize medicines independently where optimal:</div></div></div></div> While the Roivant platform ensures flexibility on our path to value creation from each asset, we believe independently commercializing our drug candidates will unlock maximal value over the long run. Our plan for building commercial capabilities will be informed by the identification of specific, targeted opportunities to create additional value across Vants. We are presently evaluating which commercial functions to potentially build <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">in-house</div> and centralize across the Vants. Based on our current pipeline, we expect to market our first drug, tapinarof, in 2022. </div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Our Management Team </div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">We are led by a management team of leaders with diverse backgrounds, bringing together an expansive set of capabilities across healthcare investing, clinical development, technology, medicine, venture capital, operations, finance and data science. We believe we are well-positioned to redefine what it means to be a large pharmaceutical company today based on our ability to leverage experience from within and beyond the world of pharmaceuticals. </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">Our management team is led by our Chief Executive Officer, Matthew Gline, with strategic guidance from our Founder and Executive Chairman, Vivek Ramaswamy. Our Chief Operating Officer, Eric Venker, M.D., Pharm.D., oversees the operations of the Roivant platform and provides oversight to our Vants as a board member. Our Chief Investment Officer, Mayukh Sukhatme, M.D., is responsible for generating hypotheses for potential new drugs, ultimately guiding target selection for our small molecule discovery engine and overseeing the evaluation of new assets to bring into our pipeline through our <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">in-licensing</div> strategy. Our Chief Financial Officer, Richard Pulik, manages our financial strategy and operations. Our Chief Computational Scientist, Woody Sherman, Ph.D., manages our computational physics platform. Our Vant Chair, Frank Torti, M.D., serves as chair of the board for certain of our Vants and, in that capacity, is responsible for ensuring successful execution of Vant strategy. We created the role of Vant Chair to establish clear accountability for our Vant CEOs, ensuring each Vant maintains the freedom to deploy their relevant expertise while maintaining connectivity to the Roivant platform. </div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">We build impressive teams across all levels of the organization. We hire and develop world-class talent from diverse backgrounds in biopharma, academia, technology and finance to ensure we have all of the capabilities to design and deliver creative solutions. </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Our team is united by our core values: </div></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Create value:</div></div></div></div><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"> </div></div>We maximize value for patients and for shareholders. </div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">138 </div></div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;;font-weight: bold;"><a href="#toc">Table of Contents</a></div> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;">
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Be contrarian:</div></div></div></div><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"> </div></div>We question convention, others, and ourselves. </div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Climb the wall:</div></div></div></div><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"> </div></div>If an obstacle arises, we focus on finding the best solution to overcome that obstacle. </div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Sweat the details:</div></div></div></div><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"> </div></div>We are thorough, we follow facts not stories, and we accept and learn from mistakes. </div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Evolve or die:</div></div></div></div><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"> </div></div>&#8220;It&#8217;s working now&#8221; is never satisfactory. </div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Our Vants and Pipeline </div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;">Today, we have 14 Vants. We plan to create additional Vants based on the outputs of the Roivant platform, including our <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">in-licensing</div> efforts and our small molecule discovery engine, Roivant Discovery. The following table summarizes our Vants. </div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">139 </div></div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;;font-weight: bold;"><a href="#toc">Table of Contents</a></div> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;">
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="font-size: 0px;">
<td style="width: 8%;"></td>
<td style="width: 1%; vertical-align: bottom;"></td>
<td></td>
<td style="width: 1%; vertical-align: bottom;"></td>
<td></td>
<td style="width: 1%; vertical-align: bottom;"></td>
<td style="width: 15%;"></td>
<td style="width: 1%; vertical-align: bottom;"></td>
<td style="width: 18%;"></td>
<td style="width: 1%; vertical-align: bottom;"></td>
<td style="width: 9%;"></td>
<td style="width: 1%; vertical-align: bottom;"></td>
<td style="width: 18%;"></td>
<td style="width: 1%; vertical-align: bottom;"></td>
<td style="width: 17%;"></td> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td colspan="3" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Roivant<br/>Ownership at</div></div><br/><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">June&#160;30, 2021</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; white-space: nowrap; padding-bottom: 1pt;"> <div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt; border-bottom: 1pt solid rgb(0, 0, 0); display: table-cell; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">Vant</div></div></div> </td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Basic</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Diluted</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 1pt; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">Description</div></div></div> </td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 1pt; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">Lead Program / Mechanism</div></div></div> </td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 1pt; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">Modality</div></div></div> </td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 1pt; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">Indication(s) / Phase</div></div></div> </td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 1pt; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">Upcoming Milestones</div></div></div> </td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;">Dermavant</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: top;">100%</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: top;">84%</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: top;">Developing treatments for unmet needs in immuno-dermatology</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: top;">Tapinarof / Therapeutic aryl hydrocarbon receptor modulating agent</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: top;">Topical</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: top;"> <div style="text-indent: -1.5em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 2em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#8226;&#8195;&#8202;Psoriasis&#160;/Registration</div></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-indent: -1.5em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 1pt; margin-left: 2em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#8226;&#8195;&#8202;Atopic dermatitis / Phase 3</div></div> </td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: top;"> <div style="text-indent: -1.5em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 2em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#8226;&#8195;&#8202;Q2 &#8216;22: FDA approval decision on Tapinarof for psoriasis</div></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-indent: -1.5em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 1pt; margin-left: 2em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#8226;&#8195;&#8202;1H &#8216;23: Topline Phase 3 data in atopic dermatitis</div></div> </td> </tr>
<tr style="font-size: 1pt;">
<td style="height: 6pt; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td colspan="2" style="height: 6pt; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td colspan="2" style="height: 6pt; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td colspan="2" style="height: 6pt; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td colspan="2" style="height: 6pt; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td colspan="2" style="height: 6pt; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td colspan="2" style="height: 6pt; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td colspan="2" style="height: 6pt; font-family: &quot;Times New Roman&quot;;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;">Immunovant</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: top;">58%*</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: top;">53%*</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: top;">Developing an anti-FcRn monoclonal antibody for <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">IgG-mediated</div> autoimmune diseases</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: top;">IMVT-1401 / Anti-FcRn monoclonal antibody</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: top;">Biologic</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: top;"> <div style="text-indent: -1.5em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 2em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#8226;&#8195;&#8202;Myasthenia gravis, thyroid eye disease, and warm autoimmune hemolytic anemia / Phase 2</div></div> </td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: top;"> <div style="text-indent: -1.5em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 2em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#8226;&#8195;&#8202;Early 2022: Initiate pivotal trial in MG</div></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-indent: -1.5em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 2em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#8226;&#8195;&#8202;TBA: Reinitiate program in TED</div></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-indent: -1.5em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 2em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#8226;&#8195;&#8202;TBA: Reinitiate program in WAIHA</div></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-indent: -1.5em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 1pt; margin-left: 2em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#8226;&#8195;&#8202;2H &#8216;22: Announce at least two new indications for IMVT-1401</div></div> </td> </tr>
<tr style="font-size: 1pt;">
<td style="height: 6pt; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td colspan="2" style="height: 6pt; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td colspan="2" style="height: 6pt; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td colspan="2" style="height: 6pt; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td colspan="2" style="height: 6pt; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td colspan="2" style="height: 6pt; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td colspan="2" style="height: 6pt; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td colspan="2" style="height: 6pt; font-family: &quot;Times New Roman&quot;;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;">Aruvant</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: top;">88%</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: top;">79%</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: top;">Developing transformative gene therapies for severe blood disorders</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: top;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">ARU-1801</div> / Ex vivo lentiviral gene therapy delivering a novel, highly potent variant of fetal hemoglobin (HbF)</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: top;">Gene&#160;therapy</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: top;"> <div style="text-indent: -1.5em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 2em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#8226;&#8195;&#8202;Sickle cell disease / Phase 1/2</div></div> </td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: top;"> <div style="text-indent: -1.5em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 2em; line-height: normal;">&#8226;&#8195;&#8202;2H &#8216;21: Ongoing new patient and follow up data from additional <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">ARU-1801</div> Phase 1/2 patients</div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-indent: -1.5em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 1pt; margin-left: 2em; line-height: normal;">&#8226;&#8195;&#8202;1H &#8216;23: <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">ARU-1801</div> Phase 3 initiation</div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">140 </div></div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;;font-weight: bold;"><a href="#toc">Table of Contents</a></div> </div> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;">
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="font-size: 0px;">
<td style="width: 7%;"></td>
<td style="width: 1%; vertical-align: bottom;"></td>
<td></td>
<td style="width: 1%; vertical-align: bottom;"></td>
<td></td>
<td style="width: 1%; vertical-align: bottom;"></td>
<td style="width: 13%;"></td>
<td style="width: 1%; vertical-align: bottom;"></td>
<td style="width: 17%;"></td>
<td style="width: 1%; vertical-align: bottom;"></td>
<td style="width: 16%;"></td>
<td style="width: 1%; vertical-align: bottom;"></td>
<td style="width: 16%;"></td>
<td style="width: 1%; vertical-align: bottom;"></td>
<td style="width: 16%;"></td> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td colspan="3" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Roivant<br/>Ownership at</div></div><br/><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">June&#160;30, 2021</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; white-space: nowrap; padding-bottom: 1pt;"> <div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt; border-bottom: 1pt solid rgb(0, 0, 0); display: table-cell; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">Vant</div></div></div> </td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Basic</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Diluted</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 1pt; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">Description</div></div></div> </td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 1pt; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">Lead Program / Mechanism</div></div></div> </td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 1pt; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">Modality</div></div></div> </td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 1pt; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">Indication(s) / Phase</div></div></div> </td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 1pt; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">Upcoming Milestones</div></div></div> </td> </tr>
<tr style="font-size: 1pt;">
<td style="height: 6pt; font-family: &quot;Times New Roman&quot;;"></td>
<td colspan="2" style="height: 6pt; font-family: &quot;Times New Roman&quot;;"></td>
<td colspan="2" style="height: 6pt; font-family: &quot;Times New Roman&quot;;"></td>
<td colspan="2" style="height: 6pt; font-family: &quot;Times New Roman&quot;;"></td>
<td colspan="2" style="height: 6pt; font-family: &quot;Times New Roman&quot;;"></td>
<td colspan="2" style="height: 6pt; font-family: &quot;Times New Roman&quot;;"></td>
<td colspan="2" style="height: 6pt; font-family: &quot;Times New Roman&quot;;"></td>
<td colspan="2" style="height: 6pt; font-family: &quot;Times New Roman&quot;;"></td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;">Proteovant</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: top;">60%</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: top;">60%</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: top;">Developing heterobifunctional protein degraders for oncology, neurology, and immunology, with exclusive access to VantAI</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: top;">AR Degrader</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: top;">Small Molecule</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: top;"> <div style="text-indent: -1.5em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 2em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#8226;&#8195;&#8202;Prostate cancer / Preclinical</div></div> </td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: top;"> <div style="text-indent: -1.5em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 2em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#8226;&#8195;&#8202;2022: AR degrader Phase 1 initiation</div></div> </td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;">Lysovant</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: top;">100%</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: top;">99%</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: top;">Developing a novel endolysin for <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">hard-to-treat</div></div> Staph aureus infection</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: top;">LSVT-1701 / Endolysin</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: top;">Biologic</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: top;"> <div style="text-indent: -1.5em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 2em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#8226;&#8195;&#8202;Staph aureus bacteremia and infective endocarditis / Phase 1</div></div> </td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: top;"> <div style="text-indent: -1.5em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 2em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#8226;&#8195;&#8202;1H &#8216;22: LSVT-1701 MAD initiation</div></div> </td> </tr>
<tr style="font-size: 1pt;">
<td style="height: 6pt; font-family: &quot;Times New Roman&quot;;"></td>
<td colspan="2" style="height: 6pt; font-family: &quot;Times New Roman&quot;;"></td>
<td colspan="2" style="height: 6pt; font-family: &quot;Times New Roman&quot;;"></td>
<td colspan="2" style="height: 6pt; font-family: &quot;Times New Roman&quot;;"></td>
<td colspan="2" style="height: 6pt; font-family: &quot;Times New Roman&quot;;"></td>
<td colspan="2" style="height: 6pt; font-family: &quot;Times New Roman&quot;;"></td>
<td colspan="2" style="height: 6pt; font-family: &quot;Times New Roman&quot;;"></td>
<td colspan="2" style="height: 6pt; font-family: &quot;Times New Roman&quot;;"></td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;">Kinevant</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: top;">88%</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: top;">88%</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: top;">Developing an <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">anti-GM-CSF</div></div> monoclonal antibody for autoimmune diseases</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: top;">Namilumab / <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">Anti-GM-CSF</div></div> monoclonal antibody</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: top;">Biologic</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: top;"> <div style="text-indent: -1.5em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 2em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#8226;&#8195;&#8202;Sarcoidosis / Phase 1</div></div> </td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: top;"> <div style="text-indent: -1.5em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 2em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#8226;&#8195;&#8202;1H &#8216;22: Namilumab Phase 2 initiation</div></div> </td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;">Affivant</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: top;">100%</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: top;">100%</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: top;">Developing bispecific antibodies for oncology indications with unmet medical need</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: top;">AFM32 / Bispecific antibody</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: top;">Biologic</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: top;"> <div style="text-indent: -1.5em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 2em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#8226;&#8195;&#8202;Solid Tumors / Preclinical</div></div> </td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: top;"> <div style="text-indent: -1.5em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 2em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#8226;&#8195;&#8202;1H &#8216;23: File IND</div></div> </td> </tr>
<tr style="font-size: 1pt;">
<td style="height: 6pt; font-family: &quot;Times New Roman&quot;;"></td>
<td colspan="2" style="height: 6pt; font-family: &quot;Times New Roman&quot;;"></td>
<td colspan="2" style="height: 6pt; font-family: &quot;Times New Roman&quot;;"></td>
<td colspan="2" style="height: 6pt; font-family: &quot;Times New Roman&quot;;"></td>
<td colspan="2" style="height: 6pt; font-family: &quot;Times New Roman&quot;;"></td>
<td colspan="2" style="height: 6pt; font-family: &quot;Times New Roman&quot;;"></td>
<td colspan="2" style="height: 6pt; font-family: &quot;Times New Roman&quot;;"></td>
<td colspan="2" style="height: 6pt; font-family: &quot;Times New Roman&quot;;"></td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;">Cytovant</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: top;">72%</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: top;">68%</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: top;">Developing cellular medicines uniquely suited to Asian patients</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: top;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">CVT-TCR-01</div></div> / <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">TCR-T</div> targeting <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">NY-ESO-1</div></div></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: top;">Cell therapy</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: top;"> <div style="text-indent: -1.5em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 2em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#8226;&#8195;&#8202;Oncologic malignancies / Preclinical</div></div> </td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: top;"> <div style="text-indent: -1.5em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 2em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#8226;&#8195;&#8202;2H &#8216;21: Initiation of CMC activities</div></div> </td> </tr>
<tr style="font-size: 1pt;">
<td style="height: 6pt; font-family: &quot;Times New Roman&quot;;"></td>
<td colspan="2" style="height: 6pt; font-family: &quot;Times New Roman&quot;;"></td>
<td colspan="2" style="height: 6pt; font-family: &quot;Times New Roman&quot;;"></td>
<td colspan="2" style="height: 6pt; font-family: &quot;Times New Roman&quot;;"></td>
<td colspan="2" style="height: 6pt; font-family: &quot;Times New Roman&quot;;"></td>
<td colspan="2" style="height: 6pt; font-family: &quot;Times New Roman&quot;;"></td>
<td colspan="2" style="height: 6pt; font-family: &quot;Times New Roman&quot;;"></td>
<td colspan="2" style="height: 6pt; font-family: &quot;Times New Roman&quot;;"></td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;">Arbutus</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: top;">32%*</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: top;">29%*</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: top;">Developing a potential cure for chronic HBV infection</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: top;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">AB-729</div> / RNAi inhibiting HBV replication</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: top;">RNA therapy</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: top;"> <div style="text-indent: -1.5em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 2em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#8226;&#8195;&#8202;Hepatitis B / Phase 2</div></div> </td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: top;"> <div style="text-indent: -1.5em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 2em; line-height: normal;">&#8226;&#8195;&#8202;2H &#8216;21: Additional data from <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">AB-729</div> trial</div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-indent: -1.5em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 2em; line-height: normal;">&#8226;&#8195;&#8202;2H &#8216;21: Initial data from Phase 1a/b <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">AB-836</div> trial</div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-indent: -1.5em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 1pt; margin-left: 2em; line-height: normal;">&#8226;&#8195;&#8202;2H &#8216;21 and 1H &#8216;22: Initiation of <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">AB-729</div> Phase 2 combination trials</div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">141 </div></div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;;font-weight: bold;"><a href="#toc">Table of Contents</a></div> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;">
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="font-size: 0px;">
<td style="width: 7%;"></td>
<td style="width: 1%; vertical-align: bottom;"></td>
<td></td>
<td style="width: 1%; vertical-align: bottom;"></td>
<td></td>
<td style="width: 1%; vertical-align: bottom;"></td>
<td style="width: 13%;"></td>
<td style="width: 1%; vertical-align: bottom;"></td>
<td style="width: 17%;"></td>
<td style="width: 1%; vertical-align: bottom;"></td>
<td style="width: 16%;"></td>
<td style="width: 1%; vertical-align: bottom;"></td>
<td style="width: 16%;"></td>
<td style="width: 1%; vertical-align: bottom;"></td>
<td style="width: 16%;"></td> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td colspan="3" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Roivant<br/>Ownership at</div></div><br/><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">June&#160;30, 2021</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; white-space: nowrap; padding-bottom: 1pt;"> <div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt; border-bottom: 1pt solid rgb(0, 0, 0); display: table-cell; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">Vant</div></div></div> </td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Basic</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Diluted</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 1pt; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">Description</div></div></div> </td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 1pt; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">Lead Program / Mechanism</div></div></div> </td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 1pt; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">Modality</div></div></div> </td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 1pt; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">Indication(s) / Phase</div></div></div> </td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 1pt; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">Upcoming Milestones</div></div></div> </td> </tr>
<tr style="font-size: 1pt;">
<td style="height: 6pt; font-family: &quot;Times New Roman&quot;;"></td>
<td colspan="2" style="height: 6pt; font-family: &quot;Times New Roman&quot;;"></td>
<td colspan="2" style="height: 6pt; font-family: &quot;Times New Roman&quot;;"></td>
<td colspan="2" style="height: 6pt; font-family: &quot;Times New Roman&quot;;"></td>
<td colspan="2" style="height: 6pt; font-family: &quot;Times New Roman&quot;;"></td>
<td colspan="2" style="height: 6pt; font-family: &quot;Times New Roman&quot;;"></td>
<td colspan="2" style="height: 6pt; font-family: &quot;Times New Roman&quot;;"></td>
<td colspan="2" style="height: 6pt; font-family: &quot;Times New Roman&quot;;"></td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;">Sio Gene Therapies</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: top;">27%*</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: top;">24%*</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: top;">Developing gene therapies for neurodegenerative diseases</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: top;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">AXO-AAV-GM1</div></div> / In vivo AAV9 gene therapy</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: top;">Gene therapy</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: top;"> <div style="text-indent: -1.5em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 2em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#8226;&#8195;&#8202;GM1 gangliosidosis / Phase 1/2</div></div> </td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: top;"> <div style="text-indent: -1.5em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 2em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#8226;&#8195;&#8202;1H &#8216;22: Data update from ongoing Phase 1/2 trial</div></div> </td> </tr>
<tr style="font-size: 1pt;">
<td style="height: 6pt; font-family: &quot;Times New Roman&quot;;"></td>
<td colspan="2" style="height: 6pt; font-family: &quot;Times New Roman&quot;;"></td>
<td colspan="2" style="height: 6pt; font-family: &quot;Times New Roman&quot;;"></td>
<td colspan="2" style="height: 6pt; font-family: &quot;Times New Roman&quot;;"></td>
<td colspan="2" style="height: 6pt; font-family: &quot;Times New Roman&quot;;"></td>
<td colspan="2" style="height: 6pt; font-family: &quot;Times New Roman&quot;;"></td>
<td colspan="2" style="height: 6pt; font-family: &quot;Times New Roman&quot;;"></td>
<td colspan="2" style="height: 6pt; font-family: &quot;Times New Roman&quot;;"></td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;">Genevant</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: top;">83%</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: top;">69%</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: top;">Advancing delivery of nucleic acid therapeutics</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: top;">&#8212;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: top;">&#8212;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: top;">&#8212;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: top;">&#8212;</td> </tr>
<tr style="font-size: 1pt;">
<td style="height: 6pt;"></td>
<td colspan="2" style="height: 6pt;"></td>
<td colspan="2" style="height: 6pt;"></td>
<td colspan="2" style="height: 6pt;"></td>
<td colspan="2" style="height: 6pt;"></td>
<td colspan="2" style="height: 6pt;"></td>
<td colspan="2" style="height: 6pt;"></td>
<td colspan="2" style="height: 6pt;"></td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;">Lokavant</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: top;">90%</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: top;">85%</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: top;">Optimizing trial operations with an <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">end-to-end</div></div> risk monitoring solution</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: top;">&#8212;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: top;">&#8212;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: top;">&#8212;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: top;">&#8212;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;">Datavant**</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: top;">52%</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: top;">48%</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: top;">Connecting patient-level health data through privacy-first, HIPAA-compliant tokens</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: top;">&#8212;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: top;">&#8212;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: top;">&#8212;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: top;">&#8212;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;">Alyvant</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: top;">97%</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: top;">95%</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: top;">Leveraging data and artificial intelligence to connect patients to therapies</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: top;">&#8212;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: top;">&#8212;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: top;">&#8212;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: top;">&#8212;</td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-family: Times New Roman; font-size: 8pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">Note: Excludes early-stage pipeline of protein degraders and inhibitors being developed through our small molecule discovery engine. All drugs in current pipeline are investigational and subject to health authority approval. Where applicable, upcoming milestones are contingent on FDA feedback. </div></div> <div style="font-family: Times New Roman; font-size: 8pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">Ownership figures as of June&#160;30, 2021. Arbutus basic and fully diluted ownership includes the conversion of preferred shares held by Roivant into Common Shares, which was completed on October&#160;18, 2021. Roivant ownership in Cytovant includes both direct and indirect ownership. </div></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 8pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 4%; vertical-align: top;;text-align:left;">*</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">Denotes entities that are publicly traded. </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 8pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 4%; vertical-align: top;;text-align:left;">**</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">In June 2021, Datavant entered into a definitive merger agreement to combine with Ciox Health. The transaction closed in July 2021. Following the closing of the merger, Roivant has a minority equity ownership in the combined entity. For more information, see &#8220;Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations&#8211;Recent Developments.&#8221; </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">142 </div></div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;;font-weight: bold;"><a href="#toc">Table of Contents</a></div> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The following table summarizes our development-stage product candidate pipeline: </div></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="font-size: 0px;">
<td style="width: 15%; font-family: &quot;Times New Roman&quot;;"></td>
<td style="width: 1%; vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="width: 41%; font-family: &quot;Times New Roman&quot;;"></td>
<td style="width: 1%; vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="width: 16%; font-family: &quot;Times New Roman&quot;;"></td>
<td style="width: 1%; vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="width: 16%; font-family: &quot;Times New Roman&quot;;"></td>
<td style="width: 1%; vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="width: 8%; font-family: &quot;Times New Roman&quot;;"></td> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;"> <div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 1pt; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">Product&#160;Candidate&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</div></div></div> </td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;&#160;</td>
<td style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 1pt; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">Indication</div></div></div> </td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;&#160;</td>
<td style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 1pt; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">Vant</div></div></div> </td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;&#160;</td>
<td style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 1pt; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">Modality</div></div></div> </td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;&#160;</td>
<td style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 1pt; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">Phase</div></div></div> </td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: bottom;">Tapinarof</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">Psoriasis</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">Dermavant</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">Topical</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;;text-align:center;">Registration</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: bottom;">Tapinarof</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">Atopic Dermatitis</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">Dermavant</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">Topical</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;;text-align:center;">Phase 3</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: bottom;">Cerdulatinib</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">Vitiligo</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">Dermavant</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">Topical</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;;text-align:center;">Phase 2</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: bottom;">IMVT-1401</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">Myasthenia Gravis</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">Immunovant</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">Biologic</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;;text-align:center;">Phase 2</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: bottom;">IMVT-1401</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">Warm&#160;Autoimmune&#160;Hemolytic Anemia</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">Immunovant&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">Biologic</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;;text-align:center;">Phase 2</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: bottom;">IMVT-1401</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">Thyroid Eye Disease</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">Immunovant</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">Biologic</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;;text-align:center;">Phase 2</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: bottom;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">ARU-1801</div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">Sickle Cell Disease</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">Aruvant</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">Gene Therapy</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;;text-align:center;">Phase 2</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: bottom;">Namilumab</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">Sarcoidosis</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">Kinevant</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">Biologic</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;;text-align:center;">Phase 1</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: bottom;">LSVT-1701</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">Staph Aureus Bacteremia</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">Lysovant</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">Biologic</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;;text-align:center;">Phase 1</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: bottom;">Cerdulatinib</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">Atopic Dermatitis</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">Dermavant</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">Topical</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;;text-align:center;">Phase 1</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: bottom;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">DMVT-504</div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">Hyperhidrosis</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">Dermavant</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">Small&#160;Molecule&#160;&#160;&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;;text-align:center;">Phase 1</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: bottom;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">DMVT-503</div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">Acne</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">Dermavant</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">Topical</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;;text-align:center;">Preclinical</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: bottom;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">ARU-2801</div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">Hypophosphatasia</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">Aruvant</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">Gene&#160;Therapy</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;;text-align:center;">Preclinical</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: bottom;">AFM32</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">Solid Tumors</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">Affivant</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">Biologic</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;;text-align:center;">Preclinical</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: bottom;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">CVT-TCR-01</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">Oncologic&#160;Malignancies</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">Cytovant</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">Cell Therapy</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;;text-align:center;">Preclinical</td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-family: Times New Roman; font-size: 8pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">Note: All drugs in current pipeline are investigational and subject to health authority approval. </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The following table summarizes our discovery stage pipeline: </div></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="font-size: 0px;">
<td style="width: 29%; font-family: &quot;Times New Roman&quot;;"></td>
<td style="width: 1%; vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="width: 33%; font-family: &quot;Times New Roman&quot;;"></td>
<td style="width: 1%; vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="width: 17%; font-family: &quot;Times New Roman&quot;;"></td>
<td style="width: 1%; vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="width: 8%; font-family: &quot;Times New Roman&quot;;"></td>
<td style="width: 1%; vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="width: 9%; font-family: &quot;Times New Roman&quot;;"></td> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;"> <div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 1pt; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">Target</div></div></div> </td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;&#160;</td>
<td style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 1pt; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">Therapeutic Area</div></div></div> </td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;&#160;</td>
<td style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 1pt; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">Vant</div></div></div> </td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;&#160;</td>
<td style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 1pt; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">Modality</div></div></div> </td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;&#160;</td>
<td style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 1pt; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">Phase</div></div></div> </td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: bottom;">AR</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">Prostate Cancer</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">Proteovant</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">Degrader</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">Preclinical</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: bottom;">STAT3</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">Oncology, Immunology</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">Proteovant</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">Degrader</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">Preclinical</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: bottom;">Undisclosed</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">Oncology</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">Proteovant</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">Degrader</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">Discovery</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: bottom;">CBP/p300</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">Oncology</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">Proteovant</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">Degrader</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">Discovery</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: bottom;">SMARCA2/4</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">Oncology</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">Proteovant</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">Degrader</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">Discovery</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: bottom;">Undisclosed</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">Oncology</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">Proteovant</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">Degrader</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">Discovery</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: bottom;">Multiple&#160;Additional&#160;Targets&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">Oncology, Immunology</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">Proteovant</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">Degrader</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">Discovery</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: bottom;">WRN</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">Oncology</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">Roivant Discovery</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">Inhibitor</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">Discovery</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: bottom;">JAK2-617F</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">Oncology</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">Roivant&#160;Discovery</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">Inhibitor</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">Discovery</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: bottom;">CRAF</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">Oncology</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">Roivant Discovery</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">Inhibitor</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">Discovery</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: bottom;">HIF2A</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">Oncology</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">Roivant Discovery</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">Degrader</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">Discovery</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: bottom;">ADAR1</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">Oncology</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">Roivant Discovery</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">Inhibitor</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">Discovery</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: bottom;">STING</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">Immunology</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">Roivant Discovery</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">Degrader</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">Discovery</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: bottom;">NLRP3</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">Immunology</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">Roivant Discovery</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">Degrader</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">Discovery</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: middle;">Multiple Additional Targets</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: middle;">Oncology,&#160;Neurology, Immunology</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: middle;">Roivant Discovery</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: middle;">Degrader</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: middle;">Discovery</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: bottom;">KRAS G12D</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">Oncology</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">Proteovant, Roivant Discovery</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">Degrader</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">Discovery</td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-family: Times New Roman; font-size: 8pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">Note: All drugs in current pipeline are investigational and subject to health authority approval. </div></div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">143 </div></div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;;font-weight: bold;"><a href="#toc">Table of Contents</a></div> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The following table summarizes the opportunity profile as well as potential indications and target populations for select programs in our discovery stage pipeline at Roivant Discovery: </div></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="font-size: 0px;">
<td style="width: 9%; font-family: &quot;Times New Roman&quot;;"></td>
<td style="width: 1%; vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="width: 45%; font-family: &quot;Times New Roman&quot;;"></td>
<td style="width: 1%; vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="width: 44%; font-family: &quot;Times New Roman&quot;;"></td> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; white-space: nowrap; padding-bottom: 1pt;;text-align:center;"> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt; border-bottom: 1pt solid rgb(0, 0, 0); display: inline-block; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">Target &amp;<br/>MoA</div></div></div> </td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;&#160;</td>
<td style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 1pt; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">Opportunity Profile</div></div></div> </td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;&#160;</td>
<td style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 1pt; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">Potential Indications/Patient Populations</div></div></div> </td> </tr>
<tr style="font-size: 1pt;">
<td style="height: 6pt; font-family: &quot;Times New Roman&quot;;"></td>
<td colspan="2" style="height: 6pt; font-family: &quot;Times New Roman&quot;;"></td>
<td colspan="2" style="height: 6pt; font-family: &quot;Times New Roman&quot;;"></td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td rowspan="2" style="vertical-align: top;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">KRAS<br/>G12D<br/>Degrader</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: top;">&#8226;&#8195;&#8202;Historically undruggable oncogene variant<br/>G12D</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: top;">&#8226;&#8195;&#8202;KRAS G12D mutant tumors</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: top;">&#8226;&#8195;&#8202;Most frequently mutated oncogene in<br/>human cancers</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: top;">&#8226;&#8195;&#8202;Highest rates in PDAC, CRC, endometrial<br/>and lung cancer</td> </tr>
<tr style="font-size: 1pt;">
<td style="height: 6pt;"></td>
<td colspan="2" style="height: 6pt;"></td>
<td colspan="2" style="height: 6pt;"></td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td rowspan="2" style="vertical-align: top;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">NLRP3<br/>Degrader</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: top;">&#8226;&#8195;&#8202;Inflammasome; innate immune pathway<br/>target; central regulator of <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">IL-1&#223;</div> and <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">IL-18</div><br/>cytokine secretion</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: top;">&#8226;&#8195;&#8202;Autoimmune and inflammatory diseases<br/>such as Cryoporin-associated periodic<br/>syndromes (CAPS), gout, SLE, IBD,<br/>Behcet&#8217;s, and asthma</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: top;">&#8226;&#8195;&#8202;Drives inflammation across a broad range<br/>of chronic disorders</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: top;">&#160;</td> </tr>
<tr style="font-size: 1pt;">
<td style="height: 6pt;"></td>
<td colspan="2" style="height: 6pt;"></td>
<td colspan="2" style="height: 6pt;"></td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td rowspan="2" style="vertical-align: top;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">ADAR1<br/>Inhibitor</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: top;">&#8226;&#8195;&#8202;Intracellular innate immune checkpoint<br/>target and biomarker defined tumor cell<br/>dependency</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: top;">&#8226;&#8195;&#8202;Type I <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">IFN-high</div> solid tumors including<br/>lung, colon, breast, ovarian</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: top;">&#8226;&#8195;&#8202;Potential to overcome PD1/PDL1<br/>resistance</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: top;">&#160;</td> </tr>
<tr style="font-size: 1pt;">
<td style="height: 6pt; font-family: &quot;Times New Roman&quot;;"></td>
<td colspan="2" style="height: 6pt; font-family: &quot;Times New Roman&quot;;"></td>
<td colspan="2" style="height: 6pt; font-family: &quot;Times New Roman&quot;;"></td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td rowspan="3" style="vertical-align: top;;text-align:center;"> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">WRN<br/>Inhibitor</div></div></div> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 1pt; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">JAK2-<br/>617F<br/>Inhibitor</div></div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: top;">&#8226;&#8195;&#8202;Synthetic lethal target required in tumors<br/>with DNA damage repair deficiency</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: top;">&#8226;&#8195;&#8202;MSI colorectal and gastric cancers </td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: top;">&#8226;&#8195;&#8202;Potential for precision medicine approach </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: top;">&#8226;&#8195;&#8202;PARP inhibitor combinations</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: top;">&#8226;&#8195;&#8202;Selective for mutants of blood neoplasm<br/>driver</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: top;">&#8226;&#8195;&#8202;V617F driven myeloproliferative<br/>neoplasms: polycythemia vera, essential<br/>thrombocythemia, primary myelofibrosis<br/>and AML</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: top;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: top;">&#8226;&#8195;&#8202;NRAS mutant melanoma </td> </tr>
<tr style="font-size: 1pt;">
<td style="height: 6pt;"></td>
<td colspan="2" style="height: 6pt;"></td>
<td colspan="2" style="height: 6pt;"></td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td rowspan="2" style="vertical-align: top;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">CRAF<br/>Inhibitor</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: top;">&#8226;&#8195;&#8202;Synthetic lethal target required in KRAS<br/>and NRAS mutant tumors </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: top;">&#8226;&#8195;&#8202;KRASG12X (non G12C) tumors: lung,<br/>colon, many other GIs</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: top;">&#8226;&#8195;&#8202;CRAF mutant tumors</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: top;">&#8226;&#8195;&#8202;CRAF mutant GI cancers: gastric, colon,<br/>lung and other</td> </tr>
<tr style="font-size: 1pt;">
<td style="height: 6pt;"></td>
<td colspan="2" style="height: 6pt;"></td>
<td colspan="2" style="height: 6pt;"></td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">HIF2A<br/>Degrader</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: top;">&#8226;&#8195;&#8202;Synthetic lethal target required specifically<br/>in tumors with &#8220;Achilles&#8217; heel&#8221; mutation</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: top;">&#8226;&#8195;&#8202;VHL mutant RCC </td> </tr>
<tr style="font-size: 1pt;">
<td style="height: 6pt;"></td>
<td colspan="2" style="height: 6pt;"></td>
<td colspan="2" style="height: 6pt;"></td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: top;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: top;">&#8226;&#8195;&#8202;Pheochromocytoma</td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-family: Times New Roman; font-size: 8pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">Note: All drugs in current pipeline are investigational and subject to health authority approval. </div></div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">144 </div></div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;;font-weight: bold;"><a href="#toc">Table of Contents</a></div> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="text-decoration: underline; letter-spacing: 0px; top: 0px;;display:inline;">Dermavant Overview </div></div></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 3%; vertical-align: top;;text-align:left;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#8226;</div></div></td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="text-decoration: underline; letter-spacing: 0px; top: 0px;;display:inline;">Overview</div>: </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 9%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Dermavant is developing tapinarof for the treatment of psoriasis and atopic dermatitis, alongside an earlier-stage development pipeline focused on multiple unmet medical needs in immuno-dermatology. </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 3%; vertical-align: top;;text-align:left;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#8226;</div></div></td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="text-decoration: underline; letter-spacing: 0px; top: 0px;;display:inline;">Lead program</div>: </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 9%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Tapinarof is a novel, once daily, steroid-free topical cream for the treatment of plaque psoriasis and atopic dermatitis. </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 9%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Tapinarof is a therapeutic aryl hydrocarbon receptor (AhR) modulating agent (TAMA) that directly targets the AhR, a key regulator of skin homeostasis and inflammation. </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 3%; vertical-align: top;;text-align:left;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#8226;</div></div></td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="text-decoration: underline; letter-spacing: 0px; top: 0px;;display:inline;">Disease overview</div>: </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 9%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Plaque psoriasis is a chronic, inflammatory disease with skin lesions characterized by red patches and plaques with silvery scales. </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 9%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Atopic dermatitis, the most common type of eczema, is a chronic condition characterized by dry, itchy skin. </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 9%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Psoriasis and atopic dermatitis affect approximately 8&#160;million and 26&#160;million people in the United States, respectively. </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 3%; vertical-align: top;;text-align:left;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#8226;</div></div></td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="text-decoration: underline; letter-spacing: 0px; top: 0px;;display:inline;">Limitations of current treatment</div>: </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 9%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Topical corticosteroids (TCS) are the most common first-line therapy but use typically cannot exceed four weeks due to risk of significant side effects. </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 9%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;">While oral and biologic therapies have become increasingly available, they are often limited to <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">moderate-to-severe</div></div> psoriasis and atopic dermatitis patients that comprise the smallest percentage of the affected populations. </div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 3%; vertical-align: top;;text-align:left;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#8226;</div></div></td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="text-decoration: underline; letter-spacing: 0px; top: 0px;;display:inline;">Clinical data</div>: </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 9%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">We completed two pivotal Phase 3 clinical trials, PSOARING 1 and PSOARING 2, for the use of tapinarof in treating mild, moderate, and severe plaque psoriasis in adults. </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 9%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">In both pivotal Phase 3 trials, which enrolled over 500 patients each, tapinarof met its primary endpoint and secondary endpoints with clinically meaningful and statistically significant responses. </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 9%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;">Our long-term open-label PSOARING 3 study provides supportive evidence of tapinarof&#8217;s increased therapeutic effect beyond the <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">12-week</div> double-blind treatment periods, suggesting treatment durability over time, as well as supportive evidence of a remittive effect, measured by time until disease worsening following treatment discontinuation. </div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 3%; vertical-align: top;;text-align:left;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#8226;</div></div></td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="text-decoration: underline; letter-spacing: 0px; top: 0px;;display:inline;">Development plan and upcoming milestones</div>: </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 9%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">We have filed an NDA with the FDA for tapinarof cream for the treatment of adults with plaque psoriasis and are expecting a decision on tapinarof&#8217;s approval in the second quarter of calendar year 2022. </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 9%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">If approved, tapinarof would be the first novel topical therapy approved by the FDA for plaque psoriasis in over 20 years, potentially offering a favorable mix of treatment effect, safety, durability of therapy, and remittive effect. </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">145 </div></div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;;font-weight: bold;"><a href="#toc">Table of Contents</a></div> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;">
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 9%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">In September 2021, we dosed the first patient in a Phase 3 trial of tapinarof for the treatment of atopic dermatitis. We expect to release topline data from our Phase 3 program in atopic dermatitis in the first half of calendar year 2023. </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 3%; vertical-align: top;;text-align:left;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#8226;</div></div></td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="text-decoration: underline; letter-spacing: 0px; top: 0px;;display:inline;">Roivant ownership</div>: </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 9%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">As of June&#160;30, 2021, we own 100% of the issued and outstanding Common Shares of Dermavant and 84% on a fully diluted basis. </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 3%; vertical-align: top;;text-align:left;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#8226;</div></div></td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="text-decoration: underline; letter-spacing: 0px; top: 0px;;display:inline;">Pipeline</div>: </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; margin-top: 0pt; margin-bottom: 0pt;">
<img alt="" src="g164680g99s99.jpg" style="width: 605px; height: 174px;"/><br/></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Tapinarof for the Treatment of Psoriasis and Atopic Dermatitis </div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;">Tapinarof is a novel, once daily, cosmetically elegant, steroid-free topical cream TAMA. Tapinarof directly targets the AhR, a key regulator of skin homeostasis and inflammation, to help reduce Th17 and Th2 cytokines, two <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">pro-inflammatory</div> pathways implicated in plaque psoriasis and atopic dermatitis, increase antioxidant activity, and promote skin barrier restoration. Tapinarof cream is designed to be easy to apply, <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-greasy</div> and odorless, which we believe makes it cosmetically elegant. To date, over 2,200 subjects have been enrolled in 18 clinical trials of tapinarof and predecessor formulations of tapinarof cream. </div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Psoriasis and atopic dermatitis </div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Psoriasis and atopic dermatitis (&#8220;AD&#8221;) affect hundreds of millions of people globally each year, impacting their quality of life, including their physical health, psychological state, and overall well-being. While topical therapies are the foundation of treatment, many patients fail to achieve their desired outcome due to subpar efficacy, tolerability and safety concerns, application site restrictions and limits on duration of therapy. </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Psoriasis is a chronic, inflammatory disease with skin lesions characterized by red patches and plaques with silvery scale that affects an estimated 8&#160;million people in the United States. Its most common form, psoriasis vulgaris or plaque psoriasis, constitutes approximately 80 to 90% of all cases of psoriasis. Psoriasis severity is typically classified by body surface area (&#8220;BSA&#8221;) involvement: mild (less than 3% BSA), moderate (3% to 10% BSA) and severe (greater than 10% BSA). Based on this guideline, approximately 80% of patients with psoriasis in the United States have mild to moderate disease, which is most often amenable to topical treatment. Common signs and symptoms of psoriasis include itching and burning, which can be very intense and frequent. Other symptoms can include cracking and bleeding of the skin. Psoriasis can cause significant social and emotional distress. </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Atopic dermatitis is the most common type of eczema, affecting more than 9.6&#160;million children and about 16.5&#160;million adults in the United States. It is a chronic condition characterized by dry, itchy skin that often turns into a red rash. Atopic dermatitis can come and go for years or throughout life and can overlap with other types of eczema. Atopic dermatitis has a complex pathophysiology involving genetic, immunologic and environmental factors, culminating in skin barrier dysfunction and immune system dysregulation. The condition occurs most </div></div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">146 </div></div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;;font-weight: bold;"><a href="#toc">Table of Contents</a></div> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">frequently in children (15 to 30% worldwide). Approximately 60% of those who develop atopic dermatitis show symptoms in the first year of life and up to 90% show symptoms by five years of age. While more prevalent in infancy and adolescence, one in ten people will develop atopic dermatitis. Approximately 89% of adult patients have mild to moderate atopic dermatitis, while 11% have severe atopic dermatitis. Atopic dermatitis is associated with several comorbidities, including asthma, allergies depression, and sleep disruption, and could negatively impact quality of life. </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">While topical therapies are the foundation of treatment, many patients fail to achieve their desired outcome due to subpar efficacy, tolerability and safety concerns, application site restrictions and limits on duration of therapy. Topical corticosteroids (&#8220;TCS&#8221;) are commonly used as the first-line therapy for the treatment of inflammatory skin conditions, such as psoriasis and atopic dermatitis. They are broadly available in generic form and carry FDA class labeling that restrict their duration of use, typically to no more than four weeks, and their location of use, prohibiting use in sensitive skin areas such as the face, groin, or axillae (armpit). While many people experience improvement with TCS, the continual long-term use of TCS has the potential to cause significant side effects including skin atrophy. As a result, healthcare professionals and patients are limited to intermittent treatment cycles of TCS therapy, leading to frequent disease flares and recurrence of disease, providing an inadequate solution for chronic conditions in immuno-dermatology. Topical calcineurin inhibitors (&#8220;TCI&#8221;) are an additional <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-steroidal</div> option for the topical treatment of atopic dermatitis, but their use is limited by safety concerns, including boxed warnings of malignancy reported in patients treated with TCIs. Oral and biologic therapies have become increasingly available but are often limited to <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">moderate-to-severe</div></div> psoriasis and atopic dermatitis patients which comprise the smallest percentage of the affected populations. While biologics have proven to be very effective, their use has also been limited by concerns with systemic side effects, high cost, and reimbursement and access restrictions. Oral therapies are functionally limited to <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">moderate-to-severe</div></div> psoriasis patients. Oral therapies also have significant side effects and have not achieved the same level of efficacy as biologics. Additionally, recent FDA action regarding Janus kinase inhibitors (&#8220;JAKs&#8221;) have resulted in restrictive labeling and black box warnings relating to safety concerns with the product class, including oral and topical forms, and including for the topical treatment of atopic dermatitis. </div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Given the limitations associated with TCS, other topicals, orals, and biologics therapies, patients with inflammatory skin conditions often report dissatisfaction with their current treatment options. </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Psoriasis and atopic dermatitis represent the two largest markets in immuno-dermatology and are expected to reach total sales of approximately $31&#160;billion in the U.S. and $44&#160;billion globally by 2026. Topical treatments serve as the foundation of dermatologic treatment, representing 83% of all U.S. prescriptions written by dermatologists in 2020. Additionally, we believe that tapinarof has the potential to be prescribed alongside biologics and oral therapies. Annual U.S. prescriptions for both psoriasis and atopic dermatitis are outlined below: </div></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 8pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="font-size: 0px;">
<td style="width: 58%;"></td>
<td style="width: 2%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td>
<td style="width: 2%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td>
<td style="width: 2%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td>
<td style="width: 2%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td>
<td style="width: 2%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">TCS</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Vitamin&#160;D&#160;/<br/>Combos<br/>/ Retinoids</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Biologics</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Otezla</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Other&#160;Oral</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Annual Scripts for PsO (2020)</div></div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">~2.35M</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">~508K</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">~1.05M</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">~258K</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">~241K</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 8pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="font-size: 0px;">
<td style="width: 71%;"></td>
<td style="width: 1%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td>
<td style="width: 1%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td>
<td style="width: 1%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td>
<td style="width: 1%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">TCS</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">TCI</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Eucrisa</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Dupixent</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Annual Scripts for AD (2020)</div></div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">~16.4M</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">~996K</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">~352K</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">~344K</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">147 </div></div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;;font-weight: bold;"><a href="#toc">Table of Contents</a></div> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"> <div style="text-align: center; margin-top: 0pt; margin-bottom: 0pt;">
<img alt="" src="g164680g98s98.jpg" style="width: 605px; height: 283px;"/><br/></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Source: EvaluatePharma </div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Tapinarof for the Treatment of Psoriasis </div></div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Clinical data </div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;">We completed two pivotal Phase 3 clinical trials, PSOARING 1 and PSOARING 2, evaluating the use of tapinarof in treating mild, moderate and severe plaque psoriasis in adults. In both of these trials, which enrolled over 500 patients each, tapinarof met its primary endpoint and all secondary endpoints with clinically meaningful and statistically significant responses as well as favorable safety and tolerability findings. At week 12, 35.4% and 40.2% of patients treated with tapinarof in PSOARING 1 and PSOARING 2, respectively, achieved the primary efficacy endpoint of a Physician Global Assessment (PGA) score of clear (0)&#160;or almost clear (1)&#160;with a minimum <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">2-grade</div> improvement from baseline as compared to 6.0% and 6.3% of patients treated with vehicle cream (p&lt;0.0001; p&lt;0.0001). When this endpoint was evaluated over time, rapid onset of activity was observed with separation emerging by the first evaluation trial visit (week 2) and statistically significant differences between tapinarof and vehicle cream at week 4 and continuing at all measured time points thereafter. </div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">Tapinarof met all secondary endpoints with statistical significance in PSOARING 1 and PSOARING 2, including a key secondary endpoint, the proportion of subjects with <div style="font-family: SYMBOL; letter-spacing: 0px; top: 0px;;display:inline;">&#179;</div>75% improvement in Psoriasis Area and Severity Index (PASI75). In PSOARING 1 and 2, 36.1% and 47.6% of patients achieved PASI75 at Week 12 with tapinarof 1% cream QD vs 10.2% and 6.9% for vehicle, respectively. The PASI assessment is a more quantitative assessment of disease activity relative to the PGA and provides additional insight into a drug&#8217;s impact on disease modification. Similar to what was observed with PGA, evaluating reduction in the burden of disease via a PASI assessment confirms rapid onset of action with separation of tapinarof from vehicle cream control at week 2, and statistically significant differences were noted as early as week 4 and each evaluation thereafter. </div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Additionally, tapinarof was observed to be well-tolerated, consistent with previous trials, and had low discontinuation rates due to adverse events (&#8220;AEs&#8221;), no treatment related serious adverse events (&#8220;SAEs&#8221;), and minimal severe application site reactions. </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Tapinarof was observed to be well-tolerated in both trials, with AEs generally mild to moderate in nature and the majority consisting of localized skin reactions. Overall trial discontinuations due to adverse events were </div></div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">148 </div></div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;;font-weight: bold;"><a href="#toc">Table of Contents</a></div> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">5.6% in PSOARING 1 and 5.8% in PSOARING 2. Trial discontinuation rates due to folliculitis were 1.8% in PSOARING 1 and 0.9% in PSOARING 2. No tapinarof-related severe adverse events were observed, and over 90% of eligible patients enrolled in the long-term extension study. To date, over 2,200 subjects have been enrolled in 18 clinical trials of tapinarof and predecessor formulations of tapinarof cream. </div></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; margin-top: 0pt; margin-bottom: 0pt;">
<img alt="" src="g164680g00y06.jpg" style="width: 605px; height: 233px;"/><br/></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 8pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 2%; vertical-align: top;;text-align:left;">*</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;">Patients with PGA of 2 (mild) and PGA of 4 (severe) limited to ~10% each of the total randomized population;~80% of the total randomized population with PGA of 3 (moderate); &#8224;Patients electing not to participate in LTE had <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">follow-up</div> visit 4 weeks after completion of treatment period. BSA, body surface area; LTE, long-term extension; PASI75, <div style="font-family: SYMBOL; letter-spacing: 0px; top: 0px;;display:inline;">&#179;</div> 75% improvement in Psoriasis Area and Severity Index; PASI90, <div style="font-family: SYMBOL; letter-spacing: 0px; top: 0px;;display:inline;">&#179;</div> 90% improvement in Psoriasis Area and Severity Index; PGA, Physician Global Assessment; QD, once daily. 1. Clinicaltrials.gov; NCT03956355. 2. Clinicaltrials.gov; NCT03983980. 3. Clinicaltrials.gov; NCT04053387. </div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; margin-top: 0pt; margin-bottom: 0pt;">
<img alt="" src="g164680g00y07.jpg" style="width: 545px; height: 379px;"/><br/></div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">149 </div></div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;;font-weight: bold;"><a href="#toc">Table of Contents</a></div> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"> <div style="text-align: center; margin-top: 0pt; margin-bottom: 0pt;">
<img alt="" src="g164680g00y08.jpg" style="width: 546px; height: 384px;"/><br/></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; margin-top: 0pt; margin-bottom: 0pt;">
<img alt="" src="g164680g00y09.jpg" style="width: 599px; height: 293px;"/><br/></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The below figure shows rapid and complete clearance of plaque psoriasis in a patient achieving the defined trial endpoint. At baseline, this patient&#8217;s PGA score was 3, indicative of moderate disease, and the PASI score was 17.6. The baseline image demonstrates classic plaque psoriasis with well demarcated erythematous scaling plaques. At week 4, the PGA had decreased from 3 to 2 and the PASI from 17.6 to 4, the latter having passed the threshold 75% reduction in PASI (PASI75). The target plaques on the forearm are completely resolved. At week 12, both the PGA and PASI scores were 0, indicating complete clearance of disease. PGA and PASI are global efficacy assessments. </div></div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">150 </div></div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;;font-weight: bold;"><a href="#toc" style="text-indent: 0px;">Table of Contents</a></div> <div> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"> <div style="font-size: 13.28px; margin-top: 0pt; margin-bottom: 0pt; line-height: 0pt;;font-weight: bold;"><br/></div> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"> <div style="text-align: center; margin-top: 0pt; margin-bottom: 0pt;">
<img alt="" src="g164680g00y10.jpg" style="width: 596px; height: 306px;"/><br/></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">In September 2021, we reported the final results from our long-term open-label study, PSOARING 3, which showed that 58.2% of subjects who entered the PSOARING 3 study with a PGA score of <div style="font-family: SYMBOL; letter-spacing: 0px; top: 0px;;display:inline;">&#179;</div> 2 achieved a PGA score of 0 or 1 at least once during the study. Although PSOARING 3 was not a vehicle-controlled study unlike the prior two PSOARING studies, we believe these data provide supportive evidence regarding tapinarof&#8217;s potential therapeutic effect beyond the <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">12-week</div> doubleblind treatment periods utilized in PSOARING 1 and PSOARING 2. In addition, 312 out of 763 subjects (40.9%) achieved complete disease clearance (PGA score of 0) at least once during the study. We observed no evidence of tachyphylaxis, or a diminishing response to treatment, throughout the study, which we believe suggests treatment durability over time. </div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">At the time of an interim analysis of PSOARING 3 open-label study results in February 2021, we completed an integrated summary of efficacy (ISE) that included data from PSOARING 1, PSOARING 2 and the PSOARING 3 interim analysis summary from subjects with a PGA score of <div style="font-family: SYMBOL; letter-spacing: 0px; top: 0px;;display:inline;">&#179;</div> 2 prior to tapinarof administration. In the integrated analysis, we identified a PGA response of clear (0)&#160;or almost clear (1), plus at least a <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">2-grade</div> improvement from baseline, at any time point, in 57% of subjects, PASI75, at any time point, in 63.5% of subjects, and PASI90, at any time point, in 44.2% of subjects, providing evidence of improvement beyond the 12 week double-blind treatment period. </div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">In our pivotal Phase 3 clinical trials, we observed that tapinarof&#8217;s treatment effect did not decline with continued use over the duration of the trials, which we refer to as durability on therapy. While statistically significant differences in favor of tapinarof were observed in the <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">12-week,</div> double-blind studies, in our open-label, <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">single-arm</div> PSOARING 3 long-term study, continued improvement was observed in both PGA and PASI beyond 12 weeks with continued use of tapinarof. This observation of continued improvement in reducing disease burden (durability on therapy) was evidenced by the number of patients who achieved complete disease clearance at 12 weeks (n=79) and with continued use beyond 12 weeks, an additional 233 patients achieved complete disease clearance, indicating no evidence of loss of treatment effect over time. </div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">Relatedly, in our clinical trials we have also observed, including data from our PSOARING 3 long-term open-label study, that some patients treated with tapinarof maintained clinically meaningful disease control for an extended period of time after therapy had been discontinued. In PSOARING 3, subjects discontinued applying tapinarof when they achieved complete clearance of their disease (PGA=0). These subjects were then followed, and the time to first worsening (defined as PGA <div style="font-family: SYMBOL; letter-spacing: 0px; top: 0px;;display:inline;">&#179;</div> 2) was utilized to determine the maintenance of clinical benefit off therapy, and we refer to maintenance of clear/almost clear (PGA 0/1) while off therapy as remittive effect. At </div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">151 </div></div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> </div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em; text-align: left;;font-weight: bold;"><a href="#toc">Table of Contents</a></div> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0px;">the completion of the Week 12 visit of the PSOARING 1 and PSOARING 2 trials, subjects were offered enrollment in the PSOARING 3 long-term open-label study. Subjects with a PGA <div style="font-family: SYMBOL; letter-spacing: 0px; top: 0px;;display:inline;">&#179;</div> 1 began treatment with tapinarof cream applied QD until they achieved a PGA score of 0. Treatment was discontinued when a subject achieved a PGA score of 0 and <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">re-initiated</div> for subsequent worsening disease (PGA&#160;<div style="font-family: SYMBOL; letter-spacing: 0px; top: 0px;;display:inline;">&#179;</div> 2). </div> </div> </div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">In PSOARING 3, for subjects entering the study with a PGA score of 0 (79/763), the median time to disease worsening (defined as a PGA score of <div style="font-family: SYMBOL; letter-spacing: 0px; top: 0px;;display:inline;">&#179;</div> 2) following complete disease clearance and treatment discontinuation was approximately 115 days. In addition, among patients entering PSOARING 3 with or achieving a PGA score of 0 (312/763), the mean total duration of time to disease worsening following treatment discontinuation was approximately 130 days. </div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Development plan </div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">We have filed an NDA with the FDA for tapinarof cream for the treatment of adults with plaque psoriasis and are expecting a decision on tapinarof&#8217;s approval in the second quarter of calendar year 2022. Tapinarof has the potential to be the first novel topical therapy approved by the FDA for plaque psoriasis in over 20 years. </div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Tapinarof for the Treatment of Atopic Dermatitis </div></div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Clinical data </div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;">In 2017, GSK completed a multicenter randomized, double-blind, vehicle cream-controlled Phase 2b clinical trial of tapinarof for the treatment of atopic dermatitis in 247 adult (aged 18 to 65 years) and adolescent (aged 12 to 17 years) patients. Patients were randomized equally to six treatment groups: tapinarof cream 0.5%, tapinarof cream 1% or vehicle cream, each applied to atopic dermatitis lesions either QD or BID. The primary endpoint was the percentage of patients who achieved a minimum <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">two-point</div> improvement in IGA score and resulted in an assessment of &#8220;clear&#8221; or &#8220;almost clear&#8221; skin at week 12. These cases were considered a &#8220;treatment success.&#8221; Secondary endpoints included the percentage of patients with at least 75% improvement in Eczema Area and Severity Index (EASI) from baseline. Efficacy was evaluated in the intent to treat (ITT) population. </div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Overall, the percentage of patients achieving treatment success at week 12 was much higher than vehicle cream for both tapinarof concentrations, with a robust dose response. Treatment success at week 12 was higher for both tapinarof concentrations when compared with vehicle cream. 53% of patients who applied tapinarof cream 1% BID and 46% of those who applied it QD were considered a treatment success at week 12. This compares favorably to the 24% and 28% levels for vehicle cream BID and QD, respectively. At week 12, 60% and 51% of patients treated with tapinarof cream 1% BID and QD, respectively, achieved EASI75. The treatment effect across adults and adolescents was observed to be consistent. Patient-reported outcome data was collected during the Phase 2b clinical trial, including data on reduction in severity of pruritus. At week 12, most patients treated with tapinarof cream 1% (78% of patients treated BID and 87% of patients treated QD) reported &#8220;moderately improved&#8221; to &#8220;very improved&#8221; pruritus, compared to patients treated with vehicle cream (47% of patients treated BID and 64% of patients treated QD). </div></div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">152 </div></div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;;font-weight: bold;"><a href="#toc">Table of Contents</a></div> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">IGA score 0 or 1 and </div></div><div style="font-family: SYMBOL; letter-spacing: 0px; top: 0px;;display:inline;">&#179;</div><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">2-grade</div> improvement at Week 8 </div></div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Primary Endpoint was at 12 Weeks: Assessed in ITT Population (NRI Analysis) </div></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; margin-top: 0pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="color: red; letter-spacing: 0px; top: 0px;;display:inline;">
<img alt="" src="g164680g00y11.jpg" style="width: 605px; height: 331px;"/></div> </div></div> <div style="font-family: Times New Roman; font-size: 8pt; margin-top: 12pt; margin-bottom: 0pt;">IGA response: IGA score of 0 or 1 and a <div style="font-family: SYMBOL; letter-spacing: 0px; top: 0px;;display:inline;">&#179;</div><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">2-grade</div> improvement from baseline. </div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 8pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 2%; vertical-align: top;;text-align:left;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">*</div></div></td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Difference versus vehicle cream is statistically significant at p=0.05 level (the 95% confidence interval excludes 0). </div></div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Tapinarof was observed to be well-tolerated in this Phase 2b trial for atopic dermatitis, with the majority of AEs reported as mild or moderate in intensity. In the trial, TEAEs were considered treatment-related in 10% to 19% of dosed patients across the treatment arms. The most commonly reported TEAEs were folliculitis, application-site pain and atopic dermatitis. TEAEs led to permanent discontinuation of trial treatment in 4% of dosed patients (seven patients from treatment groups total) compared to 7% of patients receiving vehicle cream (six patients total). Only one patient (tapinarof 1% BID) experienced a SAE of anxiety and hyperactive disorder, which was not considered to be related to treatment. </div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt; margin-left: 4%;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Development plan </div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;">We recently initiated ADORING 1 and ADORING 2, two identically designed, multi-center, randomized, vehicle-controlled, double-blind parallel Phase 3 clinical trials of tapinarof for the treatment of atopic dermatitis, and we dosed the first patient in September 2021. We expect to release topline data from ADORING 1 and ADORING 2 in the first half of calendar year 2023. The two trials will enroll up to 800 patients across both trials to evaluate the safety and efficacy of tapinarof cream, 1% dosed once daily (QD) for 8 weeks versus vehicle cream QD in patients aged 2 years and older diagnosed with moderate to severe atopic dermatitis. The primary endpoint of both studies will be the percentage of patients achieving a Validated Investigator Global Assessment for Atopic Dermatitis <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">(vIGA-AD</div><div style="font-size: 85%; vertical-align: top;;display:inline;;font-size:9.4px">&#8482;</div>), of 0 or 1 with at least a <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">2-grade</div> improvement from baseline at week 8. </div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">Additionally, we are planning ADORING 3, a long-term, open-label, extension study to evaluate the safety and efficacy of tapinarof cream, 1% in patients with atopic dermatitis. Subjects in the study will include those who have previously completed treatment with tapinarof or vehicle in ADORING 1 or ADORING 2. ADORING 3 will consist of up to 48 weeks of tapinarof cream, 1%, and a <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">7-day</div> safety <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">follow-up</div> period. </div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">153 </div></div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;;font-weight: bold;"><a href="#toc">Table of Contents</a></div> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Potential Benefits of Tapinarof&#8212;Limitations of Current Treatments </div></div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Tapinarof&#8217;s potential in psoriasis </div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;">While TCS, especially high potency TCS, are the most commonly prescribed first line topical agents for plaque psoriasis treatment, continual and long-term TCS treatment carries the risk of a variety of significant side effects, as well as the inability to utilize them in sensitive skin areas (e.g., areas such as the face, groin, or axillae), and is associated with HPA axis suppression, skin atrophy (thinning), striae (stretch marks), and telangiectasia (spider veins), among other side effects. Furthermore, some of these side effects are irreversible, persisting even after therapy is discontinued. Consequently, high-potency TCS are not recommended for chronic use, and physicians generally will not prescribe them for treatment on the face or in the intertriginous regions where skin opposes skin, such as skin folds. For example, the label for clobetasol propionate, the most commonly used high-potency steroid, limits use to two consecutive weeks, and use on the face or intertriginous regions is contraindicated. Facial psoriasis affects <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">33%-50%</div> of psoriasis patients, and between <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">21%-30%</div> of people living with psoriasis develop intertriginous psoriasis. </div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Oral and biologic therapies are also available but are only indicated for a small percentage of the affected population, are expensive and often face access and reimbursement restrictions. While highly efficacious, biologic therapies may require frequent injections and regular physician appointments, have potential systemic toxicities and often require laboratory monitoring. As a result, use of biologics remains limited to patients with significant disease burden. Patients on biologics often continue to use TCS on resistant patches and plaques. Oral therapies have not yet achieved the same level of efficacy as biologics, but also have potential systemic side-effects, often requiring dose titration to mitigate adverse reactions. Systemic exposure to PDE4 inhibitors has been linked to depression and suicidal ideation. For example, the FDA labeling for both Otezla, the leading branded oral PDE4 inhibitor, and roflumilast, recommends advising patients to be alert for the emergence or worsening of suicidal thoughts or other mood changes, and indicates that instances of suicidal ideation and behavior were observed in clinical trials. In addition, Otezla requires dosing twice daily (BID), which can compromise adherence to the treatment regimen. Despite inferior efficacy compared to biologics, oral therapies comprise significant market share. Otezla generated over $2&#160;billion in worldwide sales in psoriasis and psoriatic arthritis in 2020, indicating a need for more convenient treatment options with efficacy across the disease spectrum of mild to severe. In two Phase 3 trials in psoriasis patients, 20% and 22% of patients on oral Otezla achieved a PGA response at week 16, vs. 4% and 4% for placebo, respectively. </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">We believe tapinarof&#8217;s differentiated clinical profile has five key attributes that will position it favorably over current standard of care treatments in psoriasis, including TCS therapies, if approved. </div></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; margin-top: 0pt; margin-bottom: 0pt;">
<img alt="" src="g164680g97s97.jpg" style="width: 606px; height: 279px;"/><br/></div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">154 </div></div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;;font-weight: bold;"><a href="#toc">Table of Contents</a></div> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">We have commissioned robust qualitative and quantitative prescriber, payor and patient third party market research, involving more than 500 health care providers, more than 300 patients and 65 payors. Based on this market research, we believe that an unmet need exists in psoriasis for a safe and conveniently administered <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-steroidal</div> topical therapy that can be applied without interruption or long-term safety concerns and has potential efficacy similar to that of TCS and some systemically administered products. If approved, such a treatment could provide a significant improvement for those patients who do not receive adequate relief from current topical therapies or who have reservations about the safety and cost of oral medications or biologics or are unable to access these therapies. Our market research indicates that payors perceive tapinarof as a novel therapy that, if approved, could provide the potential to arrest the increasing cost trend of the psoriasis category, based on a survey of 15 payors. If approved, tapinarof could give national payors the opportunity to reduce spend in the overall psoriasis therapeutic class while allowing physicians and patients access to a potentially highly potent, safe, and tolerable treatment option for plaque psoriasis before moving to more costly oral and biologic therapies. TCS, due to their FDA label safety limitations, do not allow payors the versatility to aggressively manage a chronic condition in a manner that can effectively control the psoriasis therapeutic category cost trend. </div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Based the clinically meaningful and statistically significant reduction in psoriasis symptoms tapinarof demonstrated in both Phase 3 trials, coupled with safety data, we believe tapinarof could be used broadly without restriction on skin application sites, or duration of use if approved. We believe the Phase 3 data we have generated and the data observed in our open-label, long-term extension study support the chronic use of tapinarof, potentially in place of other topical and oral treatments, for the treatment of mild, moderate and severe plaque psoriasis, if approved. </div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Tapinarof&#8217;s potential in atopic dermatitis </div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;">TCS, especially <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">low-to-mid</div></div> potency TCS, represent the <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">standard-of-care</div></div> for atopic dermatitis treatment. Although they are used commonly, TCS pose a specific concern in pediatric patients due to the risk of systemic absorption, HPA axis suppression, skin thinning and other potential side effects. The increased body surface area to mass ratio in children results in increased absorption and systemic exposure. The American Academy of Dermatology guidelines suggest limiting long-term use of TCS in children to avoid the risk of systemic side effects. As such, 86% of U.S. patients report dissatisfaction with current treatment options for atopic dermatitis according to the National Eczema Association. There is also considerable concern among many parents about treating their children with steroids, which can be an obstacle to treatment for physicians. Due to these risks and patient dissatisfaction, health care providers are less likely to use them long-term in children and also in sensitive skin areas such as the face or diaper/groin area. In addition, topical PDE4 inhibitors developed to treat atopic dermatitis have been associated with side effects including application site burning and stinging. Topical calcineurin inhibitors are an additional <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-steroidal</div> option for the topical treatment of atopic dermatitis; however, their use has been limited by safety including boxed warnings of malignancy (e.g., skin and lymphoma) having been reported in patients treated with topical calcineurin inhibitors. </div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">Patients whose disease flares despite topical treatments may be prescribed systemic agents such as oral corticosteroids or oral cyclosporine to rapidly relieve severe signs and symptoms of the disease. While these are effective as temporary treatments of <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">flare-ups,</div> extended use has been associated with many potential side effects or adverse events. Systemic steroids, such as prednisone, can lead to symptom relief, but their use is not recommended to induce stable remission due to numerous side effects associated with steroids and the propensity of severe disease flares upon abrupt treatment cessation. Cyclosporine is also generally not recommended for use lasting longer than one to two years, as it has been associated with renal toxicity, hirsutism, nausea and lymphoma. Based on data from the 2014 Adelphi U.S. AD Disease Specific Program, over 58% of adults with <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">moderate-to-severe</div></div> atopic dermatitis have disease which physicians consider to be inadequately controlled by these therapeutic modalities. While biologic therapies are more efficacious, as is the case in psoriasis, use of therapies such as the recently approved Dupixent is limited to patients with significant disease burden as they are expensive, necessitate frequent injections, entail regular physician appointments, have potential systemic toxicities and often require laboratory monitoring. Additionally, recent </div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">155 </div></div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;;font-weight: bold;"><a href="#toc">Table of Contents</a></div> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">FDA action regarding JAKs have resulted in restrictive labeling and black box warnings relating to safety concerns with the product class, including oral and topical forms, and including for the topical treatment of atopic dermatitis. </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">We believe tapinarof has the potential to fill the need for a long-term treatment option for atopic dermatitis. We also believe that tapinarof has the potential to offer significant clinical advancement to address the incessant flare cycle experienced by atopic dermatitis patients that is the result of the short-term use limitation of <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">standard-of-care</div></div> TCS. </div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Since acquiring tapinarof in 2018, we have expanded our intellectual property with multiple patents, which are expected to expire beginning in 2036. </div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Tapinarof sales and marketing </div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;">If tapinarof is approved by the FDA for the treatment of mild, moderate or severe plaque psoriasis, we intend to commercialize it in the United States by building a highly specialized commercial sales organization focused on high value dermatology healthcare providers and their patients and implementing a <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">&#8220;best-in-class&#8221;</div></div> payor reimbursement and patient point of sale access strategy, which we believe will ensure broad patient access at launch. </div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">As psoriasis patients are predominantly managed by dermatologists, we intend to deploy a specialty sales team focused on a core target base of <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">top-decile</div> dermatologists who write more than 80% of all commercial prescriptions in the psoriasis market. We believe a scientifically oriented, customer-focused team of approximately 75 to 100 sales representatives will allow us to reach the approximately 6,000 highest value dermatology healthcare providers. For markets outside of the U.S., we may opportunistically seek strategic collaborations to maximize the commercial opportunities for tapinarof. </div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">If tapinarof or topical cerdulatinib are approved by the FDA for the treatment of atopic dermatitis, we plan to expand our psoriasis sales team to be able to reach additional specialists who see a significant amount of atopic dermatitis patients, such as pediatric dermatologists and allergists. Based on our commercial team&#8217;s experience developing and launching dermatology products in U.S., we believe we can effectively reach the psoriasis and atopic dermatitis core target base with a highly specialized sales team of 125 to 150 total sales representatives. </div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Earlier-Stage Pipeline </div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Beyond tapinarof, Dermavant&#8217;s pipeline consists of three novel product candidates targeting an array of significant unmet medical needs in the field of dermatology. </div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Cerdulatinib <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">(DMVT-502)</div> </div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;">We are evaluating topical cerdulatinib as a differentiated dual inhibitor of the JAK and Syk pathways. Given its unique mechanism of action, we believe that topical cerdulatinib, if approved, could provide a differentiated treatment option for vitiligo, a condition for which there are no FDA approved treatments that suppress vitiligo disease activity, as well as other inflammatory skin conditions that have already been validated for JAK inhibition, such as atopic dermatitis. We initiated a Phase 2a clinical trial of topical cerdulatinib for the treatment of vitiligo in 2019 and received <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">top-line</div> results in the first half of 2021 that met the primary endpoints of safety and tolerability. </div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Vitiligo is an inflammatory skin condition characterized by skin depigmentation resulting from the loss of skin melanocytes. It usually involves the face, digits, arms, inguinal area, anogenital area, umbilicus and nipples, and can also affect the hair. Affected patches of skin are sharply demarcated and noticeable, particularly among </div></div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">156 </div></div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;;font-weight: bold;"><a href="#toc">Table of Contents</a></div> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">patients with a darker natural skin color. Vitiligo is the most common skin depigmentation (color loss) disorder, affecting up to 1% of people of all ages, sexes, and ethnicities, worldwide. Vitiligo can severely impact patients&#8217; quality of life and psychological well-being due to its appearance and visibility, which can each persist for the duration of a patient&#8217;s life. </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">Based on preclinical data observed to date, we believe topical cerdulatinib&#8217;s dual JAK/Syk inhibition has the potential to be a powerful combination for the treatment of vitiligo. In a mouse model of vitiligo, the effect of topical cerdulatinib (dosed orally QD) on epidermal depigmentation and melanocyte-specific immunity was evaluated versus placebo over a five-week span. We observed a significant decrease in vitiligo scores compared with vehicle gel at doses of 30 mg/kg (<div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">p</div></div>=0.0003) and 60 mg/kg (<div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">p</div></div>=0.0001). The drug prevented epidermal depigmentation in the mice and was associated with a significant reduction of melanocyte-specific T cells in skin tissues. Topical administration has the potential to avoid systemic toxicities that are often associated with oral JAK inhibitors. </div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Given topical cerdulatinib&#8217;s unique dual JAK/Syk inhibitor mechanism of action, we believe it also has the potential to offer particular advantages for the treatment of atopic dermatitis. In a preclinical mouse model of atopic dermatitis, contact sensitization is experimentally induced via the application of dinitrochlorobenzene. Syk knockout mice are resistant to this chemically-induced contact dermatitis. By blocking Syk activity, topical cerdulatinib may suppress the role that exogenous contact antigens play in the activity and flares associated with atopic dermatitis. Inhibiting both pathways simultaneously has the potential to not only control inflammatory disease activity but also to reduce flare frequency. </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">We conducted a Phase 1 trial to investigate the safety, tolerability and PK profile of topical cerdulatinib over a <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">14-day</div> trial period in healthy volunteers and adults with atopic dermatitis. The results showed reductions in atopic dermatitis disease activity and evidence of drug-target engagement via biomarkers. Measures of epidermal hyperplasia showed improvements from treatment with topical cerdulatinib. Gene expression of immune markers was also reduced, which correlated with improvement in clinical response. Topical cerdulatinib gel 0.37% was generally observed to be well-tolerated among patients in this trial, with no serious AEs reported or trial discontinuations. </div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">DMVT-504</div> </div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">DMVT-504</div> is an investigational oral candidate that we are developing for the treatment of primary focal hyperhidrosis (PFH). <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">DMVT-504</div> combines an immediate-release muscarinic antagonist, oxybutynin, with a delayed-release muscarinic agonist, pilocarpine, designed to mitigate dry mouth typically observed with anticholinergic therapies for better long-term tolerability. </div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Primary focal hyperhidrosis is a condition characterized by excessive sweating&#8212;beyond what is physiologically required by the body or what is expected given the local environment and temperature. The most common focal areas affected by the disease are the underarms, palms of hands, soles of feet, and face. Approximately 80% of patients experience symptoms in multiple areas of the body, with 70% of patients reporting excessive sweating in multiple areas. Hyperhidrosis results in substantial impairments for patients; excessive sweating, which can range from mild to &#8220;dripping,&#8221; can severely limit social interactions, work productivity and physical activity. Hyperhidrosis has an estimated prevalence in the United States of 4.8%, representing approximately 15.3&#160;million people, half of whom are reportedly undiagnosed. </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">In a Phase 2a <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">proof-of-concept</div></div> clinical trial conducted by TheraVida, Inc. (TheraVida) in patients with PFH, <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">THVD-102</div> (a predecessor formulation of <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">DMVT-504)</div> significantly reduced Hyperhidrosis Disease Severity Score (HDSS) compared with placebo (p=0.04) and was also able to provide a statistically significant reduction (p=0.027) in dry mouth symptoms. In connection with additional formulation work, we have completed a Phase 1 clinical trial to investigate the safety, tolerability and PK profile of multiple formulations of <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">DMVT-504.</div> All formulations of <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">DMVT-504</div> assessed in the study were observed to be generally well-tolerated, and mean PK results showed a relationship between formulation and delayed-release characteristics. </div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">157 </div></div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;;font-weight: bold;"><a href="#toc">Table of Contents</a></div> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Given the site-specific nature of treating hyperhidrosis, we believe patients would benefit from an oral therapy that provides a <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-invasive</div> treatment approach with a simple dosing regimen, efficacy across multiple focal sites of excessive sweating, and limited side effects commonly associated with oral and biologic anti-cholinergic therapies. </div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">DMVT-503</div> </div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;">In addition to its clinical pipeline, Dermavant is developing <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">DMVT-503,</div> a topical DGAT1 inhibitor, as a treatment for acne vulgaris. We are conducting a <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">pre-clinical</div> mouse model study to explore the potential for <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">DMVT-503</div> to induce dose-dependent atrophy of sebum-producing sebaceous glands, a similar effect to and potential biomarker of isotretinoin efficacy. </div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">158 </div></div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;;font-weight: bold;"><a href="#toc">Table of Contents</a></div> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="text-decoration: underline; letter-spacing: 0px; top: 0px;;display:inline;">Immunovant Overview </div></div></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 3%; vertical-align: top;;text-align:left;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#8226;</div></div></td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="text-decoration: underline; letter-spacing: 0px; top: 0px;;display:inline;">Overview: </div> </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Immunovant is developing IMVT-1401 for the treatment of Myasthenia Gravis (&#8220;MG&#8221;), Warm Autoimmune Hemolytic Anemia (&#8220;WAIHA&#8221;) and Thyroid Eye Disease (&#8220;TED&#8221;). </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 3%; vertical-align: top;;text-align:left;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#8226;</div></div></td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="text-decoration: underline; letter-spacing: 0px; top: 0px;;display:inline;">Lead program:</div> </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">IMVT-1401 is a novel, fully human monoclonal antibody that selectively binds to and inhibits the neonatal fragment crystallizable receptor (&#8220;FcRn&#8221;). </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Designed to be a fixed-dose, self-administered subcutaneous (&#8220;SC&#8221;) injection on a convenient weekly, or less frequent, dosing schedule. </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">In nonclinical studies and in clinical trials conducted to date, IMVT-1401 has been observed to reduce immunoglobulin G (&#8220;IgG&#8221;) antibody levels. High levels of pathogenic IgG antibodies drive a variety of autoimmune diseases and, as a result, we believe IMVT-1401 has the potential for broad application in related disease areas. </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 3%; vertical-align: top;;text-align:left;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#8226;</div></div></td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="text-decoration: underline; letter-spacing: 0px; top: 0px;;display:inline;">Disease overview: </div> </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;">Advanced <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">IgG-mediated</div> autoimmune diseases had an aggregate prevalence of approximately 758,000 patients in 2020 in the United States and Europe. </div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">MG is a rare autoimmune disorder characterized by weakness of muscles including ocular, head, oropharyngeal, limb and respiratory muscles and affected an estimated 66,000 people in the U.S. in 2020. </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">WAIHA is a rare hematologic disease in which autoantibodies mediate hemolysis, or the destruction of red blood cells (&#8220;RBCs&#8221;), affecting approximately 42,000 patients in the U.S. and 67,000 patients in Europe. </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">TED is most commonly caused by IgG autoantibodies that active cell types present in tissues surrounding the eye and can ultimately be sight-threatening and has an estimated annual incidence of 16 in 100,000 women and 2.9 in 100,000 men in North America and Europe. </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 3%; vertical-align: top;;text-align:left;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#8226;</div></div></td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="text-decoration: underline; letter-spacing: 0px; top: 0px;;display:inline;">Limitations of current treatments:</div> </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Early-stage disease: corticosteroids and immunosuppressants </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Later-stage disease: intravenous immunoglobulin (&#8220;IVIg&#8221;), or plasma exchange </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Approaches are limited by delayed onset of action, waning therapeutic benefit over time and unfavorable safety profiles </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 3%; vertical-align: top;;text-align:left;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#8226;</div></div></td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="text-decoration: underline; letter-spacing: 0px; top: 0px;;display:inline;">Clinical data: </div> </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;">In February 2021, we voluntarily paused dosing in our clinical trials for IMVT-1401 due to elevated total cholesterol and <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">low-density</div> lipoprotein (&#8220;LDL&#8221;) levels observed in some trial subjects treated with IMVT-1401 and informed regulatory authorities and trial subjects and investigators of this voluntary pause of dosing in our studies that were ongoing at that time. Following a program-wide data review from February 2021 through May 2021 suggesting that lipid elevations are predictable, manageable, and appear to be driven by reductions in albumin, we plan to resume clinical development of IMVT-1401 in MG, TED and WAIHA. </div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;">Statistically significant improvements on the Myasthenia Gravis Activities of Daily Living <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">(&#8220;MG-ADL&#8221;)</div> scale and Myasthenia Gravis Composite (&#8220;MGC&#8221;) scale in ASCEND MG Phase 2a trial of IMVT-1401 in patients with MG. </div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;">In the ASCEND <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">GO-2</div> Phase 2b trial in TED, treatment with IMVT-1401 reduced both IgG and disease specific pathogenic IgG over the <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">12-week</div> treatment period. However, the efficacy results, based on </div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">159 </div></div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;;font-weight: bold;"><a href="#toc">Table of Contents</a></div> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;">
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 9%;">&#160;</td>
<td style="vertical-align: top;"> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">approximately half the anticipated number of subjects who had reached the week 13 primary efficacy analysis at the time of the termination of the trial, were inconclusive. </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 3%; vertical-align: top;;text-align:left;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#8226;</div></div></td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="text-decoration: underline; letter-spacing: 0px; top: 0px;;display:inline;">Development plan and upcoming milestones:</div> </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Following alignment with the regulatory authorities from the Neuro division of the FDA, and contingent on that feedback, we plan to initiate a pivotal trial in MG in the early part of calendar year 2022. </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;">Contingent upon FDA feedback, we plan to <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">re-initiate</div> our program in TED following initiation of our MG program. </div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;">Contingent upon FDA feedback, we plan to <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">re-initiate</div> our WAIHA program following initiation of our MG program. </div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">We plan to announce at least two new indications and submit INDs and our trial designs for those new indications to the FDA by August 2022. </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 3%; vertical-align: top;;text-align:left;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#8226;</div></div></td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="text-decoration: underline; letter-spacing: 0px; top: 0px;;display:inline;">Roivant ownership:</div> </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">As of June&#160;30, 2021, we owned 58% of the issued and outstanding shares of Immunovant common stock and 53% on a fully diluted basis. In August 2021, Roivant purchased from Immunovant 17,021,276 shares of Immunovant common stock at a price of $11.75 per share, for an aggregate purchase price of $200.0&#160;million. Following this transaction, Roivant beneficially owns 73,398,664 shares of Immunovant common stock, representing a basic ownership interest of approximately 63.8%. </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 3%; vertical-align: top;;text-align:left;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#8226;</div></div></td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="text-decoration: underline; letter-spacing: 0px; top: 0px;;display:inline;">Pipeline:</div> </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; margin-top: 0pt; margin-bottom: 0pt;">
<img alt="" src="g164680g96s96.jpg" style="width: 606px; height: 136px;"/><br/></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">IMVT-1401 </div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">IMVT-1401 is a novel, fully human monoclonal antibody that selectively binds to and inhibits FcRn. In nonclinical studies and in clinical trials conducted to date, IMVT-1401 has been observed to reduce IgG antibody levels. High levels of pathogenic IgG antibodies drive a variety of autoimmune diseases and, as a result, we believe IMVT-1401 has the potential for broad application in these disease areas. </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">In addition to generating clinically meaningful IgG reductions, IMVT-1401 has been designed from inception to be a fixed-dose, self-administered SC injection on a convenient weekly, or less frequent, dosing schedule. We believe that IMVT-1401, if developed and approved for commercial sale, would be differentiated from currently available, more invasive treatments for advanced <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">IgG-mediated</div> autoimmune diseases. The patent family directed to the composition of matter of IMVT-1401 has a natural projected expiration date in 2035 in the U.S. and in foreign jurisdictions. </div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Mechanism of action </div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;">The neonatal fragment crystallizable receptor, or FcRn plays a pivotal role in preventing the degradation of IgG antibodies. The physiologic function of FcRn is to modulate the catabolism of IgG antibodies. FcRn intercepts IgG, which would otherwise be degraded in lysosomes. The <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">FcRn-IgG</div> complex is then recycled to the </div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">160 </div></div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;;font-weight: bold;"><a href="#toc" style="text-indent: 0px;">Table of Contents</a></div> </div> <div> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">cell surface and free IgG is released back into circulation. Anti-FcRn antibodies bind to FcRn, thereby preventing it from recycling IgG antibodies back to circulation. As a result, IgG is increasingly delivered to lysosomes for degradation. The inhibition of FcRn, such as through use of an anti-FcRn antibody, has been shown to reduce levels of pathogenic IgG antibodies, suggesting utility in the many autoimmune diseases associated with high levels of such IgG antibodies. </div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Autoimmune Diseases </div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Autoimmune diseases are conditions where an immune response is inappropriately directed against the body&#8217;s own healthy cells and tissues. Many of these diseases are associated with high levels of pathogenic IgG antibodies, which are the most abundant type of antibody produced by the human immune system, accounting for approximately 75% of antibodies in the plasma of healthy people. IgG antibodies are important in the defense against pathogens, such as viruses and bacteria. In many autoimmune diseases, IgG antibodies inappropriately develop against normal proteins found in the body, directing the immune system to attack specific organs or organ systems. </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Unfortunately, safe and effective treatment options for patients suffering from autoimmune diseases are inadequate. Currently available treatments are generally limited in early-stage disease to corticosteroids and immunosuppressants, and in later-stage disease to IVIg or plasma exchange. These approaches often fail to address patients&#8217; needs since they are limited by delayed onset of action, waning therapeutic benefit over time and unfavorable safety profiles. </div></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; margin-top: 0pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="color: red; letter-spacing: 0px; top: 0px;;display:inline;">
<img alt="" src="g164680g00y14.jpg" style="width: 605px; height: 257px;"/></div> </div></div> <div style="font-family: Times New Roman; font-size: 8pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">Europe includes all E.U. countries, the U.K. and Switzerland. MG: Myasthenia Gravis; WAIHA: Warm Autoimmune Hemolytic Anemia; TED: Thyroid Eye Disease; ITP: Idiopathic Thrombocytopenic Purpura; PV: Pemphigus Vulgaris; CIDP: Chronic Inflammatory Demyelinating Polyneuropathy; BP: Bullous Pemphigoid; NMO: Neuromyelitis Optica; PF: Pemphigus Foliaceus; GBS: Guillain-Barr&#233; Syndrome; PMN: PLA2R+ Membranous Nephropathy. </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">As a result of the rational design of IMVT-1401, we believe that IMVT-1401, if approved for use, could provide the following benefits: </div></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Subcutaneous delivery</div></div></div></div><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">.</div></div> Based on pharmacokinetics (&#8220;PK&#8221;) and pharmacodynamics (&#8220;PD&#8221;) and clinical data, we believe that we will be able to obtain therapeutically relevant levels of IgG reduction <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">using&#160;2-mL&#160;or</div> lesser volume SC injections. The current formulation is concentrated at 170 mg/mL. </div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Simple dosing schedule</div></div></div></div><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">.</div></div> We are developing IMVT-1401 as a fixed-dose subcutaneously administered regimen without the need for preceding intravenous induction doses or lengthy SC infusions. If approved, we intend to market IMVT-1401 as a <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">fixed-dose&#160;pre-filled&#160;syringe</div> or auto-injector, which </div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">161 </div></div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;;font-weight: bold;"><a href="#toc">Table of Contents</a></div> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;">
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 9%;">&#160;</td>
<td style="vertical-align: top;"> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">would allow for convenient self-administration, eliminating the need for frequent and costly clinic visits, and reduce complexity and errors associated with calculating individual doses. </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Low immunogenicity risk</div></div></div></div><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">.</div></div>&#160;IMVT-1401 is a fully human monoclonal antibody, and therefore contains only amino acid sequences native to humans, hypothesizing a lower risk of immunogenicity development. </div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Low effector function.</div></div></div></div>&#160;IMVT-1401 has been engineered to prevent activation of other components of the immune system, and, as a result, unintended immune response to IMVT-1401 is not expected. Specifically, well-characterized and validated mutations introduced into the fragment crystallizable domain of IMVT-1401 have reduced its ability to cause antibody-dependent cell-mediated cytotoxicity (&#8220;ADCC&#8221;) and complement-dependent cytotoxicity (&#8220;CDC&#8221;). </div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Recent Developments in Our Clinical Programs </div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;">In February 2021, we voluntarily paused dosing in our clinical trials for IMVT-1401 due to elevated total cholesterol and LDL levels observed in some trial subjects treated with IMVT-1401. We have informed regulatory authorities and trial subjects and investigators of this voluntary pause of dosing in our studies that were ongoing at that time, ASCEND <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">GO-2,</div> a Phase 2b trial in Thyroid Eye Disease and ASCEND-WAIHA, a Phase 2 trial in Warm Autoimmune Hemolytic Anemia. </div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Program-Wide Review </div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">In order to better characterize the observed lipid findings, we conducted from February 2021 through May 2021 a program-wide data review (including both clinical and nonclinical data) with input from external scientific and medical experts. </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">In our ASCEND <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">GO-2</div> trial, lipid parameters were assessed at baseline, at week 12, and at week 20 following eight weeks off drug. Based on preliminary, unblinded data, median LDL cholesterol at week 12 was increased by approximately 12 mg/dL in the 255 mg dose group (corresponding to an increase from baseline of approximately 15%), by approximately 33 mg/dL in the 340 mg dose group (corresponding to an increase from baseline of approximately 37%), by approximately 62 mg/dL in the 680 mg dose group (corresponding to an increase from baseline of approximately 52%) and did not increase in the control group. The data analysis indicates a dose-dependent increase in lipids. Average high-density lipoprotein (&#8220;HDL&#8221;) and triglyceride levels also increased but to a much lesser degree. We also observed correlated decreases in albumin levels and the rate and extent of albumin reductions were dose-dependent. Subjects receiving the 255 mg weekly dose (&#8220;QW&#8221;) experienced the smallest reductions in albumin through week 12, with a median reduction of about 16% from baseline, while subjects receiving the 340 mg or 680 mg QW dose experienced median reductions of albumin of 26% or 40%, respectively. At week 20, both lipids and albumin returned to baseline. </div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">In our open label ASCEND WAIHA trial, only two subjects completed 12 weeks of dosing prior to the program-wide pause in dosing, with three additional subjects partially completing the dosing period. <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">Pre-specified</div> and <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">post-hoc</div> lipid test results from these five subjects were analyzed along with <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">post-hoc</div> lipid test results performed on frozen samples from ASCEND MG subjects (where available) and <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">post-hoc</div> lipid test results from our Phase 1 Injection Site study. LDL elevations observed in the ASCEND WAIHA and ASCEND MG subject populations and in healthy subjects in the Phase 1 Injection Site Study also appeared to be dose-dependent and were generally consistent in magnitude with the elevations observed in ASCEND <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">GO-2</div> subjects. </div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">No major adverse cardiovascular events have been reported to date in IMVT-1401 clinical trials. </div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Integrated Safety Assessment and Regulatory Interactions </div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">It is our intent to resume development across multiple indications for IMVT-1401. We are in the process of drafting multiple study protocols and updating our program-wide safety strategy for discussions with regulatory </div></div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">162 </div></div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;;font-weight: bold;"><a href="#toc">Table of Contents</a></div> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">agencies. The elements of our development program will include extensive PK and PD modeling to select dosing regimens for IMVT-1401 which optimize reductions in total IgG levels while minimizing the impact on albumin and LDL levels, particularly for clinical studies containing long-term treatment extensions. These protocols will likely include protocol-directed guidelines for the management of any observed lipid abnormalities. While increases in LDL over a short-term treatment duration would not be expected to pose a safety concern for patients, the risk-benefit profile of long-term administration of IMVT-1401 will need to incorporate any unfavorable effects on lipid profiles. We have initiated discussions with the FDA and expect to continue to engage with the FDA and other regulatory agencies during the second half of calendar year 2021. </div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Phase 1 Clinical Trials of IMVT-1401 in Healthy Volunteers </div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">We have completed a multi-part, placebo-controlled Phase 1 clinical trial involving 99 healthy volunteers in Australia and Canada, administering IMVT-1401 both as an intravenous infusion and as a SC injection. In this trial, 77 subjects received at least one dose of IMVT-1401 and 22 subjects received placebo. </div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Program-Wide Data Review </div></div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Pharmacokinetics and Pharmacodynamics </div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;">The PK and PD (including serum concentrations of total IgG, albumin, and lipids) of IMVT-1401 were evaluated in healthy subjects in our Phase 1 clinical trial and Phase 1 Injection Site Study, and in patients with MG, TED and WAIHA in our ASCEND MG, ASCEND <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">GO-1,</div> ASCEND <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">GO-2</div> and ASCEND WAIHA trials. To date, single doses of IMVT-1401 ranged from 100 mg to 1530 mg IV and 1.5 mg/kg to 765 mg SC and were administered to healthy subjects. Multiple doses of 255 mg, 340 mg and 680 mg SC QW have been studied in healthy subjects (up to 4 weeks of dosing) and patients with TED, MG or WAIHA (up to 12 weeks of dosing). </div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Pharmacokinetics </div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;">IMVT-1401 exhibited a <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-linear</div> PK profile which was typical of that characterized by target-mediated drug disposition (&#8220;TMDD&#8221;). The elimination of IMVT-1401 can be divided into three phases according to the concentrations. The first phase shows linear elimination; when drug concentrations are high enough to saturate targets, drug elimination is governed by linear <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-target-related</div> routes, together with a fixed rate of target-mediated elimination, which is negligible in this phase. At the second phase, the drug concentrations become lower, the targets are not all saturated and both <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-target-mediated</div> and target-mediated elimination routes are important, resulting in nonlinear PK. At the last phase, the drug concentrations are so low that targets are not saturated, the target mediated elimination becomes the main route of elimination, and the PK becomes linear again. The drug concentrations achieved after 680 mg SC QW dose were mainly in the linear elimination phase of the PK profile, may maintain target saturation during the dosing intervals for most of the subjects. However, the drug concentrations achieved after the 340 mg or 255 mg SC QW dose may not always maintain target saturation during the dosing intervals for majority of the subjects. </div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Pharmacodynamics </div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;">Currently, ASCEND <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">GO-2</div> in TED is the largest study (total of 65 subjects, including 18 subjects on placebo) which evaluated placebo and <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">3-dose</div> levels of IMVT-1401 at 255 mg, 340 mg and 680 mg administered SC weekly for 12 weeks (&#8220;QW*12&#8221;). The preliminary PD results of total IgG by time and treatment group is presented in the below figure. The baseline serum levels of total IgG, albumin, LDL, and HDL were comparable across all treatment groups. After active treatment, the levels of total IgG and albumin started to decrease, but the levels of LDL and HDL started to increase; both the rate and extent of reductions in total IgG and albumin or elevations of LDL and HDL were dose dependent. After 255 mg, 340 mg or 680 mg QW*12, the median Emax of total IgG reduction was 62%, 69% or 80%, respectively. For Groups 255 mg and 340 mg, total IgG levels continued to decrease as of week 12 (the last injection). For Group 680 mg, total IgG reached maximum reduction around week 7, and maintained in a plateau-like manner between weeks 7 to 12. The median Emax of </div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">163 </div></div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;;font-weight: bold;"><a href="#toc">Table of Contents</a></div> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">albumin reduction was 16%, 26% or 40% for the 255 mg, 340 mg or 680 mg QW*12 doses, respectively. For Groups 340 mg and 680 mg, albumin levels continued to decrease as of week 12 (the last injection). For Group 255 mg, albumin reduction reached maximum around week 8, and maintained in a plateau-like manner between weeks 8 to 12. After 255 mg, 340 mg or 680 mg QW*12, the median elevation at Week 12 was 15%, 37% or 52%, respectively for LDL, and 14%, 10% or 25%, respectively for HDL. For all three active dose groups, the levels of total IgG, albumin, LDL and HDL returned to baseline within 8 weeks after the last dose of the <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">12-week</div> treatment. </div> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 24pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;">Mean (&#177;SD) Percentage Change from Baseline of Serum Concentrations of Total IgG in Subjects in ASCEND <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">GO-2</div> (Preliminary Results) </div></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; margin-top: 0pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="color: red; letter-spacing: 0px; top: 0px;;display:inline;">
<img alt="" src="g164680g00y15.jpg" style="width: 394px; height: 283px;"/></div> </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The relationships of the PD effects in total LDL vs. albumin indicate that the time course and extent of LDL elevations were highly correlated with albumin reductions. The reductions in both IgG and albumin were also highly correlated, with a coefficient of determination of R<div style="font-size: 85%; vertical-align: top;;display:inline;;font-size:9.4px">2</div> = 0.793. It was also noted that the lipid elevations were not correlated with changes in thyroid hormone levels (no correlations to changes in T3, T4 or TSH were observed). </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Within the dose range studied, the rate and extent of total IgG reductions, albumin reductions and lipid elevations were dose dependent across different populations and the shoulder region of the dose-response curve for total IgG reductions was covered and observed. However, the shoulder region of the dose-response curve for albumin reductions or lipid elevations was not clearly observed. The extent of PD response was much larger in reductions of total IgG than reductions of albumin or elevations of lipids. </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Comprehensive understanding of the PK and PD characteristics of IMVT-1401 has enabled creation of robust mathematical models to support the selection of future dosing regimens. The discordance between the PK/PD response relationship for IgG and that of albumin or LDL suggests options for dosing regimens that provide potentially effective reductions in total IgG (and pathologic autoantibodies) while minimizing effects on albumin and LDL levels. Optimized dosing regimens, if shown to be effective, could improve the risk/benefit profile of IMVT-1401 while the ease of administration of our current formulation could enhance the overall patient experience. </div></div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">164 </div></div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;;font-weight: bold;"><a href="#toc">Table of Contents</a></div> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Safety data </div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">We conducted, from February 2021 through May 2021, a program-wide data review, including safety data review, with input from external scientific and medical experts. The safety data review for each of the studies is described below. </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">In our multi-part, placebo-controlled Phase 1 clinical trial, IMVT-1401 was observed to be generally well-tolerated with no Grade 3 or Grade 4 treatment-emergent AEs and no discontinuations due to AEs. The most commonly reported AEs were mild erythema and swelling at the injection site, which typically resolved within hours and had a similar incidence between subjects receiving IMVT-1401 and placebo. These reactions at the injection site were not considered dose-related and did not increase with multiple administrations of IMVT-1401 in the multiple-dose cohorts. As previously disclosed, two serious AEs were reported, both of which were assessed as unrelated to IMVT-1401 by the study investigator. There were no treatment-related serious AEs reported. </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">A summary of the most commonly reported AEs, defined as the AE reported occurred in more than one subject, is set forth in the table below: </div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Most Common Adverse Events Reported in Phase 1 Clinical Trial of IMVT-1401 </div></div></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 8pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="font-size: 0px;">
<td style="width: 50%;"></td>
<td style="width: 1%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td>
<td style="width: 1%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td>
<td style="width: 1%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td>
<td style="width: 1%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td>
<td style="width: 1%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td>
<td style="width: 1%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td>
<td style="width: 1%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td>
<td style="width: 1%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td>
<td style="width: 1%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td>
<td style="width: 1%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td>
<td style="width: 1%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td>
<td style="width: 1%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td>
<td style="width: 1%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td>
<td style="width: 1%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td>
<td style="width: 1%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td>
<td style="width: 1%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td> </tr>
<tr style="font-family: Times New Roman; font-size: 7pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td colspan="50" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Single Ascending Dose</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td colspan="2" style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td colspan="2" style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td colspan="2" style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 7pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td colspan="22" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Intravenous Infusion</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td colspan="26" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Subcutaneous Injection</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td colspan="10" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Multiple&#160;Ascending&#160;Dose<br/>Subcutaneous Injection</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 7pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; white-space: nowrap; padding-bottom: 1pt;"> <div style="font-family: &quot;Times New Roman&quot;; font-size: 7pt; margin-top: 0pt; margin-bottom: 0pt; border-bottom: 1pt solid rgb(0, 0, 0); display: table-cell; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 7pt; letter-spacing: 0px; top: 0px;;display:inline;">Number of Subjects</div></div></div> </td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">0.1<br/>MG/<br/>KG<br/>N=4</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">100<br/>MG<br/>N=6</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">340<br/>MG<br/>N=6</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">765<br/>MG<br/>N=6</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">1530<br/>MG<br/>N=6</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Placebo<br/>N=8</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">0.5<br/>MG/<br/>KG<br/>N=3</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">1.5<br/>MG/<br/>KG<br/>N=6</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">5<br/>MG/<br/>KG<br/>N=6</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">340<br/>MG<br/>N=6</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">500<br/>MG<br/>N=6</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">765<br/>MG<br/>N=6</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Placebo<br/>N=10</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">340<br/>MG<br/>N=8</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">680<br/>MG<br/>N=8</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Placebo<br/>N=4</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">MedDRA Preferred Term</div></div></div> </td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">Abdominal pain</div></div> </td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">1</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">1</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">Abdominal pain upper</div></div> </td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">2</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">1</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">Abnormal sensation in eye</div></div> </td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">1</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">1</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">Back pain</div></div> </td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">2</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">1</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">1</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">1</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">Constipation</div></div> </td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">1</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">1</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">Cough</div></div> </td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">1</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">2</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">Diarrhea</div></div> </td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">2</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">Dizziness</div></div> </td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">1</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">1</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">1</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">Dry skin</div></div> </td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">1</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">1</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">Erythema</div></div> </td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">1</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">1</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">Fatigue</div></div> </td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">1</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">1</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">1</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">1</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">1</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">1</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">1</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">Headache</div></div> </td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">1</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">1</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">1</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">1</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">1</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">1</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">1</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">4</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">1</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">1</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">2</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">Injection site erythema</div></div> </td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">5</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">1</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">5</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">6</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">7</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">8</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">7</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">4</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">Injection site pain</div></div> </td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">1</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">2</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">1</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">Injection site swelling</div></div> </td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">3</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">2</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">4</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">3</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">7</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">6</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">2</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">Insomnia</div></div> </td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">1</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">4</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">Myalgia</div></div> </td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">1</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">1</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">Nasal congestion</div></div> </td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">1</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">1</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">1</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">1</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">Nausea</div></div> </td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">1</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">1</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">1</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">1</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">1</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">Ocular hyperaemia</div></div> </td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">2</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">Oropharyngeal pain</div></div> </td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">1</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">1</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">2</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">1</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">1</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">1</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">2</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">Pain in extremity</div></div> </td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">1</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">1</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">Procedural complication</div></div> </td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">1</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">1</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">Procedural dizziness</div></div> </td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">2</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">1</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">Pyrexia</div></div> </td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">1</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">1</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">1</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">Rash</div></div> </td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">2</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">2</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">2</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">1</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">Rhinorrhoea</div></div> </td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">1</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">2</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">Sinusitis</div></div> </td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">1</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">1</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">Somnolence</div></div> </td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">1</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">1</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">Upper respiratory tract infection</div></div> </td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">1</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">1</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">1</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">3</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">1</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">1</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">1</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">Vision blurred</div></div> </td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">1</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">1</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">In November 2018, one serious AE (malpighian carcinoma) occurred in a <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">51-year-old</div></div> subject who had received a single 765 mg subcutaneous administration of IMVT-1401. Fifty-five days after study drug </div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">165 </div></div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;;font-weight: bold;"><a href="#toc">Table of Contents</a></div> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">administration, the subject presented to his personal physician with a left-sided neck mass. Biopsy results determined the mass to be a poorly differentiated malpighian carcinoma, which was assessed as unrelated to IMVT-1401 by the study investigator. In February 2019, a <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">25-year-old</div></div> subject who received a single dose 1530 mg of IMVT-1401 by intravenous infusion presented five days later with uncomplicated acute appendicitis and the presence of an appendiceal stone. The subject underwent laparoscopic appendectomy and recovered with an uneventful post-operative course. The event was considered unrelated to study drug by the study investigator. </div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">Dose-dependent and reversible albumin reductions were observed in the single-ascending and multiple-ascending dose cohorts. In the 680 mg multiple-ascending dose cohort, most subjects appeared to reach nadir before administration of the final dose. Mean reduction in albumin levels at day 28 were 20% in the 340 mg multiple-dose cohort, and 31% in the 680 mg multiple-dose cohort. For subjects in the 340 mg and 680 mg cohorts, the mean albumin levels at day 28 were 37.5 g/L and 32.4 g/L, respectively (normal range <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">36-51</div> g/L). These reductions were not associated with any AEs or clinical symptoms and did not lead to any study discontinuations. </div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Our Phase 1 Injection Site study, a randomized, double-blinded, placebo-controlled, crossover study to characterize the PK, PD, safety and tolerability of IMVT-1401 was administered as single subcutaneous doses in three different injection sites in healthy participants (N = 21). In this trial, IMVT-1401 was generally well tolerated with no serious AEs reported and there were no discontinuations due to AEs. All AEs were assessed to be unrelated to IMVT-1401 by the study investigator. Mild headache was reported in 33% of the overall group as compared with 25% of the placebo group. </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">In our <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">ASCEND&#160;GO-1&#160;clinical</div> trial, where seven participants completed the&#160;treatment period of the study and five of those participants completed the <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">follow-up,</div> off treatment period (the two discontinuations were not related to the study), the safety and tolerability profile observed was consistent with the Phase 1 clinical trials. In this trial, no serious AEs were observed and there were no discontinuations due to AEs. IMVT-1401 was generally well-tolerated, with the reported AEs, ranging from mild to moderate, being increase in weight, cough, fatigue, palpitations, light-headedness, and low blood pressure. One participant had a <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">pre-existing</div> condition of hypertension with borderline low platelets at baseline and a low platelet count after week 18. </div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">In our ASCEND MG clinical trial, which included five participants in the 340 mg dose group, six participants in the 680 mg dose group and six participants in the placebo group, two serious AEs were reported but determined to be unrelated to IMVT-1401 by the study investigator. </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">In our ASCEND <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">GO-2</div> clinical trial, five out of 18 participants in the 680 mg dose group reported peripheral edema with no such events noted in the other treatment groups. The events were Grade 1 or 2 (on a scale of 1 to&#160;5), were limited in duration, and did not require permanent discontinuation of study drug. There were no reported cardiac events and injection site erythema was more common in the treated groups as compared with the placebo group. In the 255 mg dose group, one AE, optic neuropathy, was considered serious due to hospitalization, but was ultimately determined to be unrelated to the study and the participant later recovered. Triglycerides were elevated in the 340 mg and 680 mg dose groups with two participants reporting levels above 300 mg/dL and &lt;400 mg/dL. No other serious AEs were reported. </div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">The ASCEND WAIHA study is an open-label trial that has been evaluated with interim results. To date, one of the five trial subjects discontinued therapy after three 680 mg SC QW doses due to a serious AE (Immune thrombocytopenia). In January 2021, a <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">59-year-old</div></div> subject presented for the scheduled week 4 study visit and reported gingival bleeding. The week 4 dose was not administered and laboratory results revealed decreases in platelet count. Platelet count was already at a decreased level at the time of enrollment. The subject received multiple platelet transfusions over the following few weeks. In February 2021, the AE was considered as resolved and no further transfusions were needed at that time. The study investigator considered the event related to aggravation of underlying disease activity (hemolytic anemia with immune thrombocytopenia) since the subject had decreased platelet counts at initial diagnosis; however, the study investigator stated that the investigational product&#8217;s role in causing or aggravating thrombocytopenia cannot be ruled out. The adverse event was determined to be possibly related to study drug. </div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">166 </div></div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;;font-weight: bold;"><a href="#toc">Table of Contents</a></div> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">As previously disclosed, lipid levels were not measured contemporaneously during these Phase 1, ASCEND MG and ASCEND <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">GO-1</div> clinical trials of IMVT-1401. See &#8220;Recent Developments in Our Clinical Programs&#8221; for further discussion about lipid and albumin changes noted in our clinical trials. </div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">Across all the clinical trial groups to date, we believe the safety profile of IMVT-1401 at the doses studied over a treatment interval of at least 12 weeks is acceptable and supports further development of these dosing regimens. As discussed in &#8220;<div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Recent Developments in Our Clinical Programs,</div></div>&#8221; dose-dependent decreases in albumin levels have been observed with IMVT-1401; however, these decreases were generally asymptomatic except for the potentially expected AE of peripheral edema which was observed only in the 680 mg dose group and resolved without permanent discontinuation of IMVT-1401. Dose-related increases in LDL and total cholesterol have also been observed with IMVT-1401. While increases in LDL of this magnitude over a <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">12-week</div> treatment duration would not be expected to pose a safety concern for patients, the risk-benefit profile of long-term administration of IMVT-1401 will need to incorporate any unfavorable effects on lipid profiles. Future study designs which include long-term treatment extensions will employ extensive PK/PD modeling to select dosing regimens that optimize reductions in total IgG while minimizing effects on albumin and LDL. These protocols will likely include protocol-directed guidelines for the management of any observed lipid abnormalities. The indications that we are pursuing with IMVT-1401 are associated with substantial morbidity and currently available treatments (e.g., high dose intravenous methylprednisolone) associated with significant side effects. Therefore, we believe that, if IMVT-1401 is found to be effective in these diseases, the safety profile observed to date should result in a favorable risk-benefit profile for IMVT-1401. </div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">No major adverse cardiovascular events have been reported to date in IMVT clinical trials. </div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Immunogenicity Data </div></div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;">The development of anti-drug antibodies (&#8220;ADA&#8221;) to IMVT-1401 was assessed across all dosed cohorts following single (IV and SC formulations) and multiple (SC formulation) administrations of IMVT-1401. Preliminary data show a similar frequency of treatment-emergent ADA development among subjects who received at least one administration of IMVT-1401 or placebo (8% and 6%, respectively). The antibody titers were low (<div style="font-family: SYMBOL; letter-spacing: 0px; top: 0px;;display:inline;">&#163;</div> 1:16) consistent with the high sensitivity of the ADA assay. No subjects in either the 340 mg or 680 mg multiple ascending dose cohorts developed ADAs with treatment. ADAs will continue to be monitored throughout the development program. </div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">IMVT-1401 for the Treatment of Myasthenia Gravis </div></div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">MG overview and limitations of current treatments </div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Myasthenia Gravis is a rare autoimmune disorder, characterized by weakness of muscles including ocular, head, oropharyngeal, limb and respiratory muscles. The prevalence of MG is estimated to be one in 5,000, with up to 66,000 cases expected in the United States. Existing therapies are associated with significant side effects and an unmet medical need persists. Approximately 10% of MG patients are refractory to current treatments, while up to 80% fail to achieve complete stable remission. </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Very early-stage MG is symptomatically treated with acetylcholinesterase inhibitors such as pyridostigmine, which block the breakdown of acetylcholine at the neuromuscular junction, thereby increasing its concentration and capacity to activate the muscle. As the disease progresses, patients are typically treated with immunosuppressive agents such as glucocorticoids, azathioprine, mycophenolate mofetil and cyclosporine. As MG becomes more advanced, patients can be treated during exacerbations with IVIg, which provides therapeutic benefit through multiple potential mechanisms including the saturation of FcRn. However, IVIg requires recurrent, burdensome infusions to obtain significant reductions in symptoms, and the large volumes of intravenous fluid associated with the administration of IVIg can lead to significant side effects, including pulmonary edema and renal complications and treatment can be complicated by events associated with intravascular thrombosis. </div></div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">167 </div></div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;;font-weight: bold;"><a href="#toc">Table of Contents</a></div> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Physicians direct patients with more advanced chronic disease and patients in times of crisis to therapies that reduce levels of circulating IgG antibodies. One method of reducing IgG levels is to take blood from a patient and physically remove the patient&#8217;s plasma before returning the red blood cells as well as outside obtained albumin or plasma to the patient in a process called plasma exchange. This is a slow process that typically takes several hours and often requires multiple treatment sequences due to limited daily tolerance (a reported mean of 6 treatments in MG) over a number of days in order to achieve a significant reduction in IgG antibody levels. A variant of this procedure is immunoadsorption in which bacterial proteins are used to selectively remove IgG antibodies from serum. The most recent agent approved for MG is eculizumab, a complement C5 inhibitor, the use of which is limited to patients refractory to available therapy with anti-AChR-positive MG. Anti-MuSK antibodies have a low propensity to activate complement proteins, thus C5 inhibition may not be therapeutically relevant in anti-MuSK-positive patients. Studies indicate that patients with MuSK-positive disease are more likely to become treatment refractory thus presenting an additional unmet need. </div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Development plan </div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Before the voluntary pause of dosing, we had a favorable end of Phase 2 meeting with the FDA on the design of our Phase 3 registrational program in MG and we are planning on advancing our clinical trials for this indication. Based on our integrated safety analysis, we plan to meet with the FDA to propose further development to evaluate additional dosing levels and regimens as well as to include additional safety monitoring and considerations such as lipid and albumin monitoring and incorporating an independent safety monitoring committee. Contingent upon FDA feedback, we plan to initiate a pivotal study in MG in the early part of calendar year 2022. </div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">IMVT-1401 for the Treatment of Warm Autoimmune Hemolytic Anemia </div></div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">WAIHA overview and limitations of current treatments </div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;">WAIHA is a rare hematologic disease in which autoantibodies mediate hemolysis, or the destruction of RBCs. The clinical presentation is variable and most commonly includes <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-specific</div> symptoms of anemia such as fatigue, weakness, skin paleness and shortness of breath. Symptoms typically develop chronically over several weeks to months, however, rapid progression over a span of days has also been observed. In severe cases, hemoglobin levels are unable to meet the body&#8217;s oxygen demand, which can lead to heart attacks, heart failure and even death. Though the exact causes of WAIHA are unknown, roughly half of cases occur in patients with an underlying lymphoproliferative or autoimmune disease, most commonly chronic lymphocytic leukemia, rheumatoid arthritis or systemic lupus erythematosus. </div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">In WAIHA, autoantibodies react with surface proteins on RBCs at temperatures at or above 37 degrees Celsius, or normal body temperature. These antibodies are of the IgG subtype in the majority of patients. WAIHA is differentiated from cold autoimmune hemolytic anemia, or cold agglutinin disease, which shares a similar clinical presentation but is triggered by autoantibodies that react at temperatures below 37 degrees Celsius. In WAIHA, antibody-coated RBCs are removed from circulation primarily in the spleen, where they are destroyed by macrophages. Studies have suggested the severity of WAIHA correlates with the amount and potency of autoantibodies present. The laboratory evaluation of WAIHA begins with a peripheral blood analysis revealing evidence of extravascular hemolysis (spherocytes, low haptoglobin, elevated bilirubin and elevated LDH). In over 97% of cases, patients have a positive direct antiglobulin test, which detects the presence of IgG or complement proteins bound to the surface of RBCs. </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The annual incidence of WAIHA in the United States and Europe is estimated at one to three in 100,000 persons. Based on published estimates, we believe that there are approximately 42,000 patients in the United States and 67,000 patients in Europe living with WAIHA. The disease may be more common in females, with some sources suggesting a 2:1 female predominance. Peak incidence occurs during the sixth and seventh decades of life, however, WAIHA can occur in children as well. </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">High doses of corticosteroids (&gt;1 mg/kg of prednisone) are typically the first-line treatment option for WAIHA and lead to initial disease control in approximately <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">70-85%</div> of cases. Once initial disease control is </div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">168 </div></div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;;font-weight: bold;"><a href="#toc">Table of Contents</a></div> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">achieved, doses of steroids are tapered. However, only 33% of patients maintain sustained disease control once steroids are discontinued and, as a result, the majority of patients will require either long-term steroid treatment or additional therapies. </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">There are few studies to guide which treatment options to use in patients failing corticosteroids. Until recently, splenectomy had been a common second-line treatment option for patients not responding adequately to corticosteroids. The therapeutic benefit of splenectomy is thought to be twofold: first, it eliminates the major site of RBC destruction in WAIHA; second, removal of the spleen reduces the total lymphoid tissue capable of producing autoantibodies. However, because of the lack of reliable predictors of the outcome, morbidity and potential operative complications of splenectomy, rituximab has become the default second-line option despite not being approved for use in WAIHA. In case studies looking at patients with relapsed disease after treatment with steroids, single-agent rituximab led to responses in 65% to 90% of patients. In such a course of treatment, maximal therapeutic effect is not immediate. </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Patients with persistent disease despite use of corticosteroids and rituximab may be offered a course of other immunosuppressive drugs, such as cyclophosphamide, mycophenolate mofetil or azathioprine sirolimus. IVIg is not routinely used alone for the treatment of WAIHA, however, small case series have suggested some evidence for a therapeutic effect in patients suffering from life-threatening complications of the disease. In these reports, IVIg has been given at high doses (greater than or equal to 1 g/kg per day), and the results have been inconsistent, requiring repeated courses of treatment in at least one case. RBC transfusions are indicated in patients who require immediate stabilization. Such patients are monitored closely for evidence of a transfusion reaction. In contrast to other treatment modalities that lead to nonspecific suppression of the immune system, IMVT-1401 may offer a more targeted approach for reducing levels of the causative IgG species responsible for most cases of WAIHA. We believe this could provide a favorable therapeutic window and avoid the significant side effects associated with less targeted immunosuppression. </div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Development plan </div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">In November 2019, we submitted our IND to the FDA for WAIHA and, in December 2019, our IND was cleared for Phase 2 trial initiation. Prior to the clinical pause, the ASCEND WAIHA trial explored the potential of IMVT-1401 to increase hemoglobin levels and assess the safety and tolerability of IMVT-1401 in this population. Subjects in this trial were treated with one of two doses of IMVT-1401 (680 mg or 340 mg) administered weekly by subcutaneous injection for 12 weeks. The primary endpoint of this trial is the proportion of responders, defined as subjects achieving a hemoglobin level of at least 10 g/dL and at least a 2 g/dL increase from baseline. Secondary endpoints include change from baseline in other hematologic and chemistry parameters, time to response, patient reported outcome measures, total IgG antibodies and IgG antibodies by subclasses. </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">For our open lable trial, ASCEN WAIHA, we plan to initiate discussions with the FDA following alignment on our MG program and, based on a favorable outcome from these meetings, we anticipate <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">re-initiating</div> our WAIHA program after <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">re-initiating</div> our MG program. </div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">IMVT-1401 for the Treatment of Thyroid Eye Disease </div></div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">TED overview and limitations of current treatments </div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">TED is an autoimmune inflammatory disorder that affects the muscles and other tissues around the eyes and can ultimately be sight-threatening. TED has an estimated annual incidence of 16 in 100,000 women and 2.9 in 100,000 men in North America and Europe. The natural history of TED begins with an inflammatory phase lasting between six and 24 months. Treatment of patients with immunosuppressive therapies during this active inflammatory phase can lead to reduction in symptoms and can alter the course of the disease. However, once the initial inflammatory phase is over, immunosuppressive therapies are ineffective and levels of fibrosis that have developed as the result of acute inflammation are only reversible by surgery. We estimate that 15,000 to 20,000 </div></div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">169 </div></div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;;font-weight: bold;"><a href="#toc">Table of Contents</a></div> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">patients in the United States have active inflammatory TED and are eligible for treatment. There are few treatment options currently available for TED patients. As a first option, patients with active TED are treated with immunosuppressive therapy such as high doses of corticosteroids, typically administered intravenously or orally. Corticosteroids are not effective in all patients, and approximately <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">one-third</div> of patients will relapse. This therapy is associated with an increased risk of acute and severe organ damage, bone thinning, weight gain, diabetes, hypertension, osteoporosis and depression. In January 2020, the FDA approved Horizon Therapeutics&#8217; Tepezza (teprotumumab), an <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">anti-IGF-1R</div></div> antibody, for the treatment of TED. Orbital radiation therapy may reduce the infiltration of lymphocytes and can be used in conjunction with corticosteroids or immunosuppressive therapy. Similar to these anti-inflammatory and immunosuppressive drugs, radiation therapy is most effective in the active stage of TED. Patients with <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">moderate-to-severe</div></div> active TED which is still in the active stage and who do not respond adequately to corticosteroids can be treated with cyclosporine or mycophenolate mofetil, two broad immunosuppressive drugs. These powerful drugs are associated with numerous general immunosuppressive side effects as well as inherent toxicities, such as hypertension, kidney disease, and gastrointestinal toxicity. Small case studies have identified Roche&#8217;s Rituxan (rituximab) as an alternate way of inducing immunosuppression in patients with TED. However, rituximab is associated with the potential for serious side effects, such as infusion-related reactions. Surgery is considered to be a treatment option in patients with a high Clinical Activity Score (&#8220;CAS&#8221;), a measure of disease activity in TED patients, who have been treated with corticosteroids or immunosuppressive therapy but continue to have progressive disease. The goal of surgery is to reduce the pressure causing proptosis, reduced eye movement and loss of visual acuity. Due to its invasive nature, surgery is typically reserved for inactive disease. </div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">We believe that a therapy for TED focused on addressing the cause of the disease, namely the presence of autoimmune antibodies, represents an attractive approach that has the potential to avoid many of the serious side effects of current therapies. Because the mode of action of IMVT-1401 is independent of the antigen recognized by the autoimmune antibodies, we believe that IMVT-1401 can address TED that arises through any IgG autoantibody mechanism whether it be anti-TSHR, anti-IGF1R, or any other IgG autoantibodies. </div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Clinical data </div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;">In March 2020, we announced initial results from our ASCEND <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">GO-1</div> trial, an open label <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">single-arm</div> Phase 2a clinical trial of IMVT-1401 in Canada in patients with TED. Subjects recruited for this trial have <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">moderate-to-severe</div></div> active TED with confirmed autoantibodies to TSHR. A total of seven subjects were dosed weekly with SC injections for six weeks. Subjects received a 680 mg dose for the first two administrations of the study followed by a 340 mg dose for the final four administrations. The primary endpoints of this trial were safety and tolerability of IMVT-1401 over the <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">six-week</div> treatment period, as well as the change from baseline in levels of anti-TSHR antibodies, total IgG antibodies and IgG antibodies by subclasses. Secondary clinical endpoints included mean changes in proptosis, or protrusion of the eyeball, the proptosis responder rate, defined as the percentage of subjects with a greater than or equal to 2 mm reduction in proptosis in the study eye without deterioration in the fellow eye, PK and anti-drug antibodies. </div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">170 </div></div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;;font-weight: bold;"><a href="#toc">Table of Contents</a></div> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;">Trial Design of ASCEND <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">GO-1</div> Trial </div></div> <div style="text-align: center; margin-top: 0pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="color: red; letter-spacing: 0px; top: 0px;;display:inline;">
<img alt="" src="g164680g00y16.jpg" style="width: 560px; height: 272px;"/></div> </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">All seven subjects completed the <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">six-week</div> treatment phase of the trial and entered the <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">12-week</div> <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">follow-up</div> phase. Mean reduction in total IgG levels from baseline to end of treatment was 65%. As evaluated at the end of treatment, four of seven subjects (57%) improved by <div style="font-family: SYMBOL; letter-spacing: 0px; top: 0px;;display:inline;">&#179;</div>2 points on the CAS. Of six subjects with baseline diplopia, four subjects (67%) demonstrated improvement in diplopia. Three of seven subjects (43%) were proptosis responders. The safety and tolerability profile observed was consistent with the prior Phase 1 trial of IMVT-1401 in 99 healthy volunteers; as previously disclosed, lipid levels were not measured contemporaneously during the Phase 1 and ASCEND <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">GO-1</div> Phase 2a clinical trials of IMVT-1401. Mean albumin reduction from baseline to end of treatment was 24%. All AEs were mild or moderate and there were no headaches reported. </div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">In October 2019, we initiated dosing in our ASCEND <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">GO-2</div> trial, a randomized, masked, placebo-controlled Phase 2b clinical trial in 77 subjects with <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">moderate-to-severe</div></div> active TED with confirmed autoantibodies to TSHR. The ASCEND <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">GO-2</div> trial explored the potential of IMVT-1401 to improve proptosis and assesses the safety and tolerability of IMVT-1401 in this population. Subjects in this trial were treated with one of three doses of IMVT-1401 (680 mg, 340 mg or 255 mg) or placebo administered weekly by subcutaneous injection for 12 weeks. The primary endpoints of this trial were the proptosis responder rate measured at week 13, defined as the percentage of subjects with a greater than or equal to 2 mm reduction in proptosis in the study eye without deterioration in the fellow eye, and safety and tolerability. Secondary endpoints included the proptosis responder rate measured at weeks 2, 3, 4, 5, 6, 8, 10, 12, 14, 16 and 20, the proportion of subjects with a CAS of 0 or 1, the mean change from baseline in proptosis, CAS, diplopia, ophthalmic improvement and <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">GO-QOL</div> and PK, PD, defined as anti-TSHR antibodies and total IgG and IgG antibodies by subclasses, and anti-drug antibodies. Exploratory endpoints included assessment of <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">CT-measured</div> muscle volume, fat volume, total orbital volume and proptosis, as well as multiple biomarkers including gene expression profiles, <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">pro-inflammatory</div> markers and receptor occupancy. </div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">171 </div></div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;;font-weight: bold;"><a href="#toc">Table of Contents</a></div> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;">Trial Design of ASCEND <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">GO-2</div> Trial </div></div> <div style="text-align: center; margin-top: 0pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="color: red; letter-spacing: 0px; top: 0px;;display:inline;">
<img alt="" src="g164680g00y17.jpg" style="width: 559px; height: 288px;"/></div> </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">Our voluntary pause in dosing resulted in unblinding the ASCEND <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">GO-2</div> trial. As a result, following the last patient last visit of the post-treatment <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">follow-up</div> period, the ASCEND <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">GO-2</div> trial was terminated. Treatment with IMVT-1401 reduced both IgG and disease specific pathogenic IgG over the <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">12-week</div> treatment period. However, the efficacy results, based on approximately half the anticipated number of subjects who had reached the week 13 primary efficacy analysis at the time of the termination of the trial, were inconclusive. The primary endpoint of the proportion of proptosis responders was not met, and although not tested statistically, post hoc evaluation of other endpoints measured (CAS and diplopia scores) indicated the desired magnitude of treatment effect likely would not have been achieved. However, levels of IgG were reduced across IMVT-1401 dosing groups, and analysis of the receptor occupancy data suggest binding of IMVT-1401 to the Fc receptor. </div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Development plan </div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;">For TED, efficacy results based on the data at the time of pausing our ASCEND <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">GO-2</div> trial were inconclusive. We intend to initiate discussions with regulatory authorities following alignment on our MG program and <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">re-initiate</div> our program in TED after <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">re-initiating</div> our MG program. </div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">172 </div></div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;;font-weight: bold;"><a href="#toc" style="text-indent: 0px;">Table of Contents</a></div> </div> <div> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="text-decoration: underline; letter-spacing: 0px; top: 0px;;display:inline;">Aruvant Overview </div></div></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="text-decoration: underline; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Overview:</div></div> </div> </div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;">Aruvant is developing <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">ARU-1801</div> as a <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">one-time,</div> potentially curative gene therapy for the treatment of sickle cell disease (&#8220;SCD&#8221;), as well <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">ARU-2801,</div> a gene therapy designed to deliver potentially curative efficacy without the limitations of chronic administration for patients with hypophosphatasia (&#8220;HPP&#8221;). </div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 3%; vertical-align: top;;text-align:left;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#8226;</div></div></td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="text-decoration: underline; letter-spacing: 0px; top: 0px;;display:inline;">Lead program:</div> </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">ARU-1801</div> is an <div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">ex vivo</div></div> lentiviral gene therapy that contains a proprietary gamma-globin gene for a novel, highly potent variant of fetal hemoglobin (&#8220;HbF&#8221;) and has been observed in preliminary clinical studies to engraft with only reduced intensity conditioning (&#8220;RIC&#8221;). </div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 3%; vertical-align: top;;text-align:left;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#8226;</div></div></td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="text-decoration: underline; letter-spacing: 0px; top: 0px;;display:inline;">Disease overview: </div> </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">SCD results from a defect in the gene that encodes beta-globin, a component of hemoglobin, the protein that carries oxygen in the blood. </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;">The abnormal sickle beta-globin can cause red blood cells to sickle, leading to obstruction of small blood vessels, resulting in pain crises, progressive damage to bones, joints and major organs, and mortality in the <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">mid-40s.</div> </div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">SCD is predominantly concentrated among individuals of African, Middle Eastern, South American and South Asian descent. </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">An estimated 100,000 people in the U.S. and 125,000 people in the E.U. suffer from SCD, with approximately 100,000 of these patients experiencing severe disease. </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 3%; vertical-align: top;;text-align:left;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#8226;</div></div></td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="text-decoration: underline; letter-spacing: 0px; top: 0px;;display:inline;">Limitations of current treatments: </div> </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Common treatment for patients with SCD is the oral cytotoxic agent hydroxyurea which is required to be taken daily. </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">For patients experiencing a vaso-occlusive episode (&#8220;VOE&#8221;), only palliative therapy is currently available; treatment typically consists of hydration, oxygenation and analgesia for pain often requiring oral or intervenous opioids. </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">One potentially curative treatment available for patients with sickle cell disease is allogeneic hematopoietic stem cell transplant, in which a patient&#8217;s own bone marrow is replaced by that of a healthy donor. According to an analysis of data from the National Marrow Donor Program, fewer than 15% of sickle cell patients have a sibling matched donor. Additionally, allogeneic transplant comes with the risk of graft rejection and graft versus host disease. </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;">Other gene therapies are in development as a potential cure; however, unlike <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">ARU-1801,</div> they require the use of myeloablative chemotherapy. </div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 3%; vertical-align: top;;text-align:left;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#8226;</div></div></td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="text-decoration: underline; letter-spacing: 0px; top: 0px;;display:inline;">Clinical data: </div> </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;">All study participants for whom sufficient <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">follow-up</div> has been completed have realized clinically meaningful reductions in disease burden, as seen with significant reductions in hospitalized VOEs and total VOEs. </div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">These participants have experienced durable engraftment and improvement in SCD burden without the use of myeloablative chemotherapy. The two patients who have received product manufactured with an updated process have experienced complete resolution of VOEs out to 18 and 12 months post-treatment. </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 3%; vertical-align: top;;text-align:left;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#8226;</div></div></td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="text-decoration: underline; letter-spacing: 0px; top: 0px;;display:inline;">Development plan and upcoming milestones: </div> </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;">We are currently conducting the MOMENTUM Phase 1/2 study of <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">ARU-1801</div> in patients with severe sickle cell disease. </div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">We expect to initiate a pivotal trial in the first half of calendar year 2023. </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">173 </div></div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;;font-weight: bold;"><a href="#toc">Table of Contents</a></div> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;">
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 3%; vertical-align: top;;text-align:left;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#8226;</div></div></td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="text-decoration: underline; letter-spacing: 0px; top: 0px;;display:inline;">Roivant ownership: </div> </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">As of June&#160;30, 2021, we own 88% of the issued and outstanding Common Shares of Aruvant and 79% on a fully diluted basis. </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 3%; vertical-align: top;;text-align:left;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#8226;</div></div></td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="text-decoration: underline; letter-spacing: 0px; top: 0px;;display:inline;">Pipeline: </div> </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="text-align: center; margin-top: 0pt; margin-bottom: 0pt;">
<img alt="" src="g164680g54t55.jpg" style="width: 606px; height: 73px;"/><br/></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">ARU-1801</div> </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">ARU-1801</div> is an <div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">ex vivo</div></div> gene therapy with the ability to engraft with only reduced intensity conditioning (&#8220;RIC&#8221;). <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">ARU-1801</div> uses a self-inactivating lentiviral vector that contains a proprietary gamma-globin gene for a novel, highly potent variant of fetal hemoglobin (&#8220;HbF&#8221;): HbF<div style="font-size: 85%; vertical-align: top;;display:inline;;font-size:9.4px">G16D</div>. </div> <div style="text-align: center; margin-top: 0pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="color: red; letter-spacing: 0px; top: 0px;;display:inline;">
<img alt="" src="g164680g00y19.jpg" style="width: 532px; height: 142px;"/></div> </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">HbF is a more potent anti-sickling globin compared to adult hemoglobin (&#8220;HbA&#8221;). HbF has mechanistic and clinical benefits observed in SCD, which makes it suitable for the treatment of SCD. HbF disrupts both axial and lateral contacts that cause polymerization of sickle hemoglobin (&#8220;HbS&#8221;) polymers, and has an approximately 1.5 times higher affinity for oxygen than HbA. </div></div> <div style="text-align: center; margin-top: 0pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="color: red; letter-spacing: 0px; top: 0px;;display:inline;">
<img alt="" src="g164680g00y20.jpg" style="width: 605px; height: 261px;"/></div> </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The clinical benefits of increasing HbF have been well-described in scientific literature. HbF levels greater than 8.6% improve survival by approximately 16 years in patients with SCD. HbF levels greater than 20% reduce hospitalizations by two to four-fold for vaso-occlusive events and acute chest syndrome. Further, HbF levels </div></div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">174 </div></div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;;font-weight: bold;"><a href="#toc">Table of Contents</a></div> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">greater than 30% result in asymptomatic disease and patients do not develop sickle cell complications, as demonstrated in patients with SCD who also inherit Hereditary Persistence of Fetal Hemoglobin. </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">ARU-1801</div> originated in the laboratory of Punam Malik, MD, director of the Cincinnati Comprehensive Sickle Cell Center at Cincinnati Children&#8217;s Hospital Medical Center (&#8220;Cincinnati Children&#8217;s&#8221;). Dr.&#160;Malik previously served as the director of the Cincinnati Children&#8217;s Translational Core Services, which developed and manufactured viral vectors for multiple clinical trials. A leading expert in lentiviral gene therapy, stem cell biology and clinical care of hemoglobinopathies, Dr.&#160;Malik remains a key scientific advisor to Aruvant. </div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Potential benefits of <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">ARU-1801</div> </div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;">There are several unique attributes of <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">ARU-1801</div> that we believe enable the use of reduced intensity conditioning for engraftment, and potential clinical efficacy at lower vector copy number (&#8220;VCN&#8221;). </div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 1%;">&#160;</td>
<td style="width: 2%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Proprietary G16D modification drives higher HbF payload per vector copy.</div></div></div></div> A proprietary G16D point mutation that changes glycine (G)&#160;at position 16 to aspartic acid (D)&#160;drives higher HbF payload per vector copy. Gamme-globin<div style="font-size: 85%; vertical-align: top;;display:inline;;font-size:9.4px">G16D </div>has a higher affinity for alpha-globin and is thus more likely to form HbF, as compared to unmodified gamma-globin. In well-established SCD mouse models, vector encoding gamma-globin<div style="font-size: 85%; vertical-align: top;;display:inline;;font-size:9.4px">G16D </div>led to 1.5x to 2x more HbF per vector than vector encoding unmodified gamma-globin. </div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="text-align: center; margin-top: 0pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="color: red; letter-spacing: 0px; top: 0px;;display:inline;">
<img alt="" src="g164680g01m01.jpg" style="width: 605px; height: 191px;"/></div> </div></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 1%;">&#160;</td>
<td style="width: 2%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">High HbF</div></div></div></div><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;"><div style="font-size: 85%; vertical-align: top;;display:inline;;font-size:9.4px">G16D</div></div></div></div></div><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;"> payload may have a more potent clinical anti-sickling effect than endogenous HbF.</div></div></div></div> HbF<div style="font-size: 85%; vertical-align: top;;display:inline;;font-size:9.4px">G16D</div> may have a more potent anti-sickling effect than endogenous HbF. In preclinical studies, a lower percentage of reticulocytes indicates less sickling and hemolysis. At the same level percentage of HbF, highlighted below, HbF<div style="font-size: 85%; vertical-align: top;;display:inline;;font-size:9.4px">G16D</div> is superior to endogenous HbF at reducing reticulocyte count. </div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">175 </div></div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;;font-weight: bold;"><a href="#toc">Table of Contents</a></div> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Hemolysis in SCD mice </div></div></div> <div style="text-align: center; margin-top: 0pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="color: red; letter-spacing: 0px; top: 0px;;display:inline;">
<img alt="" src="g164680g01m02.jpg" style="width: 340px; height: 301px;"/></div> </div></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 1%;">&#160;</td>
<td style="width: 2%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Our proprietary stemness enhancer facilitates engraftment</div></div></div></div><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">.</div></div> Our cellular manufacturing process leverages a proprietary stemness enhancer to facilitate the transduction and engraftment of more true stem cells. Stemness enhancers allow for a higher chance of engraftment for a given VCN compared to engraftment without a stemness enhancer, as illustrated below. </div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="text-align: center; margin-top: 0pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="color: red; letter-spacing: 0px; top: 0px;;display:inline;">
<img alt="" src="g164680g01m03.jpg" style="width: 605px; height: 244px;"/></div> </div></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 1%;">&#160;</td>
<td style="width: 2%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Ability to engraft using only reduced intensity conditioning</div></div></div></div>. In preliminary clinical studies, <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">ARU-1801</div> demonstrated engraftment and the ability to deliver potentially curative treatment without fully myeloablative chemotherapy. </div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt; margin-left: 4%;">We believe that the RIC regimen used for <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">ARU-1801,</div> melphalan 140mg/m<div style="font-size: 85%; vertical-align: top;;display:inline;;font-size:9.4px">2</div>, may provide significant clinical benefits compared to the higher intensity myeloablative busulfan-based regimen used by the other investigational SCD gene therapy candidates, including: </div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 10%;">&#160;</td>
<td style="width: 2%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">reduced duration of neutropenia and thrombocytopenia; </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">176 </div></div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;;font-weight: bold;"><a href="#toc">Table of Contents</a></div> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;">
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 10%;">&#160;</td>
<td style="width: 2%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">potential for outpatient administration, which would significantly reduce resource utilization in the health care setting; </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 14%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 2%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;">reduced intensity conditioning with melphalan for autologous transplants has required a median hospital stay between <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">0-5</div> days within 30 days of infusion, which represents a significant improvement in both patient experience and reduction in health care cost compared to myeloablative conditioning regimens that require a median hospital stay of 44 days; and </div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 10%;">&#160;</td>
<td style="width: 2%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;">reduced likelihood to result in infertility, with a risk of ovarian failure around <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">30-40%</div> compared to <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">70-80%</div> with myeloablative regimens. </div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt; margin-left: 4%;">High-intensity fully myeloablative conditioning regimens have been associated with increased risk of malignancy. The reduced-intensity melphalan-based conditioning regimens for autologous transplants in the setting of multiple myeloma have been associated with a 0.2% risk of AML and a <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">1-1.4%</div> combined risk of AML and other secondary hematologic malignancies. </div> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 24pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">ARU-1801</div> with reduced intensity conditioning (melphalan 140mg/m2) has the potential to provide benefit to patients, providers and payors </div></div> <div style="text-align: center; margin-top: 0pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="color: red; letter-spacing: 0px; top: 0px;;display:inline;">
<img alt="" src="g164680g01m04.jpg" style="width: 605px; height: 207px;"/></div> </div></div> <div style="font-family: Times New Roman; font-size: 8pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">Table reflects combination of gene therapy protocols, reported results from gene therapy trials, and literature on the use of these conditioning agents in other settings. </div></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 8pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 2%; vertical-align: top;;text-align:left;">*</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;">Dose adjusted to a targeted AUC for busulfan of 4200 &#181;M*min. 1. bluebird bio ASGCT 2020. Resolution of Sickle Cell Disease (SCD) Manifestations in Patients Treated with LentiGlobin Gene Therapy: Updated Results of Phase 1/2 <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">HGB-206</div> Group C Study. 2. Based on data from 3 <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">ARU-1801</div> patients. 3. Busulfan label; seizure prophylaxis required but not with phenytoin due to PK interaction with busulfan. 4. ALKERAN label. 5. Estimated based on Kaplan-Meier plot in post-pubescent female children based on time to elevated FSH level with up to 8 years follow up (Panasuik et al. BJH 2015). 6. ZYNTEGLO EPAR. 7. Boston Medical Center. B Freeman et al. (2014)&#160;Bone Marrow Transplantation and Guru Murthy GS et al. (2019)&#160;Biol. Blood Marrow Transplant; outpatient autologous HSCT are already performed for multiple myeloma and AL amyloidosis 8. Rescue cell collection required per bluebird bio protocol. 9. Based on Aruvant protocol. </div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">ARU-1801</div> for the Treatment of SCD </div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Sickle cell disease and limitations of current treatments </div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;">SCD results from a defect in the gene that encodes beta-globin, a component of hemoglobin, the protein that carries oxygen in the blood.<div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"> </div></div>A proportion of sickled cells rising relative to <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-sickled</div> cells can obstruct small blood vessels and reduce blood flow to bones, joints and major organs. This obstruction can cause intense pain and lasting tissue damage. Patients can suffer additional complications such as stroke and frequent infections because of inadequate oxygen delivery to the brain and spleen.<div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"> </div></div>Over time repeated tissue damage leads to a loss of vital organ function and a vastly reduced life expectancy; mean age of death in the US for patients with SCD is 44 years.<div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"> </div></div>SCD is predominantly concentrated among individuals of African, Middle Eastern, South American </div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">177 </div></div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;;font-weight: bold;"><a href="#toc">Table of Contents</a></div> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">and South Asian descent. An estimated 100,000 people in the U.S. and 125,000 people in the E.U. suffer from SCD, with approximately 100,000 patients experiencing severe disease. Market research based on a survey of over 100 physicians conducted in 2020 suggests that use of busulfan conditioning is a major barrier to adoption, restricting patient groups eligible or willing to receive treatment. The same survey of physicians suggests that of the patients with severe SCD, they would consider 49% eligible for myeloablative gene therapy, versus 70% that they would consider eligible for gene therapy with a reduced intensity conditioning regimen. </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The oral cytotoxic agent hydroxyurea is a mainstay in the overall management of individuals with SCD since it reduces the incidence of VOEs, decreases hospitalization rates, and prolongs survival. However, its use is significantly limited by its side effect profile, variable patient response and long-term toxicity. For patients experiencing a VOEs, only palliative therapy is currently available; treatment typically consists of hydration, oxygenation and analgesia for pain, usually using intravenous or oral opioids. </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">In November 2019, the FDA approved ADAKVEO to reduce the frequency of VOEs in adults and pediatric patients aged 16 years and older with SCD. In November 2019, the FDA also approved Oxbryta for the treatment of SCD in adults and pediatric patients aged 12 years and older. Oxbryta is a once-daily oral therapy that inhibits sickle hemoglobin polymerization. </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">One curative treatment available for some patients with SCD is allogeneic hematopoietic stem cell transplant (&#8220;HSCT&#8221;), in which a patient&#8217;s own bone marrow is replaced by that of a healthy donor. However, it requires identification of a suitable donor and carries significant morbidity and mortality risks, including an approximately 7% mortality rate. Ideal sibling matches are only available to approximately 14% of patients. Furthermore, according to the Center for International Blood and Marrow Transplant Research, only 737 HSCTs were performed for the treatment of SCD in the U.S. between 2013 and 2017, highlighting the need to bring alternative curative therapies to the remainder of the estimated 100,000 patients in the U.S. as well as the millions of patients worldwide. </div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Clinical data </div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;">We are currently conducting the MOMENTUM Phase 1/2 study of <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">ARU-1801</div> in patients with severe SCD. Eligible patients include those between the age of 18 and 45 that have failed hydroxyurea and are not candidates for allogeneic transplant. After enrollment, patients are transfused to reduce HbS below 30%, stem cells are collected, and patients receive RIC consisting of a single dose of melphalan 140 mg/m<div style="font-size: 85%; vertical-align: top;;display:inline;;font-size:9.4px">2</div>. <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">ARU-1801</div> is manufactured in a <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">two-day</div> period and administered via intravenous infusion. </div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">Prior to treating the patients, we looked at the number of VOEs each participant had for the two years prior. The chart below shows that all patients had significant numbers of VOEs before receiving <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">ARU-1801</div> and while being treated with the standard of care therapies. </div> <div style="text-align: center; margin-top: 0pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="color: red; letter-spacing: 0px; top: 0px;;display:inline;">
<img alt="" src="g164680g56s66.jpg" style="width: 605px; height: 237px;"/></div> </div></div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">178 </div></div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;;font-weight: bold;"><a href="#toc">Table of Contents</a></div> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">The first two patients were treated before Aruvant licensed the product and updated <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">ARU-1801&#8217;s</div> manufacturing process. We made, and continue to make, major investments in continuously improving our manufacturing process. Patients three and four have received product manufactured with an updated process. The first two patients have had a 93 and 85&#160;percent reduction in their VOEs in the two years post-treatment. The more recently treated patients have seen a 100&#160;percent reduction in their VOEs. Patient three is 18 months from treatment and patient four is 12 months from being treated. Below are the results from all four patients. </div> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 24pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;">Treatment with <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">ARU-1801</div> has resulted in a clinically significant reduction in VOEs </div></div> <div style="text-align: center; margin-top: 0pt; margin-bottom: 0pt;">
<img alt="" src="g164680g58s99.jpg" style="width: 605px; height: 227px;"/><br/></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">ARU-1801</div> was generally well tolerated, with no <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">ARU-1801</div> or chemotherapy related serious adverse events reported to date. </div> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 24pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Adverse Events </div></div></div> <div style="text-align: center; margin-top: 0pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="color: red; letter-spacing: 0px; top: 0px;;display:inline;">
<img alt="" src="g164680g01m07.jpg" style="width: 605px; height: 134px;"/></div> </div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Development plan </div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;">We are continuing to screen additional patients who may be eligible for <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">ARU-1801</div> and gathering <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">follow-up</div> data on our patients dosed to date. We also continue to evolve our manufacturing process in preparation for our pivotal trial of <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">ARU-1801</div> in SCD, which we expect to initiate in the first half of calendar year 2023. </div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">ARU-2801</div> for Hypophosphatasia </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;">We are also developing <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">ARU-2801,</div> a preclinical adeno-associated virus (&#8220;AAV&#8221;) gene therapy designed to deliver potentially curative efficacy without the limitations of chronic administration for patients with HPP. This devastating, ultra-orphan disorder can result in multi-organ damage and high mortality when left untreated. HPP is caused by mutations in the gene encoding the tissue <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-specific</div> alkaline phosphatase (&#8220;TNAP&#8221;) enzyme and is wide-ranging in severity. This genetic and chronic disease is most often characterized by limited hydroxyapatite </div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">179 </div></div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;;font-weight: bold;"><a href="#toc">Table of Contents</a></div> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">formation resulting in limited bone mineralization that can lead to destruction and deformity of bones, profound muscle weakness, seizures, respiratory failure and premature death. There are five types of HPP, including perinatal, infantile, childhood, adult and odontohypophosphatasia. There is currently an approved chronic therapy available for perinatal, infantile and juvenile-onset HPP, the enzyme replacement therapy Strensiq (asfotase alfa). Chronic administration, injection site reactions, and poor durability of Strensiq leave high unmet need that we believe <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">ARU-2801</div> could potentially address. </div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">Preclinical research shows that treatment of HPP disease model mice with <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">ARU-2801</div> results in sustained elevation of TNAP at levels that ameliorated disease symptoms. In a murine model of HPP, <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">ARU-2801</div> resulted in durable, high levels of ALP and survival to 18 months, as shown below. There was no evidence of ectopic calcifications at these therapeutic doses. </div> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 24pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">High ALP levels in HPP murine model (Akp2-/-) </div></div></div> <div style="text-align: center; margin-top: 0pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="color: red; letter-spacing: 0px; top: 0px;;display:inline;">
<img alt="" src="g164680g01m08.jpg" style="width: 572px; height: 309px;"/></div> </div></div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">180 </div></div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;;font-weight: bold;"><a href="#toc">Table of Contents</a></div> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;">Durable <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">18-month</div> OS of 70% in HPP murine model (Akp2-/-) </div></div> <div style="text-align: center; margin-top: 0pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="color: red; letter-spacing: 0px; top: 0px;;display:inline;">
<img alt="" src="g164680g01m09.jpg" style="width: 458px; height: 292px;"/></div> </div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Investigational new drug application-enabling studies are currently underway. </div><br/></div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">181 </div></div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;;font-weight: bold;"><a href="#toc" style="text-indent: 0px;">Table of Contents</a></div> </div> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="text-decoration: underline; letter-spacing: 0px; top: 0px;;display:inline;">Proteovant Overview </div></div></div> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Selected Pipeline Programs </div></div></div> <div style="text-align: center; margin-top: 0pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="color: red; letter-spacing: 0px; top: 0px;;display:inline;">
<img alt="" src="g164680g60t85.jpg" style="width: 605px; height: 166px;"/></div> </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Proteovant is enhancing its pipeline with degraders to new targets and novel E3 ligase discovery work through the capabilities described below. As of June&#160;30, 2021, we own 60% of the issued and outstanding Common Shares of Proteovant and 60% on a fully diluted basis. </div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Protein degraders </div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Protein degraders are a novel class of small molecules that target and destroy cellular proteins, rather than inhibiting them. Degraders are small molecules engineered to induce the degradation of specific disease-causing proteins through the ubiquitin-proteasome system (&#8220;UPS&#8221;), which ordinarily tags and degrades proteins that have been misfolded or have already fulfilled their biological function. In heterobifunctional degraders, the protein ligand domain, commonly referred to as a &#8220;warhead,&#8221; targets the specific protein of interest. At the other end of the complex, the ligase ligand recruits a specific E3 ubiquitin ligase. Both ends of the complex are connected by a linker that orients the target protein and E3 ligase in a cooperative ternary complex, driving ubiquitination. Similar to heterobifunctional degraders, molecular-glue-type degraders are small molecules that induce a novel interaction between a substrate receptor of an E3 ubiquitin ligase and a target protein leading to proteolysis of the target via UPS. </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">We believe degraders represent a promising new approach to drug previously &#8220;undruggable&#8221; targets and transform the treatment of diseases with significant unmet medical need. Degraders open a new set of opportunities for small molecule drug development, with multiple distinct potential advantages over inhibitors: </div></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Not bound by &#8220;active site&#8221; requirements, allowing degraders to target historically &#8220;undruggable&#8221; proteins, including transcription factors and scaffolding proteins that lack a catalytic pocket </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Achieve efficacy at lower doses to decrease dose-limiting toxicities (which have similar but not identical function to the target protein) </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Efficacy in tumors that are resistant to inhibitors, as a function of protein depletion </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Our degrader strategy </div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">We believe we are positioned for leadership in the field of targeted protein degradation given our long-term partnership with a leading academic lab, our degrader-specific ML capabilities, and our well-established clinical development capabilities. </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">We have access to leading medicinal chemistry capabilities via our long-term partnership with the lab of Dr.&#160;Shaomeng Wang, a world-renowned scientist focused on the discovery of protein degraders, at the University of Michigan. Over 15 years, Dr.&#160;Wang and his team have developed an initial pipeline of degraders for over 10 targets and have over 50 U.S. patents and hundreds of international patents related to degrader technology. Through our acquisition of Oncopia Therapeutics, which was <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">co-founded</div> by Dr.&#160;Wang, we obtained Oncopia&#8217;s </div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">182 </div></div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;;font-weight: bold;"><a href="#toc">Table of Contents</a></div> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">pipeline, ongoing work on new targets, broad patent estate and deep knowledge and experience in the degrader space. </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">We expect to initiate a Phase 1 trial for our first degrader candidate in 2022 and rapidly build upon the early pipeline of degraders. </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">Our medicinal chemistry and degrader biology expertise are complemented by our degrader-specific ML capabilities. Proteovant has an exclusive partnership with VantAI, which, through its focus on the <div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">in silico</div></div> design and optimization of targeted protein degraders, has developed a number of powerful and distinctive tools, including: </div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;">A novel protein contact-first workflow that utilizes information about known protein-protein interactions to build new degraders that can effectively stabilize <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">target-E3</div> interfaces </div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">A degron knowledge graph, which we believe to be industry-leading, that maps the ubiquitin proteasome system and enables the analysis of interactions between E3 ligases and degrons, the protein components that bind to E3 ligases and regulate degradation </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">A unique model for predicting degradation based on millions of carefully curated protein stability datapoints </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">These techniques may enable quick and effective generation of degrader candidates and facilitate drugging targets with little or no structural information and recruiting novel E3 ligases with no known ligands. We believe that degrader drug development will uniquely benefit from the application of computational approaches because of the combinatorial nature of target binder, linker, and E3 ligase, as well as the ability to bind to the protein of interest outside the active site. Computational techniques can also help predict protein surface conformation changes in the identification of novel molecular glues. Our first VantAI-designed degraders have generated early-stage preclinical data that suggests our computational approach can generate candidates that achieve real-world degradation against multiple relevant targets. </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">We expect to face competition within a growing class of degrader-focused companies. We believe that our computational capabilities provide critical differentiation in an area that is uniquely suited to the application of computational techniques. The combinatorial nature and modularity of degrader structures allows for computational techniques to provide meaningful acceleration in the identification, design and optimization of protein degraders. To our knowledge, no competitor has a computational platform as advanced or robust as the capabilities we have built through our small molecule discovery engine. Today, our preclinical and clinical development organizations, initial pipeline, and long-term access to a leading academic lab are integrated with our computational capabilities. Further, VantAI algorithms have incorporated over five years of real-world laboratory data generated by Dr.&#160;Wang&#8217;s lab, in turn informing the identification of targets and discovery of novel degraders to further evaluate in the lab and ultimately advance into the clinic. </div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">AR Degrader for the Treatment of Prostate Cancer </div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;">Our lead degrader candidate, <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">ARD-1671,</div> is an orally-administered androgen receptor (&#8220;AR&#8221;) protein degrader currently undergoing <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">IND-enabling</div> studies. <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">ARD-1671</div> is designed to shut down the AR pathway by targeting and degrading the AR protein, the primary driver of prostate cancer. Based on its <div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">in vitro</div></div> potency and selectivity, as well as its encouraging safety and tolerability demonstrated to date in canine and rat <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-GLP</div> dose range finding studies described below, we believe <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">ARD-1671</div> has the potential to provide meaningful clinical benefit to prostate cancer patients. </div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Prostate cancer overview </div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Prostate cancer is the second most common form of cancer in men, with nearly 200,000 annual new cases in the US alone. Additionally, with over 30,000 annual U.S. deaths, prostate cancer is the second most common cause of cancer death in the US. Prostate cancer occurs more frequently in older men and is associated with </div></div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">183 </div></div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;;font-weight: bold;"><a href="#toc">Table of Contents</a></div> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">various other risk factors, including a family history of prostate, breast, or ovarian cancer, <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">high-fat</div> diets or obesity, smoking and maintenance of a sedentary lifestyle. While prostate cancer can be slow-growing, such that some men die of other causes before their cancer, many patients experience metastases to other parts of the body. Prostate cancer that continues to progress following androgen deprivation therapy (&#8220;ADT&#8221;) is considered to be castration-resistant. It is estimated that over 40,000 cases of metastatic castration-resistant prostate cancer (&#8220;mCRPC&#8221;) occur annually in the US, with over 20% of all prostate cancer deaths occurring in men with mCRPC. </div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The AR signaling axis is critical to the development, function and homeostasis of the normal prostate. After binding androgen, cytoplasmic AR translocates to the nucleus, where it activates transcription of target genes. The AR also plays a role in prostate carcinogenesis and progression to androgen-resistant disease and is expressed in nearly all primary prostate cancers. </div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Limitations of current treatments </div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;">The current prostate cancer treatment paradigm involves the use of <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">AR-targeted</div> therapies throughout the progression of the disease. For more advanced forms of prostate cancer, ADT is one of the primary treatment options. Among the most common ADTs are AR antagonists such as Xtandi (enzalutamide), which functions by blocking AR, and androgen synthesis inhibitors, including Zytiga (abiraterone acetate). While these treatments have been successful in improving patient outcomes, resistance remains a major concern. At least 10% of patients whose disease has spread beyond the prostate on first-line ADT do not experience suppression of prostate-specific antigen (&#8220;PSA&#8221;), an <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">AR-regulated</div> gene. Additionally, while dramatic initial responses to ADT are often observed, these responses are often not sustained, with median duration of response of up to 18 months, and virtually all patients treated with ADTs ultimately progressing to castration resistance. For patients who do not respond, chemotherapy is often chosen as the next line of treatment, although its use is often postponed due to its severe side effects. </div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">Of patients with mCRPC, including those whose cancer progresses following treatment with androgen receptor signaling inhibitors, between 40% and 50% have alterations involving the AR, suggesting that their tumors may still be driven by AR signaling. Furthermore, progressive disease experienced by patients while undergoing treatment with Xtandi or Zytiga is often accompanied by increase in serum PSA, further suggesting continued <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">AR-driven</div> cellular proliferation. We believe that AR degraders have the potential to improve the response rates and durability achieved with existing AR antagonists and inhibitors by degrading the AR, thereby fully shutting down the AR pathway, both in refractory and earlier-line prostate cancer patients. </div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Preclinical data </div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;">In preclinical testing, <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">ARD-1671</div> has demonstrated high potency and selectivity and has produced encouraging tolerability data in toxicology studies completed to date. </div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">ARD-1671</div> has shown <div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">in vitro </div></div>activity in wild type AR as well as multiple clinically relevant AR cell lines with known mutations. The table below shows the DC<div style="font-size: 85%; vertical-align: bottom;;display:inline;;font-size:9.4px">50</div>, or the concentration at which half-maximal degradation is achieved at 24 hours, of <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">ARD-1671</div> in four different cell lines: vertebral cancer of the prostate (&#8220;VCaP&#8221;), which exhibits wild-type AR; and three cell lines exhibiting mutant AR: lymph node cancer of the prostate (&#8220;LNCaP&#8221;), 22RV1 and <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">MDA-PCa-2b.</div></div> Each of these cell lines are well defined populations of cells that have been immortalized from human prostate cancer patients. </div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="font-size: 0px;">
<td style="width: 35%; font-family: &quot;Times New Roman&quot;;"></td>
<td style="width: 2%; vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="width: 32%; font-family: &quot;Times New Roman&quot;;"></td>
<td style="width: 2%; vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="width: 31%; font-family: &quot;Times New Roman&quot;;"></td> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid; white-space: nowrap;;text-align:center;"> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 1pt; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">Cell Line</div></div></div> </td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;&#160;</td>
<td style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 1pt; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">AR Variant</div></div></div> </td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;&#160;</td>
<td style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 1pt; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">DC<div style="font-size: 85%; vertical-align: bottom;;display:inline;;font-size:7.5px">50</div>&#160;(nM)</div></div></div> </td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: bottom;;text-align:center;">VCaP</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;;text-align:center;">Wild&#160;type</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;;text-align:center;">0.05</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: bottom;;text-align:center;">LNCaP</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;;text-align:center;">T878A</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;;text-align:center;">0.082</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: bottom;;text-align:center;">22RV1</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;;text-align:center;">H875Y</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;;text-align:center;">0.9</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: bottom;;text-align:center;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">MDA-PCa-2b</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;;text-align:center;">L702H/T878A</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;;text-align:center;">6</td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">184 </div></div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;;font-weight: bold;"><a href="#toc">Table of Contents</a></div> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">The western blots below demonstrate <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">ARD-1671&#8217;s</div> degradation ability in each of these cell lines. As the concentration of <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">ARD-1671</div> increases to the right across each blot, the presence of AR, as indicated by the size and opacity of each band, decreases. </div> <div style="text-align: center; margin-top: 0pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="color: red; letter-spacing: 0px; top: 0px;;display:inline;">
<img alt="" src="g164680g01m11.jpg" style="width: 406px; height: 282px;"/></div> </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">In a <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">head-to-head</div></div> study with an intact VCaP xenograft model in severe combined immunodeficient (&#8220;SCID&#8221;) mice, which has high AR expression and in which enzalutamide is inactive, <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">ARD-1671</div> demonstrated tumor growth inhibition (64%) compared to enzlutamide <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">(-1%)</div> on treatment day 25. </div> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 24pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Antitumor Activity in VCaP </div></div></div> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Xenograft Tumor Model </div></div></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; margin-top: 0pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="color: red; letter-spacing: 0px; top: 0px;;display:inline;">
<img alt="" src="g164680g01m12.jpg" style="width: 408px; height: 187px;"/></div> </div></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">In a <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">21-day</div> <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-GLP</div> dose range finding canine study, maximal prostate weight reduction was achieved at the lowest dose of 1 mg/kg, consistent with the expected pharmacodynamic effect. No significant adverse events were observed at dose levels up to 10 mg/kg. In a <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">21-day</div> <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-GLP</div> dose range finding rat study, no significant adverse events were observed at dose levels up to 300 mg/kg and prostate weight reduction was also attained. These results indicate that <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">ARD-1671</div> may have a wide therapeutic window, which is currently being assessed in GLP toxicology studies. </div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Development plan </div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;">Our lead AR candidate <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">ARD-1671</div> is in IND enabling development. We intend to pursue the development of our AR program in refractory prostate cancer and to explore its potential in early-line settings, such as mCRPC </div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">185 </div></div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;;font-weight: bold;"><a href="#toc">Table of Contents</a></div> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">or <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-metastatic</div> castration-resistant prostate cancer, as well as in a combination therapy. We expect to initiate a Phase 1 study for our AR program in 2022. </div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">STAT3 Degrader </div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">We are developing signal transducer and activator of transcription 3 (&#8220;STAT3&#8221;) degraders for the treatment of STAT3-driven hematologic malignancies and immuno-oncology indications. Due to potency and selectivity challenges, STAT3 has traditionally been considered to lack an easily druggable pocket. We believe that preclinical data we have generated to date suggest the potential of STAT3 degraders to overcome these challenges. </div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">STAT3-Implicated diseases </div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;">STAT3 is a transcription factor that regulates many biological processes and has been implicated as a direct driver of multiple tumor types. STAT3 controls, among other processes, differentiation, survival, proliferation and angiogenesis, typically in response to growth factors and cytokines. Activation of STAT3 normally involves Janus kinase (JAK)-mediated phosphorylation and dimerization of STAT3 following binding of <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">IL-6</div> to its receptor. Aberrant constitutive activation of STAT3 has been observed in many different cancers and has been associated with poor prognosis and tumor progression. STAT3 activation is also reported as a mechanism of resistance to inhibitors of the receptor tyrosine kinases EGFR and ALK. </div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">STAT3 contributes to an immunosuppressive microenvironment (&#8220;TME&#8221;), suggesting STAT3 degraders have significant potential as immune-oncology agents. Phosphorylated STAT3 (&#8220;pSTAT3&#8221;) acts to negatively regulate neutrophils, natural killer, effector T and dendritic cells. STAT3 also promotes myeloid-derived suppressor cells (&#8220;MDSCs&#8221;) and regulatory T cells and has been shown to mediate the <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">up-regulation</div> of immunosuppressive factors such as <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">IL-10</div> and <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">TGF-&#223;.</div> Additionally, a STAT3 antisense oligonucleotide inhibitor demonstrated early evidence of clinical activity in lymphoma and lung cancer. </div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">Given the broad activity of STAT3, we believe a STAT3 degrader has significant potential in numerous solid tumors and hematologic malignancies, including <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-Hodgkin</div> lymphoma, multiple myeloma, and breast, lung, hepatocellular and head and neck cancer. </div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Limitations of current STAT3 approaches </div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;">Due to STAT3&#8217;s lack of an easily druggable pocket, previous attempts to target STAT3 have been largely unsuccessful. One common approach, inhibition of dimerization with small molecules targeting the SH2 domain of STAT3, has been limited by the transcriptional activity of monomeric STAT3 and by specificity challenges due to the high homology of SH2 domains across STAT proteins. Another common approach, attempting to regulate STAT3 via inhibition of JAK, which is upstream of STAT3, has demonstrated significant <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">off-target</div> effects and STAT3 activation and homodimerization can occur independently of JAK. A third common approach, the use of STAT3 antisense oligonucleotides, has been limited by low cell penetration due to large size, low bioavailability and poor pharmacokinetics, and short half-life <div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">in vivo</div></div>. We believe that the degrader modality has the potential to address many of the historical challenges associated with STAT3 targeting. </div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Preclinical data </div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;">Our STAT3 degrader discovery program has identified a lead compound, <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">SD-436,</div> that potently and rapidly degrades the target with high specificity with respect to degradation of other STAT proteins. <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">SD-436</div> exhibits promising potency against wild type STAT3 in human peripheral blood mononuclear cells (&#8220;PBMCs&#8221;) as well as a mutated STAT3 protein (K658R) in the Pfeiffer cell line, with degradation achieved at low nM concentrations. Furthermore, in an unbiased proteomics analysis in which megakaryoblastic leukemia cell line <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">MOLM-16</div> cells </div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">186 </div></div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;;font-weight: bold;"><a href="#toc">Table of Contents</a></div> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">were treated with <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">SD-436,</div> STAT3 was the only protein observed to be degraded with statistical significance among the approximately 5,000 proteins analyzed, indicating <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">SD-436&#8217;s</div> high specificity. </div> <div style="text-align: center; margin-top: 0pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="color: red; letter-spacing: 0px; top: 0px;;display:inline;">
<img alt="" src="g164680g01m13.jpg" style="width: 561px; height: 167px;"/></div> </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">In a leukemia xenograft tumor model with an activated STAT3 pathway, IV administration of <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">SD-436</div> resulted in deep reductions in tumor volume. The lowest dose tested, 5 mg/kg weekly, achieved rapid and complete tumor regression. </div> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 24pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;">Effect of IV <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">SD-436</div> on Tumor Volume in MOLM16 Xenograft Model </div></div> <div style="text-align: center; margin-top: 0pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="color: red; letter-spacing: 0px; top: 0px;;display:inline;">
<img alt="" src="g164680g01m14.jpg" style="width: 534px; height: 187px;"/></div> </div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Development plan </div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">We plan to explore the potential use of a STAT3 degrader as monotherapy, combination therapy, or, in sequence with chemotherapy or radiation, in tumors that are driven by the STAT3 pathway. In addition, we are exploring the potential for the STAT3 degrader as a potentially important immuno-oncology program both alone and in combination studies. </div></div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">187 </div></div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;;font-weight: bold;"><a href="#toc">Table of Contents</a></div> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Additional Discovery Programs </div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">In addition to AR and STAT3, we are pursuing numerous additional targets with strong scientific rationale and potentially attractive market opportunities. We do not expect to ultimately advance programs for all of these targets into clinical development. We are also discovering drug candidates for additional undisclosed targets and plan to continue to add new discovery programs over time. </div></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="font-size: 0px;">
<td style="width: 12%; font-family: &quot;Times New Roman&quot;;"></td>
<td style="width: 1%; vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="width: 43%; font-family: &quot;Times New Roman&quot;;"></td>
<td style="width: 1%; vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="width: 43%; font-family: &quot;Times New Roman&quot;;"></td> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; white-space: nowrap; padding-bottom: 1pt;;text-align:center;"> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt; border-bottom: 1pt solid rgb(0, 0, 0); display: inline-block; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">Target &amp;<br/>MoA</div></div></div> </td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 1pt; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">Opportunity Profile</div></div></div> </td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 1pt; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">Potential Indications/Patient Populations</div></div></div> </td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">CBP/P300<br/>Degrader</div></div></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: top;">&#8226;&#8195;&#8202;CBP/P300 control expression of oncogenic<br/>factors (e.g., AR, <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">c-Myc)</div> in prostate cancer <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#8226;&#8195;&#8202;Synthetic lethality target (LOF mutations)<br/>with precision medicine approach</div></div> </td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: top;">&#8226;&#8195;&#8202;AR+ prostate cancer (including AR<br/>mutants and splice variant subsets), tumors<br/>with CBP or P300 LOF (e.g., DLBCL, FL,<br/>NSCLC, bladder cancer)</td> </tr>
<tr style="font-size: 1pt;">
<td style="height: 6pt; font-family: &quot;Times New Roman&quot;;"></td>
<td colspan="2" style="height: 6pt; font-family: &quot;Times New Roman&quot;;"></td>
<td colspan="2" style="height: 6pt; font-family: &quot;Times New Roman&quot;;"></td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">SMARCA2/4<br/>Degrader</div></div></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: top;">&#8226;&#8195;&#8202;Synthetic lethality target in multiple tumor<br/>types (e.g., SMARCA4 LOF)</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: top;">&#8226;&#8195;&#8202;SMARCA4-mutated NSCLC (~10% of<br/> NSCLC overall) <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#8226;&#8195;&#8202;Tumor agonistic indication: SMARCA4-<br/>mutated solid tumors</div></div> </td> </tr>
<tr style="font-size: 1pt;">
<td style="height: 6pt; font-family: &quot;Times New Roman&quot;;"></td>
<td colspan="2" style="height: 6pt; font-family: &quot;Times New Roman&quot;;"></td>
<td colspan="2" style="height: 6pt; font-family: &quot;Times New Roman&quot;;"></td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">KRAS G12D<br/>Degrader</div></div></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: top;">&#8226;&#8195;&#8202;Historically undruggable oncogene variant<br/> G12D <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#8226;&#8195;&#8202;Most frequently mutated oncogene in<br/>human cancers</div></div> </td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: top;">&#8226;&#8195;&#8202;KRAS G12D mutant tumors <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#8226;&#8195;&#8202;Highest rates in PDAC, CRC, endometrial<br/>and lung cancer</div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">188 </div></div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;;font-weight: bold;"><a href="#toc">Table of Contents</a></div> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="text-decoration: underline; letter-spacing: 0px; top: 0px;;display:inline;">Genevant Overview </div></div></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 3%; vertical-align: top;;text-align:left;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#8226;</div></div></td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="text-decoration: underline; letter-spacing: 0px; top: 0px;;display:inline;">Overview</div>: </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Genevant is a technology-focused nucleic acid delivery and development company with a lipid nanoparticle (&#8220;LNP&#8221;) platform, an expansive intellectual property portfolio and deep scientific expertise, currently focused on partnering with other pharmaceutical or biotechnology companies to enable the development of nucleic acid therapeutics for unmet medical needs. </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 3%; vertical-align: top;;text-align:left;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#8226;</div></div></td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="text-decoration: underline; letter-spacing: 0px; top: 0px;;display:inline;">Delivery platforms:</div> </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Genevant has two delivery platforms: LNP and ligand conjugate. </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 10%;">&#160;</td>
<td style="width: 2%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">LNP platform: </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 16%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;">Proven technology as demonstrated by <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">head-to-head</div></div> <div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">in vivo </div></div>ionizable lipid study assessing LNP potency and immune stimulation </div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 16%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;">Clinically validated for hepatocyte and vaccine use and under development for other traditionally <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">hard-to-reach</div></div> tissues and cell types, including lung, eye, central nervous system, and hepatic stellate and immune cells </div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 16%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Over 700 issued patents and pending patent applications as of October&#160;15, 2021 </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 10%;">&#160;</td>
<td style="width: 2%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Ligand conjugate platform: </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 16%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Novel GalNAc ligands with demonstrated ability to deliver to the liver in preclinical studies </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 16%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;">In preclinical <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">head-to-head</div></div> testing, demonstrated equal or better preclinical potency, assessed by duration and magnitude of knockdown, compared to a current industry benchmark </div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 16%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Applying delivery expertise to design of novel extrahepatic ligands to expand therapeutic reach </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 3%; vertical-align: top;;text-align:left;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#8226;</div></div></td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="text-decoration: underline; letter-spacing: 0px; top: 0px;;display:inline;">Collaboration-based business model:</div> </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Genevant uses its expertise in the delivery of nucleic acid therapeutics to develop optimal delivery systems for its collaborators&#8217; identified payloads or target tissues. </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;">Genevant collaboration-based business model is to seek some or all of upfront payments, R&amp;D reimbursements, and milestones and royalties (or profit share) upon success, while also retaining certain rights in the delivery-related intellectual property developed in the context of the collaboration for potential use in other nonexclusive <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">out-licenses.</div> </div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Some current collaboration partners include BioNTech, Takeda, Sarepta and Gritstone. </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 3%; vertical-align: top;;text-align:left;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#8226;</div></div></td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="text-decoration: underline; letter-spacing: 0px; top: 0px;;display:inline;">Clinical data:</div> </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Genevant LNP technology has been in clinical testing in over a dozen distinct product candidates, representing hundreds of subjects of clinical experience. </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;">Genevant LNP technology is included in the first <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">siRNA-LNP</div> product to receive <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">FDA-approval,</div> Alnylam&#8217;s Onpattro (patisiran). </div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="text-decoration: underline; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Roivant ownership:</div></div></div> </div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">As of June&#160;30, 2021, we own 83% of the issued and outstanding Common Shares of Genevant and 69% on a fully diluted basis. </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">189 </div></div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;;font-weight: bold;"><a href="#toc">Table of Contents</a></div> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Nucleic Acid Therapeutics </div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Nucleic acid therapeutics represent an attractive, novel modality that we believe may overcome challenges associated with traditional small molecule drug development in the treatment of genetically defined disease. The vast majority of human proteins are considered &#8220;undruggable&#8221; by small molecules based on their protein structure. Nucleic acid therapeutics circumvent the question of whether or not a target is undruggable by impacting protein expression itself. </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">The field of nucleic acid therapeutics has gained significant momentum in recent years, with FDA approval of Alnylam&#8217;s Onpattro and Givlaari (givosiran), and emergency use authorization of multiple mRNA <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">COVID-19</div> vaccines. There is a substantial pipeline of nucleic acid therapeutics in clinical development that further underscores the transformative potential of nucleic acid therapeutics in the near term. However, nucleic acid therapeutics remain challenged by obstacles in the delivery of nucleic acids to specific cell types. RNA molecules cannot passively cross most cell membranes given their large size and negative charge, and therefore must be administered in conjunction with a delivery technology to ensure transport to target cell types. </div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">We work with two proprietary technologies, an LNP delivery system and a ligand conjugate delivery system, to improve the likelihood of clinical success of nucleic acid therapeutics. Some of the intellectual property with respect to each of these technologies was licensed from Arbutus Biopharma in 2018. </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">We have continued to advance our platforms, expanding into novel tissue types by leveraging the scientific expertise of several members of the technical team that originally developed or advanced the technologies at Arbutus and its predecessors. </div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Lipid Nanoparticle Platform </div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Our LNP technology platform is designed to deliver nucleic acids, including mRNA, siRNA, antisense and gene editing constructs. </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Some key features of our LNP technology are: </div></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 7%;">&#160;</td>
<td style="width: 4%; vertical-align: top;;text-align:left;">1.</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Multi-component formulations that contain specialized lipids optimized for potency and tolerability, are capable of encapsulating a broad range of nucleic acid payloads, and have limited constraints on nucleic acid composition, structure or size </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 7%;">&#160;</td>
<td style="width: 4%; vertical-align: top;;text-align:left;">2.</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">A manufacturing process developed and scaled to produce stable uniform dispersion of colloidal nanoparticles with particle size appropriate for parenteral or intramuscular administration </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 7%;">&#160;</td>
<td style="width: 4%; vertical-align: top;;text-align:left;">3.</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Efficient intracellular delivery of nucleic acids to cell cytoplasm via engineered active endosomal escape mechanism </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">190 </div></div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;;font-weight: bold;"><a href="#toc">Table of Contents</a></div> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"> <div style="text-align: center; margin-top: 0pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="color: red; letter-spacing: 0px; top: 0px;;display:inline;">
<img alt="" src="g164680g01m19.jpg" style="width: 605px; height: 350px;"/></div> </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">In a <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">head-to-head</div></div> study comparing multiple LNP formulations varying only the key ionizable lipid, a newer Genevant formulation outperformed third party formulations. In particular, our formulation showed superior potency and avoidance of immune stimulation relative to others, including when compared with the LNP utilized in the first <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">FDA-approved</div> <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">siRNA-LNP</div> therapeutic, Alnylam&#8217;s Onpattro (&#8220;MC3&#8221; in figure below). </div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">191 </div></div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;;font-weight: bold;"><a href="#toc" style="text-indent: 0px;">Table of Contents</a></div> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;">Genevant LNP Outperformed Third Party LNPs in <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">Head-to-Head</div></div> Study </div></div> <div style="text-align: center; margin-top: 0pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="color: red; letter-spacing: 0px; top: 0px;;display:inline;">
<img alt="" src="g164680g01m16.jpg" style="width: 585px; height: 439px;"/></div> </div></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 2%; vertical-align: top;;text-align:left;">*Key</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;">lipid of first <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">FDA-approved</div> <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">siRNA-LNP</div> (Alnylam&#8217;s Onpattro) </div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">In addition, Genevant LNP technology has entered the clinic in more than a dozen distinct product candidates, representing hundreds of subjects of clinical experience. </div></div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">192 </div></div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;;font-weight: bold;"><a href="#toc">Table of Contents</a></div> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Substantial clinical experience with Genevant LNP technology </div></div></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; margin-top: 0pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="color: red; letter-spacing: 0px; top: 0px;;display:inline;">
<img alt="" src="g164680g01m17.jpg" style="width: 605px; height: 285px;"/></div> </div></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">With this track record of success, we are now also focusing our LNP capabilities on historically challenging cell and tissue types, including hepatic stellate cells and the lung. </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">We have demonstrated our ability to deliver nucleic acid therapeutics to challenging targets through our efforts to access hepatic stellate cells (&#8220;HSCs&#8221;) in preclinical studies. Historically, attempts to address certain diseases have been limited by the inability to access specific cell types outside of the hepatocyte. The activation of HSCs is well established as a central driver of fibrosis, and thus technologies that target activated HSCs may be key to address certain liver diseases. </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">In preclinical studies, delivery of RNAis to HSCs via Genevant&#8217;s LNP technology demonstrated selective knockdown of an HSC target with minimal activity in hepatocytes, as shown below. Additional preclinical studies support our ability to design LNPs to deliver nucleic acids to the lung, and we believe that our scientific expertise will allow us to direct LNPs toward additional cell and tissue types, such as the central nervous system and eye. </div></div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">193 </div></div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;;font-weight: bold;"><a href="#toc">Table of Contents</a></div> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">LNP delivery of siRNA to HSCs demonstrated selective knockdown of target mRNA in mice with minimal activity in hepatocytes </div></div></div> <div style="text-align: center; margin-top: 0pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="color: red; letter-spacing: 0px; top: 0px;;display:inline;">
<img alt="" src="g164680g01m18.jpg" style="width: 430px; height: 238px;"/></div> </div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Ligand Conjugate Platform </div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">In addition to our LNP platform, we also have a proprietary RNAi ligand conjugate platform. Novel ligands can successfully deliver siRNA and certain other oligonucleotides to the liver, and our delivery expertise enables the design of novel ligands potentially to expand therapeutic reach to hepatic stellate cells. Our ligand conjugate technology has demonstrated equal or better preclinical potency, assessed by duration and magnitude of knockdown compared to current industry benchmark. We currently have multiple patents pending with respect to our ligand conjugate platform. </div></div> <div style="text-align: center; margin-top: 0pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="color: red; letter-spacing: 0px; top: 0px;;display:inline;">
<img alt="" src="g164680g01m19.jpg" style="width: 605px; height: 350px;"/></div> </div></div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">194 </div></div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;;font-weight: bold;"><a href="#toc">Table of Contents</a></div> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"> <div style="text-align: center; margin-top: 0pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="color: red; letter-spacing: 0px; top: 0px;;display:inline;">
<img alt="" src="g164680g01m20.jpg" style="width: 605px; height: 165px;"/></div> </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">We are developing a next-generation ligand conjugate (&#8220;RNAi 2.0&#8221;) platform. Our RNAi 2.0 platform has demonstrated superior strength and duration of knockdown compared to legacy ligand conjugates (&#8220;RNAi 1.0&#8221;) in a <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">head-to-head</div></div> nonclinical study in nonhuman primates. In addition, our RNAi 2.0 platform: </div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Contains intrinsic endosomolytic properties </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;">Has demonstrated marked <div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">in vivo</div></div> enhancement in potency </div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Has maintained a subcutaneous dosing regimen and would be dosed subcutaneously in clinical trials </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Remains compatible with other ligand types </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 24pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Next Generation RNAi 2.0 Conjugate Platform Shows Improved Potency, Magnitude and Duration of Knockdown </div></div></div> <div style="text-align: center; margin-top: 0pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="color: red; letter-spacing: 0px; top: 0px;;display:inline;">
<img alt="" src="g164680g64e02.jpg" style="width: 605px; height: 241px;"/></div> </div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Strategy </div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Genevant seeks to partner with other pharmaceutical or biotechnology companies in the development of RNA therapeutics, crafting mutually beneficial collaborations that allow collaboration partners to access innovative technologies while providing Genevant the opportunity to leverage our expertise to expand the technology and corresponding therapeutic reach. </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">This provides the following benefits to collaborators: </div></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Access to validated technology to deliver nucleic acid therapeutics to hepatocytes or for vaccine applications </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">195 </div></div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;;font-weight: bold;"><a href="#toc">Table of Contents</a></div> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;">
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 9%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;">Potential to deliver RNA payloads to historically <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">challenging-to-reach</div></div> tissue or cell types, as well as nucleic acid design capabilities </div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 9%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">No need to build internal delivery expertise or build intellectual property estate from scratch in an increasingly complex field </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">This provides the following benefits to Genevant: </div></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 9%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Opportunity to expand core delivery technology and capabilities, maintaining leadership position in nucleic acid delivery </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 9%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;">Typically, certain rights to delivery-related intellectual property developed in the context of collaboration and ability to exploit through other nonexclusive <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">out-licenses</div> </div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 9%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Opportunity to generate revenue through deal structures including some combination of upfront payments, R&amp;D reimbursements and additional milestones and royalties upon successful outcomes </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">To date, Genevant has partnered with leading companies with a shared vision of advancing innovative nucleic acid medicines to transform the lives of patients. Our collaborations currently include: </div></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Gritstone</div></div>&#8212;Access to Genevant&#8217;s LNP technology for use in Gritstone&#8217;s self-amplifying RNA <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">COVID-19</div> vaccine program </div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Gritstone</div></div>&#8212;Access to LNP technology for use with self-amplifying RNA for an unspecified indication </div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Sarepta</div></div>&#8212;Research collaboration and option agreement for the delivery of <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">LNP-gene</div> editing therapeutics for specified neuromuscular diseases; Genevant will design and collaborate with Sarepta in the development of muscle targeted LNPs to be applied to gene editing targets in multiple indications, including Duchenne muscular dystrophy </div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">BioNTech</div></div><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">&#8212;Co-development</div> in up to five rare diseases with high unmet medical need, and access to LNP technology for use with BioNTech&#8217;s mRNA for a specified number of oncology targets </div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Takeda</div></div>&#8212;Access to LNP technology to develop nucleic acid therapeutics directed to specified targets in hepatic stellate cells to treat liver fibrosis </div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Takeda</div></div>&#8212;Access to LNP technology to develop nonviral gene therapies for up to two rare liver diseases </div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">ST Pharm</div></div>&#8212;Access to Genevant&#8217;s LNP technology for use in specified territories in an mRNA <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">COVID-19</div> vaccine </div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Providence</div></div>&#8212;Access to Genevant&#8217;s LNP technology for use in Providence&#8217;s mRNA <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">COVID-19</div> vaccine program </div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Potential Benefits of Genevant&#8217;s Delivery Platforms </div></div></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Robust and expansive patent estate.</div></div> As of October&#160;15, 2021, over 700 issued patents and pending patent applications for our LNP platform, including coverage of individual lipid structure, particle composition, particle morphology, manufacturing and <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">mRNA-LNP</div> formulations. As we continue to develop these technologies, we expect to have the opportunity to expand intellectual property protection further, to enhance protection and support additional licensing opportunities. </div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Experienced leadership team.</div></div> Our leadership team has deep technical expertise in nucleic acid drug development and a track record of executing successfully in innovative areas. We believe this positions Genevant to expand delivery to historically challenging tissues and cell types, thereby creating potential opportunities for creative collaboration. </div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">196 </div></div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;;font-weight: bold;"><a href="#toc">Table of Contents</a></div> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;">
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Manufacturing <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">know-how.</div></div></div> Since inception, we have made strategic investments in expanding our manufacturing <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">know-how.</div> Our manufacturing process is rapid and reproducible, has intellectual property protection and is capable of commercial scale. </div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Expansive Patent Portfolio </div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Our LNP platform is protected with a robust patent portfolio, covering a wide range of aspects required for successful nucleic acid delivery. </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Our patents are directed to: </div></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 9%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;">Structures and individual lipid compositions, including cationic and <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">PEG-lipids</div> </div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 9%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Particle compositions, including commonly used, most active ranges of lipid ratios for nucleic acid-containing particles </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 9%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Nucleic acid-containing particles with certain structural characteristics </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 9%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">mRNA-containing LNP formulations </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 9%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Various aspects of our manufacturing process </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">197 </div></div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;;font-weight: bold;"><a href="#toc">Table of Contents</a></div> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="text-decoration: underline; letter-spacing: 0px; top: 0px;;display:inline;">Lysovant Overview </div></div></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 3%; vertical-align: top;;text-align:left;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#8226;</div></div></td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="text-decoration: underline; letter-spacing: 0px; top: 0px;;display:inline;">Overview:</div> </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;">Lysovant is developing LSVT-1701, a novel endolysin, for the treatment of <div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Staph aureus</div></div> bacteremia (&#8220;SAB&#8221;) to potentially address significant unmet medical need in the treatment of serious bacterial infections. </div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 3%; vertical-align: top;;text-align:left;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#8226;</div></div></td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="text-decoration: underline; letter-spacing: 0px; top: 0px;;display:inline;">Lead program: </div> </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">LSVT-1701: </div></div>Novel bacteriophage-derived biologic candidate with potent, selective and rapid bactericidal anti-staphylococcal activity including multi-resistant strains via cell wall hydrolysis. </div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 3%; vertical-align: top;;text-align:left;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#8226;</div></div></td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="text-decoration: underline; letter-spacing: 0px; top: 0px;;display:inline;">Disease overview: </div> </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Staph aureus</div></div> is a major cause of infections in the United States and can be serious or fatal by causing bacteremia or sepsis when the bacteria enter the bloodstream. Unless promptly treated, SAB can metastasize to deep tissues and significantly increase the risk of mortality. The most common complications include infective endocarditis (&#8220;IE&#8221;), vertebral osteomyelitis and pulmonary infections. </div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;">In the United States, there are an estimated 226,000 patients with SAB and 50,000 with IE per year. The incidence of SAB is increasing<div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"> </div></div>due to the growth of invasive procedures, expansion of implanted medical devices and rise in number of immunocompromised patients. </div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 3%; vertical-align: top;;text-align:left;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#8226;</div></div></td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="text-decoration: underline; letter-spacing: 0px; top: 0px;;display:inline;">Limitations of current treatments:</div> </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Current standard of care antibiotics for SAB are vancomycin and daptomycin for MRSA, and beta-lactam antibiotics for MSSA, and there has been no innovation for decades. Current antibiotic treatments take days to suppress the bacteria in hospitalized SAB patients. There exists significant unmet need for rapid bactericidal antibiotics for complicated SAB and IE, as patients require more effective treatments to reduce the high mortality of these diseases. </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 3%; vertical-align: top;;text-align:left;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#8226;</div></div></td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="text-decoration: underline; letter-spacing: 0px; top: 0px;;display:inline;">Clinical data:</div> </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Results from Phase 1/2a clinical trials suggest that LSVT-1701 is generally well-tolerated with an adequate safety profile on top of standard of care antibiotics. </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 3%; vertical-align: top;;text-align:left;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#8226;</div></div></td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="text-decoration: underline; letter-spacing: 0px; top: 0px;;display:inline;">Development plan and upcoming milestones:</div> </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">We anticipate initiating a Multiple Ascending Dose (MAD) study of LSVT-1701 in patients with complicated SAB including IE in the first half of calendar year 2022. </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 3%; vertical-align: top;;text-align:left;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#8226;</div></div></td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="text-decoration: underline; letter-spacing: 0px; top: 0px;;display:inline;">Roivant ownership:</div> </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">As of June&#160;30, 2021, we own 100% of the issued and outstanding common shares of Lysovant and 99% on a fully diluted basis. </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 3%; vertical-align: top;;text-align:left;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#8226;</div></div></td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="text-decoration: underline; letter-spacing: 0px; top: 0px;;display:inline;">Pipeline:</div> </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="text-align: center; margin-top: 0pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="color: red; letter-spacing: 0px; top: 0px;;display:inline;">
<img alt="" src="g164680g83e66.jpg" style="width: 605px; height: 50px;"/></div> </div></div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">198 </div></div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;;font-weight: bold;"><a href="#toc">Table of Contents</a></div> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">LSVT-1701 </div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">LSVT-1701 is a selective and efficient bactericide due to its unique endolysin mechanism. Where other antibiotics and treatments inhibit the synthesis or function of the bacteria&#8217;s cell wall, nucleic acid, membrane, and protein, LSVT-1701 directly cleaves the bacteria&#8217;s cell wall leading to rapid bacterial lysis. </div></div> <div style="text-align: center; margin-top: 0pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="color: red; letter-spacing: 0px; top: 0px;;display:inline;">
<img alt="" src="g164680g84a55.jpg" style="width: 601px; height: 204px;"/></div> </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">We believe LSVT-1701 may be the most effective lysin due to its use of two catalytic domains, called amidase and endopeptidase. These domains provide peptidoglycan (cell wall) hydrolysis. While the amidase cuts between the sugar stands and stem peptides, the endopeptidase cleaves the bonds between the stem peptide and the pentaglycine bridge. As shown below, this novel endolysin mechanism potentially allows for more rapid bactericidal effect. Additionally, endolysin target binding sites are highly conserved and essential to <div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">S. aureus</div></div> bacteria viability<div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">.</div></div> We believe this may contribute to lower propensity for resistance. </div> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 24pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">LSVT-1701 Mechanism of Action </div></div></div> <div style="text-align: center; margin-top: 0pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="color: red; letter-spacing: 0px; top: 0px;;display:inline;">
<img alt="" src="g164680g84w55.jpg" style="width: 605px; height: 261px;"/></div> </div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">LSVT-1701 for the Treatment of </div></div><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Staph aureus</div></div></div></div><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"> Bacteremia </div></div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Staph aureus bacteremia and limitations of current treatments </div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Staph aureus</div></div> is a major cause of infections in the United States and can be serious or fatal by causing bacteremia or sepsis when the bacteria enter the bloodstream. Other complications from infection include </div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">199 </div></div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;;font-weight: bold;"><a href="#toc">Table of Contents</a></div> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">infective endocarditis, where the infection reaches heart valves and may cause heart failure or stroke, and osteomyelitis, where the bone becomes infected.<div style="font-size: 85%; vertical-align: top;;display:inline;;font-size:9.4px"> </div>Common strains of <div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Staph aureus</div></div> are either methicillin-resistant (&#8220;MRSA&#8221;) or methicillin-susceptible (&#8220;MSSA&#8221;). </div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">In the United States, there are an estimated 226,000 patients with <div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">S. aureus</div></div> bacteremia and 50,000 with infective endocarditis per year.<div style="font-size: 85%; vertical-align: top;;display:inline;;font-size:9.4px"> </div>Of all SAB cases, around 45% are caused by MRSA and 55% by MSSA. Complicated bacteremia due to sepsis, comorbidities or dialysis accounts for approximately 32% of SAB cases per year and refractory bacteremia accounts for approximately 28% of SAB cases per year. In addition to being a leading cause of infections, SAB is also a major cost driver to U.S. hospitals and results in high mortality rates. Average <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">30-day</div> mortality of <div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">S. aureus </div></div>infections is around 20% with current antibiotic treatment. Complicated bacteremia is associated with higher mortality rates of up to 30%. MRSA and MSSA bacteremia is associated with long hospital stays and high ICU utilization, particularly for complicated bacteremia and IE. Cost of care for SAB across MRSA and MSSA is around $7.4&#160;billion annually, with sepsis due to the bacteria accounting for 79% of this annual cost. These burdens are in part due to rising resistance of infections to current standard of care antibiotics. Consequently, there is a great need for new therapies efficacious for both <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">hard-to-treat</div></div> MRSA and MSSA. </div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">We believe that if approved for commercial sale, LSVT-1701 would be differentiated from both current standard of care and emerging endolysin treatments for SAB and IE. Endolysins have been clinically validated as a novel class of bacterial treatment by results from ContraFect&#8217;s Phase 2 trial of exebacase, which showed efficacy in MRSA but not MSSA and in right-sided infective endocarditis compared to standard of care antibiotics alone. While exebacase&#8217;s endolysin mechanism only cleaves at one site in the cell wall, LSVT-1701 cleaves at two, potentially increasing its bactericidal capability. Based on preclinical and clinical trials, we believe that if approved, LSVT-1701 can also be given in multiple doses and at higher dosing levels compared to exebacase, which cannot be dosed twice and has a compound-specific dose-limiting toxicology signal (vasculitis). If approved, we believe that LSVT-1701 could be an attractive treatment on top of standard of care for populations with high medical needs, such as those with complicated MRSA and MSSA bacteremia, and left-sided infective endocarditis. </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">As a result of the novel endolysin mechanism of LSVT-1701, we believe that LSVT-1701, if approved for use, could provide the following potential benefits: </div></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Rapid antibacterial activity.</div></div> Where current antibiotic treatments take a long time to suppress the bacteria, LSVT-1701 has the potential to provide rapid and highly effective lytic action. </div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Species specificity. </div></div>Anti-staphylococcal endolysins provide pathogen-targeted bacteriolysis and preserve normal flora </div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Low propensity for resistance.</div></div> Target binding sites are highly conserved and essential to bacteria viability. </div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Synergy with standard of care. </div></div>LSVT-1701 has the potential to be used to treat antibiotic-resistant bacteria and administered concurrently with antibiotics. </div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Effective against biofilms. </div></div>In animal models,<div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;"> </div></div>LSVT-1701 eradicated and cleared biofilm where standard of care is ineffective. </div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Effective against all strains.</div></div> <div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">In vitro </div></div>susceptibility data demonstrate an activity profile for both MRSA and MSSA, and multi-resistant clinical isolates<div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">.</div></div> </div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Clinical data </div></div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt; margin-left: 4%;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Phase 1 </div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">In February 2019, iNtRON Biotechnology completed Phase 1 studies evaluating the safety, pharmocokinetics and pharmacodynamics of LSVT-1701. In these double-blind, placebo-controlled studies, 51 healthy subjects were given single or multiple ascending doses. All adverse events reported were mild or </div></div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">200 </div></div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;;font-weight: bold;"><a href="#toc" style="text-indent: 0px;">Table of Contents</a></div> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">moderate and included chills or rigors, infusion site reaction, pyrexia, headache, myalgia and fatigue. These adverse events appeared dose-dependently but were not frequency-dependent. There were no reported severe adverse events reported. </div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt; margin-left: 4%;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Phase 2a </div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;">In November 2019, Lysovant completed a randomized, placebo-controlled Phase 2a clinical trial evaluating the safety of LSVT-1701 in <div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">S. aureus</div></div> bacteremia. In this trial, 12 subjects with persistent MRSA or MSSA bacteremia received a single IV dose of LSVT-1701 3 mg/kg in addition to standard of care antibiotics. 13 subjects received placebo, alongside standard of care antibiotics. LSVT-1701 was generally well-tolerated, with similar proportion of subjects reporting adverse events in both placebo and LSVT-1701 arms. Additionally, there was also no evidence of cytokine storm or anaphylaxis. The safety profile observed potentially allows for higher dosing in future trials. </div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Preclinical data </div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;">In a <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-neutropenic</div> murine bacteremia (i.e., MSSA sepsis) model, postantibiotic effect (&#8220;PAE&#8221;) occurred after 48 hours. PAE occurs when bacterial growth is successfully suppressed after drug administration. There were no dose-limiting toxicities like vascular lesions or immunogenicity following administration of multiple doses, which suggests safety and tolerability within the model. In a rabbit infectious endocarditis model, a multi-dose regimen of LSVT-1701 demonstrated complete sterilization of tissues. The data also suggest the ability to dissolve bacterial vegetations, as LSVT-1701 achieved complete experimental sterilization on top of daptomycin, whereas the daptomycin antibiotic regimen alone and exebacase on top of daptomycin did not (not a <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">head-to-head</div></div> study). <div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">In vitro</div></div>, LSVT-1701 has demonstrated a narrow and well-defined minimum inhibitory concentration (MIC) range (MIC<div style="font-size: 85%; vertical-align: bottom;;display:inline;;font-size:9.4px">90</div> 2 ug/ml) across a diverse collection of current clinical <div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">S. aureus </div></div>isolates including MRSA, MSSA, vancomycin-intermediate <div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">S. aureus</div></div> (VISA), and glycopeptide-intermediate <div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">S. aureus</div></div> (GISA). LSVT-1701 also exhibited a comparable MIC range in 82 coagulase negative staphylococci (CoNS) isolates. MIC measures the lowest concentration of drug necessary to prevent visible bacterial growth, and a narrower MIC range suggests that LSVT-1701 is an efficient bactericide against multi-resistant clinical isolates. LSVT-1701 was also not adversely affected by decreased susceptibility or resistance to various antibiotics, further confirming its bactericidal activity. </div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Development plan </div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">LSVT-1701 is being developed for the treatment of SAB and IE, and we plan to initiate a Multiple Ascending Dose (MAD) study in the first half of calendar year 2022. </div></div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">201 </div></div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;;font-weight: bold;"><a href="#toc">Table of Contents</a></div> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="text-decoration: underline; letter-spacing: 0px; top: 0px;;display:inline;">Kinevant Overview </div></div></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 3%; vertical-align: top;;text-align:left;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#8226;</div></div></td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="text-decoration: underline; letter-spacing: 0px; top: 0px;;display:inline;">Overview:</div> </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Kinevant is focused on developing namilumab for pulmonary sarcoidosis and other autoimmune diseases. </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 3%; vertical-align: top;;text-align:left;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#8226;</div></div></td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="text-decoration: underline; letter-spacing: 0px; top: 0px;;display:inline;">Lead program:</div> </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Namilumab: </div></div>Fully human <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">anti-GM-CSF</div></div> monoclonal antibody with broad potential in autoimmune diseases. </div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 3%; vertical-align: top;;text-align:left;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#8226;</div></div></td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="text-decoration: underline; letter-spacing: 0px; top: 0px;;display:inline;">Disease overview:</div> </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Sarcoidosis is a multisystem autoimmune disease that affects approximately 200,000 people in the United States, with 95% of cases presenting with pulmonary involvement. </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 3%; vertical-align: top;;text-align:left;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#8226;</div></div></td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="text-decoration: underline; letter-spacing: 0px; top: 0px;;display:inline;">Limitations of current treatments:</div> </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Corticosteroids are the most widely used treatment for sarcoidosis, but they carry significant side effects when used longer-term. Second- and third-line treatment options, including immunosuppressive therapies and biologics, are limited by slow onset, safety risk, inconsistent effectiveness, and reimbursement challenges, leaving significant unmet medical need that could be met by a novel biologic. </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 3%; vertical-align: top;;text-align:left;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#8226;</div></div></td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="text-decoration: underline; letter-spacing: 0px; top: 0px;;display:inline;">Clinical data:</div> </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Early clinical data in pharmacokinetic/pharmacodynamic (PK/PD) and subsequent Phase 2 studies showed namilumab to be well tolerated with a single subcutaneous injection given up to every four weeks. </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 3%; vertical-align: top;;text-align:left;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#8226;</div></div></td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="text-decoration: underline; letter-spacing: 0px; top: 0px;;display:inline;">Development plan and upcoming milestones:</div> </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">We plan to initiate a Phase 2 trial to test for the safety and efficacy of namilumab in pulmonary sarcoidosis in the first half of calendar year 2022. </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 3%; vertical-align: top;;text-align:left;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#8226;</div></div></td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="text-decoration: underline; letter-spacing: 0px; top: 0px;;display:inline;">Roivant ownership:</div> </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">As of June&#160;30, 2021, we own 88% of the issued and outstanding common shares of Pharmavant 3 (renamed Kinevant in October 2021), and 88% on a fully diluted basis. </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 3%; vertical-align: top;;text-align:left;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#8226;</div></div></td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="text-decoration: underline; letter-spacing: 0px; top: 0px;;display:inline;">Pipeline:</div> </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="text-align: center; margin-top: 0pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="color: red; letter-spacing: 0px; top: 0px;;display:inline;">
<img alt="" src="g164680g68z96.jpg" style="width: 605px; height: 42px;"/></div> </div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="text-decoration: underline; letter-spacing: 0px; top: 0px;;display:inline;">Namilumab </div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;">Namilumab is a fully human monoclonal antibody that neutralizes granulocyte-macrophage colony-stimulating factor <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">(&#8220;GM-CSF&#8221;)</div> activity by preventing it from binding to high-affinity cell surface receptors, neutralizing the otherwise pathogenic cytokine in conditions such as pulmonary sarcoidosis. </div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">GM-CSF</div> provides key functions as a <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">pro-inflammatory</div> cytokine and growth factor. Following antigen stimulation or activation by cytokines, <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">GM-CSF</div> can be secreted by a variety of cell types, including activated B and T cells. <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">GM-CSF</div> is <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">pro-inflammatory</div> as it activates macrophages and other cells to drive inflammation and tissue damage. <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">GM-CSF</div> also acts as a growth factor; for example, recombinant <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">GM-CSF</div> is used for the treatment of low white blood cell counts in cancer patients undergoing chemotherapy to increase white blood cells and mobilize them into peripheral blood. </div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">202 </div></div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;;font-weight: bold;"><a href="#toc">Table of Contents</a></div> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">GM-CSF&#8217;s</div> Role in Sarcoid Pathogenesis </div></div> <div style="text-align: center; margin-top: 0pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="color: red; letter-spacing: 0px; top: 0px;;display:inline;">
<img alt="" src="g164680g88l67.jpg" style="width: 271px; height: 379px;"/></div> </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">Due to its targeting of a common <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">pro-inflammatory</div> cytokine, we intend to evaluate the development of namilumab for the treatment of a number of potential autoimmune indications. <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">GM-CSF</div> administration has been found to drive disease progression in a variety of preclinical models, including inflammatory arthritis, multiple sclerosis, interstitial lung disease, nephritis, myocarditis, and giant cell arteritis, among others, suggesting broad utility of the <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">anti-GM-CSF</div></div> mechanism. Macrophages have been implicated in the progression of fibrosis in lung injury, which indicates a potential role of <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">anti-GM-CSF</div></div> as an antifibrotic. Numerous other cytokine inhibitors, including those targeting <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">TNF-&#206;&#177;,</div> <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">IL-6,</div> <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">IL-23,</div> and <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">IL-17,</div> have been successfully clinically validated across a broad range of indications, which we believe suggests potentially broad and flexible application of namilumab. Targeting <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">GM-CSF</div> has been clinically validated in two other autoimmune diseases, rheumatoid arthritis and giant cell arteritis, where Phase 2 trials have shown <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">anti-GM-CSFs</div></div> to be generally well tolerated and to have demonstrated the potential for symptom resolution. Additionally, namilumab is being developed with potentially the least frequent dosing schedule of other subcutaneous <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">anti-GM-CSFs</div></div> in Phase 2 or Phase&#160;3 clinical trials, with a single dose every four weeks after an initial loading period, and has been studied in approximately 300 patients to date. Based on the <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">anti-GM-CSF</div></div> development landscape, we believe that namilumab has potential for pulmonary sarcoidosis and multiple avenues for expansion across both clinically validated indications and indications with no known <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">anti-GM-CSF</div></div> development. The three other <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">anti-GM-CSFs</div></div> currently in Phase 2 or Phase 3 clinical trials are GlaxoSmithKline&#8217;s otilimab, which is subcutaneous, dosed weekly, and currently undergoing Phase 3 trials in rheumatoid arthritis and a Phase 2 trial in <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">COVID-19;</div> Kiniksa&#8217;s mavrilumab, which is subcutaneous, dosed every two weeks, and last completed a positive Phase 2 trial in giant cell arteritis and is undergoing a Phase 3 trial in <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">COVID-19</div> pneumonia and hyperinflammation; and Humanigen&#8217;s lenzilumab, which is intravenous, dosed every four weeks, and reported positive topline results in a Phase 3 trial in <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">COVID-19</div> pneumonia. </div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Namilumab for the Treatment of Sarcoidosis </div></div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Sarcoidosis overview and limitations of current treatments </div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Sarcoidosis is a multi-organ autoimmune disease characterized by the presence of granulomas believed to form via an exaggerated immune response to unidentified antigens. Sarcoidosis primarily affects the lungs and </div></div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">203 </div></div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;;font-weight: bold;"><a href="#toc">Table of Contents</a></div> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">lymphatic system, though sarcoidosis may damage any organ. Granulomas are compact, centrally organized collections of macrophages and epithelioid cells encircled by lymphocytes and form during a normal immune response to trap foreign pathogens, restrict inflammation, and protect the surrounding tissue. The hallmark of sarcoidosis is the presence of CD4+ T cells that interact with antigen-presenting cells to initiate the formation, maintenance, and accumulation of granulomas. </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">Sarcoidosis affects approximately 200,000 patients in the United States alone and can present itself acutely or subacutely with lymph node enlargement, shortness of breath, dry cough, skin, joint or eye lesions, or abnormalities on chest <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">x-ray</div> or CT. Approximately 95% of sarcoidosis patients have lung involvement, and around 20 to 30% of patients develop permanent lung damage from the disease. An estimated 54% of pulmonary sarcoidosis patients are diagnosed, and approximately 90% of these patients receive some form of treatment. The annual incidence of sarcoidosis in African-Americans is threefold that of Caucasian Americans. Some studies report a slight predominance of sarcoidosis among females compared to males, while others show no gender predilection. Age at onset ranges from 20s to over the age of 50. Corticosteroids are the most widely used treatment for sarcoidosis, but they carry significant side effects when used longer-term, and relapses are common when attempting to taper. There are multiple second- and third-line treatment options, including immunosuppressive therapies such as methotrexate and azathioprine as well as biologics such as TNF inhibitors, but their use is limited by slow onset, safety risk, inconsistent effectiveness, and reimbursement challenges. There remains significant unmet medical need for patients who are not well-controlled by steroids or immunosuppressants (patients may remain symptomatic or may not be able to tolerate effective doses) that could be met by a novel biologic. Market research with HCPs and third-party analysis of claims data suggest that approximately 25% of diagnosed and treated pulmonary sarcoidosis would be eligible for treatment with second-line or later therapy. </div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">The granulomatous response is believed to begin when an antigen chronically stimulates and activates antigen-presenting cells, including alveolar macrophages. Macrophages process and present the antigen, leading to the activation of CD4+ helper T cells, which form and maintain the granuloma by the production of <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">pro-inflammatory</div> cytokines such as <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">TNF-&#206;&#177;,</div> <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">GM-CSF,</div> and <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">IL-12</div> that in turn recruit inflammatory cells such as peripheral blood monocytes. The activated immune environment of the granuloma may lead to significant damage to the surrounding tissue, and the development of advanced fibrosis permanently alters organ structure and function. </div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">GM-CSF,</div> a key pathogenic cytokine, has been critically implicated in multiple parts of the granulomatous response. <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">GM-CSF</div> is involved in the activation and fusion of alveolar macrophages into multinucleated giant cells, the priming and maintenance of T cell activation and the interactions between lymphoid and myeloid cells that promote granuloma formation. Further, <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">GM-CSF</div> production appears to amplify cellular immunity mediated by helper T cells (Th1, Th2, and Th17) that are also believed to be critical during the granulomatous response and thereby driving the local immune response. In patients with sarcoidosis, <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">GM-CSF</div> has been shown to be increased in serum and broncho-alveolar fluid and correlated with disease activity. </div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Clinical data </div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;">In a Phase 1 study of healthy volunteers with a single subcutaneous injection, namliumab was observed to be generally well-tolerated. In a Phase 2 trial in patients with moderate to severe rheumatoid arthritis (RA) conducted by Takeda, namilumab demonstrated decreased disease activity compared to placebo. In this trial, patients were given a subcutaneous injection of either 20, 80, or 150 mg of namilumab four times over a <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">ten-week</div> period. Results showed a dose-dependent response to treatment, with a statistically significant difference for the 150 mg dose in the <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">28-joint</div> Disease Activity Score, <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">C-reactive</div> protein version <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">(DAS28-CRP),</div> the primary endpoint, at week 12. Compared to placebo, namilumab also increased patients&#8217; ACR score, which measures RA signs and symptom improvement. Over the <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">12-week</div> study period, 14 of 27 (52%) subjects receiving placebo and 45 of 81 (56%) receiving namilumab experienced a treatment-emergent adverse event (TEAE). The most common TEAEs, shown in the table below, were nasopharyngitis, dyspnea, bronchitis, and </div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">204 </div></div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;;font-weight: bold;"><a href="#toc">Table of Contents</a></div> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">headache. One serious adverse event, a myocardial infarction, was reported in the 150 mg arm. The patient, a <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">63-year</div> old smoker, was withdrawn from the trial and recovered after cardiac catheterization. Although we believe namilumab has significant potential in RA, we believe we can deliver greater value to patients if we pursue development in sarcoidosis first, where the unmet medical need is greater. </div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="font-size: 0px;">
<td style="width: 44%; font-family: &quot;Times New Roman&quot;;"></td>
<td style="width: 8%; vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="font-family: &quot;Times New Roman&quot;;"></td>
<td style="width: 8%; vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="font-family: &quot;Times New Roman&quot;;"></td>
<td style="width: 8%; vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="font-family: &quot;Times New Roman&quot;;"></td>
<td style="width: 8%; vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="font-family: &quot;Times New Roman&quot;;"></td> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td rowspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 1pt; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">Preferred term</div></div></div> </td>
<td rowspan="2" style="vertical-align: bottom; padding-bottom: 1pt;">&#160;&#160;</td>
<td rowspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Placebo&#160;(</div></div><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">N</div></div></div></div><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;=&#160;27)</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;&#160;</td>
<td colspan="5" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Namilumab</div></div></td> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;&#160;</td>
<td style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">20&#160;mg&#160;(</div></div><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">N</div></div></div></div><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;=&#160;28)</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">80&#160;mg&#160;(</div></div><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">N</div></div></div></div><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;=&#160;25)</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">150&#160;mg&#160;(</div></div><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">N</div></div></div></div><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;=&#160;28)</div></div></td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Nasopharyngitis</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:center;">5(18.5)</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:center;">5(17.9)</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:center;">1(4.0)</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:center;">4(14.3)</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Dyspnea</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:center;">0</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:center;">1(3.6)</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:center;">2(8.0)</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:center;">3(10.7)</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Bronchitis</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:center;">2(7.4)</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:center;">1(3.6)</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:center;">1(4.0)</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:center;">1(3.6)</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Headache</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:center;">1(3.7)</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:center;">1(3.6)</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:center;">3(12.0)</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:center;">0</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Upper respiratory tract infection</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:center;">0</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:center;">0</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:center;">2(8.0)</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:center;">1(3.6)</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Rheumatoid arthritis</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:center;">0</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:center;">2(7.1)</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:center;">2(8.0)</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:center;">0</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Hypertension</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:center;">0</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:center;">0</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:center;">0</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:center;">2(7.1)</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Laryngitis</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:center;">0</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:center;">0</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:center;">2(8.0)</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:center;">0</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Menorrhagia</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:center;">0</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:center;">2(7.1)</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:center;">0</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:center;">0</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Urticaria</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:center;">0</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:center;">2(7.1)</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:center;">0</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:center;">0</td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">Values are <div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">n</div></div> (%). <div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">TEAE</div></div> treatment-emergent adverse event </div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Development plan </div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;">We plan to initiate a Phase 2 trial to test the safety and efficacy of namilumab in pulmonary sarcoidosis in the first half of calendar year 2022. We believe the <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">anti-GM-CSF</div></div> mechanism has potential for broad application due to the numerous disease functions of <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">GM-CSF,</div> giving the opportunity to expand autoimmune disease indications. </div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">205 </div></div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;;font-weight: bold;"><a href="#toc">Table of Contents</a></div> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="text-decoration: underline; letter-spacing: 0px; top: 0px;;display:inline;">Affivant Overview </div></div></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 3%; vertical-align: top;;text-align:left;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#8226;</div></div></td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="text-decoration: underline; letter-spacing: 0px; top: 0px;;display:inline;">Overview: </div> </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Affivant is focused on the future development and commercialization of AFM32 and other bispecific antibodies through its licensing and strategic collaboration agreement with Affimed to develop and commercialize novel innate cell engagers for multiple cancer targets. </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 3%; vertical-align: top;;text-align:left;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#8226;</div></div></td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="text-decoration: underline; letter-spacing: 0px; top: 0px;;display:inline;">Lead program: </div> </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">AFM32 is a preclinical immune-engaging bispecific antibody licensed from Affimed with potential applicability to several solid tumor indications. </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 3%; vertical-align: top;;text-align:left;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#8226;</div></div></td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="text-decoration: underline; letter-spacing: 0px; top: 0px;;display:inline;">Preclinical data:</div> </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;">In a <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">head-to-head</div></div> preclinical study, AFM32&#8217;s potency exceeded that of a monoclonal antibody (&#8220;mAb&#8221;) that has been clinically validated against the same tumor target. </div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">AFM32&#8217;s potency also exceeded the potency of antibody-drug conjugate (&#8220;ADC&#8221;) agents that have been clinically validated against the same tumor target, as reported in published preclinical studies. </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 3%; vertical-align: top;;text-align:left;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#8226;</div></div></td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="text-decoration: underline; letter-spacing: 0px; top: 0px;;display:inline;">Development plan and upcoming milestones: </div> </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">We expect to file an IND for AFM32 in the first half of calendar year 2023. </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 3%; vertical-align: top;;text-align:left;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#8226;</div></div></td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="text-decoration: underline; letter-spacing: 0px; top: 0px;;display:inline;">Roivant ownership: </div> </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">As of June&#160;30, 2021, we own 100% of the issued and outstanding common shares of Affivant and 100% on a fully diluted basis. </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 3%; vertical-align: top;;text-align:left;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#8226;</div></div></td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="text-decoration: underline; letter-spacing: 0px; top: 0px;;display:inline;">Pipeline:</div> </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; margin-top: 0pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="color: red; letter-spacing: 0px; top: 0px;;display:inline;">
<img alt="" src="g164680g91u88.jpg" style="width: 605px; height: 47px;"/></div> </div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Bispecific Innate Cell Engagers and Affimed&#8217;s ROCK Platform </div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Bispecific innate cell engagers (&#8220;ICE&#8221;) are a novel class of drugs that activate the innate immune system and trigger a concerted anti-tumoral immune response. These bispecific antibodies consist of tumor-associated antigen binding domains, which cause high affinity and high specificity binding to the tumor surface, and immune cell binding domains, which bind and activate specific immune cell subsets able to kill the tumor cell. The Fc region of the antibody links the two domains together and improves pharmaceutical properties. The cross-linking of tumor and immune cells acts as a bridge that increases their proximity and creates a spatial stimulus, enabling the immune cell to kill the tumor cell. </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">Affimed&#8217;s Redirected Optimized Cell Killing (&#8220;ROCK&#8221;) platform technology generates diverse, tetravalent, bispecific antibodies known as ICE, which can be customized to target specific binding domains on hematologic and solid tumor cells. The immune cell binding domain of ICE includes a high affinity CD16A-directed domain that binds to CD16A receptors on natural killer (&#8220;NK&#8221;) cells with a unique epitope. CD16A is sufficient to fully activate cell killing by NK cells and macrophages, differentiating ICE from other platforms that can engage NK cells. In addition, there is no dilution or sink effect through neutrophils (CD16B+) as the molecules are highly selective for CD16A. These ICE antibodies are superior to mAbs and <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">Fc-enhanced</div> mAbs in their ability to bind with high affinity to CD16A with minimal serum IgG competition. The ROCK<div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;"> </div></div>platform has generated clinical proof of concept through clinical trials of AFM13 in patients with peripheral <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">T-cell</div> lymphoma, where AFM13 was well-tolerated and demonstrated tumor shrinkage or slowing of tumor growth. Our goal is to develop CD16A NK antibodies with the potential for targeted immune activation and tumor destruction, along with a safety profile more like traditional antibody-based products. </div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">206 </div></div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;;font-weight: bold;"><a href="#toc">Table of Contents</a></div> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"> <div style="text-align: center; margin-top: 0pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="color: red; letter-spacing: 0px; top: 0px;;display:inline;">
<img alt="" src="g164680g92k66.jpg" style="width: 605px; height: 176px;"/></div> </div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">AFM32 </div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">AFM32 is an ICE program currently in the preclinical stage of development. AFM32&#8217;s Fc region is fused to two high affinity CD16A binding single chain variable regions to maximize NK cell and macrophage engagement. The biological target of AFM32&#8217;s tumor-associated antigen binding domain has been clinically validated via other targeted agents (mAb and ADC), including both evidence of single agent activity and a generally well-tolerated safety profile of the corresponding mAb in published studies. We believe AFM32 has potential applicability across several highly prevalent solid tumor types, providing the optionality to pursue multiple large-market indications. </div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Preclinical data </div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;">In a <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">head-to-head</div></div> preclinical study, AFM32 potency, as measured by target cell killing, exceeded that of a mAb, and in preclinical studies, AFM32&#8217;s potency exceeded the potency (as reported in published preclinical studies) of ADC agents that have been clinically validated against the same tumor target. Furthermore, based on preclinical and clinical experiences with other ICE antibodies in separate studies, we believe that the tolerability of AFM32 has the potential to be superior to that observed to date with antibody-drug conjugates in published literature. </div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Development plan </div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;">Pursuant to a collaboration and licensing agreement between Affivant and Affimed, Affimed is conducting a significant portion of the AFM32 preclinical work for the collaboration under the governance of a Joint Steering Committee controlled by Affivant. Pursuant to the agreement Affivant will be responsible for submitting any IND or equivalent for AFM32, and will be responsible for all future clinical development and commercialization worldwide, with Affimed retaining an option for <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">co-promotion.</div> We also have the option to license from Affimed additional ICE molecules directed against targets that are not (a)&#160;currently licensed or optioned to third parties or (b)&#160;directed against targets included in Affimed&#8217;s current pipeline. </div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">207 </div></div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;;font-weight: bold;"><a href="#toc">Table of Contents</a></div> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="text-decoration: underline; letter-spacing: 0px; top: 0px;;display:inline;">Cytovant Overview </div></div></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 3%; vertical-align: top;;text-align:left;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#8226;</div></div></td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="text-decoration: underline; letter-spacing: 0px; top: 0px;;display:inline;">Overview: </div> </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Cytovant&#8217;s mission is to discover, develop and commercialize cell therapies that are uniquely suited to Asian patients. </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 3%; vertical-align: top;;text-align:left;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#8226;</div></div></td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="text-decoration: underline; letter-spacing: 0px; top: 0px;;display:inline;">Lead program:</div> </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">CVT-TCR-01:</div></div></div></div> <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">TCR-T</div> therapeutic targeting <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">NY-ESO-1,</div></div> an intracellular cancer testis antigen whose expression is nearly exclusive to malignant tissue, being developed in Asia for the treatment of soft tissue sarcoma and other tumors with high disease burden in the region. </div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 3%; vertical-align: top;;text-align:left;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#8226;</div></div></td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="text-decoration: underline; letter-spacing: 0px; top: 0px;;display:inline;">Disease overview:</div> </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">NY-ESO-1</div></div> is expressed in many tumor types associated with substantial unmet need in Asia, including soft tissue sarcoma, ovarian cancer, esophageal cancer and lung cancer. In 2020, the estimated incidences of colorectal, lung and esophageal cancer in China were 38.4, 56.3 and 22.4 cases per 100,000 individuals; these tumors are associated with <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">NY-ESO-1</div></div> positivity rates of 17%, 19% and 21%, respectively. </div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 3%; vertical-align: top;;text-align:left;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#8226;</div></div></td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="text-decoration: underline; letter-spacing: 0px; top: 0px;;display:inline;">Limitations of current treatments:</div> </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The current treatment options for soft tissue sarcoma leave significant unmet need, as chemotherapy for systemic treatment has an overall survival of approximately 12 months, and up to 40% of patients who receive surgery and radiotherapy eventually recur at distant sites. </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 3%; vertical-align: top;;text-align:left;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#8226;</div></div></td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="text-decoration: underline; letter-spacing: 0px; top: 0px;;display:inline;">Preclinical data:</div> </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">CVT-TCR-01</div></div> has demonstrated strong activity against <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">NY-ESO-1-positive</div></div></div> cell lines in preclinical experiments and has further demonstrated highly specific <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">on-target</div> activity by sparing cell lines that are <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">NY-ESO-1-negative.</div></div></div> Moreover, in preclinical experiments, <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">CVT-TCR-01</div></div> has been shown to induce strong proinflammatory cytokine secretion upon exposure to <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">NY-ESO-1</div></div> positive cell lines, further supporting its antitumor activity. </div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 3%; vertical-align: top;;text-align:left;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#8226;</div></div></td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="text-decoration: underline; letter-spacing: 0px; top: 0px;;display:inline;">Development plan and upcoming milestones:</div> </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;">We expect to initiate CMC activities for <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">CVT-TCR-01</div></div> in the second half of 2021. </div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 3%; vertical-align: top;;text-align:left;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#8226;</div></div></td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="text-decoration: underline; letter-spacing: 0px; top: 0px;;display:inline;">Roivant ownership:</div> </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">As of June&#160;30, 2021, we own 72% of the issued and outstanding common shares of Cytovant and 68% on a fully diluted basis, in each case including both direct and indirect ownership in Cytovant. </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 3%; vertical-align: top;;text-align:left;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#8226;</div></div></td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="text-decoration: underline; letter-spacing: 0px; top: 0px;;display:inline;">Pipeline: </div> </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; margin-top: 0pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="color: red; letter-spacing: 0px; top: 0px;;display:inline;">
<img alt="" src="g164680g22s22.jpg" style="width: 605px; height: 46px;"/></div> </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Cytovant holds development and commercialization rights for Greater China (includes People&#8217;s Republic of China, Hong Kong, Taiwan, and Macau), Japan, and the Republic of Korea. </div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">TCR-T</div> Background </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;">As part of normal immune surveillance, the body identifies diseased cells through the <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">T-cell</div> receptor (&#8220;TCR&#8221;), which binds and recognizes the HLA peptide complex. The HLA peptide complex is comprised of short fragments of cellular proteins bound to HLA; this complex is then trafficked to the cell surface for presentation to T cells. When a T cell binds to a specific HLA peptide complex on a diseased cell, that cell is </div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">208 </div></div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;;font-weight: bold;"><a href="#toc">Table of Contents</a></div> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">targeted for destruction. Importantly, peptide fragments that are bound to HLA are derived from intracellular, extracellular and transmembrane proteins, meaning that TCRs can target the entire array of cellular proteins. Notably, HLA types vary substantially across global populations, with markedly different HLA types commonly observed in Asian populations relative to Caucasian populations. For example, two high-frequency alleles in Southern Chinese people, <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">HLA-A*02:07</div> (20%) and <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">HLA-A*02:03</div> (10%), are not addressed by any current <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">TCR-based</div> therapy. The ability of a specific TCR to bind and recognize an HLA peptide complex is limited to matched HLA types; thus, a TCR that recognizes an HLA peptide complex found in Caucasian patients may not recognize an HLA peptide complex found in Asian patients. </div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">The ability of T cells to recognize and kill diseased cells via the TCR can be manipulated to target specific cells, including cancerous cells. This constitutes the basis of <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">TCR-T</div> therapeutics, in which affinity- or specificity-enhanced T cell receptors are genetically engineered into a patient&#8217;s own T cells and then used as a direct anti-cancer treatment. This technology affords several advantages compared to other forms of adoptive cell therapy (&#8220;ACT&#8221;), including chimeric antigen receptor <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">T-cells</div> <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">(&#8220;CAR-T&#8221;).</div> Two key advantages include: </div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Greater range of target antigens</div></div>: Unlike <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">CAR-T,</div> which relies upon antibody fragment binding to cell surface proteins for cell recognition and destruction, <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">TCR-T</div> can recognize intracellular antigens as well. As most cancerous cells express cancer-specific intracellular antigens, this widens the range of addressable targets for <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">TCR-T</div> relative to <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">CAR-T.</div> </div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Specificity for malignant tissue</div></div>: To date, all approved <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">CAR-T</div> products are specific to targets expressed on both healthy and diseased tissue. By contrast, <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">TCR-T</div> targets can be specific exclusively or nearly exclusively to malignant tissue, potentially limiting <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">off-target</div> toxicities. </div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">Because <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">TCR-T</div> therapeutics must be specific to both an antigen (which discriminates specific tumor types) and an HLA type (which discriminates specific addressable populations), we believe that Cytovant&#8217;s focus on the unique medical needs of Asian patients will give the company an advantage relative to organizations that lack an explicit focus on Asian markets. Similarly, because of the complexity of cell therapy manufacturing as well as China&#8217;s comprehensive regulatory regime regarding human tissue, we believe that Cytovant&#8217;s local focus and the team&#8217;s <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">on-the-ground</div></div> manufacturing experience represent a key competitive advantage over global competitors. </div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">The cell therapy landscape in China is saturated with <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">CAR-T</div> treatments, primarily for hematologic oncology. Cytovant&#8217;s <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">TCR-T</div> approach will face fewer <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">TCR-T</div> competitors and may better enable solid tumor targeting, a larger market opportunity than blood cancers. </div> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 24pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Development-Stage Cellular Therapeutics in China </div></div></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; margin-top: 0pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="color: red; letter-spacing: 0px; top: 0px;;display:inline;">
<img alt="" src="g164680g23s23.jpg" style="width: 261px; height: 106px;"/></div> </div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Clarivate Analytics as of January 2021 </div></div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">CVT-TCR-01</div></div> </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">CVT-TCR-01</div></div> is a preclinical <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">TCR-T</div> therapeutic candidate being developed to target cancer testis antigen <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">NY-ESO-1</div></div> presented by <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">HLA-A*02.</div> <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">NY-ESO-1</div></div> has several characteristics that make it well-suited to <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">ACT-based</div> immunotherapeutic approaches. First, <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">NY-ESO-1</div></div> is an oncofetal protein expressed primarily in malignant tissue; in particular, it is highly expressed in soft tissue sarcoma, ovarian cancer, esophageal cancer </div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">209 </div></div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;;font-weight: bold;"><a href="#toc">Table of Contents</a></div> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">and lung cancer, among other common tumors. Second, <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">NY-ESO-1</div></div> is highly immunogenic and its expression is associated with decreased survival. Finally, because <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">NY-ESO-1</div></div> is expressed only intracellularly, we believe it is a suitable target for a <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">TCR-T-based</div></div> approach. </div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">NY-ESO-1</div></div> positive cancers and limitations of current treatments </div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">NY-ESO-1</div></div> positive cancers represent a substantial health burden in East Asia. The estimated incidences of colorectal, lung and esophageal cancer in China are 38.4, 56.3 and 22.4 cases per 100,000 individuals; these tumors are associated with <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">NY-ESO-1</div></div> positivity rates of 17%, 19% and 21%, respectively. Among certain less common tumors, <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">NY-ESO-1</div></div> positivity increases significantly, with 35% of bladder cancers, 43% of ovarian cancers and more than 80% of soft tissue sarcomas expressing the antigen. The estimated incidences of these tumor types in China are 5.9, 7.8 and 3.2 cases per 100,000 individuals. In aggregate, these six tumor types represent a prevalent population of more than 3,000,000 patients in China alone, of which we estimate more than 600,000 are likely to be <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">NY-ESO-1</div></div> positive. </div> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 24pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">NY-ESO-1</div></div> is Highly Expressed Across Many Fatal Cancers in Asia </div></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; margin-top: 0pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="color: red; letter-spacing: 0px; top: 0px;;display:inline;">
<img alt="" src="g164680g83n58.jpg" style="width: 309px; height: 222px;"/></div> </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">While local control of soft tissue sarcoma is achievable through surgery and radiotherapy, up to 40% of patients eventually recur at distant sites, of whom over 90% ultimately die of this malignancy. For patients with locally advanced or metastatic sarcoma, conventional chemotherapy with doxorubicin and/or ifosfamide used sequentially or in combination represents the backbone of systemic treatment, for which overall survival is approximately 12 months. The high mortality and limited development of novel treatment options leaves significant unmet need for patients suffering from soft tissue sarcoma. </div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Preclinical data </div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;">In preclinical testing, <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">CVT-TCR-01</div></div> demonstrated specific and potent killing of <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">NY-ESO-1-positive</div></div></div> cell lines as assessed by <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">IFN-g</div> release. Moreover, <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">CVT-TCR-01</div></div> was shown to spare <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">NY-ESO-1</div></div> negative cell lines, indicating the candidate&#8217;s specificity for <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">NY-ESO-1.</div></div> In subsequent cytotoxicity assays, <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">CVT-TCR-01&#8217;s</div></div> activity was shown to be dependent on both <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">NY-ESO-1</div></div> and <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">HLA-A2</div> expression, consistent with <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">CVT-TCR-01&#8217;s</div></div> specificity for <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">NY-ESO-1</div></div> presented by <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">HLA-A2.</div> Finally, cytokine release assays indicated that <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">CVT-TCR-01</div></div> induces strongly proinflammatory <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">Th1-type</div> cytokine secretion upon exposure to <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">NY-ESO-1</div></div> positive cell lines, further supporting <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">CVT-TCR-01&#8217;s</div></div> antitumor activity. Additionally, preliminary clinical results from <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">NY-ESO-1</div></div> directed TCR therapy demonstrate promising overall response rates in a wide variety of tumor types, including synovial sarcoma, multiple myeloma and myxoid round cell liposarcoma. </div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">210 </div></div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;;font-weight: bold;"><a href="#toc" style="text-indent: 0px;">Table of Contents</a></div> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">CVT-TCR-01</div></div> Shows Comparable Cytotoxic Activity in Three Donors </div></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; margin-top: 0pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="color: red; letter-spacing: 0px; top: 0px;;display:inline;">
<img alt="" src="g164680g24s24.jpg" style="width: 605px; height: 352px;"/></div> </div></div> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">CVT-TCR-01</div></div> Transduced Effector Cells Secrete <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">Th1-Type</div> Cytokines </div></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; margin-top: 0pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="color: red; letter-spacing: 0px; top: 0px;;display:inline;">
<img alt="" src="g164680g25s25.jpg" style="width: 435px; height: 219px;"/></div> </div></div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">211 </div></div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;;font-weight: bold;"><a href="#toc">Table of Contents</a></div> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"> <div style="text-align: center; margin-top: 0pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="color: red; letter-spacing: 0px; top: 0px;;display:inline;">
<img alt="" src="g164680g26s26.jpg" style="width: 435px; height: 219px;"/></div> </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">There are multiple competing cellular therapeutics targeting <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">NY-ESO-1</div></div> in development both globally and in Asia specifically. Among global programs, the most advanced is letetresgene autoleucel, which GlaxoSmithKline is currently developing in multiple solid tumor types in several Phase 1 and 2 studies. Prior studies of letetresgene autoleucel demonstrated strong antitumor activity in patients with <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">NY-ESO-1-positive</div></div></div> soft tissue sarcoma, in which overall response rates of up to 50% were observed. Among Asia- and China-specific programs, competing <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">NY-ESO-1-targeting</div></div></div> <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">TCR-Ts</div> include TAEST-16001, which is being developed by Xiangxue Life Sciences; <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">TBI-1301,</div> which is being developed by Takara Bio and Otsuka Pharmaceutical Co.; and a program in development by Shenzhen Binde Bio. </div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Development plan </div></div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;">Cytovant is developing <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">CVT-TCR-01</div></div> for the treatment of tumors with high disease burden in Asia. We expect to initiate CMC activities for <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">CVT-TCR-01</div></div> in the second half of 2021. </div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">212 </div></div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;;font-weight: bold;"><a href="#toc">Table of Contents</a></div> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="text-decoration: underline; letter-spacing: 0px; top: 0px;;display:inline;">Arbutus Overview </div></div></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 3%; vertical-align: top;;text-align:left;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#8226;</div></div></td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="text-decoration: underline; letter-spacing: 0px; top: 0px;;display:inline;">Overview: </div> </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;">Arbutus Biopharma Corporation is a clinical-stage biopharmaceutical company primarily focused on discovering, developing and commercializing a broad portfolio of wholly-owned assets with different mechanisms of action to provide a cure for people with chronic hepatitis B virus (HBV) infection and to treat coronaviruses (including <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">COVID-19).</div> </div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 3%; vertical-align: top;;text-align:left;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#8226;</div></div></td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="text-decoration: underline; letter-spacing: 0px; top: 0px;;display:inline;">Lead programs:</div> </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">AB-729:</div></div></div> Subcutaneously-delivered RNAi therapeutic targeted to hepatocytes using Arbutus&#8217;s proprietary covalently conjugated GalNAc delivery technology that inhibits viral replication. </div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">AB-836:</div></div></div> Proprietary advanced-generation oral capsid inhibitor that suppresses HBV DNA replication. </div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 3%; vertical-align: top;;text-align:left;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#8226;</div></div></td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="text-decoration: underline; letter-spacing: 0px; top: 0px;;display:inline;">Disease overview: </div> </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Hepatitis B is a potentially life-threatening liver infection caused by HBV. HBV can cause chronic infection which leads to a higher risk of death from cirrhosis and liver cancer. The World Health Organization estimates that over 250&#160;million people worldwide suffer from chronic HBV infection, while other estimates indicate that approximately 2&#160;million people in the United States suffer from chronic HBV infection. Approximately 900,000 people die every year from complications related to chronic HBV infection despite the availability of effective vaccines and current treatment options. </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 3%; vertical-align: top;;text-align:left;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#8226;</div></div></td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="text-decoration: underline; letter-spacing: 0px; top: 0px;;display:inline;">Limitations of current treatments:</div> </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Current treatment options include nucleos(t)ide analogs (&#8220;NA&#8221;) and pegylated interferon regimens. However, fewer than 5% of patients are functionally cured by these current treatment options after a finite treatment duration. With such low cure rates, most patients with chronic HBV infection are required to take NA therapy daily for the rest of their lives. </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 3%; vertical-align: top;;text-align:left;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#8226;</div></div></td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="text-decoration: underline; letter-spacing: 0px; top: 0px;;display:inline;">Clinical data:</div> </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;">Preliminary data from ongoing single- and multi-dose Phase 1a/1b clinical trials for <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">AB-729</div> demonstrate robust hepatitis B surface antigen (HBsAg) reductions in multiple patient cohorts. <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">AB-729</div> has been observed to be well-tolerated after single and repeat doses based on results to date. These data support dosing intervals of up to 8 weeks. </div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;">Repeat dosing of <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">AB-729</div> 60 mg every 8 weeks results in comparable mean HBsAg declines relative to 60 mg every 4 weeks at week 44 <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">(-1.87</div> log10 IU/mL vs <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">-1.81</div> log10 IU/mL, p=0.8). </div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;">In HBV DNA positive chronic hepatitis B subjects, a single 90 mg <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">AB-729</div> dose resulted in robust mean HBsAg <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">(-1.02</div> log10 IU/mL) and HBV DNA <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">(-1.53</div> log10 IU/mL) declines at week 12, as well as decreases in HBV RNA and core-related antigen. </div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 3%; vertical-align: top;;text-align:left;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#8226;</div></div></td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="text-decoration: underline; letter-spacing: 0px; top: 0px;;display:inline;">Development plan and upcoming milestones:</div> </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Arbutus expects to report data from the 90 mg every 12 weeks cohort and 90 mg every 8 weeks cohort in HBV DNA positive subjects, in the fourth quarter of 2021. </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;">Arbutus initiated a Phase 2 clinical trial of a triple combination of <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">AB-729,</div> Assembly Biosciences&#8217; vebicorvir, and an NA in February 2021. </div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;">Arbutus announced plans to evaluate a triple combination of <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">AB-729,</div> Antios Therapeutics&#8217;s proprietary active site polymerase inhibitor nucleuotide <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">ATI-2173,</div> and Viread (tenofovir disoproxil fumarate) in a single cohort in the ongoing Antios Phase 2a ANTT201 clinical trial. The multi-center, double-blind, placebo-controlled, multiple-dose cohort will evaluate the safety, pharmacokinetics, immunogenicity, and antiviral activity of this triple combination and is expected to initiate in the second half of 2021. </div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">213 </div></div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;;font-weight: bold;"><a href="#toc">Table of Contents</a></div> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;">
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;">Arbutus expects to initiate a Phase 2a trial evaluating a triple combination of <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">AB-729,</div> Vaccitech&#8217;s <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">VTP-300,</div> an immunotherapeutic designed to elicit an HBV specific immune response, and an NA compared to the double combinations of <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">AB-729</div> with an NA and <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">VTP-300</div> with an NA in subjects with chronic HBV infection in early calendar year 2022. </div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;">Arbutus received authorization from the FDA to proceed with its IND application for <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">AB-729</div> in a Phase 2a clinical trial. The Phase 2a <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">proof-of-concept</div></div> clinical trial will evaluate the safety and efficacy of <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">AB-729</div> in combination with ongoing NA therapy and short courses of <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">Peg-IFN-2a</div> in subjects with chronic HBV infection. </div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;">Arbutus expects to provide initial data from the Phase 1a/1b clinical trial of <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">AB-836</div> in the fourth quarter of 2021. </div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 3%; vertical-align: top;;text-align:left;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#8226;</div></div></td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="text-decoration: underline; letter-spacing: 0px; top: 0px;;display:inline;">Roivant ownership:</div> </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">As of June&#160;30, 2021, we own 32% of the issued and outstanding common shares of Arbutus and 29% on a fully diluted basis, in each case including the conversion of preferred shares held by Roivant into common shares, which was completed on October&#160;18, 2021. </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">214 </div></div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;;font-weight: bold;"><a href="#toc">Table of Contents</a></div> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="text-decoration: underline; letter-spacing: 0px; top: 0px;;display:inline;">Sio Gene Therapies Overview </div></div></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 3%; vertical-align: top;;text-align:left;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#8226;</div></div></td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="text-decoration: underline; letter-spacing: 0px; top: 0px;;display:inline;">Overview: </div> </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;">Sio Gene Therapies is a clinical-stage company focused on developing gene therapies for neurodegenerative diseases, with a pipeline of innovative product candidates for the treatment of GM1 gangliosidosis, GM2 gangliosidosis (including <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">Tay-Sachs</div> disease and Sandhoff disease) and Parkinson&#8217;s disease. </div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 3%; vertical-align: top;;text-align:left;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#8226;</div></div></td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="text-decoration: underline; letter-spacing: 0px; top: 0px;;display:inline;">Lead programs:</div> </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">AXO-AAV-GM1:</div></div></div></div> Investigational gene therapy currently being developed as a potential <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">one-time</div> disease modifying treatment for GM1 gangliosidosis, a rare disease caused by <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">loss-of-function</div></div> mutations in the GLB1 gene. The program utilizes an adeno-associated virus (AAV) vector to deliver a functional copy of the GLB1 gene with the goals of restoring &#223; <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">-gal</div> enzyme activity in the CNS and reducing GM1 ganglioside accumulation, to ultimately improve neurological function and extend survival. </div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">AXO-AAV-GM2:</div></div></div></div> Investigational gene therapy currently being developed as a potential <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">one-time</div> disease modifying treatment for GM2 gangliosidosis (including <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">Tay-Sachs</div> disease and Sandhoff disease). The <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">AXO-AAV-GM2</div></div> program utilizes AAV dual vectors to deliver functional copies of both the HEXA gene and the HEXB gene, with the goal of restoring normal Hex A enzyme function in the central nervous system. </div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">AXO-Lenti-PD:</div></div> In vivo </div></div>lentiviral gene therapy investigational product candidate currently being developed as a potential <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">one-time</div> treatment of Parkinson&#8217;s disease. <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">AXO-Lenti-PD</div></div> delivers a construct of three genes that encode the critical enzymes required for the biochemical synthesis of dopamine from endogenous tyrosine. </div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 3%; vertical-align: top;;text-align:left;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#8226;</div></div></td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="text-decoration: underline; letter-spacing: 0px; top: 0px;;display:inline;">Disease overview:</div> </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">GM1 gangliosidosis is a rare, inherited neurodegenerative lysosomal storage disorder characterized by the accumulation of GM1 ganglioside with an estimated incidence of approximately one in 100,000 live births worldwide. </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;">GM2 gangliosidosis, also known as <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">Tay-Sachs</div> or Sandhoff diseases, is a rare, inherited neurodegenerative lysosomal storage disorder characterized by buildup of GM2 ganglioside in lysosomes with an estimated incidence of approximately one in 150,000 live births worldwide. </div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Parkinson&#8217;s disease is a chronic neurodegenerative disorder that primarily results in progressive and debilitating motor symptoms. It is estimated that up to 1&#160;million people in the U.S. and 7 to 10&#160;million people worldwide suffer from Parkinson&#8217;s disease. </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 3%; vertical-align: top;;text-align:left;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#8226;</div></div></td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="text-decoration: underline; letter-spacing: 0px; top: 0px;;display:inline;">Limitations of current treatments:</div> </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">AXO-AAV-GM1:</div></div></div></div> GM1 gangliosidosis is uniformly fatal, and there are no disease-modifying treatment options. Management is limited to symptomatic treatment and palliative care. </div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">AXO-AAV-GM2:</div></div></div></div> There are no disease-modifying treatment options for either <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">Tay-Sachs</div> disease or Sandhoff disease, and management is limited to symptomatic treatment and palliative care. </div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">AXO-Lenti-PD:</div></div> </div></div>The treatment of Parkinson&#8217;s disease is limited to symptomatic treatments, as no therapies have proven effective in altering the course of the disease or addressing the underlying pathophysiological processes. <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">One-time</div> gene therapy has the potential to reduce reliance on levodopa-based therapies, reduce troublesome side effects such as dyskinesia, and slow the course of disease progression. </div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 3%; vertical-align: top;;text-align:left;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#8226;</div></div></td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="text-decoration: underline; letter-spacing: 0px; top: 0px;;display:inline;">Clinical data:</div> </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">AXO-AAV-GM1:</div></div></div></div> Data from the ongoing Phase 1/2 trial have shown <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">AXO-AAV-GM1</div></div> to be generally well-tolerated, with a dose-dependent improvement in key biomarkers of disease </div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">215 </div></div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;;font-weight: bold;"><a href="#toc">Table of Contents</a></div> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;">
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 9%;">&#160;</td>
<td style="vertical-align: top;"> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;">activity and no overt disease progression in six out of seven patients treated across the <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">low-</div> and high-dose cohorts. At six months, in both patients in the high dose cohort, serum &#206;&#178;-galactosidase activity achieved a normal range, increasing by 12x and 17x <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">pre-treatment</div> levels, respectively, and levels of GM1 ganglioside were normalized with 42% and 72% reductions, respectively. A total of ten patients have received <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">AXO-AAV-GM1</div></div> to date, with no SAEs attributable to <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">AXO-AAV-GM1.</div></div> </div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">AXO-AAV-GM2:</div></div> </div></div>Clinically meaningful improvement in motor skills and disease stabilization were observed in two infants with <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">Tay-Sachs</div> disease following administration under expanded access protocol. An IND was cleared by FDA in November 2020 and two patients have been dosed to date. </div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">AXO-Lenti-PD:</div></div> </div></div>Preliminary data from ongoing Phase 2 trial have shown <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">AXO-Lenti-PD</div></div> to be generally well-tolerated and to demonstrate dose-dependent improvements in motor function. To date, 21 patients have received gene therapy in dose-escalation studies spanning 5 dose cohorts. </div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 3%; vertical-align: top;;text-align:left;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#8226;</div></div></td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="text-decoration: underline; letter-spacing: 0px; top: 0px;;display:inline;">Development plan and upcoming milestones:</div> </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">AXO-AAV-GM1:</div></div></div></div> Sio expects to provide a data update from Stage 1 of its ongoing Phase 1/2 trial, including both Type 1 and Type II patients, in the first half of calendar year 2022. </div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">AXO-AAV-GM2:</div></div> </div></div>Sio expects to continue patient identification, screening and enrollment in Stage 1 of its ongoing Phase 1/2 trial throughout 2021. </div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">AXO-Lenti-PD:</div></div> </div></div>Sio expects to complete Qualified Person certification of clinical trial material in the fourth quarter of 2021 and resume enrollment of patients in calendar year 2022. </div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 3%; vertical-align: top;;text-align:left;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#8226;</div></div></td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="text-decoration: underline; letter-spacing: 0px; top: 0px;;display:inline;">Roivant ownership:</div> </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">As of June&#160;30, 2021, we own 27% of the issued and outstanding shares of Sio common stock and 24% on a fully diluted basis. </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Asset Acquisition and License Agreements; Other Vant Agreements </div></div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Immunovant </div></div></div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">License Agreement with HanAll Biopharma Co., Ltd.</div></div><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="background: none;;font-weight:bold;display:inline;"><div style="font-style: normal; background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;"> </div></div></div></div><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;"> </div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">In December 2017, our wholly owned subsidiary, Roivant Sciences GmbH (&#8220;RSG&#8221;), entered into a license agreement with HanAll Biopharma Co., Ltd. (&#8220;HanAll&#8221;) (the &#8220;HanAll Agreement&#8221;). Under the HanAll Agreement, RSG received (i)&#160;the <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-exclusive</div> right to manufacture and (ii)&#160;the exclusive, royalty-bearing right to develop, import and use the antibody referred to as IMVT-1401 and certain <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">back-up</div> and next-generation antibodies, and products containing such antibodies, and to commercialize such products, in the United States, Canada, Mexico, the E.U., the U.K., Switzerland, the Middle East, North Africa and Latin America (the &#8220;HanAll Licensed Territory&#8221;), for all human and animal uses. RSG also received the right to grant a sublicense, with prior written notice to HanAll of such sublicense, to: (i)&#160;a third party in any country in the HanAll Licensed Territory outside of the United States and E.U.; (ii) an affiliate of RSG in any country in the HanAll Licensed Territory; and (iii)&#160;a third party in the United States and E.U. only after submission of a biologics license application in the United States or a Marketing Authorization Application in the E.U. Pursuant to the HanAll Agreement, RSG granted to HanAll an exclusive, royalty-free license under certain RSG patents, <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">know-how</div> and other intellectual property relating to such antibodies and products to develop, manufacture and commercialize such antibodies and products for use outside of the HanAll Licensed Territory. </div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">In December 2018, Immunovant Sciences GmbH, (&#8220;ISG&#8221;) obtained and assumed all rights, title, interest and obligations under the HanAll Agreement from RSG, including all rights to IMVT-1401 in the HanAll Licensed Territory, for an aggregate purchase price of $37.8&#160;million plus Swiss value-added tax of $2.9&#160;million. HanAll and RSG have agreed that neither they nor certain of their affiliates will clinically develop or commercialize certain competitive products in the HanAll Licensed Territory. </div></div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">216 </div></div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;;font-weight: bold;"><a href="#toc">Table of Contents</a></div> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Under the HanAll Agreement, the parties may choose to collaborate on a research program directed to the research and development of next generation FcRn inhibitors in accordance with an agreed plan and budget. ISG is obligated to reimburse HanAll for half of such research and development expenses incurred by HanAll, up to an aggregate reimbursement amount of $20.0&#160;million. </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">Pursuant to the HanAll Agreement, RSG made an upfront payment of $30.0&#160;million to HanAll in December 2017. In May 2019, ISG achieved its first development and regulatory milestone, which resulted in a $10.0&#160;million milestone payment that ISG subsequently paid to HanAll in August 2019. ISG will be responsible for future contingent payments and royalties, including up to a maximum of $442.5&#160;million upon the achievement of certain development, regulatory and sales milestone events. ISG is also obligated to pay HanAll tiered royalties ranging from the <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">mid-single</div> digits to <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">mid-teens</div> on net sales of licensed products, subject to standard offsets and reductions as set forth in the HanAll Agreement. These royalty obligations apply on a <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">product-by-product</div></div> and <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">country-by-country</div></div> basis and end upon the latest of (i)&#160;the date on which the last valid claim of the licensed patents that cover such licensed product in such country expires, (ii)&#160;the date on which the data or market exclusivity for such licensed product in such country expires or (iii) 11 years after the first commercial sale of such licensed product in such country. The HanAll Agreement will expire on a <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">product-by-product</div></div> basis on the expiration of the last royalty term with respect to a given licensed product, unless earlier terminated. ISG may terminate the HanAll Agreement in its entirety without cause upon 180 days&#8217; written notice following 30 days of discussion. Either party may terminate the HanAll Agreement upon 60 days&#8217; written notice for uncured material breach (or 30 days in the case <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">of&#160;non-payment),&#160;or</div> immediately upon written notice if the other party files a voluntary petition, is subject to a substantiated involuntary petition or for certain other solvency events. HanAll may terminate the HanAll Agreement if ISG or its affiliates challenge the validity or enforceability of any of the licensed patents. </div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Proteovant </div></div></div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Michigan Research Agreement </div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">In January 2018, our subsidiary Oncopia Therapeutics, Inc. (&#8220;Oncopia&#8221;) entered into a research agreement with the Regents of the University of Michigan (the &#8220;University of Michigan&#8221;) (the &#8220;Michigan Research Agreement&#8221;). Pursuant to the Michigan Research Agreement, Oncopia and the University of Michigan are collaborating to discover and optimize small molecule protein degraders. Any intellectual property developed under the Michigan Research Agreement that is directed to certain targets will be licensed by the University of Michigan to Oncopia pursuant to the Michigan License Agreement, as described below. Pursuant to the Michigan Research Agreement, Oncopia is obligated to provide a low eight-digit amount in funding between 2021 and 2023. Unless earlier terminated based on customary termination rights or extended by mutual agreement, the Research Agreement continues until December 2023. </div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Michigan License Agreement </div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">In November 2020, Oncopia entered into an amended and restated patent license agreement with the University of Michigan (the &#8220;Michigan License Agreement&#8221;), pursuant to which the University of Michigan granted Oncopia an exclusive, worldwide, sublicensable license under certain patents related to certain existing small molecule protein degraders and certain future small molecule protein degraders that may be developed under the Michigan Research Agreement to make, use and commercialize certain products covered by such patents. Such license grant is subject to, among other things, certain rights required to be granted under prior research or sponsorship agreements. </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">Under the Michigan License Agreement, Oncopia is obligated to pay the University of Michigan a <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">low-to-mid</div></div> single-digit royalty on net sales of each licensed product. Oncopia&#8217;s royalty obligations apply on <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">product-by-product,</div></div> <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">country-by-country</div></div> basis and end upon the expiration of the <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">last-to-expire</div></div> valid claim of the licensed patents under the University of Michigan Agreement which covers such licensed product in such country. The patents and pending patent applications, if granted, currently licensed under the Michigan License Agreement are expected to expire as early as 2037, and as late as 2042, without giving effect to any potential </div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">217 </div></div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;;font-weight: bold;"><a href="#toc">Table of Contents</a></div> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">patent term extensions or patent term adjustments. Oncopia is obligated to pay the University of Michigan minimum annual royalties in the low five-digit range from March 2021 until the first commercial sale of a licensed product, at which time such minimum annual royalties will increase to a low <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">six-digit</div> amount. Oncopia may also be obligated to pay up to a maximum of a high seven-digit amount in development and commercial milestone payments on a per product basis. Unless earlier terminated based on customary termination rights, the term of the Michigan License Agreement will continue until the expiration of the <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">last-to-expire</div></div> valid claim of the licensed patents. </div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Dermavant </div></div></div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Agreements Relating to Tapinarof </div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">In July 2018, our subsidiary Dermavant Sciences GmbH (&#8220;DSG&#8221;) acquired the worldwide rights (other than for China) with respect to certain intellectual property rights retained by Welichem Biotech Inc. (&#8220;Welichem&#8221;) to tapinarof and related compounds from Glaxo Group Limited and GlaxoSmithKline Intellectual Property Development Ltd. (collectively, &#8220;GSK&#8221;) pursuant to an asset purchase agreement (the &#8220;GSK Agreement&#8221;). GSK previously acquired rights to a predecessor formulation of tapinarof from Welichem pursuant to an asset purchase agreement between GSK and Welichem entered into in May 2012 (the &#8220;Welichem Agreement&#8221;). Under the GSK Agreement, DSG made an upfront payment of &#163;150.0&#160;million (approximately $191 million) to GSK. </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">DSG is also obligated to pay GSK &#163;100.0&#160;million (approximately $133 million) within 70 days following the receipt of marketing approval of tapinarof in the United States. The GSK Agreement does not require DSG to pay any royalties on sales of tapinarof following commercialization or make any commercial milestone payments, except for milestones owed to Welichem as described below. </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">In addition, under the GSK Agreement, DSG assumed all obligations under the Welichem Agreement, including payment of up to C$80.0&#160;million (approximately $61 million) in potential development milestone payments and up to C$100.0&#160;million (approximately $76 million) in potential commercial milestone payments. Following the commencement of the two pivotal Phase 3 clinical trials of tapinarof for the treatment of psoriasis in May 2019, on June&#160;5, 2019, DSG paid to Welichem a milestone payment of C$30.0&#160;million (approximately $23&#160;million). In the future DSG may seek to enter into a royalty financing or similar transaction to fund its milestone payments. </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">In August 2018, in connection with the GSK Agreement, DSG and GlaxoSmithKline Trading Services Limited (&#8220;GSK Trading&#8221;) entered into a clinical manufacturing and supply agreement for tapinarof pursuant to which DSG obtained an existing supply of tapinarof drug product and drug substance as well as additional supply of tapinarof drug product for clinical trials on a cost plus basis. As required under the GSK Agreement, in April 2019, DSG and GSK Trading also entered into a commercial manufacturing and supply agreement (the &#8220;Commercial Supply Agreement&#8221;) pursuant to which DSG will obtain tapinarof drug product and drug substance from GSK Trading. Under the Commercial Supply Agreement, GSK Trading will provide development services to prepare for the manufacture and supply of tapinarof at commercial scale. DSG will obtain commercial supply of tapinarof on a cost plus basis under the commercial supply agreement. As required under the GSK Agreement, DSG entered into a letter agreement with GSK whereby GSK has agreed to make certain planned capital improvements, including design work, the purchase and modification of additional equipment items, and the reconfiguration of the existing production modules at GSK&#8217;s manufacturing site in Cork, Ireland with DSG agreeing to reimburse GSK an anticipated aggregate capital expenditure amount, which is not expected to exceed approximately &#8364;11.4&#160;million (approximately $13 million). DSG is not required to reimburse GSK for any actual amounts incurred in excess of 110% of the anticipated aggregate capital expenditure amount and the letter agreement will terminate at the later of (i)&#160;the completion of the Planned Capital Improvements and (ii)&#160;reimbursement by DSG of GSK&#8217;s actual capital expenditures related to such planned capital improvements. </div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Collaboration and License Agreement with Japan Tobacco Inc. </div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">In January 2020, DSG entered into a collaboration and license agreement with Japan Tobacco Inc. (&#8220;Japan Tobacco&#8221;) (the &#8220;Japan Tobacco Agreement&#8221;). Pursuant to the Japan Tobacco Agreement, DSG granted Japan </div></div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">218 </div></div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;;font-weight: bold;"><a href="#toc">Table of Contents</a></div> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Tobacco exclusive rights to develop, register and market tapinarof in Japan for the treatment of dermatological diseases and conditions, including psoriasis and atopic dermatitis. In connection with the Japan Tobacco Agreement, Japan Tobacco has signed an exclusive license with its subsidiary, Torii, for <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">co-development</div> and commercialization of tapinarof in Japan. </div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Under the Japan Tobacco Agreement, in January 2020, DSG received an upfront payment of $60.0&#160;million and may receive up to an additional $53.0&#160;million upon the achievement of certain development milestones for tapinarof in psoriasis and atopic dermatitis. In addition, DSG will be entitled to tiered purchase prices specified in the Japan Tobacco Agreement in consideration of DSG&#8217;s commercial supply of tapinarof to Japan Tobacco under the terms of a separate commercial supply agreement to be negotiated by the parties. DSG also has the right to receive royalties, to be negotiated by the parties and consistent with the purchase prices, based on product sales of tapinarof in the indications to the extent that DSG is no longer responsible for supplying tapinarof to Japan Tobacco. </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The Japan Tobacco Agreement will remain in effect until expiration of the obligation to pay royalties, unless terminated in accordance with the following: (1)&#160;for any reason by Japan Tobacco upon written notice to DSG, which notice must be provided (x)&#160;at least 90 days in advance, if the termination is prior to regulatory approval of tapinarof in Japan for any dermatological disease or condition, and (y)&#160;at least 180 days in advance, if the termination is subsequent to regulatory approval of tapinarof in Japan for any dermatological disease or condition; (2)&#160;by either party upon written notice for the other party&#8217;s material breach if such party fails to cure such breach within the specified cure period; or (3)&#160;by DSG if Japan Tobacco or its affiliates or sublicenses participate in a challenge to certain of our patents. </div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Dermavant Financing Agreements&#8212;Dermavant Revenue Interest Purchase and Sale Agreement </div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;">In May 2021, DSG, as seller, entered into a Revenue Interest Purchase and Sale Agreement (the &#8220;RIPSA&#8221;) with XYQ Luxco S.&#192; R.L. (&#8220;XYQ Luxco&#8221;), NovaQuest <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">Co-Investment</div> Fund XVII, L.P., an affiliate of NovaQuest Capital Management, LLC, and MAM Tapir Lender, LLC, an affiliate of Marathon Asset Management, L.P. (collectively, the &#8220;Purchasers&#8221;), together with U.S. Bank National Association, as collateral agent. </div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Following satisfaction of the funding conditions set forth in the RIPSA, including receipt of marketing approval from the FDA for tapinarof, the Purchasers are obligated to pay DSG a total of $160.0&#160;million in accordance with the terms and conditions set forth in the RIPSA (the &#8220;Purchase Price&#8221;). In consideration therefor, each of the Purchasers will have the right to receive a low single-digit to high single-digit tiered percentage of quarterly revenues based on the achievement of specified net sales thresholds for tapinarof in the U.S., up to a cap set at a multiple of the Purchase Price paid to DSG by the Purchasers. Payments of such quarterly revenues to the Purchasers under the RIPSA are secured by a security interest in certain tapinarof-related assets, including intellectual property rights and certain other assets that are owned by, licensed to or otherwise controlled by DSG related to the development and commercialization of tapinarof. </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">The RIPSA contains certain representations and warranties and covenants applicable to DSL and its subsidiaries. The RIPSA also contains certain Events of Default (as defined in the RIPSA) such as the breach of payment and other obligations, bankruptcy-related events and cross-defaults with respect to other related documents and agreements creating indebtedness. The occurrence of an Event of Default following the Purchasers&#8217; funding of the Purchase Price triggers DSG&#8217;s obligation to pay an Event of Default Fee (as defined in the RIPSA) of $160.0&#160;million, less revenue payments previously paid, as liquidated damages. In addition, the occurrence of a change of control of DSG prior to the Purchasers funding the Purchase Price triggers DSG&#8217;s right, but not the obligation, to terminate the RIPSA by payment of the <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">Pre-Funding</div> Change of Control Option Price (as defined in the RIPSA) to all of the Purchasers, which varies based on the date of termination and certain milestones with respect to tapinarof. </div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">219 </div></div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;;font-weight: bold;"><a href="#toc">Table of Contents</a></div> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Dermavant Financing Agreements&#8212;Dermavant Credit Agreement with XYQ Luxco </div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">In May 2021, our subsidiaries Dermavant Sciences Ltd. (&#8220;DSL&#8221;), Dermavant Holdings Limited, Dermavant Sciences IRL Limited and DSG, as borrowers (the &#8220;Borrowers&#8221;), and certain other subsidiaries of DSL, as initial guarantors, entered into a credit agreement (the &#8220;Credit Agreement&#8221;) with XYQ Luxco, as lender, and U.S. Bank National Association, as collateral agent. The Credit Agreement provides for a term loan of $40.0&#160;million (the &#8220;Term Loan&#8221;), the proceeds of which were used by the Borrowers to repay in full and terminate an existing credit facility with Hercules Capital Inc., with the remaining proceeds to be used for working capital and other general corporate purposes. </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The Term Loan bears interest at a fixed interest rate of 10.0% per annum, with interest paid quarterly in arrears until maturity in May 2026, at which time the principal amount is due. The Borrowers have the option to prepay the Term Loan in whole or in part, subject to (i)&#160;until May 2023, a prepayment premium of 5.0% of the principal amount being repaid (plus the present value of all future scheduled interest on the principal being prepaid that would accrue through May 2023 calculated based on a discount rate equal to the treasury rate plus 100 basis points, except in the event the prepayment is due to a change of control), (ii) from May 2023 to May 2024, a prepayment premium of 5.0% of the principal amount being repaid, and (iii)&#160;from May 2024 to May 2025, a prepayment premium of 2.5% of the principal amount being repaid. From May 2025 through maturity, the Term Loan may be prepaid in whole or part without a prepayment premium. Optional and mandatory prepayment of the Term Loan, as well as other forms of prepayment, repayment, applications or reductions, will also require that DSL pays an Exit Fee (as defined in the Credit Agreement), calculated based on the amount so prepaid, repaid, applied or reduced. </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The Borrowers&#8217; obligations under the Credit Agreement are unconditionally guaranteed by the initial guarantors and secured by first priority security interests in substantially all of the tangible and intangible assets of the Borrowers and guarantors, including certain intellectual property rights, bank accounts, any and all insurance receivables, intercompany receivables and/or trade receivables and certain quotas and/or participation rights. </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The Credit Agreement contains certain representations and warranties, affirmative covenants, negative covenants and conditions that are customarily required for similar financings, including a covenant against the occurrence of a &#8220;change in control&#8221; (subject to the Borrowers&#8217; right to prepay the Term Loan), financial reporting obligations and certain limitations on indebtedness, liens (including on intellectual property and other assets), investments, distributions (including dividends), collateral, transfers, mergers or acquisitions, taxes, corporate changes and deposit accounts. </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The Credit Agreement contains a minimum cash covenant that requires the initial Borrowers and the guarantors thereunder to maintain a minimum cash balance of $10.0&#160;million until the earlier of (a)&#160;a Qualified IPO (as defined in the Credit Agreement), (b) an Ultimate Parent Spinout (as defined in the Credit Agreement), and (c)&#160;the date that XYQ Luxco, in its capacity as a purchaser under the RIPSA, has received cumulative payments from DSG under the RIPSA in an aggregate amount equal to its pro rata portion of the funding amount thereunder. The Credit Agreement also contains customary events of default (subject, in certain instances, to specified grace periods) including, but not limited to, the failure to make payments of interest, premium, fees, indemnity or principal under the Term Loan, the failure to comply with certain covenants and agreements specified in the Credit Agreement, defaults in respect of certain other indebtedness and certain events relating to bankruptcy or insolvency. If any event of default occurs, the principal, premium, if any, interest and any other monetary obligations on all the then outstanding amounts under the Term Loan may become due and payable immediately. Upon the occurrence of an event of default, a default interest rate of an additional 2% per year may be applied to the outstanding principal balance, and the lender may declare all outstanding obligations immediately due and payable and take such other actions as set forth in the Credit Agreement. Upon the occurrence of certain bankruptcy and insolvency events, the obligations under the Credit Agreement would automatically become due and payable. </div></div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">220 </div></div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;;font-weight: bold;"><a href="#toc" style="text-indent: 0px;">Table of Contents</a></div> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">On the closing date of the Term Loan and in accordance with the Credit Agreement, DSL issued to XYQ Luxco a warrant to purchase an aggregate of 1,199,072 common shares of DSL. The warrant is exercisable at any time until the earlier of (x)&#160;seven years from the date of issuance and (y)&#160;three years from the closing of an underwritten initial public offering of DSL&#8217;s common shares pursuant to an effective registration statement. The warrant includes customary registration rights and customary anti-dilution provisions for the common shares underlying the warrant in respect of certain corporate events (including share splits, share combinations, share dividends and other recapitalization transactions). </div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Genevant </div></div></div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Cross-License Agreement with Arbutus Biopharma Corporation </div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;">In April 2018, our subsidiary, Genevant Sciences Ltd (&#8220;Genevant&#8221;), entered into a cross-license agreement with our affiliate, Arbutus Biopharma Corporation (&#8220;Arbutus&#8221;), which the parties amended twice in June 2018 (as amended, the &#8220;Arbutus Cross-License Agreement&#8221;). Pursuant to the Arbutus Cross-License Agreement Arbutus granted Genevant an exclusive, sublicensable, worldwide, transferable, irrevocable and perpetual license under certain patents and <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">know-how</div> relating to Arbutus&#8217;s lipid nanoparticle and GaINAc technology for <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">RNA-based</div> applications other than hepatitis B virus (&#8220;HBV&#8221;), and certain other excluded fields. The license is subject to certain rights which have previously licensed by Arbutus to other third parties. Under the Arbutus Cross-License Agreement, Genevant granted back to Arbutus an exclusive, sublicensable, worldwide, irrevocable, perpetual, royalty-free license under the intellectual property licensed under the Arbutus Cross-License Agreement and certain intellectual property acquired by Genevant after the effective date of the Arbutus Cross-License Agreement for applications involving the treatment and prevention of HBV. </div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">Genevant is obligated to pay Arbutus tiered low single-digit percentage royalties on sales of products covered by the licensed patents. If Genevant sublicenses intellectual property licensed from Arbutus or collaborates with any third party to develop, manufacture or commercialize any products covered by the intellectual property licensed by Arbutus, it will be required to pay Arbutus the lesser of (i)&#160;up to 20% of the Royalty-Related Receipts (as defined in the Arbutus Cross-License Agreement) received by Genevant from such sublicensees or collaborators and (ii)&#160;tiered low single-digit royalties on net sales by sublicensees. Genevant&#8217;s royalty obligations apply on <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">product-by-product,</div></div> <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">country-by-country</div></div> basis and end on the date on which the last valid claim of the licensed patents in such country that covers such licensed product expires. The patents and pending patent applications, if granted, currently licensed under the Arbutus Cross-License Agreement are expected to expire as early as 2023, and as late as 2039, without giving effect to any potential patent term extensions or patent term adjustments. Unless earlier terminated based on customary termination rights, the Arbutus Cross-License Agreement will continue until the expiration of Genevant&#8217;s royalty obligations. </div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Aruvant </div></div></div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">License Agreement with Cincinnati Children&#8217;s Hospital Medical Center</div></div><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"> </div></div><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;"> </div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;">In November 2018, our subsidiary Aruvant Sciences Ltd. (&#8220;Aruvant&#8221;), through its wholly owned subsidiary Aruvant Sciences GmbH (&#8220;ASG&#8221;), entered into a license agreement with Cincinnati Children&#8217;s Hospital Medical Center (&#8220;CCHMC&#8221;), pursuant to which CCHMC granted ASG (i)&#160;an exclusive, royalty-bearing, worldwide license for the use of certain patents, <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">know-how</div> and data relating to certain gene therapies for sickle cell anemia and certain other hemoglobinopathies, including <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">ARU-1801,</div> and for related manufacturing processes, and (ii)&#160;a <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-exclusive,</div> royalty-bearing, worldwide license for the use of relevant future CCHMC&#8217;s patents and general manufacturing <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">know-how</div> (the &#8220;CCHMC License Agreement&#8221;). The license is subject to, among other things, a <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-exclusive</div> license previously granted by CCHMC to another party. </div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">In consideration for entering into the CCHMC License Agreement, Aruvant issued nine million common shares to CCHMC. Aruvant is obligated to issue additional shares to CCHMC upon the earliest of (i)&#160;immediately prior to a change of control event, (ii)&#160;immediately following Aruvant&#8217;s issuance, in the </div></div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">221 </div></div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;;font-weight: bold;"><a href="#toc">Table of Contents</a></div> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">aggregate, of equity securities, convertible or exchangeable securities, or other securities in exchange for cash equal to or in excess of $150.0&#160;million or (iii)&#160;immediately prior to the effectiveness of a registration statement in connection with an initial public offering by Aruvant. When such a triggering event occurs, Aruvant must issue CCHMC additional shares equal to the difference between 12% of Aruvant&#8217;s fully diluted share capital, less the closing shares. </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">ASG has paid CCHMC approximately $25.0&#160;million in upfront licensing fees and is obligated to pay up to $30.0&#160;million in the aggregate in sales, development and regulatory milestones for the first licensed product to reach certain specified milestones. Additionally, ASG is obligated to pay to CCHMC a low to mid single-digit royalty on net sales of licensed products subject to certain potential downward adjustments for third-party licenses, expiration of certain patent claims or the entry into the market of a competing generic product. ASG&#8217;s royalty obligations continue on <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">product-by-product</div></div> and <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">country-by-country</div></div> basis until the latest to occur of (i)&#160;the date on which the last valid claim of the licensed patents covering such licensed product in such country expires, (ii)&#160;the <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">ten-year</div> anniversary of the first commercial sale of such licensed product in such country or (iii)&#160;the expiration of regulatory exclusivity for such licensed product in such country. Unless earlier terminated based on customary termination rights, the CCHMC License Agreement will continue on a <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">product-by-product</div></div> basis until the expiration of the royalty term for such licensed product. In the event of termination, the license granted to ASG under the agreement will terminate and, in the case of ASG&#8217;s termination for convenience or CCHMC termination for ASG&#8217;s material breach or bankruptcy, ASG will be deemed to grant CCHMC a <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-exclusive,</div> worldwide, perpetual license under ASG&#8217;s patents and <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">know-how</div> that relate to the licensed products and any patents for jointly developed inventions to develop and commercialize any product. Such license is royalty-free in the case of termination for ASG&#8217;s material breach or bankruptcy, and will be royalty-bearing on terms to be negotiated in good faith in the case of termination by ASG for convenience. </div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Lysovant </div></div></div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">License Agreement with iNtRON Biotechnology, Inc. </div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">In November 2018, our subsidiary, Lysovant Sciences GmbH (&#8220;LSG&#8221;), entered into a license agreement with iNtRON Biotechnology, Inc. (&#8220;iNtRON&#8221;), which the parties amended in March 2019 and August 2019 (the &#8220;iNtRON License Agreement&#8221;). Pursuant to the iNtRON License Agreement, iNtRON granted LSG an exclusive, worldwide, sublicensable, royalty-bearing license under certain patents and <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">know-how</div> to develop and commercialize certain antimicrobial bacteriophage-derived endolysins for any use other than uses involving topical administration. iNtRON also granted LSG an exclusive option during a specified exclusivity period extending until the expiration of a certain evaluation period to obtain an exclusive license to develop, manufacture and commercialize products containing certain other endolysins. LSG granted iNtRON a <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-exclusive,</div> worldwide, sublicensable, royalty-free, license under certain patents and <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">know-how</div> to develop and commercialize products containing the endolysins licensed under the iNtRON License Agreement formulated for topical administration. </div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">LSG paid iNtRON an upfront fee of $10.0&#160;million and is obligated to pay an option exercise fee to iNtRON upon each exercise of its option to obtain a license to additional endolysins. LSG may also be obligated up pay up to a maximum of $42.5&#160;million in development and regulatory milestone payments (with respect to the originally licensed endolysin), up to a maximum of $37.5&#160;million in development and regulatory milestone payments (with respect to each of any new endolysins) and a maximum of $940.0&#160;million in commercial milestone payments. LSG may also be obligated to pay a tiered <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">low-to-mid</div></div> teens percentage royalty, subject to certain customary reductions, on net sales of products covered by licensed patents. LSG&#8217;s royalty obligations apply on <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">product-by-product,</div></div> <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">country-by-country</div></div> basis and end upon the latest of (i)&#160;the date on which the last valid claim of the licensed patents that covers such licensed product in such country expires, (ii)&#160;ten years after the first commercial sale of such licensed product in such country and (iii)&#160;the date on which the regulatory exclusivity for such licensed product in such country expires. Unless earlier terminated based on customary termination rights, the iNtRON License Agreement will continue in effect on a <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">product-by-product</div></div> basis until the expiration of all royalty obligations. </div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">222 </div></div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;;font-weight: bold;"><a href="#toc">Table of Contents</a></div> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Intellectual Property </div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;">Our commercial success depends in part on our ability to obtain and maintain proprietary protection for current and future products and product candidates, technologies and <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">know-how;</div> to operate without infringing, misappropriating or otherwise violating the proprietary rights of others; and to prevent others from infringing our proprietary rights. Our policy is to seek to protect our proprietary position by, among other methods, filing or <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">in-licensing</div> U.S. and foreign patents and patent applications related to our proprietary technology, inventions and improvements that are important to the development and implementation of our business. We may also rely on trade secrets, <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">know-how,</div> continuing technological innovation and potential <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">in-licensing</div> opportunities to develop and maintain our proprietary position. </div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The patent positions of companies like us are generally uncertain and involve complex legal and factual questions. No consistent policy regarding the scope of claims allowable in patents in the fields of genetic therapy, cell therapy, biologics or pharmaceutical products generally has emerged in the United States or in Europe, among other countries. Changes in the patent laws and rules, either by legislation, judicial decisions, or regulatory interpretation in other countries may diminish our ability to protect our inventions and enforce our intellectual property rights, and more generally could affect the value of our intellectual property. In particular, our ability to stop third parties from making, using, selling, offering to sell, importing or otherwise commercializing any of our patented inventions, either directly or indirectly, will depend in part on our success in obtaining, defending and enforcing patent claims that cover our technology, inventions, and improvements. We cannot be sure that any patents will be granted with respect to any of our pending patent applications or with respect to any patent applications filed by us in the future, nor can we be sure that any of our existing patents or any patents that may be granted to us in the future will be commercially useful in protecting our product candidates and technology. Moreover, our issued patents and those that may issue in the future may not guarantee us the right to practice our technology in relation to the commercialization of our product candidates or technology. The area of patents and other intellectual property rights in biotechnology is an evolving one with many risks and uncertainties, which may prevent us from commercializing our current and future products and product candidates and practicing our proprietary technology. </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Our issued patents and those that may issue in the future may be challenged, narrowed, circumvented or invalidated, which could limit our ability to stop competitors from marketing related products or technologies or limit the length of the term of patent protection that we may have for our current and future products and product candidates and technologies. In addition, the rights granted under any issued patents may not provide us with complete protection or competitive advantages against competitors or other third parties with similar technology. Furthermore, our competitors may independently develop similar technologies that achieve similar outcomes but with different approaches. For these reasons, we may have competition for our product candidates. Moreover, the time required for development, testing and regulatory review of our product candidates may shorten the length of effective patent protection following commercialization. For this and other risks related to our proprietary technology, inventions, improvements, platforms and product candidates, please see the section entitled &#8220;Risk Factors&#8212;Risks Related to Roivant&#8217;s Business and Industry&#8212;Risks Related to Our Intellectual Property.&#8221; </div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt; margin-left: 2%;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Patents and Patent Applications </div></div></div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt; margin-left: 4%;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">ARU-1801</div> </div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">As of June&#160;30, 2021, ASG has licensed rights to six patent families containing at least 18 issued patents and 21 pending patent applications in the U.S. and other jurisdictions, including the European Union and Japan, with claims relating to a mutant human-Globin gene, lentiviral vectors and methods for producing lentiviral vectors. These patents and pending applications, if issued, are expected to expire as early as 2035, in each case without taking into account any possible patent term adjustment or extensions and assuming payment of all appropriate maintenance, renewal, annuity, or other governmental fees. </div></div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">223 </div></div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;;font-weight: bold;"><a href="#toc">Table of Contents</a></div> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 4%;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Tapinarof </div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">As of June&#160;30, 2021, DSG is the exclusive owner of patent families that include five issued U.S. patents and at least 10 pending U.S. patent applications, as well as more than 20 issued patents and at least 55 pending patent applications in other jurisdictions, including the European Union and Japan, relating to tapinarof, the synthesis of tapinarof, intermediates made in the synthesis, the drug substance crystal form, topical formulations of tapinarof and uses thereof in certain diseases and disorders. </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">One of these patent families is directed to the topical formulation of tapinarof, and its use to treat plaque psoriasis, that Dermavant has evaluated in Phase 3 clinical trials, as well as its use to treat atopic dermatitis which has been evaluated in Phase 2b clinical trials, which includes a patent that was issued in the United States and has a natural expiration date in 2036, without taking into account any possible patent term adjustment or extensions and assuming payment of all appropriate maintenance, renewal, annuity, or other governmental fees. This formulation patent includes 113 claims directed to topical, homogeneous, <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">oil-in-water</div></div> micro-emulsions containing tapinarof, an oil phase, a surfactant and other specific ingredients. DSG also owns an issued patent in the United States covering methods of using the patented formulations to treat inflammatory diseases, including psoriasis and atopic dermatitis. Like the formulation patent, the <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">method-of-use</div></div> patent has a natural expiration date in 2036 in the United States, without taking into account any possible patent term adjustment or extensions and assuming payment of all appropriate maintenance, renewal, annuity, or other governmental fees. The foreign counterpart formulation and <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">method-of-use</div></div> applications are pending, and if patents issue from these applications, they will also have a natural expiration date in 2036, without taking into account any possible patent term adjustment or extensions and assuming payment of all appropriate maintenance, renewal, annuity, or other governmental fees. </div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">DSG also owns a drug substance (&#8220;DS&#8221;) patent in the United States covering the high purity crystal form of tapinarof, as DS, the DS synthesis and several novel intermediates that are formed in the synthesis. This DS patent has a natural expiration date in 2038, without taking into account any possible patent term adjustment or extensions and assuming payment of all appropriate maintenance, renewal, annuity, or other governmental fees. DSG has also filed foreign counterpart DS applications that are still pending in foreign jurisdictions and, if patents issue from these applications, they will similarly have a natural expiration date in 2038, without taking into account any possible patent term adjustment or extensions and assuming payment of all appropriate maintenance, renewal, annuity, or other governmental fees. </div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt; margin-left: 4%;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Genevant </div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;">As of June 30, 2021, we own or <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">co-own</div> 16 patent families containing at least 44 issued patents and at least 46 pending patent applications in the U.S., European Union and numerous other jurisdictions, including claims relating to lipid nanoparticle delivery technology and polymers. These patents and pending applications, if issued, are expected to expire between 2024 and 2041, in each case without taking into account any possible patent term adjustment or extensions and assuming payment of all appropriate maintenance, renewal, annuity or other governmental fees. </div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">As of June 30, 2021, we have licensed 40 patent families containing at least 465 issued patents and at least 218 pending patent applications in the U.S., European Union and numerous other jurisdictions, including claims relating to delivery systems. These patents and pending applications, if issued, are expected to expire between 2021 and 2039,&#160;in each case without taking into account any possible patent term adjustment or extensions and assuming payment of all appropriate maintenance, renewal, annuity or other governmental fees. </div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt; margin-left: 4%;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">IMVT-1401 </div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Following ISG&#8217;s assumption of all rights, title, interest and obligations under the license agreement between RSG and HanAll Biophama (the &#8220;HanAll Agreement&#8221;) from RSG in December 2018, by virtue of the license of </div></div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">224 </div></div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;;font-weight: bold;"><a href="#toc">Table of Contents</a></div> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">patent rights under the HanAll Agreement, ISG is the exclusive licensee of technology directed to IMVT-1401, and certain <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">back-up</div> and next-generation antibodies, and products containing such antibodies, in the licensed territory. As of June&#160;30, 2021, the patent portfolio includes pending patent applications and/or issued patent(s) in the U.S. and other jurisdictions. The <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">in-licensed</div> patent portfolio includes a patent family that discloses anti-FcRn antibodies, pharmaceutical compositions thereof, methods of treating autoimmune disease using the same, polynucleotides encoding such antibodies, expression vectors including such polynucleotides, host cells transfected with such recombinant expression vectors, methods of manufacturing such antibodies and methods of detecting FcRn in vivo or in vitro using such antibodies. This patent family includes an issued U.S. patent with claims directed to an isolated anti-FcRn antibody or antigen-binding fragment thereof, and a pharmaceutical composition comprising such antibody or antigen-binding fragment thereof and a second issued U.S. patent with claims directed to an isolated anti-FcRn antibody or antigen-binding fragment thereof, a pharmaceutical composition thereof as well as methods of treating various autoimmune diseases using such antibody or antigen-binding fragment, polynucleotides and expression vectors encoding the same, host cells capable of expressing the same and methods of producing such antibody or antigen-binding fragment. The patents and pending applications of this patent family, if issued, are expected to expire as early as 2035, in each case without taking into account any possible patent term adjustment or extensions and assuming payment of all appropriate maintenance, renewal, annuity, or other governmental fees. For information regarding ISG&#8217;s license agreement with HanAll, please see &#8220;&#8212;Asset Acquisitions and License Arrangements.&#8221; </div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Additionally, as of June&#160;30, 2021, independent of the licensed patent portfolio, ISG has a patent family directed to methods of treating thyroid eye disease using anti-FcRn antibodies that includes patent applications in the U.S. as well as counterparts in certain other jurisdictions within its licensed territory and another patent family that includes an internationally filed patent application directed to methods of treating warm autoimmune hemolytic anemia using anti-FcRn antibodies. Any patent issued from these patent families is expected to expire in 2039 and 2040, respectively, exclusive of any patent term adjustment or extension. </div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt; margin-left: 4%;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">LSVT-1701 </div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">As of June&#160;30, 2021, we have licensed rights to six patent families containing at least 47 issued patents and at least 33 pending patent applications in numerous jurisdictions, including the U.S. and European Union, with claims relating to LSVT-1701, formulations thereof and methods of treatment. These patents and pending applications, if issued, are expected to expire as early as 2027, in each case without taking into account any possible patent term adjustment or extensions and assuming payment of all appropriate maintenance, renewal, annuity, or other governmental fees. </div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt; margin-left: 4%;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Targeted Protein Degradation Platform </div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">As of June&#160;30, 2021, we have licensed rights to 21 patent families containing three issued U.S. patents, two issued European patents, one issued South African patent, one issued Ukraine patent and at least 70 pending patent applications in the U.S., European Union and a number of other jurisdictions.&#160;These patents and pending applications, if issued, are expected to expire as early as 2037, without taking into account any possible patent term adjustment or extensions and assuming payment of all appropriate maintenance, renewal, annuity, or other governmental fees. </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">We cannot predict whether the patent applications we pursue or license will issue as patents in any particular jurisdiction. Even if our pending patent applications are granted as issued patents, those patents, as well as any patents we license from third parties now or in the future, may be challenged, circumvented or invalidated by third parties. While we seek broad coverage under our existing patent applications, there is always a risk that an alteration to the products or technologies may provide sufficient basis for a competitor or other third party to avoid infringing our patent claims. In addition, patents, if granted, expire and we cannot provide any assurance that any patents will be issued from our pending or any future applications or that any potentially </div></div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">225 </div></div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;;font-weight: bold;"><a href="#toc">Table of Contents</a></div> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">issued patents will adequately protect our products or product candidates. Consequently, we may not obtain or maintain adequate patent protection for any of our products or product candidates. </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">Individual patents extend for varying periods depending on the date of filing of the patent application or the date of patent issuance and the legal term of patents in the countries in which they are obtained. Generally, patents issued for regularly filed applications in the United States are granted a term of 20 years from the earliest effective <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-provisional</div> filing date. The duration of foreign patents varies in accordance with provisions of applicable local law, but typically is also 20 years from the earliest effective <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-provisional</div> filing date. A U.S. patent also may be accorded patent term adjustment, or PTA, under certain circumstances to compensate for delays in obtaining the patent from the USPTO. In some instances, such a PTA may result in a U.S. patent term extending beyond 20 years from the earliest date of filing a <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-provisional</div> patent application related to the U.S. patent. In addition, in the United States, the term of a U.S. patent that covers an <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">FDA-approved</div> drug may also be eligible for PTE, which permits patent term restoration as compensation for the patent term lost during the FDA regulatory review process. The Hatch-Waxman Act permits a PTE of up to five years beyond the expiration of the patent. The length of the PTE is related to the length of time the drug is under regulatory review. PTE cannot extend the remaining term of a patent beyond a total of 14 years from the date of product approval, only one patent applicable to an approved drug may be extended and only those claims covering the approved drug, a method for using it, or a method for manufacturing it may be extended. Similar provisions are available in Europe and certain other jurisdictions to extend the term of a patent that covers an approved drug. In the future, if and when our products receive FDA approval, we expect to apply for PTEs on patents covering products eligible for PTE. We plan to seek PTEs for any of our issued patents in any jurisdiction where these are available; however, there is no guarantee that the applicable authorities, including the USPTO in the United States, will agree with our assessment of whether such extensions should be granted, and if granted, the length of such extensions. The actual protection afforded by a patent varies on a <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">product-by-product</div></div> basis, from country to country, and depends upon many factors, including the type of patent, the scope of its coverage, the availability of regulatory-related extensions, the availability of legal remedies in a particular country and the validity and enforceability of the patent. </div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">Our commercial success will also depend in part on not infringing upon the proprietary rights of third parties. It is uncertain whether the issuance of any third-party patent would require us to alter our development or<div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"> </div></div>commercial strategies for our products or processes, or to obtain licenses or cease certain activities. Our breach of any license agreements or failure to obtain a license to proprietary rights that we may require to develop or commercialize our future products may have an adverse impact on us. If third parties prepare and file patent applications in the United States that also claim technology to which we have rights, we may have to participate in interference or derivation proceedings in the USPTO to determine priority of invention. For more information, please see &#8220;Risk Factors&#8212;Risks Related to Roivant&#8217;s Business and Industry&#8212;Risks Related to Our Intellectual Property.&#8221; </div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt; margin-left: 4%;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Trade Secrets </div></div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;">In addition to our reliance on patent protection for our inventions, product candidates and research programs, we also rely on trade secrets, <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">know-how,</div> continuing technological innovation and potential <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">in-licensing</div> opportunities to develop and maintain our competitive position. We seek to protect our proprietary information, in part, using confidentiality and invention assignment agreements with our commercial partners, collaborators, employees and consultants. These agreements are designed to protect our proprietary information and, in the case of the invention assignment agreements, to grant us ownership of technologies that are developed through a relationship with an employee or a third party. These agreements may be breached, and we may not have adequate remedies for any breach. In addition, our trade secrets may otherwise become known or be independently discovered by competitors or other third parties. As a result, we may not be able to meaningfully protect our trade secrets. For more information regarding the risks related to our intellectual property, see &#8220;Risk Factors&#8212;Risks Related to Roivant&#8217;s Business and Industry&#8212;Risks Related to Our Intellectual Property.&#8221; </div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">226 </div></div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;;font-weight: bold;"><a href="#toc">Table of Contents</a></div> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Government Regulation </div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Government authorities in the United States at the federal, state and local level and in other countries regulate, among other things, the research, development, manufacture, testing, quality control, approval, labeling, packaging, storage, record-keeping, promotion, advertising, distribution, post-approval monitoring and reporting, marketing and export and import of drug and biological products, including gene therapies, as well as diagnostics, and any future product candidates. Generally, before a new drug, biologic or diagnostic can be marketed, considerable data demonstrating its quality, safety and efficacy must be obtained, organized into a format specific for each regulatory authority, submitted for review and approved, authorized, or cleared by the applicable regulatory authority. </div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt; margin-left: 2%;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">U.S. Government Regulation of Drug and Biological Products </div></div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">In the United States, the FDA regulates drugs under the Federal Food, Drug and Cosmetic Act (the &#8220;FDCA&#8221;) and its implementing regulations and biologics under the FDCA and the Public Health Service Act (the &#8220;PHSA&#8221;), and their implementing regulations. Both drugs and biologics also are subject to other federal, state and local statutes and regulations, such as those related to competition. The process of obtaining regulatory approvals and the subsequent compliance with appropriate federal, state, and local statutes and regulations requires the expenditure of substantial time and financial resources. Failure to comply with the applicable U.S. requirements at any time during the product development process, approval process or following approval may subject an applicant to administrative actions or judicial sanctions. These actions and sanctions could include, among other actions, the FDA&#8217;s refusal to approve pending applications, withdrawal of an approval, license revocation, a clinical hold, untitled or warning letters, voluntary or mandatory product recalls or market withdrawals, product seizures, total or partial suspension of production or distribution, injunctions, fines, refusals of government contracts, restitution, disgorgement, debarment from producing or marketing drug products or biologics, disqualification from conducting research, and civil or criminal fines or penalties. Any agency or judicial enforcement action could have a material adverse effect on our business, the market acceptance of our products and our reputation. </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Our product candidates must be approved by the FDA through either an NDA or a BLA, process before they may be legally marketed in the United States. The process generally involves the following: </div></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">completion of extensive preclinical studies in accordance with applicable regulations, including studies conducted in accordance with GLP requirements; </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">submission to the FDA of an IND, which must become effective before human clinical trials may begin; </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">approval by an IRB, or independent ethics committee at each clinical trial site before each human trial may be initiated; </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">performance of adequate and well-controlled human clinical trials in accordance with applicable IND regulations and requirements, GCP requirements and other clinical trial-related regulations to establish the safety and efficacy of the investigational product for each proposed indication; </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">submission to the FDA of an NDA or BLA; </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">a determination by the FDA within 60 days of its receipt of an NDA or BLA to accept the filing for review; </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;">satisfactory completion of one or more FDA <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">pre-approval</div> inspections of the manufacturing facility or facilities where the drug or biologic will be produced to assess compliance with cGMP requirements to assure that the facilities, methods and controls are adequate to preserve the drug or biologic&#8217;s identity, strength, quality and purity; </div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">227 </div></div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;;font-weight: bold;"><a href="#toc">Table of Contents</a></div> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;">
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">potential FDA inspection of the clinical trial sites that generated the data in support of the NDA or BLA and/or us as the sponsor </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">payment of user fees for FDA review of the NDA or BLA (unless a fee waiver applies) </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">agreement with FDA on the final labeling for the product and the design and implementation of any required REMS; and </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">FDA review and approval of the NDA or BLA, including consideration of the views of any FDA advisory committee, prior to any commercial marketing or sale of the drug or biologic in the United States. </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The preclinical and clinical testing and approval process requires substantial time, effort and financial resources, and the regulatory scheme for drugs and biologics is evolving and subject to change at any time. We cannot be certain that any approvals for our product candidates will be granted on a timely basis, or at all. </div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt; margin-left: 2%;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Preclinical Studies </div></div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Before testing any drug, biological or gene therapy candidate in humans, the product candidate must undergo rigorous preclinical testing. Preclinical studies include laboratory evaluation of product chemistry and formulation, as well as in vitro and animal studies to assess safety and in some cases to establish a rationale for therapeutic use. In the U.S., the conduct of preclinical studies is subject to federal and state regulations and requirements, including GLP regulations for safety/toxicology studies. </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">In the U.S., an IND sponsor must submit the results of the preclinical tests, together with manufacturing information, analytical data, any available clinical data or literature and plans for clinical trials, among other things, to the FDA as part of an IND. An IND is a request for authorization from the FDA to administer an investigational product to humans, and must become effective before human clinical trials may begin. Some long-term preclinical testing, such as animal tests of reproductive AEs and carcinogenicity, may continue, and additional preclinical testing may commence, after the IND is submitted. An IND automatically becomes effective 30 days after receipt by the FDA, unless before that time, the FDA raises concerns or questions related to one or more proposed clinical trials and places the trial on clinical hold. In such a case, the IND sponsor and the FDA must resolve any outstanding concerns before the clinical trial can begin. As a result, submission of an IND may not result in the FDA allowing clinical trials to commence. Additionally, the review of information in an IND submission may prompt FDA to, among other things, scrutinize existing INDs or marketed products and could generate requests for information or clinical holds on other product candidates or programs. </div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt; margin-left: 2%;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Clinical Trials </div></div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The clinical stage of development involves the administration of the investigational product to healthy volunteers or patients under the supervision of qualified investigators, generally physicians not employed by or under the trial sponsor&#8217;s control, in accordance with GCP requirements, which include the requirement that all research subjects provide their informed consent for their participation in any clinical trial. Clinical trials are conducted under protocols detailing, among other things, the objectives of the clinical trial, dosing procedures, subject selection and exclusion criteria and the parameters to be used to monitor subject safety and assess efficacy. In the U.S., each protocol, and any subsequent amendments to the protocol, must be submitted to the FDA as part of the IND. Furthermore, each clinical trial must be reviewed and approved by an IRB for each institution at which the clinical trial will be conducted to ensure that the risks to individuals participating in the clinical trials are minimized and are reasonable in relation to anticipated benefits. The IRB also approves the informed consent form that must be provided to each clinical trial subject or his or her legal representative, and must monitor the clinical trial until completed. There also are requirements governing the reporting of ongoing clinical trials and completed clinical trial results to public registries. Information about certain clinical trials, including clinical trial results, must be submitted within specific timeframes for publication on the www.clinicaltrials.gov website. </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">In addition to the submission of an IND to the FDA before initiation of a clinical trial in the United States, certain human clinical trials involving recombinant or synthetic nucleic acid molecules had historically been </div></div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">228 </div></div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;;font-weight: bold;"><a href="#toc">Table of Contents</a></div> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">subject to review by the NIH Recombinant DNA Advisory Committee (the &#8220;RAC&#8221;), of the NIH Office of Biotechnology Activities (the &#8220;OBA&#8221;), pursuant to the NIH Guideline. On August&#160;17, 2018, the NIH issued a notice in the Federal Register and issued a public statement proposing changes to the oversight framework for gene therapy trials, including changes to the applicable NIH Guidelines to modify the roles and responsibilities of the RAC with respect to human clinical trials of gene therapy products, and requesting public comment on its proposed modifications. During the public comment period, which closed October&#160;16, 2018, the NIH announced that it will no longer accept new human gene transfer protocols for review as a part of the protocol registration process or convene the RAC to review individual clinical protocols. In April 2019, NIH announced the updated guidelines, which reflect these proposed changes, and clarify that these trials will remain subject to the FDA&#8217;s oversight and other clinical trial regulations, and oversight at the local level will continue as set forth in the NIH Guidelines. Specifically, under the NIH Guidelines, supervision of human gene transfer trials includes evaluation and assessment by an IBC, a local institutional committee that reviews and oversees research utilizing recombinant or synthetic nucleic acid molecules at that institution. The IBC assesses the safety of the research and identifies any potential risk to public health or the environment, and such review may result in some delay before initiation of a clinical trial. While the NIH Guidelines are not mandatory unless the research in question being conducted at or sponsored by institutions receiving NIH funding of recombinant or synthetic nucleic acid molecule research, many companies and other institutions not otherwise subject to the NIH Guidelines voluntarily follow them. </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">A sponsor who wishes to conduct a clinical trial outside of the United States may, but need not, obtain FDA authorization to conduct the clinical trial under an IND. If a foreign clinical trial is not conducted under an IND, the sponsor may submit data from the clinical trial to the FDA in support of an NDA or BLA. The FDA will accept a well-designed and well-conducted foreign clinical study not conducted under an IND if the study was conducted in accordance with GCP requirements, and the FDA is able to validate the data through an onsite inspection if deemed necessary. </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Clinical trials generally are conducted in three sequential phases, known as Phase 1, Phase 2 and Phase 3, and may overlap or be combined. </div></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Phase 1 clinical trials generally involve a small number of healthy volunteers or disease-affected patients who are initially exposed to a single dose and then multiple doses of the product candidate. The primary purpose of these clinical trials is to assess the metabolism, pharmacologic action, side effect tolerability and safety of the product candidate. </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Phase 2 clinical trials involve studies in disease-affected patients to evaluate proof of concept and/or determine the dose required to produce the desired benefits. At the same time, safety and further PK and PD information is collected, possible adverse effects and safety risks are identified, and a preliminary evaluation of efficacy is conducted. </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Phase 3 clinical trials generally involve a large number of patients at multiple sites and are designed to provide the data necessary to demonstrate the effectiveness of the product for its intended use, its safety in use and to establish the overall benefit/risk relationship of the product and provide an adequate basis for product labeling. </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">In August 2018, the FDA released a draft guidance entitled &#8220;Expansion Cohorts: Use in <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">First-In-Human</div></div> Clinical Trials to Expedite Development of Oncology Drugs and Biologics,&#8221; which outlines how drug developers can utilize an adaptive trial design commonly referred to as a seamless trial design in early stages of oncology drug development, i.e., the <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">first-in-human</div></div> clinical trial, to compress the traditional three phases of trials into one continuous trial called an expansion cohort trial. Information to support the design of individual expansion cohorts are included in IND applications and assessed by FDA. Expansion cohort trials can potentially bring efficiency to drug development and reduce developmental costs and time. </div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Post-approval trials, sometimes referred to as Phase 4 clinical trials, may be conducted after initial marketing approval. These trials are used to gain additional experience from the treatment of patients in the </div></div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">229 </div></div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;;font-weight: bold;"><a href="#toc">Table of Contents</a></div> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">intended therapeutic indication and are commonly intended to generate additional safety data regarding use of the product in a clinical setting. In certain instances, the FDA may mandate the performance of Phase 4 clinical trials as a condition of approval of an NDA or BLA or post-approval. </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Progress reports detailing the results of the clinical trials, among other information, must be submitted at least annually to the FDA and written IND safety reports must be submitted to the FDA and the investigators 15&#160;days after the trial sponsor determines the information qualifies for reporting for serious and unexpected suspected AEs, findings from other studies or animal or in vitro testing that suggest a significant risk for human subjects and any clinically important increase in the rate of a serious suspected adverse reaction over that listed in the protocol or investigator brochure. The sponsor must also notify the FDA of any unexpected fatal or life-threatening suspected adverse reaction as soon as possible but in no case later than seven calendar days after the sponsor&#8217;s initial receipt of the information. </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Phase 1, Phase 2, Phase 3 and other types of clinical trials may not be completed successfully within any specified period, if at all. The FDA or the sponsor may suspend or terminate a clinical trial at any time on various grounds, including a finding that the research subjects or patients are being exposed to an unacceptable health risk. Similarly, an IRB can suspend or terminate approval of a clinical trial at its institution if the clinical trial is not being conducted in accordance with the IRB&#8217;s requirements or if the drug or biologic has been associated with unexpected serious harm to patients. Additionally, some clinical trials are overseen by an independent group of qualified experts organized by the clinical trial sponsor, known as a data safety monitoring board or committee. This group provides authorization for whether a trial may move forward at designated check points based on access to certain data from the trial. Concurrent with clinical trials, companies usually complete additional animal studies and also must develop additional information about the chemistry and physical characteristics of the drug or biologic as well as finalize a process for manufacturing the product in commercial quantities in accordance with cGMP requirements. The manufacturing process must be capable of consistently producing quality batches of the product and, among other things, companies must develop methods for testing the identity, strength, quality and purity of the final product. Additionally, appropriate packaging must be selected and tested, and stability studies must be conducted to demonstrate that the product candidates do not undergo unacceptable deterioration over their shelf life. </div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt; margin-left: 2%;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">FDA Review Process </div></div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Following completion of the clinical trials, data are analyzed to assess whether the investigational product is safe and effective for the proposed indicated use or uses. The results of preclinical studies and clinical trials are then submitted to the FDA as part of an NDA or BLA, along with proposed labeling, chemistry and manufacturing information to ensure product quality and other relevant data. The NDA or BLA is a request for approval to market the drug or biologic for one or more specified indications and must contain proof of safety and efficacy for a drug or safety, purity and potency for a biologic. The application may include both negative and ambiguous results of preclinical studies and clinical trials, as well as positive findings. Data may come from company-sponsored clinical trials intended to test the safety and efficacy of a product&#8217;s use or from a number of alternative sources, including studies initiated by investigators. To support marketing approval, the data submitted must be sufficient in quality and quantity to establish the safety and efficacy of the investigational product to the satisfaction of FDA. FDA approval of an NDA or BLA must be obtained before a drug or biologic may be marketed in the United States. </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">Under the Prescription Drug User Fee Act (the &#8220;PDUFA&#8221;), as amended, each NDA or BLA must be accompanied by a user fee. FDA adjusts the PDUFA user fees on an annual basis. Fee waivers or reductions are available in certain circumstances, including a waiver of the application fee for the first application filed by a small business. Additionally, no user fees are assessed on NDAs or BLAs for products designated as orphan drugs, unless the product also includes a <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-orphan</div> indication. </div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The FDA reviews all submitted NDAs and BLAs before it accepts them for filing, and may request additional information rather than accepting the NDA or BLA for filing. The FDA must make a decision on </div></div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">230 </div></div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;;font-weight: bold;"><a href="#toc" style="text-indent: 0px;">Table of Contents</a></div> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">accepting an NDA or BLA for filing within 60 days of receipt, and such decision could include a refusal to file by the FDA. Once the submission is accepted for filing, the FDA begins an <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">in-depth</div> review of the NDA or BLA. Under the goals and policies agreed to by the FDA under PDUFA, the FDA targets ten months, from the filing date, in which to complete its initial review of a new molecular entity NDA or original BLA and respond to the applicant, and six months from the filing date of a new molecular entity NDA or original BLA designated for priority review. The FDA does not always meet its PDUFA goal dates for standard and priority NDAs or BLAs, and the review process is often extended by FDA requests for additional information or clarification. During the <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">COVID-19</div> pandemic, because of travel and other restrictions, the FDA has significantly curtailed its inspection program. The reduction in <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">pre-approval</div> inspections has resulted in delays to some product approvals. There may be delays to product approvals in the future based on continuing problems with respect to the FDA&#8217;s ability to conduct inspections and then, even after a resumption of the FDA&#8217;s normal inspection program, a possible backlog in applications under review by the agency. </div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The FDA has developed the Oncology Center of Excellence RTOR pilot program to facilitate a more efficient review process for certain oncology product candidates. Although this program allows FDA to begin reviewing clinical data prior to submission of a complete NDA or BLA, the program is not intended to change the PDUFA review timelines. </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">Before approving an NDA or BLA, the FDA will typically conduct a <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">pre-approval</div> inspection of the manufacturing facilities for the new product to determine whether they comply with cGMP requirements. The FDA will not approve the product unless it determines that the manufacturing processes and facilities are in compliance with cGMP requirements and adequate to assure consistent production of the product within required specifications. The FDA also may audit data from clinical trials to ensure compliance with GCP requirements. Additionally, the FDA may refer applications for novel products or products which present difficult questions of safety or efficacy to an advisory committee, typically a panel that includes clinicians and other experts, for review, evaluation and a recommendation as to whether the application should be approved and under what conditions, if any. The FDA is not bound by recommendations of an advisory committee, but it considers such recommendations when making decisions on approval. The FDA likely will reanalyze the clinical trial data, which could result in extensive discussions between the FDA and the applicant during the review process. After the FDA evaluates an NDA or BLA, it will issue an approval letter or a Complete Response Letter. An approval letter authorizes commercial marketing of the drug or biologic with specific prescribing information for specific indications. A Complete Response Letter indicates that the review cycle of the application is complete, and the application will not be approved in its present form. A Complete Response Letter usually describes all of the specific deficiencies in the NDA or BLA identified by the FDA. The Complete Response Letter may require the applicant to obtain additional clinical data, including the potential requirement to conduct additional pivotal Phase 3 clinical trial(s) and/or to complete other significant and time-consuming requirements related to clinical trials, or to conduct additional preclinical studies or manufacturing activities. If a Complete Response Letter is issued, the applicant may either resubmit the NDA or BLA, addressing all of the deficiencies identified in the letter, or withdraw the application or request an opportunity for a hearing. Even if such data and information are submitted, the FDA may decide that the NDA or BLA does not satisfy the criteria for approval. Data obtained from clinical trials are not always conclusive and the FDA may interpret data differently than we interpret the same data. </div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt; margin-left: 2%;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Orphan Drug Designation and Exclusivity </div></div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Under the Orphan Drug Act, the FDA may grant orphan designation to a drug or biological product intended to treat a rare disease or condition, which is generally a disease or condition that affects fewer than 200,000 individuals in the United States, or more than 200,000 individuals in the United States and for which there is no reasonable expectation that the cost of developing and making the product available in the United States for this type of disease or condition will be recovered from sales of the product. </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Orphan drug designation must be requested before submitting an NDA or BLA. After the FDA grants orphan drug designation, the identity of the therapeutic agent and its potential orphan use are disclosed publicly by the FDA. Orphan drug designation does not convey any advantage in or shorten the duration of the regulatory review and approval process. </div></div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">231 </div></div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;;font-weight: bold;"><a href="#toc">Table of Contents</a></div> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">If a product that has orphan drug designation subsequently receives the first FDA approval for the disease or condition for which it has such designation, the product is entitled to orphan drug exclusivity, which means that the FDA may not approve any other applications to market the same drug for the same indication for seven years from the date of such approval, except in limited circumstances, such as a showing of clinical superiority to the product with orphan exclusivity by means of greater effectiveness, greater safety or providing a major contribution to patient care or in instances of drug supply issues. Competitors, however, may receive approval of either a different product for the same indication or the same product for a different indication but that could be used <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">off-label</div> in the orphan indication. Orphan drug exclusivity also could block the approval of one of our products for seven years if a competitor obtains approval before we do for the same product, as defined by the FDA, for the same indication we are seeking approval, or if our product is determined to be contained within the scope of the competitor&#8217;s product for the same indication or disease. If we pursue marketing approval for an indication broader than the orphan drug designation we have received, we may not be entitled to orphan drug exclusivity. Orphan drug status in the European Union has similar, but not identical, requirements and benefits. </div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt; margin-left: 2%;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Rare Pediatric Disease Designation and Priority Review Vouchers </div></div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Under the FDCA, as amended, the FDA incentivizes the development of drugs and biologics that meet the definition of a &#8220;rare pediatric disease,&#8221; defined to mean a serious or life-threatening disease in which the serious of life-threatening manifestations primarily affect individuals aged from birth to 18 years and the disease affects fewer than 200,000 individuals in the United States or affects more than 200,000 in the United States and for which there is no reasonable expectation that the cost of developing and making in the United States a drug for such disease or condition will be received from sales in the United States of such drug. The sponsor of a product candidate for a rare pediatric disease may be eligible for a voucher that can be used to obtain a priority review for a subsequent human drug or biologic application after the date of approval of the rare pediatric disease drug product, referred to as a priority review voucher (a &#8220;PRV&#8221;). A sponsor may request rare pediatric disease designation from the FDA prior to the submission of its NDA or BLA. A rare pediatric disease designation does not guarantee that a sponsor will receive a PRV upon approval of its NDA or BLA. Moreover, a sponsor who chooses not to submit a rare pediatric disease designation request may nonetheless receive a PRV upon approval of their marketing application if they request such a voucher in their original marketing application and meet all of the eligibility criteria. If a PRV is received, it may be sold or transferred an unlimited number of times. Congress has extended the PRV program through September&#160;30, 2024, with the potential for PRVs to be granted through September&#160;30, 2026. </div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt; margin-left: 2%;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Expedited Development and Review Programs </div></div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;">A sponsor may seek to develop and obtain approval of its product candidates under programs designed to accelerate the development, FDA review and approval of new drugs and biologics that meet certain criteria. For example, the FDA has a fast-track program that is intended to expedite or facilitate the process for reviewing new drugs and biologics that are intended to treat a serious or life-threatening disease or condition and demonstrate the potential to address unmet medical needs for the disease or condition. Fast track designation applies to both the product and the specific indication for which it is being studied. For a fast track-designated product, the FDA may consider sections of the NDA or BLA for review on a rolling basis before the complete application is submitted, if the sponsor provides a schedule for the submission of the sections of the application, the FDA agrees to accept sections of the application and determines that the schedule is acceptable, and the sponsor pays any required user fees upon submission of the first section of the application. The sponsor can request the FDA to designate the product for fast-track status any time before receiving NDA or BLA approval, but ideally no later than the <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">pre-NDA</div> or <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">pre-BLA</div> meeting. </div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">A product submitted to the FDA for marketing, including under a fast-track program, may be eligible for other types of FDA programs intended to expedite development or review, such as priority review and accelerated approval. Priority review means that, for a new molecular entity or original BLA, the FDA sets a target date for FDA action on the marketing application at six months after accepting the application for filing as </div></div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">232 </div></div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;;font-weight: bold;"><a href="#toc">Table of Contents</a></div> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">opposed to ten months. A product is eligible for priority review if it is designed to treat a serious or life-threatening disease condition and, if approved, would provide a significant improvement in safety and effectiveness compared to available therapies. The FDA will attempt to direct additional resources to the evaluation of an application for a new drug or biologic designated for priority review in an effort to facilitate the review. If criteria are not met for priority review, the application for a new molecular entity or original BLA is subject to the standard FDA review period of ten months after FDA accepts the application for filing. Priority review designation does not change the scientific/medical standard for approval or the quality of evidence necessary to support approval. </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">A product may also be eligible for accelerated approval if it is designed to treat a serious or life-threatening disease or condition, generally provides a meaningful advantage over other available therapies, and demonstrates an effect on either a surrogate endpoint that is reasonably likely to predict clinical benefit or on a clinical endpoint that can be measured earlier than irreversible morbidity or mortality (&#8220;IMM&#8221;), that is reasonably likely to predict an effect on IMM or other clinical benefit, taking into account the severity, rarity, or prevalence of the disease or condition and the availability or lack of alternative treatments. As a condition of approval, the FDA may require that a sponsor of a drug or biologic receiving accelerated approval perform adequate and well-controlled post-marketing clinical trials. In addition, the FDA currently requires as a condition for accelerated approval <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">pre-approval</div> of promotional materials, which could adversely impact the timing of the commercial launch of the product. FDA may withdraw approval of a drug or indication approved under accelerated approval if, for example, the confirmatory trial fails to verify the predicted clinical benefit of the product. </div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Additionally, a drug or biologic may be eligible for designation as a breakthrough therapy if the product is intended, alone or in combination with one or more other drugs or biologics, to treat a serious or life-threatening condition and preliminary clinical evidence indicates that the product may demonstrate substantial improvement over currently approved therapies on one or more clinically significant endpoints, such as substantial treatment effects observed early in clinical development. If the FDA designates a breakthrough therapy, it may take actions appropriate to expedite the development and review of the application, which may include holding meetings with the sponsor and the review team throughout the development of the therapy; providing timely advice to, and interactive communication with, the sponsor regarding the development of the drug to ensure that the development program to gather the nonclinical and clinical data necessary for approval is as efficient as practicable; involving senior managers and experienced review staff, as appropriate, in a collaborative, cross-disciplinary review; assigning a cross-disciplinary project lead for the FDA review team to facilitate an efficient review of the development program and to serve as a scientific liaison between the review team and the sponsor; and considering alternative clinical trial designs when scientifically appropriate, which may result in smaller trials or more efficient trials that require less time to complete and may minimize the number of patients exposed to a potentially less efficacious treatment. Breakthrough therapy designation comes with all of the benefits of fast-track designation, which means that the sponsor may file sections of the NDA or BLA for review on a rolling basis if certain conditions are satisfied, including an agreement with the FDA on the proposed schedule for submission of portions of the application and the payment of applicable user fees before the FDA may initiate a review. </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">As part of the 21st Century Cures Act, Congress amended the FDCA to facilitate an efficient development program for, and expedite review of regenerative medicine advanced therapies (&#8220;RMATs&#8221;), which include cell and gene therapies, therapeutic tissue engineering products, human cell and tissue products, and combination products using any such therapies or products. RMATs do not include those human cells, tissues, and cellular and tissue-based products regulated solely under section 361 of the PHSA and 21 CFR Part 1271. This program is intended to facilitate efficient development and expedite review of regenerative medicine therapies, which are intended to treat, modify, reverse, or cure a serious or life-threatening disease or condition and qualify for RMAT designation. A drug sponsor may request that the FDA designate a drug as a RMAT concurrently with or at any time after submission of an IND although ideally no later than the end-of-Phase 2 meeting. The FDA has 60 calendar days to determine whether the therapy meets the criteria, including whether there is preliminary clinical evidence indicating that the product has the potential to address unmet medical needs for a serious or life-threatening disease or condition. A BLA for a regenerative medicine therapy that has received RMAT </div></div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">233 </div></div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;;font-weight: bold;"><a href="#toc">Table of Contents</a></div> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">designation may be eligible for priority review or accelerated approval through use of surrogate or intermediate endpoints reasonably likely to predict long-term clinical benefit, or reliance upon data obtained from a meaningful number of sites. Benefits of RMAT designation also include early interactions with FDA to discuss any potential surrogate or intermediate endpoint to be used to support accelerated approval. A regenerative medicine therapy with RMAT designation that is granted accelerated approval and is subject to post-approval requirements may fulfill such requirements through the submission of clinical evidence from clinical studies, patient registries, or other sources of real-world evidence, such as electronic health records; the collection of larger confirmatory data sets; or post-approval monitoring of all patients treated with such therapy prior to its approval. </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The FDA has also announced the availability of the RTOR pilot program for oncology product candidates that are likely to demonstrate substantial improvements over available therapy, which may include drugs previously granted breakthrough therapy designation for the same or other indications and candidates meeting other criteria for other expedited programs, such as fast track and priority review. Submissions for RTOR consideration should also have straightforward study designs and endpoints that can be easily interpreted (such as overall survival or progression free survival). Acceptance into the RTOR pilot does not guarantee or influence approvability of the application, which is subject to the usual benefit-risk evaluation by FDA reviewers, but the program allows FDA to review data earlier, before an applicant formally submits a complete application. The RTOR pilot program does not affect FDA&#8217;s PDUFA timelines. </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Even if a product qualifies for one or more of these programs, the FDA may later decide that the product no longer meets the conditions for qualification or the time period for FDA review or approval may not be shortened. Furthermore, fast track designation, priority review, accelerated approval, breakthrough therapy and RMAT designation do not change the standards for approval. </div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt; margin-left: 2%;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Pediatric Information and Pediatric Exclusivity </div></div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;">Under the Pediatric Research Equity Act (the &#8220;PREA&#8221;), certain NDAs and BLAs and certain supplements to an NDA or BLA must contain data to assess the safety and efficacy of the drug for the claimed indications in all relevant pediatric subpopulations and to support dosing and administration for each pediatric subpopulation for which the product is safe and effective. The FDA may grant deferrals for submission of pediatric data or full or partial waivers. The Food and Drug Administration Safety and Innovation Act (the &#8220;FDASIA&#8221;), amended the FDCA to require that a sponsor who is planning to submit a marketing application for a drug that includes a new active ingredient, new indication, new dosage form, new dosing regimen or new route of administration submit an initial Pediatric Study Plan (&#8220;PSP&#8221;), within 60 days of an <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">end-of-Phase</div></div> 2 meeting or, if there is no such meeting, as early as practicable before the initiation of the Phase 3 or Phase 2/3 study. The initial PSP must include an outline of the pediatric study or studies that the sponsor plans to conduct, including study objectives and design, age groups, relevant endpoints and statistical approach, or a justification for not including such detailed information, and any request for a deferral of pediatric assessments or a full or partial waiver of the requirement to provide data from pediatric studies along with supporting information. The FDA and the sponsor must reach an agreement on the PSP. A sponsor can submit amendments to an agreed-upon initial PSP at any time if changes to the pediatric plan need to be considered based on data collected from preclinical studies, early phase clinical trials and/or other clinical development programs. </div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">A drug or biologic product can also obtain pediatric market exclusivity in the United States. Pediatric exclusivity, if granted, adds six months to existing exclusivity periods and patent terms. This <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">six-month</div> exclusivity, which runs from the end of other exclusivity protection or patent term, may be granted based on the voluntary completion of a pediatric study in accordance with an <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">FDA-issued</div> &#8220;Written Request&#8221; for such a study. </div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt; margin-left: 2%;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Post-Marketing Requirements </div></div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Following approval of a new product, the manufacturer and the approved product are subject to continuing regulation by the FDA, including, among other things, monitoring and record-keeping activities, reporting of </div></div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">234 </div></div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;;font-weight: bold;"><a href="#toc">Table of Contents</a></div> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">adverse experiences and certain problems in the manufacturing process, complying with promotion and advertising requirements, which include restrictions on promoting products for unapproved uses or patient populations (known as <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">&#8220;off-label</div> use&#8221;) and limitations on industry-sponsored scientific and educational activities. Although physicians may prescribe legally available products for <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">off-label</div> uses, manufacturers may not market or promote such uses. The FDA and other agencies actively enforce the laws and regulations prohibiting the promotion of <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">off-label</div> uses and any promotion that is false or misleading, and a company that is found to have improperly promoted <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">off-label</div> uses or in a false or misleading manner may be subject to significant liability, including investigation by federal and state authorities. Prescription drug promotional materials must be submitted to the FDA in conjunction with their first use or first publication. Further, if there are any modifications to the drug or biologic, including changes in indications, labeling or manufacturing processes or facilities, the applicant may be required to submit and obtain FDA approval of a new NDA/BLA or NDA/BLA supplement, which may require the development of additional data or preclinical studies and clinical trials. </div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">The FDA may also place other conditions on approvals including the requirement for a REMS, to assure the safe use of the product. If the FDA concludes a REMS is needed, the sponsor of the NDA or BLA must submit a proposed REMS. The FDA will not approve the NDA or BLA without an approved REMS, if required. A REMS could include medication guides, physician communication plans or elements to assure safe use, such as restricted distribution methods, patient registries and other risk minimization tools. Any of these limitations on approval or marketing could restrict the commercial promotion, distribution, prescription or dispensing of products. Product approvals may be withdrawn for <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-compliance</div> with regulatory standards or if problems occur following initial marketing. </div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">FDA regulations require that products be manufactured in specific approved facilities and in accordance with cGMP regulations. We rely, and expect to continue to rely, on third parties for the production of clinical and commercial quantities of our products in accordance with cGMP regulations. These manufacturers must comply with cGMP regulations that require, among other things, quality control and quality assurance, the maintenance of records and documentation and the obligation to investigate and correct any deviations from cGMP. Manufacturers and other entities involved in the manufacture and distribution of approved drugs or biologics are required to register their establishments with the FDA and certain state agencies, and are subject to periodic unannounced inspections by the FDA and certain state agencies for compliance with cGMP requirements and other laws. Accordingly, manufacturers must continue to expend time, money and effort in the area of production and quality control to maintain cGMP compliance. The discovery of violative conditions, including failure to conform to cGMP regulations, could result in enforcement actions, and the discovery of problems with a product after approval may result in restrictions on a product, manufacturer or holder of an approved NDA or BLA, including recall. </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Once an approval is granted, the FDA may issue enforcement letters or withdraw the approval of the product if compliance with regulatory requirements and standards is not maintained or if problems occur after the drug or biologic reaches the market. Corrective action could delay drug or biologic distribution and require significant time and financial expenditures. Later discovery of previously unknown problems with a drug or biologic, including AEs of unanticipated severity or frequency, or with manufacturing processes, or failure to comply with regulatory requirements, may result in revisions to the approved labeling to add new safety information; imposition of post-market studies or clinical trials to assess new safety risks; or imposition of distribution or other restrictions under a REMS program. Other potential consequences include, among other things: </div></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">restrictions on the marketing or manufacturing of the drug or biologic, suspension of the approval, complete withdrawal of the drug from the market or product recalls; </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">fines, warning letters or holds on post-approval clinical trials; </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">refusal of the FDA to approve applications or supplements to approved applications, or suspension or revocation of drug or biologic approvals; </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">235 </div></div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;;font-weight: bold;"><a href="#toc">Table of Contents</a></div> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;">
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">drug or biologic seizure or detention, or refusal to permit the import or export of drugs; or </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">injunctions or the imposition of civil or criminal penalties; or </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">debarment from producing or marketing drug products or biologics. </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt; margin-left: 2%;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Regulation of Companion Diagnostics </div></div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;">Success of certain product candidates may depend, in part, on the development and commercialization of a companion diagnostic. A companion diagnostic is a medical device, often an <div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">in vitro</div></div> device, which provides information that is essential for the safe and effective use of a corresponding drug or biological product. Companion diagnostics can identify patients who are most likely to benefit from a particular therapeutic product; identify patients likely to be at increased risk for serious side effects as a result of treatment with a particular therapeutic product; or monitor response to treatment with a particular therapeutic product for the purpose of adjusting treatment to achieve improved safety or effectiveness. Companion diagnostics are generally regulated as medical devices by the FDA. In the United States, the FDCA and its implementing regulations, and other federal and state statutes and regulations govern, among other things, medical device design and development, preclinical and clinical testing, premarket clearance or approval, registration and listing, manufacturing, labeling, storage, advertising and promotion, sales and distribution, export and import, and post-market surveillance. Unless an exemption or FDA exercise of enforcement discretion applies, diagnostic tests generally require marketing clearance through the premarket notification process (&#8220;510(k) clearance&#8221;) or premarket approval from the FDA prior to commercialization. </div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">To obtain 510(k) clearance for a medical device, or for certain modifications to devices that have received 510(k) clearance, a manufacturer must submit a premarket notification demonstrating that the proposed device is substantially equivalent to a previously cleared 510(k) device or to a preamendment device that was in commercial distribution before May&#160;28, 1976, or a predicate device, for which the FDA has not yet called for the submission of a premarket approval application (&#8220;PMA&#8221;). In making a determination that the device is substantially equivalent to a predicate device, the FDA compares the proposed device to the predicate device or predicate devices and assesses whether the subject device is comparable to the predicate device or predicate devices with respect to intended use, technology, design and other features which could affect safety and effectiveness. If the FDA determines that the subject device is substantially equivalent to the predicate device or predicate devices, the subject device may be cleared for marketing. The 510(k) premarket notification pathway generally takes from three to twelve months from the date the application is completed, but can take significantly longer. </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">PMA applications must be supported by valid scientific evidence, which typically requires extensive data, including technical, preclinical, clinical and manufacturing data, to demonstrate to the FDA&#8217;s satisfaction the safety and effectiveness of the device. For diagnostic tests, a PMA, typically includes data regarding analytical and clinical validation studies. As part of its review of the PMA, the FDA will typically conduct a <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">pre-approval</div> inspection of the manufacturing facility or facilities to ensure compliance with the Quality System Regulation (the &#8220;QSR&#8221;), which requires manufacturers to follow design, testing, control, corrective and preventative action, documentation, and other quality assurance procedures. The FDA&#8217;s review of an initial PMA application is generally required by statute to take six months, although the process typically takes longer, and may require several years to complete. If the FDA evaluations of both the PMA application and the manufacturing facilities are favorable, the FDA will either issue an approval letter or an approvable letter, which usually contains a number of conditions that must be met in order to secure the final approval of the PMA. If the FDA&#8217;s evaluation of the PMA or manufacturing facilities is not favorable, the FDA will deny the approval of the PMA or issue a not approvable letter. A not approvable letter will outline the deficiencies in the application and, where practical, will identify what is necessary to make the PMA approvable. Once granted, PMA approval may be withdrawn by the FDA if compliance with post-approval requirements, conditions of approval or other regulatory standards is not maintained or problems are identified following initial marketing. Once cleared or approved, the companion diagnostic device must adhere to post-marketing requirements including the requirements of FDA&#8217;s quality system regulation, adverse event reporting, recalls and </div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">236 </div></div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;;font-weight: bold;"><a href="#toc">Table of Contents</a></div> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">corrections along with product marketing requirements and limitations. Like drug and biologic makers, companion diagnostic makers are subject to unannounced FDA inspections at any time during which the FDA is able to conduct an inspection of the product(s) and the company&#8217;s facilities for compliance with its authorities. </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">FDA has taken the position that developers of companion diagnostic tests associated with novel therapeutic products should seek clearance or approval at the same time that the therapeutic developer seeks approval. FDA has recognized that contemporaneous clearance or approval of a companion diagnostic with a therapeutic is not always possible, though FDA has indicated that coordination of contemporaneous clearances/approvals is a policy goal. In October 2018, FDA issued a safety alert warning against the use of unapproved or uncleared genetic tests to predict patient response to specific medications. While FDA has historically exercised enforcement discretion against laboratory developed tests&#8212;tests which are developed and performed in a single Clinical Laboratory Improvement Amendments (CLIA) certified laboratory&#8212;the 2018 alert and a subsequent 2019 Warning Letter against Inova Genomics Laboratory suggest that FDA may prioritize for enforcement certain uncleared or unapproved tests marketed as companion diagnostic tests. Subsequently, FDA has attempted to encourage collaboration between <div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">in vitro </div></div>diagnostic test developers and therapeutic developers and to clarify FDA expectations as to companion diagnostic labeling, particularly through guidance in the oncology area. In June 2021, the Verifying Accurate Leading-edge IVCT Development Act of 2021 (the &#8220;VALID Act&#8221;) was introduced in the U.S. House of Representatives and Senate. Similar to the 2020 iteration of the bill, among other things, the VALID Act would likely classify all companion diagnostic tests as requiring FDA premarket review and would formalize and arguably expand FDA&#8217;s regulatory authority over diagnostic testing. Though passage of the VALID Act is uncertain, strong bipartisan support remains for some kind of diagnostic testing legislative reform in the near term. </div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt; margin-left: 2%;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Biosimilars and Exclusivity </div></div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;">Certain of our product candidates, including IMVT-1401 and <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">ARU-1801,</div> are regulated as biologics. An abbreviated approval pathway for biological products shown to be similar to, or interchangeable with, an <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">FDA-licensed</div> reference biological product was created by the Biologics Price Competition and Innovation Act of 2009 (the &#8220;BPCI Act&#8221;), as part of the Affordable Care Act (the &#8220;ACA&#8221;). This amendment to the PHSA, in part, attempts to minimize duplicative testing. Biosimilarity, which requires that the biological product be highly similar to the reference product notwithstanding minor differences in clinically inactive components and that there be no clinically meaningful differences between the product and the reference product in terms of safety, purity and potency, can be shown through analytical studies, animal studies and a clinical trial or trials. Interchangeability requires that a biological product be biosimilar to the reference product and that the product can be expected to produce the same clinical results as the reference product in any given patient and, for products administered multiple times to an individual, that the product and the reference product may be alternated or switched after one has been previously administered without increasing safety risks or risks of diminished efficacy relative to exclusive use of the reference biological product without such alternation or switch. Complexities associated with the larger, and often more complex, structure of biological products as compared to small molecule drugs, as well as the processes by which such products are manufactured, pose significant hurdles to implementation that are still being worked out by the FDA. </div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">A reference biological product is granted four and twelve year exclusivity periods from the time of first licensure of the product. The FDA will not accept an application for a biosimilar or interchangeable product based on the reference biological product until four years after the date of first licensure of the reference product, and the FDA will not approve an application for a biosimilar or interchangeable product based on the reference biological product until twelve years after the date of first licensure of the reference product. &#8220;First licensure&#8221; typically means the initial date the particular product at issue was licensed in the United States. Date of first licensure does not include the date of licensure of (and a new period of exclusivity is not available for) a biological product if the licensure is for a supplement for the biological product or for a subsequent application by the same sponsor or manufacturer of the biological product (or licensor, predecessor in interest, or other related entity) for a change (not including a modification to the structure of the biological product) that results in </div></div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">237 </div></div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;;font-weight: bold;"><a href="#toc">Table of Contents</a></div> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">a new indication, route of administration, dosing schedule, dosage form, delivery system, delivery device or strength, or for a modification to the structure of the biological product that does not result in a change in safety, purity, or potency. Therefore, one must determine whether a new product includes a modification to the structure of a previously licensed product that results in a change in safety, purity, or potency to assess whether the licensure of the new product is a first licensure that triggers its own period of exclusivity. Whether a subsequent application, if approved, warrants exclusivity as the &#8220;first licensure&#8221; of a biological product is determined on a <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">case-by-case</div></div> basis with data submitted by the sponsor. </div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt; margin-left: 2%;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Other Regulatory Matters </div></div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Manufacturing, sales, promotion and other activities following product approval are also subject to regulation by numerous regulatory authorities in the United States in addition to the FDA, including the Centers for Medicare and Medicaid Services (the &#8220;CMS&#8221;), the Office of Inspector General and Office for Civil Rights, other divisions of the Department of HHS, the Department of Justice, the Drug Enforcement Administration, the Consumer Product Safety Commission, the Federal Trade Commission, the Occupational Safety&#160;&amp; Health Administration, the Environmental Protection Agency and state and local governments. </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Healthcare providers, physicians, and third-party payors will play a primary role in the recommendation and prescription of any products for which we obtain marketing approval. Our current and future arrangements with healthcare providers and physicians and any future arrangements with third party payers, may expose us to broadly applicable fraud and abuse and other healthcare laws and regulations that may constrain the business or financial arrangements and relationships through which we market, sell and distribute any drugs for which we obtain marketing approval. In the United States, these laws include: the federal Anti-Kickback Statute, the False Claims Act, and HIPAA. </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The Anti-Kickback Statute makes it illegal for any person, including a prescription drug manufacturer (or a party acting on its behalf), to knowingly and willfully solicit, receive, offer or pay any remuneration, directly or indirectly, in cash or in kind, that is intended to induce or reward referrals, including the purchase, recommendation, order or prescription of a particular drug, for which payment may be made under a federal healthcare program, such as Medicare or Medicaid. Violations of this law are punishable by imprisonment, criminal fines, administrative civil money penalties and exclusion from participation in federal healthcare programs. In addition, a person or entity does not need to have actual knowledge of the statute or specific intent to violate it. Moreover, the ACA provides that the government may assert that a claim including items or services resulting from a violation of the federal Anti-Kickback Statute constitutes a false or fraudulent claim for purposes of the federal civil False Claims Act. </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">Drug manufacturers can be held liable under the federal civil False Claims Act, which imposes civil penalties, including through civil whistleblower or qui tam actions, against individuals or entities (including manufacturers) for, among other things, knowingly presenting, or causing to be presented to federal programs (including Medicare and Medicaid) claims for items or services, including drugs, that are false or fraudulent, claims for items or services not provided as claimed, or claims for medically unnecessary items or services. Penalties for a False Claims Act violation include three times the actual damages sustained by the government, plus mandatory civil penalties for each separate false claim, the potential for exclusion from participation in federal healthcare programs and, although the federal False Claims Act is a civil statute, conduct that results in a False Claims Act violation may also implicate various federal criminal statutes. The government may deem manufacturers to have &#8220;caused&#8221; the submission of false or fraudulent claims by, for example, providing certain billing or coding information to customers or promoting a product <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">off-label.</div> Claims which include items or services resulting from a violation of the federal Anti-Kickback Statute are false or fraudulent claims for purposes of the False Claims Act. Our future marketing and activities relating to federal, state, and commercial reimbursement for our products, and the sale and marketing of our product candidates, are subject to scrutiny under this law. </div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">238 </div></div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;;font-weight: bold;"><a href="#toc">Table of Contents</a></div> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">HIPAA created federal criminal statutes that prohibit among other things, knowingly and willfully executing, or attempting to execute, a scheme to defraud or to obtain, by means of false or fraudulent pretenses, representations or promises, any money or property owned by, or under the control or custody of, any healthcare benefit program, including private third party payors, knowingly and willfully embezzling or stealing from a healthcare benefit program, willfully obstructing a criminal investigation of a healthcare offense, and knowingly and willfully falsifying, concealing or covering up by trick, scheme or device, a material fact or making any materially false, fictitious or fraudulent statement in connection with the delivery of or payment for healthcare benefits, items or services. Like the federal Anti-Kickback Statute a person or entity does not need to have actual knowledge of the statute or specific intent to violate it in order to have committed a violation. </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The civil monetary penalties statute imposes penalties against any person or entity that, among other things, is determined to have presented or caused to be presented a claim to a federal health program that the person knows or should know is for an item or service that was not provided as claimed or is false or fraudulent. </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">We are subject to data privacy and security regulations administered and enforced by the federal government as well as statutes and regulations adopted in the states in which we conduct our business. At the federal level, the data privacy and security regulations implementing HIPAA, as amended by the Health Information and Technology for Economic and Clinical Health Act, mandate, among other things, compliance with standards relating to the privacy and security of individually identifiable health information, which requires, among other things, the adoption of administrative, physical and technical safeguards to protect such information. Civil and criminal penalties may be imposed on entities subject to HIPAA, both by the HHS Office for Civil Rights and by state attorneys general, who have the authority to file civil actions for damages or injunctions in federal courts to enforce the HIPAA privacy and security regulations and to seek attorney&#8217;s fees and costs associated with pursuing such actions. In addition, certain state laws govern the privacy and security of health information in certain circumstances, some of which are more stringent than HIPAA and many of which differ from each other in significant ways and may not have the same effect, thus complicating compliance efforts. Failure to comply with these laws, where applicable, can result in the imposition of significant civil and criminal penalties. Further, the states are rapidly expanding their data privacy and security laws and we may be subject to a variety of different restrictions and requirements under such laws. </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">Additionally, the federal Physician Payments Sunshine Act (the &#8220;Sunshine Act&#8221;), within the ACA, and its implementing regulations, require that certain manufacturers of drugs, devices, biological and medical supplies for which payment is available under Medicare, Medicaid or the Children&#8217;s Health Insurance Program (with certain exceptions) report annually to CMS information related to certain payments or other transfers of value made or distributed to physicians and teaching hospitals, or to entities or individuals at the request of, or designated on behalf of, physicians, certain other healthcare professionals, and teaching hospitals and to report annually certain ownership and investment interests held by physicians, certain other healthcare professionals, and their immediate family members. Effective January&#160;1, 2022, these reporting obligations will extend to include transfers of value made to certain <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-physician</div> providers such as physician assistants and nurse practitioners. In addition, many states also govern the reporting of payments or other transfers of value, many of which differ from each other in significant ways, are often not preempted, and may have a more prohibitive effect than the Sunshine Act, thus further complicating compliance efforts. </div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Similar federal, state and foreign fraud and abuse laws and regulations, such as state anti-kickback and false claims laws, may apply to sales or marketing arrangements and claims involving healthcare items or services. Such laws are generally broad and are enforced by various state agencies and private actions. Also, many states have similar fraud and abuse statutes or regulations that may be broader in scope and may apply regardless of payor, in addition to items and services reimbursed under Medicaid and other state programs. Some state laws require pharmaceutical companies to comply with the pharmaceutical industry&#8217;s voluntary compliance guidelines and the relevant federal government compliance guidance, and require drug manufacturers to report information related to payments and other transfers of value to physicians and other healthcare providers or marketing expenditures. </div></div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">239 </div></div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;;font-weight: bold;"><a href="#toc">Table of Contents</a></div> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">In order to distribute products commercially, we must comply with state laws that require the registration of manufacturers and wholesale distributors of drug and biological products in a state, including, in certain states, manufacturers and distributors who ship products into the state even if such manufacturers or distributors have no place of business within the state. Several states have enacted legislation requiring pharmaceutical and biotechnology companies to establish marketing compliance programs, file periodic reports with the state, make periodic public disclosures on sales, marketing, pricing, clinical trials and other activities, and/or register their sales representatives, as well as to prohibit pharmacies and other healthcare entities from providing certain physician prescribing data to pharmaceutical and biotechnology companies for use in sales and marketing, and to prohibit certain other sales and marketing practices. All of our activities are potentially subject to federal and state consumer protection and unfair competition laws. </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The scope and enforcement of each of these laws is uncertain and subject to rapid change in the current environment of healthcare reform, especially in light of the lack of applicable precedent and regulations. Federal and state enforcement bodies have recently increased their scrutiny of interactions between healthcare companies and healthcare providers, which has led to a number of investigations, prosecutions, convictions and settlements in the healthcare industry. It is possible that governmental authorities will conclude that our business practices may not comply with current or future statutes, regulations or case law involving applicable fraud and abuse or other healthcare laws and regulations. If our operations are found to be in violation of any of these laws or any other governmental regulations that may apply to us, we may be subject to significant civil, criminal and administrative penalties, damages, fines, disgorgement, contractual damages, reputational harm, diminished profits and future earnings, individual imprisonment, exclusion of drugs from government funded healthcare programs, such as Medicare and Medicaid, and the curtailment or restructuring of our operations, any of which could adversely affect our ability to operate our business and our financial results. If any of the physicians or other healthcare providers or entities with whom we expect to do business is found to be not in compliance with applicable laws, they may be subject to criminal, civil or administrative sanctions, including exclusions from government funded healthcare programs. Ensuring business arrangements comply with applicable healthcare laws, as well as responding to possible investigations by government authorities, can be time- and resource-consuming and can divert a company&#8217;s attention from the business. </div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt; margin-left: 2%;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Current and Future Legislation </div></div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">In the United States and some foreign jurisdictions, there have been, and likely will continue to be, a number of legislative and regulatory changes and proposed changes regarding the healthcare system directed at broadening the availability of healthcare, improving the quality of healthcare, and containing or lowering the cost of healthcare. </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">For example, in March 2010, the ACA was enacted in the United States. The ACA includes measures that have significantly changed, and are expected to continue to significantly change, the way healthcare is financed by both governmental and private insurers. Among the changes made by the ACA to preexisting law of importance to the pharmaceutical industry are that the ACA: </div></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">made several changes to the Medicaid Drug Rebate Program, including increasing pharmaceutical manufacturers&#8217; rebate liability by raising the minimum basic Medicaid rebate on most branded prescription drugs to 23.1% of average manufacturer price (&#8220;AMP&#8221;), and adding a new rebate calculation for &#8220;line extensions&#8221; (i.e., new formulations, such as extended release formulations) of solid oral dosage forms of branded products, as well as potentially impacting their rebate liability by modifying the statutory definition of AMP. </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;">imposed a requirement on manufacturers of branded drugs to provide a 70% (increased pursuant to the Bipartisan Budget Act of 2018, effective as of 2019) <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">point-of-sale</div></div> discount off the negotiated price of branded drugs dispensed to Medicare Part D beneficiaries in the coverage gap (i.e., &#8220;donut hole&#8221;) as a condition for a manufacturer&#8217;s outpatient drugs being covered under Medicare Part D. </div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">240 </div></div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;;font-weight: bold;"><a href="#toc" style="text-indent: 0px;">Table of Contents</a></div> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;">
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">extended a manufacturer&#8217;s Medicaid rebate liability to covered drugs dispensed to individuals who are enrolled in Medicaid managed care organizations. </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">expanded the entities eligible for discounts under the 340B Drug Discount Program. </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">established a new methodology by which rebates owed by manufacturers under the Medicaid Drug Rebate Program are calculated for drugs that are inhaled, infused, instilled, implanted, or injected. </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">imposed an annual, nondeductible fee on any entity that manufactures or imports certain branded prescription drugs, apportioned among these entities according to their market share in certain government healthcare programs. </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">established a new Patient-Centered Outcomes Research Institute to oversee, identify priorities in, and conduct comparative clinical effectiveness research, along with funding for such research. The research conducted by the Patient-Centered Outcomes Research Institute may affect the market for certain pharmaceutical products. The ACA established the Center for Medicare and Medicaid Innovation within CMS to test innovative payment and service delivery models to lower Medicare and Medicaid spending, potentially including prescription drug spending. </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Since its enactment, there have been numerous judicial, administrative, executive, and legislative challenges to certain aspects of the ACA, and we expect there will be additional challenges and amendments to the ACA in the future. Most recently, the Supreme Court upheld the constitutionality of the law in June 2021; however, future legal disputes remain possible. Additionally, Congress has introduced several pieces of legislation aimed at significantly revising or repealing the ACA, and the law may be subjected to various Executive Orders and/or regulatory action to expand or reduce the scope of the law, based on the administration controlling the White House. The implementation of the ACA is ongoing, and the law may continue to exert significant pressure on pharmaceutical pricing and our profitability. </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">Moreover, in May 2018, the Trump administration released its &#8220;Blueprint to Lower Drug Prices and Reduce <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">Out-of-Pocket</div></div> Costs,&#8221; or the Blueprint, and former President Trump also issued a number of Executive Orders in 2020 that were aimed at lowering the prices of prescription drugs. Some rules enacted under the Trump Administration have been stayed as a result of pending litigation or are under review or have been rescinded by the Biden Administration. For example, a rule enacted under the Trump Administration known as the &#8220;Most Favored Nations&#8221; rule would set Medicare Part B reimbursement at an amount no higher than the lowest price that a drug manufacturer receives on a particular product in an index of foreign countries. This rule currently was the subject of litigation, and was formally rescinded the Biden Administration in August 2021. Other initiatives under the Trump administration have taken effect. For example, in May 2019, CMS issued a final rule to allow Medicare Advantage Plans the option of using step therapy, a form of drug utilization management, for Part B drugs beginning January&#160;1, 2020. </div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">Other legislative changes have been proposed and adopted in the United States since the ACA was enacted. In August 2011, the Budget Control Act of 2011, among other things, created measures for spending reductions by Congress. A Joint Select Committee on Deficit Reduction, tasked with recommending a targeted deficit reduction of at least $1.2 trillion for the years 2013 through 2021, was unable to reach required goals, thereby triggering the legislation&#8217;s automatic reduction to several government programs. This includes aggregate reductions of Medicare payments to providers up to 2% per fiscal year, which went into effect in April 2013, following passage of the Bipartisan Budget Act of 2013, and will remain in effect through 2029 unless additional congressional action is taken. Pursuant to the CARES Act and subsequent legislation, these reductions were suspended from May&#160;1, 2020 through December&#160;31, 2021 due to the <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">COVID-19</div> pandemic. As the legislation currently stands, the reductions will go back into effect as of January 2022 and remain in effect through 2030 unless additional Congressional action is take, The American Rescue Plan Act of 2021 eliminates the Medicaid unit rebate cap effective as of January&#160;1, 2024, and the removal of this rebate cap could significantly impact our Medicaid rebate liability beginning in 2024. </div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">241 </div></div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;;font-weight: bold;"><a href="#toc">Table of Contents</a></div> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Specifically, there have been several recent U.S. Congressional inquiries and proposed bills designed to, among other things, require drug pricing negotiations in Medicare, redesign the Part D benefit to lower patient costs and overall spending, introduce enhanced transparency measures into drug pricing, and reform government program reimbursement methodologies for drugs, for example, by introducing inflationary penalties for Parts B and D drugs. The Biden Administration has indicated that lowering prescription drug prices is a priority. In July 2021, President Biden issued an executive order pertaining to drug pricing, which expressed support for legislation allowing direct negotiation in Medicare Part D and inflationary rebates, and directed various executive branch agencies to take actions to lower drug prices and promote generic competition. Additionally, Democratic leadership has elected to pursue drug pricing reform as a part of a broader legislative package encompassing President Biden&#8217;s Build Back Better reconciliation bill, which aims to incorporate components of H.R. 3 passed by the House of Representatives in 2020. In particular, H.R. 3 would require the federal government to negotiate the pricing for certain prescription drugs and set a cap on the price Medicare would pay that is tied to the price of the drug in other wealthy nations. Manufacturers also would face fines if their drug prices increase faster than the rate of inflation. The Build Back Better Act, as well as various other legislative proposals, also include reforms to redesign the Part D benefit to protect beneficiaries from high out-of-pocket costs and reduce overall program spending. We cannot predict whether these or other drug pricing initiatives will be adopted in the future. Further federal, state and foreign legislative and regulatory developments are likely, and we expect ongoing initiatives to increase pressure on drug pricing. Reforms could have an adverse effect on anticipated revenues from product candidates and may affect our overall financial condition and ability to develop product candidates. </div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt; margin-left: 2%;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Packaging and Distribution in the United States </div></div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">If our products are made available to authorized users of the Federal Supply Schedule of the General Services Administration, additional laws and requirements apply. Products must meet applicable child-resistant packaging requirements under the U.S. Poison Prevention Packaging Act. Manufacturing, sales, promotion and other activities also are potentially subject to federal and state consumer protection and unfair competition laws. </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The distribution of pharmaceutical products is subject to additional requirements and regulations, including extensive record-keeping, licensing, storage and security requirements intended to prevent the unauthorized sale of pharmaceutical products. </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The failure to comply with any of these laws or regulatory requirements subjects firms to possible legal or regulatory action. Depending on the circumstances, failure to meet applicable regulatory requirements can result in criminal prosecution, fines or other penalties, injunctions, exclusion from federal healthcare programs, requests for recall, seizure of products, total or partial suspension of production, denial or withdrawal of product approvals, or refusal to allow a firm to enter into supply contracts, including government contracts. Any action against us for violation of these laws, even if we successfully defend against it, could cause us to incur significant legal expenses and divert our management&#8217;s attention from the operation of our business. Prohibitions or restrictions on sales or withdrawal of future products marketed by us could materially affect our business in an adverse way. </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Changes in regulations, statutes or the interpretation of existing regulations could impact our business in the future by requiring, for example: (i)&#160;changes to our manufacturing arrangements; (ii)&#160;additions or modifications to product labeling; (iii)&#160;the recall or discontinuation of our products; or (iv)&#160;additional record-keeping requirements. If any such changes were to be imposed, they could adversely affect the operation of our business. </div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt; margin-left: 2%;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Other U.S. Environmental, Health and Safety Laws and Regulations </div></div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">We may be subject to numerous environmental, health and safety laws and regulations, including those governing laboratory procedures and the handling, use, storage, treatment and disposal of hazardous materials and wastes. From time to time and in the future, our operations may involve the use of hazardous and flammable materials, including chemicals and biological materials, and may also produce hazardous waste products. Even if </div></div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">242 </div></div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;;font-weight: bold;"><a href="#toc">Table of Contents</a></div> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">we contract with third parties for the disposal of these materials and waste products, we cannot completely eliminate the risk of contamination or injury resulting from these materials. In the event of contamination or injury resulting from the use or disposal of our hazardous materials, we could be held liable for any resulting damages, and any liability could exceed our resources. We also could incur significant costs associated with civil or criminal fines and penalties for failure to comply with such laws and regulations. </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">We maintain workers&#8217; compensation insurance to cover us for costs and expenses we may incur due to injuries to our employees, but this insurance may not provide adequate coverage against potential liabilities. However, we do not maintain insurance for environmental liability or toxic tort claims that may be asserted against us. </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">In addition, we may incur substantial costs in order to comply with current or future environmental, health and safety laws and regulations. Current or future environmental laws and regulations may impair our research, development or production efforts. In addition, failure to comply with these laws and regulations may result in substantial fines, penalties or other sanctions. </div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt; margin-left: 2%;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">U.S. Patent Term Restoration and Marketing Exclusivity </div></div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;">Depending upon the timing, duration and specifics of FDA approval of our future product candidates, some of our U.S. patents may be eligible for limited patent term extension under the Drug Price Competition and Patent Term Restoration Act of 1984, commonly referred to as the Hatch-Waxman Amendments. The Hatch-Waxman Amendments permit restoration of the patent term of up to five years as compensation for patent term lost during the FDA regulatory review process. Patent-term restoration, however, cannot extend the remaining term of a patent beyond a total of 14 years from the product&#8217;s approval date and only those claims covering such approved drug product, a method for using it or a method for manufacturing it may be extended. The patent-term restoration period is generally <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">one-half</div> the time between the effective date of an IND and the submission date of an NDA or BLA plus the time between the submission date of an NDA or BLA and the approval of that application, except that the review period is reduced by any time during which the applicant failed to exercise due diligence. Only one patent applicable to an approved drug is eligible for the extension and the application for the extension must be submitted prior to the expiration of the patent. The USPTO, in consultation with the FDA, reviews and approves the application for any patent term extension or restoration. In the future, we may apply for restoration of patent term for our currently owned or licensed patents to add patent life beyond its current expiration date, depending on the expected length of the clinical trials and other factors involved in the filing of the relevant NDA or BLA. </div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">Marketing exclusivity provisions under the FDCA also can delay the submission or the approval of certain applications. The FDCA provides a five-year period of <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-patent</div> marketing exclusivity within the United States to the first applicant to gain approval of an NDA for a new chemical entity. A drug is a new chemical entity if the FDA has not previously approved any other new drug containing the same active moiety, which is the molecule or ion responsible for the action of the drug substance. During the exclusivity period, the FDA may not accept for review an ANDA, or a 505(b)(2) NDA submitted by another company for another version of such drug where the applicant does not own or have a legal right of reference to all the data required for approval. However, an application may be submitted after four years if it contains a certification of patent invalidity or <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-infringement.</div> The FDCA also provides three years of marketing exclusivity for an NDA, 505(b)(2) NDA or supplement to an existing NDA if new clinical investigations, other than bioavailability studies, that were conducted or sponsored by the applicant are deemed by the FDA to be essential to the approval of the application, for example, new indications, dosages or strengths of an existing drug. This three-year exclusivity covers only the conditions of use associated with the new clinical investigations and does not prohibit the FDA from approving ANDAs for drugs containing the original active agent. Five-year and three-year exclusivity will not delay the submission or approval of a full NDA. However, an applicant submitting a full NDA would be required to conduct or obtain a right of reference to all of the preclinical studies and adequate and well-controlled clinical trials necessary to demonstrate safety and effectiveness. </div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">243 </div></div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;;font-weight: bold;"><a href="#toc">Table of Contents</a></div> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 2%;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">European Union and United Kingdom Drug Development </div></div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">In the European Union and European Economic Area and United Kingdom, our future products also may be subject to extensive regulatory requirements. As in the United States, medicinal products can be marketed only if a marketing authorization from the competent regulatory agencies has been obtained. </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Similar to the United States, the various phases of preclinical and clinical research in the European Union and European Economic Area and United Kingdom are subject to significant regulatory controls. Although the EU Clinical Trials Directive 2001/20/EC (the &#8220;Directive&#8221;), has sought to harmonize the EU clinical trials regulatory framework, setting out common rules for the control and authorization of clinical trials in the EU, the EU Member States have transposed and applied the provisions of the Directive differently into their national laws, including in the UK. This has led to significant variations in the Member State regimes. Under the current regime, before a clinical trial can be initiated it must be approved in each of the EU/UK countries where the trial is to be conducted by two distinct bodies: the National Competent Authority (the &#8220;NCA&#8221;), and one or more Ethics Committees (&#8220;ECs&#8221;). Under the current regime all suspected unexpected serious adverse reactions to the investigated drug that occur during the clinical trial have to be reported to the NCA and ECs of the country where they occurred. </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The EU clinical trials legislation currently is undergoing a transition process mainly aimed at harmonizing and streamlining clinical trial authorization, simplifying adverse-event reporting procedures, improving the supervision of clinical trials and increasing their transparency. In April 2014, the EU adopted a new Clinical Trials Regulation (EU) No 536/2014 (the &#8220;Regulation&#8221;), which is set to replace the current Directive. Specifically, the new Regulation, which will be directly applicable in all Member States without the need for EU Member States to transpose it into national law, aims at simplifying and streamlining the approval of clinical trials in the EU. For instance, the new Regulation provides for a streamlined application procedure via a single entry point and strictly defined deadlines for the assessment of clinical trial applications. Following confirmation of full functionality of the Clinical Trials Information System, the centralized EU portal and database for clinical trials foreseen by the Regulation, through an independent audit, the System will go live at the end of Janurary 2022. This Regulation will not be applicable in the UK. </div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt; margin-left: 2%;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">European Union and United Kingdom Drug Marketing </div></div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Much like the federal Anti-Kickback Statue prohibition in the United States, the provision of benefits or advantages to physicians to induce or encourage the prescription, recommendation, endorsement, purchase, supply, order or use of medicinal products is also prohibited in the European Union and European Economic Area and United Kingdom. The provision of benefits or advantages to induce or reward improper performance generally is governed by Directive 2001/83/EC as implemented in the relevant country, the national anti-bribery laws of the European Union Member States, and the Bribery Act 2010 in the UK, as well as the industry Codes of Practice that are based on the European Federation of Pharmaceutical Industries and Associations (EFPIA) Code of Practice. Infringement of these laws could result in substantial fines and imprisonment. EU Directive 2001/83/EC, which is the Directive governing medicinal products for human use, further provides that, where medicinal products are being promoted to persons qualified to prescribe or supply them, no gifts, pecuniary advantages or benefits in kind may be supplied, offered or promised to such persons unless they are inexpensive and relevant to the practice of medicine or pharmacy. This provision has been transposed into the national laws of the EU Member States, as well as in the Human Medicines Regulations 2012 and so remains applicable in the UK despite its departure from the EU. </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Depending on the applicable national rules in the EU Member States and the UK, payments and other transfers of value made to physicians, physician associations, medical students, healthcare organizations, patient organizations and other stakeholders in the EU Member States, the UK and Member States of the European Economic Area must be publicly disclosed. Moreover, agreements with physicians often must be the subject of prior notification and approval by the physician&#8217;s employer, his or her competent professional organization and/or the regulatory authorities of the individual country. These requirements are provided in the national laws, </div></div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">244 </div></div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;;font-weight: bold;"><a href="#toc">Table of Contents</a></div> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">industry codes or professional codes of conduct, applicable in the relevant country. Failure to comply with these requirements could result in reputational risk, public reprimands, administrative penalties, fines or imprisonment. </div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt; margin-left: 2%;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">European Union and United Kingdom Drug Review and Approval </div></div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">In the European Economic Area (the &#8220;EEA&#8221;), which is comprised of the Member States of the European Union plus Norway, Iceland and Liechtenstein, medicinal products can only be commercialized after obtaining a marketing authorization (&#8220;MA&#8221;). There are two types of marketing authorizations which, however, are based on identical regulatory rules, requirements and timelines, including identical requirements concerning the presentation and content of the application for marketing authorization. </div></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The centralized MA is issued by the European Commission through the centralized procedure, based on the opinion of the Committee for Medicinal Products for Human Use (the &#8220;CHMP&#8221;), of the EMA, and is valid throughout the entire territory of the EEA. The centralized procedure is mandatory for certain types of products, such as biotechnology medicinal products, orphan medicinal products, advanced-therapy medicinal products (gene-therapy, somatic cell-therapy or tissue-engineered medicines) and medicinal products containing a new active substance indicated for the treatment of HIV, AIDS, cancer, neurodegenerative disorders, diabetes, auto-immune and other immune dysfunctions and viral diseases. The centralized procedure is optional for products containing a new active substance not yet authorized in the EEA, or for products that constitute a significant therapeutic, scientific or technical innovation or which are in the interest of public health in the EEA. </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt; margin-left: 9%;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Under the centralized procedure the maximum timeframe for the evaluation of a marketing authorization application (a &#8220;MAA&#8221;), by the EMA is 210 days, excluding clock stops, when additional written or oral information is to be provided by the applicant in response to questions asked by the CHMP. Clock stops may extend the timeframe of evaluation of a MAA considerably beyond 210 days. Where the CHMP gives a positive opinion, it provides the opinion together with supporting documentation to the European Commission, who make the final decision to grant a marketing authorization, which is issued within 67 days of receipt of the EMA&#8217;s recommendation. Accelerated assessment might be granted by the CHMP in exceptional cases, when a medicinal product is expected to be of major public health interest, particularly from the point of view of therapeutic innovation. The timeframe for the evaluation of a MAA under the accelerated assessment procedure is 150 days, excluding clock stops, but it is possible that the CHMP may revert to the standard time limit for the centralized procedure if it determines that the application is no longer appropriate to conduct an accelerated assessment. </div></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">National MAs, which are issued by the competent authorities of the Member States of the EEA and only cover their respective territory, are available for products not falling within the mandatory scope of the centralized procedure. If a product is to be authorized in more than one Member State, the assessment procedure is coordinated between the relevant EU Member States. Where a product has already been authorized for marketing in a Member State of the EEA, the national MA can be recognized in another Member States through the mutual recognition procedure. If the product has not received a national MA in any Member State at the time of application, it can be approved simultaneously in various Member States through the decentralized procedure. Under the decentralized procedure an identical dossier is submitted to the competent authorities of each of the Member States in which the MA is sought, one of which is selected by the applicant as the Reference Member State (the &#8220;RMS&#8221;). The competent authority of the RMS coordinates the preparation of a draft assessment report, a draft summary of the product characteristics (the &#8220;SmPC&#8221;), and a draft of the labeling and package leaflet, which are sent to the other Member States (referred to as the Concerned Member States) for their final approval. If the Concerned Member States raise no objections, based on a potential serious risk to public health, to the assessment, SmPC, labeling, or packaging circulated by the RMS, the coordinated procedures is closed, and the product is subsequently granted a national MA in all the Member States (i.e., in the RMS and the Concerned Member States). </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">245 </div></div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;;font-weight: bold;"><a href="#toc">Table of Contents</a></div> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Under the above-described procedures, during the assessment of the documents submitted in the MAA and before granting the MA, the EMA or the competent authorities of the Member States of the EEA make an assessment of the risk-benefit balance of the product on the basis of scientific criteria concerning its quality, safety and efficacy. </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Now that the United Kingdom (which comprises Great Britain and Northern Ireland) has left the European Union, Great Britain will no longer be covered by centralized MAs (under the Northern Irish Protocol of the Withdrawal Agreement, centralized MAs will continue to apply in Northern Ireland). All medicinal products with a valid centralized MA as of December&#160;31, 2020, were automatically converted to Great Britain MAs on January, 1 2021 (unless the MA holder opted out of this procedure). For a period of two years from January&#160;1, 2021, the Medicines and Healthcare products Regulatory Agency (the &#8220;MHRA&#8221;), the UK medicines regulator, may rely on a decision taken by the European Commission on the approval of a new MA in the centralized procedure, in order to more quickly grant a new Great Britain MA. A separate application will, however, still be required. The MHRA also has the power to have regard to MAs approved in EEA Member States through decentralized or mutual recognition procedures with a view to more quickly granting a MA in the United Kingdom or Great Britain. </div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt; margin-left: 2%;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">European Union and United Kingdom New Chemical Entity Exclusivity </div></div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;">In the EEA and UK, innovative medicinal products, approved on the basis of a full dossier of preclinical and clinical data as part of the MAA, qualify for eight years of data exclusivity upon marketing authorization and an additional two years of market exclusivity. The data exclusivity, if granted, prevents generic or biosimilar applicants from referencing the innovator&#8217;s <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">pre-clinical</div> and clinical trial data contained in the dossier of the reference innovative product when applying for a generic or biosimilar MA in the EEA/UK, for a period of eight years from the date of authorization of the reference product. During the additional <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">two-year</div> period of market exclusivity, a generic or biosimilar marketing authorization application can be submitted, and the innovator&#8217;s data may be referenced, but no generic or biosimilar product can be marketed until the expiration of the market exclusivity. The overall <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">ten-year</div> period can be extended to a maximum of 11 years if, during the first eight years of those ten years, the marketing authorization holder obtains an authorization for one or more new therapeutic indications which, during the scientific evaluation prior to their authorization, are determined to bring a significant clinical benefit in comparison with currently approved therapies. Even if an innovative medicinal product gains the prescribed period of data exclusivity, however, another company may market another version of the product if such company obtained a MA based on a marketing authorization application with a complete independent data package of pharmaceutical tests, preclinical tests and clinical trials (i.e. without cross-referencing to the data within the reference innovative product). </div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt; margin-left: 2%;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">European Union and United Kingdom Orphan Designation and Exclusivity </div></div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">In the EEA, the EMA&#8217;s Committee for Orphan Medicinal Products grants orphan drug designation to promote the development of products that are intended for the diagnosis, prevention or treatment of life-threatening or chronically debilitating conditions and either (i)&#160;such condition affects not more than five in 10,000 persons in the EEA, or (ii)&#160;it is unlikely that the development of the medicine would generate sufficient return to justify the necessary investment in its development. In either case, the applicant must also demonstrate that no satisfactory method of diagnosis, prevention or treatment has been authorized (or, if a method exists, the product would be a significant benefit to those affected compared to the product available). </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">In the EEA, orphan drug designation entitles a party to financial incentives such as reduction of fees or fee waivers. In addition, if the criteria for orphan designation are found to be maintained at the time of authorization of the product, ten years of market exclusivity is granted following grant of an orphan marketing authorization. During this market exclusivity period, neither the EMA nor the European Commission nor any of the competent authorities in the EEA Members States can accept an application or grant a marketing authorization for a &#8220;similar medicinal product&#8221; for the same indication. A &#8220;similar medicinal product&#8221; is defined as a medicinal product </div></div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">246 </div></div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;;font-weight: bold;"><a href="#toc">Table of Contents</a></div> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">containing a similar active substance or substances as contained in an authorized orphan medicinal product, and which is intended for the same therapeutic indication. This orphan exclusivity period may be reduced to six years if the orphan drug designation criteria are no longer met, including where it is shown that the product is sufficiently profitable not to justify maintenance of market exclusivity. Market exclusivity may also be broken, so a similar product may be authorized for the same indication, in very select cases, such as if (i)&#160;it is established that a similar medicinal product is safer, more effective or otherwise clinically superior to the authorized product; (ii)&#160;the marketing authorization holder consents to the grant of the similar product; or (iii)&#160;the marketing authorization holder cannot supply enough orphan medicinal product. Orphan drug designation must be requested before submitting an application for marketing approval. Orphan drug designation does not convey any advantage in, or shorten the duration of, the regulatory review and approval process. </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The upcoming legislative reforms in the EU, which are part of the new EU Pharmaceutical Strategy and some of which could materialize as early as 2022, may result in a reduction of market exclusivity periods for orphan medicinal products and/or imposition of additional requirements for grant of such exclusivity. </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">From January&#160;1, 2021, a separate process for orphan drug designation has applied in Great Britain. There is no <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">pre-marketing</div> authorization orphan designation (as there is in the EEA) and the application for orphan designation will be reviewed by the MHRA at the time of the marketing authorization application. The criteria are the same as in the EEA, save that they apply to Great Britain only (e.g., there must be no satisfactory method of diagnosis, prevention or treatment of the condition concerned in Great Britain). Orphan exclusivity granted to a centralized marketing authorization will also apply in Northern Ireland. </div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt; margin-left: 2%;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">European Union and United Kingdom Pediatric Investigation Plan </div></div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;">In the EEA and UK, MAAs for new medicinal products have to include the results of studies conducted in the pediatric population, in compliance with a pediatric investigation plan (a &#8220;PIP&#8221;), agreed with the EMA&#8217;s Pediatric Committee (a &#8220;PDCO&#8221;) or MHRA as relevant. The PIP sets out the timing and measures proposed to generate data to support a pediatric indication of the drug for which marketing authorization is being sought. The PDCO/MHRA can grant a deferral of the obligation to implement some or all of the measures of the PIP until there are sufficient data to demonstrate the efficacy and safety of the product in adults. Further, the obligation to provide pediatric clinical trial data can be waived by the PDCO/MHRA when this data is not needed or appropriate because the product is likely to be ineffective or unsafe in children, the disease or condition for which the product is intended occurs only in adult populations, or when the product does not represent a significant therapeutic benefit over existing treatments for pediatric patients. If a marketing authorization is obtained and trial results are included in the product information, even when negative, and the product is approved in all Member States, <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-orphan</div> products are eligible for six months&#8217; supplementary protection certificate extension. In the case of orphan medicinal products, a <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">two-year</div> extension of the orphan market exclusivity may be available. This pediatric reward is subject to specific conditions and is not automatically available when data in compliance with the PIP are developed and submitted. </div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The upcoming legislative reforms in the EU, which are part of the new EU Pharmaceutical Strategy and some of which could materialize as early as 2022, may result in a reduction of the above pediatric rewards and/or imposition of additional requirements for grant of rewards. </div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt; margin-left: 2%;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Brexit and the Regulatory Framework in the United Kingdom </div></div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">On June&#160;23, 2016, the electorate in the United Kingdom voted in favor of leaving the European Union (commonly referred to as Brexit). Thereafter, on March&#160;29, 2017, the country formally notified the European Union of its intention to withdraw pursuant to Article 50 of the Lisbon Treaty. The United Kingdom formally left the European Union on January&#160;31, 2020. A transition period began on February&#160;1, 2020, during which EU pharmaceutical law remained applicable in the United Kingdom. However this ended on December&#160;31, 2020. On December&#160;30, 2020, the United Kingdom and European Union signed the Trade and Cooperation Agreement, which includes an agreement on free trade between the two parties. Since the regulatory framework in the </div></div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">247 </div></div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;;font-weight: bold;"><a href="#toc">Table of Contents</a></div> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">United&#160;Kingdom covering the quality, safety and efficacy of pharmaceutical products, clinical trials, marketing authorizations, commercial sales, and distribution of pharmaceutical products is derived from EU Directives and Regulations, Brexit could materially impact the future regulatory regime which applies to products and the approval of product candidates in the United Kingdom, as the UK legislation now has the potential to diverge from EU legislation. It remains to be seen how Brexit will impact regulatory requirements for medicinal products and devices in the United Kingdom in the long term. The MHRA has published detailed guidance for industry and organizations to follow now the transition period is over, which will be updated as the United&#160;Kingdom&#8217;s regulatory position on medicinal products and medical devices evolves over time. There are also a number of ongoing consultations on the future legislation in the UK. </div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt; margin-left: 2%;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">European Union and United Kingdom data protection regime </div></div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;">The processing of personal data, including health data, in the EEA is governed by the General Data Protection Regulation (the &#8220;GDPR&#8221;), which became effective May&#160;25, 2018. The GDPR applies to any company established in the EEA and to companies established outside the EEA that process personal data in connection with the offering of goods or services to data subjects in the European Union or EEA or the monitoring of the behavior of data subjects in the European Union or EEA. The GDPR enhances data protection obligations for data controllers of personal data, including<div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;"> inter alia</div></div> stringent requirements relating to lawful and legitimate basis and purposes for the processing of personal data, the consent of data subjects, expanded disclosures about how personal data is used, requirements to conduct privacy impact assessments for &#8220;high risk&#8221; processing, limitations on retention of personal data, appointment of a data protection officers, conclusion of data processing agreements, mandatory data breach notification and &#8220;privacy by design&#8221; requirements, and creates direct obligations on service providers acting as data processors. The GDPR also imposes strict rules on the transfer of personal data outside of the EEA to countries that do not ensure an adequate level of protection, like the United States. Until recently, one such data transfer mechanism was the EU-US Privacy Shield, but the Privacy Shield was invalidated for international transfers of personal data in July 2020 by the CJEU. The CJEU upheld the validity of standard contractual clauses (&#8220;SCCs&#8221;) as a legal mechanism to transfer personal data but companies relying on SCCs will, subject to additional guidance from regulators in the EEA and the U.K., need to evaluate and implement supplementary measures that provide privacy protections additional to those provided under SCCs. It remains to be seen whether SCCs will remain available and whether additional means for lawful data transfers will become available. Failure to comply with the requirements of the GDPR and the related national data protection laws of the EEA Member States may result in fines up to &#8364;20&#160;million or 4% of a company&#8217;s global annual revenues for the preceding financial year, whichever is higher. Moreover, the GDPR grants data subjects the right to claim material and <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-material</div> damages resulting from infringement of the GDPR. </div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">In addition, further to the United Kingdom&#8217;s exit from the European Union on January&#160;31, 2020, the GDPR ceased to apply in the United Kingdom at the end of the transition period on December&#160;31, 2020. However, as of January&#160;1, 2021, the United Kingdom&#8217;s European Union (Withdrawal) Act 2018 incorporated the GDPR (as it existed on December&#160;31, 2020 but subject to certain UK specific amendments) into UK law, referred to as the UK GDPR. The UK GDPR and the UK Data Protection Act 2018 set out the United Kingdom&#8217;s data protection regime, which is independent from but aligned to the European Union&#8217;s data protection regime. <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">Non-compliance</div> with the UK GDPR may result in monetary penalties of up to &#163;17.5&#160;million or 4% of worldwide revenue, whichever is higher. With respect to transfers of personal data from the EEA to the United Kingdom, on June&#160;28, 2021 the European Commission issued an adequacy decision in respect of the UK&#8217;s data protection framework, enabling data transfers from EU member states to the UK to continue without requiring organizations to put in place contractual or other measures in order to lawfully transfer personal data between the territories. While it is intended to last for at least four years, the European Commission may unilaterally revoke the adequacy decision at any point, and if this occurs it could lead to additional costs and increase our overall risk exposure. </div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt; margin-left: 2%;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Rest of the World Regulation </div></div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">For other countries outside of the European Union and the United States, such as countries in Eastern Europe, Latin America or Asia, the requirements governing the conduct of clinical trials, product licensing, </div></div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">248 </div></div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;;font-weight: bold;"><a href="#toc">Table of Contents</a></div> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">pricing and reimbursement vary from country to country. Additionally, the clinical trials must be conducted in accordance with GCP requirements and the applicable regulatory requirements and the ethical principles that have their origin in the Declaration of Helsinki. </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">If we fail to comply with applicable foreign regulatory requirements, we may be subject to, among other things, fines, suspension or withdrawal of regulatory approvals, product recalls, seizure of products, operating restrictions and </div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt; margin-left: 2%;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Additional Laws and Regulations Governing International Operations </div></div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">If we further expand our operations outside of the United States, we must dedicate additional resources to comply with numerous laws and regulations in each jurisdiction in which we plan to operate. The U.S. Foreign Corrupt Practices Act (the &#8220;FCPA&#8221;), prohibits any U.S. individual or business from paying, offering, authorizing payment or offering of anything of value, directly or indirectly, to any foreign official, political party or candidate for the purpose of influencing any act or decision of the foreign entity in order to assist the individual or business in obtaining or retaining business. The FCPA also obligates companies whose securities are listed in the United States to comply with certain accounting provisions requiring the company to maintain books and records that accurately and fairly reflect all transactions of the corporation, including international subsidiaries, and to devise and maintain an adequate system of internal accounting controls for international operations. </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">Compliance with the FCPA is expensive and difficult, particularly in countries in which corruption is a recognized problem. In addition, the FCPA presents particular challenges in the pharmaceutical industry, because, in many countries, hospitals are operated by the government, and doctors and other hospital employees are considered foreign officials. Certain payments to hospitals in connection with clinical trials and other work have been deemed to be improper payments to government officials and have led to FCPA enforcement actions. Further, other anti-corruption laws, such as the UK Bribery Act, are broader and can regulate payments to <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-governmental</div> entities. </div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">Various laws, regulations and executive orders also restrict the use and dissemination outside of the United&#160;States, or the sharing with certain <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-U.S.</div> nationals, of information classified for national security purposes, as well as certain products and technical data relating to those products. If we expand our presence outside of the United States, it will require us to dedicate additional resources to comply with these laws, and these laws may preclude us from developing, manufacturing, or selling certain products and product candidates outside of the United States, which could limit our growth potential and increase our development costs. </div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The failure to comply with laws governing international business practices may result in substantial civil and criminal penalties and suspension or debarment from government contracting. The SEC also may suspend or bar issuers from trading securities on U.S. exchanges for violations of the FCPA&#8217;s accounting provisions. </div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt; margin-left: 2%;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Coverage and Reimbursement </div></div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Successful commercialization of new drug products depends in part on the extent to which reimbursement for those drug products will be available from government health administration authorities, private health insurers, and other organizations. Government authorities and third-party payors, such as private health insurers and health maintenance organizations, decide which drug products they will pay for and establish reimbursement levels. The availability and extent of reimbursement by governmental and private payors is essential for most patients to be able to afford a drug product. Sales of drug products depend substantially, both domestically and abroad, on the extent to which the costs of drugs products are covered or paid for by the federal or national government as well as commercial managed care organizations, pharmacy benefit managers, and similar healthcare management organizations. </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">A primary trend in the U.S. healthcare industry and elsewhere is cost containment. Government authorities and third-party payors have attempted to control costs by limiting coverage and the amount of reimbursement for </div></div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">249 </div></div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;;font-weight: bold;"><a href="#toc">Table of Contents</a></div> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">particular drug products. In many countries, the prices of drug products are subject to varying price control mechanisms as part of national health systems. In general, the prices of drug products under such systems are substantially lower than in the United States. Other countries allow companies to fix their own prices for drug products, but monitor and control company profits. Accordingly, in markets outside the United States, the acquisition costs and reimbursement for drug products may lower than within the United States. </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">In the United States, the decisions about reimbursement for new drug products under the Medicare program are made by CMS, an agency within HHS. CMS determines coverage standards for products reimbursed by Medicare, and private payors often adopt coverage standards established by CMS for the commercial marketplace. However, no uniform policy of coverage and reimbursement for drug products exists among third-party payors and coverage and reimbursement levels for drug products can differ significantly from payor to payor. </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">Third-party payors may limit coverage to specific products on an approved list or formulary, which might not include all of the <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">FDA-approved</div> products for a particular indication. Also, third-party payors may refuse to include a particular branded drug on their formularies or otherwise restrict patient access to a branded drug when a less costly generic equivalent or another alternative is available. Third-party payors are increasingly challenging the prices charged for medical products and services, examining the medical necessity, and reviewing the cost-effectiveness of medical products and services and imposing controls to manage costs. Further, due to the <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">COVID-19</div> pandemic, millions of individuals have lost or are expected to lose employer-based insurance coverage, which may adversely affect our ability to successfully commercialize our products. </div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">The Medicare Prescription Drug, Improvement, and Modernization Act of 2003 (the &#8220;MMA&#8221;), established the Medicare Part D program to provide a voluntary prescription drug benefit to Medicare beneficiaries. Under Part D, Medicare beneficiaries may enroll in prescription drug plans offered by private entities that provide coverage of outpatient prescription drugs. Unlike Medicare Parts A and B, Part D coverage is not standardized. Part D prescription drug plan sponsors are not required to pay for all covered Part D drugs, and each drug plan can develop its own drug formulary that identifies which drugs it will cover and at what tier or level. While all Medicare drug plans must give at least a standard level of coverage set by Medicare, Part D prescription drug plan sponsors are not required to pay for all covered Part D drugs, and each drug plan can develop its own drug formulary that identifies which drugs it will cover and at what tier or level. However, Part D prescription drug formularies must include drugs within each therapeutic category and class of covered Part D drugs, though not necessarily all the drugs in each category or class. Any formulary used by a Part D prescription drug plan must be developed and reviewed by a pharmacy and therapeutic committee. Government payment for some of the costs of prescription drugs may increase demand for drugs for which we obtain marketing approval. Any negotiated prices for any of our products covered by a Part D prescription drug plan will likely be lower than the prices we might otherwise obtain. Moreover, while the MMA applies only to drug benefits for Medicare beneficiaries, private payors often follow Medicare coverage policy and payment limitations in setting their own payment rates. Any reduction in payment that results from the MMA may result in a similar reduction in payments from <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-governmental</div> payors. </div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">For a drug product to receive federal reimbursement under the Medicaid or Medicare Part B programs, a manufacturer must enter into agreements with the Secretary of HHS to participate in the Medicaid Drug Rebate Program and the 340B drug discount program. Under the Medicaid Drug Rebate Program, manufacturers are obligated to pay rebates to the State Medicaid Programs on each unit of the manufacturer&#8217;s drugs that are reimbursed by State Medicaid Programs&#8212;both with regard to Medicaid Fee for Service and Medicaid Managed Care. Additionally, under the 340B drug discount program, manufacturers extend discounts to &#8220;covered entities&#8221; eligible to participate in the 340B program, including various hospital providers. The required 340B discount on a given product is calculated based on the average manufacturer price (the &#8220;AMP&#8221;) and Medicaid rebate amounts reported and paid by the manufacturer under the Medicaid Drug Rebate Program. As of 2010, the ACA expanded the types of entities eligible to receive discounted 340B pricing, although under current law these newly eligible entities (with the exception of children&#8217;s hospitals) will not be eligible to receive discounted 340B pricing on </div></div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">250 </div></div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;;font-weight: bold;"><a href="#toc" style="text-indent: 0px;">Table of Contents</a></div> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">drugs that receive an orphan designation by the FDA. As 340B drug pricing is determined based on AMP and Medicaid rebate data, revisions to the statute and regulations governing the Medicaid Drug Rebate Program may cause the required 340B discount to increase. Additional legislation surrounding the 340B program, including which providers are eligible for the program, may be enacted in the future. These developments could affect our profitability. </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The American Recovery and Reinvestment Act of 2009 provides funding for the federal government to compare the effectiveness of different treatments for the same illness. The plan for the research was published in 2012 by the Department of HHS, the Agency for Healthcare Research and Quality and the National Institutes for Health, and periodic reports on the status of the research and related expenditures are made to Congress. Although the results of the comparative effectiveness studies are not intended to mandate coverage policies for public or private payors, it is not clear what effect, if any, the research will have on the sales of our drug candidates, if any such drug or the condition that they are intended to treat are the subject of a trial. It is also possible that comparative effectiveness research demonstrating benefits in a competitor&#8217;s drug could adversely affect the sales of our drug candidate. If third-party payors do not consider our drugs to be cost-effective compared to other available therapies, they may not cover our drugs after approval as a benefit under their plans or, if they do, the level of payment may not be sufficient to allow us to sell our drugs on a profitable basis. </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">These laws, and future state and federal healthcare reform measures may be adopted in the future, any of which may result in additional reductions in Medicare and other healthcare funding and otherwise affect the prices we may obtain for any product candidates for which we may obtain regulatory approval or the frequency with which any such product candidate is prescribed or used. </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">Outside of the United States, the pricing of pharmaceutical products and medical devices is subject to governmental control in many countries. For example, in the European Union and UK, pricing and reimbursement schemes vary widely from country to country. Some countries provide that products may be marketed only after a reimbursement price has been agreed. Some countries may require the completion of additional studies that compare the cost effectiveness of a particular therapy to currently available therapies or <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">so-called</div> health technology assessments, in order to obtain reimbursement or pricing approval. Other countries may allow companies to fix their own prices for products, but monitor and control product volumes or the amount of profit made on those profits, and issue guidance to physicians to limit prescriptions. Efforts to control prices and utilization of pharmaceutical products and medical devices will likely continue as countries attempt to manage healthcare expenditures. </div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Human Capital Management </div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">As of June&#160;30, 2021, we and our subsidiaries had approximately 665 full-time employees. </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Our human capital objectives include sourcing, recruiting, retaining, incentivizing and developing our existing and future employees. We seek to create nimble, entrepreneurial Vants that operate similar to independent biotechnology companies where each management team, comprised of world-class drug developers and clinical operators, is solely focused on their respective Vant&#8217;s mission. Our and our Vants&#8217; equity incentive plans are designed to attract, retain and motivate selected employees, consultants and directors through the granting of share-based compensation awards to encourage focus and calculated risk-taking. In connection with becoming a public company, we expect to hire additional personnel and to implement procedures and processes to address public company regulatory requirements and customary practices. </div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Corporate and Other Information </div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;">We were registered as an exempted limited company in Bermuda in 2014, under the name Valor Biotechnology Ltd. In November 2014 we changed our name to Roivant Sciences Ltd. Our principal executive offices are located at Suite 1, 3rd Floor, <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">11-12</div> St. James&#8217;s Square, London SW1Y 4LB, United Kingdom. Our telephone number is +44 207 400 3347. </div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">251 </div></div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;;font-weight: bold;"><a href="#toc">Table of Contents</a></div> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Our web page address is https://roivant.com. Our investor relations website is located at https://investor.roivant.com/. We will make available free of charge on our investor relations website under &#8220;SEC Filings&#8221; our Annual Reports on <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">Form&#160;10-K,</div> Quarterly Reports on Form <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">10-Q,</div> Current Reports on Form <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">8-K,</div> our directors&#8217; and officers&#8217; Section&#160;16 Reports and any amendments to those reports after filing or furnishing such materials to the SEC. References to our website address do not constitute incorporation by reference of the information contained on the website, and the information contained on the website is not part of this document or any other document that we file with or furnish to the SEC. </div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">We are an &#8220;emerging growth company&#8221; (an &#8220;EGC&#8221;), as defined in the Jumpstart Our Business Startups Act of 2012. As an EGC, we are eligible for exemptions from various reporting requirements applicable to other public companies that are not emerging growth companies, including, but not limited to, not being required to comply with the auditor attestation requirements of Section&#160;404 of the Sarbanes-Oxley Act of 2002 and reduced disclosure obligations regarding executive compensation. </div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Legal Proceedings </div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">We are involved in various claims and legal actions arising in the ordinary course of business. In the opinion of management, the ultimate disposition of these matters will not have a material adverse effect on our consolidated financial position, results of operations or liquidity. </div></div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">252 </div></div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;;font-weight: bold;"><a href="#toc">Table of Contents</a></div> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"> <div id="rom164680_12" style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">MANAGEMENT </div></div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Executive Officers and Directors </div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The following table sets forth certain information, as of October&#160;29, 2021, regarding Roivant&#8217;s executive officers and directors. The executive officers of Roivant are employees of Roivant Sciences, Inc., a wholly owned subsidiary of Roivant, and provide services pursuant to an inter-company agreement. For biographical information concerning the executive officers and directors, see below. </div></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="font-size: 0px;">
<td style="width: 48%; font-family: &quot;Times New Roman&quot;;"></td>
<td style="width: 2%; vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="width: 3%; font-family: &quot;Times New Roman&quot;;"></td>
<td style="width: 2%; vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="width: 45%; font-family: &quot;Times New Roman&quot;;"></td> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;"> <div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 1pt; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">Name</div></div></div> </td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;&#160;</td>
<td style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 1pt; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">Age</div></div></div> </td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;&#160;</td>
<td style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 1pt; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">Position</div></div></div> </td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Executive Officers</div></div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Matthew Gline</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:center;">37</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">Chief Executive Officer and Director</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Eric Venker</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:center;">35</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">President and Chief Operating Officer</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Mayukh Sukhatme</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:center;">46</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">President and Chief Investment Officer</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Richard Pulik</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:center;">42</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">Chief Financial Officer</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Rakhi Kumar</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:center;">41</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">Chief Accounting Officer</td> </tr>
<tr style="font-size: 1pt;">
<td style="height: 6pt; font-family: &quot;Times New Roman&quot;;"></td>
<td colspan="2" style="height: 6pt; font-family: &quot;Times New Roman&quot;;"></td>
<td colspan="2" style="height: 6pt; font-family: &quot;Times New Roman&quot;;"></td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Directors</div></div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Vivek Ramaswamy</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:center;">36</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">Founder and Chair</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Andrew Lo</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:center;">61</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">Director</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Patrick Machado</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:center;">57</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">Director</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Keith Manchester</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:center;">52</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">Director</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Ilan Oren</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:center;">37</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">Director</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Daniel Gold</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:center;">53</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">Director</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Masayo Tada</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:center;">76</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">Director</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">James C. Momtazee</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:center;">49</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">Director</td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt; margin-left: 2%;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Executive Officers </div></div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Matthew Gline</div></div></div></div><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;"> </div></div>has served as our Chief Executive Officer since January 2021 and as a Director of Roivant from the closing of the Business Combination in September 2021. Mr.&#160;Gline joined Roivant in March 2016 and previously served as Chief Financial Officer, from September 2017 through his appointment as Chief Executive Officer, and as Senior VP, Finance and Business Operations. Prior to joining Roivant, Mr.&#160;Gline was a Vice President at Goldman Sachs, Fixed Income Digital Structuring, from 2014 to 2016, and <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">co-founded</div> Fourthree, a risk analytics technology and consulting company, from 2012 to 2014. Mr.&#160;Gline earned his A.B. in Physics from Harvard College. Our board of directors believes that Mr.&#160;Gline&#8217;s experience in various roles at our company and his prior professional experience qualify him to serve as a member of our board of directors. </div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Eric Venker</div></div></div></div> has served as our President and Chief Operating Officer since January 2021 and, prior to that role, as Chief Operating Officer, from November 2018. From October 2017 to October 2018, Dr.&#160;Venker served as Chief of Staff to our Chief Executive Officer, and from 2014 to 2015, as an Analyst at Roivant. From 2015 to 2017, Dr.&#160;Venker was a physician at New York Presbyterian Hospital/Columbia University Medical Center, where he trained in internal medicine, and also served as Chair of the Housestaff Quality Council leading operational initiatives to improve efficiencies. From 2011 to 2015, Dr.&#160;Venker was a Clinical Pharmacist at <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">Yale-New</div> Haven Hospital. Dr.&#160;Venker also serves on the boards of directors of Immunovant, Arbutus Biopharma, Sio Gene Therapies and several private biopharmaceutical companies. He received his Pharm.D. from St. Louis College of Pharmacy and his M.D. from Yale School of Medicine. </div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Mayukh Sukhatme </div></div></div></div>has served as our President and Chief Investment Officer since January 2021, overseeing the creation and support of biopharmaceutical companies in the Roivant family. Dr.&#160;Sukhatme joined Roivant in 2015 and previously served as President of Roivant Pharma and as our Chief Business Officer. From 2000 to 2015, Dr.&#160;Sukhatme was a healthcare-focused analyst and portfolio manager for several large institutional investment firms, including both public markets and venture capital firms. His principal focus was </div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">253 </div></div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;;font-weight: bold;"><a href="#toc">Table of Contents</a></div> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">on development-stage biotechnology and pharmaceutical companies, where he led diligence and investment decisions on numerous companies and pharmaceutical compounds across a wide variety of therapeutic areas. Dr.&#160;Sukhatme earned his M.D. from Harvard Medical School and his B.S. in Biology and B.S. in Literature from MIT. </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Richard Pulik</div></div></div></div><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;"> </div></div>has served as our Chief Financial Officer since October 2021. Prior to joining Roivant, Mr.&#160;Pulik was the Global Head of Business Development&#160;&amp; Licensing and Portfolio Management, Oncology at Novartis and a member of Novartis&#8217;s Innovation Management Board and the Novartis Oncology Leadership Team, from August 2019 to September 2021. Mr.&#160;Pulik joined Novartis in 2012 as a Senior Director, Mergers&#160;&amp; Acquisitions based in Basel, Switzerland working on the strategy and execution of the deals that shaped Novartis. In 2015, Mr.&#160;Pulik was appointed as Vice President, Head of North America Investor Relations for Novartis. Prior to these roles at Novartis, Mr.&#160;Pulik worked at Bank of America Merrill Lynch, Monitor Group and UBS Investment Bank, focusing on mergers and acquisitions and strategy in the healthcare sector. Mr.&#160;Pulik received a B.S. in Finance from The Wharton School and a B.A. in Economics and International Relations at the University of Pennsylvania in 2001. </div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Rakhi Kumar</div></div></div></div> has served as our Chief Accounting Officer since August 2018, leading the accounting and financial operations and related internal controls functions. Ms.&#160;Kumar joined Roivant in September 2015, and previously served as Vice President, Finance and External Reporting. Prior to joining Roivant, Ms.&#160;Kumar was responsible for external reporting, corporate and technical accounting at The Medicines Company from 2013 to 2015. Earlier in her career, Ms.&#160;Kumar was in the assurance services at Ernst and Young. Ms.&#160;Kumar also serves as a director and as chair of the audit committee for NeuroPace (Nasdaq: NPCE), a medical device company. She is a licensed Certified Public Accountant and a Chartered Professional Accountant in Ontario, Canada. She received her M.S. in Accounting and Taxation from the University of Hartford. </div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt; margin-left: 2%;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Directors </div></div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Vivek Ramaswamy </div></div></div></div>is our Founder and Chair of our board of directors. He has also served as our Executive Chairman since January 2021 and, prior to taking that role, as Chief Executive Officer, from May 2014. Mr.&#160;Ramaswamy previously served as a member of the investment team at QVT Financial, from 2007 to 2014. Mr.&#160;Ramaswamy was previously as a director of Myovant Sciences, Axovant Sciences and Arbutus Biopharma. Mr.&#160;Ramaswamy received his A.B. in Biology from Harvard College and his J.D. from Yale Law School, where he was a Paul&#160;&amp; Daisy Soros Fellow. Our board of directors believes that Mr.&#160;Ramaswamy&#8217;s status as our Founder and his extensive prior experience in the biopharmaceutical industry qualifies him to serve as a member of our board of directors. </div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Andrew Lo</div></div></div></div> has served as a Director of Roivant since 2016. He is a Charles E. and Susan T. Harris Professor at MIT Sloan School of Management since 1988, Founder and Chairman of QLS Advisors since 2019, Member of Thal&#275;s Advisory Board since 2019, Chairman Emeritus and Senior Advisor of AlphaSimplex Group since 2018 and member of the Competitive Market Advisory Counsel of the Chicago Mercantile Exchange since 2013. Dr.&#160;Lo has served as Director of BridgeBio Pharma since 2020 and advisor of the same company from 2015 to 2020. Our board of directors believes that Dr.&#160;Lo&#8217;s extensive experience as director and advisor of various companies, including in the biopharmaceutical industry, qualifies him to serve as a member of our board of directors. </div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Patrick Machado</div></div></div></div> has served as a Director of Roivant since 2017. He was a <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">co-founder</div> of Medivation, Inc., a biopharmaceutical company, and served on its board of directors from April 2014 through its acquisition by Pfizer in 2016. Mr.&#160;Machado also served as Medivation&#8217;s Chief Financial Officer from its inception in September 2003 and as its Chief Business Officer from December 2009, in each case through 2014. Since 2014, Mr.&#160;Machado has served as a professional independent board member to more than 15 private and public biotechnology companies, including Medivation (acquired by Pfizer), Endocyte (acquired by Novartis), Principia (acquired by Sanofi) and Therachon (acquired by Pfizer). Mr.&#160;Machado received a J.D. from Harvard Law </div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">254 </div></div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;;font-weight: bold;"><a href="#toc">Table of Contents</a></div> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">School and a B.A. and B.S. in German and Economics, respectively, from Santa Clara University. Our board of directors believes that Mr.&#160;Machado&#8217;s extensive experience as director and officer in the biopharmaceutical industry qualifies him to serve as a member of our board of directors. </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Keith Manchester </div></div></div></div>has served as a Director of Roivant since 2014. He serves as a Partner and the Head of Life Sciences at QVT Financial, New York, USA, an investment firm, where he has been employed since 2005. He focuses on investments in both publicly traded and privately owned life science companies. Prior to joining QVT, Dr.&#160;Manchester was Vice President of Business Development from 2002 to 2004 and Director of Business Development from 2000 to 2002 at Applied Molecular Evolution, a biotechnology company. From 1999 to 2000, Dr.&#160;Manchester was an associate at Vestar Capital Partners, a private equity firm. From 1997 to 1999, Dr.&#160;Manchester was an investment banker in the healthcare group at Goldman, Sachs&#160;&amp; Co. He received his A.B. from Harvard College and his M.D. from Harvard Medical School. Dr.&#160;Manchester serves as a director for the following companies: Roivant Sciences Ltd., Roivant Sciences, Inc., Arbutus Biopharma Corporation, and Kriya Therapeutics. Dr.&#160;Manchester also sits on the Supervisory Board of Medigene AG. Our board of directors believes that Dr.&#160;Manchester&#8217;s extensive experience investing in the life sciences industry qualifies him to serve as a member of our board of directors. </div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Ilan Oren </div></div></div></div>has served as a Director of Roivant since 2014. He has served as <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">Co-Chief</div> Executive Officer of Dexcel Pharma, a privately-owned Israeli group of pharmaceutical companies, since November 2019. Prior to serving as <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">Co-CEO,</div> Ilan served as Vice President for the group and led corporate and business development activities, including formation of strategic ventures, product partnerships, product portfolio selection, product acquisitions, strategic investments, and mergers and acquisitions. He holds an A.B. in Economics from Harvard College. Our board of directors believes that Mr.&#160;Oren&#8217;s extensive experience as a high-level executive in the pharmaceutical industry qualifies him to serve as a member of our board of directors. </div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Daniel Gold</div></div></div></div> has served as a Director of Roivant since 2020. Mr.&#160;Gold serves as the CEO, managing partner and founder of QVT Financial LP, an asset management company with offices in New York and New Delhi. QVT Financial, through its managed and affiliated multi-strategy funds, is an experienced global investor in multiple industries, including biotech, financial, shipping and offshore industries. Mr.&#160;Gold founded QVT Financial LP in 2003. Mr.&#160;Gold holds an A.B. in Physics from Harvard College. Mr.&#160;Gold also currently serves on the board of public companies MP Materials, Okeanis Eco Tankers Corp. and Awilco Drilling PLC, in addition to various private companies. Our board of directors believes that Mr.&#160;Gold&#8217;s extensive experience investing in the life sciences industry qualifies him to serve as a member of our board of directors. </div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Masayo Tada </div></div></div></div>has served as a Director of Roivant since 2019. He has served as Chairman of the Board of Sumitomo Dainippon Pharma Co., Ltd. (&#8220;Sumitomo&#8221;) since April 2018 and as a Director since April 2021, having previously served as Representative Director from April 2008 to March 2021. Prior to serving as Chairman of Sumitomo, he served as President and CEO of Sumitomo since June 2008, as well as other positions since 2005. Our board of directors believes that Mr.&#160;Tada&#8217;s extensive experience as a director and high-level executive in the pharmaceutical industry qualifies him to serve as a member of our board of directors. </div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">James C. Momtazee</div></div></div></div> has served as a Director of Roivant from the closing of the Business Combination in September 2021. Mr.&#160;Momtazee is the Managing Partner of Patient Square Capital, a dedicated health care investing firm. Mr.&#160;Momtazee has over 25 years of investment and acquisition experience, the vast majority of which was focused on the health care sector. Prior to founding Patient Square, he held various positions at KKR&#160;&amp; Co., Inc. (&#8220;KKR&#8221;) since 1996. He helped form KKR&#8217;s health care industry group in 2001 and ran that team for over 10 years.&#160;Mr.&#160;Momtazee currently also serves on the board of directors of BridgeBio Pharma, Apollo Therapeutics, Kriya Therapeutics and the Medical Device Manufacturers Association and has previously served on the board of directors of multiple other health care companies, including PRA Health Sciences, Inc. (lead independent director), Envision Healthcare, Heartland Dental, Ajax Health, Global Medical Response, BrightSpring Health Services, Covenant Surgical Partners, Entellus Medical, Inc., EchoNous, Spirox, Inc., Arbor </div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">255 </div></div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;;font-weight: bold;"><a href="#toc">Table of Contents</a></div> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Pharmaceuticals, Lake Region Medical, HCA Healthcare, Jazz Pharmaceuticals, and Alliance Imaging. Our board of directors believes that Mr.&#160;Momtazee&#8217;s extensive experience investing in the biopharmaceutical industry qualifies him to serve as a member of our board of directors. </div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Family Relationships </div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">There are no family relationships between the members of our board of directors and our executive officers. </div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Board of Directors </div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;">Our business and affairs are managed under the direction of our board of directors. Our board of directors consists of nine members, with Vivek Ramaswamy serving as Chair. Our amended and restated <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">bye-laws</div> provide for a classified board of directors divided into three classes serving staggered three-year terms as follows: </div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Class&#160;I directors are Mr.&#160;Machado, Dr.&#160;Manchester and Mr.&#160;Gline, and they will serve until our annual meeting of shareholders in 2022; </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Class&#160;II directors are Mr.&#160;Gold, Dr.&#160;Lo and Mr.&#160;Ramaswamy, and they will serve until our annual meeting of shareholders in 2023; and </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Class&#160;III directors are Mr.&#160;Tada, Mr.&#160;Oren and Mr.&#160;Momtazee, and they will serve until our annual meeting of shareholders in 2024; </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">At each annual meeting of shareholders, directors will be elected to succeed the class of directors whose terms have expired. This classification of our board of directors could have the effect of increasing the length of time necessary to change the composition of a majority of the board of directors. Our amended and restated <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">bye-laws</div> provide that the authorized number of directors (being no less than 5 directors and no more than 15 directors) may be changed only by resolution approved by a majority of our board of directors. </div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Director Independence </div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Our board of directors has undertaken a review of the independence of the directors and has considered whether any director has a material relationship with us that could compromise his or her ability to exercise independent judgment in carrying out his or her responsibilities. As a result of this review, our board of directors has determined that each of Mr.&#160;Machado, Dr.&#160;Manchester, Mr.&#160;Gold, Dr.&#160;Lo, Mr.&#160;Oren and Mr.&#160;Momtazee, representing six of the nine individuals expected to serve as members of our board of directors, are independent, as that term is defined under the applicable rules and regulations of the SEC and the Nasdaq listing rules. We comply with the corporate governance requirements of the SEC and the Nasdaq listing rules. </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">We comply with the requirements of Rule <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">10A-3</div> of the Exchange Act and the Nasdaq listing rules, which rules require that our audit committee be composed of at least three members. Under Rule <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">10A-3</div> of the Exchange Act, we are permitted to phase in our compliance with the independent audit committee requirements set forth in Rule <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">10A-3</div> of the Exchange Act as follows: (1)&#160;one independent member at the time of listing, (2)&#160;a majority of independent members within 90 days of listing and (3)&#160;all independent members within one year of listing. </div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Committees of the Board of Directors </div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Our board of directors established an audit committee, a compensation committee and a nominating and governance committee, each of which has the composition and responsibilities described below. From time to time, our board of directors may establish other committees to facilitate the management of our business. </div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt; margin-left: 2%;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Audit Committee </div></div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The members of our audit committee are Mr.&#160;Momtazee (Chair), Mr.&#160;Machado and Mr.&#160;Oren. The composition of our audit committee meets the requirements for independence under the current Nasdaq listing </div></div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">256 </div></div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;;font-weight: bold;"><a href="#toc">Table of Contents</a></div> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">standards and SEC rules and regulations. Each member of our audit committee is financially literate. In addition, our board of directors has determined that Mr.&#160;Momtazee is an &#8220;audit committee financial expert&#8221; as defined in Item 407(d)(5)(ii) of Regulation <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">S-K</div> promulgated under the Securities Act. This designation will not impose any duties, obligations or liabilities that are greater than are generally imposed on members of our audit committee and our board of directors. Our audit committee is directly responsible for, among other things: </div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">selecting a firm to serve as the independent registered public accounting firm to audit our financial statements; </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">ensuring the independence of the independent registered public accounting firm; </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;">discussing the scope and results of the audit with the independent registered public accounting firm and reviewing, with management and that firm, our interim and <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">year-end</div> operating results; </div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">establishing procedures for employees to anonymously submit concerns about questionable accounting or audit matters; </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">considering the adequacy of our internal controls and internal audit function; </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">reviewing material related party transactions or those that require disclosure; and </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;">approving or, as permitted, <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">pre-approving</div> all audit and <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-audit</div> services to be performed by the independent registered public accounting firm. </div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt; margin-left: 2%;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Compensation Committee </div></div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;">The members of our compensation committee are Mr.&#160;Gold (Chair), Mr.&#160;Machado and Mr.&#160;Oren. Each member of our compensation committee is a <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-employee</div> director, as defined by Rule <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">16b-3</div> promulgated under the Exchange Act, and an outside director, as defined pursuant to Section&#160;162(m) of the Code, and meets the requirements for independence under the current Nasdaq listing standards and SEC rules and regulations. Our compensation committee is responsible for, among other things: </div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">reviewing and approving the compensation of our Principal Executive Officer, each of our other executive officers and Mr. Ramaswamy; </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">reviewing and recommending to our board of directors the compensation of our directors; </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">administering our stock and equity incentive plans; </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">reviewing and approving, or making recommendations to our board of directors with respect to, incentive compensation and equity plans; and </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">reviewing our overall compensation philosophy. </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt; margin-left: 2%;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Nominating and Governance Committee </div></div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The members of our nominating and governance committee are Dr.&#160;Lo (Chair), Dr.&#160;Manchester and Mr.&#160;Momtazee. Dr.&#160;Lo, Dr.&#160;Manchester and Mr.&#160;Momtazee meet the requirements for independence under the current Nasdaq listing standards. Our nominating and governance committee is responsible for, among other things: </div></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">identifying and recommending candidates for membership on our board of directors; </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">developing and recommending our corporate governance guidelines and policies; </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">reviewing proposed waivers of the code of conduct for directors, executive officers and other senior financial officers; </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">overseeing the process of evaluating the performance of our board of directors; and </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">assisting our board of directors on corporate governance matters. </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">257 </div></div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;;font-weight: bold;"><a href="#toc">Table of Contents</a></div> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Code of Business Conduct and Ethics for Employees, Executive Officers and Directors </div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Our board of directors has adopted a Code of Business Conduct and Ethics (the &#8220;Code of Conduct&#8221;) that is currently applicable to all of our employees, executive officers and directors. The Code of Conduct is available on our website at www.roivant.com. The nominating and governance committee of our board of directors is responsible for overseeing the Code of Conduct and must approve any waivers of the Code of Conduct for employees, executive officers and directors. </div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Compensation Committee Interlocks and Insider Participation </div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">None of our directors who serve as a member of our compensation committee is, or has at any time during the past year been, one of our officers or employees. None of our executive officers currently serves, or in the past year has served, as a member of the board of directors or compensation committee of any other entity that has one or more executive officers serving on our board of directors or compensation committee. </div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Director Compensation </div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">See &#8220;Executive and Director Compensation&#8221; for information regarding compensation paid to our directors. </div></div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">258 </div></div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;;font-weight: bold;"><a href="#toc">Table of Contents</a></div> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"> <div id="rom164680_13" style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">EXECUTIVE AND DIRECTOR COMPENSATION </div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Roivant&#8217;s named executive officers (&#8220;NEOs&#8221;) for Roivant&#8217;s fiscal year ended March&#160;31, 2021 (&#8220;Fiscal 2020&#8221;), each of whom was an employee of Roivant Sciences, Inc. (&#8220;RSI&#8221;), a wholly owned subsidiary of Roivant, during Fiscal 2020 are as follows: </div></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Matthew Gline, Chief Executive Officer and former Chief Financial Officer; </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Eric Venker, President and Chief Operating Officer; </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Benjamin Zimmer, former President, Roivant Health; and </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Vivek Ramaswamy, Founder, Executive Chairman and former Chief Executive Officer. </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Summary Compensation Table </div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The following table sets forth information regarding the compensation paid to the NEOs in respect of Fiscal 2020. </div></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="font-size: 0px;">
<td style="width: 37%; font-family: &quot;Times New Roman&quot;;"></td>
<td style="width: 1%; vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="font-family: &quot;Times New Roman&quot;;"></td>
<td style="font-family: &quot;Times New Roman&quot;;"></td>
<td style="font-family: &quot;Times New Roman&quot;;"></td>
<td style="width: 1%; vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="font-family: &quot;Times New Roman&quot;;"></td>
<td style="font-family: &quot;Times New Roman&quot;;"></td>
<td style="font-family: &quot;Times New Roman&quot;;"></td>
<td style="width: 1%; vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="font-family: &quot;Times New Roman&quot;;"></td>
<td style="font-family: &quot;Times New Roman&quot;;"></td>
<td style="font-family: &quot;Times New Roman&quot;;"></td>
<td style="width: 1%; vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="font-family: &quot;Times New Roman&quot;;"></td>
<td style="font-family: &quot;Times New Roman&quot;;"></td>
<td style="font-family: &quot;Times New Roman&quot;;"></td>
<td style="width: 1%; vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="font-family: &quot;Times New Roman&quot;;"></td>
<td style="font-family: &quot;Times New Roman&quot;;"></td>
<td style="font-family: &quot;Times New Roman&quot;;"></td>
<td style="width: 1%; vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="font-family: &quot;Times New Roman&quot;;"></td>
<td style="width: 1%; vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="font-family: &quot;Times New Roman&quot;;"></td>
<td style="font-family: &quot;Times New Roman&quot;;"></td>
<td style="font-family: &quot;Times New Roman&quot;;"></td>
<td style="width: 1%; vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="font-family: &quot;Times New Roman&quot;;"></td>
<td style="font-family: &quot;Times New Roman&quot;;"></td>
<td style="font-family: &quot;Times New Roman&quot;;"></td> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; white-space: nowrap; padding-bottom: 1pt;"> <div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt; border-bottom: 1pt solid rgb(0, 0, 0); display: table-cell; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">Name and Principal <br/>Position</div></div></div> </td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Fiscal<br/>Year</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Salary<br/>($)</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Bonus<br/>($)<div style="font-size: 85%; vertical-align: top;;display:inline;;font-size:7.5px">(1)</div></div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Stock<br/>Awards<br/>($)<div style="font-size: 85%; vertical-align: top;;display:inline;;font-size:7.5px">(2)</div></div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Option<br/>Awards<br/>($)<div style="font-size: 85%; vertical-align: top;;display:inline;;font-size:7.5px">(2)</div></div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">Non-Equity</div><br/>Incentive<br/>Plan<br/>Compensation<br/>($)</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">All Other<br/>Compensation<br/>($)<div style="font-size: 85%; vertical-align: top;;display:inline;;font-size:7.5px">(3)</div></div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Total<br/>($)</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Matthew Gline <br/>Chief Executive Officer and former Chief Financial Officer<div style="font-size: 85%; vertical-align: top;;display:inline;;font-size:9.4px">(4)</div></div></div> </td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">2020</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">350,000</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">455,000</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:center;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">7,497,000</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:center;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">8,550</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">8,310,550</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Eric Venker <br/>President and Chief Operating Officer</div></div> </td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">2020</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">275,000</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">455,000</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">5,734,500</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">3,748,500</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:center;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">83,550</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">10,296,550</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Benjamin Zimmer <br/>Former President, Roivant Health<div style="font-size: 85%; vertical-align: top;;display:inline;;font-size:9.4px">(5)</div></div></div> </td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">2020</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">350,000</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">455,000</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:center;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">5,247,900</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:center;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">6,052,900</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Vivek Ramaswamy <br/>Founder, Executive Chairman and Former Chief Executive Officer<div style="font-size: 85%; vertical-align: top;;display:inline;;font-size:9.4px">(4)</div></div></div> </td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">2020</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">350,000</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:center;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:center;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:center;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">11,800</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">361,800</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="width: 11%; line-height: 8pt; margin-top: 0pt; margin-bottom: 2pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 4%; vertical-align: top;;text-align:left;">(1)</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The amounts reported in this column reflect the annual cash discretionary performance bonus paid to each of the NEOs in respect of Fiscal 2020, which were earned and paid based on an assessment by our board of directors of overall company and individual performance for Fiscal 2020. </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 4%; vertical-align: top;;text-align:left;">(2)</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The amounts reported in this column represent the aggregate grant date fair value of the awards of restricted stock units (&#8220;RSUs&#8221;) and nonqualified stock options granted to each of the NEOs during Fiscal 2020 under the Roivant Sciences Ltd. Amended and Restated 2015 Equity Incentive Plan (&#8220;2015 EIP&#8221;) and as described in further detail below. The grant date fair value was calculated in accordance with FASB ASC Topic 718, excluding the effect of estimated forfeitures. The amounts reported for any awards subject to performance conditions were calculated based on the probable outcome of the performance conditions as of the grant date, consistent with the estimate of aggregate compensation cost to be recognized over the service period determined as of the grant date under FASB ASC Topic 718, excluding the effect of estimated forfeitures. The assumptions used in calculating such grant date fair value are set forth in the notes to Roivant&#8217;s audited consolidated financial statements included elsewhere in this prospectus. Amounts reported do not reflect the actual economic value that may be realized by the applicable NEO. </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">259 </div></div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;;font-weight: bold;"><a href="#toc">Table of Contents</a></div> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 4%;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The grant date fair value of the RSUs granted to Dr.&#160;Venker in Fiscal 2020, if the maximum level of the applicable performance conditions were achieved, is $5,734,500. </div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt; margin-left: 4%;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The following are the grant date fair values of the stock options granted to the NEOs in Fiscal 2020, if the maximum level of the applicable performance conditions were achieved: Mr.&#160;Gline ($7,497,000), Dr.&#160;Venker ($3,748,500) and Mr.&#160;Zimmer ($5,247,900). </div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 4%; vertical-align: top;;text-align:left;">(3)</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The amounts reported for Fiscal 2020 in this column reflect the following: </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 4%;">&#160;</td>
<td style="width: 5%; vertical-align: top;;text-align:left;">(a)</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">For Mr.&#160;Gline, reflects company matching contributions under RSI&#8217;s 401(k) plan ($8,550); </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 4%;">&#160;</td>
<td style="width: 5%; vertical-align: top;;text-align:left;">(b)</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">For Dr.&#160;Venker, reflects (i)&#160;company matching contributions under RSI&#8217;s 401(k) plan ($8,550) and (ii)&#160;fees received by Dr.&#160;Venker in Fiscal 2020 for his service on the board of directors of certain private company affiliates of Roivant ($75,000); and </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 4%;">&#160;</td>
<td style="width: 5%; vertical-align: top;;text-align:left;">(c)</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">For Mr.&#160;Ramaswamy, reflects company matching contributions under RSI&#8217;s 401(k) plan ($11,800). </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 4%; vertical-align: top;;text-align:left;">(4)</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Effective January&#160;26, 2021, Mr.&#160;Ramaswamy ceased serving as Roivant&#8217;s Chief Executive Officer and transitioned to his current role as Executive Chairman. In addition, effective as of such date, Mr.&#160;Gline, Roivant&#8217;s then-current Chief Financial Officer, was appointed to serve as Chief Executive Officer. Effective as of September&#160;28, 2021, Mr.&#160;Gline ceased serving as Roivant&#8217;s Chief Financial Officer upon the appointment of Richard Pulik as Chief Financial Officer. </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 4%; vertical-align: top;;text-align:left;">(5)</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Mr.&#160;Zimmer has transferred from the role of President, Roivant Health to the role of Chief Executive Officer of a newly-formed Vant. </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Outstanding Equity Awards at Fiscal Year End </div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The following table sets forth information concerning outstanding equity awards for the NEOs as of the end of Fiscal 2020. At the consummation of the Business Combination, each outstanding equity award reflected in the table below was equitably adjusted in accordance with the terms of the Business Combination Agreement and the 2015 EIP. The amounts set forth in the table do not reflect these adjustments. For additional details regarding the treatment of outstanding equity awards held by the NEOs in connection with the Business Combination, see &#8220;Treatment of Equity Awards in Connection with the Business Combination&#8221; below. </div></div> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 24pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">OUTSTANDING EQUITY AWARDS AT 2020 FISCAL YEAR END<div style="font-size: 85%; vertical-align: top;;display:inline;;font-size:9.4px">(1)</div> </div></div></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="font-size: 0px;">
<td style="width: 26%;"></td>
<td style="width: 2%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td>
<td style="width: 2%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td>
<td style="width: 2%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td>
<td style="width: 2%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td>
<td style="width: 2%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td>
<td style="width: 2%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td>
<td style="width: 2%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td colspan="18" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Option Awards</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td colspan="6" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Stock Awards</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; white-space: nowrap; padding-bottom: 1pt;"> <div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt; border-bottom: 1pt solid rgb(0, 0, 0); display: table-cell; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">Name</div></div></div> </td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Grant Date</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Numbers of<br/>Securities<br/>Underlying<br/>Unexercised<br/>Options (#)<br/>Exercisable</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Numbers of<br/>Securities<br/>Underlying<br/>Unexercised<br/>Options (#)<br/>Unexercisable</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Option<br/>Exercise<br/>Price<br/>($)</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Option<br/>Expiration&#160;Date</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Number&#160;of<br/>shares&#160;or&#160;units&#160;of<br/>stock that have<br/>not&#160;vested (#)</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Market&#160;value&#160;of<br/>shares&#160;or&#160;units&#160;of<br/>stock&#160;that&#160;have&#160;not<br/>vested ($)</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Matthew Gline</div></div> </td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">4/20/2016</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">80,000</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">11.87</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">4/19/2026</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">5/21/2018</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">49,856</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">29,152</td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="font-size: 85%; vertical-align: top;;display:inline;;font-size:9.4px">(2) </div>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">23.36</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">5/20/2028</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">5/20/2019</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">250,000</td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="font-size: 85%; vertical-align: top;;display:inline;;font-size:9.4px">(3)</div>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">9,625,000</td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="font-size: 85%; vertical-align: top;;display:inline;;font-size:9.4px">(3)</div>&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">3/26/2020</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">466,035</td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="font-size: 85%; vertical-align: top;;display:inline;;font-size:9.4px">(4)</div>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">37.10</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">3/31/2026</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">3/26/2020</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">776,725</td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="font-size: 85%; vertical-align: top;;display:inline;;font-size:9.4px">(4)</div>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">37.10</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">3/31/2026</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">3/26/2020</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">466,035</td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="font-size: 85%; vertical-align: top;;display:inline;;font-size:9.4px">(5)</div>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">18.70</td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="font-size: 85%; vertical-align: top;;display:inline;;font-size:9.4px">(6)</div>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">3/31/2026</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">3/26/2020</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">776,725</td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="font-size: 85%; vertical-align: top;;display:inline;;font-size:9.4px">(5)</div>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">33.63</td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="font-size: 85%; vertical-align: top;;display:inline;;font-size:9.4px">(6)</div>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">3/31/2026</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">5/20/2020</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">300,000</td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="font-size: 85%; vertical-align: top;;display:inline;;font-size:9.4px">(2)</div>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">38.23</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">5/19/2030</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Eric Venker</div></div> </td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">11/20/2017</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">74,400</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">14,564</td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="font-size: 85%; vertical-align: top;;display:inline;;font-size:9.4px">(2) </div>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">21.80</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">11/19/2027</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">5/21/2018</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">12,510</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">11,652</td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="font-size: 85%; vertical-align: top;;display:inline;;font-size:9.4px">(2) </div>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">23.36</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">5/20/2028</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">5/20/2019</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">45,840</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">54,160</td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="font-size: 85%; vertical-align: top;;display:inline;;font-size:9.4px">(2) </div>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">32.07</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">5/19/2029</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">3/26/2020</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">403,897</td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="font-size: 85%; vertical-align: top;;display:inline;;font-size:9.4px">(4)</div>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">46.38</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">3/31/2026</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">5/20/2020</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">150,000</td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="font-size: 85%; vertical-align: top;;display:inline;;font-size:9.4px">(2)</div>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">38.23</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">5/19/2030</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">5/20/2020</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">150,000</td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="font-size: 85%; vertical-align: top;;display:inline;;font-size:9.4px">(3)</div>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">5,775,000</td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="font-size: 85%; vertical-align: top;;display:inline;;font-size:9.4px">(3)</div>&#160;</td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">260 </div></div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;;font-weight: bold;"><a href="#toc" style="text-indent: 0px;">Table of Contents</a></div> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;">
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="font-size: 0px;">
<td style="width: 26%;"></td>
<td style="width: 2%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td>
<td style="width: 2%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td>
<td style="width: 2%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td>
<td style="width: 2%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td>
<td style="width: 2%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td>
<td style="width: 2%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td>
<td style="width: 2%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td colspan="18" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Option Awards</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td colspan="6" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Stock Awards</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; white-space: nowrap; padding-bottom: 1pt;"> <div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt; border-bottom: 1pt solid rgb(0, 0, 0); display: table-cell; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">Name</div></div></div> </td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Grant Date</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Numbers of<br/>Securities<br/>Underlying<br/>Unexercised<br/>Options (#)<br/>Exercisable</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Numbers of<br/>Securities<br/>Underlying<br/>Unexercised<br/>Options (#)<br/>Unexercisable</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Option<br/>Exercise<br/>Price<br/>($)</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Option<br/>Expiration&#160;Date</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Number&#160;of<br/>shares&#160;or&#160;units&#160;of<br/>stock that have<br/>not&#160;vested (#)</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Market&#160;value&#160;of<br/>shares&#160;or&#160;units&#160;of<br/>stock&#160;that&#160;have&#160;not<br/>vested ($)</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Benjamin Zimmer</div></div> </td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">12/30/2015</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">405</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">14.96</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">12/29/2025</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">5/20/2016</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">1,512</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">11.60</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">5/19/2026</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">5/20/2019</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">229,170</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">270,830</td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="font-size: 85%; vertical-align: top;;display:inline;;font-size:9.4px">(2)</div>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">32.07</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">5/19/2029</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">5/20/2019</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">250,000</td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="font-size: 85%; vertical-align: top;;display:inline;;font-size:9.4px">(3)</div>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">9,625,000</td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="font-size: 85%; vertical-align: top;;display:inline;;font-size:9.4px">(3)</div>&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">3/26/2020</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">62,138</td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="font-size: 85%; vertical-align: top;;display:inline;;font-size:9.4px">(4) </div>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">37.10</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">3/31/2026</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">3/26/2020</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">144,545</td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="font-size: 85%; vertical-align: top;;display:inline;;font-size:9.4px">(4)</div>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">40.31</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">3/31/2026</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">3/26/2020</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">62,138</td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="font-size: 85%; vertical-align: top;;display:inline;;font-size:9.4px">(5) </div>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">33.63</td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="font-size: 85%; vertical-align: top;;display:inline;;font-size:9.4px">(6)</div>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">3/31/2026</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">5/20/2020</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">210,000</td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="font-size: 85%; vertical-align: top;;display:inline;;font-size:9.4px">(2)</div>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">38.23</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">5/19/2030</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Vivek Ramaswamy</div></div> </td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">3/26/2020</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">4,126,118</td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="font-size: 85%; vertical-align: top;;display:inline;;font-size:9.4px">(4)</div>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">37.10</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">3/31/2026</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">3/26/2020</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">3,343,002</td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="font-size: 85%; vertical-align: top;;display:inline;;font-size:9.4px">(4)</div>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">37.10</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">3/31/2026</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">3/26/2020</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">599,380</td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="font-size: 85%; vertical-align: top;;display:inline;;font-size:9.4px">(4)</div>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">40.31</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">3/31/2026</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">3/26/2020</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">2,021,411</td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="font-size: 85%; vertical-align: top;;display:inline;;font-size:9.4px">(4)</div>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">46.38</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">3/31/2026</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">3/26/2020</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">3,343,002</td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="font-size: 85%; vertical-align: top;;display:inline;;font-size:9.4px">(5)</div>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">18.70</td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="font-size: 85%; vertical-align: top;;display:inline;;font-size:9.4px">(6)</div>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">3/31/2026</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">3/26/2020</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">4,126,118</td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="font-size: 85%; vertical-align: top;;display:inline;;font-size:9.4px">(5)</div>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">33.63</td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="font-size: 85%; vertical-align: top;;display:inline;;font-size:9.4px">(6)</div>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">3/31/2026</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="width: 11%; line-height: 8pt; margin-top: 0pt; margin-bottom: 2pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 4%; vertical-align: top;;text-align:left;">(1)</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;">Pursuant to the terms of the Business Combination Agreement, effective as of the closing of the Business Combination on September&#160;30, 2021, outstanding equity awards were adjusted as follows: (i)&#160;each share subject to an outstanding Roivant option was multipled by the exhchange ratio of 2.9262:1 (the &#8220;Exchange Ratio&#8221;), rounded down to the nearest whole share, and the per share exercise price was divided by the Exchange Ratio, rounded up to the nearest whole cent, (ii)&#160;each share subject to an outstanding and unvested RSU was multiplied by the Exchange Ratio, rounded down to the nearest whole share, and (iii)&#160;each share subject to a capped value appreciation right (&#8220;CVAR&#8221;) was multipled by the Exchange Ratio, rounded down to the nearest whole share, and the per share hurdle price, <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">&#8220;knock-in&#8221;</div> price and value cap price, as applicable, was divided by the Exchange Ratio, rounded up to the nearest whole cent, as described further below under &#8220;Treatment of Equity Awards in Connection with the Business Combination.&#8221; The numbers in the table reflect the share numbers outstanding as of March&#160;31, 2021 and do not reflect these adjustments that occurred in connection with the closing of the Business Combination on September&#160;30, 2021. However, on September&#160;30, 2021, these numbers were all adjusted pursuant to the Business Combination Agreement. </div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 4%; vertical-align: top;;text-align:left;">(2)</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Reflects the grant of nonqualified stock options to purchase Common Shares outstanding under the 2015 EIP that vest and become exercisable as follows: (i) 25% of the stock options vest and become exercisable on the first anniversary of the vesting commencement date and (ii)&#160;the remaining 75% vest in 36 successive equal monthly installments thereafter, in each case, subject to the holder&#8217;s continuous service through the applicable vesting date. For stock options held by Messrs. Gline and Venker that were granted in 2017 or 2018, immediately prior to (and contingent upon) the occurrence of a &#8220;change in control&#8221; (as defined in the 2015 EIP), the stock options will become fully vested. For stock options held by the NEOs that were granted after 2018, in the event the NEO&#8217;s employment is involuntarily terminated without &#8220;cause&#8221; (as defined in the 2015 EIP and the applicable award agreement) within 12 months following the consummation of a &#8220;change in control,&#8221; the stock options will become fully vested. </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 4%; vertical-align: top;;text-align:left;">(3)</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Reflects the grant of RSUs outstanding under the 2015 EIP that vest upon the satisfaction of both a &#8220;service requirement&#8221; and a &#8220;liquidity event requirement.&#8221; The service requirement applicable to the RSUs is satisfied as follows: (i) 25% of the RSUs satisfy the service requirement on the first anniversary of the vesting commencement date and (ii)&#160;the remaining 75% of the RSUs satisfy the service requirement in 36 successive equal monthly installments thereafter, in each case, subject to the holder&#8217;s continuous service through the applicable vesting date. The liquidity event requirement will be satisfied upon the first to occur of a &#8220;change in control&#8221; or &#8220;initial public offering&#8221; of Roivant (as defined in the </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">261 </div></div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;;font-weight: bold;"><a href="#toc">Table of Contents</a></div> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;">
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 4%;">&#160;</td>
<td style="vertical-align: top;;text-align:left;">2015 EIP and the applicable award agreement) prior to the expiration date of the RSUs, which is eight years from the grant date. If the liquidity event requirement is not satisfied before the expiration date, the RSUs will be forfeited. The number of RSUs reflected in the table above reflects full attainment of the liquidity event requirement, which was satisfied on the closing of the Business Combination. The market value of the RSUs reflected in the table above is based on a share price of $38.50 per share, the fair market value of Common Shares as of March&#160;31, 2021. In the event the NEO&#8217;s employment is involuntarily terminated for any reason other than for &#8220;cause&#8221; within 12 months following the consummation of a &#8220;change in control,&#8221; the RSUs will become fully vested. </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 4%; vertical-align: top;;text-align:left;">(4)</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Reflects the grant of nonqualified performance-based stock options to purchase Common Shares outstanding under the 2015 EIP (&#8220;Performance Options&#8221;) that vest and become exercisable upon the satisfaction of both a &#8220;service requirement&#8221; and a &#8220;liquidity event requirement.&#8221; The service requirement applicable to the Performance Options is satisfied as follows: (i) 25% of the Performance Options satisfy the service requirement on December&#160;27, 2020 and (ii)&#160;the remaining 75% of the Performance Options satisfy the service requirement in 36 successive equal monthly installments thereafter, in each case, subject to the holder&#8217;s continuous service through the applicable vesting date. The liquidity event requirement will be satisfied upon the first to occur of a &#8220;change in control&#8221; or &#8220;public listing&#8221; of Roivant (as defined in the 2015 EIP and the applicable award agreement) prior to the expiration date of the Performance Options. If the liquidity event requirement is not satisfied before the expiration date, the Performance Options will be forfeited. The number of Performance Options reflected in the table above reflects full attainment of the liquidity event requirement, which was satisfied on the closing of the Business Combination. </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 4%; vertical-align: top;;text-align:left;">(5)</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;">Reflects the grant of CVARs with respect to Common Shares outstanding under the 2015 EIP that vest upon the satisfaction of both a &#8220;service requirement&#8221; and a &#8220;liquidity event requirement.&#8221; The service requirement applicable to the CVARs is satisfied as follows: (i) 25% of the CVARs satisfy the service requirement on December&#160;27, 2020 and (ii)&#160;the remaining 75% of the CVARs satisfy the service requirement in 36 successive equal monthly installments thereafter, in each case, subject to the holder&#8217;s continuous service through the applicable vesting date. The liquidity event requirement will be satisfied upon the first to occur of a &#8220;change in control&#8221; or &#8220;public listing&#8221; of Roivant (as defined in the 2015 EIP and the applicable award agreement) prior to the expiration date of the CVARs. If the liquidity event requirement is not satisfied before the expiration date, the CVARs will be forfeited. Upon vesting, the CVARs will entitle the holder to a payment equal to the product of (i)&#160;the number of vested CVARs <div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">multiplied by</div></div> (ii)&#160;the excess (if any) of (A)&#160;the fair market value of a Common Share as of the relevant date of determination (capped at $37.10 per share) <div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">over</div></div> (B)&#160;the applicable hurdle price (as described in the footnote 5 below) (the &#8220;CVAR Amount&#8221;). However, for CVARs with a hurdle price of $18.70 per share, no CVAR Amount will be payable in respect of vested CVARs if the fair market value of a Common Share is less than $26.90 per share as of the relevant date of determination (the <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">&#8220;knock-in</div> condition&#8221;); instead, such CVARs will remain outstanding unless and until the <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">knock-in</div> condition is satisfied as of any applicable measurement date thereafter before the expiration date of the CVARs. Once payable, the CVARs will be settled in a number of Common Shares determined by dividing (i)&#160;the applicable CVAR Amount by (ii)&#160;the fair market value of a Common Share as of the applicable payment date. The number of CVARs reflected in the table above reflects full attainment of the liquidity event requirement, which was satisfied on the closing of the Business Combination. </div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 4%; vertical-align: top;;text-align:left;">(6)</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">This amount reflects the per share hurdle price applicable to this award of CVARs. </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Employment Arrangements </div></div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="text-decoration: underline; letter-spacing: 0px; top: 0px;;display:inline;">Matthew Gline </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;">Mr. Gline is party to an employment agreement with RSI, dated May&#160;14, 2021, which provides for <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">at-will</div> employment and no specified term of employment. Pursuant to Mr. Gline&#8217;s employment agreement, Mr. Gline&#8217;s annual base salary is $725,000, which is subject to adjustment at the discretion of our board of directors or the compensation committee thereof. In addition, Mr.&#160;Gline is eligible to receive a discretionary annual performance bonus, with a target annual bonus equal to 100% of his annual base salary. The actual amount of any annual </div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">262 </div></div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;;font-weight: bold;"><a href="#toc">Table of Contents</a></div> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">bonus will be based on an assessment by the compensation committee of our board of directors of Mr.&#160;Gline&#8217;s performance, as well as business conditions at the company. Mr.&#160;Gline will also be eligible to receive discretionary periodic or annual equity incentive awards, based on Mr.&#160;Gline&#8217;s performance and business conditions at the company, as determined in the sole discretion of the compensation committee of our board of directors. Mr.&#160;Gline is also entitled to participate in the employee benefit plans and programs (including any medical, dental, vision, life and disability insurance benefit plans and 401(k) plan) as provided by RSI to similarly situated full-time employees from time to time. </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">Pursuant to Mr.&#160;Gline&#8217;s employment agreement, in the event Mr.&#160;Gline&#8217;s employment is terminated by RSI without &#8220;cause&#8221; (other than due to Mr.&#160;Gline&#8217;s death or &#8220;disability&#8221;) or Mr.&#160;Gline resigns for &#8220;good reason&#8221; (each as defined in Mr.&#160;Gline&#8217;s employment agreement), then, subject to Mr.&#160;Gline&#8217;s timely execution and <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-revocation</div> of a release of claims and continued compliance with applicable restrictive covenants, Mr.&#160;Gline will be entitled to receive (i)&#160;continued payment of his base salary for 12 months following the date of his termination, payable in accordance with RSI&#8217;s customary payroll procedures, (ii)&#160;an amount equal to his target annual bonus for the year of termination, payable in 12 equal monthly installments following the date of his termination and (iii)&#160;monthly reimbursement of COBRA premiums (less active employee rates) for 12 months following the date of his termination (or, if earlier, until the date Mr.&#160;Gline becomes eligible for coverage under a subsequent employer&#8217;s group health insurance plan). </div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">Pursuant to Mr.&#160;Gline&#8217;s employment agreement, in the event of a termination of Mr.&#160;Gline&#8217;s employment due to his death or disability, to the extent not already provided under the applicable award agreements and subject to the execution and <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-revocation</div> of a release of claims and continued compliance with applicable restrictive covenants, all service-based vesting conditions with respect to 50% of Mr.&#160;Gline&#8217;s then-outstanding equity awards granted prior to March&#160;31, 2021 will be immediately waived, and will thereafter otherwise remain subject to the other existing terms and conditions of such awards (including the achievement of any applicable performance-based vesting conditions and any liquidity event vesting conditions, as the case may be). In addition, pursuant to the terms of Mr.&#160;Gline&#8217;s outstanding Performance Options and CVARs granted prior to March&#160;31, 2021, in the event Mr.&#160;Gline&#8217;s employment is terminated by RSI without cause, due to Mr.&#160;Gline&#8217;s death or disability or Mr.&#160;Gline resigns for any reason (with or without good reason), subject to Mr.&#160;Gline&#8217;s timely execution and <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-revocation</div> of a release of claims and continued compliance with applicable restrictive covenants, all service-based vesting conditions with respect to 50% of Mr.&#160;Gline&#8217;s then-outstanding Performance Options and CVARs will be immediately waived, and will thereafter otherwise remain subject to the other existing terms and conditions of such awards (including the achievement of any applicable performance-based vesting conditions and any liquidity event vesting conditions, as the case may be). </div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="text-decoration: underline; letter-spacing: 0px; top: 0px;;display:inline;">Eric Venker </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;">Dr.&#160;Venker is party to an employment agreement with RSI, dated May&#160;14, 2021, which provides for <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">at-will</div> employment and no specified term of employment. Pursuant to Dr.&#160;Venker&#8217;s employment agreement, Dr.&#160;Venker&#8217;s annual base salary is $620,000, which is subject to adjustment at the discretion of the compensation committee of our board of directors. In addition, Dr.&#160;Venker is entitled to receive quarterly board fees in the amount of $3,125 per fiscal quarter (or such other amount as may be determined by Roivant) in respect of each private company affiliate of Roivant based in the United Kingdom for which Dr.&#160;Venker serves as a member of the board of directors. Dr.&#160;Venker&#8217;s annual base salary is reduced by the aggregate annual amount of such board fees payable to Dr.&#160;Venker. Dr.&#160;Venker is also eligible to receive a discretionary annual performance bonus, with a target annual bonus equal to 55% of his annual base salary (without giving effect to any reductions in such base salary for board fees). The actual amount of any annual bonus will be based on an assessment by the compensation committee of our board of directors of Dr.&#160;Venker&#8217;s performance, as well as business conditions at the company. Dr.&#160;Venker will also be eligible to receive discretionary periodic or annual equity incentive awards, based on Dr.&#160;Venker&#8217;s performance and business conditions at the company, as determined in the sole discretion of the compensation committee of our board of directors. Dr.&#160;Venker is also entitled to participate in the employee benefit plans and programs (including any medical, dental, vision, life and disability insurance benefit plans and 401(k) plan) as provided by RSI to similarly situated full-time employees from time to time. </div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">263 </div></div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;;font-weight: bold;"><a href="#toc">Table of Contents</a></div> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Pursuant to Dr.&#160;Venker&#8217;s employment agreement, in the event Dr.&#160;Venker&#8217;s employment is terminated by RSI without &#8220;cause&#8221; (other than due to Dr.&#160;Venker&#8217;s death or &#8220;disability&#8221;) or Dr.&#160;Venker resigns for &#8220;good reason&#8221; (each as defined in Dr.&#160;Venker&#8217;s employment agreement), then, subject to Dr.&#160;Venker&#8217;s timely execution and <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-revocation</div> of a release of claims and continued compliance with applicable restrictive covenants, Dr.&#160;Venker will be entitled to receive (i)&#160;continued payment of his base salary (without giving effect to any reductions in such base salary for board fees) for 12 months following the date of his termination, payable in accordance with RSI&#8217;s customary payroll procedures, (ii)&#160;an amount equal to his target annual bonus for the year of termination, payable in 12 equal monthly installments following the date of his termination and (iii)&#160;monthly reimbursement of COBRA premiums (less active employee rates) for 12 months following the date of his termination (or, if earlier, until the date Dr.&#160;Venker becomes eligible for coverage under a subsequent employer&#8217;s group health insurance plan). </div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">In addition, in the event of a termination of Dr.&#160;Venker&#8217;s employment due to his death or disability, subject to the execution and <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-revocation</div> of a release of claims and continued compliance with applicable restrictive covenants, all service-based vesting conditions with respect to 50% of Dr.&#160;Venker&#8217;s then-outstanding equity awards granted prior to March&#160;31, 2021 will be immediately waived, and will thereafter otherwise remain subject to the other existing terms and conditions of such awards (including the achievement of any applicable performance-based vesting conditions and any liquidity event vesting conditions, as the case may be). </div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="text-decoration: underline; letter-spacing: 0px; top: 0px;;display:inline;">Vivek Ramaswamy </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;">Mr.&#160;Ramaswamy is party to an employment agreement with RSI, dated May&#160;14, 2021, which provides for <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">at-will</div> employment and no specified term of employment. Pursuant to Mr.&#160;Ramaswamy&#8217;s employment agreement, Mr.&#160;Ramaswamy&#8217;s annual base salary is $350,000, which is subject to increase at the discretion of our board of directors. In addition, Mr.&#160;Ramaswamy is entitled to receive an annual bonus for each fiscal year of employment, with a target annual bonus equal to 100% of his annual base salary. Mr.&#160;Ramaswamy is also entitled to participate in the employee benefit plans and programs provided by RSI to its employees from time to time. </div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">Pursuant to Mr.&#160;Ramaswamy&#8217;s employment agreement, in the event Mr.&#160;Ramaswamy&#8217;s employment is&#160;terminated by RSI without &#8220;cause&#8221; or Mr.&#160;Ramaswamy resigns for &#8220;good reason&#8221; (each as defined in Mr.&#160;Ramaswamy&#8217;s employment agreement), then, subject to Mr.&#160;Ramaswamy&#8217;s timely execution and <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-revocation</div> of a release of claims, Mr.&#160;Ramaswamy will be entitled to receive (i)&#160;continued payment of his base salary for two years following the date of his termination, payable in accordance with RSI&#8217;s customary payroll procedures, (ii)&#160;a lump sum payment equal to the average of his target annual bonus for the three years prior to the termination date and (iii)&#160;monthly payment (or reimbursement) of COBRA premiums (less active employee rates) for 18 months following the date of his termination (or, if earlier, until the date Mr.&#160;Ramaswamy becomes eligible for coverage under a subsequent employer&#8217;s group health insurance plan). </div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">In addition, with respect to equity awards granted to Mr.&#160;Ramaswamy prior to March&#160;31, 2021, subject to his timely execution and <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-revocation</div> of a release of claims, (i)&#160;in the event Mr.&#160;Ramaswamy&#8217;s employment is terminated by RSI without cause, by Mr.&#160;Ramaswamy for good reason or by mutual agreement between him and RSI, then all service-based vesting conditions with respect to 100% of such awards then outstanding will be immediately waived and (ii)&#160;in the event Mr.&#160;Ramaswamy&#8217;s employment is terminated due to his death or disability, then all service-based vesting conditions with respect to 50% of such awards then outstanding will be immediately waived, in each case provided that all such awards will thereafter otherwise remain subject to the other existing terms and conditions of such awards (including the achievement of any applicable performance-based vesting conditions and any liquidity event vesting conditions, as the case may be). </div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="text-decoration: underline; letter-spacing: 0px; top: 0px;;display:inline;">Benjamin Zimmer </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;">Mr.&#160;Zimmer is party to an employment agreement with RSI, dated May&#160;14, 2021, which provides for <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">at-will</div> employment and no specified term of employment. Pursuant to Mr.&#160;Zimmer&#8217;s employment agreement, </div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">264 </div></div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;;font-weight: bold;"><a href="#toc">Table of Contents</a></div> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Mr.&#160;Zimmer&#8217;s annual base salary is $350,000, which is subject to adjustment at the discretion of the compensation committee of our board of directors. In addition, Mr.&#160;Zimmer is eligible to receive a discretionary annual performance bonus, with a target annual bonus equal to 100% of his annual base salary. The actual amount of any annual bonus will be based on an assessment by the compensation committee of our board of directors of Mr.&#160;Zimmer&#8217;s performance, as well as business conditions at the company. Mr.&#160;Zimmer will also be eligible to receive discretionary periodic or annual equity incentive awards, based on Mr.&#160;Zimmer&#8217;s performance and business conditions at the company, as determined in the sole discretion of the compensation committee of our board of directors. Mr.&#160;Zimmer is also entitled to participate in the employee benefit plans and programs (including any medical, dental, vision, life and disability insurance benefit plans and 401(k) plan) as provided by RSI to similarly situated full-time employees from time to time. </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">Pursuant to Mr.&#160;Zimmer&#8217;s employment agreement, in the event Mr.&#160;Zimmer&#8217;s employment is terminated by RSI without &#8220;cause&#8221; (other than due to Mr.&#160;Zimmer&#8217;s death or &#8220;disability&#8221;) or Mr.&#160;Zimmer resigns for &#8220;good reason&#8221; (each as defined in Mr.&#160;Zimmer&#8217;s employment agreement), then, subject to Mr.&#160;Zimmer&#8217;s timely execution and <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-revocation</div> of a release of claims and continued compliance with applicable restrictive covenants, Mr.&#160;Zimmer will be entitled to receive (i)&#160;continued payment of his base salary for 12 months following the date of his termination, payable in accordance with RSI&#8217;s customary payroll procedures, (ii)&#160;an amount equal to his target annual bonus for the year of termination, payable in 12 equal monthly installments following the date of his termination and (iii)&#160;monthly reimbursement of COBRA premiums (less active employee rates) for 12 months following the date of his termination (or, if earlier, until the date Mr.&#160;Zimmer becomes eligible for coverage under a subsequent employer&#8217;s group health insurance plan). </div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">In addition, in the event of a termination of Mr.&#160;Zimmer&#8217;s employment due to his death or disability, subject to the execution and <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-revocation</div> of a release of claims and continued compliance with applicable restrictive covenants, all service-based vesting conditions with respect to 50% of Mr.&#160;Zimmer&#8217;s then-outstanding equity awards granted prior to March&#160;31, 2021 will be immediately waived, and will thereafter otherwise remain subject to the other existing terms and conditions of such awards (including the achievement of any applicable performance-based vesting conditions and any liquidity event vesting conditions, as the case may be). </div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;"><div style="text-decoration: underline; letter-spacing: 0px; top: 0px;;display:inline;">Restrictive Covenants </div></div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;">The employment agreements for each of the NEOs provide for customary <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-competition</div> and <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-solicitation</div> covenants that apply during the term of the NEO&#8217;s employment and at least 12 months thereafter. In addition, the employment agreements contain standard confidentiality and <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-disparagement</div> provisions that apply during the term of the NEO&#8217;s employment and perpetually thereafter. </div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Benefit Plans </div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;">Roivant&#8217;s NEOs participate in employee benefit programs available to its employees generally, including health, dental and vision insurance and a <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">tax-qualified</div> 401(k) plan maintained by RSI. Neither Roivant nor its subsidiaries maintained any executive-specific benefit or perquisite programs in Fiscal 2020. </div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">Under RSI&#8217;s 401(k) plan, eligible employees (including the NEOs) are able to defer up to 90% of their eligible compensation subject to applicable annual limits under the Internal Revenue Code. All participants are 100% vested in their deferrals when contributed. Currently, RSI provides matching contributions for employees&#8217; <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">pre-tax</div> contributions on a <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">dollar-for-dollar</div></div> basis up to $8,550 annually per employee. These matching contributions generally become vested after two years of service by an employee. </div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Employee Stock Purchase Plan </div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">In connection with the Business Combination, our board of directors approved and adopted the Roivant Sciences Ltd. 2021 Employee Stock Purchase Plan (the &#8220;ESPP&#8221;). </div></div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">265 </div></div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;;font-weight: bold;"><a href="#toc">Table of Contents</a></div> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The following summary of the material terms of the ESPP does not purport to be complete and is qualified in its entirety by the terms of the ESPP, a form of which is filed as an exhibit to the registration statement to which this prospectus forms a part. </div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Purpose </div></div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The ESPP is intended to provide employees of Roivant and participating subsidiaries with an opportunity to acquire a proprietary interest in Roivant through the purchase of shares at a discount through payroll deductions. </div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Administration </div></div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The ESPP is administered by the compensation committee of our board of directors, which may delegate its authority to one or more officers of Roivant and to one or more committees of the board of directors. </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Our compensation committee has the authority to construe and interpret the ESPP, prescribe, amend and rescind rules relating to the ESPP&#8217;s administration and take any other actions necessary or desirable for the administration of the ESPP and correct any defect or supply any omission or reconcile any inconsistency or ambiguity in the ESPP. </div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Authorized Shares </div></div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;">Subject to certain adjustments as described below, the aggregate number of Common Shares that initially may be issued under the ESPP will be 13,900,000. In addition, on the first day of each fiscal year following the effective date of the ESPP, the number of Common Shares reserved for issuance under the ESPP will automatically increase by an amount equal to the least of (i) 13,900,000 Common Shares, (ii) 1% of the Common Shares outstanding as of the last day of the immediately preceding fiscal year and (iii)&#160;such number of Common Shares as determined by our board of directors in its discretion. The maximum number of Common Shares that may be issued under the ESPP is 147,447,650 Common Shares (subject to adjustment as noted under &#8220;&#8211;<div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Adjustments</div></div>&#8221; below). </div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Eligibility and Participation </div></div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;">Any employee of Roivant or a participating subsidiary who has completed (or who has been credited with) at least three (3)&#160;months of continuous employment or service with Roivant or any participating subsidiary and is customarily employed for at least twenty (20)&#160;hours per week may participate in the ESPP. The compensation committee may exclude from participation in the ESPP any employees who are &#8220;highly compensated employees,&#8221; or any <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">sub-set</div> of such &#8220;highly compensated employees.&#8221; The compensation committee may also exclude any employees located outside of the United States to the extent permitted under Section&#160;423 of the Code. </div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Offering Periods </div></div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;">The ESPP will be implemented through a series of <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">six-month</div> offering periods (each, an &#8220;Offering Period&#8221;), expected to commence on January&#160;1 and July&#160;1 of each year. The compensation committee has the authority to change the duration and start and end dates of the Offering Periods. </div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Adjustments </div></div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;">In the event that any dividend or other distribution (whether in the form of cash, Common Shares, or other property), recapitalization, stock split, reverse stock split, reorganization, merger, consolidation, amalgamation, <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">split-up,</div> <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">spin-off,</div> combination, repurchase or exchange of Common Shares or other securities of Roivant, or other change in Roivant&#8217;s structure affecting the Common Shares occurs, then in order to prevent dilution or enlargement of the benefits or potential benefits intended to be made available under the ESPP, the compensation committee will, in such manner as it deems equitable adjust the number of Common Shares and class of Common Shares that may be delivered under the ESPP, adjust the purchase price per Common Share and the number of Common Shares covered by each outstanding option under the ESPP; and adjust the Common Share numerical limits. </div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">266 </div></div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;;font-weight: bold;"><a href="#toc">Table of Contents</a></div> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Term; Amendment and Termination </div></div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The ESPP has a 10 year term. </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The compensation committee has the authority to amend, suspend or terminate the ESPP at any time and for any reason. If the ESPP is terminated, the compensation committee may elect either to terminate all outstanding offering periods either immediately or once Common Shares have been purchased on the next purchase date; or permit offering periods to expire in accordance with their terms. If an offering period is terminated before its scheduled expiration, all amounts that have not been used to purchase Common Shares will be returned to participants. </div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Equity Incentive Compensation Plans </div></div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Amended and Restated 2015 Equity Incentive Plan </div></div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Roivant maintains the Amended and Restated Roivant Sciences Ltd. 2015 Equity Incentive Plan (the &#8220;2015 EIP&#8221;), which provides for the discretionary grant of equity awards to eligible participants. Effective at the consummation of the Business Combination, the 2015 EIP was terminated and no further awards will be granted under the 2015 EIP. All awards outstanding under the 2015 EIP will remain subject to the terms of the 2015 EIP and the applicable award agreement, subject to adjustments made at the closing of the Business Combination. There are currently awards of nonqualified stock options (including Performance Options), RSUs and CVARs outstanding under the 2015 EIP. The following sets forth a summary of certain material features of the 2015 EIP, and is qualified in its entirety by the text of the 2015 EIP, a form of which is filed as an exhibit to the registration statement of which this prospectus forms a part. </div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Purpose </div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The 2015 EIP is intended to help Roivant secure and retain the services of eligible award recipients, provide incentives for such persons to exert maximum efforts for the success of the Roivant and its affiliates and provide a means by which the eligible recipients may benefit from increases in value of Roivant&#8217;s shares. </div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Administration </div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The 2015 EIP is administered by our board of directors, which may delegate its duties and responsibilities to one or more committees of its directors (referred to collectively as the &#8220;plan administrator&#8221;). </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Our board of directors has the authority to, among other things and subject to the limitations imposed under the 2015 EIP, stock exchange rules and other applicable law, determine the eligible participants to be granted awards and the terms and conditions of such awards; construe and interpret the 2015 EIP and awards granted thereunder and to establish, amend and revoke rules for the administration of the 2015 EIP and awards granted thereunder; settle all controversies regarding the 2021 EIP and awards granted under it; accelerate, in whole or in part, the time at which an award may be exercised or vest; approve forms of award agreements for use under the 2015 EIP; amend the terms of any one or more awards; effect, with the consent of any adversely affected participant, the reduction of the exercise price of any outstanding award, the cancellation of any outstanding award and the grant in substitution therefor of a new award, cash and/or other valuable consideration, or any other action that is treated as a repricing under generally accepted accounting principles; and exercise such powers and perform such acts as our board of directors deems necessary or expedient to promote the best interests of Roivant. </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">To the extent permitted by applicable law, our board of directors may also delegate its authority under the 2015 EIP to one or more officers to designate employees to be recipients of awards and to determine the number of shares to be granted pursuant to awards, subject to specified limits. </div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Eligibility </div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Employees, consultants and directors of Roivant and certain of its affiliates are eligible to receive awards under the 2015 EIP to the extent our board of directors determines that the grant of such award furthers the purpose of the 2015 EIP (as described above). </div></div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">267 </div></div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;;font-weight: bold;"><a href="#toc">Table of Contents</a></div> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Awards </div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The 2015 EIP provides for the grant of incentive stock options, nonqualified stock options, stock appreciation rights, restricted stock awards, restricted stock units and other stock awards. </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">As of June&#160;30, 2021, there were 48,572,113 Common Shares underlying outstanding awards under the 2015 EIP (without giving effect to the adjustments noted below which occurred in connection with the Business Combination). At the consummation of the Business Combination, all awards outstanding under the 2015 EIP remain subject to the terms of the 2015 EIP and the applicable award agreement, subject to the adjustments made at the closing of the Business Combination as described in more detail below. No further awards will be granted under the 2015 EIP. </div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Capitalization Adjustments </div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;">In the event there is a specified type of change in Roivant&#8217;s capital structure, such as a merger, consolidation, reorganization, recapitalization, reincorporation, share dividend, dividend in property other than cash, large nonrecurring cash dividend, share split, reverse share split, liquidating dividend, combination of shares, exchange of shares, change in corporate structure, or any similar equity restructuring transaction, appropriate adjustments will be made to the class and maximum number of shares reserved for issuance under the 2015 EIP, the class and maximum number of shares that may be issued upon the exercise of incentive stock options, and the class and number of shares and exercise price, strike price, <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">knock-in</div> price measure, threshold, target or maximum price measure or other price measure, if applicable, of all outstanding awards. </div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Change in Control </div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The 2015 EIP provides that, in the event of a change in control of Roivant (as described below), our board of directors may take one or more of the following actions with respect to outstanding awards, contingent upon the closing or completion of the change in control: </div></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">arrange for the assumption, continuation or substitution of the award by the successor or acquiring corporation (or its parent); </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">arrange for lapse of, or the assignment to the successor or acquiring corporation (or its parent) of, any reacquisition or repurchase rights held by Roivant; </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">accelerate the vesting (in whole or in part) of the award and provide for its termination prior to the effective time of the change in control; </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">cancel the award prior to the effective time of the change in control in exchange for a cash payment, which may be reduced by the exercise price payable in connection with the award; or </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">make a payment, in such form as determined by the Roivant, equal to the excess, if any, of the value of the property that would have been received if such award was exercised immediately prior to the effective time of the change in control over any exercise price payable (which may be $0 if the value of the property is equal to or less than the exercise price), which such payments may be delayed to the same extent that payment of consideration to Roivant shareholders in connection with the change in control is delayed as a result of escrows, earn outs, holdbacks or any other contingencies). </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Our board of directors is not obligated to treat all awards or portions of awards in the same manner. Our board of directors may take different actions with respect to the vested and unvested portions of an award. </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">A &#8220;change in control&#8221; is generally defined under the 2015 EIP to include the following: </div></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">a transaction or series of related transactions in which a person, or a group of related persons, acquires from Roivant shares representing a majority of the voting power or economic interests of Roivant; </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">268 </div></div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;;font-weight: bold;"><a href="#toc">Table of Contents</a></div> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;">
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">a merger, amalgamation or scheme of arrangement in which Roivant is a constituent party and Roivant issues shares pursuant to such transaction, except in circumstances where, Roivant shares outstanding immediately prior to such transaction continue to represent, or are converted into or exchanged for shares that represent, immediately following such transaction, at least a majority of the voting power of the surviving or amalgamated corporation or Roivant (or, if such surviving or amalgamated corporation or Roivant is a wholly owned subsidiary of another corporation immediately following such transaction, the parent corporation of such surviving or amalgamated corporation or Roivant); </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">the sale, lease, transfer, exclusive license or other disposition, in a single transaction or series of related transactions, by Roivant or any subsidiary of Roivant of all or substantially all the assets of Roivant and its subsidiaries taken as a whole; or </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">the sale or disposition (whether by merger, amalgamation, scheme of arrangement or otherwise) of one or more subsidiaries of Roivant if substantially all of the assets of Roivant and its subsidiaries taken as a whole are held by such subsidiary or subsidiaries, except where such sale, lease, transfer, exclusive license or other disposition is to a wholly owned subsidiary of Roivant. </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Plan Amendment, Suspension or Termination </div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;">Our board of directors has the authority to amend, suspend, or terminate the 2015 EIP at any time; <div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">provided</div></div> that such action does not materially impair the existing rights of any participant without such participant&#8217;s written consent. No awards may be granted under the 2015 EIP while the 2015 EIP is suspended or after it is terminated. </div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">2021 Equity Incentive Plan </div></div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">In connection with the Business Combination, our board of directors approved and adopted the Roivant Sciences Ltd. 2021 Equity Incentive Plan (the &#8220;2021 EIP&#8221;). The following sets forth a summary of certain material features of the 2021 EIP, and is qualified in its entirety by the text of the 2021 EIP, a form of which is filed as an exhibit to the registration statement of which this prospectus forms a part. </div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Purpose </div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The 2021 EIP is intended to help Roivant secure and retain the services of eligible award recipients, provide incentives for such persons to exert maximum efforts for the success of the Roivant and its affiliates and provide a means by which the eligible recipients may benefit from increases in value of Roivant&#8217;s shares. </div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Administration </div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The 2021 EIP is administered by our board of directors, which may delegate its duties and responsibilities to one or more committees of its directors (referred to collectively as the &#8220;plan administrator&#8221;). </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Our board of directors has the authority to, among other things and subject to the limitations imposed under the 2021 EIP, stock exchange rules and other applicable law: determine the eligible participants to be granted awards and the terms and conditions of such awards; construe and interpret the 2021 EIP and awards granted thereunder; settle all controversies regarding the 2021 EIP and awards granted under it; accelerate, in whole or in part, the time at which an award may be exercised or vest; approve forms of award agreements for use under the 2021 EIP; amend the terms of any one or more awards; effect, with the consent of any adversely affected participant, the reduction of the exercise price of any outstanding award, the cancellation of any outstanding award and the grant in substitution therefor of a new award, cash and/or other valuable consideration, or any other action that is treated as a repricing under generally accepted accounting principles; and exercise such powers, perform such acts and make any other determinations as our board of directors deems necessary, expedient or desirable to promote the best interests of Roivant and for due compliance with applicable law, stock market or exchange rules and regulations or accounting or tax rules and regulations. </div></div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">269 </div></div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;;font-weight: bold;"><a href="#toc">Table of Contents</a></div> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">To the extent permitted by applicable law, our board of directors may also delegate its authority under the 2021 EIP to one or more officers to designate employees to be recipients of awards and to determine the number of shares to be granted pursuant to awards, subject to specified limits. </div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Authorized Shares </div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Subject to certain adjustments as described below, the aggregate number of Common Shares that initially may be issued under the 2021 EIP is 69,300,000. In addition, on the first day of each fiscal year of Roivant following the effective date of the 2021 EIP and prior to the termination of the 2021 EIP, the number of Common Shares reserved for issuance under the 2021 EIP will automatically increase by an amount equal to the lesser of (i) 5% of the Common Shares outstanding as of the last day of the immediately preceding fiscal year and (ii)&#160;such number of Common Shares as determined by our board of directors in its discretion. The maximum number of Common Shares that may be issued pursuant to the exercise of incentive stock options under the 2021 EIP is equal to the initial share reserve under the 2021 EIP as described above. </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">The maximum number of Common Shares subject to any awards granted under the 2021 EIP during any fiscal year to any <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-employee</div> director, taken together with any cash fees paid by Roivant to such director during such fiscal year, will not exceed $750,000 (or $1,000,000 for such director&#8217;s first fiscal year of service on our board of directors) in total value. </div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Common Shares subject to awards granted under the 2021 EIP that expire or terminate without being exercised in full, or that are paid out in cash rather than in shares, will not reduce the number of Common Shares available for issuance under the 2021 EIP. Additionally, Common Shares issued pursuant to awards under the 2021 EIP that are repurchased by Roivant or are forfeited, as well as Common Shares reacquired by Roivant as consideration for the exercise or purchase price of an award or to satisfy tax withholding obligations related to an award, will become available for future grant under the 2021 EIP. </div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Eligibility </div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Employees, consultants and directors of Roivant and certain of its affiliates (including individuals who has accepted an offer of employment or service from Roivant and certain of its affiliates) are eligible to receive awards under the 2021 EIP to the extent our board of directors determines that the grant of such award furthers the purpose of the 2021 EIP (as described above). </div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Awards </div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The 2021 EIP provides for the grant of incentive stock options, nonqualified stock options, stock appreciation rights, restricted stock awards, restricted stock units and other stock awards. </div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Capitalization Adjustments </div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;">In the event there is a specified type of change in Roivant&#8217;s capital structure, such as a merger, consolidation, amalgamation, reorganization, recapitalization, reincorporation, share dividend, dividend in property other than cash, large nonrecurring cash dividend, share split, reverse share split, liquidating dividend, combination of shares, exchange of shares, change in corporate structure, or any similar equity restructuring transaction, appropriate adjustments will be made to the class and maximum number of shares reserved for issuance under the 2021 EIP, the class and maximum number of shares that may be issued upon the exercise of incentive stock options, and the class and number of shares and exercise price, strike price, <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">knock-in</div> price measure, threshold, target or maximum price measure or other price measure, if applicable, of all outstanding awards. </div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">270 </div></div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;;font-weight: bold;"><a href="#toc" style="text-indent: 0px;">Table of Contents</a></div> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Change in Control </div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The 2021 EIP provides that in the event of a change in control of Roivant (as described below), our board of directors may take one or more of the following actions with respect to outstanding awards upon the closing of the change in control: </div></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">arrange for the assumption, continuation or substitution of the award by the successor or acquiring corporation (or its parent); </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">arrange for the assignment of any reacquisition or repurchase rights held by Roivant to the successor or acquiring corporation (or its parent); </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">accelerate the vesting of the award and provide for its termination prior to the effective time of the change in control; </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">arrange for the lapse, in whole or in part, of any reacquisition or repurchase right held by Roivant; </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">determine the level of attainment of any performance conditions applicable to the award; </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">cancel the award prior to the effective time of the change in control in exchange for a cash payment, which may be reduced by the exercise price payable in connection with the award; or </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">cancel the award in exchange for a payment, in such form as determined by our board of directors, equal to the excess, if any, of the value of the property that would have been received if such award was exercised immediately prior to the effective time of the change in control over any exercise price payable (which may be $0 if the value of the property is equal to or less than the exercise price), which such payments may be delayed to the same extent that payment of consideration to Roivant shareholders in connection with the change in control is delayed as a result of escrows, earn outs, holdbacks or any other contingencies). </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Our board of directors is not obligated to treat all awards or portions of awards in the same manner. Our board of directors may take different actions with respect to the vested and unvested portions of an award. </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">A &#8220;change in control&#8221; is generally defined under the 2021 EIP to include the following: </div></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;">any person, entity or group is (or becomes during any <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">12-month</div> period) the beneficial owner of 50% or more of the total voting power of Roivant shares; </div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;">a change in the composition of our board of directors such that, during any <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">12-month</div> period, the individuals who, as of the beginning of such period, constitute our board of directors (&#8220;Existing Board&#8221;) cease for any reason to constitute a majority of our board of directors (with any individuals whose appointment to our board of directors was approved by a vote of at least a majority of the members of the Existing Board being considered a member of the Existing Board); </div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">the consummation of a merger, amalgamation or consolidation of Roivant with any another corporation or entity, or the issuance of voting securities in connection with such a transaction pursuant to applicable stock exchange requirements, except in circumstances where, immediately following such transaction, the voting securities of Roivant continue to represent 50% or more of the total voting power and total fair market value of the surviving entity or its parent; or </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;">the sale or disposition by Roivant of all or substantially all of its assets in which any person, entity or group acquires (or has acquiring during a <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">12-month</div> period) more than 50% of the total gross fair market value of all of the assets of Roivant. </div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Clawback </div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Awards granted under the 2021 EIP are subject to recoupment in accordance with any clawback policy that Roivant is required to adopt pursuant to the listing standards of any national securities exchange or association on which Roivant&#8217;s securities are listed or as is otherwise required by the Dodd-Frank Wall Street Reform and </div></div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">271 </div></div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;;font-weight: bold;"><a href="#toc">Table of Contents</a></div> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Consumer Protection Act or other applicable law. In addition, our board of directors may impose such other clawback, recovery or recoupment provisions in an award agreement as our board of directors determines necessary or appropriate. </div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Term; Plan Amendment, Suspension or Termination </div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;">The 2021 EIP has a 10 year term. Our board of directors has the authority to amend, suspend, or terminate the 2021 EIP at any time; <div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">provided</div></div> that such action does not materially impair the existing rights of any participant without such participant&#8217;s written consent. Unless terminated sooner by our board of directors, the 2021 EIP will automatically terminate on the day before the tenth anniversary of the effective date of the 2021 EIP. No awards may be granted under the 2021 EIP while the 2021 EIP is suspended or after it is terminated. </div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Treatment of Equity Awards in Connection with the Business Combination </div></div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">In connection with the Business Combination, equity incentive awards then-outstanding under the 2015 EIP were equitably adjusted in accordance with the terms of the 2015 EIP and the Business Combination Agreement. Specifically, on the date of the consummation of the Business Combination: </div></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;">each outstanding Roivant option, whether vested or unvested, was adjusted as follows: (i)&#160;the number of post-closing Common Shares subject to such Roivant option equals the product of (a)&#160;the number of Common Shares subject to the Roivant option before such adjustment,<div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">&#160;multiplied by</div></div>&#160;(b)&#160;the &#8220;exchange ratio,&#8221; rounded down to the nearest whole share, and (ii)&#160;the per share exercise price of such Roivant option equals the quotient of (x)&#160;the per share exercise price at which the Roivant option was exercisable before such adjustment,<div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">&#160;divided by</div></div>&#160;(y)&#160;the exchange ratio, rounded up to the nearest whole cent. Following such adjustment, the Roivant options otherwise remain subject to the same terms and conditions (including the applicable vesting, expiration and forfeiture provisions) as applied before such adjustment. </div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;">each outstanding and vested Roivant RSU was adjusted by multiplying (i)&#160;the number of Common Shares that were subject to the vested Roivant RSU before the adjustment<div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">&#160;by</div></div>&#160;(ii)&#160;the exchange ratio, <div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">minus</div></div> (iii)&#160;that number of post-closing Common Shares with a fair market value equal to all required withholding taxes due upon settlement of such vested Roivant RSU, which such vested Roivant RSUs will be settled (including as to timing) in accordance with the terms of the 2015 EIP and the applicable award agreement thereunder. </div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;">each outstanding unvested Roivant RSU was adjusted as follows: the number of post-closing Common Shares subject to such unvested Roivant RSU is equal to the product of (i)&#160;the number of Common Shares that were subject to the unvested Roivant RSU before the adjustment<div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">&#160;multiplied by</div></div>&#160;(ii) the exchange ratio, rounded down to the nearest whole share. Following such adjustment, the unvested Roivant RSUs otherwise remain subject to the same terms and conditions (including the applicable vesting, expiration and forfeiture provisions) as applied before such adjustment. </div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;">each outstanding Roivant CVAR, whether vested or unvested, was adjusted as follows: (i)&#160;the number of post-closing Common Shares subject to such CVAR is equal to the product of (a)&#160;the number of Common Shares that were subject to the Roivant CVAR before the adjustment,<div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">&#160;multiplied by</div></div>&#160;(b)&#160;the exchange ratio, rounded down to the nearest whole share, and (ii)&#160;the per share hurdle price, <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">&#8220;knock-in&#8221;</div> price and value cap price, as applicable, of such CVAR is equal to the quotient of (x)&#160;the per share hurdle price, <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">&#8220;knock-in&#8221;</div> price and value cap price, as applicable, applicable to the Roivant CVAR before the adjustment,<div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">&#160;divided by</div></div>&#160;(y)&#160;the exchange ratio, rounded up to the nearest whole cent. Following such adjustment, the Roivant CVARs otherwise remain subject to the same terms and conditions (including the applicable vesting, expiration and forfeiture provisions) as applied before such adjustment. </div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">272 </div></div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;;font-weight: bold;"><a href="#toc">Table of Contents</a></div> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 2%;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Director Compensation </div></div></div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Fiscal 2020 Director Compensation Table </div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The following table sets forth information regarding the annual cash retainer paid to directors of our board of directors in respect of Fiscal 2020. Roivant did not grant equity incentive compensation to directors in respect of Fiscal 2020. </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">During Fiscal 2020, only Messrs. Ramaswamy, Lo and Machado were provided compensation for their services on our board of directors. During Fiscal 2020, Mr.&#160;Ramaswamy served as both an executive officer and a director of Roivant and his compensation for his service as former executive officer is set forth above in &#8220;Executive Compensation&#8212;Summary Compensation Table.&#8221; </div></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 84%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="font-size: 0px;">
<td style="width: 62%; font-family: &quot;Times New Roman&quot;;"></td>
<td style="width: 6%; vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="font-family: &quot;Times New Roman&quot;;"></td>
<td style="font-family: &quot;Times New Roman&quot;;"></td>
<td style="font-family: &quot;Times New Roman&quot;;"></td>
<td style="width: 6%; vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="font-family: &quot;Times New Roman&quot;;"></td>
<td style="font-family: &quot;Times New Roman&quot;;"></td>
<td style="font-family: &quot;Times New Roman&quot;;"></td>
<td style="width: 6%; vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="font-family: &quot;Times New Roman&quot;;"></td>
<td style="font-family: &quot;Times New Roman&quot;;"></td>
<td style="font-family: &quot;Times New Roman&quot;;"></td> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; white-space: nowrap; padding-bottom: 1pt;"> <div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt; border-bottom: 1pt solid rgb(0, 0, 0); display: table-cell; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">Name</div></div></div> </td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Fees&#160;Earned<br/>or Paid<br/>in&#160;Cash<br/>($)</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Stock<br/>Awards<br/>($)<div style="font-size: 85%; vertical-align: top;;display:inline;;font-size:7.5px">(1)</div></div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Total<br/>($)</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Vivek Ramaswamy</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">150,000</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">150,000</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Andrew Lo</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">200,000</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">200,000</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Patrick Machado</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">75,000</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">75,000</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 4%; vertical-align: top;;text-align:left;">(1)</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Mr.&#160;Ramaswamy&#8217;s equity incentive awards as of March&#160;31, 2021 are set forth above in &#8220;Executive Compensation&#8212;Outstanding Equity Awards at Fiscal Year End.&#8221; As of March&#160;31, 2021, each of Messrs. Lo and Machado held the following Roivant equity incentive awards granted under the 2015 EIP: </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 9%;">&#160;</td>
<td style="width: 4%; vertical-align: top;;text-align:left;">(a)</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Dr.&#160;Lo holds 236,000 stock options granted on October&#160;20, 2016 with an exercise price of $15.17 per share, all of which were vested and exercisable. Following this grant of stock options, Dr.&#160;Lo has not been eligible to receive any other equity compensation for his services on our board of directors. </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 9%;">&#160;</td>
<td style="width: 4%; vertical-align: top;;text-align:left;">(b)</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Mr.&#160;Machado holds (i) 58,153 stock options granted on October&#160;20, 2016 with an exercise price of $15.17 per share, all of which were vested and exercisable, (ii) 37,500 stock options granted on December&#160;20, 2017 with an exercise price of $21.72 per share, all of which were vested and exercisable, (iii) 37,500 stock options granted on January&#160;22, 2019 with an exercise price of $32.72 per share, of which 29,172 were vested and exercisable and the remaining will vest and become exercisable in equal monthly installments through the period ending on November&#160;30, 2021, and (iv) 37,500 stock options granted on January&#160;20, 2020 with an exercise price of $37.10 per share, of which 16,668 were vested and exercisable and the remaining will vest and become exercisable in equal monthly installments through the period ending on November&#160;30, 2022. </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">Annual cash retainers payable to directors are calculated based upon the prorated number of quarterly periods each <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-employee</div> director served in their respective capacity as a board and/or committee member in a given fiscal year. Except for Dr.&#160;Lo, who is not eligible to receive any expense reimbursement in connection with his service on our board of directors, directors are also eligible to be reimbursed for actual expenses incurred in attending meetings of our board of directors and any of its committees. </div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Post-Business Combination Director Compensation Program </div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;">Our board of directors has also approved a <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">Non-Employee</div> Directors Compensation Policy pursuant to which our <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-employee</div> directors will receive compensation for their service on the board of directors, as described below. The compensation payable to our <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-employee</div> directors under this policy is subject to the limitations on <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-employee</div> director compensation set forth in the 2021 EIP (as described above). </div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">273 </div></div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;;font-weight: bold;"><a href="#toc">Table of Contents</a></div> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Cash Retainers </div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;">Our <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-employee</div> directors are entitled to receive annual cash retainers for their service, which are payable in equal quarterly installments as follows: </div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 68%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="font-size: 0px;">
<td style="width: 85%; font-family: &quot;Times New Roman&quot;;"></td>
<td style="width: 6%; vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="font-family: &quot;Times New Roman&quot;;"></td>
<td style="font-family: &quot;Times New Roman&quot;;"></td>
<td style="font-family: &quot;Times New Roman&quot;;"></td> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; white-space: nowrap;"> <div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt; border-bottom: 1pt solid rgb(0, 0, 0); display: table-cell; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">Role</div></div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; white-space: nowrap;;text-align:center;"> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt; border-bottom: 1pt solid rgb(0, 0, 0); display: inline-block; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">Retainer</div></div></div> </td>
<td style="vertical-align: bottom;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Board Member</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">40,000</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Lead Independent Director</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">25,000</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Board Chair</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">35,000</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Audit Committee Chair</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">20,000</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Audit Committee Member</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">10,000</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Compensation Committee Chair</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">15,000</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Compensation Committee Member</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">7,500</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Nominating and Governance Committee Chair</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">10,000</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Nominating and Governance Committee Member</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">5,000</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">Prior to the last day of any fiscal year, a <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-employee</div> director may elect that either 50% or 100% of his or her annual cash retainers payable in the following fiscal year be paid in the form of unrestricted Common Shares. </div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Initial Equity Retainer </div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;">Upon a <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-employee</div> director&#8217;s initial commencement of service on our board of directors, each <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-employee</div> director will be entitled to receive an initial, <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">one-time</div> award of stock options under the 2021 EIP with an aggregate grant date value of $600,000. The initial option award will vest over a three-year period, with 1/3 vesting on the first anniversary of the applicable vesting commencement date and the remaining portion of the award vesting in 24 equal monthly installments, subject to the <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-employee</div> director&#8217;s continuous service through the applicable vesting date, except that, in the event of a change in control (as defined under the 2021 EIP), such stock options will become fully vested and exercisable. </div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Annual Equity Retainers </div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;">On the date of our annual general meeting of shareholders, each <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-employee</div> director (i)&#160;who has completed at least three (3)&#160;months of continuous service as a <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-employee</div> director as of the date of such meeting and (ii)&#160;whose term is scheduled to continue at least through the date of the next annual meeting will be entitled to receive (1)&#160;an annual award of stock options under the 2021 EIP with an aggregate grant date value of $200,000, and (2)&#160;an annual award of restricted stock units under the 2021 EIP with an aggregate grant date value of $200,000. If the <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-employee</div> director commences service on our board on a date other than at the annual meeting of shareholders, then they will be entitled to receive a prorated annual equity award on the date of the next annual meeting following his or her start date, if he or she otherwise satisfies the eligibility requirements. Each annual equity award will vest and, if applicable, become exercisable in full on the <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">one-year</div> anniversary of the applicable vesting commencement date, subject to the <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-employee</div> director&#8217;s continuous service through such vesting date, except that, in the event of a change in control, any the annual equity awards will become fully vested and, if applicable, exercisable. </div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Emerging Growth Company Status </div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">As an emerging growth company, Roivant is exempt from certain requirements related to executive compensation, including the requirements to hold a nonbinding advisory vote on executive compensation and to provide information relating to the ratio of total compensation of Roivant&#8217;s chief executive officer to the median of the annual total compensation of all of Roivant&#8217;s employees, each as required by the Investor Protection and Securities Reform Act of 2010, which is part of the Dodd-Frank Wall Street Reform and Consumer Protection Act. </div></div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">274 </div></div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;;font-weight: bold;"><a href="#toc">Table of Contents</a></div> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"> <div id="rom164680_14" style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">CERTAIN RELATIONSHIPS AND RELATED PARTY TRANSACTIONS </div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The following is a description of transactions occurring during our last three fiscal years or currently proposed, to which (i)&#160;Roivant Sciences Ltd. has been a participant, (ii)&#160;the amount involved exceeded or will exceed $120,000 and (iii)&#160;any of Roivant&#8217;s directors, executive officers or holders of more than 5% of Roivant&#8217;s share capital, or any members of their immediate family (collectively &#8220;Roivant Related Parties&#8221;), had or will have a direct or indirect material interest. </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Other than as described below, there have not been, nor are there any currently proposed, transactions or series of similar transactions meeting these criteria to which we have been or will be a party other than compensation arrangements, which are described where required under &#8220;Executive Compensation&#8212;Director Compensation&#8221; and &#8220;Executive Compensation&#8212;Post-Business Combination Director Compensation Program.&#8221; </div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Transactions with Sumitomo Dainippon Pharma Co., Ltd. </div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">On October&#160;31, 2019, we entered into a transaction agreement with Sumitomo (the &#8220;Sumitomo Transaction Agreement&#8221;), which closed on December&#160;27, 2019 (the &#8220;Sumitomo Closing Date&#8221;). Pursuant to the Sumitomo Transaction Agreement, we transferred our entire ownership interest in Myovant, Urovant, Enzyvant, Altavant and Spirovant (collectively &#8220;Sumitovant Vants&#8221;) to a newly formed, wholly-owned entity (&#8220;Sumitovant&#8221;). Our ownership interest in Sumitovant was then transferred to Sumitomo, such that following the Sumitomo Closing Date, Sumitovant and its subsidiaries, including the Sumitovant Vants, were each directly or indirectly owned by Sumitomo. </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Additionally, in connection with the Sumitomo Transaction Agreement, we (i)&#160;granted Sumitomo options to purchase all, or in the case of Dermavant, 75%, of our ownership interests in six other subsidiaries (Dermavant, Genevant, Lysovant, Metavant, Cytovant and Sinovant (collectively the &#8220;Option Vants&#8221;)), (ii) (a) transferred the proprietary technology platform DrugOme to Sumitomo (for which Roivant retains a perpetual royalty free license for internal use) and (b) licensed the Digital Innovation technology platform to Sumitomo (for which both parties retain ongoing access) and (iii)&#160;transferred 26,952,143 of our Common Shares to Sumitomo. On the Sumitomo Closing Date, the Company received approximately $3.0&#160;billion in cash, resulting in a gain of $2.0&#160;billion after taking into account all of the components of the transaction. </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Concurrently with the Sumitomo Transaction Agreement, (i)&#160;Roivant, Sumitomo and Sumitovant entered into a transition services agreement, whereby each of the parties thereto agreed to provide certain services to one another at cost for a period of time following the Sumitomo Closing Date and (ii)&#160;Roivant and Sumitomo entered into a strategic cooperation agreement relating to certain ongoing technology-related collaborations between the parties. Pursuant to the terms of the transition services agreement and strategic cooperation agreement, we billed Sumitovant $1.4&#160;million and $0.2&#160;million, net of amounts billed by Sumitovant to us, respectively, during the years ended March&#160;31, 2021 and 2020 for costs incurred on behalf of Sumitovant. </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Additionally, on the Sumitomo Closing Date, Sumitomo deposited $75.0&#160;million of the consideration payable pursuant to the Sumitomo Transaction Agreement in a segregated escrow account for the purpose of fulfilling our indemnification obligations that may become due to Sumitomo. Upon the expiration of the escrow period, being 18 months from the Sumitomo Closing Date, any remaining escrow funds will be disbursed to us. </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">On the Sumitomo Closing Date, we also entered into an agreement with Sumitomo, pursuant to which we granted Sumitomo a right of first refusal with respect to potential transfers of Roivant&#8217;s ownership interest in common shares of Sio Gene Therapies (formerly Axovant Gene Therapies) (the &#8220;ROFR&#8221;). Among other things, such agreement provides that Roivant must promptly deliver notice to Sumitomo if it desires to transfer equity interests of Sio Gene Therapies and provide Sumitomo with an opportunity to make a matching offer for the subject shares in accordance with the terms and conditions set forth therein. The ROFR terminates on October&#160;31, 2024. The ROFR also includes certain notification rights in favor of Sumitomo, in the event Roivant takes certain specified corporate actions. </div></div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">275 </div></div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;;font-weight: bold;"><a href="#toc">Table of Contents</a></div> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">At the Sumitomo Closing Date, we also entered into a Share Return Agreement (the &#8220;Share Return Agreement&#8221;) with Sumitomo pursuant to which, subject to certain conditions provided therein, if Sumitomo directly or indirectly holds greater than 55.0% of the then issued and outstanding Common Shares of Myovant Sciences Ltd. (the &#8220;Requisite Threshold&#8221;), Sumitomo shall return to Roivant for no consideration Common Shares, up to a total of 4,243,005 Common Shares, such that Sumitomo directly or indirectly continues to hold Common Shares in excess of the Requisite Threshold. </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">In connection with the foregoing transactions with Sumitomo, our board of directors approved an exchange and offer to repurchase equity securities for up to $1.0&#160;billion of the proceeds received from Sumitomo. See &#8220;&#8212;Equity Exchange and Offer to Purchase.&#8221; </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">During the years ended March&#160;31, 2021 and 2020, we paid Sumitomo a $1.0&#160;million access fee pursuant to the strategic cooperation agreement. </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">In May&#160;2021, we entered into an Asset Purchase Agreement with Sumitomo and its subsidiary Sumitomo Pharmaceuticals (Suzhou) Co., Ltd. (&#8220;SPC&#8221;) (the &#8220;Asset Purchase Agreement&#8221;). The transactions contemplated by the Asset Purchase Agreement closed in June 2021. Pursuant to the Asset Purchase Agreement: (i)&#160;Sumitomo terminated all of its existing options to acquire our equity interests in the Option Vants; (ii)&#160;we transferred and assigned to SPC all of our intellectual property, development, regulatory and commercialization rights to (a)&#160;lefamulin in Mainland China, Taiwan, Hong Kong, and Macau (collectively &#8220;Greater China&#8221;), (b) vibegron in Mainland China, (c)&#160;rodatristat ethyl in Greater China and South Korea, and <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">(d)&#160;RVT-802</div> in Greater China and South Korea; (iii)&#160;we received a $5&#160;million cash payment; and (iv)&#160;Sumitomo entered into an agreement with us in respect of certain future collaborations with Genevant. </div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Equity Exchange and Offer to Purchase </div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">In February 2020, we commenced (i)&#160;an offer to purchase our Common Shares from our eligible shareholders (including certain of our eligible employees and former employees) at a price per share of $37.10, (ii) an offer to surrender for cash performance options and capped value appreciation rights (&#8220;CVARs&#8221;) issued in exchange for certain performance restricted stock units (&#8220;pRSUs&#8221;) held by certain of our eligible employees and former employees, whereby such holder&#8217;s eligible pRSUs were exchanged at a rate of approximately 0.7 performance options per eligible pRSU and, if applicable, approximately 0.7 CVARs per eligible pRSU (the &#8220;Exchange&#8221;) and, immediately thereafter, 11.23% of such performance options and CVARs were surrendered to us for cash and (iii)&#160;an offer to purchase outstanding options from certain of our eligible employees and former employees, the maximum aggregate repurchase value being equal to the lesser of (a)&#160;the fair market value of approximately 11.23% of the eligible holder&#8217;s outstanding vested and unvested unexercised options held as of December&#160;27, 2019 and (b)&#160;the fair market value of 100% of the eligible holder&#8217;s outstanding options that were vested and exercisable as of December&#160;27, 2019 (subject to certain adjustments). The foregoing transactions are referred to herein as the &#8220;2020 Equity Exchange and Offer to Purchase.&#8221; We additionally entered into an agreement with our Founder to repurchase a portion of his common stock held and exchange his Performance RSUs for performance options and capped value appreciation rights. </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">In total, in the 2020 Equity Exchange and Offer to Purchase, including participation by certain Roivant Related Parties, we purchased 25,625,933 Common Shares, exchanged 18,016,310 primarily for pRSUs for performance options and CVARs, received 631,527 surrendered performance options, received 518,893 surrendered CVARs and purchased 895,923 options in connection with the various offers to exchange and purchase, for an aggregate purchase price of approximately $1.0&#160;billion. </div></div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">276 </div></div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;;font-weight: bold;"><a href="#toc">Table of Contents</a></div> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">2018 Equity Financing </div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">From September through December 2018, Roivant completed an equity financing in which certain Roivant Related Parties participated: </div></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">the Viking Global Entities (as defined herein) and certain of their affiliates purchased 155,038 Common Shares for an aggregate purchase price of $4,999,975. </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Dexxon Holdings Ltd. purchased 775,194 Common Shares for an aggregate purchase price of $25,000,006. </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">SVF Investments (as defined herein) purchased 1,085,271 Common Shares for an aggregate purchase price of $34,999,989. </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">the QVT Entities (as defined herein) and certain of their affiliates purchased 62,015 Common Shares for an aggregate purchase price of $1,999,983. </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Certain Employment and Compensatory Arrangements </div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Brett Venker, currently Director, Compensation and Data, is the brother of Eric Venker, Roivant&#8217;s President and Chief Operating Officer. During the fiscal year ended March&#160;31, 2019, Brett Venker earned total cash compensation, consisting of salary and bonus, of $205,048 and was granted incentive equity awards with an aggregate grant date fair value, as computed in accordance with FASB ASC 718, of $1,025,505. During the fiscal year ended March&#160;31, 2020, Dr.&#160;Venker earned total cash compensation, consisting of salary and bonus, of $338,273 and was granted incentive equity awards with an aggregate grant date fair value, as computed in accordance with FASB ASC 718, of $64,140. During the fiscal year ended March&#160;31, 2021, Dr.&#160;Venker earned total cash compensation, consisting of salary and bonus, of $360,634 and was granted incentive equity awards with an aggregate grant date fair value, as computed in accordance with FASB ASC 718, of $400,039. </div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Other Transactions </div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">We have granted and intend to continue to grant equity awards to our executive officers and certain of our directors. For a description of these equity awards, see the sections titled &#8220;Executive Compensation&#8212;Director Compensation&#8221; and &#8220;Executive Compensation&#8212;Post-Business Combination Director Compensation Program.&#8221; </div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Indemnification Agreements </div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;">We have entered into indemnification agreements with each of our directors and executive officers. These indemnification agreements provide the directors and executive officers with contractual rights to indemnification and expense advancement that are, in some cases, broader than the specific indemnification provisions contained under Bermuda law. See the section titled &#8220;Description of Securities&#8212;Indemnification of Directors and Officers&#8221; for additional information regarding indemnification under Bermuda law and our amended and restated <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">bye-laws.</div> </div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Related Person Transaction Policy </div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">We have adopted a related person transaction policy that sets forth our procedures for the identification, review, consideration and approval or ratification of related person transactions. For purposes of our policy only, a related person transaction is a transaction, arrangement or relationship, or any series of similar transactions, arrangements or relationships, in which we and any related person are, were or will be participants in which the amount involved exceeds $120,000. Transactions involving compensation for services provided to us as an employee or director are not covered by this policy. A related person is any executive officer, director or beneficial owner of more than 5% of any class of Roivant&#8217;s voting securities, and any of their respective immediate family members and any entity owned or controlled by such persons. </div></div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">277 </div></div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;;font-weight: bold;"><a href="#toc">Table of Contents</a></div> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Under the policy, if a transaction has been identified as a related person transaction, including any transaction that was not a related person transaction when originally consummated or any transaction that was not initially identified as a related person transaction prior to consummation, our management must present information regarding the related person transaction to our audit committee, or, if audit committee approval would be inappropriate, to another independent body of our board of directors, for review, consideration and approval or ratification. The presentation must include a description of, among other things, the material facts, the interests, direct and indirect, of the related persons, the benefits to us of the transaction and whether the transaction is on terms that are comparable to the terms available to or from, as the case may be, an unrelated third party or to or from employees generally. Under the policy, we will collect information that we deem reasonably necessary from each director, executive officer and, to the extent feasible, significant shareholder to enable us to identify any existing or potential related-person transactions and to effectuate the terms of the policy. In addition, under our Code of Conduct, our employees and directors have an affirmative responsibility to disclose any transaction or relationship that reasonably could be expected to give rise to a conflict of interest. In considering related person transactions, our audit committee, or other independent body of our board of directors, is required to take into account the relevant available facts and circumstances including, but not limited to: </div></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">the risks, costs and benefits to us; </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">the impact on a director&#8217;s independence in the event that the related person is a director, immediate family member of a director or an entity with which a director is affiliated; </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">the availability of other sources for comparable services or products; and </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">the terms available to or from, as the case may be, unrelated third parties or to or from employees generally. </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The policy requires that, in determining whether to approve, ratify or reject a related person transaction, our audit committee, or other independent body of our board of directors, must consider, in light of known circumstances, whether the transaction is in, or is not inconsistent with, our best interests and those of our shareholders, as our audit committee, or other independent body of our board of directors, determines in the good faith exercise of its discretion. </div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Post-Business Combination Arrangements </div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">In connection with the Business Combination, certain agreements with certain Roivant Related Parties were entered into pursuant to the Business Combination Agreement. The agreements described in this section, or forms of such agreements as they will be in effect substantially concurrently with the completion of the business combination, are filed as exhibits to the registration statement of which this prospectus forms a part, and the following descriptions are qualified by reference thereto. These agreements include: </div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Transaction Support Agreement </div></div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Concurrently with the signing of the Business Combination Agreement, certain shareholders of Roivant entered into a Transaction Support Agreement (collectively, the &#8220;Transaction Support Agreements&#8221;) with MAAC and Roivant, pursuant to which such shareholders of Roivant have agreed to, among other things, certain covenants and agreements, to support, or that are otherwise related to, the Business Combination, including an agreement to terminate certain existing agreements between Roivant and such shareholders, an agreement to not transfer his, her or its Roivant shares prior to the Closing and, in the case of certain Roivant shareholders also participating in the PIPE Financing, certain covenants related to the expiration or termination of the waiting period under the HSR Act, to the extent applicable, with respect to the issuance of Common Shares to such shareholder in connection with the Business Combination. </div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Sponsor Support Agreement </div></div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Concurrently with the execution of the Business Combination Agreement, MAAC, the MAAC Sponsor, Roivant and each of the MAAC Insiders, entered into the Sponsor Support Agreement, which was subsequently </div></div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">278 </div></div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;;font-weight: bold;"><a href="#toc">Table of Contents</a></div> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">amended on June&#160;9, 2021 to reflect the MAAC Independent Directors and Roivant entering into respective <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">Lock-Up</div> Agreements and further amended on September&#160;30, 2021. </div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">Pursuant to the Sponsor Support Agreement, among other things: (i)&#160;the MAAC Sponsor and the MAAC Insiders reaffirmed his, her or its obligations in existing arrangements with MAAC to vote in favor of each of the proposals to be voted upon at the meeting of MAAC stockholders in connection with the Business Combination, including approval of the Business Combination Agreement and the transactions contemplated thereby; (ii)&#160;the MAAC Sponsor waived any adjustment to the conversion ratio set forth in the governing documents of MAAC or any other anti-dilution or similar protection with respect to the MAAC Class&#160;B Shares that may result from the transactions contemplated by the Business Combination; (iii)&#160;subject to, and conditioned upon, the occurrence of and effective as of, the Effective Time, the MAAC Sponsor and the MAAC Insiders agreed to terminate certain existing arrangements with MAAC, including existing registration rights and the existing <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">lock-up</div> obligations with respect to his, her or its MAAC Shares; (iv)&#160;the MAAC Sponsor and the MAAC Insiders that hold Common Shares immediately following the Effective Time will be granted the right to include his, her or its Common Shares in a resale registration statement to be filed in connection with the transactions contemplated by the Subscription Agreements following the Effective Time; (v)&#160;the MAAC Sponsor, Roivant and MAAC have each agreed to certain covenants related to the expiration or termination of the waiting period under the HSR Act with respect to the issuance of Common Shares to the MAAC Sponsor in connection with the Business Combination; and (vi)&#160;subject to, and conditioned upon the occurrence of, and effective as of immediately after, the Effective Time, (a) 2,033,591 shares of the Common Shares issued to the MAAC Sponsor and 10,000 shares of the Common Shares issued to each MAAC Independent Director, each in respect of its MAAC Class&#160;B Shares, will be subject to the vesting conditions described below and the other restrictions set forth in the Sponsor Support Agreement with respect to the $15 <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">Earn-Out</div> Shares and (b) 1,016,796 shares of the Common Shares issued to the MAAC Sponsor and 5,000 shares of the Common Shares issued to each MAAC Independent Director, each in respect of its MAAC Class&#160;B Shares, will be subject to the vesting conditions described below and the other restrictions set forth in the Sponsor Support Agreement with respect to the $20 <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">Earn-Out</div> Shares. </div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">The $15 <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">Earn-Out</div> Shares will vest if the closing price of the Common Shares is greater than or equal to $15.00 over any twenty out of thirty trading day period during the period commencing on the earlier of (a)&#160;the date on which the registration statement of which this prospectus forms a part is declared effective or (b)&#160;November&#160;15, 2021, and ending no later than the fifth anniversary of the Closing Date following the Closing (the &#8220;vesting period&#8221;), and the $20 <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">Earn-Out</div> Shares will vest if the closing price of the Common Shares is greater than or equal to $20.00 over any twenty out of thirty trading day period during the vesting period. The vesting period will, if a definitive purchase agreement with respect to a Sale (as defined in the Sponsor Support Agreement) is entered into on or prior to the end of such period, be extended to the earlier of one day after the consummation of such Sale and the termination of such definitive transaction agreement, and if a Sale occurs during such vesting period, then all of the <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">Earn-Out</div> Shares unvested as of such time will automatically vest immediately prior to the consummation of such Sale. If any <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">Earn-Out</div> Shares have not vested on or prior to the end of such vesting period, then such <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">Earn-Out</div> Shares will be forfeited. </div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">PIPE Agreements </div></div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Prior to the consummation of the Business Combination, MAAC and Roivant entered into subscription agreements (collectively, the &#8220;Subscription Agreements&#8221;) with certain institutional and accredited investors, pursuant to which such investors agreed to subscribe for and purchase, and MAAC agreed to issue and sell to such investors, prior to and substantially concurrently with the closing of the Business Combination, an aggregate of 22,000,000 MAAC Class&#160;A Shares at a purchase price of $10.00 per share, for aggregate gross proceeds of $220,000,000 (the &#8220;PIPE Financing&#8221;). The PIPE Financing was consummated substantially concurrently with the closing of the Business Combination. Each MAAC Class&#160;A Share issued in the PIPE Financing was converted into one Common Share in connection with the closing of the Business Combination. The issuance of the Common Shares pursuant to the PIPE Financing was not registered the Securities Act and the Common Shares were issued in reliance upon the exemption provided in Section&#160;4(a)(2) of the Securities Act. </div></div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">279 </div></div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;;font-weight: bold;"><a href="#toc">Table of Contents</a></div> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The Subscription Agreements included provisions requiring us to provide certain customary registration rights to the investors in the PIPE Financing, which we intend to satisfy with the registration statement of which this prospectus forms a part. </div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Registration Rights Agreement </div></div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Concurrently with the execution of the Business Combination Agreement, certain Roivant shareholders entered into the Third Amended and Restated Registration Rights Agreement (the &#8220;Registration Rights Agreement&#8221;) pursuant to which, among other things, certain Roivant shareholders party thereto, subject to certain exceptions, were be granted certain customary registration rights. </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Pursuant to the terms of the Registration Rights Agreement, Roivant is obligated to file a registration statement to register the resale of certain Common Shares within 30 days after the consummation of the Business Combination, which Roivant intends to satisfy with the registration statement of which this prospectus forms a part. In addition, pursuant to the terms of the Registration Rights Agreement and subject to certain requirements and customary conditions, including with regard to the number of demand rights that may be exercised and other requirements, at any time after March&#160;30, 2022, certain significant shareholders (as provided in the Registration Rights Agreement), if any, holding at least five percent (5.0%)&#160;of the then-outstanding number of registrable securities of Roivant who is party to the Registration Rights Agreement may request that Roivant file a registration statement to register the registrable securities of Roivant held by such significant shareholder. The Registration Rights Agreement will also provide certain shareholders with &#8220;piggy-back&#8221; registration rights, subject to certain requirements and customary conditions. </div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">Lock-Up</div> Agreements </div></div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;">On May&#160;1, 2021 and June&#160;9, 2021, Roivant, on the one hand, and the MAAC Sponsor, both of MAAC&#8217;s independent directors (the &#8220;MAAC Independent Directors&#8221;) and certain Roivant equityholders, on the other hand, entered into <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">lock-up</div> agreements (the <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">&#8220;Lock-Up</div> Agreements&#8221;), pursuant to which, among other things, the MAAC Sponsor, MAAC Independent Directors and such Roivant equityholders have agreed not to, subject to, and conditioned upon the effectiveness of, the Closing, effect any sale or distribution of the Common Shares (including those underlying incentive equity awards or Warrants) held by the MAAC Sponsor, MAAC Independent Directors or such equityholders as of immediately following the Closing during the applicable <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">lock-up</div> period, subject to customary exceptions. The <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">lock-up</div> period applicable to Common Shares held by the MAAC Sponsor and MAAC Independent Directors as of immediately following the Closing will be (i)&#160;with respect to 25% of the Common Shares held by the MAAC Sponsor, six months following the Closing, (ii)&#160;with respect to an additional 25% of the Common Shares held by the MAAC Sponsor, the earlier of twelve months following the achievement of certain price-based vesting restrictions or six years from the Closing and (iii)&#160;with respect to 50% of the Common Shares held by the MAAC Sponsor, <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">thirty-six</div> months following the Closing. The Warrants and the Common Shares underlying Warrants held by the MAAC Sponsor as of immediately following the Closing will be subject to a corresponding <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">lock-up</div> period for (a)&#160;with respect to 25% of such Warrants held by the MAAC Sponsor, six months from the Closing, (b)&#160;with respect to an additional 25% of such Warrants held by the MAAC Sponsor, twelve months from Closing and (c)&#160;with respect to 50% of such warrants held by the MAAC Sponsor, <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">thirty-six</div> months from the Closing. The <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">lock-up</div> period applicable to Common Shares (including those underlying incentive equity awards) held by certain Roivant equityholders as of immediately following the Closing will be (x)&#160;with respect to 25% of the Common Shares (including those underlying incentive equity awards) held by such Roivant equityholders, six months following the Closing, (y)&#160;with respect to an additional 25% of the Common Shares (including those underlying incentive equity awards) held by such Roivant equityholders, twelve months following the Closing and (z)&#160;with respect to 50% of the Common Shares (including those underlying incentive equity awards) held by such Roivant equityholders, <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">thirty-six</div> months following the Closing. </div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">280 </div></div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;;font-weight: bold;"><a href="#toc" style="text-indent: 0px;">Table of Contents</a></div> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"> <div id="rom164680_15" style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">PRINCIPAL SECURITYHOLDERS </div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The following table sets forth information regarding the beneficial ownership of the Common Shares as of September&#160;30, 2021 by: </div></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">each person known by the Company to be the beneficial owner of more than 5% of outstanding Common Shares; </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">each of the Company&#8217;s named executive officers and directors; and </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">all executive officers and directors of the Company as a group. </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Beneficial ownership is determined according to the rules of the SEC, which generally provide that a person has beneficial ownership of a security if he, she, or it possesses sole or shared voting or investment power over that security, including options and warrants that are currently exercisable or exercisable within 60 days. The ownership percentages set forth in the table below are based on 684,789,169 Common Shares issued and outstanding as of September&#160;30, 2021 and unless otherwise noted below, do not take into account the issuance of any Common Shares issuable upon exercise of Warrants. However, shares that a person has the right to acquire within 60 days of September&#160;30, 2021 are deemed issued and outstanding for purposes of computing the percentage ownership of the person holding such rights, but are not deemed issued and outstanding for purposes of computing the percentage ownership of any other person, except with respect to the percentage ownership of all directors and executive officers as a group. Unless otherwise noted in the footnotes to the following table, and subject to applicable community property laws, we believe the persons and entities named in the table have sole voting and investment power with respect to their beneficially owned Common Shares. </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">Unless otherwise indicated, the Company believes that each person named in the table below has sole voting and investment power with respect to all shares of common stock beneficially owned by such person. Except as otherwise noted below, the address for persons or entities listed in the table is c/o Roivant Sciences Ltd., Suite 1, 3rd Floor, <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">11-12</div> St. James&#8217;s Square, London SW1Y 4LB, United Kingdom. </div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="font-size: 0px;">
<td style="width: 65%; font-family: &quot;Times New Roman&quot;;"></td>
<td style="width: 11%; vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="font-family: &quot;Times New Roman&quot;;"></td>
<td style="font-family: &quot;Times New Roman&quot;;"></td>
<td style="font-family: &quot;Times New Roman&quot;;"></td>
<td style="width: 11%; vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="font-family: &quot;Times New Roman&quot;;"></td>
<td style="font-family: &quot;Times New Roman&quot;;"></td>
<td style="font-family: &quot;Times New Roman&quot;;"></td> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid; white-space: nowrap;;text-align:center;"> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 1pt; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">Name and Address of<br/>Beneficial Owners</div></div></div> </td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid; white-space: nowrap;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Number&#160;of&#160;Common&#160;Shares</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid; white-space: nowrap;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">%&#160;of&#160;Ownership</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Directors and current named executive officers:</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: top; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: top; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: top; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: top; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: top; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: top; font-family: &quot;Times New Roman&quot;;"></td> </tr>
<tr style="font-size: 1pt;">
<td style="height: 6pt; font-family: &quot;Times New Roman&quot;;"></td>
<td colspan="4" style="height: 6pt; font-family: &quot;Times New Roman&quot;;"></td>
<td colspan="4" style="height: 6pt; font-family: &quot;Times New Roman&quot;;"></td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;">Matthew Gline<br/><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Chief Executive Officer and Director</div></div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">2,500,486</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">*</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;">Eric Venker<br/><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">President and Chief Operating Officer</div></div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">1,230,296</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">*</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;">Benjamin Zimmer<br/><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Former President, Roivant Health</div></div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">1,610,224</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">*</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;">James C. Momtazee<br/><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Director</div></div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;">Vivek Ramaswamy<br/><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Director</div></div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">72,556,652</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">10.4</td>
<td style="vertical-align: bottom; white-space: nowrap;">%&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;">Andrew Lo<br/><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Director</div></div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">690,583</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">*</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;">Patrick Machado<br/><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Director</div></div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">456,722</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">*</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;">Keith Manchester<br/><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Director</div></div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;">Ilan Oren<br/><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Director</div></div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;">Daniel Gold<br/><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Director</div></div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;">Masayo Tada<br/><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Director</div></div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">281 </div></div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;;font-weight: bold;"><a href="#toc">Table of Contents</a></div> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;">
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="font-size: 0px;">
<td style="width: 64%; font-family: &quot;Times New Roman&quot;;"></td>
<td style="width: 11%; vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="font-family: &quot;Times New Roman&quot;;"></td>
<td style="font-family: &quot;Times New Roman&quot;;"></td>
<td style="font-family: &quot;Times New Roman&quot;;"></td>
<td style="width: 11%; vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="font-family: &quot;Times New Roman&quot;;"></td>
<td style="font-family: &quot;Times New Roman&quot;;"></td>
<td style="font-family: &quot;Times New Roman&quot;;"></td> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid; white-space: nowrap;;text-align:center;"> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 1pt; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">Name and Address of<br/>Beneficial Owners</div></div></div> </td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid; white-space: nowrap;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Number&#160;of&#160;Common&#160;Shares</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid; white-space: nowrap;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">%&#160;of&#160;Ownership</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">All directors and executive officers as a group (14 persons)</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">86,618,953</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">12.2</td>
<td style="vertical-align: bottom; white-space: nowrap;">%&#160;</td> </tr>
<tr style="font-size: 1pt;">
<td style="height: 12pt; font-family: &quot;Times New Roman&quot;;"></td>
<td colspan="4" style="height: 12pt; font-family: &quot;Times New Roman&quot;;"></td>
<td colspan="4" style="height: 12pt; font-family: &quot;Times New Roman&quot;;"></td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Five Percent Holders (excluding directors)</div></div>:</div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">SVF Investments(1)</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">99,375,586</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">14.5</td>
<td style="vertical-align: bottom; white-space: nowrap;">%&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">QVT Entities(2)</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">129,393,817</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">18.9</td>
<td style="vertical-align: bottom; white-space: nowrap;">%&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Dexxon Holdings(3)</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">98,809,158</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">14.4</td>
<td style="vertical-align: bottom; white-space: nowrap;">%&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Viking Global Entities(4)</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">88,238,700</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">12.9</td>
<td style="vertical-align: bottom; white-space: nowrap;">%&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Sumitomo Dainippon Pharma Co., Ltd.(5).</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">86,367,360</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">12.6</td>
<td style="vertical-align: bottom; white-space: nowrap;">%&#160;</td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="width: 11%; line-height: 8pt; margin-top: 0pt; margin-bottom: 2pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 4%; vertical-align: top;;text-align:left;">*</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Less than 1% </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 4%; vertical-align: top;;text-align:left;">(1)</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Securities held of record by SVF Investments (UK) Limited (&#8220;SVF Investments&#8221;). SVF GP (Jersey) Limited is the general partner of Softbank Vision Fund LP, which is the managing member of SVF Holdings (UK) LLP, which is the sole owner of SVF Investments. SB Investment Advisers (UK) Limited (&#8220;SBIA UK&#8221;) has been appointed by SVF GP (Jersey) Limited as the alternative investment fund manager (&#8220;AIFM&#8221;) of SoftBank Vision Fund LP. SBIA UK is authorized and regulated by the UK Financial Conduct Authority and is exclusively responsible for making all decisions related to the acquisition, structuring, financing and disposal of SoftBank Vision Fund LP&#8217;s investments. The principal address of SVF Investments is 69 Grosvenor Street, London, United Kingdom W1K 3JP. </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 4%; vertical-align: top;;text-align:left;">(2)</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Consists of Common Shares held by QVT Financial Investment Cayman Ltd., QVT Roiv Hldgs Offshore Ltd., QVT Roiv Hldgs Onshore Ltd., QVT Deferred Compensation Holdings Ltd., QVT P&amp;E Roiv Hldgs Ltd. and Fourth Avenue Capital Partners LP (together, the &#8220;QVT Entities&#8221;). Fourth Avenue Capital Partners GP LLC may be deemed to share beneficial ownership of the Common Shares held by Fourth Avenue Capital Partners LP. Each of QVT Financial LP and QVT Financial GP LLC may be deemed to share beneficial ownership of the Common Shares held by the QVT Entities. The Managing Members of QVT Financial GP LLC and Fourth Avenue Capital Partners GP LLC are Daniel Gold, Nicholas Brumm, Arthur Chu and Tracy Fu, each of whom disclaims beneficial ownership of the securities held by the QVT Entities except to the extent of any pecuniary interest. The principal business address for the QVT Entities, QVT Financial LP, QVT Financial GP LLC, Fourth Avenue Capital Partners GP LLC and the Managing Members is 888 Seventh Avenue, 27th Floor, New York, NY 10106. </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 4%; vertical-align: top;;text-align:left;">(3)</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Consists of Common Shares held by Dexxon Holdings Ltd. (&#8220;Dexxon Holdings&#8221;) and Dexcel Pharma Technologies Ltd. (&#8220;Dexcel Pharma&#8221;). Dan Oren is the sole shareholder and sole director of Dexxon Holdings and the ultimate (indirect) sole shareholder and the Executive Chairman of Dexcel Pharma. As such, each of Dexxon Holdings, Dexcel Pharma and Dan Oren may be deemed to share beneficial ownership of the Common Shares. The principal business address of Dexxon Holdings and Dan Oren is 1 Dexcel Street, Or Akiva, 3060000, Israel. The principal business address of Dexcel Pharma is 21 Nahum Haftzadi Street, Jerusalem, 9548402, Israel. </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 4%; vertical-align: top;;text-align:left;">(4)</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;">Consists of Common Shares held by Viking Global Equities Master Ltd. (&#8220;VGEM&#8221;), Viking Global Equities II LP (&#8220;VGEII&#8221;), Viking Long Fund Master Ltd. (&#8220;VLFM&#8221;) and Viking Global Opportunities Illiquid Investments <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">Sub-Master</div> LP (&#8220;Opportunities Fund,&#8221; and together with all of the preceding entities, the &#8220;Viking Global Entities&#8221;) and includes 1,000,000 Common Shares issued to the Viking Global Entities in connection with the PIPE Financing. VGEM has the power to dispose of and vote the shares directly owned by it, which power may be exercised by its investment manager, Viking Global Performance LLC (&#8220;VGP&#8221;), and by Viking Global Investors LP (&#8220;VGI&#8221;), which provides managerial services to VGEM. VGEII has the authority to dispose of and vote the shares directly owned by it, which power may be exercised by its general partner, VGP, and by VGI, which provides managerial services to VGEII. VLFM has the authority to dispose of and vote the shares directly owned by it, which power may be exercised by its investment manager, Viking Long Fund GP LLC (&#8220;VLFGP&#8221;), and by VGI, which provides managerial services to VLFM. Opportunities Fund has the authority to dispose of and vote the shares directly owned by it, which power may be exercised by its general partner, Viking Global Opportunities Portfolio GP LLC (&#8220;Opportunities GP&#8221;), and by VGI, which provides managerial services to Opportunities Fund. O. Andreas </div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">282 </div></div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;;font-weight: bold;"><a href="#toc">Table of Contents</a></div> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;">
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 4%;">&#160;</td>
<td style="vertical-align: top;;text-align:left;">Halvorsen, David C. Ott and Rose Shabet, as Executive Committee members of Viking Global Partners LLC (the general partner of VGI), VGP, VLFGP and Viking Global Opportunities GP LLC (the sole member of Opportunities GP) have shared authority to direct the voting and disposition of investments beneficially owned by VGI, VGP, VLFGP and Opportunities GP. The business address of each of the Viking Global Entities is 55 Railroad Avenue, Greenwich, Connecticut 06830. </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 4%; vertical-align: top;;text-align:left;">(5)</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;">Consists of Common Shares held by Sumitomo Dainippon Pharma Co., Ltd. (&#8220;Sumitomo&#8221;), including 7,500,000 Common Shares issued to Sumitomo in connection with the PIPE Financing. The principal business address of Sumitomo is <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">6-8</div> Doshomachi <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">2-chome,</div> <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">Chuo-ku,</div> Osaka <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">541-0045</div> Japan. </div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">283 </div></div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;;font-weight: bold;"><a href="#toc">Table of Contents</a></div> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"> <div id="rom164680_16" style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">SELLING HOLDERS </div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">This prospectus relates to the possible offer and resale by the Holders of (i)&#160;up to 595,134,445 Common Shares, consisting of (x) 22,000,000 Common Shares issued in the PIPE Financing, (y)&#160;up to 10,214,365 Common Shares issuable upon exercise of the Private Placement Warrants and (z) 562,920,080 issued and outstanding Common Shares held by certain Holders (including Common Shares underlying vested restricted share awards), and (ii)&#160;the Private Placement Warrants. </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">Other than the Common Shares issued in the PIPE Financing, the Common Shares and Warrants included in the tables below are all subject to the <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">lock-up</div> provisions described in &#8220;Securities Act Restrictions on Resale of <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">Securities&#8212;Lock-up</div> Provisions&#8221; extending for a period at least six months from the closing of the Business Combination. Subject to the requirements of that <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">lock-up,</div> as applicable, the Holders may from time to time offer and sell any or all of the Common Shares and Warrants set forth below pursuant to this prospectus. When we refer to the &#8220;<div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Holders</div></div>&#8221; in this prospectus, we mean the persons listed in the table below, and the pledgees, donees, transferees, assignees, successors and others who later come to hold any of the Holders&#8217; interest in the securities of the Company listed in the table below after the date of this prospectus such that registration rights shall apply to those securities. </div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The following tables are prepared based on information provided to us by the Holders. They set forth the name and address of the Holders, the aggregate number of Common Shares and Private Warrants that the Holders may offer pursuant to this prospectus, and the beneficial ownership of the Holders both before and after the offering. We have based percentage ownership prior to this offering on 684,789,169 Common Shares and 30,750,261 Warrants outstanding, in each case as of September&#160;30, 2021. In calculating percentages of Common Shares owned by a particular Holder, we treated as outstanding the number of Common Shares issuable upon exercise of that particular Holder&#8217;s Warrants, if any, and did not assume the exercise of any other Holder&#8217;s Warrants. The following tables do not reflect the beneficial ownership of any Common Shares Stock issuable upon exercise of Warrants or incentive equity awards unless such securities are exercisable or convertible within 60 days. </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">We cannot advise you as to whether the Holders will in fact sell any or all of the securities set forth in the tables below. In addition, subject to the <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">lock-up</div> provisions described in &#8220;Securities Act Restrictions on Resale of <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">Securities&#8212;Lock-up</div> Provisions,&#8221; the Holders may sell, transfer or otherwise dispose of, at any time and from time to time, such securities in transactions exempt from the registration requirements of the Securities Act after the date of this prospectus. For purposes of the below tables, unless otherwise indicated below, we have assumed that the Holders will have sold all of the securities covered by this prospectus upon the completion of the offering. </div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">Unless otherwise indicated below, the address of each beneficial owner listed in the tables below is c/o Roivant Sciences Ltd., Suite 1, 3rd Floor, <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">11-12</div> St. James&#8217;s Square, London SW1Y 4LB, United Kingdom. </div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">Lock-Up</div> </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;">As noted above, from the closing of the Business Combination, all <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">pre-Business</div> Combination equity holders, the MAAC Sponsor and MAAC&#8217;s former independent directors are subject to a <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">lock-up</div> covering all Roivant Common Shares, Warrants and incentive equity awards held by such entities and individuals. The term of these <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">lock-ups</div> is summarized below. </div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 8pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="font-size: 0px;">
<td style="width: 39%; font-family: &quot;Times New Roman&quot;;"></td>
<td style="width: 2%; vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="width: 59%; font-family: &quot;Times New Roman&quot;;"></td> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; white-space: nowrap; padding-bottom: 1pt;"> <div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt; border-bottom: 1pt solid rgb(0, 0, 0); display: table-cell; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">Holder</div></div></div> </td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;&#160;</td>
<td style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;"> <div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 1pt; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">Lock-Up</div> Terms</div></div> </td> </tr>
<tr style="font-size: 1pt;">
<td style="height: 6pt; font-family: &quot;Times New Roman&quot;;"></td>
<td colspan="2" style="height: 6pt; font-family: &quot;Times New Roman&quot;;"></td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;">All <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">pre-Business</div> Combination holders</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;"> <div style="text-indent: -2em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 2em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#8226;&#8195;&#8194;&#8202;100% of holdings are subject to a six month lock-up, measured from the closing of the Business Combination</div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">284 </div></div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;;font-weight: bold;"><a href="#toc">Table of Contents</a></div> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;">
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="font-size: 0px;">
<td style="width: 39%; font-family: &quot;Times New Roman&quot;;"></td>
<td style="width: 2%; vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="width: 59%; font-family: &quot;Times New Roman&quot;;"></td> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; white-space: nowrap; padding-bottom: 1pt;"> <div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt; border-bottom: 1pt solid rgb(0, 0, 0); display: table-cell; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">Holder</div></div></div> </td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;&#160;</td>
<td style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;"> <div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 1pt; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">Lock-Up</div> Terms</div></div> </td> </tr>
<tr style="font-size: 1pt;">
<td style="height: 6pt; font-family: &quot;Times New Roman&quot;;"></td>
<td colspan="2" style="height: 6pt; font-family: &quot;Times New Roman&quot;;"></td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Dexxon Holdings*</div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Matthew Gline*</div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Patient Square Capital*</div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 1pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Vivek Ramaswamy*</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;"> <div style="text-indent: -2em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 2em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#8226;&#8195;&#8194;&#8202;25% of holdings are subject to a six month lock-up, measured from the closing of the Business Combination</div></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-indent: -2em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 2em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#8226;&#8195;&#8194;&#8202;25% of holdings are subject to a one year lock-up, measured from the closing of the Business Combination (or, in the case of the Common Shares held by Patient Square Capital, a one year lock-up measured from the achievement of the applicable earn-out threshold)</div></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-indent: -2em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 1pt; margin-left: 2em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#8226;&#8195;&#8194;&#8202;50% of holdings are subject to a three year lock-up, measured from the closing of the Business Combination</div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="width: 11%; line-height: 8pt; margin-top: 0pt; margin-bottom: 2pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 4%; vertical-align: top;;text-align:left;">*</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Each of these holders has voluntarily agreed to the extended lock-up set forth in this table with respect to the Roivant equity securities and Warrants, as applicable, held by such holder, including those registered hereby. </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">See &#8220;Certain Relationships and Related Party Transactions&#8211;Post-Business Combination Arrangements&#8221; for more information. </div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Common Shares </div></div></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="font-size: 0px;">
<td style="width: 58%;"></td>
<td style="width: 1%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td>
<td style="width: 1%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td>
<td style="width: 1%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td>
<td style="width: 1%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td>
<td style="width: 1%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;&#160;</td>
<td colspan="6" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Beneficial Ownership<br/>Before the Offering</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Shares to be<br/>Registered<br/>Hereby</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;&#160;</td>
<td colspan="6" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Beneficial<br/>Ownership<br/>After Offering</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid; white-space: nowrap;;text-align:center;"> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 1pt; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">Name and Address of<br/>Holders</div></div></div> </td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Number of<br/>Shares</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">%</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Number of<br/>Shares</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Number of<br/>Shares</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">%</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">PIPE Investors &#8211; Not Subject to <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">Lock-Up</div></div></div></div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Averill Master Fund, Ltd.(1)</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">500,000</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">*</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">500,000</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Castanea Biosciences Inc.(2)</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">2,000,000</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">*</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">2,000,000</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Eventide Healthcare&#160;&amp; Life Sciences Fund(3)</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">700,000</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">*</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">700,000</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Fidelity Select Portfolios: Biotechnology Portfolio(4)</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">2,500,000</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">*</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">2,500,000</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Kepos Alpha Master Fund L.P.(5)</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">832,364</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">*</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">500,000</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">332,364</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">*</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Entities affiliated with Millennium Management LLC(6)</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">2,161,044</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">*</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">800,000</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">1,361,044</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">*</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Palantir Technologies Inc.(7)</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">3,000,000</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">*</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">3,000,000</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">PTC Trustees GY Limited as Trustee of the GYF Trust(8)</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">250,000</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">*</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">250,000</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Pura Vida Investments, LLC and Certain of its Affiliates(9)</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">610,738</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">*</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">300,000</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">310,738</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">*</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">RTW Funds(10)</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">802,719</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">*</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">400,000</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">402,719</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">*</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">SB Northstar LP(11)</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">2,500,000</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">*</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">2,500,000</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The Eleven Fund LLC(12)</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">50,000</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">*</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">50,000</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-size: 1pt;">
<td style="height: 6pt; font-family: &quot;Times New Roman&quot;;"></td>
<td colspan="4" style="height: 6pt; font-family: &quot;Times New Roman&quot;;"></td>
<td colspan="4" style="height: 6pt; font-family: &quot;Times New Roman&quot;;"></td>
<td colspan="4" style="height: 6pt; font-family: &quot;Times New Roman&quot;;"></td>
<td colspan="4" style="height: 6pt; font-family: &quot;Times New Roman&quot;;"></td>
<td colspan="4" style="height: 6pt; font-family: &quot;Times New Roman&quot;;"></td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Holders Subject to Extended <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">Lock-Up**</div></div></div></div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Dexxon Holdings(13)</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">98,809,158</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">14.4</td>
<td style="vertical-align: bottom; white-space: nowrap;">%&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">98,809,158</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Patient Square Capital LLC(14)</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">17,840,332</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">2.6</td>
<td style="vertical-align: bottom; white-space: nowrap;">%&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">17,840,332</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Vivek Ramaswamy</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">72,556,652</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">10.4</td>
<td style="vertical-align: bottom; white-space: nowrap;">%&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">58,409,211</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">14,147,441</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">2.0</td>
<td style="vertical-align: bottom; white-space: nowrap;">%&#160;</td> </tr>
<tr style="font-size: 1pt;">
<td style="height: 6pt; font-family: &quot;Times New Roman&quot;;"></td>
<td colspan="4" style="height: 6pt; font-family: &quot;Times New Roman&quot;;"></td>
<td colspan="4" style="height: 6pt; font-family: &quot;Times New Roman&quot;;"></td>
<td colspan="4" style="height: 6pt; font-family: &quot;Times New Roman&quot;;"></td>
<td colspan="4" style="height: 6pt; font-family: &quot;Times New Roman&quot;;"></td>
<td colspan="4" style="height: 6pt; font-family: &quot;Times New Roman&quot;;"></td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Five Percent Holders &#8211; Subject to Six Month Lock-Up</div></div></div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">QVT Entities(15)</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">129,393,817</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">18.9</td>
<td style="vertical-align: bottom; white-space: nowrap;">%&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">129,393,817</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Sumitomo Dainippon Pharma Co., Ltd.(16)</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">86,367,360</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">12.6</td>
<td style="vertical-align: bottom; white-space: nowrap;">%&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">86,367,360</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">SVF Investments(17)</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">99,375,586</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">14.5</td>
<td style="vertical-align: bottom; white-space: nowrap;">%&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">99,375,586</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Viking Global Entities(18)</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">88,238,700</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">12.9</td>
<td style="vertical-align: bottom; white-space: nowrap;">%&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">88,238,700</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">285 </div></div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;;font-weight: bold;"><a href="#toc">Table of Contents</a></div> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;">
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="font-size: 0px;">
<td style="width: 56%;"></td>
<td style="width: 1%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td>
<td style="width: 1%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td>
<td style="width: 1%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td>
<td style="width: 1%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td>
<td style="width: 1%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;&#160;</td>
<td colspan="6" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Beneficial Ownership<br/>Before the Offering</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Shares to be<br/>Registered<br/>Hereby</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;&#160;</td>
<td colspan="6" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Beneficial<br/>Ownership<br/>After Offering</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid; white-space: nowrap;;text-align:center;"> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 1pt; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">Name and Address of<br/>Holders</div></div></div> </td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Number of<br/>Shares</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">%</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Number of<br/>Shares</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Number of<br/>Shares</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">%</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td> </tr>
<tr style="font-size: 1pt;">
<td style="height: 6pt; font-family: &quot;Times New Roman&quot;;"></td>
<td colspan="4" style="height: 6pt; font-family: &quot;Times New Roman&quot;;"></td>
<td colspan="4" style="height: 6pt; font-family: &quot;Times New Roman&quot;;"></td>
<td colspan="4" style="height: 6pt; font-family: &quot;Times New Roman&quot;;"></td>
<td colspan="4" style="height: 6pt; font-family: &quot;Times New Roman&quot;;"></td>
<td colspan="4" style="height: 6pt; font-family: &quot;Times New Roman&quot;;"></td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Other Holders &#8211; Subject to Six Month Lock-Up</div></div></div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Elliot Lorne Chaikof(19)</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">916,992</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">*</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">916,992</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Finith Ewin Jernigan, III(20)</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">519,628</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">*</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">519,628</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Lijun Sun(21)</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">1,344,922</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">*</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">1,344,922</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Parkway Limited(22)</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">398,364</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">*</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">398,364</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Ross Charles Walker(23)</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">20,375</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">*</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">20,375</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="width: 11%; line-height: 8pt; margin-top: 0pt; margin-bottom: 2pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 4%; vertical-align: top;;text-align:left;">*</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Less than 1%. </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 4%; vertical-align: top;;text-align:left;">**</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;">Each of these holders is subject to an extended <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">lock-up</div> covering their equity securities, including those registered hereby, as follows: (i) 25% of holdings are subject to a six month lock-up, measured from the closing of the Business Combination, (ii) an additional 25% of holdings are subject to a one year lock-up, measured from the closing of the Business Combination (or, in the case of the Common Shares held by Patient Square Capital, a one year lock-up measured from the achievement of the applicable earn-out threshold) and (iii) the remaining 50% of holdings are subject to a three year lock-up, measured from the closing of the Business Combination. See &#8220;Certain Relationships and Related Party Transactions&#8211;Post-Business Combination Arrangements&#8221; for more information. </div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 4%; vertical-align: top;;text-align:left;">(1)</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Suvretta Capital Management, LLC is the investment manager of Averill Master Fund, Ltd. Aaron Cowen is the control person of Suvretta Capital Management, LLC. The address of Averill Master Fund, Ltd. is 540 Madison Ave., 7th Floor, New York, NY 10022. </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 4%; vertical-align: top;;text-align:left;">(2)</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Castanea Biosciences Inc. is a wholly-owned subsidiary of SK Inc. Kiel Kim, Donghoon Lee and Joonsik Chai are members of the board of directors of Castanea Biosciences Inc. and have shared dispositive and voting power over the Common Shares. The address of Castanea Biosciences Inc. is 55 E. 59th Street, 10th Floor, New York, NY 10022. </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 4%; vertical-align: top;;text-align:left;">(3)</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Finny Kuruvilla has dispositive and voting power over the Common Shares as a portfolio manager for Eventide Asset Management, LLC, which is the investment advisor to Mutual Fund Series Trust on behalf of Eventide Healthcare&#160;&amp; Life Sciences Fund. Mr.&#160;Kuruvilla disclaims beneficial ownership of such shares except to the extent of his pecuniary interest therein. The address of each of Mutual Fund Series Trust on behalf of Eventide Healthcare&#160;&amp; Life Sciences Fund and Eventide Asset Management, LLC is 1 International Place, Suite 4210, Boston, MA 02110. </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 4%; vertical-align: top;;text-align:left;">(4)</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">These accounts are managed by direct or indirect subsidiaries of FMR LLC. Abigail P. Johnson is a Director, the Chairman, the Chief Executive Officer and the President of FMR LLC. Members of the Johnson family, including Abigail P. Johnson, are the predominant owners, directly or through trusts, of Series B voting common shares of FMR LLC, representing 49% of the voting power of FMR LLC. The Johnson family group and all other Series B shareholders have entered into a shareholders&#8217; voting agreement under which all Series B voting common shares will be voted in accordance with the majority vote of Series B voting common shares. Accordingly, through their ownership of voting common shares and the execution of the shareholders&#8217; voting agreement, members of the Johnson family may be deemed, under the Investment Company Act of 1940, to form a controlling group with respect to FMR LLC. Neither FMR LLC nor Abigail P. Johnson has the sole power to vote or direct the voting of the shares owned directly by the various investment companies registered under the Investment Company Act (&#8220;Fidelity Funds&#8221;) advised by Fidelity Management&#160;&amp; Research Company (&#8220;FMR Co&#8221;), a wholly owned subsidiary of FMR LLC, which power resides with the Fidelity Funds&#8217; Boards of Trustees. Fidelity Management&#160;&amp; Research Company carries out the voting of the shares under written guidelines established by the Fidelity Funds&#8217; Boards of Trustees. The address of FMR LLC and the Fidelity Funds is c/o Brown Brothers Harriman&#160;&amp; Co. Attn: Corporate Actions /Vault 140 Broadway New York, NY 10005. </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 4%; vertical-align: top;;text-align:left;">(5)</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Consists of (i) 500,000 Common Shares issued in connection with the PIPE Financing being registered for resale hereunder, (ii) 94,864 other Common Shares and (iii) 237,500 Common Shares issuable upon </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">286 </div></div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;;font-weight: bold;"><a href="#toc">Table of Contents</a></div> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;">
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 4%;">&#160;</td>
<td style="vertical-align: top;;text-align:left;">exercise of Public Warrants. Kepos Capital LP is the investment manager of Kepos Alpha Master Fund L.P. and Kepos Partners LLC is the General Partner of Kepos Alpha Master Fund L.P. and each may be deemed to have voting and dispositive power with respect to the shares. The general partner of Kepos Capital LP is Kepos Capital GP LLC (the &#8220;Kepos GP&#8221;) and the Managing Member of Kepos Partners LLC is Kepos Partners MM LLC (&#8220;Kepos MM&#8221;). Mark Carhart controls Kepos GP and Kepos MM and, accordingly, may be deemed to have voting and dispositive power with respect to the shares held by Kepos Alpha Master Fund L.P. Mr.&#160;Carhart disclaims beneficial ownership of the shares held by Kepos Alpha Master Fund L.P. The address of Kepos Capital LP and Mr.&#160;Carhart is 11 Times Square, 35th Floor, New York, New York 10036. </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 4%; vertical-align: top;;text-align:left;">(6)</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Includes (i) 911,044 Common Shares held by Integrated Core Strategies (US) LLC, a Delaware limited liability company (&#8220;Integrated Core Strategies&#8221;), consisting of (x) 200,000 Common Shares issued in connection with the PIPE Financing being registered for resale hereunder and (y) 711,044 Common Shares issuable upon exercise of Public Warrants and (ii) 1,250,000 Common Shares held by ICS Opportunities, Ltd., an exempted company organized under the laws of the Cayman Islands (&#8220;ICS Opportunities&#8221;), consisting of (x) 600,000 Common Shares issued in connection with the PIPE Financing being registered for resale hereunder and (y) 650,000 Common Shares issuable upon exercise of Public Warrants. Millennium International Management LP, a Delaware limited partnership (&#8220;Millennium International Management&#8221;), is the investment manager to ICS Opportunities and may be deemed to have shared voting control and investment discretion over securities owned by ICS Opportunities. Millennium Management LLC, a Delaware limited liability company (&#8220;Millennium Management&#8221;), is the general partner of the managing member of Integrated Core Strategies and may be deemed to have shared voting control and investment discretion over securities owned by Integrated Core Strategies. Millennium Management is also the general partner of the 100% owner of ICS Opportunities and may also be deemed to have shared voting control and investment discretion over securities owned by ICS Opportunities. Millennium Group Management LLC, a Delaware limited liability company (&#8220;Millennium Group Management&#8221;), is the managing member of Millennium Management and may also be deemed to have shared voting control and investment discretion over securities owned by Integrated Core Strategies. Millennium Group Management is also the general partner of Millennium International Management and may also be deemed to have shared voting control and investment discretion over securities owned by ICS Opportunities. The managing member of Millennium Group Management is a trust of which Israel A. Englander, a United States citizen (&#8220;Mr. Englander&#8221;), currently serves as the sole voting trustee. Therefore, Mr. Englander may also be deemed to have shared voting control and investment discretion over securities owned by Integrated Core Strategies and ICS Opportunities. The foregoing should not be construed in and of itself as an admission by Millennium International Management, Millennium Management, Millennium Group Management or Mr. Englander as to beneficial ownership of the securities owned by Integrated Core Strategies or ICS Opportunities, as the case may be. The address for each of the above entities and Mr. Englander is c/o Millennium Management LLC, 399 Park Avenue, New York, New York 10022. </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 4%; vertical-align: top;;text-align:left;">(7)</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Palantir Technologies Inc. is currently controlled by its seven-member board of directors. For more information, please see Palantir Technologies Inc.&#8217;s public filings with the SEC. The address of Palantir Technologies Inc. is 1555 Blake Street, Suite 250, Denver, CO 80202. </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 4%; vertical-align: top;;text-align:left;">(8)</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Gavril Yushvaev has sole voting and dispositive power over the Common Shares held by PTC Trustees Limited as Trustee of the GYF Trust. The address of the business office of PTC Trustees Limited as Trustee of the GYF Trust is Anastasios Leventis 5, Leventis Gallery Tower, 8th Floor, 1097 Nicosia, Cyprus. </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 4%; vertical-align: top;;text-align:left;">(9)</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Consists of (i) (x) 172,500 Common Shares issued in connection with the PIPE Financing being registered for resale hereunder and (y) 124,267 Common Shares issuable upon exercise of Public Warrants, each held by Pura Vida Master Fund, Ltd.; (ii) (x) 68,700 Common Shares issued in connection with the PIPE Financing being registered for resale hereunder and (y) 47,653 Common Shares issuable upon exercise of Public Warrants, each held by Highmark Limited, in respect of its Segregated Account Highmark Long/Short Equity 20; (iii) (x) 18,600 Common Shares issued in connection with the PIPE Financing being registered for resale hereunder and (y) 10,064 Common Shares issuable upon exercise of Public Warrants, each held by Walleye Manager Opportunities LLC; (iv) (x) 28,200 Common Shares issued in connection with the PIPE Financing being registered for resale hereunder, (y) 58,744 other Common Shares and (z) 61,588 Common Shares issuable upon exercise of Public Warrants, each held by Walleye Opportunities </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">287 </div></div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;;font-weight: bold;"><a href="#toc">Table of Contents</a></div> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;">
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 4%;">&#160;</td>
<td style="vertical-align: top;;text-align:left;">Master Fund Ltd; and (v) (x) 12,000 Common Shares issued in connection with the PIPE Financing being registered for resale hereunder and (y) 8,422 Common Shares issuable upon exercise of Public Warrants, each held by Sea Hawk Multi-Strategy Master Fund Ltd (together with Pura Vida Master Fund, Ltd, Highmark Limited, in respect of its Segregated Account Highmark Long/Short Equity 20, Walleye Manager Opportunities LLC, and Walleye Opportunities Master Fund Ltd, the &#8220;Pura Vida Entities&#8221;). Pura Vida Investments, LLC (&#8220;PVI&#8221;) serves as the investment manager or <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">sub-adviser</div> to each of the Pura Vida Entities. Efrem Kamen serves as the managing member of PVI. By virtue of these relationships, PVI and Efrem Kamen may be deemed to have shared voting and dispositive power with respect to the Common Shares and certain other securities owned by the Pura Vida Entities. Each of PVI and Efrem Kamen disclaims beneficial ownership of the Common Shares and other securities described herein except to the extent of each PVI&#8217;s and Efrem Kamen&#8217;s pecuniary interest therein. The address for each of the Pura Vida Entities, PVI and Efrem Kamen is c/o Pura Vida Investments, LLC, 888 Seventh Ave., 6th Floor, New York, NY 10106. </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 4%; vertical-align: top;;text-align:left;">(10)</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Consists of (i) (x) 254,066 Common Shares issued in connection with the PIPE Financing being registered for resale hereunder and (y) 349,810 other Common Shares, each held by RTW Master Fund, Ltd.; (ii) (x) 119,901 Common Shares issued in connection with the PIPE Financing being registered for resale hereunder and (y) 52,909 other Common Shares, each held by RTW Innovation Master Fund, Ltd.; and (iii) 26,033 Common Shares issued in connection with the PIPE Financing being registered for resale hereunder held by RTW Venture Fund Limited (together with RTW Master Fund, Ltd. and RTW Innovation Master Fund, Ltd., the &#8220;RTW Funds&#8221;). Roderick Wong, M.D., is the managing partner of each of the RTW Funds and has ultimate voting and dispositive power over the Common Shares. The address for each of the RTW Funds and Dr.&#160;Wong is 40 10th Avenue, Floor 7, New York, NY 10014. </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 4%; vertical-align: top;;text-align:left;">(11)</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;">SB Management Limited is the investment manager of SB Northstar LP and as such may be deemed to have voting and investment power over the securities held by SB Northstar LP. SB Management Limited is owned by Softbank Group Corp. The address of SB Northstar LP is 190 Elgin Avenue, George Town, Grand Cayman <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">KY1-9008,</div> Cayman Islands. </div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 4%; vertical-align: top;;text-align:left;">(12)</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Hartley Wasko is the manager of The Eleven Fund LLC and has voting and dispositive power over the Common Shares. The address of each of Hartley Wasko and The Eleven Fund LLC is 463 Adams Street, Denver, CO 80206. </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 4%; vertical-align: top;;text-align:left;">(13)</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Consists of Common Shares held by Dexxon Holdings Ltd. (&#8220;Dexxon Holdings&#8221;) and Dexcel Pharma Technologies Ltd. (&#8220;Dexcel Pharma&#8221;). Dan Oren is the sole shareholder and sole director of Dexxon Holdings and the ultimate (indirect) sole shareholder and the Executive Chairman of Dexcel Pharma. As such, each of Dexxon Holdings, Dexcel Pharma and Dan Oren may be deemed to share beneficial ownership of the Common Shares. The principal business address of Dexxon Holdings and Dan Oren is 1 Dexcel Street, Or Akiva, 3060000, Israel. The principal business address of Dexcel Pharma is 21 Nahum Haftzadi Street, Jerusalem, 9548402, Israel. </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 4%; vertical-align: top;;text-align:left;">(14)</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The number of Common Shares consists of (i) 7,625,967 Common Shares and (ii) 10,214,365 Common Shares that are issuable upon the exercise of the Private Placement Warrants. James C. Momtazee, Alex Albert and Adam Fliss are members of the committee of Patient Square Capital LLC (the &#8220;MAAC Committee&#8221;). The MAAC Committee holds voting and dispositive power with respect to such securities. The address of Patient Square Capital LLC is 2884 Sand Hill Road, Suite 100, Menlo Park, CA 94025. </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 4%; vertical-align: top;;text-align:left;">(15)</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Consists of Common Shares held by QVT Financial Investment Cayman Ltd., QVT Roiv Hldgs Offshore Ltd., QVT Roiv Hldgs Onshore Ltd., QVT Deferred Compensation Holdings Ltd., QVT P&amp;E Roiv Hldgs Ltd. and Fourth Avenue Capital Partners LP (together, the &#8220;QVT Entities&#8221;). Fourth Avenue Capital Partners GP LLC may be deemed to share beneficial ownership of the Common Shares held by Fourth Avenue Capital Partners LP. Each of QVT Financial LP and QVT Financial GP LLC may be deemed to share beneficial ownership of the Common Shares held by the QVT Entities. The Managing Members of QVT Financial GP LLC and Fourth Avenue Capital Partners GP LLC are Daniel Gold, Nicholas Brumm, Arthur Chu and Tracy Fu, each of whom disclaims beneficial ownership of the securities held by the QVT Entities except to the extent of any pecuniary interest. The principal business address for the QVT Entities, QVT Financial LP, QVT Financial GP LLC, Fourth Avenue Capital Partners GP LLC and the Managing Members is 888 Seventh Avenue, 27th Floor, New York, NY 10106. </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">288 </div></div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;;font-weight: bold;"><a href="#toc">Table of Contents</a></div> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;">
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 4%; vertical-align: top;;text-align:left;">(16)</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;">Consists of Common Shares held by Sumitomo Dainippon Pharma Co., Ltd. (&#8220;Sumitomo&#8221;), including 7,500,000 Common Shares issued to Sumitomo in connection with the PIPE Financing. Common Shares issued in connection with the PIPE Financing are not subject to the <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">lock-up</div> described above. The principal business address of Sumitomo is <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">6-8</div> Doshomachi <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">2-chome,</div> Chuo-ku, Osaka <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">541-0045</div> Japan. </div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 4%; vertical-align: top;;text-align:left;">(17)</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Securities held of record by SVF Investments (UK) Limited (&#8220;SVF Investments&#8221;). SVF GP (Jersey) Limited is the general partner of Softbank Vision Fund LP, which is the managing member of SVF Holdings (UK) LLP, which is the sole owner of SVF Investments. SB Investment Advisers (UK) Limited (&#8220;SBIA UK&#8221;) has been appointed by SVF GP (Jersey) Limited as the alternative investment fund manager (&#8220;AIFM&#8221;) of SoftBank Vision Fund LP. SBIA UK is authorized and regulated by the UK Financial Conduct Authority and is exclusively responsible for making all decisions related to the acquisition, structuring, financing and disposal of SoftBank Vision Fund LP&#8217;s investments. The principal address of SVF Investments is 69 Grosvenor Street, London, United Kingdom W1K 3JP. </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 4%; vertical-align: top;;text-align:left;">(18)</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;">Consists of Common Shares held by Viking Global Equities Master Ltd. (&#8220;VGEM&#8221;), Viking Global Equities II LP (&#8220;VGEII&#8221;), Viking Long Fund Master Ltd. (&#8220;VLFM&#8221;) and Viking Global Opportunities Illiquid Investments <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">Sub-Master</div> LP (&#8220;Opportunities Fund,&#8221; and together with all of the preceding entities, the &#8220;Viking Global Entities&#8221;) and includes 1,000,000 Common Shares issued to the Viking Global Entities in connection with the PIPE Financing. Common Shares issued in connection with the PIPE Financing are not subject to the <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">lock-up</div> described above. VGEM has the power to dispose of and vote the shares directly owned by it, which power may be exercised by its investment manager, Viking Global Performance LLC (&#8220;VGP&#8221;), and by Viking Global Investors LP (&#8220;VGI&#8221;), which provides managerial services to VGEM. VGEII has the authority to dispose of and vote the shares directly owned by it, which power may be exercised by its general partner, VGP, and by VGI, which provides managerial services to VGEII. VLFM has the authority to dispose of and vote the shares directly owned by it, which power may be exercised by its investment manager, Viking Long Fund GP LLC (&#8220;VLFGP&#8221;), and by VGI, which provides managerial services to VLFM. Opportunities Fund has the authority to dispose of and vote the shares directly owned by it, which power may be exercised by its general partner, Viking Global Opportunities Portfolio GP LLC (&#8220;Opportunities GP&#8221;), and by VGI, which provides managerial services to Opportunities Fund. O. Andreas Halvorsen, David C. Ott and Rose Shabet, as Executive Committee members of Viking Global Partners LLC (the general partner of VGI), VGP, VLFGP and Viking Global Opportunities GP LLC (the sole member of Opportunities GP) have shared authority to direct the voting and disposition of investments beneficially owned by VGI, VGP, VLFGP and Opportunities GP. The business address of each of the Viking Global Entities is 55 Railroad Avenue, Greenwich, Connecticut 06830. </div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 4%; vertical-align: top;;text-align:left;">(19)</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The address of Mr.&#160;Chaikof is 165 Bigelow Road, Newton, MA 02465. </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 4%; vertical-align: top;;text-align:left;">(20)</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The address of Mr.&#160;Jernigan is 55 SE 6th Street #4301, Miami, FL 33131. </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">(21) The address of Mr.&#160;Sun is 178 Depot Rd., Harvard, MA 01451. </div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 4%; vertical-align: top;;text-align:left;">(22)</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Xie Yi Jing is a director of Parkway Limited and has voting and dispositive power over the Common Shares. The address of each of Mr.&#160;Jing and Parkway Limited is 25F East Tower, Raffles City, the Bund, No.&#160;1089 East Daming Road, Shanghai, China. </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">(23) The address of Mr.&#160;Walker is 1721 Valley Forge Road Unit 343, Valley Forge, PA 19481-0343. </div></div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">289 </div></div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;;font-weight: bold;"><a href="#toc">Table of Contents</a></div> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Warrants </div></div></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 8pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="font-size: 0px;">
<td style="width: 56%;"></td>
<td style="width: 2%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td>
<td style="width: 2%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td>
<td style="width: 2%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td>
<td style="width: 2%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td>
<td style="width: 2%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td>
<td style="width: 2%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;&#160;</td>
<td colspan="6" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Beneficial<br/>Ownership<br/>Before the Offering</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td colspan="6" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Shares to be Sold in<br/>the<br/>Offering</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td colspan="6" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Beneficial<br/>Ownership<br/>After Offering</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid; white-space: nowrap;;text-align:center;"> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 1pt; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">Name and Address of<br/>Holders</div></div></div> </td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Number of<br/>Warrants</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">%</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Number of<br/>Warrants</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">%</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Number<br/>of<br/>Warrants</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">%</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Holders Subject to Extended <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">Lock-Up*</div></div></div></div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Patient Square Capital LLC(14)</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">10,214,365</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">33.2</td>
<td style="vertical-align: bottom; white-space: nowrap;">%&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">10,214,365</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">33.2</td>
<td style="vertical-align: bottom; white-space: nowrap;">%&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="width: 11%; line-height: 8pt; margin-top: 0pt; margin-bottom: 2pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 4%; vertical-align: top;;text-align:left;">*</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;">The warrants held by Patient Square Capital are subject to an extended <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">lock-up,</div> as follows: (i)&#160;25% of holdings are subject to a six month lock-up, (ii)&#160;an additional 25% of holdings are subject to a one year lock-up and (iii)&#160;the remaining 50% of holdings are subject to a three year lock-up, in each case measured from the closing of the Business Combination. See &#8220;Certain Relationships and Related Party Transactions&#8211;Post-Business Combination Arrangements&#8221; for more information. </div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Material Relationships with the Holders </div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;">For a description of our relationships with the Holders and their affiliates see the sections entitled &#8220;<div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Management</div></div>,&#8221; &#8220;<div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Certain Relationships and Related Transactions</div></div>&#8221; and &#8220;<div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Executive Compensation</div></div>.&#8221; </div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">290 </div></div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;;font-weight: bold;"><a href="#toc" style="text-indent: 0px;">Table of Contents</a></div> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"> <div id="rom164680_17" style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">DESCRIPTION OF SECURITIES </div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">The following summary of the material terms of our securities is not intended to be a complete summary of the rights and preferences of such securities, and is qualified by reference to our Charter, our Bylaws and the warrant-related documents described herein, which are exhibits to the registration statement of which this prospectus is a part.</div></div> We urge to you read each of the Charter, the Bylaws and the warrant-related documents described herein in their entirety for a complete description of the rights and preferences of our securities. </div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">General </div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">We are an exempted company incorporated under the laws of Bermuda. We are registered with the Registrar of Companies in Bermuda under registration number 48931. We were incorporated on 7&#160;April 2014 under the name Valor Biotechnology Ltd. We changed our name to Roivant Sciences Ltd. on 5&#160;November 2014. Our registered office is located at Clarendon House, 2 Church Street, Hamilton HM11, Bermuda. </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">The objects of our business are unrestricted, and Roivant Sciences Ltd. has the capacity of a natural person. We can therefore undertake activities without restriction on our capacity. Prior to the consummation of the Business Combination, our shareholders will approve certain amendments to our <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">bye-laws</div> that will become effective upon the closing of this offering. The following description assumes that such amendments have become effective. </div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">There have been no public takeover offers by third parties for our shares nor any public takeover offers by us for the shares of another company that have occurred during the last or current financial years. </div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Share Capital </div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;">Immediately following the closing of the Business Combination and after giving effect to the subdivision of Common Shares, our authorized share capital will consist of 7,000,000,000 Common Shares, $0.000000341740141 par value per common share. As of September&#160;30, 2021, we had 684,789,169 Common Shares issued and outstanding. All of the issued Common Shares prior to the closing of this offering are fully paid. Pursuant to our amended and restated <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">bye-laws,</div> subject to the requirements of Nasdaq, and to any resolution of the shareholders to the contrary, our board of directors is authorized to issue any of our authorized but unissued shares. There are no limitations on the right of <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-Bermudians</div> or <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-residents</div> of Bermuda to hold or vote our shares provided Common Shares remain listed on an appointed stock exchange, which includes Nasdaq. </div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Common Shares </div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;">Holders of Common Shares have no <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">pre-emptive,</div> redemption, conversion or sinking fund rights. Holders of Common Shares are entitled to one vote per share on all matters submitted to a vote of holders of Common Shares. Unless a different majority is required by law or by our amended and restated <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">bye-laws,</div> resolutions to be approved by holders of Common Shares require approval by a simple majority of votes cast at a meeting at which a quorum is present. </div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">In the event of our liquidation, dissolution or winding up, the holders of Common Shares are entitled to share equally and ratably in our assets, if any, remaining after the payment of all of our debts and liabilities, subject to any liquidation preference on any issued and outstanding preference shares. </div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Preference Shares </div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;">Pursuant to Bermuda law and our amended and restated <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">bye-laws,</div> our board of directors may, by resolution, establish one or more series of preference shares having such number of shares, designations, dividend rates, </div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">291 </div></div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;;font-weight: bold;"><a href="#toc">Table of Contents</a></div> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">relative voting rights, conversion or exchange rights, redemption rights, liquidation rights, rights to elect or appoint directors and other relative participation, optional or other special rights, qualifications, limitations or restrictions as may be fixed by the board of directors without any further shareholder approval. Such rights, preferences, powers and limitations, as may be established, could have the effect of discouraging an attempt to obtain control of our company. </div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Dividend Rights </div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;">Under Bermuda law, a company may not declare or pay dividends if there are reasonable grounds for believing that (1)&#160;the company is, or would after the payment be, unable to pay its liabilities as they become due; or (2)&#160;that the realizable value of its assets would thereby be less than its liabilities. Under our amended and restated <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">bye-laws,</div> each common share is entitled to dividends if, as and when dividends are declared by our board of directors, subject to any preferred dividend right of the holders of any preference shares. We do not anticipate paying cash dividends in the foreseeable future. </div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Variation of Rights </div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;">If at any time we have more than one class of shares, the rights attaching to any class, unless otherwise provided for by the terms of issue of the relevant class, may be varied either: (1)&#160;with the consent in writing of the holders of 66 2/3% of the issued shares of that class; or (2)&#160;with the sanction of a resolution passed by a majority of the votes cast at a general meeting of the relevant class of shareholders at which a quorum consisting of at least one person holding or representing a majority of the issued shares of the relevant class is present. Our amended and restated <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">bye-laws</div> specify that the creation or issue of shares ranking equally with existing shares will not, unless expressly provided by the terms of issue of existing shares, vary the rights attached to existing shares. In addition, the creation or issue of preference shares ranking prior to Common Shares will not be deemed to vary the rights attached to Common Shares or, subject to the terms of any other class or series of preference shares, to vary the rights attached to any other class or series of preference shares. </div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Transfer of Shares </div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Our board of directors may, in its absolute discretion and without assigning any reason, refuse to register the transfer of a share on the basis that it is not fully paid. Our board of directors may also refuse to recognize an instrument of transfer of a share unless it is accompanied by the relevant share certificate and such other evidence of the transferor&#8217;s right to make the transfer as our board of directors shall reasonably require or unless all applicable consents, authorizations and permissions of any governmental agency or body in Bermuda have been obtained. Subject to these restrictions, a holder of Common Shares may transfer the title to all or any of his or her Common Shares by completing an instrument of transfer in writing in such form as our board of directors may accept. The instrument of transfer must be signed by the transferor and transferee, although in the case of a fully paid share our board of directors may accept the instrument signed only by the transferor. </div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Meetings of Shareholders </div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;">Under Bermuda law, a company is required to convene at least one general meeting of shareholders each calendar year, which we refer to as the annual general meeting. While Bermuda law permits the shareholders to waive the requirement to hold an annual general meeting by resolution (either for a specific year or a period of time or indefinitely), our amended and restated <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">bye-laws</div> provide that, notwithstanding, an annual general meeting shall be held in each year. </div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">Bermuda law provides that a special general meeting of shareholders may be called by the board of directors of a company and must be called upon the request of shareholders holding not less than 10% of the <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">paid-up</div> capital of the company carrying the right to vote at general meetings. Bermuda law also requires that shareholders be given at least five days&#8217; advance notice of a general meeting, but the accidental omission to give </div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">292 </div></div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;;font-weight: bold;"><a href="#toc">Table of Contents</a></div> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">notice to any person does not invalidate the proceedings at a meeting. Our amended and restated <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">bye-laws</div> provide that our principal executive officer or the chairperson of our board of directors or any two directors or any director and the secretary or our board of directors may convene an annual general meeting and our principal executive officer or the chairperson of our board of directors or our board of directors may convene a special general meeting. Under our amended and restated <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">bye-laws,</div> at least 14 days&#8217; notice of an annual general meeting or 10 days&#8217; notice of a special general meeting must be given to each shareholder entitled to vote at such meeting. This notice requirement is subject to the ability to hold such meetings on shorter notice if such notice is agreed: (1)&#160;in the case of an annual general meeting by all of the shareholders entitled to attend and vote at such meeting; or (2)&#160;in the case of a special general meeting by a majority in number of the shareholders entitled to attend and vote at the meeting holding not less than 95% in nominal value of the shares entitled to vote at such meeting. The quorum required for a general meeting of shareholders is two or more persons present in person at the start of the meeting and representing in person or by proxy in excess of 50% of all issued and outstanding Common Shares. </div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Access to Books and Records and Dissemination of Information </div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;">Members of the general public have a right to inspect the public documents of a company available at the office of the Registrar of Companies in Bermuda. These documents include a company&#8217;s memorandum of association, including its objects and powers, and certain alterations to the memorandum of association. The shareholders have the additional right to inspect the <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">bye-laws</div> of the company, minutes of general meetings and the company&#8217;s audited financial statements, which must be presented in the annual general meeting. The register of members of a company is also open to inspection by shareholders and by members of the general public without charge. The register of members is required to be open for inspection for not less than two hours in any business day (subject to the ability of a company to close the register of members for not more than thirty days in a year). A company is required to maintain its share register in Bermuda but may, subject to the provisions of the Companies Act establish a branch register outside of Bermuda. A company is required to keep at its registered office a register of directors and officers that is open for inspection for not less than two hours in any business day by members of the public without charge. Bermuda law does not, however, provide a general right for shareholders to inspect or obtain copies of any other corporate records. </div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Election and Removal of Directors </div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;">Our amended and restated <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">bye-laws</div> provide that our board of directors shall consist of not less than five (5)&#160;Directors and not more than such maximum number of Directors as the Board may from time to time determine, being initially fifteen (15)&#160;Directors. Upon the closing of this offering, our board of directors will consist of six directors. Our board of directors will be divided into three classes that are, as nearly as possible, of equal size. Each class of directors will be elected for a three-year term of office, but the terms will be staggered so that the term of only one class of directors expires at each annual general meeting. The initial terms of the Class&#160;I, Class&#160;II and Class&#160;III directors will expire in 2022, 2023 and 2024, respectively. At each succeeding annual general meeting, successors to the class of directors whose term expires at the annual general meeting will be elected for a three-year term. </div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">A shareholder holding any percentage of the Common Shares in issue may propose for election as a director someone who is not an existing director or is not proposed by our board of directors. Where a director is to be elected at an annual general meeting, notice of any such proposal for election must be given not less than 90 days nor more than 120 days before the anniversary of the last annual general meeting prior to the giving of the notice or, in the event the annual general meeting is called for a date that is not less than 30 days before or after such anniversary the notice must be given not later than 10 days following the earlier of the date on which notice of the annual general meeting was posted to shareholders or the date on which public disclosure of the date of the annual general meeting was made. Where a director is to be elected at a special general meeting; provided, that our board of directors has determined that shareholders may nominate persons for election at such special general meeting, that notice must be given not later than seven days following the earlier of the date on which notice of the special general meeting was posted to shareholders or the date on which public disclosure of the date of the special general meeting was made. </div></div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">293 </div></div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;;font-weight: bold;"><a href="#toc">Table of Contents</a></div> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">A director may be removed, only with cause, by the shareholders by the affirmative vote of at least 66<div style="font-size: 85%; vertical-align: top;;display:inline;;font-size:9.4px">2/3</div>% of the issued and outstanding voting shares entitled to vote for the election of directors, provided notice of the shareholders meeting convened to remove the director is given to the director. The notice must contain a statement of the intention to remove the director and a summary of the facts justifying the removal and must be served on the director not less than 14 days before the meeting. The director is entitled to attend the meeting and be heard on the motion for his or her removal. </div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Proceedings of Board of Directors </div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;">Our amended and restated <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">bye-laws</div> provide that our business is to be managed and conducted by our board of directors. Bermuda law permits individual and corporate directors and there is no requirement in our <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">bye-laws</div> or Bermuda law that directors hold any of our shares. There is also no requirement in our amended and restated <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">bye-laws</div> or Bermuda law that our directors must retire at a certain age. </div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">The compensation of our directors will be determined by the board of directors, and there is no requirement that a specified number or percentage of &#8220;independent&#8221; directors must approve any such determination. Our directors may also be paid all travel, hotel and other reasonable <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">out-of-pocket</div></div> expenses properly incurred by them in connection with our business or their duties as directors. </div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">A director who discloses a direct or indirect interest in any contract or arrangement with us as required by Bermuda law may be entitled to be counted in the quorum for such meeting and to vote in respect of any such contract or arrangement in which he or she is interested unless the chairman of the relevant meeting of the board of directors determines that such director is disqualified from voting. </div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Indemnification of Directors and Officers </div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Section&#160;98 of the Companies Act provides generally that a Bermuda company may indemnify its directors, officers and auditors against any liability which by virtue of any rule of law would otherwise be imposed on them in respect of any negligence, default, breach of duty or breach of trust, except in cases where such liability arises from fraud or dishonesty of which such director, officer or auditor may be guilty in relation to the company. Section&#160;98 further provides that a Bermuda company may indemnify its directors, officers and auditors against any liability incurred by them in defending any proceedings, whether civil or criminal, in which judgment is awarded in their favor or in which they are acquitted or granted relief by the Supreme Court of Bermuda pursuant to Section&#160;281 of the Companies Act. </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">Our amended and restated <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">bye-laws</div> provide that we shall indemnify our officers and directors in respect of their actions and omissions, except in respect of their fraud or dishonesty, and that we shall advance funds to our officers and directors for expenses incurred in their defense upon receipt of an undertaking to repay the funds if any allegation of fraud or dishonesty is proved. Our amended and restated <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">bye-laws</div> provide that the shareholders waive all claims or rights of action that they might have, individually or in right of the company, against any of the company&#8217;s directors or officers for any act or failure to act in the performance of such director&#8217;s or officer&#8217;s duties, except in respect of any fraud or dishonesty of such director or officer. Section&#160;98A of the Companies Act permits us to purchase and maintain insurance for the benefit of any officer or director in respect of any loss or liability attaching to him in respect of any negligence, default, breach of duty or breach of trust, whether or not we may otherwise indemnify such officer or director. We have purchased and maintain a directors&#8217; and officers&#8217; liability policy for such purpose. </div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;">Amendment of Memorandum of Association and <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">Bye-laws</div> </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;">Bermuda law provides that the memorandum of association of a company may be amended by a resolution passed at a general meeting of shareholders. Our amended and restated <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">bye-laws</div> provide that no <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">bye-law</div> shall be rescinded, altered or amended, and no new <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">bye-law</div> shall be made, unless it shall have been approved by a </div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">294 </div></div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;;font-weight: bold;"><a href="#toc">Table of Contents</a></div> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">resolution of our board of directors and by a resolution of our shareholders holding at least 66<div style="font-size: 85%; vertical-align: top;;display:inline;;font-size:9.4px">2/3</div>% of all votes cast on the resolution. The memorandum or association shall not be rescinded, altered or amended without a resolution of our board of directors and a resolution of our shareholders holding at least 66<div style="font-size: 85%; vertical-align: top;;display:inline;;font-size:9.4px">2/3</div>% of all votes cast on the resolution. </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Under Bermuda law, the holders of an aggregate of not less than 20% in par value of a company&#8217;s issued share capital or any class thereof have the right to apply to the Supreme Court of Bermuda for an annulment of any amendment of the memorandum of association adopted by shareholders at any general meeting, other than an amendment that alters or reduces a company&#8217;s share capital as provided in the Companies Act. Where such an application is made, the amendment becomes effective only to the extent that it is confirmed by the Supreme Court of Bermuda. An application for an annulment of an amendment of the memorandum of association must be made within 21 days after the date on which the resolution altering the company&#8217;s memorandum of association is passed and may be made on behalf of persons entitled to make the application by one or more of their number as they may appoint in writing for the purpose. No application may be made by shareholders voting in favor of the amendment. </div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Amalgamations and Mergers </div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;">The amalgamation or merger of a Bermuda company with another company or corporation (other than certain affiliated companies) requires the amalgamation or merger agreement to be approved by the company&#8217;s board of directors and by its shareholders. Unless the company&#8217;s <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">bye-laws</div> provide otherwise, the approval of 75% of the shareholders voting at such meeting is required to approve the amalgamation or merger agreement, and the quorum for such meeting must be two or more persons holding or representing more than <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">one-third</div> of the issued shares of the company. Our amended and restated <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">bye-laws</div> provide that the approval of a 66<div style="font-size: 85%; vertical-align: top;;display:inline;;font-size:9.4px">2/3</div>% of shareholders voting at a meeting to approve the amalgamation or merger agreement shall be sufficient (other than in respect of an amalgamation or merger constituting a &#8220;business combination&#8221;), and the quorum for such meeting shall be two or more Persons present in person and representing in person or by proxy in excess of 50% of the total voting rights of all issued and outstanding shares of the Company. </div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Under Bermuda law, in the event of an amalgamation or merger of a Bermuda company with another company or corporation, a shareholder of the Bermuda company who did not vote in favor of the amalgamation or merger and who is not satisfied that fair value has been offered for such shareholder&#8217;s shares may, within one month of notice of the shareholders meeting, apply to the Supreme Court of Bermuda to appraise the fair value of those shares. </div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Business Combinations </div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;">Although the Companies Act does not contain specific provisions regarding &#8220;business combinations&#8221; between companies organized under the laws of Bermuda and &#8220;interested shareholders,&#8221; we have included these provisions in our <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">bye-laws.</div> Specifically, our <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">bye-laws</div> contain provisions which prohibit us from engaging in a business combination with an interested shareholder for a period of three years after the date of the transaction in which the person became an interested shareholder, unless, in addition to any other approval that may be required by applicable law: </div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">prior to the date of the transaction that resulted in the shareholder becoming an interested shareholder, our board of directors approved either the business combination or the transaction that resulted in the shareholder becoming an interested shareholder; </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">upon consummation of the transaction that resulted in the shareholder becoming an interested shareholder, the interested shareholder owned at least 85% of our issued and voting shares outstanding at the time the transaction commenced; or </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">295 </div></div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;;font-weight: bold;"><a href="#toc">Table of Contents</a></div> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;">
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">after the date of the transaction that resulted in the shareholder becoming an interested shareholder, the business combination is approved by our board of directors and authorized at an annual or special meeting of shareholders by the affirmative vote of at least 66<div style="font-size: 85%; vertical-align: top;;display:inline;;font-size:9.4px">2/3</div>% of our issued and outstanding voting shares that are not owned by the interested shareholder. </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">For purposes of these provisions, a &#8220;business combination&#8221; includes recapitalizations, mergers, amalgamations, consolidations, exchanges, asset sales, leases, certain issues or transfers of shares or other securities and other transactions resulting in a financial benefit to the interested shareholder. An &#8220;interested shareholder&#8221; is any person or entity that beneficially owns 15% or more of our issued and outstanding voting shares and any person or entity affiliated with or controlling or controlled by that person or entity. </div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Shareholder Suits </div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;">Class&#160;actions and derivative actions are generally not available to shareholders under Bermuda law. The Bermuda courts, however, would ordinarily be expected to permit a shareholder to commence an action in the name of a company to remedy a wrong to the company where the act complained of is alleged to be beyond the corporate power of the company or illegal, or would result in the violation of the company&#8217;s memorandum of association or <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">bye-laws.</div> Furthermore, consideration would be given by a Bermuda court to acts that are alleged to constitute a fraud against the minority shareholders or, for instance, where an act requires the approval of a greater percentage of the company&#8217;s shareholders than that which actually approved it. </div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">When the affairs of a company are being conducted in a manner that is oppressive or prejudicial to the interests of some part of the shareholders, one or more shareholders may apply to the Supreme Court of Bermuda, which may make such order as it sees fit, including an order regulating the conduct of the company&#8217;s affairs in the future or ordering the purchase of the shares of any shareholders by other shareholders or by the company. </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">Our amended and restated <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">bye-laws</div> contain a provision by virtue of which our shareholders waive any claim or right of action that they have, both individually and on our behalf, against any director or officer in relation to any action or failure to take action by such director or officer, except in respect of any fraud or dishonesty of such director or officer. We have been advised by the SEC that in the opinion of the SEC, the operation of this provision as a waiver of the right to sue for violations of federal securities laws would likely be unenforceable in U.S. courts. </div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Capitalization of Profits and Reserves </div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;">Pursuant to our amended and restated <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">bye-laws,</div> our board of directors may (1)&#160;capitalize any part of the amount of our share premium or other reserve accounts or any amount credited to our profit and loss account or otherwise available for distribution by applying such sum in paying up unissued shares to be allotted as fully paid bonus shares pro rata (except in connection with the conversion of shares) to the shareholders; or (2)&#160;capitalize any sum standing to the credit of a reserve account or sums otherwise available for dividend or distribution by paying up in full, partly paid or nil paid shares of those shareholders who would have been entitled to such sums if they were distributed by way of dividend or distribution. </div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Untraced Shareholders </div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;">Our amended and restated <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">bye-laws</div> provide that our board of directors may forfeit any dividend or other monies payable in respect of any shares that remain unclaimed for six years from the date when such monies became due for payment. In addition, we are entitled to cease sending dividend warrants and checks by post or otherwise to a shareholder if such instruments have been returned undelivered to, or left uncashed by, such shareholder on at least two consecutive occasions or, following one such occasion, reasonable enquires have failed to establish the shareholder&#8217;s new address. This entitlement ceases if the shareholder claims a dividend or cashes a dividend check or a warrant. </div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">296 </div></div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;;font-weight: bold;"><a href="#toc">Table of Contents</a></div> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Warrants </div></div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Public Warrants </div></div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Each whole Warrant entitles the registered holder to purchase one Common Share at a price of $11.50 per share, subject to adjustment as discussed below, at any time commencing October&#160;30, 2021, provided in each case that Roivant has an effective registration statement under the Securities Act covering the Common Shares issuable upon exercise of the Warrants and a current prospectus relating to them is available (or Roivant permits holders to exercise their Warrants on a cashless basis under the circumstances specified in the warrant agreement) and such shares are registered, qualified or exempt from registration under the securities, or blue sky, laws of the state of residence of the holder. Pursuant to the warrant agreement, a holder of Warrants may exercise its Warrants only for a whole number of Common Shares. This means only a whole Warrant may be exercised at a given time by a Warrant holder. No fractional Warrants will be issued upon separation of the units and only whole Warrants will trade. Accordingly, unless you purchase at least two units, you will not be able to receive or trade a whole warrant. The Warrants will expire at 5:00&#160;p.m., New York City time on September&#160;30, 2026. </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Roivant will not be obligated to deliver any Common Shares pursuant to the exercise of a Warrant and will have no obligation to settle such Warrant exercise unless a registration statement under the Securities Act with respect to the Common Shares underlying the Warrants is then effective and a prospectus relating thereto is current, subject to our satisfying our obligations described below with respect to registration, or a valid exemption from registration is available. No Warrant will be exercisable and Roivant will not be obligated to issue a Common Share upon exercise of a Warrant unless the Common Shares issuable upon such Warrant exercise has been registered, qualified or deemed to be exempt under the securities laws of the state of residence of the registered holder of the Warrants. In the event that the conditions in the two immediately preceding sentences are not satisfied with respect to a warrant, the holder of such Warrant will not be entitled to exercise such Warrant and such Warrant may have no value and expire worthless. In no event will Roivant be required to net cash settle any warrant. In the event that a registration statement is not effective for the exercised Warrants, the purchaser of a unit containing such Warrant will have paid the full purchase price for the unit solely for the share of Common Shares underlying such unit. </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">As soon as practicable, but in no event later than twenty business days after the Closing, Roivant will use its commercially reasonable efforts to file with the SEC a registration statement for the registration, under the Securities Act, of the Common Shares issuable upon exercise of the Warrants. Roivant will use its commercially reasonable efforts to cause the same to become effective and to maintain the effectiveness of such registration statement, and a current prospectus relating thereto, until the expiration or redemption of the Warrants in accordance with the provisions of the warrant agreement. If a registration statement covering the issuance of the Common Shares issuable upon exercise of the Warrants is not effective by the 60th&#160;business day after the Closing, Warrant holders may, until such time as there is an effective registration statement and during any period when Roivant will have failed to maintain an effective registration statement, exercise Warrants on a &#8220;cashless basis&#8221; in accordance with Section&#160;3(a)(9)&#160;of the Securities Act or another exemption. In addition, if Common Shares are at the time of any exercise of a Warrant not listed on a national securities exchange such that they satisfy the definition of a &#8220;covered security&#8221; under Section&#160;18(b)(1)&#160;of the Securities Act, Roivant may, at its option, require holders of its public Warrants who exercise their Warrants to do so on a &#8220;cashless basis&#8221; in accordance with Section&#160;3(a)(9)&#160;of the Securities Act and, in the event Roivant elects to do so, Roivant will not be required to file or maintain in effect a registration statement, but Roivant will use its best efforts to register or qualify the shares under applicable blue sky laws to the extent an exemption is not available. In such event, each holder would pay the exercise price by surrendering each such Warrant for that number of Common Shares equal to the lesser of (A)&#160;the quotient obtained by dividing (x)&#160;the product of the number of Common Shares underlying the Warrants, multiplied the excess of the &#8220;fair market value&#8221; less the exercise price of the Warrants by (y)&#160;the fair market value and (B)&#160;0.361. The &#8220;fair market value&#8221; shall mean the volume weighted average price of Common Shares for the 10 trading days ending on the trading day prior to the date on which the notice of exercise is received by the warrant agent. </div></div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">297 </div></div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;;font-weight: bold;"><a href="#toc">Table of Contents</a></div> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 4%;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Redemption of Warrants When the Price per Common Share Equals or Exceeds $18.00 </div></div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Once the Warrants become exercisable, Roivant may redeem the outstanding Warrants (except as described herein with respect to the private placement Warrants): </div></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">in whole and not in part; </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">at a price of $0.01 per warrant; </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">upon not less than 30&#160;days&#8217; prior written notice of redemption to each Warrant holder; and </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;">if, and only if, the last reported sale price of the Common Shares for any 20 trading days within a <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">30-trading</div> day period ending three business days before Roivant sends to the notice of redemption to the Warrant holders (which Roivant refers to as the &#8220;Reference Value&#8221;) equals or exceeds $18.00 per share (as adjusted for share subdivisions, share capitalizations, dividends, reorganizations, recapitalizations and the like). </div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">If and when the Warrants become redeemable by us, Roivant may exercise its redemption right even if Roivant is unable to register or qualify the underlying securities for sale under all applicable state securities laws. However, Roivant will not redeem the Warrants unless an effective registration statement under the Securities Act covering the Common Shares issuable upon exercise of the Warrants is effective and a current prospectus relating to those Common Shares is available throughout the <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">30-day</div> redemption period. </div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Roivant established the last of the redemption criterion discussed above to prevent a redemption call unless there is at the time of the call a significant premium to the Warrant exercise price. If the foregoing conditions are satisfied and Roivant issues a notice of redemption of the Warrants, each Warrant holder will be entitled to exercise his, her or its Warrant prior to the scheduled redemption date. Any such exercise would not be done on a &#8220;cashless&#8221; basis and would require the exercising Warrant holder to pay the exercise price for each Warrant being exercised. However, the price of the Common Shares may fall below the $18.00 redemption trigger price (as adjusted for share subdivisions, share capitalizations, reorganizations, recapitalizations and the like) as well as the $11.50 (for whole shares) Warrant exercise price after the redemption notice is issued. </div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Redemption of Warrants When the Price per Common Share Equals or Exceeds $10.00 </div></div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Once the Warrants become exercisable, Roivant may redeem the outstanding Warrants: </div></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">in whole and not in part; </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">at $0.10 per Warrant upon a minimum of 30&#160;days&#8217; prior written notice of redemption; provided that holders will be able to exercise their Warrants on a cashless basis prior to redemption and receive that number of shares determined by reference to the table below, based on the redemption date and the &#8220;fair market value&#8221; of Common Shares (as defined below); </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">if, and only if, the Reference Value (as defined above under&#8212;&#8221;Redemption of Warrants When the Price per Common Share Equals or Exceeds $18.00&#8221;) equals or exceeds $10.00 per share (as adjusted for share subdivisions, share capitalizations, reorganizations, recapitalizations and the like); and </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">if the Reference Value is less than $18.00 per share (as adjusted for share subdivisions, share capitalizations, reorganizations, recapitalizations and the like) the private placement Warrants must also be concurrently called for redemption on the same terms (except as described above with respect to a holder&#8217;s ability to cashless exercise its Warrants) as the outstanding public Warrants, as described above. </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The numbers in the table below represent the number of Common Shares that a Warrant holder will receive upon exercise in connection with a redemption by Roivant pursuant to this redemption feature, based on the &#8220;fair market value&#8221; of Common Shares on the corresponding redemption date (assuming holders elect to exercise their </div></div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">298 </div></div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;;font-weight: bold;"><a href="#toc">Table of Contents</a></div> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Warrants and such Warrants are not redeemed for $0.10 per warrant), determined based on volume-weighted average price of Common Shares as reported during the 10 trading days immediately following the date on which the notice of redemption is sent to the holders of Warrants, and the number of months that the corresponding redemption date precedes the expiration date of the Warrants, each as set forth in the table below. Roivant provides its Warrant holders with the final fair market value no later than one business day after the <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">10-trading</div> day period described above ends. </div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Pursuant to the warrant agreement, references above to Common Shares shall include a security other than Common Shares into which the Common Shares have been converted or exchanged for in the event Roivant is not the surviving company in an initial business combination. The numbers in the table below will not be adjusted when determining the number of Common Shares to be issued upon exercise of the Warrants if Roivant is not the surviving entity following an initial business combination. </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">The share prices set forth in the column headings of the table below will be adjusted as of any date on which the number of shares issuable upon exercise of a Warrant is adjusted as set forth under the heading &#8220;&#8212;<div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Anti-dilution Adjustments</div></div>&#8221; below. The adjusted share prices in the column headings will equal the share prices immediately prior to such adjustment, multiplied by a fraction, the numerator of which is the number of shares deliverable upon exercise of a Warrant immediately prior to such adjustment and the denominator of which is the number of shares deliverable upon exercise of a Warrant as so adjusted. The number of shares in the table below shall be adjusted in the same manner and at the same time as the number of shares issuable upon exercise of a warrant. </div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="font-size: 0px;">
<td style="width: 46%;"></td>
<td style="width: 1%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td>
<td style="width: 1%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td>
<td style="width: 1%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td>
<td style="width: 1%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td>
<td style="width: 1%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td>
<td style="width: 1%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td>
<td style="width: 1%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td>
<td style="width: 1%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td>
<td style="width: 1%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;&#160;</td>
<td colspan="34" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Fair Market Value of Common Shares</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; white-space: nowrap; padding-bottom: 1pt;"> <div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt; border-bottom: 1pt solid rgb(0, 0, 0); display: table-cell; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">Redemption Date <br/>(period to expiration of Warrants)</div></div></div> </td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="font-family: SYMBOL; letter-spacing: 0px; top: 0px;;display:inline;">&#163;</div><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">$10.00</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">$11.00</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">$12.00</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">$13.00</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">$14.00</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">$15.00</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">$16.00</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">$17.00</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="font-family: SYMBOL; letter-spacing: 0px; top: 0px;;display:inline;">&#179;</div><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">$18.00</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">60&#160;months</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">0.261</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">0.281</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">0.297</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">0.311</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">0.324</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">0.337</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">0.348</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">0.358</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">0.361</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">57&#160;months</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">0.257</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">0.277</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">0.294</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">0.310</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">0.324</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">0.337</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">0.348</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">0.358</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">0.361</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">54&#160;months</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">0.252</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">0.272</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">0.291</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">0.307</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">0.322</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">0.335</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">0.347</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">0.357</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">0.361</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">51&#160;months</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">0.246</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">0.268</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">0.287</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">0.304</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">0.320</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">0.333</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">0.346</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">0.357</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">0.361</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">48&#160;months</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">0.241</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">0.263</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">0.283</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">0.301</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">0.317</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">0.332</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">0.344</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">0.356</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">0.361</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">45&#160;months</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">0.235</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">0.258</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">0.279</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">0.298</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">0.315</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">0.330</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">0.343</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">0.356</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">0.361</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">42&#160;months</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">0.228</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">0.252</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">0.274</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">0.294</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">0.312</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">0.328</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">0.342</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">0.355</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">0.361</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">39&#160;months</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">0.221</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">0.246</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">0.269</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">0.290</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">0.309</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">0.325</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">0.340</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">0.354</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">0.361</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">36&#160;months</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">0.213</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">0.239</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">0.263</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">0.285</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">0.305</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">0.323</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">0.339</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">0.353</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">0.361</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">33&#160;months</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">0.205</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">0.232</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">0.257</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">0.280</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">0.301</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">0.320</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">0.337</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">0.352</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">0.361</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">30&#160;months</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">0.196</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">0.224</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">0.250</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">0.274</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">0.297</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">0.316</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">0.335</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">0.351</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">0.361</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">27&#160;months</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">0.185</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">0.214</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">0.242</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">0.268</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">0.291</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">0.313</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">0.332</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">0.350</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">0.361</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">24&#160;months</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">0.173</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">0.204</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">0.233</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">0.260</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">0.285</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">0.308</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">0.329</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">0.348</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">0.361</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">21&#160;months</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">0.161</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">0.193</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">0.223</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">0.252</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">0.279</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">0.304</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">0.326</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">0.347</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">0.361</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">18&#160;months</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">0.146</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">0.179</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">0.211</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">0.242</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">0.271</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">0.298</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">0.322</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">0.345</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">0.361</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">15&#160;months</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">0.130</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">0.164</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">0.197</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">0.230</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">0.262</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">0.291</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">0.317</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">0.342</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">0.361</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">12&#160;months</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">0.111</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">0.146</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">0.181</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">0.216</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">0.250</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">0.282</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">0.312</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">0.339</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">0.361</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">9&#160;months</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">0.090</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">0.125</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">0.162</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">0.199</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">0.237</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">0.272</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">0.305</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">0.336</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">0.361</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">6&#160;months</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">0.065</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">0.099</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">0.137</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">0.178</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">0.219</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">0.259</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">0.296</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">0.331</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">0.361</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">3&#160;months</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">0.034</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">0.065</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">0.104</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">0.150</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">0.197</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">0.243</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">0.286</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">0.326</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">0.361</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">0&#160;months</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">0.042</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">0.115</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">0.179</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">0.233</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">0.281</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">0.323</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">0.361</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">The exact fair market value and redemption date may not be set forth in the table above, in which case, if the fair market value is between two values in the table or the redemption date is between two redemption dates in the table, the number of Common Shares to be issued for each Warrant exercised will be determined by a straight-line interpolation between the number of shares set forth for the higher and lower fair market values and the earlier and later redemption dates, as applicable, based on a 365 or <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">366-day</div> year, as applicable. For example, </div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">299 </div></div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;;font-weight: bold;"><a href="#toc">Table of Contents</a></div> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">if the volume-weighted average price of Common Shares as reported during the 10 trading days immediately following the date on which the notice of redemption is sent to the holders of the Warrants is $11.00 per share, and at such time there are 57&#160;months until the expiration of the Warrants, holders may choose to, in connection with this redemption feature, exercise their Warrants for 0.277 Common Shares for each whole warrant. For an example where the exact fair market value and redemption date are not as set forth in the table above, if the volume-weighted average price of Common Shares as reported during the 10 trading days immediately following the date on which the notice of redemption is sent to the holders of the Warrants is $13.50 per share, and at such time there are 38&#160;months until the expiration of the Warrants, holders may choose to, in connection with this redemption feature, exercise their Warrants for 0.298 Common Shares for each whole warrant. In no event will the Warrants be exercisable in connection with this redemption feature for more than 0.361 Common Shares per Warrant (subject to adjustment). </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">This redemption feature differs from the typical warrant redemption features used in some other blank check offerings, which typically only provide for a redemption of Warrants for cash (other than the Private Placement Warrants) when the trading price for the Common Shares exceeds $18.00 per share for a specified period of time. This redemption feature is structured to allow for all of the outstanding Warrants to be redeemed when the Common Shares are trading at or above $10.00 per share, which may be at a time when the trading price of Common Shares is below the exercise price of the Warrants. Roivant has established this redemption feature to provide Roivant with the flexibility to redeem the Warrants without the Warrants having to reach the $18.00 per share threshold set forth above under &#8220;&#8212;Redemption of Warrants When the Price per Common Share Equals or Exceeds $18.00.&#8221; Holders choosing to exercise their Warrants in connection with a redemption pursuant to this feature will, in effect, receive a number of shares for their Warrants based on an option pricing model with a fixed volatility input as of the date of this prospectus. This redemption right provides Roivant with an additional mechanism by which to redeem all of the outstanding Warrants, and therefore have certainty as to our capital structure as the Warrants would no longer be outstanding and would have been exercised or redeemed. Roivant will be required to pay the applicable redemption price to Warrant holders if Roivant<div style="text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"><div style="text-decoration:underline;display:inline;"> </div></div>chooses to exercise this redemption right and it will allow Roivant to quickly proceed with a redemption of the Warrants if Roivant determines it is in our best interest to do so. As such, Roivant would redeem the Warrants in this manner when Roivant believes it is in our best interest to update our capital structure to remove the Warrants and pay the redemption price to the Warrant holders. </div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">As stated above, Roivant can redeem the Warrants when the Common Shares are trading at a price starting at $10.00, which is below the exercise price of $11.50, because it provides certainty with respect to our capital structure and cash position while providing Warrant holders with the opportunity to exercise their Warrants on a cashless basis for the applicable number of shares. If Roivant chooses to redeem the Warrants when the Common Shares are trading at a price below the exercise price of the Warrants, this could result in the Warrant holders receiving fewer Common Shares than they would have received if they had chosen to wait to exercise their Warrants for Common Shares if and when such Common Shares were trading at a price higher than the exercise price of $11.50. </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">No fractional Common Shares will be issued upon exercise. If, upon exercise, a holder would be entitled to receive a fractional interest in a share, Roivant will round down to the nearest whole number of the number of Common Shares to be issued to the holder. If, at the time of redemption, the Warrants are exercisable for a security other than the Common Shares pursuant to the warrant agreement (for instance, if Roivant is not the surviving company in an initial business combination), the Warrants may be exercised for such security. At such time as the Warrants become exercisable for a security other than the Common Shares, Roivant (or surviving company) will use its commercially reasonable efforts to register under the Securities Act the security issuable upon the exercise of the Warrants. </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Redemption Procedures.</div></div> A holder of a Warrant may notify Roivant in writing in the event it elects to be subject to a requirement that such holder will not have the right to exercise such warrant, to the extent that after giving effect to such exercise, such person (together with such person&#8217;s affiliates), to the warrant agent&#8217;s actual </div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">300 </div></div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;;font-weight: bold;"><a href="#toc" style="text-indent: 0px;">Table of Contents</a></div> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">knowledge, would beneficially own in excess of 4.9% or 9.8% (as specified by the holder) of the Common Shares issued and outstanding immediately after giving effect to such exercise. </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Anti-dilution Adjustments.</div></div> If the number of outstanding Common Shares is increased by a share subdivisions, share capitalization or dividend payable in Common Shares, or by a <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">split-up</div> of Common Shares or other similar event, then, on the effective date of such share subdivision, share capitalization, <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">split-up</div> or similar event, the number of Common Shares issuable on exercise of each Warrant will be increased in proportion to such increase in the outstanding shares of Common Shares. A rights offering to holders of Common Shares entitling holders to purchase Common Shares at a price less than the &#8220;historical fair market value&#8221; (as defined below) will be deemed a dividend of a number of Common Shares equal to the product of (i)&#160;the number of Common Shares actually sold in such rights offering (or issuable under any other equity securities sold in such rights offering that are convertible into or exercisable for Common Shares) and (ii)&#160;one minus the quotient of (x)&#160;the price per Roivant Common Share paid in such rights offering and (y)&#160;the historical fair market value. For these purposes, (i)&#160;if the rights offering is for securities convertible into or exercisable for Common Shares, in determining the price payable for Common Shares, there will be taken into account any consideration received for such rights, as well as any additional amount payable upon exercise or conversion and (ii)&#160;&#8221;historical fair market value&#8221; means the volume-weighted average price of Common Shares as reported during the 10 trading day period ending on the trading day prior to the first date on which the Common Shares trade on the applicable exchange or in the applicable market, regular way, without the right to receive such rights. </div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">In addition, if we, at any time while the Warrants are outstanding and unexpired, pay a dividend or make a distribution in cash, securities or other assets to the holders of Common Shares on account of such Common Shares (or other securities into which the Warrants are convertible), other than (a)&#160;as described above, (b)&#160;any cash dividends or cash distributions which, when combined on a per share basis with all other cash dividends and cash distributions paid on the Common Shares during the <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">365-day</div> period ending on the date of declaration of such dividend or distribution does not exceed $0.50 (as adjusted to appropriately reflect any other adjustments and excluding cash dividends or cash distributions that resulted in an adjustment to the exercise price or to the number of Common Shares issuable on exercise of each warrant) but only with respect to the amount of the aggregate cash dividends or cash distributions equal to or less than $0.50 per share, (c)&#160;to satisfy the redemption rights of the holders of Common Shares in connection with a proposed initial business combination, (d)&#160;to satisfy the redemption rights of the holders of Common Shares in connection with a shareholder vote to amend our amended and restated <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">bye-laws</div> (A)&#160;to modify the substance or timing of our obligation to allow redemption in connection with an initial business combination or to redeem 100% of Common Shares if Roivant does not complete an initial business combination within 24&#160;months from the closing of the initial public offering or (B)&#160;with respect to any other provision relating to shareholders&#8217; rights or <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">pre-initial</div> business combination activity, or (e)&#160;in connection with the redemption of Common Shares upon our failure to complete an initial business combination, then the Warrant exercise price will be decreased, effective immediately after the effective date of such event, by the amount of cash and/or the fair market value of any securities or other assets paid on each Roivant Common Share in respect of such event. </div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">If the number of outstanding Common Shares is decreased by a consolidation, combination, reverse share split or reclassification of Common Shares or other similar event, then, on the effective date of such consolidation, combination, reverse share split, reclassification or similar event, the number of Common Shares issuable on exercise of each Roivant Warrant will be decreased in proportion to such decrease in outstanding Common Shares. </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Whenever the number of Common Shares purchasable upon the exercise of the Warrants is adjusted, as described above, the Warrant exercise price will be adjusted by multiplying the Warrant exercise price immediately prior to such adjustment by a fraction (x)&#160;the numerator of which will be the number of Common Shares purchasable upon the exercise of the Warrants immediately prior to such adjustment and (y)&#160;the denominator of which will be the number of Common Shares so purchasable immediately thereafter. </div></div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">301 </div></div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;;font-weight: bold;"><a href="#toc">Table of Contents</a></div> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">In addition, if (x)&#160;Roivant issues additional Common Shares or equity-linked securities for capital raising purposes in connection with the closing of an initial business combination at an issue price or effective issue price of less than $9.20 per Roivant Common Share (with such issue price or effective issue price to be determined in good faith by our board of directors and, in the case of any such issuance to our sponsor or its affiliates, without taking into account any shares held by the MAAC Sponsor or its affiliates, as applicable, prior to such issuance (the &#8220;Newly Issued Price&#8221;), (y)&#160;the aggregate gross proceeds from such issuances represent more than 60% of the total equity proceeds, and interest thereon, available for the funding of an initial business combination on the date of the completion of an initial business combination (net of redemptions), and (z)&#160;the volume-weighted average trading price of Common Shares during the 20 trading day period starting on the trading day prior to Closing (such price, the &#8220;Market Value&#8221;) is below $9.20 per share, the exercise price of the Warrants will be adjusted (to the nearest cent) to be equal to 115% of the higher of the Market Value and the Newly Issued Price, and the $10.00 and $18.00 per share redemption trigger prices described adjacent to &#8220;Redemption of Warrants When the Price per Roivant Common Share Equals or Exceeds $18.00&#8221; and &#8220;Redemption of Warrants When the Price per Roivant Common Share Equals or Exceeds $10.00&#8221; will be adjusted (to the nearest cent) to be equal to 100% and 180% of the higher of the Market Value and the Newly Issued Price, respectively. </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">In case of any reclassification or reorganization of the outstanding Common Shares (other than those described above or that solely affects the par value of such Common Shares), or in the case of any merger or consolidation of Roivant with or into another corporation (other than a consolidation or merger in which Roivant is the continuing corporation and that does not result in any reclassification or reorganization of our outstanding Common Shares), or in the case of any sale or conveyance to another corporation or entity of the assets or other property of Roivant as an entirety or substantially as an entirety in connection with which Roivant is dissolved, the holders of the Warrants will thereafter have the right to purchase and receive, upon the basis and upon the terms and conditions specified in the Warrants and in lieu of the Common Shares immediately theretofore purchasable and receivable upon the exercise of the rights represented thereby, the kind and amount of Common Shares or other securities or property (including cash) receivable upon such reclassification, reorganization, merger or consolidation, or upon a dissolution following any such sale or transfer, that the holder of the Warrants would have received if such holder had exercised their Warrants immediately prior to such event. If less than 70% of the consideration receivable by the holders of Common Shares in such a transaction is payable in the form of Common Shares in the successor entity that is listed for trading on a national securities exchange or is quoted in an established <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">over-the-counter</div></div> market, or is to be so listed for trading or quoted immediately following such event, and if the registered holder of the Roivant Warrant properly exercises the Roivant Warrant within thirty days following public disclosure of such transaction, the Warrant exercise price will be reduced as specified in the warrant agreement based on the Black-Scholes value (as defined in the warrant agreement) of the warrant. The purpose of such exercise price reduction is to provide additional value to holders of the Warrants when an extraordinary transaction occurs during the exercise period of the Warrants pursuant to which the holders of the Warrants otherwise do not receive the full potential value of the Warrants. </div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The Warrants are issued in registered form under a warrant agreement between American Stock Transfer&#160;&amp; Trust Company, LLC as warrant agent, and us. </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The warrant agreement provides that the terms of the Warrants may be amended without the consent of any holder for the purpose of (i)&#160;curing any ambiguity or correct any mistake, including to conform the provisions of the warrant agreement to the description of the terms of the Warrants and the warrant agreement set forth in this prospectus, or defective provision (ii)&#160;amending the provisions relating to cash dividends on Common Shares as contemplated by and in accordance with the warrant agreement or (iii)&#160;adding or changing any provisions with respect to matters or questions arising under the warrant agreement as the parties to the warrant agreement may deem necessary or desirable and that the parties deem to not adversely affect the rights of the registered holders of the Warrants, provided that the approval by the holders of at least 50% of the then-outstanding public Warrants is required to make any change that adversely affects the interests of the registered holders of public Warrants. You should review a copy of the warrant agreement for a complete description of the terms and conditions applicable to the Warrants. </div></div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">302 </div></div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;;font-weight: bold;"><a href="#toc">Table of Contents</a></div> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The Warrants may be exercised upon surrender of the warrant certificate on or prior to the expiration date at the offices of the warrant agent, with the exercise form on the reverse side of the warrant certificate completed and executed as indicated, accompanied by full payment of the exercise price (or on a cashless basis, if applicable), by certified or official bank check payable to us, for the number of Warrants being exercised. The Warrant holders do not have the rights or privileges of holders of Common Shares and any voting rights until they exercise their Warrants and receive Common Shares. After the issuance of Common Shares upon exercise of the Warrants, each holder will be entitled to one vote for each share held of record on all matters to be voted on by shareholders. </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">No fractional shares will be issued upon exercise of the Warrants. If, upon exercise of the Warrants, a holder would be entitled to receive a fractional interest in a share, Roivant will, upon exercise, round down to the nearest whole number, the number of Common Shares to be issued to the Warrant holder. </div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Private Placement Warrants </div></div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The Private Placement Warrants (including the Common Shares issuable upon exercise of the Private Placement Warrants) will not be transferable, assignable or salable until 30&#160;days after the completion of an initial business combination (except pursuant to limited exceptions) and they will not be redeemable by Roivant so long as they are held by our sponsor or its permitted transferees (except as otherwise set forth herein). Our sponsor, or its permitted transferees, have the option to exercise the Private Placement Warrants on a cashless basis. Except as described below, the Private Placement Warrants have terms and provisions that are identical to those of the Warrants sold as part of the units in the initial public offering. If the Private Placement Warrants are held by holders other than our sponsor or its permitted transferees, the Private Placement Warrants will be redeemable by Roivant in all redemption scenarios and exercisable by the holders on the same basis as the Warrants included in the units being sold in the initial public offering. </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">If holders of the Private Placement Warrants elect to exercise them on a cashless basis, they would pay the exercise price by surrendering his, her or its Warrants for that number of Common Shares equal to the quotient obtained by dividing (x)&#160;the product of the number of Common Shares underlying the Warrants, multiplied by the excess of the &#8220;historical fair market value&#8221; (defined below) over the exercise price of the Warrants by (y)&#160;the historical fair market value. For these purposes, the &#8220;historical fair market value&#8221; shall mean the average last reported sale price of the Common Shares for the 10 trading days ending on the third trading day prior to the date on which the notice of Warrant exercise is sent to the warrant agent. The reason that Roivant has agreed that these Warrants will be exercisable on a cashless basis so long as they are held by our sponsor and its permitted transferees is because it is not known at this time whether they will be affiliated with Roivant following a business combination. If they remain affiliated with us, their ability to sell our securities in the open market will be significantly limited. Roivant expects to have policies in place that restrict insiders from selling our securities except during specific periods of time. Even during such periods of time when insiders will be permitted to sell our securities, an insider cannot trade in our securities if he or she is in possession of material <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-public</div> information. Accordingly, unlike public shareholders who could exercise their Warrants and sell the Common Shares received upon such exercise freely in the open market in order to recoup the cost of such exercise, the insiders could be significantly restricted from selling such securities. As a result, Roivant believes that allowing the holders to exercise such Warrants on a cashless basis is appropriate. </div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Certain Provisions of Bermuda Law </div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;">We have been designated by the Bermuda Monetary Authority as a <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-resident</div> for Bermuda exchange control purposes. This designation allows us to engage in transactions in currencies other than the Bermuda dollar, and there are no restrictions on our ability to transfer funds (other than funds denominated in Bermuda dollars) in and out of Bermuda or to pay dividends to U.S. residents who are holders of Common Shares. </div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">303 </div></div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;;font-weight: bold;"><a href="#toc">Table of Contents</a></div> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">The Bermuda Monetary Authority has given its consent for the issue and free transferability of all of the Common Shares that are the subject of this offering to and between residents and <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-residents</div> of Bermuda for exchange control purposes, provided our shares remain listed on an appointed stock exchange, which includes Nasdaq. Approvals or permissions given by the Bermuda Monetary Authority do not constitute a guarantee by the Bermuda Monetary Authority as to our performance or our creditworthiness. Accordingly, in giving such consent or permissions, neither the Bermuda Monetary Authority nor the Registrar of Companies in Bermuda shall be liable for the financial soundness, performance or default of our business or for the correctness of any opinions or statements expressed in this prospectus. Certain issues and transfers of Common Shares involving persons deemed resident in Bermuda for exchange control purposes require the specific consent of the Bermuda Monetary Authority. We have sought and have obtained a specific permission from the Bermuda Monetary Authority for the issue and transfer of Common Shares up to the amount of our authorized capital from time to time, and options, warrants, depository receipts, rights, loan notes, debt instruments and our other securities to persons resident and <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-resident</div> for exchange control purposes with the need for prior approval of such issue or transfer. </div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">In accordance with Bermuda law, share certificates are only issued in the names of companies, partnerships or individuals. In the case of a shareholder acting in a special capacity (for example as a trustee), certificates may, at the request of the shareholder, record the capacity in which the shareholder is acting. Notwithstanding such recording of any special capacity, we are not bound to investigate or see to the execution of any such trust. </div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Exchange Controls </div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;">The permission of the Bermuda Monetary Authority is required, pursuant to the provisions of the Exchange Control Act 1972 and related regulations, for all issuances and transfers of shares (which includes Common Shares) of Bermuda companies to or from a <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-resident</div> of Bermuda for exchange control purposes, other than in cases where the Bermuda Monetary Authority has granted a general permission. The Bermuda Monetary Authority, in its notice to the public dated June&#160;1, 2005, has granted a general permission for the issue and subsequent transfer of any securities of a Bermuda company from or to a <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-resident</div> of Bermuda for exchange control purposes for so long as any &#8220;Equity Securities&#8221; of the company (which would include Common Shares) are listed on an &#8220;Appointed Stock Exchange&#8221; (which would include Nasdaq). Certain issues and transfers of Common Shares involving persons deemed resident in Bermuda for exchange control purposes require the specific consent of the Bermuda Monetary Authority. We have sought and have obtained a specific permission from the Bermuda Monetary Authority for the issue and transfer of Common Shares up to the amount of our authorized capital from time to time, and options, warrants, depository receipts, rights, loan notes, debt instruments and our other securities to persons resident and <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-resident</div> for exchange control purposes with the need for prior approval of such issue or transfer. </div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Transfer Agent and Warrant Agent </div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The transfer agent for the Common Shares and warrant agent for the Public Warrants and Private Placement Warrants is American Stock Transfer&#160;&amp; Trust Company, LLC. </div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Listing of Common Stock and Warrants </div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The Common Shares and Public Warrants are listed on The Nasdaq Global Market under the symbols &#8220;ROIV&#8221; and &#8220;ROIVW,&#8221; respectively. </div></div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">304 </div></div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;;font-weight: bold;"><a href="#toc">Table of Contents</a></div> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"> <div id="rom164680_18" style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">PLAN OF DISTRIBUTION </div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">We are registering the issuance by us of up to 30,750,261 shares of our Common Shares that may be issued upon exercise of Warrants to purchase Common Shares, including the Public Warrants and the Private Placement Warrants. We are also registering the resale by the Holders or their permitted transferees of (i)&#160;up to 595,134,445 Common Shares, consisting of (x) 22,000,000 Common Shares issued in the PIPE Financing, (y)&#160;up to 10,214,365 Common Shares issuable upon exercise of the Private Placement Warrants and (z) 562,920,080 issued and outstanding Common Shares held by certain Holders (including Common Shares underlying vested restricted share awards), and (ii)&#160;the Private Placement Warrants. </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">We will not receive any of the proceeds from the sale of the securities by the Holders. We will receive proceeds from Warrants exercised in the event that such Warrants are exercised for cash. The aggregate proceeds to the Holders will be the purchase price of the securities less any discounts and commissions borne by the Holders. </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">The Common Shares beneficially owned by the Holders covered by this prospectus may be offered and sold from time to time by the Holders. The term &#8220;Holders&#8221; includes donees, pledgees, transferees or other successors in interest selling securities received after the date of this prospectus from a Holder as a gift, pledge, partnership distribution or other transfer. The Holders will act independently of us in making decisions with respect to the timing, manner and size of each sale. Such sales may be made on one or more exchanges or in the <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">over-the-counter</div></div> market or otherwise, at prices and under terms then prevailing or at prices related to the then current market price or in negotiated transactions. The Holders may sell their Common Shares or Warrants by one or more of, or a combination of, the following methods: </div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 4%;">&#160;</td>
<td style="width: 4%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">purchases by a broker-dealer as principal and resale by such broker-dealer for its own account pursuant to this prospectus; </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 4%;">&#160;</td>
<td style="width: 4%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">ordinary brokerage transactions and transactions in which the broker solicits purchasers; </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 4%;">&#160;</td>
<td style="width: 4%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">block trades in which the broker-dealer so engaged will attempt to sell the shares as agent but may position and resell a portion of the block as principal to facilitate the transaction; </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 4%;">&#160;</td>
<td style="width: 4%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;">an <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">over-the-counter</div></div> distribution in accordance with the rules of Nasdaq; </div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 4%;">&#160;</td>
<td style="width: 4%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;">through trading plans entered into by a Holder pursuant to Rule <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">10b5-1</div> under the Exchange Act, that are in place at the time of an offering pursuant to this prospectus and any applicable prospectus supplement hereto that provide for periodic sales of their securities on the basis of parameters described in such trading plans; </div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 4%;">&#160;</td>
<td style="width: 4%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">to or through underwriters or broker-dealers; </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 4%;">&#160;</td>
<td style="width: 4%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">in &#8220;at the market&#8221; offerings, as defined in Rule 415 under the Securities Act, at negotiated prices, at prices prevailing at the time of sale or at prices related to such prevailing market prices, including sales made directly on a national securities exchange or sales made through a market maker other than on an exchange or other similar offerings through sales agents; </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 4%;">&#160;</td>
<td style="width: 4%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">in privately negotiated transactions; </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 4%;">&#160;</td>
<td style="width: 4%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">in options transactions; </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 4%;">&#160;</td>
<td style="width: 4%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">through a combination of any of the above methods of sale; or </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 4%;">&#160;</td>
<td style="width: 4%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">any other method permitted pursuant to applicable law. </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">In addition, any shares that qualify for sale pursuant to Rule 144 may be sold under Rule 144 rather than pursuant to this prospectus. </div></div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">305 </div></div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;;font-weight: bold;"><a href="#toc">Table of Contents</a></div> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">To the extent required, this prospectus may be amended or supplemented from time to time to describe a specific plan of distribution. In connection with distributions of the shares or otherwise, the Holders may enter into hedging transactions with broker-dealers or other financial institutions. In connection with such transactions, broker-dealers or other financial institutions may engage in short sales of Common Shares in the course of hedging transactions, and broker-dealers or other financial institutions may engage in short sales of Common Shares in the course of hedging the positions they assume with Holders. The Holders may also sell Common Shares short and redeliver the shares to close out such short positions. The Holders may also enter into option or other transactions with broker-dealers or other financial institutions which require the delivery to such broker-dealer or other financial institution of shares offered by this prospectus, which shares such broker- dealer or other financial institution may resell pursuant to this prospectus (as supplemented or amended to reflect such transaction). The Holders may also pledge shares to a broker-dealer or other financial institution, and, upon a default, such broker-dealer or other financial institution may effect sales of the pledged shares pursuant to this prospectus (as supplemented or amended to reflect such transaction). </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">A Holder may enter into derivative transactions with third parties, or sell securities not covered by this prospectus to third parties in privately negotiated transactions. If the applicable prospectus supplement indicates, in connection with those derivatives, the third parties may sell securities covered by this prospectus and the applicable prospectus supplement, including in short sale transactions. If so, the third party may use securities pledged by any Holder or borrowed from any Holder or others to settle those sales or to close out any related open borrowings of stock, and may use securities received from any Holder in settlement of those derivatives to close out any related open borrowings of stock. The third party in such sale transactions will be an underwriter and will be identified in the applicable prospectus supplement (or a post-effective amendment). In addition, any Holder may otherwise loan or pledge securities to a financial institution or other third party that in turn may sell the securities short using this prospectus. Such financial institution or other third party may transfer its economic short position to investors in our securities or in connection with a concurrent offering of other securities. </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">In effecting sales, broker-dealers or agents engaged by the Holders may arrange for other broker-dealers to participate. Broker-dealers or agents may receive commissions, discounts or concessions from the Holders in amounts to be negotiated immediately prior to the sale. </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">In offering the shares covered by this prospectus, the Holders and any broker-dealers who execute sales for the Holders may be deemed to be &#8220;underwriters&#8221; within the meaning of the Securities Act in connection with such sales. Any profits realized by the Holders and the compensation of any broker-dealer may be deemed to be underwriting discounts and commissions. </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">In order to comply with the securities laws of certain states, if applicable, the shares must be sold in such jurisdictions only through registered or licensed brokers or dealers. In addition, in certain states the shares may not be sold unless they have been registered or qualified for sale in the applicable state or an exemption from the registration or qualification requirement is available and is complied with. </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">We have advised the Holders that the anti-manipulation rules of Regulation M under the Exchange Act may apply to sales of shares in the market and to the activities of the Holders and their affiliates. In addition, we will make copies of this prospectus available to the Holders for the purpose of satisfying the prospectus delivery requirements of the Securities Act. The Holders may indemnify any broker-dealer that participates in transactions involving the sale of the shares against certain liabilities, including liabilities arising under the Securities Act. </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">At the time a particular offer of shares is made, if required, a prospectus supplement will be distributed that will set forth the number of shares being offered and the terms of the offering, including the name of any underwriter, dealer or agent, the purchase price paid by any underwriter, any discount, commission and other item constituting compensation, any discount, commission or concession allowed or reallowed or paid to any dealer, and the proposed selling price to the public. </div></div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">306 </div></div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;;font-weight: bold;"><a href="#toc">Table of Contents</a></div> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">A holder of Warrants may exercise its Warrants in accordance with the Warrant Agreement on or before the expiration date set forth therein by surrendering, at the office of the warrant agent, American Stock Transfer&#160;&amp; Trust Company, LLC, the certificate evidencing such Warrant, with the form of election to purchase set forth thereon, properly completed and duly executed, accompanied by full payment of the exercise price and any and all applicable taxes due in connection with the exercise of the Warrant, subject to any applicable provisions relating to cashless exercises in accordance with the Warrant Agreement. </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The Holders party to a Subscription Agreement or party to the Registration Rights Agreement have agreed, and the other Holders may agree, to indemnify the underwriters, their officers, directors and each person who controls such underwriters (within the meaning of the Securities Act), against certain liabilities related to the sale of the securities, including liabilities under the Securities Act, in each case as further described in the Subscription Agreement or the Registration Rights Agreement, respectively. </div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Restrictions to Sell </div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;">Refer to below under &#8220;Securities Act Restrictions on Resale of Securities &#8211; <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">Lock-up</div> Provisions.&#8221; </div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">307 </div></div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;;font-weight: bold;"><a href="#toc">Table of Contents</a></div> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"> <div id="rom164680_19" style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">SECURITIES ACT RESTRICTIONS ON RESALE OF SECURITIES </div></div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Rule 144 </div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Pursuant to Rule 144 under the Securities Act (&#8220;Rule 144&#8221;), a person who has beneficially owned restricted Common Shares or our Warrants for at least six months would, subject to the restrictions noted in the section below, be entitled to sell their securities provided that (i)&#160;such person is not deemed to have been an affiliate of us at the time of, or at any time during the three months preceding, a sale and (ii)&#160;we are subject to the Exchange Act periodic reporting requirements for at least three months before the sale and have filed all required reports under Section&#160;13 or 15(d) of the Exchange Act during the 12 months (or such shorter period as we were required to file reports) preceding the sale. </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Persons who have beneficially owned restricted Common Shares or our Warrants for at least six months but who are affiliates of us at the time of, or at any time during the three months preceding, a sale, would be subject to additional restrictions, by which such person would be entitled to sell within any three-month period only a number of securities that does not exceed the greater of: </div></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 4%;">&#160;</td>
<td style="width: 4%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">1% of the total number of Common Shares or Warrants, as applicable, then outstanding; or </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 4%;">&#160;</td>
<td style="width: 4%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">the average weekly reported trading volume of such securities during the four calendar weeks preceding the filing of a notice on Form 144 with respect to the sale. </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Sales by our affiliates under Rule 144 are also limited by manner of sale provisions and notice requirements and to the availability of current public information about us. </div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">Lock-up</div> Provisions </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;">Our <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">bye-laws</div> contain a <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">lock-up</div> provision (the <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">&#8220;Bye-laws</div> <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">Lock-up&#8221;)</div> which provides that, without the prior consent of the board of directors of Roivant and subject to certain customary exceptions, each holder will not, for a period ending 180 calendar days following the effective time of the Merger, lend, offer, pledge, sell, contract to sell, sell any option or contract to purchase, purchase any option or contract to sell, grant any option, right or warrant to purchase, or otherwise transfer or dispose of, directly or indirectly, any (a)&#160;Common Shares or (b)&#160;any securities convertible into or exercisable or exchangeable (directly or indirectly) for Common Shares (including Common Shares underlying incentive equity awards), in each case that are outstanding immediately prior to the Effective Time. For the avoidance of doubt, such restriction will not apply to any Common Shares or any securities convertible into or exercisable or exchangeable (directly or indirectly) for Common Shares held by or on behalf of any stockholder of MAAC (other than a stockholder of MAAC who is also a Roivant shareholder that did not purchase MAAC Shares directly from MAAC) prior to, or received in connection with, the closing of the transactions contemplated by the Business Combination Agreement, including Common Shares issued in connection with the PIPE Financing. </div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">In addition, concurrently with the signing of the Business Combination Agreement, Roivant and certain Roivant equityholders entered into the Registration Rights Agreement. The Registration Rights Agreement contains a <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">lock-up</div> provision agreements (the &#8220;Registration Rights Agreement <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">Lock-up&#8221;</div> and, together with the <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">Lock-up</div> Agreements and the <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">Bye-laws</div> <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">Lock-up,</div> the <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">&#8220;Lock-ups&#8221;),</div> which provides that, without the prior consent of the board of directors of Roivant and subject to certain customary exceptions, each holder will not, for a period ending 180 calendar days following the closing of the Business Combination, lend, offer, pledge, sell, contract to sell, sell any option or contract to purchase, purchase any option or contract to sell, grant any option, right or warrant to purchase, or otherwise transfer or dispose of, directly or indirectly, any Common Shares or any securities convertible into or exercisable or exchangeable (directly or indirectly) for Common Shares (including Common Shares underlying incentive equity awards), in each case that were outstanding immediately prior to the closing of the Business Combination. </div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">308 </div></div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;;font-weight: bold;"><a href="#toc">Table of Contents</a></div> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;">Form <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">S-8</div> Registration Statement </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;">We have filed a registration statement on Form <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">S-8</div> under the Securities Act to register the Common Shares issued or issuable under our equity incentive plans. The Form <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">S-8</div> registration statement become effective automatically upon filing on October&#160;8, 2021. The initial registration statement on Form <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">S-8</div> covered approximately 167,200,000 Common Shares. Because the offering of such shares is registered, they can be sold in the public market upon issuance, subject to the <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">lock-up</div> provisions described above and Rule 144 limitations applicable to affiliates and vesting restrictions. </div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">309 </div></div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;;font-weight: bold;"><a href="#toc">Table of Contents</a></div> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"> <div id="rom164680_20" style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">MATERIAL UNITED STATES TAX </div></div></div> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">CONSIDERATIONS </div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The following discussion is a description of material U.S. federal income tax considerations to U.S. Holders (as defined below) of the Common Shares and/or Warrants, as the case may be, as a consequence of&#160;the ownership and disposition of Common Shares or Warrants. </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">This discussion applies only to a U.S. Holder that holds the Common Shares and/or Warrants, as the case may be, as capital assets for U.S. federal income tax purposes (generally, property held for investment). In addition, it does not describe all of the U.S. federal income tax consequences that may be relevant in light of a U.S. Holder&#8217;s particular circumstances, including any alternative minimum tax considerations, the potential application of the provisions of the Code known as the Medicare contribution tax and tax considerations applicable to U.S. Holders subject to special rules, such as: </div></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">certain financial institutions; </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;">dealers or traders in securities that use <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">mark-to-market</div></div> method of tax accounting; </div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">persons holding the Common Shares and/or Warrants, as the case may be, as part of a straddle, wash sale, hedging transaction, conversion transaction or integrated transaction or entering into a constructive sale with respect to such securities; </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">persons whose functional currency for U.S. federal income tax purposes is not the U.S. dollar; </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">persons that are subject to the &#8220;applicable financial statement&#8221; rules under Section&#160;451(b) of the Code; </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">entities classified as partnerships for U.S. federal income tax purposes and their partners; </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">tax-exempt</div> entities, &#8220;individual retirement accounts&#8221; or &#8220;Roth IRAs&#8221;; </div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">persons actually or constructively owning ten percent or more of the combined voting power or value of our Common Shares; </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">persons owning shares in connection with a trade or business conducted outside of the United States; </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">persons who acquire Common Shares or Warrants, as the case may be, pursuant to an exercise of employee share options, in connection with employee share incentive plans or otherwise as compensation; and </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">persons subject to special tax accounting rules as a result of any item of gross income with respect to Common Shares or Warrants, as the case may be, being taken into account in an applicable financial statement. </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">If a partnership (or other entity that is classified as a partnership for U.S. federal income tax purposes) holds the Common Shares and/or Warrants, as the case may be, the tax treatment of a partner in such partnership will generally depend upon the status of the partner and the activities of the partnership. Partnerships holding the Common Shares and/or Warrants and partners in such partnerships should consult their tax advisor as to the particular tax consequences of the ownership and disposition of Common Shares or Warrants by the partnership. </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">As used here in, a &#8220;U.S. Holder&#8221; is a person that for U.S. federal income tax purposes is a beneficial owner of Common Shares and/or Warrants, as the case may be, and: </div></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">a citizen or individual resident of the United States; </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">a corporation, or other entity taxable as a corporation, created or organized in or under the laws of the United States, any state therein or the District of Columbia; </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">an estate the income of which is subject to U.S. federal income taxation regardless of its source; or </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">310 </div></div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;;font-weight: bold;"><a href="#toc" style="text-indent: 0px;">Table of Contents</a></div> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;">
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">a trust that (1)&#160;is subject to the primary supervision of a U.S. court and the control of one or more &#8220;United States persons&#8221; (within the meaning of Section&#160;7701(a)(30) of the Code) or (2)&#160;has a valid election in effect to be treated as a United States person for U.S. federal income tax purposes. </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">This discussion is based on the Code, administrative pronouncements, judicial decisions, and final, temporary and proposed Treasury regulations, all as of the date hereof, and of which is subject to change, possibly with retroactive effect. We have not sought, and will not seek, a ruling from the IRS as to any U.S. federal income tax consequences described herein. The IRS may disagree with the discussion herein, and its determination may be upheld by a court. Moreover, there can be no assurance that future legislation, regulations, administrative rulings or court decisions will not adversely affect the accuracy of the statements in this discussion. This discussion does not address any U.S. federal taxes (such as estate or gift taxes) other than income taxes, nor does it address any state, local or <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-U.S.</div> tax considerations. U.S. Holders should consult their tax advisors concerning the U.S. federal, state, local and foreign tax consequences of&#160;the ownership and disposition of Common Shares or Warrants in their particular circumstances. </div> <div style="text-indent: 4%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">EACH U.S. HOLDER SHOULD CONSULT ITS TAX ADVISOR WITH RESPECT TO THE PARTICULAR TAX CONSEQUENCES TO SUCH HOLDER OF THE OWNERSHIP AND DISPOSITION OF COMMON SHARES OR WARRANTS. </div></div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt; margin-left: 4%;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Dividends and Other Distributions on the Common Shares </div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;">Subject to the PFIC rules discussed below under the heading &#8220;&#8212;Passive Foreign Investment Company Rules,&#8221; distributions (including, for the avoidance of doubt and for the purpose of the balance of this discussion, deemed distributions) on Common Shares will generally be taxable as a dividend for U.S. federal income tax purposes to the extent paid from Roivant&#8217;s current or accumulated earnings and profits, as determined under U.S. federal income tax principles. Distributions in excess of Roivant&#8217;s current and accumulated earnings and profits will constitute a return of capital that will be applied against and reduce (but not below zero) the U.S. Holder&#8217;s adjusted tax basis in its Common Shares. Any remaining excess will be treated as gain realized on the sale or other disposition of the Common Shares and will be treated as described below under the heading &#8220;&#8212;Gain or Loss on Sale, Taxable Exchange or Other Taxable Disposition of Common Shares or Warrants.&#8221; The amount of any such distribution will include any amounts withheld by us (or another applicable withholding agent). Subject to applicable limitations, dividends paid to certain <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-corporate</div> U.S. Holders generally will be taxed at the lower applicable long-term capital gains rate if the Common Shares are readily tradable on an established securities market in the United States (such as the Nasdaq, where the Common Shares are currently listed) or Roivant is eligible for benefits under an applicable tax treaty with the United States, and, in each case, Roivant is not treated as a PFIC with respect to such U.S. Holder at the time the dividend was paid or in the preceding year and provided certain holding period requirements are met. The amount of any dividend distribution paid in foreign currency will be the U.S. dollar amount calculated by reference to the applicable exchange rate in effect on the date of actual or constructive receipt, regardless of whether the payment is in fact converted into U.S. dollars at that time. A U.S. Holder may have foreign currency gain or loss if the dividend is converted into U.S. dollars after the date of receipt. </div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Amounts taxable as dividends generally will be treated as income from sources outside the U.S. and will, depending on the circumstances of the U.S. Holder, be &#8220;passive&#8221; or &#8220;general&#8221; category income which, in either case, is treated separately from other types of income for purposes of computing the foreign tax credit allowable to such U.S. Holder. The rules governing foreign tax credits are complex and U.S. Holders are urged to consult their tax advisors regarding the creditability of foreign taxes in their particular circumstances. In lieu of claiming a foreign tax credit, a U.S. Holder may, in certain circumstances, deduct foreign taxes in computing their taxable income, subject to generally applicable limitations under U.S. law. Generally, an election to deduct foreign taxes instead of claiming foreign tax credits applies to all foreign taxes paid or accrued in the taxable year. Notwithstanding the foregoing, if (a)&#160;Roivant is 50% or more owned, by vote or value, by U.S. persons and (b)&#160;at least 10% of Roivant&#8217;s earnings and profits are attributable to sources within the U.S., then for foreign tax credit </div></div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">311 </div></div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;;font-weight: bold;"><a href="#toc">Table of Contents</a></div> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">purposes, a portion of Roivant&#8217;s dividends would be treated as derived from sources within the U.S. In such case, with respect to any dividend paid for any taxable year, the U.S.-source ratio of such dividends for foreign tax credit purposes would be equal to the portion of Roivant&#8217;s earnings and profits from sources within the U.S. for such taxable year, divided by the total amount of Roivant&#8217;s earnings and profits for such taxable year. </div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt; margin-left: 4%;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Gain or Loss on Sale, Taxable Exchange or Other Taxable Disposition of Common Shares or Warrants </div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;">Subject to the PFIC rules discussed below under the heading &#8220;&#8212;Passive Foreign Investment Company Rules,&#8221; upon any sale, exchange or other taxable disposition of Common Shares or Warrants, a U.S. Holder generally will recognize gain or loss in an amount equal to the difference between (i)&#160;the sum of (x)&#160;the amount of cash and (y)&#160;the fair market value of any other property, received in such sale, exchange or other taxable disposition and (ii)&#160;the U.S. Holder&#8217;s adjusted tax basis in such Common Shares or Warrants (determined as described above or below), in each case as calculated in U.S. dollars. Any such gain or loss generally will be capital gain or loss and will be long-term capital gain or loss if the U.S. Holder&#8217;s holding period for such Common Shares or Warrants exceeds one year. Long-term capital gain realized by a <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-corporate</div> U.S. Holder generally will be taxable at a reduced rate. The deductibility of capital losses is subject to limitations. </div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">Any gain or loss recognized on the sale, exchange or other taxable disposition of Common Shares or Warrants generally will be U.S.-source income or loss for purposes of computing the foreign tax credit allowable to a U.S. Holder. Consequently, a U.S. Holder may not be able to claim a credit for any <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-U.S.</div> tax imposed upon a disposition of Common Shares or Warrants unless such credit can be applied (subject to applicable limitations) against tax due on other income treated as derived from foreign sources. Prospective U.S. Holders should consult their tax advisors as to the foreign tax credit implications of such sale, exchange or other taxable disposition of Common Shares or Warrants. </div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt; margin-left: 4%;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Exercise, Lapse or Redemption of Warrants </div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Subject to the PFIC rules discussed below and except as discussed below with respect to the cashless exercise of a Warrant, a U.S. Holder generally will not recognize taxable gain or loss on the exercise of a Warrant. The U.S. Holder&#8217;s tax basis in the Common Share received upon exercise of a Warrant generally will be an amount equal to the sum of the amount the U.S. Holder paid for the Warrant and the exercise price of such Warrant. It is unclear whether the U.S. Holder&#8217;s holding period for the Common Share received upon exercise of the Warrant will begin on the date following the date of exercise or on the date of exercise of the Warrant; in either case, the holding period will not include the period during which the U.S. Holder held the Warrant. If a Warrant is allowed to lapse unexercised, a U.S. Holder generally will recognize a capital loss equal to such U.S. Holder&#8217;s tax basis in the Warrant. </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">The tax consequences of a cashless exercise of a Warrant are not clear under current tax law. Subject to the PFIC rules discussed below, a cashless exercise may be <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">tax-free,</div> either because the exercise is not a realization event or because the exercise is treated as a recapitalization for U.S. federal income tax purposes. In either <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">tax-free</div> situation, a U.S. Holder&#8217;s basis in the Common Shares received generally should equal the U.S. Holder&#8217;s basis in the Warrants exercised therefor. If the cashless exercise were treated as not being a realization event (and not a recapitalization), it is unclear whether a U.S. Holder&#8217;s holding period in the Common Shares would be treated as commencing on the date following the date of exercise or on the date of exercise of the Warrant; in either case, the holding period would not include the period during which the U.S. Holder held the Warrants. If the cashless exercise were treated as a recapitalization, the holding period of the Common Shares would include the holding period of the Warrants exercised therefor. </div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">It is also possible that a cashless exercise could be treated in part as a taxable exchange in which gain or loss would be recognized. In such event, a U.S. Holder could be deemed to have surrendered a number of Warrants with an aggregate fair market value equal to the exercise price for the total number of Warrants deemed exercised. Subject to the PFIC rules discussed below, the U.S. Holder would recognize capital gain or loss in an </div></div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">312 </div></div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;;font-weight: bold;"><a href="#toc">Table of Contents</a></div> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">amount equal to the difference between the total exercise price for the total number of Warrants to be exercised and the U.S. Holder&#8217;s adjusted tax basis in the Warrants deemed surrendered. In this case, a U.S. Holder&#8217;s tax basis in the Common Shares received would equal the sum of the U.S. Holder&#8217;s tax basis in the Warrants exercised and the exercise price of such Warrants. It is unclear whether a U.S. Holder&#8217;s holding period for Common Shares would commence on the date following the date of exercise or on the date of exercise of the Warrants; in either case, the holding period would not include the period during which the U.S. Holder held the Warrants. </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Due to the absence of authority on the U.S. federal income tax treatment of a cashless exercise, including when a U.S. Holder&#8217;s holding period would commence with respect to the Common Shares received, there can be no assurance which, if any, of the alternative tax consequences and holding periods described above would be adopted by the IRS or a court of law. Accordingly, U.S. Holders should consult their tax advisors regarding the tax consequences of a cashless exercise. </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Subject to the PFIC rules discussed below, if we redeem Warrants for cash pursuant to the redemption provisions described in the section entitled &#8220;Description of Securities&#8212;Warrants&#8212;Redemption of Warrants When the Price per Common Share Equals or Exceeds $18.00&#8221; or the redemption provisions described in the section entitled &#8220;Description of Securities&#8212;Warrants&#8212;Redemption of Warrants When the Price per Common Share Equals or Exceeds $10.00&#8221; or if we purchase Warrants in an open market transaction, such redemption or purchase generally will be treated as a taxable disposition to the U.S. Holder, taxed as described above under &#8220;&#8212;Gain or Loss on Sale, Taxable Exchange or Other Taxable Disposition of Common Shares or Warrants.&#8221; </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">The tax consequences of a cashless exercise of a Warrant occurring after our giving notice of an intention to redeem the Warrant for $0.01 as described in the section entitled &#8220;Description of Securities&#8212;Warrants&#8212;Redemption of Warrants When the Price per Common Share Equals or Exceeds $18.00&#8221; or for $0.10 as described in the section of this prospectus entitled &#8220;Description of Securities&#8212;Warrants&#8212;Redemption of Warrants When the Price per Common Share Equals or Exceeds $10.00&#8221; are unclear under current law. Such cashless exercise may be treated either as if we redeemed such Warrant for Common Shares or as an exercise of the Warrant. If the cashless exercise of a Warrant for Common Shares is treated as a redemption, then such redemption generally should be treated as a <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">tax-deferred</div> recapitalization for U.S. federal income tax purposes, in which case a U.S. Holder should not recognize any gain or loss on such redemption, and accordingly, a U.S. Holder&#8217;s basis in the Common Shares received should equal the U.S. Holder&#8217;s basis in the Warrant and the holding period of the Common Share should include the holding period of the Warrant. If the cashless exercise of a Warrant is treated as such, the tax consequences generally should be as described under the heading &#8220;&#8212;Exercise, Lapse or Redemption of Warrants.&#8221; Due to the lack of clarity under current law regarding the treatment of a cashless exercise of a Warrant after our giving notice of an intention to redeem the Warrant for $0.01 or $0.10, there can be no assurance as to which, if any, of the alternative tax consequences described above would be adopted by the IRS or a court of law. Accordingly, U.S. Holders should consult their tax advisors regarding the tax consequences of the exercise of a Warrant occurring after our giving notice of an intention to redeem the Warrant as described above. </div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt; margin-left: 4%;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Possible Constructive Distributions </div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The terms of each Warrant provide for an adjustment to the number of Common Shares for which the Warrant may be exercised or to the exercise price of the Warrant in certain events, as discussed in the section entitled &#8220;Description of Securities&#8212;Warrants&#8212;Anti-Dilution Adjustments.&#8221; An adjustment which has the effect of preventing dilution generally is not taxable. The U.S. Holders of the Warrants would, however, be treated as receiving a constructive distribution from us if, for example, the adjustment to the number of such Common Shares received upon exercise of the Warrants or to the exercise price of the Warrants increases the proportionate interest of the U.S. Holder of Warrants in our assets or earnings and profits (e.g., through an increase in the number of Common Shares that would be obtained upon exercise or through a decrease in the exercise price of a Warrant) as a result of a distribution (or a transaction treated as a distribution) of cash or other property, such as </div></div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">313 </div></div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;;font-weight: bold;"><a href="#toc">Table of Contents</a></div> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">other securities, to the holders of Common Shares, which is taxable to the holders of such shares as a distribution as described under &#8220;&#8212;Dividends and Other Distributions on the Common Shares.&#8221; Such constructive distribution would be subject to tax as described under that section in the same manner as if the U.S. Holders of the Warrants received a cash distribution from us equal to the fair market value of such increased interest. For certain information reporting purposes, we are required to determine the date and amount of such constructive distributions. Proposed Treasury regulations, on which we may rely prior to the issuance of final regulations, specify how the date and amount of constructive distributions are determined. </div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt; margin-left: 4%;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Passive Foreign Investment Company Rules </div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;">The treatment of U.S. Holders of Common Shares or Warrants could be materially different from that described above if Roivant is treated as a PFIC for U.S. federal income tax purposes<div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">.</div></div> </div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">A foreign (i.e., <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-U.S.)</div> corporation will be classified as a PFIC for U.S. federal income tax purposes if either (i)&#160;at least 75% of its gross income in a taxable year, including its pro rata share of the gross income of any corporation in which it is considered to own at least 25% of the shares by value, is passive income or (ii)&#160;at least 50% of its assets in a taxable year (ordinarily determined based on fair market value and averaged quarterly over the year), including its pro rata share of the assets of any corporation in which it is considered to own at least 25% of the shares by value, are held for the production of, or produce, passive income. Passive income generally includes, among other things, dividends, interest, rents and royalties (other than rents or royalties derived from the active conduct of a trade or business) and gains from the disposition of passive assets. </div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Roivant&#8217;s status as a PFIC will depend on the nature and composition of its income and the nature, composition and value of its assets from time to time. The 50% passive asset test described above is generally based on the fair market value of each asset. If Roivant is a CFC (determined by disregarding certain downward attribution rules) and not publicly traded for the relevant taxable year, however, the test will be applied based on the adjusted basis of Roivant&#8217;s assets. </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">The New Regulations modify certain of the rules described above. Such modifications include, for example, permitting asset value to be determined more frequently than on a quarterly basis and treating a <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-U.S.</div> corporation as publicly traded for a taxable year if the stock of such corporation is publicly traded, other than in de minimis quantities, for at least twenty trading days during such taxable year. </div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">The New Regulations generally apply to taxable years of shareholders beginning on or after January&#160;14, 2021. A shareholder, however, may choose to apply such rules for any open taxable year beginning before January&#160;14, 2021, provided that, with respect to a <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-U.S.</div> corporation being tested for PFIC status, the shareholder consistently applies certain of the provisions of the New Regulations and certain other Treasury regulations for such year and all subsequent years. Investors who are U.S. Holders should consult their own tax advisors regarding the impact and applicability of the New Regulations. </div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">Because our Common Shares should be considered to be &#8220;publicly traded&#8221; for the current taxable year that ends on March&#160;31, 2022, we should apply the 50% passive asset test using the fair market value of its assets. This determination, however, is subject to uncertainty. In addition, Roivant&#8217;s status may also depend, in part, on how quickly it utilizes its cash <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">on-hand</div> and cash from future financings in its business. </div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Based on the foregoing, with respect to the taxable year that ended on March&#160;31, 2021, Roivant believes that it was not a PFIC (based in part on its belief that it was not classified as a CFC in the taxable year that ended on March&#160;31, 2021) and presently does not anticipate that it will be a PFIC based upon the expected value of its assets, including any goodwill and intangible assets, and the expected nature and composition of its income and assets. However, Roivant&#8217;s status as a PFIC is a fact-intensive determination made on an annual basis, and it cannot provide any assurances regarding its PFIC status for the current or future taxable years. Roivant&#8217;s U.S. counsel expresses no opinion with respect to Roivant&#8217;s PFIC status for the current or future taxable years. Roivant will determine its PFIC status for each taxable year and make such determination available to U.S. Holders. </div></div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">314 </div></div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;;font-weight: bold;"><a href="#toc">Table of Contents</a></div> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Roivant has implemented structures and arrangements intended to mitigate the possibility that it will be classified as a PFIC. There can be no assurance that the IRS will not successfully challenge these structures and arrangements, which may result in an adverse impact on the determination of whether Roivant is classified as a PFIC in the current and future taxable years. In addition, recently finalized U.S. Treasury regulations, the impact of which Roivant is continuing to assess, may also adversely affect the treatment of these structures and arrangements with respect to its PFIC status.Although Roivant&#8217;s PFIC status is determined annually, an initial determination that Roivant is a PFIC will generally apply for subsequent years to a U.S. Holder who held Common Shares or Warrants while Roivant was a PFIC, whether or not Roivant meets the test for PFIC status in those subsequent years. If Roivant is determined to be a PFIC for any taxable year (or portion thereof) that is included in the holding period of a U.S. Holder of Common Shares or Warrants and, in the case of Common Shares, the U.S. Holder did not make an applicable PFIC election (or elections), as further described below under the heading &#8220;&#8212;PFIC Elections,&#8221; for the first taxable year of Roivant in which it was treated as a PFIC, and in which the U.S. Holder held (or was deemed to hold) such Common Shares, such U.S. Holder generally will be subject to special and adverse rules. Such rules apply to (i)&#160;any gain recognized by the U.S. Holder on the sale or other disposition of its Common Shares or Warrants (which may include gain realized by reason of transfers of Common Shares or Warrants that would otherwise qualify as nonrecognition transactions for U.S. federal income tax purposes) and (ii)&#160;any &#8220;excess distribution&#8221; made to the U.S. Holder (generally, any distributions to such U.S. Holder during a taxable year of the U.S. Holder that are greater than 125% of the average annual distributions received by such U.S. Holder in respect of the Common Shares during the three preceding taxable years of such U.S. Holder or, if shorter, the portion of such U.S. Holder&#8217;s holding period for the Common Shares that preceded the taxable year of the distribution). </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Under these rules: </div></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">the U.S. Holder&#8217;s gain or excess distribution will be allocated ratably over the U.S. Holder&#8217;s holding period for the Common Shares or Warrants; </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">the amount allocated to the U.S. Holder&#8217;s taxable year in which the U.S. Holder recognized the gain or received the excess distribution, or to the period in the U.S. Holder&#8217;s holding period before the first day of Roivant&#8217;s first taxable year in which Roivant is a PFIC, will be taxed as ordinary income; </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">the amount allocated to other taxable years (or portions thereof) of the U.S. Holder and included in its holding period will be taxed at the highest tax rate in effect for that year and applicable to the U.S. Holder without regard to the U.S. Holder&#8217;s other items of income and loss for such year; and </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">an additional tax equal to the interest charge generally applicable to underpayments of tax will be imposed on the U.S. Holder with respect to the tax attributable to each such other taxable year of the U.S. Holder. </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt; margin-left: 4%;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">PFIC Elections </div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;">If Roivant is a PFIC and Common Shares constitute &#8220;marketable stock,&#8221; a U.S. Holder may avoid the adverse PFIC tax consequences discussed above with respect to its Common Shares if such U.S. Holder makes a <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">mark-to-market</div></div> election with respect to such shares for the first taxable year in which it holds (or is deemed to hold) Common Shares and each subsequent taxable year. Such U.S. Holder generally will include for each of its taxable years as ordinary income the excess, if any, of the fair market value of its Common Shares at the end of such year over its adjusted basis in its Common Shares. These amounts of ordinary income would not be eligible for the favorable tax rates applicable to qualified dividend income or long-term capital gains. The U.S. Holder also will recognize an ordinary loss in respect of the excess, if any, of its adjusted basis of its Common Shares over the fair market value of its Common Shares at the end of its taxable year (but only to the extent of the net amount of previously included income as a result of the <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">mark-to-market</div></div> election). The U.S. Holder&#8217;s basis in its Common Shares will be adjusted to reflect any such income or loss amounts, and any further gain recognized on a sale or other taxable disposition of its Common Shares will be treated as ordinary income. Currently, a <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">mark-to-market</div></div> election likely may not be made with respect to Warrants. </div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">315 </div></div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;;font-weight: bold;"><a href="#toc">Table of Contents</a></div> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">The <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">mark-to-market</div></div> election is available only for &#8220;marketable stock,&#8221; generally, stock that is regularly traded on a national securities exchange that is registered with the Securities and Exchange Commission, including the Nasdaq (on which Common Shares are currently listed), or on a foreign exchange or market that the IRS determines has rules sufficient to ensure that the market price represents a legitimate and sound fair market value. If made, a <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">mark-to-market</div></div> election would be effective for the taxable year for which the election was made and for all subsequent taxable years unless the Common Shares cease to qualify as &#8220;marketable stock&#8221; for purposes of the PFIC rules or the IRS consents to the revocation of the election. U.S. Holders are urged to consult their tax advisors regarding the availability and tax consequences of a <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">mark-to-market</div></div> election with respect to Common Shares under their particular circumstances. </div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Alternatively, if Roivant is determined to be a PFIC, a U.S. Holder may avoid the adverse PFIC tax consequences described above in respect of Common Shares (but not Warrants) by making and maintaining a timely and valid qualified electing fund (&#8220;QEF&#8221;) election (if eligible to do so). If a U.S. Holder makes a QEF election with respect to a PFIC, the U.S. Holder will be taxed on its pro rata share of the PFIC&#8217;s ordinary earnings and net capital gain (at ordinary income and capital gain rates, respectively) for each taxable year that the entity is a PFIC. If a U.S. Holder makes a QEF election with respect to the Common Shares, any distributions paid by Roivant out of its earnings and profits that were previously included in the U.S. Holder&#8217;s income under the QEF election would not be taxable to the U.S. Holder. A U.S. Holder will increase its tax basis in its Common Shares by an amount equal to any income included under the QEF election and will decrease its tax basis by any amount distributed on the Common Shares that is not included in the U.S. Holder&#8217;s income. In addition, a U.S. Holder will recognize capital gain or loss on the disposition of Common Shares in an amount equal to the difference between the amount realized and the U.S. Holder&#8217;s adjusted tax basis in the Common Shares, as determined in U.S. dollars. U.S. Holders should note that if they make QEF elections with respect to Roivant, they may be required to pay U.S. federal income tax with respect to their Common Shares for any taxable year significantly in excess of any cash distributions received on the Common Shares for such taxable year. U.S. Holders should consult their tax advisers regarding making QEF elections in their particular circumstances. A U.S. Holder generally may make a separate election to defer the payment of taxes on undistributed income inclusions under the QEF rules, but if deferred, any such taxes will be subject to an interest charge. </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">A U.S. Holder must make the QEF election for each PFIC by attaching a separate properly completed IRS Form 8621 for each PFIC to the U.S. Holder&#8217;s timely filed U.S. federal income tax return. However, Roivant currently does not intend to provide information necessary for U.S. Holders to make QEF elections with respect to Common Shares, and the QEF election would be unavailable with respect to the Warrants in all cases under current law. </div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt; margin-left: 4%;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Related PFIC Rules </div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;">If Roivant is a PFIC and, at any time, has a foreign subsidiary that is classified as a PFIC, a U.S. Holder generally would be deemed to own a proportionate amount of the shares of such lower-tier PFIC, and generally could incur liability for the deferred tax and interest charge described above if Roivant receives a distribution from, or disposes of all or part of its interest in, the lower-tier PFIC, or the U.S. Holder otherwise was deemed to have disposed of an interest in the lower-tier PFIC. Roivant currently does not intend to cause any lower-tier PFIC to provide to a U.S. Holder the information that may be required to make or maintain a QEF election with respect to the lower-tier PFIC. A <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">mark-to-market</div></div> election generally would not be available with respect to such lower-tier PFIC. U.S. Holders are urged to consult their tax advisors regarding the tax issues raised by lower-tier PFICs. </div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">A U.S. Holder that owns (or is deemed to own) shares in a PFIC during any taxable year of the U.S. Holder, may have to file an IRS Form 8621 (whether or not a QEF or <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">mark-to-market</div></div> election is made) and to provide such other information as may be required by the U.S. Treasury Department. Failure to do so, if required, will extend the statute of limitations applicable to such U.S. Holder until such required information is furnished to the IRS. </div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">316 </div></div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;;font-weight: bold;"><a href="#toc">Table of Contents</a></div> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">The rules dealing with PFICs and with the <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">mark-to-market</div></div> and QEF elections are very complex and are affected by various factors in addition to those described above. Accordingly, U.S. Holders of Common Shares or Warrants are urged to consult their own tax advisors concerning the application of the PFIC rules to Roivant securities under their particular circumstances. </div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt; margin-left: 4%;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Additional Reporting</div></div><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="background: none;;font-weight:bold;display:inline;"><div style="font-style: normal; background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;"> </div></div></div></div><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Requirements </div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Certain U.S. Holders holding specified foreign financial assets with an aggregate value in excess of the applicable dollar thresholds are required to report information to the IRS relating to Common Shares, subject to certain exceptions (including an exception for Common Shares held in accounts maintained by U.S. financial institutions), by attaching a complete IRS Form 8938 (Statement of Specified Foreign Financial Assets) with their tax return for each year in which they hold Common Shares. Substantial penalties apply to any failure to file IRS Form 8938 and the period of limitations on assessment and collection of U.S. federal income taxes will be extended in the event of a failure to comply. U.S. Holders are urged to consult their tax advisors regarding the effect, if any, of these rules on the ownership and disposition of Common Shares. </div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Information Reporting and Backup Withholding </div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Payments of dividends and sales proceeds that are made within the United States or through certain U.S.-related financial intermediaries are subject to information reporting, and may be subject to backup withholding. Backup withholding generally will not apply, however, to a U.S. Holder if (i)&#160;the U.S. Holder is a corporation or other exempt recipient or (ii)&#160;the U.S. Holder provides a correct taxpayer identification number and certifies that it is not subject to backup withholding. </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Backup withholding is not an additional tax. The amount of any backup withholding from a payment to a holder will be allowed as a credit against such holder&#8217;s U.S. federal income tax liability and may entitle it to a refund, provided that the required information is timely furnished to the IRS. </div></div> <div style="text-indent: 4%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">THE U.S. FEDERAL INCOME TAX DISCUSSION SET FORTH ABOVE MAY NOT BE APPLICABLE TO YOU DEPENDING UPON YOUR PARTICULAR SITUATION. YOU ARE URGED TO CONSULT YOUR OWN TAX ADVISOR WITH RESPECT TO THE TAX CONSEQUENCES TO YOU OF THE ACQUISITION, OWNERSHIP AND DISPOSITION OF COMMON SHARES OR WARRANTS INCLUDING THE TAX CONSEQUENCES UNDER STATE, LOCAL, ESTATE, FOREIGN AND OTHER TAX LAWS AND TAX TREATIES AND THE POSSIBLE EFFECTS OF CHANGES IN U.S. OR OTHER TAX LAWS. </div></div></div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">317 </div></div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;;font-weight: bold;"><a href="#toc">Table of Contents</a></div> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"> <div id="rom164680_20a" style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">MATERIAL UNITED KINGDOM TAX CONSIDERATIONS </div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">In the opinion of Davis Polk&#160;&amp; Wardwell London LLP, the following is a description of material United Kingdom tax considerations relating to the ownership and disposal of the Common Shares and Warrants applicable to a <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-UK</div> Holder. The comments set out below are based on current United Kingdom tax law as applied in England and Wales and HM Revenue&#160;&amp; Customs, or HMRC, practice (which may not be binding on HMRC) as at the date of this summary, both of which are subject to change, possibly with retrospective effect. They are intended as a general guide and, save where expressly stated otherwise, apply only to absolute beneficial owners of the Common Shares or Warrants who are (i)&#160;individuals not resident in the United Kingdom for United Kingdom tax purposes who do not hold Common Shares or Warrants for the purposes of a trade, profession, or vocation which they carry on in the United Kingdom through a branch or agency, or (ii)&#160;companies not resident in the United Kingdom for United Kingdom tax purposes which do not hold the Common Shares or Warrants for the purpose of a trade carried on in the United Kingdom through a permanent establishment in the United Kingdom, together, <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">&#8220;non-UK</div> Holders.&#8221; </div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">This summary does not address all possible tax consequences relating to an investment in the Common Shares or Warrants. Certain categories of holders, including those falling outside the category described above (such as those who are resident in the United Kingdom for United Kingdom tax purposes), those carrying on certain financial activities, those subject to specific tax regimes or benefitting from certain reliefs or exemptions, those connected with Roivant and those for whom the shares are employment-related securities may be subject to special rules and this summary does not apply to such holders and any general statements made in this disclosure do not take them into account. </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Potential investors should satisfy themselves prior to investing as to the overall tax consequences, including, specifically, the consequences under United Kingdom tax law and HMRC practice of the acquisition, ownership and disposal of the Common Shares or Warrants in their own particular circumstances by consulting their own tax advisors. </div></div> <div style="text-indent: 4%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">EACH HOLDER SHOULD CONSULT ITS OWN TAX ADVISOR WITH RESPECT TO THE PARTICULAR TAX CONSEQUENCES TO SUCH HOLDER OF THE OWNERSHIP AND DISPOSAL OF COMMON SHARES AND EXERCISE OF WARRANTS, INCLUDING THE EFFECTS OF UNITED KINGDOM TAX LAWS. </div></div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">United Kingdom Taxation of Dividends </div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;">Roivant will not be required to withhold amounts on account of United Kingdom tax at source when paying a dividend in respect of Common Shares to a <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-UK</div> Holder. </div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">Non-UK</div> Holders who hold their Common Shares as an investment should not be subject to United Kingdom tax in respect of any dividends. </div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">United Kingdom Taxation of Capital Gains </div></div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Acquisition of Common Shares on exercise of the Warrants </div></div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;">An individual that is a <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-UK</div> Holder will generally not be liable to United Kingdom capital gains tax on capital gains realized (if any) on the exercise of Warrants. </div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">A company that is a <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-UK</div> Holder will generally not be liable to United Kingdom corporation tax on chargeable gains realized (if any) on the exercise of Warrants. </div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">An individual <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-UK</div> Holder who is only temporarily a <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-UK</div> resident for United Kingdom tax purposes, may, in certain circumstances, become liable to United Kingdom tax on capital gains in respect of gains realized (if any) while he or she was not resident in the United Kingdom. </div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">318 </div></div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;;font-weight: bold;"><a href="#toc">Table of Contents</a></div> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Disposal of Common Shares or Warrants </div></div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;">An individual who is a <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-UK</div> Holder will generally not be liable to United Kingdom capital gains tax on capital gains realized on the disposal of his or her Common Shares or Warrants. </div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">A company that is a <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-UK</div> Holder will generally not be liable for United Kingdom corporation tax on chargeable gains realized on the disposal of its Common Shares or Warrants. </div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">An individual <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-UK</div> Holder who is only temporarily a <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-UK</div> resident for United Kingdom tax purposes will, in certain circumstances, become liable to United Kingdom tax on capital gains in respect of gains realized while he or she was not resident in the United Kingdom. </div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">United Kingdom Stamp Duty (&#8220;stamp duty&#8221;) and Stamp Duty Reserve Tax (&#8220;SDRT&#8221;) </div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">No stamp duty or SDRT is expected to be payable on the issue or transfer of Common Shares or the transfer of Warrants, subject to the comments below. </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Stamp duty will in principle be payable on any instrument that transfers Common Shares or Warrants that is executed in the United Kingdom or that relates to any property situated, or to any matter or thing done or to be done, in the United Kingdom. Holders of Common Shares or Warrants should be aware that, even where such an instrument is in principle subject to stamp duty, stamp duty is not required to be paid unless it is necessary to rely on the instrument for legal purposes, for example to register a change of ownership or in litigation in a United Kingdom court. Provided that the Common Shares and Warrants are not registered in any register maintained in the United Kingdom, any agreement to transfer Common Shares or Warrants will not be subject to SDRT. Roivant currently does not intend that any register of its Common Shares or Warrants will be maintained in the United Kingdom. </div></div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">319 </div></div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;;font-weight: bold;"><a href="#toc">Table of Contents</a></div> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"> <div id="rom164680_21" style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">LEGAL MATTERS </div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Conyers Dill&#160;&amp; Pearman Limited have passed upon the validity of the Common Shares offered by this prospectus and certain other legal matters related to this prospectus. Davis Polk&#160;&amp; Wardwell LLP have passed upon the validity of the Warrants under New York law. </div></div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">320 </div></div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;;font-weight: bold;"><a href="#toc">Table of Contents</a></div> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"> <div id="rom164680_22" style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">EXPERTS </div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The consolidated financial statements of Roivant Sciences Ltd. at March 31, 2021 and 2020, and for each of the two years in the period ended March 31, 2021, appearing in this Prospectus and Registration Statement have been audited by Ernst &amp; Young LLP, independent registered public accounting firm, as set forth in their report thereon appearing elsewhere herein, and are included in reliance upon such report given on the authority of such firm as experts in accounting and auditing. </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The financial statements of MAAC as of December 31, 2020 and for the period from July 6, 2020 (inception) through December 31, 2020, have been audited by Marcum LLP, an independent registered public accounting firm, as stated in their report thereon, and have been included in this registration statement in reliance upon such reports and upon the authority of such firm as experts in accounting and auditing. </div></div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">321 </div></div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;;font-weight: bold;"><a href="#toc">Table of Contents</a></div> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"> <div id="rom164680_23" style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">WHERE YOU CAN FIND MORE INFORMATION </div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">We have filed a registration statement on Form <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">S-1,</div> including exhibits, under the Securities Act of 1933, as amended, with respect to the securities offered by this prospectus. This prospectus does not contain all of the information included in the registration statement. For further information pertaining to us and our securities, you should refer to the registration statement and our exhibits. </div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">In addition, we file annual, quarterly and current reports, proxy statements and other information with the SEC. Our SEC filings are available to the public on a website maintained by the SEC located at www.sec.gov. We also maintain a website at https://roivant.com. Through our website, we make available, free of charge, annual, quarterly and current reports, proxy statements and other information as soon as reasonably practicable after they are electronically filed with, or furnished to, the SEC. The information contained on, or that may be accessed through, our website is not part of, and is not incorporated into, this prospectus. </div></div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">322 </div></div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;;font-weight: bold;"><a href="#toc" style="text-indent: 0px;">Table of Contents</a></div> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"> <div id="rom164680_37" style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div id="rom164680_24" style="letter-spacing: 0px; top: 0px;;display:inline;"></div>INDEX TO FINANCIAL STATEMENTS </div></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="font-size: 0px;">
<td style="width: 92%;"></td>
<td style="width: 4%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Page&#160;No.</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td> </tr>
<tr style="font-size: 1pt;">
<td style="height: 12pt; font-family: &quot;Times New Roman&quot;;"></td>
<td colspan="4" style="height: 12pt; font-family: &quot;Times New Roman&quot;;"></td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Audited Consolidated Financial Statements for Roivant Sciences Ltd.</div></div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;&#160;&#160;&#160;</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"><a href="#fin164680_ff1">Report of Independent Registered Public Accounting Firm </a></div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">F-2</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"><a href="#fin164680_ff2">Consolidated Balance Sheets as of March&#160;31, 2021 and 2020</a></div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">F-3</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"><a href="#fin164680_ff3">Consolidated Statements of Operations for the Years Ended March&#160;31, 2021 and 2020</a></div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">F-4</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"><a href="#fin164680_ff4">Consolidated Statements of Comprehensive (Loss) Income for the Years Ended March&#160;31, 2021 and&#160;2020</a></div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">F-5</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"><a href="#fin164680_ff5">Consolidated Statements of Shareholders&#8217; Equity and Redeemable Noncontrolling Interest for the Years Ended March&#160;31, 2021 and 2020</a></div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">F-6</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"><a href="#fin164680_ff6">Consolidated Statements of Cash Flows for the Years Ended March&#160;31, 2021 and 2020</a></div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">F-7</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"><a href="#fin164680_ff7">Notes to Consolidated Financial Statements</a></div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">F-9</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-size: 1pt;">
<td style="height: 12pt; font-family: &quot;Times New Roman&quot;;"></td>
<td colspan="4" style="height: 12pt; font-family: &quot;Times New Roman&quot;;"></td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Unaudited Interim Financial Statements for Roivant Sciences Ltd.</div></div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;&#160;&#160;&#160;</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"><a href="#fin164680_101">Condensed Consolidated Balance Sheets as of June 30, 2021 and March 31, 2021</a></div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">F-43</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"><a href="#fin164680_102">Condensed Consolidated Statements of Operations for the Three Months Ended June 30, 2021 and 2020</a></div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">F-44</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"><a href="#fin164680_103">Condensed Consolidated Statements of Comprehensive Loss for the Three Months Ended June&#160;30, 2021 and&#160;2020</a></div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">F-45</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"><a href="#fin164680_104">Condensed Consolidated Statements of Shareholders&#8217; Equity and Redeemable Noncontrolling Interest for the Three Months Ended June&#160;30, 2021 and 2020</a></div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">F-46</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"><a href="#fin164680_105">Condensed Consolidated Statements of Cash Flows for the Three Months Ended June&#160;30, 2021 and 2020</a></div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">F-47</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"><a href="#fin164680_106">Notes to Condensed Consolidated Financial Statements</a></div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">F-48</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-size: 1pt;">
<td style="height: 12pt; font-family: &quot;Times New Roman&quot;;"></td>
<td colspan="4" style="height: 12pt; font-family: &quot;Times New Roman&quot;;"></td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Audited Financial Statements for Montes Archimedes Acquisition Corp.</div></div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;&#160;&#160;&#160;</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"><a href="#fin164680_15">Report of Independent Registered Public Accounting Firm</a></div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">F-65</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"><a href="#fin164680_16">Balance Sheet as of December 31, 2020</a></div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">F-66</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"><a href="#fin164680_17">Statement of Operations for the period from July 6, 2020 (inception) through December 31, 2020</a></div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">F-67</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"><a href="#fin164680_18">Statement of Changes in Stockholders&#8217; Equity for the period from July 6, 2020 (inception) through December 31, 2020</a></div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">F-68</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"><a href="#fin164680_19">Statement of Cash Flows for the period from July 6, 2020 (inception) through December 31, 2020</a></div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">F-69</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"><a href="#fin164680_20">Notes to Financial Statements</a></div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">F-70</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-size: 1pt;">
<td style="height: 12pt; font-family: &quot;Times New Roman&quot;;"></td>
<td colspan="4" style="height: 12pt; font-family: &quot;Times New Roman&quot;;"></td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Unaudited Interim Financial Statements for Montes Archimedes Acquisition Corp.</div></div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;"><br/><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><br/><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;&#160;&#160;&#160;</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><br/><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"><a href="#fin164680_21">Condensed Balance Sheet as of June 30, 2021 (Unaudited) and December 31, 2020</a></div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">F-88</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"><a href="#fin164680_22">Unaudited Condensed Statement of Operations for the three and six months ended June 30, 2021</a></div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">F-89</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"><a href="#fin164680_23">Unaudited Condensed Statement of Changes in Stockholders&#8217; Equity for the three and six months ended June&#160;30, 2021</a></div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">F-90</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"><a href="#fin164680_24">Unaudited Condensed Statement of Cash Flows for the six months ended June 30, 2021</a></div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">F-91</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"><a href="#fin164680_25">Notes to Unaudited Condensed Financial Statements</a></div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">F-92</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">F-1 </div></div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;;font-weight: bold;"><a href="#toc">Table of Contents</a></div> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"> <div id="fin164680_ff1" style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Report of Independent Registered Public Accounting Firm </div></div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">To the Shareholders and the Board of Directors of Roivant Sciences Ltd. </div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Opinion on the Financial Statements </div></div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">We have audited the accompanying consolidated balance sheets of Roivant Sciences Ltd. (the Company) as of March&#160;31, 2021 and 2020, the related consolidated statements of operations, comprehensive (loss) income, shareholders&#8217; equity and redeemable noncontrolling interest and cash flows for each of the two years in the period ended March&#160;31, 2021, and the related notes (collectively referred to as the &#8220;consolidated financial statements&#8221;). In our opinion, the consolidated financial statements present fairly, in all material respects, the financial position of the Company at March&#160;31, 2021 and 2020, and the results of its operations and its cash flows for each of the two years in the period ended March&#160;31, 2021, in conformity with U.S. generally accepted accounting principles. </div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Basis for Opinion </div></div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">These financial statements are the responsibility of the Company&#8217;s management. Our responsibility is to express an opinion on the Company&#8217;s financial statements based on our audits. We are a public accounting firm registered with the Public Company Accounting Oversight Board (United States) (PCAOB) and are required to be independent with respect to the Company in accordance with the U.S. federal securities laws and the applicable rules and regulations of the Securities and Exchange Commission and the PCAOB. </div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">We conducted our audits in accordance with the standards of the PCAOB. Those standards require that we plan and perform the audit to obtain reasonable assurance about whether the financial statements are free of material misstatement, whether due to error or fraud. The Company is not required to have, nor were we engaged to perform, an audit of internal control over financial reporting. As part of our audits we are required to obtain an understanding of internal control over financial reporting but not for the purpose of expressing an opinion on the effectiveness of the Company&#8217;s internal control over financial reporting. Accordingly, we express no such opinion. </div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Our audits included performing procedures to assess the risks of material misstatement of the financial statements, whether due to error or fraud, and performing procedures that respond to those risks. Such procedures included examining, on a test basis, evidence regarding the amounts and disclosures in the financial statements. Our audits also included evaluating the accounting principles used and significant estimates made by management, as well as evaluating the overall presentation of the financial statements. We believe that our audits provide a reasonable basis for our opinion. </div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">/s/ Ernst&#160;&amp; Young LLP </div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">We have served as the Company&#8217;s auditor since 2016. </div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Iselin, New Jersey </div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">June 30, 2021 </div></div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">F-2 </div></div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;;font-weight: bold;"><a href="#toc" style="text-indent: 0px;">Table of Contents</a></div> <div style="text-align: center;"><div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"><div id="fin164680_ff2" style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">ROIVANT SCIENCES LTD. </div></div></div></div><div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Consolidated Balance Sheets </div></div></div></div><div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">(in thousands, except share and per share data) </div></div></div></div></div></div><div style="text-align: center;"><div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"><div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="font-size: 0px;">
<td style="width: 74%;"></td>
<td style="width: 4%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td>
<td style="width: 4%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">March&#160;31,&#160;2021</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">March&#160;31,&#160;2020</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Assets</div></div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Current assets:</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Cash and cash equivalents</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:CashAndCashEquivalentsAtCarryingValue" contextRef="PAsOn03_31_2021" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">2,055,044</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:CashAndCashEquivalentsAtCarryingValue" contextRef="PAsOn03_31_2020" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">2,183,207</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Restricted cash</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:RestrictedCashCurrent" contextRef="PAsOn03_31_2021" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">77,701</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:RestrictedCashCurrent" contextRef="PAsOn03_31_2020" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">2,275</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Other current assets</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:OtherAssetsCurrent" contextRef="PAsOn03_31_2021" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">54,250</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:OtherAssetsCurrent" contextRef="PAsOn03_31_2020" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">33,763</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;">&#160;</td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 5em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Total current assets</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:AssetsCurrent" contextRef="PAsOn03_31_2021" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">2,186,995</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:AssetsCurrent" contextRef="PAsOn03_31_2020" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">2,219,245</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Property and equipment, net</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:PropertyPlantAndEquipmentNet" contextRef="PAsOn03_31_2021" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">14,749</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:PropertyPlantAndEquipmentNet" contextRef="PAsOn03_31_2020" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">8,962</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;">Operating lease <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">right-of-use</div></div> assets</div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:OperatingLeaseRightOfUseAsset" contextRef="PAsOn03_31_2021" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">62,279</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:OperatingLeaseRightOfUseAsset" contextRef="PAsOn03_31_2020" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">64,970</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Restricted cash, net of current portion</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:RestrictedCashNoncurrent" contextRef="PAsOn03_31_2021" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">8,931</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:RestrictedCashNoncurrent" contextRef="PAsOn03_31_2020" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">83,770</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Investments measured at fair value</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:InvestmentsFairValueDisclosure" contextRef="PAsOn03_31_2021" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">188,978</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:InvestmentsFairValueDisclosure" contextRef="PAsOn03_31_2020" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">93,445</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Long-term investment</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:LongTermInvestments" contextRef="PAsOn03_31_2021" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">100,563</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:LongTermInvestments" contextRef="PAsOn03_31_2020" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:zerodash">&#8212;</ix:nonFraction>&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Other assets</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:OtherAssetsNoncurrent" contextRef="PAsOn03_31_2021" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">27,197</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:OtherAssetsNoncurrent" contextRef="PAsOn03_31_2020" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">6,659</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;">&#160;</td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 5em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Total assets</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:Assets" contextRef="PAsOn03_31_2021" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">2,589,692</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:Assets" contextRef="PAsOn03_31_2020" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">2,477,051</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;">&#160;</td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Liabilities, Redeemable Noncontrolling Interest and Shareholders&#8217; Equity</div></div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Current liabilities:</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Accounts payable</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:AccountsPayableCurrent" contextRef="PAsOn03_31_2021" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">20,550</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:AccountsPayableCurrent" contextRef="PAsOn03_31_2020" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">10,306</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Accrued expenses</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:AccruedLiabilitiesCurrent" contextRef="PAsOn03_31_2021" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">76,936</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:AccruedLiabilitiesCurrent" contextRef="PAsOn03_31_2020" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">68,621</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Operating lease liabilities</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:OperatingLeaseLiabilityCurrent" contextRef="PAsOn03_31_2021" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">12,313</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:OperatingLeaseLiabilityCurrent" contextRef="PAsOn03_31_2020" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">7,839</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Deferred consideration liability</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="roiv:DeferredConsiderationLiabilityCurrent" contextRef="PAsOn03_31_2021" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">100,000</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="roiv:DeferredConsiderationLiabilityCurrent" contextRef="PAsOn03_31_2020" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:zerodash">&#8212;</ix:nonFraction>&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Other current liabilities</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:OtherLiabilitiesCurrent" contextRef="PAsOn03_31_2021" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">9,162</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:OtherLiabilitiesCurrent" contextRef="PAsOn03_31_2020" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">5,352</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;">&#160;</td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 5em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Total current liabilities</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:LiabilitiesCurrent" contextRef="PAsOn03_31_2021" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">218,961</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:LiabilitiesCurrent" contextRef="PAsOn03_31_2020" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">92,118</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Liability instruments measured at fair value</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="roiv:LiabilityInstrumentsMeasuredAtFairValue" contextRef="PAsOn03_31_2021" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">67,893</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="roiv:LiabilityInstrumentsMeasuredAtFairValue" contextRef="PAsOn03_31_2020" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">102,373</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Operating lease liabilities, noncurrent</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:OperatingLeaseLiabilityNoncurrent" contextRef="PAsOn03_31_2021" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">62,384</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:OperatingLeaseLiabilityNoncurrent" contextRef="PAsOn03_31_2020" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">64,452</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Long-term debt (includes $<ix:nonFraction name="us-gaap:LongTermDebtFairValue" contextRef="PAsOn03_31_2021" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">150,100</ix:nonFraction> and $<ix:nonFraction name="us-gaap:LongTermDebtFairValue" contextRef="PAsOn03_31_2020" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">89,100</ix:nonFraction> accounted for under the fair value option at March&#160;31, 2021 and 2020, respectively)</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:LongTermDebtNoncurrent" contextRef="PAsOn03_31_2021" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">170,280</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:LongTermDebtNoncurrent" contextRef="PAsOn03_31_2020" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">108,592</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Other liabilities</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:OtherLiabilitiesNoncurrent" contextRef="PAsOn03_31_2021" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">8,169</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:OtherLiabilitiesNoncurrent" contextRef="PAsOn03_31_2020" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">821</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;">&#160;</td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 5em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Total liabilities</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:Liabilities" contextRef="PAsOn03_31_2021" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">527,687</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:Liabilities" contextRef="PAsOn03_31_2020" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">368,356</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;">&#160;</td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Commitments and contingencies (Note 14)</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Redeemable noncontrolling interest</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:RedeemableNoncontrollingInterestEquityCarryingAmount" contextRef="PAsOn03_31_2021" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">22,491</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:RedeemableNoncontrollingInterestEquityCarryingAmount" contextRef="PAsOn03_31_2020" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">22,491</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Shareholders&#8217; equity:</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Common shares, par value $<ix:nonFraction name="us-gaap:CommonStockParOrStatedValuePerShare" contextRef="PAsOn03_31_2020" unitRef="Unit_USD_per_Share" decimals="INF" format="ixt:numdotdecimal"><ix:nonFraction name="us-gaap:CommonStockParOrStatedValuePerShare" contextRef="PAsOn03_31_2021" unitRef="Unit_USD_per_Share" decimals="INF" format="ixt:numdotdecimal"> 0.0000001</ix:nonFraction></ix:nonFraction> per share, <ix:nonFraction name="us-gaap:CommonStockSharesAuthorized" contextRef="PAsOn03_31_2020" unitRef="Unit_shares" decimals="INF" scale="0" format="ixt:numdotdecimal"><ix:nonFraction name="us-gaap:CommonStockSharesAuthorized" contextRef="PAsOn03_31_2021" unitRef="Unit_shares" decimals="INF" scale="0" format="ixt:numdotdecimal">100,000,000,000</ix:nonFraction></ix:nonFraction> shares authorized and <ix:nonFraction name="us-gaap:CommonStockSharesOutstanding" contextRef="PAsOn03_31_2021" unitRef="Unit_shares" decimals="INF" scale="0" format="ixt:numdotdecimal"><ix:nonFraction name="us-gaap:CommonStockSharesIssued" contextRef="PAsOn03_31_2021" unitRef="Unit_shares" decimals="INF" scale="0" format="ixt:numdotdecimal">222,669,799</ix:nonFraction></ix:nonFraction> and <ix:nonFraction name="us-gaap:CommonStockSharesOutstanding" contextRef="PAsOn03_31_2020" unitRef="Unit_shares" decimals="INF" scale="0" format="ixt:numdotdecimal"><ix:nonFraction name="us-gaap:CommonStockSharesIssued" contextRef="PAsOn03_31_2020" unitRef="Unit_shares" decimals="INF" scale="0" format="ixt:numdotdecimal">214,879,058</ix:nonFraction></ix:nonFraction> shares issued and outstanding at March&#160;31, 2021 and 2020, respectively</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:CommonStockValue" contextRef="PAsOn03_31_2021" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:zerodash">&#8212;</ix:nonFraction>&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:CommonStockValue" contextRef="PAsOn03_31_2020" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:zerodash">&#8212;</ix:nonFraction>&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;">Additional <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">paid-in</div> capital</div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:AdditionalPaidInCapital" contextRef="PAsOn03_31_2021" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">3,814,805</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:AdditionalPaidInCapital" contextRef="PAsOn03_31_2020" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">3,143,739</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Subscription receivable</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(<ix:nonFraction name="roiv:SubscriptionsReceivable" contextRef="PAsOn03_31_2021" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:numdotdecimal">100,000</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="roiv:SubscriptionsReceivable" contextRef="PAsOn03_31_2020" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:zerodash">&#8212;</ix:nonFraction>&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Accumulated deficit</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(<ix:nonFraction name="us-gaap:RetainedEarningsAccumulatedDeficit" contextRef="PAsOn03_31_2021" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:numdotdecimal">1,918,462</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(<ix:nonFraction name="us-gaap:RetainedEarningsAccumulatedDeficit" contextRef="PAsOn03_31_2020" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:numdotdecimal">1,109,228</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Accumulated other comprehensive income (loss)</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax" contextRef="PAsOn03_31_2021" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">1,445</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(<ix:nonFraction name="us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax" contextRef="PAsOn03_31_2020" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:numdotdecimal">2,349</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 5em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Shareholders&#8217; equity attributable to Roivant Sciences Ltd.</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="PAsOn03_31_2021" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">1,797,788</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="PAsOn03_31_2020" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">2,032,162</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 5em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Noncontrolling interests</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:MinorityInterest" contextRef="PAsOn03_31_2021" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">241,726</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:MinorityInterest" contextRef="PAsOn03_31_2020" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">54,042</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;">&#160;</td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 5em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Total shareholders&#8217; equity</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextRef="PAsOn03_31_2021" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">2,039,514</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextRef="PAsOn03_31_2020" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">2,086,204</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;">&#160;</td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 5em; line-height: normal;">Total liabilities, redeemable noncontrolling interest and shareholders&#8217;<div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"> </div></div>equity</div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:LiabilitiesAndStockholdersEquity" contextRef="PAsOn03_31_2021" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">2,589,692</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:LiabilitiesAndStockholdersEquity" contextRef="PAsOn03_31_2020" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">2,477,051</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;">&#160;</td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td></tr></table><div style="clear: both; max-height: 0px;"></div><div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">The accompanying notes are an integral part of these consolidated financial statements. </div></div></div><div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div><div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">F-<div style="letter-spacing: 0px; top: 0px;;display:inline;">3</div> </div></div></div></div><div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div><hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/><div style="text-align: center;"><div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em; text-align: left;;font-weight: bold;"><div style="display:inline;"><a href="#toc" style="text-indent: 0px;">Table of Contents</a></div></div><div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"><div id="fin164680_ff3" style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">ROIVANT SCIENCES LTD. </div></div></div><div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Consolidated Statements of Operations </div></div></div><div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">(in thousands, except share and per share data) </div></div></div><div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="font-size: 0px;">
<td style="width: 73%;"></td>
<td style="width: 5%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td>
<td style="width: 5%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;&#160;</td>
<td colspan="6" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Years Ended March&#160;31,</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2021</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2020</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Revenue, net</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="P04_01_2020To03_31_2021" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">23,795</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="P04_01_2019To03_31_2020" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">67,689</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Operating expenses:</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Cost of revenues</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="roiv:OperatingCosts" contextRef="P04_01_2020To03_31_2021" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">2,057</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="roiv:OperatingCosts" contextRef="P04_01_2019To03_31_2020" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">1,131</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Research and development</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:ResearchAndDevelopmentExpense" contextRef="P04_01_2020To03_31_2021" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">832,758</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:ResearchAndDevelopmentExpense" contextRef="P04_01_2019To03_31_2020" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">263,217</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">General and administrative</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:GeneralAndAdministrativeExpense" contextRef="P04_01_2020To03_31_2021" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">259,878</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:GeneralAndAdministrativeExpense" contextRef="P04_01_2019To03_31_2020" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">335,766</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;">&#160;</td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 5em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Total operating expenses</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:OperatingExpenses" contextRef="P04_01_2020To03_31_2021" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">1,094,693</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:OperatingExpenses" contextRef="P04_01_2019To03_31_2020" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">600,114</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;">&#160;</td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Loss from operations</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(<ix:nonFraction name="us-gaap:OperatingIncomeLoss" contextRef="P04_01_2020To03_31_2021" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:numdotdecimal">1,070,898</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(<ix:nonFraction name="us-gaap:OperatingIncomeLoss" contextRef="P04_01_2019To03_31_2020" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:numdotdecimal">532,425</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Change in fair value of investments</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(<ix:nonFraction name="us-gaap:GainLossOnInvestments" contextRef="P04_01_2020To03_31_2021" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">95,533</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:GainLossOnInvestments" contextRef="P04_01_2019To03_31_2020" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:numdotdecimal">136,005</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Change in fair value of debt and liability instruments</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="roiv:GainLossOnFairValueOfDebtAndLiabilityInstruments" contextRef="P04_01_2020To03_31_2021" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:numdotdecimal">29,845</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(<ix:nonFraction name="roiv:GainLossOnFairValueOfDebtAndLiabilityInstruments" contextRef="P04_01_2019To03_31_2020" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">13,722</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Gain on deconsolidation of subsidiary and consolidation of unconsolidated entity</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(<ix:nonFraction name="roiv:DeconsolidationAndConsolidationOnGainOrLossOfConsolidatedEntity" contextRef="P04_01_2020To03_31_2021" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">115,364</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(<ix:nonFraction name="roiv:DeconsolidationAndConsolidationOnGainOrLossOfConsolidatedEntity" contextRef="P04_01_2019To03_31_2020" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">107,344</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Other expense, net</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:OtherNonoperatingIncomeExpense" contextRef="P04_01_2020To03_31_2021" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:numdotdecimal">8,701</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:OtherNonoperatingIncomeExpense" contextRef="P04_01_2019To03_31_2020" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:numdotdecimal">13,622</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;">&#160;</td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Loss from continuing operations before income taxes</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(<ix:nonFraction name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments" contextRef="P04_01_2020To03_31_2021" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:numdotdecimal">898,547</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(<ix:nonFraction name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments" contextRef="P04_01_2019To03_31_2020" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:numdotdecimal">560,986</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Income tax expense</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:IncomeTaxExpenseBenefit" contextRef="P04_01_2020To03_31_2021" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">1,686</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:IncomeTaxExpenseBenefit" contextRef="P04_01_2019To03_31_2020" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">7,124</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;">&#160;</td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Loss from continuing operations, net of tax</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(<ix:nonFraction name="us-gaap:IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest" contextRef="P04_01_2020To03_31_2021" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:numdotdecimal">900,233</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(<ix:nonFraction name="us-gaap:IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest" contextRef="P04_01_2019To03_31_2020" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:numdotdecimal">568,110</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Income from discontinued operations, net of tax</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTax" contextRef="P04_01_2020To03_31_2021" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:zerodash">&#8212;</ix:nonFraction>&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTax" contextRef="P04_01_2019To03_31_2020" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">1,578,426</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;">&#160;</td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Net (loss) income</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(<ix:nonFraction name="us-gaap:ProfitLoss" contextRef="P04_01_2020To03_31_2021" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:numdotdecimal">900,233</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:ProfitLoss" contextRef="P04_01_2019To03_31_2020" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">1,010,316</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;">&#160;</td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Net loss attributable to noncontrolling interests</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(<ix:nonFraction name="us-gaap:NetIncomeLossAttributableToNoncontrollingInterest" contextRef="P04_01_2020To03_31_2021" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:numdotdecimal">90,999</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(<ix:nonFraction name="us-gaap:NetIncomeLossAttributableToNoncontrollingInterest" contextRef="P04_01_2019To03_31_2020" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:numdotdecimal">190,193</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Net (loss) income attributable to Roivant Sciences Ltd.</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(<ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="P04_01_2020To03_31_2021" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:numdotdecimal">809,234</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="P04_01_2019To03_31_2020" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">1,200,509</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;">&#160;</td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Amounts attributable to Roivant Sciences Ltd.:</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Loss from continuing operations, net of tax</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(<ix:nonFraction name="us-gaap:IncomeLossFromContinuingOperations" contextRef="P04_01_2020To03_31_2021" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">809,234</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(<ix:nonFraction name="us-gaap:IncomeLossFromContinuingOperations" contextRef="P04_01_2019To03_31_2020" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">519,394</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Income from discontinued operations, net of tax</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity" contextRef="P04_01_2020To03_31_2021" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:zerodash">&#8212;</ix:nonFraction>&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity" contextRef="P04_01_2019To03_31_2020" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">1,719,903</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;">&#160;</td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Net (loss) income attributable to Roivant Sciences Ltd.</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(<ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="P04_01_2020To03_31_2021" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:numdotdecimal">809,234</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="P04_01_2019To03_31_2020" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">1,200,509</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;">&#160;</td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Basic and diluted net (loss) income per common share:</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Basic and diluted loss from continuing operations</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(<ix:nonFraction name="us-gaap:IncomeLossFromContinuingOperationsPerBasicAndDilutedShare" contextRef="P04_01_2020To03_31_2021" unitRef="Unit_USD_per_Share" decimals="2" scale="0" sign="-" format="ixt:numdotdecimal">3.76</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(<ix:nonFraction name="us-gaap:IncomeLossFromContinuingOperationsPerBasicAndDilutedShare" contextRef="P04_01_2019To03_31_2020" unitRef="Unit_USD_per_Share" decimals="2" scale="0" sign="-" format="ixt:numdotdecimal">2.72</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Basic and diluted income from discontinued operations</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicAndDilutedShare" contextRef="P04_01_2020To03_31_2021" unitRef="Unit_USD_per_Share" decimals="0" scale="0" format="ixt:zerodash">&#8212;</ix:nonFraction>&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicAndDilutedShare" contextRef="P04_01_2019To03_31_2020" unitRef="Unit_USD_per_Share" decimals="2" scale="0" format="ixt:numdotdecimal">7.85</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Basic and diluted net (loss) income per common share</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(<ix:nonFraction name="us-gaap:EarningsPerShareBasicAndDiluted" contextRef="P04_01_2020To03_31_2021" unitRef="Unit_USD_per_Share" decimals="2" scale="0" sign="-" format="ixt:numdotdecimal">3.76</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:EarningsPerShareBasicAndDiluted" contextRef="P04_01_2019To03_31_2020" unitRef="Unit_USD_per_Share" decimals="2" scale="0" format="ixt:numdotdecimal">5.13</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Basic and diluted weighted average shares outstanding:</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Basic</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" contextRef="P04_01_2020To03_31_2021" unitRef="Unit_shares" decimals="0" scale="0" format="ixt:numdotdecimal">215,312,273</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" contextRef="P04_01_2019To03_31_2020" unitRef="Unit_shares" decimals="0" scale="0" format="ixt:numdotdecimal">219,036,630</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Diluted</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" contextRef="P04_01_2020To03_31_2021" unitRef="Unit_shares" decimals="0" scale="0" format="ixt:numdotdecimal">215,312,273</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" contextRef="P04_01_2019To03_31_2020" unitRef="Unit_shares" decimals="0" scale="0" format="ixt:numdotdecimal">219,036,630</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;">&#160;</td></tr></table><div style="clear: both; max-height: 0px;"></div><div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">The accompanying notes are an integral part of these consolidated financial statements. </div></div></div><div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div><div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">F-4</div></div></div></div><div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div><hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/><div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;;font-weight: bold;"><div style="display:inline;"><a href="#toc" style="text-indent: 0px;">Table of Contents</a></div></div><div style="text-align: center;"><div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"><div id="fin164680_ff4" style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">ROIVANT SCIENCES LTD. </div></div></div><div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Consolidated Statements of Comprehensive (Loss) Income </div></div></div><div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">(in thousands) </div></div></div><div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="font-size: 0px;">
<td style="width: 79%;"></td>
<td style="width: 2%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td>
<td style="width: 2%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;&#160;</td>
<td colspan="6" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Years Ended March&#160;31,</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2021</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2020</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Net (loss) income</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(<ix:nonFraction name="us-gaap:ProfitLoss" contextRef="P04_01_2020To03_31_2021" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:numdotdecimal">900,233</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:ProfitLoss" contextRef="P04_01_2019To03_31_2020" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">1,010,316</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Other comprehensive income (loss):</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Foreign currency translation adjustment</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax" contextRef="P04_01_2020To03_31_2021" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">3,826</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(<ix:nonFraction name="us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax" contextRef="P04_01_2019To03_31_2020" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:numdotdecimal">5,536</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Total other comprehensive income (loss)</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:OtherComprehensiveIncomeLossNetOfTax" contextRef="P04_01_2020To03_31_2021" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">3,826</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(<ix:nonFraction name="us-gaap:OtherComprehensiveIncomeLossNetOfTax" contextRef="P04_01_2019To03_31_2020" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:numdotdecimal">5,536</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Comprehensive (loss) income</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(<ix:nonFraction name="us-gaap:ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest" contextRef="P04_01_2020To03_31_2021" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:numdotdecimal">896,407</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest" contextRef="P04_01_2019To03_31_2020" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">1,004,780</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Comprehensive loss attributable to noncontrolling interests</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(<ix:nonFraction name="us-gaap:ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest" contextRef="P04_01_2020To03_31_2021" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:numdotdecimal">90,967</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(<ix:nonFraction name="us-gaap:ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest" contextRef="P04_01_2019To03_31_2020" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:numdotdecimal">190,862</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Comprehensive (loss) income attributable to Roivant Sciences Ltd.</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(<ix:nonFraction name="us-gaap:ComprehensiveIncomeNetOfTax" contextRef="P04_01_2020To03_31_2021" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:numdotdecimal">805,440</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:ComprehensiveIncomeNetOfTax" contextRef="P04_01_2019To03_31_2020" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">1,195,642</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;">&#160;</td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td></tr></table><div style="clear: both; max-height: 0px;"></div><div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">The accompanying notes are an integral part of these consolidated financial statements. </div></div></div><div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div><div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">F-<div style="letter-spacing: 0px; top: 0px;;display:inline;">5</div> </div></div></div></div><div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div><hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/><div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;;font-weight: bold;"><div style="display:inline;"><a href="#toc" style="text-indent: 0px;">Table of Contents</a></div></div><div style="text-align: center;"><div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"><div id="fin164680_ff5" style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">ROIVANT SCIENCES LTD. </div></div></div><div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Consolidated Statement of Shareholders&#8217; Equity and Redeemable Noncontrolling Interest </div></div></div><div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">(in thousands, except share data) </div></div></div><div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 8pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="font-size: 0px;">
<td style="width: 45%;"></td>
<td style="width: 1%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td>
<td style="width: 1%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td>
<td style="width: 1%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td>
<td style="width: 1%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td>
<td style="width: 1%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td>
<td style="width: 1%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td>
<td style="width: 1%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td>
<td style="width: 1%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td>
<td style="width: 1%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td colspan="2" style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td colspan="30" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Shareholders&#8217; Equity</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td rowspan="2" style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td colspan="2" rowspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Redeemable<br/> Noncontrolling<br/> Interest</div></div></td>
<td rowspan="2" style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td colspan="6" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Common Stock</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td rowspan="2" style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td colspan="2" rowspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Additional<br/> <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">Paid-in</div><br/> Capital</div></div></td>
<td rowspan="2" style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td rowspan="2" style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td colspan="2" rowspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Subscription<br/> Receivable</div></div></td>
<td rowspan="2" style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td rowspan="2" style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td colspan="2" rowspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Accumulated<br/> Other<br/> Comprehensive<br/> Income (Loss)</div></div></td>
<td rowspan="2" style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td rowspan="2" style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td colspan="2" rowspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Accumulated<br/> Deficit</div></div></td>
<td rowspan="2" style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td rowspan="2" style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td colspan="2" rowspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Noncontrolling<br/> Interests</div></div></td>
<td rowspan="2" style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td rowspan="2" style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td colspan="2" rowspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Total<br/> Shareholders&#8217;<br/> Equity</div></div></td>
<td rowspan="2" style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Shares</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Amount</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">Balance at March&#160;31, 2019</div></div></div></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:TemporaryEquityCarryingAmountIncludingPortionAttributableToNoncontrollingInterests" contextRef="PAsOn03_31_2019_RedeemableNoncontrollingInterestMemberusgaapStatementClassOfStockAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">50,130</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:SharesOutstanding" contextRef="PAsOn03_31_2019_CommonStockMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_shares" decimals="INF" scale="0" format="ixt:numdotdecimal">213,555,119</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextRef="PAsOn03_31_2019_CommonStockMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:zerodash">&#8212;</ix:nonFraction>&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextRef="PAsOn03_31_2019_AdditionalPaidInCapitalMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">3,024,172</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextRef="PAsOn03_31_2019_SubscriptionsReceivablesMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:zerodash">&#8212;</ix:nonFraction>&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextRef="PAsOn03_31_2019_AccumulatedOtherComprehensiveIncomeMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">2,518</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(<ix:nonFraction name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextRef="PAsOn03_31_2019_RetainedEarningsMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:numdotdecimal">2,309,737</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextRef="PAsOn03_31_2019_NoncontrollingInterestMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">170,216</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextRef="PAsOn03_31_2019" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">887,169</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">Issuance of subsidiary common shares, net</div></div></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="roiv:IssuanceOfSubsidiaryCommonSharesNetValue" contextRef="P04_01_2019To03_31_2020_AdditionalPaidInCapitalMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">59,052</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="roiv:IssuanceOfSubsidiaryCommonSharesNetValue" contextRef="P04_01_2019To03_31_2020_NoncontrollingInterestMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">58,606</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="roiv:IssuanceOfSubsidiaryCommonSharesNetValue" contextRef="P04_01_2019To03_31_2020" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">117,658</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">Issuance of subsidiary common shares to the Company</div></div></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(<ix:nonFraction name="roiv:IssuanceOfSubsidiaryCommonSharesToTheCompanyValue" contextRef="P04_01_2019To03_31_2020_AdditionalPaidInCapitalMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:numdotdecimal">9,962</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="roiv:IssuanceOfSubsidiaryCommonSharesToTheCompanyValue" contextRef="P04_01_2019To03_31_2020_NoncontrollingInterestMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">9,962</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">Purchase of subsidiary common shares</div></div></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(<ix:nonFraction name="roiv:PurchaseOfSubsidiaryCommonSharesValue" contextRef="P04_01_2019To03_31_2020_AdditionalPaidInCapitalMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">62,913</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(<ix:nonFraction name="roiv:PurchaseOfSubsidiaryCommonSharesValue" contextRef="P04_01_2019To03_31_2020_NoncontrollingInterestMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">2,631</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(<ix:nonFraction name="roiv:PurchaseOfSubsidiaryCommonSharesValue" contextRef="P04_01_2019To03_31_2020" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">65,544</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">Issuance of subsidiary convertible and redeemable preferred stock, net</div></div></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:TemporaryEquityStockIssuedDuringPeriodValueNewIssues" contextRef="P04_01_2019To03_31_2020_RedeemableNoncontrollingInterestMemberusgaapStatementClassOfStockAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">27,491</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">Purchase of subsidiary convertible and redeemable preferred stock</div></div></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(<ix:nonFraction name="us-gaap:AdjustmentsToAdditionalPaidInCapitalIncreaseInCarryingAmountOfRedeemablePreferredStock" contextRef="P04_01_2019To03_31_2020_RedeemableNoncontrollingInterestMemberusgaapStatementClassOfStockAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">55,130</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(<ix:nonFraction name="us-gaap:AdjustmentsToAdditionalPaidInCapitalIncreaseInCarryingAmountOfRedeemablePreferredStock" contextRef="P04_01_2019To03_31_2020_AdditionalPaidInCapitalMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">77,777</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(<ix:nonFraction name="us-gaap:AdjustmentsToAdditionalPaidInCapitalIncreaseInCarryingAmountOfRedeemablePreferredStock" contextRef="P04_01_2019To03_31_2020" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">77,777</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">Issuance of subsidiary warrants</div></div></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="roiv:IssuanceOfSubsidiaryWarrants" contextRef="P04_01_2019To03_31_2020_NoncontrollingInterestMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">907</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="roiv:IssuanceOfSubsidiaryWarrants" contextRef="P04_01_2019To03_31_2020" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">907</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">Exercise of subsidiary stock options</div></div></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" contextRef="P04_01_2019To03_31_2020_AdditionalPaidInCapitalMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">875</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" contextRef="P04_01_2019To03_31_2020_NoncontrollingInterestMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">532</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" contextRef="P04_01_2019To03_31_2020" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">1,407</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">Issuance of the Company&#8217;s common shares, net</div></div></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" contextRef="P04_01_2019To03_31_2020_CommonStockMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_shares" decimals="INF" scale="0" format="ixt:numdotdecimal">26,952,143</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueNewIssues" contextRef="P04_01_2019To03_31_2020_AdditionalPaidInCapitalMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">999,193</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueNewIssues" contextRef="P04_01_2019To03_31_2020" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">999,193</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">Repurchase of common shares and other equity instruments</div></div></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(<ix:nonFraction name="roiv:RepurchaseOfCommonSharesAndOtherEquityInstrumentsShares" contextRef="P04_01_2019To03_31_2020_CommonStockMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_shares" decimals="INF" scale="0" format="ixt:numdotdecimal">25,625,933</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(<ix:nonFraction name="roiv:RepurchaseOfCommonSharesAndOtherEquityInstrumentsValue" contextRef="P04_01_2019To03_31_2020_AdditionalPaidInCapitalMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">990,014</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(<ix:nonFraction name="roiv:RepurchaseOfCommonSharesAndOtherEquityInstrumentsValue" contextRef="P04_01_2019To03_31_2020" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">990,014</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">Sale of interests in subsidiaries</div></div></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(<ix:nonFraction name="us-gaap:GainOrLossOnSaleOfStockInSubsidiary" contextRef="P04_01_2019To03_31_2020_NoncontrollingInterestMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:numdotdecimal">43,398</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(<ix:nonFraction name="us-gaap:GainOrLossOnSaleOfStockInSubsidiary" contextRef="P04_01_2019To03_31_2020" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:numdotdecimal">43,398</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">Issuance of equity by subsidiary upon Business Combination and recapitalization</div></div></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="roiv:IssuanceOfEquityBySubsidiaryUponBusinessCombinationAndRecapitalization" contextRef="P04_01_2019To03_31_2020_AdditionalPaidInCapitalMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">69,379</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="roiv:IssuanceOfEquityBySubsidiaryUponBusinessCombinationAndRecapitalization" contextRef="P04_01_2019To03_31_2020_NoncontrollingInterestMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">35,307</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="roiv:IssuanceOfEquityBySubsidiaryUponBusinessCombinationAndRecapitalization" contextRef="P04_01_2019To03_31_2020" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">104,686</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">Issuance of equity by subsidiary to the Company upon Business Combination and recapitalization</div></div></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(<ix:nonFraction name="roiv:IssuanceOfEquityBySubsidiaryToTheCompanyUponBusinessCombinationAndRecapitalization" contextRef="P04_01_2019To03_31_2020_AdditionalPaidInCapitalMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:numdotdecimal">2,559</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="roiv:IssuanceOfEquityBySubsidiaryToTheCompanyUponBusinessCombinationAndRecapitalization" contextRef="P04_01_2019To03_31_2020_NoncontrollingInterestMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">2,559</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">Conversion of subsidiary convertible promissory notes</div></div></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="roiv:ConversionOfSubsidiaryConvertiblePromissoryNotes" contextRef="P04_01_2019To03_31_2020_AdditionalPaidInCapitalMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">21,928</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="roiv:ConversionOfSubsidiaryConvertiblePromissoryNotes" contextRef="P04_01_2019To03_31_2020_NoncontrollingInterestMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">11,159</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="roiv:ConversionOfSubsidiaryConvertiblePromissoryNotes" contextRef="P04_01_2019To03_31_2020" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">33,087</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">Issuance of equity instruments</div></div></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="roiv:IssuanceOfEquityInstruments" contextRef="P04_01_2019To03_31_2020_AdditionalPaidInCapitalMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">24,842</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="roiv:IssuanceOfEquityInstruments" contextRef="P04_01_2019To03_31_2020" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">24,842</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">Settlement in equity of liability-classified instruments</div></div></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="roiv:SettlementOfLiabilityClassifiedInstruments" contextRef="P04_01_2019To03_31_2020_AdditionalPaidInCapitalMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">13,119</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="roiv:SettlementOfLiabilityClassifiedInstruments" contextRef="P04_01_2019To03_31_2020" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">13,119</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">Deconsolidation of subsidiary</div></div></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(<ix:nonFraction name="roiv:DeconsolidationOfSubsidiary" contextRef="P04_01_2019To03_31_2020_NoncontrollingInterestMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:numdotdecimal">46,483</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(<ix:nonFraction name="roiv:DeconsolidationOfSubsidiary" contextRef="P04_01_2019To03_31_2020" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:numdotdecimal">46,483</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">Capital contributions to majority-owned subsidiaries</div></div></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(<ix:nonFraction name="roiv:CapitalContributionsToSubsidiaries" contextRef="P04_01_2019To03_31_2020_AdditionalPaidInCapitalMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:numdotdecimal">4,699</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="roiv:CapitalContributionsToSubsidiaries" contextRef="P04_01_2019To03_31_2020_NoncontrollingInterestMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">4,699</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">Share-based compensation</div></div></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(<ix:nonFraction name="roiv:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationRequisiteServicePeriodRecognitionShares" contextRef="P04_01_2019To03_31_2020_CommonStockMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_shares" decimals="INF" scale="0" sign="-" format="ixt:numdotdecimal">2,271</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" contextRef="P04_01_2019To03_31_2020_AdditionalPaidInCapitalMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">79,103</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" contextRef="P04_01_2019To03_31_2020_NoncontrollingInterestMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">43,469</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" contextRef="P04_01_2019To03_31_2020" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">122,572</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">Foreign currency translation adjustment</div></div></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(<ix:nonFraction name="us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent" contextRef="P04_01_2019To03_31_2020_AccumulatedOtherComprehensiveIncomeMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:numdotdecimal">4,867</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(<ix:nonFraction name="us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent" contextRef="P04_01_2019To03_31_2020_NoncontrollingInterestMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:numdotdecimal">669</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(<ix:nonFraction name="us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent" contextRef="P04_01_2019To03_31_2020" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:numdotdecimal">5,536</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">Net income (loss)</div></div></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:ProfitLoss" contextRef="P04_01_2019To03_31_2020_RetainedEarningsMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">1,200,509</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(<ix:nonFraction name="us-gaap:ProfitLoss" contextRef="P04_01_2019To03_31_2020_NoncontrollingInterestMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:numdotdecimal">190,193</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:ProfitLoss" contextRef="P04_01_2019To03_31_2020" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">1,010,316</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;">&#160;</td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">Balance at March&#160;31, 2020</div></div></div></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:TemporaryEquityCarryingAmountIncludingPortionAttributableToNoncontrollingInterests" contextRef="PAsOn03_31_2020_RedeemableNoncontrollingInterestMemberusgaapStatementClassOfStockAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">22,491</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:SharesOutstanding" contextRef="PAsOn03_31_2020_CommonStockMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_shares" decimals="INF" scale="0" format="ixt:numdotdecimal">214,879,058</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextRef="PAsOn03_31_2020_CommonStockMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:zerodash">&#8212;</ix:nonFraction>&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextRef="PAsOn03_31_2020_AdditionalPaidInCapitalMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">3,143,739</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextRef="PAsOn03_31_2020_SubscriptionsReceivablesMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:zerodash">&#8212;</ix:nonFraction>&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(<ix:nonFraction name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextRef="PAsOn03_31_2020_AccumulatedOtherComprehensiveIncomeMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:numdotdecimal">2,349</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(<ix:nonFraction name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextRef="PAsOn03_31_2020_RetainedEarningsMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:numdotdecimal">1,109,228</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextRef="PAsOn03_31_2020_NoncontrollingInterestMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">54,042</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextRef="PAsOn03_31_2020" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">2,086,204</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;">&#160;</td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">Issuance of the Company&#8217;s common shares</div></div></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueNewIssues" contextRef="P04_01_2020To03_31_2021_RedeemableNoncontrollingInterestMemberusgaapStatementClassOfStockAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:zerodash">&#8212;</ix:nonFraction>&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" contextRef="P04_01_2020To03_31_2021_CommonStockMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_shares" decimals="INF" scale="0" format="ixt:numdotdecimal">7,202,917</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueNewIssues" contextRef="P04_01_2020To03_31_2021_CommonStockMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:zerodash">&#8212;</ix:nonFraction>&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueNewIssues" contextRef="P04_01_2020To03_31_2021_AdditionalPaidInCapitalMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">301,744</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueNewIssues" contextRef="P04_01_2020To03_31_2021_SubscriptionsReceivablesMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:zerodash">&#8212;</ix:nonFraction>&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueNewIssues" contextRef="P04_01_2020To03_31_2021_AccumulatedOtherComprehensiveIncomeMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:zerodash">&#8212;</ix:nonFraction>&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueNewIssues" contextRef="P04_01_2020To03_31_2021_RetainedEarningsMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:zerodash">&#8212;</ix:nonFraction>&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueNewIssues" contextRef="P04_01_2020To03_31_2021_NoncontrollingInterestMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:zerodash">&#8212;</ix:nonFraction>&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueNewIssues" contextRef="P04_01_2020To03_31_2021" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">301,744</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">Issuance of subsidiary common shares, net</div></div></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="roiv:IssuanceOfSubsidiaryCommonSharesNetValue" contextRef="P04_01_2020To03_31_2021_AdditionalPaidInCapitalMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">324,995</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(<ix:nonFraction name="roiv:IssuanceOfSubsidiaryCommonSharesNetValue" contextRef="P04_01_2020To03_31_2021_SubscriptionsReceivablesMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:numdotdecimal">100,000</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="roiv:IssuanceOfSubsidiaryCommonSharesNetValue" contextRef="P04_01_2020To03_31_2021_NoncontrollingInterestMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">231,102</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="roiv:IssuanceOfSubsidiaryCommonSharesNetValue" contextRef="P04_01_2020To03_31_2021" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">456,097</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">Issuance of subsidiary common shares to the Company</div></div></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(<ix:nonFraction name="roiv:IssuanceOfSubsidiaryCommonSharesToTheCompanyValue" contextRef="P04_01_2020To03_31_2021_AdditionalPaidInCapitalMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:numdotdecimal">11,692</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="roiv:IssuanceOfSubsidiaryCommonSharesToTheCompanyValue" contextRef="P04_01_2020To03_31_2021_NoncontrollingInterestMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">11,692</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">Exercise of subsidiary stock options and vesting of subsidiary restricted stock units</div></div></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="roiv:ExerciseOfSubsidiaryStockOptionsAndVestingOfSubsidiaryRestrictedStockUnits" contextRef="P04_01_2020To03_31_2021_AdditionalPaidInCapitalMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">522</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="roiv:ExerciseOfSubsidiaryStockOptionsAndVestingOfSubsidiaryRestrictedStockUnits" contextRef="P04_01_2020To03_31_2021_NoncontrollingInterestMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">385</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="roiv:ExerciseOfSubsidiaryStockOptionsAndVestingOfSubsidiaryRestrictedStockUnits" contextRef="P04_01_2020To03_31_2021" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">907</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">Deconsolidation of subsidiary</div></div></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(<ix:nonFraction name="roiv:DeconsolidationOfSubsidiary" contextRef="P04_01_2020To03_31_2021_NoncontrollingInterestMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:numdotdecimal">3,054</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(<ix:nonFraction name="roiv:DeconsolidationOfSubsidiary" contextRef="P04_01_2020To03_31_2021" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:numdotdecimal">3,054</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">Consolidation of unconsolidated entity</div></div></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="roiv:ConsolidationOfUnconsolidatedEntity" contextRef="P04_01_2020To03_31_2021_NoncontrollingInterestMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">9,178</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="roiv:ConsolidationOfUnconsolidatedEntity" contextRef="P04_01_2020To03_31_2021" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">9,178</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">Repurchase of equity awards</div></div></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(<ix:nonFraction name="roiv:RepurchaseOfEquityAwards" contextRef="P04_01_2020To03_31_2021_AdditionalPaidInCapitalMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:numdotdecimal">113</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(<ix:nonFraction name="roiv:RepurchaseOfEquityAwards" contextRef="P04_01_2020To03_31_2021" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:numdotdecimal">113</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">Cash contribution to majority-owned subsidiaries</div></div></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(<ix:nonFraction name="roiv:CapitalContributionsToSubsidiaries" contextRef="P04_01_2020To03_31_2021_AdditionalPaidInCapitalMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:numdotdecimal">1,642</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="roiv:CapitalContributionsToSubsidiaries" contextRef="P04_01_2020To03_31_2021_NoncontrollingInterestMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">1,642</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">Share-based compensation</div></div></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="roiv:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationRequisiteServicePeriodRecognitionShares" contextRef="P04_01_2020To03_31_2021_CommonStockMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_shares" decimals="INF" scale="0" format="ixt:numdotdecimal">587,824</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" contextRef="P04_01_2020To03_31_2021_AdditionalPaidInCapitalMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">57,252</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" contextRef="P04_01_2020To03_31_2021_NoncontrollingInterestMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">27,706</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" contextRef="P04_01_2020To03_31_2021" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">84,958</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">Foreign currency translation adjustment</div></div></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent" contextRef="P04_01_2020To03_31_2021_AccumulatedOtherComprehensiveIncomeMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">3,794</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent" contextRef="P04_01_2020To03_31_2021_NoncontrollingInterestMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">32</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent" contextRef="P04_01_2020To03_31_2021" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">3,826</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">Net loss</div></div></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(<ix:nonFraction name="us-gaap:ProfitLoss" contextRef="P04_01_2020To03_31_2021_RetainedEarningsMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:numdotdecimal">809,234</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(<ix:nonFraction name="us-gaap:ProfitLoss" contextRef="P04_01_2020To03_31_2021_NoncontrollingInterestMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:numdotdecimal">90,999</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(<ix:nonFraction name="us-gaap:ProfitLoss" contextRef="P04_01_2020To03_31_2021" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:numdotdecimal">900,233</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">Balance at March&#160;31, 2021</div></div></div></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:TemporaryEquityCarryingAmountIncludingPortionAttributableToNoncontrollingInterests" contextRef="PAsOn03_31_2021_RedeemableNoncontrollingInterestMemberusgaapStatementClassOfStockAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">22,491</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:SharesOutstanding" contextRef="PAsOn03_31_2021_CommonStockMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_shares" decimals="INF" scale="0" format="ixt:numdotdecimal">222,669,799</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextRef="PAsOn03_31_2021_CommonStockMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:zerodash">&#8212;</ix:nonFraction>&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextRef="PAsOn03_31_2021_AdditionalPaidInCapitalMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">3,814,805</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(<ix:nonFraction name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextRef="PAsOn03_31_2021_SubscriptionsReceivablesMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:numdotdecimal">100,000</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextRef="PAsOn03_31_2021_AccumulatedOtherComprehensiveIncomeMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">1,445</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(<ix:nonFraction name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextRef="PAsOn03_31_2021_RetainedEarningsMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:numdotdecimal">1,918,462</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextRef="PAsOn03_31_2021_NoncontrollingInterestMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">241,726</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextRef="PAsOn03_31_2021" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">2,039,514</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;">&#160;</td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td></tr></table><div style="clear: both; max-height: 0px;"></div><div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">The accompanying notes are an integral part of these consolidated financial statements. </div></div></div><div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div><div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">F-<div style="letter-spacing: 0px; top: 0px;;display:inline;">6</div> </div></div></div></div><div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div><hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/><div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;;font-weight: bold;"><div style="display:inline;"><a href="#toc" style="text-indent: 0px;">Table of Contents</a></div></div><div style="text-align: center;"><div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"><div id="fin164680_ff6" style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">ROIVANT SCIENCES LTD. </div></div></div><div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Consolidated Statements of Cash Flows </div></div></div><div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">(in thousands) </div></div></div><div style="font-size: 12pt; margin-top: 0px; margin-bottom: 0px;">&#160;</div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 9.5pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="font-size: 0px;">
<td style="width: 80%;"></td>
<td style="width: 1%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td>
<td style="width: 1%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td colspan="6" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Years Ended March&#160;31,</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2021</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2020</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 9.5pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 9.5pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 9.5pt; letter-spacing: 0px; top: 0px;;display:inline;">Cash flows from operating activities:</div></div></div></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 9.5pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 9.5pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 9.5pt; letter-spacing: 0px; top: 0px;;display:inline;">Net (loss) income</div></div></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(<ix:nonFraction name="us-gaap:ProfitLoss" contextRef="P04_01_2020To03_31_2021" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:numdotdecimal">900,233</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:ProfitLoss" contextRef="P04_01_2019To03_31_2020" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">1,010,316</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 9.5pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 9.5pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 9.5pt; letter-spacing: 0px; top: 0px;;display:inline;">Adjustments to reconcile net (loss) income to net cash used in operating activities:</div></div></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 9.5pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 9.5pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;">Acquired <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">in-process</div> research and development</div></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:ResearchAndDevelopmentInProcess" contextRef="P04_01_2020To03_31_2021" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">351,523</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:ResearchAndDevelopmentInProcess" contextRef="P04_01_2019To03_31_2020" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">16,405</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 9.5pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 9.5pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 9.5pt; letter-spacing: 0px; top: 0px;;display:inline;">Unrealized foreign currency translation adjustment</div></div></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax" contextRef="P04_01_2020To03_31_2021" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">3,826</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(<ix:nonFraction name="us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax" contextRef="P04_01_2019To03_31_2020" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:numdotdecimal">5,536</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 9.5pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 9.5pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 9.5pt; letter-spacing: 0px; top: 0px;;display:inline;">Share-based compensation</div></div></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:ShareBasedCompensation" contextRef="P04_01_2020To03_31_2021" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">84,958</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:ShareBasedCompensation" contextRef="P04_01_2019To03_31_2020" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">122,572</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 9.5pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 9.5pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 9.5pt; letter-spacing: 0px; top: 0px;;display:inline;">Gain on sale of business</div></div></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:GainLossOnSaleOfBusiness" contextRef="P04_01_2020To03_31_2021" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:zerodash">&#8212;</ix:nonFraction>&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(<ix:nonFraction name="us-gaap:GainLossOnSaleOfBusiness" contextRef="P04_01_2019To03_31_2020" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">1,985,949</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 9.5pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 9.5pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 9.5pt; letter-spacing: 0px; top: 0px;;display:inline;">Change in fair value of investments</div></div></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(<ix:nonFraction name="us-gaap:GainLossOnInvestments" contextRef="P04_01_2020To03_31_2021" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">95,533</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:GainLossOnInvestments" contextRef="P04_01_2019To03_31_2020" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:numdotdecimal">136,005</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 9.5pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 9.5pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 9.5pt; letter-spacing: 0px; top: 0px;;display:inline;">Change in fair value of debt and liability instruments</div></div></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="roiv:GainLossOnFairValueOfDebtAndLiabilityInstruments" contextRef="P04_01_2020To03_31_2021" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:numdotdecimal">29,845</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(<ix:nonFraction name="roiv:GainLossOnFairValueOfDebtAndLiabilityInstruments" contextRef="P04_01_2019To03_31_2020" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">13,722</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 9.5pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 9.5pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 9.5pt; letter-spacing: 0px; top: 0px;;display:inline;">Gain on deconsolidation of subsidiary and consolidation of unconsolidated entity</div></div></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(<ix:nonFraction name="roiv:GainOrLossOnDeconsolidationOfSubsidiary" contextRef="P04_01_2020To03_31_2021" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">115,364</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(<ix:nonFraction name="roiv:GainOrLossOnDeconsolidationOfSubsidiary" contextRef="P04_01_2019To03_31_2020" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">107,344</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 9.5pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 9.5pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 9.5pt; letter-spacing: 0px; top: 0px;;display:inline;">Loss from equity method investment</div></div></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:IncomeLossFromEquityMethodInvestments" contextRef="P04_01_2020To03_31_2021" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:numdotdecimal">3,750</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:IncomeLossFromEquityMethodInvestments" contextRef="P04_01_2019To03_31_2020" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:numdotdecimal">21,386</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 9.5pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 9.5pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 9.5pt; letter-spacing: 0px; top: 0px;;display:inline;">Other</div></div></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:OtherNoncashIncomeExpense" contextRef="P04_01_2020To03_31_2021" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:numdotdecimal">13,152</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:OtherNoncashIncomeExpense" contextRef="P04_01_2019To03_31_2020" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:numdotdecimal">31,821</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 9.5pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 9.5pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 9.5pt; letter-spacing: 0px; top: 0px;;display:inline;">Changes in assets and liabilities, net of effects from acquisition and divestiture:</div></div></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 9.5pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 9.5pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 9.5pt; letter-spacing: 0px; top: 0px;;display:inline;">Accounts payable</div></div></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:IncreaseDecreaseInAccountsPayableTrade" contextRef="P04_01_2020To03_31_2021" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">3,752</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:IncreaseDecreaseInAccountsPayableTrade" contextRef="P04_01_2019To03_31_2020" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">6,598</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 9.5pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 9.5pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 9.5pt; letter-spacing: 0px; top: 0px;;display:inline;">Accrued expenses</div></div></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:IncreaseDecreaseInAccruedLiabilities" contextRef="P04_01_2020To03_31_2021" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">9,225</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:IncreaseDecreaseInAccruedLiabilities" contextRef="P04_01_2019To03_31_2020" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">14,845</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 9.5pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 9.5pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 9.5pt; letter-spacing: 0px; top: 0px;;display:inline;">Deferred consideration liability</div></div></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:IncreaseDecreaseInDeferredLiabilities" contextRef="P04_01_2020To03_31_2021" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">100,000</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:IncreaseDecreaseInDeferredLiabilities" contextRef="P04_01_2019To03_31_2020" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:zerodash">&#8212;</ix:nonFraction>&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 9.5pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 9.5pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 9.5pt; letter-spacing: 0px; top: 0px;;display:inline;">Operating lease liabilities</div></div></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(<ix:nonFraction name="roiv:IncreaseDecreaseInOperatingLeaseLiabilities" contextRef="P04_01_2020To03_31_2021" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:numdotdecimal">5,497</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(<ix:nonFraction name="roiv:IncreaseDecreaseInOperatingLeaseLiabilities" contextRef="P04_01_2019To03_31_2020" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:numdotdecimal">8,419</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 9.5pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 9.5pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 9.5pt; letter-spacing: 0px; top: 0px;;display:inline;">Other</div></div></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(<ix:nonFraction name="us-gaap:IncreaseDecreaseInOtherOperatingCapitalNet" contextRef="P04_01_2020To03_31_2021" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">35,542</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:IncreaseDecreaseInOtherOperatingCapitalNet" contextRef="P04_01_2019To03_31_2020" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:numdotdecimal">2,272</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;">&#160;</td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 9.5pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 9.5pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 5em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 9.5pt; letter-spacing: 0px; top: 0px;;display:inline;">Net cash used in operating activities</div></div></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(<ix:nonFraction name="us-gaap:NetCashProvidedByUsedInOperatingActivities" contextRef="P04_01_2020To03_31_2021" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:numdotdecimal">552,138</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(<ix:nonFraction name="us-gaap:NetCashProvidedByUsedInOperatingActivities" contextRef="P04_01_2019To03_31_2020" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:numdotdecimal">758,750</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 9.5pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 9.5pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 9.5pt; letter-spacing: 0px; top: 0px;;display:inline;">Cash flows from investing activities:</div></div></div></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 9.5pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 9.5pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 9.5pt; letter-spacing: 0px; top: 0px;;display:inline;">Proceeds from sale of business, net of cash disposed</div></div></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:ProceedsFromDivestitureOfBusinesses" contextRef="P04_01_2020To03_31_2021" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:zerodash">&#8212;</ix:nonFraction>&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:ProceedsFromDivestitureOfBusinesses" contextRef="P04_01_2019To03_31_2020" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">1,772,191</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 9.5pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 9.5pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 9.5pt; letter-spacing: 0px; top: 0px;;display:inline;">Cash disposed upon deconsolidation of subsidiary</div></div></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(<ix:nonFraction name="us-gaap:CashDivestedFromDeconsolidation" contextRef="P04_01_2020To03_31_2021" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">19,085</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(<ix:nonFraction name="us-gaap:CashDivestedFromDeconsolidation" contextRef="P04_01_2019To03_31_2020" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">20,049</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 9.5pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 9.5pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 9.5pt; letter-spacing: 0px; top: 0px;;display:inline;">Cash acquired upon consolidation of unconsolidated entity</div></div></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="roiv:CashAcquiredUponConsolidationOfUnconsolidatedEntity" contextRef="P04_01_2020To03_31_2021" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">21,439</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="roiv:CashAcquiredUponConsolidationOfUnconsolidatedEntity" contextRef="P04_01_2019To03_31_2020" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:zerodash">&#8212;</ix:nonFraction>&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 9.5pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 9.5pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 9.5pt; letter-spacing: 0px; top: 0px;;display:inline;">Investments in unconsolidated entities</div></div></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(<ix:nonFraction name="roiv:PaymentsToAcquireInvestmentsInUnconsolidatedEntities" contextRef="P04_01_2020To03_31_2021" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">28,250</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(<ix:nonFraction name="roiv:PaymentsToAcquireInvestmentsInUnconsolidatedEntities" contextRef="P04_01_2019To03_31_2020" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">36,300</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 9.5pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 9.5pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 9.5pt; letter-spacing: 0px; top: 0px;;display:inline;">Purchase of marketable securities</div></div></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:PaymentsToAcquireMarketableSecurities" contextRef="P04_01_2020To03_31_2021" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:zerodash">&#8212;</ix:nonFraction>&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(<ix:nonFraction name="us-gaap:PaymentsToAcquireMarketableSecurities" contextRef="P04_01_2019To03_31_2020" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">32,076</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 9.5pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 9.5pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 9.5pt; letter-spacing: 0px; top: 0px;;display:inline;">Maturity of marketable securities</div></div></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:ProceedsFromSaleAndMaturityOfMarketableSecurities" contextRef="P04_01_2020To03_31_2021" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:zerodash">&#8212;</ix:nonFraction>&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:ProceedsFromSaleAndMaturityOfMarketableSecurities" contextRef="P04_01_2019To03_31_2020" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">16,440</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 9.5pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 9.5pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 9.5pt; letter-spacing: 0px; top: 0px;;display:inline;">Acquisitions, net of cash acquired</div></div></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:PaymentsToAcquireBusinessesNetOfCashAcquired" contextRef="P04_01_2020To03_31_2021" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:zerodash">&#8212;</ix:nonFraction>&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(<ix:nonFraction name="us-gaap:PaymentsToAcquireBusinessesNetOfCashAcquired" contextRef="P04_01_2019To03_31_2020" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">500</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 9.5pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 9.5pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 9.5pt; letter-spacing: 0px; top: 0px;;display:inline;">Purchase of property and equipment</div></div></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(<ix:nonFraction name="us-gaap:PaymentsToAcquirePropertyPlantAndEquipment" contextRef="P04_01_2020To03_31_2021" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">5,806</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(<ix:nonFraction name="us-gaap:PaymentsToAcquirePropertyPlantAndEquipment" contextRef="P04_01_2019To03_31_2020" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">4,916</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 9.5pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 9.5pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 5em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 9.5pt; letter-spacing: 0px; top: 0px;;display:inline;">Net cash (used in) provided by investing activities</div></div></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(<ix:nonFraction name="us-gaap:NetCashProvidedByUsedInInvestingActivities" contextRef="P04_01_2020To03_31_2021" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:numdotdecimal">31,702</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:NetCashProvidedByUsedInInvestingActivities" contextRef="P04_01_2019To03_31_2020" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">1,694,790</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;">&#160;</td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:9.5pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 9.5pt; font-family: &quot;Times New Roman&quot;; line-height: normal;"><div style="font-weight:bold;display:inline;">Cash flows from financing activities:</div></div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 9.5pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 9.5pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 9.5pt; letter-spacing: 0px; top: 0px;;display:inline;">Proceeds from issuance of the Company&#8217;s common shares, net</div></div></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:ProceedsFromIssuanceOfCommonStock" contextRef="P04_01_2020To03_31_2021" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:zerodash">&#8212;</ix:nonFraction>&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:ProceedsFromIssuanceOfCommonStock" contextRef="P04_01_2019To03_31_2020" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">999,193</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 9.5pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 9.5pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 9.5pt; letter-spacing: 0px; top: 0px;;display:inline;">Repurchase of common stock and equity awards</div></div></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(<ix:nonFraction name="us-gaap:PaymentsForRepurchaseOfEquity" contextRef="P04_01_2020To03_31_2021" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">113</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(<ix:nonFraction name="us-gaap:PaymentsForRepurchaseOfEquity" contextRef="P04_01_2019To03_31_2020" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">990,014</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 9.5pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 9.5pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 9.5pt; letter-spacing: 0px; top: 0px;;display:inline;">Proceeds from issuance of liability instruments</div></div></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:ProceedsFromIssuanceOfDebt" contextRef="P04_01_2020To03_31_2021" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:zerodash">&#8212;</ix:nonFraction>&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:ProceedsFromIssuanceOfDebt" contextRef="P04_01_2019To03_31_2020" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">101,567</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 9.5pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 9.5pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 9.5pt; letter-spacing: 0px; top: 0px;;display:inline;">Proceeds from issuance of subsidiary common shares, net</div></div></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="roiv:ProceedsFromIssuanceOfSubsidiaryCommonSharesNet" contextRef="P04_01_2020To03_31_2021" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">455,756</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="roiv:ProceedsFromIssuanceOfSubsidiaryCommonSharesNet" contextRef="P04_01_2019To03_31_2020" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">117,658</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 9.5pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 9.5pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 9.5pt; letter-spacing: 0px; top: 0px;;display:inline;">Proceeds from issuance of equity by subsidiary upon Business Combination and recapitalization</div></div></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="roiv:ProceedsFromIssuanceOfEquityBySubsidiaryUponBusinessCombinationAndRecapitalization" contextRef="P04_01_2020To03_31_2021" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:zerodash">&#8212;</ix:nonFraction>&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="roiv:ProceedsFromIssuanceOfEquityBySubsidiaryUponBusinessCombinationAndRecapitalization" contextRef="P04_01_2019To03_31_2020" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">105,930</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 9.5pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 9.5pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 9.5pt; letter-spacing: 0px; top: 0px;;display:inline;">Purchase of subsidiary common shares</div></div></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="roiv:PurchaseOfSubsidiaryCommonShares" contextRef="P04_01_2020To03_31_2021" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:zerodash">&#8212;</ix:nonFraction>&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(<ix:nonFraction name="roiv:PurchaseOfSubsidiaryCommonShares" contextRef="P04_01_2019To03_31_2020" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:numdotdecimal">65,544</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 9.5pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 9.5pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 9.5pt; letter-spacing: 0px; top: 0px;;display:inline;">Proceeds from issuance of subsidiary convertible and redeemable preferred stock, net</div></div></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="roiv:ProceedsFromIssuanceOfSubsidiaryConvertibleAndRedeemablePreferredStockNet" contextRef="P04_01_2020To03_31_2021" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:zerodash">&#8212;</ix:nonFraction>&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="roiv:ProceedsFromIssuanceOfSubsidiaryConvertibleAndRedeemablePreferredStockNet" contextRef="P04_01_2019To03_31_2020" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">28,455</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 9.5pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 9.5pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 9.5pt; letter-spacing: 0px; top: 0px;;display:inline;">Purchase of subsidiary convertible and redeemable preferred stock</div></div></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="roiv:PaymentsForPurchaseOfSubsidiaryConvertibleAndRedeemablePreferredStock" contextRef="P04_01_2020To03_31_2021" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:zerodash">&#8212;</ix:nonFraction>&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(<ix:nonFraction name="roiv:PaymentsForPurchaseOfSubsidiaryConvertibleAndRedeemablePreferredStock" contextRef="P04_01_2019To03_31_2020" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">132,907</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 9.5pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 9.5pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 9.5pt; letter-spacing: 0px; top: 0px;;display:inline;">Proceeds from subsidiary debt financings, net</div></div></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="roiv:ProceedsFromSubsidiaryDebtFinancingsNet" contextRef="P04_01_2020To03_31_2021" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:zerodash">&#8212;</ix:nonFraction>&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="roiv:ProceedsFromSubsidiaryDebtFinancingsNet" contextRef="P04_01_2019To03_31_2020" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">83,781</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 9.5pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 9.5pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 9.5pt; letter-spacing: 0px; top: 0px;;display:inline;">Repayment of long-term debt and convertible debt by subsidiary</div></div></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="roiv:RepaymentOfLongTermDebtAndConvertibleDebtBySubsidiary" contextRef="P04_01_2020To03_31_2021" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:zerodash">&#8212;</ix:nonFraction>&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(<ix:nonFraction name="roiv:RepaymentOfLongTermDebtAndConvertibleDebtBySubsidiary" contextRef="P04_01_2019To03_31_2020" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">32,063</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 9.5pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 9.5pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 9.5pt; letter-spacing: 0px; top: 0px;;display:inline;">Payment of deferred offering costs</div></div></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(<ix:nonFraction name="us-gaap:PaymentsOfStockIssuanceCosts" contextRef="P04_01_2020To03_31_2021" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">286</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(<ix:nonFraction name="us-gaap:PaymentsOfStockIssuanceCosts" contextRef="P04_01_2019To03_31_2020" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">3,082</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 9.5pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 9.5pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 9.5pt; letter-spacing: 0px; top: 0px;;display:inline;">Payment for debt maintenance fee by subsidiary</div></div></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="roiv:PaymentForDebtMaintenanceFeeBySubsidiary" contextRef="P04_01_2020To03_31_2021" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:zerodash">&#8212;</ix:nonFraction>&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(<ix:nonFraction name="roiv:PaymentForDebtMaintenanceFeeBySubsidiary" contextRef="P04_01_2019To03_31_2020" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:numdotdecimal">300</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 9.5pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 9.5pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 9.5pt; letter-spacing: 0px; top: 0px;;display:inline;">Proceeds from exercise of subsidiary stock options</div></div></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:ProceedsFromStockOptionsExercised" contextRef="P04_01_2020To03_31_2021" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">907</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:ProceedsFromStockOptionsExercised" contextRef="P04_01_2019To03_31_2020" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">1,407</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;">&#160;</td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 9.5pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 9.5pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 5em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 9.5pt; letter-spacing: 0px; top: 0px;;display:inline;">Net cash provided by financing activities</div></div></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:NetCashProvidedByUsedInFinancingActivities" contextRef="P04_01_2020To03_31_2021" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">456,264</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:NetCashProvidedByUsedInFinancingActivities" contextRef="P04_01_2019To03_31_2020" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">214,081</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;">&#160;</td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 9.5pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 9.5pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 9.5pt; letter-spacing: 0px; top: 0px;;display:inline;">Net change in cash, cash equivalents and restricted cash</div></div></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(<ix:nonFraction name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect" contextRef="P04_01_2020To03_31_2021" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:numdotdecimal">127,576</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect" contextRef="P04_01_2019To03_31_2020" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">1,150,121</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 9.5pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 9.5pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 5em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 9.5pt; letter-spacing: 0px; top: 0px;;display:inline;">Cash, cash equivalents and restricted cash at beginning of period</div></div></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" contextRef="PAsOn03_31_2020" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">2,269,252</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" contextRef="PAsOn03_31_2019" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">1,119,131</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;">&#160;</td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 9.5pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 9.5pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 5em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 9.5pt; letter-spacing: 0px; top: 0px;;display:inline;">Cash, cash equivalents and restricted cash at end of period</div></div></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" contextRef="PAsOn03_31_2021" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">2,141,676</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" contextRef="PAsOn03_31_2020" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">2,269,252</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;">&#160;</td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td></tr></table><div style="clear: both; max-height: 0px;"></div><div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">The accompanying notes are an integral part of these consolidated financial statements. </div></div></div><div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div><div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">F-<div style="letter-spacing: 0px; top: 0px;;display:inline;">7</div> </div></div></div></div><div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div><hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/><div style="text-align: center;"><div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"><div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0px;"></div></div></div><div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;;font-weight: bold;"><div style="display:inline;"><a href="#toc" style="text-indent: 0px;">Table of Contents</a></div></div> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">ROIVANT SCIENCES LTD. </div></div></div> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Consolidated Statements of Cash Flows (Continued) </div></div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">(in thousands) </div></div></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="font-size: 0px;">
<td style="width: 83%;"></td>
<td style="width: 2%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td>
<td style="width: 2%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;&#160;</td>
<td colspan="6" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Years&#160;Ended&#160;March&#160;31,</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2021</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2020</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">Non-cash</div> investing and financing activities:</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;">Operating lease <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">right-of-use</div></div> assets obtained and exchanged for operating lease liabilities</div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" contextRef="P04_01_2020To03_31_2021" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">5,491</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" contextRef="P04_01_2019To03_31_2020" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">56,025</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;">Operating lease <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">right-of-use</div></div> assets and operating lease liabilities, including amounts reclassified from other current liabilities and other liabilities to operating lease liabilities, recognized upon the adoption of ASC 842, Leases, on April&#160;1, 2019</div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="roiv:OperatingLeaseRightOfUseAssetsAndAmountsReclassifiedFromOtherLiabilitiesToOperatingLeaseLiabilities" contextRef="P04_01_2020To03_31_2021" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:zerodash">&#8212;</ix:nonFraction>&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="roiv:OperatingLeaseRightOfUseAssetsAndAmountsReclassifiedFromOtherLiabilitiesToOperatingLeaseLiabilities" contextRef="P04_01_2019To03_31_2020" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">43,026</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Subscription receivable related to issuance of subsidiary common shares</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="roiv:SubscriptionReceivableRelatedToIssuanceOfSubsidiaryCommonShares" contextRef="P04_01_2020To03_31_2021" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">100,000</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="roiv:SubscriptionReceivableRelatedToIssuanceOfSubsidiaryCommonShares" contextRef="P04_01_2019To03_31_2020" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:zerodash">&#8212;</ix:nonFraction>&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Conversion of subsidiary convertible promissory notes to common shares</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="roiv:ConversionOfSubsidiaryConvertiblePromissoryNotesToCommonShares" contextRef="P04_01_2020To03_31_2021" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:zerodash">&#8212;</ix:nonFraction>&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="roiv:ConversionOfSubsidiaryConvertiblePromissoryNotesToCommonShares" contextRef="P04_01_2019To03_31_2020" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">32,500</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Other</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(<ix:nonFraction name="roiv:OtherNonCashTransactions" contextRef="P04_01_2020To03_31_2021" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:numdotdecimal">960</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="roiv:OtherNonCashTransactions" contextRef="P04_01_2019To03_31_2020" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">3,601</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Supplemental disclosure of cash paid:</div></div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Income taxes paid</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:IncomeTaxesPaidNet" contextRef="P04_01_2020To03_31_2021" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">4,076</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:IncomeTaxesPaidNet" contextRef="P04_01_2019To03_31_2020" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">4,936</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Interest paid</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:InterestPaidNet" contextRef="P04_01_2020To03_31_2021" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">2,017</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:InterestPaidNet" contextRef="P04_01_2019To03_31_2020" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">12,158</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;">&#160;</td> </tr> </table> <div style="clear: both; max-height: 0px;"></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">The accompanying notes are an integral part of these consolidated financial statements. </div></div></div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">F-<div style="letter-spacing: 0px; top: 0px;;display:inline;">8</div> </div></div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;;font-weight: bold;"><div style="display:inline;"><a href="#toc" style="text-indent: 0px;">Table of Contents</a></div></div> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"> <div id="fin164680_ff7" style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">ROIVANT SCIENCES LTD. </div></div></div> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Notes to Consolidated Financial Statements </div></div></div> <ix:nonNumeric name="us-gaap:BusinessDescriptionAndBasisOfPresentationTextBlock" contextRef="P04_01_2020To03_31_2021" escape="true"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Note 1&#8212;Description of Business and Liquidity </div></div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">(A) Description of Business </div></div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Roivant Sciences Ltd., inclusive of its consolidated subsidiaries (the &#8220;Company&#8221; or &#8220;RSL&#8221;), aims to improve health by rapidly delivering innovative medicines and technologies to patients. The Company does this by building biotech and healthcare technology companies (&#8220;Vants&#8221;) and deploying technology to drive greater efficiency in research and development and commercialization.&#160;In addition to biopharmaceutical subsidiaries, the Company also builds technology Vants focused on improving the process of developing and commercializing medicines. The Company was founded on April&#160;7, 2014 as a Bermuda exempted limited company. </div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The Company has determined that it has <ix:nonFraction name="us-gaap:NumberOfOperatingSegments" contextRef="P04_01_2020To03_31_2021" unitRef="Unit_Segment" decimals="0" scale="0" format="ixt-sec:numwordsen">one </ix:nonFraction>operating and reporting segment as it allocates resources and assesses financial performance on a consolidated basis. The Company&#8217;s subsidiaries are wholly owned subsidiaries and majority-owned or controlled subsidiaries. Refer to Note 3, &#8220;Investments&#8221; for further discussion of the Company&#8217;s investments in unconsolidated entities. </div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">(B) Liquidity </div></div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The Company has incurred significant losses and negative cash flows from operations since its inception. As of March&#160;31, 2021, the Company had cash and cash equivalents of approximately $<ix:nonFraction name="us-gaap:CashAndCashEquivalentsAtCarryingValue" contextRef="PAsOn03_31_2021" unitRef="Unit_USD" decimals="-8" scale="9" format="ixt:numdotdecimal">2.1</ix:nonFraction>&#160;billion and its accumulated deficit was approximately $<ix:nonFraction name="us-gaap:RetainedEarningsAccumulatedDeficit" contextRef="PAsOn03_31_2021" unitRef="Unit_USD" decimals="-8" scale="9" sign="-" format="ixt:numdotdecimal">1.9</ix:nonFraction>&#160;billion. For the years ended March&#160;31, 2021 and 2020, the Company incurred losses from continuing operations of $<ix:nonFraction name="us-gaap:NetIncomeLossAttributableToRedeemableNoncontrollingInterest" contextRef="P04_01_2020To03_31_2021" unitRef="Unit_USD" decimals="-5" scale="6" format="ixt:numdotdecimal">900.2</ix:nonFraction>&#160;million and $<ix:nonFraction name="us-gaap:NetIncomeLossAttributableToRedeemableNoncontrollingInterest" contextRef="P04_01_2019To03_31_2020" unitRef="Unit_USD" decimals="-5" scale="6" format="ixt:numdotdecimal">568.1</ix:nonFraction>&#160;million, respectively. The Company has historically financed its operations primarily through the sale of equity securities, sale of subsidiary interests, debt financings and revenue generated from licensing and collaboration arrangements. The Company has not generated any revenues to date from the sale of its product candidates and does not anticipate generating any revenues from the sale of its product candidates unless and until it successfully completes development and obtains regulatory approval to market its product candidates. Management expects to incur additional losses in the future to fund its operations and conduct product research and development and recognizes the need to raise additional capital to fully implement its business plan. </div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The Company intends to raise such additional capital through the issuance of equity securities, debt financings or other sources in order to further implement its business plan. However, if such financing is not available at adequate levels, the Company will need to reevaluate its operating plan and may be required to delay the development of its product candidates or take other steps to conserve capital. The Company expects its existing cash and cash equivalents will be sufficient to fund its committed operating expenses and capital expenditure requirements for at least the next 12 months from the date of issuance of these consolidated financial statements. </div></div></ix:nonNumeric> <ix:nonNumeric name="us-gaap:SignificantAccountingPoliciesTextBlock" contextRef="P04_01_2020To03_31_2021" escape="true" continuedAt="TextSelection_28230379"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Note 2&#8212;Summary of Significant Accounting Policies </div></div></div> <ix:nonNumeric name="us-gaap:BasisOfAccountingPolicyPolicyTextBlock" contextRef="P04_01_2020To03_31_2021" escape="true" continuedAt="TextSelection_28230377"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">(A) Basis of Presentation and Principles of Consolidation </div></div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The Company&#8217;s fiscal year ends on March&#160;31, and its fiscal quarters end on June&#160;30, September&#160;30, and December 31. </div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The accompanying audited consolidated financial statements and notes thereto have been prepared in accordance with accounting principles generally accepted in the United States (&#8220;U.S. GAAP&#8221;). </div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Any references in these notes to applicable accounting guidance are meant to refer to the authoritative U.S. GAAP as found in the Accounting Standards Codification (&#8220;ASC&#8221;) and Accounting Standards Updates </div></div></ix:nonNumeric> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></ix:nonNumeric> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">F-<div style="letter-spacing: 0px; top: 0px;;display:inline;">9</div> </div></div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;;font-weight: bold;"><div style="display:inline;"><a href="#toc" style="text-indent: 0px;">Table of Contents</a></div></div> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"><ix:continuation id="TextSelection_28230379" continuedAt="TextSelectionAppend_28230379_1"><ix:continuation id="TextSelection_28230377"> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">(&#8220;ASU&#8221;) of the Financial Accounting Standards Board (&#8220;FASB&#8221;). The consolidated financial statements include the accounts of RSL and the subsidiaries in which it has a controlling financial interest, most often through a majority voting interest. All intercompany balances and transactions have been eliminated in consolidation. </div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">For consolidated entities where the Company owns or is exposed to less than 100% of the economics, the Company records net loss attributable to noncontrolling interests in its consolidated statements of operations equal to the percentage of the economic or ownership interest retained in the respective operations by the noncontrolling parties. The Company presents noncontrolling interests as a component of shareholders&#8217; equity on its consolidated balance sheets. </div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The Company accounts for changes in its ownership interest in its subsidiaries while control is retained as equity transactions. The carrying amount of the noncontrolling interest is adjusted to reflect the change in RSL&#8217;s ownership interest in the subsidiary. Any difference between the fair value of the consideration received or paid and the amount by which the noncontrolling interest is adjusted is recognized within shareholders&#8217; equity attributable to RSL. </div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Additionally, the Company concluded that the disposition of RSL&#8217;s ownership interests in Myovant Sciences Ltd. (&#8220;Myovant&#8221;), Urovant Sciences Ltd. (&#8220;Urovant&#8221;), Enzyvant Therapeutics Ltd. (&#8220;Enzyvant&#8221;), Altavant Sciences Ltd. (&#8220;Altavant&#8221;), and Spirovant Sciences Ltd. (&#8220;Spirovant&#8221;) (collectively, the &#8220;Sumitovant Vants&#8221;), pursuant to the transaction agreement entered into with Sumitomo Dainippon Pharma Co., Ltd. (&#8220;Sumitomo&#8221;) on October&#160;31, 2019 (the &#8220;Sumitomo Transaction Agreement&#8221;) that closed on December&#160;27, 2019 (the &#8220;Sumitomo Transaction&#8221;), met the requirements to be presented as discontinued operations. As such, results relating to the transferred interests prior to disposition are classified as discontinued operations in prior period consolidated financial statements. See Note 5, &#8220;Sumitomo Transaction Agreement&#8221; and Note 6, &#8220;Discontinued Operations&#8221; for further discussion. Certain prior year amounts were reclassified to conform to current year presentation. </div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">In April 2012, the Jumpstart Our Business Startups Act of 2012 (the &#8220;JOBS Act&#8221;) was enacted. Section&#160;107(b) of the JOBS Act provides that an emerging growth company can take advantage of an extended transition period for complying with new or revised accounting standards. Thus, an emerging growth company can delay the adoption of certain accounting standards until those standards would otherwise apply to private companies. The Company has irrevocably elected not to avail itself of this extended transition period, and, as a result, the Company will adopt new or revised accounting standards on the relevant dates on which adoption of such standards is required for other public companies. </div></div> </ix:continuation> <ix:nonNumeric name="us-gaap:UseOfEstimates" contextRef="P04_01_2020To03_31_2021" escape="true"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">(B) Use of Estimates </div></div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The preparation of financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the amounts reported in the financial statements and accompanying notes. The Company regularly evaluates estimates and assumptions related to assets, liabilities, costs, expenses, contingent liabilities, share-based compensation and research and development costs. The Company bases its estimates and assumptions on historical experience and on various other factors that it believes to be reasonable under the circumstances, the results of which form the basis for making judgments about the carrying values of assets and liabilities that are not readily apparent from other sources. Actual results could differ from those estimates. </div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">Additionally, the Company assessed the impact that the <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">COVID-19</div> pandemic has had on its operations and financial results as of March&#160;31, 2021 and through the issuance of these consolidated financial statements. The Company&#8217;s analysis was informed by the facts and circumstances as they were known to the Company. This assessment considered the impact <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">COVID-19</div> may have on financial estimates and assumptions that affect the reported amounts of assets and liabilities and expenses. </div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></ix:nonNumeric></ix:continuation> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">F-<div style="letter-spacing: 0px; top: 0px;;display:inline;">10</div></div></div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;;font-weight: bold;"><div style="display:inline;"><a href="#toc" style="text-indent: 0px;">Table of Contents</a></div></div> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"><ix:continuation id="TextSelectionAppend_28230379_1" continuedAt="TextSelectionAppend_28230379_2"> <ix:nonNumeric name="us-gaap:UnusualRisksAndUncertaintiesTextBlock" contextRef="P04_01_2020To03_31_2021" escape="true"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">(C) Risks and Uncertainties </div></div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The Company is subject to risks common to companies in the biopharmaceutical industry including, but not limited to, uncertainties related to commercialization of products, regulatory approvals, dependence on key products, dependence on third-party service providers, such as contract research organizations, and protection of intellectual property rights. </div></div></ix:nonNumeric> <ix:nonNumeric name="us-gaap:ConcentrationRiskCreditRisk" contextRef="P04_01_2020To03_31_2021" escape="true"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">(D) Concentrations of Credit Risk </div></div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Financial instruments that potentially subject the Company to concentration of credit risk include cash and cash equivalents. The Company maintains cash deposits and cash equivalents in highly-rated, federally-insured financial institutions in excess of federally insured limits. The Company has established guidelines relative to diversification and maturities to maintain safety and liquidity. The Company has not experienced any credit losses related to these financial instruments and does not believe that it is exposed to any significant credit risk related to these instruments. </div></div></ix:nonNumeric> <ix:nonNumeric name="us-gaap:CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy" contextRef="P04_01_2020To03_31_2021" escape="true"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">(E) Cash, Cash Equivalents, and Restricted Cash </div></div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Cash and cash equivalents include cash deposits in banks and all highly liquid investments that are readily convertible to cash. The Company considers all highly liquid investments purchased with original maturities of three months or less to be cash equivalents. </div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">Restricted cash classified as a current asset consists of the amount held in escrow relating to the Sumitomo Transaction (see Note 5, &#8220;Sumitomo Transaction Agreement&#8221;) and the legally restricted <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-interest</div> bearing deposit account relating to the Company&#8217;s corporate credit card program. Restricted cash classified as a long-term asset consists of restricted deposit accounts related to irrevocable standby letters of credit. </div> <ix:nonNumeric name="us-gaap:ScheduleOfCashAndCashEquivalentsTableTextBlock" contextRef="P04_01_2020To03_31_2021" escape="true"><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Cash as reported in the accompanying consolidated statements of cash flows includes the aggregate amounts of cash, cash equivalents, and restricted cash as presented on the accompanying consolidated balance sheets as follows (in thousands): </div></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 76%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="font-size: 0px;">
<td style="width: 62%;"></td>
<td style="width: 8%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td>
<td style="width: 8%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">March&#160;31,&#160;2021</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">March&#160;31,&#160;2020</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Cash and cash equivalents</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:CashAndCashEquivalentsAtCarryingValue" contextRef="PAsOn03_31_2021" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">2,055,044</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:CashAndCashEquivalentsAtCarryingValue" contextRef="PAsOn03_31_2020" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">2,183,207</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Restricted cash</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:RestrictedCash" contextRef="PAsOn03_31_2021" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">86,632</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:RestrictedCash" contextRef="PAsOn03_31_2020" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">86,045</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;">&#160;</td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Cash, cash equivalents and restricted cash</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="roiv:CashAndCashEquivalentsAndRestrictedCash" contextRef="PAsOn03_31_2021" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">2,141,676</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="roiv:CashAndCashEquivalentsAndRestrictedCash" contextRef="PAsOn03_31_2020" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">2,269,252</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;">&#160;</td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td> </tr> </table> </ix:nonNumeric></ix:nonNumeric> <ix:nonNumeric name="us-gaap:TradeAndOtherAccountsReceivablePolicy" contextRef="P04_01_2020To03_31_2021" escape="true"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">(F) Trade Receivables, Net </div></div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The Company monitors the financial performance and creditworthiness of its customers so that it can properly assess and respond to changes in customer credit profiles. The Company reserves against trade receivables for estimated losses that may arise from a customer&#8217;s inability to pay and any amounts determined to be uncollectible are written off against the reserve when it is probable that the receivable will not be collected. The reserve amount for estimated losses was de minimis as of March&#160;31, 2021 and 2020. Trade receivables, net is included in &#8220;Other current assets&#8221; on the accompanying consolidated balance sheets. </div></div></ix:nonNumeric> <ix:nonNumeric name="us-gaap:CommitmentsAndContingenciesPolicyTextBlock" contextRef="P04_01_2020To03_31_2021" escape="true" continuedAt="TextSelection_28230371"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">(G) Contingencies </div></div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The Company may be, from time to time, a party to various disputes and claims arising from normal business activities. The Company continually assesses any litigation or other claims it may confront to determine if an unfavorable outcome would lead to a probable loss or reasonably possible loss which could be estimated. The Company accrues for all contingencies at the earliest date at which the Company deems it probable that a liability has been incurred and the amount of such liability can be reasonably estimated. If the estimate of a probable loss </div></div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></ix:nonNumeric></ix:continuation> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">F-<div style="letter-spacing: 0px; top: 0px;;display:inline;">11</div> </div></div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;;font-weight: bold;"><div style="display:inline;"><a href="#toc" style="text-indent: 0px;">Table of Contents</a></div></div> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"><ix:continuation id="TextSelectionAppend_28230379_2" continuedAt="TextSelectionAppend_28230379_3"> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"><ix:continuation id="TextSelection_28230371">is a range and no amount within the range is more likely than another, the Company accrues the minimum of the range. In the cases where the Company believes that a reasonably possible loss exists, the Company discloses the facts and circumstances of the litigation, including an estimable range, if possible.</ix:continuation> </div></div> <ix:nonNumeric name="us-gaap:PropertyPlantAndEquipmentPolicyTextBlock" contextRef="P04_01_2020To03_31_2021" escape="true"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">(H) Property and Equipment </div></div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Property and equipment, consisting primarily of computers, equipment, furniture and fixtures, software, and leasehold improvements, is recorded at cost, less accumulated depreciation. Maintenance and repairs that do not improve or extend the lives of the respective assets are expensed to operations as incurred. Upon disposal, retirement or sale, the related cost and accumulated depreciation is removed from the accounts and any resulting gain or loss is included in the results of operations. Depreciation of property and equipment is recorded using the straight-line method over the estimated useful lives of the related assets once the asset has been placed in service. Leasehold improvements are amortized using the straight-line method over the estimated useful life or remaining lease term, whichever is shorter. <ix:nonNumeric name="roiv:ScheduleOfPropertyPlantAndEquipmentEstimatedUsefulLivesTableTextBlock" contextRef="P04_01_2020To03_31_2021" escape="true" continuedAt="TextSelection_28230355">The following table provides the range of estimated useful lives used for each asset type:</ix:nonNumeric> </div></div> <ix:continuation id="TextSelection_28230355"> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="font-size: 0px;">
<td style="width: 33%; font-family: &quot;Times New Roman&quot;;"></td>
<td style="width: 1%; vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="width: 66%; font-family: &quot;Times New Roman&quot;;"></td> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; white-space: nowrap;"> <div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt; border-bottom: 1pt solid rgb(0, 0, 0); display: table-cell; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">Property and Equipment</div></div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;"> <div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt; border-bottom: 1pt solid rgb(0, 0, 0); display: table-cell; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">Estimated Useful Life</div></div></div> </td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Computers</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;"><ix:nonNumeric name="us-gaap:PropertyPlantAndEquipmentUsefulLife" contextRef="P04_01_2020To03_31_2021_ComputerEquipmentMemberusgaapPropertyPlantAndEquipmentByTypeAxis" format="ixt-sec:duryear">3 </ix:nonNumeric> years</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Equipment</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;"><ix:nonNumeric name="us-gaap:PropertyPlantAndEquipmentUsefulLife" contextRef="P04_01_2020To03_31_2021_EquipmentMemberusgaapPropertyPlantAndEquipmentByTypeAxis" format="ixt-sec:duryear">5 </ix:nonNumeric> years</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Furniture and fixtures</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;"><ix:nonNumeric name="us-gaap:PropertyPlantAndEquipmentUsefulLife" contextRef="P04_01_2020To03_31_2021_FurnitureAndFixturesMemberusgaapPropertyPlantAndEquipmentByTypeAxis" format="ixt-sec:duryear">7 </ix:nonNumeric> years</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Software</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;"><ix:nonNumeric name="us-gaap:PropertyPlantAndEquipmentUsefulLife" contextRef="P04_01_2020To03_31_2021_SoftwareDevelopmentMemberusgaapPropertyPlantAndEquipmentByTypeAxis" format="ixt-sec:duryear">3 </ix:nonNumeric> years</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Leasehold improvements</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;"><ix:nonNumeric name="us-gaap:PropertyPlantAndEquipmentEstimatedUsefulLives" contextRef="P04_01_2020To03_31_2021_LeaseholdImprovementsMemberusgaapPropertyPlantAndEquipmentByTypeAxis">Lesser of estimated useful life or remaining lease term</ix:nonNumeric></td> </tr> </table> </ix:continuation> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The Company reviews the recoverability of all long-lived assets, including the related useful lives, whenever events or changes in circumstances indicate that the carrying amount of a long-lived asset might not be recoverable. Recoverability is measured by comparison of the book values of the assets to the future net undiscounted cash flows that the assets are expected to generate. If such assets are considered to be impaired, the impairment to be recognized is measured by the amount by which the book value of the assets exceed their fair value, which is measured based on the projected discounted future net cash flows arising from the assets. </div></div></ix:nonNumeric> <ix:nonNumeric name="us-gaap:InvestmentPolicyTextBlock" contextRef="P04_01_2020To03_31_2021" escape="true"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">(I) Investments </div></div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">For investments in entities over which the Company has significant influence but do not meet the requirements for consolidation and for which the Company has not elected the fair value option, the Company applies the equity method of accounting with the Company&#8217;s share of the underlying income or loss of such entities reported in &#8220;Other expense, net&#8221; on the consolidated statements of operations. The Company applies the equity method to investments in common stock and to other investments in entities that have risk and reward characteristics that are substantially similar to an investment in the investee&#8217;s common stock. </div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Investments in equity securities may also be accounted for using (i)&#160;the fair value option if elected, (ii)&#160;fair value through earnings if fair value is readily determinable or (iii)&#160;for equity investments without readily determinable fair values, the measurement alternative to measure at cost adjusted for any impairment and observable price changes, as applicable. The election to use the measurement alternative is made for each eligible investment. </div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The Company has elected the fair value option to account for certain investments over which the Company has significant influence. The Company believes the fair value option best reflects the underlying economics of the investment. See Note 3, &#8220;Investments.&#8221; </div></div></ix:nonNumeric> <ix:nonNumeric name="us-gaap:ResearchAndDevelopmentExpensePolicy" contextRef="P04_01_2020To03_31_2021" escape="true" continuedAt="TextSelection_28230368"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">(J) Research and Development Expenses </div></div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Research and development (&#8220;R&amp;D&#8221;) costs are expensed as incurred. Preclinical and clinical study costs are accrued over the service periods specified in the contracts and adjusted as necessary based upon an ongoing </div></div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></ix:nonNumeric></ix:continuation> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">F-<div style="letter-spacing: 0px; top: 0px;;display:inline;">12</div> </div></div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;;font-weight: bold;"><div style="display:inline;"><a href="#toc" style="text-indent: 0px;">Table of Contents</a></div></div> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"><ix:continuation id="TextSelectionAppend_28230379_3" continuedAt="TextSelectionAppend_28230379_4"><ix:continuation id="TextSelection_28230368"> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">review of the level of effort and costs actually incurred. Payments for a product license prior to regulatory approval of the product and payments for milestones achieved prior to regulatory approval of the product are expensed in the period incurred as R&amp;D. Milestone payments made in connection with regulatory approvals are capitalized and amortized to cost of revenue over the remaining useful life of the asset. R&amp;D costs primarily consist of the intellectual property and R&amp;D materials acquired and expenses from third parties who conduct R&amp;D activities on behalf of the Company. </div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">The Company evaluates <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">in-licensed</div> agreements for <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">in-process</div> research and development projects (&#8220;IPR&amp;D&#8221;) to determine if it meets the definition of a business and thus should be accounted for as a business combination. If the <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">in-licensed</div> agreement for IPR&amp;D does not meet the definition of a business and the assets have not reached technological feasibility and therefore have no alternative future use, the Company expenses payments made under such license agreements as R&amp;D expense in its consolidated statements of operations. The Company initially recognizes contingent consideration in an asset acquisition at fair value. The carrying value of contingent consideration is subsequently adjusted when the contingency is resolved and is paid or becomes payable. </div> </ix:continuation> <ix:nonNumeric name="roiv:GeneralAndAdministrativeExpensesPolicyTextBlock" contextRef="P04_01_2020To03_31_2021" escape="true"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">(K) General and Administrative Expenses </div></div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;">General and administrative (&#8220;G&amp;A&#8221;) expenses consist primarily of employee-related expenses for G&amp;A personnel, including those responsible for the identification and acquisition or <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">in-license</div> of new drug candidates as well as for overseeing Vant operations and facilitating the use of the Company&#8217;s platform and technologies at Vants. G&amp;A expenses also consist of legal and accounting fees, consulting services and other operating costs relating to corporate matters and daily operations. G&amp;A expenses include costs incurred relating to the identification, acquisition or <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">in-license</div> and technology transfer of promising drug candidates along with costs incurred relating to the integration of new technologies. </div></ix:nonNumeric> <ix:nonNumeric name="us-gaap:IncomeTaxPolicyTextBlock" contextRef="P04_01_2020To03_31_2021" escape="true"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">(L) Income Taxes </div></div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Deferred tax assets and liabilities are recognized for the future tax consequences attributable to differences between the financial statement carrying amounts of existing assets and liabilities and the respective tax bases. Deferred tax assets and liabilities are measured using enacted tax rates expected to apply to taxable income in the years in which those temporary differences are expected to be recovered or settled. The effect on deferred tax assets and liabilities of a change in tax rates is recognized in income in the period that includes the enactment date. A valuation allowance is recorded when, after consideration of all positive and negative evidence, it is not more likely than not that the Company&#8217;s deferred tax assets will be realizable. If the Company determines that it would be able to realize its deferred tax assets in the future in excess of its net recorded amount, the Company would make an adjustment to the deferred tax asset valuation allowance, which would reduce the provision for income taxes. </div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">When uncertain tax positions exist, the Company recognizes the tax benefit of tax positions to the extent that the benefit will more likely than not be realized. The determination as to whether the tax benefit will more likely than not be realized is based upon the technical merits of the tax position as well as consideration of the available facts and circumstances. </div></div></ix:nonNumeric> <ix:nonNumeric name="us-gaap:ShareBasedCompensationOptionAndIncentivePlansPolicy" contextRef="P04_01_2020To03_31_2021" escape="true" continuedAt="TextSelection_28230365"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">(M) Share-Based Compensation </div></div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Share-based awards to employees, directors, and consultants, including stock options, restricted stock units, performance options and capped value appreciation rights, are measured at fair value on the date of the grant and that fair value is recognized as share-based compensation expense in the Company&#8217;s consolidated statements of operations over the requisite service period of the respective award. The estimated fair value of awards that contain performance conditions is expensed when the Company concludes that it is probable that the performance condition will be achieved. The Company may grant awards with graded-vesting features. When such awards have only service vesting requirements, the Company elected to record share-based compensation </div></div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></ix:nonNumeric></ix:continuation> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">F-<div style="letter-spacing: 0px; top: 0px;;display:inline;">13</div> </div></div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;;font-weight: bold;"><div style="display:inline;"><a href="#toc" style="text-indent: 0px;">Table of Contents</a></div></div> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"><ix:continuation id="TextSelectionAppend_28230379_4" continuedAt="TextSelectionAppend_28230379_5"><ix:continuation id="TextSelection_28230365"> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">expense on a straight-line basis. If awards with graded-vesting features contain performance or market conditions, then the Company records share-based compensation expense using the accelerated attribution method. </div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The Company measures the fair value of its stock options that only have service vesting requirements or performance-based options without market conditions using the Black-Scholes option pricing model. For performance-based awards with market conditions, the Company determines the fair value of the awards as of the grant date using a Monte Carlo simulation model. </div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">Certain assumptions need to be made with respect to utilizing the Black-Scholes option pricing model, including the expected life of the award, volatility of the underlying shares, the risk-free interest rate and the fair value of the Company&#8217;s common shares. Since the Company has no option exercise history, it has generally elected to estimate the expected life of an award based upon the &#8220;simplified method&#8221; with the continued use of this method extended until such time the Company has sufficient exercise history. The risk-free interest rate is based on the rates paid on securities issued by the U.S. Treasury with a term approximating the expected life of the equity award. The expected share price volatility for the Company&#8217;s common shares is estimated by taking the average historical price volatility for industry peers. The Company accounts for <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">pre-vesting</div> award forfeitures when they occur. </div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">As part of the valuation of share-based compensation under the Black-Scholes option pricing model, it is necessary for the Company to estimate the fair value of its common shares for RSL and privately held Vants. Given the absence of a public trading market, and in accordance with the American Institute of Certified Public Accountants&#8217; Practice Guide, Valuation of Privately-Held-Company Equity Securities Issued as Compensation, the Company exercises reasonable judgment and considers numerous objective and subjective factors to determine its best estimate of the fair value of its common shares. The estimation of the fair value of the common shares considers factors including the following: the prices of the Company&#8217;s common shares sold to investors in arm&#8217;s length transactions, the estimated present value of the Company&#8217;s future cash flows; the Company&#8217;s business, financial condition and results of operations; the Company&#8217;s forecasted operating performance; the illiquid nature of the Company&#8217;s common shares; industry information such as market size and growth; market capitalization of comparable companies and the estimated value of transactions such companies have engaged in; and macroeconomic conditions. </div></div> </ix:continuation> <ix:nonNumeric name="us-gaap:FairValueMeasurementPolicyPolicyTextBlock" contextRef="P04_01_2020To03_31_2021" escape="true" continuedAt="TextSelection_28230364"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">(N) Fair Value Measurements </div></div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The Company utilizes fair value measurement guidance prescribed by accounting standards to value its financial instruments. The guidance establishes a fair value hierarchy for financial instruments measured at fair value that distinguishes between assumptions based on market data (observable inputs) and the Company&#8217;s own assumptions (unobservable inputs). Observable inputs are inputs that market participants would use in pricing the asset or liability based on market data obtained from sources independent of the Company. Unobservable inputs are inputs that reflect the Company&#8217;s assumptions about the inputs that market participants would use in pricing the asset or liability, and are developed based on the best information available in the circumstances. Fair value is defined as the exchange price, or exit price, representing the amount that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants at the reporting date. As a basis for considering market participant assumptions in fair value measurements, the guidance establishes a three-tier fair value hierarchy that distinguishes among the following: </div></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;">Level <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">1-Valuations</div> are based on unadjusted quoted prices in active markets for identical assets or liabilities that the Company has the ability to access. </div> </td> </tr> </table> <div style="clear: both; max-height: 0px;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;">Level <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">2-Valuations</div> are based on quoted prices for similar assets or liabilities in active markets, quoted prices for identical or similar assets or liabilities in markets that are not active and models for which all significant inputs are observable, either directly or indirectly. </div> </td> </tr> </table> <div style="clear: both; max-height: 0px;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;">Level <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">3-Valuations</div> are based on inputs that are unobservable (supported by little or no market activity) and significant to the overall fair value measurement. </div> </td> </tr> </table> <div style="clear: both; max-height: 0px;"></div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></ix:nonNumeric></ix:continuation> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">F-<div style="letter-spacing: 0px; top: 0px;;display:inline;">14</div> </div></div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;;font-weight: bold;"><div style="display:inline;"><a href="#toc" style="text-indent: 0px;">Table of Contents</a></div></div> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"><ix:continuation id="TextSelectionAppend_28230379_5" continuedAt="TextSelectionAppend_28230379_6"><ix:continuation id="TextSelection_28230364"> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">To the extent the valuation is based on models or inputs that are less observable or unobservable in the market, the determination of fair value requires more judgment. Accordingly, the degree of judgment exercised by the Company in determining fair value is greatest for instruments categorized in Level&#160;3. A financial instrument&#8217;s level within the fair value hierarchy is based on the lowest level of any input that is significant to the fair value measurement. </div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The Company&#8217;s financial instruments include shares of common stock of Arbutus Biopharma Corporation (&#8220;Arbutus&#8221;); shares of Arbutus&#8217;s Series A participating convertible preferred shares (&#8220;Arbutus Preferred Shares&#8221;); shares of common stock of Sio Gene Therapies Inc. (&#8220;Sio&#8221;); liability instruments issued, including options granted to Sumitomo (the &#8220;Sumitomo Options&#8221;) to purchase all, or 75% in one case, of RSL&#8217;s ownership interests in certain subsidiaries under the Sumitomo Transaction Agreement; deferred consideration liability; its investments in other entities; cash and cash equivalents consisting of money market funds; accounts payable; and long-term debt. </div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The shares of Arbutus and Sio common stock and investments in common stock with a readily determinable fair value are classified as Level&#160;1, and their fair value is determined based upon quoted market prices in an active market. The Arbutus Preferred Shares held by the Company are classified as Level&#160;2 as the fair value of such preferred shares is determined based upon the quoted market price of Arbutus common stock into which such preferred shares are convertible. The liability instruments issued, including the Sumitomo Options, are classified as Level&#160;3 within the fair value hierarchy as the assumptions and estimates used in the valuations are unobservable in the market. Cash, accounts payable, and deferred consideration liability are stated at their respective historical carrying amounts, which approximate fair value due to their short-term nature. The deferred consideration liability is based on a fixed monetary amount, and payment is based solely on the passage of time. Money market funds are included in Level&#160;1 of the fair value hierarchy and are valued at the closing price reported by an actively traded exchange. The carrying value of long-term debt issued by Dermavant Sciences Ltd. (together with its wholly owned subsidiaries, &#8220;Dermavant&#8221;), which is stated at amortized cost, approximates fair value&#160;based on current interest rates for similar types of borrowings and therefore is included in Level&#160;2 of the fair value hierarchy. Long-term debt issued by Dermavant for which the fair value option has been elected is included in Level&#160;3 of the fair value hierarchy as the assumptions and estimates used in the valuation are unobservable in the market. </div></div> </ix:continuation> <ix:nonNumeric name="us-gaap:ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock" contextRef="P04_01_2020To03_31_2021" escape="true"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">(O) Foreign Currency </div></div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Assets and liabilities of foreign operations are translated using exchange rates in effect at the balance sheet date and their results of operations are translated using average exchange rates for the year. Certain transactions of the Company and its subsidiaries are denominated in currencies other than their functional currency. Adjustments resulting from the translation of the financial statements of the Company&#8217;s foreign functional currency subsidiaries into U.S. dollars are excluded from the determination of net loss and are accumulated in a separate component of shareholders&#8217; equity. Foreign exchange transaction gains and losses are included in &#8220;Other expense, net&#8221; in the Company&#8217;s statements of operations. </div></div></ix:nonNumeric> <ix:nonNumeric name="us-gaap:RevenueFromContractWithCustomerPolicyTextBlock" contextRef="P04_01_2020To03_31_2021" escape="true" continuedAt="TextSelection_28230362"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">(P) Revenue Recognition </div></div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The Company recognizes revenue when its customer obtains control of promised goods or services, in an amount that reflects the consideration which the Company expects to receive in exchange for those goods or services. To determine revenue recognition for its arrangements, the Company performs the following five steps: (i)&#160;identify the contract(s) with a customer; (ii)&#160;identify the performance obligations in the contract; (iii)&#160;determine the transaction price; (iv)&#160;allocate the transaction price to the performance obligations in the contract; and (v)&#160;recognize revenue when or as the Company satisfies a performance obligation. </div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The Company applies significant judgment when evaluating whether contractual obligations represent distinct performance obligations, allocating transaction price to performance obligations within a contract, determining </div></div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></ix:nonNumeric></ix:continuation> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">F-<div style="letter-spacing: 0px; top: 0px;;display:inline;">15</div> </div></div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;;font-weight: bold;"><div style="display:inline;"><a href="#toc" style="text-indent: 0px;">Table of Contents</a></div></div> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"><ix:continuation id="TextSelectionAppend_28230379_6" continuedAt="TextSelectionAppend_28230379_7"><ix:continuation id="TextSelection_28230362"> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">when performance obligations have been met, assessing the recognition and future reversal of variable consideration, and determining and applying appropriate methods of measuring progress for performance obligations satisfied over time. These judgments are discussed in more detail below. </div></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Licenses of intellectual property:</div></div> If the licenses to intellectual property are determined to be distinct from the other performance obligations identified in the arrangement, the Company recognizes revenues from <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-refundable,</div> upfront fees allocated to the license when the license is transferred to the licensee and the licensee is able to use and benefit from the license. For licenses that are not distinct from other promises, the Company applies judgment to assess the nature of the combined performance obligation to determine whether the combined performance obligation is satisfied over time or at a point in time and, if over time, the appropriate method of measuring progress for purposes of recognizing revenue from <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-refundable,</div> upfront fees. The Company evaluates the measure of progress each reporting period and, if necessary, adjusts the related revenue recognition accordingly. </div> </td> </tr> </table> <div style="clear: both; max-height: 0px;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Milestone payments: </div></div>At the inception of each arrangement that includes research, development or regulatory milestone payments, the Company<div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;"> </div></div>evaluates whether the milestones are considered probable of being reached and estimates the amount to be included in the transaction price using the most likely amount method. If it is probable that a significant revenue reversal would not occur, the associated milestone value is included in the transaction price. Milestone payments that are not within the control of the Company or the licensee, such as regulatory approvals, are not considered probable of being achieved until those approvals are received. The transaction price is then allocated to each performance obligation on a relative standalone selling price basis, for which the Company recognizes revenue as or when the performance obligations under the contract are satisfied. At the end of each subsequent reporting period, the Company <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">re-evaluates</div> the probability of achievement of such development milestones and any related constraint, and if necessary, adjusts its estimate of the overall transaction price on a cumulative <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">catch-up</div> basis in earnings in the period of the adjustment. </div> </td> </tr> </table> <div style="clear: both; max-height: 0px;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Royalties and commercial milestone payments: </div></div>For arrangements that include sales-based royalties, including commercial milestone payments<div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;"> </div></div>based on a <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">pre-specified</div> level of sales, the Company recognizes revenue at the later of (i)&#160;when the related sales occur, or (ii)&#160;when the performance obligation to which some or all of the royalty has been allocated has been satisfied (or partially satisfied). Achievement of these royalties and commercial milestones may solely depend upon performance of the licensee. </div> </td> </tr> </table> <div style="clear: both; max-height: 0px;"></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Revenue is also generated by certain technology-focused Vants from subscription and service-based fees recognized for the use of certain technology developed by these Vants. Subscription revenue is recognized ratably over the contract period. </div></div> </ix:continuation> <ix:nonNumeric name="us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock" contextRef="P04_01_2020To03_31_2021" escape="true"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">(Q) Recently Adopted Accounting Pronouncements </div></div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;">In June 2016, the FASB issued ASU <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">No.&#160;2016-13,</div> &#8220;Financial Instruments-Credit Losses (Topic 326): Measurement of Credit Losses on Financial Instruments&#8221; (&#8220;ASU <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">No.&#160;2016-13&#8221;),</div> which requires the measurement and recognition of expected credit losses for financial assets held at amortized cost. ASU <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">No.&#160;2016-13</div> replaces the existing incurred loss impairment model with an expected loss model that requires the use of forward-looking information to calculate credit loss estimates. It also eliminates the concept of other-than-temporary impairment and requires credit losses on <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">available-for-sale</div></div> debt securities to be recorded through an allowance for credit losses instead of as a reduction in the amortized cost basis of the securities. ASU <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">No.&#160;2016-13</div> is effective for fiscal years beginning after December&#160;15, 2019 and interim periods within those fiscal years. The adoption of ASU <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">No.&#160;2016-13</div> on April&#160;1, 2020 did not have a material impact on the Company&#8217;s consolidated financial statements. </div></ix:nonNumeric> <ix:nonNumeric name="roiv:NewAccountingPronouncementsNotYetAdoptedPolicyTextBlock" contextRef="P04_01_2020To03_31_2021" escape="true" continuedAt="TextSelection_28230360"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">(R) Recently Issued Accounting Pronouncements Not Yet Adopted </div></div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;">In August 2020, the FASB issued ASU <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">No.&#160;2020-06,</div> &#8220;Debt&#8212;Debt with Conversion and Other Options (Subtopic <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">470-20)</div> and Derivatives and Hedging&#8212;Contracts in Entity&#8217;s Own Equity (Subtopic <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">815-40):</div> Accounting for </div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></ix:nonNumeric></ix:continuation> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">F-<div style="letter-spacing: 0px; top: 0px;;display:inline;">16</div> </div></div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;;font-weight: bold;"><div style="display:inline;"><a href="#toc" style="text-indent: 0px;">Table of Contents</a></div></div> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"><ix:continuation id="TextSelection_28230360"><ix:continuation id="TextSelectionAppend_28230379_7"> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Convertible Instruments and Contracts in an Entity&#8217;s Own Equity&#8221; (&#8220;ASU <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">No.&#160;2020-06&#8221;).</div> ASU <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">No.&#160;2020-06</div> will simplify the accounting for convertible instruments by reducing the number of accounting models for convertible debt instruments and convertible preferred stock. Limiting the accounting models will result in fewer embedded conversion features being separately recognized from the host contract as compared with current GAAP. ASU <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">No.&#160;2020-06</div> also removes certain settlement conditions that are required for equity contracts to qualify for the derivatives scope exception, which will permit more equity contracts to qualify for it. Either a modified retrospective transition method or a fully retrospective transition method is permissible for the adoption of this standard. Update <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">No.&#160;2020-06</div> is effective for fiscal years beginning after December&#160;15, 2021, including interim periods within those fiscal years. Early adoption is permitted no earlier than the fiscal year beginning after December&#160;15, 2020. The adoption of ASU <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">No.&#160;2020-06</div> is not expected to have a material impact on the Company&#8217;s consolidated financial statements. </div> </ix:continuation></ix:continuation> <ix:nonNumeric name="us-gaap:InvestmentsAndOtherNoncurrentAssetsTextBlock" contextRef="P04_01_2020To03_31_2021" escape="true" continuedAt="TextSelection_28230330"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Note 3&#8212;Investments </div></div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">(A) Investments Measured at Fair Value </div></div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Investment in Arbutus </div></div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;">RSL owns <ix:nonFraction name="us-gaap:CommonStockSharesOutstanding" contextRef="PAsOn03_31_2020_ArbutusBiopharmaCorporationMemberdeiLegalEntityAxis" unitRef="Unit_shares" decimals="0" scale="0" format="ixt:numdotdecimal"><ix:nonFraction name="us-gaap:CommonStockSharesOutstanding" contextRef="PAsOn03_31_2021_ArbutusBiopharmaCorporationMemberdeiLegalEntityAxis" unitRef="Unit_shares" decimals="0" scale="0" format="ixt:numdotdecimal">16,013,540</ix:nonFraction></ix:nonFraction> shares of common stock of Arbutus and <ix:nonFraction name="us-gaap:PreferredStockSharesOutstanding" contextRef="PAsOn03_31_2020_ArbutusBiopharmaCorporationMemberdeiLegalEntityAxis" unitRef="Unit_shares" decimals="0" scale="0" format="ixt:numdotdecimal"><ix:nonFraction name="us-gaap:PreferredStockSharesOutstanding" contextRef="PAsOn03_31_2021_ArbutusBiopharmaCorporationMemberdeiLegalEntityAxis" unitRef="Unit_shares" decimals="0" scale="0" format="ixt:numdotdecimal">1,164,000</ix:nonFraction></ix:nonFraction> Arbutus Preferred Shares that are mandatorily convertible into shares of Arbutus common stock on October&#160;18, 2021 subject to conversion earlier upon a sale, merger or other transaction considered a fundamental change of control of Arbutus. The Arbutus Preferred Shares are <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-voting</div> and are convertible into common shares of Arbutus based on the subscription price plus <ix:nonFraction name="roiv:AnnualCompoundedConversionRateForPreferredShare" contextRef="P04_01_2020To03_31_2021_ArbutusBiopharmaCorporationMemberdeiLegalEntityAxis" unitRef="Unit_pure" decimals="4" scale="-2" format="ixt:numdotdecimal">8.75</ix:nonFraction>% per annum, compounded annually, divided by a conversion price of $<ix:nonFraction name="roiv:ConversionPrice" contextRef="PAsOn03_31_2021_ArbutusBiopharmaCorporationMemberdeiLegalEntityAxis" unitRef="Unit_USD_per_Share" decimals="2" scale="0" format="ixt:numdotdecimal">7.13</ix:nonFraction> per share (which represented a <ix:nonFraction name="roiv:PremiumOnConversionPricePercentage" contextRef="P09_29_2017To09_29_2017_ArbutusBiopharmaCorporationMemberdeiLegalEntityAxis" unitRef="Unit_pure" decimals="2" scale="-2" format="ixt:numdotdecimal">15</ix:nonFraction>% premium to the closing price of $<ix:nonFraction name="roiv:ClosingPricePerShare" contextRef="PAsOn09_29_2017_ArbutusBiopharmaCorporationMemberdeiLegalEntityAxis" unitRef="Unit_USD_per_Share" decimals="2" scale="0" format="ixt:numdotdecimal">6.20</ix:nonFraction> per share on September&#160;29, 2017). RSL&#8217;s investments in Arbutus have been measured using the fair value option. Due to the Company&#8217;s significant influence over operating and financial policies, Arbutus is considered a related party of the Company. </div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">After conversion of the Arbutus Preferred Shares into common shares, based on the number of Arbutus&#8217;s common shares outstanding on October&#160;2, 2017, the Company would hold&#160;<ix:nonFraction name="roiv:OwnershipInterestPercentage" contextRef="PAsOn12_31_2020_ArbutusBiopharmaCorporationMemberdeiLegalEntityAxis" unitRef="Unit_pure" decimals="4" scale="-2" format="ixt:numdotdecimal">49.90</ix:nonFraction>%&#160;of Arbutus&#8217;s common shares. In addition, the Company agreed to a four-year standstill to not acquire greater than <ix:nonFraction name="roiv:MaximumAllowedOwnershipInterestPercentage" contextRef="P04_01_2020To12_31_2020_ArbutusBiopharmaCorporationMemberdeiLegalEntityAxis" unitRef="Unit_pure" decimals="4" scale="-2" format="ixt:numdotdecimal">49.99</ix:nonFraction>% of common shares or securities convertible into common shares of Arbutus. </div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">At March&#160;31, 2021 and 2020, the aggregate fair value of the Company&#8217;s investment in Arbutus was $<ix:nonFraction name="us-gaap:InvestmentsFairValueDisclosure" contextRef="PAsOn03_31_2021_ArbutusBiopharmaCorporationMemberdeiLegalEntityAxis" unitRef="Unit_USD" decimals="-5" scale="6" format="ixt:numdotdecimal">129.4</ix:nonFraction>&#160;million and $<ix:nonFraction name="us-gaap:InvestmentsFairValueDisclosure" contextRef="PAsOn03_31_2020_ArbutusBiopharmaCorporationMemberdeiLegalEntityAxis" unitRef="Unit_USD" decimals="-5" scale="6" format="ixt:numdotdecimal">39.2</ix:nonFraction>&#160;million, respectively, with the Company recognizing an unrealized gain on its investments in Arbutus of $<ix:nonFraction name="us-gaap:UnrealizedGainLossOnInvestments" contextRef="P04_01_2020To03_31_2021_ArbutusBiopharmaCorporationMemberdeiLegalEntityAxis" unitRef="Unit_USD" decimals="-5" scale="6" format="ixt:numdotdecimal">90.2</ix:nonFraction>&#160;million and an unrealized loss of $<ix:nonFraction name="us-gaap:UnrealizedGainLossOnInvestments" contextRef="P04_01_2019To03_31_2020_ArbutusBiopharmaCorporationMemberdeiLegalEntityAxis" unitRef="Unit_USD" decimals="-5" scale="6" format="ixt:numdotdecimal">99.9</ix:nonFraction>&#160;million in the accompanying consolidated statements of operations for the years ended March&#160;31, 2021 and 2020, respectively. The fair value of the common stock and preferred shares held by the Company was determined using the closing price of Arbutus&#8217;s common stock on March&#160;31, 2021 and 2020 of $<ix:nonFraction name="us-gaap:SharePrice" contextRef="PAsOn03_31_2021_ArbutusBiopharmaCorporationMemberdeiLegalEntityAxis" unitRef="Unit_USD_per_Share" decimals="2" scale="0" format="ixt:numdotdecimal">3.33</ix:nonFraction> and $<ix:nonFraction name="us-gaap:SharePrice" contextRef="PAsOn03_31_2020_ArbutusBiopharmaCorporationMemberdeiLegalEntityAxis" unitRef="Unit_USD_per_Share" decimals="2" scale="0" format="ixt:numdotdecimal">1.01</ix:nonFraction>, respectively. </div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Investment in Sio </div></div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Following the completion of Sio&#8217;s underwritten public offering in February 2020, RSL&#8217;s ownership interest fell below 50.0%. As such, the Company no longer has a controlling financial interest in Sio. Accordingly, the Company deconsolidated Sio in February 2020. Due to the Company&#8217;s significant influence over operating and financial policies, Sio remains a related party of the Company following deconsolidation. As the Company still has the ability to exercise significant influence over the operating and financial policies of Sio, the Company has determined that its retained interest represents an equity method investment after the date of deconsolidation. Upon deconsolidation, the retained interest was recorded at fair market value based on the closing price of Sio&#8217;s common stock. The Company recognized a gain on deconsolidation of $<ix:nonFraction name="us-gaap:DeconsolidationGainOrLossAmount" contextRef="P04_01_2019To03_31_2020_SioGeneTherapiesIncMemberdeiLegalEntityAxis" unitRef="Unit_USD" decimals="-5" scale="6" format="ixt:numdotdecimal">107.3</ix:nonFraction>&#160;million in the accompanying consolidated statements of operations for the year ended March&#160;31, 2020. The fair value option was elected to continuously remeasure the investment to fair value each reporting period after the initial measurement. </div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">At March&#160;31, 2021 and 2020, the fair value of the Company&#8217;s investment in Sio was $<ix:nonFraction name="us-gaap:InvestmentsFairValueDisclosure" contextRef="PAsOn03_31_2021_SioGeneTherapiesIncMemberdeiLegalEntityAxis" unitRef="Unit_USD" decimals="-5" scale="6" format="ixt:numdotdecimal">48.5</ix:nonFraction>&#160;million<div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"> </div></div>and<div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"> </div></div>$<ix:nonFraction name="us-gaap:InvestmentsFairValueDisclosure" contextRef="PAsOn03_31_2020_SioGeneTherapiesIncMemberdeiLegalEntityAxis" unitRef="Unit_USD" decimals="-5" scale="6" format="ixt:numdotdecimal">45.3</ix:nonFraction>&#160;million, respectively, with the Company recognizing an unrealized gain on its investment in Sio of </div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></ix:nonNumeric> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">F-<div style="letter-spacing: 0px; top: 0px;;display:inline;">17</div> </div></div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;;font-weight: bold;"><div style="display:inline;"><a href="#toc" style="text-indent: 0px;">Table of Contents</a></div></div> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0px;"></div> </div> </div> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"><ix:continuation id="TextSelection_28230330"> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">$<ix:nonFraction name="us-gaap:UnrealizedGainLossOnInvestments" contextRef="P04_01_2020To03_31_2021_SioGeneTherapiesIncMemberdeiLegalEntityAxis" unitRef="Unit_USD" decimals="-5" scale="6" format="ixt:numdotdecimal">3.2</ix:nonFraction>&#160;million and an unrealized loss of $<ix:nonFraction name="us-gaap:UnrealizedGainLossOnInvestments" contextRef="P04_01_2019To03_31_2020_SioGeneTherapiesIncMemberdeiLegalEntityAxis" unitRef="Unit_USD" decimals="-5" scale="6" format="ixt:numdotdecimal">31.6</ix:nonFraction>&#160;million in the accompanying consolidated statements of operations for the years ended March&#160;31, 2021 and 2020, respectively. The fair value of common shares held by the Company was determined using the closing price of Sio&#8217;s common stock on March&#160;31, 2021 and 2020 of $<ix:nonFraction name="us-gaap:SharePrice" contextRef="PAsOn03_31_2021_SioGeneTherapiesIncMemberdeiLegalEntityAxis" unitRef="Unit_USD_per_Share" decimals="2" scale="0" format="ixt:numdotdecimal">2.61</ix:nonFraction> and $<ix:nonFraction name="us-gaap:SharePrice" contextRef="PAsOn03_31_2020_SioGeneTherapiesIncMemberdeiLegalEntityAxis" unitRef="Unit_USD_per_Share" decimals="2" scale="0" format="ixt:numdotdecimal">2.44</ix:nonFraction>, respectively. </div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Other Investment </div></div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The Company holds an additional equity investment that is measured using the fair value option. The fair value of this investment was $<ix:nonFraction name="us-gaap:InvestmentsFairValueDisclosure" contextRef="PAsOn03_31_2021_OtherInvestmentCompaniesMemberusgaapInvestmentTypeAxis" unitRef="Unit_USD" decimals="-5" scale="6" format="ixt:numdotdecimal">11.1</ix:nonFraction>&#160;million and $<ix:nonFraction name="us-gaap:InvestmentsFairValueDisclosure" contextRef="PAsOn03_31_2020_OtherInvestmentCompaniesMemberusgaapInvestmentTypeAxis" unitRef="Unit_USD" decimals="-5" scale="6" format="ixt:numdotdecimal">8.9</ix:nonFraction>&#160;million as of March&#160;31, 2021 and 2020, respectively. </div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">(B) Investment Accounted for Using Measurement Alternative </div></div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Investment in Datavant </div></div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">In April 2020, Datavant Holdings, Inc. (&#8220;Datavant&#8221;) completed an initial round of a Series B equity raise by which <ix:nonFraction name="roiv:PreferredStockSharesIssuedAndSoldToCompanyDuringPeriodShares" contextRef="PAsOn04_30_2020" unitRef="Unit_shares" decimals="INF" scale="0" format="ixt:numdotdecimal">13,411,311</ix:nonFraction> Series B preferred shares were issued in April 2020 for gross proceeds of $<ix:nonFraction name="roiv:ProceedsFromIssuanceOfPreferredStockAndPreferenceStocks" contextRef="PAsOn04_30_2020_DatavantHoldingsIncMemberdeiLegalEntityAxis_SeriesBPreferredStockMemberusgaapStatementClassOfStockAxis" unitRef="Unit_USD" decimals="-5" scale="6" format="ixt:numdotdecimal">27.2</ix:nonFraction>&#160;million, including <ix:nonFraction name="roiv:PreferredStockSharesIssuedAndSoldToCompanyDuringPeriodShares" contextRef="PAsOn04_30_2020_DatavantHoldingsIncMemberdeiLegalEntityAxis_SeriesBPreferredStockMemberusgaapStatementClassOfStockAxis" unitRef="Unit_shares" decimals="0" scale="0" format="ixt:numdotdecimal">1,065,234</ix:nonFraction> Series B preferred shares issued and sold to RSL for a total purchase price of $<ix:nonFraction name="roiv:PreferredStockPurchased" contextRef="PAsOn04_30_2020_DatavantHoldingsIncMemberdeiLegalEntityAxis_SeriesBPreferredStockMemberusgaapStatementClassOfStockAxis" unitRef="Unit_USD" decimals="-5" scale="6" format="ixt:numdotdecimal">2.5</ix:nonFraction>&#160;million and <ix:nonFraction name="us-gaap:ConvertiblePreferredStockSharesIssuedUponConversion" contextRef="PAsOn04_30_2020_DatavantHoldingsIncMemberdeiLegalEntityAxis_SeriesBPreferredStockMemberusgaapStatementClassOfStockAxis" unitRef="Unit_shares" decimals="0" scale="0" format="ixt:numdotdecimal">1,800,253</ix:nonFraction> Series B shares issued relating to the conversion of certain liability instruments. As a result of this transaction, along with a restructuring of Datavant&#8217;s equity classes, RSL no longer controls Datavant. As such, the Company deconsolidated Datavant as of April 2020. Due to the Company&#8217;s significant influence over operating and financial policies, Datavant remains a related party of the Company following deconsolidation. Upon deconsolidation, the Company recorded its investment in Datavant based on the fair value of Datavant preferred shares held of $<ix:nonFraction name="us-gaap:InvestmentsFairValueDisclosure" contextRef="PAsOn03_31_2021_DatavantHoldingsIncMemberdeiLegalEntityAxis" unitRef="Unit_USD" decimals="-5" scale="6" format="ixt:numdotdecimal">99.0</ix:nonFraction>&#160;million. The Company accounts for its investment in Datavant using the measurement alternative to fair value. The investment will be remeasured upon future observable price changes in orderly transactions or upon impairment, if any. The Company recognized a gain on deconsolidation of $<ix:nonFraction name="us-gaap:DeconsolidationGainOrLossAmount" contextRef="P04_01_2020To03_31_2021_DatavantHoldingsIncMemberdeiLegalEntityAxis" unitRef="Unit_USD" decimals="-5" scale="6" format="ixt:numdotdecimal">86.5</ix:nonFraction>&#160;million in the accompanying consolidated statements of operations for the year ended March&#160;31, 2021. In July 2020, Datavant issued and sold <ix:nonFraction name="roiv:PreferredStockSharesIssuedAndSoldToCompanyDuringPeriodShares" contextRef="PAsOn07_31_2021" unitRef="Unit_shares" decimals="INF" scale="0" format="ixt:numdotdecimal">639,140</ix:nonFraction> Series B preferred shares to RSL at a price consistent with that of the initial round of Datavant&#8217;s Series B equity raise. At March&#160;31, 2021, the carrying value of the Company&#8217;s investment in Datavant was $<ix:nonFraction name="us-gaap:LongTermInvestments" contextRef="PAsOn03_31_2021_DatavantHoldingsIncMemberdeiLegalEntityAxis" unitRef="Unit_USD" decimals="-5" scale="6" format="ixt:numdotdecimal">100.6</ix:nonFraction>&#160;million. </div></div> </ix:continuation> <ix:nonNumeric name="roiv:AssetAcquisitionsAndLicenseAgreementsDisclosureTextBlock" contextRef="P04_01_2020To03_31_2021" escape="true" continuedAt="TextSelection_28230352"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Note 4&#8212;Asset Acquisitions and License Agreements </div></div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">During the years ended March&#160;31, 2021 and 2020, the Company, directly or indirectly through Vants, completed the following key asset acquisitions and license agreements. The Company evaluated the below agreements, except the collaboration and license agreement entered into between Dermavant and Japan Tobacco Inc. that is evaluated separately below, and determined that the acquired assets did not meet the definition of a business as substantially all the fair value of the assets acquired were concentrated in a single asset or group of similar assets and/or the acquired assets were not capable of producing outputs due to the lack of an assembled workforce and early stage of development and thus, each transaction was accounted for as an asset acquisition. </div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">The Company then evaluated whether each <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">in-process</div> research and development asset had an alternative future use and concluded it did not. As a result, the Company recorded the consideration attributable to <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">in-process</div> research and development under the below agreements as research and development expense in the accompanying consolidated statements of operations for the years ended March&#160;31, 2021 and 2020. </div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Dermavant </div></div></div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">In August 2018, Dermavant acquired the worldwide rights (other than with respect to certain rights in China) to tapinarof, an investigational therapeutic aryl hydrocarbon receptor modulating agent for the treatment of psoriasis and atopic dermatitis, from GlaxoSmithKline Intellectual Property Development Ltd. and Glaxo Group Limited (collectively &#8220;GSK&#8221;) pursuant to an asset purchase agreement (the &#8220;GSK Agreement&#8221;). GSK previously acquired rights to a predecessor formulation of tapinarof from Welichem Biotech Inc. (&#8220;Welichem&#8221;) pursuant to an asset </div></div></ix:nonNumeric> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">F-<div style="letter-spacing: 0px; top: 0px;;display:inline;">18</div> </div></div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;;font-weight: bold;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><a href="#toc" style="text-indent: 0px;">Table of Contents</a></div></div> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"><ix:continuation id="TextSelection_28230352" continuedAt="TextSelectionAppend_28230352_1"> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">purchase agreement between GSK and Welichem entered into in May 2012 (the &#8220;Welichem Agreement&#8221;). Under the GSK Agreement, Dermavant made an upfront payment of &#163;<ix:nonFraction name="roiv:UpfrontCashPayments" contextRef="P05_01_2012To05_31_2012_DermavantSciencesLtdMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis" unitRef="Unit_EUR" decimals="-5" scale="6" format="ixt:numdotdecimal">150.0</ix:nonFraction>&#160;million (approximately $<ix:nonFraction name="roiv:UpfrontCashPayments" contextRef="P05_01_2012To05_31_2012_DermavantSciencesLtdMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:numdotdecimal">191</ix:nonFraction> million) and agreed to a contingent payment of &#163;<ix:nonFraction name="roiv:BusinessCollaborationContingentMilestonePayment" contextRef="P05_01_2012To05_31_2012_DermavantSciencesLtdMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis" unitRef="Unit_EUR" decimals="-5" scale="6" format="ixt:numdotdecimal">100.0</ix:nonFraction>&#160;million (approximately $<ix:nonFraction name="roiv:BusinessCollaborationContingentMilestonePayment" contextRef="P05_01_2012To05_31_2012_DermavantSciencesLtdMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:numdotdecimal">133</ix:nonFraction> million) upon the first approval of an NDA by the FDA for a product that contains tapinarof. Dermavant assumed responsibility for all obligations under the Welichem Agreement, including payment of up to C$<ix:nonFraction name="roiv:FutureDevelopmentAndCommercialMilestonePayments" contextRef="P05_01_2012To05_31_2012_DermavantSciencesLtdMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis" unitRef="Unit_CAD" decimals="-5" scale="6" format="ixt:numdotdecimal">180.0</ix:nonFraction>&#160;million (approximately $<ix:nonFraction name="roiv:FutureDevelopmentAndCommercialMilestonePayments" contextRef="P05_01_2012To05_31_2012_DermavantSciencesLtdMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:numdotdecimal">137</ix:nonFraction> million) in potential development and commercial milestones. The purchase was funded in part by a $<ix:nonFraction name="us-gaap:LongTermDebt" contextRef="PAsOn05_31_2012_DermavantSciencesLtdMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis" unitRef="Unit_USD" decimals="-5" scale="6" format="ixt:numdotdecimal">117.5</ix:nonFraction>&#160;million borrowing from NovaQuest <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">Co-Investment</div> Fund VIII, L.P. (&#8220;NovaQuest&#8221;), an affiliate of NovaQuest Capital Management, LLC, as described in Note 8, &#8220;Long-Term Debt.&#8221; In connection with the GSK Agreement, Dermavant and GSK have entered into a clinical manufacturing and supply agreement for tapinarof pursuant to which Dermavant will obtain supply of tapinarof for clinical trials on a cost-plus basis. In May 2019, Dermavant achieved a development and regulatory milestone under the GSK Agreement, which resulted in a C$<ix:nonFraction name="roiv:MilestonePayment" contextRef="P08_01_2019To08_31_2019_DermavantSciencesLtdMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis" unitRef="Unit_CAD" decimals="-5" scale="6" format="ixt:numdotdecimal">30.0</ix:nonFraction>&#160;million (approximately $<ix:nonFraction name="roiv:MilestonePayment" contextRef="P08_01_2019To08_31_2019_DermavantSciencesLtdMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:numdotdecimal">23</ix:nonFraction> million) milestone payment that Dermavant subsequently paid to Welichem in August 2019. The milestone payment was recorded as research and development expense in the accompanying consolidated statements of operations for the year ended March&#160;31, 2020. </div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">In January 2020, Dermavant entered into a collaboration and license agreement with Japan Tobacco Inc. (&#8220;JT&#8221;) for exclusive rights to develop, register, and market tapinarof in Japan for the treatment of dermatological diseases and conditions, including psoriasis and atopic dermatitis. In conjunction with this agreement, JT executed an exclusive license agreement with its subsidiary, Torii Pharmaceutical Co., Ltd., for <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">co-development</div> and commercialization of tapinarof in Japan. Under the terms of the license agreement, Dermavant received a nonrefundable, upfront payment of $<ix:nonFraction name="roiv:NonRefundableUpfrontPaymentReceived" contextRef="P01_01_2020To01_31_2020_DermavantSciencesLtdMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis" unitRef="Unit_USD" decimals="-5" scale="6" format="ixt:numdotdecimal">60.0</ix:nonFraction>&#160;million in January 2020 and may receive up to $<ix:nonFraction name="roiv:PotentialMilestonePaymentReceivable" contextRef="P01_01_2020To01_31_2020_DermavantSciencesLtdMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis" unitRef="Unit_USD" decimals="-5" scale="6" format="ixt:numdotdecimal">53.0</ix:nonFraction>&#160;million upon the achievement of certain development milestones for tapinarof for the treatment of psoriasis and atopic dermatitis. In addition, Dermavant will have the right to receive royalties based on product sales of tapinarof in the indications. </div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">The Company evaluated the collaboration and license agreement and concluded that JT is a customer. The Company&#8217;s performance obligations under the agreement are the following: (i)&#160;an exclusive license to JT of the right to develop, register and market tapinarof in Japan and (ii)&#160;the associated transfer to JT of technology and <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">know-how</div> related to the license. The Company determined that the monetary value of participation in the Joint Steering Committee under the agreement was immaterial in the context of the contract and therefore was disregarded when identifying the performance obligations. The Company determined that the exclusive license is not capable of being distinct from the associated technology transfer because the customer cannot benefit from or utilize the license without the technology and <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">know-how</div> transfer and as such does not have standalone value as JT cannot benefit from the exclusive license without the associated technology and <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">know-how</div> transfer. Accordingly, the Company concluded that these performance obligations should be combined into a single performance obligation. </div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">Based on management&#8217;s evaluation, the <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-refundable,</div> <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">up-front</div> payment of $<ix:nonFraction name="roiv:NonRefundableUpfrontPaymentReceived" contextRef="P01_01_2020To01_31_2020_DermavantSciencesLtdMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis" unitRef="Unit_USD" decimals="-5" scale="6" format="ixt:numdotdecimal">60.0</ix:nonFraction>&#160;million constituted the amount of consideration to be included in the transaction price. The remaining $<ix:nonFraction name="roiv:PotentialMilestonePaymentReceivable" contextRef="P01_01_2020To01_31_2020_DermavantSciencesLtdMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis" unitRef="Unit_USD" decimals="-5" scale="6" format="ixt:numdotdecimal">53.0</ix:nonFraction>&#160;million of consideration related to potential development and regulatory approval milestones constitutes variable consideration and has not been recognized because of the inherent uncertainty of the occurrence of the future events and because it is highly susceptible to factors outside of the Company&#8217;s control. Any consideration related to potential royalty payments will be recognized when the related sales occur, since these amounts have been determined to relate predominantly to the license granted to JT and therefore are recognized at the later of when the performance obligations are satisfied or the related sales occur.&#160;The Company will <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">re-evaluate</div> the transaction price in each reporting period and as uncertain events are resolved or other changes in circumstances occur. Upon transfer of the technology and <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">know-how</div> related to the license, the Company recognized the $<ix:nonFraction name="us-gaap:RevenueRecognitionMilestoneMethodRevenueRecognized" contextRef="P04_01_2019To03_31_2020_DermavantSciencesLtdMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis" unitRef="Unit_USD" decimals="-5" scale="6" format="ixt:numdotdecimal">60.0</ix:nonFraction>&#160;million <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-refundable</div> upfront payment as license revenue in the accompanying consolidated statements of operations for the year ended March&#160;31, 2020. </div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </ix:continuation> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">F-<div style="letter-spacing: 0px; top: 0px;;display:inline;">19</div> </div></div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;;font-weight: bold;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><a href="#toc" style="text-indent: 0px;">Table of Contents</a></div></div> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"><ix:continuation id="TextSelectionAppend_28230352_1" continuedAt="TextSelectionAppend_28230352_2"> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Genevant </div></div></div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;">In July 2020, RSL increased its investment in Genevant Sciences Ltd. (&#8220;Genevant&#8221;) as part of a recapitalization transaction (the &#8220;Recapitalization&#8221;). Genevant, an entity focused on the discovery, development, and commercialization of a broad range of <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">RNA-based</div> therapeutics enabled by Arbutus&#8217; proprietary lipid nanoparticle and ligand conjugate delivery technologies, was created in April 2018 as part of an agreement between RSL and Arbutus. As part of the initial transaction entered into in April 2018, RSL contributed $<ix:nonFraction name="us-gaap:PaymentsToAcquireEquityMethodInvestments" contextRef="P04_01_2018To04_30_2018_GenevantSciencesLtdMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis" unitRef="Unit_USD" decimals="-5" scale="6" format="ixt:numdotdecimal">38.7</ix:nonFraction>&#160;million in cash, including transaction costs, for an equity ownership interest in Genevant. Prior to the Recapitalization, RSL accounted for its investment in Genevant under the equity method of accounting as it had determined that it was not the primary beneficiary of Genevant since it did not have the power to direct its most significant activities. Additionally, RSL made additional investments in the form of promissory notes issued by Genevant amounting to $<ix:nonFraction name="us-gaap:ProceedsFromNotesPayable" contextRef="P05_01_2018To06_30_2020_GenevantSciencesLtdMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis" unitRef="Unit_USD" decimals="-5" scale="6" format="ixt:numdotdecimal">20.1</ix:nonFraction>&#160;million aggregate principal amount outstanding (the &#8220;Genevant Outstanding Notes&#8221;) prior to the Recapitalization. RSL applied its share of losses relating to its equity method investment in Genevant against the Company&#8217;s carrying value of its investment in Genevant&#8217;s common shares and against the carrying value of the Genevant Outstanding Notes. The carrying value of RSL&#8217;s investment in Genevant was reduced to zero prior to the Recapitalization. </div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Pursuant to the Recapitalization, the following transactions were completed: </div></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Genevant issued <ix:nonFraction name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" contextRef="P07_31_2020To07_31_2020_GenevantSciencesLtdMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis" unitRef="Unit_shares" decimals="INF" scale="0" format="ixt:numdotdecimal">74,272,043</ix:nonFraction> common shares to RSL for an aggregated purchase price of $<ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueNewIssues" contextRef="P07_31_2020To07_31_2020_GenevantSciencesLtdMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis" unitRef="Unit_USD" decimals="-5" scale="6" format="ixt:numdotdecimal">20.5</ix:nonFraction>&#160;million; </div></div> </td> </tr> </table> <div style="clear: both; max-height: 0px;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">$<ix:nonFraction name="us-gaap:DebtConversionOriginalDebtAmount1" contextRef="P07_31_2020To07_31_2020_GenevantSciencesLtdMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis" unitRef="Unit_USD" decimals="-5" scale="6" format="ixt:numdotdecimal">15.1</ix:nonFraction>&#160;million aggregate principal amount of the Genevant Outstanding Notes were converted into <ix:nonFraction name="us-gaap:DebtConversionConvertedInstrumentSharesIssued1" contextRef="P07_31_2020To07_31_2020_GenevantSciencesLtdMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis" unitRef="Unit_shares" decimals="INF" scale="0" format="ixt:numdotdecimal">54,526,549</ix:nonFraction> common shares; and </div></div> </td> </tr> </table> <div style="clear: both; max-height: 0px;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Genevant issued <ix:nonFraction name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" contextRef="P07_31_2020To07_31_2020_ArbutusBiopharmaCorporationMemberdeiLegalEntityAxis_GenevantSciencesLtdMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis" unitRef="Unit_shares" decimals="INF" scale="0" format="ixt:numdotdecimal">9,057,566</ix:nonFraction> common shares to Arbutus for an aggregated purchase price of $<ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueNewIssues" contextRef="P07_31_2020To07_31_2020_ArbutusBiopharmaCorporationMemberdeiLegalEntityAxis_GenevantSciencesLtdMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis" unitRef="Unit_USD" decimals="-5" scale="6" format="ixt:numdotdecimal">2.5</ix:nonFraction>&#160;million. </div></div> </td> </tr> </table> <div style="clear: both; max-height: 0px;"></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Following the Recapitalization, RSL held an <ix:nonFraction name="roiv:PercentageOfControllingInterestHeld" contextRef="PAsOn07_31_2020_GenevantSciencesLtdMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis" unitRef="Unit_pure" decimals="3" scale="-2" format="ixt:numdotdecimal">82.9</ix:nonFraction>% controlling interest in Genevant. </div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Concurrent with the Recapitalization, the composition of Genevant&#8217;s Board of Directors was restructured to include two directors designated by RSL and one director who is a senior officer of Genevant. </div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">As a result of the Recapitalization and changes to the <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">bye-laws,</div> RSL determined that it controls the most significant activities of Genevant and is the primary beneficiary of Genevant following the Recapitalization. As such, RSL began consolidating Genevant into the Company&#8217;s consolidated financial statements from the date of the Recapitalization. The Company evaluated the acquired set of assets and activities and determined that the acquired set did not meet the definition of a business and thus the transaction was not considered a business combination. </div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">The transactions completed as part of the Recapitalization represent an acquisition achieved in stages, which required the remeasurement of RSL&#8217;s previously held interest in Genevant. As such, RSL&#8217;s investments in Genevant were remeasured to fair value of $<ix:nonFraction name="us-gaap:InvestmentsInAffiliatesSubsidiariesAssociatesAndJointVenturesFairValueDisclosure" contextRef="PAsOn03_31_2021_GenevantSciencesLtdMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis" unitRef="Unit_USD" decimals="-5" scale="6" format="ixt:numdotdecimal">28.8</ix:nonFraction>&#160;million, also resulting in a gain of $<ix:nonFraction name="us-gaap:GainLossOnInvestments" contextRef="P04_01_2020To03_31_2021_GenevantSciencesLtdMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis" unitRef="Unit_USD" decimals="-5" scale="6" format="ixt:numdotdecimal">28.8</ix:nonFraction>&#160;million in the accompanying consolidated statements of operations for the year ended March&#160;31, 2021. Along with the fair value of noncontrolling interests in Genevant of $<ix:nonFraction name="us-gaap:EquityMethodInvestmentsFairValueDisclosure" contextRef="PAsOn03_31_2021_GenevantSciencesLtdMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis" unitRef="Unit_USD" decimals="-5" scale="6" format="ixt:numdotdecimal">9.2</ix:nonFraction>&#160;million and cash paid of $<ix:nonFraction name="us-gaap:PaymentsToAcquireInterestInSubsidiariesAndAffiliates" contextRef="P04_01_2020To03_31_2021_GenevantSciencesLtdMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis" unitRef="Unit_USD" decimals="-5" scale="6" format="ixt:numdotdecimal">20.5</ix:nonFraction>&#160;million for common shares of Genevant as part of the Recapitalization, total consideration paid was $<ix:nonFraction name="us-gaap:BusinessCombinationConsiderationTransferred1" contextRef="P07_01_2020To07_31_2020_GenevantSciencesLtdMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis" unitRef="Unit_USD" decimals="-5" scale="6" format="ixt:numdotdecimal">58.5</ix:nonFraction>&#160;million. Of this amount, $<ix:nonFraction name="us-gaap:ResearchAndDevelopmentExpense" contextRef="P04_01_2020To03_31_2021_GenevantSciencesLtdMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis" unitRef="Unit_USD" decimals="-5" scale="6" format="ixt:numdotdecimal">41.4</ix:nonFraction>&#160;million was attributed to <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">in-process</div> research and development, which was determined by the Company to have not reached technological feasibility and therefore have no alternative future use. Accordingly, the Company recorded $<ix:nonFraction name="us-gaap:ResearchAndDevelopmentExpense" contextRef="P04_01_2020To03_31_2021_GenevantSciencesLtdMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis" unitRef="Unit_USD" decimals="-5" scale="6" format="ixt:numdotdecimal">41.4</ix:nonFraction>&#160;million as research and development expense in the accompanying consolidated statements of operations for the year ended March&#160;31, 2021. </div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Proteovant </div></div></div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">In November 2020, Proteovant Sciences, Inc. (formerly known as Pharmavant 5, Inc.) (&#8220;ProteoVant&#8221;) entered into a stock purchase agreement to acquire Oncopia Therapeutics, Inc. (&#8220;Oncopia&#8221;), a preclinical biotechnology </div></div> </ix:continuation> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">F-<div style="letter-spacing: 0px; top: 0px;;display:inline;">20</div> </div></div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;;font-weight: bold;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><a href="#toc" style="text-indent: 0px;">Table of Contents</a></div></div> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"><ix:continuation id="TextSelectionAppend_28230352_2" continuedAt="TextSelectionAppend_28230352_3"> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">company developing small molecule protein degraders primarily against certain oncology targets. Upfront proceeds to Oncopia&#8217;s shareholders were $<ix:nonFraction name="roiv:PaymentForUpfrontPayments" contextRef="PAsOn11_30_2020_ProteovantSciencesIncMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis" unitRef="Unit_USD" decimals="-5" scale="6" format="ixt:numdotdecimal">105.0</ix:nonFraction>&#160;million, prior to certain adjustments in accordance with the terms of the agreement. Proteovant is also obligated to make future development and commercial milestone payments of up to $<ix:nonFraction name="roiv:MilestonePayment" contextRef="P01_01_2021To01_31_2021_ProteovantSciencesIncMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis" unitRef="Unit_USD" decimals="-5" scale="6" format="ixt:numdotdecimal">100.0</ix:nonFraction>&#160;million for the first product targeting each of the two specified initial targets, and up to $<ix:nonFraction name="roiv:FutureDevelopmentAndCommercialMilestonePayments" contextRef="P11_01_2020To11_30_2020_FirstProductTargetsEachOfCertainSpecifiedAdditionalMoleculartargetsMemberROIVMilestoneEventsAxis_MaximumMembersrtRangeAxis_ProteovantSciencesIncMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis" unitRef="Unit_USD" decimals="-5" scale="6" format="ixt:numdotdecimal">51.0</ix:nonFraction>&#160;million for the first product targeting each of certain specified additional molecular targets. Additionally, the Company&#8217;s investments in promissory notes issued by Oncopia for an aggregate principal amount of $<ix:nonFraction name="us-gaap:DebtConversionOriginalDebtAmount1" contextRef="P11_01_2020To11_30_2020_ProteovantSciencesIncMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis" unitRef="Unit_USD" decimals="-5" scale="6" format="ixt:numdotdecimal">11.5</ix:nonFraction>&#160;million were settled through either conversion to equity or cancellation. </div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">Oncopia&#8217;s intellectual property was developed by the University of Michigan laboratory run by Oncopia&#8217;s <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">co-founder</div> (the <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">&#8220;Co-Founder&#8221;).</div> In connection with Proteovant&#8217;s acquisition, Oncopia amended and restated its existing license agreements with the University of Michigan. Under the new license agreement, Oncopia will be obligated to make future development and commercial milestone payments of up to $<ix:nonFraction name="roiv:FutureDevelopmentAndCommercialMilestonePayments" contextRef="P11_01_2020To11_30_2020_FirstProductFirstProductForEachMolecularTargetCoveredByIntellectualPropertyMemberROIVMilestoneEventsAxis_MaximumMembersrtRangeAxis_ProteovantSciencesIncMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis" unitRef="Unit_USD" decimals="-5" scale="6" format="ixt:numdotdecimal">8.6</ix:nonFraction>&#160;million for the first product for each molecular target covered by intellectual property included in the agreement, in addition to paying tiered royalties on net sales ranging from <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">low-</div> to <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">mid-single</div> digits, subject to certain adjustments. </div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">The <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">Co-Founder&#8217;s</div> lab at the University of Michigan had been providing <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">on-going</div> discovery and optimization services to Oncopia under a sponsored research agreement (the &#8220;SRA&#8221;). Immediately after closing the acquisition, Oncopia extended the SRA through at least December&#160;31, 2023, and expanded the potential molecular targets to be pursued under the SRA. As revised, Oncopia is obligated to pay the University of Michigan approximately $<ix:nonFraction name="roiv:PaymentUnderSponsoredResearchAgreement" contextRef="P11_01_2020To11_30_2020_ProteovantSciencesIncMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis" unitRef="Unit_USD" decimals="-5" scale="6" format="ixt:numdotdecimal">15.5</ix:nonFraction>&#160;million under the SRA. </div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">Lastly, in connection with the acquisition of Oncopia, the <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">Co-Founder</div> entered into an agreement with the Company to serve as a consultant. In exchange for these services, the Company has agreed to grant the <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">Co-Founder</div> RSL restricted stock units for which the majority will vest upon achievement of development milestones for products directed to targets for which no milestones are payable to Oncopia shareholders and the remaining portion will be subject to time-based service requirements. All of these restricted stock units are subject to a liquidity requirement to vest. The Company will also make a cash payment to the <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">Co-Founder</div> upon achievement of development milestones for each such product. </div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">During the year ended March&#160;31, 2021, the Company recorded $<ix:nonFraction name="us-gaap:ResearchAndDevelopmentExpense" contextRef="P04_01_2020To03_31_2021_ProteovantSciencesIncMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis" unitRef="Unit_USD" decimals="-5" scale="6" format="ixt:numdotdecimal">116.5</ix:nonFraction>&#160;million, relating to the net upfront cash payment of $<ix:nonFraction name="roiv:UpfrontCashPayments" contextRef="P04_01_2020To03_31_2021_ProteovantSciencesIncMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis" unitRef="Unit_USD" decimals="-5" scale="6" format="ixt:numdotdecimal">101.2</ix:nonFraction>&#160;million, settlement of promissory notes receivable, including accrued interest, of $<ix:nonFraction name="us-gaap:RepaymentOfNotesReceivableFromRelatedParties" contextRef="P04_01_2020To03_31_2021_ProteovantSciencesIncMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis" unitRef="Unit_USD" decimals="-5" scale="6" format="ixt:numdotdecimal">11.9</ix:nonFraction>&#160;million, and fair value of future contingent consideration payments of $<ix:nonFraction name="us-gaap:BusinessCombinationContingentConsiderationLiability" contextRef="PAsOn03_31_2021_ProteovantSciencesIncMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis" unitRef="Unit_USD" decimals="-5" scale="6" format="ixt:numdotdecimal">3.4</ix:nonFraction>&#160;million, as research and development expense in the accompanying consolidated statements of operations. </div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">In December 2020, RSL, Proteovant and SK, Inc. (formerly known as SK Holdings Co., Ltd.) (&#8220;SK&#8221;) entered into a subscription agreement (the &#8220;Subscription Agreement&#8221;) pursuant to which SK agreed to make a $<ix:nonFraction name="us-gaap:EquityMethodInvestmentUnderlyingEquityInNetAssets" contextRef="PAsOn12_31_2020_ProteovantSciencesIncMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis" unitRef="Unit_USD" decimals="-5" scale="6" format="ixt:numdotdecimal">200.0</ix:nonFraction>&#160;million equity investment in Proteovant, representing an ownership interest of <ix:nonFraction name="us-gaap:SubsidiaryOrEquityMethodInvesteeCumulativePercentageOwnershipAfterAllTransactions" contextRef="P12_01_2020To12_31_2020_ProteovantSciencesIncMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis" unitRef="Unit_pure" decimals="3" scale="-2" format="ixt:numdotdecimal">40.0</ix:nonFraction>% on the closing date. In January 2021, in accordance with the terms of the Subscription Agreement, SK made the first payment of $<ix:nonFraction name="us-gaap:StockholdersEquityNoteSubscriptionsReceivable" contextRef="PAsOn01_31_2021_ProteovantSciencesIncMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis" unitRef="Unit_USD" decimals="-5" scale="6" format="ixt:numdotdecimal">100.0</ix:nonFraction>&#160;million to Proteovant. A second $<ix:nonFraction name="roiv:FutureDevelopmentAndCommercialMilestonePayments" contextRef="P11_01_2020To11_30_2020_FirstProductTargetsTargetingEachOfTwoSpecifiedInitialTargetsMemberROIVMilestoneEventsAxis_MaximumMembersrtRangeAxis_ProteovantSciencesIncMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis" unitRef="Unit_USD" decimals="-5" scale="6" format="ixt:numdotdecimal">100.0</ix:nonFraction>&#160;million payment is expected to be made by SK to Proteovant on or about July&#160;12, 2021, the date six months from the closing date. The second $<ix:nonFraction name="us-gaap:StockholdersEquityNoteSubscriptionsReceivable" contextRef="PAsOn03_31_2021" unitRef="Unit_USD" decimals="-5" scale="6" format="ixt:numdotdecimal">100.0</ix:nonFraction>&#160;million payment is classified as a subscription receivable in the accompanying consolidated balance sheets and consolidated statements of shareholders&#8217; equity and redeemable noncontrolling interest as of March&#160;31, 2021. </div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Affivant </div></div></div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;">In November 2020, RSL and its indirect subsidiary Affivant Sciences GmbH (&#8220;Affivant&#8221;) entered into a licensing and strategic collaboration agreement with Affimed N.V. (&#8220;Affimed&#8221;) to develop and commercialize novel innate cell engagers for multiple cancer targets in exchange for consideration that includes $<ix:nonFraction name="roiv:UpfrontCashPayments" contextRef="P11_01_2020To11_30_2020_AffivantSciencesMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis" unitRef="Unit_USD" decimals="-5" scale="6" format="ixt:numdotdecimal">40.0</ix:nonFraction>&#160;million in upfront cash and <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">pre-paid</div> R&amp;D funding and $<ix:nonFraction name="roiv:StockIssuedDuringPeriodValue" contextRef="P11_01_2020To11_30_2020_AffivantSciencesMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis" unitRef="Unit_USD" decimals="-5" scale="6" format="ixt:numdotdecimal">20.0</ix:nonFraction>&#160;million of newly issued shares in RSL. Affimed could receive further short-term proceeds in the form of option fees contingent on the commencement of additional programs contemplated under the agreement. Affimed is eligible to receive up to an additional approximately $<ix:nonFraction name="roiv:FutureDevelopmentAndCommercialMilestonePayments" contextRef="P11_01_2020To11_30_2020_AffivantSciencesMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis_MaximumMembersrtRangeAxis" unitRef="Unit_USD" decimals="-8" scale="9" format="ixt:numdotdecimal">2.0</ix:nonFraction>&#160;billion in milestones over time upon achievement of specified development, regulatory and commercial milestones, as well as tiered royalties on net sales. </div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </ix:continuation> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">F-<div style="letter-spacing: 0px; top: 0px;;display:inline;">21</div> </div></div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;;font-weight: bold;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><a href="#toc" style="text-indent: 0px;">Table of Contents</a></div></div> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"><ix:continuation id="TextSelectionAppend_28230352_3"> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Acquisition of Silicon Therapeutics </div></div></div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">In March 2021, the Company completed the acquisition of the business of Silicon Therapeutics, LLC (&#8220;SiTX&#8221;), a physics-driven computational drug discovery company, for total consideration of approximately $<ix:nonFraction name="us-gaap:BusinessCombinationConsiderationTransferred1" contextRef="P03_01_2021To03_31_2021_SiliconTherapeuticsMemberusgaapBusinessAcquisitionAxis" unitRef="Unit_USD" decimals="-5" scale="6" format="ixt:numdotdecimal">450.0</ix:nonFraction>&#160;million, with additional cash payments payable subject to the satisfaction of certain regulatory and commercial milestones. This acquisition did not include one of SiTX&#8217;s subsidiaries, Silicon SWAT, Inc. Approximately $<ix:nonFraction name="us-gaap:BusinessCombinationConsiderationTransferredLiabilitiesIncurred" contextRef="P03_01_2021To03_31_2021_FirstTrancheMemberusgaapRestructuringPlanAxis_SiliconTherapeuticsMemberusgaapBusinessAcquisitionAxis" unitRef="Unit_USD" decimals="-5" scale="6" format="ixt:numdotdecimal">350.0</ix:nonFraction>&#160;million of the consideration was payable primarily in the Company&#8217;s common stock at or near closing of the acquisition (the &#8220;First Tranche&#8221;). At closing of the acquisition, the Company issued <ix:nonFraction name="us-gaap:BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued" contextRef="P03_01_2021To03_31_2021_SiliconTherapeuticsMemberusgaapBusinessAcquisitionAxis" unitRef="Unit_shares" decimals="INF" scale="0" format="ixt:numdotdecimal">7,316,583</ix:nonFraction> common shares and paid approximately $<ix:nonFraction name="us-gaap:PaymentsToAcquireBusinessesNetOfCashAcquired" contextRef="P03_01_2021To03_31_2021_SiliconTherapeuticsMemberusgaapBusinessAcquisitionAxis" unitRef="Unit_USD" decimals="-5" scale="6" format="ixt:numdotdecimal">14.0</ix:nonFraction>&#160;million in cash, net of cash received, to SiTX after giving effect to certain transaction adjustments and holdbacks. The remainder of the First Tranche is expected to be paid in a combination of common shares and cash as certain holdbacks are released. Approximately $<ix:nonFraction name="us-gaap:BusinessCombinationConsiderationTransferredLiabilitiesIncurred" contextRef="P03_01_2021To03_31_2021_SecondTrancheMemberusgaapRestructuringPlanAxis_SiliconTherapeuticsMemberusgaapBusinessAcquisitionAxis" unitRef="Unit_USD" decimals="-5" scale="6" format="ixt:numdotdecimal">100.0</ix:nonFraction>&#160;million (the &#8220;Second Tranche Consideration&#8221;) is payable to SiTX on the earlier of (x)&#160;approximately 30 to 60 days following the public listing of the Company&#8217;s common shares, in either cash or common shares (at the Company&#8217;s election), and (y) 12 months following the closing of the acquisition, in cash. </div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The transaction was accounted for as an asset acquisition as substantially all of the fair value of the assets acquired were concentrated in a single asset, IPR&amp;D related to the computational drug discovery platform that designs and develops small molecule therapeutics. For accounting purposes, the fair value of consideration transferred was $<ix:nonFraction name="us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet" contextRef="PAsOn03_31_2021_SiliconTherapeuticsMemberusgaapBusinessAcquisitionAxis" unitRef="Unit_USD" decimals="-5" scale="6" format="ixt:numdotdecimal">402.4</ix:nonFraction>&#160;million, consisting of $<ix:nonFraction name="us-gaap:BusinessAcquisitionEquityInterestIssuedOrIssuableValueAssigned" contextRef="PAsOn03_31_2021_SiliconTherapeuticsMemberusgaapBusinessAcquisitionAxis" unitRef="Unit_USD" decimals="-5" scale="6" format="ixt:numdotdecimal">281.7</ix:nonFraction>&#160;million relating to the fair value of common shares issued upfront and expected to be issued shortly thereafter; $<ix:nonFraction name="us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccountsPayable" contextRef="PAsOn03_31_2021_SiliconTherapeuticsMemberusgaapBusinessAcquisitionAxis" unitRef="Unit_USD" decimals="-5" scale="6" format="ixt:numdotdecimal">105.1</ix:nonFraction>&#160;million relating to the fair value of liabilities due to the sellers, including the Second Tranche Consideration, future contingent consideration payments, and closing consideration to be paid in cash; and cash of $<ix:nonFraction name="us-gaap:PaymentsToAcquireBusinessesNetOfCashAcquired" contextRef="P04_01_2020To03_31_2021_SiliconTherapeuticsMemberusgaapBusinessAcquisitionAxis" unitRef="Unit_USD" decimals="-5" scale="6" format="ixt:numdotdecimal">15.6</ix:nonFraction>&#160;million paid at closing. Of this amount, $<ix:nonFraction name="us-gaap:ResearchAndDevelopmentExpense" contextRef="P04_01_2020To03_31_2021_SiliconTherapeuticsMemberusgaapBusinessAcquisitionAxis" unitRef="Unit_USD" decimals="-5" scale="6" format="ixt:numdotdecimal">399.6</ix:nonFraction>&#160;million was attributed to IPR&amp;D, which was determined to have no alternative future use. Accordingly, the Company recorded $<ix:nonFraction name="us-gaap:ResearchAndDevelopmentExpense" contextRef="P04_01_2020To03_31_2021_SiliconTherapeuticsMemberusgaapBusinessAcquisitionAxis" unitRef="Unit_USD" decimals="-5" scale="6" format="ixt:numdotdecimal">399.6</ix:nonFraction>&#160;million as research and development expense in the accompanying consolidated statement of operations for the year ended March&#160;31, 2021. </div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">In connection with the transaction, the vesting of certain outstanding SiTX share-based compensation awards held by employees of SiTX was discretionarily accelerated at closing. As a result, the Company recorded share-based compensation expense of $<ix:nonFraction name="us-gaap:ShareBasedCompensation" contextRef="P04_01_2020To03_31_2021_SiliconTherapeuticsMemberusgaapBusinessAcquisitionAxis" unitRef="Unit_USD" decimals="-5" scale="6" format="ixt:numdotdecimal">23.5</ix:nonFraction>&#160;million in the accompanying consolidated statements of operations for the year ended March&#160;31, 2021. </div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">In addition, certain share-based compensation awards of SiTX were exchanged with restricted common stock of the Company, subject to certain service-based vesting requirements, with a fair value of $<ix:nonFraction name="roiv:FairValueOfCommonShares" contextRef="PAsOn03_31_2021_SiliconTherapeuticsMemberusgaapBusinessAcquisitionAxis" unitRef="Unit_USD" decimals="-5" scale="6" format="ixt:numdotdecimal">22.6</ix:nonFraction>&#160;million. Of this amount, $<ix:nonFraction name="roiv:FairValueOfRestrictedStock" contextRef="P04_01_2020To03_31_2021_SiliconTherapeuticsMemberusgaapBusinessAcquisitionAxis" unitRef="Unit_USD" decimals="-5" scale="6" format="ixt:numdotdecimal">15.6</ix:nonFraction> million was attributed to precombination service and therefore included in the total fair value of consideration transferred. Refer to Note 11, &#8220;Share-Based Compensation,&#8221; for additional detail regarding this restricted common stock. </div></div> </ix:continuation> <ix:nonNumeric name="roiv:TransactionAgreementDisclosureTextBlock" contextRef="P04_01_2020To03_31_2021" escape="true" continuedAt="TextSelection_28230213"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt; text-indent: 0px;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Note 5&#8212;Sumitomo Transaction Agreement </div></div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt; text-indent: 0px;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">On December&#160;27, 2019 (the &#8220;Sumitomo Closing Date&#8221;), RSL and Sumitomo completed the transactions contemplated by the Sumitomo Transaction Agreement. Pursuant to the Sumitomo Transaction Agreement, RSL transferred its entire ownership interest in Myovant, Urovant, Enzyvant, Altavant, and Spirovant to a newly formed, wholly-owned entity (&#8220;Sumitovant&#8221;). </div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt; text-indent: 0px;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">RSL&#8217;s ownership interest in Sumitovant was then transferred to Sumitomo, such that following the Sumitomo Closing Date, Sumitovant and its subsidiaries, including the Sumitovant Vants, were each directly or indirectly owned by Sumitomo. Additionally, in connection with the Sumitomo Transaction Agreement, RSL (i)&#160;granted Sumitomo options to purchase all, or in the case of Dermavant, <ix:nonFraction name="roiv:PercentageOfGrantedOptionToPurchaseOwnershipInterest" contextRef="P12_27_2019To12_27_2019_SumitomoMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis" unitRef="Unit_pure" decimals="2" scale="-2" format="ixt:numdotdecimal">75</ix:nonFraction>%, of RSL&#8217;s ownership interests in six other subsidiaries (Dermavant, Genevant, Lysovant Sciences Ltd. (&#8220;Lysovant&#8221;), Metavant Sciences Ltd. (&#8220;Metavant&#8221;), Roivant Asia Cell Therapy Holdings Ltd. (&#8220;Cytovant Parent&#8221;), and Sinovant Sciences HK Limited (&#8220;Sinovant&#8221;)), </div><div style="display:inline;">(ii) (a) transferred the proprietary technology platform DrugOme to Sumitomo (for which RSL retains a perpetual royalty free license for internal use) and (b) licensed the Digital Innovation technology platform to Sumitomo (for which both parties retain ongoing access) and (iii)&#160; </div><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">transferred <ix:nonFraction name="roiv:SaleOfStockNumberOfShareIssuedInTransaction" contextRef="PAsOn12_31_2019_SumitomoMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis" unitRef="Unit_shares" decimals="INF" scale="0" format="ixt:numdotdecimal">26,952,143</ix:nonFraction> common shares of RSL to Sumitomo. On the Sumitomo Closing Date, the Company received approximately $<ix:nonFraction name="us-gaap:SaleOfStockConsiderationReceivedOnTransaction" contextRef="P04_01_2019To03_31_2020_SumitomoMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis" unitRef="Unit_USD" decimals="-8" scale="9" format="ixt:numdotdecimal">2.9</ix:nonFraction>&#160;billion in cash, resulting in a gain of $<ix:nonFraction name="us-gaap:GainOrLossOnSaleOfStockInSubsidiary" contextRef="P04_01_2019To03_31_2020_SumitomoMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis" unitRef="Unit_USD" decimals="-8" scale="9" format="ixt:numdotdecimal">2.0</ix:nonFraction>&#160;billion after taking into account all of the components of the transaction. </div></div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0px;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></ix:nonNumeric> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">F-<div style="letter-spacing: 0px; top: 0px;;display:inline;">22</div> </div></div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;;font-weight: bold;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><a href="#toc" style="text-indent: 0px;">Table of Contents</a></div></div> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"><ix:continuation id="TextSelection_28230213"> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Additionally, on the Sumitomo Closing Date, $<ix:nonFraction name="us-gaap:EscrowDeposit" contextRef="PAsOn12_27_2019_SumitomoMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis" unitRef="Unit_USD" decimals="-5" scale="6" format="ixt:numdotdecimal">75.0</ix:nonFraction>&#160;million of the consideration was deposited into a segregated escrow account for the purpose of fulfilling indemnification obligations of RSL that may become due to Sumitomo. Upon the expiration of the escrow period, being 18 months from the Sumitomo Closing Date, any remaining escrow funds will be disbursed to RSL. As of March&#160;31, 2021, the Company does not believe that a reasonably possible loss of the funds in the escrow account exists. As such, the full escrow amount of $<ix:nonFraction name="us-gaap:RestrictedCash" contextRef="PAsOn03_31_2021_SumitomoMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis" unitRef="Unit_USD" decimals="-5" scale="6" format="ixt:numdotdecimal">75.0</ix:nonFraction>&#160;million was recorded by the Company as restricted cash on the accompanying consolidated balance sheets as of March&#160;31, 2021. In connection with the Sumitomo Transaction, RSL&#8217;s board of directors approved a repurchase of RSL&#8217;s equity securities for up to $<ix:nonFraction name="us-gaap:StockRepurchaseProgramAuthorizedAmount1" contextRef="PAsOn12_31_2019_MaximumMembersrtRangeAxis_SumitomoMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis" unitRef="Unit_USD" decimals="-8" scale="9" format="ixt:numdotdecimal">1.0</ix:nonFraction>&#160;billion of the proceeds received from Sumitomo. Refer to Note 10, &#8220;Shareholders&#8217; Equity and Redeemable Noncontrolling Interest&#8221; for further detail. </div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">In conjunction with the Sumitomo Transaction, certain employees of the Company became employees of Sumitovant or its subsidiaries. The Company issued certain instruments with an aggregate fair value of $<ix:nonFraction name="roiv:AggregateFairValueOfEquityAndLiabilityInstrumentsIssued" contextRef="PAsOn12_31_2019_EmployeeMembersrtTitleOfIndividualAxis_SumitomoMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis" unitRef="Unit_USD" decimals="-5" scale="6" format="ixt:numdotdecimal">39.1</ix:nonFraction>&#160;million to these employees, of which $<ix:nonFraction name="us-gaap:DeferredCompensationEquity" contextRef="PAsOn12_31_2019_EmployeeMembersrtTitleOfIndividualAxis_SumitomoMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis" unitRef="Unit_USD" decimals="-5" scale="6" format="ixt:numdotdecimal">24.8</ix:nonFraction>&#160;million was classified within shareholders&#8217; equity and $<ix:nonFraction name="us-gaap:DeferredCompensationLiabilityCurrent" contextRef="PAsOn12_31_2019_EmployeeMembersrtTitleOfIndividualAxis_SumitomoMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis" unitRef="Unit_USD" decimals="-5" scale="6" format="ixt:numdotdecimal">14.3</ix:nonFraction>&#160;million was classified as a liability. The liability classified awards were subsequently surrendered and exchanged for cash and other newly issued equity as part of the repurchase in March 2020. The remaining instruments vest based on the achievement of time-based, performance or liquidity event requirements. As of March&#160;31, 2021 and 2020, there were <ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber" contextRef="PAsOn03_31_2021_EmployeeMembersrtTitleOfIndividualAxis_SumitomoMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis" unitRef="Unit_shares" decimals="INF" scale="0" format="ixt:numdotdecimal">1,865,416</ix:nonFraction> and <ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber" contextRef="PAsOn03_31_2020_EmployeeMembersrtTitleOfIndividualAxis_SumitomoMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis" unitRef="Unit_shares" decimals="INF" scale="0" format="ixt:numdotdecimal">1,880,980</ix:nonFraction> outstanding instruments, respectively, held by Sumitovant employees for which aggregate fair value was recorded against the gain on sale of business. </div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">In June 2021, RSL completed a transaction with Sumitomo pursuant to which Sumitomo terminated its existing options to acquire RSL&#8217;s equity interests in certain of its subsidiaries. See Note 19, &#8220;Subsequent Events&#8221; for additional information. </div></div> </ix:continuation> <ix:nonNumeric name="us-gaap:DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock" contextRef="P04_01_2020To03_31_2021" escape="true" continuedAt="TextSelection_28230268"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Note 6&#8212;Discontinued Operations </div></div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">As a result of the Sumitomo Transaction Agreement, see Note 5, &#8220;Sumitomo Transaction Agreement,&#8221; the financial results of the Sumitovant Vants are presented as &#8220;Income from discontinued operations, net of tax&#8221; in the accompanying consolidated statements of operations for the year ended March&#160;31, 2020. There were no operating results from discontinued operations for the year ended March&#160;31, 2021. </div></div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></ix:nonNumeric> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">F-<div style="letter-spacing: 0px; top: 0px;;display:inline;">23</div> </div></div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;;font-weight: bold;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><a href="#toc" style="text-indent: 0px;">Table of Contents</a></div></div> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"><ix:continuation id="TextSelection_28230268"> <ix:nonNumeric name="us-gaap:ScheduleOfDisposalGroupsIncludingDiscontinuedOperationsIncomeStatementBalanceSheetAndAdditionalDisclosuresTextBlock" contextRef="P04_01_2020To03_31_2021" escape="true"><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The following table presents components of discontinued operations included in &#8220;Income from discontinued operations, net of tax&#8221; for the year ended March&#160;31, 2020 (in thousands). </div></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 92%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="font-size: 0px;">
<td style="width: 85%;"></td>
<td style="width: 5%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Year Ended<br/> March&#160;31,&#160;2020</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Operating expenses:</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Research and development</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="roiv:DisposalGroupIncludingDiscontinuedOperationResearchAndDevelopmentExpense" contextRef="P04_01_2019To03_31_2020" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">265,452</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">General and administrative</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:DisposalGroupIncludingDiscontinuedOperationGeneralAndAdministrativeExpense" contextRef="P04_01_2019To03_31_2020" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">119,885</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;">&#160;</td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 5em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Total operating expenses</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:DisposalGroupIncludingDiscontinuedOperationOperatingExpense" contextRef="P04_01_2019To03_31_2020" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">385,337</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;">&#160;</td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Loss from operations</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(<ix:nonFraction name="us-gaap:DisposalGroupIncludingDiscontinuedOperationOperatingIncomeLoss" contextRef="P04_01_2019To03_31_2020" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:numdotdecimal">385,337</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Gain on sale of business</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(<ix:nonFraction name="roiv:DisposalGroupIncludingDiscontinuedOperationGainLossOnSaleOfBusiness" contextRef="P04_01_2019To03_31_2020" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">1,985,949</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Interest income</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(<ix:nonFraction name="us-gaap:DisposalGroupIncludingDiscontinuedOperationInterestIncome" contextRef="P04_01_2019To03_31_2020" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">2,305</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Interest expense<div style="font-size: 85%; vertical-align: top;;display:inline;;font-size:9.4px">(1)</div></div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:DisposalGroupIncludingDiscontinuedOperationInterestExpense" contextRef="P04_01_2019To03_31_2020" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">13,733</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Other expense</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:DisposalGroupIncludingDiscontinuedOperationOtherExpense" contextRef="P04_01_2019To03_31_2020" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">8,866</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;">&#160;</td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Income from discontinued operations before income taxes</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:DiscontinuedOperationIncomeLossFromDiscontinuedOperationBeforeIncomeTax" contextRef="P04_01_2019To03_31_2020" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">1,580,318</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Income tax expense</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:DiscontinuedOperationTaxEffectOfDiscontinuedOperation" contextRef="P04_01_2019To03_31_2020" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">1,892</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;">&#160;</td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: bottom;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Income from discontinued operations, net of tax</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">$</td>
<td style="vertical-align: bottom;;text-align:right;"><ix:nonFraction name="us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTax" contextRef="P04_01_2019To03_31_2020" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">1,578,426</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;">&#160;</td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Loss from discontinued operations before income taxes attributable to noncontrolling interests</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(<ix:nonFraction name="us-gaap:DiscontinuedOperationIncomeLossFromDiscontinuedOperationDuringPhaseOutPeriodBeforeIncomeTaxAttributableToNoncontrollingInterest" contextRef="P04_01_2019To03_31_2020" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:numdotdecimal">141,783</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Income from discontinued operations before income taxes attributable to Roivant Sciences Ltd.</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:DiscontinuedOperationIncomeLossFromDiscontinuedOperationDuringPhaseOutPeriodBeforeIncomeTaxAttributableToParent" contextRef="P04_01_2019To03_31_2020" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">1,722,101</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;">&#160;</td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Income from discontinued operations before income taxes</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:DiscontinuedOperationIncomeLossFromDiscontinuedOperationDuringPhaseOutPeriodBeforeIncomeTax" contextRef="P04_01_2019To03_31_2020" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">1,580,318</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;">&#160;</td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td> </tr> </table> <div style="clear: both; max-height: 0px;"></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 4%; vertical-align: top;;text-align:left;"><div style="font-size: 85%; vertical-align: top;;display:inline;;font-size:9.4px">(1)</div>&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;">Interest expense consists of interest payments related to outstanding debt held by Myovant and Urovant as well as the associated <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-cash</div> amortization of debt discounts and issuance costs. </div> </td> </tr> </table> </ix:nonNumeric> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">In the accompanying consolidated statements of cash flows, the cash flows from discontinued operations are not separately classified. <ix:nonNumeric name="roiv:ScheduleOfDisposalGroupsIncludingDiscontinuedCondensedConsolidatedStatementsOfCashFlowsTableTextBlock" contextRef="P04_01_2020To03_31_2021" escape="true" continuedAt="TextSelection_28230169">The significant cash flow items from discontinued operations were as follows (in thousands):</ix:nonNumeric> </div></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <ix:continuation id="TextSelection_28230169">
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 68%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="font-size: 0px;">
<td style="width: 78%;"></td>
<td style="width: 8%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Year Ended<br/> March&#160;31,&#160;2020</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Gain on sale of business</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(<ix:nonFraction name="roiv:DisposalGroupIncludingDiscontinuedOperationGainLossOnSaleOfBusiness" contextRef="P04_01_2019To03_31_2020" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">1,985,949</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Share-based compensation</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="roiv:DisposalGroupIncludingDiscontinuedOperationShareBasedCompensation" contextRef="P04_01_2019To03_31_2020" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">54,821</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;">Acquired <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">in-process</div> research and development</div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="roiv:DisposalGroupIncludingDiscontinuedOperationResearchAndDevelopmentInProcess" contextRef="P04_01_2019To03_31_2020" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">16,405</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;">&#160;</td> </tr> </table> </ix:continuation></ix:continuation> <ix:nonNumeric name="us-gaap:SupplementalBalanceSheetDisclosuresTextBlock" contextRef="P04_01_2020To03_31_2021" escape="true" continuedAt="TextSelection_28230173"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Note 7&#8212;Balance Sheet Components </div></div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">(A) Other Current Assets </div></div></div> <ix:nonNumeric name="us-gaap:ScheduleOfOtherCurrentAssetsTableTextBlock" contextRef="P04_01_2020To03_31_2021" escape="true"><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Other current assets at March&#160;31, 2021 and 2020 consisted of the following (in thousands): </div></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 76%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="font-size: 0px;">
<td style="width: 62%;"></td>
<td style="width: 11%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td>
<td style="width: 11%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">March&#160;31,&#160;2021</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">March&#160;31,&#160;2020</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: bottom;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Prepaid expenses</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">$</td>
<td style="vertical-align: bottom;;text-align:right;"><ix:nonFraction name="us-gaap:PrepaidExpenseCurrent" contextRef="PAsOn03_31_2021" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">39,544</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">$</td>
<td style="vertical-align: bottom;;text-align:right;"><ix:nonFraction name="us-gaap:PrepaidExpenseCurrent" contextRef="PAsOn03_31_2020" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">16,344</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Receivables for value added tax (VAT) paid</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:ValueAddedTaxReceivable" contextRef="PAsOn03_31_2021" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">807</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:ValueAddedTaxReceivable" contextRef="PAsOn03_31_2020" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">5,978</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Note receivable</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:NotesAndLoansReceivableNetCurrent" contextRef="PAsOn03_31_2021" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:zerodash">&#8212;</ix:nonFraction>&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:NotesAndLoansReceivableNetCurrent" contextRef="PAsOn03_31_2020" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">5,000</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Trade receivables, net</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:AccountsReceivableNetCurrent" contextRef="PAsOn03_31_2021" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">11,222</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:AccountsReceivableNetCurrent" contextRef="PAsOn03_31_2020" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">3,669</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Income tax receivable</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:IncomeTaxesReceivable" contextRef="PAsOn03_31_2021" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">1,803</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:IncomeTaxesReceivable" contextRef="PAsOn03_31_2020" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">632</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Other</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">874</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:OtherAssetsMiscellaneousCurrent" contextRef="PAsOn03_31_2020" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">2,140</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;">&#160;</td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Total other current assets</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:OtherAssetsCurrent" contextRef="PAsOn03_31_2021" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">54,250</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:OtherAssetsCurrent" contextRef="PAsOn03_31_2020" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">33,763</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;">&#160;</td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td> </tr> </table> </ix:nonNumeric> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></ix:nonNumeric> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">F-<div style="letter-spacing: 0px; top: 0px;;display:inline;">24</div> </div></div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;;font-weight: bold;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><a href="#toc" style="text-indent: 0px;">Table of Contents</a></div></div> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"><ix:continuation id="TextSelection_28230173"> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">(B) Accrued Expenses </div></div></div> <ix:nonNumeric name="us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock" contextRef="P04_01_2020To03_31_2021" escape="true"><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Accrued expenses at March&#160;31, 2021 and 2020 consisted of the following (in thousands): </div></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 76%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="font-size: 0px;">
<td style="width: 62%;"></td>
<td style="width: 11%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td>
<td style="width: 11%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">March&#160;31,&#160;2021</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">March&#160;31,&#160;2020</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: bottom;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Research and development expenses</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">$</td>
<td style="vertical-align: bottom;;text-align:right;"><ix:nonFraction name="us-gaap:AccruedLiabilitiesCurrent" contextRef="PAsOn03_31_2021_ResearchAndDevelopmentExpenseMemberusgaapIncomeStatementLocationAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">20,755</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">$</td>
<td style="vertical-align: bottom;;text-align:right;"><ix:nonFraction name="us-gaap:AccruedLiabilitiesCurrent" contextRef="PAsOn03_31_2020_ResearchAndDevelopmentExpenseMemberusgaapIncomeStatementLocationAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">21,607</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Compensation-related expenses</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:AccruedLiabilitiesCurrent" contextRef="PAsOn03_31_2021_EmployeeRelatedExpensesMemberusgaapIncomeStatementLocationAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">38,552</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:AccruedLiabilitiesCurrent" contextRef="PAsOn03_31_2020_EmployeeRelatedExpensesMemberusgaapIncomeStatementLocationAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">29,113</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Professional services expenses</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:AccruedLiabilitiesCurrent" contextRef="PAsOn03_31_2021_ProfessionalServicesExpensesMemberusgaapIncomeStatementLocationAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">10,267</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:AccruedLiabilitiesCurrent" contextRef="PAsOn03_31_2020_ProfessionalServicesExpensesMemberusgaapIncomeStatementLocationAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">5,135</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Other general and administrative expenses</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:AccruedLiabilitiesCurrent" contextRef="PAsOn03_31_2021_OtherGeneralAndAdministrativeExpensesMemberusgaapIncomeStatementLocationAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">7,362</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:AccruedLiabilitiesCurrent" contextRef="PAsOn03_31_2020_OtherGeneralAndAdministrativeExpensesMemberusgaapIncomeStatementLocationAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">12,766</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;">&#160;</td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Total accrued expenses</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:AccruedLiabilitiesCurrent" contextRef="PAsOn03_31_2021" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">76,936</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:AccruedLiabilitiesCurrent" contextRef="PAsOn03_31_2020" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">68,621</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;">&#160;</td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td> </tr> </table> </ix:nonNumeric> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">(C) Other Current Liabilities </div></div></div> <ix:nonNumeric name="us-gaap:OtherCurrentLiabilitiesTableTextBlock" contextRef="P04_01_2020To03_31_2021" escape="true"><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Other current liabilities at March&#160;31, 2021 and 2020 consisted of the following (in thousands): </div></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 76%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="font-size: 0px;">
<td style="width: 62%;"></td>
<td style="width: 13%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td>
<td style="width: 13%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">March&#160;31,&#160;2021</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">March&#160;31,&#160;2020</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Deferred revenue</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="roiv:DeferredRevenueOtherCurrentLiabilities" contextRef="PAsOn03_31_2021" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">5,918</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="roiv:DeferredRevenueOtherCurrentLiabilities" contextRef="PAsOn03_31_2020" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">3,621</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Income tax payable</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:TaxesPayableCurrent" contextRef="PAsOn03_31_2021" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">207</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:TaxesPayableCurrent" contextRef="PAsOn03_31_2020" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">1,497</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Other</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:OtherSundryLiabilitiesCurrent" contextRef="PAsOn03_31_2021" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">3,037</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:OtherSundryLiabilitiesCurrent" contextRef="PAsOn03_31_2020" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">234</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;">&#160;</td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Total other current liabilities</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:OtherLiabilitiesCurrent" contextRef="PAsOn03_31_2021" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">9,162</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:OtherLiabilitiesCurrent" contextRef="PAsOn03_31_2020" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">5,352</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;">&#160;</td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td> </tr> </table> </ix:nonNumeric> </ix:continuation> <ix:nonNumeric name="us-gaap:LongTermDebtTextBlock" contextRef="P04_01_2020To03_31_2021" escape="true" continuedAt="TextSelection_28230258"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Note 8&#8212;Long-Term Debt </div></div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">(A) Long-Term Debt </div></div></div> <ix:nonNumeric name="us-gaap:ScheduleOfDebtTableTextBlock" contextRef="P04_01_2020To03_31_2021" escape="true"><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Long-term debt, net consists of the following (in thousands): </div></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 84%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="font-size: 0px;">
<td style="width: 66%;"></td>
<td style="width: 9%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td>
<td style="width: 9%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">March&#160;31,&#160;2021</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">March&#160;31,&#160;2020</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Principal amount</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="roiv:DebtInstrumentAmount" contextRef="PAsOn03_31_2021" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">171,490</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="roiv:DebtInstrumentAmount" contextRef="PAsOn03_31_2020" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">110,490</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Less: unamortized debt discount and issuance costs</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(<ix:nonFraction name="us-gaap:DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet" contextRef="PAsOn03_31_2021" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">1,210</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(<ix:nonFraction name="us-gaap:DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet" contextRef="PAsOn03_31_2020" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">1,898</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Total debt, net</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:LongTermDebt" contextRef="PAsOn03_31_2021" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">170,280</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:LongTermDebt" contextRef="PAsOn03_31_2020" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">108,592</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Less: current portion</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:LongTermDebtCurrent" contextRef="PAsOn03_31_2021" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:zerodash">&#8212;</ix:nonFraction>&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:LongTermDebtCurrent" contextRef="PAsOn03_31_2020" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:zerodash">&#8212;</ix:nonFraction>&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Total long-term debt, net</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:LongTermDebtNoncurrent" contextRef="PAsOn03_31_2021" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">170,280</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:LongTermDebtNoncurrent" contextRef="PAsOn03_31_2020" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">108,592</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;">&#160;</td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td> </tr> </table> </ix:nonNumeric> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Dermavant </div></div></div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">In May 2019, Dermavant and certain of its subsidiaries entered into a loan and security agreement (the &#8220;Hercules Loan Agreement&#8221;) with Hercules Capital, Inc. (&#8220;Hercules&#8221;), pursuant to which Dermavant borrowed an aggregate of $<ix:nonFraction name="us-gaap:DebtInstrumentFaceAmount" contextRef="PAsOn05_31_2019" unitRef="Unit_USD" decimals="-5" scale="6" format="ixt:numdotdecimal">20.0</ix:nonFraction>&#160;million which bears interest at a variable per annum rate at the greater of (i)&#160;<ix:nonFraction name="us-gaap:LongTermDebtPercentageBearingVariableInterestRate" contextRef="PAsOn05_31_2019" unitRef="Unit_pure" decimals="4" scale="-2" format="ixt:numdotdecimal">9.95</ix:nonFraction>%&#160;or (ii)&#160;the prime rate plus <ix:nonFraction name="us-gaap:LongTermDebtPercentageBearingVariableInterestRate" contextRef="PAsOn05_31_2019_PrimeRateMemberusgaapVariableRateAxis" unitRef="Unit_pure" decimals="4" scale="-2" format="ixt:numdotdecimal">4.45</ix:nonFraction>%. Dermavant is obligated to pay an end of term charge of&#160;$<ix:nonFraction name="us-gaap:DebtInstrumentFeeAmount" contextRef="PAsOn05_31_2019" unitRef="Unit_USD" decimals="-5" scale="6" format="ixt:numdotdecimal">1.4</ix:nonFraction>&#160;million with the debt maturing 36 months from closing, subject to extension with the achievement of a clinical milestone. Dermavant is obligated to make monthly payments of accrued interest for the first 15 months after closing (the &#8220;Interest-only Period&#8221;), followed by monthly installments of principal and interest through the maturity date, subject to extension upon certain milestone achievements. In January 2020, the Interest-only Period was extended through June 2021 upon Dermavant&#8217;s receipt of net proceeds from equity or debt financings, capital contributions, and proceeds from business development or similar transaction of at least $<ix:nonFraction name="roiv:ProceedsFromSaleOfDebtAndEquitySecurities" contextRef="P01_01_2020To01_31_2020" unitRef="Unit_USD" decimals="-5" scale="6" format="ixt:numdotdecimal">110.0</ix:nonFraction>&#160;million. In July 2020, the clinical milestone was achieved and the term loan maturity was extended to June&#160;1, 2023 and the Interest-only Period was further extended through December 2021. As of March&#160;31, 2021 and March&#160;31, 2020, an aggregate principal amount of $<ix:nonFraction name="us-gaap:DebtInstrumentFaceAmount" contextRef="PAsOn03_31_2021" unitRef="Unit_USD" decimals="-5" scale="6" format="ixt:numdotdecimal">20.0</ix:nonFraction>&#160;million and end of term charge of $<ix:nonFraction name="us-gaap:DebtInstrumentFeeAmount" contextRef="PAsOn03_31_2020" unitRef="Unit_USD" decimals="-5" scale="6" format="ixt:numdotdecimal">1.4</ix:nonFraction>&#160;million remained outstanding. In May 2021, Dermavant repaid all amounts outstanding under the Hercules Loan Agreement using the proceeds from the $<ix:nonFraction name="us-gaap:ProceedsFromLinesOfCredit" contextRef="P05_01_2021To05_31_2021" unitRef="Unit_USD" decimals="-5" scale="6" format="ixt:numdotdecimal">40.0</ix:nonFraction>&#160;million Credit Facility entered into by Dermavant and certain of its subsidiaries in May 2021. Refer to Note 19, &#8220;Subsequent Events&#8221; for additional detail. </div></div></ix:nonNumeric> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">F-<div style="letter-spacing: 0px; top: 0px;;display:inline;">25</div> </div></div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;;font-weight: bold;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><a href="#toc" style="text-indent: 0px;">Table of Contents</a></div></div> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"><ix:continuation id="TextSelection_28230258"> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">In connection with Dermavant&#8217;s acquisition of tapinarof from GSK, Dermavant and NovaQuest <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">Co-Investment</div> Fund VIII, L.P. (&#8220;NovaQuest&#8221;) entered into a funding agreement (the &#8220;NovaQuest Agreement&#8221;). Pursuant to the NovaQuest Agreement, Dermavant borrowed $<ix:nonFraction name="us-gaap:DebtInstrumentFaceAmount" contextRef="PAsOn08_31_2018_NovaquestMemberusgaapTypeOfArrangementAxis" unitRef="Unit_USD" decimals="-5" scale="6" format="ixt:numdotdecimal">100.0</ix:nonFraction>&#160;million in August 2018 and $<ix:nonFraction name="us-gaap:DebtInstrumentFaceAmount" contextRef="PAsOn10_31_2018_NovaquestMemberusgaapTypeOfArrangementAxis" unitRef="Unit_USD" decimals="-5" scale="6" format="ixt:numdotdecimal">17.5</ix:nonFraction>&#160;million in October 2018 in exchange for an obligation to make certain variable future payments calculated as a function of the achievement of regulatory and commercial milestones or events of termination. The aggregate maximum amount of regulatory milestone payments that Dermavant could be required to make under the NovaQuest Agreement is $<ix:nonFraction name="roiv:MaximumMilestonePaymentObligation" contextRef="PAsOn03_31_2021_NovaquestMemberusgaapTypeOfArrangementAxis_RegulatoryMilestoneMemberusgaapTransactionTypeAxis" unitRef="Unit_USD" decimals="-5" scale="6" format="ixt:numdotdecimal">440.6</ix:nonFraction>&#160;million, and the maximum aggregate amount of commercial milestone payments is $<ix:nonFraction name="roiv:MaximumMilestonePaymentObligation" contextRef="PAsOn03_31_2021_CommercialMilestoneMemberusgaapTransactionTypeAxis_NovaquestMemberusgaapTypeOfArrangementAxis" unitRef="Unit_USD" decimals="-5" scale="6" format="ixt:numdotdecimal">141.0</ix:nonFraction>&#160;million. In some circumstances, Dermavant may be able to offset certain of the regulatory milestone payments with up to $<ix:nonFraction name="roiv:MaximumMilestonePaymentOffsetAmount" contextRef="PAsOn03_31_2021_NovaquestMemberusgaapTypeOfArrangementAxis_RegulatoryMilestoneMemberusgaapTransactionTypeAxis" unitRef="Unit_USD" decimals="-5" scale="6" format="ixt:numdotdecimal">88.1</ix:nonFraction>&#160;million of the commercial milestone payments. At issuance, the Company concluded that certain features of the long-term debt would be considered derivatives that would require bifurcation. In lieu of bifurcating various features in the agreement, the Company has elected the fair value option for this financial instrument and will record the changes in the fair value within the statements of operations at the end of each reporting period. Direct costs and fees related to the debt issued under the NovaQuest Agreement were recognized in earnings. As of March&#160;31, 2021 and 2020, the fair value of the debt was $<ix:nonFraction name="us-gaap:DebtInstrumentFairValue" contextRef="PAsOn03_31_2021_NovaquestMemberusgaapTypeOfArrangementAxis" unitRef="Unit_USD" decimals="-5" scale="6" format="ixt:numdotdecimal">150.1</ix:nonFraction>&#160;million and $<ix:nonFraction name="us-gaap:DebtInstrumentFairValue" contextRef="PAsOn03_31_2020_NovaquestMemberusgaapTypeOfArrangementAxis" unitRef="Unit_USD" decimals="-5" scale="6" format="ixt:numdotdecimal">89.1</ix:nonFraction>&#160;million, respectively. Refer to Note 15, &#8220;Fair Value Measurements&#8221; for additional details regarding the fair value measurement. </div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">(B) Debt Maturities </div></div></div> <ix:nonNumeric name="srt:ContractualObligationFiscalYearMaturityScheduleTableTextBlock" contextRef="P04_01_2020To03_31_2021" escape="true"><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Annual maturities, including the end of term charge, of debt outstanding as of&#160;March&#160;31, 2021&#160;are as follows (in thousands). Long-term debt held by Dermavant for which the fair value option has been elected is excluded from the below as the repayment terms are variable. </div></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 68%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="font-size: 0px;">
<td style="width: 85%; font-family: &quot;Times New Roman&quot;;"></td>
<td style="width: 6%; vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="font-family: &quot;Times New Roman&quot;;"></td>
<td style="font-family: &quot;Times New Roman&quot;;"></td>
<td style="font-family: &quot;Times New Roman&quot;;"></td> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; white-space: nowrap;"> <div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt; border-bottom: 1pt solid rgb(0, 0, 0); display: table-cell; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">Years Ending March&#160;31,</div></div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">2022</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths" contextRef="PAsOn03_31_2021" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">3,129</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">2023</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo" contextRef="PAsOn03_31_2021" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">13,306</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">2024</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree" contextRef="PAsOn03_31_2021" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">4,955</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">2025</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour" contextRef="PAsOn03_31_2021" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:zerodash">&#8212;</ix:nonFraction>&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">2026</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive" contextRef="PAsOn03_31_2021" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:zerodash">&#8212;</ix:nonFraction>&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Thereafter</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalAfterYearFive" contextRef="PAsOn03_31_2021" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:zerodash">&#8212;</ix:nonFraction>&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Total</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="roiv:LongTermDebtExcludingDebtWithFairValueOption" contextRef="PAsOn03_31_2021" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">21,390</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;">&#160;</td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td> </tr> </table> </ix:nonNumeric></ix:continuation> <ix:nonNumeric name="us-gaap:RelatedPartyTransactionsDisclosureTextBlock" contextRef="P04_01_2020To03_31_2021" escape="true"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Note 9&#8212;Related Party Transactions </div></div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Transition Services Agreement and Strategic Cooperation Agreement with Sumitomo </div></div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Concurrently with the Sumitomo Transaction Agreement, (i)&#160;RSL, Sumitomo and Sumitovant entered into a transition services agreement, whereby each of the parties thereto agreed to provide certain services to one another at cost for a period of time following the Sumitomo Closing Date and (ii)&#160;RSL and Sumitomo entered into a strategic cooperation agreement relating to certain ongoing technology-related collaborations between the parties. Pursuant to the terms of the transition services agreement and strategic cooperation agreement, RSL billed Sumitovant $<ix:nonFraction name="us-gaap:CostsAndExpensesRelatedParty" contextRef="P04_01_2020To03_31_2021_SumitovantMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis" unitRef="Unit_USD" decimals="-5" scale="6" format="ixt:numdotdecimal">1.4</ix:nonFraction>&#160;million and $<ix:nonFraction name="us-gaap:CostsAndExpensesRelatedParty" contextRef="P04_01_2019To03_31_2020_SumitovantMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis" unitRef="Unit_USD" decimals="-5" scale="6" format="ixt:numdotdecimal">0.2</ix:nonFraction>&#160;million, net of amounts billed by Sumitovant to RSL, respectively, during the years ended March&#160;31, 2021 and 2020 for costs incurred on behalf of Sumitovant, which were recorded as offsets to the general and administrative expenses initially charged. Additionally, during the years ended March&#160;31, 2021 and 2020, the Company paid Sumitomo a $<ix:nonFraction name="us-gaap:RelatedPartyTransactionAmountsOfTransaction" contextRef="P04_01_2019To03_31_2020_SumitomoMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis" unitRef="Unit_USD" decimals="-5" scale="6" format="ixt:numdotdecimal"><ix:nonFraction name="us-gaap:RelatedPartyTransactionAmountsOfTransaction" contextRef="P04_01_2020To03_31_2021_SumitomoMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis" unitRef="Unit_USD" decimals="-5" scale="6" format="ixt:numdotdecimal">1.0</ix:nonFraction></ix:nonFraction>&#160;million access fee pursuant to the strategic cooperation agreement. </div></div></ix:nonNumeric> <ix:nonNumeric name="us-gaap:StockholdersEquityNoteDisclosureTextBlock" contextRef="P04_01_2020To03_31_2021" escape="true" continuedAt="TextSelection_28230200"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Note 10&#8212;Shareholders&#8217; Equity and Redeemable Noncontrolling Interest </div></div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">(A) Sumitomo Transaction Agreement and Roivant Equity Repurchase </div></div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">In December 2019, RSL and Sumitomo completed the transactions contemplated by the Sumitomo Transaction Agreement; see Note 5, &#8220;Sumitomo Transaction Agreement.&#8221; Pursuant to the Sumitomo Transaction Agreement, </div></div></ix:nonNumeric> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">F-<div style="letter-spacing: 0px; top: 0px;;display:inline;">26</div> </div></div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;;font-weight: bold;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><a href="#toc" style="text-indent: 0px;">Table of Contents</a></div></div> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"><ix:continuation id="TextSelection_28230200" continuedAt="TextSelectionAppend_28230200_1"> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">RSL issued <ix:nonFraction name="us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction" contextRef="P12_27_2019To12_27_2019_SumitomoMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis" unitRef="Unit_shares" decimals="0" scale="0" format="ixt:numdotdecimal"><ix:nonFraction name="us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction" contextRef="P12_01_2019To12_31_2019_SumitomoMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis" unitRef="Unit_shares" decimals="0" scale="0" format="ixt:numdotdecimal"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" contextRef="P04_01_2019To03_31_2020_CommonStockMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_shares" decimals="0" scale="0" format="ixt:numdotdecimal">26,952,143</ix:nonFraction></ix:nonFraction></ix:nonFraction> common shares to Sumitomo at closing at a price per share of $<ix:nonFraction name="us-gaap:SaleOfStockPricePerShare" contextRef="PAsOn12_26_2019_RoivantEquityRepurchaseMemberusgaapShareRepurchaseProgramAxis_SumitomoTransactionAgreementMemberusgaapTypeOfArrangementAxis" unitRef="Unit_USD_per_Share" decimals="2" scale="0" format="ixt:numdotdecimal"><ix:nonFraction name="us-gaap:SharesIssuedPricePerShare" contextRef="PAsOn12_31_2019_SumitomoMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis" unitRef="Unit_USD_per_Share" decimals="2" scale="0" format="ixt:numdotdecimal">37.10</ix:nonFraction></ix:nonFraction> for allocated net proceeds of approximately $<ix:nonFraction name="us-gaap:SaleOfStockConsiderationReceivedOnTransaction" contextRef="P12_01_2019To12_31_2019_SumitomoMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis" unitRef="Unit_USD" decimals="-5" scale="6" format="ixt:numdotdecimal">999.2</ix:nonFraction>&#160;million, after offering expenses incurred. In connection with the Sumitomo Closing Date, RSL&#8217;s board of directors approved a repurchase of up to $<ix:nonFraction name="us-gaap:StockRepurchaseProgramAuthorizedAmount1" contextRef="PAsOn12_31_2019_MaximumMembersrtRangeAxis_SumitomoMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis" unitRef="Unit_USD" decimals="-8" scale="9" format="ixt:numdotdecimal">1.0</ix:nonFraction>&#160;billion of the Company&#8217;s equity securities using the proceeds received from Sumitomo. </div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">In February 2020, the Company launched <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">one-time</div> offers to purchase up to $<ix:nonFraction name="us-gaap:StockRepurchaseProgramAuthorizedAmount1" contextRef="PAsOn02_29_2020_MaximumMembersrtRangeAxis_RoivantEquityRepurchaseMemberusgaapShareRepurchaseProgramAxis_SumitomoTransactionAgreementMemberusgaapTypeOfArrangementAxis" unitRef="Unit_USD" decimals="-8" scale="9" format="ixt:numdotdecimal">1.0</ix:nonFraction>&#160;billion of issued and outstanding equity securities of the Company (the &#8220;Roivant Equity Repurchase&#8221;). <ix:nonNumeric name="us-gaap:TreasuryStockAcquiredRepurchaseAuthorization" contextRef="P04_01_2020To03_31_2021_RoivantEquityRepurchaseMemberusgaapShareRepurchaseProgramAxis_SumitomoTransactionAgreementMemberusgaapTypeOfArrangementAxis">The offers included (i) an offer to repurchase up to approximately <ix:nonFraction name="roiv:PercentageSharesOfCommonStockOfferedToBeRepurchased" contextRef="P12_26_2019To12_26_2019_RoivantEquityRepurchaseMemberusgaapShareRepurchaseProgramAxis_SumitomoTransactionAgreementMemberusgaapTypeOfArrangementAxis" unitRef="Unit_pure" decimals="4" scale="-2" format="ixt:numdotdecimal">11.23</ix:nonFraction>% of the common stock held by each holder (and its affiliates) of the Company&#8217;s common stock as of December 26, 2019, at a price per share of $37.10 representing fair value of the common stock, (ii) an offer to purchase vested stock options whose fair market value (as determined as of December 27, 2019) was less than or equal to the fair market value of approximately 11.23% of the earliest-granted of such holder&#8217;s outstanding vested and unvested stock options, at a purchase price equal to such vested option&#8217;s fair market value, and (iii) an offer to holders of performance restricted stock units (&#8220;pRSUs&#8221;) to surrender 100% of their existing pRSUs in exchange for newly issued performance stock options and capped value appreciation rights. The offer to the holders of pRSUs included an offer by the Company to immediately purchase approximately 11.23% of the newly issued performance stock options and capped value appreciation rights for cash.</ix:nonNumeric> The Company additionally entered into an agreement with the Company&#8217;s Founder to repurchase a portion of his common stock held and exchange his pRSUs for performance stock options and capped value appreciation rights. <ix:nonNumeric name="us-gaap:ScheduleOfStockholdersEquityTableTextBlock" contextRef="P04_01_2020To03_31_2021" escape="true" continuedAt="TextSelection_28230202">A summary of payments made during the year ended March&#160;31, 2020 relating to the purchase of equity securities by the Company is as follows (in thousands):</ix:nonNumeric> </div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <ix:continuation id="TextSelection_28230202">
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 68%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="font-size: 0px;">
<td style="width: 79%;"></td>
<td style="width: 11%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Cash&#160;Payment</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Common stock</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:PaymentsForRepurchaseOfCommonStock" contextRef="P04_01_2019To03_31_2020" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">950,722</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Other equity instruments</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:PaymentsForRepurchaseOfOtherEquity" contextRef="P04_01_2019To03_31_2020" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">39,292</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;">&#160;</td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Total cash paid</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:PaymentsForRepurchaseOfEquity" contextRef="P04_01_2019To03_31_2020" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">990,014</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;">&#160;</td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td> </tr> </table> </ix:continuation> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">(B) Consolidated Vant Equity Transactions </div></div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Cytovant Sciences HK Limited </div></div></div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;">In March 2020, Cytovant Sciences HK Limited (&#8220;Cytovant&#8221;), a subsidiary of the Company, issued and sold <ix:nonFraction name="us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction" contextRef="P03_01_2020To03_31_2020_CytovantScienceHkLtdMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis_SeriesA1PreferredStockMemberusgaapStatementClassOfStockAxis" unitRef="Unit_shares" decimals="0" scale="0" format="ixt:numdotdecimal">20,085,301</ix:nonFraction> Series <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">A-1</div> preference shares at a purchase price of $<div style="letter-spacing: 0px; top: 0px;;display:inline;"><ix:nonFraction name="us-gaap:SharesIssuedPricePerShare" contextRef="PAsOn03_31_2020_CytovantScienceHkLtdMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis_SeriesA1PreferredStockMemberusgaapStatementClassOfStockAxis" unitRef="Unit_USD_per_Share" decimals="2" scale="0" format="ixt:numdotdecimal">1.17</ix:nonFraction></div> per share to third party investors for aggregate net proceeds of $<ix:nonFraction name="us-gaap:SaleOfStockConsiderationReceivedOnTransaction" contextRef="P03_01_2020To03_31_2020_CytovantScienceHkLtdMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis_SeriesA1PreferredStockMemberusgaapStatementClassOfStockAxis" unitRef="Unit_USD" decimals="-5" scale="6" format="ixt:numdotdecimal">22.5</ix:nonFraction>&#160;million after deducting offering costs. The preferred stock is convertible into ordinary shares of Cytovant at any time at the option of the investor, or automatically upon a qualified initial public offering (&#8220;Qualified IPO&#8221;) as defined in the subscription agreement. If a Qualified IPO is not completed within five years of the initial investment, Series A preference shareholders can force a sale or liquidation of Cytovant. The Series <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">A-1</div> preference shares are classified as redeemable noncontrolling interest in the accompanying consolidated balance sheets and consolidated statements of shareholders&#8217; equity and redeemable noncontrolling interest as the Company can be obligated to repurchase the Series A-1 preference shares upon the occurrence of certain contingent events outside the Company&#8217;s control. No dividends shall accrue or be payable on the convertible and redeemable preferred stock unless otherwise determined by the board of directors of Cytovant. The Company did not accrete changes in the redemption value as of March&#160;31, 2021 as the Company considers the events leading to a redemption of the convertible and redeemable preferred stock as not probable. </div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Immunovant </div></div></div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">In September 2019, Immunovant Sciences Ltd. (&#8220;ISL&#8221;) entered into a share exchange agreement (the &#8220;Share Exchange Agreement&#8221;) with Health Sciences Acquisitions Corporation (&#8220;HSAC&#8221;), and in December 2019, ISL and HSAC completed the transactions contemplated by the Share Exchange Agreement (the &#8220;Business Combination&#8221;). At closing, HSAC acquired <ix:nonFraction name="us-gaap:BusinessAcquisitionPercentageOfVotingInterestsAcquired" contextRef="PAsOn09_30_2019_HealthSciencesMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis_ImmunovantINCMemberusgaapBusinessAcquisitionAxis" unitRef="Unit_pure" decimals="2" scale="-2" format="ixt:numdotdecimal">100</ix:nonFraction>% of the issued and outstanding common shares of ISL in exchange for <ix:nonFraction name="us-gaap:BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued" contextRef="P09_01_2019To09_30_2019_CommonStockMemberusgaapStatementEquityComponentsAxis_HealthSciencesMemberusgaapBusinessAcquisitionAxis" unitRef="Unit_shares" decimals="0" scale="0" format="ixt:numdotdecimal">42,080,376</ix:nonFraction> shares of HSAC&#8217;s common stock issued to HSAC, ISL, and the shareholders of ISL (together, the &#8220;Sellers&#8221;) and <ix:nonFraction name="us-gaap:BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued" contextRef="P09_01_2019To09_30_2019_HealthSciencesMemberusgaapBusinessAcquisitionAxis_SeriesA1PreferredStockMemberusgaapStatementClassOfStockAxis" unitRef="Unit_shares" decimals="0" scale="0" format="ixt:numdotdecimal">10,000</ix:nonFraction> shares of HSAC Series A preferred shares issued to RSL. Additionally, as </div></div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </ix:continuation> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">F-<div style="letter-spacing: 0px; top: 0px;;display:inline;">27</div> </div></div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0px;"></div> </div> </div> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;;font-weight: bold;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><a href="#toc" style="text-indent: 0px;">Table of Contents</a></div></div> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"><ix:continuation id="TextSelectionAppend_28230200_1" continuedAt="TextSelectionAppend_28230200_2"> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">part of its initial public offering in May 2019, HSAC issued common stock warrants, which are classified in equity. Upon completion of the Business Combination, <ix:nonFraction name="us-gaap:ClassOfWarrantOrRightOutstanding" contextRef="PAsOn09_30_2019_HealthSciencesMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis" unitRef="Unit_shares" decimals="0" scale="0" format="ixt:numdotdecimal">11,500,000</ix:nonFraction> warrants were outstanding for the purchase of <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">one-half</div> of one share of common stock (an aggregate of <ix:nonFraction name="us-gaap:ClassOfWarrantOrRightOutstanding" contextRef="PAsOn09_30_2019_CommonStockMemberusgaapStatementEquityComponentsAxis_HealthSciencesMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis" unitRef="Unit_shares" decimals="0" scale="0" format="ixt:numdotdecimal">5,750,000</ix:nonFraction> common shares) at a price of $<ix:nonFraction name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" contextRef="PAsOn09_30_2019_HealthSciencesMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis" unitRef="Unit_USD_per_Share" decimals="2" scale="0" format="ixt:numdotdecimal">11.50</ix:nonFraction> per whole share. Upon closing, ISL became a wholly owned subsidiary of HSAC and HSAC was renamed &#8220;Immunovant, Inc.&#8221; The Business Combination was accounted for as a reverse recapitalization and HSAC was treated as the &#8220;acquired&#8221; company for accounting purposes. Accordingly, for accounting purposes, the Business Combination was treated as the equivalent of ISL issuing equity for the net assets of HSAC, accompanied by a recapitalization. Immunovant, Inc. received $<ix:nonFraction name="us-gaap:PaymentsForProceedsFromBusinessesAndInterestInAffiliates" contextRef="P09_01_2019To09_30_2019_HealthSciencesMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis_ImmunovantINCMemberusgaapBusinessAcquisitionAxis" unitRef="Unit_USD" decimals="-5" scale="6" format="ixt:numdotdecimal">111.0</ix:nonFraction>&#160;million in cash as a result of the Business Combination, consisting of the funds held in HSAC&#8217;s trust account. The proceeds included $<ix:nonFraction name="us-gaap:BusinessAcquisitionEquityInterestIssuedOrIssuableValueAssigned" contextRef="PAsOn09_30_2019_HealthSciencesMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis_ImmunovantINCMemberusgaapBusinessAcquisitionAxis" unitRef="Unit_USD" decimals="-5" scale="6" format="ixt:numdotdecimal">5.1</ix:nonFraction>&#160;million related to common shares purchased by RSL. </div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">The sellers were entitled to receive an additional <ix:nonFraction name="us-gaap:WeightedAverageNumberOfSharesContingentlyIssuable" contextRef="P04_01_2020To03_31_2021_ImmunovantINCMemberusgaapBusinessAcquisitionAxis" unitRef="Unit_shares" decimals="0" scale="0" format="ixt:numdotdecimal">20,000,000</ix:nonFraction> shares of Immunovant, Inc.&#8217;s common stock (the &#8220;Earnout Shares&#8221;) if the volume-weighted average price of Immunovant, Inc.&#8217;s shares equaled or exceeded the following prices for any 20 trading days within any 30 <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">trading-day</div> period (the &#8220;Trading Period&#8221;) following the closing of the Business Combination: </div> <ix:nonNumeric name="roiv:EarnOutSharesTermsDescription" contextRef="P04_01_2020To03_31_2021"><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt; margin-left: 4%;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">(i) during any Trading Period prior to March&#160;31, 2023, 10,000,000 Earnout Shares upon the achievement of a volume-weighted average price of at least $17.50 per share; and </div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt; margin-left: 4%;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">(ii) during any Trading Period prior to March&#160;31, 2025, 10,000,000 Earnout Shares upon the achievement of a volume-weighted average price of at least $31.50 per share. </div></div></ix:nonNumeric> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">In May 2020 and September 2020, Immunovant, Inc. achieved the first earnout milestone and second earnout milestone, respectively, under the Share Exchange Agreement and, as a result, all of the <ix:nonFraction name="us-gaap:CommonStockSharesIssued" contextRef="PAsOn05_31_2020_ImmunovantSciencesLtdMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis" unitRef="Unit_shares" decimals="0" scale="0" format="ixt:numdotdecimal"><ix:nonFraction name="us-gaap:CommonStockSharesIssued" contextRef="PAsOn09_30_2020_ImmunovantSciencesLtdMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis" unitRef="Unit_shares" decimals="0" scale="0" format="ixt:numdotdecimal">20,000,000</ix:nonFraction></ix:nonFraction> earnout shares of Immunovant, Inc.&#8217;s common stock were issued to former stockholders of ISL, including <ix:nonFraction name="us-gaap:CommonStockSharesIssued" contextRef="PAsOn09_30_2020" unitRef="Unit_shares" decimals="0" scale="0" format="ixt:numdotdecimal"><ix:nonFraction name="us-gaap:CommonStockSharesIssued" contextRef="PAsOn05_31_2021" unitRef="Unit_shares" decimals="0" scale="0" format="ixt:numdotdecimal">17,547,938</ix:nonFraction></ix:nonFraction> shares of common stock issued to RSL. In addition, upon the achievement of the first earnout milestone and second earnout milestone and pursuant to the restricted stock agreement entered into between HSAC and Health Sciences Holdings, LLC (the &#8220;Sponsor&#8221;), all of the <ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" contextRef="P05_01_2020To05_31_2020_ImmunovantSciencesLtdMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis_RestrictedStockMemberusgaapAwardTypeAxis" unitRef="Unit_shares" decimals="0" scale="0" format="ixt:numdotdecimal"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" contextRef="P08_25_2020To09_30_2020_ImmunovantSciencesLtdMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis_RestrictedStockMemberusgaapAwardTypeAxis" unitRef="Unit_shares" decimals="0" scale="0" format="ixt:numdotdecimal">1,800,000</ix:nonFraction></ix:nonFraction> shares of the Sponsor&#8217;s restricted shares vested and are no longer subject to forfeiture. </div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Immediately prior to the closing of the Business Combination, as described above, ISL&#8217;s convertible promissory notes were automatically converted into an aggregate of <ix:nonFraction name="us-gaap:DebtConversionConvertedInstrumentSharesIssued1" contextRef="P04_01_2020To03_31_2021_ConvertibleNotesPayableMemberusgaapShortTermDebtTypeAxis_ImmunovantINCMemberusgaapBusinessAcquisitionAxis" unitRef="Unit_shares" decimals="0" scale="0" format="ixt:numdotdecimal">7,156,495</ix:nonFraction> common shares of ISL, which were then exchanged for an aggregate of <ix:nonFraction name="us-gaap:DebtConversionConvertedInstrumentSharesIssued1" contextRef="P04_01_2020To03_31_2021_ConvertibleNotesPayableMemberusgaapShortTermDebtTypeAxis_ImmunovantSciencesLtdMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis" unitRef="Unit_shares" decimals="0" scale="0" format="ixt:numdotdecimal">3,499,995</ix:nonFraction> shares of Immunovant, Inc. common stock upon the closing of transactions contemplated by the Share Exchange Agreement. The conversion of ISL&#8217;s convertible promissory notes resulted in an increase to equity by $<div style="letter-spacing: 0px; top: 0px;;display:inline;"><ix:nonFraction name="us-gaap:DebtInstrumentConvertibleCarryingAmountOfTheEquityComponent" contextRef="PAsOn03_31_2021_ConvertibleNotesPayableMemberusgaapShortTermDebtTypeAxis" unitRef="Unit_USD" decimals="-5" scale="6" format="ixt:numdotdecimal">35.6</ix:nonFraction>&#160;</div>million, the carrying amount of the convertible promissory notes. The conversion included a convertible promissory note held by RSL for $<ix:nonFraction name="us-gaap:DebtConversionConvertedInstrumentSharesIssued1" contextRef="P04_01_2020To03_31_2021_ConvertibleNotesPayableMemberusgaapShortTermDebtTypeAxis" unitRef="Unit_shares" decimals="-5" scale="6" format="ixt:numdotdecimal">2.5</ix:nonFraction>&#160;million. </div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">In April 2020, Immunovant, Inc. completed an underwritten public offering of <ix:nonFraction name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" contextRef="P04_01_2020To04_30_2020_CommonStockMemberusgaapStatementEquityComponentsAxis_ImmunovantINCMemberusgaapBusinessAcquisitionAxis_UnderwrittenPublicOfferingMemberusgaapSubsidiarySaleOfStockAxis" unitRef="Unit_shares" decimals="0" scale="0" format="ixt:numdotdecimal">9,613,365</ix:nonFraction> shares of its common stock, including <ix:nonFraction name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" contextRef="P04_01_2020To04_30_2020_CommonStockMemberusgaapStatementEquityComponentsAxis_UnderwrittenPublicOfferingMemberusgaapSubsidiarySaleOfStockAxis" unitRef="Unit_shares" decimals="0" scale="0" format="ixt:numdotdecimal">1,034,483</ix:nonFraction> shares of common stock purchased by RSL, at a price of $<ix:nonFraction name="us-gaap:SaleOfStockPricePerShare" contextRef="PAsOn04_30_2020_CommonStockMemberusgaapStatementEquityComponentsAxis_ImmunovantINCMemberusgaapBusinessAcquisitionAxis_UnderwrittenPublicOfferingMemberusgaapSubsidiarySaleOfStockAxis" unitRef="Unit_USD_per_Share" decimals="2" scale="0" format="ixt:numdotdecimal">14.50</ix:nonFraction> per share for net proceeds to Immunovant, Inc. of approximately $<ix:nonFraction name="us-gaap:ProceedsFromIssuanceOfCommonStock" contextRef="P04_01_2020To04_30_2020_CommonStockMemberusgaapStatementEquityComponentsAxis_ImmunovantINCMemberusgaapBusinessAcquisitionAxis_UnderwrittenPublicOfferingMemberusgaapSubsidiarySaleOfStockAxis" unitRef="Unit_USD" decimals="-5" scale="6" format="ixt:numdotdecimal">131.0</ix:nonFraction>&#160;million, after deducting underwriting discounts and commissions and offering expenses. The proceeds included $<ix:nonFraction name="us-gaap:ProceedsFromIssuanceOfCommonStock" contextRef="P04_01_2020To04_30_2020_CommonStockMemberusgaapStatementEquityComponentsAxis_UnderwrittenPublicOfferingMemberusgaapSubsidiarySaleOfStockAxis" unitRef="Unit_USD" decimals="-5" scale="6" format="ixt:numdotdecimal">15.0</ix:nonFraction>&#160;million received from RSL. </div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">In May 2020, Immunovant, Inc.&#8217;s <ix:nonFraction name="roiv:ClassOfWarrantOrRightExercisable" contextRef="PAsOn05_31_2020_ImmunovantINCMemberusgaapBusinessAcquisitionAxis_WarrantMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_shares" decimals="0" scale="0" format="ixt:numdotdecimal">11,500,000</ix:nonFraction> outstanding warrants became exercisable for an aggregate of <ix:nonFraction name="us-gaap:ClassOfWarrantOrRightOutstanding" contextRef="PAsOn05_31_2020_ImmunovantINCMemberusgaapBusinessAcquisitionAxis_WarrantMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_shares" decimals="0" scale="0" format="ixt:numdotdecimal">5,750,000</ix:nonFraction> shares of Immunovant, Inc.&#8217;s common stock at a price of $<ix:nonFraction name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" contextRef="PAsOn05_31_2020_ImmunovantINCMemberusgaapBusinessAcquisitionAxis_WarrantMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_USD_per_Share" decimals="2" scale="0" format="ixt:numdotdecimal">11.50</ix:nonFraction> per share. An aggregate of <ix:nonFraction name="roiv:ClassOfWarrantOrRightExercisable" contextRef="PAsOn03_31_2021_ImmunovantINCMemberusgaapBusinessAcquisitionAxis_WarrantMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_shares" decimals="0" scale="0" format="ixt:numdotdecimal"><ix:nonFraction name="roiv:ClassOfWarrantOrRightExercisable" contextRef="PAsOn03_31_2021_ImmunovantINCMemberusgaapBusinessAcquisitionAxis_WarrantMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_shares" decimals="0" scale="0" format="ixt:numdotdecimal">11,438,290</ix:nonFraction></ix:nonFraction> outstanding warrants were exercised for an aggregate of <ix:nonFraction name="us-gaap:ClassOfWarrantOrRightOutstanding" contextRef="PAsOn03_31_2021_ImmunovantINCMemberusgaapBusinessAcquisitionAxis_WarrantMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_shares" decimals="0" scale="0" format="ixt:numdotdecimal"><ix:nonFraction name="us-gaap:ClassOfWarrantOrRightOutstanding" contextRef="PAsOn03_31_2021_ImmunovantINCMemberusgaapBusinessAcquisitionAxis_WarrantMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_shares" decimals="0" scale="0" format="ixt:numdotdecimal">5,719,145</ix:nonFraction></ix:nonFraction> shares of Immunovant, Inc.&#8217;s common stock at a price of $<ix:nonFraction name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" contextRef="PAsOn03_31_2021_ImmunovantINCMemberusgaapBusinessAcquisitionAxis_WarrantMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_USD_per_Share" decimals="2" scale="0" format="ixt:numdotdecimal"><ix:nonFraction name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" contextRef="PAsOn03_31_2021_ImmunovantINCMemberusgaapBusinessAcquisitionAxis_WarrantMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_USD_per_Share" decimals="2" scale="0" format="ixt:numdotdecimal">11.50</ix:nonFraction></ix:nonFraction> per share, for net proceeds of approximately $<ix:nonFraction name="us-gaap:ProceedsFromIssuanceOfWarrants" contextRef="P04_01_2020To03_31_2021_ImmunovantINCMemberusgaapBusinessAcquisitionAxis_WarrantMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_USD" decimals="-5" scale="6" format="ixt:numdotdecimal">65.8</ix:nonFraction>&#160;million. The remaining <ix:nonFraction name="us-gaap:AdjustmentOfWarrantsGrantedForServices" contextRef="P04_01_2020To03_31_2021_ImmunovantINCMemberusgaapBusinessAcquisitionAxis_WarrantMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">61,710</ix:nonFraction> warrants were cancelled. </div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">In September 2020, Immunovant, Inc. completed an underwritten public offering of <ix:nonFraction name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" contextRef="P08_25_2020To09_30_2020_CommonStockMemberusgaapStatementEquityComponentsAxis_ImmunovantINCMemberusgaapBusinessAcquisitionAxis_UnderwrittenPublicOfferingMemberusgaapSubsidiarySaleOfStockAxis" unitRef="Unit_shares" decimals="0" scale="0" format="ixt:numdotdecimal">6,060,606</ix:nonFraction> shares of its common stock, including <ix:nonFraction name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" contextRef="P08_25_2020To09_30_2020_CommonStockMemberusgaapStatementEquityComponentsAxis_UnderwrittenPublicOfferingMemberusgaapSubsidiarySaleOfStockAxis" unitRef="Unit_shares" decimals="0" scale="0" format="ixt:numdotdecimal">380,000</ix:nonFraction> shares of common stock purchased by RSL, at a price of $<ix:nonFraction name="us-gaap:SaleOfStockPricePerShare" contextRef="PAsOn09_30_2020_CommonStockMemberusgaapStatementEquityComponentsAxis_ImmunovantINCMemberusgaapBusinessAcquisitionAxis_UnderwrittenPublicOfferingMemberusgaapSubsidiarySaleOfStockAxis" unitRef="Unit_USD_per_Share" decimals="2" scale="0" format="ixt:numdotdecimal">33.00</ix:nonFraction> per share for net proceeds to Immunovant, Inc. of approximately $<ix:nonFraction name="us-gaap:ProceedsFromIssuanceOfCommonStock" contextRef="P08_25_2020To09_30_2020_CommonStockMemberusgaapStatementEquityComponentsAxis_ImmunovantINCMemberusgaapBusinessAcquisitionAxis_UnderwrittenPublicOfferingMemberusgaapSubsidiarySaleOfStockAxis" unitRef="Unit_USD" decimals="-5" scale="6" format="ixt:numdotdecimal">188.1</ix:nonFraction>&#160;million, after deducting underwriting discounts and commissions and offering expenses. The proceeds included $<ix:nonFraction name="us-gaap:ProceedsFromIssuanceOfCommonStock" contextRef="P08_25_2020To09_30_2020_CommonStockMemberusgaapStatementEquityComponentsAxis_UnderwrittenPublicOfferingMemberusgaapSubsidiarySaleOfStockAxis" unitRef="Unit_USD" decimals="-5" scale="6" format="ixt:numdotdecimal">12.5</ix:nonFraction>&#160;million received from RSL. </div></div> </ix:continuation> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">F-<div style="letter-spacing: 0px; top: 0px;;display:inline;">28</div> </div></div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;;font-weight: bold;"><div style="display:inline;"><a href="#toc" style="text-indent: 0px;">Table of Contents</a></div></div> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"><ix:continuation id="TextSelectionAppend_28230200_2"> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Sinovant </div></div></div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Sinovant, a subsidiary of the Company, previously issued and sold preferred stock convertible into ordinary shares of Sinovant at any time at the option of the investors or automatically upon a qualified initial public offering (&#8220;Qualified IPO&#8221;) as defined in the subscription agreement relating to the sale of the preferred stock. The convertible preferred stock was redeemable at the option of the investor if a Qualified IPO was not completed within five years of the initial investment and was payable in cash equal to the investment amount plus an annualized return of <ix:nonFraction name="us-gaap:InvestmentCompanyInternalRateOfReturnSinceInception" contextRef="P03_01_2021To03_31_2021_SinovantIncMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis" unitRef="Unit_pure" decimals="2" scale="-2" format="ixt:numdotdecimal">12</ix:nonFraction>%. As such events are not within the control of the Company, the preferred stock was previously classified as redeemable noncontrolling interest in the accompanying consolidated balance sheets and consolidated statements of shareholders&#8217; equity and redeemable noncontrolling interest. No dividends accrued or were payable on the convertible preferred stock. In January 2020, Sinovant&#8217;s parent company, Roivant China Holdings Ltd. (&#8220;RCHL&#8221;), purchased all preferred stock of Sinovant held by third parties at a purchase price of $<ix:nonFraction name="us-gaap:PreferredStockRedemptionPricePerShare" contextRef="PAsOn01_31_2020_SinovantIncMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis" unitRef="Unit_USD_per_Share" decimals="2" scale="0" format="ixt:numdotdecimal">12.26</ix:nonFraction> per preferred share for an aggregate purchase price of $<ix:nonFraction name="us-gaap:PaymentsForRepurchaseOfRedeemableConvertiblePreferredStock" contextRef="P01_01_2020To01_31_2020_SinovantIncMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis" unitRef="Unit_USD" decimals="-5" scale="6" format="ixt:numdotdecimal">132.9</ix:nonFraction>&#160;million. Consideration paid in excess of the carrying value for the repurchase of redeemable noncontrolling interest of $<ix:nonFraction name="us-gaap:PaymentsForRepurchaseOfRedeemableNoncontrollingInterest" contextRef="P01_01_2020To01_31_2020_SinovantIncMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis" unitRef="Unit_USD" decimals="-5" scale="6" format="ixt:numdotdecimal">77.8</ix:nonFraction>&#160;million is considered a deemed dividend. See Note 18, &#8220;Earnings per Common Share&#8221; for resulting impact to earnings per share. </div></div> </ix:continuation> <ix:nonNumeric name="us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" contextRef="P04_01_2020To03_31_2021" escape="true" continuedAt="TextSelection_28230214"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Note 11&#8212;Share-Based Compensation </div></div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">(A) RSL 2015 Equity Incentive Plan </div></div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">As of March&#160;31, 2021, <ix:nonFraction name="us-gaap:CommonStockCapitalSharesReservedForFutureIssuance" contextRef="PAsOn03_31_2021_TwoThousandFifteenEquityIncentivePlanMemberusgaapPlanNameAxis" unitRef="Unit_shares" decimals="INF" scale="0" format="ixt:numdotdecimal">22,800,000</ix:nonFraction> of the Company&#8217;s common shares (the &#8220;Share Reserve&#8221;) are reserved for issuance under the RSL Amended and Restated 2015 Equity Incentive Plan (the &#8220;RSL 2015 EIP&#8221;). At March&#160;31, 2021, a total of <ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" contextRef="PAsOn03_31_2021_TwoThousandFifteenEquityIncentivePlanMemberusgaapPlanNameAxis" unitRef="Unit_shares" decimals="INF" scale="0" format="ixt:numdotdecimal">10,296,392</ix:nonFraction> common shares are available for future grants under the RSL 2015 EIP. The Company&#8217;s employees, directors, and consultants are eligible to receive nonstatutory and incentive stock options, stock appreciation rights, restricted stock awards, restricted stock unit awards, and other stock awards under the RSL 2015 EIP. </div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">As of March&#160;31, 2021, an aggregate of <ix:nonFraction name="us-gaap:CommonStockCapitalSharesReservedForFutureIssuance" contextRef="PAsOn03_31_2021_SpecialReserveMemberusgaapAwardTypeAxis_TwoThousandFifteenEquityIncentivePlanMemberusgaapPlanNameAxis" unitRef="Unit_shares" decimals="INF" scale="0" format="ixt:numdotdecimal">26,558,238</ix:nonFraction> of the Company&#8217;s common shares (the &#8220;Special Reserve&#8221;) were reserved for the granting under RSL 2015 EIP of performance stock options (&#8220;Performance Options&#8221;) and capped value appreciation rights (&#8220;CVARs&#8221;) to the Company&#8217;s employees, directors and consultants. At March&#160;31, 2021, there are <ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" contextRef="PAsOn03_31_2021_SpecialReserveMemberusgaapAwardTypeAxis_TwoThousandFifteenEquityIncentivePlanMemberusgaapPlanNameAxis" unitRef="Unit_shares" decimals="INF" scale="0" format="ixt-sec:numwordsen">no </ix:nonFraction>common shares available for future grant under the Special Reserve. </div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Stock Options </div></div></div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">For the years ended March&#160;31, 2021 and 2020, the Company recorded share-based compensation expense related to stock options issued under the RSL 2015 EIP to employees and directors of approximately $<ix:nonFraction name="us-gaap:AllocatedShareBasedCompensationExpense" contextRef="P04_01_2020To03_31_2021_TwoThousandFifteenEquityIncentivePlanMemberusgaapPlanNameAxis" unitRef="Unit_USD" decimals="INF" scale="6" format="ixt:numdotdecimal">32.3</ix:nonFraction>&#160;million and $<ix:nonFraction name="us-gaap:AllocatedShareBasedCompensationExpense" contextRef="P04_01_2019To03_31_2020_TwoThousandFifteenEquityIncentivePlanMemberusgaapPlanNameAxis" unitRef="Unit_USD" decimals="INF" scale="6" format="ixt:numdotdecimal">31.8</ix:nonFraction>&#160;million, respectively, and was included in research and development and general and administrative expenses in the accompanying consolidated statements of operations. </div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">At March&#160;31, 2021, total unrecognized compensation expense related to <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-vested</div> stock options was approximately $<ix:nonFraction name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" contextRef="PAsOn03_31_2021_TwoThousandFifteenEquityIncentivePlanMemberusgaapPlanNameAxis" unitRef="Unit_USD" decimals="-5" scale="6" format="ixt:numdotdecimal">70.8</ix:nonFraction>&#160;million and is expected to be recognized over the remaining weighted-average service period of <ix:nonNumeric name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" contextRef="P04_01_2020To03_31_2021_TwoThousandFifteenEquityIncentivePlanMemberusgaapPlanNameAxis" format="ixt-sec:duryear">2.96</ix:nonNumeric> years. </div> <ix:nonNumeric name="us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" contextRef="P04_01_2020To03_31_2021" escape="true"><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The Company estimated the fair value of each stock option on the date of grant using the Black-Scholes closed form option-pricing model applying the weighted average assumptions in the following table. </div></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 76%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="font-size: 0px;">
<td style="width: 73%;"></td>
<td style="width: 9%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td>
<td style="width: 8%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;&#160;</td>
<td colspan="6" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Years&#160;Ended&#160;March&#160;31,</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 1pt;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Assumptions</div></div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;&#160;2021&#160;&#160;</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;&#160;2020&#160;&#160;</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Expected stock price volatility</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate" contextRef="P04_01_2020To03_31_2021_EmployeeStockOptionMemberusgaapAwardTypeAxis" unitRef="Unit_pure" decimals="4" scale="-2" format="ixt:numdotdecimal">74.84</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">%&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate" contextRef="P04_01_2019To03_31_2020_EmployeeStockOptionMemberusgaapAwardTypeAxis" unitRef="Unit_pure" decimals="4" scale="-2" format="ixt:numdotdecimal">66.47</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">%&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Expected risk free interest rate</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" contextRef="P04_01_2020To03_31_2021_EmployeeStockOptionMemberusgaapAwardTypeAxis" unitRef="Unit_pure" decimals="4" scale="-2" format="ixt:numdotdecimal">0.43</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">%&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" contextRef="P04_01_2019To03_31_2020_EmployeeStockOptionMemberusgaapAwardTypeAxis" unitRef="Unit_pure" decimals="4" scale="-2" format="ixt:numdotdecimal">2.27</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">%&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Expected term, in years</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonNumeric name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" contextRef="P04_01_2020To03_31_2021_EmployeeStockOptionMemberusgaapAwardTypeAxis" format="ixt-sec:duryear">6.25</ix:nonNumeric></td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonNumeric name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" contextRef="P04_01_2019To03_31_2020_EmployeeStockOptionMemberusgaapAwardTypeAxis" format="ixt-sec:duryear">6.72</ix:nonNumeric></td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Expected dividend yield</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" contextRef="P04_01_2020To03_31_2021_EmployeeStockOptionMemberusgaapAwardTypeAxis" unitRef="Unit_pure" decimals="2" scale="-2" format="ixt:zerodash">&#8212;</ix:nonFraction>&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">%&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" contextRef="P04_01_2019To03_31_2020_EmployeeStockOptionMemberusgaapAwardTypeAxis" unitRef="Unit_pure" decimals="2" scale="-2" format="ixt:zerodash">&#8212;</ix:nonFraction>&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">%&#160;</td> </tr> </table> </ix:nonNumeric></ix:nonNumeric> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">F-<div style="letter-spacing: 0px; top: 0px;;display:inline;">29</div> </div></div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;;font-weight: bold;"><div style="display:inline;"><a href="#toc" style="text-indent: 0px;">Table of Contents</a></div></div> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"><ix:continuation id="TextSelection_28230214" continuedAt="TextSelectionAppend_28230214_1"> <ix:nonNumeric name="us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" contextRef="P04_01_2020To03_31_2021" escape="true"><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">A summary of stock option activity and data under the RSL 2015 EIP for the year ended March&#160;31, 2021 is as follows: </div></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 92%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="font-size: 0px;">
<td style="width: 48%;"></td>
<td style="width: 7%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td>
<td style="width: 7%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td>
<td style="width: 7%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td>
<td style="width: 7%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Number of<br/> Stock<br/> Options</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Weighted<br/> Average<br/> Exercise<br/> Price</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Weighted<br/> Average Grant<br/> Date&#160;Fair&#160;Value</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Weighted<br/> Average<br/> Remaining<br/> Contractual&#160;Life</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Stock options outstanding at March&#160;31, 2020</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" contextRef="PAsOn03_31_2020_EmployeeStockOptionMemberusgaapAwardTypeAxis_TwoThousandFifteenEquityIncentivePlanMemberusgaapPlanNameAxis" unitRef="Unit_shares" decimals="INF" scale="0" format="ixt:numdotdecimal">8,176,814</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" contextRef="PAsOn03_31_2020_EmployeeStockOptionMemberusgaapAwardTypeAxis_TwoThousandFifteenEquityIncentivePlanMemberusgaapPlanNameAxis" unitRef="Unit_USD_per_Share" decimals="2" scale="0" format="ixt:numdotdecimal">24.52</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="roiv:ShareBasedCompensationArrangementByShareBasedPaymentAwardWeightedAverageGrantDateFairValue" contextRef="PAsOn03_31_2020_EmployeeStockOptionMemberusgaapAwardTypeAxis_TwoThousandFifteenEquityIncentivePlanMemberusgaapPlanNameAxis" unitRef="Unit_USD_per_Share" decimals="2" scale="0" format="ixt:numdotdecimal">16.53</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonNumeric name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" contextRef="P04_01_2019To03_31_2020_EmployeeStockOptionMemberusgaapAwardTypeAxis_TwoThousandFifteenEquityIncentivePlanMemberusgaapPlanNameAxis" format="ixt-sec:duryear">7.93</ix:nonNumeric></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Granted</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" contextRef="P04_01_2020To03_31_2021_EmployeeStockOptionMemberusgaapAwardTypeAxis_TwoThousandFifteenEquityIncentivePlanMemberusgaapPlanNameAxis" unitRef="Unit_shares" decimals="INF" scale="0" format="ixt:numdotdecimal">1,482,604</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" contextRef="P04_01_2020To03_31_2021_EmployeeStockOptionMemberusgaapAwardTypeAxis_TwoThousandFifteenEquityIncentivePlanMemberusgaapPlanNameAxis" unitRef="Unit_USD_per_Share" decimals="2" scale="0" format="ixt:numdotdecimal">38.71</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" contextRef="P04_01_2020To03_31_2021_EmployeeStockOptionMemberusgaapAwardTypeAxis_TwoThousandFifteenEquityIncentivePlanMemberusgaapPlanNameAxis" unitRef="Unit_USD_per_Share" decimals="2" scale="0" format="ixt:numdotdecimal">25.37</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Forfeited/Canceled</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(<ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" contextRef="P04_01_2020To03_31_2021_EmployeeStockOptionMemberusgaapAwardTypeAxis_TwoThousandFifteenEquityIncentivePlanMemberusgaapPlanNameAxis" unitRef="Unit_shares" decimals="INF" scale="0" format="ixt:numdotdecimal">270,047</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" contextRef="P04_01_2020To03_31_2021_EmployeeStockOptionMemberusgaapAwardTypeAxis_TwoThousandFifteenEquityIncentivePlanMemberusgaapPlanNameAxis" unitRef="Unit_USD_per_Share" decimals="2" scale="0" format="ixt:numdotdecimal">29.89</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedWeightedAverageGrantDateFairValue" contextRef="P04_01_2020To03_31_2021_EmployeeStockOptionMemberusgaapAwardTypeAxis_TwoThousandFifteenEquityIncentivePlanMemberusgaapPlanNameAxis" unitRef="Unit_USD_per_Share" decimals="2" scale="0" format="ixt:numdotdecimal">19.85</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Stock options outstanding at March&#160;31, 2021</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" contextRef="PAsOn03_31_2021_EmployeeStockOptionMemberusgaapAwardTypeAxis_TwoThousandFifteenEquityIncentivePlanMemberusgaapPlanNameAxis" unitRef="Unit_shares" decimals="INF" scale="0" format="ixt:numdotdecimal">9,389,371</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" contextRef="PAsOn03_31_2021_EmployeeStockOptionMemberusgaapAwardTypeAxis_TwoThousandFifteenEquityIncentivePlanMemberusgaapPlanNameAxis" unitRef="Unit_USD_per_Share" decimals="2" scale="0" format="ixt:numdotdecimal">26.61</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="roiv:ShareBasedCompensationArrangementByShareBasedPaymentAwardWeightedAverageGrantDateFairValue" contextRef="PAsOn03_31_2021_EmployeeStockOptionMemberusgaapAwardTypeAxis_TwoThousandFifteenEquityIncentivePlanMemberusgaapPlanNameAxis" unitRef="Unit_USD_per_Share" decimals="2" scale="0" format="ixt:numdotdecimal">17.90</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonNumeric name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" contextRef="P04_01_2020To03_31_2021_EmployeeStockOptionMemberusgaapAwardTypeAxis_TwoThousandFifteenEquityIncentivePlanMemberusgaapPlanNameAxis" format="ixt-sec:duryear">7.26</ix:nonNumeric></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Stock options exercisable at March&#160;31, 2021</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" contextRef="PAsOn03_31_2021_EmployeeStockOptionMemberusgaapAwardTypeAxis_TwoThousandFifteenEquityIncentivePlanMemberusgaapPlanNameAxis" unitRef="Unit_shares" decimals="INF" scale="0" format="ixt:numdotdecimal">5,533,848</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" contextRef="PAsOn03_31_2021_EmployeeStockOptionMemberusgaapAwardTypeAxis_TwoThousandFifteenEquityIncentivePlanMemberusgaapPlanNameAxis" unitRef="Unit_USD_per_Share" decimals="2" scale="0" format="ixt:numdotdecimal">21.52</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="roiv:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExcercisableWeightedAverageGrantDateFairValue" contextRef="P04_01_2020To03_31_2021_EmployeeStockOptionMemberusgaapAwardTypeAxis_TwoThousandFifteenEquityIncentivePlanMemberusgaapPlanNameAxis" unitRef="Unit_USD_per_Share" decimals="2" scale="0" format="ixt:numdotdecimal">14.95</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonNumeric name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" contextRef="P04_01_2020To03_31_2021_EmployeeStockOptionMemberusgaapAwardTypeAxis_TwoThousandFifteenEquityIncentivePlanMemberusgaapPlanNameAxis" format="ixt-sec:duryear">6.49</ix:nonNumeric></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td> </tr> </table> </ix:nonNumeric> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">At March&#160;31, 2021 and 2020, there were <ix:nonFraction name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares" contextRef="P04_01_2020To03_31_2021_TwoThousandFifteenEquityIncentivePlanMemberusgaapPlanNameAxis" unitRef="Unit_shares" decimals="INF" scale="0" format="ixt:numdotdecimal">5,533,848</ix:nonFraction> and <ix:nonFraction name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares" contextRef="P04_01_2019To03_31_2020_TwoThousandFifteenEquityIncentivePlanMemberusgaapPlanNameAxis" unitRef="Unit_shares" decimals="INF" scale="0" format="ixt:numdotdecimal">4,123,953</ix:nonFraction> vested stock options, respectively. <ix:nonNumeric name="roiv:ScheduleOfSharebasedPaymentArrangementFairValueOfVestedStockOptionTableTextBlock" contextRef="P04_01_2020To03_31_2021" escape="true" continuedAt="TextSelection_28230217">Additional information regarding stock options is set forth below (in thousands, except per share data).</ix:nonNumeric> </div></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <ix:continuation id="TextSelection_28230217">
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 84%; font-family: &quot;Times New Roman&quot;; font-size: 8pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="font-size: 0px;">
<td style="width: 78%;"></td>
<td style="width: 4%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td>
<td style="width: 4%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;&#160;</td>
<td colspan="6" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Years&#160;Ended&#160;March&#160;31,</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2021</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2020</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Grant date fair value of stock options vested</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1" contextRef="P04_01_2020To03_31_2021" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">25,711</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1" contextRef="P04_01_2019To03_31_2020" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">33,789</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Weighted-average grant date fair value per share of stock options granted</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue" contextRef="P04_01_2020To03_31_2021" unitRef="Unit_USD_per_Share" decimals="2" scale="0" format="ixt:numdotdecimal">25.37</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue" contextRef="P04_01_2019To03_31_2020" unitRef="Unit_USD_per_Share" decimals="2" scale="0" format="ixt:numdotdecimal">20.63</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;">&#160;</td> </tr> </table> </ix:continuation> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Restricted Stock Units </div></div></div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;">Restricted stock units will vest upon the achievement of both time-based service requirements and liquidity requirements on or before the grant expiration date. Restricted stock units expire <ix:nonNumeric name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" contextRef="P04_01_2020To03_31_2021_RestrictedStockUnitsRSUMemberusgaapAwardTypeAxis" format="ixt-sec:durwordsen">eight years</ix:nonNumeric> after the date of grant. During the year ended March&#160;31, 2021, the Company recorded <ix:nonFraction name="us-gaap:AllocatedShareBasedCompensationExpense" contextRef="P04_01_2020To03_31_2021_RestrictedStockUnitsRSUMemberusgaapAwardTypeAxis" unitRef="Unit_USD" decimals="INF" scale="3" format="ixt-sec:numwordsen">no </ix:nonFraction>share-based compensation expense related to these restricted stock units as the liquidity event requirement had not been met and was deemed not probable of being met. At March&#160;31, 2021, there was approximately $<ix:nonFraction name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions" contextRef="PAsOn03_31_2021_RestrictedStockUnitsRSUMemberusgaapAwardTypeAxis" unitRef="Unit_USD" decimals="-5" scale="6" format="ixt:numdotdecimal">83.8</ix:nonFraction>&#160;million of unrecognized compensation expense related to <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-vested</div> restricted stock units. The Company will recognize the expense upon achievement of both the time-based service requirement and liquidity requirements through the requisite service period. </div> <ix:nonNumeric name="us-gaap:ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock" contextRef="P04_01_2020To03_31_2021" escape="true"><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">A summary of restricted stock units under the RSL 2015 EIP is as follows: </div></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 76%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="font-size: 0px;">
<td style="width: 58%;"></td>
<td style="width: 12%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td>
<td style="width: 12%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Number of<br/> Restricted&#160;Stock<br/> Units</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Weighted&#160;Average<br/> Grant Date Fair<br/> Value</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">Non-vested</div> balance at March&#160;31, 2020</div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" contextRef="PAsOn03_31_2020_RestrictedStockUnitsRSUMemberusgaapAwardTypeAxis_TwoThousandFifteenEquityIncentivePlanMemberusgaapPlanNameAxis" unitRef="Unit_shares" decimals="INF" scale="0" format="ixt:numdotdecimal">1,008,175</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue" contextRef="PAsOn03_31_2020_RestrictedStockUnitsRSUMemberusgaapAwardTypeAxis_TwoThousandFifteenEquityIncentivePlanMemberusgaapPlanNameAxis" unitRef="Unit_USD_per_Share" decimals="2" scale="0" format="ixt:numdotdecimal">32.50</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Granted</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" contextRef="P04_01_2020To03_31_2021_RestrictedStockUnitsRSUMemberusgaapAwardTypeAxis_TwoThousandFifteenEquityIncentivePlanMemberusgaapPlanNameAxis" unitRef="Unit_shares" decimals="INF" scale="0" format="ixt:numdotdecimal">1,454,199</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" contextRef="P04_01_2020To03_31_2021_RestrictedStockUnitsRSUMemberusgaapAwardTypeAxis_TwoThousandFifteenEquityIncentivePlanMemberusgaapPlanNameAxis" unitRef="Unit_USD_per_Share" decimals="2" scale="0" format="ixt:numdotdecimal">39.19</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Forfeited</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(<ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" contextRef="P04_01_2020To03_31_2021_RestrictedStockUnitsRSUMemberusgaapAwardTypeAxis_TwoThousandFifteenEquityIncentivePlanMemberusgaapPlanNameAxis" unitRef="Unit_shares" decimals="INF" scale="0" format="ixt:numdotdecimal">169,636</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedWeightedAverageGrantDateFairValue" contextRef="P04_01_2020To03_31_2021_RestrictedStockUnitsRSUMemberusgaapAwardTypeAxis_TwoThousandFifteenEquityIncentivePlanMemberusgaapPlanNameAxis" unitRef="Unit_USD_per_Share" decimals="2" scale="0" format="ixt:numdotdecimal">36.36</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;">&#160;</td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">Non-vested</div> balance at March&#160;31, 2021</div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" contextRef="PAsOn03_31_2021_RestrictedStockUnitsRSUMemberusgaapAwardTypeAxis_TwoThousandFifteenEquityIncentivePlanMemberusgaapPlanNameAxis" unitRef="Unit_shares" decimals="INF" scale="0" format="ixt:numdotdecimal">2,292,738</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue" contextRef="PAsOn03_31_2021_RestrictedStockUnitsRSUMemberusgaapAwardTypeAxis_TwoThousandFifteenEquityIncentivePlanMemberusgaapPlanNameAxis" unitRef="Unit_USD_per_Share" decimals="2" scale="0" format="ixt:numdotdecimal">36.53</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;">&#160;</td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td> </tr> </table> </ix:nonNumeric> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Performance Options </div></div></div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;">Performance Options will vest upon the achievement of both time-based service requirements and liquidity requirements on or before the grant expiration date of March&#160;31, 2026. During the year ended March&#160;31, 2021, the Company recorded <ix:nonFraction name="us-gaap:AllocatedShareBasedCompensationExpense" contextRef="P04_01_2020To03_31_2021_PerformanceOptionsMemberusgaapAwardTypeAxis" unitRef="Unit_USD" decimals="INF" scale="3" format="ixt-sec:numwordsen">no </ix:nonFraction>share-based compensation expense related to these Performance Options as the liquidity event requirement had not been met and was deemed not probable of being met. At March&#160;31, 2021, there was approximately $<ix:nonFraction name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" contextRef="PAsOn03_31_2021_PerformanceOptionsMemberusgaapAwardTypeAxis" unitRef="Unit_USD" decimals="-5" scale="6" format="ixt:numdotdecimal">337.8</ix:nonFraction>&#160;million of unrecognized compensation expense related to <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-vested</div> </div> </ix:continuation> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">F-<div style="letter-spacing: 0px; top: 0px;;display:inline;">30</div> </div></div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;;font-weight: bold;"><div style="display:inline;"><a href="#toc" style="text-indent: 0px;">Table of Contents</a></div></div> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"><ix:continuation id="TextSelectionAppend_28230214_1" continuedAt="TextSelectionAppend_28230214_2"> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Performance Options. The Company will recognize the expense upon achievement of both the time-based service requirement and liquidity requirements through the requisite service period. </div></div> <ix:nonNumeric name="us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" contextRef="P04_01_2020To03_31_2021_PerformanceOptionsMemberusgaapAwardTypeAxis" escape="true"><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The Company estimated the fair value of each Performance Option on the date of grant using the Black-Scholes closed form option-pricing model applying the weighted average assumptions in the following table. </div></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 68%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="font-size: 0px;">
<td style="width: 70%;"></td>
<td style="width: 22%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Year&#160;Ended&#160;March&#160;31,</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 1pt;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Assumptions</div></div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2020</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Expected stock price volatility</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate" contextRef="P04_01_2020To03_31_2021_PerformanceOptionsMemberusgaapAwardTypeAxis" unitRef="Unit_pure" decimals="4" scale="-2" format="ixt:numdotdecimal">73.60</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">%&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Expected risk free interest rate</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" contextRef="P04_01_2020To03_31_2021_PerformanceOptionsMemberusgaapAwardTypeAxis" unitRef="Unit_pure" decimals="4" scale="-2" format="ixt:numdotdecimal">0.62</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">%&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Expected term</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonNumeric name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" contextRef="P04_01_2020To03_31_2021_PerformanceOptionsMemberusgaapAwardTypeAxis" format="ixt-sec:durwordsen">6 years</ix:nonNumeric></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Expected dividend yield</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" contextRef="P04_01_2020To03_31_2021_PerformanceOptionsMemberusgaapAwardTypeAxis" unitRef="Unit_pure" decimals="2" scale="-2" format="ixt:zerodash">&#8212;</ix:nonFraction>&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">%&#160;</td> </tr> </table> </ix:nonNumeric> <ix:nonNumeric name="us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" contextRef="P04_01_2020To03_31_2021_PerformanceOptionsMemberusgaapAwardTypeAxis" escape="true"><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">A summary of Performance Option activity and data under the RSL 2015 EIP for the year ended March&#160;31, 2021 is as follows: </div></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 92%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="font-size: 0px;">
<td style="width: 76%;"></td>
<td style="width: 4%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td>
<td style="width: 4%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td>
<td style="width: 4%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td>
<td style="width: 4%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Number of<br/> Options</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Weighted<br/> Average<br/> Exercise&#160;Price</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Weighted<br/> Average Grant<br/> Date&#160;Fair&#160;Value</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Weighted<br/> Average<br/> Remaining<br/> Contractual&#160;Life</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Performance Options outstanding at March&#160;31, 2020</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" contextRef="PAsOn03_31_2020_PerformanceOptionsMemberusgaapAwardTypeAxis_TwoThousandFifteenEquityIncentivePlanMemberusgaapPlanNameAxis" unitRef="Unit_shares" decimals="INF" scale="0" format="ixt:numdotdecimal">14,518,870</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" contextRef="PAsOn03_31_2020_PerformanceOptionsMemberusgaapAwardTypeAxis_TwoThousandFifteenEquityIncentivePlanMemberusgaapPlanNameAxis" unitRef="Unit_USD_per_Share" decimals="2" scale="0" format="ixt:numdotdecimal">38.97</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="roiv:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageGrantDateFairValue" contextRef="PAsOn03_31_2020_PerformanceOptionsMemberusgaapAwardTypeAxis_TwoThousandFifteenEquityIncentivePlanMemberusgaapPlanNameAxis" unitRef="Unit_USD_per_Share" decimals="2" scale="0" format="ixt:numdotdecimal">23.78</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonNumeric name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" contextRef="P04_01_2019To03_31_2020_PerformanceOptionsMemberusgaapAwardTypeAxis_TwoThousandFifteenEquityIncentivePlanMemberusgaapPlanNameAxis" format="ixt-sec:duryear">6.00</ix:nonNumeric></td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Granted</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" contextRef="P04_01_2020To03_31_2021_PerformanceOptionsMemberusgaapAwardTypeAxis_TwoThousandFifteenEquityIncentivePlanMemberusgaapPlanNameAxis" unitRef="Unit_shares" decimals="INF" scale="0" format="ixt:zerodash">&#8212;</ix:nonFraction>&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" contextRef="P04_01_2020To03_31_2021_PerformanceOptionsMemberusgaapAwardTypeAxis_TwoThousandFifteenEquityIncentivePlanMemberusgaapPlanNameAxis" unitRef="Unit_USD_per_Share" decimals="0" scale="0" format="ixt:zerodash">&#8212;</ix:nonFraction>&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" contextRef="P04_01_2020To03_31_2021_PerformanceOptionsMemberusgaapAwardTypeAxis_TwoThousandFifteenEquityIncentivePlanMemberusgaapPlanNameAxis" unitRef="Unit_USD_per_Share" decimals="0" scale="0" format="ixt:zerodash">&#8212;</ix:nonFraction>&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Forfeited</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(<ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" contextRef="P04_01_2020To03_31_2021_PerformanceOptionsMemberusgaapAwardTypeAxis_TwoThousandFifteenEquityIncentivePlanMemberusgaapPlanNameAxis" unitRef="Unit_shares" decimals="INF" scale="0" format="ixt:numdotdecimal">93,207</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" contextRef="P04_01_2020To03_31_2021_PerformanceOptionsMemberusgaapAwardTypeAxis_TwoThousandFifteenEquityIncentivePlanMemberusgaapPlanNameAxis" unitRef="Unit_USD_per_Share" decimals="2" scale="0" format="ixt:numdotdecimal">46.38</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="roiv:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeitedInPeriodWeightedAverageGrantDateFairValue" contextRef="P04_01_2020To03_31_2021_PerformanceOptionsMemberusgaapAwardTypeAxis_TwoThousandFifteenEquityIncentivePlanMemberusgaapPlanNameAxis" unitRef="Unit_USD_per_Share" decimals="2" scale="0" format="ixt:numdotdecimal">22.18</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Performance Options outstanding at March&#160;31, 2021</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" contextRef="PAsOn03_31_2021_PerformanceOptionsMemberusgaapAwardTypeAxis_TwoThousandFifteenEquityIncentivePlanMemberusgaapPlanNameAxis" unitRef="Unit_shares" decimals="INF" scale="0" format="ixt:numdotdecimal">14,425,663</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" contextRef="PAsOn03_31_2021_PerformanceOptionsMemberusgaapAwardTypeAxis_TwoThousandFifteenEquityIncentivePlanMemberusgaapPlanNameAxis" unitRef="Unit_USD_per_Share" decimals="2" scale="0" format="ixt:numdotdecimal">38.93</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="roiv:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageGrantDateFairValue" contextRef="PAsOn03_31_2021_PerformanceOptionsMemberusgaapAwardTypeAxis_TwoThousandFifteenEquityIncentivePlanMemberusgaapPlanNameAxis" unitRef="Unit_USD_per_Share" decimals="2" scale="0" format="ixt:numdotdecimal">23.42</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonNumeric name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" contextRef="P04_01_2020To03_31_2021_PerformanceOptionsMemberusgaapAwardTypeAxis_TwoThousandFifteenEquityIncentivePlanMemberusgaapPlanNameAxis" format="ixt-sec:duryear">5.00</ix:nonNumeric></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td> </tr> </table> </ix:nonNumeric> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">No Performance Options were exercisable at March&#160;31, 2021. </div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">CVARs </div></div></div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;">CVARs will vest upon the achievement of both time-based service requirements and liquidity requirements on or before the grant expiration date of <ix:nonNumeric name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardExpirationDate" contextRef="P04_01_2020To03_31_2021_CappedValueAppreciationRightsMemberusgaapAwardTypeAxis" format="ixt:datemonthdayyearen">March 31, 2026</ix:nonNumeric>. At settlement, <ix:nonNumeric name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardDescription" contextRef="P04_01_2020To03_31_2021_CappedValueAppreciationRightsMemberusgaapAwardTypeAxis">each CVAR pays in common shares the excess of (a) the lesser of (i) the fair market value of a common share as of the settlement date or (ii) the cap of $37.10, over (b) the hurdle price of either $18.70 or $33.63, as applicable to each grant.</ix:nonNumeric> During the year ended March&#160;31, 2021, the Company recorded <ix:nonFraction name="us-gaap:AllocatedShareBasedCompensationExpense" contextRef="P04_01_2020To03_31_2021_CappedValueAppreciationRightsMemberusgaapAwardTypeAxis" unitRef="Unit_USD" decimals="INF" scale="3" format="ixt-sec:numwordsen">no </ix:nonFraction>share-based compensation expense related to these CVARs as the liquidity event requirement had not been met and was deemed not probable of being met. At March&#160;31, 2021, there was approximately $<ix:nonFraction name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" contextRef="PAsOn03_31_2021_CappedValueAppreciationRightsMemberusgaapAwardTypeAxis" unitRef="Unit_USD" decimals="-5" scale="6" format="ixt:numdotdecimal">23.0</ix:nonFraction>&#160;million of unrecognized compensation expense related to <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-vested</div> CVARs. The Company will recognize the expense upon achievement of both the time-based service requirement and liquidity requirements through the requisite service period. </div> <ix:nonNumeric name="us-gaap:ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock" contextRef="P04_01_2020To03_31_2021_CappedValueAppreciationRightsMemberusgaapAwardTypeAxis" escape="true"><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">A summary of CVARs under the RSL 2015 EIP is as follows: </div></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 76%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="font-size: 0px;">
<td style="width: 56%;"></td>
<td style="width: 13%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td>
<td style="width: 13%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Number&#160;of&#160;CVARs</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Weighted&#160;Average<br/> Grant Date Fair<br/> Value</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">Non-vested</div> balance at March&#160;31, 2020</div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" contextRef="PAsOn03_31_2020_CappedValueAppreciationRightsMemberusgaapAwardTypeAxis_TwoThousandFifteenEquityIncentivePlanMemberusgaapPlanNameAxis" unitRef="Unit_shares" decimals="INF" scale="0" format="ixt:numdotdecimal">11,088,658</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue" contextRef="PAsOn03_31_2020_CappedValueAppreciationRightsMemberusgaapAwardTypeAxis_TwoThousandFifteenEquityIncentivePlanMemberusgaapPlanNameAxis" unitRef="Unit_USD_per_Share" decimals="2" scale="0" format="ixt:numdotdecimal">2.07</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Granted</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" contextRef="P04_01_2020To03_31_2021_CappedValueAppreciationRightsMemberusgaapAwardTypeAxis_TwoThousandFifteenEquityIncentivePlanMemberusgaapPlanNameAxis" unitRef="Unit_shares" decimals="INF" scale="0" format="ixt:zerodash">&#8212;</ix:nonFraction>&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" contextRef="P04_01_2020To03_31_2021_CappedValueAppreciationRightsMemberusgaapAwardTypeAxis_TwoThousandFifteenEquityIncentivePlanMemberusgaapPlanNameAxis" unitRef="Unit_USD_per_Share" decimals="0" scale="0" format="ixt:zerodash">&#8212;</ix:nonFraction>&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Forfeited</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" contextRef="P04_01_2020To03_31_2021_CappedValueAppreciationRightsMemberusgaapAwardTypeAxis_TwoThousandFifteenEquityIncentivePlanMemberusgaapPlanNameAxis" unitRef="Unit_shares" decimals="INF" scale="0" format="ixt:zerodash">&#8212;</ix:nonFraction>&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedWeightedAverageGrantDateFairValue" contextRef="P04_01_2020To03_31_2021_CappedValueAppreciationRightsMemberusgaapAwardTypeAxis_TwoThousandFifteenEquityIncentivePlanMemberusgaapPlanNameAxis" unitRef="Unit_USD_per_Share" decimals="0" scale="0" format="ixt:zerodash">&#8212;</ix:nonFraction>&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;">&#160;</td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">Non-vested</div> balance at March&#160;31, 2021</div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" contextRef="PAsOn03_31_2021_CappedValueAppreciationRightsMemberusgaapAwardTypeAxis_TwoThousandFifteenEquityIncentivePlanMemberusgaapPlanNameAxis" unitRef="Unit_shares" decimals="INF" scale="0" format="ixt:numdotdecimal">11,088,658</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue" contextRef="PAsOn03_31_2021_CappedValueAppreciationRightsMemberusgaapAwardTypeAxis_TwoThousandFifteenEquityIncentivePlanMemberusgaapPlanNameAxis" unitRef="Unit_USD_per_Share" decimals="2" scale="0" format="ixt:numdotdecimal">2.07</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;">&#160;</td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td> </tr> </table> </ix:nonNumeric> </ix:continuation> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">F-<div style="letter-spacing: 0px; top: 0px;;display:inline;">31</div> </div></div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="text-align: center;"> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em; text-align: left;;font-weight: bold;"><div style="display:inline;"><a href="#toc" style="text-indent: 0px;">Table of Contents</a></div></div> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"><ix:continuation id="TextSelectionAppend_28230214_2" continuedAt="TextSelectionAppend_28230214_3"> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">(B) RSL 2015 Restricted Stock Unit Plan </div></div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Under the Amended and Restated RSL 2015 Restricted Stock Unit Plan (the &#8220;pRSU Plan&#8221;), as of March&#160;31, 2021, there are <ix:nonFraction name="us-gaap:CommonStockCapitalSharesReservedForFutureIssuance" contextRef="PAsOn03_31_2021_PerformanceRestrictedStockUnitsPlanMemberusgaapPlanNameAxis" unitRef="Unit_shares" decimals="INF" scale="0" format="ixt:numdotdecimal">200,000</ix:nonFraction> of the Company&#8217;s common shares reserved for issuance in connection with pRSUs that may be granted to employees, officers, directors and consultants of the Company under the pRSU Plan. The pRSUs expire <ix:nonNumeric name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" contextRef="P04_01_2020To03_31_2021_PerformanceRestrictedStockUnitsPlanMemberusgaapPlanNameAxis" format="ixt-sec:durwordsen">eight years</ix:nonNumeric> after the date of grant. At March&#160;31, 2021, none of the Company&#8217;s common shares were reserved for future grants under this plan. </div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">As part of the Roivant Equity Repurchase, <ix:nonFraction name="roiv:SharebasedCompensationArrangementBySharebasedPaymentAwardAggregateRepurchasePrice" contextRef="P04_01_2020To03_31_2021_PerformanceRestrictedStockUnitsPlanMemberusgaapPlanNameAxis" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:numdotdecimal">17,044,465</ix:nonFraction> existing pRSUs were surrendered and exchanged for newly issued Performance Options and CVARs issued under an amended and restated RSL 2015 EIP (see above), of which approximately <ix:nonFraction name="roiv:ShareBasedCompensationRightToRepurchasePercentage" contextRef="P04_01_2020To03_31_2021_PerformanceRestrictedStockUnitsPlanMemberusgaapPlanNameAxis" unitRef="Unit_pure" decimals="4" scale="-2" format="ixt:numdotdecimal">11.23</ix:nonFraction>% were then immediately purchased by the Company, during the year ended March&#160;31, 2020. Refer to Note 10, &#8220;Shareholders&#8217; Equity and Redeemable Noncontrolling Interest&#8221; for additional detail regarding the Roivant Equity Repurchase. </div></div> <ix:nonNumeric name="us-gaap:ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock" contextRef="P04_01_2020To03_31_2021_PerformanceRestrictedStockUnitsMemberusgaapAwardTypeAxis" escape="true"><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">A summary of pRSU activity under the pRSU Plan is as follows: </div></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 76%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="font-size: 0px;">
<td style="width: 64%;"></td>
<td style="width: 10%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td>
<td style="width: 10%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Number&#160;of<br/> pRSUs</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Weighted&#160;Average<br/> Grant Date Fair<br/> Value</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">Non-vested</div> balance at March&#160;31, 2020</div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" contextRef="PAsOn03_31_2020_PerformanceRestrictedStockUnitsMemberusgaapAwardTypeAxis_PerformanceRestrictedStockUnitsPlanMemberusgaapPlanNameAxis" unitRef="Unit_shares" decimals="INF" scale="0" format="ixt:numdotdecimal">266,845</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue" contextRef="PAsOn03_31_2020_PerformanceRestrictedStockUnitsMemberusgaapAwardTypeAxis_PerformanceRestrictedStockUnitsPlanMemberusgaapPlanNameAxis" unitRef="Unit_USD_per_Share" decimals="2" scale="0" format="ixt:numdotdecimal">13.92</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Granted</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" contextRef="P04_01_2020To03_31_2021_PerformanceRestrictedStockUnitsMemberusgaapAwardTypeAxis_PerformanceRestrictedStockUnitsPlanMemberusgaapPlanNameAxis" unitRef="Unit_shares" decimals="INF" scale="0" format="ixt:zerodash">&#8212;</ix:nonFraction>&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" contextRef="P04_01_2020To03_31_2021_PerformanceRestrictedStockUnitsMemberusgaapAwardTypeAxis_PerformanceRestrictedStockUnitsPlanMemberusgaapPlanNameAxis" unitRef="Unit_USD_per_Share" decimals="0" scale="0" format="ixt:zerodash">&#8212;</ix:nonFraction>&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Forfeited</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(<ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" contextRef="P04_01_2020To03_31_2021_PerformanceRestrictedStockUnitsMemberusgaapAwardTypeAxis_PerformanceRestrictedStockUnitsPlanMemberusgaapPlanNameAxis" unitRef="Unit_shares" decimals="INF" scale="0" format="ixt:numdotdecimal">66,845</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedWeightedAverageGrantDateFairValue" contextRef="P04_01_2020To03_31_2021_PerformanceRestrictedStockUnitsMemberusgaapAwardTypeAxis_PerformanceRestrictedStockUnitsPlanMemberusgaapPlanNameAxis" unitRef="Unit_USD_per_Share" decimals="2" scale="0" format="ixt:numdotdecimal">13.92</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;">&#160;</td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">Non-vested</div> balance at March&#160;31, 2021</div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" contextRef="PAsOn03_31_2021_PerformanceRestrictedStockUnitsMemberusgaapAwardTypeAxis_PerformanceRestrictedStockUnitsPlanMemberusgaapPlanNameAxis" unitRef="Unit_shares" decimals="INF" scale="0" format="ixt:numdotdecimal">200,000</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue" contextRef="PAsOn03_31_2021_PerformanceRestrictedStockUnitsMemberusgaapAwardTypeAxis_PerformanceRestrictedStockUnitsPlanMemberusgaapPlanNameAxis" unitRef="Unit_USD_per_Share" decimals="2" scale="0" format="ixt:numdotdecimal">13.92</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;">&#160;</td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td> </tr> </table> </ix:nonNumeric> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">These pRSUs will vest to the extent certain performance criteria are achieved and certain liquidity conditions are satisfied within specified years of the grant date, provided that the recipient has provided continued service through such date. As of&#160;March&#160;31, 2021, the performance conditions had not been met and were deemed not probable of being met. During the year ended March&#160;31, 2021, the Company recorded&#160;no share-based compensation expense related to these pRSUs. During the year ended March&#160;31, 2020, the Company recorded $<ix:nonFraction name="us-gaap:AllocatedShareBasedCompensationExpense" contextRef="P04_01_2020To03_31_2021_PerformanceRestrictedStockUnitsMemberusgaapAwardTypeAxis" unitRef="Unit_USD" decimals="INF" scale="6" format="ixt:numdotdecimal">12.3</ix:nonFraction>&#160;million of share-based compensation expense relating to cash payments made for the purchase of a portion of the Performance Options and CVARs issued in replacement of pRSUs. At March&#160;31, 2021, there was approximately $<ix:nonFraction name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" contextRef="PAsOn03_31_2021_PerformanceRestrictedStockUnitsMemberusgaapAwardTypeAxis" unitRef="Unit_USD" decimals="-5" scale="6" format="ixt:numdotdecimal">2.8</ix:nonFraction>&#160;million of unrecognized compensation expense related to <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-vested</div> pRSUs. The Company will recognize the expense upon achievement of the performance and liquidity conditions through the requisite service period. </div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">(C) RSL Restricted Common Stock </div></div></div> <ix:nonNumeric name="us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" contextRef="P04_01_2020To03_31_2021_CommonStockAwardsMemberusgaapAwardTypeAxis" escape="true"><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">A summary of RSL restricted common stock activity as of March&#160;31, 2021 is as follows: </div></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 76%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="font-size: 0px;">
<td style="width: 64%;"></td>
<td style="width: 10%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td>
<td style="width: 10%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Number&#160;of<br/> Restricted<br/> Common<br/> Stock</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Weighted&#160;Average<br/> Grant Date Fair<br/> Value</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">Non-vested</div> balance at March&#160;31, 2020</div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" contextRef="PAsOn03_31_2020_CommonStockAwardsMemberusgaapAwardTypeAxis" unitRef="Unit_shares" decimals="INF" scale="0" format="ixt:zerodash">&#8212;</ix:nonFraction>&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Granted</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" contextRef="P04_01_2020To03_31_2021_CommonStockAwardsMemberusgaapAwardTypeAxis" unitRef="Unit_shares" decimals="INF" scale="0" format="ixt:numdotdecimal">587,824</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" contextRef="P04_01_2020To03_31_2021_CommonStockAwardsMemberusgaapAwardTypeAxis" unitRef="Unit_USD_per_Share" decimals="2" scale="0" format="ixt:numdotdecimal">38.50</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Vested</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" contextRef="P04_01_2020To03_31_2021_CommonStockAwardsMemberusgaapAwardTypeAxis" unitRef="Unit_shares" decimals="INF" scale="0" format="ixt:zerodash">&#8212;</ix:nonFraction>&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" contextRef="P04_01_2020To03_31_2021_CommonStockAwardsMemberusgaapAwardTypeAxis" unitRef="Unit_USD_per_Share" decimals="0" scale="0" format="ixt:zerodash">&#8212;</ix:nonFraction>&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Forfeited</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" contextRef="P04_01_2020To03_31_2021_CommonStockAwardsMemberusgaapAwardTypeAxis" unitRef="Unit_shares" decimals="INF" scale="0" format="ixt:zerodash">&#8212;</ix:nonFraction>&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" contextRef="P04_01_2020To03_31_2021_CommonStockAwardsMemberusgaapAwardTypeAxis" unitRef="Unit_USD_per_Share" decimals="0" scale="0" format="ixt:zerodash">&#8212;</ix:nonFraction>&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;">&#160;</td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">Non-vested</div> balance at March&#160;31, 2021</div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" contextRef="PAsOn03_31_2021_CommonStockAwardsMemberusgaapAwardTypeAxis" unitRef="Unit_shares" decimals="INF" scale="0" format="ixt:numdotdecimal">587,824</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" contextRef="PAsOn03_31_2021_CommonStockAwardsMemberusgaapAwardTypeAxis" unitRef="Unit_USD_per_Share" decimals="2" scale="0" format="ixt:numdotdecimal">38.50</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;">&#160;</td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td> </tr> </table> </ix:nonNumeric> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">For the year ended March&#160;31, 2021, the Company recorded share-based compensation expense of $<ix:nonFraction name="us-gaap:AllocatedShareBasedCompensationExpense" contextRef="P04_01_2020To03_31_2021_CommonStockAwardsMemberusgaapAwardTypeAxis" unitRef="Unit_USD" decimals="INF" scale="6" format="ixt:numdotdecimal">0.1</ix:nonFraction>&#160;million in relation to the RSL restricted common stock. At March&#160;31, 2021, total unrecognized compensation expense related to <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-vested</div> restricted common stock was approximately $<ix:nonFraction name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" contextRef="PAsOn03_31_2021_CommonStockAwardsMemberusgaapAwardTypeAxis" unitRef="Unit_USD" decimals="-5" scale="6" format="ixt:numdotdecimal">6.9</ix:nonFraction>&#160;million and is expected to be recognized over the remaining weighted-average service period of <ix:nonNumeric name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" contextRef="P04_01_2020To03_31_2021_CommonStockAwardsMemberusgaapAwardTypeAxis" format="ixt-sec:duryear">3.39</ix:nonNumeric> years. $<ix:nonFraction name="us-gaap:RestrictedInvestmentsAtFairValue" contextRef="PAsOn03_31_2021_CommonStockAwardsMemberusgaapAwardTypeAxis" unitRef="Unit_USD" decimals="-5" scale="6" format="ixt:numdotdecimal">15.6</ix:nonFraction>&#160;million of the fair value associated with these restricted common stock was attributed to precombination service. Refer to Note 4, &#8220;Asset Acquisitions and License Agreements.&#8221; </div> </ix:continuation> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">F-<div style="letter-spacing: 0px; top: 0px;;display:inline;">32</div> </div></div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;;font-weight: bold;"><div style="display:inline;"><a href="#toc" style="text-indent: 0px;">Table of Contents</a></div></div> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"><ix:continuation id="TextSelectionAppend_28230214_3"> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">(D) Subsidiary Equity Incentive Plans </div></div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;">Certain wholly owned and majority-owned or controlled subsidiaries of RSL adopt their own equity incentive plan (&#8220;EIP&#8221;). Each EIP is generally structured so that the applicable subsidiary, and its affiliates&#8217; employees, directors, officers and consultants are eligible to receive <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-qualified</div> and incentive stock options, stock appreciation rights, restricted share awards, restricted stock unit awards, and other share awards under their respective EIP. Standard option grants have time-based vesting requirements, generally vesting over a period of <ix:nonNumeric name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" contextRef="P04_01_2020To03_31_2021_SubsidiaryEquityIncentivePlanMemberusgaapPlanNameAxis" format="ixt-sec:durwordsen">four years</ix:nonNumeric> with a contractual term of <ix:nonNumeric name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" contextRef="P04_01_2020To03_31_2021_SubsidiaryEquityIncentivePlanMemberusgaapPlanNameAxis" format="ixt-sec:durwordsen">ten years</ix:nonNumeric>. Such time-based stock options use the Black-Scholes option pricing model. The grant date fair value of awards subject to market conditions is estimated using a Monte Carlo valuation model. For the years ended March&#160;31, 2021 and 2020, the Company recorded share-based compensation expense of $<ix:nonFraction name="us-gaap:AllocatedShareBasedCompensationExpense" contextRef="P04_01_2020To03_31_2021_SubsidiaryEquityIncentivePlanMemberusgaapPlanNameAxis" unitRef="Unit_USD" decimals="INF" scale="6" format="ixt:numdotdecimal">29.1</ix:nonFraction>&#160;million and $<ix:nonFraction name="us-gaap:AllocatedShareBasedCompensationExpense" contextRef="P04_01_2019To03_31_2020_SubsidiaryEquityIncentivePlanMemberusgaapPlanNameAxis" unitRef="Unit_USD" decimals="INF" scale="6" format="ixt:numdotdecimal">22.1</ix:nonFraction>&#160;million, respectively, in relation to subsidiary EIPs. </div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">(E) Share-Based Compensation Expense </div></div></div> <ix:nonNumeric name="us-gaap:ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock" contextRef="P04_01_2020To03_31_2021" escape="true"><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Share-based compensation expense from continuing operations was as follows (in thousands): </div></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 76%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="font-size: 0px;">
<td style="width: 74%;"></td>
<td style="width: 5%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td>
<td style="width: 5%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;&#160;</td>
<td colspan="6" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Years Ended<br/> March&#160;31,</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2021</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2020</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Share-based compensation expense recognized as:</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: bottom;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">R&amp;D expenses</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">$</td>
<td style="vertical-align: bottom;;text-align:right;"><ix:nonFraction name="us-gaap:AllocatedShareBasedCompensationExpense" contextRef="P04_01_2020To03_31_2021_ResearchAndDevelopmentExpenseMemberusgaapIncomeStatementLocationAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">22,637</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">$</td>
<td style="vertical-align: bottom;;text-align:right;"><ix:nonFraction name="us-gaap:AllocatedShareBasedCompensationExpense" contextRef="P04_01_2019To03_31_2020_ResearchAndDevelopmentExpenseMemberusgaapIncomeStatementLocationAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">7,738</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">G&amp;A expenses</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:AllocatedShareBasedCompensationExpense" contextRef="P04_01_2020To03_31_2021_GeneralAndAdministrativeExpenseMemberusgaapIncomeStatementLocationAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">62,321</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:AllocatedShareBasedCompensationExpense" contextRef="P04_01_2019To03_31_2020_GeneralAndAdministrativeExpenseMemberusgaapIncomeStatementLocationAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">60,013</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;">&#160;</td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Total</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:AllocatedShareBasedCompensationExpense" contextRef="P04_01_2020To03_31_2021" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">84,958</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:AllocatedShareBasedCompensationExpense" contextRef="P04_01_2019To03_31_2020" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">67,751</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;">&#160;</td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td> </tr> </table> </ix:nonNumeric> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The classification of share-based compensation expense between R&amp;D and G&amp;A expenses in the accompanying consolidated statements of operations is consistent with the classification of grantee&#8217;s salary expense. </div></div> </ix:continuation> <ix:nonNumeric name="us-gaap:IncomeTaxDisclosureTextBlock" contextRef="P04_01_2020To03_31_2021" escape="true" continuedAt="TextSelection_28230172"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Note 12&#8212;Income Taxes </div></div></div> <ix:nonNumeric name="us-gaap:ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock" contextRef="P04_01_2020To03_31_2021" escape="true" continuedAt="TextSelection_28230176"><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The loss before income taxes and the related expense/(benefit) are as follows (in thousands): </div></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 76%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="font-size: 0px;">
<td style="width: 70%;"></td>
<td style="width: 5%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td>
<td style="width: 5%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;&#160;</td>
<td colspan="6" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Years Ended March&#160;31,</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2021</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2020</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Loss before income taxes:</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">United States</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(<ix:nonFraction name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments" contextRef="P04_01_2020To03_31_2021_USsrtStatementGeographicalAxis" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:numdotdecimal">212,921</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(<ix:nonFraction name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments" contextRef="P04_01_2019To03_31_2020_USsrtStatementGeographicalAxis" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:numdotdecimal">69,264</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Switzerland</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(<ix:nonFraction name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments" contextRef="P04_01_2020To03_31_2021_CHsrtStatementGeographicalAxis" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:numdotdecimal">424,494</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(<ix:nonFraction name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments" contextRef="P04_01_2019To03_31_2020_CHsrtStatementGeographicalAxis" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:numdotdecimal">355,422</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Bermuda</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(<ix:nonFraction name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments" contextRef="P04_01_2020To03_31_2021_BMsrtStatementGeographicalAxis" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:numdotdecimal">227,471</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(<ix:nonFraction name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments" contextRef="P04_01_2019To03_31_2020_BMsrtStatementGeographicalAxis" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:numdotdecimal">105,604</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Other<div style="font-size: 85%; vertical-align: top;;display:inline;;font-size:9.4px">(1)</div></div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(<ix:nonFraction name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments" contextRef="P04_01_2020To03_31_2021_OtherMembersrtStatementGeographicalAxis" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:numdotdecimal" id="Fact_28229787">33,661</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(<ix:nonFraction name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments" contextRef="P04_01_2019To03_31_2020_OtherMembersrtStatementGeographicalAxis" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:numdotdecimal" id="Fact_28229788">30,696</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 5em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Total loss before income taxes</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(<ix:nonFraction name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments" contextRef="P04_01_2020To03_31_2021" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:numdotdecimal">898,547</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(<ix:nonFraction name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments" contextRef="P04_01_2019To03_31_2020" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:numdotdecimal">560,986</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td> </tr> </table> <div style="clear: both; max-height: 0px;"></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 4%; vertical-align: top;;text-align:left;"><div style="font-size: 85%; vertical-align: top;;display:inline;;font-size:9.4px">(1)</div>&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Primarily Greater China and United Kingdom activity </div></div> </td> </tr> </table> </ix:nonNumeric> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></ix:nonNumeric> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">F-<div style="letter-spacing: 0px; top: 0px;;display:inline;">33</div> </div></div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="text-align: center;"> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em; text-align: left;;font-weight: bold;"><div style="display:inline;"><a href="#toc" style="text-indent: 0px;">Table of Contents</a></div></div> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"><ix:continuation id="TextSelection_28230172" continuedAt="TextSelectionAppend_28230172_1"><ix:continuation id="TextSelection_28230176">
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 76%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="font-size: 0px;">
<td style="width: 74%;"></td>
<td style="width: 7%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td>
<td style="width: 7%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;&#160;</td>
<td colspan="6" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Years&#160;Ended&#160;March&#160;31,</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;&#160;&#160;&#160;2021&#160;&#160;&#160;&#160;</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;&#160;&#160;&#160;2020&#160;&#160;&#160;&#160;</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Current taxes:</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">United States</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:CurrentIncomeTaxExpenseBenefit" contextRef="P04_01_2020To03_31_2021_USsrtStatementGeographicalAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">1,365</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:CurrentIncomeTaxExpenseBenefit" contextRef="P04_01_2019To03_31_2020_USsrtStatementGeographicalAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">6,327</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Switzerland</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:CurrentIncomeTaxExpenseBenefit" contextRef="P04_01_2020To03_31_2021_CHsrtStatementGeographicalAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:zerodash">&#8212;</ix:nonFraction>&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:CurrentIncomeTaxExpenseBenefit" contextRef="P04_01_2019To03_31_2020_CHsrtStatementGeographicalAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:zerodash">&#8212;</ix:nonFraction>&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Bermuda</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:CurrentIncomeTaxExpenseBenefit" contextRef="P04_01_2020To03_31_2021_BMsrtStatementGeographicalAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:zerodash">&#8212;</ix:nonFraction>&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:CurrentIncomeTaxExpenseBenefit" contextRef="P04_01_2019To03_31_2020_BMsrtStatementGeographicalAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:zerodash">&#8212;</ix:nonFraction>&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Other<div style="font-size: 85%; vertical-align: top;;display:inline;;font-size:9.4px">(1)</div></div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:CurrentIncomeTaxExpenseBenefit" contextRef="P04_01_2020To03_31_2021_OtherMembersrtStatementGeographicalAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal" id="Fact_28229485">321</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:CurrentIncomeTaxExpenseBenefit" contextRef="P04_01_2019To03_31_2020_OtherMembersrtStatementGeographicalAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal" id="Fact_28229486">797</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;">&#160;</td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 5em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Total current tax expense</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:CurrentIncomeTaxExpenseBenefit" contextRef="P04_01_2020To03_31_2021" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">1,686</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:CurrentIncomeTaxExpenseBenefit" contextRef="P04_01_2019To03_31_2020" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">7,124</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;">&#160;</td> </tr>
<tr style="font-size: 1pt;">
<td style="height: 6pt; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td colspan="4" style="height: 6pt; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td colspan="4" style="height: 6pt; font-family: &quot;Times New Roman&quot;;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Deferred taxes:</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">United States</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:DeferredIncomeTaxExpenseBenefit" contextRef="P04_01_2020To03_31_2021_USsrtStatementGeographicalAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:zerodash">&#8212;</ix:nonFraction>&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:DeferredIncomeTaxExpenseBenefit" contextRef="P04_01_2019To03_31_2020_USsrtStatementGeographicalAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:zerodash">&#8212;</ix:nonFraction>&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Switzerland</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:DeferredIncomeTaxExpenseBenefit" contextRef="P04_01_2020To03_31_2021_CHsrtStatementGeographicalAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:zerodash">&#8212;</ix:nonFraction>&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:DeferredIncomeTaxExpenseBenefit" contextRef="P04_01_2019To03_31_2020_CHsrtStatementGeographicalAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:zerodash">&#8212;</ix:nonFraction>&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Bermuda</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:DeferredIncomeTaxExpenseBenefit" contextRef="P04_01_2020To03_31_2021_BMsrtStatementGeographicalAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:zerodash">&#8212;</ix:nonFraction>&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:DeferredIncomeTaxExpenseBenefit" contextRef="P04_01_2019To03_31_2020_BMsrtStatementGeographicalAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:zerodash">&#8212;</ix:nonFraction>&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Other<div style="font-size: 85%; vertical-align: top;;display:inline;;font-size:9.4px">(1)</div></div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:DeferredIncomeTaxExpenseBenefit" contextRef="P04_01_2020To03_31_2021_OtherMembersrtStatementGeographicalAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:zerodash">&#8212;</ix:nonFraction>&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:DeferredIncomeTaxExpenseBenefit" contextRef="P04_01_2019To03_31_2020_OtherMembersrtStatementGeographicalAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:zerodash">&#8212;</ix:nonFraction>&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 5em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Total deferred tax benefit</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:DeferredIncomeTaxExpenseBenefit" contextRef="P04_01_2020To03_31_2021" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:zerodash">&#8212;</ix:nonFraction>&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:DeferredIncomeTaxExpenseBenefit" contextRef="P04_01_2019To03_31_2020" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:zerodash">&#8212;</ix:nonFraction>&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;">&#160;</td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 7em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Total income tax expense</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:IncomeTaxExpenseBenefit" contextRef="P04_01_2020To03_31_2021" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">1,686</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:IncomeTaxExpenseBenefit" contextRef="P04_01_2019To03_31_2020" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">7,124</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;">&#160;</td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td> </tr> </table> <div style="clear: both; max-height: 0px;"></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 4%; vertical-align: top;;text-align:left;"><div style="font-size: 85%; vertical-align: top;;display:inline;;font-size:9.4px">(1)</div></td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Primarily Greater China, United States state and local and United Kingdom activity </div></div> </td> </tr> </table> </ix:continuation> <ix:nonNumeric name="us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" contextRef="P04_01_2020To03_31_2021" escape="true"><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">A reconciliation of income tax provision/(benefit) computed at the Bermuda statutory rate to income tax expense reflected in the consolidated financial statements is as follows (in thousands, except percentages): </div></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 92%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="font-size: 0px;">
<td style="width: 59%;"></td>
<td style="width: 6%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td>
<td style="width: 6%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td>
<td style="width: 5%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td>
<td style="width: 6%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;&#160;</td>
<td colspan="6" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Year Ended March&#160;31,<br/> 2021</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td colspan="6" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Year Ended<br/> March&#160;31, 2020</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Income tax benefit at Bermuda statutory rate</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate" contextRef="P04_01_2020To03_31_2021" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:zerodash">&#8212;</ix:nonFraction>&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">%&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate" contextRef="P04_01_2019To03_31_2020" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:zerodash">&#8212;</ix:nonFraction>&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">%&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Foreign rate differential<div style="font-size: 85%; vertical-align: top;;display:inline;;font-size:9.4px">(1)</div></div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(<ix:nonFraction name="us-gaap:IncomeTaxReconciliationForeignIncomeTaxRateDifferential" contextRef="P04_01_2020To03_31_2021" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:numdotdecimal" id="Fact_28229520">150,778</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential" contextRef="P04_01_2020To03_31_2021" unitRef="Unit_pure" decimals="4" scale="-2" format="ixt:numdotdecimal" id="Fact_28229521">16.78</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">%&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(<ix:nonFraction name="us-gaap:IncomeTaxReconciliationForeignIncomeTaxRateDifferential" contextRef="P04_01_2019To03_31_2020" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:numdotdecimal" id="Fact_28229522">74,922</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential" contextRef="P04_01_2019To03_31_2020" unitRef="Unit_pure" decimals="4" scale="-2" format="ixt:numdotdecimal" id="Fact_28229523">13.36</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">%&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Permanent disallowed IPR&amp;D</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:IncomeTaxReconciliationNondeductibleExpenseResearchAndDevelopment" contextRef="P04_01_2020To03_31_2021" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">111,432</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(<ix:nonFraction name="us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseResearchAndDevelopment" contextRef="P04_01_2020To03_31_2021" unitRef="Unit_pure" decimals="4" scale="-2" sign="-" format="ixt:numdotdecimal">12.40</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)%&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">%&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Nondeductible changes in the fair value of investments and loss from equity method investment</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(<ix:nonFraction name="us-gaap:IncomeTaxReconciliationNondeductibleExpense" contextRef="P04_01_2020To03_31_2021" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:numdotdecimal">22,472</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpense" contextRef="P04_01_2020To03_31_2021" unitRef="Unit_pure" decimals="4" scale="-2" format="ixt:numdotdecimal">2.50</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">%&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:IncomeTaxReconciliationNondeductibleExpense" contextRef="P04_01_2019To03_31_2020" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">20,840</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(<ix:nonFraction name="us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpense" contextRef="P04_01_2019To03_31_2020" unitRef="Unit_pure" decimals="4" scale="-2" sign="-" format="ixt:numdotdecimal">3.72</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)%&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Nontaxable (loss) gain on deconsolidation of business</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(<ix:nonFraction name="us-gaap:IncomeTaxReconciliationDispositionOfBusiness" contextRef="P04_01_2020To03_31_2021" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:numdotdecimal">16,438</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:EffectiveIncomeTaxRateReconciliationDispositionOfBusiness" contextRef="P04_01_2020To03_31_2021" unitRef="Unit_pure" decimals="4" scale="-2" sign="-" format="ixt:numdotdecimal">1.83</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">%&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:IncomeTaxReconciliationDispositionOfBusiness" contextRef="P04_01_2019To03_31_2020" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">29,041</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(<ix:nonFraction name="us-gaap:EffectiveIncomeTaxRateReconciliationDispositionOfBusiness" contextRef="P04_01_2019To03_31_2020" unitRef="Unit_pure" decimals="4" scale="-2" format="ixt:numdotdecimal">5.18</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)%&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Permanent adjustments</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="roiv:IncomeTaxReconciliationPermanentAdjustments" contextRef="P04_01_2020To03_31_2021" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">2,923</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(<ix:nonFraction name="roiv:EffectiveIncomeTaxReconciliationPermanentDifferences" contextRef="P04_01_2020To03_31_2021" unitRef="Unit_pure" decimals="4" scale="-2" sign="-" format="ixt:numdotdecimal">0.33</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)%&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(<ix:nonFraction name="roiv:IncomeTaxReconciliationPermanentAdjustments" contextRef="P04_01_2019To03_31_2020" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:numdotdecimal">20,395</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="roiv:EffectiveIncomeTaxReconciliationPermanentDifferences" contextRef="P04_01_2019To03_31_2020" unitRef="Unit_pure" decimals="4" scale="-2" format="ixt:numdotdecimal">3.64</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">%&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">R&amp;D tax credits</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(<ix:nonFraction name="us-gaap:IncomeTaxReconciliationTaxCreditsResearch" contextRef="P04_01_2020To03_31_2021" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">10,555</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:EffectiveIncomeTaxRateReconciliationTaxCreditsResearch" contextRef="P04_01_2020To03_31_2021" unitRef="Unit_pure" decimals="4" scale="-2" sign="-" format="ixt:numdotdecimal">1.17</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">%&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(<ix:nonFraction name="us-gaap:IncomeTaxReconciliationTaxCreditsResearch" contextRef="P04_01_2019To03_31_2020" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">5,990</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:EffectiveIncomeTaxRateReconciliationTaxCreditsResearch" contextRef="P04_01_2019To03_31_2020" unitRef="Unit_pure" decimals="4" scale="-2" sign="-" format="ixt:numdotdecimal">1.07</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">%&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Rate changes</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:IncomeTaxReconciliationChangeInEnactedTaxRate" contextRef="P04_01_2020To03_31_2021" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">2,443</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(<ix:nonFraction name="us-gaap:EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate" contextRef="P04_01_2020To03_31_2021" unitRef="Unit_pure" decimals="4" scale="-2" sign="-" format="ixt:numdotdecimal">0.27</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)%&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(<ix:nonFraction name="us-gaap:IncomeTaxReconciliationChangeInEnactedTaxRate" contextRef="P04_01_2019To03_31_2020" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:numdotdecimal">29,238</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate" contextRef="P04_01_2019To03_31_2020" unitRef="Unit_pure" decimals="4" scale="-2" format="ixt:numdotdecimal">5.21</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">%&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Valuation allowance</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance" contextRef="P04_01_2020To03_31_2021" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">85,046</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(<ix:nonFraction name="us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" contextRef="P04_01_2020To03_31_2021" unitRef="Unit_pure" decimals="4" scale="-2" format="ixt:numdotdecimal">9.46</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)%&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance" contextRef="P04_01_2019To03_31_2020" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">87,677</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(<ix:nonFraction name="us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" contextRef="P04_01_2019To03_31_2020" unitRef="Unit_pure" decimals="4" scale="-2" format="ixt:numdotdecimal">15.63</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)%&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Other</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:IncomeTaxReconciliationOtherAdjustments" contextRef="P04_01_2020To03_31_2021" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">85</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(<ix:nonFraction name="us-gaap:EffectiveIncomeTaxRateReconciliationOtherAdjustments" contextRef="P04_01_2020To03_31_2021" unitRef="Unit_pure" decimals="4" scale="-2" format="ixt:numdotdecimal">0.01</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)%&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:IncomeTaxReconciliationOtherAdjustments" contextRef="P04_01_2019To03_31_2020" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">111</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(<ix:nonFraction name="us-gaap:EffectiveIncomeTaxRateReconciliationOtherAdjustments" contextRef="P04_01_2019To03_31_2020" unitRef="Unit_pure" decimals="4" scale="-2" format="ixt:numdotdecimal">0.02</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)%&#160;</td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: bottom;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Total income tax expense</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">$</td>
<td style="vertical-align: bottom;;text-align:right;"><ix:nonFraction name="us-gaap:IncomeTaxExpenseBenefit" contextRef="P04_01_2020To03_31_2021" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">1,686</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">(<ix:nonFraction name="us-gaap:EffectiveIncomeTaxRateContinuingOperations" contextRef="P04_01_2020To03_31_2021" unitRef="Unit_pure" decimals="4" scale="-2" sign="-" format="ixt:numdotdecimal">0.19</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)%&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">$</td>
<td style="vertical-align: bottom;;text-align:right;"><ix:nonFraction name="us-gaap:IncomeTaxExpenseBenefit" contextRef="P04_01_2019To03_31_2020" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">7,124</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">(<ix:nonFraction name="us-gaap:EffectiveIncomeTaxRateContinuingOperations" contextRef="P04_01_2019To03_31_2020" unitRef="Unit_pure" decimals="4" scale="-2" sign="-" format="ixt:numdotdecimal">1.27</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)%&#160;</td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td> </tr> </table> <div style="clear: both; max-height: 0px;"></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 4%; vertical-align: top;;text-align:left;"><div style="font-size: 85%; vertical-align: top;;display:inline;;font-size:9.4px">(1)</div></td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Primarily related to operations in Switzerland, the United Kingdom, and other jurisdictions with statutory tax rates different than the Bermuda rate. </div></div> </td> </tr> </table> </ix:nonNumeric> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The Company&#8217;s effective tax rates were (<ix:nonFraction name="us-gaap:EffectiveIncomeTaxRateContinuingOperations" contextRef="P04_01_2020To03_31_2021" unitRef="Unit_pure" decimals="4" scale="-2" sign="-" format="ixt:numdotdecimal">0.19</ix:nonFraction>)% and (<ix:nonFraction name="us-gaap:EffectiveIncomeTaxRateContinuingOperations" contextRef="P04_01_2019To03_31_2020" unitRef="Unit_pure" decimals="4" scale="-2" sign="-" format="ixt:numdotdecimal">1.27</ix:nonFraction>)% for the years ended March&#160;31, 2021 and 2020, respectively, driven by the Company&#8217;s jurisdictional earnings by location and a valuation allowance that eliminates the Company&#8217;s global net deferred tax assets. </div></div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </ix:continuation> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">F-<div style="letter-spacing: 0px; top: 0px;;display:inline;">34</div> </div></div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;;font-weight: bold;"><div style="display:inline;"><a href="#toc" style="text-indent: 0px;">Table of Contents</a></div></div> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"><ix:continuation id="TextSelectionAppend_28230172_1" continuedAt="TextSelectionAppend_28230172_2"> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Deferred taxes reflect the tax effects of the differences between the amounts recorded as assets and liabilities for financial reporting purposes and the comparable amounts recorded for income tax purposes. <ix:nonNumeric name="us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" contextRef="P04_01_2020To03_31_2021" escape="true" continuedAt="TextSelection_28230180">Significant components of the deferred tax assets (liabilities) at March&#160;31, 2021 and 2020 are as follows (in thousands):</ix:nonNumeric> </div></div> <ix:continuation id="TextSelection_28230180"> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 76%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="font-size: 0px;">
<td style="width: 62%;"></td>
<td style="width: 12%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td>
<td style="width: 12%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">March&#160;31,&#160;2021</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">March&#160;31,&#160;2020</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Deferred tax assets</div></div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Research tax credits</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:DeferredTaxAssetsTaxCreditCarryforwardsResearch" contextRef="PAsOn03_31_2021" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">19,063</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:DeferredTaxAssetsTaxCreditCarryforwardsResearch" contextRef="PAsOn03_31_2020" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">6,303</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Intangible assets</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:DeferredTaxAssetsGoodwillAndIntangibleAssets" contextRef="PAsOn03_31_2021" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">50,564</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:DeferredTaxAssetsGoodwillAndIntangibleAssets" contextRef="PAsOn03_31_2020" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">43,626</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Net operating loss</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:DeferredTaxAssetsOperatingLossCarryforwards" contextRef="PAsOn03_31_2021" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">202,906</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:DeferredTaxAssetsOperatingLossCarryforwards" contextRef="PAsOn03_31_2020" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">116,619</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Share-based compensation</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" contextRef="PAsOn03_31_2021" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">26,623</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" contextRef="PAsOn03_31_2020" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">18,413</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Lease liabilities</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="roiv:DeferredTaxAssetsLeaseLiabilities" contextRef="PAsOn03_31_2021" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">16,638</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="roiv:DeferredTaxAssetsLeaseLiabilities" contextRef="PAsOn03_31_2020" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">17,194</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Other</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:DeferredTaxAssetsOther" contextRef="PAsOn03_31_2021" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">7,303</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:DeferredTaxAssetsOther" contextRef="PAsOn03_31_2020" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">7,060</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;">&#160;</td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 5em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Subtotal</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:DeferredTaxAssetsGross" contextRef="PAsOn03_31_2021" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">323,097</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:DeferredTaxAssetsGross" contextRef="PAsOn03_31_2020" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">209,215</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Valuation allowance</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(<ix:nonFraction name="us-gaap:DeferredTaxAssetsValuationAllowance" contextRef="PAsOn03_31_2021" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">303,287</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(<ix:nonFraction name="us-gaap:DeferredTaxAssetsValuationAllowance" contextRef="PAsOn03_31_2020" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">187,831</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td> </tr>
<tr style="font-size: 1pt;">
<td style="height: 6pt; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td colspan="4" style="height: 6pt; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td colspan="4" style="height: 6pt; font-family: &quot;Times New Roman&quot;;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Deferred tax liabilities</div></div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Depreciation</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(<ix:nonFraction name="roiv:DeferredTaxLiabilitiesDepreciation" contextRef="PAsOn03_31_2021" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">1,214</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(<ix:nonFraction name="roiv:DeferredTaxLiabilitiesDepreciation" contextRef="PAsOn03_31_2020" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">1,833</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">Right-of-use</div></div> assets</div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(<ix:nonFraction name="roiv:DeferredTaxLiabilitiesRightOfUseAssets" contextRef="PAsOn03_31_2021" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">13,908</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(<ix:nonFraction name="roiv:DeferredTaxLiabilitiesRightOfUseAssets" contextRef="PAsOn03_31_2020" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">15,409</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Other</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(<ix:nonFraction name="us-gaap:DeferredTaxLiabilitiesOther" contextRef="PAsOn03_31_2021" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">4,688</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(<ix:nonFraction name="us-gaap:DeferredTaxLiabilitiesOther" contextRef="PAsOn03_31_2020" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">4,142</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Total deferred tax assets (liabilities)</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:DeferredTaxAssetsLiabilitiesNet" contextRef="PAsOn03_31_2021" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:zerodash">&#8212;</ix:nonFraction>&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:DeferredTaxAssetsLiabilitiesNet" contextRef="PAsOn03_31_2020" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:zerodash">&#8212;</ix:nonFraction>&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;">&#160;</td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td> </tr> </table> </ix:continuation> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The Company has Federal net operating losses in Switzerland, the United States, the United Kingdom and other jurisdictions in the amount of $<ix:nonFraction name="us-gaap:OperatingLossCarryforwards" contextRef="PAsOn03_31_2021_CHsrtStatementGeographicalAxis" unitRef="Unit_USD" decimals="-5" scale="6" format="ixt:numdotdecimal">1,181.1</ix:nonFraction>&#160;million, $<ix:nonFraction name="us-gaap:OperatingLossCarryforwards" contextRef="PAsOn03_31_2021_USsrtStatementGeographicalAxis" unitRef="Unit_USD" decimals="-5" scale="6" format="ixt:numdotdecimal">122.2</ix:nonFraction>&#160;million, $<ix:nonFraction name="us-gaap:OperatingLossCarryforwards" contextRef="PAsOn03_31_2021_GBsrtStatementGeographicalAxis" unitRef="Unit_USD" decimals="-5" scale="6" format="ixt:numdotdecimal">28.6</ix:nonFraction>&#160;million, and $<ix:nonFraction name="us-gaap:OperatingLossCarryforwards" contextRef="PAsOn03_31_2021_TaxAuthorityInOtherJurisdictionsMembersrtStatementGeographicalAxis" unitRef="Unit_USD" decimals="-5" scale="6" format="ixt:numdotdecimal">75.8</ix:nonFraction>&#160;million, respectively. The Switzerland net operating losses will expire in varying amounts between March&#160;31, 2025 and March&#160;31, 2028. The United States net operating losses can be carried forward indefinitely with utilization limited to <ix:nonFraction name="roiv:PercentageOfFutureTaxableIncome" contextRef="P04_01_2020To03_31_2021_USsrtStatementGeographicalAxis" unitRef="Unit_pure" decimals="2" scale="-2" format="ixt:numdotdecimal">80</ix:nonFraction>% of future taxable income for tax years beginning on or after January&#160;1, 2021, while the United Kingdom and other net operating losses can be carried forward indefinitely as well, with an annual limitation on utilization. The Company has generated net operating losses from United States state and local jurisdictions in the amount of $<ix:nonFraction name="us-gaap:OperatingLossCarryforwards" contextRef="PAsOn03_31_2021_StateAndLocalJurisdictionMemberusgaapIncomeTaxAuthorityAxis" unitRef="Unit_USD" decimals="-5" scale="6" format="ixt:numdotdecimal">69.7</ix:nonFraction>&#160;million which will expire in varying amounts between <ix:nonNumeric name="us-gaap:OperatingLossCarryforwardsExpirationDate" contextRef="P04_01_2020To03_31_2021_MinimumMembersrtRangeAxis_StateAndLocalJurisdictionMemberusgaapIncomeTaxAuthorityAxis" format="ixt:datemonthdayyearen">March 31, 2035</ix:nonNumeric> and <ix:nonNumeric name="us-gaap:OperatingLossCarryforwardsExpirationDate" contextRef="P04_01_2020To03_31_2021_MaximumMembersrtRangeAxis_StateAndLocalJurisdictionMemberusgaapIncomeTaxAuthorityAxis" format="ixt:datemonthdayyearen">March 31, 2041</ix:nonNumeric>. The Company has generated $<ix:nonFraction name="us-gaap:TaxCreditCarryforwardAmount" contextRef="PAsOn03_31_2021_USsrtStatementGeographicalAxis" unitRef="Unit_USD" decimals="-5" scale="6" format="ixt:numdotdecimal">19.1</ix:nonFraction>&#160;million of research tax credit carryforwards primarily in the United States, which will expire in varying amounts between <ix:nonNumeric name="us-gaap:TaxCreditCarryforwardExpirationDate" contextRef="P04_01_2020To03_31_2021_MinimumMembersrtRangeAxis_USsrtStatementGeographicalAxis" format="ixt:datemonthdayyearen">March 31, 2035</ix:nonNumeric> and <ix:nonNumeric name="us-gaap:TaxCreditCarryforwardExpirationDate" contextRef="P04_01_2020To03_31_2021_MaximumMembersrtRangeAxis_USsrtStatementGeographicalAxis" format="ixt:datemonthdayyearen">March 31, 2041</ix:nonNumeric>. </div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The Company assesses the realizability of the deferred tax assets at each balance sheet date based on available positive and negative evidence in order to determine the amount which is more likely than not to be realized and record a valuation allowance as necessary. Due to the Company&#8217;s cumulative loss position which provides significant negative evidence difficult to overcome, the Company has recorded a valuation allowance of $<ix:nonFraction name="us-gaap:DeferredTaxAssetsValuationAllowance" contextRef="PAsOn03_31_2021" unitRef="Unit_USD" decimals="-5" scale="6" format="ixt:numdotdecimal">303.3</ix:nonFraction>&#160;million as of March&#160;31, 2021, representing the portion of the deferred tax asset that is not more likely than not to be realized. The amount of the deferred tax asset considered realizable could be adjusted for future factors that would impact the assessment of the objective and subjective evidence of the Company. For the period April&#160;1, 2020 through March&#160;31, 2021, the valuation allowance increased by $<ix:nonFraction name="us-gaap:ValuationAllowanceDeferredTaxAssetChangeInAmount" contextRef="P04_01_2020To03_31_2021" unitRef="Unit_USD" decimals="-5" scale="6" format="ixt:numdotdecimal">115.5</ix:nonFraction>&#160;million primarily as a result of corresponding increases in our global net operating losses, as well as our Research Tax Credits. For the period April&#160;1, 2019 through March&#160;31, 2020, the valuation allowance decreased by $<ix:nonFraction name="us-gaap:ValuationAllowanceDeferredTaxAssetChangeInAmount" contextRef="P04_01_2019To03_31_2020" unitRef="Unit_USD" decimals="-5" scale="6" format="ixt:numdotdecimal">168.0</ix:nonFraction>&#160;million primarily as a result of the Sumitomo Transaction and the deconsolidation of Sio. The Company will continue to assess the realizability of deferred tax assets at each balance sheet date in order to determine the amount, if any, required for a valuation allowance. </div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">There are outside basis differences related to the Company&#8217;s investment in subsidiaries for which no deferred taxes have been recorded as these would not be subject to tax on repatriation as Bermuda has no tax regime for Bermuda exempted limited companies, and the United Kingdom tax regime relating to company distributions and sales generally provides for exemption from tax for most overseas profits, subject to certain exceptions. </div></div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </ix:continuation> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">F-<div style="letter-spacing: 0px; top: 0px;;display:inline;">35</div> </div></div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;;font-weight: bold;"><div style="display:inline;"><a href="#toc" style="text-indent: 0px;">Table of Contents</a></div></div> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"><ix:continuation id="TextSelectionAppend_28230172_2">The Company is subject to tax and is required to file United States, United Kingdom, and Switzerland federal income tax returns, as well as income tax returns in various state, local, and foreign jurisdictions. The Company is subject to tax examinations for tax years ended March&#160;31, 2018 and forward in major taxing jurisdictions. Tax audits and examinations can involve complex issues, interpretations and judgments. The resolution of matters may span multiple years particularly if subject to litigation or negotiation. The Company believes it has appropriately recorded its tax position using reasonable estimates and assumptions, however, the potential tax benefits may impact the results of operations or cash flows in the period of resolution, settlement or when the statutes of limitations expire. There are <ix:nonFraction name="us-gaap:UnrecognizedTaxBenefits" contextRef="PAsOn03_31_2020" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt-sec:numwordsen"><ix:nonFraction name="us-gaap:UnrecognizedTaxBenefits" contextRef="PAsOn03_31_2021" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt-sec:numwordsen">no</ix:nonFraction></ix:nonFraction> unrecognized tax benefits recorded as of March&#160;31, 2021 and 2020.</ix:continuation> </div></div> <ix:nonNumeric name="us-gaap:LesseeOperatingLeasesTextBlock" contextRef="P04_01_2020To03_31_2021" escape="true" continuedAt="TextSelection_28230254"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Note 13&#8212;Leases </div></div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;">The Company&#8217;s operating leases consist primarily of real estate leases, including those entered into by certain wholly owned and majority-owned or controlled subsidiaries of RSL. The Company determines if an agreement is or contains a lease at inception. Leases with an initial term of 12 months or less are not recorded on the balance sheet. For real estate leases, the Company&#160;elected the expedient to account for lease and <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-lease</div> components as a single component. </div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">Right-of-use</div></div> (&#8220;ROU&#8221;) assets represent the Company&#8217;s right to use an underlying asset for the lease term and lease liabilities represent the Company&#8217;s obligation to make lease payments arising from the lease. ROU assets and liabilities are based on the estimated present value of fixed lease payments over the expected lease term and are recognized at the lease commencement date. </div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">As most of the Company&#8217;s leases do not provide an implicit rate, the Company uses an estimated incremental borrowing rate in determining the present value of fixed lease payments based on information available at the lease commencement date. The Company&#8217;s incremental borrowing rates are determined based on the term of the lease, the economic environment of the lease, and the effect of collateralization. Certain leases include one or more renewal options, generally for the same period as the initial term of the lease. The exercise of lease renewal options is generally at the Company&#8217;s sole discretion and, as such, the Company typically determines that exercise of these renewal options is not reasonably certain. As a result, the Company does not include the renewal option period in the expected lease term and the associated lease payments are not included in the measurement of the ROU asset and lease liability. Certain leases also contain termination options with an associated penalty. Generally, the Company is reasonably certain not to exercise these options and as such, they are not included in the determination of the expected lease term. The Company recognizes operating lease expense on a straight-line basis over the lease term. </div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Leases generally provide for payments of nonlease components, such as common area maintenance, real estate taxes and other costs associated with the leased property. For lease agreements entered into or modified after April&#160;1, 2019, the Company accounts for lease components and nonlease components together as a single lease component and, as such, includes fixed payments of nonlease components in the measurement of the ROU assets and lease liabilities. Variable lease payments, such as periodic adjustments for inflation, reimbursement of real estate taxes, any variable common area maintenance and any other variable costs associated with the leased property are expensed as incurred as variable lease costs and are not recorded on the balance sheet. </div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The Company&#8217;s lease agreements do not contain any material residual value guarantees or material restrictions or covenants. </div></div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></ix:nonNumeric> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">F-<div style="letter-spacing: 0px; top: 0px;;display:inline;">36</div> </div></div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;;font-weight: bold;"><div style="display:inline;"><a href="#toc" style="text-indent: 0px;">Table of Contents</a></div></div> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"><ix:continuation id="TextSelection_28230254"> <ix:nonNumeric name="us-gaap:LeaseCostTableTextBlock" contextRef="P04_01_2020To03_31_2021" escape="true"><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The components of operating lease expense for the Company were as follows (in thousands): </div></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 68%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="font-size: 0px;">
<td style="width: 70%;"></td>
<td style="width: 6%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td>
<td style="width: 6%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;&#160;</td>
<td colspan="6" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Years&#160;Ended&#160;March&#160;31,</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2021</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2020</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Operating lease cost</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:OperatingLeaseCost" contextRef="P04_01_2020To03_31_2021" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">11,931</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:OperatingLeaseCost" contextRef="P04_01_2019To03_31_2020" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">11,515</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Short-term lease cost</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:ShortTermLeaseCost" contextRef="P04_01_2020To03_31_2021" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">237</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:ShortTermLeaseCost" contextRef="P04_01_2019To03_31_2020" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">872</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Variable lease cost</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:VariableLeaseCost" contextRef="P04_01_2020To03_31_2021" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">704</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:VariableLeaseCost" contextRef="P04_01_2019To03_31_2020" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">379</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;">&#160;</td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Total operating lease cost</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:LeaseCost" contextRef="P04_01_2020To03_31_2021" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">12,872</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:LeaseCost" contextRef="P04_01_2019To03_31_2020" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">12,766</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;">&#160;</td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td> </tr> </table> </ix:nonNumeric> <ix:nonNumeric name="us-gaap:LeasesOfLesseeDisclosureTextBlock" contextRef="P04_01_2020To03_31_2021" escape="true"><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Information related to the Company&#8217;s operating lease ROU assets and operating lease liabilities was as follows (in thousands, except periods and percentages): </div></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 68%; font-family: &quot;Times New Roman&quot;; font-size: 8pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="font-size: 0px;">
<td style="width: 72%;"></td>
<td style="width: 6%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td>
<td style="width: 6%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;&#160;</td>
<td colspan="6" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">During the Year<br/> Ended March&#160;31,</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2021</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2020</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Cash paid for operating lease liabilities</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:OperatingLeasePayments" contextRef="P04_01_2020To03_31_2021" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">8,830</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:OperatingLeasePayments" contextRef="P04_01_2019To03_31_2020" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">8,108</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Operating lease ROU assets obtained in exchange for operating lease liabilities</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" contextRef="P04_01_2020To03_31_2021" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">5,491</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" contextRef="P04_01_2019To03_31_2020" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">56,025</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;">&#160;</td> </tr> </table> <div style="clear: both; max-height: 0px;"></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 84%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="font-size: 0px;">
<td style="width: 66%;"></td>
<td style="width: 15%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td>
<td style="width: 14%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">March&#160;31,&#160;2021</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">March&#160;31,&#160;2020</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Weighted average remaining lease term (in years)</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonNumeric name="us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1" contextRef="PAsOn03_31_2021" format="ixt-sec:duryear">9.6</ix:nonNumeric></td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonNumeric name="us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1" contextRef="PAsOn03_31_2020" format="ixt-sec:duryear">10.2</ix:nonNumeric></td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Weighted average discount rate</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent" contextRef="PAsOn03_31_2021" unitRef="Unit_pure" decimals="3" scale="-2" format="ixt:numdotdecimal">7.1</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">%&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent" contextRef="PAsOn03_31_2020" unitRef="Unit_pure" decimals="3" scale="-2" format="ixt:numdotdecimal">7.1</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">%&#160;</td> </tr> </table> </ix:nonNumeric> <ix:nonNumeric name="us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock" contextRef="P04_01_2020To03_31_2021" escape="true"><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">As of March&#160;31, 2021, maturities of operating lease liabilities were as follows (in thousands): </div></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 68%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="font-size: 0px;">
<td style="width: 83%; font-family: &quot;Times New Roman&quot;;"></td>
<td style="width: 9%; vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="font-family: &quot;Times New Roman&quot;;"></td>
<td style="font-family: &quot;Times New Roman&quot;;"></td>
<td style="font-family: &quot;Times New Roman&quot;;"></td> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; white-space: nowrap;"> <div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt; border-bottom: 1pt solid rgb(0, 0, 0); display: table-cell; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">Years Ending March&#160;31,</div></div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">2022</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" contextRef="PAsOn03_31_2021" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">13,386</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">2023</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" contextRef="PAsOn03_31_2021" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">11,814</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">2024</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearThree" contextRef="PAsOn03_31_2021" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">11,718</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">2025</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFour" contextRef="PAsOn03_31_2021" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">9,734</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">2026</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFive" contextRef="PAsOn03_31_2021" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">8,617</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Thereafter</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive" contextRef="PAsOn03_31_2021" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">51,674</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;">&#160;</td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Total lease payments</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue" contextRef="PAsOn03_31_2021" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">106,943</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Less: present value adjustment</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(<ix:nonFraction name="roiv:OperatingLeaseLiabilityPresentValueAdjustments" contextRef="PAsOn03_31_2021" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">29,348</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Less: tenant improvement allowance</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(<ix:nonFraction name="roiv:LesseeOperatingLeaseLiabilityTenantImprovementAllowance" contextRef="PAsOn03_31_2021" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">2,898</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Total</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:OperatingLeaseLiability" contextRef="PAsOn03_31_2021" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">74,697</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;">&#160;</td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td> </tr> </table> </ix:nonNumeric> </ix:continuation> <ix:nonNumeric name="us-gaap:CommitmentsAndContingenciesDisclosureTextBlock" contextRef="P04_01_2020To03_31_2021" escape="true" continuedAt="TextSelection_28230267"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Note 14&#8212;Commitments and Contingencies </div></div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">(A) Significant Agreements </div></div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The Company, primarily through its subsidiaries has entered into commitments under various asset acquisition and license agreements including those described in Note 4, &#8220;Asset Acquisitions and License Agreements.&#8221; Additionally, the Company through its subsidiaries enters into agreements with contract service providers to assist in the performance of its R&amp;D activities. Expenditures to contract research organizations and contract manufacturing organizations represent significant costs in the clinical development of its product candidates. Subject to required notice periods and certain obligations under binding purchase orders, the Company can elect to discontinue the work under these agreements at any time. The Company expects to enter into additional collaborative research, contract research, manufacturing, and supplier agreements in the future, which may require upfront payments and long-term commitments of capital resources. </div></div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></ix:nonNumeric> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">F-<div style="letter-spacing: 0px; top: 0px;;display:inline;">37</div> </div></div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;;font-weight: bold;"><div style="display:inline;"><a href="#toc" style="text-indent: 0px;">Table of Contents</a></div></div> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"><ix:continuation id="TextSelection_28230267"> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">(B) Loss Contingencies </div></div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The Company may be, from time to time, a party to various disputes and claims arising from normal business activities. The Company accrues for loss contingencies when available information indicates that it is probable that a liability has been incurred and the amount of such loss can be reasonably estimated, and if the Company believes that a reasonably possible loss exists, the Company discloses the facts and circumstances of the litigation or claim, including an estimable range, if possible. The Company is currently not involved in any legal proceedings with a probable and estimable material loss. </div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">(C) Intellectual Property Agreements </div></div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">As of March&#160;31, 2021, the Company did not have any ongoing material financial commitments, other than pursuant to various asset acquisition and license agreements including those described in Note 4, &#8220;Asset Acquisitions and License Agreements.&#8221; </div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;">(D) <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">COVID-19</div> Pandemic </div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;">The Company has been actively monitoring the impact of the <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">COVID-19</div> pandemic on its employees and business. Based on guidance issued by federal, state and local authorities, the Company transitioned to a remote work model for its employees in March 2020 and its workforce continues to primarily work remotely. </div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">The <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">COVID-19</div> pandemic has had a variable impact on clinical trials by disrupting certain study sites. In the conduct of business activities, the Company continues to take actions designed to protect the safety and well-being of its patients and employees. Although some of the Company&#8217;s clinical development timelines have been impacted by delays related to the <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">COVID-19</div> pandemic, the Company has not experienced material financial impacts on its business and operations as a result of the <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">COVID-19</div> pandemic. However, the impact on the Company&#8217;s future results will largely depend on future developments related to <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">COVID-19,</div> which are highly uncertain and cannot be predicted with confidence, such as the emergence of new variants, the ultimate duration and spread of the outbreak, the continuing impact of the <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">COVID-19</div> pandemic on financial markets and the global economy, travel restrictions and social distancing in the United States and other countries, business closures or business disruptions and the effectiveness of actions taken in the United States and other countries to contain, treat, and prevent the disease, including the availability and effectiveness of vaccines. </div> </ix:continuation> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">F-<div style="letter-spacing: 0px; top: 0px;;display:inline;">38</div> </div></div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;;font-weight: bold;"><div style="display:inline;"><a href="#toc" style="text-indent: 0px;">Table of Contents</a></div></div> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"> <ix:nonNumeric name="us-gaap:FairValueDisclosuresTextBlock" contextRef="P04_01_2020To03_31_2021" escape="true" continuedAt="TextSelection_28230308"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Note 15&#8212;Fair Value Measurements </div></div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Recurring Fair Value Measurements </div></div></div> <ix:nonNumeric name="us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock" contextRef="P04_01_2020To03_31_2021" escape="true"><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The following table sets forth the Company&#8217;s assets and liabilities that are measured at fair value on a recurring basis as of&#160;March&#160;31, 2021 and 2020, by level, within the fair value hierarchy (in thousands): </div></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 8pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="font-size: 0px;">
<td style="width: 42%;"></td>
<td style="width: 1%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td>
<td style="width: 1%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td>
<td style="width: 1%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td>
<td style="width: 1%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td>
<td style="width: 1%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td>
<td style="width: 1%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td>
<td style="width: 1%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td>
<td style="width: 1%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td colspan="14" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">As of March&#160;31, 2021</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td colspan="14" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">As of March&#160;31, 2020</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Level&#160;1</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Level&#160;2</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Level&#160;3</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Balance&#160;as&#160;of<br/> March&#160;31,<br/> 2021</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Level&#160;1</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Level&#160;2</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Level&#160;3</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Balance&#160;as&#160;of<br/> March&#160;31,<br/> 2020</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">Assets:</div></div> </td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">Money market funds</div></div> </td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" contextRef="PAsOn03_31_2021_FairValueInputsLevel1MemberusgaapFairValueByFairValueHierarchyLevelAxis_FairValueMeasurementsRecurringMemberusgaapFairValueByMeasurementFrequencyAxis_MoneyMarketFundsMemberusgaapFairValueByAssetClassAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">1,420,597</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" contextRef="PAsOn03_31_2021_FairValueMeasurementsRecurringMemberusgaapFairValueByMeasurementFrequencyAxis_MoneyMarketFundsMemberusgaapFairValueByAssetClassAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">1,420,597</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" contextRef="PAsOn03_31_2020_FairValueInputsLevel1MemberusgaapFairValueByFairValueHierarchyLevelAxis_FairValueMeasurementsRecurringMemberusgaapFairValueByMeasurementFrequencyAxis_MoneyMarketFundsMemberusgaapFairValueByAssetClassAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">1,874,662</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" contextRef="PAsOn03_31_2020_FairValueMeasurementsRecurringMemberusgaapFairValueByMeasurementFrequencyAxis_MoneyMarketFundsMemberusgaapFairValueByAssetClassAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">1,874,662</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">Investment in Sio common shares</div></div> </td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:InvestmentsFairValueDisclosure" contextRef="PAsOn03_31_2021_CommonStockMemberusgaapFairValueByAssetClassAxis_FairValueInputsLevel1MemberusgaapFairValueByFairValueHierarchyLevelAxis_FairValueMeasurementsRecurringMemberusgaapFairValueByMeasurementFrequencyAxis_SioGeneTherapiesIncMemberdeiLegalEntityAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">48,487</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:InvestmentsFairValueDisclosure" contextRef="PAsOn03_31_2021_CommonStockMemberusgaapFairValueByAssetClassAxis_FairValueMeasurementsRecurringMemberusgaapFairValueByMeasurementFrequencyAxis_SioGeneTherapiesIncMemberdeiLegalEntityAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">48,487</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:InvestmentsFairValueDisclosure" contextRef="PAsOn03_31_2020_CommonStockMemberusgaapFairValueByAssetClassAxis_FairValueInputsLevel1MemberusgaapFairValueByFairValueHierarchyLevelAxis_FairValueMeasurementsRecurringMemberusgaapFairValueByMeasurementFrequencyAxis_SioGeneTherapiesIncMemberdeiLegalEntityAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">45,329</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:InvestmentsFairValueDisclosure" contextRef="PAsOn03_31_2020_CommonStockMemberusgaapFairValueByAssetClassAxis_FairValueMeasurementsRecurringMemberusgaapFairValueByMeasurementFrequencyAxis_SioGeneTherapiesIncMemberdeiLegalEntityAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">45,329</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">Investment in Arbutus common shares</div></div> </td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:InvestmentsFairValueDisclosure" contextRef="PAsOn03_31_2021_ArbutusBiopharmaCorporationMemberdeiLegalEntityAxis_CommonStockMemberusgaapFairValueByAssetClassAxis_FairValueInputsLevel1MemberusgaapFairValueByFairValueHierarchyLevelAxis_FairValueMeasurementsRecurringMemberusgaapFairValueByMeasurementFrequencyAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">53,325</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:InvestmentsFairValueDisclosure" contextRef="PAsOn03_31_2021_ArbutusBiopharmaCorporationMemberdeiLegalEntityAxis_CommonStockMemberusgaapFairValueByAssetClassAxis_FairValueMeasurementsRecurringMemberusgaapFairValueByMeasurementFrequencyAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">53,325</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:InvestmentsFairValueDisclosure" contextRef="PAsOn03_31_2020_ArbutusBiopharmaCorporationMemberdeiLegalEntityAxis_CommonStockMemberusgaapFairValueByAssetClassAxis_FairValueInputsLevel1MemberusgaapFairValueByFairValueHierarchyLevelAxis_FairValueMeasurementsRecurringMemberusgaapFairValueByMeasurementFrequencyAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">16,174</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:InvestmentsFairValueDisclosure" contextRef="PAsOn03_31_2020_ArbutusBiopharmaCorporationMemberdeiLegalEntityAxis_CommonStockMemberusgaapFairValueByAssetClassAxis_FairValueMeasurementsRecurringMemberusgaapFairValueByMeasurementFrequencyAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">16,174</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">Investment in Arbutus convertible preferred shares</div></div> </td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:InvestmentsFairValueDisclosure" contextRef="PAsOn03_31_2021_ArbutusBiopharmaCorporationMemberdeiLegalEntityAxis_ConvertiblePreferredStockMemberusgaapFairValueByAssetClassAxis_FairValueInputsLevel2MemberusgaapFairValueByFairValueHierarchyLevelAxis_FairValueMeasurementsRecurringMemberusgaapFairValueByMeasurementFrequencyAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">76,037</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:InvestmentsFairValueDisclosure" contextRef="PAsOn03_31_2021_ArbutusBiopharmaCorporationMemberdeiLegalEntityAxis_ConvertiblePreferredStockMemberusgaapFairValueByAssetClassAxis_FairValueMeasurementsRecurringMemberusgaapFairValueByMeasurementFrequencyAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">76,037</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:InvestmentsFairValueDisclosure" contextRef="PAsOn03_31_2020_ArbutusBiopharmaCorporationMemberdeiLegalEntityAxis_ConvertiblePreferredStockMemberusgaapFairValueByAssetClassAxis_FairValueInputsLevel2MemberusgaapFairValueByFairValueHierarchyLevelAxis_FairValueMeasurementsRecurringMemberusgaapFairValueByMeasurementFrequencyAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">23,062</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:InvestmentsFairValueDisclosure" contextRef="PAsOn03_31_2020_ArbutusBiopharmaCorporationMemberdeiLegalEntityAxis_ConvertiblePreferredStockMemberusgaapFairValueByAssetClassAxis_FairValueMeasurementsRecurringMemberusgaapFairValueByMeasurementFrequencyAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">23,062</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">Other investments</div></div> </td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:InvestmentsFairValueDisclosure" contextRef="PAsOn03_31_2021_FairValueInputsLevel1MemberusgaapFairValueByFairValueHierarchyLevelAxis_FairValueMeasurementsRecurringMemberusgaapFairValueByMeasurementFrequencyAxis_OtherInvestmentCompaniesMemberusgaapFairValueByAssetClassAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">11,129</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:InvestmentsFairValueDisclosure" contextRef="PAsOn03_31_2021_FairValueMeasurementsRecurringMemberusgaapFairValueByMeasurementFrequencyAxis_OtherInvestmentCompaniesMemberusgaapFairValueByAssetClassAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">11,129</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:InvestmentsFairValueDisclosure" contextRef="PAsOn03_31_2020_FairValueInputsLevel1MemberusgaapFairValueByFairValueHierarchyLevelAxis_FairValueMeasurementsRecurringMemberusgaapFairValueByMeasurementFrequencyAxis_OtherInvestmentCompaniesMemberusgaapFairValueByAssetClassAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">8,880</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:InvestmentsFairValueDisclosure" contextRef="PAsOn03_31_2020_FairValueMeasurementsRecurringMemberusgaapFairValueByMeasurementFrequencyAxis_OtherInvestmentCompaniesMemberusgaapFairValueByAssetClassAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">8,880</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;">&#160;</td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">Total assets at fair value</div></div> </td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:AssetsFairValueDisclosure" contextRef="PAsOn03_31_2021_FairValueInputsLevel1MemberusgaapFairValueByFairValueHierarchyLevelAxis_FairValueMeasurementsRecurringMemberusgaapFairValueByMeasurementFrequencyAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">1,533,538</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:AssetsFairValueDisclosure" contextRef="PAsOn03_31_2021_FairValueInputsLevel2MemberusgaapFairValueByFairValueHierarchyLevelAxis_FairValueMeasurementsRecurringMemberusgaapFairValueByMeasurementFrequencyAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">76,037</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:AssetsFairValueDisclosure" contextRef="PAsOn03_31_2021_FairValueMeasurementsRecurringMemberusgaapFairValueByMeasurementFrequencyAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">1,609,575</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:AssetsFairValueDisclosure" contextRef="PAsOn03_31_2020_FairValueInputsLevel1MemberusgaapFairValueByFairValueHierarchyLevelAxis_FairValueMeasurementsRecurringMemberusgaapFairValueByMeasurementFrequencyAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">1,945,045</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:AssetsFairValueDisclosure" contextRef="PAsOn03_31_2020_FairValueInputsLevel2MemberusgaapFairValueByFairValueHierarchyLevelAxis_FairValueMeasurementsRecurringMemberusgaapFairValueByMeasurementFrequencyAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">23,062</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:AssetsFairValueDisclosure" contextRef="PAsOn03_31_2020_FairValueMeasurementsRecurringMemberusgaapFairValueByMeasurementFrequencyAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">1,968,107</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;">&#160;</td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">Liabilities:</div></div> </td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">Debt held by Dermavant with NovaQuest</div></div> </td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:DebtInstrumentFairValue" contextRef="PAsOn03_31_2021_FairValueInputsLevel3MemberusgaapFairValueByFairValueHierarchyLevelAxis_FairValueMeasurementsRecurringMemberusgaapFairValueByMeasurementFrequencyAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">150,100</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:DebtInstrumentFairValue" contextRef="PAsOn03_31_2021_FairValueMeasurementsRecurringMemberusgaapFairValueByMeasurementFrequencyAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">150,100</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:DebtInstrumentFairValue" contextRef="PAsOn03_31_2020_FairValueInputsLevel3MemberusgaapFairValueByFairValueHierarchyLevelAxis_FairValueMeasurementsRecurringMemberusgaapFairValueByMeasurementFrequencyAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">89,100</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:DebtInstrumentFairValue" contextRef="PAsOn03_31_2020_FairValueMeasurementsRecurringMemberusgaapFairValueByMeasurementFrequencyAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">89,100</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">Liability instruments measured at fair value</div></div> </td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:DerivativeInstrumentsNotDesignatedAsHedgingInstrumentsLiabilityAtFairValue" contextRef="PAsOn03_31_2021_FairValueInputsLevel3MemberusgaapFairValueByFairValueHierarchyLevelAxis_FairValueMeasurementsRecurringMemberusgaapFairValueByMeasurementFrequencyAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">67,893</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:DerivativeInstrumentsNotDesignatedAsHedgingInstrumentsLiabilityAtFairValue" contextRef="PAsOn03_31_2021_FairValueMeasurementsRecurringMemberusgaapFairValueByMeasurementFrequencyAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">67,893</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:DerivativeInstrumentsNotDesignatedAsHedgingInstrumentsLiabilityAtFairValue" contextRef="PAsOn03_31_2020_FairValueInputsLevel3MemberusgaapFairValueByFairValueHierarchyLevelAxis_FairValueMeasurementsRecurringMemberusgaapFairValueByMeasurementFrequencyAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">102,373</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:DerivativeInstrumentsNotDesignatedAsHedgingInstrumentsLiabilityAtFairValue" contextRef="PAsOn03_31_2020_FairValueMeasurementsRecurringMemberusgaapFairValueByMeasurementFrequencyAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">102,373</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;">&#160;</td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">Total liabilities at fair value</div></div> </td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:LiabilitiesFairValueDisclosure" contextRef="PAsOn03_31_2021_FairValueInputsLevel3MemberusgaapFairValueByFairValueHierarchyLevelAxis_FairValueMeasurementsRecurringMemberusgaapFairValueByMeasurementFrequencyAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">217,993</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:LiabilitiesFairValueDisclosure" contextRef="PAsOn03_31_2021_FairValueMeasurementsRecurringMemberusgaapFairValueByMeasurementFrequencyAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">217,993</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:LiabilitiesFairValueDisclosure" contextRef="PAsOn03_31_2020_FairValueInputsLevel3MemberusgaapFairValueByFairValueHierarchyLevelAxis_FairValueMeasurementsRecurringMemberusgaapFairValueByMeasurementFrequencyAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">191,473</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:LiabilitiesFairValueDisclosure" contextRef="PAsOn03_31_2020_FairValueMeasurementsRecurringMemberusgaapFairValueByMeasurementFrequencyAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">191,473</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;">&#160;</td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td> </tr> </table> </ix:nonNumeric> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">There were no transfers of assets between Level&#160;1 and Level&#160;2 of the fair value measurement hierarchy that occurred during the years ended March&#160;31, 2021 and 2020. </div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Level&#160;3 Disclosures </div></div></div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The Company measures its Level&#160;3 liabilities, including debt issued by Dermavant to NovaQuest and the Sumitomo Options, at fair value based on significant inputs not observable in the market, which causes them to be classified as a Level&#160;3 measurement within the fair value hierarchy. The valuation of the Level&#160;3 liabilities uses assumptions and estimates the Company believes would be made by a market participant in making the same valuation. The Company assesses these assumptions and estimates on an ongoing basis as additional data impacting the assumptions and estimates are obtained. Changes in the fair value related to updated assumptions and estimates are recorded within the statements of operations at the end of each reporting period. </div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The fair value of Level&#160;3 liabilities may change significantly as additional data are obtained, impacting the Company&#8217;s assumptions regarding probabilities of potential scenarios used to estimate fair value. In evaluating this information, considerable judgment is required to interpret the data used to develop the assumptions and estimates. Accordingly, the use of different market assumptions and/or different valuation techniques may have a material effect on the estimated fair value amounts, and such changes could materially impact the Company&#8217;s results of operations in future periods. </div></div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></ix:nonNumeric> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">F-<div style="letter-spacing: 0px; top: 0px;;display:inline;">39</div> </div></div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="text-align: center;"> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em; text-align: left;;font-weight: bold;"><div style="display:inline;"><a href="#toc" style="text-indent: 0px;">Table of Contents</a></div></div> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"><ix:continuation id="TextSelection_28230308"> <ix:nonNumeric name="us-gaap:FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock" contextRef="P04_01_2020To03_31_2021" escape="true"><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The changes in fair value of the Level&#160;3 liabilities during the&#160;years ended March&#160;31, 2021 and 2020 were as follows (in thousands): </div></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 68%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="font-size: 0px;">
<td style="width: 83%; font-family: &quot;Times New Roman&quot;;"></td>
<td style="width: 7%; vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="font-family: &quot;Times New Roman&quot;;"></td>
<td style="font-family: &quot;Times New Roman&quot;;"></td>
<td style="font-family: &quot;Times New Roman&quot;;"></td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: bottom;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Balance at March&#160;31, 2019</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">$</td>
<td style="vertical-align: bottom;;text-align:right;"><ix:nonFraction name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" contextRef="PAsOn03_31_2019_FairValueInputsLevel3MemberusgaapFairValueByFairValueHierarchyLevelAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">103,628</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Issuance of liability instruments measured at fair value</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="roiv:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityDisposedDueToDeconsolidationOfSubsidiary" contextRef="P04_01_2019To03_31_2020_FairValueInputsLevel3MemberusgaapFairValueByFairValueHierarchyLevelAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">101,567</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Changes in fair value of debt and liability instruments, included in net loss</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(<ix:nonFraction name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings" contextRef="P04_01_2019To03_31_2020_FairValueInputsLevel3MemberusgaapFairValueByFairValueHierarchyLevelAxis" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:numdotdecimal">13,722</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Balance at March&#160;31, 2020</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" contextRef="PAsOn03_31_2020_FairValueInputsLevel3MemberusgaapFairValueByFairValueHierarchyLevelAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">191,473</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Changes in fair value of debt and liability instruments, included in net loss</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings" contextRef="P04_01_2020To03_31_2021_FairValueInputsLevel3MemberusgaapFairValueByFairValueHierarchyLevelAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">29,845</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Liability instruments disposed due to deconsolidation of subsidiary</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(<ix:nonFraction name="roiv:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityDisposedDueToDeconsolidationOfSubsidiary" contextRef="P04_01_2020To03_31_2021_FairValueInputsLevel3MemberusgaapFairValueByFairValueHierarchyLevelAxis" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:numdotdecimal">3,325</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: bottom;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Balance at March&#160;31, 2021</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">$</td>
<td style="vertical-align: bottom;;text-align:right;"><ix:nonFraction name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" contextRef="PAsOn03_31_2021_FairValueInputsLevel3MemberusgaapFairValueByFairValueHierarchyLevelAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">217,993</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;">&#160;</td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td> </tr> </table> </ix:nonNumeric> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Debt issued by Dermavant to NovaQuest </div></div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The fair value of the debt instrument as of&#160;March&#160;31, 2021 and 2020 represents the fair value of amounts payable to NovaQuest using a Monte Carlo simulation model under the income approach determined by using probability assessments of the expected future payments through 2032 and applying discount rates ranging from <ix:nonFraction name="us-gaap:DebtInstrumentMeasurementInput" contextRef="PAsOn03_31_2021_MeasurementInputDiscountRateMemberusgaapMeasurementInputTypeAxis_MinimumMembersrtRangeAxis" unitRef="Unit_pure" decimals="INF" scale="-2" format="ixt:numdotdecimal">6</ix:nonFraction>% to <ix:nonFraction name="us-gaap:DebtInstrumentMeasurementInput" contextRef="PAsOn03_31_2021_MaximumMembersrtRangeAxis_MeasurementInputDiscountRateMemberusgaapMeasurementInputTypeAxis" unitRef="Unit_pure" decimals="INF" scale="-2" format="ixt:numdotdecimal">17</ix:nonFraction>%. The future payments are based on significant inputs that are not observable in the market which are subject to remeasurement at each reporting date. The estimates of fair value may not be indicative of the amounts that could ultimately be paid by Dermavant to NovaQuest. </div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Sumitomo Options </div></div></div> <ix:nonNumeric name="us-gaap:FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock" contextRef="P04_01_2020To03_31_2021" escape="true"><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The fair value of the options to acquire the Company&#8217;s interest in Dermavant, Genevant, Lysovant, Metavant, Cytovant Parent, and Sinovant (collectively, the &#8220;Option Vants&#8221;) granted to Sumitomo under the Sumitomo Transaction Agreement as of March&#160;31, 2021 and 2020 was calculated using significant unobservable inputs including the following: </div></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 84%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="font-size: 0px;">
<td style="width: 55%;"></td>
<td style="width: 7%; vertical-align: bottom;"></td>
<td></td>
<td style="width: 6%; vertical-align: bottom;"></td>
<td></td> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;&#160;</td>
<td colspan="3" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Range&#160;or&#160;Point&#160;Estimate&#160;Used</div></div></td> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; white-space: nowrap; padding-bottom: 1pt;"> <div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt; border-bottom: 1pt solid rgb(0, 0, 0); display: table-cell; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">Input</div></div></div> </td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;&#160;</td>
<td style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">As&#160;of&#160;March&#160;31,&#160;2021</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">As&#160;of&#160;March&#160;31,&#160;2020</div></div></td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Time to expiration (in years)</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:center;"><ix:nonNumeric name="roiv:AlternativeInvestmentExpectedTerm" contextRef="P04_01_2020To03_31_2021_MaximumMembersrtRangeAxis_MeasurementInputExpectedTermMemberusgaapMeasurementInputTypeAxis" format="ixt-sec:duryear"><ix:nonNumeric name="roiv:AlternativeInvestmentExpectedTerm" contextRef="P04_01_2020To03_31_2021_MeasurementInputExpectedTermMemberusgaapMeasurementInputTypeAxis_MinimumMembersrtRangeAxis" format="ixt-sec:duryear">3.59</ix:nonNumeric></ix:nonNumeric></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:center;"><ix:nonNumeric name="roiv:AlternativeInvestmentExpectedTerm" contextRef="P04_01_2019To03_31_2020_MeasurementInputExpectedTermMemberusgaapMeasurementInputTypeAxis_MinimumMembersrtRangeAxis" format="ixt-sec:duryear">0.49</ix:nonNumeric>&#160;-&#160;<ix:nonNumeric name="roiv:AlternativeInvestmentExpectedTerm" contextRef="P04_01_2019To03_31_2020_MaximumMembersrtRangeAxis_MeasurementInputExpectedTermMemberusgaapMeasurementInputTypeAxis" format="ixt-sec:duryear">4.59</ix:nonNumeric></td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Risk-free rate</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:center;"><ix:nonFraction name="us-gaap:AlternativeInvestmentMeasurementInput" contextRef="PAsOn03_31_2021_MaximumMembersrtRangeAxis_MeasurementInputRiskFreeInterestRateMemberusgaapMeasurementInputTypeAxis" unitRef="Unit_pure" decimals="INF" scale="-2" format="ixt:numdotdecimal"><ix:nonFraction name="us-gaap:AlternativeInvestmentMeasurementInput" contextRef="PAsOn03_31_2021_MeasurementInputRiskFreeInterestRateMemberusgaapMeasurementInputTypeAxis_MinimumMembersrtRangeAxis" unitRef="Unit_pure" decimals="INF" scale="-2" format="ixt:numdotdecimal">0.52</ix:nonFraction></ix:nonFraction>%</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:center;"><ix:nonFraction name="us-gaap:AlternativeInvestmentMeasurementInput" contextRef="PAsOn03_31_2020_MeasurementInputRiskFreeInterestRateMemberusgaapMeasurementInputTypeAxis_MinimumMembersrtRangeAxis" unitRef="Unit_pure" decimals="INF" scale="-2" format="ixt:numdotdecimal">0.15</ix:nonFraction>%&#160;-&#160;<ix:nonFraction name="us-gaap:AlternativeInvestmentMeasurementInput" contextRef="PAsOn03_31_2020_MaximumMembersrtRangeAxis_MeasurementInputRiskFreeInterestRateMemberusgaapMeasurementInputTypeAxis" unitRef="Unit_pure" decimals="INF" scale="-2" format="ixt:numdotdecimal">0.35</ix:nonFraction>%</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Volatility</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:center;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"><ix:nonFraction name="us-gaap:AlternativeInvestmentMeasurementInput" contextRef="PAsOn03_31_2021_MeasurementInputOptionVolatilityMemberusgaapMeasurementInputTypeAxis_MinimumMembersrtRangeAxis" unitRef="Unit_pure" decimals="INF" scale="-2" format="ixt:numdotdecimal">89.0</ix:nonFraction>%&#160;-&#160;<ix:nonFraction name="us-gaap:AlternativeInvestmentMeasurementInput" contextRef="PAsOn03_31_2021_MaximumMembersrtRangeAxis_MeasurementInputOptionVolatilityMemberusgaapMeasurementInputTypeAxis" unitRef="Unit_pure" decimals="INF" scale="-2" format="ixt:numdotdecimal">95.0</ix:nonFraction>%</div></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:center;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"><ix:nonFraction name="us-gaap:AlternativeInvestmentMeasurementInput" contextRef="PAsOn03_31_2020_MeasurementInputOptionVolatilityMemberusgaapMeasurementInputTypeAxis_MinimumMembersrtRangeAxis" unitRef="Unit_pure" decimals="INF" scale="-2" format="ixt:numdotdecimal">91.0</ix:nonFraction>%&#160;-&#160;<ix:nonFraction name="us-gaap:AlternativeInvestmentMeasurementInput" contextRef="PAsOn03_31_2020_MaximumMembersrtRangeAxis_MeasurementInputOptionVolatilityMemberusgaapMeasurementInputTypeAxis" unitRef="Unit_pure" decimals="INF" scale="-2" format="ixt:numdotdecimal">110.0</ix:nonFraction>%</div></td> </tr> </table> </ix:nonNumeric> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">As of March&#160;31, 2021 and 2020, the fair value of the Sumitomo Options was $<ix:nonFraction name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1" contextRef="P04_01_2020To03_31_2021_LiabilityInstrumentsMeasuredAtFairValueMemberusgaapBalanceSheetLocationAxis" unitRef="Unit_USD" decimals="-5" scale="6" format="ixt:numdotdecimal">62.4</ix:nonFraction>&#160;million and $<ix:nonFraction name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1" contextRef="P04_01_2019To03_31_2020_LiabilityInstrumentsMeasuredAtFairValueMemberusgaapBalanceSheetLocationAxis" unitRef="Unit_USD" decimals="-5" scale="6" format="ixt:numdotdecimal">95.9</ix:nonFraction>&#160;million, respectively. Sumitomo Options are included in &#8220;Liability instruments measured at fair value&#8221; in the accompanying consolidated balance sheets. </div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">In June 2021, the Company completed a transaction with Sumitomo pursuant to which Sumitomo terminated all of its existing options to acquire the Company&#8217;s equity interests in certain subsidiaries. See Note 19, &#8220;Subsequent Events&#8221; for additional information. </div></div> </ix:continuation> <ix:nonNumeric name="us-gaap:DefinedContributionPlanTextBlock" contextRef="P04_01_2020To03_31_2021" escape="true"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Note 16&#8212;Defined Contribution Plan </div></div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The Company and certain of its subsidiaries sponsor defined contribution plans pursuant to Section&#160;401(k) of the U.S. Internal Revenue Code. Employee contributions are voluntary and subject to the maximum allowable under federal tax regulations. For the years ended March&#160;31, 2021 and 2020, the Company recorded total expense for employer matching contributions of $<ix:nonFraction name="us-gaap:DefinedContributionPlanEmployerDiscretionaryContributionAmount" contextRef="P04_01_2020To03_31_2021" unitRef="Unit_USD" decimals="-5" scale="6" format="ixt:numdotdecimal">1.7</ix:nonFraction>&#160;million and $<ix:nonFraction name="us-gaap:DefinedContributionPlanEmployerDiscretionaryContributionAmount" contextRef="P04_01_2019To03_31_2020" unitRef="Unit_USD" decimals="-5" scale="6" format="ixt:numdotdecimal">1.7</ix:nonFraction>&#160;million, respectively. </div></div></ix:nonNumeric> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">F-<div style="letter-spacing: 0px; top: 0px;;display:inline;">40</div> </div></div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;;font-weight: bold;"><div style="display:inline;"><a href="#toc" style="text-indent: 0px;">Table of Contents</a></div></div> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"> <ix:nonNumeric name="us-gaap:OtherOperatingIncomeAndExpenseTextBlock" contextRef="P04_01_2020To03_31_2021" escape="true"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Note 17&#8212;Other Expense, Net </div></div></div> <ix:nonNumeric name="us-gaap:ScheduleOfOtherOperatingCostAndExpenseByComponentTextBlock" contextRef="P04_01_2020To03_31_2021" escape="true"><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Other expense, net from continuing operations was as follows (in thousands): </div></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 76%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="font-size: 0px;">
<td style="width: 74%;"></td>
<td style="width: 6%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td>
<td style="width: 6%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;&#160;</td>
<td colspan="6" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Years Ended March&#160;31,</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2021</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2020</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: bottom;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Loss from equity method investment</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">$</td>
<td style="vertical-align: bottom;;text-align:right;"><ix:nonFraction name="us-gaap:IncomeLossFromEquityMethodInvestments" contextRef="P04_01_2020To03_31_2021" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:numdotdecimal">3,750</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">$</td>
<td style="vertical-align: bottom;;text-align:right;"><ix:nonFraction name="us-gaap:IncomeLossFromEquityMethodInvestments" contextRef="P04_01_2019To03_31_2020" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:numdotdecimal">21,386</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Interest income</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(<ix:nonFraction name="us-gaap:InterestIncomeOther" contextRef="P04_01_2020To03_31_2021" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">1,418</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(<ix:nonFraction name="us-gaap:InterestIncomeOther" contextRef="P04_01_2019To03_31_2020" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">17,990</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Interest expense</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:InterestExpense" contextRef="P04_01_2020To03_31_2021" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">2,809</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:InterestExpense" contextRef="P04_01_2019To03_31_2020" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">7,683</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Other expense</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="roiv:OtherIncomeExpense" contextRef="P04_01_2020To03_31_2021" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:numdotdecimal">3,560</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="roiv:OtherIncomeExpense" contextRef="P04_01_2019To03_31_2020" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:numdotdecimal">2,543</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;">&#160;</td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: bottom;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Total</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">$</td>
<td style="vertical-align: bottom;;text-align:right;"><ix:nonFraction name="us-gaap:OtherOperatingIncomeExpenseNet" contextRef="P04_01_2020To03_31_2021" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:numdotdecimal">8,701</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">$</td>
<td style="vertical-align: bottom;;text-align:right;"><ix:nonFraction name="us-gaap:OtherOperatingIncomeExpenseNet" contextRef="P04_01_2019To03_31_2020" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:numdotdecimal">13,622</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;">&#160;</td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td> </tr> </table> </ix:nonNumeric></ix:nonNumeric> <ix:nonNumeric name="us-gaap:EarningsPerShareTextBlock" contextRef="P04_01_2020To03_31_2021" escape="true" continuedAt="TextSelection_28230203"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Note 18&#8212;Earnings per Common Share </div></div></div> <ix:nonNumeric name="us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" contextRef="P04_01_2020To03_31_2021" escape="true"><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The computations of the numerator to derive the basic and diluted earnings per share amounts presented on the face of the accompanying consolidated statements of operations are as follows (in thousands): </div></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 92%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="font-size: 0px;">
<td style="width: 75%;"></td>
<td style="width: 3%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td>
<td style="width: 3%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;&#160;</td>
<td colspan="6" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Years Ended March&#160;31,</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2021</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2020</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Loss from continuing operations, net of tax</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(<ix:nonFraction name="us-gaap:IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest" contextRef="P04_01_2020To03_31_2021" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:numdotdecimal">900,233</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(<ix:nonFraction name="us-gaap:IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest" contextRef="P04_01_2019To03_31_2020" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:numdotdecimal">568,110</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Net loss from continuing operations, net of tax, attributable to noncontrolling interest</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(<ix:nonFraction name="us-gaap:IncomeLossFromContinuingOperationsAttributableToNoncontrollingEntity" contextRef="P04_01_2020To03_31_2021" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:numdotdecimal">90,999</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(<ix:nonFraction name="us-gaap:IncomeLossFromContinuingOperationsAttributableToNoncontrollingEntity" contextRef="P04_01_2019To03_31_2020" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:numdotdecimal">48,716</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Loss from continuing operations, net of tax, attributable to Roivant Sciences Ltd.</div></div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(<ix:nonFraction name="us-gaap:IncomeLossFromContinuingOperations" contextRef="P04_01_2020To03_31_2021" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">809,234</ix:nonFraction></div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">)&#160;</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(<ix:nonFraction name="us-gaap:IncomeLossFromContinuingOperations" contextRef="P04_01_2019To03_31_2020" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">519,394</ix:nonFraction></div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">)&#160;</div></div></td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Deemed dividend on repurchase of redeemable noncontrolling interest relating to subsidiary convertible and redeemable preferred stock<div style="font-size: 85%; vertical-align: top;;display:inline;;font-size:9.4px">(1)</div></div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(<ix:nonFraction name="us-gaap:PreferredStockDividendsAndOtherAdjustments" contextRef="P04_01_2019To03_31_2020" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">77,777</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Basic and diluted loss from continuing operations, net of tax, attributable to Roivant Sciences Ltd.</div></div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">$</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(<ix:nonFraction name="roiv:BasicAndDilutedLossFromContinuingOperationsNetOfTax" contextRef="P04_01_2020To03_31_2021" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:numdotdecimal">809,234</ix:nonFraction></div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">)&#160;</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">$</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(<ix:nonFraction name="roiv:BasicAndDilutedLossFromContinuingOperationsNetOfTax" contextRef="P04_01_2019To03_31_2020" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:numdotdecimal">597,171</ix:nonFraction></div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">)&#160;</div></div></td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Income from discontinued operations, net of tax</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTax" contextRef="P04_01_2020To03_31_2021" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:zerodash">&#8212;</ix:nonFraction>&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTax" contextRef="P04_01_2019To03_31_2020" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">1,578,426</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Net loss from discontinued operations, net of tax, attributable to noncontrolling interest</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(<ix:nonFraction name="us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToNoncontrollingInterest" contextRef="P04_01_2019To03_31_2020" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:numdotdecimal">141,477</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Net income from discontinued operations, net of tax, attributable to Roivant Sciences Ltd.</div></div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">$</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><ix:nonFraction name="us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity" contextRef="P04_01_2020To03_31_2021" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:zerodash">&#8212;</ix:nonFraction>&#160;&#160;</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">$</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><ix:nonFraction name="us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity" contextRef="P04_01_2019To03_31_2020" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">1,719,903</ix:nonFraction></div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Basic and diluted income from discontinued operations, net of tax</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="roiv:BasicAndDilutedIncomeFromDiscontinuedOperationsNetOfTax" contextRef="P04_01_2019To03_31_2020" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">1,719,903</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;">&#160;</td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Basic and diluted net (loss) income attributable to Roivant Sciences</div></div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">$</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(<ix:nonFraction name="roiv:BasicAndDilutedNetLossIncome" contextRef="P04_01_2020To03_31_2021" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:numdotdecimal">809,234</ix:nonFraction></div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">)&#160;</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">$</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><ix:nonFraction name="roiv:BasicAndDilutedNetLossIncome" contextRef="P04_01_2019To03_31_2020" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">1,122,732</ix:nonFraction></div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td> </tr> </table> <div style="clear: both; max-height: 0px;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 4%; vertical-align: top;;text-align:left;"><div style="font-size: 85%; vertical-align: top;;display:inline;;font-size:9.4px">(1)</div></td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Consideration paid in excess of carrying value for the repurchase of redeemable noncontrolling interest relating to subsidiary convertible and redeemable preferred stock of $<ix:nonFraction name="us-gaap:PreferredStockDividendsAndOtherAdjustments" contextRef="P04_01_2019To03_31_2020" unitRef="Unit_USD" decimals="-5" scale="6" format="ixt:numdotdecimal">77.8</ix:nonFraction>&#160;million is considered a deemed dividend and, for purposes of calculating net loss per share, increases the loss from continuing operations, net of tax, attributable to Roivant Sciences Ltd. for the year ended March&#160;31, 2020. See Note 10, &#8220;Shareholders&#8217; Equity and Redeemable Noncontrolling Interest.&#8221; </div></div> </td> </tr> </table> </ix:nonNumeric> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Basic net (loss) income per common share is computed by dividing net (loss) income attributable to Roivant Sciences Ltd. by the weighted-average number of common stock outstanding during the period. Diluted net (loss) income per common share is computed by dividing the net income (loss) attributable to Roivant Sciences Ltd. by the diluted weighted-average number of common stock outstanding during the period. </div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">For periods of loss from continuing operations, diluted loss per share is calculated similar to basic loss per share as the effect of including all potentially dilutive common share equivalents is anti-dilutive. All outstanding common stock equivalents have been excluded from the computation of diluted loss per share because their </div></div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></ix:nonNumeric> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">F-<div style="letter-spacing: 0px; top: 0px;;display:inline;">41</div> </div></div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;;font-weight: bold;"><div style="display:inline;"><a href="#toc" style="text-indent: 0px;">Table of Contents</a></div></div> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"><ix:continuation id="TextSelection_28230203"> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">effect was anti-dilutive due to the loss from continuing operations. Refer to Note 11, &#8220;Share-Based Compensation&#8221; and Note 5, &#8220;Sumitomo Transaction Agreement&#8221; for additional detail regarding outstanding common stock equivalents. </div></div> </ix:continuation> <ix:nonNumeric name="us-gaap:SubsequentEventsTextBlock" contextRef="P04_01_2020To03_31_2021" escape="true"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Note 19&#8212;Subsequent Events </div></div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The Company has evaluated subsequent events for appropriate disclosures through June 30, 2021, the date that the consolidated financial statements were available to be issued. All subsequent events requiring recognition as of March&#160;31, 2021 have been incorporated in these financial statements. </div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Option Vants Transaction </div></div></div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;">On May&#160;1, 2021, the Company entered into an Asset Purchase Agreement with Sumitomo and its subsidiary Sumitomo Pharmaceuticals (Suzhou) Co., Ltd. (&#8220;SPC&#8221;) (the &#8220;Asset Purchase Agreement&#8221;). The transactions contemplated by the Asset Purchase Agreement closed in June 2021. Pursuant to the Asset Purchase Agreement: (i)&#160;Sumitomo terminated all of its existing options to acquire the Company&#8217;s equity interests in the Option Vants; (ii)&#160;the Company transferred and assigned to SPC all of its intellectual property, development and commercialization rights for (a)&#160;lefamulin in Mainland China, Taiwan, Hong Kong, and Macau (collectively &#8220;Greater China&#8221;), (b) vibegron in Mainland China, (c)&#160;rodatristat ethyl in Greater China and South Korea and <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">(d)&#160;RVT-802</div> in Greater China and South Korea; (iii)&#160;we will receive a $<ix:nonFraction name="roiv:BusinessAcquisitionCostOfAcquiredEntityAdjustmentPaidInCash" contextRef="P05_01_2021To05_01_2021_SubsequentEventMemberusgaapSubsequentEventTypeAxis_SumitomoPharmaceuticalsCoLtdMemberusgaapBusinessAcquisitionAxis" unitRef="Unit_USD" decimals="-5" scale="6" format="ixt:numdotdecimal">5.0</ix:nonFraction>&#160;million cash payment; and (iv)&#160;Sumitomo entered into an agreement with the Company to pursue future collaborations with Genevant. </div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Dermavant </div></div></div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">On May&#160;14, 2021, Dermavant entered into a $<ix:nonFraction name="roiv:RevenueInterestPurchaseAndSaleAgreementAmount" contextRef="PAsOn05_14_2021_DermavantSciencesLtdMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis_RevenueInterestPurchaseAndSaleAgreementMemberusgaapTypeOfArrangementAxis_SubsequentEventMemberusgaapSubsequentEventTypeAxis" unitRef="Unit_USD" decimals="-5" scale="6" format="ixt:numdotdecimal">160.0</ix:nonFraction>&#160;million revenue interest purchase and sale agreement (the &#8220;RIPSA&#8221;) for its investigational product tapinarof with three institutional investors. Under the terms of the RIPSA, the participants purchased a capped single-digit revenue interest in net sales of tapinarof for all dermatological indications in the United States in exchange for $<ix:nonFraction name="roiv:RevenueInterestPurchaseAndSaleAgreementCommittedFundToBePaid" contextRef="PAsOn05_14_2021_DermavantSciencesLtdMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis_RevenueInterestPurchaseAndSaleAgreementMemberusgaapTypeOfArrangementAxis_SubsequentEventMemberusgaapSubsequentEventTypeAxis" unitRef="Unit_USD" decimals="-5" scale="6" format="ixt:numdotdecimal">160.0</ix:nonFraction>&#160;million in committed funding to be paid to Dermavant, subject to approval of tapinarof by the FDA. </div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Dermavant concurrently entered into a $<ix:nonFraction name="us-gaap:DebtInstrumentFaceAmount" contextRef="PAsOn05_14_2021_CreditFacilityMemberusgaapDebtInstrumentAxis_DermavantSciencesLtdMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis_SubsequentEventMemberusgaapSubsequentEventTypeAxis" unitRef="Unit_USD" decimals="-5" scale="6" format="ixt:numdotdecimal">40.0</ix:nonFraction>&#160;million senior secured credit facility (the &#8220;Credit Facility&#8221;) with one of the institutional investors. The Credit Facility has a <span style="-sec-ix-hidden:hidden28230199">five</span>-year maturity and bears an interest rate of <ix:nonFraction name="us-gaap:DebtInstrumentInterestRateStatedPercentage" contextRef="PAsOn05_14_2021_CreditFacilityMemberusgaapDebtInstrumentAxis_DermavantSciencesLtdMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis_SubsequentEventMemberusgaapSubsequentEventTypeAxis" unitRef="Unit_pure" decimals="2" scale="-2" format="ixt:numdotdecimal">10</ix:nonFraction>% per annum. In connection with the funding of the Credit Facility, Dermavant issued to the institutional investor a warrant to purchase <ix:nonFraction name="us-gaap:ClassOfWarrantOrRightOutstanding" contextRef="PAsOn05_14_2021_DermavantSciencesLtdMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis_SubsequentEventMemberusgaapSubsequentEventTypeAxis" unitRef="Unit_shares" decimals="INF" scale="0" format="ixt:numdotdecimal">1,199,072</ix:nonFraction> common shares of Dermavant at an exercise price of $<ix:nonFraction name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" contextRef="PAsOn05_14_2021_DermavantSciencesLtdMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis_SubsequentEventMemberusgaapSubsequentEventTypeAxis" unitRef="Unit_USD_per_Share" decimals="INF" scale="0" format="ixt:numdotdecimal">0.01</ix:nonFraction> per common share. </div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The proceeds from the Credit Facility were used to repay all amounts outstanding under the loan and security agreement with Hercules, with the remainder of net proceeds used for working capital and general corporate purposes. The Company reclassified $<ix:nonFraction name="us-gaap:LongTermDebtNoncurrent" contextRef="PAsOn03_31_2021_DermavantSciencesLtdMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis_RevisionOfPriorPeriodReclassificationAdjustmentMembersrtRestatementAxis_SubsequentEventMemberusgaapSubsequentEventTypeAxis" unitRef="Unit_USD" decimals="-5" scale="6" format="ixt:numdotdecimal">3.1</ix:nonFraction>&#160;million on the consolidated balance sheets as of March&#160;31, 2021 from current to long-term given that Dermavant had the intent and ability to refinance the short-term obligation on a long-term basis after March&#160;31, 2021 and before the financial statements were issued. </div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Datavant</div></div></div></div> </div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">In June 2021, Datavant and CIOX Health, LLC entered into a definitive agreement to merge the two companies. </div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The merger closed on July 27, 2021. At closing, Roivant received approximately $<ix:nonFraction name="us-gaap:BusinessCombinationConsiderationTransferred1" contextRef="P07_01_2021To07_31_2021_DatavantMemberusgaapBusinessAcquisitionAxis_SubsequentEventMemberusgaapSubsequentEventTypeAxis" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:numdotdecimal">320</ix:nonFraction> million in cash. </div></div></ix:nonNumeric> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">F-<div style="letter-spacing: 0px; top: 0px;;display:inline;">42</div> </div></div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;;font-weight: bold;"><div style="display:inline;"><a href="#toc" style="text-indent: 0px;">Table of Contents</a></div></div> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0px;"></div> </div> </div> <div> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"> <div style="clear: both; max-height: 0px; text-indent: 0px;"></div> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">ROIVANT SCIENCES LTD. </div></div></div></div> <div id="fin164680_101" style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Condensed Consolidated Balance Sheets </div></div></div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px; text-indent: 0px;;display:inline;">(unaudited, in thousands, except share and per share amounts)</div></div></div> </div> </div> </div> </div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;width:100%;">
<tr style="font-size: 0px;">
<td style="width: 76%;"></td>
<td style="width: 3%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td>
<td style="width: 3%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">June&#160;30,&#160;2021</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">March&#160;31,&#160;2021</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top; width: 76%;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Assets</div></div></div> </td>
<td style="vertical-align: bottom; width: 3%;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; width: 3%;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; width: 76%;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Current assets:</div></div> </td>
<td style="vertical-align: bottom; width: 3%;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; width: 3%;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top; width: 76%;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Cash and cash equivalents</div></div> </td>
<td style="vertical-align: bottom; width: 3%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:CashAndCashEquivalentsAtCarryingValue" contextRef="PAsOn06_30_2021" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">1,996,733</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 3%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:CashAndCashEquivalentsAtCarryingValue" contextRef="PAsOn03_31_2021" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">2,055,044</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; width: 76%;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Restricted cash</div></div> </td>
<td style="vertical-align: bottom; width: 3%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:RestrictedCashCurrent" contextRef="PAsOn06_30_2021" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">2,711</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 3%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:RestrictedCashCurrent" contextRef="PAsOn03_31_2021" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">77,701</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top; width: 76%;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Other current assets</div></div> </td>
<td style="vertical-align: bottom; width: 3%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:OtherAssetsCurrent" contextRef="PAsOn06_30_2021" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">58,165</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 3%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:OtherAssetsCurrent" contextRef="PAsOn03_31_2021" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">54,250</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 76%;">&#160;</td>
<td style="vertical-align: bottom; width: 3%;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom; width: 3%;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; width: 76%;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 5em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Total current assets</div></div> </td>
<td style="vertical-align: bottom; width: 3%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:AssetsCurrent" contextRef="PAsOn06_30_2021" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">2,057,609</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 3%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:AssetsCurrent" contextRef="PAsOn03_31_2021" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">2,186,995</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top; width: 76%;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Property and equipment, net</div></div> </td>
<td style="vertical-align: bottom; width: 3%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:PropertyPlantAndEquipmentNet" contextRef="PAsOn06_30_2021" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">15,550</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 3%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:PropertyPlantAndEquipmentNet" contextRef="PAsOn03_31_2021" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">14,749</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; width: 76%;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;">Operating lease <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">right-of-use</div></div> assets</div> </td>
<td style="vertical-align: bottom; width: 3%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:OperatingLeaseRightOfUseAsset" contextRef="PAsOn06_30_2021" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">65,163</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 3%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:OperatingLeaseRightOfUseAsset" contextRef="PAsOn03_31_2021" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">62,279</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top; width: 76%;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Restricted cash, net of current portion</div></div> </td>
<td style="vertical-align: bottom; width: 3%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:RestrictedCashNoncurrent" contextRef="PAsOn06_30_2021" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">8,933</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 3%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:RestrictedCashNoncurrent" contextRef="PAsOn03_31_2021" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">8,931</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; width: 76%;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Investments measured at fair value</div></div> </td>
<td style="vertical-align: bottom; width: 3%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:InvestmentsFairValueDisclosure" contextRef="PAsOn06_30_2021" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">180,359</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 3%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:InvestmentsFairValueDisclosure" contextRef="PAsOn03_31_2021" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">188,978</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top; width: 76%;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Long-term investment</div></div> </td>
<td style="vertical-align: bottom; width: 3%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:LongTermInvestments" contextRef="PAsOn06_30_2021" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">100,563</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 3%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:LongTermInvestments" contextRef="PAsOn03_31_2021" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">100,563</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; width: 76%;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Other assets</div></div> </td>
<td style="vertical-align: bottom; width: 3%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:OtherAssetsNoncurrent" contextRef="PAsOn06_30_2021" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">26,520</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 3%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:OtherAssetsNoncurrent" contextRef="PAsOn03_31_2021" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">27,197</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 76%;">&#160;</td>
<td style="vertical-align: bottom; width: 3%;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom; width: 3%;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top; width: 76%;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 5em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Total assets</div></div> </td>
<td style="vertical-align: bottom; width: 3%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:Assets" contextRef="PAsOn06_30_2021" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">2,454,697</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 3%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:Assets" contextRef="PAsOn03_31_2021" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">2,589,692</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 76%;">&#160;</td>
<td style="vertical-align: bottom; width: 3%;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom; width: 3%;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; width: 76%;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Liabilities, Redeemable Noncontrolling Interest and Shareholders&#8217; Equity</div></div></div> </td>
<td style="vertical-align: bottom; width: 3%;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; width: 3%;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top; width: 76%;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Current liabilities:</div></div> </td>
<td style="vertical-align: bottom; width: 3%;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; width: 3%;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; width: 76%;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Accounts payable</div></div> </td>
<td style="vertical-align: bottom; width: 3%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:AccountsPayableCurrent" contextRef="PAsOn06_30_2021" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">15,014</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 3%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:AccountsPayableCurrent" contextRef="PAsOn03_31_2021" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">20,550</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top; width: 76%;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Accrued expenses</div></div> </td>
<td style="vertical-align: bottom; width: 3%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:AccruedLiabilitiesCurrent" contextRef="PAsOn06_30_2021" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">73,788</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 3%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:AccruedLiabilitiesCurrent" contextRef="PAsOn03_31_2021" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">76,936</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; width: 76%;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Operating lease liabilities</div></div> </td>
<td style="vertical-align: bottom; width: 3%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:OperatingLeaseLiabilityCurrent" contextRef="PAsOn06_30_2021" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">12,055</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 3%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:OperatingLeaseLiabilityCurrent" contextRef="PAsOn03_31_2021" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">12,313</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top; width: 76%;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Deferred consideration liability</div></div> </td>
<td style="vertical-align: bottom; width: 3%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="roiv:DeferredConsiderationLiabilityCurrent" contextRef="PAsOn06_30_2021" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">100,000</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 3%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="roiv:DeferredConsiderationLiabilityCurrent" contextRef="PAsOn03_31_2021" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">100,000</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; width: 76%;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Other current liabilities</div></div> </td>
<td style="vertical-align: bottom; width: 3%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:OtherLiabilitiesCurrent" contextRef="PAsOn06_30_2021" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">8,301</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 3%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:OtherLiabilitiesCurrent" contextRef="PAsOn03_31_2021" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">9,162</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 76%;">&#160;</td>
<td style="vertical-align: bottom; width: 3%;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom; width: 3%;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top; width: 76%;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 5em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Total current liabilities</div></div> </td>
<td style="vertical-align: bottom; width: 3%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:LiabilitiesCurrent" contextRef="PAsOn06_30_2021" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">209,158</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 3%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:LiabilitiesCurrent" contextRef="PAsOn03_31_2021" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">218,961</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; width: 76%;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Liability instruments measured at fair value</div></div> </td>
<td style="vertical-align: bottom; width: 3%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="roiv:LiabilityInstrumentsMeasuredAtFairValue" contextRef="PAsOn06_30_2021" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">5,906</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 3%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="roiv:LiabilityInstrumentsMeasuredAtFairValue" contextRef="PAsOn03_31_2021" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">67,893</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top; width: 76%;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Operating lease liabilities, noncurrent</div></div> </td>
<td style="vertical-align: bottom; width: 3%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:OperatingLeaseLiabilityNoncurrent" contextRef="PAsOn06_30_2021" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">65,263</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 3%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:OperatingLeaseLiabilityNoncurrent" contextRef="PAsOn03_31_2021" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">62,384</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; width: 76%;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Long-term debt (includes $<ix:nonFraction name="us-gaap:LongTermDebtFairValue" contextRef="PAsOn06_30_2021" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">155,200</ix:nonFraction> and $<ix:nonFraction name="us-gaap:LongTermDebtFairValue" contextRef="PAsOn03_31_2021" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">150,100</ix:nonFraction> accounted for under the fair value option at June&#160;30, 2021 and March&#160;31, 2021, respectively)</div></div> </td>
<td style="vertical-align: bottom; width: 3%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:LongTermDebtNoncurrent" contextRef="PAsOn06_30_2021" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">186,350</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 3%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:LongTermDebtNoncurrent" contextRef="PAsOn03_31_2021" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">170,280</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top; width: 76%;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Other liabilities</div></div> </td>
<td style="vertical-align: bottom; width: 3%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:OtherLiabilitiesNoncurrent" contextRef="PAsOn06_30_2021" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">8,188</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 3%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:OtherLiabilitiesNoncurrent" contextRef="PAsOn03_31_2021" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">8,169</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 76%;">&#160;</td>
<td style="vertical-align: bottom; width: 3%;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom; width: 3%;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; width: 76%;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 5em; line-height: normal;">Total liabilities</div> </td>
<td style="vertical-align: bottom; width: 3%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:Liabilities" contextRef="PAsOn06_30_2021" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">474,865</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 3%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:Liabilities" contextRef="PAsOn03_31_2021" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">527,687</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 76%;">&#160;</td>
<td style="vertical-align: bottom; width: 3%;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom; width: 3%;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top; width: 76%;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Commitments and contingencies (Note 10)</div></div> </td>
<td style="vertical-align: bottom; width: 3%;"><ix:nonFraction name="us-gaap:CommitmentsAndContingencies" contextRef="PAsOn06_30_2021" unitRef="Unit_USD" xsi:nil="true"></ix:nonFraction></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; width: 3%;"><ix:nonFraction name="us-gaap:CommitmentsAndContingencies" contextRef="PAsOn03_31_2021" unitRef="Unit_USD" xsi:nil="true"></ix:nonFraction></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; width: 76%;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Redeemable noncontrolling interest</div></div> </td>
<td style="vertical-align: bottom; width: 3%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:RedeemableNoncontrollingInterestEquityCarryingAmount" contextRef="PAsOn06_30_2021" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">22,491</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 3%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:RedeemableNoncontrollingInterestEquityCarryingAmount" contextRef="PAsOn03_31_2021" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">22,491</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-size: 10pt; break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top; width: 76%;"> <div style="text-indent: -1em; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Shareholders&#8217; equity:</div></div> </td>
<td style="vertical-align: bottom; width: 3%;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; width: 3%;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td> </tr>
<tr style="font-size: 10pt; break-inside: avoid;">
<td style="vertical-align: top; width: 76%;"> <div style="text-indent: -1em; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Common shares, par value $<span style="-sec-ix-hidden:hidden28228642">0.0000001</span> per share, <ix:nonFraction name="us-gaap:CommonStockSharesAuthorized" contextRef="PAsOn03_31_2021" unitRef="Unit_shares" decimals="INF" scale="0" format="ixt:numdotdecimal"><ix:nonFraction name="us-gaap:CommonStockSharesAuthorized" contextRef="PAsOn06_30_2021" unitRef="Unit_shares" decimals="INF" scale="0" format="ixt:numdotdecimal">100,000,000,000</ix:nonFraction></ix:nonFraction> shares authorized and <ix:nonFraction name="us-gaap:CommonStockSharesIssued" contextRef="PAsOn03_31_2021" unitRef="Unit_shares" decimals="INF" scale="0" format="ixt:numdotdecimal"><ix:nonFraction name="us-gaap:CommonStockSharesOutstanding" contextRef="PAsOn06_30_2021" unitRef="Unit_shares" decimals="INF" scale="0" format="ixt:numdotdecimal"><ix:nonFraction name="us-gaap:CommonStockSharesOutstanding" contextRef="PAsOn03_31_2021" unitRef="Unit_shares" decimals="INF" scale="0" format="ixt:numdotdecimal"><ix:nonFraction name="us-gaap:CommonStockSharesIssued" contextRef="PAsOn06_30_2021" unitRef="Unit_shares" decimals="INF" scale="0" format="ixt:numdotdecimal">222,669,799</ix:nonFraction></ix:nonFraction></ix:nonFraction></ix:nonFraction> shares issued and outstanding at June&#160;30, 2021 and March&#160;31, 2021</div></div> </td>
<td style="vertical-align: bottom; width: 3%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:CommonStockValue" contextRef="PAsOn06_30_2021" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:zerodash">&#8212;</ix:nonFraction>&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 3%;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:CommonStockValue" contextRef="PAsOn03_31_2021" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:zerodash">&#8212;</ix:nonFraction>&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-size: 10pt; break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top; width: 76%;"> <div style="text-indent: -1em; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;">Additional <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">paid-in</div> capital</div> </td>
<td style="vertical-align: bottom; width: 3%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:AdditionalPaidInCapital" contextRef="PAsOn06_30_2021" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">3,824,974</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 3%;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:AdditionalPaidInCapital" contextRef="PAsOn03_31_2021" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">3,814,805</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-size: 10pt; break-inside: avoid;">
<td style="vertical-align: top; width: 76%;"> <div style="text-indent: -1em; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Subscription receivable</div></div> </td>
<td style="vertical-align: bottom; width: 3%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(<ix:nonFraction name="roiv:SubscriptionsReceivable" contextRef="PAsOn06_30_2021" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:numdotdecimal">100,000</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom; width: 3%;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(<ix:nonFraction name="roiv:SubscriptionsReceivable" contextRef="PAsOn03_31_2021" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:numdotdecimal">100,000</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td> </tr>
<tr style="font-size: 10pt; break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top; width: 76%;"> <div style="text-indent: -1em; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Accumulated deficit</div></div> </td>
<td style="vertical-align: bottom; width: 3%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(<ix:nonFraction name="us-gaap:RetainedEarningsAccumulatedDeficit" contextRef="PAsOn06_30_2021" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:numdotdecimal">2,000,645</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom; width: 3%;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(<ix:nonFraction name="us-gaap:RetainedEarningsAccumulatedDeficit" contextRef="PAsOn03_31_2021" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:numdotdecimal">1,918,462</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td> </tr>
<tr style="font-size: 10pt; break-inside: avoid;">
<td style="vertical-align: top; width: 76%;"> <div style="text-indent: -1em; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Accumulated other comprehensive (loss) income</div></div> </td>
<td style="vertical-align: bottom; width: 3%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(<ix:nonFraction name="us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax" contextRef="PAsOn06_30_2021" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:numdotdecimal">1,207</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom; width: 3%;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax" contextRef="PAsOn03_31_2021" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">1,445</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; width: 76%;">&#160;</td>
<td style="vertical-align: bottom; width: 3%;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom; width: 3%;">&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td> </tr>
<tr style="font-size: 10pt; break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top; width: 76%;"> <div style="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.52in; line-height: normal;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Shareholders&#8217; equity attributable to Roivant Sciences Ltd.</div></div> </td>
<td style="vertical-align: bottom; width: 3%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="PAsOn06_30_2021" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">1,723,122</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 3%;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="PAsOn03_31_2021" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">1,797,788</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-size: 10pt; break-inside: avoid;">
<td style="vertical-align: top; width: 76%;"> <div style="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.52in; line-height: normal;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Noncontrolling interests</div></div> </td>
<td style="vertical-align: bottom; width: 3%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:MinorityInterest" contextRef="PAsOn06_30_2021" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">234,219</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 3%;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:MinorityInterest" contextRef="PAsOn03_31_2021" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">241,726</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; width: 76%;"> <div style="margin-left: 0.52in; line-height: normal; margin-bottom: 0px; margin-top: 0px;">&#160;</div> </td>
<td style="vertical-align: bottom; width: 3%;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom; width: 3%;">&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td> </tr>
<tr style="font-size: 10pt; break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top; width: 76%;"> <div style="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.52in; line-height: normal;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Total shareholders&#8217; equity</div></div> </td>
<td style="vertical-align: bottom; width: 3%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextRef="PAsOn06_30_2021" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">1,957,341</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 3%;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextRef="PAsOn03_31_2021" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">2,039,514</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; width: 76%;"> <div style="margin-left: 0.52in; line-height: normal; margin-bottom: 0px; margin-top: 0px;">&#160;</div> </td>
<td style="vertical-align: bottom; width: 3%;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom; width: 3%;">&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td> </tr>
<tr style="font-size: 10pt; break-inside: avoid;">
<td style="vertical-align: top; width: 76%;"> <div style="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.52in; line-height: normal;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Total liabilities, redeemable noncontrolling interest and shareholders&#8217; equity</div></div> </td>
<td style="vertical-align: bottom; width: 3%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:LiabilitiesAndStockholdersEquity" contextRef="PAsOn06_30_2021" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">2,454,697</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 3%;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:LiabilitiesAndStockholdersEquity" contextRef="PAsOn03_31_2021" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">2,589,692</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; width: 76%;">&#160;</td>
<td style="vertical-align: bottom; width: 3%;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom; width: 3%;">&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td> </tr> </table> </div> </div> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"> <div style="clear: both; max-height: 0px;"></div> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt; text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The accompanying notes are an integral part of these unaudited condensed consolidated financial statements. </div></div></div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">F-<div style="letter-spacing: 0px; top: 0px;;display:inline;">43</div> </div></div></div> </div> </div> </div> </div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="text-align: center;"></div> </div> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;;font-weight: bold;"><div style="display:inline;"><a href="#toc" style="text-indent: 0px;">Table of Contents</a></div></div> <div> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"> <div style="font-size: 13.28px; margin-top: 0pt; margin-bottom: 0pt; line-height: 0pt;;font-weight: bold;">&#160;</div> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">ROIVANT SCIENCES LTD. </div></div></div></div> <div id="fin164680_102" style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Condensed Consolidated Statements of Operations </div></div></div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px; text-indent: 0px;;display:inline;">(unaudited, in thousands, except share and per share amounts)</div></div></div> </div> </div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;width:100%;">
<tr style="font-size: 0px;">
<td style="width: 73%;"></td>
<td style="width: 7%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td>
<td style="width: 7%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;&#160;</td>
<td colspan="6" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Three Months Ended June&#160;30,</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2021</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2020</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top; width: 73%;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Revenue, net</div></div> </td>
<td style="vertical-align: bottom; width: 7%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="P04_01_2021To06_30_2021" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">7,735</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 7%;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="P04_01_2020To06_30_2020" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">1,576</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; width: 73%;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Operating expenses:</div></div> </td>
<td style="vertical-align: bottom; width: 7%;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; width: 7%;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top; width: 73%;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Cost of revenues</div></div> </td>
<td style="vertical-align: bottom; width: 7%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="roiv:OperatingCosts" contextRef="P04_01_2021To06_30_2021" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">742</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 7%;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="roiv:OperatingCosts" contextRef="P04_01_2020To06_30_2020" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">180</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; width: 73%;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Research and development</div></div> </td>
<td style="vertical-align: bottom; width: 7%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:ResearchAndDevelopmentExpense" contextRef="P04_01_2021To06_30_2021" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">78,626</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 7%;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:ResearchAndDevelopmentExpense" contextRef="P04_01_2020To06_30_2020" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">58,734</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top; width: 73%;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">General and administrative</div></div> </td>
<td style="vertical-align: bottom; width: 7%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:GeneralAndAdministrativeExpense" contextRef="P04_01_2021To06_30_2021" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">82,754</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 7%;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:GeneralAndAdministrativeExpense" contextRef="P04_01_2020To06_30_2020" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">57,115</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 73%;">&#160;</td>
<td style="vertical-align: bottom; width: 7%;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom; width: 7%;">&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; width: 73%;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 5em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Total operating expenses</div></div> </td>
<td style="vertical-align: bottom; width: 7%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:OperatingExpenses" contextRef="P04_01_2021To06_30_2021" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">162,122</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 7%;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:OperatingExpenses" contextRef="P04_01_2020To06_30_2020" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">116,029</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 73%;">&#160;</td>
<td style="vertical-align: bottom; width: 7%;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom; width: 7%;">&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top; width: 73%;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Loss from operations</div></div> </td>
<td style="vertical-align: bottom; width: 7%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(<ix:nonFraction name="us-gaap:OperatingIncomeLoss" contextRef="P04_01_2021To06_30_2021" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:numdotdecimal">154,387</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom; width: 7%;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(<ix:nonFraction name="us-gaap:OperatingIncomeLoss" contextRef="P04_01_2020To06_30_2020" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:numdotdecimal">114,453</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 73%;">&#160;</td>
<td style="vertical-align: bottom; width: 7%;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom; width: 7%;">&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; width: 73%;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Change in fair value of investments</div></div> </td>
<td style="vertical-align: bottom; width: 7%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:GainLossOnInvestments" contextRef="P04_01_2021To06_30_2021" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:numdotdecimal">8,619</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 7%;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(<ix:nonFraction name="us-gaap:GainLossOnInvestments" contextRef="P04_01_2020To06_30_2020" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">41,148</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top; width: 73%;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Change in fair value of debt and liability instruments</div></div> </td>
<td style="vertical-align: bottom; width: 7%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="roiv:GainLossOnFairValueOfDebtAndLiabilityInstruments" contextRef="P04_01_2021To06_30_2021" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:numdotdecimal">4,585</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 7%;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="roiv:GainLossOnFairValueOfDebtAndLiabilityInstruments" contextRef="P04_01_2020To06_30_2020" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:numdotdecimal">17,125</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; width: 73%;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Gain on termination of Sumitomo Options</div></div> </td>
<td style="vertical-align: bottom; width: 7%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(<ix:nonFraction name="roiv:EquityInterestOptionToThirdPartyPurchaserGainOnTermination" contextRef="P04_01_2021To06_30_2021" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">66,472</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom; width: 7%;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="roiv:EquityInterestOptionToThirdPartyPurchaserGainOnTermination" contextRef="P04_01_2020To06_30_2020" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:zerodash">&#8212;</ix:nonFraction>&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top; width: 73%;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Gain on deconsolidation of subsidiary</div></div> </td>
<td style="vertical-align: bottom; width: 7%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="roiv:GainOrLossOnDeconsolidationOfSubsidiary" contextRef="P04_01_2021To06_30_2021" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:zerodash">&#8212;</ix:nonFraction>&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 7%;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(<ix:nonFraction name="roiv:GainOrLossOnDeconsolidationOfSubsidiary" contextRef="P04_01_2020To06_30_2020" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">86,516</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; width: 73%;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Other (income) expense, net</div></div> </td>
<td style="vertical-align: bottom; width: 7%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(<ix:nonFraction name="us-gaap:OtherNonoperatingIncomeExpense" contextRef="P04_01_2021To06_30_2021" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">134</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom; width: 7%;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:OtherNonoperatingIncomeExpense" contextRef="P04_01_2020To06_30_2020" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:numdotdecimal">2,842</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 73%;">&#160;</td>
<td style="vertical-align: bottom; width: 7%;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom; width: 7%;">&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top; width: 73%;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Loss before income taxes</div></div> </td>
<td style="vertical-align: bottom; width: 7%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(<ix:nonFraction name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" contextRef="P04_01_2021To06_30_2021" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:numdotdecimal">100,985</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom; width: 7%;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(<ix:nonFraction name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" contextRef="P04_01_2020To06_30_2020" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:numdotdecimal">6,756</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; width: 73%;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Income tax expense</div></div> </td>
<td style="vertical-align: bottom; width: 7%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:IncomeTaxExpenseBenefit" contextRef="P04_01_2021To06_30_2021" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">93</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 7%;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:IncomeTaxExpenseBenefit" contextRef="P04_01_2020To06_30_2020" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">1,221</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr>
<td style="vertical-align: top; padding-bottom: 0.75pt; width: 73%;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0px; margin-bottom: 0px; margin-left: 1em; line-height: 1pt;">&#160;</div> </td>
<td style="vertical-align: bottom; padding-bottom: 0.75pt; width: 7%;"> <div style="margin-top: 0px; margin-bottom: 0px; line-height: 1pt;">&#160;</div> </td>
<td style="vertical-align: bottom; white-space: nowrap; border-bottom: 0.75pt solid black;"> <div style="margin-top: 0px; margin-bottom: 0px; line-height: 1pt;">&#160;</div> </td>
<td style="vertical-align: bottom; white-space: nowrap; border-bottom: 0.75pt solid black;"> <div style="margin-top: 0px; margin-bottom: 0px; line-height: 1pt;">&#160;</div> </td>
<td style="vertical-align: bottom; white-space: nowrap; padding-bottom: 0.75pt;"> <div style="margin-top: 0px; margin-bottom: 0px; line-height: 1pt;">&#160;</div> </td>
<td style="vertical-align: bottom; padding-bottom: 0.75pt; width: 7%;"> <div style="margin-top: 0px; margin-bottom: 0px; line-height: 1pt;">&#160;</div> </td>
<td style="vertical-align: bottom; white-space: nowrap; border-bottom: 0.75pt solid black;"> <div style="margin-top: 0px; margin-bottom: 0px; line-height: 1pt;">&#160;</div> </td>
<td style="vertical-align: bottom; white-space: nowrap; border-bottom: 0.75pt solid black;"> <div style="margin-top: 0px; margin-bottom: 0px; line-height: 1pt;">&#160;</div> </td>
<td style="vertical-align: bottom; white-space: nowrap; padding-bottom: 0.75pt;"> <div style="margin-top: 0px; margin-bottom: 0px; line-height: 1pt;">&#160;</div> </td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top; width: 73%;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Net loss</div></div> </td>
<td style="vertical-align: bottom; width: 7%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(<ix:nonFraction name="us-gaap:ProfitLoss" contextRef="P04_01_2021To06_30_2021" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:numdotdecimal">101,078</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom; width: 7%;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(<ix:nonFraction name="us-gaap:ProfitLoss" contextRef="P04_01_2020To06_30_2020" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:numdotdecimal">7,977</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; width: 73%;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Net loss attributable to noncontrolling interests</div></div> </td>
<td style="vertical-align: bottom; width: 7%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(<ix:nonFraction name="us-gaap:NetIncomeLossAttributableToNoncontrollingInterest" contextRef="P04_01_2021To06_30_2021" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:numdotdecimal">18,895</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom; width: 7%;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(<ix:nonFraction name="us-gaap:NetIncomeLossAttributableToNoncontrollingInterest" contextRef="P04_01_2020To06_30_2020" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:numdotdecimal">4,734</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 73%;">&#160;</td>
<td style="vertical-align: bottom; width: 7%;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom; width: 7%;">&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top; width: 73%;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Net loss attributable to Roivant Sciences Ltd.</div></div> </td>
<td style="vertical-align: bottom; width: 7%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(<ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="P04_01_2021To06_30_2021" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:numdotdecimal">82,183</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom; width: 7%;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(<ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="P04_01_2020To06_30_2020" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:numdotdecimal">3,243</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 73%;">&#160;</td>
<td style="vertical-align: bottom; width: 7%;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom; width: 7%;">&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; width: 73%;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Net loss per common share&#8212;basic and diluted</div></div> </td>
<td style="vertical-align: bottom; width: 7%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(<ix:nonFraction name="us-gaap:EarningsPerShareBasicAndDiluted" contextRef="P04_01_2021To06_30_2021" unitRef="Unit_USD_per_Share" decimals="2" scale="0" sign="-" format="ixt:numdotdecimal">0.37</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom; width: 7%;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(<ix:nonFraction name="us-gaap:EarningsPerShareBasicAndDiluted" contextRef="P04_01_2020To06_30_2020" unitRef="Unit_USD_per_Share" decimals="2" scale="0" sign="-" format="ixt:numdotdecimal">0.02</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 73%;">&#160;</td>
<td style="vertical-align: bottom; width: 7%;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom; width: 7%;">&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top; width: 73%;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Weighted average shares outstanding&#8212;basic and diluted</div></div> </td>
<td style="vertical-align: bottom; width: 7%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted" contextRef="P04_01_2021To06_30_2021" unitRef="Unit_shares" decimals="0" scale="0" format="ixt:numdotdecimal">222,081,975</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 7%;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted" contextRef="P04_01_2020To06_30_2020" unitRef="Unit_shares" decimals="0" scale="0" format="ixt:numdotdecimal">214,879,058</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 73%;">&#160;</td>
<td style="vertical-align: bottom; width: 7%;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom; width: 7%;">&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td> </tr> </table> <div style="clear: both; max-height: 0px;"></div> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt; text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The accompanying notes are an integral part of these unaudited condensed consolidated financial statements. </div></div></div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0px;"></div> </div> </div> </div> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">F-<div style="letter-spacing: 0px; top: 0px;;display:inline;">44</div> </div></div></div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0px;"></div> </div> </div> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;;font-weight: bold;"><div style="display:inline;"><a href="#toc" style="text-indent: 0px;">Table of Contents</a></div></div> <div> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"> <div style="font-size: 13.28px; margin-top: 0pt; margin-bottom: 0pt; line-height: 0pt;;font-weight: bold;">&#160;</div> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">ROIVANT SCIENCES LTD. </div></div></div></div> <div id="fin164680_103" style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Condensed Consolidated Statements of Comprehensive Loss </div></div></div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px; text-indent: 0px;;display:inline;">(unaudited, in thousands)</div></div></div> </div> </div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div> </div> </div> </div> </div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;width:100%;">
<tr style="font-size: 0px;">
<td style="width: 82%;"></td>
<td style="width: 2%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td>
<td style="width: 2%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;&#160;</td>
<td colspan="6" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"> <div style="margin-top: 0px; margin-bottom: 0px; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Three&#160;Months&#160;Ended&#160;</div></div></div> <div style="margin-top: 0px; margin-bottom: 0px; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">June&#160;30,</div></div></div> </td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2021</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2020</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top; width: 82%;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Net loss</div></div> </td>
<td style="vertical-align: bottom; width: 2%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(<ix:nonFraction name="us-gaap:ProfitLoss" contextRef="P04_01_2021To06_30_2021" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:numdotdecimal">101,078</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom; width: 2%;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(<ix:nonFraction name="us-gaap:ProfitLoss" contextRef="P04_01_2020To06_30_2020" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:numdotdecimal">7,977</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; width: 82%;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Other comprehensive loss:</div></div> </td>
<td style="vertical-align: bottom; width: 2%;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; width: 2%;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top; width: 82%;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Foreign currency translation adjustment</div></div> </td>
<td style="vertical-align: bottom; width: 2%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(<ix:nonFraction name="us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax" contextRef="P04_01_2021To06_30_2021" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:numdotdecimal">2,439</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom; width: 2%;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(<ix:nonFraction name="us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax" contextRef="P04_01_2020To06_30_2020" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:numdotdecimal">820</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 82%;">&#160;</td>
<td style="vertical-align: bottom; width: 2%;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom; width: 2%;">&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; width: 82%;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Total other comprehensive loss</div></div> </td>
<td style="vertical-align: bottom; width: 2%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(<ix:nonFraction name="us-gaap:OtherComprehensiveIncomeLossNetOfTax" contextRef="P04_01_2021To06_30_2021" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:numdotdecimal">2,439</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom; width: 2%;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(<ix:nonFraction name="us-gaap:OtherComprehensiveIncomeLossNetOfTax" contextRef="P04_01_2020To06_30_2020" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:numdotdecimal">820</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 82%;">&#160;</td>
<td style="vertical-align: bottom; width: 2%;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom; width: 2%;">&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top; width: 82%;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Comprehensive loss</div></div> </td>
<td style="vertical-align: bottom; width: 2%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(<ix:nonFraction name="us-gaap:ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest" contextRef="P04_01_2021To06_30_2021" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:numdotdecimal">103,517</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom; width: 2%;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(<ix:nonFraction name="us-gaap:ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest" contextRef="P04_01_2020To06_30_2020" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:numdotdecimal">8,797</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; width: 82%;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Comprehensive loss attributable to noncontrolling interests</div></div> </td>
<td style="vertical-align: bottom; width: 2%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(<ix:nonFraction name="us-gaap:ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest" contextRef="P04_01_2021To06_30_2021" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:numdotdecimal">18,682</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom; width: 2%;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(<ix:nonFraction name="us-gaap:ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest" contextRef="P04_01_2020To06_30_2020" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:numdotdecimal">4,700</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 82%;">&#160;</td>
<td style="vertical-align: bottom; width: 2%;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom; width: 2%;">&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top; width: 82%;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Comprehensive loss attributable to Roivant Sciences Ltd.</div></div> </td>
<td style="vertical-align: bottom; width: 2%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(<ix:nonFraction name="us-gaap:ComprehensiveIncomeNetOfTax" contextRef="P04_01_2021To06_30_2021" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:numdotdecimal">84,835</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom; width: 2%;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(<ix:nonFraction name="us-gaap:ComprehensiveIncomeNetOfTax" contextRef="P04_01_2020To06_30_2020" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:numdotdecimal">4,097</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 82%;">&#160;</td>
<td style="vertical-align: bottom; width: 2%;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom; width: 2%;">&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td> </tr> </table> <div style="clear: both; max-height: 0px;"></div> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt; text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The accompanying notes are an integral part of these unaudited condensed consolidated financial statements. </div></div></div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">F-<div style="letter-spacing: 0px; top: 0px;;display:inline;">45</div> </div></div></div> </div> </div> </div> </div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="text-align: center;"></div> </div> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;;font-weight: bold;"><div style="display:inline;"><a href="#toc" style="text-indent: 0px;">Table of Contents</a></div></div> <div> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"> <div style="font-size: 13.28px; margin-top: 0pt; margin-bottom: 0pt; line-height: 0pt;;font-weight: bold;">&#160;</div> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">ROIVANT SCIENCES LTD. </div></div></div></div> <div id="fin164680_104" style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Condensed Consolidated Statements of Shareholders&#8217; Equity and Redeemable Noncontrolling Interest </div></div></div></div> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">(unaudited, in thousands, except share data) </div></div></div> </div> </div> </div> </div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 9.5pt; border-collapse: collapse; border-spacing: 0px; text-indent: 0px;">
<tr style="font-size: 0px;">
<td style="width: 38%;"></td>
<td style="width: 1%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td>
<td style="width: 1%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td>
<td style="width: 1%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td>
<td style="width: 1%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td>
<td style="width: 1%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td>
<td style="width: 1%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td>
<td style="width: 1%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td>
<td style="width: 1%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td>
<td style="width: 1%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 1pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td colspan="2" style="vertical-align: bottom; padding-bottom: 1pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td colspan="30" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Shareholders&#8217; Equity</div></div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 1pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td rowspan="2" style="vertical-align: bottom; padding-bottom: 1pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td colspan="2" rowspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Redeemable<br/> Noncontrolling<br/> Interest</div></div></div></td>
<td rowspan="2" style="vertical-align: bottom; padding-bottom: 1pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td colspan="6" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Common&#160;Stock</div></div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td rowspan="2" style="vertical-align: bottom; padding-bottom: 1pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td colspan="2" rowspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Additional<br/> <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">Paid-in</div><br/> Capital</div></div></div></td>
<td rowspan="2" style="vertical-align: bottom; padding-bottom: 1pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td rowspan="2" style="vertical-align: bottom; padding-bottom: 1pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td colspan="2" rowspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Subscription<br/> Receivable</div></div></div></td>
<td rowspan="2" style="vertical-align: bottom; padding-bottom: 1pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td rowspan="2" style="vertical-align: bottom; padding-bottom: 1pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td colspan="2" rowspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Accumulated<br/> Other<br/> Comprehensive<br/> Income (Loss)</div></div></div></td>
<td rowspan="2" style="vertical-align: bottom; padding-bottom: 1pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td rowspan="2" style="vertical-align: bottom; padding-bottom: 1pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td colspan="2" rowspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Accumulated<br/> Deficit</div></div></div></td>
<td rowspan="2" style="vertical-align: bottom; padding-bottom: 1pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td rowspan="2" style="vertical-align: bottom; padding-bottom: 1pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td colspan="2" rowspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Noncontrolling<br/> Interests</div></div></div></td>
<td rowspan="2" style="vertical-align: bottom; padding-bottom: 1pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td rowspan="2" style="vertical-align: bottom; padding-bottom: 1pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td colspan="2" rowspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Total<br/> Shareholders&#8217;<br/> Equity</div></div></div></td>
<td rowspan="2" style="vertical-align: bottom; padding-bottom: 1pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 1pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Shares</div></div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Amount</div></div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td> </tr>
<tr style="font-size: 0px;">
<td style="width: 38%;"></td>
<td style="width: 1%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td>
<td style="width: 1%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td>
<td style="width: 1%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td>
<td style="width: 1%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td>
<td style="width: 1%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td>
<td style="width: 1%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td>
<td style="width: 1%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td>
<td style="width: 1%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td>
<td style="width: 1%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top; width: 38%; white-space: nowrap;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal; white-space: nowrap;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px; white-space: nowrap;;display:inline;">Balance at March&#160;31, 2021</div></div></div> </td>
<td style="vertical-align: bottom; width: 1%;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextRef="PAsOn03_31_2021_RedeemableNoncontrollingInterestMemberusgaapStatementClassOfStockAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">22,491</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 1%;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:SharesOutstanding" contextRef="PAsOn03_31_2021_CommonStockMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_shares" decimals="INF" scale="0" format="ixt:numdotdecimal">222,669,799</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 1%;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextRef="PAsOn03_31_2021_CommonStockMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:zerodash">&#8212;</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 1%;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextRef="PAsOn03_31_2021_AdditionalPaidInCapitalMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">3,814,805</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 1%;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(<ix:nonFraction name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextRef="PAsOn03_31_2021_SubscriptionsReceivablesMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:numdotdecimal">100,000</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom; width: 1%;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextRef="PAsOn03_31_2021_AccumulatedOtherComprehensiveIncomeMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">1,445</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 1%;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(<ix:nonFraction name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextRef="PAsOn03_31_2021_RetainedEarningsMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:numdotdecimal">1,918,462</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom; width: 1%;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextRef="PAsOn03_31_2021_NoncontrollingInterestMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">241,726</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 1%;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextRef="PAsOn03_31_2021" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">2,039,514</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; width: 38%; white-space: nowrap;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal; white-space: nowrap;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px; white-space: nowrap;;display:inline;">Issuance of subsidiary warrants</div></div> </td>
<td style="vertical-align: bottom; width: 1%;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 1%;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 1%;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 1%;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="roiv:IssuanceOfSubsidiaryWarrants" contextRef="P04_01_2021To06_30_2021_AdditionalPaidInCapitalMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">2,051</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 1%;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 1%;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 1%;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 1%;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="roiv:IssuanceOfSubsidiaryWarrants" contextRef="P04_01_2021To06_30_2021_NoncontrollingInterestMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">24</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 1%;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="roiv:IssuanceOfSubsidiaryWarrants" contextRef="P04_01_2021To06_30_2021" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">2,075</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top; width: 38%;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Cash contributions to majority-owned subsidiaries</div></div> </td>
<td style="vertical-align: bottom; width: 1%;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 1%;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 1%;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 1%;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(<ix:nonFraction name="roiv:CapitalContributionsToSubsidiaries" contextRef="P04_01_2021To06_30_2021_AdditionalPaidInCapitalMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:numdotdecimal">2,973</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom; width: 1%;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 1%;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 1%;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 1%;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="roiv:CapitalContributionsToSubsidiaries" contextRef="P04_01_2021To06_30_2021_NoncontrollingInterestMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">2,973</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 1%;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="roiv:CapitalContributionsToSubsidiaries" contextRef="P04_01_2021To06_30_2021" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:zerodash">&#8212;</ix:nonFraction>&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; width: 38%;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Share-based compensation</div></div> </td>
<td style="vertical-align: bottom; width: 1%;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 1%;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 1%;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 1%;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" contextRef="P04_01_2021To06_30_2021_AdditionalPaidInCapitalMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">11,091</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 1%;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 1%;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 1%;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 1%;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" contextRef="P04_01_2021To06_30_2021_NoncontrollingInterestMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">8,178</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 1%;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" contextRef="P04_01_2021To06_30_2021" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">19,269</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top; width: 38%;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Foreign currency translation adjustment</div></div> </td>
<td style="vertical-align: bottom; width: 1%;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 1%;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 1%;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 1%;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 1%;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 1%;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(<ix:nonFraction name="us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent" contextRef="P04_01_2021To06_30_2021_AccumulatedOtherComprehensiveIncomeMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:numdotdecimal">2,652</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom; width: 1%;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 1%;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent" contextRef="P04_01_2021To06_30_2021_NoncontrollingInterestMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">213</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 1%;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(<ix:nonFraction name="us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent" contextRef="P04_01_2021To06_30_2021" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:numdotdecimal">2,439</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; width: 38%;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Net loss</div></div> </td>
<td style="vertical-align: bottom; width: 1%;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 1%;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 1%;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 1%;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 1%;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 1%;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 1%;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(<ix:nonFraction name="us-gaap:ProfitLoss" contextRef="P04_01_2021To06_30_2021_RetainedEarningsMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:numdotdecimal">82,183</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom; width: 1%;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(<ix:nonFraction name="us-gaap:ProfitLoss" contextRef="P04_01_2021To06_30_2021_NoncontrollingInterestMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:numdotdecimal">18,895</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom; width: 1%;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(<ix:nonFraction name="us-gaap:ProfitLoss" contextRef="P04_01_2021To06_30_2021" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:numdotdecimal">101,078</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 38%;">&#160;</td>
<td style="vertical-align: bottom; width: 1%;">&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom; width: 1%;">&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom; width: 1%;">&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom; width: 1%;">&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom; width: 1%;">&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom; width: 1%;">&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom; width: 1%;">&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom; width: 1%;">&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom; width: 1%;">&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top; width: 38%;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Balance at June&#160;30, 2021</div></div></div> </td>
<td style="vertical-align: bottom; width: 1%;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextRef="PAsOn06_30_2021_RedeemableNoncontrollingInterestMemberusgaapStatementClassOfStockAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">22,491</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 1%;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:SharesOutstanding" contextRef="PAsOn06_30_2021_CommonStockMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_shares" decimals="INF" scale="0" format="ixt:numdotdecimal">222,669,799</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 1%;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextRef="PAsOn06_30_2021_CommonStockMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:zerodash">&#8212;</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 1%;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextRef="PAsOn06_30_2021_AdditionalPaidInCapitalMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">3,824,974</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 1%;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(<ix:nonFraction name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextRef="PAsOn06_30_2021_SubscriptionsReceivablesMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:numdotdecimal">100,000</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom; width: 1%;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(<ix:nonFraction name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextRef="PAsOn06_30_2021_AccumulatedOtherComprehensiveIncomeMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:numdotdecimal">1,207</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom; width: 1%;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(<ix:nonFraction name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextRef="PAsOn06_30_2021_RetainedEarningsMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:numdotdecimal">2,000,645</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom; width: 1%;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextRef="PAsOn06_30_2021_NoncontrollingInterestMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">234,219</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 1%;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextRef="PAsOn06_30_2021" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">1,957,341</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 38%;">&#160;</td>
<td style="vertical-align: bottom; width: 1%;">&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom; width: 1%;">&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom; width: 1%;">&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom; width: 1%;">&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom; width: 1%;">&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom; width: 1%;">&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom; width: 1%;">&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom; width: 1%;">&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom; width: 1%;">&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td> </tr> </table> <div style="font-size: 12pt; margin-top: 0px; margin-bottom: 0px;">&#160;</div> </div> </div> </div> </div> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;">
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px; text-indent: 0px;;width:100%;">
<tr style="font-size: 1px;">
<td></td> </tr> </table> <div style="clear: both; max-height: 0px; text-indent: 0px;"></div> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0px;"></div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 9.5pt; border-collapse: collapse; border-spacing: 0px; text-indent: 0px;">
<tr style="font-size: 0px;">
<td style="width: 41%;"></td>
<td style="width: 1%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td>
<td style="width: 1%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td>
<td style="width: 1%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td>
<td style="width: 1%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td>
<td style="width: 1%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td>
<td style="width: 1%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td>
<td style="width: 1%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td>
<td style="width: 1%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td>
<td style="width: 1%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 1pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td colspan="2" style="vertical-align: bottom; padding-bottom: 1pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td colspan="30" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Shareholders&#8217; Equity</div></div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td rowspan="2" style="vertical-align: bottom; padding-bottom: 1pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td rowspan="2" style="vertical-align: bottom; padding-bottom: 1pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td colspan="2" rowspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Redeemable<br/> Noncontrolling<br/> Interest</div></div></div></td>
<td rowspan="2" style="vertical-align: bottom; padding-bottom: 1pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td colspan="6" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Common Stock</div></div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td rowspan="2" style="vertical-align: bottom; padding-bottom: 1pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td colspan="2" rowspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Additional<br/> <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">Paid-in</div><br/> Capital</div></div></div></td>
<td rowspan="2" style="vertical-align: bottom; padding-bottom: 1pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td rowspan="2" style="vertical-align: bottom; padding-bottom: 1pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td colspan="2" rowspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Subscription<br/> Receivable</div></div></div></td>
<td rowspan="2" style="vertical-align: bottom; padding-bottom: 1pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td rowspan="2" style="vertical-align: bottom; padding-bottom: 1pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td colspan="2" rowspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Accumulated<br/> Other<br/> Comprehensive<br/> Loss</div></div></div></td>
<td rowspan="2" style="vertical-align: bottom; padding-bottom: 1pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td rowspan="2" style="vertical-align: bottom; padding-bottom: 1pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td colspan="2" rowspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Accumulated<br/> Deficit</div></div></div></td>
<td rowspan="2" style="vertical-align: bottom; padding-bottom: 1pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td rowspan="2" style="vertical-align: bottom; padding-bottom: 1pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td colspan="2" rowspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Noncontrolling<br/> Interests</div></div></div></td>
<td rowspan="2" style="vertical-align: bottom; padding-bottom: 1pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td rowspan="2" style="vertical-align: bottom; padding-bottom: 1pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td colspan="2" rowspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Total<br/> Shareholders&#8217;<br/> Equity</div></div></div></td>
<td rowspan="2" style="vertical-align: bottom; padding-bottom: 1pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 1pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Shares</div></div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Amount</div></div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td> </tr>
<tr style="font-size: 0px;">
<td style="width: 38%;"></td>
<td style="width: 1%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td>
<td style="width: 1%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td>
<td style="width: 1%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td>
<td style="width: 1%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td>
<td style="width: 1%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td>
<td style="width: 1%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td>
<td style="width: 1%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td>
<td style="width: 1%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td>
<td style="width: 1%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top; width: 38%; white-space: nowrap;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal; white-space: nowrap;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px; white-space: nowrap;;display:inline;">Balance at March&#160;31, 2020</div></div></div> </td>
<td style="vertical-align: bottom; width: 1%;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextRef="PAsOn03_31_2020_RedeemableNoncontrollingInterestMemberusgaapStatementClassOfStockAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">22,491</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 1%;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:SharesOutstanding" contextRef="PAsOn03_31_2020_CommonStockMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_shares" decimals="INF" scale="0" format="ixt:numdotdecimal">214,879,058</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 1%;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextRef="PAsOn03_31_2020_CommonStockMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:zerodash">&#8212;</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 1%;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextRef="PAsOn03_31_2020_AdditionalPaidInCapitalMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">3,143,739</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 1%;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextRef="PAsOn03_31_2020_SubscriptionsReceivablesMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:zerodash">&#8212;</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 1%;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(<ix:nonFraction name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextRef="PAsOn03_31_2020_AccumulatedOtherComprehensiveIncomeMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:numdotdecimal">2,349</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom; width: 1%;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(<ix:nonFraction name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextRef="PAsOn03_31_2020_RetainedEarningsMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:numdotdecimal">1,109,228</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom; width: 1%;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextRef="PAsOn03_31_2020_NoncontrollingInterestMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">54,042</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 1%;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextRef="PAsOn03_31_2020" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">2,086,204</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; width: 38%; white-space: nowrap;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal; white-space: nowrap;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px; white-space: nowrap;;display:inline;">Issuance of subsidiary common <br/> shares, net of issuance costs <br/> paid</div></div> </td>
<td style="vertical-align: bottom; width: 1%;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 1%;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 1%;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 1%;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="roiv:IssuanceOfSubsidiaryCommonSharesNetValue" contextRef="P04_01_2020To06_30_2020_AdditionalPaidInCapitalMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">104,581</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 1%;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 1%;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 1%;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 1%;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="roiv:IssuanceOfSubsidiaryCommonSharesNetValue" contextRef="P04_01_2020To06_30_2020_NoncontrollingInterestMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">76,599</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 1%;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="roiv:IssuanceOfSubsidiaryCommonSharesNetValue" contextRef="P04_01_2020To06_30_2020" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">181,180</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top; width: 38%;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Issuance of subsidiary common shares to the Company</div></div> </td>
<td style="vertical-align: bottom; width: 1%;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 1%;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 1%;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 1%;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(<ix:nonFraction name="roiv:IssuanceOfSubsidiaryCommonSharesToTheCompanyValue" contextRef="P04_01_2020To06_30_2020_AdditionalPaidInCapitalMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:numdotdecimal">6,342</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom; width: 1%;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 1%;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 1%;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 1%;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="roiv:IssuanceOfSubsidiaryCommonSharesToTheCompanyValue" contextRef="P04_01_2020To06_30_2020_NoncontrollingInterestMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">6,342</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 1%;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="roiv:IssuanceOfSubsidiaryCommonSharesToTheCompanyValue" contextRef="P04_01_2020To06_30_2020" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:zerodash">&#8212;</ix:nonFraction>&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:9.5pt">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 9.5pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Exercise of subsidiary stock options</div> </td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" contextRef="P04_01_2020To06_30_2020_AdditionalPaidInCapitalMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">36</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" contextRef="P04_01_2020To06_30_2020_NoncontrollingInterestMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">27</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" contextRef="P04_01_2020To06_30_2020" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">63</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top; width: 38%;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Deconsolidation of subsidiary</div></div> </td>
<td style="vertical-align: bottom; width: 1%;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 1%;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 1%;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 1%;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 1%;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 1%;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 1%;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 1%;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(<ix:nonFraction name="roiv:DeconsolidationOfSubsidiary" contextRef="P04_01_2020To06_30_2020_NoncontrollingInterestMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:numdotdecimal">3,054</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom; width: 1%;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(<ix:nonFraction name="roiv:DeconsolidationOfSubsidiary" contextRef="P04_01_2020To06_30_2020" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:numdotdecimal">3,054</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; width: 38%;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Repurchase of equity awards</div></div> </td>
<td style="vertical-align: bottom; width: 1%;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 1%;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 1%;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 1%;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(<ix:nonFraction name="roiv:RepurchaseOfEquityAwards" contextRef="P04_01_2020To06_30_2020_AdditionalPaidInCapitalMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:numdotdecimal">113</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom; width: 1%;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 1%;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 1%;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 1%;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 1%;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(<ix:nonFraction name="roiv:RepurchaseOfEquityAwards" contextRef="P04_01_2020To06_30_2020" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:numdotdecimal">113</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top; width: 38%;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Cash contribution to majority-owned subsidiaries</div></div> </td>
<td style="vertical-align: bottom; width: 1%;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 1%;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 1%;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 1%;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(<ix:nonFraction name="roiv:CapitalContributionsToSubsidiaries" contextRef="P04_01_2020To06_30_2020_AdditionalPaidInCapitalMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:numdotdecimal">149</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom; width: 1%;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 1%;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 1%;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 1%;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="roiv:CapitalContributionsToSubsidiaries" contextRef="P04_01_2020To06_30_2020_NoncontrollingInterestMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">149</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 1%;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="roiv:CapitalContributionsToSubsidiaries" contextRef="P04_01_2020To06_30_2020" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:zerodash">&#8212;</ix:nonFraction>&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; width: 38%;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Share-based compensation</div></div> </td>
<td style="vertical-align: bottom; width: 1%;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 1%;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 1%;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 1%;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" contextRef="P04_01_2020To06_30_2020_AdditionalPaidInCapitalMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">9,285</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 1%;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 1%;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 1%;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 1%;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" contextRef="P04_01_2020To06_30_2020_NoncontrollingInterestMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">4,993</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 1%;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" contextRef="P04_01_2020To06_30_2020" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">14,278</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top; width: 38%;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Foreign currency translation adjustment</div></div> </td>
<td style="vertical-align: bottom; width: 1%;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 1%;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 1%;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 1%;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 1%;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 1%;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(<ix:nonFraction name="us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent" contextRef="P04_01_2020To06_30_2020_AccumulatedOtherComprehensiveIncomeMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:numdotdecimal">854</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom; width: 1%;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 1%;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent" contextRef="P04_01_2020To06_30_2020_NoncontrollingInterestMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">34</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 1%;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(<ix:nonFraction name="us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent" contextRef="P04_01_2020To06_30_2020" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:numdotdecimal">820</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; width: 38%;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Net loss</div></div> </td>
<td style="vertical-align: bottom; width: 1%;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 1%;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 1%;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 1%;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 1%;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 1%;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 1%;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(<ix:nonFraction name="us-gaap:ProfitLoss" contextRef="P04_01_2020To06_30_2020_RetainedEarningsMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:numdotdecimal">3,243</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom; width: 1%;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(<ix:nonFraction name="us-gaap:ProfitLoss" contextRef="P04_01_2020To06_30_2020_NoncontrollingInterestMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:numdotdecimal">4,734</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom; width: 1%;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(<ix:nonFraction name="us-gaap:ProfitLoss" contextRef="P04_01_2020To06_30_2020" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:numdotdecimal">7,977</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 38%;">&#160;</td>
<td style="vertical-align: bottom; width: 1%;">&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom; width: 1%;">&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom; width: 1%;">&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom; width: 1%;">&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom; width: 1%;">&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom; width: 1%;">&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom; width: 1%;">&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom; width: 1%;">&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom; width: 1%;">&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top; width: 38%;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Balance at June&#160;30, 2020</div></div></div> </td>
<td style="vertical-align: bottom; width: 1%;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextRef="PAsOn06_30_2020_RedeemableNoncontrollingInterestMemberusgaapStatementClassOfStockAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">22,491</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 1%;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:SharesOutstanding" contextRef="PAsOn06_30_2020_CommonStockMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_shares" decimals="INF" scale="0" format="ixt:numdotdecimal">214,879,058</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 1%;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextRef="PAsOn06_30_2020_CommonStockMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:zerodash">&#8212;</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 1%;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextRef="PAsOn06_30_2020_AdditionalPaidInCapitalMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">3,251,037</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 1%;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextRef="PAsOn06_30_2020_SubscriptionsReceivablesMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:zerodash">&#8212;</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 1%;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(<ix:nonFraction name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextRef="PAsOn06_30_2020_AccumulatedOtherComprehensiveIncomeMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:numdotdecimal">3,203</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom; width: 1%;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(<ix:nonFraction name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextRef="PAsOn06_30_2020_RetainedEarningsMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:numdotdecimal">1,112,471</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom; width: 1%;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextRef="PAsOn06_30_2020_NoncontrollingInterestMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">134,398</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 1%;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextRef="PAsOn06_30_2020" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">2,269,761</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 38%;">&#160;</td>
<td style="vertical-align: bottom; width: 1%;">&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom; width: 1%;">&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom; width: 1%;">&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom; width: 1%;">&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom; width: 1%;">&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom; width: 1%;">&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom; width: 1%;">&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom; width: 1%;">&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom; width: 1%;">&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td> </tr> </table> <div style="clear: both; max-height: 0px; text-indent: 0px;"></div> </div> </div> </div> </div> </div> </div> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"> <div style="clear: both; max-height: 0px; text-indent: 0px;"></div> </div> </div> <div style="clear: both; max-height: 0px;"></div> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt; text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The accompanying notes are an integral part of these unaudited condensed consolidated financial statements. </div></div></div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">F-<div style="letter-spacing: 0px; top: 0px;;display:inline;">46</div> </div></div></div> </div> </div> </div> </div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="text-align: center;"></div> </div> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;;font-weight: bold;"><div style="display:inline;"><a href="#toc" style="text-indent: 0px;">Table of Contents</a></div></div> <div> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">ROIVANT SCIENCES LTD. </div></div></div></div> <div id="fin164680_105" style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Condensed Consolidated Statements of Cash Flows </div></div></div></div> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">(unaudited, in thousands) </div></div></div> </div> </div> </div> </div> </div> </div> </div> </div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;width:100%;">
<tr style="font-size: 0px;">
<td style="width: 78%;"></td>
<td style="width: 2%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td>
<td style="width: 2%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;&#160;</td>
<td colspan="6" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Three Months Ended<br/> June&#160;30,</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2021</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2020</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top; width: 78%;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-weight:bold;display:inline;width:100%;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Cash flows from operating activities:</div></div></div> </td>
<td style="vertical-align: bottom; width: 2%;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; width: 2%;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; width: 78%;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Net loss</div></div> </td>
<td style="vertical-align: bottom; width: 2%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(<ix:nonFraction name="us-gaap:ProfitLoss" contextRef="P04_01_2021To06_30_2021" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:numdotdecimal">101,078</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom; width: 2%;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(<ix:nonFraction name="us-gaap:ProfitLoss" contextRef="P04_01_2020To06_30_2020" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:numdotdecimal">7,977</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top; width: 78%;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Adjustments to reconcile net loss to net cash used in operating activities:</div></div> </td>
<td style="vertical-align: bottom; width: 2%;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; width: 2%;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; width: 78%;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Share-based compensation</div></div> </td>
<td style="vertical-align: bottom; width: 2%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:ShareBasedCompensation" contextRef="P04_01_2021To06_30_2021" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">19,269</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 2%;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:ShareBasedCompensation" contextRef="P04_01_2020To06_30_2020" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">14,278</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top; width: 78%;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Change in fair value of investments</div></div> </td>
<td style="vertical-align: bottom; width: 2%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:GainLossOnInvestments" contextRef="P04_01_2021To06_30_2021" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:numdotdecimal">8,619</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 2%;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(<ix:nonFraction name="us-gaap:GainLossOnInvestments" contextRef="P04_01_2020To06_30_2020" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">41,148</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; width: 78%;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Change in fair value of debt and liability instruments</div></div> </td>
<td style="vertical-align: bottom; width: 2%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="roiv:GainLossOnFairValueOfDebtAndLiabilityInstruments" contextRef="P04_01_2021To06_30_2021" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:numdotdecimal">4,585</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 2%;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="roiv:GainLossOnFairValueOfDebtAndLiabilityInstruments" contextRef="P04_01_2020To06_30_2020" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:numdotdecimal">17,125</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top; width: 78%;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Gain on deconsolidation of subsidiary</div></div> </td>
<td style="vertical-align: bottom; width: 2%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="roiv:GainOrLossOnDeconsolidationOfSubsidiary" contextRef="P04_01_2021To06_30_2021" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:zerodash">&#8212;</ix:nonFraction>&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 2%;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(<ix:nonFraction name="roiv:GainOrLossOnDeconsolidationOfSubsidiary" contextRef="P04_01_2020To06_30_2020" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">86,516</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; width: 78%;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Gain on termination of Sumitomo Options</div></div> </td>
<td style="vertical-align: bottom; width: 2%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(<ix:nonFraction name="roiv:GainOnTerminationOfEquityInterestOptions" contextRef="P04_01_2021To06_30_2021" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">61,472</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom; width: 2%;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="roiv:GainOnTerminationOfEquityInterestOptions" contextRef="P04_01_2020To06_30_2020" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:zerodash">&#8212;</ix:nonFraction>&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top; width: 78%;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Loss from equity method investment</div></div> </td>
<td style="vertical-align: bottom; width: 2%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:IncomeLossFromEquityMethodInvestments" contextRef="P04_01_2021To06_30_2021" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:zerodash">&#8212;</ix:nonFraction>&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 2%;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:IncomeLossFromEquityMethodInvestments" contextRef="P04_01_2020To06_30_2020" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:numdotdecimal">3,750</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; width: 78%;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Other</div></div> </td>
<td style="vertical-align: bottom; width: 2%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:OtherNoncashIncomeExpense" contextRef="P04_01_2021To06_30_2021" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:numdotdecimal">838</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 2%;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:OtherNoncashIncomeExpense" contextRef="P04_01_2020To06_30_2020" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:numdotdecimal">3,307</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top; width: 78%;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Changes in assets and liabilities, net of effects from acquisition and divestiture:</div></div> </td>
<td style="vertical-align: bottom; width: 2%;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; width: 2%;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; width: 78%;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Accounts payable</div></div> </td>
<td style="vertical-align: bottom; width: 2%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(<ix:nonFraction name="us-gaap:IncreaseDecreaseInAccountsPayableTrade" contextRef="P04_01_2021To06_30_2021" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:numdotdecimal">6,343</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom; width: 2%;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:IncreaseDecreaseInAccountsPayableTrade" contextRef="P04_01_2020To06_30_2020" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">7,501</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top; width: 78%;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Accrued expenses</div></div> </td>
<td style="vertical-align: bottom; width: 2%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(<ix:nonFraction name="us-gaap:IncreaseDecreaseInAccruedLiabilities" contextRef="P04_01_2021To06_30_2021" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:numdotdecimal">7,340</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom; width: 2%;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(<ix:nonFraction name="us-gaap:IncreaseDecreaseInAccruedLiabilities" contextRef="P04_01_2020To06_30_2020" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:numdotdecimal">15,982</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; width: 78%;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Operating lease liabilities</div></div> </td>
<td style="vertical-align: bottom; width: 2%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(<ix:nonFraction name="roiv:IncreaseDecreaseInOperatingLeaseLiabilities" contextRef="P04_01_2021To06_30_2021" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:numdotdecimal">1,957</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom; width: 2%;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(<ix:nonFraction name="roiv:IncreaseDecreaseInOperatingLeaseLiabilities" contextRef="P04_01_2020To06_30_2020" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:numdotdecimal">1,769</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top; width: 78%;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Other</div></div> </td>
<td style="vertical-align: bottom; width: 2%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:IncreaseDecreaseInOtherOperatingCapitalNet" contextRef="P04_01_2021To06_30_2021" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:numdotdecimal">3,709</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 2%;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(<ix:nonFraction name="us-gaap:IncreaseDecreaseInOtherOperatingCapitalNet" contextRef="P04_01_2020To06_30_2020" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">3,736</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 78%;">&#160;</td>
<td style="vertical-align: bottom; width: 2%;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom; width: 2%;">&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; width: 78%;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 5em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Net cash used in operating activities</div></div> </td>
<td style="vertical-align: bottom; width: 2%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(<ix:nonFraction name="us-gaap:NetCashProvidedByUsedInOperatingActivities" contextRef="P04_01_2021To06_30_2021" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:numdotdecimal">141,170</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom; width: 2%;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(<ix:nonFraction name="us-gaap:NetCashProvidedByUsedInOperatingActivities" contextRef="P04_01_2020To06_30_2020" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:numdotdecimal">111,167</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 78%;">&#160;</td>
<td style="vertical-align: bottom; width: 2%;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom; width: 2%;">&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top; width: 78%;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Cash flows from investing activities:</div></div></div> </td>
<td style="vertical-align: bottom; width: 2%;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; width: 2%;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; width: 78%;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Cash disposed upon deconsolidation of subsidiary</div></div> </td>
<td style="vertical-align: bottom; width: 2%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:CashDivestedFromDeconsolidation" contextRef="P04_01_2021To06_30_2021" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:zerodash">&#8212;</ix:nonFraction>&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 2%;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(<ix:nonFraction name="us-gaap:CashDivestedFromDeconsolidation" contextRef="P04_01_2020To06_30_2020" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">19,085</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top; width: 78%;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Investments in unconsolidated entities</div></div> </td>
<td style="vertical-align: bottom; width: 2%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="roiv:PaymentsToAcquireInvestmentsInUnconsolidatedEntities" contextRef="P04_01_2021To06_30_2021" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:zerodash">&#8212;</ix:nonFraction>&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 2%;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(<ix:nonFraction name="roiv:PaymentsToAcquireInvestmentsInUnconsolidatedEntities" contextRef="P04_01_2020To06_30_2020" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">6,250</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; width: 78%;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Purchase of property and equipment</div></div> </td>
<td style="vertical-align: bottom; width: 2%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(<ix:nonFraction name="us-gaap:PaymentsToAcquirePropertyPlantAndEquipment" contextRef="P04_01_2021To06_30_2021" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">2,339</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom; width: 2%;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(<ix:nonFraction name="us-gaap:PaymentsToAcquirePropertyPlantAndEquipment" contextRef="P04_01_2020To06_30_2020" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">306</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 78%;">&#160;</td>
<td style="vertical-align: bottom; width: 2%;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom; width: 2%;">&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top; width: 78%;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 5em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Net cash used in investing activities</div></div> </td>
<td style="vertical-align: bottom; width: 2%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(<ix:nonFraction name="us-gaap:NetCashProvidedByUsedInInvestingActivities" contextRef="P04_01_2021To06_30_2021" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:numdotdecimal">2,339</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom; width: 2%;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(<ix:nonFraction name="us-gaap:NetCashProvidedByUsedInInvestingActivities" contextRef="P04_01_2020To06_30_2020" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:numdotdecimal">25,641</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 78%;">&#160;</td>
<td style="vertical-align: bottom; width: 2%;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom; width: 2%;">&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; width: 78%;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Cash flows from financing activities:</div></div></div> </td>
<td style="vertical-align: bottom; width: 2%;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; width: 2%;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top; width: 78%;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Proceeds from issuance of subsidiary common shares, net of issuance costs paid</div></div> </td>
<td style="vertical-align: bottom; width: 2%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="roiv:ProceedsFromIssuanceOfSubsidiaryCommonSharesNet" contextRef="P04_01_2021To06_30_2021" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:zerodash">&#8212;</ix:nonFraction>&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 2%;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="roiv:ProceedsFromIssuanceOfSubsidiaryCommonSharesNet" contextRef="P04_01_2020To06_30_2020" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">181,180</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; width: 78%;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Proceeds from subsidiary debt financings, net of financing costs paid</div></div> </td>
<td style="vertical-align: bottom; width: 2%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="roiv:ProceedsFromSubsidiaryDebtFinancingsNet" contextRef="P04_01_2021To06_30_2021" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">36,400</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 2%;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="roiv:ProceedsFromSubsidiaryDebtFinancingsNet" contextRef="P04_01_2020To06_30_2020" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:zerodash">&#8212;</ix:nonFraction>&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top; width: 78%;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Repayment of long-term debt by subsidiary</div></div> </td>
<td style="vertical-align: bottom; width: 2%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(<ix:nonFraction name="roiv:RepaymentOfLongTermDebtAndConvertibleDebtBySubsidiary" contextRef="P04_01_2021To06_30_2021" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">21,590</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom; width: 2%;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="roiv:RepaymentOfLongTermDebtAndConvertibleDebtBySubsidiary" contextRef="P04_01_2020To06_30_2020" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:zerodash">&#8212;</ix:nonFraction>&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; width: 78%;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Payment of deferred offering and loan origination costs</div></div> </td>
<td style="vertical-align: bottom; width: 2%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(<ix:nonFraction name="roiv:PaymentForDebtMaintenanceFeeBySubsidiary" contextRef="P04_01_2021To06_30_2021" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:numdotdecimal">4,600</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom; width: 2%;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="roiv:PaymentForDebtMaintenanceFeeBySubsidiary" contextRef="P04_01_2020To06_30_2020" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:zerodash">&#8212;</ix:nonFraction>&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top; width: 78%;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Repurchase of equity awards</div></div> </td>
<td style="vertical-align: bottom; width: 2%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:PaymentsForRepurchaseOfEquity" contextRef="P04_01_2021To06_30_2021" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:zerodash">&#8212;</ix:nonFraction>&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 2%;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(<ix:nonFraction name="us-gaap:PaymentsForRepurchaseOfEquity" contextRef="P04_01_2020To06_30_2020" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">113</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; width: 78%;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Proceeds from exercise of subsidiary stock options</div></div> </td>
<td style="vertical-align: bottom; width: 2%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:ProceedsFromStockOptionsExercised" contextRef="P04_01_2021To06_30_2021" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:zerodash">&#8212;</ix:nonFraction>&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 2%;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:ProceedsFromStockOptionsExercised" contextRef="P04_01_2020To06_30_2020" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">63</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 78%;">&#160;</td>
<td style="vertical-align: bottom; width: 2%;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom; width: 2%;">&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top; width: 78%;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 5em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Net cash provided by financing activities</div></div> </td>
<td style="vertical-align: bottom; width: 2%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:NetCashProvidedByUsedInFinancingActivities" contextRef="P04_01_2021To06_30_2021" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">10,210</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 2%;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:NetCashProvidedByUsedInFinancingActivities" contextRef="P04_01_2020To06_30_2020" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">181,130</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 78%;">&#160;</td>
<td style="vertical-align: bottom; width: 2%;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom; width: 2%;">&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; width: 78%;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Net change in cash, cash equivalents and restricted cash</div></div> </td>
<td style="vertical-align: bottom; width: 2%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(<ix:nonFraction name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect" contextRef="P04_01_2021To06_30_2021" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:numdotdecimal">133,299</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom; width: 2%;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect" contextRef="P04_01_2020To06_30_2020" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">44,322</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top; width: 78%;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 5em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Cash, cash equivalents and restricted cash at beginning of period</div></div> </td>
<td style="vertical-align: bottom; width: 2%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" contextRef="PAsOn03_31_2021" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">2,141,676</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 2%;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" contextRef="PAsOn03_31_2020" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">2,269,252</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 78%;">&#160;</td>
<td style="vertical-align: bottom; width: 2%;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom; width: 2%;">&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; width: 78%;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 5em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Cash, cash equivalents and restricted cash at end of period</div></div> </td>
<td style="vertical-align: bottom; width: 2%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" contextRef="PAsOn06_30_2021" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">2,008,377</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 2%;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" contextRef="PAsOn06_30_2020" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">2,313,574</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 78%;">&#160;</td>
<td style="vertical-align: bottom; width: 2%;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom; width: 2%;">&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top; width: 78%;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">Non-cash</div> investing and financing activities:</div></div> </td>
<td style="vertical-align: bottom; width: 2%;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; width: 2%;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; width: 78%;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;">Operating lease <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">right-of-use</div></div> assets obtained and exchanged for operating lease liabilities</div> </td>
<td style="vertical-align: bottom; width: 2%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" contextRef="P04_01_2021To06_30_2021" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">4,579</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 2%;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" contextRef="P04_01_2020To06_30_2020" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">555</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top; width: 78%;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Issuance of subsidiary warrant in connection with debt financing</div></div> </td>
<td style="vertical-align: bottom; width: 2%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="roiv:IssuanceOfSubsidiaryWarrantInConnectionWithDebtFinancing" contextRef="P04_01_2021To06_30_2021" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">2,075</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 2%;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="roiv:IssuanceOfSubsidiaryWarrantInConnectionWithDebtFinancing" contextRef="P04_01_2020To06_30_2020" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:zerodash">&#8212;</ix:nonFraction>&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; width: 78%;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Deferred offering and financing costs included in accounts payable and accrued expenses</div></div> </td>
<td style="vertical-align: bottom; width: 2%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="roiv:DeferredOfferingAndFinancingCostsIncludedInAccountsPayableAndAccruedExpenses" contextRef="P04_01_2021To06_30_2021" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">4,999</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 2%;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="roiv:DeferredOfferingAndFinancingCostsIncludedInAccountsPayableAndAccruedExpenses" contextRef="P04_01_2020To06_30_2020" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:zerodash">&#8212;</ix:nonFraction>&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr> </table> <div style="clear: both; max-height: 0px;"></div> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt; text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The accompanying notes are an integral part of these unaudited condensed consolidated financial statements. </div></div></div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">F-<div style="letter-spacing: 0px; top: 0px;;display:inline;">47</div> </div></div></div> </div> </div> </div> </div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="text-align: center;"></div> </div> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;;font-weight: bold;"><div style="display:inline;"><a href="#toc" style="text-indent: 0px;">Table of Contents</a></div></div> <div> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">ROIVANT SCIENCES LTD. </div></div></div></div> <div id="fin164680_106" style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Notes to Condensed Consolidated Financial Statements </div></div></div></div> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">(Unaudited) </div></div></div></div> <ix:nonNumeric name="us-gaap:BusinessDescriptionAndBasisOfPresentationTextBlock" contextRef="P04_01_2021To06_30_2021" escape="true"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt; text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Note 1&#8212;Description of Business and Liquidity</div></div></div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">(A) Description of Business </div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Roivant Sciences Ltd. (inclusive of its consolidated subsidiaries, the &#8220;Company&#8221; or &#8220;RSL&#8221;), aims to improve health by rapidly delivering innovative medicines and technologies to patients. The Company does this by building biotech and healthcare technology companies (&#8220;Vants&#8221;) and deploying technology to drive greater efficiency in research and development and commercialization. In addition to biopharmaceutical subsidiaries, the Company also builds technology Vants focused on improving the process of developing and commercializing medicines. The Company was founded on April&#160;7, 2014 as a Bermuda exempted limited company. </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The Company has determined that it has <ix:nonFraction name="us-gaap:NumberOfOperatingSegments" contextRef="P01_01_2021To03_31_2021" unitRef="Unit_Segment" decimals="INF" scale="0" format="ixt-sec:numwordsen"><ix:nonFraction name="us-gaap:NumberOfOperatingSegments" contextRef="P04_01_2021To06_30_2021" unitRef="Unit_Segment" decimals="INF" scale="0" format="ixt-sec:numwordsen">one</ix:nonFraction></ix:nonFraction> operating and reporting segment as it allocates resources and assesses financial performance on a consolidated basis. The Company&#8217;s subsidiaries are wholly owned subsidiaries and majority-owned or controlled subsidiaries. Refer to Note 3, &#8220;Investments&#8221; for further discussion of the Company&#8217;s investments in unconsolidated entities<div style="letter-spacing: 0px; top: 0px;;display:inline;">.</div></div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">(B) Liquidity </div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The Company has incurred significant losses and negative cash flows from operations since its inception. As of June&#160;30, 2021, the Company had cash and cash equivalents of approximately $<ix:nonFraction name="us-gaap:CashAndCashEquivalentsAtCarryingValue" contextRef="PAsOn06_30_2021" unitRef="Unit_USD" decimals="-8" scale="9" format="ixt:numdotdecimal">2.0</ix:nonFraction>&#160;billion and its accumulated deficit was approximately $<ix:nonFraction name="us-gaap:RetainedEarningsAccumulatedDeficit" contextRef="PAsOn06_30_2021" unitRef="Unit_USD" decimals="-8" scale="9" sign="-" format="ixt:numdotdecimal">2.0</ix:nonFraction>&#160;billion. For the three months ended June&#160;30, 2021 and 2020, the Company incurred net losses of $<ix:nonFraction name="us-gaap:ProfitLoss" contextRef="P04_01_2021To06_30_2021" unitRef="Unit_USD" decimals="-5" scale="6" sign="-" format="ixt:numdotdecimal">101.1</ix:nonFraction>&#160;million and $<ix:nonFraction name="us-gaap:ProfitLoss" contextRef="P04_01_2020To06_30_2020" unitRef="Unit_USD" decimals="-5" scale="6" sign="-" format="ixt:numdotdecimal">8.0</ix:nonFraction>&#160;million, respectively. The Company has historically financed its operations primarily through the sale of equity securities, sale of subsidiary interests, debt financings and revenue generated from licensing and collaboration arrangements. The Company has not generated any revenues to date from the sale of its product candidates and does not anticipate generating any revenues from the sale of its product candidates unless and until it successfully completes development and obtains regulatory approval to market its product candidates. Management expects to incur additional losses in the future to fund its operations and conduct product research and development and recognizes the need to raise additional capital to fully implement its business plan. </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The Company intends to raise such additional capital through the issuance of equity securities, debt financings or other sources in order to further implement its business plan. However, if such financing is not available at adequate levels, the Company will need to reevaluate its operating plan and may be required to delay the development of its product candidates or take other steps to conserve capital. The Company expects its existing cash and cash equivalents will be sufficient to fund its committed operating expenses and capital expenditure requirements for at least the next 12 months from the date of issuance of these condensed consolidated financial statements. </div></div></ix:nonNumeric> <ix:nonNumeric name="us-gaap:SignificantAccountingPoliciesTextBlock" contextRef="P04_01_2021To06_30_2021" escape="true" continuedAt="TextSelection_28230071"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Note 2&#8212;Summary of Significant Accounting Policies </div></div></div> <ix:nonNumeric name="us-gaap:BasisOfAccountingPolicyPolicyTextBlock" contextRef="P04_01_2021To06_30_2021" escape="true" continuedAt="TextSelection_28230061"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">(A) Basis of Presentation and Principles of Consolidation </div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The Company&#8217;s fiscal year ends on March&#160;31, and its fiscal quarters end on June&#160;30, September&#160;30, and December 31. </div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The accompanying unaudited condensed consolidated financial statements have been prepared in accordance with accounting principles generally accepted in the United States (&#8220;U.S. GAAP&#8221;) for interim financial information and follow the requirements of the Securities and Exchange Commission (&#8220;SEC&#8221;) for interim financial reporting. Accordingly, these unaudited condensed consolidated financial statements do not include all of the information and </div></div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"> </div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></ix:nonNumeric></ix:nonNumeric> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px; text-indent: 0px;;display:inline;">F-<div style="letter-spacing: 0px; top: 0px;;display:inline;">48</div></div></div></div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;;font-weight: bold;"><div style="display:inline;"><a href="#toc" style="text-indent: 0px;">Table of Contents</a></div></div> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"><ix:continuation id="TextSelection_28230071" continuedAt="TextSelectionAppend_28230071_1"><ix:continuation id="TextSelection_28230061"> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">disclosures required by U.S. GAAP for complete financial statements as certain footnotes or other financial information that are normally required by U.S. GAAP can be condensed or omitted. The unaudited condensed consolidated financial statements have been prepared on the same basis as the audited consolidated financial statements. </div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">These unaudited condensed consolidated financial statements should be read in conjunction with the Company&#8217;s audited consolidated financial statements and notes thereto for the fiscal year ended March&#160;31, 2021 issued on June&#160;30, 2021. The unaudited condensed consolidated balance sheet at March&#160;31, 2021 has been derived from the audited consolidated financial statements at that date. In the opinion of management, the unaudited condensed consolidated financial statements include all normal and recurring adjustments that are considered necessary to present fairly the financial position of the Company and its results of operations and cash flows for the interim periods presented. Certain prior year amounts were reclassified to conform to current year presentation. Operating results for the three months ended June&#160;30, 2021 are not necessarily indicative of the results that may be expected for the fiscal year ending March&#160;31, 2022, for any other interim period, or for any other future year. </div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Any references in these notes to applicable accounting guidance are meant to refer to the authoritative U.S. GAAP as found in the Accounting Standards Codification (&#8220;ASC&#8221;) and Accounting Standards Updates (&#8220;ASU&#8221;) of the Financial Accounting Standards Board (&#8220;FASB&#8221;). The unaudited condensed consolidated financial statements include the accounts of RSL and the subsidiaries in which it has a controlling financial interest, most often through a majority voting interest. All intercompany balances and transactions have been eliminated in consolidation. </div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">For consolidated entities where the Company owns or is exposed to less than 100% of the economics, the Company records net loss attributable to noncontrolling interests in its unaudited condensed consolidated statements of operations equal to the percentage of the economic or ownership interest retained in the respective operations by the noncontrolling parties. The Company presents noncontrolling interests as a component of shareholders&#8217; equity on its unaudited condensed consolidated balance sheets. </div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The Company accounts for changes in its ownership interest in its subsidiaries while control is retained as equity transactions. The carrying amount of the noncontrolling interest is adjusted to reflect the change in RSL&#8217;s ownership interest in the subsidiary. Any difference between the fair value of the consideration received or paid and the amount by which the noncontrolling interest is adjusted is recognized within shareholders&#8217; equity attributable to RSL. </div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">There have been no significant changes in the Company&#8217;s accounting policies from those disclosed in the Company&#8217;s audited consolidated financial statements for the fiscal year ended March&#160;31, 2021 issued on June&#160;30, 2021. </div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">In April 2012, the Jumpstart Our Business Startups Act of 2012 (the &#8220;JOBS Act&#8221;) was enacted. Section&#160;107(b) of the JOBS Act provides that an emerging growth company can take advantage of an extended transition period for complying with new or revised accounting standards. Thus, an emerging growth company can delay the adoption of certain accounting standards until those standards would otherwise apply to private companies. The Company has irrevocably elected not to avail itself of this extended transition period, and, as a result, the Company will adopt new or revised accounting standards on the relevant dates on which adoption of such standards is required for other public companies. </div></div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"> </div> </ix:continuation> <ix:nonNumeric name="us-gaap:UseOfEstimates" contextRef="P04_01_2021To06_30_2021" escape="true" continuedAt="TextSelection_28230062"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt; text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">(B) Use of Estimates </div></div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The preparation of financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the amounts reported in the financial statements and accompanying notes. The Company regularly evaluates estimates and assumptions related to assets, liabilities, costs, expenses,</div></div></div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></ix:nonNumeric></ix:continuation> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">F-<div style="letter-spacing: 0px; top: 0px;;display:inline;">49</div> </div></div></div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="text-align: center;"> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em; text-align: left;;font-weight: bold;"><div style="display:inline;"><a href="#toc" style="text-indent: 0px;">Table of Contents</a></div></div> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"><ix:continuation id="TextSelectionAppend_28230071_1" continuedAt="TextSelectionAppend_28230071_2"> <ix:continuation id="TextSelection_28230062"> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">contingent liabilities, share-based compensation and research and development costs. The Company bases its estimates and assumptions on historical experience and on various other factors that it believes to be reasonable under the circumstances, the results of which form the basis for making judgments about the carrying values of assets and liabilities that are not readily apparent from other sources. Actual results could differ from those estimates. </div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">Additionally, the Company assessed the impact that the <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">COVID-19</div> pandemic has had on its operations and financial results as of June&#160;30, 2021 and through the issuance of these condensed consolidated financial statements. The Company&#8217;s analysis was informed by the facts and circumstances as they were known to the Company. This assessment considered the impact <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">COVID-19</div> may have on financial estimates and assumptions that affect the reported amounts of assets and liabilities and expenses. </div></div> </ix:continuation> <ix:nonNumeric name="us-gaap:UnusualRisksAndUncertaintiesTextBlock" contextRef="P04_01_2021To06_30_2021" escape="true"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt; text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">(C) Risks and Uncertainties </div></div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The Company is subject to risks common to companies in the biopharmaceutical industry including, but not limited to, uncertainties related to commercialization of products, regulatory approvals, dependence on key products, dependence on third-party service providers, such as contract research organizations, and protection of intellectual property rights. </div></div></div></ix:nonNumeric> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"> </div> <ix:nonNumeric name="us-gaap:ConcentrationRiskCreditRisk" contextRef="P04_01_2021To06_30_2021" escape="true"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt; text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">(D) Concentrations of Credit Risk </div></div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Financial instruments that potentially subject the Company to concentration of credit risk include cash and cash equivalents. The Company maintains cash deposits and cash equivalents in highly-rated, federally-insured financial institutions in excess of federally insured limits. The Company has established guidelines relative to diversification and maturities to maintain safety and liquidity. The Company has not experienced any credit losses related to these financial instruments and does not believe that it is exposed to any significant credit risk related to these instruments. </div></div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"> </div></ix:nonNumeric> <ix:nonNumeric name="us-gaap:CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy" contextRef="P04_01_2021To06_30_2021" escape="true"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">(E) Cash, Cash Equivalents, and Restricted Cash </div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Cash and cash equivalents include cash deposits in banks and all highly liquid investments that are readily convertible to cash. The Company considers all highly liquid investments purchased with original maturities of three months or less to be cash equivalents. </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">Restricted cash classified as a current asset consists of legally restricted <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-interest</div> bearing deposit accounts relating to the Company&#8217;s corporate credit card programs. Restricted cash classified as a long-term asset consists of restricted deposit accounts related to irrevocable standby letters of credit. As of March&#160;31, 2021, restricted cash classified as a current asset included $<ix:nonFraction name="us-gaap:EscrowDeposit" contextRef="PAsOn03_31_2021" unitRef="Unit_USD" decimals="-5" scale="6" format="ixt:numdotdecimal">75.0</ix:nonFraction>&#160;million held in escrow for the purpose of fulfilling certain indemnification obligations. The full escrow amount of $<ix:nonFraction name="roiv:ProceedsFromReleaseOfEscrowDeposit" contextRef="PAsOn06_30_2021" unitRef="Unit_USD" decimals="-5" scale="6" format="ixt:numdotdecimal">75.0</ix:nonFraction>&#160;million was disbursed to the Company in June 2021. See Note 4, &#8220;Sumitomo Transaction Agreement&#8221; for additional information. </div> <ix:nonNumeric name="us-gaap:ScheduleOfCashAndCashEquivalentsTableTextBlock" contextRef="P04_01_2021To06_30_2021" escape="true"><div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Cash as reported in the condensed consolidated statements of cash flows includes the aggregate amounts of cash, cash equivalents, and restricted cash as presented on the condensed consolidated balance sheets as follows (in thousands): </div></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;width:76%;">
<tr style="font-size: 0px;">
<td style="width: 64%;"></td>
<td style="width: 7%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td>
<td style="width: 7%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">June&#160;30,&#160;2021</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">March&#160;31,&#160;2021</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top; width: 64%;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Cash and cash equivalents</div></div> </td>
<td style="vertical-align: bottom; width: 7%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:CashAndCashEquivalentsAtCarryingValue" contextRef="PAsOn06_30_2021" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">1,996,733</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 7%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:CashAndCashEquivalentsAtCarryingValue" contextRef="PAsOn03_31_2021" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">2,055,044</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; width: 64%;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Restricted cash</div></div> </td>
<td style="vertical-align: bottom; width: 7%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:RestrictedCash" contextRef="PAsOn06_30_2021" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">11,644</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 7%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:RestrictedCash" contextRef="PAsOn03_31_2021" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">86,632</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 64%;">&#160;</td>
<td style="vertical-align: bottom; width: 7%;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom; width: 7%;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top; width: 64%;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Cash, cash equivalents and restricted cash</div></div> </td>
<td style="vertical-align: bottom; width: 7%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="roiv:CashAndCashEquivalentsAndRestrictedCash" contextRef="PAsOn06_30_2021" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">2,008,377</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 7%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="roiv:CashAndCashEquivalentsAndRestrictedCash" contextRef="PAsOn03_31_2021" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">2,141,676</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 64%;">&#160;</td>
<td style="vertical-align: bottom; width: 7%;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom; width: 7%;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td> </tr> </table> </ix:nonNumeric></ix:nonNumeric>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 76%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px; text-indent: 0px;">
<tr style="font-size: 1px;">
<td></td> </tr> </table> <div style="clear: both; max-height: 0px; text-indent: 0px;"></div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div> </ix:continuation> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">F-</div><div style="letter-spacing: 0px; top: 0px;;display:inline;">50</div></div></div></div></div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="text-align: center;"></div> </div> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;;font-weight: bold;"><div style="display:inline;"><a href="#toc" style="text-indent: 0px;">Table of Contents</a></div></div> <div> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"><ix:continuation id="TextSelectionAppend_28230071_2" continuedAt="TextSelectionAppend_28230071_3"> <ix:nonNumeric name="us-gaap:CommitmentsAndContingenciesPolicyTextBlock" contextRef="P04_01_2021To06_30_2021" escape="true"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">(F) Contingencies </div></div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The Company may be, from time to time, a party to various disputes and claims arising from normal business activities. The Company continually assesses any litigation or other claims it may confront to determine if an unfavorable outcome would lead to a probable loss or reasonably possible loss which could be estimated. The Company accrues for all contingencies at the earliest date at which the Company deems it probable that a liability has been incurred and the amount of such liability can be reasonably estimated. If the estimate of a probable loss is a range and no amount within the range is more likely than another, the Company accrues the minimum of the range. In the cases where the Company believes that a reasonably possible loss exists, the Company discloses the facts and circumstances of the litigation, including an estimable range, if possible<div style="letter-spacing: 0px; top: 0px;;display:inline;">.</div></div></div></div></ix:nonNumeric> <ix:nonNumeric name="us-gaap:InvestmentPolicyTextBlock" contextRef="P04_01_2021To06_30_2021" escape="true"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt; text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">(G) Investments </div></div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">For investments in entities over which the Company has significant influence but do not meet the requirements for consolidation and for which the Company has not elected the fair value option, the Company applies the equity method of accounting with the Company&#8217;s share of the underlying income or loss of such entities reported in &#8220;Other (income) expense, net&#8221; on the condensed consolidated statements of operations. The Company applies the equity method to investments in common stock and to other investments in entities that have risk and reward characteristics that are substantially similar to an investment in the investee&#8217;s common stock. </div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Investments in equity securities may also be accounted for using (i)&#160;the fair value option if elected, (ii)&#160;fair value through earnings if fair value is readily determinable or (iii)&#160;for equity investments without readily determinable fair values, the measurement alternative to measure at cost adjusted for any impairment and observable price changes, as applicable. The election to use the measurement alternative is made for each eligible investment. </div></div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"> </div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The Company has elected the fair value option to account for certain investments over which the Company has significant influence. The Company believes the fair value option best reflects the underlying economics of the investment. See Note 3, &#8220;Investments.&#8221; </div></div></ix:nonNumeric> <ix:nonNumeric name="us-gaap:ResearchAndDevelopmentExpensePolicy" contextRef="P04_01_2021To06_30_2021" escape="true"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">(H) Research and Development<div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div>Expenses </div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">Research and development (&#8220;R&amp;D&#8221;) costs are expensed as incurred. Preclinical and clinical study costs are accrued over the service periods specified in the contracts and adjusted as necessary based upon an ongoing <div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">review </div>of the <div style="letter-spacing: 0px; top: 0px;;display:inline;">level </div>of <div style="letter-spacing: 0px; top: 0px;;display:inline;">effort </div>and costs</div> actually incurred. Payments for a product license prior to regulatory approval of the product and payments for milestones achieved prior to regulatory approval of the product are expensed in the period incurred as R&amp;D. Milestone payments made in connection <div style="letter-spacing: 0px; top: 0px;;display:inline;">with </div><div style="letter-spacing: 0px; top: 0px;;display:inline;">regulatory </div>approvals are capitalized and amortized to cost of revenue over the remaining useful life of the asset. R&amp;D costs primarily consist of the intellectual property and R&amp;D materials acquired and expenses from third parties who conduct R&amp;D activities on behalf of the <div style="letter-spacing: 0px; top: 0px;;display:inline;">Company</div>.</div> </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">The Company evaluates <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">in-licensed</div> agreements for <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">in-process</div> research and development projects (&#8220;IPR&amp;D&#8221;) to determine if it meets the definition of a business and thus should be accounted for as a business combination. If the <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">in-licensed</div> agreement for IPR&amp;D does not meet the definition of a business and the assets have not reached technological feasibility and therefore have no alternative future use, the Company expenses payments made under such license agreements as R&amp;D expense in its condensed consolidated statements of operations. The Company initially recognizes contingent consideration in an asset acquisition at fair value. The carrying value of contingent consideration is subsequently adjusted when the contingency is resolved and is paid or becomes payable. </div></div></ix:nonNumeric></ix:continuation> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">F-<div style="letter-spacing: 0px; top: 0px;;display:inline;">51</div> </div></div></div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> </div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em; text-align: left;;font-weight: bold;"><div style="display:inline;"><a href="#toc" style="text-indent: 0px;">Table of Contents</a></div></div> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"><ix:continuation id="TextSelectionAppend_28230071_3" continuedAt="TextSelectionAppend_28230071_4"> <ix:nonNumeric name="us-gaap:FairValueMeasurementPolicyPolicyTextBlock" contextRef="P04_01_2021To06_30_2021" escape="true" continuedAt="TextSelection_28230256"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">(I) Fair Value Measurements </div></div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The Company utilizes fair value measurement guidance prescribed by accounting standards to value its financial instruments. The guidance establishes a fair value hierarchy for financial instruments measured at fair value that distinguishes between assumptions based on market data (observable inputs) and the Company&#8217;s own assumptions (unobservable inputs). Observable inputs are inputs that market participants would use in pricing the asset or liability based on market data obtained from sources independent of the Company. Unobservable inputs are inputs that reflect the Company&#8217;s assumptions about the inputs that market participants would use in pricing the asset or liability, and are developed based on the best information available in the circumstances. Fair value is defined as the exchange price, or exit price, representing the amount that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants at the reporting date. As a basis for considering market participant assumptions in fair value measurements, the guidance establishes a three-tier fair value hierarchy that distinguishes among the following: </div></div></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px; text-indent: 0px;;width:100%;">
<tr style="page-break-inside: avoid;">
<td style="width: 4%;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="width: 4%; vertical-align: top;;text-align:left;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#8226;</div></td>
<td style="width: 1%; vertical-align: top;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">Level <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">1-Valuations</div> are based on unadjusted quoted prices in active markets for identical assets or liabilities that the Company has the ability to access. </div></div> </td> </tr> </table> <div style="clear: both; max-height: 0px; text-indent: 0px;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px; text-indent: 0px;;width:100%;">
<tr style="page-break-inside: avoid;">
<td style="width: 4%;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="width: 4%; vertical-align: top;;text-align:left;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#8226;</div></td>
<td style="width: 1%; vertical-align: top;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">Level <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">2-Valuations</div> are based on quoted prices for similar assets or liabilities in active markets, quoted prices for identical or similar assets or liabilities in markets that are not active and models for which all significant inputs are observable, either directly or indirectly. </div></div> </td> </tr> </table> <div style="clear: both; max-height: 0px; text-indent: 0px;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px; text-indent: 0px;;width:100%;">
<tr style="page-break-inside: avoid;">
<td style="width: 4%;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="width: 4%; vertical-align: top;;text-align:left;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#8226;</div></td>
<td style="width: 1%; vertical-align: top;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">Level <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">3-Valuations</div> are based on inputs that are unobservable (supported by little or no market activity) and significant to the overall fair value measurement. </div></div> </td> </tr> </table> <div style="clear: both; max-height: 0px; text-indent: 0px;"></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">To the extent the valuation is based on models or inputs that are less observable or unobservable in the market, the determination of fair value requires more judgment. Accordingly, the degree of judgment exercised by the Company in determining fair value is greatest for instruments categorized in Level&#160;3. A financial instrument&#8217;s level within the fair value hierarchy is based on the lowest level of any input that is significant to the fair value measurement. </div></div></div></ix:nonNumeric></ix:continuation> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"> </div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"></div> </div> </div> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"><ix:continuation id="TextSelectionAppend_28230071_4" continuedAt="TextSelectionAppend_28230071_5"><ix:continuation id="TextSelection_28230256"> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The Company&#8217;s financial instruments include shares of common stock of Arbutus Biopharma Corporation (&#8220;Arbutus&#8221;); shares of Arbutus&#8217;s Series A participating convertible preferred shares (&#8220;Arbutus Preferred Shares&#8221;); shares of common stock of Sio Gene Therapies Inc. (&#8220;Sio&#8221;); liability instruments issued; deferred consideration liability; its investments in other entities; cash and cash equivalents consisting of money market funds; accounts payable; and long-term debt. </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">The shares of Arbutus and Sio common stock and investments in common stock with a readily determinable fair value are classified as Level&#160;1, and their fair value is determined based upon quoted market prices in an active market. The Arbutus Preferred Shares held by the Company are classified as Level&#160;2 as the fair value of such preferred shares is determined based upon the quoted market price of Arbutus common stock into which such preferred shares are convertible. The liability instruments issued are classified as Level&#160;3 within the fair value hierarchy as the assumptions and estimates used in the valuations are unobservable in the market. Cash, accounts payable, and deferred consideration liability are stated at their respective historical carrying amounts, which approximate fair value due to their short-term nature. The deferred consideration liability is based on a fixed monetary amount, and payment is based solely on the passage of time. Money market funds are included in <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">Level-1</div> of the fair value hierarchy and are valued at the closing price reported by an actively traded exchange. The carrying value of long-term debt issued by Dermavant Sciences Ltd. (together with its wholly owned subsidiaries, &#8220;Dermavant&#8221;), which is stated at amortized cost, approximates fair value based on current interest rates for similar types of borrowings and therefore is included in Level&#160;2 of the fair value hierarchy. Long-term debt issued by Dermavant for which the fair value option has been elected is included in Level&#160;3 of the fair value hierarchy as the assumptions and estimates used in the valuation are unobservable in the market. </div></div> </ix:continuation></ix:continuation> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">F-<div style="letter-spacing: 0px; top: 0px;;display:inline;">52</div> </div></div></div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> </div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em; text-align: left;;font-weight: bold;"><div style="display:inline;"><a href="#toc" style="text-indent: 0px;">Table of Contents</a></div></div> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"><ix:continuation id="TextSelectionAppend_28230071_5"> <ix:nonNumeric name="us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock" contextRef="P04_01_2021To06_30_2021" escape="true"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">(J) Recently Adopted Accounting Pronouncements </div></div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;">In August 2020, the FASB issued ASU <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">No.&#160;2020-06,</div> &#8220;Debt&#8212;Debt with Conversion and Other Options (Subtopic <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">470-20)</div> and Derivatives and Hedging&#8212;Contracts in Entity&#8217;s Own Equity (Subtopic <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">815-40):</div> Accounting for Convertible Instruments and Contracts in an Entity&#8217;s Own Equity&#8221; (&#8220;ASU <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">No.&#160;2020-06&#8221;).</div> ASU <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">No.&#160;2020-06</div> will simplify the accounting for convertible instruments by reducing the number of accounting models for convertible debt instruments and convertible preferred stock. Limiting the accounting models will result in fewer embedded conversion features being separately recognized from the host contract as compared with current U.S. GAAP. ASU <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">No.&#160;2020-06</div> also removes certain settlement conditions that are required for equity contracts to qualify for the derivatives scope exception, which will permit more equity contracts to qualify for it. Either a modified retrospective transition method or a fully retrospective transition method is permissible for the adoption of this standard. Update <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">No.&#160;2020-06</div> is effective for fiscal years beginning after December&#160;15, 2021, including interim periods within those fiscal years. The early-adoption of ASU <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">No.&#160;2020-06</div> on April&#160;1, 2021 did not have a material impact on the Company&#8217;s unaudited condensed consolidated financial statements. </div></ix:nonNumeric></ix:continuation> <ix:nonNumeric name="us-gaap:InvestmentsAndOtherNoncurrentAssetsTextBlock" contextRef="P04_01_2021To06_30_2021" escape="true" continuedAt="TextSelection_28230194"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Note 3&#8212;Investments </div></div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">(A) Investments Measured at Fair Value </div></div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt; margin-left: 4%;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Investment in Arbutus </div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;">RSL owns <ix:nonFraction name="roiv:CommonStockOwnedBalanceSharesOfArbutus" contextRef="PAsOn03_31_2021" unitRef="Unit_shares" decimals="0" scale="0" format="ixt:numdotdecimal"><ix:nonFraction name="roiv:CommonStockOwnedBalanceSharesOfArbutus" contextRef="PAsOn06_30_2021" unitRef="Unit_shares" decimals="0" scale="0" format="ixt:numdotdecimal">16,013,540</ix:nonFraction></ix:nonFraction> shares of common stock of Arbutus and <ix:nonFraction name="roiv:PreferredStockOwnedBalanceSharesOfArbutus" contextRef="PAsOn03_31_2021" unitRef="Unit_shares" decimals="0" scale="0" format="ixt:numdotdecimal"><ix:nonFraction name="roiv:PreferredStockOwnedBalanceSharesOfArbutus" contextRef="PAsOn06_30_2021" unitRef="Unit_shares" decimals="0" scale="0" format="ixt:numdotdecimal">1,164,000</ix:nonFraction></ix:nonFraction> Arbutus Preferred Shares that are mandatorily convertible into shares of Arbutus common stock on October&#160;18, 2021 subject to conversion earlier upon a sale, merger or other transaction considered a fundamental change of control of Arbutus. The Arbutus Preferred Shares are <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-voting</div> and are convertible into common shares of Arbutus based on the subscription price plus <ix:nonFraction name="roiv:AnnualCompoundedConversionRateForPreferredShare" contextRef="P01_01_2021To03_31_2021_ArbutusBiopharmaCorporationMemberdeiLegalEntityAxis" unitRef="Unit_pure" decimals="4" scale="-2" format="ixt:numdotdecimal"><ix:nonFraction name="roiv:AnnualCompoundedConversionRateForPreferredShare" contextRef="P04_01_2021To06_30_2021_ArbutusBiopharmaCorporationMemberdeiLegalEntityAxis" unitRef="Unit_pure" decimals="4" scale="-2" format="ixt:numdotdecimal">8.75</ix:nonFraction></ix:nonFraction>% per annum, compounded annually, divided by a conversion price of $<ix:nonFraction name="roiv:ConversionPrice" contextRef="PAsOn03_31_2021_ArbutusBiopharmaCorporationMemberdeiLegalEntityAxis" unitRef="Unit_USD_per_Share" decimals="2" scale="0" format="ixt:numdotdecimal"><ix:nonFraction name="roiv:ConversionPrice" contextRef="PAsOn06_30_2021_ArbutusBiopharmaCorporationMemberdeiLegalEntityAxis" unitRef="Unit_USD_per_Share" decimals="2" scale="0" format="ixt:numdotdecimal">7.13</ix:nonFraction></ix:nonFraction> per share (which represented a <ix:nonFraction name="roiv:PremiumOnConversionPricePercentage" contextRef="P09_29_2017To09_29_2017_ArbutusBiopharmaCorporationMemberdeiLegalEntityAxis" unitRef="Unit_pure" decimals="2" scale="-2" format="ixt:numdotdecimal">15</ix:nonFraction>% premium to the closing price of $<ix:nonFraction name="roiv:ClosingPricePerShare" contextRef="PAsOn09_29_2017_ArbutusBiopharmaCorporationMemberdeiLegalEntityAxis" unitRef="Unit_USD_per_Share" decimals="2" scale="0" format="ixt:numdotdecimal">6.20</ix:nonFraction> per share on September&#160;29, 2017). The fair value option was elected to continuously remeasure the investment to fair value each reporting period after the initial measurement. Due to the Company&#8217;s significant influence over operating and financial policies, Arbutus is considered a related party of the Company. <div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">At June&#160;30, 2021, RSL held <ix:nonFraction name="us-gaap:EquityMethodInvestmentOwnershipPercentage" contextRef="PAsOn06_30_2021_ArbutusBiopharmaCorporationMemberdeiLegalEntityAxis" unitRef="Unit_pure" decimals="2" scale="-2" format="ixt:numdotdecimal">32</ix:nonFraction>% of issued and outstanding shares of Arbutus, including the conversion of the Arbutus Preferred Shares held by RSL into common shares. </div></div></div></ix:nonNumeric> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"></div> </div> </div> <div style="margin-top: 1em; margin-bottom: 1em"></div> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"><ix:continuation id="TextSelection_28230194" continuedAt="TextSelectionAppend_28230194_1"> <div style="text-indent: 4%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">At June&#160;30, 2021 and March&#160;31, 2021, the aggregate fair value of the <div style="letter-spacing: 0px; top: 0px;;display:inline;">RSL</div> investment in Arbutus was $<ix:nonFraction name="us-gaap:InvestmentsFairValueDisclosure" contextRef="PAsOn06_30_2021_ArbutusBiopharmaCorporationMemberdeiLegalEntityAxis" unitRef="Unit_USD" decimals="-5" scale="6" format="ixt:numdotdecimal">117.7</ix:nonFraction>&#160;million and $<ix:nonFraction name="us-gaap:InvestmentsFairValueDisclosure" contextRef="PAsOn03_31_2021_ArbutusBiopharmaCorporationMemberdeiLegalEntityAxis" unitRef="Unit_USD" decimals="-5" scale="6" format="ixt:numdotdecimal">129.4</ix:nonFraction>&#160;million, respectively, with the Company recognizing an unrealized loss on its investments in Arbutus of $<ix:nonFraction name="us-gaap:UnrealizedGainLossOnInvestments" contextRef="P04_01_2021To06_30_2021_ArbutusBiopharmaCorporationMemberdeiLegalEntityAxis" unitRef="Unit_USD" decimals="-5" scale="6" sign="-" format="ixt:numdotdecimal">11.7</ix:nonFraction>&#160;million and an unrealized gain of $<ix:nonFraction name="us-gaap:UnrealizedGainLossOnInvestments" contextRef="P04_01_2020To06_30_2020_ArbutusBiopharmaCorporationMemberdeiLegalEntityAxis" unitRef="Unit_USD" decimals="-5" scale="6" format="ixt:numdotdecimal">31.5</ix:nonFraction>&#160;million in the accompanying condensed consolidated statements of operations for the three months ended June&#160;30, 2021 and 2020, respectively. The fair value of the common stock and preferred shares held by the Company was determined using the closing price of Arbutus&#8217;s common stock on June&#160;30, 2021 and March&#160;31, 2021 of $<ix:nonFraction name="us-gaap:SharePrice" contextRef="PAsOn06_30_2021_ArbutusBiopharmaCorporationMemberdeiLegalEntityAxis" unitRef="Unit_USD_per_Share" decimals="2" scale="0" format="ixt:numdotdecimal">3.03</ix:nonFraction> and $<ix:nonFraction name="us-gaap:SharePrice" contextRef="PAsOn03_31_2021_ArbutusBiopharmaCorporationMemberdeiLegalEntityAxis" unitRef="Unit_USD_per_Share" decimals="2" scale="0" format="ixt:numdotdecimal">3.33</ix:nonFraction>, respectively<div style="letter-spacing: 0px; top: 0px;;display:inline;">.</div></div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt; margin-left: 4%;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Investment in Sio </div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Following the completion of Sio&#8217;s underwritten public offering in February 2020, RSL&#8217;s ownership interest fell below <div style="letter-spacing: 0px; top: 0px;;display:inline;">50.0</div>%. As such, the Company no longer has a controlling financial interest in Sio. Accordingly, the Company deconsolidated Sio in February 2020. Due to the Company&#8217;s significant influence over operating and financial policies, Sio remains a related party of the Company following deconsolidation. As the Company still has the ability to exercise significant influence over the operating and financial policies of Sio, the Company has determined that its retained interest represents an equity method investment after the date of deconsolidation. Upon deconsolidation, the retained interest was recorded at fair market value based on the closing price of Sio&#8217;s common stock. The fair value option was elected to continuously remeasure the investment to fair value each reporting period after the initial measurement. At June&#160;30, 2021, RSL held <ix:nonFraction name="roiv:OwnershipInterestPercentage" contextRef="PAsOn06_30_2021_SioGeneTherapiesIncMemberdeiLegalEntityAxis" unitRef="Unit_pure" decimals="2" scale="-2" format="ixt:numdotdecimal">27</ix:nonFraction>% of Sio&#8217;s issued and outstanding common shares. </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">At June&#160;30, 2021 and March&#160;31, 2021, the fair value of the Company&#8217;s investment in Sio was $<ix:nonFraction name="us-gaap:InvestmentsFairValueDisclosure" contextRef="PAsOn06_30_2021_SioGeneTherapiesIncMemberdeiLegalEntityAxis" unitRef="Unit_USD" decimals="-5" scale="6" format="ixt:numdotdecimal">50.7</ix:nonFraction>&#160;million and $<ix:nonFraction name="us-gaap:InvestmentsFairValueDisclosure" contextRef="PAsOn03_31_2021_SioGeneTherapiesIncMemberdeiLegalEntityAxis" unitRef="Unit_USD" decimals="-5" scale="6" format="ixt:numdotdecimal">48.5</ix:nonFraction>&#160;million, respectively, with the Company recognizing unrealized gains on its investment in Sio of </div></div> </ix:continuation> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">F-<div style="letter-spacing: 0px; top: 0px;;display:inline;">53</div> </div></div></div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> </div> <div style="text-align: center;"> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/></div> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em; text-align: left;;font-weight: bold;"><div style="display:inline;"><a href="#toc" style="text-indent: 0px;">Table of Contents</a></div></div> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"><ix:continuation id="TextSelectionAppend_28230194_1"> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0px;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">$<ix:nonFraction name="us-gaap:UnrealizedGainLossOnInvestments" contextRef="P04_01_2021To06_30_2021_SioGeneTherapiesIncMemberdeiLegalEntityAxis" unitRef="Unit_USD" decimals="-5" scale="6" format="ixt:numdotdecimal">2.2</ix:nonFraction>&#160;million and $<ix:nonFraction name="us-gaap:UnrealizedGainLossOnInvestments" contextRef="P04_01_2020To06_30_2020_SioGeneTherapiesIncMemberdeiLegalEntityAxis" unitRef="Unit_USD" decimals="-5" scale="6" format="ixt:numdotdecimal">7.1</ix:nonFraction>&#160;million in the accompanying condensed consolidated statements of operations for the three months ended June&#160;30, 2021 and 2020, respectively. The fair value of common shares held by the Company was determined using the closing price of Sio&#8217;s common stock on June&#160;30, 2021 and March&#160;31, 2021 of $<ix:nonFraction name="us-gaap:SharePrice" contextRef="PAsOn06_30_2021_SioGeneTherapiesIncMemberdeiLegalEntityAxis" unitRef="Unit_USD_per_Share" decimals="2" scale="0" format="ixt:numdotdecimal">2.73</ix:nonFraction> and $<ix:nonFraction name="us-gaap:SharePrice" contextRef="PAsOn03_31_2021_SioGeneTherapiesIncMemberdeiLegalEntityAxis" unitRef="Unit_USD_per_Share" decimals="2" scale="0" format="ixt:numdotdecimal">2.61</ix:nonFraction>, respectively. </div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt; margin-left: 4%;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Other Investment </div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The Company holds an additional equity investment that is measured using the fair value option. The fair value of this investment was $<ix:nonFraction name="us-gaap:InvestmentsFairValueDisclosure" contextRef="PAsOn06_30_2021_OtherInvestmentCompaniesMemberusgaapInvestmentTypeAxis" unitRef="Unit_USD" decimals="-5" scale="6" format="ixt:numdotdecimal">11.9</ix:nonFraction>&#160;million and $<ix:nonFraction name="us-gaap:InvestmentsFairValueDisclosure" contextRef="PAsOn03_31_2021_OtherInvestmentCompaniesMemberusgaapInvestmentTypeAxis" unitRef="Unit_USD" decimals="-5" scale="6" format="ixt:numdotdecimal">11.1</ix:nonFraction>&#160;million as of June&#160;30, 2021 and March&#160;31, 2021, respectively. </div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">(B) Investment Accounted for Using Measurement Alternative </div></div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt; margin-left: 4%;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Investment in Datavant </div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">In April 2020, Datavant Holdings, Inc. (&#8220;Datavant&#8221;) completed an initial round of a Series B equity raise by which <ix:nonFraction name="roiv:PreferredStockSharesIssuedAndSoldToCompanyDuringPeriodShares" contextRef="PAsOn07_31_2020_SeriesBPreferredStockMemberusgaapStatementClassOfStockAxis" unitRef="Unit_shares" decimals="INF" scale="0" format="ixt:numdotdecimal">13,411,311</ix:nonFraction> Series B preferred shares were issued in April 2020 for gross proceeds of $<ix:nonFraction name="roiv:ProceedsFromIssuanceOfPreferredStockAndPreferenceStocks" contextRef="PAsOn07_31_2020_DatavantHoldingsIncMemberdeiLegalEntityAxis_SeriesBPreferredStockMemberusgaapStatementClassOfStockAxis" unitRef="Unit_USD" decimals="-5" scale="6" format="ixt:numdotdecimal">27.2</ix:nonFraction>&#160;million, including <ix:nonFraction name="roiv:PreferredStockSharesIssuedAndSoldToCompanyDuringPeriodShares" contextRef="PAsOn07_31_2020_DatavantHoldingsIncMemberdeiLegalEntityAxis_SeriesBPreferredStockMemberusgaapStatementClassOfStockAxis" unitRef="Unit_shares" decimals="0" scale="0" format="ixt:numdotdecimal">1,065,234</ix:nonFraction> Series B preferred shares issued and sold to RSL for a total purchase price of $<ix:nonFraction name="roiv:PreferredStockPurchased" contextRef="PAsOn04_30_2020_DatavantHoldingsIncMemberdeiLegalEntityAxis_SeriesBPreferredStockMemberusgaapStatementClassOfStockAxis" unitRef="Unit_USD" decimals="-5" scale="6" format="ixt:numdotdecimal">2.5</ix:nonFraction>&#160;million and <ix:nonFraction name="us-gaap:ConvertiblePreferredStockSharesIssuedUponConversion" contextRef="PAsOn04_30_2020_DatavantHoldingsIncMemberdeiLegalEntityAxis_SeriesBPreferredStockMemberusgaapStatementClassOfStockAxis" unitRef="Unit_shares" decimals="0" scale="0" format="ixt:numdotdecimal">1,800,253</ix:nonFraction> Series B shares issued relating to the conversion of certain liability instruments. As a result of this transaction, along with a restructuring of Datavant&#8217;s equity classes, RSL no longer controls Datavant. As such, the Company deconsolidated Datavant as of April 2020. Due to the Company&#8217;s significant influence over operating and financial policies, Datavant remains a related party of the Company following deconsolidation. Upon deconsolidation, the Company recorded its investment in Datavant based on the fair value of Datavant preferred shares held of $<ix:nonFraction name="us-gaap:InvestmentsFairValueDisclosure" contextRef="PAsOn06_30_2021_DatavantHoldingsIncMemberdeiLegalEntityAxis" unitRef="Unit_USD" decimals="-5" scale="6" format="ixt:numdotdecimal">99.0</ix:nonFraction>&#160;million. The Company accounts for its investment in Datavant using the measurement alternative to fair value. The investment will be remeasured upon future observable price changes in orderly transactions or upon impairment, if any. The Company recognized a gain on deconsolidation of $<ix:nonFraction name="us-gaap:DeconsolidationGainOrLossAmount" contextRef="P04_01_2020To06_30_2020_DatavantHoldingsIncMemberdeiLegalEntityAxis" unitRef="Unit_USD" decimals="-5" scale="6" format="ixt:numdotdecimal">86.5</ix:nonFraction>&#160;million in the accompanying condensed consolidated statements of operations for the three months ended June&#160;30, 2020. In July 2020, Datavant issued and sold <ix:nonFraction name="roiv:PreferredStockSharesIssuedAndSoldToCompanyDuringPeriodShares" contextRef="PAsOn07_31_2020" unitRef="Unit_shares" decimals="INF" scale="0" format="ixt:numdotdecimal">639,140</ix:nonFraction> Series B preferred shares to RSL at a price consistent with that of the initial round of Datavant&#8217;s Series B equity raise. At June&#160;30, 2021 and March&#160;31, 2021, the carrying value of the Company&#8217;s investment in Datavant was $<ix:nonFraction name="us-gaap:LongTermInvestments" contextRef="PAsOn06_30_2021_DatavantHoldingsIncMemberdeiLegalEntityAxis" unitRef="Unit_USD" decimals="-5" scale="6" format="ixt:numdotdecimal"><ix:nonFraction name="us-gaap:LongTermInvestments" contextRef="PAsOn03_31_2021_DatavantHoldingsIncMemberdeiLegalEntityAxis" unitRef="Unit_USD" decimals="-5" scale="6" format="ixt:numdotdecimal">100.6</ix:nonFraction></ix:nonFraction>&#160;million. </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">In June 2021, Datavant and CIOX Health, LLC entered into a definitive agreement to merge the two companies, subject to regulatory approvals. See Note 14, &#8220;Subsequent Events&#8221; for additional information. </div></div> </ix:continuation> <ix:nonNumeric name="roiv:TransactionAgreementDisclosureTextBlock" contextRef="P04_01_2021To06_30_2021" escape="true" continuedAt="TextSelection_28230272"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt; text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Note 4&#8212;Sumitomo Transaction Agreement </div></div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">On December&#160;27, 2019 (the &#8220;Sumitomo Closing Date&#8221;), RSL and Sumitomo Dainippon Pharma Co., Ltd. (&#8220;Sumitomo&#8221;) completed the transactions contemplated by the transaction agreement by and between RSL and Sumitomo, dated as of October&#160;31, 2019 (the &#8220;Sumitomo Transaction Agreement&#8221;). Pursuant to the Sumitomo Transaction Agreement, RSL transferred its entire ownership interest in Myovant Sciences Ltd., Urovant Sciences Ltd., Enzyvant Therapeutics Ltd., Altavant Sciences Ltd. and Spirovant Sciences Ltd. (collectively, the &#8220;Sumitovant Vants&#8221;) to a newly formed, wholly-owned entity (&#8220;Sumitovant&#8221;). </div></div></div></ix:nonNumeric> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"></div> </div> </div> </div> <div> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"><ix:continuation id="TextSelection_28230272" continuedAt="TextSelectionAppend_28230272_1"> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">RSL&#8217;s ownership interest in Sumitovant was then transferred to Sumitomo, such that following the Sumitomo Closing Date, Sumitovant and its subsidiaries, including the Sumitovant Vants, were each directly or indirectly owned by Sumitomo. Additionally, in connection with the Sumitomo Transaction Agreement, RSL (i)&#160;granted Sumitomo options to purchase all, or in the case of Dermavant, <ix:nonFraction name="roiv:PercentageOfGrantedOptionToPurchaseOwnershipInterest" contextRef="P03_31_2021To03_31_2021_SumitomoMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis" unitRef="Unit_pure" decimals="2" scale="-2" format="ixt:numdotdecimal">75</ix:nonFraction>%, of RSL&#8217;s ownership interests in six other subsidiaries (Dermavant, Genevant Sciences Ltd. (&#8220;Genevant&#8221;), Lysovant Sciences Ltd., Metavant Sciences Ltd., Roivant Asia Cell Therapy Holdings Ltd., and Sinovant Sciences HK Limited (collectively, the &#8220;Option Vants&#8221;)), </div><div style="display:inline;">(ii) (a) transferred the proprietary technology platform DrugOme to Sumitomo (for which RSL retains a perpetual royalty free license for internal use) and (b) licensed the Digital Innovation technology platform to Sumitomo (for which both parties retain ongoing access) and (iii)&#160;</div><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">transferred <ix:nonFraction name="roiv:SaleOfStockNumberOfShareIssuedInTransaction" contextRef="PAsOn12_31_2019_SumitomoMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis" unitRef="Unit_shares" decimals="0" scale="0" format="ixt:numdotdecimal">26,952,143</ix:nonFraction> common shares of RSL to Sumitomo. On the Sumitomo Closing Date, the Company received approximately $<ix:nonFraction name="roiv:SaleOfStockConsiderationCashReceivedOnTransaction" contextRef="PAsOn12_31_2019_SumitomoMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis" unitRef="Unit_USD" decimals="-8" scale="9" format="ixt:numdotdecimal">2.9</ix:nonFraction>&#160;billion</div></div> <div style="text-indent: 0px; margin-bottom: 1em; margin-top: 1em"></div> <div style="text-indent: 0px; margin-bottom: 1em; margin-top: 1em"></div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div> </ix:continuation> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">F-<div style="letter-spacing: 0px; top: 0px;;display:inline;">54</div> </div></div></div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> </div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em; text-align: left;;font-weight: bold;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><a href="#toc" style="text-indent: 0px;">Table of Contents</a></div></div> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"><ix:continuation id="TextSelectionAppend_28230272_1" continuedAt="TextSelectionAppend_28230272_2"> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0px;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">in cash. Additionally, $<ix:nonFraction name="us-gaap:EscrowDeposit" contextRef="PAsOn12_31_2019_SumitomoMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis" unitRef="Unit_USD" decimals="-5" scale="6" format="ixt:numdotdecimal">75.0</ix:nonFraction>&#160;million was deposited into a segregated escrow account for the purpose of fulfilling indemnification obligations of RSL that may become due to Sumitomo. The full escrow amount of $<ix:nonFraction name="us-gaap:RestrictedCash" contextRef="PAsOn12_31_2019_SumitomoMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis" unitRef="Unit_USD" decimals="-5" scale="6" format="ixt:numdotdecimal">75.0</ix:nonFraction>&#160;million was disbursed to the Company in June 2021.<div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">In connection with the Sumitomo Transaction, RSL&#8217;s board of directors approved an exchange and offer to repurchase RSL equity securities for up to $<div style="letter-spacing: 0px; top: 0px;;display:inline;"><ix:nonFraction name="roiv:StockOfferToRepurchaseDuringPeriodValueOfTheProceedsReceivedFromTransactionAgreement" contextRef="P04_01_2021To06_30_2021_SumitomoMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis" unitRef="Unit_USD" decimals="-8" scale="9" format="ixt:numdotdecimal">1.0</ix:nonFraction> </div>billion of the proceeds received from Sumitomo. </div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Concurrently with the Sumitomo Transaction Agreement, (i)&#160;RSL, Sumitomo and Sumitovant entered into a transition services agreement, whereby each of the parties thereto agreed to provide certain services to one another at cost for a period of time following the Sumitomo Closing Date and (ii)&#160;RSL and Sumitomo entered into a strategic cooperation agreement relating to certain ongoing technology-related collaborations between the parties. Pursuant to the terms of the transition services agreement and strategic cooperation agreement, RSL billed Sumitovant $<ix:nonFraction name="roiv:AgreementRelatedBilledAmountForCostsIncurredOnBehalfOfSubsidiarynetOfAmountsBilledBySubsidiary" contextRef="P04_01_2021To06_30_2021_TransitionServicesAndStrategicCooperationAgreementMemberROIVAgreementAxis" unitRef="Unit_USD" decimals="-5" scale="6" format="ixt:numdotdecimal">0.3</ix:nonFraction><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div>million and $<ix:nonFraction name="roiv:AgreementRelatedBilledAmountForCostsIncurredOnBehalfOfSubsidiarynetOfAmountsBilledBySubsidiary" contextRef="P04_01_2020To06_30_2020_TransitionServicesAndStrategicCooperationAgreementMemberROIVAgreementAxis" unitRef="Unit_USD" decimals="-5" scale="6" format="ixt:numdotdecimal">0.4</ix:nonFraction><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div>million, net of amounts billed by Sumitovant to RSL, during the three months ended June&#160;30, 2021 and 2020, respectively, for costs incurred on behalf of Sumitovant, which were recorded as offsets to the general and administrative expenses initially charged. The period for certain services provided under the Transition Services Agreement expired in December 2020. </div></div> </ix:continuation><ix:continuation id="TextSelectionAppend_28230272_2"> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">In conjunction with the Sumitomo Transaction, certain employees of the Company became employees of Sumitovant or its subsidiaries. The Company issued certain instruments to these employees that vest based on the achievement of time-based, performance or liquidity event requirements. As of June&#160;30, 2021 and 2020, there were <ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber" contextRef="PAsOn06_30_2021_EmployeeMembersrtTitleOfIndividualAxis_SumitomoMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis" unitRef="Unit_shares" decimals="0" scale="0" format="ixt:numdotdecimal">1,863,451</ix:nonFraction> and <ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber" contextRef="PAsOn06_30_2020_EmployeeMembersrtTitleOfIndividualAxis_SumitomoMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis" unitRef="Unit_shares" decimals="0" scale="0" format="ixt:numdotdecimal">1,873,480</ix:nonFraction> outstanding instruments, respectively, held by Sumitovant employees for which aggregate fair value was recorded against the gain on sale of business. </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">In May 2021, the Company entered into an Asset Purchase Agreement with Sumitomo and its subsidiary Sumitomo Pharmaceuticals (Suzhou) Co., Ltd. (&#8220;SPC&#8221;) (the &#8220;Asset Purchase Agreement&#8221;). The transactions contemplated by the Asset Purchase Agreement closed in June 2021. Pursuant to the Asset Purchase Agreement: (i)&#160;Sumitomo terminated all of its existing options to acquire the Company&#8217;s equity interests in the Option Vants (the &#8220;Sumitomo Options&#8221;); (ii) the Company transferred and assigned to SPC all of its intellectual property, development and commercialization rights for (a)&#160;lefamulin in Mainland China, Taiwan, Hong Kong, and Macau (collectively &#8220;Greater China&#8221;), (b) vibegron in Mainland China, (c)&#160;rodatristat ethyl in Greater China and South Korea and <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">(d)&#160;RVT-802</div> in Greater China and South Korea; (iii)&#160;Sumitomo agreed to pay the Company $<ix:nonFraction name="roiv:AssetPurchaseTransactionConsiderationReceivedInCash" contextRef="PAsOn05_31_2021_AssetPurchaseAgreementMemberROIVAgreementAxis" unitRef="Unit_USD" decimals="-5" scale="6" format="ixt:numdotdecimal">5.0</ix:nonFraction><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div>million in cash; and (iv)&#160;Sumitomo entered into an agreement with the Company to pursue future collaborations with Genevant. The Company received the cash payment, net of certain withholding taxes, in August 2021. The Company recorded a gain on the termination of the Sumitomo Options of $<ix:nonFraction name="roiv:EquityInterestOptionToThirdPartyPurchaserGainOnTermination" contextRef="P04_01_2021To06_30_2021_AssetPurchaseAgreementMemberROIVAgreementAxis" unitRef="Unit_USD" decimals="-5" scale="6" format="ixt:numdotdecimal">66.5</ix:nonFraction><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div>million, consisting of the fair value of the Sumitomo Options on the date of termination and the expected cash payment, in the accompanying condensed consolidated statements of operations for the three months ended June&#160;30, 2021. </div> </ix:continuation> <ix:nonNumeric name="us-gaap:SupplementalBalanceSheetDisclosuresTextBlock" contextRef="P04_01_2021To06_30_2021" escape="true" continuedAt="TextSelection_28230399"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Note 5&#8212;Balance Sheet Components </div></div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">(A) Other Current Assets </div></div></div> <ix:nonNumeric name="us-gaap:ScheduleOfOtherCurrentAssetsTableTextBlock" contextRef="P04_01_2021To06_30_2021" escape="true"><div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Other current assets at June&#160;30, 2021 and March&#160;31, 2021 consisted of the following (in thousands): </div></div></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 76%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px; text-indent: 0px;">
<tr style="font-size: 0px;">
<td style="width: 64%;"></td>
<td style="width: 10%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td>
<td style="width: 10%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 1pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">June&#160;30,&#160;2021</div></div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">March&#160;31,&#160;2021</div></div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td> </tr>
<tr style="font-size: 0px;">
<td style="width: 75%;"></td>
<td style="width: 7%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td>
<td style="width: 6%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top; width: 75%;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Prepaid expenses</div></div> </td>
<td style="vertical-align: bottom; width: 7%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:PrepaidExpenseCurrent" contextRef="PAsOn06_30_2021" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">44,941</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 6%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:PrepaidExpenseCurrent" contextRef="PAsOn03_31_2021" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">39,544</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; width: 75%;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Trade receivables, net</div></div> </td>
<td style="vertical-align: bottom; width: 7%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:AccountsReceivableNetCurrent" contextRef="PAsOn06_30_2021" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">3,416</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 6%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:AccountsReceivableNetCurrent" contextRef="PAsOn03_31_2021" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">11,222</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top; width: 75%;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Income tax receivable</div></div> </td>
<td style="vertical-align: bottom; width: 7%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:IncomeTaxesReceivable" contextRef="PAsOn06_30_2021" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">1,993</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 6%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:IncomeTaxesReceivable" contextRef="PAsOn03_31_2021" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">1,803</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-size: 0px;">
<td style="width: 75%;"></td>
<td style="width: 7%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td>
<td style="width: 6%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td> </tr>
<tr style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; break-inside: avoid;">
<td style="vertical-align: top; background-color: rgb(255, 255, 255); width: 75%;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Other</div></div> </td>
<td style="vertical-align: bottom; background-color: rgb(255, 255, 255); width: 7%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(255, 255, 255);">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(255, 255, 255);;text-align:right;"><ix:nonFraction name="us-gaap:OtherAssetsMiscellaneousCurrent" contextRef="PAsOn06_30_2021" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">7,815</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(255, 255, 255);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(255, 255, 255); width: 6%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(255, 255, 255);">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(255, 255, 255);;text-align:right;"><ix:nonFraction name="us-gaap:OtherAssetsMiscellaneousCurrent" contextRef="PAsOn03_31_2021" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">1,681</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(255, 255, 255);">&#160;</td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; background-color: rgb(204, 238, 255); width: 75%;">&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255); width: 7%;">&#160;&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="background-color: rgb(204, 238, 255);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255); width: 6%;">&#160;&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="background-color: rgb(204, 238, 255);">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; background-color: rgb(204, 238, 255); width: 75%;"> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.26in; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Total other current assets</div></div> </td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255); width: 7%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);">$</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;"><ix:nonFraction name="us-gaap:OtherAssetsCurrent" contextRef="PAsOn06_30_2021" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">58,165</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255); width: 6%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);">$</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;"><ix:nonFraction name="us-gaap:OtherAssetsCurrent" contextRef="PAsOn03_31_2021" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">54,250</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);">&#160;</td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; background-color: rgb(255, 255, 255); width: 75%;">&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(255, 255, 255); width: 7%;">&#160;&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="background-color: rgb(255, 255, 255);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(255, 255, 255); width: 6%;">&#160;&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="background-color: rgb(255, 255, 255);">&#160;</td> </tr> </table> </ix:nonNumeric> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"></div> <div style="clear: both; max-height: 0px;"></div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div></ix:nonNumeric> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">F-<div style="letter-spacing: 0px; top: 0px;;display:inline;">55</div> </div></div></div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> </div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"> </div> </div> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;;font-weight: bold;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><a href="#toc" style="text-indent: 0px;">Table of Contents</a></div></div> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"><ix:continuation id="TextSelection_28230399" continuedAt="TextSelectionAppend_28230399_1"> <div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;;"><div style="font-weight:bold;display:inline;">(B) Accrued Expenses </div></div> </ix:continuation> <ix:continuation id="TextSelectionAppend_28230399_1"> <ix:nonNumeric name="us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock" contextRef="P04_01_2021To06_30_2021" escape="true"><div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Accrued expenses at June&#160;30, 2021 and March&#160;31, 2021 consisted of the following (in thousands): </div></div></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 76%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px; text-indent: 0px;">
<tr style="font-size: 0px;">
<td style="width: 64%;"></td>
<td style="width: 10%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td>
<td style="width: 10%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 1pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">June&#160;30,&#160;2021</div></div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">March&#160;31,&#160;2021</div></div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td> </tr>
<tr style="font-size: 0px;">
<td style="width: 64%;"></td>
<td style="width: 10%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td>
<td style="width: 10%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top; width: 64%;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Research and development expenses</div></div> </td>
<td style="vertical-align: bottom; width: 10%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:AccruedLiabilitiesCurrent" contextRef="PAsOn06_30_2021_ResearchAndDevelopmentExpenseMemberusgaapIncomeStatementLocationAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">28,347</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 10%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:AccruedLiabilitiesCurrent" contextRef="PAsOn03_31_2021_ResearchAndDevelopmentExpenseMemberusgaapIncomeStatementLocationAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">20,755</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; width: 64%;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Compensation-related expenses</div></div> </td>
<td style="vertical-align: bottom; width: 10%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:AccruedLiabilitiesCurrent" contextRef="PAsOn06_30_2021_EmployeeRelatedExpensesMemberusgaapIncomeStatementLocationAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">15,242</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 10%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:AccruedLiabilitiesCurrent" contextRef="PAsOn03_31_2021_EmployeeRelatedExpensesMemberusgaapIncomeStatementLocationAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">38,552</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top; width: 64%;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Professional services expenses</div></div> </td>
<td style="vertical-align: bottom; width: 10%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:AccruedLiabilitiesCurrent" contextRef="PAsOn06_30_2021_ProfessionalServicesExpensesMemberusgaapIncomeStatementLocationAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">16,489</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 10%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:AccruedLiabilitiesCurrent" contextRef="PAsOn03_31_2021_ProfessionalServicesExpensesMemberusgaapIncomeStatementLocationAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">10,267</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; width: 64%;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Other general and administrative expenses</div></div> </td>
<td style="vertical-align: bottom; width: 10%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:AccruedLiabilitiesCurrent" contextRef="PAsOn06_30_2021_OtherGeneralAndAdministrativeExpensesMemberusgaapIncomeStatementLocationAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">13,710</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 10%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:AccruedLiabilitiesCurrent" contextRef="PAsOn03_31_2021_OtherGeneralAndAdministrativeExpensesMemberusgaapIncomeStatementLocationAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">7,362</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 64%;">&#160;</td>
<td style="vertical-align: bottom; width: 10%;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom; width: 10%;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top; width: 64%;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Total accrued expenses</div></div> </td>
<td style="vertical-align: bottom; width: 10%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:AccruedLiabilitiesCurrent" contextRef="PAsOn06_30_2021" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">73,788</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 10%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:AccruedLiabilitiesCurrent" contextRef="PAsOn03_31_2021" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">76,936</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 64%;">&#160;</td>
<td style="vertical-align: bottom; width: 10%;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom; width: 10%;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td> </tr> </table> </ix:nonNumeric> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">(C) Other Current Liabilities </div></div></div> <ix:nonNumeric name="us-gaap:OtherCurrentLiabilitiesTableTextBlock" contextRef="P04_01_2021To06_30_2021" escape="true"><div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Other current liabilities at June&#160;30, 2021 and March&#160;31, 2021 consisted of the following (in thousands): </div></div></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 76%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px; text-indent: 0px;">
<tr style="font-size: 0px;">
<td style="width: 64%;"></td>
<td style="width: 12%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td>
<td style="width: 12%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 1pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">June&#160;30,&#160;2021</div></div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">March&#160;31,&#160;2021</div></div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td> </tr>
<tr style="font-size: 0px;">
<td style="width: 64%;"></td>
<td style="width: 12%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td>
<td style="width: 12%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top; width: 64%;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Deferred revenue</div></div> </td>
<td style="vertical-align: bottom; width: 12%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="roiv:DeferredRevenueOtherCurrentLiabilities" contextRef="PAsOn06_30_2021" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">3,777</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 12%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="roiv:DeferredRevenueOtherCurrentLiabilities" contextRef="PAsOn03_31_2021" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">5,918</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; width: 64%;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Income tax payable</div></div> </td>
<td style="vertical-align: bottom; width: 12%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:TaxesPayableCurrent" contextRef="PAsOn06_30_2021" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">199</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 12%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:TaxesPayableCurrent" contextRef="PAsOn03_31_2021" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">207</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top; width: 64%;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Other</div></div> </td>
<td style="vertical-align: bottom; width: 12%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:OtherSundryLiabilitiesCurrent" contextRef="PAsOn06_30_2021" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">4,325</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 12%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:OtherSundryLiabilitiesCurrent" contextRef="PAsOn03_31_2021" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">3,037</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 64%;">&#160;</td>
<td style="vertical-align: bottom; width: 12%;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom; width: 12%;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; width: 64%;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Total other current liabilities</div></div> </td>
<td style="vertical-align: bottom; width: 12%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:OtherLiabilitiesCurrent" contextRef="PAsOn06_30_2021" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">8,301</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 12%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:OtherLiabilitiesCurrent" contextRef="PAsOn03_31_2021" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">9,162</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 64%;">&#160;</td>
<td style="vertical-align: bottom; width: 12%;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom; width: 12%;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td> </tr> </table> </ix:nonNumeric></ix:continuation> <ix:nonNumeric name="us-gaap:LongTermDebtTextBlock" contextRef="P04_01_2021To06_30_2021" escape="true" continuedAt="TextSelection_28230402"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Note 6&#8212;Long-Term Debt and Loan Commitment </div></div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">(A) Long-Term Debt </div></div></div> <ix:nonNumeric name="us-gaap:ScheduleOfDebtTableTextBlock" contextRef="P04_01_2021To06_30_2021" escape="true"><div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Long-term debt, net consists of the following (in thousands): </div></div></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 84%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px; text-indent: 0px;">
<tr style="font-size: 0px;">
<td style="width: 68%;"></td>
<td style="width: 8%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td>
<td style="width: 8%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 1pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">June&#160;30,&#160;2021</div></div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">March&#160;31,&#160;2021</div></div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td> </tr>
<tr style="font-size: 0px;">
<td style="width: 68%;"></td>
<td style="width: 8%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td>
<td style="width: 8%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top; width: 68%;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Principal amount</div></div> </td>
<td style="vertical-align: bottom; width: 8%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:DebtInstrumentCarryingAmount" contextRef="PAsOn06_30_2021" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">195,200</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 8%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:DebtInstrumentCarryingAmount" contextRef="PAsOn03_31_2021" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">170,100</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; width: 68%;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Exit fee / end of term charge</div></div> </td>
<td style="vertical-align: bottom; width: 8%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="roiv:DebtInstrumentExitFeeAndEndOfTermCharge" contextRef="PAsOn06_30_2021" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">5,000</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 8%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="roiv:DebtInstrumentExitFeeAndEndOfTermCharge" contextRef="PAsOn03_31_2021" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">1,390</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top; width: 68%;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Less: unamortized debt discount and issuance costs</div></div> </td>
<td style="vertical-align: bottom; width: 8%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(<ix:nonFraction name="us-gaap:DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet" contextRef="PAsOn06_30_2021" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">13,850</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom; width: 8%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(<ix:nonFraction name="us-gaap:DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet" contextRef="PAsOn03_31_2021" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">1,210</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 68%;">&#160;</td>
<td style="vertical-align: bottom; width: 8%;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom; width: 8%;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; width: 68%;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Total debt, net</div></div> </td>
<td style="vertical-align: bottom; width: 8%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:LongTermDebt" contextRef="PAsOn06_30_2021" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">186,350</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 8%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:LongTermDebt" contextRef="PAsOn03_31_2021" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">170,280</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top; width: 68%;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Less: current portion</div></div> </td>
<td style="vertical-align: bottom; width: 8%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:LongTermDebtCurrent" contextRef="PAsOn06_30_2021" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:zerodash">&#8212;</ix:nonFraction>&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 8%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:LongTermDebtCurrent" contextRef="PAsOn03_31_2021" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:zerodash">&#8212;</ix:nonFraction>&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 68%;">&#160;</td>
<td style="vertical-align: bottom; width: 8%;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom; width: 8%;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; width: 68%;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Total long-term debt, net</div></div> </td>
<td style="vertical-align: bottom; width: 8%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:LongTermDebtNoncurrent" contextRef="PAsOn06_30_2021" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">186,350</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 8%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:LongTermDebtNoncurrent" contextRef="PAsOn03_31_2021" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">170,280</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 68%;">&#160;</td>
<td style="vertical-align: bottom; width: 8%;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom; width: 8%;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td> </tr> </table> </ix:nonNumeric> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt; margin-left: 2%;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Dermavant </div></div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">In May 2019, Dermavant entered into a loan and security agreement (the &#8220;Hercules Loan Agreement&#8221;) with Hercules Capital, Inc. (&#8220;Hercules&#8221;), pursuant to which Dermavant borrowed an aggregate of<div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">$</div><ix:nonFraction name="us-gaap:DebtInstrumentFaceAmount" contextRef="PAsOn05_31_2019" unitRef="Unit_USD" decimals="-5" scale="6" format="ixt:numdotdecimal">20.0</ix:nonFraction><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;million, which bore interest at a variable per annum rate at the greater of (i) </div><ix:nonFraction name="us-gaap:LongTermDebtPercentageBearingVariableInterestRate" contextRef="PAsOn05_31_2019" unitRef="Unit_pure" decimals="4" scale="-2" format="ixt:numdotdecimal">9.95</ix:nonFraction><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">% or (ii)&#160;the prime rate plus </div><ix:nonFraction name="us-gaap:LongTermDebtPercentageBearingVariableInterestRate" contextRef="PAsOn05_31_2019_PrimeRateMemberusgaapVariableRateAxis" unitRef="Unit_pure" decimals="4" scale="-2" format="ixt:numdotdecimal">4.45</ix:nonFraction><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">%. Dermavant was also obligated to pay an end of term charge of $</div><ix:nonFraction name="us-gaap:DebtInstrumentFeeAmount" contextRef="PAsOn05_31_2019" unitRef="Unit_USD" decimals="-5" scale="6" format="ixt:numdotdecimal">1.4</ix:nonFraction><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;million. Following the achievement of certain milestones, the term loan maturity was extended to June&#160;1, 2023 with interest-only monthly payments through December 2021. All amounts outstanding under the Hercules Loan Agreement were repaid in May 2021 using the proceeds from a $</div><ix:nonFraction name="us-gaap:ProceedsFromLinesOfCredit" contextRef="P05_01_2021To05_01_2021" unitRef="Unit_USD" decimals="-5" scale="6" format="ixt:numdotdecimal">40.0</ix:nonFraction><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;million senior secured credit facility (the &#8220;Credit Facility&#8221;) entered into by Dermavant and certain of its subsidiaries in May 2021 with XYQ Luxco S.A.R.L (&#8220;XYQ Luxco&#8221;), as lender, and U.S. Bank National Association, as collateral agent. The Credit Facility has a </div><ix:nonNumeric name="us-gaap:DebtInstrumentTerm" contextRef="P05_01_2021To05_01_2021" format="ixt-sec:durwordsen">five-year</ix:nonNumeric><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"> maturity and bears an interest rate of </div><ix:nonFraction name="us-gaap:DebtInstrumentInterestRateStatedPercentage" contextRef="PAsOn05_01_2021" unitRef="Unit_pure" decimals="3" scale="-2" format="ixt:numdotdecimal">10.0</ix:nonFraction><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">% per annum. Interest is payable quarterly in arrears on the last day of each calendar quarter through the maturity date. A lump sum principal payment is due on the maturity date.&#160;</div><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Dermavant is also obligated to pay an exit fee of $<ix:nonFraction name="roiv:DebtInstrumentExitFeeAndEndOfTermCharge" contextRef="PAsOn05_31_2019" unitRef="Unit_USD" decimals="-2" scale="3" format="ixt:numdotdecimal">5.0</ix:nonFraction>&#160;million. The exit fee can be reduced to $<ix:nonFraction name="us-gaap:DebtInstrumentFeeAmount" contextRef="PAsOn06_30_2021" unitRef="Unit_USD" decimals="-2" scale="3" format="ixt:numdotdecimal">4.0</ix:nonFraction>&#160;million upon achievement of certain equity milestones defined in the agreement, which are not deemed likely as of June&#160;30, 2021. In connection with the </div></div></div></ix:nonNumeric> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">F-<div style="letter-spacing: 0px; top: 0px;;display:inline;">56</div> </div></div></div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> </div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0px;"></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"></div> </div> </div> </div> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;;font-weight: bold;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><a href="#toc" style="text-indent: 0px;">Table of Contents</a></div></div> <div><div style="text-align: center;"><div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"><ix:continuation id="TextSelection_28230402"> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0px;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">funding of the Credit Facility, Dermavant issued a warrant to XYQ Luxco to purchase </div><ix:nonFraction name="us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight" contextRef="PAsOn05_31_2021" unitRef="Unit_shares" decimals="0" scale="0" format="ixt:numdotdecimal">1,199,072</ix:nonFraction><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"> common shares of Dermavant at an exercise price of $</div><ix:nonFraction name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" contextRef="PAsOn05_31_2021" unitRef="Unit_USD_per_Share" decimals="2" scale="0" format="ixt:numdotdecimal">0.01</ix:nonFraction><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"> per common share.</div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">In connection with Dermavant&#8217;s acquisition of tapinarof from GlaxoSmithKline Intellectual Property Development Ltd. and Glaxo Group Limited (collectively &#8220;GSK&#8221;) pursuant to an asset purchase agreement (the &#8220;GSK Agreement&#8221;), Dermavant and NovaQuest <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">Co-Investment</div> Fund VIII, L.P. (&#8220;NovaQuest&#8221;) entered into a funding agreement (the &#8220;NovaQuest Agreement&#8221;). Pursuant to the NovaQuest Agreement, Dermavant borrowed $<ix:nonFraction name="us-gaap:DebtInstrumentFaceAmount" contextRef="PAsOn08_31_2018_NovaquestMemberusgaapTypeOfArrangementAxis" unitRef="Unit_USD" decimals="-5" scale="6" format="ixt:numdotdecimal">100.0</ix:nonFraction>&#160;million in August 2018 and $<ix:nonFraction name="us-gaap:DebtInstrumentFaceAmount" contextRef="PAsOn10_31_2018_NovaquestMemberusgaapTypeOfArrangementAxis" unitRef="Unit_USD" decimals="-5" scale="6" format="ixt:numdotdecimal">17.5</ix:nonFraction>&#160;million in October 2018 in exchange for an obligation to make certain variable future payments calculated as a function of the achievement of regulatory and commercial milestones or events of termination. The aggregate maximum amount of regulatory milestone payments that Dermavant could be required to make under the NovaQuest Agreement is $<ix:nonFraction name="roiv:MaximumMilestonePaymentObligation" contextRef="PAsOn08_31_2018_NovaquestMemberusgaapTypeOfArrangementAxis_RegulatoryMilestoneMemberusgaapTransactionTypeAxis" unitRef="Unit_USD" decimals="-5" scale="6" format="ixt:numdotdecimal">440.6</ix:nonFraction>&#160;million, and the maximum aggregate amount of commercial milestone payments is $<ix:nonFraction name="roiv:MaximumMilestonePaymentObligation" contextRef="PAsOn08_31_2018_CommercialMilestoneMemberusgaapTransactionTypeAxis_NovaquestMemberusgaapTypeOfArrangementAxis" unitRef="Unit_USD" decimals="-5" scale="6" format="ixt:numdotdecimal">141.0</ix:nonFraction>&#160;million. In some circumstances, Dermavant may be able to offset certain of the regulatory milestone payments with up to $<ix:nonFraction name="roiv:MaximumMilestonePaymentOffsetAmount" contextRef="PAsOn08_31_2018_NovaquestMemberusgaapTypeOfArrangementAxis_RegulatoryMilestoneMemberusgaapTransactionTypeAxis" unitRef="Unit_USD" decimals="-5" scale="6" format="ixt:numdotdecimal">88.1</ix:nonFraction>&#160;million of the commercial milestone payments. At issuance, the Company concluded that certain features of the long-term debt would be considered derivatives that would require bifurcation. In lieu of bifurcating various features in the agreement, the Company has elected the fair value option for this financial instrument and will record the changes in the fair value within the statements of operations at the end of each reporting period. Direct costs and fees related to the debt issued under the NovaQuest Agreement were recognized in earnings. As of June&#160;30, 2021 and March&#160;31, 2021, the fair value of the debt was $<ix:nonFraction name="us-gaap:DebtInstrumentFairValue" contextRef="PAsOn06_30_2021_NovaquestMemberusgaapTypeOfArrangementAxis" unitRef="Unit_USD" decimals="-5" scale="6" format="ixt:numdotdecimal">155.2</ix:nonFraction>&#160;million and $<ix:nonFraction name="us-gaap:DebtInstrumentFairValue" contextRef="PAsOn03_31_2021_NovaquestMemberusgaapTypeOfArrangementAxis" unitRef="Unit_USD" decimals="-5" scale="6" format="ixt:numdotdecimal">150.1</ix:nonFraction>&#160;million, respectively. Refer to Note 11, &#8220;Fair Value Measurements&#8221; for additional details regarding the fair value measurement. </div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">(B) Loan Commitment </div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;">In May 2021, Dermavant, as seller, entered into a $<ix:nonFraction name="us-gaap:SecuritiesPurchasedUnderAgreementsToResellIncrease" contextRef="P05_01_2021To05_31_2021_RevenueInterestPurchaseAndSaleAgreementMemberusgaapFinancialInstrumentAxis" unitRef="Unit_USD" decimals="-5" scale="6" format="ixt:numdotdecimal">160.0</ix:nonFraction>&#160;million revenue interest purchase and sale agreement (the &#8220;RIPSA&#8221;) for its investigational product tapinarof with XYQ Luxco, NovaQuest <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">Co-Investment</div> Fund XVII, L.P., an affiliate of NovaQuest Capital Management, LLC, and MAM Tapir Lender, LLC, an affiliate of Marathon Asset Management, L.P. (collectively, the &#8220;Purchasers&#8221;), together with U.S. Bank National Association, as collateral agent. Under the terms of the RIPSA, the Purchasers procured a capped single-digit revenue interest in net sales of tapinarof for all dermatological indications in the United States in exchange for $<ix:nonFraction name="roiv:MinimumAmountOfAnnualNetSalesToQualifyUnderRevenueInterestPurchaseAgreementContingentThreshold" contextRef="P05_01_2021To05_31_2021_RevenueInterestPurchaseAndSaleAgreementMemberusgaapFinancialInstrumentAxis" unitRef="Unit_USD" decimals="-5" scale="6" format="ixt:numdotdecimal">160.0</ix:nonFraction>&#160;million in committed funding to be paid to Dermavant, conditional based on the approval of tapinarof by the FDA. The agreement will be canceled if funding has not occurred by July 2023. Dermavant acquired the worldwide rights to tapinarof (other than with respect to certain rights in China) in August 2018 pursuant to the GSK Agreement. Dermavant intends to use the RIPSA proceeds for the payment of certain <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">one-time</div> milestone obligations that become payable upon the approval and commercialization of tapinarof for the treatment of psoriasis in the United States as well as for other general corporate purposes. </div> </ix:continuation> <ix:nonNumeric name="us-gaap:StockholdersEquityNoteDisclosureTextBlock" contextRef="P04_01_2021To06_30_2021" escape="true" continuedAt="TextSelection_28230400"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt; text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Note 7&#8212;Shareholders&#8217; Equity and Redeemable Noncontrolling Interest </div></div></div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt; text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Business Combination Agreement </div></div></div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">On May&#160;1, 2021, the Company entered into a Business Combination Agreement (the &#8220;Business Combination Agreement&#8221;) with Montes Archimedes Acquisition Corporation (&#8220;MAAC&#8221;) and Rhine Merger Sub, Inc. (&#8220;Merger Sub&#8221;). MAAC was incorporated in Delaware on July&#160;6, 2020 and was formed as a blank check company for the purpose of effecting a merger, share exchange, asset acquisition, stock purchase, recapitalization, reorganization or similar business combination with one or more businesses. Pursuant to the Business Combination Agreement, and assuming a favorable vote by MAAC&#8217;s stockholders at a special meeting of MAAC&#8217;s stockholders convened for purposes of approving the transactions contemplated by the Business Combination Agreement (the &#8220;Business Combination&#8221;), and the satisfaction or waiver of all other closing conditions pursuant to the Business Combination Agreement, Merger Sub will merge with and into MAAC, with MAAC surviving the merger as the Company&#8217;s wholly owned subsidiary. </div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">For financial accounting and reporting purposes, MAAC will be treated as the acquired company. Accordingly, because MAAC does not represent a business for accounting purposes and its primary asset </div></div></div></ix:nonNumeric> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">F-<div style="letter-spacing: 0px; top: 0px;;display:inline;">57</div> </div></div></div> </div></div><div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div><hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/><div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;;font-weight: bold;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><a href="#toc" style="text-indent: 0px;">Table of Contents</a></div></div><div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"><ix:continuation id="TextSelection_28230400"> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">represents cash and cash equivalents, the Business Combination will be treated as an equity contribution in exchange for the issuance of RSL shares. The net assets of MAAC will be stated at historical cost, with no goodwill or other intangible assets recorded. RSL will be deemed both the accounting predecessor and the successor SEC registrant, which means that the Company&#8217;s financial statements for previous periods will be disclosed in the Company&#8217;s future periodic reports filed with the SEC. </div></div></div> </ix:continuation></div><div style="text-align: center;"><div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"> <ix:nonNumeric name="us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" contextRef="P04_01_2021To06_30_2021" escape="true" continuedAt="TextSelection_28230178"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Note 8&#8212;Share-Based Compensation </div></div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">(A) RSL 2015 Equity Incentive Plan </div></div></div></ix:nonNumeric> <ix:continuation id="TextSelection_28230178" continuedAt="TextSelectionAppend_28230178_1"> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">As of June&#160;30, 2021, <ix:nonFraction name="us-gaap:CommonStockCapitalSharesReservedForFutureIssuance" contextRef="PAsOn06_30_2021_TwoThousandFifteenEquityIncentivePlanMemberusgaapPlanNameAxis" unitRef="Unit_shares" decimals="INF" scale="0" format="ixt:numdotdecimal">22,800,000</ix:nonFraction> of the Company&#8217;s common shares (the &#8220;Share Reserve&#8221;) are reserved for issuance under the RSL Amended and Restated 2015 Equity Incentive Plan (the &#8220;RSL 2015 EIP&#8221;). At June&#160;30, 2021, a total of <ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" contextRef="PAsOn06_30_2021_TwoThousandFifteenEquityIncentivePlanMemberusgaapPlanNameAxis" unitRef="Unit_shares" decimals="INF" scale="0" format="ixt:numdotdecimal">786,125</ix:nonFraction> common shares are available for future grants under the RSL 2015 EIP. The Company&#8217;s employees, directors, and consultants are eligible to receive nonstatutory and incentive stock options, stock appreciation rights, restricted stock awards, restricted stock unit awards, and other stock awards under the RSL 2015 EIP. </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">As of June&#160;30, 2021, an aggregate of <ix:nonFraction name="roiv:CommonSharesReservedForPerformanceOptionsAndCappedValueAppreciationRights" contextRef="PAsOn06_30_2021_SpecialReserveMemberusgaapAwardTypeAxis_TwoThousandFifteenEquityIncentivePlanMemberusgaapPlanNameAxis" unitRef="Unit_shares" decimals="INF" scale="0" format="ixt:numdotdecimal">26,558,238</ix:nonFraction> of the Company&#8217;s common shares (the &#8220;Special Reserve&#8221;) are reserved for the granting under RSL 2015 EIP of performance stock options (&#8220;Performance Options&#8221;) and capped value appreciation rights (&#8220;CVARs&#8221;) to the Company&#8217;s employees, directors and consultants. At June&#160;30, 2021, there are <ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" contextRef="PAsOn06_30_2021_SpecialReserveMemberusgaapAwardTypeAxis_TwoThousandFifteenEquityIncentivePlanMemberusgaapPlanNameAxis" unitRef="Unit_shares" decimals="INF" scale="0" format="ixt-sec:numwordsen">no </ix:nonFraction>common shares available for future grant under the Special Reserve. </div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt; margin-left: 2%;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Stock Options </div></div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">During the three months ended June&#160;30, 2021 and 2020, the Company recorded share-based compensation expense related to stock options issued under the RSL 2015 EIP to employees and directors of approximately $<ix:nonFraction name="us-gaap:AllocatedShareBasedCompensationExpense" contextRef="P04_01_2021To06_30_2021_EmployeeStockOptionMemberusgaapAwardTypeAxis_TwoThousandFifteenEquityIncentivePlanMemberusgaapPlanNameAxis" unitRef="Unit_USD" decimals="INF" scale="6" format="ixt:numdotdecimal">10.3</ix:nonFraction>&#160;million and $<ix:nonFraction name="us-gaap:AllocatedShareBasedCompensationExpense" contextRef="P04_01_2020To06_30_2020_EmployeeStockOptionMemberusgaapAwardTypeAxis_TwoThousandFifteenEquityIncentivePlanMemberusgaapPlanNameAxis" unitRef="Unit_USD" decimals="INF" scale="6" format="ixt:numdotdecimal">7.8</ix:nonFraction>&#160;million, respectively, and was included in research and development and general and administrative expenses in the accompanying condensed consolidated statements of operations. </div></div> <ix:nonNumeric name="us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" contextRef="P04_01_2021To06_30_2021" escape="true"><div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">A summary of stock option activity and data under the RSL 2015 EIP for the three months ended June&#160;30, 2021 is as follows: </div></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;width:76%;">
<tr style="font-size: 0px;">
<td style="width: 65%;"></td>
<td style="width: 8%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td>
<td style="width: 8%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Number&#160;of<br/> Stock<br/> Options</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="margin-top: 0px; margin-bottom: 0px; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Weighted&#160;</div></div></div><div style="margin-top: 0px; margin-bottom: 0px; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Average<br/> Exercise<div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div>Price</div></div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top; width: 65%;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Stock options outstanding at March&#160;31, 2021</div></div></td>
<td style="vertical-align: bottom; width: 8%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" contextRef="PAsOn03_31_2021_EmployeeStockOptionMemberusgaapAwardTypeAxis_TwoThousandFifteenEquityIncentivePlanMemberusgaapPlanNameAxis" unitRef="Unit_shares" decimals="INF" scale="0" format="ixt:numdotdecimal">9,389,371</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 8%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" contextRef="PAsOn03_31_2021_EmployeeStockOptionMemberusgaapAwardTypeAxis_TwoThousandFifteenEquityIncentivePlanMemberusgaapPlanNameAxis" unitRef="Unit_USD_per_Share" decimals="2" scale="0" format="ixt:numdotdecimal">26.61</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; width: 65%;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Granted</div></div></td>
<td style="vertical-align: bottom; width: 8%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" contextRef="P04_01_2021To06_30_2021_EmployeeStockOptionMemberusgaapAwardTypeAxis_TwoThousandFifteenEquityIncentivePlanMemberusgaapPlanNameAxis" unitRef="Unit_shares" decimals="INF" scale="0" format="ixt:numdotdecimal">3,798,605</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 8%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" contextRef="P04_01_2021To06_30_2021_EmployeeStockOptionMemberusgaapAwardTypeAxis_TwoThousandFifteenEquityIncentivePlanMemberusgaapPlanNameAxis" unitRef="Unit_USD_per_Share" decimals="2" scale="0" format="ixt:numdotdecimal">29.26</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top; width: 65%;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Forfeited</div></div></td>
<td style="vertical-align: bottom; width: 8%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(<ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" contextRef="P04_01_2021To06_30_2021_EmployeeStockOptionMemberusgaapAwardTypeAxis_TwoThousandFifteenEquityIncentivePlanMemberusgaapPlanNameAxis" unitRef="Unit_shares" decimals="INF" scale="0" format="ixt:numdotdecimal">106,428</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom; width: 8%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" contextRef="P04_01_2021To06_30_2021_EmployeeStockOptionMemberusgaapAwardTypeAxis_TwoThousandFifteenEquityIncentivePlanMemberusgaapPlanNameAxis" unitRef="Unit_USD_per_Share" decimals="2" scale="0" format="ixt:numdotdecimal">30.27</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 65%;">&#160;</td>
<td style="vertical-align: bottom; width: 8%;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom; width: 8%;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; width: 65%;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Stock options outstanding at June&#160;30, 2021</div></div></td>
<td style="vertical-align: bottom; width: 8%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" contextRef="PAsOn06_30_2021_EmployeeStockOptionMemberusgaapAwardTypeAxis_TwoThousandFifteenEquityIncentivePlanMemberusgaapPlanNameAxis" unitRef="Unit_shares" decimals="INF" scale="0" format="ixt:numdotdecimal">13,081,548</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 8%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" contextRef="PAsOn06_30_2021_EmployeeStockOptionMemberusgaapAwardTypeAxis_TwoThousandFifteenEquityIncentivePlanMemberusgaapPlanNameAxis" unitRef="Unit_USD_per_Share" decimals="2" scale="0" format="ixt:numdotdecimal">27.35</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 65%;">&#160;</td>
<td style="vertical-align: bottom; width: 8%;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom; width: 8%;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td></tr></table> </ix:nonNumeric> </ix:continuation> <ix:continuation id="TextSelectionAppend_28230178_1" continuedAt="TextSelectionAppend_28230178_2"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt; margin-left: 2%;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Restricted Stock Units </div></div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Restricted stock units will generally vest upon the achievement of both time-based service requirements and liquidity requirements on or before the grant expiration date. Certain restricted stock units have also been granted that will vest upon the achievement of development milestones and liquidity requirements. As of June&#160;30, 2021, the liquidity event requirement had not been met and was deemed not probable of being met. During the three months ended June&#160;30, 2021 and 2020, the Company recorded <ix:nonFraction name="us-gaap:AllocatedShareBasedCompensationExpense" contextRef="P04_01_2020To06_30_2020_RestrictedStockUnitsRSUMemberusgaapAwardTypeAxis_TwoThousandFifteenEquityIncentivePlanMemberusgaapPlanNameAxis" unitRef="Unit_USD" decimals="INF" scale="0" format="ixt-sec:numwordsen"><ix:nonFraction name="us-gaap:AllocatedShareBasedCompensationExpense" contextRef="P04_01_2021To06_30_2021_RestrictedStockUnitsRSUMemberusgaapAwardTypeAxis_TwoThousandFifteenEquityIncentivePlanMemberusgaapPlanNameAxis" unitRef="Unit_USD" decimals="INF" scale="0" format="ixt-sec:numwordsen">no</ix:nonFraction></ix:nonFraction> share-based compensation expense related to these restricted stock units. The Company will recognize the expense upon achievement of both the time-based service requirement and liquidity requirements through the requisite </div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0in;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">service period.</div></div></div></ix:continuation> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px; text-indent: 0px;;display:inline;">F-</div></div><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">58</div></div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> </div><hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/><div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em; text-align: left;;font-weight: bold;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><a href="#toc" style="text-indent: 0px;">Table of Contents</a></div></div><div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"><ix:continuation id="TextSelectionAppend_28230178_2" continuedAt="TextSelectionAppend_28230178_3"> <ix:nonNumeric name="us-gaap:ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock" contextRef="P04_01_2021To06_30_2021" escape="true"><div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">A summary of restricted stock units under the RSL 2015 EIP is as follows: </div></div></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;width:68%;">
<tr style="font-size: 0px;">
<td style="width: 77%;"></td>
<td style="width: 10%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Number&#160;of<br/> Restricted&#160;Stock<br/> Units</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top; width: 77%;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">Non-vested</div> balance at March&#160;31, 2021</div></td>
<td style="vertical-align: bottom; width: 10%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" contextRef="PAsOn03_31_2021_RestrictedStockUnitsRSUMemberusgaapAwardTypeAxis_TwoThousandFifteenEquityIncentivePlanMemberusgaapPlanNameAxis" unitRef="Unit_shares" decimals="INF" scale="0" format="ixt:numdotdecimal">2,292,738</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; width: 77%;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Granted</div></div></td>
<td style="vertical-align: bottom; width: 10%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" contextRef="P04_01_2021To06_30_2021_RestrictedStockUnitsRSUMemberusgaapAwardTypeAxis_TwoThousandFifteenEquityIncentivePlanMemberusgaapPlanNameAxis" unitRef="Unit_shares" decimals="INF" scale="0" format="ixt:numdotdecimal">5,939,340</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top; width: 77%;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Forfeited</div></div></td>
<td style="vertical-align: bottom; width: 10%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(<ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" contextRef="P04_01_2021To06_30_2021_RestrictedStockUnitsRSUMemberusgaapAwardTypeAxis_TwoThousandFifteenEquityIncentivePlanMemberusgaapPlanNameAxis" unitRef="Unit_shares" decimals="INF" scale="0" format="ixt:numdotdecimal">119,285</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 77%;">&#160;</td>
<td style="vertical-align: bottom; width: 10%;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; width: 77%;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">Non-vested</div> balance at June&#160;30, 2021</div></td>
<td style="vertical-align: bottom; width: 10%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" contextRef="PAsOn06_30_2021_RestrictedStockUnitsRSUMemberusgaapAwardTypeAxis_TwoThousandFifteenEquityIncentivePlanMemberusgaapPlanNameAxis" unitRef="Unit_shares" decimals="INF" scale="0" format="ixt:numdotdecimal">8,112,793</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; width: 77%;">&#160;</td>
<td style="vertical-align: bottom; width: 10%;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td></tr></table> </ix:nonNumeric> </ix:continuation> </div></div></div> <div> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;">
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 68%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px; text-indent: 0px;">
<tr style="font-size: 1px;">
<td><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td> </tr> </table> <div style="clear: both; max-height: 0px; text-indent: 0px;"></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt; margin-left: 2%; text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;"><ix:continuation id="TextSelectionAppend_28230178_3" continuedAt="TextSelectionAppend_28230178_4">Performance Options</ix:continuation> </div></div></div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"><ix:continuation id="TextSelectionAppend_28230178_4" continuedAt="TextSelectionAppend_28230178_5">Performance Options will vest upon the achievement of both time-based service requirements and liquidity requirements on or before the grant expiration date of March&#160;31, 2026. As of June&#160;30, 2021, the liquidity event requirement had not been met and was deemed not probable of being met. During the three months ended June&#160;30, 2021 and 2020, the Company recorded <ix:nonFraction name="us-gaap:AllocatedShareBasedCompensationExpense" contextRef="P04_01_2021To06_30_2021_PerformanceOptionsMemberusgaapAwardTypeAxis_TwoThousandFifteenEquityIncentivePlanMemberusgaapPlanNameAxis" unitRef="Unit_USD" decimals="INF" scale="0" format="ixt-sec:numwordsen"><ix:nonFraction name="us-gaap:AllocatedShareBasedCompensationExpense" contextRef="P04_01_2020To06_30_2020_PerformanceOptionsMemberusgaapAwardTypeAxis_TwoThousandFifteenEquityIncentivePlanMemberusgaapPlanNameAxis" unitRef="Unit_USD" decimals="INF" scale="0" format="ixt-sec:numwordsen">no </ix:nonFraction></ix:nonFraction>share-based compensation expense related to these Performance Options. The Company will recognize the expense upon achievement of both the time-based service requirement and liquidity requirements through the requisite service period.</ix:continuation> </div></div> <ix:continuation id="TextSelectionAppend_28230178_5" continuedAt="TextSelectionAppend_28230178_6"> <ix:nonNumeric name="us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" contextRef="P04_01_2021To06_30_2021_PerformanceOptionsMemberusgaapAwardTypeAxis" escape="true"><div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">A summary of Performance Option activity and data under the RSL 2015 EIP for the three months ended June&#160;30, 2021 is as follows: </div></div></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 84%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px; text-indent: 0px;">
<tr style="font-size: 0px;">
<td style="width: 70%;"></td>
<td style="width: 6%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td>
<td style="width: 6%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 1pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Number of<br/> Performance<br/> Options</div></div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Weighted<br/> Average<br/> Exercise&#160;Price</div></div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td> </tr>
<tr style="font-size: 0px;">
<td style="width: 70%;"></td>
<td style="width: 6%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td>
<td style="width: 6%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top; width: 70%;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Performance Options outstanding at March&#160;31, 2021</div></div> </td>
<td style="vertical-align: bottom; width: 6%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" contextRef="PAsOn03_31_2021_PerformanceOptionsMemberusgaapAwardTypeAxis_TwoThousandFifteenEquityIncentivePlanMemberusgaapPlanNameAxis" unitRef="Unit_shares" decimals="INF" scale="0" format="ixt:numdotdecimal">14,425,663</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 6%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" contextRef="PAsOn03_31_2021_PerformanceOptionsMemberusgaapAwardTypeAxis_TwoThousandFifteenEquityIncentivePlanMemberusgaapPlanNameAxis" unitRef="Unit_USD_per_Share" decimals="2" scale="0" format="ixt:numdotdecimal">38.93</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; width: 70%;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Granted</div></div> </td>
<td style="vertical-align: bottom; width: 6%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" contextRef="P04_01_2021To06_30_2021_PerformanceOptionsMemberusgaapAwardTypeAxis_TwoThousandFifteenEquityIncentivePlanMemberusgaapPlanNameAxis" unitRef="Unit_shares" decimals="INF" scale="0" format="ixt:zerodash">&#8212;</ix:nonFraction>&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 6%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" contextRef="P04_01_2021To06_30_2021_PerformanceOptionsMemberusgaapAwardTypeAxis_TwoThousandFifteenEquityIncentivePlanMemberusgaapPlanNameAxis" unitRef="Unit_USD_per_Share" decimals="0" scale="0" format="ixt:zerodash">&#8212;</ix:nonFraction>&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top; width: 70%;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Forfeited</div></div> </td>
<td style="vertical-align: bottom; width: 6%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" contextRef="P04_01_2021To06_30_2021_PerformanceOptionsMemberusgaapAwardTypeAxis_TwoThousandFifteenEquityIncentivePlanMemberusgaapPlanNameAxis" unitRef="Unit_shares" decimals="INF" scale="0" format="ixt:zerodash">&#8212;</ix:nonFraction>&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 6%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" contextRef="P04_01_2021To06_30_2021_PerformanceOptionsMemberusgaapAwardTypeAxis_TwoThousandFifteenEquityIncentivePlanMemberusgaapPlanNameAxis" unitRef="Unit_USD_per_Share" decimals="0" scale="0" format="ixt:zerodash">&#8212;</ix:nonFraction>&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 70%;">&#160;</td>
<td style="vertical-align: bottom; width: 6%;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom; width: 6%;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; width: 70%;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Performance Options outstanding at June&#160;30, 2021</div></div> </td>
<td style="vertical-align: bottom; width: 6%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" contextRef="PAsOn06_30_2021_PerformanceOptionsMemberusgaapAwardTypeAxis_TwoThousandFifteenEquityIncentivePlanMemberusgaapPlanNameAxis" unitRef="Unit_shares" decimals="INF" scale="0" format="ixt:numdotdecimal">14,425,663</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 6%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" contextRef="PAsOn06_30_2021_PerformanceOptionsMemberusgaapAwardTypeAxis_TwoThousandFifteenEquityIncentivePlanMemberusgaapPlanNameAxis" unitRef="Unit_USD_per_Share" decimals="2" scale="0" format="ixt:numdotdecimal">38.93</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 70%;">&#160;</td>
<td style="vertical-align: bottom; width: 6%;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom; width: 6%;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td> </tr> </table> </ix:nonNumeric></ix:continuation> <ix:continuation id="TextSelectionAppend_28230178_6" continuedAt="TextSelectionAppend_28230178_7"> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt; margin-left: 2%;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">CVARs </div></div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">CVARs will vest upon the achievement of both time-based service requirements and liquidity requirements on or before the grant expiration date of March&#160;31, 2026. At settlement, each CVAR pays the excess in shares of (a)&#160;the lesser of (i)&#160;the fair market value of a common share as of the settlement date or (ii)&#160;the cap of $<div style="letter-spacing: 0px; top: 0px;;display:inline;">37.10</div>, over (b)&#160;the hurdle price of either $<div style="letter-spacing: 0px; top: 0px;;display:inline;">18.70 </div>or $<div style="letter-spacing: 0px; top: 0px;;display:inline;">33.63</div>, as applicable to each grant. As of June&#160;30, 2021, the liquidity event requirement had not been met and was deemed not probable of being met. During the three months ended June&#160;30, 2021 and 2020, the Company recorded <ix:nonFraction name="us-gaap:AllocatedShareBasedCompensationExpense" contextRef="P04_01_2020To06_30_2020_CappedValueAppreciationRightsMemberusgaapAwardTypeAxis_TwoThousandFifteenEquityIncentivePlanMemberusgaapPlanNameAxis" unitRef="Unit_USD" decimals="INF" scale="0" format="ixt-sec:numwordsen"><ix:nonFraction name="us-gaap:AllocatedShareBasedCompensationExpense" contextRef="P04_01_2021To06_30_2021_CappedValueAppreciationRightsMemberusgaapAwardTypeAxis_TwoThousandFifteenEquityIncentivePlanMemberusgaapPlanNameAxis" unitRef="Unit_USD" decimals="INF" scale="0" format="ixt-sec:numwordsen">no</ix:nonFraction></ix:nonFraction> share-based compensation expense related to these CVARs. The Company will recognize the expense upon achievement of both the time-based service requirement and liquidity requirements through the requisite service period<div style="letter-spacing: 0px; top: 0px;;display:inline;">.</div></div></div> </ix:continuation> <ix:continuation id="TextSelectionAppend_28230178_7" continuedAt="TextSelectionAppend_28230178_8"> <ix:nonNumeric name="us-gaap:ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock" contextRef="P04_01_2021To06_30_2021_CappedValueAppreciationRightsMemberusgaapAwardTypeAxis" escape="true"><div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">A summary of CVARs under the RSL 2015 EIP is as follows: </div></div></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 68%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px; text-indent: 0px;">
<tr style="font-size: 0px;">
<td style="width: 81%;"></td>
<td style="width: 4%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 1pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Number of<br/> CVARs</div></div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td> </tr>
<tr style="font-size: 0px;">
<td style="width: 81%;"></td>
<td style="width: 4%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top; width: 81%;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">Non-vested</div> balance at March&#160;31, 2021</div> </td>
<td style="vertical-align: bottom; width: 4%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" contextRef="PAsOn03_31_2021_CappedValueAppreciationRightsMemberusgaapAwardTypeAxis_TwoThousandFifteenEquityIncentivePlanMemberusgaapPlanNameAxis" unitRef="Unit_shares" decimals="INF" scale="0" format="ixt:numdotdecimal">11,088,658</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; width: 81%;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Granted</div></div> </td>
<td style="vertical-align: bottom; width: 4%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" contextRef="P04_01_2021To06_30_2021_CappedValueAppreciationRightsMemberusgaapAwardTypeAxis_TwoThousandFifteenEquityIncentivePlanMemberusgaapPlanNameAxis" unitRef="Unit_shares" decimals="INF" scale="0" format="ixt:zerodash">&#8212;</ix:nonFraction>&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top; width: 81%;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Forfeited</div></div> </td>
<td style="vertical-align: bottom; width: 4%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" contextRef="P04_01_2021To06_30_2021_CappedValueAppreciationRightsMemberusgaapAwardTypeAxis_TwoThousandFifteenEquityIncentivePlanMemberusgaapPlanNameAxis" unitRef="Unit_shares" decimals="INF" scale="0" format="ixt:zerodash">&#8212;</ix:nonFraction>&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 81%;">&#160;</td>
<td style="vertical-align: bottom; width: 4%;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; width: 81%;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">Non-vested</div> balance at June&#160;30, 2021</div> </td>
<td style="vertical-align: bottom; width: 4%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" contextRef="PAsOn06_30_2021_CappedValueAppreciationRightsMemberusgaapAwardTypeAxis_TwoThousandFifteenEquityIncentivePlanMemberusgaapPlanNameAxis" unitRef="Unit_shares" decimals="INF" scale="0" format="ixt:numdotdecimal">11,088,658</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; width: 81%;">&#160;</td>
<td style="vertical-align: bottom; width: 4%;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td> </tr> </table> </ix:nonNumeric></ix:continuation> <div style="clear: both; max-height: 0px;"></div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">F-<div style="letter-spacing: 0px; top: 0px;;display:inline;">59</div> </div></div></div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> </div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em; text-align: left;;font-weight: bold;"><div style="display:inline;"><a href="#toc" style="text-indent: 0px;">Table of Contents</a></div></div> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"><ix:continuation id="TextSelectionAppend_28230178_8" continuedAt="TextSelectionAppend_28230178_9"> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">(B) RSL 2015 Restricted Stock Unit Plan </div></div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Under the Amended and Restated RSL 2015 Restricted Stock Unit Plan (the &#8220;pRSU Plan&#8221;), as of June&#160;30, 2021, there are <ix:nonFraction name="us-gaap:CommonStockCapitalSharesReservedForFutureIssuance" contextRef="PAsOn06_30_2021_PerformanceRestrictedStockUnitsPlanMemberusgaapPlanNameAxis" unitRef="Unit_shares" decimals="INF" scale="0" format="ixt:numdotdecimal">200,000</ix:nonFraction> of the Company&#8217;s common shares reserved for the granting under the pRSU Plan of restricted stock units (&#8220;Performance RSUs&#8221;) to the Company&#8217;s employees, officers, directors and consultants. The Performance RSUs expire <ix:nonNumeric name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" contextRef="P04_01_2021To06_30_2021_PerformanceRestrictedStockUnitsPlanMemberusgaapPlanNameAxis" format="ixt-sec:durwordsen">eight years</ix:nonNumeric> after the date of grant. At June&#160;30, 2021, there are no common shares available for future grants under this plan.&#160;</div></div> </ix:continuation> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"></div> </div> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"><ix:continuation id="TextSelectionAppend_28230178_9" continuedAt="TextSelectionAppend_28230178_10"> <ix:nonNumeric name="us-gaap:ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock" contextRef="P04_01_2021To06_30_2021_PerformanceRestrictedStockUnitsMemberusgaapAwardTypeAxis" escape="true"><div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">A summary of Performance RSU activity under the pRSU Plan is as follows: </div></div></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 68%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px; text-indent: 0px;">
<tr style="font-size: 0px;">
<td style="width: 81%;"></td>
<td style="width: 8%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 1pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Number of<br/> Performance<br/> RSUs</div></div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td> </tr>
<tr style="font-size: 0px;">
<td style="width: 85%;"></td>
<td style="width: 6%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">Non-vested</div> balance at March&#160;31, 2021</div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" contextRef="PAsOn03_31_2021_PerformanceRestrictedStockUnitsMemberusgaapAwardTypeAxis_PerformanceRestrictedStockUnitsPlanMemberusgaapPlanNameAxis" unitRef="Unit_shares" decimals="INF" scale="0" format="ixt:numdotdecimal">200,000</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; break-inside: avoid;">
<td style="vertical-align: top; background-color: rgb(255, 255, 255);"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Granted</div></div> </td>
<td style="vertical-align: bottom; background-color: rgb(255, 255, 255);">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(255, 255, 255);">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(255, 255, 255);;text-align:right;"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" contextRef="P04_01_2021To06_30_2021_PerformanceRestrictedStockUnitsMemberusgaapAwardTypeAxis_PerformanceRestrictedStockUnitsPlanMemberusgaapPlanNameAxis" unitRef="Unit_shares" decimals="INF" scale="0" format="ixt:zerodash">&#8212;</ix:nonFraction>&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(255, 255, 255);">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; background-color: rgb(204, 238, 255);"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Forfeited</div></div> </td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255);">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" contextRef="P04_01_2021To06_30_2021_PerformanceRestrictedStockUnitsMemberusgaapAwardTypeAxis_PerformanceRestrictedStockUnitsPlanMemberusgaapPlanNameAxis" unitRef="Unit_shares" decimals="INF" scale="0" format="ixt:zerodash">&#8212;</ix:nonFraction>&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);">&#160;</td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; background-color: rgb(255, 255, 255);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(255, 255, 255);">&#160;&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="background-color: rgb(255, 255, 255);">&#160;</td> </tr>
<tr style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; break-inside: avoid;">
<td style="vertical-align: top; background-color: rgb(255, 255, 255);"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">Non-vested</div> balance at June&#160;30, 2021</div> </td>
<td style="vertical-align: bottom; background-color: rgb(255, 255, 255);">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(255, 255, 255);">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(255, 255, 255);;text-align:right;"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" contextRef="PAsOn06_30_2021_PerformanceRestrictedStockUnitsMemberusgaapAwardTypeAxis_PerformanceRestrictedStockUnitsPlanMemberusgaapPlanNameAxis" unitRef="Unit_shares" decimals="INF" scale="0" format="ixt:numdotdecimal">200,000</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(255, 255, 255);">&#160;</td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; background-color: rgb(255, 255, 255);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(255, 255, 255);">&#160;&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="background-color: rgb(255, 255, 255);">&#160;</td> </tr> </table> </ix:nonNumeric></ix:continuation> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"></div> </div> </div> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"><ix:continuation id="TextSelectionAppend_28230178_10" continuedAt="TextSelectionAppend_28230178_11">These Performance RSUs will vest to the extent certain performance criteria are achieved and certain liquidity conditions are satisfied within specified years of the grant date, provided that the recipient has provided continued service through such date. As of June&#160;30, 2021, the performance conditions had not been met and were deemed not probable of being met. During the three months ended June&#160;30, 2021 and 2020, the Company recorded <ix:nonFraction name="us-gaap:AllocatedShareBasedCompensationExpense" contextRef="P04_01_2020To06_30_2020_PerformanceRestrictedStockUnitsMemberusgaapAwardTypeAxis" unitRef="Unit_USD" decimals="INF" scale="0" format="ixt-sec:numwordsen"><ix:nonFraction name="us-gaap:AllocatedShareBasedCompensationExpense" contextRef="P04_01_2021To06_30_2021_PerformanceRestrictedStockUnitsMemberusgaapAwardTypeAxis" unitRef="Unit_USD" decimals="INF" scale="0" format="ixt-sec:numwordsen">no</ix:nonFraction></ix:nonFraction> share-based compensation expense related to these Performance RSUs. The Company will recognize the expense upon achievement of the performance and liquidity conditions through the requisite service period.</ix:continuation> </div></div> <ix:continuation id="TextSelectionAppend_28230178_11" continuedAt="TextSelectionAppend_28230178_12"> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">(C) RSL Restricted Common Stock </div></div></div> <ix:nonNumeric name="us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" contextRef="P04_01_2021To06_30_2021_CommonStockAwardsMemberusgaapAwardTypeAxis" escape="true"><div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">A summary of RSL restricted common stock activity as of June&#160;30, 2021 is as follows: </div></div></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 68%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px; text-indent: 0px;">
<tr style="font-size: 0px;">
<td style="width: 78%;"></td>
<td style="width: 11%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 1pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Number of<br/> Restricted<br/> Common&#160;Stock</div></div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td> </tr>
<tr style="font-size: 0px;">
<td style="width: 83%;"></td>
<td style="width: 8%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">Non-vested</div> balance at March&#160;31, 2021</div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" contextRef="PAsOn03_31_2021_CommonStockAwardsMemberusgaapAwardTypeAxis" unitRef="Unit_shares" decimals="INF" scale="0" format="ixt:numdotdecimal">587,824</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Granted</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" contextRef="P04_01_2021To06_30_2021_CommonStockAwardsMemberusgaapAwardTypeAxis" unitRef="Unit_shares" decimals="INF" scale="0" format="ixt:zerodash">&#8212;</ix:nonFraction>&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Forfeited</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" contextRef="P04_01_2021To06_30_2021_CommonStockAwardsMemberusgaapAwardTypeAxis" unitRef="Unit_shares" decimals="INF" scale="0" format="ixt:zerodash">&#8212;</ix:nonFraction>&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">Non-vested</div> balance at June&#160;30, 2021</div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" contextRef="PAsOn06_30_2021_CommonStockAwardsMemberusgaapAwardTypeAxis" unitRef="Unit_shares" decimals="INF" scale="0" format="ixt:numdotdecimal">587,824</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td> </tr> </table> </ix:nonNumeric> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">For the three months ended June&#160;30, 2021, the Company recorded share-based compensation expense of $<ix:nonFraction name="us-gaap:AllocatedShareBasedCompensationExpense" contextRef="P04_01_2021To06_30_2021_CommonStockAwardsMemberusgaapAwardTypeAxis" unitRef="Unit_USD" decimals="INF" scale="6" format="ixt:numdotdecimal">0.8</ix:nonFraction>&#160;million in relation to the RSL restricted common stock. The RSL restricted common stock will vest upon the achievement of time-based service requirements. </div></div> </ix:continuation> <ix:continuation id="TextSelectionAppend_28230178_12" continuedAt="TextSelectionAppend_28230178_13"> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">(D) Subsidiary Equity Incentive Plans </div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;">Certain wholly owned and majority-owned or controlled subsidiaries of RSL adopt their own equity incentive plan (&#8220;EIP&#8221;). Each EIP is generally structured so that the applicable subsidiary, and its affiliates&#8217; employees, directors, officers and consultants are eligible to receive <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-qualified</div> and incentive stock options, stock appreciation rights, restricted share awards, restricted stock unit awards, and other share awards under their respective EIP. Standard option grants have time-based vesting requirements, generally vesting over a period of <ix:nonNumeric name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" contextRef="P04_01_2021To06_30_2021_SubsidiaryEquityIncentivePlanMemberusgaapPlanNameAxis" format="ixt-sec:durwordsen">four years</ix:nonNumeric> with a contractual term of <ix:nonNumeric name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" contextRef="P04_01_2021To06_30_2021_SubsidiaryEquityIncentivePlanMemberusgaapPlanNameAxis" format="ixt-sec:durwordsen">ten years</ix:nonNumeric>. Such time-based stock options use the Black-Scholes option pricing model. The grant date fair value of awards subject to market conditions is estimated using a Monte Carlo valuation model. For the three months ended June&#160;31, 2021 and 2020, the Company recorded share-based compensation expense of $<ix:nonFraction name="us-gaap:AllocatedShareBasedCompensationExpense" contextRef="P04_01_2021To06_30_2021_SubsidiaryEquityIncentivePlanMemberusgaapPlanNameAxis" unitRef="Unit_USD" decimals="INF" scale="6" format="ixt:numdotdecimal">8.2</ix:nonFraction>&#160;million and $<ix:nonFraction name="us-gaap:AllocatedShareBasedCompensationExpense" contextRef="P04_01_2020To06_30_2020_SubsidiaryEquityIncentivePlanMemberusgaapPlanNameAxis" unitRef="Unit_USD" decimals="INF" scale="6" format="ixt:numdotdecimal">6.5</ix:nonFraction>&#160;million, respectively, in relation to subsidiary EIPs. </div> </ix:continuation> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">F-<div style="letter-spacing: 0px; top: 0px;;display:inline;">60</div> </div></div></div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> </div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em; text-align: left;;font-weight: bold;"><div style="display:inline;"><a href="#toc" style="text-indent: 0px;">Table of Contents</a></div></div> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"><ix:continuation id="TextSelectionAppend_28230178_13" continuedAt="TextSelectionAppend_28230178_14">(E) Share-Based Compensation Expense</ix:continuation> </div></div></div></div> <ix:continuation id="TextSelectionAppend_28230178_14" continuedAt="TextSelectionAppend_28230178_15"> <ix:nonNumeric name="us-gaap:ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock" contextRef="P04_01_2021To06_30_2021" escape="true"><div style="text-indent: 4%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt; padding-top: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Share-based compensation expense was as follows (in thousands): </div></div></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0px; padding-top: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 76%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px; text-indent: 0px;">
<tr style="font-size: 0px;">
<td style="width: 74%;"></td>
<td style="width: 5%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td>
<td style="width: 5%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 1pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td colspan="6" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Three&#160;Months&#160;Ended<br/> June&#160;30,</div></div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 1pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2021</div></div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2020</div></div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top; font-size: 10pt;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; padding-top: 0pt; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Share-based compensation expense recognized as:</div></div></div> </td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td> </tr>
<tr style="font-size: 0px;">
<td style="width: 80%;"></td>
<td style="width: 4%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td>
<td style="width: 4%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; padding-top: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">R&amp;D expenses</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:AllocatedShareBasedCompensationExpense" contextRef="P04_01_2021To06_30_2021_ResearchAndDevelopmentExpenseMemberusgaapIncomeStatementLocationAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">1,615</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:AllocatedShareBasedCompensationExpense" contextRef="P04_01_2020To06_30_2020_ResearchAndDevelopmentExpenseMemberusgaapIncomeStatementLocationAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">1,119</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; padding-top: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">G&amp;A expenses</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:AllocatedShareBasedCompensationExpense" contextRef="P04_01_2021To06_30_2021_GeneralAndAdministrativeExpenseMemberusgaapIncomeStatementLocationAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">17,654</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:AllocatedShareBasedCompensationExpense" contextRef="P04_01_2020To06_30_2020_GeneralAndAdministrativeExpenseMemberusgaapIncomeStatementLocationAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">13,159</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); padding-top: 0pt; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); padding-top: 0pt; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); padding-top: 0pt; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); padding-top: 0pt; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; padding-top: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Total</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:AllocatedShareBasedCompensationExpense" contextRef="P04_01_2021To06_30_2021" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">19,269</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:AllocatedShareBasedCompensationExpense" contextRef="P04_01_2020To06_30_2020" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">14,278</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); padding-top: 0pt; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); padding-top: 0pt; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); padding-top: 0pt; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); padding-top: 0pt; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td> </tr> </table> </ix:nonNumeric></ix:continuation> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"></div> </div> </div> </div> <div><div style="text-align: center;"><div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto; margin-bottom: 10pt; line-height: 10pt;"><div style="text-indent: 4%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0px; margin-bottom: 0px;">&#160;</div><div style="text-indent: 4%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: 12pt;"><ix:continuation id="TextSelectionAppend_28230178_15"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px; text-indent: 0px;;display:inline;">The classification of share-based compensation expense between R&amp;D and G&amp;A expenses in the accompanying condensed consolidated statements of operations is consistent with the classification of grantee&#8217;s salary expense.</div></div></ix:continuation></div><div style="text-indent: 4%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"></div> <ix:nonNumeric name="us-gaap:IncomeTaxDisclosureTextBlock" contextRef="P04_01_2021To06_30_2021" escape="true"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt; text-indent: 0px; line-height: 12pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Note 9&#8212;Income Taxes </div></div></div></div> <div style="text-indent: 4%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt; line-height: 12pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The Company&#8217;s effective tax rate for the three months ended June&#160;30, 2021 and 2020 was<div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div><div style="font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif; letter-spacing: 0px; top: 0px; line-height: 10pt;;display:inline;">(<ix:nonFraction name="us-gaap:EffectiveIncomeTaxRateContinuingOperations" contextRef="P04_01_2021To06_30_2021" unitRef="Unit_pure" decimals="3" scale="-2" sign="-" format="ixt:numdotdecimal">0.1</ix:nonFraction>)</div><div style="font-size: 10pt; line-height: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;, Times, serif; letter-spacing: 0px; top: 0px; line-height: 10pt;;display:inline;">% and (<ix:nonFraction name="us-gaap:EffectiveIncomeTaxRateContinuingOperations" contextRef="P04_01_2020To06_30_2020" unitRef="Unit_pure" decimals="3" scale="-2" sign="-" format="ixt:numdotdecimal">18.1</ix:nonFraction>)</div></div><div style="letter-spacing: 0px; top: 0px;;display:inline;">%, respectively, and is driven by the Company&#8217;s jurisdictional earnings by location and a valuation allowance that eliminates the Company&#8217;s global net deferred tax assets. However, for the three months ended June&#160;30, 2020, the effective tax rate was also favorably impacted by the <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-taxable</div> gains associated with the deconsolidation of subsidiary and changes in fair value of investments. </div></div> <div style="text-indent: 4%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt; line-height: 12pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The Company assesses the realizability of its deferred tax assets at each balance sheet date based on available positive and negative evidence in order to determine the amount which is more likely than not to be realized and records a valuation allowance as necessary. </div></div></div></ix:nonNumeric> <ix:nonNumeric name="us-gaap:CommitmentsAndContingenciesDisclosureTextBlock" contextRef="P04_01_2021To06_30_2021" escape="true" continuedAt="TextSelection_28400627"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt; text-indent: 0px; line-height: 12pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Note 10&#8212;Commitments and Contingencies </div></div></div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt; text-indent: 0px; line-height: 12pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">(A) Significant Agreements </div></div></div></div> <div style="text-indent: 4%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt; line-height: 12pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The Company, primarily through its subsidiaries, has entered into commitments under various asset acquisition and license agreements. Additionally, the Company, through its subsidiaries, enters into agreements with contract service providers to assist in the performance of its R&amp;D activities. Expenditures to contract research organizations and contract manufacturing organizations represent significant costs in the clinical development of its product candidates. Subject to required notice periods and certain obligations under binding purchase orders, the Company can elect to discontinue the work under these agreements at any time. The Company expects to enter into additional collaborative research, contract research, manufacturing, and supplier agreements in the future, which may require upfront payments and long-term commitments of capital resources. </div></div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt; text-indent: 0px; line-height: 12pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">(B) Loss Contingencies </div></div></div></div> <div style="text-indent: 4%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt; line-height: 12pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The Company may be, from time to time, a party to various disputes and claims arising from normal business activities. The Company accrues for loss contingencies when available information indicates that it is probable that a liability has been incurred and the amount of such loss can be reasonably estimated, and if the Company believes that a reasonably possible loss exists, the Company discloses the facts and circumstances of the litigation or claim, including an estimable range, if possible. The Company is currently not involved in any legal proceedings with a probable and estimable material loss. </div></div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt; text-indent: 0px; line-height: 12pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">(C) Intellectual Property Agreements </div></div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">As of June&#160;30, 2021, the Company did not have any ongoing material financial commitments, other than pursuant to various asset acquisition and license agreements. </div></div></div></ix:nonNumeric> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt; text-indent: 0px; line-height: 10pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">F-<div style="letter-spacing: 0px; top: 0px;;display:inline;">61</div> </div></div></div> </div></div><hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/><div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;;font-weight: bold;"><div style="display:inline;"><a href="#toc" style="text-indent: 0px;">Table of Contents</a></div></div><div style="text-align: center;"><div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"><ix:continuation id="TextSelection_28400627"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(D) <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">COVID-19</div> Pandemic </div></div></div><div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">The Company has been actively monitoring the impact of the <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">COVID-19</div> pandemic on its employees and business. Based on guidance issued by federal, state and local authorities, the Company transitioned to a remote work model for its employees in March 2020 and its workforce continues to primarily work remotely. </div></div><div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">The <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">COVID-19</div> pandemic has had a variable impact on clinical trials by disrupting certain study sites. In the conduct of business activities, the Company continues to take actions designed to protect the safety and well-being of its patients and employees. Although some of the Company&#8217;s clinical development timelines have been impacted by delays related to the <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">COVID-19</div> pandemic, the Company has not experienced material financial impacts on its business and operations as a result of the <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">COVID-19</div> pandemic. However, the impact on the Company&#8217;s future results will largely depend on future developments related to <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">COVID-19,</div> which are highly uncertain and cannot be predicted with confidence, such as the emergence of new variants, the ultimate duration and spread of the outbreak, the continuing impact of the <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">COVID-19</div> pandemic on financial markets and the global economy, travel restrictions and social distancing in the United States and other countries, business closures or business disruptions and the effectiveness of actions taken in the United States and other countries to contain, treat, and prevent the disease, including the availability and effectiveness of vaccines. </div></div></ix:continuation></div></div><div style="text-align: center;"><div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"> <ix:nonNumeric name="us-gaap:FairValueDisclosuresTextBlock" contextRef="P04_01_2021To06_30_2021" escape="true" continuedAt="TextSelection_28230205"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Note 11&#8212;Fair Value Measurements </div></div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Recurring Fair Value Measurements </div></div></div> <ix:nonNumeric name="us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock" contextRef="P04_01_2021To06_30_2021" escape="true"><div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The following table sets forth the Company&#8217;s assets and liabilities that are measured at fair value on a recurring basis as of June&#160;30, 2021 and March&#160;31, 2021, by level, within the fair value hierarchy (in thousands): </div></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;width:100%;">
<tr style="font-size: 0px;">
<td style="width: 30%;"></td>
<td style="width: 1%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td>
<td style="width: 1%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td>
<td style="width: 1%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td>
<td style="width: 1%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td>
<td style="width: 1%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td>
<td style="width: 1%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td>
<td style="width: 1%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td>
<td style="width: 1%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;&#160;</td>
<td colspan="14" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">As of June&#160;30, 2021</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;&#160;</td>
<td colspan="14" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">As of March&#160;31, 2021</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Level&#160;1</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Level&#160;2</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Level&#160;3</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Balance as<br/> of&#160;June&#160;30,<br/> 2021</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Level&#160;1</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Level&#160;2</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Level&#160;3</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Balance as<br/> of&#160;March&#160;31,<br/> 2021</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top; width: 30%;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Assets:</div></div></td>
<td style="vertical-align: bottom; width: 1%;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; width: 1%;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; width: 1%;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; width: 1%;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; width: 1%;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; width: 1%;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; width: 1%;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; width: 1%;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; width: 30%;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Money market funds</div></div></td>
<td style="vertical-align: bottom; width: 1%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" contextRef="PAsOn06_30_2021_FairValueInputsLevel1MemberusgaapFairValueByFairValueHierarchyLevelAxis_FairValueMeasurementsRecurringMemberusgaapFairValueByMeasurementFrequencyAxis_MoneyMarketFundsMemberusgaapFairValueByAssetClassAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">1,340,662</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 1%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 1%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 1%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" contextRef="PAsOn06_30_2021_FairValueMeasurementsRecurringMemberusgaapFairValueByMeasurementFrequencyAxis_MoneyMarketFundsMemberusgaapFairValueByAssetClassAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">1,340,662</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 1%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" contextRef="PAsOn03_31_2021_FairValueInputsLevel1MemberusgaapFairValueByFairValueHierarchyLevelAxis_FairValueMeasurementsRecurringMemberusgaapFairValueByMeasurementFrequencyAxis_MoneyMarketFundsMemberusgaapFairValueByAssetClassAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">1,420,597</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 1%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 1%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 1%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" contextRef="PAsOn03_31_2021_FairValueMeasurementsRecurringMemberusgaapFairValueByMeasurementFrequencyAxis_MoneyMarketFundsMemberusgaapFairValueByAssetClassAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">1,420,597</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top; width: 30%;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Investment in Sio common shares</div></div></td>
<td style="vertical-align: bottom; width: 1%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:InvestmentsFairValueDisclosure" contextRef="PAsOn06_30_2021_CommonStockMemberusgaapFairValueByAssetClassAxis_FairValueInputsLevel1MemberusgaapFairValueByFairValueHierarchyLevelAxis_FairValueMeasurementsRecurringMemberusgaapFairValueByMeasurementFrequencyAxis_SioGeneTherapiesIncMemberdeiLegalEntityAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">50,716</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 1%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 1%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 1%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:InvestmentsFairValueDisclosure" contextRef="PAsOn06_30_2021_CommonStockMemberusgaapFairValueByAssetClassAxis_FairValueMeasurementsRecurringMemberusgaapFairValueByMeasurementFrequencyAxis_SioGeneTherapiesIncMemberdeiLegalEntityAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">50,716</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 1%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:InvestmentsFairValueDisclosure" contextRef="PAsOn03_31_2021_CommonStockMemberusgaapFairValueByAssetClassAxis_FairValueInputsLevel1MemberusgaapFairValueByFairValueHierarchyLevelAxis_FairValueMeasurementsRecurringMemberusgaapFairValueByMeasurementFrequencyAxis_SioGeneTherapiesIncMemberdeiLegalEntityAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">48,487</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 1%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 1%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 1%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:InvestmentsFairValueDisclosure" contextRef="PAsOn03_31_2021_CommonStockMemberusgaapFairValueByAssetClassAxis_FairValueMeasurementsRecurringMemberusgaapFairValueByMeasurementFrequencyAxis_SioGeneTherapiesIncMemberdeiLegalEntityAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">48,487</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; width: 30%;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Investment in Arbutus common shares</div></div></td>
<td style="vertical-align: bottom; width: 1%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:InvestmentsFairValueDisclosure" contextRef="PAsOn06_30_2021_ArbutusBiopharmaCorporationMemberdeiLegalEntityAxis_CommonStockMemberusgaapFairValueByAssetClassAxis_FairValueInputsLevel1MemberusgaapFairValueByFairValueHierarchyLevelAxis_FairValueMeasurementsRecurringMemberusgaapFairValueByMeasurementFrequencyAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">48,521</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 1%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 1%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 1%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:InvestmentsFairValueDisclosure" contextRef="PAsOn06_30_2021_ArbutusBiopharmaCorporationMemberdeiLegalEntityAxis_CommonStockMemberusgaapFairValueByAssetClassAxis_FairValueMeasurementsRecurringMemberusgaapFairValueByMeasurementFrequencyAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">48,521</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 1%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:InvestmentsFairValueDisclosure" contextRef="PAsOn03_31_2021_ArbutusBiopharmaCorporationMemberdeiLegalEntityAxis_CommonStockMemberusgaapFairValueByAssetClassAxis_FairValueInputsLevel1MemberusgaapFairValueByFairValueHierarchyLevelAxis_FairValueMeasurementsRecurringMemberusgaapFairValueByMeasurementFrequencyAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">53,325</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 1%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 1%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 1%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:InvestmentsFairValueDisclosure" contextRef="PAsOn03_31_2021_ArbutusBiopharmaCorporationMemberdeiLegalEntityAxis_CommonStockMemberusgaapFairValueByAssetClassAxis_FairValueMeasurementsRecurringMemberusgaapFairValueByMeasurementFrequencyAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">53,325</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top; width: 30%;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Investment in Arbutus convertible preferred shares</div></div></td>
<td style="vertical-align: bottom; width: 1%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 1%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:InvestmentsFairValueDisclosure" contextRef="PAsOn06_30_2021_ArbutusBiopharmaCorporationMemberdeiLegalEntityAxis_ConvertiblePreferredStockMemberusgaapFairValueByAssetClassAxis_FairValueInputsLevel2MemberusgaapFairValueByFairValueHierarchyLevelAxis_FairValueMeasurementsRecurringMemberusgaapFairValueByMeasurementFrequencyAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">69,187</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 1%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 1%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:InvestmentsFairValueDisclosure" contextRef="PAsOn06_30_2021_ArbutusBiopharmaCorporationMemberdeiLegalEntityAxis_ConvertiblePreferredStockMemberusgaapFairValueByAssetClassAxis_FairValueMeasurementsRecurringMemberusgaapFairValueByMeasurementFrequencyAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">69,187</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 1%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 1%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:InvestmentsFairValueDisclosure" contextRef="PAsOn03_31_2021_ArbutusBiopharmaCorporationMemberdeiLegalEntityAxis_ConvertiblePreferredStockMemberusgaapFairValueByAssetClassAxis_FairValueInputsLevel2MemberusgaapFairValueByFairValueHierarchyLevelAxis_FairValueMeasurementsRecurringMemberusgaapFairValueByMeasurementFrequencyAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">76,037</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 1%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 1%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:InvestmentsFairValueDisclosure" contextRef="PAsOn03_31_2021_ArbutusBiopharmaCorporationMemberdeiLegalEntityAxis_ConvertiblePreferredStockMemberusgaapFairValueByAssetClassAxis_FairValueMeasurementsRecurringMemberusgaapFairValueByMeasurementFrequencyAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">76,037</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; width: 30%;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Other investment</div></div></td>
<td style="vertical-align: bottom; width: 1%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:InvestmentsFairValueDisclosure" contextRef="PAsOn06_30_2021_FairValueInputsLevel1MemberusgaapFairValueByFairValueHierarchyLevelAxis_FairValueMeasurementsRecurringMemberusgaapFairValueByMeasurementFrequencyAxis_OtherInvestmentCompaniesMemberusgaapFairValueByAssetClassAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">11,935</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 1%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 1%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 1%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:InvestmentsFairValueDisclosure" contextRef="PAsOn06_30_2021_FairValueMeasurementsRecurringMemberusgaapFairValueByMeasurementFrequencyAxis_OtherInvestmentCompaniesMemberusgaapFairValueByAssetClassAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">11,935</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 1%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:InvestmentsFairValueDisclosure" contextRef="PAsOn03_31_2021_FairValueInputsLevel1MemberusgaapFairValueByFairValueHierarchyLevelAxis_FairValueMeasurementsRecurringMemberusgaapFairValueByMeasurementFrequencyAxis_OtherInvestmentCompaniesMemberusgaapFairValueByAssetClassAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">11,129</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 1%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 1%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 1%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:InvestmentsFairValueDisclosure" contextRef="PAsOn03_31_2021_FairValueMeasurementsRecurringMemberusgaapFairValueByMeasurementFrequencyAxis_OtherInvestmentCompaniesMemberusgaapFairValueByAssetClassAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">11,129</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 30%;">&#160;</td>
<td style="vertical-align: bottom; width: 1%;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom; width: 1%;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom; width: 1%;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom; width: 1%;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom; width: 1%;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom; width: 1%;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom; width: 1%;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom; width: 1%;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top; width: 30%;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Total assets at fair value</div></div></td>
<td style="vertical-align: bottom; width: 1%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:AssetsFairValueDisclosure" contextRef="PAsOn06_30_2021_FairValueInputsLevel1MemberusgaapFairValueByFairValueHierarchyLevelAxis_FairValueMeasurementsRecurringMemberusgaapFairValueByMeasurementFrequencyAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">1,451,834</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 1%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:AssetsFairValueDisclosure" contextRef="PAsOn06_30_2021_FairValueInputsLevel2MemberusgaapFairValueByFairValueHierarchyLevelAxis_FairValueMeasurementsRecurringMemberusgaapFairValueByMeasurementFrequencyAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">69,187</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 1%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 1%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:AssetsFairValueDisclosure" contextRef="PAsOn06_30_2021_FairValueMeasurementsRecurringMemberusgaapFairValueByMeasurementFrequencyAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">1,521,021</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 1%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:AssetsFairValueDisclosure" contextRef="PAsOn03_31_2021_FairValueInputsLevel1MemberusgaapFairValueByFairValueHierarchyLevelAxis_FairValueMeasurementsRecurringMemberusgaapFairValueByMeasurementFrequencyAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">1,533,538</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 1%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:AssetsFairValueDisclosure" contextRef="PAsOn03_31_2021_FairValueInputsLevel2MemberusgaapFairValueByFairValueHierarchyLevelAxis_FairValueMeasurementsRecurringMemberusgaapFairValueByMeasurementFrequencyAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">76,037</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 1%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 1%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:AssetsFairValueDisclosure" contextRef="PAsOn03_31_2021_FairValueMeasurementsRecurringMemberusgaapFairValueByMeasurementFrequencyAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">1,609,575</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 30%;">&#160;</td>
<td style="vertical-align: bottom; width: 1%;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom; width: 1%;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom; width: 1%;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom; width: 1%;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom; width: 1%;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom; width: 1%;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom; width: 1%;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom; width: 1%;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; width: 30%;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Liabilities:</div></div></td>
<td style="vertical-align: bottom; width: 1%;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; width: 1%;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; width: 1%;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; width: 1%;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; width: 1%;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; width: 1%;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; width: 1%;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; width: 1%;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top; text-indent: 0px; width: 30%;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Debt issued by Dermavant to NovaQuest</div></div></td>
<td style="vertical-align: bottom; text-indent: 0px; width: 1%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">$</div></td>
<td style="vertical-align: bottom; white-space: nowrap; text-indent: 0px;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; text-indent: 0px;">&#160;</td>
<td style="vertical-align: bottom; text-indent: 0px; width: 1%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">$</div></td>
<td style="vertical-align: bottom; white-space: nowrap; text-indent: 0px;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; text-indent: 0px;">&#160;</td>
<td style="vertical-align: bottom; text-indent: 0px; width: 1%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">$</div></td>
<td style="vertical-align: bottom; white-space: nowrap; text-indent: 0px;;text-align:right;"><ix:nonFraction name="us-gaap:DebtInstrumentFairValue" contextRef="PAsOn06_30_2021_FairValueInputsLevel3MemberusgaapFairValueByFairValueHierarchyLevelAxis_FairValueMeasurementsRecurringMemberusgaapFairValueByMeasurementFrequencyAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">155,200</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; text-indent: 0px;">&#160;</td>
<td style="vertical-align: bottom; text-indent: 0px; width: 1%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">$</div></td>
<td style="vertical-align: bottom; white-space: nowrap; text-indent: 0px;;text-align:right;"><ix:nonFraction name="us-gaap:DebtInstrumentFairValue" contextRef="PAsOn06_30_2021_FairValueMeasurementsRecurringMemberusgaapFairValueByMeasurementFrequencyAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">155,200</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; text-indent: 0px;">&#160;</td>
<td style="vertical-align: bottom; text-indent: 0px; width: 1%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">$</div></td>
<td style="vertical-align: bottom; white-space: nowrap; text-indent: 0px;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; text-indent: 0px;">&#160;</td>
<td style="vertical-align: bottom; text-indent: 0px; width: 1%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">$</div></td>
<td style="vertical-align: bottom; white-space: nowrap; text-indent: 0px;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; text-indent: 0px;">&#160;</td>
<td style="vertical-align: bottom; text-indent: 0px; width: 1%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">$</div></td>
<td style="vertical-align: bottom; white-space: nowrap; text-indent: 0px;;text-align:right;"><ix:nonFraction name="us-gaap:DebtInstrumentFairValue" contextRef="PAsOn03_31_2021_FairValueInputsLevel3MemberusgaapFairValueByFairValueHierarchyLevelAxis_FairValueMeasurementsRecurringMemberusgaapFairValueByMeasurementFrequencyAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">150,100</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; text-indent: 0px;">&#160;</td>
<td style="vertical-align: bottom; text-indent: 0px; width: 1%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">$</div></td>
<td style="vertical-align: bottom; white-space: nowrap; text-indent: 0px;;text-align:right;"><ix:nonFraction name="us-gaap:DebtInstrumentFairValue" contextRef="PAsOn03_31_2021_FairValueMeasurementsRecurringMemberusgaapFairValueByMeasurementFrequencyAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">150,100</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; text-indent: 0px;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; width: 30%;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Liability instruments measured at fair value</div></div></td>
<td style="vertical-align: bottom; width: 1%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 1%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 1%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:DerivativeInstrumentsNotDesignatedAsHedgingInstrumentsLiabilityAtFairValue" contextRef="PAsOn06_30_2021_FairValueInputsLevel3MemberusgaapFairValueByFairValueHierarchyLevelAxis_FairValueMeasurementsRecurringMemberusgaapFairValueByMeasurementFrequencyAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">5,906</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 1%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:DerivativeInstrumentsNotDesignatedAsHedgingInstrumentsLiabilityAtFairValue" contextRef="PAsOn06_30_2021_FairValueMeasurementsRecurringMemberusgaapFairValueByMeasurementFrequencyAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">5,906</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 1%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 1%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 1%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:DerivativeInstrumentsNotDesignatedAsHedgingInstrumentsLiabilityAtFairValue" contextRef="PAsOn03_31_2021_FairValueInputsLevel3MemberusgaapFairValueByFairValueHierarchyLevelAxis_FairValueMeasurementsRecurringMemberusgaapFairValueByMeasurementFrequencyAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">67,893</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 1%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:DerivativeInstrumentsNotDesignatedAsHedgingInstrumentsLiabilityAtFairValue" contextRef="PAsOn03_31_2021_FairValueMeasurementsRecurringMemberusgaapFairValueByMeasurementFrequencyAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">67,893</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 30%;">&#160;</td>
<td style="vertical-align: bottom; width: 1%;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom; width: 1%;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom; width: 1%;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom; width: 1%;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom; width: 1%;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom; width: 1%;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom; width: 1%;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom; width: 1%;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top; width: 30%;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Total liabilities at fair value</div></div></td>
<td style="vertical-align: bottom; width: 1%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 1%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 1%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:LiabilitiesFairValueDisclosure" contextRef="PAsOn06_30_2021_FairValueInputsLevel3MemberusgaapFairValueByFairValueHierarchyLevelAxis_FairValueMeasurementsRecurringMemberusgaapFairValueByMeasurementFrequencyAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">161,106</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 1%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:LiabilitiesFairValueDisclosure" contextRef="PAsOn06_30_2021_FairValueMeasurementsRecurringMemberusgaapFairValueByMeasurementFrequencyAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">161,106</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 1%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 1%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 1%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:LiabilitiesFairValueDisclosure" contextRef="PAsOn03_31_2021_FairValueInputsLevel3MemberusgaapFairValueByFairValueHierarchyLevelAxis_FairValueMeasurementsRecurringMemberusgaapFairValueByMeasurementFrequencyAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">217,993</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 1%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:LiabilitiesFairValueDisclosure" contextRef="PAsOn03_31_2021_FairValueMeasurementsRecurringMemberusgaapFairValueByMeasurementFrequencyAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">217,993</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 30%;">&#160;</td>
<td style="vertical-align: bottom; width: 1%;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom; width: 1%;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom; width: 1%;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom; width: 1%;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom; width: 1%;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom; width: 1%;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom; width: 1%;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom; width: 1%;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td></tr></table> </ix:nonNumeric> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">There were no transfers of assets between Level&#160;1 and Level&#160;2 of the fair value measurement hierarchy that occurred during the three months ended June&#160;30, 2021. </div></div></div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div></ix:nonNumeric> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">F-<div style="letter-spacing: 0px; top: 0px;;display:inline;">62</div> </div></div></div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> </div><hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/><div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em; text-align: left;;font-weight: bold;"><div style="display:inline;"><a href="#toc" style="text-indent: 0px;">Table of Contents</a></div></div><div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 2%; text-indent: 0px;"></div><ix:continuation id="TextSelection_28230205" continuedAt="TextSelectionAppend_28230205_1"> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 2%;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Level&#160;3 Disclosures </div></div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The Company measures its Level&#160;3 liabilities at fair value based on significant inputs not observable in the market, which causes them to be classified as a Level&#160;3 measurement within the fair value hierarchy. The valuation of the Level&#160;3 liabilities uses assumptions and estimates the Company believes would be made by a market participant in making the same valuation. The Company assesses these assumptions and estimates on an ongoing basis as additional data impacting the assumptions and estimates are obtained. Changes in the fair value related to updated assumptions and estimates are recorded within the statements of operations at the end of each reporting period. </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The fair value of Level&#160;3 liabilities may change significantly as additional data are obtained, impacting the Company&#8217;s assumptions regarding probabilities of potential scenarios used to estimate fair value. In evaluating this information, considerable judgment is required to interpret the data used to develop the assumptions and estimates. Accordingly, the use of different market assumptions and/or different valuation techniques may have a material effect on the estimated fair value amounts, and such changes could materially impact the Company&#8217;s results of operations in future periods. </div></div> <ix:nonNumeric name="us-gaap:FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock" contextRef="P04_01_2021To06_30_2021" escape="true"><div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The changes in fair value of the Level&#160;3 liabilities during the three months ended June&#160;30, 2021 and 2020 were as follows (in thousands): </div></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;width:68%;">
<tr style="font-size: 0px;">
<td style="width: 83%; font-family: &quot;Times New Roman&quot;;"></td>
<td style="width: 7%; vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="font-family: &quot;Times New Roman&quot;;"></td>
<td style="font-family: &quot;Times New Roman&quot;;"></td>
<td style="font-family: &quot;Times New Roman&quot;;"></td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top; width: 83%;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Balance at March&#160;31, 2020</div></div></td>
<td style="vertical-align: bottom; width: 7%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" contextRef="PAsOn03_31_2020_FairValueInputsLevel3MemberusgaapFairValueByFairValueHierarchyLevelAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">191,473</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; width: 83%;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Changes in fair value of debt and liability instruments, included in net loss</div></div></td>
<td style="vertical-align: bottom; width: 7%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings" contextRef="P04_01_2020To06_30_2020_FairValueInputsLevel3MemberusgaapFairValueByFairValueHierarchyLevelAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">17,125</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top; width: 83%;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Liability instruments disposed due to deconsolidation of subsidiary</div></div></td>
<td style="vertical-align: bottom; width: 7%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(<ix:nonFraction name="roiv:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityDisposedDueToDeconsolidationOfSubsidiary" contextRef="P04_01_2020To06_30_2020_FairValueInputsLevel3MemberusgaapFairValueByFairValueHierarchyLevelAxis" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:numdotdecimal">3,325</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 83%;">&#160;</td>
<td style="vertical-align: bottom; width: 7%;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; width: 83%;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Balance at June&#160;30, 2020</div></div></td>
<td style="vertical-align: bottom; width: 7%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" contextRef="PAsOn06_30_2020_FairValueInputsLevel3MemberusgaapFairValueByFairValueHierarchyLevelAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">205,273</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 83%;">&#160;</td>
<td style="vertical-align: bottom; width: 7%;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td></tr>
<tr>
<td style="vertical-align: top; line-height: 5pt; font-size: 5pt; width: 83%;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 5pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: 5pt;"><div style="font-size: 5pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom; line-height: 5pt; font-size: 5pt; width: 7%;"><div style="font-size: 5pt; line-height: 5pt;"><div style="font-size: 5pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap; line-height: 5pt; font-size: 5pt;"><div style="font-size: 5pt; line-height: 5pt;"><div style="font-size: 5pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap; line-height: 5pt; font-size: 5pt;;text-align:right;"><div style="font-size: 5pt; line-height: 5pt;"><div style="font-size: 5pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap; line-height: 5pt; font-size: 5pt;"><div style="font-size: 5pt; line-height: 5pt;"><div style="font-size: 5pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top; width: 83%;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Balance at March&#160;31, 2021</div></div></td>
<td style="vertical-align: bottom; width: 7%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" contextRef="PAsOn03_31_2021_FairValueInputsLevel3MemberusgaapFairValueByFairValueHierarchyLevelAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">217,993</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; width: 83%;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Changes in fair value of debt and liability instruments, included in net loss</div></div></td>
<td style="vertical-align: bottom; width: 7%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings" contextRef="P04_01_2021To06_30_2021_FairValueInputsLevel3MemberusgaapFairValueByFairValueHierarchyLevelAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">4,585</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top; width: 83%;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Termination of DSP Options</div></div></td>
<td style="vertical-align: bottom; width: 7%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(<ix:nonFraction name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements" contextRef="P04_01_2021To06_30_2021_FairValueInputsLevel3MemberusgaapFairValueByFairValueHierarchyLevelAxis" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:numdotdecimal">61,472</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 83%;">&#160;</td>
<td style="vertical-align: bottom; width: 7%;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; width: 83%;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Balance at June&#160;30, 2021</div></div></td>
<td style="vertical-align: bottom; width: 7%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" contextRef="PAsOn06_30_2021_FairValueInputsLevel3MemberusgaapFairValueByFairValueHierarchyLevelAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">161,106</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 83%;">&#160;</td>
<td style="vertical-align: bottom; width: 7%;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td></tr></table> </ix:nonNumeric> </ix:continuation> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"></div> </div></div></div> <div> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"><ix:continuation id="TextSelectionAppend_28230205_1"> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Debt issued by Dermavant to NovaQuest </div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The fair value of the debt instrument as of June&#160;30, 2021 and March&#160;31, 2021 represents the fair value of amounts payable to NovaQuest using a Monte Carlo simulation model under the income approach determined by using probability assessments of the expected future payments through 2032 and applying discount rates ranging from <span style="-sec-ix-hidden:hidden28229202">11</span>% to <span style="-sec-ix-hidden:hidden28229201">12</span>%. The future payments are based on significant inputs that are not observable in the market which are subject to remeasurement at each reporting date. The estimates of fair value may not be indicative of the amounts that could ultimately be paid by Dermavant to NovaQuest. </div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Sumitomo Options </div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">In June 2021, the Company completed a transaction with Sumitomo pursuant to which the Sumitomo Options were terminated, resulting in the extinguishment of the related liability. As of the termination date, the fair value of the Sumitomo Options was </div></div><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">$<ix:nonFraction name="roiv:EquityInterestOptionToThirdPartyPurchaser" contextRef="PAsOn03_31_2021" unitRef="Unit_USD" decimals="-5" scale="6" format="ixt:numdotdecimal">61.5</ix:nonFraction>&#160;million, and as of March&#160;31, 2021, the fair value was $<ix:nonFraction name="roiv:EquityInterestOptionToThirdPartyPurchaser" contextRef="PAsOn06_30_2021" unitRef="Unit_USD" decimals="-5" scale="6" format="ixt:numdotdecimal">62.4</ix:nonFraction>&#160;million. See Note 4, &#8220;Sumitomo Transaction Agreement&#8221; for additional information. </div></div> </ix:continuation> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"></div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">F-<div style="letter-spacing: 0px; top: 0px;;display:inline;">63</div> </div></div></div> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0px;"></div> </div> </div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;;font-weight: bold;"><div style="display:inline;"><a href="#toc" style="text-indent: 0px;">Table of Contents</a></div></div> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"> <ix:nonNumeric name="us-gaap:OtherOperatingIncomeAndExpenseTextBlock" contextRef="P04_01_2021To06_30_2021" escape="true"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Note 12&#8212;Other (Income) Expense, Net </div></div></div></div> <ix:nonNumeric name="us-gaap:ScheduleOfOtherOperatingCostAndExpenseByComponentTextBlock" contextRef="P04_01_2021To06_30_2021" escape="true"><div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Other (income) expense, net was as follows (in thousands): </div></div></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 76%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px; text-indent: 0px;">
<tr style="font-size: 0px;">
<td style="width: 75%;"></td>
<td style="width: 7%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td>
<td style="width: 7%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 1pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td colspan="6" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Three&#160;Months&#160;Ended<br/> June&#160;30,</div></div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 1pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2021</div></div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2020</div></div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td> </tr>
<tr style="font-size: 0px;">
<td style="width: 80%;"></td>
<td style="width: 6%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td>
<td style="width: 5%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Loss from equity method investment</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:IncomeLossFromEquityMethodInvestments" contextRef="P04_01_2021To06_30_2021" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:zerodash">&#8212;</ix:nonFraction>&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:IncomeLossFromEquityMethodInvestments" contextRef="P04_01_2020To06_30_2020" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:numdotdecimal">3,750</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Interest income</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(<ix:nonFraction name="us-gaap:InterestIncomeOther" contextRef="P04_01_2021To06_30_2021" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">71</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(<ix:nonFraction name="us-gaap:InterestIncomeOther" contextRef="P04_01_2020To06_30_2020" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">621</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Interest expense</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:InterestExpense" contextRef="P04_01_2021To06_30_2021" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">2,513</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:InterestExpense" contextRef="P04_01_2020To06_30_2020" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">791</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Other income</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(<ix:nonFraction name="roiv:OtherIncomeExpense" contextRef="P04_01_2021To06_30_2021" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">2,576</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(<ix:nonFraction name="roiv:OtherIncomeExpense" contextRef="P04_01_2020To06_30_2020" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">1,078</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Total</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(<ix:nonFraction name="us-gaap:OtherOperatingIncomeExpenseNet" contextRef="P04_01_2021To06_30_2021" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:numdotdecimal">134</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:OtherOperatingIncomeExpenseNet" contextRef="P04_01_2020To06_30_2020" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:numdotdecimal">2,842</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td> </tr> </table> </ix:nonNumeric></ix:nonNumeric> <ix:nonNumeric name="us-gaap:EarningsPerShareTextBlock" contextRef="P04_01_2021To06_30_2021" escape="true"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Note 13&#8212;Net Loss per Common Share </div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Basic net loss per common share is computed by dividing net loss attributable to Roivant Sciences Ltd. by the weighted-average number of common stock outstanding during the period. Diluted net loss per common share is computed by dividing the net loss attributable to Roivant Sciences Ltd. by the diluted weighted-average number of common stock outstanding during the period. </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">For periods of loss, diluted loss per share is calculated similar to basic loss per share as the effect of including all potentially dilutive common share equivalents is anti-dilutive. All outstanding common stock equivalents have been excluded from the computation of diluted loss per share because their effect was anti-dilutive due to the net loss. Refer to Note 8, &#8220;Share-Based Compensation&#8221; and Note 4, &#8220;Sumitomo Transaction Agreement&#8221; for additional detail regarding outstanding common stock equivalents. </div></div></ix:nonNumeric> <ix:nonNumeric name="us-gaap:SubsequentEventsTextBlock" contextRef="P04_01_2021To06_30_2021" escape="true"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Note 14&#8212;Subsequent Events </div></div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt; margin-left: 2%;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Proteovant </div></div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">In July 2021, Proteovant Sciences, Inc. (&#8220;Proteovant&#8221;) received the second $<ix:nonFraction name="roiv:SubscriptionsReceivable" contextRef="PAsOn07_31_2021_ProteovantSciencesIncMemberusgaapBusinessAcquisitionAxis_SubsequentEventMemberusgaapSubsequentEventTypeAxis" unitRef="Unit_USD" decimals="-5" scale="6" sign="-" format="ixt:numdotdecimal">100.0</ix:nonFraction>&#160;million payment due under a subscription agreement entered into with SK, Inc. (&#8220;SK&#8221;) in December 2020 pursuant to which SK agreed to make a $<ix:nonFraction name="us-gaap:EquityMethodInvestments" contextRef="PAsOn07_31_2021_ProteovantSciencesIncMemberusgaapBusinessAcquisitionAxis_SubsequentEventMemberusgaapSubsequentEventTypeAxis" unitRef="Unit_USD" decimals="-5" scale="6" format="ixt:numdotdecimal">200.0</ix:nonFraction>&#160;million equity investment in Proteovant, representing an ownership interest of <ix:nonFraction name="us-gaap:EquityMethodInvestmentOwnershipPercentage" contextRef="PAsOn07_31_2021_ProteovantSciencesIncMemberusgaapBusinessAcquisitionAxis_SubsequentEventMemberusgaapSubsequentEventTypeAxis" unitRef="Unit_pure" decimals="3" scale="-2" format="ixt:numdotdecimal">40.0</ix:nonFraction>% on the closing date. The second $<ix:nonFraction name="roiv:SubscriptionsReceivable" contextRef="PAsOn06_30_2021" unitRef="Unit_USD" decimals="-5" scale="6" sign="-" format="ixt:numdotdecimal">100.0</ix:nonFraction>&#160;million payment was classified as a subscription receivable in the accompanying condensed consolidated balance sheets and condensed consolidated statements of shareholders&#8217; equity and redeemable noncontrolling interest as of June&#160;30, 2021.</div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt; margin-left: 2%; text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Datavant </div></div></div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">In July 2021, Datavant closed its merger with CIOX Health, LLC. At closing, RSL received approximately $<ix:nonFraction name="us-gaap:BusinessCombinationConsiderationTransferred1" contextRef="P07_01_2021To07_31_2021_DatavantMemberusgaapBusinessAcquisitionAxis_SubsequentEventMemberusgaapSubsequentEventTypeAxis" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:numdotdecimal">320</ix:nonFraction>&#160;million in cash and a minority equity stake in the combined company.</div></div></ix:nonNumeric> </div> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">F-64 </div></div></div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;;font-weight: bold;"><div style="display:inline;"><a href="#toc" style="text-indent: 0px;">Table of Contents</a></div></div> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"> <div id="fin164680_15" style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">REPORT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM </div></div></div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">To the Stockholders and Board of Directors of </div></div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Montes Archimedes Acquisition Corp. </div></div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Opinion on the Financial Statements </div></div></div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">We have audited the accompanying balance sheet of Montes Archimedes Acquisition Corp. (the &#8220;Company&#8221;) as of December&#160;31, 2020, the related statements of operations, changes in stockholders&#8217; equity and cash flows for the period from July&#160;6, 2020 (inception) through December&#160;31, 2020, and the related notes (collectively referred to as the &#8220;financial statements&#8221;). In our opinion, the financial statements present fairly, in all material respects, the financial position of the Company as of December&#160;31, 2020, and the results of its operations and its cash flows for the period from July&#160;6, 2020 (inception) through December&#160;31, 2020, in conformity with accounting principles generally accepted in the United States of America. </div></div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Restatement of the 2020 Financial Statements </div></div></div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">As discussed in Note 2 to the financial statements, the accompanying financial statements as of December&#160;31, 2020 and for period from July&#160;6, 2020 (inception) through December&#160;31, 2020, have been restated. </div></div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Basis for Opinion </div></div></div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">These financial statements are the responsibility of the Company&#8217;s management. Our responsibility is to express an opinion on the Company&#8217;s financial statements based on our audit. We are a public accounting firm registered with the Public Company Accounting Oversight Board (United States) (&#8220;PCAOB&#8221;) and are required to be independent with respect to the Company in accordance with the U.S. federal securities laws and the applicable rules and regulations of the Securities and Exchange Commission and the PCAOB. </div></div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">We conducted our audit in accordance with the standards of the PCAOB. Those standards require that we plan and perform the audits to obtain reasonable assurance about whether the financial statements are free of material misstatement, whether due to error or fraud. The Company is not required to have, nor were we engaged to perform, an audit of its internal control over financial reporting. As part of our audit we are required to obtain an understanding of internal control over financial reporting but not for the purpose of expressing an opinion on the effectiveness of the Company&#8217;s internal control over financial reporting. Accordingly, we express no such opinion. </div></div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Our audit included performing procedures to assess the risks of material misstatement of the financial statements, whether due to error or fraud, and performing procedures that respond to those risks. Such procedures included examining, on a test basis, evidence regarding the amounts and disclosures in the financial statements. Our audit also included evaluating the accounting principles used and significant estimates made by management, as well as evaluating the overall presentation of the financial statements. We believe that our audit provides a reasonable basis for our opinion. </div></div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">/s/ Marcum&#160;<div style="display:inline;;font-size:11.07px">LLP</div> </div></div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Marcum&#160;<div style="display:inline;;font-size:11.07px">LLP</div> </div></div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">We have served as the Company&#8217;s auditor since 2020. </div></div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Houston, Texas </div></div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">March&#160;22, 2021 except for the effects of the restatement discussed in Note 2 and subsequent events discussed in Note 11 as to which the date is May&#160;13, 2021 </div></div></div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">F-65 </div></div></div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0px;"></div> </div> </div> </div> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;;font-weight: bold;"><div style="display:inline;"><a href="#toc" style="text-indent: 0px;">Table of Contents</a></div></div> <div> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"> <div id="fin164680_16" style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">MONTES ARCHIMEDES ACQUISITION CORP. </div></div></div> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">BALANCE SHEET </div></div></div> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">December&#160;31, 2020 </div></div></div> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">(Restated&#8212;See Note 2) </div></div></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="font-size: 0px;">
<td style="width: 87%; font-family: &quot;Times New Roman&quot;;"></td>
<td style="width: 2%; vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="font-family: &quot;Times New Roman&quot;;"></td>
<td style="font-family: &quot;Times New Roman&quot;;"></td>
<td style="font-family: &quot;Times New Roman&quot;;"></td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Assets:</div></div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Current assets:</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Cash</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">1,696,491</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Prepaid expenses</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">276,093</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Due from underwriters</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">4,877</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Total current assets</div></div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">1,977,461</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Cash and Marketable Securities held in Trust Account</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">410,803,411</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Total Assets</div></div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">$</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">412,780,872</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Liabilities and Stockholders&#8217; Equity:</div></div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Current liabilities:</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Accounts payable</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">207,029</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Accrued expenses</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">240,402</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Accrued income tax</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">16,709</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Franchise tax payable</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">88,583</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Total current liabilities</div></div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">552,723</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Derivative warrant liability</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">49,097,230</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Deferred underwriting commissions</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">14,375,138</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: bottom;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Total liabilities</div></div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">64,025,091</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Commitments and Contingencies</div></div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Class&#160;A common stock, $0.0001 par value; 34,375,578 shares subject to possible redemption at $10.00 per share</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">343,755,780</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-size: 1pt;">
<td style="height: 6pt; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td colspan="4" style="height: 6pt; font-family: &quot;Times New Roman&quot;;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Stockholders&#8217; Equity:</div></div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Preferred stock, $0.0001 par value; 1,000,000 shares authorized; none issued and outstanding</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Class&#160;A common stock, $0.0001 par value; 400,000,000 shares authorized; 6,696,245 shares issued and outstanding (excluding 34,375,578 shares subject to possible redemption)</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">670</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Class&#160;B common stock, $0.0001 par value; 40,000,000 shares authorized; 10,267,956 shares issued and outstanding</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">1,027</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;">Additional <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">paid-in</div> capital</div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">15,772,622</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Accumulated deficit</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(10,774,318</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Total stockholders&#8217; equity</div></div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">5,000,001</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Total Liabilities and Stockholders&#8217; Equity</div></div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">$</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">412,780,872</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">The accompanying notes are an integral part of these financial statements. </div></div></div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">F-66 </div></div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0px;"></div> </div> </div> </div> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;;font-weight: bold;"><a href="#toc" style="text-indent: 0px;">Table of Contents</a></div> <div> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"> <div id="fin164680_17" style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">MONTES ARCHIMEDES ACQUISITION CORP. </div></div></div> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">STATEMENT OF OPERATIONS </div></div></div> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">For the Period From July&#160;6, 2020 (Inception) Through December&#160;31, 2020 </div></div></div> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">(Restated&#8212;See Note 2) </div></div></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="font-size: 0px;">
<td style="width: 87%; font-family: &quot;Times New Roman&quot;;"></td>
<td style="width: 2%; vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="font-family: &quot;Times New Roman&quot;;"></td>
<td style="font-family: &quot;Times New Roman&quot;;"></td>
<td style="font-family: &quot;Times New Roman&quot;;"></td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">General and administrative expenses</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">338,227</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Administrative expenses&#8212;related party</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">28,065</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Franchise tax expense</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">88,583</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Loss from operations</div></div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(454,875</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Other Income:</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Change in fair value of derivative warrant liability</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(3,587,890</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Financing costs&#8212;derivative warrant liability</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(6,800,025</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Interest earned on marketable securities held in Trust Account</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">79,568</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Unrealized gain on marketable securities held in Trust Account</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">5,613</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Net loss before taxes</div></div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(10,757,609</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Income tax expense</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">16,709</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Net loss</div></div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(10,774,318</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Weighted average shares outstanding of common stock subject to redemption, basic and diluted</div></div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">34,386,548</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Basic and diluted net income per share, common stock subject to redemption</div></div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Weighted average shares outstanding of common stock, basic and diluted</div></div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">13,324,191</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Basic and diluted net loss per share, common stock</div></div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(0.81</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">The accompanying notes are an integral part of these financial statements. </div></div></div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">F-67 </div></div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0px;"></div> </div> </div> </div> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;;font-weight: bold;"><a href="#toc" style="text-indent: 0px;">Table of Contents</a></div> <div> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"> <div id="fin164680_18" style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">MONTES ARCHIMEDES ACQUISITION CORP. </div></div></div> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">STATEMENT OF CHANGES IN STOCKHOLDERS&#8217; EQUITY </div></div></div> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">For the Period From July&#160;6, 2020 (Inception) Through December&#160;31, 2020 </div></div></div> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">(Restated&#8212;See Note 2) </div></div></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="font-size: 0px;">
<td style="width: 34%;"></td>
<td style="width: 1%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td>
<td style="width: 1%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td>
<td style="width: 1%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td>
<td style="width: 1%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td>
<td style="width: 1%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td>
<td style="width: 1%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td>
<td style="width: 1%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td rowspan="3" style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td colspan="14" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Common Stock</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td rowspan="3" style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td colspan="2" rowspan="3" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Additional<br/><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">Paid-In</div></div></div><br/><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Capital</div></div></td>
<td rowspan="3" style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td rowspan="3" style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td colspan="2" rowspan="3" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Accumulated<br/>Deficit</div></div></td>
<td rowspan="3" style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td rowspan="3" style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td colspan="2" rowspan="3" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Total</div></div><br/><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Stockholders&#8217;</div></div><br/><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Equity</div></div></td>
<td rowspan="3" style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td colspan="6" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Class&#160;A</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td colspan="6" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Class&#160;B</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Shares</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Amount</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Shares</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Amount</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Balance&#8212;July 6, 2020 (inception)</div></div></div> </td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#8212;&#160;&#160;</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">$</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#8212;&#160;&#160;</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#8212;&#160;&#160;</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">$</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#8212;&#160;&#160;</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">$</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#8212;&#160;&#160;</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">$</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#8212;&#160;&#160;</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">$</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#8212;&#160;&#160;</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: bottom;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Issuance of Class&#160;B common stock to initial stockholders</div></div> </td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">11,500,000</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">1,150</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">23,850</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">25,000</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: bottom;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Sale of units in initial public offering, gross</div></div></div> </td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">41,071,823</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">4,107</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">380,526,333</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">380,530,440</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: bottom;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Offering costs</div></div> </td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(21,025,341</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">)&#160;</div></div></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(21,025,341</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">)&#160;</div></div></td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: bottom;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Common stock subject to possible redemption</div></div></div> </td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(34,375,578</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">)&#160;</div></div></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(3,437</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">)&#160;</div></div></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(343,752,343</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">)&#160;</div></div></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(343,755,780</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">)&#160;</div></div></td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: bottom;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;">Forfeiture <div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">of Class</div></div>&#160;B common stock</div> </td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(1,232,044</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">)&#160;</div></div></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(123</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">)&#160;</div></div></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">123</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: bottom;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Net loss</div></div></div> </td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(10,774,318</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">)&#160;</div></div></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(10,774,318</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">)&#160;</div></div></td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Balance&#8212;December 31, 2020</div></div></div> </td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">6,696,245</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">$</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">670</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">10,267,956</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">$</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">1,027</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">$</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">15,772,622</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">$</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(10,774,318</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">)&#160;</div></div></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">$</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">5,000,001</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="text-align: center; font-family: Times New Roman; font-size: 8pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">The accompanying notes are an integral part of these financial statements. </div></div></div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">F-68 </div></div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0px;"></div> </div> </div> </div> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;;font-weight: bold;"><a href="#toc" style="text-indent: 0px;">Table of Contents</a></div> <div> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"> <div id="fin164680_19" style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">MONTES ARCHIMEDES ACQUISITION CORP. </div></div></div> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">STATEMENT OF CASH FLOWS </div></div></div> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">For the Period From July&#160;6, 2020 (Inception) Through December&#160;31, 2020 </div></div></div> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">(Restated&#8212;See Note 2) </div></div></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="font-size: 0px;">
<td style="width: 86%;"></td>
<td style="width: 3%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Cash Flows from Operating Activities:</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: top; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: top; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: top; font-family: &quot;Times New Roman&quot;;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Net loss</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(10,774,318</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Adjustments to reconcile net (loss) income to net cash used in operating activities:</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Change in fair value of warrant liabilities</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">3,587,890</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Financing cost&#8212;derivative warrant liabilities</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">6,800,025</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Interest earned on marketable securities held in Trust Account</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(79,568</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Unrealized gain on marketable securities held in Trust Account</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(5,613</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Changes in operating assets and liabilities:</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Prepaid expenses</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(260,093</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Accounts payable</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">207,029</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Accrued expenses</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">170,402</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Accrued income tax</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">16,709</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Franchise tax payable</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">88,583</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Net cash used in operating activities</div></div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(248,954</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Cash Flows from Investing Activities</div></div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Cash deposited in Trust Account</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(410,718,230</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Net cash used in investing activities</div></div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(410,718,230</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Cash Flows from Financing Activities:</div></div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Proceeds from note payable to related party</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">200,000</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Repayment of note payable to related party</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(200,000</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Proceeds received from initial public offering, gross</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">410,718,230</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Proceeds received from private placement</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">10,214,366</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Offering costs paid</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(8,797,978</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Reimbursement of offering costs from underwriters</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">529,057</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Net cash provided by financing activities</div></div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">412,663,675</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Net increase in cash</div></div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">1,696,491</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Cash&#8212;beginning of the period</div></div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Cash&#8212;end of the period</div></div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">$</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">1,696,491</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Supplemental disclosure of noncash activities:</div></div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Forfeiture of Class B common stock</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">123</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Offering costs paid by Sponsor in exchange for issuance of Class B common stock</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">9,000</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Prepaid expenses paid by Sponsor in exchange for issuance of Class B common stock</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">16,000</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Offering costs included in accrued expenses</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">70,000</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">The accompanying notes are an integral part of these financial statements. </div></div></div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">F-69 </div></div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0px;"></div> </div> </div> </div> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;;font-weight: bold;"><a href="#toc" style="text-indent: 0px;">Table of Contents</a></div> <div> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"> <div id="fin164680_20" style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Note 1&#8212;Description of Organization, Business Operations and Basis of Presentation </div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Montes Archimedes Acquisition Corp, (the &#8220;Company&#8221;) is a blank check company incorporated in Delaware on July&#160;6, 2020. The Company was formed for the purpose of effecting a merger, capital stock exchange, asset acquisition, stock purchase, reorganization or similar business combination with one or more businesses (the &#8220;Business Combination&#8221;). The Company is an emerging growth company and, as such, the Company is subject to all of the risks associated with emerging growth companies. </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">As of December&#160;31, 2020, the Company had not commenced any operations. All activity for the period from July&#160;6, 2020 (inception) through December&#160;31, 2020 relates to the Company&#8217;s formation and the initial public offering (the &#8220;Initial Public Offering&#8221;) described below, and the search for a target for its initial Business Combination. The Company will not generate any operating revenues until after the completion of its initial Business Combination, at the earliest. The Company will generate <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-operating</div> income in the form of interest income on cash and cash equivalents from the proceeds derived from the Initial Public Offering and placed in Trust Account (as defined below). The Company has selected December&#160;31 as its fiscal year end. </div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The Company&#8217;s sponsor is Patient Square Capital LLC (the &#8220;Sponsor&#8221;). The registration statement for the Company&#8217;s Initial Public Offering was declared effective on October&#160;6, 2020. On October&#160;9, 2020, the Company consummated its Initial Public Offering of 40,000,000 units (the &#8220;Units&#8221;) at $10.00 per Unit, generating gross proceeds of $400.0&#160;million, and incurring offering costs of approximately $22.1&#160;million (net of reimbursement of offering costs of $520,000 from the underwriters), inclusive of $14.0&#160;million in deferred underwriting commissions (Note 6). The underwriters exercised the over-allotment option in part and on November&#160;12, 2020 purchased an additional 1,071,823 Units (the &#8220;Over-Allotment Units&#8221;), generating gross proceeds of approximately $10.7&#160;million, and incurred additional offering costs of approximately $576,000 in underwriting fees (net of reimbursement of offering costs of approximately $14,000 from the underwriters and inclusive of approximately $375,000 in deferred underwriting fees) (the &#8220;Over-Allotment&#8221;). </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Simultaneously with the closing of the Initial Public Offering, the Company consummated the private placement (&#8220;Private Placement&#8221;) of 10,000,000 warrants (each, a &#8220;Private Placement Warrant&#8221; and collectively, the &#8220;Private Placement Warrants&#8221;) at a price of $1.00 per Private Placement Warrant to the Sponsor, generating proceeds of $10.0&#160;million (Note 5). Simultaneously with the closing of the Over-allotment on November&#160;12, 2020, the Company consummated the second closing of the Private Placement, resulting in the purchase of an aggregate of an additional 214,365 Private Placement Warrants by the Sponsor, generating gross proceeds to the Company of approximately $214,000. </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">Upon the closing of the Initial Public Offering, the Over-Allotment, and the Private Placement, approximately $410.7&#160;million ($10.00 per Unit) of the net proceeds of the sale of the Units in the Initial Public Offering and of the Private Placement Warrants in the Private Placement were placed in a trust account (&#8220;Trust Account&#8221;) located in the United States with Continental Stock Transfer&#160;&amp; Trust Company acting as trustee, and invested only in U.S. &#8220;government securities,&#8221; within the meaning set forth in Section&#160;2(a)( 16) of the Investment Company Act, with a maturity of 185 days or less, or in money market funds meeting certain conditions under Rule <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">2a-7</div> under the Investment Company Act, which invest only in direct U.S. government treasury obligations, as determined by the Company, until the earlier of: (i)&#160;the completion of a Business Combination and (ii)&#160;the distribution of the Trust Account as described below. </div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The Company&#8217;s management has broad discretion with respect to the specific application of the net proceeds of the Initial Public Offering and the sale of Private Placement Warrants, although substantially all of the net proceeds are intended to be applied generally toward consummating a Business Combination. There is no assurance that the Company will be able to complete a Business Combination successfully. The Company must complete one or more initial Business Combinations having an aggregate fair market value of at least 80% of the net assets held in the Trust Account (as defined below) (excluding the amount of deferred underwriting discounts held in Trust and taxes payable on the income earned on the Trust Account) at the time of the agreement to enter </div></div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">F-70 </div></div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="text-align: center;"> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em; text-align: left;;font-weight: bold;"><a href="#toc" style="text-indent: 0px;">Table of Contents</a></div> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">into the initial Business Combination. However, the Company only intends to complete a Business Combination if the post-transaction company owns or acquires 50% or more of the issued and outstanding voting securities of the target or otherwise acquires a controlling interest in the target sufficient for it not to be required to register as an investment company under the Investment Company Act 1940, as amended (the &#8220;Investment Company Act&#8221;). </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">The Company will provide holders (the &#8220;Public Stockholders&#8221;) of the Company&#8217;s outstanding shares of Class&#160;A common stock sold in the Initial Public Offering (the &#8220;Public Shares&#8221;) with the opportunity to redeem all or a portion of their Public Shares upon the completion of a Business Combination either (i)&#160;in connection with a stockholder meeting called to approve the Business Combination or (ii)&#160;by means of a tender offer. The decision as to whether the Company will seek stockholder approval of a Business Combination or conduct a tender offer will be made by the Company, solely in its discretion. The Public Stockholders will be entitled to redeem their Public Shares for a pro rata portion of the amount then held in the Trust Account (initially anticipated to be $10.00 per Public Share), calculated as of two business days prior to the initial Business Combination, including interest earned on the funds held in the trust account and not previously released to the Company to pay the Company&#8217;s taxes, net of taxes payable. The <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">per-share</div> amount to be distributed to Public Stockholders who redeem their Public Shares will not be reduced by the deferred underwriting commissions the Company will pay to the underwriters (as discussed in Note 6). The Company will proceed with a Business Combination if a majority of the shares voted are voted in favor of the Business Combination. The Company will not redeem the Public Shares in an amount that would cause its net tangible assets to be less than $5,000,001. If a stockholder vote is not required by applicable law or stock exchange rule and the Company does not decide to hold a stockholder vote for business or other reasons, the Company will, pursuant to its amended and restated certificate of incorporation (the &#8220;Certificate of Incorporation&#8221;), conduct the redemptions pursuant to the tender offer rules of the U.S. Securities and Exchange Commission (&#8220;SEC&#8221;) and file tender offer documents with the SEC prior to completing a Business Combination. If, however, stockholder approval of the transaction is required by applicable law or stock exchange rule, or the Company decides to obtain stockholder approval for business or reasons, the Company will offer to redeem shares in conjunction with a proxy solicitation pursuant to the proxy rules and not pursuant to the tender offer rules. Additionally, each Public Stockholder may elect to redeem their Public Shares without voting, and if they do vote, irrespective of whether they vote for or against the proposed transaction. If the Company seeks stockholder approval in connection with a Business Combination, the initial stockholders (as defined below) agreed to vote any Founder Shares (as defined below in Note 5) and any Public Shares held by them in favor of a Business Combination. In addition, the initial stockholders agreed to waive their redemption rights with respect to any Founder Shares and any Public Shares held by them in connection with the completion of a Business Combination. </div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">The Certificate of Incorporation will provide that a Public Stockholder, together with any affiliate of such stockholder or any other person with whom such stockholder is acting in concert or as a &#8220;group&#8221; (as defined under Section&#160;13 of the Securities Exchange Act of 1934, as amended (the &#8220;Exchange Act&#8221;)), will be restricted from redeeming its shares with respect to more than an aggregate of 15% or more of the Public Shares, without the prior consent of the Company. The Sponsor and the Company&#8217;s officers and directors (the &#8220;initial stockholders&#8221;) agreed, pursuant to a letter agreement with the Company, that they will not propose any amendment to the Certificate of Incorporation (A)&#160;to modify the substance or timing of the Company&#8217;s obligation to allow redemption in connection with the initial Business Combination or to redeem 100% of the Public Shares if the Company does not complete a Business Combination within the Combination Period (as defined below) or (B)&#160;with respect to any other provision relating to stockholders&#8217; rights or <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">pre-initial</div> Business Combination activity, unless the Company provides the Public Stockholders with the opportunity to redeem their Public Shares upon approval of any such amendment at a <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">per-share</div> price, payable in cash, equal to the aggregate amount then on deposit in the Trust Account, including interest (which interest shall be net of taxes payable) divided by the number of then outstanding Public Shares. </div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">If the Company is unable to complete a Business Combination within 24 months from the closing of the Initial Public Offering, or October&#160;9, 2022, (as such period may be extended pursuant to the Certificate of Incorporation, the &#8220;Combination Period&#8221;), the Company will (i)&#160;cease all operations except for the purpose of </div></div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">F-71 </div></div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0px;"></div> </div> </div> </div> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;;font-weight: bold;"><a href="#toc" style="text-indent: 0px;">Table of Contents</a></div> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">winding up, (ii)&#160;as promptly as reasonably possible but not more than ten business days thereafter, redeem the Public Shares, at a <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">per-share</div> price, payable in cash, equal to the aggregate amount then on deposit in the Trust Account including interest earned on the funds held in the Trust Account and not previously released to the Company to pay its taxes, if any (less up to $100,000 of interest to pay dissolution expenses), divided by the number of the then outstanding Public Shares, which redemption will completely extinguish Public Stockholders&#8217; rights as stockholders (including the right to receive further liquidation distributions, if any), subject to applicable law, and (iii)&#160;as promptly as reasonably possible following such redemption, subject to the approval of the remaining stockholders and the board of directors, liquidate and dissolve, subject in each case, to the Company&#8217;s obligations under Delaware law to provide for claims of creditors and the requirements of other applicable law. </div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The initial stockholders agreed to waive their rights to liquidating distributions from the Trust Account with respect to any Founder Shares held by them if the Company fails to complete a Business Combination within the Combination Period. However, if the initial stockholders acquire Public Shares in or after the Initial Public Offering, they will be entitled to liquidating distributions from the Trust Account with respect to such Public Shares if the Company fails to complete a Business Combination within the Combination Period. The underwriters agreed to waive their rights to the deferred underwriting commission (see Note 6) held in the Trust Account in the event the Company does not complete a Business Combination within in the Combination Period and, in such event, such amounts will be included with the other funds held in the Trust Account that will be available to fund the redemption of the Public Shares. In the event of such distribution, it is possible that the per share value of the residual assets remaining available for distribution (including Trust Account assets) will be only, or less than, $10.00. In order to protect the amounts held in the Trust Account, the Sponsor has agreed to be liable to the Company if and to the extent any claims by a third party (except for the Company&#8217;s independent registered public accounting firm) for services rendered or products sold to the Company, or a prospective target business with which the Company has discussed entering into a transaction agreement (a &#8220;Target&#8221;), reduce the amount of funds in the Trust Account to below the lesser of (i) $10.00 per Public Share and (ii)&#160;the actual amount per Public Share held in the Trust Account as of the date of the liquidation of the Trust Account, if less than $10.00 per Public Share due to reductions in the value of the trust assets, less taxes payable, provided that such liability will not apply to any claims by a third party or Target that executed a waiver of any and all rights to the monies held in the Trust Account nor will it apply to any claims under the Company&#8217;s indemnity of the underwriters of the Initial Public Offering against certain liabilities, including liabilities under the Securities Act of 1933, as amended (the &#8220;Securities Act&#8221;). Moreover, in the event that an executed waiver is deemed to be unenforceable against a third party, then the Sponsor will not be responsible to the extent of any liability for such third-party claims. The Company will seek to reduce the possibility that the Sponsor will have to indemnify the Trust Account due to claims of creditors by endeavoring to have all vendors, service providers, prospective target businesses and other entities with which the Company does business, execute agreements with the Company waiving any right, title, interest or claim of any kind in or to monies held in the Trust Account. </div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt; margin-left: 4%;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Basis of Presentation </div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The accompanying financial statements of the Company have been prepared in accordance with United States generally accepted accounting principles (&#8220;U.S. GAAP&#8221;) and pursuant to the rules and regulations of the SEC. </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">As described in Note 2&#8212;Restatement of Previously Issued Financial Statements, the Company&#8217;s financial statements for the period as of December&#160;31, 2020, and the period from July&#160;6, 2020 (inception) through December&#160;31, 2020 (collectively, the &#8220;Affected Period&#8221;), are restated in this Annual Report on Form <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">10-K/A</div> (Amendment No.&#160;1) (this &#8220;Annual Report&#8221;) to correct the misapplication of accounting guidance related to the Company&#8217;s warrants in the Company&#8217;s previously issued audited and unaudited condensed financial statements for such periods. The restated financial statements are indicated as &#8220;Restated&#8221; in the audited and unaudited condensed financial statements and accompanying notes, as applicable. See Note 2&#8212;Restatement of Previously Issued Financial Statements for further discussion. </div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">F-72 </div></div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;;font-weight: bold;"><a href="#toc">Table of Contents</a></div> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 4%;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Emerging Growth Company </div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The Company is an &#8220;emerging growth company,&#8221; as defined in Section&#160;2(a) of the Securities Act, as modified by the Jumpstart Our Business Startups Act of 2012 (the &#8220;JOBS Act&#8221;), and it may take advantage of certain exemptions from various reporting requirements that are applicable to other public companies that are not emerging growth companies including, but not limited to, not being required to comply with the independent registered public accounting firm attestation requirements of Section&#160;404 of the Sarbanes-Oxley Act of 2002, reduced disclosure obligations regarding executive compensation in its periodic reports and proxy statements, and exemptions from the requirements of holding a nonbinding advisory vote on executive compensation and stockholder approval of any golden parachute payments not previously approved. </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">Further, Section&#160;102(b)(1) of the JOBS Act exempts emerging growth companies from being required to comply with new or revised financial accounting standards until private companies (that is, those that have not had a Securities Act registration statement declared effective or do not have a class of securities registered under the Exchange Act) are required to comply with the new or revised financial accounting standards. The JOBS Act provides that an emerging growth company can elect to opt out of the extended transition period and comply with the requirements that apply to <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-emerging</div> growth companies but any such an election to opt out is irrevocable. The Company has elected not to opt out of such extended transition period, which means that when a standard is issued or revised and it has different application dates for public or private companies, the Company, as an emerging growth company, can adopt the new or revised standard at the time private companies adopt the new or revised standard. </div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">This may make comparison of the Company&#8217;s financial statements with another public company that is neither an emerging growth company nor an emerging growth company that has opted out of using the extended transition period difficult or impossible because of the potential differences in accounting standards used. </div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt; margin-left: 4%;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Liquidity and Capital Resources </div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">As of December&#160;31, 2020, the Company had approximately $1.7&#160;million in its operating bank account and working capital of approximately $1.5&#160;million (not taking into account approximately $ 105,000 of taxes that may be paid using interest income from the Trust Account). </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The Company&#8217;s liquidity needs prior to the consummation of the Initial Public Offering were satisfied through a payment of $25,000 from the Sponsor to cover certain expenses on behalf of the Company in exchange for the issuance of the Founder Shares (as defined below), the loan under the Note from the Sponsor of $200,000 (see Note 5) to the Company. The Company folly repaid the Note on October&#160;9, 2020. Subsequent to the consummation of the Initial Public Offering, the Company&#8217;s liquidity has been satisfied through the portion of the proceeds of the Initial Public Offering and the Private Placement held outside of the Trust Account. In addition, in order to finance transaction costs in connection with a Business Combination, the Sponsor or an affiliate of the Sponsor, or certain of the Company&#8217;s officers and directors may, but are not obligated to, provide the Company Working Capital Loans (see Note 5). To date, there were no amounts outstanding under any Working Capital Loans. </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Based on the foregoing, management believes that the Company will have sufficient working capital and borrowing capacity to meet its needs through the earlier of the consummation of a Business Combination or one year from this filing. Over this time period, the Company will be using these funds for paying existing accounts payable, identifying and evaluating prospective initial Business Combination candidates, performing due diligence on prospective target businesses, paying for travel expenditures, selecting the target business to merge with or acquire, and structuring, negotiating and consummating the Business Combination. </div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt; margin-left: 4%;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Risks and uncertainties </div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;">Management continues to evaluate the impact of the <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">COVID-19</div> pandemic on the industry and has concluded that while it is reasonably possible that the virus could have an effect on the Company&#8217;s financial </div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">F-73 </div></div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;;font-weight: bold;"><a href="#toc" style="text-indent: 0px;">Table of Contents</a></div> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">position, results of its operations and/or search for a target company, the specific impact is not readily determinable as of the date of these financial statements. The financial statements do not include any adjustments that might result from the outcome of this uncertainty. </div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Note 2 &#8212;Restatement of Previously Issued Financial Statements </div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">In May 2021, the Audit Committee of the Company, in consultation with management, concluded that, because of a misapplication of the accounting guidance related to its public and private placement warrants to purchase common stock that the Company issued in October 2020 (the &#8220;Warrants&#8221;), the Company&#8217;s previously issued financial statements for the Affected Period should no longer be relied upon. As such, the Company is restating its financial statements for the Affected Period included in this Annual Report. </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">On April&#160;12, 2021, the staff of the Securities and Exchange Commission (the &#8220;SEC Staff&#8217;) issued a public statement entitled &#8220;Staff Statement on Accounting and Reporting Considerations for Warrants issued by Special Purpose Acquisition Companies (&#8220;SPACs&#8221;)&#8221; (the &#8220;Public Statement&#8221;). In the Public Statement, the SEC Staff expressed its view that certain terms and conditions common to SPAC warrants may require the warrants to be classified as liabilities on the SPAC&#8217;s balance sheet and, based on our application of Financial Accounting Standards Board (&#8220;FASB&#8221;) Accounting Standard Codification (&#8220;ASC&#8221;) Topic <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">815-40,</div> Derivatives and Hedging, Contracts in Entity&#8217;s Own Equity (&#8220;ASC <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">815-40&#8221;),</div> our statement of operations did not include subsequent <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-cash</div> changes in estimated fair value of the Warrants. The views expressed in the Public Statement were not consistent with our historical interpretation of specific provisions within our warrant agreement, dated as of October&#160;6, 2021 (&#8220;warrant agreement&#8221;), and our application of ASC <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">815-40</div> to the warrant agreement. Since issuance on October&#160;9, 2020, the Company&#8217;s warrants were accounted for as equity within the Company&#8217;s previously reported balance sheets. After discussion and evaluation, including with the Company&#8217;s independent registered public accounting firm and the Company&#8217;s audit committee, management concluded that the warrants should be presented as liabilities with subsequent fair value remeasurement. </div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Therefore, the Company, in consultation with its Audit Committee, concluded that its previously issued Financial Statements as of December&#160;31, 2020, and for the period from July&#160;6, 2020 (inception) through December&#160;31, 2020 should be restated because of a reclassification of of our outstanding warrants to purchase common stock (the &#8220;Warrants&#8221;) and, solely as a result of this material weakness, should no longer be relied upon. </div></div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">F-74 </div></div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;;font-weight: bold;"><a href="#toc">Table of Contents</a></div> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Impact of the Restatement </div></div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The impact of the restatement on the balance sheets, statements of operations and statements of cash flows for the Affected Period is presented below. The restatement had no impact on net cash flows from operating, investing or financing activities. </div></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="font-size: 0px;">
<td style="width: 63%;"></td>
<td style="width: 4%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td>
<td style="width: 4%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td>
<td style="width: 4%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;&#160;</td>
<td colspan="10" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">As of December&#160;31, 2020</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">As Previously</div></div><br/><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Reported</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Restatement<br/>Adjustment</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">As Restated</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td colspan="12" style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Balance Sheet</div></div></div> </td>
<td style="vertical-align: top;"> <div style="text-indent: 0em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0em; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div> </td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Total assets</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">412,780,872</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">412,780,872</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Liabilities and stockholders&#8217; equity</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Total current liabilities</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">552,723</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">552,723</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Deferred underwriting commissions</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">14,375,138</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">14,375,138</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Derivative warrant liabilities</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">49,097,230</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">49,097,230</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Total liabilities</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">14,927,861</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">49,097,230</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">64,025,091</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Class&#160;A common stock, $0.0001 par value; shares subject to possible redemption</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">392,853,010</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(49,097,230</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">343,755,780</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td colspan="12" style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Stockholders&#8217; equity</div></div> </td>
<td style="vertical-align: top;"> <div style="text-indent: 0em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Preferred stock- $0.0001 par value</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Class&#160;A common stock&#8212;$0.0001 par value</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">179</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">491</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">670</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Class&#160;B common stock&#8212;$0.0001 par value</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">1,027</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">1.027</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;">Additional <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">paid-in-capital</div></div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">5,385,198</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">10,387,424</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">15,772,622</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Accumulated deficit</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(386,403</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(10,387,915</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(10,774,318</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Total stockholders&#8217; equity</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">5,000,001</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">5,000,001</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Total liabilities and stockholders&#8217; equity</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">412,780,872</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">412,780,872</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="font-size: 0px;">
<td style="width: 63%;"></td>
<td style="width: 3%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td>
<td style="width: 3%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td>
<td style="width: 3%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;&#160;</td>
<td colspan="10" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Period From July&#160;6, 2020 (Inception) Through<br/>December&#160;31, 2020</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">As&#160;Previously<br/>Reported</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Restatement<br/>Adjustment</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">As Restated</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td colspan="12" style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Statement of Operations</div></div></div> </td>
<td style="vertical-align: top;"> <div style="text-indent: 0em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0em; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div> </td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Loss from operations</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(454,875</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(454,875</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td colspan="12" style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Other (expense) income:</div></div> </td>
<td style="vertical-align: top;"> <div style="text-indent: 0em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Financing costs&#8212;derivative warrant liabilities</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(6,800,025</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(6,800,025</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Change in fair value of derivative warrant liabilities</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(3,587,890</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(3,587,890</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Interest earned on marketable securities held in Trust Account</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">79,568</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">79,568</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Unrealized gain on marketable securtities held in Trust Account</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">5,613</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">5,613</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Total other (expense) income</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">85,181</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(10,387,915</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(10,302,734</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Income tax expense</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">16,709</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">16,709</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Net loss</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(386,403</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(10,387,915</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(10,774,318</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Weighted average shares outstanding of common stock subject to redemption, basic and diluted</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">38,896,852</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(4,510,304</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">34.386,548</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Basic and diluted net loss per share, common stock subject to redemption</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Weighted average shares outstanding of common stock, basic and diluted</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">10,985,515</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">2,338,676</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">13,324,191</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Basic and diluted net loss per share, common stock</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(0.04&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">) $&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(0.77&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">) $&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(0.81</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">F-75 </div></div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;;font-weight: bold;"><a href="#toc" style="text-indent: 0px;">Table of Contents</a></div> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;">
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="font-size: 0px;">
<td style="width: 63%;"></td>
<td style="width: 5%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td>
<td style="width: 5%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td>
<td style="width: 5%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td rowspan="2" style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;&#160;</td>
<td colspan="10" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Period From July&#160;6, 2020 (Inception) Through<br/>December&#160;31, 2020</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">As Previously</div></div><br/><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Reported</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Restatement<br/>Adjustment</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">As Restated</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td colspan="12" style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Statement of Cash Flows</div></div></div> </td>
<td style="vertical-align: top;"> <div style="text-indent: 0em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0em; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div> </td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: bottom;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Net cash used in operating activities</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">(248,954</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#8212;&#160;&#160;</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">(248,954</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: bottom;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Net cash used in investing activities</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">(410,718,230</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#8212;&#160;&#160;</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">(410,718,230</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: bottom;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Net cash provided by financing activities</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">412,663,675</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#8212;&#160;&#160;</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">412,663,675</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Net change in cash</div></div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">1,696,491</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#160;&#160;&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">1,696,491</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">In addition, the impact to the balance sheet dated October&#160;9, 2020, filed on <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">Form&#160;8-K</div> on October&#160;16, 2020 related to the impact of accounting for the Public Warrants and Private Placement Warrants as liabilities at fair value resulted in a $44.4&#160;million increase to the derivative warrant liabilities line item at October&#160;9, 2020 and offsetting decrease to the Class&#160;A common stock subject to possible redemption mezzanine equity line item. There was no change to total stockholders&#8217; equity at the reported balance sheet date. </div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Note 3&#8212;Summary of Significant Accounting Policies </div></div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt; margin-left: 4%;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Use of Estimates </div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The preparation of the financial statements in conformity with U.S. GAAP requires the Company&#8217;s management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenue and expenses during the reporting period. Making estimates requires management to exercise significant judgment. It is at least reasonably possible that the estimate of the effect of a condition, situation or set of circumstances that existed at the date of the financial statements, which management considered in formulating its estimate, could change in the near term due to one or more future confirming events. Accordingly, the actual results could differ significantly from those estimates. </div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt; margin-left: 4%;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Cash and Cash Equivalents </div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The Company considers all short-term investments with an original maturity of three months or less when purchased to be cash equivalents. </div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt; margin-left: 4%;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Cash and Marketable Securities Held in Trust Account </div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The Company&#8217;s portfolio of investments held in the Trust Account is comprised of cash and U.S. government securities, within the meaning set forth in Section&#160;2(a)(16) of the Investment Company Act. with a maturity of 185 days or less. </div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt; margin-left: 4%;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Concentration of Credit Risk </div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Financial instruments that potentially subject the Company to concentrations of credit risk consist of cash accounts in a financial institution, which, at times, may exceed the Federal Depository Insurance Coverage limit of $250,000. and any investments held in Trust Account. As of December&#160;31, 2020. the Company had not experienced losses on these accounts and management believes the Company is not exposed to significant risks on such accounts. The Company&#8217;s investments held in the Trust Account as of December&#160;31, 2020 is comprised of investments in U.S. Treasury securities with an original maturity of 185 days or less. </div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt; margin-left: 4%;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Fair Value of Financial Instruments </div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Fair value is defined as the price that would be received for sale of an asset or paid for transfer of a liability, in an orderly transaction between market participants at the measurement date. U.S. GAAP establishes a three-tier fair value hierarchy, which prioritizes the inputs used in measuring fair value. </div></div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">F-76 </div></div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;;font-weight: bold;"><a href="#toc">Table of Contents</a></div> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The hierarchy gives the highest priority to unadjusted quoted prices in active markets for identical assets or liabilities (Level 1 measurements) and the lowest priority to unobservable inputs (Level 3 measurements). These tiers include: </div></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Level&#160;1, defined as observable inputs such as quoted prices for identical instruments in active markets; </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Level&#160;2, defined as inputs other than quoted prices in active markets that are either directly or indirectly observable such as quoted prices for similar instruments in active markets or quoted prices for identical or similar instruments in markets that are not active; and </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Level&#160;3, defined as unobservable inputs in which little or no market data exists, therefore requiring an entity to develop its own assumptions, such as valuations derived from valuation techniques in which one or more significant inputs or significant value drivers are unobservable. </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">In some circumstances, the inputs used to measure fair value might be categorized within different levels of the fair value hierarchy. In those instances, the fair value measurement is categorized in its entirety in the fair value hierarchy based on the lowest level input that is significant to the fair value measurement. </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The fair value of the Company&#8217;s assets and liabilities, which qualify as financial instruments under ASC 820, &#8220;Fair Value Measurements and Disclosures,&#8221; approximates the carrying amounts represented in the accompanying balance sheet, primarily due to their short-term nature. </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The fair value of the Public Warrants (if not market observed) and Private Placement Warrants is estimated using a Binomial Lattice in a risk-neutral framework. The future stock price of the Company is modeled assuming a Geometric Brownian Motion in a risk-neutral framework. For each modeled future price, the warrant payoff is calculated based on the contractual terms (incorporating any optimal early exercise / redemption), and then discounted at the term-matched risk-free rate. The value of the Warrants is calculated as the probability-weighted present value over all future modeled payoffs. </div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt; margin-left: 4%;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Offering Costs Associated with the Initial Public Offering </div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;">Offering costs consisted of legal, accounting, underwriting fees and other costs incurred that were directly related to the Initial Public Offering. Offering costs are allocated to the separable financial instruments issued in the Initial Public Offering based on a relative fair value basis, compared to total proceeds received. Offering costs associated with warrant liabilities are expensed as incurred, presented as <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-operating</div> expenses in the statement of operations. Offering costs associated with the Public Shares were charged to stockholders&#8217; equity upon the completion of the Initial Public Offering. </div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt; margin-left: 4%;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Class&#160;A Common Stock Subject to Possible Redemption </div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The Company accounts for its Class&#160;A common stock subject to possible redemption in accordance with the guidance in ASC Topic 480 &#8220;Distinguishing Liabilities from Equity.&#8221; Shares of Class&#160;A common stock subject to mandatory redemption (if any) are classified as liability instruments and are measured at fair value. Conditionally redeemable shares of Class&#160;A common stock (including shares of Class&#160;A common stock that feature redemption rights that are either within the control of the holder or subject to redemption upon the occurrence of uncertain events not solely within the Company&#8217;s control) are classified as temporary equity. At all other times, shares of Class&#160;A common stock are classified as stockholders&#8217; equity. Shares of Class&#160;A common stock of the Company feature certain redemption rights that are considered to be outside of the Company&#8217;s control and subject to the occurrence of uncertain future events. Accordingly, as of December&#160;31, 2020, 34,375,578 shares of Class&#160;A common stock subject to possible redemption were presented as temporary equity, outside of the stockholders&#8217; equity section of the Company&#8217;s balance sheet. </div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt; margin-left: 4%;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Derivative Warrant Liabilities </div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The Company does not use derivative instruments to hedge exposures to cash flow, market, or foreign currency risks. The Company evaluates all of its financial instruments, including issued stock purchase warrants, </div></div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">F-77 </div></div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;;font-weight: bold;"><a href="#toc" style="text-indent: 0px;">Table of Contents</a></div> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">to determine if such instruments are derivatives or contain features that qualify as embedded derivatives, pursuant to ASC 480 and ASC <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">815-15.</div> The classification of derivative instruments, including whether such instruments should be recorded as liabilities or as equity, is <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">re-assessed</div> at the end of each reporting period. </div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">The Company issued 20,535,912 warrants in connection with the Initial Public Offering (the &#8220;Public Warrants&#8221;) 10,214,365 warrants in a Private Placement Placement (the &#8220;Private Placement Warrants&#8221;). These warrants are recognized as derivative liabilities in accordance with ASC <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">815-40.</div> The excess of the fair value of the Private Placement Warrants over the proceeds received is recognized as a financing cost of the derivative liability. Accordingly, the Company recognizes the warrant instruments as liabilities at fair value and adjust the instruments to fair value at each reporting period. The liabilities are subject to <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">re-measurement</div> at each balance sheet date until exercised, and any change in fair value is recognized in the Company&#8217;s statement of operations. The fair value of the Public Warrants (if not market observed) and Private Placement Warrants is estimated using a Binomial Lattice in a risk-neutral framework. The future stock price of the Company is modeled assuming a Geometric Brownian Motion in a risk-neutral framework. For each modeled future price, the Warrant payoff is calculated based on the contractual terms (incorporating any optimal early exercise / redemption), and then discounted at the term-matched risk-free rate. The value of the Warrants is calculated as the probability-weighted present value over all future modeled payoffs. </div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt; margin-left: 4%;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Income Taxes </div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The Company complies with the accounting and reporting requirements of FASB ASC 740, &#8220;Income Taxes,&#8221; which requires an asset and liability approach to financial accounting and reporting for income taxes. Deferred income tax assets and liabilities are computed for differences between the financial statement and tax bases of assets and liabilities that will result in future taxable or deductible amounts, based on enacted tax laws and rates applicable to the periods in which the differences are expected to affect taxable income. Valuation allowances are established, when necessary, to reduce deferred tax assets to the amount expected to be realized. </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">FASB ASC 740 prescribes a recognition threshold and a measurement attribute for the financial statement recognition and measurement of tax positions taken or expected to be taken in a tax return. For those benefits to be recognized, a tax position must be <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">more-likely-than-not</div> to be sustained upon examination by taxing authorities. The Company recognizes accrued interest and penalties related to unrecognized tax benefits as income tax expense. </div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt; margin-left: 4%;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Net Income (Loss) Per Common Share </div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The Company complies with accounting and disclosure requirements of FASB ASC Topic 260, &#8220;Earnings Per Share.&#8221; Net income (loss) per common share is computed by dividing net loss by the weighted average number of shares of common stock outstanding during the period. The Company has not considered the effect of the warrants sold in the Initial Public Offering and Private Placement to purchase an aggregate of 30,750,277 shares of the Company&#8217;s common stock in the calculation of diluted loss per share, since the exercise of the warrants are contingent upon the occurrence of future events and the inclusion of such warrants would be anti-dilutive. </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">The Company&#8217;s statement of operations includes a presentation of income (loss) per common share for Class&#160;A common shares subject to possible redemption in a manner similar to the <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">two-class</div> method of income (loss) per common share. Net income (loss) per common share, basic and diluted, for Class&#160;A common stock subject to possible redemption is calculated by dividing the proportionate share of income or loss on marketable securities held by the Trust Account, net of applicable franchise and income taxes, by the weighted average number of shares of Class&#160;A common stock subject to possible redemption outstanding since original issuance. </div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">Net income (loss) per common share, basic and diluted, for <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-redeemable</div> common stock is calculated by dividing the net income (loss), adjusted for income or loss on marketable securities attributable to common stock </div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">F-78 </div></div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;;font-weight: bold;"><a href="#toc">Table of Contents</a></div> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">subject to possible redemption, by the weighted average number of <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-redeemable</div> common stock outstanding for the period. </div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">Non-redeemable</div> common stock includes Founder Shares and <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-redeemable</div> shares of Class&#160;A common stock as these shares do not have any redemption features. <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">Non-redeemable</div> common stock participates in the income or loss on marketable securities based on <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-redeemable</div> shares&#8217; proportionate interest. </div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The following table reflects the calculation of basic and diluted net income (loss) per common share: </div></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="font-size: 0px;">
<td style="width: 87%;"></td>
<td style="width: 2%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">For the Period<br/>from July&#160;6,<br/>2020<br/>(inception)<br/>through<br/>December&#160;31,<br/>2020</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Class&#160;A Common stock subject to possible redemption</div></div></div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Numerator: Earnings allocable to Common stock subject to possible redemption</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Income from investments held in trust Account</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">71,296</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Less: Company&#8217;s portion available to be withdrawn to pay taxes</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(71,296</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 5em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Net income attributable</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Denominator: Weighted average Class&#160;A common stock subject to possible redemption</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Basic and diluted weighted average shares outstanding</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">34,386,548</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Basic and diluted net income per share</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">Non-Redeemable</div> Common Stock</div></div></div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Numerator: Net Loss minus Net Earnings</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Net loss</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(10,774,318</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: bottom;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Net income allocable to Class&#160;A common stock subject to possible redemption</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#8212;&#160;&#160;</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 5em; line-height: normal;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">Non-redeemable</div> net loss</div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">$</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(10,774,318</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">)&#160;</div></div></td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom;"></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;">Denominator: weighted average <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">Non-redeemable</div> common stock</div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"></td>
<td style="vertical-align: bottom;"></td>
<td style="vertical-align: bottom;"></td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: bottom;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;">Basic and diluted weighted average shares outstanding, <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">Non-redeemable</div> common stock</div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">13,324,191</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom;"></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: bottom;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;">Basic and diluted net loss per share, <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">Non-redeemable</div> common stock</div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">$</div></div></td>
<td style="vertical-align: bottom;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(0.81</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">)&#160;</div></div></td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom;"></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt; margin-left: 4%;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Recent Accounting Pronouncements </div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Management does not believe that any recently issued, but not yet effective, accounting pronouncement if currently adopted would have a material effect on the Company&#8217;s financial statements. </div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Note 4&#8212;Initial Public Offering </div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">On October&#160;9, 2020, the Company consummated its Initial Public Offering of 40,000,000 Units at $ 10.00 per Unit, generating gross proceeds of $400.0&#160;million, and incurring offering costs of approximately $22.1&#160;million (net of reimbursement of offering costs of $520,000 from the underwriters), inclusive of $14.0&#160;million in deferred underwriting commissions. The Underwriters exercised the over-allotment option in part and on November&#160;12, 2020 purchased an additional 1,071,823 Over-Allotment Units, generating gross proceeds of approximately $10.7&#160;million, and incurred additional offering costs of approximately $576,000 in underwriting fees (net of reimbursement of offering costs of approximately $14,000 from the underwriters and inclusive of approximately $375,000 in deferred underwriting fees). </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">Each Unit consists of one share of Class&#160;A common stock, and <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">one-half</div> of one redeemable warrant (each, a &#8220;Public Warrant&#8221;). Each whole Public Warrant entitles the holder to purchase one share of Class&#160;A common stock at a price of $ 11.50 per share, subject to adjustment (see Note 7). </div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">F-79 </div></div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;;font-weight: bold;"><a href="#toc" style="text-indent: 0px;">Table of Contents</a></div> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Note 5&#8212;Related Party Transactions </div></div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Founder Shares </div></div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">On July&#160;23, 2020, an affiliate of the Sponsor paid an aggregate of $25,000 for certain expenses on behalf of the Company in exchange for issuance of 14,375,000 shares of the Company&#8217;s Class&#160;B common stock, par value $0.0001 per share (the &#8220;Founder Shares&#8221;), with such shares subsequently transferred to the Sponsor. On October&#160;6, 2020, the Sponsor surrendered 2,875,000 shares of Class&#160;B common stock to the Company for no consideration, resulting in a decrease of the Founder Shares from 14,375,000 shares to 11,500,000 shares. All shares and associated amounts have been retroactively restated to reflect the share surrender. The initial stockholders agreed to forfeit up to 1,500,000 Founder Shares to the extent that the over-allotment option was not exercised in full by the underwriters, so that the Founder Shares will represent 20.0% of the Company&#8217;s issued and outstanding shares of common stock after the Initial Public Offering. The underwriters partially exercised their over-allotment option in part on November&#160;12, 2020; and the remaining over-allotment expired unexercised on November&#160;20, 2020 resulting in the forfeiture of 1,232,044 share of Class&#160;B common stock. At December&#160;31, 2020, there were 10,267,956 shares of Class&#160;B common stock outstanding, none subject to forfeiture. </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">The Initial Stockholders agreed, subject to limited exceptions, not to transfer, assign or sell any of the Founder Shares until the earlier to occur of: (A)&#160;one year after the completion of the initial Business Combination or (B)&#160;subsequent to the initial Business Combination; (x)&#160;if the last reported sale price of Class&#160;A common stock equals or exceeds $12.00 per share (as adjusted for stock splits, stock capitalizations, reorganizations, recapitalizations and the like) for any 20 trading days within any <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">30-trading</div> day period commencing at least 150 days after the initial Business Combination; or (y)&#160;the date on which the Company completes a liquidation, merger, capital stock exchange or other similar transaction that results in all of the stockholders having the right to exchange their common stock for cash, securities or other property. </div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Private Placement Warrants </div></div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Simultaneously with the closing of the Initial Public Offering, the Company consummated the Private Placement of 10,000,000 Private Placement Warrants at a price of $1.00 per Private Placement Warrant to the Sponsor, generating proceeds of $10.0&#160;million. Simultaneously with the closing of the Over-allotment on November&#160;12, 2020, the Company consummated the second closing of the Private Placement, resulting in the purchase of an aggregate of an additional 214,365 Private Placement Warrants by the Sponsor, generating gross proceeds to the Company of approximately $214,000. The excess of fair value of the Private Placement Warrants of $5.1&#160;million has been recognized as financing costs&#8212;derivative warrant liabilities. </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">Each whole Private Placement Warrant is exercisable for one whole share of Class&#160;A common stock at a price of $ 11.50 per share, subject to adjustment. A portion of the proceeds from the sale of the Private Placement Warrants to the Sponsor was added to the proceeds from the Initial Public Offering held in the Trust Account. If the Company does not complete a Business Combination within the Combination Period, the Private Placement Warrants will expire worthless. The Private Placement Warrants will be <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-redeemable</div> for cash (except as described below) and exercisable on a cashless basis so long as they are held by the Sponsor or its permitted transferees. </div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The Sponsor agreed, subject to limited exceptions, not to transfer, assign or sell the Private Placement Warrants until 30 days after the completion of the initial Business Combination. </div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Related Party Loans </div></div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;">On July&#160;23, 2020, the Sponsor agreed to loan the Company an aggregate of up to $300,000 to cover expenses related to the Initial Public Offering pursuant to a promissory note (the &#8220;Note&#8221;). This loan was <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-interest</div> bearing and payable upon the completion of the Initial Public Offering. The Company borrowed $200,000 under the Note and fully repaid on October&#160;9, 2020. </div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">F-80 </div></div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;;font-weight: bold;"><a href="#toc">Table of Contents</a></div> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">In addition, in order to fund working capital deficiencies or finance transaction costs in connection with a Business Combination, the Sponsor or an affiliate of the Sponsor, or certain of the Company&#8217;s officers and directors may, but are not obligated to, loan the Company funds as may be required (&#8220;Working Capital Loans&#8221;). If the Company completes a Business Combination, the Company may repay the Working Capital Loans out of the proceeds of the Trust Account released to the Company. Otherwise, the Working Capital Loans could be repaid only out of funds held outside the Trust Account. In the event that a Business Combination does not close, the Company may use a portion of proceeds held outside the Trust Account to repay the Working Capital Loans but no proceeds held in the Trust Account would be used to repay the Working Capital Loans. The Working Capital Loans would either be repaid upon consummation of a Business Combination or, at the lender&#8217;s discretion, up to $1,500,000 of such Working Capital Loans may be convertible into warrants of the post Business Combination entity at a price of $1.00 per warrant. The warrants would be identical to the Private Placement Warrants. Except for the foregoing, the terms of such Working Capital Loans, if any, have not been determined and no written agreements exist with respect to such loans. As of December&#160;31, 2020, the Company had no borrowings under the Working Capital Loans. </div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Administrative Services Agreement </div></div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Commencing October&#160;7, 2020 through the earlier of consummation of the initial Business Combination and the liquidation, the Company has agreed to pay the Sponsor a total of $10,000 per month for office space, utilities, secretarial and administrative support services. The Company incurred and paid $28,065 for such services for the period from October&#160;7, 2020 through December&#160;31, 2020. </div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Note 6&#8212;Commitments and Contingencies </div></div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Registration Rights </div></div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The holders of the Founder Shares, Private Placement Warrants and warrants that may be issued upon conversion of Working Capital Loans (and any Class&#160;A common stock issuable upon the exercise of the Private Placement Warrants and warrants that may be issued upon conversion of Working Capital Loans) are entitled to registration rights pursuant to the registration rights agreement. The holders of these securities are entitled to make up to three demands, excluding short form demands, that the Company registers such securities. In addition, the holders have certain &#8220;piggy-back&#8221; registration rights with respect to registration statements filed subsequent to the completion of the initial Business Combination. The Company will bear the expenses incurred in connection with the filing of any such registration statements. </div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Underwriting Agreement </div></div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The underwriters were entitled to an underwriting discount of $0.20 per unit, or $8.0&#160;million in the aggregate, paid upon the closing of the Initial Public Offering. In addition, $0.35 per unit, or $14.0&#160;million in the aggregate will be payable to the underwriters for deferred underwriting commissions. The deferred fee will become payable to the underwriters from the amounts held in the Trust Account solely in the event that the Company completes a Business Combination, subject to the terms of the underwriting agreement. The underwriters agreed to make a payment to the Company in an amount of 0.13% of the gross proceeds of the Initial Public Offering, or $520,000, to reimburse certain of offering expenses. The Company received such reimbursement on October&#160;27, 2020. </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Upon closing of the Over-allotment on November&#160;12, 2020, the underwriters received approximately $214,000 in fees paid upfront and eligible for an additional deferred underwriting commissions of approximately $375,000. In addition, the underwriters agreed to make an addition payment to the Company in an amount of 0.13% of the gross proceeds of the Over-allotment, or approximately $14,000, to reimburse certain of offering expenses. As of December&#160;31, 2020, approximately $5,000 remained unpaid. </div></div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">F-81 </div></div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;;font-weight: bold;"><a href="#toc" style="text-indent: 0px;">Table of Contents</a></div> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Note 7&#8212;Derivative Warrant Liabilities </div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Public Warrants may only be exercised for a whole number of shares. No fractional Public Warrants will be issued upon separation of the Units and only whole Public Warrants will trade. The Public Warrants will become exercisable on the later of (a) 30 days after the completion of a Business Combination and (b) 12 months from the closing of the Initial Public Offering; provided in each case that the Company has an effective registration statement under the Securities Act covering the shares of Class&#160;A common stock issuable upon exercise of the warrants and a current prospectus relating to them is available and such shares are registered, qualified or exempt from registration under the securities, or blue sky, laws of the state of residence of the holder (or holders are permitted to exercise their warrants on a cashless basis under the circumstances specified in the warrant agreement as a result of (i)&#160;the Company&#8217;s failure to have an effective registration statement by the 60th business day after the closing of the initial Business Combination or (ii)&#160;a notice of redemption described below under &#8220;Redemption of warrants when the price per Class&#160;A common stock equals or exceeds $10.00&#8221;). If and when the warrants become redeemable by the Company, the Company may exercise its redemption right even if the Company is unable to register or qualify the underlying securities for sale under all applicable state securities laws. </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The Company is not registering the shares of Class&#160;A common stock issuable upon exercise of the warrants at this time. However, the Company has agreed that as soon as practicable, but in no event later than twenty business days after the closing of the initial Business Combination, the Company will use its commercially reasonable efforts to file with the SEC and have an effective registration statement covering the shares of Class&#160;A common stock issuable upon exercise of the warrants and to maintain a current prospectus relating to those shares of Class&#160;A common stock until the warrants expire or are redeemed. If a registration statement covering the Class&#160;A common stock issuable upon exercise of the warrants is not effective by the 60th business day after the closing of the initial Business Combination, warrant holders may, until such time as there is an effective registration statement and during any period when the Company will have failed to maintain an effective registration statement, exercise warrants on a &#8220;cashless basis&#8221; in accordance with Section&#160;3(a)&#160;(9) of the Securities Act or another exemption. </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The warrants will have an exercise price of $ 11.50 per share and will expire five years after the completion of a Business Combination or earlier upon redemption or liquidation. If (x)&#160;the Company issues additional shares of Class&#160;A common stock or equity-linked securities for capital raising purposes in connection with the closing of the initial Business Combination at an issue price or effective issue price of less than $9.20 per share of Class&#160;A common stock (with such issue price or effective issue price to be determined in good faith by the Company and, (i)&#160;in the case of any such issuance to the Sponsor or its affiliates, without taking into account any Founder Shares held by the Sponsor or such affiliates, as applicable, prior to such issuance, and (ii)&#160;to the extent that such issuance is made to the Sponsor or its affiliates, without taking into account the transfer of Founder Shares or Private Placement Warrants (including if such transfer is effectuated as a surrender to the Company and subsequent reissuance by the Company) by the Sponsor in connection with such issuance) (the &#8220;Newly Issued Price&#8221;), (y) the aggregate gross proceeds from such issuances represent more than 60% of the total equity proceeds, and interest thereon, available for the funding of the initial Business Combination on the date of the completion of the initial Business Combination (net of redemptions), and (z)&#160;the volume-weighted average trading price of Class&#160;A common stock during the 20 trading day period starting on the trading day prior to the day on which the Company completes its initial Business Combination (such price, the &#8220;Market Value&#8221;) is below $9.20 per share, the exercise price of the warrants will be adjusted (to the nearest cent) to be equal to 115% of the higher of the Market Value and the Newly Issued Price, and the $10.00 and $18.00 per share redemption trigger prices described under &#8220;Redemption of warrants when the price per Class&#160;A common stock equals or exceeds $18.00&#8221; and &#8220;Redemption of warrants when the price per Class&#160;A common stock equals or exceeds $10.00&#8221; will be adjusted (to the nearest cent) to be equal to 100% and 180% of the higher of the Market Value and the Newly Issued Price, respectively. </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The Private Placement Warrants will be identical to the Public Warrants, except that the Private Placement Warrants (including the Class&#160;A common stock issuable upon exercise of the Private Placement Warrants) will </div></div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">F-82 </div></div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;;font-weight: bold;"><a href="#toc">Table of Contents</a></div> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">not be transferable, assignable or salable until 30 days after the completion of the initial Business Combination and they will not be redeemable by the Company so long as they are held by the Sponsor or its permitted transferees. </div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt; margin-left: 4%;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Redemption of warrants when the price per share of Class&#160;A common stock equals or exceeds $18.00. </div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Once the warrants become exercisable, the Company may redeem the outstanding warrants for cash (except as described herein with respect to the Private Placement Warrants): </div></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">in whole and not in part; </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">at a price of $0.01 per warrant; </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">upon a minimum of 30 days&#8217; prior written notice of redemption; and </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;">if, and only if, the last reported sale price of Class&#160;A common stock for any 20 trading days within a <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">30-trading</div> day period ending on the third trading day prior to the date on which the Company sends the notice of redemption to the warrant holders (the &#8220;Reference Value&#8221;) equals or exceeds $18.00 per share (as adjusted for stock splits, stock capitalizations, reorganizations, recapitalizations and the like. </div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">However, in this case, the Company will not redeem the warrants unless an effective registration statement under the Securities Act covering the Class&#160;A common stock issuable upon exercise of the warrants is effective and a current prospectus relating to those shares of Class&#160;A common stock is available throughout the <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">30-day</div> redemption period. Any such exercise would not be on a &#8220;cashless&#8221; basis and would require the exercising warrant holder to pay the exercise price for each warrant being exercised. </div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt; margin-left: 4%;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Redemption of warrants when the price per share of Class&#160;A common stock equals or exceeds $10.00. </div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Once the warrants become exercisable, the Company may redeem the outstanding warrants (except as described herein with respect to the Private Placement Warrants): </div></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">in whole and not in part; </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">at $0.10 per warrant upon a minimum of 30 days&#8217; prior written notice of redemption provided that holders will be able to exercise their warrants on a cashless basis prior to redemption and receive that number of shares determined by reference to an agreed table based on the redemption date and the &#8220;fair market value&#8221; of the Shares of Class&#160;A common stock; and </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">if, and only if, the Reference Value equals or exceeds $10.00 per share (as adjusted for stock splits, stock dividends, rights issuances, subdivisions, reorganizations, recapitalizations and the like); and </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">if the Reference Value is less than $18.00 per share (as adjusted for stock splits, stock dividends, rights issuances, subdivisions, reorganizations, recapitalizations and the like), the Private Placement Warrants must also concurrently be called for redemption on the same terms (except as described herein with respect to a holder&#8217;s ability to cashless exercise its warrants) as the outstanding Public Warrants, as described above. </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The &#8220;fair market value&#8221; of Class&#160;A common stock shall mean the volume-weighted average price of Class&#160;A common stock for the 10 trading days immediately following the date on which the notice of redemption is sent to the holders of warrants. In no event will the warrants be exercisable in connection with this redemption feature for more than 0.361 shares of Class&#160;A common stock per warrant (subject to adjustment). </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">In no event will the Company be required to net cash settle any warrant. If the Company is unable to complete a Business Combination within the Combination Period and the Company liquidates the funds held in the Trust Account, holders of warrants will not receive any of such funds with respect to their warrants, nor will they receive any distribution from the Company&#8217;s assets held outside of the Trust Account with the respect to such warrants. Accordingly, the warrants may expire worthless. </div></div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">F-83 </div></div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;;font-weight: bold;"><a href="#toc" style="text-indent: 0px;">Table of Contents</a></div> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Note 8&#8212;Stockholders&#8217; Equity </div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Class</div></div></div></div><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"></div></div></div><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">&#160;A Common Stock&#8212;</div></div></div></div>The Company is authorized to issue 400,000,000 shares of Class&#160;A common stock with a par value of $0.0001 per share. As of December&#160;31, 2020, there were 41,071,823 shares of Class&#160;A common stock outstanding, including 34,375,578 shares of Class&#160;A common stock subject to possible redemption that were classified as temporary equity in the accompanying balance sheet. </div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Class</div></div></div></div><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"></div></div></div><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">&#160;B Common Stock&#8212;</div></div></div></div>The Company is authorized to issue 40,000,000 shares of Class&#160;B common stock with a par value of $0.0001 per share. On July&#160;23, 2020, an affiliate of the Sponsor paid an aggregate of $25,000 for certain expenses on behalf of the Company in exchange for issuance of 14,375,000 shares of Class&#160;B common stock, with such shares subsequently transferred to the Sponsor. On October&#160;6, 2020, the Sponsor surrendered 2,875,000 shares of Class&#160;B common stock to the Company for no consideration, resulting in a decrease of the outstanding Class&#160;B common stock from 14,375,000 shares to 11,500,000 shares. All shares and associated amounts have been retroactively restated to reflect the share surrender. Of these, an aggregate of up to 1,500,000 shares of Class&#160;B common stock that are subject to forfeiture to the Company by the initial stockholders for no consideration to the extent that the underwriters&#8217; over-allotment option is not exercised in full or in part, so that the number of Founder Shares will equal 20% of the Company&#8217;s issued and outstanding shares of common stock after the Initial Public Offering. The underwriters partially exercised their over-allotment option on November&#160;12, 2020, and the remaining over-allotment expired unexercised on November&#160;20, 2020 resulting in the forfeiture of 1,232,044 Class&#160;B common shares. As of December&#160;31, 2020, 10,267,956 shares of Class&#160;B common stock were outstanding with no shares subject to forfeiture. </div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Stockholders of record are entitled to one vote for each share held on all matters to be voted on by stockholders. Holders of our Class&#160;A common stock and holders of our Class&#160;B common stock will vote together as a single class on all matters submitted to a vote of our stockholders except as required by law. </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">The Class&#160;B common stock will automatically convert into Class&#160;A common stock on the first business day following the completion of the initial Business Combination at a ratio such that the number of shares of Class&#160;A common stock issuable upon conversion of all Founder Shares will equal, in the aggregate, on an <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">as-converted</div> basis, 20% of the sum of (i)&#160;the total number of shares of Class&#160;A common stock issued and outstanding upon completion of the Initial Public Offering, plus (ii)&#160;the sum of (a)&#160;the total number of shares of Class&#160;A common stock issued or deemed issued or issuable upon conversion or exercise of any equity-linked securities or rights issued or deemed issued, by the Company in connection with or in relation to the completion of the initial Business Combination, excluding any shares of Class&#160;A common stock or equity-linked securities exercisable for or convertible into shares of Class&#160;A common stock issued, or to be issued, to any seller in the initial Business Combination and any Private Placement Warrants issued to the Sponsor upon conversion of Working Capital Loans, minus (b)&#160;the number of Public Shares redeemed by Public Stockholders in connection with the initial Business Combination. In no event will the shares of Class&#160;B common stock convert into shares of Class&#160;A common stock at a rate of less than one to one. </div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Preferred Stock&#8212;</div></div></div></div>The Company is authorized to issue 1,000,000 shares of preferred stock, par value $0.0001 per share, with such designations, voting and other rights and preferences as may be determined from time to time by the Company&#8217;s board of directors. As of December&#160;31, 2020, there were no shares of preferred stock issued or outstanding. </div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">F-84 </div></div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;;font-weight: bold;"><a href="#toc">Table of Contents</a></div> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Note 9&#8212;Fair Value Measurements </div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The following table presents information about the Company&#8217;s assets that are measured at fair value on a recurring basis as of December&#160;31, 2020 and indicates the fair value hierarchy of the valuation techniques that the Company utilized to determine such fair value. </div></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="font-size: 0px;">
<td style="width: 57%; font-family: &quot;Times New Roman&quot;;"></td>
<td style="width: 6%; vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="font-family: &quot;Times New Roman&quot;;"></td>
<td style="font-family: &quot;Times New Roman&quot;;"></td>
<td style="font-family: &quot;Times New Roman&quot;;"></td>
<td style="width: 6%; vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="font-family: &quot;Times New Roman&quot;;"></td>
<td style="font-family: &quot;Times New Roman&quot;;"></td>
<td style="font-family: &quot;Times New Roman&quot;;"></td>
<td style="width: 6%; vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="font-family: &quot;Times New Roman&quot;;"></td>
<td style="font-family: &quot;Times New Roman&quot;;"></td>
<td style="font-family: &quot;Times New Roman&quot;;"></td> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; white-space: nowrap; padding-bottom: 1pt;"> <div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt; border-bottom: 1pt solid rgb(0, 0, 0); display: table-cell; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">Description</div></div></div> </td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Quoted Prices<br/>in Active<br/>Markets</div></div><br/><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(Level 1)</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Significant Other<br/>Observable&#160;Inputs</div></div><br/><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(Level 2)</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Significant&#160;Other</div></div><br/><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Unobservable&#160;Inputs</div></div><br/><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(Level 3)</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Assets:</div></div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Cash and Marketable Securities held in Trust Accounting:</div></div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">U.S. Treasury securities maturing on April&#160;8, 2021</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">410,803,122</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#160;&#160;&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Cash</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">289</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">410,803,411</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Liabilities:</div></div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Derivative warrant liabilities</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">32,652,100</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">16,445,130</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Transfers to/from Levels 1. 2. and 3 are recognized at the end of the reporting period. The estimated fair value of the Public Warrants transferred from a Level&#160;3 measurement to a Level&#160;1 fair value measurement as of December 2020 as the Public Warrants were separately listed and traded beginning in November 2020. The amount transferred to Level&#160;1 was $30.2&#160;million. </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Level&#160;1 instruments include investments in mutual funds invested in government securities. The Company uses inputs such as actual trade data, benchmark yields, quoted market prices from dealers or brokers, and other similar sources to determine the fair value of its investments. </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The fair value of the Public Warrants (if not market observed) and Private Placement Warrants is estimated using a Binomial Lattice in a risk-neutral framework. Specifically, the future stock price of the Company is modeled assuming a Geometric Brownian Motion in a risk-neutral framework. For each modeled future price, the Warrant payoff is calculated based on the contractual terms (incorporating any optimal early exercise / redemption), and then discounted at the term-matched risk-free rate. The value of the Warrants is calculated as the probability-weighted present value over all future modeled payoffs. </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The following table provides quantitative information regarding Level&#160;3 fair value measurements inputs at their measurement dates: </div></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 68%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="font-size: 0px;">
<td style="width: 77%;"></td>
<td style="width: 15%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">As&#160;of&#160;October&#160;9,<br/>2020</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Volatility</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">22.5</td>
<td style="vertical-align: bottom; white-space: nowrap;">%&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Expected date of Business Combination</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">Mar-21</div></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Risk-free rate</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">0.39</td>
<td style="vertical-align: bottom; white-space: nowrap;">%&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Dividend yield</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">0.0</td>
<td style="vertical-align: bottom; white-space: nowrap;">%&#160;</td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The change in the fair value of the derivative warrant liabilities for the period from July&#160;6, 2020 (inception) through December&#160;31, 2020 is summarized as follows: </div></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 76%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="font-size: 0px;">
<td style="width: 82%; font-family: &quot;Times New Roman&quot;;"></td>
<td style="width: 5%; vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="font-family: &quot;Times New Roman&quot;;"></td>
<td style="font-family: &quot;Times New Roman&quot;;"></td>
<td style="font-family: &quot;Times New Roman&quot;;"></td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Derivative warrant liabilities at July&#160;6, 2020 (inception)</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Issuance of Public and Private Placement Warrants</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">45,509,340</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Change in fair value of derivative warrant liabilities</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">3,587,890</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Derivative warrant liabilities at December&#160;31, 2020</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">49,097,230</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">F-85 </div></div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;;font-weight: bold;"><a href="#toc" style="text-indent: 0px;">Table of Contents</a></div> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Note 10&#8212;Income Taxes </div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;">The Company does not currently have taxable income but will generate taxable income in the future primarily consisting of interest income earned on the Trust Account. The Company&#8217;s general and administrative costs are generally considered <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">start-up</div> costs and are not currently deductible. The income tax provision (benefit) consists of the following: </div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 68%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="font-size: 0px;">
<td style="width: 80%;"></td>
<td style="width: 12%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">For the<br/>Period from<br/>July&#160;6, 2020<br/>(inception)<br/>through<br/>December&#160;31,<br/>2020</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Current</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Federal</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">16,709</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">State</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td colspan="4" style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Deferred</div></div> </td>
<td style="vertical-align: top;"> <div style="text-indent: 0em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Federal</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">94,345</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">State</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Valuation on allowance</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(94,345</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Income tax provision</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">16,709</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The Company&#8217;s net deferred tax assets are as follows: </div></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 84%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="font-size: 0px;">
<td style="width: 85%;"></td>
<td style="width: 8%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">December&#160;31,</div></div><br/><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2020</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Deferred tax assets:</div></div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"></td>
<td style="vertical-align: bottom;"></td>
<td style="vertical-align: bottom;"></td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">Start-up/Organization</div> costs</div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">95,524</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Total deferred tax assets</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">95,524</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Valuation allowance</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(94,345</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Deferred tax asset, net of allowance</div></div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">1,179</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td colspan="4" style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Deferred tax liabilities:</div></div></div> </td>
<td style="vertical-align: top;"> <div style="text-indent: 0em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0em; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div> </td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Unrealized gain on marketable securities held in the Trust Account</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(1,179</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Total deferred tax liabilities</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(1,179</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Net Deferred tax assets/(liabilities), net of valuation allowance</div></div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">In assessing the realization of deferred tax assets, management considers whether it is more likely than not that some portion or all of the deferred tax assets will not be realized. The ultimate realization of deferred tax assets is dependent upon the generation of future taxable income during the periods in which temporary differences representing net future deductible amounts become deductible. Management considers the scheduled reversal of deferred tax assets, projected future taxable income and tax planning strategies in making this assessment. After consideration of all of the information available, management believes that significant uncertainty exists with respect to future realization of the deferred tax assets and has therefore established a full valuation allowance. </div></div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">F-86 </div></div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;;font-weight: bold;"><a href="#toc">Table of Contents</a></div> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">A reconciliation of the statutory federal income tax rate (benefit) to the Company&#8217;s effective tax rate (benefit) is as follows: </div></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 68%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="font-size: 0px;">
<td style="width: 80%;"></td>
<td style="width: 16%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">For the<br/>Period from<br/>July&#160;6, 2020<br/>(inception)<br/>through<br/>December&#160;31,<br/>2020</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Statutory Federal income tax rate</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">21.0</td>
<td style="vertical-align: bottom; white-space: nowrap;">%&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Change in fair value of derivative warrant liabilities</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(7.0</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Financing Cost</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(13.3</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Change in Valuation Allowance</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(0.9</td>
<td style="vertical-align: bottom; white-space: nowrap;">)%&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Income Taxes Benefit</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(0.2</td>
<td style="vertical-align: bottom; white-space: nowrap;">)%&#160;</td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">There were no unrecognized tax benefits as of December&#160;31, 2020. No amounts were accrued for the payment of interest and penalties as of December&#160;31, 2020. The Company is currently not aware of any issues under review that could result in significant payments, accruals or material deviation from its position. The Company is subject to income tax examinations by major taxing authorities since inception. The Company&#8217;s management does not expect that the total amount of unrecognized tax benefits will materially change over the next twelve months. </div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Note 11&#8212;Subsequent Events </div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Management has evaluated subsequent events to determine if events or transactions occurring through March&#160;22, 2021, the date the financial statements were available for issuance, require potential adjustment to or disclosure in the financial statements and has concluded that all such events that would require recognition or disclosure have been recognized or disclosed. </div></div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">F-87 </div></div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;;font-weight: bold;"><a href="#toc" style="text-indent: 0px;">Table of Contents</a></div> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><br/></div> <div id="fin164680_21" style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">MONTES ARCHIMEDES ACQUISITION CORP. </div></div></div> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">UNAUDITED CONDENSED&#160;BALANCE SHEETS </div></div></div> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">JUNE&#160;30, 2021 AND DECEMBER&#160;31, 2020 </div></div></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="font-size: 0px;">
<td style="width: 72%;"></td>
<td style="width: 3%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td>
<td style="width: 3%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">June&#160;30,&#160;2021</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">December&#160;31,&#160;2020</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(Unaudited)</div></div></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td colspan="2" style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Assets:</div></div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Current assets:</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Cash</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">1,173,304</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">1,696,491</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Prepaid expenses</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">128,136</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">276,093</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Due from underwriters</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">4,877</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Total current assets</div></div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">1,301,440</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">1,977,461</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Cash and Marketable Securities held in Trust Account</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">410,798,072</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">410,803,411</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Total Assets</div></div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">$</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">412,099,512</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">$</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">412,780,872</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Liabilities and Stockholders&#8217; Equity:</div></div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Current liabilities:</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Accounts payable</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">3,256,767</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">207,029</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Accrued expenses</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">5,615,000</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">240,402</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Accrued income tax</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">19,504</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">16,709</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Franchise tax payable</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">85,276</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">88,583</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Total current liabilities</div></div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">8,976,547</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">552,723</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Derivative warrant liabilities</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">47,355,420</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">49,097,230</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Deferred underwriting commissions</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">14,375,138</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">14,375,138</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Total liabilities</div></div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">70,707,105</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">64,025,091</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Commitments and Contingencies</div></div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Class&#160;A common stock, $0.0001 par value; 33,639,240 and 34,375,578 shares subject to possible redemption at $10.00 per share as of June&#160;30, 2021 and December&#160;31, 2020, respectively</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">336,392,400</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">343,755,780</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Stockholders&#8217; Equity:</div></div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Preferred stock, $0.0001 par value; 1,000,000 shares authorized; none issued and outstanding</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Class&#160;A common stock, $0.0001 par value; 400,000,000 shares authorized; 7,432,583 and 6,696,245 shares issued and outstanding (excluding 33,639,240 and 34,375,578 shares subject to possible redemption) as of June&#160;30, 2021 and December&#160;31, 2020, respectively</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">743</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">670</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Class&#160;B common stock, $0.0001 par value; 40,000,000 shares authorized; 10,267,956 shares issued and outstanding as of June&#160;30, 2021 and December&#160;31, 2020</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">1,027</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">1,027</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;">Additional <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">paid-in</div> capital</div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">23,135,928</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">15,772,622</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Accumulated deficit</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(18,137,691</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(10,774,318</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Total stockholders&#8217; equity</div></div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">5,000,007</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">5,000,001</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Total Liabilities and Stockholders&#8217; Equity</div></div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">$</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">412,099,512</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">$</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">412,780,872</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">The accompanying notes are an integral part of these unaudited condensed financial statements. </div></div></div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">F-88 </div></div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;;font-weight: bold;"><a href="#toc" style="text-indent: 0px;">Table of Contents</a></div> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"> <div id="fin164680_22" style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">MONTES ARCHIMEDES ACQUISITION CORP. </div></div></div> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">UNAUDITED CONDENSED STATEMENTS OF OPERATIONS </div></div></div> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">FOR THE THREE AND SIX MONTHS ENDED JUNE&#160;30, 2021 </div></div></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="font-size: 0px;">
<td style="width: 67%;"></td>
<td style="width: 6%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td>
<td style="width: 6%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">For&#160;the&#160;Three&#160;Months<br/>Ended June&#160;30, 2021</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">For&#160;the&#160;Six&#160;Months<br/>Ended&#160;June&#160;30,&#160;2021</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">General and administrative expenses</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">5,105,898</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">9,040,356</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Administrative expenses&#8212;related party</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">30,000</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">60,000</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Franchise tax expense</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">35,961</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">85,276</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Loss from operations</div></div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(5,171,859</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(9,185,632</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Other income (expense):</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Change in fair value of derivative warrant liabilities</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(21,217,690</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">1,741,810</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Interest earned on marketable securities held in Trust Account</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">7,076</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">99,953</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Net loss before taxes</div></div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(26,382,473</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(7,343,869</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Income tax expense</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">19,504</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Net loss</div></div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(26,382,473</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(7,363,373</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Weighted average shares outstanding of common stock subject to redemption, basic and diluted</div></div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">36,248,495</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">35,327,718</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Basic and diluted net income per share, common stock subject to redemption</div></div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">0.00</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">0.00</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-weight:bold;display:inline;">Weighted average shares outstanding of <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-redeemable</div> common stock, basic and diluted</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">15,091,284</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">16,012,061</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom;"></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-weight:bold;display:inline;">Basic and diluted net loss per share, <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-redeemable</div> common stock</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(1.75</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(0.46</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom;"></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">The accompanying notes are an integral part of these unaudited condensed financial statements. </div></div></div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">F-89 </div></div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;;font-weight: bold;"><a href="#toc" style="text-indent: 0px;">Table of Contents</a></div> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"> <div id="fin164680_23" style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">MONTES ARCHIMEDES ACQUISITION CORP. </div></div></div> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">UNAUDITED CONDENSED STATEMENTS OF CHANGES IN STOCKHOLDERS&#8217; EQUITY </div></div></div> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">FOR THE THREE AND SIX MONTHS ENDED JUNE&#160;30, 2021 </div></div></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="font-size: 0px;">
<td style="width: 35%;"></td>
<td style="width: 1%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td>
<td style="width: 1%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td>
<td style="width: 1%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td>
<td style="width: 1%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td>
<td style="width: 1%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td>
<td style="width: 1%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td>
<td style="width: 1%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td colspan="14" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Common Stock</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td rowspan="3" style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td colspan="2" rowspan="3" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Additional<br/><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">Paid-In</div></div></div><br/><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Capital</div></div></td>
<td rowspan="3" style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td rowspan="3" style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td colspan="2" rowspan="3" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Retained<br/>Earnings</div></div><br/><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(Accumulated</div></div><br/><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Deficit)</div></div></td>
<td rowspan="3" style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td rowspan="3" style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td colspan="2" rowspan="3" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Total</div></div><br/><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Stockholders&#8217;</div></div><br/><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Equity</div></div></td>
<td rowspan="3" style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td colspan="6" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Class&#160;A</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td colspan="6" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Class&#160;B</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Shares</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Amount</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Shares</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Amount</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Balance&#8212;December 31, 2020</div></div></div> </td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">6,696,245</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">$</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">670</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">10,267,956</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">$</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">1,027</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">$</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">15,772,622</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">$</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(10,774,318</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">)&#160;</div></div></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">$</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">5,000,001</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Class&#160;A common stock subject to possible redemption</div></div> </td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(1,901,909</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(191</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(15,772,622</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(3,246,278</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(19,019,091</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Net income</div></div> </td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">19,019,100</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">19,019,100</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Balance&#8212;March 31, 2021 (Unaudited)</div></div></div> </td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">4,794,336</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">479</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">10,267,956</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">1,027</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#8212;&#160;&#160;</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">4,998,504</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">5,000,010</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Class&#160;A common stock subject to possible redemption</div></div> </td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">2,638,247</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">264</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">23,135,928</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">3,246,278</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">26,382,470</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Net loss</div></div> </td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(26,382,473</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(26,382,473</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Balance&#8212;June 30, 2021 (Unaudited)</div></div></div> </td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">7,432,583</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">$</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">743</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">10,267,956</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">$</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">1,027</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">$</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">23,135,928</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">$</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(18,137,691</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">)&#160;</div></div></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">$</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">5,000,007</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">The accompanying notes are an integral part of these unaudited condensed financial statements. </div></div></div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">F-90 </div></div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;;font-weight: bold;"><a href="#toc" style="text-indent: 0px;">Table of Contents</a></div> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"> <div id="fin164680_24" style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">MONTES ARCHIMEDES ACQUISITION CORP. </div></div></div> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">UNAUDITED CONDENSED STATEMENT OF&#160;CASH FLOWS </div></div></div> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">FOR THE SIX MONTHS ENDED JUNE&#160;30, 2021 </div></div></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="font-size: 0px;">
<td style="width: 88%; font-family: &quot;Times New Roman&quot;;"></td>
<td style="width: 2%; vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="font-family: &quot;Times New Roman&quot;;"></td>
<td style="font-family: &quot;Times New Roman&quot;;"></td>
<td style="font-family: &quot;Times New Roman&quot;;"></td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Cash Flows from Operating Activities:</div></div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Net loss</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(7,363,373</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Adjustments to reconcile net loss to net cash used in operating activities:</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Interest earned on marketable securities held in Trust Account</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(99,953</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Change in fair value of derivative warrant liabilities</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(1,741,810</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Changes in operating assets and liabilities:</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Prepaid expenses</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">147,957</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Accounts payable</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">3,049,738</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Accrued expenses</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">5,374,598</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Accrued income tax</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">2,795</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Franchise tax payable</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">101,984</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Net cash used in operating activities</div></div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(528,064</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Cash Flows from Financing Activities:</div></div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Reimbursement of offering costs from underwriters</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">4,877</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Net cash provided by financing activities</div></div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">4,877</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Net decrease in cash</div></div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(523,187</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td> </tr>
<tr style="font-size: 1pt;">
<td style="height: 6pt; font-family: &quot;Times New Roman&quot;;"></td>
<td colspan="4" style="height: 6pt; font-family: &quot;Times New Roman&quot;;"></td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Cash&#8212;beginning of the period</div></div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">1,696,491</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Cash&#8212;end of the period</div></div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">$</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">1,173,304</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Supplemental disclosure of noncash activities:</div></div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Change in Value of Class&#160;A common stock subject to possible redemption</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(7,363,379</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">The accompanying notes are an integral part of these unaudited condensed financial statements. </div></div></div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">F-91 </div></div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;;font-weight: bold;"><a href="#toc" style="text-indent: 0px;">Table of Contents</a></div> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"> <div id="fin164680_25" style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">MONTES ARCHIMEDES ACQUISITION CORP. </div></div></div> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">NOTES TO UNAUDITED CONDENSED FINANCIAL STATEMENTS </div></div></div> <div id="FIN164680_9" style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Note&#160;1&#8212;Description of Organization, Business Operations and Basis of Presentation </div></div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Montes Archimedes Acquisition Corp. (the &#8220;Company&#8221;) was incorporated in Delaware on July&#160;6, 2020. The Company was formed for the purpose of effecting a merger, capital stock exchange, asset acquisition, stock purchase, reorganization or similar business combination with one or more businesses (the &#8220;Business Combination&#8221;). The Company is an emerging growth company and, as such, the Company is subject to all of the risks associated with emerging growth companies. </div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">As of June&#160;30, 2021, the Company had not commenced any operations. All activity for the period from July&#160;6, 2020 (inception) through June&#160;30, 2021 relates to the Company&#8217;s formation and the preparation for the initial public offering (the &#8220;Initial Public Offering&#8221;) described below. The Company will not generate any operating revenues until after the completion of its initial Business Combination, at the earliest. The Company generates <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-operating</div> income in the form of interest income on cash and cash equivalents from the proceeds derived from the Initial Public Offering. The Company has selected December&#160;31 as its fiscal&#160;year end. </div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The Company&#8217;s sponsor is Patient Square Capital LLC (the &#8220;Sponsor&#8221;). The registration statement for the Company&#8217;s Initial Public Offering was declared effective on October&#160;6, 2020. On October&#160;9, 2020, the Company consummated its Initial Public Offering of 40,000,000 units (the &#8220;Units&#8221;) at $10.00 per Unit, generating gross proceeds of $400.0&#160;million, and incurring offering costs of approximately $22.1&#160;million (net of reimbursement of offering costs of $520,000 from the underwriters), inclusive of $14.0&#160;million in deferred underwriting commissions (Note&#160;5). The underwriters exercised the over-allotment option in full and on November&#160;12, 2020 purchased an additional 1,071,823 Units (the &#8220;Over-Allotment Units&#8221;), generating gross proceeds of approximately $10.7&#160;million, and incurred additional offering costs of approximately $576,000 in underwriting fees (net of reimbursement of offering costs of approximately $14,000 from the underwriters and inclusive of approximately $375,000 in deferred underwriting fees) (the &#8220;Over-Allotment&#8221;). </div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Simultaneously with the closing of the Initial Public Offering, the Company consummated the private placement (&#8220;Private Placement&#8221;) of 10,000,000 warrants (each, a &#8220;Private Placement Warrant&#8221; and collectively, the &#8220;Private Placement Warrants&#8221;) at a price of $1.00 per Private Placement Warrant to the Sponsor, generating proceeds of $10.0&#160;million (Note&#160;4).&#160;Simultaneously with the closing of the Over-allotment on November&#160;12, 2020, the Company consummated the second closing of the Private Placement, resulting in the purchase of an aggregate of&#160;an additional&#160;214,365 Private Placement Warrants&#160;by the Sponsor, generating gross proceeds to the Company of approximately $214,000. </div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">Upon the closing of the Initial Public Offering, the Over-Allotment, and the Private Placement, approximately $410.7&#160;million ($10.00 per Unit) of the net proceeds of the sale of the Units in the Initial Public Offering and of the Private Placement Warrants in the Private Placement were placed in a trust account (&#8220;Trust Account&#8221;) located in the United States with Continental Stock Transfer&#160;&amp; Trust Company acting as trustee, and invested only in U.S. &#8220;government securities,&#8221; within the meaning set forth in Section&#160;2(a)(16) of the Investment Company Act, with a maturity of 185 days or less, or in money market funds meeting certain conditions under Rule <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">2a-7</div> under the Investment Company Act, which invest only in direct U.S. government treasury obligations, as determined by the Company, until the earlier of: (i)&#160;the completion of a Business Combination and (ii)&#160;the distribution of the Trust Account as described below. </div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The Company&#8217;s management has broad discretion with respect to the specific application of the net proceeds of the Initial Public Offering and the sale of the Private Placement Warrants, although substantially all of the net proceeds are intended to be applied generally toward consummating a Business Combination. There is no assurance that the Company will be able to complete a Business Combination successfully. The Company must complete an initial Business Combination with one or more operating businesses or assets with a fair market </div></div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">F-92 </div></div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;;font-weight: bold;"><a href="#toc" style="text-indent: 0px;">Table of Contents</a></div> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">MONTES ARCHIMEDES ACQUISITION CORP. </div></div></div> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">NOTES TO UNAUDITED CONDENSED FINANCIAL STATEMENTS </div></div></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">value equal to at least 80% of the net assets held in the Trust Account (as defined below) (excluding the deferred underwriting commissions and taxes payable on the interest earned on the Trust Account). However, the Company will only complete a Business Combination if the post-transaction company owns or acquires 50% or more of the outstanding voting securities of the target or otherwise acquires a controlling interest in the target business sufficient for it not to be required to register as an investment company under the Investment Company Act 1940, as amended (the &#8220;Investment Company Act&#8221;). </div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">The Company will provide holders (the &#8220;Public Stockholders&#8221;) of the Company&#8217;s outstanding shares of Class&#160;A common stock sold in the Initial Public Offering (the &#8220;Public Shares&#8221;) with the opportunity to redeem all or a portion of their Public Shares upon the completion of a Business Combination either (i)&#160;in connection with a stockholder meeting called to approve the Business Combination or (ii)&#160;by means of a tender offer. The decision as to whether the Company will seek stockholder approval of a Business Combination or conduct a tender offer will be made by the Company, solely in its discretion. The Public Stockholders will be entitled to redeem their Public Shares for a pro rata portion of the amount then held in the Trust Account (initially anticipated to be $10.00 per Public Share), calculated as of two business&#160;days prior to the initial Business Combination, including interest earned on the funds held in the trust account and not previously released to the Company to pay the Company&#8217;s taxes, net of taxes payable. The <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">per-share</div> amount to be distributed to Public Stockholders who redeem their Public Shares will not be reduced by the deferred underwriting commissions the Company will pay to the underwriters (as discussed in Note&#160;5). The Company will proceed with a Business Combination if a majority of the shares voted are voted in favor of the Business Combination. The Company will not redeem the Public Shares in an amount that would cause its net tangible assets to be less than $5,000,001. If a stockholder vote is not required by applicable law or stock exchange rule&#160;and the Company does not decide to hold a stockholder vote for business or other reasons, the Company will, pursuant to its amended and restated certificate of incorporation (the &#8220;Certificate of Incorporation&#8221;), conduct the redemptions pursuant to the tender offer rules&#160;of the U.S. Securities and Exchange Commission (&#8220;SEC&#8221;) and file tender offer documents with the SEC prior to completing a Business Combination. If, however, stockholder approval of the transaction is required by applicable law or stock exchange rule, or the Company decides to obtain stockholder approval for business or reasons, the Company will offer to redeem shares in conjunction with a proxy solicitation pursuant to the proxy rules&#160;and not pursuant to the tender offer rules. Additionally, each Public Stockholder may elect to redeem their Public Shares without voting, and if they do vote, irrespective of whether they vote for or against the proposed transaction. If the Company seeks stockholder approval in connection with a Business Combination, the initial stockholders (as defined below) agreed to vote any Founder Shares (as defined below in Note&#160;4) and any Public Shares held by them in favor of a Business Combination. In addition, the initial stockholders agreed to waive their redemption rights with respect to any Founder Shares and any Public Shares held by them in connection with the completion of a Business Combination. </div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">The Certificate of Incorporation will provide that a Public Stockholder, together with any affiliate of such stockholder or any other person with whom such stockholder is acting in concert or as a &#8220;group&#8221; (as defined under Section&#160;13 of the Securities Exchange Act of 1934, as amended (the &#8220;Exchange Act&#8221;)), will be restricted from redeeming its shares with respect to more than an aggregate of 15% or more of the Public Shares, without the prior consent of the Company. The Sponsor and the Company&#8217;s officers and directors (the &#8220;initial stockholders&#8221;) agreed, pursuant to a letter agreement with the Company, that they will not propose any amendment to the Certificate of Incorporation (A)&#160;to modify the substance or timing of the Company&#8217;s obligation to allow redemption in connection with the initial Business Combination or to redeem 100% of the Public Shares if the Company does not complete a Business Combination within the Combination Period (as defined below) or (B)&#160;with respect to any other provision relating to stockholders&#8217; rights or <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">pre-initial</div> Business Combination activity, unless the Company provides the Public Stockholders with the opportunity to redeem their Public Shares upon approval of any such amendment at a <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">per-share</div> price, payable in cash, equal to the aggregate amount then </div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">F-93 </div></div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;;font-weight: bold;"><a href="#toc">Table of Contents</a></div> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">MONTES ARCHIMEDES ACQUISITION CORP. </div></div></div> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">NOTES TO UNAUDITED CONDENSED FINANCIAL STATEMENTS </div></div></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">on deposit in the Trust Account, including interest (which interest shall be net of taxes payable) divided by the number of then outstanding Public Shares. </div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">If the Company is unable to complete a Business Combination within 24 months&#160;from the closing of the Initial Public Offering, or October&#160;9, 2022, (as such period may be extended pursuant to the Certificate of Incorporation, the &#8220;Combination Period&#8221;), the Company will (i)&#160;cease all operations except for the purpose of winding up; (ii)&#160;as promptly as reasonably possible but not more than ten business&#160;days thereafter, redeem the Public Shares, at a <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">per-share</div> price, payable in cash, equal to the aggregate amount then on deposit in the Trust Account including interest earned on the funds held in the Trust Account and not previously released to the Company to pay its taxes, if any (less up to $100,000 of interest to pay dissolution expenses), divided by the number of the then outstanding Public Shares, which redemption will completely extinguish Public Stockholders&#8217; rights as stockholders (including the right to receive further liquidation distributions, if any), subject to applicable law; and (iii)&#160;as promptly as reasonably possible following such redemption, subject to the approval of the remaining stockholders and the board of directors, liquidate and dissolve, subject in each case, to the Company&#8217;s obligations under Delaware law to provide for claims of creditors and the requirements of other applicable law. </div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The initial stockholders agreed to waive their rights to liquidating distributions from the Trust Account with respect to any Founder Shares held by them if the Company fails to complete a Business Combination within the Combination Period. However, if the initial stockholders acquire Public Shares in or after the Initial Public Offering, they will be entitled to liquidating distributions from the Trust Account with respect to such Public Shares if the Company fails to complete a Business Combination within the Combination Period. The underwriters agreed to waive their rights to the deferred underwriting commission (see Note 5) held in the Trust Account in the event the Company does not complete a Business Combination within in the Combination Period and, in such event, such amounts will be included with the other funds held in the Trust Account that will be available to fund the redemption of the Public Shares. In the event of such distribution, it is possible that the per share value of the residual assets remaining available for distribution (including Trust Account assets) will be only, or less than, $10.00. In order to protect the amounts held in the Trust Account, the Sponsor has agreed to be liable to the Company if and to the extent any claims by a third party (except for the Company&#8217;s independent registered public accounting firm) for services rendered or products sold to the Company, or a prospective target business with which the Company has discussed entering into a transaction agreement (a &#8220;Target&#8221;), reduce the amount of funds in the Trust Account to below the lesser of (i) $10.00 per Public Share and (ii)&#160;the actual amount per Public Share held in the Trust Account as of the date of the liquidation of the Trust Account, if less than $10.00 per Public Share due to reductions in the value of the trust assets, less taxes payable, provided that such liability will not apply to any claims by a third party or Target that executed a waiver of any and all rights to the monies held in the Trust Account nor will it apply to any claims under the Company&#8217;s indemnity of the underwriters of the Initial Public Offering against certain liabilities, including liabilities under the Securities Act of 1933, as amended (the &#8220;Securities Act&#8221;). Moreover, in the event that an executed waiver is deemed to be unenforceable against a third party, then the Sponsor will not be responsible to the extent of any liability for such third-party claims. The Company will seek to reduce the possibility that the Sponsor will have to indemnify the Trust Account due to claims of creditors by endeavoring to have all vendors, service providers, prospective target businesses and other entities with which the Company does business, execute agreements with the Company waiving any right, title, interest or claim of any kind in or to monies held in the Trust Account. </div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Proposed Business Combination </div></div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;">On May&#160;1, 2021, we entered into a business combination agreement (the &#8220;<div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Business Combination Agreement</div></div>&#8221;) with Roivant Sciences Ltd., a Bermuda exempted limited company (&#8220;<div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Roivant</div></div>&#8221;), and Rhine Merger Sub, Inc., a Delaware corporation (&#8220;<div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Merger Sub&#8221;</div></div>). </div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">F-94 </div></div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;;font-weight: bold;"><a href="#toc" style="text-indent: 0px;">Table of Contents</a></div> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">MONTES ARCHIMEDES ACQUISITION CORP. </div></div></div> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">NOTES TO UNAUDITED CONDENSED FINANCIAL STATEMENTS </div></div></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">The Business Combination Agreement and the transactions contemplated thereby (collectively, the &#8220;<div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Transaction</div></div>&#8221;) were approved by the boards of directors of each of MAAC, Roivant and Merger Sub, the requisite shareholders of Roivant and Roivant in its capacity as the sole stockholder of Merger Sub. </div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">The Business Combination Agreement provides for, among other things, the following transactions: (i)&#160;Roivant&#8217;s <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">bye-laws</div> will be amended and restated, each outstanding share of Roivant will be subdivided (and in the case of certain <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-voting</div> shares of Roivant, converted) into common shares of Roivant (the &#8220;<div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Roivant Common Shares</div></div>&#8221;) based on a fixed exchange ratio of 2.9262 (the &#8220;<div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Roivant Exchange Ratio</div></div>&#8221;), and each outstanding equity award of Roivant will be subdivided and adjusted into comparable equity awards of Roivant, based on the Roivant Exchange Ratio (the steps contemplated by this clause (i), collectively, the &#8220;<div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">Pre-Closing</div> Steps</div></div>&#8221;); and (ii)&#160;Merger Sub will merge with and into MAAC, with MAAC surviving the merger as a wholly-owned subsidiary of Roivant (the &#8220;<div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Merger</div></div>&#8221;). At the effective time of the Merger (the &#8220;<div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Effective Time</div></div>&#8221;), (a) each outstanding share of MAAC Class&#160;A common stock and MAAC Class&#160;B common stock (other than treasury shares and any shares held by Patient Square Capital LLC, a Delaware limited liability company (the &#8220;<div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">MAAC Sponsor</div></div>&#8221;), or its affiliates) will be exchanged for one Roivant Common Share, (b)&#160;each outstanding share of MAAC Class&#160;B common stock held by the MAAC Sponsor or its affiliates will be exchanged for a number of Roivant Common Shares based on an exchange ratio (the &#8220;<div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">MAAC Sponsor Exchange Ratio</div></div>&#8221;), with a portion of such Roivant Common Shares issued to the MAAC Sponsor by virtue of the Merger being subject to the vesting and other terms and conditions set forth in the Sponsor Support Agreement (as more fully described in the section entitled &#8220;Sponsor Support Agreement&#8221; below), and (c)&#160;each outstanding warrant to purchase shares of MAAC Class&#160;A common stock will be converted into a comparable warrant to purchase Roivant Common Shares on the terms and subject to the conditions set forth in the Warrant Agreement, dated as of October&#160;6, 2020, by and between MAAC and the Continental Stock Transfer&#160;&amp; Trust Company. The MAAC Sponsor Exchange Ratio is 1.0, subject to reduction in an amount equal to <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">one-half</div> of the percentage of shares of MAAC Class&#160;A common stock redeemed in connection with the Business Combination (i.e., if 10% of the shares of MAAC Class&#160;A common stock are so redeemed, then the MAAC Sponsor Exchange Ratio will be equal to 0.95), provided that in no event will the MAAC Sponsor Exchange Ratio be less than 0.75. </div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">The Transaction is expected to close (the &#8220;<div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Closing</div></div>&#8221;) in early fourth quarter of 2021, subject to the required approvals by MAAC&#8217;s stockholders and the fulfillment of other closing conditions. </div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">Refer to the Company&#8217;s current report on Form <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">8-K,</div> filed with the SEC on May&#160;1, 2021, for more information. </div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Liquidity and Going Concern Considerations </div></div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">As of June&#160;30, 2021, the Company had approximately $1,173,000 cash and a working capital deficit of approximately $7,570,000. </div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The Company&#8217;s liquidity needs prior to the consummation of the Initial Public Offering were satisfied through a payment of $25,000 from the Sponsor to cover certain expenses on behalf of the Company in exchange for the issuance of the Founder Shares (as defined below), the loan under the Note from the Sponsor of $200,000 (see Note 4) to the Company. The Company fully repaid the Note on October&#160;9, 2020. Subsequent to the consummation of the Initial Public Offering, the Company&#8217;s liquidity has been satisfied through the portion of the proceeds of the Initial Public Offering and the Private Placement held outside of the Trust Account. In addition, in order to finance transaction costs in connection with a Business Combination, the Sponsor or an affiliate of the Sponsor, or certain of the Company&#8217;s officers and directors may, but are not obligated to, provide the Company Working Capital Loans (see Note 4). To date, there were no amounts outstanding under any Working Capital Loans. </div></div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">F-95 </div></div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;;font-weight: bold;"><a href="#toc">Table of Contents</a></div> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">MONTES ARCHIMEDES ACQUISITION CORP. </div></div></div> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">NOTES TO UNAUDITED CONDENSED FINANCIAL STATEMENTS </div></div></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">In connection with our assessment of going concern considerations in accordance with ASU <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">2014-15,</div> &#8220;Disclosures of Uncertainties about an Entity&#8217;s Ability to Continue as a Going Concern,&#8221; as of June&#160;30, 2021, we do not have sufficient liquidity to meet our obligations in the next twelve months. However, management has determined that it has access to funds from the Sponsor that are sufficient to fund our working capital needs until the earlier of the consummation of a Business Combination or a minimum one year from the date of issuance of these financial statements. </div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">Management continues to evaluate the impact of <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">the&#160;COVID-19&#160;pandemic</div> and has concluded that the specific impact is not readily determinable as of the date of the financial statements. The financial statements do not include any adjustments that might result from the outcome of this uncertainty. </div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Basis of Presentation </div></div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The accompanying unaudited condensed financial statements are presented in U.S. dollars in conformity with accounting principles generally accepted in the United States of America (&#8220;GAAP&#8221;) for financial information and pursuant to the rules and regulations of the SEC. Accordingly, they do not include all of the information and footnotes required by GAAP. In the opinion of management, the unaudited condensed financial statements reflect all adjustments, which include only normal recurring adjustments necessary for the fair statement of the balances and results for the period presented. Operating results for the three and six months ended June&#160;30, 2021 are not necessarily indicative of the results that may be expected through December&#160;31, 2021. </div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">The accompanying unaudited condensed financial statements should be read in conjunction with the audited financial statements and notes thereto included in the Form <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">10-K,</div> as amended, filed by the Company with the SEC on May&#160;14, 2021. </div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Emerging Growth Company </div></div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The Company is an &#8220;emerging growth company,&#8221; as defined in Section&#160;2(a)&#160;of the Securities Act, as modified by the Jumpstart Our Business Startups Act of 2012 (the &#8220;JOBS Act&#8221;), and it may take advantage of certain exemptions from various reporting requirements that are applicable to other public companies that are not emerging growth companies including, but not limited to, not being required to comply with the independent registered public accounting firm attestation requirements of Section&#160;404 of the Sarbanes-Oxley Act, reduced disclosure obligations regarding executive compensation in its periodic reports and proxy statements, and exemptions from the requirements of holding a nonbinding advisory vote on executive compensation and stockholder approval of any golden parachute payments not previously approved. </div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">Further, Section&#160;102(b)(1)&#160;of the JOBS Act exempts emerging growth companies from being required to comply with new or revised financial accounting standards until private companies (that is, those that have not had a Securities Act registration statement declared effective or do not have a class of securities registered under the Exchange Act) are required to comply with the new or revised financial accounting standards. The JOBS Act provides that an emerging growth company can elect to opt out of the extended transition period and comply with the requirements that apply to <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-emerging</div> growth companies but any such an election to opt out is irrevocable. The Company has elected not to opt out of such extended transition period, which means that when a standard is issued or revised and it has different application dates for public or private companies, the Company, as an emerging growth company, can adopt the new or revised standard at the time private companies adopt the new or revised standard. </div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">This may make comparison of the Company&#8217;s financial statements with another public company that is neither an emerging growth company nor an emerging growth company that has opted out of using the extended transition period difficult or impossible because of the potential differences in accounting standards used. </div></div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">F-96 </div></div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;;font-weight: bold;"><a href="#toc" style="text-indent: 0px;">Table of Contents</a></div> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">MONTES ARCHIMEDES ACQUISITION CORP. </div></div></div> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">NOTES TO UNAUDITED CONDENSED FINANCIAL STATEMENTS </div></div></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Note&#160;2&#8212;Summary of Significant Accounting Policies </div></div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Concentration of Credit Risk </div></div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Financial instruments that potentially subject the Company to concentrations of credit risk consist of cash accounts in a financial institution, which, at times, may exceed the Federal Depository Insurance Coverage limit of $250,000. At June&#160;30, 2021, the Company has not experienced losses on these accounts and management believes the Company is not exposed to significant risks on such accounts. </div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Cash and Cash Equivalents </div></div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The Company considers all short-term investments with an original maturity of three&#160;months or less when purchased to be cash equivalents. The Company had no cash equivalents as of June&#160;30, 2021 and December&#160;31, 2020. </div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Cash and Marketable Securities Held in Trust Account </div></div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The Company&#8217;s portfolio of investments held in the Trust Account is comprised of cash and U.S. government securities, within the meaning set forth in Section&#160;2(a)(16) of the Investment Company Act, with a maturity of 185 days or less. </div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Fair Value of Financial Instruments </div></div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Fair value is defined as the price that would be received for sale of an asset or paid for transfer of a liability, in an orderly transaction between market participants at the measurement date. U.S. GAAP establishes a three-tier fair value hierarchy, which prioritizes the inputs used in measuring fair value. </div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The hierarchy gives the highest priority to unadjusted quoted prices in active markets for identical assets or liabilities (Level 1 measurements) and the lowest priority to unobservable inputs (Level 3 measurements). These tiers include: </div></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 1%;">&#160;</td>
<td style="width: 2%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Level&#160;1, defined as observable inputs such as quoted prices for identical instruments in active markets; </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 1%;">&#160;</td>
<td style="width: 2%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Level&#160;2, defined as inputs other than quoted prices in active markets that are either directly or indirectly observable such as quoted prices for similar instruments in active markets or quoted prices for identical or similar instruments in markets that are not active; and </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 1%;">&#160;</td>
<td style="width: 2%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Level&#160;3, defined as unobservable inputs in which little or no market data exists, therefore requiring an entity to develop its own assumptions, such as valuations derived from valuation techniques in which one or more significant inputs or significant value drivers are unobservable. </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">In some circumstances, the inputs used to measure fair value might be categorized within different levels of the fair value hierarchy. In those instances, the fair value measurement is categorized in its entirety in the fair value hierarchy based on the lowest level input that is significant to the fair value measurement. </div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The fair value of the Company&#8217;s assets and liabilities, which qualify as financial instruments under ASC 820, &#8220;Fair Value Measurements and Disclosures,&#8221; approximates the carrying amounts represented in the accompanying balance sheet, primarily due to their short-term nature. </div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Use of Estimates </div></div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The preparation of the financial statements in conformity with U.S.&#160;GAAP requires the Company&#8217;s management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of </div></div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">F-97 </div></div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;;font-weight: bold;"><a href="#toc">Table of Contents</a></div> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">MONTES ARCHIMEDES ACQUISITION CORP. </div></div></div> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">NOTES TO UNAUDITED CONDENSED FINANCIAL STATEMENTS </div></div></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">contingent assets and liabilities at the date of the financial statements and the reported amounts of expenses during the reporting period. Actual results could differ from those estimates. </div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Derivative Warrant Liabilities </div></div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;">The Company does not use derivative instruments to hedge exposures to cash flow, market, or foreign currency risks. The Company evaluates all of its financial instruments, including issued stock purchase warrants, to determine if such instruments are derivatives or contain features that qualify as embedded derivatives, pursuant to ASC 480 and ASC <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">815-15.</div> The classification of derivative instruments, including whether such instruments should be recorded as liabilities or as equity, is <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">re-assessed</div> at the end of each reporting period. </div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">The Company accounts for its 30,750,277 warrants issued in connection with its Initial Public Offering (20,535,912)and Private Placement (10,214,365) as derivative warrant liabilities in accordance with ASC <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">815-40.</div> Accordingly, the Company recognizes the warrant instruments as liabilities at fair value and adjusts the instruments to fair value at each reporting period. The liabilities are subject to <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">re-measurement</div> at each balance sheet date until exercised, and any change in fair value is recognized in the Company&#8217;s statement of operations. The fair value of the Public Warrants (if not market observed) and Private Placement Warrants is estimated using a Binomial Lattice in a risk-neutral framework. Specifically, the future stock price of the Company is modeled assuming a Geometric Brownian Motion in a risk-neutral framework. For each modeled future price, the Warrant payoff is calculated based on the contractual terms (incorporating any optimal early exercise / redemption), and then discounted at the term-matched risk-free rate. The value of the Warrants is calculated as the probability-weighted present value over all future modeled payoffs. </div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Offering Costs Associated with the Initial Public Offering </div></div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;">Offering costs consisted of legal, accounting, underwriting fees and other costs incurred that were directly related to the Initial Public Offering. Offering costs are allocated to the separable financial instruments issued in the Initial Public Offering based on a relative fair value basis, compared to total proceeds received. Offering costs associated with warrant liabilities are expensed as incurred, presented as <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-operating</div> expenses in the statement of operations. Offering costs associated with the Public Shares were charged to stockholders&#8217; equity upon the completion of the Initial Public Offering. </div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Class&#160;A Common Stock Subject to Possible Redemption </div></div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The Company accounts for its Class&#160;A common stock subject to possible redemption in accordance with the guidance in ASC Topic 480 &#8220;Distinguishing Liabilities from Equity.&#8221; Shares of Class&#160;A common stock subject to mandatory redemption (if any) are classified as liability instruments and are measured at fair value. Conditionally redeemable shares of Class&#160;A common stock (including shares of Class&#160;A common stock that feature redemption rights that are either within the control of the holder or subject to redemption upon the occurrence of uncertain events not solely within the Company&#8217;s control) are classified as temporary equity. At all other times, shares of Class&#160;A common stock are classified as stockholders&#8217; equity. Shares of Class&#160;A common stock of the Company feature certain redemption rights that are considered to be outside of the Company&#8217;s control and subject to the occurrence of uncertain future events. Accordingly, as of June&#160;30, 2021 and December&#160;31, 2020, 33,639,240 and 34,375,578 shares, respectively, of Class&#160;A common stock subject to possible redemption were presented as temporary equity, outside of the stockholders&#8217; equity section of the Company&#8217;s balance sheet. </div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Income Taxes </div></div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The Company complies with the accounting and reporting requirements of FASB ASC 740, &#8220;Income Taxes,&#8221; which requires an asset and liability approach to financial accounting and reporting for income taxes. Deferred </div></div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">F-98 </div></div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;;font-weight: bold;"><a href="#toc" style="text-indent: 0px;">Table of Contents</a></div> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">MONTES ARCHIMEDES ACQUISITION CORP. </div></div></div> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">NOTES TO UNAUDITED CONDENSED FINANCIAL STATEMENTS </div></div></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">income tax assets and liabilities are computed for differences between the financial statement and tax bases of assets and liabilities that will result in future taxable or deductible amounts, based on enacted tax laws and rates applicable to the periods in which the differences are expected to affect taxable income. Valuation allowances are established, when necessary, to reduce deferred tax assets to the amount expected to be realized. </div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">FASB ASC 740 prescribes a recognition threshold and a measurement attribute for the financial statement recognition and measurement of tax positions taken or expected to be taken in a tax return. For those benefits to be recognized, a tax position must be <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">more-likely-than-not</div> to be sustained upon examination by taxing authorities. No amounts were accrued for the payment of interest and penalties as of June&#160;30, 2021. The Company is currently not aware of any issues under review that could result in significant payments, accruals or material deviation from its position. The Company recognizes accrued interest and penalties related to unrecognized tax benefits as income tax expense. </div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Net Income Per Common Share </div></div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The Company complies with accounting and disclosure requirements of FASB ASC Topic 260, &#8220;Earnings Per Share.&#8221; Net income (loss) per common share is computed by dividing net income (loss) by the weighted average number of shares of common stock outstanding during the period. The Company has not considered the effect of the warrants sold in the Initial Public Offering and Private Placement to purchase an aggregate of 30,750,277 shares of the Company&#8217;s common stock in the calculation of diluted income per share, since the inclusion of such warrants would be anti-dilutive. </div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">The Company&#8217;s statement of operations includes a presentation of income (loss) per common share for Class&#160;A common shares subject to possible redemption in a manner similar to the <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">two-class</div> method of income (loss) per common share. Net income (loss) per common share, basic and diluted, for Class&#160;A common stock subject to possible redemption is calculated by dividing the proportionate share of income or loss on marketable securities held by the Trust Account, net of applicable franchise and income taxes, by the weighted average number of shares of Class&#160;A common stock subject to possible redemption outstanding since original issuance. </div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">Net income per common share, basic and diluted, for <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-redeemable</div> common stock is calculated by dividing the net income, adjusted for income or loss on marketable securities attributable to common stock subject to possible redemption, by the weighted average number of <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-redeemable</div> common stock outstanding for the period. </div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">Non-redeemable</div> common stock includes Founder Shares and <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-redeemable</div> shares of Class&#160;A common stock as these shares do not have any redemption features. <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">Non-redeemable</div> common stock participates in the income or loss on marketable securities based on <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-redeemable</div> shares&#8217; proportionate interest. </div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">F-99 </div></div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;;font-weight: bold;"><a href="#toc">Table of Contents</a></div> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">MONTES ARCHIMEDES ACQUISITION CORP. </div></div></div> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">NOTES TO UNAUDITED CONDENSED FINANCIAL STATEMENTS </div></div></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The following table reflects the calculation of basic and diluted net income per common share: </div></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="font-size: 0px;">
<td style="width: 69%;"></td>
<td style="width: 5%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td>
<td style="width: 5%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">For&#160;the&#160;Three&#160;Months<br/>Ended&#160;June 30,&#160;2021</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">For&#160;the&#160;Six&#160;Months<br/>Ended&#160;June&#160;30,&#160;2021</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Class&#160;A Common stock subject to possible redemption</div></div></div></div> </td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Numerator: Earnings allocable to Common stock subject to possible redemption</div></div> </td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Income from investments held in Trust Account</div></div> </td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">5,795</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">81,862</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Less: Company&#8217;s portion available to be withdrawn to pay taxes</div></div> </td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(5,795</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(81,862</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 5em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Net income attributable</div></div> </td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">$</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#8212;&#160;&#160;</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">$</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#8212;&#160;&#160;</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Denominator: Weighted average Class&#160;A common stock subject to possible redemption</div></div> </td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Basic and diluted weighted average shares outstanding</div></div> </td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">36,248,495</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">35,327,718</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Basic and diluted net income per share</div></div> </td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">$</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">0.00</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">$</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">0.00</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td> </tr>
<tr style="font-size: 1pt;">
<td style="height: 6pt; font-family: &quot;Times New Roman&quot;;"></td>
<td colspan="4" style="height: 6pt; font-family: &quot;Times New Roman&quot;;"></td>
<td colspan="4" style="height: 6pt; font-family: &quot;Times New Roman&quot;;"></td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">Non-Redeemable</div> Common Stock</div></div></div></div> </td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Numerator: Net Loss minus Net Earnings</div></div> </td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Net loss</div></div> </td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(26,382,473</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(7,363,373</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Less: Net income allocable to Class&#160;A common stock subject to possible redemption</div></div> </td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 5em; line-height: normal;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">Non-redeemable</div> net gain</div> </td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">$</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(26,382,473</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">)&#160;</div></div></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">$</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(7,363,373</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">)&#160;</div></div></td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;">Denominator: weighted average <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">Non-redeemable</div> common stock</div> </td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"></td>
<td style="vertical-align: bottom;"></td>
<td style="vertical-align: bottom;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"></td>
<td style="vertical-align: bottom;"></td>
<td style="vertical-align: bottom;"></td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;">Basic and diluted weighted average shares outstanding, <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">Non-redeemable</div> common stock</div> </td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">15,091,284</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">16,012,061</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;">Basic and diluted net loss per share, <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">Non-redeemable</div> common stock</div> </td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">$</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(1.75</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">)&#160;</div></div></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">$</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(0.46</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">)&#160;</div></div></td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Recent Issued Accounting Standards </div></div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The Company&#8217;s management does not believe that any recently issued, but not yet effective, accounting standards updates, if currently adopted, would have a material effect on the accompanying financial statement. </div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Note&#160;3&#8212;Initial Public Offering </div></div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">On October&#160;9, 2020, the Company consummated its&#160;Initial Public Offering of 40,000,000 Units at $10.00 per Unit, generating gross proceeds of&#160;$400.0&#160;million, and incurring offering costs of approximately $22.1&#160;million (net of reimbursement of offering costs of $520,000 from the underwriters), inclusive of $14.0&#160;million in deferred underwriting commissions. The Underwriters exercised the over-allotment option in full and on November&#160;12, 2020 purchased an additional 1,071,823 Over-Allotment Units, generating gross proceeds of approximately $10.7&#160;million, and incurred additional offering costs of approximately $576,000 in underwriting fees (net of reimbursement of offering costs of approximately $14,000 from the underwriters and inclusive of approximately $375,000 in deferred underwriting fees). </div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">Each Unit consists of one share of Class&#160;A common stock, and <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">one-half</div> of one redeemable warrant (each, a &#8220;Public Warrant&#8221;). Each whole Public Warrant entitles the holder to purchase one share of Class&#160;A common stock at a price of $11.50 per share, subject to adjustment (see Note&#160;6). </div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">F-100 </div></div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;;font-weight: bold;"><a href="#toc" style="text-indent: 0px;">Table of Contents</a></div> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">MONTES ARCHIMEDES ACQUISITION CORP. </div></div></div> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">NOTES TO UNAUDITED CONDENSED FINANCIAL STATEMENTS </div></div></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Note&#160;4&#8212;Related Party Transactions </div></div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Founder Shares </div></div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">On&#160;July&#160;23, 2020, an affiliate&#160;of the Sponsor paid an aggregate of $25,000 for certain expenses on behalf of the Company in exchange for issuance of 14,375,000 shares of the Company&#8217;s Class&#160;B common stock, par value $0.0001 per share (the &#8220;Founder Shares&#8221;), with such shares subsequently transferred to the Sponsor. On October&#160;6, 2020, the Sponsor surrendered 2,875,000 shares of Class&#160;B common stock to the Company for no consideration, resulting in a decrease of the Founder Shares from 14,375,000 shares to 11,500,000 shares. All shares and associated amounts have been retroactively restated to reflect the share surrender. The initial stockholders agreed to forfeit up to 1,500,000 Founder Shares to the extent that the over-allotment option is not exercised in full by the underwriters, so that the Founder Shares will represent 20.0% of the Company&#8217;s issued and outstanding shares of common stock after the Initial Public Offering. The underwriters exercised their Over-Allotment option in part on November&#160;12, 2020; and the remaining over-allotment expired unexercised on November&#160;20, 2020 resulting in a forfeiture of 1,232,044 shares of Class&#160;B common stock. </div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">The Initial Stockholders agreed, subject to limited exceptions, not to transfer, assign or sell any of the Founder Shares until the earlier to occur of: (A)&#160;one&#160;year after the completion of the initial Business Combination or (B)&#160;subsequent to the initial Business Combination; (x)&#160;if the last reported sale price of Class&#160;A common stock equals or exceeds $12.00 per share (as adjusted for stock splits, stock capitalizations, reorganizations, recapitalizations and the like) for any 20 trading&#160;days within any <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">30-trading</div> day period commencing at least 150&#160;days after the initial Business Combination; or (y)&#160;the date on which the Company completes a liquidation, merger, capital stock exchange or other similar transaction that results in all of the stockholders having the right to exchange their common stock for cash, securities or other property. </div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Private Placement Warrants </div></div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Simultaneously with the closing of the Initial Public Offering, the Company consummated the Private Placement of 10,000,000 Private Placement Warrants at a price of $1.00 per Private Placement Warrant to the Sponsor, generating proceeds of $10.0&#160;million.&#160;Simultaneously with the closing of the Over-allotment on November&#160;12, 2020, the Company consummated the second closing of the Private Placement, resulting in the purchase of an aggregate of&#160;an additional&#160;214,365 Private Placement Warrants&#160;by the Sponsor, generating gross proceeds to the Company of approximately $214,000. </div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">Each whole Private Placement Warrant is exercisable for one whole share of Class&#160;A common stock at a price of $11.50 per share, subject to adjustment. A portion of the proceeds from the sale of the Private Placement Warrants to the Sponsor was added to the proceeds from the Initial Public Offering held in the Trust Account. If the Company does not complete a Business Combination within the Combination Period, the Private Placement Warrants will expire worthless. The Private Placement Warrants will be <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-redeemable</div> for cash (except as described below) and exercisable on a cashless basis so long as they are held by the Sponsor or its permitted transferees. </div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The Sponsor agreed, subject to limited exceptions, not to transfer, assign or sell the Private Placement Warrants until 30&#160;days after the completion of the initial Business Combination. </div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Related Party Loans </div></div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;">On&#160;July&#160;23, 2020, the Sponsor agreed to loan the Company an aggregate of up to $300,000 to cover expenses related to the Initial Public Offering pursuant to a promissory note (the &#8220;Note&#8221;). This loan was <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-interest</div> bearing and payable upon the completion of the Initial Public Offering. As of September&#160;30, 2020, the Company borrowed $200,000 under the Note. The Note&#160;was fully repaid on October&#160;9, 2020. </div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">F-101 </div></div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;;font-weight: bold;"><a href="#toc">Table of Contents</a></div> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">MONTES ARCHIMEDES ACQUISITION CORP. </div></div></div> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">NOTES TO UNAUDITED CONDENSED FINANCIAL STATEMENTS </div></div></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">In addition, in order to fund working capital deficiencies or finance transaction costs in connection with a Business Combination, the Sponsor or an affiliate of the Sponsor, or certain of the Company&#8217;s officers and directors may, but are not obligated to, loan the Company funds as may be required (&#8220;Working Capital Loans&#8221;). If the Company completes a Business Combination, the Company may repay the Working Capital Loans out of the proceeds of the Trust Account released to the Company. Otherwise, the Working Capital Loans could be repaid only out of funds held outside the Trust Account. In the event that a Business Combination does not close, the Company may use a portion of proceeds held outside the Trust Account to repay the Working Capital Loans but no proceeds held in the Trust Account would be used to repay the Working Capital Loans. The Working Capital Loans would either be repaid upon consummation of a Business Combination or, at the lender&#8217;s discretion, up to $1,500,000 of such Working Capital Loans may be convertible into warrants of the post Business Combination entity at a price of $1.00 per warrant. The warrants would be identical to the Private Placement Warrants. Except for the foregoing, the terms of such Working Capital Loans, if any, have not been determined and no written agreements exist with respect to such loans. To date, the Company had no borrowings under the Working Capital Loans. </div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Administrative Services Agreement </div></div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The Company entered into an agreement that will provide that, commencing on October&#160;7, 2020 through the earlier of consummation of the Business Combination and the liquidation, the Company will pay an affiliate of the Sponsor $10,000 per&#160;month for office space and administrative support services. For the three and six months ended June&#160;30, 2021, the Company incurred approximately $30,000 and $60,000, respectively, within General and administrative expenses &#8211; related party. As of June&#160;30, 2021 there was $0 in accounts payable &#8211; related party outstanding, as reflected in the accompanying unaudited condensed balance sheets. </div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Note&#160;5&#8212;Commitments&#160;&amp; Contingencies </div></div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Registration and Stockholder Rights </div></div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The holders of the Founder Shares, Private Placement Warrants and warrants that may be issued upon conversion of Working Capital Loans (and any Class&#160;A common stock issuable upon the exercise of the Private Placement Warrants and warrants that may be issued upon conversion of Working Capital Loans) are entitled to registration rights pursuant to the registration rights agreement. The holders of these securities are entitled to make up to three demands, excluding short form demands, that the Company registers such securities. In addition, the holders have certain &#8220;piggy-back&#8221; registration rights with respect to registration statements filed subsequent to the completion of the Business Combination. The Company will bear the expenses incurred in connection with the filing of any such registration statements. </div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Underwriting Agreement </div></div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The underwriters were entitled to an underwriting discount of $0.20 per unit, or $8.0&#160;million in the aggregate, paid upon the closing of the Initial Public Offering. In addition, $0.35 per unit, or $14.0&#160;million in the aggregate will be payable to the underwriters for deferred underwriting commissions. The deferred fee will become payable to the underwriters from the amounts held in the Trust Account solely in the event that the Company completes a Business Combination, subject to the terms of the underwriting agreement. The underwriters agreed to make a payment to the Company in an amount of 0.13% of the gross proceeds of the Initial Public Offering, or $520,000, to reimburse certain of offering expenses. The Company received such reimbursement on October&#160;27, 2020. </div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Upon closing of the Over-allotment on November&#160;12, 2020, the underwriters received approximately $214,000 in fees paid upfront and eligible for an additional deferred underwriting commissions of approximately $375,000. In </div></div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">F-102 </div></div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;;font-weight: bold;"><a href="#toc" style="text-indent: 0px;">Table of Contents</a></div> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">MONTES ARCHIMEDES ACQUISITION CORP. </div></div></div> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">NOTES TO UNAUDITED CONDENSED FINANCIAL STATEMENTS </div></div></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">addition, the underwriters agreed to make an addition payment to the Company in an amount of 0.13% of the gross proceeds of the Over-allotment, or approximately $14,000, to reimburse certain of offering expenses. As of June&#160;30, 2021, there was no outstanding balance. </div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Note&#160;6&#8212;Stockholders&#8217; Equity </div></div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Preferred Stock</div></div></div></div>&#8212; The Company is authorized to issue 1,000,000 shares of preferred stock, par value $0.0001 per share, with such designations, voting and other rights and preferences as may be determined from time to time by the Company&#8217;s board of directors. As of June&#160;30, 2021, there were no shares of preferred stock issued or outstanding. </div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Class</div></div></div></div><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"></div></div></div><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">&#160;A Common Stock</div></div></div></div>&#8212; The Company is authorized to issue 400,000,000 shares of Class&#160;A common stock with a par value of $0.0001 per share. As of June&#160;30, 2021, there were 41,071,823 shares of Class&#160;A common stock outstanding, including 33,639,240 shares of Class&#160;A common stock subject to possible redemption that were classified as temporary equity in the accompanying balance sheet. </div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Class</div></div></div></div><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"></div></div></div><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">&#160;B Common Stock</div></div></div></div>&#8212; The Company is authorized to issue 40,000,000 shares of Class&#160;B common stock with a par value of $0.0001 per share. On July&#160;23, 2020, an affiliate of the Sponsor paid an aggregate of $25,000 for certain expenses on behalf of the Company in exchange for issuance of 14,375,000 shares of Class&#160;B common stock, with such shares subsequently transferred to the Sponsor. On October&#160;6, 2020, the Sponsor surrendered 2,875,000 shares of Class&#160;B common stock to the Company for no consideration, resulting in a decrease of the outstanding Class&#160;B common stock from 14,375,000 shares to 11,500,000 shares. All shares and associated amounts have been retroactively restated to reflect the share surrender. Of these, an aggregate of up to 1,500,000&#160;shares of Class&#160;B common stock that are subject to forfeiture to the Company by the initial stockholders for no consideration to the extent that the underwriters&#8217; over-allotment option is not exercised in full or in part, so that the number of Founder Shares will equal 20% of the Company&#8217;s issued and outstanding shares of common stock after the Initial Public Offering. The underwriters partially exercised their over-allotment option on November&#160;12, 2020, and the remaining over-allotment expired unexercised on November&#160;20, 2020 resulting in the forfeiture of 1,232,044 Class&#160;B common shares. As of June&#160;30, 2021, 10,267,956 shares of Class&#160;B common stock were outstanding with no shares subject to forfeiture. </div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Stockholders of record are entitled to one vote for each share held on all matters to be voted on by stockholders. Holders of our Class&#160;A common stock and holders of our Class&#160;B common stock will vote together as a single class on all matters submitted to a vote of our stockholders except as required by law. </div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">The Class&#160;B common stock will automatically convert into Class&#160;A common stock on the first business day following the completion of the Business Combination at a ratio such that the number of shares of Class&#160;A common stock issuable upon conversion of all Founder Shares will equal, in the aggregate, on an <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">as-converted</div> basis, 20% of the sum of (i)&#160;the total number of shares of Class&#160;A common stock issued and outstanding upon completion of the Initial Public Offering, plus (ii)&#160;the sum of (a)&#160;the total number of shares of Class&#160;A common stock issued or deemed issued or issuable upon conversion or exercise of any equity-linked securities or rights issued or deemed issued, by the Company in connection with or in relation to the completion of the Business Combination, excluding any shares of Class&#160;A common stock or equity-linked securities exercisable for or convertible into shares of Class&#160;A common stock issued, or to be issued, to any seller in the initial Business Combination and any Private Placement Warrants issued to the Sponsor upon conversion of Working Capital Loans, minus (b)&#160;the number of Public Shares redeemed by Public Stockholders in connection with the initial Business Combination. In no event will the shares of Class&#160;B common stock convert into shares of Class&#160;A common stock at a rate of less than one to one. </div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">F-103 </div></div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;;font-weight: bold;"><a href="#toc">Table of Contents</a></div> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">MONTES ARCHIMEDES ACQUISITION CORP. </div></div></div> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">NOTES TO UNAUDITED CONDENSED FINANCIAL STATEMENTS </div></div></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Note&#160;7&#8212;Warrants </div></div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Public Warrants may only be exercised for a whole number of shares. No fractional Public Warrants will be issued upon separation of the Units and only whole Public Warrants will trade. The Public Warrants will become exercisable on the later of (a)&#160;30&#160;days after the completion of a Business Combination and (b)&#160;12&#160;months from the closing of the Initial Public Offering; provided in each case that the Company has an effective registration statement under the Securities Act covering the shares of Class&#160;A common stock issuable upon exercise of the warrants and a current prospectus relating to them is available and such shares are registered, qualified or exempt from registration under the securities, or blue sky, laws of the state of residence of the holder (or holders are permitted to exercise their warrants on a cashless basis under the circumstances specified in the warrant agreement as a result of (i)&#160;the Company&#8217;s failure to have an effective registration statement by the 60th&#160;business day after the closing of the initial Business Combination or (ii)&#160;a notice of redemption described below under &#8220;Redemption of warrants when the price per Class&#160;A common stock equals or exceeds $10.00&#8221;). If and when the warrants become redeemable by the Company, the Company may exercise its redemption right even if the Company is unable to register or qualify the underlying securities for sale under all applicable state securities laws. </div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The Company is not registering the shares of Class&#160;A common stock issuable upon exercise of the warrants at this time. However, the Company has agreed that as soon as practicable, but in no event later than twenty business&#160;days after the closing of the initial Business Combination, the Company will use its commercially reasonable efforts to file with the SEC and have an effective registration statement covering the shares of Class&#160;A common stock issuable upon exercise of the warrants and to maintain a current prospectus relating to those shares of Class&#160;A common stock until the warrants expire or are redeemed. If a registration statement covering the Class&#160;A common stock issuable upon exercise of the warrants is not effective by the 60th&#160;business day after the closing of the initial Business Combination, warrant holders may, until such time as there is an effective registration statement and during any period when the Company will have failed to maintain an effective registration statement, exercise warrants on a &#8220;cashless basis&#8221; in accordance with Section&#160;3(a)(9)&#160;of the Securities Act or another exemption. </div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The warrants will have an exercise price of $11.50 per share and will expire five&#160;years after the completion of a Business Combination or earlier upon redemption or liquidation. If (x)&#160;the Company issues additional shares of Class&#160;A common stock or equity-linked securities for capital raising purposes in connection with the closing of the initial Business Combination at an issue price or effective issue price of less than $9.20 per share of Class&#160;A common stock (with such issue price or effective issue price to be determined in good faith by the Company and, (i)&#160;in the case of any such issuance to the Sponsor or its affiliates, without taking into account any Founder Shares held by the Sponsor or such affiliates, as applicable, prior to such issuance, and (ii)&#160;to the extent that such issuance is made to the Sponsor or its affiliates, without taking into account the transfer of Founder Shares or Private Placement Warrants (including if such transfer is effectuated as a surrender to the Company and subsequent reissuance by the Company) by the Sponsor in connection with such issuance) (the &#8220;Newly Issued Price&#8221;), (y)&#160;the aggregate gross proceeds from such issuances represent more than 60% of the total equity proceeds, and interest thereon, available for the funding of the initial Business Combination on the date of the completion of the initial Business Combination (net of redemptions), and (z)&#160;the volume-weighted average trading price of Class&#160;A common stock during the 20 trading day period starting on the trading day prior to the day on which the Company completes its initial Business Combination (such price, the &#8220;Market Value&#8221;) is below $9.20 per share, the exercise price of the warrants will be adjusted (to the nearest cent) to be equal to 115% of the higher of the Market Value and the Newly Issued Price, and the $10.00 and $18.00 per share redemption trigger prices described under &#8220;Redemption of warrants when the price per Class&#160;A common stock equals or exceeds $18.00&#8221; and &#8220;Redemption of warrants when the price per Class&#160;A common stock equals or exceeds $10.00&#8221; will be adjusted (to the nearest cent) to be equal to 100% and 180% of the higher of the Market Value and the Newly Issued Price, respectively. </div></div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">F-104 </div></div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;;font-weight: bold;"><a href="#toc" style="text-indent: 0px;">Table of Contents</a></div> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">MONTES ARCHIMEDES ACQUISITION CORP. </div></div></div> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">NOTES TO UNAUDITED CONDENSED FINANCIAL STATEMENTS </div></div></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The Private Placement Warrants will be identical to the Public Warrants, except that the Private Placement Warrants (including the Class&#160;A common stock issuable upon exercise of the Private Placement Warrants) will not be transferable, assignable or salable until 30&#160;days after the completion of the initial Business Combination and they will not be redeemable by the Company so long as they are held by the Sponsor or its permitted transferees. </div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Redemption of warrants when the price per share of our Class&#160;A common stock equals or exceeds $18.00: </div></div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Once the warrants become exercisable, the Company may redeem the outstanding warrants (except as described herein with respect to the Private Placement Warrants): </div></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">in whole and not in part; </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">at a price of $0.01 per warrant; </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">upon a minimum of 30 days &#8216;prior written notice of redemption; and </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;">if, and only if, the last reported sale price of Class&#160;A common stock for any 20 trading days within a <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">30-trading</div> day period ending on the third trading day prior to the date on which the Company sends the notice of redemption to the warrant holders (the &#8220;Reference Value&#8221;) equals or exceeds $18.00 per share (as adjusted for stock splits, stock capitalizations, reorganizations, recapitalizations and the like). </div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">However, in this case, the Company will not redeem the warrants unless an effective registration statement under the Securities Act covering the Class&#160;A common stock issuable upon exercise of the warrants is effective and a current prospectus relating to those shares of Class&#160;A common stock is available throughout the <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">30-day</div> redemption period. Any such exercise would not be on a &#8220;cashless&#8221; basis and would require the exercising warrant holder to pay the exercise price for each warrant being exercised. </div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Redemption of warrants when the price per share of our Class&#160;A common stock equals or exceeds $10.00 </div></div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Once the warrants become exercisable, the Company may redeem the outstanding warrants (except as described herein with respect to the Private Placement Warrants): </div></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">in whole and not in part; </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">at $0.10 per warrant upon a minimum of 30 days&#8217; prior written notice of redemption, provided that holders will be able to exercise their warrants on a cashless basis prior to redemption and receive that number of shares determined by reference to an agreed table based on the redemption date and the &#8220;fair market value&#8221; of Class&#160;A common stock; </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">if, and only if, the Reference Value equals or exceeds $10.00 per share (as adjusted for stock splits, stock dividends, rights issuances, subdivisions, reorganizations, recapitalizations and the like); and </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">if the Reference Value is less than $18.00 per share (as adjusted for stock splits, stock dividends, rights issuances, subdivisions, reorganizations, recapitalizations and the like), the Private Placement Warrants must also concurrently be called for redemption on the same terms (except as described herein with respect to a holder&#8217;s ability to cashless exercise its warrants) as the outstanding Public Warrants, as described above. </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The &#8220;fair market value&#8221; of Class&#160;A common stock shall mean the volume-weighted average price of Class&#160;A common stock for the 10 trading&#160;days immediately following the date on which the notice of redemption is sent to the holders of warrants. In no event will the warrants be exercisable in connection with this redemption feature for more than 0.361 shares of Class&#160;A common stock per warrant (subject to adjustment). </div></div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">F-105 </div></div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;;font-weight: bold;"><a href="#toc">Table of Contents</a></div> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">MONTES ARCHIMEDES ACQUISITION CORP. </div></div></div> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">NOTES TO UNAUDITED CONDENSED FINANCIAL STATEMENTS </div></div></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">In no event will the Company be required to net cash settle any warrant. If the Company is unable to complete a Business Combination within the Combination Period and the Company liquidates the funds held in the Trust Account, holders of warrants will not receive any of such funds with respect to their warrants, nor will they receive any distribution from the Company&#8217;s assets held outside of the Trust Account with the respect to such warrants. Accordingly, the warrants may expire worthless. </div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Note&#160;8&#8212;Fair Value Measurements </div></div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The following table presents information about the Company&#8217;s financial assets and liabilities that are measured at fair value on a recurring basis as of June&#160;30, 2021 and indicates the fair value hierarchy of the valuation techniques that the Company utilized to determine such fair value. </div></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="font-size: 0px;">
<td style="width: 55%;"></td>
<td style="width: 7%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td>
<td style="width: 7%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td>
<td style="width: 7%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;&#160;</td>
<td colspan="10" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Fair&#160;Value&#160;Measured&#160;as&#160;of&#160;June 30,&#160;2021</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; white-space: nowrap; padding-bottom: 1pt;"> <div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt; border-bottom: 1pt solid rgb(0, 0, 0); display: table-cell; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">Description</div></div></div> </td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Quoted&#160;Prices&#160;in<br/>Active&#160;Markets<br/>(Level&#160;1)</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Significant&#160;Other<br/>Observable&#160;Inputs<br/>(Level&#160;2)</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Significant&#160;Other<br/>Unobservable&#160;Inputs<br/>(Level&#160;3)</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Assets:</div></div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Investments held in Trust Account&#8212;U.S. Treasury securities</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">410,798,072</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Liabilities:</div></div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Derivative warrant liabilities&#8212;public warrants</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">31,625,300</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Derivative warrant liabilities&#8212;private warrants</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">15,730,120</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Total Fair Value</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">442,423,372</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">15,730,120</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The following table presents information about the Company&#8217;s financial assets and liabilities that are measured at fair value on a recurring basis as of December&#160;31, 2020 by level within the fair value hierarchy: </div></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="font-size: 0px;">
<td style="width: 55%;"></td>
<td style="width: 7%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td>
<td style="width: 7%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td>
<td style="width: 7%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;&#160;</td>
<td colspan="10" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Fair&#160;Value&#160;Measured&#160;as&#160;of&#160;December 31, 2020</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; white-space: nowrap; padding-bottom: 1pt;"> <div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt; border-bottom: 1pt solid rgb(0, 0, 0); display: table-cell; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">Description</div></div></div> </td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Quoted&#160;Prices&#160;in<br/>Active&#160;Markets<br/>(Level&#160;1)</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Significant&#160;Other<br/>Observable&#160;Inputs<br/>(Level&#160;2)</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Significant&#160;Other<br/>Unobservable&#160;Inputs<br/>(Level&#160;3)</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Assets:</div></div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Investment held in Trust Account</div></div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">U.S. Treasury securities maturing on April&#160;8, 2021</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">410,803,122</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Cash</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">289</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Liabilities:</div></div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Derivative warrant liabilities&#8212;public warrants</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">32,652,100</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Derivative warrant liabilities&#8212;private warrants</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">16,445,130</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Total Fair Value</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">443,455,511</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">16,445,130</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Transfers to/from Levels 1, 2, and 3 are recognized at the beginning of the reporting period. There were no transfers between levels for the three and six months ended June&#160;30, 2021. </div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Level&#160;1 assets include investments in U.S. government securities. The Company uses inputs such as actual trade data, benchmark yields, quoted market prices from dealers or brokers, and other similar sources to determine the fair value of its investments. </div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The fair value of the Public Warrants has been measured by the observable listed trading price, a Level&#160;1 measurement, as of June&#160;30, 2021 and December&#160;31, 2020. The fair value of the Private Placement Warrants is </div></div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">F-106 </div></div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;;font-weight: bold;"><a href="#toc">Table of Contents</a></div> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">MONTES ARCHIMEDES ACQUISITION CORP. </div></div></div> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">NOTES TO UNAUDITED CONDENSED FINANCIAL STATEMENTS </div></div></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">estimated using a Binomial Lattice in a risk-neutral framework. Specifically, the future stock price of the Company is modeled assuming a Geometric Brownian Motion in a risk-neutral framework. For each modeled future price, the Warrant payoff is calculated based on the contractual terms (incorporating any optimal early exercise / redemption), and then discounted at the term-matched risk-free rate. The value of the Warrants is calculated as the probability-weighted present value over all future modeled payoffs with changes in fair value recognized in the statement of operations. </div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">For the three months ended June&#160;30, 2021, the Company recognized a loss for the change in the fair value of warrant liabilities of approximately $21.2&#160;million, presented on the accompanying statement of operations. For the six months ended June&#160;30, 2021, the Company recognized a gain for the change in the fair value of warrant liabilities of approximately $1.7&#160;million, presented on the accompanying statement of operations. </div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The change in the fair value of the level 3 derivative warrant liabilities for three and six months ended June&#160;30, 2021 is summarized as follows: </div></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="font-size: 0px;">
<td style="width: 88%; font-family: &quot;Times New Roman&quot;;"></td>
<td style="width: 2%; vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="font-family: &quot;Times New Roman&quot;;"></td>
<td style="font-family: &quot;Times New Roman&quot;;"></td>
<td style="font-family: &quot;Times New Roman&quot;;"></td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Derivative warrant liabilities at December&#160;31, 2020</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">16,445,130</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Change in fair value of derivative warrant liabilities</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(7,762,920</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Derivative warrant liabilities at March&#160;31, 2021</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">8,682,210</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Change in fair value of derivative warrant liabilities</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">7,047,910</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Derivative warrant liabilities at June&#160;30, 2021</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">15,730,120</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The following table provides quantitative information regarding Level&#160;3 fair value measurements inputs as their measurement dates: </div></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="font-size: 0px;">
<td style="width: 70%;"></td>
<td style="width: 11%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td>
<td style="width: 11%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">June&#160;30,&#160;2021</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">As&#160;of&#160;December&#160;31,&#160;2020</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Exercise price</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">11.50</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">11.50</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Stock Price</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">9.89</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">10.17</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Volatility</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">23.1</td>
<td style="vertical-align: bottom; white-space: nowrap;">%&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">22.8</td>
<td style="vertical-align: bottom; white-space: nowrap;">%&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Risk-free rate</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">0.90</td>
<td style="vertical-align: bottom; white-space: nowrap;">%&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">0.42</td>
<td style="vertical-align: bottom; white-space: nowrap;">%&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Dividend yield</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">0.00</td>
<td style="vertical-align: bottom; white-space: nowrap;">%&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">0.00</td>
<td style="vertical-align: bottom; white-space: nowrap;">%&#160;</td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Note&#160;9&#8212;Subsequent Events </div></div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Management has evaluated subsequent events and transactions that occurred after the balance sheet date through the date the balance sheet was issued. Based on this review, the Company did not identify any subsequent events that would have required adjustment or disclosure in the unaudited condensed financial statements. </div></div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">F-107 </div></div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;;font-weight: bold;"><a href="#toc" style="text-indent: 0px;">Table of Contents</a></div> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: 0pt;"><br/></div> </div> </div> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"> <div style="line-height: 2pt; margin-top: 0pt; margin-bottom: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 2pt; border-bottom-style: solid;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="line-height: 3pt; margin-top: 0pt; margin-bottom: 2pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 16pt; margin-top: 120pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 16pt; letter-spacing: 0px; top: 0px;;display:inline;">595,134,445 Common Shares </div></div></div> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 14pt; margin-top: 24pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 14pt; letter-spacing: 0px; top: 0px;;display:inline;">30,750,261 Common Shares Issuable Upon Exercise of Warrants </div></div></div> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 14pt; margin-top: 24pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 14pt; letter-spacing: 0px; top: 0px;;display:inline;">10,214,365 Private Placement Warrants </div></div></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="font-size: 24pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 24pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; margin-top: 0pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="color: red; letter-spacing: 0px; top: 0px;;display:inline;">
<img alt="" src="g164680g00y01.jpg"/></div> </div></div> <div style="font-size: 96pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 96pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center;"> <div style="margin: 0pt auto 2pt; width: 21%; text-align: center; line-height: 6pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </div> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 12pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">PROSPECTUS </div></div></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center;"> <div style="margin: 0pt auto 2pt; width: 21%; text-align: center; line-height: 6pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </div> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 42pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">October 29, 2021 </div></div></div> <div style="font-size: 120pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 120pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="line-height: 1pt; margin-top: 0pt; margin-bottom: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="line-height: 4.5pt; margin-top: 0pt; margin-bottom: 2pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 2pt; border-bottom-style: solid;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;;font-weight: bold;"><a href="#toc">Table of Contents</a></div> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"></div></div> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"></div></div> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"></div></div> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">PART II </div></div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Information Not Required in Prospectus </div></div></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 10%; vertical-align: top;;text-align:left;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Item&#160;13.</div></div></td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Other Expenses of Issuance and Distribution. </div></div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The following is an estimate of the expenses (all of which are to be paid by the registrant) that we may incur in connection with the securities being registered hereby. </div></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 68%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="font-size: 0px;">
<td style="width: 83%;"></td>
<td style="width: 7%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Amount</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">SEC registration fee</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">387,280</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Legal fees and expenses</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#160;&#160;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">*&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Accounting fees and expenses</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#160;&#160;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">*&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Miscellaneous</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#160;&#160;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">*&#160;</td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Total</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#160;&#160;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">*&#160;</td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="width: 11%; line-height: 8pt; margin-top: 0pt; margin-bottom: 2pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 2%; vertical-align: top;;text-align:left;">*</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">These fees are calculated based on the securities offered and the number of issuances and accordingly cannot be defined at this time. </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">We will bear all costs, expenses and fees in connection with the registration of the securities, including with regard to compliance with state securities or &#8220;blue sky&#8221; laws. The Holders, however, will bear all underwriting commissions and discounts, if any, attributable to their sale of the securities. All amounts are estimates except the SEC registration fee and the FINRA filing fee. </div></div> <div style="font-size: 18pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 18pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 10%; vertical-align: top;;text-align:left;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Item&#160;14.</div></div></td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Indemnification of Directors and Officers. </div></div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Section&#160;98 of the Companies Act provides generally that a Bermuda company may indemnify its directors, officers and auditors against any liability which by virtue of any rule of law would otherwise be imposed on them in respect of any negligence, default, breach of duty or breach of trust, except in cases where such liability arises from fraud or dishonesty of which such director, officer or auditor may be guilty in relation to the company. Section&#160;98 further provides that a Bermuda company may indemnify its directors, officers and auditors against any liability incurred by them in defending any proceedings, whether civil or criminal, in which judgment is awarded in their favor or in which they are acquitted or granted relief by the Supreme Court of Bermuda pursuant to Section&#160;281 of the Companies Act. </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">Our amended and restated <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">bye-laws</div> provide that we shall indemnify our officers and directors in respect of their actions and omissions, except in respect of their fraud or dishonesty, and that we shall advance funds to our officers and directors for expenses incurred in their defense upon receipt of an undertaking to repay the funds if any allegation of fraud or dishonesty is proved. Our amended and restated <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">bye-laws</div> provide that the shareholders waive all claims or rights of action that they might have, individually or in right of the company, against any of the company&#8217;s directors or officers for any act or failure to act in the performance of such director&#8217;s or officer&#8217;s duties, except in respect of any fraud or dishonesty of such director or officer. Section&#160;98A of the Companies Act permits us to purchase and maintain insurance for the benefit of any officer or director in respect of any loss or liability attaching to him in respect of any negligence, default, breach of duty or breach of trust, whether or not we may otherwise indemnify such officer or director. We have purchased and maintain a directors&#8217; and officers&#8217; liability policy for such purpose. </div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">We have entered into indemnification agreements with each of our directors and executive officers. These indemnification agreements will provide the directors and executive officers with contractual rights to indemnification and expense advancement that are, in some cases, broader than the specific indemnification provisions contained under Bermuda law. </div></div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">II-1 </div></div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> </div> </div> </div> <div style="text-align: center;"></div> </div> </div> <div style="text-align: center;"> <div style="text-align: center;"> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em; text-align: left;;font-weight: bold;"><a href="#toc">Table of Contents</a></div> </div> </div> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"> <div style="text-align: center;"> <div style="text-align: center;"></div> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;">
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 10%; vertical-align: top;;text-align:left;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Item&#160;15.</div></div></td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Recent Sales of Unregistered Securities. </div></div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The following sets forth information regarding all unregistered securities sold since January&#160;1, 2018. Note that all Common Share totals presented below give effect to the 2.9262:1 share subdivision completed in connection with the Business Combination, rounding down to the nearest whole share. </div></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">In the fiscal year ended March&#160;31, 2019, we issued an aggregate of 17,539,045 Common Shares to various investment funds, institutional investors and other persons for aggregate consideration of approximately $193.3&#160;million. </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">In December 2019, we issued 78,867,360 Common Shares to Sumitomo Dainippon Pharma Co., Ltd. in connection with the Transaction Agreement, dated as of October&#160;31, 2019, by and among Sumitomo Dainippon Pharma Co., Ltd. and Roivant, for aggregate consideration of $1.0 billion. </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">In November 2020, we issued 1,387,481 Common Shares to a pharmaceutical company in connection with a strategic transaction at with an aggregate value of $20.0 million. </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">On March&#160;19, 2021 and September&#160;29, 2021, we issued an aggregate of 22,250,195 Common Shares to Silicon Therapeutics LLC, in each case in connection with the Agreement and Plan of Merger, dated as of February&#160;2, 2021, by and among Roivant, Silicon Insite, Inc., Silicon TX China and Silicon Therapeutics LLC, as consideration in connection with the transaction, with an aggregate value of approximately $304.2&#160;million. </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">On September&#160;30, 2021, we issued 22,000,000 Common Shares pursuant to the Subscription Agreements entered into in connection with the PIPE Financing for aggregate consideration of $220.0&#160;million. </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">We issued the foregoing securities in transactions not involving an underwriter and not requiring registration under Section&#160;5 of the Securities Act of 1933, as amended, in reliance on the exemption afforded by Section&#160;4(a)(2) thereof. </div></div> <div style="font-size: 18pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 18pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 10%; vertical-align: top;;text-align:left;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Item&#160;16.</div></div></td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Exhibits. </div></div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="font-size: 0px;">
<td style="font-family: &quot;Times New Roman&quot;;"></td>
<td style="width: 9%; vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="width: 88%; font-family: &quot;Times New Roman&quot;;"></td> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; white-space: nowrap;;text-align:center;"> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt; border-bottom: 1pt solid rgb(0, 0, 0); display: inline-block; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">Exhibit&#160;No.</div></div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;"> <div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt; border-bottom: 1pt solid rgb(0, 0, 0); display: table-cell; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">Description of Exhibit</div></div></div> </td> </tr>
<tr style="font-size: 1pt;">
<td style="height: 6pt; font-family: &quot;Times New Roman&quot;;"></td>
<td colspan="2" style="height: 6pt; font-family: &quot;Times New Roman&quot;;"></td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; white-space: nowrap;">2.1**</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: top;"><a href="http://www.sec.gov/Archives/edgar/data/1635088/000119312521239461/d65062ds4a.htm#rom65062_39">Business Combination Agreement, dated as of May&#160;1, 2021, by and among Montes Archimedes Acquisition Corp., Roivant Sciences Ltd. and Rhine Merger Sub, Inc. (included as Annex A to the joint proxy statement/prospectus which is part of Roivant Sciences Ltd.&#8217;s Form <span style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">S-4</span> filed with the SEC on August&#160;6, 2021) (incorporated by reference to Exhibit 2.1 to Roivant Sciences Ltd.&#8217;s Form <span style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">S-4</span> filed with the SEC on August&#160;6, 2021, as amended) </a></td> </tr>
<tr style="font-size: 1pt;">
<td style="height: 6pt;"></td>
<td colspan="2" style="height: 6pt;"></td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; white-space: nowrap;">2.2#**</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: top;"><a href="http://www.sec.gov/Archives/edgar/data/1635088/000119312521205193/d65062dex22.htm#cov">Agreement and Plan of Merger, dated as of February&#160;2, 2021, by and among Roivant Sciences Ltd., Silicon Insite, Inc., Silicon TX China, Silicon Therapeutics, LLC and Silicon SWAT, Inc. (incorporated by reference to Exhibit 2.2 to Roivant Sciences Ltd.&#8217;s Form <span style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">S-4</span> filed with the SEC on August&#160;6, 2021, as amended) </a></td> </tr>
<tr style="font-size: 1pt;">
<td style="height: 6pt;"></td>
<td colspan="2" style="height: 6pt;"></td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; white-space: nowrap;">2.3#**</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: top;"><a href="http://www.sec.gov/Archives/edgar/data/1635088/000119312521205193/d65062dex23.htm#cov">Stock Purchase Agreement, dated as of November&#160;6, 2020, by and among Oncopia Therapeutics, Inc., Pharmavant 5, Inc., certain selling securityholders and certain seller representative (incorporated by reference to Exhibit 2.3 to Roivant Sciences Ltd.&#8217;s Form <span style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">S-4</span> filed with the SEC on August&#160;6, 2021, as amended) </a></td> </tr>
<tr style="font-size: 1pt;">
<td style="height: 6pt;"></td>
<td colspan="2" style="height: 6pt;"></td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; white-space: nowrap;">2.4#**</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: top;"><a href="http://www.sec.gov/Archives/edgar/data/1635088/000119312521205193/d65062dex24.htm">Amendment No.&#160;1 to the Stock Purchase Agreement, dated as of November&#160;17, 2020, by and among Oncopia Therapeutics, Inc., Pharmavant 5, Inc., certain selling securityholders and WRYP Stockholders Services, LLC (incorporated by reference to Exhibit 2.4 to Roivant Sciences Ltd.&#8217;s Form <span style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">S-4</span> filed with the SEC on August&#160;6, 2021, as amended) </a></td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">II-2 </div></div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> </div> </div> </div> <div style="text-align: center;"></div> </div> </div> <div style="text-align: center;"> <div style="text-align: center;"> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em; text-align: left;;font-weight: bold;"><a href="#toc">Table of Contents</a></div> </div> </div> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"> <div style="text-align: center;"> <div style="text-align: center;"></div> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;">
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="font-size: 0px;">
<td style="font-family: &quot;Times New Roman&quot;;"></td>
<td style="width: 9%; vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="width: 88%; font-family: &quot;Times New Roman&quot;;"></td> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; white-space: nowrap;;text-align:center;"> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt; border-bottom: 1pt solid rgb(0, 0, 0); display: inline-block; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">Exhibit&#160;No.</div></div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;"> <div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt; border-bottom: 1pt solid rgb(0, 0, 0); display: table-cell; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">Description of Exhibit</div></div></div> </td> </tr>
<tr style="font-size: 1pt;">
<td style="height: 6pt; font-family: &quot;Times New Roman&quot;;"></td>
<td colspan="2" style="height: 6pt; font-family: &quot;Times New Roman&quot;;"></td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; white-space: nowrap;">2.5**</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: top;"><a href="http://www.sec.gov/Archives/edgar/data/1635088/000110465919059171/a19-21684_1ex7d04.htm">Transaction Agreement, dated as of October&#160;31, 2019, by and among Sumitomo Dainippon Pharma Co., Ltd., Vant Alliance Ltd., Roivant Sciences Ltd., Enzyvant Therapeutics Ltd., Altavant Sciences Ltd. and Spirovant Sciences Ltd. (incorporated herein by reference to Exhibit 7.04 of Roivant Sciences Ltd.&#8217;s Schedule 13D/A, filed with the SEC on November&#160;4, 2019) (incorporated by reference to Exhibit 2.5 to Roivant Sciences Ltd.&#8217;s Form <span style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">S-4</span> filed with the SEC on August&#160;6, 2021, as amended) </a></td> </tr>
<tr style="font-size: 1pt;">
<td style="height: 6pt;"></td>
<td colspan="2" style="height: 6pt;"></td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; white-space: nowrap;">2.6#**</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: top;"><a href="http://www.sec.gov/Archives/edgar/data/1635088/000119312521162191/d65062dex26.htm">Asset Purchase Agreement, dated as of July&#160;10, 2018, by and among GlaxoSmithKline Intellectual Property Development Ltd., Glaxo Group Limited and Dermavant Sciences GmBH (incorporated by reference to Exhibit 2.6 to Roivant Sciences Ltd.&#8217;s Form <span style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">S-4</span> filed with the SEC on August&#160;6, 2021, as amended) </a></td> </tr>
<tr style="font-size: 1pt;">
<td style="height: 6pt;"></td>
<td colspan="2" style="height: 6pt;"></td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; white-space: nowrap;">2.7#**</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: top;"><a href="http://www.sec.gov/Archives/edgar/data/1635088/000119312521162191/d65062dex27.htm">Asset Purchase Agreement, dated as of May&#160;29, 2012, by and between Glaxo Group Limited and Welichem Biotech Inc. (incorporated by reference to Exhibit 2.7 to Roivant Sciences Ltd.&#8217;s Form <span style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">S-4</span> filed with the SEC on August&#160;6, 2021, as amended) </a></td> </tr>
<tr style="font-size: 1pt;">
<td style="height: 6pt;"></td>
<td colspan="2" style="height: 6pt;"></td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; white-space: nowrap;">2.8#**</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: top;"><a href="http://www.sec.gov/Archives/edgar/data/1635088/000119312521162191/d65062dex28.htm">First Amendment to the Asset Purchase Agreement, dated as of August&#160;31, 2012, by and between Glaxo Group Limited and Welichem Biotech, Inc. (incorporated by reference to Exhibit 2.8 to Roivant Sciences Ltd.&#8217;s Form <span style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">S-4</span> filed with the SEC on August&#160;6, 2021, as amended) </a></td> </tr>
<tr style="font-size: 1pt;">
<td style="height: 6pt;"></td>
<td colspan="2" style="height: 6pt;"></td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; white-space: nowrap;">2.9**</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: top;"><a href="http://www.sec.gov/Archives/edgar/data/1635088/000119312521235175/d65062ds4a.htm#rom65062_39a">Amendment No.&#160;1 to the Business Combination Agreement, dated June&#160;9, 2021, by and among Montes Archimedes Acquisition Corp., Roivant Sciences Ltd. and Rhine Merger Sub, Inc. (included as Annex AA to the joint proxy statement/prospectus which is part of Roivant Sciences Ltd.&#8217;s Form <span style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">S-4</span> filed with the SEC on August&#160;6, 2021) (incorporated by reference to Exhibit 2.9 to Roivant Sciences Ltd.&#8217;s Form <span style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">S-4</span> filed with the SEC on August&#160;6, 2021, as amended) </a></td> </tr>
<tr style="font-size: 1pt;">
<td style="height: 6pt;"></td>
<td colspan="2" style="height: 6pt;"></td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; white-space: nowrap;">3.1**</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: top;"><a href="http://www.sec.gov/Archives/edgar/data/1635088/000119312521205193/d65062dex31.htm">Memorandum of Association of Roivant Sciences Ltd. (incorporated by reference to Exhibit 3.1 to Roivant Sciences Ltd.&#8217;s Form <span style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">S-4</span> filed with the SEC on August&#160;6, 2021, as amended) </a></td> </tr>
<tr style="font-size: 1pt;">
<td style="height: 6pt;"></td>
<td colspan="2" style="height: 6pt;"></td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; white-space: nowrap;">3.2**</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: top;"><a href="http://www.sec.gov/Archives/edgar/data/1635088/000119312521162191/d65062dex32.htm">Amended and Restated <span style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">Bye-laws</span> of Roivant Sciences Ltd. (incorporated by reference to Exhibit 3.1 to Roivant Sciences Ltd.&#8217;s Form <span style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">8-K</span> filed with the SEC on October&#160;1, 2021) </a></td> </tr>
<tr style="font-size: 1pt;">
<td style="height: 6pt;"></td>
<td colspan="2" style="height: 6pt;"></td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; white-space: nowrap;">4.1**</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: top;"><a href="http://www.sec.gov/Archives/edgar/data/1819263/000104746920004991/a2242417zex-4_1.htm">Specimen Unit Certificate of Montes Archimedes Acquisition Corp. (incorporated herein by reference to Exhibit 4.1 of Montes Archimedes Acquisition Corp.&#8217;s Amendment No.&#160;1 to the Registration Statement on <span style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">Form&#160;S-1,&#160;filed</span> with the SEC on September&#160;24, 2020) (incorporated by reference to Exhibit 4.1 to Roivant Sciences Ltd.&#8217;s Form <span style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">S-4</span> filed with the SEC on August&#160;6, 2021, as amended) </a></td> </tr>
<tr style="font-size: 1pt;">
<td style="height: 6pt;"></td>
<td colspan="2" style="height: 6pt;"></td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; white-space: nowrap;">4.2**</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: top;"><a href="http://www.sec.gov/Archives/edgar/data/1819263/000104746920004991/a2242417zex-4_2.htm">Specimen Class&#160;A Common Stock Certificate of Montes Archimedes Acquisition Corp. (incorporated herein by reference to Exhibit 4.2 of Montes Archimedes Acquisition Corp.&#8217;s Amendment No.&#160;1 to the Registration Statement on <span style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">Form&#160;S-1,&#160;filed</span> with the SEC on September&#160;24, 2020) (incorporated by reference to Exhibit 4.2 to Roivant Sciences Ltd.&#8217;s Form <span style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">S-4</span> filed with the SEC on August&#160;6, 2021, as amended) </a></td> </tr>
<tr style="font-size: 1pt;">
<td style="height: 6pt;"></td>
<td colspan="2" style="height: 6pt;"></td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; white-space: nowrap;">4.3**</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: top;"><a href="http://www.sec.gov/Archives/edgar/data/1819263/000104746920004991/a2242417zex-4_3.htm">Specimen Warrant Certificate of Montes Archimedes Acquisition Corp. (incorporated herein by reference to Exhibit 4.3 of Montes Archimedes Acquisition Corp.&#8217;s Amendment No.&#160;1 to the Registration Statement on <span style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">Form&#160;S-1,&#160;filed</span> with the SEC on September&#160;24, 2020) (incorporated by reference to Exhibit 4.3 to Roivant Sciences Ltd.&#8217;s Form <span style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">S-4</span> filed with the SEC on August&#160;6, 2021, as amended) </a></td> </tr>
<tr style="font-size: 1pt;">
<td style="height: 6pt;"></td>
<td colspan="2" style="height: 6pt;"></td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; white-space: nowrap;">4.4**</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: top;"><a href="http://www.sec.gov/Archives/edgar/data/1819263/000110465920114035/tm2033018d1_ex4-1.htm">Warrant Agreement between Continental Stock Transfer&#160;&amp; Trust Company and Montes Archimedes Acquisition Corp. (incorporated herein by reference to Exhibit 4.1 of Montes Archimedes Acquisition Corp.&#8217;s Current Report on Form <span style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">8-K,</span> filed with the SEC on October&#160;13, 2020) </a></td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">II-3 </div></div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> </div> </div> </div> <div style="text-align: center;"></div> </div> </div> <div style="text-align: center;"> <div style="text-align: center;"> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em; text-align: left;;font-weight: bold;"><a href="#toc">Table of Contents</a></div> </div> </div> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"> <div style="text-align: center;"> <div style="text-align: center;"></div> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;">
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="font-size: 0px;">
<td style="font-family: &quot;Times New Roman&quot;;"></td>
<td style="width: 8%; vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="width: 88%; font-family: &quot;Times New Roman&quot;;"></td> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; white-space: nowrap;;text-align:center;"> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt; border-bottom: 1pt solid rgb(0, 0, 0); display: inline-block; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">Exhibit&#160;No.</div></div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;"> <div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt; border-bottom: 1pt solid rgb(0, 0, 0); display: table-cell; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">Description of Exhibit</div></div></div> </td> </tr>
<tr style="font-size: 1pt;">
<td style="height: 6pt; font-family: &quot;Times New Roman&quot;;"></td>
<td colspan="2" style="height: 6pt; font-family: &quot;Times New Roman&quot;;"></td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; white-space: nowrap;">4.5**</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: top;"><a href="http://www.sec.gov/Archives/edgar/data/1635088/000119312521235175/d65062dex45.htm">Specimen Ordinary Share Certificate of Roivant Sciences Ltd. (incorporated by reference to Exhibit 4.5 to Roivant Sciences Ltd.&#8217;s Form <span style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">S-4</span> filed with the SEC on August&#160;6, 2021, as amended) </a></td> </tr>
<tr style="font-size: 1pt;">
<td style="height: 6pt;"></td>
<td colspan="2" style="height: 6pt;"></td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; white-space: nowrap;">4.6**</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: top;"><a href="http://www.sec.gov/Archives/edgar/data/1635088/000119312521235175/d65062dex46.htm">Specimen Warrant Certificate of Roivant Sciences Ltd. (incorporated by reference to Exhibit 4.6 to Roivant Sciences Ltd.&#8217;s Form <span style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">S-4</span> filed with the SEC on August&#160;6, 2021, as amended) </a></td> </tr>
<tr style="font-size: 1pt;">
<td style="height: 6pt;"></td>
<td colspan="2" style="height: 6pt;"></td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; white-space: nowrap;">4.7**</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: top;"><a href="http://www.sec.gov/Archives/edgar/data/1635088/000119312521235175/d65062dex47.htm">Form of Warrant Assumption Agreement, by and between Montes Archimedes Acquisition Corp., Roivant Sciences Ltd. and American Stock Transfer&#160;&amp; Trust Company, LLC (incorporated by reference to Exhibit 4.7 to Roivant Sciences Ltd.&#8217;s Form <span style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">S-4</span> filed with the SEC on August&#160;6, 2021, as amended) </a></td> </tr>
<tr style="font-size: 1pt;">
<td style="height: 6pt;"></td>
<td colspan="2" style="height: 6pt;"></td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; white-space: nowrap;">5.1</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: top;"><a href="d164680dex51.htm">Opinion of Conyers Dill&#160;&amp; Pearman Limited as to matters concerning the laws of Bermuda as to the validity of the Common Shares of Roivant Sciences Ltd.</a></td> </tr>
<tr style="font-size: 1pt;">
<td style="height: 6pt;"></td>
<td colspan="2" style="height: 6pt;"></td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; white-space: nowrap;">5.2</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: top;"><a href="d164680dex52.htm">Opinion of Davis Polk&#160;&amp; Wardwell LLP regarding the validity of the Warrants under New York law </a></td> </tr>
<tr style="font-size: 1pt;">
<td style="height: 6pt;"></td>
<td colspan="2" style="height: 6pt;"></td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; white-space: nowrap;">8.1</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: top;"><a href="d164680dex81.htm">Opinion of Davis Polk&#160;&amp; Wardwell London LLP regarding certain U.K. tax matters</a></td> </tr>
<tr style="font-size: 1pt;">
<td style="height: 6pt;"></td>
<td colspan="2" style="height: 6pt;"></td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; white-space: nowrap;">8.2</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: top;"><a href="d164680dex82.htm">Opinion of Davis Polk&#160;&amp; Wardwell LLP regarding certain U.S. tax matters </a></td> </tr>
<tr style="font-size: 1pt;">
<td style="height: 6pt;"></td>
<td colspan="2" style="height: 6pt;"></td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; white-space: nowrap;">10.1**</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: top;"><a href="http://www.sec.gov/Archives/edgar/data/1635088/000119312521235175/d65062ds4a.htm#rom65062_41">Third Amended and Restated Registration Rights Agreement, dated as of May&#160;1, 2021, by and among Roivant Sciences Ltd. and the parties thereto (included as Annex C to the joint proxy statement/prospectus which is part of Roivant Sciences Ltd.&#8217;s Form <span style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">S-4</span> filed with the SEC on August&#160;6, 2021) (incorporated by reference to Exhibit 10.1 to Roivant Sciences Ltd.&#8217;s Form <span style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">S-4</span> filed with the SEC on August&#160;6, 2021, as amended) </a></td> </tr>
<tr style="font-size: 1pt;">
<td style="height: 6pt;"></td>
<td colspan="2" style="height: 6pt;"></td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; white-space: nowrap;">10.2**</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: top;"><a href="http://www.sec.gov/Archives/edgar/data/1635088/000119312521235175/d65062ds4a.htm#rom65062_40">Form of Subscription Agreement (included as Annex B to the joint proxy statement/prospectus which is part of Roivant Sciences Ltd.&#8217;s Form <span style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">S-4</span> filed with the SEC on August&#160;6, 2021) (incorporated by reference to Exhibit 10.2 to Roivant Sciences Ltd.&#8217;s Form <span style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">S-4</span> filed with the SEC on August&#160;6, 2021, as amended)</a></td> </tr>
<tr style="font-size: 1pt;">
<td style="height: 6pt;"></td>
<td colspan="2" style="height: 6pt;"></td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; white-space: nowrap;">10.3**</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: top;"><a href="http://www.sec.gov/Archives/edgar/data/1635088/000119312521235175/d65062ds4a.htm#rom65062_43">Sponsor Support Agreement, dated as of May&#160;1, 2021, by and among Roivant Sciences Ltd., Montes Archimedes Acquisition Corp., Patient Square Capital LLC and certain shareholders of Roivant Sciences Ltd. (included as Annex E to the joint proxy statement/prospectus which is part of Roivant Sciences Ltd.&#8217;s Form <span style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">S-4</span> filed with the SEC on August&#160;6, 2021) (incorporated by reference to Exhibit 10.3 to Roivant Sciences Ltd.&#8217;s Form <span style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">S-4</span> filed with the SEC on August&#160;6, 2021, as amended) </a></td> </tr>
<tr style="font-size: 1pt;">
<td style="height: 6pt;"></td>
<td colspan="2" style="height: 6pt;"></td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; white-space: nowrap;">10.4**</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: top;"><a href="http://www.sec.gov/Archives/edgar/data/1635088/000119312521235175/d65062ds4a.htm#rom65062_42">Form of Transaction Support Agreement, dated as of May&#160;1, 2021, by and among Roivant Sciences Ltd., Montes Archimedes Acquisition Corp. and certain shareholders of Roivant Sciences Ltd. (included as Annex D to the joint proxy statement/prospectus which is part of Roivant Sciences Ltd.&#8217;s Form <span style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">S-4</span> filed with the SEC on August&#160;6, 2021) (incorporated by reference to Exhibit 10.4 to Roivant Sciences Ltd.&#8217;s Form <span style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">S-4</span> filed with the SEC on August&#160;6, 2021, as amended) </a></td> </tr>
<tr style="font-size: 1pt;">
<td style="height: 6pt;"></td>
<td colspan="2" style="height: 6pt;"></td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; white-space: nowrap;">10.5**</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: top;"><a href="http://www.sec.gov/Archives/edgar/data/1819263/000110465920114035/tm2033018d1_ex10-1.htm">Investment Management Trust Agreement between Continental Stock Transfer&#160;&amp; Trust Company and Montes Archimedes Acquisition Corp. (incorporated herein by reference to Exhibit 10.1 of Montes Archimedes Acquisition Corp.&#8217;s Current Report on Form <span style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">8-K,</span> filed with the SEC on October&#160;13, 2020) (incorporated by reference to Exhibit 10.5 to Roivant Sciences Ltd.&#8217;s Form <span style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">S-4</span> filed with the SEC on August&#160;6, 2021, as amended)</a></td> </tr>
<tr style="font-size: 1pt;">
<td style="height: 6pt;"></td>
<td colspan="2" style="height: 6pt;"></td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; white-space: nowrap;">10.6#**</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: top;"><a href="http://www.sec.gov/Archives/edgar/data/1764013/000119312519321147/d839382dex106.htm">License Agreement, dated as of December&#160;19, 2017, by and between HanAll Biopharma Co., Ltd. and Roivant Sciences GmbH (incorporated herein by reference to Exhibit 10.6 of Immunovant, Inc.&#8217;s Current Report on Form <span style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">8-K,</span> filed with the SEC on December&#160;20, 2019) </a></td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">II-4 </div></div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> </div> </div> </div> <div style="text-align: center;"></div> </div> </div> <div style="text-align: center;"> <div style="text-align: center;"> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em; text-align: left;;font-weight: bold;"><a href="#toc">Table of Contents</a></div> </div> </div> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"> <div style="text-align: center;"> <div style="text-align: center;"></div> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;">
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="font-size: 0px;">
<td style="font-family: &quot;Times New Roman&quot;;"></td>
<td style="width: 7%; vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="width: 88%; font-family: &quot;Times New Roman&quot;;"></td> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; white-space: nowrap;;text-align:center;"> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt; border-bottom: 1pt solid rgb(0, 0, 0); display: inline-block; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">Exhibit&#160;No.</div></div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;"> <div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt; border-bottom: 1pt solid rgb(0, 0, 0); display: table-cell; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">Description of Exhibit</div></div></div> </td> </tr>
<tr style="font-size: 1pt;">
<td style="height: 6pt; font-family: &quot;Times New Roman&quot;;"></td>
<td colspan="2" style="height: 6pt; font-family: &quot;Times New Roman&quot;;"></td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; white-space: nowrap;">10.7#**</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: top;"><a href="http://www.sec.gov/Archives/edgar/data/1635088/000119312521162191/d65062dex107.htm">Collaboration and License Agreement, dated as of January&#160;15, 2020, by and between Dermavant Sciences GmbH and Japan Tobacco Inc. (incorporated by reference to Exhibit 10.7 to Roivant Sciences Ltd.&#8217;s Form <span style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">S-4</span> filed with the SEC on August&#160;6, 2021, as amended)</a></td> </tr>
<tr style="font-size: 1pt;">
<td style="height: 6pt;"></td>
<td colspan="2" style="height: 6pt;"></td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; white-space: nowrap;">10.8#**</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: top;"><a href="http://www.sec.gov/Archives/edgar/data/1635088/000119312521162191/d65062dex108.htm">Clinical Manufacturing and Supply Agreement, dated August&#160;20, 2018, by and between Dermavant Sciences GmbH and GlaxoSmithKline Trading Services Limited. (incorporated by reference to Exhibit 10.8 to Roivant Sciences Ltd.&#8217;s Form <span style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">S-4</span> filed with the SEC on August&#160;6, 2021, as amended) </a></td> </tr>
<tr style="font-size: 1pt;">
<td style="height: 6pt;"></td>
<td colspan="2" style="height: 6pt;"></td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; white-space: nowrap;">10.9#**</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: top;"><a href="http://www.sec.gov/Archives/edgar/data/1635088/000119312521162191/d65062dex109.htm">Commercial Manufacturing and Supply Agreement, dated April&#160;1, 2019, by and between Dermavant Sciences GmbH and GlaxoSmithKline Trading Services Limited. (incorporated by reference to Exhibit 10.9 to Roivant Sciences Ltd.&#8217;s Form <span style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">S-4</span> filed with the SEC on August&#160;6, 2021, as amended) </a></td> </tr>
<tr style="font-size: 1pt;">
<td style="height: 6pt;"></td>
<td colspan="2" style="height: 6pt;"></td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; white-space: nowrap;">10.10#**</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: top;"><a href="http://www.sec.gov/Archives/edgar/data/1635088/000119312521162191/d65062dex1010.htm">Funding Agreement, dated as of July&#160;10, 2018, by and between Dermavant Sciences GmBH and NovaQuest <span style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">Co-Investment</span> Fund VIII, L.P. (incorporated by reference to Exhibit 10.10 to Roivant Sciences Ltd.&#8217;s Form <span style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">S-4</span> filed with the SEC on August&#160;6, 2021, as amended)</a></td> </tr>
<tr style="font-size: 1pt;">
<td style="height: 6pt;"></td>
<td colspan="2" style="height: 6pt;"></td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; white-space: nowrap;">10.11#**</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: top;"><a href="http://www.sec.gov/Archives/edgar/data/1635088/000119312521162191/d65062dex1011.htm">First Amendment to Funding Agreement, dated as of October&#160;11, 2018, by and between Dermavant Sciences GmBH and NovaQuest <span style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">Co-Investment</span> Fund VIII, L.P. (incorporated by reference to Exhibit 10.11 to Roivant Sciences Ltd.&#8217;s Form <span style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">S-4</span> filed with the SEC on August&#160;6, 2021, as amended) </a></td> </tr>
<tr style="font-size: 1pt;">
<td style="height: 6pt;"></td>
<td colspan="2" style="height: 6pt;"></td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; white-space: nowrap;">10.12#**</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: top;"><a href="http://www.sec.gov/Archives/edgar/data/1635088/000119312521205193/d65062dex1012.htm">License Agreement, dated as of November&#160;21, 2018, by and between Cincinnati Children&#8217;s Hospital Medical Center and Aruvant Sciences GmbH (incorporated by reference to Exhibit 10.12 to Roivant Sciences Ltd.&#8217;s Form <span style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">S-4</span> filed with the SEC on August&#160;6, 2021, as amended)</a></td> </tr>
<tr style="font-size: 1pt;">
<td style="height: 6pt;"></td>
<td colspan="2" style="height: 6pt;"></td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; white-space: nowrap;">10.13#**</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: top;"><a href="http://www.sec.gov/Archives/edgar/data/1635088/000119312521205193/d65062dex1013.htm">Subscription Agreement, dated as of November&#160;21, 2018 by and between Cincinnati Children&#8217;s Hospital Medical Center and Aruvant Sciences Ltd. (incorporated by reference to Exhibit 10.13 to Roivant Sciences Ltd.&#8217;s Form <span style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">S-4</span> filed with the SEC on August&#160;6, 2021, as amended) </a></td> </tr>
<tr style="font-size: 1pt;">
<td style="height: 6pt;"></td>
<td colspan="2" style="height: 6pt;"></td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; white-space: nowrap;">10.14#**</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: top;"><a href="http://www.sec.gov/Archives/edgar/data/1447028/000144702820000118/a2020-q210xqex103cross.htm">Cross License Agreement, dated as of April&#160;11, 2018, by and between Genevant Sciences Ltd. and Arbutus Biopharma Corporation (incorporated herein by reference to Exhibit 10.3 of Arbutus Biopharma Corporation&#8217;s Quarterly Report on Form <span style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">10-Q</span> for the Quarter ended June&#160;30, 2020, filed with the SEC on August&#160;7, 2020</a></td> </tr>
<tr style="font-size: 1pt;">
<td style="height: 6pt;"></td>
<td colspan="2" style="height: 6pt;"></td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; white-space: nowrap;">10.15#**</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: top;"><a href="http://www.sec.gov/Archives/edgar/data/1447028/000144702820000118/a2020-q210xqex1041stam.htm">First Amendment to Cross License Agreement, dated as of June&#160;27, 2018, by and among Genevant Sciences Ltd., Genevant Sciences GmbH and Arbutus Biopharma Corporation (incorporated herein by reference to Exhibit 10.4 of Arbutus Biopharma Corporation&#8217;s Quarterly Report on Form <span style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">10-Q</span> for the Quarter ended June&#160;30, 2020, filed with the SEC on August&#160;7, 2020)</a></td> </tr>
<tr style="font-size: 1pt;">
<td style="height: 6pt;"></td>
<td colspan="2" style="height: 6pt;"></td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; white-space: nowrap;">10.16#**</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: top;"><a href="http://www.sec.gov/Archives/edgar/data/1447028/000144702820000118/a2020-q210xqex105secon.htm">Second Amendment to Cross License Agreement, dated as of June&#160;27, 2018, by and among Genevant Sciences Ltd., Genevant Sciences GmbH and Arbutus Biopharma Corporation (incorporated herein by reference to Exhibit 10.5 of Arbutus Biopharma Corporation&#8217;s Quarterly Report on Form <span style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">10-Q</span> for the Quarter ended June&#160;30, 2020, filed with the SEC on August&#160;7, 2020)</a></td> </tr>
<tr style="font-size: 1pt;">
<td style="height: 6pt;"></td>
<td colspan="2" style="height: 6pt;"></td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; white-space: nowrap;">10.17#**</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: top;"><a href="http://www.sec.gov/Archives/edgar/data/1635088/000119312521205193/d65062dex1017.htm">License Agreement, dated as of November&#160;19, 2018, by and between iNtRON Biotechnology, Inc. and Pharmavant 1 GMBH in Formation (incorporated by reference to Exhibit 10.17 to Roivant Sciences Ltd.&#8217;s Form <span style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">S-4</span> filed with the SEC on August&#160;6, 2021, as amended)</a></td> </tr>
<tr style="font-size: 1pt;">
<td style="height: 6pt;"></td>
<td colspan="2" style="height: 6pt;"></td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; white-space: nowrap;">10.18#**</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: top;"><a href="http://www.sec.gov/Archives/edgar/data/1635088/000119312521205193/d65062dex1018.htm">First Amendment to License Agreement, dated as of March&#160;23, 2019, by and between iNtRON Biotechnology, Inc. and Pharmavant 1 GMBH in Formation (incorporated by reference to Exhibit 10.18 to Roivant Sciences Ltd.&#8217;s Form <span style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">S-4</span> filed with the SEC on August&#160;6, 2021, as amended)</a></td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">II-5 </div></div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> </div> </div> </div> <div style="text-align: center;"></div> </div> </div> <div style="text-align: center;"> <div style="text-align: center;"> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em; text-align: left;;font-weight: bold;"><a href="#toc">Table of Contents</a></div> </div> </div> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"> <div style="text-align: center;"> <div style="text-align: center;"></div> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;">
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="font-size: 0px;">
<td style="font-family: &quot;Times New Roman&quot;;"></td>
<td style="width: 7%; vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="width: 88%; font-family: &quot;Times New Roman&quot;;"></td> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; white-space: nowrap;;text-align:center;"> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt; border-bottom: 1pt solid rgb(0, 0, 0); display: inline-block; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">Exhibit&#160;No.</div></div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;"> <div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt; border-bottom: 1pt solid rgb(0, 0, 0); display: table-cell; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">Description of Exhibit</div></div></div> </td> </tr>
<tr style="font-size: 1pt;">
<td style="height: 6pt; font-family: &quot;Times New Roman&quot;;"></td>
<td colspan="2" style="height: 6pt; font-family: &quot;Times New Roman&quot;;"></td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; white-space: nowrap;">10.19#**</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: top;"><a href="http://www.sec.gov/Archives/edgar/data/1635088/000119312521205193/d65062dex1019.htm">Second Amendment to License Agreement, dated as of August&#160;28, 2019, by and between iNtRON Biotechnology, Inc. and Lysovant Sciences GMBH (incorporated by reference to Exhibit 10.19 to Roivant Sciences Ltd.&#8217;s Form <span style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">S-4</span> filed with the SEC on August&#160;6, 2021, as amended)</a></td> </tr>
<tr style="font-size: 1pt;">
<td style="height: 6pt;"></td>
<td colspan="2" style="height: 6pt;"></td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; white-space: nowrap;">10.20#**</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: top;"><a href="http://www.sec.gov/Archives/edgar/data/1635088/000119312521205193/d65062dex1020.htm">Research Agreement, dated as of January&#160;1, 2018, by and between Oncopia Therapeutics, LLC and the Regents of the University of Michigan (incorporated by reference to Exhibit 10.20 to Roivant Sciences Ltd.&#8217;s Form <span style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">S-4</span> filed with the SEC on August&#160;6, 2021, as amended)</a></td> </tr>
<tr style="font-size: 1pt;">
<td style="height: 6pt;"></td>
<td colspan="2" style="height: 6pt;"></td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; white-space: nowrap;">10.21#**</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: top;"><a href="http://www.sec.gov/Archives/edgar/data/1635088/000119312521205193/d65062dex1021.htm">Fifth Amendment to the Sponsored Research Agreement, dated as of November&#160;19, 2020, by and between Oncopia Therapeutics, Inc. and the Regents of the University of Michigan (incorporated by reference to Exhibit 10.21 to Roivant Sciences Ltd.&#8217;s Form <span style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">S-4</span> filed with the SEC on August&#160;6, 2021, as amended)</a></td> </tr>
<tr style="font-size: 1pt;">
<td style="height: 6pt;"></td>
<td colspan="2" style="height: 6pt;"></td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; white-space: nowrap;">10.22#**</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: top;"><a href="http://www.sec.gov/Archives/edgar/data/1635088/000119312521205193/d65062dex1022.htm">Amended and Restated Patent License Agreement, dated as of November&#160;16, 2020, by and between Oncopia Therapeutics, Inc. and the Regents of the University of Michigan (incorporated by reference to Exhibit 10.22 to Roivant Sciences Ltd.&#8217;s Form <span style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">S-4</span> filed with the SEC on August&#160;6, 2021, as amended)</a></td> </tr>
<tr style="font-size: 1pt;">
<td style="height: 6pt;"></td>
<td colspan="2" style="height: 6pt;"></td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; white-space: nowrap;">10.23#**</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: top;"><a href="http://www.sec.gov/Archives/edgar/data/1635088/000119312521205193/d65062dex1023.htm">Investors&#8217; Rights Agreement, dated as of January&#160;11, 2021, by and among Pharmavant 5, Inc., Roivant Sciences Ltd. and SK Holdings Co., Ltd. (incorporated by reference to Exhibit 10.23 to Roivant Sciences Ltd.&#8217;s Form <span style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">S-4</span> filed with the SEC on August&#160;6, 2021, as amended)</a></td> </tr>
<tr style="font-size: 1pt;">
<td style="height: 6pt;"></td>
<td colspan="2" style="height: 6pt;"></td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; white-space: nowrap;">10.24**</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: top;"><a href="http://www.sec.gov/Archives/edgar/data/1635088/000119312521205193/d65062dex1024.htm">Form of Indemnity Agreement (incorporated by reference to Exhibit 10.24 to Roivant Sciences Ltd.&#8217;s Form <span style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">S-4</span> filed with the SEC on August&#160;6, 2021, as amended)</a></td> </tr>
<tr style="font-size: 1pt;">
<td style="height: 6pt;"></td>
<td colspan="2" style="height: 6pt;"></td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; white-space: nowrap;">10.25**</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: top;"><a href="http://www.sec.gov/Archives/edgar/data/1635088/000119312521162191/d65062dex1025.htm">Roivant Sciences Ltd. Amended and Restated 2015 Equity Incentive Plan (incorporated by reference to Exhibit 10.25 to Roivant Sciences Ltd.&#8217;s Form <span style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">S-4</span> filed with the SEC on August&#160;6, 2021, as amended)</a></td> </tr>
<tr style="font-size: 1pt;">
<td style="height: 6pt;"></td>
<td colspan="2" style="height: 6pt;"></td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; white-space: nowrap;">10.26**</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: top;"><a href="http://www.sec.gov/Archives/edgar/data/1635088/000095010321015700/dp159512_ex9901.htm">Roivant Sciences Ltd. 2021 Equity Incentive Plan (incorporated by reference to Exhibit 99.1 to Roivant Sciences Ltd.&#8217;s Form <span style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">S-8</span> filed with the SEC on October&#160;8, 2021, as amended) </a></td> </tr>
<tr style="font-size: 1pt;">
<td style="height: 6pt;"></td>
<td colspan="2" style="height: 6pt;"></td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; white-space: nowrap;">10.27**</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: top;"><a href="http://www.sec.gov/Archives/edgar/data/1635088/000119312521162191/d65062dex1027.htm">Amended and Restated Employment Agreement between Roivant Sciences, Inc. and Vivek Ramaswamy, dated as of May&#160;14, 2021 (incorporated by reference to Exhibit 10.27 to Roivant Sciences Ltd.&#8217;s Form <span style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">S-4</span> filed with the SEC on August&#160;6, 2021, as amended)</a></td> </tr>
<tr style="font-size: 1pt;">
<td style="height: 6pt;"></td>
<td colspan="2" style="height: 6pt;"></td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; white-space: nowrap;">10.28**</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: top;"><a href="http://www.sec.gov/Archives/edgar/data/1635088/000119312521162191/d65062dex1028.htm">Executive Employment Agreement between Roivant Sciences, Inc. and Matthew Gline, dated as of May&#160;14, 2021 (incorporated by reference to Exhibit 10.28 to Roivant Sciences Ltd.&#8217;s Form <span style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">S-4</span> filed with the SEC on August&#160;6, 2021, as amended)</a></td> </tr>
<tr style="font-size: 1pt;">
<td style="height: 6pt;"></td>
<td colspan="2" style="height: 6pt;"></td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; white-space: nowrap;">10.29**</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: top;"><a href="http://www.sec.gov/Archives/edgar/data/1635088/000119312521162191/d65062dex1029.htm">Executive Employment Agreement between Roivant Sciences, Inc. and Eric Venker, dated as of May&#160;14, 2021 (incorporated by reference to Exhibit 10.29 to Roivant Sciences Ltd.&#8217;s Form <span style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">S-4</span> filed with the SEC on August&#160;6, 2021, as amended)</a></td> </tr>
<tr style="font-size: 1pt;">
<td style="height: 6pt;"></td>
<td colspan="2" style="height: 6pt;"></td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; white-space: nowrap;">10.30**</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: top;"><a href="http://www.sec.gov/Archives/edgar/data/1635088/000119312521162191/d65062dex1030.htm">Executive Employment Agreement between Roivant Sciences, Inc. and Benjamin Zimmer, dated as of May&#160;14, 2021 (incorporated by reference to Exhibit 10.30 to Roivant Sciences Ltd.&#8217;s Form <span style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">S-4</span> filed with the SEC on August&#160;6, 2021, as amended)</a></td> </tr>
<tr style="font-size: 1pt;">
<td style="height: 6pt;"></td>
<td colspan="2" style="height: 6pt;"></td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; white-space: nowrap;">10.31#**</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: top;"><a href="http://www.sec.gov/Archives/edgar/data/1635088/000119312521205193/d65062dex1031.htm#cov">Credit Agreement by and among Dermavant Sciences Ltd., Dermavant Holdings Limited, Dermavant Sciences IRL Limited, Dermavant Sciences GmbH, certain subsidiaries of Dermavant Sciences Ltd., XYQ Luxco S.A.R.L. and U.S. Bank National Association, as collateral agent, dated as of May&#160;14, 2021(incorporated by reference to Exhibit 10.31 to Roivant Sciences Ltd.&#8217;s Form <span style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">S-4</span> filed with the SEC on August&#160;6, 2021, as amended) </a></td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">II-6 </div></div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> </div> </div> </div> <div style="text-align: center;"></div> </div> </div> <div style="text-align: center;"> <div style="text-align: center;"> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em; text-align: left;;font-weight: bold;"><a href="#toc">Table of Contents</a></div> </div> </div> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"> <div style="text-align: center;"> <div style="text-align: center;"></div> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;">
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="font-size: 0px;">
<td style="font-family: &quot;Times New Roman&quot;;"></td>
<td style="width: 5%; vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="width: 88%; font-family: &quot;Times New Roman&quot;;"></td> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; white-space: nowrap;;text-align:center;"> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt; border-bottom: 1pt solid rgb(0, 0, 0); display: inline-block; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">Exhibit&#160;No.</div></div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;"> <div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt; border-bottom: 1pt solid rgb(0, 0, 0); display: table-cell; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">Description of Exhibit</div></div></div> </td> </tr>
<tr style="font-size: 1pt;">
<td style="height: 6pt; font-family: &quot;Times New Roman&quot;;"></td>
<td colspan="2" style="height: 6pt; font-family: &quot;Times New Roman&quot;;"></td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; white-space: nowrap;">10.32#**</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: top;"><a href="http://www.sec.gov/Archives/edgar/data/1635088/000119312521205193/d65062dex1032.htm">Revenue Interest Purchase and Sale Agreement by and among Dermavant Sciences GmbH, certain purchasers and U.S. Bank National Association as collateral agent, dated as of May&#160;14, 2021 (incorporated by reference to Exhibit 10.32 to Roivant Sciences Ltd.&#8217;s Form <span style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">S-4</span> filed with the SEC on August&#160;6, 2021, as amended)</a></td> </tr>
<tr style="font-size: 1pt;">
<td style="height: 6pt;"></td>
<td colspan="2" style="height: 6pt;"></td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; white-space: nowrap;">10.33**</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: top;"><a href="http://www.sec.gov/Archives/edgar/data/1635088/000119312521205193/d65062ds4a.htm#anxee">Amendment No.&#160;1 to the Support Agreement, dated as of June&#160;9, 2021, by and among Roivant Sciences Ltd., Montes Archimedes Acquisition Corp., Patient Square Capital LLC and certain shareholders of Roivant Sciences Ltd. (included as Annex EE to the joint proxy statement/prospectus which is part of Roivant Sciences Ltd.&#8217;s Form <span style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">S-4</span> filed with the SEC on August&#160;6, 2021, as amended, which is incorporated by reference)</a></td> </tr>
<tr style="font-size: 1pt;">
<td style="height: 6pt;"></td>
<td colspan="2" style="height: 6pt;"></td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; white-space: nowrap;">10.34**</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: top;"><a href="http://www.sec.gov/Archives/edgar/data/1635088/000119312521288885/d230641dex101.htm">Amendment No.&#160;2 to the Support Agreement, dated as of September&#160;30, 2021, by and among Roivant Sciences Ltd., Montes Archimedes Acquisition Corp., Patient Square Capital LLC and certain shareholders of Roivant Sciences Ltd. (incorporated by reference to Exhibit 10.1 to Roivant Sciences Ltd.&#8217;s Form <span style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">8-K</span> filed with the SEC on October&#160;1, 2021)</a></td> </tr>
<tr style="font-size: 1pt;">
<td style="height: 6pt;"></td>
<td colspan="2" style="height: 6pt;"></td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; white-space: nowrap;">10.35**</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: top;"><a href="http://www.sec.gov/Archives/edgar/data/1635088/000095010321015700/dp159512_ex9902.htm">Roivant Sciences Ltd. Employee Stock Purchase Plan (incorporated by reference to Exhibit 99.2 to Roivant Sciences Ltd.&#8217;s Form <span style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">S-8</span> filed with the SEC on October&#160;8, 2021, as amended) </a></td> </tr>
<tr style="font-size: 1pt;">
<td style="height: 6pt;"></td>
<td colspan="2" style="height: 6pt;"></td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; white-space: nowrap;">21.1**</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: top;"><a href="http://www.sec.gov/Archives/edgar/data/1635088/000119312521205193/d65062dex211.htm">List of Subsidiaries of Roivant Sciences Ltd. (incorporated by reference to Exhibit 21.1 to Roivant Sciences Ltd.&#8217;s Form <span style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">S-4</span> filed with the SEC on August&#160;6, 2021, as amended) </a></td> </tr>
<tr style="font-size: 1pt;">
<td style="height: 6pt;"></td>
<td colspan="2" style="height: 6pt;"></td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; white-space: nowrap;">23.1</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: top;"><a href="d164680dex231.htm">Consent of Marcum LLP, Independent Registered Public Accounting Firm of Montes Archimedes Acquisition Corp.</a></td> </tr>
<tr style="font-size: 1pt;">
<td style="height: 6pt;"></td>
<td colspan="2" style="height: 6pt;"></td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; white-space: nowrap;">23.2</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: top;"><a href="d164680dex232.htm">Consent of Ernst&#160;&amp; Young LLP, Independent Registered Public Accounting Firm of Roivant Sciences Ltd. </a></td> </tr>
<tr style="font-size: 1pt;">
<td style="height: 6pt;"></td>
<td colspan="2" style="height: 6pt;"></td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; white-space: nowrap;">23.3</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: top;"><a href="d164680dex51.htm">Consent of Conyers Dill&#160;&amp; Pearman Limited (included in Exhibit 5.1) </a></td> </tr>
<tr style="font-size: 1pt;">
<td style="height: 6pt;"></td>
<td colspan="2" style="height: 6pt;"></td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; white-space: nowrap;">23.4</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: top;"><a href="d164680dex52.htm">Consent of Davis Polk&#160;&amp; Wardwell LLP (included in Exhibit 5.2)</a></td> </tr>
<tr style="font-size: 1pt;">
<td style="height: 6pt;"></td>
<td colspan="2" style="height: 6pt;"></td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; white-space: nowrap;">23.5</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: top;"><a href="d164680dex81.htm">Consent of Davis Polk&#160;&amp; Wardwell London LLP (included in Exhibit 8.1)</a></td> </tr>
<tr style="font-size: 1pt;">
<td style="height: 6pt;"></td>
<td colspan="2" style="height: 6pt;"></td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; white-space: nowrap;">24.1</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: top;"><a href="#sig">Power of Attorney (included on signature page)</a></td> </tr>
<tr style="font-size: 1pt;">
<td style="height: 6pt;"></td>
<td colspan="2" style="height: 6pt;"></td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; white-space: nowrap;">101.&#160;INS</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: top;">XBRL Instance Document</td> </tr>
<tr style="font-size: 1pt;">
<td style="height: 6pt;"></td>
<td colspan="2" style="height: 6pt;"></td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; white-space: nowrap;">101.SCH</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: top;">XBRL Taxonomy Extension Schema Document</td> </tr>
<tr style="font-size: 1pt;">
<td style="height: 6pt;"></td>
<td colspan="2" style="height: 6pt;"></td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; white-space: nowrap;">101.CAL</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: top;">XBRL Taxonomy Extension Calculation Linkbase Document</td> </tr>
<tr style="font-size: 1pt;">
<td style="height: 6pt;"></td>
<td colspan="2" style="height: 6pt;"></td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; white-space: nowrap;">101.DEF</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: top;">XBRL Taxonomy Extension Definition Linkbase Document</td> </tr>
<tr style="font-size: 1pt;">
<td style="height: 6pt;"></td>
<td colspan="2" style="height: 6pt;"></td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; white-space: nowrap;">101.LAB</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: top;">XBRL Taxonomy Extension Label Linkbase Document</td> </tr>
<tr style="font-size: 1pt;">
<td style="height: 6pt;"></td>
<td colspan="2" style="height: 6pt;"></td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; white-space: nowrap;">101.PRE</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: top;">XBRL Taxonomy Extension Presentation Linkbase Document</td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="width: 11%; line-height: 8pt; margin-top: 0pt; margin-bottom: 2pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 4%; vertical-align: top;;text-align:left;">**</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Previously filed. </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 4%; vertical-align: top;;text-align:left;">#</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Portions of this exhibit have been omitted because they are both (i)&#160;not material and (ii)&#160;would likely cause competitive harm to Roivant Sciences Ltd. if publicly disclosed.</div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">II-7 </div></div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> </div> </div> </div> <div style="text-align: center;"></div> </div> </div> <div style="text-align: center;"> <div style="text-align: center;"> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em; text-align: left;;font-weight: bold;"><a href="#toc" style="text-indent: 0px;">Table of Contents</a></div> </div> </div> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"> <div style="text-align: center;"> <div style="text-align: center;"></div> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"></div> </div> </div> </div> </div> <div style="text-align: center;"> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em; text-align: left;;font-weight: bold;"><a href="#toc" style="text-indent: 0px;"></a></div> </div> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"></div> </div> </div> </div> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;;font-weight: bold;"><a href="#toc" style="text-indent: 0px;"></a></div> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;">
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 10%; vertical-align: top;;text-align:left;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Item&#160;17.</div></div></td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Undertakings. </div></div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The undersigned registrant hereby undertakes: </div></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 4%;">&#160;</td>
<td style="width: 5%; vertical-align: top;;text-align:left;">A.</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">To file, during any period in which offers or sales are being made, a post-effective amendment to this registration statement: </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 9%;">&#160;</td>
<td style="width: 4%; vertical-align: top;;text-align:left;">(i)</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">To include any prospectus required by section 10(a)(3) of the Securities Act; </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 9%;">&#160;</td>
<td style="width: 4%; vertical-align: top;;text-align:left;">(ii)</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">To reflect in the prospectus any facts or events arising after the effective date of the registration statement (or the most recent post-effective amendment thereof) which, individually or in the aggregate, represent a fundamental change in the information set forth in the registration statement. Notwithstanding the foregoing, any increase or decrease in volume of securities offered (if the total dollar value of securities offered would not exceed that which was registered) and any deviation from the low or high end of the estimated maximum offering range may be reflected in the form of prospectus filed with the SEC pursuant to Rule 424(b) if, in the aggregate, the changes in volume and price represent no more than 20% change in the maximum aggregate offering price set forth in the &#8220;Calculation of Registration Fee&#8221; table in the effective registration statement. </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 9%;">&#160;</td>
<td style="width: 4%; vertical-align: top;;text-align:left;">(iii)</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">To include any material information with respect to the plan of distribution not previously disclosed in the registration statement or any material change to such information in the registration statement; </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 4%;">&#160;</td>
<td style="width: 5%; vertical-align: top;;text-align:left;">B.</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">That, for the purpose of determining any liability under the Securities Act, each such post-effective amendment shall be deemed to be a new registration statement relating to the securities offered therein, and the offering of such securities at that time shall be deemed to be the initial bona fide offering thereof. </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 4%;">&#160;</td>
<td style="width: 5%; vertical-align: top;;text-align:left;">C.</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">To remove from registration by means of a post-effective amendment any of the securities being registered which remain unsold at the termination of the offering. </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 4%;">&#160;</td>
<td style="width: 5%; vertical-align: top;;text-align:left;">D.</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">That, for the purpose of determining liability under the Securities Act to any purchaser, each prospectus filed pursuant to Rule 424(b) as part of a registration statement relating to an offering, other than registration statements relying on Rule 430B or other than prospectuses filed in reliance on Rule 430A, shall be deemed to be part of and included in the registration statement as of the date it is first used after effectiveness. Provided, however, that no statement made in a registration statement or prospectus that is part of the registration statement or made in a document incorporated or deemed incorporated by reference into the registration statement or prospectus that is part of the registration statement will, as to a purchaser with a time of contract of sale prior to such first use, supersede or modify any statement that was made in the registration statement or prospectus that was part of the registration statement or made in any such document immediately prior to such date of first use. </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 4%;">&#160;</td>
<td style="width: 5%; vertical-align: top;;text-align:left;">E.</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">That, for the purpose of determining liability of the registrant under the Securities Act to any purchaser in the initial distribution of the securities, that in a primary offering of securities of the undersigned registrant pursuant to this registration statement, regardless of the underwriting method used to sell the securities to the purchaser, if the securities are offered or sold to such purchaser by means of any of the following communications, the undersigned registrant will be a seller to the purchaser and will be considered to offer or sell such securities to such purchaser: </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 9%;">&#160;</td>
<td style="width: 4%; vertical-align: top;;text-align:left;">(i)</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Any preliminary prospectus or prospectus of the undersigned registrant relating to the offering required to be filed pursuant to Rule 424; </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 9%;">&#160;</td>
<td style="width: 4%; vertical-align: top;;text-align:left;">(ii)</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Any free writing prospectus relating to the offering prepared by or on behalf of the undersigned registrant or used or referred to by the undersigned registrant; </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 9%;">&#160;</td>
<td style="width: 4%; vertical-align: top;;text-align:left;">(iii)</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The portion of any other free writing prospectus relating to the offering containing material information about the undersigned registrant or its securities provided by or on behalf of the undersigned registrant; and </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">II-8 </div></div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;;font-weight: bold;"><a href="#toc">Table of Contents</a></div> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;">
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 9%;">&#160;</td>
<td style="width: 4%; vertical-align: top;;text-align:left;">(iv)</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Any other communication that is an offer in the offering made by the undersigned registrant to the purchaser. </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 4%;">&#160;</td>
<td style="width: 5%; vertical-align: top;;text-align:left;">F.</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Insofar as indemnification for liabilities arising under the Securities Act may be permitted to directors, officers and controlling persons of the registrant pursuant to the foregoing provisions, or otherwise, the registrant has been advised that in the opinion of the SEC such indemnification is against public policy as expressed in the Securities Act and is, therefore, unenforceable. In the event that a claim for indemnification against such liabilities (other than the payment by the registrant of expenses incurred or paid by a director, officer or controlling person of the registrant in the successful defense of any action, suit or proceeding) is asserted by such director, officer or controlling person in connection with the securities being registered, the registrant will, unless in the opinion of its counsel the matter has been settled by controlling precedent, submit to a court of appropriate jurisdiction the question whether such indemnification by it is against public policy as expressed in the Securities Act and will be governed by the final adjudication of such issue. </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">II-9 </div></div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;;font-weight: bold;"><a href="#toc">Table of Contents</a></div> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"> <div id="sig" style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">SIGNATURES </div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">Pursuant to the requirements of the Securities Act of 1933, the registrant has duly caused this Registration Statement on Form <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">S-1</div> to be signed on its behalf by the undersigned, thereunto duly authorized, on October 29, 2021. </div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 40%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: auto; border-collapse: collapse; border-spacing: 0px;">
<tr style="font-size: 0px;">
<td style="width: 7%;"></td>
<td style="width: 1%; vertical-align: bottom;"></td>
<td style="width: 92%;"></td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td colspan="3" style="vertical-align: top;">ROIVANT SCIENCES LTD.</td> </tr>
<tr style="font-size: 1pt;">
<td style="height: 12pt; font-family: &quot;Times New Roman&quot;;"></td>
<td colspan="2" style="height: 12pt; font-family: &quot;Times New Roman&quot;;"></td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;">By:</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: top;"> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 1pt; border-bottom: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">/s/ Matt Maisak</div></div> </td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: top;">Name:&#160;&#160;&#160;&#160;Matt Maisak</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: top;">Title:&#160;&#160;&#160;&#160;&#160;&#160;Authorized Signatory</td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> </div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">II-10 </div></div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;;font-weight: bold;"><a href="#toc">Table of Contents</a></div> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0px;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">POWER OF ATTORNEY </div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">KNOW ALL MEN BY THESE PRESENTS, that each of the undersigned constitutes and appoints Richard&#160;Pulik, Jo Chen and Matt Maisak his or her true and lawful <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">attorney-in-fact</div></div> and agent, with full power of substitution and revocation, for him or her and in his or her name, place and stead, in any and all capacities, to execute any or all amendments including any post-effective amendments and supplements to this Registration Statement, and any additional Registration Statement filed pursuant to Rule 462(b), and to file the same, with all exhibits thereto, and other documents in connection therewith, with the Securities and Exchange Commission, granting unto said <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">attorney-in-fact</div></div> and agent full power and authority to do and perform each and every act and thing requisite and necessary to be done, as fully to all intents and purposes as he or she might or could do in person, hereby ratifying and confirming all that said <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">attorney-in-fact</div></div> and agent, or his or her substitute or substitutes, may lawfully do or cause to be done by virtue hereof. </div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">Pursuant to the requirements of the Securities Act of 1933, as amended, this Registration Statement on <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">Form&#160;S-1</div> has been signed below by the following persons in the capacities and on the dates indicated. </div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0px;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px; text-indent: 0px;">
<tr style="font-size: 0px;">
<td style="width: 39%; font-family: &quot;Times New Roman&quot;;"></td>
<td style="width: 1%; vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="width: 39%; font-family: &quot;Times New Roman&quot;;"></td>
<td style="width: 2%; vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="width: 18%; font-family: &quot;Times New Roman&quot;;"></td> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 1pt; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">Name</div></div></div> </td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;&#160;</td>
<td style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 1pt; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">Title</div></div></div> </td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 1pt; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">Date</div></div></div> </td> </tr>
<tr style="font-size: 1pt;">
<td style="height: 12pt; font-family: &quot;Times New Roman&quot;;"></td>
<td colspan="2" style="height: 12pt; font-family: &quot;Times New Roman&quot;;"></td>
<td colspan="2" style="height: 12pt; font-family: &quot;Times New Roman&quot;;"></td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: bottom;"> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 1pt; border-bottom: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">/s/ Matthew Gline</div></div> </td>
<td rowspan="2" style="vertical-align: bottom;">&#160;&#160;</td>
<td rowspan="2" style="vertical-align: bottom;;text-align:center;"> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Chief Executive Officer and Director</div></div> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 1pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">(principal executive officer)</div></div> </td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: bottom;">Matthew Gline</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">October 29, 2021</div></div> </td> </tr>
<tr style="font-size: 1pt;">
<td style="height: 12pt; font-family: &quot;Times New Roman&quot;;"></td>
<td colspan="2" style="height: 12pt; font-family: &quot;Times New Roman&quot;;"></td>
<td colspan="2" style="height: 12pt; font-family: &quot;Times New Roman&quot;;"></td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: bottom;"> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 1pt; border-bottom: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">/s/ Richard Pulik</div></div> </td>
<td rowspan="2" style="vertical-align: bottom;">&#160;&#160;</td>
<td rowspan="2" style="vertical-align: bottom;;text-align:center;"> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Chief Financial Officer</div></div> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 1pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">(principal financial officer)</div></div> </td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">October 29, 2021</div></div> </td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;">Richard Pulik</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td> </tr>
<tr style="font-size: 1pt;">
<td style="height: 12pt; font-family: &quot;Times New Roman&quot;;"></td>
<td colspan="2" style="height: 12pt; font-family: &quot;Times New Roman&quot;;"></td>
<td colspan="2" style="height: 12pt; font-family: &quot;Times New Roman&quot;;"></td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: bottom;"> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 1pt; border-bottom: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">/s/ Rakhi Kumar</div></div> </td>
<td rowspan="2" style="vertical-align: bottom;">&#160;&#160;</td>
<td rowspan="2" style="vertical-align: bottom;;text-align:center;"> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Chief Accounting Officer</div></div> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 1pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">(principal accounting officer)</div></div> </td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:center;">October 29, 2021</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;">Rakhi Kumar</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td> </tr>
<tr style="font-size: 1pt;">
<td style="height: 12pt; font-family: &quot;Times New Roman&quot;;"></td>
<td colspan="2" style="height: 12pt; font-family: &quot;Times New Roman&quot;;"></td>
<td colspan="2" style="height: 12pt; font-family: &quot;Times New Roman&quot;;"></td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: bottom;"> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 1pt; border-bottom: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">/s/ Vivek Ramaswamy</div></div> </td>
<td rowspan="2" style="vertical-align: bottom;">&#160;&#160;</td>
<td rowspan="2" style="vertical-align: bottom;;text-align:center;">Director</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">October 29, 2021</div></div> </td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;">Vivek Ramaswamy</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td> </tr>
<tr style="font-size: 1pt;">
<td style="height: 12pt; font-family: &quot;Times New Roman&quot;;"></td>
<td colspan="2" style="height: 12pt; font-family: &quot;Times New Roman&quot;;"></td>
<td colspan="2" style="height: 12pt; font-family: &quot;Times New Roman&quot;;"></td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: bottom;"> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 1pt; border-bottom: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">/s/ Andrew Lo</div></div> </td>
<td rowspan="2" style="vertical-align: bottom;">&#160;&#160;</td>
<td rowspan="2" style="vertical-align: bottom;;text-align:center;">Director</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">October 29, 2021</div></div> </td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;">Andrew Lo</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td> </tr>
<tr style="font-size: 1pt;">
<td style="height: 12pt; font-family: &quot;Times New Roman&quot;;"></td>
<td colspan="2" style="height: 12pt; font-family: &quot;Times New Roman&quot;;"></td>
<td colspan="2" style="height: 12pt; font-family: &quot;Times New Roman&quot;;"></td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: bottom;"> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 1pt; border-bottom: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">/s/ Patrick Machado</div></div> </td>
<td rowspan="2" style="vertical-align: bottom;">&#160;&#160;</td>
<td rowspan="2" style="vertical-align: bottom;;text-align:center;">Director</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">October 29, 2021</div></div> </td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;">Patrick Machado</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td> </tr>
<tr style="font-size: 1pt;">
<td style="height: 12pt; font-family: &quot;Times New Roman&quot;;"></td>
<td colspan="2" style="height: 12pt; font-family: &quot;Times New Roman&quot;;"></td>
<td colspan="2" style="height: 12pt; font-family: &quot;Times New Roman&quot;;"></td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: bottom;"> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 1pt; border-bottom: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">/s/ Keith Manchester</div></div> </td>
<td rowspan="2" style="vertical-align: bottom;">&#160;&#160;</td>
<td rowspan="2" style="vertical-align: bottom;;text-align:center;">Director</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">October 29, 2021</div></div> </td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;">Keith Manchester</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td> </tr>
<tr style="font-size: 1pt;">
<td style="height: 12pt; font-family: &quot;Times New Roman&quot;;"></td>
<td colspan="2" style="height: 12pt; font-family: &quot;Times New Roman&quot;;"></td>
<td colspan="2" style="height: 12pt; font-family: &quot;Times New Roman&quot;;"></td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: bottom;"> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 1pt; border-bottom: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">/s/ Ilan Oren</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;;text-align:center;">Director</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">October 29, 2021</div></div> </td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;">Ilan Oren</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td> </tr>
<tr style="font-size: 1pt;">
<td style="height: 12pt; font-family: &quot;Times New Roman&quot;;"></td>
<td colspan="2" style="height: 12pt; font-family: &quot;Times New Roman&quot;;"></td>
<td colspan="2" style="height: 12pt; font-family: &quot;Times New Roman&quot;;"></td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: bottom;"> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 1pt; border-bottom: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">/s/ Daniel Gold</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;;text-align:center;">Director</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">October 29, 2021</div></div> </td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;">Daniel Gold</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td> </tr>
<tr style="font-size: 1pt;">
<td style="height: 12pt; font-family: &quot;Times New Roman&quot;;"></td>
<td colspan="2" style="height: 12pt; font-family: &quot;Times New Roman&quot;;"></td>
<td colspan="2" style="height: 12pt; font-family: &quot;Times New Roman&quot;;"></td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: bottom;"> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 1pt; border-bottom: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">/s/ Masayo Tada</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;;text-align:center;">Director</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">October 29, 2021</div></div> </td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;">Masayo Tada</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td> </tr>
<tr style="font-size: 1pt;">
<td style="height: 12pt; font-family: &quot;Times New Roman&quot;;"></td>
<td colspan="2" style="height: 12pt; font-family: &quot;Times New Roman&quot;;"></td>
<td colspan="2" style="height: 12pt; font-family: &quot;Times New Roman&quot;;"></td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: bottom;"> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 1pt; border-bottom: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">/s/ James C. Momtazee</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;;text-align:center;">Director</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">October 29, 2021</div></div> </td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;">James C. Momtazee</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td> </tr> </table> <div style="clear: both; max-height: 0pt; text-indent: 0px;"></div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0px;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0px;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">II-11 </div></div> </div> </div>
</body></html>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-5.1
<SEQUENCE>2
<FILENAME>d164680dex51.htm
<DESCRIPTION>EX-5.1
<TEXT>
<HTML><HEAD>
<TITLE>EX-5.1</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B>Exhibit 5.1 and Exhibit 23.3 </B></P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="59%"></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD WIDTH="39%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="middle">


<IMG SRC="g164680conyvers.jpg" ALT="LOGO">
</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="middle"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>CONYERS&nbsp;DILL&nbsp;&amp;&nbsp;PEARMAN&nbsp;LIMITED</B></P> <P STYLE="font-size:6pt; margin-top:0pt; margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Clarendon House, 2 Church Street</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Hamilton HM 11, Bermuda</P>
<P STYLE="font-size:6pt; margin-top:0pt; margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Mail:&nbsp;PO&nbsp;Box&nbsp;HM&nbsp;666,&nbsp;Hamilton&nbsp;HM&nbsp;CX,&nbsp;Bermuda</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">T +1 441 295 1422</P> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman">conyers.com</P></TD></TR>
</TABLE> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">29&nbsp;October 2021 </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right">Matter no.: 367954 </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right">Doc Ref:
20051483.2 </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">+1441-298-7846</FONT></FONT> </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right">neil.henderson@conyers.com </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Roivant Sciences Ltd.
</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Suite 1, 3rd&nbsp;Floor </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><FONT STYLE="white-space:nowrap">11-12</FONT> St. James&#146;s Square </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">London </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">SW1Y 4LB </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">United Kingdom </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Dear Sirs, </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Re:&nbsp;Roivant Sciences Ltd. (the &#147;Company&#148;) </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We have acted as special Bermuda legal counsel to the Company in connection with a registration statement on
<FONT STYLE="white-space:nowrap">Form&nbsp;S-1</FONT> filed with the U.S. Securities and Exchange Commission (the &#147;<B>Commission</B>&#148;) on 29&nbsp;October 2021 (the &#147;<B>Registration Statement</B>&#148;, which term does not include any
other document or agreement whether or not specifically referred to therein or attached as an exhibit or schedule thereto) relating to the registration under the U.S. Securities Act of 1933, as amended, (the &#147;<B>Securities Act</B>&#148;) of:
</P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(i)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">an aggregate of 595,296,589 common shares, par value $0.0000000341740141 per share (the
&#147;<B>Shares</B>&#148;), which term does not include any other document or agreement whether or not specifically referred to therein or attached as an exhibit or schedule thereto); and </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(ii)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">10,214,365 private placement warrants (the &#147;<B>Warrants</B>&#148;), entitling the holders thereof to
exercise each such Warrant for one common share of the Company at an exercise price of $11.50 per share pursuant to the Warrant Assumption Agreement, dated September&nbsp;30, 2021, between the Company and American Stock Transfer&nbsp;&amp; Trust
Company, LLC as warrant agent (the &#147;<B>Warrant Agreement</B>&#148;); and </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(iii)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">30,750,261 common shares of the Company issuable upon the exercise of (a)&nbsp;the Warrants and (b) 20,535,896
outstanding public warrants (each a &#147;<B>Warrant Share</B>,&#148; collectively, the &#147;<B>Warrant Shares</B>&#148; and, together with the Shares and the Warrants, the &#147;<B>Securities</B>&#148;). </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">For the purposes of giving this opinion, we have examined a copy of the Registration Statement. We have also reviewed the memorandum of association and <FONT
STYLE="white-space:nowrap">the&nbsp;bye-laws&nbsp;of</FONT> the Company as certified by the Secretary of the Company on 28&nbsp;October 2021, and an extract of unanimous written resolutions of its directors passed on 28&nbsp;September 2021
(collectively, the &#147;<B>Resolutions</B>&#148;) as certified by the Secretary of the Company on 28&nbsp;October 2021, and such other documents and made such enquiries as to questions of law as we have deemed necessary in order to render the
opinion set forth below. </P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We have assumed (a)&nbsp;the genuineness and authenticity of all signatures and the conformity to the
originals of all copies (whether or not certified) examined by us and the authenticity and completeness of the originals from which such copies were taken, (b)&nbsp;that where a document has been examined by us in draft form, it will be or has been
executed and/or filed in the form of that draft, and where a number of drafts of a document have been examined by us all changes thereto have been marked or otherwise drawn to our attention, (c)&nbsp;the accuracy and completeness of all factual
representations made in the Registration Statement and other documents reviewed by us, (d)&nbsp;that the Resolutions were passed at one or more duly convened, constituted and quorate meetings, or by unanimous written resolutions, remain in full
force and effect and have not been rescinded or amended, (e)&nbsp;that there is no provision of the law of any jurisdiction, other than Bermuda, which would have any implication in relation to the opinions expressed herein, (f)&nbsp;that upon issue
of any Shares by the Company the Company will receive consideration for the full issue price thereof which shall be equal to at least the par value thereof, (g)&nbsp;that the Company will have sufficient authorised capital to effect the issue of any
of the Warrant Shares at the time of issuance, whether as a principal issue or on the conversion, exchange or exercise of any Warrants, (h)&nbsp;that the form and terms of any and all Securities or other securities (or other obligations, rights,
currencies, commodities or other subject matter) comprising the same or subject thereto (in the case of the Warrants), the issuance and sale thereof by the Company, and the Company&#146;s incurrence and performance of its obligations thereunder or
in respect thereof (including, without limitation, its obligations under any related agreement or supplement thereto) in accordance with the terms thereof will not violate the memorandum of association and
<FONT STYLE="white-space:nowrap">bye-laws</FONT> of the Company nor any applicable law, regulation, order or decree in Bermuda, (i)&nbsp;that all necessary corporate action will be taken to authorise and approve any issuance of any Securities, the
terms of the offering thereof and related matters, (j)&nbsp;that the issuance and sale of and payment for the Securities will be in accordance with the applicable purchase, underwriting or similar agreement duly approved by the Board of Directors
and the Registration Statement (including the prospectus set forth therein and any applicable supplement thereto), (k) that upon the issue of any Warrant Shares the Company will receive consideration for the full issue price thereof which shall be
equal to at least the par value thereof, and (l)&nbsp;that the Company&#146;s Shares will be listed on an appointed stock exchange, as defined in the Companies Act 1981 as amended, and the consent will not have been revoked or amended at the time of
issuance of the Warrant Shares. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We have made no investigation of and express no opinion in relation to the laws of any jurisdiction other than Bermuda.
This opinion is to be governed by and construed in accordance with the laws of Bermuda and is limited to and is given on the basis of the current law and practice in Bermuda. This opinion is issued solely for the purposes of the filing of the
Registration Statement and is not to be relied upon in respect of any other matter. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">On the basis of and subject to the foregoing, we are of the opinion
that: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">1.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">The Company is duly incorporated and existing under the laws of Bermuda in good standing (meaning solely that
it has not failed to make any filing with any Bermuda government authority or to pay any Bermuda government fees or tax which would make it liable to be struck off the Register of Companies and thereby cease to exist under the laws of Bermuda).
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">2.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">The Shares have been validly issued, fully paid and are <FONT STYLE="white-space:nowrap">non-assessable</FONT>
(which term means when used herein that no further sums are required to be paid by the holders thereof in connection with the issue of such shares). </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">3.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Upon the due issuance of the Warrant Shares and payment of the consideration therefor in accordance with the
Warrant Agreement, such Warrant Shares will be validly issued, fully paid and <FONT STYLE="white-space:nowrap">non-assessable</FONT> (which term means when used herein that no further sums are required to be paid by the holders thereof in connection
with the issue of such shares). </P></TD></TR></TABLE>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We hereby consent to the filing of this opinion as an exhibit to the Registration Statement. In giving this
consent, we do not hereby admit that we are experts within the meaning of Section&nbsp;11 of the Securities Act or that we are within the category of persons whose consent is required under Section&nbsp;7 of the Securities Act or the Rules and
Regulations of the Commission promulgated thereunder. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Yours faithfully, </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">/s/ Conyers Dill&nbsp;&amp; Pearman Limited </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Conyers
Dill&nbsp;&amp; Pearman Limited </B></P>
</DIV></Center>

</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-5.2
<SEQUENCE>3
<FILENAME>d164680dex52.htm
<DESCRIPTION>EX-5.2
<TEXT>
<HTML><HEAD>
<TITLE>EX-5.2</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B>Exhibits 5.2 and 23.4 </B></P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="15%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="84%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">


<IMG SRC="g164680g1027213408166.jpg" ALT="LOGO">
</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Davis Polk&nbsp;&amp; Wardwell <SMALL>LLP</SMALL></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">450 Lexington Avenue</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">New York, NY 10017</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman">davispolk.com</P></TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">October&nbsp;29, 2021 </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Roivant
Sciences Ltd. </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Suite 1, 3rd Floor </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><FONT
STYLE="white-space:nowrap">11-12</FONT> St. James&#146;s Square </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">London SW1Y 4LB </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">United Kingdom </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Ladies and Gentlemen: </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Roivant Sciences Ltd., a Bermuda exempted limited company (the &#147;<B>Company</B>&#148;), has filed with the Securities and Exchange Commission a
Registration Statement on Form <FONT STYLE="white-space:nowrap">S-1</FONT> (the &#147;<B>Registration Statement</B>&#148;) and the related prospectus (the &#147;<B>Prospectus&#148;</B>) for the purpose of registering under the Securities Act of
1933, as amended (the &#147;<B>Securities Act</B>&#148;), 10,214,365 warrants (the &#147;<B>Warrants</B>&#148;) to purchase common shares of the Company. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We, as your counsel, have examined originals or copies of such documents, corporate records, certificates of public officials and other instruments as we have
deemed necessary or advisable for the purpose of rendering this opinion. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In rendering the opinion expressed herein, we have, without independent inquiry
or investigation, assumed that (i)&nbsp;all documents submitted to us as originals are authentic and complete, (ii)&nbsp;all documents submitted to us as copies conform to authentic, complete originals, (iii)&nbsp;all documents filed as exhibits to
the Registration Statement that have not been executed will conform to the forms thereof, (iv)&nbsp;all signatures on all documents that we reviewed are genuine, (v)&nbsp;all natural persons executing documents had and have the legal capacity to do
so, (vi)&nbsp;all statements in certificates of public officials and officers of the Company that we reviewed were and are accurate and (vii)&nbsp;all representations made by the Company as to matters of fact in the documents that we reviewed were
and are accurate. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Based upon the foregoing, and subject to the additional assumptions and qualifications set forth below, we advise you that, in our
opinion, assuming that the warrant agreement governing the Warrants has been duly authorized, executed and delivered by the warrant agent and the Company, and such Warrants have been duly authorized, executed, issued and delivered in accordance with
the warrant agreement and the applicable agreement against payment thereto, the Warrants are valid and binding obligations of the Company, enforceable in accordance with their terms, subject to applicable bankruptcy, insolvency and similar laws
affecting creditors&#146; rights generally, concepts of reasonableness and equitable principles of general applicability; provided that we express no opinion as to the validity, legally binding effect or enforceability of any provision in the
Warrants that requires or relates to adjustments to the exercise price at a price or in an amount that a court would determine in the circumstances under applicable law to be commercially unreasonable or a penalty or forfeiture. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">With respect to the validity of the common shares underlying the Warrants, you have received, and we understand that you are relying upon, the opinion of
Conyers Dill&nbsp;&amp; Pearman, Bermuda counsel to the Company. </P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We are members of the Bar of the State of New York and the foregoing opinion is limited to the laws of the
State of New York. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We hereby consent to the filing of this opinion as an exhibit to the Registration Statement and further consent to the reference to
our name under the caption &#147;Legal Matters&#148; in the Prospectus. In giving this consent, we do not admit that we are in the category of persons whose consent is required under Section&nbsp;7 of the Securities Act. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Very truly yours, </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">/s/ Davis Polk&nbsp;&amp; Wardwell LLP </P>
</DIV></Center>

</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-8.1
<SEQUENCE>4
<FILENAME>d164680dex81.htm
<DESCRIPTION>EX-8.1
<TEXT>
<HTML><HEAD>
<TITLE>EX-8.1</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B>Exhibit 8.1 and 23.5 </B></P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt" ALIGN="center">


<TR>

<TD WIDTH="15%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="11%"></TD>

<TD VALIGN="bottom" WIDTH="10%"></TD>
<TD WIDTH="68%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top">


<IMG SRC="g164680davispolk3.jpg" ALT="LOGO">
</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman">+44&nbsp;20&nbsp;7418&nbsp;1300</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman">davispolk.com</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman">Davis Polk &amp; Wardwell London LLP</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman">5
Aldermanbury Square</P> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman">London EC2V 7HR</P></TD></TR>
</TABLE> <P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">October&nbsp;29, 2021 </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Roivant Sciences Ltd. </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Suite 1, 3rd Floor </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><FONT STYLE="white-space:nowrap">11-12</FONT> St. James&#146;s Square </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">London SW1Y 4LB </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">United Kingdom </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Ladies and Gentlemen: </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We are acting as counsel to Roivant
Sciences Ltd., a Bermuda exempted limited company (the &#147;<B>Company</B>&#148;), as to certain matters of United Kingdom tax law in connection with<B> </B>the Company&#146;s Registration Statement on Form
<FONT STYLE="white-space:nowrap">S-1</FONT> (the &#147;<B>Registration Statement</B>&#148;) and the related prospectus (the &#147;<B>Prospectus</B>&#148;) with respect to the Company&#146;s common shares and private placement warrants (the
&#147;<B>Securities</B>&#148;). The Company is filing the Registration Statement with the Securities and Exchange Commission (the &#147;<B>Commission</B>&#148;) under the Securities Act of 1933, as amended (the &#147;<B>Securities Act</B>&#148;).
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We have examined such matters of fact and law as we have deemed necessary or advisable for the purpose of our opinion. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We hereby confirm our opinion set forth under the caption &#147;Material United Kingdom Tax Considerations&#148; in the Prospectus, subject to the limitations
and qualifications set forth therein, constitutes our opinion as to the material United Kingdom (&#147;<B>UK</B>&#148;) tax consequences to <FONT STYLE="white-space:nowrap">non-UK</FONT> holders of an investment in the Securities. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We express no opinion as to the laws of any jurisdiction other than the laws of England and Wales as applied by the English courts and on the generally
published practice of HM Revenue&nbsp;&amp; Customs, as at the date of this opinion. This opinion does not extend to (A)&nbsp;any law relating to tax made by the Scottish Parliament, the National Assembly for Wales or the Northern Irish Assembly,
(B)&nbsp;any other law relating to any law so made, or (C)&nbsp;any practice relating to any such law, and we express no opinion on any such matters. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">This opinion is furnished to you solely for use in connection with the Registration Statement. We hereby consent to the filing of this opinion with the
Commission as an exhibit to the Registration Statement, and to the references therein to us. In giving such consent, we do not thereby admit that we are in the category of persons whose consent is required under Section&nbsp;7 of the Securities Act,
or the rules and regulations of the Commission thereunder. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Very truly yours, </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">/s/ Davis Polk&nbsp;&amp; Wardwell London LLP </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="font-size:12pt; margin-top:0pt; margin-bottom:0pt">&nbsp;</P> <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="line-height:3.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman">Davis Polk &amp; Wardwell London LLP is a limited liability partnership formed under the laws of the State of New York, USA and is authorised and regulated </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman">by the Solicitors Regulation Authority with registration number 566321. </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman">Davis Polk includes Davis Polk &amp; Wardwell LLP and its associated entities </P>
</DIV></Center>

</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-8.2
<SEQUENCE>5
<FILENAME>d164680dex82.htm
<DESCRIPTION>EX-8.2
<TEXT>
<HTML><HEAD>
<TITLE>EX-8.2</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B>Exhibit 8.2 </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt" ALIGN="center">


<TR>

<TD WIDTH="51%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="48%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top">


<IMG SRC="g164680g1027213408166.jpg" ALT="LOGO">
</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman">Davis Polk &amp; Wardwell <SMALL>LLP</SMALL></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman">450
Lexington Avenue</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman">New York, NY 10017</P> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman">davispolk.com</P></TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">October&nbsp;29, 2021 </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Roivant
Sciences Ltd. </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Suite 1, 3<SUP STYLE="font-size:85%; vertical-align:top">rd</SUP> Floor </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><FONT STYLE="white-space:nowrap">11-12</FONT> St. James Square </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">London SW1Y 4LB </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">United Kingdom </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Ladies and Gentlemen: </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We are acting as United States counsel
to Roivant Sciences Ltd., a corporation incorporated in Bermuda (the &#147;<U>Company</U>&#148;), in connection with the preparation of the registration statement on Form <FONT STYLE="white-space:nowrap">S-1</FONT> (the &#147;<U>Registration
Statement</U>&#148;) and the related prospectus (the &#147;<U>Prospectus</U>&#148;) with respect to the Company&#146;s common shares and private placement warrants (the &#147;<U>Securities</U>&#148;). The Company is filing the Registration Statement
with the Securities and Exchange Commission (the &#147;<U>Commission</U>&#148;) under the Securities Act of 1933, as amended (the &#147;<U>Securities Act</U>&#148;). </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We have examined such matters of fact and law as we have deemed necessary or advisable for the purpose of our opinion. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We hereby confirm that the discussion set forth under the caption &#147;MATERIAL UNITED STATES TAX CONSIDERATIONS&#148; in the Prospectus, subject to the
limitations and qualifications set forth therein, constitutes our opinion as to the material U.S. federal income tax consequences to U.S. Holders of an investment in the Securities. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We are members of the Bar of the State of New York, and we express no opinion as to the laws of any jurisdiction other than the laws of the State of New York
and the federal laws of the United States. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">This opinion is furnished to you solely for use in connection with the Registration Statement. We hereby
consent to the filing of this opinion with the Commission as an exhibit to the Registration Statement, and to the references therein to us. In giving such consent, we do not thereby admit that we are in the category of persons whose consent is
required under Section&nbsp;7 of the Securities Act, or the rules and regulations of the Commission thereunder. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:55%; text-indent:-2%; font-size:10pt; font-family:Times New Roman">Very
truly yours, </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:55%; text-indent:-2%; font-size:10pt; font-family:Times New Roman">/s/ Davis Polk&nbsp;&amp; Wardwell LLP </P>
</DIV></Center>

</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-23.1
<SEQUENCE>6
<FILENAME>d164680dex231.htm
<DESCRIPTION>EX-23.1
<TEXT>
<HTML><HEAD>
<TITLE>EX-23.1</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B>Exhibit 23.1 </B></P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><U>INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM&#146;S CONSENT </U></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We consent to the inclusion in this Registration Statement of Roivant Sciences Ltd. on Form <FONT STYLE="white-space:nowrap">S-1</FONT> of our report dated
March&nbsp;22, 2021, except for the effects of the restatement discussed in Note 2 as to which the date is May&nbsp;13, 2021, with respect to our audits of the financial statements of Montes Archimedes Acquisition Corp. as of December&nbsp;31, 2020
and for the period from July&nbsp;6, 2020 (inception) through December&nbsp;31, 2020, which report appears in the Prospectus, which is part of this Registration Statement. We also consent to the reference to our Firm under the heading
&#147;Experts&#148; in such&nbsp;Prospectus. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">/s/ Marcum <SMALL>LLP</SMALL> </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Marcum <SMALL>LLP</SMALL> </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Costa Mesa, California </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">October&nbsp;29, 2021 </P>
</DIV></Center>

</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-23.2
<SEQUENCE>7
<FILENAME>d164680dex232.htm
<DESCRIPTION>EX-23.2
<TEXT>
<HTML><HEAD>
<TITLE>EX-23.2</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B>EXHIBIT 23.2 </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Consent of Independent Registered Public Accounting Firm </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We consent to the reference to our firm under the caption &#147;Experts&#148;&nbsp;and to the use of our report dated June&nbsp;30, 2021, in the Registration
Statement (Form <FONT STYLE="white-space:nowrap">S-1)</FONT> and related Prospectus of Roivant Sciences Ltd. dated October&nbsp;29, 2021. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">/s/
Ernst&nbsp;&amp; Young LLP </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Iselin, New Jersey </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">October&nbsp;29, 2021 </P>
</DIV></Center>

</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.SCH
<SEQUENCE>8
<FILENAME>roiv-20210630.xsd
<DESCRIPTION>XBRL TAXONOMY EXTENSION SCHEMA
<TEXT>
<XBRL>
<?xml version="1.0" encoding="utf-8"?>
<!--Generated by DFIN XBRL Instance Document - http://www.dfinsolutions.com/ - Version R3.0 - on 30-October-2021 [02:44:34] {AM}-->
<schema targetNamespace="http://roivant.com/20210630" elementFormDefault="qualified" xmlns:roiv="http://roivant.com/20210630" xmlns="http://www.w3.org/2001/XMLSchema" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:xl="http://www.xbrl.org/2003/XLink" xmlns:us-gaap="http://fasb.org/us-gaap/2021-01-31" xmlns:country="http://xbrl.sec.gov/country/2021" xmlns:currency="http://xbrl.sec.gov/currency/2021" xmlns:dei="http://xbrl.sec.gov/dei/2021" xmlns:exch="http://xbrl.sec.gov/exch/2021" xmlns:naics="http://xbrl.sec.gov/naics/2021" xmlns:sic="http://xbrl.sec.gov/sic/2021" xmlns:us-types="http://fasb.org/us-types/2021-01-31" xmlns:stpr="http://xbrl.sec.gov/stpr/2021" xmlns:deprecated="http://www.xbrl.org/2009/arcrole/fact-explanatoryFact" xmlns:srt="http://fasb.org/srt/2021-01-31" xmlns:srt-types="http://fasb.org/srt-types/2021-01-31" xmlns:dtr-types="http://www.xbrl.org/dtr/type/2020-01-21">
<annotation>
<appinfo>
<link:roleType roleURI="http://roivant.com/role/Cover" id="Cover">
<link:definition>1001 - Document - Cover</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://roivant.com/role/CondensedConsolidatedBalanceSheets" id="CondensedConsolidatedBalanceSheets">
<link:definition>1002 - Statement - Condensed Consolidated Balance Sheets</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://roivant.com/role/CondensedConsolidatedBalanceSheetsParenthetical" id="CondensedConsolidatedBalanceSheetsParenthetical">
<link:definition>1003 - Statement - Condensed Consolidated Balance Sheets (Parenthetical)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://roivant.com/role/CondensedConsolidatedStatementsOfOperations" id="CondensedConsolidatedStatementsOfOperations">
<link:definition>1004 - Statement - Condensed Consolidated Statements of Operations</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://roivant.com/role/CondensedConsolidatedStatementsOfComprehensiveLoss" id="CondensedConsolidatedStatementsOfComprehensiveLoss">
<link:definition>1005 - Statement - Condensed Consolidated Statements of Comprehensive Loss</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://roivant.com/role/CondensedConsolidatedStatementsOfShareholdersEquityAndRedeemableNoncontrollingInterest" id="CondensedConsolidatedStatementsOfShareholdersEquityAndRedeemableNoncontrollingInterest">
<link:definition>1006 - Statement - Condensed Consolidated Statements of Shareholders' Equity and Redeemable Noncontrolling Interest</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://roivant.com/role/CondensedConsolidatedStatementsOfCashFlows" id="CondensedConsolidatedStatementsOfCashFlows">
<link:definition>1007 - Statement - Condensed Consolidated Statements of Cash Flows</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://roivant.com/role/DescriptionOfBusinessAndLiquidity" id="DescriptionOfBusinessAndLiquidity">
<link:definition>1008 - Disclosure - Description of Business and Liquidity</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://roivant.com/role/SummaryOfSignificantAccountingPolicies" id="SummaryOfSignificantAccountingPolicies">
<link:definition>1009 - Disclosure - Summary of Significant Accounting Policies</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://roivant.com/role/Investments" id="Investments">
<link:definition>1010 - Disclosure - Investments</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://roivant.com/role/AssetAcquisitionsAndLicenseAgreements" id="AssetAcquisitionsAndLicenseAgreements">
<link:definition>1011 - Disclosure - Asset Acquisitions and License Agreements</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://roivant.com/role/SumitomoTransactionAgreement" id="SumitomoTransactionAgreement">
<link:definition>1012 - Disclosure - Sumitomo Transaction Agreement</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://roivant.com/role/BalanceSheetComponents" id="BalanceSheetComponents">
<link:definition>1013 - Disclosure - Balance Sheet Components</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://roivant.com/role/LongTermDebtAndLoanCommitment" id="LongTermDebtAndLoanCommitment">
<link:definition>1014 - Disclosure - Long Term Debt and Loan Commitment</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://roivant.com/role/ShareholdersEquityAndRedeemableNoncontrollingInterest" id="ShareholdersEquityAndRedeemableNoncontrollingInterest">
<link:definition>1015 - Disclosure - Shareholders' Equity and Redeemable Noncontrolling Interest</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://roivant.com/role/ShareBasedCompensation" id="ShareBasedCompensation">
<link:definition>1016 - Disclosure - Share-Based Compensation</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://roivant.com/role/RelatedPartyTransactions" id="RelatedPartyTransactions">
<link:definition>1017 - Disclosure - Related Party Transactions</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://roivant.com/role/DiscontinuedOperations" id="DiscontinuedOperations">
<link:definition>1018 - Disclosure - Discontinued Operations</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://roivant.com/role/IncomeTaxes" id="IncomeTaxes">
<link:definition>1019 - Disclosure - Income Taxes</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://roivant.com/role/Leases" id="Leases">
<link:definition>1020 - Disclosure - Leases</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://roivant.com/role/CommitmentsContingencies" id="CommitmentsContingencies">
<link:definition>1021 - Disclosure - Commitments &amp; Contingencies</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://roivant.com/role/FairValueMeasurements" id="FairValueMeasurements">
<link:definition>1022 - Disclosure - Fair Value Measurements</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://roivant.com/role/DefinedContributionPlan" id="DefinedContributionPlan">
<link:definition>1023 - Disclosure - Defined Contribution Plan</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://roivant.com/role/OtherIncomeExpenseNet" id="OtherIncomeExpenseNet">
<link:definition>1024 - Disclosure - Other (Income) Expense, Net</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://roivant.com/role/NetLossPerCommonShare" id="NetLossPerCommonShare">
<link:definition>1025 - Disclosure - Net Loss per Common Share</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://roivant.com/role/SubsequentEvents" id="SubsequentEvents">
<link:definition>1026 - Disclosure - Subsequent Events</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://roivant.com/role/SummaryOfSignificantAccountingPoliciesPolicies" id="SummaryOfSignificantAccountingPoliciesPolicies">
<link:definition>1027 - Disclosure - Summary of Significant Accounting Policies (Policies)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://roivant.com/role/SummaryOfSignificantAccountingPoliciesTables" id="SummaryOfSignificantAccountingPoliciesTables">
<link:definition>1028 - Disclosure - Summary of Significant Accounting Policies (Tables)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://roivant.com/role/DiscontinuedOperationsTables" id="DiscontinuedOperationsTables">
<link:definition>1029 - Disclosure - Discontinued Operations (Tables)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://roivant.com/role/BalanceSheetComponentsTables" id="BalanceSheetComponentsTables">
<link:definition>1030 - Disclosure - Balance Sheet Components (Tables)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://roivant.com/role/LongTermDebtAndLoanCommitmentTables" id="LongTermDebtAndLoanCommitmentTables">
<link:definition>1031 - Disclosure - Long Term Debt and Loan Commitment (Tables)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://roivant.com/role/ShareholdersEquityAndRedeemableNoncontrollingInterestTables" id="ShareholdersEquityAndRedeemableNoncontrollingInterestTables">
<link:definition>1032 - Disclosure - Shareholders' Equity and Redeemable Noncontrolling Interest (Tables)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://roivant.com/role/ShareBasedCompensationTables" id="ShareBasedCompensationTables">
<link:definition>1033 - Disclosure - Share-Based Compensation (Tables)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://roivant.com/role/IncomeTaxesTables" id="IncomeTaxesTables">
<link:definition>1034 - Disclosure - Income Taxes (Tables)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://roivant.com/role/LeasesTables" id="LeasesTables">
<link:definition>1035 - Disclosure - Leases (Tables)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://roivant.com/role/FairValueMeasurementsTables" id="FairValueMeasurementsTables">
<link:definition>1036 - Disclosure - Fair Value Measurements (Tables)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://roivant.com/role/OtherIncomeExpenseNetTables" id="OtherIncomeExpenseNetTables">
<link:definition>1037 - Disclosure - Other (Income) Expense, Net (Tables)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://roivant.com/role/NetLossPerCommonShareTables" id="NetLossPerCommonShareTables">
<link:definition>1038 - Disclosure - Net Loss per Common Share (Tables)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://roivant.com/role/DescriptionOfBusinessAndLiquidityAdditionalInformationDetail" id="DescriptionOfBusinessAndLiquidityAdditionalInformationDetail">
<link:definition>1039 - Disclosure - Description of Business and Liquidity - Additional Information (Detail)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://roivant.com/role/SummaryOfSignificantAccountingPoliciesAdditionalInformationDetail" id="SummaryOfSignificantAccountingPoliciesAdditionalInformationDetail">
<link:definition>1040 - Disclosure - Summary of Significant Accounting Policies - Additional Information (Detail)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://roivant.com/role/SummaryOfSignificantAccountingPoliciesScheduleOfAggregateAmountsOfCashCashEquivalentsAndRestrictedCashDetail" id="SummaryOfSignificantAccountingPoliciesScheduleOfAggregateAmountsOfCashCashEquivalentsAndRestrictedCashDetail">
<link:definition>1041 - Disclosure - Summary of Significant Accounting Policies - Schedule of Aggregate Amounts of Cash, Cash Equivalents, and Restricted Cash (Detail)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://roivant.com/role/SummaryOfSignificantAccountingPoliciesScheduleOfEstimatedUsefulLivesDetail" id="SummaryOfSignificantAccountingPoliciesScheduleOfEstimatedUsefulLivesDetail">
<link:definition>1042 - Disclosure - Summary of Significant Accounting Policies - Schedule of Estimated Useful Lives (Detail)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://roivant.com/role/InvestmentsAdditionalInformationDetail" id="InvestmentsAdditionalInformationDetail">
<link:definition>1043 - Disclosure - Investments - Additional Information (Detail)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://roivant.com/role/AssetAcquisitionsAndLicenseAgreementsAdditionalInformationDetail" id="AssetAcquisitionsAndLicenseAgreementsAdditionalInformationDetail">
<link:definition>1044 - Disclosure - Asset Acquisitions and License Agreements -Additional Information (Detail)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://roivant.com/role/SumitomoTransactionAgreementAdditionalInformationDetail" id="SumitomoTransactionAgreementAdditionalInformationDetail">
<link:definition>1045 - Disclosure - Sumitomo Transaction Agreement - Additional Information (Detail)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://roivant.com/role/BalanceSheetComponentsScheduleOfOtherCurrentAssetsDetail" id="BalanceSheetComponentsScheduleOfOtherCurrentAssetsDetail">
<link:definition>1046 - Disclosure - Balance Sheet Components - Schedule of Other Current Assets (Detail)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://roivant.com/role/BalanceSheetComponentsScheduleOfAccruedExpensesDetail" id="BalanceSheetComponentsScheduleOfAccruedExpensesDetail">
<link:definition>1047 - Disclosure - Balance Sheet Components - Schedule of Accrued Expenses (Detail)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://roivant.com/role/BalanceSheetComponentsScheduleOfOtherCurrentLiabilitiesDetail" id="BalanceSheetComponentsScheduleOfOtherCurrentLiabilitiesDetail">
<link:definition>1048 - Disclosure - Balance Sheet Components - Schedule of Other Current Liabilities (Detail)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://roivant.com/role/LongTermDebtAndLoanCommitmentDetail" id="LongTermDebtAndLoanCommitmentDetail">
<link:definition>1049 - Disclosure - Long Term Debt and Loan Commitment (Detail)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://roivant.com/role/LongTermDebtAndLoanCommitmentAdditionalInformationDetail" id="LongTermDebtAndLoanCommitmentAdditionalInformationDetail">
<link:definition>1050 - Disclosure - Long-Term Debt and Loan Commitment - Additional Information (Detail)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://roivant.com/role/LongTermDebtAndConvertibleNotesPayableScheduleOfCompanysAnnualPaymentsDetail" id="LongTermDebtAndConvertibleNotesPayableScheduleOfCompanysAnnualPaymentsDetail">
<link:definition>1051 - Disclosure - Long Term Debt and Convertible Notes Payable - Schedule of Company's Annual Payments (Detail)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://roivant.com/role/ShareholdersEquityAndRedeemableNonControllingInterestAdditionalInformationDetail" id="ShareholdersEquityAndRedeemableNonControllingInterestAdditionalInformationDetail">
<link:definition>1052 - Disclosure - Shareholders' Equity and Redeemable Non-Controlling Interest - Additional Information (Detail)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://roivant.com/role/ShareholdersEquityAndRedeemableNonControllingInterestScheduleOfPaymentsOfEquitySecuritiesDetail" id="ShareholdersEquityAndRedeemableNonControllingInterestScheduleOfPaymentsOfEquitySecuritiesDetail">
<link:definition>1053 - Disclosure - Shareholders' Equity and Redeemable Non-Controlling Interest - Schedule of payments of equity securities (Detail)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://roivant.com/role/ShareBasedCompensationAdditionalInformationDetail" id="ShareBasedCompensationAdditionalInformationDetail">
<link:definition>1054 - Disclosure - Share-Based Compensation - Additional Information (Detail)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://roivant.com/role/ShareBasedCompensationScheduleOfFairValueAssumptionsDetail" id="ShareBasedCompensationScheduleOfFairValueAssumptionsDetail">
<link:definition>1055 - Disclosure - Share-Based Compensation - Schedule of Fair Value Assumptions (Detail)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://roivant.com/role/ShareBasedCompensationSummaryOfStockOptionActivityDetail" id="ShareBasedCompensationSummaryOfStockOptionActivityDetail">
<link:definition>1056 - Disclosure - Share-Based Compensation - Summary of Stock Option Activity (Detail)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://roivant.com/role/ShareBasedCompensationSummaryOfFairValueOfVestedStockOptionDetail" id="ShareBasedCompensationSummaryOfFairValueOfVestedStockOptionDetail">
<link:definition>1057 - Disclosure - Share-Based Compensation - Summary of Fair Value of Vested Stock Option (Detail)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://roivant.com/role/ShareBasedCompensationSummaryOfRestrictedStockUnitsDetail" id="ShareBasedCompensationSummaryOfRestrictedStockUnitsDetail">
<link:definition>1058 - Disclosure - Share-Based Compensation - Summary of Restricted Stock Units (Detail)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://roivant.com/role/ShareBasedCompensationSummaryOfPerformanceOptionsActivityDetail" id="ShareBasedCompensationSummaryOfPerformanceOptionsActivityDetail">
<link:definition>1059 - Disclosure - Share-Based Compensation - Summary of Performance Options Activity (Detail)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://roivant.com/role/ShareBasedCompensationSummaryOfCappedValueAppreciationRightsDetail" id="ShareBasedCompensationSummaryOfCappedValueAppreciationRightsDetail">
<link:definition>1060 - Disclosure - Share-Based Compensation - Summary of Capped Value Appreciation Rights (Detail)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://roivant.com/role/ShareBasedCompensationSummaryOfPerformanceRestrictedStockUnitsDetail" id="ShareBasedCompensationSummaryOfPerformanceRestrictedStockUnitsDetail">
<link:definition>1061 - Disclosure - Share-Based Compensation - Summary of Performance Restricted Stock Units (Detail)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://roivant.com/role/ShareBasedCompensationSummaryOfCommonShareAwardActivityDetail" id="ShareBasedCompensationSummaryOfCommonShareAwardActivityDetail">
<link:definition>1062 - Disclosure - Share-Based Compensation - Summary of Common Share Award Activity (Detail)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://roivant.com/role/ShareBasedCompensationSummaryOfShareBasedCompensationExpenseDetail" id="ShareBasedCompensationSummaryOfShareBasedCompensationExpenseDetail">
<link:definition>1063 - Disclosure - Share-Based Compensation - Summary of Share-Based Compensation Expense (Detail)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://roivant.com/role/DiscontinuedOperationsSummaryOfDisposalGroupsIncludingDiscontinuedOperationsIncomeStatementDetail" id="DiscontinuedOperationsSummaryOfDisposalGroupsIncludingDiscontinuedOperationsIncomeStatementDetail">
<link:definition>1064 - Disclosure - Discontinued Operations - Summary Of Disposal Groups Including Discontinued Operations Income Statement (Detail)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://roivant.com/role/DiscontinuedOperationsSummaryOfCashFlowsFromDiscontinuedOperationsDetail" id="DiscontinuedOperationsSummaryOfCashFlowsFromDiscontinuedOperationsDetail">
<link:definition>1065 - Disclosure - Discontinued Operations - Summary of Cash Flows From Discontinued Operations (Detail)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://roivant.com/role/RelatedPartyTransactionsAdditionalInformationDetail" id="RelatedPartyTransactionsAdditionalInformationDetail">
<link:definition>1066 - Disclosure - Related Party Transactions - Additional Information (Detail)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://roivant.com/role/IncomeTaxesScheduleOfLossBeforeIncomeTaxesByGeographicRegionDetail" id="IncomeTaxesScheduleOfLossBeforeIncomeTaxesByGeographicRegionDetail">
<link:definition>1067 - Disclosure - Income Taxes - Schedule of Loss Before Income Taxes by Geographic Region (Detail)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://roivant.com/role/IncomeTaxesScheduleComponentsOfIncomeTaxExpenseBenefitDetail" id="IncomeTaxesScheduleComponentsOfIncomeTaxExpenseBenefitDetail">
<link:definition>1068 - Disclosure - Income Taxes - Schedule Components of Income Tax Expense (Benefit) (Detail)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://roivant.com/role/IncomeTaxesAdditionalInformationDetail" id="IncomeTaxesAdditionalInformationDetail">
<link:definition>1069 - Disclosure - Income Taxes - Additional Information (Detail)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://roivant.com/role/IncomeTaxesScheduleOfDeferredTaxAssetsLiabilitiesDetail" id="IncomeTaxesScheduleOfDeferredTaxAssetsLiabilitiesDetail">
<link:definition>1070 - Disclosure - Income Taxes - Schedule of Deferred Tax Assets (Liabilities) (Detail)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://roivant.com/role/IncomeTaxesScheduleOfEffectiveIncomeTaxRateReconciliationDetail" id="IncomeTaxesScheduleOfEffectiveIncomeTaxRateReconciliationDetail">
<link:definition>1071 - Disclosure - Income Taxes - Schedule of Effective Income Tax Rate Reconciliation (Detail)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://roivant.com/role/LeasesScheduleOfMaturitiesOfOperatingLeaseLiabilitiesDetail" id="LeasesScheduleOfMaturitiesOfOperatingLeaseLiabilitiesDetail">
<link:definition>1072 - Disclosure - Leases - Schedule of Maturities of Operating Lease Liabilities (Detail)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://roivant.com/role/LeasesSummaryOfOperatingLeaseRouAssetsAndOperatingLeaseLiabilitiesDetail" id="LeasesSummaryOfOperatingLeaseRouAssetsAndOperatingLeaseLiabilitiesDetail">
<link:definition>1073 - Disclosure - Leases - Summary of Operating Lease ROU Assets and Operating Lease Liabilities (Detail)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://roivant.com/role/LeasesScheduleOfOperatingLeaseCostsDetail" id="LeasesScheduleOfOperatingLeaseCostsDetail">
<link:definition>1074 - Disclosure - Leases - Schedule of Operating Lease Costs (Detail)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://roivant.com/role/FairValueMeasurementsScheduleOfAssetsAndLiabilitiesMeasuredAtFairValueOnARecurringBasisDetail" id="FairValueMeasurementsScheduleOfAssetsAndLiabilitiesMeasuredAtFairValueOnARecurringBasisDetail">
<link:definition>1075 - Disclosure - Fair Value Measurements - Schedule of Assets and Liabilities Measured at Fair Value on a Recurring Basis (Detail)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://roivant.com/role/FairValueMeasurementsAdditionalInformationDetail" id="FairValueMeasurementsAdditionalInformationDetail">
<link:definition>1076 - Disclosure - Fair Value Measurements - Additional Information (Detail)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://roivant.com/role/FairValueMeasurementsChangeInTheFairValueOfTheDerivativeWarrantLiabilitiesDetail" id="FairValueMeasurementsChangeInTheFairValueOfTheDerivativeWarrantLiabilitiesDetail">
<link:definition>1077 - Disclosure - Fair Value Measurements - Change in the Fair Value of the Derivative Warrant Liabilities (Detail)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://roivant.com/role/FairValueMeasurementsScheduleOfFairValueOfUnobservableInputRelatedToOptionsToAcquireUnderSumitomoTransactionAgreementDetail" id="FairValueMeasurementsScheduleOfFairValueOfUnobservableInputRelatedToOptionsToAcquireUnderSumitomoTransactionAgreementDetail">
<link:definition>1078 - Disclosure - Fair Value Measurements - Schedule of Fair Value of Unobservable Input Related To Options to Acquire Under Sumitomo Transaction Agreement (Detail)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://roivant.com/role/DefinedContributionPlanAdditionalInformationDetail" id="DefinedContributionPlanAdditionalInformationDetail">
<link:definition>1079 - Disclosure - Defined Contribution Plan - Additional Information (Detail)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://roivant.com/role/OtherIncomeExpenseNetSummaryOfOtherIncomeExpenseNetFromContinuingOperationsDetail" id="OtherIncomeExpenseNetSummaryOfOtherIncomeExpenseNetFromContinuingOperationsDetail">
<link:definition>1080 - Disclosure - Other (Income) Expense, Net - Summary of Other (Income) Expense, Net From Continuing Operations (Detail)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://roivant.com/role/NetLossPerCommonShareSummaryOfBasicAndDilutedNetIncomePerShareOfCommonStockDetail" id="NetLossPerCommonShareSummaryOfBasicAndDilutedNetIncomePerShareOfCommonStockDetail">
<link:definition>1081 - Disclosure - Net Loss per Common Share - Summary of Basic and Diluted Net Income Per Share of Common Stock (Detail)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://roivant.com/role/NetLossPerCommonShareSummaryOfBasicAndDilutedNetIncomePerShareOfCommonStockParentheticalDetail" id="NetLossPerCommonShareSummaryOfBasicAndDilutedNetIncomePerShareOfCommonStockParentheticalDetail">
<link:definition>1082 - Disclosure - Net Loss per Common Share - Summary of Basic and Diluted Net Income Per Share of Common Stock (Parenthetical) (Detail)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://roivant.com/role/SubsequentEventsAdditionalInformationDetail" id="SubsequentEventsAdditionalInformationDetail">
<link:definition>1083 - Disclosure - Subsequent Events - Additional Information (Detail)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:linkbaseRef xlink:type="simple" xlink:href="roiv-20210630_pre.xml" xlink:role="http://www.xbrl.org/2003/role/presentationLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" />
<link:linkbaseRef xlink:type="simple" xlink:href="roiv-20210630_def.xml" xlink:role="http://www.xbrl.org/2003/role/definitionLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" />
<link:linkbaseRef xlink:type="simple" xlink:href="roiv-20210630_lab.xml" xlink:role="http://www.xbrl.org/2003/role/labelLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" />
<link:linkbaseRef xlink:type="simple" xlink:href="roiv-20210630_cal.xml" xlink:role="http://www.xbrl.org/2003/role/calculationLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" />
</appinfo>
</annotation>
<import namespace="http://www.xbrl.org/2003/instance" schemaLocation="http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd" />
<import namespace="http://www.xbrl.org/2003/linkbase" schemaLocation="http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" />
<import namespace="http://xbrl.org/2005/xbrldt" schemaLocation="http://www.xbrl.org/2005/xbrldt-2005.xsd" />
<import namespace="http://fasb.org/us-gaap/2021-01-31" schemaLocation="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd" />
<import namespace="http://xbrl.sec.gov/country/2021" schemaLocation="https://xbrl.sec.gov/country/2021/country-2021.xsd" />
<import namespace="http://xbrl.sec.gov/currency/2021" schemaLocation="https://xbrl.sec.gov/currency/2021/currency-2021.xsd" />
<import namespace="http://xbrl.sec.gov/exch/2021" schemaLocation="https://xbrl.sec.gov/exch/2021/exch-2021.xsd" />
<import namespace="http://xbrl.sec.gov/naics/2021" schemaLocation="https://xbrl.sec.gov/naics/2021/naics-2021.xsd" />
<import namespace="http://xbrl.sec.gov/sic/2021" schemaLocation="https://xbrl.sec.gov/sic/2021/sic-2021.xsd" />
<import namespace="http://xbrl.sec.gov/stpr/2021" schemaLocation="https://xbrl.sec.gov/stpr/2021/stpr-2021.xsd" />
<import namespace="http://www.xbrl.org/2009/role/negated" schemaLocation="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd" />
<import namespace="http://www.xbrl.org/2009/role/net" schemaLocation="http://www.xbrl.org/lrr/role/net-2009-12-16.xsd" />
<import namespace="http://www.xbrl.org/2009/arcrole/fact-explanatoryFact" schemaLocation="http://www.xbrl.org/lrr/arcrole/factExplanatory-2009-12-16.xsd" />
<import namespace="http://xbrl.sec.gov/dei/2021" schemaLocation="https://xbrl.sec.gov/dei/2021/dei-2021.xsd" />
<import namespace="http://fasb.org/us-types/2021-01-31" schemaLocation="https://xbrl.fasb.org/us-gaap/2021/elts/us-types-2021-01-31.xsd" />
<import namespace="http://fasb.org/srt-types/2021-01-31" schemaLocation="https://xbrl.fasb.org/srt/2021/elts/srt-types-2021-01-31.xsd" />
<import namespace="http://fasb.org/srt/2021-01-31" schemaLocation="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd" />
<import namespace="http://www.xbrl.org/dtr/type/2020-01-21" schemaLocation="https://www.xbrl.org/dtr/type/2020-01-21/types.xsd" />
<element name="DeferredConsiderationLiabilityCurrent" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" nillable="true" id="roiv_DeferredConsiderationLiabilityCurrent" substitutionGroup="xbrli:item" xbrli:balance="credit" />
<element name="SubscriptionsReceivable" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" nillable="true" id="roiv_SubscriptionsReceivable" substitutionGroup="xbrli:item" xbrli:balance="credit" />
<element name="LiabilityInstrumentsMeasuredAtFairValue" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" nillable="true" id="roiv_LiabilityInstrumentsMeasuredAtFairValue" substitutionGroup="xbrli:item" xbrli:balance="credit" />
<element name="OperatingCosts" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="roiv_OperatingCosts" substitutionGroup="xbrli:item" xbrli:balance="debit" />
<element name="GainLossOnFairValueOfDebtAndLiabilityInstruments" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="roiv_GainLossOnFairValueOfDebtAndLiabilityInstruments" substitutionGroup="xbrli:item" xbrli:balance="credit" />
<element name="DeconsolidationAndConsolidationOnGainOrLossOfConsolidatedEntity" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="roiv_DeconsolidationAndConsolidationOnGainOrLossOfConsolidatedEntity" substitutionGroup="xbrli:item" xbrli:balance="credit" />
<element name="EquityInterestOptionToThirdPartyPurchaserGainOnTermination" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="roiv_EquityInterestOptionToThirdPartyPurchaserGainOnTermination" substitutionGroup="xbrli:item" xbrli:balance="credit" />
<element name="GainOrLossOnDeconsolidationOfSubsidiary" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="roiv_GainOrLossOnDeconsolidationOfSubsidiary" substitutionGroup="xbrli:item" xbrli:balance="credit" />
<element name="RedeemableNoncontrollingInterestMember" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="roiv_RedeemableNoncontrollingInterestMember" substitutionGroup="xbrli:item" />
<element name="SubscriptionsReceivablesMember" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="roiv_SubscriptionsReceivablesMember" substitutionGroup="xbrli:item" />
<element name="CapitalContributionsToSubsidiaries" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="roiv_CapitalContributionsToSubsidiaries" substitutionGroup="xbrli:item" xbrli:balance="credit" />
<element name="AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationRequisiteServicePeriodRecognitionShares" type="xbrli:sharesItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="roiv_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationRequisiteServicePeriodRecognitionShares" substitutionGroup="xbrli:item" />
<element name="ConsolidationOfUnconsolidatedEntity" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="roiv_ConsolidationOfUnconsolidatedEntity" substitutionGroup="xbrli:item" xbrli:balance="credit" />
<element name="ConversionOfSubsidiaryConvertiblePromissoryNotes" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="roiv_ConversionOfSubsidiaryConvertiblePromissoryNotes" substitutionGroup="xbrli:item" xbrli:balance="credit" />
<element name="DeconsolidationOfSubsidiary" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="roiv_DeconsolidationOfSubsidiary" substitutionGroup="xbrli:item" xbrli:balance="credit" />
<element name="IssuanceOfSubsidiaryCommonSharesNetValue" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="roiv_IssuanceOfSubsidiaryCommonSharesNetValue" substitutionGroup="xbrli:item" xbrli:balance="credit" />
<element name="IssuanceOfSubsidiaryCommonSharesToTheCompanyValue" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="roiv_IssuanceOfSubsidiaryCommonSharesToTheCompanyValue" substitutionGroup="xbrli:item" xbrli:balance="credit" />
<element name="ExerciseOfSubsidiaryStockOptionsAndVestingOfSubsidiaryRestrictedStockUnits" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="roiv_ExerciseOfSubsidiaryStockOptionsAndVestingOfSubsidiaryRestrictedStockUnits" substitutionGroup="xbrli:item" xbrli:balance="credit" />
<element name="IssuanceOfEquityBySubsidiaryToTheCompanyUponBusinessCombinationAndRecapitalization" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="roiv_IssuanceOfEquityBySubsidiaryToTheCompanyUponBusinessCombinationAndRecapitalization" substitutionGroup="xbrli:item" xbrli:balance="credit" />
<element name="IssuanceOfEquityBySubsidiaryUponBusinessCombinationAndRecapitalization" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="roiv_IssuanceOfEquityBySubsidiaryUponBusinessCombinationAndRecapitalization" substitutionGroup="xbrli:item" xbrli:balance="credit" />
<element name="IssuanceOfEquityInstruments" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="roiv_IssuanceOfEquityInstruments" substitutionGroup="xbrli:item" xbrli:balance="credit" />
<element name="IssuanceOfSubsidiaryWarrants" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="roiv_IssuanceOfSubsidiaryWarrants" substitutionGroup="xbrli:item" xbrli:balance="credit" />
<element name="PurchaseOfSubsidiaryCommonSharesValue" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="roiv_PurchaseOfSubsidiaryCommonSharesValue" substitutionGroup="xbrli:item" xbrli:balance="debit" />
<element name="RepurchaseOfCommonSharesAndOtherEquityInstrumentsShares" type="xbrli:sharesItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="roiv_RepurchaseOfCommonSharesAndOtherEquityInstrumentsShares" substitutionGroup="xbrli:item" />
<element name="RepurchaseOfCommonSharesAndOtherEquityInstrumentsValue" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="roiv_RepurchaseOfCommonSharesAndOtherEquityInstrumentsValue" substitutionGroup="xbrli:item" xbrli:balance="debit" />
<element name="RepurchaseOfEquityAwards" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="roiv_RepurchaseOfEquityAwards" substitutionGroup="xbrli:item" xbrli:balance="credit" />
<element name="SettlementOfLiabilityClassifiedInstruments" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="roiv_SettlementOfLiabilityClassifiedInstruments" substitutionGroup="xbrli:item" xbrli:balance="credit" />
<element name="DeferredOfferingAndFinancingCostsIncludedInAccountsPayableAndAccruedExpenses" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="roiv_DeferredOfferingAndFinancingCostsIncludedInAccountsPayableAndAccruedExpenses" substitutionGroup="xbrli:item" xbrli:balance="debit" />
<element name="OperatingLeaseRightOfUseAssetsAndAmountsReclassifiedFromOtherLiabilitiesToOperatingLeaseLiabilities" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="roiv_OperatingLeaseRightOfUseAssetsAndAmountsReclassifiedFromOtherLiabilitiesToOperatingLeaseLiabilities" substitutionGroup="xbrli:item" xbrli:balance="debit" />
<element name="OtherNonCashTransactions" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="roiv_OtherNonCashTransactions" substitutionGroup="xbrli:item" xbrli:balance="debit" />
<element name="IssuanceOfSubsidiaryWarrantInConnectionWithDebtFinancing" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="roiv_IssuanceOfSubsidiaryWarrantInConnectionWithDebtFinancing" substitutionGroup="xbrli:item" xbrli:balance="credit" />
<element name="ConversionOfSubsidiaryConvertiblePromissoryNotesToCommonShares" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="roiv_ConversionOfSubsidiaryConvertiblePromissoryNotesToCommonShares" substitutionGroup="xbrli:item" xbrli:balance="debit" />
<element name="SubscriptionReceivableRelatedToIssuanceOfSubsidiaryCommonShares" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="roiv_SubscriptionReceivableRelatedToIssuanceOfSubsidiaryCommonShares" substitutionGroup="xbrli:item" xbrli:balance="credit" />
<element name="PaymentForDebtMaintenanceFeeBySubsidiary" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="roiv_PaymentForDebtMaintenanceFeeBySubsidiary" substitutionGroup="xbrli:item" xbrli:balance="debit" />
<element name="PaymentsForPurchaseOfSubsidiaryConvertibleAndRedeemablePreferredStock" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="roiv_PaymentsForPurchaseOfSubsidiaryConvertibleAndRedeemablePreferredStock" substitutionGroup="xbrli:item" xbrli:balance="credit" />
<element name="ProceedsFromIssuanceOfEquityBySubsidiaryUponBusinessCombinationAndRecapitalization" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="roiv_ProceedsFromIssuanceOfEquityBySubsidiaryUponBusinessCombinationAndRecapitalization" substitutionGroup="xbrli:item" xbrli:balance="debit" />
<element name="ProceedsFromIssuanceOfSubsidiaryCommonSharesNet" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="roiv_ProceedsFromIssuanceOfSubsidiaryCommonSharesNet" substitutionGroup="xbrli:item" xbrli:balance="debit" />
<element name="ProceedsFromIssuanceOfSubsidiaryConvertibleAndRedeemablePreferredStockNet" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="roiv_ProceedsFromIssuanceOfSubsidiaryConvertibleAndRedeemablePreferredStockNet" substitutionGroup="xbrli:item" xbrli:balance="debit" />
<element name="ProceedsFromSubsidiaryDebtFinancingsNet" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="roiv_ProceedsFromSubsidiaryDebtFinancingsNet" substitutionGroup="xbrli:item" xbrli:balance="debit" />
<element name="PurchaseOfSubsidiaryCommonShares" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="roiv_PurchaseOfSubsidiaryCommonShares" substitutionGroup="xbrli:item" xbrli:balance="debit" />
<element name="RepaymentOfLongTermDebtAndConvertibleDebtBySubsidiary" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="roiv_RepaymentOfLongTermDebtAndConvertibleDebtBySubsidiary" substitutionGroup="xbrli:item" xbrli:balance="credit" />
<element name="CashAcquiredUponConsolidationOfUnconsolidatedEntity" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="roiv_CashAcquiredUponConsolidationOfUnconsolidatedEntity" substitutionGroup="xbrli:item" xbrli:balance="debit" />
<element name="PaymentsToAcquireInvestmentsInUnconsolidatedEntities" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="roiv_PaymentsToAcquireInvestmentsInUnconsolidatedEntities" substitutionGroup="xbrli:item" xbrli:balance="credit" />
<element name="GainOnTerminationOfEquityInterestOptions" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="roiv_GainOnTerminationOfEquityInterestOptions" substitutionGroup="xbrli:item" xbrli:balance="credit" />
<element name="IncreaseDecreaseInOperatingLeaseLiabilities" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="roiv_IncreaseDecreaseInOperatingLeaseLiabilities" substitutionGroup="xbrli:item" xbrli:balance="debit" />
<element name="AssetAcquisitionsAndLicenseAgreementsDisclosureTextBlock" type="dtr-types:textBlockItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="roiv_AssetAcquisitionsAndLicenseAgreementsDisclosureTextBlock" substitutionGroup="xbrli:item" />
<element name="TransactionAgreementAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="roiv_TransactionAgreementAbstract" substitutionGroup="xbrli:item" />
<element name="TransactionAgreementDisclosureTextBlock" type="dtr-types:textBlockItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="roiv_TransactionAgreementDisclosureTextBlock" substitutionGroup="xbrli:item" />
<element name="NewAccountingPronouncementsNotYetAdoptedPolicyTextBlock" type="dtr-types:textBlockItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="roiv_NewAccountingPronouncementsNotYetAdoptedPolicyTextBlock" substitutionGroup="xbrli:item" />
<element name="GeneralAndAdministrativeExpensesPolicyTextBlock" type="dtr-types:textBlockItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="roiv_GeneralAndAdministrativeExpensesPolicyTextBlock" substitutionGroup="xbrli:item" />
<element name="ScheduleOfPropertyPlantAndEquipmentEstimatedUsefulLivesTableTextBlock" type="dtr-types:textBlockItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="roiv_ScheduleOfPropertyPlantAndEquipmentEstimatedUsefulLivesTableTextBlock" substitutionGroup="xbrli:item" />
<element name="ScheduleOfDisposalGroupsIncludingDiscontinuedCondensedConsolidatedStatementsOfCashFlowsTableTextBlock" type="dtr-types:textBlockItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="roiv_ScheduleOfDisposalGroupsIncludingDiscontinuedCondensedConsolidatedStatementsOfCashFlowsTableTextBlock" substitutionGroup="xbrli:item" />
<element name="CappedValueAppreciationRightsMember" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="roiv_CappedValueAppreciationRightsMember" substitutionGroup="xbrli:item" />
<element name="CommonStockAwardsMember" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="roiv_CommonStockAwardsMember" substitutionGroup="xbrli:item" />
<element name="PerformanceOptionsMember" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="roiv_PerformanceOptionsMember" substitutionGroup="xbrli:item" />
<element name="PerformanceRestrictedStockUnitsMember" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="roiv_PerformanceRestrictedStockUnitsMember" substitutionGroup="xbrli:item" />
<element name="ScheduleOfSharebasedPaymentArrangementFairValueOfVestedStockOptionTableTextBlock" type="dtr-types:textBlockItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="roiv_ScheduleOfSharebasedPaymentArrangementFairValueOfVestedStockOptionTableTextBlock" substitutionGroup="xbrli:item" />
<element name="ScheduleOfAccountingPoliciesTable" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="roiv_ScheduleOfAccountingPoliciesTable" substitutionGroup="xbrldt:hypercubeItem" />
<element name="ScheduleOfAccountingPoliciesLineItems" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="roiv_ScheduleOfAccountingPoliciesLineItems" substitutionGroup="xbrli:item" />
<element name="ProceedsFromReleaseOfEscrowDeposit" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" nillable="true" id="roiv_ProceedsFromReleaseOfEscrowDeposit" substitutionGroup="xbrli:item" xbrli:balance="debit" />
<element name="CashAndCashEquivalentsAndRestrictedCash" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" nillable="true" id="roiv_CashAndCashEquivalentsAndRestrictedCash" substitutionGroup="xbrli:item" xbrli:balance="debit" />
<element name="UncategorizedAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="roiv_UncategorizedAbstract" substitutionGroup="xbrli:item" />
<element name="InvestmentsTable" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="roiv_InvestmentsTable" substitutionGroup="xbrldt:hypercubeItem" />
<element name="ArbutusBiopharmaCorporationMember" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="roiv_ArbutusBiopharmaCorporationMember" substitutionGroup="xbrli:item" />
<element name="DatavantHoldingsIncMember" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="roiv_DatavantHoldingsIncMember" substitutionGroup="xbrli:item" />
<element name="SioGeneTherapiesIncMember" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="roiv_SioGeneTherapiesIncMember" substitutionGroup="xbrli:item" />
<element name="InvestmentsLineItems" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="roiv_InvestmentsLineItems" substitutionGroup="xbrli:item" />
<element name="AnnualCompoundedConversionRateForPreferredShare" type="dtr-types:percentItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="roiv_AnnualCompoundedConversionRateForPreferredShare" substitutionGroup="xbrli:item" />
<element name="CommonStockOwnedBalanceSharesOfArbutus" type="xbrli:sharesItemType" abstract="false" xbrli:periodType="instant" nillable="true" id="roiv_CommonStockOwnedBalanceSharesOfArbutus" substitutionGroup="xbrli:item" />
<element name="MaximumAllowedOwnershipInterestPercentage" type="dtr-types:percentItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="roiv_MaximumAllowedOwnershipInterestPercentage" substitutionGroup="xbrli:item" />
<element name="ClosingPricePerShare" type="dtr-types:perShareItemType" abstract="false" xbrli:periodType="instant" nillable="true" id="roiv_ClosingPricePerShare" substitutionGroup="xbrli:item" />
<element name="ProceedsFromIssuanceOfPreferredStockAndPreferenceStocks" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" nillable="true" id="roiv_ProceedsFromIssuanceOfPreferredStockAndPreferenceStocks" substitutionGroup="xbrli:item" xbrli:balance="debit" />
<element name="PreferredStockSharesIssuedAndSoldToCompanyDuringPeriodShares" type="xbrli:sharesItemType" abstract="false" xbrli:periodType="instant" nillable="true" id="roiv_PreferredStockSharesIssuedAndSoldToCompanyDuringPeriodShares" substitutionGroup="xbrli:item" />
<element name="ConversionPrice" type="dtr-types:perShareItemType" abstract="false" xbrli:periodType="instant" nillable="true" id="roiv_ConversionPrice" substitutionGroup="xbrli:item" />
<element name="OwnershipInterestPercentage" type="dtr-types:percentItemType" abstract="false" xbrli:periodType="instant" nillable="true" id="roiv_OwnershipInterestPercentage" substitutionGroup="xbrli:item" />
<element name="PreferredStockPurchased" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" nillable="true" id="roiv_PreferredStockPurchased" substitutionGroup="xbrli:item" xbrli:balance="debit" />
<element name="PreferredStockOwnedBalanceSharesOfArbutus" type="xbrli:sharesItemType" abstract="false" xbrli:periodType="instant" nillable="true" id="roiv_PreferredStockOwnedBalanceSharesOfArbutus" substitutionGroup="xbrli:item" />
<element name="PremiumOnConversionPricePercentage" type="dtr-types:percentItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="roiv_PremiumOnConversionPricePercentage" substitutionGroup="xbrli:item" />
<element name="SiliconTherapeuticsMember" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="roiv_SiliconTherapeuticsMember" substitutionGroup="xbrli:item" />
<element name="FutureDevelopmentAndCommercialMilestonePayments" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="roiv_FutureDevelopmentAndCommercialMilestonePayments" substitutionGroup="xbrli:item" xbrli:balance="credit" />
<element name="BusinessCollaborationContingentMilestonePayment" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="roiv_BusinessCollaborationContingentMilestonePayment" substitutionGroup="xbrli:item" xbrli:balance="credit" />
<element name="FairValueOfRestrictedStock" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="roiv_FairValueOfRestrictedStock" substitutionGroup="xbrli:item" xbrli:balance="debit" />
<element name="FairValueOfCommonShares" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" nillable="true" id="roiv_FairValueOfCommonShares" substitutionGroup="xbrli:item" xbrli:balance="credit" />
<element name="PercentageOfControllingInterestHeld" type="dtr-types:percentItemType" abstract="false" xbrli:periodType="instant" nillable="true" id="roiv_PercentageOfControllingInterestHeld" substitutionGroup="xbrli:item" />
<element name="PaymentUnderSponsoredResearchAgreement" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="roiv_PaymentUnderSponsoredResearchAgreement" substitutionGroup="xbrli:item" xbrli:balance="credit" />
<element name="MilestonePayment" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="roiv_MilestonePayment" substitutionGroup="xbrli:item" xbrli:balance="debit" />
<element name="NonRefundableUpfrontPaymentReceived" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="roiv_NonRefundableUpfrontPaymentReceived" substitutionGroup="xbrli:item" xbrli:balance="debit" />
<element name="PaymentForUpfrontPayments" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" nillable="true" id="roiv_PaymentForUpfrontPayments" substitutionGroup="xbrli:item" xbrli:balance="credit" />
<element name="UpfrontCashPayments" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="roiv_UpfrontCashPayments" substitutionGroup="xbrli:item" xbrli:balance="credit" />
<element name="StockIssuedDuringPeriodValue" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="roiv_StockIssuedDuringPeriodValue" substitutionGroup="xbrli:item" xbrli:balance="credit" />
<element name="PotentialMilestonePaymentReceivable" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="roiv_PotentialMilestonePaymentReceivable" substitutionGroup="xbrli:item" xbrli:balance="debit" />
<element name="MilestoneEventsAxis" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="roiv_MilestoneEventsAxis" substitutionGroup="xbrldt:dimensionItem" />
<element name="MilestoneEventsDomain" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="roiv_MilestoneEventsDomain" substitutionGroup="xbrli:item" />
<element name="FirstProductFirstProductForEachMolecularTargetCoveredByIntellectualPropertyMember" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="roiv_FirstProductFirstProductForEachMolecularTargetCoveredByIntellectualPropertyMember" substitutionGroup="xbrli:item" />
<element name="FirstProductTargetsEachOfCertainSpecifiedAdditionalMoleculartargetsMember" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="roiv_FirstProductTargetsEachOfCertainSpecifiedAdditionalMoleculartargetsMember" substitutionGroup="xbrli:item" />
<element name="FirstProductTargetsTargetingEachOfTwoSpecifiedInitialTargetsMember" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="roiv_FirstProductTargetsTargetingEachOfTwoSpecifiedInitialTargetsMember" substitutionGroup="xbrli:item" />
<element name="AffivantSciencesMember" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="roiv_AffivantSciencesMember" substitutionGroup="xbrli:item" />
<element name="GenevantSciencesLtdMember" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="roiv_GenevantSciencesLtdMember" substitutionGroup="xbrli:item" />
<element name="DermavantSciencesLtdMember" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="roiv_DermavantSciencesLtdMember" substitutionGroup="xbrli:item" />
<element name="ProteovantSciencesIncMember" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="roiv_ProteovantSciencesIncMember" substitutionGroup="xbrli:item" />
<element name="FirstTrancheMember" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="roiv_FirstTrancheMember" substitutionGroup="xbrli:item" />
<element name="SecondTrancheMember" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="roiv_SecondTrancheMember" substitutionGroup="xbrli:item" />
<element name="TransactionAgreementTable" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="roiv_TransactionAgreementTable" substitutionGroup="xbrldt:hypercubeItem" />
<element name="TransactionAgreementLineItems" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="roiv_TransactionAgreementLineItems" substitutionGroup="xbrli:item" />
<element name="AgreementRelatedBilledAmountForCostsIncurredOnBehalfOfSubsidiarynetOfAmountsBilledBySubsidiary" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="roiv_AgreementRelatedBilledAmountForCostsIncurredOnBehalfOfSubsidiarynetOfAmountsBilledBySubsidiary" substitutionGroup="xbrli:item" xbrli:balance="credit" />
<element name="AggregateFairValueOfEquityAndLiabilityInstrumentsIssued" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" nillable="true" id="roiv_AggregateFairValueOfEquityAndLiabilityInstrumentsIssued" substitutionGroup="xbrli:item" xbrli:balance="credit" />
<element name="PercentageOfGrantedOptionToPurchaseOwnershipInterest" type="dtr-types:percentItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="roiv_PercentageOfGrantedOptionToPurchaseOwnershipInterest" substitutionGroup="xbrli:item" />
<element name="AssetPurchaseTransactionConsiderationReceivedInCash" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" nillable="true" id="roiv_AssetPurchaseTransactionConsiderationReceivedInCash" substitutionGroup="xbrli:item" xbrli:balance="debit" />
<element name="SaleOfStockNumberOfShareIssuedInTransaction" type="xbrli:sharesItemType" abstract="false" xbrli:periodType="instant" nillable="true" id="roiv_SaleOfStockNumberOfShareIssuedInTransaction" substitutionGroup="xbrli:item" />
<element name="SaleOfStockConsiderationCashReceivedOnTransaction" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" nillable="true" id="roiv_SaleOfStockConsiderationCashReceivedOnTransaction" substitutionGroup="xbrli:item" xbrli:balance="debit" />
<element name="StockOfferToRepurchaseDuringPeriodValueOfTheProceedsReceivedFromTransactionAgreement" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="roiv_StockOfferToRepurchaseDuringPeriodValueOfTheProceedsReceivedFromTransactionAgreement" substitutionGroup="xbrli:item" xbrli:balance="debit" />
<element name="AgreementAxis" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="roiv_AgreementAxis" substitutionGroup="xbrldt:dimensionItem" />
<element name="AgreementDomain" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="roiv_AgreementDomain" substitutionGroup="xbrli:item" />
<element name="TransitionServicesAndStrategicCooperationAgreementMember" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="roiv_TransitionServicesAndStrategicCooperationAgreementMember" substitutionGroup="xbrli:item" />
<element name="AssetPurchaseAgreementMember" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="roiv_AssetPurchaseAgreementMember" substitutionGroup="xbrli:item" />
<element name="EmployeeMember" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="roiv_EmployeeMember" substitutionGroup="xbrli:item" />
<element name="SumitomoMember" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="roiv_SumitomoMember" substitutionGroup="xbrli:item" />
<element name="BalanceSheetComponentsTable" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="roiv_BalanceSheetComponentsTable" substitutionGroup="xbrldt:hypercubeItem" />
<element name="BalanceSheetComponentsLineItems" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="roiv_BalanceSheetComponentsLineItems" substitutionGroup="xbrli:item" />
<element name="OtherGeneralAndAdministrativeExpensesMember" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="roiv_OtherGeneralAndAdministrativeExpensesMember" substitutionGroup="xbrli:item" />
<element name="ProfessionalServicesExpensesMember" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="roiv_ProfessionalServicesExpensesMember" substitutionGroup="xbrli:item" />
<element name="EmployeeRelatedExpensesMember" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="roiv_EmployeeRelatedExpensesMember" substitutionGroup="xbrli:item" />
<element name="DeferredRevenueOtherCurrentLiabilities" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" nillable="true" id="roiv_DeferredRevenueOtherCurrentLiabilities" substitutionGroup="xbrli:item" xbrli:balance="credit" />
<element name="DebtInstrumentExitFeeAndEndOfTermCharge" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" nillable="true" id="roiv_DebtInstrumentExitFeeAndEndOfTermCharge" substitutionGroup="xbrli:item" xbrli:balance="credit" />
<element name="DebtInstrumentAmount" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" nillable="true" id="roiv_DebtInstrumentAmount" substitutionGroup="xbrli:item" xbrli:balance="credit" />
<element name="CommercialMilestoneMember" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="roiv_CommercialMilestoneMember" substitutionGroup="xbrli:item" />
<element name="RegulatoryMilestoneMember" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="roiv_RegulatoryMilestoneMember" substitutionGroup="xbrli:item" />
<element name="MaximumMilestonePaymentObligation" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" nillable="true" id="roiv_MaximumMilestonePaymentObligation" substitutionGroup="xbrli:item" xbrli:balance="credit" />
<element name="MaximumMilestonePaymentOffsetAmount" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" nillable="true" id="roiv_MaximumMilestonePaymentOffsetAmount" substitutionGroup="xbrli:item" xbrli:balance="debit" />
<element name="ProceedsFromSaleOfDebtAndEquitySecurities" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="roiv_ProceedsFromSaleOfDebtAndEquitySecurities" substitutionGroup="xbrli:item" xbrli:balance="debit" />
<element name="MinimumAmountOfAnnualNetSalesToQualifyUnderRevenueInterestPurchaseAgreementContingentThreshold" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="roiv_MinimumAmountOfAnnualNetSalesToQualifyUnderRevenueInterestPurchaseAgreementContingentThreshold" substitutionGroup="xbrli:item" xbrli:balance="debit" />
<element name="NovaquestMember" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="roiv_NovaquestMember" substitutionGroup="xbrli:item" />
<element name="RevenueInterestPurchaseAndSaleAgreementMember" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="roiv_RevenueInterestPurchaseAndSaleAgreementMember" substitutionGroup="xbrli:item" />
<element name="LongTermDebtExcludingDebtWithFairValueOption" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" nillable="true" id="roiv_LongTermDebtExcludingDebtWithFairValueOption" substitutionGroup="xbrli:item" xbrli:balance="credit" />
<element name="ClassOfWarrantOrRightExercisable" type="xbrli:sharesItemType" abstract="false" xbrli:periodType="instant" nillable="true" id="roiv_ClassOfWarrantOrRightExercisable" substitutionGroup="xbrli:item" />
<element name="EarnOutSharesTermsDescription" type="xbrli:stringItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="roiv_EarnOutSharesTermsDescription" substitutionGroup="xbrli:item" />
<element name="PercentageSharesOfCommonStockOfferedToBeRepurchased" type="dtr-types:percentItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="roiv_PercentageSharesOfCommonStockOfferedToBeRepurchased" substitutionGroup="xbrli:item" />
<element name="ImmunovantINCMember" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="roiv_ImmunovantINCMember" substitutionGroup="xbrli:item" />
<element name="HealthSciencesMember" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="roiv_HealthSciencesMember" substitutionGroup="xbrli:item" />
<element name="ImmunovantSciencesLtdMember" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="roiv_ImmunovantSciencesLtdMember" substitutionGroup="xbrli:item" />
<element name="CytovantScienceHkLtdMember" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="roiv_CytovantScienceHkLtdMember" substitutionGroup="xbrli:item" />
<element name="SinovantIncMember" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="roiv_SinovantIncMember" substitutionGroup="xbrli:item" />
<element name="SeriesA1PreferredStockMember" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="roiv_SeriesA1PreferredStockMember" substitutionGroup="xbrli:item" />
<element name="UnderwrittenPublicOfferingMember" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="roiv_UnderwrittenPublicOfferingMember" substitutionGroup="xbrli:item" />
<element name="SumitomoTransactionAgreementMember" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="roiv_SumitomoTransactionAgreementMember" substitutionGroup="xbrli:item" />
<element name="RoivantEquityRepurchaseMember" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="roiv_RoivantEquityRepurchaseMember" substitutionGroup="xbrli:item" />
<element name="PerformanceRestrictedStockUnitsPlanMember" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="roiv_PerformanceRestrictedStockUnitsPlanMember" substitutionGroup="xbrli:item" />
<element name="SubsidiaryEquityIncentivePlanMember" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="roiv_SubsidiaryEquityIncentivePlanMember" substitutionGroup="xbrli:item" />
<element name="TwoThousandFifteenEquityIncentivePlanMember" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="roiv_TwoThousandFifteenEquityIncentivePlanMember" substitutionGroup="xbrli:item" />
<element name="SpecialReserveMember" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="roiv_SpecialReserveMember" substitutionGroup="xbrli:item" />
<element name="SharebasedCompensationArrangementBySharebasedPaymentAwardAggregateRepurchasePrice" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="roiv_SharebasedCompensationArrangementBySharebasedPaymentAwardAggregateRepurchasePrice" substitutionGroup="xbrli:item" xbrli:balance="debit" />
<element name="CommonSharesReservedForPerformanceOptionsAndCappedValueAppreciationRights" type="xbrli:sharesItemType" abstract="false" xbrli:periodType="instant" nillable="true" id="roiv_CommonSharesReservedForPerformanceOptionsAndCappedValueAppreciationRights" substitutionGroup="xbrli:item" />
<element name="ShareBasedCompensationRightToRepurchasePercentage" type="dtr-types:percentItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="roiv_ShareBasedCompensationRightToRepurchasePercentage" substitutionGroup="xbrli:item" />
<element name="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExcercisableWeightedAverageGrantDateFairValue" type="dtr-types:perShareItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="roiv_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExcercisableWeightedAverageGrantDateFairValue" substitutionGroup="xbrli:item" />
<element name="ShareBasedCompensationArrangementByShareBasedPaymentAwardWeightedAverageGrantDateFairValue" type="dtr-types:perShareItemType" abstract="false" xbrli:periodType="instant" nillable="true" id="roiv_ShareBasedCompensationArrangementByShareBasedPaymentAwardWeightedAverageGrantDateFairValue" substitutionGroup="xbrli:item" />
<element name="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeitedInPeriodWeightedAverageGrantDateFairValue" type="dtr-types:perShareItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="roiv_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeitedInPeriodWeightedAverageGrantDateFairValue" substitutionGroup="xbrli:item" />
<element name="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageGrantDateFairValue" type="dtr-types:perShareItemType" abstract="false" xbrli:periodType="instant" nillable="true" id="roiv_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageGrantDateFairValue" substitutionGroup="xbrli:item" />
<element name="DisposalGroupIncludingDiscontinuedOperationOperatingExpenseAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="roiv_DisposalGroupIncludingDiscontinuedOperationOperatingExpenseAbstract" substitutionGroup="xbrli:item" />
<element name="DisposalGroupIncludingDiscontinuedOperationGainLossOnSaleOfBusiness" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="roiv_DisposalGroupIncludingDiscontinuedOperationGainLossOnSaleOfBusiness" substitutionGroup="xbrli:item" xbrli:balance="credit" />
<element name="DisposalGroupIncludingDiscontinuedOperationResearchAndDevelopmentExpense" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="roiv_DisposalGroupIncludingDiscontinuedOperationResearchAndDevelopmentExpense" substitutionGroup="xbrli:item" xbrli:balance="debit" />
<element name="DisposalGroupIncludingDiscontinuedOperationResearchAndDevelopmentInProcess" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="roiv_DisposalGroupIncludingDiscontinuedOperationResearchAndDevelopmentInProcess" substitutionGroup="xbrli:item" xbrli:balance="debit" />
<element name="DisposalGroupIncludingDiscontinuedOperationShareBasedCompensation" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="roiv_DisposalGroupIncludingDiscontinuedOperationShareBasedCompensation" substitutionGroup="xbrli:item" xbrli:balance="debit" />
<element name="SumitovantMember" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="roiv_SumitovantMember" substitutionGroup="xbrli:item" />
<element name="IncomeTaxDisclosureTable" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="roiv_IncomeTaxDisclosureTable" substitutionGroup="xbrldt:hypercubeItem" />
<element name="IncomeTaxDisclosureLineItems" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="roiv_IncomeTaxDisclosureLineItems" substitutionGroup="xbrli:item" />
<element name="OtherMember" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="roiv_OtherMember" substitutionGroup="xbrli:item" />
<element name="ComponentsOfIncomeTaxExpenseTable" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="roiv_ComponentsOfIncomeTaxExpenseTable" substitutionGroup="xbrldt:hypercubeItem" />
<element name="ComponentsOfIncomeTaxExpenseLineItems" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="roiv_ComponentsOfIncomeTaxExpenseLineItems" substitutionGroup="xbrli:item" />
<element name="TaxAuthorityInOtherJurisdictionsMember" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="roiv_TaxAuthorityInOtherJurisdictionsMember" substitutionGroup="xbrli:item" />
<element name="PercentageOfFutureTaxableIncome" type="dtr-types:percentItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="roiv_PercentageOfFutureTaxableIncome" substitutionGroup="xbrli:item" />
<element name="DeferredTaxAssetsLiabilitiesTable" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="roiv_DeferredTaxAssetsLiabilitiesTable" substitutionGroup="xbrldt:hypercubeItem" />
<element name="DeferredTaxAssetsLiabilitiesLineItems" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="roiv_DeferredTaxAssetsLiabilitiesLineItems" substitutionGroup="xbrli:item" />
<element name="DeferredTaxLiabilitiesDepreciation" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" nillable="true" id="roiv_DeferredTaxLiabilitiesDepreciation" substitutionGroup="xbrli:item" xbrli:balance="credit" />
<element name="DeferredTaxLiabilitiesRightOfUseAssets" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" nillable="true" id="roiv_DeferredTaxLiabilitiesRightOfUseAssets" substitutionGroup="xbrli:item" xbrli:balance="credit" />
<element name="DeferredTaxAssetsLeaseLiabilities" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" nillable="true" id="roiv_DeferredTaxAssetsLeaseLiabilities" substitutionGroup="xbrli:item" xbrli:balance="debit" />
<element name="TaxRatesAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="roiv_TaxRatesAbstract" substitutionGroup="xbrli:item" />
<element name="EffectiveTaxRateReconcilingItemsTable" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="roiv_EffectiveTaxRateReconcilingItemsTable" substitutionGroup="xbrldt:hypercubeItem" />
<element name="EffectiveTaxRateReconcilingItemsLineItems" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="roiv_EffectiveTaxRateReconcilingItemsLineItems" substitutionGroup="xbrli:item" />
<element name="EffectiveIncomeTaxReconciliationPermanentDifferences" type="dtr-types:percentItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="roiv_EffectiveIncomeTaxReconciliationPermanentDifferences" substitutionGroup="xbrli:item" />
<element name="IncomeTaxReconciliationPermanentAdjustments" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="roiv_IncomeTaxReconciliationPermanentAdjustments" substitutionGroup="xbrli:item" xbrli:balance="debit" />
<element name="LesseeOperatingLeaseLiabilityTenantImprovementAllowance" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" nillable="true" id="roiv_LesseeOperatingLeaseLiabilityTenantImprovementAllowance" substitutionGroup="xbrli:item" xbrli:balance="credit" />
<element name="OperatingLeaseLiabilityPresentValueAdjustments" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" nillable="true" id="roiv_OperatingLeaseLiabilityPresentValueAdjustments" substitutionGroup="xbrli:item" xbrli:balance="credit" />
<element name="FairValueDisclosuresTable" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="roiv_FairValueDisclosuresTable" substitutionGroup="xbrldt:hypercubeItem" />
<element name="FairValueDisclosuresLineItems" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="roiv_FairValueDisclosuresLineItems" substitutionGroup="xbrli:item" />
<element name="EquityInterestOptionToThirdPartyPurchaser" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" nillable="true" id="roiv_EquityInterestOptionToThirdPartyPurchaser" substitutionGroup="xbrli:item" xbrli:balance="credit" />
<element name="LiabilityInstrumentsMeasuredAtFairValueMember" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="roiv_LiabilityInstrumentsMeasuredAtFairValueMember" substitutionGroup="xbrli:item" />
<element name="FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityDisposedDueToDeconsolidationOfSubsidiary" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="roiv_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityDisposedDueToDeconsolidationOfSubsidiary" substitutionGroup="xbrli:item" xbrli:balance="debit" />
<element name="AlternativeInvestmentExpectedTerm" type="xbrli:durationItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="roiv_AlternativeInvestmentExpectedTerm" substitutionGroup="xbrli:item" />
<element name="OtherIncomeExpense" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="roiv_OtherIncomeExpense" substitutionGroup="xbrli:item" xbrli:balance="credit" />
<element name="BasicAndDilutedNetLossIncome" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="roiv_BasicAndDilutedNetLossIncome" substitutionGroup="xbrli:item" xbrli:balance="credit" />
<element name="BasicAndDilutedIncomeFromDiscontinuedOperationsNetOfTax" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="roiv_BasicAndDilutedIncomeFromDiscontinuedOperationsNetOfTax" substitutionGroup="xbrli:item" xbrli:balance="credit" />
<element name="BasicAndDilutedLossFromContinuingOperationsNetOfTax" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="roiv_BasicAndDilutedLossFromContinuingOperationsNetOfTax" substitutionGroup="xbrli:item" xbrli:balance="credit" />
<element name="SumitomoPharmaceuticalsCoLtdMember" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="roiv_SumitomoPharmaceuticalsCoLtdMember" substitutionGroup="xbrli:item" />
<element name="DatavantMember" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="roiv_DatavantMember" substitutionGroup="xbrli:item" />
<element name="CreditFacilityMember" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="roiv_CreditFacilityMember" substitutionGroup="xbrli:item" />
<element name="BusinessAcquisitionCostOfAcquiredEntityAdjustmentPaidInCash" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="roiv_BusinessAcquisitionCostOfAcquiredEntityAdjustmentPaidInCash" substitutionGroup="xbrli:item" xbrli:balance="debit" />
<element name="RevenueInterestPurchaseAndSaleAgreementAmount" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" nillable="true" id="roiv_RevenueInterestPurchaseAndSaleAgreementAmount" substitutionGroup="xbrli:item" xbrli:balance="debit" />
<element name="RevenueInterestPurchaseAndSaleAgreementCommittedFundToBePaid" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" nillable="true" id="roiv_RevenueInterestPurchaseAndSaleAgreementCommittedFundToBePaid" substitutionGroup="xbrli:item" xbrli:balance="credit" />
</schema>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.CAL
<SEQUENCE>9
<FILENAME>roiv-20210630_cal.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION CALCULATION LINKBASE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="utf-8"?>
<!--Generated by DFIN XBRL Instance Document - http://www.dfinsolutions.com/ - Version R3.0 - on 30-October-2021 [02:44:34] {AM}-->
<linkbase xmlns="http://www.xbrl.org/2003/linkbase" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
<roleRef xlink:type="simple" xlink:href="roiv-20210630.xsd#CondensedConsolidatedBalanceSheets" roleURI="http://roivant.com/role/CondensedConsolidatedBalanceSheets" />
<roleRef xlink:type="simple" xlink:href="roiv-20210630.xsd#CondensedConsolidatedStatementsOfOperations" roleURI="http://roivant.com/role/CondensedConsolidatedStatementsOfOperations" />
<roleRef xlink:type="simple" xlink:href="roiv-20210630.xsd#CondensedConsolidatedStatementsOfComprehensiveLoss" roleURI="http://roivant.com/role/CondensedConsolidatedStatementsOfComprehensiveLoss" />
<roleRef xlink:type="simple" xlink:href="roiv-20210630.xsd#CondensedConsolidatedStatementsOfCashFlows" roleURI="http://roivant.com/role/CondensedConsolidatedStatementsOfCashFlows" />
<roleRef xlink:type="simple" xlink:href="roiv-20210630.xsd#SummaryOfSignificantAccountingPoliciesScheduleOfAggregateAmountsOfCashCashEquivalentsAndRestrictedCashDetail" roleURI="http://roivant.com/role/SummaryOfSignificantAccountingPoliciesScheduleOfAggregateAmountsOfCashCashEquivalentsAndRestrictedCashDetail" />
<roleRef xlink:type="simple" xlink:href="roiv-20210630.xsd#BalanceSheetComponentsScheduleOfOtherCurrentAssetsDetail" roleURI="http://roivant.com/role/BalanceSheetComponentsScheduleOfOtherCurrentAssetsDetail" />
<roleRef xlink:type="simple" xlink:href="roiv-20210630.xsd#BalanceSheetComponentsScheduleOfOtherCurrentLiabilitiesDetail" roleURI="http://roivant.com/role/BalanceSheetComponentsScheduleOfOtherCurrentLiabilitiesDetail" />
<roleRef xlink:type="simple" xlink:href="roiv-20210630.xsd#LongTermDebtAndLoanCommitmentDetail" roleURI="http://roivant.com/role/LongTermDebtAndLoanCommitmentDetail" />
<roleRef xlink:type="simple" xlink:href="roiv-20210630.xsd#LongTermDebtAndConvertibleNotesPayableScheduleOfCompanysAnnualPaymentsDetail" roleURI="http://roivant.com/role/LongTermDebtAndConvertibleNotesPayableScheduleOfCompanysAnnualPaymentsDetail" />
<roleRef xlink:type="simple" xlink:href="roiv-20210630.xsd#ShareholdersEquityAndRedeemableNonControllingInterestScheduleOfPaymentsOfEquitySecuritiesDetail" roleURI="http://roivant.com/role/ShareholdersEquityAndRedeemableNonControllingInterestScheduleOfPaymentsOfEquitySecuritiesDetail" />
<roleRef xlink:type="simple" xlink:href="roiv-20210630.xsd#DiscontinuedOperationsSummaryOfDisposalGroupsIncludingDiscontinuedOperationsIncomeStatementDetail" roleURI="http://roivant.com/role/DiscontinuedOperationsSummaryOfDisposalGroupsIncludingDiscontinuedOperationsIncomeStatementDetail" />
<roleRef xlink:type="simple" xlink:href="roiv-20210630.xsd#IncomeTaxesScheduleOfDeferredTaxAssetsLiabilitiesDetail" roleURI="http://roivant.com/role/IncomeTaxesScheduleOfDeferredTaxAssetsLiabilitiesDetail" />
<roleRef xlink:type="simple" xlink:href="roiv-20210630.xsd#IncomeTaxesScheduleOfEffectiveIncomeTaxRateReconciliationDetail" roleURI="http://roivant.com/role/IncomeTaxesScheduleOfEffectiveIncomeTaxRateReconciliationDetail" />
<roleRef xlink:type="simple" xlink:href="roiv-20210630.xsd#LeasesScheduleOfMaturitiesOfOperatingLeaseLiabilitiesDetail" roleURI="http://roivant.com/role/LeasesScheduleOfMaturitiesOfOperatingLeaseLiabilitiesDetail" />
<roleRef xlink:type="simple" xlink:href="roiv-20210630.xsd#LeasesScheduleOfOperatingLeaseCostsDetail" roleURI="http://roivant.com/role/LeasesScheduleOfOperatingLeaseCostsDetail" />
<roleRef xlink:type="simple" xlink:href="roiv-20210630.xsd#OtherIncomeExpenseNetSummaryOfOtherIncomeExpenseNetFromContinuingOperationsDetail" roleURI="http://roivant.com/role/OtherIncomeExpenseNetSummaryOfOtherIncomeExpenseNetFromContinuingOperationsDetail" />
<calculationLink xlink:type="extended" xlink:role="http://roivant.com/role/CondensedConsolidatedStatementsOfOperations">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingIncomeLoss" xlink:label="loc_us-gaap_OperatingIncomeLoss" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:to="loc_us-gaap_OperatingIncomeLoss" use="optional" order="1" weight="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingExpenses" xlink:label="loc_us-gaap_OperatingExpenses" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingIncomeLoss" xlink:to="loc_us-gaap_OperatingExpenses" use="optional" order="2" weight="-1" />
<loc xlink:type="locator" xlink:href="roiv-20210630.xsd#roiv_OperatingCosts" xlink:label="loc_ROIV_OperatingCosts" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingExpenses" xlink:to="loc_ROIV_OperatingCosts" use="optional" order="3" weight="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpense" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingExpenses" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpense" use="optional" order="4" weight="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GeneralAndAdministrativeExpense" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpense" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingExpenses" xlink:to="loc_us-gaap_GeneralAndAdministrativeExpense" use="optional" order="5" weight="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingIncomeLoss" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" use="optional" order="6" weight="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GainLossOnInvestments" xlink:label="loc_us-gaap_GainLossOnInvestments" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:to="loc_us-gaap_GainLossOnInvestments" use="optional" order="7" weight="1" />
<loc xlink:type="locator" xlink:href="roiv-20210630.xsd#roiv_GainLossOnFairValueOfDebtAndLiabilityInstruments" xlink:label="loc_ROIV_GainLossOnFairValueOfDebtAndLiabilityInstruments" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:to="loc_ROIV_GainLossOnFairValueOfDebtAndLiabilityInstruments" use="optional" order="8" weight="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherNonoperatingIncomeExpense" xlink:label="loc_us-gaap_OtherNonoperatingIncomeExpense" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:to="loc_us-gaap_OtherNonoperatingIncomeExpense" use="optional" order="9" weight="1" />
<loc xlink:type="locator" xlink:href="roiv-20210630.xsd#roiv_EquityInterestOptionToThirdPartyPurchaserGainOnTermination" xlink:label="loc_ROIV_EquityInterestOptionToThirdPartyPurchaserGainOnTermination" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:to="loc_ROIV_EquityInterestOptionToThirdPartyPurchaserGainOnTermination" use="optional" order="10" weight="1" />
<loc xlink:type="locator" xlink:href="roiv-20210630.xsd#roiv_GainOrLossOnDeconsolidationOfSubsidiary" xlink:label="loc_ROIV_GainOrLossOnDeconsolidationOfSubsidiary" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:to="loc_ROIV_GainOrLossOnDeconsolidationOfSubsidiary" use="optional" order="11" weight="1" />
</calculationLink>
<calculationLink xlink:type="extended" xlink:role="http://roivant.com/role/CondensedConsolidatedStatementsOfOperations">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity" xlink:label="loc_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaap_NetIncomeLoss" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity" xlink:to="loc_us-gaap_NetIncomeLoss" use="optional" order="12" weight="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetIncomeLossAttributableToNoncontrollingInterest" xlink:label="loc_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetIncomeLoss" xlink:to="loc_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest" use="optional" order="13" weight="-1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProfitLoss" xlink:label="loc_us-gaap_ProfitLoss" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetIncomeLoss" xlink:to="loc_us-gaap_ProfitLoss" use="optional" order="14" weight="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_ProfitLoss" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest" use="optional" order="15" weight="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxExpenseBenefit" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest" xlink:to="loc_us-gaap_IncomeTaxExpenseBenefit" use="optional" order="16" weight="-1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTax" xlink:label="loc_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTax" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_ProfitLoss" xlink:to="loc_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTax" use="optional" order="17" weight="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeLossFromContinuingOperations" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperations" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperations" use="optional" order="18" weight="1" />
</calculationLink>
<calculationLink xlink:type="extended" xlink:role="http://roivant.com/role/CondensedConsolidatedStatementsOfOperations">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments" />
<loc xlink:type="locator" xlink:href="roiv-20210630.xsd#roiv_DeconsolidationAndConsolidationOnGainOrLossOfConsolidatedEntity" xlink:label="loc_ROIV_DeconsolidationAndConsolidationOnGainOrLossOfConsolidatedEntity" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments" xlink:to="loc_ROIV_DeconsolidationAndConsolidationOnGainOrLossOfConsolidatedEntity" use="optional" order="19" weight="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherNonoperatingIncomeExpense" xlink:label="loc_us-gaap_OtherNonoperatingIncomeExpense" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments" xlink:to="loc_us-gaap_OtherNonoperatingIncomeExpense" use="optional" order="20" weight="1" />
</calculationLink>
<calculationLink xlink:type="extended" xlink:role="http://roivant.com/role/CondensedConsolidatedStatementsOfComprehensiveLoss">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ComprehensiveIncomeNetOfTax" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTax" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_ComprehensiveIncomeNetOfTax" xlink:to="loc_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest" use="optional" order="1" weight="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProfitLoss" xlink:label="loc_us-gaap_ProfitLoss" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest" xlink:to="loc_us-gaap_ProfitLoss" use="optional" order="2" weight="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTax" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTax" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTax" use="optional" order="3" weight="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax" xlink:label="loc_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTax" xlink:to="loc_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax" use="optional" order="4" weight="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_ComprehensiveIncomeNetOfTax" xlink:to="loc_us-gaap_ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest" use="optional" order="5" weight="-1" />
</calculationLink>
<calculationLink xlink:type="extended" xlink:role="http://roivant.com/role/CondensedConsolidatedStatementsOfCashFlows">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect" xlink:to="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities" use="optional" order="1" weight="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProfitLoss" xlink:label="loc_us-gaap_ProfitLoss" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaap_ProfitLoss" use="optional" order="2" weight="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensation" xlink:label="loc_us-gaap_ShareBasedCompensation" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaap_ShareBasedCompensation" use="optional" order="3" weight="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GainLossOnInvestments" xlink:label="loc_us-gaap_GainLossOnInvestments" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaap_GainLossOnInvestments" use="optional" order="4" weight="-1" />
<loc xlink:type="locator" xlink:href="roiv-20210630.xsd#roiv_GainLossOnFairValueOfDebtAndLiabilityInstruments" xlink:label="loc_ROIV_GainLossOnFairValueOfDebtAndLiabilityInstruments" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="loc_ROIV_GainLossOnFairValueOfDebtAndLiabilityInstruments" use="optional" order="5" weight="-1" />
<loc xlink:type="locator" xlink:href="roiv-20210630.xsd#roiv_GainOrLossOnDeconsolidationOfSubsidiary" xlink:label="loc_ROIV_GainOrLossOnDeconsolidationOfSubsidiary" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="loc_ROIV_GainOrLossOnDeconsolidationOfSubsidiary" use="optional" order="6" weight="-1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeLossFromEquityMethodInvestments" xlink:label="loc_us-gaap_IncomeLossFromEquityMethodInvestments" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaap_IncomeLossFromEquityMethodInvestments" use="optional" order="7" weight="-1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherNoncashIncomeExpense" xlink:label="loc_us-gaap_OtherNoncashIncomeExpense" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaap_OtherNoncashIncomeExpense" use="optional" order="8" weight="-1" />
<loc xlink:type="locator" xlink:href="roiv-20210630.xsd#roiv_GainOnTerminationOfEquityInterestOptions" xlink:label="loc_ROIV_GainOnTerminationOfEquityInterestOptions" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="loc_ROIV_GainOnTerminationOfEquityInterestOptions" use="optional" order="9" weight="-1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsPayableTrade" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsPayableTrade" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaap_IncreaseDecreaseInAccountsPayableTrade" use="optional" order="10" weight="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInAccruedLiabilities" xlink:label="loc_us-gaap_IncreaseDecreaseInAccruedLiabilities" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaap_IncreaseDecreaseInAccruedLiabilities" use="optional" order="11" weight="1" />
<loc xlink:type="locator" xlink:href="roiv-20210630.xsd#roiv_IncreaseDecreaseInOperatingLeaseLiabilities" xlink:label="loc_ROIV_IncreaseDecreaseInOperatingLeaseLiabilities" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="loc_ROIV_IncreaseDecreaseInOperatingLeaseLiabilities" use="optional" order="12" weight="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInOtherOperatingCapitalNet" xlink:label="loc_us-gaap_IncreaseDecreaseInOtherOperatingCapitalNet" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaap_IncreaseDecreaseInOtherOperatingCapitalNet" use="optional" order="13" weight="-1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInDeferredLiabilities" xlink:label="loc_us-gaap_IncreaseDecreaseInDeferredLiabilities" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaap_IncreaseDecreaseInDeferredLiabilities" use="optional" order="14" weight="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GainLossOnSaleOfBusiness" xlink:label="loc_us-gaap_GainLossOnSaleOfBusiness" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaap_GainLossOnSaleOfBusiness" use="optional" order="15" weight="-1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ResearchAndDevelopmentInProcess" xlink:label="loc_us-gaap_ResearchAndDevelopmentInProcess" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaap_ResearchAndDevelopmentInProcess" use="optional" order="16" weight="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax" xlink:label="loc_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax" use="optional" order="17" weight="-1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect" xlink:to="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities" use="optional" order="18" weight="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashDivestedFromDeconsolidation" xlink:label="loc_us-gaap_CashDivestedFromDeconsolidation" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:to="loc_us-gaap_CashDivestedFromDeconsolidation" use="optional" order="19" weight="-1" />
<loc xlink:type="locator" xlink:href="roiv-20210630.xsd#roiv_PaymentsToAcquireInvestmentsInUnconsolidatedEntities" xlink:label="loc_ROIV_PaymentsToAcquireInvestmentsInUnconsolidatedEntities" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:to="loc_ROIV_PaymentsToAcquireInvestmentsInUnconsolidatedEntities" use="optional" order="20" weight="-1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:label="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:to="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" use="optional" order="21" weight="-1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired" xlink:label="loc_us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:to="loc_us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired" use="optional" order="22" weight="-1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities" xlink:label="loc_us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:to="loc_us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities" use="optional" order="23" weight="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsToAcquireMarketableSecurities" xlink:label="loc_us-gaap_PaymentsToAcquireMarketableSecurities" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:to="loc_us-gaap_PaymentsToAcquireMarketableSecurities" use="optional" order="24" weight="-1" />
<loc xlink:type="locator" xlink:href="roiv-20210630.xsd#roiv_CashAcquiredUponConsolidationOfUnconsolidatedEntity" xlink:label="loc_ROIV_CashAcquiredUponConsolidationOfUnconsolidatedEntity" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:to="loc_ROIV_CashAcquiredUponConsolidationOfUnconsolidatedEntity" use="optional" order="25" weight="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromDivestitureOfBusinesses" xlink:label="loc_us-gaap_ProceedsFromDivestitureOfBusinesses" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:to="loc_us-gaap_ProceedsFromDivestitureOfBusinesses" use="optional" order="26" weight="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect" xlink:to="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities" use="optional" order="27" weight="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsForRepurchaseOfEquity" xlink:label="loc_us-gaap_PaymentsForRepurchaseOfEquity" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="loc_us-gaap_PaymentsForRepurchaseOfEquity" use="optional" order="28" weight="-1" />
<loc xlink:type="locator" xlink:href="roiv-20210630.xsd#roiv_ProceedsFromIssuanceOfSubsidiaryCommonSharesNet" xlink:label="loc_ROIV_ProceedsFromIssuanceOfSubsidiaryCommonSharesNet" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="loc_ROIV_ProceedsFromIssuanceOfSubsidiaryCommonSharesNet" use="optional" order="29" weight="1" />
<loc xlink:type="locator" xlink:href="roiv-20210630.xsd#roiv_ProceedsFromSubsidiaryDebtFinancingsNet" xlink:label="loc_ROIV_ProceedsFromSubsidiaryDebtFinancingsNet" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="loc_ROIV_ProceedsFromSubsidiaryDebtFinancingsNet" use="optional" order="30" weight="1" />
<loc xlink:type="locator" xlink:href="roiv-20210630.xsd#roiv_RepaymentOfLongTermDebtAndConvertibleDebtBySubsidiary" xlink:label="loc_ROIV_RepaymentOfLongTermDebtAndConvertibleDebtBySubsidiary" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="loc_ROIV_RepaymentOfLongTermDebtAndConvertibleDebtBySubsidiary" use="optional" order="31" weight="-1" />
<loc xlink:type="locator" xlink:href="roiv-20210630.xsd#roiv_PaymentForDebtMaintenanceFeeBySubsidiary" xlink:label="loc_ROIV_PaymentForDebtMaintenanceFeeBySubsidiary" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="loc_ROIV_PaymentForDebtMaintenanceFeeBySubsidiary" use="optional" order="32" weight="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromStockOptionsExercised" xlink:label="loc_us-gaap_ProceedsFromStockOptionsExercised" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="loc_us-gaap_ProceedsFromStockOptionsExercised" use="optional" order="33" weight="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsOfStockIssuanceCosts" xlink:label="loc_us-gaap_PaymentsOfStockIssuanceCosts" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="loc_us-gaap_PaymentsOfStockIssuanceCosts" use="optional" order="34" weight="-1" />
<loc xlink:type="locator" xlink:href="roiv-20210630.xsd#roiv_PaymentsForPurchaseOfSubsidiaryConvertibleAndRedeemablePreferredStock" xlink:label="loc_ROIV_PaymentsForPurchaseOfSubsidiaryConvertibleAndRedeemablePreferredStock" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="loc_ROIV_PaymentsForPurchaseOfSubsidiaryConvertibleAndRedeemablePreferredStock" use="optional" order="35" weight="-1" />
<loc xlink:type="locator" xlink:href="roiv-20210630.xsd#roiv_ProceedsFromIssuanceOfSubsidiaryConvertibleAndRedeemablePreferredStockNet" xlink:label="loc_ROIV_ProceedsFromIssuanceOfSubsidiaryConvertibleAndRedeemablePreferredStockNet" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="loc_ROIV_ProceedsFromIssuanceOfSubsidiaryConvertibleAndRedeemablePreferredStockNet" use="optional" order="36" weight="1" />
<loc xlink:type="locator" xlink:href="roiv-20210630.xsd#roiv_PurchaseOfSubsidiaryCommonShares" xlink:label="loc_ROIV_PurchaseOfSubsidiaryCommonShares" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="loc_ROIV_PurchaseOfSubsidiaryCommonShares" use="optional" order="37" weight="1" />
<loc xlink:type="locator" xlink:href="roiv-20210630.xsd#roiv_ProceedsFromIssuanceOfEquityBySubsidiaryUponBusinessCombinationAndRecapitalization" xlink:label="loc_ROIV_ProceedsFromIssuanceOfEquityBySubsidiaryUponBusinessCombinationAndRecapitalization" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="loc_ROIV_ProceedsFromIssuanceOfEquityBySubsidiaryUponBusinessCombinationAndRecapitalization" use="optional" order="38" weight="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromIssuanceOfDebt" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfDebt" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfDebt" use="optional" order="39" weight="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfCommonStock" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfCommonStock" use="optional" order="40" weight="1" />
</calculationLink>
<calculationLink xlink:type="extended" xlink:role="http://roivant.com/role/BalanceSheetComponentsScheduleOfOtherCurrentLiabilitiesDetail">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherLiabilitiesCurrent" xlink:label="loc_us-gaap_OtherLiabilitiesCurrent" />
<loc xlink:type="locator" xlink:href="roiv-20210630.xsd#roiv_DeferredRevenueOtherCurrentLiabilities" xlink:label="loc_ROIV_DeferredRevenueOtherCurrentLiabilities" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OtherLiabilitiesCurrent" xlink:to="loc_ROIV_DeferredRevenueOtherCurrentLiabilities" use="optional" order="1" weight="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TaxesPayableCurrent" xlink:label="loc_us-gaap_TaxesPayableCurrent" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OtherLiabilitiesCurrent" xlink:to="loc_us-gaap_TaxesPayableCurrent" use="optional" order="2" weight="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherSundryLiabilitiesCurrent" xlink:label="loc_us-gaap_OtherSundryLiabilitiesCurrent" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OtherLiabilitiesCurrent" xlink:to="loc_us-gaap_OtherSundryLiabilitiesCurrent" use="optional" order="3" weight="1" />
</calculationLink>
<calculationLink xlink:type="extended" xlink:role="http://roivant.com/role/LongTermDebtAndLoanCommitmentDetail">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongTermDebtNoncurrent" xlink:label="loc_us-gaap_LongTermDebtNoncurrent" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongTermDebtCurrent" xlink:label="loc_us-gaap_LongTermDebtCurrent" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LongTermDebtNoncurrent" xlink:to="loc_us-gaap_LongTermDebtCurrent" use="optional" order="1" weight="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongTermDebt" xlink:label="loc_us-gaap_LongTermDebt" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LongTermDebtNoncurrent" xlink:to="loc_us-gaap_LongTermDebt" use="optional" order="2" weight="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentCarryingAmount" xlink:label="loc_us-gaap_DebtInstrumentCarryingAmount" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LongTermDebt" xlink:to="loc_us-gaap_DebtInstrumentCarryingAmount" use="optional" order="3" weight="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet" xlink:label="loc_us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LongTermDebt" xlink:to="loc_us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet" use="optional" order="4" weight="-1" />
<loc xlink:type="locator" xlink:href="roiv-20210630.xsd#roiv_DebtInstrumentExitFeeAndEndOfTermCharge" xlink:label="loc_ROIV_DebtInstrumentExitFeeAndEndOfTermCharge" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LongTermDebt" xlink:to="loc_ROIV_DebtInstrumentExitFeeAndEndOfTermCharge" use="optional" order="5" weight="1" />
</calculationLink>
<calculationLink xlink:type="extended" xlink:role="http://roivant.com/role/SummaryOfSignificantAccountingPoliciesScheduleOfAggregateAmountsOfCashCashEquivalentsAndRestrictedCashDetail">
<loc xlink:type="locator" xlink:href="roiv-20210630.xsd#roiv_CashAndCashEquivalentsAndRestrictedCash" xlink:label="loc_ROIV_CashAndCashEquivalentsAndRestrictedCash" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ROIV_CashAndCashEquivalentsAndRestrictedCash" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue" use="optional" order="1" weight="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestrictedCash" xlink:label="loc_us-gaap_RestrictedCash" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ROIV_CashAndCashEquivalentsAndRestrictedCash" xlink:to="loc_us-gaap_RestrictedCash" use="optional" order="2" weight="1" />
</calculationLink>
<calculationLink xlink:type="extended" xlink:role="http://roivant.com/role/DiscontinuedOperationsSummaryOfDisposalGroupsIncludingDiscontinuedOperationsIncomeStatementDetail">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationOperatingExpense" xlink:label="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationOperatingExpense" />
<loc xlink:type="locator" xlink:href="roiv-20210630.xsd#roiv_DisposalGroupIncludingDiscontinuedOperationResearchAndDevelopmentExpense" xlink:label="loc_ROIV_DisposalGroupIncludingDiscontinuedOperationResearchAndDevelopmentExpense" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationOperatingExpense" xlink:to="loc_ROIV_DisposalGroupIncludingDiscontinuedOperationResearchAndDevelopmentExpense" use="optional" order="1" weight="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationGeneralAndAdministrativeExpense" xlink:label="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationGeneralAndAdministrativeExpense" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationOperatingExpense" xlink:to="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationGeneralAndAdministrativeExpense" use="optional" order="2" weight="1" />
</calculationLink>
<calculationLink xlink:type="extended" xlink:role="http://roivant.com/role/DiscontinuedOperationsSummaryOfDisposalGroupsIncludingDiscontinuedOperationsIncomeStatementDetail">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTax" xlink:label="loc_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTax" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DiscontinuedOperationIncomeLossFromDiscontinuedOperationBeforeIncomeTax" xlink:label="loc_us-gaap_DiscontinuedOperationIncomeLossFromDiscontinuedOperationBeforeIncomeTax" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTax" xlink:to="loc_us-gaap_DiscontinuedOperationIncomeLossFromDiscontinuedOperationBeforeIncomeTax" use="optional" order="3" weight="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationOperatingIncomeLoss" xlink:label="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationOperatingIncomeLoss" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DiscontinuedOperationIncomeLossFromDiscontinuedOperationBeforeIncomeTax" xlink:to="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationOperatingIncomeLoss" use="optional" order="4" weight="1" />
<loc xlink:type="locator" xlink:href="roiv-20210630.xsd#roiv_DisposalGroupIncludingDiscontinuedOperationGainLossOnSaleOfBusiness" xlink:label="loc_ROIV_DisposalGroupIncludingDiscontinuedOperationGainLossOnSaleOfBusiness" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DiscontinuedOperationIncomeLossFromDiscontinuedOperationBeforeIncomeTax" xlink:to="loc_ROIV_DisposalGroupIncludingDiscontinuedOperationGainLossOnSaleOfBusiness" use="optional" order="5" weight="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationInterestIncome" xlink:label="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationInterestIncome" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DiscontinuedOperationIncomeLossFromDiscontinuedOperationBeforeIncomeTax" xlink:to="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationInterestIncome" use="optional" order="6" weight="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationInterestExpense" xlink:label="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationInterestExpense" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DiscontinuedOperationIncomeLossFromDiscontinuedOperationBeforeIncomeTax" xlink:to="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationInterestExpense" use="optional" order="7" weight="-1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationOtherExpense" xlink:label="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationOtherExpense" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DiscontinuedOperationIncomeLossFromDiscontinuedOperationBeforeIncomeTax" xlink:to="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationOtherExpense" use="optional" order="8" weight="-1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DiscontinuedOperationTaxEffectOfDiscontinuedOperation" xlink:label="loc_us-gaap_DiscontinuedOperationTaxEffectOfDiscontinuedOperation" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTax" xlink:to="loc_us-gaap_DiscontinuedOperationTaxEffectOfDiscontinuedOperation" use="optional" order="9" weight="-1" />
</calculationLink>
<calculationLink xlink:type="extended" xlink:role="http://roivant.com/role/IncomeTaxesScheduleOfDeferredTaxAssetsLiabilitiesDetail">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsLiabilitiesNet" xlink:label="loc_us-gaap_DeferredTaxAssetsLiabilitiesNet" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsGross" xlink:label="loc_us-gaap_DeferredTaxAssetsGross" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxAssetsLiabilitiesNet" xlink:to="loc_us-gaap_DeferredTaxAssetsGross" use="optional" order="1" weight="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch" xlink:label="loc_us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxAssetsGross" xlink:to="loc_us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch" use="optional" order="2" weight="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsGoodwillAndIntangibleAssets" xlink:label="loc_us-gaap_DeferredTaxAssetsGoodwillAndIntangibleAssets" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxAssetsGross" xlink:to="loc_us-gaap_DeferredTaxAssetsGoodwillAndIntangibleAssets" use="optional" order="3" weight="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:label="loc_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxAssetsGross" xlink:to="loc_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" use="optional" order="4" weight="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" xlink:label="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxAssetsGross" xlink:to="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" use="optional" order="5" weight="1" />
<loc xlink:type="locator" xlink:href="roiv-20210630.xsd#roiv_DeferredTaxAssetsLeaseLiabilities" xlink:label="loc_ROIV_DeferredTaxAssetsLeaseLiabilities" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxAssetsGross" xlink:to="loc_ROIV_DeferredTaxAssetsLeaseLiabilities" use="optional" order="6" weight="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsOther" xlink:label="loc_us-gaap_DeferredTaxAssetsOther" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxAssetsGross" xlink:to="loc_us-gaap_DeferredTaxAssetsOther" use="optional" order="7" weight="1" />
<loc xlink:type="locator" xlink:href="roiv-20210630.xsd#roiv_DeferredTaxLiabilitiesDepreciation" xlink:label="loc_ROIV_DeferredTaxLiabilitiesDepreciation" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxAssetsLiabilitiesNet" xlink:to="loc_ROIV_DeferredTaxLiabilitiesDepreciation" use="optional" order="8" weight="-1" />
<loc xlink:type="locator" xlink:href="roiv-20210630.xsd#roiv_DeferredTaxLiabilitiesRightOfUseAssets" xlink:label="loc_ROIV_DeferredTaxLiabilitiesRightOfUseAssets" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxAssetsLiabilitiesNet" xlink:to="loc_ROIV_DeferredTaxLiabilitiesRightOfUseAssets" use="optional" order="9" weight="-1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxLiabilitiesOther" xlink:label="loc_us-gaap_DeferredTaxLiabilitiesOther" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxAssetsLiabilitiesNet" xlink:to="loc_us-gaap_DeferredTaxLiabilitiesOther" use="optional" order="10" weight="-1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsValuationAllowance" xlink:label="loc_us-gaap_DeferredTaxAssetsValuationAllowance" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxAssetsLiabilitiesNet" xlink:to="loc_us-gaap_DeferredTaxAssetsValuationAllowance" use="optional" order="11" weight="-1" />
</calculationLink>
<calculationLink xlink:type="extended" xlink:role="http://roivant.com/role/LongTermDebtAndConvertibleNotesPayableScheduleOfCompanysAnnualPaymentsDetail">
<loc xlink:type="locator" xlink:href="roiv-20210630.xsd#roiv_LongTermDebtExcludingDebtWithFairValueOption" xlink:label="loc_ROIV_LongTermDebtExcludingDebtWithFairValueOption" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths" xlink:label="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ROIV_LongTermDebtExcludingDebtWithFairValueOption" xlink:to="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths" use="optional" order="1" weight="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo" xlink:label="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ROIV_LongTermDebtExcludingDebtWithFairValueOption" xlink:to="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo" use="optional" order="2" weight="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree" xlink:label="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ROIV_LongTermDebtExcludingDebtWithFairValueOption" xlink:to="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree" use="optional" order="3" weight="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour" xlink:label="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ROIV_LongTermDebtExcludingDebtWithFairValueOption" xlink:to="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour" use="optional" order="4" weight="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive" xlink:label="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ROIV_LongTermDebtExcludingDebtWithFairValueOption" xlink:to="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive" use="optional" order="5" weight="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalAfterYearFive" xlink:label="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalAfterYearFive" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ROIV_LongTermDebtExcludingDebtWithFairValueOption" xlink:to="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalAfterYearFive" use="optional" order="6" weight="1" />
</calculationLink>
<calculationLink xlink:type="extended" xlink:role="http://roivant.com/role/IncomeTaxesScheduleOfEffectiveIncomeTaxRateReconciliationDetail">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxExpenseBenefit" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate" xlink:label="loc_us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefit" xlink:to="loc_us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate" use="optional" order="1" weight="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxReconciliationForeignIncomeTaxRateDifferential" xlink:label="loc_us-gaap_IncomeTaxReconciliationForeignIncomeTaxRateDifferential" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefit" xlink:to="loc_us-gaap_IncomeTaxReconciliationForeignIncomeTaxRateDifferential" use="optional" order="2" weight="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxReconciliationNondeductibleExpenseResearchAndDevelopment" xlink:label="loc_us-gaap_IncomeTaxReconciliationNondeductibleExpenseResearchAndDevelopment" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefit" xlink:to="loc_us-gaap_IncomeTaxReconciliationNondeductibleExpenseResearchAndDevelopment" use="optional" order="3" weight="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxReconciliationNondeductibleExpense" xlink:label="loc_us-gaap_IncomeTaxReconciliationNondeductibleExpense" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefit" xlink:to="loc_us-gaap_IncomeTaxReconciliationNondeductibleExpense" use="optional" order="4" weight="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxReconciliationDispositionOfBusiness" xlink:label="loc_us-gaap_IncomeTaxReconciliationDispositionOfBusiness" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefit" xlink:to="loc_us-gaap_IncomeTaxReconciliationDispositionOfBusiness" use="optional" order="5" weight="1" />
<loc xlink:type="locator" xlink:href="roiv-20210630.xsd#roiv_IncomeTaxReconciliationPermanentAdjustments" xlink:label="loc_ROIV_IncomeTaxReconciliationPermanentAdjustments" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefit" xlink:to="loc_ROIV_IncomeTaxReconciliationPermanentAdjustments" use="optional" order="6" weight="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxReconciliationTaxCreditsResearch" xlink:label="loc_us-gaap_IncomeTaxReconciliationTaxCreditsResearch" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefit" xlink:to="loc_us-gaap_IncomeTaxReconciliationTaxCreditsResearch" use="optional" order="7" weight="-1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxReconciliationChangeInEnactedTaxRate" xlink:label="loc_us-gaap_IncomeTaxReconciliationChangeInEnactedTaxRate" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefit" xlink:to="loc_us-gaap_IncomeTaxReconciliationChangeInEnactedTaxRate" use="optional" order="8" weight="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:label="loc_us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefit" xlink:to="loc_us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance" use="optional" order="9" weight="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxReconciliationOtherAdjustments" xlink:label="loc_us-gaap_IncomeTaxReconciliationOtherAdjustments" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefit" xlink:to="loc_us-gaap_IncomeTaxReconciliationOtherAdjustments" use="optional" order="10" weight="1" />
</calculationLink>
<calculationLink xlink:type="extended" xlink:role="http://roivant.com/role/IncomeTaxesScheduleOfEffectiveIncomeTaxRateReconciliationDetail">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential" use="optional" order="11" weight="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseResearchAndDevelopment" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseResearchAndDevelopment" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseResearchAndDevelopment" use="optional" order="12" weight="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpense" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpense" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpense" use="optional" order="13" weight="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationDispositionOfBusiness" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationDispositionOfBusiness" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationDispositionOfBusiness" use="optional" order="14" weight="1" />
<loc xlink:type="locator" xlink:href="roiv-20210630.xsd#roiv_EffectiveIncomeTaxReconciliationPermanentDifferences" xlink:label="loc_ROIV_EffectiveIncomeTaxReconciliationPermanentDifferences" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:to="loc_ROIV_EffectiveIncomeTaxReconciliationPermanentDifferences" use="optional" order="15" weight="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsResearch" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsResearch" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsResearch" use="optional" order="16" weight="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate" use="optional" order="17" weight="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" use="optional" order="18" weight="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments" use="optional" order="19" weight="1" />
</calculationLink>
<calculationLink xlink:type="extended" xlink:role="http://roivant.com/role/LeasesScheduleOfOperatingLeaseCostsDetail">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LeaseCost" xlink:label="loc_us-gaap_LeaseCost" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseCost" xlink:label="loc_us-gaap_OperatingLeaseCost" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LeaseCost" xlink:to="loc_us-gaap_OperatingLeaseCost" use="optional" order="1" weight="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShortTermLeaseCost" xlink:label="loc_us-gaap_ShortTermLeaseCost" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LeaseCost" xlink:to="loc_us-gaap_ShortTermLeaseCost" use="optional" order="2" weight="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_VariableLeaseCost" xlink:label="loc_us-gaap_VariableLeaseCost" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LeaseCost" xlink:to="loc_us-gaap_VariableLeaseCost" use="optional" order="3" weight="1" />
</calculationLink>
<calculationLink xlink:type="extended" xlink:role="http://roivant.com/role/LeasesScheduleOfMaturitiesOfOperatingLeaseLiabilitiesDetail">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" use="optional" order="1" weight="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" use="optional" order="2" weight="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" use="optional" order="3" weight="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" use="optional" order="4" weight="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive" use="optional" order="5" weight="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive" use="optional" order="6" weight="1" />
</calculationLink>
<calculationLink xlink:type="extended" xlink:role="http://roivant.com/role/OtherIncomeExpenseNetSummaryOfOtherIncomeExpenseNetFromContinuingOperationsDetail">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherOperatingIncomeExpenseNet" xlink:label="loc_us-gaap_OtherOperatingIncomeExpenseNet" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeLossFromEquityMethodInvestments" xlink:label="loc_us-gaap_IncomeLossFromEquityMethodInvestments" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OtherOperatingIncomeExpenseNet" xlink:to="loc_us-gaap_IncomeLossFromEquityMethodInvestments" use="optional" order="1" weight="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InterestIncomeOther" xlink:label="loc_us-gaap_InterestIncomeOther" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OtherOperatingIncomeExpenseNet" xlink:to="loc_us-gaap_InterestIncomeOther" use="optional" order="2" weight="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InterestExpense" xlink:label="loc_us-gaap_InterestExpense" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OtherOperatingIncomeExpenseNet" xlink:to="loc_us-gaap_InterestExpense" use="optional" order="3" weight="-1" />
<loc xlink:type="locator" xlink:href="roiv-20210630.xsd#roiv_OtherIncomeExpense" xlink:label="loc_ROIV_OtherIncomeExpense" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OtherOperatingIncomeExpenseNet" xlink:to="loc_ROIV_OtherIncomeExpense" use="optional" order="4" weight="1" />
</calculationLink>
<calculationLink xlink:type="extended" xlink:role="http://roivant.com/role/CondensedConsolidatedBalanceSheets">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Assets" xlink:label="loc_us-gaap_Assets" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetsCurrent" xlink:label="loc_us-gaap_AssetsCurrent" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets" xlink:to="loc_us-gaap_AssetsCurrent" use="optional" order="1" weight="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue" use="optional" order="2" weight="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestrictedCashCurrent" xlink:label="loc_us-gaap_RestrictedCashCurrent" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent" xlink:to="loc_us-gaap_RestrictedCashCurrent" use="optional" order="3" weight="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherAssetsCurrent" xlink:label="loc_us-gaap_OtherAssetsCurrent" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent" xlink:to="loc_us-gaap_OtherAssetsCurrent" use="optional" order="4" weight="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentNet" use="optional" order="5" weight="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseRightOfUseAsset" xlink:label="loc_us-gaap_OperatingLeaseRightOfUseAsset" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets" xlink:to="loc_us-gaap_OperatingLeaseRightOfUseAsset" use="optional" order="6" weight="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestrictedCashNoncurrent" xlink:label="loc_us-gaap_RestrictedCashNoncurrent" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets" xlink:to="loc_us-gaap_RestrictedCashNoncurrent" use="optional" order="7" weight="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InvestmentsFairValueDisclosure" xlink:label="loc_us-gaap_InvestmentsFairValueDisclosure" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets" xlink:to="loc_us-gaap_InvestmentsFairValueDisclosure" use="optional" order="8" weight="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongTermInvestments" xlink:label="loc_us-gaap_LongTermInvestments" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets" xlink:to="loc_us-gaap_LongTermInvestments" use="optional" order="9" weight="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherAssetsNoncurrent" xlink:label="loc_us-gaap_OtherAssetsNoncurrent" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets" xlink:to="loc_us-gaap_OtherAssetsNoncurrent" use="optional" order="10" weight="1" />
</calculationLink>
<calculationLink xlink:type="extended" xlink:role="http://roivant.com/role/CondensedConsolidatedBalanceSheets">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquity" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Liabilities" xlink:label="loc_us-gaap_Liabilities" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="loc_us-gaap_Liabilities" use="optional" order="11" weight="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesCurrent" xlink:label="loc_us-gaap_LiabilitiesCurrent" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Liabilities" xlink:to="loc_us-gaap_LiabilitiesCurrent" use="optional" order="12" weight="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountsPayableCurrent" xlink:label="loc_us-gaap_AccountsPayableCurrent" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent" xlink:to="loc_us-gaap_AccountsPayableCurrent" use="optional" order="13" weight="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccruedLiabilitiesCurrent" xlink:label="loc_us-gaap_AccruedLiabilitiesCurrent" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent" xlink:to="loc_us-gaap_AccruedLiabilitiesCurrent" use="optional" order="14" weight="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseLiabilityCurrent" xlink:label="loc_us-gaap_OperatingLeaseLiabilityCurrent" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent" xlink:to="loc_us-gaap_OperatingLeaseLiabilityCurrent" use="optional" order="15" weight="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherLiabilitiesCurrent" xlink:label="loc_us-gaap_OtherLiabilitiesCurrent" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent" xlink:to="loc_us-gaap_OtherLiabilitiesCurrent" use="optional" order="16" weight="1" />
<loc xlink:type="locator" xlink:href="roiv-20210630.xsd#roiv_DeferredConsiderationLiabilityCurrent" xlink:label="loc_ROIV_DeferredConsiderationLiabilityCurrent" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent" xlink:to="loc_ROIV_DeferredConsiderationLiabilityCurrent" use="optional" order="17" weight="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:label="loc_us-gaap_OperatingLeaseLiabilityNoncurrent" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Liabilities" xlink:to="loc_us-gaap_OperatingLeaseLiabilityNoncurrent" use="optional" order="18" weight="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongTermDebtNoncurrent" xlink:label="loc_us-gaap_LongTermDebtNoncurrent" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Liabilities" xlink:to="loc_us-gaap_LongTermDebtNoncurrent" use="optional" order="19" weight="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherLiabilitiesNoncurrent" xlink:label="loc_us-gaap_OtherLiabilitiesNoncurrent" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Liabilities" xlink:to="loc_us-gaap_OtherLiabilitiesNoncurrent" use="optional" order="20" weight="1" />
<loc xlink:type="locator" xlink:href="roiv-20210630.xsd#roiv_LiabilityInstrumentsMeasuredAtFairValue" xlink:label="loc_ROIV_LiabilityInstrumentsMeasuredAtFairValue" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Liabilities" xlink:to="loc_ROIV_LiabilityInstrumentsMeasuredAtFairValue" use="optional" order="21" weight="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommitmentsAndContingencies" xlink:label="loc_us-gaap_CommitmentsAndContingencies" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="loc_us-gaap_CommitmentsAndContingencies" use="optional" order="22" weight="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RedeemableNoncontrollingInterestEquityCarryingAmount" xlink:label="loc_us-gaap_RedeemableNoncontrollingInterestEquityCarryingAmount" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="loc_us-gaap_RedeemableNoncontrollingInterestEquityCarryingAmount" use="optional" order="23" weight="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:label="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" use="optional" order="24" weight="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquity" xlink:label="loc_us-gaap_StockholdersEquity" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:to="loc_us-gaap_StockholdersEquity" use="optional" order="25" weight="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockValue" xlink:label="loc_us-gaap_CommonStockValue" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity" xlink:to="loc_us-gaap_CommonStockValue" use="optional" order="26" weight="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdditionalPaidInCapital" xlink:label="loc_us-gaap_AdditionalPaidInCapital" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity" xlink:to="loc_us-gaap_AdditionalPaidInCapital" use="optional" order="27" weight="1" />
<loc xlink:type="locator" xlink:href="roiv-20210630.xsd#roiv_SubscriptionsReceivable" xlink:label="loc_ROIV_SubscriptionsReceivable" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity" xlink:to="loc_ROIV_SubscriptionsReceivable" use="optional" order="28" weight="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity" xlink:to="loc_us-gaap_RetainedEarningsAccumulatedDeficit" use="optional" order="29" weight="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" use="optional" order="30" weight="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MinorityInterest" xlink:label="loc_us-gaap_MinorityInterest" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:to="loc_us-gaap_MinorityInterest" use="optional" order="31" weight="1" />
</calculationLink>
<calculationLink xlink:type="extended" xlink:role="http://roivant.com/role/ShareholdersEquityAndRedeemableNonControllingInterestScheduleOfPaymentsOfEquitySecuritiesDetail">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsForRepurchaseOfEquity" xlink:label="loc_us-gaap_PaymentsForRepurchaseOfEquity" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsForRepurchaseOfCommonStock" xlink:label="loc_us-gaap_PaymentsForRepurchaseOfCommonStock" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_PaymentsForRepurchaseOfEquity" xlink:to="loc_us-gaap_PaymentsForRepurchaseOfCommonStock" use="optional" order="1" weight="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsForRepurchaseOfOtherEquity" xlink:label="loc_us-gaap_PaymentsForRepurchaseOfOtherEquity" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_PaymentsForRepurchaseOfEquity" xlink:to="loc_us-gaap_PaymentsForRepurchaseOfOtherEquity" use="optional" order="2" weight="1" />
</calculationLink>
<calculationLink xlink:type="extended" xlink:role="http://roivant.com/role/BalanceSheetComponentsScheduleOfOtherCurrentAssetsDetail">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherAssetsCurrent" xlink:label="loc_us-gaap_OtherAssetsCurrent" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PrepaidExpenseCurrent" xlink:label="loc_us-gaap_PrepaidExpenseCurrent" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OtherAssetsCurrent" xlink:to="loc_us-gaap_PrepaidExpenseCurrent" use="optional" order="1" weight="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ValueAddedTaxReceivable" xlink:label="loc_us-gaap_ValueAddedTaxReceivable" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OtherAssetsCurrent" xlink:to="loc_us-gaap_ValueAddedTaxReceivable" use="optional" order="2" weight="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NotesAndLoansReceivableNetCurrent" xlink:label="loc_us-gaap_NotesAndLoansReceivableNetCurrent" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OtherAssetsCurrent" xlink:to="loc_us-gaap_NotesAndLoansReceivableNetCurrent" use="optional" order="3" weight="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountsReceivableNetCurrent" xlink:label="loc_us-gaap_AccountsReceivableNetCurrent" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OtherAssetsCurrent" xlink:to="loc_us-gaap_AccountsReceivableNetCurrent" use="optional" order="4" weight="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxesReceivable" xlink:label="loc_us-gaap_IncomeTaxesReceivable" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OtherAssetsCurrent" xlink:to="loc_us-gaap_IncomeTaxesReceivable" use="optional" order="5" weight="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherAssetsMiscellaneousCurrent" xlink:label="loc_us-gaap_OtherAssetsMiscellaneousCurrent" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OtherAssetsCurrent" xlink:to="loc_us-gaap_OtherAssetsMiscellaneousCurrent" use="optional" order="6" weight="1" />
</calculationLink>
</linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.DEF
<SEQUENCE>10
<FILENAME>roiv-20210630_def.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION DEFINITION LINKBASE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="utf-8"?>
<!--Generated by DFIN XBRL Instance Document - http://www.dfinsolutions.com/ - Version R3.0 - on 30-October-2021 [02:44:34] {AM}-->
<linkbase xmlns="http://www.xbrl.org/2003/linkbase" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" xmlns:xbrldt="http://xbrl.org/2005/xbrldt">
<roleRef xlink:type="simple" xlink:href="roiv-20210630.xsd#CondensedConsolidatedBalanceSheets" roleURI="http://roivant.com/role/CondensedConsolidatedBalanceSheets" />
<roleRef xlink:type="simple" xlink:href="roiv-20210630.xsd#CondensedConsolidatedBalanceSheetsParenthetical" roleURI="http://roivant.com/role/CondensedConsolidatedBalanceSheetsParenthetical" />
<roleRef xlink:type="simple" xlink:href="roiv-20210630.xsd#CondensedConsolidatedStatementsOfOperations" roleURI="http://roivant.com/role/CondensedConsolidatedStatementsOfOperations" />
<roleRef xlink:type="simple" xlink:href="roiv-20210630.xsd#CondensedConsolidatedStatementsOfShareholdersEquityAndRedeemableNoncontrollingInterest" roleURI="http://roivant.com/role/CondensedConsolidatedStatementsOfShareholdersEquityAndRedeemableNoncontrollingInterest" />
<roleRef xlink:type="simple" xlink:href="roiv-20210630.xsd#CondensedConsolidatedStatementsOfCashFlows" roleURI="http://roivant.com/role/CondensedConsolidatedStatementsOfCashFlows" />
<roleRef xlink:type="simple" xlink:href="roiv-20210630.xsd#SummaryOfSignificantAccountingPolicies" roleURI="http://roivant.com/role/SummaryOfSignificantAccountingPolicies" />
<roleRef xlink:type="simple" xlink:href="roiv-20210630.xsd#ShareholdersEquityAndRedeemableNoncontrollingInterest" roleURI="http://roivant.com/role/ShareholdersEquityAndRedeemableNoncontrollingInterest" />
<roleRef xlink:type="simple" xlink:href="roiv-20210630.xsd#RelatedPartyTransactions" roleURI="http://roivant.com/role/RelatedPartyTransactions" />
<roleRef xlink:type="simple" xlink:href="roiv-20210630.xsd#IncomeTaxes" roleURI="http://roivant.com/role/IncomeTaxes" />
<roleRef xlink:type="simple" xlink:href="roiv-20210630.xsd#CommitmentsContingencies" roleURI="http://roivant.com/role/CommitmentsContingencies" />
<roleRef xlink:type="simple" xlink:href="roiv-20210630.xsd#FairValueMeasurements" roleURI="http://roivant.com/role/FairValueMeasurements" />
<roleRef xlink:type="simple" xlink:href="roiv-20210630.xsd#SubsequentEvents" roleURI="http://roivant.com/role/SubsequentEvents" />
<roleRef xlink:type="simple" xlink:href="roiv-20210630.xsd#SummaryOfSignificantAccountingPoliciesPolicies" roleURI="http://roivant.com/role/SummaryOfSignificantAccountingPoliciesPolicies" />
<roleRef xlink:type="simple" xlink:href="roiv-20210630.xsd#ShareBasedCompensationTables" roleURI="http://roivant.com/role/ShareBasedCompensationTables" />
<roleRef xlink:type="simple" xlink:href="roiv-20210630.xsd#IncomeTaxesTables" roleURI="http://roivant.com/role/IncomeTaxesTables" />
<roleRef xlink:type="simple" xlink:href="roiv-20210630.xsd#FairValueMeasurementsTables" roleURI="http://roivant.com/role/FairValueMeasurementsTables" />
<roleRef xlink:type="simple" xlink:href="roiv-20210630.xsd#NetLossPerCommonShareTables" roleURI="http://roivant.com/role/NetLossPerCommonShareTables" />
<roleRef xlink:type="simple" xlink:href="roiv-20210630.xsd#SummaryOfSignificantAccountingPoliciesAdditionalInformationDetail" roleURI="http://roivant.com/role/SummaryOfSignificantAccountingPoliciesAdditionalInformationDetail" />
<roleRef xlink:type="simple" xlink:href="roiv-20210630.xsd#SummaryOfSignificantAccountingPoliciesScheduleOfEstimatedUsefulLivesDetail" roleURI="http://roivant.com/role/SummaryOfSignificantAccountingPoliciesScheduleOfEstimatedUsefulLivesDetail" />
<roleRef xlink:type="simple" xlink:href="roiv-20210630.xsd#InvestmentsAdditionalInformationDetail" roleURI="http://roivant.com/role/InvestmentsAdditionalInformationDetail" />
<roleRef xlink:type="simple" xlink:href="roiv-20210630.xsd#AssetAcquisitionsAndLicenseAgreementsAdditionalInformationDetail" roleURI="http://roivant.com/role/AssetAcquisitionsAndLicenseAgreementsAdditionalInformationDetail" />
<roleRef xlink:type="simple" xlink:href="roiv-20210630.xsd#SumitomoTransactionAgreementAdditionalInformationDetail" roleURI="http://roivant.com/role/SumitomoTransactionAgreementAdditionalInformationDetail" />
<roleRef xlink:type="simple" xlink:href="roiv-20210630.xsd#BalanceSheetComponentsScheduleOfAccruedExpensesDetail" roleURI="http://roivant.com/role/BalanceSheetComponentsScheduleOfAccruedExpensesDetail" />
<roleRef xlink:type="simple" xlink:href="roiv-20210630.xsd#LongTermDebtAndLoanCommitmentAdditionalInformationDetail" roleURI="http://roivant.com/role/LongTermDebtAndLoanCommitmentAdditionalInformationDetail" />
<roleRef xlink:type="simple" xlink:href="roiv-20210630.xsd#ShareholdersEquityAndRedeemableNonControllingInterestAdditionalInformationDetail" roleURI="http://roivant.com/role/ShareholdersEquityAndRedeemableNonControllingInterestAdditionalInformationDetail" />
<roleRef xlink:type="simple" xlink:href="roiv-20210630.xsd#ShareBasedCompensationAdditionalInformationDetail" roleURI="http://roivant.com/role/ShareBasedCompensationAdditionalInformationDetail" />
<roleRef xlink:type="simple" xlink:href="roiv-20210630.xsd#ShareBasedCompensationScheduleOfFairValueAssumptionsDetail" roleURI="http://roivant.com/role/ShareBasedCompensationScheduleOfFairValueAssumptionsDetail" />
<roleRef xlink:type="simple" xlink:href="roiv-20210630.xsd#ShareBasedCompensationSummaryOfStockOptionActivityDetail" roleURI="http://roivant.com/role/ShareBasedCompensationSummaryOfStockOptionActivityDetail" />
<roleRef xlink:type="simple" xlink:href="roiv-20210630.xsd#ShareBasedCompensationSummaryOfRestrictedStockUnitsDetail" roleURI="http://roivant.com/role/ShareBasedCompensationSummaryOfRestrictedStockUnitsDetail" />
<roleRef xlink:type="simple" xlink:href="roiv-20210630.xsd#ShareBasedCompensationSummaryOfPerformanceOptionsActivityDetail" roleURI="http://roivant.com/role/ShareBasedCompensationSummaryOfPerformanceOptionsActivityDetail" />
<roleRef xlink:type="simple" xlink:href="roiv-20210630.xsd#ShareBasedCompensationSummaryOfCappedValueAppreciationRightsDetail" roleURI="http://roivant.com/role/ShareBasedCompensationSummaryOfCappedValueAppreciationRightsDetail" />
<roleRef xlink:type="simple" xlink:href="roiv-20210630.xsd#ShareBasedCompensationSummaryOfPerformanceRestrictedStockUnitsDetail" roleURI="http://roivant.com/role/ShareBasedCompensationSummaryOfPerformanceRestrictedStockUnitsDetail" />
<roleRef xlink:type="simple" xlink:href="roiv-20210630.xsd#ShareBasedCompensationSummaryOfCommonShareAwardActivityDetail" roleURI="http://roivant.com/role/ShareBasedCompensationSummaryOfCommonShareAwardActivityDetail" />
<roleRef xlink:type="simple" xlink:href="roiv-20210630.xsd#ShareBasedCompensationSummaryOfShareBasedCompensationExpenseDetail" roleURI="http://roivant.com/role/ShareBasedCompensationSummaryOfShareBasedCompensationExpenseDetail" />
<roleRef xlink:type="simple" xlink:href="roiv-20210630.xsd#RelatedPartyTransactionsAdditionalInformationDetail" roleURI="http://roivant.com/role/RelatedPartyTransactionsAdditionalInformationDetail" />
<roleRef xlink:type="simple" xlink:href="roiv-20210630.xsd#IncomeTaxesScheduleOfLossBeforeIncomeTaxesByGeographicRegionDetail" roleURI="http://roivant.com/role/IncomeTaxesScheduleOfLossBeforeIncomeTaxesByGeographicRegionDetail" />
<roleRef xlink:type="simple" xlink:href="roiv-20210630.xsd#IncomeTaxesScheduleComponentsOfIncomeTaxExpenseBenefitDetail" roleURI="http://roivant.com/role/IncomeTaxesScheduleComponentsOfIncomeTaxExpenseBenefitDetail" />
<roleRef xlink:type="simple" xlink:href="roiv-20210630.xsd#IncomeTaxesAdditionalInformationDetail" roleURI="http://roivant.com/role/IncomeTaxesAdditionalInformationDetail" />
<roleRef xlink:type="simple" xlink:href="roiv-20210630.xsd#IncomeTaxesScheduleOfDeferredTaxAssetsLiabilitiesDetail" roleURI="http://roivant.com/role/IncomeTaxesScheduleOfDeferredTaxAssetsLiabilitiesDetail" />
<roleRef xlink:type="simple" xlink:href="roiv-20210630.xsd#IncomeTaxesScheduleOfEffectiveIncomeTaxRateReconciliationDetail" roleURI="http://roivant.com/role/IncomeTaxesScheduleOfEffectiveIncomeTaxRateReconciliationDetail" />
<roleRef xlink:type="simple" xlink:href="roiv-20210630.xsd#FairValueMeasurementsScheduleOfAssetsAndLiabilitiesMeasuredAtFairValueOnARecurringBasisDetail" roleURI="http://roivant.com/role/FairValueMeasurementsScheduleOfAssetsAndLiabilitiesMeasuredAtFairValueOnARecurringBasisDetail" />
<roleRef xlink:type="simple" xlink:href="roiv-20210630.xsd#FairValueMeasurementsAdditionalInformationDetail" roleURI="http://roivant.com/role/FairValueMeasurementsAdditionalInformationDetail" />
<roleRef xlink:type="simple" xlink:href="roiv-20210630.xsd#FairValueMeasurementsChangeInTheFairValueOfTheDerivativeWarrantLiabilitiesDetail" roleURI="http://roivant.com/role/FairValueMeasurementsChangeInTheFairValueOfTheDerivativeWarrantLiabilitiesDetail" />
<roleRef xlink:type="simple" xlink:href="roiv-20210630.xsd#FairValueMeasurementsScheduleOfFairValueOfUnobservableInputRelatedToOptionsToAcquireUnderSumitomoTransactionAgreementDetail" roleURI="http://roivant.com/role/FairValueMeasurementsScheduleOfFairValueOfUnobservableInputRelatedToOptionsToAcquireUnderSumitomoTransactionAgreementDetail" />
<roleRef xlink:type="simple" xlink:href="roiv-20210630.xsd#SubsequentEventsAdditionalInformationDetail" roleURI="http://roivant.com/role/SubsequentEventsAdditionalInformationDetail" />
<roleRef xlink:type="simple" xlink:href="roiv-20210630.xsd#Cover" roleURI="http://roivant.com/role/Cover" />
<roleRef xlink:type="simple" xlink:href="roiv-20210630.xsd#CondensedConsolidatedStatementsOfComprehensiveLoss" roleURI="http://roivant.com/role/CondensedConsolidatedStatementsOfComprehensiveLoss" />
<roleRef xlink:type="simple" xlink:href="roiv-20210630.xsd#DescriptionOfBusinessAndLiquidityAdditionalInformationDetail" roleURI="http://roivant.com/role/DescriptionOfBusinessAndLiquidityAdditionalInformationDetail" />
<roleRef xlink:type="simple" xlink:href="roiv-20210630.xsd#SummaryOfSignificantAccountingPoliciesScheduleOfAggregateAmountsOfCashCashEquivalentsAndRestrictedCashDetail" roleURI="http://roivant.com/role/SummaryOfSignificantAccountingPoliciesScheduleOfAggregateAmountsOfCashCashEquivalentsAndRestrictedCashDetail" />
<roleRef xlink:type="simple" xlink:href="roiv-20210630.xsd#BalanceSheetComponentsScheduleOfOtherCurrentAssetsDetail" roleURI="http://roivant.com/role/BalanceSheetComponentsScheduleOfOtherCurrentAssetsDetail" />
<roleRef xlink:type="simple" xlink:href="roiv-20210630.xsd#BalanceSheetComponentsScheduleOfOtherCurrentLiabilitiesDetail" roleURI="http://roivant.com/role/BalanceSheetComponentsScheduleOfOtherCurrentLiabilitiesDetail" />
<roleRef xlink:type="simple" xlink:href="roiv-20210630.xsd#LongTermDebtAndLoanCommitmentDetail" roleURI="http://roivant.com/role/LongTermDebtAndLoanCommitmentDetail" />
<roleRef xlink:type="simple" xlink:href="roiv-20210630.xsd#DiscontinuedOperationsSummaryOfCashFlowsFromDiscontinuedOperationsDetail" roleURI="http://roivant.com/role/DiscontinuedOperationsSummaryOfCashFlowsFromDiscontinuedOperationsDetail" />
<roleRef xlink:type="simple" xlink:href="roiv-20210630.xsd#LongTermDebtAndConvertibleNotesPayableScheduleOfCompanysAnnualPaymentsDetail" roleURI="http://roivant.com/role/LongTermDebtAndConvertibleNotesPayableScheduleOfCompanysAnnualPaymentsDetail" />
<roleRef xlink:type="simple" xlink:href="roiv-20210630.xsd#LeasesScheduleOfOperatingLeaseCostsDetail" roleURI="http://roivant.com/role/LeasesScheduleOfOperatingLeaseCostsDetail" />
<roleRef xlink:type="simple" xlink:href="roiv-20210630.xsd#LeasesSummaryOfOperatingLeaseRouAssetsAndOperatingLeaseLiabilitiesDetail" roleURI="http://roivant.com/role/LeasesSummaryOfOperatingLeaseRouAssetsAndOperatingLeaseLiabilitiesDetail" />
<roleRef xlink:type="simple" xlink:href="roiv-20210630.xsd#DefinedContributionPlanAdditionalInformationDetail" roleURI="http://roivant.com/role/DefinedContributionPlanAdditionalInformationDetail" />
<roleRef xlink:type="simple" xlink:href="roiv-20210630.xsd#NetLossPerCommonShareSummaryOfBasicAndDilutedNetIncomePerShareOfCommonStockDetail" roleURI="http://roivant.com/role/NetLossPerCommonShareSummaryOfBasicAndDilutedNetIncomePerShareOfCommonStockDetail" />
<roleRef xlink:type="simple" xlink:href="roiv-20210630.xsd#NetLossPerCommonShareSummaryOfBasicAndDilutedNetIncomePerShareOfCommonStockParentheticalDetail" roleURI="http://roivant.com/role/NetLossPerCommonShareSummaryOfBasicAndDilutedNetIncomePerShareOfCommonStockParentheticalDetail" />
<roleRef xlink:type="simple" xlink:href="roiv-20210630.xsd#ShareBasedCompensationSummaryOfFairValueOfVestedStockOptionDetail" roleURI="http://roivant.com/role/ShareBasedCompensationSummaryOfFairValueOfVestedStockOptionDetail" />
<roleRef xlink:type="simple" xlink:href="roiv-20210630.xsd#Investments" roleURI="http://roivant.com/role/Investments" />
<roleRef xlink:type="simple" xlink:href="roiv-20210630.xsd#AssetAcquisitionsAndLicenseAgreements" roleURI="http://roivant.com/role/AssetAcquisitionsAndLicenseAgreements" />
<roleRef xlink:type="simple" xlink:href="roiv-20210630.xsd#SumitomoTransactionAgreement" roleURI="http://roivant.com/role/SumitomoTransactionAgreement" />
<roleRef xlink:type="simple" xlink:href="roiv-20210630.xsd#DiscontinuedOperations" roleURI="http://roivant.com/role/DiscontinuedOperations" />
<roleRef xlink:type="simple" xlink:href="roiv-20210630.xsd#DiscontinuedOperationsTables" roleURI="http://roivant.com/role/DiscontinuedOperationsTables" />
<roleRef xlink:type="simple" xlink:href="roiv-20210630.xsd#BalanceSheetComponents" roleURI="http://roivant.com/role/BalanceSheetComponents" />
<roleRef xlink:type="simple" xlink:href="roiv-20210630.xsd#BalanceSheetComponentsTables" roleURI="http://roivant.com/role/BalanceSheetComponentsTables" />
<roleRef xlink:type="simple" xlink:href="roiv-20210630.xsd#DescriptionOfBusinessAndLiquidity" roleURI="http://roivant.com/role/DescriptionOfBusinessAndLiquidity" />
<roleRef xlink:type="simple" xlink:href="roiv-20210630.xsd#SummaryOfSignificantAccountingPoliciesTables" roleURI="http://roivant.com/role/SummaryOfSignificantAccountingPoliciesTables" />
<roleRef xlink:type="simple" xlink:href="roiv-20210630.xsd#LongTermDebtAndLoanCommitment" roleURI="http://roivant.com/role/LongTermDebtAndLoanCommitment" />
<roleRef xlink:type="simple" xlink:href="roiv-20210630.xsd#LongTermDebtAndLoanCommitmentTables" roleURI="http://roivant.com/role/LongTermDebtAndLoanCommitmentTables" />
<roleRef xlink:type="simple" xlink:href="roiv-20210630.xsd#ShareholdersEquityAndRedeemableNoncontrollingInterestTables" roleURI="http://roivant.com/role/ShareholdersEquityAndRedeemableNoncontrollingInterestTables" />
<roleRef xlink:type="simple" xlink:href="roiv-20210630.xsd#ShareBasedCompensation" roleURI="http://roivant.com/role/ShareBasedCompensation" />
<roleRef xlink:type="simple" xlink:href="roiv-20210630.xsd#DefinedContributionPlan" roleURI="http://roivant.com/role/DefinedContributionPlan" />
<roleRef xlink:type="simple" xlink:href="roiv-20210630.xsd#OtherIncomeExpenseNet" roleURI="http://roivant.com/role/OtherIncomeExpenseNet" />
<roleRef xlink:type="simple" xlink:href="roiv-20210630.xsd#OtherIncomeExpenseNetTables" roleURI="http://roivant.com/role/OtherIncomeExpenseNetTables" />
<roleRef xlink:type="simple" xlink:href="roiv-20210630.xsd#NetLossPerCommonShare" roleURI="http://roivant.com/role/NetLossPerCommonShare" />
<roleRef xlink:type="simple" xlink:href="roiv-20210630.xsd#Leases" roleURI="http://roivant.com/role/Leases" />
<roleRef xlink:type="simple" xlink:href="roiv-20210630.xsd#LeasesTables" roleURI="http://roivant.com/role/LeasesTables" />
<roleRef xlink:type="simple" xlink:href="roiv-20210630.xsd#ShareholdersEquityAndRedeemableNonControllingInterestScheduleOfPaymentsOfEquitySecuritiesDetail" roleURI="http://roivant.com/role/ShareholdersEquityAndRedeemableNonControllingInterestScheduleOfPaymentsOfEquitySecuritiesDetail" />
<roleRef xlink:type="simple" xlink:href="roiv-20210630.xsd#DiscontinuedOperationsSummaryOfDisposalGroupsIncludingDiscontinuedOperationsIncomeStatementDetail" roleURI="http://roivant.com/role/DiscontinuedOperationsSummaryOfDisposalGroupsIncludingDiscontinuedOperationsIncomeStatementDetail" />
<roleRef xlink:type="simple" xlink:href="roiv-20210630.xsd#OtherIncomeExpenseNetSummaryOfOtherIncomeExpenseNetFromContinuingOperationsDetail" roleURI="http://roivant.com/role/OtherIncomeExpenseNetSummaryOfOtherIncomeExpenseNetFromContinuingOperationsDetail" />
<roleRef xlink:type="simple" xlink:href="roiv-20210630.xsd#LeasesScheduleOfMaturitiesOfOperatingLeaseLiabilitiesDetail" roleURI="http://roivant.com/role/LeasesScheduleOfMaturitiesOfOperatingLeaseLiabilitiesDetail" />
<arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/all" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#all" />
<arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-default" />
<arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-domain" />
<arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/domain-member" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#domain-member" />
<arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#hypercube-dimension" />
<arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/notAll" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#notAll" />
<definitionLink xlink:type="extended" xlink:role="http://roivant.com/role/CondensedConsolidatedBalanceSheets">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaap_StatementLineItems_21" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetsAbstract" xlink:label="loc_us-gaap_AssetsAbstract_13" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_21" xlink:to="loc_us-gaap_AssetsAbstract_13" use="optional" order="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Assets" xlink:label="loc_us-gaap_Assets_31" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsAbstract_13" xlink:to="loc_us-gaap_Assets_31" use="optional" order="2" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetsCurrentAbstract" xlink:label="loc_us-gaap_AssetsCurrentAbstract_14" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsAbstract_13" xlink:to="loc_us-gaap_AssetsCurrentAbstract_14" use="optional" order="3" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetsCurrent" xlink:label="loc_us-gaap_AssetsCurrent_38" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsCurrentAbstract_14" xlink:to="loc_us-gaap_AssetsCurrent_38" use="optional" order="4" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherAssetsCurrent" xlink:label="loc_us-gaap_OtherAssetsCurrent_36" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsCurrentAbstract_14" xlink:to="loc_us-gaap_OtherAssetsCurrent_36" use="optional" order="5" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_32" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsCurrentAbstract_14" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_32" use="optional" order="6" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestrictedCashCurrent" xlink:label="loc_us-gaap_RestrictedCashCurrent_34" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsCurrentAbstract_14" xlink:to="loc_us-gaap_RestrictedCashCurrent_34" use="optional" order="7" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongTermInvestments" xlink:label="loc_us-gaap_LongTermInvestments_29" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsAbstract_13" xlink:to="loc_us-gaap_LongTermInvestments_29" use="optional" order="8" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseRightOfUseAsset" xlink:label="loc_us-gaap_OperatingLeaseRightOfUseAsset_26" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsAbstract_13" xlink:to="loc_us-gaap_OperatingLeaseRightOfUseAsset_26" use="optional" order="9" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherAssetsNoncurrent" xlink:label="loc_us-gaap_OtherAssetsNoncurrent_30" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsAbstract_13" xlink:to="loc_us-gaap_OtherAssetsNoncurrent_30" use="optional" order="10" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InvestmentsFairValueDisclosure" xlink:label="loc_us-gaap_InvestmentsFairValueDisclosure_28" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsAbstract_13" xlink:to="loc_us-gaap_InvestmentsFairValueDisclosure_28" use="optional" order="11" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet_24" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsAbstract_13" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentNet_24" use="optional" order="12" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestrictedCashNoncurrent" xlink:label="loc_us-gaap_RestrictedCashNoncurrent_27" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsAbstract_13" xlink:to="loc_us-gaap_RestrictedCashNoncurrent_27" use="optional" order="13" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_18" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_21" xlink:to="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_18" use="optional" order="14" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesCurrentAbstract" xlink:label="loc_us-gaap_LiabilitiesCurrentAbstract_19" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_18" xlink:to="loc_us-gaap_LiabilitiesCurrentAbstract_19" use="optional" order="15" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccruedLiabilitiesCurrent" xlink:label="loc_us-gaap_AccruedLiabilitiesCurrent_56" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_19" xlink:to="loc_us-gaap_AccruedLiabilitiesCurrent_56" use="optional" order="16" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountsPayableCurrent" xlink:label="loc_us-gaap_AccountsPayableCurrent_55" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_19" xlink:to="loc_us-gaap_AccountsPayableCurrent_55" use="optional" order="17" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesCurrent" xlink:label="loc_us-gaap_LiabilitiesCurrent_62" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_19" xlink:to="loc_us-gaap_LiabilitiesCurrent_62" use="optional" order="18" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseLiabilityCurrent" xlink:label="loc_us-gaap_OperatingLeaseLiabilityCurrent_57" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_19" xlink:to="loc_us-gaap_OperatingLeaseLiabilityCurrent_57" use="optional" order="19" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherLiabilitiesCurrent" xlink:label="loc_us-gaap_OtherLiabilitiesCurrent_61" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_19" xlink:to="loc_us-gaap_OtherLiabilitiesCurrent_61" use="optional" order="20" />
<loc xlink:type="locator" xlink:href="roiv-20210630.xsd#roiv_DeferredConsiderationLiabilityCurrent" xlink:label="loc_roiv_DeferredConsiderationLiabilityCurrent_1106509" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_19" xlink:to="loc_roiv_DeferredConsiderationLiabilityCurrent_1106509" use="optional" order="21" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongTermDebtNoncurrent" xlink:label="loc_us-gaap_LongTermDebtNoncurrent_46" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_18" xlink:to="loc_us-gaap_LongTermDebtNoncurrent_46" use="optional" order="22" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MinorityInterest" xlink:label="loc_us-gaap_MinorityInterest_52" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_18" xlink:to="loc_us-gaap_MinorityInterest_52" use="optional" order="23" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:label="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_44" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_18" xlink:to="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_44" use="optional" order="24" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherLiabilitiesNoncurrent" xlink:label="loc_us-gaap_OtherLiabilitiesNoncurrent_47" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_18" xlink:to="loc_us-gaap_OtherLiabilitiesNoncurrent_47" use="optional" order="25" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommitmentsAndContingencies" xlink:label="loc_us-gaap_CommitmentsAndContingencies_49" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_18" xlink:to="loc_us-gaap_CommitmentsAndContingencies_49" use="optional" order="26" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Liabilities" xlink:label="loc_us-gaap_Liabilities_48" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_18" xlink:to="loc_us-gaap_Liabilities_48" use="optional" order="27" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquity_54" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_18" xlink:to="loc_us-gaap_LiabilitiesAndStockholdersEquity_54" use="optional" order="28" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquityAbstract" xlink:label="loc_us-gaap_StockholdersEquityAbstract_23" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_18" xlink:to="loc_us-gaap_StockholdersEquityAbstract_23" use="optional" order="29" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_68" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StockholdersEquityAbstract_23" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_68" use="optional" order="30" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockValue" xlink:label="loc_us-gaap_CommonStockValue_64" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StockholdersEquityAbstract_23" xlink:to="loc_us-gaap_CommonStockValue_64" use="optional" order="31" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdditionalPaidInCapital" xlink:label="loc_us-gaap_AdditionalPaidInCapital_65" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StockholdersEquityAbstract_23" xlink:to="loc_us-gaap_AdditionalPaidInCapital_65" use="optional" order="32" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquity" xlink:label="loc_us-gaap_StockholdersEquity_69" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StockholdersEquityAbstract_23" xlink:to="loc_us-gaap_StockholdersEquity_69" use="optional" order="33" />
<loc xlink:type="locator" xlink:href="roiv-20210630.xsd#roiv_SubscriptionsReceivable" xlink:label="loc_roiv_SubscriptionsReceivable_66" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StockholdersEquityAbstract_23" xlink:to="loc_roiv_SubscriptionsReceivable_66" use="optional" order="34" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit_67" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StockholdersEquityAbstract_23" xlink:to="loc_us-gaap_RetainedEarningsAccumulatedDeficit_67" use="optional" order="35" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:label="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_53" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_18" xlink:to="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_53" use="optional" order="36" />
<loc xlink:type="locator" xlink:href="roiv-20210630.xsd#roiv_LiabilityInstrumentsMeasuredAtFairValue" xlink:label="loc_roiv_LiabilityInstrumentsMeasuredAtFairValue_1106513" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_18" xlink:to="loc_roiv_LiabilityInstrumentsMeasuredAtFairValue_1106513" use="optional" order="37" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RedeemableNoncontrollingInterestEquityCarryingAmount" xlink:label="loc_us-gaap_RedeemableNoncontrollingInterestEquityCarryingAmount_50" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_18" xlink:to="loc_us-gaap_RedeemableNoncontrollingInterestEquityCarryingAmount_50" use="optional" order="38" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaap_StatementTable_22" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_StatementLineItems_21" xlink:to="loc_us-gaap_StatementTable_22" xbrldt:contextElement="segment" xbrldt:closed="true" use="optional" order="39" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_LegalEntityAxis" xlink:label="loc_dei_LegalEntityAxis_17" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_22" xlink:to="loc_dei_LegalEntityAxis_17" use="optional" order="40" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityDomain" xlink:label="loc_dei_EntityDomain_16" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_dei_LegalEntityAxis_17" xlink:to="loc_dei_EntityDomain_16" use="optional" order="41" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityDomain" xlink:label="loc_dei_EntityDomain_16_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_dei_LegalEntityAxis_17" xlink:to="loc_dei_EntityDomain_16_default" use="optional" order="42" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="loc_us-gaap_StatementClassOfStockAxis_20" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_22" xlink:to="loc_us-gaap_StatementClassOfStockAxis_20" use="optional" order="43" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaap_ClassOfStockDomain_15" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementClassOfStockAxis_20" xlink:to="loc_us-gaap_ClassOfStockDomain_15" use="optional" order="44" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaap_ClassOfStockDomain_15_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementClassOfStockAxis_20" xlink:to="loc_us-gaap_ClassOfStockDomain_15_default" use="optional" order="45" />
</definitionLink>
<definitionLink xlink:type="extended" xlink:role="http://roivant.com/role/CondensedConsolidatedBalanceSheetsParenthetical">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaap_StatementLineItems_76" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockSharesAuthorized" xlink:label="loc_us-gaap_CommonStockSharesAuthorized_90" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_76" xlink:to="loc_us-gaap_CommonStockSharesAuthorized_90" use="optional" order="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockSharesIssued" xlink:label="loc_us-gaap_CommonStockSharesIssued_91" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_76" xlink:to="loc_us-gaap_CommonStockSharesIssued_91" use="optional" order="2" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockSharesOutstanding" xlink:label="loc_us-gaap_CommonStockSharesOutstanding_92" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_76" xlink:to="loc_us-gaap_CommonStockSharesOutstanding_92" use="optional" order="3" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongTermDebtFairValue" xlink:label="loc_us-gaap_LongTermDebtFairValue_82" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_76" xlink:to="loc_us-gaap_LongTermDebtFairValue_82" use="optional" order="4" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaap_StatementTable_77" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_StatementLineItems_76" xlink:to="loc_us-gaap_StatementTable_77" xbrldt:contextElement="segment" xbrldt:closed="true" use="optional" order="5" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="loc_us-gaap_StatementClassOfStockAxis_75" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_77" xlink:to="loc_us-gaap_StatementClassOfStockAxis_75" use="optional" order="6" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaap_ClassOfStockDomain_72" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementClassOfStockAxis_75" xlink:to="loc_us-gaap_ClassOfStockDomain_72" use="optional" order="7" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaap_ClassOfStockDomain_72_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementClassOfStockAxis_75" xlink:to="loc_us-gaap_ClassOfStockDomain_72_default" use="optional" order="8" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_LegalEntityAxis" xlink:label="loc_dei_LegalEntityAxis_74" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_77" xlink:to="loc_dei_LegalEntityAxis_74" use="optional" order="9" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityDomain" xlink:label="loc_dei_EntityDomain_73" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_dei_LegalEntityAxis_74" xlink:to="loc_dei_EntityDomain_73" use="optional" order="10" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityDomain" xlink:label="loc_dei_EntityDomain_73_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_dei_LegalEntityAxis_74" xlink:to="loc_dei_EntityDomain_73_default" use="optional" order="11" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:label="loc_us-gaap_CommonStockParOrStatedValuePerShare_89" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_76" xlink:to="loc_us-gaap_CommonStockParOrStatedValuePerShare_89" use="optional" order="12" />
</definitionLink>
<definitionLink xlink:type="extended" xlink:role="http://roivant.com/role/CondensedConsolidatedStatementsOfOperations">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaap_StatementLineItems_103" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeAmountsAttributableToReportingEntityDisclosuresAbstract" xlink:label="loc_us-gaap_IncomeAmountsAttributableToReportingEntityDisclosuresAbstract_99" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_103" xlink:to="loc_us-gaap_IncomeAmountsAttributableToReportingEntityDisclosuresAbstract_99" use="optional" order="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeLossFromContinuingOperations" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperations_114" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeAmountsAttributableToReportingEntityDisclosuresAbstract_99" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperations_114" use="optional" order="2" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity" xlink:label="loc_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity_115" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeAmountsAttributableToReportingEntityDisclosuresAbstract_99" xlink:to="loc_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity_115" use="optional" order="3" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaap_NetIncomeLoss_139" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_103" xlink:to="loc_us-gaap_NetIncomeLoss_139" use="optional" order="4" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetIncomeLossAttributableToNoncontrollingInterest" xlink:label="loc_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest_138" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_103" xlink:to="loc_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest_138" use="optional" order="5" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingExpensesAbstract" xlink:label="loc_us-gaap_OperatingExpensesAbstract_101" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_103" xlink:to="loc_us-gaap_OperatingExpensesAbstract_101" use="optional" order="6" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GeneralAndAdministrativeExpense" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpense_118" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OperatingExpensesAbstract_101" xlink:to="loc_us-gaap_GeneralAndAdministrativeExpense_118" use="optional" order="7" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingExpenses" xlink:label="loc_us-gaap_OperatingExpenses_119" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OperatingExpensesAbstract_101" xlink:to="loc_us-gaap_OperatingExpenses_119" use="optional" order="8" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpense_117" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OperatingExpensesAbstract_101" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpense_117" use="optional" order="9" />
<loc xlink:type="locator" xlink:href="roiv-20210630.xsd#roiv_OperatingCosts" xlink:label="loc_roiv_OperatingCosts_116" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OperatingExpensesAbstract_101" xlink:to="loc_roiv_OperatingCosts_116" use="optional" order="10" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingIncomeLoss" xlink:label="loc_us-gaap_OperatingIncomeLoss_131" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_103" xlink:to="loc_us-gaap_OperatingIncomeLoss_131" use="optional" order="11" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest_135" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_103" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest_135" use="optional" order="12" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_133" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_103" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_133" use="optional" order="13" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerShareBasicAndDilutedAbstract" xlink:label="loc_us-gaap_EarningsPerShareBasicAndDilutedAbstract_96" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_103" xlink:to="loc_us-gaap_EarningsPerShareBasicAndDilutedAbstract_96" use="optional" order="14" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerShareBasicAndDiluted" xlink:label="loc_us-gaap_EarningsPerShareBasicAndDiluted_107" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EarningsPerShareBasicAndDilutedAbstract_96" xlink:to="loc_us-gaap_EarningsPerShareBasicAndDiluted_107" use="optional" order="15" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsPerBasicAndDilutedShare" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsPerBasicAndDilutedShare_105" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EarningsPerShareBasicAndDilutedAbstract_96" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsPerBasicAndDilutedShare_105" use="optional" order="16" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicAndDilutedShare" xlink:label="loc_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicAndDilutedShare_106" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EarningsPerShareBasicAndDilutedAbstract_96" xlink:to="loc_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicAndDilutedShare_106" use="optional" order="17" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerShareBasicAndDilutedOtherDisclosuresAbstract" xlink:label="loc_us-gaap_EarningsPerShareBasicAndDilutedOtherDisclosuresAbstract_97" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_103" xlink:to="loc_us-gaap_EarningsPerShareBasicAndDilutedOtherDisclosuresAbstract_97" use="optional" order="18" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:label="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_110" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EarningsPerShareBasicAndDilutedOtherDisclosuresAbstract_97" xlink:to="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_110" use="optional" order="19" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_108" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EarningsPerShareBasicAndDilutedOtherDisclosuresAbstract_97" xlink:to="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_108" use="optional" order="20" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted" xlink:label="loc_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted_112" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EarningsPerShareBasicAndDilutedOtherDisclosuresAbstract_97" xlink:to="loc_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted_112" use="optional" order="21" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments_132" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_103" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments_132" use="optional" order="22" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_130" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_103" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_130" use="optional" order="23" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaap_StatementTable_104" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_StatementLineItems_103" xlink:to="loc_us-gaap_StatementTable_104" xbrldt:contextElement="segment" xbrldt:closed="true" use="optional" order="24" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_LegalEntityAxis" xlink:label="loc_dei_LegalEntityAxis_100" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_104" xlink:to="loc_dei_LegalEntityAxis_100" use="optional" order="25" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityDomain" xlink:label="loc_dei_EntityDomain_98" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_dei_LegalEntityAxis_100" xlink:to="loc_dei_EntityDomain_98" use="optional" order="26" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityDomain" xlink:label="loc_dei_EntityDomain_98_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_dei_LegalEntityAxis_100" xlink:to="loc_dei_EntityDomain_98_default" use="optional" order="27" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTax" xlink:label="loc_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTax_136" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_103" xlink:to="loc_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTax_136" use="optional" order="28" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxExpenseBenefit" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit_134" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_103" xlink:to="loc_us-gaap_IncomeTaxExpenseBenefit_134" use="optional" order="29" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherNonoperatingIncomeExpenseAbstract" xlink:label="loc_us-gaap_OtherNonoperatingIncomeExpenseAbstract_102" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_103" xlink:to="loc_us-gaap_OtherNonoperatingIncomeExpenseAbstract_102" use="optional" order="30" />
<loc xlink:type="locator" xlink:href="roiv-20210630.xsd#roiv_GainLossOnFairValueOfDebtAndLiabilityInstruments" xlink:label="loc_roiv_GainLossOnFairValueOfDebtAndLiabilityInstruments_124" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OtherNonoperatingIncomeExpenseAbstract_102" xlink:to="loc_roiv_GainLossOnFairValueOfDebtAndLiabilityInstruments_124" use="optional" order="31" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherNonoperatingIncomeExpense" xlink:label="loc_us-gaap_OtherNonoperatingIncomeExpense_128" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OtherNonoperatingIncomeExpenseAbstract_102" xlink:to="loc_us-gaap_OtherNonoperatingIncomeExpense_128" use="optional" order="32" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GainLossOnInvestments" xlink:label="loc_us-gaap_GainLossOnInvestments_122" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OtherNonoperatingIncomeExpenseAbstract_102" xlink:to="loc_us-gaap_GainLossOnInvestments_122" use="optional" order="33" />
<loc xlink:type="locator" xlink:href="roiv-20210630.xsd#roiv_DeconsolidationAndConsolidationOnGainOrLossOfConsolidatedEntity" xlink:label="loc_roiv_DeconsolidationAndConsolidationOnGainOrLossOfConsolidatedEntity_126" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OtherNonoperatingIncomeExpenseAbstract_102" xlink:to="loc_roiv_DeconsolidationAndConsolidationOnGainOrLossOfConsolidatedEntity_126" use="optional" order="34" />
<loc xlink:type="locator" xlink:href="roiv-20210630.xsd#roiv_EquityInterestOptionToThirdPartyPurchaserGainOnTermination" xlink:label="loc_roiv_EquityInterestOptionToThirdPartyPurchaserGainOnTermination_1106522" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OtherNonoperatingIncomeExpenseAbstract_102" xlink:to="loc_roiv_EquityInterestOptionToThirdPartyPurchaserGainOnTermination_1106522" use="optional" order="35" />
<loc xlink:type="locator" xlink:href="roiv-20210630.xsd#roiv_GainOrLossOnDeconsolidationOfSubsidiary" xlink:label="loc_roiv_GainOrLossOnDeconsolidationOfSubsidiary_1107932" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OtherNonoperatingIncomeExpenseAbstract_102" xlink:to="loc_roiv_GainOrLossOnDeconsolidationOfSubsidiary_1107932" use="optional" order="36" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProfitLoss" xlink:label="loc_us-gaap_ProfitLoss_137" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_103" xlink:to="loc_us-gaap_ProfitLoss_137" use="optional" order="37" />
</definitionLink>
<definitionLink xlink:type="extended" xlink:role="http://roivant.com/role/CondensedConsolidatedStatementsOfShareholdersEquityAndRedeemableNoncontrollingInterest">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaap_StatementLineItems_149" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalIncreaseInCarryingAmountOfRedeemablePreferredStock" xlink:label="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalIncreaseInCarryingAmountOfRedeemablePreferredStock_171" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_149" xlink:to="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalIncreaseInCarryingAmountOfRedeemablePreferredStock_171" use="optional" order="1" />
<loc xlink:type="locator" xlink:href="roiv-20210630.xsd#roiv_CapitalContributionsToSubsidiaries" xlink:label="loc_roiv_CapitalContributionsToSubsidiaries_197" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_149" xlink:to="loc_roiv_CapitalContributionsToSubsidiaries_197" use="optional" order="2" />
<loc xlink:type="locator" xlink:href="roiv-20210630.xsd#roiv_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationRequisiteServicePeriodRecognitionShares" xlink:label="loc_roiv_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationRequisiteServicePeriodRecognitionShares_199" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_149" xlink:to="loc_roiv_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationRequisiteServicePeriodRecognitionShares_199" use="optional" order="3" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:label="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_198" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_149" xlink:to="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_198" use="optional" order="4" />
<loc xlink:type="locator" xlink:href="roiv-20210630.xsd#roiv_ConsolidationOfUnconsolidatedEntity" xlink:label="loc_roiv_ConsolidationOfUnconsolidatedEntity_195" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_149" xlink:to="loc_roiv_ConsolidationOfUnconsolidatedEntity_195" use="optional" order="5" />
<loc xlink:type="locator" xlink:href="roiv-20210630.xsd#roiv_ConversionOfSubsidiaryConvertiblePromissoryNotes" xlink:label="loc_roiv_ConversionOfSubsidiaryConvertiblePromissoryNotes_187" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_149" xlink:to="loc_roiv_ConversionOfSubsidiaryConvertiblePromissoryNotes_187" use="optional" order="6" />
<loc xlink:type="locator" xlink:href="roiv-20210630.xsd#roiv_DeconsolidationOfSubsidiary" xlink:label="loc_roiv_DeconsolidationOfSubsidiary_194" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_149" xlink:to="loc_roiv_DeconsolidationOfSubsidiary_194" use="optional" order="7" />
<loc xlink:type="locator" xlink:href="roiv-20210630.xsd#roiv_IssuanceOfSubsidiaryCommonSharesNetValue" xlink:label="loc_roiv_IssuanceOfSubsidiaryCommonSharesNetValue_168" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_149" xlink:to="loc_roiv_IssuanceOfSubsidiaryCommonSharesNetValue_168" use="optional" order="8" />
<loc xlink:type="locator" xlink:href="roiv-20210630.xsd#roiv_IssuanceOfSubsidiaryCommonSharesToTheCompanyValue" xlink:label="loc_roiv_IssuanceOfSubsidiaryCommonSharesToTheCompanyValue_169" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_149" xlink:to="loc_roiv_IssuanceOfSubsidiaryCommonSharesToTheCompanyValue_169" use="optional" order="9" />
<loc xlink:type="locator" xlink:href="roiv-20210630.xsd#roiv_ExerciseOfSubsidiaryStockOptionsAndVestingOfSubsidiaryRestrictedStockUnits" xlink:label="loc_roiv_ExerciseOfSubsidiaryStockOptionsAndVestingOfSubsidiaryRestrictedStockUnits_178" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_149" xlink:to="loc_roiv_ExerciseOfSubsidiaryStockOptionsAndVestingOfSubsidiaryRestrictedStockUnits_178" use="optional" order="10" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GainOrLossOnSaleOfStockInSubsidiary" xlink:label="loc_us-gaap_GainOrLossOnSaleOfStockInSubsidiary_181" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_149" xlink:to="loc_us-gaap_GainOrLossOnSaleOfStockInSubsidiary_181" use="optional" order="11" />
<loc xlink:type="locator" xlink:href="roiv-20210630.xsd#roiv_IssuanceOfEquityBySubsidiaryToTheCompanyUponBusinessCombinationAndRecapitalization" xlink:label="loc_roiv_IssuanceOfEquityBySubsidiaryToTheCompanyUponBusinessCombinationAndRecapitalization_185" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_149" xlink:to="loc_roiv_IssuanceOfEquityBySubsidiaryToTheCompanyUponBusinessCombinationAndRecapitalization_185" use="optional" order="12" />
<loc xlink:type="locator" xlink:href="roiv-20210630.xsd#roiv_IssuanceOfEquityBySubsidiaryUponBusinessCombinationAndRecapitalization" xlink:label="loc_roiv_IssuanceOfEquityBySubsidiaryUponBusinessCombinationAndRecapitalization_183" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_149" xlink:to="loc_roiv_IssuanceOfEquityBySubsidiaryUponBusinessCombinationAndRecapitalization_183" use="optional" order="13" />
<loc xlink:type="locator" xlink:href="roiv-20210630.xsd#roiv_IssuanceOfEquityInstruments" xlink:label="loc_roiv_IssuanceOfEquityInstruments_189" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_149" xlink:to="loc_roiv_IssuanceOfEquityInstruments_189" use="optional" order="14" />
<loc xlink:type="locator" xlink:href="roiv-20210630.xsd#roiv_IssuanceOfSubsidiaryWarrants" xlink:label="loc_roiv_IssuanceOfSubsidiaryWarrants_172" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_149" xlink:to="loc_roiv_IssuanceOfSubsidiaryWarrants_172" use="optional" order="15" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent" xlink:label="loc_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent_200" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_149" xlink:to="loc_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent_200" use="optional" order="16" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaap_StatementTable_150" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_StatementLineItems_149" xlink:to="loc_us-gaap_StatementTable_150" xbrldt:contextElement="segment" xbrldt:closed="true" use="optional" order="17" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="loc_us-gaap_StatementClassOfStockAxis_147" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_150" xlink:to="loc_us-gaap_StatementClassOfStockAxis_147" use="optional" order="18" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaap_ClassOfStockDomain_143" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementClassOfStockAxis_147" xlink:to="loc_us-gaap_ClassOfStockDomain_143" use="optional" order="19" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaap_ClassOfStockDomain_143_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementClassOfStockAxis_147" xlink:to="loc_us-gaap_ClassOfStockDomain_143_default" use="optional" order="20" />
<loc xlink:type="locator" xlink:href="roiv-20210630.xsd#roiv_RedeemableNoncontrollingInterestMember" xlink:label="loc_roiv_RedeemableNoncontrollingInterestMember_153" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockDomain_143" xlink:to="loc_roiv_RedeemableNoncontrollingInterestMember_153" use="optional" order="21" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_148" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_150" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_148" use="optional" order="22" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaap_EquityComponentDomain_145" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_148" xlink:to="loc_us-gaap_EquityComponentDomain_145" use="optional" order="23" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaap_EquityComponentDomain_145_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_148" xlink:to="loc_us-gaap_EquityComponentDomain_145_default" use="optional" order="24" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember_159" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_145" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember_159" use="optional" order="25" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdditionalPaidInCapitalMember" xlink:label="loc_us-gaap_AdditionalPaidInCapitalMember_156" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_145" xlink:to="loc_us-gaap_AdditionalPaidInCapitalMember_156" use="optional" order="26" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockMember" xlink:label="loc_us-gaap_CommonStockMember_155" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_145" xlink:to="loc_us-gaap_CommonStockMember_155" use="optional" order="27" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NoncontrollingInterestMember" xlink:label="loc_us-gaap_NoncontrollingInterestMember_160" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_145" xlink:to="loc_us-gaap_NoncontrollingInterestMember_160" use="optional" order="28" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RetainedEarningsMember" xlink:label="loc_us-gaap_RetainedEarningsMember_157" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_145" xlink:to="loc_us-gaap_RetainedEarningsMember_157" use="optional" order="29" />
<loc xlink:type="locator" xlink:href="roiv-20210630.xsd#roiv_SubscriptionsReceivablesMember" xlink:label="loc_roiv_SubscriptionsReceivablesMember_158" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_145" xlink:to="loc_roiv_SubscriptionsReceivablesMember_158" use="optional" order="30" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TemporaryEquityStockIssuedDuringPeriodValueNewIssues" xlink:label="loc_us-gaap_TemporaryEquityStockIssuedDuringPeriodValueNewIssues_163" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_149" xlink:to="loc_us-gaap_TemporaryEquityStockIssuedDuringPeriodValueNewIssues_163" use="optional" order="31" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProfitLoss" xlink:label="loc_us-gaap_ProfitLoss_201" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_149" xlink:to="loc_us-gaap_ProfitLoss_201" use="optional" order="32" />
<loc xlink:type="locator" xlink:href="roiv-20210630.xsd#roiv_PurchaseOfSubsidiaryCommonSharesValue" xlink:label="loc_roiv_PurchaseOfSubsidiaryCommonSharesValue_170" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_149" xlink:to="loc_roiv_PurchaseOfSubsidiaryCommonSharesValue_170" use="optional" order="33" />
<loc xlink:type="locator" xlink:href="roiv-20210630.xsd#roiv_RepurchaseOfCommonSharesAndOtherEquityInstrumentsShares" xlink:label="loc_roiv_RepurchaseOfCommonSharesAndOtherEquityInstrumentsShares_179" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_149" xlink:to="loc_roiv_RepurchaseOfCommonSharesAndOtherEquityInstrumentsShares_179" use="optional" order="34" />
<loc xlink:type="locator" xlink:href="roiv-20210630.xsd#roiv_RepurchaseOfCommonSharesAndOtherEquityInstrumentsValue" xlink:label="loc_roiv_RepurchaseOfCommonSharesAndOtherEquityInstrumentsValue_176" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_149" xlink:to="loc_roiv_RepurchaseOfCommonSharesAndOtherEquityInstrumentsValue_176" use="optional" order="35" />
<loc xlink:type="locator" xlink:href="roiv-20210630.xsd#roiv_RepurchaseOfEquityAwards" xlink:label="loc_roiv_RepurchaseOfEquityAwards_196" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_149" xlink:to="loc_roiv_RepurchaseOfEquityAwards_196" use="optional" order="36" />
<loc xlink:type="locator" xlink:href="roiv-20210630.xsd#roiv_SettlementOfLiabilityClassifiedInstruments" xlink:label="loc_roiv_SettlementOfLiabilityClassifiedInstruments_191" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_149" xlink:to="loc_roiv_SettlementOfLiabilityClassifiedInstruments_191" use="optional" order="37" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharesOutstanding" xlink:label="loc_us-gaap_SharesOutstanding_167" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_149" xlink:to="loc_us-gaap_SharesOutstanding_167" use="optional" order="38" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:label="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_166" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_149" xlink:to="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_166" use="optional" order="39" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_175" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_149" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_175" use="optional" order="40" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueNewIssues_174" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_149" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueNewIssues_174" use="optional" order="41" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_173" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_149" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_173" use="optional" order="42" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TemporaryEquityCarryingAmountIncludingPortionAttributableToNoncontrollingInterests" xlink:label="loc_us-gaap_TemporaryEquityCarryingAmountIncludingPortionAttributableToNoncontrollingInterests_161" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_149" xlink:to="loc_us-gaap_TemporaryEquityCarryingAmountIncludingPortionAttributableToNoncontrollingInterests_161" use="optional" order="43" />
</definitionLink>
<definitionLink xlink:type="extended" xlink:role="http://roivant.com/role/CondensedConsolidatedStatementsOfCashFlows">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaap_StatementLineItems_215" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_283" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_215" xlink:to="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_283" use="optional" order="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect_282" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_215" xlink:to="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect_282" use="optional" order="2" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:label="loc_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_207" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_215" xlink:to="loc_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_207" use="optional" order="3" />
<loc xlink:type="locator" xlink:href="roiv-20210630.xsd#roiv_DeferredOfferingAndFinancingCostsIncludedInAccountsPayableAndAccruedExpenses" xlink:label="loc_roiv_DeferredOfferingAndFinancingCostsIncludedInAccountsPayableAndAccruedExpenses_234" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_207" xlink:to="loc_roiv_DeferredOfferingAndFinancingCostsIncludedInAccountsPayableAndAccruedExpenses_234" use="optional" order="4" />
<loc xlink:type="locator" xlink:href="roiv-20210630.xsd#roiv_OperatingLeaseRightOfUseAssetsAndAmountsReclassifiedFromOtherLiabilitiesToOperatingLeaseLiabilities" xlink:label="loc_roiv_OperatingLeaseRightOfUseAssetsAndAmountsReclassifiedFromOtherLiabilitiesToOperatingLeaseLiabilities_232" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_207" xlink:to="loc_roiv_OperatingLeaseRightOfUseAssetsAndAmountsReclassifiedFromOtherLiabilitiesToOperatingLeaseLiabilities_232" use="optional" order="5" />
<loc xlink:type="locator" xlink:href="roiv-20210630.xsd#roiv_OtherNonCashTransactions" xlink:label="loc_roiv_OtherNonCashTransactions_235" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_207" xlink:to="loc_roiv_OtherNonCashTransactions_235" use="optional" order="6" />
<loc xlink:type="locator" xlink:href="roiv-20210630.xsd#roiv_IssuanceOfSubsidiaryWarrantInConnectionWithDebtFinancing" xlink:label="loc_roiv_IssuanceOfSubsidiaryWarrantInConnectionWithDebtFinancing_233" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_207" xlink:to="loc_roiv_IssuanceOfSubsidiaryWarrantInConnectionWithDebtFinancing_233" use="optional" order="7" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" xlink:label="loc_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability_231" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_207" xlink:to="loc_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability_231" use="optional" order="8" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NoncashInvestingAndFinancingItemsAbstract" xlink:label="loc_us-gaap_NoncashInvestingAndFinancingItemsAbstract_214" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_215" xlink:to="loc_us-gaap_NoncashInvestingAndFinancingItemsAbstract_214" use="optional" order="9" />
<loc xlink:type="locator" xlink:href="roiv-20210630.xsd#roiv_ConversionOfSubsidiaryConvertiblePromissoryNotesToCommonShares" xlink:label="loc_roiv_ConversionOfSubsidiaryConvertiblePromissoryNotesToCommonShares_1139676" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NoncashInvestingAndFinancingItemsAbstract_214" xlink:to="loc_roiv_ConversionOfSubsidiaryConvertiblePromissoryNotesToCommonShares_1139676" use="optional" order="10" />
<loc xlink:type="locator" xlink:href="roiv-20210630.xsd#roiv_SubscriptionReceivableRelatedToIssuanceOfSubsidiaryCommonShares" xlink:label="loc_roiv_SubscriptionReceivableRelatedToIssuanceOfSubsidiaryCommonShares_1139677" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NoncashInvestingAndFinancingItemsAbstract_214" xlink:to="loc_roiv_SubscriptionReceivableRelatedToIssuanceOfSubsidiaryCommonShares_1139677" use="optional" order="11" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_211" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_215" xlink:to="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_211" use="optional" order="12" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_264" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_211" xlink:to="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_264" use="optional" order="13" />
<loc xlink:type="locator" xlink:href="roiv-20210630.xsd#roiv_PaymentForDebtMaintenanceFeeBySubsidiary" xlink:label="loc_roiv_PaymentForDebtMaintenanceFeeBySubsidiary_261" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_211" xlink:to="loc_roiv_PaymentForDebtMaintenanceFeeBySubsidiary_261" use="optional" order="14" />
<loc xlink:type="locator" xlink:href="roiv-20210630.xsd#roiv_PaymentsForPurchaseOfSubsidiaryConvertibleAndRedeemablePreferredStock" xlink:label="loc_roiv_PaymentsForPurchaseOfSubsidiaryConvertibleAndRedeemablePreferredStock_257" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_211" xlink:to="loc_roiv_PaymentsForPurchaseOfSubsidiaryConvertibleAndRedeemablePreferredStock_257" use="optional" order="15" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsForRepurchaseOfEquity" xlink:label="loc_us-gaap_PaymentsForRepurchaseOfEquity_248" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_211" xlink:to="loc_us-gaap_PaymentsForRepurchaseOfEquity_248" use="optional" order="16" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsOfStockIssuanceCosts" xlink:label="loc_us-gaap_PaymentsOfStockIssuanceCosts_260" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_211" xlink:to="loc_us-gaap_PaymentsOfStockIssuanceCosts_260" use="optional" order="17" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfCommonStock_246" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_211" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfCommonStock_246" use="optional" order="18" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromIssuanceOfDebt" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfDebt_250" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_211" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfDebt_250" use="optional" order="19" />
<loc xlink:type="locator" xlink:href="roiv-20210630.xsd#roiv_ProceedsFromIssuanceOfEquityBySubsidiaryUponBusinessCombinationAndRecapitalization" xlink:label="loc_roiv_ProceedsFromIssuanceOfEquityBySubsidiaryUponBusinessCombinationAndRecapitalization_254" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_211" xlink:to="loc_roiv_ProceedsFromIssuanceOfEquityBySubsidiaryUponBusinessCombinationAndRecapitalization_254" use="optional" order="20" />
<loc xlink:type="locator" xlink:href="roiv-20210630.xsd#roiv_ProceedsFromIssuanceOfSubsidiaryCommonSharesNet" xlink:label="loc_roiv_ProceedsFromIssuanceOfSubsidiaryCommonSharesNet_252" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_211" xlink:to="loc_roiv_ProceedsFromIssuanceOfSubsidiaryCommonSharesNet_252" use="optional" order="21" />
<loc xlink:type="locator" xlink:href="roiv-20210630.xsd#roiv_ProceedsFromIssuanceOfSubsidiaryConvertibleAndRedeemablePreferredStockNet" xlink:label="loc_roiv_ProceedsFromIssuanceOfSubsidiaryConvertibleAndRedeemablePreferredStockNet_256" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_211" xlink:to="loc_roiv_ProceedsFromIssuanceOfSubsidiaryConvertibleAndRedeemablePreferredStockNet_256" use="optional" order="22" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromStockOptionsExercised" xlink:label="loc_us-gaap_ProceedsFromStockOptionsExercised_263" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_211" xlink:to="loc_us-gaap_ProceedsFromStockOptionsExercised_263" use="optional" order="23" />
<loc xlink:type="locator" xlink:href="roiv-20210630.xsd#roiv_ProceedsFromSubsidiaryDebtFinancingsNet" xlink:label="loc_roiv_ProceedsFromSubsidiaryDebtFinancingsNet_258" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_211" xlink:to="loc_roiv_ProceedsFromSubsidiaryDebtFinancingsNet_258" use="optional" order="24" />
<loc xlink:type="locator" xlink:href="roiv-20210630.xsd#roiv_PurchaseOfSubsidiaryCommonShares" xlink:label="loc_roiv_PurchaseOfSubsidiaryCommonShares_255" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_211" xlink:to="loc_roiv_PurchaseOfSubsidiaryCommonShares_255" use="optional" order="25" />
<loc xlink:type="locator" xlink:href="roiv-20210630.xsd#roiv_RepaymentOfLongTermDebtAndConvertibleDebtBySubsidiary" xlink:label="loc_roiv_RepaymentOfLongTermDebtAndConvertibleDebtBySubsidiary_259" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_211" xlink:to="loc_roiv_RepaymentOfLongTermDebtAndConvertibleDebtBySubsidiary_259" use="optional" order="26" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_212" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_215" xlink:to="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_212" use="optional" order="27" />
<loc xlink:type="locator" xlink:href="roiv-20210630.xsd#roiv_CashAcquiredUponConsolidationOfUnconsolidatedEntity" xlink:label="loc_roiv_CashAcquiredUponConsolidationOfUnconsolidatedEntity_268" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_212" xlink:to="loc_roiv_CashAcquiredUponConsolidationOfUnconsolidatedEntity_268" use="optional" order="28" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashDivestedFromDeconsolidation" xlink:label="loc_us-gaap_CashDivestedFromDeconsolidation_267" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_212" xlink:to="loc_us-gaap_CashDivestedFromDeconsolidation_267" use="optional" order="29" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_274" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_212" xlink:to="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_274" use="optional" order="30" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired" xlink:label="loc_us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired_272" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_212" xlink:to="loc_us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired_272" use="optional" order="31" />
<loc xlink:type="locator" xlink:href="roiv-20210630.xsd#roiv_PaymentsToAcquireInvestmentsInUnconsolidatedEntities" xlink:label="loc_roiv_PaymentsToAcquireInvestmentsInUnconsolidatedEntities_269" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_212" xlink:to="loc_roiv_PaymentsToAcquireInvestmentsInUnconsolidatedEntities_269" use="optional" order="32" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsToAcquireMarketableSecurities" xlink:label="loc_us-gaap_PaymentsToAcquireMarketableSecurities_270" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_212" xlink:to="loc_us-gaap_PaymentsToAcquireMarketableSecurities_270" use="optional" order="33" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:label="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_273" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_212" xlink:to="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_273" use="optional" order="34" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromDivestitureOfBusinesses" xlink:label="loc_us-gaap_ProceedsFromDivestitureOfBusinesses_265" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_212" xlink:to="loc_us-gaap_ProceedsFromDivestitureOfBusinesses_265" use="optional" order="35" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities" xlink:label="loc_us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities_271" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_212" xlink:to="loc_us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities_271" use="optional" order="36" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_213" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_215" xlink:to="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_213" use="optional" order="37" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_206" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_213" xlink:to="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_206" use="optional" order="38" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeLossFromEquityMethodInvestments" xlink:label="loc_us-gaap_IncomeLossFromEquityMethodInvestments_229" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_206" xlink:to="loc_us-gaap_IncomeLossFromEquityMethodInvestments_229" use="optional" order="39" />
<loc xlink:type="locator" xlink:href="roiv-20210630.xsd#roiv_GainLossOnFairValueOfDebtAndLiabilityInstruments" xlink:label="loc_roiv_GainLossOnFairValueOfDebtAndLiabilityInstruments_227" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_206" xlink:to="loc_roiv_GainLossOnFairValueOfDebtAndLiabilityInstruments_227" use="optional" order="40" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GainLossOnInvestments" xlink:label="loc_us-gaap_GainLossOnInvestments_226" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_206" xlink:to="loc_us-gaap_GainLossOnInvestments_226" use="optional" order="41" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GainLossOnSaleOfBusiness" xlink:label="loc_us-gaap_GainLossOnSaleOfBusiness_224" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_206" xlink:to="loc_us-gaap_GainLossOnSaleOfBusiness_224" use="optional" order="42" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax" xlink:label="loc_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax_220" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_206" xlink:to="loc_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax_220" use="optional" order="43" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherNoncashIncomeExpense" xlink:label="loc_us-gaap_OtherNoncashIncomeExpense_230" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_206" xlink:to="loc_us-gaap_OtherNoncashIncomeExpense_230" use="optional" order="44" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensation" xlink:label="loc_us-gaap_ShareBasedCompensation_222" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_206" xlink:to="loc_us-gaap_ShareBasedCompensation_222" use="optional" order="45" />
<loc xlink:type="locator" xlink:href="roiv-20210630.xsd#roiv_GainOnTerminationOfEquityInterestOptions" xlink:label="loc_roiv_GainOnTerminationOfEquityInterestOptions_1106544" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_206" xlink:to="loc_roiv_GainOnTerminationOfEquityInterestOptions_1106544" use="optional" order="46" />
<loc xlink:type="locator" xlink:href="roiv-20210630.xsd#roiv_GainOrLossOnDeconsolidationOfSubsidiary" xlink:label="loc_roiv_GainOrLossOnDeconsolidationOfSubsidiary_228" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_206" xlink:to="loc_roiv_GainOrLossOnDeconsolidationOfSubsidiary_228" use="optional" order="47" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ResearchAndDevelopmentInProcess" xlink:label="loc_us-gaap_ResearchAndDevelopmentInProcess_218" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_206" xlink:to="loc_us-gaap_ResearchAndDevelopmentInProcess_218" use="optional" order="48" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:label="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_209" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_213" xlink:to="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_209" use="optional" order="49" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsPayableTrade" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsPayableTrade_237" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_209" xlink:to="loc_us-gaap_IncreaseDecreaseInAccountsPayableTrade_237" use="optional" order="50" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInAccruedLiabilities" xlink:label="loc_us-gaap_IncreaseDecreaseInAccruedLiabilities_240" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_209" xlink:to="loc_us-gaap_IncreaseDecreaseInAccruedLiabilities_240" use="optional" order="51" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInDeferredLiabilities" xlink:label="loc_us-gaap_IncreaseDecreaseInDeferredLiabilities_241" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_209" xlink:to="loc_us-gaap_IncreaseDecreaseInDeferredLiabilities_241" use="optional" order="52" />
<loc xlink:type="locator" xlink:href="roiv-20210630.xsd#roiv_IncreaseDecreaseInOperatingLeaseLiabilities" xlink:label="loc_roiv_IncreaseDecreaseInOperatingLeaseLiabilities_243" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_209" xlink:to="loc_roiv_IncreaseDecreaseInOperatingLeaseLiabilities_243" use="optional" order="53" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInOtherOperatingCapitalNet" xlink:label="loc_us-gaap_IncreaseDecreaseInOtherOperatingCapitalNet_245" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_209" xlink:to="loc_us-gaap_IncreaseDecreaseInOtherOperatingCapitalNet_245" use="optional" order="54" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_276" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_213" xlink:to="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_276" use="optional" order="55" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProfitLoss" xlink:label="loc_us-gaap_ProfitLoss_275" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_213" xlink:to="loc_us-gaap_ProfitLoss_275" use="optional" order="56" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaap_StatementTable_216" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_StatementLineItems_215" xlink:to="loc_us-gaap_StatementTable_216" xbrldt:contextElement="segment" xbrldt:closed="true" use="optional" order="57" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_LegalEntityAxis" xlink:label="loc_dei_LegalEntityAxis_210" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_216" xlink:to="loc_dei_LegalEntityAxis_210" use="optional" order="58" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityDomain" xlink:label="loc_dei_EntityDomain_208" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_dei_LegalEntityAxis_210" xlink:to="loc_dei_EntityDomain_208" use="optional" order="59" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityDomain" xlink:label="loc_dei_EntityDomain_208_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_dei_LegalEntityAxis_210" xlink:to="loc_dei_EntityDomain_208_default" use="optional" order="60" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SupplementalCashFlowInformationAbstract" xlink:label="loc_us-gaap_SupplementalCashFlowInformationAbstract_217" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_215" xlink:to="loc_us-gaap_SupplementalCashFlowInformationAbstract_217" use="optional" order="61" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxesPaidNet" xlink:label="loc_us-gaap_IncomeTaxesPaidNet_285" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SupplementalCashFlowInformationAbstract_217" xlink:to="loc_us-gaap_IncomeTaxesPaidNet_285" use="optional" order="62" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InterestPaidNet" xlink:label="loc_us-gaap_InterestPaidNet_286" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SupplementalCashFlowInformationAbstract_217" xlink:to="loc_us-gaap_InterestPaidNet_286" use="optional" order="63" />
</definitionLink>
<definitionLink xlink:type="extended" xlink:role="http://roivant.com/role/SummaryOfSignificantAccountingPolicies">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaap_StatementLineItems_1574" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SignificantAccountingPoliciesTextBlock" xlink:label="loc_us-gaap_SignificantAccountingPoliciesTextBlock_1577" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_1574" xlink:to="loc_us-gaap_SignificantAccountingPoliciesTextBlock_1577" use="optional" order="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaap_StatementTable_1575" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_StatementLineItems_1574" xlink:to="loc_us-gaap_StatementTable_1575" xbrldt:contextElement="segment" xbrldt:closed="true" use="optional" order="2" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_LegalEntityAxis" xlink:label="loc_dei_LegalEntityAxis_1573" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_1575" xlink:to="loc_dei_LegalEntityAxis_1573" use="optional" order="3" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityDomain" xlink:label="loc_dei_EntityDomain_1572" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_dei_LegalEntityAxis_1573" xlink:to="loc_dei_EntityDomain_1572" use="optional" order="4" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityDomain" xlink:label="loc_dei_EntityDomain_1572_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_dei_LegalEntityAxis_1573" xlink:to="loc_dei_EntityDomain_1572_default" use="optional" order="5" />
</definitionLink>
<definitionLink xlink:type="extended" xlink:role="http://roivant.com/role/ShareholdersEquityAndRedeemableNoncontrollingInterest">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaap_StatementLineItems_1622" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaap_StatementTable_1623" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_StatementLineItems_1622" xlink:to="loc_us-gaap_StatementTable_1623" xbrldt:contextElement="segment" xbrldt:closed="true" use="optional" order="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_LegalEntityAxis" xlink:label="loc_dei_LegalEntityAxis_1621" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_1623" xlink:to="loc_dei_LegalEntityAxis_1621" use="optional" order="2" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityDomain" xlink:label="loc_dei_EntityDomain_1620" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_dei_LegalEntityAxis_1621" xlink:to="loc_dei_EntityDomain_1620" use="optional" order="3" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityDomain" xlink:label="loc_dei_EntityDomain_1620_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_dei_LegalEntityAxis_1621" xlink:to="loc_dei_EntityDomain_1620_default" use="optional" order="4" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:label="loc_us-gaap_StockholdersEquityNoteDisclosureTextBlock_1625" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_1622" xlink:to="loc_us-gaap_StockholdersEquityNoteDisclosureTextBlock_1625" use="optional" order="5" />
</definitionLink>
<definitionLink xlink:type="extended" xlink:role="http://roivant.com/role/RelatedPartyTransactions">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaap_StatementLineItems_1598" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RelatedPartyTransactionsDisclosureTextBlock" xlink:label="loc_us-gaap_RelatedPartyTransactionsDisclosureTextBlock_1601" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_1598" xlink:to="loc_us-gaap_RelatedPartyTransactionsDisclosureTextBlock_1601" use="optional" order="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaap_StatementTable_1599" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_StatementLineItems_1598" xlink:to="loc_us-gaap_StatementTable_1599" xbrldt:contextElement="segment" xbrldt:closed="true" use="optional" order="2" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_LegalEntityAxis" xlink:label="loc_dei_LegalEntityAxis_1597" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_1599" xlink:to="loc_dei_LegalEntityAxis_1597" use="optional" order="3" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityDomain" xlink:label="loc_dei_EntityDomain_1596" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_dei_LegalEntityAxis_1597" xlink:to="loc_dei_EntityDomain_1596" use="optional" order="4" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityDomain" xlink:label="loc_dei_EntityDomain_1596_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_dei_LegalEntityAxis_1597" xlink:to="loc_dei_EntityDomain_1596_default" use="optional" order="5" />
</definitionLink>
<definitionLink xlink:type="extended" xlink:role="http://roivant.com/role/IncomeTaxes">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaap_StatementLineItems_1648" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaap_StatementTable_1649" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_StatementLineItems_1648" xlink:to="loc_us-gaap_StatementTable_1649" xbrldt:contextElement="segment" xbrldt:closed="true" use="optional" order="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_LegalEntityAxis" xlink:label="loc_dei_LegalEntityAxis_1647" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_1649" xlink:to="loc_dei_LegalEntityAxis_1647" use="optional" order="2" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityDomain" xlink:label="loc_dei_EntityDomain_1646" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_dei_LegalEntityAxis_1647" xlink:to="loc_dei_EntityDomain_1646" use="optional" order="3" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityDomain" xlink:label="loc_dei_EntityDomain_1646_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_dei_LegalEntityAxis_1647" xlink:to="loc_dei_EntityDomain_1646_default" use="optional" order="4" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxDisclosureTextBlock" xlink:label="loc_us-gaap_IncomeTaxDisclosureTextBlock_1651" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_1648" xlink:to="loc_us-gaap_IncomeTaxDisclosureTextBlock_1651" use="optional" order="5" />
</definitionLink>
<definitionLink xlink:type="extended" xlink:role="http://roivant.com/role/CommitmentsContingencies">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaap_StatementLineItems_1606" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaap_StatementTable_1607" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_StatementLineItems_1606" xlink:to="loc_us-gaap_StatementTable_1607" xbrldt:contextElement="segment" xbrldt:closed="true" use="optional" order="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_LegalEntityAxis" xlink:label="loc_dei_LegalEntityAxis_1605" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_1607" xlink:to="loc_dei_LegalEntityAxis_1605" use="optional" order="2" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityDomain" xlink:label="loc_dei_EntityDomain_1604" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_dei_LegalEntityAxis_1605" xlink:to="loc_dei_EntityDomain_1604" use="optional" order="3" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityDomain" xlink:label="loc_dei_EntityDomain_1604_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_dei_LegalEntityAxis_1605" xlink:to="loc_dei_EntityDomain_1604_default" use="optional" order="4" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_1609" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_1606" xlink:to="loc_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_1609" use="optional" order="5" />
</definitionLink>
<definitionLink xlink:type="extended" xlink:role="http://roivant.com/role/FairValueMeasurements">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaap_StatementLineItems_1630" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueDisclosuresTextBlock" xlink:label="loc_us-gaap_FairValueDisclosuresTextBlock_1633" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_1630" xlink:to="loc_us-gaap_FairValueDisclosuresTextBlock_1633" use="optional" order="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaap_StatementTable_1631" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_StatementLineItems_1630" xlink:to="loc_us-gaap_StatementTable_1631" xbrldt:contextElement="segment" xbrldt:closed="true" use="optional" order="2" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_LegalEntityAxis" xlink:label="loc_dei_LegalEntityAxis_1629" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_1631" xlink:to="loc_dei_LegalEntityAxis_1629" use="optional" order="3" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityDomain" xlink:label="loc_dei_EntityDomain_1628" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_dei_LegalEntityAxis_1629" xlink:to="loc_dei_EntityDomain_1628" use="optional" order="4" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityDomain" xlink:label="loc_dei_EntityDomain_1628_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_dei_LegalEntityAxis_1629" xlink:to="loc_dei_EntityDomain_1628_default" use="optional" order="5" />
</definitionLink>
<definitionLink xlink:type="extended" xlink:role="http://roivant.com/role/SubsequentEvents">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaap_StatementLineItems_1667" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventsTextBlock" xlink:label="loc_us-gaap_SubsequentEventsTextBlock_1670" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_1667" xlink:to="loc_us-gaap_SubsequentEventsTextBlock_1670" use="optional" order="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaap_StatementTable_1668" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_StatementLineItems_1667" xlink:to="loc_us-gaap_StatementTable_1668" xbrldt:contextElement="segment" xbrldt:closed="true" use="optional" order="2" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_LegalEntityAxis" xlink:label="loc_dei_LegalEntityAxis_1666" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_1668" xlink:to="loc_dei_LegalEntityAxis_1666" use="optional" order="3" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityDomain" xlink:label="loc_dei_EntityDomain_1665" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_dei_LegalEntityAxis_1666" xlink:to="loc_dei_EntityDomain_1665" use="optional" order="4" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityDomain" xlink:label="loc_dei_EntityDomain_1665_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_dei_LegalEntityAxis_1666" xlink:to="loc_dei_EntityDomain_1665_default" use="optional" order="5" />
</definitionLink>
<definitionLink xlink:type="extended" xlink:role="http://roivant.com/role/SummaryOfSignificantAccountingPoliciesPolicies">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaap_StatementLineItems_1526" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommitmentsAndContingenciesPolicyTextBlock" xlink:label="loc_us-gaap_CommitmentsAndContingenciesPolicyTextBlock_1544" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_1526" xlink:to="loc_us-gaap_CommitmentsAndContingenciesPolicyTextBlock_1544" use="optional" order="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy" xlink:label="loc_us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy_1542" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_1526" xlink:to="loc_us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy_1542" use="optional" order="2" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:label="loc_us-gaap_BasisOfAccountingPolicyPolicyTextBlock_1529" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_1526" xlink:to="loc_us-gaap_BasisOfAccountingPolicyPolicyTextBlock_1529" use="optional" order="3" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConcentrationRiskCreditRisk" xlink:label="loc_us-gaap_ConcentrationRiskCreditRisk_1533" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_1526" xlink:to="loc_us-gaap_ConcentrationRiskCreditRisk_1533" use="optional" order="4" />
<loc xlink:type="locator" xlink:href="roiv-20210630.xsd#roiv_NewAccountingPronouncementsNotYetAdoptedPolicyTextBlock" xlink:label="loc_roiv_NewAccountingPronouncementsNotYetAdoptedPolicyTextBlock_1553" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_1526" xlink:to="loc_roiv_NewAccountingPronouncementsNotYetAdoptedPolicyTextBlock_1553" use="optional" order="5" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:label="loc_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_1540" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_1526" xlink:to="loc_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_1540" use="optional" order="6" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock_1545" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_1526" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock_1545" use="optional" order="7" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpensePolicy_1547" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_1526" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpensePolicy_1547" use="optional" order="8" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevenueFromContractWithCustomerPolicyTextBlock" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock_1552" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_1526" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock_1552" use="optional" order="9" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:label="loc_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy_1549" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_1526" xlink:to="loc_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy_1549" use="optional" order="10" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaap_StatementTable_1527" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_StatementLineItems_1526" xlink:to="loc_us-gaap_StatementTable_1527" xbrldt:contextElement="segment" xbrldt:closed="true" use="optional" order="11" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_LegalEntityAxis" xlink:label="loc_dei_LegalEntityAxis_1525" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_1527" xlink:to="loc_dei_LegalEntityAxis_1525" use="optional" order="12" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityDomain" xlink:label="loc_dei_EntityDomain_1524" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_dei_LegalEntityAxis_1525" xlink:to="loc_dei_EntityDomain_1524" use="optional" order="13" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityDomain" xlink:label="loc_dei_EntityDomain_1524_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_dei_LegalEntityAxis_1525" xlink:to="loc_dei_EntityDomain_1524_default" use="optional" order="14" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TradeAndOtherAccountsReceivablePolicy" xlink:label="loc_us-gaap_TradeAndOtherAccountsReceivablePolicy_1543" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_1526" xlink:to="loc_us-gaap_TradeAndOtherAccountsReceivablePolicy_1543" use="optional" order="15" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_UnusualRisksAndUncertaintiesTextBlock" xlink:label="loc_us-gaap_UnusualRisksAndUncertaintiesTextBlock_1541" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_1526" xlink:to="loc_us-gaap_UnusualRisksAndUncertaintiesTextBlock_1541" use="optional" order="16" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_UseOfEstimates" xlink:label="loc_us-gaap_UseOfEstimates_1531" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_1526" xlink:to="loc_us-gaap_UseOfEstimates_1531" use="optional" order="17" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementPolicyPolicyTextBlock" xlink:label="loc_us-gaap_FairValueMeasurementPolicyPolicyTextBlock_1550" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_1526" xlink:to="loc_us-gaap_FairValueMeasurementPolicyPolicyTextBlock_1550" use="optional" order="18" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock" xlink:label="loc_us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock_1551" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_1526" xlink:to="loc_us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock_1551" use="optional" order="19" />
<loc xlink:type="locator" xlink:href="roiv-20210630.xsd#roiv_GeneralAndAdministrativeExpensesPolicyTextBlock" xlink:label="loc_roiv_GeneralAndAdministrativeExpensesPolicyTextBlock_1548" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_1526" xlink:to="loc_roiv_GeneralAndAdministrativeExpensesPolicyTextBlock_1548" use="optional" order="20" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxPolicyTextBlock" xlink:label="loc_us-gaap_IncomeTaxPolicyTextBlock_1538" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_1526" xlink:to="loc_us-gaap_IncomeTaxPolicyTextBlock_1538" use="optional" order="21" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InvestmentPolicyTextBlock" xlink:label="loc_us-gaap_InvestmentPolicyTextBlock_1546" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_1526" xlink:to="loc_us-gaap_InvestmentPolicyTextBlock_1546" use="optional" order="22" />
</definitionLink>
<definitionLink xlink:type="extended" xlink:role="http://roivant.com/role/ShareBasedCompensationTables">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaap_StatementLineItems_1727" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_1733" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_1727" xlink:to="loc_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_1733" use="optional" order="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaap_StatementTable_1728" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_StatementLineItems_1727" xlink:to="loc_us-gaap_StatementTable_1728" xbrldt:contextElement="segment" xbrldt:closed="true" use="optional" order="2" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AwardTypeAxis" xlink:label="loc_us-gaap_AwardTypeAxis_1725" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_1728" xlink:to="loc_us-gaap_AwardTypeAxis_1725" use="optional" order="3" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_1726" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AwardTypeAxis_1725" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_1726" use="optional" order="4" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_1726_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AwardTypeAxis_1725" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_1726_default" use="optional" order="5" />
<loc xlink:type="locator" xlink:href="roiv-20210630.xsd#roiv_CappedValueAppreciationRightsMember" xlink:label="loc_roiv_CappedValueAppreciationRightsMember_1730" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_1726" xlink:to="loc_roiv_CappedValueAppreciationRightsMember_1730" use="optional" order="6" />
<loc xlink:type="locator" xlink:href="roiv-20210630.xsd#roiv_CommonStockAwardsMember" xlink:label="loc_roiv_CommonStockAwardsMember_1732" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_1726" xlink:to="loc_roiv_CommonStockAwardsMember_1732" use="optional" order="7" />
<loc xlink:type="locator" xlink:href="roiv-20210630.xsd#roiv_PerformanceOptionsMember" xlink:label="loc_roiv_PerformanceOptionsMember_1729" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_1726" xlink:to="loc_roiv_PerformanceOptionsMember_1729" use="optional" order="8" />
<loc xlink:type="locator" xlink:href="roiv-20210630.xsd#roiv_PerformanceRestrictedStockUnitsMember" xlink:label="loc_roiv_PerformanceRestrictedStockUnitsMember_1731" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_1726" xlink:to="loc_roiv_PerformanceRestrictedStockUnitsMember_1731" use="optional" order="9" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock_1737" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_1727" xlink:to="loc_us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock_1737" use="optional" order="10" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock_1736" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_1727" xlink:to="loc_us-gaap_ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock_1736" use="optional" order="11" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_1734" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_1727" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_1734" use="optional" order="12" />
<loc xlink:type="locator" xlink:href="roiv-20210630.xsd#roiv_ScheduleOfSharebasedPaymentArrangementFairValueOfVestedStockOptionTableTextBlock" xlink:label="loc_roiv_ScheduleOfSharebasedPaymentArrangementFairValueOfVestedStockOptionTableTextBlock_1735" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_1727" xlink:to="loc_roiv_ScheduleOfSharebasedPaymentArrangementFairValueOfVestedStockOptionTableTextBlock_1735" use="optional" order="13" />
</definitionLink>
<definitionLink xlink:type="extended" xlink:role="http://roivant.com/role/IncomeTaxesTables">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaap_StatementLineItems_1656" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaap_StatementTable_1657" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_StatementLineItems_1656" xlink:to="loc_us-gaap_StatementTable_1657" xbrldt:contextElement="segment" xbrldt:closed="true" use="optional" order="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_LegalEntityAxis" xlink:label="loc_dei_LegalEntityAxis_1655" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_1657" xlink:to="loc_dei_LegalEntityAxis_1655" use="optional" order="2" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityDomain" xlink:label="loc_dei_EntityDomain_1654" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_dei_LegalEntityAxis_1655" xlink:to="loc_dei_EntityDomain_1654" use="optional" order="3" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityDomain" xlink:label="loc_dei_EntityDomain_1654_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_dei_LegalEntityAxis_1655" xlink:to="loc_dei_EntityDomain_1654_default" use="optional" order="4" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_1660" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_1656" xlink:to="loc_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_1660" use="optional" order="5" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_1661" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_1656" xlink:to="loc_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_1661" use="optional" order="6" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock_1662" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_1656" xlink:to="loc_us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock_1662" use="optional" order="7" />
</definitionLink>
<definitionLink xlink:type="extended" xlink:role="http://roivant.com/role/FairValueMeasurementsTables">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaap_StatementLineItems_1638" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock_1642" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_1638" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock_1642" use="optional" order="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock" xlink:label="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock_1643" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_1638" xlink:to="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock_1643" use="optional" order="2" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock_1641" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_1638" xlink:to="loc_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock_1641" use="optional" order="3" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaap_StatementTable_1639" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_StatementLineItems_1638" xlink:to="loc_us-gaap_StatementTable_1639" xbrldt:contextElement="segment" xbrldt:closed="true" use="optional" order="4" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_LegalEntityAxis" xlink:label="loc_dei_LegalEntityAxis_1637" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_1639" xlink:to="loc_dei_LegalEntityAxis_1637" use="optional" order="5" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityDomain" xlink:label="loc_dei_EntityDomain_1636" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_dei_LegalEntityAxis_1637" xlink:to="loc_dei_EntityDomain_1636" use="optional" order="6" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityDomain" xlink:label="loc_dei_EntityDomain_1636_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_dei_LegalEntityAxis_1637" xlink:to="loc_dei_EntityDomain_1636_default" use="optional" order="7" />
</definitionLink>
<definitionLink xlink:type="extended" xlink:role="http://roivant.com/role/NetLossPerCommonShareTables">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaap_StatementLineItems_1582" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_1585" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_1582" xlink:to="loc_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_1585" use="optional" order="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaap_StatementTable_1583" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_StatementLineItems_1582" xlink:to="loc_us-gaap_StatementTable_1583" xbrldt:contextElement="segment" xbrldt:closed="true" use="optional" order="2" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_LegalEntityAxis" xlink:label="loc_dei_LegalEntityAxis_1581" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_1583" xlink:to="loc_dei_LegalEntityAxis_1581" use="optional" order="3" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityDomain" xlink:label="loc_dei_EntityDomain_1580" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_dei_LegalEntityAxis_1581" xlink:to="loc_dei_EntityDomain_1580" use="optional" order="4" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityDomain" xlink:label="loc_dei_EntityDomain_1580_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_dei_LegalEntityAxis_1581" xlink:to="loc_dei_EntityDomain_1580_default" use="optional" order="5" />
</definitionLink>
<definitionLink xlink:type="extended" xlink:role="http://roivant.com/role/SummaryOfSignificantAccountingPoliciesAdditionalInformationDetail">
<loc xlink:type="locator" xlink:href="roiv-20210630.xsd#roiv_ScheduleOfAccountingPoliciesLineItems" xlink:label="loc_roiv_ScheduleOfAccountingPoliciesLineItems_453" />
<loc xlink:type="locator" xlink:href="roiv-20210630.xsd#roiv_ProceedsFromReleaseOfEscrowDeposit" xlink:label="loc_roiv_ProceedsFromReleaseOfEscrowDeposit_1105109" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_roiv_ScheduleOfAccountingPoliciesLineItems_453" xlink:to="loc_roiv_ProceedsFromReleaseOfEscrowDeposit_1105109" use="optional" order="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EscrowDeposit" xlink:label="loc_us-gaap_EscrowDeposit_1097060" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_roiv_ScheduleOfAccountingPoliciesLineItems_453" xlink:to="loc_us-gaap_EscrowDeposit_1097060" use="optional" order="2" />
<loc xlink:type="locator" xlink:href="roiv-20210630.xsd#roiv_ScheduleOfAccountingPoliciesTable" xlink:label="loc_roiv_ScheduleOfAccountingPoliciesTable_454" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_roiv_ScheduleOfAccountingPoliciesLineItems_453" xlink:to="loc_roiv_ScheduleOfAccountingPoliciesTable_454" xbrldt:contextElement="segment" xbrldt:closed="true" use="optional" order="3" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_LegalEntityAxis" xlink:label="loc_dei_LegalEntityAxis_451" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_roiv_ScheduleOfAccountingPoliciesTable_454" xlink:to="loc_dei_LegalEntityAxis_451" use="optional" order="4" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityDomain" xlink:label="loc_dei_EntityDomain_450" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_dei_LegalEntityAxis_451" xlink:to="loc_dei_EntityDomain_450" use="optional" order="5" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityDomain" xlink:label="loc_dei_EntityDomain_450_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_dei_LegalEntityAxis_451" xlink:to="loc_dei_EntityDomain_450_default" use="optional" order="6" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="loc_us-gaap_StatementClassOfStockAxis_455" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_roiv_ScheduleOfAccountingPoliciesTable_454" xlink:to="loc_us-gaap_StatementClassOfStockAxis_455" use="optional" order="7" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaap_ClassOfStockDomain_449" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementClassOfStockAxis_455" xlink:to="loc_us-gaap_ClassOfStockDomain_449" use="optional" order="8" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaap_ClassOfStockDomain_449_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementClassOfStockAxis_455" xlink:to="loc_us-gaap_ClassOfStockDomain_449_default" use="optional" order="9" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="loc_us-gaap_SubsidiarySaleOfStockAxis_456" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_roiv_ScheduleOfAccountingPoliciesTable_454" xlink:to="loc_us-gaap_SubsidiarySaleOfStockAxis_456" use="optional" order="10" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain_452" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis_456" xlink:to="loc_us-gaap_SaleOfStockNameOfTransactionDomain_452" use="optional" order="11" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain_452_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis_456" xlink:to="loc_us-gaap_SaleOfStockNameOfTransactionDomain_452_default" use="optional" order="12" />
</definitionLink>
<definitionLink xlink:type="extended" xlink:role="http://roivant.com/role/SummaryOfSignificantAccountingPoliciesScheduleOfEstimatedUsefulLivesDetail">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentLineItems" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentLineItems_904" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentEstimatedUsefulLives" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentEstimatedUsefulLives_908" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_904" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentEstimatedUsefulLives_908" use="optional" order="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentUsefulLife_907" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_904" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentUsefulLife_907" use="optional" order="2" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:label="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_906" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_904" xlink:to="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_906" xbrldt:contextElement="segment" xbrldt:closed="true" use="optional" order="3" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_903" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_906" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_903" use="optional" order="4" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_905" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_903" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_905" use="optional" order="5" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_905_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_903" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_905_default" use="optional" order="6" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FurnitureAndFixturesMember" xlink:label="loc_us-gaap_FurnitureAndFixturesMember_911" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_905" xlink:to="loc_us-gaap_FurnitureAndFixturesMember_911" use="optional" order="7" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LeaseholdImprovementsMember" xlink:label="loc_us-gaap_LeaseholdImprovementsMember_913" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_905" xlink:to="loc_us-gaap_LeaseholdImprovementsMember_913" use="optional" order="8" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SoftwareDevelopmentMember" xlink:label="loc_us-gaap_SoftwareDevelopmentMember_912" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_905" xlink:to="loc_us-gaap_SoftwareDevelopmentMember_912" use="optional" order="9" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ComputerEquipmentMember" xlink:label="loc_us-gaap_ComputerEquipmentMember_909" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_905" xlink:to="loc_us-gaap_ComputerEquipmentMember_909" use="optional" order="10" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquipmentMember" xlink:label="loc_us-gaap_EquipmentMember_910" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_905" xlink:to="loc_us-gaap_EquipmentMember_910" use="optional" order="11" />
</definitionLink>
<definitionLink xlink:type="extended" xlink:role="http://roivant.com/role/InvestmentsAdditionalInformationDetail">
<loc xlink:type="locator" xlink:href="roiv-20210630.xsd#roiv_InvestmentsLineItems" xlink:label="loc_roiv_InvestmentsLineItems_918" />
<loc xlink:type="locator" xlink:href="roiv-20210630.xsd#roiv_AnnualCompoundedConversionRateForPreferredShare" xlink:label="loc_roiv_AnnualCompoundedConversionRateForPreferredShare_931" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_roiv_InvestmentsLineItems_918" xlink:to="loc_roiv_AnnualCompoundedConversionRateForPreferredShare_931" use="optional" order="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion" xlink:label="loc_us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion_944" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_roiv_InvestmentsLineItems_918" xlink:to="loc_us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion_944" use="optional" order="2" />
<loc xlink:type="locator" xlink:href="roiv-20210630.xsd#roiv_CommonStockOwnedBalanceSharesOfArbutus" xlink:label="loc_roiv_CommonStockOwnedBalanceSharesOfArbutus_928" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_roiv_InvestmentsLineItems_918" xlink:to="loc_roiv_CommonStockOwnedBalanceSharesOfArbutus_928" use="optional" order="3" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_UnrealizedGainLossOnInvestments" xlink:label="loc_us-gaap_UnrealizedGainLossOnInvestments_937" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_roiv_InvestmentsLineItems_918" xlink:to="loc_us-gaap_UnrealizedGainLossOnInvestments_937" use="optional" order="4" />
<loc xlink:type="locator" xlink:href="roiv-20210630.xsd#roiv_InvestmentsTable" xlink:label="loc_roiv_InvestmentsTable_919" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_roiv_InvestmentsLineItems_918" xlink:to="loc_roiv_InvestmentsTable_919" xbrldt:contextElement="segment" xbrldt:closed="true" use="optional" order="5" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="loc_us-gaap_StatementClassOfStockAxis_923" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_roiv_InvestmentsTable_919" xlink:to="loc_us-gaap_StatementClassOfStockAxis_923" use="optional" order="6" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaap_ClassOfStockDomain_916" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementClassOfStockAxis_923" xlink:to="loc_us-gaap_ClassOfStockDomain_916" use="optional" order="7" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaap_ClassOfStockDomain_916_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementClassOfStockAxis_923" xlink:to="loc_us-gaap_ClassOfStockDomain_916_default" use="optional" order="8" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SeriesBPreferredStockMember" xlink:label="loc_us-gaap_SeriesBPreferredStockMember_924" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockDomain_916" xlink:to="loc_us-gaap_SeriesBPreferredStockMember_924" use="optional" order="9" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InvestmentTypeAxis" xlink:label="loc_us-gaap_InvestmentTypeAxis_920" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_roiv_InvestmentsTable_919" xlink:to="loc_us-gaap_InvestmentTypeAxis_920" use="optional" order="10" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InvestmentTypeCategorizationMember" xlink:label="loc_us-gaap_InvestmentTypeCategorizationMember_921" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_InvestmentTypeAxis_920" xlink:to="loc_us-gaap_InvestmentTypeCategorizationMember_921" use="optional" order="11" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InvestmentTypeCategorizationMember" xlink:label="loc_us-gaap_InvestmentTypeCategorizationMember_921_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_InvestmentTypeAxis_920" xlink:to="loc_us-gaap_InvestmentTypeCategorizationMember_921_default" use="optional" order="12" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherInvestmentCompaniesMember" xlink:label="loc_us-gaap_OtherInvestmentCompaniesMember_946" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_InvestmentTypeCategorizationMember_921" xlink:to="loc_us-gaap_OtherInvestmentCompaniesMember_946" use="optional" order="13" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_LegalEntityAxis" xlink:label="loc_dei_LegalEntityAxis_922" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_roiv_InvestmentsTable_919" xlink:to="loc_dei_LegalEntityAxis_922" use="optional" order="14" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityDomain" xlink:label="loc_dei_EntityDomain_917" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_dei_LegalEntityAxis_922" xlink:to="loc_dei_EntityDomain_917" use="optional" order="15" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityDomain" xlink:label="loc_dei_EntityDomain_917_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_dei_LegalEntityAxis_922" xlink:to="loc_dei_EntityDomain_917_default" use="optional" order="16" />
<loc xlink:type="locator" xlink:href="roiv-20210630.xsd#roiv_ArbutusBiopharmaCorporationMember" xlink:label="loc_roiv_ArbutusBiopharmaCorporationMember_925" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityDomain_917" xlink:to="loc_roiv_ArbutusBiopharmaCorporationMember_925" use="optional" order="17" />
<loc xlink:type="locator" xlink:href="roiv-20210630.xsd#roiv_DatavantHoldingsIncMember" xlink:label="loc_roiv_DatavantHoldingsIncMember_927" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityDomain_917" xlink:to="loc_roiv_DatavantHoldingsIncMember_927" use="optional" order="18" />
<loc xlink:type="locator" xlink:href="roiv-20210630.xsd#roiv_SioGeneTherapiesIncMember" xlink:label="loc_roiv_SioGeneTherapiesIncMember_926" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityDomain_917" xlink:to="loc_roiv_SioGeneTherapiesIncMember_926" use="optional" order="19" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeconsolidationGainOrLossAmount" xlink:label="loc_us-gaap_DeconsolidationGainOrLossAmount_939" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_roiv_InvestmentsLineItems_918" xlink:to="loc_us-gaap_DeconsolidationGainOrLossAmount_939" use="optional" order="20" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InvestmentsFairValueDisclosure" xlink:label="loc_us-gaap_InvestmentsFairValueDisclosure_936" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_roiv_InvestmentsLineItems_918" xlink:to="loc_us-gaap_InvestmentsFairValueDisclosure_936" use="optional" order="21" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongTermInvestments" xlink:label="loc_us-gaap_LongTermInvestments_945" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_roiv_InvestmentsLineItems_918" xlink:to="loc_us-gaap_LongTermInvestments_945" use="optional" order="22" />
<loc xlink:type="locator" xlink:href="roiv-20210630.xsd#roiv_MaximumAllowedOwnershipInterestPercentage" xlink:label="loc_roiv_MaximumAllowedOwnershipInterestPercentage_935" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_roiv_InvestmentsLineItems_918" xlink:to="loc_roiv_MaximumAllowedOwnershipInterestPercentage_935" use="optional" order="23" />
<loc xlink:type="locator" xlink:href="roiv-20210630.xsd#roiv_ClosingPricePerShare" xlink:label="loc_roiv_ClosingPricePerShare_1105114" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_roiv_InvestmentsLineItems_918" xlink:to="loc_roiv_ClosingPricePerShare_1105114" use="optional" order="24" />
<loc xlink:type="locator" xlink:href="roiv-20210630.xsd#roiv_ProceedsFromIssuanceOfPreferredStockAndPreferenceStocks" xlink:label="loc_roiv_ProceedsFromIssuanceOfPreferredStockAndPreferenceStocks_1105116" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_roiv_InvestmentsLineItems_918" xlink:to="loc_roiv_ProceedsFromIssuanceOfPreferredStockAndPreferenceStocks_1105116" use="optional" order="25" />
<loc xlink:type="locator" xlink:href="roiv-20210630.xsd#roiv_PreferredStockSharesIssuedAndSoldToCompanyDuringPeriodShares" xlink:label="loc_roiv_PreferredStockSharesIssuedAndSoldToCompanyDuringPeriodShares_1105117" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_roiv_InvestmentsLineItems_918" xlink:to="loc_roiv_PreferredStockSharesIssuedAndSoldToCompanyDuringPeriodShares_1105117" use="optional" order="26" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityMethodInvestmentOwnershipPercentage" xlink:label="loc_us-gaap_EquityMethodInvestmentOwnershipPercentage_1105159" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_roiv_InvestmentsLineItems_918" xlink:to="loc_us-gaap_EquityMethodInvestmentOwnershipPercentage_1105159" use="optional" order="27" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockSharesOutstanding" xlink:label="loc_us-gaap_CommonStockSharesOutstanding_1139348" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_roiv_InvestmentsLineItems_918" xlink:to="loc_us-gaap_CommonStockSharesOutstanding_1139348" use="optional" order="28" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PreferredStockSharesOutstanding" xlink:label="loc_us-gaap_PreferredStockSharesOutstanding_1139351" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_roiv_InvestmentsLineItems_918" xlink:to="loc_us-gaap_PreferredStockSharesOutstanding_1139351" use="optional" order="29" />
<loc xlink:type="locator" xlink:href="roiv-20210630.xsd#roiv_ConversionPrice" xlink:label="loc_roiv_ConversionPrice_932" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_roiv_InvestmentsLineItems_918" xlink:to="loc_roiv_ConversionPrice_932" use="optional" order="30" />
<loc xlink:type="locator" xlink:href="roiv-20210630.xsd#roiv_OwnershipInterestPercentage" xlink:label="loc_roiv_OwnershipInterestPercentage_934" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_roiv_InvestmentsLineItems_918" xlink:to="loc_roiv_OwnershipInterestPercentage_934" use="optional" order="31" />
<loc xlink:type="locator" xlink:href="roiv-20210630.xsd#roiv_PreferredStockPurchased" xlink:label="loc_roiv_PreferredStockPurchased_943" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_roiv_InvestmentsLineItems_918" xlink:to="loc_roiv_PreferredStockPurchased_943" use="optional" order="32" />
<loc xlink:type="locator" xlink:href="roiv-20210630.xsd#roiv_PreferredStockOwnedBalanceSharesOfArbutus" xlink:label="loc_roiv_PreferredStockOwnedBalanceSharesOfArbutus_929" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_roiv_InvestmentsLineItems_918" xlink:to="loc_roiv_PreferredStockOwnedBalanceSharesOfArbutus_929" use="optional" order="33" />
<loc xlink:type="locator" xlink:href="roiv-20210630.xsd#roiv_PremiumOnConversionPricePercentage" xlink:label="loc_roiv_PremiumOnConversionPricePercentage_930" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_roiv_InvestmentsLineItems_918" xlink:to="loc_roiv_PremiumOnConversionPricePercentage_930" use="optional" order="34" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharePrice" xlink:label="loc_us-gaap_SharePrice_938" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_roiv_InvestmentsLineItems_918" xlink:to="loc_us-gaap_SharePrice_938" use="optional" order="35" />
</definitionLink>
<definitionLink xlink:type="extended" xlink:role="http://roivant.com/role/AssetAcquisitionsAndLicenseAgreementsAdditionalInformationDetail">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessAcquisitionLineItems" xlink:label="loc_us-gaap_BusinessAcquisitionLineItems_951" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessAcquisitionEquityInterestIssuedOrIssuableValueAssigned" xlink:label="loc_us-gaap_BusinessAcquisitionEquityInterestIssuedOrIssuableValueAssigned_997" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_951" xlink:to="loc_us-gaap_BusinessAcquisitionEquityInterestIssuedOrIssuableValueAssigned_997" use="optional" order="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtConversionOriginalDebtAmount1" xlink:label="loc_us-gaap_DebtConversionOriginalDebtAmount1_976" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_951" xlink:to="loc_us-gaap_DebtConversionOriginalDebtAmount1_976" use="optional" order="2" />
<loc xlink:type="locator" xlink:href="roiv-20210630.xsd#roiv_FutureDevelopmentAndCommercialMilestonePayments" xlink:label="loc_roiv_FutureDevelopmentAndCommercialMilestonePayments_966" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_951" xlink:to="loc_roiv_FutureDevelopmentAndCommercialMilestonePayments_966" use="optional" order="3" />
<loc xlink:type="locator" xlink:href="roiv-20210630.xsd#roiv_BusinessCollaborationContingentMilestonePayment" xlink:label="loc_roiv_BusinessCollaborationContingentMilestonePayment_965" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_951" xlink:to="loc_roiv_BusinessCollaborationContingentMilestonePayment_965" use="optional" order="4" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationConsiderationTransferred1" xlink:label="loc_us-gaap_BusinessCombinationConsiderationTransferred1_983" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_951" xlink:to="loc_us-gaap_BusinessCombinationConsiderationTransferred1_983" use="optional" order="5" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationConsiderationTransferredLiabilitiesIncurred" xlink:label="loc_us-gaap_BusinessCombinationConsiderationTransferredLiabilitiesIncurred_993" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_951" xlink:to="loc_us-gaap_BusinessCombinationConsiderationTransferredLiabilitiesIncurred_993" use="optional" order="6" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationContingentConsiderationLiability" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationLiability_988" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_951" xlink:to="loc_us-gaap_BusinessCombinationContingentConsiderationLiability_988" use="optional" order="7" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccountsPayable" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccountsPayable_998" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_951" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccountsPayable_998" use="optional" order="8" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet_996" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_951" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet_996" use="optional" order="9" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtConversionConvertedInstrumentSharesIssued1" xlink:label="loc_us-gaap_DebtConversionConvertedInstrumentSharesIssued1_977" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_951" xlink:to="loc_us-gaap_DebtConversionConvertedInstrumentSharesIssued1_977" use="optional" order="10" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued" xlink:label="loc_us-gaap_BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued_994" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_951" xlink:to="loc_us-gaap_BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued_994" use="optional" order="11" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GainLossOnInvestments" xlink:label="loc_us-gaap_GainLossOnInvestments_980" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_951" xlink:to="loc_us-gaap_GainLossOnInvestments_980" use="optional" order="12" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsToAcquireEquityMethodInvestments" xlink:label="loc_us-gaap_PaymentsToAcquireEquityMethodInvestments_972" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_951" xlink:to="loc_us-gaap_PaymentsToAcquireEquityMethodInvestments_972" use="optional" order="13" />
<loc xlink:type="locator" xlink:href="roiv-20210630.xsd#roiv_FairValueOfRestrictedStock" xlink:label="loc_roiv_FairValueOfRestrictedStock_1001" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_951" xlink:to="loc_roiv_FairValueOfRestrictedStock_1001" use="optional" order="14" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityMethodInvestmentsFairValueDisclosure" xlink:label="loc_us-gaap_EquityMethodInvestmentsFairValueDisclosure_981" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_951" xlink:to="loc_us-gaap_EquityMethodInvestmentsFairValueDisclosure_981" use="optional" order="15" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityMethodInvestmentUnderlyingEquityInNetAssets" xlink:label="loc_us-gaap_EquityMethodInvestmentUnderlyingEquityInNetAssets_989" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_951" xlink:to="loc_us-gaap_EquityMethodInvestmentUnderlyingEquityInNetAssets_989" use="optional" order="16" />
<loc xlink:type="locator" xlink:href="roiv-20210630.xsd#roiv_FairValueOfCommonShares" xlink:label="loc_roiv_FairValueOfCommonShares_1000" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_951" xlink:to="loc_roiv_FairValueOfCommonShares_1000" use="optional" order="17" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsToAcquireInterestInSubsidiariesAndAffiliates" xlink:label="loc_us-gaap_PaymentsToAcquireInterestInSubsidiariesAndAffiliates_982" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_951" xlink:to="loc_us-gaap_PaymentsToAcquireInterestInSubsidiariesAndAffiliates_982" use="optional" order="18" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired" xlink:label="loc_us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired_995" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_951" xlink:to="loc_us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired_995" use="optional" order="19" />
<loc xlink:type="locator" xlink:href="roiv-20210630.xsd#roiv_PercentageOfControllingInterestHeld" xlink:label="loc_roiv_PercentageOfControllingInterestHeld_978" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_951" xlink:to="loc_roiv_PercentageOfControllingInterestHeld_978" use="optional" order="20" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevenueRecognitionMilestoneMethodRevenueRecognized" xlink:label="loc_us-gaap_RevenueRecognitionMilestoneMethodRevenueRecognized_971" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_951" xlink:to="loc_us-gaap_RevenueRecognitionMilestoneMethodRevenueRecognized_971" use="optional" order="21" />
<loc xlink:type="locator" xlink:href="roiv-20210630.xsd#roiv_PaymentUnderSponsoredResearchAgreement" xlink:label="loc_roiv_PaymentUnderSponsoredResearchAgreement_986" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_951" xlink:to="loc_roiv_PaymentUnderSponsoredResearchAgreement_986" use="optional" order="22" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InvestmentsInAffiliatesSubsidiariesAssociatesAndJointVenturesFairValueDisclosure" xlink:label="loc_us-gaap_InvestmentsInAffiliatesSubsidiariesAssociatesAndJointVenturesFairValueDisclosure_979" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_951" xlink:to="loc_us-gaap_InvestmentsInAffiliatesSubsidiariesAssociatesAndJointVenturesFairValueDisclosure_979" use="optional" order="23" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongTermDebt" xlink:label="loc_us-gaap_LongTermDebt_967" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_951" xlink:to="loc_us-gaap_LongTermDebt_967" use="optional" order="24" />
<loc xlink:type="locator" xlink:href="roiv-20210630.xsd#roiv_MilestonePayment" xlink:label="loc_roiv_MilestonePayment_968" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_951" xlink:to="loc_roiv_MilestonePayment_968" use="optional" order="25" />
<loc xlink:type="locator" xlink:href="roiv-20210630.xsd#roiv_NonRefundableUpfrontPaymentReceived" xlink:label="loc_roiv_NonRefundableUpfrontPaymentReceived_969" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_951" xlink:to="loc_roiv_NonRefundableUpfrontPaymentReceived_969" use="optional" order="26" />
<loc xlink:type="locator" xlink:href="roiv-20210630.xsd#roiv_PaymentForUpfrontPayments" xlink:label="loc_roiv_PaymentForUpfrontPayments_985" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_951" xlink:to="loc_roiv_PaymentForUpfrontPayments_985" use="optional" order="27" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable" xlink:label="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_962" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_951" xlink:to="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_962" xbrldt:contextElement="segment" xbrldt:closed="true" use="optional" order="28" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessAcquisitionAxis" xlink:label="loc_us-gaap_BusinessAcquisitionAxis_950" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_962" xlink:to="loc_us-gaap_BusinessAcquisitionAxis_950" use="optional" order="29" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_949" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_950" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_949" use="optional" order="30" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_949_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_950" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_949_default" use="optional" order="31" />
<loc xlink:type="locator" xlink:href="roiv-20210630.xsd#roiv_SiliconTherapeuticsMember" xlink:label="loc_roiv_SiliconTherapeuticsMember_963" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_949" xlink:to="loc_roiv_SiliconTherapeuticsMember_963" use="optional" order="32" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_LegalEntityAxis" xlink:label="loc_dei_LegalEntityAxis_953" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_962" xlink:to="loc_dei_LegalEntityAxis_953" use="optional" order="33" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityDomain" xlink:label="loc_dei_EntityDomain_952" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_dei_LegalEntityAxis_953" xlink:to="loc_dei_EntityDomain_952" use="optional" order="34" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityDomain" xlink:label="loc_dei_EntityDomain_952_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_dei_LegalEntityAxis_953" xlink:to="loc_dei_EntityDomain_952_default" use="optional" order="35" />
<loc xlink:type="locator" xlink:href="roiv-20210630.xsd#roiv_ArbutusBiopharmaCorporationMember" xlink:label="loc_roiv_ArbutusBiopharmaCorporationMember_1002" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityDomain_952" xlink:to="loc_roiv_ArbutusBiopharmaCorporationMember_1002" use="optional" order="36" />
<loc xlink:type="locator" xlink:href="roiv-20210630.xsd#roiv_MilestoneEventsAxis" xlink:label="loc_roiv_MilestoneEventsAxis_954" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_962" xlink:to="loc_roiv_MilestoneEventsAxis_954" use="optional" order="37" />
<loc xlink:type="locator" xlink:href="roiv-20210630.xsd#roiv_MilestoneEventsDomain" xlink:label="loc_roiv_MilestoneEventsDomain_955" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_roiv_MilestoneEventsAxis_954" xlink:to="loc_roiv_MilestoneEventsDomain_955" use="optional" order="38" />
<loc xlink:type="locator" xlink:href="roiv-20210630.xsd#roiv_MilestoneEventsDomain" xlink:label="loc_roiv_MilestoneEventsDomain_955_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_roiv_MilestoneEventsAxis_954" xlink:to="loc_roiv_MilestoneEventsDomain_955_default" use="optional" order="39" />
<loc xlink:type="locator" xlink:href="roiv-20210630.xsd#roiv_FirstProductFirstProductForEachMolecularTargetCoveredByIntellectualPropertyMember" xlink:label="loc_roiv_FirstProductFirstProductForEachMolecularTargetCoveredByIntellectualPropertyMember_1003" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_roiv_MilestoneEventsDomain_955" xlink:to="loc_roiv_FirstProductFirstProductForEachMolecularTargetCoveredByIntellectualPropertyMember_1003" use="optional" order="40" />
<loc xlink:type="locator" xlink:href="roiv-20210630.xsd#roiv_FirstProductTargetsEachOfCertainSpecifiedAdditionalMoleculartargetsMember" xlink:label="loc_roiv_FirstProductTargetsEachOfCertainSpecifiedAdditionalMoleculartargetsMember_1005" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_roiv_MilestoneEventsDomain_955" xlink:to="loc_roiv_FirstProductTargetsEachOfCertainSpecifiedAdditionalMoleculartargetsMember_1005" use="optional" order="41" />
<loc xlink:type="locator" xlink:href="roiv-20210630.xsd#roiv_FirstProductTargetsTargetingEachOfTwoSpecifiedInitialTargetsMember" xlink:label="loc_roiv_FirstProductTargetsTargetingEachOfTwoSpecifiedInitialTargetsMember_1004" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_roiv_MilestoneEventsDomain_955" xlink:to="loc_roiv_FirstProductTargetsTargetingEachOfTwoSpecifiedInitialTargetsMember_1004" use="optional" order="42" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeAxis" xlink:label="loc_srt_RangeAxis_956" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_962" xlink:to="loc_srt_RangeAxis_956" use="optional" order="43" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeMember" xlink:label="loc_srt_RangeMember_957" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_RangeAxis_956" xlink:to="loc_srt_RangeMember_957" use="optional" order="44" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeMember" xlink:label="loc_srt_RangeMember_957_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_RangeAxis_956" xlink:to="loc_srt_RangeMember_957_default" use="optional" order="45" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MaximumMember" xlink:label="loc_srt_MaximumMember_1006" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_957" xlink:to="loc_srt_MaximumMember_1006" use="optional" order="46" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:label="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_959" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_962" xlink:to="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_959" use="optional" order="47" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RelatedPartyDomain" xlink:label="loc_us-gaap_RelatedPartyDomain_958" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_959" xlink:to="loc_us-gaap_RelatedPartyDomain_958" use="optional" order="48" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RelatedPartyDomain" xlink:label="loc_us-gaap_RelatedPartyDomain_958_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_959" xlink:to="loc_us-gaap_RelatedPartyDomain_958_default" use="optional" order="49" />
<loc xlink:type="locator" xlink:href="roiv-20210630.xsd#roiv_AffivantSciencesMember" xlink:label="loc_roiv_AffivantSciencesMember_1010" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyDomain_958" xlink:to="loc_roiv_AffivantSciencesMember_1010" use="optional" order="50" />
<loc xlink:type="locator" xlink:href="roiv-20210630.xsd#roiv_GenevantSciencesLtdMember" xlink:label="loc_roiv_GenevantSciencesLtdMember_1008" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyDomain_958" xlink:to="loc_roiv_GenevantSciencesLtdMember_1008" use="optional" order="51" />
<loc xlink:type="locator" xlink:href="roiv-20210630.xsd#roiv_DermavantSciencesLtdMember" xlink:label="loc_roiv_DermavantSciencesLtdMember_1007" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyDomain_958" xlink:to="loc_roiv_DermavantSciencesLtdMember_1007" use="optional" order="52" />
<loc xlink:type="locator" xlink:href="roiv-20210630.xsd#roiv_ProteovantSciencesIncMember" xlink:label="loc_roiv_ProteovantSciencesIncMember_1009" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyDomain_958" xlink:to="loc_roiv_ProteovantSciencesIncMember_1009" use="optional" order="53" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestructuringPlanAxis" xlink:label="loc_us-gaap_RestructuringPlanAxis_960" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_962" xlink:to="loc_us-gaap_RestructuringPlanAxis_960" use="optional" order="54" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestructuringPlanDomain" xlink:label="loc_us-gaap_RestructuringPlanDomain_961" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_RestructuringPlanAxis_960" xlink:to="loc_us-gaap_RestructuringPlanDomain_961" use="optional" order="55" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestructuringPlanDomain" xlink:label="loc_us-gaap_RestructuringPlanDomain_961_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_RestructuringPlanAxis_960" xlink:to="loc_us-gaap_RestructuringPlanDomain_961_default" use="optional" order="56" />
<loc xlink:type="locator" xlink:href="roiv-20210630.xsd#roiv_FirstTrancheMember" xlink:label="loc_roiv_FirstTrancheMember_1011" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RestructuringPlanDomain_961" xlink:to="loc_roiv_FirstTrancheMember_1011" use="optional" order="57" />
<loc xlink:type="locator" xlink:href="roiv-20210630.xsd#roiv_SecondTrancheMember" xlink:label="loc_roiv_SecondTrancheMember_1012" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RestructuringPlanDomain_961" xlink:to="loc_roiv_SecondTrancheMember_1012" use="optional" order="58" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RepaymentOfNotesReceivableFromRelatedParties" xlink:label="loc_us-gaap_RepaymentOfNotesReceivableFromRelatedParties_987" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_951" xlink:to="loc_us-gaap_RepaymentOfNotesReceivableFromRelatedParties_987" use="optional" order="59" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpense_984" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_951" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpense_984" use="optional" order="60" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsidiaryOrEquityMethodInvesteeCumulativePercentageOwnershipAfterAllTransactions" xlink:label="loc_us-gaap_SubsidiaryOrEquityMethodInvesteeCumulativePercentageOwnershipAfterAllTransactions_990" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_951" xlink:to="loc_us-gaap_SubsidiaryOrEquityMethodInvesteeCumulativePercentageOwnershipAfterAllTransactions_990" use="optional" order="61" />
<loc xlink:type="locator" xlink:href="roiv-20210630.xsd#roiv_UpfrontCashPayments" xlink:label="loc_roiv_UpfrontCashPayments_964" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_951" xlink:to="loc_roiv_UpfrontCashPayments_964" use="optional" order="62" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensation" xlink:label="loc_us-gaap_ShareBasedCompensation_999" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_951" xlink:to="loc_us-gaap_ShareBasedCompensation_999" use="optional" order="63" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquityNoteSubscriptionsReceivable" xlink:label="loc_us-gaap_StockholdersEquityNoteSubscriptionsReceivable_991" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_951" xlink:to="loc_us-gaap_StockholdersEquityNoteSubscriptionsReceivable_991" use="optional" order="64" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_974" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_951" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_974" use="optional" order="65" />
<loc xlink:type="locator" xlink:href="roiv-20210630.xsd#roiv_StockIssuedDuringPeriodValue" xlink:label="loc_roiv_StockIssuedDuringPeriodValue_992" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_951" xlink:to="loc_roiv_StockIssuedDuringPeriodValue_992" use="optional" order="66" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueNewIssues_975" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_951" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueNewIssues_975" use="optional" order="67" />
<loc xlink:type="locator" xlink:href="roiv-20210630.xsd#roiv_PotentialMilestonePaymentReceivable" xlink:label="loc_roiv_PotentialMilestonePaymentReceivable_970" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_951" xlink:to="loc_roiv_PotentialMilestonePaymentReceivable_970" use="optional" order="68" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromNotesPayable" xlink:label="loc_us-gaap_ProceedsFromNotesPayable_973" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_951" xlink:to="loc_us-gaap_ProceedsFromNotesPayable_973" use="optional" order="69" />
</definitionLink>
<definitionLink xlink:type="extended" xlink:role="http://roivant.com/role/SumitomoTransactionAgreementAdditionalInformationDetail">
<loc xlink:type="locator" xlink:href="roiv-20210630.xsd#roiv_TransactionAgreementLineItems" xlink:label="loc_roiv_TransactionAgreementLineItems_1021" />
<loc xlink:type="locator" xlink:href="roiv-20210630.xsd#roiv_TransactionAgreementTable" xlink:label="loc_roiv_TransactionAgreementTable_1022" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_roiv_TransactionAgreementLineItems_1021" xlink:to="loc_roiv_TransactionAgreementTable_1022" xbrldt:contextElement="segment" xbrldt:closed="true" use="optional" order="1" />
<loc xlink:type="locator" xlink:href="roiv-20210630.xsd#roiv_AgreementAxis" xlink:label="loc_roiv_AgreementAxis_1097947" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_roiv_TransactionAgreementTable_1022" xlink:to="loc_roiv_AgreementAxis_1097947" use="optional" order="2" />
<loc xlink:type="locator" xlink:href="roiv-20210630.xsd#roiv_AgreementDomain" xlink:label="loc_roiv_AgreementDomain_1097950" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_roiv_AgreementAxis_1097947" xlink:to="loc_roiv_AgreementDomain_1097950" use="optional" order="3" />
<loc xlink:type="locator" xlink:href="roiv-20210630.xsd#roiv_AgreementDomain" xlink:label="loc_roiv_AgreementDomain_1097950_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_roiv_AgreementAxis_1097947" xlink:to="loc_roiv_AgreementDomain_1097950_default" use="optional" order="4" />
<loc xlink:type="locator" xlink:href="roiv-20210630.xsd#roiv_TransitionServicesAndStrategicCooperationAgreementMember" xlink:label="loc_roiv_TransitionServicesAndStrategicCooperationAgreementMember_1097953" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_roiv_AgreementDomain_1097950" xlink:to="loc_roiv_TransitionServicesAndStrategicCooperationAgreementMember_1097953" use="optional" order="5" />
<loc xlink:type="locator" xlink:href="roiv-20210630.xsd#roiv_AssetPurchaseAgreementMember" xlink:label="loc_roiv_AssetPurchaseAgreementMember_1098006" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_roiv_AgreementDomain_1097950" xlink:to="loc_roiv_AssetPurchaseAgreementMember_1098006" use="optional" order="6" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeAxis" xlink:label="loc_srt_RangeAxis_1015" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_roiv_TransactionAgreementTable_1022" xlink:to="loc_srt_RangeAxis_1015" use="optional" order="7" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeMember" xlink:label="loc_srt_RangeMember_1016" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_RangeAxis_1015" xlink:to="loc_srt_RangeMember_1016" use="optional" order="8" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeMember" xlink:label="loc_srt_RangeMember_1016_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_RangeAxis_1015" xlink:to="loc_srt_RangeMember_1016_default" use="optional" order="9" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MaximumMember" xlink:label="loc_srt_MaximumMember_1023" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_1016" xlink:to="loc_srt_MaximumMember_1023" use="optional" order="10" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_TitleOfIndividualAxis" xlink:label="loc_srt_TitleOfIndividualAxis_1019" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_roiv_TransactionAgreementTable_1022" xlink:to="loc_srt_TitleOfIndividualAxis_1019" use="optional" order="11" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:label="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain_1020" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_TitleOfIndividualAxis_1019" xlink:to="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain_1020" use="optional" order="12" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:label="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain_1020_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_TitleOfIndividualAxis_1019" xlink:to="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain_1020_default" use="optional" order="13" />
<loc xlink:type="locator" xlink:href="roiv-20210630.xsd#roiv_EmployeeMember" xlink:label="loc_roiv_EmployeeMember_1025" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain_1020" xlink:to="loc_roiv_EmployeeMember_1025" use="optional" order="14" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:label="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_1018" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_roiv_TransactionAgreementTable_1022" xlink:to="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_1018" use="optional" order="15" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RelatedPartyDomain" xlink:label="loc_us-gaap_RelatedPartyDomain_1017" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_1018" xlink:to="loc_us-gaap_RelatedPartyDomain_1017" use="optional" order="16" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RelatedPartyDomain" xlink:label="loc_us-gaap_RelatedPartyDomain_1017_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_1018" xlink:to="loc_us-gaap_RelatedPartyDomain_1017_default" use="optional" order="17" />
<loc xlink:type="locator" xlink:href="roiv-20210630.xsd#roiv_SumitomoMember" xlink:label="loc_roiv_SumitomoMember_1024" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyDomain_1017" xlink:to="loc_roiv_SumitomoMember_1024" use="optional" order="18" />
<loc xlink:type="locator" xlink:href="roiv-20210630.xsd#roiv_AgreementRelatedBilledAmountForCostsIncurredOnBehalfOfSubsidiarynetOfAmountsBilledBySubsidiary" xlink:label="loc_roiv_AgreementRelatedBilledAmountForCostsIncurredOnBehalfOfSubsidiarynetOfAmountsBilledBySubsidiary_1097922" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_roiv_TransactionAgreementLineItems_1021" xlink:to="loc_roiv_AgreementRelatedBilledAmountForCostsIncurredOnBehalfOfSubsidiarynetOfAmountsBilledBySubsidiary_1097922" use="optional" order="19" />
<loc xlink:type="locator" xlink:href="roiv-20210630.xsd#roiv_AggregateFairValueOfEquityAndLiabilityInstrumentsIssued" xlink:label="loc_roiv_AggregateFairValueOfEquityAndLiabilityInstrumentsIssued_1033" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_roiv_TransactionAgreementLineItems_1021" xlink:to="loc_roiv_AggregateFairValueOfEquityAndLiabilityInstrumentsIssued_1033" use="optional" order="20" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredCompensationEquity" xlink:label="loc_us-gaap_DeferredCompensationEquity_1034" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_roiv_TransactionAgreementLineItems_1021" xlink:to="loc_us-gaap_DeferredCompensationEquity_1034" use="optional" order="21" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredCompensationLiabilityCurrent" xlink:label="loc_us-gaap_DeferredCompensationLiabilityCurrent_1035" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_roiv_TransactionAgreementLineItems_1021" xlink:to="loc_us-gaap_DeferredCompensationLiabilityCurrent_1035" use="optional" order="22" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EscrowDeposit" xlink:label="loc_us-gaap_EscrowDeposit_1030" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_roiv_TransactionAgreementLineItems_1021" xlink:to="loc_us-gaap_EscrowDeposit_1030" use="optional" order="23" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GainOrLossOnSaleOfStockInSubsidiary" xlink:label="loc_us-gaap_GainOrLossOnSaleOfStockInSubsidiary_1029" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_roiv_TransactionAgreementLineItems_1021" xlink:to="loc_us-gaap_GainOrLossOnSaleOfStockInSubsidiary_1029" use="optional" order="24" />
<loc xlink:type="locator" xlink:href="roiv-20210630.xsd#roiv_PercentageOfGrantedOptionToPurchaseOwnershipInterest" xlink:label="loc_roiv_PercentageOfGrantedOptionToPurchaseOwnershipInterest_1026" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_roiv_TransactionAgreementLineItems_1021" xlink:to="loc_roiv_PercentageOfGrantedOptionToPurchaseOwnershipInterest_1026" use="optional" order="25" />
<loc xlink:type="locator" xlink:href="roiv-20210630.xsd#roiv_AssetPurchaseTransactionConsiderationReceivedInCash" xlink:label="loc_roiv_AssetPurchaseTransactionConsiderationReceivedInCash_1105119" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_roiv_TransactionAgreementLineItems_1021" xlink:to="loc_roiv_AssetPurchaseTransactionConsiderationReceivedInCash_1105119" use="optional" order="26" />
<loc xlink:type="locator" xlink:href="roiv-20210630.xsd#roiv_SaleOfStockNumberOfShareIssuedInTransaction" xlink:label="loc_roiv_SaleOfStockNumberOfShareIssuedInTransaction_1105120" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_roiv_TransactionAgreementLineItems_1021" xlink:to="loc_roiv_SaleOfStockNumberOfShareIssuedInTransaction_1105120" use="optional" order="27" />
<loc xlink:type="locator" xlink:href="roiv-20210630.xsd#roiv_SaleOfStockConsiderationCashReceivedOnTransaction" xlink:label="loc_roiv_SaleOfStockConsiderationCashReceivedOnTransaction_1105122" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_roiv_TransactionAgreementLineItems_1021" xlink:to="loc_roiv_SaleOfStockConsiderationCashReceivedOnTransaction_1105122" use="optional" order="28" />
<loc xlink:type="locator" xlink:href="roiv-20210630.xsd#roiv_StockOfferToRepurchaseDuringPeriodValueOfTheProceedsReceivedFromTransactionAgreement" xlink:label="loc_roiv_StockOfferToRepurchaseDuringPeriodValueOfTheProceedsReceivedFromTransactionAgreement_1105154" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_roiv_TransactionAgreementLineItems_1021" xlink:to="loc_roiv_StockOfferToRepurchaseDuringPeriodValueOfTheProceedsReceivedFromTransactionAgreement_1105154" use="optional" order="29" />
<loc xlink:type="locator" xlink:href="roiv-20210630.xsd#roiv_EquityInterestOptionToThirdPartyPurchaserGainOnTermination" xlink:label="loc_roiv_EquityInterestOptionToThirdPartyPurchaserGainOnTermination_1107964" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_roiv_TransactionAgreementLineItems_1021" xlink:to="loc_roiv_EquityInterestOptionToThirdPartyPurchaserGainOnTermination_1107964" use="optional" order="30" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestrictedCash" xlink:label="loc_us-gaap_RestrictedCash_1031" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_roiv_TransactionAgreementLineItems_1021" xlink:to="loc_us-gaap_RestrictedCash_1031" use="optional" order="31" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SaleOfStockConsiderationReceivedOnTransaction" xlink:label="loc_us-gaap_SaleOfStockConsiderationReceivedOnTransaction_1028" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_roiv_TransactionAgreementLineItems_1021" xlink:to="loc_us-gaap_SaleOfStockConsiderationReceivedOnTransaction_1028" use="optional" order="32" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_1036" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_roiv_TransactionAgreementLineItems_1021" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_1036" use="optional" order="33" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockRepurchaseProgramAuthorizedAmount1" xlink:label="loc_us-gaap_StockRepurchaseProgramAuthorizedAmount1_1032" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_roiv_TransactionAgreementLineItems_1021" xlink:to="loc_us-gaap_StockRepurchaseProgramAuthorizedAmount1_1032" use="optional" order="34" />
</definitionLink>
<definitionLink xlink:type="extended" xlink:role="http://roivant.com/role/BalanceSheetComponentsScheduleOfAccruedExpensesDetail">
<loc xlink:type="locator" xlink:href="roiv-20210630.xsd#roiv_BalanceSheetComponentsLineItems" xlink:label="loc_roiv_BalanceSheetComponentsLineItems_1070" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccruedLiabilitiesCurrent" xlink:label="loc_us-gaap_AccruedLiabilitiesCurrent_1074" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_roiv_BalanceSheetComponentsLineItems_1070" xlink:to="loc_us-gaap_AccruedLiabilitiesCurrent_1074" use="optional" order="1" />
<loc xlink:type="locator" xlink:href="roiv-20210630.xsd#roiv_BalanceSheetComponentsTable" xlink:label="loc_roiv_BalanceSheetComponentsTable_1071" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_roiv_BalanceSheetComponentsLineItems_1070" xlink:to="loc_roiv_BalanceSheetComponentsTable_1071" xbrldt:contextElement="segment" xbrldt:closed="true" use="optional" order="2" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeStatementLocationAxis" xlink:label="loc_us-gaap_IncomeStatementLocationAxis_1072" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_roiv_BalanceSheetComponentsTable_1071" xlink:to="loc_us-gaap_IncomeStatementLocationAxis_1072" use="optional" order="3" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_1073" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_1072" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_1073" use="optional" order="4" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_1073_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_1072" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_1073_default" use="optional" order="5" />
<loc xlink:type="locator" xlink:href="roiv-20210630.xsd#roiv_OtherGeneralAndAdministrativeExpensesMember" xlink:label="loc_roiv_OtherGeneralAndAdministrativeExpensesMember_1078" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_1073" xlink:to="loc_roiv_OtherGeneralAndAdministrativeExpensesMember_1078" use="optional" order="6" />
<loc xlink:type="locator" xlink:href="roiv-20210630.xsd#roiv_ProfessionalServicesExpensesMember" xlink:label="loc_roiv_ProfessionalServicesExpensesMember_1077" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_1073" xlink:to="loc_roiv_ProfessionalServicesExpensesMember_1077" use="optional" order="7" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ResearchAndDevelopmentExpenseMember" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpenseMember_1075" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_1073" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpenseMember_1075" use="optional" order="8" />
<loc xlink:type="locator" xlink:href="roiv-20210630.xsd#roiv_EmployeeRelatedExpensesMember" xlink:label="loc_roiv_EmployeeRelatedExpensesMember_1076" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_1073" xlink:to="loc_roiv_EmployeeRelatedExpensesMember_1076" use="optional" order="9" />
</definitionLink>
<definitionLink xlink:type="extended" xlink:role="http://roivant.com/role/LongTermDebtAndLoanCommitmentAdditionalInformationDetail">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentLineItems" xlink:label="loc_us-gaap_DebtInstrumentLineItems_1095" />
<loc xlink:type="locator" xlink:href="roiv-20210630.xsd#roiv_MaximumMilestonePaymentObligation" xlink:label="loc_roiv_MaximumMilestonePaymentObligation_1111" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_1095" xlink:to="loc_roiv_MaximumMilestonePaymentObligation_1111" use="optional" order="1" />
<loc xlink:type="locator" xlink:href="roiv-20210630.xsd#roiv_MaximumMilestonePaymentOffsetAmount" xlink:label="loc_roiv_MaximumMilestonePaymentOffsetAmount_1112" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_1095" xlink:to="loc_roiv_MaximumMilestonePaymentOffsetAmount_1112" use="optional" order="2" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:label="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_1097048" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_1095" xlink:to="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_1097048" use="optional" order="3" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentTerm" xlink:label="loc_us-gaap_DebtInstrumentTerm_1097050" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_1095" xlink:to="loc_us-gaap_DebtInstrumentTerm_1097050" use="optional" order="4" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentFaceAmount" xlink:label="loc_us-gaap_DebtInstrumentFaceAmount_1105" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_1095" xlink:to="loc_us-gaap_DebtInstrumentFaceAmount_1105" use="optional" order="5" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentFairValue" xlink:label="loc_us-gaap_DebtInstrumentFairValue_1113" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_1095" xlink:to="loc_us-gaap_DebtInstrumentFairValue_1113" use="optional" order="6" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentFeeAmount" xlink:label="loc_us-gaap_DebtInstrumentFeeAmount_1108" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_1095" xlink:to="loc_us-gaap_DebtInstrumentFeeAmount_1108" use="optional" order="7" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentTable" xlink:label="loc_us-gaap_DebtInstrumentTable_1096" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_DebtInstrumentLineItems_1095" xlink:to="loc_us-gaap_DebtInstrumentTable_1096" xbrldt:contextElement="segment" xbrldt:closed="true" use="optional" order="8" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TransactionTypeAxis" xlink:label="loc_us-gaap_TransactionTypeAxis_1100" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtInstrumentTable_1096" xlink:to="loc_us-gaap_TransactionTypeAxis_1100" use="optional" order="9" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TransactionDomain" xlink:label="loc_us-gaap_TransactionDomain_1099" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_TransactionTypeAxis_1100" xlink:to="loc_us-gaap_TransactionDomain_1099" use="optional" order="10" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TransactionDomain" xlink:label="loc_us-gaap_TransactionDomain_1099_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_TransactionTypeAxis_1100" xlink:to="loc_us-gaap_TransactionDomain_1099_default" use="optional" order="11" />
<loc xlink:type="locator" xlink:href="roiv-20210630.xsd#roiv_CommercialMilestoneMember" xlink:label="loc_roiv_CommercialMilestoneMember_1116" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransactionDomain_1099" xlink:to="loc_roiv_CommercialMilestoneMember_1116" use="optional" order="12" />
<loc xlink:type="locator" xlink:href="roiv-20210630.xsd#roiv_RegulatoryMilestoneMember" xlink:label="loc_roiv_RegulatoryMilestoneMember_1115" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransactionDomain_1099" xlink:to="loc_roiv_RegulatoryMilestoneMember_1115" use="optional" order="13" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:label="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_1098" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtInstrumentTable_1096" xlink:to="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_1098" use="optional" order="14" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RelatedPartyDomain" xlink:label="loc_us-gaap_RelatedPartyDomain_1097" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_1098" xlink:to="loc_us-gaap_RelatedPartyDomain_1097" use="optional" order="15" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RelatedPartyDomain" xlink:label="loc_us-gaap_RelatedPartyDomain_1097_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_1098" xlink:to="loc_us-gaap_RelatedPartyDomain_1097_default" use="optional" order="16" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="loc_us-gaap_TypeOfArrangementAxis_1101" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtInstrumentTable_1096" xlink:to="loc_us-gaap_TypeOfArrangementAxis_1101" use="optional" order="17" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_1094" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_TypeOfArrangementAxis_1101" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_1094" use="optional" order="18" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_1094_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_TypeOfArrangementAxis_1101" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_1094_default" use="optional" order="19" />
<loc xlink:type="locator" xlink:href="roiv-20210630.xsd#roiv_NovaquestMember" xlink:label="loc_roiv_NovaquestMember_1104" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_1094" xlink:to="loc_roiv_NovaquestMember_1104" use="optional" order="20" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_VariableRateAxis" xlink:label="loc_us-gaap_VariableRateAxis_1102" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtInstrumentTable_1096" xlink:to="loc_us-gaap_VariableRateAxis_1102" use="optional" order="21" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_VariableRateDomain" xlink:label="loc_us-gaap_VariableRateDomain_1103" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_VariableRateAxis_1102" xlink:to="loc_us-gaap_VariableRateDomain_1103" use="optional" order="22" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_VariableRateDomain" xlink:label="loc_us-gaap_VariableRateDomain_1103_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_VariableRateAxis_1102" xlink:to="loc_us-gaap_VariableRateDomain_1103_default" use="optional" order="23" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PrimeRateMember" xlink:label="loc_us-gaap_PrimeRateMember_1117" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_VariableRateDomain_1103" xlink:to="loc_us-gaap_PrimeRateMember_1117" use="optional" order="24" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeAxis" xlink:label="loc_srt_RangeAxis_1097057" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtInstrumentTable_1096" xlink:to="loc_srt_RangeAxis_1097057" use="optional" order="25" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeMember" xlink:label="loc_srt_RangeMember_1097058" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_RangeAxis_1097057" xlink:to="loc_srt_RangeMember_1097058" use="optional" order="26" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeMember" xlink:label="loc_srt_RangeMember_1097058_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_RangeAxis_1097057" xlink:to="loc_srt_RangeMember_1097058_default" use="optional" order="27" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FinancialInstrumentAxis" xlink:label="loc_us-gaap_FinancialInstrumentAxis_1097323" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtInstrumentTable_1096" xlink:to="loc_us-gaap_FinancialInstrumentAxis_1097323" use="optional" order="28" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_1097324" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FinancialInstrumentAxis_1097323" xlink:to="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_1097324" use="optional" order="29" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_1097324_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FinancialInstrumentAxis_1097323" xlink:to="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_1097324_default" use="optional" order="30" />
<loc xlink:type="locator" xlink:href="roiv-20210630.xsd#roiv_RevenueInterestPurchaseAndSaleAgreementMember" xlink:label="loc_roiv_RevenueInterestPurchaseAndSaleAgreementMember_1097325" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_1097324" xlink:to="loc_roiv_RevenueInterestPurchaseAndSaleAgreementMember_1097325" use="optional" order="31" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight" xlink:label="loc_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight_1097053" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_1095" xlink:to="loc_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight_1097053" use="optional" order="32" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromLinesOfCredit" xlink:label="loc_us-gaap_ProceedsFromLinesOfCredit_1110" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_1095" xlink:to="loc_us-gaap_ProceedsFromLinesOfCredit_1110" use="optional" order="33" />
<loc xlink:type="locator" xlink:href="roiv-20210630.xsd#roiv_ProceedsFromSaleOfDebtAndEquitySecurities" xlink:label="loc_roiv_ProceedsFromSaleOfDebtAndEquitySecurities_1109" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_1095" xlink:to="loc_roiv_ProceedsFromSaleOfDebtAndEquitySecurities_1109" use="optional" order="34" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongTermDebtPercentageBearingVariableInterestRate" xlink:label="loc_us-gaap_LongTermDebtPercentageBearingVariableInterestRate_1106" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_1095" xlink:to="loc_us-gaap_LongTermDebtPercentageBearingVariableInterestRate_1106" use="optional" order="35" />
<loc xlink:type="locator" xlink:href="roiv-20210630.xsd#roiv_DebtInstrumentExitFeeAndEndOfTermCharge" xlink:label="loc_roiv_DebtInstrumentExitFeeAndEndOfTermCharge_1105123" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_1095" xlink:to="loc_roiv_DebtInstrumentExitFeeAndEndOfTermCharge_1105123" use="optional" order="36" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:label="loc_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_1097054" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_1095" xlink:to="loc_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_1097054" use="optional" order="37" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SecuritiesPurchasedUnderAgreementsToResellIncrease" xlink:label="loc_us-gaap_SecuritiesPurchasedUnderAgreementsToResellIncrease_1097321" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_1095" xlink:to="loc_us-gaap_SecuritiesPurchasedUnderAgreementsToResellIncrease_1097321" use="optional" order="38" />
<loc xlink:type="locator" xlink:href="roiv-20210630.xsd#roiv_MinimumAmountOfAnnualNetSalesToQualifyUnderRevenueInterestPurchaseAgreementContingentThreshold" xlink:label="loc_roiv_MinimumAmountOfAnnualNetSalesToQualifyUnderRevenueInterestPurchaseAgreementContingentThreshold_1097322" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_1095" xlink:to="loc_roiv_MinimumAmountOfAnnualNetSalesToQualifyUnderRevenueInterestPurchaseAgreementContingentThreshold_1097322" use="optional" order="39" />
</definitionLink>
<definitionLink xlink:type="extended" xlink:role="http://roivant.com/role/ShareholdersEquityAndRedeemableNonControllingInterestAdditionalInformationDetail">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfStockLineItems" xlink:label="loc_us-gaap_ClassOfStockLineItems_1144" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessAcquisitionEquityInterestIssuedOrIssuableValueAssigned" xlink:label="loc_us-gaap_BusinessAcquisitionEquityInterestIssuedOrIssuableValueAssigned_1176" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_1144" xlink:to="loc_us-gaap_BusinessAcquisitionEquityInterestIssuedOrIssuableValueAssigned_1176" use="optional" order="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued" xlink:label="loc_us-gaap_BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued_1172" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_1144" xlink:to="loc_us-gaap_BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued_1172" use="optional" order="2" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessAcquisitionPercentageOfVotingInterestsAcquired" xlink:label="loc_us-gaap_BusinessAcquisitionPercentageOfVotingInterestsAcquired_1171" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_1144" xlink:to="loc_us-gaap_BusinessAcquisitionPercentageOfVotingInterestsAcquired_1171" use="optional" order="3" />
<loc xlink:type="locator" xlink:href="roiv-20210630.xsd#roiv_ClassOfWarrantOrRightExercisable" xlink:label="loc_roiv_ClassOfWarrantOrRightExercisable_1185" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_1144" xlink:to="loc_roiv_ClassOfWarrantOrRightExercisable_1185" use="optional" order="4" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:label="loc_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_1174" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_1144" xlink:to="loc_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_1174" use="optional" order="5" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfWarrantOrRightOutstanding" xlink:label="loc_us-gaap_ClassOfWarrantOrRightOutstanding_1173" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_1144" xlink:to="loc_us-gaap_ClassOfWarrantOrRightOutstanding_1173" use="optional" order="6" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockSharesIssued" xlink:label="loc_us-gaap_CommonStockSharesIssued_1179" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_1144" xlink:to="loc_us-gaap_CommonStockSharesIssued_1179" use="optional" order="7" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdjustmentOfWarrantsGrantedForServices" xlink:label="loc_us-gaap_AdjustmentOfWarrantsGrantedForServices_1187" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_1144" xlink:to="loc_us-gaap_AdjustmentOfWarrantsGrantedForServices_1187" use="optional" order="8" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsForProceedsFromBusinessesAndInterestInAffiliates" xlink:label="loc_us-gaap_PaymentsForProceedsFromBusinessesAndInterestInAffiliates_1175" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_1144" xlink:to="loc_us-gaap_PaymentsForProceedsFromBusinessesAndInterestInAffiliates_1175" use="optional" order="9" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsForRepurchaseOfRedeemableConvertiblePreferredStock" xlink:label="loc_us-gaap_PaymentsForRepurchaseOfRedeemableConvertiblePreferredStock_1190" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_1144" xlink:to="loc_us-gaap_PaymentsForRepurchaseOfRedeemableConvertiblePreferredStock_1190" use="optional" order="10" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsForRepurchaseOfRedeemableNoncontrollingInterest" xlink:label="loc_us-gaap_PaymentsForRepurchaseOfRedeemableNoncontrollingInterest_1191" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_1144" xlink:to="loc_us-gaap_PaymentsForRepurchaseOfRedeemableNoncontrollingInterest_1191" use="optional" order="11" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InvestmentCompanyInternalRateOfReturnSinceInception" xlink:label="loc_us-gaap_InvestmentCompanyInternalRateOfReturnSinceInception_1188" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_1144" xlink:to="loc_us-gaap_InvestmentCompanyInternalRateOfReturnSinceInception_1188" use="optional" order="12" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtConversionConvertedInstrumentSharesIssued1" xlink:label="loc_us-gaap_DebtConversionConvertedInstrumentSharesIssued1_1181" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_1144" xlink:to="loc_us-gaap_DebtConversionConvertedInstrumentSharesIssued1_1181" use="optional" order="13" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentConvertibleCarryingAmountOfTheEquityComponent" xlink:label="loc_us-gaap_DebtInstrumentConvertibleCarryingAmountOfTheEquityComponent_1182" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_1144" xlink:to="loc_us-gaap_DebtInstrumentConvertibleCarryingAmountOfTheEquityComponent_1182" use="optional" order="14" />
<loc xlink:type="locator" xlink:href="roiv-20210630.xsd#roiv_EarnOutSharesTermsDescription" xlink:label="loc_roiv_EarnOutSharesTermsDescription_1178" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_1144" xlink:to="loc_roiv_EarnOutSharesTermsDescription_1178" use="optional" order="15" />
<loc xlink:type="locator" xlink:href="roiv-20210630.xsd#roiv_PercentageSharesOfCommonStockOfferedToBeRepurchased" xlink:label="loc_roiv_PercentageSharesOfCommonStockOfferedToBeRepurchased_1168" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_1144" xlink:to="loc_roiv_PercentageSharesOfCommonStockOfferedToBeRepurchased_1168" use="optional" order="16" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PreferredStockRedemptionPricePerShare" xlink:label="loc_us-gaap_PreferredStockRedemptionPricePerShare_1189" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_1144" xlink:to="loc_us-gaap_PreferredStockRedemptionPricePerShare_1189" use="optional" order="17" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfCommonStock_1184" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_1144" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfCommonStock_1184" use="optional" order="18" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromIssuanceOfWarrants" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfWarrants_1186" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_1144" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfWarrants_1186" use="optional" order="19" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SaleOfStockConsiderationReceivedOnTransaction" xlink:label="loc_us-gaap_SaleOfStockConsiderationReceivedOnTransaction_1166" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_1144" xlink:to="loc_us-gaap_SaleOfStockConsiderationReceivedOnTransaction_1166" use="optional" order="20" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_1183" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_1144" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_1183" use="optional" order="21" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockRepurchaseProgramAuthorizedAmount1" xlink:label="loc_us-gaap_StockRepurchaseProgramAuthorizedAmount1_1167" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_1144" xlink:to="loc_us-gaap_StockRepurchaseProgramAuthorizedAmount1_1167" use="optional" order="22" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TreasuryStockAcquiredRepurchaseAuthorization" xlink:label="loc_us-gaap_TreasuryStockAcquiredRepurchaseAuthorization_1170" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_1144" xlink:to="loc_us-gaap_TreasuryStockAcquiredRepurchaseAuthorization_1170" use="optional" order="23" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_WeightedAverageNumberOfSharesContingentlyIssuable" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesContingentlyIssuable_1177" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_1144" xlink:to="loc_us-gaap_WeightedAverageNumberOfSharesContingentlyIssuable_1177" use="optional" order="24" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" xlink:label="loc_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_1164" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_1144" xlink:to="loc_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_1164" use="optional" order="25" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SaleOfStockPricePerShare" xlink:label="loc_us-gaap_SaleOfStockPricePerShare_1169" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_1144" xlink:to="loc_us-gaap_SaleOfStockPricePerShare_1169" use="optional" order="26" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfStockByClassTable" xlink:label="loc_us-gaap_ScheduleOfStockByClassTable_1151" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ClassOfStockLineItems_1144" xlink:to="loc_us-gaap_ScheduleOfStockByClassTable_1151" xbrldt:contextElement="segment" xbrldt:closed="true" use="optional" order="27" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AwardTypeAxis" xlink:label="loc_us-gaap_AwardTypeAxis_1140" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_1151" xlink:to="loc_us-gaap_AwardTypeAxis_1140" use="optional" order="28" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_1152" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AwardTypeAxis_1140" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_1152" use="optional" order="29" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_1152_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AwardTypeAxis_1140" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_1152_default" use="optional" order="30" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestrictedStockMember" xlink:label="loc_us-gaap_RestrictedStockMember_1201" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_1152" xlink:to="loc_us-gaap_RestrictedStockMember_1201" use="optional" order="31" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessAcquisitionAxis" xlink:label="loc_us-gaap_BusinessAcquisitionAxis_1142" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_1151" xlink:to="loc_us-gaap_BusinessAcquisitionAxis_1142" use="optional" order="32" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_1141" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_1142" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_1141" use="optional" order="33" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_1141_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_1142" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_1141_default" use="optional" order="34" />
<loc xlink:type="locator" xlink:href="roiv-20210630.xsd#roiv_ImmunovantINCMember" xlink:label="loc_roiv_ImmunovantINCMember_1162" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_1141" xlink:to="loc_roiv_ImmunovantINCMember_1162" use="optional" order="35" />
<loc xlink:type="locator" xlink:href="roiv-20210630.xsd#roiv_HealthSciencesMember" xlink:label="loc_roiv_HealthSciencesMember_1197" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyDomain_1148" xlink:to="loc_roiv_HealthSciencesMember_1197" use="optional" order="36" />
<loc xlink:type="locator" xlink:href="roiv-20210630.xsd#roiv_HealthSciencesMember" xlink:label="loc_roiv_HealthSciencesMember_1140124" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_1141" xlink:to="loc_roiv_HealthSciencesMember_1140124" use="optional" order="37" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeAxis" xlink:label="loc_srt_RangeAxis_1146" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_1151" xlink:to="loc_srt_RangeAxis_1146" use="optional" order="38" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeMember" xlink:label="loc_srt_RangeMember_1147" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_RangeAxis_1146" xlink:to="loc_srt_RangeMember_1147" use="optional" order="39" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeMember" xlink:label="loc_srt_RangeMember_1147_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_RangeAxis_1146" xlink:to="loc_srt_RangeMember_1147_default" use="optional" order="40" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MaximumMember" xlink:label="loc_srt_MaximumMember_1194" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_1147" xlink:to="loc_srt_MaximumMember_1194" use="optional" order="41" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:label="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_1149" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_1151" xlink:to="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_1149" use="optional" order="42" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RelatedPartyDomain" xlink:label="loc_us-gaap_RelatedPartyDomain_1148" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_1149" xlink:to="loc_us-gaap_RelatedPartyDomain_1148" use="optional" order="43" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RelatedPartyDomain" xlink:label="loc_us-gaap_RelatedPartyDomain_1148_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_1149" xlink:to="loc_us-gaap_RelatedPartyDomain_1148_default" use="optional" order="44" />
<loc xlink:type="locator" xlink:href="roiv-20210630.xsd#roiv_ImmunovantSciencesLtdMember" xlink:label="loc_roiv_ImmunovantSciencesLtdMember_1198" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyDomain_1148" xlink:to="loc_roiv_ImmunovantSciencesLtdMember_1198" use="optional" order="45" />
<loc xlink:type="locator" xlink:href="roiv-20210630.xsd#roiv_CytovantScienceHkLtdMember" xlink:label="loc_roiv_CytovantScienceHkLtdMember_1196" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyDomain_1148" xlink:to="loc_roiv_CytovantScienceHkLtdMember_1196" use="optional" order="46" />
<loc xlink:type="locator" xlink:href="roiv-20210630.xsd#roiv_SinovantIncMember" xlink:label="loc_roiv_SinovantIncMember_1199" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyDomain_1148" xlink:to="loc_roiv_SinovantIncMember_1199" use="optional" order="47" />
<loc xlink:type="locator" xlink:href="roiv-20210630.xsd#roiv_SumitomoMember" xlink:label="loc_roiv_SumitomoMember_1195" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyDomain_1148" xlink:to="loc_roiv_SumitomoMember_1195" use="optional" order="48" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="loc_us-gaap_StatementClassOfStockAxis_1157" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_1151" xlink:to="loc_us-gaap_StatementClassOfStockAxis_1157" use="optional" order="49" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaap_ClassOfStockDomain_1143" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementClassOfStockAxis_1157" xlink:to="loc_us-gaap_ClassOfStockDomain_1143" use="optional" order="50" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaap_ClassOfStockDomain_1143_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementClassOfStockAxis_1157" xlink:to="loc_us-gaap_ClassOfStockDomain_1143_default" use="optional" order="51" />
<loc xlink:type="locator" xlink:href="roiv-20210630.xsd#roiv_SeriesA1PreferredStockMember" xlink:label="loc_roiv_SeriesA1PreferredStockMember_1163" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockDomain_1143" xlink:to="loc_roiv_SeriesA1PreferredStockMember_1163" use="optional" order="52" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_1158" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_1151" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_1158" use="optional" order="53" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaap_EquityComponentDomain_1145" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_1158" xlink:to="loc_us-gaap_EquityComponentDomain_1145" use="optional" order="54" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaap_EquityComponentDomain_1145_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_1158" xlink:to="loc_us-gaap_EquityComponentDomain_1145_default" use="optional" order="55" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockMember" xlink:label="loc_us-gaap_CommonStockMember_1192" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_1145" xlink:to="loc_us-gaap_CommonStockMember_1192" use="optional" order="56" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_WarrantMember" xlink:label="loc_us-gaap_WarrantMember_1193" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_1145" xlink:to="loc_us-gaap_WarrantMember_1193" use="optional" order="57" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="loc_us-gaap_SubsidiarySaleOfStockAxis_1159" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_1151" xlink:to="loc_us-gaap_SubsidiarySaleOfStockAxis_1159" use="optional" order="58" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain_1150" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis_1159" xlink:to="loc_us-gaap_SaleOfStockNameOfTransactionDomain_1150" use="optional" order="59" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain_1150_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis_1159" xlink:to="loc_us-gaap_SaleOfStockNameOfTransactionDomain_1150_default" use="optional" order="60" />
<loc xlink:type="locator" xlink:href="roiv-20210630.xsd#roiv_UnderwrittenPublicOfferingMember" xlink:label="loc_roiv_UnderwrittenPublicOfferingMember_1200" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_1150" xlink:to="loc_roiv_UnderwrittenPublicOfferingMember_1200" use="optional" order="61" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="loc_us-gaap_TypeOfArrangementAxis_1160" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_1151" xlink:to="loc_us-gaap_TypeOfArrangementAxis_1160" use="optional" order="62" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_1139" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_TypeOfArrangementAxis_1160" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_1139" use="optional" order="63" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_1139_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_TypeOfArrangementAxis_1160" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_1139_default" use="optional" order="64" />
<loc xlink:type="locator" xlink:href="roiv-20210630.xsd#roiv_SumitomoTransactionAgreementMember" xlink:label="loc_roiv_SumitomoTransactionAgreementMember_1161" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_1139" xlink:to="loc_roiv_SumitomoTransactionAgreementMember_1161" use="optional" order="65" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareRepurchaseProgramAxis" xlink:label="loc_us-gaap_ShareRepurchaseProgramAxis_1153" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_1151" xlink:to="loc_us-gaap_ShareRepurchaseProgramAxis_1153" use="optional" order="66" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareRepurchaseProgramDomain" xlink:label="loc_us-gaap_ShareRepurchaseProgramDomain_1154" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_ShareRepurchaseProgramAxis_1153" xlink:to="loc_us-gaap_ShareRepurchaseProgramDomain_1154" use="optional" order="67" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareRepurchaseProgramDomain" xlink:label="loc_us-gaap_ShareRepurchaseProgramDomain_1154_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_ShareRepurchaseProgramAxis_1153" xlink:to="loc_us-gaap_ShareRepurchaseProgramDomain_1154_default" use="optional" order="68" />
<loc xlink:type="locator" xlink:href="roiv-20210630.xsd#roiv_RoivantEquityRepurchaseMember" xlink:label="loc_roiv_RoivantEquityRepurchaseMember_1202" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareRepurchaseProgramDomain_1154" xlink:to="loc_roiv_RoivantEquityRepurchaseMember_1202" use="optional" order="69" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShortTermDebtTypeAxis" xlink:label="loc_us-gaap_ShortTermDebtTypeAxis_1155" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_1151" xlink:to="loc_us-gaap_ShortTermDebtTypeAxis_1155" use="optional" order="70" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShortTermDebtTypeDomain" xlink:label="loc_us-gaap_ShortTermDebtTypeDomain_1156" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_ShortTermDebtTypeAxis_1155" xlink:to="loc_us-gaap_ShortTermDebtTypeDomain_1156" use="optional" order="71" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShortTermDebtTypeDomain" xlink:label="loc_us-gaap_ShortTermDebtTypeDomain_1156_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_ShortTermDebtTypeAxis_1155" xlink:to="loc_us-gaap_ShortTermDebtTypeDomain_1156_default" use="optional" order="72" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConvertibleNotesPayableMember" xlink:label="loc_us-gaap_ConvertibleNotesPayableMember_1203" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShortTermDebtTypeDomain_1156" xlink:to="loc_us-gaap_ConvertibleNotesPayableMember_1203" use="optional" order="73" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_1180" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_1144" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_1180" use="optional" order="74" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharesIssuedPricePerShare" xlink:label="loc_us-gaap_SharesIssuedPricePerShare_1165" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_1144" xlink:to="loc_us-gaap_SharesIssuedPricePerShare_1165" use="optional" order="75" />
</definitionLink>
<definitionLink xlink:type="extended" xlink:role="http://roivant.com/role/ShareBasedCompensationAdditionalInformationDetail">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_1215" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AllocatedShareBasedCompensationExpense" xlink:label="loc_us-gaap_AllocatedShareBasedCompensationExpense_1222" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_1215" xlink:to="loc_us-gaap_AllocatedShareBasedCompensationExpense_1222" use="optional" order="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestrictedInvestmentsAtFairValue" xlink:label="loc_us-gaap_RestrictedInvestmentsAtFairValue_1233" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_1215" xlink:to="loc_us-gaap_RestrictedInvestmentsAtFairValue_1233" use="optional" order="2" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_1214" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_1215" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_1214" xbrldt:contextElement="segment" xbrldt:closed="true" use="optional" order="3" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PlanNameAxis" xlink:label="loc_us-gaap_PlanNameAxis_1212" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_1214" xlink:to="loc_us-gaap_PlanNameAxis_1212" use="optional" order="4" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PlanNameDomain" xlink:label="loc_us-gaap_PlanNameDomain_1213" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_PlanNameAxis_1212" xlink:to="loc_us-gaap_PlanNameDomain_1213" use="optional" order="5" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PlanNameDomain" xlink:label="loc_us-gaap_PlanNameDomain_1213_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_PlanNameAxis_1212" xlink:to="loc_us-gaap_PlanNameDomain_1213_default" use="optional" order="6" />
<loc xlink:type="locator" xlink:href="roiv-20210630.xsd#roiv_PerformanceRestrictedStockUnitsPlanMember" xlink:label="loc_roiv_PerformanceRestrictedStockUnitsPlanMember_1219" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PlanNameDomain_1213" xlink:to="loc_roiv_PerformanceRestrictedStockUnitsPlanMember_1219" use="optional" order="7" />
<loc xlink:type="locator" xlink:href="roiv-20210630.xsd#roiv_SubsidiaryEquityIncentivePlanMember" xlink:label="loc_roiv_SubsidiaryEquityIncentivePlanMember_1218" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PlanNameDomain_1213" xlink:to="loc_roiv_SubsidiaryEquityIncentivePlanMember_1218" use="optional" order="8" />
<loc xlink:type="locator" xlink:href="roiv-20210630.xsd#roiv_TwoThousandFifteenEquityIncentivePlanMember" xlink:label="loc_roiv_TwoThousandFifteenEquityIncentivePlanMember_1217" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PlanNameDomain_1213" xlink:to="loc_roiv_TwoThousandFifteenEquityIncentivePlanMember_1217" use="optional" order="9" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AwardTypeAxis" xlink:label="loc_us-gaap_AwardTypeAxis_1211" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_1214" xlink:to="loc_us-gaap_AwardTypeAxis_1211" use="optional" order="10" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_1216" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AwardTypeAxis_1211" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_1216" use="optional" order="11" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_1216_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AwardTypeAxis_1211" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_1216_default" use="optional" order="12" />
<loc xlink:type="locator" xlink:href="roiv-20210630.xsd#roiv_PerformanceOptionsMember" xlink:label="loc_roiv_PerformanceOptionsMember_1238" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_1216" xlink:to="loc_roiv_PerformanceOptionsMember_1238" use="optional" order="13" />
<loc xlink:type="locator" xlink:href="roiv-20210630.xsd#roiv_PerformanceRestrictedStockUnitsMember" xlink:label="loc_roiv_PerformanceRestrictedStockUnitsMember_1240" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_1216" xlink:to="loc_roiv_PerformanceRestrictedStockUnitsMember_1240" use="optional" order="14" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestrictedStockUnitsRSUMember" xlink:label="loc_us-gaap_RestrictedStockUnitsRSUMember_1237" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_1216" xlink:to="loc_us-gaap_RestrictedStockUnitsRSUMember_1237" use="optional" order="15" />
<loc xlink:type="locator" xlink:href="roiv-20210630.xsd#roiv_CappedValueAppreciationRightsMember" xlink:label="loc_roiv_CappedValueAppreciationRightsMember_1239" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_1216" xlink:to="loc_roiv_CappedValueAppreciationRightsMember_1239" use="optional" order="16" />
<loc xlink:type="locator" xlink:href="roiv-20210630.xsd#roiv_CommonStockAwardsMember" xlink:label="loc_roiv_CommonStockAwardsMember_1241" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_1216" xlink:to="loc_roiv_CommonStockAwardsMember_1241" use="optional" order="17" />
<loc xlink:type="locator" xlink:href="roiv-20210630.xsd#roiv_SpecialReserveMember" xlink:label="loc_roiv_SpecialReserveMember_1236" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_1216" xlink:to="loc_roiv_SpecialReserveMember_1236" use="optional" order="18" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="loc_us-gaap_EmployeeStockOptionMember_1106699" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_1216" xlink:to="loc_us-gaap_EmployeeStockOptionMember_1106699" use="optional" order="19" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_1234" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_1215" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_1234" use="optional" order="20" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:label="loc_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_1220" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_1215" xlink:to="loc_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_1220" use="optional" order="21" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_1230" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_1215" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_1230" use="optional" order="22" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_1224" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_1215" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_1224" use="optional" order="23" />
<loc xlink:type="locator" xlink:href="roiv-20210630.xsd#roiv_SharebasedCompensationArrangementBySharebasedPaymentAwardAggregateRepurchasePrice" xlink:label="loc_roiv_SharebasedCompensationArrangementBySharebasedPaymentAwardAggregateRepurchasePrice_1231" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_1215" xlink:to="loc_roiv_SharebasedCompensationArrangementBySharebasedPaymentAwardAggregateRepurchasePrice_1231" use="optional" order="24" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions_1227" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_1215" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions_1227" use="optional" order="25" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_1223" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_1215" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_1223" use="optional" order="26" />
<loc xlink:type="locator" xlink:href="roiv-20210630.xsd#roiv_CommonSharesReservedForPerformanceOptionsAndCappedValueAppreciationRights" xlink:label="loc_roiv_CommonSharesReservedForPerformanceOptionsAndCappedValueAppreciationRights_1108003" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_1215" xlink:to="loc_roiv_CommonSharesReservedForPerformanceOptionsAndCappedValueAppreciationRights_1108003" use="optional" order="27" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardDescription" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardDescription_1229" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_1215" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardDescription_1229" use="optional" order="28" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardExpirationDate" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardExpirationDate_1228" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_1215" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardExpirationDate_1228" use="optional" order="29" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_1226" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_1215" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_1226" use="optional" order="30" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_1221" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_1215" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_1221" use="optional" order="31" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_1235" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_1215" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_1235" use="optional" order="32" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares_1225" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_1215" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares_1225" use="optional" order="33" />
<loc xlink:type="locator" xlink:href="roiv-20210630.xsd#roiv_ShareBasedCompensationRightToRepurchasePercentage" xlink:label="loc_roiv_ShareBasedCompensationRightToRepurchasePercentage_1232" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_1215" xlink:to="loc_roiv_ShareBasedCompensationRightToRepurchasePercentage_1232" use="optional" order="34" />
</definitionLink>
<definitionLink xlink:type="extended" xlink:role="http://roivant.com/role/ShareBasedCompensationScheduleOfFairValueAssumptionsDetail">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_1246" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_1245" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_1246" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_1245" xbrldt:contextElement="segment" xbrldt:closed="true" use="optional" order="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AwardTypeAxis" xlink:label="loc_us-gaap_AwardTypeAxis_1244" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_1245" xlink:to="loc_us-gaap_AwardTypeAxis_1244" use="optional" order="2" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_1247" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AwardTypeAxis_1244" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_1247" use="optional" order="3" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_1247_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AwardTypeAxis_1244" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_1247_default" use="optional" order="4" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="loc_us-gaap_EmployeeStockOptionMember_1252" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_1247" xlink:to="loc_us-gaap_EmployeeStockOptionMember_1252" use="optional" order="5" />
<loc xlink:type="locator" xlink:href="roiv-20210630.xsd#roiv_PerformanceOptionsMember" xlink:label="loc_roiv_PerformanceOptionsMember_1253" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_1247" xlink:to="loc_roiv_PerformanceOptionsMember_1253" use="optional" order="6" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_1251" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_1246" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_1251" use="optional" order="7" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_1250" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_1246" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_1250" use="optional" order="8" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_1249" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_1246" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_1249" use="optional" order="9" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate_1248" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_1246" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate_1248" use="optional" order="10" />
</definitionLink>
<definitionLink xlink:type="extended" xlink:role="http://roivant.com/role/ShareBasedCompensationSummaryOfStockOptionActivityDetail">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_1260" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_1267" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_1260" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_1267" use="optional" order="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_1259" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_1260" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_1259" xbrldt:contextElement="segment" xbrldt:closed="true" use="optional" order="2" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AwardTypeAxis" xlink:label="loc_us-gaap_AwardTypeAxis_1256" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_1259" xlink:to="loc_us-gaap_AwardTypeAxis_1256" use="optional" order="3" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_1261" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AwardTypeAxis_1256" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_1261" use="optional" order="4" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_1261_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AwardTypeAxis_1256" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_1261_default" use="optional" order="5" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="loc_us-gaap_EmployeeStockOptionMember_1280" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_1261" xlink:to="loc_us-gaap_EmployeeStockOptionMember_1280" use="optional" order="6" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PlanNameAxis" xlink:label="loc_us-gaap_PlanNameAxis_1257" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_1259" xlink:to="loc_us-gaap_PlanNameAxis_1257" use="optional" order="7" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PlanNameDomain" xlink:label="loc_us-gaap_PlanNameDomain_1258" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_PlanNameAxis_1257" xlink:to="loc_us-gaap_PlanNameDomain_1258" use="optional" order="8" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PlanNameDomain" xlink:label="loc_us-gaap_PlanNameDomain_1258_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_PlanNameAxis_1257" xlink:to="loc_us-gaap_PlanNameDomain_1258_default" use="optional" order="9" />
<loc xlink:type="locator" xlink:href="roiv-20210630.xsd#roiv_TwoThousandFifteenEquityIncentivePlanMember" xlink:label="loc_roiv_TwoThousandFifteenEquityIncentivePlanMember_1262" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PlanNameDomain_1258" xlink:to="loc_roiv_TwoThousandFifteenEquityIncentivePlanMember_1262" use="optional" order="10" />
<loc xlink:type="locator" xlink:href="roiv-20210630.xsd#roiv_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExcercisableWeightedAverageGrantDateFairValue" xlink:label="loc_roiv_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExcercisableWeightedAverageGrantDateFairValue_1277" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_1260" xlink:to="loc_roiv_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExcercisableWeightedAverageGrantDateFairValue_1277" use="optional" order="11" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_1278" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_1260" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_1278" use="optional" order="12" />
<loc xlink:type="locator" xlink:href="roiv-20210630.xsd#roiv_ShareBasedCompensationArrangementByShareBasedPaymentAwardWeightedAverageGrantDateFairValue" xlink:label="loc_roiv_ShareBasedCompensationArrangementByShareBasedPaymentAwardWeightedAverageGrantDateFairValue_1273" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_1260" xlink:to="loc_roiv_ShareBasedCompensationArrangementByShareBasedPaymentAwardWeightedAverageGrantDateFairValue_1273" use="optional" order="13" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_1270" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_1260" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_1270" use="optional" order="14" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_1269" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_1260" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_1269" use="optional" order="15" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_1265" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_1260" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_1265" use="optional" order="16" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_1264" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_1260" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_1264" use="optional" order="17" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_1274" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_1260" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_1274" use="optional" order="18" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedWeightedAverageGrantDateFairValue" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedWeightedAverageGrantDateFairValue_1275" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_1260" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedWeightedAverageGrantDateFairValue_1275" use="optional" order="19" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_1263" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_1260" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_1263" use="optional" order="20" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_1268" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_1260" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_1268" use="optional" order="21" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_1272" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_1260" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_1272" use="optional" order="22" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_1279" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_1260" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_1279" use="optional" order="23" />
</definitionLink>
<definitionLink xlink:type="extended" xlink:role="http://roivant.com/role/ShareBasedCompensationSummaryOfRestrictedStockUnitsDetail">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_1291" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_1290" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_1291" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_1290" xbrldt:contextElement="segment" xbrldt:closed="true" use="optional" order="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AwardTypeAxis" xlink:label="loc_us-gaap_AwardTypeAxis_1287" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_1290" xlink:to="loc_us-gaap_AwardTypeAxis_1287" use="optional" order="2" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_1292" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AwardTypeAxis_1287" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_1292" use="optional" order="3" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_1292_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AwardTypeAxis_1287" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_1292_default" use="optional" order="4" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestrictedStockUnitsRSUMember" xlink:label="loc_us-gaap_RestrictedStockUnitsRSUMember_1302" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_1292" xlink:to="loc_us-gaap_RestrictedStockUnitsRSUMember_1302" use="optional" order="5" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PlanNameAxis" xlink:label="loc_us-gaap_PlanNameAxis_1288" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_1290" xlink:to="loc_us-gaap_PlanNameAxis_1288" use="optional" order="6" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PlanNameDomain" xlink:label="loc_us-gaap_PlanNameDomain_1289" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_PlanNameAxis_1288" xlink:to="loc_us-gaap_PlanNameDomain_1289" use="optional" order="7" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PlanNameDomain" xlink:label="loc_us-gaap_PlanNameDomain_1289_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_PlanNameAxis_1288" xlink:to="loc_us-gaap_PlanNameDomain_1289_default" use="optional" order="8" />
<loc xlink:type="locator" xlink:href="roiv-20210630.xsd#roiv_TwoThousandFifteenEquityIncentivePlanMember" xlink:label="loc_roiv_TwoThousandFifteenEquityIncentivePlanMember_1293" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PlanNameDomain_1289" xlink:to="loc_roiv_TwoThousandFifteenEquityIncentivePlanMember_1293" use="optional" order="9" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_1296" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_1291" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_1296" use="optional" order="10" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_1295" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_1291" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_1295" use="optional" order="11" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_1294" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_1291" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_1294" use="optional" order="12" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_1299" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_1291" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_1299" use="optional" order="13" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedWeightedAverageGrantDateFairValue" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedWeightedAverageGrantDateFairValue_1300" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_1291" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedWeightedAverageGrantDateFairValue_1300" use="optional" order="14" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue_1298" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_1291" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue_1298" use="optional" order="15" />
</definitionLink>
<definitionLink xlink:type="extended" xlink:role="http://roivant.com/role/ShareBasedCompensationSummaryOfPerformanceOptionsActivityDetail">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_1309" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_1312" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_1309" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_1312" use="optional" order="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_1308" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_1309" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_1308" xbrldt:contextElement="segment" xbrldt:closed="true" use="optional" order="2" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PlanNameAxis" xlink:label="loc_us-gaap_PlanNameAxis_1306" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_1308" xlink:to="loc_us-gaap_PlanNameAxis_1306" use="optional" order="3" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PlanNameDomain" xlink:label="loc_us-gaap_PlanNameDomain_1307" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_PlanNameAxis_1306" xlink:to="loc_us-gaap_PlanNameDomain_1307" use="optional" order="4" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PlanNameDomain" xlink:label="loc_us-gaap_PlanNameDomain_1307_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_PlanNameAxis_1306" xlink:to="loc_us-gaap_PlanNameDomain_1307_default" use="optional" order="5" />
<loc xlink:type="locator" xlink:href="roiv-20210630.xsd#roiv_TwoThousandFifteenEquityIncentivePlanMember" xlink:label="loc_roiv_TwoThousandFifteenEquityIncentivePlanMember_1311" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PlanNameDomain_1307" xlink:to="loc_roiv_TwoThousandFifteenEquityIncentivePlanMember_1311" use="optional" order="6" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AwardTypeAxis" xlink:label="loc_us-gaap_AwardTypeAxis_1305" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_1308" xlink:to="loc_us-gaap_AwardTypeAxis_1305" use="optional" order="7" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_1310" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AwardTypeAxis_1305" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_1310" use="optional" order="8" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_1310_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AwardTypeAxis_1305" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_1310_default" use="optional" order="9" />
<loc xlink:type="locator" xlink:href="roiv-20210630.xsd#roiv_PerformanceOptionsMember" xlink:label="loc_roiv_PerformanceOptionsMember_1325" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_1310" xlink:to="loc_roiv_PerformanceOptionsMember_1325" use="optional" order="10" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_1314" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_1309" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_1314" use="optional" order="11" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_1313" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_1309" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_1313" use="optional" order="12" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_1318" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_1309" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_1318" use="optional" order="13" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_1317" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_1309" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_1317" use="optional" order="14" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_1321" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_1309" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_1321" use="optional" order="15" />
<loc xlink:type="locator" xlink:href="roiv-20210630.xsd#roiv_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeitedInPeriodWeightedAverageGrantDateFairValue" xlink:label="loc_roiv_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeitedInPeriodWeightedAverageGrantDateFairValue_1322" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_1309" xlink:to="loc_roiv_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeitedInPeriodWeightedAverageGrantDateFairValue_1322" use="optional" order="16" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_1316" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_1309" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_1316" use="optional" order="17" />
<loc xlink:type="locator" xlink:href="roiv-20210630.xsd#roiv_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageGrantDateFairValue" xlink:label="loc_roiv_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageGrantDateFairValue_1320" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_1309" xlink:to="loc_roiv_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageGrantDateFairValue_1320" use="optional" order="18" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_1324" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_1309" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_1324" use="optional" order="19" />
</definitionLink>
<definitionLink xlink:type="extended" xlink:role="http://roivant.com/role/ShareBasedCompensationSummaryOfCappedValueAppreciationRightsDetail">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_1332" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_1335" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_1332" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_1335" use="optional" order="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_1331" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_1332" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_1331" xbrldt:contextElement="segment" xbrldt:closed="true" use="optional" order="2" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AwardTypeAxis" xlink:label="loc_us-gaap_AwardTypeAxis_1328" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_1331" xlink:to="loc_us-gaap_AwardTypeAxis_1328" use="optional" order="3" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_1333" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AwardTypeAxis_1328" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_1333" use="optional" order="4" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_1333_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AwardTypeAxis_1328" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_1333_default" use="optional" order="5" />
<loc xlink:type="locator" xlink:href="roiv-20210630.xsd#roiv_CappedValueAppreciationRightsMember" xlink:label="loc_roiv_CappedValueAppreciationRightsMember_1343" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_1333" xlink:to="loc_roiv_CappedValueAppreciationRightsMember_1343" use="optional" order="6" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PlanNameAxis" xlink:label="loc_us-gaap_PlanNameAxis_1329" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_1331" xlink:to="loc_us-gaap_PlanNameAxis_1329" use="optional" order="7" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PlanNameDomain" xlink:label="loc_us-gaap_PlanNameDomain_1330" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_PlanNameAxis_1329" xlink:to="loc_us-gaap_PlanNameDomain_1330" use="optional" order="8" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PlanNameDomain" xlink:label="loc_us-gaap_PlanNameDomain_1330_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_PlanNameAxis_1329" xlink:to="loc_us-gaap_PlanNameDomain_1330_default" use="optional" order="9" />
<loc xlink:type="locator" xlink:href="roiv-20210630.xsd#roiv_TwoThousandFifteenEquityIncentivePlanMember" xlink:label="loc_roiv_TwoThousandFifteenEquityIncentivePlanMember_1334" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PlanNameDomain_1330" xlink:to="loc_roiv_TwoThousandFifteenEquityIncentivePlanMember_1334" use="optional" order="10" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_1337" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_1332" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_1337" use="optional" order="11" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_1336" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_1332" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_1336" use="optional" order="12" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_1340" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_1332" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_1340" use="optional" order="13" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedWeightedAverageGrantDateFairValue" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedWeightedAverageGrantDateFairValue_1341" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_1332" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedWeightedAverageGrantDateFairValue_1341" use="optional" order="14" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue_1339" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_1332" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue_1339" use="optional" order="15" />
</definitionLink>
<definitionLink xlink:type="extended" xlink:role="http://roivant.com/role/ShareBasedCompensationSummaryOfPerformanceRestrictedStockUnitsDetail">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_1350" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_1349" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_1350" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_1349" xbrldt:contextElement="segment" xbrldt:closed="true" use="optional" order="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AwardTypeAxis" xlink:label="loc_us-gaap_AwardTypeAxis_1346" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_1349" xlink:to="loc_us-gaap_AwardTypeAxis_1346" use="optional" order="2" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_1351" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AwardTypeAxis_1346" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_1351" use="optional" order="3" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_1351_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AwardTypeAxis_1346" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_1351_default" use="optional" order="4" />
<loc xlink:type="locator" xlink:href="roiv-20210630.xsd#roiv_PerformanceRestrictedStockUnitsMember" xlink:label="loc_roiv_PerformanceRestrictedStockUnitsMember_1361" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_1351" xlink:to="loc_roiv_PerformanceRestrictedStockUnitsMember_1361" use="optional" order="5" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PlanNameAxis" xlink:label="loc_us-gaap_PlanNameAxis_1347" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_1349" xlink:to="loc_us-gaap_PlanNameAxis_1347" use="optional" order="6" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PlanNameDomain" xlink:label="loc_us-gaap_PlanNameDomain_1348" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_PlanNameAxis_1347" xlink:to="loc_us-gaap_PlanNameDomain_1348" use="optional" order="7" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PlanNameDomain" xlink:label="loc_us-gaap_PlanNameDomain_1348_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_PlanNameAxis_1347" xlink:to="loc_us-gaap_PlanNameDomain_1348_default" use="optional" order="8" />
<loc xlink:type="locator" xlink:href="roiv-20210630.xsd#roiv_PerformanceRestrictedStockUnitsPlanMember" xlink:label="loc_roiv_PerformanceRestrictedStockUnitsPlanMember_1352" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PlanNameDomain_1348" xlink:to="loc_roiv_PerformanceRestrictedStockUnitsPlanMember_1352" use="optional" order="9" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue_1357" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_1350" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue_1357" use="optional" order="10" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_1354" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_1350" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_1354" use="optional" order="11" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_1353" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_1350" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_1353" use="optional" order="12" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_1358" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_1350" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_1358" use="optional" order="13" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedWeightedAverageGrantDateFairValue" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedWeightedAverageGrantDateFairValue_1359" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_1350" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedWeightedAverageGrantDateFairValue_1359" use="optional" order="14" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_1355" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_1350" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_1355" use="optional" order="15" />
</definitionLink>
<definitionLink xlink:type="extended" xlink:role="http://roivant.com/role/ShareBasedCompensationSummaryOfCommonShareAwardActivityDetail">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_1366" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_1365" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_1366" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_1365" xbrldt:contextElement="segment" xbrldt:closed="true" use="optional" order="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AwardTypeAxis" xlink:label="loc_us-gaap_AwardTypeAxis_1364" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_1365" xlink:to="loc_us-gaap_AwardTypeAxis_1364" use="optional" order="2" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_1367" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AwardTypeAxis_1364" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_1367" use="optional" order="3" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_1367_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AwardTypeAxis_1364" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_1367_default" use="optional" order="4" />
<loc xlink:type="locator" xlink:href="roiv-20210630.xsd#roiv_CommonStockAwardsMember" xlink:label="loc_roiv_CommonStockAwardsMember_1378" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_1367" xlink:to="loc_roiv_CommonStockAwardsMember_1378" use="optional" order="5" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_1371" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_1366" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_1371" use="optional" order="6" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_1377" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_1366" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_1377" use="optional" order="7" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_1370" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_1366" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_1370" use="optional" order="8" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_1375" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_1366" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_1375" use="optional" order="9" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_1368" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_1366" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_1368" use="optional" order="10" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_1376" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_1366" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_1376" use="optional" order="11" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_1369" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_1366" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_1369" use="optional" order="12" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_1374" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_1366" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_1374" use="optional" order="13" />
</definitionLink>
<definitionLink xlink:type="extended" xlink:role="http://roivant.com/role/ShareBasedCompensationSummaryOfShareBasedCompensationExpenseDetail">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_1384" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_1383" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_1384" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_1383" xbrldt:contextElement="segment" xbrldt:closed="true" use="optional" order="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeStatementLocationAxis" xlink:label="loc_us-gaap_IncomeStatementLocationAxis_1381" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_1383" xlink:to="loc_us-gaap_IncomeStatementLocationAxis_1381" use="optional" order="2" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_1382" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_1381" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_1382" use="optional" order="3" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_1382_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_1381" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_1382_default" use="optional" order="4" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GeneralAndAdministrativeExpenseMember" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpenseMember_1386" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_1382" xlink:to="loc_us-gaap_GeneralAndAdministrativeExpenseMember_1386" use="optional" order="5" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ResearchAndDevelopmentExpenseMember" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpenseMember_1385" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_1382" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpenseMember_1385" use="optional" order="6" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AllocatedShareBasedCompensationExpense" xlink:label="loc_us-gaap_AllocatedShareBasedCompensationExpense_1387" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_1384" xlink:to="loc_us-gaap_AllocatedShareBasedCompensationExpense_1387" use="optional" order="7" />
</definitionLink>
<definitionLink xlink:type="extended" xlink:role="http://roivant.com/role/RelatedPartyTransactionsAdditionalInformationDetail">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RelatedPartyTransactionLineItems" xlink:label="loc_us-gaap_RelatedPartyTransactionLineItems_1130" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CostsAndExpensesRelatedParty" xlink:label="loc_us-gaap_CostsAndExpensesRelatedParty_1135" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_1130" xlink:to="loc_us-gaap_CostsAndExpensesRelatedParty_1135" use="optional" order="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RelatedPartyTransactionAmountsOfTransaction" xlink:label="loc_us-gaap_RelatedPartyTransactionAmountsOfTransaction_1136" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_1130" xlink:to="loc_us-gaap_RelatedPartyTransactionAmountsOfTransaction_1136" use="optional" order="2" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:label="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_1132" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_1130" xlink:to="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_1132" xbrldt:contextElement="segment" xbrldt:closed="true" use="optional" order="3" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:label="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_1131" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_1132" xlink:to="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_1131" use="optional" order="4" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RelatedPartyDomain" xlink:label="loc_us-gaap_RelatedPartyDomain_1129" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_1131" xlink:to="loc_us-gaap_RelatedPartyDomain_1129" use="optional" order="5" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RelatedPartyDomain" xlink:label="loc_us-gaap_RelatedPartyDomain_1129_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_1131" xlink:to="loc_us-gaap_RelatedPartyDomain_1129_default" use="optional" order="6" />
<loc xlink:type="locator" xlink:href="roiv-20210630.xsd#roiv_SumitomoMember" xlink:label="loc_roiv_SumitomoMember_1134" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyDomain_1129" xlink:to="loc_roiv_SumitomoMember_1134" use="optional" order="7" />
<loc xlink:type="locator" xlink:href="roiv-20210630.xsd#roiv_SumitovantMember" xlink:label="loc_roiv_SumitovantMember_1133" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyDomain_1129" xlink:to="loc_roiv_SumitovantMember_1133" use="optional" order="8" />
</definitionLink>
<definitionLink xlink:type="extended" xlink:role="http://roivant.com/role/IncomeTaxesScheduleOfLossBeforeIncomeTaxesByGeographicRegionDetail">
<loc xlink:type="locator" xlink:href="roiv-20210630.xsd#roiv_IncomeTaxDisclosureLineItems" xlink:label="loc_roiv_IncomeTaxDisclosureLineItems_1391" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestmentsAbstract" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestmentsAbstract_1390" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_roiv_IncomeTaxDisclosureLineItems_1391" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestmentsAbstract_1390" use="optional" order="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments_1395" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestmentsAbstract_1390" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments_1395" use="optional" order="2" />
<loc xlink:type="locator" xlink:href="roiv-20210630.xsd#roiv_IncomeTaxDisclosureTable" xlink:label="loc_roiv_IncomeTaxDisclosureTable_1392" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_roiv_IncomeTaxDisclosureLineItems_1391" xlink:to="loc_roiv_IncomeTaxDisclosureTable_1392" xbrldt:contextElement="segment" xbrldt:closed="true" use="optional" order="3" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_StatementGeographicalAxis" xlink:label="loc_srt_StatementGeographicalAxis_1394" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_roiv_IncomeTaxDisclosureTable_1392" xlink:to="loc_srt_StatementGeographicalAxis_1394" use="optional" order="4" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_SegmentGeographicalDomain" xlink:label="loc_srt_SegmentGeographicalDomain_1393" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_StatementGeographicalAxis_1394" xlink:to="loc_srt_SegmentGeographicalDomain_1393" use="optional" order="5" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_SegmentGeographicalDomain" xlink:label="loc_srt_SegmentGeographicalDomain_1393_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_StatementGeographicalAxis_1394" xlink:to="loc_srt_SegmentGeographicalDomain_1393_default" use="optional" order="6" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/country/2021/country-2021.xsd#country_BM" xlink:label="loc_country_BM_1398" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_SegmentGeographicalDomain_1393" xlink:to="loc_country_BM_1398" use="optional" order="7" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/country/2021/country-2021.xsd#country_CH" xlink:label="loc_country_CH_1397" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_SegmentGeographicalDomain_1393" xlink:to="loc_country_CH_1397" use="optional" order="8" />
<loc xlink:type="locator" xlink:href="roiv-20210630.xsd#roiv_OtherMember" xlink:label="loc_roiv_OtherMember_1399" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_SegmentGeographicalDomain_1393" xlink:to="loc_roiv_OtherMember_1399" use="optional" order="9" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/country/2021/country-2021.xsd#country_US" xlink:label="loc_country_US_1396" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_SegmentGeographicalDomain_1393" xlink:to="loc_country_US_1396" use="optional" order="10" />
</definitionLink>
<definitionLink xlink:type="extended" xlink:role="http://roivant.com/role/IncomeTaxesScheduleComponentsOfIncomeTaxExpenseBenefitDetail">
<loc xlink:type="locator" xlink:href="roiv-20210630.xsd#roiv_ComponentsOfIncomeTaxExpenseLineItems" xlink:label="loc_roiv_ComponentsOfIncomeTaxExpenseLineItems_772" />
<loc xlink:type="locator" xlink:href="roiv-20210630.xsd#roiv_ComponentsOfIncomeTaxExpenseTable" xlink:label="loc_roiv_ComponentsOfIncomeTaxExpenseTable_773" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_roiv_ComponentsOfIncomeTaxExpenseLineItems_772" xlink:to="loc_roiv_ComponentsOfIncomeTaxExpenseTable_773" xbrldt:contextElement="segment" xbrldt:closed="true" use="optional" order="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_StatementGeographicalAxis" xlink:label="loc_srt_StatementGeographicalAxis_779" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_roiv_ComponentsOfIncomeTaxExpenseTable_773" xlink:to="loc_srt_StatementGeographicalAxis_779" use="optional" order="2" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_SegmentGeographicalDomain" xlink:label="loc_srt_SegmentGeographicalDomain_778" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_StatementGeographicalAxis_779" xlink:to="loc_srt_SegmentGeographicalDomain_778" use="optional" order="3" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_SegmentGeographicalDomain" xlink:label="loc_srt_SegmentGeographicalDomain_778_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_StatementGeographicalAxis_779" xlink:to="loc_srt_SegmentGeographicalDomain_778_default" use="optional" order="4" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/country/2021/country-2021.xsd#country_US" xlink:label="loc_country_US_789" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_SegmentGeographicalDomain_778" xlink:to="loc_country_US_789" use="optional" order="5" />
<loc xlink:type="locator" xlink:href="roiv-20210630.xsd#roiv_OtherMember" xlink:label="loc_roiv_OtherMember_792" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_SegmentGeographicalDomain_778" xlink:to="loc_roiv_OtherMember_792" use="optional" order="6" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/country/2021/country-2021.xsd#country_BM" xlink:label="loc_country_BM_791" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_SegmentGeographicalDomain_778" xlink:to="loc_country_BM_791" use="optional" order="7" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/country/2021/country-2021.xsd#country_CH" xlink:label="loc_country_CH_790" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_SegmentGeographicalDomain_778" xlink:to="loc_country_CH_790" use="optional" order="8" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_LegalEntityAxis" xlink:label="loc_dei_LegalEntityAxis_777" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_roiv_ComponentsOfIncomeTaxExpenseTable_773" xlink:to="loc_dei_LegalEntityAxis_777" use="optional" order="9" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityDomain" xlink:label="loc_dei_EntityDomain_776" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_dei_LegalEntityAxis_777" xlink:to="loc_dei_EntityDomain_776" use="optional" order="10" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityDomain" xlink:label="loc_dei_EntityDomain_776_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_dei_LegalEntityAxis_777" xlink:to="loc_dei_EntityDomain_776_default" use="optional" order="11" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract" xlink:label="loc_us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract_774" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_roiv_ComponentsOfIncomeTaxExpenseLineItems_772" xlink:to="loc_us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract_774" use="optional" order="12" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CurrentIncomeTaxExpenseBenefit" xlink:label="loc_us-gaap_CurrentIncomeTaxExpenseBenefit_782" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract_774" xlink:to="loc_us-gaap_CurrentIncomeTaxExpenseBenefit_782" use="optional" order="13" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract" xlink:label="loc_us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract_775" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_roiv_ComponentsOfIncomeTaxExpenseLineItems_772" xlink:to="loc_us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract_775" use="optional" order="14" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredIncomeTaxExpenseBenefit" xlink:label="loc_us-gaap_DeferredIncomeTaxExpenseBenefit_786" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract_775" xlink:to="loc_us-gaap_DeferredIncomeTaxExpenseBenefit_786" use="optional" order="15" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxExpenseBenefit" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit_781" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_roiv_ComponentsOfIncomeTaxExpenseLineItems_772" xlink:to="loc_us-gaap_IncomeTaxExpenseBenefit_781" use="optional" order="16" />
</definitionLink>
<definitionLink xlink:type="extended" xlink:role="http://roivant.com/role/IncomeTaxesAdditionalInformationDetail">
<loc xlink:type="locator" xlink:href="roiv-20210630.xsd#roiv_IncomeTaxDisclosureLineItems" xlink:label="loc_roiv_IncomeTaxDisclosureLineItems_857" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLossCarryforwards" xlink:label="loc_us-gaap_OperatingLossCarryforwards_864" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_roiv_IncomeTaxDisclosureLineItems_857" xlink:to="loc_us-gaap_OperatingLossCarryforwards_864" use="optional" order="1" />
<loc xlink:type="locator" xlink:href="roiv-20210630.xsd#roiv_IncomeTaxDisclosureTable" xlink:label="loc_roiv_IncomeTaxDisclosureTable_858" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_roiv_IncomeTaxDisclosureLineItems_857" xlink:to="loc_roiv_IncomeTaxDisclosureTable_858" xbrldt:contextElement="segment" xbrldt:closed="true" use="optional" order="2" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_StatementGeographicalAxis" xlink:label="loc_srt_StatementGeographicalAxis_863" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_roiv_IncomeTaxDisclosureTable_858" xlink:to="loc_srt_StatementGeographicalAxis_863" use="optional" order="3" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_SegmentGeographicalDomain" xlink:label="loc_srt_SegmentGeographicalDomain_862" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_StatementGeographicalAxis_863" xlink:to="loc_srt_SegmentGeographicalDomain_862" use="optional" order="4" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_SegmentGeographicalDomain" xlink:label="loc_srt_SegmentGeographicalDomain_862_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_StatementGeographicalAxis_863" xlink:to="loc_srt_SegmentGeographicalDomain_862_default" use="optional" order="5" />
<loc xlink:type="locator" xlink:href="roiv-20210630.xsd#roiv_TaxAuthorityInOtherJurisdictionsMember" xlink:label="loc_roiv_TaxAuthorityInOtherJurisdictionsMember_880" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_SegmentGeographicalDomain_862" xlink:to="loc_roiv_TaxAuthorityInOtherJurisdictionsMember_880" use="optional" order="6" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/country/2021/country-2021.xsd#country_US" xlink:label="loc_country_US_878" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_SegmentGeographicalDomain_862" xlink:to="loc_country_US_878" use="optional" order="7" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/country/2021/country-2021.xsd#country_GB" xlink:label="loc_country_GB_879" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_SegmentGeographicalDomain_862" xlink:to="loc_country_GB_879" use="optional" order="8" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/country/2021/country-2021.xsd#country_CH" xlink:label="loc_country_CH_877" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_SegmentGeographicalDomain_862" xlink:to="loc_country_CH_877" use="optional" order="9" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_LegalEntityAxis" xlink:label="loc_dei_LegalEntityAxis_859" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_roiv_IncomeTaxDisclosureTable_858" xlink:to="loc_dei_LegalEntityAxis_859" use="optional" order="10" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityDomain" xlink:label="loc_dei_EntityDomain_854" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_dei_LegalEntityAxis_859" xlink:to="loc_dei_EntityDomain_854" use="optional" order="11" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityDomain" xlink:label="loc_dei_EntityDomain_854_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_dei_LegalEntityAxis_859" xlink:to="loc_dei_EntityDomain_854_default" use="optional" order="12" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxAuthorityAxis" xlink:label="loc_us-gaap_IncomeTaxAuthorityAxis_855" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_roiv_IncomeTaxDisclosureTable_858" xlink:to="loc_us-gaap_IncomeTaxAuthorityAxis_855" use="optional" order="13" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxAuthorityDomain" xlink:label="loc_us-gaap_IncomeTaxAuthorityDomain_856" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_IncomeTaxAuthorityAxis_855" xlink:to="loc_us-gaap_IncomeTaxAuthorityDomain_856" use="optional" order="14" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxAuthorityDomain" xlink:label="loc_us-gaap_IncomeTaxAuthorityDomain_856_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_IncomeTaxAuthorityAxis_855" xlink:to="loc_us-gaap_IncomeTaxAuthorityDomain_856_default" use="optional" order="15" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StateAndLocalJurisdictionMember" xlink:label="loc_us-gaap_StateAndLocalJurisdictionMember_873" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeTaxAuthorityDomain_856" xlink:to="loc_us-gaap_StateAndLocalJurisdictionMember_873" use="optional" order="16" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeAxis" xlink:label="loc_srt_RangeAxis_860" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_roiv_IncomeTaxDisclosureTable_858" xlink:to="loc_srt_RangeAxis_860" use="optional" order="17" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeMember" xlink:label="loc_srt_RangeMember_861" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_RangeAxis_860" xlink:to="loc_srt_RangeMember_861" use="optional" order="18" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeMember" xlink:label="loc_srt_RangeMember_861_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_RangeAxis_860" xlink:to="loc_srt_RangeMember_861_default" use="optional" order="19" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MinimumMember" xlink:label="loc_srt_MinimumMember_875" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_861" xlink:to="loc_srt_MinimumMember_875" use="optional" order="20" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MaximumMember" xlink:label="loc_srt_MaximumMember_876" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_861" xlink:to="loc_srt_MaximumMember_876" use="optional" order="21" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLossCarryforwardsExpirationDate" xlink:label="loc_us-gaap_OperatingLossCarryforwardsExpirationDate_866" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_roiv_IncomeTaxDisclosureLineItems_857" xlink:to="loc_us-gaap_OperatingLossCarryforwardsExpirationDate_866" use="optional" order="22" />
<loc xlink:type="locator" xlink:href="roiv-20210630.xsd#roiv_PercentageOfFutureTaxableIncome" xlink:label="loc_roiv_PercentageOfFutureTaxableIncome_865" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_roiv_IncomeTaxDisclosureLineItems_857" xlink:to="loc_roiv_PercentageOfFutureTaxableIncome_865" use="optional" order="23" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TaxCreditCarryforwardAmount" xlink:label="loc_us-gaap_TaxCreditCarryforwardAmount_867" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_roiv_IncomeTaxDisclosureLineItems_857" xlink:to="loc_us-gaap_TaxCreditCarryforwardAmount_867" use="optional" order="24" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TaxCreditCarryforwardExpirationDate" xlink:label="loc_us-gaap_TaxCreditCarryforwardExpirationDate_868" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_roiv_IncomeTaxDisclosureLineItems_857" xlink:to="loc_us-gaap_TaxCreditCarryforwardExpirationDate_868" use="optional" order="25" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_UnrecognizedTaxBenefits" xlink:label="loc_us-gaap_UnrecognizedTaxBenefits_871" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_roiv_IncomeTaxDisclosureLineItems_857" xlink:to="loc_us-gaap_UnrecognizedTaxBenefits_871" use="optional" order="26" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount" xlink:label="loc_us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount_870" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_roiv_IncomeTaxDisclosureLineItems_857" xlink:to="loc_us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount_870" use="optional" order="27" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsValuationAllowance" xlink:label="loc_us-gaap_DeferredTaxAssetsValuationAllowance_869" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_roiv_IncomeTaxDisclosureLineItems_857" xlink:to="loc_us-gaap_DeferredTaxAssetsValuationAllowance_869" use="optional" order="28" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations_853" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_roiv_IncomeTaxDisclosureLineItems_857" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations_853" use="optional" order="29" />
</definitionLink>
<definitionLink xlink:type="extended" xlink:role="http://roivant.com/role/IncomeTaxesScheduleOfDeferredTaxAssetsLiabilitiesDetail">
<loc xlink:type="locator" xlink:href="roiv-20210630.xsd#roiv_DeferredTaxAssetsLiabilitiesLineItems" xlink:label="loc_roiv_DeferredTaxAssetsLiabilitiesLineItems_796" />
<loc xlink:type="locator" xlink:href="roiv-20210630.xsd#roiv_DeferredTaxAssetsLiabilitiesTable" xlink:label="loc_roiv_DeferredTaxAssetsLiabilitiesTable_797" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_roiv_DeferredTaxAssetsLiabilitiesLineItems_796" xlink:to="loc_roiv_DeferredTaxAssetsLiabilitiesTable_797" xbrldt:contextElement="segment" xbrldt:closed="true" use="optional" order="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_LegalEntityAxis" xlink:label="loc_dei_LegalEntityAxis_800" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_roiv_DeferredTaxAssetsLiabilitiesTable_797" xlink:to="loc_dei_LegalEntityAxis_800" use="optional" order="2" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityDomain" xlink:label="loc_dei_EntityDomain_799" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_dei_LegalEntityAxis_800" xlink:to="loc_dei_EntityDomain_799" use="optional" order="3" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityDomain" xlink:label="loc_dei_EntityDomain_799_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_dei_LegalEntityAxis_800" xlink:to="loc_dei_EntityDomain_799_default" use="optional" order="4" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsValuationAllowance" xlink:label="loc_us-gaap_DeferredTaxAssetsValuationAllowance_809" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_roiv_DeferredTaxAssetsLiabilitiesLineItems_796" xlink:to="loc_us-gaap_DeferredTaxAssetsValuationAllowance_809" use="optional" order="5" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxLiabilitiesAbstract" xlink:label="loc_us-gaap_DeferredTaxLiabilitiesAbstract_798" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_roiv_DeferredTaxAssetsLiabilitiesLineItems_796" xlink:to="loc_us-gaap_DeferredTaxLiabilitiesAbstract_798" use="optional" order="6" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsLiabilitiesNet" xlink:label="loc_us-gaap_DeferredTaxAssetsLiabilitiesNet_816" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DeferredTaxLiabilitiesAbstract_798" xlink:to="loc_us-gaap_DeferredTaxAssetsLiabilitiesNet_816" use="optional" order="7" />
<loc xlink:type="locator" xlink:href="roiv-20210630.xsd#roiv_DeferredTaxLiabilitiesDepreciation" xlink:label="loc_roiv_DeferredTaxLiabilitiesDepreciation_811" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DeferredTaxLiabilitiesAbstract_798" xlink:to="loc_roiv_DeferredTaxLiabilitiesDepreciation_811" use="optional" order="8" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxLiabilitiesOther" xlink:label="loc_us-gaap_DeferredTaxLiabilitiesOther_815" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DeferredTaxLiabilitiesAbstract_798" xlink:to="loc_us-gaap_DeferredTaxLiabilitiesOther_815" use="optional" order="9" />
<loc xlink:type="locator" xlink:href="roiv-20210630.xsd#roiv_DeferredTaxLiabilitiesRightOfUseAssets" xlink:label="loc_roiv_DeferredTaxLiabilitiesRightOfUseAssets_813" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DeferredTaxLiabilitiesAbstract_798" xlink:to="loc_roiv_DeferredTaxLiabilitiesRightOfUseAssets_813" use="optional" order="10" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsGrossAbstract" xlink:label="loc_us-gaap_DeferredTaxAssetsGrossAbstract_795" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_roiv_DeferredTaxAssetsLiabilitiesLineItems_796" xlink:to="loc_us-gaap_DeferredTaxAssetsGrossAbstract_795" use="optional" order="11" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsGoodwillAndIntangibleAssets" xlink:label="loc_us-gaap_DeferredTaxAssetsGoodwillAndIntangibleAssets_803" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DeferredTaxAssetsGrossAbstract_795" xlink:to="loc_us-gaap_DeferredTaxAssetsGoodwillAndIntangibleAssets_803" use="optional" order="12" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsGross" xlink:label="loc_us-gaap_DeferredTaxAssetsGross_808" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DeferredTaxAssetsGrossAbstract_795" xlink:to="loc_us-gaap_DeferredTaxAssetsGross_808" use="optional" order="13" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:label="loc_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_804" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DeferredTaxAssetsGrossAbstract_795" xlink:to="loc_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_804" use="optional" order="14" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsOther" xlink:label="loc_us-gaap_DeferredTaxAssetsOther_807" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DeferredTaxAssetsGrossAbstract_795" xlink:to="loc_us-gaap_DeferredTaxAssetsOther_807" use="optional" order="15" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch" xlink:label="loc_us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch_801" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DeferredTaxAssetsGrossAbstract_795" xlink:to="loc_us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch_801" use="optional" order="16" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" xlink:label="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost_805" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DeferredTaxAssetsGrossAbstract_795" xlink:to="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost_805" use="optional" order="17" />
<loc xlink:type="locator" xlink:href="roiv-20210630.xsd#roiv_DeferredTaxAssetsLeaseLiabilities" xlink:label="loc_roiv_DeferredTaxAssetsLeaseLiabilities_806" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DeferredTaxAssetsGrossAbstract_795" xlink:to="loc_roiv_DeferredTaxAssetsLeaseLiabilities_806" use="optional" order="18" />
</definitionLink>
<definitionLink xlink:type="extended" xlink:role="http://roivant.com/role/IncomeTaxesScheduleOfEffectiveIncomeTaxRateReconciliationDetail">
<loc xlink:type="locator" xlink:href="roiv-20210630.xsd#roiv_EffectiveTaxRateReconcilingItemsLineItems" xlink:label="loc_roiv_EffectiveTaxRateReconcilingItemsLineItems_821" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract_820" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_roiv_EffectiveTaxRateReconcilingItemsLineItems_821" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract_820" use="optional" order="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance_836" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract_820" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance_836" use="optional" order="2" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations_838" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract_820" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations_838" use="optional" order="3" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential_827" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract_820" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential_827" use="optional" order="4" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate_835" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract_820" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate_835" use="optional" order="5" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationDispositionOfBusiness" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationDispositionOfBusiness_832" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract_820" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationDispositionOfBusiness_832" use="optional" order="6" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseResearchAndDevelopment" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseResearchAndDevelopment_829" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract_820" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseResearchAndDevelopment_829" use="optional" order="7" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments_837" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract_820" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments_837" use="optional" order="8" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsResearch" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsResearch_834" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract_820" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsResearch_834" use="optional" order="9" />
<loc xlink:type="locator" xlink:href="roiv-20210630.xsd#roiv_EffectiveIncomeTaxReconciliationPermanentDifferences" xlink:label="loc_roiv_EffectiveIncomeTaxReconciliationPermanentDifferences_833" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract_820" xlink:to="loc_roiv_EffectiveIncomeTaxReconciliationPermanentDifferences_833" use="optional" order="10" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpense" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpense_831" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract_820" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpense_831" use="optional" order="11" />
<loc xlink:type="locator" xlink:href="roiv-20210630.xsd#roiv_EffectiveTaxRateReconcilingItemsTable" xlink:label="loc_roiv_EffectiveTaxRateReconcilingItemsTable_822" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_roiv_EffectiveTaxRateReconcilingItemsLineItems_821" xlink:to="loc_roiv_EffectiveTaxRateReconcilingItemsTable_822" xbrldt:contextElement="segment" xbrldt:closed="true" use="optional" order="12" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_LegalEntityAxis" xlink:label="loc_dei_LegalEntityAxis_825" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_roiv_EffectiveTaxRateReconcilingItemsTable_822" xlink:to="loc_dei_LegalEntityAxis_825" use="optional" order="13" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityDomain" xlink:label="loc_dei_EntityDomain_823" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_dei_LegalEntityAxis_825" xlink:to="loc_dei_EntityDomain_823" use="optional" order="14" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityDomain" xlink:label="loc_dei_EntityDomain_823_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_dei_LegalEntityAxis_825" xlink:to="loc_dei_EntityDomain_823_default" use="optional" order="15" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxExpenseBenefitContinuingOperationsIncomeTaxReconciliationAbstract" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefitContinuingOperationsIncomeTaxReconciliationAbstract_824" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_roiv_EffectiveTaxRateReconcilingItemsLineItems_821" xlink:to="loc_us-gaap_IncomeTaxExpenseBenefitContinuingOperationsIncomeTaxReconciliationAbstract_824" use="optional" order="16" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxReconciliationNondeductibleExpenseResearchAndDevelopment" xlink:label="loc_us-gaap_IncomeTaxReconciliationNondeductibleExpenseResearchAndDevelopment_842" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefitContinuingOperationsIncomeTaxReconciliationAbstract_824" xlink:to="loc_us-gaap_IncomeTaxReconciliationNondeductibleExpenseResearchAndDevelopment_842" use="optional" order="17" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxReconciliationOtherAdjustments" xlink:label="loc_us-gaap_IncomeTaxReconciliationOtherAdjustments_849" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefitContinuingOperationsIncomeTaxReconciliationAbstract_824" xlink:to="loc_us-gaap_IncomeTaxReconciliationOtherAdjustments_849" use="optional" order="18" />
<loc xlink:type="locator" xlink:href="roiv-20210630.xsd#roiv_IncomeTaxReconciliationPermanentAdjustments" xlink:label="loc_roiv_IncomeTaxReconciliationPermanentAdjustments_845" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefitContinuingOperationsIncomeTaxReconciliationAbstract_824" xlink:to="loc_roiv_IncomeTaxReconciliationPermanentAdjustments_845" use="optional" order="19" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxReconciliationTaxCreditsResearch" xlink:label="loc_us-gaap_IncomeTaxReconciliationTaxCreditsResearch_846" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefitContinuingOperationsIncomeTaxReconciliationAbstract_824" xlink:to="loc_us-gaap_IncomeTaxReconciliationTaxCreditsResearch_846" use="optional" order="20" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:label="loc_us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance_848" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefitContinuingOperationsIncomeTaxReconciliationAbstract_824" xlink:to="loc_us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance_848" use="optional" order="21" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxReconciliationChangeInEnactedTaxRate" xlink:label="loc_us-gaap_IncomeTaxReconciliationChangeInEnactedTaxRate_847" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefitContinuingOperationsIncomeTaxReconciliationAbstract_824" xlink:to="loc_us-gaap_IncomeTaxReconciliationChangeInEnactedTaxRate_847" use="optional" order="22" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxReconciliationDispositionOfBusiness" xlink:label="loc_us-gaap_IncomeTaxReconciliationDispositionOfBusiness_844" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefitContinuingOperationsIncomeTaxReconciliationAbstract_824" xlink:to="loc_us-gaap_IncomeTaxReconciliationDispositionOfBusiness_844" use="optional" order="23" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxReconciliationForeignIncomeTaxRateDifferential" xlink:label="loc_us-gaap_IncomeTaxReconciliationForeignIncomeTaxRateDifferential_841" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefitContinuingOperationsIncomeTaxReconciliationAbstract_824" xlink:to="loc_us-gaap_IncomeTaxReconciliationForeignIncomeTaxRateDifferential_841" use="optional" order="24" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate" xlink:label="loc_us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate_840" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefitContinuingOperationsIncomeTaxReconciliationAbstract_824" xlink:to="loc_us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate_840" use="optional" order="25" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxReconciliationNondeductibleExpense" xlink:label="loc_us-gaap_IncomeTaxReconciliationNondeductibleExpense_843" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefitContinuingOperationsIncomeTaxReconciliationAbstract_824" xlink:to="loc_us-gaap_IncomeTaxReconciliationNondeductibleExpense_843" use="optional" order="26" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxExpenseBenefit" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit_850" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefitContinuingOperationsIncomeTaxReconciliationAbstract_824" xlink:to="loc_us-gaap_IncomeTaxExpenseBenefit_850" use="optional" order="27" />
</definitionLink>
<definitionLink xlink:type="extended" xlink:role="http://roivant.com/role/FairValueMeasurementsScheduleOfAssetsAndLiabilitiesMeasuredAtFairValueOnARecurringBasisDetail">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_685" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentFairValue" xlink:label="loc_us-gaap_DebtInstrumentFairValue_702" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_685" xlink:to="loc_us-gaap_DebtInstrumentFairValue_702" use="optional" order="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DerivativeInstrumentsNotDesignatedAsHedgingInstrumentsLiabilityAtFairValue" xlink:label="loc_us-gaap_DerivativeInstrumentsNotDesignatedAsHedgingInstrumentsLiabilityAtFairValue_704" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_685" xlink:to="loc_us-gaap_DerivativeInstrumentsNotDesignatedAsHedgingInstrumentsLiabilityAtFairValue_704" use="optional" order="2" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_686" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_685" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_686" xbrldt:contextElement="segment" xbrldt:closed="true" use="optional" order="3" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfWarrantOrRightAxis" xlink:label="loc_us-gaap_ClassOfWarrantOrRightAxis_682" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_686" xlink:to="loc_us-gaap_ClassOfWarrantOrRightAxis_682" use="optional" order="4" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfWarrantOrRightDomain" xlink:label="loc_us-gaap_ClassOfWarrantOrRightDomain_683" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_ClassOfWarrantOrRightAxis_682" xlink:to="loc_us-gaap_ClassOfWarrantOrRightDomain_683" use="optional" order="5" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfWarrantOrRightDomain" xlink:label="loc_us-gaap_ClassOfWarrantOrRightDomain_683_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_ClassOfWarrantOrRightAxis_682" xlink:to="loc_us-gaap_ClassOfWarrantOrRightDomain_683_default" use="optional" order="6" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueByAssetClassAxis" xlink:label="loc_us-gaap_FairValueByAssetClassAxis_688" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_686" xlink:to="loc_us-gaap_FairValueByAssetClassAxis_688" use="optional" order="7" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" xlink:label="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_687" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FairValueByAssetClassAxis_688" xlink:to="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_687" use="optional" order="8" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" xlink:label="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_687_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FairValueByAssetClassAxis_688" xlink:to="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_687_default" use="optional" order="9" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockMember" xlink:label="loc_us-gaap_CommonStockMember_710" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_687" xlink:to="loc_us-gaap_CommonStockMember_710" use="optional" order="10" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConvertiblePreferredStockMember" xlink:label="loc_us-gaap_ConvertiblePreferredStockMember_711" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_687" xlink:to="loc_us-gaap_ConvertiblePreferredStockMember_711" use="optional" order="11" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MoneyMarketFundsMember" xlink:label="loc_us-gaap_MoneyMarketFundsMember_709" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_687" xlink:to="loc_us-gaap_MoneyMarketFundsMember_709" use="optional" order="12" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherInvestmentCompaniesMember" xlink:label="loc_us-gaap_OtherInvestmentCompaniesMember_712" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_687" xlink:to="loc_us-gaap_OtherInvestmentCompaniesMember_712" use="optional" order="13" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:label="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_689" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_686" xlink:to="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_689" use="optional" order="14" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_692" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_689" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_692" use="optional" order="15" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_692_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_689" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_692_default" use="optional" order="16" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueInputsLevel2Member" xlink:label="loc_us-gaap_FairValueInputsLevel2Member_715" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_692" xlink:to="loc_us-gaap_FairValueInputsLevel2Member_715" use="optional" order="17" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueInputsLevel3Member" xlink:label="loc_us-gaap_FairValueInputsLevel3Member_716" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_692" xlink:to="loc_us-gaap_FairValueInputsLevel3Member_716" use="optional" order="18" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueInputsLevel1Member" xlink:label="loc_us-gaap_FairValueInputsLevel1Member_714" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_692" xlink:to="loc_us-gaap_FairValueInputsLevel1Member_714" use="optional" order="19" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueByMeasurementFrequencyAxis" xlink:label="loc_us-gaap_FairValueByMeasurementFrequencyAxis_690" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_686" xlink:to="loc_us-gaap_FairValueByMeasurementFrequencyAxis_690" use="optional" order="20" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementFrequencyDomain" xlink:label="loc_us-gaap_FairValueMeasurementFrequencyDomain_691" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FairValueByMeasurementFrequencyAxis_690" xlink:to="loc_us-gaap_FairValueMeasurementFrequencyDomain_691" use="optional" order="21" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementFrequencyDomain" xlink:label="loc_us-gaap_FairValueMeasurementFrequencyDomain_691_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FairValueByMeasurementFrequencyAxis_690" xlink:to="loc_us-gaap_FairValueMeasurementFrequencyDomain_691_default" use="optional" order="22" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementsRecurringMember" xlink:label="loc_us-gaap_FairValueMeasurementsRecurringMember_713" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementFrequencyDomain_691" xlink:to="loc_us-gaap_FairValueMeasurementsRecurringMember_713" use="optional" order="23" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_LegalEntityAxis" xlink:label="loc_dei_LegalEntityAxis_693" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_686" xlink:to="loc_dei_LegalEntityAxis_693" use="optional" order="24" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityDomain" xlink:label="loc_dei_EntityDomain_684" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_dei_LegalEntityAxis_693" xlink:to="loc_dei_EntityDomain_684" use="optional" order="25" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityDomain" xlink:label="loc_dei_EntityDomain_684_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_dei_LegalEntityAxis_693" xlink:to="loc_dei_EntityDomain_684_default" use="optional" order="26" />
<loc xlink:type="locator" xlink:href="roiv-20210630.xsd#roiv_ArbutusBiopharmaCorporationMember" xlink:label="loc_roiv_ArbutusBiopharmaCorporationMember_698" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityDomain_684" xlink:to="loc_roiv_ArbutusBiopharmaCorporationMember_698" use="optional" order="27" />
<loc xlink:type="locator" xlink:href="roiv-20210630.xsd#roiv_SioGeneTherapiesIncMember" xlink:label="loc_roiv_SioGeneTherapiesIncMember_697" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityDomain_684" xlink:to="loc_roiv_SioGeneTherapiesIncMember_697" use="optional" order="28" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetsFairValueDisclosure" xlink:label="loc_us-gaap_AssetsFairValueDisclosure_701" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_685" xlink:to="loc_us-gaap_AssetsFairValueDisclosure_701" use="optional" order="29" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashAndCashEquivalentsFairValueDisclosure" xlink:label="loc_us-gaap_CashAndCashEquivalentsFairValueDisclosure_699" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_685" xlink:to="loc_us-gaap_CashAndCashEquivalentsFairValueDisclosure_699" use="optional" order="30" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InvestmentsFairValueDisclosure" xlink:label="loc_us-gaap_InvestmentsFairValueDisclosure_700" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_685" xlink:to="loc_us-gaap_InvestmentsFairValueDisclosure_700" use="optional" order="31" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesFairValueDisclosure" xlink:label="loc_us-gaap_LiabilitiesFairValueDisclosure_706" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_685" xlink:to="loc_us-gaap_LiabilitiesFairValueDisclosure_706" use="optional" order="32" />
</definitionLink>
<definitionLink xlink:type="extended" xlink:role="http://roivant.com/role/FairValueMeasurementsAdditionalInformationDetail">
<loc xlink:type="locator" xlink:href="roiv-20210630.xsd#roiv_FairValueDisclosuresLineItems" xlink:label="loc_roiv_FairValueDisclosuresLineItems_722" />
<loc xlink:type="locator" xlink:href="roiv-20210630.xsd#roiv_FairValueDisclosuresTable" xlink:label="loc_roiv_FairValueDisclosuresTable_723" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_roiv_FairValueDisclosuresLineItems_722" xlink:to="loc_roiv_FairValueDisclosuresTable_723" xbrldt:contextElement="segment" xbrldt:closed="true" use="optional" order="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_LegalEntityAxis" xlink:label="loc_dei_LegalEntityAxis_724" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_roiv_FairValueDisclosuresTable_723" xlink:to="loc_dei_LegalEntityAxis_724" use="optional" order="2" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityDomain" xlink:label="loc_dei_EntityDomain_721" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_dei_LegalEntityAxis_724" xlink:to="loc_dei_EntityDomain_721" use="optional" order="3" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityDomain" xlink:label="loc_dei_EntityDomain_721_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_dei_LegalEntityAxis_724" xlink:to="loc_dei_EntityDomain_721_default" use="optional" order="4" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MeasurementInputTypeAxis" xlink:label="loc_us-gaap_MeasurementInputTypeAxis_725" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_roiv_FairValueDisclosuresTable_723" xlink:to="loc_us-gaap_MeasurementInputTypeAxis_725" use="optional" order="5" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MeasurementInputTypeDomain" xlink:label="loc_us-gaap_MeasurementInputTypeDomain_726" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_MeasurementInputTypeAxis_725" xlink:to="loc_us-gaap_MeasurementInputTypeDomain_726" use="optional" order="6" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MeasurementInputTypeDomain" xlink:label="loc_us-gaap_MeasurementInputTypeDomain_726_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_MeasurementInputTypeAxis_725" xlink:to="loc_us-gaap_MeasurementInputTypeDomain_726_default" use="optional" order="7" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MeasurementInputDiscountRateMember" xlink:label="loc_us-gaap_MeasurementInputDiscountRateMember_736" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_MeasurementInputTypeDomain_726" xlink:to="loc_us-gaap_MeasurementInputDiscountRateMember_736" use="optional" order="8" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeAxis" xlink:label="loc_srt_RangeAxis_727" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_roiv_FairValueDisclosuresTable_723" xlink:to="loc_srt_RangeAxis_727" use="optional" order="9" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeMember" xlink:label="loc_srt_RangeMember_728" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_RangeAxis_727" xlink:to="loc_srt_RangeMember_728" use="optional" order="10" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeMember" xlink:label="loc_srt_RangeMember_728_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_RangeAxis_727" xlink:to="loc_srt_RangeMember_728_default" use="optional" order="11" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MaximumMember" xlink:label="loc_srt_MaximumMember_738" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_728" xlink:to="loc_srt_MaximumMember_738" use="optional" order="12" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MinimumMember" xlink:label="loc_srt_MinimumMember_737" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_728" xlink:to="loc_srt_MinimumMember_737" use="optional" order="13" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BalanceSheetLocationAxis" xlink:label="loc_us-gaap_BalanceSheetLocationAxis_719" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_roiv_FairValueDisclosuresTable_723" xlink:to="loc_us-gaap_BalanceSheetLocationAxis_719" use="optional" order="14" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BalanceSheetLocationDomain" xlink:label="loc_us-gaap_BalanceSheetLocationDomain_720" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_BalanceSheetLocationAxis_719" xlink:to="loc_us-gaap_BalanceSheetLocationDomain_720" use="optional" order="15" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BalanceSheetLocationDomain" xlink:label="loc_us-gaap_BalanceSheetLocationDomain_720_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_BalanceSheetLocationAxis_719" xlink:to="loc_us-gaap_BalanceSheetLocationDomain_720_default" use="optional" order="16" />
<loc xlink:type="locator" xlink:href="roiv-20210630.xsd#roiv_LiabilityInstrumentsMeasuredAtFairValueMember" xlink:label="loc_roiv_LiabilityInstrumentsMeasuredAtFairValueMember_729" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BalanceSheetLocationDomain_720" xlink:to="loc_roiv_LiabilityInstrumentsMeasuredAtFairValueMember_729" use="optional" order="17" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1_735" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_roiv_FairValueDisclosuresLineItems_722" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1_735" use="optional" order="18" />
<loc xlink:type="locator" xlink:href="roiv-20210630.xsd#roiv_EquityInterestOptionToThirdPartyPurchaser" xlink:label="loc_roiv_EquityInterestOptionToThirdPartyPurchaser_1106618" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_roiv_FairValueDisclosuresLineItems_722" xlink:to="loc_roiv_EquityInterestOptionToThirdPartyPurchaser_1106618" use="optional" order="19" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentMeasurementInput" xlink:label="loc_us-gaap_DebtInstrumentMeasurementInput_734" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_roiv_FairValueDisclosuresLineItems_722" xlink:to="loc_us-gaap_DebtInstrumentMeasurementInput_734" use="optional" order="20" />
</definitionLink>
<definitionLink xlink:type="extended" xlink:role="http://roivant.com/role/FairValueMeasurementsChangeInTheFairValueOfTheDerivativeWarrantLiabilitiesDetail">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaap_StatementLineItems_763" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_767" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_763" xlink:to="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_767" use="optional" order="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings_768" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_763" xlink:to="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings_768" use="optional" order="2" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements_1096967" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_763" xlink:to="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements_1096967" use="optional" order="3" />
<loc xlink:type="locator" xlink:href="roiv-20210630.xsd#roiv_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityDisposedDueToDeconsolidationOfSubsidiary" xlink:label="loc_roiv_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityDisposedDueToDeconsolidationOfSubsidiary_1096985" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_763" xlink:to="loc_roiv_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityDisposedDueToDeconsolidationOfSubsidiary_1096985" use="optional" order="4" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaap_StatementTable_764" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_StatementLineItems_763" xlink:to="loc_us-gaap_StatementTable_764" xbrldt:contextElement="segment" xbrldt:closed="true" use="optional" order="5" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:label="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_760" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_764" xlink:to="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_760" use="optional" order="6" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_761" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_760" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_761" use="optional" order="7" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_761_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_760" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_761_default" use="optional" order="8" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueInputsLevel3Member" xlink:label="loc_us-gaap_FairValueInputsLevel3Member_766" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_761" xlink:to="loc_us-gaap_FairValueInputsLevel3Member_766" use="optional" order="9" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_LegalEntityAxis" xlink:label="loc_dei_LegalEntityAxis_762" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_764" xlink:to="loc_dei_LegalEntityAxis_762" use="optional" order="10" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityDomain" xlink:label="loc_dei_EntityDomain_759" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_dei_LegalEntityAxis_762" xlink:to="loc_dei_EntityDomain_759" use="optional" order="11" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityDomain" xlink:label="loc_dei_EntityDomain_759_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_dei_LegalEntityAxis_762" xlink:to="loc_dei_EntityDomain_759_default" use="optional" order="12" />
</definitionLink>
<definitionLink xlink:type="extended" xlink:role="http://roivant.com/role/FairValueMeasurementsScheduleOfFairValueOfUnobservableInputRelatedToOptionsToAcquireUnderSumitomoTransactionAgreementDetail">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_1443" />
<loc xlink:type="locator" xlink:href="roiv-20210630.xsd#roiv_AlternativeInvestmentExpectedTerm" xlink:label="loc_roiv_AlternativeInvestmentExpectedTerm_1449" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_1443" xlink:to="loc_roiv_AlternativeInvestmentExpectedTerm_1449" use="optional" order="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AlternativeInvestmentMeasurementInput" xlink:label="loc_us-gaap_AlternativeInvestmentMeasurementInput_1450" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_1443" xlink:to="loc_us-gaap_AlternativeInvestmentMeasurementInput_1450" use="optional" order="2" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable_1444" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_1443" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable_1444" xbrldt:contextElement="segment" xbrldt:closed="true" use="optional" order="3" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MeasurementInputTypeAxis" xlink:label="loc_us-gaap_MeasurementInputTypeAxis_1445" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable_1444" xlink:to="loc_us-gaap_MeasurementInputTypeAxis_1445" use="optional" order="4" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MeasurementInputTypeDomain" xlink:label="loc_us-gaap_MeasurementInputTypeDomain_1446" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_MeasurementInputTypeAxis_1445" xlink:to="loc_us-gaap_MeasurementInputTypeDomain_1446" use="optional" order="5" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MeasurementInputTypeDomain" xlink:label="loc_us-gaap_MeasurementInputTypeDomain_1446_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_MeasurementInputTypeAxis_1445" xlink:to="loc_us-gaap_MeasurementInputTypeDomain_1446_default" use="optional" order="6" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MeasurementInputOptionVolatilityMember" xlink:label="loc_us-gaap_MeasurementInputOptionVolatilityMember_1453" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_MeasurementInputTypeDomain_1446" xlink:to="loc_us-gaap_MeasurementInputOptionVolatilityMember_1453" use="optional" order="7" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MeasurementInputRiskFreeInterestRateMember" xlink:label="loc_us-gaap_MeasurementInputRiskFreeInterestRateMember_1452" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_MeasurementInputTypeDomain_1446" xlink:to="loc_us-gaap_MeasurementInputRiskFreeInterestRateMember_1452" use="optional" order="8" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MeasurementInputExpectedTermMember" xlink:label="loc_us-gaap_MeasurementInputExpectedTermMember_1451" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_MeasurementInputTypeDomain_1446" xlink:to="loc_us-gaap_MeasurementInputExpectedTermMember_1451" use="optional" order="9" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeAxis" xlink:label="loc_srt_RangeAxis_1447" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable_1444" xlink:to="loc_srt_RangeAxis_1447" use="optional" order="10" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeMember" xlink:label="loc_srt_RangeMember_1448" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_RangeAxis_1447" xlink:to="loc_srt_RangeMember_1448" use="optional" order="11" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeMember" xlink:label="loc_srt_RangeMember_1448_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_RangeAxis_1447" xlink:to="loc_srt_RangeMember_1448_default" use="optional" order="12" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MinimumMember" xlink:label="loc_srt_MinimumMember_1454" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_1448" xlink:to="loc_srt_MinimumMember_1454" use="optional" order="13" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MaximumMember" xlink:label="loc_srt_MaximumMember_1455" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_1448" xlink:to="loc_srt_MaximumMember_1455" use="optional" order="14" />
</definitionLink>
<definitionLink xlink:type="extended" xlink:role="http://roivant.com/role/SubsequentEventsAdditionalInformationDetail">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaap_StatementLineItems_1493" />
<loc xlink:type="locator" xlink:href="roiv-20210630.xsd#roiv_BusinessAcquisitionCostOfAcquiredEntityAdjustmentPaidInCash" xlink:label="loc_roiv_BusinessAcquisitionCostOfAcquiredEntityAdjustmentPaidInCash_1503" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_1493" xlink:to="loc_roiv_BusinessAcquisitionCostOfAcquiredEntityAdjustmentPaidInCash_1503" use="optional" order="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:label="loc_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_1511" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_1493" xlink:to="loc_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_1511" use="optional" order="2" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfWarrantOrRightOutstanding" xlink:label="loc_us-gaap_ClassOfWarrantOrRightOutstanding_1509" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_1493" xlink:to="loc_us-gaap_ClassOfWarrantOrRightOutstanding_1509" use="optional" order="3" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentFaceAmount" xlink:label="loc_us-gaap_DebtInstrumentFaceAmount_1506" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_1493" xlink:to="loc_us-gaap_DebtInstrumentFaceAmount_1506" use="optional" order="4" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:label="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_1507" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_1493" xlink:to="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_1507" use="optional" order="5" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentTerm" xlink:label="loc_us-gaap_DebtInstrumentTerm_1508" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_1493" xlink:to="loc_us-gaap_DebtInstrumentTerm_1508" use="optional" order="6" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongTermDebtNoncurrent" xlink:label="loc_us-gaap_LongTermDebtNoncurrent_1512" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_1493" xlink:to="loc_us-gaap_LongTermDebtNoncurrent_1512" use="optional" order="7" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaap_StatementTable_1494" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_StatementLineItems_1493" xlink:to="loc_us-gaap_StatementTable_1494" xbrldt:contextElement="segment" xbrldt:closed="true" use="optional" order="8" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessAcquisitionAxis" xlink:label="loc_us-gaap_BusinessAcquisitionAxis_1486" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_1494" xlink:to="loc_us-gaap_BusinessAcquisitionAxis_1486" use="optional" order="9" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_1485" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_1486" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_1485" use="optional" order="10" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_1485_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_1486" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_1485_default" use="optional" order="11" />
<loc xlink:type="locator" xlink:href="roiv-20210630.xsd#roiv_SumitomoPharmaceuticalsCoLtdMember" xlink:label="loc_roiv_SumitomoPharmaceuticalsCoLtdMember_1499" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_1485" xlink:to="loc_roiv_SumitomoPharmaceuticalsCoLtdMember_1499" use="optional" order="12" />
<loc xlink:type="locator" xlink:href="roiv-20210630.xsd#roiv_ProteovantSciencesIncMember" xlink:label="loc_roiv_ProteovantSciencesIncMember_1096954" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_1485" xlink:to="loc_roiv_ProteovantSciencesIncMember_1096954" use="optional" order="13" />
<loc xlink:type="locator" xlink:href="roiv-20210630.xsd#roiv_DatavantMember" xlink:label="loc_roiv_DatavantMember_1096955" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_1485" xlink:to="loc_roiv_DatavantMember_1096955" use="optional" order="14" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:label="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_1490" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_1494" xlink:to="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_1490" use="optional" order="15" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RelatedPartyDomain" xlink:label="loc_us-gaap_RelatedPartyDomain_1489" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_1490" xlink:to="loc_us-gaap_RelatedPartyDomain_1489" use="optional" order="16" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RelatedPartyDomain" xlink:label="loc_us-gaap_RelatedPartyDomain_1489_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_1490" xlink:to="loc_us-gaap_RelatedPartyDomain_1489_default" use="optional" order="17" />
<loc xlink:type="locator" xlink:href="roiv-20210630.xsd#roiv_DermavantSciencesLtdMember" xlink:label="loc_roiv_DermavantSciencesLtdMember_1501" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyDomain_1489" xlink:to="loc_roiv_DermavantSciencesLtdMember_1501" use="optional" order="18" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RestatementAxis" xlink:label="loc_srt_RestatementAxis_1491" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_1494" xlink:to="loc_srt_RestatementAxis_1491" use="optional" order="19" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RestatementDomain" xlink:label="loc_srt_RestatementDomain_1492" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_RestatementAxis_1491" xlink:to="loc_srt_RestatementDomain_1492" use="optional" order="20" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RestatementDomain" xlink:label="loc_srt_RestatementDomain_1492_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_RestatementAxis_1491" xlink:to="loc_srt_RestatementDomain_1492_default" use="optional" order="21" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RevisionOfPriorPeriodReclassificationAdjustmentMember" xlink:label="loc_srt_RevisionOfPriorPeriodReclassificationAdjustmentMember_1502" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RestatementDomain_1492" xlink:to="loc_srt_RevisionOfPriorPeriodReclassificationAdjustmentMember_1502" use="optional" order="22" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentAxis" xlink:label="loc_us-gaap_DebtInstrumentAxis_1487" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_1494" xlink:to="loc_us-gaap_DebtInstrumentAxis_1487" use="optional" order="23" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_1488" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_DebtInstrumentAxis_1487" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_1488" use="optional" order="24" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_1488_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_DebtInstrumentAxis_1487" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_1488_default" use="optional" order="25" />
<loc xlink:type="locator" xlink:href="roiv-20210630.xsd#roiv_CreditFacilityMember" xlink:label="loc_roiv_CreditFacilityMember_1500" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_1488" xlink:to="loc_roiv_CreditFacilityMember_1500" use="optional" order="26" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="loc_us-gaap_TypeOfArrangementAxis_1497" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_1494" xlink:to="loc_us-gaap_TypeOfArrangementAxis_1497" use="optional" order="27" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_1484" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_TypeOfArrangementAxis_1497" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_1484" use="optional" order="28" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_1484_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_TypeOfArrangementAxis_1497" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_1484_default" use="optional" order="29" />
<loc xlink:type="locator" xlink:href="roiv-20210630.xsd#roiv_RevenueInterestPurchaseAndSaleAgreementMember" xlink:label="loc_roiv_RevenueInterestPurchaseAndSaleAgreementMember_1498" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_1484" xlink:to="loc_roiv_RevenueInterestPurchaseAndSaleAgreementMember_1498" use="optional" order="30" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventTypeAxis" xlink:label="loc_us-gaap_SubsequentEventTypeAxis_1495" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_1494" xlink:to="loc_us-gaap_SubsequentEventTypeAxis_1495" use="optional" order="31" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="loc_us-gaap_SubsequentEventTypeDomain_1496" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_SubsequentEventTypeAxis_1495" xlink:to="loc_us-gaap_SubsequentEventTypeDomain_1496" use="optional" order="32" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="loc_us-gaap_SubsequentEventTypeDomain_1496_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_SubsequentEventTypeAxis_1495" xlink:to="loc_us-gaap_SubsequentEventTypeDomain_1496_default" use="optional" order="33" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventMember" xlink:label="loc_us-gaap_SubsequentEventMember_1513" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsequentEventTypeDomain_1496" xlink:to="loc_us-gaap_SubsequentEventMember_1513" use="optional" order="34" />
<loc xlink:type="locator" xlink:href="roiv-20210630.xsd#roiv_SubscriptionsReceivable" xlink:label="loc_roiv_SubscriptionsReceivable_1107994" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_1493" xlink:to="loc_roiv_SubscriptionsReceivable_1107994" use="optional" order="35" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityMethodInvestments" xlink:label="loc_us-gaap_EquityMethodInvestments_1096951" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_1493" xlink:to="loc_us-gaap_EquityMethodInvestments_1096951" use="optional" order="36" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityMethodInvestmentOwnershipPercentage" xlink:label="loc_us-gaap_EquityMethodInvestmentOwnershipPercentage_1096952" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_1493" xlink:to="loc_us-gaap_EquityMethodInvestmentOwnershipPercentage_1096952" use="optional" order="37" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationConsiderationTransferred1" xlink:label="loc_us-gaap_BusinessCombinationConsiderationTransferred1_1096953" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_1493" xlink:to="loc_us-gaap_BusinessCombinationConsiderationTransferred1_1096953" use="optional" order="38" />
<loc xlink:type="locator" xlink:href="roiv-20210630.xsd#roiv_RevenueInterestPurchaseAndSaleAgreementAmount" xlink:label="loc_roiv_RevenueInterestPurchaseAndSaleAgreementAmount_1504" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_1493" xlink:to="loc_roiv_RevenueInterestPurchaseAndSaleAgreementAmount_1504" use="optional" order="39" />
<loc xlink:type="locator" xlink:href="roiv-20210630.xsd#roiv_RevenueInterestPurchaseAndSaleAgreementCommittedFundToBePaid" xlink:label="loc_roiv_RevenueInterestPurchaseAndSaleAgreementCommittedFundToBePaid_1505" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_1493" xlink:to="loc_roiv_RevenueInterestPurchaseAndSaleAgreementCommittedFundToBePaid_1505" use="optional" order="40" />
</definitionLink>
</linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.LAB
<SEQUENCE>11
<FILENAME>roiv-20210630_lab.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION LABEL LINKBASE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="utf-8"?>
<!--Generated by DFIN XBRL Instance Document - http://www.dfinsolutions.com/ - Version R3.0 - on 30-October-2021 [02:44:34] {AM}-->
<linkbase xmlns="http://www.xbrl.org/2003/linkbase" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
<roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedLabel" roleURI="http://www.xbrl.org/2009/role/negatedLabel" />
<roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodEndLabel" roleURI="http://www.xbrl.org/2009/role/negatedPeriodEndLabel" />
<roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodStartLabel" roleURI="http://www.xbrl.org/2009/role/negatedPeriodStartLabel" />
<roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTotalLabel" roleURI="http://www.xbrl.org/2009/role/negatedTotalLabel" />
<roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedNetLabel" roleURI="http://www.xbrl.org/2009/role/negatedNetLabel" />
<roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTerseLabel" roleURI="http://www.xbrl.org/2009/role/negatedTerseLabel" />
<roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/net-2009-12-16.xsd#netLabel" roleURI="http://www.xbrl.org/2009/role/netLabel" />
<labelLink xlink:type="extended" xlink:role="http://www.xbrl.org/2003/role/link">
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_CoverAbstract" xlink:label="loc_dei_CoverAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_dei_CoverAbstract" xml:lang="en-US">Cover [Abstract]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_CoverAbstract" xlink:to="lab_dei_CoverAbstract" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_AmendmentFlag" xlink:label="loc_dei_AmendmentFlag" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_dei_AmendmentFlag" xml:lang="en-US">Amendment Flag</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_dei_AmendmentFlag" xml:lang="en-US">Amendment Flag</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_AmendmentFlag" xlink:to="lab_dei_AmendmentFlag" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_DocumentType" xlink:label="loc_dei_DocumentType" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_dei_DocumentType" xml:lang="en-US">Document Type</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_dei_DocumentType" xml:lang="en-US">Document Type</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentType" xlink:to="lab_dei_DocumentType" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityCentralIndexKey" xlink:label="loc_dei_EntityCentralIndexKey" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_dei_EntityCentralIndexKey" xml:lang="en-US">Entity Central Index Key</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_dei_EntityCentralIndexKey" xml:lang="en-US">Entity Central Index Key</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityCentralIndexKey" xlink:to="lab_dei_EntityCentralIndexKey" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityEmergingGrowthCompany" xlink:label="loc_dei_EntityEmergingGrowthCompany" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_dei_EntityEmergingGrowthCompany" xml:lang="en-US">Entity Emerging Growth Company</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_dei_EntityEmergingGrowthCompany" xml:lang="en-US">Emerging Growth Company</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityEmergingGrowthCompany" xlink:to="lab_dei_EntityEmergingGrowthCompany" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityExTransitionPeriod" xlink:label="loc_dei_EntityExTransitionPeriod" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_dei_EntityExTransitionPeriod" xml:lang="en-US">Entity Ex Transition Period</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_dei_EntityExTransitionPeriod" xml:lang="en-US">Entity Ex Transition Period</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityExTransitionPeriod" xlink:to="lab_dei_EntityExTransitionPeriod" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityFilerCategory" xlink:label="loc_dei_EntityFilerCategory" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_dei_EntityFilerCategory" xml:lang="en-US">Entity Filer Category</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_dei_EntityFilerCategory" xml:lang="en-US">Entity Filer Category</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityFilerCategory" xlink:to="lab_dei_EntityFilerCategory" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityRegistrantName" xlink:label="loc_dei_EntityRegistrantName" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_dei_EntityRegistrantName" xml:lang="en-US">Entity Registrant Name</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_dei_EntityRegistrantName" xml:lang="en-US">Entity Registrant Name</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityRegistrantName" xlink:to="lab_dei_EntityRegistrantName" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntitySmallBusiness" xlink:label="loc_dei_EntitySmallBusiness" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_dei_EntitySmallBusiness" xml:lang="en-US">Entity Small Business</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_dei_EntitySmallBusiness" xml:lang="en-US">Entity Small Business</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntitySmallBusiness" xlink:to="lab_dei_EntitySmallBusiness" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementOfFinancialPositionAbstract" xlink:label="loc_us-gaap_StatementOfFinancialPositionAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_StatementOfFinancialPositionAbstract" xml:lang="en-US">Statement of Financial Position [Abstract]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract" xlink:to="lab_us-gaap_StatementOfFinancialPositionAbstract" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaap_StatementTable" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_StatementTable" xml:lang="en-US">Statement [Table]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_StatementTable" xml:lang="en-US">Statement [Table]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementTable" xlink:to="lab_us-gaap_StatementTable" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_LegalEntityAxis" xlink:label="loc_dei_LegalEntityAxis" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_dei_LegalEntityAxis" xml:lang="en-US">Legal Entity [Axis]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_dei_LegalEntityAxis" xml:lang="en-US">Legal Entity [Axis]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_LegalEntityAxis" xlink:to="lab_dei_LegalEntityAxis" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityDomain" xlink:label="loc_dei_EntityDomain" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_dei_EntityDomain" xml:lang="en-US">Entity [Domain]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_dei_EntityDomain" xml:lang="en-US">Entity [Domain]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityDomain" xlink:to="lab_dei_EntityDomain" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaap_StatementLineItems" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_StatementLineItems" xml:lang="en-US">Statement [Line Items]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_StatementLineItems" xml:lang="en-US">Statement [Line Items]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementLineItems" xlink:to="lab_us-gaap_StatementLineItems" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetsAbstract" xlink:label="loc_us-gaap_AssetsAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_AssetsAbstract" xml:lang="en-US">Assets [Abstract]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_AssetsAbstract" xml:lang="en-US">Assets</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsAbstract" xlink:to="lab_us-gaap_AssetsAbstract" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Assets" xlink:label="loc_us-gaap_Assets" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_Assets" xml:lang="en-US">Assets</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_us-gaap_Assets" xml:lang="en-US">Total assets</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_Assets" xlink:to="lab_us-gaap_Assets" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetsCurrentAbstract" xlink:label="loc_us-gaap_AssetsCurrentAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_AssetsCurrentAbstract" xml:lang="en-US">Assets, Current [Abstract]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_AssetsCurrentAbstract" xml:lang="en-US">Current assets:</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsCurrentAbstract" xlink:to="lab_us-gaap_AssetsCurrentAbstract" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetsCurrent" xlink:label="loc_us-gaap_AssetsCurrent" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_AssetsCurrent" xml:lang="en-US">Assets, Current</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_us-gaap_AssetsCurrent" xml:lang="en-US">Total current assets</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsCurrent" xlink:to="lab_us-gaap_AssetsCurrent" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherAssetsCurrent" xlink:label="loc_us-gaap_OtherAssetsCurrent" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_OtherAssetsCurrent" xml:lang="en-US">Other Assets, Current</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_OtherAssetsCurrent" xml:lang="en-US">Other current assets</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_us-gaap_OtherAssetsCurrent" xml:lang="en-US">Total other current assets</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherAssetsCurrent" xlink:to="lab_us-gaap_OtherAssetsCurrent" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue" xml:lang="en-US">Cash and Cash Equivalents, at Carrying Value</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue" xml:lang="en-US">Cash and cash equivalents</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:to="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestrictedCashCurrent" xlink:label="loc_us-gaap_RestrictedCashCurrent" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_RestrictedCashCurrent" xml:lang="en-US">Restricted Cash, Current</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_RestrictedCashCurrent" xml:lang="en-US">Restricted cash</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestrictedCashCurrent" xlink:to="lab_us-gaap_RestrictedCashCurrent" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongTermInvestments" xlink:label="loc_us-gaap_LongTermInvestments" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_LongTermInvestments" xml:lang="en-US">Long-term Investments</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_LongTermInvestments" xml:lang="en-US">Long-term investment</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_LongTermInvestments" xml:lang="en-US">Carrying value of long-term investment</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongTermInvestments" xlink:to="lab_us-gaap_LongTermInvestments" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseRightOfUseAsset" xlink:label="loc_us-gaap_OperatingLeaseRightOfUseAsset" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_OperatingLeaseRightOfUseAsset" xml:lang="en-US">Operating Lease, Right-of-Use Asset</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_OperatingLeaseRightOfUseAsset" xml:lang="en-US">Operating lease right-of-use assets</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseRightOfUseAsset" xlink:to="lab_us-gaap_OperatingLeaseRightOfUseAsset" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherAssetsNoncurrent" xlink:label="loc_us-gaap_OtherAssetsNoncurrent" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_OtherAssetsNoncurrent" xml:lang="en-US">Other Assets, Noncurrent</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_OtherAssetsNoncurrent" xml:lang="en-US">Other assets</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherAssetsNoncurrent" xlink:to="lab_us-gaap_OtherAssetsNoncurrent" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InvestmentsFairValueDisclosure" xlink:label="loc_us-gaap_InvestmentsFairValueDisclosure" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_InvestmentsFairValueDisclosure" xml:lang="en-US">Investments, Fair Value Disclosure</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/positiveLabel" xlink:label="lab_us-gaap_InvestmentsFairValueDisclosure" xml:lang="en-US">Investments measured at fair value</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_InvestmentsFairValueDisclosure" xml:lang="en-US">Aggregate fair value investment</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_InvestmentsFairValueDisclosure" xml:lang="en-US">Investment</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InvestmentsFairValueDisclosure" xlink:to="lab_us-gaap_InvestmentsFairValueDisclosure" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentNet" xml:lang="en-US">Property, Plant and Equipment, Net</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentNet" xml:lang="en-US">Property and equipment, net</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentNet" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentNet" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestrictedCashNoncurrent" xlink:label="loc_us-gaap_RestrictedCashNoncurrent" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_RestrictedCashNoncurrent" xml:lang="en-US">Restricted Cash, Noncurrent</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_RestrictedCashNoncurrent" xml:lang="en-US">Restricted cash, net of current portion</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestrictedCashNoncurrent" xlink:to="lab_us-gaap_RestrictedCashNoncurrent" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xml:lang="en-US">Liabilities and Equity [Abstract]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xml:lang="en-US">Liabilities, Redeemable Noncontrolling Interest and Shareholders' Equity</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesCurrentAbstract" xlink:label="loc_us-gaap_LiabilitiesCurrentAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_LiabilitiesCurrentAbstract" xml:lang="en-US">Liabilities, Current [Abstract]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_LiabilitiesCurrentAbstract" xml:lang="en-US">Current liabilities:</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract" xlink:to="lab_us-gaap_LiabilitiesCurrentAbstract" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccruedLiabilitiesCurrent" xlink:label="loc_us-gaap_AccruedLiabilitiesCurrent" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_AccruedLiabilitiesCurrent" xml:lang="en-US">Accrued Liabilities, Current</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_AccruedLiabilitiesCurrent" xml:lang="en-US">Accrued expenses</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_AccruedLiabilitiesCurrent" xml:lang="en-US">Total accrued expenses</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccruedLiabilitiesCurrent" xlink:to="lab_us-gaap_AccruedLiabilitiesCurrent" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountsPayableCurrent" xlink:label="loc_us-gaap_AccountsPayableCurrent" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_AccountsPayableCurrent" xml:lang="en-US">Accounts Payable, Current</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_AccountsPayableCurrent" xml:lang="en-US">Accounts payable</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountsPayableCurrent" xlink:to="lab_us-gaap_AccountsPayableCurrent" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesCurrent" xlink:label="loc_us-gaap_LiabilitiesCurrent" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_LiabilitiesCurrent" xml:lang="en-US">Liabilities, Current</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_us-gaap_LiabilitiesCurrent" xml:lang="en-US">Total current liabilities</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesCurrent" xlink:to="lab_us-gaap_LiabilitiesCurrent" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseLiabilityCurrent" xlink:label="loc_us-gaap_OperatingLeaseLiabilityCurrent" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_OperatingLeaseLiabilityCurrent" xml:lang="en-US">Operating Lease, Liability, Current</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_OperatingLeaseLiabilityCurrent" xml:lang="en-US">Operating lease liabilities</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseLiabilityCurrent" xlink:to="lab_us-gaap_OperatingLeaseLiabilityCurrent" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherLiabilitiesCurrent" xlink:label="loc_us-gaap_OtherLiabilitiesCurrent" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_OtherLiabilitiesCurrent" xml:lang="en-US">Other Liabilities, Current</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_OtherLiabilitiesCurrent" xml:lang="en-US">Other current liabilities</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_us-gaap_OtherLiabilitiesCurrent" xml:lang="en-US">Total other current liabilities</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherLiabilitiesCurrent" xlink:to="lab_us-gaap_OtherLiabilitiesCurrent" />
<loc xlink:type="locator" xlink:href="roiv-20210630.xsd#roiv_DeferredConsiderationLiabilityCurrent" xlink:label="loc_roiv_DeferredConsiderationLiabilityCurrent" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_roiv_DeferredConsiderationLiabilityCurrent" xml:lang="en-US">Deferred Consideration Liability Current</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_roiv_DeferredConsiderationLiabilityCurrent" xml:lang="en-US">Deferred consideration liability</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_roiv_DeferredConsiderationLiabilityCurrent" xlink:to="lab_roiv_DeferredConsiderationLiabilityCurrent" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_roiv_DeferredConsiderationLiabilityCurrent" xml:lang="en-US">Deferred consideration liability current.</label>
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongTermDebtNoncurrent" xlink:label="loc_us-gaap_LongTermDebtNoncurrent" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_LongTermDebtNoncurrent" xml:lang="en-US">Long-term Debt, Excluding Current Maturities</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_LongTermDebtNoncurrent" xml:lang="en-US">Long-term debt</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_us-gaap_LongTermDebtNoncurrent" xml:lang="en-US">Total long term debt, net</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_LongTermDebtNoncurrent" xml:lang="en-US">Long term debt</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongTermDebtNoncurrent" xlink:to="lab_us-gaap_LongTermDebtNoncurrent" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MinorityInterest" xlink:label="loc_us-gaap_MinorityInterest" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_MinorityInterest" xml:lang="en-US">Stockholders' Equity Attributable to Noncontrolling Interest</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_MinorityInterest" xml:lang="en-US">Noncontrolling interests</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MinorityInterest" xlink:to="lab_us-gaap_MinorityInterest" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:label="loc_us-gaap_OperatingLeaseLiabilityNoncurrent" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_OperatingLeaseLiabilityNoncurrent" xml:lang="en-US">Operating Lease, Liability, Noncurrent</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_OperatingLeaseLiabilityNoncurrent" xml:lang="en-US">Operating lease liabilities, noncurrent</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:to="lab_us-gaap_OperatingLeaseLiabilityNoncurrent" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherLiabilitiesNoncurrent" xlink:label="loc_us-gaap_OtherLiabilitiesNoncurrent" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_OtherLiabilitiesNoncurrent" xml:lang="en-US">Other Liabilities, Noncurrent</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_OtherLiabilitiesNoncurrent" xml:lang="en-US">Other liabilities</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherLiabilitiesNoncurrent" xlink:to="lab_us-gaap_OtherLiabilitiesNoncurrent" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommitmentsAndContingencies" xlink:label="loc_us-gaap_CommitmentsAndContingencies" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_CommitmentsAndContingencies" xml:lang="en-US">Commitments and Contingencies</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_CommitmentsAndContingencies" xml:lang="en-US">Commitments and Contingencies</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommitmentsAndContingencies" xlink:to="lab_us-gaap_CommitmentsAndContingencies" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Liabilities" xlink:label="loc_us-gaap_Liabilities" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_Liabilities" xml:lang="en-US">Liabilities</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_us-gaap_Liabilities" xml:lang="en-US">Total liabilities</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_Liabilities" xlink:to="lab_us-gaap_Liabilities" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquity" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquity" xml:lang="en-US">Liabilities and Equity</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquity" xml:lang="en-US">Total liabilities, redeemable noncontrolling interest and shareholders' equity</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="lab_us-gaap_LiabilitiesAndStockholdersEquity" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquityAbstract" xlink:label="loc_us-gaap_StockholdersEquityAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_StockholdersEquityAbstract" xml:lang="en-US">Stockholders' Equity Attributable to Parent [Abstract]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_StockholdersEquityAbstract" xml:lang="en-US">Shareholders' equity:</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquityAbstract" xlink:to="lab_us-gaap_StockholdersEquityAbstract" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xml:lang="en-US">Accumulated Other Comprehensive Income (Loss), Net of Tax</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xml:lang="en-US">Accumulated other comprehensive (loss) income</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:to="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockValue" xlink:label="loc_us-gaap_CommonStockValue" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_CommonStockValue" xml:lang="en-US">Common Stock, Value, Issued</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_CommonStockValue" xml:lang="en-US">Common shares</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockValue" xlink:to="lab_us-gaap_CommonStockValue" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdditionalPaidInCapital" xlink:label="loc_us-gaap_AdditionalPaidInCapital" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_AdditionalPaidInCapital" xml:lang="en-US">Additional Paid in Capital</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_AdditionalPaidInCapital" xml:lang="en-US">Additional paid-in capital</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdditionalPaidInCapital" xlink:to="lab_us-gaap_AdditionalPaidInCapital" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquity" xlink:label="loc_us-gaap_StockholdersEquity" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_StockholdersEquity" xml:lang="en-US">Stockholders' Equity Attributable to Parent</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_us-gaap_StockholdersEquity" xml:lang="en-US">Shareholders' equity attributable to Roivant Sciences Ltd.</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquity" xlink:to="lab_us-gaap_StockholdersEquity" />
<loc xlink:type="locator" xlink:href="roiv-20210630.xsd#roiv_SubscriptionsReceivable" xlink:label="loc_roiv_SubscriptionsReceivable" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_roiv_SubscriptionsReceivable" xml:lang="en-US">Subscriptions Receivable</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_roiv_SubscriptionsReceivable" xml:lang="en-US">Subscription receivable</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="lab_roiv_SubscriptionsReceivable" xml:lang="en-US">Subscription receivable</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_roiv_SubscriptionsReceivable" xlink:to="lab_roiv_SubscriptionsReceivable" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_roiv_SubscriptionsReceivable" xml:lang="en-US">Subscriptions receivable.</label>
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_RetainedEarningsAccumulatedDeficit" xml:lang="en-US">Retained Earnings (Accumulated Deficit)</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_RetainedEarningsAccumulatedDeficit" xml:lang="en-US">Accumulated deficit</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="lab_us-gaap_RetainedEarningsAccumulatedDeficit" xml:lang="en-US">Accumulated deficit</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:to="lab_us-gaap_RetainedEarningsAccumulatedDeficit" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:label="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xml:lang="en-US">Stockholders' Equity, Including Portion Attributable to Noncontrolling Interest</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xml:lang="en-US">Total shareholders' equity</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xml:lang="en-US">Balance</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xml:lang="en-US">Balance</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:to="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" />
<loc xlink:type="locator" xlink:href="roiv-20210630.xsd#roiv_LiabilityInstrumentsMeasuredAtFairValue" xlink:label="loc_roiv_LiabilityInstrumentsMeasuredAtFairValue" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_roiv_LiabilityInstrumentsMeasuredAtFairValue" xml:lang="en-US">Liability Instruments Measured At Fair Value</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_roiv_LiabilityInstrumentsMeasuredAtFairValue" xml:lang="en-US">Liability instruments measured at fair value</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_roiv_LiabilityInstrumentsMeasuredAtFairValue" xlink:to="lab_roiv_LiabilityInstrumentsMeasuredAtFairValue" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_roiv_LiabilityInstrumentsMeasuredAtFairValue" xml:lang="en-US">Liability instruments measured at fair value.</label>
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RedeemableNoncontrollingInterestEquityCarryingAmount" xlink:label="loc_us-gaap_RedeemableNoncontrollingInterestEquityCarryingAmount" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_RedeemableNoncontrollingInterestEquityCarryingAmount" xml:lang="en-US">Redeemable Noncontrolling Interest, Equity, Carrying Amount</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_RedeemableNoncontrollingInterestEquityCarryingAmount" xml:lang="en-US">Redeemable noncontrolling interest</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RedeemableNoncontrollingInterestEquityCarryingAmount" xlink:to="lab_us-gaap_RedeemableNoncontrollingInterestEquityCarryingAmount" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="loc_us-gaap_StatementClassOfStockAxis" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_StatementClassOfStockAxis" xml:lang="en-US">Class of Stock [Axis]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_StatementClassOfStockAxis" xml:lang="en-US">Class of Stock [Axis]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementClassOfStockAxis" xlink:to="lab_us-gaap_StatementClassOfStockAxis" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaap_ClassOfStockDomain" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ClassOfStockDomain" xml:lang="en-US">Class of Stock [Domain]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_ClassOfStockDomain" xml:lang="en-US">Class of Stock [Domain]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ClassOfStockDomain" xlink:to="lab_us-gaap_ClassOfStockDomain" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockSharesAuthorized" xlink:label="loc_us-gaap_CommonStockSharesAuthorized" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_CommonStockSharesAuthorized" xml:lang="en-US">Common Stock, Shares Authorized</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_CommonStockSharesAuthorized" xml:lang="en-US">Common stock, shares authorized</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockSharesAuthorized" xlink:to="lab_us-gaap_CommonStockSharesAuthorized" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockSharesIssued" xlink:label="loc_us-gaap_CommonStockSharesIssued" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_CommonStockSharesIssued" xml:lang="en-US">Common Stock, Shares, Issued</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_CommonStockSharesIssued" xml:lang="en-US">Common stock, shares issued</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_CommonStockSharesIssued" xml:lang="en-US">Common stock issued</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockSharesIssued" xlink:to="lab_us-gaap_CommonStockSharesIssued" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockSharesOutstanding" xlink:label="loc_us-gaap_CommonStockSharesOutstanding" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_CommonStockSharesOutstanding" xml:lang="en-US">Common Stock, Shares, Outstanding</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/positiveLabel" xlink:label="lab_us-gaap_CommonStockSharesOutstanding" xml:lang="en-US">Common stock, shares outstanding</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_CommonStockSharesOutstanding" xml:lang="en-US">Common stock</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockSharesOutstanding" xlink:to="lab_us-gaap_CommonStockSharesOutstanding" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongTermDebtFairValue" xlink:label="loc_us-gaap_LongTermDebtFairValue" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_LongTermDebtFairValue" xml:lang="en-US">Long-term Debt, Fair Value</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_LongTermDebtFairValue" xml:lang="en-US">Long term debt accounted under fair value option</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongTermDebtFairValue" xlink:to="lab_us-gaap_LongTermDebtFairValue" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:label="loc_us-gaap_CommonStockParOrStatedValuePerShare" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_CommonStockParOrStatedValuePerShare" xml:lang="en-US">Common Stock, Par or Stated Value Per Share</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_CommonStockParOrStatedValuePerShare" xml:lang="en-US">Common stock, par or stated value per share</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockParOrStatedValuePerShare" xlink:to="lab_us-gaap_CommonStockParOrStatedValuePerShare" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeStatementAbstract" xlink:label="loc_us-gaap_IncomeStatementAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_IncomeStatementAbstract" xml:lang="en-US">Income Statement [Abstract]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeStatementAbstract" xlink:to="lab_us-gaap_IncomeStatementAbstract" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeAmountsAttributableToReportingEntityDisclosuresAbstract" xlink:label="loc_us-gaap_IncomeAmountsAttributableToReportingEntityDisclosuresAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_IncomeAmountsAttributableToReportingEntityDisclosuresAbstract" xml:lang="en-US">Income Amounts Attributable to Parent, Disclosures [Abstract]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_IncomeAmountsAttributableToReportingEntityDisclosuresAbstract" xml:lang="en-US">Amounts attributable to Roivant Sciences Ltd.:</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeAmountsAttributableToReportingEntityDisclosuresAbstract" xlink:to="lab_us-gaap_IncomeAmountsAttributableToReportingEntityDisclosuresAbstract" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeLossFromContinuingOperations" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperations" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_IncomeLossFromContinuingOperations" xml:lang="en-US">Income (Loss) from Continuing Operations, Net of Tax, Attributable to Parent</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="lab_us-gaap_IncomeLossFromContinuingOperations" xml:lang="en-US">Loss from continuing operations, net of tax</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:label="lab_us-gaap_IncomeLossFromContinuingOperations" xml:lang="en-US">Loss from continuing operations, net of tax, attributable to Roivant Sciences Ltd.</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperations" xlink:to="lab_us-gaap_IncomeLossFromContinuingOperations" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity" xlink:label="loc_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity" xml:lang="en-US">Income (Loss) from Discontinued Operations, Net of Tax, Attributable to Parent</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity" xml:lang="en-US">Income from discontinued operations, net of tax</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity" xml:lang="en-US">Net income from discontinued operations, net of tax, attributable to Roivant Sciences Ltd.</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity" xlink:to="lab_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaap_NetIncomeLoss" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_NetIncomeLoss" xml:lang="en-US">Net Income (Loss) Attributable to Parent</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_us-gaap_NetIncomeLoss" xml:lang="en-US">Net loss attributable to Roivant Sciences Ltd.</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_NetIncomeLoss" xml:lang="en-US">Net (loss) income attributable to Roivant Sciences Ltd.</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetIncomeLoss" xlink:to="lab_us-gaap_NetIncomeLoss" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetIncomeLossAttributableToNoncontrollingInterest" xlink:label="loc_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest" xml:lang="en-US">Net Income (Loss) Attributable to Noncontrolling Interest</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest" xml:lang="en-US">Net loss attributable to noncontrolling interests</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest" xlink:to="lab_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingExpensesAbstract" xlink:label="loc_us-gaap_OperatingExpensesAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_OperatingExpensesAbstract" xml:lang="en-US">Operating Expenses [Abstract]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_OperatingExpensesAbstract" xml:lang="en-US">Operating expenses:</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingExpensesAbstract" xlink:to="lab_us-gaap_OperatingExpensesAbstract" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GeneralAndAdministrativeExpense" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpense" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_GeneralAndAdministrativeExpense" xml:lang="en-US">General and Administrative Expense</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_GeneralAndAdministrativeExpense" xml:lang="en-US">General and administrative</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GeneralAndAdministrativeExpense" xlink:to="lab_us-gaap_GeneralAndAdministrativeExpense" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingExpenses" xlink:label="loc_us-gaap_OperatingExpenses" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_OperatingExpenses" xml:lang="en-US">Operating Expenses</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_us-gaap_OperatingExpenses" xml:lang="en-US">Total operating expenses</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingExpenses" xlink:to="lab_us-gaap_OperatingExpenses" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpense" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpense" xml:lang="en-US">Research and Development Expense</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpense" xml:lang="en-US">Research and development</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpense" xml:lang="en-US">Research and development expense</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ResearchAndDevelopmentExpense" xlink:to="lab_us-gaap_ResearchAndDevelopmentExpense" />
<loc xlink:type="locator" xlink:href="roiv-20210630.xsd#roiv_OperatingCosts" xlink:label="loc_roiv_OperatingCosts" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_roiv_OperatingCosts" xml:lang="en-US">Operating Costs</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_roiv_OperatingCosts" xml:lang="en-US">Cost of revenues</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_roiv_OperatingCosts" xlink:to="lab_roiv_OperatingCosts" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_roiv_OperatingCosts" xml:lang="en-US">Operating costs.</label>
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingIncomeLoss" xlink:label="loc_us-gaap_OperatingIncomeLoss" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_OperatingIncomeLoss" xml:lang="en-US">Operating Income (Loss)</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_us-gaap_OperatingIncomeLoss" xml:lang="en-US">Loss from operations</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingIncomeLoss" xlink:to="lab_us-gaap_OperatingIncomeLoss" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest" xml:lang="en-US">Income (Loss) from Continuing Operations, Net of Tax, Including Portion Attributable to Noncontrolling Interest</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_us-gaap_IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest" xml:lang="en-US">Loss from continuing operations, net of tax</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest" xml:lang="en-US">Loss from continuing operations, net of tax</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest" xlink:to="lab_us-gaap_IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xml:lang="en-US">Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xml:lang="en-US">Loss before income taxes</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:to="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerShareBasicAndDilutedAbstract" xlink:label="loc_us-gaap_EarningsPerShareBasicAndDilutedAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_EarningsPerShareBasicAndDilutedAbstract" xml:lang="en-US">Earnings Per Share, Basic and Diluted [Abstract]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_EarningsPerShareBasicAndDilutedAbstract" xml:lang="en-US">Basic and diluted net (loss) income per common share:</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareBasicAndDilutedAbstract" xlink:to="lab_us-gaap_EarningsPerShareBasicAndDilutedAbstract" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerShareBasicAndDiluted" xlink:label="loc_us-gaap_EarningsPerShareBasicAndDiluted" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_EarningsPerShareBasicAndDiluted" xml:lang="en-US">Earnings Per Share, Basic and Diluted</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_EarningsPerShareBasicAndDiluted" xml:lang="en-US">Net loss per common share&#8212;basic and diluted</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareBasicAndDiluted" xlink:to="lab_us-gaap_EarningsPerShareBasicAndDiluted" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsPerBasicAndDilutedShare" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsPerBasicAndDilutedShare" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_IncomeLossFromContinuingOperationsPerBasicAndDilutedShare" xml:lang="en-US">Income (Loss) from Continuing Operations, Per Basic and Diluted Share</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_IncomeLossFromContinuingOperationsPerBasicAndDilutedShare" xml:lang="en-US">Basic and diluted loss from continuing operations</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsPerBasicAndDilutedShare" xlink:to="lab_us-gaap_IncomeLossFromContinuingOperationsPerBasicAndDilutedShare" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicAndDilutedShare" xlink:label="loc_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicAndDilutedShare" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicAndDilutedShare" xml:lang="en-US">Income (Loss) from Discontinued Operations and Disposal of Discontinued Operations, Net of Tax, Per Basic and Diluted Share</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicAndDilutedShare" xml:lang="en-US">Basic and diluted income from discontinued operations</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicAndDilutedShare" xlink:to="lab_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicAndDilutedShare" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerShareBasicAndDilutedOtherDisclosuresAbstract" xlink:label="loc_us-gaap_EarningsPerShareBasicAndDilutedOtherDisclosuresAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_EarningsPerShareBasicAndDilutedOtherDisclosuresAbstract" xml:lang="en-US">Earnings Per Share, Basic and Diluted, Other Disclosures [Abstract]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_EarningsPerShareBasicAndDilutedOtherDisclosuresAbstract" xml:lang="en-US">Basic and diluted weighted average shares outstanding:</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareBasicAndDilutedOtherDisclosuresAbstract" xlink:to="lab_us-gaap_EarningsPerShareBasicAndDilutedOtherDisclosuresAbstract" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:label="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xml:lang="en-US">Weighted Average Number of Shares Outstanding, Diluted</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xml:lang="en-US">Diluted</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:to="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xml:lang="en-US">Weighted Average Number of Shares Outstanding, Basic</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xml:lang="en-US">Basic</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:to="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted" xlink:label="loc_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted" xml:lang="en-US">Weighted Average Number of Shares Outstanding, Basic and Diluted</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted" xml:lang="en-US">Weighted average shares outstanding&#8212;basic and diluted</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted" xlink:to="lab_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments" xml:lang="en-US">Income (Loss) from Continuing Operations before Equity Method Investments, Income Taxes, Noncontrolling Interest</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments" xml:lang="en-US">Loss from continuing operations before income taxes</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments" xml:lang="en-US">Total loss before income taxes</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments" xlink:to="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xml:lang="en-US">Revenue from Contract with Customer, Excluding Assessed Tax</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xml:lang="en-US">Revenue, net</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:to="lab_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTax" xlink:label="loc_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTax" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTax" xml:lang="en-US">Income (Loss) from Discontinued Operations, Net of Tax, Including Portion Attributable to Noncontrolling Interest</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTax" xml:lang="en-US">Income from discontinued operations, net of tax</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTax" xml:lang="en-US">Income from discontinued operations, net of tax</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTax" xlink:to="lab_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTax" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxExpenseBenefit" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_IncomeTaxExpenseBenefit" xml:lang="en-US">Income Tax Expense (Benefit)</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_IncomeTaxExpenseBenefit" xml:lang="en-US">Income tax expense</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_us-gaap_IncomeTaxExpenseBenefit" xml:lang="en-US">Income tax provision</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefit" xlink:to="lab_us-gaap_IncomeTaxExpenseBenefit" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherNonoperatingIncomeExpenseAbstract" xlink:label="loc_us-gaap_OtherNonoperatingIncomeExpenseAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_OtherNonoperatingIncomeExpenseAbstract" xml:lang="en-US">Other Nonoperating Income (Expense) [Abstract]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_OtherNonoperatingIncomeExpenseAbstract" xml:lang="en-US">Other income (expense):</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherNonoperatingIncomeExpenseAbstract" xlink:to="lab_us-gaap_OtherNonoperatingIncomeExpenseAbstract" />
<loc xlink:type="locator" xlink:href="roiv-20210630.xsd#roiv_GainLossOnFairValueOfDebtAndLiabilityInstruments" xlink:label="loc_roiv_GainLossOnFairValueOfDebtAndLiabilityInstruments" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_roiv_GainLossOnFairValueOfDebtAndLiabilityInstruments" xml:lang="en-US">Gain Loss on Fair Value of Debt and Liability Instruments</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="lab_roiv_GainLossOnFairValueOfDebtAndLiabilityInstruments" xml:lang="en-US">Change in fair value of debt and liability instruments</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_roiv_GainLossOnFairValueOfDebtAndLiabilityInstruments" xlink:to="lab_roiv_GainLossOnFairValueOfDebtAndLiabilityInstruments" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_roiv_GainLossOnFairValueOfDebtAndLiabilityInstruments" xml:lang="en-US">Gain Loss on Fair Value of Debt and Liability Instruments</label>
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherNonoperatingIncomeExpense" xlink:label="loc_us-gaap_OtherNonoperatingIncomeExpense" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_OtherNonoperatingIncomeExpense" xml:lang="en-US">Other Nonoperating Income (Expense)</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="lab_us-gaap_OtherNonoperatingIncomeExpense" xml:lang="en-US">Other (income) expense, net</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherNonoperatingIncomeExpense" xlink:to="lab_us-gaap_OtherNonoperatingIncomeExpense" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GainLossOnInvestments" xlink:label="loc_us-gaap_GainLossOnInvestments" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_GainLossOnInvestments" xml:lang="en-US">Gain (Loss) on Investments</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="lab_us-gaap_GainLossOnInvestments" xml:lang="en-US">Change in fair value of investments</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_GainLossOnInvestments" xml:lang="en-US">Gain (loss) on remeasurement of investment</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GainLossOnInvestments" xlink:to="lab_us-gaap_GainLossOnInvestments" />
<loc xlink:type="locator" xlink:href="roiv-20210630.xsd#roiv_DeconsolidationAndConsolidationOnGainOrLossOfConsolidatedEntity" xlink:label="loc_roiv_DeconsolidationAndConsolidationOnGainOrLossOfConsolidatedEntity" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_roiv_DeconsolidationAndConsolidationOnGainOrLossOfConsolidatedEntity" xml:lang="en-US">Deconsolidation and Consolidation on Gain or Loss of Consolidated Entity</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="lab_roiv_DeconsolidationAndConsolidationOnGainOrLossOfConsolidatedEntity" xml:lang="en-US">Gain on deconsolidation of subsidiary and consolidation of unconsolidated entity</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_roiv_DeconsolidationAndConsolidationOnGainOrLossOfConsolidatedEntity" xlink:to="lab_roiv_DeconsolidationAndConsolidationOnGainOrLossOfConsolidatedEntity" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_roiv_DeconsolidationAndConsolidationOnGainOrLossOfConsolidatedEntity" xml:lang="en-US">Deconsolidation and consolidation on gain or loss of consolidated entity.</label>
<loc xlink:type="locator" xlink:href="roiv-20210630.xsd#roiv_EquityInterestOptionToThirdPartyPurchaserGainOnTermination" xlink:label="loc_roiv_EquityInterestOptionToThirdPartyPurchaserGainOnTermination" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_roiv_EquityInterestOptionToThirdPartyPurchaserGainOnTermination" xml:lang="en-US">Equity Interest Option to Third Party Purchaser Gain On Termination</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="lab_roiv_EquityInterestOptionToThirdPartyPurchaserGainOnTermination" xml:lang="en-US">Gain on termination of Sumitomo Options</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_roiv_EquityInterestOptionToThirdPartyPurchaserGainOnTermination" xml:lang="en-US">Gain on termination of Sumitomo Options</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_roiv_EquityInterestOptionToThirdPartyPurchaserGainOnTermination" xlink:to="lab_roiv_EquityInterestOptionToThirdPartyPurchaserGainOnTermination" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_roiv_EquityInterestOptionToThirdPartyPurchaserGainOnTermination" xml:lang="en-US">Equity interest option to third party purchaser gain on termination.</label>
<loc xlink:type="locator" xlink:href="roiv-20210630.xsd#roiv_GainOrLossOnDeconsolidationOfSubsidiary" xlink:label="loc_roiv_GainOrLossOnDeconsolidationOfSubsidiary" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_roiv_GainOrLossOnDeconsolidationOfSubsidiary" xml:lang="en-US">Gain Or Loss On Deconsolidation Of Subsidiary</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="lab_roiv_GainOrLossOnDeconsolidationOfSubsidiary" xml:lang="en-US">Gain on deconsolidation of subsidiary</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_roiv_GainOrLossOnDeconsolidationOfSubsidiary" xlink:to="lab_roiv_GainOrLossOnDeconsolidationOfSubsidiary" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_roiv_GainOrLossOnDeconsolidationOfSubsidiary" xml:lang="en-US">Gain or (loss) on deconsolidation of subsidiary.</label>
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProfitLoss" xlink:label="loc_us-gaap_ProfitLoss" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ProfitLoss" xml:lang="en-US">Net Income (Loss), Including Portion Attributable to Noncontrolling Interest</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_us-gaap_ProfitLoss" xml:lang="en-US">Net loss</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_ProfitLoss" xml:lang="en-US">Net loss</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_ProfitLoss" xml:lang="en-US">Net loss</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProfitLoss" xlink:to="lab_us-gaap_ProfitLoss" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementOfStockholdersEquityAbstract" xlink:label="loc_us-gaap_StatementOfStockholdersEquityAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_StatementOfStockholdersEquityAbstract" xml:lang="en-US">Statement of Stockholders' Equity [Abstract]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementOfStockholdersEquityAbstract" xlink:to="lab_us-gaap_StatementOfStockholdersEquityAbstract" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossTaxAbstract" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossTaxAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossTaxAbstract" xml:lang="en-US">Other Comprehensive Income (Loss), Tax [Abstract]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossTaxAbstract" xml:lang="en-US">Other comprehensive loss:</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossTaxAbstract" xlink:to="lab_us-gaap_OtherComprehensiveIncomeLossTaxAbstract" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax" xlink:label="loc_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax" xml:lang="en-US">Other Comprehensive Income (Loss), Foreign Currency Transaction and Translation Gain (Loss) Arising During Period, Net of Tax</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax" xml:lang="en-US">Foreign currency translation adjustment</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax" xml:lang="en-US">Unrealized foreign currency translation adjustment</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax" xlink:to="lab_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTax" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTax" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTax" xml:lang="en-US">Other Comprehensive Income (Loss), Net of Tax</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTax" xml:lang="en-US">Total other comprehensive loss</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTax" xlink:to="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTax" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ComprehensiveIncomeNetOfTax" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTax" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ComprehensiveIncomeNetOfTax" xml:lang="en-US">Comprehensive Income (Loss), Net of Tax, Attributable to Parent</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_us-gaap_ComprehensiveIncomeNetOfTax" xml:lang="en-US">Comprehensive loss attributable to Roivant Sciences Ltd.</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ComprehensiveIncomeNetOfTax" xlink:to="lab_us-gaap_ComprehensiveIncomeNetOfTax" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest" xml:lang="en-US">Comprehensive Income (Loss), Net of Tax, Attributable to Noncontrolling Interest</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest" xml:lang="en-US">Comprehensive loss attributable to noncontrolling interests</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest" xlink:to="lab_us-gaap_ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest" xml:lang="en-US">Comprehensive Income (Loss), Net of Tax, Including Portion Attributable to Noncontrolling Interest</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest" xml:lang="en-US">Comprehensive loss</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest" xlink:to="lab_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementOfPartnersCapitalAbstract" xlink:label="loc_us-gaap_StatementOfPartnersCapitalAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_StatementOfPartnersCapitalAbstract" xml:lang="en-US">Statement of Partners' Capital [Abstract]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementOfPartnersCapitalAbstract" xlink:to="lab_us-gaap_StatementOfPartnersCapitalAbstract" />
<loc xlink:type="locator" xlink:href="roiv-20210630.xsd#roiv_RedeemableNoncontrollingInterestMember" xlink:label="loc_roiv_RedeemableNoncontrollingInterestMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_roiv_RedeemableNoncontrollingInterestMember" xml:lang="en-US">Redeemable Noncontrolling Interest [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_roiv_RedeemableNoncontrollingInterestMember" xml:lang="en-US">Redeemable Noncontrolling Interest [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_roiv_RedeemableNoncontrollingInterestMember" xlink:to="lab_roiv_RedeemableNoncontrollingInterestMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_roiv_RedeemableNoncontrollingInterestMember" xml:lang="en-US">Redeemable Noncontrolling Interest [Member]</label>
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="loc_us-gaap_StatementEquityComponentsAxis" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_StatementEquityComponentsAxis" xml:lang="en-US">Equity Components [Axis]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_StatementEquityComponentsAxis" xml:lang="en-US">Equity Components [Axis]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementEquityComponentsAxis" xlink:to="lab_us-gaap_StatementEquityComponentsAxis" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaap_EquityComponentDomain" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_EquityComponentDomain" xml:lang="en-US">Equity Component [Domain]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_EquityComponentDomain" xml:lang="en-US">Equity Component [Domain]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquityComponentDomain" xlink:to="lab_us-gaap_EquityComponentDomain" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeMember" xml:lang="en-US">AOCI Attributable to Parent [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeMember" xml:lang="en-US">AOCI Attributable to Parent [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:to="lab_us-gaap_AccumulatedOtherComprehensiveIncomeMember" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdditionalPaidInCapitalMember" xlink:label="loc_us-gaap_AdditionalPaidInCapitalMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_AdditionalPaidInCapitalMember" xml:lang="en-US">Additional Paid-in Capital [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_AdditionalPaidInCapitalMember" xml:lang="en-US">Additional Paid-in Capital [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdditionalPaidInCapitalMember" xlink:to="lab_us-gaap_AdditionalPaidInCapitalMember" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockMember" xlink:label="loc_us-gaap_CommonStockMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_CommonStockMember" xml:lang="en-US">Common Stock [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_CommonStockMember" xml:lang="en-US">Common Stock [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockMember" xlink:to="lab_us-gaap_CommonStockMember" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NoncontrollingInterestMember" xlink:label="loc_us-gaap_NoncontrollingInterestMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_NoncontrollingInterestMember" xml:lang="en-US">Noncontrolling Interest [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_NoncontrollingInterestMember" xml:lang="en-US">Noncontrolling Interest [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NoncontrollingInterestMember" xlink:to="lab_us-gaap_NoncontrollingInterestMember" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RetainedEarningsMember" xlink:label="loc_us-gaap_RetainedEarningsMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_RetainedEarningsMember" xml:lang="en-US">Retained Earnings [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_RetainedEarningsMember" xml:lang="en-US">Accumulated Deficit [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RetainedEarningsMember" xlink:to="lab_us-gaap_RetainedEarningsMember" />
<loc xlink:type="locator" xlink:href="roiv-20210630.xsd#roiv_SubscriptionsReceivablesMember" xlink:label="loc_roiv_SubscriptionsReceivablesMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_roiv_SubscriptionsReceivablesMember" xml:lang="en-US">Subscriptions Receivables [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_roiv_SubscriptionsReceivablesMember" xml:lang="en-US">Subscriptions Receivables [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_roiv_SubscriptionsReceivablesMember" xlink:to="lab_roiv_SubscriptionsReceivablesMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_roiv_SubscriptionsReceivablesMember" xml:lang="en-US">Subscriptions Receivables [Member]</label>
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalIncreaseInCarryingAmountOfRedeemablePreferredStock" xlink:label="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalIncreaseInCarryingAmountOfRedeemablePreferredStock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalIncreaseInCarryingAmountOfRedeemablePreferredStock" xml:lang="en-US">Adjustments to Additional Paid in Capital, Increase in Carrying Amount of Redeemable Preferred Stock</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalIncreaseInCarryingAmountOfRedeemablePreferredStock" xml:lang="en-US">Purchase of subsidiary convertible and redeemable preferred stock</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalIncreaseInCarryingAmountOfRedeemablePreferredStock" xlink:to="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalIncreaseInCarryingAmountOfRedeemablePreferredStock" />
<loc xlink:type="locator" xlink:href="roiv-20210630.xsd#roiv_CapitalContributionsToSubsidiaries" xlink:label="loc_roiv_CapitalContributionsToSubsidiaries" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_roiv_CapitalContributionsToSubsidiaries" xml:lang="en-US">Capital Contributions To Subsidiaries</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_roiv_CapitalContributionsToSubsidiaries" xml:lang="en-US">Cash contributions to majority-owned subsidiaries</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_roiv_CapitalContributionsToSubsidiaries" xlink:to="lab_roiv_CapitalContributionsToSubsidiaries" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_roiv_CapitalContributionsToSubsidiaries" xml:lang="en-US">Capital Contributions To Subsidiaries</label>
<loc xlink:type="locator" xlink:href="roiv-20210630.xsd#roiv_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationRequisiteServicePeriodRecognitionShares" xlink:label="loc_roiv_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationRequisiteServicePeriodRecognitionShares" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_roiv_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationRequisiteServicePeriodRecognitionShares" xml:lang="en-US">Adjustments to Additional Paid in Capital, Share-based Compensation, Requisite Service Period Recognition, Shares</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_roiv_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationRequisiteServicePeriodRecognitionShares" xml:lang="en-US">Share-based compensation, shares</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_roiv_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationRequisiteServicePeriodRecognitionShares" xlink:to="lab_roiv_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationRequisiteServicePeriodRecognitionShares" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_roiv_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationRequisiteServicePeriodRecognitionShares" xml:lang="en-US">Adjustments to Additional Paid in Capital, Share-based Compensation, Requisite Service Period Recognition, Shares</label>
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:label="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xml:lang="en-US">APIC, Share-based Payment Arrangement, Increase for Cost Recognition</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xml:lang="en-US">Share-based compensation</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:to="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" />
<loc xlink:type="locator" xlink:href="roiv-20210630.xsd#roiv_ConsolidationOfUnconsolidatedEntity" xlink:label="loc_roiv_ConsolidationOfUnconsolidatedEntity" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_roiv_ConsolidationOfUnconsolidatedEntity" xml:lang="en-US">Consolidation of Unconsolidated Entity</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_roiv_ConsolidationOfUnconsolidatedEntity" xml:lang="en-US">Consolidation of unconsolidated entity</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_roiv_ConsolidationOfUnconsolidatedEntity" xlink:to="lab_roiv_ConsolidationOfUnconsolidatedEntity" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_roiv_ConsolidationOfUnconsolidatedEntity" xml:lang="en-US">Consolidation of Unconsolidated Entity</label>
<loc xlink:type="locator" xlink:href="roiv-20210630.xsd#roiv_ConversionOfSubsidiaryConvertiblePromissoryNotes" xlink:label="loc_roiv_ConversionOfSubsidiaryConvertiblePromissoryNotes" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_roiv_ConversionOfSubsidiaryConvertiblePromissoryNotes" xml:lang="en-US">Conversion of Subsidiary Convertible Promissory Notes</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_roiv_ConversionOfSubsidiaryConvertiblePromissoryNotes" xml:lang="en-US">Conversion of subsidiary convertible promissory notes</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_roiv_ConversionOfSubsidiaryConvertiblePromissoryNotes" xlink:to="lab_roiv_ConversionOfSubsidiaryConvertiblePromissoryNotes" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_roiv_ConversionOfSubsidiaryConvertiblePromissoryNotes" xml:lang="en-US">Conversion of Subsidiary Convertible Promissory Notes</label>
<loc xlink:type="locator" xlink:href="roiv-20210630.xsd#roiv_DeconsolidationOfSubsidiary" xlink:label="loc_roiv_DeconsolidationOfSubsidiary" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_roiv_DeconsolidationOfSubsidiary" xml:lang="en-US">Deconsolidation Of Subsidiary</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_roiv_DeconsolidationOfSubsidiary" xml:lang="en-US">Deconsolidation of subsidiary</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_roiv_DeconsolidationOfSubsidiary" xlink:to="lab_roiv_DeconsolidationOfSubsidiary" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_roiv_DeconsolidationOfSubsidiary" xml:lang="en-US">Deconsolidation Of Subsidiary</label>
<loc xlink:type="locator" xlink:href="roiv-20210630.xsd#roiv_IssuanceOfSubsidiaryCommonSharesNetValue" xlink:label="loc_roiv_IssuanceOfSubsidiaryCommonSharesNetValue" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_roiv_IssuanceOfSubsidiaryCommonSharesNetValue" xml:lang="en-US">Issuance of Subsidiary Common Shares Net Value</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_roiv_IssuanceOfSubsidiaryCommonSharesNetValue" xml:lang="en-US">Issuance of subsidiary common shares, net of issuance costs paid</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_roiv_IssuanceOfSubsidiaryCommonSharesNetValue" xlink:to="lab_roiv_IssuanceOfSubsidiaryCommonSharesNetValue" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_roiv_IssuanceOfSubsidiaryCommonSharesNetValue" xml:lang="en-US">Issuance of Subsidiary Common Shares Net Value</label>
<loc xlink:type="locator" xlink:href="roiv-20210630.xsd#roiv_IssuanceOfSubsidiaryCommonSharesToTheCompanyValue" xlink:label="loc_roiv_IssuanceOfSubsidiaryCommonSharesToTheCompanyValue" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_roiv_IssuanceOfSubsidiaryCommonSharesToTheCompanyValue" xml:lang="en-US">Issuance of Subsidiary Common Shares to the Company Value</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_roiv_IssuanceOfSubsidiaryCommonSharesToTheCompanyValue" xml:lang="en-US">Issuance of subsidiary common shares to the Company</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_roiv_IssuanceOfSubsidiaryCommonSharesToTheCompanyValue" xlink:to="lab_roiv_IssuanceOfSubsidiaryCommonSharesToTheCompanyValue" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_roiv_IssuanceOfSubsidiaryCommonSharesToTheCompanyValue" xml:lang="en-US">Issuance of Subsidiary Common Shares to the Company Value</label>
<loc xlink:type="locator" xlink:href="roiv-20210630.xsd#roiv_ExerciseOfSubsidiaryStockOptionsAndVestingOfSubsidiaryRestrictedStockUnits" xlink:label="loc_roiv_ExerciseOfSubsidiaryStockOptionsAndVestingOfSubsidiaryRestrictedStockUnits" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_roiv_ExerciseOfSubsidiaryStockOptionsAndVestingOfSubsidiaryRestrictedStockUnits" xml:lang="en-US">Exercise of Subsidiary Stock Options and Vesting of Subsidiary Restricted Stock Units</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_roiv_ExerciseOfSubsidiaryStockOptionsAndVestingOfSubsidiaryRestrictedStockUnits" xml:lang="en-US">Exercise of subsidiary stock options and vesting of subsidiary restricted stock units</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_roiv_ExerciseOfSubsidiaryStockOptionsAndVestingOfSubsidiaryRestrictedStockUnits" xlink:to="lab_roiv_ExerciseOfSubsidiaryStockOptionsAndVestingOfSubsidiaryRestrictedStockUnits" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_roiv_ExerciseOfSubsidiaryStockOptionsAndVestingOfSubsidiaryRestrictedStockUnits" xml:lang="en-US">Exercise of Subsidiary Stock Options and Vesting of Subsidiary Restricted Stock Units</label>
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GainOrLossOnSaleOfStockInSubsidiary" xlink:label="loc_us-gaap_GainOrLossOnSaleOfStockInSubsidiary" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_GainOrLossOnSaleOfStockInSubsidiary" xml:lang="en-US">Gain (Loss) on Disposition of Stock in Subsidiary</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_GainOrLossOnSaleOfStockInSubsidiary" xml:lang="en-US">Sale of interests in subsidiaries</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_GainOrLossOnSaleOfStockInSubsidiary" xml:lang="en-US">Gain (loss) on sale of stock transactions</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GainOrLossOnSaleOfStockInSubsidiary" xlink:to="lab_us-gaap_GainOrLossOnSaleOfStockInSubsidiary" />
<loc xlink:type="locator" xlink:href="roiv-20210630.xsd#roiv_IssuanceOfEquityBySubsidiaryToTheCompanyUponBusinessCombinationAndRecapitalization" xlink:label="loc_roiv_IssuanceOfEquityBySubsidiaryToTheCompanyUponBusinessCombinationAndRecapitalization" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_roiv_IssuanceOfEquityBySubsidiaryToTheCompanyUponBusinessCombinationAndRecapitalization" xml:lang="en-US">Issuance of Equity by Subsidiary to the Company upon Business Combination and Recapitalization</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_roiv_IssuanceOfEquityBySubsidiaryToTheCompanyUponBusinessCombinationAndRecapitalization" xml:lang="en-US">Issuance of equity by subsidiary to the Company upon Business Combination and recapitalization</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_roiv_IssuanceOfEquityBySubsidiaryToTheCompanyUponBusinessCombinationAndRecapitalization" xlink:to="lab_roiv_IssuanceOfEquityBySubsidiaryToTheCompanyUponBusinessCombinationAndRecapitalization" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_roiv_IssuanceOfEquityBySubsidiaryToTheCompanyUponBusinessCombinationAndRecapitalization" xml:lang="en-US">Issuance of Equity by Subsidiary to the Company upon Business Combination and Recapitalization</label>
<loc xlink:type="locator" xlink:href="roiv-20210630.xsd#roiv_IssuanceOfEquityBySubsidiaryUponBusinessCombinationAndRecapitalization" xlink:label="loc_roiv_IssuanceOfEquityBySubsidiaryUponBusinessCombinationAndRecapitalization" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_roiv_IssuanceOfEquityBySubsidiaryUponBusinessCombinationAndRecapitalization" xml:lang="en-US">Issuance of Equity by Subsidiary upon Business Combination and Recapitalization</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_roiv_IssuanceOfEquityBySubsidiaryUponBusinessCombinationAndRecapitalization" xml:lang="en-US">Issuance of equity by subsidiary upon Business Combination and recapitalization</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_roiv_IssuanceOfEquityBySubsidiaryUponBusinessCombinationAndRecapitalization" xlink:to="lab_roiv_IssuanceOfEquityBySubsidiaryUponBusinessCombinationAndRecapitalization" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_roiv_IssuanceOfEquityBySubsidiaryUponBusinessCombinationAndRecapitalization" xml:lang="en-US">Issuance of Equity by Subsidiary upon Business Combination and Recapitalization</label>
<loc xlink:type="locator" xlink:href="roiv-20210630.xsd#roiv_IssuanceOfEquityInstruments" xlink:label="loc_roiv_IssuanceOfEquityInstruments" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_roiv_IssuanceOfEquityInstruments" xml:lang="en-US">Issuance of Equity Instruments</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_roiv_IssuanceOfEquityInstruments" xml:lang="en-US">Issuance of equity instruments</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_roiv_IssuanceOfEquityInstruments" xlink:to="lab_roiv_IssuanceOfEquityInstruments" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_roiv_IssuanceOfEquityInstruments" xml:lang="en-US">Issuance of Equity Instruments</label>
<loc xlink:type="locator" xlink:href="roiv-20210630.xsd#roiv_IssuanceOfSubsidiaryWarrants" xlink:label="loc_roiv_IssuanceOfSubsidiaryWarrants" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_roiv_IssuanceOfSubsidiaryWarrants" xml:lang="en-US">Issuance of Subsidiary Warrants</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_roiv_IssuanceOfSubsidiaryWarrants" xml:lang="en-US">Issuance of subsidiary warrants</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_roiv_IssuanceOfSubsidiaryWarrants" xlink:to="lab_roiv_IssuanceOfSubsidiaryWarrants" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_roiv_IssuanceOfSubsidiaryWarrants" xml:lang="en-US">Issuance of Subsidiary Warrants</label>
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent" xlink:label="loc_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent" xml:lang="en-US">Other Comprehensive Income (Loss), Foreign Currency Transaction and Translation Adjustment, Net of Tax, Portion Attributable to Parent</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent" xml:lang="en-US">Foreign currency translation adjustment</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent" xlink:to="lab_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TemporaryEquityStockIssuedDuringPeriodValueNewIssues" xlink:label="loc_us-gaap_TemporaryEquityStockIssuedDuringPeriodValueNewIssues" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_TemporaryEquityStockIssuedDuringPeriodValueNewIssues" xml:lang="en-US">Temporary Equity, Stock Issued During Period, Value, New Issues</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_TemporaryEquityStockIssuedDuringPeriodValueNewIssues" xml:lang="en-US">Issuance of subsidiary convertible and redeemable preferred stock, net</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TemporaryEquityStockIssuedDuringPeriodValueNewIssues" xlink:to="lab_us-gaap_TemporaryEquityStockIssuedDuringPeriodValueNewIssues" />
<loc xlink:type="locator" xlink:href="roiv-20210630.xsd#roiv_PurchaseOfSubsidiaryCommonSharesValue" xlink:label="loc_roiv_PurchaseOfSubsidiaryCommonSharesValue" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_roiv_PurchaseOfSubsidiaryCommonSharesValue" xml:lang="en-US">Purchase of Subsidiary Common Shares Value</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="lab_roiv_PurchaseOfSubsidiaryCommonSharesValue" xml:lang="en-US">Purchase of subsidiary common shares</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_roiv_PurchaseOfSubsidiaryCommonSharesValue" xlink:to="lab_roiv_PurchaseOfSubsidiaryCommonSharesValue" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_roiv_PurchaseOfSubsidiaryCommonSharesValue" xml:lang="en-US">Purchase of Subsidiary Common Shares Value</label>
<loc xlink:type="locator" xlink:href="roiv-20210630.xsd#roiv_RepurchaseOfCommonSharesAndOtherEquityInstrumentsShares" xlink:label="loc_roiv_RepurchaseOfCommonSharesAndOtherEquityInstrumentsShares" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_roiv_RepurchaseOfCommonSharesAndOtherEquityInstrumentsShares" xml:lang="en-US">Repurchase of Common Shares and Other Equity Instruments Shares</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="lab_roiv_RepurchaseOfCommonSharesAndOtherEquityInstrumentsShares" xml:lang="en-US">Repurchase of common shares and other equity instruments, shares</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_roiv_RepurchaseOfCommonSharesAndOtherEquityInstrumentsShares" xlink:to="lab_roiv_RepurchaseOfCommonSharesAndOtherEquityInstrumentsShares" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_roiv_RepurchaseOfCommonSharesAndOtherEquityInstrumentsShares" xml:lang="en-US">Repurchase of Common Shares and Other Equity Instruments Shares</label>
<loc xlink:type="locator" xlink:href="roiv-20210630.xsd#roiv_RepurchaseOfCommonSharesAndOtherEquityInstrumentsValue" xlink:label="loc_roiv_RepurchaseOfCommonSharesAndOtherEquityInstrumentsValue" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_roiv_RepurchaseOfCommonSharesAndOtherEquityInstrumentsValue" xml:lang="en-US">Repurchase of Common Shares and Other Equity Instruments Value</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="lab_roiv_RepurchaseOfCommonSharesAndOtherEquityInstrumentsValue" xml:lang="en-US">Repurchase of common shares and other equity instruments</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_roiv_RepurchaseOfCommonSharesAndOtherEquityInstrumentsValue" xlink:to="lab_roiv_RepurchaseOfCommonSharesAndOtherEquityInstrumentsValue" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_roiv_RepurchaseOfCommonSharesAndOtherEquityInstrumentsValue" xml:lang="en-US">Repurchase of Common Shares and Other Equity Instruments Value</label>
<loc xlink:type="locator" xlink:href="roiv-20210630.xsd#roiv_RepurchaseOfEquityAwards" xlink:label="loc_roiv_RepurchaseOfEquityAwards" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_roiv_RepurchaseOfEquityAwards" xml:lang="en-US">Repurchase of Equity Awards</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_roiv_RepurchaseOfEquityAwards" xml:lang="en-US">Repurchase of equity awards</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_roiv_RepurchaseOfEquityAwards" xlink:to="lab_roiv_RepurchaseOfEquityAwards" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_roiv_RepurchaseOfEquityAwards" xml:lang="en-US">Repurchase of Equity Awards</label>
<loc xlink:type="locator" xlink:href="roiv-20210630.xsd#roiv_SettlementOfLiabilityClassifiedInstruments" xlink:label="loc_roiv_SettlementOfLiabilityClassifiedInstruments" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_roiv_SettlementOfLiabilityClassifiedInstruments" xml:lang="en-US">Settlement of Liability Classified Instruments</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_roiv_SettlementOfLiabilityClassifiedInstruments" xml:lang="en-US">Settlement in equity of liability-classified instruments</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_roiv_SettlementOfLiabilityClassifiedInstruments" xlink:to="lab_roiv_SettlementOfLiabilityClassifiedInstruments" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_roiv_SettlementOfLiabilityClassifiedInstruments" xml:lang="en-US">Settlement of Liability Classified Instruments</label>
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharesOutstanding" xlink:label="loc_us-gaap_SharesOutstanding" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_SharesOutstanding" xml:lang="en-US">Shares, Outstanding</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="lab_us-gaap_SharesOutstanding" xml:lang="en-US">Balance, shares</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="lab_us-gaap_SharesOutstanding" xml:lang="en-US">Balance, shares</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharesOutstanding" xlink:to="lab_us-gaap_SharesOutstanding" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesNewIssues" xml:lang="en-US">Stock Issued During Period, Shares, New Issues</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesNewIssues" xml:lang="en-US">Issuance of the Company's common shares, net, shares</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/positiveTerseLabel" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesNewIssues" xml:lang="en-US">Stock issued</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/positiveLabel" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesNewIssues" xml:lang="en-US">Public offering shares of common stock</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:to="lab_us-gaap_StockIssuedDuringPeriodSharesNewIssues" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueNewIssues" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueNewIssues" xml:lang="en-US">Stock Issued During Period, Value, New Issues</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueNewIssues" xml:lang="en-US">Issuance of the Company's common shares</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueNewIssues" xml:lang="en-US">Stock issued, value</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:to="lab_us-gaap_StockIssuedDuringPeriodValueNewIssues" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xml:lang="en-US">Stock Issued During Period, Value, Stock Options Exercised</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xml:lang="en-US">Exercise of subsidiary stock options</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:to="lab_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TemporaryEquityCarryingAmountIncludingPortionAttributableToNoncontrollingInterests" xlink:label="loc_us-gaap_TemporaryEquityCarryingAmountIncludingPortionAttributableToNoncontrollingInterests" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_TemporaryEquityCarryingAmountIncludingPortionAttributableToNoncontrollingInterests" xml:lang="en-US">Temporary Equity, Carrying Amount, Including Portion Attributable to Noncontrolling Interests</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="lab_us-gaap_TemporaryEquityCarryingAmountIncludingPortionAttributableToNoncontrollingInterests" xml:lang="en-US">Balance, temporary equity</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="lab_us-gaap_TemporaryEquityCarryingAmountIncludingPortionAttributableToNoncontrollingInterests" xml:lang="en-US">Balance, temporary equity</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TemporaryEquityCarryingAmountIncludingPortionAttributableToNoncontrollingInterests" xlink:to="lab_us-gaap_TemporaryEquityCarryingAmountIncludingPortionAttributableToNoncontrollingInterests" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementOfCashFlowsAbstract" xlink:label="loc_us-gaap_StatementOfCashFlowsAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_StatementOfCashFlowsAbstract" xml:lang="en-US">Statement of Cash Flows [Abstract]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract" xlink:to="lab_us-gaap_StatementOfCashFlowsAbstract" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xml:lang="en-US">Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xml:lang="en-US">Cash, cash equivalents and restricted cash at beginning of period</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xml:lang="en-US">Cash, cash equivalents and restricted cash at end of period</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:to="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect" xml:lang="en-US">Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Excluding Exchange Rate Effect</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect" xml:lang="en-US">Net change in cash, cash equivalents and restricted cash</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect" xlink:to="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:label="loc_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xml:lang="en-US">Cash Flow, Noncash Investing and Financing Activities Disclosure [Abstract]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xml:lang="en-US">Non-cash investing and financing activities:</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:to="lab_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" />
<loc xlink:type="locator" xlink:href="roiv-20210630.xsd#roiv_DeferredOfferingAndFinancingCostsIncludedInAccountsPayableAndAccruedExpenses" xlink:label="loc_roiv_DeferredOfferingAndFinancingCostsIncludedInAccountsPayableAndAccruedExpenses" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_roiv_DeferredOfferingAndFinancingCostsIncludedInAccountsPayableAndAccruedExpenses" xml:lang="en-US">Deferred Offering And Financing Costs Included In Accounts Payable And Accrued Expenses</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_roiv_DeferredOfferingAndFinancingCostsIncludedInAccountsPayableAndAccruedExpenses" xml:lang="en-US">Deferred offering and financing costs included in accounts payable and accrued expenses</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_roiv_DeferredOfferingAndFinancingCostsIncludedInAccountsPayableAndAccruedExpenses" xlink:to="lab_roiv_DeferredOfferingAndFinancingCostsIncludedInAccountsPayableAndAccruedExpenses" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_roiv_DeferredOfferingAndFinancingCostsIncludedInAccountsPayableAndAccruedExpenses" xml:lang="en-US">Deferred offering and financing costs included in accounts payable and accrued expenses.</label>
<loc xlink:type="locator" xlink:href="roiv-20210630.xsd#roiv_OperatingLeaseRightOfUseAssetsAndAmountsReclassifiedFromOtherLiabilitiesToOperatingLeaseLiabilities" xlink:label="loc_roiv_OperatingLeaseRightOfUseAssetsAndAmountsReclassifiedFromOtherLiabilitiesToOperatingLeaseLiabilities" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_roiv_OperatingLeaseRightOfUseAssetsAndAmountsReclassifiedFromOtherLiabilitiesToOperatingLeaseLiabilities" xml:lang="en-US">Operating Lease Right of Use Assets and Amounts Reclassified from Other Liabilities to Operating Lease Liabilities</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_roiv_OperatingLeaseRightOfUseAssetsAndAmountsReclassifiedFromOtherLiabilitiesToOperatingLeaseLiabilities" xml:lang="en-US">Operating lease right-of-use assets and operating lease liabilities, including amounts reclassified from other current liabilities and other liabilities to operating lease liabilities, recognized upon the adoption of ASC 842, Leases, on April 1, 2019</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_roiv_OperatingLeaseRightOfUseAssetsAndAmountsReclassifiedFromOtherLiabilitiesToOperatingLeaseLiabilities" xlink:to="lab_roiv_OperatingLeaseRightOfUseAssetsAndAmountsReclassifiedFromOtherLiabilitiesToOperatingLeaseLiabilities" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_roiv_OperatingLeaseRightOfUseAssetsAndAmountsReclassifiedFromOtherLiabilitiesToOperatingLeaseLiabilities" xml:lang="en-US">Operating Lease Right of Use Assets and Amounts Reclassified from Other Liabilities to Operating Lease Liabilities</label>
<loc xlink:type="locator" xlink:href="roiv-20210630.xsd#roiv_OtherNonCashTransactions" xlink:label="loc_roiv_OtherNonCashTransactions" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_roiv_OtherNonCashTransactions" xml:lang="en-US">Other Non Cash Transactions</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_roiv_OtherNonCashTransactions" xml:lang="en-US">Other</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_roiv_OtherNonCashTransactions" xlink:to="lab_roiv_OtherNonCashTransactions" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_roiv_OtherNonCashTransactions" xml:lang="en-US">Other Non Cash Transactions</label>
<loc xlink:type="locator" xlink:href="roiv-20210630.xsd#roiv_IssuanceOfSubsidiaryWarrantInConnectionWithDebtFinancing" xlink:label="loc_roiv_IssuanceOfSubsidiaryWarrantInConnectionWithDebtFinancing" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_roiv_IssuanceOfSubsidiaryWarrantInConnectionWithDebtFinancing" xml:lang="en-US">Issuance Of Subsidiary Warrant In Connection With Debt Financing</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_roiv_IssuanceOfSubsidiaryWarrantInConnectionWithDebtFinancing" xml:lang="en-US">Issuance of subsidiary warrant in connection with debt financing</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_roiv_IssuanceOfSubsidiaryWarrantInConnectionWithDebtFinancing" xlink:to="lab_roiv_IssuanceOfSubsidiaryWarrantInConnectionWithDebtFinancing" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_roiv_IssuanceOfSubsidiaryWarrantInConnectionWithDebtFinancing" xml:lang="en-US">Issuance of subsidiary warrant in connection with debt financing.</label>
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" xlink:label="loc_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" xml:lang="en-US">Right-of-Use Asset Obtained in Exchange for Operating Lease Liability</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" xml:lang="en-US">Operating lease right-of-use assets obtained and exchanged for operating lease liabilities</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" xml:lang="en-US">Operating lease ROU assets obtained in exchange for operating lease liabilities</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" xlink:to="lab_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NoncashInvestingAndFinancingItemsAbstract" xlink:label="loc_us-gaap_NoncashInvestingAndFinancingItemsAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_NoncashInvestingAndFinancingItemsAbstract" xml:lang="en-US">Noncash Investing and Financing Items [Abstract]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_NoncashInvestingAndFinancingItemsAbstract" xml:lang="en-US">Supplemental disclosure of noncash activities:</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NoncashInvestingAndFinancingItemsAbstract" xlink:to="lab_us-gaap_NoncashInvestingAndFinancingItemsAbstract" />
<loc xlink:type="locator" xlink:href="roiv-20210630.xsd#roiv_ConversionOfSubsidiaryConvertiblePromissoryNotesToCommonShares" xlink:label="loc_roiv_ConversionOfSubsidiaryConvertiblePromissoryNotesToCommonShares" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_roiv_ConversionOfSubsidiaryConvertiblePromissoryNotesToCommonShares" xml:lang="en-US">Conversion Of Subsidiary Convertible Promissory Notes To Common Shares</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_roiv_ConversionOfSubsidiaryConvertiblePromissoryNotesToCommonShares" xlink:to="lab_roiv_ConversionOfSubsidiaryConvertiblePromissoryNotesToCommonShares" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_roiv_ConversionOfSubsidiaryConvertiblePromissoryNotesToCommonShares" xml:lang="en-US">Conversion of subsidiary convertible promissory notes to common shares.</label>
<loc xlink:type="locator" xlink:href="roiv-20210630.xsd#roiv_SubscriptionReceivableRelatedToIssuanceOfSubsidiaryCommonShares" xlink:label="loc_roiv_SubscriptionReceivableRelatedToIssuanceOfSubsidiaryCommonShares" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_roiv_SubscriptionReceivableRelatedToIssuanceOfSubsidiaryCommonShares" xml:lang="en-US">Subscription Receivable Related To Issuance Of Subsidiary Common Shares</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_roiv_SubscriptionReceivableRelatedToIssuanceOfSubsidiaryCommonShares" xlink:to="lab_roiv_SubscriptionReceivableRelatedToIssuanceOfSubsidiaryCommonShares" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_roiv_SubscriptionReceivableRelatedToIssuanceOfSubsidiaryCommonShares" xml:lang="en-US">Subscription Receivable Related To Issuance Of Subsidiary Common Shares.</label>
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xml:lang="en-US">Net Cash Provided by (Used in) Financing Activities [Abstract]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xml:lang="en-US">Cash flows from financing activities:</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities" xml:lang="en-US">Net Cash Provided by (Used in) Financing Activities</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities" xml:lang="en-US">Net cash provided by financing activities</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities" />
<loc xlink:type="locator" xlink:href="roiv-20210630.xsd#roiv_PaymentForDebtMaintenanceFeeBySubsidiary" xlink:label="loc_roiv_PaymentForDebtMaintenanceFeeBySubsidiary" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_roiv_PaymentForDebtMaintenanceFeeBySubsidiary" xml:lang="en-US">Payment for Debt Maintenance Fee by Subsidiary</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_roiv_PaymentForDebtMaintenanceFeeBySubsidiary" xml:lang="en-US">Payment of deferred offering and loan origination costs</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_roiv_PaymentForDebtMaintenanceFeeBySubsidiary" xlink:to="lab_roiv_PaymentForDebtMaintenanceFeeBySubsidiary" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_roiv_PaymentForDebtMaintenanceFeeBySubsidiary" xml:lang="en-US">Payment for Debt Maintenance Fee by Subsidiary</label>
<loc xlink:type="locator" xlink:href="roiv-20210630.xsd#roiv_PaymentsForPurchaseOfSubsidiaryConvertibleAndRedeemablePreferredStock" xlink:label="loc_roiv_PaymentsForPurchaseOfSubsidiaryConvertibleAndRedeemablePreferredStock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_roiv_PaymentsForPurchaseOfSubsidiaryConvertibleAndRedeemablePreferredStock" xml:lang="en-US">Payments for Purchase of Subsidiary Convertible and Redeemable Preferred Stock</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="lab_roiv_PaymentsForPurchaseOfSubsidiaryConvertibleAndRedeemablePreferredStock" xml:lang="en-US">Purchase of subsidiary convertible and redeemable preferred stock</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_roiv_PaymentsForPurchaseOfSubsidiaryConvertibleAndRedeemablePreferredStock" xlink:to="lab_roiv_PaymentsForPurchaseOfSubsidiaryConvertibleAndRedeemablePreferredStock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_roiv_PaymentsForPurchaseOfSubsidiaryConvertibleAndRedeemablePreferredStock" xml:lang="en-US">Payments for Purchase of Subsidiary Convertible and Redeemable Preferred Stock</label>
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsForRepurchaseOfEquity" xlink:label="loc_us-gaap_PaymentsForRepurchaseOfEquity" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_PaymentsForRepurchaseOfEquity" xml:lang="en-US">Payments for Repurchase of Equity</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="lab_us-gaap_PaymentsForRepurchaseOfEquity" xml:lang="en-US">Repurchase of equity awards</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_us-gaap_PaymentsForRepurchaseOfEquity" xml:lang="en-US">Total cash paid</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsForRepurchaseOfEquity" xlink:to="lab_us-gaap_PaymentsForRepurchaseOfEquity" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsOfStockIssuanceCosts" xlink:label="loc_us-gaap_PaymentsOfStockIssuanceCosts" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_PaymentsOfStockIssuanceCosts" xml:lang="en-US">Payments of Stock Issuance Costs</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="lab_us-gaap_PaymentsOfStockIssuanceCosts" xml:lang="en-US">Offering costs paid</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsOfStockIssuanceCosts" xlink:to="lab_us-gaap_PaymentsOfStockIssuanceCosts" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfCommonStock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ProceedsFromIssuanceOfCommonStock" xml:lang="en-US">Proceeds from Issuance of Common Stock</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_ProceedsFromIssuanceOfCommonStock" xml:lang="en-US">Proceeds from issuance of the Company's common shares, net</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_ProceedsFromIssuanceOfCommonStock" xml:lang="en-US">Net proceeds of common stock</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:to="lab_us-gaap_ProceedsFromIssuanceOfCommonStock" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromIssuanceOfDebt" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfDebt" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ProceedsFromIssuanceOfDebt" xml:lang="en-US">Proceeds from Issuance of Debt</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_ProceedsFromIssuanceOfDebt" xml:lang="en-US">Proceeds from issuance of liability instruments</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromIssuanceOfDebt" xlink:to="lab_us-gaap_ProceedsFromIssuanceOfDebt" />
<loc xlink:type="locator" xlink:href="roiv-20210630.xsd#roiv_ProceedsFromIssuanceOfEquityBySubsidiaryUponBusinessCombinationAndRecapitalization" xlink:label="loc_roiv_ProceedsFromIssuanceOfEquityBySubsidiaryUponBusinessCombinationAndRecapitalization" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_roiv_ProceedsFromIssuanceOfEquityBySubsidiaryUponBusinessCombinationAndRecapitalization" xml:lang="en-US">Proceeds from Issuance of Equity by Subsidiary Upon Business Combination and Recapitalization</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_roiv_ProceedsFromIssuanceOfEquityBySubsidiaryUponBusinessCombinationAndRecapitalization" xml:lang="en-US">Proceeds from issuance of equity by subsidiary upon Business Combination and recapitalization</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_roiv_ProceedsFromIssuanceOfEquityBySubsidiaryUponBusinessCombinationAndRecapitalization" xlink:to="lab_roiv_ProceedsFromIssuanceOfEquityBySubsidiaryUponBusinessCombinationAndRecapitalization" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_roiv_ProceedsFromIssuanceOfEquityBySubsidiaryUponBusinessCombinationAndRecapitalization" xml:lang="en-US">Proceeds from Issuance of Equity by Subsidiary Upon Business Combination and Recapitalization</label>
<loc xlink:type="locator" xlink:href="roiv-20210630.xsd#roiv_ProceedsFromIssuanceOfSubsidiaryCommonSharesNet" xlink:label="loc_roiv_ProceedsFromIssuanceOfSubsidiaryCommonSharesNet" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_roiv_ProceedsFromIssuanceOfSubsidiaryCommonSharesNet" xml:lang="en-US">Proceeds from Issuance of Subsidiary Common Shares Net</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_roiv_ProceedsFromIssuanceOfSubsidiaryCommonSharesNet" xml:lang="en-US">Proceeds from issuance of subsidiary common shares, net of issuance costs paid</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_roiv_ProceedsFromIssuanceOfSubsidiaryCommonSharesNet" xlink:to="lab_roiv_ProceedsFromIssuanceOfSubsidiaryCommonSharesNet" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_roiv_ProceedsFromIssuanceOfSubsidiaryCommonSharesNet" xml:lang="en-US">Proceeds from Issuance of Subsidiary Common Shares Net</label>
<loc xlink:type="locator" xlink:href="roiv-20210630.xsd#roiv_ProceedsFromIssuanceOfSubsidiaryConvertibleAndRedeemablePreferredStockNet" xlink:label="loc_roiv_ProceedsFromIssuanceOfSubsidiaryConvertibleAndRedeemablePreferredStockNet" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_roiv_ProceedsFromIssuanceOfSubsidiaryConvertibleAndRedeemablePreferredStockNet" xml:lang="en-US">Proceeds from Issuance of Subsidiary Convertible and Redeemable Preferred Stock Net</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_roiv_ProceedsFromIssuanceOfSubsidiaryConvertibleAndRedeemablePreferredStockNet" xml:lang="en-US">Proceeds from issuance of subsidiary convertible and redeemable preferred stock, net</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_roiv_ProceedsFromIssuanceOfSubsidiaryConvertibleAndRedeemablePreferredStockNet" xlink:to="lab_roiv_ProceedsFromIssuanceOfSubsidiaryConvertibleAndRedeemablePreferredStockNet" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_roiv_ProceedsFromIssuanceOfSubsidiaryConvertibleAndRedeemablePreferredStockNet" xml:lang="en-US">Proceeds from Issuance of Subsidiary Convertible and Redeemable Preferred Stock Net</label>
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromStockOptionsExercised" xlink:label="loc_us-gaap_ProceedsFromStockOptionsExercised" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ProceedsFromStockOptionsExercised" xml:lang="en-US">Proceeds from Stock Options Exercised</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_ProceedsFromStockOptionsExercised" xml:lang="en-US">Proceeds from exercise of subsidiary stock options</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromStockOptionsExercised" xlink:to="lab_us-gaap_ProceedsFromStockOptionsExercised" />
<loc xlink:type="locator" xlink:href="roiv-20210630.xsd#roiv_ProceedsFromSubsidiaryDebtFinancingsNet" xlink:label="loc_roiv_ProceedsFromSubsidiaryDebtFinancingsNet" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_roiv_ProceedsFromSubsidiaryDebtFinancingsNet" xml:lang="en-US">Proceeds from Subsidiary Debt Financings Net</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_roiv_ProceedsFromSubsidiaryDebtFinancingsNet" xml:lang="en-US">Proceeds from subsidiary debt financings, net of financing costs paid</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_roiv_ProceedsFromSubsidiaryDebtFinancingsNet" xlink:to="lab_roiv_ProceedsFromSubsidiaryDebtFinancingsNet" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_roiv_ProceedsFromSubsidiaryDebtFinancingsNet" xml:lang="en-US">Proceeds from Subsidiary Debt Financings Net</label>
<loc xlink:type="locator" xlink:href="roiv-20210630.xsd#roiv_PurchaseOfSubsidiaryCommonShares" xlink:label="loc_roiv_PurchaseOfSubsidiaryCommonShares" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_roiv_PurchaseOfSubsidiaryCommonShares" xml:lang="en-US">Purchase of Subsidiary Common Shares</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_roiv_PurchaseOfSubsidiaryCommonShares" xml:lang="en-US">Purchase of subsidiary common shares</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_roiv_PurchaseOfSubsidiaryCommonShares" xlink:to="lab_roiv_PurchaseOfSubsidiaryCommonShares" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_roiv_PurchaseOfSubsidiaryCommonShares" xml:lang="en-US">Purchase of Subsidiary Common Shares</label>
<loc xlink:type="locator" xlink:href="roiv-20210630.xsd#roiv_RepaymentOfLongTermDebtAndConvertibleDebtBySubsidiary" xlink:label="loc_roiv_RepaymentOfLongTermDebtAndConvertibleDebtBySubsidiary" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_roiv_RepaymentOfLongTermDebtAndConvertibleDebtBySubsidiary" xml:lang="en-US">Repayment of Long Term Debt and Convertible Debt by Subsidiary</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="lab_roiv_RepaymentOfLongTermDebtAndConvertibleDebtBySubsidiary" xml:lang="en-US">Repayment of long-term debt by subsidiary</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_roiv_RepaymentOfLongTermDebtAndConvertibleDebtBySubsidiary" xlink:to="lab_roiv_RepaymentOfLongTermDebtAndConvertibleDebtBySubsidiary" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_roiv_RepaymentOfLongTermDebtAndConvertibleDebtBySubsidiary" xml:lang="en-US">Repayment of Long Term Debt and Convertible Debt by Subsidiary</label>
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xml:lang="en-US">Net Cash Provided by (Used in) Investing Activities [Abstract]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xml:lang="en-US">Cash flows from investing activities:</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" />
<loc xlink:type="locator" xlink:href="roiv-20210630.xsd#roiv_CashAcquiredUponConsolidationOfUnconsolidatedEntity" xlink:label="loc_roiv_CashAcquiredUponConsolidationOfUnconsolidatedEntity" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_roiv_CashAcquiredUponConsolidationOfUnconsolidatedEntity" xml:lang="en-US">Cash Acquired Upon Consolidation of Unconsolidated Entity</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_roiv_CashAcquiredUponConsolidationOfUnconsolidatedEntity" xml:lang="en-US">Cash acquired upon consolidation of unconsolidated entity</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_roiv_CashAcquiredUponConsolidationOfUnconsolidatedEntity" xlink:to="lab_roiv_CashAcquiredUponConsolidationOfUnconsolidatedEntity" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_roiv_CashAcquiredUponConsolidationOfUnconsolidatedEntity" xml:lang="en-US">Cash Acquired Upon Consolidation of Unconsolidated Entity</label>
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashDivestedFromDeconsolidation" xlink:label="loc_us-gaap_CashDivestedFromDeconsolidation" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_CashDivestedFromDeconsolidation" xml:lang="en-US">Cash Divested from Deconsolidation</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="lab_us-gaap_CashDivestedFromDeconsolidation" xml:lang="en-US">Cash disposed upon deconsolidation of subsidiary</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashDivestedFromDeconsolidation" xlink:to="lab_us-gaap_CashDivestedFromDeconsolidation" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities" xml:lang="en-US">Net Cash Provided by (Used in) Investing Activities</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities" xml:lang="en-US">Net cash used in investing activities</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:to="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired" xlink:label="loc_us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired" xml:lang="en-US">Payments to Acquire Businesses, Net of Cash Acquired</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="lab_us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired" xml:lang="en-US">Acquisitions, net of cash acquired</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired" xml:lang="en-US">Payment to acquire business, net</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired" xlink:to="lab_us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired" />
<loc xlink:type="locator" xlink:href="roiv-20210630.xsd#roiv_PaymentsToAcquireInvestmentsInUnconsolidatedEntities" xlink:label="loc_roiv_PaymentsToAcquireInvestmentsInUnconsolidatedEntities" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_roiv_PaymentsToAcquireInvestmentsInUnconsolidatedEntities" xml:lang="en-US">Payments to Acquire Investments in Unconsolidated Entities</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="lab_roiv_PaymentsToAcquireInvestmentsInUnconsolidatedEntities" xml:lang="en-US">Investments in unconsolidated entities</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_roiv_PaymentsToAcquireInvestmentsInUnconsolidatedEntities" xlink:to="lab_roiv_PaymentsToAcquireInvestmentsInUnconsolidatedEntities" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_roiv_PaymentsToAcquireInvestmentsInUnconsolidatedEntities" xml:lang="en-US">Payments to Acquire Investments in Unconsolidated Entities</label>
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsToAcquireMarketableSecurities" xlink:label="loc_us-gaap_PaymentsToAcquireMarketableSecurities" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_PaymentsToAcquireMarketableSecurities" xml:lang="en-US">Payments to Acquire Marketable Securities</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="lab_us-gaap_PaymentsToAcquireMarketableSecurities" xml:lang="en-US">Purchase of marketable securities</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsToAcquireMarketableSecurities" xlink:to="lab_us-gaap_PaymentsToAcquireMarketableSecurities" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:label="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xml:lang="en-US">Payments to Acquire Property, Plant, and Equipment</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xml:lang="en-US">Purchase of property and equipment</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:to="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromDivestitureOfBusinesses" xlink:label="loc_us-gaap_ProceedsFromDivestitureOfBusinesses" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ProceedsFromDivestitureOfBusinesses" xml:lang="en-US">Proceeds from Divestiture of Businesses</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_ProceedsFromDivestitureOfBusinesses" xml:lang="en-US">Proceeds from sale of business, net of cash disposed</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromDivestitureOfBusinesses" xlink:to="lab_us-gaap_ProceedsFromDivestitureOfBusinesses" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities" xlink:label="loc_us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities" xml:lang="en-US">Proceeds from Sale and Maturity of Marketable Securities</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities" xml:lang="en-US">Maturity of marketable securities</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities" xlink:to="lab_us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xml:lang="en-US">Net Cash Provided by (Used in) Operating Activities [Abstract]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xml:lang="en-US">Cash flows from operating activities:</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xml:lang="en-US">Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xml:lang="en-US">Adjustments to reconcile net loss to net cash used in operating activities:</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeLossFromEquityMethodInvestments" xlink:label="loc_us-gaap_IncomeLossFromEquityMethodInvestments" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_IncomeLossFromEquityMethodInvestments" xml:lang="en-US">Income (Loss) from Equity Method Investments</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="lab_us-gaap_IncomeLossFromEquityMethodInvestments" xml:lang="en-US">Loss from equity method investment</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeLossFromEquityMethodInvestments" xlink:to="lab_us-gaap_IncomeLossFromEquityMethodInvestments" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GainLossOnSaleOfBusiness" xlink:label="loc_us-gaap_GainLossOnSaleOfBusiness" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_GainLossOnSaleOfBusiness" xml:lang="en-US">Gain (Loss) on Disposition of Business</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="lab_us-gaap_GainLossOnSaleOfBusiness" xml:lang="en-US">Gain on sale of business</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GainLossOnSaleOfBusiness" xlink:to="lab_us-gaap_GainLossOnSaleOfBusiness" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherNoncashIncomeExpense" xlink:label="loc_us-gaap_OtherNoncashIncomeExpense" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_OtherNoncashIncomeExpense" xml:lang="en-US">Other Noncash Income (Expense)</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="lab_us-gaap_OtherNoncashIncomeExpense" xml:lang="en-US">Other</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherNoncashIncomeExpense" xlink:to="lab_us-gaap_OtherNoncashIncomeExpense" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensation" xlink:label="loc_us-gaap_ShareBasedCompensation" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ShareBasedCompensation" xml:lang="en-US">Share-based Payment Arrangement, Noncash Expense</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_ShareBasedCompensation" xml:lang="en-US">Share-based compensation</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_ShareBasedCompensation" xml:lang="en-US">Share-based compensation expense</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensation" xlink:to="lab_us-gaap_ShareBasedCompensation" />
<loc xlink:type="locator" xlink:href="roiv-20210630.xsd#roiv_GainOnTerminationOfEquityInterestOptions" xlink:label="loc_roiv_GainOnTerminationOfEquityInterestOptions" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_roiv_GainOnTerminationOfEquityInterestOptions" xml:lang="en-US">Gain On Termination Of Equity Interest Options</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="lab_roiv_GainOnTerminationOfEquityInterestOptions" xml:lang="en-US">Gain on termination of Sumitomo Options</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_roiv_GainOnTerminationOfEquityInterestOptions" xlink:to="lab_roiv_GainOnTerminationOfEquityInterestOptions" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_roiv_GainOnTerminationOfEquityInterestOptions" xml:lang="en-US">Gain on termination of equity interest options.</label>
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ResearchAndDevelopmentInProcess" xlink:label="loc_us-gaap_ResearchAndDevelopmentInProcess" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ResearchAndDevelopmentInProcess" xml:lang="en-US">Research and Development in Process</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_ResearchAndDevelopmentInProcess" xml:lang="en-US">Acquired in-processresearch and development</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ResearchAndDevelopmentInProcess" xlink:to="lab_us-gaap_ResearchAndDevelopmentInProcess" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:label="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xml:lang="en-US">Increase (Decrease) in Operating Capital [Abstract]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xml:lang="en-US">Changes in assets and liabilities, net of effects from acquisition and divestiture:</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsPayableTrade" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsPayableTrade" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_IncreaseDecreaseInAccountsPayableTrade" xml:lang="en-US">Increase (Decrease) in Accounts Payable, Trade</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_IncreaseDecreaseInAccountsPayableTrade" xml:lang="en-US">Accounts payable</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInAccountsPayableTrade" xlink:to="lab_us-gaap_IncreaseDecreaseInAccountsPayableTrade" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInAccruedLiabilities" xlink:label="loc_us-gaap_IncreaseDecreaseInAccruedLiabilities" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_IncreaseDecreaseInAccruedLiabilities" xml:lang="en-US">Increase (Decrease) in Accrued Liabilities</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_IncreaseDecreaseInAccruedLiabilities" xml:lang="en-US">Accrued expenses</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInAccruedLiabilities" xlink:to="lab_us-gaap_IncreaseDecreaseInAccruedLiabilities" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInDeferredLiabilities" xlink:label="loc_us-gaap_IncreaseDecreaseInDeferredLiabilities" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_IncreaseDecreaseInDeferredLiabilities" xml:lang="en-US">Increase (Decrease) in Deferred Liabilities</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_IncreaseDecreaseInDeferredLiabilities" xml:lang="en-US">Deferred consideration liability</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInDeferredLiabilities" xlink:to="lab_us-gaap_IncreaseDecreaseInDeferredLiabilities" />
<loc xlink:type="locator" xlink:href="roiv-20210630.xsd#roiv_IncreaseDecreaseInOperatingLeaseLiabilities" xlink:label="loc_roiv_IncreaseDecreaseInOperatingLeaseLiabilities" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_roiv_IncreaseDecreaseInOperatingLeaseLiabilities" xml:lang="en-US">Increase Decrease In Operating Lease Liabilities</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_roiv_IncreaseDecreaseInOperatingLeaseLiabilities" xml:lang="en-US">Operating lease liabilities</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_roiv_IncreaseDecreaseInOperatingLeaseLiabilities" xlink:to="lab_roiv_IncreaseDecreaseInOperatingLeaseLiabilities" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_roiv_IncreaseDecreaseInOperatingLeaseLiabilities" xml:lang="en-US">Increase decrease in operating lease liabilities</label>
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInOtherOperatingCapitalNet" xlink:label="loc_us-gaap_IncreaseDecreaseInOtherOperatingCapitalNet" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_IncreaseDecreaseInOtherOperatingCapitalNet" xml:lang="en-US">Increase (Decrease) in Other Operating Assets and Liabilities, Net</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="lab_us-gaap_IncreaseDecreaseInOtherOperatingCapitalNet" xml:lang="en-US">Other</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInOtherOperatingCapitalNet" xlink:to="lab_us-gaap_IncreaseDecreaseInOtherOperatingCapitalNet" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities" xml:lang="en-US">Net Cash Provided by (Used in) Operating Activities</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities" xml:lang="en-US">Net cash used in operating activities</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SupplementalCashFlowInformationAbstract" xlink:label="loc_us-gaap_SupplementalCashFlowInformationAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_SupplementalCashFlowInformationAbstract" xml:lang="en-US">Supplemental Cash Flow Information [Abstract]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_SupplementalCashFlowInformationAbstract" xml:lang="en-US">Supplemental disclosure of cash paid:</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SupplementalCashFlowInformationAbstract" xlink:to="lab_us-gaap_SupplementalCashFlowInformationAbstract" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxesPaidNet" xlink:label="loc_us-gaap_IncomeTaxesPaidNet" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_IncomeTaxesPaidNet" xml:lang="en-US">Income Taxes Paid, Net</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_IncomeTaxesPaidNet" xml:lang="en-US">Income taxes paid</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxesPaidNet" xlink:to="lab_us-gaap_IncomeTaxesPaidNet" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InterestPaidNet" xlink:label="loc_us-gaap_InterestPaidNet" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_InterestPaidNet" xml:lang="en-US">Interest Paid, Excluding Capitalized Interest, Operating Activities</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_InterestPaidNet" xml:lang="en-US">Interest paid</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InterestPaidNet" xlink:to="lab_us-gaap_InterestPaidNet" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xml:lang="en-US">Organization, Consolidation and Presentation of Financial Statements [Abstract]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock" xlink:label="loc_us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock" xml:lang="en-US">Business Description and Basis of Presentation [Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock" xml:lang="en-US">Description of Business and Liquidity</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock" xlink:to="lab_us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="loc_us-gaap_AccountingPoliciesAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_AccountingPoliciesAbstract" xml:lang="en-US">Accounting Policies [Abstract]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountingPoliciesAbstract" xlink:to="lab_us-gaap_AccountingPoliciesAbstract" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SignificantAccountingPoliciesTextBlock" xlink:label="loc_us-gaap_SignificantAccountingPoliciesTextBlock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_SignificantAccountingPoliciesTextBlock" xml:lang="en-US">Significant Accounting Policies [Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_SignificantAccountingPoliciesTextBlock" xml:lang="en-US">Summary of Significant Accounting Policies</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SignificantAccountingPoliciesTextBlock" xlink:to="lab_us-gaap_SignificantAccountingPoliciesTextBlock" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InvestmentsAllOtherInvestmentsAbstract" xlink:label="loc_us-gaap_InvestmentsAllOtherInvestmentsAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_InvestmentsAllOtherInvestmentsAbstract" xml:lang="en-US">Investments, All Other Investments [Abstract]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InvestmentsAllOtherInvestmentsAbstract" xlink:to="lab_us-gaap_InvestmentsAllOtherInvestmentsAbstract" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InvestmentsAndOtherNoncurrentAssetsTextBlock" xlink:label="loc_us-gaap_InvestmentsAndOtherNoncurrentAssetsTextBlock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_InvestmentsAndOtherNoncurrentAssetsTextBlock" xml:lang="en-US">Investments and Other Noncurrent Assets [Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_InvestmentsAndOtherNoncurrentAssetsTextBlock" xml:lang="en-US">Investments</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InvestmentsAndOtherNoncurrentAssetsTextBlock" xlink:to="lab_us-gaap_InvestmentsAndOtherNoncurrentAssetsTextBlock" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationsAbstract" xlink:label="loc_us-gaap_BusinessCombinationsAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_BusinessCombinationsAbstract" xml:lang="en-US">Business Combinations [Abstract]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationsAbstract" xlink:to="lab_us-gaap_BusinessCombinationsAbstract" />
<loc xlink:type="locator" xlink:href="roiv-20210630.xsd#roiv_AssetAcquisitionsAndLicenseAgreementsDisclosureTextBlock" xlink:label="loc_roiv_AssetAcquisitionsAndLicenseAgreementsDisclosureTextBlock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_roiv_AssetAcquisitionsAndLicenseAgreementsDisclosureTextBlock" xml:lang="en-US">Asset Acquisitions and License Agreements Disclosure [Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_roiv_AssetAcquisitionsAndLicenseAgreementsDisclosureTextBlock" xml:lang="en-US">Asset Acquisitions and License Agreements</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_roiv_AssetAcquisitionsAndLicenseAgreementsDisclosureTextBlock" xlink:to="lab_roiv_AssetAcquisitionsAndLicenseAgreementsDisclosureTextBlock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_roiv_AssetAcquisitionsAndLicenseAgreementsDisclosureTextBlock" xml:lang="en-US">Asset acquisitions and license agreements disclosure.</label>
<loc xlink:type="locator" xlink:href="roiv-20210630.xsd#roiv_TransactionAgreementAbstract" xlink:label="loc_roiv_TransactionAgreementAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_roiv_TransactionAgreementAbstract" xml:lang="en-US">Transaction Agreement [Abstract]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_roiv_TransactionAgreementAbstract" xlink:to="lab_roiv_TransactionAgreementAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_roiv_TransactionAgreementAbstract" xml:lang="en-US">Transaction Agreement.</label>
<loc xlink:type="locator" xlink:href="roiv-20210630.xsd#roiv_TransactionAgreementDisclosureTextBlock" xlink:label="loc_roiv_TransactionAgreementDisclosureTextBlock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_roiv_TransactionAgreementDisclosureTextBlock" xml:lang="en-US">Transaction Agreement Disclosure [Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_roiv_TransactionAgreementDisclosureTextBlock" xml:lang="en-US">Sumitomo Transaction Agreement</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_roiv_TransactionAgreementDisclosureTextBlock" xlink:to="lab_roiv_TransactionAgreementDisclosureTextBlock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_roiv_TransactionAgreementDisclosureTextBlock" xml:lang="en-US">Transaction Agreement Disclosure.</label>
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SupplementalBalanceSheetDisclosuresTextBlock" xlink:label="loc_us-gaap_SupplementalBalanceSheetDisclosuresTextBlock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_SupplementalBalanceSheetDisclosuresTextBlock" xml:lang="en-US">Supplemental Balance Sheet Disclosures [Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_SupplementalBalanceSheetDisclosuresTextBlock" xml:lang="en-US">Balance Sheet Components</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SupplementalBalanceSheetDisclosuresTextBlock" xlink:to="lab_us-gaap_SupplementalBalanceSheetDisclosuresTextBlock" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtDisclosureAbstract" xlink:label="loc_us-gaap_DebtDisclosureAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_DebtDisclosureAbstract" xml:lang="en-US">Debt Disclosure [Abstract]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtDisclosureAbstract" xlink:to="lab_us-gaap_DebtDisclosureAbstract" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongTermDebtTextBlock" xlink:label="loc_us-gaap_LongTermDebtTextBlock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_LongTermDebtTextBlock" xml:lang="en-US">Long-term Debt [Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_LongTermDebtTextBlock" xml:lang="en-US">Long Term Debt</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongTermDebtTextBlock" xlink:to="lab_us-gaap_LongTermDebtTextBlock" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityAbstract" xlink:label="loc_us-gaap_EquityAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_EquityAbstract" xml:lang="en-US">Equity [Abstract]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquityAbstract" xlink:to="lab_us-gaap_EquityAbstract" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:label="loc_us-gaap_StockholdersEquityNoteDisclosureTextBlock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_StockholdersEquityNoteDisclosureTextBlock" xml:lang="en-US">Stockholders' Equity Note Disclosure [Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_StockholdersEquityNoteDisclosureTextBlock" xml:lang="en-US">Shareholders' Equity and Redeemable Noncontrolling Interest</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:to="lab_us-gaap_StockholdersEquityNoteDisclosureTextBlock" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xml:lang="en-US">Share-based Payment Arrangement [Abstract]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="lab_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xml:lang="en-US">Share-based Payment Arrangement [Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xml:lang="en-US">Share-Based Compensation</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:to="lab_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RelatedPartyTransactionsAbstract" xlink:label="loc_us-gaap_RelatedPartyTransactionsAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_RelatedPartyTransactionsAbstract" xml:lang="en-US">Related Party Transactions [Abstract]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RelatedPartyTransactionsAbstract" xlink:to="lab_us-gaap_RelatedPartyTransactionsAbstract" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RelatedPartyTransactionsDisclosureTextBlock" xlink:label="loc_us-gaap_RelatedPartyTransactionsDisclosureTextBlock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_RelatedPartyTransactionsDisclosureTextBlock" xml:lang="en-US">Related Party Transactions Disclosure [Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_RelatedPartyTransactionsDisclosureTextBlock" xml:lang="en-US">Related Party Transactions</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RelatedPartyTransactionsDisclosureTextBlock" xlink:to="lab_us-gaap_RelatedPartyTransactionsDisclosureTextBlock" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DiscontinuedOperationsAndDisposalGroupsAbstract" xlink:label="loc_us-gaap_DiscontinuedOperationsAndDisposalGroupsAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_DiscontinuedOperationsAndDisposalGroupsAbstract" xml:lang="en-US">Discontinued Operations and Disposal Groups [Abstract]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DiscontinuedOperationsAndDisposalGroupsAbstract" xlink:to="lab_us-gaap_DiscontinuedOperationsAndDisposalGroupsAbstract" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock" xlink:label="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock" xml:lang="en-US">Disposal Groups, Including Discontinued Operations, Disclosure [Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock" xml:lang="en-US">Discontinued Operations</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock" xlink:to="lab_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_IncomeTaxDisclosureAbstract" xml:lang="en-US">Income Tax Disclosure [Abstract]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract" xlink:to="lab_us-gaap_IncomeTaxDisclosureAbstract" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxDisclosureTextBlock" xlink:label="loc_us-gaap_IncomeTaxDisclosureTextBlock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_IncomeTaxDisclosureTextBlock" xml:lang="en-US">Income Tax Disclosure [Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_IncomeTaxDisclosureTextBlock" xml:lang="en-US">Income Taxes</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxDisclosureTextBlock" xlink:to="lab_us-gaap_IncomeTaxDisclosureTextBlock" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LeasesAbstract" xlink:label="loc_us-gaap_LeasesAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_LeasesAbstract" xml:lang="en-US">Leases [Abstract]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LeasesAbstract" xlink:to="lab_us-gaap_LeasesAbstract" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeasesTextBlock" xlink:label="loc_us-gaap_LesseeOperatingLeasesTextBlock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_LesseeOperatingLeasesTextBlock" xml:lang="en-US">Lessee, Operating Leases [Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_LesseeOperatingLeasesTextBlock" xml:lang="en-US">Leases</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeasesTextBlock" xlink:to="lab_us-gaap_LesseeOperatingLeasesTextBlock" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xml:lang="en-US">Commitments and Contingencies Disclosure [Abstract]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="lab_us-gaap_CommitmentsAndContingenciesDisclosureAbstract" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xml:lang="en-US">Commitments and Contingencies Disclosure [Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xml:lang="en-US">Commitments &amp; Contingencies</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:to="lab_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueDisclosuresAbstract" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_FairValueDisclosuresAbstract" xml:lang="en-US">Fair Value Disclosures [Abstract]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract" xlink:to="lab_us-gaap_FairValueDisclosuresAbstract" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueDisclosuresTextBlock" xlink:label="loc_us-gaap_FairValueDisclosuresTextBlock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_FairValueDisclosuresTextBlock" xml:lang="en-US">Fair Value Disclosures [Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_FairValueDisclosuresTextBlock" xml:lang="en-US">Fair Value Measurements</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueDisclosuresTextBlock" xlink:to="lab_us-gaap_FairValueDisclosuresTextBlock" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CompensationAndRetirementDisclosureAbstract" xlink:label="loc_us-gaap_CompensationAndRetirementDisclosureAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_CompensationAndRetirementDisclosureAbstract" xml:lang="en-US">Retirement Benefits [Abstract]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CompensationAndRetirementDisclosureAbstract" xlink:to="lab_us-gaap_CompensationAndRetirementDisclosureAbstract" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DefinedContributionPlanTextBlock" xlink:label="loc_us-gaap_DefinedContributionPlanTextBlock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_DefinedContributionPlanTextBlock" xml:lang="en-US">Defined Contribution Plan [Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_DefinedContributionPlanTextBlock" xml:lang="en-US">Defined Contribution Plan</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DefinedContributionPlanTextBlock" xlink:to="lab_us-gaap_DefinedContributionPlanTextBlock" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherIncomeAndExpensesAbstract" xlink:label="loc_us-gaap_OtherIncomeAndExpensesAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_OtherIncomeAndExpensesAbstract" xml:lang="en-US">Other Income and Expenses [Abstract]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_OtherIncomeAndExpensesAbstract" xml:lang="en-US">Other (Income) Expense, Net [Abstract]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_OtherIncomeAndExpensesAbstract" xml:lang="en-US">Other (income) expense [Abstract]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherIncomeAndExpensesAbstract" xlink:to="lab_us-gaap_OtherIncomeAndExpensesAbstract" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherOperatingIncomeAndExpenseTextBlock" xlink:label="loc_us-gaap_OtherOperatingIncomeAndExpenseTextBlock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_OtherOperatingIncomeAndExpenseTextBlock" xml:lang="en-US">Other Operating Income and Expense [Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_OtherOperatingIncomeAndExpenseTextBlock" xml:lang="en-US">Other (Income) Expense, Net</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherOperatingIncomeAndExpenseTextBlock" xlink:to="lab_us-gaap_OtherOperatingIncomeAndExpenseTextBlock" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerShareAbstract" xlink:label="loc_us-gaap_EarningsPerShareAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_EarningsPerShareAbstract" xml:lang="en-US">Earnings Per Share [Abstract]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareAbstract" xlink:to="lab_us-gaap_EarningsPerShareAbstract" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerShareTextBlock" xlink:label="loc_us-gaap_EarningsPerShareTextBlock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_EarningsPerShareTextBlock" xml:lang="en-US">Earnings Per Share [Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_EarningsPerShareTextBlock" xml:lang="en-US">Net Loss per Common Share</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareTextBlock" xlink:to="lab_us-gaap_EarningsPerShareTextBlock" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventsAbstract" xlink:label="loc_us-gaap_SubsequentEventsAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_SubsequentEventsAbstract" xml:lang="en-US">Subsequent Events [Abstract]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsequentEventsAbstract" xlink:to="lab_us-gaap_SubsequentEventsAbstract" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventsTextBlock" xlink:label="loc_us-gaap_SubsequentEventsTextBlock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_SubsequentEventsTextBlock" xml:lang="en-US">Subsequent Events [Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_SubsequentEventsTextBlock" xml:lang="en-US">Subsequent Events</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsequentEventsTextBlock" xlink:to="lab_us-gaap_SubsequentEventsTextBlock" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommitmentsAndContingenciesPolicyTextBlock" xlink:label="loc_us-gaap_CommitmentsAndContingenciesPolicyTextBlock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_CommitmentsAndContingenciesPolicyTextBlock" xml:lang="en-US">Commitments and Contingencies, Policy [Policy Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_CommitmentsAndContingenciesPolicyTextBlock" xml:lang="en-US">Contingencies</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommitmentsAndContingenciesPolicyTextBlock" xlink:to="lab_us-gaap_CommitmentsAndContingenciesPolicyTextBlock" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy" xlink:label="loc_us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy" xml:lang="en-US">Cash and Cash Equivalents, Restricted Cash and Cash Equivalents, Policy [Policy Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy" xml:lang="en-US">Cash, Cash Equivalents, and Restricted Cash</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy" xlink:to="lab_us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:label="loc_us-gaap_BasisOfAccountingPolicyPolicyTextBlock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xml:lang="en-US">Basis of Accounting, Policy [Policy Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xml:lang="en-US">Basis of Presentation and Principles of Consolidation</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:to="lab_us-gaap_BasisOfAccountingPolicyPolicyTextBlock" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConcentrationRiskCreditRisk" xlink:label="loc_us-gaap_ConcentrationRiskCreditRisk" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ConcentrationRiskCreditRisk" xml:lang="en-US">Concentration Risk, Credit Risk, Policy [Policy Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_ConcentrationRiskCreditRisk" xml:lang="en-US">Concentrations of Credit Risk</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConcentrationRiskCreditRisk" xlink:to="lab_us-gaap_ConcentrationRiskCreditRisk" />
<loc xlink:type="locator" xlink:href="roiv-20210630.xsd#roiv_NewAccountingPronouncementsNotYetAdoptedPolicyTextBlock" xlink:label="loc_roiv_NewAccountingPronouncementsNotYetAdoptedPolicyTextBlock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_roiv_NewAccountingPronouncementsNotYetAdoptedPolicyTextBlock" xml:lang="en-US">New Accounting Pronouncements Not Yet Adopted [Policy Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_roiv_NewAccountingPronouncementsNotYetAdoptedPolicyTextBlock" xml:lang="en-US">Recently Issued Accounting Pronouncements Not Yet Adopted</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_roiv_NewAccountingPronouncementsNotYetAdoptedPolicyTextBlock" xlink:to="lab_roiv_NewAccountingPronouncementsNotYetAdoptedPolicyTextBlock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_roiv_NewAccountingPronouncementsNotYetAdoptedPolicyTextBlock" xml:lang="en-US">New Accounting Pronouncements Not Yet Adopted [Policy Text Block]</label>
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:label="loc_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xml:lang="en-US">New Accounting Pronouncements, Policy [Policy Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xml:lang="en-US">Recently Adopted Accounting Pronouncements</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:to="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xml:lang="en-US">Property, Plant and Equipment, Policy [Policy Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xml:lang="en-US">Property and Equipment</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpensePolicy" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpensePolicy" xml:lang="en-US">Research and Development Expense, Policy [Policy Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpensePolicy" xml:lang="en-US">Research and Development Expenses</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:to="lab_us-gaap_ResearchAndDevelopmentExpensePolicy" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevenueFromContractWithCustomerPolicyTextBlock" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock" xml:lang="en-US">Revenue from Contract with Customer [Policy Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock" xml:lang="en-US">Revenue Recognition</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock" xlink:to="lab_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:label="loc_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xml:lang="en-US">Share-based Payment Arrangement [Policy Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xml:lang="en-US">Share-Based Compensation</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:to="lab_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TradeAndOtherAccountsReceivablePolicy" xlink:label="loc_us-gaap_TradeAndOtherAccountsReceivablePolicy" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_TradeAndOtherAccountsReceivablePolicy" xml:lang="en-US">Accounts Receivable [Policy Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_TradeAndOtherAccountsReceivablePolicy" xml:lang="en-US">Trade Receivables, Net</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TradeAndOtherAccountsReceivablePolicy" xlink:to="lab_us-gaap_TradeAndOtherAccountsReceivablePolicy" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_UnusualRisksAndUncertaintiesTextBlock" xlink:label="loc_us-gaap_UnusualRisksAndUncertaintiesTextBlock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_UnusualRisksAndUncertaintiesTextBlock" xml:lang="en-US">Unusual Risks and Uncertainties [Table Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_UnusualRisksAndUncertaintiesTextBlock" xml:lang="en-US">Risks and Uncertainties</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_UnusualRisksAndUncertaintiesTextBlock" xlink:to="lab_us-gaap_UnusualRisksAndUncertaintiesTextBlock" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_UseOfEstimates" xlink:label="loc_us-gaap_UseOfEstimates" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_UseOfEstimates" xml:lang="en-US">Use of Estimates, Policy [Policy Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_UseOfEstimates" xml:lang="en-US">Use of Estimates</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_UseOfEstimates" xlink:to="lab_us-gaap_UseOfEstimates" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementPolicyPolicyTextBlock" xlink:label="loc_us-gaap_FairValueMeasurementPolicyPolicyTextBlock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_FairValueMeasurementPolicyPolicyTextBlock" xml:lang="en-US">Fair Value Measurement, Policy [Policy Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_FairValueMeasurementPolicyPolicyTextBlock" xml:lang="en-US">Fair Value Measurements</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueMeasurementPolicyPolicyTextBlock" xlink:to="lab_us-gaap_FairValueMeasurementPolicyPolicyTextBlock" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock" xlink:label="loc_us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock" xml:lang="en-US">Foreign Currency Transactions and Translations Policy [Policy Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock" xml:lang="en-US">Foreign Currency</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock" xlink:to="lab_us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock" />
<loc xlink:type="locator" xlink:href="roiv-20210630.xsd#roiv_GeneralAndAdministrativeExpensesPolicyTextBlock" xlink:label="loc_roiv_GeneralAndAdministrativeExpensesPolicyTextBlock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_roiv_GeneralAndAdministrativeExpensesPolicyTextBlock" xml:lang="en-US">General and Administrative Expenses [Policy Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_roiv_GeneralAndAdministrativeExpensesPolicyTextBlock" xml:lang="en-US">General and Administrative Expenses</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_roiv_GeneralAndAdministrativeExpensesPolicyTextBlock" xlink:to="lab_roiv_GeneralAndAdministrativeExpensesPolicyTextBlock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_roiv_GeneralAndAdministrativeExpensesPolicyTextBlock" xml:lang="en-US">General and Administrative Expenses, Policy [Text Block]</label>
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxPolicyTextBlock" xlink:label="loc_us-gaap_IncomeTaxPolicyTextBlock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_IncomeTaxPolicyTextBlock" xml:lang="en-US">Income Tax, Policy [Policy Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_IncomeTaxPolicyTextBlock" xml:lang="en-US">Income Taxes</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxPolicyTextBlock" xlink:to="lab_us-gaap_IncomeTaxPolicyTextBlock" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InvestmentPolicyTextBlock" xlink:label="loc_us-gaap_InvestmentPolicyTextBlock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_InvestmentPolicyTextBlock" xml:lang="en-US">Investment, Policy [Policy Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_InvestmentPolicyTextBlock" xml:lang="en-US">Investments</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InvestmentPolicyTextBlock" xlink:to="lab_us-gaap_InvestmentPolicyTextBlock" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfCashAndCashEquivalentsTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfCashAndCashEquivalentsTableTextBlock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ScheduleOfCashAndCashEquivalentsTableTextBlock" xml:lang="en-US">Schedule of Cash and Cash Equivalents [Table Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_ScheduleOfCashAndCashEquivalentsTableTextBlock" xml:lang="en-US">Schedule of Aggregate Amounts of Cash, Cash Equivalents, and Restricted Cash</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfCashAndCashEquivalentsTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfCashAndCashEquivalentsTableTextBlock" />
<loc xlink:type="locator" xlink:href="roiv-20210630.xsd#roiv_ScheduleOfPropertyPlantAndEquipmentEstimatedUsefulLivesTableTextBlock" xlink:label="loc_roiv_ScheduleOfPropertyPlantAndEquipmentEstimatedUsefulLivesTableTextBlock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_roiv_ScheduleOfPropertyPlantAndEquipmentEstimatedUsefulLivesTableTextBlock" xml:lang="en-US">Schedule Of Property Plant And Equipment Estimated Useful Lives [Table Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_roiv_ScheduleOfPropertyPlantAndEquipmentEstimatedUsefulLivesTableTextBlock" xml:lang="en-US">Schedule of Estimated Useful Lives Used for Asset Type</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_roiv_ScheduleOfPropertyPlantAndEquipmentEstimatedUsefulLivesTableTextBlock" xlink:to="lab_roiv_ScheduleOfPropertyPlantAndEquipmentEstimatedUsefulLivesTableTextBlock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_roiv_ScheduleOfPropertyPlantAndEquipmentEstimatedUsefulLivesTableTextBlock" xml:lang="en-US">Schedule Of Property Plant And Equipment Estimated Useful Lives.</label>
<loc xlink:type="locator" xlink:href="roiv-20210630.xsd#roiv_ScheduleOfDisposalGroupsIncludingDiscontinuedCondensedConsolidatedStatementsOfCashFlowsTableTextBlock" xlink:label="loc_roiv_ScheduleOfDisposalGroupsIncludingDiscontinuedCondensedConsolidatedStatementsOfCashFlowsTableTextBlock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_roiv_ScheduleOfDisposalGroupsIncludingDiscontinuedCondensedConsolidatedStatementsOfCashFlowsTableTextBlock" xml:lang="en-US">Schedule Of Disposal Groups Including Discontinued Condensed Consolidated Statements Of Cash Flows Table [Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_roiv_ScheduleOfDisposalGroupsIncludingDiscontinuedCondensedConsolidatedStatementsOfCashFlowsTableTextBlock" xml:lang="en-US">Summary of Cash Flows from Discontinued Operations</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_roiv_ScheduleOfDisposalGroupsIncludingDiscontinuedCondensedConsolidatedStatementsOfCashFlowsTableTextBlock" xlink:to="lab_roiv_ScheduleOfDisposalGroupsIncludingDiscontinuedCondensedConsolidatedStatementsOfCashFlowsTableTextBlock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_roiv_ScheduleOfDisposalGroupsIncludingDiscontinuedCondensedConsolidatedStatementsOfCashFlowsTableTextBlock" xml:lang="en-US">Schedule Of Disposal Groups Including Discontinued Condensed Consolidated Statements Of Cash Flows Table [Text Block]</label>
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfDisposalGroupsIncludingDiscontinuedOperationsIncomeStatementBalanceSheetAndAdditionalDisclosuresTextBlock" xlink:label="loc_us-gaap_ScheduleOfDisposalGroupsIncludingDiscontinuedOperationsIncomeStatementBalanceSheetAndAdditionalDisclosuresTextBlock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ScheduleOfDisposalGroupsIncludingDiscontinuedOperationsIncomeStatementBalanceSheetAndAdditionalDisclosuresTextBlock" xml:lang="en-US">Disposal Groups, Including Discontinued Operations [Table Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_ScheduleOfDisposalGroupsIncludingDiscontinuedOperationsIncomeStatementBalanceSheetAndAdditionalDisclosuresTextBlock" xml:lang="en-US">Summary Of Disposal Groups Including Discontinued Operations Income Statement</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfDisposalGroupsIncludingDiscontinuedOperationsIncomeStatementBalanceSheetAndAdditionalDisclosuresTextBlock" xlink:to="lab_us-gaap_ScheduleOfDisposalGroupsIncludingDiscontinuedOperationsIncomeStatementBalanceSheetAndAdditionalDisclosuresTextBlock" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherCurrentLiabilitiesTableTextBlock" xlink:label="loc_us-gaap_OtherCurrentLiabilitiesTableTextBlock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_OtherCurrentLiabilitiesTableTextBlock" xml:lang="en-US">Other Current Liabilities [Table Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_OtherCurrentLiabilitiesTableTextBlock" xml:lang="en-US">Schedule of Other Current Liabilities</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherCurrentLiabilitiesTableTextBlock" xlink:to="lab_us-gaap_OtherCurrentLiabilitiesTableTextBlock" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock" xml:lang="en-US">Schedule of Accrued Liabilities [Table Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock" xml:lang="en-US">Schedule of Accrued Expenses</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfOtherCurrentAssetsTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfOtherCurrentAssetsTableTextBlock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ScheduleOfOtherCurrentAssetsTableTextBlock" xml:lang="en-US">Schedule of Other Current Assets [Table Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_ScheduleOfOtherCurrentAssetsTableTextBlock" xml:lang="en-US">Schedule of Other Current Assets</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfOtherCurrentAssetsTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfOtherCurrentAssetsTableTextBlock" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ContractualObligationFiscalYearMaturityScheduleTableTextBlock" xlink:label="loc_srt_ContractualObligationFiscalYearMaturityScheduleTableTextBlock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_srt_ContractualObligationFiscalYearMaturityScheduleTableTextBlock" xml:lang="en-US">Contractual Obligation, Fiscal Year Maturity [Table Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_srt_ContractualObligationFiscalYearMaturityScheduleTableTextBlock" xml:lang="en-US">Schedule of Company's Annual Payments</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_ContractualObligationFiscalYearMaturityScheduleTableTextBlock" xlink:to="lab_srt_ContractualObligationFiscalYearMaturityScheduleTableTextBlock" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfDebtTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfDebtTableTextBlock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ScheduleOfDebtTableTextBlock" xml:lang="en-US">Schedule of Debt [Table Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_ScheduleOfDebtTableTextBlock" xml:lang="en-US">Schedule of Long Term Debt</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfDebtTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfDebtTableTextBlock" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfStockholdersEquityTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfStockholdersEquityTableTextBlock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ScheduleOfStockholdersEquityTableTextBlock" xml:lang="en-US">Schedule of Stockholders Equity [Table Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_ScheduleOfStockholdersEquityTableTextBlock" xml:lang="en-US">Shareholders' Equity and Redeemable Non-Controlling Interest</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfStockholdersEquityTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfStockholdersEquityTableTextBlock" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AwardTypeAxis" xlink:label="loc_us-gaap_AwardTypeAxis" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_AwardTypeAxis" xml:lang="en-US">Award Type [Axis]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_AwardTypeAxis" xml:lang="en-US">Award Type [Axis]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AwardTypeAxis" xlink:to="lab_us-gaap_AwardTypeAxis" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xml:lang="en-US">Award Type [Domain]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xml:lang="en-US">Award Type [Domain]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" />
<loc xlink:type="locator" xlink:href="roiv-20210630.xsd#roiv_CappedValueAppreciationRightsMember" xlink:label="loc_roiv_CappedValueAppreciationRightsMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_roiv_CappedValueAppreciationRightsMember" xml:lang="en-US">Capped Value Appreciation Rights [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_roiv_CappedValueAppreciationRightsMember" xml:lang="en-US">CVARs [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_roiv_CappedValueAppreciationRightsMember" xlink:to="lab_roiv_CappedValueAppreciationRightsMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_roiv_CappedValueAppreciationRightsMember" xml:lang="en-US">Capped Value Appreciation Rights [Member]</label>
<loc xlink:type="locator" xlink:href="roiv-20210630.xsd#roiv_CommonStockAwardsMember" xlink:label="loc_roiv_CommonStockAwardsMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_roiv_CommonStockAwardsMember" xml:lang="en-US">Common Stock Awards [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_roiv_CommonStockAwardsMember" xml:lang="en-US">RSL Common Share Award</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_roiv_CommonStockAwardsMember" xlink:to="lab_roiv_CommonStockAwardsMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_roiv_CommonStockAwardsMember" xml:lang="en-US">Common Stock Awards [Member]</label>
<loc xlink:type="locator" xlink:href="roiv-20210630.xsd#roiv_PerformanceOptionsMember" xlink:label="loc_roiv_PerformanceOptionsMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_roiv_PerformanceOptionsMember" xml:lang="en-US">Performance Options [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_roiv_PerformanceOptionsMember" xml:lang="en-US">Performance Options [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_roiv_PerformanceOptionsMember" xlink:to="lab_roiv_PerformanceOptionsMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_roiv_PerformanceOptionsMember" xml:lang="en-US">Performance Options [Member]</label>
<loc xlink:type="locator" xlink:href="roiv-20210630.xsd#roiv_PerformanceRestrictedStockUnitsMember" xlink:label="loc_roiv_PerformanceRestrictedStockUnitsMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_roiv_PerformanceRestrictedStockUnitsMember" xml:lang="en-US">Performance Restricted Stock Units [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_roiv_PerformanceRestrictedStockUnitsMember" xml:lang="en-US">Performance RSU [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_roiv_PerformanceRestrictedStockUnitsMember" xlink:to="lab_roiv_PerformanceRestrictedStockUnitsMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_roiv_PerformanceRestrictedStockUnitsMember" xml:lang="en-US">Performance Restricted Stock Units [Member]</label>
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xml:lang="en-US">Schedule of Share-based Payment Award, Stock Options, Valuation Assumptions [Table Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xml:lang="en-US">Schedule of Fair Value Assumptions</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock" xml:lang="en-US">Share-based Payment Arrangement, Cost by Plan [Table Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock" xml:lang="en-US">Summary of Share-Based Compensation Expense</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock" xml:lang="en-US">Schedule of Nonvested Restricted Stock Units Activity [Table Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock" xml:lang="en-US">Summary of Restricted Stock Units</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xml:lang="en-US">Share-based Payment Arrangement, Option, Activity [Table Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xml:lang="en-US">Summary of Stock Option Activity</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" />
<loc xlink:type="locator" xlink:href="roiv-20210630.xsd#roiv_ScheduleOfSharebasedPaymentArrangementFairValueOfVestedStockOptionTableTextBlock" xlink:label="loc_roiv_ScheduleOfSharebasedPaymentArrangementFairValueOfVestedStockOptionTableTextBlock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_roiv_ScheduleOfSharebasedPaymentArrangementFairValueOfVestedStockOptionTableTextBlock" xml:lang="en-US">Schedule of Share-based Payment Arrangement, Fair Value of Vested Stock Option [Table Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_roiv_ScheduleOfSharebasedPaymentArrangementFairValueOfVestedStockOptionTableTextBlock" xml:lang="en-US">Summary of Fair Value of Vested Stock Option</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_roiv_ScheduleOfSharebasedPaymentArrangementFairValueOfVestedStockOptionTableTextBlock" xlink:to="lab_roiv_ScheduleOfSharebasedPaymentArrangementFairValueOfVestedStockOptionTableTextBlock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_roiv_ScheduleOfSharebasedPaymentArrangementFairValueOfVestedStockOptionTableTextBlock" xml:lang="en-US">Schedule of Share-based Payment Arrangement, Fair Value of Vested Stock Option.</label>
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xml:lang="en-US">Schedule of Deferred Tax Assets and Liabilities [Table Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xml:lang="en-US">Schedule of Company's net deferred tax assets</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xml:lang="en-US">Schedule of Effective Income Tax Rate Reconciliation [Table Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xml:lang="en-US">Reconciliation of Federal Statutory Income Taxes Rate</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock" xml:lang="en-US">Schedule of Income before Income Tax, Domestic and Foreign [Table Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock" xml:lang="en-US">Schedule of Loss Before Income Taxes and Related Expense/(Benefit)</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LeaseCostTableTextBlock" xlink:label="loc_us-gaap_LeaseCostTableTextBlock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_LeaseCostTableTextBlock" xml:lang="en-US">Lease, Cost [Table Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_LeaseCostTableTextBlock" xml:lang="en-US">Schedule of Operating Lease Costs</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LeaseCostTableTextBlock" xlink:to="lab_us-gaap_LeaseCostTableTextBlock" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LeasesOfLesseeDisclosureTextBlock" xlink:label="loc_us-gaap_LeasesOfLesseeDisclosureTextBlock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_LeasesOfLesseeDisclosureTextBlock" xml:lang="en-US">Leases of Lessee Disclosure [Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_LeasesOfLesseeDisclosureTextBlock" xml:lang="en-US">Summary of Operating Lease ROU Assets and Operating Lease Liabilities</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LeasesOfLesseeDisclosureTextBlock" xlink:to="lab_us-gaap_LeasesOfLesseeDisclosureTextBlock" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xml:lang="en-US">Lessee, Operating Lease, Liability, Maturity [Table Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xml:lang="en-US">Schedule of Maturities of Operating Lease Liabilities</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock" xml:lang="en-US">Fair Value Measurement Inputs and Valuation Techniques [Table Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock" xml:lang="en-US">Schedule of Fair Value of Unobservable Input Related To Options to Acquire Under Sumitomo Transaction Agreement</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock" xlink:to="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock" xlink:label="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock" xml:lang="en-US">Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Table Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock" xml:lang="en-US">Schedule of change in the fair value of the derivative warrant liabilities</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock" xlink:to="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock" xml:lang="en-US">Schedule of Fair Value, Assets and Liabilities Measured on Recurring Basis [Table Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock" xml:lang="en-US">Schedule of Assets and Liabilities Measured at Fair Value on a Recurring Basis</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfOtherOperatingCostAndExpenseByComponentTextBlock" xlink:label="loc_us-gaap_ScheduleOfOtherOperatingCostAndExpenseByComponentTextBlock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ScheduleOfOtherOperatingCostAndExpenseByComponentTextBlock" xml:lang="en-US">Schedule of Other Operating Cost and Expense, by Component [Table Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_ScheduleOfOtherOperatingCostAndExpenseByComponentTextBlock" xml:lang="en-US">Summary of Other (Income) Expense, Net From Continuing Operations</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfOtherOperatingCostAndExpenseByComponentTextBlock" xlink:to="lab_us-gaap_ScheduleOfOtherOperatingCostAndExpenseByComponentTextBlock" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xml:lang="en-US">Schedule of Earnings Per Share, Basic and Diluted [Table Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xml:lang="en-US">Schedule of basic and diluted per share of common stock</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NumberOfOperatingSegments" xlink:label="loc_us-gaap_NumberOfOperatingSegments" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_NumberOfOperatingSegments" xml:lang="en-US">Number of Operating Segments</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_NumberOfOperatingSegments" xml:lang="en-US">Number of operating and reporting segments</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NumberOfOperatingSegments" xlink:to="lab_us-gaap_NumberOfOperatingSegments" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetIncomeLossAttributableToRedeemableNoncontrollingInterest" xlink:label="loc_us-gaap_NetIncomeLossAttributableToRedeemableNoncontrollingInterest" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_NetIncomeLossAttributableToRedeemableNoncontrollingInterest" xml:lang="en-US">Net Income (Loss) Attributable to Redeemable Noncontrolling Interest</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_NetIncomeLossAttributableToRedeemableNoncontrollingInterest" xml:lang="en-US">Net losses from continuing operations</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetIncomeLossAttributableToRedeemableNoncontrollingInterest" xlink:to="lab_us-gaap_NetIncomeLossAttributableToRedeemableNoncontrollingInterest" />
<loc xlink:type="locator" xlink:href="roiv-20210630.xsd#roiv_ScheduleOfAccountingPoliciesTable" xlink:label="loc_roiv_ScheduleOfAccountingPoliciesTable" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_roiv_ScheduleOfAccountingPoliciesTable" xml:lang="en-US">Schedule Of Accounting Policies [Table]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_roiv_ScheduleOfAccountingPoliciesTable" xml:lang="en-US">Schedule Of Accounting Policies [Table]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_roiv_ScheduleOfAccountingPoliciesTable" xlink:to="lab_roiv_ScheduleOfAccountingPoliciesTable" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_roiv_ScheduleOfAccountingPoliciesTable" xml:lang="en-US">Schedule Of Accounting Policies [Table]</label>
<loc xlink:type="locator" xlink:href="roiv-20210630.xsd#roiv_ScheduleOfAccountingPoliciesLineItems" xlink:label="loc_roiv_ScheduleOfAccountingPoliciesLineItems" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_roiv_ScheduleOfAccountingPoliciesLineItems" xml:lang="en-US">Schedule Of Accounting Policies [Line Items]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_roiv_ScheduleOfAccountingPoliciesLineItems" xml:lang="en-US">Schedule Of Accounting Policies [Line Items]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_roiv_ScheduleOfAccountingPoliciesLineItems" xlink:to="lab_roiv_ScheduleOfAccountingPoliciesLineItems" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_roiv_ScheduleOfAccountingPoliciesLineItems" xml:lang="en-US">Schedule Of Accounting Policies [Line Items]</label>
<loc xlink:type="locator" xlink:href="roiv-20210630.xsd#roiv_ProceedsFromReleaseOfEscrowDeposit" xlink:label="loc_roiv_ProceedsFromReleaseOfEscrowDeposit" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_roiv_ProceedsFromReleaseOfEscrowDeposit" xml:lang="en-US">Proceeds from Release of Escrow Deposit</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_roiv_ProceedsFromReleaseOfEscrowDeposit" xml:lang="en-US">Proceeds from release of escrow deposit</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_roiv_ProceedsFromReleaseOfEscrowDeposit" xlink:to="lab_roiv_ProceedsFromReleaseOfEscrowDeposit" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_roiv_ProceedsFromReleaseOfEscrowDeposit" xml:lang="en-US">Proceeds from Release of Escrow Deposit.</label>
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EscrowDeposit" xlink:label="loc_us-gaap_EscrowDeposit" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_EscrowDeposit" xml:lang="en-US">Escrow Deposit</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_EscrowDeposit" xml:lang="en-US">Escrowed deposit</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_EscrowDeposit" xml:lang="en-US">Escrow amount</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EscrowDeposit" xlink:to="lab_us-gaap_EscrowDeposit" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="loc_us-gaap_SubsidiarySaleOfStockAxis" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_SubsidiarySaleOfStockAxis" xml:lang="en-US">Sale of Stock [Axis]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_SubsidiarySaleOfStockAxis" xml:lang="en-US">Sale of Stock [Axis]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis" xlink:to="lab_us-gaap_SubsidiarySaleOfStockAxis" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_SaleOfStockNameOfTransactionDomain" xml:lang="en-US">Sale of Stock [Domain]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_SaleOfStockNameOfTransactionDomain" xml:lang="en-US">Sale of Stock [Domain]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="lab_us-gaap_SaleOfStockNameOfTransactionDomain" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashAndCashEquivalentsAbstract" xlink:label="loc_us-gaap_CashAndCashEquivalentsAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_CashAndCashEquivalentsAbstract" xml:lang="en-US">Cash and Cash Equivalents [Abstract]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashAndCashEquivalentsAbstract" xlink:to="lab_us-gaap_CashAndCashEquivalentsAbstract" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestrictedCash" xlink:label="loc_us-gaap_RestrictedCash" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_RestrictedCash" xml:lang="en-US">Restricted Cash</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_RestrictedCash" xml:lang="en-US">Restricted cash</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestrictedCash" xlink:to="lab_us-gaap_RestrictedCash" />
<loc xlink:type="locator" xlink:href="roiv-20210630.xsd#roiv_CashAndCashEquivalentsAndRestrictedCash" xlink:label="loc_roiv_CashAndCashEquivalentsAndRestrictedCash" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_roiv_CashAndCashEquivalentsAndRestrictedCash" xml:lang="en-US">Cash and Cash Equivalents and Restricted Cash</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_roiv_CashAndCashEquivalentsAndRestrictedCash" xml:lang="en-US">Cash, cash equivalents and restricted cash</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_roiv_CashAndCashEquivalentsAndRestrictedCash" xlink:to="lab_roiv_CashAndCashEquivalentsAndRestrictedCash" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_roiv_CashAndCashEquivalentsAndRestrictedCash" xml:lang="en-US">Cash and Cash Equivalents and Restricted Cash</label>
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:label="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xml:lang="en-US">Property, Plant and Equipment [Table]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xml:lang="en-US">Property, Plant and Equipment [Table]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:to="lab_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentByTypeAxis" xml:lang="en-US">Long-Lived Tangible Asset [Axis]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentByTypeAxis" xml:lang="en-US">Long-Lived Tangible Asset [Axis]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentByTypeAxis" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentTypeDomain" xml:lang="en-US">Long-Lived Tangible Asset [Domain]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentTypeDomain" xml:lang="en-US">Long-Lived Tangible Asset [Domain]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentTypeDomain" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FurnitureAndFixturesMember" xlink:label="loc_us-gaap_FurnitureAndFixturesMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_FurnitureAndFixturesMember" xml:lang="en-US">Furniture and Fixtures [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_FurnitureAndFixturesMember" xml:lang="en-US">Furniture and Fixtures [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FurnitureAndFixturesMember" xlink:to="lab_us-gaap_FurnitureAndFixturesMember" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LeaseholdImprovementsMember" xlink:label="loc_us-gaap_LeaseholdImprovementsMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_LeaseholdImprovementsMember" xml:lang="en-US">Leasehold Improvements [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_LeaseholdImprovementsMember" xml:lang="en-US">Leasehold Improvements [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LeaseholdImprovementsMember" xlink:to="lab_us-gaap_LeaseholdImprovementsMember" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SoftwareDevelopmentMember" xlink:label="loc_us-gaap_SoftwareDevelopmentMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_SoftwareDevelopmentMember" xml:lang="en-US">Software Development [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_SoftwareDevelopmentMember" xml:lang="en-US">Software [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SoftwareDevelopmentMember" xlink:to="lab_us-gaap_SoftwareDevelopmentMember" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ComputerEquipmentMember" xlink:label="loc_us-gaap_ComputerEquipmentMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ComputerEquipmentMember" xml:lang="en-US">Computer Equipment [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_ComputerEquipmentMember" xml:lang="en-US">Computer [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ComputerEquipmentMember" xlink:to="lab_us-gaap_ComputerEquipmentMember" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquipmentMember" xlink:label="loc_us-gaap_EquipmentMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_EquipmentMember" xml:lang="en-US">Equipment [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_EquipmentMember" xml:lang="en-US">Equipment [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquipmentMember" xlink:to="lab_us-gaap_EquipmentMember" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentLineItems" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentLineItems" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentLineItems" xml:lang="en-US">Property, Plant and Equipment [Line Items]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentLineItems" xml:lang="en-US">Property, Plant and Equipment [Line Items]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentLineItems" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentEstimatedUsefulLives" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentEstimatedUsefulLives" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentEstimatedUsefulLives" xml:lang="en-US">Property, Plant and Equipment, Estimated Useful Lives</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentEstimatedUsefulLives" xml:lang="en-US">Estimated useful lives</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentEstimatedUsefulLives" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentEstimatedUsefulLives" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentUsefulLife" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentUsefulLife" xml:lang="en-US">Property, Plant and Equipment, Useful Life</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentUsefulLife" xml:lang="en-US">Estimated useful lives</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentUsefulLife" />
<loc xlink:type="locator" xlink:href="roiv-20210630.xsd#roiv_UncategorizedAbstract" xlink:label="loc_roiv_UncategorizedAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_roiv_UncategorizedAbstract" xml:lang="en-US">Uncategorized [Abstract]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_roiv_UncategorizedAbstract" xlink:to="lab_roiv_UncategorizedAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_roiv_UncategorizedAbstract" xml:lang="en-US">Uncategorized [Abstract]</label>
<loc xlink:type="locator" xlink:href="roiv-20210630.xsd#roiv_InvestmentsTable" xlink:label="loc_roiv_InvestmentsTable" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_roiv_InvestmentsTable" xml:lang="en-US">Investments [Table]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_roiv_InvestmentsTable" xml:lang="en-US">Investments [Table]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_roiv_InvestmentsTable" xlink:to="lab_roiv_InvestmentsTable" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_roiv_InvestmentsTable" xml:lang="en-US">Investments [Table]</label>
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SeriesBPreferredStockMember" xlink:label="loc_us-gaap_SeriesBPreferredStockMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_SeriesBPreferredStockMember" xml:lang="en-US">Series B Preferred Stock [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_SeriesBPreferredStockMember" xml:lang="en-US">Series B Preferred Stock [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SeriesBPreferredStockMember" xlink:to="lab_us-gaap_SeriesBPreferredStockMember" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InvestmentTypeAxis" xlink:label="loc_us-gaap_InvestmentTypeAxis" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_InvestmentTypeAxis" xml:lang="en-US">Investment Type [Axis]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_InvestmentTypeAxis" xml:lang="en-US">Investment Type [Axis]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InvestmentTypeAxis" xlink:to="lab_us-gaap_InvestmentTypeAxis" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InvestmentTypeCategorizationMember" xlink:label="loc_us-gaap_InvestmentTypeCategorizationMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_InvestmentTypeCategorizationMember" xml:lang="en-US">Investments [Domain]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_InvestmentTypeCategorizationMember" xml:lang="en-US">Investments [Domain]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InvestmentTypeCategorizationMember" xlink:to="lab_us-gaap_InvestmentTypeCategorizationMember" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherInvestmentCompaniesMember" xlink:label="loc_us-gaap_OtherInvestmentCompaniesMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_OtherInvestmentCompaniesMember" xml:lang="en-US">Other Investment Companies [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_OtherInvestmentCompaniesMember" xml:lang="en-US">Other Investments [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_OtherInvestmentCompaniesMember" xml:lang="en-US">Other Investment [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherInvestmentCompaniesMember" xlink:to="lab_us-gaap_OtherInvestmentCompaniesMember" />
<loc xlink:type="locator" xlink:href="roiv-20210630.xsd#roiv_ArbutusBiopharmaCorporationMember" xlink:label="loc_roiv_ArbutusBiopharmaCorporationMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_roiv_ArbutusBiopharmaCorporationMember" xml:lang="en-US">Arbutus Biopharma Corporation [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_roiv_ArbutusBiopharmaCorporationMember" xml:lang="en-US">Arbutus Biopharma Corporation [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_roiv_ArbutusBiopharmaCorporationMember" xlink:to="lab_roiv_ArbutusBiopharmaCorporationMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_roiv_ArbutusBiopharmaCorporationMember" xml:lang="en-US">Arbutus Biopharma Corporation [Member]</label>
<loc xlink:type="locator" xlink:href="roiv-20210630.xsd#roiv_DatavantHoldingsIncMember" xlink:label="loc_roiv_DatavantHoldingsIncMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_roiv_DatavantHoldingsIncMember" xml:lang="en-US">Datavant Holdings, Inc [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_roiv_DatavantHoldingsIncMember" xml:lang="en-US">Datavant Holdings, Inc [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_roiv_DatavantHoldingsIncMember" xlink:to="lab_roiv_DatavantHoldingsIncMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_roiv_DatavantHoldingsIncMember" xml:lang="en-US">Datavant Holdings, Inc [Member]</label>
<loc xlink:type="locator" xlink:href="roiv-20210630.xsd#roiv_SioGeneTherapiesIncMember" xlink:label="loc_roiv_SioGeneTherapiesIncMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_roiv_SioGeneTherapiesIncMember" xml:lang="en-US">Sio Gene Therapies Inc [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_roiv_SioGeneTherapiesIncMember" xml:lang="en-US">Sio Gene Therapies Inc [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_roiv_SioGeneTherapiesIncMember" xlink:to="lab_roiv_SioGeneTherapiesIncMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_roiv_SioGeneTherapiesIncMember" xml:lang="en-US">Sio Gene Therapies Inc [Member]</label>
<loc xlink:type="locator" xlink:href="roiv-20210630.xsd#roiv_InvestmentsLineItems" xlink:label="loc_roiv_InvestmentsLineItems" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_roiv_InvestmentsLineItems" xml:lang="en-US">Investments [Line Items]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_roiv_InvestmentsLineItems" xml:lang="en-US">Investments [Line Items]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_roiv_InvestmentsLineItems" xlink:to="lab_roiv_InvestmentsLineItems" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_roiv_InvestmentsLineItems" xml:lang="en-US">Investments [Line Items]</label>
<loc xlink:type="locator" xlink:href="roiv-20210630.xsd#roiv_AnnualCompoundedConversionRateForPreferredShare" xlink:label="loc_roiv_AnnualCompoundedConversionRateForPreferredShare" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_roiv_AnnualCompoundedConversionRateForPreferredShare" xml:lang="en-US">Annual compounded conversion rate for preferred share</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_roiv_AnnualCompoundedConversionRateForPreferredShare" xml:lang="en-US">Annual compounded conversion rate for preferred share</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_roiv_AnnualCompoundedConversionRateForPreferredShare" xlink:to="lab_roiv_AnnualCompoundedConversionRateForPreferredShare" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_roiv_AnnualCompoundedConversionRateForPreferredShare" xml:lang="en-US">Annual Compunded Conversion Rate for Preferred Share</label>
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion" xlink:label="loc_us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion" xml:lang="en-US">Convertible Preferred Stock, Shares Issued upon Conversion</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion" xml:lang="en-US">Issued relating to the conversion of certain liability instruments</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion" xlink:to="lab_us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion" />
<loc xlink:type="locator" xlink:href="roiv-20210630.xsd#roiv_CommonStockOwnedBalanceSharesOfArbutus" xlink:label="loc_roiv_CommonStockOwnedBalanceSharesOfArbutus" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_roiv_CommonStockOwnedBalanceSharesOfArbutus" xml:lang="en-US">Common stock Owned, Balance, Shares of Arbutus</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_roiv_CommonStockOwnedBalanceSharesOfArbutus" xml:lang="en-US">Common stock Owned, Balance, Shares of Arbutus</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_roiv_CommonStockOwnedBalanceSharesOfArbutus" xlink:to="lab_roiv_CommonStockOwnedBalanceSharesOfArbutus" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_roiv_CommonStockOwnedBalanceSharesOfArbutus" xml:lang="en-US">Common stock Owned, Balance, Shares of Arbutus.</label>
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_UnrealizedGainLossOnInvestments" xlink:label="loc_us-gaap_UnrealizedGainLossOnInvestments" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_UnrealizedGainLossOnInvestments" xml:lang="en-US">Unrealized Gain (Loss) on Investments</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_UnrealizedGainLossOnInvestments" xml:lang="en-US">Unrealized gain (loss) on investments</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_UnrealizedGainLossOnInvestments" xlink:to="lab_us-gaap_UnrealizedGainLossOnInvestments" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeconsolidationGainOrLossAmount" xlink:label="loc_us-gaap_DeconsolidationGainOrLossAmount" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_DeconsolidationGainOrLossAmount" xml:lang="en-US">Deconsolidation, Gain (Loss), Amount</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_DeconsolidationGainOrLossAmount" xml:lang="en-US">Gain on deconsolidation</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeconsolidationGainOrLossAmount" xlink:to="lab_us-gaap_DeconsolidationGainOrLossAmount" />
<loc xlink:type="locator" xlink:href="roiv-20210630.xsd#roiv_MaximumAllowedOwnershipInterestPercentage" xlink:label="loc_roiv_MaximumAllowedOwnershipInterestPercentage" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_roiv_MaximumAllowedOwnershipInterestPercentage" xml:lang="en-US">Maximum Allowed Ownership Interest Percentage</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_roiv_MaximumAllowedOwnershipInterestPercentage" xml:lang="en-US">Maximum allowed ownership interest percentage</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_roiv_MaximumAllowedOwnershipInterestPercentage" xlink:to="lab_roiv_MaximumAllowedOwnershipInterestPercentage" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_roiv_MaximumAllowedOwnershipInterestPercentage" xml:lang="en-US">Maximum Allowed Ownership Interest Percentage</label>
<loc xlink:type="locator" xlink:href="roiv-20210630.xsd#roiv_ClosingPricePerShare" xlink:label="loc_roiv_ClosingPricePerShare" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_roiv_ClosingPricePerShare" xml:lang="en-US">Closing Price Per Share</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_roiv_ClosingPricePerShare" xml:lang="en-US">Closing price</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_roiv_ClosingPricePerShare" xlink:to="lab_roiv_ClosingPricePerShare" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_roiv_ClosingPricePerShare" xml:lang="en-US">Closing Price Per Share.</label>
<loc xlink:type="locator" xlink:href="roiv-20210630.xsd#roiv_ProceedsFromIssuanceOfPreferredStockAndPreferenceStocks" xlink:label="loc_roiv_ProceedsFromIssuanceOfPreferredStockAndPreferenceStocks" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_roiv_ProceedsFromIssuanceOfPreferredStockAndPreferenceStocks" xml:lang="en-US">Proceeds from Issuance of Preferred Stock and Preference Stocks</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_roiv_ProceedsFromIssuanceOfPreferredStockAndPreferenceStocks" xml:lang="en-US">Gross proceeds from issuance of stock</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_roiv_ProceedsFromIssuanceOfPreferredStockAndPreferenceStocks" xlink:to="lab_roiv_ProceedsFromIssuanceOfPreferredStockAndPreferenceStocks" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_roiv_ProceedsFromIssuanceOfPreferredStockAndPreferenceStocks" xml:lang="en-US">Proceeds from Issuance of Preferred Stock and Preference Stocks.</label>
<loc xlink:type="locator" xlink:href="roiv-20210630.xsd#roiv_PreferredStockSharesIssuedAndSoldToCompanyDuringPeriodShares" xlink:label="loc_roiv_PreferredStockSharesIssuedAndSoldToCompanyDuringPeriodShares" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_roiv_PreferredStockSharesIssuedAndSoldToCompanyDuringPeriodShares" xml:lang="en-US">Preferred Stock Shares Issued And Sold to Company During Period, Shares</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_roiv_PreferredStockSharesIssuedAndSoldToCompanyDuringPeriodShares" xml:lang="en-US">Preferred stock issued and sold</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_roiv_PreferredStockSharesIssuedAndSoldToCompanyDuringPeriodShares" xlink:to="lab_roiv_PreferredStockSharesIssuedAndSoldToCompanyDuringPeriodShares" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_roiv_PreferredStockSharesIssuedAndSoldToCompanyDuringPeriodShares" xml:lang="en-US">Preferred Stock Shares Issued And Sold to Company During Period, Shares</label>
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityMethodInvestmentOwnershipPercentage" xlink:label="loc_us-gaap_EquityMethodInvestmentOwnershipPercentage" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_EquityMethodInvestmentOwnershipPercentage" xml:lang="en-US">Equity Method Investment, Ownership Percentage</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_EquityMethodInvestmentOwnershipPercentage" xml:lang="en-US">Equity method investment ownership percentage</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_EquityMethodInvestmentOwnershipPercentage" xml:lang="en-US">Equity Method Investment, Ownership Percentage</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquityMethodInvestmentOwnershipPercentage" xlink:to="lab_us-gaap_EquityMethodInvestmentOwnershipPercentage" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PreferredStockSharesOutstanding" xlink:label="loc_us-gaap_PreferredStockSharesOutstanding" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_PreferredStockSharesOutstanding" xml:lang="en-US">Preferred Stock, Shares Outstanding</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_PreferredStockSharesOutstanding" xml:lang="en-US">Preferred stock</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PreferredStockSharesOutstanding" xlink:to="lab_us-gaap_PreferredStockSharesOutstanding" />
<loc xlink:type="locator" xlink:href="roiv-20210630.xsd#roiv_ConversionPrice" xlink:label="loc_roiv_ConversionPrice" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_roiv_ConversionPrice" xml:lang="en-US">Conversion Price</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_roiv_ConversionPrice" xml:lang="en-US">Conversion price</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_roiv_ConversionPrice" xlink:to="lab_roiv_ConversionPrice" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_roiv_ConversionPrice" xml:lang="en-US">Conversion Price</label>
<loc xlink:type="locator" xlink:href="roiv-20210630.xsd#roiv_OwnershipInterestPercentage" xlink:label="loc_roiv_OwnershipInterestPercentage" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_roiv_OwnershipInterestPercentage" xml:lang="en-US">Ownership Interest Percentage</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_roiv_OwnershipInterestPercentage" xml:lang="en-US">Ownership interest, percentage</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_roiv_OwnershipInterestPercentage" xlink:to="lab_roiv_OwnershipInterestPercentage" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_roiv_OwnershipInterestPercentage" xml:lang="en-US">Ownership Interest Percentage</label>
<loc xlink:type="locator" xlink:href="roiv-20210630.xsd#roiv_PreferredStockPurchased" xlink:label="loc_roiv_PreferredStockPurchased" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_roiv_PreferredStockPurchased" xml:lang="en-US">Preferred Stock Purchased</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_roiv_PreferredStockPurchased" xml:lang="en-US">Total purchase price</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_roiv_PreferredStockPurchased" xlink:to="lab_roiv_PreferredStockPurchased" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_roiv_PreferredStockPurchased" xml:lang="en-US">Preferred Stock Purchased</label>
<loc xlink:type="locator" xlink:href="roiv-20210630.xsd#roiv_PreferredStockOwnedBalanceSharesOfArbutus" xlink:label="loc_roiv_PreferredStockOwnedBalanceSharesOfArbutus" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_roiv_PreferredStockOwnedBalanceSharesOfArbutus" xml:lang="en-US">Preferred stock Owned, Balance, Shares of Arbutus</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_roiv_PreferredStockOwnedBalanceSharesOfArbutus" xml:lang="en-US">Preferred stock Owned, Balance, Shares of Arbutus</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_roiv_PreferredStockOwnedBalanceSharesOfArbutus" xlink:to="lab_roiv_PreferredStockOwnedBalanceSharesOfArbutus" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_roiv_PreferredStockOwnedBalanceSharesOfArbutus" xml:lang="en-US">Preferred stock Owned, Balance, Shares of Arbutus.</label>
<loc xlink:type="locator" xlink:href="roiv-20210630.xsd#roiv_PremiumOnConversionPricePercentage" xlink:label="loc_roiv_PremiumOnConversionPricePercentage" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_roiv_PremiumOnConversionPricePercentage" xml:lang="en-US">Premium on Conversion Price, Percentage</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_roiv_PremiumOnConversionPricePercentage" xml:lang="en-US">Premium on the conversion price, percentage</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_roiv_PremiumOnConversionPricePercentage" xlink:to="lab_roiv_PremiumOnConversionPricePercentage" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_roiv_PremiumOnConversionPricePercentage" xml:lang="en-US">Premium on Conversion Price, Percentage</label>
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharePrice" xlink:label="loc_us-gaap_SharePrice" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_SharePrice" xml:lang="en-US">Share Price</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_SharePrice" xml:lang="en-US">Closing price of common stock</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharePrice" xlink:to="lab_us-gaap_SharePrice" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable" xlink:label="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable" xml:lang="en-US">Schedule of Business Acquisitions, by Acquisition [Table]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable" xml:lang="en-US">Schedule of Business Acquisitions, by Acquisition [Table]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable" xlink:to="lab_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessAcquisitionAxis" xlink:label="loc_us-gaap_BusinessAcquisitionAxis" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_BusinessAcquisitionAxis" xml:lang="en-US">Business Acquisition [Axis]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_BusinessAcquisitionAxis" xml:lang="en-US">Business Acquisition [Axis]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessAcquisitionAxis" xlink:to="lab_us-gaap_BusinessAcquisitionAxis" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_BusinessAcquisitionAcquireeDomain" xml:lang="en-US">Business Acquisition, Acquiree [Domain]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_BusinessAcquisitionAcquireeDomain" xml:lang="en-US">Business Acquisition, Acquiree [Domain]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain" xlink:to="lab_us-gaap_BusinessAcquisitionAcquireeDomain" />
<loc xlink:type="locator" xlink:href="roiv-20210630.xsd#roiv_SiliconTherapeuticsMember" xlink:label="loc_roiv_SiliconTherapeuticsMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_roiv_SiliconTherapeuticsMember" xml:lang="en-US">Silicon Therapeutics [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_roiv_SiliconTherapeuticsMember" xml:lang="en-US">Silicon Therapeutics [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_roiv_SiliconTherapeuticsMember" xlink:to="lab_roiv_SiliconTherapeuticsMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_roiv_SiliconTherapeuticsMember" xml:lang="en-US">Silicon Therapeutics</label>
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessAcquisitionLineItems" xlink:label="loc_us-gaap_BusinessAcquisitionLineItems" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_BusinessAcquisitionLineItems" xml:lang="en-US">Business Acquisition [Line Items]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_BusinessAcquisitionLineItems" xml:lang="en-US">Business Acquisition [Line Items]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems" xlink:to="lab_us-gaap_BusinessAcquisitionLineItems" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessAcquisitionEquityInterestIssuedOrIssuableValueAssigned" xlink:label="loc_us-gaap_BusinessAcquisitionEquityInterestIssuedOrIssuableValueAssigned" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_BusinessAcquisitionEquityInterestIssuedOrIssuableValueAssigned" xml:lang="en-US">Business Acquisition, Equity Interest Issued or Issuable, Value Assigned</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_BusinessAcquisitionEquityInterestIssuedOrIssuableValueAssigned" xml:lang="en-US">Business combination, recognized identifiable assets acquired and liabilities assumed, current liabilities, accounts payable</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_BusinessAcquisitionEquityInterestIssuedOrIssuableValueAssigned" xml:lang="en-US">Proceeds related to common stock purchase by RSL</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessAcquisitionEquityInterestIssuedOrIssuableValueAssigned" xlink:to="lab_us-gaap_BusinessAcquisitionEquityInterestIssuedOrIssuableValueAssigned" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtConversionOriginalDebtAmount1" xlink:label="loc_us-gaap_DebtConversionOriginalDebtAmount1" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_DebtConversionOriginalDebtAmount1" xml:lang="en-US">Debt Conversion, Original Debt, Amount</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_DebtConversionOriginalDebtAmount1" xml:lang="en-US">Aggregate principal amount of notes converted</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtConversionOriginalDebtAmount1" xlink:to="lab_us-gaap_DebtConversionOriginalDebtAmount1" />
<loc xlink:type="locator" xlink:href="roiv-20210630.xsd#roiv_FutureDevelopmentAndCommercialMilestonePayments" xlink:label="loc_roiv_FutureDevelopmentAndCommercialMilestonePayments" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_roiv_FutureDevelopmentAndCommercialMilestonePayments" xml:lang="en-US">Future Development And Commercial Milestone Payments</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_roiv_FutureDevelopmentAndCommercialMilestonePayments" xml:lang="en-US">Future development and commercial milestone payments</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_roiv_FutureDevelopmentAndCommercialMilestonePayments" xlink:to="lab_roiv_FutureDevelopmentAndCommercialMilestonePayments" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_roiv_FutureDevelopmentAndCommercialMilestonePayments" xml:lang="en-US">Future Development And Commercial Milestone Payments.</label>
<loc xlink:type="locator" xlink:href="roiv-20210630.xsd#roiv_BusinessCollaborationContingentMilestonePayment" xlink:label="loc_roiv_BusinessCollaborationContingentMilestonePayment" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_roiv_BusinessCollaborationContingentMilestonePayment" xml:lang="en-US">Business Collaboration Contingent Milestone Payment</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_roiv_BusinessCollaborationContingentMilestonePayment" xml:lang="en-US">Contingent payment</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_roiv_BusinessCollaborationContingentMilestonePayment" xlink:to="lab_roiv_BusinessCollaborationContingentMilestonePayment" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_roiv_BusinessCollaborationContingentMilestonePayment" xml:lang="en-US">Business Collaboration Contingent Milestone Payment</label>
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationConsiderationTransferred1" xlink:label="loc_us-gaap_BusinessCombinationConsiderationTransferred1" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_BusinessCombinationConsiderationTransferred1" xml:lang="en-US">Business Combination, Consideration Transferred</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_BusinessCombinationConsiderationTransferred1" xml:lang="en-US">Business combination, consideration transferred</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationConsiderationTransferred1" xlink:to="lab_us-gaap_BusinessCombinationConsiderationTransferred1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationConsiderationTransferredLiabilitiesIncurred" xlink:label="loc_us-gaap_BusinessCombinationConsiderationTransferredLiabilitiesIncurred" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_BusinessCombinationConsiderationTransferredLiabilitiesIncurred" xml:lang="en-US">Business Combination, Consideration Transferred, Liabilities Incurred</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_BusinessCombinationConsiderationTransferredLiabilitiesIncurred" xml:lang="en-US">Business combination, consideration transferred, liabilities incurred</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationConsiderationTransferredLiabilitiesIncurred" xlink:to="lab_us-gaap_BusinessCombinationConsiderationTransferredLiabilitiesIncurred" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationContingentConsiderationLiability" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationLiability" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_BusinessCombinationContingentConsiderationLiability" xml:lang="en-US">Business Combination, Contingent Consideration, Liability</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_BusinessCombinationContingentConsiderationLiability" xml:lang="en-US">Fair value of future contingent consideration payments</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationContingentConsiderationLiability" xlink:to="lab_us-gaap_BusinessCombinationContingentConsiderationLiability" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccountsPayable" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccountsPayable" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccountsPayable" xml:lang="en-US">Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Current Liabilities, Accounts Payable</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccountsPayable" xml:lang="en-US">Business acquisition, equity interest issued or issuable, value assigned</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccountsPayable" xlink:to="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccountsPayable" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet" xml:lang="en-US">Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Net</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet" xml:lang="en-US">Business combination, recognized identifiable assets acquired and liabilities assumed, assets</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet" xlink:to="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtConversionConvertedInstrumentSharesIssued1" xlink:label="loc_us-gaap_DebtConversionConvertedInstrumentSharesIssued1" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_DebtConversionConvertedInstrumentSharesIssued1" xml:lang="en-US">Debt Conversion, Converted Instrument, Shares Issued</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_DebtConversionConvertedInstrumentSharesIssued1" xml:lang="en-US">Notes converted, shares issued</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_DebtConversionConvertedInstrumentSharesIssued1" xml:lang="en-US">Conversion of stock , share converted</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtConversionConvertedInstrumentSharesIssued1" xlink:to="lab_us-gaap_DebtConversionConvertedInstrumentSharesIssued1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued" xlink:label="loc_us-gaap_BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued" xml:lang="en-US">Business Acquisition, Equity Interest Issued or Issuable, Number of Shares</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued" xml:lang="en-US">Number of shares issued in business combination</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued" xml:lang="en-US">Stock acquired related to business acquisition</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued" xlink:to="lab_us-gaap_BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsToAcquireEquityMethodInvestments" xlink:label="loc_us-gaap_PaymentsToAcquireEquityMethodInvestments" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_PaymentsToAcquireEquityMethodInvestments" xml:lang="en-US">Payments to Acquire Equity Method Investments</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_PaymentsToAcquireEquityMethodInvestments" xml:lang="en-US">Equity ownership interest, additional cash contribution</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsToAcquireEquityMethodInvestments" xlink:to="lab_us-gaap_PaymentsToAcquireEquityMethodInvestments" />
<loc xlink:type="locator" xlink:href="roiv-20210630.xsd#roiv_FairValueOfRestrictedStock" xlink:label="loc_roiv_FairValueOfRestrictedStock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_roiv_FairValueOfRestrictedStock" xml:lang="en-US">Fair Value Of Restricted Stock</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_roiv_FairValueOfRestrictedStock" xml:lang="en-US">Fair value of restricted stock</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_roiv_FairValueOfRestrictedStock" xlink:to="lab_roiv_FairValueOfRestrictedStock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_roiv_FairValueOfRestrictedStock" xml:lang="en-US">Fair Value Of Restricted Stock</label>
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityMethodInvestmentsFairValueDisclosure" xlink:label="loc_us-gaap_EquityMethodInvestmentsFairValueDisclosure" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_EquityMethodInvestmentsFairValueDisclosure" xml:lang="en-US">Equity Method Investments, Fair Value Disclosure</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_EquityMethodInvestmentsFairValueDisclosure" xml:lang="en-US">Fair value of noncontrolling interests</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquityMethodInvestmentsFairValueDisclosure" xlink:to="lab_us-gaap_EquityMethodInvestmentsFairValueDisclosure" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityMethodInvestmentUnderlyingEquityInNetAssets" xlink:label="loc_us-gaap_EquityMethodInvestmentUnderlyingEquityInNetAssets" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_EquityMethodInvestmentUnderlyingEquityInNetAssets" xml:lang="en-US">Equity Method Investment, Underlying Equity in Net Assets</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_EquityMethodInvestmentUnderlyingEquityInNetAssets" xml:lang="en-US">Equity investment</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquityMethodInvestmentUnderlyingEquityInNetAssets" xlink:to="lab_us-gaap_EquityMethodInvestmentUnderlyingEquityInNetAssets" />
<loc xlink:type="locator" xlink:href="roiv-20210630.xsd#roiv_FairValueOfCommonShares" xlink:label="loc_roiv_FairValueOfCommonShares" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_roiv_FairValueOfCommonShares" xml:lang="en-US">Fair Value Of Common Shares</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_roiv_FairValueOfCommonShares" xml:lang="en-US">Fair value of common shares</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_roiv_FairValueOfCommonShares" xlink:to="lab_roiv_FairValueOfCommonShares" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_roiv_FairValueOfCommonShares" xml:lang="en-US">Fair Value Of Common Shares</label>
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsToAcquireInterestInSubsidiariesAndAffiliates" xlink:label="loc_us-gaap_PaymentsToAcquireInterestInSubsidiariesAndAffiliates" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_PaymentsToAcquireInterestInSubsidiariesAndAffiliates" xml:lang="en-US">Payments to Acquire Interest in Subsidiaries and Affiliates</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_PaymentsToAcquireInterestInSubsidiariesAndAffiliates" xml:lang="en-US">Cash paid for common shares</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsToAcquireInterestInSubsidiariesAndAffiliates" xlink:to="lab_us-gaap_PaymentsToAcquireInterestInSubsidiariesAndAffiliates" />
<loc xlink:type="locator" xlink:href="roiv-20210630.xsd#roiv_PercentageOfControllingInterestHeld" xlink:label="loc_roiv_PercentageOfControllingInterestHeld" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_roiv_PercentageOfControllingInterestHeld" xml:lang="en-US">Percentage Of Controlling Interest Held</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_roiv_PercentageOfControllingInterestHeld" xml:lang="en-US">Percentage controlling interest</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_roiv_PercentageOfControllingInterestHeld" xlink:to="lab_roiv_PercentageOfControllingInterestHeld" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_roiv_PercentageOfControllingInterestHeld" xml:lang="en-US">Percentage of controlling interest held.</label>
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevenueRecognitionMilestoneMethodRevenueRecognized" xlink:label="loc_us-gaap_RevenueRecognitionMilestoneMethodRevenueRecognized" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_RevenueRecognitionMilestoneMethodRevenueRecognized" xml:lang="en-US">Revenue Recognition, Milestone Method, Revenue Recognized</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_RevenueRecognitionMilestoneMethodRevenueRecognized" xml:lang="en-US">Non-refundable, up-front payment recognized</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RevenueRecognitionMilestoneMethodRevenueRecognized" xlink:to="lab_us-gaap_RevenueRecognitionMilestoneMethodRevenueRecognized" />
<loc xlink:type="locator" xlink:href="roiv-20210630.xsd#roiv_PaymentUnderSponsoredResearchAgreement" xlink:label="loc_roiv_PaymentUnderSponsoredResearchAgreement" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_roiv_PaymentUnderSponsoredResearchAgreement" xml:lang="en-US">Payment Under Sponsored Research Agreement</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_roiv_PaymentUnderSponsoredResearchAgreement" xml:lang="en-US">Payment under SRA</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_roiv_PaymentUnderSponsoredResearchAgreement" xlink:to="lab_roiv_PaymentUnderSponsoredResearchAgreement" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_roiv_PaymentUnderSponsoredResearchAgreement" xml:lang="en-US">Payment under sponsored research agreement.</label>
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InvestmentsInAffiliatesSubsidiariesAssociatesAndJointVenturesFairValueDisclosure" xlink:label="loc_us-gaap_InvestmentsInAffiliatesSubsidiariesAssociatesAndJointVenturesFairValueDisclosure" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_InvestmentsInAffiliatesSubsidiariesAssociatesAndJointVenturesFairValueDisclosure" xml:lang="en-US">Investments in Affiliates, Subsidiaries, Associates, and Joint Ventures, Fair Value Disclosure</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_InvestmentsInAffiliatesSubsidiariesAssociatesAndJointVenturesFairValueDisclosure" xml:lang="en-US">Investment, fair value</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InvestmentsInAffiliatesSubsidiariesAssociatesAndJointVenturesFairValueDisclosure" xlink:to="lab_us-gaap_InvestmentsInAffiliatesSubsidiariesAssociatesAndJointVenturesFairValueDisclosure" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongTermDebt" xlink:label="loc_us-gaap_LongTermDebt" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_LongTermDebt" xml:lang="en-US">Long-term Debt</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_LongTermDebt" xml:lang="en-US">Long term debt</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_us-gaap_LongTermDebt" xml:lang="en-US">Total debt, net</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongTermDebt" xlink:to="lab_us-gaap_LongTermDebt" />
<loc xlink:type="locator" xlink:href="roiv-20210630.xsd#roiv_MilestonePayment" xlink:label="loc_roiv_MilestonePayment" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_roiv_MilestonePayment" xml:lang="en-US">Milestone Payment</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_roiv_MilestonePayment" xml:lang="en-US">Milestone payment</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_roiv_MilestonePayment" xlink:to="lab_roiv_MilestonePayment" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_roiv_MilestonePayment" xml:lang="en-US">Milestone Payment</label>
<loc xlink:type="locator" xlink:href="roiv-20210630.xsd#roiv_NonRefundableUpfrontPaymentReceived" xlink:label="loc_roiv_NonRefundableUpfrontPaymentReceived" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_roiv_NonRefundableUpfrontPaymentReceived" xml:lang="en-US">Non Refundable Upfront Payment Received</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_roiv_NonRefundableUpfrontPaymentReceived" xml:lang="en-US">Nonrefundable, upfront payment</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_roiv_NonRefundableUpfrontPaymentReceived" xlink:to="lab_roiv_NonRefundableUpfrontPaymentReceived" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_roiv_NonRefundableUpfrontPaymentReceived" xml:lang="en-US">Non Refundable Upfront Payment Received</label>
<loc xlink:type="locator" xlink:href="roiv-20210630.xsd#roiv_PaymentForUpfrontPayments" xlink:label="loc_roiv_PaymentForUpfrontPayments" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_roiv_PaymentForUpfrontPayments" xml:lang="en-US">Payment For Upfront payments</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_roiv_PaymentForUpfrontPayments" xml:lang="en-US">Upfront proceeds</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_roiv_PaymentForUpfrontPayments" xlink:to="lab_roiv_PaymentForUpfrontPayments" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_roiv_PaymentForUpfrontPayments" xml:lang="en-US">Payment for upfront payments.</label>
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RepaymentOfNotesReceivableFromRelatedParties" xlink:label="loc_us-gaap_RepaymentOfNotesReceivableFromRelatedParties" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_RepaymentOfNotesReceivableFromRelatedParties" xml:lang="en-US">Repayment of Notes Receivable from Related Parties</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_RepaymentOfNotesReceivableFromRelatedParties" xml:lang="en-US">Settlement of promissory notes receivable</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RepaymentOfNotesReceivableFromRelatedParties" xlink:to="lab_us-gaap_RepaymentOfNotesReceivableFromRelatedParties" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsidiaryOrEquityMethodInvesteeCumulativePercentageOwnershipAfterAllTransactions" xlink:label="loc_us-gaap_SubsidiaryOrEquityMethodInvesteeCumulativePercentageOwnershipAfterAllTransactions" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_SubsidiaryOrEquityMethodInvesteeCumulativePercentageOwnershipAfterAllTransactions" xml:lang="en-US">Subsidiary or Equity Method Investee, Cumulative Percentage Ownership after All Transactions</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_SubsidiaryOrEquityMethodInvesteeCumulativePercentageOwnershipAfterAllTransactions" xml:lang="en-US">Ownership interest</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsidiaryOrEquityMethodInvesteeCumulativePercentageOwnershipAfterAllTransactions" xlink:to="lab_us-gaap_SubsidiaryOrEquityMethodInvesteeCumulativePercentageOwnershipAfterAllTransactions" />
<loc xlink:type="locator" xlink:href="roiv-20210630.xsd#roiv_UpfrontCashPayments" xlink:label="loc_roiv_UpfrontCashPayments" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_roiv_UpfrontCashPayments" xml:lang="en-US">Upfront Cash Payments</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_roiv_UpfrontCashPayments" xml:lang="en-US">Net upfront cash payment</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_roiv_UpfrontCashPayments" xlink:to="lab_roiv_UpfrontCashPayments" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_roiv_UpfrontCashPayments" xml:lang="en-US">Upfront Cash Payments</label>
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquityNoteSubscriptionsReceivable" xlink:label="loc_us-gaap_StockholdersEquityNoteSubscriptionsReceivable" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_StockholdersEquityNoteSubscriptionsReceivable" xml:lang="en-US">Stockholders' Equity Note, Subscriptions Receivable</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_StockholdersEquityNoteSubscriptionsReceivable" xml:lang="en-US">Subscription receivable</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquityNoteSubscriptionsReceivable" xlink:to="lab_us-gaap_StockholdersEquityNoteSubscriptionsReceivable" />
<loc xlink:type="locator" xlink:href="roiv-20210630.xsd#roiv_StockIssuedDuringPeriodValue" xlink:label="loc_roiv_StockIssuedDuringPeriodValue" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_roiv_StockIssuedDuringPeriodValue" xml:lang="en-US">Stock Issued During Period</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_roiv_StockIssuedDuringPeriodValue" xml:lang="en-US">Newly issued shares</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_roiv_StockIssuedDuringPeriodValue" xlink:to="lab_roiv_StockIssuedDuringPeriodValue" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_roiv_StockIssuedDuringPeriodValue" xml:lang="en-US">Stock Issued During Period</label>
<loc xlink:type="locator" xlink:href="roiv-20210630.xsd#roiv_PotentialMilestonePaymentReceivable" xlink:label="loc_roiv_PotentialMilestonePaymentReceivable" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_roiv_PotentialMilestonePaymentReceivable" xml:lang="en-US">Potential Milestone Payment Receivable</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_roiv_PotentialMilestonePaymentReceivable" xml:lang="en-US">Nonrefundable, upfront payment</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_roiv_PotentialMilestonePaymentReceivable" xlink:to="lab_roiv_PotentialMilestonePaymentReceivable" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_roiv_PotentialMilestonePaymentReceivable" xml:lang="en-US">Potential milestone payment receivable.</label>
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromNotesPayable" xlink:label="loc_us-gaap_ProceedsFromNotesPayable" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ProceedsFromNotesPayable" xml:lang="en-US">Proceeds from Notes Payable</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_ProceedsFromNotesPayable" xml:lang="en-US">Promissory notes issued</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromNotesPayable" xlink:to="lab_us-gaap_ProceedsFromNotesPayable" />
<loc xlink:type="locator" xlink:href="roiv-20210630.xsd#roiv_MilestoneEventsAxis" xlink:label="loc_roiv_MilestoneEventsAxis" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_roiv_MilestoneEventsAxis" xml:lang="en-US">Milestone Events [Axis]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_roiv_MilestoneEventsAxis" xml:lang="en-US">Milestone Events [Axis]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_roiv_MilestoneEventsAxis" xlink:to="lab_roiv_MilestoneEventsAxis" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_roiv_MilestoneEventsAxis" xml:lang="en-US">Milestone Events [Axis]</label>
<loc xlink:type="locator" xlink:href="roiv-20210630.xsd#roiv_MilestoneEventsDomain" xlink:label="loc_roiv_MilestoneEventsDomain" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_roiv_MilestoneEventsDomain" xml:lang="en-US">Milestone Events [Domain]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_roiv_MilestoneEventsDomain" xml:lang="en-US">Milestone Events [Domain]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_roiv_MilestoneEventsDomain" xlink:to="lab_roiv_MilestoneEventsDomain" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_roiv_MilestoneEventsDomain" xml:lang="en-US">Milestone Events [Domain]</label>
<loc xlink:type="locator" xlink:href="roiv-20210630.xsd#roiv_FirstProductFirstProductForEachMolecularTargetCoveredByIntellectualPropertyMember" xlink:label="loc_roiv_FirstProductFirstProductForEachMolecularTargetCoveredByIntellectualPropertyMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_roiv_FirstProductFirstProductForEachMolecularTargetCoveredByIntellectualPropertyMember" xml:lang="en-US">First Product First Product for Each Molecular Target Covered by Intellectual Property [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_roiv_FirstProductFirstProductForEachMolecularTargetCoveredByIntellectualPropertyMember" xml:lang="en-US">First Product First Product for Each Molecular Target Covered by Intellectual Property [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_roiv_FirstProductFirstProductForEachMolecularTargetCoveredByIntellectualPropertyMember" xlink:to="lab_roiv_FirstProductFirstProductForEachMolecularTargetCoveredByIntellectualPropertyMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_roiv_FirstProductFirstProductForEachMolecularTargetCoveredByIntellectualPropertyMember" xml:lang="en-US">First Product First Product for Each Molecular Target Covered by Intellectual Property [Member]</label>
<loc xlink:type="locator" xlink:href="roiv-20210630.xsd#roiv_FirstProductTargetsEachOfCertainSpecifiedAdditionalMoleculartargetsMember" xlink:label="loc_roiv_FirstProductTargetsEachOfCertainSpecifiedAdditionalMoleculartargetsMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_roiv_FirstProductTargetsEachOfCertainSpecifiedAdditionalMoleculartargetsMember" xml:lang="en-US">First Product Targets Each of Certain Specified Additional MolecularTargets [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_roiv_FirstProductTargetsEachOfCertainSpecifiedAdditionalMoleculartargetsMember" xml:lang="en-US">First Product Targets Each of Certain Specified Additional MolecularTargets [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_roiv_FirstProductTargetsEachOfCertainSpecifiedAdditionalMoleculartargetsMember" xlink:to="lab_roiv_FirstProductTargetsEachOfCertainSpecifiedAdditionalMoleculartargetsMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_roiv_FirstProductTargetsEachOfCertainSpecifiedAdditionalMoleculartargetsMember" xml:lang="en-US">First Product Targets Each of Certain Specified Additional MolecularTargets [Member]</label>
<loc xlink:type="locator" xlink:href="roiv-20210630.xsd#roiv_FirstProductTargetsTargetingEachOfTwoSpecifiedInitialTargetsMember" xlink:label="loc_roiv_FirstProductTargetsTargetingEachOfTwoSpecifiedInitialTargetsMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_roiv_FirstProductTargetsTargetingEachOfTwoSpecifiedInitialTargetsMember" xml:lang="en-US">First Product Targets Targeting Each of Two Specified Initial Targets [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_roiv_FirstProductTargetsTargetingEachOfTwoSpecifiedInitialTargetsMember" xml:lang="en-US">First Product Targets Targeting Each of Two Specified Initial Targets [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_roiv_FirstProductTargetsTargetingEachOfTwoSpecifiedInitialTargetsMember" xlink:to="lab_roiv_FirstProductTargetsTargetingEachOfTwoSpecifiedInitialTargetsMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_roiv_FirstProductTargetsTargetingEachOfTwoSpecifiedInitialTargetsMember" xml:lang="en-US">First Product Targets Targeting Each of Two Specified Initial Targets [Member]</label>
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeAxis" xlink:label="loc_srt_RangeAxis" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_srt_RangeAxis" xml:lang="en-US">Statistical Measurement [Axis]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_srt_RangeAxis" xml:lang="en-US">Statistical Measurement [Axis]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_RangeAxis" xlink:to="lab_srt_RangeAxis" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeMember" xlink:label="loc_srt_RangeMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_srt_RangeMember" xml:lang="en-US">Statistical Measurement [Domain]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_srt_RangeMember" xml:lang="en-US">Statistical Measurement [Domain]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_RangeMember" xlink:to="lab_srt_RangeMember" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MaximumMember" xlink:label="loc_srt_MaximumMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_srt_MaximumMember" xml:lang="en-US">Maximum [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_srt_MaximumMember" xml:lang="en-US">Maximum</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_MaximumMember" xlink:to="lab_srt_MaximumMember" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:label="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xml:lang="en-US">Related Party [Axis]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xml:lang="en-US">Related Party [Axis]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:to="lab_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RelatedPartyDomain" xlink:label="loc_us-gaap_RelatedPartyDomain" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_RelatedPartyDomain" xml:lang="en-US">Related Party [Domain]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_RelatedPartyDomain" xml:lang="en-US">Related Party [Domain]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RelatedPartyDomain" xlink:to="lab_us-gaap_RelatedPartyDomain" />
<loc xlink:type="locator" xlink:href="roiv-20210630.xsd#roiv_AffivantSciencesMember" xlink:label="loc_roiv_AffivantSciencesMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_roiv_AffivantSciencesMember" xml:lang="en-US">Affivant Sciences [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_roiv_AffivantSciencesMember" xml:lang="en-US">Affivant Sciences [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_roiv_AffivantSciencesMember" xlink:to="lab_roiv_AffivantSciencesMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_roiv_AffivantSciencesMember" xml:lang="en-US">Affivant Sciences [Member]</label>
<loc xlink:type="locator" xlink:href="roiv-20210630.xsd#roiv_GenevantSciencesLtdMember" xlink:label="loc_roiv_GenevantSciencesLtdMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_roiv_GenevantSciencesLtdMember" xml:lang="en-US">Genevant Sciences Ltd [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_roiv_GenevantSciencesLtdMember" xml:lang="en-US">Genevant Sciences Ltd [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_roiv_GenevantSciencesLtdMember" xlink:to="lab_roiv_GenevantSciencesLtdMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_roiv_GenevantSciencesLtdMember" xml:lang="en-US">Genevant Sciences Ltd [Member]</label>
<loc xlink:type="locator" xlink:href="roiv-20210630.xsd#roiv_DermavantSciencesLtdMember" xlink:label="loc_roiv_DermavantSciencesLtdMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_roiv_DermavantSciencesLtdMember" xml:lang="en-US">Dermavant Sciences Ltd [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_roiv_DermavantSciencesLtdMember" xml:lang="en-US">Dermavant Sciences Ltd [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_roiv_DermavantSciencesLtdMember" xlink:to="lab_roiv_DermavantSciencesLtdMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_roiv_DermavantSciencesLtdMember" xml:lang="en-US">Dermavant Sciences Ltd [Member]</label>
<loc xlink:type="locator" xlink:href="roiv-20210630.xsd#roiv_ProteovantSciencesIncMember" xlink:label="loc_roiv_ProteovantSciencesIncMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_roiv_ProteovantSciencesIncMember" xml:lang="en-US">ProteoVant Sciences, Inc [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_roiv_ProteovantSciencesIncMember" xml:lang="en-US">ProteoVant Sciences, Inc [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_roiv_ProteovantSciencesIncMember" xlink:to="lab_roiv_ProteovantSciencesIncMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_roiv_ProteovantSciencesIncMember" xml:lang="en-US">ProteoVant Sciences, Inc [Member].</label>
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestructuringPlanAxis" xlink:label="loc_us-gaap_RestructuringPlanAxis" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_RestructuringPlanAxis" xml:lang="en-US">Restructuring Plan [Axis]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_RestructuringPlanAxis" xml:lang="en-US">Restructuring Plan [Axis]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestructuringPlanAxis" xlink:to="lab_us-gaap_RestructuringPlanAxis" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestructuringPlanDomain" xlink:label="loc_us-gaap_RestructuringPlanDomain" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_RestructuringPlanDomain" xml:lang="en-US">Restructuring Plan [Domain]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_RestructuringPlanDomain" xml:lang="en-US">Restructuring Plan [Domain]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestructuringPlanDomain" xlink:to="lab_us-gaap_RestructuringPlanDomain" />
<loc xlink:type="locator" xlink:href="roiv-20210630.xsd#roiv_FirstTrancheMember" xlink:label="loc_roiv_FirstTrancheMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_roiv_FirstTrancheMember" xml:lang="en-US">First Tranche [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_roiv_FirstTrancheMember" xml:lang="en-US">First Tranche [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_roiv_FirstTrancheMember" xlink:to="lab_roiv_FirstTrancheMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_roiv_FirstTrancheMember" xml:lang="en-US">First Tranche [Member]</label>
<loc xlink:type="locator" xlink:href="roiv-20210630.xsd#roiv_SecondTrancheMember" xlink:label="loc_roiv_SecondTrancheMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_roiv_SecondTrancheMember" xml:lang="en-US">Second Tranche [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_roiv_SecondTrancheMember" xml:lang="en-US">Second Tranche [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_roiv_SecondTrancheMember" xlink:to="lab_roiv_SecondTrancheMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_roiv_SecondTrancheMember" xml:lang="en-US">Second Tranche [Member]</label>
<loc xlink:type="locator" xlink:href="roiv-20210630.xsd#roiv_TransactionAgreementTable" xlink:label="loc_roiv_TransactionAgreementTable" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_roiv_TransactionAgreementTable" xml:lang="en-US">Transaction Agreement [Table]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_roiv_TransactionAgreementTable" xml:lang="en-US">Transaction Agreement [Table]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_roiv_TransactionAgreementTable" xlink:to="lab_roiv_TransactionAgreementTable" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_roiv_TransactionAgreementTable" xml:lang="en-US">Transaction Agreement [Table]</label>
<loc xlink:type="locator" xlink:href="roiv-20210630.xsd#roiv_TransactionAgreementLineItems" xlink:label="loc_roiv_TransactionAgreementLineItems" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_roiv_TransactionAgreementLineItems" xml:lang="en-US">Transaction Agreement [Line Items]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_roiv_TransactionAgreementLineItems" xml:lang="en-US">Transaction Agreement [Line Items]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_roiv_TransactionAgreementLineItems" xlink:to="lab_roiv_TransactionAgreementLineItems" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_roiv_TransactionAgreementLineItems" xml:lang="en-US">Transaction Agreement [Line Items]</label>
<loc xlink:type="locator" xlink:href="roiv-20210630.xsd#roiv_AgreementRelatedBilledAmountForCostsIncurredOnBehalfOfSubsidiarynetOfAmountsBilledBySubsidiary" xlink:label="loc_roiv_AgreementRelatedBilledAmountForCostsIncurredOnBehalfOfSubsidiarynetOfAmountsBilledBySubsidiary" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_roiv_AgreementRelatedBilledAmountForCostsIncurredOnBehalfOfSubsidiarynetOfAmountsBilledBySubsidiary" xml:lang="en-US">Agreement Related Billed Amount For Costs Incurred On Behalf Of Subsidiary,Net Of Amounts Billed By Subsidiary</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_roiv_AgreementRelatedBilledAmountForCostsIncurredOnBehalfOfSubsidiarynetOfAmountsBilledBySubsidiary" xml:lang="en-US">Transition and cooperation agreement billed amount,Net of amounts billed by sumitovant</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_roiv_AgreementRelatedBilledAmountForCostsIncurredOnBehalfOfSubsidiarynetOfAmountsBilledBySubsidiary" xlink:to="lab_roiv_AgreementRelatedBilledAmountForCostsIncurredOnBehalfOfSubsidiarynetOfAmountsBilledBySubsidiary" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_roiv_AgreementRelatedBilledAmountForCostsIncurredOnBehalfOfSubsidiarynetOfAmountsBilledBySubsidiary" xml:lang="en-US">Agreement related billed amount for costs incurred on behalf of subsidiary,net of amounts billed by subsidiary.</label>
<loc xlink:type="locator" xlink:href="roiv-20210630.xsd#roiv_AggregateFairValueOfEquityAndLiabilityInstrumentsIssued" xlink:label="loc_roiv_AggregateFairValueOfEquityAndLiabilityInstrumentsIssued" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_roiv_AggregateFairValueOfEquityAndLiabilityInstrumentsIssued" xml:lang="en-US">Aggregate Fair Value of Equity and Liability Instruments Issued</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_roiv_AggregateFairValueOfEquityAndLiabilityInstrumentsIssued" xml:lang="en-US">Aggregate fair value of issued instruments to employees on transaction</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_roiv_AggregateFairValueOfEquityAndLiabilityInstrumentsIssued" xlink:to="lab_roiv_AggregateFairValueOfEquityAndLiabilityInstrumentsIssued" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_roiv_AggregateFairValueOfEquityAndLiabilityInstrumentsIssued" xml:lang="en-US">Aggregate Fair Value of Equity and Liability Instruments Issued</label>
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredCompensationEquity" xlink:label="loc_us-gaap_DeferredCompensationEquity" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_DeferredCompensationEquity" xml:lang="en-US">Deferred Compensation Equity</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_DeferredCompensationEquity" xml:lang="en-US">Deferred compensation equity</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredCompensationEquity" xlink:to="lab_us-gaap_DeferredCompensationEquity" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredCompensationLiabilityCurrent" xlink:label="loc_us-gaap_DeferredCompensationLiabilityCurrent" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_DeferredCompensationLiabilityCurrent" xml:lang="en-US">Deferred Compensation Liability, Current</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_DeferredCompensationLiabilityCurrent" xml:lang="en-US">Deferred compensation liability</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredCompensationLiabilityCurrent" xlink:to="lab_us-gaap_DeferredCompensationLiabilityCurrent" />
<loc xlink:type="locator" xlink:href="roiv-20210630.xsd#roiv_PercentageOfGrantedOptionToPurchaseOwnershipInterest" xlink:label="loc_roiv_PercentageOfGrantedOptionToPurchaseOwnershipInterest" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_roiv_PercentageOfGrantedOptionToPurchaseOwnershipInterest" xml:lang="en-US">Percentage of granted option to purchase ownership interest</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_roiv_PercentageOfGrantedOptionToPurchaseOwnershipInterest" xml:lang="en-US">Percentage of granted option to purchase ownership interest</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_roiv_PercentageOfGrantedOptionToPurchaseOwnershipInterest" xlink:to="lab_roiv_PercentageOfGrantedOptionToPurchaseOwnershipInterest" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_roiv_PercentageOfGrantedOptionToPurchaseOwnershipInterest" xml:lang="en-US">Percentage of granted option to purchase ownership interest.</label>
<loc xlink:type="locator" xlink:href="roiv-20210630.xsd#roiv_AssetPurchaseTransactionConsiderationReceivedInCash" xlink:label="loc_roiv_AssetPurchaseTransactionConsiderationReceivedInCash" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_roiv_AssetPurchaseTransactionConsiderationReceivedInCash" xml:lang="en-US">Asset Purchase Transaction Consideration Received In Cash</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_roiv_AssetPurchaseTransactionConsiderationReceivedInCash" xml:lang="en-US">Consideration received in cash</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_roiv_AssetPurchaseTransactionConsiderationReceivedInCash" xlink:to="lab_roiv_AssetPurchaseTransactionConsiderationReceivedInCash" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_roiv_AssetPurchaseTransactionConsiderationReceivedInCash" xml:lang="en-US">Asset Purchase Transaction Consideration Received In Cash.</label>
<loc xlink:type="locator" xlink:href="roiv-20210630.xsd#roiv_SaleOfStockNumberOfShareIssuedInTransaction" xlink:label="loc_roiv_SaleOfStockNumberOfShareIssuedInTransaction" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_roiv_SaleOfStockNumberOfShareIssuedInTransaction" xml:lang="en-US">Sale Of Stock Number Of Share Issued In Transaction</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_roiv_SaleOfStockNumberOfShareIssuedInTransaction" xml:lang="en-US">Number of shares transferred</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_roiv_SaleOfStockNumberOfShareIssuedInTransaction" xlink:to="lab_roiv_SaleOfStockNumberOfShareIssuedInTransaction" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_roiv_SaleOfStockNumberOfShareIssuedInTransaction" xml:lang="en-US">Sale Of Stock Number Of Share Issued In Transaction</label>
<loc xlink:type="locator" xlink:href="roiv-20210630.xsd#roiv_SaleOfStockConsiderationCashReceivedOnTransaction" xlink:label="loc_roiv_SaleOfStockConsiderationCashReceivedOnTransaction" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_roiv_SaleOfStockConsiderationCashReceivedOnTransaction" xml:lang="en-US">Sale Of Stock Consideration Cash Received On Transaction</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_roiv_SaleOfStockConsiderationCashReceivedOnTransaction" xlink:to="lab_roiv_SaleOfStockConsiderationCashReceivedOnTransaction" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_roiv_SaleOfStockConsiderationCashReceivedOnTransaction" xml:lang="en-US">Sale Of Stock Consideration Cash Received On Transaction.</label>
<loc xlink:type="locator" xlink:href="roiv-20210630.xsd#roiv_StockOfferToRepurchaseDuringPeriodValueOfTheProceedsReceivedFromTransactionAgreement" xlink:label="loc_roiv_StockOfferToRepurchaseDuringPeriodValueOfTheProceedsReceivedFromTransactionAgreement" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_roiv_StockOfferToRepurchaseDuringPeriodValueOfTheProceedsReceivedFromTransactionAgreement" xml:lang="en-US">Stock Offer To Repurchase During Period Value Of the Proceeds Received From Transaction Agreement</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_roiv_StockOfferToRepurchaseDuringPeriodValueOfTheProceedsReceivedFromTransactionAgreement" xml:lang="en-US">Stock offer to repurchase during period value of the proceeds received from transaction agreement</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_roiv_StockOfferToRepurchaseDuringPeriodValueOfTheProceedsReceivedFromTransactionAgreement" xlink:to="lab_roiv_StockOfferToRepurchaseDuringPeriodValueOfTheProceedsReceivedFromTransactionAgreement" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_roiv_StockOfferToRepurchaseDuringPeriodValueOfTheProceedsReceivedFromTransactionAgreement" xml:lang="en-US">Stock offer to repurchase during period value of the proceeds received from transaction agreement.</label>
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SaleOfStockConsiderationReceivedOnTransaction" xlink:label="loc_us-gaap_SaleOfStockConsiderationReceivedOnTransaction" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_SaleOfStockConsiderationReceivedOnTransaction" xml:lang="en-US">Sale of Stock, Consideration Received on Transaction</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_SaleOfStockConsiderationReceivedOnTransaction" xml:lang="en-US">Consideration received in transaction</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_SaleOfStockConsiderationReceivedOnTransaction" xml:lang="en-US">Net proceeds from sale of stock</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SaleOfStockConsiderationReceivedOnTransaction" xlink:to="lab_us-gaap_SaleOfStockConsiderationReceivedOnTransaction" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Non-Option Equity Instruments, Outstanding, Number</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber" xml:lang="en-US">Outstanding instruments vest based on the achievement of time-based, performance or liquidity event requirements</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockRepurchaseProgramAuthorizedAmount1" xlink:label="loc_us-gaap_StockRepurchaseProgramAuthorizedAmount1" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_StockRepurchaseProgramAuthorizedAmount1" xml:lang="en-US">Stock Repurchase Program, Authorized Amount</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_StockRepurchaseProgramAuthorizedAmount1" xml:lang="en-US">Repurchase of RSL's equity securities approved amount</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_StockRepurchaseProgramAuthorizedAmount1" xml:lang="en-US">Equity securities authorized for repurchase</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockRepurchaseProgramAuthorizedAmount1" xlink:to="lab_us-gaap_StockRepurchaseProgramAuthorizedAmount1" />
<loc xlink:type="locator" xlink:href="roiv-20210630.xsd#roiv_AgreementAxis" xlink:label="loc_roiv_AgreementAxis" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_roiv_AgreementAxis" xml:lang="en-US">Agreement [Axis]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_roiv_AgreementAxis" xlink:to="lab_roiv_AgreementAxis" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_roiv_AgreementAxis" xml:lang="en-US">Agreement [Axis].</label>
<loc xlink:type="locator" xlink:href="roiv-20210630.xsd#roiv_AgreementDomain" xlink:label="loc_roiv_AgreementDomain" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_roiv_AgreementDomain" xml:lang="en-US">Agreement [Domain]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_roiv_AgreementDomain" xlink:to="lab_roiv_AgreementDomain" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_roiv_AgreementDomain" xml:lang="en-US">Agreement [Domain].</label>
<loc xlink:type="locator" xlink:href="roiv-20210630.xsd#roiv_TransitionServicesAndStrategicCooperationAgreementMember" xlink:label="loc_roiv_TransitionServicesAndStrategicCooperationAgreementMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_roiv_TransitionServicesAndStrategicCooperationAgreementMember" xml:lang="en-US">Transition Services And Strategic Cooperation Agreement [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_roiv_TransitionServicesAndStrategicCooperationAgreementMember" xml:lang="en-US">Transition Services And Strategic Cooperation Agreement [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_roiv_TransitionServicesAndStrategicCooperationAgreementMember" xlink:to="lab_roiv_TransitionServicesAndStrategicCooperationAgreementMember" />
<loc xlink:type="locator" xlink:href="roiv-20210630.xsd#roiv_AssetPurchaseAgreementMember" xlink:label="loc_roiv_AssetPurchaseAgreementMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_roiv_AssetPurchaseAgreementMember" xml:lang="en-US">Asset Purchase Agreement [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_roiv_AssetPurchaseAgreementMember" xml:lang="en-US">Asset Purchase Agreement [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_roiv_AssetPurchaseAgreementMember" xlink:to="lab_roiv_AssetPurchaseAgreementMember" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_TitleOfIndividualAxis" xlink:label="loc_srt_TitleOfIndividualAxis" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_srt_TitleOfIndividualAxis" xml:lang="en-US">Title of Individual [Axis]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_srt_TitleOfIndividualAxis" xml:lang="en-US">Title of Individual [Axis]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_TitleOfIndividualAxis" xlink:to="lab_srt_TitleOfIndividualAxis" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:label="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_srt_TitleOfIndividualWithRelationshipToEntityDomain" xml:lang="en-US">Title of Individual [Domain]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_srt_TitleOfIndividualWithRelationshipToEntityDomain" xml:lang="en-US">Title of Individual [Domain]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:to="lab_srt_TitleOfIndividualWithRelationshipToEntityDomain" />
<loc xlink:type="locator" xlink:href="roiv-20210630.xsd#roiv_EmployeeMember" xlink:label="loc_roiv_EmployeeMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_roiv_EmployeeMember" xml:lang="en-US">Employee [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_roiv_EmployeeMember" xml:lang="en-US">Employee [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_roiv_EmployeeMember" xlink:to="lab_roiv_EmployeeMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_roiv_EmployeeMember" xml:lang="en-US">Employee [Member]</label>
<loc xlink:type="locator" xlink:href="roiv-20210630.xsd#roiv_SumitomoMember" xlink:label="loc_roiv_SumitomoMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_roiv_SumitomoMember" xml:lang="en-US">Sumitomo [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_roiv_SumitomoMember" xml:lang="en-US">Sumitomo [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_roiv_SumitomoMember" xlink:to="lab_roiv_SumitomoMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_roiv_SumitomoMember" xml:lang="en-US">Sumitomo [Member]</label>
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BalanceSheetRelatedDisclosuresAbstract" xlink:label="loc_us-gaap_BalanceSheetRelatedDisclosuresAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_BalanceSheetRelatedDisclosuresAbstract" xml:lang="en-US">Balance Sheet Related Disclosures [Abstract]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BalanceSheetRelatedDisclosuresAbstract" xlink:to="lab_us-gaap_BalanceSheetRelatedDisclosuresAbstract" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherAssetsMiscellaneousCurrent" xlink:label="loc_us-gaap_OtherAssetsMiscellaneousCurrent" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_OtherAssetsMiscellaneousCurrent" xml:lang="en-US">Other Assets, Miscellaneous, Current</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_OtherAssetsMiscellaneousCurrent" xml:lang="en-US">Other</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherAssetsMiscellaneousCurrent" xlink:to="lab_us-gaap_OtherAssetsMiscellaneousCurrent" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PrepaidExpenseCurrent" xlink:label="loc_us-gaap_PrepaidExpenseCurrent" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_PrepaidExpenseCurrent" xml:lang="en-US">Prepaid Expense, Current</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_PrepaidExpenseCurrent" xml:lang="en-US">Prepaid expenses</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PrepaidExpenseCurrent" xlink:to="lab_us-gaap_PrepaidExpenseCurrent" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ValueAddedTaxReceivable" xlink:label="loc_us-gaap_ValueAddedTaxReceivable" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ValueAddedTaxReceivable" xml:lang="en-US">Value Added Tax Receivable</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_ValueAddedTaxReceivable" xml:lang="en-US">Receivables for value added tax (VAT) paid</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ValueAddedTaxReceivable" xlink:to="lab_us-gaap_ValueAddedTaxReceivable" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountsReceivableNetCurrent" xlink:label="loc_us-gaap_AccountsReceivableNetCurrent" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_AccountsReceivableNetCurrent" xml:lang="en-US">Accounts Receivable, after Allowance for Credit Loss, Current</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_AccountsReceivableNetCurrent" xml:lang="en-US">Trade receivables, net</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountsReceivableNetCurrent" xlink:to="lab_us-gaap_AccountsReceivableNetCurrent" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxesReceivable" xlink:label="loc_us-gaap_IncomeTaxesReceivable" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_IncomeTaxesReceivable" xml:lang="en-US">Income Taxes Receivable, Current</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_IncomeTaxesReceivable" xml:lang="en-US">Income tax receivable</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxesReceivable" xlink:to="lab_us-gaap_IncomeTaxesReceivable" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NotesAndLoansReceivableNetCurrent" xlink:label="loc_us-gaap_NotesAndLoansReceivableNetCurrent" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_NotesAndLoansReceivableNetCurrent" xml:lang="en-US">Financing Receivable, after Allowance for Credit Loss, Current</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_NotesAndLoansReceivableNetCurrent" xml:lang="en-US">Note receivable</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NotesAndLoansReceivableNetCurrent" xlink:to="lab_us-gaap_NotesAndLoansReceivableNetCurrent" />
<loc xlink:type="locator" xlink:href="roiv-20210630.xsd#roiv_BalanceSheetComponentsTable" xlink:label="loc_roiv_BalanceSheetComponentsTable" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_roiv_BalanceSheetComponentsTable" xml:lang="en-US">Balance Sheet Components [Table]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_roiv_BalanceSheetComponentsTable" xml:lang="en-US">Balance Sheet Components [Table]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_roiv_BalanceSheetComponentsTable" xlink:to="lab_roiv_BalanceSheetComponentsTable" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_roiv_BalanceSheetComponentsTable" xml:lang="en-US">Balance Sheet Components [Table]</label>
<loc xlink:type="locator" xlink:href="roiv-20210630.xsd#roiv_BalanceSheetComponentsLineItems" xlink:label="loc_roiv_BalanceSheetComponentsLineItems" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_roiv_BalanceSheetComponentsLineItems" xml:lang="en-US">Balance Sheet Components [Line Items]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_roiv_BalanceSheetComponentsLineItems" xml:lang="en-US">Balance Sheet Components [Line Items]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_roiv_BalanceSheetComponentsLineItems" xlink:to="lab_roiv_BalanceSheetComponentsLineItems" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_roiv_BalanceSheetComponentsLineItems" xml:lang="en-US">Balance Sheet Components [Line Items]</label>
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeStatementLocationAxis" xlink:label="loc_us-gaap_IncomeStatementLocationAxis" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_IncomeStatementLocationAxis" xml:lang="en-US">Income Statement Location [Axis]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_IncomeStatementLocationAxis" xml:lang="en-US">Income Statement Location [Axis]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeStatementLocationAxis" xlink:to="lab_us-gaap_IncomeStatementLocationAxis" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="loc_us-gaap_IncomeStatementLocationDomain" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_IncomeStatementLocationDomain" xml:lang="en-US">Income Statement Location [Domain]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_IncomeStatementLocationDomain" xml:lang="en-US">Income Statement Location [Domain]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeStatementLocationDomain" xlink:to="lab_us-gaap_IncomeStatementLocationDomain" />
<loc xlink:type="locator" xlink:href="roiv-20210630.xsd#roiv_OtherGeneralAndAdministrativeExpensesMember" xlink:label="loc_roiv_OtherGeneralAndAdministrativeExpensesMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_roiv_OtherGeneralAndAdministrativeExpensesMember" xml:lang="en-US">Other General and Administrative Expenses [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_roiv_OtherGeneralAndAdministrativeExpensesMember" xml:lang="en-US">Other General and Administrative Expenses [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_roiv_OtherGeneralAndAdministrativeExpensesMember" xlink:to="lab_roiv_OtherGeneralAndAdministrativeExpensesMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_roiv_OtherGeneralAndAdministrativeExpensesMember" xml:lang="en-US">Other General and Administrative Expenses [Member]</label>
<loc xlink:type="locator" xlink:href="roiv-20210630.xsd#roiv_ProfessionalServicesExpensesMember" xlink:label="loc_roiv_ProfessionalServicesExpensesMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_roiv_ProfessionalServicesExpensesMember" xml:lang="en-US">Professional Services Expenses [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_roiv_ProfessionalServicesExpensesMember" xml:lang="en-US">Professional Services Expenses [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_roiv_ProfessionalServicesExpensesMember" xlink:to="lab_roiv_ProfessionalServicesExpensesMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_roiv_ProfessionalServicesExpensesMember" xml:lang="en-US">Professional Services Expenses [Member]</label>
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ResearchAndDevelopmentExpenseMember" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpenseMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpenseMember" xml:lang="en-US">Research and Development Expense [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpenseMember" xml:lang="en-US">R&amp;D Expenses [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ResearchAndDevelopmentExpenseMember" xlink:to="lab_us-gaap_ResearchAndDevelopmentExpenseMember" />
<loc xlink:type="locator" xlink:href="roiv-20210630.xsd#roiv_EmployeeRelatedExpensesMember" xlink:label="loc_roiv_EmployeeRelatedExpensesMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_roiv_EmployeeRelatedExpensesMember" xml:lang="en-US">Employee Related Expenses [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_roiv_EmployeeRelatedExpensesMember" xml:lang="en-US">Employee Related Expenses [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_roiv_EmployeeRelatedExpensesMember" xlink:to="lab_roiv_EmployeeRelatedExpensesMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_roiv_EmployeeRelatedExpensesMember" xml:lang="en-US">Employee Related Expenses [Member]</label>
<loc xlink:type="locator" xlink:href="roiv-20210630.xsd#roiv_DeferredRevenueOtherCurrentLiabilities" xlink:label="loc_roiv_DeferredRevenueOtherCurrentLiabilities" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_roiv_DeferredRevenueOtherCurrentLiabilities" xml:lang="en-US">Deferred Revenue Other Current Liabilities</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_roiv_DeferredRevenueOtherCurrentLiabilities" xml:lang="en-US">Deferred revenue</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_roiv_DeferredRevenueOtherCurrentLiabilities" xlink:to="lab_roiv_DeferredRevenueOtherCurrentLiabilities" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_roiv_DeferredRevenueOtherCurrentLiabilities" xml:lang="en-US">Deferred Revenue Other Current Liabilities</label>
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherSundryLiabilitiesCurrent" xlink:label="loc_us-gaap_OtherSundryLiabilitiesCurrent" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_OtherSundryLiabilitiesCurrent" xml:lang="en-US">Other Sundry Liabilities, Current</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_OtherSundryLiabilitiesCurrent" xml:lang="en-US">Other</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherSundryLiabilitiesCurrent" xlink:to="lab_us-gaap_OtherSundryLiabilitiesCurrent" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TaxesPayableCurrent" xlink:label="loc_us-gaap_TaxesPayableCurrent" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_TaxesPayableCurrent" xml:lang="en-US">Taxes Payable, Current</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_TaxesPayableCurrent" xml:lang="en-US">Income tax payable</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TaxesPayableCurrent" xlink:to="lab_us-gaap_TaxesPayableCurrent" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongTermDebtAbstract" xlink:label="loc_us-gaap_LongTermDebtAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_LongTermDebtAbstract" xml:lang="en-US">Long-term Debt, Unclassified [Abstract]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongTermDebtAbstract" xlink:to="lab_us-gaap_LongTermDebtAbstract" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentCarryingAmount" xlink:label="loc_us-gaap_DebtInstrumentCarryingAmount" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_DebtInstrumentCarryingAmount" xml:lang="en-US">Long-term Debt, Gross</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_DebtInstrumentCarryingAmount" xml:lang="en-US">Principal amount</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentCarryingAmount" xlink:to="lab_us-gaap_DebtInstrumentCarryingAmount" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet" xlink:label="loc_us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet" xml:lang="en-US">Debt Instrument, Unamortized Discount (Premium) and Debt Issuance Costs, Net</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="lab_us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet" xml:lang="en-US">Less: unamortized debt discount and issuance costs</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet" xlink:to="lab_us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongTermDebtCurrent" xlink:label="loc_us-gaap_LongTermDebtCurrent" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_LongTermDebtCurrent" xml:lang="en-US">Long-term Debt, Current Maturities</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="lab_us-gaap_LongTermDebtCurrent" xml:lang="en-US">Less: current portion</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongTermDebtCurrent" xlink:to="lab_us-gaap_LongTermDebtCurrent" />
<loc xlink:type="locator" xlink:href="roiv-20210630.xsd#roiv_DebtInstrumentExitFeeAndEndOfTermCharge" xlink:label="loc_roiv_DebtInstrumentExitFeeAndEndOfTermCharge" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_roiv_DebtInstrumentExitFeeAndEndOfTermCharge" xml:lang="en-US">Debt Instrument Exit Fee And End Of Term Charge</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_roiv_DebtInstrumentExitFeeAndEndOfTermCharge" xml:lang="en-US">Exit fee / end of term charge</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_roiv_DebtInstrumentExitFeeAndEndOfTermCharge" xlink:to="lab_roiv_DebtInstrumentExitFeeAndEndOfTermCharge" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_roiv_DebtInstrumentExitFeeAndEndOfTermCharge" xml:lang="en-US">Debt instrument exit fee and end of term charge.</label>
<loc xlink:type="locator" xlink:href="roiv-20210630.xsd#roiv_DebtInstrumentAmount" xlink:label="loc_roiv_DebtInstrumentAmount" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_roiv_DebtInstrumentAmount" xml:lang="en-US">Debt Instrument Amount</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_roiv_DebtInstrumentAmount" xml:lang="en-US">Principal amount</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_roiv_DebtInstrumentAmount" xlink:to="lab_roiv_DebtInstrumentAmount" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_roiv_DebtInstrumentAmount" xml:lang="en-US">Debt instrument amount.</label>
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentTable" xlink:label="loc_us-gaap_DebtInstrumentTable" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_DebtInstrumentTable" xml:lang="en-US">Schedule of Long-term Debt Instruments [Table]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_DebtInstrumentTable" xml:lang="en-US">Schedule of Long-term Debt Instruments [Table]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentTable" xlink:to="lab_us-gaap_DebtInstrumentTable" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TransactionTypeAxis" xlink:label="loc_us-gaap_TransactionTypeAxis" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_TransactionTypeAxis" xml:lang="en-US">Transaction Type [Axis]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_TransactionTypeAxis" xml:lang="en-US">Transaction Type [Axis]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TransactionTypeAxis" xlink:to="lab_us-gaap_TransactionTypeAxis" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TransactionDomain" xlink:label="loc_us-gaap_TransactionDomain" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_TransactionDomain" xml:lang="en-US">Transaction [Domain]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_TransactionDomain" xml:lang="en-US">Transaction [Domain]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TransactionDomain" xlink:to="lab_us-gaap_TransactionDomain" />
<loc xlink:type="locator" xlink:href="roiv-20210630.xsd#roiv_CommercialMilestoneMember" xlink:label="loc_roiv_CommercialMilestoneMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_roiv_CommercialMilestoneMember" xml:lang="en-US">Commercial Milestone [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_roiv_CommercialMilestoneMember" xml:lang="en-US">Commercial Milestone [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_roiv_CommercialMilestoneMember" xlink:to="lab_roiv_CommercialMilestoneMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_roiv_CommercialMilestoneMember" xml:lang="en-US">Commercial Milestone [Member]</label>
<loc xlink:type="locator" xlink:href="roiv-20210630.xsd#roiv_RegulatoryMilestoneMember" xlink:label="loc_roiv_RegulatoryMilestoneMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_roiv_RegulatoryMilestoneMember" xml:lang="en-US">Regulatory Milestone [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_roiv_RegulatoryMilestoneMember" xml:lang="en-US">Regulatory Milestone [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_roiv_RegulatoryMilestoneMember" xlink:to="lab_roiv_RegulatoryMilestoneMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_roiv_RegulatoryMilestoneMember" xml:lang="en-US">Regulatory Milestone [Member]</label>
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentLineItems" xlink:label="loc_us-gaap_DebtInstrumentLineItems" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_DebtInstrumentLineItems" xml:lang="en-US">Debt Instrument [Line Items]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_DebtInstrumentLineItems" xml:lang="en-US">Debt Instrument [Line Items]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentLineItems" xlink:to="lab_us-gaap_DebtInstrumentLineItems" />
<loc xlink:type="locator" xlink:href="roiv-20210630.xsd#roiv_MaximumMilestonePaymentObligation" xlink:label="loc_roiv_MaximumMilestonePaymentObligation" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_roiv_MaximumMilestonePaymentObligation" xml:lang="en-US">Maximum Milestone Payment Obligation</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_roiv_MaximumMilestonePaymentObligation" xml:lang="en-US">Maximum amount required milestone payments</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_roiv_MaximumMilestonePaymentObligation" xlink:to="lab_roiv_MaximumMilestonePaymentObligation" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_roiv_MaximumMilestonePaymentObligation" xml:lang="en-US">Maximum milestone payment obligation.</label>
<loc xlink:type="locator" xlink:href="roiv-20210630.xsd#roiv_MaximumMilestonePaymentOffsetAmount" xlink:label="loc_roiv_MaximumMilestonePaymentOffsetAmount" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_roiv_MaximumMilestonePaymentOffsetAmount" xml:lang="en-US">Maximum Milestone Payment Offset Amount</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_roiv_MaximumMilestonePaymentOffsetAmount" xml:lang="en-US">Possible offset of regulatory milestone payments with commercial milestone</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_roiv_MaximumMilestonePaymentOffsetAmount" xlink:to="lab_roiv_MaximumMilestonePaymentOffsetAmount" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_roiv_MaximumMilestonePaymentOffsetAmount" xml:lang="en-US">Maximum Milestone Payment Offset Amount</label>
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:label="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_DebtInstrumentInterestRateStatedPercentage" xml:lang="en-US">Debt Instrument, Interest Rate, Stated Percentage</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_DebtInstrumentInterestRateStatedPercentage" xml:lang="en-US">Interest rate</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:to="lab_us-gaap_DebtInstrumentInterestRateStatedPercentage" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentTerm" xlink:label="loc_us-gaap_DebtInstrumentTerm" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_DebtInstrumentTerm" xml:lang="en-US">Debt Instrument, Term</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_DebtInstrumentTerm" xml:lang="en-US">Maturity date</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentTerm" xlink:to="lab_us-gaap_DebtInstrumentTerm" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentFaceAmount" xlink:label="loc_us-gaap_DebtInstrumentFaceAmount" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_DebtInstrumentFaceAmount" xml:lang="en-US">Debt Instrument, Face Amount</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_DebtInstrumentFaceAmount" xml:lang="en-US">Debt principal amount</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentFaceAmount" xlink:to="lab_us-gaap_DebtInstrumentFaceAmount" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentFairValue" xlink:label="loc_us-gaap_DebtInstrumentFairValue" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_DebtInstrumentFairValue" xml:lang="en-US">Debt Instrument, Fair Value Disclosure</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_DebtInstrumentFairValue" xml:lang="en-US">Debt fair value</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_DebtInstrumentFairValue" xml:lang="en-US">Debt issued by Dermavant to NovaQuest</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentFairValue" xlink:to="lab_us-gaap_DebtInstrumentFairValue" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentFeeAmount" xlink:label="loc_us-gaap_DebtInstrumentFeeAmount" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_DebtInstrumentFeeAmount" xml:lang="en-US">Debt Instrument, Fee Amount</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/definitionGuidance" xlink:label="lab_us-gaap_DebtInstrumentFeeAmount" xml:lang="en-US">Debt Instrument, Fee Amount</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentFeeAmount" xlink:to="lab_us-gaap_DebtInstrumentFeeAmount" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight" xlink:label="loc_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight" xml:lang="en-US">Class of Warrant or Right, Number of Securities Called by Each Warrant or Right</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight" xml:lang="en-US">Class of warrants or rights number of shares called by each warrant or right</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight" xlink:to="lab_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromLinesOfCredit" xlink:label="loc_us-gaap_ProceedsFromLinesOfCredit" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ProceedsFromLinesOfCredit" xml:lang="en-US">Proceeds from Lines of Credit</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_ProceedsFromLinesOfCredit" xml:lang="en-US">Proceeds from credit facility</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromLinesOfCredit" xlink:to="lab_us-gaap_ProceedsFromLinesOfCredit" />
<loc xlink:type="locator" xlink:href="roiv-20210630.xsd#roiv_ProceedsFromSaleOfDebtAndEquitySecurities" xlink:label="loc_roiv_ProceedsFromSaleOfDebtAndEquitySecurities" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_roiv_ProceedsFromSaleOfDebtAndEquitySecurities" xml:lang="en-US">Proceeds from Sale of Debt and Equity Securities</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_roiv_ProceedsFromSaleOfDebtAndEquitySecurities" xml:lang="en-US">Proceed from equity and debt financing</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_roiv_ProceedsFromSaleOfDebtAndEquitySecurities" xlink:to="lab_roiv_ProceedsFromSaleOfDebtAndEquitySecurities" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_roiv_ProceedsFromSaleOfDebtAndEquitySecurities" xml:lang="en-US">Proceeds from the sale of debt and equity securities.</label>
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongTermDebtPercentageBearingVariableInterestRate" xlink:label="loc_us-gaap_LongTermDebtPercentageBearingVariableInterestRate" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_LongTermDebtPercentageBearingVariableInterestRate" xml:lang="en-US">Long-term Debt, Percentage Bearing Variable Interest, Percentage Rate</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_LongTermDebtPercentageBearingVariableInterestRate" xml:lang="en-US">Debt interest rate</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongTermDebtPercentageBearingVariableInterestRate" xlink:to="lab_us-gaap_LongTermDebtPercentageBearingVariableInterestRate" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:label="loc_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xml:lang="en-US">Class of Warrant or Right, Exercise Price of Warrants or Rights</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/disclosureGuidance" xlink:label="lab_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xml:lang="en-US">Class of Warrant or Right, Exercise Price per share</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xml:lang="en-US">Warrant exercise price per share</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/positiveLabel" xlink:label="lab_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xml:lang="en-US">Warrants exercise price</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:to="lab_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SecuritiesPurchasedUnderAgreementsToResellIncrease" xlink:label="loc_us-gaap_SecuritiesPurchasedUnderAgreementsToResellIncrease" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_SecuritiesPurchasedUnderAgreementsToResellIncrease" xml:lang="en-US">Securities Purchased under Agreements to Resell, Increase</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_SecuritiesPurchasedUnderAgreementsToResellIncrease" xml:lang="en-US">Securities Purchased under Agreements to Resell</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SecuritiesPurchasedUnderAgreementsToResellIncrease" xlink:to="lab_us-gaap_SecuritiesPurchasedUnderAgreementsToResellIncrease" />
<loc xlink:type="locator" xlink:href="roiv-20210630.xsd#roiv_MinimumAmountOfAnnualNetSalesToQualifyUnderRevenueInterestPurchaseAgreementContingentThreshold" xlink:label="loc_roiv_MinimumAmountOfAnnualNetSalesToQualifyUnderRevenueInterestPurchaseAgreementContingentThreshold" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_roiv_MinimumAmountOfAnnualNetSalesToQualifyUnderRevenueInterestPurchaseAgreementContingentThreshold" xml:lang="en-US">Minimum Amount Of Annual Net Sales To Qualify Under Revenue Interest Purchase Agreement Contingent Threshold</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_roiv_MinimumAmountOfAnnualNetSalesToQualifyUnderRevenueInterestPurchaseAgreementContingentThreshold" xml:lang="en-US">Minimum Amount of Annual Net Sales To Qualify Under Revenue Interest Purchase Agreement, Contingent Threshold</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_roiv_MinimumAmountOfAnnualNetSalesToQualifyUnderRevenueInterestPurchaseAgreementContingentThreshold" xlink:to="lab_roiv_MinimumAmountOfAnnualNetSalesToQualifyUnderRevenueInterestPurchaseAgreementContingentThreshold" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_roiv_MinimumAmountOfAnnualNetSalesToQualifyUnderRevenueInterestPurchaseAgreementContingentThreshold" xml:lang="en-US">Minimum amount of annual net sales to qualify under revenue interest purchase agreement, contingent threshold.</label>
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="loc_us-gaap_TypeOfArrangementAxis" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_TypeOfArrangementAxis" xml:lang="en-US">Collaborative Arrangement and Arrangement Other than Collaborative [Axis]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_TypeOfArrangementAxis" xml:lang="en-US">Collaborative Arrangement and Arrangement Other than Collaborative [Axis]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TypeOfArrangementAxis" xlink:to="lab_us-gaap_TypeOfArrangementAxis" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ArrangementsAndNonarrangementTransactionsMember" xml:lang="en-US">Collaborative Arrangement and Arrangement Other than Collaborative [Domain]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_ArrangementsAndNonarrangementTransactionsMember" xml:lang="en-US">Collaborative Arrangement and Arrangement Other than Collaborative [Domain]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="lab_us-gaap_ArrangementsAndNonarrangementTransactionsMember" />
<loc xlink:type="locator" xlink:href="roiv-20210630.xsd#roiv_NovaquestMember" xlink:label="loc_roiv_NovaquestMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_roiv_NovaquestMember" xml:lang="en-US">Novaquest [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_roiv_NovaquestMember" xml:lang="en-US">NovaQuest Agreement [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_roiv_NovaquestMember" xlink:to="lab_roiv_NovaquestMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_roiv_NovaquestMember" xml:lang="en-US">Novaquest.</label>
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_VariableRateAxis" xlink:label="loc_us-gaap_VariableRateAxis" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_VariableRateAxis" xml:lang="en-US">Variable Rate [Axis]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_VariableRateAxis" xml:lang="en-US">Variable Rate [Axis]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_VariableRateAxis" xlink:to="lab_us-gaap_VariableRateAxis" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_VariableRateDomain" xlink:label="loc_us-gaap_VariableRateDomain" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_VariableRateDomain" xml:lang="en-US">Variable Rate [Domain]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_VariableRateDomain" xml:lang="en-US">Variable Rate [Domain]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_VariableRateDomain" xlink:to="lab_us-gaap_VariableRateDomain" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PrimeRateMember" xlink:label="loc_us-gaap_PrimeRateMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_PrimeRateMember" xml:lang="en-US">Prime Rate [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_PrimeRateMember" xml:lang="en-US">Prime Rate [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PrimeRateMember" xlink:to="lab_us-gaap_PrimeRateMember" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FinancialInstrumentAxis" xlink:label="loc_us-gaap_FinancialInstrumentAxis" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_FinancialInstrumentAxis" xml:lang="en-US">Financial Instrument [Axis]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FinancialInstrumentAxis" xlink:to="lab_us-gaap_FinancialInstrumentAxis" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xml:lang="en-US">Financial Instruments [Domain]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:to="lab_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" />
<loc xlink:type="locator" xlink:href="roiv-20210630.xsd#roiv_RevenueInterestPurchaseAndSaleAgreementMember" xlink:label="loc_roiv_RevenueInterestPurchaseAndSaleAgreementMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_roiv_RevenueInterestPurchaseAndSaleAgreementMember" xml:lang="en-US">Revenue Interest Purchase And Sale Agreement [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_roiv_RevenueInterestPurchaseAndSaleAgreementMember" xml:lang="en-US">Revenue Interest Purchase and Sale Agreement [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_roiv_RevenueInterestPurchaseAndSaleAgreementMember" xlink:to="lab_roiv_RevenueInterestPurchaseAndSaleAgreementMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_roiv_RevenueInterestPurchaseAndSaleAgreementMember" xml:lang="en-US">Revenue Interest Purchase And Sale Agreement [Member].</label>
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongTermDebtByMaturityAbstract" xlink:label="loc_us-gaap_LongTermDebtByMaturityAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_LongTermDebtByMaturityAbstract" xml:lang="en-US">Long-term Debt, Fiscal Year Maturity [Abstract]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongTermDebtByMaturityAbstract" xlink:to="lab_us-gaap_LongTermDebtByMaturityAbstract" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo" xlink:label="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo" xml:lang="en-US">Long-Term Debt, Maturity, Year Two</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo" xml:lang="en-US">2023</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo" xlink:to="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo" />
<loc xlink:type="locator" xlink:href="roiv-20210630.xsd#roiv_LongTermDebtExcludingDebtWithFairValueOption" xlink:label="loc_roiv_LongTermDebtExcludingDebtWithFairValueOption" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_roiv_LongTermDebtExcludingDebtWithFairValueOption" xml:lang="en-US">Long Term Debt Excluding Debt With Fair Value Option</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_roiv_LongTermDebtExcludingDebtWithFairValueOption" xml:lang="en-US">Total</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_roiv_LongTermDebtExcludingDebtWithFairValueOption" xlink:to="lab_roiv_LongTermDebtExcludingDebtWithFairValueOption" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_roiv_LongTermDebtExcludingDebtWithFairValueOption" xml:lang="en-US">Long Term Debt Excluding Debt With Fair Value Option</label>
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalAfterYearFive" xlink:label="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalAfterYearFive" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalAfterYearFive" xml:lang="en-US">Long-Term Debt, Maturity, after Year Five</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalAfterYearFive" xml:lang="en-US">Thereafter</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalAfterYearFive" xlink:to="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalAfterYearFive" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths" xlink:label="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths" xml:lang="en-US">Long-Term Debt, Maturity, Year One</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths" xml:lang="en-US">2022</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths" xlink:to="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive" xlink:label="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive" xml:lang="en-US">Long-Term Debt, Maturity, Year Five</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive" xml:lang="en-US">2026</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive" xlink:to="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour" xlink:label="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour" xml:lang="en-US">Long-Term Debt, Maturity, Year Four</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour" xml:lang="en-US">2025</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour" xlink:to="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree" xlink:label="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree" xml:lang="en-US">Long-Term Debt, Maturity, Year Three</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree" xml:lang="en-US">2024</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree" xlink:to="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfStockByClassTable" xlink:label="loc_us-gaap_ScheduleOfStockByClassTable" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ScheduleOfStockByClassTable" xml:lang="en-US">Schedule of Stock by Class [Table]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_ScheduleOfStockByClassTable" xml:lang="en-US">Schedule of Stock by Class [Table]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable" xlink:to="lab_us-gaap_ScheduleOfStockByClassTable" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfStockLineItems" xlink:label="loc_us-gaap_ClassOfStockLineItems" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ClassOfStockLineItems" xml:lang="en-US">Class of Stock [Line Items]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_ClassOfStockLineItems" xml:lang="en-US">Class of Stock [Line Items]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ClassOfStockLineItems" xlink:to="lab_us-gaap_ClassOfStockLineItems" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessAcquisitionPercentageOfVotingInterestsAcquired" xlink:label="loc_us-gaap_BusinessAcquisitionPercentageOfVotingInterestsAcquired" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_BusinessAcquisitionPercentageOfVotingInterestsAcquired" xml:lang="en-US">Business Acquisition, Percentage of Voting Interests Acquired</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_BusinessAcquisitionPercentageOfVotingInterestsAcquired" xml:lang="en-US">Percentage of common stock acquired related to business acquisition</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessAcquisitionPercentageOfVotingInterestsAcquired" xlink:to="lab_us-gaap_BusinessAcquisitionPercentageOfVotingInterestsAcquired" />
<loc xlink:type="locator" xlink:href="roiv-20210630.xsd#roiv_ClassOfWarrantOrRightExercisable" xlink:label="loc_roiv_ClassOfWarrantOrRightExercisable" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_roiv_ClassOfWarrantOrRightExercisable" xml:lang="en-US">Class of Warrant or Right, Exercisable</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_roiv_ClassOfWarrantOrRightExercisable" xml:lang="en-US">Number of exercisable outstanding warrants</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_roiv_ClassOfWarrantOrRightExercisable" xlink:to="lab_roiv_ClassOfWarrantOrRightExercisable" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_roiv_ClassOfWarrantOrRightExercisable" xml:lang="en-US">Class of Warrant or Right, Exercisable</label>
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfWarrantOrRightOutstanding" xlink:label="loc_us-gaap_ClassOfWarrantOrRightOutstanding" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ClassOfWarrantOrRightOutstanding" xml:lang="en-US">Class of Warrant or Right, Outstanding</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_ClassOfWarrantOrRightOutstanding" xml:lang="en-US">Number of outstanding warrants</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_ClassOfWarrantOrRightOutstanding" xml:lang="en-US">Warrants issued to purchase common shares</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ClassOfWarrantOrRightOutstanding" xlink:to="lab_us-gaap_ClassOfWarrantOrRightOutstanding" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdjustmentOfWarrantsGrantedForServices" xlink:label="loc_us-gaap_AdjustmentOfWarrantsGrantedForServices" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_AdjustmentOfWarrantsGrantedForServices" xml:lang="en-US">Adjustment of Warrants Granted for Services</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_AdjustmentOfWarrantsGrantedForServices" xml:lang="en-US">Warrants cancellation</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdjustmentOfWarrantsGrantedForServices" xlink:to="lab_us-gaap_AdjustmentOfWarrantsGrantedForServices" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsForProceedsFromBusinessesAndInterestInAffiliates" xlink:label="loc_us-gaap_PaymentsForProceedsFromBusinessesAndInterestInAffiliates" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_PaymentsForProceedsFromBusinessesAndInterestInAffiliates" xml:lang="en-US">Payments for (Proceeds from) Businesses and Interest in Affiliates</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_PaymentsForProceedsFromBusinessesAndInterestInAffiliates" xml:lang="en-US">Cash as a result of the Business Combination</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsForProceedsFromBusinessesAndInterestInAffiliates" xlink:to="lab_us-gaap_PaymentsForProceedsFromBusinessesAndInterestInAffiliates" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsForRepurchaseOfRedeemableConvertiblePreferredStock" xlink:label="loc_us-gaap_PaymentsForRepurchaseOfRedeemableConvertiblePreferredStock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_PaymentsForRepurchaseOfRedeemableConvertiblePreferredStock" xml:lang="en-US">Payments for Repurchase of Redeemable Convertible Preferred Stock</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_PaymentsForRepurchaseOfRedeemableConvertiblePreferredStock" xml:lang="en-US">Preferred stock purchase price</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsForRepurchaseOfRedeemableConvertiblePreferredStock" xlink:to="lab_us-gaap_PaymentsForRepurchaseOfRedeemableConvertiblePreferredStock" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsForRepurchaseOfRedeemableNoncontrollingInterest" xlink:label="loc_us-gaap_PaymentsForRepurchaseOfRedeemableNoncontrollingInterest" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_PaymentsForRepurchaseOfRedeemableNoncontrollingInterest" xml:lang="en-US">Payments for Repurchase of Redeemable Noncontrolling Interest</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_PaymentsForRepurchaseOfRedeemableNoncontrollingInterest" xml:lang="en-US">Repurchase of redeemable noncontrolling interest</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsForRepurchaseOfRedeemableNoncontrollingInterest" xlink:to="lab_us-gaap_PaymentsForRepurchaseOfRedeemableNoncontrollingInterest" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InvestmentCompanyInternalRateOfReturnSinceInception" xlink:label="loc_us-gaap_InvestmentCompanyInternalRateOfReturnSinceInception" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_InvestmentCompanyInternalRateOfReturnSinceInception" xml:lang="en-US">Investment Company, Internal Rate of Return since Inception</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_InvestmentCompanyInternalRateOfReturnSinceInception" xml:lang="en-US">Annualized return rate</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InvestmentCompanyInternalRateOfReturnSinceInception" xlink:to="lab_us-gaap_InvestmentCompanyInternalRateOfReturnSinceInception" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentConvertibleCarryingAmountOfTheEquityComponent" xlink:label="loc_us-gaap_DebtInstrumentConvertibleCarryingAmountOfTheEquityComponent" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_DebtInstrumentConvertibleCarryingAmountOfTheEquityComponent" xml:lang="en-US">Debt Instrument, Convertible, Carrying Amount of Equity Component</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_DebtInstrumentConvertibleCarryingAmountOfTheEquityComponent" xml:lang="en-US">Carrying amount of the convertible promissory</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentConvertibleCarryingAmountOfTheEquityComponent" xlink:to="lab_us-gaap_DebtInstrumentConvertibleCarryingAmountOfTheEquityComponent" />
<loc xlink:type="locator" xlink:href="roiv-20210630.xsd#roiv_EarnOutSharesTermsDescription" xlink:label="loc_roiv_EarnOutSharesTermsDescription" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_roiv_EarnOutSharesTermsDescription" xml:lang="en-US">Earn Out Shares Terms Description</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_roiv_EarnOutSharesTermsDescription" xml:lang="en-US">Earnout shares</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_roiv_EarnOutSharesTermsDescription" xlink:to="lab_roiv_EarnOutSharesTermsDescription" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_roiv_EarnOutSharesTermsDescription" xml:lang="en-US">Earnout shares terms description.</label>
<loc xlink:type="locator" xlink:href="roiv-20210630.xsd#roiv_PercentageSharesOfCommonStockOfferedToBeRepurchased" xlink:label="loc_roiv_PercentageSharesOfCommonStockOfferedToBeRepurchased" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_roiv_PercentageSharesOfCommonStockOfferedToBeRepurchased" xml:lang="en-US">Percentage Shares of Common Stock Offered To Be Repurchased</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_roiv_PercentageSharesOfCommonStockOfferedToBeRepurchased" xml:lang="en-US">Offer to repurchase common stock held by each holder</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_roiv_PercentageSharesOfCommonStockOfferedToBeRepurchased" xlink:to="lab_roiv_PercentageSharesOfCommonStockOfferedToBeRepurchased" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_roiv_PercentageSharesOfCommonStockOfferedToBeRepurchased" xml:lang="en-US">Percentage Shares of Common Stock Offered To Be Repurchased</label>
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PreferredStockRedemptionPricePerShare" xlink:label="loc_us-gaap_PreferredStockRedemptionPricePerShare" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_PreferredStockRedemptionPricePerShare" xml:lang="en-US">Preferred Stock, Redemption Price Per Share</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_PreferredStockRedemptionPricePerShare" xml:lang="en-US">Preferred stock purchase price per share</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PreferredStockRedemptionPricePerShare" xlink:to="lab_us-gaap_PreferredStockRedemptionPricePerShare" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromIssuanceOfWarrants" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfWarrants" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ProceedsFromIssuanceOfWarrants" xml:lang="en-US">Proceeds from Issuance of Warrants</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_ProceedsFromIssuanceOfWarrants" xml:lang="en-US">Proceeds of warrants</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromIssuanceOfWarrants" xlink:to="lab_us-gaap_ProceedsFromIssuanceOfWarrants" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TreasuryStockAcquiredRepurchaseAuthorization" xlink:label="loc_us-gaap_TreasuryStockAcquiredRepurchaseAuthorization" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_TreasuryStockAcquiredRepurchaseAuthorization" xml:lang="en-US">Treasury Stock Acquired, Repurchase Authorization</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_TreasuryStockAcquiredRepurchaseAuthorization" xml:lang="en-US">Description of share repurchase offer</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TreasuryStockAcquiredRepurchaseAuthorization" xlink:to="lab_us-gaap_TreasuryStockAcquiredRepurchaseAuthorization" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_WeightedAverageNumberOfSharesContingentlyIssuable" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesContingentlyIssuable" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_WeightedAverageNumberOfSharesContingentlyIssuable" xml:lang="en-US">Weighted Average Number of Shares, Contingently Issuable</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_WeightedAverageNumberOfSharesContingentlyIssuable" xml:lang="en-US">Earnout shares</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_WeightedAverageNumberOfSharesContingentlyIssuable" xlink:to="lab_us-gaap_WeightedAverageNumberOfSharesContingentlyIssuable" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" xlink:label="loc_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" xml:lang="en-US">Sale of Stock, Number of Shares Issued in Transaction</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" xml:lang="en-US">Number of shares transferred</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" xlink:to="lab_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SaleOfStockPricePerShare" xlink:label="loc_us-gaap_SaleOfStockPricePerShare" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_SaleOfStockPricePerShare" xml:lang="en-US">Sale of Stock, Price Per Share</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_SaleOfStockPricePerShare" xml:lang="en-US">Common stock per share</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SaleOfStockPricePerShare" xlink:to="lab_us-gaap_SaleOfStockPricePerShare" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Vested in Period</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xml:lang="en-US">Restricted shares vested</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xml:lang="en-US">Vested</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharesIssuedPricePerShare" xlink:label="loc_us-gaap_SharesIssuedPricePerShare" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_SharesIssuedPricePerShare" xml:lang="en-US">Shares Issued, Price Per Share</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_SharesIssuedPricePerShare" xml:lang="en-US">Share price</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharesIssuedPricePerShare" xlink:to="lab_us-gaap_SharesIssuedPricePerShare" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestrictedStockMember" xlink:label="loc_us-gaap_RestrictedStockMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_RestrictedStockMember" xml:lang="en-US">Restricted Stock [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_RestrictedStockMember" xml:lang="en-US">Restricted Stock [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestrictedStockMember" xlink:to="lab_us-gaap_RestrictedStockMember" />
<loc xlink:type="locator" xlink:href="roiv-20210630.xsd#roiv_ImmunovantINCMember" xlink:label="loc_roiv_ImmunovantINCMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_roiv_ImmunovantINCMember" xml:lang="en-US">Immunovant INC [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_roiv_ImmunovantINCMember" xml:lang="en-US">Immunovant, Inc [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_roiv_ImmunovantINCMember" xlink:to="lab_roiv_ImmunovantINCMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_roiv_ImmunovantINCMember" xml:lang="en-US">Immunovant INC.</label>
<loc xlink:type="locator" xlink:href="roiv-20210630.xsd#roiv_HealthSciencesMember" xlink:label="loc_roiv_HealthSciencesMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_roiv_HealthSciencesMember" xml:lang="en-US">Health Sciences [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_roiv_HealthSciencesMember" xml:lang="en-US">Health Sciences [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_roiv_HealthSciencesMember" xlink:to="lab_roiv_HealthSciencesMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_roiv_HealthSciencesMember" xml:lang="en-US">HSAC [Member]</label>
<loc xlink:type="locator" xlink:href="roiv-20210630.xsd#roiv_ImmunovantSciencesLtdMember" xlink:label="loc_roiv_ImmunovantSciencesLtdMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_roiv_ImmunovantSciencesLtdMember" xml:lang="en-US">Immunovant Sciences Ltd [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_roiv_ImmunovantSciencesLtdMember" xml:lang="en-US">Immunovant Sciences Ltd [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_roiv_ImmunovantSciencesLtdMember" xlink:to="lab_roiv_ImmunovantSciencesLtdMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_roiv_ImmunovantSciencesLtdMember" xml:lang="en-US">Immunovant Sciences Ltd [Member]</label>
<loc xlink:type="locator" xlink:href="roiv-20210630.xsd#roiv_CytovantScienceHkLtdMember" xlink:label="loc_roiv_CytovantScienceHkLtdMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_roiv_CytovantScienceHkLtdMember" xml:lang="en-US">Cytovant Science HK Ltd [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_roiv_CytovantScienceHkLtdMember" xml:lang="en-US">Cytovant Science HK Ltd [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_roiv_CytovantScienceHkLtdMember" xlink:to="lab_roiv_CytovantScienceHkLtdMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_roiv_CytovantScienceHkLtdMember" xml:lang="en-US">Cytovant Science HK Ltd [Member]</label>
<loc xlink:type="locator" xlink:href="roiv-20210630.xsd#roiv_SinovantIncMember" xlink:label="loc_roiv_SinovantIncMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_roiv_SinovantIncMember" xml:lang="en-US">Sinovant Inc [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_roiv_SinovantIncMember" xml:lang="en-US">Sinovant Inc [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_roiv_SinovantIncMember" xlink:to="lab_roiv_SinovantIncMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_roiv_SinovantIncMember" xml:lang="en-US">Sinovant Inc [Member]</label>
<loc xlink:type="locator" xlink:href="roiv-20210630.xsd#roiv_SeriesA1PreferredStockMember" xlink:label="loc_roiv_SeriesA1PreferredStockMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_roiv_SeriesA1PreferredStockMember" xml:lang="en-US">Series A 1 Preferred Stock [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_roiv_SeriesA1PreferredStockMember" xml:lang="en-US">Series A 1 Preferred Stock [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_roiv_SeriesA1PreferredStockMember" xlink:to="lab_roiv_SeriesA1PreferredStockMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_roiv_SeriesA1PreferredStockMember" xml:lang="en-US">Series A 1 Preferred Stock [Member]</label>
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_WarrantMember" xlink:label="loc_us-gaap_WarrantMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_WarrantMember" xml:lang="en-US">Warrant [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_WarrantMember" xml:lang="en-US">Warrant</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_WarrantMember" xlink:to="lab_us-gaap_WarrantMember" />
<loc xlink:type="locator" xlink:href="roiv-20210630.xsd#roiv_UnderwrittenPublicOfferingMember" xlink:label="loc_roiv_UnderwrittenPublicOfferingMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_roiv_UnderwrittenPublicOfferingMember" xml:lang="en-US">Underwritten Public Offering [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_roiv_UnderwrittenPublicOfferingMember" xml:lang="en-US">Underwritten Public Offering [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_roiv_UnderwrittenPublicOfferingMember" xlink:to="lab_roiv_UnderwrittenPublicOfferingMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_roiv_UnderwrittenPublicOfferingMember" xml:lang="en-US">Underwritten Public Offering [Member]</label>
<loc xlink:type="locator" xlink:href="roiv-20210630.xsd#roiv_SumitomoTransactionAgreementMember" xlink:label="loc_roiv_SumitomoTransactionAgreementMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_roiv_SumitomoTransactionAgreementMember" xml:lang="en-US">Sumitomo Transaction Agreement [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_roiv_SumitomoTransactionAgreementMember" xml:lang="en-US">Sumitomo Transaction Agreement [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_roiv_SumitomoTransactionAgreementMember" xlink:to="lab_roiv_SumitomoTransactionAgreementMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_roiv_SumitomoTransactionAgreementMember" xml:lang="en-US">Sumitomo Transaction Agreement [Member]</label>
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareRepurchaseProgramAxis" xlink:label="loc_us-gaap_ShareRepurchaseProgramAxis" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ShareRepurchaseProgramAxis" xml:lang="en-US">Share Repurchase Program [Axis]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_ShareRepurchaseProgramAxis" xml:lang="en-US">Share Repurchase Program [Axis]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareRepurchaseProgramAxis" xlink:to="lab_us-gaap_ShareRepurchaseProgramAxis" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareRepurchaseProgramDomain" xlink:label="loc_us-gaap_ShareRepurchaseProgramDomain" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ShareRepurchaseProgramDomain" xml:lang="en-US">Share Repurchase Program [Domain]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_ShareRepurchaseProgramDomain" xml:lang="en-US">Share Repurchase Program [Domain]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareRepurchaseProgramDomain" xlink:to="lab_us-gaap_ShareRepurchaseProgramDomain" />
<loc xlink:type="locator" xlink:href="roiv-20210630.xsd#roiv_RoivantEquityRepurchaseMember" xlink:label="loc_roiv_RoivantEquityRepurchaseMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_roiv_RoivantEquityRepurchaseMember" xml:lang="en-US">Roivant Equity Repurchase [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_roiv_RoivantEquityRepurchaseMember" xml:lang="en-US">Roivant Equity Repurchase [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_roiv_RoivantEquityRepurchaseMember" xlink:to="lab_roiv_RoivantEquityRepurchaseMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_roiv_RoivantEquityRepurchaseMember" xml:lang="en-US">Roivant Equity Repurchase [Member]</label>
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShortTermDebtTypeAxis" xlink:label="loc_us-gaap_ShortTermDebtTypeAxis" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ShortTermDebtTypeAxis" xml:lang="en-US">Short-term Debt, Type [Axis]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_ShortTermDebtTypeAxis" xml:lang="en-US">Short-term Debt, Type [Axis]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShortTermDebtTypeAxis" xlink:to="lab_us-gaap_ShortTermDebtTypeAxis" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShortTermDebtTypeDomain" xlink:label="loc_us-gaap_ShortTermDebtTypeDomain" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ShortTermDebtTypeDomain" xml:lang="en-US">Short-term Debt, Type [Domain]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_ShortTermDebtTypeDomain" xml:lang="en-US">Short-term Debt, Type [Domain]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShortTermDebtTypeDomain" xlink:to="lab_us-gaap_ShortTermDebtTypeDomain" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConvertibleNotesPayableMember" xlink:label="loc_us-gaap_ConvertibleNotesPayableMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ConvertibleNotesPayableMember" xml:lang="en-US">Convertible Notes Payable [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_ConvertibleNotesPayableMember" xml:lang="en-US">Convertible Notes Payable [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConvertibleNotesPayableMember" xlink:to="lab_us-gaap_ConvertibleNotesPayableMember" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsForRepurchaseOfEquityAbstract" xlink:label="loc_us-gaap_PaymentsForRepurchaseOfEquityAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_PaymentsForRepurchaseOfEquityAbstract" xml:lang="en-US">Payments for Repurchase of Equity [Abstract]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsForRepurchaseOfEquityAbstract" xlink:to="lab_us-gaap_PaymentsForRepurchaseOfEquityAbstract" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsForRepurchaseOfOtherEquity" xlink:label="loc_us-gaap_PaymentsForRepurchaseOfOtherEquity" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_PaymentsForRepurchaseOfOtherEquity" xml:lang="en-US">Payments for Repurchase of Other Equity</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_PaymentsForRepurchaseOfOtherEquity" xml:lang="en-US">Other equity instruments</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsForRepurchaseOfOtherEquity" xlink:to="lab_us-gaap_PaymentsForRepurchaseOfOtherEquity" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsForRepurchaseOfCommonStock" xlink:label="loc_us-gaap_PaymentsForRepurchaseOfCommonStock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_PaymentsForRepurchaseOfCommonStock" xml:lang="en-US">Payments for Repurchase of Common Stock</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_PaymentsForRepurchaseOfCommonStock" xml:lang="en-US">Common stock</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsForRepurchaseOfCommonStock" xlink:to="lab_us-gaap_PaymentsForRepurchaseOfCommonStock" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xml:lang="en-US">Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xml:lang="en-US">Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PlanNameAxis" xlink:label="loc_us-gaap_PlanNameAxis" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_PlanNameAxis" xml:lang="en-US">Plan Name [Axis]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_PlanNameAxis" xml:lang="en-US">Plan Name [Axis]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PlanNameAxis" xlink:to="lab_us-gaap_PlanNameAxis" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PlanNameDomain" xlink:label="loc_us-gaap_PlanNameDomain" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_PlanNameDomain" xml:lang="en-US">Plan Name [Domain]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_PlanNameDomain" xml:lang="en-US">Plan Name [Domain]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PlanNameDomain" xlink:to="lab_us-gaap_PlanNameDomain" />
<loc xlink:type="locator" xlink:href="roiv-20210630.xsd#roiv_PerformanceRestrictedStockUnitsPlanMember" xlink:label="loc_roiv_PerformanceRestrictedStockUnitsPlanMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_roiv_PerformanceRestrictedStockUnitsPlanMember" xml:lang="en-US">Performance Restricted Stock Units Plan [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_roiv_PerformanceRestrictedStockUnitsPlanMember" xml:lang="en-US">pRSU Plan [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_roiv_PerformanceRestrictedStockUnitsPlanMember" xlink:to="lab_roiv_PerformanceRestrictedStockUnitsPlanMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_roiv_PerformanceRestrictedStockUnitsPlanMember" xml:lang="en-US">Performance Restricted Stock Units Plan [Member]</label>
<loc xlink:type="locator" xlink:href="roiv-20210630.xsd#roiv_SubsidiaryEquityIncentivePlanMember" xlink:label="loc_roiv_SubsidiaryEquityIncentivePlanMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_roiv_SubsidiaryEquityIncentivePlanMember" xml:lang="en-US">Subsidiary Equity Incentive Plan [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_roiv_SubsidiaryEquityIncentivePlanMember" xml:lang="en-US">Subsidiary EIPs [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_roiv_SubsidiaryEquityIncentivePlanMember" xlink:to="lab_roiv_SubsidiaryEquityIncentivePlanMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_roiv_SubsidiaryEquityIncentivePlanMember" xml:lang="en-US">Subsidiary Equity Incentive Plan [Member]</label>
<loc xlink:type="locator" xlink:href="roiv-20210630.xsd#roiv_TwoThousandFifteenEquityIncentivePlanMember" xlink:label="loc_roiv_TwoThousandFifteenEquityIncentivePlanMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_roiv_TwoThousandFifteenEquityIncentivePlanMember" xml:lang="en-US">Two Thousand Fifteen Equity Incentive Plan [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_roiv_TwoThousandFifteenEquityIncentivePlanMember" xml:lang="en-US">2015 EIP [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_roiv_TwoThousandFifteenEquityIncentivePlanMember" xlink:to="lab_roiv_TwoThousandFifteenEquityIncentivePlanMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_roiv_TwoThousandFifteenEquityIncentivePlanMember" xml:lang="en-US">Two Thousand Fifteen Equity Incentive Plan [Member]</label>
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestrictedStockUnitsRSUMember" xlink:label="loc_us-gaap_RestrictedStockUnitsRSUMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_RestrictedStockUnitsRSUMember" xml:lang="en-US">Restricted Stock Units (RSUs) [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_RestrictedStockUnitsRSUMember" xml:lang="en-US">RSUs [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestrictedStockUnitsRSUMember" xlink:to="lab_us-gaap_RestrictedStockUnitsRSUMember" />
<loc xlink:type="locator" xlink:href="roiv-20210630.xsd#roiv_SpecialReserveMember" xlink:label="loc_roiv_SpecialReserveMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_roiv_SpecialReserveMember" xml:lang="en-US">Special Reserve [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_roiv_SpecialReserveMember" xml:lang="en-US">Special Reserve [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_roiv_SpecialReserveMember" xlink:to="lab_roiv_SpecialReserveMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_roiv_SpecialReserveMember" xml:lang="en-US">Special Reserve [Member]</label>
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="loc_us-gaap_EmployeeStockOptionMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_EmployeeStockOptionMember" xml:lang="en-US">Share-based Payment Arrangement, Option [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_EmployeeStockOptionMember" xml:lang="en-US">Stock Option [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeStockOptionMember" xlink:to="lab_us-gaap_EmployeeStockOptionMember" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AllocatedShareBasedCompensationExpense" xlink:label="loc_us-gaap_AllocatedShareBasedCompensationExpense" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_AllocatedShareBasedCompensationExpense" xml:lang="en-US">Share-based Payment Arrangement, Expense</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_AllocatedShareBasedCompensationExpense" xml:lang="en-US">Share-based compensation expense</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AllocatedShareBasedCompensationExpense" xlink:to="lab_us-gaap_AllocatedShareBasedCompensationExpense" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestrictedInvestmentsAtFairValue" xlink:label="loc_us-gaap_RestrictedInvestmentsAtFairValue" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_RestrictedInvestmentsAtFairValue" xml:lang="en-US">Restricted Investments, at Fair Value</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_RestrictedInvestmentsAtFairValue" xml:lang="en-US">Restricted common stock fair value</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestrictedInvestmentsAtFairValue" xlink:to="lab_us-gaap_RestrictedInvestmentsAtFairValue" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Period</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xml:lang="en-US">Grant vesting period</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:label="loc_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xml:lang="en-US">Common Stock, Capital Shares Reserved for Future Issuance</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xml:lang="en-US">Common shares reserved for future issuance</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:to="lab_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" xml:lang="en-US">Share-based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Amount</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" xml:lang="en-US">Unrecognized compensation expense</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" xlink:to="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xml:lang="en-US">Share-based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Period for Recognition</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xml:lang="en-US">Remaining weighted-average service period</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:to="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" />
<loc xlink:type="locator" xlink:href="roiv-20210630.xsd#roiv_SharebasedCompensationArrangementBySharebasedPaymentAwardAggregateRepurchasePrice" xlink:label="loc_roiv_SharebasedCompensationArrangementBySharebasedPaymentAwardAggregateRepurchasePrice" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_roiv_SharebasedCompensationArrangementBySharebasedPaymentAwardAggregateRepurchasePrice" xml:lang="en-US">Sharebased Compensation Arrangement By Sharebased Payment Award Aggregate Repurchase Price</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_roiv_SharebasedCompensationArrangementBySharebasedPaymentAwardAggregateRepurchasePrice" xml:lang="en-US">Equity repurchase</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_roiv_SharebasedCompensationArrangementBySharebasedPaymentAwardAggregateRepurchasePrice" xlink:to="lab_roiv_SharebasedCompensationArrangementBySharebasedPaymentAwardAggregateRepurchasePrice" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_roiv_SharebasedCompensationArrangementBySharebasedPaymentAwardAggregateRepurchasePrice" xml:lang="en-US">Sharebased Compensation Arrangement By Sharebased Payment Award Aggregate Repurchase Price</label>
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions" xml:lang="en-US">Share-based Payment Arrangement, Nonvested Award, Excluding Option, Cost Not yet Recognized, Amount</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions" xml:lang="en-US">Unrecognized compensation expense related to non-vested stock</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions" xlink:to="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" xml:lang="en-US">Share-based Payment Arrangement, Nonvested Award, Option, Cost Not yet Recognized, Amount</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" xml:lang="en-US">Unrecognized compensation expense related to non-vested stock</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" xlink:to="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" />
<loc xlink:type="locator" xlink:href="roiv-20210630.xsd#roiv_CommonSharesReservedForPerformanceOptionsAndCappedValueAppreciationRights" xlink:label="loc_roiv_CommonSharesReservedForPerformanceOptionsAndCappedValueAppreciationRights" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_roiv_CommonSharesReservedForPerformanceOptionsAndCappedValueAppreciationRights" xml:lang="en-US">Common Shares Reserved For Performance Options And Capped Value Appreciation Rights</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_roiv_CommonSharesReservedForPerformanceOptionsAndCappedValueAppreciationRights" xml:lang="en-US">Common shares reserved for performance options and capped value appreciation rights</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_roiv_CommonSharesReservedForPerformanceOptionsAndCappedValueAppreciationRights" xlink:to="lab_roiv_CommonSharesReservedForPerformanceOptionsAndCappedValueAppreciationRights" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_roiv_CommonSharesReservedForPerformanceOptionsAndCappedValueAppreciationRights" xml:lang="en-US">Common shares reserved for performance options and capped value appreciation rights.</label>
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardDescription" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardDescription" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardDescription" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Description</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardDescription" xml:lang="en-US">Grant, Description</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardDescription" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardDescription" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardExpirationDate" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardExpirationDate" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardExpirationDate" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Expiration Date</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardExpirationDate" xml:lang="en-US">Grant expiration date</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardExpirationDate" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardExpirationDate" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Expiration Period</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xml:lang="en-US">Grant expiration period</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Available for Grant</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xml:lang="en-US">Common shares available for grant</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Weighted Average Remaining Contractual Term</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xml:lang="en-US">Grant contractual term</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xml:lang="en-US">Weighted Average Remaining Contractual Life, exercisable</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested, Number of Shares</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares" xml:lang="en-US">Stock options vested</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares" />
<loc xlink:type="locator" xlink:href="roiv-20210630.xsd#roiv_ShareBasedCompensationRightToRepurchasePercentage" xlink:label="loc_roiv_ShareBasedCompensationRightToRepurchasePercentage" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_roiv_ShareBasedCompensationRightToRepurchasePercentage" xml:lang="en-US">Share Based Compensation Right To Repurchase Percentage</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_roiv_ShareBasedCompensationRightToRepurchasePercentage" xml:lang="en-US">Percentage of share repurchased</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_roiv_ShareBasedCompensationRightToRepurchasePercentage" xlink:to="lab_roiv_ShareBasedCompensationRightToRepurchasePercentage" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_roiv_ShareBasedCompensationRightToRepurchasePercentage" xml:lang="en-US">Share based compensation right to repurchase percentage.</label>
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Dividend Rate</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xml:lang="en-US">Expected dividend yield</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Term</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xml:lang="en-US">Expected term</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xml:lang="en-US">Expected risk free interest rate</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Weighted Average Volatility Rate</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate" xml:lang="en-US">Expected stock price volatility</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Number</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xml:lang="en-US">Stock options exercisable</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" />
<loc xlink:type="locator" xlink:href="roiv-20210630.xsd#roiv_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExcercisableWeightedAverageGrantDateFairValue" xlink:label="loc_roiv_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExcercisableWeightedAverageGrantDateFairValue" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_roiv_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExcercisableWeightedAverageGrantDateFairValue" xml:lang="en-US">Share Based Compensation Arrangement by Share Based Payment Award Options Excercisable Weighted Average Grant Date Fair Value</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_roiv_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExcercisableWeightedAverageGrantDateFairValue" xml:lang="en-US">Weighted Average Grant Date Fair Value, exercisable</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_roiv_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExcercisableWeightedAverageGrantDateFairValue" xlink:to="lab_roiv_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExcercisableWeightedAverageGrantDateFairValue" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_roiv_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExcercisableWeightedAverageGrantDateFairValue" xml:lang="en-US">Share Based Compensation Arrangement by Share Based Payment Award Options Excercisable Weighted Average Grant Date Fair Value.</label>
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Remaining Contractual Term</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xml:lang="en-US">Weighted Average Remaining Contractual Life</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xml:lang="en-US">Performance Options outstanding at March 31, 2020</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" />
<loc xlink:type="locator" xlink:href="roiv-20210630.xsd#roiv_ShareBasedCompensationArrangementByShareBasedPaymentAwardWeightedAverageGrantDateFairValue" xlink:label="loc_roiv_ShareBasedCompensationArrangementByShareBasedPaymentAwardWeightedAverageGrantDateFairValue" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_roiv_ShareBasedCompensationArrangementByShareBasedPaymentAwardWeightedAverageGrantDateFairValue" xml:lang="en-US">Share Based Compensation Arrangement By Share Based Payment Award, Weighted Average Grant Date Fair Value</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="lab_roiv_ShareBasedCompensationArrangementByShareBasedPaymentAwardWeightedAverageGrantDateFairValue" xml:lang="en-US">Weighted Average Grant Date Fair Value, Beginning balance</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="lab_roiv_ShareBasedCompensationArrangementByShareBasedPaymentAwardWeightedAverageGrantDateFairValue" xml:lang="en-US">Weighted Average Grant Date Fair Value, Ending balance</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_roiv_ShareBasedCompensationArrangementByShareBasedPaymentAwardWeightedAverageGrantDateFairValue" xlink:to="lab_roiv_ShareBasedCompensationArrangementByShareBasedPaymentAwardWeightedAverageGrantDateFairValue" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_roiv_ShareBasedCompensationArrangementByShareBasedPaymentAwardWeightedAverageGrantDateFairValue" xml:lang="en-US">Share Based Compensation Arrangement By Share Based Payment Award, Weighted Average Grant Date Fair Value</label>
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xml:lang="en-US">Share-based Compensation Arrangements by Share-based Payment Award, Options, Forfeitures in Period, Weighted Average Exercise Price</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xml:lang="en-US">Weighted average exercise price,Forfeited/Canceled</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xml:lang="en-US">Weighted average exercise price, Forfeited</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xml:lang="en-US">Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xml:lang="en-US">Weighted average exercise price, Granted</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures in Period</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xml:lang="en-US">Options Forfeited/Canceled</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xml:lang="en-US">Options Forfeited</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xml:lang="en-US">Options Granted</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xml:lang="en-US">Weighted average grant date fair value, Granted</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/positiveLabel" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xml:lang="en-US">Weighted Average Grant Date Fair Value,Granted</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xml:lang="en-US">Units Granted</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedWeightedAverageGrantDateFairValue" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedWeightedAverageGrantDateFairValue" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedWeightedAverageGrantDateFairValue" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Nonvested Options Forfeited, Weighted Average Grant Date Fair Value</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/positiveLabel" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedWeightedAverageGrantDateFairValue" xml:lang="en-US">Weighted Average Grant Date Fair Value, Granted</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/positiveTerseLabel" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedWeightedAverageGrantDateFairValue" xml:lang="en-US">Weighted Average Grant Date Fair Value,Forfeited</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedWeightedAverageGrantDateFairValue" xml:lang="en-US">Weighted average grant date fair value, forfeited</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedWeightedAverageGrantDateFairValue" xml:lang="en-US">Units Forfeited</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedWeightedAverageGrantDateFairValue" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedWeightedAverageGrantDateFairValue" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Number</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xml:lang="en-US">Stock options outstanding ,Beginning balance</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xml:lang="en-US">Stock options outstanding , Ending balance</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xml:lang="en-US">Weighted average exercise price, Beginning balance</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xml:lang="en-US">Weighted average exercise price, Ending balance</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Weighted Average Exercise Price</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xml:lang="en-US">Weighted average exercise price, exercisable</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested, Weighted Average Grant Date Fair Value</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue" xml:lang="en-US">Weighted-average grant date fair value per share of stock options granted</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested in Period, Fair Value</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1" xml:lang="en-US">Grant date fair value of stock options vested</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1" xml:lang="en-US">Fair value of options</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Forfeited in Period</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xml:lang="en-US">Forfeited</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xml:lang="en-US">Units Forfeited</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xml:lang="en-US">Granted</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xml:lang="en-US">Units Granted</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Number</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xml:lang="en-US">Non-vested balance, beginning</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xml:lang="en-US">Non-vested balance, ending</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Option, Nonvested, Weighted Average Exercise Price</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue" xml:lang="en-US">Non-vested units, Beginning balance</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue" xml:lang="en-US">Non-vested units , Ending balance</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue" />
<loc xlink:type="locator" xlink:href="roiv-20210630.xsd#roiv_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeitedInPeriodWeightedAverageGrantDateFairValue" xlink:label="loc_roiv_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeitedInPeriodWeightedAverageGrantDateFairValue" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_roiv_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeitedInPeriodWeightedAverageGrantDateFairValue" xml:lang="en-US">Share Based Compensation Arrangement By Share Based Payment Award Options Forfeited In Period Weighted Average Grant Date Fair Value</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_roiv_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeitedInPeriodWeightedAverageGrantDateFairValue" xml:lang="en-US">Weighted average grant date fair value, Forfeited</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_roiv_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeitedInPeriodWeightedAverageGrantDateFairValue" xlink:to="lab_roiv_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeitedInPeriodWeightedAverageGrantDateFairValue" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_roiv_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeitedInPeriodWeightedAverageGrantDateFairValue" xml:lang="en-US">Share Based Compensation Arrangement By Share Based Payment Award Options Forfeited In Period Weighted Average Grant Date Fair Value</label>
<loc xlink:type="locator" xlink:href="roiv-20210630.xsd#roiv_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageGrantDateFairValue" xlink:label="loc_roiv_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageGrantDateFairValue" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_roiv_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageGrantDateFairValue" xml:lang="en-US">Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Grant Date Fair Value</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="lab_roiv_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageGrantDateFairValue" xml:lang="en-US">Weighted average grant date fair value, Beginning balance</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="lab_roiv_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageGrantDateFairValue" xml:lang="en-US">Weighted average grant date fair value, Ending balance</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_roiv_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageGrantDateFairValue" xlink:to="lab_roiv_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageGrantDateFairValue" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_roiv_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageGrantDateFairValue" xml:lang="en-US">Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Grant Date Fair Value</label>
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xml:lang="en-US">Weighted Average Grant Date Fair Value, Ending Balance</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Vested in Period, Weighted Average Grant Date Fair Value</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" xml:lang="en-US">Weighted Average Grant Date Fair Value, vested</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Forfeitures, Weighted Average Grant Date Fair Value</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" xml:lang="en-US">Weighted Average Grant Date Fair Value, Forfeited</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period, Weighted Average Grant Date Fair Value</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xml:lang="en-US">Weighted Average Grant Date Fair Value, vested</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GeneralAndAdministrativeExpenseMember" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpenseMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_GeneralAndAdministrativeExpenseMember" xml:lang="en-US">General and Administrative Expense [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_GeneralAndAdministrativeExpenseMember" xml:lang="en-US">G&amp;A Expenses [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GeneralAndAdministrativeExpenseMember" xlink:to="lab_us-gaap_GeneralAndAdministrativeExpenseMember" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DiscontinuedOperationIncomeLossFromDiscontinuedOperationDuringPhaseOutPeriodBeforeIncomeTax" xlink:label="loc_us-gaap_DiscontinuedOperationIncomeLossFromDiscontinuedOperationDuringPhaseOutPeriodBeforeIncomeTax" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_DiscontinuedOperationIncomeLossFromDiscontinuedOperationDuringPhaseOutPeriodBeforeIncomeTax" xml:lang="en-US">Discontinued Operation, Income (Loss) from Discontinued Operation During Phase-out Period, before Income Tax</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_DiscontinuedOperationIncomeLossFromDiscontinuedOperationDuringPhaseOutPeriodBeforeIncomeTax" xml:lang="en-US">Income from discontinued operations before income taxes</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DiscontinuedOperationIncomeLossFromDiscontinuedOperationDuringPhaseOutPeriodBeforeIncomeTax" xlink:to="lab_us-gaap_DiscontinuedOperationIncomeLossFromDiscontinuedOperationDuringPhaseOutPeriodBeforeIncomeTax" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DiscontinuedOperationIncomeLossFromDiscontinuedOperationDuringPhaseOutPeriodBeforeIncomeTaxAttributableToNoncontrollingInterest" xlink:label="loc_us-gaap_DiscontinuedOperationIncomeLossFromDiscontinuedOperationDuringPhaseOutPeriodBeforeIncomeTaxAttributableToNoncontrollingInterest" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_DiscontinuedOperationIncomeLossFromDiscontinuedOperationDuringPhaseOutPeriodBeforeIncomeTaxAttributableToNoncontrollingInterest" xml:lang="en-US">Discontinued Operation, Income (Loss) from Discontinued Operation During Phase-out Period, before Income Tax, Attributable to Noncontrolling Interest</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_DiscontinuedOperationIncomeLossFromDiscontinuedOperationDuringPhaseOutPeriodBeforeIncomeTaxAttributableToNoncontrollingInterest" xml:lang="en-US">Loss from discontinued operations before income taxes attributable to noncontrolling interests</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DiscontinuedOperationIncomeLossFromDiscontinuedOperationDuringPhaseOutPeriodBeforeIncomeTaxAttributableToNoncontrollingInterest" xlink:to="lab_us-gaap_DiscontinuedOperationIncomeLossFromDiscontinuedOperationDuringPhaseOutPeriodBeforeIncomeTaxAttributableToNoncontrollingInterest" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DiscontinuedOperationIncomeLossFromDiscontinuedOperationDuringPhaseOutPeriodBeforeIncomeTaxAttributableToParent" xlink:label="loc_us-gaap_DiscontinuedOperationIncomeLossFromDiscontinuedOperationDuringPhaseOutPeriodBeforeIncomeTaxAttributableToParent" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_DiscontinuedOperationIncomeLossFromDiscontinuedOperationDuringPhaseOutPeriodBeforeIncomeTaxAttributableToParent" xml:lang="en-US">Discontinued Operation, Income (Loss) from Discontinued Operation During Phase-out Period, before Income Tax, Attributable to Parent</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_DiscontinuedOperationIncomeLossFromDiscontinuedOperationDuringPhaseOutPeriodBeforeIncomeTaxAttributableToParent" xml:lang="en-US">Income from discontinued operations before income taxes attributable to Roivant Sciences Ltd.</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DiscontinuedOperationIncomeLossFromDiscontinuedOperationDuringPhaseOutPeriodBeforeIncomeTaxAttributableToParent" xlink:to="lab_us-gaap_DiscontinuedOperationIncomeLossFromDiscontinuedOperationDuringPhaseOutPeriodBeforeIncomeTaxAttributableToParent" />
<loc xlink:type="locator" xlink:href="roiv-20210630.xsd#roiv_DisposalGroupIncludingDiscontinuedOperationOperatingExpenseAbstract" xlink:label="loc_roiv_DisposalGroupIncludingDiscontinuedOperationOperatingExpenseAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_roiv_DisposalGroupIncludingDiscontinuedOperationOperatingExpenseAbstract" xml:lang="en-US">Disposal Group, Including Discontinued Operation, Operating Expense [Abstract]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_roiv_DisposalGroupIncludingDiscontinuedOperationOperatingExpenseAbstract" xml:lang="en-US">Operating expenses:</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_roiv_DisposalGroupIncludingDiscontinuedOperationOperatingExpenseAbstract" xlink:to="lab_roiv_DisposalGroupIncludingDiscontinuedOperationOperatingExpenseAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_roiv_DisposalGroupIncludingDiscontinuedOperationOperatingExpenseAbstract" xml:lang="en-US">Disposal Group, Including Discontinued Operation, Operating Expense [Abstract]</label>
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DiscontinuedOperationTaxEffectOfDiscontinuedOperation" xlink:label="loc_us-gaap_DiscontinuedOperationTaxEffectOfDiscontinuedOperation" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_DiscontinuedOperationTaxEffectOfDiscontinuedOperation" xml:lang="en-US">Discontinued Operation, Tax Effect of Discontinued Operation</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_DiscontinuedOperationTaxEffectOfDiscontinuedOperation" xml:lang="en-US">Income tax expense</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DiscontinuedOperationTaxEffectOfDiscontinuedOperation" xlink:to="lab_us-gaap_DiscontinuedOperationTaxEffectOfDiscontinuedOperation" />
<loc xlink:type="locator" xlink:href="roiv-20210630.xsd#roiv_DisposalGroupIncludingDiscontinuedOperationGainLossOnSaleOfBusiness" xlink:label="loc_roiv_DisposalGroupIncludingDiscontinuedOperationGainLossOnSaleOfBusiness" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_roiv_DisposalGroupIncludingDiscontinuedOperationGainLossOnSaleOfBusiness" xml:lang="en-US">Disposal Group, Including Discontinued Operation, Gain (Loss) on Sale of Business</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="lab_roiv_DisposalGroupIncludingDiscontinuedOperationGainLossOnSaleOfBusiness" xml:lang="en-US">Gain on sale of business</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_roiv_DisposalGroupIncludingDiscontinuedOperationGainLossOnSaleOfBusiness" xlink:to="lab_roiv_DisposalGroupIncludingDiscontinuedOperationGainLossOnSaleOfBusiness" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_roiv_DisposalGroupIncludingDiscontinuedOperationGainLossOnSaleOfBusiness" xml:lang="en-US">Disposal Group, Including Discontinued Operation, Gain (Loss) on Sale of Business</label>
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationGeneralAndAdministrativeExpense" xlink:label="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationGeneralAndAdministrativeExpense" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationGeneralAndAdministrativeExpense" xml:lang="en-US">Disposal Group, Including Discontinued Operation, General and Administrative Expense</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationGeneralAndAdministrativeExpense" xml:lang="en-US">General and administrative</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationGeneralAndAdministrativeExpense" xlink:to="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationGeneralAndAdministrativeExpense" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationInterestExpense" xlink:label="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationInterestExpense" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationInterestExpense" xml:lang="en-US">Disposal Group, Including Discontinued Operation, Interest Expense</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationInterestExpense" xml:lang="en-US">Interest expense(1)</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationInterestExpense" xlink:to="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationInterestExpense" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationInterestIncome" xlink:label="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationInterestIncome" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationInterestIncome" xml:lang="en-US">Disposal Group, Including Discontinued Operation, Interest Income</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationInterestIncome" xml:lang="en-US">Interest income</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationInterestIncome" xlink:to="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationInterestIncome" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationOperatingExpense" xlink:label="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationOperatingExpense" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationOperatingExpense" xml:lang="en-US">Disposal Group, Including Discontinued Operation, Operating Expense</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationOperatingExpense" xml:lang="en-US">Total operating expenses</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationOperatingExpense" xlink:to="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationOperatingExpense" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationOperatingIncomeLoss" xlink:label="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationOperatingIncomeLoss" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationOperatingIncomeLoss" xml:lang="en-US">Disposal Group, Including Discontinued Operation, Operating Income (Loss)</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationOperatingIncomeLoss" xml:lang="en-US">Loss from operations</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationOperatingIncomeLoss" xlink:to="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationOperatingIncomeLoss" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationOtherExpense" xlink:label="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationOtherExpense" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationOtherExpense" xml:lang="en-US">Disposal Group, Including Discontinued Operation, Other Expense</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationOtherExpense" xml:lang="en-US">Other expense</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationOtherExpense" xlink:to="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationOtherExpense" />
<loc xlink:type="locator" xlink:href="roiv-20210630.xsd#roiv_DisposalGroupIncludingDiscontinuedOperationResearchAndDevelopmentExpense" xlink:label="loc_roiv_DisposalGroupIncludingDiscontinuedOperationResearchAndDevelopmentExpense" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_roiv_DisposalGroupIncludingDiscontinuedOperationResearchAndDevelopmentExpense" xml:lang="en-US">Disposal Group Including Discontinued Operation Research And Development Expense</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_roiv_DisposalGroupIncludingDiscontinuedOperationResearchAndDevelopmentExpense" xml:lang="en-US">Research and development</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_roiv_DisposalGroupIncludingDiscontinuedOperationResearchAndDevelopmentExpense" xlink:to="lab_roiv_DisposalGroupIncludingDiscontinuedOperationResearchAndDevelopmentExpense" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_roiv_DisposalGroupIncludingDiscontinuedOperationResearchAndDevelopmentExpense" xml:lang="en-US">Disposal Group Including Discontinued Operation Research And Development Expense</label>
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DiscontinuedOperationIncomeLossFromDiscontinuedOperationBeforeIncomeTax" xlink:label="loc_us-gaap_DiscontinuedOperationIncomeLossFromDiscontinuedOperationBeforeIncomeTax" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_DiscontinuedOperationIncomeLossFromDiscontinuedOperationBeforeIncomeTax" xml:lang="en-US">Discontinued Operation, Income (Loss) from Discontinued Operation, before Income Tax</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_us-gaap_DiscontinuedOperationIncomeLossFromDiscontinuedOperationBeforeIncomeTax" xml:lang="en-US">Income from discontinued operations before income taxes</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DiscontinuedOperationIncomeLossFromDiscontinuedOperationBeforeIncomeTax" xlink:to="lab_us-gaap_DiscontinuedOperationIncomeLossFromDiscontinuedOperationBeforeIncomeTax" />
<loc xlink:type="locator" xlink:href="roiv-20210630.xsd#roiv_DisposalGroupIncludingDiscontinuedOperationResearchAndDevelopmentInProcess" xlink:label="loc_roiv_DisposalGroupIncludingDiscontinuedOperationResearchAndDevelopmentInProcess" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_roiv_DisposalGroupIncludingDiscontinuedOperationResearchAndDevelopmentInProcess" xml:lang="en-US">Disposal Group Including Discontinued Operation Research and Development In Process</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_roiv_DisposalGroupIncludingDiscontinuedOperationResearchAndDevelopmentInProcess" xml:lang="en-US">Acquired in-processresearch and development</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_roiv_DisposalGroupIncludingDiscontinuedOperationResearchAndDevelopmentInProcess" xlink:to="lab_roiv_DisposalGroupIncludingDiscontinuedOperationResearchAndDevelopmentInProcess" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_roiv_DisposalGroupIncludingDiscontinuedOperationResearchAndDevelopmentInProcess" xml:lang="en-US">Disposal group including discontinued operation research and development in process.</label>
<loc xlink:type="locator" xlink:href="roiv-20210630.xsd#roiv_DisposalGroupIncludingDiscontinuedOperationShareBasedCompensation" xlink:label="loc_roiv_DisposalGroupIncludingDiscontinuedOperationShareBasedCompensation" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_roiv_DisposalGroupIncludingDiscontinuedOperationShareBasedCompensation" xml:lang="en-US">Disposal Group Including Discontinued Operation Share Based Compensation</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_roiv_DisposalGroupIncludingDiscontinuedOperationShareBasedCompensation" xml:lang="en-US">Share-based compensation</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_roiv_DisposalGroupIncludingDiscontinuedOperationShareBasedCompensation" xlink:to="lab_roiv_DisposalGroupIncludingDiscontinuedOperationShareBasedCompensation" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_roiv_DisposalGroupIncludingDiscontinuedOperationShareBasedCompensation" xml:lang="en-US">Disposal group including discontinued operation share based compensation.</label>
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:label="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xml:lang="en-US">Schedule of Related Party Transactions, by Related Party [Table]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xml:lang="en-US">Schedule of Related Party Transactions, by Related Party [Table]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:to="lab_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RelatedPartyTransactionLineItems" xlink:label="loc_us-gaap_RelatedPartyTransactionLineItems" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_RelatedPartyTransactionLineItems" xml:lang="en-US">Related Party Transaction [Line Items]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_RelatedPartyTransactionLineItems" xml:lang="en-US">Related Party Transaction [Line Items]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems" xlink:to="lab_us-gaap_RelatedPartyTransactionLineItems" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CostsAndExpensesRelatedParty" xlink:label="loc_us-gaap_CostsAndExpensesRelatedParty" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_CostsAndExpensesRelatedParty" xml:lang="en-US">Costs and Expenses, Related Party</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_CostsAndExpensesRelatedParty" xml:lang="en-US">Cost incurred and recorded as offsets to general and administrative expenses</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CostsAndExpensesRelatedParty" xlink:to="lab_us-gaap_CostsAndExpensesRelatedParty" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RelatedPartyTransactionAmountsOfTransaction" xlink:label="loc_us-gaap_RelatedPartyTransactionAmountsOfTransaction" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_RelatedPartyTransactionAmountsOfTransaction" xml:lang="en-US">Related Party Transaction, Amounts of Transaction</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_RelatedPartyTransactionAmountsOfTransaction" xml:lang="en-US">Access fee paid pursuant to strategic cooperation agreement</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RelatedPartyTransactionAmountsOfTransaction" xlink:to="lab_us-gaap_RelatedPartyTransactionAmountsOfTransaction" />
<loc xlink:type="locator" xlink:href="roiv-20210630.xsd#roiv_SumitovantMember" xlink:label="loc_roiv_SumitovantMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_roiv_SumitovantMember" xml:lang="en-US">Sumitovant [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_roiv_SumitovantMember" xml:lang="en-US">Sumitovant [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_roiv_SumitovantMember" xlink:to="lab_roiv_SumitovantMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_roiv_SumitovantMember" xml:lang="en-US">Sumitovant.</label>
<loc xlink:type="locator" xlink:href="roiv-20210630.xsd#roiv_IncomeTaxDisclosureTable" xlink:label="loc_roiv_IncomeTaxDisclosureTable" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_roiv_IncomeTaxDisclosureTable" xml:lang="en-US">Income Tax Disclosure [Table]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_roiv_IncomeTaxDisclosureTable" xml:lang="en-US">Income Tax Disclosure [Table]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_roiv_IncomeTaxDisclosureTable" xlink:to="lab_roiv_IncomeTaxDisclosureTable" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_roiv_IncomeTaxDisclosureTable" xml:lang="en-US">Income Tax Disclosure [Table]</label>
<loc xlink:type="locator" xlink:href="roiv-20210630.xsd#roiv_IncomeTaxDisclosureLineItems" xlink:label="loc_roiv_IncomeTaxDisclosureLineItems" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_roiv_IncomeTaxDisclosureLineItems" xml:lang="en-US">Income Tax Disclosure [Line Items]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_roiv_IncomeTaxDisclosureLineItems" xml:lang="en-US">Income Tax Disclosure [Line Items]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_roiv_IncomeTaxDisclosureLineItems" xlink:to="lab_roiv_IncomeTaxDisclosureLineItems" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_roiv_IncomeTaxDisclosureLineItems" xml:lang="en-US">Income Tax Disclosure [Line Items]</label>
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestmentsAbstract" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestmentsAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestmentsAbstract" xml:lang="en-US">Income (Loss) from Continuing Operations before Equity Method Investments, Income Taxes, Noncontrolling Interest [Abstract]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestmentsAbstract" xml:lang="en-US">Loss before income taxes:</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestmentsAbstract" xlink:to="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestmentsAbstract" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_StatementGeographicalAxis" xlink:label="loc_srt_StatementGeographicalAxis" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_srt_StatementGeographicalAxis" xml:lang="en-US">Geographical [Axis]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_srt_StatementGeographicalAxis" xml:lang="en-US">Geographical [Axis]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_StatementGeographicalAxis" xlink:to="lab_srt_StatementGeographicalAxis" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_SegmentGeographicalDomain" xlink:label="loc_srt_SegmentGeographicalDomain" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_srt_SegmentGeographicalDomain" xml:lang="en-US">Geographical [Domain]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_srt_SegmentGeographicalDomain" xml:lang="en-US">Geographical [Domain]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_SegmentGeographicalDomain" xlink:to="lab_srt_SegmentGeographicalDomain" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/country/2021/country-2021.xsd#country_BM" xlink:label="loc_country_BM" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_country_BM" xml:lang="en-US">BERMUDA</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_country_BM" xml:lang="en-US">Bermuda [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_country_BM" xlink:to="lab_country_BM" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/country/2021/country-2021.xsd#country_CH" xlink:label="loc_country_CH" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_country_CH" xml:lang="en-US">SWITZERLAND</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_country_CH" xml:lang="en-US">Switzerland [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_country_CH" xlink:to="lab_country_CH" />
<loc xlink:type="locator" xlink:href="roiv-20210630.xsd#roiv_OtherMember" xlink:label="loc_roiv_OtherMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_roiv_OtherMember" xml:lang="en-US">Other [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_roiv_OtherMember" xml:lang="en-US">Other [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_roiv_OtherMember" xlink:to="lab_roiv_OtherMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_roiv_OtherMember" xml:lang="en-US">Other [Member]</label>
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/country/2021/country-2021.xsd#country_US" xlink:label="loc_country_US" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_country_US" xml:lang="en-US">UNITED STATES</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_country_US" xml:lang="en-US">United States [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_country_US" xlink:to="lab_country_US" />
<loc xlink:type="locator" xlink:href="roiv-20210630.xsd#roiv_ComponentsOfIncomeTaxExpenseTable" xlink:label="loc_roiv_ComponentsOfIncomeTaxExpenseTable" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_roiv_ComponentsOfIncomeTaxExpenseTable" xml:lang="en-US">Components Of Income Tax Expense [Table]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_roiv_ComponentsOfIncomeTaxExpenseTable" xml:lang="en-US">Components Of Income Tax Expense [Table]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_roiv_ComponentsOfIncomeTaxExpenseTable" xlink:to="lab_roiv_ComponentsOfIncomeTaxExpenseTable" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_roiv_ComponentsOfIncomeTaxExpenseTable" xml:lang="en-US">Components Of Income Tax Expense [Table]</label>
<loc xlink:type="locator" xlink:href="roiv-20210630.xsd#roiv_ComponentsOfIncomeTaxExpenseLineItems" xlink:label="loc_roiv_ComponentsOfIncomeTaxExpenseLineItems" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_roiv_ComponentsOfIncomeTaxExpenseLineItems" xml:lang="en-US">Components Of Income Tax Expense [Line Items]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_roiv_ComponentsOfIncomeTaxExpenseLineItems" xml:lang="en-US">Components Of Income Tax Expense [Line Items]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_roiv_ComponentsOfIncomeTaxExpenseLineItems" xlink:to="lab_roiv_ComponentsOfIncomeTaxExpenseLineItems" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_roiv_ComponentsOfIncomeTaxExpenseLineItems" xml:lang="en-US">Components Of Income Tax Expense [Line Items]</label>
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract" xlink:label="loc_us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract" xml:lang="en-US">Current Income Tax Expense (Benefit), Continuing Operations [Abstract]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract" xml:lang="en-US">Current taxes:</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract" xlink:to="lab_us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CurrentIncomeTaxExpenseBenefit" xlink:label="loc_us-gaap_CurrentIncomeTaxExpenseBenefit" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_CurrentIncomeTaxExpenseBenefit" xml:lang="en-US">Current Income Tax Expense (Benefit)</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_CurrentIncomeTaxExpenseBenefit" xml:lang="en-US">Total current tax expense</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CurrentIncomeTaxExpenseBenefit" xlink:to="lab_us-gaap_CurrentIncomeTaxExpenseBenefit" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract" xlink:label="loc_us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract" xml:lang="en-US">Deferred Income Tax Expense (Benefit), Continuing Operations [Abstract]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract" xml:lang="en-US">Deferred taxes:</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract" xlink:to="lab_us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredIncomeTaxExpenseBenefit" xlink:label="loc_us-gaap_DeferredIncomeTaxExpenseBenefit" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_DeferredIncomeTaxExpenseBenefit" xml:lang="en-US">Deferred Income Tax Expense (Benefit)</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_DeferredIncomeTaxExpenseBenefit" xml:lang="en-US">Total deferred tax benefit</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredIncomeTaxExpenseBenefit" xlink:to="lab_us-gaap_DeferredIncomeTaxExpenseBenefit" />
<loc xlink:type="locator" xlink:href="roiv-20210630.xsd#roiv_TaxAuthorityInOtherJurisdictionsMember" xlink:label="loc_roiv_TaxAuthorityInOtherJurisdictionsMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_roiv_TaxAuthorityInOtherJurisdictionsMember" xml:lang="en-US">Tax Authority In Other Jurisdictions [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_roiv_TaxAuthorityInOtherJurisdictionsMember" xml:lang="en-US">Other Jurisdictions [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_roiv_TaxAuthorityInOtherJurisdictionsMember" xlink:to="lab_roiv_TaxAuthorityInOtherJurisdictionsMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_roiv_TaxAuthorityInOtherJurisdictionsMember" xml:lang="en-US">Tax Authority In Other Jurisdictions [Member]</label>
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/country/2021/country-2021.xsd#country_GB" xlink:label="loc_country_GB" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_country_GB" xml:lang="en-US">UNITED KINGDOM</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_country_GB" xml:lang="en-US">United Kingdom [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_country_GB" xlink:to="lab_country_GB" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLossCarryforwards" xlink:label="loc_us-gaap_OperatingLossCarryforwards" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_OperatingLossCarryforwards" xml:lang="en-US">Operating Loss Carryforwards</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_OperatingLossCarryforwards" xml:lang="en-US">Net operating losses</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLossCarryforwards" xlink:to="lab_us-gaap_OperatingLossCarryforwards" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLossCarryforwardsExpirationDate" xlink:label="loc_us-gaap_OperatingLossCarryforwardsExpirationDate" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_OperatingLossCarryforwardsExpirationDate" xml:lang="en-US">Operating Loss Carryforwards, Expiration Date</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_OperatingLossCarryforwardsExpirationDate" xml:lang="en-US">Net operating losses expiration date</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLossCarryforwardsExpirationDate" xlink:to="lab_us-gaap_OperatingLossCarryforwardsExpirationDate" />
<loc xlink:type="locator" xlink:href="roiv-20210630.xsd#roiv_PercentageOfFutureTaxableIncome" xlink:label="loc_roiv_PercentageOfFutureTaxableIncome" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_roiv_PercentageOfFutureTaxableIncome" xml:lang="en-US">Percentage Of Future Taxable Income</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_roiv_PercentageOfFutureTaxableIncome" xml:lang="en-US">Percentage of future taxable income</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_roiv_PercentageOfFutureTaxableIncome" xlink:to="lab_roiv_PercentageOfFutureTaxableIncome" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_roiv_PercentageOfFutureTaxableIncome" xml:lang="en-US">Percentage of future taxable income.</label>
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TaxCreditCarryforwardAmount" xlink:label="loc_us-gaap_TaxCreditCarryforwardAmount" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_TaxCreditCarryforwardAmount" xml:lang="en-US">Tax Credit Carryforward, Amount</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_TaxCreditCarryforwardAmount" xml:lang="en-US">Research and development tax credit carryforwards</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TaxCreditCarryforwardAmount" xlink:to="lab_us-gaap_TaxCreditCarryforwardAmount" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TaxCreditCarryforwardExpirationDate" xlink:label="loc_us-gaap_TaxCreditCarryforwardExpirationDate" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_TaxCreditCarryforwardExpirationDate" xml:lang="en-US">Tax Credit Carryforward, Expiration Date</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_TaxCreditCarryforwardExpirationDate" xml:lang="en-US">Research and development tax credit expiration date</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TaxCreditCarryforwardExpirationDate" xlink:to="lab_us-gaap_TaxCreditCarryforwardExpirationDate" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_UnrecognizedTaxBenefits" xlink:label="loc_us-gaap_UnrecognizedTaxBenefits" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_UnrecognizedTaxBenefits" xml:lang="en-US">Unrecognized Tax Benefits</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_UnrecognizedTaxBenefits" xml:lang="en-US">Unrecognized tax benefits</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_UnrecognizedTaxBenefits" xlink:to="lab_us-gaap_UnrecognizedTaxBenefits" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount" xlink:label="loc_us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount" xml:lang="en-US">Valuation Allowance, Deferred Tax Asset, Increase (Decrease), Amount</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount" xml:lang="en-US">Valuation allowance increase (decrease)</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount" xlink:to="lab_us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsValuationAllowance" xlink:label="loc_us-gaap_DeferredTaxAssetsValuationAllowance" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_DeferredTaxAssetsValuationAllowance" xml:lang="en-US">Deferred Tax Assets, Valuation Allowance</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_DeferredTaxAssetsValuationAllowance" xml:lang="en-US">Valuation allowance</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="lab_us-gaap_DeferredTaxAssetsValuationAllowance" xml:lang="en-US">Valuation allowance</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsValuationAllowance" xlink:to="lab_us-gaap_DeferredTaxAssetsValuationAllowance" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateContinuingOperations" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Percent</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateContinuingOperations" xml:lang="en-US">Effective tax rate</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateContinuingOperations" xml:lang="en-US">Total income tax expense</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:to="lab_us-gaap_EffectiveIncomeTaxRateContinuingOperations" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxAuthorityAxis" xlink:label="loc_us-gaap_IncomeTaxAuthorityAxis" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_IncomeTaxAuthorityAxis" xml:lang="en-US">Income Tax Authority [Axis]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_IncomeTaxAuthorityAxis" xml:lang="en-US">Income Tax Authority [Axis]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxAuthorityAxis" xlink:to="lab_us-gaap_IncomeTaxAuthorityAxis" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxAuthorityDomain" xlink:label="loc_us-gaap_IncomeTaxAuthorityDomain" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_IncomeTaxAuthorityDomain" xml:lang="en-US">Income Tax Authority [Domain]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_IncomeTaxAuthorityDomain" xml:lang="en-US">Income Tax Authority [Domain]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxAuthorityDomain" xlink:to="lab_us-gaap_IncomeTaxAuthorityDomain" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StateAndLocalJurisdictionMember" xlink:label="loc_us-gaap_StateAndLocalJurisdictionMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_StateAndLocalJurisdictionMember" xml:lang="en-US">State and Local Jurisdiction [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_StateAndLocalJurisdictionMember" xml:lang="en-US">United States and Local Jurisdiction [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StateAndLocalJurisdictionMember" xlink:to="lab_us-gaap_StateAndLocalJurisdictionMember" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MinimumMember" xlink:label="loc_srt_MinimumMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_srt_MinimumMember" xml:lang="en-US">Minimum [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_srt_MinimumMember" xml:lang="en-US">Minimum</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_MinimumMember" xlink:to="lab_srt_MinimumMember" />
<loc xlink:type="locator" xlink:href="roiv-20210630.xsd#roiv_DeferredTaxAssetsLiabilitiesTable" xlink:label="loc_roiv_DeferredTaxAssetsLiabilitiesTable" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_roiv_DeferredTaxAssetsLiabilitiesTable" xml:lang="en-US">Deferred Tax Assets Liabilities [Table]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_roiv_DeferredTaxAssetsLiabilitiesTable" xml:lang="en-US">Deferred Tax Assets Liabilities [Table]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_roiv_DeferredTaxAssetsLiabilitiesTable" xlink:to="lab_roiv_DeferredTaxAssetsLiabilitiesTable" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_roiv_DeferredTaxAssetsLiabilitiesTable" xml:lang="en-US">Deferred Tax Assets Liabilities [Table]</label>
<loc xlink:type="locator" xlink:href="roiv-20210630.xsd#roiv_DeferredTaxAssetsLiabilitiesLineItems" xlink:label="loc_roiv_DeferredTaxAssetsLiabilitiesLineItems" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_roiv_DeferredTaxAssetsLiabilitiesLineItems" xml:lang="en-US">Deferred Tax Assets Liabilities [Line Items]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_roiv_DeferredTaxAssetsLiabilitiesLineItems" xml:lang="en-US">Deferred Tax Assets Liabilities [Line Items]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_roiv_DeferredTaxAssetsLiabilitiesLineItems" xlink:to="lab_roiv_DeferredTaxAssetsLiabilitiesLineItems" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_roiv_DeferredTaxAssetsLiabilitiesLineItems" xml:lang="en-US">Deferred Tax Assets Liabilities [Line Items]</label>
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxLiabilitiesAbstract" xlink:label="loc_us-gaap_DeferredTaxLiabilitiesAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_DeferredTaxLiabilitiesAbstract" xml:lang="en-US">Deferred Tax Liabilities, Gross [Abstract]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_DeferredTaxLiabilitiesAbstract" xml:lang="en-US">Deferred tax liabilities</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxLiabilitiesAbstract" xlink:to="lab_us-gaap_DeferredTaxLiabilitiesAbstract" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsLiabilitiesNet" xlink:label="loc_us-gaap_DeferredTaxAssetsLiabilitiesNet" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_DeferredTaxAssetsLiabilitiesNet" xml:lang="en-US">Deferred Tax Assets, Net</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_us-gaap_DeferredTaxAssetsLiabilitiesNet" xml:lang="en-US">Net Deferred tax assets/(liabilities), net of valuation allowance</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsLiabilitiesNet" xlink:to="lab_us-gaap_DeferredTaxAssetsLiabilitiesNet" />
<loc xlink:type="locator" xlink:href="roiv-20210630.xsd#roiv_DeferredTaxLiabilitiesDepreciation" xlink:label="loc_roiv_DeferredTaxLiabilitiesDepreciation" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_roiv_DeferredTaxLiabilitiesDepreciation" xml:lang="en-US">Deferred Tax Liabilities, Depreciation</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="lab_roiv_DeferredTaxLiabilitiesDepreciation" xml:lang="en-US">Depreciation</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_roiv_DeferredTaxLiabilitiesDepreciation" xlink:to="lab_roiv_DeferredTaxLiabilitiesDepreciation" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_roiv_DeferredTaxLiabilitiesDepreciation" xml:lang="en-US">Deferred Tax Liabilities, Depreciation</label>
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxLiabilitiesOther" xlink:label="loc_us-gaap_DeferredTaxLiabilitiesOther" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_DeferredTaxLiabilitiesOther" xml:lang="en-US">Deferred Tax Liabilities, Other</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="lab_us-gaap_DeferredTaxLiabilitiesOther" xml:lang="en-US">Other</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxLiabilitiesOther" xlink:to="lab_us-gaap_DeferredTaxLiabilitiesOther" />
<loc xlink:type="locator" xlink:href="roiv-20210630.xsd#roiv_DeferredTaxLiabilitiesRightOfUseAssets" xlink:label="loc_roiv_DeferredTaxLiabilitiesRightOfUseAssets" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_roiv_DeferredTaxLiabilitiesRightOfUseAssets" xml:lang="en-US">Deferred tax liabilities right of use assets</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="lab_roiv_DeferredTaxLiabilitiesRightOfUseAssets" xml:lang="en-US">Right-of-use assets</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_roiv_DeferredTaxLiabilitiesRightOfUseAssets" xlink:to="lab_roiv_DeferredTaxLiabilitiesRightOfUseAssets" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_roiv_DeferredTaxLiabilitiesRightOfUseAssets" xml:lang="en-US">Deferred tax liabilities right of use assets</label>
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsGrossAbstract" xlink:label="loc_us-gaap_DeferredTaxAssetsGrossAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_DeferredTaxAssetsGrossAbstract" xml:lang="en-US">Deferred Tax Assets, Gross [Abstract]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_DeferredTaxAssetsGrossAbstract" xml:lang="en-US">Deferred tax assets</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsGrossAbstract" xlink:to="lab_us-gaap_DeferredTaxAssetsGrossAbstract" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsGoodwillAndIntangibleAssets" xlink:label="loc_us-gaap_DeferredTaxAssetsGoodwillAndIntangibleAssets" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_DeferredTaxAssetsGoodwillAndIntangibleAssets" xml:lang="en-US">Deferred Tax Assets, Goodwill and Intangible Assets</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_DeferredTaxAssetsGoodwillAndIntangibleAssets" xml:lang="en-US">Intangible assets</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsGoodwillAndIntangibleAssets" xlink:to="lab_us-gaap_DeferredTaxAssetsGoodwillAndIntangibleAssets" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsGross" xlink:label="loc_us-gaap_DeferredTaxAssetsGross" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_DeferredTaxAssetsGross" xml:lang="en-US">Deferred Tax Assets, Gross</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_us-gaap_DeferredTaxAssetsGross" xml:lang="en-US">Subtotal</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsGross" xlink:to="lab_us-gaap_DeferredTaxAssetsGross" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:label="loc_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xml:lang="en-US">Deferred Tax Assets, Operating Loss Carryforwards</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xml:lang="en-US">Net operating loss</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:to="lab_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsOther" xlink:label="loc_us-gaap_DeferredTaxAssetsOther" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_DeferredTaxAssetsOther" xml:lang="en-US">Deferred Tax Assets, Other</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_DeferredTaxAssetsOther" xml:lang="en-US">Other</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsOther" xlink:to="lab_us-gaap_DeferredTaxAssetsOther" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch" xlink:label="loc_us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch" xml:lang="en-US">Deferred Tax Assets, Tax Credit Carryforwards, Research</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch" xml:lang="en-US">Research tax credits</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch" xlink:to="lab_us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" xlink:label="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" xml:lang="en-US">Deferred Tax Assets, Tax Deferred Expense, Compensation and Benefits, Share-based Compensation Cost</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" xml:lang="en-US">Share-based compensation</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" xlink:to="lab_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" />
<loc xlink:type="locator" xlink:href="roiv-20210630.xsd#roiv_DeferredTaxAssetsLeaseLiabilities" xlink:label="loc_roiv_DeferredTaxAssetsLeaseLiabilities" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_roiv_DeferredTaxAssetsLeaseLiabilities" xml:lang="en-US">Deferred tax assets lease liabilities</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_roiv_DeferredTaxAssetsLeaseLiabilities" xml:lang="en-US">Lease liabilities</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_roiv_DeferredTaxAssetsLeaseLiabilities" xlink:to="lab_roiv_DeferredTaxAssetsLeaseLiabilities" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_roiv_DeferredTaxAssetsLeaseLiabilities" xml:lang="en-US">Deferred tax assets lease liabilities</label>
<loc xlink:type="locator" xlink:href="roiv-20210630.xsd#roiv_TaxRatesAbstract" xlink:label="loc_roiv_TaxRatesAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_roiv_TaxRatesAbstract" xml:lang="en-US">Tax Rates [Abstract]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_roiv_TaxRatesAbstract" xlink:to="lab_roiv_TaxRatesAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_roiv_TaxRatesAbstract" xml:lang="en-US">Tax Rates [Abstract]</label>
<loc xlink:type="locator" xlink:href="roiv-20210630.xsd#roiv_EffectiveTaxRateReconcilingItemsTable" xlink:label="loc_roiv_EffectiveTaxRateReconcilingItemsTable" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_roiv_EffectiveTaxRateReconcilingItemsTable" xml:lang="en-US">Effective Tax Rate Reconciling Items [Table]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_roiv_EffectiveTaxRateReconcilingItemsTable" xml:lang="en-US">Effective Tax Rate Reconciling Items [Table]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_roiv_EffectiveTaxRateReconcilingItemsTable" xlink:to="lab_roiv_EffectiveTaxRateReconcilingItemsTable" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_roiv_EffectiveTaxRateReconcilingItemsTable" xml:lang="en-US">Effective Tax Rate Reconciling Items [Table]</label>
<loc xlink:type="locator" xlink:href="roiv-20210630.xsd#roiv_EffectiveTaxRateReconcilingItemsLineItems" xlink:label="loc_roiv_EffectiveTaxRateReconcilingItemsLineItems" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_roiv_EffectiveTaxRateReconcilingItemsLineItems" xml:lang="en-US">Effective Tax Rate Reconciling Items [Line Items]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_roiv_EffectiveTaxRateReconcilingItemsLineItems" xml:lang="en-US">Effective Tax Rate Reconciling Items [Line Items]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_roiv_EffectiveTaxRateReconcilingItemsLineItems" xlink:to="lab_roiv_EffectiveTaxRateReconcilingItemsLineItems" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_roiv_EffectiveTaxRateReconcilingItemsLineItems" xml:lang="en-US">Effective Tax Rate Reconciling Items [Line Items]</label>
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Percent [Abstract]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Percent [Abstract]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract" xlink:to="lab_us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Change in Deferred Tax Assets Valuation Allowance, Percent</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" xml:lang="en-US">Change in Valuation Allowance</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:to="lab_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Foreign Income Tax Rate Differential, Percent</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential" xml:lang="en-US">Foreign rate differential(1)</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential" xlink:to="lab_us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Change in Enacted Tax Rate, Percent</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate" xml:lang="en-US">Rate changes</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate" xlink:to="lab_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationDispositionOfBusiness" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationDispositionOfBusiness" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationDispositionOfBusiness" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Disposition of Business, Percent</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationDispositionOfBusiness" xml:lang="en-US">Nontaxable (loss) gain on deconsolidation of business</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateReconciliationDispositionOfBusiness" xlink:to="lab_us-gaap_EffectiveIncomeTaxRateReconciliationDispositionOfBusiness" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseResearchAndDevelopment" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseResearchAndDevelopment" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseResearchAndDevelopment" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Nondeductible Expense, Research and Development, Percent</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseResearchAndDevelopment" xml:lang="en-US">Permanent disallowed IPR&amp;D</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseResearchAndDevelopment" xlink:to="lab_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseResearchAndDevelopment" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Other Adjustments, Percent</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments" xml:lang="en-US">Other</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments" xlink:to="lab_us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsResearch" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsResearch" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsResearch" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Tax Credit, Research, Percent</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsResearch" xml:lang="en-US">R&amp;D tax credits</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsResearch" xlink:to="lab_us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsResearch" />
<loc xlink:type="locator" xlink:href="roiv-20210630.xsd#roiv_EffectiveIncomeTaxReconciliationPermanentDifferences" xlink:label="loc_roiv_EffectiveIncomeTaxReconciliationPermanentDifferences" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_roiv_EffectiveIncomeTaxReconciliationPermanentDifferences" xml:lang="en-US">Effective Income Tax Reconciliation Permanent Differences</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_roiv_EffectiveIncomeTaxReconciliationPermanentDifferences" xml:lang="en-US">Permanent adjustments</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_roiv_EffectiveIncomeTaxReconciliationPermanentDifferences" xlink:to="lab_roiv_EffectiveIncomeTaxReconciliationPermanentDifferences" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_roiv_EffectiveIncomeTaxReconciliationPermanentDifferences" xml:lang="en-US">Effective Income Tax Reconciliation Permanent Differences</label>
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpense" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpense" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpense" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Nondeductible Expense, Percent</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpense" xml:lang="en-US">Nondeductible changes in the fair value of investments and loss from equity method investment</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpense" xlink:to="lab_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpense" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxExpenseBenefitContinuingOperationsIncomeTaxReconciliationAbstract" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefitContinuingOperationsIncomeTaxReconciliationAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_IncomeTaxExpenseBenefitContinuingOperationsIncomeTaxReconciliationAbstract" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Amount [Abstract]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_IncomeTaxExpenseBenefitContinuingOperationsIncomeTaxReconciliationAbstract" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Amount [Abstract]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefitContinuingOperationsIncomeTaxReconciliationAbstract" xlink:to="lab_us-gaap_IncomeTaxExpenseBenefitContinuingOperationsIncomeTaxReconciliationAbstract" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxReconciliationNondeductibleExpenseResearchAndDevelopment" xlink:label="loc_us-gaap_IncomeTaxReconciliationNondeductibleExpenseResearchAndDevelopment" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_IncomeTaxReconciliationNondeductibleExpenseResearchAndDevelopment" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Nondeductible Expense, Research and Development, Amount</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_IncomeTaxReconciliationNondeductibleExpenseResearchAndDevelopment" xml:lang="en-US">Permanent disallowed IPR&amp;D</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxReconciliationNondeductibleExpenseResearchAndDevelopment" xlink:to="lab_us-gaap_IncomeTaxReconciliationNondeductibleExpenseResearchAndDevelopment" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxReconciliationOtherAdjustments" xlink:label="loc_us-gaap_IncomeTaxReconciliationOtherAdjustments" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_IncomeTaxReconciliationOtherAdjustments" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Other Adjustments, Amount</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_IncomeTaxReconciliationOtherAdjustments" xml:lang="en-US">Other</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxReconciliationOtherAdjustments" xlink:to="lab_us-gaap_IncomeTaxReconciliationOtherAdjustments" />
<loc xlink:type="locator" xlink:href="roiv-20210630.xsd#roiv_IncomeTaxReconciliationPermanentAdjustments" xlink:label="loc_roiv_IncomeTaxReconciliationPermanentAdjustments" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_roiv_IncomeTaxReconciliationPermanentAdjustments" xml:lang="en-US">Income Tax Reconciliation Permanent Adjustments</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_roiv_IncomeTaxReconciliationPermanentAdjustments" xml:lang="en-US">Permanent adjustments</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_roiv_IncomeTaxReconciliationPermanentAdjustments" xlink:to="lab_roiv_IncomeTaxReconciliationPermanentAdjustments" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_roiv_IncomeTaxReconciliationPermanentAdjustments" xml:lang="en-US">Income Tax Reconciliation Permanent Adjustments</label>
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxReconciliationTaxCreditsResearch" xlink:label="loc_us-gaap_IncomeTaxReconciliationTaxCreditsResearch" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_IncomeTaxReconciliationTaxCreditsResearch" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Tax Credit, Research, Amount</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="lab_us-gaap_IncomeTaxReconciliationTaxCreditsResearch" xml:lang="en-US">R&amp;D tax credits</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxReconciliationTaxCreditsResearch" xlink:to="lab_us-gaap_IncomeTaxReconciliationTaxCreditsResearch" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:label="loc_us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Change in Deferred Tax Assets Valuation Allowance, Amount</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance" xml:lang="en-US">Valuation allowance</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:to="lab_us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxReconciliationChangeInEnactedTaxRate" xlink:label="loc_us-gaap_IncomeTaxReconciliationChangeInEnactedTaxRate" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_IncomeTaxReconciliationChangeInEnactedTaxRate" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Change in Enacted Tax Rate, Amount</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_IncomeTaxReconciliationChangeInEnactedTaxRate" xml:lang="en-US">Rate changes</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxReconciliationChangeInEnactedTaxRate" xlink:to="lab_us-gaap_IncomeTaxReconciliationChangeInEnactedTaxRate" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxReconciliationDispositionOfBusiness" xlink:label="loc_us-gaap_IncomeTaxReconciliationDispositionOfBusiness" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_IncomeTaxReconciliationDispositionOfBusiness" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Disposition of Business, Amount</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_IncomeTaxReconciliationDispositionOfBusiness" xml:lang="en-US">Nontaxable (loss) gain on deconsolidation of business</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxReconciliationDispositionOfBusiness" xlink:to="lab_us-gaap_IncomeTaxReconciliationDispositionOfBusiness" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxReconciliationForeignIncomeTaxRateDifferential" xlink:label="loc_us-gaap_IncomeTaxReconciliationForeignIncomeTaxRateDifferential" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_IncomeTaxReconciliationForeignIncomeTaxRateDifferential" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Foreign Income Tax Rate Differential, Amount</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_IncomeTaxReconciliationForeignIncomeTaxRateDifferential" xml:lang="en-US">Foreign rate differential</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxReconciliationForeignIncomeTaxRateDifferential" xlink:to="lab_us-gaap_IncomeTaxReconciliationForeignIncomeTaxRateDifferential" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate" xlink:label="loc_us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate" xml:lang="en-US">Effective Income Tax Rate Reconciliation at Federal Statutory Income Tax Rate, Amount</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate" xml:lang="en-US">Income tax benefit at Bermuda statutory rate</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate" xlink:to="lab_us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxReconciliationNondeductibleExpense" xlink:label="loc_us-gaap_IncomeTaxReconciliationNondeductibleExpense" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_IncomeTaxReconciliationNondeductibleExpense" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Nondeductible Expense, Amount</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_IncomeTaxReconciliationNondeductibleExpense" xml:lang="en-US">Nondeductible changes in the fair value of investments and loss from equity method investment</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxReconciliationNondeductibleExpense" xlink:to="lab_us-gaap_IncomeTaxReconciliationNondeductibleExpense" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract" xlink:label="loc_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract" xml:lang="en-US">Lessee, Operating Lease, Liability, Payment, Due [Abstract]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract" xml:lang="en-US">Maturities of operating lease liabilities [Abstract]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract" xlink:to="lab_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xml:lang="en-US">Total lease payments</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid, after Year Five</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive" xml:lang="en-US">Thereafter</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid, Year One</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xml:lang="en-US">2022</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid, Year Five</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive" xml:lang="en-US">2026</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid, Year Four</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xml:lang="en-US">2025</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid, Year Three</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xml:lang="en-US">2024</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid, Year Two</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xml:lang="en-US">2023</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" />
<loc xlink:type="locator" xlink:href="roiv-20210630.xsd#roiv_LesseeOperatingLeaseLiabilityTenantImprovementAllowance" xlink:label="loc_roiv_LesseeOperatingLeaseLiabilityTenantImprovementAllowance" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_roiv_LesseeOperatingLeaseLiabilityTenantImprovementAllowance" xml:lang="en-US">Lessee Operating Lease Liability Tenant Improvement Allowance</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="lab_roiv_LesseeOperatingLeaseLiabilityTenantImprovementAllowance" xml:lang="en-US">Less: tenant improvement allowance</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_roiv_LesseeOperatingLeaseLiabilityTenantImprovementAllowance" xlink:to="lab_roiv_LesseeOperatingLeaseLiabilityTenantImprovementAllowance" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_roiv_LesseeOperatingLeaseLiabilityTenantImprovementAllowance" xml:lang="en-US">Lessee operating lease liability tenant improvement allowance..</label>
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseLiability" xlink:label="loc_us-gaap_OperatingLeaseLiability" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_OperatingLeaseLiability" xml:lang="en-US">Operating Lease, Liability</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_OperatingLeaseLiability" xml:lang="en-US">Total</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseLiability" xlink:to="lab_us-gaap_OperatingLeaseLiability" />
<loc xlink:type="locator" xlink:href="roiv-20210630.xsd#roiv_OperatingLeaseLiabilityPresentValueAdjustments" xlink:label="loc_roiv_OperatingLeaseLiabilityPresentValueAdjustments" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_roiv_OperatingLeaseLiabilityPresentValueAdjustments" xml:lang="en-US">Operating Lease Liability Present Value Adjustments</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="lab_roiv_OperatingLeaseLiabilityPresentValueAdjustments" xml:lang="en-US">Less: present value adjustment</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_roiv_OperatingLeaseLiabilityPresentValueAdjustments" xlink:to="lab_roiv_OperatingLeaseLiabilityPresentValueAdjustments" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_roiv_OperatingLeaseLiabilityPresentValueAdjustments" xml:lang="en-US">Operating Lease Liability Present Value Adjustments</label>
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeasePayments" xlink:label="loc_us-gaap_OperatingLeasePayments" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_OperatingLeasePayments" xml:lang="en-US">Operating Lease, Payments</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_OperatingLeasePayments" xml:lang="en-US">Cash paid for operating lease liabilities</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeasePayments" xlink:to="lab_us-gaap_OperatingLeasePayments" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:label="loc_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xml:lang="en-US">Operating Lease, Weighted Average Discount Rate, Percent</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xml:lang="en-US">Weighted average discount rate</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:to="lab_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:label="loc_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xml:lang="en-US">Operating Lease, Weighted Average Remaining Lease Term</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xml:lang="en-US">Weighted average remaining lease term (in years)</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:to="lab_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LeaseCostAbstract" xlink:label="loc_us-gaap_LeaseCostAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_LeaseCostAbstract" xml:lang="en-US">Lease, Cost [Abstract]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LeaseCostAbstract" xlink:to="lab_us-gaap_LeaseCostAbstract" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LeaseCost" xlink:label="loc_us-gaap_LeaseCost" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_LeaseCost" xml:lang="en-US">Lease, Cost</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_us-gaap_LeaseCost" xml:lang="en-US">Total operating lease cost</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LeaseCost" xlink:to="lab_us-gaap_LeaseCost" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseCost" xlink:label="loc_us-gaap_OperatingLeaseCost" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_OperatingLeaseCost" xml:lang="en-US">Operating Lease, Cost</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_OperatingLeaseCost" xml:lang="en-US">Operating lease cost</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseCost" xlink:to="lab_us-gaap_OperatingLeaseCost" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShortTermLeaseCost" xlink:label="loc_us-gaap_ShortTermLeaseCost" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ShortTermLeaseCost" xml:lang="en-US">Short-term Lease, Cost</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_ShortTermLeaseCost" xml:lang="en-US">Short-term lease cost</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShortTermLeaseCost" xlink:to="lab_us-gaap_ShortTermLeaseCost" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_VariableLeaseCost" xlink:label="loc_us-gaap_VariableLeaseCost" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_VariableLeaseCost" xml:lang="en-US">Variable Lease, Cost</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_VariableLeaseCost" xml:lang="en-US">Variable lease cost</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_VariableLeaseCost" xlink:to="lab_us-gaap_VariableLeaseCost" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisAbstract" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisAbstract" xml:lang="en-US">Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Abstract]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisAbstract" xlink:to="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisAbstract" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xml:lang="en-US">Fair Value, Recurring and Nonrecurring [Table]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xml:lang="en-US">Fair Value, Recurring and Nonrecurring [Table]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xml:lang="en-US">Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xml:lang="en-US">Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DerivativeInstrumentsNotDesignatedAsHedgingInstrumentsLiabilityAtFairValue" xlink:label="loc_us-gaap_DerivativeInstrumentsNotDesignatedAsHedgingInstrumentsLiabilityAtFairValue" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_DerivativeInstrumentsNotDesignatedAsHedgingInstrumentsLiabilityAtFairValue" xml:lang="en-US">Derivative Instruments Not Designated as Hedging Instruments, Liability, at Fair Value</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_DerivativeInstrumentsNotDesignatedAsHedgingInstrumentsLiabilityAtFairValue" xml:lang="en-US">Liability instruments measured at fair value</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DerivativeInstrumentsNotDesignatedAsHedgingInstrumentsLiabilityAtFairValue" xlink:to="lab_us-gaap_DerivativeInstrumentsNotDesignatedAsHedgingInstrumentsLiabilityAtFairValue" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetsFairValueDisclosure" xlink:label="loc_us-gaap_AssetsFairValueDisclosure" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_AssetsFairValueDisclosure" xml:lang="en-US">Assets, Fair Value Disclosure</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_AssetsFairValueDisclosure" xml:lang="en-US">Assets held in Trust Account</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsFairValueDisclosure" xlink:to="lab_us-gaap_AssetsFairValueDisclosure" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashAndCashEquivalentsFairValueDisclosure" xlink:label="loc_us-gaap_CashAndCashEquivalentsFairValueDisclosure" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_CashAndCashEquivalentsFairValueDisclosure" xml:lang="en-US">Cash and Cash Equivalents, Fair Value Disclosure</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_CashAndCashEquivalentsFairValueDisclosure" xml:lang="en-US">Money market funds</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashAndCashEquivalentsFairValueDisclosure" xlink:to="lab_us-gaap_CashAndCashEquivalentsFairValueDisclosure" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesFairValueDisclosure" xlink:label="loc_us-gaap_LiabilitiesFairValueDisclosure" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_LiabilitiesFairValueDisclosure" xml:lang="en-US">Financial and Nonfinancial Liabilities, Fair Value Disclosure</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_LiabilitiesFairValueDisclosure" xml:lang="en-US">Total liabilities at fair value</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesFairValueDisclosure" xlink:to="lab_us-gaap_LiabilitiesFairValueDisclosure" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfWarrantOrRightAxis" xlink:label="loc_us-gaap_ClassOfWarrantOrRightAxis" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ClassOfWarrantOrRightAxis" xml:lang="en-US">Class of Warrant or Right [Axis]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_ClassOfWarrantOrRightAxis" xml:lang="en-US">Class of Warrant or Right [Axis]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ClassOfWarrantOrRightAxis" xlink:to="lab_us-gaap_ClassOfWarrantOrRightAxis" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfWarrantOrRightDomain" xlink:label="loc_us-gaap_ClassOfWarrantOrRightDomain" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ClassOfWarrantOrRightDomain" xml:lang="en-US">Class of Warrant or Right [Domain]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_ClassOfWarrantOrRightDomain" xml:lang="en-US">Class of Warrant or Right [Domain]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ClassOfWarrantOrRightDomain" xlink:to="lab_us-gaap_ClassOfWarrantOrRightDomain" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueByAssetClassAxis" xlink:label="loc_us-gaap_FairValueByAssetClassAxis" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_FairValueByAssetClassAxis" xml:lang="en-US">Asset Class [Axis]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_FairValueByAssetClassAxis" xml:lang="en-US">Asset Class [Axis]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueByAssetClassAxis" xlink:to="lab_us-gaap_FairValueByAssetClassAxis" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" xlink:label="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" xml:lang="en-US">Asset Class [Domain]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" xml:lang="en-US">Asset Class [Domain]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" xlink:to="lab_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConvertiblePreferredStockMember" xlink:label="loc_us-gaap_ConvertiblePreferredStockMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ConvertiblePreferredStockMember" xml:lang="en-US">Convertible Preferred Stock [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_ConvertiblePreferredStockMember" xml:lang="en-US">Convertible Preferred Stock [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConvertiblePreferredStockMember" xlink:to="lab_us-gaap_ConvertiblePreferredStockMember" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MoneyMarketFundsMember" xlink:label="loc_us-gaap_MoneyMarketFundsMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_MoneyMarketFundsMember" xml:lang="en-US">Money Market Funds [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_MoneyMarketFundsMember" xml:lang="en-US">Money Market Funds [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MoneyMarketFundsMember" xlink:to="lab_us-gaap_MoneyMarketFundsMember" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:label="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis" xml:lang="en-US">Fair Value Hierarchy and NAV [Axis]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis" xml:lang="en-US">Fair Value Hierarchy and NAV [Axis]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:to="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xml:lang="en-US">Fair Value Hierarchy and NAV [Domain]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xml:lang="en-US">Fair Value Hierarchy and NAV [Domain]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:to="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueInputsLevel2Member" xlink:label="loc_us-gaap_FairValueInputsLevel2Member" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_FairValueInputsLevel2Member" xml:lang="en-US">Fair Value, Inputs, Level 2 [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_FairValueInputsLevel2Member" xml:lang="en-US">Fair Value, Inputs, Level 2 [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueInputsLevel2Member" xlink:to="lab_us-gaap_FairValueInputsLevel2Member" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueInputsLevel3Member" xlink:label="loc_us-gaap_FairValueInputsLevel3Member" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_FairValueInputsLevel3Member" xml:lang="en-US">Fair Value, Inputs, Level 3 [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_FairValueInputsLevel3Member" xml:lang="en-US">Fair Value, Inputs, Level 3 [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueInputsLevel3Member" xlink:to="lab_us-gaap_FairValueInputsLevel3Member" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueInputsLevel1Member" xlink:label="loc_us-gaap_FairValueInputsLevel1Member" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_FairValueInputsLevel1Member" xml:lang="en-US">Fair Value, Inputs, Level 1 [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_FairValueInputsLevel1Member" xml:lang="en-US">Fair Value, Inputs, Level 1 [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueInputsLevel1Member" xlink:to="lab_us-gaap_FairValueInputsLevel1Member" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueByMeasurementFrequencyAxis" xlink:label="loc_us-gaap_FairValueByMeasurementFrequencyAxis" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_FairValueByMeasurementFrequencyAxis" xml:lang="en-US">Measurement Frequency [Axis]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_FairValueByMeasurementFrequencyAxis" xml:lang="en-US">Measurement Frequency [Axis]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueByMeasurementFrequencyAxis" xlink:to="lab_us-gaap_FairValueByMeasurementFrequencyAxis" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementFrequencyDomain" xlink:label="loc_us-gaap_FairValueMeasurementFrequencyDomain" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_FairValueMeasurementFrequencyDomain" xml:lang="en-US">Measurement Frequency [Domain]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_FairValueMeasurementFrequencyDomain" xml:lang="en-US">Measurement Frequency [Domain]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueMeasurementFrequencyDomain" xlink:to="lab_us-gaap_FairValueMeasurementFrequencyDomain" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementsRecurringMember" xlink:label="loc_us-gaap_FairValueMeasurementsRecurringMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_FairValueMeasurementsRecurringMember" xml:lang="en-US">Fair Value, Recurring [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_FairValueMeasurementsRecurringMember" xml:lang="en-US">Fair Value, Recurring [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueMeasurementsRecurringMember" xlink:to="lab_us-gaap_FairValueMeasurementsRecurringMember" />
<loc xlink:type="locator" xlink:href="roiv-20210630.xsd#roiv_FairValueDisclosuresTable" xlink:label="loc_roiv_FairValueDisclosuresTable" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_roiv_FairValueDisclosuresTable" xml:lang="en-US">Fair Value Disclosures [Table]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_roiv_FairValueDisclosuresTable" xml:lang="en-US">Fair Value Disclosures [Table]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_roiv_FairValueDisclosuresTable" xlink:to="lab_roiv_FairValueDisclosuresTable" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_roiv_FairValueDisclosuresTable" xml:lang="en-US">Fair Value Disclosures [Table]</label>
<loc xlink:type="locator" xlink:href="roiv-20210630.xsd#roiv_FairValueDisclosuresLineItems" xlink:label="loc_roiv_FairValueDisclosuresLineItems" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_roiv_FairValueDisclosuresLineItems" xml:lang="en-US">Fair Value Disclosures [Line Items]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_roiv_FairValueDisclosuresLineItems" xml:lang="en-US">Fair Value Disclosures [Line Items]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_roiv_FairValueDisclosuresLineItems" xlink:to="lab_roiv_FairValueDisclosuresLineItems" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_roiv_FairValueDisclosuresLineItems" xml:lang="en-US">Fair Value Disclosures [Line Items]</label>
<loc xlink:type="locator" xlink:href="roiv-20210630.xsd#roiv_EquityInterestOptionToThirdPartyPurchaser" xlink:label="loc_roiv_EquityInterestOptionToThirdPartyPurchaser" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_roiv_EquityInterestOptionToThirdPartyPurchaser" xml:lang="en-US">Equity Interest Option to Third Party Purchaser</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_roiv_EquityInterestOptionToThirdPartyPurchaser" xml:lang="en-US">Fair value of options</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_roiv_EquityInterestOptionToThirdPartyPurchaser" xlink:to="lab_roiv_EquityInterestOptionToThirdPartyPurchaser" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_roiv_EquityInterestOptionToThirdPartyPurchaser" xml:lang="en-US">Equity interest option to third party purchaser.</label>
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentMeasurementInput" xlink:label="loc_us-gaap_DebtInstrumentMeasurementInput" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_DebtInstrumentMeasurementInput" xml:lang="en-US">Debt Instrument, Measurement Input</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_DebtInstrumentMeasurementInput" xml:lang="en-US">Discount rate</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentMeasurementInput" xlink:to="lab_us-gaap_DebtInstrumentMeasurementInput" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MeasurementInputTypeAxis" xlink:label="loc_us-gaap_MeasurementInputTypeAxis" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_MeasurementInputTypeAxis" xml:lang="en-US">Measurement Input Type [Axis]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_MeasurementInputTypeAxis" xml:lang="en-US">Measurement Input Type [Axis]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MeasurementInputTypeAxis" xlink:to="lab_us-gaap_MeasurementInputTypeAxis" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MeasurementInputTypeDomain" xlink:label="loc_us-gaap_MeasurementInputTypeDomain" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_MeasurementInputTypeDomain" xml:lang="en-US">Measurement Input Type [Domain]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_MeasurementInputTypeDomain" xml:lang="en-US">Measurement Input Type [Domain]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MeasurementInputTypeDomain" xlink:to="lab_us-gaap_MeasurementInputTypeDomain" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MeasurementInputDiscountRateMember" xlink:label="loc_us-gaap_MeasurementInputDiscountRateMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_MeasurementInputDiscountRateMember" xml:lang="en-US">Measurement Input, Discount Rate [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_MeasurementInputDiscountRateMember" xml:lang="en-US">Measurement Input, Discount Rate [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MeasurementInputDiscountRateMember" xlink:to="lab_us-gaap_MeasurementInputDiscountRateMember" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BalanceSheetLocationAxis" xlink:label="loc_us-gaap_BalanceSheetLocationAxis" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_BalanceSheetLocationAxis" xml:lang="en-US">Balance Sheet Location [Axis]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_BalanceSheetLocationAxis" xml:lang="en-US">Balance Sheet Location [Axis]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BalanceSheetLocationAxis" xlink:to="lab_us-gaap_BalanceSheetLocationAxis" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BalanceSheetLocationDomain" xlink:label="loc_us-gaap_BalanceSheetLocationDomain" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_BalanceSheetLocationDomain" xml:lang="en-US">Balance Sheet Location [Domain]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_BalanceSheetLocationDomain" xml:lang="en-US">Balance Sheet Location [Domain]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BalanceSheetLocationDomain" xlink:to="lab_us-gaap_BalanceSheetLocationDomain" />
<loc xlink:type="locator" xlink:href="roiv-20210630.xsd#roiv_LiabilityInstrumentsMeasuredAtFairValueMember" xlink:label="loc_roiv_LiabilityInstrumentsMeasuredAtFairValueMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_roiv_LiabilityInstrumentsMeasuredAtFairValueMember" xml:lang="en-US">Liability Instruments Measured At Fair Value [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_roiv_LiabilityInstrumentsMeasuredAtFairValueMember" xml:lang="en-US">Liability Instruments Measured At Fair Value [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_roiv_LiabilityInstrumentsMeasuredAtFairValueMember" xlink:to="lab_roiv_LiabilityInstrumentsMeasuredAtFairValueMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_roiv_LiabilityInstrumentsMeasuredAtFairValueMember" xml:lang="en-US">Liability Instruments Measured At Fair Value [Member]</label>
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" xml:lang="en-US">Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability Value</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" xml:lang="en-US">Balance at end of period</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" xml:lang="en-US">Balance at beginning of period</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" xlink:to="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings" xml:lang="en-US">Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Gain (Loss) Included in Earnings</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings" xml:lang="en-US">Changes in fair value of debt and liability instruments, included in net loss</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings" xlink:to="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements" xml:lang="en-US">Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Settlements</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements" xml:lang="en-US">Termination of DSP Options</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements" xlink:to="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements" />
<loc xlink:type="locator" xlink:href="roiv-20210630.xsd#roiv_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityDisposedDueToDeconsolidationOfSubsidiary" xlink:label="loc_roiv_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityDisposedDueToDeconsolidationOfSubsidiary" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_roiv_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityDisposedDueToDeconsolidationOfSubsidiary" xml:lang="en-US">Fair Value, Measurement With Unobservable Inputs Reconciliation, Recurring Basis, Liability, Disposed Due to Deconsolidation of Subsidiary</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_roiv_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityDisposedDueToDeconsolidationOfSubsidiary" xml:lang="en-US">Liability instruments disposed due to deconsolidation of subsidiary</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_roiv_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityDisposedDueToDeconsolidationOfSubsidiary" xlink:to="lab_roiv_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityDisposedDueToDeconsolidationOfSubsidiary" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_roiv_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityDisposedDueToDeconsolidationOfSubsidiary" xml:lang="en-US">Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, disposed due to deconsolidation of subsidiary.</label>
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable" xml:lang="en-US">Fair Value Measurement Inputs and Valuation Techniques [Table]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable" xml:lang="en-US">Fair Value Measurement Inputs and Valuation Techniques [Table]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable" xlink:to="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MeasurementInputOptionVolatilityMember" xlink:label="loc_us-gaap_MeasurementInputOptionVolatilityMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_MeasurementInputOptionVolatilityMember" xml:lang="en-US">Measurement Input, Option Volatility [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_MeasurementInputOptionVolatilityMember" xml:lang="en-US">Measurement Input, Option Volatility [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MeasurementInputOptionVolatilityMember" xlink:to="lab_us-gaap_MeasurementInputOptionVolatilityMember" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MeasurementInputRiskFreeInterestRateMember" xlink:label="loc_us-gaap_MeasurementInputRiskFreeInterestRateMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_MeasurementInputRiskFreeInterestRateMember" xml:lang="en-US">Measurement Input, Risk Free Interest Rate [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_MeasurementInputRiskFreeInterestRateMember" xml:lang="en-US">Risk-free rate</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MeasurementInputRiskFreeInterestRateMember" xlink:to="lab_us-gaap_MeasurementInputRiskFreeInterestRateMember" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MeasurementInputExpectedTermMember" xlink:label="loc_us-gaap_MeasurementInputExpectedTermMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_MeasurementInputExpectedTermMember" xml:lang="en-US">Measurement Input, Expected Term [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_MeasurementInputExpectedTermMember" xml:lang="en-US">Measurement Input, Expected Term [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MeasurementInputExpectedTermMember" xlink:to="lab_us-gaap_MeasurementInputExpectedTermMember" />
<loc xlink:type="locator" xlink:href="roiv-20210630.xsd#roiv_AlternativeInvestmentExpectedTerm" xlink:label="loc_roiv_AlternativeInvestmentExpectedTerm" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_roiv_AlternativeInvestmentExpectedTerm" xml:lang="en-US">Alternative Investment Expected Term</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_roiv_AlternativeInvestmentExpectedTerm" xml:lang="en-US">Time to expiration (in years)</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_roiv_AlternativeInvestmentExpectedTerm" xlink:to="lab_roiv_AlternativeInvestmentExpectedTerm" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_roiv_AlternativeInvestmentExpectedTerm" xml:lang="en-US">Alternative investment expected term.</label>
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AlternativeInvestmentMeasurementInput" xlink:label="loc_us-gaap_AlternativeInvestmentMeasurementInput" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_AlternativeInvestmentMeasurementInput" xml:lang="en-US">Alternative Investment, Measurement Input</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_AlternativeInvestmentMeasurementInput" xml:lang="en-US">Investment</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AlternativeInvestmentMeasurementInput" xlink:to="lab_us-gaap_AlternativeInvestmentMeasurementInput" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DefinedContributionPlanEmployerDiscretionaryContributionAmount" xlink:label="loc_us-gaap_DefinedContributionPlanEmployerDiscretionaryContributionAmount" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_DefinedContributionPlanEmployerDiscretionaryContributionAmount" xml:lang="en-US">Defined Contribution Plan, Employer Discretionary Contribution Amount</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_DefinedContributionPlanEmployerDiscretionaryContributionAmount" xml:lang="en-US">Defined contribution plan, employer matching contribution</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DefinedContributionPlanEmployerDiscretionaryContributionAmount" xlink:to="lab_us-gaap_DefinedContributionPlanEmployerDiscretionaryContributionAmount" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherExpensesAbstract" xlink:label="loc_us-gaap_OtherExpensesAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_OtherExpensesAbstract" xml:lang="en-US">Other Expenses [Abstract]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherExpensesAbstract" xlink:to="lab_us-gaap_OtherExpensesAbstract" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherOperatingIncomeExpenseNet" xlink:label="loc_us-gaap_OtherOperatingIncomeExpenseNet" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_OtherOperatingIncomeExpenseNet" xml:lang="en-US">Other Operating Income (Expense), Net</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedTotalLabel" xlink:label="lab_us-gaap_OtherOperatingIncomeExpenseNet" xml:lang="en-US">Total</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherOperatingIncomeExpenseNet" xlink:to="lab_us-gaap_OtherOperatingIncomeExpenseNet" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InterestExpense" xlink:label="loc_us-gaap_InterestExpense" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_InterestExpense" xml:lang="en-US">Interest Expense</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_InterestExpense" xml:lang="en-US">Interest expense</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InterestExpense" xlink:to="lab_us-gaap_InterestExpense" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InterestIncomeOther" xlink:label="loc_us-gaap_InterestIncomeOther" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_InterestIncomeOther" xml:lang="en-US">Interest Income, Other</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="lab_us-gaap_InterestIncomeOther" xml:lang="en-US">Interest income</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InterestIncomeOther" xlink:to="lab_us-gaap_InterestIncomeOther" />
<loc xlink:type="locator" xlink:href="roiv-20210630.xsd#roiv_OtherIncomeExpense" xlink:label="loc_roiv_OtherIncomeExpense" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_roiv_OtherIncomeExpense" xml:lang="en-US">Other Income Expense</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="lab_roiv_OtherIncomeExpense" xml:lang="en-US">Other (expense) income</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_roiv_OtherIncomeExpense" xlink:to="lab_roiv_OtherIncomeExpense" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_roiv_OtherIncomeExpense" xml:lang="en-US">Other Income Expense</label>
<loc xlink:type="locator" xlink:href="roiv-20210630.xsd#roiv_BasicAndDilutedNetLossIncome" xlink:label="loc_roiv_BasicAndDilutedNetLossIncome" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_roiv_BasicAndDilutedNetLossIncome" xml:lang="en-US">Basic and Diluted Net (Loss) Income</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_roiv_BasicAndDilutedNetLossIncome" xml:lang="en-US">Basic and diluted net (loss) income attributable to Roivant Sciences</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_roiv_BasicAndDilutedNetLossIncome" xlink:to="lab_roiv_BasicAndDilutedNetLossIncome" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_roiv_BasicAndDilutedNetLossIncome" xml:lang="en-US">Basic and Diluted Net (Loss) Income.</label>
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsAttributableToNoncontrollingEntity" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsAttributableToNoncontrollingEntity" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_IncomeLossFromContinuingOperationsAttributableToNoncontrollingEntity" xml:lang="en-US">Income (Loss) from Continuing Operations, Net of Tax, Attributable to Noncontrolling Interest</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_IncomeLossFromContinuingOperationsAttributableToNoncontrollingEntity" xml:lang="en-US">Net loss from continuing operations, net of tax, attributable to noncontrolling interest</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsAttributableToNoncontrollingEntity" xlink:to="lab_us-gaap_IncomeLossFromContinuingOperationsAttributableToNoncontrollingEntity" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PreferredStockDividendsAndOtherAdjustments" xlink:label="loc_us-gaap_PreferredStockDividendsAndOtherAdjustments" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_PreferredStockDividendsAndOtherAdjustments" xml:lang="en-US">Preferred Stock Dividends and Other Adjustments</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="lab_us-gaap_PreferredStockDividendsAndOtherAdjustments" xml:lang="en-US">Deemed dividend on repurchase of redeemable noncontrolling interest relating to subsidiary convertible and redeemable preferred stock</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_PreferredStockDividendsAndOtherAdjustments" xml:lang="en-US">Deemed dividend on repurchase of redeemable noncontrolling interest relating to subsidiary convertible and redeemable preferred stock</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PreferredStockDividendsAndOtherAdjustments" xlink:to="lab_us-gaap_PreferredStockDividendsAndOtherAdjustments" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToNoncontrollingInterest" xlink:label="loc_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToNoncontrollingInterest" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToNoncontrollingInterest" xml:lang="en-US">Income (Loss) from Discontinued Operations, Net of Tax, Attributable to Noncontrolling Interest</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToNoncontrollingInterest" xml:lang="en-US">Net loss from discontinued operations, net of tax, attributable to noncontrolling interest</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToNoncontrollingInterest" xlink:to="lab_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToNoncontrollingInterest" />
<loc xlink:type="locator" xlink:href="roiv-20210630.xsd#roiv_BasicAndDilutedIncomeFromDiscontinuedOperationsNetOfTax" xlink:label="loc_roiv_BasicAndDilutedIncomeFromDiscontinuedOperationsNetOfTax" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_roiv_BasicAndDilutedIncomeFromDiscontinuedOperationsNetOfTax" xml:lang="en-US">Basic and Diluted Income From Discontinued Operations, Net of Tax</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_roiv_BasicAndDilutedIncomeFromDiscontinuedOperationsNetOfTax" xml:lang="en-US">Basic and diluted income from discontinued operations, net of tax</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_roiv_BasicAndDilutedIncomeFromDiscontinuedOperationsNetOfTax" xlink:to="lab_roiv_BasicAndDilutedIncomeFromDiscontinuedOperationsNetOfTax" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_roiv_BasicAndDilutedIncomeFromDiscontinuedOperationsNetOfTax" xml:lang="en-US">Basic and Diluted Income From Discontinued Operations, Net of Tax.</label>
<loc xlink:type="locator" xlink:href="roiv-20210630.xsd#roiv_BasicAndDilutedLossFromContinuingOperationsNetOfTax" xlink:label="loc_roiv_BasicAndDilutedLossFromContinuingOperationsNetOfTax" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_roiv_BasicAndDilutedLossFromContinuingOperationsNetOfTax" xml:lang="en-US">Basic and Diluted Loss From Continuing Operations, Net of Tax</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_roiv_BasicAndDilutedLossFromContinuingOperationsNetOfTax" xml:lang="en-US">Basic and diluted loss from continuing operations, net of tax, attributable to Roivant Sciences Ltd.</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_roiv_BasicAndDilutedLossFromContinuingOperationsNetOfTax" xlink:to="lab_roiv_BasicAndDilutedLossFromContinuingOperationsNetOfTax" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_roiv_BasicAndDilutedLossFromContinuingOperationsNetOfTax" xml:lang="en-US">Basic and Diluted Loss From Continuing Operations, Net of Tax.</label>
<loc xlink:type="locator" xlink:href="roiv-20210630.xsd#roiv_SumitomoPharmaceuticalsCoLtdMember" xlink:label="loc_roiv_SumitomoPharmaceuticalsCoLtdMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_roiv_SumitomoPharmaceuticalsCoLtdMember" xml:lang="en-US">Sumitomo Pharmaceuticals Co., Ltd. [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_roiv_SumitomoPharmaceuticalsCoLtdMember" xml:lang="en-US">Sumitomo Pharmaceuticals (Suzhou) Co., Ltd. [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_roiv_SumitomoPharmaceuticalsCoLtdMember" xlink:to="lab_roiv_SumitomoPharmaceuticalsCoLtdMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_roiv_SumitomoPharmaceuticalsCoLtdMember" xml:lang="en-US">Sumitomo Pharmaceuticals Co., Ltd.</label>
<loc xlink:type="locator" xlink:href="roiv-20210630.xsd#roiv_DatavantMember" xlink:label="loc_roiv_DatavantMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_roiv_DatavantMember" xml:lang="en-US">Datavant [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_roiv_DatavantMember" xlink:to="lab_roiv_DatavantMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_roiv_DatavantMember" xml:lang="en-US">Datavant [Member].</label>
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RestatementAxis" xlink:label="loc_srt_RestatementAxis" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_srt_RestatementAxis" xml:lang="en-US">Revision of Prior Period [Axis]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_srt_RestatementAxis" xml:lang="en-US">Revision of Prior Period [Axis]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_RestatementAxis" xlink:to="lab_srt_RestatementAxis" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RestatementDomain" xlink:label="loc_srt_RestatementDomain" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_srt_RestatementDomain" xml:lang="en-US">Revision of Prior Period [Domain]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_srt_RestatementDomain" xml:lang="en-US">Revision of Prior Period [Domain]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_RestatementDomain" xlink:to="lab_srt_RestatementDomain" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RevisionOfPriorPeriodReclassificationAdjustmentMember" xlink:label="loc_srt_RevisionOfPriorPeriodReclassificationAdjustmentMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_srt_RevisionOfPriorPeriodReclassificationAdjustmentMember" xml:lang="en-US">Revision of Prior Period, Reclassification, Adjustment [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_srt_RevisionOfPriorPeriodReclassificationAdjustmentMember" xml:lang="en-US">Revision of Prior Period, Reclassification, Adjustment</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_RevisionOfPriorPeriodReclassificationAdjustmentMember" xlink:to="lab_srt_RevisionOfPriorPeriodReclassificationAdjustmentMember" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentAxis" xlink:label="loc_us-gaap_DebtInstrumentAxis" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_DebtInstrumentAxis" xml:lang="en-US">Debt Instrument [Axis]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_DebtInstrumentAxis" xml:lang="en-US">Debt Instrument [Axis]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentAxis" xlink:to="lab_us-gaap_DebtInstrumentAxis" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="loc_us-gaap_DebtInstrumentNameDomain" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_DebtInstrumentNameDomain" xml:lang="en-US">Debt Instrument, Name [Domain]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_DebtInstrumentNameDomain" xml:lang="en-US">Debt Instrument, Name [Domain]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentNameDomain" xlink:to="lab_us-gaap_DebtInstrumentNameDomain" />
<loc xlink:type="locator" xlink:href="roiv-20210630.xsd#roiv_CreditFacilityMember" xlink:label="loc_roiv_CreditFacilityMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_roiv_CreditFacilityMember" xml:lang="en-US">Credit Facility [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_roiv_CreditFacilityMember" xml:lang="en-US">Credit Facility [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_roiv_CreditFacilityMember" xlink:to="lab_roiv_CreditFacilityMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_roiv_CreditFacilityMember" xml:lang="en-US">Credit Facility [Member]</label>
<loc xlink:type="locator" xlink:href="roiv-20210630.xsd#roiv_BusinessAcquisitionCostOfAcquiredEntityAdjustmentPaidInCash" xlink:label="loc_roiv_BusinessAcquisitionCostOfAcquiredEntityAdjustmentPaidInCash" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_roiv_BusinessAcquisitionCostOfAcquiredEntityAdjustmentPaidInCash" xml:lang="en-US">Business Acquisition Cost Of Acquired Entity Adjustment Paid In Cash</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_roiv_BusinessAcquisitionCostOfAcquiredEntityAdjustmentPaidInCash" xml:lang="en-US">Business combination, paid in cash</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_roiv_BusinessAcquisitionCostOfAcquiredEntityAdjustmentPaidInCash" xlink:to="lab_roiv_BusinessAcquisitionCostOfAcquiredEntityAdjustmentPaidInCash" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_roiv_BusinessAcquisitionCostOfAcquiredEntityAdjustmentPaidInCash" xml:lang="en-US">Business Acquisition Cost Of Acquired Entity Adjustment Paid In Cash</label>
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityMethodInvestments" xlink:label="loc_us-gaap_EquityMethodInvestments" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_EquityMethodInvestments" xml:lang="en-US">Equity Method Investments</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_EquityMethodInvestments" xml:lang="en-US">Equity Method Investments</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquityMethodInvestments" xlink:to="lab_us-gaap_EquityMethodInvestments" />
<loc xlink:type="locator" xlink:href="roiv-20210630.xsd#roiv_RevenueInterestPurchaseAndSaleAgreementAmount" xlink:label="loc_roiv_RevenueInterestPurchaseAndSaleAgreementAmount" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_roiv_RevenueInterestPurchaseAndSaleAgreementAmount" xml:lang="en-US">Revenue Interest Purchase And Sale Agreement Amount</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_roiv_RevenueInterestPurchaseAndSaleAgreementAmount" xml:lang="en-US">Revenue interest purchase and sale agreement amount</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_roiv_RevenueInterestPurchaseAndSaleAgreementAmount" xlink:to="lab_roiv_RevenueInterestPurchaseAndSaleAgreementAmount" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_roiv_RevenueInterestPurchaseAndSaleAgreementAmount" xml:lang="en-US">Revenue interest purchase and sale agreement amount.</label>
<loc xlink:type="locator" xlink:href="roiv-20210630.xsd#roiv_RevenueInterestPurchaseAndSaleAgreementCommittedFundToBePaid" xlink:label="loc_roiv_RevenueInterestPurchaseAndSaleAgreementCommittedFundToBePaid" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_roiv_RevenueInterestPurchaseAndSaleAgreementCommittedFundToBePaid" xml:lang="en-US">Revenue Interest Purchase And Sale Agreement Committed Fund To Be Paid</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_roiv_RevenueInterestPurchaseAndSaleAgreementCommittedFundToBePaid" xml:lang="en-US">Revenue interest purchase and sale agreement committed fund to be paid</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_roiv_RevenueInterestPurchaseAndSaleAgreementCommittedFundToBePaid" xlink:to="lab_roiv_RevenueInterestPurchaseAndSaleAgreementCommittedFundToBePaid" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_roiv_RevenueInterestPurchaseAndSaleAgreementCommittedFundToBePaid" xml:lang="en-US">Revenue interest purchase and sale agreement committed fund to be paid.</label>
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventTypeAxis" xlink:label="loc_us-gaap_SubsequentEventTypeAxis" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_SubsequentEventTypeAxis" xml:lang="en-US">Subsequent Event Type [Axis]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_SubsequentEventTypeAxis" xml:lang="en-US">Subsequent Event Type [Axis]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsequentEventTypeAxis" xlink:to="lab_us-gaap_SubsequentEventTypeAxis" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="loc_us-gaap_SubsequentEventTypeDomain" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_SubsequentEventTypeDomain" xml:lang="en-US">Subsequent Event Type [Domain]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_SubsequentEventTypeDomain" xml:lang="en-US">Subsequent Event Type [Domain]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsequentEventTypeDomain" xlink:to="lab_us-gaap_SubsequentEventTypeDomain" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventMember" xlink:label="loc_us-gaap_SubsequentEventMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_SubsequentEventMember" xml:lang="en-US">Subsequent Event [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_SubsequentEventMember" xml:lang="en-US">Subsequent Event [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsequentEventMember" xlink:to="lab_us-gaap_SubsequentEventMember" />
</labelLink>
</linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.PRE
<SEQUENCE>12
<FILENAME>roiv-20210630_pre.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="utf-8"?>
<!--Generated by DFIN XBRL Instance Document - http://www.dfinsolutions.com/ - Version R3.0 - on 30-October-2021 [02:44:34] {AM}-->
<linkbase xmlns="http://www.xbrl.org/2003/linkbase" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
<roleRef xlink:type="simple" xlink:href="roiv-20210630.xsd#Cover" roleURI="http://roivant.com/role/Cover" />
<roleRef xlink:type="simple" xlink:href="roiv-20210630.xsd#CondensedConsolidatedBalanceSheets" roleURI="http://roivant.com/role/CondensedConsolidatedBalanceSheets" />
<roleRef xlink:type="simple" xlink:href="roiv-20210630.xsd#CondensedConsolidatedBalanceSheetsParenthetical" roleURI="http://roivant.com/role/CondensedConsolidatedBalanceSheetsParenthetical" />
<roleRef xlink:type="simple" xlink:href="roiv-20210630.xsd#CondensedConsolidatedStatementsOfOperations" roleURI="http://roivant.com/role/CondensedConsolidatedStatementsOfOperations" />
<roleRef xlink:type="simple" xlink:href="roiv-20210630.xsd#CondensedConsolidatedStatementsOfComprehensiveLoss" roleURI="http://roivant.com/role/CondensedConsolidatedStatementsOfComprehensiveLoss" />
<roleRef xlink:type="simple" xlink:href="roiv-20210630.xsd#CondensedConsolidatedStatementsOfShareholdersEquityAndRedeemableNoncontrollingInterest" roleURI="http://roivant.com/role/CondensedConsolidatedStatementsOfShareholdersEquityAndRedeemableNoncontrollingInterest" />
<roleRef xlink:type="simple" xlink:href="roiv-20210630.xsd#CondensedConsolidatedStatementsOfCashFlows" roleURI="http://roivant.com/role/CondensedConsolidatedStatementsOfCashFlows" />
<roleRef xlink:type="simple" xlink:href="roiv-20210630.xsd#DescriptionOfBusinessAndLiquidity" roleURI="http://roivant.com/role/DescriptionOfBusinessAndLiquidity" />
<roleRef xlink:type="simple" xlink:href="roiv-20210630.xsd#SummaryOfSignificantAccountingPolicies" roleURI="http://roivant.com/role/SummaryOfSignificantAccountingPolicies" />
<roleRef xlink:type="simple" xlink:href="roiv-20210630.xsd#Investments" roleURI="http://roivant.com/role/Investments" />
<roleRef xlink:type="simple" xlink:href="roiv-20210630.xsd#AssetAcquisitionsAndLicenseAgreements" roleURI="http://roivant.com/role/AssetAcquisitionsAndLicenseAgreements" />
<roleRef xlink:type="simple" xlink:href="roiv-20210630.xsd#SumitomoTransactionAgreement" roleURI="http://roivant.com/role/SumitomoTransactionAgreement" />
<roleRef xlink:type="simple" xlink:href="roiv-20210630.xsd#BalanceSheetComponents" roleURI="http://roivant.com/role/BalanceSheetComponents" />
<roleRef xlink:type="simple" xlink:href="roiv-20210630.xsd#LongTermDebtAndLoanCommitment" roleURI="http://roivant.com/role/LongTermDebtAndLoanCommitment" />
<roleRef xlink:type="simple" xlink:href="roiv-20210630.xsd#ShareholdersEquityAndRedeemableNoncontrollingInterest" roleURI="http://roivant.com/role/ShareholdersEquityAndRedeemableNoncontrollingInterest" />
<roleRef xlink:type="simple" xlink:href="roiv-20210630.xsd#ShareBasedCompensation" roleURI="http://roivant.com/role/ShareBasedCompensation" />
<roleRef xlink:type="simple" xlink:href="roiv-20210630.xsd#RelatedPartyTransactions" roleURI="http://roivant.com/role/RelatedPartyTransactions" />
<roleRef xlink:type="simple" xlink:href="roiv-20210630.xsd#DiscontinuedOperations" roleURI="http://roivant.com/role/DiscontinuedOperations" />
<roleRef xlink:type="simple" xlink:href="roiv-20210630.xsd#IncomeTaxes" roleURI="http://roivant.com/role/IncomeTaxes" />
<roleRef xlink:type="simple" xlink:href="roiv-20210630.xsd#Leases" roleURI="http://roivant.com/role/Leases" />
<roleRef xlink:type="simple" xlink:href="roiv-20210630.xsd#CommitmentsContingencies" roleURI="http://roivant.com/role/CommitmentsContingencies" />
<roleRef xlink:type="simple" xlink:href="roiv-20210630.xsd#FairValueMeasurements" roleURI="http://roivant.com/role/FairValueMeasurements" />
<roleRef xlink:type="simple" xlink:href="roiv-20210630.xsd#DefinedContributionPlan" roleURI="http://roivant.com/role/DefinedContributionPlan" />
<roleRef xlink:type="simple" xlink:href="roiv-20210630.xsd#OtherIncomeExpenseNet" roleURI="http://roivant.com/role/OtherIncomeExpenseNet" />
<roleRef xlink:type="simple" xlink:href="roiv-20210630.xsd#NetLossPerCommonShare" roleURI="http://roivant.com/role/NetLossPerCommonShare" />
<roleRef xlink:type="simple" xlink:href="roiv-20210630.xsd#SubsequentEvents" roleURI="http://roivant.com/role/SubsequentEvents" />
<roleRef xlink:type="simple" xlink:href="roiv-20210630.xsd#SummaryOfSignificantAccountingPoliciesPolicies" roleURI="http://roivant.com/role/SummaryOfSignificantAccountingPoliciesPolicies" />
<roleRef xlink:type="simple" xlink:href="roiv-20210630.xsd#SummaryOfSignificantAccountingPoliciesTables" roleURI="http://roivant.com/role/SummaryOfSignificantAccountingPoliciesTables" />
<roleRef xlink:type="simple" xlink:href="roiv-20210630.xsd#DiscontinuedOperationsTables" roleURI="http://roivant.com/role/DiscontinuedOperationsTables" />
<roleRef xlink:type="simple" xlink:href="roiv-20210630.xsd#BalanceSheetComponentsTables" roleURI="http://roivant.com/role/BalanceSheetComponentsTables" />
<roleRef xlink:type="simple" xlink:href="roiv-20210630.xsd#LongTermDebtAndLoanCommitmentTables" roleURI="http://roivant.com/role/LongTermDebtAndLoanCommitmentTables" />
<roleRef xlink:type="simple" xlink:href="roiv-20210630.xsd#ShareholdersEquityAndRedeemableNoncontrollingInterestTables" roleURI="http://roivant.com/role/ShareholdersEquityAndRedeemableNoncontrollingInterestTables" />
<roleRef xlink:type="simple" xlink:href="roiv-20210630.xsd#ShareBasedCompensationTables" roleURI="http://roivant.com/role/ShareBasedCompensationTables" />
<roleRef xlink:type="simple" xlink:href="roiv-20210630.xsd#IncomeTaxesTables" roleURI="http://roivant.com/role/IncomeTaxesTables" />
<roleRef xlink:type="simple" xlink:href="roiv-20210630.xsd#LeasesTables" roleURI="http://roivant.com/role/LeasesTables" />
<roleRef xlink:type="simple" xlink:href="roiv-20210630.xsd#FairValueMeasurementsTables" roleURI="http://roivant.com/role/FairValueMeasurementsTables" />
<roleRef xlink:type="simple" xlink:href="roiv-20210630.xsd#OtherIncomeExpenseNetTables" roleURI="http://roivant.com/role/OtherIncomeExpenseNetTables" />
<roleRef xlink:type="simple" xlink:href="roiv-20210630.xsd#NetLossPerCommonShareTables" roleURI="http://roivant.com/role/NetLossPerCommonShareTables" />
<roleRef xlink:type="simple" xlink:href="roiv-20210630.xsd#DescriptionOfBusinessAndLiquidityAdditionalInformationDetail" roleURI="http://roivant.com/role/DescriptionOfBusinessAndLiquidityAdditionalInformationDetail" />
<roleRef xlink:type="simple" xlink:href="roiv-20210630.xsd#SummaryOfSignificantAccountingPoliciesAdditionalInformationDetail" roleURI="http://roivant.com/role/SummaryOfSignificantAccountingPoliciesAdditionalInformationDetail" />
<roleRef xlink:type="simple" xlink:href="roiv-20210630.xsd#SummaryOfSignificantAccountingPoliciesScheduleOfAggregateAmountsOfCashCashEquivalentsAndRestrictedCashDetail" roleURI="http://roivant.com/role/SummaryOfSignificantAccountingPoliciesScheduleOfAggregateAmountsOfCashCashEquivalentsAndRestrictedCashDetail" />
<roleRef xlink:type="simple" xlink:href="roiv-20210630.xsd#SummaryOfSignificantAccountingPoliciesScheduleOfEstimatedUsefulLivesDetail" roleURI="http://roivant.com/role/SummaryOfSignificantAccountingPoliciesScheduleOfEstimatedUsefulLivesDetail" />
<roleRef xlink:type="simple" xlink:href="roiv-20210630.xsd#InvestmentsAdditionalInformationDetail" roleURI="http://roivant.com/role/InvestmentsAdditionalInformationDetail" />
<roleRef xlink:type="simple" xlink:href="roiv-20210630.xsd#AssetAcquisitionsAndLicenseAgreementsAdditionalInformationDetail" roleURI="http://roivant.com/role/AssetAcquisitionsAndLicenseAgreementsAdditionalInformationDetail" />
<roleRef xlink:type="simple" xlink:href="roiv-20210630.xsd#SumitomoTransactionAgreementAdditionalInformationDetail" roleURI="http://roivant.com/role/SumitomoTransactionAgreementAdditionalInformationDetail" />
<roleRef xlink:type="simple" xlink:href="roiv-20210630.xsd#BalanceSheetComponentsScheduleOfOtherCurrentAssetsDetail" roleURI="http://roivant.com/role/BalanceSheetComponentsScheduleOfOtherCurrentAssetsDetail" />
<roleRef xlink:type="simple" xlink:href="roiv-20210630.xsd#BalanceSheetComponentsScheduleOfAccruedExpensesDetail" roleURI="http://roivant.com/role/BalanceSheetComponentsScheduleOfAccruedExpensesDetail" />
<roleRef xlink:type="simple" xlink:href="roiv-20210630.xsd#BalanceSheetComponentsScheduleOfOtherCurrentLiabilitiesDetail" roleURI="http://roivant.com/role/BalanceSheetComponentsScheduleOfOtherCurrentLiabilitiesDetail" />
<roleRef xlink:type="simple" xlink:href="roiv-20210630.xsd#LongTermDebtAndLoanCommitmentDetail" roleURI="http://roivant.com/role/LongTermDebtAndLoanCommitmentDetail" />
<roleRef xlink:type="simple" xlink:href="roiv-20210630.xsd#LongTermDebtAndLoanCommitmentAdditionalInformationDetail" roleURI="http://roivant.com/role/LongTermDebtAndLoanCommitmentAdditionalInformationDetail" />
<roleRef xlink:type="simple" xlink:href="roiv-20210630.xsd#LongTermDebtAndConvertibleNotesPayableScheduleOfCompanysAnnualPaymentsDetail" roleURI="http://roivant.com/role/LongTermDebtAndConvertibleNotesPayableScheduleOfCompanysAnnualPaymentsDetail" />
<roleRef xlink:type="simple" xlink:href="roiv-20210630.xsd#ShareholdersEquityAndRedeemableNonControllingInterestAdditionalInformationDetail" roleURI="http://roivant.com/role/ShareholdersEquityAndRedeemableNonControllingInterestAdditionalInformationDetail" />
<roleRef xlink:type="simple" xlink:href="roiv-20210630.xsd#ShareholdersEquityAndRedeemableNonControllingInterestScheduleOfPaymentsOfEquitySecuritiesDetail" roleURI="http://roivant.com/role/ShareholdersEquityAndRedeemableNonControllingInterestScheduleOfPaymentsOfEquitySecuritiesDetail" />
<roleRef xlink:type="simple" xlink:href="roiv-20210630.xsd#ShareBasedCompensationAdditionalInformationDetail" roleURI="http://roivant.com/role/ShareBasedCompensationAdditionalInformationDetail" />
<roleRef xlink:type="simple" xlink:href="roiv-20210630.xsd#ShareBasedCompensationScheduleOfFairValueAssumptionsDetail" roleURI="http://roivant.com/role/ShareBasedCompensationScheduleOfFairValueAssumptionsDetail" />
<roleRef xlink:type="simple" xlink:href="roiv-20210630.xsd#ShareBasedCompensationSummaryOfStockOptionActivityDetail" roleURI="http://roivant.com/role/ShareBasedCompensationSummaryOfStockOptionActivityDetail" />
<roleRef xlink:type="simple" xlink:href="roiv-20210630.xsd#ShareBasedCompensationSummaryOfFairValueOfVestedStockOptionDetail" roleURI="http://roivant.com/role/ShareBasedCompensationSummaryOfFairValueOfVestedStockOptionDetail" />
<roleRef xlink:type="simple" xlink:href="roiv-20210630.xsd#ShareBasedCompensationSummaryOfRestrictedStockUnitsDetail" roleURI="http://roivant.com/role/ShareBasedCompensationSummaryOfRestrictedStockUnitsDetail" />
<roleRef xlink:type="simple" xlink:href="roiv-20210630.xsd#ShareBasedCompensationSummaryOfPerformanceOptionsActivityDetail" roleURI="http://roivant.com/role/ShareBasedCompensationSummaryOfPerformanceOptionsActivityDetail" />
<roleRef xlink:type="simple" xlink:href="roiv-20210630.xsd#ShareBasedCompensationSummaryOfCappedValueAppreciationRightsDetail" roleURI="http://roivant.com/role/ShareBasedCompensationSummaryOfCappedValueAppreciationRightsDetail" />
<roleRef xlink:type="simple" xlink:href="roiv-20210630.xsd#ShareBasedCompensationSummaryOfPerformanceRestrictedStockUnitsDetail" roleURI="http://roivant.com/role/ShareBasedCompensationSummaryOfPerformanceRestrictedStockUnitsDetail" />
<roleRef xlink:type="simple" xlink:href="roiv-20210630.xsd#ShareBasedCompensationSummaryOfCommonShareAwardActivityDetail" roleURI="http://roivant.com/role/ShareBasedCompensationSummaryOfCommonShareAwardActivityDetail" />
<roleRef xlink:type="simple" xlink:href="roiv-20210630.xsd#ShareBasedCompensationSummaryOfShareBasedCompensationExpenseDetail" roleURI="http://roivant.com/role/ShareBasedCompensationSummaryOfShareBasedCompensationExpenseDetail" />
<roleRef xlink:type="simple" xlink:href="roiv-20210630.xsd#DiscontinuedOperationsSummaryOfDisposalGroupsIncludingDiscontinuedOperationsIncomeStatementDetail" roleURI="http://roivant.com/role/DiscontinuedOperationsSummaryOfDisposalGroupsIncludingDiscontinuedOperationsIncomeStatementDetail" />
<roleRef xlink:type="simple" xlink:href="roiv-20210630.xsd#DiscontinuedOperationsSummaryOfCashFlowsFromDiscontinuedOperationsDetail" roleURI="http://roivant.com/role/DiscontinuedOperationsSummaryOfCashFlowsFromDiscontinuedOperationsDetail" />
<roleRef xlink:type="simple" xlink:href="roiv-20210630.xsd#RelatedPartyTransactionsAdditionalInformationDetail" roleURI="http://roivant.com/role/RelatedPartyTransactionsAdditionalInformationDetail" />
<roleRef xlink:type="simple" xlink:href="roiv-20210630.xsd#IncomeTaxesScheduleOfLossBeforeIncomeTaxesByGeographicRegionDetail" roleURI="http://roivant.com/role/IncomeTaxesScheduleOfLossBeforeIncomeTaxesByGeographicRegionDetail" />
<roleRef xlink:type="simple" xlink:href="roiv-20210630.xsd#IncomeTaxesScheduleComponentsOfIncomeTaxExpenseBenefitDetail" roleURI="http://roivant.com/role/IncomeTaxesScheduleComponentsOfIncomeTaxExpenseBenefitDetail" />
<roleRef xlink:type="simple" xlink:href="roiv-20210630.xsd#IncomeTaxesAdditionalInformationDetail" roleURI="http://roivant.com/role/IncomeTaxesAdditionalInformationDetail" />
<roleRef xlink:type="simple" xlink:href="roiv-20210630.xsd#IncomeTaxesScheduleOfDeferredTaxAssetsLiabilitiesDetail" roleURI="http://roivant.com/role/IncomeTaxesScheduleOfDeferredTaxAssetsLiabilitiesDetail" />
<roleRef xlink:type="simple" xlink:href="roiv-20210630.xsd#IncomeTaxesScheduleOfEffectiveIncomeTaxRateReconciliationDetail" roleURI="http://roivant.com/role/IncomeTaxesScheduleOfEffectiveIncomeTaxRateReconciliationDetail" />
<roleRef xlink:type="simple" xlink:href="roiv-20210630.xsd#LeasesScheduleOfMaturitiesOfOperatingLeaseLiabilitiesDetail" roleURI="http://roivant.com/role/LeasesScheduleOfMaturitiesOfOperatingLeaseLiabilitiesDetail" />
<roleRef xlink:type="simple" xlink:href="roiv-20210630.xsd#LeasesSummaryOfOperatingLeaseRouAssetsAndOperatingLeaseLiabilitiesDetail" roleURI="http://roivant.com/role/LeasesSummaryOfOperatingLeaseRouAssetsAndOperatingLeaseLiabilitiesDetail" />
<roleRef xlink:type="simple" xlink:href="roiv-20210630.xsd#LeasesScheduleOfOperatingLeaseCostsDetail" roleURI="http://roivant.com/role/LeasesScheduleOfOperatingLeaseCostsDetail" />
<roleRef xlink:type="simple" xlink:href="roiv-20210630.xsd#FairValueMeasurementsScheduleOfAssetsAndLiabilitiesMeasuredAtFairValueOnARecurringBasisDetail" roleURI="http://roivant.com/role/FairValueMeasurementsScheduleOfAssetsAndLiabilitiesMeasuredAtFairValueOnARecurringBasisDetail" />
<roleRef xlink:type="simple" xlink:href="roiv-20210630.xsd#FairValueMeasurementsAdditionalInformationDetail" roleURI="http://roivant.com/role/FairValueMeasurementsAdditionalInformationDetail" />
<roleRef xlink:type="simple" xlink:href="roiv-20210630.xsd#FairValueMeasurementsChangeInTheFairValueOfTheDerivativeWarrantLiabilitiesDetail" roleURI="http://roivant.com/role/FairValueMeasurementsChangeInTheFairValueOfTheDerivativeWarrantLiabilitiesDetail" />
<roleRef xlink:type="simple" xlink:href="roiv-20210630.xsd#FairValueMeasurementsScheduleOfFairValueOfUnobservableInputRelatedToOptionsToAcquireUnderSumitomoTransactionAgreementDetail" roleURI="http://roivant.com/role/FairValueMeasurementsScheduleOfFairValueOfUnobservableInputRelatedToOptionsToAcquireUnderSumitomoTransactionAgreementDetail" />
<roleRef xlink:type="simple" xlink:href="roiv-20210630.xsd#DefinedContributionPlanAdditionalInformationDetail" roleURI="http://roivant.com/role/DefinedContributionPlanAdditionalInformationDetail" />
<roleRef xlink:type="simple" xlink:href="roiv-20210630.xsd#OtherIncomeExpenseNetSummaryOfOtherIncomeExpenseNetFromContinuingOperationsDetail" roleURI="http://roivant.com/role/OtherIncomeExpenseNetSummaryOfOtherIncomeExpenseNetFromContinuingOperationsDetail" />
<roleRef xlink:type="simple" xlink:href="roiv-20210630.xsd#NetLossPerCommonShareSummaryOfBasicAndDilutedNetIncomePerShareOfCommonStockDetail" roleURI="http://roivant.com/role/NetLossPerCommonShareSummaryOfBasicAndDilutedNetIncomePerShareOfCommonStockDetail" />
<roleRef xlink:type="simple" xlink:href="roiv-20210630.xsd#NetLossPerCommonShareSummaryOfBasicAndDilutedNetIncomePerShareOfCommonStockParentheticalDetail" roleURI="http://roivant.com/role/NetLossPerCommonShareSummaryOfBasicAndDilutedNetIncomePerShareOfCommonStockParentheticalDetail" />
<roleRef xlink:type="simple" xlink:href="roiv-20210630.xsd#SubsequentEventsAdditionalInformationDetail" roleURI="http://roivant.com/role/SubsequentEventsAdditionalInformationDetail" />
<presentationLink xlink:type="extended" xlink:role="http://roivant.com/role/Cover">
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_CoverAbstract" xlink:label="loc_dei_CoverAbstract_2" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_DocumentType" xlink:label="loc_dei_DocumentType_3" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_2" xlink:to="loc_dei_DocumentType_3" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_AmendmentFlag" xlink:label="loc_dei_AmendmentFlag_4" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_2" xlink:to="loc_dei_AmendmentFlag_4" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityRegistrantName" xlink:label="loc_dei_EntityRegistrantName_5" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_2" xlink:to="loc_dei_EntityRegistrantName_5" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityCentralIndexKey" xlink:label="loc_dei_EntityCentralIndexKey_6" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_2" xlink:to="loc_dei_EntityCentralIndexKey_6" use="optional" order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityFilerCategory" xlink:label="loc_dei_EntityFilerCategory_7" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_2" xlink:to="loc_dei_EntityFilerCategory_7" use="optional" order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntitySmallBusiness" xlink:label="loc_dei_EntitySmallBusiness_8" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_2" xlink:to="loc_dei_EntitySmallBusiness_8" use="optional" order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityEmergingGrowthCompany" xlink:label="loc_dei_EntityEmergingGrowthCompany_9" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_2" xlink:to="loc_dei_EntityEmergingGrowthCompany_9" use="optional" order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityExTransitionPeriod" xlink:label="loc_dei_EntityExTransitionPeriod_10" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_2" xlink:to="loc_dei_EntityExTransitionPeriod_10" use="optional" order="8" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://roivant.com/role/CondensedConsolidatedBalanceSheets">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementOfFinancialPositionAbstract" xlink:label="loc_us-gaap_StatementOfFinancialPositionAbstract_12" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaap_StatementTable_22" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_12" xlink:to="loc_us-gaap_StatementTable_22" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_LegalEntityAxis" xlink:label="loc_dei_LegalEntityAxis_17" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_22" xlink:to="loc_dei_LegalEntityAxis_17" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityDomain" xlink:label="loc_dei_EntityDomain_16" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_LegalEntityAxis_17" xlink:to="loc_dei_EntityDomain_16" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="loc_us-gaap_StatementClassOfStockAxis_20" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_22" xlink:to="loc_us-gaap_StatementClassOfStockAxis_20" use="optional" order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaap_ClassOfStockDomain_15" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementClassOfStockAxis_20" xlink:to="loc_us-gaap_ClassOfStockDomain_15" use="optional" order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaap_StatementLineItems_21" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_22" xlink:to="loc_us-gaap_StatementLineItems_21" use="optional" order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetsAbstract" xlink:label="loc_us-gaap_AssetsAbstract_13" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_21" xlink:to="loc_us-gaap_AssetsAbstract_13" use="optional" order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetsCurrentAbstract" xlink:label="loc_us-gaap_AssetsCurrentAbstract_14" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_13" xlink:to="loc_us-gaap_AssetsCurrentAbstract_14" use="optional" order="8" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_32" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_14" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_32" use="optional" order="9" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestrictedCashCurrent" xlink:label="loc_us-gaap_RestrictedCashCurrent_34" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_14" xlink:to="loc_us-gaap_RestrictedCashCurrent_34" use="optional" order="10" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherAssetsCurrent" xlink:label="loc_us-gaap_OtherAssetsCurrent_36" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_14" xlink:to="loc_us-gaap_OtherAssetsCurrent_36" use="optional" order="11" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetsCurrent" xlink:label="loc_us-gaap_AssetsCurrent_38" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_14" xlink:to="loc_us-gaap_AssetsCurrent_38" use="optional" order="12" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet_24" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_13" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentNet_24" use="optional" order="13" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseRightOfUseAsset" xlink:label="loc_us-gaap_OperatingLeaseRightOfUseAsset_26" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_13" xlink:to="loc_us-gaap_OperatingLeaseRightOfUseAsset_26" use="optional" order="14" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestrictedCashNoncurrent" xlink:label="loc_us-gaap_RestrictedCashNoncurrent_27" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_13" xlink:to="loc_us-gaap_RestrictedCashNoncurrent_27" use="optional" order="15" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InvestmentsFairValueDisclosure" xlink:label="loc_us-gaap_InvestmentsFairValueDisclosure_28" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_13" xlink:to="loc_us-gaap_InvestmentsFairValueDisclosure_28" use="optional" order="16" preferredLabel="http://www.xbrl.org/2003/role/positiveLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongTermInvestments" xlink:label="loc_us-gaap_LongTermInvestments_29" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_13" xlink:to="loc_us-gaap_LongTermInvestments_29" use="optional" order="17" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherAssetsNoncurrent" xlink:label="loc_us-gaap_OtherAssetsNoncurrent_30" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_13" xlink:to="loc_us-gaap_OtherAssetsNoncurrent_30" use="optional" order="18" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Assets" xlink:label="loc_us-gaap_Assets_31" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_13" xlink:to="loc_us-gaap_Assets_31" use="optional" order="19" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_18" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_21" xlink:to="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_18" use="optional" order="20" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesCurrentAbstract" xlink:label="loc_us-gaap_LiabilitiesCurrentAbstract_19" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_18" xlink:to="loc_us-gaap_LiabilitiesCurrentAbstract_19" use="optional" order="21" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountsPayableCurrent" xlink:label="loc_us-gaap_AccountsPayableCurrent_55" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_19" xlink:to="loc_us-gaap_AccountsPayableCurrent_55" use="optional" order="22" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccruedLiabilitiesCurrent" xlink:label="loc_us-gaap_AccruedLiabilitiesCurrent_56" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_19" xlink:to="loc_us-gaap_AccruedLiabilitiesCurrent_56" use="optional" order="23" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseLiabilityCurrent" xlink:label="loc_us-gaap_OperatingLeaseLiabilityCurrent_57" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_19" xlink:to="loc_us-gaap_OperatingLeaseLiabilityCurrent_57" use="optional" order="24" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="roiv-20210630.xsd#roiv_DeferredConsiderationLiabilityCurrent" xlink:label="loc_roiv_DeferredConsiderationLiabilityCurrent_1106509" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_19" xlink:to="loc_roiv_DeferredConsiderationLiabilityCurrent_1106509" use="optional" order="25" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherLiabilitiesCurrent" xlink:label="loc_us-gaap_OtherLiabilitiesCurrent_61" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_19" xlink:to="loc_us-gaap_OtherLiabilitiesCurrent_61" use="optional" order="26" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesCurrent" xlink:label="loc_us-gaap_LiabilitiesCurrent_62" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_19" xlink:to="loc_us-gaap_LiabilitiesCurrent_62" use="optional" order="27" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
<loc xlink:type="locator" xlink:href="roiv-20210630.xsd#roiv_LiabilityInstrumentsMeasuredAtFairValue" xlink:label="loc_roiv_LiabilityInstrumentsMeasuredAtFairValue_1106513" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_18" xlink:to="loc_roiv_LiabilityInstrumentsMeasuredAtFairValue_1106513" use="optional" order="28" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:label="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_44" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_18" xlink:to="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_44" use="optional" order="29" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongTermDebtNoncurrent" xlink:label="loc_us-gaap_LongTermDebtNoncurrent_46" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_18" xlink:to="loc_us-gaap_LongTermDebtNoncurrent_46" use="optional" order="30" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherLiabilitiesNoncurrent" xlink:label="loc_us-gaap_OtherLiabilitiesNoncurrent_47" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_18" xlink:to="loc_us-gaap_OtherLiabilitiesNoncurrent_47" use="optional" order="31" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Liabilities" xlink:label="loc_us-gaap_Liabilities_48" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_18" xlink:to="loc_us-gaap_Liabilities_48" use="optional" order="32" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommitmentsAndContingencies" xlink:label="loc_us-gaap_CommitmentsAndContingencies_49" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_18" xlink:to="loc_us-gaap_CommitmentsAndContingencies_49" use="optional" order="33" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RedeemableNoncontrollingInterestEquityCarryingAmount" xlink:label="loc_us-gaap_RedeemableNoncontrollingInterestEquityCarryingAmount_50" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_18" xlink:to="loc_us-gaap_RedeemableNoncontrollingInterestEquityCarryingAmount_50" use="optional" order="34" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquityAbstract" xlink:label="loc_us-gaap_StockholdersEquityAbstract_23" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_18" xlink:to="loc_us-gaap_StockholdersEquityAbstract_23" use="optional" order="35" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockValue" xlink:label="loc_us-gaap_CommonStockValue_64" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_23" xlink:to="loc_us-gaap_CommonStockValue_64" use="optional" order="36" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdditionalPaidInCapital" xlink:label="loc_us-gaap_AdditionalPaidInCapital_65" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_23" xlink:to="loc_us-gaap_AdditionalPaidInCapital_65" use="optional" order="37" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="roiv-20210630.xsd#roiv_SubscriptionsReceivable" xlink:label="loc_roiv_SubscriptionsReceivable_66" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_23" xlink:to="loc_roiv_SubscriptionsReceivable_66" use="optional" order="38" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit_67" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_23" xlink:to="loc_us-gaap_RetainedEarningsAccumulatedDeficit_67" use="optional" order="39" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_68" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_23" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_68" use="optional" order="40" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquity" xlink:label="loc_us-gaap_StockholdersEquity_69" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_23" xlink:to="loc_us-gaap_StockholdersEquity_69" use="optional" order="41" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MinorityInterest" xlink:label="loc_us-gaap_MinorityInterest_52" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_18" xlink:to="loc_us-gaap_MinorityInterest_52" use="optional" order="42" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:label="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_53" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_18" xlink:to="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_53" use="optional" order="43" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquity_54" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_18" xlink:to="loc_us-gaap_LiabilitiesAndStockholdersEquity_54" use="optional" order="44" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://roivant.com/role/CondensedConsolidatedBalanceSheetsParenthetical">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementOfFinancialPositionAbstract" xlink:label="loc_us-gaap_StatementOfFinancialPositionAbstract_71" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaap_StatementTable_77" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_71" xlink:to="loc_us-gaap_StatementTable_77" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="loc_us-gaap_StatementClassOfStockAxis_75" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_77" xlink:to="loc_us-gaap_StatementClassOfStockAxis_75" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaap_ClassOfStockDomain_72" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementClassOfStockAxis_75" xlink:to="loc_us-gaap_ClassOfStockDomain_72" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_LegalEntityAxis" xlink:label="loc_dei_LegalEntityAxis_74" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_77" xlink:to="loc_dei_LegalEntityAxis_74" use="optional" order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityDomain" xlink:label="loc_dei_EntityDomain_73" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_LegalEntityAxis_74" xlink:to="loc_dei_EntityDomain_73" use="optional" order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaap_StatementLineItems_76" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_77" xlink:to="loc_us-gaap_StatementLineItems_76" use="optional" order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongTermDebtFairValue" xlink:label="loc_us-gaap_LongTermDebtFairValue_82" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_76" xlink:to="loc_us-gaap_LongTermDebtFairValue_82" use="optional" order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:label="loc_us-gaap_CommonStockParOrStatedValuePerShare_89" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_76" xlink:to="loc_us-gaap_CommonStockParOrStatedValuePerShare_89" use="optional" order="8" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockSharesAuthorized" xlink:label="loc_us-gaap_CommonStockSharesAuthorized_90" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_76" xlink:to="loc_us-gaap_CommonStockSharesAuthorized_90" use="optional" order="9" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockSharesIssued" xlink:label="loc_us-gaap_CommonStockSharesIssued_91" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_76" xlink:to="loc_us-gaap_CommonStockSharesIssued_91" use="optional" order="10" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockSharesOutstanding" xlink:label="loc_us-gaap_CommonStockSharesOutstanding_92" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_76" xlink:to="loc_us-gaap_CommonStockSharesOutstanding_92" use="optional" order="11" preferredLabel="http://www.xbrl.org/2003/role/positiveLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://roivant.com/role/CondensedConsolidatedStatementsOfOperations">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeStatementAbstract" xlink:label="loc_us-gaap_IncomeStatementAbstract_95" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaap_StatementTable_104" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_95" xlink:to="loc_us-gaap_StatementTable_104" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_LegalEntityAxis" xlink:label="loc_dei_LegalEntityAxis_100" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_104" xlink:to="loc_dei_LegalEntityAxis_100" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityDomain" xlink:label="loc_dei_EntityDomain_98" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_LegalEntityAxis_100" xlink:to="loc_dei_EntityDomain_98" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaap_StatementLineItems_103" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_104" xlink:to="loc_us-gaap_StatementLineItems_103" use="optional" order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_130" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_103" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_130" use="optional" order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingExpensesAbstract" xlink:label="loc_us-gaap_OperatingExpensesAbstract_101" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_103" xlink:to="loc_us-gaap_OperatingExpensesAbstract_101" use="optional" order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="roiv-20210630.xsd#roiv_OperatingCosts" xlink:label="loc_roiv_OperatingCosts_116" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingExpensesAbstract_101" xlink:to="loc_roiv_OperatingCosts_116" use="optional" order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpense_117" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingExpensesAbstract_101" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpense_117" use="optional" order="8" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GeneralAndAdministrativeExpense" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpense_118" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingExpensesAbstract_101" xlink:to="loc_us-gaap_GeneralAndAdministrativeExpense_118" use="optional" order="9" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingExpenses" xlink:label="loc_us-gaap_OperatingExpenses_119" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingExpensesAbstract_101" xlink:to="loc_us-gaap_OperatingExpenses_119" use="optional" order="10" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingIncomeLoss" xlink:label="loc_us-gaap_OperatingIncomeLoss_131" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_103" xlink:to="loc_us-gaap_OperatingIncomeLoss_131" use="optional" order="11" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherNonoperatingIncomeExpenseAbstract" xlink:label="loc_us-gaap_OtherNonoperatingIncomeExpenseAbstract_102" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_103" xlink:to="loc_us-gaap_OtherNonoperatingIncomeExpenseAbstract_102" use="optional" order="12" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GainLossOnInvestments" xlink:label="loc_us-gaap_GainLossOnInvestments_122" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherNonoperatingIncomeExpenseAbstract_102" xlink:to="loc_us-gaap_GainLossOnInvestments_122" use="optional" order="13" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
<loc xlink:type="locator" xlink:href="roiv-20210630.xsd#roiv_GainLossOnFairValueOfDebtAndLiabilityInstruments" xlink:label="loc_roiv_GainLossOnFairValueOfDebtAndLiabilityInstruments_124" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherNonoperatingIncomeExpenseAbstract_102" xlink:to="loc_roiv_GainLossOnFairValueOfDebtAndLiabilityInstruments_124" use="optional" order="14" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
<loc xlink:type="locator" xlink:href="roiv-20210630.xsd#roiv_EquityInterestOptionToThirdPartyPurchaserGainOnTermination" xlink:label="loc_roiv_EquityInterestOptionToThirdPartyPurchaserGainOnTermination_1106522" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherNonoperatingIncomeExpenseAbstract_102" xlink:to="loc_roiv_EquityInterestOptionToThirdPartyPurchaserGainOnTermination_1106522" use="optional" order="15" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
<loc xlink:type="locator" xlink:href="roiv-20210630.xsd#roiv_GainOrLossOnDeconsolidationOfSubsidiary" xlink:label="loc_roiv_GainOrLossOnDeconsolidationOfSubsidiary_1107932" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherNonoperatingIncomeExpenseAbstract_102" xlink:to="loc_roiv_GainOrLossOnDeconsolidationOfSubsidiary_1107932" use="optional" order="16" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
<loc xlink:type="locator" xlink:href="roiv-20210630.xsd#roiv_DeconsolidationAndConsolidationOnGainOrLossOfConsolidatedEntity" xlink:label="loc_roiv_DeconsolidationAndConsolidationOnGainOrLossOfConsolidatedEntity_126" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherNonoperatingIncomeExpenseAbstract_102" xlink:to="loc_roiv_DeconsolidationAndConsolidationOnGainOrLossOfConsolidatedEntity_126" use="optional" order="17" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherNonoperatingIncomeExpense" xlink:label="loc_us-gaap_OtherNonoperatingIncomeExpense_128" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherNonoperatingIncomeExpenseAbstract_102" xlink:to="loc_us-gaap_OtherNonoperatingIncomeExpense_128" use="optional" order="18" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments_132" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_103" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments_132" use="optional" order="19" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_133" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_103" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_133" use="optional" order="20" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxExpenseBenefit" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit_134" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_103" xlink:to="loc_us-gaap_IncomeTaxExpenseBenefit_134" use="optional" order="21" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest_135" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_103" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest_135" use="optional" order="22" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTax" xlink:label="loc_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTax_136" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_103" xlink:to="loc_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTax_136" use="optional" order="23" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProfitLoss" xlink:label="loc_us-gaap_ProfitLoss_137" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_103" xlink:to="loc_us-gaap_ProfitLoss_137" use="optional" order="24" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetIncomeLossAttributableToNoncontrollingInterest" xlink:label="loc_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest_138" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_103" xlink:to="loc_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest_138" use="optional" order="25" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaap_NetIncomeLoss_139" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_103" xlink:to="loc_us-gaap_NetIncomeLoss_139" use="optional" order="26" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeAmountsAttributableToReportingEntityDisclosuresAbstract" xlink:label="loc_us-gaap_IncomeAmountsAttributableToReportingEntityDisclosuresAbstract_99" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_103" xlink:to="loc_us-gaap_IncomeAmountsAttributableToReportingEntityDisclosuresAbstract_99" use="optional" order="27" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeLossFromContinuingOperations" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperations_114" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeAmountsAttributableToReportingEntityDisclosuresAbstract_99" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperations_114" use="optional" order="28" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity" xlink:label="loc_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity_115" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeAmountsAttributableToReportingEntityDisclosuresAbstract_99" xlink:to="loc_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity_115" use="optional" order="29" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaap_NetIncomeLoss_140" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_103" xlink:to="loc_us-gaap_NetIncomeLoss_140" use="optional" order="30" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerShareBasicAndDilutedAbstract" xlink:label="loc_us-gaap_EarningsPerShareBasicAndDilutedAbstract_96" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_103" xlink:to="loc_us-gaap_EarningsPerShareBasicAndDilutedAbstract_96" use="optional" order="31" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsPerBasicAndDilutedShare" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsPerBasicAndDilutedShare_105" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareBasicAndDilutedAbstract_96" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsPerBasicAndDilutedShare_105" use="optional" order="32" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicAndDilutedShare" xlink:label="loc_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicAndDilutedShare_106" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareBasicAndDilutedAbstract_96" xlink:to="loc_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicAndDilutedShare_106" use="optional" order="33" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerShareBasicAndDiluted" xlink:label="loc_us-gaap_EarningsPerShareBasicAndDiluted_107" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareBasicAndDilutedAbstract_96" xlink:to="loc_us-gaap_EarningsPerShareBasicAndDiluted_107" use="optional" order="34" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerShareBasicAndDilutedOtherDisclosuresAbstract" xlink:label="loc_us-gaap_EarningsPerShareBasicAndDilutedOtherDisclosuresAbstract_97" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_103" xlink:to="loc_us-gaap_EarningsPerShareBasicAndDilutedOtherDisclosuresAbstract_97" use="optional" order="35" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_108" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareBasicAndDilutedOtherDisclosuresAbstract_97" xlink:to="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_108" use="optional" order="36" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:label="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_110" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareBasicAndDilutedOtherDisclosuresAbstract_97" xlink:to="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_110" use="optional" order="37" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted" xlink:label="loc_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted_112" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareBasicAndDilutedOtherDisclosuresAbstract_97" xlink:to="loc_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted_112" use="optional" order="38" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://roivant.com/role/CondensedConsolidatedStatementsOfComprehensiveLoss">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementOfStockholdersEquityAbstract" xlink:label="loc_us-gaap_StatementOfStockholdersEquityAbstract_882" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProfitLoss" xlink:label="loc_us-gaap_ProfitLoss_886" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfStockholdersEquityAbstract_882" xlink:to="loc_us-gaap_ProfitLoss_886" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossTaxAbstract" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossTaxAbstract_883" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfStockholdersEquityAbstract_882" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossTaxAbstract_883" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax" xlink:label="loc_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax_884" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossTaxAbstract_883" xlink:to="loc_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax_884" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTax" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTax_885" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossTaxAbstract_883" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTax_885" use="optional" order="4" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest_887" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfStockholdersEquityAbstract_882" xlink:to="loc_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest_887" use="optional" order="5" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest_888" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfStockholdersEquityAbstract_882" xlink:to="loc_us-gaap_ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest_888" use="optional" order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ComprehensiveIncomeNetOfTax" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTax_889" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfStockholdersEquityAbstract_882" xlink:to="loc_us-gaap_ComprehensiveIncomeNetOfTax_889" use="optional" order="7" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://roivant.com/role/CondensedConsolidatedStatementsOfShareholdersEquityAndRedeemableNoncontrollingInterest">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementOfPartnersCapitalAbstract" xlink:label="loc_us-gaap_StatementOfPartnersCapitalAbstract_142" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaap_StatementTable_150" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfPartnersCapitalAbstract_142" xlink:to="loc_us-gaap_StatementTable_150" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_148" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_150" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_148" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaap_EquityComponentDomain_145" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_148" xlink:to="loc_us-gaap_EquityComponentDomain_145" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockMember" xlink:label="loc_us-gaap_CommonStockMember_155" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_145" xlink:to="loc_us-gaap_CommonStockMember_155" use="optional" order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdditionalPaidInCapitalMember" xlink:label="loc_us-gaap_AdditionalPaidInCapitalMember_156" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_145" xlink:to="loc_us-gaap_AdditionalPaidInCapitalMember_156" use="optional" order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="roiv-20210630.xsd#roiv_SubscriptionsReceivablesMember" xlink:label="loc_roiv_SubscriptionsReceivablesMember_158" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_145" xlink:to="loc_roiv_SubscriptionsReceivablesMember_158" use="optional" order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember_159" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_145" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember_159" use="optional" order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RetainedEarningsMember" xlink:label="loc_us-gaap_RetainedEarningsMember_157" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_145" xlink:to="loc_us-gaap_RetainedEarningsMember_157" use="optional" order="8" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NoncontrollingInterestMember" xlink:label="loc_us-gaap_NoncontrollingInterestMember_160" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_145" xlink:to="loc_us-gaap_NoncontrollingInterestMember_160" use="optional" order="9" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="loc_us-gaap_StatementClassOfStockAxis_147" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_150" xlink:to="loc_us-gaap_StatementClassOfStockAxis_147" use="optional" order="10" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaap_ClassOfStockDomain_143" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementClassOfStockAxis_147" xlink:to="loc_us-gaap_ClassOfStockDomain_143" use="optional" order="11" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="roiv-20210630.xsd#roiv_RedeemableNoncontrollingInterestMember" xlink:label="loc_roiv_RedeemableNoncontrollingInterestMember_153" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockDomain_143" xlink:to="loc_roiv_RedeemableNoncontrollingInterestMember_153" use="optional" order="12" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaap_StatementLineItems_149" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_150" xlink:to="loc_us-gaap_StatementLineItems_149" use="optional" order="13" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TemporaryEquityCarryingAmountIncludingPortionAttributableToNoncontrollingInterests" xlink:label="loc_us-gaap_TemporaryEquityCarryingAmountIncludingPortionAttributableToNoncontrollingInterests_161" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_149" xlink:to="loc_us-gaap_TemporaryEquityCarryingAmountIncludingPortionAttributableToNoncontrollingInterests_161" use="optional" order="14" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:label="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_166" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_149" xlink:to="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_166" use="optional" order="15" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharesOutstanding" xlink:label="loc_us-gaap_SharesOutstanding_167" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_149" xlink:to="loc_us-gaap_SharesOutstanding_167" use="optional" order="16" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TemporaryEquityStockIssuedDuringPeriodValueNewIssues" xlink:label="loc_us-gaap_TemporaryEquityStockIssuedDuringPeriodValueNewIssues_163" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_149" xlink:to="loc_us-gaap_TemporaryEquityStockIssuedDuringPeriodValueNewIssues_163" use="optional" order="17" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalIncreaseInCarryingAmountOfRedeemablePreferredStock" xlink:label="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalIncreaseInCarryingAmountOfRedeemablePreferredStock_171" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_149" xlink:to="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalIncreaseInCarryingAmountOfRedeemablePreferredStock_171" use="optional" order="18" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
<loc xlink:type="locator" xlink:href="roiv-20210630.xsd#roiv_IssuanceOfSubsidiaryCommonSharesNetValue" xlink:label="loc_roiv_IssuanceOfSubsidiaryCommonSharesNetValue_168" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_149" xlink:to="loc_roiv_IssuanceOfSubsidiaryCommonSharesNetValue_168" use="optional" order="19" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="roiv-20210630.xsd#roiv_IssuanceOfSubsidiaryCommonSharesToTheCompanyValue" xlink:label="loc_roiv_IssuanceOfSubsidiaryCommonSharesToTheCompanyValue_169" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_149" xlink:to="loc_roiv_IssuanceOfSubsidiaryCommonSharesToTheCompanyValue_169" use="optional" order="20" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="roiv-20210630.xsd#roiv_PurchaseOfSubsidiaryCommonSharesValue" xlink:label="loc_roiv_PurchaseOfSubsidiaryCommonSharesValue_170" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_149" xlink:to="loc_roiv_PurchaseOfSubsidiaryCommonSharesValue_170" use="optional" order="21" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
<loc xlink:type="locator" xlink:href="roiv-20210630.xsd#roiv_IssuanceOfSubsidiaryWarrants" xlink:label="loc_roiv_IssuanceOfSubsidiaryWarrants_172" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_149" xlink:to="loc_roiv_IssuanceOfSubsidiaryWarrants_172" use="optional" order="22" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_173" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_149" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_173" use="optional" order="23" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueNewIssues_174" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_149" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueNewIssues_174" use="optional" order="24" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_175" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_149" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_175" use="optional" order="25" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="roiv-20210630.xsd#roiv_RepurchaseOfCommonSharesAndOtherEquityInstrumentsValue" xlink:label="loc_roiv_RepurchaseOfCommonSharesAndOtherEquityInstrumentsValue_176" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_149" xlink:to="loc_roiv_RepurchaseOfCommonSharesAndOtherEquityInstrumentsValue_176" use="optional" order="26" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
<loc xlink:type="locator" xlink:href="roiv-20210630.xsd#roiv_ExerciseOfSubsidiaryStockOptionsAndVestingOfSubsidiaryRestrictedStockUnits" xlink:label="loc_roiv_ExerciseOfSubsidiaryStockOptionsAndVestingOfSubsidiaryRestrictedStockUnits_178" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_149" xlink:to="loc_roiv_ExerciseOfSubsidiaryStockOptionsAndVestingOfSubsidiaryRestrictedStockUnits_178" use="optional" order="27" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="roiv-20210630.xsd#roiv_RepurchaseOfCommonSharesAndOtherEquityInstrumentsShares" xlink:label="loc_roiv_RepurchaseOfCommonSharesAndOtherEquityInstrumentsShares_179" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_149" xlink:to="loc_roiv_RepurchaseOfCommonSharesAndOtherEquityInstrumentsShares_179" use="optional" order="28" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GainOrLossOnSaleOfStockInSubsidiary" xlink:label="loc_us-gaap_GainOrLossOnSaleOfStockInSubsidiary_181" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_149" xlink:to="loc_us-gaap_GainOrLossOnSaleOfStockInSubsidiary_181" use="optional" order="29" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="roiv-20210630.xsd#roiv_IssuanceOfEquityBySubsidiaryUponBusinessCombinationAndRecapitalization" xlink:label="loc_roiv_IssuanceOfEquityBySubsidiaryUponBusinessCombinationAndRecapitalization_183" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_149" xlink:to="loc_roiv_IssuanceOfEquityBySubsidiaryUponBusinessCombinationAndRecapitalization_183" use="optional" order="30" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="roiv-20210630.xsd#roiv_IssuanceOfEquityBySubsidiaryToTheCompanyUponBusinessCombinationAndRecapitalization" xlink:label="loc_roiv_IssuanceOfEquityBySubsidiaryToTheCompanyUponBusinessCombinationAndRecapitalization_185" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_149" xlink:to="loc_roiv_IssuanceOfEquityBySubsidiaryToTheCompanyUponBusinessCombinationAndRecapitalization_185" use="optional" order="31" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="roiv-20210630.xsd#roiv_ConversionOfSubsidiaryConvertiblePromissoryNotes" xlink:label="loc_roiv_ConversionOfSubsidiaryConvertiblePromissoryNotes_187" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_149" xlink:to="loc_roiv_ConversionOfSubsidiaryConvertiblePromissoryNotes_187" use="optional" order="32" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="roiv-20210630.xsd#roiv_IssuanceOfEquityInstruments" xlink:label="loc_roiv_IssuanceOfEquityInstruments_189" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_149" xlink:to="loc_roiv_IssuanceOfEquityInstruments_189" use="optional" order="33" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="roiv-20210630.xsd#roiv_SettlementOfLiabilityClassifiedInstruments" xlink:label="loc_roiv_SettlementOfLiabilityClassifiedInstruments_191" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_149" xlink:to="loc_roiv_SettlementOfLiabilityClassifiedInstruments_191" use="optional" order="34" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="roiv-20210630.xsd#roiv_DeconsolidationOfSubsidiary" xlink:label="loc_roiv_DeconsolidationOfSubsidiary_194" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_149" xlink:to="loc_roiv_DeconsolidationOfSubsidiary_194" use="optional" order="35" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="roiv-20210630.xsd#roiv_ConsolidationOfUnconsolidatedEntity" xlink:label="loc_roiv_ConsolidationOfUnconsolidatedEntity_195" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_149" xlink:to="loc_roiv_ConsolidationOfUnconsolidatedEntity_195" use="optional" order="36" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="roiv-20210630.xsd#roiv_RepurchaseOfEquityAwards" xlink:label="loc_roiv_RepurchaseOfEquityAwards_196" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_149" xlink:to="loc_roiv_RepurchaseOfEquityAwards_196" use="optional" order="37" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="roiv-20210630.xsd#roiv_CapitalContributionsToSubsidiaries" xlink:label="loc_roiv_CapitalContributionsToSubsidiaries_197" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_149" xlink:to="loc_roiv_CapitalContributionsToSubsidiaries_197" use="optional" order="38" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:label="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_198" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_149" xlink:to="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_198" use="optional" order="39" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="roiv-20210630.xsd#roiv_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationRequisiteServicePeriodRecognitionShares" xlink:label="loc_roiv_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationRequisiteServicePeriodRecognitionShares_199" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_149" xlink:to="loc_roiv_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationRequisiteServicePeriodRecognitionShares_199" use="optional" order="40" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent" xlink:label="loc_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent_200" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_149" xlink:to="loc_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent_200" use="optional" order="41" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProfitLoss" xlink:label="loc_us-gaap_ProfitLoss_201" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_149" xlink:to="loc_us-gaap_ProfitLoss_201" use="optional" order="42" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TemporaryEquityCarryingAmountIncludingPortionAttributableToNoncontrollingInterests" xlink:label="loc_us-gaap_TemporaryEquityCarryingAmountIncludingPortionAttributableToNoncontrollingInterests_165" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_149" xlink:to="loc_us-gaap_TemporaryEquityCarryingAmountIncludingPortionAttributableToNoncontrollingInterests_165" use="optional" order="43" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:label="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_202" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_149" xlink:to="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_202" use="optional" order="44" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharesOutstanding" xlink:label="loc_us-gaap_SharesOutstanding_203" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_149" xlink:to="loc_us-gaap_SharesOutstanding_203" use="optional" order="45" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://roivant.com/role/CondensedConsolidatedStatementsOfCashFlows">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementOfCashFlowsAbstract" xlink:label="loc_us-gaap_StatementOfCashFlowsAbstract_205" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaap_StatementTable_216" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_205" xlink:to="loc_us-gaap_StatementTable_216" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_LegalEntityAxis" xlink:label="loc_dei_LegalEntityAxis_210" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_216" xlink:to="loc_dei_LegalEntityAxis_210" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityDomain" xlink:label="loc_dei_EntityDomain_208" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_LegalEntityAxis_210" xlink:to="loc_dei_EntityDomain_208" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaap_StatementLineItems_215" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_216" xlink:to="loc_us-gaap_StatementLineItems_215" use="optional" order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_213" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_215" xlink:to="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_213" use="optional" order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProfitLoss" xlink:label="loc_us-gaap_ProfitLoss_275" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_213" xlink:to="loc_us-gaap_ProfitLoss_275" use="optional" order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_206" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_213" xlink:to="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_206" use="optional" order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ResearchAndDevelopmentInProcess" xlink:label="loc_us-gaap_ResearchAndDevelopmentInProcess_218" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_206" xlink:to="loc_us-gaap_ResearchAndDevelopmentInProcess_218" use="optional" order="8" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax" xlink:label="loc_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax_220" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_206" xlink:to="loc_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax_220" use="optional" order="9" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensation" xlink:label="loc_us-gaap_ShareBasedCompensation_222" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_206" xlink:to="loc_us-gaap_ShareBasedCompensation_222" use="optional" order="10" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GainLossOnSaleOfBusiness" xlink:label="loc_us-gaap_GainLossOnSaleOfBusiness_224" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_206" xlink:to="loc_us-gaap_GainLossOnSaleOfBusiness_224" use="optional" order="11" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GainLossOnInvestments" xlink:label="loc_us-gaap_GainLossOnInvestments_226" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_206" xlink:to="loc_us-gaap_GainLossOnInvestments_226" use="optional" order="12" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
<loc xlink:type="locator" xlink:href="roiv-20210630.xsd#roiv_GainLossOnFairValueOfDebtAndLiabilityInstruments" xlink:label="loc_roiv_GainLossOnFairValueOfDebtAndLiabilityInstruments_227" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_206" xlink:to="loc_roiv_GainLossOnFairValueOfDebtAndLiabilityInstruments_227" use="optional" order="13" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
<loc xlink:type="locator" xlink:href="roiv-20210630.xsd#roiv_GainOrLossOnDeconsolidationOfSubsidiary" xlink:label="loc_roiv_GainOrLossOnDeconsolidationOfSubsidiary_228" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_206" xlink:to="loc_roiv_GainOrLossOnDeconsolidationOfSubsidiary_228" use="optional" order="14" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
<loc xlink:type="locator" xlink:href="roiv-20210630.xsd#roiv_GainOnTerminationOfEquityInterestOptions" xlink:label="loc_roiv_GainOnTerminationOfEquityInterestOptions_1106544" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_206" xlink:to="loc_roiv_GainOnTerminationOfEquityInterestOptions_1106544" use="optional" order="15" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeLossFromEquityMethodInvestments" xlink:label="loc_us-gaap_IncomeLossFromEquityMethodInvestments_229" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_206" xlink:to="loc_us-gaap_IncomeLossFromEquityMethodInvestments_229" use="optional" order="16" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherNoncashIncomeExpense" xlink:label="loc_us-gaap_OtherNoncashIncomeExpense_230" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_206" xlink:to="loc_us-gaap_OtherNoncashIncomeExpense_230" use="optional" order="17" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:label="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_209" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_213" xlink:to="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_209" use="optional" order="18" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsPayableTrade" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsPayableTrade_237" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_209" xlink:to="loc_us-gaap_IncreaseDecreaseInAccountsPayableTrade_237" use="optional" order="19" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInAccruedLiabilities" xlink:label="loc_us-gaap_IncreaseDecreaseInAccruedLiabilities_240" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_209" xlink:to="loc_us-gaap_IncreaseDecreaseInAccruedLiabilities_240" use="optional" order="20" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInDeferredLiabilities" xlink:label="loc_us-gaap_IncreaseDecreaseInDeferredLiabilities_241" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_209" xlink:to="loc_us-gaap_IncreaseDecreaseInDeferredLiabilities_241" use="optional" order="21" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="roiv-20210630.xsd#roiv_IncreaseDecreaseInOperatingLeaseLiabilities" xlink:label="loc_roiv_IncreaseDecreaseInOperatingLeaseLiabilities_243" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_209" xlink:to="loc_roiv_IncreaseDecreaseInOperatingLeaseLiabilities_243" use="optional" order="22" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInOtherOperatingCapitalNet" xlink:label="loc_us-gaap_IncreaseDecreaseInOtherOperatingCapitalNet_245" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_209" xlink:to="loc_us-gaap_IncreaseDecreaseInOtherOperatingCapitalNet_245" use="optional" order="23" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_276" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_213" xlink:to="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_276" use="optional" order="24" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_212" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_215" xlink:to="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_212" use="optional" order="25" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromDivestitureOfBusinesses" xlink:label="loc_us-gaap_ProceedsFromDivestitureOfBusinesses_265" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_212" xlink:to="loc_us-gaap_ProceedsFromDivestitureOfBusinesses_265" use="optional" order="26" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashDivestedFromDeconsolidation" xlink:label="loc_us-gaap_CashDivestedFromDeconsolidation_267" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_212" xlink:to="loc_us-gaap_CashDivestedFromDeconsolidation_267" use="optional" order="27" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
<loc xlink:type="locator" xlink:href="roiv-20210630.xsd#roiv_CashAcquiredUponConsolidationOfUnconsolidatedEntity" xlink:label="loc_roiv_CashAcquiredUponConsolidationOfUnconsolidatedEntity_268" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_212" xlink:to="loc_roiv_CashAcquiredUponConsolidationOfUnconsolidatedEntity_268" use="optional" order="28" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="roiv-20210630.xsd#roiv_PaymentsToAcquireInvestmentsInUnconsolidatedEntities" xlink:label="loc_roiv_PaymentsToAcquireInvestmentsInUnconsolidatedEntities_269" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_212" xlink:to="loc_roiv_PaymentsToAcquireInvestmentsInUnconsolidatedEntities_269" use="optional" order="29" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsToAcquireMarketableSecurities" xlink:label="loc_us-gaap_PaymentsToAcquireMarketableSecurities_270" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_212" xlink:to="loc_us-gaap_PaymentsToAcquireMarketableSecurities_270" use="optional" order="30" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities" xlink:label="loc_us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities_271" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_212" xlink:to="loc_us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities_271" use="optional" order="31" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired" xlink:label="loc_us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired_272" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_212" xlink:to="loc_us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired_272" use="optional" order="32" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:label="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_273" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_212" xlink:to="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_273" use="optional" order="33" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_274" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_212" xlink:to="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_274" use="optional" order="34" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_211" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_215" xlink:to="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_211" use="optional" order="35" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfCommonStock_246" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_211" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfCommonStock_246" use="optional" order="36" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsForRepurchaseOfEquity" xlink:label="loc_us-gaap_PaymentsForRepurchaseOfEquity_248" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_211" xlink:to="loc_us-gaap_PaymentsForRepurchaseOfEquity_248" use="optional" order="37" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromIssuanceOfDebt" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfDebt_250" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_211" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfDebt_250" use="optional" order="38" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="roiv-20210630.xsd#roiv_ProceedsFromIssuanceOfSubsidiaryCommonSharesNet" xlink:label="loc_roiv_ProceedsFromIssuanceOfSubsidiaryCommonSharesNet_252" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_211" xlink:to="loc_roiv_ProceedsFromIssuanceOfSubsidiaryCommonSharesNet_252" use="optional" order="39" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="roiv-20210630.xsd#roiv_ProceedsFromIssuanceOfEquityBySubsidiaryUponBusinessCombinationAndRecapitalization" xlink:label="loc_roiv_ProceedsFromIssuanceOfEquityBySubsidiaryUponBusinessCombinationAndRecapitalization_254" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_211" xlink:to="loc_roiv_ProceedsFromIssuanceOfEquityBySubsidiaryUponBusinessCombinationAndRecapitalization_254" use="optional" order="40" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="roiv-20210630.xsd#roiv_PurchaseOfSubsidiaryCommonShares" xlink:label="loc_roiv_PurchaseOfSubsidiaryCommonShares_255" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_211" xlink:to="loc_roiv_PurchaseOfSubsidiaryCommonShares_255" use="optional" order="41" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="roiv-20210630.xsd#roiv_ProceedsFromIssuanceOfSubsidiaryConvertibleAndRedeemablePreferredStockNet" xlink:label="loc_roiv_ProceedsFromIssuanceOfSubsidiaryConvertibleAndRedeemablePreferredStockNet_256" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_211" xlink:to="loc_roiv_ProceedsFromIssuanceOfSubsidiaryConvertibleAndRedeemablePreferredStockNet_256" use="optional" order="42" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="roiv-20210630.xsd#roiv_PaymentsForPurchaseOfSubsidiaryConvertibleAndRedeemablePreferredStock" xlink:label="loc_roiv_PaymentsForPurchaseOfSubsidiaryConvertibleAndRedeemablePreferredStock_257" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_211" xlink:to="loc_roiv_PaymentsForPurchaseOfSubsidiaryConvertibleAndRedeemablePreferredStock_257" use="optional" order="43" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
<loc xlink:type="locator" xlink:href="roiv-20210630.xsd#roiv_ProceedsFromSubsidiaryDebtFinancingsNet" xlink:label="loc_roiv_ProceedsFromSubsidiaryDebtFinancingsNet_258" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_211" xlink:to="loc_roiv_ProceedsFromSubsidiaryDebtFinancingsNet_258" use="optional" order="44" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="roiv-20210630.xsd#roiv_RepaymentOfLongTermDebtAndConvertibleDebtBySubsidiary" xlink:label="loc_roiv_RepaymentOfLongTermDebtAndConvertibleDebtBySubsidiary_259" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_211" xlink:to="loc_roiv_RepaymentOfLongTermDebtAndConvertibleDebtBySubsidiary_259" use="optional" order="45" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsOfStockIssuanceCosts" xlink:label="loc_us-gaap_PaymentsOfStockIssuanceCosts_260" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_211" xlink:to="loc_us-gaap_PaymentsOfStockIssuanceCosts_260" use="optional" order="46" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
<loc xlink:type="locator" xlink:href="roiv-20210630.xsd#roiv_PaymentForDebtMaintenanceFeeBySubsidiary" xlink:label="loc_roiv_PaymentForDebtMaintenanceFeeBySubsidiary_261" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_211" xlink:to="loc_roiv_PaymentForDebtMaintenanceFeeBySubsidiary_261" use="optional" order="47" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromStockOptionsExercised" xlink:label="loc_us-gaap_ProceedsFromStockOptionsExercised_263" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_211" xlink:to="loc_us-gaap_ProceedsFromStockOptionsExercised_263" use="optional" order="48" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_264" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_211" xlink:to="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_264" use="optional" order="49" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect_282" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_215" xlink:to="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect_282" use="optional" order="50" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_283" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_215" xlink:to="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_283" use="optional" order="51" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_284" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_215" xlink:to="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_284" use="optional" order="52" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:label="loc_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_207" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_215" xlink:to="loc_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_207" use="optional" order="53" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" xlink:label="loc_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability_231" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_207" xlink:to="loc_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability_231" use="optional" order="54" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="roiv-20210630.xsd#roiv_OperatingLeaseRightOfUseAssetsAndAmountsReclassifiedFromOtherLiabilitiesToOperatingLeaseLiabilities" xlink:label="loc_roiv_OperatingLeaseRightOfUseAssetsAndAmountsReclassifiedFromOtherLiabilitiesToOperatingLeaseLiabilities_232" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_207" xlink:to="loc_roiv_OperatingLeaseRightOfUseAssetsAndAmountsReclassifiedFromOtherLiabilitiesToOperatingLeaseLiabilities_232" use="optional" order="55" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="roiv-20210630.xsd#roiv_IssuanceOfSubsidiaryWarrantInConnectionWithDebtFinancing" xlink:label="loc_roiv_IssuanceOfSubsidiaryWarrantInConnectionWithDebtFinancing_233" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_207" xlink:to="loc_roiv_IssuanceOfSubsidiaryWarrantInConnectionWithDebtFinancing_233" use="optional" order="56" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="roiv-20210630.xsd#roiv_DeferredOfferingAndFinancingCostsIncludedInAccountsPayableAndAccruedExpenses" xlink:label="loc_roiv_DeferredOfferingAndFinancingCostsIncludedInAccountsPayableAndAccruedExpenses_234" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_207" xlink:to="loc_roiv_DeferredOfferingAndFinancingCostsIncludedInAccountsPayableAndAccruedExpenses_234" use="optional" order="57" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="roiv-20210630.xsd#roiv_OtherNonCashTransactions" xlink:label="loc_roiv_OtherNonCashTransactions_235" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_207" xlink:to="loc_roiv_OtherNonCashTransactions_235" use="optional" order="58" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NoncashInvestingAndFinancingItemsAbstract" xlink:label="loc_us-gaap_NoncashInvestingAndFinancingItemsAbstract_214" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_215" xlink:to="loc_us-gaap_NoncashInvestingAndFinancingItemsAbstract_214" use="optional" order="59" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="roiv-20210630.xsd#roiv_ConversionOfSubsidiaryConvertiblePromissoryNotesToCommonShares" xlink:label="loc_roiv_ConversionOfSubsidiaryConvertiblePromissoryNotesToCommonShares_1139676" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NoncashInvestingAndFinancingItemsAbstract_214" xlink:to="loc_roiv_ConversionOfSubsidiaryConvertiblePromissoryNotesToCommonShares_1139676" use="optional" order="60" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="roiv-20210630.xsd#roiv_SubscriptionReceivableRelatedToIssuanceOfSubsidiaryCommonShares" xlink:label="loc_roiv_SubscriptionReceivableRelatedToIssuanceOfSubsidiaryCommonShares_1139677" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NoncashInvestingAndFinancingItemsAbstract_214" xlink:to="loc_roiv_SubscriptionReceivableRelatedToIssuanceOfSubsidiaryCommonShares_1139677" use="optional" order="61" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SupplementalCashFlowInformationAbstract" xlink:label="loc_us-gaap_SupplementalCashFlowInformationAbstract_217" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_215" xlink:to="loc_us-gaap_SupplementalCashFlowInformationAbstract_217" use="optional" order="62" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxesPaidNet" xlink:label="loc_us-gaap_IncomeTaxesPaidNet_285" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SupplementalCashFlowInformationAbstract_217" xlink:to="loc_us-gaap_IncomeTaxesPaidNet_285" use="optional" order="63" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InterestPaidNet" xlink:label="loc_us-gaap_InterestPaidNet_286" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SupplementalCashFlowInformationAbstract_217" xlink:to="loc_us-gaap_InterestPaidNet_286" use="optional" order="64" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://roivant.com/role/DescriptionOfBusinessAndLiquidity">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_1680" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock" xlink:label="loc_us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock_1681" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_1680" xlink:to="loc_us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock_1681" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://roivant.com/role/SummaryOfSignificantAccountingPolicies">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_1571" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaap_StatementTable_1575" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_1571" xlink:to="loc_us-gaap_StatementTable_1575" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_LegalEntityAxis" xlink:label="loc_dei_LegalEntityAxis_1573" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_1575" xlink:to="loc_dei_LegalEntityAxis_1573" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityDomain" xlink:label="loc_dei_EntityDomain_1572" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_LegalEntityAxis_1573" xlink:to="loc_dei_EntityDomain_1572" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaap_StatementLineItems_1574" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_1575" xlink:to="loc_us-gaap_StatementLineItems_1574" use="optional" order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SignificantAccountingPoliciesTextBlock" xlink:label="loc_us-gaap_SignificantAccountingPoliciesTextBlock_1577" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_1574" xlink:to="loc_us-gaap_SignificantAccountingPoliciesTextBlock_1577" use="optional" order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://roivant.com/role/Investments">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InvestmentsAllOtherInvestmentsAbstract" xlink:label="loc_us-gaap_InvestmentsAllOtherInvestmentsAbstract_1687" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InvestmentsAndOtherNoncurrentAssetsTextBlock" xlink:label="loc_us-gaap_InvestmentsAndOtherNoncurrentAssetsTextBlock_1688" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentsAllOtherInvestmentsAbstract_1687" xlink:to="loc_us-gaap_InvestmentsAndOtherNoncurrentAssetsTextBlock_1688" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://roivant.com/role/AssetAcquisitionsAndLicenseAgreements">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationsAbstract" xlink:label="loc_us-gaap_BusinessCombinationsAbstract_1690" />
<loc xlink:type="locator" xlink:href="roiv-20210630.xsd#roiv_AssetAcquisitionsAndLicenseAgreementsDisclosureTextBlock" xlink:label="loc_roiv_AssetAcquisitionsAndLicenseAgreementsDisclosureTextBlock_1691" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessCombinationsAbstract_1690" xlink:to="loc_roiv_AssetAcquisitionsAndLicenseAgreementsDisclosureTextBlock_1691" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://roivant.com/role/SumitomoTransactionAgreement">
<loc xlink:type="locator" xlink:href="roiv-20210630.xsd#roiv_TransactionAgreementAbstract" xlink:label="loc_roiv_TransactionAgreementAbstract_1693" />
<loc xlink:type="locator" xlink:href="roiv-20210630.xsd#roiv_TransactionAgreementDisclosureTextBlock" xlink:label="loc_roiv_TransactionAgreementDisclosureTextBlock_1694" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_roiv_TransactionAgreementAbstract_1693" xlink:to="loc_roiv_TransactionAgreementDisclosureTextBlock_1694" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://roivant.com/role/BalanceSheetComponents">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_1703" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SupplementalBalanceSheetDisclosuresTextBlock" xlink:label="loc_us-gaap_SupplementalBalanceSheetDisclosuresTextBlock_1704" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_1703" xlink:to="loc_us-gaap_SupplementalBalanceSheetDisclosuresTextBlock_1704" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://roivant.com/role/LongTermDebtAndLoanCommitment">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtDisclosureAbstract" xlink:label="loc_us-gaap_DebtDisclosureAbstract_1711" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongTermDebtTextBlock" xlink:label="loc_us-gaap_LongTermDebtTextBlock_1712" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_1711" xlink:to="loc_us-gaap_LongTermDebtTextBlock_1712" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://roivant.com/role/ShareholdersEquityAndRedeemableNoncontrollingInterest">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityAbstract" xlink:label="loc_us-gaap_EquityAbstract_1619" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaap_StatementTable_1623" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_1619" xlink:to="loc_us-gaap_StatementTable_1623" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_LegalEntityAxis" xlink:label="loc_dei_LegalEntityAxis_1621" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_1623" xlink:to="loc_dei_LegalEntityAxis_1621" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityDomain" xlink:label="loc_dei_EntityDomain_1620" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_LegalEntityAxis_1621" xlink:to="loc_dei_EntityDomain_1620" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaap_StatementLineItems_1622" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_1623" xlink:to="loc_us-gaap_StatementLineItems_1622" use="optional" order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:label="loc_us-gaap_StockholdersEquityNoteDisclosureTextBlock_1625" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_1622" xlink:to="loc_us-gaap_StockholdersEquityNoteDisclosureTextBlock_1625" use="optional" order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://roivant.com/role/ShareBasedCompensation">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_1721" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_1722" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_1721" xlink:to="loc_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_1722" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://roivant.com/role/RelatedPartyTransactions">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RelatedPartyTransactionsAbstract" xlink:label="loc_us-gaap_RelatedPartyTransactionsAbstract_1595" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaap_StatementTable_1599" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionsAbstract_1595" xlink:to="loc_us-gaap_StatementTable_1599" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_LegalEntityAxis" xlink:label="loc_dei_LegalEntityAxis_1597" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_1599" xlink:to="loc_dei_LegalEntityAxis_1597" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityDomain" xlink:label="loc_dei_EntityDomain_1596" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_LegalEntityAxis_1597" xlink:to="loc_dei_EntityDomain_1596" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaap_StatementLineItems_1598" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_1599" xlink:to="loc_us-gaap_StatementLineItems_1598" use="optional" order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RelatedPartyTransactionsDisclosureTextBlock" xlink:label="loc_us-gaap_RelatedPartyTransactionsDisclosureTextBlock_1601" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_1598" xlink:to="loc_us-gaap_RelatedPartyTransactionsDisclosureTextBlock_1601" use="optional" order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://roivant.com/role/DiscontinuedOperations">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DiscontinuedOperationsAndDisposalGroupsAbstract" xlink:label="loc_us-gaap_DiscontinuedOperationsAndDisposalGroupsAbstract_1696" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock" xlink:label="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock_1697" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DiscontinuedOperationsAndDisposalGroupsAbstract_1696" xlink:to="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock_1697" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://roivant.com/role/IncomeTaxes">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract_1645" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaap_StatementTable_1649" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_1645" xlink:to="loc_us-gaap_StatementTable_1649" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_LegalEntityAxis" xlink:label="loc_dei_LegalEntityAxis_1647" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_1649" xlink:to="loc_dei_LegalEntityAxis_1647" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityDomain" xlink:label="loc_dei_EntityDomain_1646" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_LegalEntityAxis_1647" xlink:to="loc_dei_EntityDomain_1646" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaap_StatementLineItems_1648" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_1649" xlink:to="loc_us-gaap_StatementLineItems_1648" use="optional" order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxDisclosureTextBlock" xlink:label="loc_us-gaap_IncomeTaxDisclosureTextBlock_1651" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_1648" xlink:to="loc_us-gaap_IncomeTaxDisclosureTextBlock_1651" use="optional" order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://roivant.com/role/Leases">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LeasesAbstract" xlink:label="loc_us-gaap_LeasesAbstract_1739" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeasesTextBlock" xlink:label="loc_us-gaap_LesseeOperatingLeasesTextBlock_1740" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_1739" xlink:to="loc_us-gaap_LesseeOperatingLeasesTextBlock_1740" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://roivant.com/role/CommitmentsContingencies">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_1603" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaap_StatementTable_1607" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_1603" xlink:to="loc_us-gaap_StatementTable_1607" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_LegalEntityAxis" xlink:label="loc_dei_LegalEntityAxis_1605" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_1607" xlink:to="loc_dei_LegalEntityAxis_1605" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityDomain" xlink:label="loc_dei_EntityDomain_1604" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_LegalEntityAxis_1605" xlink:to="loc_dei_EntityDomain_1604" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaap_StatementLineItems_1606" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_1607" xlink:to="loc_us-gaap_StatementLineItems_1606" use="optional" order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_1609" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_1606" xlink:to="loc_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_1609" use="optional" order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://roivant.com/role/FairValueMeasurements">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueDisclosuresAbstract" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract_1627" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaap_StatementTable_1631" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_1627" xlink:to="loc_us-gaap_StatementTable_1631" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_LegalEntityAxis" xlink:label="loc_dei_LegalEntityAxis_1629" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_1631" xlink:to="loc_dei_LegalEntityAxis_1629" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityDomain" xlink:label="loc_dei_EntityDomain_1628" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_LegalEntityAxis_1629" xlink:to="loc_dei_EntityDomain_1628" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaap_StatementLineItems_1630" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_1631" xlink:to="loc_us-gaap_StatementLineItems_1630" use="optional" order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueDisclosuresTextBlock" xlink:label="loc_us-gaap_FairValueDisclosuresTextBlock_1633" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_1630" xlink:to="loc_us-gaap_FairValueDisclosuresTextBlock_1633" use="optional" order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://roivant.com/role/DefinedContributionPlan">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CompensationAndRetirementDisclosureAbstract" xlink:label="loc_us-gaap_CompensationAndRetirementDisclosureAbstract_1747" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DefinedContributionPlanTextBlock" xlink:label="loc_us-gaap_DefinedContributionPlanTextBlock_1748" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CompensationAndRetirementDisclosureAbstract_1747" xlink:to="loc_us-gaap_DefinedContributionPlanTextBlock_1748" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://roivant.com/role/OtherIncomeExpenseNet">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherIncomeAndExpensesAbstract" xlink:label="loc_us-gaap_OtherIncomeAndExpensesAbstract_1750" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherOperatingIncomeAndExpenseTextBlock" xlink:label="loc_us-gaap_OtherOperatingIncomeAndExpenseTextBlock_1751" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherIncomeAndExpensesAbstract_1750" xlink:to="loc_us-gaap_OtherOperatingIncomeAndExpenseTextBlock_1751" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://roivant.com/role/NetLossPerCommonShare">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerShareAbstract" xlink:label="loc_us-gaap_EarningsPerShareAbstract_1756" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerShareTextBlock" xlink:label="loc_us-gaap_EarningsPerShareTextBlock_1757" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_1756" xlink:to="loc_us-gaap_EarningsPerShareTextBlock_1757" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://roivant.com/role/SubsequentEvents">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventsAbstract" xlink:label="loc_us-gaap_SubsequentEventsAbstract_1664" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaap_StatementTable_1668" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventsAbstract_1664" xlink:to="loc_us-gaap_StatementTable_1668" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_LegalEntityAxis" xlink:label="loc_dei_LegalEntityAxis_1666" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_1668" xlink:to="loc_dei_LegalEntityAxis_1666" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityDomain" xlink:label="loc_dei_EntityDomain_1665" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_LegalEntityAxis_1666" xlink:to="loc_dei_EntityDomain_1665" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaap_StatementLineItems_1667" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_1668" xlink:to="loc_us-gaap_StatementLineItems_1667" use="optional" order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventsTextBlock" xlink:label="loc_us-gaap_SubsequentEventsTextBlock_1670" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_1667" xlink:to="loc_us-gaap_SubsequentEventsTextBlock_1670" use="optional" order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://roivant.com/role/SummaryOfSignificantAccountingPoliciesPolicies">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_1523" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaap_StatementTable_1527" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_1523" xlink:to="loc_us-gaap_StatementTable_1527" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_LegalEntityAxis" xlink:label="loc_dei_LegalEntityAxis_1525" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_1527" xlink:to="loc_dei_LegalEntityAxis_1525" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityDomain" xlink:label="loc_dei_EntityDomain_1524" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_LegalEntityAxis_1525" xlink:to="loc_dei_EntityDomain_1524" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaap_StatementLineItems_1526" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_1527" xlink:to="loc_us-gaap_StatementLineItems_1526" use="optional" order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:label="loc_us-gaap_BasisOfAccountingPolicyPolicyTextBlock_1529" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_1526" xlink:to="loc_us-gaap_BasisOfAccountingPolicyPolicyTextBlock_1529" use="optional" order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_UseOfEstimates" xlink:label="loc_us-gaap_UseOfEstimates_1531" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_1526" xlink:to="loc_us-gaap_UseOfEstimates_1531" use="optional" order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_UnusualRisksAndUncertaintiesTextBlock" xlink:label="loc_us-gaap_UnusualRisksAndUncertaintiesTextBlock_1541" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_1526" xlink:to="loc_us-gaap_UnusualRisksAndUncertaintiesTextBlock_1541" use="optional" order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConcentrationRiskCreditRisk" xlink:label="loc_us-gaap_ConcentrationRiskCreditRisk_1533" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_1526" xlink:to="loc_us-gaap_ConcentrationRiskCreditRisk_1533" use="optional" order="8" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy" xlink:label="loc_us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy_1542" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_1526" xlink:to="loc_us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy_1542" use="optional" order="9" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TradeAndOtherAccountsReceivablePolicy" xlink:label="loc_us-gaap_TradeAndOtherAccountsReceivablePolicy_1543" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_1526" xlink:to="loc_us-gaap_TradeAndOtherAccountsReceivablePolicy_1543" use="optional" order="10" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommitmentsAndContingenciesPolicyTextBlock" xlink:label="loc_us-gaap_CommitmentsAndContingenciesPolicyTextBlock_1544" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_1526" xlink:to="loc_us-gaap_CommitmentsAndContingenciesPolicyTextBlock_1544" use="optional" order="11" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock_1545" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_1526" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock_1545" use="optional" order="12" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InvestmentPolicyTextBlock" xlink:label="loc_us-gaap_InvestmentPolicyTextBlock_1546" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_1526" xlink:to="loc_us-gaap_InvestmentPolicyTextBlock_1546" use="optional" order="13" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpensePolicy_1547" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_1526" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpensePolicy_1547" use="optional" order="14" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="roiv-20210630.xsd#roiv_GeneralAndAdministrativeExpensesPolicyTextBlock" xlink:label="loc_roiv_GeneralAndAdministrativeExpensesPolicyTextBlock_1548" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_1526" xlink:to="loc_roiv_GeneralAndAdministrativeExpensesPolicyTextBlock_1548" use="optional" order="15" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxPolicyTextBlock" xlink:label="loc_us-gaap_IncomeTaxPolicyTextBlock_1538" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_1526" xlink:to="loc_us-gaap_IncomeTaxPolicyTextBlock_1538" use="optional" order="16" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:label="loc_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy_1549" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_1526" xlink:to="loc_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy_1549" use="optional" order="17" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementPolicyPolicyTextBlock" xlink:label="loc_us-gaap_FairValueMeasurementPolicyPolicyTextBlock_1550" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_1526" xlink:to="loc_us-gaap_FairValueMeasurementPolicyPolicyTextBlock_1550" use="optional" order="18" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock" xlink:label="loc_us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock_1551" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_1526" xlink:to="loc_us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock_1551" use="optional" order="19" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevenueFromContractWithCustomerPolicyTextBlock" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock_1552" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_1526" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock_1552" use="optional" order="20" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:label="loc_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_1540" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_1526" xlink:to="loc_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_1540" use="optional" order="21" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="roiv-20210630.xsd#roiv_NewAccountingPronouncementsNotYetAdoptedPolicyTextBlock" xlink:label="loc_roiv_NewAccountingPronouncementsNotYetAdoptedPolicyTextBlock_1553" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_1526" xlink:to="loc_roiv_NewAccountingPronouncementsNotYetAdoptedPolicyTextBlock_1553" use="optional" order="22" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://roivant.com/role/SummaryOfSignificantAccountingPoliciesTables">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_1683" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfCashAndCashEquivalentsTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfCashAndCashEquivalentsTableTextBlock_1684" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_1683" xlink:to="loc_us-gaap_ScheduleOfCashAndCashEquivalentsTableTextBlock_1684" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="roiv-20210630.xsd#roiv_ScheduleOfPropertyPlantAndEquipmentEstimatedUsefulLivesTableTextBlock" xlink:label="loc_roiv_ScheduleOfPropertyPlantAndEquipmentEstimatedUsefulLivesTableTextBlock_1685" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_1683" xlink:to="loc_roiv_ScheduleOfPropertyPlantAndEquipmentEstimatedUsefulLivesTableTextBlock_1685" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://roivant.com/role/DiscontinuedOperationsTables">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DiscontinuedOperationsAndDisposalGroupsAbstract" xlink:label="loc_us-gaap_DiscontinuedOperationsAndDisposalGroupsAbstract_1699" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfDisposalGroupsIncludingDiscontinuedOperationsIncomeStatementBalanceSheetAndAdditionalDisclosuresTextBlock" xlink:label="loc_us-gaap_ScheduleOfDisposalGroupsIncludingDiscontinuedOperationsIncomeStatementBalanceSheetAndAdditionalDisclosuresTextBlock_1700" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DiscontinuedOperationsAndDisposalGroupsAbstract_1699" xlink:to="loc_us-gaap_ScheduleOfDisposalGroupsIncludingDiscontinuedOperationsIncomeStatementBalanceSheetAndAdditionalDisclosuresTextBlock_1700" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="roiv-20210630.xsd#roiv_ScheduleOfDisposalGroupsIncludingDiscontinuedCondensedConsolidatedStatementsOfCashFlowsTableTextBlock" xlink:label="loc_roiv_ScheduleOfDisposalGroupsIncludingDiscontinuedCondensedConsolidatedStatementsOfCashFlowsTableTextBlock_1701" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DiscontinuedOperationsAndDisposalGroupsAbstract_1699" xlink:to="loc_roiv_ScheduleOfDisposalGroupsIncludingDiscontinuedCondensedConsolidatedStatementsOfCashFlowsTableTextBlock_1701" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://roivant.com/role/BalanceSheetComponentsTables">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_1706" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfOtherCurrentAssetsTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfOtherCurrentAssetsTableTextBlock_1707" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_1706" xlink:to="loc_us-gaap_ScheduleOfOtherCurrentAssetsTableTextBlock_1707" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock_1708" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_1706" xlink:to="loc_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock_1708" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherCurrentLiabilitiesTableTextBlock" xlink:label="loc_us-gaap_OtherCurrentLiabilitiesTableTextBlock_1709" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_1706" xlink:to="loc_us-gaap_OtherCurrentLiabilitiesTableTextBlock_1709" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://roivant.com/role/LongTermDebtAndLoanCommitmentTables">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtDisclosureAbstract" xlink:label="loc_us-gaap_DebtDisclosureAbstract_1714" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfDebtTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfDebtTableTextBlock_1715" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_1714" xlink:to="loc_us-gaap_ScheduleOfDebtTableTextBlock_1715" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ContractualObligationFiscalYearMaturityScheduleTableTextBlock" xlink:label="loc_srt_ContractualObligationFiscalYearMaturityScheduleTableTextBlock_1716" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_1714" xlink:to="loc_srt_ContractualObligationFiscalYearMaturityScheduleTableTextBlock_1716" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://roivant.com/role/ShareholdersEquityAndRedeemableNoncontrollingInterestTables">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityAbstract" xlink:label="loc_us-gaap_EquityAbstract_1718" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfStockholdersEquityTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfStockholdersEquityTableTextBlock_1719" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_1718" xlink:to="loc_us-gaap_ScheduleOfStockholdersEquityTableTextBlock_1719" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://roivant.com/role/ShareBasedCompensationTables">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_1724" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaap_StatementTable_1728" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_1724" xlink:to="loc_us-gaap_StatementTable_1728" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AwardTypeAxis" xlink:label="loc_us-gaap_AwardTypeAxis_1725" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_1728" xlink:to="loc_us-gaap_AwardTypeAxis_1725" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_1726" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AwardTypeAxis_1725" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_1726" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="roiv-20210630.xsd#roiv_PerformanceOptionsMember" xlink:label="loc_roiv_PerformanceOptionsMember_1729" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_1726" xlink:to="loc_roiv_PerformanceOptionsMember_1729" use="optional" order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="roiv-20210630.xsd#roiv_CappedValueAppreciationRightsMember" xlink:label="loc_roiv_CappedValueAppreciationRightsMember_1730" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_1726" xlink:to="loc_roiv_CappedValueAppreciationRightsMember_1730" use="optional" order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="roiv-20210630.xsd#roiv_PerformanceRestrictedStockUnitsMember" xlink:label="loc_roiv_PerformanceRestrictedStockUnitsMember_1731" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_1726" xlink:to="loc_roiv_PerformanceRestrictedStockUnitsMember_1731" use="optional" order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="roiv-20210630.xsd#roiv_CommonStockAwardsMember" xlink:label="loc_roiv_CommonStockAwardsMember_1732" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_1726" xlink:to="loc_roiv_CommonStockAwardsMember_1732" use="optional" order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaap_StatementLineItems_1727" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_1728" xlink:to="loc_us-gaap_StatementLineItems_1727" use="optional" order="8" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_1733" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_1727" xlink:to="loc_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_1733" use="optional" order="9" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_1734" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_1727" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_1734" use="optional" order="10" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="roiv-20210630.xsd#roiv_ScheduleOfSharebasedPaymentArrangementFairValueOfVestedStockOptionTableTextBlock" xlink:label="loc_roiv_ScheduleOfSharebasedPaymentArrangementFairValueOfVestedStockOptionTableTextBlock_1735" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_1727" xlink:to="loc_roiv_ScheduleOfSharebasedPaymentArrangementFairValueOfVestedStockOptionTableTextBlock_1735" use="optional" order="11" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock_1736" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_1727" xlink:to="loc_us-gaap_ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock_1736" use="optional" order="12" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock_1737" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_1727" xlink:to="loc_us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock_1737" use="optional" order="13" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://roivant.com/role/IncomeTaxesTables">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract_1653" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaap_StatementTable_1657" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_1653" xlink:to="loc_us-gaap_StatementTable_1657" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_LegalEntityAxis" xlink:label="loc_dei_LegalEntityAxis_1655" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_1657" xlink:to="loc_dei_LegalEntityAxis_1655" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityDomain" xlink:label="loc_dei_EntityDomain_1654" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_LegalEntityAxis_1655" xlink:to="loc_dei_EntityDomain_1654" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaap_StatementLineItems_1656" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_1657" xlink:to="loc_us-gaap_StatementLineItems_1656" use="optional" order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_1660" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_1656" xlink:to="loc_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_1660" use="optional" order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_1661" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_1656" xlink:to="loc_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_1661" use="optional" order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock_1662" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_1656" xlink:to="loc_us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock_1662" use="optional" order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://roivant.com/role/LeasesTables">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LeasesAbstract" xlink:label="loc_us-gaap_LeasesAbstract_1742" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LeaseCostTableTextBlock" xlink:label="loc_us-gaap_LeaseCostTableTextBlock_1743" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_1742" xlink:to="loc_us-gaap_LeaseCostTableTextBlock_1743" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LeasesOfLesseeDisclosureTextBlock" xlink:label="loc_us-gaap_LeasesOfLesseeDisclosureTextBlock_1744" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_1742" xlink:to="loc_us-gaap_LeasesOfLesseeDisclosureTextBlock_1744" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_1745" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_1742" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_1745" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://roivant.com/role/FairValueMeasurementsTables">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueDisclosuresAbstract" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract_1635" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaap_StatementTable_1639" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_1635" xlink:to="loc_us-gaap_StatementTable_1639" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_LegalEntityAxis" xlink:label="loc_dei_LegalEntityAxis_1637" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_1639" xlink:to="loc_dei_LegalEntityAxis_1637" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityDomain" xlink:label="loc_dei_EntityDomain_1636" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_LegalEntityAxis_1637" xlink:to="loc_dei_EntityDomain_1636" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaap_StatementLineItems_1638" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_1639" xlink:to="loc_us-gaap_StatementLineItems_1638" use="optional" order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock_1641" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_1638" xlink:to="loc_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock_1641" use="optional" order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock_1642" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_1638" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock_1642" use="optional" order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock" xlink:label="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock_1643" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_1638" xlink:to="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock_1643" use="optional" order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://roivant.com/role/OtherIncomeExpenseNetTables">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherIncomeAndExpensesAbstract" xlink:label="loc_us-gaap_OtherIncomeAndExpensesAbstract_1753" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfOtherOperatingCostAndExpenseByComponentTextBlock" xlink:label="loc_us-gaap_ScheduleOfOtherOperatingCostAndExpenseByComponentTextBlock_1754" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherIncomeAndExpensesAbstract_1753" xlink:to="loc_us-gaap_ScheduleOfOtherOperatingCostAndExpenseByComponentTextBlock_1754" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://roivant.com/role/NetLossPerCommonShareTables">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerShareAbstract" xlink:label="loc_us-gaap_EarningsPerShareAbstract_1579" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaap_StatementTable_1583" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_1579" xlink:to="loc_us-gaap_StatementTable_1583" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_LegalEntityAxis" xlink:label="loc_dei_LegalEntityAxis_1581" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_1583" xlink:to="loc_dei_LegalEntityAxis_1581" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityDomain" xlink:label="loc_dei_EntityDomain_1580" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_LegalEntityAxis_1581" xlink:to="loc_dei_EntityDomain_1580" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaap_StatementLineItems_1582" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_1583" xlink:to="loc_us-gaap_StatementLineItems_1582" use="optional" order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_1585" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_1582" xlink:to="loc_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_1585" use="optional" order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://roivant.com/role/DescriptionOfBusinessAndLiquidityAdditionalInformationDetail">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_891" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NumberOfOperatingSegments" xlink:label="loc_us-gaap_NumberOfOperatingSegments_892" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_891" xlink:to="loc_us-gaap_NumberOfOperatingSegments_892" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_893" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_891" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_893" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit_894" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_891" xlink:to="loc_us-gaap_RetainedEarningsAccumulatedDeficit_894" use="optional" order="3" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProfitLoss" xlink:label="loc_us-gaap_ProfitLoss_895" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_891" xlink:to="loc_us-gaap_ProfitLoss_895" use="optional" order="4" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetIncomeLossAttributableToRedeemableNoncontrollingInterest" xlink:label="loc_us-gaap_NetIncomeLossAttributableToRedeemableNoncontrollingInterest_1140060" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_891" xlink:to="loc_us-gaap_NetIncomeLossAttributableToRedeemableNoncontrollingInterest_1140060" use="optional" order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://roivant.com/role/SummaryOfSignificantAccountingPoliciesAdditionalInformationDetail">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_448" />
<loc xlink:type="locator" xlink:href="roiv-20210630.xsd#roiv_ScheduleOfAccountingPoliciesTable" xlink:label="loc_roiv_ScheduleOfAccountingPoliciesTable_454" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_448" xlink:to="loc_roiv_ScheduleOfAccountingPoliciesTable_454" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_LegalEntityAxis" xlink:label="loc_dei_LegalEntityAxis_451" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_roiv_ScheduleOfAccountingPoliciesTable_454" xlink:to="loc_dei_LegalEntityAxis_451" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityDomain" xlink:label="loc_dei_EntityDomain_450" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_LegalEntityAxis_451" xlink:to="loc_dei_EntityDomain_450" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="loc_us-gaap_StatementClassOfStockAxis_455" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_roiv_ScheduleOfAccountingPoliciesTable_454" xlink:to="loc_us-gaap_StatementClassOfStockAxis_455" use="optional" order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaap_ClassOfStockDomain_449" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementClassOfStockAxis_455" xlink:to="loc_us-gaap_ClassOfStockDomain_449" use="optional" order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="loc_us-gaap_SubsidiarySaleOfStockAxis_456" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_roiv_ScheduleOfAccountingPoliciesTable_454" xlink:to="loc_us-gaap_SubsidiarySaleOfStockAxis_456" use="optional" order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain_452" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis_456" xlink:to="loc_us-gaap_SaleOfStockNameOfTransactionDomain_452" use="optional" order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="roiv-20210630.xsd#roiv_ScheduleOfAccountingPoliciesLineItems" xlink:label="loc_roiv_ScheduleOfAccountingPoliciesLineItems_453" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_roiv_ScheduleOfAccountingPoliciesTable_454" xlink:to="loc_roiv_ScheduleOfAccountingPoliciesLineItems_453" use="optional" order="8" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EscrowDeposit" xlink:label="loc_us-gaap_EscrowDeposit_1097060" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_roiv_ScheduleOfAccountingPoliciesLineItems_453" xlink:to="loc_us-gaap_EscrowDeposit_1097060" use="optional" order="9" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="roiv-20210630.xsd#roiv_ProceedsFromReleaseOfEscrowDeposit" xlink:label="loc_roiv_ProceedsFromReleaseOfEscrowDeposit_1105109" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_roiv_ScheduleOfAccountingPoliciesLineItems_453" xlink:to="loc_roiv_ProceedsFromReleaseOfEscrowDeposit_1105109" use="optional" order="10" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://roivant.com/role/SummaryOfSignificantAccountingPoliciesScheduleOfAggregateAmountsOfCashCashEquivalentsAndRestrictedCashDetail">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashAndCashEquivalentsAbstract" xlink:label="loc_us-gaap_CashAndCashEquivalentsAbstract_897" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_898" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CashAndCashEquivalentsAbstract_897" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_898" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestrictedCash" xlink:label="loc_us-gaap_RestrictedCash_899" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CashAndCashEquivalentsAbstract_897" xlink:to="loc_us-gaap_RestrictedCash_899" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="roiv-20210630.xsd#roiv_CashAndCashEquivalentsAndRestrictedCash" xlink:label="loc_roiv_CashAndCashEquivalentsAndRestrictedCash_900" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CashAndCashEquivalentsAbstract_897" xlink:to="loc_roiv_CashAndCashEquivalentsAndRestrictedCash_900" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://roivant.com/role/SummaryOfSignificantAccountingPoliciesScheduleOfEstimatedUsefulLivesDetail">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_902" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:label="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_906" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_902" xlink:to="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_906" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_903" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_906" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_903" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_905" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_903" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_905" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ComputerEquipmentMember" xlink:label="loc_us-gaap_ComputerEquipmentMember_909" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_905" xlink:to="loc_us-gaap_ComputerEquipmentMember_909" use="optional" order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquipmentMember" xlink:label="loc_us-gaap_EquipmentMember_910" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_905" xlink:to="loc_us-gaap_EquipmentMember_910" use="optional" order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FurnitureAndFixturesMember" xlink:label="loc_us-gaap_FurnitureAndFixturesMember_911" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_905" xlink:to="loc_us-gaap_FurnitureAndFixturesMember_911" use="optional" order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SoftwareDevelopmentMember" xlink:label="loc_us-gaap_SoftwareDevelopmentMember_912" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_905" xlink:to="loc_us-gaap_SoftwareDevelopmentMember_912" use="optional" order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LeaseholdImprovementsMember" xlink:label="loc_us-gaap_LeaseholdImprovementsMember_913" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_905" xlink:to="loc_us-gaap_LeaseholdImprovementsMember_913" use="optional" order="8" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentLineItems" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentLineItems_904" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_906" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentLineItems_904" use="optional" order="9" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentUsefulLife_907" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_904" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentUsefulLife_907" use="optional" order="10" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentEstimatedUsefulLives" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentEstimatedUsefulLives_908" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_904" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentEstimatedUsefulLives_908" use="optional" order="11" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://roivant.com/role/InvestmentsAdditionalInformationDetail">
<loc xlink:type="locator" xlink:href="roiv-20210630.xsd#roiv_UncategorizedAbstract" xlink:label="loc_roiv_UncategorizedAbstract_915" />
<loc xlink:type="locator" xlink:href="roiv-20210630.xsd#roiv_InvestmentsTable" xlink:label="loc_roiv_InvestmentsTable_919" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_roiv_UncategorizedAbstract_915" xlink:to="loc_roiv_InvestmentsTable_919" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_LegalEntityAxis" xlink:label="loc_dei_LegalEntityAxis_922" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_roiv_InvestmentsTable_919" xlink:to="loc_dei_LegalEntityAxis_922" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityDomain" xlink:label="loc_dei_EntityDomain_917" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_LegalEntityAxis_922" xlink:to="loc_dei_EntityDomain_917" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="roiv-20210630.xsd#roiv_ArbutusBiopharmaCorporationMember" xlink:label="loc_roiv_ArbutusBiopharmaCorporationMember_925" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityDomain_917" xlink:to="loc_roiv_ArbutusBiopharmaCorporationMember_925" use="optional" order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="roiv-20210630.xsd#roiv_SioGeneTherapiesIncMember" xlink:label="loc_roiv_SioGeneTherapiesIncMember_926" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityDomain_917" xlink:to="loc_roiv_SioGeneTherapiesIncMember_926" use="optional" order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="roiv-20210630.xsd#roiv_DatavantHoldingsIncMember" xlink:label="loc_roiv_DatavantHoldingsIncMember_927" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityDomain_917" xlink:to="loc_roiv_DatavantHoldingsIncMember_927" use="optional" order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InvestmentTypeAxis" xlink:label="loc_us-gaap_InvestmentTypeAxis_920" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_roiv_InvestmentsTable_919" xlink:to="loc_us-gaap_InvestmentTypeAxis_920" use="optional" order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InvestmentTypeCategorizationMember" xlink:label="loc_us-gaap_InvestmentTypeCategorizationMember_921" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentTypeAxis_920" xlink:to="loc_us-gaap_InvestmentTypeCategorizationMember_921" use="optional" order="8" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherInvestmentCompaniesMember" xlink:label="loc_us-gaap_OtherInvestmentCompaniesMember_946" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentTypeCategorizationMember_921" xlink:to="loc_us-gaap_OtherInvestmentCompaniesMember_946" use="optional" order="9" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="loc_us-gaap_StatementClassOfStockAxis_923" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_roiv_InvestmentsTable_919" xlink:to="loc_us-gaap_StatementClassOfStockAxis_923" use="optional" order="10" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaap_ClassOfStockDomain_916" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementClassOfStockAxis_923" xlink:to="loc_us-gaap_ClassOfStockDomain_916" use="optional" order="11" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SeriesBPreferredStockMember" xlink:label="loc_us-gaap_SeriesBPreferredStockMember_924" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockDomain_916" xlink:to="loc_us-gaap_SeriesBPreferredStockMember_924" use="optional" order="12" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="roiv-20210630.xsd#roiv_InvestmentsLineItems" xlink:label="loc_roiv_InvestmentsLineItems_918" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_roiv_InvestmentsTable_919" xlink:to="loc_roiv_InvestmentsLineItems_918" use="optional" order="13" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="roiv-20210630.xsd#roiv_CommonStockOwnedBalanceSharesOfArbutus" xlink:label="loc_roiv_CommonStockOwnedBalanceSharesOfArbutus_928" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_roiv_InvestmentsLineItems_918" xlink:to="loc_roiv_CommonStockOwnedBalanceSharesOfArbutus_928" use="optional" order="14" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="roiv-20210630.xsd#roiv_PreferredStockOwnedBalanceSharesOfArbutus" xlink:label="loc_roiv_PreferredStockOwnedBalanceSharesOfArbutus_929" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_roiv_InvestmentsLineItems_918" xlink:to="loc_roiv_PreferredStockOwnedBalanceSharesOfArbutus_929" use="optional" order="15" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="roiv-20210630.xsd#roiv_PremiumOnConversionPricePercentage" xlink:label="loc_roiv_PremiumOnConversionPricePercentage_930" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_roiv_InvestmentsLineItems_918" xlink:to="loc_roiv_PremiumOnConversionPricePercentage_930" use="optional" order="16" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="roiv-20210630.xsd#roiv_AnnualCompoundedConversionRateForPreferredShare" xlink:label="loc_roiv_AnnualCompoundedConversionRateForPreferredShare_931" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_roiv_InvestmentsLineItems_918" xlink:to="loc_roiv_AnnualCompoundedConversionRateForPreferredShare_931" use="optional" order="17" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="roiv-20210630.xsd#roiv_ConversionPrice" xlink:label="loc_roiv_ConversionPrice_932" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_roiv_InvestmentsLineItems_918" xlink:to="loc_roiv_ConversionPrice_932" use="optional" order="18" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="roiv-20210630.xsd#roiv_ClosingPricePerShare" xlink:label="loc_roiv_ClosingPricePerShare_1105114" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_roiv_InvestmentsLineItems_918" xlink:to="loc_roiv_ClosingPricePerShare_1105114" use="optional" order="19" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="roiv-20210630.xsd#roiv_OwnershipInterestPercentage" xlink:label="loc_roiv_OwnershipInterestPercentage_934" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_roiv_InvestmentsLineItems_918" xlink:to="loc_roiv_OwnershipInterestPercentage_934" use="optional" order="20" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="roiv-20210630.xsd#roiv_MaximumAllowedOwnershipInterestPercentage" xlink:label="loc_roiv_MaximumAllowedOwnershipInterestPercentage_935" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_roiv_InvestmentsLineItems_918" xlink:to="loc_roiv_MaximumAllowedOwnershipInterestPercentage_935" use="optional" order="21" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InvestmentsFairValueDisclosure" xlink:label="loc_us-gaap_InvestmentsFairValueDisclosure_936" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_roiv_InvestmentsLineItems_918" xlink:to="loc_us-gaap_InvestmentsFairValueDisclosure_936" use="optional" order="22" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_UnrealizedGainLossOnInvestments" xlink:label="loc_us-gaap_UnrealizedGainLossOnInvestments_937" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_roiv_InvestmentsLineItems_918" xlink:to="loc_us-gaap_UnrealizedGainLossOnInvestments_937" use="optional" order="23" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharePrice" xlink:label="loc_us-gaap_SharePrice_938" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_roiv_InvestmentsLineItems_918" xlink:to="loc_us-gaap_SharePrice_938" use="optional" order="24" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeconsolidationGainOrLossAmount" xlink:label="loc_us-gaap_DeconsolidationGainOrLossAmount_939" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_roiv_InvestmentsLineItems_918" xlink:to="loc_us-gaap_DeconsolidationGainOrLossAmount_939" use="optional" order="25" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="roiv-20210630.xsd#roiv_ProceedsFromIssuanceOfPreferredStockAndPreferenceStocks" xlink:label="loc_roiv_ProceedsFromIssuanceOfPreferredStockAndPreferenceStocks_1105116" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_roiv_InvestmentsLineItems_918" xlink:to="loc_roiv_ProceedsFromIssuanceOfPreferredStockAndPreferenceStocks_1105116" use="optional" order="26" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="roiv-20210630.xsd#roiv_PreferredStockSharesIssuedAndSoldToCompanyDuringPeriodShares" xlink:label="loc_roiv_PreferredStockSharesIssuedAndSoldToCompanyDuringPeriodShares_1105117" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_roiv_InvestmentsLineItems_918" xlink:to="loc_roiv_PreferredStockSharesIssuedAndSoldToCompanyDuringPeriodShares_1105117" use="optional" order="27" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="roiv-20210630.xsd#roiv_PreferredStockPurchased" xlink:label="loc_roiv_PreferredStockPurchased_943" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_roiv_InvestmentsLineItems_918" xlink:to="loc_roiv_PreferredStockPurchased_943" use="optional" order="28" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion" xlink:label="loc_us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion_944" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_roiv_InvestmentsLineItems_918" xlink:to="loc_us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion_944" use="optional" order="29" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongTermInvestments" xlink:label="loc_us-gaap_LongTermInvestments_945" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_roiv_InvestmentsLineItems_918" xlink:to="loc_us-gaap_LongTermInvestments_945" use="optional" order="30" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityMethodInvestmentOwnershipPercentage" xlink:label="loc_us-gaap_EquityMethodInvestmentOwnershipPercentage_1105159" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_roiv_InvestmentsLineItems_918" xlink:to="loc_us-gaap_EquityMethodInvestmentOwnershipPercentage_1105159" use="optional" order="31" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockSharesOutstanding" xlink:label="loc_us-gaap_CommonStockSharesOutstanding_1139348" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_roiv_InvestmentsLineItems_918" xlink:to="loc_us-gaap_CommonStockSharesOutstanding_1139348" use="optional" order="32" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PreferredStockSharesOutstanding" xlink:label="loc_us-gaap_PreferredStockSharesOutstanding_1139351" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_roiv_InvestmentsLineItems_918" xlink:to="loc_us-gaap_PreferredStockSharesOutstanding_1139351" use="optional" order="33" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://roivant.com/role/AssetAcquisitionsAndLicenseAgreementsAdditionalInformationDetail">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationsAbstract" xlink:label="loc_us-gaap_BusinessCombinationsAbstract_948" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable" xlink:label="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_962" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessCombinationsAbstract_948" xlink:to="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_962" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:label="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_959" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_962" xlink:to="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_959" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RelatedPartyDomain" xlink:label="loc_us-gaap_RelatedPartyDomain_958" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_959" xlink:to="loc_us-gaap_RelatedPartyDomain_958" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="roiv-20210630.xsd#roiv_DermavantSciencesLtdMember" xlink:label="loc_roiv_DermavantSciencesLtdMember_1007" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyDomain_958" xlink:to="loc_roiv_DermavantSciencesLtdMember_1007" use="optional" order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="roiv-20210630.xsd#roiv_GenevantSciencesLtdMember" xlink:label="loc_roiv_GenevantSciencesLtdMember_1008" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyDomain_958" xlink:to="loc_roiv_GenevantSciencesLtdMember_1008" use="optional" order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="roiv-20210630.xsd#roiv_ProteovantSciencesIncMember" xlink:label="loc_roiv_ProteovantSciencesIncMember_1009" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyDomain_958" xlink:to="loc_roiv_ProteovantSciencesIncMember_1009" use="optional" order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="roiv-20210630.xsd#roiv_AffivantSciencesMember" xlink:label="loc_roiv_AffivantSciencesMember_1010" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyDomain_958" xlink:to="loc_roiv_AffivantSciencesMember_1010" use="optional" order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_LegalEntityAxis" xlink:label="loc_dei_LegalEntityAxis_953" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_962" xlink:to="loc_dei_LegalEntityAxis_953" use="optional" order="8" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityDomain" xlink:label="loc_dei_EntityDomain_952" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_LegalEntityAxis_953" xlink:to="loc_dei_EntityDomain_952" use="optional" order="9" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="roiv-20210630.xsd#roiv_ArbutusBiopharmaCorporationMember" xlink:label="loc_roiv_ArbutusBiopharmaCorporationMember_1002" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityDomain_952" xlink:to="loc_roiv_ArbutusBiopharmaCorporationMember_1002" use="optional" order="10" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessAcquisitionAxis" xlink:label="loc_us-gaap_BusinessAcquisitionAxis_950" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_962" xlink:to="loc_us-gaap_BusinessAcquisitionAxis_950" use="optional" order="11" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_949" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_950" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_949" use="optional" order="12" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="roiv-20210630.xsd#roiv_SiliconTherapeuticsMember" xlink:label="loc_roiv_SiliconTherapeuticsMember_963" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_949" xlink:to="loc_roiv_SiliconTherapeuticsMember_963" use="optional" order="13" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestructuringPlanAxis" xlink:label="loc_us-gaap_RestructuringPlanAxis_960" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_962" xlink:to="loc_us-gaap_RestructuringPlanAxis_960" use="optional" order="14" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestructuringPlanDomain" xlink:label="loc_us-gaap_RestructuringPlanDomain_961" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestructuringPlanAxis_960" xlink:to="loc_us-gaap_RestructuringPlanDomain_961" use="optional" order="15" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="roiv-20210630.xsd#roiv_FirstTrancheMember" xlink:label="loc_roiv_FirstTrancheMember_1011" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestructuringPlanDomain_961" xlink:to="loc_roiv_FirstTrancheMember_1011" use="optional" order="16" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="roiv-20210630.xsd#roiv_SecondTrancheMember" xlink:label="loc_roiv_SecondTrancheMember_1012" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestructuringPlanDomain_961" xlink:to="loc_roiv_SecondTrancheMember_1012" use="optional" order="17" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="roiv-20210630.xsd#roiv_MilestoneEventsAxis" xlink:label="loc_roiv_MilestoneEventsAxis_954" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_962" xlink:to="loc_roiv_MilestoneEventsAxis_954" use="optional" order="18" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="roiv-20210630.xsd#roiv_MilestoneEventsDomain" xlink:label="loc_roiv_MilestoneEventsDomain_955" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_roiv_MilestoneEventsAxis_954" xlink:to="loc_roiv_MilestoneEventsDomain_955" use="optional" order="19" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="roiv-20210630.xsd#roiv_FirstProductFirstProductForEachMolecularTargetCoveredByIntellectualPropertyMember" xlink:label="loc_roiv_FirstProductFirstProductForEachMolecularTargetCoveredByIntellectualPropertyMember_1003" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_roiv_MilestoneEventsDomain_955" xlink:to="loc_roiv_FirstProductFirstProductForEachMolecularTargetCoveredByIntellectualPropertyMember_1003" use="optional" order="20" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="roiv-20210630.xsd#roiv_FirstProductTargetsTargetingEachOfTwoSpecifiedInitialTargetsMember" xlink:label="loc_roiv_FirstProductTargetsTargetingEachOfTwoSpecifiedInitialTargetsMember_1004" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_roiv_MilestoneEventsDomain_955" xlink:to="loc_roiv_FirstProductTargetsTargetingEachOfTwoSpecifiedInitialTargetsMember_1004" use="optional" order="21" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="roiv-20210630.xsd#roiv_FirstProductTargetsEachOfCertainSpecifiedAdditionalMoleculartargetsMember" xlink:label="loc_roiv_FirstProductTargetsEachOfCertainSpecifiedAdditionalMoleculartargetsMember_1005" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_roiv_MilestoneEventsDomain_955" xlink:to="loc_roiv_FirstProductTargetsEachOfCertainSpecifiedAdditionalMoleculartargetsMember_1005" use="optional" order="22" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeAxis" xlink:label="loc_srt_RangeAxis_956" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_962" xlink:to="loc_srt_RangeAxis_956" use="optional" order="23" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeMember" xlink:label="loc_srt_RangeMember_957" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeAxis_956" xlink:to="loc_srt_RangeMember_957" use="optional" order="24" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MaximumMember" xlink:label="loc_srt_MaximumMember_1006" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_957" xlink:to="loc_srt_MaximumMember_1006" use="optional" order="25" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessAcquisitionLineItems" xlink:label="loc_us-gaap_BusinessAcquisitionLineItems_951" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_962" xlink:to="loc_us-gaap_BusinessAcquisitionLineItems_951" use="optional" order="26" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="roiv-20210630.xsd#roiv_UpfrontCashPayments" xlink:label="loc_roiv_UpfrontCashPayments_964" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_951" xlink:to="loc_roiv_UpfrontCashPayments_964" use="optional" order="27" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="roiv-20210630.xsd#roiv_BusinessCollaborationContingentMilestonePayment" xlink:label="loc_roiv_BusinessCollaborationContingentMilestonePayment_965" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_951" xlink:to="loc_roiv_BusinessCollaborationContingentMilestonePayment_965" use="optional" order="28" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="roiv-20210630.xsd#roiv_FutureDevelopmentAndCommercialMilestonePayments" xlink:label="loc_roiv_FutureDevelopmentAndCommercialMilestonePayments_966" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_951" xlink:to="loc_roiv_FutureDevelopmentAndCommercialMilestonePayments_966" use="optional" order="29" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongTermDebt" xlink:label="loc_us-gaap_LongTermDebt_967" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_951" xlink:to="loc_us-gaap_LongTermDebt_967" use="optional" order="30" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="roiv-20210630.xsd#roiv_MilestonePayment" xlink:label="loc_roiv_MilestonePayment_968" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_951" xlink:to="loc_roiv_MilestonePayment_968" use="optional" order="31" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="roiv-20210630.xsd#roiv_NonRefundableUpfrontPaymentReceived" xlink:label="loc_roiv_NonRefundableUpfrontPaymentReceived_969" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_951" xlink:to="loc_roiv_NonRefundableUpfrontPaymentReceived_969" use="optional" order="32" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="roiv-20210630.xsd#roiv_PotentialMilestonePaymentReceivable" xlink:label="loc_roiv_PotentialMilestonePaymentReceivable_970" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_951" xlink:to="loc_roiv_PotentialMilestonePaymentReceivable_970" use="optional" order="33" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevenueRecognitionMilestoneMethodRevenueRecognized" xlink:label="loc_us-gaap_RevenueRecognitionMilestoneMethodRevenueRecognized_971" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_951" xlink:to="loc_us-gaap_RevenueRecognitionMilestoneMethodRevenueRecognized_971" use="optional" order="34" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsToAcquireEquityMethodInvestments" xlink:label="loc_us-gaap_PaymentsToAcquireEquityMethodInvestments_972" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_951" xlink:to="loc_us-gaap_PaymentsToAcquireEquityMethodInvestments_972" use="optional" order="35" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromNotesPayable" xlink:label="loc_us-gaap_ProceedsFromNotesPayable_973" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_951" xlink:to="loc_us-gaap_ProceedsFromNotesPayable_973" use="optional" order="36" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_974" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_951" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_974" use="optional" order="37" preferredLabel="http://www.xbrl.org/2003/role/positiveTerseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueNewIssues_975" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_951" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueNewIssues_975" use="optional" order="38" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtConversionOriginalDebtAmount1" xlink:label="loc_us-gaap_DebtConversionOriginalDebtAmount1_976" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_951" xlink:to="loc_us-gaap_DebtConversionOriginalDebtAmount1_976" use="optional" order="39" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtConversionConvertedInstrumentSharesIssued1" xlink:label="loc_us-gaap_DebtConversionConvertedInstrumentSharesIssued1_977" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_951" xlink:to="loc_us-gaap_DebtConversionConvertedInstrumentSharesIssued1_977" use="optional" order="40" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="roiv-20210630.xsd#roiv_PercentageOfControllingInterestHeld" xlink:label="loc_roiv_PercentageOfControllingInterestHeld_978" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_951" xlink:to="loc_roiv_PercentageOfControllingInterestHeld_978" use="optional" order="41" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InvestmentsInAffiliatesSubsidiariesAssociatesAndJointVenturesFairValueDisclosure" xlink:label="loc_us-gaap_InvestmentsInAffiliatesSubsidiariesAssociatesAndJointVenturesFairValueDisclosure_979" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_951" xlink:to="loc_us-gaap_InvestmentsInAffiliatesSubsidiariesAssociatesAndJointVenturesFairValueDisclosure_979" use="optional" order="42" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GainLossOnInvestments" xlink:label="loc_us-gaap_GainLossOnInvestments_980" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_951" xlink:to="loc_us-gaap_GainLossOnInvestments_980" use="optional" order="43" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityMethodInvestmentsFairValueDisclosure" xlink:label="loc_us-gaap_EquityMethodInvestmentsFairValueDisclosure_981" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_951" xlink:to="loc_us-gaap_EquityMethodInvestmentsFairValueDisclosure_981" use="optional" order="44" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsToAcquireInterestInSubsidiariesAndAffiliates" xlink:label="loc_us-gaap_PaymentsToAcquireInterestInSubsidiariesAndAffiliates_982" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_951" xlink:to="loc_us-gaap_PaymentsToAcquireInterestInSubsidiariesAndAffiliates_982" use="optional" order="45" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationConsiderationTransferred1" xlink:label="loc_us-gaap_BusinessCombinationConsiderationTransferred1_983" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_951" xlink:to="loc_us-gaap_BusinessCombinationConsiderationTransferred1_983" use="optional" order="46" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpense_984" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_951" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpense_984" use="optional" order="47" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="roiv-20210630.xsd#roiv_PaymentForUpfrontPayments" xlink:label="loc_roiv_PaymentForUpfrontPayments_985" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_951" xlink:to="loc_roiv_PaymentForUpfrontPayments_985" use="optional" order="48" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="roiv-20210630.xsd#roiv_PaymentUnderSponsoredResearchAgreement" xlink:label="loc_roiv_PaymentUnderSponsoredResearchAgreement_986" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_951" xlink:to="loc_roiv_PaymentUnderSponsoredResearchAgreement_986" use="optional" order="49" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RepaymentOfNotesReceivableFromRelatedParties" xlink:label="loc_us-gaap_RepaymentOfNotesReceivableFromRelatedParties_987" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_951" xlink:to="loc_us-gaap_RepaymentOfNotesReceivableFromRelatedParties_987" use="optional" order="50" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationContingentConsiderationLiability" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationLiability_988" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_951" xlink:to="loc_us-gaap_BusinessCombinationContingentConsiderationLiability_988" use="optional" order="51" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityMethodInvestmentUnderlyingEquityInNetAssets" xlink:label="loc_us-gaap_EquityMethodInvestmentUnderlyingEquityInNetAssets_989" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_951" xlink:to="loc_us-gaap_EquityMethodInvestmentUnderlyingEquityInNetAssets_989" use="optional" order="52" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsidiaryOrEquityMethodInvesteeCumulativePercentageOwnershipAfterAllTransactions" xlink:label="loc_us-gaap_SubsidiaryOrEquityMethodInvesteeCumulativePercentageOwnershipAfterAllTransactions_990" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_951" xlink:to="loc_us-gaap_SubsidiaryOrEquityMethodInvesteeCumulativePercentageOwnershipAfterAllTransactions_990" use="optional" order="53" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquityNoteSubscriptionsReceivable" xlink:label="loc_us-gaap_StockholdersEquityNoteSubscriptionsReceivable_991" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_951" xlink:to="loc_us-gaap_StockholdersEquityNoteSubscriptionsReceivable_991" use="optional" order="54" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="roiv-20210630.xsd#roiv_StockIssuedDuringPeriodValue" xlink:label="loc_roiv_StockIssuedDuringPeriodValue_992" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_951" xlink:to="loc_roiv_StockIssuedDuringPeriodValue_992" use="optional" order="55" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationConsiderationTransferredLiabilitiesIncurred" xlink:label="loc_us-gaap_BusinessCombinationConsiderationTransferredLiabilitiesIncurred_993" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_951" xlink:to="loc_us-gaap_BusinessCombinationConsiderationTransferredLiabilitiesIncurred_993" use="optional" order="56" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued" xlink:label="loc_us-gaap_BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued_994" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_951" xlink:to="loc_us-gaap_BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued_994" use="optional" order="57" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired" xlink:label="loc_us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired_995" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_951" xlink:to="loc_us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired_995" use="optional" order="58" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet_996" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_951" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet_996" use="optional" order="59" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessAcquisitionEquityInterestIssuedOrIssuableValueAssigned" xlink:label="loc_us-gaap_BusinessAcquisitionEquityInterestIssuedOrIssuableValueAssigned_997" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_951" xlink:to="loc_us-gaap_BusinessAcquisitionEquityInterestIssuedOrIssuableValueAssigned_997" use="optional" order="60" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccountsPayable" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccountsPayable_998" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_951" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccountsPayable_998" use="optional" order="61" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensation" xlink:label="loc_us-gaap_ShareBasedCompensation_999" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_951" xlink:to="loc_us-gaap_ShareBasedCompensation_999" use="optional" order="62" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="roiv-20210630.xsd#roiv_FairValueOfCommonShares" xlink:label="loc_roiv_FairValueOfCommonShares_1000" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_951" xlink:to="loc_roiv_FairValueOfCommonShares_1000" use="optional" order="63" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="roiv-20210630.xsd#roiv_FairValueOfRestrictedStock" xlink:label="loc_roiv_FairValueOfRestrictedStock_1001" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_951" xlink:to="loc_roiv_FairValueOfRestrictedStock_1001" use="optional" order="64" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://roivant.com/role/SumitomoTransactionAgreementAdditionalInformationDetail">
<loc xlink:type="locator" xlink:href="roiv-20210630.xsd#roiv_TransactionAgreementAbstract" xlink:label="loc_roiv_TransactionAgreementAbstract_1014" />
<loc xlink:type="locator" xlink:href="roiv-20210630.xsd#roiv_TransactionAgreementTable" xlink:label="loc_roiv_TransactionAgreementTable_1022" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_roiv_TransactionAgreementAbstract_1014" xlink:to="loc_roiv_TransactionAgreementTable_1022" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:label="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_1018" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_roiv_TransactionAgreementTable_1022" xlink:to="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_1018" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RelatedPartyDomain" xlink:label="loc_us-gaap_RelatedPartyDomain_1017" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_1018" xlink:to="loc_us-gaap_RelatedPartyDomain_1017" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="roiv-20210630.xsd#roiv_SumitomoMember" xlink:label="loc_roiv_SumitomoMember_1024" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyDomain_1017" xlink:to="loc_roiv_SumitomoMember_1024" use="optional" order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeAxis" xlink:label="loc_srt_RangeAxis_1015" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_roiv_TransactionAgreementTable_1022" xlink:to="loc_srt_RangeAxis_1015" use="optional" order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeMember" xlink:label="loc_srt_RangeMember_1016" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeAxis_1015" xlink:to="loc_srt_RangeMember_1016" use="optional" order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MaximumMember" xlink:label="loc_srt_MaximumMember_1023" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_1016" xlink:to="loc_srt_MaximumMember_1023" use="optional" order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_TitleOfIndividualAxis" xlink:label="loc_srt_TitleOfIndividualAxis_1019" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_roiv_TransactionAgreementTable_1022" xlink:to="loc_srt_TitleOfIndividualAxis_1019" use="optional" order="8" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:label="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain_1020" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_TitleOfIndividualAxis_1019" xlink:to="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain_1020" use="optional" order="9" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="roiv-20210630.xsd#roiv_EmployeeMember" xlink:label="loc_roiv_EmployeeMember_1025" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain_1020" xlink:to="loc_roiv_EmployeeMember_1025" use="optional" order="10" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="roiv-20210630.xsd#roiv_AgreementAxis" xlink:label="loc_roiv_AgreementAxis_1097947" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_roiv_TransactionAgreementTable_1022" xlink:to="loc_roiv_AgreementAxis_1097947" use="optional" order="11" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="roiv-20210630.xsd#roiv_AgreementDomain" xlink:label="loc_roiv_AgreementDomain_1097950" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_roiv_AgreementAxis_1097947" xlink:to="loc_roiv_AgreementDomain_1097950" use="optional" order="12" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="roiv-20210630.xsd#roiv_TransitionServicesAndStrategicCooperationAgreementMember" xlink:label="loc_roiv_TransitionServicesAndStrategicCooperationAgreementMember_1097953" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_roiv_AgreementDomain_1097950" xlink:to="loc_roiv_TransitionServicesAndStrategicCooperationAgreementMember_1097953" use="optional" order="13" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="roiv-20210630.xsd#roiv_AssetPurchaseAgreementMember" xlink:label="loc_roiv_AssetPurchaseAgreementMember_1098006" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_roiv_AgreementDomain_1097950" xlink:to="loc_roiv_AssetPurchaseAgreementMember_1098006" use="optional" order="14" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="roiv-20210630.xsd#roiv_TransactionAgreementLineItems" xlink:label="loc_roiv_TransactionAgreementLineItems_1021" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_roiv_TransactionAgreementTable_1022" xlink:to="loc_roiv_TransactionAgreementLineItems_1021" use="optional" order="15" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="roiv-20210630.xsd#roiv_PercentageOfGrantedOptionToPurchaseOwnershipInterest" xlink:label="loc_roiv_PercentageOfGrantedOptionToPurchaseOwnershipInterest_1026" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_roiv_TransactionAgreementLineItems_1021" xlink:to="loc_roiv_PercentageOfGrantedOptionToPurchaseOwnershipInterest_1026" use="optional" order="16" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="roiv-20210630.xsd#roiv_SaleOfStockNumberOfShareIssuedInTransaction" xlink:label="loc_roiv_SaleOfStockNumberOfShareIssuedInTransaction_1105120" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_roiv_TransactionAgreementLineItems_1021" xlink:to="loc_roiv_SaleOfStockNumberOfShareIssuedInTransaction_1105120" use="optional" order="17" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SaleOfStockConsiderationReceivedOnTransaction" xlink:label="loc_us-gaap_SaleOfStockConsiderationReceivedOnTransaction_1028" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_roiv_TransactionAgreementLineItems_1021" xlink:to="loc_us-gaap_SaleOfStockConsiderationReceivedOnTransaction_1028" use="optional" order="18" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GainOrLossOnSaleOfStockInSubsidiary" xlink:label="loc_us-gaap_GainOrLossOnSaleOfStockInSubsidiary_1029" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_roiv_TransactionAgreementLineItems_1021" xlink:to="loc_us-gaap_GainOrLossOnSaleOfStockInSubsidiary_1029" use="optional" order="19" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EscrowDeposit" xlink:label="loc_us-gaap_EscrowDeposit_1030" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_roiv_TransactionAgreementLineItems_1021" xlink:to="loc_us-gaap_EscrowDeposit_1030" use="optional" order="20" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestrictedCash" xlink:label="loc_us-gaap_RestrictedCash_1031" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_roiv_TransactionAgreementLineItems_1021" xlink:to="loc_us-gaap_RestrictedCash_1031" use="optional" order="21" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockRepurchaseProgramAuthorizedAmount1" xlink:label="loc_us-gaap_StockRepurchaseProgramAuthorizedAmount1_1032" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_roiv_TransactionAgreementLineItems_1021" xlink:to="loc_us-gaap_StockRepurchaseProgramAuthorizedAmount1_1032" use="optional" order="22" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="roiv-20210630.xsd#roiv_AggregateFairValueOfEquityAndLiabilityInstrumentsIssued" xlink:label="loc_roiv_AggregateFairValueOfEquityAndLiabilityInstrumentsIssued_1033" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_roiv_TransactionAgreementLineItems_1021" xlink:to="loc_roiv_AggregateFairValueOfEquityAndLiabilityInstrumentsIssued_1033" use="optional" order="23" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredCompensationEquity" xlink:label="loc_us-gaap_DeferredCompensationEquity_1034" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_roiv_TransactionAgreementLineItems_1021" xlink:to="loc_us-gaap_DeferredCompensationEquity_1034" use="optional" order="24" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredCompensationLiabilityCurrent" xlink:label="loc_us-gaap_DeferredCompensationLiabilityCurrent_1035" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_roiv_TransactionAgreementLineItems_1021" xlink:to="loc_us-gaap_DeferredCompensationLiabilityCurrent_1035" use="optional" order="25" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_1036" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_roiv_TransactionAgreementLineItems_1021" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_1036" use="optional" order="26" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="roiv-20210630.xsd#roiv_AgreementRelatedBilledAmountForCostsIncurredOnBehalfOfSubsidiarynetOfAmountsBilledBySubsidiary" xlink:label="loc_roiv_AgreementRelatedBilledAmountForCostsIncurredOnBehalfOfSubsidiarynetOfAmountsBilledBySubsidiary_1097922" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_roiv_TransactionAgreementLineItems_1021" xlink:to="loc_roiv_AgreementRelatedBilledAmountForCostsIncurredOnBehalfOfSubsidiarynetOfAmountsBilledBySubsidiary_1097922" use="optional" order="27" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="roiv-20210630.xsd#roiv_AssetPurchaseTransactionConsiderationReceivedInCash" xlink:label="loc_roiv_AssetPurchaseTransactionConsiderationReceivedInCash_1105119" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_roiv_TransactionAgreementLineItems_1021" xlink:to="loc_roiv_AssetPurchaseTransactionConsiderationReceivedInCash_1105119" use="optional" order="28" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="roiv-20210630.xsd#roiv_SaleOfStockConsiderationCashReceivedOnTransaction" xlink:label="loc_roiv_SaleOfStockConsiderationCashReceivedOnTransaction_1105122" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_roiv_TransactionAgreementLineItems_1021" xlink:to="loc_roiv_SaleOfStockConsiderationCashReceivedOnTransaction_1105122" use="optional" order="29" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="roiv-20210630.xsd#roiv_StockOfferToRepurchaseDuringPeriodValueOfTheProceedsReceivedFromTransactionAgreement" xlink:label="loc_roiv_StockOfferToRepurchaseDuringPeriodValueOfTheProceedsReceivedFromTransactionAgreement_1105154" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_roiv_TransactionAgreementLineItems_1021" xlink:to="loc_roiv_StockOfferToRepurchaseDuringPeriodValueOfTheProceedsReceivedFromTransactionAgreement_1105154" use="optional" order="30" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="roiv-20210630.xsd#roiv_EquityInterestOptionToThirdPartyPurchaserGainOnTermination" xlink:label="loc_roiv_EquityInterestOptionToThirdPartyPurchaserGainOnTermination_1107964" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_roiv_TransactionAgreementLineItems_1021" xlink:to="loc_roiv_EquityInterestOptionToThirdPartyPurchaserGainOnTermination_1107964" use="optional" order="31" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://roivant.com/role/BalanceSheetComponentsScheduleOfOtherCurrentAssetsDetail">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BalanceSheetRelatedDisclosuresAbstract" xlink:label="loc_us-gaap_BalanceSheetRelatedDisclosuresAbstract_1060" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PrepaidExpenseCurrent" xlink:label="loc_us-gaap_PrepaidExpenseCurrent_1061" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BalanceSheetRelatedDisclosuresAbstract_1060" xlink:to="loc_us-gaap_PrepaidExpenseCurrent_1061" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ValueAddedTaxReceivable" xlink:label="loc_us-gaap_ValueAddedTaxReceivable_1062" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BalanceSheetRelatedDisclosuresAbstract_1060" xlink:to="loc_us-gaap_ValueAddedTaxReceivable_1062" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NotesAndLoansReceivableNetCurrent" xlink:label="loc_us-gaap_NotesAndLoansReceivableNetCurrent_1063" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BalanceSheetRelatedDisclosuresAbstract_1060" xlink:to="loc_us-gaap_NotesAndLoansReceivableNetCurrent_1063" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountsReceivableNetCurrent" xlink:label="loc_us-gaap_AccountsReceivableNetCurrent_1064" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BalanceSheetRelatedDisclosuresAbstract_1060" xlink:to="loc_us-gaap_AccountsReceivableNetCurrent_1064" use="optional" order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxesReceivable" xlink:label="loc_us-gaap_IncomeTaxesReceivable_1065" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BalanceSheetRelatedDisclosuresAbstract_1060" xlink:to="loc_us-gaap_IncomeTaxesReceivable_1065" use="optional" order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherAssetsMiscellaneousCurrent" xlink:label="loc_us-gaap_OtherAssetsMiscellaneousCurrent_1066" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BalanceSheetRelatedDisclosuresAbstract_1060" xlink:to="loc_us-gaap_OtherAssetsMiscellaneousCurrent_1066" use="optional" order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherAssetsCurrent" xlink:label="loc_us-gaap_OtherAssetsCurrent_1067" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BalanceSheetRelatedDisclosuresAbstract_1060" xlink:to="loc_us-gaap_OtherAssetsCurrent_1067" use="optional" order="7" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://roivant.com/role/BalanceSheetComponentsScheduleOfAccruedExpensesDetail">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BalanceSheetRelatedDisclosuresAbstract" xlink:label="loc_us-gaap_BalanceSheetRelatedDisclosuresAbstract_1069" />
<loc xlink:type="locator" xlink:href="roiv-20210630.xsd#roiv_BalanceSheetComponentsTable" xlink:label="loc_roiv_BalanceSheetComponentsTable_1071" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BalanceSheetRelatedDisclosuresAbstract_1069" xlink:to="loc_roiv_BalanceSheetComponentsTable_1071" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeStatementLocationAxis" xlink:label="loc_us-gaap_IncomeStatementLocationAxis_1072" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_roiv_BalanceSheetComponentsTable_1071" xlink:to="loc_us-gaap_IncomeStatementLocationAxis_1072" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_1073" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_1072" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_1073" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ResearchAndDevelopmentExpenseMember" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpenseMember_1075" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_1073" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpenseMember_1075" use="optional" order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="roiv-20210630.xsd#roiv_EmployeeRelatedExpensesMember" xlink:label="loc_roiv_EmployeeRelatedExpensesMember_1076" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_1073" xlink:to="loc_roiv_EmployeeRelatedExpensesMember_1076" use="optional" order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="roiv-20210630.xsd#roiv_ProfessionalServicesExpensesMember" xlink:label="loc_roiv_ProfessionalServicesExpensesMember_1077" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_1073" xlink:to="loc_roiv_ProfessionalServicesExpensesMember_1077" use="optional" order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="roiv-20210630.xsd#roiv_OtherGeneralAndAdministrativeExpensesMember" xlink:label="loc_roiv_OtherGeneralAndAdministrativeExpensesMember_1078" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_1073" xlink:to="loc_roiv_OtherGeneralAndAdministrativeExpensesMember_1078" use="optional" order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="roiv-20210630.xsd#roiv_BalanceSheetComponentsLineItems" xlink:label="loc_roiv_BalanceSheetComponentsLineItems_1070" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_roiv_BalanceSheetComponentsTable_1071" xlink:to="loc_roiv_BalanceSheetComponentsLineItems_1070" use="optional" order="8" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccruedLiabilitiesCurrent" xlink:label="loc_us-gaap_AccruedLiabilitiesCurrent_1074" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_roiv_BalanceSheetComponentsLineItems_1070" xlink:to="loc_us-gaap_AccruedLiabilitiesCurrent_1074" use="optional" order="9" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://roivant.com/role/BalanceSheetComponentsScheduleOfOtherCurrentLiabilitiesDetail">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BalanceSheetRelatedDisclosuresAbstract" xlink:label="loc_us-gaap_BalanceSheetRelatedDisclosuresAbstract_1080" />
<loc xlink:type="locator" xlink:href="roiv-20210630.xsd#roiv_DeferredRevenueOtherCurrentLiabilities" xlink:label="loc_roiv_DeferredRevenueOtherCurrentLiabilities_1081" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BalanceSheetRelatedDisclosuresAbstract_1080" xlink:to="loc_roiv_DeferredRevenueOtherCurrentLiabilities_1081" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TaxesPayableCurrent" xlink:label="loc_us-gaap_TaxesPayableCurrent_1082" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BalanceSheetRelatedDisclosuresAbstract_1080" xlink:to="loc_us-gaap_TaxesPayableCurrent_1082" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherSundryLiabilitiesCurrent" xlink:label="loc_us-gaap_OtherSundryLiabilitiesCurrent_1083" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BalanceSheetRelatedDisclosuresAbstract_1080" xlink:to="loc_us-gaap_OtherSundryLiabilitiesCurrent_1083" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherLiabilitiesCurrent" xlink:label="loc_us-gaap_OtherLiabilitiesCurrent_1084" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BalanceSheetRelatedDisclosuresAbstract_1080" xlink:to="loc_us-gaap_OtherLiabilitiesCurrent_1084" use="optional" order="4" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://roivant.com/role/LongTermDebtAndLoanCommitmentDetail">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongTermDebtAbstract" xlink:label="loc_us-gaap_LongTermDebtAbstract_1086" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentCarryingAmount" xlink:label="loc_us-gaap_DebtInstrumentCarryingAmount_1087" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongTermDebtAbstract_1086" xlink:to="loc_us-gaap_DebtInstrumentCarryingAmount_1087" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="roiv-20210630.xsd#roiv_DebtInstrumentAmount" xlink:label="loc_roiv_DebtInstrumentAmount_1140150" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongTermDebtAbstract_1086" xlink:to="loc_roiv_DebtInstrumentAmount_1140150" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="roiv-20210630.xsd#roiv_DebtInstrumentExitFeeAndEndOfTermCharge" xlink:label="loc_roiv_DebtInstrumentExitFeeAndEndOfTermCharge_1099196" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongTermDebtAbstract_1086" xlink:to="loc_roiv_DebtInstrumentExitFeeAndEndOfTermCharge_1099196" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet" xlink:label="loc_us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet_1088" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongTermDebtAbstract_1086" xlink:to="loc_us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet_1088" use="optional" order="4" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongTermDebt" xlink:label="loc_us-gaap_LongTermDebt_1089" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongTermDebtAbstract_1086" xlink:to="loc_us-gaap_LongTermDebt_1089" use="optional" order="5" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongTermDebtCurrent" xlink:label="loc_us-gaap_LongTermDebtCurrent_1090" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongTermDebtAbstract_1086" xlink:to="loc_us-gaap_LongTermDebtCurrent_1090" use="optional" order="6" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongTermDebtNoncurrent" xlink:label="loc_us-gaap_LongTermDebtNoncurrent_1091" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongTermDebtAbstract_1086" xlink:to="loc_us-gaap_LongTermDebtNoncurrent_1091" use="optional" order="7" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://roivant.com/role/LongTermDebtAndLoanCommitmentAdditionalInformationDetail">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtDisclosureAbstract" xlink:label="loc_us-gaap_DebtDisclosureAbstract_1093" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentTable" xlink:label="loc_us-gaap_DebtInstrumentTable_1096" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_1093" xlink:to="loc_us-gaap_DebtInstrumentTable_1096" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="loc_us-gaap_TypeOfArrangementAxis_1101" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_1096" xlink:to="loc_us-gaap_TypeOfArrangementAxis_1101" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_1094" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TypeOfArrangementAxis_1101" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_1094" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="roiv-20210630.xsd#roiv_NovaquestMember" xlink:label="loc_roiv_NovaquestMember_1104" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_1094" xlink:to="loc_roiv_NovaquestMember_1104" use="optional" order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:label="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_1098" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_1096" xlink:to="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_1098" use="optional" order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RelatedPartyDomain" xlink:label="loc_us-gaap_RelatedPartyDomain_1097" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_1098" xlink:to="loc_us-gaap_RelatedPartyDomain_1097" use="optional" order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_VariableRateAxis" xlink:label="loc_us-gaap_VariableRateAxis_1102" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_1096" xlink:to="loc_us-gaap_VariableRateAxis_1102" use="optional" order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_VariableRateDomain" xlink:label="loc_us-gaap_VariableRateDomain_1103" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_VariableRateAxis_1102" xlink:to="loc_us-gaap_VariableRateDomain_1103" use="optional" order="8" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PrimeRateMember" xlink:label="loc_us-gaap_PrimeRateMember_1117" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_VariableRateDomain_1103" xlink:to="loc_us-gaap_PrimeRateMember_1117" use="optional" order="9" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TransactionTypeAxis" xlink:label="loc_us-gaap_TransactionTypeAxis_1100" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_1096" xlink:to="loc_us-gaap_TransactionTypeAxis_1100" use="optional" order="10" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TransactionDomain" xlink:label="loc_us-gaap_TransactionDomain_1099" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransactionTypeAxis_1100" xlink:to="loc_us-gaap_TransactionDomain_1099" use="optional" order="11" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="roiv-20210630.xsd#roiv_RegulatoryMilestoneMember" xlink:label="loc_roiv_RegulatoryMilestoneMember_1115" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransactionDomain_1099" xlink:to="loc_roiv_RegulatoryMilestoneMember_1115" use="optional" order="12" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="roiv-20210630.xsd#roiv_CommercialMilestoneMember" xlink:label="loc_roiv_CommercialMilestoneMember_1116" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransactionDomain_1099" xlink:to="loc_roiv_CommercialMilestoneMember_1116" use="optional" order="13" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeAxis" xlink:label="loc_srt_RangeAxis_1097057" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_1096" xlink:to="loc_srt_RangeAxis_1097057" use="optional" order="14" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeMember" xlink:label="loc_srt_RangeMember_1097058" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeAxis_1097057" xlink:to="loc_srt_RangeMember_1097058" use="optional" order="15" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FinancialInstrumentAxis" xlink:label="loc_us-gaap_FinancialInstrumentAxis_1097323" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_1096" xlink:to="loc_us-gaap_FinancialInstrumentAxis_1097323" use="optional" order="16" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_1097324" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FinancialInstrumentAxis_1097323" xlink:to="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_1097324" use="optional" order="17" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="roiv-20210630.xsd#roiv_RevenueInterestPurchaseAndSaleAgreementMember" xlink:label="loc_roiv_RevenueInterestPurchaseAndSaleAgreementMember_1097325" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_1097324" xlink:to="loc_roiv_RevenueInterestPurchaseAndSaleAgreementMember_1097325" use="optional" order="18" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentLineItems" xlink:label="loc_us-gaap_DebtInstrumentLineItems_1095" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_1096" xlink:to="loc_us-gaap_DebtInstrumentLineItems_1095" use="optional" order="19" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentFaceAmount" xlink:label="loc_us-gaap_DebtInstrumentFaceAmount_1105" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_1095" xlink:to="loc_us-gaap_DebtInstrumentFaceAmount_1105" use="optional" order="20" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongTermDebtPercentageBearingVariableInterestRate" xlink:label="loc_us-gaap_LongTermDebtPercentageBearingVariableInterestRate_1106" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_1095" xlink:to="loc_us-gaap_LongTermDebtPercentageBearingVariableInterestRate_1106" use="optional" order="21" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentFeeAmount" xlink:label="loc_us-gaap_DebtInstrumentFeeAmount_1108" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_1095" xlink:to="loc_us-gaap_DebtInstrumentFeeAmount_1108" use="optional" order="22" preferredLabel="http://www.xbrl.org/2003/role/definitionGuidance" />
<loc xlink:type="locator" xlink:href="roiv-20210630.xsd#roiv_DebtInstrumentExitFeeAndEndOfTermCharge" xlink:label="loc_roiv_DebtInstrumentExitFeeAndEndOfTermCharge_1105123" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_1095" xlink:to="loc_roiv_DebtInstrumentExitFeeAndEndOfTermCharge_1105123" use="optional" order="23" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="roiv-20210630.xsd#roiv_ProceedsFromSaleOfDebtAndEquitySecurities" xlink:label="loc_roiv_ProceedsFromSaleOfDebtAndEquitySecurities_1109" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_1095" xlink:to="loc_roiv_ProceedsFromSaleOfDebtAndEquitySecurities_1109" use="optional" order="24" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromLinesOfCredit" xlink:label="loc_us-gaap_ProceedsFromLinesOfCredit_1110" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_1095" xlink:to="loc_us-gaap_ProceedsFromLinesOfCredit_1110" use="optional" order="25" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="roiv-20210630.xsd#roiv_MaximumMilestonePaymentObligation" xlink:label="loc_roiv_MaximumMilestonePaymentObligation_1111" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_1095" xlink:to="loc_roiv_MaximumMilestonePaymentObligation_1111" use="optional" order="26" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="roiv-20210630.xsd#roiv_MaximumMilestonePaymentOffsetAmount" xlink:label="loc_roiv_MaximumMilestonePaymentOffsetAmount_1112" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_1095" xlink:to="loc_roiv_MaximumMilestonePaymentOffsetAmount_1112" use="optional" order="27" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentFairValue" xlink:label="loc_us-gaap_DebtInstrumentFairValue_1113" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_1095" xlink:to="loc_us-gaap_DebtInstrumentFairValue_1113" use="optional" order="28" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:label="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_1097048" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_1095" xlink:to="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_1097048" use="optional" order="29" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentTerm" xlink:label="loc_us-gaap_DebtInstrumentTerm_1097050" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_1095" xlink:to="loc_us-gaap_DebtInstrumentTerm_1097050" use="optional" order="30" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight" xlink:label="loc_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight_1097053" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_1095" xlink:to="loc_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight_1097053" use="optional" order="31" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:label="loc_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_1097054" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_1095" xlink:to="loc_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_1097054" use="optional" order="32" preferredLabel="http://www.xbrl.org/2003/role/disclosureGuidance" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SecuritiesPurchasedUnderAgreementsToResellIncrease" xlink:label="loc_us-gaap_SecuritiesPurchasedUnderAgreementsToResellIncrease_1097321" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_1095" xlink:to="loc_us-gaap_SecuritiesPurchasedUnderAgreementsToResellIncrease_1097321" use="optional" order="33" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="roiv-20210630.xsd#roiv_MinimumAmountOfAnnualNetSalesToQualifyUnderRevenueInterestPurchaseAgreementContingentThreshold" xlink:label="loc_roiv_MinimumAmountOfAnnualNetSalesToQualifyUnderRevenueInterestPurchaseAgreementContingentThreshold_1097322" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_1095" xlink:to="loc_roiv_MinimumAmountOfAnnualNetSalesToQualifyUnderRevenueInterestPurchaseAgreementContingentThreshold_1097322" use="optional" order="34" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://roivant.com/role/LongTermDebtAndConvertibleNotesPayableScheduleOfCompanysAnnualPaymentsDetail">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongTermDebtByMaturityAbstract" xlink:label="loc_us-gaap_LongTermDebtByMaturityAbstract_1119" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths" xlink:label="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths_1120" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongTermDebtByMaturityAbstract_1119" xlink:to="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths_1120" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo" xlink:label="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo_1121" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongTermDebtByMaturityAbstract_1119" xlink:to="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo_1121" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree" xlink:label="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree_1122" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongTermDebtByMaturityAbstract_1119" xlink:to="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree_1122" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour" xlink:label="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour_1123" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongTermDebtByMaturityAbstract_1119" xlink:to="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour_1123" use="optional" order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive" xlink:label="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive_1124" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongTermDebtByMaturityAbstract_1119" xlink:to="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive_1124" use="optional" order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalAfterYearFive" xlink:label="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalAfterYearFive_1125" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongTermDebtByMaturityAbstract_1119" xlink:to="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalAfterYearFive_1125" use="optional" order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="roiv-20210630.xsd#roiv_LongTermDebtExcludingDebtWithFairValueOption" xlink:label="loc_roiv_LongTermDebtExcludingDebtWithFairValueOption_1126" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongTermDebtByMaturityAbstract_1119" xlink:to="loc_roiv_LongTermDebtExcludingDebtWithFairValueOption_1126" use="optional" order="7" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://roivant.com/role/ShareholdersEquityAndRedeemableNonControllingInterestAdditionalInformationDetail">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityAbstract" xlink:label="loc_us-gaap_EquityAbstract_1138" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfStockByClassTable" xlink:label="loc_us-gaap_ScheduleOfStockByClassTable_1151" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_1138" xlink:to="loc_us-gaap_ScheduleOfStockByClassTable_1151" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:label="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_1149" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_1151" xlink:to="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_1149" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RelatedPartyDomain" xlink:label="loc_us-gaap_RelatedPartyDomain_1148" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_1149" xlink:to="loc_us-gaap_RelatedPartyDomain_1148" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="roiv-20210630.xsd#roiv_SumitomoMember" xlink:label="loc_roiv_SumitomoMember_1195" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyDomain_1148" xlink:to="loc_roiv_SumitomoMember_1195" use="optional" order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="roiv-20210630.xsd#roiv_CytovantScienceHkLtdMember" xlink:label="loc_roiv_CytovantScienceHkLtdMember_1196" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyDomain_1148" xlink:to="loc_roiv_CytovantScienceHkLtdMember_1196" use="optional" order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="roiv-20210630.xsd#roiv_HealthSciencesMember" xlink:label="loc_roiv_HealthSciencesMember_1197" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyDomain_1148" xlink:to="loc_roiv_HealthSciencesMember_1197" use="optional" order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="roiv-20210630.xsd#roiv_ImmunovantSciencesLtdMember" xlink:label="loc_roiv_ImmunovantSciencesLtdMember_1198" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyDomain_1148" xlink:to="loc_roiv_ImmunovantSciencesLtdMember_1198" use="optional" order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="roiv-20210630.xsd#roiv_SinovantIncMember" xlink:label="loc_roiv_SinovantIncMember_1199" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyDomain_1148" xlink:to="loc_roiv_SinovantIncMember_1199" use="optional" order="8" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessAcquisitionAxis" xlink:label="loc_us-gaap_BusinessAcquisitionAxis_1142" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_1151" xlink:to="loc_us-gaap_BusinessAcquisitionAxis_1142" use="optional" order="9" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_1141" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_1142" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_1141" use="optional" order="10" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="roiv-20210630.xsd#roiv_ImmunovantINCMember" xlink:label="loc_roiv_ImmunovantINCMember_1162" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_1141" xlink:to="loc_roiv_ImmunovantINCMember_1162" use="optional" order="11" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="roiv-20210630.xsd#roiv_HealthSciencesMember" xlink:label="loc_roiv_HealthSciencesMember_1140124" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_1141" xlink:to="loc_roiv_HealthSciencesMember_1140124" use="optional" order="12" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeAxis" xlink:label="loc_srt_RangeAxis_1146" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_1151" xlink:to="loc_srt_RangeAxis_1146" use="optional" order="13" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeMember" xlink:label="loc_srt_RangeMember_1147" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeAxis_1146" xlink:to="loc_srt_RangeMember_1147" use="optional" order="14" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MaximumMember" xlink:label="loc_srt_MaximumMember_1194" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_1147" xlink:to="loc_srt_MaximumMember_1194" use="optional" order="15" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="loc_us-gaap_TypeOfArrangementAxis_1160" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_1151" xlink:to="loc_us-gaap_TypeOfArrangementAxis_1160" use="optional" order="16" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_1139" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TypeOfArrangementAxis_1160" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_1139" use="optional" order="17" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="roiv-20210630.xsd#roiv_SumitomoTransactionAgreementMember" xlink:label="loc_roiv_SumitomoTransactionAgreementMember_1161" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_1139" xlink:to="loc_roiv_SumitomoTransactionAgreementMember_1161" use="optional" order="18" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="loc_us-gaap_SubsidiarySaleOfStockAxis_1159" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_1151" xlink:to="loc_us-gaap_SubsidiarySaleOfStockAxis_1159" use="optional" order="19" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain_1150" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis_1159" xlink:to="loc_us-gaap_SaleOfStockNameOfTransactionDomain_1150" use="optional" order="20" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="roiv-20210630.xsd#roiv_UnderwrittenPublicOfferingMember" xlink:label="loc_roiv_UnderwrittenPublicOfferingMember_1200" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_1150" xlink:to="loc_roiv_UnderwrittenPublicOfferingMember_1200" use="optional" order="21" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareRepurchaseProgramAxis" xlink:label="loc_us-gaap_ShareRepurchaseProgramAxis_1153" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_1151" xlink:to="loc_us-gaap_ShareRepurchaseProgramAxis_1153" use="optional" order="22" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareRepurchaseProgramDomain" xlink:label="loc_us-gaap_ShareRepurchaseProgramDomain_1154" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareRepurchaseProgramAxis_1153" xlink:to="loc_us-gaap_ShareRepurchaseProgramDomain_1154" use="optional" order="23" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="roiv-20210630.xsd#roiv_RoivantEquityRepurchaseMember" xlink:label="loc_roiv_RoivantEquityRepurchaseMember_1202" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareRepurchaseProgramDomain_1154" xlink:to="loc_roiv_RoivantEquityRepurchaseMember_1202" use="optional" order="24" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="loc_us-gaap_StatementClassOfStockAxis_1157" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_1151" xlink:to="loc_us-gaap_StatementClassOfStockAxis_1157" use="optional" order="25" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaap_ClassOfStockDomain_1143" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementClassOfStockAxis_1157" xlink:to="loc_us-gaap_ClassOfStockDomain_1143" use="optional" order="26" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="roiv-20210630.xsd#roiv_SeriesA1PreferredStockMember" xlink:label="loc_roiv_SeriesA1PreferredStockMember_1163" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockDomain_1143" xlink:to="loc_roiv_SeriesA1PreferredStockMember_1163" use="optional" order="27" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_1158" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_1151" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_1158" use="optional" order="28" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaap_EquityComponentDomain_1145" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_1158" xlink:to="loc_us-gaap_EquityComponentDomain_1145" use="optional" order="29" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockMember" xlink:label="loc_us-gaap_CommonStockMember_1192" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_1145" xlink:to="loc_us-gaap_CommonStockMember_1192" use="optional" order="30" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_WarrantMember" xlink:label="loc_us-gaap_WarrantMember_1193" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_1145" xlink:to="loc_us-gaap_WarrantMember_1193" use="optional" order="31" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShortTermDebtTypeAxis" xlink:label="loc_us-gaap_ShortTermDebtTypeAxis_1155" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_1151" xlink:to="loc_us-gaap_ShortTermDebtTypeAxis_1155" use="optional" order="32" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShortTermDebtTypeDomain" xlink:label="loc_us-gaap_ShortTermDebtTypeDomain_1156" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShortTermDebtTypeAxis_1155" xlink:to="loc_us-gaap_ShortTermDebtTypeDomain_1156" use="optional" order="33" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConvertibleNotesPayableMember" xlink:label="loc_us-gaap_ConvertibleNotesPayableMember_1203" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShortTermDebtTypeDomain_1156" xlink:to="loc_us-gaap_ConvertibleNotesPayableMember_1203" use="optional" order="34" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AwardTypeAxis" xlink:label="loc_us-gaap_AwardTypeAxis_1140" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_1151" xlink:to="loc_us-gaap_AwardTypeAxis_1140" use="optional" order="35" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_1152" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AwardTypeAxis_1140" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_1152" use="optional" order="36" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestrictedStockMember" xlink:label="loc_us-gaap_RestrictedStockMember_1201" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_1152" xlink:to="loc_us-gaap_RestrictedStockMember_1201" use="optional" order="37" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfStockLineItems" xlink:label="loc_us-gaap_ClassOfStockLineItems_1144" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_1151" xlink:to="loc_us-gaap_ClassOfStockLineItems_1144" use="optional" order="38" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" xlink:label="loc_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_1164" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_1144" xlink:to="loc_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_1164" use="optional" order="39" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharesIssuedPricePerShare" xlink:label="loc_us-gaap_SharesIssuedPricePerShare_1165" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_1144" xlink:to="loc_us-gaap_SharesIssuedPricePerShare_1165" use="optional" order="40" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SaleOfStockConsiderationReceivedOnTransaction" xlink:label="loc_us-gaap_SaleOfStockConsiderationReceivedOnTransaction_1166" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_1144" xlink:to="loc_us-gaap_SaleOfStockConsiderationReceivedOnTransaction_1166" use="optional" order="41" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockRepurchaseProgramAuthorizedAmount1" xlink:label="loc_us-gaap_StockRepurchaseProgramAuthorizedAmount1_1167" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_1144" xlink:to="loc_us-gaap_StockRepurchaseProgramAuthorizedAmount1_1167" use="optional" order="42" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="roiv-20210630.xsd#roiv_PercentageSharesOfCommonStockOfferedToBeRepurchased" xlink:label="loc_roiv_PercentageSharesOfCommonStockOfferedToBeRepurchased_1168" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_1144" xlink:to="loc_roiv_PercentageSharesOfCommonStockOfferedToBeRepurchased_1168" use="optional" order="43" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SaleOfStockPricePerShare" xlink:label="loc_us-gaap_SaleOfStockPricePerShare_1169" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_1144" xlink:to="loc_us-gaap_SaleOfStockPricePerShare_1169" use="optional" order="44" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TreasuryStockAcquiredRepurchaseAuthorization" xlink:label="loc_us-gaap_TreasuryStockAcquiredRepurchaseAuthorization_1170" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_1144" xlink:to="loc_us-gaap_TreasuryStockAcquiredRepurchaseAuthorization_1170" use="optional" order="45" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessAcquisitionPercentageOfVotingInterestsAcquired" xlink:label="loc_us-gaap_BusinessAcquisitionPercentageOfVotingInterestsAcquired_1171" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_1144" xlink:to="loc_us-gaap_BusinessAcquisitionPercentageOfVotingInterestsAcquired_1171" use="optional" order="46" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued" xlink:label="loc_us-gaap_BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued_1172" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_1144" xlink:to="loc_us-gaap_BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued_1172" use="optional" order="47" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfWarrantOrRightOutstanding" xlink:label="loc_us-gaap_ClassOfWarrantOrRightOutstanding_1173" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_1144" xlink:to="loc_us-gaap_ClassOfWarrantOrRightOutstanding_1173" use="optional" order="48" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:label="loc_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_1174" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_1144" xlink:to="loc_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_1174" use="optional" order="49" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsForProceedsFromBusinessesAndInterestInAffiliates" xlink:label="loc_us-gaap_PaymentsForProceedsFromBusinessesAndInterestInAffiliates_1175" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_1144" xlink:to="loc_us-gaap_PaymentsForProceedsFromBusinessesAndInterestInAffiliates_1175" use="optional" order="50" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessAcquisitionEquityInterestIssuedOrIssuableValueAssigned" xlink:label="loc_us-gaap_BusinessAcquisitionEquityInterestIssuedOrIssuableValueAssigned_1176" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_1144" xlink:to="loc_us-gaap_BusinessAcquisitionEquityInterestIssuedOrIssuableValueAssigned_1176" use="optional" order="51" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_WeightedAverageNumberOfSharesContingentlyIssuable" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesContingentlyIssuable_1177" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_1144" xlink:to="loc_us-gaap_WeightedAverageNumberOfSharesContingentlyIssuable_1177" use="optional" order="52" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="roiv-20210630.xsd#roiv_EarnOutSharesTermsDescription" xlink:label="loc_roiv_EarnOutSharesTermsDescription_1178" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_1144" xlink:to="loc_roiv_EarnOutSharesTermsDescription_1178" use="optional" order="53" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockSharesIssued" xlink:label="loc_us-gaap_CommonStockSharesIssued_1179" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_1144" xlink:to="loc_us-gaap_CommonStockSharesIssued_1179" use="optional" order="54" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_1180" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_1144" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_1180" use="optional" order="55" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtConversionConvertedInstrumentSharesIssued1" xlink:label="loc_us-gaap_DebtConversionConvertedInstrumentSharesIssued1_1181" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_1144" xlink:to="loc_us-gaap_DebtConversionConvertedInstrumentSharesIssued1_1181" use="optional" order="56" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentConvertibleCarryingAmountOfTheEquityComponent" xlink:label="loc_us-gaap_DebtInstrumentConvertibleCarryingAmountOfTheEquityComponent_1182" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_1144" xlink:to="loc_us-gaap_DebtInstrumentConvertibleCarryingAmountOfTheEquityComponent_1182" use="optional" order="57" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_1183" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_1144" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_1183" use="optional" order="58" preferredLabel="http://www.xbrl.org/2003/role/positiveLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfCommonStock_1184" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_1144" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfCommonStock_1184" use="optional" order="59" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="roiv-20210630.xsd#roiv_ClassOfWarrantOrRightExercisable" xlink:label="loc_roiv_ClassOfWarrantOrRightExercisable_1185" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_1144" xlink:to="loc_roiv_ClassOfWarrantOrRightExercisable_1185" use="optional" order="60" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromIssuanceOfWarrants" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfWarrants_1186" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_1144" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfWarrants_1186" use="optional" order="61" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdjustmentOfWarrantsGrantedForServices" xlink:label="loc_us-gaap_AdjustmentOfWarrantsGrantedForServices_1187" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_1144" xlink:to="loc_us-gaap_AdjustmentOfWarrantsGrantedForServices_1187" use="optional" order="62" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InvestmentCompanyInternalRateOfReturnSinceInception" xlink:label="loc_us-gaap_InvestmentCompanyInternalRateOfReturnSinceInception_1188" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_1144" xlink:to="loc_us-gaap_InvestmentCompanyInternalRateOfReturnSinceInception_1188" use="optional" order="63" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PreferredStockRedemptionPricePerShare" xlink:label="loc_us-gaap_PreferredStockRedemptionPricePerShare_1189" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_1144" xlink:to="loc_us-gaap_PreferredStockRedemptionPricePerShare_1189" use="optional" order="64" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsForRepurchaseOfRedeemableConvertiblePreferredStock" xlink:label="loc_us-gaap_PaymentsForRepurchaseOfRedeemableConvertiblePreferredStock_1190" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_1144" xlink:to="loc_us-gaap_PaymentsForRepurchaseOfRedeemableConvertiblePreferredStock_1190" use="optional" order="65" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsForRepurchaseOfRedeemableNoncontrollingInterest" xlink:label="loc_us-gaap_PaymentsForRepurchaseOfRedeemableNoncontrollingInterest_1191" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_1144" xlink:to="loc_us-gaap_PaymentsForRepurchaseOfRedeemableNoncontrollingInterest_1191" use="optional" order="66" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://roivant.com/role/ShareholdersEquityAndRedeemableNonControllingInterestScheduleOfPaymentsOfEquitySecuritiesDetail">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsForRepurchaseOfEquityAbstract" xlink:label="loc_us-gaap_PaymentsForRepurchaseOfEquityAbstract_1205" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsForRepurchaseOfCommonStock" xlink:label="loc_us-gaap_PaymentsForRepurchaseOfCommonStock_1206" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PaymentsForRepurchaseOfEquityAbstract_1205" xlink:to="loc_us-gaap_PaymentsForRepurchaseOfCommonStock_1206" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsForRepurchaseOfOtherEquity" xlink:label="loc_us-gaap_PaymentsForRepurchaseOfOtherEquity_1207" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PaymentsForRepurchaseOfEquityAbstract_1205" xlink:to="loc_us-gaap_PaymentsForRepurchaseOfOtherEquity_1207" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsForRepurchaseOfEquity" xlink:label="loc_us-gaap_PaymentsForRepurchaseOfEquity_1208" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PaymentsForRepurchaseOfEquityAbstract_1205" xlink:to="loc_us-gaap_PaymentsForRepurchaseOfEquity_1208" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://roivant.com/role/ShareBasedCompensationAdditionalInformationDetail">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_1210" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_1214" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_1210" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_1214" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PlanNameAxis" xlink:label="loc_us-gaap_PlanNameAxis_1212" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_1214" xlink:to="loc_us-gaap_PlanNameAxis_1212" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PlanNameDomain" xlink:label="loc_us-gaap_PlanNameDomain_1213" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PlanNameAxis_1212" xlink:to="loc_us-gaap_PlanNameDomain_1213" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="roiv-20210630.xsd#roiv_TwoThousandFifteenEquityIncentivePlanMember" xlink:label="loc_roiv_TwoThousandFifteenEquityIncentivePlanMember_1217" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PlanNameDomain_1213" xlink:to="loc_roiv_TwoThousandFifteenEquityIncentivePlanMember_1217" use="optional" order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="roiv-20210630.xsd#roiv_SubsidiaryEquityIncentivePlanMember" xlink:label="loc_roiv_SubsidiaryEquityIncentivePlanMember_1218" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PlanNameDomain_1213" xlink:to="loc_roiv_SubsidiaryEquityIncentivePlanMember_1218" use="optional" order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="roiv-20210630.xsd#roiv_PerformanceRestrictedStockUnitsPlanMember" xlink:label="loc_roiv_PerformanceRestrictedStockUnitsPlanMember_1219" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PlanNameDomain_1213" xlink:to="loc_roiv_PerformanceRestrictedStockUnitsPlanMember_1219" use="optional" order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AwardTypeAxis" xlink:label="loc_us-gaap_AwardTypeAxis_1211" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_1214" xlink:to="loc_us-gaap_AwardTypeAxis_1211" use="optional" order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_1216" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AwardTypeAxis_1211" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_1216" use="optional" order="8" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="roiv-20210630.xsd#roiv_SpecialReserveMember" xlink:label="loc_roiv_SpecialReserveMember_1236" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_1216" xlink:to="loc_roiv_SpecialReserveMember_1236" use="optional" order="9" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestrictedStockUnitsRSUMember" xlink:label="loc_us-gaap_RestrictedStockUnitsRSUMember_1237" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_1216" xlink:to="loc_us-gaap_RestrictedStockUnitsRSUMember_1237" use="optional" order="10" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="roiv-20210630.xsd#roiv_PerformanceOptionsMember" xlink:label="loc_roiv_PerformanceOptionsMember_1238" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_1216" xlink:to="loc_roiv_PerformanceOptionsMember_1238" use="optional" order="11" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="roiv-20210630.xsd#roiv_CappedValueAppreciationRightsMember" xlink:label="loc_roiv_CappedValueAppreciationRightsMember_1239" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_1216" xlink:to="loc_roiv_CappedValueAppreciationRightsMember_1239" use="optional" order="12" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="roiv-20210630.xsd#roiv_PerformanceRestrictedStockUnitsMember" xlink:label="loc_roiv_PerformanceRestrictedStockUnitsMember_1240" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_1216" xlink:to="loc_roiv_PerformanceRestrictedStockUnitsMember_1240" use="optional" order="13" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="roiv-20210630.xsd#roiv_CommonStockAwardsMember" xlink:label="loc_roiv_CommonStockAwardsMember_1241" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_1216" xlink:to="loc_roiv_CommonStockAwardsMember_1241" use="optional" order="14" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="loc_us-gaap_EmployeeStockOptionMember_1106699" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_1216" xlink:to="loc_us-gaap_EmployeeStockOptionMember_1106699" use="optional" order="15" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_1215" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_1214" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_1215" use="optional" order="16" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:label="loc_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_1220" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_1215" xlink:to="loc_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_1220" use="optional" order="17" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="roiv-20210630.xsd#roiv_CommonSharesReservedForPerformanceOptionsAndCappedValueAppreciationRights" xlink:label="loc_roiv_CommonSharesReservedForPerformanceOptionsAndCappedValueAppreciationRights_1108003" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_1215" xlink:to="loc_roiv_CommonSharesReservedForPerformanceOptionsAndCappedValueAppreciationRights_1108003" use="optional" order="18" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_1221" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_1215" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_1221" use="optional" order="19" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AllocatedShareBasedCompensationExpense" xlink:label="loc_us-gaap_AllocatedShareBasedCompensationExpense_1222" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_1215" xlink:to="loc_us-gaap_AllocatedShareBasedCompensationExpense_1222" use="optional" order="20" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_1223" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_1215" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_1223" use="optional" order="21" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_1224" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_1215" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_1224" use="optional" order="22" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares_1225" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_1215" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares_1225" use="optional" order="23" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_1226" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_1215" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_1226" use="optional" order="24" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions_1227" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_1215" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions_1227" use="optional" order="25" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardExpirationDate" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardExpirationDate_1228" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_1215" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardExpirationDate_1228" use="optional" order="26" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardDescription" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardDescription_1229" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_1215" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardDescription_1229" use="optional" order="27" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_1230" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_1215" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_1230" use="optional" order="28" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="roiv-20210630.xsd#roiv_SharebasedCompensationArrangementBySharebasedPaymentAwardAggregateRepurchasePrice" xlink:label="loc_roiv_SharebasedCompensationArrangementBySharebasedPaymentAwardAggregateRepurchasePrice_1231" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_1215" xlink:to="loc_roiv_SharebasedCompensationArrangementBySharebasedPaymentAwardAggregateRepurchasePrice_1231" use="optional" order="29" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="roiv-20210630.xsd#roiv_ShareBasedCompensationRightToRepurchasePercentage" xlink:label="loc_roiv_ShareBasedCompensationRightToRepurchasePercentage_1232" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_1215" xlink:to="loc_roiv_ShareBasedCompensationRightToRepurchasePercentage_1232" use="optional" order="30" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestrictedInvestmentsAtFairValue" xlink:label="loc_us-gaap_RestrictedInvestmentsAtFairValue_1233" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_1215" xlink:to="loc_us-gaap_RestrictedInvestmentsAtFairValue_1233" use="optional" order="31" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_1234" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_1215" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_1234" use="optional" order="32" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_1235" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_1215" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_1235" use="optional" order="33" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://roivant.com/role/ShareBasedCompensationScheduleOfFairValueAssumptionsDetail">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_1243" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_1245" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_1243" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_1245" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AwardTypeAxis" xlink:label="loc_us-gaap_AwardTypeAxis_1244" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_1245" xlink:to="loc_us-gaap_AwardTypeAxis_1244" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_1247" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AwardTypeAxis_1244" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_1247" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="loc_us-gaap_EmployeeStockOptionMember_1252" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_1247" xlink:to="loc_us-gaap_EmployeeStockOptionMember_1252" use="optional" order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="roiv-20210630.xsd#roiv_PerformanceOptionsMember" xlink:label="loc_roiv_PerformanceOptionsMember_1253" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_1247" xlink:to="loc_roiv_PerformanceOptionsMember_1253" use="optional" order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_1246" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_1245" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_1246" use="optional" order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate_1248" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_1246" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate_1248" use="optional" order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_1249" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_1246" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_1249" use="optional" order="8" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_1250" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_1246" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_1250" use="optional" order="9" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_1251" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_1246" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_1251" use="optional" order="10" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://roivant.com/role/ShareBasedCompensationSummaryOfStockOptionActivityDetail">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_1255" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_1259" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_1255" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_1259" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AwardTypeAxis" xlink:label="loc_us-gaap_AwardTypeAxis_1256" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_1259" xlink:to="loc_us-gaap_AwardTypeAxis_1256" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_1261" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AwardTypeAxis_1256" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_1261" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="loc_us-gaap_EmployeeStockOptionMember_1280" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_1261" xlink:to="loc_us-gaap_EmployeeStockOptionMember_1280" use="optional" order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PlanNameAxis" xlink:label="loc_us-gaap_PlanNameAxis_1257" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_1259" xlink:to="loc_us-gaap_PlanNameAxis_1257" use="optional" order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PlanNameDomain" xlink:label="loc_us-gaap_PlanNameDomain_1258" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PlanNameAxis_1257" xlink:to="loc_us-gaap_PlanNameDomain_1258" use="optional" order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="roiv-20210630.xsd#roiv_TwoThousandFifteenEquityIncentivePlanMember" xlink:label="loc_roiv_TwoThousandFifteenEquityIncentivePlanMember_1262" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PlanNameDomain_1258" xlink:to="loc_roiv_TwoThousandFifteenEquityIncentivePlanMember_1262" use="optional" order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_1260" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_1259" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_1260" use="optional" order="8" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_1263" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_1260" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_1263" use="optional" order="9" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_1264" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_1260" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_1264" use="optional" order="10" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_1265" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_1260" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_1265" use="optional" order="11" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_1266" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_1260" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_1266" use="optional" order="12" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_1267" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_1260" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_1267" use="optional" order="13" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_1268" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_1260" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_1268" use="optional" order="14" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_1269" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_1260" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_1269" use="optional" order="15" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_1270" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_1260" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_1270" use="optional" order="16" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_1271" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_1260" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_1271" use="optional" order="17" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_1272" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_1260" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_1272" use="optional" order="18" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="roiv-20210630.xsd#roiv_ShareBasedCompensationArrangementByShareBasedPaymentAwardWeightedAverageGrantDateFairValue" xlink:label="loc_roiv_ShareBasedCompensationArrangementByShareBasedPaymentAwardWeightedAverageGrantDateFairValue_1273" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_1260" xlink:to="loc_roiv_ShareBasedCompensationArrangementByShareBasedPaymentAwardWeightedAverageGrantDateFairValue_1273" use="optional" order="19" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_1274" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_1260" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_1274" use="optional" order="20" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedWeightedAverageGrantDateFairValue" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedWeightedAverageGrantDateFairValue_1275" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_1260" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedWeightedAverageGrantDateFairValue_1275" use="optional" order="21" preferredLabel="http://www.xbrl.org/2003/role/positiveLabel" />
<loc xlink:type="locator" xlink:href="roiv-20210630.xsd#roiv_ShareBasedCompensationArrangementByShareBasedPaymentAwardWeightedAverageGrantDateFairValue" xlink:label="loc_roiv_ShareBasedCompensationArrangementByShareBasedPaymentAwardWeightedAverageGrantDateFairValue_1276" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_1260" xlink:to="loc_roiv_ShareBasedCompensationArrangementByShareBasedPaymentAwardWeightedAverageGrantDateFairValue_1276" use="optional" order="22" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
<loc xlink:type="locator" xlink:href="roiv-20210630.xsd#roiv_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExcercisableWeightedAverageGrantDateFairValue" xlink:label="loc_roiv_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExcercisableWeightedAverageGrantDateFairValue_1277" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_1260" xlink:to="loc_roiv_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExcercisableWeightedAverageGrantDateFairValue_1277" use="optional" order="23" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_1278" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_1260" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_1278" use="optional" order="24" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_1279" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_1260" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_1279" use="optional" order="25" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://roivant.com/role/ShareBasedCompensationSummaryOfFairValueOfVestedStockOptionDetail">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_1282" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1_1283" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_1282" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1_1283" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue_1284" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_1282" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue_1284" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://roivant.com/role/ShareBasedCompensationSummaryOfRestrictedStockUnitsDetail">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_1286" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_1290" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_1286" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_1290" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AwardTypeAxis" xlink:label="loc_us-gaap_AwardTypeAxis_1287" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_1290" xlink:to="loc_us-gaap_AwardTypeAxis_1287" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_1292" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AwardTypeAxis_1287" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_1292" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestrictedStockUnitsRSUMember" xlink:label="loc_us-gaap_RestrictedStockUnitsRSUMember_1302" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_1292" xlink:to="loc_us-gaap_RestrictedStockUnitsRSUMember_1302" use="optional" order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PlanNameAxis" xlink:label="loc_us-gaap_PlanNameAxis_1288" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_1290" xlink:to="loc_us-gaap_PlanNameAxis_1288" use="optional" order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PlanNameDomain" xlink:label="loc_us-gaap_PlanNameDomain_1289" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PlanNameAxis_1288" xlink:to="loc_us-gaap_PlanNameDomain_1289" use="optional" order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="roiv-20210630.xsd#roiv_TwoThousandFifteenEquityIncentivePlanMember" xlink:label="loc_roiv_TwoThousandFifteenEquityIncentivePlanMember_1293" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PlanNameDomain_1289" xlink:to="loc_roiv_TwoThousandFifteenEquityIncentivePlanMember_1293" use="optional" order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_1291" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_1290" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_1291" use="optional" order="8" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_1294" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_1291" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_1294" use="optional" order="9" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_1295" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_1291" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_1295" use="optional" order="10" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_1296" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_1291" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_1296" use="optional" order="11" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_1297" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_1291" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_1297" use="optional" order="12" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue_1298" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_1291" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue_1298" use="optional" order="13" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_1299" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_1291" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_1299" use="optional" order="14" preferredLabel="http://www.xbrl.org/2003/role/positiveLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedWeightedAverageGrantDateFairValue" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedWeightedAverageGrantDateFairValue_1300" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_1291" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedWeightedAverageGrantDateFairValue_1300" use="optional" order="15" preferredLabel="http://www.xbrl.org/2003/role/positiveTerseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue_1301" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_1291" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue_1301" use="optional" order="16" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://roivant.com/role/ShareBasedCompensationSummaryOfPerformanceOptionsActivityDetail">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_1304" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_1308" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_1304" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_1308" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AwardTypeAxis" xlink:label="loc_us-gaap_AwardTypeAxis_1305" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_1308" xlink:to="loc_us-gaap_AwardTypeAxis_1305" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_1310" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AwardTypeAxis_1305" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_1310" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="roiv-20210630.xsd#roiv_PerformanceOptionsMember" xlink:label="loc_roiv_PerformanceOptionsMember_1325" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_1310" xlink:to="loc_roiv_PerformanceOptionsMember_1325" use="optional" order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PlanNameAxis" xlink:label="loc_us-gaap_PlanNameAxis_1306" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_1308" xlink:to="loc_us-gaap_PlanNameAxis_1306" use="optional" order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PlanNameDomain" xlink:label="loc_us-gaap_PlanNameDomain_1307" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PlanNameAxis_1306" xlink:to="loc_us-gaap_PlanNameDomain_1307" use="optional" order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="roiv-20210630.xsd#roiv_TwoThousandFifteenEquityIncentivePlanMember" xlink:label="loc_roiv_TwoThousandFifteenEquityIncentivePlanMember_1311" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PlanNameDomain_1307" xlink:to="loc_roiv_TwoThousandFifteenEquityIncentivePlanMember_1311" use="optional" order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_1309" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_1308" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_1309" use="optional" order="8" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_1312" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_1309" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_1312" use="optional" order="9" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_1313" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_1309" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_1313" use="optional" order="10" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_1314" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_1309" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_1314" use="optional" order="11" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_1315" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_1309" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_1315" use="optional" order="12" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_1316" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_1309" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_1316" use="optional" order="13" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_1317" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_1309" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_1317" use="optional" order="14" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_1318" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_1309" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_1318" use="optional" order="15" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_1319" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_1309" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_1319" use="optional" order="16" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
<loc xlink:type="locator" xlink:href="roiv-20210630.xsd#roiv_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageGrantDateFairValue" xlink:label="loc_roiv_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageGrantDateFairValue_1320" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_1309" xlink:to="loc_roiv_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageGrantDateFairValue_1320" use="optional" order="17" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_1321" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_1309" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_1321" use="optional" order="18" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="roiv-20210630.xsd#roiv_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeitedInPeriodWeightedAverageGrantDateFairValue" xlink:label="loc_roiv_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeitedInPeriodWeightedAverageGrantDateFairValue_1322" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_1309" xlink:to="loc_roiv_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeitedInPeriodWeightedAverageGrantDateFairValue_1322" use="optional" order="19" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="roiv-20210630.xsd#roiv_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageGrantDateFairValue" xlink:label="loc_roiv_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageGrantDateFairValue_1323" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_1309" xlink:to="loc_roiv_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageGrantDateFairValue_1323" use="optional" order="20" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_1324" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_1309" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_1324" use="optional" order="21" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://roivant.com/role/ShareBasedCompensationSummaryOfCappedValueAppreciationRightsDetail">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_1327" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_1331" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_1327" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_1331" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AwardTypeAxis" xlink:label="loc_us-gaap_AwardTypeAxis_1328" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_1331" xlink:to="loc_us-gaap_AwardTypeAxis_1328" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_1333" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AwardTypeAxis_1328" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_1333" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="roiv-20210630.xsd#roiv_CappedValueAppreciationRightsMember" xlink:label="loc_roiv_CappedValueAppreciationRightsMember_1343" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_1333" xlink:to="loc_roiv_CappedValueAppreciationRightsMember_1343" use="optional" order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PlanNameAxis" xlink:label="loc_us-gaap_PlanNameAxis_1329" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_1331" xlink:to="loc_us-gaap_PlanNameAxis_1329" use="optional" order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PlanNameDomain" xlink:label="loc_us-gaap_PlanNameDomain_1330" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PlanNameAxis_1329" xlink:to="loc_us-gaap_PlanNameDomain_1330" use="optional" order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="roiv-20210630.xsd#roiv_TwoThousandFifteenEquityIncentivePlanMember" xlink:label="loc_roiv_TwoThousandFifteenEquityIncentivePlanMember_1334" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PlanNameDomain_1330" xlink:to="loc_roiv_TwoThousandFifteenEquityIncentivePlanMember_1334" use="optional" order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_1332" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_1331" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_1332" use="optional" order="8" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_1335" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_1332" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_1335" use="optional" order="9" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_1336" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_1332" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_1336" use="optional" order="10" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_1337" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_1332" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_1337" use="optional" order="11" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_1338" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_1332" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_1338" use="optional" order="12" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue_1339" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_1332" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue_1339" use="optional" order="13" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_1340" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_1332" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_1340" use="optional" order="14" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedWeightedAverageGrantDateFairValue" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedWeightedAverageGrantDateFairValue_1341" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_1332" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedWeightedAverageGrantDateFairValue_1341" use="optional" order="15" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue_1342" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_1332" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue_1342" use="optional" order="16" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://roivant.com/role/ShareBasedCompensationSummaryOfPerformanceRestrictedStockUnitsDetail">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_1345" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_1349" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_1345" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_1349" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AwardTypeAxis" xlink:label="loc_us-gaap_AwardTypeAxis_1346" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_1349" xlink:to="loc_us-gaap_AwardTypeAxis_1346" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_1351" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AwardTypeAxis_1346" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_1351" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="roiv-20210630.xsd#roiv_PerformanceRestrictedStockUnitsMember" xlink:label="loc_roiv_PerformanceRestrictedStockUnitsMember_1361" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_1351" xlink:to="loc_roiv_PerformanceRestrictedStockUnitsMember_1361" use="optional" order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PlanNameAxis" xlink:label="loc_us-gaap_PlanNameAxis_1347" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_1349" xlink:to="loc_us-gaap_PlanNameAxis_1347" use="optional" order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PlanNameDomain" xlink:label="loc_us-gaap_PlanNameDomain_1348" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PlanNameAxis_1347" xlink:to="loc_us-gaap_PlanNameDomain_1348" use="optional" order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="roiv-20210630.xsd#roiv_PerformanceRestrictedStockUnitsPlanMember" xlink:label="loc_roiv_PerformanceRestrictedStockUnitsPlanMember_1352" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PlanNameDomain_1348" xlink:to="loc_roiv_PerformanceRestrictedStockUnitsPlanMember_1352" use="optional" order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_1350" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_1349" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_1350" use="optional" order="8" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_1353" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_1350" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_1353" use="optional" order="9" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_1354" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_1350" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_1354" use="optional" order="10" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_1355" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_1350" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_1355" use="optional" order="11" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_1356" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_1350" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_1356" use="optional" order="12" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue_1357" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_1350" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue_1357" use="optional" order="13" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_1358" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_1350" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_1358" use="optional" order="14" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedWeightedAverageGrantDateFairValue" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedWeightedAverageGrantDateFairValue_1359" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_1350" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedWeightedAverageGrantDateFairValue_1359" use="optional" order="15" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue_1360" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_1350" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue_1360" use="optional" order="16" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://roivant.com/role/ShareBasedCompensationSummaryOfCommonShareAwardActivityDetail">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_1363" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_1365" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_1363" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_1365" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AwardTypeAxis" xlink:label="loc_us-gaap_AwardTypeAxis_1364" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_1365" xlink:to="loc_us-gaap_AwardTypeAxis_1364" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_1367" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AwardTypeAxis_1364" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_1367" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="roiv-20210630.xsd#roiv_CommonStockAwardsMember" xlink:label="loc_roiv_CommonStockAwardsMember_1378" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_1367" xlink:to="loc_roiv_CommonStockAwardsMember_1378" use="optional" order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_1366" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_1365" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_1366" use="optional" order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_1368" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_1366" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_1368" use="optional" order="6" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_1369" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_1366" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_1369" use="optional" order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_1370" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_1366" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_1370" use="optional" order="8" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_1371" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_1366" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_1371" use="optional" order="9" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_1372" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_1366" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_1372" use="optional" order="10" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_1374" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_1366" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_1374" use="optional" order="11" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_1375" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_1366" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_1375" use="optional" order="12" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_1376" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_1366" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_1376" use="optional" order="13" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_1377" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_1366" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_1377" use="optional" order="14" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://roivant.com/role/ShareBasedCompensationSummaryOfShareBasedCompensationExpenseDetail">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_1380" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_1383" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_1380" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_1383" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeStatementLocationAxis" xlink:label="loc_us-gaap_IncomeStatementLocationAxis_1381" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_1383" xlink:to="loc_us-gaap_IncomeStatementLocationAxis_1381" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_1382" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_1381" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_1382" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ResearchAndDevelopmentExpenseMember" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpenseMember_1385" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_1382" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpenseMember_1385" use="optional" order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GeneralAndAdministrativeExpenseMember" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpenseMember_1386" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_1382" xlink:to="loc_us-gaap_GeneralAndAdministrativeExpenseMember_1386" use="optional" order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_1384" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_1383" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_1384" use="optional" order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AllocatedShareBasedCompensationExpense" xlink:label="loc_us-gaap_AllocatedShareBasedCompensationExpense_1387" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_1384" xlink:to="loc_us-gaap_AllocatedShareBasedCompensationExpense_1387" use="optional" order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://roivant.com/role/DiscontinuedOperationsSummaryOfDisposalGroupsIncludingDiscontinuedOperationsIncomeStatementDetail">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DiscontinuedOperationsAndDisposalGroupsAbstract" xlink:label="loc_us-gaap_DiscontinuedOperationsAndDisposalGroupsAbstract_1038" />
<loc xlink:type="locator" xlink:href="roiv-20210630.xsd#roiv_DisposalGroupIncludingDiscontinuedOperationOperatingExpenseAbstract" xlink:label="loc_roiv_DisposalGroupIncludingDiscontinuedOperationOperatingExpenseAbstract_1039" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DiscontinuedOperationsAndDisposalGroupsAbstract_1038" xlink:to="loc_roiv_DisposalGroupIncludingDiscontinuedOperationOperatingExpenseAbstract_1039" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="roiv-20210630.xsd#roiv_DisposalGroupIncludingDiscontinuedOperationResearchAndDevelopmentExpense" xlink:label="loc_roiv_DisposalGroupIncludingDiscontinuedOperationResearchAndDevelopmentExpense_1043" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_roiv_DisposalGroupIncludingDiscontinuedOperationOperatingExpenseAbstract_1039" xlink:to="loc_roiv_DisposalGroupIncludingDiscontinuedOperationResearchAndDevelopmentExpense_1043" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationGeneralAndAdministrativeExpense" xlink:label="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationGeneralAndAdministrativeExpense_1044" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_roiv_DisposalGroupIncludingDiscontinuedOperationOperatingExpenseAbstract_1039" xlink:to="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationGeneralAndAdministrativeExpense_1044" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationOperatingExpense" xlink:label="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationOperatingExpense_1045" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_roiv_DisposalGroupIncludingDiscontinuedOperationOperatingExpenseAbstract_1039" xlink:to="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationOperatingExpense_1045" use="optional" order="4" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationOperatingIncomeLoss" xlink:label="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationOperatingIncomeLoss_1046" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_roiv_DisposalGroupIncludingDiscontinuedOperationOperatingExpenseAbstract_1039" xlink:to="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationOperatingIncomeLoss_1046" use="optional" order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="roiv-20210630.xsd#roiv_DisposalGroupIncludingDiscontinuedOperationGainLossOnSaleOfBusiness" xlink:label="loc_roiv_DisposalGroupIncludingDiscontinuedOperationGainLossOnSaleOfBusiness_1047" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_roiv_DisposalGroupIncludingDiscontinuedOperationOperatingExpenseAbstract_1039" xlink:to="loc_roiv_DisposalGroupIncludingDiscontinuedOperationGainLossOnSaleOfBusiness_1047" use="optional" order="6" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationInterestIncome" xlink:label="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationInterestIncome_1048" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_roiv_DisposalGroupIncludingDiscontinuedOperationOperatingExpenseAbstract_1039" xlink:to="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationInterestIncome_1048" use="optional" order="7" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationInterestExpense" xlink:label="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationInterestExpense_1049" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_roiv_DisposalGroupIncludingDiscontinuedOperationOperatingExpenseAbstract_1039" xlink:to="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationInterestExpense_1049" use="optional" order="8" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationOtherExpense" xlink:label="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationOtherExpense_1050" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_roiv_DisposalGroupIncludingDiscontinuedOperationOperatingExpenseAbstract_1039" xlink:to="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationOtherExpense_1050" use="optional" order="9" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DiscontinuedOperationIncomeLossFromDiscontinuedOperationBeforeIncomeTax" xlink:label="loc_us-gaap_DiscontinuedOperationIncomeLossFromDiscontinuedOperationBeforeIncomeTax_1051" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_roiv_DisposalGroupIncludingDiscontinuedOperationOperatingExpenseAbstract_1039" xlink:to="loc_us-gaap_DiscontinuedOperationIncomeLossFromDiscontinuedOperationBeforeIncomeTax_1051" use="optional" order="10" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DiscontinuedOperationTaxEffectOfDiscontinuedOperation" xlink:label="loc_us-gaap_DiscontinuedOperationTaxEffectOfDiscontinuedOperation_1052" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_roiv_DisposalGroupIncludingDiscontinuedOperationOperatingExpenseAbstract_1039" xlink:to="loc_us-gaap_DiscontinuedOperationTaxEffectOfDiscontinuedOperation_1052" use="optional" order="11" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTax" xlink:label="loc_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTax_1053" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_roiv_DisposalGroupIncludingDiscontinuedOperationOperatingExpenseAbstract_1039" xlink:to="loc_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTax_1053" use="optional" order="12" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DiscontinuedOperationIncomeLossFromDiscontinuedOperationDuringPhaseOutPeriodBeforeIncomeTaxAttributableToNoncontrollingInterest" xlink:label="loc_us-gaap_DiscontinuedOperationIncomeLossFromDiscontinuedOperationDuringPhaseOutPeriodBeforeIncomeTaxAttributableToNoncontrollingInterest_1040" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DiscontinuedOperationsAndDisposalGroupsAbstract_1038" xlink:to="loc_us-gaap_DiscontinuedOperationIncomeLossFromDiscontinuedOperationDuringPhaseOutPeriodBeforeIncomeTaxAttributableToNoncontrollingInterest_1040" use="optional" order="13" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DiscontinuedOperationIncomeLossFromDiscontinuedOperationDuringPhaseOutPeriodBeforeIncomeTaxAttributableToParent" xlink:label="loc_us-gaap_DiscontinuedOperationIncomeLossFromDiscontinuedOperationDuringPhaseOutPeriodBeforeIncomeTaxAttributableToParent_1041" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DiscontinuedOperationsAndDisposalGroupsAbstract_1038" xlink:to="loc_us-gaap_DiscontinuedOperationIncomeLossFromDiscontinuedOperationDuringPhaseOutPeriodBeforeIncomeTaxAttributableToParent_1041" use="optional" order="14" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DiscontinuedOperationIncomeLossFromDiscontinuedOperationDuringPhaseOutPeriodBeforeIncomeTax" xlink:label="loc_us-gaap_DiscontinuedOperationIncomeLossFromDiscontinuedOperationDuringPhaseOutPeriodBeforeIncomeTax_1042" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DiscontinuedOperationsAndDisposalGroupsAbstract_1038" xlink:to="loc_us-gaap_DiscontinuedOperationIncomeLossFromDiscontinuedOperationDuringPhaseOutPeriodBeforeIncomeTax_1042" use="optional" order="15" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://roivant.com/role/DiscontinuedOperationsSummaryOfCashFlowsFromDiscontinuedOperationsDetail">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DiscontinuedOperationsAndDisposalGroupsAbstract" xlink:label="loc_us-gaap_DiscontinuedOperationsAndDisposalGroupsAbstract_1055" />
<loc xlink:type="locator" xlink:href="roiv-20210630.xsd#roiv_DisposalGroupIncludingDiscontinuedOperationGainLossOnSaleOfBusiness" xlink:label="loc_roiv_DisposalGroupIncludingDiscontinuedOperationGainLossOnSaleOfBusiness_1056" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DiscontinuedOperationsAndDisposalGroupsAbstract_1055" xlink:to="loc_roiv_DisposalGroupIncludingDiscontinuedOperationGainLossOnSaleOfBusiness_1056" use="optional" order="1" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
<loc xlink:type="locator" xlink:href="roiv-20210630.xsd#roiv_DisposalGroupIncludingDiscontinuedOperationShareBasedCompensation" xlink:label="loc_roiv_DisposalGroupIncludingDiscontinuedOperationShareBasedCompensation_1057" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DiscontinuedOperationsAndDisposalGroupsAbstract_1055" xlink:to="loc_roiv_DisposalGroupIncludingDiscontinuedOperationShareBasedCompensation_1057" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="roiv-20210630.xsd#roiv_DisposalGroupIncludingDiscontinuedOperationResearchAndDevelopmentInProcess" xlink:label="loc_roiv_DisposalGroupIncludingDiscontinuedOperationResearchAndDevelopmentInProcess_1058" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DiscontinuedOperationsAndDisposalGroupsAbstract_1055" xlink:to="loc_roiv_DisposalGroupIncludingDiscontinuedOperationResearchAndDevelopmentInProcess_1058" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://roivant.com/role/RelatedPartyTransactionsAdditionalInformationDetail">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RelatedPartyTransactionsAbstract" xlink:label="loc_us-gaap_RelatedPartyTransactionsAbstract_1128" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:label="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_1132" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionsAbstract_1128" xlink:to="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_1132" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:label="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_1131" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_1132" xlink:to="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_1131" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RelatedPartyDomain" xlink:label="loc_us-gaap_RelatedPartyDomain_1129" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_1131" xlink:to="loc_us-gaap_RelatedPartyDomain_1129" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="roiv-20210630.xsd#roiv_SumitovantMember" xlink:label="loc_roiv_SumitovantMember_1133" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyDomain_1129" xlink:to="loc_roiv_SumitovantMember_1133" use="optional" order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="roiv-20210630.xsd#roiv_SumitomoMember" xlink:label="loc_roiv_SumitomoMember_1134" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyDomain_1129" xlink:to="loc_roiv_SumitomoMember_1134" use="optional" order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RelatedPartyTransactionLineItems" xlink:label="loc_us-gaap_RelatedPartyTransactionLineItems_1130" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_1132" xlink:to="loc_us-gaap_RelatedPartyTransactionLineItems_1130" use="optional" order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CostsAndExpensesRelatedParty" xlink:label="loc_us-gaap_CostsAndExpensesRelatedParty_1135" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_1130" xlink:to="loc_us-gaap_CostsAndExpensesRelatedParty_1135" use="optional" order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RelatedPartyTransactionAmountsOfTransaction" xlink:label="loc_us-gaap_RelatedPartyTransactionAmountsOfTransaction_1136" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_1130" xlink:to="loc_us-gaap_RelatedPartyTransactionAmountsOfTransaction_1136" use="optional" order="8" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://roivant.com/role/IncomeTaxesScheduleOfLossBeforeIncomeTaxesByGeographicRegionDetail">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract_1389" />
<loc xlink:type="locator" xlink:href="roiv-20210630.xsd#roiv_IncomeTaxDisclosureTable" xlink:label="loc_roiv_IncomeTaxDisclosureTable_1392" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_1389" xlink:to="loc_roiv_IncomeTaxDisclosureTable_1392" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_StatementGeographicalAxis" xlink:label="loc_srt_StatementGeographicalAxis_1394" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_roiv_IncomeTaxDisclosureTable_1392" xlink:to="loc_srt_StatementGeographicalAxis_1394" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_SegmentGeographicalDomain" xlink:label="loc_srt_SegmentGeographicalDomain_1393" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_StatementGeographicalAxis_1394" xlink:to="loc_srt_SegmentGeographicalDomain_1393" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/country/2021/country-2021.xsd#country_US" xlink:label="loc_country_US_1396" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_SegmentGeographicalDomain_1393" xlink:to="loc_country_US_1396" use="optional" order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/country/2021/country-2021.xsd#country_CH" xlink:label="loc_country_CH_1397" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_SegmentGeographicalDomain_1393" xlink:to="loc_country_CH_1397" use="optional" order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/country/2021/country-2021.xsd#country_BM" xlink:label="loc_country_BM_1398" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_SegmentGeographicalDomain_1393" xlink:to="loc_country_BM_1398" use="optional" order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="roiv-20210630.xsd#roiv_OtherMember" xlink:label="loc_roiv_OtherMember_1399" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_SegmentGeographicalDomain_1393" xlink:to="loc_roiv_OtherMember_1399" use="optional" order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="roiv-20210630.xsd#roiv_IncomeTaxDisclosureLineItems" xlink:label="loc_roiv_IncomeTaxDisclosureLineItems_1391" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_roiv_IncomeTaxDisclosureTable_1392" xlink:to="loc_roiv_IncomeTaxDisclosureLineItems_1391" use="optional" order="8" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestmentsAbstract" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestmentsAbstract_1390" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_roiv_IncomeTaxDisclosureLineItems_1391" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestmentsAbstract_1390" use="optional" order="9" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments_1395" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestmentsAbstract_1390" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments_1395" use="optional" order="10" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://roivant.com/role/IncomeTaxesScheduleComponentsOfIncomeTaxExpenseBenefitDetail">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract_771" />
<loc xlink:type="locator" xlink:href="roiv-20210630.xsd#roiv_ComponentsOfIncomeTaxExpenseTable" xlink:label="loc_roiv_ComponentsOfIncomeTaxExpenseTable_773" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_771" xlink:to="loc_roiv_ComponentsOfIncomeTaxExpenseTable_773" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_LegalEntityAxis" xlink:label="loc_dei_LegalEntityAxis_777" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_roiv_ComponentsOfIncomeTaxExpenseTable_773" xlink:to="loc_dei_LegalEntityAxis_777" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityDomain" xlink:label="loc_dei_EntityDomain_776" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_LegalEntityAxis_777" xlink:to="loc_dei_EntityDomain_776" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_StatementGeographicalAxis" xlink:label="loc_srt_StatementGeographicalAxis_779" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_roiv_ComponentsOfIncomeTaxExpenseTable_773" xlink:to="loc_srt_StatementGeographicalAxis_779" use="optional" order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_SegmentGeographicalDomain" xlink:label="loc_srt_SegmentGeographicalDomain_778" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_StatementGeographicalAxis_779" xlink:to="loc_srt_SegmentGeographicalDomain_778" use="optional" order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/country/2021/country-2021.xsd#country_US" xlink:label="loc_country_US_789" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_SegmentGeographicalDomain_778" xlink:to="loc_country_US_789" use="optional" order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/country/2021/country-2021.xsd#country_CH" xlink:label="loc_country_CH_790" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_SegmentGeographicalDomain_778" xlink:to="loc_country_CH_790" use="optional" order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/country/2021/country-2021.xsd#country_BM" xlink:label="loc_country_BM_791" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_SegmentGeographicalDomain_778" xlink:to="loc_country_BM_791" use="optional" order="8" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="roiv-20210630.xsd#roiv_OtherMember" xlink:label="loc_roiv_OtherMember_792" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_SegmentGeographicalDomain_778" xlink:to="loc_roiv_OtherMember_792" use="optional" order="9" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="roiv-20210630.xsd#roiv_ComponentsOfIncomeTaxExpenseLineItems" xlink:label="loc_roiv_ComponentsOfIncomeTaxExpenseLineItems_772" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_roiv_ComponentsOfIncomeTaxExpenseTable_773" xlink:to="loc_roiv_ComponentsOfIncomeTaxExpenseLineItems_772" use="optional" order="10" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract" xlink:label="loc_us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract_774" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_roiv_ComponentsOfIncomeTaxExpenseLineItems_772" xlink:to="loc_us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract_774" use="optional" order="11" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CurrentIncomeTaxExpenseBenefit" xlink:label="loc_us-gaap_CurrentIncomeTaxExpenseBenefit_782" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract_774" xlink:to="loc_us-gaap_CurrentIncomeTaxExpenseBenefit_782" use="optional" order="12" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract" xlink:label="loc_us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract_775" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_roiv_ComponentsOfIncomeTaxExpenseLineItems_772" xlink:to="loc_us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract_775" use="optional" order="13" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredIncomeTaxExpenseBenefit" xlink:label="loc_us-gaap_DeferredIncomeTaxExpenseBenefit_786" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract_775" xlink:to="loc_us-gaap_DeferredIncomeTaxExpenseBenefit_786" use="optional" order="14" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxExpenseBenefit" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit_781" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_roiv_ComponentsOfIncomeTaxExpenseLineItems_772" xlink:to="loc_us-gaap_IncomeTaxExpenseBenefit_781" use="optional" order="15" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://roivant.com/role/IncomeTaxesAdditionalInformationDetail">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract_852" />
<loc xlink:type="locator" xlink:href="roiv-20210630.xsd#roiv_IncomeTaxDisclosureTable" xlink:label="loc_roiv_IncomeTaxDisclosureTable_858" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_852" xlink:to="loc_roiv_IncomeTaxDisclosureTable_858" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_LegalEntityAxis" xlink:label="loc_dei_LegalEntityAxis_859" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_roiv_IncomeTaxDisclosureTable_858" xlink:to="loc_dei_LegalEntityAxis_859" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityDomain" xlink:label="loc_dei_EntityDomain_854" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_LegalEntityAxis_859" xlink:to="loc_dei_EntityDomain_854" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_StatementGeographicalAxis" xlink:label="loc_srt_StatementGeographicalAxis_863" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_roiv_IncomeTaxDisclosureTable_858" xlink:to="loc_srt_StatementGeographicalAxis_863" use="optional" order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_SegmentGeographicalDomain" xlink:label="loc_srt_SegmentGeographicalDomain_862" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_StatementGeographicalAxis_863" xlink:to="loc_srt_SegmentGeographicalDomain_862" use="optional" order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/country/2021/country-2021.xsd#country_CH" xlink:label="loc_country_CH_877" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_SegmentGeographicalDomain_862" xlink:to="loc_country_CH_877" use="optional" order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/country/2021/country-2021.xsd#country_US" xlink:label="loc_country_US_878" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_SegmentGeographicalDomain_862" xlink:to="loc_country_US_878" use="optional" order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/country/2021/country-2021.xsd#country_GB" xlink:label="loc_country_GB_879" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_SegmentGeographicalDomain_862" xlink:to="loc_country_GB_879" use="optional" order="8" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="roiv-20210630.xsd#roiv_TaxAuthorityInOtherJurisdictionsMember" xlink:label="loc_roiv_TaxAuthorityInOtherJurisdictionsMember_880" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_SegmentGeographicalDomain_862" xlink:to="loc_roiv_TaxAuthorityInOtherJurisdictionsMember_880" use="optional" order="9" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeAxis" xlink:label="loc_srt_RangeAxis_860" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_roiv_IncomeTaxDisclosureTable_858" xlink:to="loc_srt_RangeAxis_860" use="optional" order="10" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeMember" xlink:label="loc_srt_RangeMember_861" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeAxis_860" xlink:to="loc_srt_RangeMember_861" use="optional" order="11" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MinimumMember" xlink:label="loc_srt_MinimumMember_875" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_861" xlink:to="loc_srt_MinimumMember_875" use="optional" order="12" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MaximumMember" xlink:label="loc_srt_MaximumMember_876" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_861" xlink:to="loc_srt_MaximumMember_876" use="optional" order="13" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxAuthorityAxis" xlink:label="loc_us-gaap_IncomeTaxAuthorityAxis_855" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_roiv_IncomeTaxDisclosureTable_858" xlink:to="loc_us-gaap_IncomeTaxAuthorityAxis_855" use="optional" order="14" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxAuthorityDomain" xlink:label="loc_us-gaap_IncomeTaxAuthorityDomain_856" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxAuthorityAxis_855" xlink:to="loc_us-gaap_IncomeTaxAuthorityDomain_856" use="optional" order="15" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StateAndLocalJurisdictionMember" xlink:label="loc_us-gaap_StateAndLocalJurisdictionMember_873" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxAuthorityDomain_856" xlink:to="loc_us-gaap_StateAndLocalJurisdictionMember_873" use="optional" order="16" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="roiv-20210630.xsd#roiv_IncomeTaxDisclosureLineItems" xlink:label="loc_roiv_IncomeTaxDisclosureLineItems_857" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_roiv_IncomeTaxDisclosureTable_858" xlink:to="loc_roiv_IncomeTaxDisclosureLineItems_857" use="optional" order="17" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations_853" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_roiv_IncomeTaxDisclosureLineItems_857" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations_853" use="optional" order="18" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLossCarryforwards" xlink:label="loc_us-gaap_OperatingLossCarryforwards_864" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_roiv_IncomeTaxDisclosureLineItems_857" xlink:to="loc_us-gaap_OperatingLossCarryforwards_864" use="optional" order="19" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="roiv-20210630.xsd#roiv_PercentageOfFutureTaxableIncome" xlink:label="loc_roiv_PercentageOfFutureTaxableIncome_865" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_roiv_IncomeTaxDisclosureLineItems_857" xlink:to="loc_roiv_PercentageOfFutureTaxableIncome_865" use="optional" order="20" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLossCarryforwardsExpirationDate" xlink:label="loc_us-gaap_OperatingLossCarryforwardsExpirationDate_866" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_roiv_IncomeTaxDisclosureLineItems_857" xlink:to="loc_us-gaap_OperatingLossCarryforwardsExpirationDate_866" use="optional" order="21" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TaxCreditCarryforwardAmount" xlink:label="loc_us-gaap_TaxCreditCarryforwardAmount_867" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_roiv_IncomeTaxDisclosureLineItems_857" xlink:to="loc_us-gaap_TaxCreditCarryforwardAmount_867" use="optional" order="22" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TaxCreditCarryforwardExpirationDate" xlink:label="loc_us-gaap_TaxCreditCarryforwardExpirationDate_868" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_roiv_IncomeTaxDisclosureLineItems_857" xlink:to="loc_us-gaap_TaxCreditCarryforwardExpirationDate_868" use="optional" order="23" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsValuationAllowance" xlink:label="loc_us-gaap_DeferredTaxAssetsValuationAllowance_869" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_roiv_IncomeTaxDisclosureLineItems_857" xlink:to="loc_us-gaap_DeferredTaxAssetsValuationAllowance_869" use="optional" order="24" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount" xlink:label="loc_us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount_870" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_roiv_IncomeTaxDisclosureLineItems_857" xlink:to="loc_us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount_870" use="optional" order="25" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_UnrecognizedTaxBenefits" xlink:label="loc_us-gaap_UnrecognizedTaxBenefits_871" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_roiv_IncomeTaxDisclosureLineItems_857" xlink:to="loc_us-gaap_UnrecognizedTaxBenefits_871" use="optional" order="26" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://roivant.com/role/IncomeTaxesScheduleOfDeferredTaxAssetsLiabilitiesDetail">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract_794" />
<loc xlink:type="locator" xlink:href="roiv-20210630.xsd#roiv_DeferredTaxAssetsLiabilitiesTable" xlink:label="loc_roiv_DeferredTaxAssetsLiabilitiesTable_797" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_794" xlink:to="loc_roiv_DeferredTaxAssetsLiabilitiesTable_797" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_LegalEntityAxis" xlink:label="loc_dei_LegalEntityAxis_800" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_roiv_DeferredTaxAssetsLiabilitiesTable_797" xlink:to="loc_dei_LegalEntityAxis_800" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityDomain" xlink:label="loc_dei_EntityDomain_799" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_LegalEntityAxis_800" xlink:to="loc_dei_EntityDomain_799" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="roiv-20210630.xsd#roiv_DeferredTaxAssetsLiabilitiesLineItems" xlink:label="loc_roiv_DeferredTaxAssetsLiabilitiesLineItems_796" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_roiv_DeferredTaxAssetsLiabilitiesTable_797" xlink:to="loc_roiv_DeferredTaxAssetsLiabilitiesLineItems_796" use="optional" order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsGrossAbstract" xlink:label="loc_us-gaap_DeferredTaxAssetsGrossAbstract_795" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_roiv_DeferredTaxAssetsLiabilitiesLineItems_796" xlink:to="loc_us-gaap_DeferredTaxAssetsGrossAbstract_795" use="optional" order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch" xlink:label="loc_us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch_801" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredTaxAssetsGrossAbstract_795" xlink:to="loc_us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch_801" use="optional" order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsGoodwillAndIntangibleAssets" xlink:label="loc_us-gaap_DeferredTaxAssetsGoodwillAndIntangibleAssets_803" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredTaxAssetsGrossAbstract_795" xlink:to="loc_us-gaap_DeferredTaxAssetsGoodwillAndIntangibleAssets_803" use="optional" order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:label="loc_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_804" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredTaxAssetsGrossAbstract_795" xlink:to="loc_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_804" use="optional" order="8" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" xlink:label="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost_805" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredTaxAssetsGrossAbstract_795" xlink:to="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost_805" use="optional" order="9" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="roiv-20210630.xsd#roiv_DeferredTaxAssetsLeaseLiabilities" xlink:label="loc_roiv_DeferredTaxAssetsLeaseLiabilities_806" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredTaxAssetsGrossAbstract_795" xlink:to="loc_roiv_DeferredTaxAssetsLeaseLiabilities_806" use="optional" order="10" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsOther" xlink:label="loc_us-gaap_DeferredTaxAssetsOther_807" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredTaxAssetsGrossAbstract_795" xlink:to="loc_us-gaap_DeferredTaxAssetsOther_807" use="optional" order="11" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsGross" xlink:label="loc_us-gaap_DeferredTaxAssetsGross_808" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredTaxAssetsGrossAbstract_795" xlink:to="loc_us-gaap_DeferredTaxAssetsGross_808" use="optional" order="12" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsValuationAllowance" xlink:label="loc_us-gaap_DeferredTaxAssetsValuationAllowance_809" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_roiv_DeferredTaxAssetsLiabilitiesLineItems_796" xlink:to="loc_us-gaap_DeferredTaxAssetsValuationAllowance_809" use="optional" order="13" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxLiabilitiesAbstract" xlink:label="loc_us-gaap_DeferredTaxLiabilitiesAbstract_798" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_roiv_DeferredTaxAssetsLiabilitiesLineItems_796" xlink:to="loc_us-gaap_DeferredTaxLiabilitiesAbstract_798" use="optional" order="14" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="roiv-20210630.xsd#roiv_DeferredTaxLiabilitiesDepreciation" xlink:label="loc_roiv_DeferredTaxLiabilitiesDepreciation_811" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredTaxLiabilitiesAbstract_798" xlink:to="loc_roiv_DeferredTaxLiabilitiesDepreciation_811" use="optional" order="15" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
<loc xlink:type="locator" xlink:href="roiv-20210630.xsd#roiv_DeferredTaxLiabilitiesRightOfUseAssets" xlink:label="loc_roiv_DeferredTaxLiabilitiesRightOfUseAssets_813" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredTaxLiabilitiesAbstract_798" xlink:to="loc_roiv_DeferredTaxLiabilitiesRightOfUseAssets_813" use="optional" order="16" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxLiabilitiesOther" xlink:label="loc_us-gaap_DeferredTaxLiabilitiesOther_815" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredTaxLiabilitiesAbstract_798" xlink:to="loc_us-gaap_DeferredTaxLiabilitiesOther_815" use="optional" order="17" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsLiabilitiesNet" xlink:label="loc_us-gaap_DeferredTaxAssetsLiabilitiesNet_816" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredTaxLiabilitiesAbstract_798" xlink:to="loc_us-gaap_DeferredTaxAssetsLiabilitiesNet_816" use="optional" order="18" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://roivant.com/role/IncomeTaxesScheduleOfEffectiveIncomeTaxRateReconciliationDetail">
<loc xlink:type="locator" xlink:href="roiv-20210630.xsd#roiv_TaxRatesAbstract" xlink:label="loc_roiv_TaxRatesAbstract_819" />
<loc xlink:type="locator" xlink:href="roiv-20210630.xsd#roiv_EffectiveTaxRateReconcilingItemsTable" xlink:label="loc_roiv_EffectiveTaxRateReconcilingItemsTable_822" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_roiv_TaxRatesAbstract_819" xlink:to="loc_roiv_EffectiveTaxRateReconcilingItemsTable_822" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_LegalEntityAxis" xlink:label="loc_dei_LegalEntityAxis_825" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_roiv_EffectiveTaxRateReconcilingItemsTable_822" xlink:to="loc_dei_LegalEntityAxis_825" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityDomain" xlink:label="loc_dei_EntityDomain_823" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_LegalEntityAxis_825" xlink:to="loc_dei_EntityDomain_823" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="roiv-20210630.xsd#roiv_EffectiveTaxRateReconcilingItemsLineItems" xlink:label="loc_roiv_EffectiveTaxRateReconcilingItemsLineItems_821" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_roiv_EffectiveTaxRateReconcilingItemsTable_822" xlink:to="loc_roiv_EffectiveTaxRateReconcilingItemsLineItems_821" use="optional" order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxExpenseBenefitContinuingOperationsIncomeTaxReconciliationAbstract" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefitContinuingOperationsIncomeTaxReconciliationAbstract_824" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_roiv_EffectiveTaxRateReconcilingItemsLineItems_821" xlink:to="loc_us-gaap_IncomeTaxExpenseBenefitContinuingOperationsIncomeTaxReconciliationAbstract_824" use="optional" order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate" xlink:label="loc_us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate_840" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefitContinuingOperationsIncomeTaxReconciliationAbstract_824" xlink:to="loc_us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate_840" use="optional" order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxReconciliationForeignIncomeTaxRateDifferential" xlink:label="loc_us-gaap_IncomeTaxReconciliationForeignIncomeTaxRateDifferential_841" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefitContinuingOperationsIncomeTaxReconciliationAbstract_824" xlink:to="loc_us-gaap_IncomeTaxReconciliationForeignIncomeTaxRateDifferential_841" use="optional" order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxReconciliationNondeductibleExpenseResearchAndDevelopment" xlink:label="loc_us-gaap_IncomeTaxReconciliationNondeductibleExpenseResearchAndDevelopment_842" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefitContinuingOperationsIncomeTaxReconciliationAbstract_824" xlink:to="loc_us-gaap_IncomeTaxReconciliationNondeductibleExpenseResearchAndDevelopment_842" use="optional" order="8" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxReconciliationNondeductibleExpense" xlink:label="loc_us-gaap_IncomeTaxReconciliationNondeductibleExpense_843" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefitContinuingOperationsIncomeTaxReconciliationAbstract_824" xlink:to="loc_us-gaap_IncomeTaxReconciliationNondeductibleExpense_843" use="optional" order="9" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxReconciliationDispositionOfBusiness" xlink:label="loc_us-gaap_IncomeTaxReconciliationDispositionOfBusiness_844" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefitContinuingOperationsIncomeTaxReconciliationAbstract_824" xlink:to="loc_us-gaap_IncomeTaxReconciliationDispositionOfBusiness_844" use="optional" order="10" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="roiv-20210630.xsd#roiv_IncomeTaxReconciliationPermanentAdjustments" xlink:label="loc_roiv_IncomeTaxReconciliationPermanentAdjustments_845" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefitContinuingOperationsIncomeTaxReconciliationAbstract_824" xlink:to="loc_roiv_IncomeTaxReconciliationPermanentAdjustments_845" use="optional" order="11" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxReconciliationTaxCreditsResearch" xlink:label="loc_us-gaap_IncomeTaxReconciliationTaxCreditsResearch_846" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefitContinuingOperationsIncomeTaxReconciliationAbstract_824" xlink:to="loc_us-gaap_IncomeTaxReconciliationTaxCreditsResearch_846" use="optional" order="12" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxReconciliationChangeInEnactedTaxRate" xlink:label="loc_us-gaap_IncomeTaxReconciliationChangeInEnactedTaxRate_847" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefitContinuingOperationsIncomeTaxReconciliationAbstract_824" xlink:to="loc_us-gaap_IncomeTaxReconciliationChangeInEnactedTaxRate_847" use="optional" order="13" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:label="loc_us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance_848" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefitContinuingOperationsIncomeTaxReconciliationAbstract_824" xlink:to="loc_us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance_848" use="optional" order="14" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxReconciliationOtherAdjustments" xlink:label="loc_us-gaap_IncomeTaxReconciliationOtherAdjustments_849" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefitContinuingOperationsIncomeTaxReconciliationAbstract_824" xlink:to="loc_us-gaap_IncomeTaxReconciliationOtherAdjustments_849" use="optional" order="15" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxExpenseBenefit" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit_850" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefitContinuingOperationsIncomeTaxReconciliationAbstract_824" xlink:to="loc_us-gaap_IncomeTaxExpenseBenefit_850" use="optional" order="16" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract_820" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_roiv_EffectiveTaxRateReconcilingItemsLineItems_821" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract_820" use="optional" order="17" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential_827" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract_820" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential_827" use="optional" order="18" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseResearchAndDevelopment" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseResearchAndDevelopment_829" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract_820" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseResearchAndDevelopment_829" use="optional" order="19" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpense" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpense_831" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract_820" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpense_831" use="optional" order="20" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationDispositionOfBusiness" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationDispositionOfBusiness_832" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract_820" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationDispositionOfBusiness_832" use="optional" order="21" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
<loc xlink:type="locator" xlink:href="roiv-20210630.xsd#roiv_EffectiveIncomeTaxReconciliationPermanentDifferences" xlink:label="loc_roiv_EffectiveIncomeTaxReconciliationPermanentDifferences_833" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract_820" xlink:to="loc_roiv_EffectiveIncomeTaxReconciliationPermanentDifferences_833" use="optional" order="22" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsResearch" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsResearch_834" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract_820" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsResearch_834" use="optional" order="23" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate_835" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract_820" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate_835" use="optional" order="24" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance_836" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract_820" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance_836" use="optional" order="25" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments_837" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract_820" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments_837" use="optional" order="26" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations_838" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract_820" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations_838" use="optional" order="27" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://roivant.com/role/LeasesScheduleOfMaturitiesOfOperatingLeaseLiabilitiesDetail">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LeasesAbstract" xlink:label="loc_us-gaap_LeasesAbstract_1413" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract" xlink:label="loc_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract_1414" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_1413" xlink:to="loc_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract_1414" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_1415" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract_1414" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_1415" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_1416" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract_1414" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_1416" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_1417" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract_1414" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_1417" use="optional" order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_1418" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract_1414" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_1418" use="optional" order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive_1419" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract_1414" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive_1419" use="optional" order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive_1420" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract_1414" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive_1420" use="optional" order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_1421" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract_1414" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_1421" use="optional" order="8" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
<loc xlink:type="locator" xlink:href="roiv-20210630.xsd#roiv_OperatingLeaseLiabilityPresentValueAdjustments" xlink:label="loc_roiv_OperatingLeaseLiabilityPresentValueAdjustments_1423" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract_1414" xlink:to="loc_roiv_OperatingLeaseLiabilityPresentValueAdjustments_1423" use="optional" order="9" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
<loc xlink:type="locator" xlink:href="roiv-20210630.xsd#roiv_LesseeOperatingLeaseLiabilityTenantImprovementAllowance" xlink:label="loc_roiv_LesseeOperatingLeaseLiabilityTenantImprovementAllowance_1424" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract_1414" xlink:to="loc_roiv_LesseeOperatingLeaseLiabilityTenantImprovementAllowance_1424" use="optional" order="10" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseLiability" xlink:label="loc_us-gaap_OperatingLeaseLiability_1425" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract_1414" xlink:to="loc_us-gaap_OperatingLeaseLiability_1425" use="optional" order="11" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://roivant.com/role/LeasesSummaryOfOperatingLeaseRouAssetsAndOperatingLeaseLiabilitiesDetail">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LeasesAbstract" xlink:label="loc_us-gaap_LeasesAbstract_1407" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeasePayments" xlink:label="loc_us-gaap_OperatingLeasePayments_1408" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_1407" xlink:to="loc_us-gaap_OperatingLeasePayments_1408" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" xlink:label="loc_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability_1409" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_1407" xlink:to="loc_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability_1409" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:label="loc_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_1410" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_1407" xlink:to="loc_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_1410" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:label="loc_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent_1411" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_1407" xlink:to="loc_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent_1411" use="optional" order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://roivant.com/role/LeasesScheduleOfOperatingLeaseCostsDetail">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LeaseCostAbstract" xlink:label="loc_us-gaap_LeaseCostAbstract_1401" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseCost" xlink:label="loc_us-gaap_OperatingLeaseCost_1402" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeaseCostAbstract_1401" xlink:to="loc_us-gaap_OperatingLeaseCost_1402" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShortTermLeaseCost" xlink:label="loc_us-gaap_ShortTermLeaseCost_1403" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeaseCostAbstract_1401" xlink:to="loc_us-gaap_ShortTermLeaseCost_1403" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_VariableLeaseCost" xlink:label="loc_us-gaap_VariableLeaseCost_1404" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeaseCostAbstract_1401" xlink:to="loc_us-gaap_VariableLeaseCost_1404" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LeaseCost" xlink:label="loc_us-gaap_LeaseCost_1405" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeaseCostAbstract_1401" xlink:to="loc_us-gaap_LeaseCost_1405" use="optional" order="4" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://roivant.com/role/FairValueMeasurementsScheduleOfAssetsAndLiabilitiesMeasuredAtFairValueOnARecurringBasisDetail">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisAbstract" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisAbstract_681" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_686" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisAbstract_681" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_686" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_LegalEntityAxis" xlink:label="loc_dei_LegalEntityAxis_693" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_686" xlink:to="loc_dei_LegalEntityAxis_693" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityDomain" xlink:label="loc_dei_EntityDomain_684" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_LegalEntityAxis_693" xlink:to="loc_dei_EntityDomain_684" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="roiv-20210630.xsd#roiv_SioGeneTherapiesIncMember" xlink:label="loc_roiv_SioGeneTherapiesIncMember_697" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityDomain_684" xlink:to="loc_roiv_SioGeneTherapiesIncMember_697" use="optional" order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="roiv-20210630.xsd#roiv_ArbutusBiopharmaCorporationMember" xlink:label="loc_roiv_ArbutusBiopharmaCorporationMember_698" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityDomain_684" xlink:to="loc_roiv_ArbutusBiopharmaCorporationMember_698" use="optional" order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueByAssetClassAxis" xlink:label="loc_us-gaap_FairValueByAssetClassAxis_688" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_686" xlink:to="loc_us-gaap_FairValueByAssetClassAxis_688" use="optional" order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" xlink:label="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_687" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueByAssetClassAxis_688" xlink:to="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_687" use="optional" order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MoneyMarketFundsMember" xlink:label="loc_us-gaap_MoneyMarketFundsMember_709" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_687" xlink:to="loc_us-gaap_MoneyMarketFundsMember_709" use="optional" order="8" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockMember" xlink:label="loc_us-gaap_CommonStockMember_710" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_687" xlink:to="loc_us-gaap_CommonStockMember_710" use="optional" order="9" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConvertiblePreferredStockMember" xlink:label="loc_us-gaap_ConvertiblePreferredStockMember_711" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_687" xlink:to="loc_us-gaap_ConvertiblePreferredStockMember_711" use="optional" order="10" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherInvestmentCompaniesMember" xlink:label="loc_us-gaap_OtherInvestmentCompaniesMember_712" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_687" xlink:to="loc_us-gaap_OtherInvestmentCompaniesMember_712" use="optional" order="11" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueByMeasurementFrequencyAxis" xlink:label="loc_us-gaap_FairValueByMeasurementFrequencyAxis_690" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_686" xlink:to="loc_us-gaap_FairValueByMeasurementFrequencyAxis_690" use="optional" order="12" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementFrequencyDomain" xlink:label="loc_us-gaap_FairValueMeasurementFrequencyDomain_691" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueByMeasurementFrequencyAxis_690" xlink:to="loc_us-gaap_FairValueMeasurementFrequencyDomain_691" use="optional" order="13" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementsRecurringMember" xlink:label="loc_us-gaap_FairValueMeasurementsRecurringMember_713" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementFrequencyDomain_691" xlink:to="loc_us-gaap_FairValueMeasurementsRecurringMember_713" use="optional" order="14" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfWarrantOrRightAxis" xlink:label="loc_us-gaap_ClassOfWarrantOrRightAxis_682" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_686" xlink:to="loc_us-gaap_ClassOfWarrantOrRightAxis_682" use="optional" order="15" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfWarrantOrRightDomain" xlink:label="loc_us-gaap_ClassOfWarrantOrRightDomain_683" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightAxis_682" xlink:to="loc_us-gaap_ClassOfWarrantOrRightDomain_683" use="optional" order="16" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:label="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_689" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_686" xlink:to="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_689" use="optional" order="17" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_692" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_689" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_692" use="optional" order="18" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueInputsLevel1Member" xlink:label="loc_us-gaap_FairValueInputsLevel1Member_714" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_692" xlink:to="loc_us-gaap_FairValueInputsLevel1Member_714" use="optional" order="19" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueInputsLevel2Member" xlink:label="loc_us-gaap_FairValueInputsLevel2Member_715" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_692" xlink:to="loc_us-gaap_FairValueInputsLevel2Member_715" use="optional" order="20" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueInputsLevel3Member" xlink:label="loc_us-gaap_FairValueInputsLevel3Member_716" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_692" xlink:to="loc_us-gaap_FairValueInputsLevel3Member_716" use="optional" order="21" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_685" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_686" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_685" use="optional" order="22" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashAndCashEquivalentsFairValueDisclosure" xlink:label="loc_us-gaap_CashAndCashEquivalentsFairValueDisclosure_699" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_685" xlink:to="loc_us-gaap_CashAndCashEquivalentsFairValueDisclosure_699" use="optional" order="23" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InvestmentsFairValueDisclosure" xlink:label="loc_us-gaap_InvestmentsFairValueDisclosure_700" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_685" xlink:to="loc_us-gaap_InvestmentsFairValueDisclosure_700" use="optional" order="24" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetsFairValueDisclosure" xlink:label="loc_us-gaap_AssetsFairValueDisclosure_701" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_685" xlink:to="loc_us-gaap_AssetsFairValueDisclosure_701" use="optional" order="25" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentFairValue" xlink:label="loc_us-gaap_DebtInstrumentFairValue_702" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_685" xlink:to="loc_us-gaap_DebtInstrumentFairValue_702" use="optional" order="26" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DerivativeInstrumentsNotDesignatedAsHedgingInstrumentsLiabilityAtFairValue" xlink:label="loc_us-gaap_DerivativeInstrumentsNotDesignatedAsHedgingInstrumentsLiabilityAtFairValue_704" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_685" xlink:to="loc_us-gaap_DerivativeInstrumentsNotDesignatedAsHedgingInstrumentsLiabilityAtFairValue_704" use="optional" order="27" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesFairValueDisclosure" xlink:label="loc_us-gaap_LiabilitiesFairValueDisclosure_706" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_685" xlink:to="loc_us-gaap_LiabilitiesFairValueDisclosure_706" use="optional" order="28" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://roivant.com/role/FairValueMeasurementsAdditionalInformationDetail">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueDisclosuresAbstract" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract_718" />
<loc xlink:type="locator" xlink:href="roiv-20210630.xsd#roiv_FairValueDisclosuresTable" xlink:label="loc_roiv_FairValueDisclosuresTable_723" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_718" xlink:to="loc_roiv_FairValueDisclosuresTable_723" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeAxis" xlink:label="loc_srt_RangeAxis_727" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_roiv_FairValueDisclosuresTable_723" xlink:to="loc_srt_RangeAxis_727" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeMember" xlink:label="loc_srt_RangeMember_728" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeAxis_727" xlink:to="loc_srt_RangeMember_728" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MinimumMember" xlink:label="loc_srt_MinimumMember_737" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_728" xlink:to="loc_srt_MinimumMember_737" use="optional" order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MaximumMember" xlink:label="loc_srt_MaximumMember_738" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_728" xlink:to="loc_srt_MaximumMember_738" use="optional" order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MeasurementInputTypeAxis" xlink:label="loc_us-gaap_MeasurementInputTypeAxis_725" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_roiv_FairValueDisclosuresTable_723" xlink:to="loc_us-gaap_MeasurementInputTypeAxis_725" use="optional" order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MeasurementInputTypeDomain" xlink:label="loc_us-gaap_MeasurementInputTypeDomain_726" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_MeasurementInputTypeAxis_725" xlink:to="loc_us-gaap_MeasurementInputTypeDomain_726" use="optional" order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MeasurementInputDiscountRateMember" xlink:label="loc_us-gaap_MeasurementInputDiscountRateMember_736" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_MeasurementInputTypeDomain_726" xlink:to="loc_us-gaap_MeasurementInputDiscountRateMember_736" use="optional" order="8" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BalanceSheetLocationAxis" xlink:label="loc_us-gaap_BalanceSheetLocationAxis_719" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_roiv_FairValueDisclosuresTable_723" xlink:to="loc_us-gaap_BalanceSheetLocationAxis_719" use="optional" order="9" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BalanceSheetLocationDomain" xlink:label="loc_us-gaap_BalanceSheetLocationDomain_720" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BalanceSheetLocationAxis_719" xlink:to="loc_us-gaap_BalanceSheetLocationDomain_720" use="optional" order="10" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="roiv-20210630.xsd#roiv_LiabilityInstrumentsMeasuredAtFairValueMember" xlink:label="loc_roiv_LiabilityInstrumentsMeasuredAtFairValueMember_729" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BalanceSheetLocationDomain_720" xlink:to="loc_roiv_LiabilityInstrumentsMeasuredAtFairValueMember_729" use="optional" order="11" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_LegalEntityAxis" xlink:label="loc_dei_LegalEntityAxis_724" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_roiv_FairValueDisclosuresTable_723" xlink:to="loc_dei_LegalEntityAxis_724" use="optional" order="12" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityDomain" xlink:label="loc_dei_EntityDomain_721" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_LegalEntityAxis_724" xlink:to="loc_dei_EntityDomain_721" use="optional" order="13" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="roiv-20210630.xsd#roiv_FairValueDisclosuresLineItems" xlink:label="loc_roiv_FairValueDisclosuresLineItems_722" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_roiv_FairValueDisclosuresTable_723" xlink:to="loc_roiv_FairValueDisclosuresLineItems_722" use="optional" order="14" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentMeasurementInput" xlink:label="loc_us-gaap_DebtInstrumentMeasurementInput_734" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_roiv_FairValueDisclosuresLineItems_722" xlink:to="loc_us-gaap_DebtInstrumentMeasurementInput_734" use="optional" order="15" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1_735" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_roiv_FairValueDisclosuresLineItems_722" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1_735" use="optional" order="16" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="roiv-20210630.xsd#roiv_EquityInterestOptionToThirdPartyPurchaser" xlink:label="loc_roiv_EquityInterestOptionToThirdPartyPurchaser_1106618" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_roiv_FairValueDisclosuresLineItems_722" xlink:to="loc_roiv_EquityInterestOptionToThirdPartyPurchaser_1106618" use="optional" order="17" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://roivant.com/role/FairValueMeasurementsChangeInTheFairValueOfTheDerivativeWarrantLiabilitiesDetail">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueDisclosuresAbstract" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract_758" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaap_StatementTable_764" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_758" xlink:to="loc_us-gaap_StatementTable_764" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_LegalEntityAxis" xlink:label="loc_dei_LegalEntityAxis_762" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_764" xlink:to="loc_dei_LegalEntityAxis_762" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityDomain" xlink:label="loc_dei_EntityDomain_759" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_LegalEntityAxis_762" xlink:to="loc_dei_EntityDomain_759" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:label="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_760" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_764" xlink:to="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_760" use="optional" order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_761" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_760" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_761" use="optional" order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueInputsLevel3Member" xlink:label="loc_us-gaap_FairValueInputsLevel3Member_766" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_761" xlink:to="loc_us-gaap_FairValueInputsLevel3Member_766" use="optional" order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaap_StatementLineItems_763" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_764" xlink:to="loc_us-gaap_StatementLineItems_763" use="optional" order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_767" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_763" xlink:to="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_767" use="optional" order="8" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings_768" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_763" xlink:to="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings_768" use="optional" order="9" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements_1096967" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_763" xlink:to="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements_1096967" use="optional" order="10" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="roiv-20210630.xsd#roiv_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityDisposedDueToDeconsolidationOfSubsidiary" xlink:label="loc_roiv_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityDisposedDueToDeconsolidationOfSubsidiary_1096985" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_763" xlink:to="loc_roiv_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityDisposedDueToDeconsolidationOfSubsidiary_1096985" use="optional" order="11" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_769" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_763" xlink:to="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_769" use="optional" order="12" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://roivant.com/role/FairValueMeasurementsScheduleOfFairValueOfUnobservableInputRelatedToOptionsToAcquireUnderSumitomoTransactionAgreementDetail">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisAbstract" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisAbstract_1442" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable_1444" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisAbstract_1442" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable_1444" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MeasurementInputTypeAxis" xlink:label="loc_us-gaap_MeasurementInputTypeAxis_1445" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable_1444" xlink:to="loc_us-gaap_MeasurementInputTypeAxis_1445" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MeasurementInputTypeDomain" xlink:label="loc_us-gaap_MeasurementInputTypeDomain_1446" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_MeasurementInputTypeAxis_1445" xlink:to="loc_us-gaap_MeasurementInputTypeDomain_1446" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MeasurementInputExpectedTermMember" xlink:label="loc_us-gaap_MeasurementInputExpectedTermMember_1451" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_MeasurementInputTypeDomain_1446" xlink:to="loc_us-gaap_MeasurementInputExpectedTermMember_1451" use="optional" order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MeasurementInputRiskFreeInterestRateMember" xlink:label="loc_us-gaap_MeasurementInputRiskFreeInterestRateMember_1452" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_MeasurementInputTypeDomain_1446" xlink:to="loc_us-gaap_MeasurementInputRiskFreeInterestRateMember_1452" use="optional" order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MeasurementInputOptionVolatilityMember" xlink:label="loc_us-gaap_MeasurementInputOptionVolatilityMember_1453" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_MeasurementInputTypeDomain_1446" xlink:to="loc_us-gaap_MeasurementInputOptionVolatilityMember_1453" use="optional" order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeAxis" xlink:label="loc_srt_RangeAxis_1447" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable_1444" xlink:to="loc_srt_RangeAxis_1447" use="optional" order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeMember" xlink:label="loc_srt_RangeMember_1448" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeAxis_1447" xlink:to="loc_srt_RangeMember_1448" use="optional" order="8" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MinimumMember" xlink:label="loc_srt_MinimumMember_1454" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_1448" xlink:to="loc_srt_MinimumMember_1454" use="optional" order="9" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MaximumMember" xlink:label="loc_srt_MaximumMember_1455" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_1448" xlink:to="loc_srt_MaximumMember_1455" use="optional" order="10" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_1443" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable_1444" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_1443" use="optional" order="11" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="roiv-20210630.xsd#roiv_AlternativeInvestmentExpectedTerm" xlink:label="loc_roiv_AlternativeInvestmentExpectedTerm_1449" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_1443" xlink:to="loc_roiv_AlternativeInvestmentExpectedTerm_1449" use="optional" order="12" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AlternativeInvestmentMeasurementInput" xlink:label="loc_us-gaap_AlternativeInvestmentMeasurementInput_1450" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_1443" xlink:to="loc_us-gaap_AlternativeInvestmentMeasurementInput_1450" use="optional" order="13" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://roivant.com/role/DefinedContributionPlanAdditionalInformationDetail">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CompensationAndRetirementDisclosureAbstract" xlink:label="loc_us-gaap_CompensationAndRetirementDisclosureAbstract_1457" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DefinedContributionPlanEmployerDiscretionaryContributionAmount" xlink:label="loc_us-gaap_DefinedContributionPlanEmployerDiscretionaryContributionAmount_1458" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CompensationAndRetirementDisclosureAbstract_1457" xlink:to="loc_us-gaap_DefinedContributionPlanEmployerDiscretionaryContributionAmount_1458" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://roivant.com/role/OtherIncomeExpenseNetSummaryOfOtherIncomeExpenseNetFromContinuingOperationsDetail">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherExpensesAbstract" xlink:label="loc_us-gaap_OtherExpensesAbstract_1460" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherIncomeAndExpensesAbstract" xlink:label="loc_us-gaap_OtherIncomeAndExpensesAbstract_1461" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherExpensesAbstract_1460" xlink:to="loc_us-gaap_OtherIncomeAndExpensesAbstract_1461" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeLossFromEquityMethodInvestments" xlink:label="loc_us-gaap_IncomeLossFromEquityMethodInvestments_1462" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherIncomeAndExpensesAbstract_1461" xlink:to="loc_us-gaap_IncomeLossFromEquityMethodInvestments_1462" use="optional" order="2" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InterestIncomeOther" xlink:label="loc_us-gaap_InterestIncomeOther_1463" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherIncomeAndExpensesAbstract_1461" xlink:to="loc_us-gaap_InterestIncomeOther_1463" use="optional" order="3" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InterestExpense" xlink:label="loc_us-gaap_InterestExpense_1464" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherIncomeAndExpensesAbstract_1461" xlink:to="loc_us-gaap_InterestExpense_1464" use="optional" order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="roiv-20210630.xsd#roiv_OtherIncomeExpense" xlink:label="loc_roiv_OtherIncomeExpense_1465" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherIncomeAndExpensesAbstract_1461" xlink:to="loc_roiv_OtherIncomeExpense_1465" use="optional" order="5" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherOperatingIncomeExpenseNet" xlink:label="loc_us-gaap_OtherOperatingIncomeExpenseNet_1466" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherIncomeAndExpensesAbstract_1461" xlink:to="loc_us-gaap_OtherOperatingIncomeExpenseNet_1466" use="optional" order="6" preferredLabel="http://www.xbrl.org/2009/role/negatedTotalLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://roivant.com/role/NetLossPerCommonShareSummaryOfBasicAndDilutedNetIncomePerShareOfCommonStockDetail">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerShareAbstract" xlink:label="loc_us-gaap_EarningsPerShareAbstract_1468" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest_1469" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_1468" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest_1469" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsAttributableToNoncontrollingEntity" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsAttributableToNoncontrollingEntity_1470" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_1468" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsAttributableToNoncontrollingEntity_1470" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeLossFromContinuingOperations" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperations_1471" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_1468" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperations_1471" use="optional" order="3" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PreferredStockDividendsAndOtherAdjustments" xlink:label="loc_us-gaap_PreferredStockDividendsAndOtherAdjustments_1472" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_1468" xlink:to="loc_us-gaap_PreferredStockDividendsAndOtherAdjustments_1472" use="optional" order="4" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
<loc xlink:type="locator" xlink:href="roiv-20210630.xsd#roiv_BasicAndDilutedLossFromContinuingOperationsNetOfTax" xlink:label="loc_roiv_BasicAndDilutedLossFromContinuingOperationsNetOfTax_1473" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_1468" xlink:to="loc_roiv_BasicAndDilutedLossFromContinuingOperationsNetOfTax_1473" use="optional" order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTax" xlink:label="loc_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTax_1474" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_1468" xlink:to="loc_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTax_1474" use="optional" order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToNoncontrollingInterest" xlink:label="loc_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToNoncontrollingInterest_1475" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_1468" xlink:to="loc_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToNoncontrollingInterest_1475" use="optional" order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity" xlink:label="loc_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity_1476" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_1468" xlink:to="loc_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity_1476" use="optional" order="8" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="roiv-20210630.xsd#roiv_BasicAndDilutedIncomeFromDiscontinuedOperationsNetOfTax" xlink:label="loc_roiv_BasicAndDilutedIncomeFromDiscontinuedOperationsNetOfTax_1477" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_1468" xlink:to="loc_roiv_BasicAndDilutedIncomeFromDiscontinuedOperationsNetOfTax_1477" use="optional" order="9" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="roiv-20210630.xsd#roiv_BasicAndDilutedNetLossIncome" xlink:label="loc_roiv_BasicAndDilutedNetLossIncome_1478" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_1468" xlink:to="loc_roiv_BasicAndDilutedNetLossIncome_1478" use="optional" order="10" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://roivant.com/role/NetLossPerCommonShareSummaryOfBasicAndDilutedNetIncomePerShareOfCommonStockParentheticalDetail">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerShareAbstract" xlink:label="loc_us-gaap_EarningsPerShareAbstract_1480" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PreferredStockDividendsAndOtherAdjustments" xlink:label="loc_us-gaap_PreferredStockDividendsAndOtherAdjustments_1481" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_1480" xlink:to="loc_us-gaap_PreferredStockDividendsAndOtherAdjustments_1481" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://roivant.com/role/SubsequentEventsAdditionalInformationDetail">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventsAbstract" xlink:label="loc_us-gaap_SubsequentEventsAbstract_1483" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaap_StatementTable_1494" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventsAbstract_1483" xlink:to="loc_us-gaap_StatementTable_1494" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessAcquisitionAxis" xlink:label="loc_us-gaap_BusinessAcquisitionAxis_1486" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_1494" xlink:to="loc_us-gaap_BusinessAcquisitionAxis_1486" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_1485" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_1486" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_1485" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="roiv-20210630.xsd#roiv_SumitomoPharmaceuticalsCoLtdMember" xlink:label="loc_roiv_SumitomoPharmaceuticalsCoLtdMember_1499" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_1485" xlink:to="loc_roiv_SumitomoPharmaceuticalsCoLtdMember_1499" use="optional" order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="roiv-20210630.xsd#roiv_ProteovantSciencesIncMember" xlink:label="loc_roiv_ProteovantSciencesIncMember_1096954" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_1485" xlink:to="loc_roiv_ProteovantSciencesIncMember_1096954" use="optional" order="5" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="roiv-20210630.xsd#roiv_DatavantMember" xlink:label="loc_roiv_DatavantMember_1096955" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_1485" xlink:to="loc_roiv_DatavantMember_1096955" use="optional" order="6" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:label="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_1490" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_1494" xlink:to="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_1490" use="optional" order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RelatedPartyDomain" xlink:label="loc_us-gaap_RelatedPartyDomain_1489" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_1490" xlink:to="loc_us-gaap_RelatedPartyDomain_1489" use="optional" order="8" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="roiv-20210630.xsd#roiv_DermavantSciencesLtdMember" xlink:label="loc_roiv_DermavantSciencesLtdMember_1501" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyDomain_1489" xlink:to="loc_roiv_DermavantSciencesLtdMember_1501" use="optional" order="9" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventTypeAxis" xlink:label="loc_us-gaap_SubsequentEventTypeAxis_1495" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_1494" xlink:to="loc_us-gaap_SubsequentEventTypeAxis_1495" use="optional" order="10" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="loc_us-gaap_SubsequentEventTypeDomain_1496" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventTypeAxis_1495" xlink:to="loc_us-gaap_SubsequentEventTypeDomain_1496" use="optional" order="11" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventMember" xlink:label="loc_us-gaap_SubsequentEventMember_1513" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventTypeDomain_1496" xlink:to="loc_us-gaap_SubsequentEventMember_1513" use="optional" order="12" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RestatementAxis" xlink:label="loc_srt_RestatementAxis_1491" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_1494" xlink:to="loc_srt_RestatementAxis_1491" use="optional" order="13" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RestatementDomain" xlink:label="loc_srt_RestatementDomain_1492" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RestatementAxis_1491" xlink:to="loc_srt_RestatementDomain_1492" use="optional" order="14" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RevisionOfPriorPeriodReclassificationAdjustmentMember" xlink:label="loc_srt_RevisionOfPriorPeriodReclassificationAdjustmentMember_1502" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RestatementDomain_1492" xlink:to="loc_srt_RevisionOfPriorPeriodReclassificationAdjustmentMember_1502" use="optional" order="15" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="loc_us-gaap_TypeOfArrangementAxis_1497" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_1494" xlink:to="loc_us-gaap_TypeOfArrangementAxis_1497" use="optional" order="16" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_1484" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TypeOfArrangementAxis_1497" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_1484" use="optional" order="17" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="roiv-20210630.xsd#roiv_RevenueInterestPurchaseAndSaleAgreementMember" xlink:label="loc_roiv_RevenueInterestPurchaseAndSaleAgreementMember_1498" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_1484" xlink:to="loc_roiv_RevenueInterestPurchaseAndSaleAgreementMember_1498" use="optional" order="18" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentAxis" xlink:label="loc_us-gaap_DebtInstrumentAxis_1487" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_1494" xlink:to="loc_us-gaap_DebtInstrumentAxis_1487" use="optional" order="19" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_1488" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentAxis_1487" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_1488" use="optional" order="20" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="roiv-20210630.xsd#roiv_CreditFacilityMember" xlink:label="loc_roiv_CreditFacilityMember_1500" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_1488" xlink:to="loc_roiv_CreditFacilityMember_1500" use="optional" order="21" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaap_StatementLineItems_1493" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_1494" xlink:to="loc_us-gaap_StatementLineItems_1493" use="optional" order="22" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="roiv-20210630.xsd#roiv_BusinessAcquisitionCostOfAcquiredEntityAdjustmentPaidInCash" xlink:label="loc_roiv_BusinessAcquisitionCostOfAcquiredEntityAdjustmentPaidInCash_1503" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_1493" xlink:to="loc_roiv_BusinessAcquisitionCostOfAcquiredEntityAdjustmentPaidInCash_1503" use="optional" order="23" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="roiv-20210630.xsd#roiv_RevenueInterestPurchaseAndSaleAgreementAmount" xlink:label="loc_roiv_RevenueInterestPurchaseAndSaleAgreementAmount_1504" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_1493" xlink:to="loc_roiv_RevenueInterestPurchaseAndSaleAgreementAmount_1504" use="optional" order="24" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="roiv-20210630.xsd#roiv_RevenueInterestPurchaseAndSaleAgreementCommittedFundToBePaid" xlink:label="loc_roiv_RevenueInterestPurchaseAndSaleAgreementCommittedFundToBePaid_1505" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_1493" xlink:to="loc_roiv_RevenueInterestPurchaseAndSaleAgreementCommittedFundToBePaid_1505" use="optional" order="25" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentFaceAmount" xlink:label="loc_us-gaap_DebtInstrumentFaceAmount_1506" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_1493" xlink:to="loc_us-gaap_DebtInstrumentFaceAmount_1506" use="optional" order="26" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:label="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_1507" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_1493" xlink:to="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_1507" use="optional" order="27" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentTerm" xlink:label="loc_us-gaap_DebtInstrumentTerm_1508" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_1493" xlink:to="loc_us-gaap_DebtInstrumentTerm_1508" use="optional" order="28" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfWarrantOrRightOutstanding" xlink:label="loc_us-gaap_ClassOfWarrantOrRightOutstanding_1509" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_1493" xlink:to="loc_us-gaap_ClassOfWarrantOrRightOutstanding_1509" use="optional" order="29" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:label="loc_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_1511" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_1493" xlink:to="loc_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_1511" use="optional" order="30" preferredLabel="http://www.xbrl.org/2003/role/positiveLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongTermDebtNoncurrent" xlink:label="loc_us-gaap_LongTermDebtNoncurrent_1512" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_1493" xlink:to="loc_us-gaap_LongTermDebtNoncurrent_1512" use="optional" order="31" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="roiv-20210630.xsd#roiv_SubscriptionsReceivable" xlink:label="loc_roiv_SubscriptionsReceivable_1107994" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_1493" xlink:to="loc_roiv_SubscriptionsReceivable_1107994" use="optional" order="32" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityMethodInvestments" xlink:label="loc_us-gaap_EquityMethodInvestments_1096951" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_1493" xlink:to="loc_us-gaap_EquityMethodInvestments_1096951" use="optional" order="33" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityMethodInvestmentOwnershipPercentage" xlink:label="loc_us-gaap_EquityMethodInvestmentOwnershipPercentage_1096952" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_1493" xlink:to="loc_us-gaap_EquityMethodInvestmentOwnershipPercentage_1096952" use="optional" order="34" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationConsiderationTransferred1" xlink:label="loc_us-gaap_BusinessCombinationConsiderationTransferred1_1096953" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_1493" xlink:to="loc_us-gaap_BusinessCombinationConsiderationTransferred1_1096953" use="optional" order="35" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
</presentationLink>
</linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>13
<FILENAME>g164680conyvers.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g164680conyvers.jpg
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M 0$! 0$! 0        $" P0%!@<("0H+$  " 0,# @0#!04$!    7T! @,
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M<\2-P)$3=,X]?1!_G(K=4U%7D<SJN3M$9#\*_B#J48GO_$"Q2MR4FO)'8?7
M(_(T_:0707LIO6Y6O/"'Q.\(#[98ZG<7D4?S,+6X>0#'K&PY_ &CFA+= XU(
M[,ZSP)\88]8NH=(U^);:_=MB3KQ'(W8$'[I_0GTJ)T[*Z-(5;NS/6 <UD;B]
M* /-O'/Q;L/#-U)ING0"_P!248;#?NXV]"1R3[#\ZUA3;U,9U>71'%PGXO\
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MFGW$H#.QPJ$_=E'L1@'_ .M71)*:NCE@^25F?008$ Y&*YCK/ /&FM7?Q/\
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M2JH/Y+G]:'5D"HQ.^T3P_I?AVQ%GI5G';0YR0O)8^I)Y)^M9.3EN;**CL:=
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LB"G[60O8Q.T\.^$=#\+1/'I%BD!?[[DEG;ZL><>W2LW)RW-8P4=C<I%'_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>14
<FILENAME>g164680davispolk3.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g164680davispolk3.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_X1$ 17AI9@  34T *@    @ ! $[  (
M   2   (2H=I  0    !   (7)R=  $    D   0U.H<  <   @,    /@
M   <Z@    @
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M                                                 %9E;F$@2')Y
M<V]U;&QA:VES   %D ,  @   !0  !"JD 0  @   !0  !"^DI$  @    ,V
M-@  DI(  @    ,V-@  ZAP !P  " P   B>     !SJ    "
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M                            ,C R,3HP-SHP.2 Q,CHS,#HS-  R,#(Q
M.C W.C Y(#$R.C,P.C,T    5@!E &X 80 @ $@ <@!Y ', ;P!U &P ; !A
M &L :0!S    _^$+)&AT=' Z+R]N<RYA9&]B92YC;VTO>&%P+S$N,"\ /#]X
M<&%C:V5T(&)E9VEN/2?ON[\G(&ED/2=7-4TP37!#96AI2'IR95-Z3E1C>FMC
M.60G/SX-"CQX.GAM<&UE=&$@>&UL;G,Z>#TB861O8F4Z;G,Z;65T82\B/CQR
M9&8Z4D1&('AM;&YS.G)D9CTB:'1T<#HO+W=W=RYW,RYO<F<O,3DY.2\P,B\R
M,BUR9&8M<WEN=&%X+6YS(R(^/')D9CI$97-C<FEP=&EO;B!R9&8Z86)O=70]
M(G5U:60Z9F%F-6)D9#4M8F$S9"TQ,61A+6%D,S$M9#,S9#<U,3@R9C%B(B!X
M;6QN<SID8STB:'1T<#HO+W!U<FPN;W)G+V1C+V5L96UE;G1S+S$N,2\B+SX\
M<F1F.D1E<V-R:7!T:6]N(')D9CIA8F]U=#TB=75I9#IF868U8F1D-2UB83-D
M+3$Q9&$M860S,2UD,S-D-S4Q.#)F,6(B('AM;&YS.GAM<#TB:'1T<#HO+VYS
M+F%D;V)E+F-O;2]X87 O,2XP+R(^/'AM<#I#<F5A=&5$871E/C(P,C$M,#<M
M,#E4,3(Z,S Z,S0N-C8P/"]X;7 Z0W)E871E1&%T93X\+W)D9CI$97-C<FEP
M=&EO;CX\<F1F.D1E<V-R:7!T:6]N(')D9CIA8F]U=#TB=75I9#IF868U8F1D
M-2UB83-D+3$Q9&$M860S,2UD,S-D-S4Q.#)F,6(B('AM;&YS.F1C/2)H='1P
M.B\O<'5R;"YO<F<O9&,O96QE;65N=',O,2XQ+R(^/&1C.F-R96%T;W(^/')D
M9CI397$@>&UL;G,Z<F1F/2)H='1P.B\O=W=W+G<S+F]R9R\Q.3DY+S R+S(R
M+7)D9BUS>6YT87@M;G,C(CX\<F1F.FQI/E9E;F$@2')Y<V]U;&QA:VES/"]R
M9&8Z;&D^/"]R9&8Z4V5Q/@T*"0D)/"]D8SIC<F5A=&]R/CPO<F1F.D1E<V-R
M:7!T:6]N/CPO<F1F.E)$1CX\+W@Z>&UP;65T83X-"B @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @
M(" @(" @(" @/#]X<&%C:V5T(&5N9#TG=R<_/O_; $, !P4%!@4$!P8%!@@'
M!P@*$0L*"0D*%0\0#!$8%1H9&!48%QL>)R$;'24=%Q@B+B(E*"DK+"L:("\S
M+RHR)RHK*O_; $,!!P@("@D*% L+%"H<&!PJ*BHJ*BHJ*BHJ*BHJ*BHJ*BHJ
M*BHJ*BHJ*BHJ*BHJ*BHJ*BHJ*BHJ*BHJ*BHJ*BHJ*O_  !$( !< ;@,!(@ "
M$0$#$0'_Q  ?   !!0$! 0$! 0           0(#! 4&!P@)"@O_Q "U$  "
M 0,# @0#!04$!    7T! @, !!$%$B$Q008346$'(G$4,H&1H0@C0K'!%5+1
M\"0S8G*""0H6%Q@9&B4F)R@I*C0U-C<X.3I#1$5&1TA)2E-455976%E:8V1E
M9F=H:6IS='5V=WAY>H.$A8:'B(F*DI.4E9:7F)F:HJ.DI::GJ*FJLK.TM;:W
MN+FZPL/$Q<;'R,G*TM/4U=;7V-G:X>+CY.7FY^CIZO'R\_3U]O?X^?K_Q  ?
M 0 # 0$! 0$! 0$!         0(#! 4&!P@)"@O_Q "U$0 " 0($! ,$!P4$
M!  ! G<  0(#$00%(3$&$D%1!V%Q$R(R@0@40I&AL<$)(S-2\!5B<M$*%B0T
MX27Q%Q@9&B8G*"DJ-38W.#DZ0T1%1D=(24I35%565UA96F-D969G:&EJ<W1U
M=G=X>7J"@X2%AH>(B8J2DY25EI>8F9JBHZ2EIJ>HJ:JRL[2UMK>XN;K"P\3%
MQL?(R<K2T]35UM?8V=KBX^3EYN?HZ>KR\_3U]O?X^?K_V@ , P$  A$#$0 _
M )+3XC_%GQ3\0O$>@^#WTMUTJ[G4+<1*N(UE*+R>IZ5K:)\8O&/A;QY9^%_B
MWI%M;+?LJP7UL, %CA6)!*LN>#C!7J:SO@;_ ,E]^(7_ %WN?_2HU6_:9N[7
M7O%/A/P[H\J7&L+-(&2([FB,K1JBG'0DJ3CV]Z />-:\8>&_#DRPZ]KNG:=*
MXRL=S<HCD>NTG./>FGQIX7738M1?Q'I*V4SE([EKZ,1NP&2H8M@D>E>'6G]@
M^(/BAXGN/"'@*?QM?+,R7MUK5["MK Q8C]VKH>/E(7OM7CBN!\+^%9?$7@GX
MG6 @CCN-*GAOH+>!BT<;Q-.'5/4;-RCUXH ^O=3UK2]%M%NM9U*ST^W=@BS7
M4ZQ(S$$@!F(&< G'M7(>&==UR^^(NMVU]K_AZ]T6&)GM+2RN5>ZA&Y<-*HZ#
M!//J17AS>(6^,$OPQ\';S*((_-U89SGRB4.[T)CB8_\ ;45:MM-75?B]\5]-
M_M2WT@7-A-"+NXD$<4>9H@ S=E;[O_ N_2@#Z A^(?@VXU$6$'BG1Y+IFV+$
MM]&2S=-HYY/M7,?'3QQK/@'P+:ZKX>>%+J748[=C-&'&PQR,>/7*BO$;G0;C
MPC\/X;7QO\.-.U31(W5E\1Z+=1B=E9^&,JABP.X*,A01@5V?QXO['4_V=?#%
MYI$EQ+92WEJ8&N3F4J+>4#>>[<<GUS0 7_C7XU^'?"$'C#4(M"OM',45Q)&B
M?,(Y,8) P1]X#@G&?2O6=!^(NA:KX TWQ7J-[;:1:7T>?],G5 L@)5D#'&[#
M*1[XZ5Y!;?#_ .+OC7P%I>DZAXHT>W\.7-G;D11H?,\D*I0'$8)( '&[!(ZU
MEZ1X+TN;]HJT\"Z\&O-%T#30MC;7!PL[&-968@<'<\DCD?[(!R!0!]&Z-XBT
M;Q%;M/H.JV>I1(<.UK.LFP^AP>/QKY:TGX\_$!/ NL:K<ZM#>75OJ-E;Q&:S
MB 1)([EGX15R28DZYZ>]==JNE6/@']J?PU:^"X5LH=4ME%[90']WM8R*WR]A
MA0V.Q7->%Z?_ ,DJU_\ [#.F_P#HF]H ^XAXHTK3M#TV[\1:M8:<]Y CJ;NX
M2$2,5!;;N(SU[5M*RNH9"&5AD$'((KY9^'MVVH_&[3A\7;21;^2QA;0H9R!;
MQ< Q@+R,D9QD_?!R-V,?4] 'C6L?LS>%-:UR_P!5N=6UE)KZYDN9%CDB"JSL
M6(&8\XR:Z'P-\#_"'@+4QJ6G17-[J" B.YOI [19X.T*JJ#[XS[T44 49?@5
MIL/B:_U;0/$NOZ"FI.7N[73;H1JY))(!QD#). <XR<8K9\"?";0OA[J&K7&B
M7%[+'J@ EM[J171 "Q 'R@G[Q'S$FBB@"IX#^"OAOX>^)+G6M'GO9[B>%H56
MZ=&6)68,=N%![ 9)/%2I\&_#9\2^(]8O'N[P^(H7AO+69U\H*S*V4PH8$% 0
M<\444 <__P ,\Z:UBFD3>+_$LN@(X==*:[7RN#G'W<8SST]^O-=9XO\ A=H7
MC#P58>%IWN=/TW3Y8Y+=;-E#+L1D5<L&R,,??WHHH ZC2=.BT?1;+3+=G>*R
MMX[>-G(W%44*"<=\"N1\=?"C0_'.H6NJ37%[I>L6@VPZCI\OER@#D \<XR<'
M@C/6BB@"'P7\(-$\'Z]+KTM[J&MZW(I4W^I3>8Z C!V^Y'&3DXXS@FN>3]FK
MPC#X>N]'AU/6A!=W4%S([31%@T2RJH'[L#!$S9X[#ISDHH Z;QI\)-!\;V.D
M0ZA/>VEQI "VUY9NJ3;0 ,$E2.H!Z<$<8R:[6UA>WLX899Y+AXT5&FDQND(&
,-QP ,GKP *** /_9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>15
<FILENAME>g164680g00y01.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g164680g00y01.jpg
M_]C_X  02D9)1@ ! 0(!>0%Y  #_[1=^4&AO=&]S:&]P(#,N,  X0DE-! 0
M    %V*^688X0DE-! 0       \< 5H  QLE1QP"   "    .$))300E
M   0S<_Z?:C'O@D%<':NKP7#3CA"24T$.@      Y0   !     !       +
M<')I;G1/=71P=70    %     %!S=%-B;V]L 0    !);G1E96YU;0    !)
M;G1E     $-L<FT    /<')I;G13:7AT965N0FET8F]O;      +<')I;G1E
M<DYA;65415A4     0      #W!R:6YT4')O;V93971U<$]B:F,    , %
M<@!O &\ 9@ @ %, 90!T '4 <       "G!R;V]F4V5T=7     !     $)L
M=&YE;G5M    #&)U:6QT:6Y0<F]O9@    EP<F]O9D--64L .$))300[
M  (M    $     $      !)P<FEN=$]U='!U=$]P=&EO;G,    7     $-P
M=&YB;V]L      !#;&)R8F]O;       4F=S36)O;VP      $-R;D-B;V]L
M      !#;G1#8F]O;       3&)L<V)O;VP      $YG='9B;V]L      !%
M;6Q$8F]O;       26YT<F)O;VP      $)C:V=/8FIC     0       %)'
M0D,    #     %)D("!D;W5B0&_@            1W)N(&1O=6) ;^
M      !";" @9&]U8D!OX            $)R9%15;G1&(U)L=
M     $)L9"!5;G1&(U)L=                %)S;'15;G1&(U!X;$!M.G1@
M        "G9E8W1O<D1A=&%B;V]L 0    !09U!S96YU;0    !09U!S
M %!G4$,     3&5F=%5N=$8C4FQT                5&]P(%5N=$8C4FQT
M                4V-L(%5N=$8C4')C0%D            08W)O<%=H96Y0
M<FEN=&EN9V)O;VP     #F-R;W!296-T0F]T=&]M;&]N9P         ,8W)O
M<%)E8W1,969T;&]N9P         -8W)O<%)E8W12:6=H=&QO;F<
M"V-R;W!296-T5&]P;&]N9P      .$))30/M       0 [_^-0 "  $#O_XU
M  (  3A"24T$)@      #@             _@   .$))300-       $
M>#A"24T$&0      !    !XX0DE- _,       D           $ .$))32<0
M       *  $          3A"24T#]0      2  O9F8  0!L9F8 !@
M 0 O9F8  0"AF9H !@       0 R     0!:    !@       0 U     0 M
M    !@       3A"24T#^       <   ____________________________
M_P/H     /____________________________\#Z     #_____________
M________________ ^@     _____________________________P/H   X
M0DE-! @      !     !   "0    D      .$))300>       $     #A"
M24T$&@     #-0    8              .(   .R          $
M                 0             #L@   .(
M 0                         0     0       &YU;&P    "    !F)O
M=6YD<T]B:F,    !        4F-T,0    0     5&]P(&QO;F<
M $QE9G1L;VYG          !"=&]M;&]N9P   .(     4F=H=&QO;F<   .R
M    !G-L:6-E<U9L3',    !3V)J8P    $       5S;&EC90   !(    '
M<VQI8V5)1&QO;F<         !V=R;W5P241L;VYG          9O<FEG:6YE
M;G5M    #$53;&EC94]R:6=I;@    UA=71O1V5N97)A=&5D     %1Y<&5E
M;G5M    "D53;&EC951Y<&4     26UG(     9B;W5N9'-/8FIC     0
M     %)C=#$    $     %1O<"!L;VYG          !,969T;&]N9P
M    0G1O;6QO;F<   #B     %)G:'1L;VYG   #L@    -U<FQ415A4
M 0       &YU;&Q415A4     0       $US9V5415A4     0      !F%L
M=%1A9U1%6%0    !       .8V5L;%1E>'1)<TA434QB;V]L 0    AC96QL
M5&5X=%1%6%0    !       ):&]R>D%L:6=N96YU;0    ]%4VQI8V5(;W)Z
M06QI9VX    '9&5F875L=     EV97)T06QI9VYE;G5M    #T53;&EC959E
M<G1!;&EG;@    =D969A=6QT    "V)G0V]L;W)4>7!E96YU;0   !%%4VQI
M8V5"1T-O;&]R5'EP90    !.;VYE    "71O<$]U='-E=&QO;F<
M"FQE9G1/=71S971L;VYG          QB;W1T;VU/=71S971L;VYG
M  MR:6=H=$]U='-E=&QO;F<      #A"24T$*       #     (_\
M #A"24T$$0       0$ .$))3004       $     CA"24T$#      -3
M  $   "@    )@   >   $=    -,  8  '_V/_M  Q!9&]B95]#30 "_^X
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MT?\ A/8Q_J2[U74V9)F]PO<XGGU18YUP_K^ID0
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
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M 0$! 0'_P  1" != 80# 1$  A$! Q$!_\0 'P   @,!  (# 0
M  H("0L'!08! P0"_\0 5Q    8" 0,! P4)"@H%#0   0(#! 4&!P@ "1$2
M$PH4%2$X.7BW%A<9(C%8=Y76&!HS87.7LK6VUR-!455667:6F-@D)397DR8R
M-69UF;&TN,'5\/'_Q  = 0 !!0$! 0$              P0%!@<" 0@)_\0
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M2!%%DYY6XTKUABG(SM;U%V)QA+)>2;:SXHLUXKM@9"X$GDLDVKE^$1]/Q ?
MS%VDF'<11_*'(_1>V[LH>8:=8_# [ -1GY3]0XBXYMX+1S"2H1=7U_3;:T+.
M6P&-]&TQPRLX&0TO^)>W-1Z9?]CG:1' &YV%CP+I$K 2$'UK#197N^1=O4B@
M)C!.%7>I#XCV"W+UUD"M]9]U;-EMDP4356UBW\;/;0O,)D*0QX6L9=71@L@U
MJ252%=*(:HR$G$E=J-UIA%PW065-L .IR:9%KFH:#INN<-S*#'QKV;ZI8<1Z
M'R>L#/+)I-WJ%IW0('>/));E<%44L501ND=L&AW>H_077;:;1M94\KZ=J%C?
M</ZO&>GK:3K$4$MP!D$FV+>J"44C8WPZ+]4;%FWDY(88O54FM;MMJJP,]MFO
M&1'C=1_+,6Y1%S:L36M-)I%91I@E*9?XC"I)2;%L N)"*18"WD7366TC:V34
M-/N8M2TR4XCO;?.%;^BN8CF2VF7.&CE (.W7:M5BD@N8$NK2>.YMG^++&<\I
M^\D4@-%(,X9' (.QWVJT+C*O:.%%)I^T?]1'=/3[:W"=%UJV MV)*E9-?VEK
MG(2O,JRY:R-A4R'>(D\HL>;@I1P5<T=&,&@E2631]-L002 XG,:\<+:987UI
M<27=LDSI<\BLQ<$+W2-@<K*.I)Z9WJ3LH8I(W9T#$/@9STY5/F.F3_KM7"N@
M1U.-\=J>H57\3;!;)77)^.G6*,G3KBJSK"J-V"LM"Q\>K%OC*1%>C7@*LU%E
M#I 5R"8B80.0X?(#GB/2=.L],::VM4AE$T2AU9R>5B>889F&#CRKJ\@ACA+)
M&%/,!G?(W_0<4]#S/JBJ2"Z_FX/4RT,W-:$P]M3DRI:_YPI4?><:PK./J#J(
MK,W#"G7,@4QB]DZP\?+C'2S:/M14EW*_N<;=HQFDJ*:'II7[ANQTK4;$]_9Q
M/<V\ACE8M(&=6R\3D!P!D%DV R8R?&I6SC@EB]>-2Z$@DY!(Z@]?+(\.E17Z
M2'7'W/E=]L%T#;'8VRY,PIEV=4Q1,QMK95-FQ@K)=DPC:'94GL7 12[0[.Z#
M!Q[Y=9X1FC"RDHLX*/I$,1YK7#]BNG7$ME:K%<0*)E*%R62/>1,,S9S'S$ #
M)95'G7=Q:Q]TYC0*Z^MD9R0,DCVY&<;=1C.:T)>9K4/1PHHX45PK9[/%8U@U
MXS/L)<3I!7\08ZM%X=-E5?0^*.X:,76AX%!3L(^^V*9&/@H\A0,=5](MTDRF
M.<I1<6EN]W<P6T?QIY4C!ZXYB 6/L5<L?( DUVB%W5!U9@/=D[GW ;GV5F=S
M777ZK4M,2THWW$R!#H24D_?HQ$9#T5..BD7CI5PG'1Y%:FJL1DQ(H5LT*JJH
MH5!),#J', F'5EX=T954&QC8@ %BTN6P,9.' R>IP!O4X+2WP 8E.V,[@].O
M7QWZ>SWT[KT"K=M_F/2L-CMPLQW/*=BS;<9:1Q@RM;6$8)US&%367K+%\T9P
M\1$B5Q;+*TLDF9RZ34![ MZV[9B#98%7%!XC2Q@O_1;&".%+= )BA8\\S@.0
M2S-M&A1<#HQ<'?815X(UE[N-54(!S%<[L=_$GH,#KUS[JO$Y7Z:U3+US>H99
M.GIIBZMN*I]A![ Y6ML3C[#KMW'Q$X:&714).W2X&K\XSD8R4:0%78N(TGO[
M%RP;3]DKIG:2Q%"MUIWA_3%U.^"3*6MH4:2?!9<@@K''SJ05+N0=B"51\=,T
MYM(1-+AAE%!9ADC/@!D;C).3C? .-Z2H_?%/5[_.F9?S':__ -U_+W]*^B?U
M1O\ J;G^+4KZ';?T7_GD\?[=/E])?=M/?O1O$.<Y:28O,G-6*] S8U9I,V@L
MLJT[TF,\]5C6":3.,2MS%2)O4='M$4FK.+M#)HBFEZ!D4\[UFP^ANH3VZ@B+
M(DMR23F&3=1D[GD/-&2=R4)/6HBXB[F5D^Y^,OX)Z?,01\E63<BZ0HX44<**
M7D]I VUV,T^U*PI?=:LJS^)+?9-BHRH3D[7F\,Y=R-;6QID:95B5B349*-RM
MSR<1&O!,DBFOZC1, 5 @G(:S<+V5K?7MQ'=PK,B6I=58L '[V)>;U64YPQ'7
M&]/;*-)9'5U# 1D@$D;\RC.WOI/.G=>?JL52V5JS/-L[A;V<!.Q<N\JEH@J2
MZKEE:1[U%TY@9U!G6&3U2)ET$U&#_P!Q>LGQ6RZAV3QJZ*DX3N[\.:.Z.@LD
M0LK*'1Y R$C 927(YE.XR",C<$9%21M+<@@QJ,@C()!!/0@YP,>&0?#.=\Z*
MN@F\6)NH+K;3-A,5.DVOQ5+X/?J0N[3<SF-L@QR" V&FS?B1(YQ:J+)/8:3%
MN@C/5Y[%3;9)))]Z*68ZEI\VFW4EM,,X]:.3&%EB)/+(OOZ,,GE8,IZ5"S1-
M"Y1O>I\&7P(_0?(Y%32XPI*CA15;75\S%DS7_IO[2YAPY;I&AY+H]1K,A5+;
M$I,5I"%>/<BTV(=+MDI)J^9'.M&R+UH8'#58H)N#B4H' IRRNB00W.J6<$Z"
M2*1W#H20& BD8 E2#U .Q\*6MU5YXU894M@@^.QK/9_#C]6#\]7)OZJH'['\
MTKZ7M&_J$7]Z7^)4SZ+;_P!$OAY^WV^[J!^ZM-75RT3]WUEUUNEJDUYJT6_!
M.([19)AR5$CF6GY_']?E9B3<$;IHH%7?R+MPZ5*@BDB514P)ID(!2AE%VBQW
M5S&@Y42XF1%&<*JR,JC?)V  WWJ"< .X&P#, /8"<4L'[2CO[N)IQF36.NZR
MYWM>(H6Z8SNTU:(^NLZXY1F)2,M4>Q8O')IN$E52J-FBJB! 0413$AQ\R&-V
M$+;PKIMC?07;W=ND[1S1JA8N.52A) Y64;G?>I"QACE60N@8AE SG8$'/0BE
MIOPX_5@_/5R;^JJ#^Q_+5]+VC?U"+^]+_$I]Z+;_ -$OY\_-FOC\./U8/SU<
MG?JJ@_L?_%_^]QX?2]HW]0B_O2_Q*\]%M]_J2YVVR=OF_P!:^?PX_5@_/5R;
M^JJ#^Q_#Z7M&_J$7]Z7^)7OHEO\ T2_G_P ?W?+1^''ZL'YZN3?U50?V/X?2
M]HW]0B_O2_Q*\]%M]L1+^?I\_P#C\VX/PX_5@_/5R;^JJ#^Q_#Z7M&_J$7]Z
M7^)1Z+!XQ+[QG_'Y_P!_A^QOUP^JX<@B?=3)HCYB'_HF@_D[%_\ 5 /\H\/I
M>T;^H1?WI?XE>^B6_P#1+^?_ !JII;^%5_E#_P!(>3-+#H/<!^;'SD]-\$;B
MFR.D!T#]5NH5IC!;'Y:RKL#4;C*7^^U->&QU-XY8UHC"JR+=FQ<)-[+C:SR@
M.UTUC&=F/*G1,< %%%$O<HTW6^([S3+]K6&&V=!%&X:592^7!)!*2J,#P]4'
MW]:87-W)!+R*J$<JD%N;.^>N&&?Y]]6A_O2[0O\ [_-N_P#>?#7]RO(CZ<]1
M_JUE_<G_ (](?1&7[R/_ ,WA_:KU>W^R2:?O85TA0MF]DZW8CIJ RE+>WQ?=
MX5!42&!([J!AJ9C]\[3(KXG432LC(RA ,F55(Q@4+VG&E\&!DM+5U\50S1L1
M[&:20#W\A]U>C49,[QH1XXY@<>\D^WP-*K=3+I2[#],>_0D-DY2-O.+KPJ\3
MQMF:JMG+:N6=Q')(KR$%+QCI1=[5+;'H+IN%X-^X=(/&@G>PDI+MFSY1G<-)
MUFUU:-FBS'-&!WL#D%DR2 RL,"1"1CF &#@,JD@%]!<).I(]5A\9#C;PSGQ!
M/CMX#'7/@^E)O+:M!-T,59?83#IMCF;G(VAYP@?56&-L&*[+(M64^X=M$^X+
MR52\TKA7E2E!9*8A6[<5!8O7[=SUK.GIJ5A- 5!E53);MXK,@)4 ^3[HW_"Q
M/4 CVXB6:)E^Z YD.V0P&1\AZ'/@?=C6$*8IRE.0Q3D.4#$.40,4Q3  E,4P
M"(&*8! 0$!$! 0$![<QNJ_7K]OMM:H-4LMYN<TPK=1IT#+6BT6"57*VC82OP
M3!>3EY5^X/\ BHM&#!LNZ<*#W\4DC" "/8!Z1'D=(T4L[LJ(HW+,Q 50/,D@
M"O0"Q"@9)(  ZDDX 'O-*N9?V*D-H[8ZVIRNC-1N*H)R\B]:L/NBN"K1T#(&
M%M&3KV!/XD7REDEJFE*6)PNV![6(=ZA0$%21\#89"?P>33M2[=^-IN&K">W3
MLTX4OKAKN>:=(=(XCU30BSZWQ%KUXQ6(\'<+2)/#;0L[V>H7EJ]](92T-M'>
MNT;C^S^#EP7%8::7_P#NSQ?I=O+J5];H9M5X2T7755='X=T&!<R)Q=Q)#)#,
M\Z<MWIUE<Q)"L4DRW*_S4L.Y"SA9X=G:JR[N]R? 1]7L(QSH[*CT.+5$IV4K
MD9^B!0D)0$#$7-'.!(0I1.DX3;12JZL?5_\ [L<5=I&I:KP+\%C4VX [*])G
MGT'BOX38TN*_XZ[0]4LBT&JZ%V)Z9?>CVNA</VSJUK-Q>[K' K+=P7B7<=G:
MZI\X6/9U9Z9Z!KO;#ITG&/'>I+'JNB=C2WDD7#7#-I<\LUKJO:/>PF5]6U-P
M3,=*ES"78QFW: SW=O:W2NFA(2T0S3RSEJ;CFP(^/W#8H3&BUR-2.02"R0>0
M+IC(JMRI&$AVKUW,(>IV,1R=,O@I/<&_!L[*.$[Q]=DX/TKBWBZY9)]0XV[4
MHT[6>,M2O5=)3J-WJ/&T6H:):ZB95+>E:)PYI3CF(YG^,="O;KC?7+1+'4.+
M;WA[1T4QP<+\! \&Z'90%>[]$A&B26U_-;"/"-!?7]]&2 1L *\Q8.DSA5TU
M,-4R/F.J3!1!1"7)?+'(*HK%_P#,4(D668%\@'L('.90Q3 4P^8 )#;#+PQP
M[<6[65[P?V;ZOI[Q-!+IFM]EO9[?:;+"XY7ADMHN';0]TZ%HW1954QL5QTQ5
MI.!Y$83:=QAQUIMXK!X[VWXOXA%Q'(OQ9$8:FF''@YR<[[U6IM'J-L-@"*4>
MW**9;18604])5Q*,D4[Y7FIC!_TJ,M,:BVF49,/(?QWB!UW!C"V9J/.ZRB6>
M6?8'P'I6N2<2=B^NZS\$WM.GD+VO$G9O>W5UV2\27;#EBTOC;LOU>XGX<72I
MB1&MI;1V-E%(1<"7O8XXW@^)]<XVL=-.E]I&CZ;VY\!H%26UXDM8$XPTJ(9/
MI>B<664,6K0ZA'NPGG[Z>3ZQ&Y5BRUTY2Q]!9&I=-N-?O]G9Q%.L#27PUGN)
M4.US-JIDIHJBO$M)R09G2?2=05> T:2;554&CQD5L+19!RWA7*]P[/\ M"XC
MU'CS5^R3M0X0T?LV^$?IVGSZFF@Z--(O9C\(OA6U$AN^+.S22X 33^((H8I+
MR]X<,C7L+F<FW5H]3MK"!MKF/L_TVRX_X(UZ^XW[%=3N8=-U1M6 ?BCLTU*<
MH(=#XQ6/F>ZT_GD$-AQ"T?+$3")II[:>&>Y9*Z5V^DMN5B2T4_,#*-K&V>N<
MPPQ_L/5(T4B1DH^=-EG%0RO4R)>*2M,RC"M33L89L4K5I(IRK%F!XM*+=O=#
MO[6&,07=F7?3[Y#-:M(I66,JW)/:SJWK)<6LH:&9&]967# .& W2.:WNH(+V
MSD$UI=Q+-;R*0P*-U4D$CF0Y5ADX(Z]:M+Y'5[2 7M:GSVM=_JO,?M4R/S1^
M#/L&[_*_^S%4QIWUI_QA_57Y:C9[,/\ 2G5?]".8OZKB_P#^<=\6_:=_RB#]
M+5W?_8YW^Z0@'^<^.]:2',MJ$JAKVB;3%/:SIZW.[5Z+4>Y0U:<N,W5$[5(I
MWCVIQK,6F6*^)A*=3W)>E>O;!0;E]X=3%*A$"&!,ZI#V+AB^]#U..-FQ#> 6
M[YZ!V.86]XDPF>@61B:=V4O=S 'XLGJ'V$G*D>WFP/8"3UQ6:,Q?/8QZSDHY
MVX82$>Z;OF#YHLHW=LWK18CAJ[:N$C%50<-UTTUD5DS%424(4Y# 8H"&JD @
M@@$$$$'H0=B#["*FST((ST\//8^>?$GV''7-:V/30VT:[N:0X V',X:JVBT4
MQK#9);-![)Q^3Z@<]9OB ("8RC5N\L$8[F8QNJ8ZH0TI&J&.H"@*&QG5K(Z?
MJ%S:[\B.6B)\89/7C]Y"D*Q&W,IJOSQ]U*Z> .5_!.X_,<5.WD=2-'"BE,/:
MM-P"4'7C$VFM9D_"R9XL9<BY%;-U0]1KB['#Y$\!'OTNY3E1MF0SLI"/5()R
MB..Y5!8I053$]RX.LN]NIKYQZELG=1'SFE!YB/P(@01_XJGPJ1T^+F=I2-D'
M*/PC_@/TBDIM5=>[9M=L=AC7.D@H2P9>O\!3DGY&XNB046^=E4L5G=-P42%5
MA5:\C*6.1(50AC,8MP!#>8EY?;RY2SM;BZD^+!$TF,XYF ]1 ?-W*H/:PJ3D
M=8T:0[A1S8VW/A@^9) %:]>*\:U+#6,\?8DH4<6(I.,J96J'4XTO@(LZ_5(=
MG"1**IR$3*LX!DR1%RN)"F<.!57.'FH81Q2:5YY99I#S232/(Y\W=BS'YR<#
MPJN,Q9BQW+$DGVDY->^\3KRLTKVBW=A3:W?RSXZK4NG(8HU52?8?J7NJOJ,G
M]V(LU<9;GR]A%,ZQ[<T+42+I&.BZCJ7'.T3B1SS5>%[#T/34E88FO")W\Q'N
M(%^1#SX\#(14Y91=W"&(]:3UCMN!]R#Y;;^6]4C2&,K_ !6.JQEN2JDPRQK<
M[3:Z35KBNV\(:;M-'CZS*6J'8K";S.XB&-PKRRRADR-ES/5D&B[AQ&RB3*?$
MT32O '4RQHDCQ@^LJ2%U1B/)C&_M& 2 &7+KF7F*Y!90&(\0&S@_F/R=>N[*
MGLMFZ 8;VSN.IMLE2MJ3M#!@]J";M8Q6K#,>/6$C*1B3<3B#=L:W4TUBBG(C
MXJR4O#U)@D)UO124JO%]AW]G'>H,R6C8DQU,$I4$GSY).4CR5G)\PQOXN:-9
M!\9#AO:K8!^8@' '0D^=:#7,UJ'HX44<**59]K4^8YKS]:Z'^R'+'+AP9]L+
MK\C/[>&I#3OKK_BS^LOSUG^\TBI?K[-_Y\OW^8]EL'2&ZF]UZ:FR;"V*+R$S
M@+)#J'K>?:&W$RWQ&N(.%R1]T@FHCX%N5$/(/).($O@,LP6EJVLL@C,^^-(;
M6])CU6U*;+<Q!FMI#MAB-XV/WDF &SGE.&&XP6]S LZ$='7)0^WQ&_@VP.^
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M=\+H/%NP^9?AT%E2LL#*C^,)B?<Q;(Z*;#Y "=TEO2$H.U2USC*P^L:C&O\
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MZY4^PFNXW,;JXZJP/S=1[B,@^PUD(99QA<,*9/R%B#(,6K"WC&-SL=$MD6L
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MHM+U=D86NJV99A:W$<A #-/$O.4 #EQ*\4?(LT-G<#%RT7.,&\I"R+&6C79
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M 2?,EVRJ*+@K1Z_;.K')!%*T+R(&>"3O8F\4<JR$@^U692#L0?, AXRJQ4D
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M&YMHY!EW.) ^2QYN8$@_6ATL^J1,"DTE<MZ^UYD94I5GAMB=AKD=)(G8PB6
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MKZ_Q&TK%*PJVH$RGD&Y2]<E#3J-WMUA,=FTCZI/)+L!83C( <'<HJ"X!9,4
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MA@CKR@>(-1^_#4[3_P"@6O\ _NID7^];CCZ"6?W]S_S(OX%*>BQ_?/\ .O\
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M)-/>Z=F?'=L;-W3)%_%K+MGJT*1FOZ4@U532<&534$Y (;G26"ZA 2"01,I
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M5HV0*6IW=R]W<27#A5+E0$7XJ(BK''&N=\)&JJ"=SC)W)IB[EW+$ 9Q@#H
* JCV!0 /=7__V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>16
<FILENAME>g164680g00y02.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g164680g00y02.jpg
M_]C_X  02D9)1@ ! 0(!>0%Y  #_[1JL4&AO=&]S:&]P(#,N,  X0DE-! 0
M    &I"^:  X0DE-! 0       \< 5H  QLE1QP"   "    .$))300E
M   0S<_Z?:C'O@D%<':NKP7#3CA"24T$.@      Y0   !     !       +
M<')I;G1/=71P=70    %     %!S=%-B;V]L 0    !);G1E96YU;0    !)
M;G1E     $-L<FT    /<')I;G13:7AT965N0FET8F]O;      +<')I;G1E
M<DYA;65415A4     0      #W!R:6YT4')O;V93971U<$]B:F,    , %
M<@!O &\ 9@ @ %, 90!T '4 <       "G!R;V]F4V5T=7     !     $)L
M=&YE;G5M    #&)U:6QT:6Y0<F]O9@    EP<F]O9D--64L .$))300[
M  (M    $     $      !)P<FEN=$]U='!U=$]P=&EO;G,    7     $-P
M=&YB;V]L      !#;&)R8F]O;       4F=S36)O;VP      $-R;D-B;V]L
M      !#;G1#8F]O;       3&)L<V)O;VP      $YG='9B;V]L      !%
M;6Q$8F]O;       26YT<F)O;VP      $)C:V=/8FIC     0       %)'
M0D,    #     %)D("!D;W5B0&_@            1W)N(&1O=6) ;^
M      !";" @9&]U8D!OX            $)R9%15;G1&(U)L=
M     $)L9"!5;G1&(U)L=                %)S;'15;G1&(U!X;$!7_)O
M        "G9E8W1O<D1A=&%B;V]L 0    !09U!S96YU;0    !09U!S
M %!G4$,     3&5F=%5N=$8C4FQT                5&]P(%5N=$8C4FQT
M                4V-L(%5N=$8C4')C0%D            08W)O<%=H96Y0
M<FEN=&EN9V)O;VP     #F-R;W!296-T0F]T=&]M;&]N9P         ,8W)O
M<%)E8W1,969T;&]N9P         -8W)O<%)E8W12:6=H=&QO;F<
M"V-R;W!296-T5&]P;&]N9P      .$))30/M       0 [_^-0 "  $#O_XU
M  (  3A"24T$)@      #@             _@   .$))300-       $
M>#A"24T$&0      !    !XX0DE- _,       D           $ .$))32<0
M       *  $          3A"24T#]0      2  O9F8  0!L9F8 !@
M 0 O9F8  0"AF9H !@       0 R     0!:    !@       0 U     0 M
M    !@       3A"24T#^       <   ____________________________
M_P/H     /____________________________\#Z     #_____________
M________________ ^@     _____________________________P/H   X
M0DE-! @      !     !   "0    D      .$))300>       $     #A"
M24T$&@     #-0    8              0D   )=          $
M                 0             "70   0D
M 0                         0     0       &YU;&P    "    !F)O
M=6YD<T]B:F,    !        4F-T,0    0     5&]P(&QO;F<
M $QE9G1L;VYG          !"=&]M;&]N9P   0D     4F=H=&QO;F<   )=
M    !G-L:6-E<U9L3',    !3V)J8P    $       5S;&EC90   !(    '
M<VQI8V5)1&QO;F<         !V=R;W5P241L;VYG          9O<FEG:6YE
M;G5M    #$53;&EC94]R:6=I;@    UA=71O1V5N97)A=&5D     %1Y<&5E
M;G5M    "D53;&EC951Y<&4     26UG(     9B;W5N9'-/8FIC     0
M     %)C=#$    $     %1O<"!L;VYG          !,969T;&]N9P
M    0G1O;6QO;F<   $)     %)G:'1L;VYG   "70    -U<FQ415A4
M 0       &YU;&Q415A4     0       $US9V5415A4     0      !F%L
M=%1A9U1%6%0    !       .8V5L;%1E>'1)<TA434QB;V]L 0    AC96QL
M5&5X=%1%6%0    !       ):&]R>D%L:6=N96YU;0    ]%4VQI8V5(;W)Z
M06QI9VX    '9&5F875L=     EV97)T06QI9VYE;G5M    #T53;&EC959E
M<G1!;&EG;@    =D969A=6QT    "V)G0V]L;W)4>7!E96YU;0   !%%4VQI
M8V5"1T-O;&]R5'EP90    !.;VYE    "71O<$]U='-E=&QO;F<
M"FQE9G1/=71S971L;VYG          QB;W1T;VU/=71S971L;VYG
M  MR:6=H=$]U='-E=&QO;F<      #A"24T$*       #     (_\
M #A"24T$$0       0$ .$))3004       $     3A"24T$#      0>@
M  $   "@    1@   >   (-    07@ 8  '_V/_M  Q!9&]B95]#30 "_^X
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MLHXS;<BRJG]D6EX:YMC*XM]-\M]#]*UGTUU(F!NU
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
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M@I*6HK+7*3A59W*'IK9C<W:3E+72*$EDA(:CQ,?5_\0 '0$!  (# 0$! 0
M          $" P0%!@<("?_$ &(1  $"! 0"!P4$!@4(!08+"0$"$0 #(3$$
M$D%1!6$&$R)Q@9'P%#*AL<$'0M'A(S-28I+Q%19R@M(7)$-35**RPC0U8V34
M""5$A).D-U56<W26L[3$T_(F-D5&@Y2CI>+_V@ , P$  A$#$0 _ /OXPA#"
M$,(0PA#"$,(0PA#"$,(0PA#"$,(0PA#"$,(0PA#"$,(0PA#"$,(0PA#"$,(0
MPA#"$,(0PA#"$,(0PA#"$,(0PA#"$,(0PA#"$,(0PA#"$,(0PA#"$,(0PA#"
M$,(0PA#"$42X[^FPNGHY[Z\^(MM-=P$/D Z;8Y>/L/7WCZ_&YQ3#\G;SL(\
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MD4>M#W2510:P53J#5'LU'K5B53UI\H#SSD2,S/MN;92D+VAHM)3%1UF*%/7
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M@O$$$/C*0>%P"+E$0"_'<]^\-?%3.<,D4;LT#[W:[\W:EJ1.'P2$@) 2 &N
M%-2N8J*JJ!+.^5T6>)ZDY?J,U::J2S:CTT9;R:B&%V\EKZ)#%.1 X> ?4P#8
M4$1AE*00 Q1   !&P 4 PP2=PY8O8@/3M6?4N"7-:QDQ6%$U@P6 !?,EG)4X
M(4 '-*@BITB1'H52%OA38J-35G(Y:11'# ID5,24E/*QS+*69&6#H8 (%(9Q
MD$ .8"@:+H8]S:A)6$@  4<4RW85)()+JJ*]FPN0-63AD2V2E*$@%3 ,X+,Z
MB5%2LZ^T'-*,  (IM RI9?&Q46<JZVZ,4\0JE3\THS<T]$UO),@J"IK 76%:
M(>_ZCKQP$XQ(@@6*?B$#&$QS6P^R *?*G,:BS"[LG.R2/NBJ'JP+1(P@2IQ*
M 5<*!&7,7=64K/5J2_9 )0#V@*.;%4'[/JCM*E57>+Q:S&J94D*I/*I#=?D^
MQBI[C;X.]7]<(J2!@-$&(+;-82..Y0A"(\ 0@*(!08("[%NT ,SU% V86(<E
MB:@$FC0C !+9D)64]HU47+ A)&<)8-F<7V(C,!^4S8]4FK/LNH[41WDTUP !
M50%V3!13)T $!*(@(V"PV$I@$! =A <",UP*/4TJS'=B]-0PUI&8X?-[R7#N
M0^MJ$*! ;2V[L(M4FY1<LZ$W7 TD2AM.4YMN@C:(Y$*5;:1()JX1EG [/*M@
M @!P;)Q$P"<#<(B8PWXC@84)+T<5H[/LY-F<NQK2S13V1&S@$V8:T!45Y@S]
ML!@IA9@U8U/R\45K-&;<S52F#,J%-M&9&;;LRZ6\D*8)XV .$HG.(=W;A$2&
M "&L'NWXA&/9'N'8-;*5!['*H%G?5Q9ZL=B?("PRD.H#DEQL6*3:CW:,6:]Y
M(91]M&G++I&%(6$R*;N!PK1J6/JAC0JK39>%:&(KB R\6(V%]N+0+IE81.TG
M5"B&*M& XC:&&,BL%F2D)<,2Q+&A#U6&))J&)(]T"D<?%</$Q*0@9<A6,I"2
MSI=BM.514HI("25@.D @.8YJ,Y#:.L^BTY2FK:0S*T1%ZH+DJDX8ZFQD] ;,
MF]'<(" LA!(,0&0BEA@+?($,HQ[&B<(PR1!*&M+P*DC*0 DJS*;)0LS.5.E)
M(8@]EP#E) ?+*P'!I"0B1+"4]9UCJ]HS(6L)2".L43+2LI"<M)>9*.R"D-F%
M3ZF;'I,U9)ETR:C>93131$95!0$6'()TH8?[*PV$3#_?F->]Q$0&^-V7)2FA
M&YN0SN6S D%F[BU8ZTC#8Y8!PB01WRP=!_I5N:<GU[[3(>3;*\WG%#>B-0NE
MZ2[83@,[99;3&VC)RG(N/FL(\6'P^HC;\0P>[+>]@UN&'V9,E0(<,7S.[JN&
M25%@'L2?$%AHR>"<.XA,1-QAR+EK$U"SUZF6@Y@I*),P, JH"PHDVL#%PZ?4
M0I/2A2>:[36GS<9:E4!5!7>\X@RWH)U]3N)O6ZX8QQ$T2ZRL'XA"X\1C<0&$
M1Q'LB9BCE62]' 8"@N'!":D /&TGA6 X5F]@!!F%*E ":E*2I2G $V9, 2 7
M(2 D9P &26YW%1NF[AJ"V:K*[*;JC4!GRL\E-)Z3:007(BIZT3A,1$7#GXB0
MSE6%8A@(8 'CB<10XC&-N)X?A99"B05,1[LT$.;AEU())#AZ -9M;B.!DS,9
M+Q*4I6N6,LM;K2I)(2R@"H)=*EK(*DJ((20>R&M[4;*EETJBY9Y]/BB=.WF\
M5%,*DSJ^X$!$4E"=32%*B"(A$ "B(@ @$3[[4+&"UAQ"3A4'M&C,*3$TM0)+
MD@L;@%K%V5DQJL3B,*F04YI:&8$R@2<P +@I(((!RDL*@@@F*P@4%I%+B]/1
MZ=M0IJA-%,83W'T(I?:EC(R&=!14=:$#7%OD0!,W"A]YP^X(" 7#%U J<NA!
MT< AJ!0 !#)<$'4MK/LX8E@Q 20ZJA)2$NQ8. $J([3U<.8\J9RTT)G%:G+@
MG*4,R97*4MSV0IVI^J $6FV12?4H(R, FL" 4A^$ERB4I1$2B74V(,D4!%&N
M"0*)*=SK4V.X(H8.&30% HP!!*7 2U!FJ"IU$OF<$.0:="FN5K+W1EQJ#QIA
M1MAL-SJ,J:3FU] ;J.G*()IK#$2$4U[(:&?A 3%AB0#!]\(^Z8,SI#,EGU)?
M>PT3:I!-.9AE H SN]02VR03E0FW:4Y<;BM_N ?+S^O:^(S<NYBS"E+<OK>)
MR\^]P[FM;\_I:.V%POTL%OKW#2VVV@?7C+$AP^S!OC<4:UJ#XP$;6M8+^ >'
M^^ !TMM?SP@2S,P?D.7[P!HUG[XNECU$;4,(0PA#"$,(0PA#"$,(0PA#"$,(
M0PA#"$,(0PA#"$,(0PA#"$,(0PA#"$,(0PA&EA:[?_LND!754%3KTX(2HB*B
MDD*4O]#58.(J@DB'>AK3\!$#@4O"/"02[<(<-\;?L<XZ)#V!5:CL+[TJ2;ZA
M]SV*94]D.UB#K7[P-/NO?7+>.#]$*]E1RS .,?*A]<O_  [\OF&(]CG;)_B$
M0,'-/\CHW+GW1#]$*]E/_M@'&&_]P^N.MAM_!Y\?MUTP]CG;)_B_*)]BFW<5
MW<?-OA#]$*]E1RS .,>@A0^N-A'H'['F_G8/'$^QSOW/XORA[%-9Z7;4U\'^
M#^4/T0KV4_\ M@''_(?7'Y_N><\1['._=_B_+TW<[V.9N/(_AZIN(?HA;LI_
M]L X_P"0^N/_ (>8>QSMD_Q?E#V*8=4_$?.(_HA7LJ/X?W)_(?7+I<?[GG+G
M^+$^QSOW/XN?=X]W.D/8IO(>!_G:MJ"[1#]$*]E1_#^Y--_V#ZXZ>?['G+#V
M.=^Y_%^4/8INXYWIW[>,/T0KV5'*O[D'I:A]<=?+]CR_SMA['._<_B/X0&"F
MG4;6/X>9%(?HA;LI_P#; ./^0^N/_AYA['._<_B_+TQY/'L<S<>1_"'Z(6[*
M?_; .,/.A]<=/'2G@_5KKMOA['._<_B_*!P<S<:[Z>J0_1"O94?P_N3^0^N.
MH=?W/-L/8YW[G\7Y1/L4W<:_!_PO:'Z(6[*C^']R?R'UQ\?_ %>^'Y:X>QSO
MW/XC^$/8INX\CSY<CY=T/T0MV5%[?3^Y \Z'UQ_!3P1^K#V.=^Y_$?P@<%-&
MH[@Y,/T0MV5'*O[D'RH?7'\-/ P]CG?N#O5^ ,0,'-.H\CKX0_1"W94?P_N2
M_3Z#ZXWOT_<\WP]CG?N?Q?E$^Q379P_C^$ _-"W94#_=_<G\A]<=/E3SX_##
MV.=^Y_%^6G\H>QS-QY'\/5=C#]$*]E1K^S^Y/#]@^N.OE^QY]ML/8YW[G\7Y
M0&"FG45K5X?HA;LJ/X?W)_(?7'Y?N>[X>QSOW/XC^$!@YA+./C7UM>'Z(5[*
MC^']R?R'UQUZ_P!SSES_ !8>QSOW/XORA[%-W&NAT;ES^!>T/T0MV5&O[/[D
M&W_J/KC\_P!SS;SU\,/8YW[G\7PM^7.'L<S<<[^M?'2'Z(5[*CE7]R#Y4/KC
MU /X//'\M,/8YW[G\7?R]/WL]BFG4?'U707Y0'\T*]E0']W]R;V_</KC_P"'
MG\_AB/8YW[O\7PM^7.!P4T7('@>7+F/3Q>K+CVP60S-O5="H?0^K:NYJDNJ4
M5)Q&;\Y3*HB##G)-#1Q<:P<RRN-B7;XEAHD,\4P#.%$0 Q2&XC$ L+PLV4DS
M%!.5/[V[,P8&Y'?859Z*PDQ&92@D@ NR@7HP8$@5+.Q<BP)H=HN-:-:&$(HE
MQ_MZ%_P8X_\ :*'S\;]=-<<O'V'C_P 1C$N_@/K%/E^O0+]-[VUT'3?;KICF
MX7WCW'Z>?=XQCU\+Z?/Z>,2E-SMJ%P\M-_KYAC5C(BY[OJ(Y"E 0U$ UM?<
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MZ!R/WG.[B/A$M*L=PC$2%7RJ0+5S+SV&1JT<G>U(^&NK,JIU8ST5+R]'FI9
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M:N\F\VW;P-(41Q$ QC;:'ME0""Q=E$!J.:LY (#AJ,;9G U!BJ@.15@6'.Y
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M!^?Y;<L:8#  1J1AY4W-BWZ89J\L.5>>:BVHKV9M)K"L(KHE9I/@I;7)1QJ
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MN$IP>&G["0PS&A)K=LI#$]8;$NX 31FL_.]B4[AV"E$,P<!)>ZRP!+@LP[(
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MOIC/%:VJY#T-K#P^.I!>D-]-!M;IMH([<AM\>EM<(7I0LVUJ$VT+>.S5B&X
M-[ %[!N(@.FUNE@O8=_FB+@%V =A<D&EFV8.QOYK &Y1&_@ _P _/GOU'"#
M722_('\]=;[F-.WYG(_K8=/_ !J;5S_YKB[<[:?/X8]GC?UP_L)^:HZV-_7#
M^PGYJC>WKP\[V'P'ZKV\.F-,6%M;6O\ 'OUC4C3#GJH56NIN?;(R\J8(+CDT
M)I46SXM5PU2D)&(=NTX<]3J&"WJ9*RRMD*846,=QE,$N-A[Z(>&$,IQL4VQ+
M *#4!06G=V=-0!5Z48%["MM^7,"9;"X6DJ<5<%)IE':JDA+W) 9[:HLOF5JJ
ML@N]E@S4OL^*H4;J?E.K<YI',U7I48;53FROE5Y%=,1;2'DAK_M#5)!<8$C.
M&(ZC?K3:0\#) YH;HA%Q8Y74<P8  #-8!P0-JT#/W5$9?:!F67&5J#-9J.S
M)K0$ FIJ7 '!D/R1YE&'7O*XVJGTJKJVJDY?:VU7>]2JRR=%J2M^G*NG+*LN
MG5U-3S*0UR)4&NR-5)"6RMTK;B%B^RL*-PP212M@H'E03E+*272&%078E@'I
M<!BY)-J 1"IZ2E3$!T@ .1H; BA&:CAU OH(K:CV0>HK+RU]G2X);*ZKM[,
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MG6P0#2H#I=A4*([6A!;W2"0:5'D5[-)+RY.12S+YB'E.YD\\]2"0YRH%:'-
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M$$RE3$DKC/T).+ZX),Q8XS\7[H:7]*ETK]*@$,;!H4  2C;KJ7B^^ <<+V3
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M#*SG.R$U(F&SEYRN5#:LK#;C5B&I^P4%H.UE-Z<9:0'=!/4Y,NMQNM]XHL
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M'P1T[X_ZG\,2P%@T(C[*M?\ >X@_Q.G[<_\ 4^(8;"$0]E&O^]M _B=.W_\
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M9D;#W\LFRL$^G,#0H93!IT.'+?FB/B_(D-YD>K1[&$3#"$42XAO.P@Z2Q_\
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M_F/+7%8R!]7&WPJ0&UOWG2L0T'0-;<@VZ#H(VZB'(+7\T10T%6T%MC0EMR-
MS]\=1V&VU_J'0!#3K?37<.B)J;%K/\#0$4W>E;C:.G@ #O?\A#P'[= PA3D
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M-48DQC1,29<I)S?HUE0:I(=1%65E < N] 02'>(1.!0D$4"G1>@!+%V4P8,
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MXF+$%KMIK3Z\M8F_,:$$.3W,UZWN!%,M_M#LQS@E*3L5(HFUXE<ZH9G7C1Q
M,Y)"J[ IJZ*<LVFT*H2[5I)(]D"%4=$1H,-91P*A3#9FHX0D1?\ O?N4"%'X
M^O$/\84\PYORTT!:QVUK%-3W:79AX&7EDU8B4J8J?+K%7*TL%_5C3TFJ[PHP
MQ6W2%3A(:,]5-!9#><]1SMZHJ_W[:!>XC0VS%29J+%@3!XY/1E_I>@O^.FMG
MK"P\*UY;FNUR+7W5)[4:KJ/,-9KTOIQ3-^O.4R^(5=GPJ-F'6NIS+<$V\AF8
MK)IS3E593!),P%IR(">"P1R5#(V6U![PL&+&#N33,0[^-:4'<W*QYO$ ?A5W
MHSD][#O\8S8S)YKG?2;+;2:KC(IW#4:LUP>M#Z>T_I6_HZB@"+TK$II(G;[@
M&'W<5*5VZC@N1#B<Q0AS"4<ICFAB,,3VUM8OWU[W_G$@5Y;-LS>(^(8Z1A<W
M.T0S3>V"4B.2E5#9A%D,_P"EY(5M3;3JJ%&5G&HS,8D5;562EKB&<T U-$>$
MJG=3B7SA+NO[B26DVH2"8Y7?Z%-.7X>,=P<5-:%Q1K>#FMW-HNR@]HB^G:DT
MC4D-D-28B5OSZN[+M3F7"<5[JN7RG"HNP'G5@3%,43KDI#:JN!C0Q!L 4L(Q
MQL EC2/G3UW/ MS#5N-3>M+CR)$814:S-9IGB],MT=FU03X; S8YHLV&8M>,
M_7&[U=1:F7.BKO*DIE.TPH!%.QV&="1(P-)OMH3 ZG5#,830F6#K")%[<V%2
MVOEX[Q/SH"2*FVOY,[;$1='+QG,S&/&3I0R*1M]G1WU7^F68/.4[U+,;5)^K
MZ-3:F\&JL5ATR24"*(EF)=OKO==X#>@'EVXTXBE!BP^"%WG?*_A5Z#?R\@#
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MTU=@S-FKC5)>RFYFD4.(1(6Y-WK4W <!@K;EM01VKA<0 >6PCI:]A&VX %A
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M  A;B 1+<+@.@AOJ #J&-/,<,2*V[C5]P=@?!HK.)F'0N2;TJ_?H *-6L<X
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MCS;G08C=BQ^.(,("0B1+=4HD5!!< A0(< J.O(L>^U8##50Y!"G8AF<"FH(
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M(,K%) $HN@164,#-D F#F*]F4,QH2D.H)54!B0X=WV! T8C2OLBVHW9;,Q%
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MFCZ(6FTFXR6V@-%I(*2VFLW4I.2$) 14V"EH:,EI90(G)Z8D01)!3B0(? !
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M;7KF)1QZIE1:>EBK*Q)R;=>B"EJJ.@+GJM)6)>$J#*IBNJPX4)="9@#WA@-
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M%QH8^0VIW9KY=Z/=J4LL7,C+OCZ LZTPX710BHJ4[ 3P9]8%I3];*]/'@M1
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M,Q91-)SYLI5+*5,04IFH=DLP%)AJD)! C:])R\"2EI:0EQM EI3T*4-KKP@
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M]9#267]F]R_HS\[F;:O:'Y G&#<=L@,F8'&ZRH%BJZ2L&N(K)'5ZD5B< G.
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MYO\ CWGQI$T9)39HLGZ1(2<8$^*$PG!%EB#Z'%*6Q3P0, C#.',2<%[!<+E
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MBHE%:?E5FJU&W*3M/G>G(Z&AI2C"1CA% S1;Z*EHI9B#$-&=(08,PY!C&*4
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M)DPLKM&A 9(H #HPVIRB#,ZX@ M?X4>H%JZB[Q.4I2AH%@W'</(=1Y!]E]!
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MI0;>.A^?,+48H@.7: <@7"P5-BF* A:^I:? -].1K[B-@QS#]CF,1B%RU<6
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M[P_$;CIMP\AN&*)P>.EN<K:GM2C\E$]^[Q@F3<.LAJ\G5?Q:OU[@8[$$Y#%
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MWEX4NPA?:^X:7\[!?2]@'7<+7#EIA![/<4?O8/1V!K<,XTI =;!;4+_9X#H
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M]WAR^/["-;=//]C_  ]FF_N^?Y17V>9NC^+\HC^B!.RT_AY<O/\ N(UMY?\
MN_P]FF_N^?Y0]GF;H_B_*(?H@3LM?X>'+R_N(UMY\OW/_P N5\/9IO[OG^4/
M9YFZ/XORA^B!.RU#^[PY?Y$:V[=?W/\ ;#V:;LGS^'JG.'L\S='\7Y1)^B!>
MRWO^[TX;:7_81K=I<;?O _!Y .(]FF[#^(1;V6;NGS-M#[MCIWQ@%F3S@?F<
M[-Q4$E4LQ/K&HC]AM^0:T1P0F'G!:TQ$1$DYCI263V*1&Q"5H917/=*:''XB
MVXK 0 .,A=7:^OF26?GO4'8Q/LQ#@*30!J$.=0]@S'?4:%LSF+VX_9"TU9#1
MIRRJR+B R*?M9N--KHLK0NOHR*&W49)AI*&DEO3LPF[E%@0RD&()C&AE*>*>
M)%*%@P\PO[M*7_*_D=XI[-,O334ZA_AF/=L&BLOT0)V6O\/#E#SHC6W_ ,/^
M>)]FF_N^?Y0]GF;H_B_*'Z(%[+3^'AR[VM]"5;?_  __ )_##V:;^[Y_E$^S
M3-T?Q?E ?S0)V6@;UX<O\B-;?E^Y_A[--V3Y^O0[GCV>8;%!_O?E#]$"=EK_
M  \.7E_<1K;S_P#=_P#ERP]FF_N^?Y0]G7NC^+\HC^B!.RU_AX<O\B-;?_#_
M ,_D.'LTW]WS_*'L\S='\7Y0'\T =ES_  ^.'X41K9^%@_SZ_+%D.X^/X1;V
M2=L/,_A%A>PL?S6JN[NT^JNR)V85&54O/<_GVT%>/(K"3%6FV\"Q5M&5O4BZ
M0JTCG,DJL*&!3"2&< ,(6 H@$J?;OM=G[C8>34HZ;)"$I!9R"#VB:A)-R0"Y
MI_PN33Z&\8XUH80AA"&$(80CRU5*3UJ2G$M5DY512U"6/***=/RQ)N3G92(!
M@/!BPHEX8@;B&X& PZ /!<"&!$6K]7H'J+W$:IG526J&2ARS]4,N4I./JBZQ
M'%0J?E_ _?SJ,'$)CNJE81#Q#P(D88 FF4XYQXN 2B2)!&&=K>]1Q:3TZ,J1
MQ>:E&)4@29>*,L(ZPIHA *$X<9BY(!5E4LG* 2E,?,OZ'F=!$S<1P:6J9A"L
MS)N%*U'(DGM$IF*Q'92S9@G,$,%$!)?,>E69RBU:D5GQ6F[$>95WF=2*CM*:
MGRRCC*HHJ8=774M138I8,S F&_+ )YL@@)80% "G/[L2+Y+C'!.)]'2N7A<-
MU@2L,I,R6F6M"W"5A<U4Q0)([2&S)< LE0CV7".-\-X_*0J=-"5-VI:NMZQ"
MD%!6FB):"0%.A:B4K[5U!0/R.OP0![/&VX/%T@.X?Z\F"_U7'\A']?<-1G[)
MU&VKM1F[F%(_&V-&29F)H5$/:M#SL/EN8O-37-+56E;+%B-4[3BM85Q57I2
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MZQ I_'64CT>9:_T>S3E!L)85 GJ="42^R0NRX+HH=C&,!N#C$_W2XGN.*?U
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MZ;V$=!VQS,1A)!1U/L065@@$XE:&=J92H A]20[Q14U14)ADYL@][K &J[
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MC)OZT'EZ.L8N9O\ +0SLX&7Y[43=X0( JTH*HRUTTI<&4^$>WJ1VAPZFL8>
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M<;BNS.'+V$-]!U ;#K^+F&VXB.H7QK1CO0U!8U_#46N2:AX@&MQ'34=PVTN
M^'7GYW$;H@5<FE3<6HX/+?7O<EU].5]M/ .H"-@\1M8!Y;X0>FCVIR&X)8<R
MS Z7B;ZK %K?6%[;;;:X1;X, S?$.UK6K#3KO;GKN.GVVY_+"%-[MK6YI\VU
M\H!SY_'GJ/4;!KISZ\L(#77QUJ=RPK37?2/1&F%,Q_M!8UN@M9%YB/+T7Y_,
M>5O59U_M*_B/XQM=>?VS\?PB/T7TT_>$QO\ JLB_XKAG7^TK^(_C#KS^V?C^
M$0^BJFO[P&3_ -54;[/1+89U_M*_B/XQDZY?[2_XA_AA]%5-N; 9(VU_J61]
M];_ZEO8>@WVW'#.O]I7\1_&'73/VU6W'PI3Y\X?153;]X#)Y?VK(V@AM;]*^
M?+GYW9U_M*_B/XPZZ9HM6NH_#\[,0T/HJIK^\!D_]5D;I;7]*VV\/PX9U_M*
M_B/XPZY?[2O,;N?NQ'Z,*:!_:$QO^JR+]GHO].&=?[2OXC^,8^O/[9^/X1#Z
M,*9_O!8W_59%^&@2OEUVOY,Z_P!I7\1_&'7G]L_'\(?153;]X#)^+51A_P#\
M6_X Z6TPSK_:5_$?QC)UTS]M3\BP\FA]%5-K_P!0#)\A:J-;ZI4/'7\&@LZ_
MVE>9_&'73-%J\2#\6]7A]%5-@_M 9.UOZE4:X^8^BX9U_M*\S#KIC^^K74:^
M',Z6H&: 4JIJ W]@&3_U51K?#]*Z?/SOAG7^TKS/XPZZ9^VKS ^F_P *0^BJ
MFVGZP&3<+#?V61KW_P#POVX9U_M*\S^,.NF?MJYU'PI3T(?153;]X#)V /ZE
M4;E__*^ :?S69U_M*\S^,.NF5[:O/\M]FB(4PIF(@/L"QQUV]ED6]]MO1=-^
MGX\0YW/F8Q]>?VS\?PBH4INMYOPHT!"1$A&@QM8T!)3I%/*<=;B<LO"A$.%M
M+& P .H!<<*M5V?5V]7BIFDLZU%J@5TMX[&D>]B(F&$(80AA"&$(80CABP84
M2'W<8H&(.X7,%Q\RB ^0WY8)=!!06WH[NV_KOM&-24J2$S [NX<C7]UN4:<J
MH=GE4:6K['S$TAJ(SI%9*\Q<TNRU5MS+62Y6%$A$@3:4+@29MRQ8A%Z&>.$W
M$BM?OS"JQC@6(?A WT?AGVC<*X9P^?P[C>$FXI$_"KPAF)FKS#K9/5B9^CPZ
MRJ8@J"PY*E*2X.8DQ\IX[]GG%.(X^5C^"XV3A)DO$HQ*4JD2RD&3,,X B;/
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M$).!QDBN6P?WI7@_;-R=NZYBL[&86:H!*TUW*@UA]Y-BPJP&C/6/7AEL #
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M^B$K(KU*^T^R<NXSD0EF7>RN9MU&3D-;*MLIVH:*NF@H!8;G_4=M0W)8L/\
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MN"&25!2C52DH!!*C6-L#0;TJTFVD-Y.&-Z"AI2<D2WI 7V "![PB:^NHC<1
M0Y#OY7%X["*43E=PX#S  :DFB'-]:UVI'K.'82?+0A"9A=* "2)=R2I9"<U!
M6@=MJB+>9@J+M+,A16J5#'H*C*->J;446DKS:5,&%2D3JQBBCJZ0;[G86TN<
M+AL>Q1X;F X ),8.&\5PZL9*[#D+2P*EG,"H4;(F[&KT)%#KT<I2 31J@DBH
M.:P+BA<J(&N@M\H64'LYZ?ST',EEA7)1?IGVC>5]Q"YJ:5 EG>L2#<J(WTA:
M(LLMT(R/WQ *(_J27V@X8?LT5<;;R*;^JDH?3N*<>DR\/(*!+.'5+(6"B?UH
M662%)F/E"#F<H,@J&17Z3M) D96.]6#@Z:AC7QU!8 /&W>//3/:09-H8S\"8
M1,S5 E8\F[6<<_JM2.]T&Z2L)@))S@8Q77!+Q@3@ P.@@M(QK 8V. A>$E*'
M9=)=WZWLEW]YR]"  $Z.5."#YS%X3%3999650(8@2^T&9@EQVGJ5%3NK* 21
ME]VF&7"EM6:'-YYT9;\RD/>.JIJ,]DM?<:S.F:RN$4"/*&)!C&#B IBD*(%
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MD20PK[SL&(9AN&^9%"*  /MT;DTM=HMDX6Z8O>'';V:W+PY02'>WYH\1./\
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ME8'?YV\@0WA'T;!X824@"JG435W)8'6C!(O<N:4$5A%B 0+\AUVOT"_]ETZ
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MR_Z+^<5_J-T]_P!FF_\ ^I_\7 >S]S@6 !HLL@(CH47*RP'P"PN3732XATL
MB%L/Z]= O]IEBKN_%*4L?\U-.\1@_J%T_P#]EF:.,O">Z_M;;;L!Y1'L_<X(
M6$:*K0!S$7*S Y!S]I M<1  '2PA?G;#^O/0(_\ I2//BNO=A-+[UIM#^H?3
M_P#V6:;GW>%:6OBK_%ZT$2_G?N<$0THLLB6PW$'*R[:7&U_:2X?4/SN,GIST
M"/\ Z2@>/%/_  GUVYF']0^GW^RS6[N$_+VI]=FN^L [/[.$-[466=1TLYF6
M.NNO]4H@(6"WC8;;".']>>@0OBI?,OQ2G_NFW(^;P_J)T_\ ]EF^7"7-_P#O
M?+Y;B(_G?N<$ $?H66>$-[N5E@  -N8.6VH&N #?XCA_7GH%_M*//BG_ (06
MYN*BE(?U#Z?,WLLT:-EX3KN/:K;_ )AP]G]G"TO198U"X7<S+L/B'ZY U&^@
M!KX8?UYZ!?[3+TUXI7_W3SL-HD= ^GU'PLTA_P!GA0__ !3^/RB_\I2CM.9&
M19:5*--=@2U-T2=;S)N:C JJ.DK"4" IIGK@8GO 1%*4D**(F$#E*!3<12@'
MF?Z6^SL*FJSR'GJE3)I*N)M,7)4#*6I/5924*#N '( )I3T8X9]IK(3U$X"6
M%H0!_1!R)F!EH!"R64"7 -E*HRE/2R5EM[1!OIC+1$!ANI(D:;KRDZ&5ZN5Z
M8R()*\N=Z"RH1 ,XQ[V$;OHUH1P.01BQ X?>,!KJXU]GR\^>;(69LM,J82>)
MJ,Q S]A3RR%!YB\H+@9E#4O4<)^TI&3+AYZ1*6J8AOZ(["CE=22%C*>PAU @
M]E+F@;GJAE[[1>LP(\*I+$75^70QGC),F$]3-NR$H99*!%<\1)0CM9 B&$I0
M (D0QS&M<3"(C=P?C7V?X8J(GR@I0&92E\5,Q1 RHS+4A:UD"@S*)K4U!B>+
M\(^TG$#_ *+,4FX2!P8)2Y)4 A*@E"7)/9#"U*Q[E/*0=II2MKS3-I^UW4A-
MR+.3\W+I<JL4S513A6C"95!(6%^(9PH/"8XG(5M7X#&&)# #")AKQCBWV>8Q
M0FYY*U)"4J6%<4(4 3E3,'5I2L)424!8(2HDI93F'".&?:9A0)?L\Z6DE92D
MC@Z6*@ K+VE%)4D)"B@@J2 E1(,>4@T#[1IKGI[$0V4NIYZ917K&I^>+.4N4
MCI,6H9S1'D8XF-Q1O79SF.3VIN$"((G*)1QD7QO[.9@GF89"CB.I$XJ/%B9O
ML]9.8B5>66*69B03&(<)^TT=6E,C$)ZKK.K#\(&0SAEF91G<=8**N5AW<4'F
M2&7+M$DLM-RIU/EB 2DR@J*%-0&<IB((,5P*1%I;,( Y+Q^-6(40*Y[E&$4!
M* D <9#Q_P"ST]>%*E$XL!,]SQ7]*GJA*"5#JG(ZK*E+73WQ5/"/M+'5Y</.
M3U#F4W]$#J^V5G*0OLLMU&KA1>E&[@Y?.T<BP$23@,IUPH+:>\_4=!-)K%,9
M%42WHLC%];*HK8.2QX9>^BF(34OW6(  /$;%N*=(/L\G$A"I"E+DRY"P/Z44
M%R4E91**>H8I!FK %CF+T81'"^#?:9) *Y$](ES%S4UX0,BU97F.)A*5$)3F
M-^P-HY:J4&[2&MDND2]3&6XG!+(I5*=298L_3)N)TJH*GNE6(J4A':PQ%Z%<
M0 3&-:YKC<QN*G!./_9W@2LRYDJ45)2"LJXLI:A+!" 5JE*64H#Y4E3 DLV8
MO/&.#_:9BPE\--F"I  X, DS,H60E*T@%6I2 [#5(:SP=G[G"$1$:++0V'7]
M<K+"YNFCE$>G,1L-AO?'=/3GH%_M4O=GXH&;_P!4%-ZQQ/ZA]/G_ .BS0_+A
M/TQ1:E*_0Q .S]S@ZA]"RU?33VE9=@Z:^TH>Z( /*]@$>0B,_P!>>@5?\ZE^
M?%?A_FGAX^,/ZA]/@W^:S6M0<)^7M3MX>$0'L_LX(6XJ++(7'7]<K+#I?9R@
M-QN CKR\;8C^O/0+_:4::\5#_P#NHOK8[0_J'T^_V6;Y<)W;_:FY]U8#V?V<
M$H:T760N%P#VE95K;!8?:8;]= Z:VP_KST"O[4CN?BGUPGAOWQ']0^G]&PLW
MRX33_P![&GA\HC^=_9P>=%EH+<5A]I6581 -;?KDOO<1$-MAWP_KST"H?:D'
MD#Q3_P (WS@.@?3]_P#HLW<=GA.I_P#I1K7D;DQ .S^SA7#]A59W$!#VF9>^
MVH^THCI< ^KG@.G/0)O^E(\^*&G_ /:&^E8?U#Z?_P"RS=ZCA/\ XN[4WY:1
M.;L^LY %$1HHM 3?B%QLRP@.PC=R%T =KW&XXI/^TW@<V<G)C)&6H]Z8*<P<
M(&WYT%"\9L;]G'3U6'.62HJ#*'_5):SBF-(+L ];FIO&7F1#*7F2I5F1:CW?
M=-9YMMY,27')1E>:66^I#)Q5QKK,(D,/4R]'A@)HIB01.,(X$-$_L# 0Q?"]
M/.DW!^,<.4B3BI<U2NK9"3,!)E3T*+),I!(!W!&4$O>/:?9CT;Z:<&QA./PZ
MD2FF&85?T:6ZQ"L@(ESU3%#.18N14@BD?19CX;'Z&AA"*)<>D["T_P!3'Y!S
M.7F'+2^N]QYV#'+Q]AZ^\?&G\J1BF7Y-^/CY13Y>?F'V"'EK?F(>8;ASL+<]
MQ_Y8IK]?7KXQ. ^/+D-K!O<>0\O#< "U\4B@//30LPNYT.G*X 9XC\=1Z:WT
MOIJ(VMY#M80TPAXU.U7H]*DLW<;,12-._:04:=-,GM3[M&<OR2:8JUE[ 9.L
M3>DC1H854HB( 9;35HH"8(@MCO%DD00AB?V1,)R1 %J-0 ]APV>)B_ZME;A9
M20X464?\Z8. $I4 "$">*YKE0$5GSE9,P#)[PJH<ASE;0AC6C'1Z!=[Z2Z)O
MYJ=H5EWD)EV4 S1-Y-E:S,B5$B=W;J'B,@+I0N<J"O'< >S;P*>X@\1<93AW
MKIL':5@S.2GHY,#%$Q:D,:)"<V,<Y9@!"TDJ Z^@4 I(4ECPY^)*%)6D.%&A
M_:(8E% ]* ME!+LZ2'SXR6TS<+.8:^_7Q"!,>=:'$-0'"WY64%.3$'UX)A1D
M7U,/O!PE6;GT][0!, @-_.\?G">E03H"FQ/NTL0'=P:O4[AXS\#D+E9BH,22
MI@PHP*3E<BN;LLP !85$9D1;B  &]Q 0N&EOE;;8.07YCCR.!["U/8D\[/07
MW!ORCN8DYB"[V +-1A;5G?Y58-$VX\_YOR_'BN(JH&@=S4@7/A\HQI:I&I.U
M/*-2':4T/=Z#/4]S]T DS%KIE<BA%>:=*\0!46BH!^O5'6=.$X-F&98*8P#8
M&FLKYC'^XM8,>ZX%B9*)7534A2%R\B@227-F[!((("DJ#%*DA0T*; E)%64&
M+6-F+U>INV[6I%K7:^$NGCH87:5Y>9&*XJ15U;T@BY@67)$AIYBJ6A$A8 >(
MX(C@AN(IFZ[S"0I?:M'#4XN@V.QA,$) 4DO1)4"0]P0X[:P6%NR14 "BDCRW
M$)ZYBD+0#E!8@**0I((+%DH.4@L0%.DU'W8SIR6T\<*2TW55Y[2X);QKHX@?
M2B@2TF,C((B3NBE!($_&)N%7#O#"(B;B*8;B B/F>/S@DLDDLH!B2* W+BOO
M4!L01<EM[@V!5E4LT*U.$I 2D;%2 K*SDA(8!+*N],W;;[\K<M1  OL&O+GS
MTUMCS<=EKWT;2I #V%=-=:5: AH(AOX>&@;=-=!N%_ ,($4)%^7*@MM6A</R
M$:ENTMR^.T#4YSU4$DPE<P.5.?%;FY>3*?BJ'2 !/[:M):X;<00RF60L V%H
M+3CM[P%,3VG1WBDM.#F8::$J1,!H07!25'266*J%)!2I"D@@DE.7'B$4<.F@
M%Z4H6'>]'<@TH*VB=#^36NOTO[3_ "^)<VJTXJV@IC;S+4_DIPH"4Q1]3G5E
MH;" K[77>-MF$ON1'4C-T $X.H;[>$PR3BIDQ:BC.HE*TW<$J 9RS@,H!(*D
MY@&#D<6:DH)4D!FRS$ER&(HHM]W-ERDJ40I*5&Z1&;629C.@B$\:ZO60,B.J
MOJN5WQ6I+<4BGH;8L)T,#I)N,PN Q5<1.<PW/Q!Q& PC?D<>G"=+6!IF#E1=
MP0DOF S%R#4DM=XC@.&7)!F*#*F*4<H"4  %LP0"P[2NR  $A)8,T9U"&X (
M"-^77E<;WN'O#J.X!X!CQ^#_ $:B2Q#N_<"/K2/38E6=+BR<K4(K4&]3<5^,
M2&#4>>PZ^7U?@PGU4&U<]SGUS/?&$,=-7KH2 ?KRC51VEV7=V+*<Q,XV7X@2
MV9'*7/ Y$WT23XQ?%-2E,=ZLU;$@AZ^M#.M' O*&9RL_NS1'.4Q?=\!Q4J7*
MZJ8 4+EY%!U#-F&A )"@_O)(*2"000\7JGP;:K4Y&Y(+@,:6818YU5$3"S](
M.U(R])<S,M!](Z<S\TC DYO]4! 1!%XU:XB(K[4<(PVW<0 @BB-HP 8#F#'7
MPF#3A\R5EE92I)T*74Y2RUU22DD;J^\"T>5Q\U<U29LNJ4K"2-0U>UV1V5,I
MBY4P+*!8QFWDG9CDGTM[YBGK) A.*OJN#EDFE+CZ"G(37*4/47><0B)G 8IA
MXA$0$P6W$3#CS''IZ4JH_9(3JX:[DC?+H:QN\&P1!5,4EES"6">RD.224LID
MD* R@42:4L,\K6VT$1#IKOIX!8!UL&G4;ACSD=EFM0DC:MZ<@P-6%-RXA\1'
MH-_#01UMOIL%QW =\(>).Q?E0FK7I8.;@WAOY;[!80'8-]^E]+\ML(7[KV#$
M&PO?9Z/I: "  &P!8+7T'3K^7/XB@" !8!@ST--_6OB;I8]1&U#"$,(0PA#"
M$,(0PA#"$,(0PA#"$,(0PA#"$,(0PA#"$,(0PA#"$,(0PA#"$,(1T?>_P7_]
MP,8.JPN_PF/Y._=O%,\_;R*/J!ZUC'6O&:6@&6DK6B5VJ8@4U*]C*L%J15SU
MK%]='1#) +)9?U/*S1N.5%:2>+O A  3!30CQ XR$@RL#<FM?=,X$N!8I)!
M"1<N:,^4M*9F,JE*=B<Z9*@"EQV@68G,: ,*E5<HB5GYJ\NK]D:9*C-JNSG+
M)5D<"NVZ;3*.H!.$=#A0T@%Y:1Y;NH<08:LB(9(<6;A3$2">&!R=["$3D+B>
MKP)9BD]JE)QS*2 ETZU<$E02R113D).4^V!^R6 JRY8RH45*.:K,G*IDI)<A
MR"[QD?8G^!#3;W]L3U.&-]/_ )S\=W[[ZQ3K)FWQ3^$1L7_ _P#;'#JL/;0,
MWZSF^KT<]\.LF;?%/X124@Z&Y/N%8:DFMI,RYFS((ZHX4*654^.LHR<OF5@0
MU%83"$",F$<!T=9/+&C$AA&!,BF@AP%BB496!).4I*F=CUHRYB2H>\2Z3<E(
M)<YCV4O)5BP!F0MG(=*I:G"0 ARU0NF1BI ( 06*C%6V+_@?^V.!DX>XJ:_Z
MS\=:Q'63-OBG\(6+_@O^V.'4X9]K,W6?C<?6'63-OBG\(Z4>/+0(9X\4Q8$"
M" B<YCB4H 4NHB(\@ >FP;VVH<1@P'ZY@"U$31448 "IM0.]XDJF@$E.]U(+
MOW^/\HH:G%2V%5UCM^H].%Y-=['=TL:=;SF28AHJ:KR)5&,FFBP#1"$B&*6-
M!B0A[R&0PF(8.$H )1==@2[3A4,6ES7+  ?=%'+-< O4.8@3L0<I$M3 @I.=
M!RDK8BY8A\]'>H=Q6X(1(8 !N"U[[&-8;_#?0-=]-QWQ)G81 _6-_<F:TJ6/
MQ\:1+S5"J*?VD_@#%GE>N-(T%Z.9BK+];"0ZV>QY.HSN25A5!,B-QC3JC$22
M.Q95IH\)%24<8LA% XQXT$0&'WQ@A0S]X>.OP"[SG)=RE$YF8%FRBY J2&NU
M7->NG)2W5ME*2RE2V+J551"2[!14[DLH)N !=J7BR\[+2\S+1"1Y>9@DF9>(
M4;EB0SE*>&<I@OH8#E$!Y .VEL6:1X5J NP-39Z/JQY4+7ZV:FR2"Q![27+Z
M6+=X>.UW?C]6&63M?^WKZ\Z7BO63-OBG\('(!A$0]X+;" ] OO\ &^UK6\I:
M2M[%M\P^;7^/A#/,2PRLUJI_#Q^,68:E<J//B5E8[5J.UE>"HOIQTR30A*I9
M/UN^&<95*[6FB18H0Q6UEO0TA8C3!4'TD ]61!+,# AC&& <*EP%=EF<"878
M.G*"0:N!N'<!P +];-400@9KEU(/:) )+IJ*5"BI)=18 O%24PJ:P:NM&2>]
M-7"F/!I*,ZM2,DNI$432$[/(2RIH*SW?$ & (2TDJ$(PB4HG,7C#B*)3&@2L
M$7RFA))3^FH5.IBY%G(-P2'#C+%5^U)+K!# ,29=D@)T)+>ZS6"@/NEI)JIK
M DZF)-()EQ)L*I2ZTU-^)C.[TWK6>9Z.J0$-26Q*)3D%-A*ZE!@%.)RF&(!R
MPRF I@Q;JL%9@Y>_7%W*B#9F <$*)2Z@0&8@5XILS424V,H!-$@5)<$LE3I&
M=DE*F42(N18O^!_[8X=3AN7_ /D_&GTB.LF;?%/X1C@H9M,MZ5,FEE*JK4D(
MT"MA,N9BS,]&*(5J.6Y:>#>$/"NF#D:T !"QHX:7IU>"20Z^T$FW7EB]B2*G
M=5M,SO%P,6H!I2LJBX+R0%![MF!  (-@6-$O'.^LTV7RF@53%]U,;C8+1*58
MTU54RD=3$K)A5+$WL,99&#+1?=<5N*4+![\0*8#1A@@(B5U6"%R7!J'G.Q91
M>IN]RX%00T/\[4"4RP1J1U5P69)S 48NQ%/==X[5$<R] LR":L*%#ZHLZI4N
MWXY9->@-=7,911#QP.,D181XY8"VD#&*0W<C,RL (@EB&(%^(L.>JP)<)-&0
M[=<XL62Q2[5+!A2]7,%6,24E2 '*V*E2RE1(H5."Q5S))I>R;Z$ P@4QR]T)
MN(1)<(@ '$(:&+IJ <K#;3D(X3Y<_K4&5._1@]H"7+H&#]I1)K6PHYB92U+E
M]I+'4."]P[@ "(&&+$,<#EN4+"0W$4.H#8 L;7G?KSUQGFIS2R):\JZ5RN]0
M]%,*AXPRUS4S"2GLZ%T%J$BP>[?6T>KB8O#"$42X_P!NPK_[&/;?^_+;3;8/
MJN&@7QR^(,P;QKKF+ZTC%,OM3\8I\O/PUVN(6VL'V_:&.;A?>/C]+^KM&/7P
M_E3SCDTVT^.H]=;AIKKK?EIJ&*Q%+4\:G>KBE:U?2E1#;3PO8/$1WL%_B.@[
MCKA"U.3L.9-V#^)H;FL="=3I*>E9F$I2TO,R4W)FD9R3FY0WJV>N7NA"Q1&X
M#O;ATT$1 <9^'8E4LCI(Y"=,I"797L@*2SZ%(/L^MLIS1L3L+V D,$T<$@T)
M<.ZO$%WTY1KZREY8GKEM>%>J9F]7K&5I66TIZT7356\^J(JBMF$BTSB\5_U
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MFP0N>$550IF;E31(?&3C (I1(0Q#"! .!ACY1+\_A8V#B]P?C6T7    +
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MG0K-C5+,B_\ ,;*U$:"B\:WKOK5Z/=EJ,NFD;X.A$!T+4XT6Z[P<IXT4I$-
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M6CPJ7+AD>HZPMH@.>&@(B$VE@A()EN(YS%F .)6F:>)#C0ROS]7T_F\35GY
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M2TYT,Y9*K(<1<9*_,QD)\-^,2)-(;G:SA@FDW-*J<<(IH0%)PRQ-:>O"S#N
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MWN AA!SZW8GE0%@Y%W!$0TMKPZ::AJ.@<A$+<OZ  11%&KEI2HJ:#0D-I_(
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MLU'L6#D'6(WWU#SOM]6H!^"P\\(E[U'>]OA4#Z,=8@-]1W\+6'0?KYC;GRN
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M/<5>[D6M>K1T$- Y (: .@Z<^8@%M?KPB:$4&@(H#0TUU(#5^,/ /'GKT'J
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MC"]PO:P=0Z:^0V\;<QMUP@[AV8;C:O<6YMJ6WB ZWVN-M[7L AJ/*]]+:?,
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$M'__V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>17
<FILENAME>g164680g00y03.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g164680g00y03.jpg
M_]C_X  02D9)1@ ! 0(!>0%Y  #_[2 \4&AO=&]S:&]P(#,N,  X0DE-! 0
M    (""^@B0X0DE-! 0       \< 5H  QLE1QP"   "    .$))300E
M   0S<_Z?:C'O@D%<':NKP7#3CA"24T$.@      Y0   !     !       +
M<')I;G1/=71P=70    %     %!S=%-B;V]L 0    !);G1E96YU;0    !)
M;G1E     $-L<FT    /<')I;G13:7AT965N0FET8F]O;      +<')I;G1E
M<DYA;65415A4     0      #W!R:6YT4')O;V93971U<$]B:F,    , %
M<@!O &\ 9@ @ %, 90!T '4 <       "G!R;V]F4V5T=7     !     $)L
M=&YE;G5M    #&)U:6QT:6Y0<F]O9@    EP<F]O9D--64L .$))300[
M  (M    $     $      !)P<FEN=$]U='!U=$]P=&EO;G,    7     $-P
M=&YB;V]L      !#;&)R8F]O;       4F=S36)O;VP      $-R;D-B;V]L
M      !#;G1#8F]O;       3&)L<V)O;VP      $YG='9B;V]L      !%
M;6Q$8F]O;       26YT<F)O;VP      $)C:V=/8FIC     0       %)'
M0D,    #     %)D("!D;W5B0&_@            1W)N(&1O=6) ;^
M      !";" @9&]U8D!OX            $)R9%15;G1&(U)L=
M     $)L9"!5;G1&(U)L=                %)S;'15;G1&(U!X;$!C$25
M        "G9E8W1O<D1A=&%B;V]L 0    !09U!S96YU;0    !09U!S
M %!G4$,     3&5F=%5N=$8C4FQT                5&]P(%5N=$8C4FQT
M                4V-L(%5N=$8C4')C0%D            08W)O<%=H96Y0
M<FEN=&EN9V)O;VP     #F-R;W!296-T0F]T=&]M;&]N9P         ,8W)O
M<%)E8W1,969T;&]N9P         -8W)O<%)E8W12:6=H=&QO;F<
M"V-R;W!296-T5&]P;&]N9P      .$))30/M       0 [_^-0 "  $#O_XU
M  (  3A"24T$)@      #@             _@   .$))300-       $
M>#A"24T$&0      !    !XX0DE- _,       D           $ .$))32<0
M       *  $          3A"24T#]0      2  O9F8  0!L9F8 !@
M 0 O9F8  0"AF9H !@       0 R     0!:    !@       0 U     0 M
M    !@       3A"24T#^       <   ____________________________
M_P/H     /____________________________\#Z     #_____________
M________________ ^@     _____________________________P/H   X
M0DE-! @      !     !   "0    D      .$))300>       $     #A"
M24T$&@     #-0    8              FL   -R          $
M                 0             #<@   FL
M 0                         0     0       &YU;&P    "    !F)O
M=6YD<T]B:F,    !        4F-T,0    0     5&]P(&QO;F<
M $QE9G1L;VYG          !"=&]M;&]N9P   FL     4F=H=&QO;F<   -R
M    !G-L:6-E<U9L3',    !3V)J8P    $       5S;&EC90   !(    '
M<VQI8V5)1&QO;F<         !V=R;W5P241L;VYG          9O<FEG:6YE
M;G5M    #$53;&EC94]R:6=I;@    UA=71O1V5N97)A=&5D     %1Y<&5E
M;G5M    "D53;&EC951Y<&4     26UG(     9B;W5N9'-/8FIC     0
M     %)C=#$    $     %1O<"!L;VYG          !,969T;&]N9P
M    0G1O;6QO;F<   )K     %)G:'1L;VYG   #<@    -U<FQ415A4
M 0       &YU;&Q415A4     0       $US9V5415A4     0      !F%L
M=%1A9U1%6%0    !       .8V5L;%1E>'1)<TA434QB;V]L 0    AC96QL
M5&5X=%1%6%0    !       ):&]R>D%L:6=N96YU;0    ]%4VQI8V5(;W)Z
M06QI9VX    '9&5F875L=     EV97)T06QI9VYE;G5M    #T53;&EC959E
M<G1!;&EG;@    =D969A=6QT    "V)G0V]L;W)4>7!E96YU;0   !%%4VQI
M8V5"1T-O;&]R5'EP90    !.;VYE    "71O<$]U='-E=&QO;F<
M"FQE9G1/=71S971L;VYG          QB;W1T;VU/=71S971L;VYG
M  MR:6=H=$]U='-E=&QO;F<      #A"24T$*       #     (_\
M #A"24T$$0       0$ .$))3004       $     3A"24T$#      6"0
M  $   "@    <    >   -(    5[0 8  '_V/_M  Q!9&]B95]#30 "_^X
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MI#VZZ./_ 'W;_;5Q)&Q^Z/Q6F)OYB
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
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M"B0R@9$8-Z&QP24S.5)WMM'A\"8G-$)$6&)R>)BUU#8X0U=C9W2"DZ*W_\0
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M&A8G8VHT!YYP<]3>N.8J<@\ZBJ>8FRZB@-"SP/L%^Q)Z=J^#$U_7Y./N_4J
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M8QEUUTGR1F_X677_ %ZWW?[VJ@U^B?"]FA[:*DZ]R6\\B_?N.$@8=(].>B
M:YEZE*MI>TLTW]HA:[V/[0E)T4/X1$BU$,:0]MJBH6:0\/MZO(<6Z:P)%A5G
M8$6$GUN.O@,!.XK=R<;:QA*(ID*IGJ4E61B)-]YH)-I-ROMB1=B!VP"+%91?
M.RH4^E.0/9 D+'SHN2%$A$Z9S)6&-'Z6O%56*2:S+D,'9F.E"3R2K\?B59MD
MV6ERD ! D2LB-,UE5JRPEOA@Y^OFI/C#<.X0Y[;P[[! [JQS #PB6V3(Z3CR
MVG@I*,.8'.CS6'Q#!V2&7&TRHI8YXUDC;N1M_(@@@D,K*0&1T8%71@&1@58
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M0VVA&,)0A&,)2G&$IQC&,8YI22Q+,2S,268DDDD[))/DDGR2?)/-B
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M!P<%D2NCQZ"1E9&4G'A\M@\/%+8SU6>Y4M3WH *WFS':DO2LKQ;>,%HUC>(
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M"^_+.$Q>)D%B]DLBU9(@3V1%I.U78JI85E#ENY5)"(Y4%4Y^PC=LX:#2B*Q
MNO)N.R'_ .SZGX%RW@D64L(Q+1U@_O?[M =/@6Y:VR+BL*SD.%<88;?-($%?
M^!L+ DEU;,X4T\<OWA<[P2CQ5V5DK^/)>Y.8J<8&OQSAF9$5W7]&LE*Z5FAA
M[OB+9%2OV%0R/,"K3[;\(6K%ZEER0Q[(BJJ[E4:SXN-"AHR.AXYA T?$@!QH
M S>/2V.$".V**PWCY\(:8:;;3CS\)3C'-7+(\TDDLC%I)7>1V/DL[L69C^98
MDGDU$6-$11I4544#V"J  /X <Y_+.7<<<<@]\US4-DQ@D9;(Q9?Z6<F6@I4
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MVSX5J6#>S9>LGHOZIR$ -.8>K#V1GN_:?N<O7G+<[GE*;(["ZGU)==;Z_O\
M9?T"R;9D"XNDLO1T@\!('!.!LNLER@XSL?%Y6^>&PPJ1(&0^\^A#:E9\^.EP
MO2.?ZAQV;RF(I?%U.GX(K.4*S0I+##*)2KQP.ZRV-+!*S+"KLJJ21K7..ZFZ
M^Z6Z/R?3.(ZAR7W?=ZNNV,?@@]>Q)!9MUC4$L<UF*-X*@[KM94>R\2.TFD8E
M6UFY'<5!BMM5[2!LJ0WL:T5.1NT-#IC)%P8BNQ13P9I;DL@948.ZV0.ZA(CY
M2"7,)PI#2DJQG,:OTYEK6 R'4T-=&P^+O5L=<L&>%7CMVU5H$6NSB>16#KMT
MC9%W^(C1Y*N]88''=483HVW:DCS_ %#2R&0Q505K#QSU<6@>Z[VDC:M 8U(*
MI-(CR>R!CRT.:/G3\<<<<<<J1.\=<YW,O03DN4/L[%1S>6(4J)DQPSZXDEH1
MPN-F714Q)[S+SOAX(8MPMI+)*ULX2.]E&_'3.8/39ZL6NCX1,D,3+92>%Y(;
MK1F5(YZRN;$2.@';*\8C9F10W<Z@\L_66 BZOAZ%EM21=26<-)GJM26M82&U
MC8I_AI9*UQHQ5FECE#]]:.4SJD4LAC$<;,/9K=VNW]R$Z%&EBR=F U)J[R,.
M/$R3P4;77R$C#E2$T@;,4(^2ZXW@<%XM)CR'6W$,Y;7A6:?V:RXZ<'5;5T3"
M-D3BH[+V($DFNK'ZKQPUF<6)5C39DE2,Q(059PP(%S=8X$=7)T,+4K]2-ACG
MWIQU;,D4&+^(:JL]FXD1J5VEG4I%#+,LTO[R(R^>6SS0\Z?CCCD%A=ET>QW:
MXZZ@["%)W+7XT$5<H43W7'J^BRL$%0C4@]AO[9LHX09PI B7E$-C*9>>;;0^
MSE>SL8;)U,9C\Q9IRP8W+26X\=:D 5+C476.T803WLD,K")I.WL,@=%8LC :
M>KU!AKN9RG3U3(5[&9PD-&?+T(F+S8Y,E$9Z MZ';%):K@6(HF;U&KM',5$<
ML3/.N:SFXY MG;-I&G:/.[&V+.L5RH5MAE^5E7V2"?:^Y)9#%98%#:?++*++
M(8&&&&9===>=2E*?'G.-IA<+D^H<I3PV'JO<R-Z0QUJZ%5+E4:5V9Y&6.-(X
MD>21W955%))^1TW4/4&(Z5PN1ZAS]V/'8?%0?$7KDH=EBC:1(8P$C5Y)))IY
M8H(8HU:26:6.-%+,!SC:IVI3MT4F,V#0R9,NLR[IK(3\O!R]=.6N/*=#(RY%
MS@8,@TC#[*_:<<'2V^WZ76E+0K"LY<_@,ETSDYL1ED@CNUUB>1:UNM=B E02
M)J>I+-"Q[2.Y0_<AVK $:Y$Z3ZLPW6N$K]08"6U-C+4D\<,ERA=QL[-7D:*0
MFK?@KV%3N4]CF/LD73(S [Y8W--SI..........4[V!KUUMFF-B5S7+Q0UXE
MZ\^)6GPI;$$6U)*?'6VIB7R2)B/<PVAS&",DL^G&<I]>/5XST725S&4.I,/<
MS*QOBZ]Q9+J2U_BHV@"N"'K]DGK#9'X.QM^^O'./Z_Q^:RO1O4..Z=>6/-V\
M>\6->"W\#*MDO&5,=PRP_#MVAOVGJIKV[AOEQ<YWG8<<<<<<<<<<<<<<<<<<
M<<<<<<<<<<<<<<<<<<<<<<<<<<<<<<<<<<<<<AMLN\35/M W&RY>QRZ7\5^I
MPS:"IZ=>'PWAW[4=;C3 8+"WF$'S<H0#!Q>'VG)*1%0XC*G'(HS1YJZ.MR6T
MWAGH_#C)(&MHM]UVL1ZD9]:/XG,](Z[P<E6&W%L'#,5L5]&,"Q)3K+<FZX_K
M^O\ A_GR=V2J0-LKI]5G $$0D@,@5T5E;H:Q\,+;=#(CR1%LD1QL<0RP7&FA
M.L%1Y@XY0CK3[+:TYZUF:G/'9KOV2Q-M20K*0059'1@4>-T+))&X*2(S(P*L
M0<4T,<\3PRKW1N-$;((UY!5@0RLI 964AE8!E((!YK%L^GC6G7UETSV6IA^U
M=43T>X"WL2 A7YB5PTKUICG;15JX&38:_;HCRE\6ZU2,,@72&/U,O%6<>3&N
M=7ALC/CLG4SO2]],3F*LHD^ FF6&(GQZBUK-AUK6:<_E)*-N1)PK>FOQ(4RK
MSF;Q-/,XNW@NI*/WGBK<1C:PL7J.#_@D>*%3/6MPG\<5NNA0,O>3"3Z9_.S9
M?HVF 6R=F>L/>[1+557E]#P^R'1@+A5",K6Y^FRJXE<VAPX0?T94>:!79!*?
M+3T6A+>'5_353[>^ZG!#U-T+GEN$*>[%DO2MKK7K0I.("L;OO4:268]C8F)/
M:/F.U_T=HA<GDP/5N(FI@E/3R2%;E4G\0AFDKM,'D1"I[V2NX!T80-$]B70[
MI=HCJU99G9\9L&:[T]KS ,QK=W@1!B*K2 #&B!"8BMV$Z3E*;26G%LRH,A,R
MUPQ-%QK;\1#0K&7"(@[RW[0_M Z@ZRACQ4]*'HCI:.19GQ]B5C=NL"'BGMUD
MCBNW/!C>&&&D*ZR:FEG8*LT?K/V??9W@.C"]^M.>J.H'1XTNP1(E2J--'+%5
MD:26M6?N66.:>6R;#1@Q)$I9HI.WFE429;GR=C;","D[Z='OP\:%%K)S7*'6
M"B1SG:O7_N,,JDBB"QAWK!;2@@I*Q/BAH^SC(D"-B0_&KMZ$UUQV/1XJ"2+-
M*\H7XB_:1606K';W"-51W6O41WBK*[GOEFDEF?URO4<3M<M.LEID,4:H6]&K
M S!C#""1WLS*IEL,BR3%5':D:)&MM<U7)_''''''''''''*STK_S-ZE_\F=#
M_P#-:*XY0>P_0?UYY9G'*\<<<<<<<<<A5XI0MR "P@U^%L,$;B8J=F"0E9U?
MFVQWAVBTLK4AJ0 (9?=$EX8I609>.>?#*3C"T.M8+$"SJOXC'+&W?#*H!:*3
M178!\,I!*O&?PNI*GY$;?#Y>3$S3;A2W1NP_"9/'S$K#>ILZ2-$74%H)T=%E
MJVXAZU2PB31$E2K5V%N959DRJIMJ)>KD[%@@G.V>!!E)^B2\8<06$)..'QPI
MQ=(281'F^N+NJ(YL=8Y;<9-6 0$F2Q'6V\/X;L31$>T\:O)6D \%^Y0S0;]R
MD_:%V0LDH4MS;2].5\D?7Z7O19"-P7?$W)Z]+.42>YEKF"Q)##F/W62*SAVG
M>;M5IZ5"6:.MR8HW)J%<3F>1M37"H-+/W"IC%XK.8M+'Q_?*/_4_M4M8SG&,
MKR[A.,YQC.?.>9?CJ79ZOQE7T];]3XB+LU]>[O[=?GOD$]*=4BW\ >FL^+W?
MZ?P9P^1^*,GG\ K_  WJE_!_#V;\>W,"5MARPIP#J2 +OD@\I*/X@):.@M>1
M3+J?Y90NVG!('L([>5)4F.I3=AD2?.,.)!&4HYK&;AE_#3C:PQ_]*0T=9 ?\
M;3,NI0-_NUQ*Q]CVC;";'TRM$F;J>['A8$!/P,;0W<[9=3YK18N&4O1D8 @V
M,NU&O'Y*F>0"!Y51Z1BK,RA\K)*LEPLSPYEML[XJ U2I K'VP0(,>AQ]J(KT
M0-E0L-"LO.MC(<),*?-EI&4DC<U>#T0[._JSRD--,1V]Y4:5579"1H/"("0-
MEB6=G9M;F<O]YM7@KUQ0Q6/22'&8U)#,*T<K^I-+-.RHUJ];DU);MNBM(5CB
MC2&K7K5X<&=K^0KI1$YJTT2OED/K,E:<<ES-'LCRL+6[G C"5N5*5*=4IQR=
MKS&$/D.**FX>=7A&$2.:7F?JM["L))$'( EUFXQ["2)6I2^6_OV&,KPWB1C"
MV<J!L$(ZYE*69F(>)%2XO IN I%#X++CDYXXXXXXXXXXXXXXXXXXXXY1FP;B
M-![EZ_51VKP4L1=SMFLB6.1&;=FJEFO49Z8>=KQ"FEK%<FVD9BY3+;C.7@%*
M:7E:<^CG48C'/:Z<ZMOK>M5TQD6$>2G"Y6MD!;RBUE6X@8"05F/KP=RMVRCN
M&CYYPW4&8BI=9?9_BGQ="W)FY^IDBR-B)7NXDX_!O<=L?(4+1-=4?"VBK)WP
M$H>X>.7GSE^=SSIU^HWJ(?>_9#I]JIZ3)A7;5$[T3&3 BEI>BYV(J(L]7S_[
MM;:U-"S46 \^VE:,NL)<;PI.58SCZ$^QWJ*;I/I'[2,_##'9-!^DC+6E *6*
MMC*S5+D!V" 9:L\R*Q!['96T=:/RG_TA^D*G7G6_V*])W;$].++S?:,D=RLQ
M6:I;K=.XV[1M+HKWBO=K5Y7B[E]:-'B+*'+"E=7=@+5<^W.M9BYQ+R-U:0ZL
M[EIFT:XZVI+KEZI1\V4V^CTH;;='L@.(^594,IQO_7G&VG%X0E:NIS/2='&?
M9UU6,5./[,=5=9=*Y/I^[L=JXS(?"QO&P)+*^/G,U:19 K#T5+*-D#@\!UOD
MLU]L/V8U>H:[#KCH3I+[1<-U;C5#>I+E,;CGDJVH6[0LD&<JPQ7*TD7>C^LP
M1F"@F&Z(VGVXMQNF]VUF*[5W6>N.Q E[,+EI"OG=>9S715@+ G(JGU(8U3U>
M-@@6T-LR3(C1*"0C''$,Y0E*]MU3T_\ 9]CEZ@Z5O6>@L72QV%D7#I'%>CZQ
MJYI:<4M2UD<D\02W!:F8N\#R-&8I8PK-LD<YT5UC]K.;;I?KO&T?M4S64RO4
M<,F>)DQDWV<7.FCD[5?(XO$X9)_5HVJ595BBOK&;"V:LWJIO17);RV9O> >W
M3T_I>PK[G;#_ &*F-AT675:[$BRLZ6<I,OLMN* G_O\ ]31# +ADQ2 FC\,*
M2[D/#&&7'&LP>E,/TM;CZ7^T;*X?%_V=J]&C#9F 8^F:4G4T&4K8/U[%-8C"
MUNPEPV_5DA[R5$H;N12.BZ]S_6U*UUY]D&!S^:'6&<^T.IG^EK!RUY<A7Z0R
M>(N=43P4;TLZS08S&V<.V,:&K.8X8IC6DC"3NC[C])=P6GL]NFY;AQ9Y][7E
M(TGJ7785=:EY-%8*V1/1 UOO<P5"_<(C7[#$%.*A7#GA7BVQG4,I(2VA*<^?
M_:7TW1Z&Z9H]/M1JKF,KU9U%EVN-7A-V+!4IFQN)K0V.UIDI6E7XL1+(BEU[
MBA+'GI?V-]9Y'[3^LK/5,64O/T]T[]G?26 DQZ6YQCK/5^6C.9SMVU5#)!)D
M\>I7&-*4E"QG2.I&N<WONA.HMJ]5.V[+:FH[7.QD:ZV06SC*<MZ_O[3P[QAK
MB/4I0D6\@[#2<MK3]W),ISE.'//(_P!D[#/8?KS[/W8&7/8-LMAD;R&S6%99
MHHXP1XEL1,"Q!!,=9@-D*.3_ +>5_LQE?LR^UB)2(^C.JX<3U#(A"E.ENJ%-
M&[/*Q=0T56TL"1QZ<B:^'TL8F;FNM!LK4EK?N-W*F-KF:E=WOLX/6FKMC@54
MFXSX-!J4Y_#D.'4:^,='DN2UI0EV*!?P2.B-(CVIA[^0%:\==E:+ULM]F?V:
MP8&//'IK#RY[/8.6^N.K3YC)5&R-DY"XT<B1P8\:GF4HQFBE>LIW,@YPN$RL
M5_%?;=]M,_5)Z9@ZGS%?I+I/JB'%MF9J/3N!NPX.K/B<=&\4MFQF;$@AK!9
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M(!.;XL<9>Y$2/U9:9O5-8E1*E<-@@"DN2(=KD5C^DF JN!_U*R4ZMY<0%<+
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M0Z*II7+PT)6R4.-G[H)9+<560E"6C,DBQ]W8Q4G0;N )7N&O(WSK(E$KQJK
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MM\OQ;/O_ (AK?.3](B%?^H+]3KNG]52SL$&:\H\V9H[K:T<UZA6&?TX&*1+
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M2\8:\X020O+CSSJLJ4M6?Z^?C"<8\)2G&,)2G&$IQA.,8QWD44<,:11(J1H
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M#);])S#&P4R=I*][>VR?D/<M\B5!\L.9#:K1SQU6FC6Q(C/% 6'J.J^"P7Y
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MUB?6^#[E[ /2]??X^<UO&^_[2\Y=<U#_ &/?<.^$-LW/^TO[3])7[.,NJ?\
MX7^X_7?;R[G#7M?I/KPC'WGC/,9/2GW+I5ZA_M%V+Y+XW[E]3X@=WX0GQW9\
M+L+^/N^(T3^SV.9U'7G]I27;I'^Q_J-H*F9_M+Z7PA[-L7^Z_4^.[2WX.WX3
M8'[;1YP*LGL=BZNYNSFDE:Y]^6]A-68O:+K@;P_^A^ZN6(7!9?QG[;]6]#>&
M\X]_[/TY]OF6^>C?NQ?NQ>IAF>ROW&^^*.,[]I\5VBNBV@FN_P"'VQ(/9ZF_
M/(^+'VC??3??;=$GIWU+?8,6F=&:]+4GP/<;<C4?4WZ7Q>E[2/4]'7X>>E*3
MV3Q.R.=BN:.56?TV1_24TIB^HG<2_NL_I.9%4Z0Y'JC<,?<8D<#(25EWV<C9
MPC"\9KDST7\+#]SKU.+WK0_$')OBC5^'[6^(]$54683=W9Z/>2@7N[]G7*84
M?:1\=8_M$W1!QOPUCX3[E3/"]\9WI\)\0;SM7^&]/U/B!$/5[^STSV]W/E2D
M]F<.3_\ :*[HI37\/F_PO_!3%_;<Q:?4W^G9G_UTAQ*J_A/O?>ICL)D<J]OV
M%8QZN79,]$ZJ?<Z]4AOBXOCOO-\2P-'3>M\)\+&I%O?;Z1FW#KN[Q[<LPH^T
MSNO_ -HFZ%*?=\_W7]RIGPPRNU^&-_XZ1@<?KO\ 7%?5G?;Z9UOGSJS'97]'
MN+=WSH94PY#*31DU86_)A\SRFR4Y_C%N7(64[#*5D3"DP^4&9;^YQY\Y:\5O
M-T7\1CCBQU4*PL@Y0WI,2;'P@9#_ /)QKHL:V0/4T;(:/N[#K0;=,6OVE?"9
M@9L]"&ZU(C!C%QY\5/CRLH'WP+;M*U+N]+8ID3%?5&P>WGRK8/8YJIVH6SLZ
M!3:&1XW&NV:V#>VJF.2APG]3Q:AY!Y4C@=+>1/TW$'EIQ+GW/W'\N6O%;DG1
MAOT'HGJOX O-][FY+BFOLA">A\ \*"'O+>IZWQ08$=G9Y[N4QT?VD+B\M'DQ
MT&,JL=8=/KCH<\N+20-+\4,LEAS9]/M]'X;X(JP;U?4\=O/MEGLJY058?SH=
MS:*+$EP=61K\J@HK*1T>%*;61FPXL6"_=]+B'<1^!\H_E]WU>:;Z*&6':.JA
M@S3(8=^)^]C>[S[,$^#^#]/MV"OK=^_/;KE>W[2C@6#GH0]4#( H?3SYP(Q?
MIK^\ID^\/O#UNX@AOA_3[?'=L\\',]E7*)$Y%SH9>T&YYY<JX<+?ET1-<]DS
M ^8E#9'\0MSWO_I_O+)=R#[.#,(QZ\L>$;=%#*V/4'50P9JJ*ZQR8D97XSNC
M[_B&9/@S5[?6[0BB7N]/9T&W69?M*."J^@>A3U.+SFV9H\^<$,;V3>G\*$D^
M\!>]3X?O,K>AV>MVCN[.>\NCLQFFU;]"<T3_ &A)?DLW-<N/?U4W(V2'_P!(
M_A9 9"9M#_V?V^)+,JXMO)'O_;>&LHQBE<]%?>5[XI>J3B"D/W:*[XD9(/V)
M\1\<9$-4IZG?Z/PZ@]G9W_BWQ;'VE_<^+^!;H7^T(DL_?)MIGSAS%ZK_  GW
M6(9!>$GH^G\3\6Q4R]_I:3MYZV1KLLJOTU525H?%O2)(?V@.60:_+K^3O6%^
MDYIOZ80B3;$PC]1_4,32W'LKR%]MG&,/^:TFZ*%S)?>"]5?=YDA^Z12DQ(N"
M+4OQ'WD9XS TA/H^C\,%77J]^_P<9)?M+^[\/]TGH7[V]*Q_: Y*//G'F?</
MPGW.*T@LB+M^(^(^-9GWZ/I^._GFVM]E\@U/^!5Z(3)X@1<WG-M&OZP<VOV6
M,'+J>(<A!"('+_W.!<3&5R6&?8P\O*_<XQYZ)]6_]ZKU48/BY/NO[O?$B44.
MYC$+_P 3&R&WV]GJ&N!#W=W:-:XRP^TOT,3]Q-T*+/P$7WX<LF?: Y7L03G$
M_!NL@H=_J>D+A:SV=@<[#;YEG3V*_5ZQFEN:43!?I41BZ_Q.Q>52ZIO!+OZ[
MFL*B2$!IBOL_9Q$8EDK+23[N3,J:]..8J)Z.^'O?>2]2FUZ]C[L^!?%BN*W8
MOPOQPL(9#/ZG=\1\.5C*=OIZ;?,N4'VB?%XS[E;HH4?A*GWU]Z)G#;-[U7^/
M^[#4<0BIZ/9\(+8,PE[_ %B4UQ,I[&?VB,YKSFE,:G_58'[A$RQ>E;$_0_:C
MOXGPRX"0FM?JN7OU;]!RMK[-+68[]02I>"?-:QZ.^YV%Q>ICG_A[78:SXL8?
MXKNF^![EEC-WX<+\/\4 WJ%O6]$@%-5NC[1/[0I]WMT6.E/BJ'J"ZF</4/P/
M;7^\^QH'&-^*+_%_ %E]$+\/\0"?4Y&+S2]S[#FIJEVD+2LMH&QD(CIN*==V
M0!L0RKK2RX4QB1B9$**'E<E-J4RZ*ZPQAK",*5ZLK\S<7DNF\16K9*C)U+7Z
MLIH9JMA1A9</'>!81L8;$$L[P!" RN&8ML@:US69O#=9]07;N&RD'15OH'(R
M+7NU7?J2#J&;%L$:5!8J6(:D=HRJ2C1.B! H)WW;V2YQG/1^...4-O7>36FP
MJJ#%4Z;V1L'8,R17Z!KZO% QQ]AD@PEGGO$2\HI$;"Q$8+A#TG*F94V(V\VO
MVG,95A/2=-]./U!-<:6]6Q.,Q=47<KE;:RR04JS2I"FH8%::Q8FD<)7KQCNE
M<%0RZWS@>O\ KN/HBEC!6PN0ZGZ@Z@R/W1TWTWBY*T%O+9#X:>W('MW'CJ4*
M5:O!)-=O67].M'IBCDZYC=3[RLELCKLYN#4=AZ_RM!2(5-HMDY#S]4?BC!73
M$R<1?(?#5?DFA&VE8DFFUH<!6MK#GJ]:O1GSO3M&A)CC@<_4ZIKY-I(JYI5;
M-2\EB*1(O1GQEG=N(RLX%=M%9M-V_+</HOKK-9NOF_[:]#Y3[-[^!CALW(\M
MD\;EL/+1GBEF^+I]18UAC;"UTA<WH]QO3)42CR2)4'V"TC(U'%^!VC2RJ9^M
M"UQ=D9G!%Q3,Z<XEH2*))POTBF$+4G#31&&LK2I+F/[M6%9A2]+]107QBYL-
MD(\@U>2VE-ZT@G>M$C22S1IK<D:(CEF3NUVL#Y!'-M5^T7H2[A6ZCJ=68*Q@
MDOPXR3*19"!J<60LSQUJ]2:4-J&>::6)(TE["_J(PVC!C]@]]:7D*5*['"V=
M2R:+!FOQLO:6IT)41'R(ZTMN $D^YX09ZE(PT-XR\_A:%,(<2M&<VR],]00Y
M"MB9</D(\E<C26K2:M*+$\4@)62-.W;)H'N;]U.UN\KVG62O]H/0]O!9'J:M
MU7@I^G\1-/7R>7CR-=J-&Q78++!8F#]L<P+($B/XY?4C,2N)$+9>%VYK&R.U
M1F O5:F'+S'2TK4$Q\H.3BQ 02&ES1$6II2D$?I2'VE2#258>%PK^^;1Z5>,
M%G!YBF,@;>-N5_NIZ\>1]6%T--K;.M43A@"@L,C")M=KD:4G8W,Q_6'2V6&$
M;&9[%WUZCANSX)JMN*9<K%C4BDR!ILA(E:DDT;68P1)"&/>@[6U%)CLIH.OQ
M<--3>VZ/%15A.DHV#/.G!1QY,R'.<C91L1:U8]UL ]IP,HC&,#-/H4VI["L>
M.3:W2/4UN>:K5P>2GL5X(+,\459W>&"U&)J[R #\/K1,)(U/XV0]P77-1D?M
M/^SW$4JF1R?6&!HT;]ZYC:5JS?ABBM7<?.]6]!"S$=YJ6(VAL2#]E%(.UW!(
MWS;/V$T?2Y=R!MFU*37YAK$)E<?*SH8A.$6-#CL&[A+CF,*8DFVG'!B$YRRI
MM/K4XE.4YSCI=+]19*$3T,+D;<):ROJ059)%[Z?;\4A[1L/ 74.A 8%@ "?'
M,^7^T;H/ 6FI9OJ[ 8NTJ8Z5H+V2KUW$66,HQLNI' ,5PPRF&4$QE49BP7SS
M#53L7KRX;OONAX@]"[=0(& G#E*(8RS*(FFWGRQXIIO*W7OT%A46N5(7EMM#
MDR&TTESPM>)%OI/+4^FL=U3-$1CLE=MTHR$?NA:KZ822<D!5%J0V$KJ.YF^$
MG+=H"[AXW[2NF,IU_F_LXJW$;J'!8C&9BQ$7C[;$&1$CM'5"LSR/1@-*>XS!
M5C3)TNPOWOV3C8V,GQ\%54YSC%TM$9!%9]&5MKAQ&#;/8AGL8RG"6I*NUZ5B
MO4M6$8=/;QZ7592RYK\/J*6U>/DXVE-:C\@$6)'BI5'7YDPV[<$^E\E8F.U
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MG_AY^<_U^,?OCQ^/\/VY4^?'S\;^7S.Q^>OX^WCY\<KG3W_-)JW_ ,G-'_\
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M0%'7>RP]1DCFG<XS[60H^:)*R]XSEE+67,8SE.,9B7Y6AI6I4_>2"0K^1[2
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M[?,49E569B%5069F("JH&V9B=   $DGP![GE+R9\I9+%4;M#WJ,5J6.C'9@
M.JF(-*V#8C4F C(D)5G"Q,U*("<^]'&CB'%2LJZVZ>M L8TR7UM.K%!4R.(F
MQ$XZBFL+7GFR,;1186C"8I96BKMVR#)6I1Z3/.B^A7!6%3)89XN)R%Z6Q<Q.
M>K9VJW2E>K);KU\3.D\W462G2:"%9;:=T!Q%2%_B$CK2M\5;9'L,L55(Y\9)
MR94J4LDE?G.?.&V\9S[;+?[-HQG^F/'J5G^9>?YE9\_CI*=.&C"L,(\  NY_
M?D;YLQ^9/R'LH\#QSC,CD+&2LO8L-Y)(CC'A(H]^$0?(#YGW8[).^8[DKD'C
MCCCCCCCCCCCCCCCCCCCCD9LE-K%N2#_$,,)(/Q1"BXB0SAP:7A3%M+949"3(
M;@\K#F*9<<945&&"OJ9<6TIS+:U)SCDBCF0I+&DB'W5U# _P(/\ /F>O:LU'
M]6M/+!)K1:)V0D?1M$!A^1V-^=;Y'#=45.68R%8"+I:XM7G#D%<=E;%M]=?;
M4E2%,%5VR6F4A"Q5(5Z%"E /#*0E"5-92A.,1(\7CXG]2.I"K[V#VEM$$$%0
MQ8*00"" "-<V,O4&9F3TY,A/VZT?3[(6(UKR\2(Y_BQ._/OS;>)@PMBZ;G]=
M(+(KZ7X ^ICF0;JXPN%;>#4B(D(M8*F%B.1V5,K&RQEKTN!Y3CPG\\W9E.!Z
MCI96."&>..S#>%>>-9()A'(/B*\D;JR,DH#!E(("R#Q[ ==2B'5'261PDUJQ
M5EFJ6<8UNM*\5JOZT)%:W#+&RR)+"65D8,"9(3LZ/+6J!$@_7(AN:E(>8L((
M(T;9CH%W#D6Y98]AL:=2,C.?<&2F2;(_U1]*"!?.&7FT+1E/.?R"0K<L&M!9
MK4Y97FI16UU.M*5B]7O(_"Y,)3]HA*/^\I((/.JQ4EB3'U!<LU+=^&&.ODIJ
M+;JMD8$6.\(@26C LK)^RDU)%^XX# CDDY"YL.......................
M............................................................
M.....82>KL+9@T@S0+9C+3R"A7,+='-CS&\*PR?&2 KC)T9(,86KV#P"!RV?
M4KVWDX4KS)JW+-*0RUI3&S*4==*\<L9(+13Q.&BGA<@=\4J/&VAW*=#D#(XR
MCE8!7OUUGC5Q+$W<\4]:=00EFI9A:.Q4LQAF].S6EBGCV>R1=G=7#)O(%W73
M:_<FY.)CZQB>DR+A"-3LE$.R4I@"MQC4A$R5:(-9.9C+*^IZ41(2*,1S"B3W
MLD)4Y->[CK'XY\7Z4O\ C..M&K$Y\DL8)X;J1L=CQ 8HA_AB4'QJX<7FZ>XJ
MG4)LUP-1IFL>F0LQ>1VH+M2SBY9T500&MK9M,2&ELR'?=+'X"^R&,,&WP*-%
M5\/+JU3:CY-2/*,Y0R=/S%H%'PM.%H<<1&*?2ESU#O#O(0]BBVL7%^*/%R32
M#]T7;[2P ^=%HJM>E(^B00#.$)&G5U)7E9<?U!9 CFZ@@J0GQ(V)PZ5[;+M3
MVQV,C=RL,7< R.PIM)VN3"\,BK(,]7JK"5ALI,4*O!,@]@F4DS229&8EBDH2
MTDB3E3G7SC5MM)2RPEY]30K"4#BMLCH0TF+;O6;K(9W'9"I2"")$AKUT)+%(
M((E2*(,Q+-VJ&=B7<LY+&?C<10Q*S"G"PEM2":Y;GEELW;LP18Q+<N6'DL6'
M6-5CC]20K#$J0PK'$BHLBY$YL^......5Q-ZTB3) FP5L^1HMK)4ATF=K"V&
M&I9YKQAO-F@267X"S)RWC[91$K'NRK F5-1LI'N8:>:<H=_(Z_K^OY\QKEVL
M].]:-B5]1,.QC&/X^IHA<C$J1G&,X=G*FVL^S5Q6%94AQX/^)X9EMK)ALS'(
M=P,TX_K_ %^7Y>/UY&MBV@.[M0M"J<N,='VT%4S:YR&-2^@*A-.);6(.6(YZ
M6R[J7C, *M+S;S<0BR'BJP5&M< ;_+WW_ 'V\CE&.A^9]OU_K_E\^9(J'B#8
M_$.;%1AD3AAL?$66$*1'^PVC#;;& GFG!O:;0E*$-^WZ$IQZ4X\8QXD1S20.
M)(99(I$_=>)VC=2?!TZ,&4;UOM(W\OGR.Z)*I21%D1OWD=0ZMYWY5@0?/GR/
M?E?)T;IG"6VTZKU_]NR\V2R%FIPN8YA]MWWVB&(W(60&GFW_  ^TXV,E:'D)
M<1E+B$J3M3U%GB2WWUE.]E*-(;UD2LC)V%3+ZH=E*'M92Q5E)! ! .N^Y,,%
M6,XK'>FCB1(_@JQC21'$BNL?I]BNL@#JZJ&5@'!V.64&$)'C-!QXHP(@Z,(8
M$#8:&'91C\-LL-(2VTC&?/A*$)3CS\)_/-2\CR,9))&ED8AG=W+,Q\?ONS$D
M_F?)U^7-BJ)&H2-51%&E55"J!] H\ ?D.0>UU20</:N%/='!N0(R!G6B7%LQ
M5NBFE..)KMB6VVXXAI"W77(69:9>-@#GEOLM%1Y,G%R&,CVT?Q:'S'DG\]_+
M_E^IR _(^VC[ ?('S[>_Y_S.AS-U6U1]K ?*$;(". *7'3L(>E#<I R[*&UD
MQD@TVIQOW6TK0XP2.X^%("N,'1Y1(1+)#@$^1]=D_D?S]_'CS\AOSRA!'Y@^
MQ^H'^GZ<H7;78U^N6]K2NEJ43N_L3)12)=C7T9*-P58H\*5E30EQW)?GQC(S
M7]4R[C*QA,C2MTLZ6GVJ;4YYP<I0V98MKWR-Z<6^TMHDL1K:Q)[NVM[\J@V"
M[+L$Y$C[AW$]J>V_<D_,*/&_U]A[$\]Z7TD&MDU&;&[A7!OLCL$ MJ6@J.7%
MKA^N&LCT8RH=%%T\05(QUAEXS.488V!LXBWV[)8_ZC!.5)HER*;-8T"D"^DF
MM%M[F<?1I  54_-$"J1H-WD;.7N"C2#M&M$[V[?7N;QX/T&A]=^_-\F&&1F6
MAQF6AQV&T-,L,-H:99:;3A+;;33>$H;;0G&$H0A.$I3C&,8QC'CD;EO/KQQQ
MQQQQQQQQQQQS3G;72S7%XLA^T=8RTYUUWR4EI;FWM0_9PY5F>%3A @VUZ4ZR
MND;BAVFO6*@.^PLI(1PKSV:[,0)V6CF<Z6'5?3<"6+_U<GD+O6S&W[T9.O/8
M0#H=ZL!KEW=X 8!E_P!UOEOW[3[J?S'*BJ_8"_:LN,!ION'7X"CVZT2BX'5^
MZZ>LS.C=W'(2M0L<$Y(/%2FI]DG#M+*<UI=3C!C5X4BCW2Z99*;!R&-75G@8
MLH +QL/VL0'C\A(@/_I%*Z/ED38!QM&-%H]D#RRGRR@_IX91[;&C_O ;'+0F
M[14]KHV-0#8Z=)I$(MBN6.R R3L1'SUA0^EZ;HL8X*ZQ)R3 P:$!6@H=28E:
M#BH)1+A+4@V-U=#%Y/"283+035$RML->HTYH4LS4J7;V5<Q861'@@:21C+0C
MD[K0,,=H($:!G\[R6:PW4,74>%M5[TF$HLF,R.0AL/4KY'(A_4NX&H\,D=JP
ML42K!E98^VH1/-0:5Y$M)%Q"2$.I&&&&'CXV/'9!BXL)IL<&- &;0R,((.TE
M#++3++;;:4MH0G"4)2E*4)2E/0UJRUU<EWFGF=IK-F9B\UF=R6DFE=BS,S,6
M.V9CY.R223R-RXUMT CCKUH(T@ITX56.O4K1J$B@AC0*B(B*JCM4#P  %"J.
M+R3R'QQQQQQQQQQQQQQQQQQQQQQQQQQQQQQS/57;5%UK.MB76WP%;9L [C(0
M\M*#"F&E")40C]/CU+R:>XEI+Z5(#'>6E*LJ5C"4YYSO4M<2TEE! D@D#*"0
M&9)"$<*#Y/XBK$#Y*?SYV'1MB2+(R0A)&BL0E7949DC>/<B,[ $(" Z L0"6
M \G0Y,M0772V;YL2OT7:$%-3]_FW-H.:_P .( EX##D5 UN>.%B2DC26 IB6
MC$3):B!&W,R\G(O8]Q+JE(Y_)W;>3Q^(>>LJKAZ:X4W!(&>R@L6[E194)[@:
M\$QJQLO='Z$$*;4J%/78G%5<+E,ZD%B0MG\@W4'P1A*PU)#4Q^/O-!*J]C"W
M9KK=E1F]0V;,\FF5RPV8YH>=%QQQQQQQQQQQQQQQQQQQQQQQQQQQQQQQQQQQ
MQQQQQQQQQQQQQQQQQQQQQQQQQQQQQQQQQQQQQQQQQQQQQQS#S]@A:M#GV"Q2
M0D1#1;&23Y US#0X[6%)0GSGQE3CKKBT,CL-)<?)(<:'';<><;;5:[I&I=V"
M(HV68Z ^0_B20 /<D@#9/,<TT4$;S3.L<48[G=SI0-Z'ZDDA54;+,0J@D@&L
MA[3M"Y)433JM%4V 7E.0;!LE$B],RK"V\.-'!4"(> .! =2M&6\66QP$XE6'
M&BJ\+X0ZJ.)+$NS'$L2;\//W%W&OWA"O:54^->I(C^X,8\'D(3WK!)KP1UH=
M_AFN=YDD4C8=*D95D4[&O7FBE!#!H%\$^4P6^&LM.8V;K UU*E9+#=U!8@Q7
M4Y5Y9;#?9W"25'YPW\.NE8E_=7_>-,L)_N^ ES8_VBLQ'[P^%D'Z:(MDJ?J3
MW[^0'"Q94%"UVB^BWJ+]W3(&!/X A^\G,94?O%O5[CY 3V$0A+/.ZXLUNE=Q
M0X4*+<9B$R%L"NEO2E"!%!A(R$C86<>,8$FJH\N19DS\&S *JTE^80'BQK+6
MAMY\0\1U901IX G1NZ'9.@'V \1/U<&,>!ZI)URANRUB!D8DAC/:!<A<R5.Y
MO';+W*LM8[_Q2J8 "H]<N>WFR6,X5C"DYQE.<8SC.,XSC.,X\XSC./C.,X^<
M9Q\9QR5S9<\\<<<<<<<<<<<<<<XAYPD6";)GOH&!CA"#C27<^&QQ!&5OD/N9
M_9#3+:UJS^R4YXXYIM7==N3.9?9H,A*4.\W^0=L9#L-EG[%,0O&&ZI"V&LDI
M?A)-04*@5<PYAIF4S,'3KP$T*X:I_EVAH?)B#OS]?;SX&O\ /S[>?&(G3$:!
M ^1'\]>/K_#DF7>)ZIXPSL>#RW'-,HRY>ZL.5(5?*O\ 94N8B?458*MGRE3K
MKA")>!#96WE^R>M2D-U]AY'D_P">_D1O>QOW_+]-TT/=3_ ^_P#R/GY#_GJR
M8^1!E0A9*+,%D8XYE! 9X1#10A([F,90\.0RMQEYM>,X]*VUJ2K/GY^,\;'@
M>X^@_>\'?U\'\QK8)]M#E-:_7^OZ\ZYR_&/CQ_7S\8Q\?G'X\?M^/\/W_&>5
M/MX/MO9^9V?)^A/MKR#K7U&J<\_G_/'Q_AC_ +?Z><>?\/ZYY4C>P?EY'^?D
MG0&B /<GV]]\<T7WS:;Q<=Q0NB>K4J'!]ACX &6VGLDV-3,T_2^E)$B1#9L-
MPBG?2!9+Y*2312-.4QQ]B0(F&9&P2CB*-&6064R)&JKZ\N^P,0JJ>TRN -H#
M[@#8,C:V%(  9AK-&OCN<;3>@/\ >8>X'T !_$VOH =GFZFA^OVN>NU0?JE!
M!.?+F9-^QWB[V,S,U?ME7$[&/U.YW^SO-MF6"PGY2EO#SJ6@HP!H6&A 8R%
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MCQ=@A&E^EXN^N0JK+X$J?@F0?X7'S&SO3#1!/U'G?/(^I<,,5<#P+JE:[G@
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M3M18]#H[&XV/I^.K9R*-TXV1%.8S5S+9@RDPGN5+W^RB.6N\BQLOHQUYD])
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MI^>0I,GCXM^I;@!'R#AS_).XG^ _U'-E#A<M. 8J%D@^Q:,QK_[TG8!_$\E
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MGQ[$$'^(XY CM+:\/"KX2HR8"S6 Y..B9&(N%RA)[]-FR639V-DK)$SX=@G
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M^GRKU=GN=LSENC0:82)6OTYN=W$*';=;3G^\<@:9AP.=D/5G"FVBIUZLA_\
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MA_GO>_?CCEOL21KW&ORWY'^FC]/EQQRH(WXW[:\#1/Y^->-_GOQY^?'''O\
MD/'=^0^FM#S]= ^3L:XXXT0-^Q_AO7L2-?P_31._/''*[!V?;1^7C>SXV1[_
M ,/S_+D+EJU,,V,.]T*S$4B^ AIC')-L)N5@K/#(=>>9@+S75O!IL42&^265
M$.,GQDS FEED0TL&V?)C'XI88YE[9!O7[I!TRG\CY]_F""#]-@$89(ED4!O?
M7@ZT?.OGK6@?J?/CY:Y+:C4-S/W8W<P^H>MK6T+=18/7M@V^S?\ 8D9*R-8J
M\Q-RL2*[K?&L)1+@(DK,R!;0#FU_NWV5"C.S>&0A,-:RQ(4B^!-B9Z\,[SQP
ME%],22I&KN&]388HBJ=(5!!('XB3KI$6-F3N)*G_ '1Y&@?+=WO\CX(!]N7;
M3M4'BV@?8^R[1F_;$$CRHN&(%CG*_2J5'GYQB1'H]17(RRH\V5;0VQ,6.8EI
MNR2 S?V"),*'5^E)A%O':HTN]GYLQ^6S]!\@/ /GW\\Q[\:'M_KKZ_U_GYY=
M7+.4XXXY%;9>J10A(\^]7*JTL&6E18*+-MEAB*X))39R75!0\>3,&!LF2IB6
M7E"QXRW"R$M.Y:97AM><9ZU6U<D,-2M/:E6-YFBK0R3R+#&5$DI2)681H74.
MY':I9>XCN&[UCD=9'2-V2)#)*ZJS+$@!)>1@"$0 $EF(  /GQSZ3=UIM9D*[
M$V.VUFORMO/7%5.,FYZ*BI"T2;:$.+C:Z$>6.3-GH;<;<6'&MDD)0M"\MX2I
M.<TBKV)Q,8()IA7B::<Q1/(((5(5I9NQ3Z<2LP5I'[5!(!.R.%CD:-YEC=H8
MB@DE56,<9E[A&'< JAD*L$#$=_:W;O1Y)N8>6<<<<<<<BLO>J17[!7:G/7&J
MPEIMRBD5.M2]AB(VP6=8+>'345V&,,9D9I0;6<.%)C1B<CMYPM["$YQGF>*K
M:GCGF@K3S1555[4L4,DD=9'+!'G=%985<JP5I"H8JP!.CJ\QR")IRCB!76-I
MBK")9'951&DUV!W9T55+!F9U !+ %/7JD564KL)9[C5:W-7 Y<94HB>L,1#R
MEHDF_:]R/KH$@8.7-G-^^SZQ(QHHA/O->IO'N(\H:MFRL[UZ\\ZUH_6L-##)
M*M>+9'JSE%811[!'?(578(WXX$<AC>81N88RJR2A&,<;.=('?7:I<^%#$%C[
M;Y*N8.6<<<<X3TE'#F"1Q!X3$A(8?4 "\4PT8:D5'NDJ$%6XE\G [?\ >/Y9
M0O#*/YW/2GYY<%8AF"L0@!8@$A02%!8CPH+$*"=;) ]R.5[6[>[1[00I;1[0
MQ!(7?MLA6('N0"1X!YS>6\ISU6M#:%..*2A"$J6M:U82A"$XRI2E*5G&$I3C
M&<J5G.,8QC.<Y\8XY4 D@ $DG0 \DD^P ^9/(=3]CZ\V&B4<H%\IEY;@SE1<
MVY3[1!V9$/)HQG*XZ45"G&ICSD8QG*A"\LD)QC.<MX\<DV*5RHL36JEFLLZ"
M2!K$$L*S1D B2(R(HD0@@AT[E((._/+I8Y(9/2FC>*4*&,<JM'(%)90W8P#=
MI964'6B58;V#R9\C<LXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXY15\J=KKE
MK3MS6 :)6:6 +%;%H"R6Q&MD5J-4ZY&D0I)1 \=%['K"7S$5J0/>&B)^/-*J
M]E)%8S 3]5FPRQR1?"V3VIW%J\^B?AY&T&#@ L]>30,BJ"Z,HDB!/J1RV$$'
MN7W]F7_>'Y>0 P]@3X(\$ZT5UR[-=<.IWU/M/&Z5VXB6)S7I5F?0!'G9IVX-
M26Y AT4W)*BI4,LB'D&V23@_;FH26K4VSY=::EP,COJVV'R^8Z3O+?HE%,B&
M,EU]>G<A+*Y0LC*'4D*VXY$EC/C:-L<Q30Q6D,<@/@[\$!T;1&QL'1\GW!4_
MGKGWZ&?39ZS?3KI-AJ.AHBPR,I<2VBKGL/8$C&3U^M38F7L1D=)245"U^)%A
MXIM]U 43#0D7'^XX\:2P1($$%NUZCZJRW5%B*?)/$J0*5@JUE>.M#W:[W5'D
ME=I'('<\DCMH!00H Y2M5BJJ1&"2W[SL06.O8;   'R  ]_KSK9OWT7?IK"=
MKB=O4JC7O8>ULV)JU_\ )<JUN@1]#P5G4ZQ)#V'8@PU75,4"H)D'AI@R%D+F
M@&4%RZ%6:38LN(@7^G@^T#JO[G%"6Q7@J^D81EI8)#D7B[2GIUW,WISS=H*+
M*("RGS+/'KU!&;'U?6]0*Q8GN])2/3#;!VP V%WY*EM'SH'VYWHZNUZ12(Z3
MD)^29L%\MQ;,O=+ .-D,%XQD9 L? UT%:G'(JFU8%*8FL1*W77FA$/2$B^9-
MR<M(&>>V9Q,RJBF."(%(8R=L%)VSR-_CFE;\4C^Q.E4"-$5=@H('D[)\D_4_
MD/D![ ?\=\M#D;EW''''''''''''(5L2KO7"G34(&^D.76PU(5Z05CSB-LT.
M0U*UR14G&<>XT',AA/$,YSZ"1DO#.8RT\M.7'*JAKI#G5$2W2A0L$'@96)G,
MF2P&U"2@;ZX^7B3WWW$M,DQ4NP5%OI4YG'W3"FT*7E2<JOV/'MYWO?D@_P 3
M_+VW\]GF J=D#SKZ?P_Y^?\ ER-_QC:[6O#5 KZ0XK*UI5=KJ*:#%.LH\I]^
MO5MMP6P6+"U>%,$FKK4,4,K!8$O(-J;;=;)\C0UK9^GR'Y^?;6O]3RN@/?R?
MH//\_;\_ /G\N9*)UQ#BGL3M@)/NEF&<R\+.6AQ@O,8[GSG.8"*'''A*ZG&,
MY3A<3'CF/-I3@PLM:?<RT =>=D?,>??Y:/Y?R]C\C0GZ:&OIX/R]SXV1^7S\
M\L+_ (YS^WQ^//X^<8QX^/S_ $Y4;.QX'L#KW^?@#^@/) /D\ISYOLLD,NC$
MM-D,$-.,/CO(2ZT\RZG*'&G6EX4VXVXWG*'$+3E"DYRG./&<XRW\_?\ ,GP0
M//C?S^@W_,]VF^:(ZRO3'1+8M>Z_[#EV1.J^U[(Y%]9KW,2+#8^G[U,.+)9Z
MQV%3RDN"4DQ+)AVDK(3G($:E;NKI,H5]BC-S$AU^(4R+HSH/VJ >954#<ZZ\
M%A_Z5?!]I-'<G;*4^JI;?XUUW+K7< /WQ\B?'XQ[[_$/!.NTSD/EO'''''''
M''''''''''''''''''''- ^S6Y[K=KI_R0^NDF]'[+G(T(_=^V L+6#USU1-
MMNLD'@'MI>$7O6X"+PWJJJ%HS]B*X5L*;9_188$.=DPQJJ^M*-H-B./YS./E
MK8_9+Y,A!V2 B^22MP[54NWMY[5_WF&O?_LC?D_H/<\M[7VJJ)J[7E6U;2($
M:%I=-AQH6!BVEN.K''8PI3A1!KZG##)0\AQZ1E90QUTZ4DBBI ]\@PI]U83R
MB1I Q#LQ[CXT=DZ4KKM"_0#P" / T1B6:17+JVF/D_0[]QKVU^0]AX&ASB2]
M9* ]3PWJ*%Q\YSC'EYK'_P#$0G'\R<?^.C'C]U)3C'GFT@MI)I7TC[(^BG]"
M?8D>=$^WS\CFSKVU<Z;\+_,;\-X/L3_/1_F>1CDODL^?YC8UOR=G0UO?G?@Z
M^0/''*Z/R()  (\'Q['Y[U]? UO]3QQQKR=C?RWO]WP-_E\SHDGR/KL\<<'0
M ^9]_(WXU_ @;_7\_?7''*[/_9!WK6OF?(_0>X^?S/D'PXY0^VOXGZ$_38/T
M_%]2 "?.^..  =G]"/)\?/6]>X\D^#_#R>..5/N0/<_\!X&AO?UWK_L_/7''
M+0 /U^>Q\M;]MC_B=^=#7(2=.66=M7]G.L84*R7E$>',3A4N8]'U"@P,@02.
M!-W*2$8+.R]++ DVZS6HD0B7L14<7ZEP\,+(S\=AGG2NH9P3W;[%'NVO?1/@
M ?,^=?0GQS%-,L0\C9;R-?,#P2?(UY\^=Z^F_>R4==-FD#_>';[<#G/0K* 8
M'6=:8I"'?*LMX?B9H^<N!32<*PA_+-^CED9;2MG['U+;SKCDI.X$11A?F"6)
M/U_$& '_ +O(?Q<OMI=>/&B?'T\G_0>/'TY-JK?+;0IJNZYW'%P0>9\G$)0=
MD4],@Q2;7*H&?*8JTQ$2Y<A+T>YE!B&DQL>7*3\!/M".HC+/^M.HKR(<G[1G
MD7>R2SJ?==GR1KP5V=;\$?,?,QV)9BWS))(^GS_E\M^_U^IV'YBY;QQQQQQS
MHZ^N_2"MEZ!ZS:X!E<P9M_[GZ@I0<WA"W,PY5IAKI!CRF&VUMN+R \<@O"$.
M(6K+7A*TJSC./3/LELFEU5D+@C$OPG2&?M>D2%$IKS8J7TRQV%#]G;L@ZWO1
M]CU'3]B.G2Z@MRQ^K%5QIL21:!]2.$2R/'H[![U4KY&O/GQS3 O?EMVIL[Z7
M6J]P8R'V'ZO]R++I'<P3ZU9)E)"M5F%$K5\:RYX<(CKY!AMRX\AC&&C2VY%U
MC*F?0I7318RI7?K#-8I3]R=2="7\KC_ 'PTCWJ/QV.<#PDU&RQBDC\>F"JZ\
M<R341C,'U931Q)6:QTU<QTH)(FQMF3)/68; ):(=T#@[<&-6DU(Y ]][?6FV
M=6]H[_FZ=N+1=&@M!;0F->TWK!<M7[#L%WW_ !%6E&8JQV@S:,(*_!4@LQ_,
MBNL MG@-85&Y8F!LI2V7*7=/_9G4MXC RV\3E\A)U#3@O6<Q3R%"M6Z?CMJ7
MJQI1G(EO,D;1/=+"0 ,[5NXJ(N3'Z9B!2B8;,<OP:S298S0O MXQRNU44^X2
M-75E2,2@!W+QL'C!D]+:C<_U)=N:QE^TRF)*,=B[5U-U!V"Z7 F0$)^HB2^Q
MBX37Q\-)*0VVBT+C=@V>,/<'E%/J2&PX,CUC^O"N=Q_1=*ZF(J]KF[2ZWL].
M]2RK)*$DHQJ^46=$_$*__P F068!)'K]HJ._XR2-;0QU*TG3]Z6-HZ4U/,-F
M4$DC*MW$!YC$)% >/UH$V5C.R#)*H10H&0ZM]_NP/8R\]#=4,2$3%WB=KV^K
M5W19568A!<<SJ"<?H<5#B"Y'=8K)%@N8CR2D1Z!R6F'1L,.-M+SG.7-])83%
M+UEDD#RXFM5Z?_LJXG<K9L9U#::0OWJ\Z4ZB!U#[61969@QCT(=_'QX^CD&F
M&[C=0KC,=VOM8ZD,(R4\LH!_:>KC[%9(I0&1;"NA/<VQ9OUFJ7+0^D]3]MZ<
M(XN]=-=T4K:+! B,Y-<I$M.1<!<X[&4)4YD)Y3L'(2./*4-A1I#[BO::<2K4
M_9I<BCZBDPMMNVAU5CKF#LACJ/UY(GGQ\C;.O5$\;U:Y(.I+I11W2 B3@U^/
MJ9K!$KW9&@\]0/[+?H*\\4@\C79#Z\I&]N8D"@R",<J<R[.=M?J:_P!J=)9C
M+3JSHKU=5=:EF2F!8FN2^Z]U5YJ>KZ)*8+5]E#H343VU&GDJ1F(Q"_<.>$N9
MQS81U9.F.A,M'9(@RG5/4/W*"48M'B<)*\5MPH =Q]X"Q&RH09@\<>@4)X;T
M1ANG<8WK1MG+GWOD!'&9)HZD$BP5X5C39DE$HAG@3M(9C8()U$3 ]-_4#[51
MO;+J]K/96\NM6]ZOV8FK?7K?3=)U0Q41HV;@QE%!QE>VQ'R1\->WVG5($DL/
MR4H0*X+(!DACNY$DE[.[TCT[+@>H9Z.)Z@QD^ HT[E3)9>PD<F929F65IL6\
M,3U4T T;11A'#HPD4@H]V2QM08NS?KU[&/EI7JM?X:S*)GL5K4OI)-*H :O*
M4U*$*Q*2P$8F0/Z=?R/>CZD4EH_M_P!CZK?M'!:_ZD]D]@TO%9L&MGC;/L:I
MUZX 1&:Z3)QYP$;!@U^&/"='/$"78Y\YXQ)4U'ML#97=6Z;Z*AL=#T<A4R\]
MOJ_ 86:22M=2*O1NY&LA^,$;H\L[36W[&A]2.M6@!=8IF_!R>^)Q#YJS@TCL
MQRM2>S%9]8,D#)%9D5%C*L9#(*LA=Y2RJ61%CT6D69GR78/:OU<NHU[AMJ5^
MJQMZZ:P>UX^LO4AF8%@-;S$F@R^ZY0\_)M8*G+'(M2#@5W6V@Z*$?!$R*0@!
MM6;*L6%Q70W7%*QCI[LM#J<8YK"V_0>Q.BRKC)]+&0B5!HRP ]EARS$IW'FM
MGDK/T9C'-?MEDS-RNKK(=)DTQD;O>(()>NT#I$E1B0C(TG>2YYAM9?4F['VC
MLBU4MP=C-%]89K&VC*H1U5W5H6^P:'J0-,OQ@9D-O!)6!I&T3@C3+L4Z8=$U
M\F3*]3*G1D,QI.8]$X8=.P7,?A<KU()<7';GSN)S%,O6O2UUF>N<,8V<0UY"
M4D1E>RJ*>X%_(D9O$5J4%PTJEF:"!>ZIEX[45B"RH16]:S B=T-?\3/)Z:@I
M&JEI8MLX[BN^XE[.Z8=E?[-K@'2+.+IR\2J;"5#HG6\043 F2=IBQA%$B^P=
M8*R+*P<;+MO>["'2(\RPV\Z$AI?EF :FF>PIR-5KE,Y2E%8J+(83-ZTZPPAI
M.UM)%9DAFEC*D311/ VEE)$;I/TFZCPBRQB0RY&I% =CLBMRS)'4L.I!$T5>
MRT4\D!T)XT:(LH<D?GKZVV[LET_Z== L=?YC2PEN[K;G$KI!3^GH2*RBO2%?
MQ&00VP9B-6J;NTQ 3*S9IVS*)!E"X]34*G+(S?JS[CU##A^I^M.IZ67&46IT
MWT]>O'MR,DH%J&Q18RT()0(*J/7E,1KE7B:74K[/CF>9:-P=2Y2U'9<8BS7K
M1HUEG=S'=RAL1)(_B*O;,4,442JPJ*7>(,Y /9U<MS]YYG?U$Z$:KV[J<+<5
M8T._O#>W9BTZH]^.,')MV:[ 5^B:M%G<PXCQ.3([$J_(E%(]E;I CH;PRF#?
M/Z>/Z4;&93K"[C<B,/'EX<)B<!!D-2R6C12W/-=R3P-((%0DQ")%?O5E<,I4
M<C"OC:=*M?NP6+!RMVVM&K%,(TK4*S,KR32Z#RS(X])0.T'<9(8/(\&N.S?J
M8]JJYU*VZ9D+7T!VKZY]M*)UTODC"PKLCK>["6&4+2'+Q,9.*/+BF[  PED]
M"'E%Q[Z'"@DAI(9%8VM'H[ 7.H^E7A:X>F^JL3D\E%!9E47J4E&A:EE@DFA[
M/4%>Q'&R/H"5 58MY8S(<)3BO9BM9EEFJU^G(LU2L*0LZQV;%:-'D0!8FEC4
MV/P$>DVT)&O)F+6__J??\J39O3-6T>MC]P<TA&=@XC;:=5SHP.N(8ATD8BD0
MU158GV[.\1--,0XTU9B3'0HW),Z^T:4MF&8PMB^A/[-CJE:.>^&QF<EPEC'G
M(5S)EY%JP6X[$EE:P6BGHS=[QUX]ED,"N-BQS#\/AQ#@[[5K8CRY:N:7KJ1!
M(CNCV#-V+)(55')A!C661HNTP)'()K2ZF_4ZM>S^OFNKIL^H0[^P) 6?CK65
M7,$1T*;+5FV3U7>/!!=<)4(@]$,V8ZPA[++9#[V!T,C^TRWESGV?4*^3L)CK
M5A*++6GK)/V/*D5JK!9".^AW%#*5!/XNT#N);9/*YY;.&S.1Q:^C,M*R\2R.
M7#,OAEWVH@) 8+OL4MK9522!W0\\DYEXXXXXXXXXXXXXXXXXXXXXXXXY [MK
M#7NQFA6[O4(.QN >[^G&GA(_58O+Z<(?5%3#'LRL6IY&,)=7'F#*<3C"5Y4G
M'CF>"S8K$F"9X]D%@I_ W;Y7O0[1]'R.Y3H^W+2JM[@'\_GY\>_O\^1 CKSJ
M8QA(IT#-2 2%M+P!(WS8,A'*RPO"VDN1YMI?"=;1E.,8:<86UE/E&491G*<Y
M%O64;N1T5B&'<L$ ;3 @_B$0()!/D'?S!WRA13K>R!K0[FUX]O&^>M%K5=UG
M?[%2ZS"1%:KEK@XZY0,/!1H<5&#R,#@6KVQ#08+3##:U#.TXQ3B4964^88XY
M_.VI;L>2629R\KO(YUMW8LQ^0&V)/@>P]@/ Y< %&@ !] -?U]?KR[>6<KQQ
MQQQQQQQQQQSA2,C'Q 1$E*G!QD>(VIXHX\ED,,9I/^TX^20MMEI&/W4XM*<?
MUXXY6*+W9+>YAG7%<5F*7C&<WZXL&15<4TYG*4$5R$QABPV[QC^_:=]->KYH
M^6W0K*^EU....4>YJZ+HFT@9:UF$7-R^$&2-?FIMD=D"N[ $8>+F@8:!%2S!
M0KMEAD+E(TH(-<P^[ S^9.4+?(9=(JOT.OY$_P  /S_G]#];&!]QOZG] /Y_
M7Q^9Y>.?G\XSG_/Q_G\_./\ +_H\_/S<3K6_?Y>=$:.AY]@-;! _7],7'X^/
MWSYS\9Q\Y_W_ #^WS\9_/Y_?E0#^I.C^OD'W.AXU[ ^=_EL/Z_T_Y_UXYYSX
MS^<>?']//Y_/X_\ 3_7_ (U\'W'R!V/SWY^OG0UO?MKW/']?U_7CD/N5TCZ9
M'COOCE2LO*D?I]:K,7AIR:LDLII3J(Z,9><::QAMI#A<@>2XR!$QS),C($#B
M#NN8H"-'>R20/&_/@>1O7DCP3[^?&M\KKSKVUX)/MOS_ .'\.5XYI6 OT%:Q
M]WPL#L$K8$ ;5[- 2 OW]5C:?)92X11H48EIG+L6AY*7SIIY@>8FI-IJ1?6(
MT)% QE8RR,'!(96_"PWM6'L01]#\_KOS]:ABI!4Z(.P1[[!\'\CL;_3^.Z)K
MM_VCT9PW6]FN7+=O4852VJSMH00ZV;7ZYPC*,9'K^X0!$%V#8^KH9C"FHW;,
M>S(VVK1(S;&Q0)4(4F[YSLB6/Q)VQSD^8R>U)C[]T9.E1S[F,GM)/X"I(C$@
M,LOMI7^:^RN?^S\@3_NG0)_=/R'9!4[=5;[6X:XTBR05OJ=B!8DX&RUJ5"FX
M*9CB486.;&2L<^0$:*ZG.,H>'><0KYQY\XSC$1E92592K Z*L""#]"#H@_KR
MA!!T001[@^"/X<D7*<IQQQQQQQQQQQQQQQSYNNM,-./ONMLL,MK=>>=6EMII
MIM.5N...+RE#;:$8RI:U9PE*<94K.,8SGCCG7-=.T-Y[$R<MJWI.<,B#$(.A
M=@=PCHT:8UE1B17OLY&#TL(<R1%;KV>([ZFU$,(=U?4G<+>L$],RPF:@7*6%
M8@'L#9\%:^R'8'R&E(\Q1Z\^_J-XTH![Q<0(QN3WUM8_\1W[%O\ =7_[X^-#
M1WR4T'K=6-%5H-G2K1(EG%>,E+5+6B6.F)C<4I*%.R<\?LJQ'K+.DK+.2;SI
M@MK<0\57WE(CXX9%:2[ KQR.\C!S[@  #]T*#X5='04?30^9))\G 7+$EO(]
MAKV  (':/EKY?QWLGEZU6U1]LCW# D$AEAOK F8212AB8@)5E*%$14L*AQW#
M!3:5H>9=;<=%/#>&D0""H\L0IZT;^0T1L'0_@!O\B![D^_TWRTC7CZZ._/M_
M7Y?+DE\9_P //^_Q^,8S_P!>?C]_C^G 'C9'\2=?3SO?CSX!'OX]OG3Q^?Y_
MS_Y?Y\B\O6!S?4\)E(Q6?.<X\9]EY7_TD^<^WG/[K1C/]5)5GDV&XT6D?\2C
MP-G\2@'0T3X/CSHG?C0/)L%QTTLFW0:\^S*!L>X]_?7D_P =>.5V6&2"[EDI
MI32\?CU8_E7C_P 9"L?RK3G^J<Y_IGQG&<8VB2)(O<C CY_4'Z$>X/Z\V:.D
MB]RMW;^8UL>2='SO?N3]?'D;\\7E_,FM@>WD#9^GOLD;_/W._._;CCE-:UL?
MGKZZ_/VU]=GQY.O;CCE-_D#Y_7?GS[^=^P!(]M_/CCE0=Z \$;/GV4'\]_YD
M?/Y<<<IH;]]CVWOZ$;_0>?S\>?/''*GY'P/?7MXULC6M@C?N3YXXX)^0T!O1
M^GGV\^3[>#Y_3QSK_P"SU1W-5NJU*[-:JV9M:F1=4W1:MS]H:_IN;'B+SLC1
M$W.N5:0=C## #$/V33&NX:L3$3#*=# )B:S8HUOWY(H)3F7$2U)LG:I6J]6>
M6U$:V/EN*S0P7(]^B'"L.V.PVXF8;*NT;> &/-3,1(\@)())56![2O;L:'R\
M^=;'@ZY,X+8F^;-KFT:-#W'8[7L^A-P>^=#;-K<X#%3?;/JM,Y44(\-)A1J@
MGKI"@GNU^:2P*M#\X)6)8WU!S+IBLX@Q\5F*\].*.I9]2A>K31EX\1E5\>49
M^[T)"HD39&HVE53W1A1S.42])5FKU[$\=J!ELQ-!)Z<MNLI/J0ANT@2:)4'M
M([Q&6\$GFU5>UE,["U5;[0/NBX7B@W;6L=8=5OVB6^]DXBQ)B79Z*M<HZV%&
M8 E*O9F(>2AOTTID@(^)^Y?+:=;2VG49&Q$A%3[OK5;<,\J6GAC*KI7"JD6V
M8D,H/>671# *NCR-A,=<2V^1;-7[V-GKPM2K6)_4):1&,SV T0"E256-(R "
M"7WH#FXFOI]^UT*D6DE/H)LM0K4^0CVU,^A^9A@I%U/M+2E;7I<)5CVUI2I'
MCTJ3C.,XYHV&B0/8$@?/Y_7G5GP3^O)?RG*<<<<U'[<=4Q>UD=H^/*N[](QI
M;L+K??;+K%?;L&;$_KQZ0>;J[J')B'_2VI7[_*5RZ5'K"]K&<1I7KSA/0=-9
MX].WKMU:JVS<PF3PQC:8P^F,D:Q-@.(Y2QA^'&HNU1)W>9%[?,V"Z8*.6I",
M-]ZT9:1D+:] 2)(GJ!.TB30D)["R;U^\-\HS>OTU=?[C[I:([K1EQ(HMXU(=
M&%6N"#K+,P'L]%?>PJNY.D53D6J /C!'C(YV2;CYE9H*@&5LM8C6_>VN"ZUN
M87IS/=-&NMNEF4?T"TQB..FG1H[<L:B*3UEL:A<Q%H522-W#,TSZEMF)7PKX
M:1.]>\&&<OYAB$T=@P^GV'O7U4=D/J+V&:3PP( C4K].&_US:.RK;UT[E[-Z
MY:YW-L)[:FS=55C7>O+<@^]GY%7-3-1N5N&+EJ8B;="&7)@# R(1*$K#=:7'
M^T(SGI]9TQC,?0S735'.SX>K\#B;L]V[4:"DO=Z5:U!5=8[T=<.5A,A1D #=
MQDW(;[&7AM*LMG'039 5(Z;76FG4210]XC>2O&R(9U61_P!L'5RY$A.QHS[M
M=].^D]KMN]6=M6>[R40=ULL8\K(1V:^'*YVC"#35<L**[.ECR,&-$-*F*ZT8
MX4-%2#"5&EI8C6,91G$7IKK&UTU#U##5JQR+GJ8KJ!*T:T)T6VD5F$.D[R&.
M.Y*GILZ,Z]O=+^'D6'(R0X6]ANWO6Z?^LLVI(5DA->V%55&WLP=J%PR>F45@
MK>5Y]^LOT]:1UI[/=FNS$-;R[#)]AY+)H%6?@$10FNAY&<.LEI!CY)N:/Q.(
ML4V0$8MY<7$+#P!AO"2?N7%ILRO5]K*=,8+IJ2NL46%V&M"4N]Q8T:*HKQ&-
M?3%6%FB'[64."" F@.7Y?*/EFQQ>/T10J?#L _?\1+Z-2#XAB40H52L0J?CT
M)G!=NU=;F;6US ;?UE?]5VEOW:[L.H6"G3&,(PXM -@C"8UY]I"E)2IX;!'W
M#'E2<8>:1GU8\><<M7GFJV*]NN_IV*EB"U ^M]D]:5)HFT"-A9$4D;&P-;Y'
MQ]Q\?>JW8U[VK3QR]A8J)%5AWQ%@"565.Z-B 2 Q(\\ZZ^K?TKM=]<^I^\^K
M<IL>P;":[ MSX=YV,U"M5&PXBY6LCU:+CXT/]:LJ&&ZZ PXX#[L@^RZ\41AP
M9##F6L]QU1U[;ZCS>(S,5&'''"R03TZGJ_%0FU#=%YIY28:_?Z\JQB5>T;5-
M]W<Q/)GWS,,W%FEBC#0+!%!68L8XX(1)N/O3TVV[SS/ZB"-T[T"G]E&17^M/
MI06^EW;JO=;?W(O6S\]1[,I[5]9G=6T^#K$?K]X'[ RFLB5R6 D,SAC+0>'[
MU-2=A,]  C#<.@=O+2IUW[0JUE.H5@Z8I4I>IJ'P^5LPW[<MB6XIW#;4SK)'
M%!$S2L:4,<8E,G=)89E#<3Y2-Z%['5J25*]VS7N:29Y'6Q#9-F229Y%8SB0L
MR1H/12N'D**>_0LL#Z9T<#U?[<]:O[8S71^UFV;]M,JX9HS"'J0[>IJ(F%PC
M$'BUJ18&XQ45@=$@Y*PRB\/Y<R&/EO"%Z>3K%WR'1M_[O4'I''X:@L7Q)(O_
M '1V:E9_0_V8S]@V@6?TM_O2<S#.,,ZV;^&!9JK5OAO5.@&AMQ=_J^GLD?%%
MNWT_\ &_Q;$AGOI]2RMS=5MXT#L'8-=V[KGJ&O:,L"!*!7+$#M36\.2P3(1#
MS,[(OXIA4[G[YDF4CTRYP3!C?V+S1(B"7+H>L(A6ZII7,/#=J=27VRB1M<F@
M?'9 &;T9TEAC!M+")$_8R+''(T0[QV.Z&"MY1A/N>2NDABN37JEOO=&K6)Z\
M5:1_27\,VHXE"*[A%+.65R4*5OL_Z9FTMZ3**]O'O3M':?7W%WC;N[I^>U-J
M0&QO$1,FS*@P^-P0<5&V4&';?8;86)$14<E8F,-XPA['W&9F+ZVQN&C@LX[I
M+'U<[6K25X<O%D<F8@987ADFDQDLTL$TK+(YW-*ZAB.U0JJHF/F(DCM"ACH*
M$UVO)6GECFGGC6&5 D@@KSLR1-VA>URTC*P9F+L[$]DNU]<#[.T_LC4B9)=?
M$V!KBW:[3+MB?J2X4>TUJ0K>)% +A0GWZXYH[[E(JS1ONLLX:44SZ\NIX6"P
MT-VK<9?4:O>JW2F^WU&K6H[)3N /8)#'V]P4]O=L*=:,'$W?NK)8W(+$)ONZ
M[3N+"7*"7X2>.81F3M<H'],*7[6*[WVG6CH4']-:.$UQT*U[_:^:XWT;O4==
M@I7^"&$+V2N/0ZC$:4'_ !4I-50[[OG)31-@RCTXQ]NKSYQV;];N^;ZIS)QJ
M@]38JSBVKBT=4ULM5)F$OP^YRGPH'88X0W>?Q#M\U^./P>=I^D/_ );MK;:3
MO_ZL5L6K'8%[?VH/Q/9W%H_W.[7XM+8G9;I!*[?V_5NQVD]^W#K%V$K5*,UH
M]L&LU2L; B;+K\Z2S+JKMFI%OPF&D?M))2RXXY+[#XSV6UNH)4(!D778#J:/
M$TKN(R.)K9S"7[,5Z;'V)[%-X[T40A6U6N52)H)&B6..0 ,K)& H1FD9Y%?)
MQ+3CHW:,5^O7LM:J]TLD$M>9D*.%DCV6B=6<M$PUW.YWIW5J3G/I/T8_K*5H
M*/VW:4VRT[VK/8/:.Z[- BV6U;(O4#-.2S[LG#L3,#'1C!C*VXP- !.6HP9G
M#N6#B77W7-HG7EA.H,;F!C:T5'#8^UC,7A:\KQ5ZE2S1GI=HG>.:21P9S/))
M(C-,Z]I**05O3-V#/EK-A$FERF*.*TA]&*K )('B]&,*^TB]$@1E@6:5V]0
M!>;,(Z?")[E6KMY_'Q&2K/U]"T,JA?PVW@<)@.9=E\6=-C_7/<?=<R[EC,1F
M$:0G&,.?J*L_R<T7W^W]E+/2_P *.VQG6S?QOK'N1FH0T?AO0]/3 "$2>KZP
M.V*^GX[C$>\6JX:KZ0'W1-+*'[]_$&5Y'[2O:/3[>_6PS[UO0WXU@TQ]*J,T
M_KF#UZSNX^?;A3+*7B5<U^/&K(S8[5-V=:,AIN)J6L"+F5!I5@ESWDCX?SAO
M+N6D=5;^T9[<PF.(1"(*L/:+Q;Q5JPU@V_A1^^(0Y&OPENW9ULPLXWWUEKV5
M8?#F[.9C"#ZHC)55[1)J/N_=WOL7WUKG;=SS3EO'''''''''''''''''''''
M''''''(19KN-!FC0,7'&6BVG-)($K42IA#[(2G<M*EIL\I;8$#"M*0[Y.D'4
M.&+9=$AQ)22P@%<F&L9%,KNL,"DJTS[(+:WZ<:*"\LA&OPH-*"&D9$VPTN2S
M45*>*A6KS9/+3J)(<;4*!T@+]C6[MB5EKT*2'NW/8=6F*-#3BM6>V!H@31[_
M &6:@+-.V^*JYU??DGHR-IT*B0<'&EH[,>;%2=ALBGTS@;N?9/<]FM02%'@Q
M;R6,*C\.$WL])!VQP2RD:_:S2]@;7=LB&(#L!!'X3-+H@GN\Z$:.IU+8?U;>
M6HX^,]Q%+&4!9:(%4"K)D<@["RR,)&,D>-I*P=4](&,R29XF#V2%A+T->XR5
M6WA.5 6NKB^P7Z5)RMO$C6B(1Z/6\WA3:2OL)% SB\/Y *0W]JY19*;>)*SH
M#_C@G.U\'SV3+('T2"5[D) *]ZD]PNFI=11:>EFZM@J!NOE,9&8YB'4E?B<?
M+3>N7C#1K*(+"Q.XE->8)Z+\JOW=PR336K3#N5*V*;<?&CG2TR41.BLIQEXR
MKV!L<1B7:9_GR2 0+&6 %M'W)\**$\*412:L%3UH)!/!L N%[)(F/LL\7<QC
M)_PN&>)SX21F#*,F/S3S6?N[*4VQ.5*N\==IA9J78D_>FQE]8X4MJH!,D$D5
M:_ H]2Q2BA>*62?<B\WO.*:<%&BOG2)8H 0K:G23#2&A11VD_*G'R'UH::;3
MC_:6XM*<?OGCCE8?Q].6MQ0NM:\X<"I.4*OMG9*B*@PM7G&'8@!S ]@N?H1Z
M"67(IB/K<@VXAMBW-.^[AERF]^W^?]?J/R^A'.9':RCW)$6?NDF=?;"(K+H9
M$XEEN!AWL_.'*_4Q<)A(YYGRI \H0Q(V)#2UM.SCR%JQERO+-XXY%;K4P;M6
MY"O'NO"?<_;D@20OHP;#R\<2T?#S(.7$K;P9%R0XQK*74+9=4SE@AMT=UUI;
MCE"5&PWVXAN@1-7&_5(4PV"L-LE"7(ZD/2\44L$PNKY80;+68(OV\20F V1X
M]AM_$2=/"3 9XHVS%.*!$DR$[0LX#I4@42VV0@,KR LD55'\=HE9I] 2+6:-
ME9HO<S,1$H< Z+L2J [T0" 6<K\^T!#[=X8%1.L439>!_/\ 'E0R9Z59_P";
M^42!ES/G*4^SB^9+2U^,9_UW+GYSA>/A.*>OC.\?['<$8/ROP^IHCS^+X )O
MY_N ?E\^7>G-K^\C+>/)B;7\O5)/\^0BV7.QZ[ =>N=.*)<=6.#!2%2(S+0D
M_,G$L@QL2248Q'NU(F0-)&:018D-00^''/,\_EA6%W&I%.CR49FG,:%I*TJ"
M*VB+MF=$5WCL(@!9WA;U$5?4DA1-E;"60@2*%!\!P=H3\@3H%6/R##1/@,3S
MQ3:;(#'OW6Z$#2E[E1LC+4+[BXBJ0[COW#57K"'?YL"L+]&96:<:9D+*<TDT
MQL41F,BHW7@'P2#[D_,^Q_=^?YGS[GQOY\R;^G@?RW^NOZ_4[)LKS_U>?G.?
MW\^,?/XSG_?^^/Z<>1O\O'TT2=D>?!^H(^@\:]Z?U_+^O?GJI.%84A:4+2I.
M4Y2K&,I4G./"L*QGSC*<XSXRG.,^?WQXX.P?.MZV#K?M[CSO]=^_\_#FA5@Z
M[S-*VN5,=-=A*Z^W"2'-M^T*QF)5<NO]H(/0L2!_B?3+TG#@P]CLLBU)&DVK
M6<U1+&0S$F&6(R;4['L.YA,' 29/6 &@W=VRIYWI93O8^05PZJ-]H^?,ZRG7
MXQWCV!WI@-_)@-'6]:8$>?&N6=']O=M:Q<9C.T?6NZPH++26W-Q]=1I??VL)
M!U.<IR2;2ZY%(WK35/I3DAP,G75FAHY+B&/XQD5)==;H8$;S#*I/G]G+J)P!
M_P!HL8F^8_?5CK837M=^!OW7&_\ =?\  W\R>T_P;?Y<OC7?;GK#M=W[.@[X
MU=/3"<Y016<V^(BK@"XE64+9DZ9-$1UJBWVW$J:<8D8<5YMU"VUHPM"DXQO!
M,GEHW (V&[25(^H8;4C\P2.5*,/=2!]=>/X'V/\  \V%8(8);2\,^R0TK'E+
MK#B'6U8SCSC*5MJ4G.,XSC/QG/QGF+EO/=2DH3E2U)0E./*E*SA*<8_KG.<X
MQC'^.<\<<IO878S0&IA\D[.W9JF@H\9RVU;+]5X,LE6$K5[00)\FR:<0K#;G
MMC!COD.90K#;:LISCF1(I9#I(W<^_P"%&;Q]? /C\^5"LWLI/Z G_3FMDCWH
MQ='$QO5[0NV^P!K^/"+C*P<CHO2H&5)\M$F[+VO$PY\_'J\I5DC5]+V.XI&'
M,-,./-J:YE%?M\S2I&-ZTI$LA/T"1D@'_P!MDW\M\J5"_ONJ_EON8_H%W_F1
MRE[5IK=&X['4?^6;L<*Q:SLIIPCF@M+*FZ-IN$G? YM8C-C6=TMN_;G!D\#&
MQK[-@,JM)D)S$2(J@+3)9:<N]6.+7HQZ)\>M(0TOGYJNBD1'OM077V$A]S:9
M5&_3&B/9F +'W!('[J_7YD?7P3S?2&A(>NQ,=!5Z*C(*#B V (F&AP!HN*C0
M!FTM#! 1X33(@8K#2$MLCCLMM-(2E+:$)QC',)VQ))WO\1).V)UHG>OQ-O>R
M=[V/8^>8"23LD[._._._Z/\ KS)_X?/G&,?/CQC./G]L8_SQX\>?^'G%#Y!U
M\_.M^?Y;/N?ZV #3_3E>6FK2.)!%RIRV!+@(.V,6,0MQF)N$2PO+F(*<RWA6
M&R&\*<_0IWVWBH,IU>?03&DR,<90^V_/<"=GY?+ZZT1O0U[?R/+@?D?(W[;]
MM_/^'GQ^?(B#N&0NA9%=U/1Y*XW.*=4'< 9P_%0JVMY9#>%.0UYMBP)G"9C"
MO&6(:H1%OEGQ'@IE0@]>D09E_.L0"+),QBC;97:]\DB[T3'&"H* KKO9D0L"
M =@KS,L'A7D;LC;]T@=SN-Z)5"1L>X)+*NP0#OQR<"Z]W\^PZ]([/U>":ZZ\
MXP'%ZHL98 +*E9R,*Z6?M)HN5=81G""9!#$,@U6,NLQD=A6&46L]?8"Q2]H"
M[[IE[MC]XKJ'\()]A^(@:!9M;Y<5A\=J2:T-EI%V3\SH1@ $^P_%KQY/OROK
MA9=CZM@RC]Q4D"WU:.%*?-V+J,:3?9#^W$60@NPZZEGI&R50%]Y"Q52418[[
M%1>%(DK%(P<1@LL/-&5[BU61D?6Q!*5[F (/:DH 20Z'[K)$6/A59M=UZ+IN
MZ!V4_**0@['S'>.U7.O.BJ$GPH)UN5-TNR-UN&GGT1QRI&+$DC6X(G]1$ 48
MR@G# IB?B6$80ZEI$J,A#)V$9,0,,RZAM,V"ZDA[)!Z<GMH_ND[UH$^0=_(_
MH">38K"/^!QV,?!W[;'T^8V=;!_0$_*,\F\D['S.P#O_ #\^-#W]] Z'S^A<
M<KH#7MX(\D[/YC6O!_(^W^?'''N??Y^ ?/@^=Z_,G?Y#?T\../8Z]]#\O<^#
MY_P[]];_ .7''*'Z_0^ =$?Q._/@?F?&OD-N.7>X!_37R.O&R!]=_J#[ '?G
MY=?[=%U4ZQ]?[QD(5$G/6ZR:N(D<YQ&7JHW23D;18*JRHI/VBK)39J7G(\JN
M-NNN%4Q4!-!-.,*F18;4WH7246$WVMVDL!HI(OUU[=V@RL=;/</=23K+,95R
MXWVN=@^/!^GCV^OR\^/ESKTJO1NR1>S;-TU(L&P:7K'6[9FX^GF^:='%%R--
MT=LV6)K.]^IUKLOI'!84&8<0[0&I%UQYBM24-+ (D7ZB5'M]*V<C^'CRXBKS
MV+!6KEJ,S*%FNUE$M'*Q1G9T>T>OVC1D1T<A90QU=RJMQ.TN\3?B'>G[P5P5
MD4;^3J2#O>CYUX'.T79Y</ TR)ZV:P;:8MUNJ[=&K\+$K]YS7NOEA)K\QL6<
M0TXEV/A*K#+=5%.&/"KLEH_2:\ 3][(.$#<>SO-))8E)9FD:1V/^.1R7U]-L
MV]C6@NSK0UR1%$D4:1QJ$CB5410- *H 51_ ?\3S8F&B@X&'BH..;RU'PT:#
M% M9SYRV''"M!C-YSGYSE##*$^<_GQYYA)V23[DD_P ^7<R7*<<<<<<<<<<<
M<<<TY[W]I'^H/7.R[:A82-MEZ>F:U2]:4N4((88N%\MLLQ'1$)C ;K)KW@?[
M^2>:$<;=R+'$*RZRVE;R-_TOA#U%GL?B"[PP6'EEN6$4,U6C6A>>U8\_A4*B
M"-6?\ EEB4AF94;:XC'QWYK!L2M!3I4K-ZY84 F&&% J,=AAIIY(8SX)(8A0
M6US ]!^W1W;?0).QKU6HS6^R:3<KGKS;U)')?P#3+;3))UDUA3TB^\0R*N,4
M&:M91#B67%%-9?6D?*^3.L>GJ_3F2AAHVWOXJ_0J9+&7W4*;-6U&&#_A55V'
M#  *#VE.X!B0(MZG+2R-G'L"[121FN5!)GKV$62O(H'EBW<T1[1II(V* HR$
MT'V0^J7J:D&:<A^N5]TYO"?N?9>A:-V#$ 6O]4+J,-;?U9LN?#8@SV7"'A28
MY PIV?O(5;SF6EN+<4VG.SP/0>2O2VFS-+)XJFG3^3S%2R]5HUGFI&L8H&:9
M"J+*D[N58+*53N0=H8\V"8>5*6:GNI/5GQN-%^O$ZA18/Q$,+(W<-GL67;JA
M$D9[>\ 'SM1V![I=?]#XM%1G]P:NBMR@TFPV>KZTL=KCP9B9/CH0R4B(\D+!
M31 N9AT=IH,=YP4R00ZG$>EY:V\YYK']/YG)P-=I8R]9H0SQQ6+<%>22*+ND
M59/Q*I#&-6V_;W>GX,F@?.+'XFQ;FIM+#/%1LV887M",]JI)+Z;2*6&BJGN!
M?1C5@0Q!!'-8M$=];UMFC]$[U8$:&HPW9Z"VM-WVN3EEM(%M9:H+Y+0N-01?
ML'C3^!6AE&6K%A/'R"(ZPX&IU2U(1TV;Z2I8C)]9T$?*6DZ<KXJ:K8BAKO$I
MO1>K(V6?:>A#Y[*S0*S.ZNK@:!-C41\+DI(DLO-4S<&*@(1#6=);ENL%FD!#
MK;E%=#7C5"CL9 Q4*.1O7'U6M?[VUOVYL6JY?4=;MG7N<LP].'V;=I-%3M5$
MKY\5$![9L\E!PZ3X*F6.3/<;CD #GE#HR(EY]YQUWVZW^@LAAY.E#D8KSP]0
M&@+:5:H^)I6+KJ3BXEED[)\C%%W'3&.)I?P#\([VGS8%Z>7@QUI;4L4M3U?5
MJPJ9&M+7GFL5XTD;1%,I&D[,P/;WN%7PHWCL/:?3&I=3:[V5O_;>J];CW>M5
M^3'D"+0VQ7IN2DXD \S^#,R/M3$Y#H<,2Z(2@%;Z(]T8@Y#&7,^.;3 Y"]E[
MV+PV/R-Z2K8LH(?A]VHH897C5K:Q=T4#Z7M?;A/5VB,3H'2U*=RZA:M7DG":
M[VB4M&I.R 7.E#$*2%)V0&(! )Y()+L]UZB=80^ZCMQZ_1J:?E8V#A]A,6($
MVJGS$N:J.CXQF6!<)&P:^>A8:AW%(<8);<9(PRXA2<8/N/,?>)Q)QMM<F%D<
MTGA9+'9#"]B1^QPI*+#&\O<-J44LI(Y2*M8F:=(H9'>M&TMB,(WJ0QJ4#-(A
M ==&1-@C?XE\>>?+5?:;KEO&QV2H:@W9K?8]GJ.%+L,)4;3&3,A',(>2.X7E
MD5]>2@6WUH8</"R2$V\XVTM]*W$)5=>Z?S>,JP7<CBKU*I9UZ$]FM)#&Y(+!
M274%&90657"LR@D @$\K8JV:C1K9@E@:4;C$B%>_7D@$C18#RR;[U'DJ!R.P
MO=+J;8]I.:3@NPVIY7:K4D3#9I 5PBGIAR9"6MLN'&2E_P"V+EQW6G678P4A
MXY+[3K.6/=;6A.8],=0C&C,'#9$8PQK,+AJR"$PL 5G![>[T&4AEF[?2*$.'
M*D'F2Q0NU8A-8JS0Q$J/4D0JJECI0^_[LEM* _:>XA?WB :\ZQ=IK1O7?7<W
M4DY6H"%B>LVSJU1:U*1+LBN1L0,W!%2SYLX@PAX9HMEUA+320&F&<MYSE25*
M\9QGRF$@H8#IC+QS2O+G8<G)/$X3TX#1OO301%0&(=$[W[R?Q'0T.9LI22A)
MCTC=G%S%4[[E];22Q$DC(O:!^!2^EWMM#R>;P<YOFMXXXXXXXXXXXXXXXXXX
MXXXXXXXXXXXXXXXY&KC8T5.M2L\H=9CP;+30 #><X<D98\EF.AHQI6$J]+DE
M*EA@H7E.<(41A:L>E.>9J\)GFCBV%#$EG/LD:@O(Y_)(U9B/GK7-;F,BN*QM
MJ^8VF>%%6"!=]UFW/(E>G670)#6;4L, ;1"F3N/@'E4V>>C.NVG-B;9MC#UC
MEJ]7)>_7LN+3A)UDEH^/R\L".<*^18P?VF8:OCDJ]B)B6ADO95ELAUR=!$^7
MR-+'P,(4GGAIU!*?P0I+($5Y.T>78L9)F4;>0MK_  @<KD[U;[/.C>I.K<K%
M)D;6+Q.0ZDZ@EIKNQD;%&F]F:&KZIVE>*.$4\?%(W96JQQ*Y)61VZ*+;_I ,
MA470FR.M@9V#L$K;6SL-YC*,#N(QZ5H<K3N<YRAUO/K2KTJ5Z\83C"<>=_U-
MTA)TY+51KL=I+:2LC",QNC0F,.'0LX[29%*,&\Z8$ C9\N^PW_I"4_MIQ^>L
MP].6<#:Z?M4H+,,MR.[!/%D5MO5DAG6&!A(HIS+8B>(=A])E=A)I,YJW_2'=
M8S=F!BMLZ*LU'KQQ+([MJK%E$MOZ.EU6$9+D8,B,A2R F<J]PA<<408VRE61
MX\QWTM9Y8U6T=,"?D-:W^6]\]X3*1E@'C90?\0(.OS(^GZ?RYWX^JG[GH$)/
M5V;:DZ[:(J+M=)N4"\C+XR3A$'P-HKYCC2\L$H9(;>94MKPXRX\$:PX.^2,O
M'#,]>7O !]TDC??9(A\/%(H()1M>1L$$!E(901?D\=7R])J\CO$Q*S5+E<JM
MFE:39@N5)&5A'/"QVI*E74O%*KQ22(T0@-BWFR"DU^(J&%7*O%DUZX6"9P[#
MT2*GP/3[C\>C+S\]8&)0)T*>BPX@=T- $F*%*6&-/;(;;NM1+%+^S),,B+-"
MS?O&-QL!CH M&P:)R  7C;7C7,&"R$^0HGXQ8X\E2L3X_)Q1 B);M5NQY(E+
MNRU[<1AO55=VD%6U")#W]P$DC]9CEFLS5]ER[[,M+;('&DVFQJ?"EH_#M=I[
M:G8\5UKXP-)3#TY/,8POT3&,/.X7'YN>6A^/QQQQQQQQQRN=@.G2.8&D1I!
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M1KM8^524#8#$#:LI*MKY'QR9T?UE6ZIK.6@-'(5W,=BH[]P[E"DO"Q"LR?B
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M?IS)59E3#18W$5)-3(L<-J#<5^M)7#]SSW#V1H@B<S,G<_X95+XOK$/[BO\
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M%;$4A:%92I*DUXS*5)5C.,I5C.,9QG&<9QG'G&>8(&9)HG1BKK(C*RDJRLK
MAE(((((V"#O?-S?AAL4;E>Q%'/!/6FAFAF19(IHI(V22*6-P4DCD1BKHP*LI
M*L""1SH.^@_IC4V_ .T)>Z]<TW:I-:-TXQ7W[Y 1UE=A690?9RY%J,7*,$9#
M;.5'@J*2QZ,/J$84YA66TYQLLI?NW)(I;5NQ8D"E \LKNP4=NE!9CH#Z#YDD
M^3SDNC>D^F.F*=JCT[@,3A*<LXL2U\91KTXI)W#]TLBPH@>0@ =S;(4!1I0!
MR9?7-ZC==M.Z8U9L[4FJ:CK6TF;+55)AZF1;4$%-0Q];EY)+<C& J:CG20S(
MIAP8U(B2TMNOL+>6RI*41*TCLY5F+#MV-G>B"/KY^?\ S_+H,C!$D:.B*C=^
MCVC6P0??]-<[5/I &EF_3XT)DLATC(H-I"'RZO*\LB#V^<2P.C.?G#3*<Y2V
MC\(3X3CQC&,8P3?WK_K_ ,!R;2.ZL7Y#7^9YO55V4BWW9S;;CBFS"*C+N-*6
MI2&C"*_B+>]I&<Y2TEP:%"6I*<8]3N7',^<K\\S3'NK4]@;59XP0-$J)2X[C
M\R#(P!)\#0\ <U6-B$6;ZC"LY6>7%VV1F+*DKT%JOZ:DZ16CIPLR@#<A=SLM
MRQN1.=!QQQQQQQQQRO)?^[VC17G,XPT[3MCQ[7G/CU'/RFN3V4IQGXRO[**D
MEX\9]6$(<\8RGUYQL(O.,O* =BYCI#^2+%D8SO\ +OEC'TWKYZWA;^_B/R].
M8#\R6A(U_!6_A_'FM^].]&I-&7%Z@2,?9K5:@0QSI@>O# )C(-LMG) H\G*R
M!XJ$GO,9;(^S#8,6R.XEPI0ZE-MN=)@NALMG::Y".2K5J.[1PM8:0RS%&[6:
M.*.-R8U;:][L@9@0@;3$0[64KU9#$5>1P 6[ .U0?(!9B/.OD =?/7-7[#L[
M4^_M0SO:[M4@ZK]<=;R<@!3:$&_*D#VPK[AF+7-2;D4V)*V.2DYE]FN0L9&+
M"BU$"%)*6Z(X6YG=6$M]&7!@L%*DN;MPQ27\BR1^I55AZD=:!)#)'"JQCUY'
MD#RZD0CM8+J/"JY919L*165F6&$,W:X'@R.P[2WXO "Z7\)]_/)-T-[E=)]N
M3\IK#05&>TS="PGY@>GV&OP4',6^&B?6I\^/,AIF=Q)NQ0[B2#X\PU!8;;RW
MF&RAV22&N:ZA3J";LM9>]+D40]HE:5Y$A9];'8RH$#$:!5=$J ='0YL8(:\
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M_+^?MQGS_CG^O_#\_&//[_M^/Z?&>5_/1[A[ZU[GP=^#_#QH^_D;/'_=^O\
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M65>X8:^XE*TFSN4:6"<V1ZE;+29N%A!7 3)RR12O8[1$%8&2&-O18& =I B
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MGQC&,8^,<[3[5%5.M,BJ*J+\/CSVJH4>:4.]   ;_3F#, #.Y\ : S-T #P
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M>M6)#+K?C"O4E><JSF^-3][[MH=V^[O[+>OR_9_%>CV[WX]/1/@[&@+?2/\
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MS["L)=PLT4.3CT%M5G,N\X-50BD)P@T>JQ\,,;A"/O&WU-IRF*\TCJ5 5(_
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M@6.RR+G*(YS/VS><X:6[\YXJ+J3.08B3 P9*Q%AY!.'H+Z?HL+,SV)M[0O\
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MX_;&>..074PSXNM*/@IE8YA5:BY0YAW*LNLGS Z98YIW*LY5EQLLUY+GG/\
MMXSX\8\8XXY87'''''&<8SC.,X\XS\9QG\9Q_3/''*RTVTD36E6B$XQA%:&.
MI[:4Y\X;:ILL?56FO/C&<9:;ATMJ2K^9*DY2O.58SG+CEF\<<<<<<<<J:R*S
M3+U!W!"TL5^WJ"I=RQE*<-LRRW5(H<^XO/RSXD""JD6IO'DM4_!J*5[$.RIE
MRGS_ "_T_P#'\OX_E;/'*\<<<<<<<<<<<<<<<<<<JNW3\M-RJ]=T@U8<VXP.
M_:[0.A@A%$A2\.J9<0V0AP8JT3;;#HT''+]>8]MS-BD&' AA1)1QR>5^ B*M
M#1]?@@T 148Q@<09*W75)3E2G''7GWUND%%$O+<(++)==)+)==))==?=<<4X
MYF..........................................................
M...........................................................8
M2QUV(M<.9!38OW0!B4>K"''!R1B&5I>$/CS&%-E1\G'DH:,CI$-UDP QEDH5
MYI]I"\..5Y5K)/5F7&H&PR,%&$J<9I-XRAI@.[BL-//XC))IO.&XZ]1P+"GI
M,-+; ,^.V[-0"4H;E8J$<<M[CCCCCCCCCCCCCCF"L]@"JM?EK#(8=<&B@W"?
MMQVU/%FD?#8<<"PC"G"9"2,6P!'BM)4Z4:2P.TA3CB4Y<<C^N:[(0%=]Z=4E
MRU60XJTVQU&4J;1/3&&W'HX=Q.<^X! !MA5V+6K*EKC(@-3BE.*6K+CD]XXX
MXXXXXY6VX?4YK"[A-J<2[,P!==94RO+3V'[+Z:^Q[+F%(4A[+TDC#2TK2I+F
M4Y2K&<8SQQRQ&&4#LLL-)2AMAIMEM"$X2E*&T80A*4XQC"4I2G&,)QC&,8QC
M&,>...?7CCCCCCCCE7ZXRL*2V;7LHPV/#;%DC(Y.%*SZP[?#PEU+=].?A'KL
M5AGT>E.<IS[?KQZ<KRA+C^ART.........8>PP0%F@Y6 E&\N 2P) 1'ISZ7
M6\/(RE!([F/YF"Q7/02&2WE+PQ33)#*T.MH6EQR+ZWGY*7@GXVPNMNVVHR)%
M4M2VT8:07)QK3#@\VR/YSD<2S1!,;9 V/*_MAY5 JG%N#N9XXY8'''''''''
M''''''*RM-ND299=#HBAB;@L=I^8DWV\DQ5#BRTJ]F7F4)\()E2DX4JO5SW&
MR)9Q"B2%"Q(Y1B7']?IR45.J15.B<1<9A]U3Q)$C*29SOW$I-S!R_=D)F6+R
ME.2CS7OYG%X2AEEM+0@C(X8XX[3CDEXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX
MXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX
MXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXYA;#7H>TQ!<'/ M'QIF&\N,N94A;
M3S#J"!#!'VU(?#/!*::+ .%<:+"+99*&=:?:0M+CE:AV68UR4/ ;!-<D:P^X
MT)6]E$)0A+>5Y0R)"["=QE# $V^YE+0-D:8&@YQU2!R414PZ,-)./Z]OZ_K]
M#RY/S^......8B<L$#68YZ7LDW$5^)'QG)$G.20<3',8PE2\Y>-/>'&:QA*%
M*SE;J?Y4J5^,9SC)'%+,XCACDED8Z5(T9W8[UH*H+$[('@>_+))(XD:261(H
MU!9GD=415'DEF8A0 /))( Y$ZKM[4]Z,7'TG9^N[B>VGU. U6ZUJPF-I^?YE
MC1$F8\E/QGY4C&/C/S\9Y(L8^_44-;HW*RM[-8K30J=>^C(B@ZV/;D:MD<?=
M+"G>IVRFN\5K4$Y7?MW")W*[^6];^7,3,9<N.Q8JN,J]5>U_@6U6I.<*PT?9
MC6W/X)AO5\H>3$H;,MDBRKT+%,;IY",N((<2F'R61O7\_P"7Y_UO]-\MGCE>
M.........5?LY2BOX @,(RMN?V55ON<8SX] ]767>_6O/YRVHJJ"L+3C&<+P
M_P"VOPVI></^/'+0XXXXXXXXXXXY6D4I(&V+@#G"4(GZ?4+ -G'C"WBXP^QP
M4QE6/./.&!/X92E6$YSGW\I6K&$MXRXY9?'''''''''''*DM2\TNZP5W;0RS
M!658%*O3Z_*4BN//NHHLZM6,X2G#$X<NLEN+PO&6;$"\XIH>-4XEQRV^....
M.......5-,6V7M<D94=;OLI6$0X#;+XMI)415LH5[)L5!Y5AP:;O3.%^ID%;
M9$-!.H4_8U+>0/!R;CDVJU6B*A%)BH=IWT*>=,/.,>67*3,H3Z5&S$P>[Y?D
M),YQ.%DE/9\^,(992T,RRRVXY(^.................................
M............................................................
M...................................<<L04\4D$X8<P(QAT4L0IEL@8
MH9]"FGQR&'4K:>8>;4IMUIQ"D.(4I*TY3G....5'B(LVL/YZL.=;]?MJ]3M/
MR_DBS5(5*,>K-,++<]R=B&E>MW^%I0K[X)G.1ZV>L9@"NX<<C!6SY?:<PJG:
M3DAAPP64*V#LXN/44S1'R&T.L5"'@9%II$ALYUG*G)*)FVFQ:&,L0^SQAQ1L
M=7Y#8PUX(8%N7 7$F_A*BL4>QVL5::5A^**JC J"H[[#JT<3(%>5(,LTLLS5
MJVE* ?$V6'<L'< 5BC4_ADLLI#:)[(4*R2!^](WEM>T7K."D1;"77F;?<QD.
M^;[?%?QA<E/$J0X:Z+-3:2EP;!;Z$NJB*TU"P(F$MCQT4$&P.,U;+DKDJ-$L
MI@KMV_[+6_85])L)W11D"5E!($DQDE.R7D9F8FZ*A6C99#&)IU[]6;'[:?<A
M!D[9).XQJY528XO3B4*JHBHBJ)E:J'2+S'XBKG4*S:XU+C;R K#!QLP.T^RZ
MV^P2PV>,^E@D=]IH@<EGVWV'VFGV7$.MH6F/#9LUG[Z\\T#Z92T4KQL58%64
ME6&U92593L,I*D$$CF:6O!.H2>&*9 RN%EC210Z,'1@&! 9&565AY5@&!! /
M*950+#I/,G8]3YEK-4'RDRUIU+*G/S,FXAL<<8V6UQ99<A^:9G6(X1I(U/GY
M*1KTJT$#"03].0E#SDU9X+Q].XL<%AC^SO1JL:%CO2W(D C:,G0-B)4EC\O(
M+ \")Z$M,=U4O+ H_%4D9I&51KS6E<M(' !U#(SHYTB&$>>7M6K)"V^ B;/7
M3V9.$FP6)".-9]6$NCOI]6$N-KPET<EE?J8+$(0V2&4T\*4TT0RXVG7RQ202
MO#*I22-BKJ?<$?F/!!]PP)# @@D$'DZ.1)HTEC8.CJ&5A[$'_0CV(/D$$$ @
MCF<YCY?QQQQQQRM)[.)#9] C/3E3</"72W/*PI6,-%-IA*M&MK3C.,*^Z'LL
MVXWE7E*<@+SX]7H5AQKV_+EE\<<<<<<<<<<<K&>:2'M37LJI*<8D8"\U7#N5
M9PK)!&*]91QTI\>%>X/69%[/\V%8P-YPE6/5E+CEG<<<<<<<<<<<<UXV=L%%
MB-GM,4&I";.N3\:,Q<039=<%2*%$324Y:(O=J%"E2XV9+CE.R5=J\)%R=HDL
MMAFN#PD*0FQ#T/GQ_7_C]..<:.U#N.1CHM%V[-79N2$; ^_1K"EZVIL-(*&#
M0P2T\BWUC9EAPT:_A99) UC"+R]G'VK@3&,C<KQ_7Z<YK.J]LP'O%5;L;<YQ
M]1*RQXK:U1US:Z\EK+:_;B_72*MK*SI!]>6\I*<LI<DCTY4LDE.<M*<?U_7]
M?ISTB]\"UR713=Z@Q&J+D0Q(%5\MZ?9/HFQ HQK[DUZ@6,L>++.F0@\I)E:5
M*Q<=:@6\/D@!3<(Q^N.N.2+.+7M#'A:)>AZ\=]&<H7@J(OMQ&S\K;<3_ '!U
M&@B$^$JQZFK@:TM2<XK.4?ZTY3W_ .7CS_7_ !^7+4B8F,@HT*'A0!(N*CAV
MQ (\%AL8009I/I;988:2E#:$X_;&/.<YRI6<JSG.7*\R''''''''''''''''
M''''''''''''''''''''''''''''''''''''''''''''''''''''''''''''
M'''''''''''''''''''''''''''''''''''''''''''''''''''''''''''(
M5LBW(H.O[I=5L**S5JQ-SC(:$...G%1T>^2''L--)6\\0>6AD,=EE"WGGGVV
MFD*<6E.9%2 V;5>N"%]>:*(L2 %#N%+$L0H"@EB20  22!S#9F%>O/.06]&*
M23M569F*(6"JJAF9F( "JK,20 "2!SC:QI:*%2H:ON/*-EO;=E;1+.YQDB>M
M\T\N4M,Z4K'Q[LI-E&E):1X8$86R$(AH09AENMRP;-B277:FPD*#P(H(P$AC
M4>=!(U5?F2=LQ+$DTK0^A"D9/<VBTCGR7E<]TKDZ'EG+'0  &E4!0 )]R-S/
MQQQQQQRBJ2WFF[=V#0AF<L5RTQ8>W*XSA+:!Q)F6E"X78\> A+F58'<F68*V
M%H]AM*9BYR9'NO9,]L?96")Z-6R3N:%VHS'SMHT19*CM^'6Q&9( >XDI70=H
M[>YH, :&Y8@ (AE1;<9.M"1W9+*+^+NUW".9AV !YV/>W=VI>O-;R=QQQSYN
M.M,I];SC;2?/CU.+2A/G^GE6<8\_[^-$^PWQL#W.N5G$X;D=MVV2:5AYB'H]
M.@VWD+PMM)LC+6J9D!T>%9QA: TP1#JL8QA:"1\>I66_"'*>_G_CX_Y?\>6A
MQRO'''''''''*TV2I(F*'-*PG&879%8\.*\X]O%D2?1UYPK'XRXW:EL^,XSA
M?N^C/C"O4EQRR^........59N6[2E%HAA]<%:/N$Y)P=,I(1&%9%=M]QEA*]
M!E')0A:U14.2=^NS*4)]>8>+/]"DJQA6'',GK+7<1K"IB5J,?)DBW""YBRV2
M25[LW<+9+O9,L-LGB<Y5E^4FY%QTEQM&4B1X^1HJ,9$B@ 0QW'.GCZB_8O:/
M8';T#]+WIK828_:U]&'E>SVUH1Q:F=#:4)PRW,#/&L.#*&L\Z%(A/+8#D!I)
MH$N-B&<MEV=HD#?8RM%6A;+7E!AC)6I"VMV; WV^#O<:$'9(T2"?/;H\SF+<
M]NPN$QSE;$H5KUA#_P!3JL=,=C6I7!': >[1'L6!$0^GMOG9_33?4E]++N):
M2YV0!;>G>G^[["4M NV->ED+6#2%E&.%.8GHS/W3,. 7)D$!O 2%39RMD"OY
M/R9*O%>KC+T4"J?PWJZC^XE'O(  !V, "2!KR&)VS!<>)M3XZVV"R,C.R@OC
M;;G_ *S![^D2=_M8_;1._!4#04MW;;-UQ [3J1E6G,.#K]\26K\Z'A")FI6J
M((0?7;9 %*QE0<S R;(YPCN/[I[#;@1C9 !10SW.\ZDC8(^O,3IBZ35VHHA-
ML9CQ+W79&6I>P08MWW8\6Z54UV*F7H_.<)<1%3.66+%"(>0A_P#0YB-4^VAU
M2D)<KRUN....................................................
M............................................................
M.........................4WV!(;C]0V^:)\_I]91"7"8\)6OS 4ZQP]I
ML.,MMH<4ZG,)$'X4UAM>'4YRVI"DJSC,[&J7NP1K^_-ZE>/9 _:V(GAB\D@#
M]I(OG8U[\B7W6.I-*YTD(6>3W/[*&199? V3N-&&M>?;G2+,=0OJP&2\H7%]
M@+@W&%2)Q,<VWV0NK+: 7RG71$-LH,PAI"1U-I0VC^5"<82GXQCGTY7Z[^Q%
M*\$<W2^/,J0QI*QZ2Q[,9%C4.2QC)8EPQ+'R?<[)Y^;%_P"Q+_ID37KLM7[2
M,XE66W9DK(OVI9^,) \SM"HC6?M0+&5 0>% [1X',=_R.OJW?_."N?\ ]Y6[
M_P#YWF;^WWV&?_NMC_\ _$,=O_X?]?EKS$_\AW_3/_\ G+SO_P!U7J#_ /+\
M?\CKZMW_ ,X.Y_\ WE;O_P#G>4'7WV&>_P#9;'C\O[(8W_\ )_U]./\ R'?]
M,_\ ^<O._P#W5>H/_P OQ_R.OJW?_."N?_WE;O\ _G>/[??89X__ #6Q_P"?
M_P":&._D/V7]#\_/'_D._P"F?_\ .7G?_NJ]0?\ Y?G9'U0H^Y:1,ZEJV]K8
M3;]I4W4>]'KE)R-MD+G). [$VSK N@J?FY);IA3"8VAV,4=)#F$B?:.#"X4A
M#WH\4ZYR?3^3NY6YTS12CAK=[#"E##1BQ\*/1QER.\%K1!41VFM12,5'X^X.
MYV5W]H_8KTYUWTWTI@,5]HV9FS75="OU(<G;M9JUG;4L.3S=:?%%K]MGFF2*
MI4DA4.VH="&,=JMKL,YYWSVSFNB++==UD/HUQ/.4750ICX)&S P@)"TWY8J_
M:,3K%N59.AH>N#F-/QS]WFXB7<FO;+548ML/,;;G-AZ<-( V(Q/:*AA69F6*
M#N&U-DH5>20J0X@1U"$J)V)#P<@EY;>Q!(8*X8@SJ%,LW:1L5^\,B1D@HTKH
MQ<!O14 I-R2QO7W48;F"Y2H"7::SAW#MFV20;L:S.X>7EQUI,Y=")L\,-2U9
MRU%QSH42(C"&0@!AVVFD8WOVV':LQAC_  GTJX%>+:C2GTX0BLP'N[!G;R68
MDDG(M.NI#-&)9 & EG)FETQVP$DA9@I.CV*0@T-*  !Q3.N^KDD/R=1ARM63
MY#R27[#J<]^@'F%-L9&:>G 8+V*_;$LL>EMH2X0M@ 1AIC.!/4.QENJW[.@L
MK+90#M$=I1.H7?<0C/N2+9\DPO&QV=GR=T:E7)+1J:[ENXR5F,+,W;V[D":2
M72^ )5=1H:&P".+"W&Y:_GX:D[9*%G8NPFHAZ3MD$-B)8EYEY64QE2OD*-G
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M.............................8^6B@)V*DX25'07&3$>9%R(CGGVR0)
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MW<MVO:VTG0J[6MK7"*I0UAV19#&AWI!-)!AGG@8"&GY%*&UOR'MNNX6Y=VZ
M)( ('CW.];/C0\;^9US&'/D:V02"?8>"1[_GHGY:_P!=E],]O=>;=+57X8\"
MY60>3<C90_2T??\ :>KXE6,LH2@[;35!@*<EY#BW4$X29D=K#>,I?6K+C;5"
MI'_?H'^6]\N# _GY(.@2/YZ_S]M@\R]>@[35]B634-?MC%4HS\0UL2D#B0;4
MI.Q\=*2;T=;JM"R,L8_$Q<-7[#]O*@!OU^4^R!N(<5%O@QL..$S'C_9R/%_A
MUZD8^@)TZ_HKZ(^@<*/"@<W^1+7Z%3+MYL+(<;D7T 99X8Q+3M/K0:2S4+0R
M-KNDEHR3REI9V=_AMC5J*]7X79\$W8KQL/4MHB]AA2%@ESIR=D(@ 8Z#V!%U
M^/\ +<-&RDWK:=M\5&1E?BH84^3+%'6EI1#A&,_-%S\Z6_\ 3G;I[>O]L*'8
MC;/<SO#+6'7O5"Z:W)FIO3O4_J['CLN2]^C+0=%!XBK9/TJ>=&$,R(XN*C)&
MQS:"'+))-BY]2Z33!RPS7<C*D."Z?BAN7JTI06LQD)2PK5UB5B9(5F0,R@CN
M(B1@(^]ENZ5P4)RE_J/J&:"1:( K548L%C8NL$42NJLSR'1F(&B=KY5W*_HQ
MZ;]3M<=+="4_1>MQ_=%A&52-ILI#+;4M>+I(-,?K]MFE-X_G,D7F&F1F<J6B
M/BA(^,95ED-O.>*ZCS]WJ7*V,K>;\<I"0PAB8ZM9"?2KQ;]D399CH%Y&>1OQ
M.>3<GD9\I<EMSGRYU'&"2L,0)*1)O_"NR2?=F+,?)/.9V[ZM:Z[C:'NNC-D"
M)^PL0+I%<GVFDKE*5<@QW_X;N,*XKY;D(0UW#N6_.&S0UEQQ'J&+>3FSI_.W
M.G,K6RE)OQPN!-$2?3LUV(]:O*/FDJC6_=6[77\2CE,=?GQMN*W ?Q(=.A)"
MRQ$COB?7NK@:_(Z8>0.?FHU#H?N'C=>-E@/PVK>['T_9FM4#?VQ;Z1,P6G^U
MW521&-%K=XF+1B*>:GK/#TV#D!)8TUIF0FZXU7I5TEFVPK8S7=]5_<<<,&0Q
M\BR8+J2&>W7IQF/XK#Y*$H;5=H@_[.'U9 54;1'$J)N+M+0NKL#"V1QW4O3T
MT$)NEOB*SMV HI46(9D0/ID+GL_P[_"K )&3^H#08$HY4IF\SL>7$3.V[A,;
M,(AI!C(TE#1,L-&PM+B98=3;;C$U'T"OU0:<&<]S(DPV<(VZZPPTO/E7*<N_
MCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCC
MCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCC
MCCCCCCCCCCCCCCCCCCCCE?W[741?6(U]XV5KUGKKY!M2NE=)0%8JP>2SAE]T
M-UYH@&0CC$(;;EJ]-A2=>FV6FFI6,+PRQEJ55MR52X"I+#, L]>9>Z*9%/<H
M8 AE93YCEC9)8R24==G<>Q6CL=C$O'+$2T,\;=LD3,I4D'15U8'3Q2*\3^.]
M&T-1)N:WC6'&@)>F5_: #2?&+/3IT.FSI2<85Z<&TFUO9AARDX2G#I(-\6*6
MXM3S4=%M^!49C'CIMM'/+38D?L9XVL1K]2MB$"0K\P&K=P'CN<CN.,/=C(5X
MH[*C_P!+$XA<^"1N"4E ?8;$^B?Q:0>!Z*V/M:09PF%Z\6^-,RZTWXO][U1!
MQR4*6C#KZBZ+<MH'9;:0I2O2F*R\XIM2,-XQE"U7&G11M/EJ\J]K'=2M?D;N
M /:O;;K41MB ">[0# [)! Q)<N2H2,59@<.J]ERQ00%21W2!J=J^-*"3VD!V
M*Z  (;G@/65BMTK&V+<DW&SJ(DH26@=;5P8D?7T!,".ME"2<J\>K]3V'-Q!;
M+!$/+3@D1#QQH[,O%5"*F&F#6:-<A@1XJ$;Q=X9);<K VI8SL%$"?@J1R*2)
M(XFD=U)C>Q)&2IO6M+*ZRW723M[6CK1 _#Q2#1[F9]-9=& ,<DB1JI D6"-]
M%;QYKN3N4Q:O=8WGIXLE]*8DFF[B@AQUI_[];C7]:34.XTYZ<^'V*O6KWC#7
MJ3[C#Q#GI5['E,V+M-&XH7<@GIR=W^[ JVHY 1]#++6\_(@#Y\AR!Q=JMW@0
MF"Y&4(&WG9JLD3 ZW^"**SL;&P^R#VC6JW>(B%A-@=2[7=H7K<30([;$K R]
MBW_)2815?F[9778^";H(XZ7H<R6E4L2#)N; (1'BH'$?4L/QDMK<]/B26KFX
M*\F5%EZ*2I#C41TEBKS!Y3;)(D6*/:LOI$,6)!!]CQ'6S5Z^3Z/NWH>FC0BS
M,M:2WU!-+%-5L7:KQUEQ04&![4_;(CBPO8J $%3^)=N*[4*K@)(<!7]<A J4
M.86Q!4AD:*+%-5G"G02V'11'W21&<IP4RV1Z%8:6XG+>6TJ\ER^,I]39.PD]
M?I[(RU6JPWCF^E;&1LOC'L3)+3ARMFW!"TCQQ7(U]%+"4Y75YJY#JLOH=5(Z
MD"K BP(_=(HJ,D,1<@:D].-?G^#;$@NH\'P"+,CX\**!$C8X9H,  =H405A/
MH9''81A#33:?V2A"<8QYSG.?'G.<YSG/.EQ>+Q^$QM##XFG!C\9C*D%&A2K(
M(Z]6I6C6*""%!X6..-551Y.AY).SRYW:1V=V+.[%F8G99B=DD_4GG5;]*)S$
MM =V[G"NI>UW>OJ"=D+!K)YAA;0!5:;/@8<TV,=RXMHT NRQDVXV6.AMAQS#
MJ4>XI"G%>@]9 ))T_7<=MJMTQB(K8+ LLQCDD56&AVLL+Q[4DG6CX! YQ?1N
MWBZ@L(P:M9ZHS,E0A"JF$2I$S*Q/[16FCETP 4$%1L@GFW.MZ&!9;9OZP%SM
MP;C)/=9K5?'KM\N5:C!A(37&M:U8&4@UV>C0'B?X]A;@Z86H1!62G717UO?:
MH><YNX5]/'J%*R)142DGR[/9M31-KY#X:2!0/.PH;QW:'35@YDNLT@>-K9,(
M7P(T2M6BDC)!/>?B8YV)(&BQ37X=GSO#6D5':NM)P,UL)UP5,0^2V?L^_P F
M N+;GXI4RDV/E;*5'%AYB,'?=,&#O,.,>XE3:OQS63_W3[]O /Z%@#_EO?.F
MZ=](9FEZWE.Z;MWW?WOPTWP^NW\7=Z_I]NO\6M^-\NS8.OH/9<!FMV ^WQH/
MW;)R2J3>[EKR:20PV^TUC]>HTY7YA8V,$+6X Z:X 0XAEP@5Y3#.49=Z_P#
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M*F(XF-)6"2V0ENE2Q/B;RNPDU&ZI:KQV)(%MU2RM-5>:!@6KVHAVL5+(Z,&
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B<<<<<<<<<<<<<<<<<<<<<<<<<<<<<<<<<<<<<<<<<<__V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>18
<FILENAME>g164680g00y06.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g164680g00y06.jpg
M_]C_X  02D9)1@ ! 0(!>0%Y  #_[19D4&AO=&]S:&]P(#,N,  X0DE-! 0
M    %DB^5P0X0DE-! 0       \< 5H  QLE1QP"   "    .$))300E
M   0S<_Z?:C'O@D%<':NKP7#3CA"24T$.@      Y0   !     !       +
M<')I;G1/=71P=70    %     %!S=%-B;V]L 0    !);G1E96YU;0    !)
M;G1E     $-L<FT    /<')I;G13:7AT965N0FET8F]O;      +<')I;G1E
M<DYA;65415A4     0      #W!R:6YT4')O;V93971U<$]B:F,    , %
M<@!O &\ 9@ @ %, 90!T '4 <       "G!R;V]F4V5T=7     !     $)L
M=&YE;G5M    #&)U:6QT:6Y0<F]O9@    EP<F]O9D--64L .$))300[
M  (M    $     $      !)P<FEN=$]U='!U=$]P=&EO;G,    7     $-P
M=&YB;V]L      !#;&)R8F]O;       4F=S36)O;VP      $-R;D-B;V]L
M      !#;G1#8F]O;       3&)L<V)O;VP      $YG='9B;V]L      !%
M;6Q$8F]O;       26YT<F)O;VP      $)C:V=/8FIC     0       %)'
M0D,    #     %)D("!D;W5B0&_@            1W)N(&1O=6) ;^
M      !";" @9&]U8D!OX            $)R9%15;G1&(U)L=
M     $)L9"!5;G1&(U)L=                %)S;'15;G1&(U!X;$!7_)O
M        "G9E8W1O<D1A=&%B;V]L 0    !09U!S96YU;0    !09U!S
M %!G4$,     3&5F=%5N=$8C4FQT                5&]P(%5N=$8C4FQT
M                4V-L(%5N=$8C4')C0%D            08W)O<%=H96Y0
M<FEN=&EN9V)O;VP     #F-R;W!296-T0F]T=&]M;&]N9P         ,8W)O
M<%)E8W1,969T;&]N9P         -8W)O<%)E8W12:6=H=&QO;F<
M"V-R;W!296-T5&]P;&]N9P      .$))30/M       0 [_^-0 "  $#O_XU
M  (  3A"24T$)@      #@             _@   .$))300-       $
M>#A"24T$&0      !    !XX0DE- _,       D           $ .$))32<0
M       *  $          3A"24T#]0      2  O9F8  0!L9F8 !@
M 0 O9F8  0"AF9H !@       0 R     0!:    !@       0 U     0 M
M    !@       3A"24T#^       <   ____________________________
M_P/H     /____________________________\#Z     #_____________
M________________ ^@     _____________________________P/H   X
M0DE-! @      !     !   "0    D      .$))300>       $     #A"
M24T$&@     #-0    8              .D   )=          $
M                 0             "70   .D
M 0                         0     0       &YU;&P    "    !F)O
M=6YD<T]B:F,    !        4F-T,0    0     5&]P(&QO;F<
M $QE9G1L;VYG          !"=&]M;&]N9P   .D     4F=H=&QO;F<   )=
M    !G-L:6-E<U9L3',    !3V)J8P    $       5S;&EC90   !(    '
M<VQI8V5)1&QO;F<         !V=R;W5P241L;VYG          9O<FEG:6YE
M;G5M    #$53;&EC94]R:6=I;@    UA=71O1V5N97)A=&5D     %1Y<&5E
M;G5M    "D53;&EC951Y<&4     26UG(     9B;W5N9'-/8FIC     0
M     %)C=#$    $     %1O<"!L;VYG          !,969T;&]N9P
M    0G1O;6QO;F<   #I     %)G:'1L;VYG   "70    -U<FQ415A4
M 0       &YU;&Q415A4     0       $US9V5415A4     0      !F%L
M=%1A9U1%6%0    !       .8V5L;%1E>'1)<TA434QB;V]L 0    AC96QL
M5&5X=%1%6%0    !       ):&]R>D%L:6=N96YU;0    ]%4VQI8V5(;W)Z
M06QI9VX    '9&5F875L=     EV97)T06QI9VYE;G5M    #T53;&EC959E
M<G1!;&EG;@    =D969A=6QT    "V)G0V]L;W)4>7!E96YU;0   !%%4VQI
M8V5"1T-O;&]R5'EP90    !.;VYE    "71O<$]U='-E=&QO;F<
M"FQE9G1/=71S971L;VYG          QB;W1T;VU/=71S971L;VYG
M  MR:6=H=$]U='-E=&QO;F<      #A"24T$*       #     (_\
M #A"24T$$0       0$ .$))3004       $     3A"24T$#      ,,0
M  $   "@    /@   >   '1    ,%0 8  '_V/_M  Q!9&]B95]#30 "_^X
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M7-#ZG,)<T.$$LY$^"H9&)D-;NQGW7
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
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M*"DX0V6"A:*DLK7"66=H=WB$AY.7HZ6VM];B_\0 ' $! 0 # 0$! 0
M      $" P0%!@<(_\0 4Q$  0($! ('!00&!@D# P,% 1$A  (Q00,246%Q
M@00BD:&QT? %$Q0RP092X?$5(T)38G(6,X*2HM(T-4-SD[+"T^(D5&.#H\,V
M9+,E1)3$U/_:  P# 0 "$0,1 #\ _OXX0APA#A"'"$.$(<(0X0APA#A"'"$.
M$(<(0X0APA#A"'"$.$(<(0X0APA#A"'"$.$(<(0X0B":DRRI"=.I]-;:WI7M
M>'PJ42FWM*J@$7JH^Q7+PE!(PH4UJMTTU<OFI/TDDIQ?1:[L::>DC&N[)J2#
ME)*<+)RM'+ECVC97%I"U0W5.,-[Z_2^)1V7Z=V6EXH!QECH^R+NA</J1^<2$
MTV5\B]);'(:DDN)8B(UK,R;\_MZL4KUJW5\ <LTP(26>>6<S$ 2C#>:9IYB0
M@:5 9@1,&()TG'E! N7 <JJ@ '*CM0EU&L>TR[94(9M+IM.6)FD5X]1L2QGI
M,#RVT;&J)W'87-YL(B[I[XI*IDF%.S%74A?+1NRA-,JIJ"N+^C9\V4Y'!F'6
M<RRF4$D A$S H9D)(E=23!TB4A78V!9: LA5$#;M&.D/;.C,1?+FQE<=D,3H
M,=F]6<N;)6Y11MD[9,Z\@T+:(6PH"I+<:<%BE+'K;'W^K($SNE;PZE1"I@6]
M=*3HM8.C&9#*002BRE0@!5 "2H,I#H)E0$$A*<>0$*#1F.EU J+Z*Y>,]>=L
M/3QQB4:>M-38SF7/,NC#->Z4,TEABM1K9L?-0Z<$>'BBS)DRX\JVMY"JM;)D
MES):,-KU.>JF6*!IKJXGHT\IF$TI $IF!J&%,P<D JB!4)RH$B^^DJSD2AS0
MFJ( R.AT>XC-OVTH\I^<C=1J2!KH7X8[5FL6&BN9B1E\@4'N6%V34D'A^D^,
MFH,QI1J[H>\5$4ZB4FD5!*JE;9\)-EKNK$(I!H:&5"46P!(!,3W\C%.)6X N
M0Y!8%=2HI&;NNUHV.5XR6T0T^G-U<JF\!A\SJ.UM$+)OT_7-M?'W1%T;Y!51
M*DU+EZI2&%S0II1;Q=26MGCI)Q*+>LO#X>8 J92<A(&8/E .8+,A"9= ,TS)
M+*N7OI7"'1@:FU*JM%HZ6D.H.JNJD(UE9XP4:?JTVN].=1M5+V\6S2NI,+6/
MZ7O>E;-(&.G51(:,?J2&0+U'J*B9J4:=NI+.H5*-0&HBGA+*)^J 3-,990B$
M*0JJDI"5GT)69:Q4-D" EU4#<*444N@8M$+;>VII/<2!HBSPQS%ED=5H7?N5
MD[U]/N\&&NX1.\F[*RO,=9M0[R1&K)X';M,LH5V:.748L2^1ZTEM[$9C7K1:
MTS'0,3&/5 F!,\H>8-*1*59 ])25(EZI.50"41&TUL@( !".$ZR$QA*';V@K
MI=KNF>#3)XC;;;S:K+GICD&F\D6R.\.M]&G1G:6M48GLFB4C\3V>K\>325'9
M9773JK 52*K61KC5'19Z-F,H("&LV8.61@H)I-U2'!FQ]_)H46JV!JFBKQ =
MHDKMVW=.F1KN[^6PK4*(<E[*69GI2SYN&ZB^22#Z@,NF4L96QX.HRX[;B/35
M[9;>YDDAD,=B"57"*R9<E-,D0=')#32EE0*2B9I3-*Y"A0$!:@)5(<>73959
M;@3)P<D.RA(L+CMRP2M&WF1Q:#3N26[<VR'W2[13B"8[3FS%IY))X(;4?42N
MI2N*E5DB3PI<GB0ET(3S*/BSE(IBS^SL3!,JY 2"2DS #*%!5"TTK,7HBF.A
M.R^JIMH 7VJT=CQ9ZJ/T<8WRZ;+QDN7=I;W6JT."K&XOVL.E%%8M]5;75JT5
M+I+P@U::EI64@D\Z5HI<LPRDK8I>H;=U_!HE^^U[</2EXD_$BPX0APA#A"'"
M$.$(_-^#]KFVJZ+Z+W*]1M*'S4.6O5&+ZAR63S)E;6W3MR3$YS(*3].F-@]@
M8^)"N#U8R;=2HLCQ6^T31^G4J6Q[CT=)YU$^66491+*#FN7FF )EJ)7!  _9
M,L:/?RV&H+D)2O5:H5:/H4BJ.W9J#=1.VU"KZ6QYNC[B\-,-MH]<29\,D9I.
M_P#9K@W:0+Z]/B8ZD)@$46]/L?F5:E$4UJ<281/ L%1AE7(=$"B7,3,DLTTN
M4Y2'"DL!,4+*2'(4+$^(EJB#<H:+0 ZCM93&<?.U1.731C5J1Q6C'UN<$E#B
MQ6>M<66SOVBM-M8GF,57M\=B]R"E5M<QYR=2NWMJLGLT*HY3*PLA2-X]G8'O
M,$>]DE$^'FFPL7-+C*9"0?=@]:<L)CFE  F8A1&!$R&Y4T0RZ$E2Y<A2#,;D
M(]JW=L+4B0RF0QMD@,$I7=Q.?!D9NG*=,%VICI)UC9M)*#C-6B-R&2RI=&1^
M\W4GMA5BL/"%M52&%164S6GF?9G1Y)<2>;%Q#DEFGG PYD*2*DAFFE$WR@#K
M(J"<HT1)U# JRL2C*2%N@4 /;6)6Q=J/4QVDR*+C#H!0C"'C3 W9HO+PB1):
M]4NT'->SDR<I53--#Y[2.TI6HE%1(4*L'(Y@9DGGZ1T3HTHF$N+.2"@S2D D
MR#$"&5!*,I0D@ $S,P WJ5L]0%57E=P3,FZHCM&+UNU=D,8D&O%&OK'=:>S?
M3BSCSAH)I&FK$DG6-=:&LTA:5)9I"PUI5.T2[4BO(=+:=.'72S;H8T4+8>-$
M%5'5T;H<DYP1)*9QB&:6<KB#W<LK*>L03E4Y5!FFZH,P6:(:E2@ " Z@J+BE
MB9:.2L8)U[;DG:E/%I81_3V35:<OG<75;L<P:*B]*EP/7<:/I5JLN12.)QIH
M,JIJK2J'>\RV+%==DJ0M1*N69\=.'[.P!F_68LDD@!!]V?U@FD$P.&,V)-,
M#E,IPY7F,LJ^[,D7WLJAA_>"AT*J  [HM!5Q&P-,^U'J%J"^P@.$)A31&7Z8
M12%NG=4L5)G .,QTU?I_;O3$],:E1A^8$4V1--2T+IU*Q?EU1R*B85+>7IOL
M_ '^TFQ.K/,%EGE $J#*LL\II,)74$@E 0 $N+H$<@NM5+A"QKL6JT8NX[5K
M=#V;M)(D6HT&NYU ]7[^-Q2(OTF:;%T;(X[+T_9&$]R,E!,B+('^054JJW%.
MV36^A3NY;';<+E=KM'L_#FFP@,PEGPQ,9\LY$LV52#U@5O*4D"D-,%E',>G8
M@S]24F6;+ES2+,A8IE>J3?/,03F-YM00;MP3)YFE6[KF%.;:&C3&-)TL:W]J
M=)+*G5[[3>NVB;U,],4Q^1RRD]H0Q1QCD\N0)5,;>VI,*[6D*%*LJ5U,_P!&
MX  7%G ()$^69)9990?U@,PRDG,7E82@33@F41B/:&*2ONY54++FEKF0&1)5
M.4   $("1++E59UHCVM=1-9YMHY:73"SQ-FDE]1='JSCLOALQIW=)^T@G$Y\
M'O*8])I,_P >?84]-+*DW$G,1KR^@[Y7!XO5MDTE,7H&#@X.)/)/-,9)A+UL
M/$D.;,)9BLQ$ID0B83 3!B09P$'5(2H"%]"KU<JK]8E:E6!,1R(:^2E$VUH<
M9#K+&35@\Y[05!FA4DUDTV:;"FV0=\F])B;7?2YGTX1J+08J$>9T5N_[B95J
M]6VHKEYM;A*C3-EZ-@9<(F:;--)AF8>ZQ<TIF0&83YSACW:YC*99B4( ((@K
M3/\ >4$@+5D:JEP0%<%HPY[:VH*G9U?*[2PV=FXP^"+8]+7^Y9&V1Z7REZU;
MU2A3VO4UX?'Z*T4R")L\<8&.9QVXD\:B%O-WV.PNA-T4Y+;RZ3[1[-P)I9DQ
M)FI/[O$F&(!AR'-(1-,!*3.@:<S$8F4$.-1SI0%3>8*""0 9B5- /F (+JI7
M83;VP]2+YC\4U('IU:M5O44V7-K3U&INANG&XT5FNJ+8^4)FQINHN($5Q %<
MB6JJ@Q1^7*T*IT8NDRG&;V;T<3RRC&F$V(%!,IDE EGPY$FF)FG$Z8@$LI!!
MF4'W9((=< V=WZTQ0W!=$4%5%0I>,(S=M^0/;FQ6A1"V<N%ZX15]E3VZ&STY
MACE3<T!+V^>S"O: IIIC*Q$M69=$:DG?8[2\6T^?E39O9> )9C[R>;*LQ$DD
MQQ)@A.4?K,I.;^"4E,HES$$[E*[%16BJZ@%%='+H2H B5Q#M0:D:H)8:+:PQ
MN.L,TE]KIE:.K"]*<Y$J0O/9[?=:53.#UY#'RQ2*/D,],1 U8U6IR^*.J)=R
MBFE5.IKFZ!T.0H<9:S$Y2))91B2X<P,PQ 1,LW6?JSRS+EE.68"3P*A;JCH.
MYD5=2L=UP*Q=V^$Q.Q?7!R='^V8FQ+O>NW('*[<>[TBX4Z^S20*IJE0JG /M
M$)\QRGRO6OKT%C9XNEEJ@]<4$37A%APA#A"'"$.$(<(1^::]8M7X])M>M076
MXU"OX%IIJ+)(A'6 JT$8=([M*S'V9HI/KUW$O6IE6A^?5R*52(U*]G;TT#V5
M"O:T56ZNN660B64@9IG0$FE+D3  ( 214NA!XYR02>LE%( )YH"%N6*LH*$1
MIZ[8<]:]2W*P>&]OL6'3F[DEGJ'%HM>B3-DIO8?IGVCYT_4(9-)#'HH]**C"
M86FL:-&FB)RUAD$(K"M535KU>T>RL X,N(,0_K#A929)LP&+-* N3$GE.4SJ
MDH1% (0SC?F*^-Z*6(=-[&C,9A*^VX[0#O1NDFF; X/K=41[NB"ZD5Y-') J
MV:(%.W=I:7NZT[BX5*1I!+)KJ338SE:K6 TT4ZA1)K>M3QE]DX6()9I)SEFF
MG$PGPYI9\( 3RB:8'%(*3RY0,ORXAG50HA)"@@'<*ZBC 4$QHCN%)?853M(U
M7UKTC>F.Q>8BSRS4:%JO'^0QU^,+>=.9^E_\$=USEX8K>.5GJ7&K#:]>W8%W
M%2+7$@HQ15PBXIIK*Y_@<('$ Q))Q+(2!(9I\3WB*@PQ," JR#,25 !#M<P"
M$LZ!:(NA;-_+9K(-=([84M9I-/K&JR168QJ.S*:7O>U.7=P."8/&]2(_I8&.
M$L=2+5:,ZD*GYV-%57Q;2YIFOP.A0N304C;\#A&20F<RF>4 RF6:8C$,N8K,
M9D:4&5I9058JBC,7"@AU5:.&)*[UN &!C])!N ?7CS(VPX0APA#A"'"$.$(<
M(0X0APA#A"'"$.$(<(0X0APA#A"'"$.$(<(0X0APA#A"'"$.$(<(0X0APA#A
M"'"$8)_CS1)&1WCSS9(OFE^:G5D=;)>.2Z;7NDJV=*2N;)Q5HU5YQN,_0'-R
MCB\_2)X-&*"[D=[@DHNOD-]#6'9AT<;VUP9*3!)+E+AX9%5[=-1=2W^:VB8.
MZ*>894:Y^_RZYU$8Q&;@@V0CDDLZB*SK70HKIJ6L=!Z?.0 9R<J@A$!S2G.L
M@ER3&8D3#-*4(8'-,NCW$JL$H[DL0B$D$(*H>U(Q[CV1>SZ\4;2TO(/7N[6T
M:NY:C6N:ZAAMOD*8Y$PASD#2F4IH/LI2RS%]I5)=(J%S,4AZJ R@$HJ)OZ0Q
M6)Q%(4 Y),P!(F(7W;*@"O*RY,R&+\/+04XS;[[[5(4@F+66:&]GZ$0^42:7
MLUVV,+(Q2B33"</,YU&<)/8MJ:L!?'1]7-4R4ROQ!&Z>E\*7$)/1D!F,)\"1
MX0>M:JH<G$]_B*5G!!!'RRY5"N1-)-\Q*S(!F5"0)4#W$C;'?QS60!W "([Z
MPE&IW9 3&)-I&_RV_HV.C<8@FL,M8&EWU,JSR#B02SO^#NSF^,2ZFHMOJ%)Y
M.O-6/>)%3>Z4\4Z5S;5*<A0NY>_F$TTPF!FFK,0I((E! 490 @((D$QRA0@0
MO<RH M  B%BY4I-Q0$H%*5$3+3.!]E6?Q&*S&",MK48[EU+0TU7FXE4?DB)/
M!IBR+>&F1,4[NK64B=QV1:6--"6KDUOXR%6,U17J*/,%OB<6@G"AGE!-+($!
M)0R]4&BE%4,##<VJCA.]BC$D5=!$CNM(.SFMZ89,I#59N0D#+)[*XL-0GQI;
MG^1/VHCSJ@P.;VP"1THW-%JG[V_RB#^(Z,A5;57E_,,30I*4BM/B,1",P0@C
MY61$ !"&50*2B64$ @!9HON9=7I=R"2J$O4U55=6(DVJCYHHTUZDIU$O+&YN
MVBR;]&;L6U=Q<;ZRL.T+,((P4V!V:&,&M0IRV0M,.1SU*04JG02:2D4JN*^(
M$\HS (%,RF4%,K#*9E-2@4*$47C(D7*.!4TF1R @7@SN\0N3Z6=F=RK.%^_V
M=F_FZA#C:7T2:YW,W1JE,:;(F]0^YJT],6:25H_-7RE'"_1Q,A1&KF5HI4A9
MT+D+I44HOQN)AD)B92*+++-, 9Q,0#E,V4S =0F:4@(5 $"06.ZN=$!&IW"$
M,40PB?9][.,RCK)-HZW.<M8YG11.K&4W6HNI,A,NLY9%(@S=[O3R_22[NY%1
MNHU#8<FDF1&Z]G2CS(4TZ-="@<_BL6H,H* ?++8DBQ+@Y:H%)J08Q]Q)J:K=
M+)=&0/4W)$; >NS[I4^VMK9WL:K&E8WTD>*%Q9/LH:G.S=YC/&?4Y]<VAX:'
MNWD#*ZUIVPLTG-Q9W-%5.XI4Z5)::"JU-$'29PJ$!40"60?*$ZW4 F$P9%"6
M E !AP);JU^L2I+)UB65'JRJD>%MV=M(J+8MH7&%WUC5ORZW=1T?)2[.%^Y&
M,.\/4YO#T\/]>[>"8^^.]G4366O\[<#5*/;8KFS=/Q<68$SK-U@.I* DQ!(E
M D4*)90LTTRH2I)!C>J ;(I8]Y3==6:-JQB.V,986=@;:5XBQ:&QO:[5#H\N
M[]?IL6Y!0A%9\?*UU(7A5(+%/VKO<+J5">=1^F0OGF.8DFY4H&71FU>X))5Q
M OV,&#=G!065CJ95QC%APA#A"'"$.$(<(1@^X&3DN$=TMN+H$7@[MI 761O[
M3Z'YYOO],U!G/F,C9[Z>HGG8LLQ*'<(AW4;&-/N9:-73:SMLE'1XQTGC#)*&
M1T8G>TKW-B]69L+M%G>.S1?+IU$\R4I>66K0>6K! /MZ%>DND#@+PI2%27&G
ME3+,4!H^6Z@RTN70$*JT(GN97O92%--220UBR)N(PL$TZBD C@C4::ZUFWW5
MW?N+BAT=7F0WSRY/"E*=G!Z>)#<WSY(*]8UE4ZE=^J55U$II)5R4T4>3";WA
M<XB\)94!-*(%:Q4@/&YZ:! OC^#5+F)TANLZ=6O<4[:V1<7('MZXH(YZI&?P
MSL5 @[@G?J<G@L[=<M1@$(H5VMH&#1=?7KAYQ0V=(X^A0^OW9 QZ="/RCZO/
MC3/)B3$$3 M>4'7<:GMC%)?N_P" ^6PCB?5+M3,>G\NUHL;J$>*J>C3%IHS,
M-G8K*9E/-<-4T/[VQ:8PZWKI*:9$:MXZ^5Y!3!!5(*RRE/A>ZSZO0N@8^,,,
M23MB"<F8Y$&#A&08D\V:<2M--)*92@.9"<HF3!:E'H*DK9"K@J2"QN@81RGH
MGVWZ;O?Z,L[5HC&&C3W5>KH@-0W5$Q>;YT8]8.V5"IMKK52T,#]&UT9(Q(K(
M0N9W'B<UJ*I'4I44^RBM:E<=/3/9^-@J#/-,4QDER22DRX$XDG'5F(228A&Z
MPF64)F,<0Q%(ZH )E!4J!-,"07':Y!1%!0QUS-.VCV<=,IQ?Z>S215(Y*&.3
MRF/WUC=,%5"+14(T98=7'M^YJ?,/#E+3M_9RB0A*J*[FMX724W Y..?H_LWI
M./+FDRS*B$S2@4"EIE8NA%5!3*D9'%D$R(6*$  DH$( F*=9%))4#JW!C5UI
M\I+V/'>VESI=N3RV=S,CF]WJWW3]WLG&44(Y(H]!7AB9:=:V0N0R&/SF9LD5
MN(V%UZ]O>5S[%-2@GWJGM_1G2PB"7K=4I-(  +ER0" >L@)F*$(5,_271PO6
M+.\LY;^ZC$T!H"ZM&'C?RBV@\GUK@VG#"UJOK>:1-/@BC0;/Z8E34I.H3Y!I
M!IO3A!54N6"G$&1D>99,Y16KV\9I1>FNJBYJ4$TQ<R;V;TJ4+-EE 4DF?#02
MY5,Y.8$HA"$*"X+*:/:. 2@F)L$EQ%F*H)4$E5N&(--)19]OK2!ZC;Y.M,&=
MPD,,@^IVGT9U%?J\<=8ZVBPU0U+^:6M,&5[JTO9=]11]%&2S**R&VMY<(?[>
MLJC0K54<S$]F]*PCARXAE!QI3EES8<QS22YII3*)FDE!)SA9 1*")9IL->M0
M712+DHBH&(-"CNI!13*&_0/N-E%S[\&MO%W@8N?=*(7\#S!.?MS]O'EEPA"]
MB]M;ZQ4E"G=VFRC;*J QZU6IMN#7]M86-4W02+LUK*C4]YPG ]I[1)%3 'GS
MXQN<@8BSBDY%N6D;#ZMWQ<^ZT1TI6^/3W>GY8P/+ICRQ_!P7$_>'US@@TBS[
MG;O=/</<;'W+V'L/<O<Z/NG+_<^RY/9\N1TY<^><\7-B?O#1*>@FU(P272U7
M,O\ >-]_JT7PHTP,!-/8 8Y$D;#"?+TV!QOQ"9R2<Y?:,<LFDG]X^4>_%C;#
MA"'"$.$(<(0X0APA'!FK/;(T9TFB6K#T]QAS>&J+ZM)T>N6-I9VI=]J--WIE
M87R8TVIE-1(N6:+LCY5JS622(6]"FACD=.H5(H4#<]$LA.5"0RJ%(!E+=94+
ME1*$%R2@S<L\P4T8H;$J'ZM1N7-F);<DGGG9RT;<62,RB^T[@=XVV,:K1YMO
M&QE:C;-TSEZ("P)94"D@4J=>1/88%)M132%O)Y@M-:JE5DDQ\4&:3-,IR]6;
M*% !1%  +&E691&U " J'<*4+HQ*D!0]BKH%U^RZ]]C6S-A%&*;Z0-UDWV\@
MDUC;V30SMD6:U46:0UW=\+FADMHTSO/@5HFTAN?SZE<74"IR"6+IU(1[6_5E
M[CI#KGLI$\JJ0K+.X4@5"ED5A CT4K9T74!NJK $ DFC1B7+M>]EUTOX;IU>
MNT<?X/J&P2BQM1?,E#PU8ND+>=)V-.G#W"GU5%_1(9.K5:'*A\81$*BJJ$U,
M(4:E('</9O3#F'NTF&6;+FD*@YD(G$V4F4_-*)LP#D 9,U65/S3>IN $9FXQ
MB;_57LET)/%)?'F>+O\ <P>70;1"W=6J.BRC>F:)K-WJ!PEV8E.S';,*6>OJ
MZGYMTR6&\XMJ[_43[>K1ITJ2Y\#TH 9I)@)Y9IY03(9III.L9!*)\WO/=@SR
MX?S$@@!!,1"BU#$!G124J"*MF=K*\=]\>?&Z'"$.$(<(0X0APA#A"'"$.$(<
M(0X0APA#A"'"$.$(<(0X0APA#A"'"$.$(<(0X0APA#A"'"$.$(<(0X0B.UWN
MSH.;.VUEH0IZ4ZIM+G*/=S?-(IFHU&K[=:"\&C[>O2H!-4JHLKR2$>PY11=%
M;3OTW9%UH8QT45W*M0/R52BDZQ(N)&4.$(YP[4FF#]K!V>M8--HNFS\32^#N
M]@QF_2$-UVYIIKKM=@Z$GF-"K73214!(2 OG*DA)!RPR)9@J5139;W<"YYQS
M3RS3 EU8J$=& .I0J!4E$C5.H/9[U-D\TU!U?TKU%;=&=1-0^S]%]*65+G$*
M,E$&DU"7OTP>Y=4H(>J#$_OH:'M+'S!%3EJLE*NF\5:XIH[\/'PY91)BB?$E
MDQ3.TTLP.4991-*@)D,Z$23!"3*LQ ,LV)PR2HZJ@AQ14+$DCY5!([&B+O?8
MWD+WV16[LXV\^CL/G<:=&R11356'QIZ)C\II3"N_U)CW3)9?*G]]D$J3?/UO
M-GJ02==Q*;J226YN#31>55\:L'I?N\3WG6)0A&<%T*AE1>J')JA2,/A09,BL
MJ@I<J%!%:A3,7 1!E"<N.GR15O58+9C;-6;"XHV,JG%JU-<JA[TZ-++I _Q&
M#0:#0N@N/:BQ&3KD.E$?@_LX;)U2WGIE^D'-1Y:M//KX7MSW9*X9(R !"!^L
M FS?L*9"LKL00N1)B99\$&<UTH/[Z"[#5SKGW?Y+:N^N.JR;[5TVS=J?+DR"
MK(6AJF#=J)197OM(0?79\:G>1_.(JWN)$%P^G&H9)4Q6E6B%N5U4)6:)HJU?
MI< 8:81&1A*/=I*DDPZA]V1EE4!C+,1;*3*7P0"H:@J4+E1I,"MW4!E-XE$1
M[ ,MT\U%T:U7:YQ%WB_T3@$?AG=#!I]3;'74-IA+%.(^TM2E/DJ5IW&GN0L[
MXS4:\IB<2AZK>L9.![.WDX52DWM03X>+A)/*,0D S3@Y1.%+B43@2S$]4SS5
M0$22Y9*.B"4RS*%"4E+H;A3:Z5%"2I[?[*>EKWHMV=-&M,)95L;F3PB 1UD?
MU-O+W5;N]LV4$.M-I4H)PUT[KVE.A@J!II!))^BGQ)BI*4*,+\4J5^A&L=JC
M6C_C^(:.BN,8L.$(C])]LZ[J\-U, AG[HIW=ZKV*;,.+F:BJ;/[5=9&7:G0#
M;<+I*Y2FD\LY2*AJXX=WXQ!YT[]E5?2Q(.$6'"$.$(<(0X0C!M3Q:/="YKT$
ME/N%]>M]W1N4I"K6_;:_LZB5;$ I)%0+!V3R$<ISPX+I1#IZUC$_1:D@$(CL
MG8_*,YPC*'"$.$(<(0X@ #"$<;RGLD:<Z@:G:I2/4R)0K4C3K5)JTW=[N%3F
M.V\DILFJ,!9Y- ZDN:%O-)=)-63:?/3)&*J*:4U*28W5J$J1);D<=^'TJ;"P
MY99)II9I9IJ9,LTD_7F,TN6=#*0* &4&82GYH!HBFG_R>O9PTND.ES["61_9
M;?2JRBU)CB]M(R(:]R:$-4D98IJ/,V04TI?M1K:UF;Z42<E-PI;L36HDI03G
M/[0QIQ/+-D.>4RJ9!GEDG(SR2% ,H$J.A49LQ*)Q#HLLI!E)8@U)!F ZA(S5
M)*I1"Q#KEM:.PGV;M?YC)YUJ/%[QS?Y?%(K!GF];W15DBJRPJ=6\V 64X4FM
M?5VINC$JJJ)]]B-#PES>[J6@,+I^/A2222F3+AK\TH<(.J,LJ F8S39B3-,7
MF(E434]%PS,I!4HR\Z$T 0(& 8 D"(BY?)U]FAWKZFU;QLE"K35.Y>'!Y9+:
M35[!M9W9]F[/JBZO;1:TZ"5+?%:AL3-*Z5:1KD88[N@!9)MK:HJDK9^G.E)*
MF)(LK@S8<DQ5#*!\BRG(2"F7,MI"93#(EKN 0/XBJFQ3,BF0%2?VHO+'Y/CL
M_MKJROE.WF%Q*XO;-B(],;N1U%29C<F?4M.JM)Z8+I5!--@6J3J33781VE:1
M(Q(KA_A-%I2%*H/MSI4V8332S2$3+(</#FE29C*1[I#*92\I"F<E2)#D&1PI
MA:EU%KHO>*!DS5P3M\GOI>+U[OXLXR.JX:CRW32KJ+()A(ZLA=[W32 ZF)U7
M7!VYYJTZ;X\&2/S.SQRK*IE=RF:F)!5NF6KJT@H:INE3SA,1#[L'*DLPFS 2
M@&8!)>I*9L\H,DJDC*$E,;DT**E7JJ975R A14"K'Z-D9\R/J../.(4)Z\1&
MV*\6$.$(<(0X0BTN[RWL;:M?7M:E:V=M05<7%Q75R)H(0GF6I9(P$I3G)SS9
M^B 2>$0KM1[H;<0O"BK%DS.)=FRQ=/<KIO\ ?[2VN!9.-O[%QM5+2I7)>TQ4
M5RK1L ,CE5S$G?9%/KUXQF.$(<(0X0APA$50Z4J4C4Q7%-5O4J-"72RKK6GV
M=^*5RJB[(IH*2 605&956H:HR'J@$HV4KA)A903* ?$K,@4"93H%4@*[K&@J
MH9 [,[&8DWZLJ +J8X0F'R?^D^KB=56G55+Q?M\FU/D^I$!?8U+95')-$5ZE
MLL'3-&LKMEHC3K[V^0M%S3%RB4T_=E4>>C:UU&B/3P?:.+T<R>[8RRY,26:2
M4RS"4'*0@EGE())11*AH$C7[NI-R$.;5"@5IBFBE5 *E8V3KUV+](>T6K3_Q
MW7E=G5T\BL]A\<,>D=9MRWSB(ICI+\2N[6].L7J4VJ50]=:ORMLM9K>3)35J
M4T(3AA],GPC.1^W/GF"  S9NME60D @3*2IE&4!3*XX9*<$8C[K.M7" )F^:
M5GC5J?DP^S@:JZ"J#[68ZVG3?INY1^M:0ZZ6XI:M(JFA]I*%S-497J/'Y&G3
MJHBQ]ZA\TBA74":QI\R_8CI'M;'E%)2LV<S3("9%42 "0/\ L9QF"/,"YB>Y
M>^FI45+&Z I8!&##Y'R;>A@\&W]5\EM2501YD<HB4U;&S3:%2IEFTB?=*GFC
M,Z2=/-.(O&1(8VC2MDC5G<58KR7L4>9'9S=,K5<BM1U_I/%((FE!!8A)9I)I
M>M+E0RJ5E129B)C(F6433$3W>E3K:A*V&4E2*RJ22R1]7/R?T4:Y!)'N)21]
M*=1]6]+I]J'9NB8DTMH;=,-43KFE30SP>)Q.W?9!(I^S1Z/7,IE*KJ:(B'O*
M!+UJH(I7&1]I3$2Y@,P$TPFD64C$FS2RD RS2MAS'-F&(%^4+* ;[DFC!@5?
MJARS$J0ELP%4*QWU</U"WD#7'Z"!<W5ZJ_N[D)JI6JS:Z5&L"YU !LCOCV+*
MBD3[05*Y4<)3A7D[79GHY?9ETTTCJ",VNA0E C=ED3A$HXD90X0APA#A"'"$
M.$(<(0X0APA#A"'"$.$(<(0X0APA#A"'"$.$(<(0X0APA#A"'"$.$(<(0X0A
MPA#A",>XMC<\VE2R=+*WO[.L!SV]U1%1!^)2L92<;9 2H#(S@D<"+'SB+V&C
M$'TQM&!\%1\C]+.OICQ%(.G_ "QT^W._Q/#MJM37M]<HB#[O=+YP\%1[)/NS
MK]+8_?$_[C'G]V/LXB<=:GS]<X?V:4^7N>!A4?.QMG4CT,CD!'7/F\>O!./:
M8-]W_E\XH87'O.V=!G/]L;^#OL=^^ ?/C,8DTM)BP%E*!A8D^M(H)'[)_P /
MG%/!,=P<VKH,]<R.0?OGOCC  2JBA:N7[XIQ#JO]WZF(J(R\=[%M[W>A!32]
MJ+0OKSXA,E-?>Q+Z*QD7A@('O82;LU>8>Q(\*@6G&1<KV]M=5YD*:V&.8A-:
M.)7**G'=*/1XE(A,>_O9T\^DBD QG_Y9]<C XQ>Q[B?KZ+QE[PZAJ?)W/Y17
MP3'B?TLZ8(\Y%(/J(_5GKDXZ8!\^"S(F;C5Z5?M^D/>'4&W[/G3TD5\%1[^]
M77]T3_\ 'T>/]>X^S//-J5UOVQ']<>.GGM%?!4>_O5U_=$__ /;'\]_7AFFU
M\(/J.SMOZWAX*CP&!;.N"-QXBD&.F/-W]-OJ&.@'&"<>T^<3^S_R^<9YN:FU
MHM19-EC;6-HC)%O;44TZ>2-R4I'TB1MODGX\6+3AS+]M-DC(<(L.$(<(0X0A
MPA$9NXLPW]>M>7+8$7M=')<W=O<5VZ^N4)  55KM-:A5J[' YE<PP  -N'I>
M-?(QCMS=%K5 #VH$XQ;^"X__ 'L[>GZXY /+_''V?^H'B)Q_O'S@@^[W2^</
M!<?/^UG7]T<@\NG]F/M_?Z\$W+;GS]4@@^[W2^<5,+C_ />[M]DCD _],<$X
M]I\X(/N=TOG#P7'QG]#.NYR?OBD'7_ECX<$X]I\X-]W_ )?.!A<?/6V=?(_K
MB?\ R.1_9?UX(-^T^<&^[_R^<?)A,>/6V=>N<B1R ;_7WP#]G[W&8Q9I @F0
M,S':X)Y]L4$BDIT_9\X>"8[_ 'LZ[[?KCD'_ &QQ%.I[3%]Z=?\ D?OCPK01
MF-(IL[I];ZH21;5[-]>$+M2>GL@NZJ(2C<!25I)*01D'*N"M9MSW!;W0=D3/
M,BDDM]T)>^0'UI&&88DX7%C;WLYO:[C(+RS"7>U:G1YM(Y9K*05-[.U"X2GV
M. $K54"JM0IYN=7,,YS=(DZV09!PGFFFW)-_[*DU53! R#QW2UM+59HSG@N/
M?WNZ_NBD/_;77RSUV^KC#XD_?&E!72D6/H0J/*Z6[F3Z^(9#GT_'.?@?L'IQ
M?>3ELQ/K7@8U&47E',#_ #[0\$1_SMG/)/[(9!G;./[-'R^/$4ZGMB99=!W?
MYX^_!4?._NSKMT^^*0>9S^-_4 _7@\8IQ[3;G&QON_\ +YP\%Q_^]G;I^R.0
M?]L=?C^_P3CVGS@@^[W2^<5\%Q_.?=G7..OB)_W^'ZK^7Q]3CJ>"#?M/G!!]
MWNE\_21\^"H^>ML[>F\CD'0]1^K'0X&1Y[9Z;5/2F*@^[O;SW\=EI3A<74JE
M<7#8;I5!7MTJ=KQS<PA>%;GOBO<9"02H\P'*0"I(X%ZOQ>OI-J1 NB58<=P/
M'S$PZ=.$90X0APA#A"'"$8IR9VEYHBV=VZQ=;9-85Q;N5G1O:25IP04TJZ%H
M!!Q@\IRGZ)2H<03B@-058TW9+^3P]>O58Q7@6$?L.BO[GFC_ *GQ81006%><
M/BIZ_P!KK2#US_>IXPED$NG8&KH36$1"I#KCQ!:T;-RJVL%K6B[AWCU*Y=T*
MJR.WN4=STVE%*HA%!@KV]9X\5L(4FVJ5F>-+12IT:LGIWFX#*XJZ D,')*K=
M>JW6);2: )OV<MVLI)W,3+P/"_V(1?\ Y :?^J<818^? L)_8=%?W/-'_4^"
M#2$9)KC[&QBX[G9VUJ-V4JNN[+*WL176D*"5+3;HIC*>97)D_1S@';/!?7KU
M74Q  %1;Z]RZ]AC,<(L.$(<(0X0APA#A"'"$.$(<(0X0APA#A"'"$.$(<(0X
M0C N,B:FZH*%Q<$UCCZ%$<R@>N,YQG&Y&^.BL;\;)<.:8*$ W->Q3W)"+#QL
MP^=6Y ]3:U,>?\1_(?3C!$4*&X^41=CW><4$V8B2.>[R.OZ$J[9Z?E\L9SQ.
M?CY1>7AYQ8G4N& X+U; ^G,"?R?5ZXW^&_!OO!!=_*,5F^[_ (A%]2F\>N:!
MN;6ZJ75L, U[>DI: 3Y'!"AU&#@>N<#/%1E4=Z^'+18*I1"%NH\[<^$/&S%U
MY[K]JK],],Y^'U[==N,LAU'?Y1<PUVYJB>N-(J)LQ'_WRZ'7K:K V]#G?)V!
M&WQQGAD.H[_*"A%\/'D',>UO+V2O6- UJUO4'E<V]2D#UQ@X5UQYX_)QD<&<
M!6.J&@YH&XP7;FWFI6P ^L2?KQHFE!V.M?K%AQE"'"$6]S<V]G;7%W<5$4;>
MWI+N*]96 E%.F@J4LGSPA.W4G  !V'")Y!PCK1+5Y/'S:7MG?6]&[LKJA=6U
M=(51KT*J*E*J""04+22%9P=@<[';8\(;^+%^/+C'\<_R@ORJ_;:TT[7NN&E^
MD&K5"":?Z=R/PO'X^V0735VYU%H8JBGI\>Y!&Y7)-ZE:HL)2BG33SE**=*FE
M"$_I?V8^R/0L3H8Q,626?,))A+-+/-E,X)11TAP%2C@=8!P?FNG^T3*21,7)
M0AF# 'JEC+* I)5DJ"=-#Y0+Y8P:5?/<-9JJ=+RHJ$K$.[-6]3=?='<0C?B7
MQ*=CX9'TO]\1PF]A="DZ3/AF23("@&29 P"Y?>GK;U301PX/M&91-FF4U4S4
M-E,M%LXS6I&E1\LG\I3G'YI6\)]/FIT=P,C&1_2X(WV.>7''1_1GV4IZTO\
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MQCKTXW3^TY\6U1L1W22C2M6&D<<GLZ3#F4(HNDP*,24SG1/HD=YI2$@)'0#
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M9,!G;_;ZP <8V)P,>8V\]Z*<YMOV91ZU#1SGYI^ W_;]/:L6ED?T+;^GN9V
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MKF_DEE:-TDD#K=N=Y:-<5TZA[;I(WX96!B[E>]+9WJ)RF0RL,9^^?Q:"<YR
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M_P"M\(<R>Q^X?2'O%Q_>-]_GMG_7/Y_DX0??_#Q_#T3#WBX_O&__ ,]L]?\
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MK>W-KBY#WNMW997MXNBFR<@I7L03RJ!HXQSX3NE7*D\U,(2.4T@W![-/7U+
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MH&6;=-]D/:@&&?> F8$F4?#*")II0#^O8J!,0%&68*7*8EN9 X6-84+]ONI
MIIB[M9Q6SN^\I$DSAW@K(RE\)P.FIS,"$DC)/D#RIOM7[*!D!PUSD S&;I
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M[E2+-'B_T#Z0&S!%)^62X9!\6+([-:\>_O\ 1&<VSIUZ=SO&?+X;_6.'],\
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M7U=8^%-SBI.%OMWC(ZV;=Y>8Y;?()'GGKG8#;BB<2%3R](?I&&)*9QU3ET0
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MS)L3V 'UZ,69G1\Q')9?.-\\:(WQ%)1;EQM[9G2$$.UT;6Y2-E*:B$EU2%;
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ML#!JK(-;5R0Q>1NCW9M7=$L <">T! ]=SS,[]J$K3F"E*H0(T3I;$8@"@B;
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MM>W5O:&[%J:E!'(NH$$K0%J"D**$E7*A8P<$<'Y+X_EW,(EVT ";*O8L:_\
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M=LP96MAE]&.B,1J>5*-*E07+$QRC&8S>"K5IVU.DA*ZU;B]K]/EZ3.)PXD"
ME4)F2@(&5Y7,R$O26N7L[!.!*1, )B5( %%0:JH)4!;*DS#>45[)]=AB&C<;
MNY';UW#1V<1J7MUS:HD@;7*LRJ>DO!2S59#X;85R=3RLI$>C-&E%N:H:(NP:
M?LO,]>FM3SMV\N-.T\MM*1V_PBQY)3R[IIXR/[O/Y=\8^W?X<8S33S60ZJ*1
MB99 :A:U(X5/T[8^LJ_N0KKT./JQ_/H?K!Q_6>LL4Y2TQ Y_B+1\^U'P_P X
M?Q<5,70]@B9Y=>X^4/:I^'Y?]7!,70]@AGEU[CY0]J/A_G#@F+H>P0SRZ]Q\
MH>U'P_SA_%P3%T/8(9Y=>X^442@)W"0?7Z7IGK\1Y^6/+B?K/66)EDV[2_!W
M@:R?A\-\^OP^'&:8GW"2FH"GGK%S2A NPK'J"?,8^T'C#]9ZRQ$DV[?QBF^W
MT1Y?UW3R]/+[?7KP_6>D@DFW;^,?%)22G"3TZC?_ $[_  ^!VXV3RS $(YX<
MXDA"$;^0CUXQE! ?6-D6-]^ C_QC_H'^G_5YC.6H_"MJM6)-0_C]-EB,,=E[
MX[7+Q6"%4;.F&MH&<*IE','51&/PEW">4'J0A6^,<HU55!V?RJS:&QC&4,._
M0K;L*Z*;E8FO$C.'"$:;G-<4I6RV]4@]XM#I1M3D_1J!(R-_/!'3?!SMOQ0"
MJ\15+7X<0L:)P]Z@T)4*UELB5":1'\ ; X. D9SD=#MN=N@_TG?/?*:.0HJO
MCKW.ZB)#/4G.3GJ=QN.GU=1OU!Z<(17[=P1ZG ZCZA@#<IV()^IZ]>OP10 _
MZ=]AYYSC\A!R?(8&_"$"1CIY'RV.Q(/0?'<8\]L;A^?KE"*GH?+X;;''ET/4
M@'J#GXG%]>N[T813IL/LVP3OZ?8D C!ZGJ#B>O'\.R$5SOG;'P)Z@=!Y'.QP
M,9QOG'%KZOYF$4(VSO\ #_03T  \B-A\03Q$]>N7:(0Q]O,#Y#T'EZYW.,G;
MZ^+P+FWAQ6$5]-O,;D'?<9W/0[="2>@Z[!LETI]3Z?80B@WW\AY$@=?CN=Q@
MG<9.>N<<2$,_ XWW(.W7;.=\GR/GMOY/7KA"*?$#R^)SDG88 ]0<#&/0D<(1
M7KY]<Y _+G&^=NAQD' X0BN4C'V'S&>F#]0^/3&W"$4SOCR&,X   VZG[-Q@
M>?D.$(JK R3G(((]#ML/3R!)QN.-TU"NG8?&_=VHJW5\2V+V1_3%W>NEZ3O@
M)+,>ISOOYCJ,8\N.#&^8"[GD *OW-SA<#D'NI[*Z]D=!<:(Z(<(0X0C'.C0V
M/5JJR=;*WO[19RJA<(YT$X(SC8@X)&Q'")O<*D0WYI]-_P!AK)^UC_+X18?-
M/IO^PUD_:Q_E\$]*817YI]-_V&LG[5__ ._YC;IPA#YI]-^O@YDW_P#!C]?]
MWZ\(0^:?3?\ 8:R?M7[?[O\ GTZ<(0^:?3?]AS)^UC]7]WZ;?5PA#YI]-_V'
M,G[6/\OX\(1*V=A9V"W]U9FZV;K<G)I6Z"E)(]2HJ4?M/"($ V]<NQHR_"+#
MA"-*2+WF)ZA>+UMCDYM#E'T,]XMLM#458&C52M&0%@JYS20K92.5*L#=)/!4
MYMWUT'UC'1?(%57C=BZATC+_ #O1H']3I3O_ ,'7'^#V>W7X<10;^G\C%0;]
MI\XI\[\:_%TI_<ZX?'_O?P/%@@W[3YQ7YWHU^+I3D^7AUPSY#8>S^KIUZ\11
MZYWY00;]I\XH=7HT.K=*1Y?K=<?7'7V>YS]O!0:>E=].<$&_:?.*_.]&OQ=*
M>N/UNN/7_,_U'@H[ET:"#?M/G%/G?C0_L=*>I_M<<>N3_P![]0?R<51KZ]$0
M0;]I\X?._&?Q=*?W.N/Q'7D^OZOLX00;]I\X'5^-#.6Z4[=?O=<?+_XGQ_GC
M9!!OVGS@=7HUC/=TIQGKX><=SOL,(W\\@=,;]."BBOI!!OVGSA\[T:/]CI5T
M)_6ZXC88!_K/+(^WIOQ% O=.9I!!OVGSCY7JZQ<H]BS2JXKK -&W0QUN=2B"
M !]/ ST)*B=_HCKQ05U-F\ J+X;P+"S:T'Y>M8^].6>]:(E?][41:W[O?.3U
M=6G15HIV.>4X!(.Q5C.0-MO.A5%RHT"Z;+KO&ELLRK?4()@03NMAV-$";ZWM
MVVP!Z)M3O]1 QDD[Y/X/4= <X [9/E#\N]#;1>T+ +3BQI2V^EUVC$2J%QZ:
M46ZA*&NW>K!JO7$BVN0"W7BGEH?&5[9WEER>_P"/&//+UE)W/,1C!&,MM?7!
M=N.AB"A:FM=!KS5#JA2.<=>I5I5V<8]IV[7&CL;=6.3:N-D6=J;!'&A)A32I
MED&J+YJ139_#N7U46&B[+)!G/TF/ R8N,0A>"$(X5M7(W0+I1"#'>O 5*#9M
M-WC"]GOM#:/:M7\/96" 6$4EL@T:A#VFC9W6G;BU,D(\'L3VRQ%/<C\B1B/Q
MA4S*E 18Q+Z!SDA62 GDG>XTLAOW0]=H"W6B(MBU3$%C7:(L-4&*!L<V[.33
M0L+C6MJTS,5?KLN(T[:7W3?QQ"'MW97_ $]BZ:D@D[$\@F.Q8RN'B)"1I,O0
MI0B7!:AB=%LP*U\/&+NE#9?'U2&B+_5[0,CI.CMH?$X/&&B3.MYJ-%G-J9I%
M?U)&_1!B?H([O!?-/(M(%O\ )H],GF0),7\6Q/[LR-*O%RI0OPJHJ.4*!=+(
MP:BUHIB,?!K6/.[.M'CLQNTMTY8[MGKQZ+,<=[B=W62V5M'[(MK89.EG?6-+
MR>X2""F/O+T1@Y'?N.+OS_-1Z[H4506M0V+;G<;Q/%>HWR<JSG;;8XSD>9.=
MR=MMCQNF8%4NE-#=>\< (1.=.U"K;/A!ZO.#L.I;;4'S(\_WAMQY^-4<3]-M
M*UV:,P%7=@>4X%J#T!$KDR@&-P)/_O6!L3OSIVV!QYC)!^ *L ZI2AY$>7>D
M9S2>\ E102X5&"DNHC.'E(P2/R\832YD>*  PBVO+ZV;[6XO;RLBC;6M%5>O
M641RHIH!*CC)5MC88W) &3G&4 U=E.]/7*+=J>&Q[LJ+DT7ULX6%<$T[JVJI
MJ4U '&Q'0YZI5RJ&1MN.'KU]="Q>"CSLGEZ,?E%K)J[J&O464M[7+GQJ:&MQ
M18VMJW7"+$ A YM^4A0YM\XW/U$\?L?V>]B>R\?!P9<?HV#BS^[PYIYIY)IR
M9S))-,%H7F(6A!:/Q+[0?:/VCT;%Q?<X^))*,7$$N4RR]43SB5![N:R*JEBI
M8QJQ.K6I(P1/94.H(#TYCX J(2-MR.F/7'G]%T[[.>Q<-!+T+HP) <89<:GK
M5])'SO0OM9[7G)$W2\8HK&>4V)_=#CRXQ0ZJZD9 \>RK<[_=MR_@(\^GU?7M
MP_H/V0%_]+@D$%#[N;D'+4*%]]N@>W_:W_N^E+I[V7M^73U>)!6F>M5@NLBO
M+)2JO1='"/)MT/B+_P!I?L8YG=?X((!!2H$XPE0P<9QKP_9/L3%EEGDP.CF6
M:23%E/NY@,N(%DF<JX!(!"BX  ,;)_;7MJ0SR8G2.D2S23SX<RSRE)I6FE3(
M02"Q-*?,&BV1/-75+LO:S"4VU%PMTWMO=W#X@MZ+$EX:0#A.0OF9'6J<_2*R
MA9',$GBR>R/8Q,PEP.CDR3B7$ D*RS)+B@%9W)$\DVH"%50QC-[:]L99#-CX
MXEGEFFDS3@B:59\,D#)\JB>0)>4RE6BUIZ@ZLU+.I>(F$H%E2M@Z4[E3RY$U
M+$NC.QA"24[J[Y>FLD>=+V@R$J6"/L?V-)DEFP,!<68R2C),\PPY\1GKDPYY
MAL"ITH]M>V9I9YATGI,PDD$\Q]Y*<LIGDD!),J@>\FDE8#K$72+ZTU$U>O+T
M-=&92HWU))O+HW;Y2;0VHV/W7P@ )V.P!3L2#L..K&^S_L>203GH_1YI1\N7
M )S _*)1+-,2JN 5N 'C'H_VF]KXT^7XG&E)/6ZTLO.8^ZE1 1\QTNQOZ,FU
MEN @4)]<>[WJ&E5A<JU#9TMSUWL'Q<?#0[%["GE4C#0\J2F-A"D!D*@GZ*\>
M-B="]A2F27X*4F<$Y?<=)EGE$HD7/(),V%-*,3#.7%$I(F5"'CZ'"Z5[8Q)3
M-\7BH)LI(QI#+,29OE.?KR@RD3&596<A1$7^=G5'&\YE0QT^[3AU^K8@YZ;=
M2=NG'O\ ]'O8O_L.C<L,E-_F^J4HK_+?TM]L?^[Q?[\O_8BHU8U*V'C^6;^7
M?+D!MG;)3L#N>N_EQ/Z/^Q/_ &'1O^%-Y\H?TL]LU^,Q;-GP_#W"W>[:1+X)
MK7J58RZ-7%:8OUXW]\-UI>6SBYB_;[YN5^&2-E<RB?I$[YW4?7Q?;OV2Z%A8
M$\^%AX<HRS$B23)-+,:UQ6*T;>/H_L_]KNE](QY,/$GG),P::<3":7,@E)&"
MB5**BDCC^P]G<BXM:=P?ZY()Q]0.VP]?3[<<?C&-+[J::4V*)SYI0Z\5C]FP
M,0XN'+-4EM';A>/%S54%LJC0(%Q<_G%$GR*AE1)Q@#E!!R0-P<\0*K6[K]R+
MRH8V%'570,:OOQW;18N;6VI6=O1M:">6E10$(3G. ,GKMYD^0^KB%XR#1<<(
M0X0C5>J\.OI7'A59:WNDD9:_OS-=@X**B?PD_41RD9(&4*'GD(U3*5-Y2AMU
M30TJNB,7M'.+%J_'55NXIK6MX5,+8CWMMD-V;!H<?,%E>T@%*MD_ ;*)'GW2
M.!O;GZU?:,"RU(32M04NA<)>\;&$B8-ON\Q#. /NRS=#@#.4$^><[8W'7<90
M;T-M5=_5H]Q(V 8YG]L^&;U6!C Q]'J1^0^F=N"@Z?G2*VA[O!&^F\?1DD>P
M,R!JQU_3K-OGX^>3\?ATVX>O7JT1/7K2*"1,.Q+^V>6 ;Q6,D>>"3@G<;@9/
MEOP4:Q6W[1Y:7[HMO$3" ?OA:\DDY-X3GKTR?B?0#.W4\%X]AB-H434/W?3G
M%SXB81C,@;">OZ=(.V=NOF=B<Y!Z$ <(K:'M_"*B1, (!D#9@$9(O5;[C.<G
M.PR1CEP,[DG<HU';NGBT&T/;^$!(F#<F0-> , >^D<V!U\_PL_W0(SUQC@OK
MUP([8-H>W\(IXC8>7]<#7D9.1>*\_P"Z&?38<OEMOY%LSKHN_JU&"P;0]OX1
M7Q&P $]_MAR-OT8L\N<D8!].F^=_@3P44:]W/Y0;0]OX1;>(F#J7]I_;9^&V
MY.P!VQ\ -NI>/88C:$<2/+UX7!D3 <D2!L3UV]\5ZDC ^ P#T)]!OE%;0]OX
M1:^(V$']7VLYVVN_K!\\C.<^77?X(B@4E/;+P&FGA2/H2)@\GYKVQD"\VV_K
MO/\ +U_AX+Q[#$Y;6IY>DBX,DC^,%^:]@0!WPS;[D'(QD'IG\+(&>F_"*@U/
M8&X._/OBV,C8.O?[5C=6#>9.^/3&^V,[Y\_+@OG0^N58-<'DC>?:!O$2DFK>
MG\=I"A6?*#X\=+*/QZ[+@XWV/[K*4D;D^0ZCC;-P":E*T%6[> *Q2_?==["F
MU 5WC8VCT=D+A=WNH<PL@V.+I:BS96C&"S-FRB@=.52^4)'D$E0P1A7'GXI6
M;4O1]AX<;WBRRWLZ'0ZU#!^:(XCH3C5&Z'"$.$(<(0X0APA#A"'"$.$(<(0X
M0APA#A"'"$.$(\_94O\ <J?^8G^+A"/GW>W_ -PH_P#[I'\GBJ=3VF(@T'8(
M^O8TO]RI_P"8GU)]/4D_63Q(L4]A0_W&EZ?[&CIC&.GIM]7"$4]WH?[A1]/]
MC1TSG'X/KO\ 7P4Z^C7M@@T]"G9'U[&C_N5/_,3_ !<(13V%#I[&ECICV:.F
MVW3X#\@].$(>PH#&*-(8Z?G:-OJ^CMU/Y>"G7?GK!!IMRTCZ]E2_W.G_ )B?
MXN$(^30HGK1I'ZZ:/A\/@/R#TX0CZ]G3_P!S1_FI_BX0CZ("@01D'8CA O'&
M4RT^ULB;JYW6E]VQ.["XW:;VDS2&S#B6T@$8:4$DTU 8.^X'T@.IX(@*7[;N
M^]PJLN@Q8FZT"*]ZA!WHJQ#O=NUT-O"FG1&.IL'7IOU(?\9Z^?IC!Y<;?>:R
M@MJ/H*MQK<K$S HX&OHOW<2@?#N#'VEGPV59ZTZTH>NXKTNS2AUC;LX^Y.B6
M9\9P\,R3($@*$?=WB.<IR?9OO,!C/$]X6.4@J5>BNB);78!7?)94<JRK9B-D
M5=+IS]VED[34<96IBCT"TP8X^QV+:TM+$UL[HVM;&ULBLLC2R,WB''*,\V0>
M48.3L3P&(0I$HL0Z:5"<->#0Y_G7PB(LFE^N$:L:39']$]!X[86\B\8VMLUP
M--@V64F"^Y$NZON\1W^(]C$F.,8^!XHQ2XRUH_!P$K;7ZN8U-FX6=W6\9:)P
M?M 0&QN&R#:4:+0UINKWO:]:HM#W:/-E^Z@!27?+!(,E?TO,\V,$ [8#%2S(
ME595+(/'LK#75-@Z("6/A;E$H]U[7?[%-._0?H!U\]_Q]DXWW.<#KL!Q?>UZ
MHKKQVOL@!HD3,&<;T\V3FMECWLFOM7OU3W*YL(7';6\3^C':R:'8.=K]$;I4
M_2$<PY1@!*CT&QWSI-"E]RM5J5/BPH;U $NA'I FK_@$[#@$1IPJ,6+(+BK>
MW* ;F_O*ZLKNK^JE/MJBNI3^ A.P.>7FR<XX( P]>N6J"%:A.8L5'FVCQ+Z]
MO1N:-2WN*-.M0KI**]&JD+0M"DX*5((4E70#&PVY@<C=#9M];)W?2,?W R?B
MENVZ?H2AM_\ ,X18L7*)1]RLK^RJM=A2#C:KM*U:A9T$5 A23@I*4#'*<* R
M,XY2K?A^/KTT0\4H!?UN>=HLXC!8W!F^M8QZP%JFO].ZN!A5Y=U$I("ZM8)2
M5*3D\@  !.=SOPAOZY>G[(_&_5Q7L=39J;G8F0.1P=MRD8/D-O,#(.3L?+]R
M^SV/T+!DPC-,A]U@E,N(?V),P*";5%&K-'X%]H^B].QCB@2+U\4?-AH^),[D
M$DH"0:"SD#7.0,<V/4CF&^QWV\OW]B<8X^AZ=T[H$\LI&)1ODQE;3JC9_!3'
MR71?9_3Y2>IS)P@:Z9S8$>A + !)6G.V,[X W(S]>X)_>QLZ1T[H&,$$S&G5
MQ52Y^2[7,;^B2^V<"83'#(>\W1S3E,S*\3.IJ ^H=$.";=O)HQ,1I-I;7B4N
M-W?\K$7R7?=F.R=2GU3%#(;' *D74HK9 .<(E(2GYO$]E] Q)YYY<:;-/B'$
M!,N*!()A,<ARSX9Q,/WF)B8DLLY.6;$)7J@2_9='^TGM?H\DLIP@!+*)"DV"
MLQ4]99L*8";+EEZH 20,"LQ\K+4*4V]6G?WM1N<7"A:M1!5=NK<V(Q+YS.,!
ME 22"N9JC@YU*4.Y,$@%(3G+]G?9"SDXTW7F) R8@RC+)(!*F,0V3.#/F)S(
M4 $@A^T7M>82CW7RA&FP"O6,S_J@%&8#J@#J@A29B;6PF[I8/-!UL;:VJ8M8
MW[X7&0NSBWJ<V5VTJ>_N0SJ!CS P :9)6.0 E;RD;IYT*DWV=]DS #W\PZTY
MZF'BRJ)AB2R@DXDTRRYI2#(5S2 JA(G2_:+VQ*3^I4($S38"A)I9E080$RD&
M4JH$DQZJY9I;"A)'6L\/#HZTK5R;W9A\(=TW=Y]$1GNCN7'?;''XL1(.9ZR3
MX5Y,$)Z<9?H;I@&4>U&$WO%^%P7G.)[Q7QB6G0Y00!1 %$>=_2R1?]4D("%'
M3)U1 *?#*666Y "U*QF[W4)-Y=V-S2@$>MJ#&B/7$;L$S1W<;!O<8>G4]%0)
M/A[F?$J&HKIG"@%^RIG&4I(Q'L/I1Q)L7])IB3C$S$=$P09A/+@R3E1C*#,.
MCX$JRH1D"=8QE_2Z4R2R?HF8R@RD2GILZ RF<RM[@ H<2<H:F8@LHB$4%511
M3[]?AR<;D^]WEYG>^<ML';&>F!L,X)R=P/HOCN@(TR , )<6ED&5*4L&72/G
M9O9_M S%,,C^UA'K;]=#<&]F2/?VE+<[;#?)]<YSYY_?Z;#B_'= ^]_AQO\
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MQ7H]@9L;E/UJ2I1'GMD =?K!\O/C(=-Z9+3&7;)ABE/V-DY\8]*8^SY@1\$
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M+FF)]XH*EY<-=2I/[1)*U?:-1?T&_M:__A)-1/K[JU)Z;?\ XYNI]!^7C/\
M271*^YGL@76G[+"CKX&-?N<?[P7:3#LGXD\&2_7'8I[ &OG9AUANM2=0NV#-
M-:X]=P]SC0B;K:3!O;0Z/;U'U!X"9!J'*P3]Q2 ,9PH'<=>/I/M#HO2<,X8P
MP"Q&=9DF"@%#(F:LJU!F*4)/LC'(+DD*JN E'ZH8S!4HHM2/UN%RZ9SWI?=1
MUND8W&2,'SWR,C88Z[8\PX/1YD_5894%@)I4M8CU7>GI,Q_:F' _^*\7CY]Z
M<L[.CA]M?U^S^$#'ETSQ/A\'[DN[6[0EJ13CXUINTO?27UVJ%TXX_51Q\_\
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M[(>_Q?O=Z6.QJQ6VB-%!=.61]U'#RZW 'D-_,=?+<^HX?#X"?(%=D"/NJM:
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M=QM%'4F-9*71E'O%)(& 4G""0 K*BDCTO9>&,3I!! ;#F+U!64,X()!+@WX
M\'M&<X>$"#^T!2Q#JN8.B\%M'0?8(JKD'8O[+3T_+J/3VZ:#:77CJZNRPY.=
M^X&',REU7-T*%JJ5>8 $K)!2$@9Y5)5C[2E]WTB>5Y1+DR@E \DI) -5F+S
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M?M6C_(X0AW$R_BIO_:E'Z_[CU.?KX1$X]I]6\=3%HX-371;G"K2;;#F18WY
M]TI8432J*4D@)!(4I.% ;G^MP-N :"*#Q/:OB$\$8)&L^S]+W>;Z:LS\]UC7
MO[D$+J$;\H0C SYXWQZ#'"OKGVO -Y"@]=Z*@>-I/?Z@O&_]C''_ )BM\1]6
M/L^!O1?ZS#_WLOB-O6HK&&(P/\I\98X%[6NL^HVCK/I%\V=BVW3]J1J^UZ?7
MB;N"O.HBF]L^;2?SM2F6%Q^1Q0O[_B$@!(ER.4@G)2K"?:*F4A2BFIZWSE4*
M@@4R]61%**4R^-CD @@ D(A10B([!T!)7,K(F4KH?\VUJ"S,-@=0]'[B%R>(
M7D%9=7PJY9G9L3*YMHXK5=\AS'RR(+85)85#FDQ7+L<B<>+%YXU=4T(U1 @R
MG, J@E/NF840(ICHV1$2YE8RO5@2!HZE5#C.M_RA+$?$Y>M)Y=' P,\HOK0N
MTAAX]^DS%#]))VQLH D05F4QO6N$8Z8F"EPA7,KE3P28AID#J54D+8("R]4@
M@(I>(DK@@&P&X8*'"7(=P $!CX9/E HJ\-E"55=+Y4SP5L9XD\ZB2IU<F>Q;
M--FV;ZSS[0T]],HJ(D>8Q(H2\2.9'"/9Q(>T5SI4E*!4A"*(0RO*07< $BB!
MB"5,!S<&A1CR4@(5#J&55)FD][;4?T_BNA<I==+-1KF_ULC8F=G%FME+A)(I
M&#W"I[+T6$?2D)$W8R(R">523]+.>':R $JB@@MF!1T*RDN=4,1PJ%">%U#N
MVA!(*$VB(4>WRPU'=<?3I+++5[?9'X<@B;V0Q&P:Y8!J//-*'IZ=GL5%"/8D
M6E[WSIE& ?O>)3]-2^"@DS A0="2$!1 *)J*N %+9?"JH)*(0BH5)!.8J[AE
M4@HJB5#KN%_*61GP P2G4'3IYME+A#4]2YTAEXT.#696]:"O7:++0S0U,B\3
MAB$99GL)DZ^9"Y<DTR4HQP.U>KH$=RJ%\I 30(V98?"L!L07*(40"7. !F&;
M52M0")P.WDD2>@RIT[<R[M=VYPV10JS=HBXNB9T^:E=G"#,@99J9'X:5'C^:
M"9=P<D'H/"V)99EU4@H23V (E2BN02H84C7"6W4+5MPJ#0N05G>C':Y>M7YD
M\-3?IFICCMG'=,G=-TZ2]F#D7*<ZC3F$/2N0;?>M(86]92 #+TIQC&<&* +*
MB,% 3<!CI0LHE*B(7\5<V*(H4,MWK01W#S=-NA]=_P IZ#USL?LXZ\J5;BGF
ME-ZM8D><E/7K?BL.8G\NWPSG;^+/EY8X9339?1IJB$T='0A/KU?RCY&_U^7I
M]0QT.?LW/3C&.B/K??K@[[9&<XVQ_P"O[<;H1YD$[<HV(ZXZ? ==^FP/\!XK
M:V;5?6^G"-N<=[U1.SZ:\8H$JZG)Q]6 -R-^OD,G&^W7@WKTE*75UI#,->X_
MG6MD9*Q4I5Y?'S!Z#KD'89QG<#S(ZYVB8(%-AKPJ:O'&15' -D^GY13E5U\L
M\H'T=]O/R ^S(&>+F&M0M#2(G>T>I4>NX],D;;^6V?(@_9GRXTIN-M^Q7V*<
MX$'<<>/?H?H7@#GH#T.!G\N-MSO\3P((KPMX^KA6@G'TO/MCR*3U ^TGS.W]
MUD=-\YV^O>A*F]@S;H$-!1'TMV&84!I<@E]E*BIJO.[V9)Z#?/I]F.AQMUS@
M[],\11ZKOP4$]U;W,->XIM9T('?2U<*QN"3@D]#U!('3'3X8V/D,':LHT'+1
MKW':FT<;G7\W[Z]\?.%8_P!'EML,;CRQMY;D;CBJ/3;GP?>KQ(^\#;/ED^9_
M>SCZNF-_0<:DE^]_A/C7E&?Q-WX-Y)]8IRIZ^8]<_6/MSG)/Y>+U?OEU5 0.
MSZ1/B-J44 EK*E=Z0(/Y,8W&YR=\@'XYQCS&^>,\TFW8?*(IHIX<?-8IRKV)
M!&.H\C@^I)]-_MW&Y!9=OS'EY0??7L/T*GM.L5"5#?&,DCJ#OZD#!^H8^)Z\
M,TJU"ZI]8/1ZTWX:TBA2H^74XV)Z'X$]0,YV.,C'P9I=>X^6[<=X/9?SVY=T
M.56#D'/GN/0D?9MY8V)SMN;FEU$$.E*[<J\XKRJW./CUW&V0<9QT&/CL"=SA
MF"HL$**C?GY>E$4 5OMN<8Z#/Y"3_"-OCC@LJ5#=UJ5@^[^OIW0Y5>AZ[=-C
MY#!SN",? ';;I,TOFQ=>5X.4Y /V#:&#\1U\\^7QP<DGSVZ[@XX+*=^2_3T^
MAB*=3#E)S@X.?@.I'ED^GK]?GEFE[-BP[&BNZKO^,>G\) \LX P!Y>9QCX>N
M>-,;X=/+8C&^X'3TWSG?'4>GHA'RKJ/M\B.H)VWZ;#J/38<9X5-CL@J>=V6R
M4:-4_>M.0]<518T=KCGN:&'.WSC-).2=CA]W.3Y]/,XSCIQQ].^1%2E$?JBX
M2RZ%="T=W0JCB5[1'95K^EK?_B*/_-IX\DU/$^,>M+0<!X1[\2+'Y%?+<9_H
M=6M'^.=)NF/\)L8_? SGX^1X]?[,?Z_PM#+B,]NBXY7TVQ+C@]I_Z-+IGE\9
M^WM&FXZ<^3NW[$'9(R,_^Q\TP\MSB'LVWEG'\?7.^K[1?Z\QA_\ )/\ _P 4
MGINYHV]!_P!'!_AE_P"F]_6L=L\>;'5#A"'"$.$(<(0X0APA#A"'"$.$(<(0
MX0APA#A"'"$.$(<(0X0APA#A"'"$.$(<(0X0APA#A"'"$.$(<(0X0C&/?ZC.
MW^++_P#Z+5X0CGOLFG.CK$?/*L[^B$>7^GSZ>62MS/@/6G-8E^0^O+T]HW\]
M_J"\?XL<?^CUN+T;^LP_][)XRQAB4/\ *?&6-&R:I%*3A#:,CHMUPX7$DS#^
M]6E3B;&3AG?AEE/1AD)CA>PHD$<F3@;@^R0)G<(902"5F (1RT\OW9K@S"YC
MQ\9LP8JJ! Q2W[0-64A0-%&@-2=08:PZJ4-.'+2N-RVZ?O DGD]]=!I3)+]4
MY>'[2=B>>XS'BI]3%8\QA$UDY61#(8KEZ=<"#\I1:J:%+ARH4EE<A-#&X5V*
M,@5%#.$)T(&Z.4U:[ZQZ-T8._P BE6C.G*FY]B$8DT=C%\\::N,GES9JD8XP
ML;--V)]]F&!2H\B%J7D2Z'HB#",3-0B6! :H5>JJ6F +2@?Q A2DS%0$ A*A
M*( 6ZP)5UHW$"JO$IU0'9)O-,&B*R>@SQK3'6.)J>;1,,9WJ,-TM@T?J*FX9
MGMY@J!SQPKFQ*8X=EI?Y*I',A4MP"J"Z(AE)#.*=65F))NQ /5 '1 #4(Z@@
MERZ%$ #BA.5"3)YOJ]V>[A+>=2H_5N1#@N36%E,]'WEPJ1-R9&:;O00RKD#
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M^'"O)4HQ CG4>;?EFRD$Y:.#-,4&50)ID(* @D.O7:8D0,LJJ@( -A*A0H"
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M>4%2$QZ)O[08PJ3+"8B:CU'<S$(E"%U,P3-,0LP  *D3(20&FE^0(""B@F8
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M>(W!9I)OHI%,0]E75 "EQ7GF<A"M4=T4D,)5JRTJX'6FE,]V-&#-= ?VLI)
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MFQB+\6-F!)W.'MZQMG#[D')SQ#-*0CIF$PE9IC-F)6G5)!" ?*4$P($;UN2
M2$)<*@1RZ NH)1P2@#P-IT6TM8'>P?6N',M%Q8;P7L<NN7F\*H#._L10RA2@
M&"/\KR])3&8NH)2K*MP0E%,TQN56P!5U,H$Q<@ C-,)95-'0%E6J!" %(,K
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M@M9'=VUY]TG]K"F!EJ-#T]/065,4HCT+9HT$)2DU(HGE!2,*XU K*4)!"U8
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MR_#GF[[CF )4_* .!GB@DE*Y2IH00 @R@3S3!Y3\Q):85#)J @(' JM50G*
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MI@2% 1 \AF)[P%+U U8R H;L"C*2R@@!&4* ;H%0ZCUQQW/%-]O'48&!Y[2
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MOIG?;/F< 9W.,>>?/TR0,Y0BO4[#.YQY@]3]8V.^.A()((X0BG7&Y\M]^HZ
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ME!Z-G.'QV9%AB+%(O#4F:8Y%+R9A2I&(S2J(E*Y';*B ER10N1('=5$6IU9
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MC3MC9IOZ]K15=(M%94JB*JJ?,*:E$Y0.5("E@8!*2];]L0A?)RW#5:%XP%*
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M3*RL*FB9]R>(PHIU-D;.\TH8 "8A$SG(Z$"*!#4Z%B 5W&]6!UBH54AD *L
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M)T'N0M40:K2]:99]TW-_DPTSU<Y7E[>_$@P!J(R:6I!.?UPR4XR,P\:U/8A
M24D4)>M'8%+WLW>BW4,I!* *S(4C8THFW::LM'(NZQ6$6[EJ==/4H]\9_<P$
M]UL/?W@3OO"00)3RL:D?>C$#SE61$ $X*02JH +,IM2R*N9LR&T$9"*LJE70
MDDDESF0L@0$7$7<E:-?WF$1VQ:WN2VT@==5-4(7+W<7C,VN3!IA.9G/&%CF;
M(-B)!%(ZF$2B%#)"AMG'+Q2P10$;=R$4! Q2R. 2%B,Z)2AW-JJFK&^L:T;I
M1VW62C;W)A#,\NSI$7-YNFEX>DALL)XRLT]8$L@W(88^M<'TLDH)RI7C^2;%
M.##\0$4A )KHTRHA#L\U"2224#Q4=RX% ":,]#0*:H%H5$;(TD?^TC>:CV]7
M46.*MX Z0[W5-W:Y41)V-[GP8R&3FB)CX7'.Y!-3X024S%,93]YR I((I "E
MQ,I)F150J31#52J%)2A$4J 24%51 I#D$(02&)H[CK%8Q\E;M7:3Y6:E.NK#
MD+K6ITO&B5--T5-K%!4LT *"]LC"?N\G/?D9A,7E@\&J)DTWG?B]* #0""A-
M+/8J@! " D*1*%)"@$/&1GJY E0$=JG[JH$H5;M/CL(0#0WU5&9:7%B*N!'F
MPX$L]P-' X+<(7!0#DAQ$4*3KYOQ=+G@D(<$Y<2.Y:CMXPAP[UT9V9!H1H\(
M<6J!GKXVM1@ [(2(0XG<5?\ +6N@'.$.*Q0$H-BU G913P5F0X@#@-<>BX>@
M2$.+L$6C!- A4!UN;GL1XC=21C. >O0[ ;9!Z8WQMG'KMGAM*!N=-5LNNN\6
M>I8&E> XQI77''<\2./^Z(S]1D?V=Z#J,$@;>HR//CS^G( 02?ENXI?Q- S[
M=W0?F'$UMURAK4T[*QV3:_I:W_XBC_S:>/+-3Q/C'L2T' >$>_$BQ^1/RW(_
M]KKUHR/[,:3#R\]38N?@ 3CTR/4'KZ_V8_U_@_RXJ_\ ^)C;Z):UK\'M/_1I
M:?.+'^/2VH1#=HZ<^3PQ^8?[)/\ ^C[I@?A^M!FZ#R_GGX:?M%_KW%_GG5?]
MU)V;NIW1MO0?]''\LO#]FGY:1O*::^Z*Z;R1OAFH&K, A,L>K1O<FABELI:8
M^YN3<\O986FK0H.RZ9JHNW\EDI)I^T5[91R$U2E(\[UKWT]7CI%+'BUF!J]
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MY(DE@C@6P:62I*XJ/9KF$BDRITM5-8,0( LP668AU!"I,$!#$NS JR(KJ-S
MXA5NBAB 10+18V1I'^::&HUO>ZG-%Y;0%RB)L[M0O(<7.PE#&]STL??;(Q$Q
MD)\.!D!1%/P9EX90$A*9B$D9:F4ZJ03,&S(4!42E @!(= E!+A0A!)!8&H<#
M]J]U+N8L'Z*:R6[W7;*)U9>+9TUK='EGEC3.F9N\*P,,L!">9D,CB(?P)#W]
M%X7&"DPQ>9+-YU"I>$J$QK@A64.;$UJK"5VF 4$$%G@(1*Z;*#3521V$I0QV
MEQV5J6"D5+*>%3JA+<(\V'!>;\ >+>)96$(<2W!*U/X <-5H(0X"_:W:A!J
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M;'XVPS*%QQ(H"XKJN&A_6JG[5*IE*+J=*)^)MZ2L2X#'57;1M4-64<!%EI#
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M4&E%TSQYCCC5'62BR("&"ERFHI:K6XJW%9AD4MEM3WZ5)MJ@/:R<+ MRU7G
M]CK]2%*:&B(RA(TA9Z&=K1T@SNPRC5:ZLY-<M%W8,E6QF$@+/3#^]1IKE!?[
MI%%3^]"XCZYC6A2362F+5WL%"HG4H1(0P^JUWW71*^/%P"4T!-@'['I05:6:
M>Z6]J6EJ8T7LXU$%OIG:2IL?+QA;9@])<G&+,41D5&-L2BM!KK3')*N()EBJ
M5"*IFZ!<>-3,D+*50*4NVKJ; /<V)OQ@:'\"A%^Q"YTX1W:]_J*[_P"*[_\
MZ)5X1E'._9*S\SS)]9_*4)S]6_EY?DX6YGM27\.^)<\!XS1T*_?J&\_XKO\
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MK,1>NG>VE"4J"&(R_OQ,KC\QFTC$5Y1,X>6*H9QM%E$L^Z%NJ#11E" $92R
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(A#A"'"$?_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>19
<FILENAME>g164680g00y07.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g164680g00y07.jpg
M_]C_X  02D9)1@ ! 0(!>0%Y  #_[1WB4&AO=&]S:&]P(#,N,  X0DE-! 0
M    '<:^=B(X0DE-! 0       \< 5H  QLE1QP"   "    .$))300E
M   0S<_Z?:C'O@D%<':NKP7#3CA"24T$.@      Y0   !     !       +
M<')I;G1/=71P=70    %     %!S=%-B;V]L 0    !);G1E96YU;0    !)
M;G1E     $-L<FT    /<')I;G13:7AT965N0FET8F]O;      +<')I;G1E
M<DYA;65415A4     0      #W!R:6YT4')O;V93971U<$]B:F,    , %
M<@!O &\ 9@ @ %, 90!T '4 <       "G!R;V]F4V5T=7     !     $)L
M=&YE;G5M    #&)U:6QT:6Y0<F]O9@    EP<F]O9D--64L .$))300[
M  (M    $     $      !)P<FEN=$]U='!U=$]P=&EO;G,    7     $-P
M=&YB;V]L      !#;&)R8F]O;       4F=S36)O;VP      $-R;D-B;V]L
M      !#;G1#8F]O;       3&)L<V)O;VP      $YG='9B;V]L      !%
M;6Q$8F]O;       26YT<F)O;VP      $)C:V=/8FIC     0       %)'
M0D,    #     %)D("!D;W5B0&_@            1W)N(&1O=6) ;^
M      !";" @9&]U8D!OX            $)R9%15;G1&(U)L=
M     $)L9"!5;G1&(U)L=                %)S;'15;G1&(U!X;$!7?UZ
M        "G9E8W1O<D1A=&%B;V]L 0    !09U!S96YU;0    !09U!S
M %!G4$,     3&5F=%5N=$8C4FQT                5&]P(%5N=$8C4FQT
M                4V-L(%5N=$8C4')C0%D            08W)O<%=H96Y0
M<FEN=&EN9V)O;VP     #F-R;W!296-T0F]T=&]M;&]N9P         ,8W)O
M<%)E8W1,969T;&]N9P         -8W)O<%)E8W12:6=H=&QO;F<
M"V-R;W!296-T5&]P;&]N9P      .$))30/M       0 [_^-0 "  $#O_XU
M  (  3A"24T$)@      #@             _@   .$))300-       $
M>#A"24T$&0      !    !XX0DE- _,       D           $ .$))32<0
M       *  $          3A"24T#]0      2  O9F8  0!L9F8 !@
M 0 O9F8  0"AF9H !@       0 R     0!:    !@       0 U     0 M
M    !@       3A"24T#^       <   ____________________________
M_P/H     /____________________________\#Z     #_____________
M________________ ^@     _____________________________P/H   X
M0DE-! @      !     !   "0    D      .$))300>       $     #A"
M24T$&@     #-0    8              7,   (6          $
M                 0             "%@   7,
M 0                         0     0       &YU;&P    "    !F)O
M=6YD<T]B:F,    !        4F-T,0    0     5&]P(&QO;F<
M $QE9G1L;VYG          !"=&]M;&]N9P   7,     4F=H=&QO;F<   (6
M    !G-L:6-E<U9L3',    !3V)J8P    $       5S;&EC90   !(    '
M<VQI8V5)1&QO;F<         !V=R;W5P241L;VYG          9O<FEG:6YE
M;G5M    #$53;&EC94]R:6=I;@    UA=71O1V5N97)A=&5D     %1Y<&5E
M;G5M    "D53;&EC951Y<&4     26UG(     9B;W5N9'-/8FIC     0
M     %)C=#$    $     %1O<"!L;VYG          !,969T;&]N9P
M    0G1O;6QO;F<   %S     %)G:'1L;VYG   "%@    -U<FQ415A4
M 0       &YU;&Q415A4     0       $US9V5415A4     0      !F%L
M=%1A9U1%6%0    !       .8V5L;%1E>'1)<TA434QB;V]L 0    AC96QL
M5&5X=%1%6%0    !       ):&]R>D%L:6=N96YU;0    ]%4VQI8V5(;W)Z
M06QI9VX    '9&5F875L=     EV97)T06QI9VYE;G5M    #T53;&EC959E
M<G1!;&EG;@    =D969A=6QT    "V)G0V]L;W)4>7!E96YU;0   !%%4VQI
M8V5"1T-O;&]R5'EP90    !.;VYE    "71O<$]U='-E=&QO;F<
M"FQE9G1/=71S971L;VYG          QB;W1T;VU/=71S971L;VYG
M  MR:6=H=$]U='-E=&QO;F<      #A"24T$*       #     (_\
M #A"24T$$0       0$ .$))3004       $     3A"24T$#      3L
M  $   "@    ;P   >   - @   3E  8  '_V/_M  Q!9&]B95]#30 "_^X
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M6UGUH:S?MEU@J(!)#;/<&,V_2_1-?_UST50_YB_6[_RM_P#!
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
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M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!_]L
M0P$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$!_\  $0@!>P(A P$1  (1 0,1 ?_$ !\
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MP=$6(T)24Y*3%20S-&)RHM+A\4-4@@<U8W.CTT1T@[+"P[,E183B5624_]H
M# ,!  (1 Q$ /P#[N*_KN7T/*^_X[@J]@2;6MKK<"XTM>^I&EC?&!1)4!8EF
M#OV\1O9J/K$@@5(<#QQCK3SA[KQLE9#5'#TKF?F"S3,_BX$S&"@7:<JF?#O0
MEQL6\!R(>4I<(X?=* *N/"WH]G>3T[')24N"4N ,N@#U,T=E-*4H>+C]NR,$
M59[$A_2!-6J>C4:OHQ:A#,1J@=WDV!C8^O1!CG8T3F@"+\M:'41QM;>-N%SQ
MQM_)>:Y#]KC3_P!3V4O5WC0^4TC0L]6RGBW^!P-QQB_^3Q[ =OT9X2_&_B5F
MC[UO$4?C\_#%?DO/WCO3_P!^'RED?63QL?\ Z;1X"N[R]SZWE;V=$*%;QN/$
MC-4ZWU_2(+^>_5QOII*\DO*TJ)ER7E.>C.; U0_4(S8AV*6O6SU$9QY6>2M!
M-GM, :8&QU)E H=7"D>DXHXW&SOR>3N?5Q?.F&UM;Z2<U2>L_I$Y:7.GFTQ7
MY(^6'V'<=G^_$&)^5ODG1YY?EC[]N%U:GKCSD=WGV DH1^;1!A.XFWTDYI7/
MOT(;<03S/7I;&VCR9VB4I1-0TU("9R7E'YU-)@=,\)HH'T:7:C05M_ OTDI8
M,A8S2BTRLM1=!ZTL*)8@NI+Z$ O%L]WHV R2D9T00Z_I(S3]%_I%!OQM;37L
MN+GR8QJ YEM9R\LZU_QS?Q04H-O82:V5=N"Q>QK*#]CZQXCG=Z>Y_H6H+SLA
M18D$"B,T2 >>OB&3H>)O<'3GC6/DCY135*5(E$2E$F77!N4OU?2G@A]Z@X>H
M@?*7#2G3U3E+.RW4P?24>%#=N46E=WQ[GRGR3G?! V'NJ&S4MZ3XAVUZ],94
M^0_E4LTED _^1H=U<3X,8%>5^"2X*1Q<K#MP.'X4O'G-=WIV!%-H6WG9!*00
M2FU#9GV(O;]89)&AL3?T\<2?)G:<AY6(EGII=)A>2*WKDGE-B+%AK5XV97E#
M@IR$S,^3.'R_.$!J  B4.9I7UQ<'=Y]@<_\ +9!6U_2-F?SOH/I"%Q\7HQ'R
M>QWV?KE_]\4[S&3\N8$?XI[#,X?\+QV1![O)L$$W&=S '4FB<P@FW"X#U"=(
M!IJ5<]0-TB\'R?Q[TDOQS2QI_P _?XUC$K;^#!($TG_2LW:E9+OXX0'=Y=@D
M?\ML(=+C?H?,E2N?$LT)N&^G @ 6N+@XCY/8_P"R(K]:50?C%WYZ=D/R_@S_
M (P_Z@]71#U1>1W>;8&"1O9TP2C<WM0^:'7P^P,@=?'X,73Y.8XBJ<I>SRB?
M_P _N>+C;^# ?I 1QZ0COZ+Q6*%]WGV!=XVSJ@TBU[>(^:''_832_+MY8GY-
MXW45U_1?]_3D.,/R]@R?3Y,9@#<NA/M,>,ON\.P(5!:\[(;A8VHK,0 @7-MU
M^A X-;:V ZCJ3B#Y-XXD)" ;:RAK_P ]WK87M:,?Y=PIF B9U6%64K4.Q,H&
M(/=Y-@)5@,[X<^>B<P+#AH+T*>5QU6.*CR4V@GK&70/?H6U:V(H'.G;2-A>W
M\#E(2H.PK\X=+L93:^ZEXOL=WAV!&T*W<Z850*B;FB<R;A1 !%F*$*.6M_*%
MNJV(^3N.MD9P6#RAJ;?/!J:N6K>-67MS# $JF@$*/T5AQ0A_FA=ZD@D,#$J[
MO/L"A0(SG@KV-_I*S0)N#QMXB"YUUN#YN)%ODUCA7HNUY9[?T]-;:1<>46"4
M2D3 ";$!=+B@Z*M=Y&][ W&N[R[ R196=$'J2=:(S0/FU%"Z>\>TVUQ'R?QQ
M/5ET!;TI;'_JTXU_K=&W,$ 09H<V.693NE>^[]L+[O/L#\$YSP0ZR:(S/OZ#
MXB#AV:'S8?)W'ZHUWRC_ /<.VIX1;\O8$_XHI]431W_-'LW1;_)Y-@A5CZ]<
M&FW5169X!]'B(02?-IB?D_C .M++EF8R^W_&;O:\6&W,$Q:8_$B93=_@CU[B
M=\4_D\6P-?>&=<$=;@^)&9__  )?TW[=>&-4>3.T1,SE!R@NV:6&&[].S1'R
MAP7H=*G[LQ[/]@S\7]<5?D\FP2D&V=4&HDZ_23F@0.P$4(+<;6%P=/)&-L;!
MQ)RCHRY%>L@5T=YS,2[L>1WV_+>#(?/1J'YP.]C^BO2G;%*N[S; V\-[.N$1
M?4!-$YDVOH2?RQ0@ -KVW+ZJN18 8M\F\<03T=!QEVT=YX:UV-Q2,1\H,"X
MFWI4++:?9$ZB_?6EUKN\NP*"J^=<.Y>WNZ)S&-O-WO08/\/3J(Q0^3V,+-*
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M;>.46SW>;8"!NYG3!*4!Q%$9H]>A\FA.79;&:1Y)8K$_.K24J?+E=)9GLV)
MKOXD'AAG^4>&DG(A14+YF47<68R"S<;\HS++WNS&Q?F[6,FHB@LTV9]54Z6X
MW+9:BEZU@ 3 MF9.JZ:<T1!H'2-PJTG>CDH!U 0I(4*XSR<FX-!4H.U=#2]^
ME5W[GJ8S8/:Z<6H!*J&]-YW&6DC<*[G$=FV6>:,HS$A%Q$MMNW6I"@ZAX. !
M)404.N]&!<^UKW%C0EM(()\Z$Y735P7(W VUW^!'>4"D@'4 \0:T(Y#PXC:^
M$1'!_;,C'FZ&>6S<_E1ZY'.QMV7.G'X>&(F?-E!W.7--W,-;0F,4LE94D5H
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M_59QIV;,SH#)S:0DT720IV*H^JITS!P$%.*4CDONHF4G744R51[K:R28^)C
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MXT[RJP*9RI9PY4E* I,WI2$J)-4MT)8AW<\A2/08;R>QIDA1G.K,I*D='U@
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M+Q:EA  &26>F6@$ T"3E<"B;6$:V)Q.&DX?$S>E29HDI25%SF5\VA52#4LH
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M^02!;&WM#94TS\0C(LA&$2<Q!91J"U0,U*L2[VK&IL[:DH)EJ)0"J>I.4U(
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MZ1W^O3=V1S+V!/\ TF,O+V^N)OK_ *AF9^?OG'F/*\MA5$;E-N9CNTCV'D8
M<2 =2EZ5=T[]7]^M(^_K8)TD; OP#8 M_P TR+^GX]>>/A2O37_JKO9_[G>_
M./NLQ@$,WH(]K1V<XI%(X.[:7V%OWX]YKOSX%?O=G5C%,]*7^_\ #GO$7DCY
MM>]GJ/V5^ 3SX1\"G=1;G.Z4]M%RVPY:S29?+C['Y#^@G]T/W'Q>/COEV?3O
M0@[Z#*Y]_MM'6FG@/,/BQ[Q5R:7(\<:N_P#:/GSMN[0_MB<11K$'?O<:_P!+
MCOAX[O%(L//+"0D&PN!;LNFX.MN('O \<9I&'EOF(%226U)<[MV_W1.+Q$P(
M "B0$@"]+ &^@.GJK'D0=U^Z.B;V!X"UE"P'"RA<VTN-+F^,&."$!@!2H?@=
M*"[<^X1.SYLQ1<J(+U+EZOJ_#Q6/(B9H\^YNO/.O%NS2>F<4Z4ALV0E*EDJ
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MF,45;RE$J"DKOQ4%HONKO<D*3O*LKBFYL=3B_F(^JD\;>T/\8I^4E_6+>MJ
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M6Q J>D9R-%"C,"P>NO'13L+$-//+)>4E+20O?!4V'DV6E2-T^5#K0?;+[RD
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MI':(J<-AE$%2@2 P4I0)'(L2'X-[(FS6@WR!_C&PQ&>:?\/OECP_&\2)$D
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MR0'E],B<@A252590!UD^DJH-$NIG%12AX&-V%ATD+,PI7+6.C^=2I151)+!
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M@YCG/SDW($ DU4L*S$G*>GC-E8:;A$)2I(7*DD24RRE)R(7-.5+)=,J4"59
M&RI4D  $#Y(*6FU/2K,BF:JGM+053TG)ZNDT^G-"F/F,)*:GIN'F\%-(RE(B
M8LNB,@8:8RQPR$1C"Q&0D*\AU]:H^"BWE?1QC53L$H"0$J4E3*$I&9+@L4JJ
M:4(>[5H(^=KP D8]*CB%90I*2CIEY722"2D@CK,2K<]&! COP[I!G,QF[W-?
MN=.:4JR[HNA(.(S/SM:EF7=)2QQZDY!)J:G$M@Y!*5H;4P],VX=J6PPF\45&
M*FCJ(AXE3T2%'Q_D_*E_*/%IVA/7*PPPDPJ7,FA.:<1*Z-\^5()#J2EA094
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MD<!,G"HED%FH@/V-_2)Z"0WZ3LSA^=0S]O.(W61J%:]=SB>DG&AED\T \=[
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M9NB)1XM(HV[YRYXEM]+ODSM2CS%_>Q-?^C[&?G$#)[,KAXF56?\ 4$_O;_\
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MFY/D$H]R2"&,Q8=L3B$@W GS1V>G5^,#A,.6)D2"UGD2BQX=6D1ZT-!ZVDK
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MG")'#^W#LMV5K'8-0ZZC<I"G'*N[R%3KE$&J>"7I*8(3$M),0(=) (;"]+6
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M*WS$K*4O/,+J6$JC*2F*CI:+;1#11AHZ(C%H:08MMU/0QV'V9ARM#H"E*2L
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ME:IJ4 +*BI2G-R23](W<F@>S7CFJD)L"D"Q M:]K:<+\NK&GE"2:,;7C;!<
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M-"3RMY^-APQ$3$X0AA"&$(80AA",#S(^Q=?^5Z?ZOU:@>O3W\#4$;X1FT/\
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M$)R)?*E@'+Z#W-'N,+19JOV0PA&'I!\>6NKQ8C[&_'Z*2JWQ'WSC:/ZH@_\
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M&U-2T2J5LL.FZVV81#/N6T@[4S%XB:Q5,+L0&H &4&NU0I09K'C& 8>2#Z'
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M(0PA#"$0>7:?D)^3"$8D1:N6+?;4O,"?1-95:W\(_!C9+^:)W=.>\(_K&LD
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MSV>,M-H"4T]%4G+LR9&[/(.03".9F4;+6F9G'RMQF)B6&V$.*#\O<((:;T4
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MRU#-0C\UEC4''O0[,-",H>B7 S"PS6XPV/PMR\/Q@'J]#OHS.2*[AWUTTWD
M   +   #J T PBT6U-!5_*6+VU!%[A>^A5R"3N&X"3="DDI6E:; (AJOX\>J
M^IBVN$;44*22A:%I<0X$MK6E2$]&-TNMN!-V5.,D@ [CKB@0XH+$OR\>.?&#
M<_'CEPB#!L%6]N@*"5)00E!Z,*"4K"-Y!LA:4("VC=H[B3T=P#B(,.S=IW>Z
MVK1Y*4A*0E( 2D      =0  'F  [,(F)PA#"$,(1;+8*BJZKFUP#8&UM#I>
MVFNN$(J4FXMO*&EK@GY^]8]M]<46DK20%*2X9TEN=6,.P'G%CO1O>4I1<65
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M(0CD8XLI;0Q=0PY4\:0!8,7-]- SO?7F.R.-V7N?F8]6U1+X&D\\-GS-V83
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M:K=U218D4CX>X%0 X',5HUV+ MOH^^&(:@KQ-'N0Y-3HQJ&(YQ!+$U!IK4:
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M>$\M_P!5!9WD+%WHZZOJSL?@(]YY$EYYXS7>S#YIQVD:7N8^YQ/VPZEVUYZ
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M^-TW%KVQA(F)H ;T?,S#UUWL-:O%<P=@03N!'K['/9RBLO(0Y92TV6=Q"MY
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M]L'\4W/O\<JQ[*%SLRMC9I/)+"5C+(J:4Y&2Z7S:#AA$1#K,9-IS%4] L,=
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M_?Q!]#L3[HH/3/+X1T/>J&?['KF)S^C67WH/KCT> #Q\_#ACUWD:0-HX=_\
M,2_:U+4]YO'EO*]_R9B-&PTVO836P?F8_/L^?S]_'V\4)I1ZZL#0_P!Q6AOI
M\-X6<6-A05KO#FE1:%QPOKU8;Z$@.SEM=[<Z<3K$5[]3\;?VAB'%*"@[SO\
M'K$"&UJV[?6C4]G!X<QRL<1RU'C0^_W19%%)I])(]8?3X1^CKW#G^QWY#<2?
M%Z,OKR\9)YQY\>'+Y/A_E=^MASJHC@7 IS;VQ]Y\FOU0\DZ:M=]:,.#1V^'W
M;GF3_P"''E5^B>SVB/0)]-7;[1%_%HR0PA#"$,(0PA#"$62=%7-[.$#G8<AZ
M+X157T?WA[X]5-8QN6P4;&N!1;;;=+A1Q;0 ZLN #52MY-K)%R3?EKED($R8
MD$@#TMX(%2'I1GK\8Q8J;T<A:C8:U)J&#<F[N0CY_P"I,Z\T!/YT&:WJ%ID3
M2.2TTW'J0A#7?#@2E">C.Z$I  %_EM^C]A>2NR,5L;9N)FR)!F3\'(FK*I3D
MK6@$DG.-=6$?EC;?EIM?#;7VE(E8B>F7)QDZ7+ G* "$S"S#*684:H9NSTAS
MLS3L5>/=1;J=5J,Q4$IM]VHH"1U&Y'*_7CK#R.V+_EY#6#26TT^<([]8YGRZ
MVVWZQB#QZ93BQ^HUHTYE9G-F&Q4F:_>684V0N8UT_'1(3-"MZ)=7 PK>^E"0
M2O1(25I! W;>;D?)?9'GDV6</**):F2GHR0 P-!F+-KQ.E8]!+\KMJKV?*FG
M$3@I:74>E(4:J2Y.3AN>O(1N0YV9JJ5;QZJ%(]R;3%1L4BQ-]S[H&_(<+\\=
MX>16PUH<X:16WS'"[B8-_9N>D>:F^6^W$3%!.)Q!8FT]6^GT#S/88YS;#N9-
M55#5E5R^J*@FD^2]+()<&U&O=*(<B)4VX I=CO+U5O6%KVOICY5_M!\GL)LZ
M2GS1$M$M"DJ9*0GJF7UA<FY3<EP]B&CZY_LW\H\5M%8\[F39DV8E:76O.043
M!D%0 P3F8D4.C/':<G0#^@V/,:::'3'R)(   M6P87\<X^U1(_'SO\[_  8"
MGKA#$PAA",#S(^Q=>E_HO3^G7]&H'#U0C-H>_>[%^/0M_P 1/S.$53Z(\:Q>
MPBT,(1KJ@?KBL]/TU/#A:_T-E^MOGKA$"P^+^O6,_=;N 4-MJ6%&Q<-B@+T6
MI"MQ=E6Y6 5S-L(-PXZ&N_7LX-RBTVRMI02E*%-6*;J4 4I]T EM#2&]5:G4
M<[$7Q-&U?E3O?W1#'LWZ]P '(Z7X1Y0O87XV%_/Z"1\)\^(BT3A"+)B&0HHZ
M1.^%]&4 W7TFX7-P('E%1;!<  N4>5[G7"#_  \>+5M%96D'=.]RUW5;HWKV
M!5;=!TU!((NF]MX71#@^-]HK!!U!N.L81,,(0PA#"$,5'I*_T^R*J!(('BL8
MG6GV,5!I>\L> X?<]OSZL;6SP58^2!]<#M8AM-V_G2^MM @8.<3HE1L^@[^R
MHO'Y2^T*"<],W2-1ZX=5_P L17+CC]!;-!3@I -P@4N:\GMSIWQ^?]II,S&S
MU"H*@"U+7H>^HK?GIS=5U'WL;Y4&U?D;\0S[ZN?<- REZ)%":.*C37LN/:86
M.NG#C@%)J[L*Z@A^#,6N]+5I2(Z)5*<ZIO7B:6>EM#4!8]7*_HP"DN+DW>KD
M'EKK?ANAT4QC3=JG1^.E(^E;U,R4IVH,YRHV",L9.LZ&]A5TO5?M W#:VHL1
MS /B/+,%>$*A4="H58!^M1BW?9A=Z1[KR-^;GC.R09S!G+4ET+.]'JV^E7C[
MG4'3C[I5Q?F+#WCY];Z8^,2[KY@=U#SKK\(^P$/E;>"=-]W]GOBL$&_8;8R
M,_$D][1,3B80PA#"$,(0PA$*) \D;QZKV^/"(+Z!]_\ 3QV&+2R;#>%CK>QN
M!H.8U'HO;&)9ZZ.8]X_ORA7*7+%CSYTUUTX1T?;9RU>NTZLDJ(@BE*+FP2%M
MZ\+:V]\\+X_1W^SQ"!@5%9""9,L"F;4Z!VXT.E(_-/\ M,Q4O#8I!*B2J=,%
M$JJ<IO150&X5XL>(:B7+I\E*5$$J4+V 4%:6UN2-VX"CJ-.KZ N7*+Y5%SP4
MWM%]::OI'R4;21G! (2X.8I4XJ]LA]^X /&MJGRU@JGGXJ2(J:M8&8P2%^"V
M97/DPDN@W5PKL*5(AS"$CI&7G$*2%[I#A)-S?&C/PQ6$A-64";"@>K$L];BO
M(4CJHVUADH8S%9JFDN;K8 B737>P,;'"&VDH0RMY6Z$,K=C%A^*?3#0T,RR\
MMY-D^7NN[Z-T*WK*4 ""=R1*EH20LM0M11+DFFH(L:^N.9/VG+6LJ3F-=RW(
M# .Z ^\O>KL6C,J!7O5K2QN4*3/I4I*A?528QJPN!8:&Q!\QZL</R@E!&SYZ
MD'-<&A# @N:FH8.U^.[UOD9C)6)VSAY"B0Z%JJE;=4I:I2-]\PWL3'T94ZI1
ME,O)%[PZ2;$'B.J]^OKN;X_+&.?SZ9^\;Z=;0MKNTUC]<X()&$DL7ZJ=]:5K
M4:@W[3K[\*2HD W(XZ$?&,8F#@ZB-@*!L?;%6)B880AA"&$(80B%$!*B>%CB
M%!P0(6BCJ[46'GZOZ\440$Y3=A3QRB@!S%6A%#W1T/>J&3?N>V8J3KNSO+\%
M/^-F-2 '*QN;\#<$#LQ['R-EJ&T)$PCJIQ,NKAP2] *FK&P/&/*>5RTG9\^6
M#UCAYCAC5AFO;T2.]M\?GV6-M1V'Y>.O]&/MF9(&M/V33O:K5HX%[,WQ,RYC
MN _,A]#O:A=MS:TB=TVO;3KT]'P_CQ(4&%[,X%B]#1M+EK#=#HIAW.>+.2SO
M5OCK$[JNKX1^/$/<'4ARVYZLW'@>^+>;S7J!QJ/8"/;W-$;IM?D.T'Y<"S$5
MXZ@@BN@/*[&U:Q*</-"@6#!0/I)=@7L\?HY]PY('<[\A2>!IV,MH>)J6=V]^
M]NSTX^'^6*3+QH"F!!4^MR&L_NUC[?Y+3$3<&2@N&3=Q8,6!;^O93M_L2M74
MH#=[; $Z7TX<[8\HJJ2U79N^/2"BR^KMW_ 1=Q:,D,(0PA#"$,(0PA%D D+L
M/[:H^CY_T814G,S7"@^EGW^YXQ*O'=REIL4FQ,*Z>?W#@(U &I\W+E;&U@T*
M7.2E(=1! #@%VOP;4VXQS=K$C"36U">=S;P\?.-.#]%YH%@!8F$9?[87,0X3
M>VF@[;<P-1C]1^3\G+L/9(*F4,!A@00]>B2]03XU-S^/]N8S#2]L;21,)$Q.
M,GA8R3"R@L@U2D@\Q1K/'I8MIB,85!Q4,U%P3Z%)B&(EOIT+!!!"!TK.XFVE
MM^UO/CL]&*]<<.J>U[]G?'(..P9%%%MW1S7[.J1V\>%<3D= T/3D=X2D%,RJ
M41JUJ=7$0D&6'G'5>Z6ZOOV(2M9O[LI-A:UB--=.$3TJEE39B*Y>'-^=*WO&
MV=LX=,A,I)5U0PZDRSUN@L][FK=F763Y7NR;J5O.JWEDK45&ZK :*40DVT%N
MK&S."LH$I9)%!0"S7S"U.Z\:"<?ARLE>8!C7+,-:-9(]@?7?'.K80WE9DS?H
MU&XE#)(X6(BE6UTY@==K]F/DG^T5<].!,O*Z@%%B4?2#WY5OQ-6C[C_LM.&G
M3Y,U*B0I:OHK!++RFA T!N*@#>\=RK.\$D*ZR1PX$GJ\UO1CX9(SY3GN^\'V
M-'Z 4STLP]5(NXSQ6&$(80C LR?L77_E>G_Y:@<(1F\/];L?N+?\1.$51Z([
M?:8O81:&$(UU0/UQ68ZJJ> [?H;+]?Q]O5PPB!8<HV+A$PPA#"$,(1Q+S\SX
MJ7*V<1,!1]+2.HG*;RES#SIJ]R>U%%2?H:3H.;T]"3&7REB#ET>F-GTSA8J:
M&61$6]#P$K$M6W,GH81<.V_)?AV[FTJ-[ZN=[UC?>YMJ:7+'6G)Q1J:W@]KF
MI&J[G-+UC14-0%/BI3!2"LJH\*4W)(622R?U#!3.<SR:5 Q+I3&PL33\%14Q
MESDGBHIIZ(S.IF#9+\9!S.'@X[/%]W*VG.(%=S@.0#5[?TJ=T<]H9YB(AV8B
M&=:>AWVD.L/,+2XRZTXD*0XTM!*5MK20I*DD@@@C"+1>PA#"$,(1256WM.%O
MAQ0$9EC497[1%5$@$CQ6,3K5:1350IU*A*8A9 2H[J-QP[Y(! 'M:P;D6MKQ
M%\^#F"7CI2B;*0;.10U-"69]]8PXM!FX2:D64E3%Q6B="18$&_*T?E,[0\/$
M>OMFX0" <PJJ596XDD&<15M%$&W;8 C46Q^@=BXS#+V;AE3#ULI>BR0RCJ$@
M=QW]OP3;.S\4-I8@2T$H=!!S2Q=*=%+?7L:L::Z&(&A(OUE37;P&]^/'5\YP
M?UE5=Z3>\T_K'+\PQMLA8'?+('\?=WZU=#$<K&W[=GX;$:?.^'G6"H"IK,Z9
M@?@>K4\*Z/6'F6,<,DN*7E'L]/L'.T2&8@ZZ6[%-::?XVO&]CSQ Q.#J'L?J
MS:VU8'UVBWF6.(/5.ZAE?S?VX1]+'J9MMY&TWG65(60<KI6D*2@J!/C+#OE
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MB&F4P2ZB!<_V&IWU.\ZTW&/#S,V=*,S-?C8V<+G4-,G)1(Y'*IE+IHIF(IZ
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M"'9AF$NAEV&BV)C%1CO2ZA25I4TDV/DJY:&T,!)D(6J4I1,J899S)9[D,:.
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MR"-X("E]$EQ2@/)W5)9"%$[IT4;I;'#3$%:MZKOJ=>9/'CJ=(GHTZ@69J,0
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MDZD XRE95+2'# J.5ZNH9:N:L _:7,8PE*9I(H&#$,0R6)&X%1)#,Y:/;)L
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M+V#,3YMUOC^$/Q_TSD.\=_\ 2'3#]K^'X1(J*#(/M,2-"=4(U(%[:.$^D@#
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M0%%93TI&QOBW!T['+HHQAGM7153H+4)&0G2L/RRSK04Q<M<X;- 2I:DG("H
M@&I2Y42<K)*<N4@$,4J469D[IVE9(F#,0GJE3&SIR@*J%A043J%) !!)/M,H
M]OY^.HC:>A=H.C)1ECG%L<,3"*S6IBG)W$SVEH^5Q<H34%*SVCYW-4HF2917
MD*I$'"RR(;5%,J6VAM.^XE&'Y- "&0_2$!)**D$*46&1W8.DL]&,2-I$N!,#
M(#J F.0Q"7)Z1P'H6H#81@.R[W1FK<]-GW:)S$K++669>9K9&R:>5 O+];DS
M\'3"E!3$16-%3-QB(F2(I+<R@G6T//[J4+4VZE!W463LJV/E5+!2Z)@"<S=<
M+O8RB&(#W<$;LL:?Y3"DEE#,"[ D)4DV):8*@JXN+L8XZT%W5':'9EV0=;9E
M9?;-$UR_S]J2FJ7E-/Y1YJSR89OT^BJ'$"!CYY1S[K[9[WWE&+;0@J81=+A0
MC4V&QI8*P 04!R2D 4#T)E,1=\I?CNI^4E91UPH*<!E,;ZA,RXW*'$NT>=G'
MW7ROLHV<ZH]>4\@G4LREVH:0R/3 RR-GAFLPI^?RJ83*83TH:C]XS.$AX%1A
M85EL!YP%++:K 8@>2X6I+,.DE],+9<JE)#?HLUU A@=7)U';4Q)(S,$JRD$S
M"0P53T[=5W)%= *1R-BNZ:4'!YEUDJ&@)9'9(TIL0PFU]"UA K4_4DT9BJK\
M!Q-'H#CZD]]1,(]$P"TN.].Q/0(-:TQ:2WC'\F"2$!(<SC)#Y&!$LS,[=&Y3
MD<Y0<^70%C%_RVNY50)"LO7S$%024YLY8U;,Q 874P/J<N]KC;UJ!>2^8E6[
M,.5+^3.<L72SC-/T;FA%+SHH6B:O(B)-5U4PU4.05*/RY$KB()V<0\DB'HIM
MYQ;-VU>YQ8_!2)$DR4J&>4 DJ8!.9!RJ11()*6!+A@%!(+@MGV=CEKFYEDC.
M7 )+Y3:8'46S$'*?V'(#@GFUM+9FYUY?TC(!L_94PF;&8-4U3+:5A1/9PU2U
M%TBS&P)F4?65;Q;"C/(^FX)M19=DTL:5,W8A1B&F5(;3O:>S\+*7,4590D!Z
M% 42Q<)&BCO!J6 (I&]M#%K1*"DDDNP/64 P%%$%F2SD$V!>,%V*MIJH=IBB
M:ZBJRI23TS6N6F9=5Y55.NC)U$SRC)Y-Z04D1E0TA.Y@AN-CY4\N.1#MNQ),
M0%-%A\(<;4V-G%X9$J:M*9E 6 )! )+  )# ,'M3E&/#3US),I;*8H"G#M5(
MU)53M^,<TQ<:+62I*4W/DBYMKH-+\+@#C?'+F'*Y"0IJ^B[FMO#QT92@ ?1#
M@7W&]:%HBY) X]? \N(T/IM>^-<'. 6"219F8%Z<"_!V(XB*K(*U$5!,4Z^_
MJ!;B;\;</>'9S.)(-FJ0"=7J'I44))IP;C6)L=;^DVN+WZQ?X/-;B<2H.]>%
M105!%=*$;G(%[0BJQ)&I(.E[Z\[#B.  /GUUTPK2NIN35M!:V\W-Z713KK8\
M+\Q:VO(\>?XM<"Y;1RVX;W8ZW[6JXA"YO8 "W5V=9ZOF;XD/0EG+"[,&>KW(
MNU[UK"/4S]]3,DF3R?JK4*5,JYI45H"E<;FQM\[8JJB6>O+TJTJQJ/#O&Q*!
M8/9RU;<.UNW?>/.J=]Z(R]E[[RRMUR+IA2UFQ)*IK+[D6L#Q-B/?QC/?0&N]
MG]L9TV[2.ZG'01M"'^H,?N+7\1.$0CT1V^TQ>PBT,(1KJ@/KBL];_34]_)LO
MMYM.6$(V+A"&$(80AA"&$(80AA"-:9ICZ74DZ 1\$;\K]\)YX@V[4T[;]D5/
MI#D7]S:.6[@=T6DJ&Z.JPM<"Y'$"_4>//L&,U2[L[6J!2A)/JO4,_#37Z1\:
M143>PT&NFHTN2?Z_,.S!S<DM<%JWY&AIN>E+Q6!*3;@ 38B^EQH/ZM#H>N^%
M"0[$C=:IH=^[DXYA"XX6OR!/5V=6O;B-*#0L2*,VIRWUW&SF$---;GJL!U<[
M_#Z>>)>FFK<-S U)K2P8\H1)(&H-CS ']0-N6GX\0 SAQ?>+#0^]P0 [B\(@
MF]C<:#AKUVMS\YUX=@Q#MU78:EG&KAFY"E.%2R!/$"W D\.RX'6 ;<->H\\7
MHSGBY=_8U6I2UN:.L':SV%U;4FV%LSYH5Q(*<JC(K*[+C-ZFZ[D<VF\="S2*
MGE9(E@IMV4RZ 2TJ),-$P25Q$8Y&-IAFRJS+F\<>CV;M(X;9L_#(44+F8A<P
M*H0G-*DIJY:N34&C-5FX6/V?YSM"1B"@*2B2B6=':9-4SL_TQ8AKU#B/;;06
MR95U/Y04-1&QS0>3TAD5)U@J;5CDG5U/2UB@\T:?BVRB80,P/><2]+)O+U.K
MF$#-.^5N1L3&///KWO(3K2-HM/Z15"!E2IRX<N2""PS*JXM0,0'C<G[-"\.9
M8!+U(-F ( #@FE6>E=":<!*7[EGG7/Z#SYF4=+\L=GZJJNS'RMS-R4RCRSCY
ME,,JZ#JW*AUZ(A)M'JB6U%J(JYY]XSA$O8;:;<AFUI"?))[.(VTXDISF:$R@
ME94Q4H,[EE /6@#.#2T<;#[%K-5E,OYPJ38#2U"2S4)S%]X53D(=G7;FVBLV
M<CZZVF)-D[E]36S5,YA7=*R'+Z>Q\^C<PLS/!BI=+8J=/S2'>,KDCQ0VX\B&
M6AQHK4H %-QIIVC+E9LCYETS*LE#T20%6&@#N+QMJV6I20""PT&JOK!TN"2
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MK;#=E(.WL[:XE=&HS)LL()ZDL=6<X*<J@]>L7>E;D!XC'[($X%(0E69*1F4
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MHJ!;R;B(Q$&^J'3$B.=:Z9+)Z,+#?1^1PT )O:X)%L3T@#!T]I%3WU:C1K+
MS*=53Q% :TY^PQX!VX*ZN#ZR43<6XS-WD.!'16M?LOS&F)Z4!ZHXAQ<]KN8K
ME3JKUBT#MPUUJ?62B;WO^>CW+0&W1VOSXV\^'2 "Z&M5NT:#2L,J/K>L0]G#
M77["40.T3)V^G#^U]GH\^'2BSHY$CXZOSKQAE1];UB(]G#77["40>SPFYKR'
M]J'+AJ-,.EXHIQ[2]:/KWPRH^MZQ$^SAKH:>LE$FYO?PF[\71#6_/7#I!^SZ
MK;KVAE3O]8^$/9PUU<$Y)1![?";OP^U<1P&EL.E%LR -0X[KVWPRH^MZQ#V<
M%= W&243V?1-WL_YO3T:\>(P,QZ.GU>/%(94?6]8B4[<%>@#=R3B+=LS=)!.
MIXM<M.RXL.-\6Z8LP4EGJ'X<^7.D9$(0SN'?>*6BOV<68'["L1;@0)FX?.#[
M7SYCE>V(SLQ^;N#0AP=&[GT^%W0HY<Q)#@NS=IM6T4^S@S M;UDW_P#VDYKV
M_4M-//ATQWBG'V5ADE[QWI^$#MPU_P#L)Q U-_HDZ>/_ &.NFA//XW2D6*=-
M6M:QTTY1.27O'>-;]^L#MPY@:#UDG[\"1,G+#46_M7GT].'3'ZP[]>_=1XC)
M+WCU6W=]8GV<-?\  Y)OGG^>;G(_N5M18<?-ATQWI=M_J=[/#(C>.\?"(]G!
M7YXY*1%P=#X3<%^'4WV6Q14Q:FZX#7K>HW\!HUSP,3EEUL7WD<S[JOI$>S?K
MZY_,3B1K87F;G5^Y:_T=MQ4E6DWUAO?SU[GB<LIW(3IJ-.%K4\-$';?K_AZR
MCXOP^B;E_0"W;CC(@T4I4P'* 0Y2*_UX6:,4U"%*2 P"B0HN-6O;CI$C;AKP
M&ZLDX@CJ\*.&^@X^U'KZAA)*<5F"RCJFA*AZW(]C=L4G2T84#HU#K5T-:5+6
MO3?4\X.W!7/'UD8C4$$^$W>7/ZG>^I^,WN,%3LLPR0I.66' )U-R-*ZL=.<3
MT,OHT3\W7F4-0^^O<(CV<->FP3DE$W''Z*."^EM?:_-PZO-@)HN"@\:<VH8K
ME2;$GM'PB3MP5YH3DG$D"PL)HYHKK!Z/Y2,.D_:':1W;M= "89$MZ5.89V'C
M^T#MPUW^PE$'L\)N6TX6]J[2>(MZ;8=*!])%]XOWW]=GAE1];UB'LX:[_83B
M>8_/-WF>/U+T_)?$=(G>C?<&@[;:<+!H94_6]8A[.&NK6]9.(Y$6F;M[C_LM
M/GRX3THK5#@%ZBVXU-(94?6]8B/9PUU?7)*(/GF;GP^U7][#I0UT <"->UJP
MRH^MZQ$^S@KJ_P"@G$:ZW,S>TZQ]2OKK?CSM;#I0&!4BF\C3MT.[=#*CZWK$
M76-M^N5O)!R5B$ A5E>$'7 BR200@-BY!U%N''#I0=4L[T/]=\62E.85)X @
MFVYHYX9%3B.J263BIYA+O!3T\B(.,,(XI2G&RN'5O).]]RI21YL5<$FH)O<>
MZ-D$:$,/5H/?QC6FT55%>T+&^,=#R6'G4RBH%N%<8B$*<AVT)4D KW""?)3?
M17NK89@""XIQ]O"*+8I4"UZ.UJ%^X^#'#,[46T]8I];F160H_P!QQ8]X;W5K
M?S<M,6Z3]H::NS4HYUUC#E3NYU/"]>41[*3:=&OK<2+K^LHO3M]U<=E].K$=
M(/KB@8U!IQ'M)AD3N]OQA[*7:>-QZW,BN;:F#B];</MOZ<3TC?2##B (9$[F
M[3\8CV4FT]<?F<R.^A'Y2B^7#GP^#$"8-%C74;Z\ZPRIW>L_&)]E)M/"WYG$
MCN-!^4HOMTX\[WZSH<.D!^D-]".!&^@+-PH\,J1ZA7UZBI_J+5>REVG@!^9Q
M(_\ ]E%]NAU[3H==<#,%76.\:6Y-3U/#*BKT;CZBYH\2-J3:>N3ZV\BN>N"B
M[CM]U< \SPQ/2?M"E;CU\(94OV6?^OKB#M2;3WE6RXD0.FI@HO0\OMN%^/7U
MXJJ:&/7% ;$&_#7</5 )0]=X>M@>WVCX13[*;:H(/YG5-V&OUE%GK[= >)\U
M\:LM9F$%2RU?2(%[WUY"]S>-WJ2R&:S7&C-419&U-M4?L=4X+:V,#%]E[75>
MW7_38[:9A0 RP+"I%6YO%63,)JD?ZF<Z.7T;EPLT#:DVIK&V6U+D\1^5(PWN
M=1[KD;^@<,3TQKUPUS4=YC#D12HIQ#T]3:VO:D3[*3:F(TRVI?4&WY4C>H7^
MWTUX>;GB>E/UQWB&1!H2&W./ IN.]FB/91[4_/+6F.J_>L9I?B2-_P ]CYN5
MK.E/UQ2U12&1&A#%W#W?C?\ I%1VI=JCEES37G$!%?*OX\1TW_$%FNFV[E$Y
M9>N6M6>C^-3%/LIMJC]CFG+<ORA%_#Y7HU))!/7KB*G?Y[?JFCD&_ @>&ADE
M;D]_]8\@;4VU/Q];JG.%M("+MY_=<;ZWXWQ&X],S :I[SWWY0R2]R>_^L6/9
M0[4]U*.6],:D\86+"C?G8J%C\7##HYBR&GABX'SB*"KT)IK[-8L9$I+* 14.
M2%5!)!L]*E^^L5.;4FU.6TI:RYIH*( 5^4XD@D#D2O4'@">(XWO@K#S4?XX:
MXZ\MZ6:O -OB!*EK)!"2*.Z@/637LB4[4>U.$("LN*8*@D;UX6,3YP0%\21?
M=' WQG$TI0E*IB2O* HY@7WG=>Y]HBS)3U00 F@KN[;1=]E+M/@7.7%/A7 [
MD'%[M_VMU$D<"--/-?&%<W+90<N[7M2Q ^/:(JR3=3\"K^O9 [4FT\=3EQ(A
MV]Y18OS'%6MNS4C%D33E!*Z\2 7KX(_O&%24DGGO<$-O>_LB/92;3VGYG,DZ
MQ^4HOD?/KJ?AQ;I&^D*\1P'?0#^IB,J#N;V^O>=#NY1/LI=IXZ^MS(S_ /DH
MOEZ>WX<.D#^DD&NHW!WTH -.,,J:^S<WKU#P]E)M/ 6&7,CL;7_*46;@^GGB
M1-KZ:3P<6\&&5+?UWLU7\=L2=J7:>)!.7$B\Q@HOS?=7MKSTN>S%>D'UP*-Z
M0'C2&1.[V_&(5M2[3IO?+B1=1M!Q9MJ?VQMKZ<6Z04&</Q(\=[[X94UH-^H;
MU_",THK/?:"K.9M2&H:&DT!*XQUM+\2PT^B(83O:J2A9/'D1IP[<0Y47 <%W
M(J S4H]8S2T,' +!^6CGGOCL)J9E3&7<N9<!2MN+IE*RH6)5X8@"3;SFP\V)
M8NP!)W:V<VW?W:+AV[3[2T;0AB##LVX=$CJ^Y'5SP-SI6 H "XIK>+^(B8A(
ML ,52"  ?%81K:@=U3]9W4 !5+_.^G@V77UO_2<7GI"R>(!'!@S:ZCQK&8 T
MYN XHW]/?&=$MWT /'B1J>OYVQJ&=(%#F<4+)7IR>+Y?VD]\1[7<Z)MRX#Y3
M\>'3R/VJ_LK\#MAE_:3WQ'D?M?@PZ>1^U]U<,O[2>^'D?M>WAAT\C]K[J_A#
M+^TGOAY'[7X,.GD?M?=7#+^TGOB?:]?<]G#X=>/P<=,.GD?M?=7\(9?VD]\/
M(TMN]O#X,.GD?M?=7\(9?VD]\6'X>&B6EL/H0XTX"%H58@@\O3U<,09N&-P3
M5_167/%N?M@4 T)01N)IXXWC"W,N:(<<4MR2096HE2E%()).NIMJ;8CI,)]3
M^&;\8='+^I)M^U[CXTBV<LJ%5KX"@]>82GS<QR][KOB1-P@_PQVHF'WPZ.7;
M))[U>W,\!EC0OZA0?$GW*>8.ATX#WQ8<;6PZ7"?9C3Z$S3M[]\,DO[.3Z_C#
MUL*%_4.#Y_:I[>SM^=AATN$^S'W)GC3PYADE_9R?XOC$^MC0MQ] H.PT]RG7
MM/;Z?C.(Z3"?4_@F?&&27]23_%_-$>M?0G*10G'0;J;?,<>>N)Z7"5^;'W)G
MC72O=#)+^SD_Q?&!RQH73Z!0?#[D#C\].'FQ'2X0?0'W)GO,,DO[.3_%\8#+
M"A0 / <& +:[J3H.O2^O _)B>EPGV8U^A,U[=-/[PR2_LY)[_>IHGUL*%N?H
M'!V('VH\G3D+=?'CU]F'2X2GS8I^Q,KSKXUADE_9R?7_ #1'K8T+>_@*#.EO
M<IMV\!QZ\.EPC-T8^Y,?V^.Z&27]23_%_-$>MC0@M>1P?&^H3[PX7'8??P,W
M"?9BS>A,[[WXB&27]23_ !?S1/K84*+_ $"@]>9 O_1ATN$^S'W)D,DOZDG^
M+^:(];"A1PD<&/0GCZ0>/Q^C#I<)]F/N3/=#HY?U)/>H>Q42,L*%L?H)"7)M
M[E-P.L:6]%O-ATN$H>C%/V)E>8?^W.&26/\ #E&F\U_BOX>'K8T+I] H/@/M
M1R)^/GATN$^S&OT)FO;W;H9)?V<GU_S0];"A3:\A@S;2^Z+G2QOY^?P6PZ7"
M?9C[DSWPR2_LY/\ %\8GUL:%N#X#@[6U&Z+>]\H/#ERPZ7",W1C[DQ_;#)+^
MSDTYU_B]L/6QH6]_ 4'V#=%O3P^7$=+A/LQ]R9IXKOUAT<OZDGO5_-$#+"A>
M<BA#QXI!O?D>&@Y8GI<)]F/N3(9)?U)/\7\T!EC0H_O%!G4G5*>?+AP'(8CI
M<)]F/N3(9)?U)/\ %\8'+"A3_>*#'F2GJ.O ZZ_ ..)$W"#_  P>:)G#CP]N
ML,DO[.3_ !?&'K84+P\!P>@')/;J=.)^?##I<(?\,?<F?'A[=YADE_9R?XOC
M$>MA0MQ>1PFG[5/7YAYN/##I<(WZ,?<F/;GX-H9)?V<G^+XQ(RQH4'\XX,WX
M @>D^?Y^<9N$/^&/N3![(9)?V<G^+XQ'K7T+SDD+V>2DVOU:<A>WS.'2X1OT
M8O\ 4F/[;=G.'1R_J2?73U^WM>)];"A ;^ X0]A2FQTY_/MU.'2X3[,?<F>/
M#6ADE_4D_P 7\T5(RSH5"@L2.#N-02E/4;7Y6)/#ARX8=+A/LQ]R9#)+^I)[
M'<<?2TC,(& E\N82Q!0[,.RFP"&P$Z"_SU\UK7&($S"@DA)!OZ"_?_>("$AV
MR!]QIH*NYJ/6'A%P$OCT]'&0K$0@BQ2XD*20#>QUZ^']>!F851<@D[RA?'AX
MM$E"3?(K@ICX]4>M\5J:_4> [?:D^CF/CQ&?"?5/W5Q'1(^K*KQ/QIV0\5J:
MY2> OSNRDZ\.OX[\M-,,^$^J?NKY>.'"!E(/T978\1XKTV;#P3 \Q]01IYC;
M\6O#$9L']3^!?PBO0HW([X&E::-_H1 V_<QR-QS^+$Y\)]4_<7%NC1]65X\?
M"'BK35OSG@.H>U#ASYWZL,^$IU3PZJ_ M#HT?5E0\5J;_4B _!#\>)S86^7^
M%?LO#HT?5E>N)\5J:U^A$#V>U)^$;UO3\&(SX7ZI^ZN(Z*7]67WD>PQ!I:FO
MU'@/2TD_+\F&?"?5/W5Q/1(9LLKO+][O 4M30-_ \!V^U)U^$X9L(/H]R5>Z
M'1(^K*[S\8H\5Z;_ %(@Q_V"/GQU_'PPZ3"6RG[DSVLT1T4OZLOO5\8N"EJ:
MT'@B  _<4FVO+7J ^'#/A/JG[J]/'PB3+1]65Z_CX[(CQ6IK]1X"_P"Y)]//
MKMAGPGU3]Q<.C1]65 4M37ZCP'X)/XSAGPOU3]U<.C1]65ZXGQ6IKE)X&_[F
MGXK_ (O-UL^%^J?NKAT2/JRN\_&(-+4UK]"(#J^I)X>_^/GZ6?"#Z)^ZL^R(
MZ)'U9?>?CXM:)%*TT3K*( >9I/Q7ZN8U]%[L^$^J:?LKAT2/JRZ<;]Y]\0:4
MIGB)1 '_ +(#C>Y&NGQZ]F&;"?5M^RO6O]^-+Q/1H^I*\=OAN4/%:FOU'@3J
M"/:D\ 2>OS?+? KPGU3]U9AT:/JRM?7XI#Q6IK]2(#\$/Q_BQ.;"_5_A7X/9
M#HT?5E;M?CZ[Q/BM3/ZD0-^7M2>.O'7AV<NW$9\+]4_=7#HD?5E=Y^,!2U,@
M6\#P/4/:D\.7,F_SOB<V%^KZE0Z)'U97>?C#Q6IJWYT0%_W(6^/\7'LQ&?"_
M5/W5Q'1(^K+[SN;>_P#4/>(%*TU^H\!>Y/U)/&VG/W^SAAFPGU=?JKO;P=W"
M)Z-'U94/%6FAPE$!IH/:AP]_LYW.&?"?5-!]58IP^$1T2/JRZUN:>OQRB?%:
MFOU'@.WVI)][7Y<,^$^J?NKB>C1]65Z_C TM35S:3P%K_P""3?X_GZ,,^$^J
M:U]%?A_7 2T?5E=KGWF/,A*<D4*L1$/*X-I8TWT-I!!!TZ]0/3;GC:E3#D D
M@A#EA45-V!8BO'^DYRA)0DI2D.2$\;G?PIR$>@S%<O3"TA*0D3:06L;"PG4"
M.S2W'LQD*IDLYD#K5[M6T-+QC"P3['%"7IX/;&=08 AF;:#<3;S;HQ1*BL9B
M&)-K\=PWQ<N]2YHY-["\>3BT1$$VN2=.JWSX_/3"*LIO2]0KPCYPNZ59@=V%
MRVSWAX+8)HR!GV5,SIB'CY['Q,@I:+ J[PE-$Q14J=S&2C>$G@Y>DDN6-[B_
M$]O 8>7/'SC,* DM8A@X(#,30$6#1RID\2U$922+@$L0#=B*UX<.$=<7LC/5
M,/$9:RTW-P12N5XTZ_LL5\?IQW!BO)$ !4L.*'J8ZXH=-\:)\^-1.74O1,AF
M[1[@>4!M%>J8M/S-);V_2ME=\M5_';TX>=^2'V8_#Q_JZM>R(_/OM5\>I*/=
M2L/9%>J8OV-9;R_2ME=Z?TV:'J'OX>=^2'V8_#QWPXQ'Y]]M,O\ 4DZ7>E']
MMB(#:+]4Q</6UENO#Z5<K[=?Z[.WA?CVFP>=^2'V8^YCOA$_GM?G5_<DUT]W
M&G"'LB_5,/[&LMX<J5RO^6K/@Z]>%L///)#[,?AX[X0;&_;3-/H2.>O"GO>\
M^R*]4Q?L:RWT4ME=_P 6'G\]+X>=^2 _PQ^'COA$?GM/G9C_ +DGMT]P[(CV
M17JF+7\S66_[*Y7_ /%FOG!'+3#SSR0I\V*_\/'^NE(G\^^U77]F32FE/:U:
M<GLBO5,7$Y:2VW[ULK[GT>-EQSZ\/._)#[,?AX[X0_/7(Z9?W)/.N@[X>R+]
M4Q$?H:2T&_ZULK[#WZL!X?#I?#SSR0^S'X>/^$/SX7G3'_<DG7>!?A_>'LB_
M5,/[&DM[?I6RO^#Z:^WY\0\[\D/LQ6WS>.KZH'S[2;,[4R;EN'/E8P]D7ZIB
M_8UENFGV*Y7_ /%NO+AI88>=^2'V8_#QWPA^>_:S*[T2:>.+;[-#V17JF+EE
MK++?O6RO[?\ K9YNOKMP!>=^2'V8_#QWPA^??:K[4217NY5)]D/9%>J8N>6D
MM]%+97<.7Z;./7U=6'G?DA]F/P\=\(?GVLU?8B4?=ZX>R+]4P_L:2[KTI7*_
MA_M8?3AYWY(?9C\/'?"(_/?MIGW)-3QI[(CV1?JF+]C26_[+97_\5Z7]-OC>
M=^2'V8_#QWPA^??:S.622W_MW^T\HGV1?JF&WZ&LM_V5RO\ ^+-?/I?#SOR0
M^S'W,=\(D>>U^=F/IU9( /-JB'LB_5,7++26\/UJY7C_ .ZSVZ:WX8>=^2'V
M8^YCOA ^?!_G5\.K)]S\:=L/9%>J8M/S-9;?C?Q5ROY7X#QLO\/FP\[\D/LQ
M]S'?"'Y]7YU?W9)?U<M^NZ'LB_5,)_Y-9;SXTME?\9JP8>=^2'V8^YCOA#\]
M%YLS[DD^RD/9%>J8CPRUEMNKQ6RN!MS_ $V?)AYYY(?9BG_#Q_\ +7LB#YZ/
M\:9]R3KV&O#OA[(OU3%Q];26]OTK97^BWTUZX>=^2'V8^YCOA$_GU!TJWK]&
M3[?;9N,/9%>J8CPRUEOII;*[XO&P>_\ ,/._)#[,?AX\_P#Q]</SVGSLS[DG
MQWM#V17JF*^F6LMTY^*N5_9P^FVW7S^7#SOR0^S'X>.^$/S[[5;?N27[1I#V
M17JF+3\S26Z_]5<K^'"P^FS77GIYL/._)#[,?AX[X0_/F'SJ^/5D^QGXU;3M
MD[17JF+]C26G_P#2V5WR56;<\/._)#[,?<QWPA^?&TU?:B2.&H\4WP]D5ZIB
M_8TEOHI;*[X/IL)^?$X>>>2'V?#]'CQ_\8C\^^U6>:)(]WJ\%[(KU3%RRUEO
MG\5LKM#_ +6=F'GGD>S]&/P\>_=E>'Y[7YZ9:Q1)Y;N-;P]D7ZIB''+67>BE
MLK[:<OLL/#32_5AYWY(?9C\/'?"'YZ_Z5=_J21H:LVI-W%M:B(]D5ZIBYY:2
MSE^E;*\]?,58-.OXQ?#SOR0^S'W,=\(?GWVLP<D23[1I#V17JF+]C66_[*Y7
M_%XV?!?7C?EAYWY(?9C\/'?")_/G_2S/N2>#:>^FO![(OU3#I^9I+>WZ5<K_
M /BOKZ[Z<],/._)#[,?AX[X0;&NW33"YU1)84T-O&^'LBO5,?[&LLX']*^5W
M'_:S@>8^$X>=^2 _PQ^'COA$/COM5_<E?"!VB_5,0'Z&DMU_ZK97D?!5>OP>
MC#SOR0^S'X>.^$/SZGSLP\T2?<GAP?6'LBO5,7[&LMO8G[%LKQYM/&P^D7OV
M8>>>2'V8_#Q_PB3Y]I.F?<DWY,:<?;#V1?JF+]C66^;Q5RO](OXV#MY:X>=^
M2'V8_#QWP@//KF:O0D!,G=I1WYV%:6B/9%^J8_V-)8+?]5<K[\?WV"_'X!PO
MH\[\D/LQ^'COA#\^^U77]F3PX<[U[Z3[(OU3%;]#66_[*Y7\?-XV^;#SOR0^
MS'W,=\(-COM5O^Y)L#O]U]V^'LBO5,5M<M)9?LI;*^W#MJP^_P!MAAYWY(#_
M  Q9_P!'C[<.K7LB/SYOTTQ]^23OY<-T/9%>J8OV-);V_2ME=\'TUZ_/AAYW
MY(?9C\/'^OJT[8#S[[5;\4R1ZV X6[7A[(KU3$!^AI+2?WK97?\ %A/QX>=^
M2'V8^YCOA G':39GW)7P,/9%>J8OV-);Z:6RN'7_ -;->75U\QAYWY(?9C[F
M.^$2?/K=+,YY)/JN# ;1?JF+GEK+>8/TJY7^C3QLO\E\/._)#[,?<QWPB'QS
M?I9C_N2FOO;=PA[(KU3%SRTENG52V5VO_O9\6@X=9P\[\D/LQ^'COA$CSW[:
M9K]"3W6'Q>CF)]D5ZIBTOEK+3UGQ7RN_XL/,]?OX>>>2'V8_#Q_PB!YZ/\69
MQZDFFYJ!Q2(]D5ZIBN/S-9;8_P#5;*\$?^]GQV].'G?DA]F/P\=\(D^?:35_
M<E>JA>)]D5ZIB_8TEO7]BV5V@[?IL^.W+TO//)#[,?AX_P"$/SW[:9]R37O#
MZ:6KP,1[(OU3"/\ DUEWHI7*_P#XL.'G?DA]F/P\=\(?GM/G9GW)/@>+P]D5
MZIBN+Y:RWT4ME<?A\;-.6IXZ\,/._)#[,?AX[X0_/OM9GW)/'>+<N7-[(KU3
M%Q];66VT_2KE=_Q;QT.EK]F'G?DA]F/P\=\(?GOVLS7Z$DV\<H>R+]4Q6TRU
MEM['C2V5W_%E_GSP\[\D/LQ^'COA$?GM?G9GW)/8;:'G$^R+]4PW_0TENHY4
MME?\M6&WF.N'G?DA]F/P\=K7=#\^^VF'?U)/N )]40-HKU3%?]#66Z<+4ME>
M/A\;+>\<///)#[,;OT>/_E]=H?GU^FF,X;J2>VC./%1$G:+]4Q?L:RW_ &5R
MN.NG'Z;+<M>OF</._)#[,?AX_G]6);&W$V9N;)( H*:/[M -\>R+]4Q<LM9:
M.7V*Y7GTGZ;!;CYM//AYWY(?9C\/'?"(_/F_33*-]"3\.V@[A2!VBO5,7++6
M6#A?Z5<KS_\ =IOJ.'+#SOR0^S'X>.^$/SVGSLP\2B3\&]D!M%>J8OV-9;_L
MME</@-68>=^2'V8_#QWPB?SU_P!+,^Y)/CO[H#:*]4Q:?F:RW_97*\?_ ';I
MZ</._)#[,?AX[X0_/7_2S/N2O':\/9%^J8M?S-9;Q_6ME?[]O&O7CR/6=,//
M/)#[,?AX[X1#8[2<OAU)(+<7! X:EN3O9%>J8OV-9;QT^E7*_P"$>-GPZ##S
MOR0^S'X>.U[(G\^UFK>_HR6 [!4[A>'LB_5,/[&DMX?K5ROX]?V68>=^2'V8
M_#QWPA^>_;3*VZDG>/'K=A$^R+]4Q"]LM9;PN/I6ROXZ?]:[CER!L#AYYY(?
M9#\/'4YT[.<&QM1TJ]PZDEBV\D6O[B\1[(SU3"/^327?[+97]>GZ:_ZL/._)
M#[,?<QWP@1CJ?.K/#+(UIN/N;B(GV1?JF']C67=7V+97?\6:8>>>2'V8_#Q_
MPB/SX#]*M]>K)[W:I[-\7T;1GJF$-[HRXEZ57)(%*97D6.FI%5G7KUT&O#3&
MN^PI^(?#24F20D,?.4',/2ZLP!5.[OBWG4^2G),F+SU+Y4!P6:R"G>^M6:@C
MECL29I]W.KW:.R_D6UU0L#+LA7HR8/UO&(D67<&MEF$E$=$RQ8,OJF(B"4S=
MN!4DIA5'2PWN&+X\;,P\@KDR$I5E+$&8;@@W*B!KQ]<;.$Q$R9,&92GH0"P!
MYLFI%>793ZEX%*40S;:%*6&@6=Y20DJZ$]%>R4H2 0D$ "P!L";8\6F:F=F6
MFV=0L14&K9@"W?'<]\>7BT(80BTXRRZ"'6D. \=Y(/PD7PB&&X4\>.-8M]YP
MGWK#GSLMGXTXER;DGMB,HW>L^/#6@8.$/&%A_P "W_-P<[SWPR@6'K+]_CUF
M)[SA!_<L/^!;O[^[@YWGOAE3N]9^/&'><(.$+#_@6_BW?GZ3@YWGOAE3N]9^
M,1WG"#A"PXOU,M_S<'(L2.V&4&X?M/QAWG"?>L/IP]I;T_\ XX.=YI;A$Y17
MC>IKZX"#A!PAF!YFD#XDX.=YB,HW>L^/'&!@X0\8:'_ M_S<'.\]\,J=WMAW
ME!_>L/IP]I;_ )N(<[XD "W.Y^,.\H.UN]8?\"WV?M>S7KYX.=\,HX]Y^,.\
MX/[UA^7]I;'#A]K@YW^!;NAE''O.M]=8=YPGWK#?@&NJWW/5@YWPRCCWGXP[
MSA/O6'_ M_S>'9P[,2Y-R>^(RC=ZSX>M#<0[SA-/RK#Z</:6_P";B'.^UN$3
ME![;U-6[8GO2$^]8?\"W_-Q+G>>\Q&5.[UGXQ'><)]ZP_P" ;_FX.=YAE''O
M/QB>\X3[UA_P+=_?W>P>?!SO/?#*G=ZS\8CO*$X=ZP^G#VEOE_HX.=YI:L,H
MW7O4_&'><)]ZP_I9;/QIP<[S$Y1_8D7[8=Y0GWLQ^"1_-P<[SWQ&5.[UGXP[
MSA#_ '+#^?H6[^_NWP<W<OO>&46:FYRWMAWG"?>L/^!;\WW/O]?/!SO/?#*F
ME+6J>>^),'"'C"P_X%O^;V8.3<GOAE L/6?C$=YPGWK#^EEL^G5/'MP<[SOO
MKOAE&[A<VW7@8.$/&%A_P+?\WCV\<')N2>V&4"P;M/QB>](3[VA_P+?\W!SO
M/?XWGOAE3N]L1WG"#^Y8?\"V>'G3@YWGOW6AE&[UGXZZ[XGO.$^]8?\  M_S
M>/;QP<[SWPRIW>L_&'><)]ZP^O\ S+?\W!SO/?NM#*-WK.M]8CO*#^]8?33Z
MBWU6^YZM,0YW^+>RD3E''O//?OK#O.$^]8?K^HMC_P /I\^O'$N=Y[^WVUB,
MHW>L\M^ZG*'>4'>_>L.?.RV?C3B(EA:O>>>^'><(1;O6'M^XM_S<(90[U?>Y
M^,.\H/[UA_P+9X>=.)<[S#*/?<_&)[SA/O6'X6^HM_S<'.\]YB,J=WK/QB.\
MX/[UA_P+?(D_<]I^+AB'.^)RCCWGXP$'"#A"PX_[!O\ FXER+$B(*0;N>9/Q
MAWG"?>L/H2?J+?$_Z.#G>8G*/4US;O\  I:)[SA/O6'_  +?\W!SO.^^N^(R
MIW>L_&'>D)][0_X%O^;@YWGO,,J=WM@8.$/&%A_P+?\ -P<FY/?#*!8>L_&(
M,'"'C"P_X%O^;KZ<'.\]\,J=WK/QB>\X3[UA_P "W_-P<[SWPRIW>L_&([SA
M-?RK#ZV_M+?+A]KIZ,'.\]\,J=V_4ZWUB>\X3[VA^%OJ+9T[;IP<[S#*G=W$
MCWQ3WE!C^Y8?\"W_ #<1$L.->)^/JB>\X0Z=ZP]AK]1;_F_!PQ+G>8C*./>?
MC$]YPGWK#]7U%OG_ *.#G>>^&5.[UGXQ'><)]ZP^NNK+9_\ #@YWGOAE&[UG
MXP[SA/O6']++9^-.F#G>>^&4;O68GO2%&O>S&NGU%OXMVV#G>>^&1.[UGXQ!
M@X0\86'_  +?+_1X=G#!SO,3E'@GXWXW:EH=YPGWK#]7U%OG_H_/T#!SO/?$
M94[O6?C P<(>,+#_ (%OM_:]IMU<L')N2890+..T_&)[SA/O6'_ -?S<'.\]
M\,J=WK/QB.\X33\JP^G#VEO^;\&#G>>^&4;O6?CQ,.\X0Z]ZP_X%OXMVWGZ\
M'.\]\,J=W&Y^,.\X3CWK#_@6]/-Y.GHP<[S2W")RC=SJ:\]_C?#O.$^]8<>9
MEL?$GY^C!R+$B&4&_M/Q\5WQ(@X0<(6'%^-F&A_X<0Y%C$%(-W/,GXQ'><(.
M$+#_ (%OG_H_/3J&)<BQ(AE!NY[3\8GO.$']RP_X%O\ F]@P<[SW^-P@4@Z>
ML_'B8CO.$U/>L/KI]1;X=7N<'.\PRC=J]S?OAWG"#A"P_P"!;^#R=/1@YWGO
JAE3=N\D^^*DPL.A04AEM!'#<2$CSV38$]I%\1$L/!.FG+A%_")AA"/_9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>20
<FILENAME>g164680g00y08.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g164680g00y08.jpg
M_]C_X  02D9)1@ ! 0(!>0%Y  #_[1TB4&AO=&]S:&]P(#,N,  X0DE-! 0
M    '0:^=# X0DE-! 0       \< 5H  QLE1QP"   "    .$))300E
M   0S<_Z?:C'O@D%<':NKP7#3CA"24T$.@      Y0   !     !       +
M<')I;G1/=71P=70    %     %!S=%-B;V]L 0    !);G1E96YU;0    !)
M;G1E     $-L<FT    /<')I;G13:7AT965N0FET8F]O;      +<')I;G1E
M<DYA;65415A4     0      #W!R:6YT4')O;V93971U<$]B:F,    , %
M<@!O &\ 9@ @ %, 90!T '4 <       "G!R;V]F4V5T=7     !     $)L
M=&YE;G5M    #&)U:6QT:6Y0<F]O9@    EP<F]O9D--64L .$))300[
M  (M    $     $      !)P<FEN=$]U='!U=$]P=&EO;G,    7     $-P
M=&YB;V]L      !#;&)R8F]O;       4F=S36)O;VP      $-R;D-B;V]L
M      !#;G1#8F]O;       3&)L<V)O;VP      $YG='9B;V]L      !%
M;6Q$8F]O;       26YT<F)O;VP      $)C:V=/8FIC     0       %)'
M0D,    #     %)D("!D;W5B0&_@            1W)N(&1O=6) ;^
M      !";" @9&]U8D!OX            $)R9%15;G1&(U)L=
M     $)L9"!5;G1&(U)L=                %)S;'15;G1&(U!X;$!7<
M        "G9E8W1O<D1A=&%B;V]L 0    !09U!S96YU;0    !09U!S
M %!G4$,     3&5F=%5N=$8C4FQT                5&]P(%5N=$8C4FQT
M                4V-L(%5N=$8C4')C0%D            08W)O<%=H96Y0
M<FEN=&EN9V)O;VP     #F-R;W!296-T0F]T=&]M;&]N9P         ,8W)O
M<%)E8W1,969T;&]N9P         -8W)O<%)E8W12:6=H=&QO;F<
M"V-R;W!296-T5&]P;&]N9P      .$))30/M       0 [_^-0 "  $#O_XU
M  (  3A"24T$)@      #@             _@   .$))300-       $
M>#A"24T$&0      !    !XX0DE- _,       D           $ .$))32<0
M       *  $          3A"24T#]0      2  O9F8  0!L9F8 !@
M 0 O9F8  0"AF9H !@       0 R     0!:    !@       0 U     0 M
M    !@       3A"24T#^       <   ____________________________
M_P/H     /____________________________\#Z     #_____________
M________________ ^@     _____________________________P/H   X
M0DE-! @      !     !   "0    D      .$))300>       $     #A"
M24T$&@     #-0    8              7<   (5          $
M                 0             "%0   7<
M 0                         0     0       &YU;&P    "    !F)O
M=6YD<T]B:F,    !        4F-T,0    0     5&]P(&QO;F<
M $QE9G1L;VYG          !"=&]M;&]N9P   7<     4F=H=&QO;F<   (5
M    !G-L:6-E<U9L3',    !3V)J8P    $       5S;&EC90   !(    '
M<VQI8V5)1&QO;F<         !V=R;W5P241L;VYG          9O<FEG:6YE
M;G5M    #$53;&EC94]R:6=I;@    UA=71O1V5N97)A=&5D     %1Y<&5E
M;G5M    "D53;&EC951Y<&4     26UG(     9B;W5N9'-/8FIC     0
M     %)C=#$    $     %1O<"!L;VYG          !,969T;&]N9P
M    0G1O;6QO;F<   %W     %)G:'1L;VYG   "%0    -U<FQ415A4
M 0       &YU;&Q415A4     0       $US9V5415A4     0      !F%L
M=%1A9U1%6%0    !       .8V5L;%1E>'1)<TA434QB;V]L 0    AC96QL
M5&5X=%1%6%0    !       ):&]R>D%L:6=N96YU;0    ]%4VQI8V5(;W)Z
M06QI9VX    '9&5F875L=     EV97)T06QI9VYE;G5M    #T53;&EC959E
M<G1!;&EG;@    =D969A=6QT    "V)G0V]L;W)4>7!E96YU;0   !%%4VQI
M8V5"1T-O;&]R5'EP90    !.;VYE    "71O<$]U='-E=&QO;F<
M"FQE9G1/=71S971L;VYG          QB;W1T;VU/=71S971L;VYG
M  MR:6=H=$]U='-E=&QO;F<      #A"24T$*       #     (_\
M #A"24T$$0       0$ .$))3004       $     3A"24T$#      2\
M  $   "@    <0   >   -/@   2U  8  '_V/_M  Q!9&]B95]#30 "_^X
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MG=]U?_I-=!]=/JSU_J/77Y.#ANR*=@;O#V-UDNC](]CEA?\ ,GZV_P#E8_\
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M8G_,GZV_^5K_ /MRK_TJMWZE?5GK_3NNLR<_#=CT
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
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M#NW./$V?E';;),M$JQ2$S$A:3,),FJKIN@<Y*611@^!WQ]"F<GIUK1)F)FE
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M?;.RVK7*':8S>HBM:Q8S"J*6U?-9D*]:F\//TU?*IY^GY-5*IS"1$4B(CYS
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M1@CM/Z5Y^?EU8@\H-G EA)(>G1D89?CGX\,6> Y.;4(!YR;7^TM&/7(SQ[:
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M22%"=Q#83WO#@;C;?1(38->]2WX"4C@GP1H;8?="W9VNT$9CG5U[X&P60O\
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M&$(80AA$$'(MU PQ4NX;!ZX84^W")ABT(80C3*B%<=+_ "UM?Q]6,)4H$L:
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M7.FR'0J1,7TB0[2RA(+*&H%","#C6-RSV,HD2Y@$Q,X(40QQ6ZF+9,[W3BX
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M%@3 0L O0T'PBGH6;I59&\DDI5N>$"0 2%<02  =>&G#3$'G"[J%<?+=?&(
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MZ6!8@Z$'L,00[X5%'UQJ,#@-^,;650*99+8&7(5O-P,*Q"-'2Y:AVDM-[U@
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M[WOK#>UOK;76POKSL/$.&$3&FIRW"P!5N;ZB$I2O?" E044J)4I0#82#OD@
M@%)*()T85J3E_/+"-JF+7NLE;99+Q2A <Z-*RLEPI ;+UR5MME0;2HK;N"=]
M(<+;/[??[X@$FC-Y+%M^A8C4Y2(]HJ*=]L+"5$-E8WCI=LK5?=:#OVA<L5<
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M''C$X#@/"/8*]M/5XF-3$QDAA"&$(80AA"&$(80AA"&$(80BT9H/KLI\_P"
MS8=FG>Q^/&PCYB9^M_VQKK^?E_J_]T76D %0%^7'CS\6->,XX@\/)BO")AA"
M&$(80AA"+8K36E*@_@N+_%G#SY>(/O'B(W%+?!^4?O"%_$-X0&?%7B8Y_")B
ME7O5<_!.GDP@<#EOTC'679NFI^/PDCM3I?AKB,2HXN?<.SA$)P!W#A'$9IUI
M3-*,4A"U-(C43-85[3]$RJ!7#0D5#LSJ=*BC!3&)3%)<:0U#IAW5;P3O[JAN
M6)Q.,*8^<?LZMU8QC16<.6$UJ3+B!I2B&X%W,B+S"EDNFC<EE<K<@%4 ].(:
M<,Q:&&4OJAXF(DD2N&6A1#B5(4M(WL(:-YX><([5I*2E)3;=*04V%AND7%AI
M86Y81.,:"H9M04#]LI2[I !"U*N%@ZG>39L@\E-I5QOA$$/XOY\X9AXH5!LK
M6%K2%J"RL;R0H [J4@@'0$!*=18G4FY4<(,*TQQBAV70SP6'4!WI0E+@=2EU
M*T) &Z4K!!2=U)(((N+C7")\^?+XM&Z9:0PVAI "4(%DA("0!<FP T %^ TZ
ML(1J80AA"&$(I"COE/( 'SXQA;S%(:B0"_'73W^,M1]Y'8WQ@56('6?1B5*(
M(  +\=\1#[8@DZC3\OCX\L+P"KI<[VU-!V:5W1&.9ZFKW>^./F4$9A"Q4(MU
MZ'1$PL3#")A'C#QD,8AAZ'5$0L0CPV8AM#Q<8=3JR\A"T@*UQDH Y=P>IL][
M]45-XD4&&;FN!\Z.Q+F.C>SIE\[+<\=HYB)S%S<G\ORQS I.DZ4E-39ASJ>R
MEJ3S;)G+.K(MJ-@(M19C8@3RH)L^W%/W=;9?;AP0TPV,:X*#-*[Q) *&8,*G
MPX.]<8RJ20$DM44U+ %SO+^YL([W)2D)"2K@HD'=MSOP'#T7UTUQ*PA;.]&.
M W[QKEU&(P[/$1K@@\/CQ8%R+HH Q?3@^[S2(B<9(0Q#5)U;NA#$PAA"&$(8
M0AA"(MK>^EK6^/$$.*%M_DB'7U4^#]\3B80PA#"$<#5/P;GI_P!:8_\ ^6<Q
MED?/2OUT^,4F?-JX&-S)C>52E7W4LE]_^"I/QXK,^<F?KJ_U&*2\!U?Z51RN
M*1FAA"&$(80AA"&$(80AA"&$(@\1QY^3AQQ5'LCK\3$'%/7Y'G!X^1/=O].Y
MS9]VX>P<E*O\O*+[/%V_%Z/DK]_=:??'G>4WWA@_MT^K'YOQT)\>/N^0W #L
M%'WT\B/@B_;5O4=/RCV><H8DN<<@.S*( >CC<:UW;L\JGJAB7<AJ4;<!4=C8
M]9@PK5P&&F(/@W7#!\!DQ&5*$$TTJ=^)RB0'=W+8D5)J*=F';NCWR_,X7ZPU
MCJ]T2MK^/V55:_F\NO5CXMRU^_9F'SRNK OQ(-?+?:N1OWC+_9H_T"/0?]LC
M[WXCCQJ<!P'A'L%>VGJ\3&IB8R0PA#"$,(0PA#"$,(0PA#"$,(1:,TM[;*<_
M=04W%NH)$*;\+ZW]&-A'S$W6\ENL%_ -A&%:?E$+<A@V3&IX9MG%V)U\+F>/
MDTQKQE& QZ\>N)OJ1U?DOA$Q.$(80AA"&$(MFL_@I4%_V+BAYVR,#@6T)TP#
M[HA66\CQC7I;X/RC]X0OXAO""<.L^)CG\(F*5^]5]Z?4<(1CK+KWE3GKJ2-/
M_1^7IX89DYDN>[SEPB$X#@(Z\[8K<HCZ$HV4QDNJ2(G,VS;HN HYZDZGE](3
M"65>8B),!-HZ?QC$2S"RV A1&.O[C3SJR&V@BZK!$.&-*:#?3#CP.H!QZ8[+
M4FIFG\]:"BI?+LPXNC)M-,XI5D;.:FS$14Y=C9*)TFNIU-*=:DLO:@6)W%,5
M*J71:8Y])<0@Q+3"HIE*D3D_"F6OAJP<#"/LTD[R4JZP#U<1?@=1A$Q.$(80
MAA"&$(80AA"&$(TSH5*'&P'+L^6O7C&!\HHZI'<U?=U0C:1D2(9E;ZK)#:%*
M-R1HD$FW:>5^?7BZ$7YP0*E12!N)('!\^S.,<U8EH4HD!@<<'TCR8YK_ #3'
M4&6V9F8F7R-FJ2S%%#UO5-)-3(UA,F7(YFG9Y&RIN,4R)>4MKB6X5+RT(4I"
M%K4E"E!(./H=AY#>FR43A/4+S8)EXC%KRG;,/CAO/@MJ<M$[.GFSF6@L@3+Q
M,W\(G,)(RU[XQ^CYJ3J1=K;+\G5=:$*O6DQ "5DA1_4Z]P$W.FZ0>.FNU/Y
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MN_NBK$Q,,(0PA#"$,(0PA#"$,(0PA'"U)\'YW_!<=PX_T,YPQEDTG2OUT]Y
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MA5U\QUN_?AP[HH!3O*<2VWO+-U*W2=2.8N-2!B0BY0C$O7NJ23PK$%=\ NX
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M80AA"&$(LZ=Z512QZVYP/^2A?R\,;,KYF?P'@?/D1J3Z3I)T.'!_CU1>"18
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MC] Y"MS]H_7ELQ+8*P<5^(.X1[M!]C-OW/\ U>/;U]M[8^/R\^KWQ]<F9O\
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MDD/5L_BJF8$!(J#E)G3$?-Z^>ED13$%#L1</#1T3,FQ+75.-3W9X#J+]4.-
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M5OT6S*)?*Z8ET! PKE$U;*:U;76D+FE3%0P-3%A:J=+0EJS9$C#)JL!@1O\
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MW.?/N_["27_[[HO'H^2OW]UI]\>>Y3_>%/TNWH^_#WQ^;\3J==+G73SZ8^\
M;\0&WO332KC<U8^"KJHAOPCE6ISQ?<STA@'KH07]W8<,^V*ZM4#/PX0Q(X\#
M6E:N#3/@_68B&!S?B[,V'?D1D<\XL*L"1G[\:@;A@:O2D>^7YG"'\X:R1^V)
M6M^WZJ+ ]1X>7CCXORU/],F?MECPC[5R-^\9?[-'^E,>@\>^1]Z/4<>,3@.
M\(]@KVT]7B8U,3&2&$(80AA"&$(80C3+A#@1;32Y\?H^7;B6H^]NYXH5&]=;
M37/'WQ62$@D\ "2?%\M,0[EA7SAQW8Q8D .: 1;$SK&G91,(>6S&;RZ"BXI*
M5,L146PP\M)64J4EMQQ)*$ 76JUDC4Z8VI=BM$V4N>B4HH0X4NZ6H':]@YJ
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MY)(9NB"#_*% I@!>(=G9Q1ZFGOBE;P"  %<4W 23=-['A8W'$VN="0"<0)B
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MY+<EI6W)2^<F34,:7+H9J?A+#YAW%&I@8^?\J^5,S8<P3$(EJ;HJ*DK41?\
MU9:B&JP;CI'6-/=!J^WAO4=(;#6R(I\DE-S8$09&MA<Z6\6N/;C_ &5R"DJ-
MHM.#D7I.!&?RQR\*1X4_[5YH4$\W(<T!N36_\CN?BT8'S>VZ:SG%59$QD92-
M/-*I[,IN=ME<:^\DQ'M7J>$=0$L-*(4S"1B'+J2I)4;#>((3J+_V>6:5SB N
M;,*P$B\4=$N"%)NS4@J%W\)TD4NY#:'^TBTS4HF7924I6[I"^DQP4#9S0N7N
ML2 .D#CFX]T KUT!\T;("D)Z)WHXQ]U+40''5!*U-PK@0E31005D(4M6[O!P
M[HVK/_LRDS4TGVAS5GD@95<S0^#4-7?"-&T?[4K0A?S=G8?H3LBXJF20>EN.
ME<^6DNWO7,RFDMEC])2)F&C8Z#A77413ZEH;?B6FE+2##M@E(4;#?!M8C>X8
MY^U?]G,K9]EM%L$V:HR$7F)E,7(2'NSE'\(&@.AH#'0V5_M+G;1M=GL=R2GT
MA=UTHFN EU4O26_!+N0PPCZN2V)3&P,%& (_34.RYX"EV"E-@FP*4Z"]A<#R
MG7'R&=+YJ=,27HHBH#TU()&618]D?:I$SG9$M0((*000X%6=G8]67 1O&TVN
M.I8\UB?3;&%9=2"<7^ BR* C0_"-QB\7AA"&$(80AA"&$(=7H\?\E\51[(Z_
M$Q4^TG^]X1\A^[?_ .AS9]\=9')>S^WNBQS\]^&/1\E/OX\4^)^V//<I?O'+
M\/P3H_QC\W\\3_)Z.6/O->B*B@ P!RI2F\"E*O41\&4SDT)*B[8XM0&M2<0*
M:0PJ:#'<[ ''/"H>C;]:AJOB!KCWA^VHAB0 20Q?4G3'(>!.;8P<L*,#H<]<
MSU;J1',=>MO%I>_7\O'B?B*%GK>+8T-6QW5+IBP2S@MD30G.C849W;MT]\OS
M.$#\X@VJVAS"K,7ZR)FKS=6O'=N-!I\5Y:_?LS]LK?D.R/M'([[RE'^R0-_L
M([J>$>A >^1]Z/4<>,3[(X"/8*]M/5XF-3$QDAA"&$(80AA"&$(T2M0="?M2
M!U<3Y/CQ+4?>W=&,J9;;@,>M^\^3!UO?0IL 64E5E$W 5P M<'4'CP&*RQ<+
MG!\-0.W&)6F\DBF!Q\MV_;'6>N=FFE:UJ683IR9U/(TU!!0<#5$!3\U;E\!4
M</"N.EM,S:5TJW"$.+8<6V4*<AW%-:Z[WHI&W9LJRBSJ3+64%9DJ4.G*=-TA
M^;4X4GH]%22P91(+QY>U<GI4ZVBT)5,0%A FI2>C,994#\Z/94+W22JK%(>+
M_7E-(Q-6XI,WGT/ "BC1!I)F8-N4X9878GHI@F6&#7$LS9#<1WH9DS'-I$+#
MP[1;'0E:N=Z?-O7V#A8F!A=%X*"C@7(.8)JY!!>.N-G2DRPC269;$WBS70P.
MC TK0!P!&+*+R4RRI^J99-X:M9E5,7*&E0]*R:>5) S&&D:'0XM_V$@X4MQ,
M1%N)Z7PWA%10:NR%A* E.]/VW/FV=4L!$OG/G%(2+RV8 $W 0S!S>4:=&E(T
MI6PY"9Z9IO*,JB IP$.22PYU3U)-VZ YKTA&9)KES!3JJY5545'Q3Z9++8N"
METC6VA$K:B(])0[,GMX=]=]B'6ME"4D!HF]@18<N7:U(!2FE05*%TJH?TDG0
M4)R$=2989<QBH D#HT4&>C^W%B4-D')Z"J1N>0LWG$T1 P\WA)#+HM4,B&DL
M).IDN:S&'AU-V>B$OQ:]Y*HI:U-!M 187!Z-IVLJTR!*4A"%*N<ZM@2NX*$W
M9::N&#E3 D #&.79]CHL<_G4J64]*XARR<*"],6*C0)=@^D=ATIL$WX@ 7\E
ML<)0)4#V]K]\>@2"  8D"Q)Z[>C%H@ NHZLW4(G"+0PA%L5I\$Z@_@N*_%GK
M_/XCPPUX'PIYIQ&,0K+B/'SK&XI:WM>E%K6[PA>'^T-X>?A 8=9\3'/X1,4K
M]XK[U7J.$(QUEW>U47_ODC?%RX>4GY#$G%7$^?YUZFBJ<J_@BGOC$VU- U!%
M9/SQJD]GJC]I*H%S" ?EN6-9^U<T_$1KD4=^H(QBMG(:31ZI.D]^&!Z:7Q3X
MNW#S%E5SB(/N.6+YZ=K,PCI!L=Y<Y79=9XQ#-4Y$LT)M+U/3\XBX^H%)V;:6
ME\ADKC25Q,CHS+/**OI]'263*:O!)FTVIN83F90K:3.:FC"XJ'0QWT[O.,
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MC^E@XQV:1(JZ/:<B$/H?@FW%+L]_GSP$1[C\1B!EA7 8C"/I@A ;0A X(2E
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M58@$%-_*>!'C''6_FQB0Z9,Q*J%1-T'$N /=$+%Z:%I90  W4))^T#)L*O\
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MAA"&$(80AA"&$(I60!J+@FUNOKYCD+X0(>ABEP"PY6/+S_%C',%!Q]X^%??
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MU8_3K@]*E3=C;PTE/$6Q8<HMJERFU3U 4<%ZC$"N5'R;&D0=A;, #V>4,*=
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M@/-)?*&G1=1W=2W[-FV":)4PI*B%$A."6;, !G.0W8QM[.VO+VA)YU 4D I
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M30N6L)::"0M!$PT4E 4'"B0UTJ !CD(C/6!>B*4B95#.>U^>1$W7%S:9P,9
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MYN&$(Q_F+E](\QY$NGY^RXY!.Q4-$)+#JV'D/,E:2I#K=EH*H=R(:)! *75
MGPL;-FM*[,L+1B'8UH^08C$@/6-"V6-%K09:G8J!=M#7%)&9[*Y1:L1DY3!G
MDOG#*IC!Q$# 0,M4AAQKO:.A9>2(-EU*T*5O("4A2P$J4 +DF^.@C;5J0A<L
M72E942Y4X*_:S8O77*L::N3UCFA"C1:+@  0"!+:Z2\NF >Z3@W#A7=GZBUP
ML)"$S!+4$J+<849D\%GOZ.5,(IET); Z%4000C46T '-]V9S,68@)50AD@,*
M\X 2Q+!0IPI&HKDU9KX4 ITJ5,34$**E7C0RZ!]&);4/'(KR3IGH)A +F4]]
MC(J>P%3B4JF2DRN'FD).X&HBJ&1N;P2['RT*B6U^"6HAQ*1X=A25MF;)FA<L
M2[XE+DWB"5<VN4N44^UDE1(#M4@@I+';G;%D3Y"Y$PJ*%S43;I4$@+3-3-%;
MI O*0 2!> +AB(N"A\MI)E^B.$B?CE0<2I1:E[SR7H>7L*B8N*?AX%*VPXTT
M[&/NO+2I1&]?<W3[[%:]HS+=,"Y[7R!TB2.D;HO$.P! >E'R C+8=F2[ @HD
MO<)+I #,/P ;H=J $M2E<\<*V?)-#1DC<DL^GL) 2.*B'I;3\PBW9I)(6#C&
MXB ?AX.&B4)?A%)@(B+::*%D0YB$*&^D XWY6W)DFSS9 DH/.IDIF347PLF4
MI*T7E)6R@%)%W# T:D:$_D](GVB7:#-4%2E3%(EJ,M24IF@I64I5+*@2E9?,
MOC2+UHG)NGZ-CX./A8R=S1Z60:Y9*C.9D_',RF7+MTL' ,+2VVRE90DE>ZHF
MUKD6&.;:-HS)Z5)*0F^J^NZE0OE\34DY.[9&-^S;+EV=25.5E"0E%\@W *,
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MD04U6EUZ #0R>GS;Q4$I2LI *@DDL#5W+LQ%,'=F=XKZ#*N@$N@$FZ2 *Y@
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MGF5FPHK3%.PT0V J'"AMR):5RZL7F!)I4.S/FQ8][XQISYBDS"$O[!.9#UQ
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MC;0%CL=MEDI"ILR64A=00E!<LQH^+%+4WQP-JV!5LM=E6 2F7+6"S.'4#@2
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MNJX>N#-^?+$CDUR1SMP_S<D^$L8=D/6/E5_5X_R4W^+%7Z(8V_![[9$I;LO
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M/6/E5_5X_P E._BQ4GYH:V^--[9%I@G7A+JM UM_@G9Z<6]6N2/Y[E^=R/\
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M#EB>=G?2S/KJ^)\8<U*^A1]1$5#N>5)@;O2LBVM]Y/FT2.H>C73$<[.=^>F
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J<:P2D**@E(4K$@ $\3B<!B3A&PZB "HD ,')H*L ,L<J5-(W.+1$?__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>21
<FILENAME>g164680g00y09.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g164680g00y09.jpg
M_]C_X  02D9)1@ ! 0(!>0%Y  #_[1>04&AO=&]S:&]P(#,N,  X0DE-! 0
M    %W2^8 0X0DE-! 0       \< 5H  QLE1QP"   "    .$))300E
M   0S<_Z?:C'O@D%<':NKP7#3CA"24T$.@      Y0   !     !       +
M<')I;G1/=71P=70    %     %!S=%-B;V]L 0    !);G1E96YU;0    !)
M;G1E     $-L<FT    /<')I;G13:7AT965N0FET8F]O;      +<')I;G1E
M<DYA;65415A4     0      #W!R:6YT4')O;V93971U<$]B:F,    , %
M<@!O &\ 9@ @ %, 90!T '4 <       "G!R;V]F4V5T=7     !     $)L
M=&YE;G5M    #&)U:6QT:6Y0<F]O9@    EP<F]O9D--64L .$))300[
M  (M    $     $      !)P<FEN=$]U='!U=$]P=&EO;G,    7     $-P
M=&YB;V]L      !#;&)R8F]O;       4F=S36)O;VP      $-R;D-B;V]L
M      !#;G1#8F]O;       3&)L<V)O;VP      $YG='9B;V]L      !%
M;6Q$8F]O;       26YT<F)O;VP      $)C:V=/8FIC     0       %)'
M0D,    #     %)D("!D;W5B0&_@            1W)N(&1O=6) ;^
M      !";" @9&]U8D!OX            $)R9%15;G1&(U)L=
M     $)L9"!5;G1&(U)L=                %)S;'15;G1&(U!X;$!80%(
M        "G9E8W1O<D1A=&%B;V]L 0    !09U!S96YU;0    !09U!S
M %!G4$,     3&5F=%5N=$8C4FQT                5&]P(%5N=$8C4FQT
M                4V-L(%5N=$8C4')C0%D            08W)O<%=H96Y0
M<FEN=&EN9V)O;VP     #F-R;W!296-T0F]T=&]M;&]N9P         ,8W)O
M<%)E8W1,969T;&]N9P         -8W)O<%)E8W12:6=H=&QO;F<
M"V-R;W!296-T5&]P;&]N9P      .$))30/M       0 [_^-0 "  $#O_XU
M  (  3A"24T$)@      #@             _@   .$))300-       $
M>#A"24T$&0      !    !XX0DE- _,       D           $ .$))32<0
M       *  $          3A"24T#]0      2  O9F8  0!L9F8 !@
M 0 O9F8  0"AF9H !@       0 R     0!:    !@       0 U     0 M
M    !@       3A"24T#^       <   ____________________________
M_P/H     /____________________________\#Z     #_____________
M________________ ^@     _____________________________P/H   X
M0DE-! @      !     !   "0    D      .$))300>       $     #A"
M24T$&@     #-0    8              2@   )=          $
M                 0             "70   2@
M 0                         0     0       &YU;&P    "    !F)O
M=6YD<T]B:F,    !        4F-T,0    0     5&]P(&QO;F<
M $QE9G1L;VYG          !"=&]M;&]N9P   2@     4F=H=&QO;F<   )=
M    !G-L:6-E<U9L3',    !3V)J8P    $       5S;&EC90   !(    '
M<VQI8V5)1&QO;F<         !V=R;W5P241L;VYG          9O<FEG:6YE
M;G5M    #$53;&EC94]R:6=I;@    UA=71O1V5N97)A=&5D     %1Y<&5E
M;G5M    "D53;&EC951Y<&4     26UG(     9B;W5N9'-/8FIC     0
M     %)C=#$    $     %1O<"!L;VYG          !,969T;&]N9P
M    0G1O;6QO;F<   $H     %)G:'1L;VYG   "70    -U<FQ415A4
M 0       &YU;&Q415A4     0       $US9V5415A4     0      !F%L
M=%1A9U1%6%0    !       .8V5L;%1E>'1)<TA434QB;V]L 0    AC96QL
M5&5X=%1%6%0    !       ):&]R>D%L:6=N96YU;0    ]%4VQI8V5(;W)Z
M06QI9VX    '9&5F875L=     EV97)T06QI9VYE;G5M    #T53;&EC959E
M<G1!;&EG;@    =D969A=6QT    "V)G0V]L;W)4>7!E96YU;0   !%%4VQI
M8V5"1T-O;&]R5'EP90    !.;VYE    "71O<$]U='-E=&QO;F<
M"FQE9G1/=71S971L;VYG          QB;W1T;VU/=71S971L;VYG
M  MR:6=H=$]U='-E=&QO;F<      #A"24T$*       #     (_\
M #A"24T$$0       0$ .$))3004       $     3A"24T$#      -7@
M  $   "@    3@   >   ))    -0@ 8  '_V/_M  Q!9&]B95]#30 "_^X
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M  P# 0 "$0,1 #\ ]/=E4M<6DF1H8:3_  2^UT>)_P UW]RI761EFKT[B7O
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MZY_C*+VBS%<QAF7-QV/=I^Y7Z[-_^<K'[6^OVLMN\HP!_P"]*P
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
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M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_P  1" $E E<# 1$  A$! Q$!_\0
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M"-I!&5TC;-F%0H.5&9JKA$WB%1(4HY;&D6154JE=MR+HPIRBH!O"RS=1$Z:
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MK;HMIEUM+NG*@FE$TDS' 51 ! 0 I=0QQF_HJ^'3%0))0@&J)I@$"@(GC+6
M%F0&+_>+XP_B*@,9)'"__C4)*[E+5U5>G!GZJW4;&FXL8\T&%*+$,QW9W5-B
MNX>)08EO;8%XNX=W[=+\+9_NJ^'$E4!5CYDQ4!/_ /:S-O9UB?WB>-"5-/W9
M64T(^R)>@#<##0Z<O2#%VNN:HHLSAS,P]0+*"T?>7/4_&-X2*<CN)1J3[2B&
MJ#< !$MP)J)AUQ/[K_A\@,NK+2FL1\I596\64!)< L[0_O%\8"0LV/W 22[_
M /IAA9%)R6-I#IX=(A$[=9K44> ,RU0W06)&*'!!.LGK!Y5J)177=*&"369Q
MSL=I8P 900+L@ %Q?[L/ARL);$_.:5 *^+!9"!<;(#^D7Q:?O!C_ .,.<O\
MIFH5<+<M&FXZ<?2!>-UFOAMBZ05AX& $@Q9?*84A+.:EI-EQOLQLPZ>2("-@
M$36[<:\'_1G\-E\5X@Z1-6271S+K3G5FF$SC5\4:N"<TO'23]O?&^*\O1CYB
M29=4B4+^%?\ II<%149;1^N/[&IF=6.<'11H>NZ\E@EZAFE)I1\^31!N1R+>
MH)-FBX!(+B05FS= Y@ =1N80#:MC_)?])OPB3X3^TFG\)H4DDT9F  +("P4Z
M2>@(I-5<&_T3^Q?CY_'?"9=+I'*2D M4(_RC .03@T?0:1D6$.T.]D7"35JB
M  994P  ";@ ".HF-V!J-N['Y&65%X>F9'O'ZR()_*]EU_I/'_GC_=CL-'/,
M% 4;1[F$'\KV77^E$?ZSY/X^?AC$(7^5[+N]O&>/O_KC_=A$48CC!_*[EW_I
M,P_/'^["+"_RN9>?Z3,.-O?CQ[.''"(HQ%%W8[(3^5W+O_29A^>/]V$6#^5W
M+O\ TF8?GC_=A"#^5W+O_2>/]9Z?[OXN&$11B,*WP@_E=R[X>,S#\\?UVMA%
MA?Y7<N^/C/'^L[,(**JV,-_E?RY_THCN7X3MX8048PO\KV77^E$=ZS"$'\KV
M77^D\?QM\)S#Y,(0?RNY=A_[3,/SQ_NP@HQA?Y7,O/\ 2:/[/A/DPA"?RNY=
M_P"DS#\\?[L(0?RNY=A_[31_"_OQ_NPA"?RO9=6OXSQ]N'OQ_NP@HQSW8P!F
M_ET/"J(_7^N//ARPB*,1QPKPA?Y7<N_])F'YX^CL_CCPP@HQ''"L'\KV75[>
M,\??_7'^[%E!F( <FC@<R@BAZ1H26;F78L'EJG8;1VZI2V,)A$PE$H !>=Q$
M L <>W'30RF7Q&C,P?7E4%F!"N%9!]8X^(_[.D%%E(7!0>\JQ_,6Z9L#,2?2
MQZ0TJPBI%VV?YP5\X9NF\>Z%%=$]32RB:I3@B)3$.F<#$,6Y1 ;@(@8+_P!_
M_9_XMH)/A,_AM).DLQT:JI($I!= M0B@AX_B7QSX7XB?Q\NGT,I,X!U4(_>
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M"83.LB4".;**B/F#P6B\V733RZPE)65U(F!2DP-2M#=XD 9:9:CJ&7M#:_\
MY5IX;W$;?YH#GQU[^V_E.G\=^+_Z'TEX>\>CRO"?Y X3_P T-4RURV!)0P9>
MT.(E(8VRG2=/&5.)2B8I"6BB;*AQ "$,81(0P@90ATBF(/;PVF\=-II)3.WS
M?@ ^668X8N'J[QC3:/P8T9/D@(B+YB5%7 -^/'R7#9ZY#-XNIIO,K)J"RF94
MSF2[RK0D)^G,OI5*1J=BT5?3J29*43GE&\; *$8.5U72!E4&BZZB"SE5,%F?
MT3]K*@:0E2J R62A0(B!EHK.L>)?!,FC"M>=MA7#8^8C;==(7H:L3,S)0M&J
ML%'"S9TN6A8IL:/2+ S4RTD2P[V*3DWS5^K2<]%QZT<WWB\HU=H")$&Y%,:$
MOB])\OF5)-=&R6:H.>*(;P_8T_[4HO6;U!"!=S+BFZXS[Z&*()HJMJ%17<0H
MRY$T,OHY5RHT8R+^#D&IDR0XG"6)*MG":\<) =IJ,':BASD,("^S>+1/,9*?
M)Z9DJ#4(RU ?8J>4.,X]3E[64Z2V>?1=?5#2M+4O05/U94%:5BWI0C&(R^@F
M"48=19TU?2*ZTI&M6W@FGU6KJ-G5DE3+M9Y!Q&M2*D3)?(T/C-&#--I!*E #
M*KYIO 0@\8J^"!7RQ5GFW,IRW[H95V=.1-(U15-.2F0ZRY*.J&$@)Z52H&F$
M8UF,]#2$HUFC&?%CP%@L2(.W9JMB'%VNH0N\+LZZ'VQDTBH%+R%7K2EK\7A_
MT7^4,$^9;!G7>,[O$NJZM,GH.EZ(GH;)FF:W?U_UQ6"IRG*>H1F[+X+B#R\V
M9^[F%&$)&FC&@)&79OI<7+N0.4C=)0QS!C4@\69D\R8'5;[MR$-%NZ6@#X20
MKY0 0J2)Z;RYW$H$I$$HO/3(6O*HA8.*R39LX2H)2F*;85LO2U!A#(U55L K
M4$/3KABF96<%<J+5TBX>>"C197J:B:#Y1'8,::72^,T2KI"K%D;:Q(L&-@N7
ME,GA-+I!_A!)BJI.FY+*5CU\IEEEJ00ME]0Y .<=E(*1IT-V4$DS#PB=+J'/
M:]KZ]F/G:3Q_C'&N5%?N\0LNZN21]D> \--H0)0!,2"MP+A)I@R)C:,?\F>6
MNG_U?T1</_RI3P:7[HKL#YPQS^W^-_S)OX"F*?*P3".7]5Z+\650,E/S*3>N
M6< 999;&L Y?4.//6E*>]-[^"!^:UN\+8W)X[QA/S:28LKZJ5#_=OB*KC&I?
MAN@E4SH1A@6PG!QJ@P 80[^3++01_P#\?4-?2UZ4IX!T$1&_\S:<!_;QQU^V
M^+;YWL65:VEJ%YWC7]7^#"_*'1?O(EJZ2EH!RRRUXAE]0]QM?_DK3W9</\SA
M\@^CY,S^+\7."!I$+%?E.2?,!BK_ $C,WP[P9'W Q4()Q2I^\4'T6&_R9Y;?
M_=_0_"W_ *J4_?MX^"!] <P$>-KXP?%>,E5-(:X2.BC\+\$X1G[)X31N-&"
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M]Q]H]P]CZ'UCSD8==+:"',-0$![>5AX]^/H24W](\.DJ/KCVNQVA1-:W >'
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MGA&,6;VWD-G%[7^ 4U"W^KVV']6!(Q&XCW:%*BM%4#C#TV$@8=6JYK!J HJ
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MS2:107X$$[;E<@XIG'LD) #/F=O>6$!8V0+_ )(M?_9*?W?/CCX:>:::=2@
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ME9RN10@BFCJ&S,_5(Q.*. Z-N .=/0/'L!BJHZ;MW"B!VV^;(*@BM<BZ9ER
MJJ4R8"*8@)QL4;B<HE$IP#&QP+&B"ZK@@-00Q!K'FGMDMU/?N$V[UPO;2][7
M H:#\O*_HX<\;*I5D%:YJQ=%%XQ":WT'0+VOPT$;>D>(A\O9C)05"$W!0%+$
M&@H"HA .EK<-! -1U#CZ;!Q'EH&F*  R$V)0 =5=&J"RF$1"J1*$IE\(F*%Z
MW-;:-;_V$KF_'C;M#6^G/1:54^\XS*XTJN91(H_>V'U'Z;(E:8>XI#;3=(6$
M+V$-T2^MK:"-N?'G@&J#D')#2AC6[[&H]FJ'5JMB<.[P\-..G*P]NO$+"(@'
MHXV#EBAP%KLN&5&]C:T9A;CQ#B/:-^&MP#@ ?P& 1U- Z*EWVH$)4D(D(4I1
M-LE, F*91/>$N >0<Y4C'$-!$" H81 !"P:VMKB*A.J,J&MEV*XMB:#0"JZ4
MN N3WPMC'A[.S-O.^B9"MXVE648NW;2V6PTL_2IYT*(Q<DVJJ3J=M(/%T)%H
M9<20+%JEMLUSF6=(LDS-'+U!R3F5#65@^:I4;:^L>B0J5"66F&Q:;%98[C',
M?,R(H_.6OI=T[FXZFF<02F8B3IMK3D@B^D(.+E) Y@8$WSQDT/.Q[!N=V"AT
M@9/$7"AUFY]G/3AQ]Q'50SUIGL/=M]13O2-SYIIK5S5E24G7+UI5L&S8R,!3
MC9] T_3*4F1C*)N>IM(N27F'B =>9$.9\@D5<5"J$; 3:H)9W&!/*(0%L%JH
M7!Q@GU-(L2O\ZLQ8+,R=9QKMGXCMZ4;R,&4(I%4&LFDU![+K3YG<4D](>1$@
MPL0W:RRB*;Y9/;3%84PP6F3<SZ+ #%U=:O1K!13)K1[.BW0OHU@^%JLS!ZQ:
M.2MEA#:; NB14413V0W2B8G$BA3!M@<!$1$<=)1FS>BD A'-Q9JQYM-][-UL
M<F=L,>9W_?:B-@X!_=Q#A< OP^7CHFV2U1=B9UID#'*&Z@(<A[;Z  \/UZ^G
M$-"JE]E"02Q% U+"T(40N%^SN'T]XZ!S'NU'CBT)^;)"02$=:[>(5@@1H@'\
MY.A#AX-1*'9<7+BP7[1UV>/:(#B J2ZE.N)!O9$Q5SK]W?T]P-KL@C<+J4!"
MP7L%PX!I;7Z0$.5M>P*2%1445V&@SKQ$9AW >(7MV]NFH\A !^C$*#%35"45
M%.:4<4 3(H+":W$1UY@&FGT7OW=G/%%N*.X(1"K*W+;"'% IP4*=0H>XG I3
MD,H0H&$H&4W9; HH4"ANRF,(7UL%A'$F"XJ0"A7$\PNQZ"H[Z(H'%S<+09]'
MH;'Y_P":&?>=;*L,S8:GJ0DZ4C:;5I0E.2\Q!-@&H&761\.OF;Y5K.1;QW)-
M0ZM#1BS- Q%$5!<+%$Z8!R+&G'9LX?2.X<,5<>K JY2J*NQ1$FS)SRJZ)AXX
MT4]DZ7D7-'T%-L@D:5+,RLM458"02-'C%) S:-:1Q2&95"JJW$C 7:"H FJB
MDG@5]P_KMY51A%!!4C>WT$<3+KI!9F2L;F4[S,1"DG,-#$=1:T; O*@:1[^/
M719*M4&C:,:O'3F3;'5E8UHNJ]!9!5%8SA "J)8@*Q$#-<[E6F5 F%8MG(W,
M*M:K<QT=5J[*67=T,WJLC]JRZ@NQ5--.(M)C+-@2231=R$>"+YZP3*!43E'9
M Q0VQU*"2 2J%@2U53A5 <\8XZ0B4E%% M;;MP7,81Z82OL@!C;S4UU;6WQK
MB(J@7D \B\M-+XWL8E1<4:@WEU1$5C' UQIG48WAUK#V\- Y@-A[ OIZ-;8M
M78&4N2E<+L26+TB0:<+B%K\?3V?+RXVX!QP"RA&.#[5&XL^.) A"DU.03:?;
M!-?04!#T7$+?3@_S9TS*43Z!0\=I/NC?ZF-B@[=<JW4!_GM'AW1;'GSUOR#A
MCE>;_=["/3+0;!&U6J8+J4J@<QB M4K !$HZ@/E: /#@(ZVY8M'P(]S[=K N
MV(/MUC:-22"J=E7)U3=9,YVEV;-0P"(6  ]R$ $.("%]0] 8G4E=MF9-T1%8
MJB;CB:DNJ%:O6H@52U!05*RK6FJFJUC#2TC3\[5#2-D4F92N:?I4K?P])(++
MM0;()LDY%-9^(&*=)-XJ8;E$3800#$HI95=>)LIB--,ULG%(XS]#,N%91+5M
M3D@99V",<0S*I&9IFFDVZ+AJB+@DJUWKHC-L0[LZ:2BJJ92)&P)HZ4IM:W/G
M .#<%:YX9<"(N7Q84_*;D>\460?_ /./ZQX!C6L<N Z1CR9,#Q^D'BPK:WA-
MUZ-RRM_Y?7Z+=^&M-CR'2'DR8'C](/%A7\INNSX%EP[/N?Z,-:;'D.D/)DP/
M&#Q84N%I-T'?N65__D#PX<0PUIL>0Z1/)EP?_<?5/:#Q84_*3FW+W%E\_P!S
M\?GPUCCE04PI%\F3 \8/%A32\FZ[QW#'Y;!U?]N&L<N Z1/)DP/YCTA/%A3\
MI.?3N67[OV:?+SPUIL>0Z1?)DSXPOBRI^4G/?[BRU#73[G[<-:;'D.D/)DSX
MP>+*OY3<W"UO<67#73[G_CNYS6.7 =(>3)@>,'BPI^4G/&X>XLM.'_-Q^?CV
MXNL<>0Q7VW0\F3 \8/%A2_\ 2;KO]P8W_P#+X:\V/(=(GDRX?Q'I">+"NO\
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MN40:,3(26)/RHCT50;@*ZKO6)<-,*<I)SRO[BRX_H_TZ>C#6..=!7&D:\F3
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MELO$U'JZH*UNH!3'3;!L;%"UP-@%-(GOK\P'AI;6[6.55 W'>3=5LIB'12A
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MRA@G:COO,15[0]]Y&%ZTCVJ>H7^KQ4V<1UB+MX'I!UI'M5_1U_JL$V<1!=O
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M$>$<Q<O5+8H7#U=T#A *B_:$EW50TE2D\]+NGDU3$-*NT +9,KJ18-G:YTQ
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MN8E%HM7B;A=!XK4]-)H/$68@5VLBL9V"2R341 KA1,1*@(@"@DN&"Y#8_7?
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MVK<;.P<'[M3X]3\U+O\ [/O^@.^]7(<^O:[$)F>72#8/>^^/Z-E.P_\ <O\
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M&VOT6Q.7>:PI<EQACDG?")QNSAH"RG+B"8CH4"\R<Q#:]/=IB[ASQV[MF;Q
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MS<S&?."E,"\*T 3*%H<HZ$N$XL#@E/:!HXE:4A38V<HN_@8^@W;;@''GPYZ
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MH1%P'W>^R[N482V_%;C];O&/<.!$GV^]3\HA-LO5C[.\,"8 *:C-V!]H3 0
M*0H@)MK:L6PQ9C>B8!S:A>H?>@8UG1*.FL=JJ0RX*18&L54RS;RYF&]9N352
MNE'44*[>I%9>*19-R1J;UY$N!3*:!M.QBDM'O(\'B0*%3D&JR!3@LB<H9+U4
MFC[4SO4 &\=I"BIJAF2BU?$I<F\:L9G7EHM!U+.-:LD$(RC%!\-%- OFR@N"
M/5HT#Q$:O3P.)TB,DS6B@!L50#R#1=@ &61,F$6SXD4!HB#NT;4*JRE&!"DY
MJYIS=P\2BB:TH^L2NAI.;%9P1LT?ODTVAH]V9H\5=I,E7#9W&,713D6;O$5T
MCB?J3@%&HD(8H@%E+U1C@.)/>Y8QI2&+%]HR9;;A>L3LZ2X@%GSSOL9.W#L$
M-+]VH8V21BF>K7]%9E]. 0VE%*DCWX\X9U=R/!Z]$.X4Q#CVB41_5;NQ%FL2
M0U@6387)79>Z&N)=VM[,4RW&#J[@-.N/ TMJ*?\ =?3T@&N@]A2CKO(%5Q"T
M^E($A:2_Q= .6V$%%< ^[7HW#75+OX6OW_0 <@Q!,7<L,CO)2V%<2(JC_17/
MI3EMM$JD27"0H<1?.PVJQV2B8R8:C2E5[( (<;C>U^(!IBDEEU@[8L"I8%$S
MXF*'4C55%8'$(QNO-%PB8$2<W-=^[ -HW$R-@$!\HHC:UPT$.?:&NM 0E"2O
M^W<JXVB$L%#YF;?@!L$/%-<= ?NP^5.]]=+B&G(>5@Y@'"KF:5^2Y'O79LC*
M_P"F7GUA=ROY\]$=+V%*W'2P@4=!#E?@(\1P=G-Q^ZV/I08/!7^[+N7F&]Q"
M;EQ8+O7?RF2#4;"''72P7M\HWQ"*J3<TE< )WD4BKE+A^]3C3%')B'5M6,30
ML065GWT\HW6=$;)(14,[GW2YMV=5<PQ\;%R*P-V;1-9ZZ=F!-%JW;J+*^YE,
M8N9DJ2:'\/,BW6]NVB<$ "ME 8%-]TP%C$2A,W<K*N93<RRJ]%_%4NV1DEI=
M]!D1BQ8I+J-VTY#2CV!*E*HI2":L<J[BSJIM'R1F:ZA' @F.0AS2C"4G$L#3
MT>.A"(@"$H5*C@H7?<;(QL\[:!D*?JNJ4JAGTH.C2@UGI)[!2[1D5(QR)J$C
MT'E-D))N$5A,V4".,H=)TD#<^RJ)2X;T2@OZ)ORV1F>P("D.6(P"@I@P%\([
M>7U>496C$/$N9<]2(R:RC=IX.4A0*PD'+E!)R2->,F+LJBSQ!PD_442-]NCL
M&$#CLXU*CJJHKZN;_-54KQCG,2*(@*,I?#Y6W*5M%C[M:]NON@'LNGQ'@(Z=
MP_3KIC5+D"O[J=N!M>ACF3B!P(-=N7MC"@DX&X@^>6MVIZ"/R#<?DL&EN>*C
M%"5%@)=S<ZA8:V4O ]>PU(04E^;YX \>*8?1L_-<!YZWQ'N3=ODRW8K[7:W^
MF7AV.,,,@X,.T#YX-@"UMWWZ7MSOJ(  6"^FF#T!)1E&K7!/J,,XJ@VE=58\
M6^IC1(W<^$')A>O"VC4;ZIA<1<+A?@(:?JXZ7Q%*NJI1!8E$9/170T!,@85K
M\R6K2M;AMICH BXX _>:;.H"F-Q I>PO*W#300TY8H%!P(0H#M4OD$YQ"15.
M))/K3GL80HI+Z7?N[ARNE?F-["6_ !U#0.[@->Z_P/VW&"Y2X4/7G6$%)QH'
M7W=PX^4B'&]AL(!H <PO>X=V&\HZ_=3-62_(P7*44Q6^![*+#3(.!&Y7CT0X
M#84M+ '<'[!N'9B'6LKJKRU=F]0<;P4&HE&W6]E_1J1#:XJ^G,NZ>>U55]3+
MQ,.P.@DX76(R4$5W1A1;,$$W,<X!5>2,<442D5$^^V023$QM<FVLJN;&OJX=
M2&8"-RXA,&6V."O;:I8QZNLRZ$R]D2)5#//228L1,R2:0IZ@>#'*N4E'(+-8
MZ!66111(*SA9R8-ANT26=G$J30YRY+$ODJ"N_-NW[:-P"@MB$"-9#L9ZJT:L
MGG%EJ@^-".:D<2*IZ;;5>]49Q*TFP;TRY;%?L%9M^C JH1;9ZR 'S!NX,3K3
M-JH[(4Z8&,$50G:&WT/"-I=,TH^XHOKBD6LQ6*_9MG[&57=LWK=!XT<H&3%%
M=LY1(LW61*+9J5-%1 Z8I)$1 I4A()!$!OCI*NJ$)8HPE]TQ^D>;2'YBTMBI
M!*[T6V^MXW-TX\]>AQYD^?WH_)^K&D.)S!$O;7Y1C6RE;(]?TM#126 ?NYV'
M=M)ARN%]. ]G,0 .0X(]2-TN:G8^%\V:V4ML>%>-FN@AAFSH1N#Q\:][6%,=
M XW$2VN V"W&X< X#DF87)<.-5U3:BVW,\4)A*XOK=A+VJ[%'HMW("4!>O0L
ML6]S)@/O2CJ%AT'L$=0'34-%7*A%)4#(,SE,<D$=92@'W:V5+EG9\+JIQWJ
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M[N^Y)VEJ\%#\L.@;DGE)%YK1,'(YDR<9FYETZRRJ!&<E&SQ:-IV:@7$--R,
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M()%?\2;9Q[99=(R$>)#>[5V%@TNP6"P]^F@B/_"X8EP=7^$\@J'EC K:9?\
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M_*/ <3<"#?5(*X!QA9+YQ1_N(_YCV$84W!.MN3F:.]V9@DD!NH+ !S@LH8Q
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MX<A(.@<K7#D(#8! < 4536BNBBY4L4#+N >.T@(EEJJG*GN_,)!E_HYJT/\
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M)" <!XC?34/U=N$%=$/!H\_9KY#45F],0DU5Y9I5I#H@5S",RD:%E=TZ1>(
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M>G=#;]>$%94.Q'@ZQQ]Q<:?V0Z^C7""T8OE3;!U@-/<''&WP0Z<=1UT#E?\
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MT$MQU[N0\,(A?OTW<ECP7F:GG[$,JL2BY&N)J1/FMUZ@RP[!NVCE:8+ 1!O
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M0@PA!A"//72--79:0C0H3QI*X/.M/"JM& 0U0IMRI+&8%0 QTQZ@M)@V2EQ
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M-9CYRY=Y7J"A6U3-:>6/3$]5[=.1?LH\[^+I]Y%-))O'@\72%PZ5<3#($6Z
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M&$0BH<]\MJ;3B'JC^4FCU#3T=54<$(W\(+*P,B5)VV>BDJLB+=D9B<TDOM&
M"LFRZMC"0"BC0DGFE664D*0"#>ZW!QO</&&5SURUBGC:.>R<M)-%J?8U4M*-
M&AG42WCY9@I-1*<@J90ADSR,4BXD&"!4E"G:LE!$0,F!3(>5,02);H:5"JHK
M4D[4<1>$,Z9RL6QE8]THYCY-JWD&+@#G %V;Q%-PU6 #:@"J*A#E"P6*8 L
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ME;F0516/.^\>4'7O"EMQ>](YC'I!9>R$+54T"%3-T*243%5DHQ(G*S(+2KJ
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M73L54#Y[&"_RWQ()MQJ>O*D&Y+^.KQO\,IQ_.X=W#NP7I0=[ZP3;Q/6.45N
MS#LPG4L:-C"A[L<-4WLB<;>5<!\H OSO8!N(X9_7D6@0K*75EZX?1Z1U 1*
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MO$PSJY-H#;2U]J^JR@_>B'XW =+W]'#3%79P$1'#FN)PO5:9=8A2I 3F*T*
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M(IE@ 4BB< "TVP)3L\*?7*,ZE2H)&5(>/D0.B4@JEV60[L51$J15+/AV#JG
M"ID.!3*"8@$ PG(!JA;/,=[,8FMDUZ_RVOA0I#"5.BH80+&R)@*H*1C$ZB<I
M50.HF9(3%>B7>E52.@*5]L'&PW$H+*)D-$BJ+8+W=,^$//4S4BFZ.R?%5%,B
MP)&-'%5,B?=@"I4S2 &,F!ED"&.4!*15=%$XE6533/4)[],3E6(IP'$\?NTS
MI7 PHU*W !$6$A?L#J.OSO@_PQ=69FKWWOP,37"*S!35N$L,\:&X@(^#Y'N
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M!=U]?8],.P<-=TIP 2W34]@+]M^'IO<(A%L"R9JE$JU6PF),>=.E1WOI )%
M$+IJ@(!S34 ;<KZ:?)\M\$9CF*)B%047!WX(-V<= 15VN.B:M_182Z:>G]H&
M0&BJ;7=B6J%?D&A[0HIGU$$E=! -$E MPU][;4=+#KB/15)4A2&JE'IA>A18
M0"10 \I-0H@%KBFH''O$E[_+:PV  N(@ 0K>CE78;L+EZ"D(39-\4H(#V$,(
MW$.0;(C8?EMQT$,1 OL"#2PE1+FR@J3!.U ]8!35O84E TOJF<+!WB)0OPMS
M#D'+%*ED9 ZL BT5%WE C&]0]D+PONA2E4-L[)#C?>"  0VT )*;LX[L N
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MG(-4"8"E948W6M()LXC;CW2L/!)7AN5NT!W2EQMS -D.[GQ'6^EC7L:J%#L
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MQ=8Y57%]ZIN2!T4ILN]/0<H/%Z(#@U,'9]L.1T[  RP@ >@.0=^&L0M'R'2
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M44E$432A@JJQ,MJ&]MHJ,8]OT&E,(T72I*A.=2?\7H<9LZA]LYI88YL,B83
MDB4;N]Z-R(I$UN! PB%%:D2W")!A"#"$%P[<(1"Z:"TY6O?-M1TX?T-'6^C
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MLAB,U/F[E92B,8]FZJ:((RD:VF(Q1!95R#^,D#H$;/$.K H*S98CE)R50OD
MVNYN"9#&"KLX#I$3([5(JR.56B+?""3S:RJAY)C%O:I8).WD2E.M1*NLJU4B
MW+<'C=RHY)M( 1ZSVGS4%# 9PV25<) 9-(Y@*7S8L.]]8(%%5!2[,2 YHALQ
M/"+/9'9OFK=XT4*X:.DDW#5PFL=1-=NL0JJ*R9P.(&353,4Z8AH)#%$-!Q.^
MTBB@KOKOC<W*>NAM>/EGU_[V$$&'TV8;H;N$NPWK%/;P@@SXGK#MR3L-QO\
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M !"PW*([86VO>[5C;-[[(VP@LN(XB/*ZW1FABTYFC"MJO45<9@-7K&/<NDD
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M!P<YQ4*OV2.$26F6Q<N';IM&2-6,VK])1$Z+6.@(VIW[=VYU*9==\2EBJ=4
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M45<Y?QU1Y?PM/+-S+*2 U [J:'@H)5NF NG[]!#8*8+8*W!P;J4V,M&I!"&
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M!-E934ICCM!QVF$(U2 I2F13V@ 0L#<HAL[1MG6V@@ A\UAO:^&JN:T*HQR
M3K6\-8Y;*KF5?G80 @W+<3HD$== ;$N'=H%N6NM_U8HE H3C8L=V0QI S+4
M\>:';#00:B:^Y+H(_P"3%#732X!V6]( .  9#; /G15?KG"2X.-R<:5HWUA>
MKM?B26#6_5BC<=;#>WHO?CB(%(4*Q1!89K8'8O&B9.=S??C7&%!!IPW!-+:B
MV+;TAY/$;\?X%JV4,I^Z%_0=VAK9'\QZX0TR3;[U%,+=K8@WXWY (=OZ\-4*
M%0JI6FP-6Y^@2+K%T;>J<7]AM,*"#<0^")SM]K%$/GL-^5_1Z,-4+0(UROI]
M<WB:Y]>^VRAP-D!XHIW -0ZN2UM?D^;6V*)18^ECBAP#90UB:@'CLH"BU>'
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MJG46VR&,0:O38ZM$3=L-5 !)9%P;UB2_R1PI8X(@D'218T),TN#+P,7J@/\
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M'XC'.E6R<&U%],3<!%,P521%W(+=1;@LN<$VZ(KNWB*(*KJ""2)!/MJJ"!2
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M%*4AE[3]/U')(NI=B21,Z]W PI=<EY!\W;JF,<P;UHS=-F9TP,8J9FXE(8Y
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MG"IWTI4;J82*^..PFT".*L05!433*0\OIZX1"0+U48@&KORV(@6/=23AL4
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M2(J$2F,PD(:HXR-EY5T5- *AG(L(=N>,+%%=%F71'\@J<R2Z"R2C(J-F4Y*
MHWL*@%<O4Q(LK>DC*5K6S>F7],,$&TG+/&#>09NNL'C/<9M9BR<D$RH*O4#P
MJGA(@D1W ND2I[PB0F%V,XAE* D![H^T*,2RV<Q[*22V1ML F&P6X 1(;G'W
MYC !;E$1"X  B40L-BCIA$%*<M]E]\*QGW8=H:_V9/9T^7""[6R/9W0;OG</
M5D_5LWP@HSX'I!N@[0_,)[.$%V_E/2(15J9?#.6VT!36KE80N4H6$*#KFUK
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M)UYHU*I)J*JBN#-NB4?%ROI@, XY/Q,K.E2_K2N5*3EZ30CR^-J=-*+,0>.
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M**I,GITG#B09IK$;OCB0QD@4,D!KJ&%&9E-B*ARHI;&RNZQ9J:3PFU<[,+B
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M>Q"B(%>-A&V\(%[ IPO_ '8LJ*%IG&9E0I5J;1&Z$O%  7DX\ V"&U>-PT,
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MJ!!(.V0JA0UV3  A< $0T$!"^F@VTP@48("I]B5AG56OFR'J4_9Q5.)@@P'
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+B(B-M1$1Q(U'_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>22
<FILENAME>g164680g00y10.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g164680g00y10.jpg
M_]C_X  02D9)1@ ! 0(!>0%Y  #_[1AL4&AO=&]S:&]P(#,N,  X0DE-! 0
M    &%"^8B0X0DE-! 0       \< 5H  QLE1QP"   "    .$))300E
M   0S<_Z?:C'O@D%<':NKP7#3CA"24T$.@      Y0   !     !       +
M<')I;G1/=71P=70    %     %!S=%-B;V]L 0    !);G1E96YU;0    !)
M;G1E     $-L<FT    /<')I;G13:7AT965N0FET8F]O;      +<')I;G1E
M<DYA;65415A4     0      #W!R:6YT4')O;V93971U<$]B:F,    , %
M<@!O &\ 9@ @ %, 90!T '4 <       "G!R;V]F4V5T=7     !     $)L
M=&YE;G5M    #&)U:6QT:6Y0<F]O9@    EP<F]O9D--64L .$))300[
M  (M    $     $      !)P<FEN=$]U='!U=$]P=&EO;G,    7     $-P
M=&YB;V]L      !#;&)R8F]O;       4F=S36)O;VP      $-R;D-B;V]L
M      !#;G1#8F]O;       3&)L<V)O;VP      $YG='9B;V]L      !%
M;6Q$8F]O;       26YT<F)O;VP      $)C:V=/8FIC     0       %)'
M0D,    #     %)D("!D;W5B0&_@            1W)N(&1O=6) ;^
M      !";" @9&]U8D!OX            $)R9%15;G1&(U)L=
M     $)L9"!5;G1&(U)L=                %)S;'15;G1&(U!X;$!7UD9
M        "G9E8W1O<D1A=&%B;V]L 0    !09U!S96YU;0    !09U!S
M %!G4$,     3&5F=%5N=$8C4FQT                5&]P(%5N=$8C4FQT
M                4V-L(%5N=$8C4')C0%D            08W)O<%=H96Y0
M<FEN=&EN9V)O;VP     #F-R;W!296-T0F]T=&]M;&]N9P         ,8W)O
M<%)E8W1,969T;&]N9P         -8W)O<%)E8W12:6=H=&QO;F<
M"V-R;W!296-T5&]P;&]N9P      .$))30/M       0 [_^-0 "  $#O_XU
M  (  3A"24T$)@      #@             _@   .$))300-       $
M>#A"24T$&0      !    !XX0DE- _,       D           $ .$))32<0
M       *  $          3A"24T#]0      2  O9F8  0!L9F8 !@
M 0 O9F8  0"AF9H !@       0 R     0!:    !@       0 U     0 M
M    !@       3A"24T#^       <   ____________________________
M_P/H     /____________________________\#Z     #_____________
M________________ ^@     _____________________________P/H   X
M0DE-! @      !     !   "0    D      .$))300>       $     #A"
M24T$&@     #-0    8              3    )0          $
M                 0             "4    3
M 0                         0     0       &YU;&P    "    !F)O
M=6YD<T]B:F,    !        4F-T,0    0     5&]P(&QO;F<
M $QE9G1L;VYG          !"=&]M;&]N9P   3      4F=H=&QO;F<   )0
M    !G-L:6-E<U9L3',    !3V)J8P    $       5S;&EC90   !(    '
M<VQI8V5)1&QO;F<         !V=R;W5P241L;VYG          9O<FEG:6YE
M;G5M    #$53;&EC94]R:6=I;@    UA=71O1V5N97)A=&5D     %1Y<&5E
M;G5M    "D53;&EC951Y<&4     26UG(     9B;W5N9'-/8FIC     0
M     %)C=#$    $     %1O<"!L;VYG          !,969T;&]N9P
M    0G1O;6QO;F<   $P     %)G:'1L;VYG   "4     -U<FQ415A4
M 0       &YU;&Q415A4     0       $US9V5415A4     0      !F%L
M=%1A9U1%6%0    !       .8V5L;%1E>'1)<TA434QB;V]L 0    AC96QL
M5&5X=%1%6%0    !       ):&]R>D%L:6=N96YU;0    ]%4VQI8V5(;W)Z
M06QI9VX    '9&5F875L=     EV97)T06QI9VYE;G5M    #T53;&EC959E
M<G1!;&EG;@    =D969A=6QT    "V)G0V]L;W)4>7!E96YU;0   !%%4VQI
M8V5"1T-O;&]R5'EP90    !.;VYE    "71O<$]U='-E=&QO;F<
M"FQE9G1/=71S971L;VYG          QB;W1T;VU/=71S971L;VYG
M  MR:6=H=$]U='-E=&QO;F<      #A"24T$*       #     (_\
M #A"24T$$0       0$ .$))3004       $     3A"24T$#      ..@
M  $   "@    4@   >   )G    .'@ 8  '_V/_M  Q!9&]B95]#30 "_^X
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MG^C_ #$;1>=79N>R
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M                         /_A..9H='1P.B\O;G,N861O8F4N8V]M+WAA
M<"\Q+C O #P_>'!A8VME="!B96=I;CTB[[N_(B!I9#TB5S5-,$UP0V5H:4AZ
M<F53>DY48WIK8SED(C\^"CQX.GAM<&UE=&$@>&UL;G,Z>#TB861O8F4Z;G,Z
M;65T82\B('@Z>&UP=&L](D%D;V)E(%A-4"!#;W)E(#4N,RUC,#$Q(#8V+C$T
M-38V,2P@,C Q,B\P,B\P-BTQ-#HU-CHR-R @(" @(" @(CX*(" @/')D9CI2
M1$8@>&UL;G,Z<F1F/2)H='1P.B\O=W=W+G<S+F]R9R\Q.3DY+S R+S(R+7)D
M9BUS>6YT87@M;G,C(CX*(" @(" @/')D9CI$97-C<FEP=&EO;B!R9&8Z86)O
M=70](B(*(" @(" @(" @(" @>&UL;G,Z>&UP/2)H='1P.B\O;G,N861O8F4N
M8V]M+WAA<"\Q+C O(CX*(" @(" @(" @/'AM<#I#<F5A=&5$871E/C(P,C$M
M,3 M,C94,3DZ,#,Z-3@K,#4Z,S \+WAM<#I#<F5A=&5$871E/@H@(" @(" @
M(" \>&UP.D-R96%T;W)4;V]L/DUI8W)O<V]F=,*N(%=O<F0@,C Q-CPO>&UP
M.D-R96%T;W)4;V]L/@H@(" @(" @(" \>&UP.DUO9&EF>41A=&4^,C R,2TQ
M,"TR-E0Q.3HR.3HT-RLP-3HS,#PO>&UP.DUO9&EF>41A=&4^"B @(" @(" @
M(#QX;7 Z365T861A=&%$871E/C(P,C$M,3 M,C94,3DZ,CDZ-#<K,#4Z,S \
M+WAM<#I-971A9&%T841A=&4^"B @(" @(#PO<F1F.D1E<V-R:7!T:6]N/@H@
M(" @(" \<F1F.D1E<V-R:7!T:6]N(')D9CIA8F]U=#TB(@H@(" @(" @(" @
M("!X;6QN<SIP9&8](FAT=' Z+R]N<RYA9&]B92YC;VTO<&1F+S$N,R\B/@H@
M(" @(" @(" \<&1F.E!R;V1U8V5R/DUI8W)O<V]F=,*N(%=O<F0@,C Q-CPO
M<&1F.E!R;V1U8V5R/@H@(" @(" \+W)D9CI$97-C<FEP=&EO;CX*(" @(" @
M/')D9CI$97-C<FEP=&EO;B!R9&8Z86)O=70](B(*(" @(" @(" @(" @>&UL
M;G,Z>&UP34T](FAT=' Z+R]N<RYA9&]B92YC;VTO>&%P+S$N,"]M;2\B"B @
M(" @(" @(" @('AM;&YS.G-T179T/2)H='1P.B\O;G,N861O8F4N8V]M+WAA
M<"\Q+C O<U1Y<&4O4F5S;W5R8V5%=F5N=",B/@H@(" @(" @(" \>&UP34TZ
M2&ES=&]R>3X*(" @(" @(" @(" @/')D9CI397$^"B @(" @(" @(" @(" @
M(#QR9&8Z;&D@<F1F.G!A<G-E5'EP93TB4F5S;W5R8V4B/@H@(" @(" @(" @
M(" @(" @(" \<W1%=G0Z86-T:6]N/F1E<FEV960\+W-T179T.F%C=&EO;CX*
M(" @(" @(" @(" @(" @(" @/'-T179T.G!A<F%M971E<G,^8V]N=F5R=&5D
M(&9R;VT@87!P;&EC871I;VXO=FYD+F%D;V)E+G!H;W1O<VAO<"!T;R!I;6%G
M92]E<'-F/"]S=$5V=#IP87)A;65T97)S/@H@(" @(" @(" @(" @(" \+W)D
M9CIL:3X*(" @(" @(" @(" @(" @/')D9CIL:2!R9&8Z<&%R<V54>7!E/2)2
M97-O=7)C92(^"B @(" @(" @(" @(" @(" @(#QS=$5V=#IA8W1I;VX^<V%V
M960\+W-T179T.F%C=&EO;CX*(" @(" @(" @(" @(" @(" @/'-T179T.FEN
M<W1A;F-E240^>&UP+FEI9#HR,D0T13DU,#8T,S9%0S$Q03%$,#DT,$0P,T%$
M0C="03PO<W1%=G0Z:6YS=&%N8V5)1#X*(" @(" @(" @(" @(" @(" @/'-T
M179T.G=H96X^,C R,2TQ,"TR-E0Q.3HR.3HT-RLP-3HS,#PO<W1%=G0Z=VAE
M;CX*(" @(" @(" @(" @(" @(" @/'-T179T.G-O9G1W87)E06=E;G0^061O
M8F4@4&AO=&]S:&]P($-3-B H5VEN9&]W<RD\+W-T179T.G-O9G1W87)E06=E
M;G0^"B @(" @(" @(" @(" @(" @(#QS=$5V=#IC:&%N9V5D/B\\+W-T179T
M.F-H86YG960^"B @(" @(" @(" @(" @(#PO<F1F.FQI/@H@(" @(" @(" @
M(" \+W)D9CI397$^"B @(" @(" @(#PO>&UP34TZ2&ES=&]R>3X*(" @(" @
M(" @/'AM<$U-.D1E<FEV961&<F]M(')D9CIP87)S951Y<&4](E)E<V]U<F-E
M(B\^"B @(" @(" @(#QX;7!-33I$;V-U;65N=$E$/GAM<"YD:60Z,C)$-$4Y
M-3 V-#,V14,Q,4$Q1# Y-#!$,#-!1$(W0D$\+WAM<$U-.D1O8W5M96YT240^
M"B @(" @(" @(#QX;7!-33I);G-T86YC94E$/GAM<"YI:60Z,C)$-$4Y-3 V
M-#,V14,Q,4$Q1# Y-#!$,#-!1$(W0D$\+WAM<$U-.DEN<W1A;F-E240^"B @
M(" @(" @(#QX;7!-33I/<FEG:6YA;$1O8W5M96YT240^>&UP+F1I9#HR,D0T
M13DU,#8T,S9%0S$Q03%$,#DT,$0P,T%$0C="03PO>&UP34TZ3W)I9VEN86Q$
M;V-U;65N=$E$/@H@(" @(" \+W)D9CI$97-C<FEP=&EO;CX*(" @(" @/')D
M9CI$97-C<FEP=&EO;B!R9&8Z86)O=70](B(*(" @(" @(" @(" @>&UL;G,Z
M9&,](FAT=' Z+R]P=7)L+F]R9R]D8R]E;&5M96YT<R\Q+C$O(CX*(" @(" @
M(" @/&1C.F9O<FUA=#YI;6%G92]E<'-F/"]D8SIF;W)M870^"B @(" @(#PO
M<F1F.D1E<V-R:7!T:6]N/@H@(" @(" \<F1F.D1E<V-R:7!T:6]N(')D9CIA
M8F]U=#TB(@H@(" @(" @(" @("!X;6QN<SIP:&]T;W-H;W ](FAT=' Z+R]N
M<RYA9&]B92YC;VTO<&AO=&]S:&]P+S$N,"\B/@H@(" @(" @(" \<&AO=&]S
M:&]P.D-O;&]R36]D93XT/"]P:&]T;W-H;W Z0V]L;W)-;V1E/@H@(" @(" \
M+W)D9CI$97-C<FEP=&EO;CX*(" @/"]R9&8Z4D1&/@H\+W@Z>&UP;65T83X*
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" */#]X<&%C:V5T(&5N
M9#TB=R(_/O_; $,  0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! ?_; $,! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! ?_  !$( 3("5 ,!$0 "$0$#$0'_Q  ?   ! P4! 0$
M         P0' 0(%!@@)"@O_Q !R$  ! P(% @(%!@8*"@L, Q$! @,1!"$
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MX#T.E+''3^;UU\:/5FN-U3_.JS[_ !O]&%?EW#[4D?W?[O6?IJ/56OSJF_\
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M)@JPOA6P5NN4P6.\$D$A1+V-MWYMTP]600I*5),$!3V@AQ<9AKL14TB8$P3
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M;84*[/VE)"2D.0X&\B68& NTASRD6J)?:&#AD#>40&)("V!4[!BAB3ND-$&
M<MCR3TU>A>H6<C=J7>H^FD:JU]E/2_3S>O.D?4[02\WU?GV5UN94664E%JS2
MV7.5%/44F59BMRMJ6O5:9;+S:G?8,-.P[2D$E# .2702-V<E.(NV<2U-':F"
M3NI47)2 X9B3&Z2DM-R&:&!-2ATF](/I9UMS76^7]+=1U6K*?IWJ*ITKJ'.:
M/)<U:TO^R.EC\(Y-E6I<PHZ;*M0.Y4I8;K59 _5,T:@E#SZ@I 5#BX*\$A"T
ML5 *>##D"$DW(L29D7>IL/'1M 5B((9!W&W6WB ";@$L")8$R"]:;5^F5Z-%
M+F_6#+7>KNGRGH%EF4YIU<J:5695F5:29SMXTN6HJ\PH:"HHJJJ75TRJ09=D
M=165_KSGJKU#XRDA3T;)BXJ4[B7.(2$H< D"3<Q&I %BIRU.5M.'A/O$0')(
M)9R0/Y##Q B[,'K=>@_I$=(_2&R7/,YZ4ZAJLUI].YVO(<]RW--.:ETEG>19
MHBEIZUNBS+(-5Y9E&:TAJ*"JIJZE6NB:;J:2I9J$2EP$MVG8\78UI1B  K2%
MI((4"#&1+,S$1,R"Y=A;4C:@5I45;IW26N9-V#WO=A=@PGK%>IJ,%%&"BC!1
M1@HHP448**,%%&"BC!11@HHP45J&@:I5;H_('U"%*R]E)N3)0"B3-P3$P?NP
M1#68-2#/GYSY^G>D-&_PK7'_ %VKY_[&R+R]T?IO."EK=L%%&"BC!11@HHP4
M48**,%%&"BJ$!0(/!$8*0R"-0:\/O3LZ)=3=7^E;TYZ@Y'T[](W4>BZ3HIKG
M1^:YQZ.NM<CT-J.DS_,<XHG,LH<RKZ[7.EG:K*JJF#XJ*=VHJT%!,TA&Y&-C
M[-VL8>'N$X:74E7[T HOI\,M:?A@S6N;;LBL;%*F4P!3\!8P[2ZXUM%F@USO
MI'T.?3,ZB:?]&WHWJ+1FB=$:-Z-:1ZF:B?>ZE9!2:QR)S-M;U^;9/H[*LXH]
M&:FTTK,-?91IS,ZW-<ZS*CKZG)QFKC54^\_7+6LY$]L;"A>.LA3XI2E6ZI07
M\#@J0=WY2J=U)#,8-ZH_X-M:DX:0KX4[R@"E&[\1!#IWR20+OO.XD6K%9CZ-
MW7"GZ']#M =9.B'7RHUIZ/68]5NG6A_2&]&_6^59=U>TSDV75=*O0N?Y-D%=
MK2B:S/1VMLNJV<KJZ7,LTSEW)V<II:>JH7*EE506I[6V-"\?%04$[1[M2\/$
M*]PE(8DGW9)(2S ,D.Z@H,SSV/MBTX>&M1(PPH A*' )<1[P/-R23HTTV:Z!
M^ELWK'T:NH/6_07I+:BJ]-]&>HND-1ZA]'O6^F=$=4Z5_,=845?I2BU[FV3:
M[TH*NOJ=/-H7FK>69D_3O5JGEUM0^ZIU:H\3;MGQ4K3AE#+7OMB@E#P+'==@
MD $, UIJ7#V'%P2DG>)0G==! 5F\@EI49:T6%=8:/K>L72_TLLKZY4?HP>DC
MK;1.<>B+D'2D4U;F?3;-^HV3ZHT]U+S&O=I]9U>HNI%%0U=4K*LO1FBJVCU!
MG+U6K-D/A3[BW",=C8:=H"@<7"03B.2B-X%KI*W)*BQ+D-%PPOX>(K"*?@60
MPA0EY<!DE@TL9F07KFCK)Z$W5[TANN/4?,M6]%]1IZ6]8/2T]'+76=4^9U6G
MJ?,Z/IO2] -0:8USFN8JRS/W#3YGI7-<TI\I<5EM2Y7IS!LC+W':$-NXRN!V
MILNRX>"@>Z4<#9L;":0#B>]0I(A+A)8NRCD=XD UCL;LG:MH7BXF\M(Q<9.)
M)WB$,IW"L0?$ H,XBP"1%0AJ'T-O3.85J=WJ#H;J=KZKTEZ:_HUZ@;UKTQSG
M3F1]0]?='^B72+5N@T=2,@S5.I,LJZ'52LJ.F*I\IS:D>;U5F68!"VU(<7B<
M]K[#O)4E.&@'"QTD8BL4I3B8RL/$92=U((W@I2@X)_E(25-$.QML8A14?CPR
M2!A@E&&%)&Z5+40K=( %F?>!8-[\^AVC,Z3ISF>49KI'TBM*U-!J&K<)])#6
M5)KC6N;*J,O; &6YVQK;6"TT%.ELI89-=3%I $%0+BD:IMJ@O&4M)PBE944C
M"#)"5+*@=WXB$L6"5*+%X=WVS!248&$@N5(PD)+GXB4H +D0Y(D@W>NPFPI+
M:$J,J2A(4?:NH) )]I2U7-_:6M7FI1DFC]SZ]6M4OKT]7X**,%%&"BC!11@H
MHP448**,%%&"BC!11@HHP448**24G\8%DI'LE"5&)&Y2"!!L25)M?F !?!1Z
M]>M>5?.3U;^3PZT]3/2B],/+W--U%-T4K]%Z]ZL] <U<JZ$T!](+J1I+1FEZ
MNM2TQF;%2W49:]D6;UH&8-(;0JIW)E#B%G;=@[;P-DV'9MGW 5I)&(5$AD>]
M6M3#<+NE6ZF;E\B#J.W=D[3M.W[3CA2MP[JD !#/[O#2D$E89E DD@E@6EB8
MQ9]$;TF*/3'H:]4=?=+NN+_42OZH>E3UH])%KH9JS2^E.IFF-1]7\L&G],4F
M5ZB=UCIUAEJIR_*--TF:,9=G+:V,@%:Q4)0ZA2,3GM[9OWH0C"2@X>SX6&C$
M2I>$$X)Q%/[M*$?"4XB4I$,4 R!3L/LC:2,,+*B=_$6M0* LJ7NL"HK,@I42
M"#"\G(J7^KO1_JKJ'J5Z+.N\NZ-^G&='=-^GG7?2>HJ[)^J.34WI!4F:ZJU%
MI3,M/G,M9HZPO5E?DF8M4V9T[.[4+P3EM#34J VRRU3M(GM?92C%C9M[%6%[
MONL08( 1AH(*  5%\,J!WP02+LQ>KL]:"E*_>'=!!W2DK *E*3(=(#*#@ @D
M*-[:[UL^3]ZG^F3U@TJ]44_7WI1H?*O08U5HJ@U'U0U9EV>:CSOK/ICKEFV<
M:)TSU<JZ35>K\UU1D685M9EG5)JE;S-=,FGTUI]KQ6E4XH&687:^S[,G$"</
M#7[S:?>;F$DX:$82L/#0=U'NVWD[CEU?$HN6?=2Y6PKQ2F5#=PR'/QJ4H%2F
M*MZQ<,+@,P8.?2VJROTG_2&] U>CE953>CEZ1NKM-T>CM4TF:*;J,KR--+FE
M-E&IJC(GM(USSM+E.M-.TE:]DKE)F*LSTM3ZB9:?6Q49<I+> Q,; /:./B(=
M>'OA:-Z5.H)62"H G=)4 3\19R2IB<SAX*_V#"#E)*%I =A&(M#$ N 0'%@
M2E, U''R7_07KET#R#T@M'=6]*:)T?E&:]>]4ZAT70:)H%TN35N5U>6Y?056
MH<C\;/\ ,JFGT[7)H*5G(Z2M:1F='2(:17H+ZG?#M=H8N"I&%B8<KW0\@,"4
MJ2A8"5 J=U$.DL%3(:ML.&O?6"!N[VF8"@5)8@R^[O,QC2?6%@E32%$;5$$J
M3N"MBB25(W )DI)*9@<<8P8+A^?@6K,$,2'?0LSC(MH1;A2N%I*,%%&"BC!1
M1@HHP448**,%%&"BC!11@HHP448**,%%&"BO&#Y0'T2>JG67TP?1<U?T\T]4
M9OTVUWE61=*_2EK$U.7-4F7],^D_6W0GI!Z):JJ:MS.@J*DYSG.4:RR.:!FO
M>0BO*7&4MK&_8^R>U<+8=CQ<):$G%&-B8^"M4@+7@HP@ -Q1C=^)BDE*R!=5
M:_VIV=C;7M6%BX9(P_<HPL4)9]U.*O$,E:0Q!#00Z7T!X J?D_/2BRKH-Z;F
MF:[0FH,_7D.>])NA7HLY7DN9Y53:NSKH!TQ]):MZI4F89/F)SFA_!B$9'J6C
M10NUM305:*G2BRNF2VEIQ[+*]HME5B82MQ(2"K$6"3O>\W A$IPLDE:2Q(8!
MC ?&?X'M>ZI+G>@!@G=/S;Q(.([.$[MG<N+U-76GHQU:Z@>C\UHS2?2+TY*O
M-,BZ^>CYKS/6NKO4_)-4ZR;TUIC.\XJ-35/2//*KJ_GRM+YYDV74XKJ:O9KM
M/O.5-7EC>](0%"OA]K;*<9.,</9$$86(C]UA+PE%2EH6Z_A5O)#&S?$2SN&L
M#L_&P\,H6<8LM*F4I*@ $D1ND-(@EV'(/FNK7HW=2_2"Z8]+^E.0:)],32M'
M3>E%H/4NL-8]<^IV7:BUGD.A7M'ZGR?4E;HC/Z?J=K"MRW+U-(:H*MI3^^AJ
M,YIJO+:5^IKJHTPCM;9\/$Q<0#9P#A[J4X6$M&\H%:DE;A1+%4,I+[R@6#$.
M_8M]*4MB/O G>((^( .D!B' &1 CA7>/R?73GJCT"TGKCT8M?:3JOV(]'-:U
MM+T;ZG[,B9H>HG3O4"JO,LFJ*U.5[JXZVTTDU&4ZHJ<QI6EYFIUFLK,US.NJ
MJI6,%VMM.%M>THQ\).Z58*/>)!) 6"0P)2DL$A-N=WK,]GX1P,%>$HN!B*W8
M!.Z0-"I_B)?NM4-9ATCU_P"C_P!<_3EZH])O1SR_5NG-4=)NC%+TCT3E%+I+
M(=/:^UID5%F"L^810>N9?24+>5YI7#-LV-53Y?\ A)]"FZ!3N953;ZG[+B!L
M)UE!0I94H+(4E,?"" 3+,X9@%%V$LQ\$J*V 5O !E!P6<!3.$O\ $\@Y:U,'
MR:^DM?Y!HGJ9J'J_TWZB:/ZP]0]=JUCU'U'U =T<@ZMSRLRFAIVTZ6RC1>=Y
MWE6GM*Z>HF*?3V590IRBJZ=J@W55+XJUNK.U\9&+BX PR-S#P$H2 22!O*(<
MDE[N^=+V=@JP</%"_F7BE1<-< 6<@6L^7!AZ6#DVCB]KVXMY<7^@XQ%9*KL%
M%&"BC!11@HHP448**,%%&"BC!11@HHP45HW3;^\G3_GZBW-HN1)F !R>>XBY
M-\(&8-9HY44:*CQM:1Q^S6OO>_\ :G([W[?3VPNOIH'Z]::+I>^Z7_VUO."G
M4FX@K$)<6V;W1$_3((M^O @I".+6Y07MQL:0\-\#^$/V[^'3$_\ ['Z,%#SG
MR:.]OKR>K5(=/_?%0+S'ATG'(!EOM]LWMASC1)_]T>('K2D<6)EI<C[]:MES
M_C3_ /)4WZ&\&Z3($<Q]3T\+TF^./A]ZJ2Y_QI\?^ZI_TMG";IMK(D?>DWQ_
M<>8'T:KMKUO[)>__ $*7[?8M]F$IV\)GRCE$^(Y578]8>LO>?S*7ZC[$?5@I
M-X27.F7>(?OHV/?\9=^&REM[_F_I(]V"C>&IYM?A;Z \:IX;O_&7>9^92<__
M *'V\X*-Y,S<-;\O.(IFA"G 5JJ'T!+BD_-IB#!-[-CD=B"(/?N]92EH38$_
M/GUZ99VBG8.*5)6 D*E0!+.S_P!I R8$ZP8I-*:CQU2\]X121OV4G8V_(GF_
M':3&&*Q\$@)!#Z?%'4WOR\*A3AX_O225;I+2E CH'&CWUUIV=X$>LO) B_A4
MQGM<>'Y6/>_QAX*2!\*'+22L=\_4"GE.(2P!#&?D,\2W >&D4!<-_6'C<\M4
MON/\7>;_ *WPKH_I3WXE)NX@R41Q"!E]H[PX#&DBEQ))WOW,S_8HYX5&SO%P
M8YXDX'PA<HL21^\?D[ZQ:^E*58J@ $*#0XW&<,\%W)O=KD4E+@B'7^XLFEX)
MFP*1;SXYGF^(EX^S(NI(.C8A-N8MUGA<W-H_I4;6]W%N)OW,>3N$$I /K3P(
M )!:IC!(O?PY[$3,1,6. 8V$JQ0Q (/[P0;%B7Z$.^52^[Q"!\*G:6W7<0<R
M+S$<K567%"/7'5=[M4P$?'8!]!\\*^$9(2"6_F7Y.INK5&K#QA8J,?THOIE^
M5+)0\4@^LOF.3X=*2/?9'','RF<*"D@ !(#,#\7U)\N8IP) !4Y+!P6$M+LP
M$\6>VE4EP?\ ?3Q_]U3>?N;_ %'OOA=Q6GIGS[N=-*Q+/PM]7+9S/E286Z21
MZT]$F/Q=(2>8_)^N0/HP;IT'>,^M1A2A_,6)<CX>N5*I#JA:J>/>?#I>/I1]
M/^C"$$7J7>%W;)OK#GZ5?X;\?PA[X^'2_P!6,)0"+N2.4?\ Q^M(;*DO+1Z\
MZ(;"@GPJ/V3/)/AE1F_Y(2.QL<+T^WZ]>E$N6.0,B<["!WAYDVI8-OGBI?/O
M#=+!^'L82G.P ;JQ)ZM'@*L4'4V-4^#_ .CINW/_  9Y^'PC#TAQ9)RG>^A9
M_34PJ .?AGKF&Z'6JA+Q$BI?O<#PZ7OY>Q)^W#3<VZ.WC-*% @&WTU<B!5Q0
M\+^L/@?^CIOM]B1[OTX2@$6WG.L?H>+/TRIL>_XR\/=LI+?6B?KPK\!X_>FD
MS\_^U_I04/#_ +Z?_DZ0_<C XT'C]Z'-PM^#)'FWG3,K<#RT!VH4H6)VT@%P
M#;V.3]/N[8%,E.\6 TG+J^MGZ4GO"24)!*AF-T.]K^5X.AI0*>( 4]4$=QX=
M*.((N$"([$6/OQ%^TX%G2_\ _(_FW6QRIP3B03OG4,B^D?<5< Z!:J>2#8RW
M2DCC_F&>2/+WSB0'#A;)((@_O-&R/J6U"%.*26W@'T06$=7T\[.>V;>N.F?_
M "-->Q!_('/)F_P$C"[^$N $3D^(>/TU^E)N8^9)N("/L8]/2:@\#9YX\#=M
MI)-IXV=KSR/+OA0<,!G0",CO\]1=_P!+D;%R2KG\$Q/<?$:%JIN? 'X]Z!;Y
ME(1: #&P\6$@3]&%"L+,IMD5M>1Z,A[& F[C3\*I_MP^KZO5I54_DNN%([E%
M*.PW$^R#?OQYC@8<%8+!V-W(*_%@0*:4[2Y;?X?#A<?*!1-4J3N>@@&PI 0#
M\ 3'<_;$ 8-[ '],7<XI'1F\RU(VT#^57!QA#6((YYR32S6\$I54/)<%U(VT
MZH$R/:\.)(@F]I\XQ$K&P=XH3N[P8P5F&XGZU,C"Q-T8BG<O_26()3_+PGT:
M7V/&1ZP_<<>'3<$=O8]\]\(0#].&A'KSISB [G2'/.!;IUJTI<1"34O@C_R=
M,3?S.PC"@%GO+/'JU-W@#<]6%[F0#Q;C T(<_P"-/?R=+_F\*QNQ;5J7?3KY
M_6J_C!S5/?2W2_H0,#'0TA4G^HCI]P:I^,_XT];OX=-_4@_0,&Z=./'N]/E1
MO)>YY-'D_?5P2\;BH?(D\-TT?_L=OU.$ISN()YMSFW"S=*3?2^@(/K3XE:00
M&Z+B8,[T@?"#/D,+TU]=*0VN9L2PZ-#OH8SYU#51XBCZR_!X'ATMN.?8@_$B
M??@Z4T [S[RB&#AAY7N^6O.JEMX$J-34 ?\ HJ8?;L^S@^4X0!X%2%0 D <9
M?N=O"DTH<>&]+]0;D3X=....&_?AP)1#"9F;]>=,3NX@WG9H:<I_IXU7U9S^
M/J/Y.G^G_@Q]'G[L+OG0>/WH*$\>GYAZJ&'@" _4<R/Q=-_FOZ<-)?(>B].W
M$\/]W? ]:6JO@O?\8J/Y.F_S7Z.P\SA*-Q'#_?Z_3FZ"T/I60E]_<6YC92V
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MV5[?WNFO _\ 1B+S86PJP S ")8F_4F&(:HT+<XCJ/S0[0&RCP+G2*5VN_\
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MM&Z\XEEIE6J\^.6H._:$![\( *0F-J5CYR1N!N,:QMG:W:B2?WRC%OA<9'.
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MRB/%RSAX(<Y<2;Y9'I4^DLM!7^WOU:.SA7[.<^OY_P#A "_ ]Y['%!&&"E)
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MU1/I#==$ALCK#U-6VMQ#;H9UCGR5)02%!:F_PC*P%"Y]\>["'9P<FT;\C?C
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MCOY^?:^+:@RB,GB&CE6O88&XF!;\O*GK?S04+*EP+DW/OMY".WV X;4C#2E
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M'*[O>*I'"92@+BY9X #N<CPIM0TXIJ5::=8!*$%Q<>R"4I.WM);)"+R04=H
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ML\8RMF38<AY4BG]_=_Q4?IP49GD/K2V"EKYNOE+7EM^D_G"-@(<TGIN"8O%
MV/<;"_N!@3C,;)\B &>.^)>1IK.0D5I'M"5!>(9%VMH7\=;Y5Y]LO2"A*O;!
M4""38[CP# [VC%]AIX:>HK";.O\ <X;F=T.",R9F\<B>>3]IZ(2HB1 ,P;][
M1V!GR[X&&@[JF]X+L[\8Z?7ZQ60:4E*P4W6ZF0),3\WB][>7Z<1*^8\Z82Y)
M>#(]=T]:;@D2%I4I4JW'SDD @=[1R38=\-HD.)&H>H@ZQ4SE5H_,/#945,N&
MI$F8;HW&7%J23Q"5*D\Q8#SJ=K89Q.SL0,_[M88@%](SO%LR<JSGLSBG#[7P
MB%%/QH$*(NUV/A7&^NZ7+W-+_A%A*6VWV_#<+9&\/.[E[2F;#VH[B.+8\W+P
M%X7;=SNG'/PN>!'PB/*-7KVALFTIQ?9X.0HC $EB3#YAWO:ULJ:='E,BE=;4
ML!:'2"2!NCQ#MFP@GV2#S>>3.,_VL!O8L#Y1D-#Z/=PK(^RX?8MD8&^)DSGW
MJB>)[M6O76&5LT8(!6I*W@TIYZ2?:0A"4A)FPA*9 @$S:<:+B$>]4!=^%O1)
MR);E75=E'[L!5BS%V;,CD[,):I1H%+JZ1</L?B4!A:C90;A.V>\*01%P#>>^
M*6* %J+"6R#F.67FQTHQ#\:FF9;,L.4D9VJK6FRIQ!74->IL&6RA"B'%/$/+
M*E?E0XM0'/&W@8-]OE<$^'+GQYU',26#P2=;O/=%R"6BMSRS+TY< &R"V;@I
M!2D[I)A)N/:)D@&8]]Z&*2<1;DF!<G1/?;TU1*^8^LA3]YMAVQ\-*DH7[:FR
ML7DD^4^T.\_'$;G,GO\ 63TQA=AJ_C>H,U^E+5)45B:EMP!]*"VE.U-D)2?9
MY'$D'F3C())_9\!Q/[R<R"O6_*6Y,]8_';?Q@P(W0X8-\F8.I?N-1'TB==8U
MOFIV[154*U!,E*8*T0J!WY[6!@6QW[V!*O\ #TZ!([Y^GA!KQK^+24CM!99+
M^\NPMO*%_4<*Z[IW%2%K_*5M)''LG8!R;>R+\6QOXD3-Q/ EGCZ5QH$M<\,O
MM.L"G3C;838!3ADD$2+R;#O'G/VX<PTI=XZGO--F5*0XM2A!(V_  C@<>7ZQ
MB9 ^"P9YXR>'"?K4A/[IW.;^$_0/#:6*K,AQ7-TJ-SS+:[_K\??BMB7F\Z7<
M>%[4NR$[U\\[M +7:?":^M;H5_O/=.KS_<IE-_\ [G3^O^C&.Q?XBNGD)ZWK
M>-B_RV$^F=237\4G^6L?<O$=6J?)^:GX#[L%(( Y"O%CY6U*U#I+M$_C,\GX
M?B?HQD-A^<>LS]^745K7M!"4_P"D^5>)A9/B%2T_D)_7]3/GP<9O$^8<A]?7
ME7/B'46;YCGKW>N=#;)"B2391F]N_OCN!!GZK89255Y*0H @&P(^!%^UC83]
MG&)4#X>9/V^E'KUX4 KVF!R2";2+<3Y#X^[#Z*T+J'E%)F^CL\8=94\H,"I8
MB;/T@+IGS$%-CR%'Z8=O2E?9N.E0!=1N-ZR1DW/Z5D,#&.!A;/B(4K#6-N2-
M])*5[NX'E)!;(A[\17ECK=+KV9,()2KQ%A\'E;:45:FPTD<;0&=P M*SCS[V
MGLQP]OQ&9("P6'PA@H$O+Y2]W#-+>PMFVT8OLQV4=XE:AL_Q;Q*B#LZPQ5>\
MF9+6KKKIM4NU-'2I&]8]6:.U0VJ]AH-D(L/9A$R/RI-R#C6^VA_S&'N@!]G0
M"  '/O<02W7H9KJ?L_O#8-B)4058&"HR9)PP23J21>VF9,]T9>;<IRFE1MVK
M2II9]M:H(*I[IB!W$I)YG&NXH+E@""XA@^IMT'VK?L+^$)<[L[SQ%CPGTU+/
MK74-LE^F9VTP+[#C:RA;#FY0(6$[=Z4P%0J022(Q3Q#_ &L1F"0QM$SQZ:FJ
MY$J9KF;<]"8O!/#7(4U*[6/4M2Z9:J-S:G0("70+NB+; "D$'N"1YX8SL6R+
MCD[<,M&BTM1+!HD2Q!=IG@Y>T",VWG*:-:&U4R*IMU263XM0((6WXB^.>+B_
MYL8KX@95FBQYD\-:E 9&18/#N;!N4QU8"L?G]0:?+VZ-H!MA06HA31<2][4%
M84/FV 24BQ ]YQ9P/B+MF6^F?W$7RK$;627#P!KS/W\IAN3^HU31P[2II&EN
MJ2I1<&Y)"B=M@9O;MVM-B3M'8#':\,D _O$L6EB2TOU YVM6C>U7_=>T"6.&
MN!G\,DS.@X\9J=NC"5C1F6)=VAM2GR(/!\4\VX/E./478:4G84$@*,29+,->
MOZ&O!7M7\/:V*$AAOB!&?#7OJ927 @[9*>!Y1]G;ZL7%%U'F=?K5)8^'#']2
M 6BXUMQST,TZIR5-["F"J(XF.)\_MPVHP"78/&?TSBPG+5A2\E!"B;MRF">Q
M /Z]_IPH< ER,H_7[U9P?X>(X 9M' +G.W7*[TJ)+B5&84)'ER) \NUL5<8\
MV?/K:^8^E,P0/>V#,3X@9=P?K7T6?)I?_1M:B8.M=2&_,;:#]8QBMJ^<2_P]
MW"M_[$_RJX;]Y/-A7?U1^\N?XI^\8JUEEOX<>'WSB^9%+8*?1@HHP448**,%
M%:-TV_O)T_ ('J+<3SW^XR/HP@L,XHU]9#UE1HS^%ZXG_EQF,7[?@C(>WQ_6
M^%I,QR/F*WG!2T8**#P?T\?3@I#8\C:_2O@=ZL.I'4_J"=A).K]3&YN/[:.\
M^\$<XOX31:^K2_B6L.658/',D6@\\W/+/@\5'Q_&+2&C)[CW1,&/??[/<',7
MB;MQ ]=\7%5*>M;W%"23%HO(]WPX]Y)\QA*.C>KT\+P1(:&[;8@\3:;?6;X5
MC'&TCEZ[KU9 B;MDS><>A>*6)#WN) []X (^$^\QP?>E)''A^9S[N+TV\$ F
M\'VA]OW^5OZ<#^,57-SG/UOE6&K"XME3:TIC>0F )B]^+V]]S'G@HKE/J*\N
MEJ$.H WBIJF%P+A*DDIO'8 1''(([:[[9X ",!3 $H1%@7'W9M=->C_AIC_Y
MH9^]6(M"AJ(B\WA\ZPNG%-LT_BNU3K2W'6' EIO=N#;(-Q!W01/>]\<_QP4[
M*P;/E*1 B/S->@_8TOVNESG)+RZWRM)'#G8S)D[695M)39FVRT]ERFU_V0E0
M%27 94"T+%<R2"+&\<8U1=SIO$@GC.61OW\17I'LG8RI0<F0"0QN[-<,'A^9
MG*?>G3"7DA]5*NN0E*?%74- U#:@GVDH0L&=I$=_+#2 [/8M/,#[FT:EZS>V
MX@V3#W@EXTD7RGCWB[5.BT,AIZG9RAY(-*@JJ8;0 7D H+B-HA0"@ DW2;#C
M#<(DJ(_N4&,9PQ<V8E[&X(K!;9M/[S 4 ?B"5.8#F1F[,XX:5#.=L+T3F])F
M+#BGJW?3NH?<$-,*.U6U1X41<$_E0#.*VVX(6) E[9EW[SG+WRK=\/#3M'9R
M-Y.\Z1)F EG?Q=G/,UVAI/5#FI-/,ONH?=S%;#"W*QI233K4MI*UH1VB5**>
M.TSVU7;<()! !-Y.;0S3F!G(=GO7)]MV9>'C[0ZD%*<?$2 E)#,M0;C#9.2+
M5%O4XL4C5/=P9CX;KA0%D> A0WPL"$[DW"H$ @V\H=CPP5$FQDG@WY\XT -8
M3:,1"2-X*)&A9Q8BO-/5M0[6ZT3/XP'QWDN225)6XXX""9)!"OJ'U]D_#D-M
M9 $!0T!;3)G=I'E'G+\9"#LN(ISNJ"B 9.[ 8GH\,.5JE;(6U)HTK) ,-D_%
M2>Q^!$#SQW'#_P PGGE_JX37F+9I3B,(^)M89\S ^];&4$@G<J"0J"9%^#S'
MTXL8A+J+9EH();F,^_B0!5C&'[I.C#O?F8]7>NA_19V#TC.@/L$J'63IP)'!
M(U3D<$?43?DBV,=C#X3<%M"8UT9WZ&;5-L#[X+%@03;4V[^_@U?=4+@&(L+>
M5N,8VME3\HY4DG]^<_Q4?<<%+F>0\U4M@I:^:SY3,G_929X)L-*:8CW?VI:,
M?7!^)\\9?9']VDO'D8OW>/.M']HY6O(,<[GOS:-'KS^;"W#!4$B !V5! Y(O
MYF>_T3C(UK&%B$8:!,"?&07OTY-602L- (LH)A(-E3Y$FQGWSS@IQQ"_!^IY
MTNTZ\E<@6<@H-[ CM(L/LYQ"KYCZ]/5M!=*3PY_2W#2*>I"U3*4$MQ.Y1"IY
M'?F.WP)MPVG#O]16NZGICF.0YG1.(0&G*"I&X *.^I26D@&)@E (,F3YVB3%
MPAB['B L^XH"V95]O/C5OLK$]UVEA&W[Q$Y0$YB[&=/.O,S5V;N4>5*R1^F0
MXMVHJ$)6E7MH]5J'60I20;$!N >>";''!NT]D3A]LE0'_B Q=X 9QG?ZVKUS
MV)M:L3L%(*F_= $<@X\IRL>-/.E+X0FH*N5UB4S%_FI2!VX-KV)^G%?M8.O$
M$V22'X3TE^[6MY]EW_8=EL3\9C-L5?.6'TG/K_(@@T0W-E7M@J-R0DKL1/'$
M#RMC1<7^(IKO.EL]?F=L]8KJNSC]WGD3:T!Q^M2C2N45.W-*TEI2PU3J><0I
M2%J6E*Y,^R=F[9/8"/+%3%<K(@AG S$!V#B8XVYTF(!OJ: XX.X&;/G&;YO-
M9NJJG7$T3;3Z"\AYM#@:3X;9V)@>P(%P$R"()DS)Q'$SHWYMH_.Y:FCR?QF.
M%O+*LIE-77O*?:J"&PA:MBU_-<3N44A \P(3;R/)Q2QF]XKDE^!W0]0J^8QG
M] 7]9]]/'JEEJBJ/'4XTZ9VI@D<V@\PH>U]-KC$7&DJ%];#Q:)2'ZL(96ZE;
M3/AI"MJ4 23$D**2H3P._(Q?2W[-@!C)Q'-_YS B,M9.K-C\9M_'UW4GO1G&
MG'Z/$?23^RM<YHZVLJ134;B?:L?8=0F.P'/'>;]SCT![ ?\ =X_TB>A\_I7C
M7\6G_P 0Q/\ U!-[%7IN$-77+ &Y=C$[@#%I,R ./OQT!-A^>O&:XP/OQSXT
M\2K:VI1O*E<WL+@S\ 1]$?!:6D6W ZLJBY(O-K1Q]-\3H^3K_P#E^??PJ7_P
MAS,=13D'VC%H2N3WDM+C_3/V8J8F7,V/+U?OHV.YYCZ5]:/0G_>>Z<_]5,JY
M_P G3]>,=B?.I]?I6\[%_EL*_P N?KT*DJOXI/\ +6/N7AE6J?)^:GX#[L%(
M+!M!7BM\K>H!/24%*E2YGGS21$!GF(YX_P!/.0V+YD\_K6M>T#[J6_I/E]+]
M*\4R?;38I!";$DVO/GWY$\?#&;Q/F#Z#ZMX5SUY)#7-N,GD7/2EAM"#*2KWB
M;S'?C[#\;891PI(D%*CM(@Q<7@1?S@CXSB5%NOVH_/+U^5-E%P)_%P05&;WD
M<><R!/OP_337U?*CZTTKF34TSE*L (K$BG6>P0XVX) [;AR3V \AB/:1O;)B
MH(@GOAFJ';,8X>!@,[?M:")F4J=Q(RN0'KRAUUERJ34-=1E0_L',*AA*HY0A
M[Q 08D25J]P)QQSMO9PC&6L B27Z_<VTFO5G8FUJQ?9OLERY)V>[$_PHY#AE
M?-JZ*Z857]@4:-WM(0E&X'A(0D[1WY*K<'=)%\<X[7+[2 7C!%KPO$,'+]>=
M>A>R$[NR=GI&>R;,=#."D"=9^Q< U.-%5%AY]Y^H=4RTR90F5*EXE.\*)D)
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MCG&T^S_^:1_ZB-,G&4?:W+2/:K_NS&O_  EMW#7R8^%=2=(DU#&C\F\0!2?
MWI  @!Q16)'<F?J(Y./4/87^10-!?@SL_?Q+\*\$^UBB.U\6Q^/I!SXCF[O4
MV-(6M$J !*I@=QV CCZ(\ABVJYYFJ6(/APW+.@-?ED#GZT5 4@E!2-A.XJ ]
MI)%@ 3<>\ #[AA*8 [7+-(=QPY!M/M0ADJ4=]IGP["%)[D_9$S$G!5K +HQ'
MEB.$9%N%S5X86I2R9 3MVGM&X<>4<7' MVQ7Q<YT ?.9TS?AEI46"WO=9OF,
MNYXRRO7T3_)IS_L;&)G^_348OW@4(F.WP^GOC$[5\Z?]/UK?^Q/\LO\ ]2)?
M(5Z .P6US$0>;CZ<5:S!L>1M?I5XL /(#!0) .HJN"EHP448**,%%:-TV_O)
MT^?.A;-C/G^OVX06'(45?HT$56N)B3K:O/T?@?(H^P GWX'OP+> /UHK=L+1
M1@HJBOFGX8*:KY3RKX%^KB'_ -M+7GMI 5K?4R1$6_MHY((',F($<Q:T8S&$
M/A<@$@9@7.;'+B\#A;5=K4?>&3<YQPXZYQUK1&FU;I%CQ ) Y@W'O_HX%W !
MBXX/HW"]S,0+7J2U^N7Z4_9+WC ;;3]EX)MS;N3Q[\!;1HB7SO,VL",WHR[_
M *4X((>B !<GD7@7[S_1YXKG-F9SH^7Y,W'*ART$]]_(50J,D@GFUS^HPAN<
MYI7.I[S2KSA $.(X!,#RY\OMO]F$INO/UZ'F]8*H><V/S?@3R())D'D=I@_'
M!2USMU ;1X@4$)4HN*4H%((DR"8CF?=R.><8CMKXL%ULIDNZ@%,[:V9X:W)Z
MVCV86K]J2,)2L-L0/N$A]7W6<$M=WSX1ID]<IEFH#+.]TU26%B)VI6HID @A
M,#N/NQS?:,5*5D$!@8#!GRB6@VD=]>L_8U P\%*R!O,/C(=1+ N][2'/(&N@
MM+L.Y!ZK1.5#27J]ZGJ*=FH7"$I,* "3(N"-UO:QJ6,0<7$(MOK;EO%N &@
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MGB1:UZVO85A@22S @"9!F+AX\<ZVF@RZE<I]WC.%L E"RT$EPI*D[EB+E)!
MGR$$QC$XA.^38. SEV8%H<3#D<'9YSB""D$9SXL=+?H\4HI+C2S6>*I3*:=Q
M 0!L5(<4@*(!L;""/R8\AAD,P$DD%R > RBQYBG&Y+L&ME?7E]":V'*ENA5.
MDJJ$H<\%UQ2BE2&Z9:D!TJ*I,)E:KF!/$1B/  7M2D/ *>KI&5]':>EZ':&)
M[O!):);NYY<?HYFSTA-*]/M'Y'HM6A]4KSNMS;(:[,=0,-5+15EZFV:-W+4A
M*4+#7BOU6<)(!$BF3N^9 S.W[,C#P04W+.6=CNIOQ%CJ0XTK5-FVW%Q<=25@
MI9; ."% $A)("H!#$@AY9W%>=.OGW'V*VJ<?*=KCY3N(42I2B84I(3(3,) %
M@!'%Z79W[PX"+_O ,F^<AM,YY-3^V,3W>%M*@W\$DD,')0QGCNZ]:VOT?*8L
M:<K*AU(*:S-#"U"=Q2V1;FR20(GD>>/4_LILX1V0E0 A S<!DO<N>=I=@U>&
M?Q VPXG;6("3)66#_P!1F]R!^E=(LE*B2F% (2+_ )VU.Z]P+@_=(OBWAG>0
M[YJ&F9M;O85IZI-F);Q ]6>K]P4DH,&#-Q>_D?OO.)&^WKE3FO>Y :V; \)#
M0TR98#&T-!*D*)E4Q-KR!_KX'U"9'R7EBVES?IZRH,8<]S6G0>LA3Q)A@E,B
M71W(,%"I[]_MQ6Q+/D]N_K5S896D<0/$^LZ^L[H=?I%T[/\ YJ91_P#>J,8W
M$^=7.MXV4O@8?)HM&E2-7\4G^6L?<O#*L4^3\U/P'W8*00!R%>+_ ,K,V7#T
ME [.YV9X[-6D?ZA].,EL, G,3XQ&71JUKV@^0?Z5>5>++X"3LD6L>9-A/ND&
M.]XN>V,OD.N<96@:B<^E<]!DV$G*+Z:$ZCC5J B8*-Q*09 @'M!-O?\  <]H
M/67'\HS[J7N\-!P[_P!75>"0@;2$$<(5R8-B!>1Y7$QSB5%NNHX:6Y94MP2[
MEWX3GWP>FH--RI2DI*S,$1\ "0//X&>\^6) =UP6=FUTT<<^34EN[+C^K&,F
MS>K5[5)VA)!0I"BM7S848*""8L4@GXCW'"E.\A1+P>%BSGG(+MI879M2@G8B
M1<8CF/[=8Z5Y]>DS1"EU8I\,^&BMH:1T*('XQXU=>E2[B52EMM,W( C@ 8YK
M[4X8]WB$V8MW AO"_F*[1^$FT*.XE_EWHX[KCIJ8<ZTIH%9>RVF=\-'A*:0M
MQT_OB'@E*%H Y@-H;4;\J/QQQ#;D[N.H%FW0[9W'-SZ+P?6?9*MS9R _\5:H
M:Y &EH;TU3IE+W@4R32E;BO$0 I0(" K:2$R;@R"8\S[SC#XF;1%[ZZ!WN.+
M6AJVC9<0QJW,N.&D.SRS16U5Y?84M324.5"RAY82D;O#4A*2E0CS2M1!,>U:
M\G#1@[V$I99TJ+DV, ]TOP.H:LIA[;L^&L8>,Q*I&]NQ<:$LX+"\\33S+ULI
M(J6%EFM6$EC8HH#=0DDI*=MT%)]I,&4F"+XJX6VIV7$8M?A#6B.9M?@U/VG#
MV+:<(N$N1?X<N28B0S<36\9EFF>9DW1U.?YI79WF5-2!EEW,JRHKW:9@*44-
M,KJG'5MMHW$A*%)2-ZHYQ8VG;$[:O#Q'E"!A\R')UL_">8K%;-LV%LZ,1&%"
M%XA4J6E@)@-9-IZU%.<5K:$/ @25J*TFXW&!?Z(YY,DS@PS:+3T$F]S>WA53
M:07)DG(-D3F#P!(\JYIU35N.UKK30W"HJ:*G@@D "H4L@7( 4%7 Y@ ]\;K[
M))WNTD%G9:1Q<OK#.)_,&N9?B!C%'9&*D ,K"5G$!CI)ZUWUI-KU+(<L90D;
MD4K 6D" DAH>R+0D >4#WQCTJ<,' PX'RH\@[O<<>Z:\,8^(5;?CS)Q,1R3D
M]N?K6MH2ZHW40DB+*'/OGW'D?J4Q@PPQ_9]=<X:I& +-8\O*ET/$N!)7(@VM
MM!'NO]?Z,0!\VZ4I:XMIZ)]6IP$;$EPI2I,\+583Y"1;[N>,2HL>=2X?R+XD
M!_OPOZ--F]H?28""L2$I-C<&XX)\_=[L18H)>\3/#33T]S4>S_Q9=MYGMG+G
M1LO)Z^C#Y-?=_L<&Y ']VFH^/.*&?U[<8Q&U?..7H\9>NA]A?Y5?_JG_ .(;
MPKOYSYBOABM6:-CR-7#@3Y#!2BP:JX**,%%&"BC!16C=-B#HG3\&8H6Q]4Q]
MF$%@^E%7:-$56N!Y:WK_ +<GR)7Z<+KQ^P'THK=\%%&"BC!2&QY&O@RZKT0/
M4W7;H$ ZPU0HI,1(S5R_Q/)GO],9#")87AS>X#^6GT-8+' <N SM80]G[C(#
MQR)CQ%%#R?"2#W((D F\1,?&;'XX5SJ>\].YW_6JCQ>.!OQ#9\INU.O52#[)
M()/$'SCF;=X^VT8'4<SWF@$Z>/Z-K:W&*&Z54SN4JYN29@\]_H]UY,8'X.]W
MZOI>^N4YC]-1<OI%XGZ4N:>%IFXM%K>\=^8[Q-[X2D*HB]N1;/EG=JO+0O?M
M821!["/=WC"L6=HUH<Z9B<B-1/AYTQ?"=[EDD!![>7'-_P!;82E%KWSC\QZF
M7KG+J.T+G:!+R9BT7'T7M<_3C$^T/^6 S"/"".E]=;5L_LF0G;1ND ^\R8$P
M6, $SI=SE U;IVP^,\4VA025OV['YWEWX 'NFW;'#>U2??*#F28FY4..<</&
MO5OLVI1V5!4HETB#+1Q-H<AF?6:ZOJ="K>?HJIMA?CA@NM/LMA0+JDA7MV,^
MU]N,8-M2  6!#)!.[80SZW^TUW+L?M%*,/!2\IPT)(!_I!#P^C]"]7Y9H+/U
MNN52@I54@*6ZOPUN;$*]H[TP0F."D  =AVP?M^&UP1I\(C@"7C+6.NZ)[02P
M+C>NQ()SYB9,F<P](#2>;OT.;4U5E+5:Q5O!27G6EI:"&UDI]D@( X5ML!SV
M!,NSXZ%+8L7)+%K%F=ST@'.K(6,5/PD J2"X(A] ';,$Q&=JPQH6&ZU3#=&=
MH9IJ1=,EI:OQ[2 TXZW:[2BDJ3%ML1VP_:I22()&6I,V+<+];TTX:PKYE2+$
MDNP+MQ+Q%B#SSCV25^6NEW,&W,OHW&T> MPDM^#3@0I*$F4#PP"!&X" ;C%C
MLH893BG$0DL#*TA1?X6N.D";95@^W6"<+< !+.H  JA0)+7<L2% ER\WJ--6
MUE*]4/YQ1/K=I:7+:AOQTJ4*<U3R DJV*.T*WI002-R2D=TVI()7MJAADI2"
MKX4D@0<@DL)CCJ*YO[28B,#9$DL%0Y@$-!E@;[W^W-JC;I_2J5#JX6=R4+CA
M2P8,"('<CN!\<>C.R1N;!L*0-T_L>S;S?#O$8*"26DR7+YGG7@+VHQ_?=J=J
MK6HJ?M';5LH[PG:,0B[LW(#I71#"2&T-N )2E*4DGDD 2H]S,=[DGOC-8;/O
M, J1O9VB>#W<16K8*P2Q (=V<%-Y#2'<Y3S :KZAA2O#V.)V$ IF/9'(GO/%
MO/XP'X1;$6\ESJ7+FF[0SE@S6 $-($<K9 &IX]&)IW_9&=!"$B$=8^G$D6!
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M3,7'C(63<W (:N;<#Z,-V_A)5LY) D'O8YZ%I8R9K:O8;&]WMX#EMY%IL1<
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M6.7CP%8=P!QS88/ [&2.\?HXPO-L[#-HRS.EIL*4%39B[21>>ZWV J$>IU.
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MK=&\[9EB>-_K70OP]VE>'VOA)3B+"2I)8*.[\P!A\X!AX LU1OIND<]<;;8
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M<4D*6D*2F4I6H$I"A.Z%09O.+24A*0>"2YD@%M,IN-<XJMA_MZ"Z5*8B)Q1
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M>MD]B,<H[9PV<,4Y:JYB8;,\[5!.G\Q<54456AQ!0I*0XC\I)5 VJ(,R.U^
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M DF2$@)%DI&.!=N8(3MN*(#NIFBY<" VO/.:];>P>V*VGLQ&(2ZD;0M#DO\
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MNTRXD$%(7<@$ $*]XL>_E-P?AAN\K4]YI?7YZ32)!$R(,B4W!!$W/T#CZ#'
MCP23M"]]U)< !3D6 SR=K=:;BD>[.Z&( <L'-L_K]6K4M?9:UG&C\ZHRV7'3
MEU6Z@0%A2J='B)@$<A0L0;&X,XA[9WL7"*$E12H-N G=TL'3J6:Y;C64[ 7[
MG'"_D4X.\ETJ!?6#DX8Y9Y<'Z5J5#,E4JTOMM%QM"W(0&T*;2A V;H-]I)B1
MN)N<<0[6V=.'M>T)W$@A>24AG (LE\\KWN#7L#\/-L&T=D[(<59QE!.("<11
M6840'*E$PP:8&@%=H:%>#0:HWE+=2M*5P.8'S2H E)]D  @'B;'&E[=ARH[H
M ),,1ED&#OPX."*Z(K$ VO#2@[H=(W4EA+-"3;,PVIUZ!IJE"V4^$"A,H2 J
M=\I&W:>X)*1:#&Z";WQ"@&,.6<Q-[NU[_:LVHNIY:S/'-G;J-:RU4RREM=4K
M\;X38+C"4 2KP_9WN0-Y@@I[@$ < &NL;I<0" !JU_)@:CWBFQ,@B26@SHPN
MX#Y1KJ-2Y35E 4.MNL!]]1NLJ4T$RA*=Y]K8M* K;( "H/&)$DA"3O$&<S/Q
M?FTM3-TK4=YV+.[F P:;^'%V+P+K*F;J2[3(#:O"6ZGPE$,^"D%20J8'B^((
M<(Y)41(@XRO9Y4I0<DR"[O%Q)@68S NU8[;TX:$%DI!8EP!K&70@OPJ%=!Y<
M%=5\JI3+PH:"IJ5.!&P$E;J[)"2);!2WNY]@7*0!CK_L5AH]\A6X@E_FW0YO
M#@.TL,P<LJX'^*&T).RXV&X/[IB(N1GGX,SZ/7<[-.$H2I&Z%(!!/)"@" 5&
MY"> . ) L,=+VT?OD LT/D"^[E%I<QS>O,VR( *B4I9P#\(:Y<V;,OSI0J+:
M=B%)0I(]LK V*@$P@Q>>#/M2.0</Q "LL&$, PR!RRA[LTEZE+$DL)-^%N?J
MV5(^(AU(;;2Z% J)(-U7/EVM8'@1&&-.7".?68TI P-@' !BUIC/SZTFXRRI
M)7ZP4*X+91N<&WN3<WB9(@<2",%/4D>ZMKH )N/32#2#>W8M0),!<;D[560N
MX/,7M'8VP4NR!.\7 ,AX^H\S#ZY_6UT&,]&^FQF9TEE!GSFF1?%+$^=7.MSV
M2,!'+*WA4F5_%+_EK'W+PRK-/D_-3\!]V"D%AR%>+7RML;>DT_QN>=[<-7_7
MF,9#8?F'/B/&Q^E:U[0?*G_2?*O%H*"8D3QQ8CV;3QP??-^V,XOYAE F^N@_
M2QK1$,Q?^HV) X9'D"+W:J.*2XCPP #)((@$3V)B]QV/:><,B9Y7_+Q'TJ00
M"98"""8)[N!LW6ZS20V0I0F4[8B#-^\WYN>)([2,)2,7U)&3GQ\"QS9[U1.U
M+I"@HS*D@?-O(X$C_P!J>P)XP4H!%G/!F[S%B<GMDT. A!*E@>R3M@W]K\HW
MM.T"#P3/E@,AC(T,CNJ3#2!+!P6=IAFDR0YD"&.M54REMM+CDKW.%*$ 2H!2
M4@[)/LSNVDC;($1VP;Q8I?X&LY8QF+,W/I4FZEPIDE:3"B Z3.;$O$,\RY!#
M^8W4BA.2=1LV6&5--.9DZ[L*8"&5K04$""$A)!*8@3)!\^8>VFRH&WX2L/"0
MA!V'#*MU 2E2QC[0%*("0"I0W7)=3 / CN_X2;:I.S8^#B8BED=I0E2RK=0=
MGP; J@;R2X F>-3#IW,J>K;I&RXZE:U*V/-[E%;?A("=ZTW5[4P#)B(QROM$
MI&\G=&]:  2S0>)S\J]*8:BE>&4J(2=PD.P+D/'%N\ZM4OY6I+2LMJ:H+AMY
M;::A*BTH($*"2!=1223NO$QP)QJN,D@RTI!;)GZ9#,L<RU;2LH4C"W$I'[E!
M.Z ZE!Y+9D7>;,Y>MX.?4 J:!M>YX/K6E:E)@N(E0 <)!\03)E?LQ;D8A;YH
M9VAP[.(=X=QR<7M4F$@!BI*20_\ *"2X%XRN"[G4"^OZ@\)--6);0A-/N2\T
M"H(*75+*2&Q(B4)2+7-^+##P&09YL2')NX&H&7C83;0$?LF,I*4A0)8A*=X
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M_N_O:^]C;SQ6K+&QR@SI5^"A-AR'E1@I:,%%&"BC!16C=-KZ)T_:/[ ;CX1
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M:T;T>:A3^L=6*4XE3:Q3.!2Y4$GQ']I3N,S8"P$  &P&/0'L'_W;M7_^W_\
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M,TS%LG@! MQ-_'BU3QZ,BGCZ1?0I1$A'5_IR!,SM&I\E@V\Q]D38XK[<6#O
M </+N,C#>+G5JRW9+;R9>3]8Z95]O*<R<  ]54J!\[Q0 KWP46]P))[<XQ)2
MU['.+Z785MR5G='PV#WRUMW]]J23FBO6W$&F( 8;6?Q@F3)([@D3$P# XP
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MBYXY@_=YW^Z9,4#>(X)\A=N\R07IR7 8%N\";P'ID\Z%N%(45*2 2G9!(($
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MMM*]I,;ANDW]J\F8]\8;TNPM(YN03S;C2AW<2;S/ZG/Z169IE>*G>F$0/F@
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M)_%[J^A/Y-XD^CBP'% G]FFI0""9@#+B #,B!-A$ V$F,8?;"Y2V0-F(:TV
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M TFC>H$JA2@2 1!VB# F1%^P! [ 3:5!=/(D5!B-O"&B>\WMX1RM5Y),>U,
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MF8 YC@F_?$V'8ME)U$1HP?GSBD5\IG4M.73/H6XTM3N0%A*$DVN4CV?:$B1
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MW3]/U&_O\[8BEK-Z^TCG3HY^'U-(H*5R=J2 ;#D6)O;O'P[>[!Z]/3U?P?\
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M&J>(@N"SYL)CNOI2$ LP;@0 [3J(U_5\BP4%&Y!=4!"X<14H5 B/X2M1(BY
M\KGB&@$3#PP.0+Y7DELIS9W0WSW29/&]Q!X-$P":O)]HJ%@J(4)@3S[1DD@
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M'XY6MGQRKHW8X? Q"3_.,G,)8W>YG745WRME2E0XS4IIPA2B:9L%[Q+>&-X
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M89W0$C)W#& 7'!V;NIQ1*I*;.FJ3UAA+RU&I6DO%;OJ50TAIII3,$);#P4M
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MQ ]MX/X5]<?07_>9Z:_]4<G_ /O5&*6)_$5S-;QLO\%'7SJ7,,JQ1@HKQ/\
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MHIVE2RI/)B 03<SWD]L+@W(XE^4:48C,!8[H(T)CSL_/KIFO"DTS9;A,-HW
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MO.:R>EUEM"&'U$H6'@V%*)VI5N<$" (O8F]_/$N+\SC-(#,S$7#%^? VM57
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M, MMX;U[],A]IM5W8,18 91:U\F(ROP;.170G27-0NBRJI?)\--(AMHJ$;W
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MY/1^]B_G@/O$-6^LXR6PRE7#S)+#G'B*U?VB#H CY3/=Y^;5XF!#P!*0% 0
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M+=<#B*52T5 "]ZQNG8H@"0 DI2"+6!)/>/$0D&PM=@'SL]P'@@.'YTBDH1B
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MEB_#G)VC#Q(U$0!G'7NNYFF>:TZ\GU%DW@ +H]1*>RI]'_!I<;VU#=2/_*%
M6W: 0)*?9G$6(2X!)<!KV9Y@3#@W/4BGK62M()9DA\\R\,P!S8\6@5F!ECJ'
M77"@HI2]N;=4"HI;4ZZTA!"I(3!;(@R !>YE'D,"=8;B#D'\^35:5B?NY(D#
M1F$%L\[:]U:1IK-?V09KJ!\5J$9?D5:,I4PT#L55,,MJ>=<5&[Q%+628($1
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M$&_,$"1[^TXK*4AR?<!BI0$K>"<C]_(U3Q,%2MHQL->.5(3BXB4@E#)2%D
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M$.)AK6E1DD%)!)O!R[OMN&BOD>/15Z>FH_ 6==72P\ZM[U6NUEEE33H4M2E
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MERMH8JIB[)AXJBHYF;YCF.[1GRJ(#\DWZ,)((J^I8CYI.J\M)MP21IX SS8
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MJV*IJNZME=-2KI0TYK+*E-*9C=M(_8NDFUYD&T2 <8A/8.SC9RAOC(+,>)(
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M2E)W0 &0D)$,.?A6]#Y*GT:P?8JNH>T'V0K4M!N2G\E'^X4V$7(DFYG&6"R
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MCM)&GS!O>#]APT[7B/!CC3O^']A4YQ,,J)>22[=%:]>-JO1\E)Z,"1 JNI1
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M;;B$(  &XD"+=S>N5<^_P#85KQ%XF&25J*A\1A[V4)XAJ73\E+Z,"2"FJZE
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M"T]U7T1D6N=-K4O+\W;JFJBGJ4*;K,MS;*JZJR?/<GK6U!);KLFSO+\PRNK
M&SUBC=\-2F]JE% \O+7J/&-:\;?3O]-7JST7]+*NZ0Z<ZSY5TGTK2^CJKJ5D
M--4](<UZFU^K=>?LEJ,II=-M-9-64U71TU;1A;PK/#6VS44K=.=SE4A!VCLS
M8MBQ]C0O%P!B8JL5:5*&(VXCX64H%20R3&ZD%3%Y%];[0VW;,';%HP\8HPTH
M24I]V"%*(^4'<47.1< 6<$.=+TIZ:_I6]:<KU<O5.O-)>B /1\Z)](-<]8:G
M4?3>NU5G.?\ 4'JZSG-?D=/29&_F-*YE&@J3*<NI4YJ655N=,YOFE-3-)6BE
M?"Y%]D;(A24X:58WOL124'>&Z@X845HW]]*-[X5L%$.4[H;=)J)/:VTE).(H
M8?ND@K) WB%D!*MT(*B#O)?=$.^8IGZ1WRGW5G0_0_T:L^Z1:EZ1:PZHZJTA
MK/K/U2SK*W*Q73[/NG'1QK-LNU3DVEF\[.4YHC.]:ZDI_P %:?:0W4+<J<GS
M5JC];:#%0ZW9^Q,/$VK:<)05N88"0Q2^\M(4X91^4*202[!P6W34Q[<448 )
M!*D%6[(8)44LX0Y4I25. <@S BO2_J]Z:6D>F'HZ:)]);),F=Z@Z+UO3:*S#
M)VJ'4>F=,+J<GUIE*LVHLT_".L,TR3+)%,MI"J%52BJ#BC"-K;GAX?$[.Q$[
M7B;.2VXM2# GXB 02;$,0+W>Q:[_ (H!@(6P*<1A<W'S/\+N[IR$.X<.EZ/O
MI69OZ4?0_7NO.E^E<NT7JG(ZS/\ 2VE\JU7JS2.J,E?U,SIG*\]R?,LXS;I[
MGNILNH\IJ*W/*6D=R]68)S@"FKW'*1AIEM;D*]E1LW:&-LN+O*PL+W1=+E6Z
MO#2LF' ;?DA[0'@V1C*7LB<7! 25%6Z'80I8G> @D1.;V%1?Z#'73K[U,ZE>
MD#H/J9K3275;2O2RHT!E&5=4M%Z2?TUIRHZC9AE^95?57I[0U+N8YC1ZA3H6
MM;RW+6LRRVH<%,M]VGS3PJ]#C#>0[3V;9<+#P\3!P_=*45 X;J)*4_(MB3NN
MX*@2[," I*A5/8<;:<3$4C%Q!B-ND**0-TD@E)82((21?XC((;TV:&YI,DJE
M(NH^TH=BH@#VB "8  -A:,8%!)2";E^&99^+7XUF6&0;E'E5^U/=(/Q /WX=
M0PTY\>>O6J>&B9V)GSVB;?1@<V>-*& L *KL3Y<_'!2U4I23)2"?,@3@HJBD
MI6(4D*'D1."@1:&LT-W4)2E(A(@3/)-_I)P4I),FKL%)5($S%_/!2,'?.U!2
M#R >\&XD=X-A]&"EHVI\A]6$  M15-J3RE)^@?T86BJ@ < #X"/NP457!2,#
M< ]*26I(,%0$I42FVXI2D[E)')(W)!)D0 .]RB!D-0 ,Q<^IYU%^F.JF2Y]U
M)U_TH725F6:MT)EVF-1N4E8A(&<:.U8,QH\FU10.M@M+H:G/-/ZGR8H*@^BK
MR2H*VT(<:*BB#H6UT]6[YKB3Y4+KSU"Z ]"]$:IZ;:QJ-#5^I>O/1[0.=:FH
MM.HU974&D=8YU64>H*K*,@\%]>9U[%"V:NGI6D*>JG*84U. X\)R79VR8.UJ
M6C&0E0"2H.2+% +_ !)L%.&+WX-B^TMIQ=F2GW1("B'8"'WY#@@,!)S86FO/
M71OID^F+J',=+=#\OUMF'X(ZU>D".GG1GTI=?](7>GF;UNA--=/:W7'4&M3T
M\SZHHTO9W2YC34>2:7?K$TM+G!J\P99:<?RYY:,PCLK8TX864 *PL'?7@(6%
M!RE4%EE1^)*P"[1O$D BL.KM;; KW>&I6YB8FXG%6F6<!_E##=4%$,X!9FFI
M(9]/G4W1CH-Z8Z,Z](G3O737G2&LT=ICIUF^;Z'S/ICJ_+-6]5WJ[361IUM0
MYU0Y?I',<OR?467YIJ++Z_(,TJ*1_2629A59D[3H#3ZVJ[&1B;9LZ$80PL-:
M-_$ 6%))"E?$#[PDA8 #7N6#&E1VPO#V+'Q%K*\08I"#NJ26*4Q_# ^&3+@D
MPX:NNODY?2SU/U_Z$:Q5U%U/IG5_5KHGJ[4^B->YKIJNRU&1ZBJLI0O,\BSZ
MAJV7O44Y5GN1UF7.MUS2AE_CM5+C=0IE!(Q_:O9R=EVG#3A;R48@06W2\N%)
M8DD%F5ND[P=AF^2[+[2_:=G6K$(*T$@DJ&1<%P "X@,&@G)ZP/HU_*0IZ_=9
M:7I.K0>E<B<JZ7/JO\)9=UOZ2:WKV59*IHJIE:7TMJ:NU&'7FW3"59<A5. ?
M'3+;A$NT]CIP=E&.5.K=2X #?$6OO'= $DD&<P[B'9^V/>[4< ))22IB22P3
MDVX"3!$'3G4$YOZ:/7VG]*G,W6=496UTCT]Z7['HHO\ 2I6G:1>89G0/:-_#
M@UY^R%=6G,?PDG,;N4=/0JI&J$H*U;UR#9NRL/%V?%4H J3@^^"@1_<P^9B(
MN!8M=F-H[57A[1AI$(5BC#*6)/\ *[C=CYI+D P"2"*]OJ=#3Z0ZL!PD)*2H
M00"D$2F$E)O)"A.Z8M&,$E.)@JQ$%9/QEK,UFB#QU,UG?W>*$KW$ONWEY)+'
MED,AQ)IXE*4B$@)'D+# Y-R]."0 P '*JP/(>? Y\\%+1 \A]6"AAI5"E*HD
M QQ@HL[0]^/.JP/(6XMQ@HH"0FP$29^DX**K@HHP448**,%%&"BC!16C=-?[
MR-/&9)H42??)M]''T6M&"U'KUI5^CI]:UQ/_ "VKH^'X&R(>0\I_2><%%;M@
MHHP448**,%%&"BC!11@HHP45&V@NG6G^G5#FU#DB*QYW/M09QJ?.LRS.I369
MIF^<YR_X]76UE8E*-P2 VPRV4I2BG:;:"2 97&VC%Q"D%+A*0E*00 $C-@
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MTXA*4K4H%DIW  $_"2H[V(X)W@N2]JZL+;!N)0LD8*)(W5 25%3J)/P@A!>
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MM:P0M;<J(0I0*MRD@$E2R9*U$NWU ,"6CJUGU:&?( 6%-.&@ER)N^A<%P+7
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M?X2-1?\ :N9V'OFHO^ML+F(!Y^OJ*3O\/7?KW5/R??\ ^4C4AF/_  MF8_\
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GBC!11@HHP448**,%%&"BC!11@HHP448**,%%&"BC!11@HHP45__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>23
<FILENAME>g164680g00y11.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g164680g00y11.jpg
M_]C_X  02D9)1@ ! 0(!>0%Y  #_[1MZ4&AO=&]S:&]P(#,N,  X0DE-! 0
M    &UZ^< 8X0DE-! 0       \< 5H  QLE1QP"   "    .$))300E
M   0S<_Z?:C'O@D%<':NKP7#3CA"24T$.@      Y0   !     !       +
M<')I;G1/=71P=70    %     %!S=%-B;V]L 0    !);G1E96YU;0    !)
M;G1E     $-L<FT    /<')I;G13:7AT965N0FET8F]O;      +<')I;G1E
M<DYA;65415A4     0      #W!R:6YT4')O;V93971U<$]B:F,    , %
M<@!O &\ 9@ @ %, 90!T '4 <       "G!R;V]F4V5T=7     !     $)L
M=&YE;G5M    #&)U:6QT:6Y0<F]O9@    EP<F]O9D--64L .$))300[
M  (M    $     $      !)P<FEN=$]U='!U=$]P=&EO;G,    7     $-P
M=&YB;V]L      !#;&)R8F]O;       4F=S36)O;VP      $-R;D-B;V]L
M      !#;G1#8F]O;       3&)L<V)O;VP      $YG='9B;V]L      !%
M;6Q$8F]O;       26YT<F)O;VP      $)C:V=/8FIC     0       %)'
M0D,    #     %)D("!D;W5B0&_@            1W)N(&1O=6) ;^
M      !";" @9&]U8D!OX            $)R9%15;G1&(U)L=
M     $)L9"!5;G1&(U)L=                %)S;'15;G1&(U!X;$!7_)O
M        "G9E8W1O<D1A=&%B;V]L 0    !09U!S96YU;0    !09U!S
M %!G4$,     3&5F=%5N=$8C4FQT                5&]P(%5N=$8C4FQT
M                4V-L(%5N=$8C4')C0%D            08W)O<%=H96Y0
M<FEN=&EN9V)O;VP     #F-R;W!296-T0F]T=&]M;&]N9P         ,8W)O
M<%)E8W1,969T;&]N9P         -8W)O<%)E8W12:6=H=&QO;F<
M"V-R;W!296-T5&]P;&]N9P      .$))30/M       0 [_^-0 "  $#O_XU
M  (  3A"24T$)@      #@             _@   .$))300-       $
M>#A"24T$&0      !    !XX0DE- _,       D           $ .$))32<0
M       *  $          3A"24T#]0      2  O9F8  0!L9F8 !@
M 0 O9F8  0"AF9H !@       0 R     0!:    !@       0 U     0 M
M    !@       3A"24T#^       <   ____________________________
M_P/H     /____________________________\#Z     #_____________
M________________ ^@     _____________________________P/H   X
M0DE-! @      !     !   "0    D      .$))300>       $     #A"
M24T$&@     #-0    8              4L   )=          $
M                 0             "70   4L
M 0                         0     0       &YU;&P    "    !F)O
M=6YD<T]B:F,    !        4F-T,0    0     5&]P(&QO;F<
M $QE9G1L;VYG          !"=&]M;&]N9P   4L     4F=H=&QO;F<   )=
M    !G-L:6-E<U9L3',    !3V)J8P    $       5S;&EC90   !(    '
M<VQI8V5)1&QO;F<         !V=R;W5P241L;VYG          9O<FEG:6YE
M;G5M    #$53;&EC94]R:6=I;@    UA=71O1V5N97)A=&5D     %1Y<&5E
M;G5M    "D53;&EC951Y<&4     26UG(     9B;W5N9'-/8FIC     0
M     %)C=#$    $     %1O<"!L;VYG          !,969T;&]N9P
M    0G1O;6QO;F<   %+     %)G:'1L;VYG   "70    -U<FQ415A4
M 0       &YU;&Q415A4     0       $US9V5415A4     0      !F%L
M=%1A9U1%6%0    !       .8V5L;%1E>'1)<TA434QB;V]L 0    AC96QL
M5&5X=%1%6%0    !       ):&]R>D%L:6=N96YU;0    ]%4VQI8V5(;W)Z
M06QI9VX    '9&5F875L=     EV97)T06QI9VYE;G5M    #T53;&EC959E
M<G1!;&EG;@    =D969A=6QT    "V)G0V]L;W)4>7!E96YU;0   !%%4VQI
M8V5"1T-O;&]R5'EP90    !.;VYE    "71O<$]U='-E=&QO;F<
M"FQE9G1/=71S971L;VYG          QB;W1T;VU/=71S971L;VYG
M  MR:6=H=$]U='-E=&QO;F<      #A"24T$*       #     (_\
M #A"24T$$0       0$ .$))3004       $     3A"24T$#      11P
M  $   "@    6    >   *4    1*P 8  '_V/_M  Q!9&]B95]#30 "_^X
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M%=PR#Z\:_IGC[H24T;^K]*]5[/VM6UU+B;JV/J<:PP[;/7VM<ZBJIWLLMO\
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MK=S&^Y_L:_U-G_!^FKZ2%))))*4DDJ'6^EGJW3;L 7NQA<-KK&!KI'[CV/\
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M>&M%[,H2UP;=4'E[07U;_=[K6?I&8_\ G_\ '*V_'ZP;'EN96&.+O3;Z.@
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
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M,N$C0E+Q%C,5)%-B@J((%S1#559RE%0F-41S=).RT]08)39C9(22HZ32_]H
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MXU-LW@;M@\["MC-+%[\6/B,;9(L[LI)"@G>(2,/77V2 H90;Q-*W1I^WPO\
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M.Z!\$K7Q+,:\ZG+Q3B5 #RPV.IC7N[KZJMX)@V'0!Y/(&2_R#=N7J8VB8/\
ME+)LK:_# ?AVR2"57K !R_ZQ4"B A\(D$ -5NMQ&IB!D=E(/)@N+S!<"&GPN
M-9)N=]@N&TL*[,PN@  9GS&F@;$VL;NY&0K:NF()E=\ZX;GI--O-CUEXL9 Q
M1?JC>B#B6:/F58#,68A&H ZSVY6-D>3'N?,JAO#Z@,8"CAQKW>_9YQS6T)(
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M7$<;,J9Y.J^"(^(:-D4*J4VDQ6'H-4Z>^=M_&^_)+6$R=AS@S?D1'K-ME9C
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M]=I4^?1K\$[3@?@MS@+C+SY&R;D69O&2LN3T;4Z5F^RA[%(1L6E)0A546*U
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M'9+,H[-7=P/: GUB\F>HBS$,N"A2I)E AD^QC%G[=]IV]/*%3]S/Z;V-^4R
M;W'A*B8EZ.+'",RL91:9?SG:1=JY#+<HVG%MF\X_+"6W+[C+'J9OSX"Z&/2Y
M!>6:0W+X\E7CLFFTD3*5X6%/H$FPC0Z\O7=)F^W/QV([Q%N\;B5:#C5Z-D(M
MB3'+/G_)>3I2\PZ-Y<:(_C1220V\QMC1WRW82"-2R50(S-!4I,ZR0\'>74D2
M-+I/,2Q@) _H6I5#K=:+QV^!_O?W*D>7EX>6VDS:#=207X#X;-C?,>+0?YV#
M#G*-XFC$MN/;+2#E:-.%8C"X%&A9M,9$[<URR0UF2E2RQ52W9@.!"('$O23E
M;]M-!-AX'U5&J^CCQT28W4CMLMYZL(^')"QY7V^-VQXQVC"T,QV\Q1F[D^%.
MGC4L]?&2Z?5'=12.2>:R=$IWFY%%,"6T?+8H'A;Q-M-?'?XZ*(OS&@'=8D^'
M=H;!5==<$\<6N,L/P&+3[+$ ?./4SF$TQ-EB*OD34R2Q.T]6D8S-N2-(XU(X
MJ\QZ2(S5V9+IAD,7NT2I)-"?AJ#:(KGFW+XJ>=]R1 ]]X.YE5/BKA=B_$4FQ
MQ,6-YGCW+<?*9P<KQ_EKJS.;ID.3<BGB$O&3I?-KA*/I=;Y<7,%8SVY8JE%X
MX0YCIJ61R'$+:/?N?[I[^/GX$_)<^>>([%FZ5V$^LLHY=Q%-TH))<6OLJQ \
MQ-I=)7C20N]N\/$&>S32,3!"V0*[(>LQ:11-.*S**W:UPM:2U,HDMS3[UV.T
M^=_/P46(.FNL1! UUVY@_*5LD?#&#OL$0QBW3C*\(@C)#<01+'\6@DD:&-NQ
M9=X4>SO<*F4(!2.KC[RDN09RR9*4+2B)RFUC]C;WD0$45/'BW?XSZF(&MS_9
M!)Y#P$]XO.D'YQJ"N]C_ (LMN-8OF>W:\KY1D>4LYF/>3K.$NO(G>9%5>$8C
M;PR/7#0UL44B^/6-"'LH)^Z+$A$B6MN*HA<DN (!B.8YVU^TV\/)-A!!C8ZW
MTY08L)'U5 DX#XF;YWC%^B[Q-HK%L81_!C'<8Z:KMH-$YZ7C@ZR20X/=I$ZN
MK#<RI.00Z2RZ0/J]Q'Y1:I2RY52)- NA4 #N5KCWOY^6W.(/P @1>QF">4R+
M[%7(Y"<6&[D%*,73PF6\M8<E^'BSL(9)<4WT-;G,$Y\SL[._ [!-X',4E$C(
M,Z!$T4T4=I@8YU%/$ J+NYBT<SII\K'O"G6\QK)C8:B]M=]N^Y5"1'@-B6)%
MASBI+<KRN61GD67E*^9#F4E;'::Y(RD;&LAQ"*LX.2,V[ >.FQS($XT,;B,9
MB! 3CT>!,R0VQSJS:_?'E&VUO6)UM!7Y^^[6('/<7F9%N6WT9.,B-2V/Y!G3
MDK,\(+RV13.]P \S*'V6*'=QDLW?)V],S\G&,=QR3/,96D#PHK[NK2TJ!3H@
M94! #>&]Z^>GG\_(!?74DQ:_G%^\>1MK(7ESB*3Y8Q>QW./"67X3L09(Q]G'
M%]HXW"MDV.4MQD](O)(JZ&0$ZB=M*X^=[BJJG25- CV94YT4R&.,'QO//76>
M<_>%(V@1;X<MC,<Q;Y^*X<1,</#%-F*YOY@D7(_)N%\KI'MY9#.%A/H6\X]?
M6%H9K@D?$$HZ9;%L?35M2^-> !GU0LJ/U%/0B9]V^7EWP)43'A;GYZ]QF8V,
MD*1Q\88W4.LLKC^#J+W :N%SQ1C,=4  0^,QK,3CV$?,_F/4([I Y*3Z=YT^
M845C>C^XI$R;>9-;L0P./NESB.589OF2&Q&&PV.@T3=0IGQ_33C<91DK=.S,
M9C1@DFM92@J2)OCU:>KB54%:) ^H,]T:B^U_JO.@7$)'!5\_Y899UE_D9ER,
MX8O\38@M\S2V*[B47341>BPEG?(_&HDF0\N?FB-A*\AS \JF]PDS -S*5$P4
MME)Y_<?76!L/+DJ=/';OF=0#&MR8CO,2KS<5,.7N N/^-L3.;JA()+'FQR<Y
MH_)$ EL]3V9/SU-9V\)$*81$EY.'Q[73ZA!3P5"F,5,X]!(]V]^_)5>&T^!U
MY0)G70B_.\CJ*4HB41*(E$2B)1$HB41*(E$2B)1$HB41*(E$2B)1%TKLX($.
MN(")2D-OZ?F]/VB&@[^7?6NW<:L. ;695.@L>[;O-IF %(.9A:+SIS[];;;D
M+Y\)3Z/6 O?,)?.:UKCTS7<Y1;7B[Q:..2C"[R"F9#>V0>67W@$C_F"3Y%-[
MSA*3 (B'248:8>YO4F=,RW@]+A_75*CV4:C757]JIF?FEK9P@&5I<6L#G5#D
M#9<\@N=R?%>"]?5-0L:1F:0RX:8(L8K-,N$R6EL$F(U/T#MMR%Q:HKE* %.4
M 'N'Z Z=[#Z!]H=_(:\KI5,35 -2GEU!.9ATN; 6UO8QWKJBVBPPQ^;+8'*\
M=W\WUF5Z1S"  )0WO[0#M]@#YUD$@:E4DN/Z1WS(N/ K4!$0[EU]FP'Z_P"P
M/IY_90$&X50 %@MP?=JA:#J/FI2I1*(E$2B)1$HB\<$3DLS)VZ72IU";HZP-
MV#>PV<==P'?GOOJ@J"JX2Z1NZ-/*!.RH>P40?RPN3F%]9L?UDQO] J.D\\C6
M.V*]?9J\V,8:6],5;IT<5^M$B?PCHPE(8@"(]@ !$1$=: 1W692P=7$EK<,#
M5,"9AD<R2\M'I Y7(!UV*XSAL"QU7B[V4*0.7/#G23$ ,P]-[B=X:TD 21%U
M&P;O+?(I0$FT'S#V)U-[=% 2LLHS"R5$3%,UD$"&@K,J0X:6NBDEIA3!1(E@
M!]FVN2APATU!3KU@V13LZFQV6.TW^(UUR0 YNP,,-US?6\0Z0@A@J8/!N<"*
MF=HQ%:FYQ<,A:*18 (!RU#$F75NTT2#@6-8AC%E08(FPV#39IB6X,E:I'0&Y
MO3"0%;]RO3=9G1U5,F!E%UU#JJ&#XU# 5(Q=5C\<_B3G.J.+NT#.C  >R&M:
MUL   &7%QU)!<9Z;@_!,+PVBUE)H8T"2!VZKGD9G/JDU'%TS=\9:9LQI :!=
MFL-;)*(E$2B)1$HB41*(L(O(+T??)K.>;5VMTD'&JRXU./)3&G(L)JU8\]V>
M4#(M!>E0(.FZ,,=!BD/28# EDR1R<\S!/9   Z"4]^XGR^FU-^\::03YS8#3
M2\@Q.JI7 /HQ\_8QSWA6VE\ZQ6Y\6>+N:>1F:L*6S#8R@<LOKIG03ILC). 6
M%.-,P1('J0&3?8P0%%>H0.F1-4Q@><7\;?N@F3\ =]_A,6D01N%<?DWP4S%G
M&3YNGS*E &I6SO<+PG F.K:0OD/CSYAMDR9!,K\B&6>N[#&A6CC]GB1L"L8O
M;ME+) +$8_&"G,94Q_#>6]KCO'O3O%TG^UYM!._P$^,2%/#A3BC(V#.+>',1
MY9DZ$OR' HF9ED#W9N;W(FTI?:CJNSLK<\2'3TYML985&B-6REQTJF19T0[
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M9WAB3.Z=:2:K))/;;6,3D*@)6<G!9,]H?J!5-&-M_>GGJAUTY1KM<FTGEXD
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MEDY'4LK]X(>$EB12])T5O6?&(^?P]Z)W 6%M_#;SG4B)BPF\&/N4N3$<XQ#
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MQ 2@ ;'>M=JZ"A^(_':0'\3#U2/YZN&8'':#U=.DSE$,!/,A:JMT-X8^00X
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MCF-IWF'&L+R!+AL/=6&2>:,C')GHSK<G:VP&9C=;E*ZNAN%P.D1.W1$PJ%,
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M ^76JL<I3&[C\)2F/H!'6@W11/A!T,S^P'G\2OGIY!>F[DF09.?"OH],5O\
ME&;N1E;1&?.,6=7.W%$#*"#K$8CX*9CVI2"53W@E(@1/1P4B*Y2B<?8>&_AF
M_A!;BNF50X6A0/6OHL+',>R[LM:K@Z]9X;D S=5D+2''.01'!5^GF!QI&'P#
M34?5AC'%M4/SNRM :TX9L]NU,9HDB!JJ4PWZ'/.W)&6)YR](WF&0/[S?"%RE
MC=@D!7-Z)8FV)F![E::@,498@#I!2-XR1*)04 X3500$E5\2_$#A71W/A.B6
M$%,4V965ZG6/HN)@NR4\72?4)$N$U#3RO[1%1IAV,SHKBN,/_,XNN]C'NDM:
MUKJL%I#>V7!L::-)(&6V9I7T!X<P/B7 <,LH9B. 1R 1VSV(6$>L"6!KM0R8
M HY.:A1.J\/"HI%%5X>SK7*IRAUJG*.C>/5N+\5Q;:E;CF(=5J.?^IS:):,P
M$Y6X9F2D"!+^K:P.<9(S&5WN%P&#IY1AV98  ,U1FB",X<^77T):2+!@A7I5
M\0$BFM3 F<1\NDINP".]"IL.VP[!H=#]@[PB"ZGFPK\I)':C-(!N(J:1?:RR
MB' P38"P,6F-]3S^H7?ZB_7^@?\ 961F;S^!^R)UE^O] _[*9V\_@?LB=)0^
M7]_]=,C>7Q/W1:]@#Z %):)'*YU/+]D74147$?B#K#8AYD+Y=]]@_HJD5&N'
M8IB9_JCYCE?X*D->T@/=(B]AS(VVWYVVE:G6.41V/3H=:T Z_3KO4S5()%*?
M^-NOG"DFEJ7#O[!^Q751754'9B 37;>R&[?3I* !]V^]:_#NXHYP&)H]4TF[
MNLP]3OF*=[Z1K8Z;U9\/!#7!P TAXUV,CQYJ,F6,S1II>+B!Q1C#)>1+BV$%
M8DVHIFLF853+D(Z3QX4 [3'V83E0 Q5NI]7()2VEFN!]I]9P_AM:LUIQ>-_*
M4"V6U'T'52\$2T,ITRTG3<L$#,QSM#RW&.*82C4.'I4?S%=XRFBT52T3;-5<
M6.IAC9[3B6D$97/IM*L@V>C^PY-7B]G'(?&V+<F3%QM#6B38,#:T8?&&Y;I.
M=J:VU83B]J)J&/X<@D95I$)2E*D:W3Z42[!_33C]&AU%#%5W,:XD9ZE*I4L0
M1EK5:3JF29(9G#!<92#)P\#T,PH>_$8EE)SWD96TF=53ICDUC*X#I;8O<)M+
MRYQ+C1$I]#YZ/B8$6%7 MA';F[()ANH=(YA&M=Q#L@RR%%G)K6@*9$PB/R =
M5-+\0.EC-*X:)T-+ASC>)-L+'QT$05M']$.'.:1D=3@W J/#YY%KJSC&AD [
MD[J)TJ_W/UQ/=/6+J)Y"SC#[@2["SM'V,O3=H!$.C3\P7%X;SW_EXGP[$W?>
MNHH?BYQFJ?\ 6<%A*C!M3:*3Y_\ 6YE1N]H:8DWV6IJ=!VTF@T<36:XD@-+:
M3R23( 8*K(,?[T:0>=AG'T V3H;<'OL(\R)!'[E/?JI'.-/4>O@[CYOL-G]O
M;!\__P U1 >_RK8-_%8Y2Q_!VN:1#FOQ5)S7"Y(+3PXB)C8R8/-8%3H=CLTT
M\<+:N=1#"T[068AQ)[S&FBVI<#_3=XM*8^.^8MK-+"T ?4[!\S#.W1Q,0! 1
M*#7-&%6-:V(]CG* B(;[]AL4>._AUBWDXC@[J+C=S\0<4[-S_P GK''8 N$>
M 5RI@>FE!H%+&-K#DQF" $=]0-DD0;=XCG2DOSQZ>_C[$9"_Y.BK7(H9&6%P
MO)!,UV#"3V5F;P1.L[RT1@4D+)%4XLB4ZG@FB9@43(902: :SF4?PPQ+VN;0
M:TDL.5E;C(%@7!IID!N5P%P&',)(-I6!4QG3J@2(S"#_ "<+(%PTF8/Z20+D
MB2 X20#E#E_!C!L2P@]YA8IO-+?,D?@3EDBVY:&R+)G"<.#\TL7MU28NKK[R
M>P'>,O9$]*1E5,\36C2BB)"$1,DHCYC@\<^O593AKJ+W]6:.5H#F.EL_H#B*
M8!<[9X(8&@&5VV,P#:#7/:8>UN8U0YQ >"#$9R.T3 ;8M,DDD$*>/&V>ON3\
M 85R3+&T&:4Y Q5 YB_-?A!JR=9%%6AX=;?H*&B%377,F5/?8 3)W$O; Q]-
MK*]5C?T->1K^F279!>^4ES9B9!\\[ N<ZDQSI+BW4ZNB 'R!!D!I!O/JK\UA
MK,2B)1$HB41*(E$2B)1$HBB-RP_C_%C^=KB_^PIQ1%+FB)1$HBL,YW')3VBY
M>Q6K"PM/K8"T>TWV: XBWB ])74$8_X0+!WWZOKXNKOK>BC?^W<3W]Q_L5TE
M;WE*FEXGLG!!A !$2E=<B'-V#?YI&03^>_, #R[]]@0D#7Y'WO[@J$V'\R<I
MWS+\A*K"7*SM\@FZV^VGD?R,VPV*"RMA#*$ QR&%C,N?13E$ICJB;O\ 'T[B
M^W?^WIXZ<S<+?+47[O?.5-[UKE-\F; W_7T^_3_Q%4J55$-4S>9W F0+7&*3
M%ZD/Y2(7<I5<O7=Z*73R@FEX(!W$>QQ =]0&I[T_?P4<N_F8WTY^7E988LUL
M#Y&<W9;]'&TV+@$6YWY@C&<8\Z6A )913"LF,\O'+]F(<5"$((ON,#@*'2(*
M*<B$! 2&(7J$[>[Q)UT^RC2=I[S87] ;F9$$PK63WD!R+;N4&4H]9YHC&-)5
MCGE= <78>PK),U2F-F>\1 G!$V5J9N*,&X_R]?+[1E*.OCY(/PF)RTPQ(3]?
M5$QC F.VU_;O]\KH)F")T),1ZS?PL+VM!BIL&V^0<5,/'W)\<S)E/U;+W/WF
M9B658RN) 'X)_<?VWS#D/B,\-,4AAD(2;%3+)?>,3#*]/#^?I[@0HZ2-]/O'
M+XV.Z B8&VO(ZR/&2"?3PIJ(\@'5ZQW@&VY!<O<A<9X@7T;6),SP*61R5,\-
MO\J9O>+A_";.I3#L<IO\209(@<F,"$+[X#.@*,.("@G$-[BWEO'OFIF#>?3Y
MVM?Y^EK3YGRM'GY6/6F1 QMB?)?,/F2\3[(,GRO?\1C/<TC[)BTT'B+OD]HQ
MUE(T"?UF)_FLE&-']U2R\(^!DI<D,85B=)F#S(TC<^GT4: QS)[MK$W)U![]
M-++)G%IM/I_Z)')TPR9,VS(TD<N-?)!/W[:BR"Z;)5'6QER*UPU[)<O<$Q8]
MO9E6%%E.:3GB46-)P3&6IB1.^(<9^WOY&?I(*<C,:$\H$:G0ZQ-M=X4">/61
M;65\E?1]+VN?\!<I;UGQGD:.!",%PEE89'@:P>,#JG=YEE%U8I-+?;<?1%@)
MC[W=E"4/'WSD-N8#^,D8$(Y?&Q_;X>&NDWOW:7[A%[FW>+@[KBX=9=PGAZ2>
MCOD^>)]CG'$/<O152MF;'/)S\QQYKOI&.9<4/)&HH2)1 !?4F%H>550 W68I
M%TTRG,<A#.4SO'QTB;?'4:J ;C2_GLVT\XGR .RR3^CA%I<DN74YQZWW+9@+
M)7*F22O FFT&N+/D<-C?'C%,Y;!FW2'_  'E.36:;O[>( D10RMSX92]($(Y
M_;O^>@^R<XVO:;S:8W$R;<I&LF%F&;B?3C&?H[838Y7R=C2^Y*YHY@S;D2\X
MV>!B4UDDX9B96FCZS.;P4IE&D]K.60T<$I"E$4F8MJ0X#L2(\=_8\!<_+<S\
M+CQ^>YMWWYVJF'VG,7*>#\</$-DG)+(U_$Y-R-QR\2N$\B<1XG<GX<5\D<KX
M^A@3*VGV()0=\D"L9C3$9206W0110?%.055%!-.W??3XV\ 9OI'G$$VG?4B/
M"X[R(TT/@H]>D2:N53KQU(SY;P?FM\PWA[%S3*UI+?Y9P9+;UUSR^Y'MF,'C
M*+Z$DQ>_R"/8KCR@+0LT3Q6?JE\@3EP"J:'10QH\/#[GWMI*"9VTG0S>;;6\
M1>+@65U>6><>-&2<AY$XG.SUA[C/D#-$9Q!)><V2\T9$Q^UO^/6P6J/BRXCA
M);F1JL,RS$=@+NV>8BJM"X,F8\T*O<S($?#:#Q\>8]Z1WVLF3'@0+3XP1XSN
M(MJLAT 569_2-Y_8(M<&4BTKXL\>,CSU&W$B;<CDL)UF""L3OLH& 7B5XZ8+
M="X FP4M(*PF.?0&W,B3;6?7;[>N\0B-^6QOS)B9)^<<[Y!ZA5)1$HB41*(E
M$2B)1$HB41*(E$2B)1$HB41*(E$2B+K$Z1()3I^& ]^GK$^_KW#N'EY?=]*H
M#:=$0PQJ0.T3._ZIYZ]ZMDNJ@9AE%]P9VVB-U3,BDD;@\?<)%+G]IBL:9;<;
MQR?7YR2;VRPL4NQEG1U=3D20( ]0F.JJGTB)2B83& #7FX?$8Y[:=)CGU'FS
M*3028$GL@-AK1))@ "238H7T,(TE[P&MD%SRXD$EUP0]V;N[1G:RP%<H?3@P
M5K=QQ)P[A-_GW)KE?J-#1(C-[TO"E'!02*$"*-3 49#.54A,J@JBB>.I%\$B
MUHM)2J"B'H'1[\/:55[7],\;4X;1I%SLU.F*U2JT$D,_U"M7;3:X#*'!KGN!
M )802>6Q?2=F)+FX(=87=G.\$=H'+F --KB"(+07-($AP)F(]8^]%]S7YRR:
MQR_Z0'+4JB<9,)K]HQJWK-))99-ZG@_O:TL) 5@6, 4\0#'NTK6[EXJ%5+<*
M)"4QPZO'],^#]#'NP_0%XK@M;GKBF]],N<P MCBK*]2I#1#LL,+0&9Q^E:(=
M&,1Q.J,3C*M227.+7&:@&=SLC&]<QC().00P-#LP:!"^@[C[Q/P)Q6BH1;"F
M-V"'6BZ8BYNMG8EO)"]'#1O$>WTXJ/CRJ ](D!==0"].R 43&ZO(N)<7Q7$'
M.JXFI(_EIM!:P3))R@$$W,N<YSH) .40.ZH8&G0LUESJ\G-8#3]0.PG+'.UP
MI+"3Q"A_HZ$==M]A^S8!^G[/M&M6S3S^@6Q!(,A<M5J$HB41*(E$2B+KE4V
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M>/[^?-/=_?\ >.^1UEXO&[I.U3N8\RW!+,!"S+<-3>J2S >_2B0R72D&^VD
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MD=])\_6<_P"9F1'?!N%/7R.3?CI"T*VWQ6\Y5!33B&->H#-)]DZ32')_7,D
M43,JE*+8P'#HJG'."]#,^&P5&GC<1&6M4H5>QG:+"I7:W$-<6N<6M92<_JP<
MG\-D+3T>'\1Z5AM:J]V'HOAS&O8W,6N-BQKG8<AKA#L[F@. )S$B5G<XP\#.
M./$-A]5Q% ;&VDEY9IVCO.9$0'S(#STI_%[5?M **!E2$,>/1X&&-)F!0;:T
MMP$IJX'I!TFXKTF.;B=8.=ERM:RG2ITVV:T=BBRD3,2XO=4=,AA:TD'K^&<
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M]!N5+I[;Q1,0=CE+[94Q4QJ9+34V4ABI83736[@!2>>UGNP)RTA+>R!)!_4
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M27NJ4W#*!H&R7&)(.N+:VQ5Z3STLUPD\98>PX[\8+ZZ\9!@/;.T>9W)M GB
MBTQ4RB<HGZBH"F89-+E20X1,*T,,;9U2]G4XCT*_"Z6X>.)XZ@'8:J:?YEE9
MA>.TRHZJ,328W,V[6G,"6EK#$K04N'8OIBPNXH*E"A_F,:Y[G,):2&N:*-3#
M7[XM, W!.;+A]Z,SC!P_1L'B'0]25Y(M+0A;C*$_Z)#+SF/H3 TF,(LD>*
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M(&UT($..P 1(&P&K^'PCZ[\K 2XFQ[,7U))<   9M,Z $A:_%<4PN#8757M
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M="*,^C%]$'<X?Z@OD&568_+YC#0-L1$-@&JNNQ'"ZK6C\O6HF;EE4/-R!<U
MYP Y-:)WO"H;A.)4G$]=3J\FNIAL=XR/8W,=.TXC?770<O9;C0&2F^ )@2W3
M 0]K8S?XGD9N,&^_2VK*1*6"'VDBBH!O6Q$1&CL-A*I<ZGBZ<B#EJBK3&_\
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MA$A;G2V34 2X[87S)R%]92'U64,4='&F*^L.QNO)F5R1!ONB"/<IXFA+3AL
M*GO0AT]/HLS#U&4^,XVAP>6ESBX5,?B #=H;1P=1^9KC$N+J<;RM%6X_48_+
MA,+7Q7: !!ITZ'Z;%[JM(Y;B.V,IO>"%PEBO.G+HB65Y-QIQLBRX'$8_B&.F
MRGD@4SI@045,FY )91!J,4H!T&9<27)RF.<P775WK'>>$8-Q- 5,:YI!S56F
MG3@$R<KFCK(-RVJP\P^&B8I5.*8QH_,-IX<0;,=3JOOO+6]FQ/:8\Q'Z8(BH
M67@+@0KC:R/)UK+N0DQL@W:2;D+*G;*-S8"J0#"+-'G94F/(\)#?_HQ$K W<
M>HQNH"A9?TOXA@Z3\/A:C,+2)(ZO"468=IS$DGK&TNNS$ RZF]CHU'.Z>C&
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MB "<SI@]EN5Y!O)+MH_5-_FMC<7Y2>G!S0C,YT9UQ#PYQ_(C(M;9:K'!M5Z
M A&N+*)$*2=9$,'225R!10(E$P 4R HH!XC7L-+B& Z 89]"E0_-\0JL+W$N
M+7O<0X,?6+&U&MH,)RL8'ASAF +GE]0<0<_2:H'._AT6U&LT) =8EK213<7
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M#>\Q<F]A?01=1%4S]*LEIBU<;XRG,4$"BI=9:E7KD;QHV=9M=#.A=VZ;]/5
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M;+/U"PLT2=BIHH$,)2%#R$2AL1$QAZCB(UI:N-=C7FH][GO=&9Q$6&@#<C
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MS.O:]I(.*IM?6>RBT2YM,!HJ-+2\-80QW'](.,N:?R^'O5<0PEHES7!W\A#
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M"0<['8=U5\Y'L;4(#7#+#V&%)J/,S-'F9"P8[*S9VNQ1+;VMBWV86UE:E((
M":21"@0A #\TI2  "(F,/4(UIJF(J5WDUG&H[4DB"!W90! !TC2VRZRAA,+1
M8*7"J75,;+6 $QH#$52+VNXEQ).NL^^F9%2V,:X.!TP4T;X3ET/4 !W)TFWL
M//6@UL>W>K3V!Y 9KYW[KD?O,*IX>QI&)-Y!FV^G^7.T?5>K17?!*(E$7D/+
MVU1]KOWQZ<K!K:&NT->NCDXWA+.RL;!(ICJWBRQQ%-,A0 0*)S$ XATE/U:
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M(E$2B)1$HB41*(E$2B)1$HB41>9<W*5O9GN5S%MT+<#&6$1V4H  " F, ;
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MBL\<H;-Q1OT<.1F]R(1K*8KC-7&]+$L4,W@ 4/$<<A/B/AOI2E$!4-#[25&
MGQ*^'^<.[P_!7/+>O<&9R13ITIK5ZEA=M-A+LK=3V21_,&BZTN(XV*<BDW/E
M +W//5TJ<WA]1S0 206C,YK'& PDV,"KR:9\YD.5Y&L42&TET5(?U>0Y,M;%
MWAW%Q@2 2).K?#PZU,E<CG_I%<BB9)5%\3JE.F591-4AD![&A@J/X?OIXCBU
M%G7EC,13PM9S!Q)E-_;IU:E&G6QOY)P:7YF$.K97 %U&HTTAQ^(Q+^GM-U/A
MM9S,.UPIU*],.=A'/9^NFUU6G@W8B'"F6O;#0X$Y7L<*AFGQJX88CX^JGF(
M>=93N;0MDZ9,DS:WI/J1#%*11JBC6UE(QPI@$Q3BG'HO:VEN5,_2L:X.4J@\
MOQSIKB.E%0TZ+^IPU/*UE"FYY&4 _P"?7KT:3ZSC$DN#&P)+"1F73<!Z*4.C
ME+-7<:U9P<75'L#'$ETMZJE2K56L ; ;E+B2.R0T%JFN82" %\71?]7PQ$/L
MV(]_/RV/V=ZY.I1?5$%VAOV1K:=Q]KKJVU&-BWG??R^>_DNM>VQ5T2I^,*1>
MQ@TF)^KOY^8:WV^?G\OE1M>C@VCK# Y]HW)U[(?K?NY:*U7I/Q &4Q>38>6I
M%B/W7IU<U5T" !R$)12E$2B)1$HB41*(E$6@B >8@'WCJB*VLHS#C"%K"C*)
MW&&:XZ>UG=.R N&]CO;:D)[H  0'XO#W\AUNGT[_ 'ZJ/J-YCTT\K;JAAY 6
MSMW@&-,KY!*H4/ O&Z)FC+"<_P /447J>+Q1(!* [$2E5*/?0=.A![]^OL*5
MN.[<EG_2K;$\88[LC%_-DSX\3V1%-H._L:/$B["&]]BC,3Z$!*8?(PN7Q'OG
M81XF=%'/7QB/G8^,1R7"IB&?OI16FN=)_?#OLUP&T9\<-0AWWHUDE=2</EO<
ML\^WEL*GN]#$>L3/OP4:>/*22?"2-M3]EZMAQUPVU7 .2D$;9$Z=(@=SF5RZ
M31P'8: 06E"[^?>]C\)0 ![AOMI\/OYFRF3]>_<Q8'E'?XJ[_L=L,WF:3M]B
M+4I;C;K-@6B(V)R"  8HH"3H,00#0@8@[T4W8P;J$CY1W^J\)GQ[ X_>F<V*
M%1)E<S@(&<&B-M#;>:$-#^Z+6T35[['?QZ$.P@(42X[Q\9FVI][<E6-%*X4N
MZ?F/81^\-:^OE_LJD?J<?#F/>G)%:K*65X'A:*N$TR#)VF(QUL3%2]=7>\\!
M(! GPIZ.54SA?G\,")IID46,/<H& AA/FX?#NK&S20-X,:V),M(:9)@7,6OI
MJ^)\4HX"F:E:HUC1.IY22&,#'29$91E L;"5@@RQSIY*\Y)=>X/X41=^C,..
MJ6RD$^N 2L'OU53J)[8OW94@'@S&?8%(F!PEAQ(55-/UDZD94]1PO1'"=#LF
M+X\VD]P$L8^IV ]S2X!II5\1UA&K<S"3E!:UKA*^=N)?B+QG\4"<#^'[ZC.'
MASV8O$M8QE1S&O%)Y+.)X7 5*5,.N>J,C/VJKF$3-3B+Z,O%7'=&RGT^4)D_
M,76C?*/3DWBHPQ=R-H5"Q-K$^M]9QT_//C71C)$.@2/IG4M1YWI!TVQ&/>[#
M\/IG"84,#,@>#5J3^LFJZBTL806C*PQ(/\1P<0/0^@WX4<*X"UF++6XCBY&:
MI6+ZK*9+ 2W)2J8U])[Y-1S8:"[/E;3#FR,J-HMX]J?5WXFA H*^K]'0'R#P
MQ*7?D.A[_;\JX$Y:K2)L=;&=^?SN#=>ME].H9HMZO06<YU] 9>.6VB[-MH4S
M "_BB(A\?A^'KR#73Y#]![_7O4L8VFW*T;DDR;\M2=%3%1MZKI,:0! FWZ?=
MUW*K4I1$HB41*(E$2B)1$HB41*(E$2B)1$HB41*(E$41N6'\?XL?SML7[_ZA
MG%$4N:(E$2B)1$HB41*(E$2B)1$HB41*(E$2B+01T C]*@F 3R46(Y@KC$X_
M+M^P?9VU5ESR[03!TD:W0 #2RZYKE%)(3KB5),@[$1$3!V$1[](=OG]F^P:\
MJG#.JUQ)IQ)($.:[3PCY6U)A0]U.B+N@;V)^4SH?10(SQSNQOC)B>[]A>V&X
MM&.X%N?<@2MT%@Q;&G02BJ5K,]J)$5G#Z ]10BF-DY1*A4TFH@F?I*;MN'=$
M<=BLCJK'4^M!ZFFP,?6<,KG"H]AK--!A+2W/6#6MJ96.RN>P.XWBO2_ 80EM
M-[7%D%[WNJ-8 '!I#2*+A6=>8HESL@SLEH=E^?G(OI"LS\E,D(0+AUCN5YWR
MD%UIKR3*(F(1N+ 14#E><=8A4-[ @:9-=*>1<FFE$M(0ZULO[MHG*!?4:7"\
M!T=I.K8^LS#4"V:V&HNJTVO!D!F+Q@=4JU6#,T-I4S1I#/4HU/S5)P X"G3Q
M/2*H T.JU<SFBM4%,MIR,A=AL-FHTJ;R!F?5<'U"6LJ4W47M).0GAEPC](MQ
MJ<IEGI_SCC+(.9LNVK/9Y#Q1EIVEU\SWS.P>*I'S&R;'CR@8].(H5TN8V!HU
M$)7"E$W544R*>&0#\!TBX[PCC&3#T,-4IX?#D=34H4FTJ;!$AK*66FYE)[0]
MS@YC'0S,*9ACEZ-P7@]7A#75*E3/5J":A>YSWN<8DN)?6)?F(!+220Z,TDQD
M;PAA'+Z.7)!R(Y$2*#N.3;R##BR%0[%I) ICK'<&.^A)'^WMWR3"D^/T@E;^
MW,"TLD9XU%DS(QN/VEO9F2M!(ER%:NQS!2IB6R'G-^HS! @M#7$M(+&W$-+<
ML!H6WH4'-=G=(<9: ",H%P;YG$7D.(#3)S9KE3F#L !]*U9 -BMJ!  Y"%M
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M?,Z"!FAVP+C(6;+AWZ);B_Q*&QDZ;!^%?*]B?UT,DSYO:W"_;G,@(F.:&,H
M9AAH^*4Q$;E%-23="PD7E%ST"H'EG'>E&*XL]Q+6T:3BXBF#+@''-VW]73S]
MJ["QK693#V.LN[X+P&CPT -.=S8&<@08@ M:'O+0T#M YG$MD$26K*N4.D/D
M';R -:[B/R[:#?R  KDY#A.H//\ ==$2 .0"W5*E4_))7&X<UJO4I>VU@:4
M#Q+YTND[1 OEVZE1*)A#8;*4#& .X@ !NBB-M!W2.?*/W5@QS+-9\8+;",$7
M=&Y0@&_"-D--TC4)$/B*)FIK$A)(_E,( 8#((6Q2"(E,8Y  0EPR?J$1J)FT
MQL3KZJ!VP8W[B+\X,1X&T +EM, DDMP@Z9HE[UE5QMQ]9MH_<"$;QPW*E*70
MM4+9#I>M!\)2'&5W4I4,3?2;Q!ZJD8C^F!,;3FWDN+2Z;WF]XF-(ZEHC4F3,
MDB#,P+Y8&VNV@"ONU6ELU6R%A8-ELW65L3P+6UM4T;>UMR$_- B:12D*'?0
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M2H)9"]-'Q?BIE$(G83O(RHI[1N61C.P68J"'YAT9NC&7[91$-^&P+%[@)3G
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MB"&N>)!!!));;CJW N'\3QM2KB'-<*1>QF5E9C^L:)+7O#V.J9-6M(+!FAA
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M<2&2* (; X#= D B/Y(!'OK>)\8Q.._S7-#0 &TZ3 UC0T '+#"X@B\.)$Z
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M(/*?Y:_>;#GZ=_X9^WV>8C\P"EN9]!]U$N_I'K^R#R>E^@UQ!Y3B/S_>;#@
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M#&P/P^&^G,\U5!>+/'%F)&0:L)XW;TH_CUQPFS6MK%FQ*Q;\3237M^ H6!4
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M\G<E1*($*'04I0DB_D#ZA1)D=Y=/E8?)2A  * %*  4         #0  !V
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+E95*K2B)1$HB_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>24
<FILENAME>g164680g00y14.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g164680g00y14.jpg
M_]C_X  02D9)1@ ! 0(!>0%Y  #_[1=T4&AO=&]S:&]P(#,N,  X0DE-! 0
M    %UB^678X0DE-! 0       \< 5H  QLE1QP"   "    .$))300E
M   0S<_Z?:C'O@D%<':NKP7#3CA"24T$.@      Y0   !     !       +
M<')I;G1/=71P=70    %     %!S=%-B;V]L 0    !);G1E96YU;0    !)
M;G1E     $-L<FT    /<')I;G13:7AT965N0FET8F]O;      +<')I;G1E
M<DYA;65415A4     0      #W!R:6YT4')O;V93971U<$]B:F,    , %
M<@!O &\ 9@ @ %, 90!T '4 <       "G!R;V]F4V5T=7     !     $)L
M=&YE;G5M    #&)U:6QT:6Y0<F]O9@    EP<F]O9D--64L .$))300[
M  (M    $     $      !)P<FEN=$]U='!U=$]P=&EO;G,    7     $-P
M=&YB;V]L      !#;&)R8F]O;       4F=S36)O;VP      $-R;D-B;V]L
M      !#;G1#8F]O;       3&)L<V)O;VP      $YG='9B;V]L      !%
M;6Q$8F]O;       26YT<F)O;VP      $)C:V=/8FIC     0       %)'
M0D,    #     %)D("!D;W5B0&_@            1W)N(&1O=6) ;^
M      !";" @9&]U8D!OX            $)R9%15;G1&(U)L=
M     $)L9"!5;G1&(U)L=                %)S;'15;G1&(U!X;$!7_)O
M        "G9E8W1O<D1A=&%B;V]L 0    !09U!S96YU;0    !09U!S
M %!G4$,     3&5F=%5N=$8C4FQT                5&]P(%5N=$8C4FQT
M                4V-L(%5N=$8C4')C0%D            08W)O<%=H96Y0
M<FEN=&EN9V)O;VP     #F-R;W!296-T0F]T=&]M;&]N9P         ,8W)O
M<%)E8W1,969T;&]N9P         -8W)O<%)E8W12:6=H=&QO;F<
M"V-R;W!296-T5&]P;&]N9P      .$))30/M       0 [_^-0 "  $#O_XU
M  (  3A"24T$)@      #@             _@   .$))300-       $
M>#A"24T$&0      !    !XX0DE- _,       D           $ .$))32<0
M       *  $          3A"24T#]0      2  O9F8  0!L9F8 !@
M 0 O9F8  0"AF9H !@       0 R     0!:    !@       0 U     0 M
M    !@       3A"24T#^       <   ____________________________
M_P/H     /____________________________\#Z     #_____________
M________________ ^@     _____________________________P/H   X
M0DE-! @      !     !   "0    D      .$))300>       $     #A"
M24T$&@     #-0    8              0$   )=          $
M                 0             "70   0$
M 0                         0     0       &YU;&P    "    !F)O
M=6YD<T]B:F,    !        4F-T,0    0     5&]P(&QO;F<
M $QE9G1L;VYG          !"=&]M;&]N9P   0$     4F=H=&QO;F<   )=
M    !G-L:6-E<U9L3',    !3V)J8P    $       5S;&EC90   !(    '
M<VQI8V5)1&QO;F<         !V=R;W5P241L;VYG          9O<FEG:6YE
M;G5M    #$53;&EC94]R:6=I;@    UA=71O1V5N97)A=&5D     %1Y<&5E
M;G5M    "D53;&EC951Y<&4     26UG(     9B;W5N9'-/8FIC     0
M     %)C=#$    $     %1O<"!L;VYG          !,969T;&]N9P
M    0G1O;6QO;F<   $!     %)G:'1L;VYG   "70    -U<FQ415A4
M 0       &YU;&Q415A4     0       $US9V5415A4     0      !F%L
M=%1A9U1%6%0    !       .8V5L;%1E>'1)<TA434QB;V]L 0    AC96QL
M5&5X=%1%6%0    !       ):&]R>D%L:6=N96YU;0    ]%4VQI8V5(;W)Z
M06QI9VX    '9&5F875L=     EV97)T06QI9VYE;G5M    #T53;&EC959E
M<G1!;&EG;@    =D969A=6QT    "V)G0V]L;W)4>7!E96YU;0   !%%4VQI
M8V5"1T-O;&]R5'EP90    !.;VYE    "71O<$]U='-E=&QO;F<
M"FQE9G1/=71S971L;VYG          QB;W1T;VU/=71S971L;VYG
M  MR:6=H=$]U='-E=&QO;F<      #A"24T$*       #     (_\
M #A"24T$$0       0$ .$))3004       $     3A"24T$#      -0@
M  $   "@    1    >   '^    -)@ 8  '_V/_M  Q!9&]B95]#30 "_^X
M#D%D;V)E &2      ?_; (0 # @(" D(# D)#!$+"@L1%0\,# \5&!,3%1,3
M&!$,# P,# P1# P,# P,# P,# P,# P,# P,# P,# P,# P,# $-"PL-#@T0
M#@X0% X.#A04#@X.#A01# P,# P1$0P,# P,#!$,# P,# P,# P,# P,# P,
M# P,# P,# P,# P,_\  $0@ 1 "@ P$B  (1 0,1 ?_=  0 "O_$ 3\   $%
M 0$! 0$!          ,  0($!08'" D*"P$  04! 0$! 0$          0 "
M P0%!@<("0H+$  !! $# @0"!0<&" 4###,!  (1 P0A$C$%05%A$R)Q@3(&
M%)&AL4(C)!52P6(S-'*"T4,')9)3\.'Q8W,U%J*R@R9$DU1D1<*C=#87TE7B
M9?*SA,/3=>/S1B>4I(6TE<34Y/2EM<75Y?569G:&EJ:VQM;F]C='5V=WAY>G
MM\?7Y_<1  (" 0($! ,$!08'!P8%-0$  A$#(3$2!$%187$B$P4R@9$4H;%"
M(\%2T? S)&+A<H*20U,58W,T\24&%J*R@P<F-<+21)-4HQ=D154V=&7B\K.$
MP]-UX_-&E*2%M)7$U.3TI;7%U>7U5F9VAI:FML;6YO8G-T=79W>'EZ>WQ__:
M  P# 0 "$0,1 #\ ]+/4<3<0'.?M)!+&/>)&CO<QCF>U976[Z+[*"PTM>QK]
MK\FV_&+=WIC]&VEK'W-=M]__ )FIX;\*B^JZWJQ8156'8#[:A6R:F-;^BAMK
M-W\][GKEO\8#>F9G5<.WU'Y!=BNVBG$9FLV>JT>J+/M6-Z3O5_0_G_N)1!-:
M[^"\B()%'3Q=3;3.W=A[0S:+/MV5^=._:SZ;=WY[MW_;B*]V,^ZR789KMK_2
MSEY'N>6[W5AH^@S[56SU;-GZ;'7FV3A=$;D/%]^3CV@C?2.FUUAI@?X']H?H
M_P!Y"^Q_5W_N9E?^P%?_ ,D$_P!OQ_YJO3X_:^F6>D]QM-N&;'.<7-.9E1#O
M?[7?F?IG/_1^EZ:=WH@M].W$TVN).9D
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
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M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_P  1" $! ET# 1$
M A$! Q$!_\0 'P !   & P$!              $$!08'" (#"0H+_\0 >A
M 0$' @,#!P(,"P\/"00+ 1$" P0%!@<A #$(05$)$F$3%!46(G&!%Y$*&!DF
M)S)"H;'!T? :(R0E*#4W.%)4X3,T-D1&1TA35UAG=X*6\4-%559B9G)S=9>8
MHJ2RUF-HAH>4MK?2UW9XI\)D9823E:.EIK7&Q__$ !P! 0 " P$! 0
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M+*!1>21*"8N\R/7BX!YE]5=8K]P^);M)Y!(;@0E.SVHHB;V>H:\L\@)R.'B
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MM>GH.H+T-5Q):/;+;EEQ2L@<-.2VV]? A=50GA5] I!0/0E2@B"@ 1NS@:J
M"Y6Z7),>DFLBV#T-RW'74ZEHQPT ;UZVX6#I2PI"&G*P![61\\[U:$-'%E.C
M=:EKPAHG?UV/<!X0U 7/.JKQK8T561\T-37)4=0K9>ON#"&GK#/?GWO"&B47
ML:WJZW[$-%H/TVJG:R:BZ&B:*ERY8,B![ZJJ0AJ"B\VZP3QM9C<60U+]9ZFM
MWJ5A#3+]"7XY CZX0U'K5<E2[*K6T#"$-31^_$\'ZU.B&BFGJX:Z\=:PAJ-
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MW:8@8M<E$9V!W7XA>848(*Z@D?10Y( K]WLX&8>*_"%^SOQT8H]8W:E8&+
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M4U2%^)[Q%29V[>"GV&&'HN'/)NSA@NVJ6>-0(##T>4U'BMK_ '_,2 #^M\!
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M^N+Z%:<2%S4S;ZKIZ/+.6JGJBJ6:/;++- NZ4==]V7B]L-=O+FVRX#><JBZ
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M#Y@!,Q265220?-:*G:ND37&FFEFE,LXW-G!FE>667S<*02B4F8AMZ8DB::8
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MG;;9K)."J8 &,*@V.D,RBFE*%UJMD#*"4$=?E20B!$7)!7 )"D=T)D]5 "8
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M^%YI]BN(Z%Z%T0?V,/$-1*7[_IR."PY^3SC4SUXF*KSC_&4?R\_'4?(7A/\
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M09MR/L/MFBY);&B&2 :RK"N:;HHWK;KA*0/0.W;4"FX3+4G[60"H "&4)4D
M AB6,= X@JM61SJRHS4N#H8YVS[-6Q=1T=0,;6]R*]I.IY];B8SJHY6)W1DO
M9@)HU.K%2.>5JU))_3K(D-O;!,W/K:F+STLH'V)ZD^O:D@:O%)O+MKRK3T"
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M%EI6ZK#R>43FJ(53Y_S73Q^/]#^=)^;$^(U'4>KTAVYUAW%7<G.=TZ[(@R?
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M_@J#A[?X2R?,&U;',&1#/AXH+*;22!' LM8_4/A]A84_P9? MM!?&Q.CO#C
MG)O)L_A5BS80Y':,5DNI5XWZU[3)6TU]M].IOCT-&K?V>T/"&H8M4.E0$*BV
M0;@A!>$-337J7NOK$(L6;YG1_P"2I=_WY\%_EW!1!G6.>O(>L]TORC:P?0-?
M2-%R&42Y!5,GENR<$[[;)@J  2 BXU2+O1\G0L2YI1&=!0(8X%AII5; V1E.
M7O!4').6EW!7)%_*I2C*%*E2-0QE?J.;$18$&E(AW %4LG)R A.V#MN%]D)T
M.I\=-, C#UJ$1Z)HSM9!4.H ]??0J^CZYU+4DEFTSCQ&0,1%>:1?F<%,X6+V
MEB[=>\!@D%5'CCI2SD2@6^=0.0%JEU49505V&*NS+:P)N6*N66)66OH&4P$3
M-94_B7Y$VE<&(2:0:J2?NB.1R/%202J"3BDLAU<5"*C"E6/O,9&N:ZT12S@-
M7G6VY[+_ $1.(Z#<KY"'B_U%N5EY.0$P@1 "B@$8UOR[22)20A(E)" ("/.5
MG"T4DLJW,D@EK,5R0W(#<(ISN-C'1/D'\1#@DHAY'8*1CF@.V0$RHXQ-FLH%
M+'T>M+K>)!.9!OV&R+DS<8OV9/:W?/88RI]5?FYE$K7S03=%,H&V I)SLNV"
MNN<9I;RRD[Q=!F5<AR392X#K$!$*45='<EZ(>U3$OY6L74AF+Z.?5%"Q$+$R
MZ,$9%1DW(W!*)DE-SUR"$4-Z44$N2$2JA10XHI<>CF7<A73VOV<[)2*U2U81
M\$3-:AG<RBI0(OS)&B9CY\F?NN\%9!QA<$<R#GQ=DPMT[AE)(+GQ@&A)!+$Y
MAZJHC <.]':[NB )4BI:,M2:H8F?&(?P#B6B7PD7B+@XP C)**A\!L-RBHFM
M#$V79Y4<DL2-V?(J$$U5O10K5-=P+<JR9W6Q=05+9#*JP,SE,Z=1+^4OO.(>
M$C!!'F4** -B4 "H, IW2 1J[7--N "JN&J$2R .@N:%TC3\1,',RFX06(NO
M#)]%B8CHV'EL-$QL>^AH>'AMO/ A4*06>84DH&4)Q@'[9LLTPE(<.H<!T1CG
M3161"4GQ)4$$@A0X7US*[@ /U%,'T?,HR>E\_FL:8E_+(W/G6XE4]0-?;*O0
M@!5GR@A,=+&QMT)+* 9OQ0 B $^;4($4H@ +1N4=J\+=J/W$9XAW <NH?R$.
M(4X_4B((#<[JJ^SDCGDA3[/%VC:"& N"7)5#5=UE%0I?.D1D"ZAR4=$- HOR
M=($;HBKA4//*X*G8(@&4().LL015$53EF]%)L$05=3%HU,H;@$0_J=KF1S8\
M#^+II%XU][-4IP36.:&!YE791>0N+6 '+D %*?#./(^ 0&'X+;+^#B[:;U\I
MQ.-X^P_\HW_KD\,OQ?!Q_P#^U^A>_.+?HKLV>#*AJDE55TW9:%A)W(O4D04P
M>U35LU;>BB93<"G:?$V$\J5_Z7:AI'=.M628ES$,M.WL,&@T^IBEF(3WGV4Q
M\/HV;"WQY."%D,HWD./+-O"<2! ,24*#>= )F,GQC#.YLNQ80E3Q8VH [QF7
MQDQ-@@FWE64RH\I5"@R79#@@X<N'RKY96ULZ:JYS4DAHZ8VXI%FJ[L7?N!([
M?T%.YK))M.J+MM3]PZ]JNG*!IM]$T_)'S4BI."ECAGT+#L.V2PP]#<8FW'&!
MD,XW2?.25#/, "#-,)!O3)*%0 H $E ;5Y'V@->C-U-&XY"_#(]_Y_FNL! F
M 0\_J[TUA'2_:[K/?"XPHSS ^?)UBQ2)$FL?7U'2$?-AVWW92<3G:$73L56=
MA(NUT+)K>T)4],U&:_JR:T[-#,)U.Q.';4D,/3%4@ L,,=YIIAGNE6 T&6&3
MKT?0730V(3;Q03$$K*A$V[+*A PIC225[Y(YW-EGEPS,)R ?Q26( 4S '="D
M.J#,&OB*X^AF.T@<O7#]S.N'F&B(2,,7"1D)="=AH*B8:MP"-@0B $G":[GQ
MDV6\A+@UGLKG[4*T-2<XMX^7.Y4(1Q^8[+:J-!_]#,=H_%OG[]_.>'J)B8F-
M,9&Q43<^>$QQ:ZAFW!0Y)4D@;($ +XR;,*2DVK/04'WFGKNL1X^7Z54)8V1/
MFHVEV>L2X^AE.T:_V2X<_A<^>?\ TUSJWQNP/H3?ES_\",GEN@ZA^9'=^AEN
MT=!_;GAQQ_A+GS63_P"K;(_ ??I\;<#Z$V7I3]7WB).W&QFY[F=6P\K)SB'Z
M&6[1W_9GARRG]<N??_38_B\?"?C;@?N<S?A3]OW/ZX>7&\Q.B2N,C]K]6=XC
M^AENT<_V9X<O^<N?#_\ YN@_,8WU'QMP#\R8M]*>FOW/VF'EQ^E,G\7+_%,]
M:\ZF'Z&6[1P?Z\<.2K_=,GR?_#8_C!\%P^-V!]";+TI_^!$^7'.:OX%'_O?!
M></T,MVCJ?MSPY=?W2Y\/O\ R;$_FJ!,OC;@!O%S9)O3_P# B/+C>:8\I!E_
M>SKV:P_0RW:.G_7GAQ_YRY]NO^+8)^8VU)\+< 5DF'\:?^C]L/+BR33:M+UM
M(.%5UI#]#*]HZ-YSPXX/*Y<^/N_K;^]=QMJ/C;L_T)E/X<[_ .@AY<<YDX2A
MM/,-+?4\?T,KVCJ+Z9X<>?\ 7+GW_P!-P?O$#X$F1X6X%I)G_"G/5]S^J'EI
M;SC:TN5OM8H5' M>('Z&6[1W/Z\\.7_.9/O'_!M^ Y3QP^-N!]"9OPI^W[G]
M</+BB+-E237^]O84 18?H97M'?\ 9GAQW_NF3[PRGR;^_?&V=/C=@?0FK]*?
M^C]D/+C]*9>$E?Y.E==&>/Z&6[1W;TSPXK_C+GR9_P#5OCEE<9ZZ?&W _<Y_
MRI[_ /D0\NF;SIM6E_X8X=MTB!^AE>T=YSGAQ7PN7/D^];?\U\,OC;@']CF/
M\:<V_P#E\H>7'Z4V5)-$;<XWA^AENT<Q^O/#EXI<N??'^ML/!%V\4T^-N /V
M.;\J?^CP.W&QF_F\Q][*:5U56B/H9;M'VC^W/#F0.7REST#9%7Y-L=$3X9*3
M)X6X /H3.E9IB0ZHOB%L<^L"->7:IY2J"JL)0.0W4M5#K%R4?]#5=HI)9SY_
M'3CA[$,84,?J6YT[3O;[?)NI!R0UL/X7/6W)X7[, \J:>>VGZW+,/=8;<O2"
M J7*(.!55$@=:,698R^U]#N<>P!(G-@AG^Z'/,J@Y6W//=<\U33:?"_9YP-U
MTNN($3CLTI3@=*1TINF<"9"9"=#-,/5A)VWN8JT%]#]<?,$ZF,.XJ6PT-#3.
M%$OC?,[C5E^KI=DAEK['(#+1*>RG>(:/OU.R^%VSAYANK0_; "&%#LQ".EE#
M%C&G/TQ@U$A0!0F^5",$\41P KJ#'-U]#Y<=C* 32P8V0&X<\W4(.]\FQ("[
M8W15 .LX\+>CI%,LQ)TEQQQ>; ,:1QY0REU5!RR&2*_**\Y^A_>.D!?3-BB#
MLEQ)Y\3FVI3/+WZSR^'FSX0 E5)14[[T"'[D+>H7HD>/D^D:7!7.J6-'*9Q4
MG78%<= &9U8H; ?7U.ME&_V-PI',>',9UG^/^S L"76L_J.Q'V<+'766\RIF
M#F,A4!4+<HJ'U!#C@_V9L44ZUW/"23NI^3A#\QZ@\M6^4'97\T]>(Z"_W'!9
M55OR2JY]^N*@Z[!SCA8WG%BAC_;W.B5PO];CDG4^_5Y?A$P!4$@:S]3;$&ZQ
MI&( "ZOD0""KER>6K4B;<=A-QM. AFUC_P#/6?\ @AS3" X'+/76S)\(^R .
M=&&(6X^0C,LG#*(05US9>%%]L55UV&/&H-YM9CJ4K6>X* )BFO?\^^GRD[)<
M'EOZ9[%Q[!K%3)*0B<P3VNZ42EQ$P>PWXTA_KO9=DM+@UM/MU7'UK[!<IUW3
M>?E'V,U)_P!*.P;'[8TY\ E<C4*IYH0B..=(J#CL0N,QP%]*V6'OK>?)_P"[
M'XQSPFH^4C9%*JFDLX__ &?K[+X#T>68&JE<[)OI8+ZWB>'8E<9H"&8677KZ
M[3_QZTN?=[O<-#\)&R6,WY,[?ZF.XO=Y!-D.O_W]_5-.NQ2XQ1O,++GW5K/R
M5'CZL97I[D93?.?A+V%O3ZITXC[B]N<:_P!CM .?6/3/:#J2D5+ZB[QBX_7&
MSJ<UK6>+\WJOR3/N/34?*7L697\7$]7DGMB/L=+] _E?^^)QUV,?%Z![4;9\
M]$K>>E1A5^MDC&,H>6<X'X3-B1A-:TX3/]IFGUZ1(Z*4L9<SYQSTG)^IJ 1/
M?4:>+U/VPL[R! JZ=?A]6MAT3;GRU'RE[#EB?S_Z+%OL190G&9:_CY:U;6)A
MWV.?%NR/VPL]_G;.FMSL4IL)G(3EC?4?*3L%4G/*?^B6IW!C7^Q1H42SD#CZ
M3^N*@Z['GBO=8,PM!X?77.@@1!CU<\3GF@Y)H?A*V$CT9R>$[UK]R#/1+,T0
M.BIE'HC-R;E+Z#*O$1/N^R'XK&0GI*T[."C0JR=%,(A'JX>\#[QXC .H/PE[
M&Q\]GI-ZQL8MF#VQSL3P4GF4'&ET\QQU8]M3[1$TZ[(?BJ.1'VH*8!-6SGP/
M^US?\!(^#Y2MCHDR?BS5L4\C3J];QJ8G@ABDE)QE1F6QV@::M:)YWV1G%2R?
M:F%J /"K)R=MOZF]OAMN#RQ?*/L@H9B]Q/\ T,WS:]0L8/B=M&8_F4_RBIS/
M4+3[GLE.*-R !'VI15/UUSH>(7ZW-AD!$]_/3Y1]DOO'\OF7V(O3-0HHT/B=
MM'T@&RD(M_A(2^:6B:8[)WBD9*F86P*)O5LXVYH13@R$^??4#X1MD=B%!#"?
MV[&>!T@/ [:'69[().W[HX1.N^RBXGA]M,+8_P"=DXW'NIS8)CJJ]=2?A'V0
MV(.?VSK_ %G74J8CXG;1]-. DX(?ND,\=Y[*?B>Y3"V'^=LY&>N*:_TKG;+Y
M2-ER/7B_T2,/Q,VK,]6%_2XGOJ5_$S_'K9!?]]LXQOR]6O@?O'GJ?E)V;Z)Z
MI_Z)%OB7M&9_T?\ 28G7?9=\2G.8VQ"! E53L[)N139R>B$<_#4_*3LEP>/G
ME^'D>>O.-7XE[73>9<L-#_K77E98F7?9?\1S)4S*V_7-1SCW("*>)7GT3 /5
M\I&RBH/(S+P_6;KR&H:)^)FU%C,:U,N$2-5\J5"73,EB(]%>!3AVKSAWEMQI
M77L1(8E]4T?345 >@X]_&L,L2AQ.W9=ME^PZ:#19B7380!4:9SW&R/">%73^
M#TOLO0DDDQ,^RCI*6<F68#[=/L\\LLI.%A[R22$S?1LSGVG0O0_V/VOI>9#N
MXYZ.F'#"P\:6::9<2<R^?-()6 *E2$ BX.&\?LG>/(I@W!LN1_S.R77QWP>?
MI3PG-CM6Q$</%X^;Q^AO#DK\%?P*?_+_  @]GA3*/9&\NO8Y>T^P,L?&X:<4
M-NP>M[Y5A#37BR/P4+>M;)F4-/;IDW>O51%B3<?KT?\ DJ7?]^?'?X;>.J3U
MZO\ >C9P2DA*+YQ]0B7!ZJ.F0,I@D%1LH3DA"[ 8XN-2G4'LS@*%&B$9 <6F
MU:[IRT,JB (5)0!6E 3X[ KJ<'91*5( () #CB&F(+G042+H "U6J>79U1I9
M?[C\X3.'2/CZ/NG>"22ZKFX0&,I650DXJ2902,J#.F)!3M6MR$$LE35& @/)
M-=C V'%Q0 )9=SZ1%@$!W=X$JC$$*JJ6@E7>RCZ\KA+M5=(_JG7 !%N?+P5^
M)E+0I6%FENKDG<LJD[D5-A$)PA ]R)KK2[!B@@384DU"3)B3JWX,R5'X9&AO
ML$#7515CE7)UH+F.F+[4;@A]&04$YO:8D0T9,HR*\UMU<DC YK3?>5$1<J.N
M3E'1R3%99;$),2I*DW%ID#E<A$'=!6A=;*B,A#\JVI$]!=K#P0>8QPC;P.//
M8>4RV$E,5%6NN43D8*^K;*%$7 ))3'>743;#,LFXHEWC-.-Y%4$"@F,SN1O2
MHJK,Q$W[!7V^Q% %46*3]5DX*&0 ^NS Q)(P!:"L<#"C]SHDJ2<G*Y/(B3T?
M*2^_4A#/B:_WT4KE9%:);K?Z]8F)YVI?!#&1HB'-WSYN(26P?[G%R,+*%!)%
M-C8)A,9*#8Q+T<DI$R*3-28D &8F4 K+0')BRFHCS:"X H:!@H];UJ8C+^U&
MX(H=U'N7UYFH9Q,H001BODYN4J("<_)V>>^<9*G)U)Z/E10%*KNK4." =X45
ME9 C4,)*KA54*4K:P7+A05,5*6]J)P "&B)7&WX:B(>)2+@_-;7WA/F$S490
M4V-PR"222B$(1G4Q/!_;2"1+*""CS2@F7Z028BIH@1+QL&24\3DK!U94++9.
MJ+CH3M7.!26P,_E4SO9%0[B: !3;FY( ^VS_ $-$#=>0.!T76Q>@=I (EW9B
M2YFFDD ?_&S#-00,A5(J<*4D&X1"72H)N:$T]42]"]K5P-2=^_<S2_+4/)S!
MCS:#-N;E'!0#^IL!,!#T4<R=;6U]&3 ;TLLN]0C>F0%5(4[RDLVZ &17$8=P
M(7IH*J574*B71TMT53VO/ W,X^&\RNDXB(>&'ZBBXJW%R)B@7 ):IM?9"(@/
MAILO19(WIR=XA"BHUI3O*2=;-I$;@'7\X&S44*X+Y6BYZ.[6G@,@G?EYS=[S
M:/RD6;6W).$"?UNL'<@G;D,#6#:-A+(B ."37,><>ULT,8F((+K6H-,ZA5>_
M"-T+$\8?#9Q,^DH.RUVY#64QEK/GD93X,VIJII?DCTTS(ZA-*5$:="A06<]T
MH2"HXN/LB$;P"JJOZI2)A4E0=VP4QCF%Q6A+(E4(28+0D[M*&@C9D+DC'>)
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M*Y-+6?K"\3-D)/6$Y;I^G#;2>U$*_/JX*9:JIGV?M@, <V?IW:999DE!,H(
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MJH()"[PF(((H<BL5--&!8D;J$.";%5J1>/T-J:G!GU.4_/?(>;>GY-*YT87
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MHR;7D\#^CL-P,0<9B0*V&+&8K0<'UG+&55$5C0\-/W<UC)/%R.),SG3V.A#
M/6I.UW0P0R6"PU)G'</?:56^\R$37'Z7\*-NV^4^4##)F*D222R (2223(2R
M!$+;I8@MUMEZ!V3!FEFD!WY4$H7$?>EW0@WTI5:F8$6C;?7'J],BU2$SJ*/P
MCJ4AJ7>Y3NME?(+RA#3A[NIH0TS?U^M:UZQS0TY=5=.(0\GK"&H9.1I9&8.X
M5&]PA&FEY:=NB]NA)YU;UB:P4&^HZG:>BYY+H231[, ^FUY:&;GK33,^5VT\
M8H5W/W@*=UEH,MLCRCMEMGM=''9),,S8QPR99IDP\0XBSRRX1F(&[O!YV4RE
MCO!9I998Y&V;'B8DXGPYC+,93*9I2Y68%5,P-@#Q+H2#AN)IF_#=34_&S5JN
MF(:43FB7$UG,B@:2-03V4R"XUZW!8F;MJGWC$UAF:<-"U&VXAG;MRR];\IW
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M6G\QF=/57(VWK3<(74-%.6FW#[O:\7X/]*[9@&? Q@<,#%F.&3-AGQF!-/.
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MY"</'$ ,FR-VF1M^Y]5GOS];YR!\V%U;[/[#?PBP#H=EP@IT9 KJI"JZK#[
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MH#$VN642#:IA+*1,!N2 @JI.]Z1WB23O&8/1(CQ(#^,$QF $PW2)94",$%0
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M][)":\Y]@]IQ<?QF'M6U84LQ4"7$DWPQ+XAG!8Y2@HR1Z#9/#H[)TG/TYC=
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MZ@^ '2B*<;;$O]U[-2B)OA_K6'Q^Q/[@?!<?RG.F/WRCA]7#L^/Z<[1(HO\
M9 V^QX8HQ#R3DB@(J:YWR8[+_#&UU;[Y77[J?AV1B^/V-_<!X,TR/_$KKVP^
MKAV>'].=HD=E_9!6^7"A5]2PO+QYGP'X,=E?]6-LM3QNN6TZ6R4Q'R@8H_[
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MJ\:<_ASC _\ P#X-(3::8<OOP[VA]7%M#_'^T27D?I@;?>'^\O'^GX/DM/\
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MW0%0*GNV\"%1!E8!3=56I&Z'07TIH0H<@$)W'=4$HS@@IE<C&1A0"-(*P#%
MK*"?-1LZ$%'#4(@4() *9*\PH'=]X)!RFP P%&D"A!*,A-'LAS0I46 # &(X
M14 4;%?X(4C"X'^Z PB;:0;)%!8V8*C*P:H#)$"1S/S@*$4$%$4A?$(@3(5
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MVYJL Y_^T7P4+K%\<97^Y\1,M\=OVEWAY=-E-^4/=#]"H7CV^F\MQMSMQ5A
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MP:[-BK^/A<"?O+<E*C,"-3>E;SCKYO#U\6?2*@/H=JY 0?3+46/'U!G/A_\
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ME24._)2"3A!G8L[@9"(6H4 OK?,@JQ -/1R>(JB$AGV62B$*2/>0/> NR(<
MHE40D!@SNH8BPY!:<(A[7=7*A=@5.V#E.8W"D%I4PJ(\Y+J :5LB]E7(5KD%
M.<Y.=P.9P,'(V3Q)R-(D*VJZ"Y8,7%$XEQ !D@J>:J<G/,\OQ-=50:(<C$>:
ME;U)5#F;5;(LY,"4(&P&,JJ KC"JA(P2 I&"FD"Q H.:H#8HM%#$@*C7A@(
MNZ^)0*",XZ; [J>B" ('JJ7*."'96% 6*D) @H5P0IQD9\5PH*9"A "G>T@5
M0JQ<Z'/K! '(-O/R4)R55P&L$X/5$)&" J@%5(TB5'6[*QOFE:$"J&IB!3F0
M41$(7 #.ZG\6W()I$%$<@H0B(#855^RE@D1PO>./  8QMR1,)X;*H&D2P\ZB
M,B4:Y:EM**H$6C4N6H%2!^D-=>K'1>0&?ARTB\9PUGJ".([TCGQ L@[_ )Y7
M5/%Z]GUPB*CKK)"&JS^B>]Q".E^G=SMX^\:IB.0.?KI0BFO"L(^4[Z()[0CB
M^X.;R\/5*<-EZ8RV,AKBW523NHX:$I6W51-3":2:K7,G9;'KW3-3,L$.GS+!
M9=NP/9))+9:UW^A=CPMI$TN)AB< .38("2'$PW5H"^9>-W8@I)0 @L=T&8!@
M47)%"(4854>!Q[:OM?7#DQ$3Q)UH(42;TZU&?(Q:)&9803Z</V/ !(4!:"D^
M)*%?1'HC8*;N%6FY."2[-.3HB<--CQ<@";DHNFZ&*H"F8N6*.PB$/VU?:^/G
M$,_A>)*LXF%BI?,IS!13%E[1?JZ32%!.9N.[;I.Z"T &?M06AW0F-3]A]@'S
M<-[;DQ4K^.J=@R!<#)*:RR%@'E# &EU"N ,K5B0F/;@]K/*C"B9\4E52QJ*@
MQ,8%F.M-8J7&.EBHRT%M[AH$($!YC&VMGXL[&721D! EG.G[JIL[7(*AQDE*
M* I)-"X8$UJP>]U2)+ZNEVK&_P!-O-_'[&UBU Y$_8\V_*.NI^+>PWE'Y,XX
M?LIAXN4T$@>^[6IN.JR$9Q'ZNEVK&?V6\W_YMK%!>N]O FXP44)R34?%O8?H
MRZ^;B:?W[MX-#Q<EA+D/1.>M-0A8NL/JZ7:L8_9;S88Q]C:Q0WY#['GN]V$Y
M:?%O8?HRZ>;B?\:'BY Z2ZAC2^E*T+YQS/;I]JPTS^^YG)"\K:6+YGFEO0NQ
MW&$79=7D\$=D4*E37QI&:OM#W"%NJ,$F$%>668ET( #+<L_KC/%)=M+VG,QD
MTNB(WB>F\5%1<*#BV5H1[30R0EO"5/BNW-,;4G@AL:.)0GX,ZBB/Y0"]06O&
M[AX,J-+*:%Y0V2*E"4"<.&8'':U=J(X<E]'WZJF%AS'F3^=1=IK1@F;\I0%M
MYN6L$H"HVW.MG#\#.B_G3 *27&,5(I^V0U0WFD$7C!-+(!24),J[H13=PBH'
M(=N47I!]JEVGWE?)1%]:J\X$V$D,-\DEN_VR;'>9DBFWB^G2&@60I4%EI4*Z
MWI/ GH>8$DR!$*'#Q?9M*6*V!5V2.?BU"2H'"94:VK*V1BH.NU@[1!E[YK%<
M1<X\Y9Q%L_)_:1VTRA[J=WY/ A"H0SW5"+E-9MD\!.CL7T\*28 L=V>5^6U#
M)WZHQ&9 "RW!0YI5GIH5- ]TP?:K=H$]7N\0L>AROJ!:0#.>=O54E>6Y4ZW,
M7X/^BI$$N%*"W[L1U':^"!ZWI&E-BDERBC)VX#MM%TNNU)X]0O[("/5!GY/K
M1\]RIM[@#P*'*HHUD/P;]'%_$RL&\[%6NFVUZC=TC4Q.D20TS+<>[#"V9P @
M#Q7W7:>\=;U/L^Q>45:(MR#L%VMX#S*E$!Y!$U?Y.NCZ>+PP+)).<L]J]OU:
M4_2.(K3%RM#F3]&C%JF+GA.TOXWVB>]?:,*?PJ)MTU[U6WIY[X7.[*Y?)ST<
MWVJ7--V=2'_PPC1\B06BL_2<X'I$%,AR*[J(4KJE56O.NT@XU7^?ENBDPA]1
M[<_,?K=&%VVW.5.GR=[!;!PZ?1F<GAM=EO[4C1GZ3G5!BSL!\Z8'K\66ZDUJ
M+H@^T5XRW^]Z(S_*HJW1SA-Z< Y>[/3>A^#GH\TPY>0F%?\ UFH]EB?/_&[;
M,R$/X!S_ ,' ?(T3JK\)VA/&*^*F\4:0"<>I=NDWSDTYXJF/#NC9\G71Y'WJ
M7JGZOUZ$!L0Z(76)/A?M:,Q7.1;Y[.%/4^0BLP?']Q;OF2R+OQ89*X]4[<H.
MN#3@13T"9*A#F-H^#G8)-IEEDEDW6*"6;(4^[%0M<H=8U\'POVT;/,JD@E]Z
M0T)OY. B&Z)4QO9P%<2][KP7CG-+7)KR*J200UO)A/(6%,BI*6?KHS.Z=8+;
M1D,C<M-=US.RP 7B%EAE66D(UX_PS\&=DZ'V:2;9\*668SR*5G42B7=K/M$X
M02RHAN2:O';\%/"7:-NQY\+&!G8S2T'G'>*@8>#(:E55-2B'VCU\O70VHBZ7
MT0\:AT^A0T'6E#4H17GVI"&E7MDSZ^[MT0U"=RUR5"!5&E0ZFL(:G,$9O9-:
M9V7W(:9Y)GU\.6L(:=\\ARO0H*E80TUJW+VUYPAH[]EEX:A[]01$-*9TI7*_
MO2Y.B&B=6JF_&P 2ZOFJ&B]^JN1>$-.W5M?53N80T/Z5HC][IE"&BY<5- S)
MVTR.<(:C2P +@_4&]=FA#4A^%0_?JRRI"&F:(&4^]D/-;!+PAI7L-;@^I0A;
MU&$-11#?GR=>LH50(Z0AJ4#A.:#4]A]?&$-3W_3"&H[$[BW"EVLZ&G'EZNMP
M-;0AH,N_O/%JB$-%[ M++UJ!ZZ0AIU\.)!NC#U-I"&I[Y^^$-02U^*$&O6]&
MS9H0T0$!$(Z^HBXL80TSOF*#5&==3SA#1>"TRJ%;BS>Z$6+-PLZ.Q_6F7[[?
M;3[\_P 1W%)Z\AZS;K]]CLX/H&OI%4K09%?7PB69.%Q[R1R', +S R"A0;$G
M6.,@+*VJD9"J#5'4BEUB/+KUZ@8*JN&@4*?='?8 ($->CV(#&MIA4K7D$@FZ
M$HI*]%.1E,A%&0%R4QI!*H<RM$4N'R10X=RC1$[$@X1.0'-!N%15*A61U&R!
M1"05")ZV10&57##.P(0O=RB%-UR05P!MS)R$4%D(@$+HZ.E?8 .=6K+$.2_:
MA!D A<-%%3?EE54*TJ:1%EH$!)"@EBRTTNK.L1'38#'BGVZG#6^ $P2%&D2,
MA0-J/G+0Z (Q+BT=07O,GGN6$9*,D@*H3* $  D')0%-9SNSJR@J R(4R"*G
M!#<1#2JH!0US**&=#JT=#Y^Z<,_JD+R4D*2J $ [DD\R >6XU2; !0DA[YIF
MA/8J,]HGRB60D";SF4),&1:B747'6D45],Y@'@'F_FX"+S\0<#GN%)/B1KL8
MH E E)(JI*GDE4>C&F9/%P#YQ4%5*#@#<TY%*Z1<JJT1S ! R$!WR3C;JO4E
M3KC[19U-N+63FB'KIU=G3<'\9'5A,5]CWM$55>8.P494!0-TRFZ'*)WFAW<<
M955<C90[!EMS2M%(3CD@D<SDILI"H %(W7&R#PTB'(*"Y?B0H".1FHIP2([D
M;%#L00H*J%(&X'3<XPJ(ERER+$(JJSI4#*NE(Y\ @V0IG!(!YLM;;LEK(0KI
M *;@):RJA0:&E031"L0)&=DWZ[M#FFRA  !_"R FD&>B5N0YS3,(B)=Z1:53
M?;P//](:S\6/]'\N-(O&;622R=URG7;\NLDE^]?T=W7GQ\M7#SP^]II.N&&I
M.(A[>2\<DJZ66DJ2L:0ME55_;ZUC6]U+RVMX@V*^II[45&U](C3=IY#5E!T+
M,[8.[9TF*LI"KJ1KY@5N&N[WF>EA>*!ED(!GGG$HS!F0B921?=1U)'F[UR4(
M.;<A8TT 1UCV?X XFZ%;VFJR^MW'-P)+/N(J[U>W5I6V=PHR:&9V:M,T_8HR
MT]$,2.=%AY3L0U;^G9)5=7R%AWW7-<5C4[T,EO(U)V0 L!VERU I"I%66CJ_
M!"%=%8H>-TC?G6*?T3R]<6CJ;R0.OXS^/6.?TCI"/B#^BL"#Q#<*:@D"S];?
M:E#BKV!@C(//;!]RZ][X)X0GDQYK^,F%40;F&;D5+>Y(Z&PJ"2J>=,P_%)NM
M53BF:1YM1':84BU:NH;..*%O)'T[5-@999J,FE97=E-0U(&!1MUY%/)R9S/I
M :F[S-0W0:J=LY]4FY+3='$>I+NK6=;/V+VH?/%5!20,Z?/+D:NC"D9P" +$
M!B"ZT9;5%KBCQ6:%[5:E+9T_2-(4Y9NL)U3]#4D*-DT5-[BRB ,>W(YS8P4+
M*&I)ZO@2*WU2,V6D3-XZ6_JPK&MZF;:&5U/V+VFN^!16PP07H=],T3W&#FE;
M#WUOEI&E/&5Q5PO%=4MO)]!T?-Z1]1J%F5,14)/JA]8BW-9W6$\KAJ5R@FGZ
M5]!T#2YG7JS1=,( PPSLH"=678MHEWDFE<[S##"H!*5.^DQ0(*I*@*B"OFZ$
MHE%S>X97K&EZ-JB_'V>OB?O;JH3GJ_D6,GI/DDGYV?8^D3O!:U8%"&)X-7M2
MA@C9YC[R_-^93) Y/(L?/LDZO3[OSG>"A9@ H()&:E0U.I6%F(WUZ?P>?N)7
MJO3QQIY%COYW9(_\[N='$;P-W(=92K%,B:A^&<<@&BFPW&^Y(4XQL?GZYRD&
MT*IF"#_%CL6X-8V9,.Y?71BE8W@X=JU=6ZJ"W-?/Z9DM8FFHSTQ!TO/OZ&XZ
M9,@&2F<LHT$[QSSSA,D[8EVA"LR J&W 0"&=TF<.-+)&Y++*,C0AB%""W>E5
M8>L%7\>]#W.?043/;8U1"OZ<OY4/$/2,J8J6DYA*V)LS5];5L*1=L_)_ZQ3F
M0U34-9R=FLQ4M6U6RT)$[%%!DU.U28P8/@_T@!NB<D"02#[S*$E"!!+BRRR%
M/H"53NBPCDXE#W=JW)0$FHJ8RI!=I!*/)AS#VWKB)AS&>9")B[AR?T@95\G%
M$42W5;1%/YNU2YHUEJBJE16#/&LC(UT)/![I%_.E<*HDP%*S;Q!/CE(F)>6A
M<$%3'.QBDU>Z !O5V1I'=>X!NS=>XERG,K]#"N*JJ2HO17G8F(@O3$W99'Z]
M ,B>% I&%)5<Z]-T7LV/A86%A2S-A2288*8;B4"6B@(-VR $($MA)!,QS)*?
M6Q-G)2EJR4*4]DL[A-P1U_ F%^<ZZ>/A;04 G5P0$P] GI<1V".>4!)1$75A
M9>ZQ>4&6N_D][;//.X0(45,KX93._OX[(4*$_,R;*]QEK')GV=C:C9]1&5N>
MMSPF3G8 '\&.0YY)]VV-3O;0?G(S_>RH "4H1E=+QSY\!SJU J:^<E$9D5<H
MNR$9(3PY#)(.W+)!!P$YDX*ZKO8]Y\U:3+@*%XY\V%,'!+*#YN;W.E*Q?$("
M ""I(V("_%$^?9,KD:Q[^T?2H]</A^D==8T)I)J$+7+,T%#G2K%Q%UP9_3B<
MCGD@KC&5)(PB[;[H@MO[22BC^8,JWU)"(L<LS;,@;)3]LO0O3/B+1<\(5'M*
M23UZ^"H@YX3.%&F]M-!-8-]KUS >N>BE8D3;,R2_2O.A?FVKK=S%VP)R22
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MPT/A)TH/VZ0G]XP>%\$@]SG$^283>:3SF;^?ZHFAV>'!:QM8JF O285:?_\
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M> 4;,$XQ/V&V2^"O_F8M>>,4X1?E!<.-E;7SF)J"@J!E-,SF+E;$GBH^ ;F
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MX/AAT+@@ ;9@-1<29#8K]J(7K#IPX&/LDYF),DSL0A0J-"K)PC*$HX6>)=R
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MY4R0U%\U[48JR (='7.$-%X!T &>1JQ>P2J+1#0<U#*CN>=+VNB0AJ>-NVM
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M5"&C6>_7J_U Y0AHC.5U:W"GK&<(:/=+*Z=]!=4,(:BS%G1 M3[,O<L(:FG
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MFKQPMHZ$DQE)FE4K],D<Q.% *L;'@(RE*.QYK&7LJ;WT]$,DIWC1$S9"@ (
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M?16F]D-6"([OC)PA4@+3TG[^_(Q(PTYE<<\<NH2/@WSZ(<&+A&'$0&VHB"!
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MH5C;YM_<F1O'=.MLL2.JK>VOHL5E#O.Z^:K.GGSQT[;<5,_>L=3"Z0\6OFY
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M4_3&M^>2/% I'H?*_A N<RYZ'RI][90#DKQS<6?# 28@ ?CLZ4E!OWI&19;
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M4 $ J3F&"'47$<3@@( -TR3M@Y0;8 *$]TY!()1!4($%B*DY"H%F +L75#$
MF$VR00N#T:"@+R5=B%T@$M1R"Z#\9P%J%6B*T1)R0>6$()4@J1L#@8&X RBY
M")NG8A*U)%+*$J '3*!)!Y+OL JY!(/0\B>0.4.D06-EK0!5H7R-0383.AB)
M\/'*%DE2-\$=$RNY((*%$Z]J$5-VX76I((8Q&"R<8WP.84%4R J'N\@2B9*
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M^3+-/,N#B22MXK<EGEFF"(""0)3OR33QS,;H[&!F)EDFWE  .[N^>"J'$?>
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M."H..8V3.![1(.1NRIW)1-5BBNH+9>JI(J*C4P5 ,@'KR0!%Q@GPSRP.2)5
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MZSI.HJ4F417[^,@X2IY+.)%,XN6MR21LNGQ<SH!ZTR"R\9'<W(:951WA\?\
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MTB[!W*A#<.@+E$*"Z5%H#.V0A!VY$H@ 4% $)!\ F-(!U1PA!I0*C!U9B0=
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M$T3):D:;M52/$?2!9%2AJMN]ZGM I&55KGJ#HK,#:@B-VA*K0@(E9J"P*D*
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M+#@$/$V"D7"7!B.R#&X4C!159 [P'Q*+@]4*&0HX6UUE 4/]1N8@@P<-*NX
M.3MD;8P0@+1[JX0(#B"'10A<O44U8$M#N@ #_A!KV0,\\G<%0"H1<872(0
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M9;9LC42$6+-_VZ(ZRF7>_#<^/S+\V>NJSAUR [2>[QL813#-#YQKP'7PB6P
M%]PWWR"%7 "IS11U!UCC*P14RNJN$7(4NB\#$<+S (Z X0 [;X 3VL\TV*'!
M7%$4(PMH!0O>RP*],]Y&4ROQ)V/A@[#!P@246^\VMZFW"M QB&P. N-_!1LI
M[P"+MCNYP4*(L;&_)LRJ(V0!L4,0,X./N=B2$(*83"<P"B8"E42'1T%J%61N
M%V5+ DJ'=Z(J)GNHJY4DXP4)4A 1XH@;J43*U5<E3<,JH@09LIRP54@*?:**
M0A !!)&V%V.D2[HC&IOYS41 "I/#*"E 4PB,E $P0>NR!HG)3&Q)TB%+$41
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GXOLA#4BLW'V"$-4DH/QC_LF$-7%9N/L$(:&LO'V&$-!6;C[!"/_9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>25
<FILENAME>g164680g00y15.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g164680g00y15.jpg
M_]C_X  02D9)1@ ! 0(!>0%Y  #_[1UV4&AO=&]S:&]P(#,N,  X0DE-! 0
M    '5J^=10X0DE-! 0       \< 5H  QLE1QP"   "    .$))300E
M   0S<_Z?:C'O@D%<':NKP7#3CA"24T$.@      Y0   !     !       +
M<')I;G1/=71P=70    %     %!S=%-B;V]L 0    !);G1E96YU;0    !)
M;G1E     $-L<FT    /<')I;G13:7AT965N0FET8F]O;      +<')I;G1E
M<DYA;65415A4     0      #W!R:6YT4')O;V93971U<$]B:F,    , %
M<@!O &\ 9@ @ %, 90!T '4 <       "G!R;V]F4V5T=7     !     $)L
M=&YE;G5M    #&)U:6QT:6Y0<F]O9@    EP<F]O9D--64L .$))300[
M  (M    $     $      !)P<FEN=$]U='!U=$]P=&EO;G,    7     $-P
M=&YB;V]L      !#;&)R8F]O;       4F=S36)O;VP      $-R;D-B;V]L
M      !#;G1#8F]O;       3&)L<V)O;VP      $YG='9B;V]L      !%
M;6Q$8F]O;       26YT<F)O;VP      $)C:V=/8FIC     0       %)'
M0D,    #     %)D("!D;W5B0&_@            1W)N(&1O=6) ;^
M      !";" @9&]U8D!OX            $)R9%15;G1&(U)L=
M     $)L9"!5;G1&(U)L=                %)S;'15;G1&(U!X;$!7: =
M        "G9E8W1O<D1A=&%B;V]L 0    !09U!S96YU;0    !09U!S
M %!G4$,     3&5F=%5N=$8C4FQT                5&]P(%5N=$8C4FQT
M                4V-L(%5N=$8C4')C0%D            08W)O<%=H96Y0
M<FEN=&EN9V)O;VP     #F-R;W!296-T0F]T=&]M;&]N9P         ,8W)O
M<%)E8W1,969T;&]N9P         -8W)O<%)E8W12:6=H=&QO;F<
M"V-R;W!296-T5&]P;&]N9P      .$))30/M       0 [_^-0 "  $#O_XU
M  (  3A"24T$)@      #@             _@   .$))300-       $
M>#A"24T$&0      !    !XX0DE- _,       D           $ .$))32<0
M       *  $          3A"24T#]0      2  O9F8  0!L9F8 !@
M 0 O9F8  0"AF9H !@       0 R     0!:    !@       0 U     0 M
M    !@       3A"24T#^       <   ____________________________
M_P/H     /____________________________\#Z     #_____________
M________________ ^@     _____________________________P/H   X
M0DE-! @      !     !   "0    D      .$))300>       $     #A"
M24T$&@     #-0    8              10   &           $
M                 0             !@    10
M 0                         0     0       &YU;&P    "    !F)O
M=6YD<T]B:F,    !        4F-T,0    0     5&]P(&QO;F<
M $QE9G1L;VYG          !"=&]M;&]N9P   10     4F=H=&QO;F<   &
M    !G-L:6-E<U9L3',    !3V)J8P    $       5S;&EC90   !(    '
M<VQI8V5)1&QO;F<         !V=R;W5P241L;VYG          9O<FEG:6YE
M;G5M    #$53;&EC94]R:6=I;@    UA=71O1V5N97)A=&5D     %1Y<&5E
M;G5M    "D53;&EC951Y<&4     26UG(     9B;W5N9'-/8FIC     0
M     %)C=#$    $     %1O<"!L;VYG          !,969T;&]N9P
M    0G1O;6QO;F<   $4     %)G:'1L;VYG   !@     -U<FQ415A4
M 0       &YU;&Q415A4     0       $US9V5415A4     0      !F%L
M=%1A9U1%6%0    !       .8V5L;%1E>'1)<TA434QB;V]L 0    AC96QL
M5&5X=%1%6%0    !       ):&]R>D%L:6=N96YU;0    ]%4VQI8V5(;W)Z
M06QI9VX    '9&5F875L=     EV97)T06QI9VYE;G5M    #T53;&EC959E
M<G1!;&EG;@    =D969A=6QT    "V)G0V]L;W)4>7!E96YU;0   !%%4VQI
M8V5"1T-O;&]R5'EP90    !.;VYE    "71O<$]U='-E=&QO;F<
M"FQE9G1/=71S971L;VYG          QB;W1T;VU/=71S971L;VYG
M  MR:6=H=$]U='-E=&QO;F<      #A"24T$*       #     (_\
M #A"24T$$0       0$ .$))3004       $     3A"24T$#      30P
M  $   "@    <P   >   ->@   3)P 8  '_V/_M  Q!9&]B95]#30 "_^X
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MU?3ZCC3^ZVUKG?YE9<Y!^L=-#Q@E^-5D%^;1
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
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M<_X3H/U'4/UAT1'@7/\ A.@_4=0_6'1%3P+H]E3H'U%43_\ Z(:(CP+H_"E
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MK'F/@Q3'ZB T_+%H[SG:R"!D!VBR? ((\WE_0HCM^WY=<#:7+GB*KNKGM/T
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M;%=;F5^94K<O*VH-&9G7-7:A384"K4%JI3O!I4N6Y3XSAG.N('AL@I9" !P
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M;8;IO2OLW0$O%:@Y5+\4X6PMU;C2R%,*2I/A*:SD9"PH'MK1/H\%:Z/C/<!
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M'2WXS"(U*4TR^%JPJ2%**<^>^XMQ/@KL#@G,P-.12!I42P<M, _],D.@3<9
M['5"""X$SN8[1M'\QE93&9^#1ZK;Q//=;X1;>6HH7V?B6K'1!C@$>LEI,EUM
M2<]P,G./:.VM#1_$M"@"*/!\&P'/Y7^O,"0A<\Q)/2^GI;^86YB? P[(3W ]
MN'O#OWN2[Y/KJ=_5RC>+[2%)I-1"2>_F!^?V<K_Q?7Y2VC@Z% Y<S6.-NC2
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M8(M%6H!\<&SB#^B+.!YHM^F8U(R5YCETSCJ;3FNH2&6F\)0A*0E)"0!V2.P
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M0"JZ*HT1)2\_N(C^.K;^?_."F>S3:-QI/I[[%#D?Z2KT1)N/]^%6_DW;W?\
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M*E56EU"K[B6?:TV339E!IM2-(JTUUB;&BU&YI,>B4E^6D);;J55<$>$0%/\
M%"]%B?J=LK;V@WL<[V"<'IPJ=:JVV\)ZY'[G75E5">M*[LN.S;HK2VD(8;#9
MFV+-GT+P6.!#;#;Y<07%J( 6D@F][WWZQE$V!D#68A2)2 $I"00 D  YR
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M&4WM'$J;*M%V'#Z#7%P:'TY:YA>07-BG4YVM<#4$@@\ES@:&+Q)%X-P;"73
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M_P"U(KEP2VJVMJR?$F/(<N]V/0'XM34Q24J4M,D+=AH*R7F7D@ -QOFL8FY
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M=0"L9#C"FP%!(27 M*0/9Z?\7T:V,Q8XCB:?PG5VM ;3#OA%U-C&@?/SN/R
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M:9!ALT[XQ49HD28L[[ 2GT/PREQ64X2,:V_$>"<-P6(J-8XUW!WS-=#@#!(
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M3*<IA$F@PW6D),5"PPCF]+]5)( <*$*( &>_'7-7XAAW5''\C2!,@@F#8YV
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MT\LH)$7(&^FT=$YA_B/ITS@1W5?#*@/6]OEQ&!_/Y8SCWXQK#XD:>O\ !3G
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M>[=KCSSC,2KK!/MP/!  ]RCW[8UA2<8=K (F ) DZ?4]RN_5: 8 @  QW/\
M&FIZ%/*5%7N[I*NV,_9#XF/(=ARXDX[G![:Z[S;L8])^Y7%IKGX?WFF=E<CO
MI1$X0I)V[J +;B>2,_&\A)7C(PL!?8XSZH'MUW*1C U1)$XEAL=0P$?0[+)E
MI/0_;WMU3M2([<J,J-(8,R*^E<9<132'VG_&'A>&6UE)*1]L1Y!.3[]=$53\
M:<H=(.UR8F,[VD:7%[07=,&2=._AIF;'72\0+=VUVWN_<#=")%FK9%$=IIIC
M%GU<Q%L%E$F-6W6&&UI#C].G-L1YB>_HZEH[DN<1MJ^.?1IX5QS<UWZ@3,$
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MC-H)&EXO-LM[+W!R7O;N!&C+2I-D;?&!*K))Y0:K<@#;K,1@X0)#+,A"4N*
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MO32SM54['N>T95XP[HBW944/TN/#8B7#;LFFU%JJ1D*5.:J*VU108LB.XV<
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M+,/A' 6?3>;Z@%H(@&!!S(B?!<8J![Z@;FPP<SG-]-ICKLG>)/%PJ2I&&WL
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MSCCD Z[_  ZN*;Y)%S!RT[Z]E4@$T2M*3R%*GC.3@QG@?6.>X*3\V<=AK?\
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MJ52F@YX)><2%8\0+2WS;< .1KL\8JX'"U0 6MJ/!<#+0"&0#I N1(B;WS@3
M</Q=>E:HZ!%I>2#D#N<M?-.;?FQM'L';*[Y]+HLCTIFFO3:C6ZVP[+FNI#C2
M9'V9Q*_#6M!6AO"@GDI() SKI<%XK3?Q/"40\'FJ.$-<#E3>;?-!-IWA=?BW
M!<1A\)B,34<2RFQI,EV1>UMR6P+D=]#$2^EDT6YS;-&=J,5V;,^+H3ADPXCP
M:6T]'0AH-A2$_:L!*5 @ J[IR,$^6X[BV4^*.Y+ 5"<P8/->\GN;G81DO<<
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MB$**2I*FU8*DJQE#BQ@>>2#V)U0]S >4N$D3RDZ&0;'0C/318OIL?^IK2=R
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M!!,&X!\%;;MKT6TJ=&HMM4R#1J/$;\*+3:9%;A0HZ2M2U%MAD< <JQV"1CL
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MC1$:(C1$:(C1$:(C1$:(O)-2MQA32'%,J=^QAU(7E"E@A!'!QM0]?B!W*22
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M1_'5M_\ $-,U1F/_ ";]1]%'9'L?HE5J*I-,$"\*J"<$VW;H ]Y^,[H/;Y\
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2\Y]Y]Y[#10YCJ8/D2C15?__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>26
<FILENAME>g164680g00y16.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g164680g00y16.jpg
M_]C_X  02D9)1@ ! 0(!>0%Y  #_[1H24&AO=&]S:&]P(#,N,  X0DE-! 0
M    &?:^9D8X0DE-! 0       \< 5H  QLE1QP"   "    .$))300E
M   0S<_Z?:C'O@D%<':NKP7#3CA"24T$.@      Y0   !     !       +
M<')I;G1/=71P=70    %     %!S=%-B;V]L 0    !);G1E96YU;0    !)
M;G1E     $-L<FT    /<')I;G13:7AT965N0FET8F]O;      +<')I;G1E
M<DYA;65415A4     0      #W!R:6YT4')O;V93971U<$]B:F,    , %
M<@!O &\ 9@ @ %, 90!T '4 <       "G!R;V]F4V5T=7     !     $)L
M=&YE;G5M    #&)U:6QT:6Y0<F]O9@    EP<F]O9D--64L .$))300[
M  (M    $     $      !)P<FEN=$]U='!U=$]P=&EO;G,    7     $-P
M=&YB;V]L      !#;&)R8F]O;       4F=S36)O;VP      $-R;D-B;V]L
M      !#;G1#8F]O;       3&)L<V)O;VP      $YG='9B;V]L      !%
M;6Q$8F]O;       26YT<F)O;VP      $)C:V=/8FIC     0       %)'
M0D,    #     %)D("!D;W5B0&_@            1W)N(&1O=6) ;^
M      !";" @9&]U8D!OX            $)R9%15;G1&(U)L=
M     $)L9"!5;G1&(U)L=                %)S;'15;G1&(U!X;$!7(05
M        "G9E8W1O<D1A=&%B;V]L 0    !09U!S96YU;0    !09U!S
M %!G4$,     3&5F=%5N=$8C4FQT                5&]P(%5N=$8C4FQT
M                4V-L(%5N=$8C4')C0%D            08W)O<%=H96Y0
M<FEN=&EN9V)O;VP     #F-R;W!296-T0F]T=&]M;&]N9P         ,8W)O
M<%)E8W1,969T;&]N9P         -8W)O<%)E8W12:6=H=&QO;F<
M"V-R;W!296-T5&]P;&]N9P      .$))30/M       0 [_^-0 "  $#O_XU
M  (  3A"24T$)@      #@             _@   .$))300-       $
M>#A"24T$&0      !    !XX0DE- _,       D           $ .$))32<0
M       *  $          3A"24T#]0      2  O9F8  0!L9F8 !@
M 0 O9F8  0"AF9H !@       0 R     0!:    !@       0 U     0 M
M    !@       3A"24T#^       <   ____________________________
M_P/H     /____________________________\#Z     #_____________
M________________ ^@     _____________________________P/H   X
M0DE-! @      !     !   "0    D      .$))300>       $     #A"
M24T$&@     #-0    8              08   (<          $
M                 0             "'    08
M 0                         0     0       &YU;&P    "    !F)O
M=6YD<T]B:F,    !        4F-T,0    0     5&]P(&QO;F<
M $QE9G1L;VYG          !"=&]M;&]N9P   08     4F=H=&QO;F<   (<
M    !G-L:6-E<U9L3',    !3V)J8P    $       5S;&EC90   !(    '
M<VQI8V5)1&QO;F<         !V=R;W5P241L;VYG          9O<FEG:6YE
M;G5M    #$53;&EC94]R:6=I;@    UA=71O1V5N97)A=&5D     %1Y<&5E
M;G5M    "D53;&EC951Y<&4     26UG(     9B;W5N9'-/8FIC     0
M     %)C=#$    $     %1O<"!L;VYG          !,969T;&]N9P
M    0G1O;6QO;F<   $&     %)G:'1L;VYG   "'     -U<FQ415A4
M 0       &YU;&Q415A4     0       $US9V5415A4     0      !F%L
M=%1A9U1%6%0    !       .8V5L;%1E>'1)<TA434QB;V]L 0    AC96QL
M5&5X=%1%6%0    !       ):&]R>D%L:6=N96YU;0    ]%4VQI8V5(;W)Z
M06QI9VX    '9&5F875L=     EV97)T06QI9VYE;G5M    #T53;&EC959E
M<G1!;&EG;@    =D969A=6QT    "V)G0V]L;W)4>7!E96YU;0   !%%4VQI
M8V5"1T-O;&]R5'EP90    !.;VYE    "71O<$]U='-E=&QO;F<
M"FQE9G1/=71S971L;VYG          QB;W1T;VU/=71S971L;VYG
M  MR:6=H=$]U='-E=&QO;F<      #A"24T$*       #     (_\
M #A"24T$$0       0$ .$))3004       $     3A"24T$#      /X
M  $   "@    3@   >   ))    /Q  8  '_V/_M  Q!9&]B95]#30 "_^X
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MS^<_.A>A.J^KP<&CZO%Q.W5N"W;+OS-Y8/YO_"?F+4_YO?5__P K,3_MB@
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
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M 1$  A$! Q$!_\0 'P !  $$ P$! 0            <!!@@) @0% PH+_\0
M>1    8! @,% P8%"0\+#0P+ 0(#! 4&!P 1"!(A"1,Q05$4%6$6&")Q@9$7
M&B,RH0H90E-5L<'1\"0E)B<S-3=#15)45Y67TR@T.$=G=7:6UN'Q-D1&6&9R
M=X6'D[.UU3E(5F)D98.&DJ.FTBEC<W2BI;2VPL/&_\0 ' $! 0$  P$! 0
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M3#2'\LDUXL?)QMZ/L']4.=H/Y2^+ \/''L6/I]7C_#]6H>X>ABL)G3Q6W/\
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M[%_=MX_HT_1]H_RG]ZT_CIKQ9_X>"?C#O:"[[>]<6]?]SZ*_Z?T==/T?:/\
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M]O6/,,J\N1L=E%.EFKI\0HIBHNJ4R8"Y9-N\70WV<[  B$.E6X+:X!#&>J"
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MI3Q]-GNOV4O0 #IOUY1\0W\=]Q^[IU\]3XFD'YA2[Z<7FCQX&4K^;$/MHJ"
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M%>1=48NX.#5W)OMMO]6WCOX[=1#Q^&X??TT_*;1_N':80)\3Q#SXH#%*8-9
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MT\:V"'@'$4NB46ZK0&38!:QC4$^QV=8:4+2PCBL[2&&SLXK,V<6L=41"SU8
M 3"1!J1 3:%W#@RI-0[G6=[BSN=\N=&#ZC.\,IN?G*H&X@0Q V[PA1V*8P[<
MHG$ V,)  IA 3%Z:].;6ULB(#9Q0R!^X;YWS;,[UQQ.)@[FK/'$O2INFG-X[
MATW\.N^WF(AMX>'IZ#\9^4VGR&F KA7J6;1R6;YF,C3&M,<U7H.X[#X>@AN'
MCT';S$>OKI^4VGR$8R&/13Q.9T>6K79Z35-Q$.A?38.OK]GAT\/4-/RFTO@B
M_=V8$W'E)U 8MM Q#8[*-TRY /0P;=?H]-^@^>^XAU$-O/S\_3A_6V^EZ/$+
M,G4UG> OC)G%U^T W\UF2T0-QDP) <9#S6\?]3V!_P#I$*X/7IC+)(;!N [?
M)]0>@!L CT  #RUY;O\ VL?Y,8#9LYLS]UC*. B>);>XW\UYK+KEZ\,D.W+[
M/WB5M'%I9N([%N.;;E/'N1X&E(/5Z!$$GY:MVFK03:LJP\E!-%YR><-58Z#9
M/%GS&$%,QW9@W*<%"AU^Y/>#LW1=$%C;1V0BLW$1B-B7)C)!$4=I!"6!I"#J
M_=+R*X8A$Y+8.Q$B Q! %0+R:B@JM)/S).,42\_S6L]]0WV#%5X#<!Z;;C62
M[!]8 (=-RAMT]+#WF[*_*R]I8:I):)]':9>^W:?]IF-]5C5BPD:R)?"9FY$C
M/9<J_,DXQ=O]BUGOZOP5W??Q\_Z&_OW'KXCYZI[S=DZQ.O8&9OL)SK*WKO4:
M+"%J EW;">YT^9)QBCO_ *EG/7CO_8KNP^.^^W]#8[_'Q'TU/M+V3\UAQL/X
M_5[W7Q5:%L?$U\JWG.Y/F2<8W3_4M9\] _I5W;?KZ_T.?I'4^TO9/S6'&PX_
MS_TR1K3 <(NL>J!X).,8.@\+6?-]Q_VJ[K_R;Z?;MZ:OVE[)^;1^-A/_ '_D
MC1W@<\#EEP!VH;@DXQ3 !#<+6?#  D-RFQ9=Q*!B")B" ?)P W*(B(#XE'<2
MCOX4=YNR?GL!NT<Y7Z1U-5H_E!.8BY3O%>54+P2\8I0.4O"UGP"'$!4*&++L
M 'Y!,)>< K>Q^43F$NX#L(F$H (CJ_:;LCYK"KB6CR_W^SU=&BE+<T7F_H'R
M0."7C&+L!>%K/I=N@ 7%MW H )0*( !:V   E "CL/YH;#T#6AWE['(G'H^;
M_DP?=\="XR.8,]@=U0O!)QC%*)2\+>?"D\!(7%MW HAOS '*%= -N8=_@.X^
M.^K]I.Q_GT;CH_\ &4G/B?"><ZY552\$G&(42B7A9SV3D A"B7%=WYB%(11,
MH$$*YN4I2*J)E OYI%#E -C& 8>\W8X,HM'H7;\GO;_O\O+! (C0 B4V+[/Q
MF/.H\$_&./*!N%O/H@4HD /P67<VQ3#N8I=ZV( 4P@ F .@B&XAOMK'VE[(^
M:PO-+#&CC2."NK'($2HS&F3XWCAER^91QD%*!C<+O$ *1!$QBEQ3=E>43$%(
M3\AJR8 'D'D'SY!$HCMN \5IWF[*)U88[%B"\]'AG, .+:8VSE4N$U2S,<V!
M'4U,<+C'M/*YCYSBN$QSQ;1V.W+&0C%*RPH62T&ONB:!<)2%9HI1)$(^'ERN
M')9N.;))LY8%1]N17$  >J>VNQS%KQ?DQ+PF?Y*2#"7A+FU?PDO"7<%S)YFB
MI,#(Q"1DQJ:2K-FI2'%."7C($1,?A=SV*AQ$YRCBZ\'.(FW_ "JIC5O85%!Y
MA.;J8Q@$3&,.PZ[<'>;LL2,5BPHYL6<5;]>"_O)0PQ7 &HF#,>9O=ZX57#YD
MG&-O_L6L][^']BN[>'U_)OP]=M;^TO9/S:.-]AZV_H4:/ /@T6][T'@DXQAZ
M#PM9['?_ '*[M^_\F]OY>6X:GVD[)^>PXV'\95K3Y1L:+KJY/F2\8H= X6L]
M_P":N[;==O\ N;]1W\?L  U?M+V3\VC\;#^.HT=6#;(FINWEUP/P2<8HD,'S
M6<]=>@".*+\IR#X\X$;0*"@B ;]1,).OTBCTVY;#O3V391ZQCL/ND!SH][-6
MW;IEN 1F*8 #7 SG(3ZEC-9$<+O9I\9.7LST2 +@C)%)AF]DAGD[:[W69.FP
MT5&1SYL\D7W>6&O-RKKHMD3F0:)NA<.U-DD@,<VNAVQWK[,M=&M!";.(F&(
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M=3Z9MS;#H>\W9'SV-&=M')N%?C?7-G58N?#*X-%[]>5?F2<8I^8IN%K/@\X
M4W-BN[F Q0$#"40^3(@)0,4I@ >8.8H#MN&^M6O>?L?X,($=@2!3_1Q?*FD2
M-Q=CS*C18%WG(M2;=8DS7,>"3C' IR_->SX)3& ZA0Q9>@*=0 .!5#@:L@!C
MASG IAW$ .8 V XZZ^C]YNR1',V$(D7_ -'XA[8"6PXR90".\"6 ,I''=N=<
M"\$_&/N)OFMY^ P[B(_@MNX&$QA#F$1^3GB;D*(F'J/*4=]]@UVK3O-V.8R=
M>Q-*?DQ>5_Z\[V/E*P@M*$M=(OG?CZ%Q1<0X).,4H"!>%K/90'?< Q7=@ 0,
M @(" 5L $! /I!MUZ=-<?VE['%8K$X?]'QO_ %_M)P7"A$9F #M$4A@#>-PH
M$#@DXQ"F$Q>%G/93")!$0Q5=@$3I[<A^8M:*(F()2\IA$>4 +R[  :YH.\_8
M^JQCL!,M/1@0"SL#;RKAC>JTYC=QN.4SMP7(."+C$$QMN%K/11,&QA_!7=^8
MP<ZBH@(A6C;_ )19900$-@.HH8-C',)NO:=YNR"7UK @7_Z/7/\ 7B4LA<C1
M/0-=(O04H)@YRN3YD?&*F/,3A;SV B(F$Q<5W<#"83&,)A'Y- .XF,81'<>H
MB(CN(ZXH.\?9)!<V((+3-@/_ ,Z@U[A#E][DS MP7#YD?&*.P?-9SWT.*H?T
MJKKT4,&QE _H;Z*& 1 QOSA 1 1$!UO[1=D?-8<;#^.C1T88&N4FZN7,>"7C
M',/,?A<SZ(AN&XXLNXCL85#&#?Y-&VYA45$?BHH(_GF$>6S[S]DV0B BL2(F
M=CH]SXZ0,>I(T5[!C<^<C,8>;NGS).,40 /FMY\$NX=/P5W<0 0*!0'_ *F-
MM^4"E 1_8E /  UR_:WLO&ROOT?_ )G\?-J_VN,7N@\$?&*'0>%K/8CX[#BN
M[] ^(C6@W^P?XM<<?>GLJT#:U@&/_P /AEI!35B% ^1UL\R3?1J7JGS)>,7P
M^:UGL/+^Q7=OT_T-B&WET\//7&>\O9/SV'&P_CE&C^6&ZZ*\W\P*/M5/F2<8
MOA\UK/?38/[%=V\.NW_8YMMT'Z]_/5^TO9/S:/QL/X[\_9&C8>&';XIN999*
MOS).,;_M6L]_YJ[K_P F]/M+V3\VC\;'^.C1X#@=OE-5#@CXQCB!!X7<]DYN
MF_X)[VIS (["010K1E4@. \HK)<BB0")R*$,','%;=YNS88#%91V CUH6:*Q
M#!P[$6[F3RI>9+<&L"-:$4)I$^52W$ 2"VP=C?V=G%$XXU,49HR!BJX8MQSA
MZ<>VF<?WF!DZFXD))"NSC*'A*]%SYTYJ3*K)K,5'KP4TTB-1665 X%[I3SO>
MCM^PTOL^*R@M8+2.,&#5@CAB($8(<B&UCU0)S+"0#DD!<Y!$YMG*=]^<F%!@
M&'Z]6$!,VY[Q7595Y7&C.SOD:[#2#-*#-($3E,,U"*<NK(,2S:.UWK>1643;
M*3)G;A*&1CVJ9@;(()%_+-&M(8+6&WC(^'!:P11%PQU8A%,F4]HO#"JP1)@'
M(&RKC "3LTI9U_ #G'LW>-'%&3K;3GW#WDZUIL9V3]WSM%IUEM]?G(U=THLR
MF&]CA85_'I@*9PYXD@('WZG. @(:_=^R>]'9([,AA-I8PQZA(AC.CPQEZ/!%
M;"*>S<6=<!!%!4W.7-S!V+O,X-,544?,BXQ ZAPMYZ'KL']*J\%Z>.X_T-%
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M73';?EL.]79-E:PDQ6#3>)]'8;?](A:M7YKD@$4R0)M1Q(X$SS?(+] /8*\
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M[<P=,V"LM(E+$M10",=+-U7K7V=8"KNA9N&W>MDU$EQ62,=,6$KSUAPG/!0
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MUP<W4ONW9L#EC/\ !E7G.+L)T"G7ZT4*?P"\8RN-[]"Q=6<2<9)D36:R3EQ
M2$(ZJ;M*39.WC(\<XA%(MD@XW9-6QT43IE)!G$\6Y2=JL)SN==OAPX/Z;PT6
M2YVF!M=HM,UD&OU*+M<C:#Q:JTO,05ZRGD25LF[1HU31?R\_E2?<N6+1%&,C
M&#5HVB6C1-+Z(#"3\S]53QGE)JN^#=56/>4>R^Q3DJ5?32UJGXZQO;1G>??2
M4A5L;W)-2%XALCKWZUUZ,B[O3+%%P1H66(N-5LL0BTM""3Q?VZ45$R1BDWU'
MG0O=[LV<JQ/ ;C*'.R+'66U @PM62+FR8D"&[MJKDBN(UA^W9I>[2IHH,&Z
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M.19NG%S,BL(%=%:YC/B)=9NMO[8W.F.X"!P-RJ (;;G*4O,8HA] Q3_GE,0
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M$&),[@U"G;DLG>^XN*WUKCNF]5)NU0Q! ID!@6+3-%DXU[0#AGL\<G*XWR'
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M[C.W\,<3'#%FXK4U/E*(R5O%&A[3$M)=_3AD;K!VVMR=EGF[J-*X7EGHQ43
M. M*;Y,4"%C53'(NUC%12*G=M-Y#9-ZX"2^6)+;P;L\AW:+H64\:V7)V=Y2
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M%WY>?E4.A[09%8$^<454D]C'[P 1$%40264.<2$(^4M^5S/C3!5*[**PI&*
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MA $ $3 &X\P@ ;D,7F'Z&Y1#F^B80Y@#+/SPE5G"5ZS;KFN N!,4IDR ;G*
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MN'EOB*.*"S$0A,7A!#$"M-PO-,T'#T7%-R)Q,44QW+N.Y>;DY?7G.0A-_'<
M,.WQUQV5M':$@P4O$3\]6$-QG>52 +P3>S^=Z^I5DAY1 Y/R@B!1YR#S"4IC
M#L(&$#;%(81 HB(  B(  "(<XA$)B-'8E[KIOMYJ*@F#G+S$\1V*("(B7Z._
MT@ -O'F#H)@Z!UW'8(8(3$(CA[BKH^%#S505*;< ,03EW Y"G*<Q#>  (!MU
MW_O@#TU2(B3/PD8#>,^5>)?,QRIB.YAW 0 0(0ZAPY@'E$Q"%,8H& #?2$-N
M@]?':"R-00,"6 DUY(#S$D7U[T! PEV,!! #;&ZE$0YQ X;?1$""0^PCS;&#
MZ(?1YCQ0@DC6()O D,T76!T85.[!,IAW$# 50!.00V .8O+YCS!XAX;AOOMK
MK0Z3&;00&SO-(Q( LQ>$,=IN*I 8$%\0U-N_BON*VP )P*F&^QA4.! +ON!0
MW$-A$QM@ -P\=_'H/<&QEDEO6M.!X+Z@._U^8=>GCZ@ [;@.P[!OH@+]3WJN
MBJ:(M<O&GQ%9QQ';L<T_"I,<M7=HK&4K;+R>0H:<FFB;7&U6=V8C".;0LW#F
M(M+':BS!=14W=J*$/W1N3E,4YW;,7+^V\K$6L\?7$M,VNHXLM+OA]HECR*PQ
MO>XS+DS!VAGC:DU/(6$YK)K>GSS9[;6YGEN-,UWW?#OEIV.:2D8RDC#&JKH)
M 8C8F>-,)-FT]ZA6V]HIGO*-(KUL0DZ%BJ.J>0<$!)8_8*6B.REEA*ST%A?)
MJ2H#GW\41I$J]DSUN/9*0,BJNHV%%T^*<3%T0>]*9WD=&]U>51[2SBIO+9LP
MC*EBV/F;K+8\8U-U/0L@G%TD]XRJPQZ:-M[*,R',RLN9)B^]J,=P6K/DI!$4
M0CC)GYTRA#WY[:.TZ$2.W.=C<0':1\2S*/S=B^M36-4)9+$O%E!P%WJE9FJ]
M+UB[X"PE;+:_L%9<*9'EYHSX;!5)%&+++5B+;1SKW<L@O,-F2ZCR]<L[^@A
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M9%-[X3<OB,(85(5NG_-2"8@R6%\4QFR0.2[D54(HCL<H:*B_W,S60--S\ED
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M.V:)PI5I8C@R'=KI('12-WO+J6VF=G:-H]MJV,5N+2%WL[2(ZOPR30AXB3(
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MR]->F_E%S^>%]DN6V2@]3YE?JG3\_L_AU^1V?[6[U57TUR(OD19,XEY1Y@.
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MYV?"?LCV1I%8+7LO18X89F( V E$&8$W@$[UFGAD6D:?7"^4Y+=UVO)=N!S
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MDZG9BO-:K-/QTYHN.<QX$P!,,;':9A+(MDN7$%/5N"@[/48-NJV8>XZX_M<
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ML@[F5,F7E67?6LM\?2:]JE7#Y[=5&#B*=VI5=20$ORA7BE B_?JZ;B9*U54
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M+W,R)?HYXDJ[=<8(-#NO1?-8Y$TSJ*;<B8 <PB "!"D$#"H(#MT3 .\';Z0
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M.  8H@7E'J.J(HH8G$JS!G3\1U,);<:+B#0I4S%(@DGN8P\B9$R@/T^4IQV
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MJ&$JC-HJD8#E,!TB#S%5^DKSE,&QA.H4!'X&'?<=]8,=L"-2<+"L1#&=U&8
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M>O;Q1PWX;PM/2$[C.BPE0D'U7AJ:\5B$#MQ<UZO.%W$&Q7^F(+D8"Z<%;G6
MZJ)#"FD8B1C%,5ZZV^BGO1$T1!\!\_AZZ(L?+H#,V?\ "*B[695>!$Y)*S79
MKG&'9F"#;]^:72*F9,161,9%H)U$MG1DQ #F H:+(J?=VW,XV<%D'HM)HB:(
MFB)HB:(FB)HB:(FB)HB:(FB)HB:(FB)HB:(FB)HB:(FB)HB:(FB)HB:(J"&X
M>7B4>OP, _?Z?'8>OAHAZZ\E &*2,BY0XB!;M)Q!X-_JXR;B47,M'OUPQ-CW
MV1Q!E%!("-48TS-DY IU0]N:N2B8#E-I>_O[\UD&D^-Y#3&(OE[K(#1:31$T
M1-$31$T1-$31$T1-$31$T1-$31$T1-$31$T1-$31$T1-$6I;M*N'O->=0QJY
MQ-7;%/KUI6SE!E%6"(C8@961CC-8AY88N3LM7%Q'\QG"0R3206=0Z@IK@Q7!
M0#$*4=VRV?B=FQ8JW3@[XF;:ROD/8\.2LOE&Y7J4D[?G6-S8:)KLIC.P6_%$
M@VQU4J^UG47P)P-9AG-6,M+0L29N6L24JB\6&<1]MC;<*\Y>==B2'#RRWRQ=
M>39N KBLB,Y71?&:\[!0(2EC-BNY1UBC5X&M8Z7Q=)5RO49X[E;@:Q(JQ=B/
M&I*-!KD@5=>-&7&4Y%0,I9[/:M^/E1#D'>39R&P"KKS<-]G[Q,N'M6C<F1UN
M3H"MUQPODBL2=QBXIM8RP*!TK99$AK]WF9!VRD%#+)&3!S&.I CH%S1R9"',
MD0EKQ0EFG+>."NRH\!7$/(7G'5>R%!RKO$L5<:/'3,8?)CDG/C>J6?C9>-(Q
MRYCI4[]V@TKU\PB+A+G,Z?),TH\7"J[9<$S7\^MLL'SF<8U8\:>2Q9NM'R%B
M6[4O#>3HB6MV7',GPT-<)>SY0%C,8PI,+Q$V,TI'! HSB<C=6TY0D%G\B\BF
M5A<H(K.XZ>7(G5%^Z'#RND^Y.O?=1KZXN=G?&9PW9NR5EM[-UJF3&0(N8Q?7
MZKBV;C;Z6I(84R,SM!WTM=IEB>8BS221XDQ (\39RG?D)[$9L4^P:=#JY2^0
M=ZBE7F1GGNJ5\:7P<YEHG!?Q,8GJ;5G!Y;R1=;O8F*[:R*%+;$7L?#@4??/O
M$X03BTJ-I=LFX*JT/&FDTU'(HE;%[MU?UZ(YJ68&5+[R3D;JO@L*[EP,\2,D
M>US6/L-VG&.++/G/)=R3PBA>*I8[>1>9X<^';'F/+LY?N[ZPBRMF=LQ]E&/6
M:?*I_,5U&V0$N$:"#:0-%2\];^?)5YM?UUO7SL7 #Q50CJ>!G6I^R-YRR8[M
MF1+!"V2!E7^6%4<%4JER";^+DKC" H]KV1X.SS<J NXM-^E-M7; '#5!-%&I
MFT\Y;+L.%,5+]9X+.(5)JPK&4\8S66K')5?'D=4<FOLIH0$9BJ$AV$RVMU=F
MXR.L!U)205]L9 BDS92:$PFF+9223(D*@D-]93VUEUDHLHO!CQA0]TX6%6^)
MG]&CL.3?!K$.G3&XP4JUC:/C3(K9WFQT\D2W?ORKRK%S9'Q*_%0<RA-PMBY5
MW*"C0[6/7^A;+H7EWDTFZIK782]^%0&;!>/C/L_N*V.QOABK57&+K"TECW'^
M"J_D8LKD6*L49><KT>S/9%[E*OM6TU*H1[2MI+KR+<HQ\4]>M)M")+%G7AEF
M[0PK@_.K=9*&\3#WA\*O=L<4S6;G9U<,W$9AC)%SG\OIV*/:O:2Q@)I:5EH9
M_&VRZ-;!(.G=CBRQMFGG#XKEBLB<9I^TAE5RB5O[ 3NQ $I<_H@!!,@V+SE1
M\3Z5)6X8-]Q#8>@!](?V0_QAMU]-P^PM+EHB:(N)@W#QVZ[[^GQ#X_7TT4-)
M^;>71HH$N2PI9ZPJB$^G'D<Q&1@""!JX44GS)PK=0?YI2(+9N5B! ?"+DY>]
M% $TMU# &B#K%\VE@I]T531$T1-$31$T1-$31$T1-$31$T1-$31$T1-$31$T
M1-$31$T1-$31$T1-$31$T14'P\0#J'C\1  #ZQ'H'H(Z(H%Q@J8<G9_3&>))
M$;WNLH^YBI."A6U%\54!X#-)98@%<(OTG"<LLHF8Y4GKYRV 0[D2@4D&&X>W
M*<[@I[T531$T1-$31$T1-$31$T1-$31$T1-$31$T1-$31$T1-$31$T1-$6#G
M&#QB0_"9$UV5DZXVLSNROYE%NT>9 QQ2@090L*]EWB<>:Z3T/*34NX*U K2$
MK<59';E0R:1P;<X"5UTWX<%*X@[ \]Q'"='42#VC=7LN+9R_T3'EG?.G%[K^
M-ZA$32D)&DD+!<^#2&XOZHZFUO;SM6\6\KUB85*5(V=O/8Y%DN8KDP &G5^6
M[HY)@3]'8@BIG5]V!5@8Q[2R2F:%6K7<L+60D+7&.(H7.=^KDG3/<./[OERF
M5NW0#.#KLE9T[/-Q9$+= ^\9 L:BA"^]V@(HRK))Z^2$]49I7XL[WH Q.9QK
M+H-DZZD?VLM2F):T5V)Q#9IVPQ#^GL*O$U6]XEM*MF-<L@L\:L6,K+5ZUS%9
MK\FE//VSMRT4FSIM67>GD5H]VB9AHC [7%^%-GUO5H6OM+,E*VI*(98M<TB$
MA:@_)D165<U2RV>KWZO\26(<,/63<["WP\-/UIV6]&22?1[E%4HS\9)N4V"$
M=(-DR8N92 _'$]37L8V[26Q1E/J3W/>$;(6VY+=Y,:X0D*PI2$6.7'M,S7"X
MH5C6D6>^S4ECAXP"]5!WW]HD64*:)=R,BG,C(]_#-'K1NO.N]2F$C,FK;;S3
M*ZY>]?>TGMRL5D&BT+ 5F/Q!XSJMLG\B426LM./#X\95PRR#.=/8T+*RB[NV
MF%2BO#Q<'(E6<M$SC**Q3T"LS,F]]BM<;MF-6GA(J-6_:W5ZB-4(2Z5>6NMZ
M?/).16C6(U.EQ\=5:[2,32\TRB#SMP65M$O(6&_HMJY&[H3$B=X=-PS;,8UP
M\4=&?"3>J 8G8#F[A[_0#.>5F$>/RHY^X@IK"<-0+/6",*\K9X&2O<M2ZO9I
MR/&!J]B9SXXKF)AMD4*Y),;.1.LVJOPTNW7]F?>]TF/LIA37T:7LQWUK0T:D
M8 7D&5Y-[NW#=L6QM(H  [!MS&,(]!+N(CU-MX#S>(F "\X[G$-Q'1:7TT1-
M$31$$0 -Q$ #U'H&B*@&*/@(#ON(;" [@ ["/V#T'T'IHBKHB:(N)@W#;;?X
M<PE_24!']&BAD"H(MY)$<\8=.BT@E&!(;(8/';]W#(3:.\2U[@L$V<NTY9X)
ME1*1^6,:+@BS,JL[$C<IU"L.-\KN:"I?*<IY;L\<G4\Z*IHB:(FB)HB:(FB)
MHB:(FB)HB:(FB)HB:(FB)HB:(FB)HB:(FB)HB:(FB)HB:(J&W !$H )MN@".
MVX_7_+ZP\=$ZZZFH+QC[Q#(^>0=LX-FS)>:R6,"/6@QE3I+8MH;AS[_0BGCI
MV@^]M4<&9)RQ$'*L09@Z2*=NNDH>D]7^IGM99 9JNQV5&X-DSX83KJ+2:(FB
M)HB:(FB)HB:(FB)HB:(FB)HB:(FB)HB:(FB)HB:(FB*FX!XB'B >/F/@'UCY
M:(L#>,"I<([^0HD]Q)V5[3YPQ;%6J?(PM^O])FI=G,Q;D)R$5&@R3![/13F.
M27.]B98Z\41$AG*A2@ET+.-TQGBSY/<#M9RK5QEP9<&,\UIF5,5PEAE:FS:U
M<U89,L@Y#1Q[*R>-L>!P_5VR2E"D)IM7[!<HC&S%OCI"RV2$<34C"QK9N[?K
M(H(+*7#KVY>:MYY':SXTDSUW.NC7>"[@??RT54X*.<V1>%B&3E]1#Y4NEIJ=
M@;4960I4&M>*H^LCBM7=:H+1CRLQ*]D:/W4&C"H1C8[9&.:$3F[S]U!.\LU2
M1^UDW!\6 5]U?L^N&&FS,/8XRI6A[+0BM=6A!L>2K]94*ZC6K8WNL(SKB,_8
M94D'&Q%@;(NV<7&I-F::::;1(G<$3*5UUUZ([2%PF&Q; .#?1C.^G=NO!9PP
M.UWEWL58F8X(5Q;+-++-[Y=82->%M%DK]PM"]E:14V$?,LGD[2Z]/MT9!D[*
MS<PK== &RNW*KUE,^^W!5VQY7R X^4SC827!?P55^/9E>1LHHQR\JK!4;WMD
MO);]*/D[78'F6S)8D!_:'2V-)27L,(\OHOZ22 >A-1I)D[I-XV; 2W<IE_K6
M_:)S4F]WD]1GA2<F.2NF9[/#ABE(I.'?UR\**.$Y\;#;6^5<FHY!NQ+*L"D\
MWR1?FUL):[_%RIN7FC[4^FT!5(8PD3(82ZB"<IB9VS)S+;>&4=VWA5X!4V]D
M]Y/?DH:GC;5KF^KF5+U3;*:%;5VD1%ZK]@DJ_8(V;F,>J0$-34K%4CGD*JNX
M3C7:[ 9 A%2D>YR'< '*\%L)S=3_ %_A!X=,6Y$/G-C$/(B5KJ=EFF!)B[SX
MXVQ\>9B&;6X62K4>1EAH=(=2L3",ALLO!0T4K**(.):7<+OG3]XNZO\ KS5>
M=">&\W4Q$ILLBZG=:K;E)UM7)N+EW-<DDXZ>1C50.:,DGK!I,I-7A0$Y2.58
M^1:/! BBA3I.$U0-]/E @#!NNN@KF<ND&J:SA91-)-!!1998X[E313 3J&,
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MP@'+R@&VP;;@/I]6VWIY:()C$'&]<]%538 \  .@!X>0;[!]0;CL'EN.B((
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MYPQRH6V-?7<B?.TR@ ANC7-O7W8X#U__ %O\ _Q.K_:2)\[3*.P?D:X ^?\
M.QR/_P#L_E\-"3<'WLBI\[3*/[37?\F./O\ ZK_!H^$^O>1PF]$7%3BVR@0H
M"="NI!R*JG4"/5Y$T4]Q%58ZJG(F38 '<1  W';H !I?UB6._;)%XD1QMVVP
M$=%KLOCV>58K'(\2BG*4HY(?\DV,V<>QR2*$:=!R1T I+HF7YTQ(94PAH[%C
MMR88GKW+WQXL\H%$2]S7Q .FYHM<@CMY"7OU-O3?O# /COL.@+^8Q;'BB?.T
MRA^T5WZO=CC?_P!( ?\ 1YZCDW3S=N+87-Y,B!Q:90VZHUW?_>QS_I!_AU9R
MH*O?L9%Y[KC&R"W<LF"R]1;/GIG!&#1=MW+F5<)(E6[AFDJ_1.H#<@]ZY "#
MLF8IO#KH'J99"9W^C(NZ7BUR>8.8K>O% =AY31ZQQ*(E 3!S$<*@(<PB!0YM
M]NH@'G'-PX[Y2=F;T::+E\[3*'[37?']S''A_P"<_EZ:KG#K?O:Z59HJ_.TR
MA^TUW_)CCI_]Y_!J^777LTR?.SRA^TUW_)CG_2:CX F6S=/V1 XM,H;C^0KF
MWQC7&_U_U3]'CTT),F&&&_JGJ5/G:90_:*[_ ),<??\ U3P_3HYPY_3;PS1/
MG9Y0_::Y_DQSX_\ G/T?IU"8KH7S=N2(/%IE#ILC7//?^=CCIZ?VP/Y>FJ";
MPQX_@B?.TRAT_(US8?$?=CCP\O[9Y_;_ !GZG7A3/@B?.SRCO_4:Y_DMS]W]
M5_@U'B;[M]'YHGSM<GAM^1K>VX;B:-< 4?7J"FX:H)PQ>]L)Y\44EXFXEKA;
M;Q#U:QLH4K29<*MDW4>W=)J(G(T<KI\NYE"[F523(;O"&*!1,(B7J8I\C5OK
ML4-YGUUMY*4<<N(^.R+Q,OV[672D$[S N9A>0605CGCUGA_'XLAB"-6B!T&?
MNA&.3=$454/[<1T(FYSCJDS+O0&^DZ7TVW,C 4D [T$Z3E[>V.4GQ;9%-(.?
M=["NMV155DD"JM':J@E3.)0,(BJ(B/3PZ=>@ZCUR?D'P570^=IE#]JKG^3'/
MV?VS4<R\+@X%YD>5S[T5?G:90_::Y]D8Y_T@_P .JYPOQY]314^=GE#]JKFW
M^]CG_2:CQ?*V;@\D5?G:9/\ VFN_Y,<?_GU9M-@>71W[T5/G:91\D:YX>/NQ
MSX^8?U3^7V:.79CGPN-#A4;$75<<8M\9K,&SI6I(+R*CP(YNX251>R^Y.]9I
M,&QEP.JH@S$KIZ5,HB41Z_1'<#U:9%1MS/7DH1F</KB^\\5XJ_'#9FDPA7',
M]CUO/.2"*,(Z712GG B&X*(1IY9)PIR]-A29%3$.IDC[]:^3-+;FKUU]75R?
M.SR@'3NJZ.P>)HQ?F$0VZCRG*41'SY2E#?J  '0,N1=@V)E/>.=,T3YVF4/V
MFN>7]S'._GO_ &SS\M4$D4;!\,3[<T5?G9Y0_::Y_DQQ_I/Y>FCF<J,V>/6U
M%TG7&%D:/3</'OR6;L6B(N'+IRT[E%NF3^K*K&4?I<B28;#N8"!OU'KI/93/
M:$780XNLEN44G*!*PLW<)D7;*HL%54EFZI04;K)JI.%4SD71,14AB*& 0.'7
MR ]92%+WW":+Z?.TRA^TUS_)CC[OZIX^.CF4N?/ICDB?.TRCU_(UP1Z;?SL<
M!]?]M_B^W1V<E@!G]/=$^=IE#]JK?Q_G8YZ?_>ZCF^&\"KUZXHGSM,H;_P!1
MKFWI[L<_O]Y_!]^K/ 4QOPHB?.TRAM_4:Y]?NQSM_P"D_AU-;RQOP^M'E5%4
M.+;*!=]VM:/Z"9@Y)M]6RO7Z_P!&J_%G;#KFBFW!7$!:,AVU:LV./C0[Y@L]
M:.8U)5$J'LA3&6*N"AS<_>\Z12<NW+L81WW#3J^M^ZG-%C9Q,G-^&.RCOU*E
M$  [%W /<46CL'0?!)90G7R.;[*6>6'M=M=CDH'F^);9<H",80VZFZ>@B >7
MCM^C6 ]!%.DQ-Q5I^\JS50!,'43&Z]  1'IUV#S^K5)SH6)? .:<#[T*@&-_
M?>0CXCX[COMYB ?O;;:$TJ":M.0)8'!SZAT5>8PC^<.Q1Z[&'KX>7W@/[_B&
MJ2SDTE^//E)%5,_,H4BG.GT,(G$1[L2  B)PW\P#?;8?$ T<X7WX;'?D&O&)
M:DN,^E5.#K%ZS51XZ+L/R>R13KEG+(A[08^3L<16.9.HS#QAC&-762C@E$ZD
MD]D"5QT8AETW:ZZ*2ZTH0-5#SN?%7OQG<0TC*XIR?CVFT/)C*31M54JC^Q6"
MIV.M4:7B7^1Z[7IHT9=C)$8N8R:(X:-F3M@J8B\9*.G@F#V=0Q9YR)N>Y^74
MD7J<+,4?&N><CXVL50IL!:G.-JK<&+O%3^=5HDG63/#P[5"4CY8P^QV!%=LH
MW4?)  2*2:;LHJ%4YQJ==?7R91MGKB_S7BF;R+0816,E;?0\GL+H<JT2DY44
MX9V=#D[W87@I(*"9Q*I&J5A@4) 2@!'C^-24^D)=XSN[L;G.>=^"+Q['QCYE
ML5CK,+4%[$A6,N9-SPXH5@H..@OEC+BG##VDT2.)#Q G[J3?6F\/YN96EQ$[
M9G6'#9QS FB(ZJ+H?/"XB9<F-,:O86\U>UR+O)!;';:[B1[9K?/05'FU("+>
M15$5$4(R0D>1.3GO:N4D6946J0 04Q$S^:*-;UQ5YBKTUAS*<U2Y-WD"#J&7
MJLJH[@EV$>A'1CE%L;(UGB&QE%XU@Q8K#)2S5,@IM%&YTR^@M_E[*3ZW?6_C
M53_G+.O$'CE>)5C,@*_(" PQ7[NXRG3\8QM]J4I<WDC-*NI')C>)64EZ7BX8
MAG!KI3;% Z16!)@552JI'Y2JVB5Z81GJ_ S;)]'2+67@XF6;O(EP=RQ61E&#
M>12%)8_Y58BJ3HCE%5<I7'LSANDJ4!2 1AWXFM&:M)5YHO8YA\!,(>8?2$.G
MW]!#T'IZ= Z1S=M)J*2%)@Y3WE$ 3;B',;H(;?2'P]1Z^?IY?;J&(M"S/%?A
MPSX(FYMPZF#J/F([ATZ^/AX!MY"/PUHT.^AGL&;RX(G,.^W,(#U\1^SPW^&X
M!Z#OYZF) H SEMLSMGF,D7=BQ,:4C $X%$7[(!YCE*'^N4_[_P"B(CZ>(] V
MZZH+OA=([^=-Z+:#:W#@F>L,M"301S92%R.=:$%FN<9TR,4S*D(.@2%%O[NV
M*Z#G.F"@)\B8&$0#5])<5D5,P1+;1W.,F#S=MJUV96V+E'(0!]$#72SB;;8.
MJ<NZ1(/P$J2::8>'T2AK))G(DACM<^9G,>:TK#*)]]Q$WAYCY[^F_3I_#J$R
MD1633>5./HBJ8QO$HB(AT'KOL'7RW\=]OCTUH/?5\_7TDB;FW'Z0^ ;=1\1$
M1Z_O?5T]-0D/458[:\&J;BSWHFY@$1$QA\P !'][UZ?;]>LDEI.)AWN)G7#A
M=<61 $?$3'#81\1$.@^O7KMY#OH3*H)E(3F#CFU&V7H@F-UZF\?(1$? ?CMU
M#;;T$?76@]]6?CB,7!P '(JB)MAW,(=?$!'H'\8_OCH^&+3. JW1(F[(N B?
M?H8P]=PZFVV'X@/0 _AU20 9T&3CC><T7+F'<1W-T]!';P$1W\M_^;XZR-9H
M9R-7K(^PWS=%B7QSV6Q5/A+SC/5@[\DXRK;..,:+<"F^00G9B+8+.F;KH1LL
MA#NGCQRY,(-X5)NF[5-WBQ0'0&V4IWW[V=AO18X\,E?<XQXA8NE6.BT"OS=P
MP4PGJS,8@L=@>P*];CYATBJVMT;-<S=U,,7"WLK>P$$?>A 4(1904!-JHO/X
ME>*W.&*+1E'&55)%R%[=S5+L>)$%HKO2*8Y*BNZR(+DI1 7+F$:,SF173YB)
MBJ4#B'4=.NNL%*5Y<NAY*Q+!QP97MSV(4Q\,VC3<PY82I./IRK48MQL["H4C
M$JF2+K,UJ"*<4[#+62<=?)ICSB9"':P,NX5 !1$VB;"]VS'\%21XQ>(-JQHV
M-W\/>8JSVC*^3*P>_L\2JR=SEZ%0F-:EVDW&XP _+'3LDI:$8IZP,'=M0@I0
MZ!1.MT*J+<J<3V9X1? %\ME%LDQ=<=7[/];C47]8>5B1L[!K4&2<;<+!3U!]
MXQB4+'"5[9&A4A,W406[DH .B===54^9&SOQ%5^(Q?)1MY<2%.F\9+7J;R3C
M?&K>^H(3"J\<[:FM%;;G-(PE!8LEUFJ\PU1.]64.D58I52B&I+RD]+]WM*B+
M91BJWDOV,<>W9.48306VF5VP#,PZ:J,++C*Q;=X$G#I.-G:4<]35*X03=E(N
M0RAR[=V"8B+W77X2O=WGU(HK\W-T^F/4=O$=NF^X!OZCOU^H \M9)D1,AIY4
MKL%W%W)!5 3!XF$?CN/\?34!)F["89[VE.]S^**@F. =!$1W]?+;;?[]A^&_
M76@;Z2!:LJOYC-D0#FYA 1';KMU'R';U^OX_8&CR?)\)'9@,)X51-S^8^?7J
M;;;X=>@Z7RBJ"0*[&83YY7HJ\P@&^XCTW\1Z]-'?$&0G)Z&F;$<:HJ 8WB)A
MV'KX^'01$/L  #Z]"2:/>[<*FAF"$3F,.VQAV\=P,/CZ#OY#Z>6DW8&==Q]1
M=EO1 ,(=1$P#L(;"81 ?7Q^'3?PU/%2M'-X?*X-AM<%%+.!QY<N48 'E_GNH
M B.XCM[$[#8H"/\ 5#%,()[?VP2[ /YHT$[1*=)$%V; B_8;B1Z99Q5!XY7L
M_$JDO.A(@C8$C-8HC55$:X@IBRG*"P<'43(!W#LQO> F RNP+ 0#!RB4NMO6
M"GUISYK6.YW]I7 !$ *NKM](W3G4,(B'7Q$1Z[_5K-YG09-?,WRPE154YA]1
M^_Q]?T]-&,GBF#.YPXD<_=KW1<0$W+^<81'SW'S\!VW\O,/#0EB9T (V.QVF
M4LRB"8>@[F^K<=Q\=^GJ&_7ZM"7<.S 3<,YG6K4:0>>2)S"&PB<1WZ>/0>OH
M'W;ZA)()8@\P).YSK?4$4D0#&$/$=P'8=QW]-^OGT_3H2V)#&3\WNF6#73>2
M+7KGFB.F7&#PIWUW<K'(!.Y M<2PIZKD2UNK,FF,) S\K-NF4@J/Y)1%)520
M4,HGWB9#D FP[ZE7=P/713K\%%^:\:8XMN3I?&6((M_9LYVB_P 9D2^Y2=R*
MCTF'8DLNVDU"%F45O9VSD6B1HRO5(H Y40,"IT#)B8PU1A@%EGQ+Y:M.$38G
MNK=^W+CP+Y%5;*QY!HD=9>.M;5[ 0DJQ>IG[B+*RL[Z .]YC F8JBI@^B :C
M9GVZS=58#4KCPS?*U) 99A$GOM,2S%FZ^5X6!&B[O!43A.EY:Q5$D;%.)V4E
M*R>;<?51\^,!55U:A:.794QMJ)?5%VJOQC\1-3BVUUL\1<[M SN+K3<Y1.PX
MF<X_@ZO/Q,>A(POR;DE1*K8JK(@\*V56 #O2"U(J<"E<AO!OWE_4HO-?Y_S[
M8*!:HF^,[U8:SD; E]GWTC9<2+XS956<8UU2=C4:G,IB);'$/B\L8W5<CS=\
M*;LIA-OJ_A?UO4KU[>;R5T8PXC.("WX#R!/T0\?"V['$'A2A5#$4M$,"7%C'
MRA::L[R$_1D7"02\I;(!Q+)4:$,/L$V[3:QX'&2<'2!CUP?\.:JRSX1,P6+)
M#?(L#<+E)3=BIDU$)'AK=0I''&0JY&R$6Q?H,+1"K)EBEU2RCMXFA,,3F2FH
MD&)2_E"'V(LT#"8#==PYOI!R[\O*/4! =Q 2CY" [#Y:P02:D#A-Z"CR_%%\
M^8X!XFZ=?'<1'?8 'KX#X_#</3KJ^>;-A*NRF>]@7+GZ[<P^OB/0-M]QU#)G
M<UY[WD":73N"+@)C;A](0VZCN(AN COM\=@Z;?8&J]]TJ3FY!.RGL$7(P[[
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4W@&=+NGIMOR4?(C&E!L>OODO_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>27
<FILENAME>g164680g00y17.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g164680g00y17.jpg
M_]C_X  02D9)1@ ! 0(!>0%Y  #_[1UX4&AO=&]S:&]P(#,N,  X0DE-! 0
M    '5R^=18X0DE-! 0       \< 5H  QLE1QP"   "    .$))300E
M   0S<_Z?:C'O@D%<':NKP7#3CA"24T$.@      Y0   !     !       +
M<')I;G1/=71P=70    %     %!S=%-B;V]L 0    !);G1E96YU;0    !)
M;G1E     $-L<FT    /<')I;G13:7AT965N0FET8F]O;      +<')I;G1E
M<DYA;65415A4     0      #W!R:6YT4')O;V93971U<$]B:F,    , %
M<@!O &\ 9@ @ %, 90!T '4 <       "G!R;V]F4V5T=7     !     $)L
M=&YE;G5M    #&)U:6QT:6Y0<F]O9@    EP<F]O9D--64L .$))300[
M  (M    $     $      !)P<FEN=$]U='!U=$]P=&EO;G,    7     $-P
M=&YB;V]L      !#;&)R8F]O;       4F=S36)O;VP      $-R;D-B;V]L
M      !#;G1#8F]O;       3&)L<V)O;VP      $YG='9B;V]L      !%
M;6Q$8F]O;       26YT<F)O;VP      $)C:V=/8FIC     0       %)'
M0D,    #     %)D("!D;W5B0&_@            1W)N(&1O=6) ;^
M      !";" @9&]U8D!OX            $)R9%15;G1&(U)L=
M     $)L9"!5;G1&(U)L=                %)S;'15;G1&(U!X;$!70
M        "G9E8W1O<D1A=&%B;V]L 0    !09U!S96YU;0    !09U!S
M %!G4$,     3&5F=%5N=$8C4FQT                5&]P(%5N=$8C4FQT
M                4V-L(%5N=$8C4')C0%D            08W)O<%=H96Y0
M<FEN=&EN9V)O;VP     #F-R;W!296-T0F]T=&]M;&]N9P         ,8W)O
M<%)E8W1,969T;&]N9P         -8W)O<%)E8W12:6=H=&QO;F<
M"V-R;W!296-T5&]P;&]N9P      .$))30/M       0 [_^-0 "  $#O_XU
M  (  3A"24T$)@      #@             _@   .$))300-       $
M>#A"24T$&0      !    !XX0DE- _,       D           $ .$))32<0
M       *  $          3A"24T#]0      2  O9F8  0!L9F8 !@
M 0 O9F8  0"AF9H !@       0 R     0!:    !@       0 U     0 M
M    !@       3A"24T#^       <   ____________________________
M_P/H     /____________________________\#Z     #_____________
M________________ ^@     _____________________________P/H   X
M0DE-! @      !     !   "0    D      .$))300>       $     #A"
M24T$&@     #-0    8              1<   (=          $
M                 0             "'0   1<
M 0                         0     0       &YU;&P    "    !F)O
M=6YD<T]B:F,    !        4F-T,0    0     5&]P(&QO;F<
M $QE9G1L;VYG          !"=&]M;&]N9P   1<     4F=H=&QO;F<   (=
M    !G-L:6-E<U9L3',    !3V)J8P    $       5S;&EC90   !(    '
M<VQI8V5)1&QO;F<         !V=R;W5P241L;VYG          9O<FEG:6YE
M;G5M    #$53;&EC94]R:6=I;@    UA=71O1V5N97)A=&5D     %1Y<&5E
M;G5M    "D53;&EC951Y<&4     26UG(     9B;W5N9'-/8FIC     0
M     %)C=#$    $     %1O<"!L;VYG          !,969T;&]N9P
M    0G1O;6QO;F<   $7     %)G:'1L;VYG   "'0    -U<FQ415A4
M 0       &YU;&Q415A4     0       $US9V5415A4     0      !F%L
M=%1A9U1%6%0    !       .8V5L;%1E>'1)<TA434QB;V]L 0    AC96QL
M5&5X=%1%6%0    !       ):&]R>D%L:6=N96YU;0    ]%4VQI8V5(;W)Z
M06QI9VX    '9&5F875L=     EV97)T06QI9VYE;G5M    #T53;&EC959E
M<G1!;&EG;@    =D969A=6QT    "V)G0V]L;W)4>7!E96YU;0   !%%4VQI
M8V5"1T-O;&]R5'EP90    !.;VYE    "71O<$]U='-E=&QO;F<
M"FQE9G1/=71S971L;VYG          QB;W1T;VU/=71S971L;VYG
M  MR:6=H=$]U='-E=&QO;F<      #A"24T$*       #     (_\
M #A"24T$$0       0$ .$))3004       $    "#A"24T$#      31@
M  $   "@    4P   >   )N@   3*@ 8  '_V/_M  Q!9&]B95]#30 "_^X
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MOU6&/=MVRW;NV_SG_GRS]&J'3<_HU=5-5[J'Y;[&[?2QG5#>?YHL8]GYE?\
MA5H]8<]N'+#D [V_T1H?;$_ROS/WUCMOSFD/-@
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M        _^$^NVAT=' Z+R]N<RYA9&]B92YC;VTO>&%P+S$N,"\ /#]X<&%C
M:V5T(&)E9VEN/2+ON[\B(&ED/2)7-4TP37!#96AI2'IR95-Z3E1C>FMC.60B
M/SX*/'@Z>&UP;65T82!X;6QN<SIX/2)A9&]B93IN<SIM971A+R(@>#IX;7!T
M:STB061O8F4@6$U0($-O<F4@-2XS+6,P,3$@-C8N,30U-C8Q+" R,#$R+S R
M+S V+3$T.C4V.C(W(" @(" @(" B/@H@(" \<F1F.E)$1B!X;6QN<SIR9&8]
M(FAT=' Z+R]W=W<N=S,N;W)G+S$Y.3DO,#(O,C(M<F1F+7-Y;G1A>"UN<R,B
M/@H@(" @(" \<F1F.D1E<V-R:7!T:6]N(')D9CIA8F]U=#TB(@H@(" @(" @
M(" @("!X;6QN<SIX;7 ](FAT=' Z+R]N<RYA9&]B92YC;VTO>&%P+S$N,"\B
M/@H@(" @(" @(" \>&UP.D-R96%T941A=&4^,C R,2TQ,"TR-E0Q.3HP,SHU
M."LP-3HS,#PO>&UP.D-R96%T941A=&4^"B @(" @(" @(#QX;7 Z0W)E871O
M<E1O;VP^36EC<F]S;V9TPJX@5V]R9" R,#$V/"]X;7 Z0W)E871O<E1O;VP^
M"B @(" @(" @(#QX;7 Z36]D:69Y1&%T93XR,#(Q+3$P+3(V5#$Y.C0Y.C0Y
M*S U.C,P/"]X;7 Z36]D:69Y1&%T93X*(" @(" @(" @/'AM<#I-971A9&%T
M841A=&4^,C R,2TQ,"TR-E0Q.3HT.3HT.2LP-3HS,#PO>&UP.DUE=&%D871A
M1&%T93X*(" @(" @/"]R9&8Z1&5S8W)I<'1I;VX^"B @(" @(#QR9&8Z1&5S
M8W)I<'1I;VX@<F1F.F%B;W5T/2(B"B @(" @(" @(" @('AM;&YS.G!D9CTB
M:'1T<#HO+VYS+F%D;V)E+F-O;2]P9&8O,2XS+R(^"B @(" @(" @(#QP9&8Z
M4')O9'5C97(^36EC<F]S;V9TPJX@5V]R9" R,#$V/"]P9&8Z4')O9'5C97(^
M"B @(" @(#PO<F1F.D1E<V-R:7!T:6]N/@H@(" @(" \<F1F.D1E<V-R:7!T
M:6]N(')D9CIA8F]U=#TB(@H@(" @(" @(" @("!X;6QN<SID8STB:'1T<#HO
M+W!U<FPN;W)G+V1C+V5L96UE;G1S+S$N,2\B/@H@(" @(" @(" \9&,Z9F]R
M;6%T/FEM86=E+V5P<V8\+V1C.F9O<FUA=#X*(" @(" @/"]R9&8Z1&5S8W)I
M<'1I;VX^"B @(" @(#QR9&8Z1&5S8W)I<'1I;VX@<F1F.F%B;W5T/2(B"B @
M(" @(" @(" @('AM;&YS.GAM<$U-/2)H='1P.B\O;G,N861O8F4N8V]M+WAA
M<"\Q+C O;6TO(@H@(" @(" @(" @("!X;6QN<SIS=$5V=#TB:'1T<#HO+VYS
M+F%D;V)E+F-O;2]X87 O,2XP+W-4>7!E+U)E<V]U<F-E179E;G0C(@H@(" @
M(" @(" @("!X;6QN<SIS=%)E9CTB:'1T<#HO+VYS+F%D;V)E+F-O;2]X87 O
M,2XP+W-4>7!E+U)E<V]U<F-E4F5F(R(^"B @(" @(" @(#QX;7!-33I);G-T
M86YC94E$/GAM<"YI:60Z-C1!,SDT-T$V-C,V14,Q,4$Q1# Y-#!$,#-!1$(W
M0D$\+WAM<$U-.DEN<W1A;F-E240^"B @(" @(" @(#QX;7!-33I$;V-U;65N
M=$E$/GAM<"YD:60Z-C)!,SDT-T$V-C,V14,Q,4$Q1# Y-#!$,#-!1$(W0D$\
M+WAM<$U-.D1O8W5M96YT240^"B @(" @(" @(#QX;7!-33I/<FEG:6YA;$1O
M8W5M96YT240^>&UP+F1I9#HV,D$S.30W038V,S9%0S$Q03%$,#DT,$0P,T%$
M0C="03PO>&UP34TZ3W)I9VEN86Q$;V-U;65N=$E$/@H@(" @(" @(" \>&UP
M34TZ2&ES=&]R>3X*(" @(" @(" @(" @/')D9CI397$^"B @(" @(" @(" @
M(" @(#QR9&8Z;&D@<F1F.G!A<G-E5'EP93TB4F5S;W5R8V4B/@H@(" @(" @
M(" @(" @(" @(" \<W1%=G0Z86-T:6]N/G-A=F5D/"]S=$5V=#IA8W1I;VX^
M"B @(" @(" @(" @(" @(" @(#QS=$5V=#II;G-T86YC94E$/GAM<"YI:60Z
M-C)!,SDT-T$V-C,V14,Q,4$Q1# Y-#!$,#-!1$(W0D$\+W-T179T.FEN<W1A
M;F-E240^"B @(" @(" @(" @(" @(" @(#QS=$5V=#IW:&5N/C(P,C$M,3 M
M,C94,3DZ-#DZ-#(K,#4Z,S \+W-T179T.G=H96X^"B @(" @(" @(" @(" @
M(" @(#QS=$5V=#IS;V9T=V%R94%G96YT/D%D;V)E(%!H;W1O<VAO<"!#4S8@
M*%=I;F1O=W,I/"]S=$5V=#IS;V9T=V%R94%G96YT/@H@(" @(" @(" @(" @
M(" @(" \<W1%=G0Z8VAA;F=E9#XO/"]S=$5V=#IC:&%N9V5D/@H@(" @(" @
M(" @(" @(" \+W)D9CIL:3X*(" @(" @(" @(" @(" @/')D9CIL:2!R9&8Z
M<&%R<V54>7!E/2)297-O=7)C92(^"B @(" @(" @(" @(" @(" @(#QS=$5V
M=#IA8W1I;VX^<V%V960\+W-T179T.F%C=&EO;CX*(" @(" @(" @(" @(" @
M(" @/'-T179T.FEN<W1A;F-E240^>&UP+FEI9#HV,T$S.30W038V,S9%0S$Q
M03%$,#DT,$0P,T%$0C="03PO<W1%=G0Z:6YS=&%N8V5)1#X*(" @(" @(" @
M(" @(" @(" @/'-T179T.G=H96X^,C R,2TQ,"TR-E0Q.3HT.3HT.2LP-3HS
M,#PO<W1%=G0Z=VAE;CX*(" @(" @(" @(" @(" @(" @/'-T179T.G-O9G1W
M87)E06=E;G0^061O8F4@4&AO=&]S:&]P($-3-B H5VEN9&]W<RD\+W-T179T
M.G-O9G1W87)E06=E;G0^"B @(" @(" @(" @(" @(" @(#QS=$5V=#IC:&%N
M9V5D/B\\+W-T179T.F-H86YG960^"B @(" @(" @(" @(" @(#PO<F1F.FQI
M/@H@(" @(" @(" @(" @(" \<F1F.FQI(')D9CIP87)S951Y<&4](E)E<V]U
M<F-E(CX*(" @(" @(" @(" @(" @(" @/'-T179T.F%C=&EO;CYC;VYV97)T
M960\+W-T179T.F%C=&EO;CX*(" @(" @(" @(" @(" @(" @/'-T179T.G!A
M<F%M971E<G,^9G)O;2!A<'!L:6-A=&EO;B]V;F0N861O8F4N<&AO=&]S:&]P
M('1O(&EM86=E+V5P<V8\+W-T179T.G!A<F%M971E<G,^"B @(" @(" @(" @
M(" @(#PO<F1F.FQI/@H@(" @(" @(" @(" @(" \<F1F.FQI(')D9CIP87)S
M951Y<&4](E)E<V]U<F-E(CX*(" @(" @(" @(" @(" @(" @/'-T179T.F%C
M=&EO;CYD97)I=F5D/"]S=$5V=#IA8W1I;VX^"B @(" @(" @(" @(" @(" @
M(#QS=$5V=#IP87)A;65T97)S/F-O;G9E<G1E9"!F<F]M(&%P<&QI8V%T:6]N
M+W9N9"YA9&]B92YP:&]T;W-H;W @=&\@:6UA9V4O97!S9CPO<W1%=G0Z<&%R
M86UE=&5R<SX*(" @(" @(" @(" @(" @/"]R9&8Z;&D^"B @(" @(" @(" @
M(" @(#QR9&8Z;&D@<F1F.G!A<G-E5'EP93TB4F5S;W5R8V4B/@H@(" @(" @
M(" @(" @(" @(" \<W1%=G0Z86-T:6]N/G-A=F5D/"]S=$5V=#IA8W1I;VX^
M"B @(" @(" @(" @(" @(" @(#QS=$5V=#II;G-T86YC94E$/GAM<"YI:60Z
M-C1!,SDT-T$V-C,V14,Q,4$Q1# Y-#!$,#-!1$(W0D$\+W-T179T.FEN<W1A
M;F-E240^"B @(" @(" @(" @(" @(" @(#QS=$5V=#IW:&5N/C(P,C$M,3 M
M,C94,3DZ-#DZ-#DK,#4Z,S \+W-T179T.G=H96X^"B @(" @(" @(" @(" @
M(" @(#QS=$5V=#IS;V9T=V%R94%G96YT/D%D;V)E(%!H;W1O<VAO<"!#4S8@
M*%=I;F1O=W,I/"]S=$5V=#IS;V9T=V%R94%G96YT/@H@(" @(" @(" @(" @
M(" @(" \<W1%=G0Z8VAA;F=E9#XO/"]S=$5V=#IC:&%N9V5D/@H@(" @(" @
M(" @(" @(" \+W)D9CIL:3X*(" @(" @(" @(" @/"]R9&8Z4V5Q/@H@(" @
M(" @(" \+WAM<$U-.DAI<W1O<GD^"B @(" @(" @(#QX;7!-33I$97)I=F5D
M1G)O;2!R9&8Z<&%R<V54>7!E/2)297-O=7)C92(^"B @(" @(" @(" @(#QS
M=%)E9CII;G-T86YC94E$/GAM<"YI:60Z-C-!,SDT-T$V-C,V14,Q,4$Q1# Y
M-#!$,#-!1$(W0D$\+W-T4F5F.FEN<W1A;F-E240^"B @(" @(" @(" @(#QS
M=%)E9CID;V-U;65N=$E$/GAM<"YD:60Z-C)!,SDT-T$V-C,V14,Q,4$Q1# Y
M-#!$,#-!1$(W0D$\+W-T4F5F.F1O8W5M96YT240^"B @(" @(" @(" @(#QS
M=%)E9CIO<FEG:6YA;$1O8W5M96YT240^>&UP+F1I9#HV,D$S.30W038V,S9%
M0S$Q03%$,#DT,$0P,T%$0C="03PO<W12968Z;W)I9VEN86Q$;V-U;65N=$E$
M/@H@(" @(" @(" \+WAM<$U-.D1E<FEV961&<F]M/@H@(" @(" \+W)D9CI$
M97-C<FEP=&EO;CX*(" @(" @/')D9CI$97-C<FEP=&EO;B!R9&8Z86)O=70]
M(B(*(" @(" @(" @(" @>&UL;G,Z<&AO=&]S:&]P/2)H='1P.B\O;G,N861O
M8F4N8V]M+W!H;W1O<VAO<"\Q+C O(CX*(" @(" @(" @/'!H;W1O<VAO<#I#
M;VQO<DUO9&4^-#PO<&AO=&]S:&]P.D-O;&]R36]D93X*(" @(" @/"]R9&8Z
M1&5S8W)I<'1I;VX^"B @(#PO<F1F.E)$1CX*/"]X.GAM<&UE=&$^"B @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@
M(" @(" @(" @(" @(" @(" @(" @(" @(" @"CP_>'!A8VME="!E;F0](G<B
M/S[_VP!#  $! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_VP!# 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0'_P  1" $@ B\# 1$  A$! Q$!_\0 'P   0,% 0$!
M  $'" (%!@D*! ,+_\0 =A    8! @,% @8*" X*"A$% 0(#! 4&!P 1"!(A
M"1,Q05$48146(G&!D1<8&2,R4J&QT? E)C,V6&+!X20G*#0W.$)#55:2EM3Q
M-45&1U=E=96BM@I(9G9WA;72T]8I4V-D9W)T@H.&AY.4H[3#QD2DIK+$_\0
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M)/NS_:6> \3=E_Y@H_\ ZF 'UZGT)T$A_8V0 N]D7_YSS5).+?[8\RE^[/\
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M80=AM",S!9DX"RB-/_F.^?<FT6F2*U/QZ"^8]M!VEPCL'$]9O^8J.'COMO\
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M6A(ABAA <$"I#5(I2_-M<8+C:!!9LFG-Y&LF;BF;#<VYBB0"[$V*4NW)][(
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MAT&,V V+ "*."("+V9)+R8DS+,\CA5@H2];J-+N#8YS4D:/Q0X5;6CB$7O\
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MS>&W7TV'].H^D']6+"A]?P4:H%7DX-)S/,/("B ,<=^@=/G_ $_7Z:;6D/\
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MR]8FLH[>%!K.V@TK#,H"*?PIW;91FLY4.H4%% '7%HNDQBQA,!A&C0QB'9!
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M7K<?+]&@[;ZL!!$4$BX]R![F_M?2N2;!O YGN:F._DE'L->TYZ@/#HH(=?\
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M?:Z*\W.17F'(V)-^^2$HIJB/QXWYTQ(02'_#*)2B40$H:?3?57V;/[EG2_\
MM]Z>S. P7J;=B+VI#!<CIEP_OVCI-(J";AID[%2"Z:)1 2(D62OI#E1(.X@0
M#<I1Z@7?6KZ8:HB/O10UKL6?\V+N94P$X&IK?QO(?#?CY?N'?:>]?ZG1QN("
M'-]D?$@AL8=S (?'L!$!$ W#KOT$?+;E6';74MD)10[O90"7&.7PSG#!&\@'
M_P!(#U&[BUZ3[AOVG0;?U.BWE_OCXCV^H+UY!OT]=:SVVU623M0,_P"S@_F^
M2;$6'>$OW#?M.NG]3HMU';ID?$F^VWC^_GIU^G;WZGTVU9]JS_AP?S</7)78
MBRY]_GY5"0>PV[3O^#JML.W^^1B3<.FWE>M_GWWVZ"&XZOTVU7]JS^Y!/?\
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M.*98]=45TT"R9A#8L8)2N2&Y@Y/DCK)2>+]<CR##OR\ABG(4Y# <ABE,4Y1
MQ3E, "4Q3!T,!@$! 0Z" [ATT55MDY2-B&<A)2LBSB&$<T.[?2<FZ29QC!JF
M18YGCQTZ50:-VZ)2*'<*JJ$3*0I3**% I1!UGUUBICCQ+</(9+W-U"*H(*IF
M*=-1%-1,Y506*8AR%,4Q5BF,"H" @(* 8P'#Y0&$!WTW3SQ04&Y>"4EXV)(V
M/*24?%INWB+%NI(/$&2;ETX$P-V3=5=9 IWKD2B#=!,QU5#%-R)FVZ$XM/H5
MO\),KF4! H (B([>?C]/J(>&_GXCHJK8[DXUM(,(MQ(-&\C*%=F8L%GQ$'K]
M./2*X>FCF8J%6>&:$404=BW3.**"@&5$"#IU1_%1WE=>03(C<)<PKF0! H<P
M[F'J;J80YAZFY>81$"@(CREWV*78 Z!HJ%XGCI)H51PY<I-&R"0JJ+N3"DV2
M*G]\4777%9-)- B>X'%82$#81$P@&P.O(=ZAZD3X=93"L-9M=5N+9XO5+9 6
MII'.SLGKFNV&/FB-7A1*L#5XYBG*Q6CDI!^4T7$%03$HCN0=M6GQ]"H)WR:7
M/$,0U&\W7M0EF#MPX;LIIB\41>.(]<$'C)P+6329'?&AW*;=<JJ+Y-BX1D2M
MB)D>^PH&<+G!(Q#FG773>=W%^^Z4G%<?*ES,H @4OWT@F7,B03"J7<VYP.(\
MJFXE$A#G2.(\I=R;!OT%UUX;TKB+@[@T.XGF^YE\8V5C9,7I(^19/U(YXK'O
MR,W:3D[%XW'E49O"I*JBW=I?WU%0$U 'J8@#HJKGHB-$1HB-$2" #X@ _.&_
MY]$7S.!2D A2%Y1,4HE#<A0 QNO0A1\1'J78"FWV,( (Z5K/O4)\<<?'%DQ$
MGWJ_$#42I,*ZM'%Q_8TG#\X0AIY-=*18';-FH&?FF1CAYCJ*@DP]B(J!.\5*
MIR\V)LX"9P0EJ/")<]P;! S#U?K-/WL&PAL&P^(;!L/SAK)5   =   #T -M
M0 "@ W21+JHC1$:(C1$:(C1$:(C1$:(C1$:(C1$:(C1$FP>.P;^NVC"K3Q1+
MHB-$1HB-$1HB-$1HB-$1HB00 ?$ ';PW#?;10@&H!WKS.12( &/W0;B(CS<A
M3G .HE3,91/8P].O,( 'X0;#K&*""-A'##$ 9;4(B SF#W)(4D<F!.5V-TTR
MN!DW!JO/DDHVO,URW^Y+()P*,81J9HM+'.W<."QRBJ?PFJ4.9^HIRKG6V,IN
M;KJ16=G$(1%!!$(2(H1%#"1#$*&$$$ BXB8N5>H??-WWWYSQJ4^0$(4PF*0I
M3"4I!,!0 PD()A(41 -Q*03G$I1Z%$QA  YAWSN:X4%P=GEP'(8(JM$1HB-$
M1HB-$1HB-$1HB-$1HB-$1HB-$1HB-$1HB-$5/*7FYN4O-MMS;!S;>F^V^WNW
MU7+,Y;"[DHPJP?%@E$ $-A !#T$-PU$848-@R715<H4SA[B%J7&EE3B'OU)N
M.5N&6K\=U\*QPXE%S2/P;+6A8J=6SPW:,C@C;X&NNB#'^QN$U&K=L<7I  P=
M"E+V:=U,*,W?WKU4W/G:;2[KB8EK'?<@U%S1*Q=[^K%V&";PM1C96B6XDG3Z
MO4I>31:1\4PN5=:)Q+V-1.Y;2,>]67,"3H1$2;NYNM_=-3->VW//$]V-_&)F
MNV(VV1M?$=BKB!R!A_'+5-<E@K&.7L!+1F,J3!(LBD7++3L;$I3+5=N7O%G5
MD;.@,=0PF$E*XN^_IL\R2S(P-Q[0R"MI;?6+ME62:07$_8,*U#$3^N%-CYUC
M&,X7E+=$3\HD9DFX(R2R?[# M'[A19$K@@MN_.83%%UUUN3'ISU?Z)IU+;Q1
MY>Q15V%HF.*&]9%B,Y\/MBO4!D.AIUZFT:[_  S8/C"RH4JP DN]AF.S<KAJ
M)@A&;/N'*9 .L<1)[N1+[R_PEN&2]4EQ3]H78*RPJT(_SY7+Q3,-\1B.2K*X
MQG)/625WB[<J-'4C$$5&S>5<-JT($C)9N!W;1N(NVY%UTD2@1[]U[R-"PSDO
M!5<K=H9:JQP_7>+I%^M.9J+%=HHQJ%GN\:>99S$@WP12WF,Y&-EY",:2+>O.
M;(XD(^M!9TE)B?F(]Q%+.3L (31+PV?FYYL.@V44W+''Y>&K*ITG*7$NZQC:
M,[\-E<'+=XHJ,!DR(/9:+=G/$)!-FY&HH-JA7YTM46CI(2>QQDDLO',C]PW3
M,=P?K>R<PS]YK\#3"BE1,(\7>7NRGR'"S[N\V?,\=<;E6Y+X09*1F0;SBZGY
M <M5F*96Z;(Z\O8:BTV3>)D [P5 4[T_><XDO)DUQO9C/OE23IB)"=;NZ?,J
M=GW@G/'"L[M61.&/'%MR82OOH-&4BY6\QK"]&84%S[0@62JU;6?*3=R4*'MZ
M9Q*HH (FW4N;+#K@H,7=\#*MU]V+<$TN2J5Q38]XAZ%88>3S8_:X[XW\]0T'
M96,(Y7"_3SO@=Q7%XBL60$612-I2&M^1XE_3K'8W39PQ%A8[2W44(Y4()S;^
MGX[[A*]'N#&53BX <B_+P7@PWEWM/,A8W"OS>0,Y04G:<U\.-:GK8ZJ*J%HI
M#RTQ]Z5SBS@W[QHFS"#AU$JTJ:-!B$+7W!DD(UP"9]@)C*DZU)GXT.(-&7ES
MA?\ C?PN;-]/Q(&>8:2<<1>8)6"R%#P!Q;W5"$BT1KQK.ZCF)Y69>S[@BCR-
M10=H0[\3*INCB4")Z*W82N\OP73?@2>LUIPKBBQW,'!;;.8XI,K:".VHLG:=
MC?5N-<397+,Q2&:+#(J.%#M3)D,W,H*0E#E  (+^?.[H\@R=S15&B(T1&B+Y
MJAN4/D\P <@B&X@/R3 (;"'F!@ 1WZ"&X>>BANR(-_E\4P,LBT'B-HBYH217
M>EQM;2)SY <$C621Y..,I'N2I&!D=VZ'E.B*I!7*1(_=FY1-H@S+]9..62D%
MHJC1$:(C1$:(J3CL0P[B&Q1'<H (AL'D [@(^X>FB+1SQ#Y"FXBV=H9>D>)?
M(M"R7@"WTA3 V,V&591K49LX<-F#KG%4O[$P2I8RUIY R)8YB.?*%A7#A-:?
M$B:@K(F$KX7=979OA'IF]3G3A.62]-D[3#+M:9N[.[J6.%X8]WRSCAK14WLP
MGE&N3.)Y@(AW:KHP*]7:$J\J1!W(&,T8,BLVJT><ZZG,=0Y.-\_3+K-_/?>.
MC+%OSUCFOXONV**O!5^1_99_9[.\4HMC5L/#[:+X]A[ ,/*,T9-[$R4<@%>9
ME<IG;2/=J'146*78E'F3EEN]?5,M#]IYF]I:IQ:+JSV6>9/L-:3AF,HWDK'4
M,=H1.+)BT3"<"Q/8*NHLUL\G'H.8=,TR4KF*7</EB.EFI2F8S^".<&XSZISY
MO/Q+<;&2<C\*^+)NJX_S;A6WWFP\,LK8;$,Z&*Z2Y:9*;04];*-5LVL)EXNW
M6CTI5>.=RX1:;4B+4P*"L)3!I\._\"CS;?(;P!U2N#J,\?Q9YRJKAM6I+(MT
MD2TW(N>(V1KPY8DKX8:YOA>2H\6MF*%<,G>1%Z^WM+OO)0AVKB+<.W\.H443
M+"H2E]>X^GGB\I.2':09WJE>^.$]2<;R59M3++4726$8XM367AY_&AR@E)6Y
M^\?+IKQ+QN4ZK]*/]B50Y3"18#&YM$NG6]VH\Z=4=22X3<\91?P?&58\G2Q\
MTRF->(]>LP<5A)N[LL<K!&Q!B&5;Q6.8J7EQ548$D9]](NV1)KND9!6:7!0J
M@*)F8H[,U\@27N)&_FI9T'*Q\UL;A 'QWFO$Y4HM9@67OE=2HTFN660>LQ?U
M5XQFY-Q[;&%(1XD^2.V4:++M%D^50@:)?UES6J>#0LY.'OB#SRZSUQ-/*S(7
M1S7>'^NJYXO_ ,)>R1<^6E5F<6L(2PR+A"\S3I*=<LS&.T0BRBV*43)Z)G=G
MU+KA+J[7K+O"-PJX8:OKJPO>59G(F(<83]YS9/R3N%2ELH72-A):1GYH7C9\
MJP@"R:B3!4SQ!99!HCSJ%,J?12ID2&$ZWO<0W'@H4Y'[6#)U*C$W+6MX^FY&
M@'L:N1 B$9N1@[3$0&3$J0C8X"3^,,8%=@)2/1>NF#TY;,HXLS)W$BV",:N^
M_*]&OF^$Q4/5ZX7*=H1GS#$O;7%N5CLKV%ED[B<IL&S@I&>0BJQ%5[C)/B.N
MIW:KDF&<2NO"0Q@;0G5C+)0J]?;EDT@?N'C@CUN-XK<'9M]UZ=^([1[B7LD=
M*A%8SQU$O*%5KM;+<^M:%@;ELD;3;RYJQ"UF.B+$^0BW$XP:F=@64E)!.+>#
MW2JJY ,&B7U% 9;YF^1_"BP13M'>(F@QMQGI;[&=IB'>:+H)R@C+R,YC^CQ=
M.I<^QB%X0ECC3!#"M.]Q\8""],T,23<DC'Q%6XMBA<3WRJ\ZXSN$K@X6TWAT
MI6:X>VY9O]_SDKE+&V4GT!;<2U-S"EC38VB7;)<R\,W>B5-5Y'K-U6!R%%)
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MS@LW$4;@03@.UM/M0Q';$3N8VB))FLMHN[WDY>\TFPD .$TRX9\O#N>S%9Y
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M?628=/NZ*8CAV.Q-5;,#!6672^R+>064F5$U'0."S)P510%(I"ECD1'E8E,
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MDR;MQ.IN8P(-VZ! ,8QU=B#WH[B7<J_QPYY7X7LKX;R$1*  8OB " [F* "
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MI:QVAC+F*(1D&)RYVL7-70$X">0+94;ERDKB4O+OU$=Q$>H[B'N#W!Y!Y:S
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M8B9N2:K%O+NW_BK@ ;;]1,(CON.VX!Y &P!T#KMON/4>NBJ71%0H4#E !'8
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M9=TYG'MB:&@GC1DL[C0+W9%7=?@HP(QGB3.F;>55X;;=NT&DJ94+=:G^1Z#
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M&T A9T*[B6W8KM3RNP5]HDI/X;?HOXZ*B;A=;'465K9(N(XJ\FS35*DX6Y7
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M:;*7M\QE).9HU;K@1AH>*DI&E2L7-21;=$1LG*LFC!(@MS4[FZ>?-&<U?<9
MY\12<R9%B5C2G:>XH87V%KPP%LF:A9%)YXE;(2BY35>0<#"U=C95I2P03W&<
M<JU.K[:8QVK>0?@RB$RRS]VFFL4FHCF3B_?QK("LU+A7BKPB2IY3O*=P3-4<
M,P;&Q9!L!HF9"(AHZ0AOC B*,@=B1D\7-"]V[7;QZZZT>DY;B[0(*I2#:5?K
MH;\D$PY8OQY3(I+Q=TUCSM ,!,:E#V=Y'YI(K-_'1X6G$P%F%;(3:M8XC:M)
M7R[2]#)1!LK7'-::WRDMY"_FC#T\'=KKD:2;-(2";895_*;=_P =Y1J8O60>
M4^X9^!'AD.T5X6(=]8!E+?:V<)6?CTS"TGQS?GE(L\KCE]\'72'HUQ:0+ZO7
M&QP#LYT)& @)*3F4E4UVA&17,?*(H,=^7XWX!^"-=//">1DVZ8H*E>NL<?O#
ME9;'7*J@YR5$O+*_@HA.2MN(,D5"!K]DN3?VVM5BU3D]7(J.JL[.-!!5A'3K
MEFY42$JBB@ )=-ZK3E@U[#@X#<'619AXOJ-P_9#IE)S'7+)4JOD64A:Y0<BL
MPC+9 V6T2JAV[.M!7Z[*RE]C)%)VHU%>7<U!:KBDN4[N?1,(E*?-C7KU\%"\
MPSRE3O))<AO@5Y>)_BXB\!V[#6/(FKN\A7/)^3<=U>=CXZ218-L:T&X7JMT9
M7(5O>A'R@,V[N=LC.!J,,Y18.[O(GFVT(L+>MV)_%7S\/Q\$<!@2[28L[EF[
MB7\U,LJ*:H[F,4YRD3Z\FQ0Z!\I(IC'*5)3D*(E(/X1! QQ, @$59[W'1DTM
MQ9\U69N8! R*A4CBH!SF$AE.8HCNHGL90.4#CL(" [$\BCY$;KQ._J\I/9S;
MB8%1 YC%.8=C" F#EW  [P! FQ1Y2;B!1,(B)@$Q3$;'+B1CE>!<=Y5::)4B
M&(7;Y2AE/D[DW,)N8 $VYCF'8H <QA,)OE#L!1 A3]==V%R2#3OEOK6N-\W;
M!,1+-^;B+I+@:JZ5,ECFUIC;B*()LV7>2C$/@I5 &YU5EG@)@LFH+I$$R)?N
M!P/N!!QX]>,T_P!HJM5W;(?VD%V_[Z:!_P!<X3]?YM=J[%?]I-7O39TO_P"B
MTA%QX*;AR;;>(B/CMU#RWV#P\NFW3<?$1]YB_5N]T;[^/EBJWBT_/#\6HJ=Q
M\? ?+W#T^??KML( /IL'GB81&#"S.X9YG?/*X,]:H6:DL32^O"Y\Z*H-@$-]
M]A$ W 2AUW /$QB% 1W -Q,4 \Q#6FVB,%GL0.),S!PPG<3C,L9&]8EF<TQW
MR\^]3SX>^+YC@^B0T G4YI];*[,Y<?1[Y@>/*B1_D&N5"+@%"JBZ*LFW1?5!
MVDLHDL4QB*%.!T1  'HVE:IMM*UA%&8A%!I!L+**$B @0P11@R,?O BUF&'U
M9.["OB"&)+N':5)RXX7)W[SV@5)M.2<=3D?C.P,L54]?+%:FJ"=R@U:26',C
M56A8[:UJ).T>MED_9F=."P1;$PK<DT<'954E-W [QV1MQ8D?*";>*SLX?:-"
M ;:SBCM#'$/:-L1QQ[,<('Z(; ,ALY&T#RD ;P[0E@S.!P)K.DS&>7XET+%=
M^)FU2T0]%7,E9=5>!C&GP9(QU0;*2+!6$@7BCD =)L(.%CD&2+9)0R9MDP*)
M>X %.19]E;6'Y*/:/[*ULHXXHX88XXQ""(BXMA.*NTTF=B[IMS+SV@0\Y95I
MX;V7DQ5Q)!CVW5F>=4V&B8>O5*5J\DCCQ*<C7UM)(MS)>U7%NO8';"8<HK 1
M5$QHU-LD4#%*SV-N'U]*[/;4-J!;11Q1Q;4(M!9[-C@+,B* @/-XC%%G101[
M+&0839W+U>LNI&:?O%O'Q"T.@4.GNL,-%W^-KKC"=B'$!*RK8'D)5W4V>R2Q
MTE%CH$L<JTLDLV"4.1TJR%<JW(Z4:QWL/7-)[):1:QQQPVK"*SM8/>ALXP#:
M; <"*W;9AV']G]6(Q1$T&TVF #"1!E(UJ:]/PP!QQ45B(NS%2K0MU1QK!<.D
MAP^0$#*.6#60EGTK4;*"ECLL*Q= T;NHZT6R2)&(+N7Z#1(B*)5MB (<_1^S
M.D6MEL16D%G'%:06D1LP)0V=K 1 -NVI%! ((RT,S&6!,CC:D"P#!\X6B-2[
M&)P][3P;?ALR_CS#CR;LEAK]WDK,BPEF$4K77D0X@WD-,0;F+?5VR-GB:RD,
ML[=.!<*S[!5RY*TW8$9B79QK=K#LY;Q@0PQV9A.SM".$1?5B=PUL-HL!L@F$
M M%M%F010PEJU+ !I!IR<2E0NXHRDU =H#62UFB5][A%K$MZM81*A\5)=XG%
M-JFM6I&OR:\.W<29DS3:[>17!3G0;-UU!4*HF94R3A'YD/9G21:&,6Q/NQ0P
MDP66U"3$(A2UI)B(H2:%[C7D 0&=Y/,3?\7\$S(\4$.RXAH3+E;A+8S@*GA>
M>Q?3VA@9M[*+E+$LW0H:?L:+,J3)$YW4\J^31;%6)&N&"238RH%(=+EP=F-)
MCL8;,VD(B%K9VL30P $06PMMD/;3/NB%R \R1"/=&.T-LF?U2'OP$VG.;"II
M.:D;1>.N!LUOH,9>5YE6.:*X99KV?($SWT/#/:'@:UXQMMJ2>LV$R\82-CMD
M]\96$@C$J*.G+&*7E5HU0#+-_D6O9K2;..T$-I$T%KI)%G9^SAVH;323;0PD
M1VL,,@-@/$(6BBD 9Y;9)!)F6GGLL3)[IOE>O7GGBRI5)L6.(FC6";R'*UF,
MQ\SR/9I*=0LIYZ"@!>+*PSBPLU%V\U,/?AF5(^4 '0 JJFH9PN)  )9Z@TF.
MS/NBR:*,V3P0!H27@)A%J&!D3"&?^[1"=DAIE@#4A\B09-2*\3FO4][2:CI6
MRHV*"P]-PS"%FY1*2CF_L@EFJQ"5Q]$X[KK@"*LU%8Z+=R3Q[9Q."9CHB@KW
M:IB@0.79=FM*,$?Y]MN"L&R(MN/]):M%:Q0B,$#V0 : "(%ZAM$B09KL@\KB
M15WK63LHL0_$Q7X_BH0XCPB+:_;)H&GI*DMWC%)M*V)U4'L3)5E=4SE5!KBU
MW8E2)H=W&K.OBQ*.($&G,9.33W?1W23H_L(K;WMG9%KLPB*&': AB$4=M$1:
MPP"49)_. 6C!ME1V+]V;2%TLL)+![SG-I.<3;O.]=-<HJ*DKQ!7=_$.7!$I9
MM%LW#.1DJY&.XM5NJZKJ*Z2T+!)=XDU+ (L5G$697O&X?3LM"M;#5\.@QQ[4
M4$%K9[9,,3F-_?+Q%RT3D;1H0Y9T,0VMH"\%A(.3.$%BP>3LV].JTXBL,H4[
M."R%2R4PR;EZ?FW;&V,6<(_9QU3E')G!*Q'@ZDT%8HCXIA+8W*<.!WY=D2E*
M5,J@\2ST"WATBPM";.*RLP2(' )M!(1_K B$'W0#"07B<T#: $503E=A=7 "
M<I35]X;^,^JX=QP3'-TQJZO"2\Q)QI5RG;G%OCZU*-G=QJ[,76RC>:?O(J(4
MCFY1%%1%-VV1=,R*'..O66I+?6&D_*H(X8-JRA@,S..!Q9Q$>U@!@A$<1BA
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MOY>.MVC_ -(L/]=9?\<*+A,PA_9KQ;_X1JO_ -86O3Z ^<?7UU^B=<?]E/\
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MHH"/>'4#8 $HY>CC%P_*5#)-\?CYX7TZZ,TVNTHY[R=L<&I ,Z?9'5M:N*_
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M*]K,[8%'E=$2-N&B!PX;=@& O.<G[@I4%2,L.Y%RD A>4H%(4Q# 8!,"VP'
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M2(2VP9Q/1AB\ILWI5"S/>'\J9U4Z.SZR?Q"T/B&IC# 35[8GUIDX^,LM*YE
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M8TO!F<S0;-$W.I6]S#(OVB5B@YMY-Q8R,.JX*G(,@.\.W=)G5(HHGRJ@3G*
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MN._=4J-*71#5OP_%7BO\#O'I5YR.LT#A')T7/Q;AFZC9)" 45<1[QFI(?T4
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MJ?@=R8/AY;MT*Q9A0BI"( V0KL*B,@X]I4=J#,'$SU _<-^[;+B',DEW9@*
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M^4'CHH6D^+[FF_3>2C_++))\2%&:GGI=%=3&]L62KJ:+OX&?)%DHXAY%TO\
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M'<0'J ^8@!1 "B  /F.X!X:^&I?UGZR5>BJ^*H"/+L([[[; !A$>;I_<G(
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MTH^8K/FG<X6N)3(64[)Q!W^QQCAZG5,08SD6%7BEW UV3GH.8S=$R4_445"
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M5^*7Z/Y?S=>O^O3@]PG.=-_)15$*40$AC&**@E3(IWA2E0,(\PKJ)C^[IE(
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MJ0,0C,+DF$BE 08687?$K$:9GK)&.K';;50K(TI\U?8:6AK(XA(N CFA8N7
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M,85%B'4 =E5!.B7O%>@'.)4B$1+S"'@D*A '\%90!YA^W%;:'90-#I.C$L6
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M 8Y@3*7[Z;H!Q .3E G( !KH[#:,3,347#Q.4R47T4-REWW  $P ._H([#L
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MAZAHB3F*/@8H]-_$/#U\?#WZ(CG)^,7_ "@_3HB.8H^!BC](?IT1'.3\8O\
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M3NU2*I'*<JA/D'*8#%^2(:$Q$LY9APGF&I*LL%&& ?&7IBOO\>;WX?'*V_\
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M\>;V&_[<K;UWZ_#TN&X#MT'[YUZA]>J26^L687RRQ &);#!1A5@^+(->KR(
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MI<B8K/V<*;=,K6CAW?GD,68M;/8PV7K7$XVO4G:LKRJ;MLNO3J\ZJ-4FHEO
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M3OY]9&4OP*1]09F981R^4]9>53OI;**Y(]X+D5'A#"Y$)HHN?E<DKO[242@
M" AU-MN%ZZZFBULE_"'S#D* _P#WSO\ 7;WZQ)8C\;P #?>6G<:HJ_ /+8/?
MX!M]/7]?GKL:N]TGK7%A3O14B/N#Q#F 0\-_,1^KR\=,'SI+U:N(/D2@'KMT
M\!Z;;^/AY;?1OJ3>6#%WNI6LS6?BB7?P$>G7;;W^&WGOU]-O?YZC8!W(),N+
M W-2M:HCF !#J&P@(CS'[L@EY1W*<_38A@Z'#KS$$Q.G,&LISEN;X]YED$4
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MF8W=.DDUT3JHGV.0JI!,4.8-%1GUA\5<=$7S,.YP+N'*!!,<H@.X[C\@0-N
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MG[](!.)'XGE)Y#>UQ^*NEYPEV@%?JM7CJ9:\R3%:?QF-Y?,*#BSDN5VE9MO
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<HB-$1HB-$1HB-$1HB-$1HB-$1HB-$1HB-$7_V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>28
<FILENAME>g164680g00y19.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g164680g00y19.jpg
M_]C_X  02D9)1@ ! 0(!>0%Y  #_[18R4&AO=&]S:&]P(#,N,  X0DE-! 0
M    %A:^5E0X0DE-! 0       \< 5H  QLE1QP"   "    .$))300E
M   0S<_Z?:C'O@D%<':NKP7#3CA"24T$.@      Y0   !     !       +
M<')I;G1/=71P=70    %     %!S=%-B;V]L 0    !);G1E96YU;0    !)
M;G1E     $-L<FT    /<')I;G13:7AT965N0FET8F]O;      +<')I;G1E
M<DYA;65415A4     0      #W!R:6YT4')O;V93971U<$]B:F,    , %
M<@!O &\ 9@ @ %, 90!T '4 <       "G!R;V]F4V5T=7     !     $)L
M=&YE;G5M    #&)U:6QT:6Y0<F]O9@    EP<F]O9D--64L .$))300[
M  (M    $     $      !)P<FEN=$]U='!U=$]P=&EO;G,    7     $-P
M=&YB;V]L      !#;&)R8F]O;       4F=S36)O;VP      $-R;D-B;V]L
M      !#;G1#8F]O;       3&)L<V)O;VP      $YG='9B;V]L      !%
M;6Q$8F]O;       26YT<F)O;VP      $)C:V=/8FIC     0       %)'
M0D,    #     %)D("!D;W5B0&_@            1W)N(&1O=6) ;^
M      !";" @9&]U8D!OX            $)R9%15;G1&(U)L=
M     $)L9"!5;G1&(U)L=                %)S;'15;G1&(U!X;$!7]UP
M        "G9E8W1O<D1A=&%B;V]L 0    !09U!S96YU;0    !09U!S
M %!G4$,     3&5F=%5N=$8C4FQT                5&]P(%5N=$8C4FQT
M                4V-L(%5N=$8C4')C0%D            08W)O<%=H96Y0
M<FEN=&EN9V)O;VP     #F-R;W!296-T0F]T=&]M;&]N9P         ,8W)O
M<%)E8W1,969T;&]N9P         -8W)O<%)E8W12:6=H=&QO;F<
M"V-R;W!296-T5&]P;&]N9P      .$))30/M       0 [_^-0 "  $#O_XU
M  (  3A"24T$)@      #@             _@   .$))300-       $
M>#A"24T$&0      !    !XX0DE- _,       D           $ .$))32<0
M       *  $          3A"24T#]0      2  O9F8  0!L9F8 !@
M 0 O9F8  0"AF9H !@       0 R     0!:    !@       0 U     0 M
M    !@       3A"24T#^       <   ____________________________
M_P/H     /____________________________\#Z     #_____________
M________________ ^@     _____________________________P/H   X
M0DE-! @      !     !   "0    D      .$))300>       $     #A"
M24T$&@     #-0    8              (X   (3          $
M                 0             "$P   (X
M 0                         0     0       &YU;&P    "    !F)O
M=6YD<T]B:F,    !        4F-T,0    0     5&]P(&QO;F<
M $QE9G1L;VYG          !"=&]M;&]N9P   (X     4F=H=&QO;F<   (3
M    !G-L:6-E<U9L3',    !3V)J8P    $       5S;&EC90   !(    '
M<VQI8V5)1&QO;F<         !V=R;W5P241L;VYG          9O<FEG:6YE
M;G5M    #$53;&EC94]R:6=I;@    UA=71O1V5N97)A=&5D     %1Y<&5E
M;G5M    "D53;&EC951Y<&4     26UG(     9B;W5N9'-/8FIC     0
M     %)C=#$    $     %1O<"!L;VYG          !,969T;&]N9P
M    0G1O;6QO;F<   ".     %)G:'1L;VYG   "$P    -U<FQ415A4
M 0       &YU;&Q415A4     0       $US9V5415A4     0      !F%L
M=%1A9U1%6%0    !       .8V5L;%1E>'1)<TA434QB;V]L 0    AC96QL
M5&5X=%1%6%0    !       ):&]R>D%L:6=N96YU;0    ]%4VQI8V5(;W)Z
M06QI9VX    '9&5F875L=     EV97)T06QI9VYE;G5M    #T53;&EC959E
M<G1!;&EG;@    =D969A=6QT    "V)G0V]L;W)4>7!E96YU;0   !%%4VQI
M8V5"1T-O;&]R5'EP90    !.;VYE    "71O<$]U='-E=&QO;F<
M"FQE9G1/=71S971L;VYG          QB;W1T;VU/=71S971L;VYG
M  MR:6=H=$]U='-E=&QO;F<      #A"24T$*       #     (_\
M #A"24T$$0       0$ .$))3004       $     3A"24T$#      +_P
M  $   "@    *P   >   %"@   +XP 8  '_V/_M  Q!9&]B95]#30 "_^X
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M@P,C+)]P_>9CLVN8W^O8S_BE+_&1U&W]3Z4PD,M!RL@#\Z#MQV._D-?ZC_\
MK=2Y#$%K;(V^VQHD$ SK[(GVN]X_L?SG^"5K#AB8\<A=[!CG,W0T>MZ1
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
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M-Q^L".K^#_TBG;QJ;%4DTF1Y#7]R>X1["8,BKTZW^11O@[< G?NF6E*0?"?
MT$U"K@$O7NJ23XT%-F:QJT4B6E)!&E/F4;BFI39^HZ-'F;'(ZA2_QVH<LXN@
MI5KC6W4@I';^>B4O\<02""IN(]D2U%)TA*= 29,J8*%C=CF2[=4DI/@<H<UM
M J 8DMTJ;.[4?Z6\8K&\JJ7:R3:1IM>NN8CJ?D6$F<B%!AAM()_$K%7=\#6_
MS!3?>A.^].O/6-@ES\66$E1<E*0G*M1()<)0D DM6B1774Q,*)()=(+.HJL
MPJI1S/X.[VC!W)_M0_0GA=Z[CM[ZL>&F["&^(LQBHDVF30VE[(+;M]COWFC0
MX-$*)<5V'P4D['6RHY;XM.2F8C"**%#,.TF8="ZZ%"IV=)_ZD@C41YZN+85!
M9<UUYF[J9BO/-V8'5LQ<VZ95\7\X<7<P8\UE?$N>X7R=C$A1_P#:'!LFJLDB
M1E=A4$V!J5J2TL%*NYL@. #:T)3^?KR\3PN=PUTS</-DJ#DI6DI2I(8J5+65
MK2MLP)"'9PPTC(3C$3&((6"SE))4G5UI"4D#J6# @G=XF'T2$!:#L$;^8_S
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M7 .X!]8S8CU,(.D(.D(LMM;1*:(7YSBU+<(98CL)"I4R2L:;:@M*6DJ>.R
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MJ.Y2F9A<. 3>@-7<6!^7>=_AASO\.)RL/S/@A([4E4J9)G8#$2%"O_$PF*Q
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M!'N1'J80=(116-A%JH3\^8Y\./'05N*^@^@'U/2();KL-S"&I:V3-D*R.WC
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MHIG@JFIP^+$HDI"AE%.GV%'$6(PP-$MM)!T- JU^;0V= G>O)\?,];\* #8
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M'QX'N?.]=(C^E_=Z>5XM&*UKU=3QTR1\:?-!L+"0K1+\R:LN/E1\;[4J 'U
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MX:4ZUYZ1!Z79Q?V1OM3I$E_<U&.T-K>V"TL5=3 E29BOS@(B5S+K[QVE._\
M=H)\)[?'N>L/'XE/#L'B,1,.42I$Q8+/^0L!1;/:H\=8SN'86;QF?(P,E/:3
M)T],I S@ K6I* Y*I8UL5-Y.8X]O4%RW8\U\OY?G\YY,B-:W$MBH:"="NQZ&
MI;-#7GWVIEILSE*'DB3[>>OS;YRXLK&<V<0Q94I07B  "2&8DI<9 X3<#**U
MU(C]?/A%RB>4_A?(X:I*)<U6'7-7E"25+7D*U#+.G %1HY6"6#D,P9(@GR?
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MIR.ZOEJVH)R)"60?_P C$XOBY=QU6#*7+D)6.^5S9O:3"$+*>T6SY$A.1"&
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MAII2_.R?&QOZ>=:/OKVU\_'CK5IDY,M&:EO!BU!8^PT>T0]/=*Z;14 [ /U
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M<.KML7FU([HIT %&%'V'D84&.8M995;QZRM;"PMI4N<[)\,UT&/_ +^TGCN
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M?;SA(PV>7+!LK%S-S=C0YW%2/8C;3]D+.>:YUS6(GRS*XWD.?P4SD=4G>O\
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MW/:3L-_ABN+LKI,LJWG4@%N;<1<@BA*DJ74D;:%>(^4J2P<GY007 -W !+]
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M(Z\+.F("9253E3IH4>\)!.&04L9BRA E@!0(EI*9BILTE@J4B8N7YR@DG,0
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M(LH0DE(4F7*ER_D%R)>%35K/1+ZZ\^X[R7@^&3T<30F?-GRT*[*9B,7B\<M
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M=MJMI"=QI)C2\HI"$]M??+L8@[0"(%\A%PI94""HF]7=)T=D)0D'?L(GI[1
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MY*?.]Z&OG^G^'5;!WZ,?4==/=HM<<D$RDD-\@/J 0 '#V+%K?7(3E3%+W-[
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MN#W6&_<JX,8AYB@0E%7=0[U<I!! )#9FV!#@QLDL[.+3ULJSD/!$2"VXZI(
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M@VJH%E&A;>SBVC.;_GKW!.]_,_R\?3YCHWH]B S:#UKOH8CP<NSC?TZVI_6
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MGK-[6ZPD(36I2IU 4WOLJ7,H,P( V<WM0"MW?ZAXJP\S#8'#S)<XJ!4I:TJ
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MM_$=P+F3#R,-B52^'\?($H#&3TRT3YBF3FE3%</E8$DDL)?:)FG_ &,'.O\
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MA.848H)4E0)*4YDYF4DFAS),H5=[W.IH3SO&\.Q&&F3$S,Z4A:@A79C*0"6
M6E1HW4D:N;MX 5%7<$A6]*"7/BH"AKN"'?=Q()TES6E A7G>NMCD*3/ (9BE
M)N.NP#L/8$:_/*$%C+S$NYSD$T=W#^%RQ!KI!Y'L-#8!&]_\_GXV?H?;QYOD
M,XT#A[6^L 00"* @$"[ V@.B?;_EY/O\_J!KSY&];]^GIT%HF)VFG)"VF8L9
MR4_(<#+$9$?[[+6]O0^[HV-)*ME(UX':G?D=4XC+*E=HXHG,:Y:,[$DFW@U:
MMJPY,R<98!/>84>H)%!3U!W8UC)KC'TR9=E;T:RRMH8O2!:7'FI+ 5=V*2 I
M;;==L-5Y5W?\65=^R7$(44ZZY[Q+FD88J3(4F<MBP04E"%.PS+$LA@0R@"54
M"6 (,;YP_EOMTI5-&0$74E0)#/0":DV((+,]#5WV'X9A=!@U)'H<>@HA0(Z4
M*6>]3DB3(3V_%DRG5%2G9#RT_$?=4HEQQ2E^ZB3SS&XV=C)R\1.4"M:EEDAD
M@K)*F#=34N6 !-!&\83"R\-*1*EIRIEI0@.25=Q(2'+FH #W!TBAL[>=<37Z
M''7$(<C+6B[O/]_&IV5%7]4CQU=J+&SD!MUE322$URU'XQ[T]O6$E&>JB"]
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M4_I7N5*D5,7.\8*BI26*7*I#C:0=D)'[2P\C*PD?E!/<L@ K4H[)YQB/X?\
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MEUTI]BXO]Y6;,5@I*72J<B@HM(4  PN%$FN]3JT9R)4@AEXDWOV"AJ:MG?\
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M3=[D=B5-0,8K6X[[\>SN[!Y1D?=VZV/*DNF;/D@-NO=-/?\ ;9_*#UH:[/\
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MJ[JEBT-O'$'"N;Z7E*;.FI8$Y_[SR^<9E/./1I>*/15MH9CW[M%(4#2MK^)
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MK3M1,*YOI>1'IDUB6;"2]/Y(FT+T@)@S,;G5P=9DQ$]#74^I^KBM@?I"5_[
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MS?B3D7#\*GX+Q=F7%;C&><>Y#R0W.H,NN>/+;[Y!<J^3^/UPKR KCR$VW87
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I]@_,@*\([W.P>?W>]?;[=ZM;(T)&QBH6'@/>L>O41,'2$'2$'2$?_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>29
<FILENAME>g164680g00y20.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g164680g00y20.jpg
M_]C_X  02D9)1@ ! 0(!>0%Y  #_[1<.4&AO=&]S:&]P(#,N,  X0DE-! 0
M    %O*^6'0X0DE-! 0       \< 5H  QLE1QP"   "    .$))300E
M   0S<_Z?:C'O@D%<':NKP7#3CA"24T$.@      Y0   !     !       +
M<')I;G1/=71P=70    %     %!S=%-B;V]L 0    !);G1E96YU;0    !)
M;G1E     $-L<FT    /<')I;G13:7AT965N0FET8F]O;      +<')I;G1E
M<DYA;65415A4     0      #W!R:6YT4')O;V93971U<$]B:F,    , %
M<@!O &\ 9@ @ %, 90!T '4 <       "G!R;V]F4V5T=7     !     $)L
M=&YE;G5M    #&)U:6QT:6Y0<F]O9@    EP<F]O9D--64L .$))300[
M  (M    $     $      !)P<FEN=$]U='!U=$]P=&EO;G,    7     $-P
M=&YB;V]L      !#;&)R8F]O;       4F=S36)O;VP      $-R;D-B;V]L
M      !#;G1#8F]O;       3&)L<V)O;VP      $YG='9B;V]L      !%
M;6Q$8F]O;       26YT<F)O;VP      $)C:V=/8FIC     0       %)'
M0D,    #     %)D("!D;W5B0&_@            1W)N(&1O=6) ;^
M      !";" @9&]U8D!OX            $)R9%15;G1&(U)L=
M     $)L9"!5;G1&(U)L=                %)S;'15;G1&(U!X;$!7_)O
M        "G9E8W1O<D1A=&%B;V]L 0    !09U!S96YU;0    !09U!S
M %!G4$,     3&5F=%5N=$8C4FQT                5&]P(%5N=$8C4FQT
M                4V-L(%5N=$8C4')C0%D            08W)O<%=H96Y0
M<FEN=&EN9V)O;VP     #F-R;W!296-T0F]T=&]M;&]N9P         ,8W)O
M<%)E8W1,969T;&]N9P         -8W)O<%)E8W12:6=H=&QO;F<
M"V-R;W!296-T5&]P;&]N9P      .$))30/M       0 [_^-0 "  $#O_XU
M  (  3A"24T$)@      #@             _@   .$))300-       $
M>#A"24T$&0      !    !XX0DE- _,       D           $ .$))32<0
M       *  $          3A"24T#]0      2  O9F8  0!L9F8 !@
M 0 O9F8  0"AF9H !@       0 R     0!:    !@       0 U     0 M
M    !@       3A"24T#^       <   ____________________________
M_P/H     /____________________________\#Z     #_____________
M________________ ^@     _____________________________P/H   X
M0DE-! @      !     !   "0    D      .$))300>       $     #A"
M24T$&@     #-0    8              04   )=          $
M                 0             "70   04
M 0                         0     0       &YU;&P    "    !F)O
M=6YD<T]B:F,    !        4F-T,0    0     5&]P(&QO;F<
M $QE9G1L;VYG          !"=&]M;&]N9P   04     4F=H=&QO;F<   )=
M    !G-L:6-E<U9L3',    !3V)J8P    $       5S;&EC90   !(    '
M<VQI8V5)1&QO;F<         !V=R;W5P241L;VYG          9O<FEG:6YE
M;G5M    #$53;&EC94]R:6=I;@    UA=71O1V5N97)A=&5D     %1Y<&5E
M;G5M    "D53;&EC951Y<&4     26UG(     9B;W5N9'-/8FIC     0
M     %)C=#$    $     %1O<"!L;VYG          !,969T;&]N9P
M    0G1O;6QO;F<   $%     %)G:'1L;VYG   "70    -U<FQ415A4
M 0       &YU;&Q415A4     0       $US9V5415A4     0      !F%L
M=%1A9U1%6%0    !       .8V5L;%1E>'1)<TA434QB;V]L 0    AC96QL
M5&5X=%1%6%0    !       ):&]R>D%L:6=N96YU;0    ]%4VQI8V5(;W)Z
M06QI9VX    '9&5F875L=     EV97)T06QI9VYE;G5M    #T53;&EC959E
M<G1!;&EG;@    =D969A=6QT    "V)G0V]L;W)4>7!E96YU;0   !%%4VQI
M8V5"1T-O;&]R5'EP90    !.;VYE    "71O<$]U='-E=&QO;F<
M"FQE9G1/=71S971L;VYG          QB;W1T;VU/=71S971L;VYG
M  MR:6=H=$]U='-E=&QO;F<      #A"24T$*       #     (_\
M #A"24T$$0       0$ .$))3004       $     3A"24T$#      ,W
M  $   "@    10   >   (%@   ,P  8  '_V/_M  Q!9&]B95]#30 "_^X
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MW8S;8STV?0_X5;7[/QM=':\
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M                                      #_X3CF:'1T<#HO+VYS+F%D
M;V)E+F-O;2]X87 O,2XP+P \/WAP86-K970@8F5G:6X](N^[OR(@:60](E<U
M33!-<$-E:&E(>G)E4WI.5&-Z:V,Y9"(_/@H\>#IX;7!M971A('AM;&YS.G@]
M(F%D;V)E.FYS.FUE=&$O(B!X.GAM<'1K/2)!9&]B92!835 @0V]R92 U+C,M
M8S Q,2 V-BXQ-#4V-C$L(#(P,3(O,#(O,#8M,30Z-38Z,C<@(" @(" @("(^
M"B @(#QR9&8Z4D1&('AM;&YS.G)D9CTB:'1T<#HO+W=W=RYW,RYO<F<O,3DY
M.2\P,B\R,BUR9&8M<WEN=&%X+6YS(R(^"B @(" @(#QR9&8Z1&5S8W)I<'1I
M;VX@<F1F.F%B;W5T/2(B"B @(" @(" @(" @('AM;&YS.GAM<#TB:'1T<#HO
M+VYS+F%D;V)E+F-O;2]X87 O,2XP+R(^"B @(" @(" @(#QX;7 Z0W)E871E
M1&%T93XR,#(Q+3$P+3(V5#$Y.C S.C4X*S U.C,P/"]X;7 Z0W)E871E1&%T
M93X*(" @(" @(" @/'AM<#I#<F5A=&]R5&]O;#Y-:6-R;W-O9G3"KB!7;W)D
M(#(P,38\+WAM<#I#<F5A=&]R5&]O;#X*(" @(" @(" @/'AM<#I-;V1I9GE$
M871E/C(P,C$M,3 M,C94,3DZ-30Z,CDK,#4Z,S \+WAM<#I-;V1I9GE$871E
M/@H@(" @(" @(" \>&UP.DUE=&%D871A1&%T93XR,#(Q+3$P+3(V5#$Y.C4T
M.C(Y*S U.C,P/"]X;7 Z365T861A=&%$871E/@H@(" @(" \+W)D9CI$97-C
M<FEP=&EO;CX*(" @(" @/')D9CI$97-C<FEP=&EO;B!R9&8Z86)O=70](B(*
M(" @(" @(" @(" @>&UL;G,Z<&1F/2)H='1P.B\O;G,N861O8F4N8V]M+W!D
M9B\Q+C,O(CX*(" @(" @(" @/'!D9CI0<F]D=6-E<CY-:6-R;W-O9G3"KB!7
M;W)D(#(P,38\+W!D9CI0<F]D=6-E<CX*(" @(" @/"]R9&8Z1&5S8W)I<'1I
M;VX^"B @(" @(#QR9&8Z1&5S8W)I<'1I;VX@<F1F.F%B;W5T/2(B"B @(" @
M(" @(" @('AM;&YS.GAM<$U-/2)H='1P.B\O;G,N861O8F4N8V]M+WAA<"\Q
M+C O;6TO(@H@(" @(" @(" @("!X;6QN<SIS=$5V=#TB:'1T<#HO+VYS+F%D
M;V)E+F-O;2]X87 O,2XP+W-4>7!E+U)E<V]U<F-E179E;G0C(CX*(" @(" @
M(" @/'AM<$U-.DAI<W1O<GD^"B @(" @(" @(" @(#QR9&8Z4V5Q/@H@(" @
M(" @(" @(" @(" \<F1F.FQI(')D9CIP87)S951Y<&4](E)E<V]U<F-E(CX*
M(" @(" @(" @(" @(" @(" @/'-T179T.F%C=&EO;CYD97)I=F5D/"]S=$5V
M=#IA8W1I;VX^"B @(" @(" @(" @(" @(" @(#QS=$5V=#IP87)A;65T97)S
M/F-O;G9E<G1E9"!F<F]M(&%P<&QI8V%T:6]N+W9N9"YA9&]B92YP:&]T;W-H
M;W @=&\@:6UA9V4O97!S9CPO<W1%=G0Z<&%R86UE=&5R<SX*(" @(" @(" @
M(" @(" @/"]R9&8Z;&D^"B @(" @(" @(" @(" @(#QR9&8Z;&D@<F1F.G!A
M<G-E5'EP93TB4F5S;W5R8V4B/@H@(" @(" @(" @(" @(" @(" \<W1%=G0Z
M86-T:6]N/G-A=F5D/"]S=$5V=#IA8W1I;VX^"B @(" @(" @(" @(" @(" @
M(#QS=$5V=#II;G-T86YC94E$/GAM<"YI:60Z13-$0C)!,D$V.#,V14,Q,4$Q
M1# Y-#!$,#-!1$(W0D$\+W-T179T.FEN<W1A;F-E240^"B @(" @(" @(" @
M(" @(" @(#QS=$5V=#IW:&5N/C(P,C$M,3 M,C94,3DZ-30Z,CDK,#4Z,S \
M+W-T179T.G=H96X^"B @(" @(" @(" @(" @(" @(#QS=$5V=#IS;V9T=V%R
M94%G96YT/D%D;V)E(%!H;W1O<VAO<"!#4S8@*%=I;F1O=W,I/"]S=$5V=#IS
M;V9T=V%R94%G96YT/@H@(" @(" @(" @(" @(" @(" \<W1%=G0Z8VAA;F=E
M9#XO/"]S=$5V=#IC:&%N9V5D/@H@(" @(" @(" @(" @(" \+W)D9CIL:3X*
M(" @(" @(" @(" @/"]R9&8Z4V5Q/@H@(" @(" @(" \+WAM<$U-.DAI<W1O
M<GD^"B @(" @(" @(#QX;7!-33I$97)I=F5D1G)O;2!R9&8Z<&%R<V54>7!E
M/2)297-O=7)C92(O/@H@(" @(" @(" \>&UP34TZ1&]C=6UE;G1)1#YX;7 N
M9&ED.D4S1$(R03)!-C@S-D5#,3%!,40P.30P1# S041"-T)!/"]X;7!-33I$
M;V-U;65N=$E$/@H@(" @(" @(" \>&UP34TZ26YS=&%N8V5)1#YX;7 N:6ED
M.D4S1$(R03)!-C@S-D5#,3%!,40P.30P1# S041"-T)!/"]X;7!-33I);G-T
M86YC94E$/@H@(" @(" @(" \>&UP34TZ3W)I9VEN86Q$;V-U;65N=$E$/GAM
M<"YD:60Z13-$0C)!,D$V.#,V14,Q,4$Q1# Y-#!$,#-!1$(W0D$\+WAM<$U-
M.D]R:6=I;F%L1&]C=6UE;G1)1#X*(" @(" @/"]R9&8Z1&5S8W)I<'1I;VX^
M"B @(" @(#QR9&8Z1&5S8W)I<'1I;VX@<F1F.F%B;W5T/2(B"B @(" @(" @
M(" @('AM;&YS.F1C/2)H='1P.B\O<'5R;"YO<F<O9&,O96QE;65N=',O,2XQ
M+R(^"B @(" @(" @(#QD8SIF;W)M870^:6UA9V4O97!S9CPO9&,Z9F]R;6%T
M/@H@(" @(" \+W)D9CI$97-C<FEP=&EO;CX*(" @(" @/')D9CI$97-C<FEP
M=&EO;B!R9&8Z86)O=70](B(*(" @(" @(" @(" @>&UL;G,Z<&AO=&]S:&]P
M/2)H='1P.B\O;G,N861O8F4N8V]M+W!H;W1O<VAO<"\Q+C O(CX*(" @(" @
M(" @/'!H;W1O<VAO<#I#;VQO<DUO9&4^-#PO<&AO=&]S:&]P.D-O;&]R36]D
M93X*(" @(" @/"]R9&8Z1&5S8W)I<'1I;VX^"B @(#PO<F1F.E)$1CX*/"]X
M.GAM<&UE=&$^"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @"CP_
M>'!A8VME="!E;F0](G<B/S[_VP!#  $! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_VP!#
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0'_P  1" $% ET# 1$  A$! Q$!_\0 'P !
M  $% 0$! 0$           <!!08("0($ PH+_\0 <!    4# @,$!@((#@H-
M"04) 0(#!08$!Q$ (0@2,1,505$)%!8B87&!D1<8(S(V4J&Q)"4F,S0X0E1T
MHL'1TO G*#5$155R=[;A-T=(4U=89&:2DY>D\4-68F5G<X*$UT9VA8>R8W6#
MAI25EJ?"_\0 '0$! 0 # 0$! 0$           $" P0%!@<("?_$ %41  $#
M @('! 0,! $'"0D!  $ $2$",4%1 P0287&!D06AL? &(L'1$Q46,D)24U23
MHN'Q%%9BHR,')"8V<I*50T5T=8*%E++2)3,T-41&57.$"/_:  P# 0 "$0,1
M #\ _OXT1-$40/MZ8'&;KP2RKNY5*%P;D1^4R.(MP-;@:@KFZ$@SB_G.\ F-
M.0Z0/;:!2Y.)ONG:%*<O(;!V80"687#M%V. EH;-UELD@D6!+YM&%@W'V*,H
M=QDV'G\JB4+C,D<JB1SJ079C4;H:N/O#>#BYV0=2M-SDRKJH$(3V?5_=G$IC
ME #!RCS%)-K+"2P829WLSX/B9M=AF<AR[!\6@6SO*M5Y^->R5B[B4-III]D1
MQGCG"BW I(_;VTMQ+C. Q=5V>&0SL"<&CTCY [Z9ET1*<H"F(IJ*<V0$6TUP
M8/"03>2,'N7DWA!2^/>\%FRP,NV%A*V-B,L;)5%F&94)'-O:),T-TBI$GUM<
MF%SHV]T;.]2@]L[R5.I9%DRB<*A-8I025*9+F$0$YJ,<KXRX+YP3D]L8>'K@
M+9@"TDM@0"'LH4B?$_:F:3)2%19PDCN\H7-G5G:ZII8A-19FF>VP;%GN2L[X
M]J,H,+(0$CXI7I5<R$C*($IQ5*DGV6PD<VQZ&&PAK,56<.&BXXB<C&4[B2ME
MTZA!4/N*R1^F0 P"/3I@! 0'I\@\-18D$8'S^Q7Z=JE_OB?_ $R^/3QT405D
M0 1%5,  ,B/.78 ^G1%&T!NG;^ZD=7ED$D[;)6"GD4CC*SM250$H22*'O:C"
M[MI5#B!0,D[-R@$P)^<@<Y1'M>76MQF'N3-P':SLX!,R799&DC \I+%[V<X9
M>WYKN7;A%DH4O/Y^X5+=&J-\C#"M5T]%7.)B5\OEK-#F4HD1*<<'>WMM(<QO
MO2BH9+F' "+L,;B')XN<C+#*\0 <G"-PP\#:,P3DI/+54YD2K@NB*)@ P*]H
M0$\"&?OQ'E#8<B&=O'6QI;&RU[0S#7O/1E&TPNU;^"/D0A\FD[:VR>?T\JJ8
M:PG4/W@_4D':1D$Q,V$0*!#@P,6*E01.F?/)R@<XF M+XOCA-G_=1Z<&+L]F
M#P'X!X&#OFOSM/=V$7OMW%KF6^<UW*)S9L%UCU154:C6X5M&4YDCCW8Z%(<G
M*)!!01R4,@(B #S:BV,1W%Q8/O&1CB(=28*Z7:]B"R7;<NR(F#FSC(CC[[&-
M@V^O11C=HS6(S28-,&B4@F;UWDLT1MF<'QS*QM3K(7?U%H()UP;61DIUGIY4
M !.(ITR2HC[R@\J9A$+:^'?QN!9N,'%L'?GO&!8,S$A\]X%U=621-+^U-+I0
MG420>FBA>:*CK$3T;B% YIE51/4-JP LD?!N50IB&Y% .7(@.3Q9/RF##W,,
M=UMV96#VAO'!;XPU">VZ<JAZBRKU(X\%;5M;FU'[QA[X[1UXPBZI(J"5)W:%
MTTU1#<H$,=05!Y27/GB'EHC<;0,E&G/B##/+DFY [N*E,E0@J3G362.7&0,5
M0HE^&1 1QGY;?'48Y)M!KA\G]OZ>]>?6J;L>V[9+L?Q^8.7Y?/X8SC?IK#U6
M9P!>TLV_&;SEFLV+LWEV\86M%+Q962J>'>OXI*>2N)K,M=$ZNM6_>SKP#B%
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MG8B:@HJ]S-6SN:>L PL_*TIJG1+4"U5'.H<H 0$Q RA Y^:&29!!C$L[F6;
M8-OLYR -F9@\V+/=QON8!Y-+:BZ*(?=5DDMOW1BEVWZ (_5L/0?H'ZL EL"0
MY<<H8BW11B; GDO7;)?[ZG_TR_TM7:&=]QMY<.$8NS%\L5^8U* ;BL@ !_\
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M9$Y&S)]^O36!DU$"Y*;MR HGRBKJ!AV..<V$DR,&G BZN<6MY/+%CN6Q 52
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M?0MX,I TL%E0('(D**AM&U5A'$ $AWQ$%H#8O=B!O:@$ $6N/FP)<@FSDLX
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M96##12%.:7%FKHTD[]CTFBATDY Q/@*F_53%0P8H&.@03 K155LE\PP,&+$
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MV-SZ@E743U)+S)*/<P9')( 4 S6G3.A(XJ02E R;283"8H;VD9CE.(#$[H/
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MX++F;_V]G%?UV_3"VP!^2 [Y\.F_EG3XK'UM/^,$^6'H_CZ#]E;_ //]>_\
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M?UV-[,>/M-U]!."JX)1R'&[Q7!G?(/-L@$/I+;HO3K@ #QW'J&6B[*.B(/\
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MT\ T^+!];3_C*?+#T?A_0;LN7MVAKO*XGR=RI]I9<S8?M[.*[/D+A;?&P?\
MW!'KMG;X@.<AI\5CZVG_ !@GRQ]'Y_T'[*(S':&NVB[TY3^DJH\%ER\A_;V<
M5O0?\)6V  WP&0& B/4<?#;R$-/BL?6T_P",$'IAZ/W^0_9>$?Q^NE^;-PYI
M]I9<P-OM[.*W?H(N-MOY8"&!^&^<;XW$7Q6/K:?\8)\L?1_^1^R]_P#[0UV.
M;=;$;T^TKN8 _M[.*T V ,.-MAS]<!''EGII\5CZVG_&"?+'T?AO0?LIR_\
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MKKX[O+&%3[2RYFP_;V<5H[#_ (0ML >0[^P(#_+L&WD^*Q];3_C!7Y8>C_\
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M?@T>]/4%A'(5N_3(4Q1Q\?OQ#Z?'3:T?V?YZE6UC[Q_:H]Z>H+=?7AW#][D
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M>/[5'OX^;T]16R/Z.'_^G*&/#\<,>&?R]--K1_9_GJ1M8^\?VJ%Z]16_?O\
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M,*0QAKQ[/,;E014/'C=>M59)HB:(FB)HB:(FB)HB:(FB)HB:(FB)HB"(!U$
M^>B)HB:(FB)HB:(FB)HB:(FB*PRC\'G?^!*_R?$.O3J&M>DKV00V%^);(K/1
M@&ND&SOT!/L6M.PX$1#Z<YWQOX;].@;!OY:\_2:0AS, <[ &0>>97IT4/@YO
MAA&<[YY+T(X\A -A^?3Y!\?S>>[:JS[A[EHV!9F?C@X]XXID-A$=OD/4!^G&
MFW5GW#W)L"0UIO\ K(,9@QN3(>8 &P8Z=<;A\@'R^>FW5GW#W)L#+C>,)W][
M[TSG(9^K(^8Y#\V-P 0QOXMJK/N"&@9/S_7BSWDYH(^(CY#N&.N0V$?$W4H=
M1Q\1TVZL^X>Y-@&&MQCBV3\4$Q<AD?D ^.,YVZCC _ ,9QIMU9^"NQB1ODV[
MXOUWB', AD-_D X'?'7'P$,_/;.VFU5GG@$^#$ANO+>6)<6/&%Y%0H;"8NPX
M-D?H'PQD!ZA\.@= ;9SMN!G+IYQ38=O5.+1GS@-8X865>;XCY]/(/#PZ;[AX
M] VPVJL^[]/#%^)'1C*,+CKE)8S>,%7F ,8'H/Y-_+^O3P'.FW5GW#W(* <.
M3G%AX-NR0#!X?4'T>&,[!TVQMOCP;=6?</<IL"[6Q#^(.X8XN'=,@.,"/T9W
M_P!8=<"&,=0\0;=6?</<FP(<</9C;,G?O5=NN<COU^8 (;!Y@'@.FW5GW!-B
MEQ&6/ZMUYK,H0'ZH:,1$!PF8<@4=O=W\1\=A'IXZHK.U3/AG^WO#K&ND;-1R
MI.>7CO/-X4_Z[5Q)HB:(FB*U\H=[@IV("'=V/6?=V_1&>3/7 AOD<; .,AD0
MN'/IEUGHL?I6PN_L_>XLKIJ+)-$31$T1-$437E?7B,6TF+XSH2NK=FME5JJ
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MAV[8([%WF7T$@B5RG9Y8H]6Q"A<TE65U@2;,Z'":R"-$*4A79V(;LCJ@"@B
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M2:ZZ#LUBG:J'K"JF@5&D-2]6%0 F+K&CJ>02P8![$AG:3>3$LSNIJM!6T+K
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MBJ:(FB)HB:(FB*.Y;-5&.II&!BH._I>] ;NUI(N;LZ,O(.75]$#'5:F1,P%
M5@*(J'YDTR@H)S%1SR_6?UL,2,9):&#3+OW"1ESR/Y1F%%:*H7QU7+(YG4TW
MJM?)*U$$C4J?:AS-3 V<ID6!B$I:A0B*1SJ")D3U%0^*&*8"ML#R\Y > ?&2
M=%4T11I)9J@R5%.W-U'42%_<:<?4F!K$0<!*)@(+HJ)ES=U,Y.3!UCA@38,0
M!,!\ZS=KGO<,1+VBS@XF972-6--)-9%.S4!4Y!I!$&D/5@8+>J*H!)=6:EAE
M:Y&1?)P07JNYPJJ*-4QC!&F(Q>4A2E3-N_/?* B21R'Q*!D48WS")@%MH8/D
M +-Q :3N<A@I\-L$B@@8/)!Y&U(R  !#AP2%+E/V?9I<NP@78/>#'@(8SX8
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M1 H+JII=L8$2"<Q2B<YL\I"YZB.1P'Q'SUFH<G9[>8[E^XB =1 -P#?;<1P
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M! -7#ED'PQF);"S,'*Z,@(8.6P 8D<0,!?@0MJ\?'(9 !VP&!WV^'0.HB(>
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M=%M!P-V=XDK>3RZ\NX@U:^I/)XE!8U$ZYV?T9/( ;(E<OB ?FYF=U?LA7*D
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M/'V+6U3<2Y\2!OX#N(@&?/QS^37#6 ::N-H#-B^7*^<OZ5%CQ]@7D=OI-T'
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M?I:F_LQWSOCF'L9' [DO%,F($* C!@*&,  \.O6&1$ON/ZGEPGOU(_.YM&+
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M;Y^XFZ8Z\@B/E^7IU ,Z[]%;EG[#^PYA>?IOG><@M@-;EI31$T1-$5NR;O4
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MS.R*9V"V::2:HJ\YRI@'*T+TZ)@'%BY!QJWOBT/BY6T$FDTA@PO; G$DR8Q
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M8FQ-+N\UK]>B<Q.R555-[,(@91GA1BS"?&35#WB!)8S%S 4<& >A?=K[!KT
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MTRLTF9W%ED#10/+(\40T+FTNM 1PH:VA5*/:4+@VKE435(8JA@,F8A@YMSE
M2E*-W<<8XI>;6.\C(L;@^Z7*T0+P%M, 6K:SA@OM>_A;HJP5A+;^!.\=G-EZ
M$Z@=J)FFSMTX]*X]#DA'/.TVW/$D0 2%23QS!K'1G9%):19\Y&38O(ALPMFD
MJ.ET=5!+%HJ&T"'@XS<7-.(6L?&5PH<1#WPMWRI+L\<4]G,3;;>NTF-%8Y9F
MRMODWETA:0R5D[[>46*3/ZF7]E9S#[-*QD!Y  IQYA)KDU[:JT=1!+4TN00"
MX)8$AW@D&*=FQ)AU]#Z&:&@=JZOH],=JK3:4:,5[)&R*IT@CU1M:*FH$BNFL
M"*5PB]'7);:1KCBL_-YI<AJ<),JZ2:F>)W<Z?)UL@$?9%[+S*/;V_=DR&,!N
M3V?$IL\Q2E')@U^-]@ZYVWK_ &MH-+K&CV=&-(354:]5B[@;%&CJ^<1( 8WS
M/]W_ .5+T-_R4>A_^2C7^S/1C3[?:9U44T4TZ+T@I.DTQT].L::LG7M;UK04
M_"'X0FDU 4[34.U(7]G;<ZM<D:DW6/5K6^-ZR9?47!K<:9PHER&$1$0*0YR&
M X\P#S"(D_&'8-?N.L:'1ZQH#1ICZVDII-=)I)&U214*7IJ#C: !FG>"Q"_S
MDU;6=>HIKT6J$?!TU$TFFK14D,2Y-5=/PE)Q -0Q:X7#;TB]I; L'%!P;NU9
M&HA#7IQE%T+G2F2+'"/T#R:V<89#,*;NL?D8EWA.;RUI?RK*%[4X,I1.<X'
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M+L;BUEZ=%CQ]@7C YSOUZ;#S  ]<>(_5C(8Z8'G?PO(9Q:'+#OEP7<9IUSG
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M0=G5DF1HS4&J8U5;-0KVA3I#M#UJBU0-)+&D;5((_L[COI$. ^FCT?05XM[
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M"VSR'677GZ?YPY^ GV864^ZVK2FB)HB:(K9C]. ^XI_W/SV^ [0/NXAR9QG
M]0#X#OU +AS'<_O[EB\BWS3+\W >T?K 5SU%DFB)HB:(FB*PR%C9Y(S.+(_M
ME ]-+E2&I*UM=J$')NK$U"@/)7MIR=FLGD"F,0P!L'4G*40*CS;Q/?AFN(W"
M]')26]L;^Q8Y%C[A&*,]/=1>K:[&MD8N8TDF$?,]O=L30FW<9D+Y;],Y'N/&
M,,HY22Q_MPJH!BHRXPK9>?/+BMA%W:08;Z37%RV98$-S/=?1:E!53^V89O\
M,9(_#_G[&.@_+.V=%#>GC["IUT531$T119&CBZ7%N*ZFY00CZ$8A"11,0QJ2
MM1:_;EX.!A'[VK2F[&0Q^429: +L)1 U+OG8"+Y=0RQ?E<G$ O+GB22Q%E*0
M  !@.FHJ0#!42ST%GFMC\$(?[C):LE5(/NP<X19E4 7<JA0$N4I$HJSQQ0I3
M%Y4WI80]X#"9Y\^<^?5JQ^"%6D9R*:J1#@G9#$B"P;:J+D@.UG4L$3(F&"%
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MP:<U:]H9!_Q*!+X %X$L#Y9CYOI?V;H]6[+TII #"HM)N[R=)5<#(EP;0_\
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MV3N\%3<5JZ,VQ4?!AG=34]%DI&,T98U&>-Y)&B!RPF-#N>,E.;XW6-;(F[@
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MF.4\D./M/,#O%6*9:/AUS6Z]*SNTL($GUBX%(?Z)#B/6DRW3JF@&B!;( WG
M7<NSN]P:2 S%;Z ("&?#XZY*22)S]R["6!.2KK)5-$31$T1-$31$T1-$5AE/
MX//'7]@K=/D']1T6=$5TG?[%K8IN)>GWI0#;<=QR&?#'CU_+OP5R*H)];,B#
M52S\</:T>E18\?8%38<8$1VP&V^PAD<^7Y!^/30XN&<@[A=@V'.4KMS]A\]Z
MAR_UF:&^<#*P)2&O@\QBC\V3JU-Q6VD$)%;RY+(/.PS)E, Y(=)5,K!,(X B
M>61)[D$.+[Y"B23%YM>^XQ*\[3$ AKR _+N>9GF2]IL_QS4#:YMMG.,,C/8&
M_*1$6YI='>L+16<O@ND02'D%G+D.Q*>.J4\A$*=4MN)!4HS*-$4]5%64$2"2
M&ST>D<AXP>9>X=@&P+@@,]V(UER>+OYW^S>M[IW$X[<RWDO@3WV-9'+A0^1Q
M!V!,0,6K9I>TU+&Z"7E$ #MD'0_, "(^^ ;&';N ),./',92UK.L3I-AB\[0
M'-P'QL:@[[^?^8FX6NG#1=)ZL!21Z02ZZL*FTCM=5PZ+M@R&1O$EA;R]0MX(
M5G8CF$YN9E-CESD,!T$<_EG;.H_P^OZ+04LU5-(,9TT2VV2+M!FR_J7T?]*#
MJ79FFT^T*C2*M)34&+AR014-!6).R00]X@ G^LWT4GHT7/A5;G"^-\Z1M6XA
M)>PBTL\7IZH:^BL_! ((=T"\<PD>)W)QVEL@3$IB%%6%*954$A/KZ^RJ=5U#
M0Z<-M5"@EG<.6O575@3)#2,U^$^D?I-I?2+M+3:-SLTUU84OZFT35_[C02Y:
M27:S+M3O@ ^G?RQT'.,^.1#IT$,#C7=$W.$2[DA\0^XW=W>3Y2>6_CC/7<<#
M\!QL(=<X$!'80U.6!)%K.'N0\O9K@6+DWZ]<[=0W\@'Z,C@ ZCG<!P%AL8<P
M#%W(S#L')L+ RB9P(9QC; ].H!X@ AX=,_F =0RX +]<3G.(EGO ER8_KN.,
M@ Y#X[#N(9 1Z;Y$_4C@\F##-F'9A?!$SX9$,!N.<>8==PVV#Q'(AXAIO:Y@
M,#D<&O@,L&+H@CC;\N 'P$/I$<>7F&<=+0)?<1X+&NWG?X7Y<CF\'_"&DVV[
M(WY"#X^0^7C\0UWZ'YMW@>V.5EY^G^</+6_?FI\UN6E-$31$T16\0_30,=F
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M-@#L3;9QT(.-NOA\-L[;#KOT,#D.]RN#3_.'/P'G%3]K:M*:(FB)HBMF![Y
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MBJ[@#U2(!S<Y.W)F-[LRP>IOK$G"F-'8YPUV C"+R(4E'04REX+E2.J, @(
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MUDCX94W&L[LL;=-P;5JBN%,LIXEJ2D;\=Z=ZE%U+!^'Z*+![H<IN64%R83"
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MV>GXLA R80MGW OZD#L9A4YC'$=#GN'L>^$.@P!@WM@\!V:Q$<2,2HNMI%>
MOA[O1.XQ#I&DRW=LM;Z271N&$DF=PY#716$W/:8.I-9:\.SW("@)C,%NHB'*
M4H&4,RQ\""8TJ]P'.7,[HY= " \(=Q;WDO-Q,8/,76?E](?P?*,K,_J7>*WT
M#M(G&-)TKI"KAM]<T.C,TL;N\NLP:2Q\TBA#&9CF4/D19%)3GB2AWJ/D(412
M/R7&P\Q; ^;("X'[1?>^1YKH/ Q_3ZES_O9Q .F-C!YCGZ/Y@U:?G#GX%8Z3
MYE7!3_KN7$FB)HB:(K8(?IP ^YNVCX>^.*D,X'RZ9V'XB&V;]'&XX6/?[EC]
M(VMSPOYQQPN>HLDT1-$31$T10;?Z)2BXUH9W"H49O4?9,S(4%)3/;NZ1IKJJ
M-5S1]H&IT?6=CDCZSTT@CI79B,O3QRN42!51 J?,KD+YZ]S+%V,![F,YRQ.^
M(B0HFX7X#>VUS:[P6=P6T\8@*,CE+["B6[NU,I8O&FQY>2O+/"Z=DD=GH;3=
MR1XZ[J"=<G*$@$#&($2[)8JB;PGV<P\!XRS0MDQZG%B6@LQ+.;9L%N7J+)0/
M5_MFV3_,;(_].XWHGGST4\:*$ P5J[4/JZCS/9(VGI"ODND;9:.# 81(J>@@
MYWHKL\'#F%,YHQ)'^=217(B*D28BF2 #8Y*?=$ P&X\=YEH"ZM6]4C:)  VF
M$[>T *1()JHJ&U1LL7=LBMAXZS4<?9&YBHA U*UTQ:,GC][DQ\YSN)CB(@/G
M@=\AJ+ESWWP/G([KK%X+2$I:)W#NQ)N*>9SBJ(BB_+/WKA#2UZ#O+MRAV2';
MJB4X1P"@2+*&%O$P*($*6SWYC$=V+S/)3,XM8#$'D[6N&P$J0]19+!XW2KIR
M&<KGI'5.GJWMKJ*>J<'8U=056(PR)J&9VPZIC,J*1R]FLD) %>H(JKD $")W
MR=_[>/)0?LXMR&8?)HBZSC4531$T1-$31$T1-$31$T1-$31$T1-$31$T1-$3
M1$T1-$31$T1-$31$T1-$31$T1-$31$T1-$31$T1-$31$T1-$31$T1-$5BD^T
M?=L]/4U<]0VVSN&X;>.F;9'O!\C#-0^T=Q7*7C%X:7WB/8;7!&:ZWU17VMN$
MY2WV,NU%QEEJ)T#S;N:PL?;1H"0J<H18)>,CAF #FE[((#L4=<-<F\M'?YEQ
M+Y+OIL)<-T.YA.,O?"5HG.?1.S645L\(A=6V="641NY!J"9-5MGMMN(#M,>%
MXW#X-MG9W[].0E@8MM<2&Q[<P)>SIL"!_:XN)'B]^#9$/=C$\7HW6$9EQ<91
M;J'<.OMD/HHGJD>ZEZMI*;*1KL72[%7'VR16C;GV.QIMN;PLVKLL(M+, >SO
MM$:X-M3W()DQHA+3/9%BJ 8@)BSS=SBV%YW"[6O@!!D6(#;\S+8F0SC%X6)P
M3T2]R88WL)#SNPDL/3RRX[JI#YY:5YF%NHPU7.9K( :9P]H*]10K)/XQ(+</
M"8$.(& )HD)S1$VX7&'8VW3&(G>79S*@LT69F@YPT2;BXXJY#Z)F9MD^ATIB
M\YLQ$J>#WYN1<9JJV>VA^]"Q>87Q->MA:WEB>G[[',ADL5 QHT9$D4B(1%)E
MC\N6F2I8P6(IKL&>29.).'$R7-YQ*.!.#0PR?JUP&M(?"?\ B4X!)9>KB-H;
MSM4OMI3MIGCAM>JPLSAST_W%@H\/5Q'J9"S6RF OYRLL>NB#QVDRR<OOL8X$
M"D*)IUYYG=>.6'!5NF7N9N]]S+6)G]$)<ECD<8>VJ\<#;BLUA7FT<C<S0Y[<
M*]Y54M!-[5\N'Q_E ,H"28%D9I)&310 'EAZ194<!(K;06#%KAWDD=7PQDED
M:3GP+!\CR#L>BEM3T9TJBLJA"UK)=:V*6T8C<)#W+8DUPYW;G:ND_#%*)NZ/
MIH<#$_&C3&2YY9F,FF,DE!^<TS.0.8 (H(BQ=H?#V"[V? !N"DP#.\\(>S,8
M &T68DXK7VQ7HE[FHV^L1)YW76>@5P813<+U74P5L@BP-QG"S0S<TX>9H\]_
M2HSW=PIKEDC9KC18%"G)!XZ43%.8#ZFX=,N&>&7<J&P,WCKXE]T9K(X-Z'J<
M0>$(,*]T;33.N:99"JHK5,[=/$@MS,6MHMU=2V 3&Y<1![*HG/ &Y821.0B7
MLTP93&+[7"908G<!YC$WECN>[68203=F?F]I:]H+ !R0X*G^Y'HZI;+^'S@W
MM'02&TC^X\+=MW:%O!;GP%ZET,F9G^TR5L1?$FHK\)F T5*\>T4*R4"#S$.!
M2B'(:88/B;X2SVF06<"%6+N#R: YFT\7+$L87R<)_!5-+3\5KQ)WH\F5M!9^
MU,*C5NJF8IM1!FUZWVW$'MC<^[C"RL,BEI )+(';>'G$LH 0]K9Q/@$W,G[K
M=P]N'AS1K9MD(O;#=B;/ <_G2^CPO/%[QNW%!!^(2A^V(?I_>V0R1LE$6:W&
MU-9&[GQ)2%,D3$S''CW&-[,L,0M#RDE<F&')>QY0]\LD 3%<H\R78LV&9?)8
MHAP <7*ML8?;A\O#P_R"DK[KN5X>(.H?HA=['$JZ=HS&8U+D&&<&DP,(/S*'
M)&HN$3B/LHR6ZBAX<,2C +I7&(N<(:V-S^UP%+X9C/B^& SF./<F _W?I,8
M.S.(CX[@8.F/'.XY#&K3\X></("QTGS*N!6PFNY<2:(FB)HBM/\ AH/V+_<X
M=Q_9GZ_X '_DO/;KC5PPOSZY>Z,5C_O?-SD\OK1[\%=M19)HB:(FB)HB:(FB
M)HB@>J_;-,G7_8-D7CM^'<;Z^?\ 7Y@19W-WJO9(LX5++1#7O=0 -+#2"D44
M2.[L<&QH.N "!$FHM28IUSJ 8IDP$!$HY M+^!?OG?(\E75Q\)4'+"DDU&H
M-3219F I+7)M)+", MK&!I!H*ZH37I:*+M98A%.]J8"N+BW\H%?)HN8N0!_E
M3YN?G(<WJJ1U0 PR<3! .X<'MO'46%H6_6 ='ZHN?6J8@L2'%)&( 8@5 ;42
M[O/FBYU@D ]4[I=O4@AP $OG/.$+QW9VGMG(-W(<<WM0(B(S4!W":>T0!D<A
MJEPS^</9.+W6 W/<@9-</ALS$ODRSO46:P&,4J",DGRJ3=04W>3TU5534(.A
MZRNK3>RC(D075I.D'<RB9"&332$_-4IE(N9, 5*8Z7=Q@S' 1;R6N%B#AU?>
M'+]0\,Y99]HLDT1-$31$T1-$31$T1-$31$T1-$31$T1-$31$T1-$31$T1-$3
M1$T1-$31$T1-$31$T1-$31$T1-$31$T1-$31$T1-$31%8I/GV?=L=?4U/AY>
M(=/GIGP._"<_-T/N\?/L6M)L8'.=O(>N=_'Y!L&<>'0=<5=^7M*]"EPU@0._
MHWL5>G0>O4<^9?/;R\/#R#&L$3R#&0V#?Q^@0SL ?+PZ!D")G8!#(AMD>@8\
M<YW^/T=>NB)@=_'/GMY@.< &VP8\?CC1%Q-XBK^>D89N("^4=LO$+J5,"98=
M<BAA--468-(X^G(&.VL)>H?,X:]FM^L1]"4OY)@H10;K2L!!D]R%1+LXCRW-
MLNOCQA[/@ZA]K/D2Y@VRI M+3917Q%2STD59;>\]HW +W/#&O2\4T,AL\MSP
M_M+C,;K5Z43M1]A=I=P98Z0(,P'2F=R#_9*B9HL DAK"4DQ-R%&5&M!(/7A&
M/C#ABR<;B]QFW'P=\E/_ !H1V75$XLL[7+LWQ'7WX?VWAU?6DMN>'Y>6C(F_
MB$>G>%BSO4U:(/((K(P$MOQ=#0^12@#Q&)S(9*4$CI@<IIOQG=W7$$S#NS0F
M8PC"&GEQ$D #-EI;PX0CBPGU^+"R*^\7X@Y-$'VSD+C%S:RH3NW'6QP@P<.C
M\R31)WFG)%(\POYIV5BCLUMT$5&[$RO (WC@LN]C3]L-[@6NW",Y<!O>G0D;
MN@OP/2T%=A> *T;W:+AMC029KE$<FERG=SO!+8;,7^6O[C;MQF@%>F.W0%G4
MAE4FCXVPCO<T=$!$QB]R"GSF H#J>?=YW]6 :?'O]JW4W_DV'PR.-L#TQX[;
M>'B50=@ZX <[[9$>N^VWT!]6V2*N #K\\C_/UP'QZ;;[;$7GY#D<CX;^>-L>
M =!_)@-:J+GARP]_EUNK^:?T\])[UFT&#$@I/_=&Z[C]Y]7S_P#'7H:*1R \
M7\%P:>XYCP/M\XS[K:M":(FB)HBM(_W:#:E_N<.^_KGZ^&P!G]:^C.=L[8"X
M87Y_MS6.5[1G;_S<LU=M19)HB:(FB)HB:(FB)HB@JI_;,,W^8R1^7_G]%_I_
MD^K10W''V%27)I,UQ.BI7!Y7"FHG"2QB,46$ ,)W>8R!GCC(40,(>\=[=D"F
M-C;G$1#G)O8CSG&%XQB5,;-.3G WD!B2=Y'-95J+)-$40VTE[))JB>-#>[G>
M*^'3Z2,[H!8W41ONA11T,Z TE+@XO*92*;R,@%2E9R*5A^90Z@A>;3:T]P;#
M=DL8&#Q=[M?B6;C8P%+VHLE"]5+8["B7=ESS6QM%IBE0W/4A5CM.961T#6U0
MUCJ%#3<Q!$3/94P5-3 80*6))T!1P)3F)<[--L^\D8"PWW6(YV$'IN8XF2\Q
M931J+)-$6+A+6D9:I"@.IWZE'BR<R'9#R=TF=#-(*E-G<PU1>4,;"4>?&PE!
M^ZG VPCIPLWBQ64:*KYZJI1HZ:HJUS<J-,BHNJ.!$2IIE,<P\H;B."C@,;CM
MHH\6P=K<O-E:(R^-DIC[')V98*AJD+71/374"0.92A=D$Z]$1Q]Z"B2I,AM@
M0*!A,8 $7AT[DR<=V,FYX=9Q"O\ HJL7<9.V-L@C\8J55".TFIW>K:2@ADJB
M3$+0+GD1V*8I'=$X".P?= '(DP-CSY/G$*' \!A#D>.,X""LHU%4T18K$Y4T
MRYMK'1F66J*2BDDKBZIE4.S,1UA4J>(6_$V*7F!-\87(O/D!%,I3B0H#RB_7
MS/DJ0YES#OW=\^0LJT56,2*5-,72:%79=5 CY(&R,4)B("<3.SVH9-M3,41
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M/. \=\]-NH#MO@<:,<L#A5Y?C&:.,QU"KW ^@']RW0/  "CW^ ;_ $"&=Q^
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M:,OST:XO<0G(>H6EBDL8[DS)<00E!SFON.[ ,\9\B07P*FYF8O@<7+3OO=C
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MU;E2.U:MDGE[99N+LT,,KD4LCR1%F)V.F$EB=(!BD$"X,8I@TFJ(8;[N&-P
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MI>WQ&L<J4Q2=RR)]975_APNQ7+LE!2EK:R9BJW9J&7479 ,0$JI(A%_;AA#
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!V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>30
<FILENAME>g164680g01m01.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g164680g01m01.jpg
M_]C_X  02D9)1@ ! 0(!>0%Y  #_[12J4&AO=&]S:&]P(#,N,  X0DE-! 0
M    %(Z^4F(X0DE-! 0      !<< 5H  QLE1QP!6@ #&R5'' (   (    X
M0DE-!"4      !#'71?E=+5N]=N^.93 Z7E<.$))300Z      #E    $
M  $       MP<FEN=$]U='!U=     4     4'-T4V)O;VP!     $EN=&5E
M;G5M     $EN=&4     0VQR;0    ]P<FEN=%-I>'1E96Y":71B;V]L
M  MP<FEN=&5R3F%M951%6%0    !       /<')I;G10<F]O9E-E='5P3V)J
M8P    P 4 !R &\ ;P!F "  4P!E '0 =0!P       *<')O;V93971U<
M  $     0FQT;F5N=6T    ,8G5I;'1I;E!R;V]F    "7!R;V]F0TU92P X
M0DE-!#L      BT    0     0      $G!R:6YT3W5T<'5T3W!T:6]N<P
M !<     0W!T;F)O;VP      $-L8G)B;V]L      !29W--8F]O;
M0W)N0V)O;VP      $-N=$-B;V]L      !,8FQS8F]O;       3F=T=F)O
M;VP      $5M;$1B;V]L      !);G1R8F]O;       0F-K9T]B:F,    !
M        4D="0P    ,     4F0@(&1O=6) ;^            !'<FX@9&]U
M8D!OX            $)L("!D;W5B0&_@            0G)D5%5N=$8C4FQT
M                0FQD(%5N=$8C4FQT                4G-L=%5N=$8C
M4'AL0%AB',         *=F5C=&]R1&%T86)O;VP!     %!G4'-E;G5M
M %!G4',     4&=00P    !,969T56YT1B-2;'0               !4;W @
M56YT1B-2;'0               !38VP@56YT1B-0<F- 60           !!C
M<F]P5VAE;E!R:6YT:6YG8F]O;      .8W)O<%)E8W1";W1T;VUL;VYG
M      QC<F]P4F5C=$QE9G1L;VYG          UC<F]P4F5C=%)I9VAT;&]N
M9P         +8W)O<%)E8W14;W!L;VYG       X0DE- ^T      ! #O_XU
M  (  0.__C4  @ !.$))300F       .             #^    X0DE- _(
M      H  /_______P  .$))300-       $    >#A"24T$&0      !
M !XX0DE- _,       D           $ .$))32<0       *  $
M 3A"24T#]0      2  O9F8  0!L9F8 !@       0 O9F8  0"AF9H !@
M     0 R     0!:    !@       0 U     0 M    !@       3A"24T#
M^       <   _____________________________P/H     /__________
M__________________\#Z     #_____________________________ ^@
M    _____________________________P/H   X0DE-! @      !     !
M   "0    D      .$))300>       $     #A"24T$&@     #-0    8
M             ,(   )G          $                          0
M           "9P   ,(                      0
M       0     0       &YU;&P    "    !F)O=6YD<T]B:F,    !
M    4F-T,0    0     5&]P(&QO;F<          $QE9G1L;VYG
M  !"=&]M;&]N9P   ,(     4F=H=&QO;F<   )G    !G-L:6-E<U9L3',
M   !3V)J8P    $       5S;&EC90   !(    '<VQI8V5)1&QO;F<
M    !V=R;W5P241L;VYG          9O<FEG:6YE;G5M    #$53;&EC94]R
M:6=I;@    UA=71O1V5N97)A=&5D     %1Y<&5E;G5M    "D53;&EC951Y
M<&4     26UG(     9B;W5N9'-/8FIC     0       %)C=#$    $
M %1O<"!L;VYG          !,969T;&]N9P          0G1O;6QO;F<   #"
M     %)G:'1L;VYG   "9P    -U<FQ415A4     0       &YU;&Q415A4
M     0       $US9V5415A4     0      !F%L=%1A9U1%6%0    !
M   .8V5L;%1E>'1)<TA434QB;V]L 0    AC96QL5&5X=%1%6%0    !
M   ):&]R>D%L:6=N96YU;0    ]%4VQI8V5(;W)Z06QI9VX    '9&5F875L
M=     EV97)T06QI9VYE;G5M    #T53;&EC959E<G1!;&EG;@    =D969A
M=6QT    "V)G0V]L;W)4>7!E96YU;0   !%%4VQI8V5"1T-O;&]R5'EP90
M  !.;VYE    "71O<$]U='-E=&QO;F<         "FQE9G1/=71S971L;VYG
M          QB;W1T;VU/=71S971L;VYG          MR:6=H=$]U='-E=&QO
M;F<      #A"24T$*       #     (_\        #A"24T$$0       0$
M.$))3004       $    !CA"24T$#      *60    $   "@    ,@   >
M %W    */0 8  '_V/_M  Q!9&]B95]#30 "_^X #D%D;V)E &2      ?_;
M (0 # @(" D(# D)#!$+"@L1%0\,# \5&!,3%1,3&!$,# P,# P1# P,# P,
M# P,# P,# P,# P,# P,# P,# P,# $-"PL-#@T0#@X0% X.#A04#@X.#A01
M# P,# P1$0P,# P,#!$,# P,# P,# P,# P,# P,# P,# P,# P,# P,_\
M$0@ ,@"@ P$B  (1 0,1 ?_=  0 "O_$ 3\   $% 0$! 0$!          ,
M 0($!08'" D*"P$  04! 0$! 0$          0 " P0%!@<("0H+$  !! $#
M @0"!0<&" 4###,!  (1 P0A$C$%05%A$R)Q@3(&%)&AL4(C)!52P6(S-'*"
MT4,')9)3\.'Q8W,U%J*R@R9$DU1D1<*C=#87TE7B9?*SA,/3=>/S1B>4I(6T
ME<34Y/2EM<75Y?569G:&EJ:VQM;F]C='5V=WAY>GM\?7Y_<1  (" 0($! ,$
M!08'!P8%-0$  A$#(3$2!$%187$B$P4R@9$
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
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M 0$! 0$! 0$!_\  $0@ OP)= P$1  (1 0,1 ?_$ !X  0  !@,!
M       #!08'" D"! H!_\0 9!   00! P(# P4("0T+"0D  0(#! 4&  <1
M$B$($S$4(D$)%5%A<0H6,E*!D:&Q&2,D,S="<K7A)30X='=XDK*SP='4\!<G
M-E998G:5EK32&B8U25AD<Z+Q&$1E9G6"A:35_\0 '0$!   ' 0$
M      $" P0%!@<("?_$ %@1  $# @0#! 8$"P0&!P8' 0$" Q$ ! 42(3$&
M05$'$V%Q(H&1H;'P%#+!T0@C-#5"4G)SLN'Q%39ULQ87)#-3=!@E-V*"DJ)#
M1$54A*,F@Y2EM,+2XO_:  P# 0 "$0,1 #\ ]_&E*:4II2FE*:4II2FE*:4I
MI2FE*:4II2FE*:4II2FE*:4II2FE*:4II2FE*:4II2FE*:4II2FE*:4II2FE
M*:4II2FE*:4II2FE*:4II2FE*:4II2FE*:4II2FE*:4II2OBN>D\'@\'@^O'
MU\:4JFK&38(L:)N,MY3"Y;R9_E-CH6S[.?+#A6D%(#G"NQ!Y^)]-*54VE*:4
MII2FE*:4II2FE*:4II2FE*:4II2FE*:4II2FE*:4II2FE*:4II2FE*:4II2F
ME*:4II2FE*:4II2FE*:4II2FE*:4II2FE*:4II2FE*:4II2FE*:4II2FE*:4
MII2FE*:4II2FE*:4II2FE*:4II2FE*:4II2FE*:4II2FE*:4II2FE*:4II2F
ME*:4II2FE*:4KXKD D>H!X^WCMI2J7LQ)%E0^2M_AR4[[4@+]PMAA2D\]1)2
M K\7I)]"3VTI(&_EZSM[ZJG2E-*4TI32E-*4TI32E-*4TI32E-*4TI32E-*4
MTI32E-*4TI32E-*4TI32E-*4TI32E-*4TI32E-*4TI32E-*4TI32E-*4TI32
ME-*4TI32E-*4TI32E-*4TI32E-*4TI32E-*4TI32E-*4TI32E-*4TI32E-*4
MTI32E-*4TI32E-*4TI32E-*4TI32E-*4TI32E-*5\/8$_0#I2J8M1(794"F0
MH 3'2\>L)Y;\@\@@#N.>.WU?1SI2JHTI32E-*4TI32E0WE^6TMS\5)/ISZ?5
MR.?SZ4JT.Y6[5;ME"H9UQ#M);619-3XK%^;(:I*8LRXD^5'E3W!PF-$!Y2MU
M7('8)ZE* "GS\_)W'C5H\(\8^U>5U>3W5S;M[?T^,Y FA^<<UE0*M%FZMZ2R
MT]&:4^76V93T1Y$13R$*=0A2@#QI2KQ;;[V[5[M^W';'<7$MP$54@1K=>+75
M?<)K7^D'R)?L;SACNDGGI<X/8_9I3Y^'W\ZNYI2FE*:4II2FE*:4II2FE*:4
MII2FE*:4II2FE*:4II2FE*:4II2NFY(#"N'5!(62E"G%(0.L_@-IY/=2CZ#O
MS\!I2NNN6&U)0MY*%N+2TVA:DI4MQ0Y"$ GE:R/>X )X![>O"E<#*6I3K0?
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M@-)NK@F4[>Y"MQ%#E=5)J+5+9"%>QOK2'PE1X*"\$K:)0>2"%)]X Z4^>?\
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M3E75II[RTM)5;81I332G Z_4H$E#;*U-,(+3BFT]QWY'8ZSV,8ZPMD@[DJ2
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M.$N6'6WTI"G,JYD!1GPW\CO,UTIKCB^N\#QA]6%<,A3;V'E,8/:@@%V"$0(
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M",/6VAH+?7F=#0<6A+SENHA;A4M4N.PH!9!NNO<3 ;!8?CY#4X\N[K?8\?\
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M+3SR,1CN)G!L)O<22@+5:MA24JD@E2TMB0%)) SR84# F:VG@GA^TXIXJP7
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M=B4%927=_,5P@!AFMC6+;3Y[!U]@A' 6D:DM>#%J2%_2WT^DL1G.R %*),:
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MUS.I0(@I@IRDS&7F9&4SSTD:Z<.T#%W<7>LF+5DLM,N*6I045AU+B4EM4*B
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MOKY<O+7E4W0.$)'T#C].H@R >HFHK^J?5\15&9S_ ,#LH_\ T"Y_[D_JUO\
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M=04)$3%*@]1">$J*E!1''O#W0>!\/7Z3SQ^?G4/J@0)Y:?&H9<RB2H@0= 8
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MFPF)@S&"[.9=Z''4J>?;2X%-A*D$@GG6-<XMX<%XETVK00E,$I0""<A$D*<
MU)^%;5_H!BUU@-Q8)</?NN!394H(4VWWJ%Y$*2@QE2A64[@^!$5KAV^N._>D
MU464B%B%PJ/D$2/*I,72:P-6 8,8.,)<4"L^6X!U#TX/PXUEL/XLX>6V6S;L
M-K<2ML%+21JO5)_W@&GAS$23-:]CG &+6[P6RIY]"'FGAW[ZRM 9S9E26]2=
M)$^D=9JB-RMX<9MZ9B@Q:IJ)$82K-;[UA4J8EMJFMQ0B9#=ZPB*E^0R^^I 2
M5IZ^GT.L#C_&%A;$V+-DPM!D*6I/XQ(.62"%$:DB=H$#E6T<%\#WSA<Q'$,3
MNVGAW:D(:< ;<" L0ZE:!.4%* )(.Y,Q4EV_W"PO'<9#=U!;E9+66K#51(77
M)D,F!:%L63DEM7!>]F0VI;+9(''4.?0ZM,-QS K5*'"RA3N= 2E:0&R%*),P
MH*@0-]=8T,U-Q+P]C]W<N"RNEBS#2R^4DJ=S-I(04D)* E29"CY'2:A[T9%@
MV7V,"UQZ6XB7'AE#\1FL+49]YQ]?2RV^7FUJ;98Z5K9<;(9(]TJ '-OQ'<X9
MBCHN4,LLN!)E+8$ B8@YI.D$3/I1!U@W?9S98MA+"[2X<6ZP7%*;6M?IG-JI
M2DY=ROT0$G5(\35';,$'>+:W^Z'AO3_VAKS]/Q';X_:-8+ALJ7Q;PPE)A*<?
MP<Z<Q_:#&_733^9D;3Q^0UP1Q@8&9?#..!4Z&3AMR.7B=/'7K7LPA_O<?_X(
M_P 1O7T[9V'D?C7QM=Y_LG[:[ROXO\H?Y]55?H_M#[:D3L/(?"N6IJC32E?%
M>A[<]CV^GMZ:4JEK1]R/94*0AM0DRW6U#R^5M ,J7U)/!XY'ND^G'U\:4JJM
M*4TI32E09"0MEU!/ 4@@_8?4=N_?T[:4K![>KP\8SOGG-!D=+NJC%[K'?:\:
MLJR'5461JGHB^1;3JX(LW$NPGVHKK8D^S@I4RZV7D]3:3I2L3_%G:Y+MM+K<
M/F3<8I<*=Q<X13R<AGX]865WA[#-) :K9,.9C-O.:0J=!CMH?4YYTB>ZTH.H
M4$:?/SK[Z>5;0MIDPHNV^!)KS&371\1HC%$=*1'5#-3',947H0TA+/D\=*$M
MM\$A(2-*5<I3W*#U<)#C9Z$D\*5R"0H<_ I_B]U CTX[Z4KRM?<ZBC_NY_*:
M'CT\1<X?G7*^WZ-0 B?$S4RDQSZ>^?NKU6%P <D< ?7_ $:B9Y;\I_E4M==Y
M\>6H@HX'3QRL@\]0Z>P!/X7'/ ]._;0!7,$'7EOY5*5::%,^)@>Z:U1[]>(3
MQ$XAF?BTJL PZ/E>-8)BF%V-9D2\N@4/WE3;##(5A8OQ*M^JFN7;P?=7.5'$
MF/UE7EI4%G@RJ4 .9W$)$JGP UFKAME2DEPE&4'4!8*B/^Z.9.NW+RK'0>,[
M>V)M7F]4_<XY>6M_?Y_38G98Y9A.;XX]0.5:H9MX+JWHT2"ZB6XPU,6VR8RE
M(>6ET'IU%))(]!T"=?Q:AZM1KN-I]=6F=PN92TYDF <JB8YG:.8\-]9K:#X5
M:G/JS;^)-W$.5IO;8Q)WDY5ED#+Y"678;:RJ-/@0:]IEAQ:NL1U(<4V2$]9X
M.HD:& 0==% @C;?IY>O2:N%A*3"<YY^DF('*>7AYQXBLJRMTIZD)21\>21^@
M<Z@)Y[U242-OM^S[37)"U$@+"02/0*Y_V^S_ &+72/7\]:B)YZ>%1=1J-8D^
M/'^PX\1_]R?+OYK>UJW&G]V<4_=-_P"<W71.R?\ [1.%?\21_EN5X91_6T?^
MTT?Y9W7B][\YK_>J^ROKH[^;,._<I_@:J+(_#;^Q6IKO\K1^PK^$5D+O\HMO
MV7O@FH6H4KZ/7\BOU'51KZQ_95\*E7]17[*O@:Y-?O2?Y9_6G4+#\W7WF?X$
MU:,_DC?[;?\ %7IO^0O_ (*MV?\ IE$_FYK7HOL0_NT__P TNOG]^%Y_>_!O
M\-5_F&M[VNU5Y%II2FE*:4KK+C!2E'K*>2%>Z #R.>Q/JI/_ #3VTI4= *4@
M$\D#N0 .?R#2E<M*5TYTQ$&,Y(6E2PV">$]O3Z>?M'IZ_#2E8^9+XA<3PJ8^
MUE,^-!=#+JXE8AP2K2R4I]3<=JOKH:79SB^EE\.%;)25H 2H ZH)6HKR]9TF
M>FW2)]>U0*DP=I3,Z].O]!RK5]XG-Y,GL,KRK(*7;C);.E9L:&VQ>XRR//I8
M:&<<J9%A.@0ZSDB0BQD,*</6N,](C *<0APGIW[AYA@A(60>:A*9U,9@3KI[
M-^0UT_'%7"BK*% 28T(Y#0&.<ZGEI)-9H>#&UR7)*W(<H>L'9>'6<AJ93,-=
M#4"'8V"?G2Q]ABM<H:C%N=%<;1UJ\KK6A*BE(U8X\;<.*;1ESH<4DF9)0DD#
M,?$QYF=]:N<$3<9$ES,49) ,@9B!R(W$F8)'LUS\0. E///2A(/?GN.!SZDG
M[3^?6HG57HGEJ9^[U"MH&P^?C4356E-*5IVW3^2YP'<7Y0K /&*M,1FMQ^K-
MGDM!Y:0W;YO7.E%/<*:Z.E:VF0EUYQPE2G0DCL.-47)6XWSR$:D:Z>\Z>J/;
M456K1:S)(2HZJ B(,2><2="-(D[5L2WER&^P?:O-LDQM$>1=TF.SYM9[1R8H
MD1T!22M X5PVVHD)Y/O)2/P=8SB!YYJP<<;E)2VH^:B-" =QIORY ZUF.%\/
MM[C$[1FY5+;EPVE<D:H4K628 '68Y&237G4@^*;<U.Z=QD&W>06]WGEO90Y+
M%W9#S*9PN-,1GZ%ZI2IN&8*9#CB0X^X&>$A;:4N]]>=N'L<Q9_%WDE;SB/I)
M" O-$9C*<OU2F3H-M =>7L;'.'<+3PRU@B\&P]EIJP%R+AA*OK.IS=ZEW6',
MHUYQ(U%9_P#B&V3WFR#'X^X.8;@R!/OJS&X,G%L7K'*!GYT0SYJ3+7#+ZYKD
M&2X/*4^M004]CQZ>Q.#[P-LM&XRYRC.00!J1J()&NX@'4&/$^ .*6[RZOUW5
MK86ZTX4IQ=M"GUJ<2VHI3),DDE68)3$:D=*R)\">%2V,6E9I<QWH%PXP<8DQ
MEK0CK56.I,I4N.E =5,6\TU*6ZZ2M:7DJ4/>U-C>*-7JBVV4D(6O4&2()  U
M(\(TU@<ZEPBS?:E]Y"FUO0M2-82I?I*3]4* 23&IV&NM;%!V0A0X]Y(Y[=CR
M ?3X<_$?#\^M;K8JMEN<+16#9.:JX10ST5$]<6X,?VA->6V77#)+ "O.2TD%
M2TI 40#P>_;"\0H?=PNY3;**'>[,* )@QT )WC;>)K.\,KMF\4M57C/TAKOD
M9V20 XG- 3F42!K!)5(ZC2O*_1SMT,MRZRH:2HK<ZLJ^7<5M N/3-.6$R8[8
MO6<FTZFI3#C:G?:&Y29$SJ5&2IIL =!3KRS9V'$1QA:5ETI#Q@PL&"Y,DE$&
M=2).DQI7N%6*\(6>"MNA3+16PWWC>="DME# 3E0 Z(  @Y1Z2M2-=-UN0^,:
M\PNIPS",P@.[8[@1:)H9?/N:5ZTQYV1!KHZF6J&8V_Y<@3W4NLH,LM)0Z %N
M$>OM; L,-ZTT% J/<MB! @Y %$R.4*)'NZ_//'K]+%S=*;^JJY?4@P3HIQ13
MI,S&@,QK&M9);!;V95N+.LH&40::.&JB-:P7*EXO>:V[86%>I#Y,AU =5[&T
M\E* $ 2$CD\<ZN,7PM-@$J$B5 $&=9UYC6-MYZ^-KAE\;HJ!W )&G0QS,^//
MU347=3Q,8K@+U&FF5$RIRPLYU;9Q8$L-2:]<0PV6^H.I*0X])F-L*4H*0&VG
M>/P>4T+#!WKD+]!2  "DD2"52"3 ]?*#&IDU5OL3:MP/2"C)F% $91MTZD#D
M=]1K,X7B'HGL S+-+6KDU$G!X\M^[HGIL)<I7D13+99@RDK;BREO-=DA!]U1
MX(''!P^+M+L$+,DP@J!U!V\8/6#&QUZUE,(=1?J;2%9<ZTIZP3IK!WF*TV9+
M\H#NGE&[^0QL'M\BH\56Q&GXMCK,"MES'YU<PA,R*_)6TZRY637 _P B(XIU
MPHY0I)!Y\PW_ !QC*<6"27\G>Y$ =X5 @PD'9,'8C0_5U.U>N,'[-N'VL#;3
MBR+1[$E-YE/9 M :<25!0)*2EY/HZJS)$&-]-TVP>[+.[^V%%F3T!^%(EM^S
MV<5YM02U91"EB7Y*C^^M+?!*%CMZCU';OW#N*OW^'L/K;4%J $PO-,:[R/5!
MV.NU>:^+<!.!8M<VK[B5L)7G9""E8[M1.20 -8B8VY:;Y#-_O:?LUL-:POZI
M]7Q%4;G/;#LH/T4%S_W)_5I?_D-[_P I<_Y*ZRV"DC%,/(W%]:$>8?0:\75U
MR+BV(4.?G.<5?:93OV_$GZ-?+"[=RW=UE_\ F7IC]XK:9^>=?9S#\3<796:5
M-Z?16 )S_P#!1/@-.GNJ7AP*!Y2GDELGA Y(0H*4D]N"AQ!+2D'L I:APM1.
MK0W5P%  J()B 3&IYP>D^(D\C62"VE *+0//ZI,Q&N_JC?D#)J_&';>8WDFW
MXR"UOX6/36]Q*>C,N>A]U+M?.I)R94-#;:DJ0@RFH?EN(22EQM*E J4=;WA7
M#-I>M!1>!476DF%H$I4A><2 1E!"3&\JZB#RCC3CG%;6\#5E;+#)L;MTD-KT
M>9?MT-DP9E25N&"0G2?$W1S?8C$(MB_!HI-HQ-B3,[LWJY39?8L*;#\TM*@L
MM62G5.LV3M:S!3$:<2$N.I0.%"2T&=C?X+L&W,B7@G*XN4E2#*6W"-RF9RS"
M3N1K)4*UKA?M,Q95BVJ_M<YN&+<)>0E:2AVZM4JE30A.1+YS*(,9',PA+9"J
M"WFP?%ZNN9N\/JVDUL;)UT*G8\NR;G18T2),EF!>UU@EQMFRBLPWRM^)(=0I
M7G=3 !;XQ7&/"5FTK/8.#*'"W(* L)(TS)RZ*3EF1S"I&FE]P+Q(IR_99Q3$
M;A3J[9#R@4,EHJ"TH6IEP*3WC9+B9"D#*"G*HYE5*]MMDW=P:*7<_.SU:Z19
MJK?W*T['<?IVT//\MI=,E]*T**5.0D(2D)!D%*E!(MN&^"6[ADKN+CT2' E!
MRE)(T $B23.XT3H8UK8N/>,;>T?MV;9]3BD.6ZRDNI2%YW("5@"$I!&J<Y4L
M$A  !)AYQLU][-AB4&NN#9LY-.B5Z9RHZ68$>5(EM,.AE[SFWDK2)"2Y"DQ4
MOM]!X<6%!6IL1X.M[!U%L'D?CE!*5 MP5$Y1J #)D$@H$ <SO0P_M"O<0;N;
MM6!84/H+2GG$%VX#A2A"G/J%R-DDI*%J!)UR[">L[*XU(>=D-Y1:IK&;6'CC
M[RZ!;KPO)LQ^M0VR4NAE$%$EGS'GD++O"BTH)6.H3L<$-M>F7LH<6AI7U-0X
MK)(44[ 21H=X.AJWN.TB[?;#9P#!U3;/W"2;IT+;[ID.^DC.3,*RZD ;[&IQ
M_P#9ZQZ%U1K;-U-6"3CRY$:+5HD-!666$B#4AA[VHA/2XRE<A0ZNI Z$!*@3
MK+?ZM</5,7:,WXK93!)[Q12""$Z1$P>9@&L;:]I^(IL]>'\)*2F\]+Z0_H+)
MM+B],VH6%0.0U*C&@Z:/#JT76H$+)9,Z[;@5MG/0FK*(7S=;3I$9I,%UZ2AJ
M7,;$1<GH#S7*2L*"0RHFD>S&VSA(NP20A49V8RJ.68"8,#RD;:"J&'=I]TXA
M]TX'@[*%%]M*P^^5I<;;S A.8>E) C]%642<U3F=X:(4-QAU68E,6T;HV*DJ
MA1R\]*NYZX*69[K4@L%#+C2G%^RJ65)Z>E?X1U+<]F-DB"+V!*"!F9CTB1OD
MGT3SDR(UD&J%IVK8JR/3LEY4]^5&79 90%@@2",X, '+&I,Z"H;WAUI*:R:E
M6F62)]#$E1X$UB+#$B>+06WS:D%//L[<3J45K<;6MU#?NE 61Q6L^SRQ94'%
M7H(;5Z0S,GZBP-LH)UZ$R.D15R]VG7]X0R+!86ZSWB"HK2B%-%T!6IB-1*@!
MORFJ?I-H\;R"_P!R*5N9,@2<?M&(>/K:\Q;"&WIR8[KDUE2NM3:&CR4J5U)/
M2$D#6.Q#@[#[V\>*+B25 )@HW*LI*DPH[#28D\Y,FL]QEC-G;V19:'=N,EQX
M2H>EW6=*4+!@RHP2F4QJ8UBVFX.#0\39J)E;;2;"NN18-M-38R8,YMZKDJB2
M2I*G>%I<<25M+0GW6R$JY5WUK&/\+)PE#+C;^;4J )1/H*V@ $ZZ0)(GK6X\
M%\5.XM])MKIC*O*ALJE2Y[]$CZQ$908$_6W&A,6V X"^I065 ?A 'H*>R2D@
M#I/2.E7;WN_/<ZUU+KZI*@K7]8*S:=?OG;P-;ZQ9V]H/Q: ")&@ .^NG7J9J
MY6RI'^[#M:/3_?#PTCU^&00/M[GG[/76S<)">*>&I !&.X2==Q_M[!U_IX:U
MI?:,2O@KBV-<O#6-Y@/\.N#[A/C7LRA_O<?_ ."/\1O7TX9V'D?C7QQ=Y_LG
M[:[ROXO\H?Y]55?H_M#[:D3L/(?"N6IJC32E?"> 3] )_-I2J8M'W$V6/]".
MM3TM]#A""0VGR">KD]T\D<<_D]1I2)^/3:JHTI32E-*5"?/#+IZNCW%#JX)X
MY''/;OSW[<=^=*5J4W2HMPMJ][I=WAF;W,U#<W)]R["HAXUAK\3&J6[K*3&;
MA4J7:$3;64MJ Y+B1>EL>8\ZE4QHH;;=$]3X_'[IJ'SORCH-.<>J>E=GQ93\
M:RV^VH;]NBU]QD>V2\BJ<PLKJ54!<1B=CEE"2S45M98%<UVR<A6@<DEN(P(C
MD/A3CZ4Z>K[O+K[JCMN?;S_G[*V,[<UK=9@.'5K"Q-9@XW2MM.A]QX/J:B,C
MS MY*'BA0Y(6L#D$?M8'8*5@3M!DGBGPNGW-<@X3?;S7:,LCN5S6XV5NX(PF
M-.D6JK%BG=D,Y-'5#I640FH8C18B93:E<J*@%!0;@>(&G+[O?RK3Y]S>3+&5
MNU\I%*NJYJHNI._JW[&H8G)LF8$QY$A;\5N>AB/[2AIPK0EXQF0L(Y*1SI51
M>L^$>O50T_F0?"O5LX]^UJZ4I4KT*'#T#Z^_Q^KCO\=!YQXG2*DA)T6?1YD"
M=-]M/(]*ECSY2TZ$L,+6I"DA(=4"5*!"0%!)Z>_ "B#T\\]^-%.!.ZYT_1,[
M?:.O]*@E%GF +BHS F4 F"==,PF!K&GG$UB?;W6\KDR_0SX<\-LHM_T1;64Y
MN'%;-U"AI]EC*L8YQ9_S.F*AM ;==6I"/<Y*0-86YN;I"5FS:2NYT+04HHDS
MKF*9(TF0.8K9V6>'.[!5?WK0 ]);=JVH@D 2)<3.NG@)YZU9;';3)G\\S&@I
MO"1MLQD\-B&K(YHS"N:$UNR"7T%4E.+CSW5!I"GN$@N*0GKYZ0!9HO\ BF$S
M9LZ1!+[D=-%%&_K'GRK8UX)PHW8MWBN(,4R. E$8<C-(&HDNP#//Q&M94X)E
M>]4V^KZW)MH<?QC'$_M;]I"SM%F]#;;:(;2W7"CA^<DD)1T!] 2.#\ -75H_
MC2WT"\M6&F5$YUH=4I8D$@A)3K)C20:UB[8X>-D\NQQ7$7[M,!IFXLVVVUZ@
M&7$+44P)CT3.U9$&1T#\%L >O"P3V^'';[.Y[:S14D<S[(Y_/W5K:4.D[3ZC
MX"=A\^VOC;J5NI]W@DG@<CD<#U(!/Z.?CW[:C(,01K4)6#E(C770QI\\_97=
MU&IJQ)\>/]AQXC_[D^7?S6]K5N-/[LXI^Z;_ ,YNNB=D_P#VB<*_XDC_ "W*
M\,H_K:/_ &FC_+.Z\7O?G-?[U7V5]='?S9AW[E/\#519'X;?V*U-=_E:/V%?
MPBLA=_E%M^R]\$U"U"E?1Z_D5^HZJ-?6/[*OA4J_J*_95\#7)K]Z3_+/ZTZA
M8?FZ^\S_  )JT9_)&_VV_P"*O3?\A?\ P5;L_P#3*)_-S6O1?8A_=I__ )I=
M?/[\+S^]^#?X:K_,-;WM=JKR+32E-*4TI32E2]R:&7O+>4R@$<IZG E1[GMW
M/ ]/R:0>E)'6NTV\%H*^W2/BE05^KD?I_)I4LF8C0<_;Y>'(^=2JYA&SKWXH
M=\LND=!((Y"2.W([@*^D\?GTJ:L%,IP3[V_$IMWDUI&BOTV:5MGA$JQEI;2B
MOOHC[V35"2X\E03[?5P;B!'*5)+KZHC?/+JDF5#2E*) .FH !@@'[IG6==>5
M4"E"%%1</IDRG:#I Z](W'/;4Y,;C[0XONG645=<O.,PZ.T9N4HBE#8EA-=,
MJ@P^!RDL.L3'4E )"E)2."?7(6U_<6"BI"0J04D*)$029TUT)//8^NI';9FZ
M 2HP)$%(&^GJV'C!]UL?#-,QG$:',=HH*68(VUSN_I(2PD,F1BUNM-YADUU:
MB//":"9%I$R>.'7:9P<]84!:OO.7*UNK5"G%%1U)C,22$STDQS]]5F6D,!+:
M0"$"#/..L1J1Y3'A66[22$A1)Y4D$CGGCD \<_'5!*<NLS54F3L!Y5%U/4*:
M4J7MQ>'5K4^7 I1)00GL?@ 0.>D=QQZ$>OIR),@"BK;K.V\S]QY>6E2)41F
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M"D-A:R$I'I SED$D3KK$:U:L8MV?8):W#-JS:W4+6P^ONT%2EZ(*([R% 9H
M28U,5*+/*-VJ>=,6Y97CCM;&%;+LZY#S\%DID!:0B4F.EA#X<47%.J0E\/*"
M^HJ).JES>\3H;1;EA20D);4\A3BE $ZJ .@4-5 Q];D"=6'89P!?I>>#5L%N
M!QY#"D(!*LI"4_648,!!!)2!($" 9)/D;C5\&JLK.5>0VK*;$9A(?,EM]YVE
M<\ZNZ4J;#KJ(K[Q>C<!0\UPJ20H@C%W%YB]DZA/TZ]<2LA(4I)!4I)$0D:D
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MLG]9JM3K$GQX_P!AQXC_ .Y/EW\UO:U;C3^[.*?NF_\ .;KHG9/_ -HG"O\
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M9:=NGG6JV?.L%I=LA#@+80M58F;(?#94&U%:0;;';%FU]/1)4-OUR!.F_I"
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MN:UZ+[$/[M/_ /-+KY_?A>?WOP;_  U7^8:WO:[57D6FE*:4II2K ;H[ZUF
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MW+BD+E<@$R5'DF*NP7#%QFQVX.Y_($;F)@F\TF!_.KA/X5W:&G]&V)DD:6T
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M\I*'$*:(;#>E7"JZ:'3Q8L&N:9B0H3+$:)#C1VH\6-%CMAIJ+'CLA#3+#*0
MPA">6Q[I4L<<*5-%_@*_DJ_4=*@K8^1^%>4K[G=_AM^4Z_OAYO\ E']2I_WJ
MOVC_ !"JSOY:W^Z;_AK>YXC 3N1L  >#[=G7?_\ BJ'ZQZ^GKK7,<$XCAXF)
M4O7>/0Z5TO@ $X%QT <I.'8?!B8_V]7*ICPK\;_Y1JE"OUO_ $BL7E<_XG_H
M33A7XW_RC2%?K?\ I%,KG_$_]":<*_&_^4:0K];_ -(IE<_XG_H37P\@<D\@
M?#CCG\HU Y@)S3$:0.M2.)6$$ER0(D90)$B1(KZYW'T?#M\.QY[_ .GG5:\<
MBU2<NT<_Y5=J(3B%B,H.8@S)TF(\X^.M1/!V>,7SP$<\[FY7P>?3]TM_;SV/
M&KW!E9F'-(_&J]P'D.<U1[0B#?X9I_\ #VSOSE0^P5F-K,5H-8D^/'^PX\1_
M]R?+OYK>UJW&G]V<4_=-_P"<W71.R?\ [1.%?\21_EN5X91_6T?^TT?Y9W7B
M][\YK_>J^ROKH[^;,._<I_@:J+(_#;^Q6IKO\K1^PK^$5D+O\HMOV7O@FH6H
M4KZ/7\BOU'51KZQ_95\*E7]17[*O@:Y-?O2?Y9_6G4+#\W7WF?X$U:,_DC?[
M;?\ %7IO^0O_ (*MV?\ IE$_FYK7HOL0_NT__P TNOG]^%Y_>_!O\-5_F&M[
MVNU5Y%II2FE*:4K59XK]KLTSC-)\^LQ1ROA-QW(B<BK(:)LV<M;12Q[8E+B5
MNQ0M7E^2I(Z.HKZB 1K>L#OK6VMFT*="G(DI/Z.FJ0(F1O//3KKI&*6ET_>.
MJ2V4HS:$93FV,DR!/*!&W6#5+^'+']XO#:%6&XV(2K/!V:MR#73L:A(DV,)M
M]9EKDV-,RX)8:\Q7+RXB)3QX]]E(22;#'[RWNTD-K22D\B),"!.GJ&_JK+82
MP]:P7$J$Z &()TY3RYGPYP!5\K3=RIWQS'"\%QZUKK;&$S8V69>J&)#(CQJV
M2$5U5:(=6PY"E2)R0LP7&W M$51/ )3K56''&22-#! .F@/B9Y;$<_**V1YI
M#R$R.0)F8Z]1/W<ITK/*/"8:92EH)0E2"E*4)2$H:4![B>D!/3P!QV)X'<Z+
M6I0.LGYUG377P'A5)M"6XA(,;1I7?+(6A(5T'@A0Y0% $<]*D@G@+';D_'X@
MZE$P)WY_(J:HZ00D J*B  5'CE1 ]3P .3Z]AJ-*^Z4II2FE*A]?/X'"N#PK
MOQP/R\:4JS^Z.4X?C&)9',S">PW5FJLVI")$E"1(0Y!?0Y#C>O2])05,'J2E
M/4M)Y[C4$X8]B#:T!"E@I5FT A)T.LC2"=M9Y::11B3>'O-N*4$'.@I)/-)"
MMHU@@$=)U/77YL'X']JK6I@9S(RG)9\J]LHV1Y#3P[R.[5SW&)AG457:]$<S
M_9ZYHL 1FY#2%%OAPK1V.D-<$VUO?+4X@YBLYM51(.8 CO"=(,]-X&E=&O>T
M7$;NS;;;6CNT(AM92CO!F1D64GNP1.@$1IH29JPGBZVFH,4WAB-X1[9B629-
M=T#T!-0INHIU0PE<J^F2$1#%C(9C!MGS''H[JGI#O*W.LDGNW![EDUE2_$-(
MRQZ6R01J!S(&VI!WUK@6-IO7+AYP$D+6I<D)W<,DF 9 )W*1RK,3P=8WD-+/
MR^3/JJR9#4\ID99"=#KDF6%!<AB(ZM@*>;<=6I4EU"@E3O4KW@>-0XUN+1QM
MGZ.HI.4*+9D*&FF823UT)T/2#%S@;=PE1SIE.7+F&6 ==O$:3ISK&?Y2#8#<
M7.KU6X402;7"*W&U0'JN$T[<SZNQ;6ZX)<"J<:2W#8E\ICV$IIQTJCGJ\D='
M)\I=IN"XCB6-82IK.JR"$AQ/HE"2J2HQ,B1HH@](V@^Q>R'M-PK .$,3X9<M
MFFL4OKAY2+N,JG6U! :0LAM>?N\JR@**8!4)U$3/P*^$ZL8Q!_+<VP.AB4>9
MX1408T2<E-E=R;%J9,=E6ILW1[=6MKC*:9^;H[S;*U<+4 I(2-EX1PF\PG$[
M=QM!3:!A$CT3F6"<RM25@0 ,OKYFM/[7,;PWB"S9P%EY+[BGB[<+0'$!I"F!
M#!'HA:DK)6%SMH(BJIR/8VOVJWIJ9=_E59A.W65XM>8^U:LIAQ%2&ZY:K-N#
M:N/-MMQW!%6[&BR@^\^[QT+2/4]H>XL9M$)%PI((U3G)$$;:Y"(U@:Z:<ZX+
M:\/W-VLM6Z%+2TG)* %**4^B#E)D\B8!V,UL]Q04<#&*9B@>3*I6*N FL>2X
M'$/1%,H\AY#J2YYB7FBEP+!()/8@>F -ZUB2UNH<"E.DJ)3.LF1O$ ;::^%9
M%;#V'?BW$%/=D)(4-01$B![>8\0"#6M+Q'^/L;*[WU.--0WIN#4;\NLS5J*Q
M!<L+&]D5RY;,6N2[,1*9,/S*_J4]&2Q-5)D(C/.+C]*^0<1\>IL\0:81JAIQ
MQIP9@,ZTG;*6RHB,L'0;P217=.'NS%W%N$O[;5*7+K*Y:.0M00QWP9)4K,EL
M+S(</=C,K($E60$$6\W!R;<_QM8QB.68C56>(;;U2[)JYAP;:&O+U2VF_P!U
MS%16E1G(2(,%]0:KU.>TV?0 8S84DZ[3P-Q2Q<V:GTH">]2@J),GZH2$DY!&
MI)\.FYKBW:9P3<87C^&8.5J>2\T75JR94C,TEU.SBI!D $+T,A0)$&H_!]03
M8.6/5U])KZ:;M9/L)5E?RGY$&?EV.74)FLK'G(3JVHSL%EV!)5+D%3R8\^.[
M$*>I'F:VG&\6MFV7$O. AQ"0 2(205*S"$2#.4;B,HZS6F8)9WMTZ PTLI;<
M4DY0%&$^C $9M==MY&];;VK!LM(6$)=:/1PXA:2@^8E!04>G6E160%#X \>H
MUI+3[#YAIP*UY2=#$$:;:\^FA-;0ZAUB"XE0',$ '0Q!YS.G6=Q%3,O=*?>2
M00#W!Y3P/K/^?Z.?JU.5)$Z[>!J9*2=AXGU]?GRJD;_,\<QV"[89!=UE-"0A
M1<?L9L>,A( /'OK6$\D@\ D$ZHK="$J4I02E(4I1,:) *B=9V'NJ\:LW72$H
M0IQ:BD)"022I1A*0-(DP 3N3[,0K_P 8N#TS3\3;K&<SW4N%.N-]&)4,]^M:
M=*B!YMNZR("FB2.7([CW2.24]M: [VD<.O./,6"WKJX:4IL=VQ<)'> E*AF6
M@(("A$@E/F-NCV791B#1MG^(KJRX0L[A*7._O'T73JF5 *"Q;,.+=)()(0H)
MWCK5DL@W&^4"W.2ZS@&V])M922ATM6=]-KIMFA"^W4OS5$MDI(Y'S<I0/(![
M<ZU"_O\ M0Q8K3@38M;=T*0ETBP44I4"D* ?3)(!F,H)C3<5T?#^'^P+AT"X
MQGC%SC!YD3_9[>&8GAK:UI$A(=;<$@GF5@1J1!BK*3/D]]_-S)'M^^OB"E/E
M3OG_ #= -A?0V2H\E,6/)DP(40^\0"S% _3SK+'8OQI>.=YBW$[E\E1*EMJM
M& $DF2$E+Z2 G42!I&PG3;[;\)+L\X1"F^&.S>WL5D%(=1B#K9<"8"%+FU>*
ME?I'-)UU)U-7KPSY*_86N2S,R"ZRG+W6Q^Z&I,ENNA/\#GI,>"VT\D=O7VA2
M^_8\]];1;]A7# "3BEBJZN-RZI]]OT@9!R-O@0()@Z2=/'2L<_"@XRQUQQ6'
MIM<.95(;0&FWG&S!@EQQA(41R(0! $SK63^*>#7PV8OY(K-J,2<<CCAI^UKE
M7KXX]"7+=Z:2?R^I[=M;_A_9_P /X<4J;MVW(_72M0,"!]9Q0D#;41ZZY;BO
M:GVD8PT6\0XBO2@Z?BA:6YC_ .E994?"2?+77(NJQ6KH8S4&CB5]5"8 2S#K
MX$>'';3^*EIE*4 >A[)'?6ULV>&VJ0AJT;; V *H)Z_=N--N=:)<W>)WCBG+
MK$7GEJT*WB%K(YC,HE0GU>'*I\I*D)X;3[H!Y!45<_#D]1)/;Z0?KU7)<V0@
M$>&4'SY <M_75H0VD:I4?_$8Y^N?7Y"I4I]:'4#I<!Y2C\,]''/3^ D!OM]/
M3^7TU3*[L&!;@@D22I (&DG:3,D[[[#F8FXMQH$1Y*5I/A'7U>-50AE"#U $
MJ('=1Y(^K5>IJBZ4II2FE*:4II2FE*:4II2FE*:4II2FE*:4KX1R"..>01QS
MQS]7/PTI5*6D=XVM"4>6A");A="5*2IQ 85TH'<\E![\$'GCUX[Z4JK-*4TI
M32E-*4TI32E-*5Q7^ K^2K]1TJ"MCY'X5Y2ON=W^&WY3K^^'F_Y1_4J?]ZK]
MH_Q"JSOY:W^Z;_AK>[XB_P"$GP__ -O9W_--%K7<;_.6'_M+_@KIG9]^8^.?
M\.P__P#GJJ9:IUCJ:4II2N*_P3^3]8U*OZI]7Q%4W?\ =J]7\0KXOT'V_P"8
MZ7OY(/559S\XX?\ ^'X"HG@]_P"#&=_W3<J_[RUJ_P #_)W/WJ__ .M4NT#\
MOPO_  YO^)=9CZS=:%6)/CQ_L./$?_<GR[^:WM:MQI_=G%/W3?\ G-UT3LG_
M .T3A7_$D?Y;E>&4?UM'_M-'^6=UXO>_.:_WJOLKZZ._FS#OW*?X&JBR/PV_
ML5J:[_*T?L*_A%9"[_*+;]E[X)J%J%*^CU_(K]1U4:^L?V5?"I5_45^RKX&N
M37[TG^6?UIU"P_-U]YG^!-6C/Y(W^VW_ !5Z;_D+_P""K=G_ *91/YN:UZ+[
M$/[M/_\ -+KY_?A>?WOP;_#5?YAK>]KM5>1::4II2FE*Z+D12RHE:2%'T4GD
M<?#D=^2#_F.J02[F)[S0G1,3 .XY3[NE5 I$ %$Z:D&#(.AV\/C5/W=*JSA/
MQ6RE2W6G&2'%*')4DI1P>3[H//*.X(]1J>%1]8;=-]3[MN7+VRK*5;) $R-O
M9M]NO.K7XCL[7T<V78R85=%L)SC2YLV$VAF5-\@J]G$A;:1U(:22$@CGE2CR
M3J8;#J ),[_/SO4HTV\JN%DV>8]A":%J]EHA(O[J/C]8\ZH-LKGO-.NMMNN.
M$!LJ;8=*2KCGIYTH=?7O5OJ/Q*[1W^2RL2A95 %U%=EL>RON>49#L*ZMJ!]$
M9:@&WE)L:6<V VH]24MJ3SYK8*E=S;'?["-VY,UG$OG%YB-71;J),EPW(T:S
MIIDB9#9G0UK'8^U0RE4=\-2$MNH<4V!SPI5[FU=:$+XXZT)5QZ\=0!XY^/'.
ME*YZ4II2NNMDJ#P0KI+B> ?Q3]/;2E:-/$M09IE-[E-16V[=_=3\GGMFHDR'
MHCIKJV25R&D-K4(;32HS2/+<6 5@$]7*M=2P6YL[:U::4RF5,H!62-5%(!Y3
M._4#UF.?X\DO.J<;N1F0X9; ,R# UVT.O7E&E7>V3\3&W^PFT\B?N%CF18U;
MR):&HBY49;K.3.*!99^;'&^J,I#!0$J0E84E(!XX(US+CW%K7 2Y>@!Y,9@V
M@Y2#N 200(Y^K?05T#@' L2XE*+-I!2HG('%00$[9H$&>7F*MYLWXO6O$3XG
M:B++PRDFU2\>LL=:8F/ME595*FB=,F/(D) 7:^8RPRJ,T"I+2SPKCD:Y1PUV
MDC&[Y5NS;+M25J$ET*RI!](\AL-=QR'CVSB'L??P? G<4N;H0R$RDLDEQ9T2
M@$'8G94:0:W#5$*OJFQ6U5?&@QF$+=89C-):;3UH!Z4)0E(!)/*B023ZG75U
M+6\VEY3I<*N>\;C2>D 1'B-*X:T6V[I5MD*,JSKRW$Z#VSSYU(\WM:['L<NK
MF]6S[&W"?"V'R$MO=3:DM,\GD$O.J#?20>3Z Z"T3B"1:A("E& LC;?6!T$F
M)W\Z7%RC#UKNTYCE0 E()2<R3OKO.FNFF^FE:K-A_%U&QW)%XCF]_$QK#L<L
MKIF.RMLNK5$MGG[2JB$)075N(D2W8S1;20$,!/?J3K958*Q986+5+8=N4*D7
M .7T1K 2=M)F=->45J^'XW=+O;IZ\<6^75*[HP 6<RR03 ],@>C,R!'G6-'C
M]WGL]X\]KL9P!-K,IL>QMFW8ENHG5T=;\E;DIZU0W(;C-)#<))C+4X%I<0KC
M@ =_,W:9>7QS-VJ%H[I2DJ(,@Y3$\B-/*-]]O:'8I@N"K2FXQ-UG/<)0H!0(
M5"T^BF1S*M1'0ZSJ,[?D[\^W*RO$\FIMP+IB[:QQK'(M 83"?96:EVI86(JI
MK:0A^8RHA+R02I!3R3SZY'LNO;]UM;=VI3A24A*C]5(CEU(T!'KC2:U7MRPG
M \.O6U81;H0'BXMXA1S+<*M\AG*G<SL)(B!5D/&!X#]R=P]R<QW'P]35[%MD
MHL*BM]L8B7$.Z$2&@ N.I#<BMCJC.B(PM0<9<D=87[@ H\2]GJL0O'+MJ[2G
M.XXYER$D*60869U $B.ITYUD^$>UIC"^";3A1ZQ47;9;JC>%R$+;6\MY"$H@
MD+05)3G.X!F(!K*+PGQ,4P+;6G;R3)&HF>Y;D\Y>;T\Y"&9,+/G&HE7:TR8[
M82EI-?(9:C,N)'EO*=:6TM:7$J/2>$,'?LL.<: 4ZO(%N+ RP4:J(3R$:A)U
M&\;FN0<=<3,\0<1V=^TT+2WL&46K%MWA<*FFV@A!4X=U'4SSUGG6-WRIUW\P
MU&V\>B=:K+"T@Y2TER&/9[&R97(H737O=/1Y\)*O:GA&4LK5/]G*$\A0.F=J
M.(WMK8MI82LJF2M)T(G01R'HGR)-=/["\,PF^Q.Z-X$!)/H!0]$$A9,00K-J
M"J=( B-2.?R?>_&[F59DO&-Q[)=Y%L\9=75QD*2B1C+F-241I+%S&Z MJ1-,
MEI3*U'WD,D@'J!.N=F^-8A<.+1>(<7(4D2I)R9>1   \--=8/.MB[9^$\ L&
M4OX4&&8<0I>5)ETN@+*D$R(!.H/,1(@@;F7XQEQ_*6XI'4GNILE) 4GTY'T=
M]=O(!&T$^KV^O7S%>94JR+S !4$Z'F*H-W:K#)$OYPETE?8S_C,LF1-?['D
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MJ/(77\<R*GK<:G9#7VTJ&NKE2+FL@56Y<O<B+7T%FZ^M<4R)3Z*V:X\M?FQ
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+-*4TI32E-*5__]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>31
<FILENAME>g164680g01m02.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g164680g01m02.jpg
M_]C_X  02D9)1@ ! 0(!>0%Y  #_[1_B4&AO=&]S:&]P(#,N,  X0DE-! 0
M    '\:^@30X0DE-! 0      !<< 5H  QLE1QP!6@ #&R5'' (   (    X
M0DE-!"4      !#'71?E=+5N]=N^.93 Z7E<.$))300Z      #E    $
M  $       MP<FEN=$]U='!U=     4     4'-T4V)O;VP!     $EN=&5E
M;G5M     $EN=&4     0VQR;0    ]P<FEN=%-I>'1E96Y":71B;V]L
M  MP<FEN=&5R3F%M951%6%0    !       /<')I;G10<F]O9E-E='5P3V)J
M8P    P 4 !R &\ ;P!F "  4P!E '0 =0!P       *<')O;V93971U<
M  $     0FQT;F5N=6T    ,8G5I;'1I;E!R;V]F    "7!R;V]F0TU92P X
M0DE-!#L      BT    0     0      $G!R:6YT3W5T<'5T3W!T:6]N<P
M !<     0W!T;F)O;VP      $-L8G)B;V]L      !29W--8F]O;
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M4'AL0&L@           *=F5C=&]R1&%T86)O;VP!     %!G4'-E;G5M
M %!G4',     4&=00P    !,969T56YT1B-2;'0               !4;W @
M56YT1B-2;'0               !38VP@56YT1B-0<F- 60           !!C
M<F]P5VAE;E!R:6YT:6YG8F]O;      .8W)O<%)E8W1";W1T;VUL;VYG
M      QC<F]P4F5C=$QE9G1L;VYG          UC<F]P4F5C=%)I9VAT;&]N
M9P         +8W)O<%)E8W14;W!L;VYG       X0DE- ^T      ! #O_XU
M  (  0.__C4  @ !.$))300F       .             #^    X0DE- _(
M      H  /_______P  .$))300-       $    >#A"24T$&0      !
M !XX0DE- _,       D           $ .$))32<0       *  $
M 3A"24T#]0      2  O9F8  0!L9F8 !@       0 O9F8  0"AF9H !@
M     0 R     0!:    !@       0 U     0 M    !@       3A"24T#
M^       <   _____________________________P/H     /__________
M__________________\#Z     #_____________________________ ^@
M    _____________________________P/H   X0DE-! @      !     !
M   "0    D      .$))300>       $     #A"24T$&@     #-0    8
M             JD   ,!          $                          0
M           # 0   JD                      0
M       0     0       &YU;&P    "    !F)O=6YD<T]B:F,    !
M    4F-T,0    0     5&]P(&QO;F<          $QE9G1L;VYG
M  !"=&]M;&]N9P   JD     4F=H=&QO;F<   ,!    !G-L:6-E<U9L3',
M   !3V)J8P    $       5S;&EC90   !(    '<VQI8V5)1&QO;F<
M    !V=R;W5P241L;VYG          9O<FEG:6YE;G5M    #$53;&EC94]R
M:6=I;@    UA=71O1V5N97)A=&5D     %1Y<&5E;G5M    "D53;&EC951Y
M<&4     26UG(     9B;W5N9'-/8FIC     0       %)C=#$    $
M %1O<"!L;VYG          !,969T;&]N9P          0G1O;6QO;F<   *I
M     %)G:'1L;VYG   # 0    -U<FQ415A4     0       &YU;&Q415A4
M     0       $US9V5415A4     0      !F%L=%1A9U1%6%0    !
M   .8V5L;%1E>'1)<TA434QB;V]L 0    AC96QL5&5X=%1%6%0    !
M   ):&]R>D%L:6=N96YU;0    ]%4VQI8V5(;W)Z06QI9VX    '9&5F875L
M=     EV97)T06QI9VYE;G5M    #T53;&EC959E<G1!;&EG;@    =D969A
M=6QT    "V)G0V]L;W)4>7!E96YU;0   !%%4VQI8V5"1T-O;&]R5'EP90
M  !.;VYE    "71O<$]U='-E=&QO;F<         "FQE9G1/=71S971L;VYG
M          QB;W1T;VU/=71S971L;VYG          MR:6=H=$]U='-E=&QO
M;F<      #A"24T$*       #     (_\        #A"24T$$0       0$
M.$))3004       $    !CA"24T$#      5D@    $   "@    C@   >
M 0I    5=@ 8  '_V/_M  Q!9&]B95]#30 "_^X #D%D;V)E &2      ?_;
M (0 # @(" D(# D)#!$+"@L1%0\,# \5&!,3%1,3&!$,# P,# P1# P,# P,
M# P,# P,# P,# P,# P,# P,# P,# $-"PL-#@T0#@X0% X.#A04#@X.#A01
M# P,# P1$0P,# P,#!$,# P,# P,# P,# P,# P,# P,# P,# P,# P,_\
M$0@ C@"@ P$B  (1 0,1 ?_=  0 "O_$ 3\   $% 0$! 0$!          ,
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M_'\"DI7Z7Q;]Q_O2_3>+?N/]Z7JU^/X%+U:_'\"DI7Z7Q;]Q_O2_3>+?N/\
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M\>EW_6%[<[?9;3;BU48[+68]KOM'Z
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
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M=41%8V1E<H*$A:7_Q  = 0$  00# 0               0,&!P@"! 4)_\0
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MJ>&2>0N-CDC:7.RC=QZ-;<DD"R[-'0U>)55-0T,,E155<\<$,432Y[WR&P
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MSRXHJ2A5\V<VAG9!9R*FO$R '^8S7I<9SOG"ZONF@'"#U< GROY?N0IQ@/:
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MY7UY+Z08'VD<,8KPRW&QB$5-!20MDGIWR .#R!DCC%SD!=[H:!J-+:Z_0O\
M)R=GRW[+6V%OZ^7&0R<OW"L6\FNL/A19CN'X4^MHH15TD8-J:$WNU@6LUA:6
M9KZ$J#9[M*SM]PC@$W#N$TU)43/J)C$'/>'$L;<-.0"]@1UM??JM ^UGCFBX
MXXEJ*R@I(J:GIWF(.:P!\I;=N8O&[;<M;G6^FNQA.:5">>&+CQ/)YJ)GW=77
M<>/D?LL76'4?7[+EZ[5/^PM_A$S[NEQX^1^R6'4?7[)Z[5/^PM_A$S[NEQX^
M1^R6'4?7[)Z[5/\ L+?X1,^[I<>/D?LEAU'U^R>NU3_L+?X1,^[I<>/D?LEA
MU'U^R>NU3_L+?X1,^[I<>/D?LEAU'U^R>NU3_L+?X1,^[I<>/D?LEAU'U^R>
MNU3_ +"W^$3/NZ7'CY'[)8=1]?LGKM4_["W^$3/NZ7'CY'[)8=1]?LGKM4_[
M"W^$3/NZ7'CY'[)8=1]?LGKM4_["W^$3/NZ7'CY'[)8=1]?LGKM4_P"PM_A$
MS[NEQX^1^R6'4?7[)Z[5/^PM_A$S[NEQX^1^R6'4?7[)Z[5/^PM_A$S[NEQX
M^1^R6'4?7[+M9S"LD.ML-LVB5NK2VDN54M" 5'I!4M2>E !(Y4KD#VZ7OU\B
M/U"6\0?/]P%*-U-N,7W<P'*MM\TANS\7S"EF4ES%9D.Q7'8<I "BV^TI*T.-
MJ"7&SSP%(!4E0\-4JBG950R4\G_IRL+'6):?>%MQM]?'3?MT%?/AE;35]/E,
MU+/'.P.;F:71N#@"-+CKJ+C1?*=VANR]NEV2,]B;=.X]>;AX3D\T5^SN24%:
MN9)M7GUD0L0O&8B%)@745+@0);J6HTR,RM](20I&M1>.NR?$:7&H*G#8W5,%
M;4,#KETCHPZ1Q<XDCW0!8 <OGK]"^S?MGX>XBP::7%9X:&LH:<]]%,6L:]\4
M;"3$TFP:Z]F@ #0^(&Y_Y/'L,RNSVQ8[Q;G/I?WIS^FC0K*N@ON"IPVA+HF-
M8TRVTL,SIC;G0;">Z72MYH(8*&NKJV"X%X*BX1H&L,SYJB6,&3WR8VEQ+W!K
M2  0793;0EI(.MUJCVP]IO\ YSB7L='%$S#Z&4MCE$;0^8- !(?J2T/!RDBY
M!&N4:[-\D8>EXY=1([:G7Y=-8QV6T\=2W7H3S;: .025K4E(Z?:?$@:OT;"_
M0+"RTYQ>P]D=9V<MCGHT+<![="AS_"KO),2E94_(H*R)%RN?-MW4T;A$)IJ'
M"<9?;#146RXKN@2=2GKUZZE2[;;83/X5WCM-6;(WV$9S2;];G[@Y3NG)#3%7
M?;?7,Z_=CUS-FV\7+!>21I;4%JA6%>AAT2G&T!2G24#[;VZ<_P!/CRLLL>RS
MV0JK#MG<1K\\F;@R;FRP)S',PP?(<L>G8PP+..IFR@L4J64-1D-MN=W'+4E2
MHH "%=?5HI5^,;[+6UV-PL@B,P[BS>RB=0S[BSN+3TVSD*QF8Q.I(RIB6&%&
M+!?CME"5H==6.KO'7"> 12!WL;[1F<U90AE=1.BRIS\"549&Y"?K(=FPY'L*
M2M6B,3%II3;SO>P_IJZG%J1(23R"*C^UWB,?&^S_ (Y78[ 4UB>WVXFS]_=U
M[ 4[T83B>?T%M?+?X!6ZB-619,R8H@E]*7%.%2W"5$\5CGG79JO<EL=Y-R:;
M"#/S6_[36RF78!E#+ZG+!.W5)'VJ9O9E5(1(XCUR8D+*6IK" T)K(DMO=XV4
M%+UZ_P HKB*[&VX]9FUAG]7E^U*I?I5U;U4$[5)CV?ILJ'-$!IZ[.1.)2XB5
M(9,F2J*0XE*^4 *YU&M^5OK]CYA/C]%87LP[+9=M=N)A.7W&!Y]B36%X#N5"
MWSN,\LV9F'SE6*I%A";VV;)]&:BRK$"2[\T=,1JN7Z(^I2U=1E.=_7W6=?8?
MJ+>I[.^++MFW&&[F^SW)J.,Z5A<?&,ESK(KS&DA"P"AMZDGPI#2.!T-/H2$@
M#1%EQHB:(M,7RTEG=TNSFR=Q,D9?$VAJ]_L)L-[7\),LVR,*AIG22IY,)*WG
M(2;%F#UM]"D&08ZNE:TCI(M"NV.,Y!GFYNT_:E1#W-':)[0?;0K[':)QH7+3
M+&QF-6<)O,?G-7*&40DU[S\5EA2D-(@M.=*4QR 2?!?<#'ZNZ1U^*^E/6?>K
MI')'YCY_IYT1=VB*V.ZNT&V.]&/-8KNKA&/9YCS,UJR8J,DK8]E"8LHR'$19
MS3,E"TM2HX==#+R %H#BP#PHZ(L%H'R7&QF,8C28MM3D><[1&G7N7$D6^$RZ
M2-876-[LV"9F6XO:)G4DV(Y6%E*8E2ZU&:GU38"HTL.=2U$]>K+8-M[@U#MG
MA&+;?XO'5$QW#Z2!04\=;A=<;@UT=##1==4 7'G.DNO+('6ZM:O#GC1%0/:0
M0@;&;I+* 2,.M_'@<\".M7A_+S^GVZ(KM4O2NHK% ><"(?'P\V&S[#[CX_GT
M3=3(MH/FD?S?W:)NK8Y=MCB5WD5+GYQ:@EYUBR'$4>02*R [=,PWCS+JHUG)
MC/2(<:: $J+*TJ0H!22D^(H200N=WSHF&5HLV0M&< Z:.W&FE][+TJ3$JR""
M2B%5.VBG!$M.)7B%S@+L<YM['*^SK;$BYNJTHK*/<069['@EU+B7&NH*4Q(9
M=+,EA:D%2%+8?0XTI2%*2HIZDDI4DGDRXTY6N!\^7A]%T9&&-Q!&I((^%O\
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M#ZLO?A:_Q=$3UZ@?5E[\+7^+HB>O4#ZLO?A:_P 71$]>H'U9>_"U_BZ(GKU
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MD-G@P3$!QN6.!:0'6]T9MC?2X)\E/ZO<"-9P8UA"HLDDQ9C29##R:N0 M"^
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M\2)&92EMEEI"0E"$@ #\^B*VO:"X_P"A;<GGR]4[?_='-$5QL:_[!I__ ,7
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MR _&P.PT/(\Q;0*H]>RNHFB)HB:(FB)HB:(FB+BM 6.#SY\^'\OO!]^B+D/
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MN8MM(2E*IJ&T2CTI2E7?=24I"N 12/M.97>5>VV>U$+!,AO*Z7B5B)&00)=
MU6P.]86E?I#5A=0K(]PGA:_18#X4#P@J5X$BNGB]Y:MXY1)1BUPM(J*\!29%
M*H'IB,CD=5H" ?,<CD\^(&GKX_7]44]]8+C[*77]-2?O;1$]8+C[*77]-2?O
M;1$]8+C[*77]-2?O;1$]8+C[*77]-2?O;1$]8+C[*77]-2?O;1$]8+C[*77]
M-2?O;1$]8+C[*77]-2?O;1$]8+<_^5+K^FI/WMINBIO*X$+-\>N,5RK;R9>X
M_?07ZVWJ;)-!*@SX4ELMO1Y#+MHM*DK23PKIZD*Z5H(4E)%.6)DT;H9HXY8G
M"Q:\7%NEOC8WOR'-5Z6IJ**HBJJ.HFI:B)P>R:%Y9(UP.I:X;7%Q\R/%4OAF
M XKMQA%?MW@>U;F+XA4,EFLIZMO'VF(?)4?26@NT<"IJ%J[Q$IP..]8"E*5T
MA.J4%)34L9CIHF1-<[,6M8 +ZZDCPTN1I?S[%9BF(5]8^MK:B2IJ'V#II7N=
M(6Z @D\K<KV/S4^I,LOHLA>/V6*7YD06F40IRI-8[\Y0D-);0](EJEQHILUJ
M;=7)C,*6D )=2H!PI34OW=KZW-@!M\3X[ :+B^%CVB5CV@$$N;:]G<]1H 2>
MIM\ JM&0W!_\J7/\C]&?[+7^3]/.JJZ9%B1>]N:CZP7'V4NOZ:D_>VBA/6"X
M^REU_34G[VT1/6"X^REU_34G[VT105?W!0H^JEQP/,*DTB2>"/\ ^:\_RZXN
M)#7$;AI()VT!/QY::;V2U]+7O^VJP][1%U8YEENWNVJ*FPBIL+!NTL(2WX"W
MWX[3Q0VMM4:<ZT &?2E</+1PIM)!\$J&H/\ $-,[B;C/@#@"&?-#6STF+UT$
M9<3ECJ7.8V5HL2&B-Q?<92+6OSRSV?P1X?A6/<0R.8U]/3F&F+@0XR/ !+=V
MC*<MQ?;3GKEK76%A6Q(L2-B-PAF-&9C(0A^DZ$H90E"0$_.WAP$^'Z3SXZVU
MH**'#J*DH*?(V&BIX::-K!E;E9&T7 TL/=UTU)^*Q742OGJ9JB1Q?)4/?*]Q
M-[N<\DZ\]_ELO=ZP7'V4NOZ:D_>VNVJ2>L%Q]E+K^FI/WMHBB+^X)X&*7/\
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MZFEFPZZ,K(;:#";]%L'7W7.AQ+Q0&U16#TJ#12M84K@*XZ5<#C$?\4V*>Q\
M-P6FE<*KB+&:.DC8T /DB<YD<A< ;M;F<T'D1<WL"I[,*1D_$,]6+]WAE%-4
M%[M+,,,C'#;5UG&P&IUV&]\<$@9C18EC=.S5TZ6ZVE@1?X2R>2LK:C-)<6I
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MIJCB3#'OP^AQN2SJFACISW!A)_#(Z$1".-]G$"]G6)!S4KZ>%35\>NJXL:!
M@QT,1(<5M++$=EI 0AIIM("4I2E( ''C[=9%@IH:2$0TT3(HV@Y6-%@#8VMX
M?,==25BB:>6JG=/4ROEDD==[WNS$W(N3?P'PL-EACNRX[N!O_@."Q^EZOQDB
MZN4$A3 4EPR.Z< !^EZ.R6_$CZ3GAX<'6GO:A*[CKMSX1X.HW=]18 QF(8M<
MET+'L@GGR$L+BV0/:P6< "7-L1K?*O#).!<"XQC3KBIKIG440;H\1ES8P\YK
M LNXN-N33X YOQTA#:$#CZ*0D<#C@)]G')XXY XY]FMQF-;&V-C19K8V,8!L
M&L;8#7D!8#]EB0ZEQ.Y<YQ/6Y)\%WZJ(FB)HB^<7Y9BOW@QW.\&S[(Y;V5[#
MN=Q28CB%:HQF*3<ET*<:E9%'Z0U9)L$)"J^;*6MJ 6UH;:*B0,'=L-%CM720
M^R3!N&-:14ACGM>"3NZPR^%SX="MO/X::_A5DU;2S4X_\A9&98))F,<QYURA
MAS9QII;+8$$\QFU$4^);BTMM5;N8[F,S'=YZ"8S;8_8UDA;5?5(CGO4X^8Z"
MEE^ [TAJ6IY!](4XLN!25D#73 .-9.&\88:1C#11D1R2'7,YK@QQ-S^(EI<#
MR)T_W7VNQSAVFXEP]]+B=+!.96&Q<R[!G:;-V#N=K6(!V/)?6WV'NU'2]J+9
M>FRL2%^O6.AC'-S:MR*8JZW,8C24S^Z2@&,Y$F$>EQ78RU(+2SU(;X UN[P[
MC4..X535L&>S@ [.!FO>^I:2+$7\^87S+[0.$:C@WB;$,*F8(XVS.=  7&S-
M/=)< ;CPN#IKO;-1"@L<@<>?GKWU9*Y:(FB)HB:(FB)HB:(NA^5&BI"Y,AEA
M)\E/.(;2?T%9 T1<FGF7T!QEUMUM0!2MM:5I4".00I)(((\00?$:(K;;SJ2-
MJ=P.2/#%;A7'/B0(;I/'\QXY\.?#1%/< =2YA6*N<A(7CU,I()'(!@,D<^SQ
M\>./=H-?7KUNBJ_J3X_2'AXGQ&B*/4GCGD<>?/(T1.I/^L/YQHB=2?/D<?I_
M1_>/Y3QHBAUIXYZD\>!\Q[?+^?1%'D<\<CGQ\/;X<<_VC^<:(G4D_P"D/YQ[
M?+1%#J3_ *R?YQ[=$3K1_K)_G&B*/4G_ %D^?'F//W?IT10ZD_ZR?YQ[?+V^
MW1$*D@<]0X_2-$40I)YX(/'GP1_/^C\^B*'4D<\J2.#P>2!P?#^\?SZ(HA23
MX@C^<:(NMTCH4.H ^ \QSSR#Q_+Y?RZ@BX(O:Z*U&[N#C/L"R"@* J2_$,BL
M)1QW5C%_AHQ"P"0''4)0L@<A!('Y\<]JO!S.-^",<P41-EK'4<D^%#*"YF(T
MX,M*YIN#<R-#=QH2-1<&X>%\7DP3&J:M:?Y;GB.9A<6M,4GNNS$ DV!N >8'
MC>V_9LS=W(,0]4[1P-9)A+JZBSB/E7I7<LN%,1Q*5*)*4I2IIQ7CRXWT^1YU
MC[^'7C(XSP>SAC%92WB?A&23"<3IISEG BE<&N#'6<Y@:&BXTO8DC0&X>T'"
M&T>*QXK2#O,.Q6%E2R5K1D[YS;R1DBX!!][-S:-0-56^9['[:9\BV5>XS7&9
M=U4NDL;2#'9B64NJG=XF;!=E(;ZU-2DKZ7SSWC@2 5I'GFR7 <*J:DUIHJ<U
M#R'.J,G\QSA<.&MLMSS&O6]@K<HN)\;P^G93P8C4FEBF;,VG=(YT5V$%H#22
M &@6(!M8WL.?S>=I/L-;N]E/)41,!QO)MV]H,EL5Q<+D8Y6+GW^*V=B^M</$
M[B%&)6*UUYXL5UN4%I#:$HENI5](ZZ=H?9'5'$CB6 Q3U KYFOJ6D9\CWN.=
MH=F)#0 VP( &8ZFY6[O9;VZX1C6',HN(JN##:O#Z7(+Y&A\$(:6G4-S.+B\W
M#@0+ VL JC[%WR9N?9[O%(W?[9^,S<-Q_$K"$SANV,M'>LY$]Z4MV*NX?AEU
MIVJ0ZPA3T5UQ(E*/+X2QP%WQP+V;4>"B*;$J5PEIVM<T2'.Q[GDR:1FX9E<]
MP)N;ZFX)-K&[4^W*.KH?]/X3K65 JV3TTLK!W<D#2]S2]SF7,CG;MO:P(OHT
M _3-32*'YOB0Z&35*KXD5AF)&JUL>CQXK:"U';9:8/=MLH2TI#:$ (2$%"0
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M  %GLP DM*'^1N2>;+18;/\ WJ\>EDEL<_Z/AHBX^J._( XLMEP4AL)(PW)
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'1-$31%__V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>32
<FILENAME>g164680g01m03.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g164680g01m03.jpg
M_]C_X  02D9)1@ ! 0(!>0%Y  #_[1=R4&AO=&]S:&]P(#,N,  X0DE-! 0
M    %U:^670X0DE-! 0      !<< 5H  QLE1QP!6@ #&R5'' (   (    X
M0DE-!"4      !#'71?E=+5N]=N^.93 Z7E<.$))300Z      #E    $
M  $       MP<FEN=$]U='!U=     4     4'-T4V)O;VP!     $EN=&5E
M;G5M     $EN=&4     0VQR;0    ]P<FEN=%-I>'1E96Y":71B;V]L
M  MP<FEN=&5R3F%M951%6%0    !       /<')I;G10<F]O9E-E='5P3V)J
M8P    P 4 !R &\ ;P!F "  4P!E '0 =0!P       *<')O;V93971U<
M  $     0FQT;F5N=6T    ,8G5I;'1I;E!R;V]F    "7!R;V]F0TU92P X
M0DE-!#L      BT    0     0      $G!R:6YT3W5T<'5T3W!T:6]N<P
M !<     0W!T;F)O;VP      $-L8G)B;V]L      !29W--8F]O;
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M4'AL0%AB',         *=F5C=&]R1&%T86)O;VP!     %!G4'-E;G5M
M %!G4',     4&=00P    !,969T56YT1B-2;'0               !4;W @
M56YT1B-2;'0               !38VP@56YT1B-0<F- 60           !!C
M<F]P5VAE;E!R:6YT:6YG8F]O;      .8W)O<%)E8W1";W1T;VUL;VYG
M      QC<F]P4F5C=$QE9G1L;VYG          UC<F]P4F5C=%)I9VAT;&]N
M9P         +8W)O<%)E8W14;W!L;VYG       X0DE- ^T      ! #O_XU
M  (  0.__C4  @ !.$))300F       .             #^    X0DE- _(
M      H  /_______P  .$))300-       $    >#A"24T$&0      !
M !XX0DE- _,       D           $ .$))32<0       *  $
M 3A"24T#]0      2  O9F8  0!L9F8 !@       0 O9F8  0"AF9H !@
M     0 R     0!:    !@       0 U     0 M    !@       3A"24T#
M^       <   _____________________________P/H     /__________
M__________________\#Z     #_____________________________ ^@
M    _____________________________P/H   X0DE-! @      !     !
M   "0    D      .$))300>       $     #A"24T$&@     #-0    8
M             /@   )G          $                          0
M           "9P   /@                      0
M       0     0       &YU;&P    "    !F)O=6YD<T]B:F,    !
M    4F-T,0    0     5&]P(&QO;F<          $QE9G1L;VYG
M  !"=&]M;&]N9P   /@     4F=H=&QO;F<   )G    !G-L:6-E<U9L3',
M   !3V)J8P    $       5S;&EC90   !(    '<VQI8V5)1&QO;F<
M    !V=R;W5P241L;VYG          9O<FEG:6YE;G5M    #$53;&EC94]R
M:6=I;@    UA=71O1V5N97)A=&5D     %1Y<&5E;G5M    "D53;&EC951Y
M<&4     26UG(     9B;W5N9'-/8FIC     0       %)C=#$    $
M %1O<"!L;VYG          !,969T;&]N9P          0G1O;6QO;F<   #X
M     %)G:'1L;VYG   "9P    -U<FQ415A4     0       &YU;&Q415A4
M     0       $US9V5415A4     0      !F%L=%1A9U1%6%0    !
M   .8V5L;%1E>'1)<TA434QB;V]L 0    AC96QL5&5X=%1%6%0    !
M   ):&]R>D%L:6=N96YU;0    ]%4VQI8V5(;W)Z06QI9VX    '9&5F875L
M=     EV97)T06QI9VYE;G5M    #T53;&EC959E<G1!;&EG;@    =D969A
M=6QT    "V)G0V]L;W)4>7!E96YU;0   !%%4VQI8V5"1T-O;&]R5'EP90
M  !.;VYE    "71O<$]U='-E=&QO;F<         "FQE9G1/=71S971L;VYG
M          QB;W1T;VU/=71S971L;VYG          MR:6=H=$]U='-E=&QO
M;F<      #A"24T$*       #     (_\        #A"24T$$0       0$
M.$))3004       $    !CA"24T$#      -(@    $   "@    00   >
M 'G@   -!@ 8  '_V/_M  Q!9&]B95]#30 "_^X #D%D;V)E &2      ?_;
M (0 # @(" D(# D)#!$+"@L1%0\,# \5&!,3%1,3&!$,# P,# P1# P,# P,
M# P,# P,# P,# P,# P,# P,# P,# $-"PL-#@T0#@X0% X.#A04#@X.#A01
M# P,# P1$0P,# P,#!$,# P,# P,# P,# P,# P,# P,# P,# P,# P,_\
M$0@ 00"@ P$B  (1 0,1 ?_=  0 "O_$ 3\   $% 0$! 0$!          ,
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MM!KG:6.+.?ZC@FKMR76;;,?TVZR_U
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
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MSBJHW4%^SJQYN"FH+'6E*_*,,M]20KIY .D(JX--I' ;0!RE7 0D#J0 $*X
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MGCYY-=]VA>(90P9\&7,>#S,4^['8J%+;AS^F1V?F$=$4,]8Y4GS2._(%5.9
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M36NE^E3Y>MS$B00[VU+\0W-[GH'@UN!-<\A(Q#)T*>N7*E:7(\4^0PDE(M7
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M)Y [EO\ JR?J4?V#ZI_L\:,?LC[H_%#ODZ>_.^6<1X1]%>B!\O1O^K'ZF_[
M_L_V>-&/V1]T?BAWR=/?\H$I/J5'L!WX/8>@_4/D/E\M&/V1]T?BAWR=/?\
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M@@#R7&75$ N:IS-[Y\AYYO&/F )4 --&:IY/SSBXRCU=022"%_$>?U]AV_\
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M(JD>4'$.QTNO0"TH$AISS"AOMP4<$@CC69P<WU$J8$D&I#OI3@SZ-XMA,9(
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M$2IM+/<62I1;4A5ICR*H14$)4 NUA?VE)&K3M=C4'2C4RL7%,@&8199Z$M4
MW \"]ZZYL-(LC/\ &[OA3;6XYN!266QNZ>3YS8;03:_:_#E6B,CQ2JS[)X]+
M:8Y?/O9';&9/B1'PQ$F!MB0,@@3XD^&EE*6XL5!O=^9KH<RUC>V<2+<@*N0Q
MUS>I8L&T9XS$\.7B81OMLWDVYT558U(BVF>JI:I?$&Q528NXJ-"7=5#JT.P9
M<:P>76VB'.@+DH2 I/6 '$-0\'YLU!5N?A!FN];TR!K>KT>UN<8@8]X\ZU",
M:SC-=JX..YTSCM3^%5C 3!F3[O&+K%\IR2F?H)Z4H>IZ^7-QIU,JO6[;N14)
M9=== Y20N#3Y9/\ %ZA_$0"34$D!G#O5K9EZ ^(8D7CSV?'=BZ-S(N=T^P6,
MEZ*S=5VY%[77-!<9#"]A1CC#=K0957PFF9\<-7\865:_&8D*:2IE;S(2 MQN
M]*ZW<<J=>,"Y =G#V #U;(EV89"QB\6._:/XMFMRJBP[:C+[JPG9[4X#C:)M
MBU7-6TBP?OF?><J9953$>I<A.4$UT1$O6Y6PN,ZB2$J\E!V#-3.XJ->.>@I2
M\0W'SK[#=BU6TKW?'QD)VRN]Q<,K,8A/Y#A&WD_(9,^[RC':AB)DKN%SLLK:
MNNQFQ$"RS"$J)%;][S::P0&G_/08"?9W'$LRS@'P%78/;*O* 3F]W-*G*A\T
MH*4BT53]H7AN$T>.5]WM3^#>0V>8L4^3XU3W<-Q$61D-AC#;N4PQ7U7,J+:2
M\S@V#S=D:YJ M<F.Y.FO)0I9]*5]H?6OG1H*#!LQXG44)8-G=R[$-%0H^T>H
MY#:DO[47D&5=-X^YA GY;218E^U?W^88]%][355;#.*QV9&(6?FR9:)K:FE5
M[00I4L*,:>WC?A3XTBC.MP*!M;ZY@C.X8F+A[8>.#$-T]WSM#28K:Q9[5.;!
MW(8]O77-$JQC45?:RXC-A4LNUEA&#<M,=JTAV<M*WFPKV=F.M!7*38.P/A7(
MFQM5J '@(D7HSC@3S&E+L2S96BR6XOVB-VKWACFU6WL=63+RV%14L^\O*NPA
MO5JLF:QRYG7-/7+7*H9B'NLU\*Q'F2PI*Q[.X"C4EM'+Y.Q+CCG6VL5,16H%
M*V:ISI;FPX1M/B%\Q(IEI:$U46.N4&06BF6$)ZT^625>3YY4$D^H ^782P42
M#F!5^H%7MJQO1HJ2=U04]02&)>GAS->F<6<WKR.[B8^[BV)1$6&597'>B1HB
M@%&##2WT39JD\**P4DI2$#S"KCRR%<'52\4F6.Z+E2@0"[<!5CF["C&M:1*,
M&J:OOW&ZE0)L1K8J#'CQ:\8B4G@!VPR*91Y=,MLHHDRD,R,SPFN3$:I,@N$*
M2N:Y8+E0I5Q7+DJ; ?%?,BH6%.*D\.+4DZ^OL\F;CD;145 R[!RQ=A7U@,VH
M+C1XV =I)LK!KV8@(2F8 "HI!4Z?620X  ) )<6H,XSKM\WV\P!>/T.0YEB6
M'KG!%5C55DF0U-/)LE0PQ&CP:EBU?:=GN);=8;=\EM:PX[''WEI!V&5A]U+I
M%K5#  6>GQ+N[7C7IV(WE$DN14LX<EB2U&X 'ASU1_:"[#[C97N%07F.8EDN
M3[92Z;(%9"WBI0_/KKNU%)4.N"(EQJ9(<GTU8N/$=@J\T.S5+0K@KZM<[287
M$3=FSY>%4I,Y:I.X4U(:>@J=U)J4A5SX:[-V<Q4B5CY"\4$F4@3=\&@5O2%@
M9+/UB,B*$&CO2?A4H(VSE%G\C<1-I^%FX\)FFA4YE#(;I,-BULL@?NKGW9(7
M'A7N66]\VT]C892S61ZFF<B-M0Y$]F!Z.SNR,4,/O8I2E!F(4*"Q+LM0#M9B
M!D0;^+M%M?#*Q)1ADI0-XU!N:T(*!D:$%ZU<U-Z]L? >Q%O*O/H28N'3(4TW
M>/P+5D6[U:^X%#JB5J'F8-!-6THI+,99*$'A*0H#CU*PN#.-EHEI2)[*8C>)
M]45&34!>HHYR,8XXO%?0)AF3%&6=T%- &404EJEJ@!69+5C*)K:_>FHF0X\*
M]PS(*ALR6FYN0UW7+BQY2E//K2U[.ZXZHN_ .J6E/20%E201K)C&IPI[D@/X
M#=YDH(Y'5XQB=G+Q+3239Z.RG<L!OBPYDU&KWYQC!6*B5&N+B<O(,D#'D^])
M3?2W"8(_\'4PDCV:NB)X 2J/RIT !P_/5!2)BA-8/7DQ>S,"?AP!CUB692"@
MB@89 T85S>S@@,!>+C<#Z#MZ?HU7%$2J_L_[0_XZI5^S_P#D/C")4\<#GY+!
M')X *>%<GTY  /('<ZA=AST?(Q[#_P".ML^3QP[;1#&;R]PX_+HA-S.TF)>D
MVQMF[\.1X*??T(\D0(<OH\EJO2$AA49:N.7"=2G.WUC8OI&(G-OT+TKP+FGG
M*,(_&FW<NY;B%8G/Z/%L>O:N?$GUDW,;C&;B8(LF586#M/$IT+,I<EAJ%"58
M22TFK2S*DK44J//(^WTY2<=*29@3+.!GA22L@EEKJ$I!(>B0HV(?(1V?T63"
MB1C)DO G$SY6+PZI<[N9,S<>6E "5SF"E2G5,,H*!4DLD%2A&6&UC4J)LWAS
M=Q;Q[]:<.CB1<U\I=E&GM>QJ)D-6#RBY-4&>A+,HGJD+1YBB2K6[; F']&]F
M$JWB=CA16%;X41*+,L@$FU6J:68QSGM7.[SM1M=4O#G#A6UIF[)F2TR#+:8Q
M"I22!*!+G=!+.EZEHP'\/F85U=NM$IZK,=U5X]997=1:.AM,QQBTJ)"G%2GU
MJLJ&-6L7-;"#R'$L1WYCSK24H6H\'OS?LSM<G;,[#A<\@8A:=Q4Y*D.#5T(0
M-P:!1)#C-P.I=LMBS4]F]G8V=)V>)IP,A1FRL#/DSMT@!([^9-6B>0/VT)0D
M&K"-@<JS+NXEG5_A)&?5&Q^!+.,HJUM2:[SI+C?O)VTZ2F8U)X\IN!YBE15)
M\_@!6NWGUI-F)#[Q%W&8RKG4=!'%9 W$J+9M0G49BG4"C"HO4A//?U]/4$'T
M^8.J9?U$\N?MCU N'\_"(:KA$P/!'RX[]O7CA/\ O/ X^7/?MKPR<,535J4:
M%1I74G45%JBM?&)TXI0 *E@![FMK;*E35HE'/'<]A\^/0'D^GJ?F?KKUS5HD
M#UBUV#&I8'(%G):L48<3)M6:[U!\<N=HM_ENZ^VF"N-L9IN)A>(ON_U#&29)
M1T<AX G@LJM[5E'!'<$(00.Q0@\C6(G;6V7@B53)Z4K422DF9119_P!@AA9_
M8P>,I*V-M/&I_P!/#SERW+*ERE+]6P;<!))9J.]2^<<F*[H;;YPM;.'9[B&7
MOH3UO,8_DM)=OQD\=UJ33./]^.>>E:@2.RE>NKV%VMLK:(W$3T*(8L@SB0;M
M1"3F"P)YWBQB-B;4V>.\.&GRTF@[Z4F6.8[Q5*G]K==["T5V""!P20?0D*22
M/D2%?$"1Z@\'ZCG62^C2Y@"4DLU!ZU@!>H- V8UCQIGS)5%L%NZ@R3ZV=@0Q
MX4RCSKBIKKVJL*:XKHMI56L1VMLX$R+&=@RX$A)2_#L(=@M >9?2M2>I *5I
M)_OH*/HX!+%F#NENI)'MUU8SO]^62 '+FA<'-@E(-F<$<F CJ4.*8WC&/P\3
MQJCKZ"AK8*X=?5TT-,*KA1E(Z2F(4<MI<;3V2E!Z!P .P[AZQ'%ZL",RSV!:
MK@9VN]H@I<$O5JFM*-2UA0U?QBQ55X6-I:C'*[':JA:B>P9+$R:7<,1*^%>W
M$EF7-F>QV4R-6NN2H2W9;GM".0OJZ >5#DPQ.5A3*NE14TMPHP$-YB6#BJ2!
M[+D<*CGJ](1/!UAR;B)=V.699>/U=5?TE,Q)C8RU[II\AA/P)%2RFIQ*LB.B
M,E_VAARRD.S MM)>>*NLJAJ9UTTIP:AN]+1.\U  P=R1K4$!W(:@8$^%^.P\
M&^!//SXT?+,LKH%U&5"R*JB-8NN/>5+@HVW:H/.4LB9#<!HH+A>I+F'<%IYY
M*Y"HW$<2P;B#K=N3\F!8W+@1 )(J[#@6MQ W0SD$A@S7BF4^ G:TS;"7(R&Y
MEN6-?*B/N7&*[8SI3!=181X\R+8VN$%V F,B<&!$8=98E.1FC-8F)=E)EP;^
M[,MEH_!ZLV45/9VI75Z"C &P>H#"Y8Q>>I\.>'5N*8+A=E9WF10-O[MV]KGK
MQ%!-=?>=\\>Q*@PJ1N)&A,"26H[4:!5,M-)0VT\&T@:,SABXT-.=N/"\4UT]
M@ =WX/RK=F:L6^L/![B4UN%4?A?ES>*1+-R<[B+D+%G*X/.6KUMY,6W&*RKK
M&RIU];,E%%;UD>;"2A$B5[1UND*OF;YUKYTYQ#D49\N0S(K;(T?@T73P;9N1
M@[YCIW'SB]QN/7SZF@Q"P541Z*@AVC[C\GV5=94U+]O+CI<0Q"D7\ZXFQ6F4
MHC!3H==>9L1;A7QL3YM$G4!K58N2.-6N3D/&,?6/ #M@T_!4YDN167L=\;6-
M%GTVWTJIA1U"H+U)4TGX,)I*%B2NJZGYV.TL"R=7+FO.25.RTKU&E'KUM3SJ
M(GUF;1R:&E,[L]6YOQBX=;X0=L:S#LGPQ]=I.A9)0RZ$6-@]71[*GAS<!K=N
MBY"2FL0AVP3708SK;2FU 6P0D#E?2*@+6J^M&#Y'/SI$*.8(;WN<JT OH!6]
M_#L/!5MA,S*5F#L^QC.2;/'KA45%'A1D,6-'=8?=I6JX?Q965L,W$S!Z]I5(
MU:@.>\9X2A*6:I%>R+6-6!>@?V.<VHU\A+D$FE2[5(H[&Q >]A:D=:=X%=IK
M+,;++Y$FV>5>S,CM+>!*I,,FQY,N_FWD^2F#9.XN]:T085D+Z6O=%I4+;,**
M25+<L%RY858%F-]1XV%+O6)=5!0M1J6(9PY=CP)IH*QX;?@(VW:J[:JK\SSQ
MI5R]0N73KS^.36K%JE@3(Q3(KK/&/=DPVKD]=I;*37*<-KY4L.JX)--.EC1\
M[C/K3WRY>I%3S9F#T<#5RUFH[')S9K:2CV=Q-K$*"=:V<5N2_(]IMWJIJ4GG
MI!2E-0E*0D  )3Y3:0GL$( "1*0#D27'(!ZGX12YY 5!K8AKD"[6&0=AE=;5
MT6'(><O<(OPU,(:0AV^? 'SY]./T_HT-CY]].L(\NZIZZ^JK"ELF&GJZYKW8
M,QB0H"*]!>;6CS&E$@@@+)"N1P1SSQZ^/:&RY.-P\R6#O*4G=4/79R"&8*8@
MB@(-]#'FD8_$8?:,F>!W8E3 L?4)I7>% 27J0Q(%@2\:?MR/#KN-M;8O18&.
MW6=X4TKHH[S'8)O[>#7) +5=<4T;B^FO]R1=4T>]BN\$W[S*RE6OF#MOZ.-J
M3L2N;A)25H*PI)1W()2"HD$+Q*%$A@=Y.\ ?547($?7'9;TI;(F;,P\G%S?H
MTZ6D2YB9JIFZ2!+#[\N04@*)(0F8I$TA*E!&Z'-(XMMMNEG,X5F,;?Y?&>=*
M"N?E^,6F$T< *[%5A.S*DC27W4#DI;H&+U"^GI5(;Z@O6$V9V%V]-Q".\PQ0
MG>'UCATI2":@M/.[J_K<#&;VOZ0NS,G#3>YQ\J8M*"-R4J=,6HER-Q*)!)J6
MJ$[MR&C:SLAM3$VDPF/0-OBTMW)!M;ZU\E,9RRN7R5/+="SRF..$1JE/2DJC
M1T\ \G7T]V0V&-EX),N8PF;K**1NU;UBR5K!0]'SH[.T?*7:[;ZMKXY4\)(0
M5@2Y:E[^XDLP<I&[,*3_ *@%BUV<WJUM$8*&D(:0B9/WD]N?B';Z]_30V/\
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ME*$@^OP'C^\$'5PH_P!8*%&!)Z,>M+MJ'BB3ZLK<-Z4=VJ"<S1[?"(ZO,#<
M^$77(L2(:F(AI")D^O[/_<G4&WBGWB*%V'/X&(@\)'<CE?'9LN\\C_\ K'=0
M^9'Z/[]0JQ\_ ^<XOG_Q]:.SU)OE;X"L<&VM6BM;S%Y&-.8][US2ULR^NZ3<
M)R,O1H+7X1-!*E"K:FA@,IJCTJC&,24CS.\(L>=(Q$YM^AL .5Z?EE&%'C"Q
MR[R;<3%J_"J?<J=F2<8>EON8;,VYK:Q['&[>6E,69,W(D)K!9B<94B$(+:9O
MEDE+G'"=<Q[=X43\;(W$K5-. FEDK0@;HF+JZR/7<EF?)@YCLOHTVS)V5LS'
M3,6N0C"_39:5+F2,5B%B:J2A/K)DH($@H8+!(<@@K"2(RWVQ@)Q_:O%J1JNG
M5K]5B\:$FHMY$&9.C3/9W"6+*96*>KGI"WR?:'(3KL12EDM$HZ1K<M@84H[-
M;,3N* 3LI*66H*4G_3+N4T47S  TS(YIVBVG)QG:C:N)"Y<P3=K3%B;(1-E2
MB@K2 J4B9O+EH8>J%*) NPI&#&T,&Z&]57,C[43:7+W;S(F=Q<EE;40<=I$U
M+WF^PO56?.-%%L0A,<I36J?<GE:A9);"!KF79[9K;<G3.Y*%'$3#,6<.E 4'
M+%*M]1(W?V@A+YUCJ/:['I7L##RACI<_##"X?Z)(E[3GXI<E0 "TS9*Y:0EU
M%3)*YHEE@D)C.=ZT2K/K*I_"@OKC8] E*Q4T@2JM#K[C0MC;M@LV F!(:37)
M($3CSQ]XZ[6H;F'!W6 264XJ EFHY#:-''9)*P?59BYK>M03E35S2D5)SSP?
MJ!_8+?R_S#W3S]/[]4RRZ$G4/UCU , - T-5PB)[\<#T Y_N]3\OEW_3QJA2
MA+25G)SHYN/DY\8H[K?6.;OI45N'UC6=XC?$K?3KV]V]VYO)%'C]"[+AY=FU
M:IL6TVR9=7$LL5Q.:0W"JW*F0T]&R#*(3R;FI>2_6U2ZO(0_;+X5Z1.WDW9!
M7+D$ND%SZN\2EBH#>PZP&+^M]8  "I45=Z]''H\E;9"<1BT[Z5A/=RF44E*C
M12BF>B8HE+#N_605$E6]NRQ(Q$Q' <RRU$JUPO;JSO($Q:UR<I==QBCAW$I*
MB77H<S*K3&[*[?E.=3HMH3@8L%+$MI12\D:Y-A<!MOM&A.+EK)EXO_72H#"I
M2I,UU@ K7ARHD$$G=3052(['C-M; [,S#@)B2)V%)D*D@8R9-0J43+)6B7*Q
M6X 0Q4K?0"/KFACRY]3(@7+U9D6/VN,Y=2E$GV6>FOB7]8E1_H\^LO:R9-LR
MCT4AR#*E-+3\3<AY!#A\V.P>W.SCJ$XI(JRDX8$/F/6GFE &%K.\>G ;3V%V
MD3NB6B8A0*7"\0I"B*$$&7)22"&4062:;H8@9M>'+Q(7D*XJ=NMRK4WD*U/N
M_%LSF^ULS/>2!YB*?)YLD%R3(D,J2S7V+H2X_P"1[.\"Z[KJWH]](V(VC.EX
M'%*WIB$HE=X0'4L.#OE.#0 "'((41?UA'%?2/Z-Y.RT*VCLZ648=:YDU6'02
M0F4HN#+2<3-<H+ND! (.\02(V'Y#'M[*CLX5!<_@]<RZ^7'J;Y<*!;"GF.LJ
M$:R526A0U/,>00OV $HE<<<\+[?04PB=)! 8J#ONDD$V&0-. ;PC@$H=Q.(/
MK *J$EAN@L"X=J,Y=B*9/'DX=59548I4UF896G-<FB5J6K?)4X\SBWOR0>RI
M(Q>.MQJM^+E7Y$EM'("24A)U: ]5-7(36AU:S4=Z/7E2!(*E$. 5%@HB@=WW
M@2^=[WO&O)S9OQ3IQ:XHX=C?1H#BV*N#BL6_P)-6J#8RWI=W.4IX^TIL8CZV
MY<=*N%!:$I9Y8*^'+QKXVOIP?.T22EVU!8L6KF2U3<BKT;ZQC@S#9KQ->VT;
M93FF3U6*6\05-M5Y7M? W$:K(-W7S8_L5O:G'C*KO9!+=D0["0Y%^#H2ZMP-
MJ(5T <7+D#Q:CO0>.41ZI!-7>I- 2U-1O5L6>C-'$_MKXPXMI9Y$T,DCY)95
M=S";E8K,VWDMJ><FXW81WLEII>?[;PI.03*^%.@+NJNZ+K,]AMU-XBJ*'%&R
M9G+-8]2Y%XETI%/J@$L2&#D,#49BK,:C.+J;PXOXCLSVPP6FAUN5O6,BAD1<
MSJ\7RW;2!:,7(*?=LF\EW#U'1V%<X0A<^/06Y67U(#35Q$]H?> /P&9)8>Z_
M6*7#EW>[U<,U,G\*@W:@C'=SPK;\NV\;.#7P(V<5*H+F/H>LL*F44)V!,S"8
MV/=47SX#SH?ET,^%':BU,9,Y!L'UHD-3)YCIKY;XVBITDUOQ<AAFQ'K4H:N]
M6>D7'K\-\<+^-V;[^;94W>Q<=<:QZ(_6;819LNY-M <F^T5T3.;6OF3$4OO$
MPK$Y]&B-><@+EU81%9;EGM73\ZTH_/*()%;.>'.M6^L32[> ;OKV_P#&/<X=
M;M6N596NRDQF:2-6)G[>8P[+QNUP^[9GR;!5-D]M)@Y- R!5/#B2_P ,'772
MH/LR7H9D/*5+YMJ;/3/X6I"S$W#TJ&8#=R'C7+C%+N81XSF6:JCHJC*:.G?G
M9*W<.HR+:1]M==<6N0PGW<D%5DBGXV3NUDBGLX>0^TY(I"V^N5 J+[VN3.CS
MKQY#EST+5.DU:I+5I9[/]:F@+M8/'J8=@GBSQY-3'BUF5U\=*\/]W(CY-M*N
M:S,JI-!#S*VW3E.Y&@956)HHEA7XVQCR\C?4\[9%V.5>Y;AN037YL_SSH/A$
M/O,X.ECFS$C]G4F@RC)WP]T&]U(R\SO%?VM^]/PW#;.2[;6.*2H]=G(=NOPO
MK*5%+RL5)6FF(*PI2>3PH]^9'$.]C0YO6]38U)JS&D4EP7'$,':I-7(HP<!@
M7JQ%SE"!VXX'Z0/3].KH  ;*(B/ ^@T8:"$0X ] !_=J" Q8"QL(D7',>^.#
M547X:0AI"'KJ%!P0+D$#Q$"=T.:@5;5JQQ-C@COU(/?GDHZ./NGJ'Q>H]1W'
M'.O%@<'/P3]\HDUJR*AW/U5+#CCKI%U,^3M##K6@5 (;U@0H.+E*+\0U(M!N
M9OMMCM.IJ#F&41XUK.83*9H:Z):9#D:X()3[T<J:)F3<,U96D)1=/M!E;G9T
M#GA7AVKVLV5LW>&)IN)4?5$Y1]4.72G#K"4TR<TH&CV]F>R>U]N8A<O!@*.1
M6N1+3G1*U3?66F@8M1MY23N@TCB/BRV1S.QCTD3))M!9V$CR83.74%WB<6?,
M2?B$:QO\>:IY#A)X0B,KS%**0D<D<8O8G;G8FV5!.'(2HJ9E(Q27H0029$KD
MY4PLU8SNW>P7:#8B#,Q:4%"4DJ[F9(FJ":&@$[?);3>L2Q>,DAZ \@\CGMW'
M' (/(['G6S3YRB$JD422 ;%JV]8.^7AQC5I,E*-\3:J:EQ:O[)(ZPUZ H,'(
M=@]1%F&JH0TA$4^H_6/]^D0JQY'W1,\A#C+B'&TNMK0I*VEE(2XDC@H45D)
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MH%?..PL-@ML[7QLV8O>K,F%RM.^5)4?MH+#= "69LA5OIGM+MK;79K8> P>
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M50P92FO_ ,KBK5C>9'H.[>;4V$-L2,%. 2E2U29R<'(Q#)-2F5,Q2)JGN-Y
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M-OTO*(<;H^/*'+O0TN5)>2TW-)*G*U+<J(VPQR0TZRCC^KY'H20XI46+ZO\
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MMHB0%%2$JZRV$JZM<B[?8M,C:,G=FKEK& G)<%+-WLP@$J(<DU85RY=N]&.
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M\1CT-DW/3.<CS5IASH@;O)$A=?#Z;20VRM$=?F=QPWTK[/WL?AU!U(.\'2Y
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MKZEH0\Q)B.N]#3I9<0PIX/,.K;*4+4H*(P ](6UL/M*6C')7+2)B0KZ0E4L
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MH<'UX/;L>./J!^VB3+^@H8K5,3<@5)#: &X]V58\N+E3,6O>EDRU TJS-IO
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MN;1=,\?+GCY=O3Z#U^@__6LTE8D^K+26.B2:9FCYG-B>$8%._. 5,4QT-&X
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MC,YIQF3",64T0^EU;R$^8H$,@@@GIYU8R(U')F:^;WI0/491:8[Q/$W!+BO
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MSB=D[22RP!WF"Q*$U(SF2&:X>C6=P0,WM/M5L;9^$FJE[7V80$%?^GC<.LL
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MUE01SP.LI'4H)Y^\4I^)0') [G@:;ZM!T/SAWP^T>H^<1"CP""CI\L.@D_\
M\7H'"1VZ/0=?W>?GJISD4=8L%8)-":FPH_"L3<J'/)1V2%GU[()X"S]$D]@K
MT)[<\Z.K5'4PWN"NGYP^/O\ =^%(4KU[)4>$J/T23V!/8GL#SHZK.A]',-\:
M*Z?G ]0Z@>D%(2I0/(Z4K/"%*^@4>R2> H]AR='5JCJ8;XT5T_."NM(Y5TI'
M7Y?*N0.O_,Y/'Q_ZOK^C1U:HZF(WQH>GYQ E0(!* 2I: "2"5MCEQ !]5-CN
MM/JD?> T<ZHZF)WQHK6V6MXEX3QSPOCAP\]N.&>/-/ZFN1YA]$<CJXYU3OJT
M!Y/\XO\ ?#[1Z_G$!TGGCJ/'7SQP>/+_ *SGCTZ/[?\ F_VN-.\/#V_.),T"
MY4.9_. Z#T\=1ZNKIXX/5T??Z?KT_P!KC[OSXTWU:#H?G$=\/M'K^<!T*Z>.
MH]14$\<'J*?O!/'J4_V@/3Y\:;ZM![?G#OA]H]1\XB D\<!9Y)2. #RH>J1]
M2/F/4:;ZM![?G#OA]H]?S@4@>J5CU]1QZ>O[/G]--]6@TL;Z7AWP^T>H^<.$
M_1?[!IOJT'0\M=:0[X?:/4?.!"1QR%CD<CD <CZCGU'Z1IODN&&8-\KB^6>D
M.^'VCU_.(<)[_?\ ZOS>P'(:_P#[>_;H^BS\'/SU:"%O]5-]#3V4AWPU)\?9
M>)'FF74>5(;2M#B?-#;_ "M4A'']8XVU%EPB"?0G]'?N1J#+4; N7#V<FEF(
MO\CK$B>.%+?5+,Q<.H*^7 ".I$KHD7K,6+&B$@*4MF+&;4\./5[B-$(/SY/J
M>_<:LR\ )1<,EB_J@$G.H[M(=\V9J,T>I6/$P,%%0R]<[J0PM_J*HVM?&.\4
MD'@]_A"R!ZA!]%?J/R/IW'?7N3.W4LQ31B2&-@-;?&/&M 6K>H[OPU#4-,_=
M$2 "KD+Y0 5\@<I"CPDJ^@4>P)XY/IJG?5H/;\XJ,T"Y4.9_.!"4\]06...>
M>!QSZ<\^G/RTWU78-JQ^<1WP^T>OYPZ1]%_L&IWU:>PYVSSAWP^T>OYQ$)!]
M$N']0Y_X:;ZA<-X'YP[X?:/7\X@0D=R%@=71W 'Q@<E'^T!WZ?7CY:C?5H/;
M\XGO1JKK^<0/2.QZ@>H)X/'WB.0G_:([@>I'<#C3?5H/;\XCOA]HZW%M;\#T
M@>@<D]0"2$DG@<*4.4I//H5#N >Y'<:;ZM!I8WTO#OA]H]?S@2A!^+J201][
M@=R.H#OQZI[CZCOZ:;Y-"P!II0\SI6'>@NQ)IJ_6MHY#U@\'I!! (///)3U
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M,2HVKP=GV<MX\GJA63UJQ_2K,I;FR@?.?!,GEU*N?Z@J4VGTZ>VC'0]//G2
M4J@WFI2I+95KGX@!F @C:S"&?9O+Q]*3$L'K5@^UV2_*FNDE;P2)(ZTJ*CPP
MM72.>R.VFZ:4)UH:0"B]VRNWB]2.+4UXS,[780V(I1CJ$>QV+]LQ_2[/\G9.
M\]4KRW)7+KJNH@)5U,I!/">VFZ=#T)AOJJ-Y77@1=SDQSK9J&#6UN$->Q*:Q
MUM*JZX7>1>J9:<M6C@4%3.\E0>=(4?@6%QASV3R!ING[)Z&AUYP*B?VU-Q)X
M/GF6+#CH'E;VNP>.819QSH,&_7E,10EV2RG(704KFN=4ASD@>B%@Q!\FO3D
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M-(1U5.M-E:UJXX*CZ*)Y0%*(X2DGL$D_4]N.>0-0H#=)-DU/@YMGG2 !*DI
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M4?..Y_*+M_\ GQB/[QU'\9I!QJ.HA_*+M_\ GQB/[QU'\9I!QJ.HA_*+M_\
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MR2%Q(L8Q2TD*6Z\S7*8"$E2W4I!(]\P2</+)&E/K T!)85#/2O2HCQ SL3,
M:ATW;.!JD]!4-5HRW\!..*EL;J;LJ*O<6?9!44F+$@>S6E=A,.153,@A/%:
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MQ&'0X9'2I*4*L(%-!KL?8<+T1AQMIKJU,1RX^::6RYQJG^STP"#+WKC[GS_
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M@2E(9"@LXB2D+)((2J65)8 N6$;EXWEL-(92 A+24MH2D=@E*0D)2$I
M   ' &OHE"!+0E"0&2 ,[ -F^7&/ETS=]:E*+.26O4EW=H[?KJN*H:0AI"&D
M(:0AI"&D(:0AI"&D(:0AI"&D(:0AI"&D(:0AI$%V+7:G..%:E! ZAW((4.Q[
M'MZ@$>AU2HK#;@MRUXZ7B$C>#*L>&7(<8P>W9\%6%YOD-GG."Y3=[0YK=/\
MM60.XZU&N<.RZ>E*66;/+L)L'&(K\U3++$>QL\<LL5OKJ-&AP+>XE0*NM9C9
MK [8Q6% 2PF "B72DTJ$ON*WNE*W+1B\=LS#3ZJ !)+EE9FX 6D @EW&1-')
MB@*'P#0IDY#N\>[=KGU3$4AP89BF.M[:XO:K0H*2O(&TY-EN23U+4 "W7Y51
MQ%CE#T5;2B@^O&=IITV7NA E FJBH+8<!W*33,D*#&L6,-L21(4Y]:H(9TU>
MY_U30\^)J3&?%/65]-75U+30(=735C+4&O@1(Z8\"#!C-I;BPXS$=U,5MID
M-A+:$D@!"FPD!U>NF:9Y,Q]XJ))+$.<V<#I5LF%LVD(E)"0"  PN1F'=CP\:
MZ15VHBJ&D(:0AI"&D(:0AI"&D(:0AI"&D(>ND02P)T#QUWDA*%E*024GA/*D
M@D ^JDA2DCOP2E)('< Z@DAF#EV X]#$BK<6\Y1C#XAO"UL[XI,%7@^[V)1+
MN&RX9=3;0GC77N.3^"VFSH+UE#\FOL6@ H)9:=BJ 2PZR\T"H^W![6Q>SE_2
M):MS<91)9:62=YRG=.\;F@WB<S'DQ6SI&*=$U(+V *DEB ]0H .-?:+ZB+G[
M K;^XM6XP\46[Z\$;>0H8_88SADN_0PAP+0RSDS#,.K>Z4DM(E6V%V,KL%.)
M=[]6VX;TBXQ<MI8<E-5,A(%&!W58, U + FS;P,8";V5P9F%0 0"26]<N+W^
MD@@7R&9:-J'A4\&&PO@\QHXUM!C+B9UFZA=]F-].:L\KR*0V.?-M;)J%!CH;
M;(/L]75P(-7&/*HT-A2E%6K[5V[M/:<Y/?\ ^I*)/U52Y:4 FY0$@J.3#4U
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MW$BEAPI,X>V6-G(-Q*<R"U?2V)BRS&BL-QH3+COOV7(5(D&7,HD$JN&)50L
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MAU!*N.3V[@CZZ0C$E-WCF&;BYCDV88?ER<AD>5'I+>#AMU>PIE3#:):C0I-
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MVZRB!;7VX&7U3E!,M(<>EI*V1'$>8W5QU^<J1)B^8X(\B2L)41UDA*4\\'D
M.>O5^%-7I$QF*$$$#T ^8/=1[\]0X X_O/?4PCDTA#2$-(0TA#2$-(0TA#2$
M-(0TA#2$-(0TA#2$-(0TA#2$-(0TA#2$-(0TA#2$-(0TA#2$-(0TA#2$-(0T
MA#2$-(0TA#2$-(0TA#2$-(0TA#2$-(0TA#2$-(0TA#2$-(0TA#2$-(0TA#2$
M-(0TA#2$-(0TA#2$-(0TA#2$-(0TA#2$-(0TA @$<'N#I".(,-!/0&T]///'
M?U_;I")O*1U=72.H)Z002#TGY=C_ /OYZ0@AMMOGH2$]1Y/KW/\ ?SI")](1
MX-]B^/Y/6N5%_51;6M>'#D24%J;4.KK[E*TK'Q=^R@?[M"'H81Q8WB.-8A7-
MU.-4\.HKF2HM18J5]""H\J(+JW%]S]5G]&D(J!+:$%2DI *NZCW[_KTA$^D(
(:0AI"&D(_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>33
<FILENAME>g164680g01m04.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g164680g01m04.jpg
M_]C_X  02D9)1@ ! 0(!>0%Y  #_[13L4&AO=&]S:&]P(#,N,  X0DE-! 0
M    %-"^4R@X0DE-! 0      !<< 5H  QLE1QP!6@ #&R5'' (   (    X
M0DE-!"4      !#'71?E=+5N]=N^.93 Z7E<.$))300Z      #E    $
M  $       MP<FEN=$]U='!U=     4     4'-T4V)O;VP!     $EN=&5E
M;G5M     $EN=&4     0VQR;0    ]P<FEN=%-I>'1E96Y":71B;V]L
M  MP<FEN=&5R3F%M951%6%0    !       /<')I;G10<F]O9E-E='5P3V)J
M8P    P 4 !R &\ ;P!F "  4P!E '0 =0!P       *<')O;V93971U<
M  $     0FQT;F5N=6T    ,8G5I;'1I;E!R;V]F    "7!R;V]F0TU92P X
M0DE-!#L      BT    0     0      $G!R:6YT3W5T<'5T3W!T:6]N<P
M !<     0W!T;F)O;VP      $-L8G)B;V]L      !29W--8F]O;
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M4'AL0%AB',         *=F5C=&]R1&%T86)O;VP!     %!G4'-E;G5M
M %!G4',     4&=00P    !,969T56YT1B-2;'0               !4;W @
M56YT1B-2;'0               !38VP@56YT1B-0<F- 60           !!C
M<F]P5VAE;E!R:6YT:6YG8F]O;      .8W)O<%)E8W1";W1T;VUL;VYG
M      QC<F]P4F5C=$QE9G1L;VYG          UC<F]P4F5C=%)I9VAT;&]N
M9P         +8W)O<%)E8W14;W!L;VYG       X0DE- ^T      ! #O_XU
M  (  0.__C4  @ !.$))300F       .             #^    X0DE- _(
M      H  /_______P  .$))300-       $    >#A"24T$&0      !
M !XX0DE- _,       D           $ .$))32<0       *  $
M 3A"24T#]0      2  O9F8  0!L9F8 !@       0 O9F8  0"AF9H !@
M     0 R     0!:    !@       0 U     0 M    !@       3A"24T#
M^       <   _____________________________P/H     /__________
M__________________\#Z     #_____________________________ ^@
M    _____________________________P/H   X0DE-! @      !     !
M   "0    D      .$))300>       $     #A"24T$&@     #-0    8
M             -(   )G          $                          0
M           "9P   -(                      0
M       0     0       &YU;&P    "    !F)O=6YD<T]B:F,    !
M    4F-T,0    0     5&]P(&QO;F<          $QE9G1L;VYG
M  !"=&]M;&]N9P   -(     4F=H=&QO;F<   )G    !G-L:6-E<U9L3',
M   !3V)J8P    $       5S;&EC90   !(    '<VQI8V5)1&QO;F<
M    !V=R;W5P241L;VYG          9O<FEG:6YE;G5M    #$53;&EC94]R
M:6=I;@    UA=71O1V5N97)A=&5D     %1Y<&5E;G5M    "D53;&EC951Y
M<&4     26UG(     9B;W5N9'-/8FIC     0       %)C=#$    $
M %1O<"!L;VYG          !,969T;&]N9P          0G1O;6QO;F<   #2
M     %)G:'1L;VYG   "9P    -U<FQ415A4     0       &YU;&Q415A4
M     0       $US9V5415A4     0      !F%L=%1A9U1%6%0    !
M   .8V5L;%1E>'1)<TA434QB;V]L 0    AC96QL5&5X=%1%6%0    !
M   ):&]R>D%L:6=N96YU;0    ]%4VQI8V5(;W)Z06QI9VX    '9&5F875L
M=     EV97)T06QI9VYE;G5M    #T53;&EC959E<G1!;&EG;@    =D969A
M=6QT    "V)G0V]L;W)4>7!E96YU;0   !%%4VQI8V5"1T-O;&]R5'EP90
M  !.;VYE    "71O<$]U='-E=&QO;F<         "FQE9G1/=71S971L;VYG
M          QB;W1T;VU/=71S971L;VYG          MR:6=H=$]U='-E=&QO
M;F<      #A"24T$*       #     (_\        #A"24T$$0       0$
M.$))3004       $    !CA"24T$#      *FP    $   "@    -P   >
M &<@   *?P 8  '_V/_M  Q!9&]B95]#30 "_^X #D%D;V)E &2      ?_;
M (0 # @(" D(# D)#!$+"@L1%0\,# \5&!,3%1,3&!$,# P,# P1# P,# P,
M# P,# P,# P,# P,# P,# P,# P,# $-"PL-#@T0#@X0% X.#A04#@X.#A01
M# P,# P1$0P,# P,#!$,# P,# P,# P,# P,# P,# P,# P,# P,# P,_\
M$0@ -P"@ P$B  (1 0,1 ?_=  0 "O_$ 3\   $% 0$! 0$!          ,
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M8W,T\24&%J*R@P<F-<(
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
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MEU]W>A_F2R=_=G!%.G_"8.R[JJ$2)GM1 G4.5,@!DCDZ(B8X@4H '<P-Q$1
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MPB*STC28+..$D@&&)W!(<M+">2\VF1Q6>BV\<),,4-F2""Q!&O!;3G[+[V2
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M+[)%-N*U*,7DG/ID?+48FR<'C6+-VY6X$H(&*T,2QBB(#Z8OHE]!8(!:'2[
M0>[,Z7HOZY$,+CV1B!)(D0&Q9B3Y_KW:;M[32,78VCAGQ< T+$&NM@N'3O9/
M>RFU8XDF,%GW4K]U&P\K//6I<M,D"+)0L0=LE*/D3%H1L<ZS(SIL&P2%P(F=
M(C80&X=K/Z&_0<Q0/I%B033Z[HA!W6=.BU%(NT>T8!>-I;D8?\P.*?K%G.V6
MY=5!]E0[*+4LQ&T[#Z0%0N)F6GFM+M&)LL\F61QGG\@G%MXIT^7H%5I'/U9!
M=NV*FX)=,J@J 4#% V,VWT0^@\!)&D6$,,(>(_7-$,A6MF2\L'!US7/]+=H
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MX"[@ .05[X-+TZ"RBC.D6T1A +&.,Y N]UM^#T5O5_V2CLK^5U5*T-7F><_
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M_'_[$]%_[)#8=;26D;  C;O:Y/@(VY $*  ??"_%?&8__C7L:PABM(M"L[0
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MPD3U!44I/3E;NX6D(>2D(I[*Y?PPUW1%%RB,5P=DJQB(F-1EX6$*1(R+]XF
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M<I(E8",0L<!9K$6SD=2W8F9XLW6U'M-'MW"Y;4-E@PK64K")SBBZ)4?R>?\
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MP&PA<![37 ;&$+\=A$.(1P1QD./- T,-#L+6T4-'H+7M;*"BPM<! ;?Q-NN
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M>-W 4+ ','%;BQT@[5TVZ&[5TB@II=NW@?:!QO90:%HAFUD-1DWE4"Z.VCD
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MZI7ZKP_3';_[WI?\VT_K3ZMH?[&S\O)/N;]'3W \G?FZI7ZKP_3';_[WI?\
M-M/ZT^K:'^QL_+R4#:-^CI:PY!Y/" \8!EU2M_T1@6]_&[/M;MN*)K73-+NM
MC:QUP_6.M0Z-HC?\JS#:H3\E(71PT="&UN\)DZ4+@'AY=TO;F_%9KA\ \VZ^
M-1]K=ID7?KNED9>UC(S;[1 ?P$IZT%AH4)O&S@<3^S 'RJ ?61DME*9BHB$A
M&,3!1D?#1#%(J#&,BFB+&/9H$ -1%JT;D20;I%#UJ::9"EYKWQ\V*.TCB,=I
M$8HXBY,3DG"9)+TSK)>EX#]@-#@)2V   #P7A#IZN*:;:=N6CBK$&"M.)TW"
M+RY)$Y2LW*#;AP':/!4N1)-8"I%2'=KF.%^/&>NNL$X[.L*G4L3/Z!T0JS-'
M/"5'%Q+%Q%5+.-H!K(=K%&CYW,K[6(DWMCJ+&AFI;QX[RKEU0$AR;L09SI0X
M?-]I2<G_ "?KT5GTAE'HS1CEG4KZHXJHHI=%@WCHZ4JLB!7$@NH];O\ A+9%
MLFJF5 I6IDE# 5/6&^\!Q>LD73IY::-$A-N(LJ[5!VVAX]^^<*UP=LS.XD'C
M@)(K)R#74.M"-2)F;L0)Z=KB)SCR28!Q;CNY517:KH]Z+T:A !/U6XB(J:*P
M<QTVI58.7<MPI^Z1,V5B!9)BTCE"(([2037UDKCJB76L%3KK^RM68RKT58QW
M,,FL\H\66<2[5@L2J3;.*7CZ1"7;&0*#=0KTCV;_ (N 7"AANH&_ ]==;TZ*
MZ_,G+7(13+[,ZKXNIX=S5+ .$4>SBIX2&UF;RG&;R/<Q*;<K5P+YFO,NTCI@
M4;)@8A]U\.NJ(K[A7^0$KDM!T#)JTHRJM7*VF9.6=.&3 ",EG69"D754TUEF
MY@ER5+"4R5*44C%'"J*\6Y2201VR2AA*SU]!O0;@NFJ3)?1A834^UINHVDLL
MSCXM6-C)BNR1[4S \Y4R,I-+S"3-87#U&";0$@2/*D"1#N14*5?:BW3G77@0
MHK;'*31A!I2+=S61&9:B&%81M1HU:5^X7<25*N5YB5F8P&"240A3]3G08H-U
M *1VRVQP QB <*B[N,RAT2'D)P\:V=IJ)5BK!+JJ5!LE>!,G"3?AY&AT!,=G
M,I LY:K7.9NF8HB("0 $BQ[7F6&2S;*RI<R*:;S46LRJ)_1T%$*RZ[U.57:N
M"G)4#5RHW(FZ:G8B7:IH'$"*:P7Y<2>76?Y>.I%=%)UU14OEWE+"5"UH!DHX
M7J=K53U&)8MIH6$:S=A!*O%A!58JJYQ2LH(%%8P 8V_?B^B/M_N_YO\ FN<Z
MRWT3SBO&]M5D7!DEBC4!:P.X*DIVM;OBR*+(&B28'(\45:)-;F*)B 6QK;W6
M/]]_BBPQI(4-E#0RU&AE9/JS8/X]RI,J!)A(&,4!0X"LJDH0!;JKB=83$(8I
M2F#4*4HA?#KKKT1:NB8PC<UP$=XAO"PCR6N-O>N/OCQX(H7'G'I'!$N/./2.
M")<><>D<$2X\X](X(EQYQZ1P1+CSCTC@B7'G'I'!$N/./2."+WR[$IORTS$O
MO_E2AQ[^*-1MT<F.WZGW?DN!J=I7K-<0XA'IQI1+CSCTC@B7'G'I'!$N/./2
M.")<><>D<$2X\X](X(EQYQZ1P1+CSCTC@B7'G'I'!$N/.;X-X_ %]X\P8(O%
M_/BK,P);//,AAES+9S1"-)+)(5A=O.JM*QA7<S !/L:+(6/[4,(BEHHKH$'3
M5124?"Z?JMU#E2(3$+!Z28TQV\)3'B%IXJ EYT/6N:RLTKW.NBM&>.E(9W6;
M=G)Y@5)$QE4S5)/:MK2(RV=MY$U*N'-.N-F_=O'"Z;5F+AVFFH@11)<X 8PB
M4V/0+$/K\7IX*$EI[GK-V(?/-CKHVNM+:5NF53LC&0JD)(A35*9?U%/51+UW
M1H1Q#GI^,83K9TX?JF;\$3J!J$JQCB.GJUI$4$A31V8 8TYB53*99J3U"38(
MY:9+OF</F#ZK*U%Y]Z5N:]=T-2E1P[RGLOLZJ%++M6\12AXV1HB,J=@X=1ZT
MI40G< ]=1!>#$<NV;ED9,ZY"F;KB)5  "M7+SX=50G#)P=O-R2^+RDO62F(A
MS3U-0$(\?J2;R&A(R*5D%P4,J\<,V2399XJ<PB94SDZ9E#',(B8QA,)A$<&?
M"K$SRV%]8P1SF[4$_GXSKJQ7=7'G'I'%42X\X](X(EQYQZ1P1+CSCTC@B7'G
M'I'!$N/./2.")<><>D<$2X\X](X(ITQ'7+O'CY\$7()Z\/\ =G_7B&4Q5Q/Q
M ])(J*8!=3<'$/)[^*Y<3-#B<X5&&05'%<YG>54Q$3!$P1,$4+ /& #\&*Y%
M"1XJ,#4 ^"6#F#=Q;N+$,PQF,C,<5:!A(98)8.8.@,9N0?##^$<D0"EY0  Y
M[87(,8(3]T<EF+[)^6U8BSU9'=Y05^5$M1*/V5-2KZ.;4J]7C:@>R#%N9Y'L
MXYXW34526=O$$4#"5(XF25.35L;=Z+$6<$0]RS J7AA83F)AQ(L,ZB<UF&&\
M&-[9@\S+A^8++56I._7D3HSY9Q5-R51U+5#M]')U]5[^.=UO4$.A,L7KV3=M
MHX!;*NSMWZK2,13U-5OKBIX)27#Z>BV6B:3I(]I9V0! $,)$, -VEZ)L&D\Y
MS"S;&.SL8C#6%S(.0\F8[QC68FVK=#Z1.E_ %H2F5H&7[6-Z*%U4-0UW2O!T
M%97@3V3%^]E%ETCLR%5239*(.CE!/:" @ E QOMQ=E]G$&(1V8B+-#9Q F9(
M A$(F^;8+Y8TS2J&S/WH1XN3TS #.[V6D[I;5:WRHJ..HQJ-+YER;I)Q"QM,
MJNW;2+,L6/2>.IDJYVY40.59\4B8ME19@4Q%AN%^479W9MB+6*.T>*Q ^T1"
M2:^X""[R>1J,EZ-&TFWCMK.&*SNB)YW80*&K3&.\KTIR=HJ?H6D0A:FETYR4
M5D9&45=(FD3)-P>N3*IM40E'+ER1LB0P$*GMU (<!U0*35#'Y/3S9VUH39P0
M0@R#76.U@*ZI3V+ZL7ND^\14FM!3;EJFLK;A*(#S@-AY>3_GC$,$(@(NAI"D
MI-7:ZY0%P7Q,M5#^2EQF["*0PCP'):4;CQ7&W-?&D4,$3!$P1,$3!$P154 #
M6'<'K1'BY;AOQ#0["HPR&Y7['?S1/X<<%WAIN_RA?/+V4F$HB3TAV2M25L]I
MQX%(1!4H]K2;N<VR9;[-8SEM+,-F C<?" -7=:_(6EYMA2N50@ CFS*&$!N
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M&=:O8I!S&ST =V@[DD9UZYE01@4F:":(LU6BT?'G>G%=179@$@4B8&*)5!
M$,3.6'.3]53K6K='1P2C<P\K:#FZOCWRE>-RGE@AB+#VE 7BK<0VSF-[3.-<
M4O 7%4$T1'6-RCBHLD5AH4R#:9:,J&J-J5)*$1EY9.KIE@JDR*\E5F$$X1G:
M;CG,8^/**)"9 [-"[),CA!ZY+JB;$PF&D7U<1PX(L1DT7:\!=C'O9NC&,P>!
M6JR7C%)%^#BGJ5+$N9\TM(.VT(K'<#5@HQRN*,/*/GA@N#IH W*-1Y?E/GUF
MRYRNB+F@1)5XW=TI(1@-N%J2T;*KEA]E)Q%.KTJW4 \2@=$*X:5E N:4(9%
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MDY-JFT&$G($%8]JX%)DX4CZC*F_0<JH@!A!%1TV4$=9-4Y+6^/;V LH_=B!
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M6GV4Y&/IZ"(T5F(OMH5:6BTY)MPF-6E8VQ#(L7#:QTCF\'44N "( .#"FHX
M ,3(8@F4PSFDG?;ZY@S>;BM 6H\G><U.2HX0)_N5":8C47:H)DT.K,$6F"1
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M9%\T?)*M'""*S)VR.1TF[1<I X0>1[T+@Y1<-QN4  1. \5[XRXRDV-)2(.
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M3"^QP$<9C>%R'4E',CMTWK]DT4>+E:M".G2#<[IR8HG*W;E54(*ZYB@)BI)
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M.@+*.W#$!,1\6-:K;(Q#:X%Y38^'/Y/X)UUN4#Z*.:3:DR5%,,&[!PL5Z="
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MF")@B8(F")@B8(F"*4]]100OX*:AAL4QQ$I2&,8 *7PA$2@(!;> B AQ8S%
M(X3 ?UI3X5!QU%9BB,,)B$VG*O7IBM3*MTL*?H[/MEDQ)T\^[7.%XF,EJ_<S
M,<TAH6=GZ:D:SB&+J/7<MEC1HP+)THH]VA$RJHE YC 4UOL6?9?M]"]L#"0"
MPL[@B+0FX06AB-\D/.$@?9889-NWNEP)&\[3(!J2)3%-LU,PTK8&<T@E,C8>
M$9N6(QS>18YA+U&T0AJC%S%-9P6M-LSP#EI-K,4'B8J@PF3BV+Z:IX);C++L
M*.S[/MM+@(A,$S9" FT!BC8>]!=9@7^R0U1-3ZS=>9)^*\2#1ZTQ#&E,&73R
MNF_E!'5\\HDI*JE6</&5&]GZL9T/6\E$-7E-NB,Y-C! E1YAJARDX4!NJZI4
MTD@AJF$Y@ @VNC]E:9;0 PV9<L!"!: E]D)</,/FTECZVTG(#S]YZ$$8RE4X
M35P---/1H>1AI9MF-K-"-T76IW.UF@^40,18YG01QJ?926HGP=4CT$B@#<R8
M\($EQ <Q?1_38+6&UCL(X1"Y)+" .68F*&+-W(EJDH=*!8")W%'+T>CBN3SP
M=7%0VD' YI25).<L8UQ5-&U 22.ZJQZRJ&E1BB,"$4 48ZI*4;K2Y'8J%! [
M>72*?PCD.H "4<Z1H9L0;\B&9B""S?"!KK" ,#-(-()<0T+5E/Q+XFD1*V+$
MXB%MW_7PX^8TW<[,-W-=H;>*TDP )G(X!\RI<5;3!$P1,$3!$P1,$3!%60]>
M/^R/ZPQ(J'8?1%?D=_-$_AQP7:&F[_+"OGA[)=5\SE]I@4C6D R9/'T)2<(N
MFSD&SY6,=F%1XFJD\X!(PCDQCIGL<$GHB)#  &$!P6O#\UJ!&:8&:4'+&>0M
M)4%#L2MG#9C!Q]/S#2)A5'SD7SV2C1:5$SJ!25>+B)';B1JEZB8HW%J?UN"+
MLG>EQ6+!AEHE2L0H1[0CV:G'RDV[GDDI*8GE5C+HMW$#*L)=&,CB+J#'D4DG
MSTXF.F=RS3$=:$/JV==:P[ECIOI$9D,ZXJJOT&4$O-U@9LG*-W$>_P" (IM%
MDG22K7;+NW0J&61(0YG+MPN);G46.<1-@QE.0Z(-!DV62+J7^?-?R-34I5[B
M/B"R]&N9-:-*@PD"MP4F)%S)N#K"J&V7 KAR<I 1'52( " ANQ45S4[I-YEP
M$:RB3P='U'#M@6($?4D/*.T%%E:A[HTY1<_"T94\E'RH>HA07B$!;E3,Z._3
MN R9;)IAJ\>>MT?^^Q9*H[39S+C'=.M:O@8BJ("%G9JH'1 :.PE'TK,LI\C@
MR23E\WI^ 9*K5"X*\5IR)2E'Z>T(=TW.(G+4/70K+/&;9V$.E9F0"B*"5*48
MVIM*-5@$J7:4[,(PC>D7M$2V6;^DA2-6!YM6,/3]5RLF"I9,\UVU5VC.H6;*
M-4C\$_.<L5&KM*S-2M*8;4C)P=&-89O3DA3AR1<+.%$R$N2F6JZR#.8GI"-0
ML%)1AC(-(]JV1177!%L@B4$R39AZ8C92AY%UL_NE'Z3E:Y>QU&EHR*;-9FFX
M%&E7KF58F79R$%%U&]J:)**+8@)D,L^DW#=TB4H%2:%MJE*4 "]==?-#.O34
M7<N=-;/QXSFD%#PR9IDC511=HA4S(&;IIKD.X;QC2;CF+I9R4P&4[;)3+4Y@
M$1CP+<@D5/[K_- I4S(4EERUN9PYDCM:3DQ6FW[M5NH_=R1#SC1 R[H[=-4X
MLFC9 QA4!%%,@ 4(0^;&H?KY!%//:8V;TZHV6<05%MS-%H]5'@T1./+A$%5*
MU3VE03T^^:IF(N<-2.>,T4Q*!4$TB@4A73>GYR_-UU^3+"V9M>.\P%X 4(MR
MQ1@(-M$)ZQK%7< J9>07!-83*%1445,#?6,<1* !K#8< &\=3*OPZ_NL8&;.
M!$1!%80YS$-?X=V*HH<%<>(5^(;JP1."N/$*_$-U8(G!7'B%?B&ZL$3@KCQ"
MOQ#=6")P5QXA7XANK!$X*X\0K\0W5@B<%<>(5^(;JP1."N/$*_$-U8(G!G'B
M%?-FZL$7O;V)<IDLM,P05 4Q/5"(D X"43!VM1WE ;7#WL=F]UL;K<%PBJ=I
M]5ZR8THF")@B8(F")@B8(F")@B?&_P#+<#?^42^$!N:V^_%OP1:@5+H+:+56
M9A2^9E0Y6Q"]0S[%="91%1ZWC7<@ZD3RBT^NW;/2$"HCNU3&1E6FM<I036(F
MJ.L7-2[93U.[76$]=<9E5Y3+:AX@L9ACQ>BK.="_*U'*&E,G:5E:XH*'H]S)
MJTQ4=+RT.>L6))IH]83"?;"K*<JF ,E+LWJZ+SA-/.'*!TVQFK]JH K%N,M6
M(SG(ZB!(R#EB4&PN]#6C!P"14F7-EKW,]B_RH:/IJKZ1J2JI#,-S254T?3TG
MF&6A9%G&I5A&,(Q\Y>35-Y<T_F<\8T\#%O+TS!)9C-(*+FTQ/&-(9!953">.
M3YMAFYS9GUHV8-YW:FX,:3!.PXL,M9>:!^55 5=E=F"C)U,]JG+*B(:D6:1T
M*3/'.QBV(LEI!>4<4V[S *SE55';^5IAE7@TX_D5RR$G!R+U,KW#$L*,&E35
M(;G8 U)0T+'$'#7,"<)<$9L09$+>(I2$*4A0LF4A2)E$B14T"DW 1%% $P(7
MCWC< "UK<6+^<G,\G)!+#?A1D+%G#N[$M[K3D(7 =@QEK.<<%$P1,$3!$P1,
M$3!$P13I^O+[^"+DI^N+_NS_ *\0_,>H14D^-3WA_6.&(V'U"*ABHF")@B8(
MF"*-AYAZ!P1+#S#T#@B6'F'H'!%$ , @(>"(& 0$2E&P@("%MH()@81"Q3''
M4(:QS7 HAC%H2((C""3E"[ER 69C1_SHC U( S+-Q!$Z3#9K7ZI-&C**K\T&
MN;=0P#V5J9LQ(P582LH]=4U(F0BW4*21GJ<!!6)EI1&'D7,6V,L!V8M%%2 !
MM75#W'M2WL-$%E#&P/O-"XM 27NPW8X0S@NXB+%B1(J&QLXIWH8B0U083.I8
M7G( ]6+SA$:,V4D#7437L-#R\2\@VQBTY2T9/2[3+JG5N $CU7D!0+12(I")
M>.612)KN(UD1TJ05-<X% XASLNVM).B6UF;.-HX1#%>LXC'% (GA#FT(($7O
M"4B;P+E2+1PT@Y!!#.1,SD!!7$ YERZQ75&@5D!5\A./YN.K)09I20>"S#,.
MM!B(MY,/"/I!Q3\"61&)@CJO$BK@NV,[((AX:"A+@;WZ-]);:PAA AA@(NAK
M2 0DM\1]J;SRE## :M$#3S?56<M$3A(D5_Z3(38F*)ZLZZJ&T&\OXO,>%J;M
MB8U-4C14I1=+P"?;E*IVA:A$W#W\G72\Y,.9%8IE%%(Q)E3\$Z9'4,(OE$;(
ME[6GTHM;>&*Q:%[2*&**.Z3![HD(0=(:$%A@^LEBJ-&AQ@B89NY?6(2Y\/"J
MV R2R R\T?864IS+J+>QK&=E5YJ75E9!64DI"15#55<N7JP@"ZAPL +"5NY,
M4+*HN#74+\ZWTR+2(@8B(B 69ZEISB)I@T0R(HNT%A#"#,0DD5(!&K[(,SL>
MDPRS:)  !M<1_P"O)CQS<T;"K\L^"Z>R@A#PQ3!HXQ%6 'JI+#S#T#BHEAYA
MZ,$4,$3!$P1,$3!$P15D/7C_ +(_K#$BH=A]$5^1W\T3^''!=H:;O\L*^=_L
MJ5<5;3FD1',X.><Q#8]%Q"IRMP(;6 QE2B<150.5*YRB6X& !,41ON$,%K%\
M6;P7F8;-C,DIM4:QF0$>(!*V.([@'UP-  PB&^X?IX\$4.^SF3;6[L9C5$=6
M^S;VN&ZU^"\=]UN?=@B@&;68Y@UBUG+B&MJW K8?" ;:O\UX[[K8(G?;S'L8
M>[.7L4!,8=1M8"@;5$1'@O$!@U1'D'=@BG#-?,H3%*%83(F,)2E*";<1,)C"
M0H '!-^L8! .<0&V"*F&;F8IB@<*TEA(8!$I@*V$H@4%!,(#P6PV!)01\A#C
M]Z."*?OL9E7 O=C,W$IS &S;W$J9!4.-N"?>I@)QYBA?BP12]]O,?VYR_KBD
M]8V]>8I3E+_-?7&*<A@#C$# ."*4V;V8A1L:M98!L(V$K8!L&K<?YKQ!KEN/
M_>#!%-WVLQ_;E,<>KZQOQB76 /YIQB7?[V_!% <W,QB[QK27  $ $1(V  $;
M" "/!>6X6]_!%$V;>8Y!L:LY<H^4C8/OM7E:^RW>_@B&S:S(* B:LI<  H&$
M1(V#P1$  W\UXA$0"_/@B#FUF. @4:SEP$3@F "1L%SB%P(%VN\PAO .,<$4
M1S:S(*)@-64P E QC )&P:I2[S"/J7< !QB."*4V;F8Q;:U:2X:PV"Y&P7&U
M[ /!>;?[V_BP13%S:S(,H"1:RF!4&]B 1MK;BZP[N"\A=X^3?@BE)FYF,H;4
M)6DN8P7\$I&PCN"X\37FW^]OP11#-O,<Q0,%9RXE,(@40(VL(AQ@ \%WCN'=
MY!YL$3OM9C^W.7^(V_\ 2X(G?:S']N<O\1M_Z7!$[[68_MSE_B-O_2X(G?:S
M']N<O\1M_P"EP1>X_8LJHJ&HLMZ_5F99W*+H54@FGMCJ))@08YN(B&P1* _!
MN$>/R=P9 EA3 '-S.0D!KF9KB&A+/*A$QJ +<6<9.O5@%QL'IA>+Q9A_3<+^
M_8+XER'+B>:CG(;AR3;CXPOFS=>%R'+B>:.=6X<DVX^,+YLW7A<ARXGFCG5N
M')-N/C"^;-UX7(<N)YHYU;AR4=N-[;0M[B%MD:]P HB%KWW 8HCY#!SX783A
MQ.S/4CG(?A'+6-ZAMQ\87S9NO"Y#EQ/-'.K<.2;<?&%\V;KPN0Y<3S1SJW#D
MFW'QA?-FZ\+D.7$\T<ZMPY*)E3V/X8>#<#>E&W#8=P[]WPX7892K29GBCG!I
M8L)<,U95<U4E0U%5?6C]%9TRI&F)^IW;5L4".73:!B7<JNW;&,8"E772:'31
M,80*"ABB.[&Y9'>.2MZ*3DL=3<6EM6')#2HRUIFDLO*MJV5D(0,R(9C-0L8E
M&RLW(-FKM-F<'4DE!I.@B8]B=XBT?S;T$(]-PL0BBQ3&*!LD#(;&WYR$O%IS
M4O%B)O5W+MJ8SI.LE:$QIPY I0TJ[IG,&GJDJ%M$Q\O&PJ3I9DYEF\LW<N(W
M:KK@'!VSL6[D&I@ H;0A43B(KI@,9S@S94R83GF\F'@CMB7?"A&LR/+QELG0
MU5FK.D*=JP&:[%&>B6T@$<H<IC-U5P&Y2'$2F.%@&X ;> <5Q#%%2\SGBQFQ
M:70H\[.H!8U D'?"4Z!@)@DU 97EPC< [4EC:P .S-8=4!$UAO8=4 &_-RXE
MV%V:8V]8*.=6X<E-MQ#_ %A=X (>EFXA"X#Q\0@ B'D >;"Y#EQ/-'.K\(Y)
MMQM?:%MS[(UNF^%V'*FL\T)(JPV@#Y*!'&O?45*:PZHZJ9AL/%;</..%V'+B
M>:.=7X1R3;CXPOFS>]S\^["Y#EQ/-'.K<.2;<?&%\V;KPN0Y<3S1SJW#DFW'
MQA?-FZ\+D.7$\T<ZMPY)MQ\87S9NO"Y#EQ/-'.K<.2;<?&%\V;KPN0Y<3S1S
MJW#DFW'QA?-FZ\+D.7$\T<ZMPY*(+&$; H6X\7I9NO"Y#EQ/-+QU;AR4Y%3Z
MUP,6XD-OU/"MNW!QV#GN/'OX@Q"  )&HD#GG/K.:HB+B8$CA+%M6X9:P:1#F
MN?5.7C 1 $QXOA$ Y^(1\@WQ2 6#9U)D)/GJYI?BFY'B-7'TS4=N/C"^;-UX
M7(<N)YJ.=6X<DVX^,+YLW7A<ARXGFCG5N')-N/C"^;-UX7(<N)YHYU;AR3;C
MXPOFS=>%R'+B>:.=6X<D%<;#90OFQ_M'$, 8L)X3YE'.K<.#!WR92;<_LP^)
MC%R++B.:E\YQ;HN2 X.-[*%&Q=<?!#<0+^$/_=W#OXMV%V++B.:MXYQ<3UM4
M074-< . B%[@!-X6 !'=Y $!]X<+D67$<TO'.+'XL*J47!P 1$X6 0#UG*.\
M ]\>,.G%$,0+M3^V&WFMV3QQPPER"6F[.Q(J&PZ+*4RQP3N!S%$PE(!B 36+
MKF*0#6-N,4-<#&* @)R7*%A, X"SOD PT+L:$58;JO*172T@N$@,"!(@3!S=
MA3$-3%:,9@Z=-#9>Y@U9EA)1QU*LIZK:*IAJP*Y(DI,,JKA6<JK+MR'!86[-
MF9<[==J*8J@HF:X7$!Q^AT7L?VUE9Q7H888H8B;P#@N!"& #L#.*\* XKP1Z
M4;.(CWBQ:DF+DL=>0#3U*/W?>3981JY<.:A4G'[#;MVT;2-7OX,LFJD]=LX)
M>IFD,E!1[]PW9G40([D$C& 0.4#!C47T=MHHPUE#%9S%YX!%=# QA[T1!. #
MZACGZW"9N06H'P-&! QF3EX*Y<L]+)KG"O2:5 4X^.[?/$F]:LJLCY^F)>EF
MKEFH[;OF2,C3Y4)F/< G?A7;)-):^T06,%BF\.E]C'0X;6.7N &%F#N9C[(B
M?%I/G@M0:48HH8027D\CKJ^8DX<8C/<$%E"W %2:FL AJAM/#$ UBB;V._=O
M&X6X[WQ\JZ6I.C,U#7*F;>)KV<AV=LP'J\G9Q,.P?P"J;92]M<+A81#4Y^+I
M_P"N+$NQ9<1S5O'.+CUB@+*B(@!P$0XPU.?BZ>3GPNQ9<1S5O1.SQ2=_M8:Z
M(5<XCZ\+!Q^!?WMP;^C%$)<.);1\CL4O$XGQ!]#53;<=WIA=X:P>E&]: ZM^
M/BUA +\^[&[L.5=9YJN<A^$<DVX^,+YLW7A<ARXGFCG5N')-N/C"^;-UX7(<
MN)YHYU;AR3;CXPOFS=>%R'+B>:.=6X<DVX^,+YLW7A<ARXGFCG5N')-N/C"^
M;-UX7(<N)YHYU;AR42J"<;:Y36WV @E'FXQ'RX&$ $@8'T1WRW >@5ZQW\T3
M^''%=8:;O\L*\$M.][3$;IY98R%8FB.YQI3L0O*=NTF9V"#1(KTQQ<@_$&R^
MT.)12;N;-3B) $;"("ZZX+5>N?7@M:#S^C;G!4,LM*Q4% ]S39./CG,K+4WE
MHVJ-LK*N.V=0E9PK4\&[E(:/$@0; BQG,@&J)0.8<.NNOR*Y5Z.T/IM@#A>6
MIYL#"D$6\?P2M(.->NWJ+M<IY"0:.SI+K3942)'3;F2*HL"FL!;"&"E,S4Z^
MLETE)0^B@RF$2E-3BCE&*.W1DJEJJ.<MG;U[$NCE<..$M!9,5F+H$B)*;0Y$
M5E1((B8<.NN*J[2*HW1;<M)"?G:KHA67;JPZL8B6JXPI6[ADFQV[92'X*W14
M9*FX259=@V>%<"!C+C83@I.NJ;=^I,>NI*P<O97(TU19VQ54'I)E 5/6]/1L
M#);2+)P2F74ZX++*4X=2.3/%M2,0146D&"96[1(XJEU2@ X-UUZ4FA?QU\5T
MV95.Z.E-495<K =HI6NE(^E6;&"A:_0J.-B9%S(U<DZF(Y\U9&)/HQ40VIY^
MLR;B8S9^^%LX#6\$:G6_KFKUI>:RI3RT@2.)#*9"@@R4J>*K:GGJ<$.:KG.4
M>W[FFI>/659A6S@Z,^[IG@<LP0-$QT P?(G,*9!Q"YDTO6M,, 9RFQ3Q,IAO
M3#;MU+LE*#T9Z?&IFT+-4'4SNIBYH%I$SRO6+A>&A &A%J#,[=&,0[2H%R.*
MF1!JX(1R"XE1.0IR& #R?4Z*ZIW)715IW,)Q!3,U2L$6$D*M;.X4V9[10J\2
MSDV#&&DW;E%KP)K52 NY4RD0X59JG:-A553=E3.#F[^I_P!\,-23ZZ-=KT7
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MHFBG/ A)/1SFH16BV:R1C[<B@V$Q@N!%H,!;!8+  ;@#6 ;6Y+C81MY0 ><
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M=Q0VL(7 .Z)K>W/_ )#!%2-EXB W-6U#;Q&PC4#;?;F'9!?R6X^3!%#O>)7
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M#R!O;\8_>AQF#>4!#!%43S6S15L*=43ZEP,8-0I3")2!K',  UN)2@("80W
M [QP11#-7-$2D.%4SXE4 YB& ":HE3$0.<1X-8I"B AKFL0;;A'!%1+F]F08
MQ"%K*5,93>0"N&QA, FU0$+(CN,8=4HCN,;<6X@(8(JBN;&9R( *U6S20&MJ
M[11$FN(F*4"D R "<PB<MBDUC"!@$ $-^"*4V;>9A!L>K9LH[K 8Z1;B*P(
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M$N5RL(<H6X_ZV B;]6'P#)=ARXGF@T^B/_WE7=Y.LPXY6L)M&F Q>D]XJET
MEGGK/R:J=SZ.[U0KN\GV_P!5L;!B$%UQ,,X'I0N0EV&;@D&H<X?G.;IW/H\B
MZG0(?_V'&+I^(\>:MV#X3^+\E#N?2\<?]/TL;'NEP2"-9V8E9,$)D1Q/- I]
M$/\ 7'#W@'Z08T8XS^MO *GLK/X>,7-1[GD/PA;X  /UB..<7M2S6C-W1UP]
M5?9V>$&UXHCB^!&K!.Y]'\(4'X.HX8U>M/C\L/)/967P$??B^;J0].H'*)17
M4$!W"%Q*%N7>4PC\'$/$.X=Q[3&-QB+H#^(ZI@X3V5E\!VWHGY</S%IX@"%W
M:IBE*)0*(>!J_> 5/6U2"3?8Q1$PW&_'8+>-7G13V4#,QWG/:P\%/W/H^/4Z
M!^GBWHL^ Y(+* 3$/&+FG<^AX]3H'Z>,1/%)P!JA'J&/@MB&$8%]41'-0[GD
M0'<N</* 6$/>\+&(;*&&(1L\0=G=I@@R?7Z9(0#*;:XB>2CV@2_"ENC[6.U[
MNP[E+D.7$\T[0)?A2W1]K"]W8=R7(<N)YIV@2_"ENC[6%[NP[DN0Y<3S3M E
M^%+='VL+W=AW)<ARXGFG:!+\*6Z/M87N[#N2Y#EQ/-.T"7X4MT?:PO=V'<ER
M'+B>:=H2!O*Y4$?^\4#!Q[[AK?J$!\N%ZLH0X:02Y#EQ*[I!$$$B) (F @6N
/(6ORB-N3&50^+>'7)?_9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>34
<FILENAME>g164680g01m07.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g164680g01m07.jpg
M_]C_X  02D9)1@ ! 0(!>0%Y  #_[12D4&AO=&]S:&]P(#,N,  X0DE-! 0
M    %(B^4E8X0DE-! 0       \< 5H  QLE1QP"   "    .$))300E
M   0S<_Z?:C'O@D%<':NKP7#3CA"24T$.@      Y0   !     !       +
M<')I;G1/=71P=70    %     %!S=%-B;V]L 0    !);G1E96YU;0    !)
M;G1E     $-L<FT    /<')I;G13:7AT965N0FET8F]O;      +<')I;G1E
M<DYA;65415A4     0      #W!R:6YT4')O;V93971U<$]B:F,    , %
M<@!O &\ 9@ @ %, 90!T '4 <       "G!R;V]F4V5T=7     !     $)L
M=&YE;G5M    #&)U:6QT:6Y0<F]O9@    EP<F]O9D--64L .$))300[
M  (M    $     $      !)P<FEN=$]U='!U=$]P=&EO;G,    7     $-P
M=&YB;V]L      !#;&)R8F]O;       4F=S36)O;VP      $-R;D-B;V]L
M      !#;G1#8F]O;       3&)L<V)O;VP      $YG='9B;V]L      !%
M;6Q$8F]O;       26YT<F)O;VP      $)C:V=/8FIC     0       %)'
M0D,    #     %)D("!D;W5B0&_@            1W)N(&1O=6) ;^
M      !";" @9&]U8D!OX            $)R9%15;G1&(U)L=
M     $)L9"!5;G1&(U)L=                %)S;'15;G1&(U!X;$!@SX4@
M        "G9E8W1O<D1A=&%B;V]L 0    !09U!S96YU;0    !09U!S
M %!G4$,     3&5F=%5N=$8C4FQT                5&]P(%5N=$8C4FQT
M                4V-L(%5N=$8C4')C0%D            08W)O<%=H96Y0
M<FEN=&EN9V)O;VP     #F-R;W!296-T0F]T=&]M;&]N9P         ,8W)O
M<%)E8W1,969T;&]N9P         -8W)O<%)E8W12:6=H=&QO;F<
M"V-R;W!296-T5&]P;&]N9P      .$))30/M       0 [_^-0 "  $#O_XU
M  (  3A"24T$)@      #@             _@   .$))300-       $
M>#A"24T$&0      !    !XX0DE- _,       D           $ .$))32<0
M       *  $          3A"24T#]0      2  O9F8  0!L9F8 !@
M 0 O9F8  0"AF9H !@       0 R     0!:    !@       0 U     0 M
M    !@       3A"24T#^       <   ____________________________
M_P/H     /____________________________\#Z     #_____________
M________________ ^@     _____________________________P/H   X
M0DE-! @      !     !   "0    D      .$))300>       $     #A"
M24T$&@     #-0    8              +L   -0          $
M                 0             #4    +L
M 0                         0     0       &YU;&P    "    !F)O
M=6YD<T]B:F,    !        4F-T,0    0     5&]P(&QO;F<
M $QE9G1L;VYG          !"=&]M;&]N9P   +L     4F=H=&QO;F<   -0
M    !G-L:6-E<U9L3',    !3V)J8P    $       5S;&EC90   !(    '
M<VQI8V5)1&QO;F<         !V=R;W5P241L;VYG          9O<FEG:6YE
M;G5M    #$53;&EC94]R:6=I;@    UA=71O1V5N97)A=&5D     %1Y<&5E
M;G5M    "D53;&EC951Y<&4     26UG(     9B;W5N9'-/8FIC     0
M     %)C=#$    $     %1O<"!L;VYG          !,969T;&]N9P
M    0G1O;6QO;F<   "[     %)G:'1L;VYG   #4     -U<FQ415A4
M 0       &YU;&Q415A4     0       $US9V5415A4     0      !F%L
M=%1A9U1%6%0    !       .8V5L;%1E>'1)<TA434QB;V]L 0    AC96QL
M5&5X=%1%6%0    !       ):&]R>D%L:6=N96YU;0    ]%4VQI8V5(;W)Z
M06QI9VX    '9&5F875L=     EV97)T06QI9VYE;G5M    #T53;&EC959E
M<G1!;&EG;@    =D969A=6QT    "V)G0V]L;W)4>7!E96YU;0   !%%4VQI
M8V5"1T-O;&]R5'EP90    !.;VYE    "71O<$]U='-E=&QO;F<
M"FQE9G1/=71S971L;VYG          QB;W1T;VU/=71S971L;VYG
M  MR:6=H=$]U='-E=&QO;F<      #A"24T$*       #     (_\
M #A"24T$$0       0$ .$))3004       $    !CA"24T$#      *<@
M  $   "@    (P   >   $&@   *5@ 8  '_V/_M  Q!9&]B95]#30 "_^X
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M(\%2T? S)&+A<H*20U,58W,T\24&%J(
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
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M3IXZ=/'3IXZ=/'3IXZ=/'3IXZ=/'3IXZ=/'3K^9_^,__ /,^18]E8C^0I/\
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M=LG)4MZT8F5,Y9V:7D!O[V[+KYA%E\/DH/:36(5M+.I:[KFSH6'CV-S<]Q)
MLR?_ *9S+7)'?(Z(MDPN-G )F(_6%7NS59T73:M=F:^?.?\ UG+*A:F>^7EO
M5'\45*Y>&Y35[[D M=@T\XA(-.4G6E76M!$QXB(_"\Q0(%U9(8='R ?+\*\W
MPV$QDA':?D-=F>P)H4"R4JCU\^CWDNL?3QTZ>.G3QTZ>.G3QTZ>.G3QTZ>.G
M3QTZY-?: R:UMNCN/JLKQ>_"(NPX=U(_-P[G^T(]4\B.'H?&JZ7A9@O(Y/.J
M_$[AXP1,/'2[14N0W4T>*_ACYK&-FF<41HMR/-1D6\\_TO/7B+L/C9M].:SY
M$U:)GR-$]=#)E6.@]F!]1 )'I3&9.-31= R_^8N(SW\5)O3%3C^=OISQ8-/Q
M:K98O_K0[M)0+(?OU1VOV@?1?-\@YYYNN./0:W+/1(<YTQ?T\$R%5L0#6U?
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M5D(B+RN;_:FW.TD\S!QRH(((%(2F4UG%71J0%SDG831MQ<PZJ E#XP,EI'B
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M;*I8JWC4J/VH,@4BRDJ5Z@9,T&9LH(,!7G(I9&31]H$BD?G1F4&P7K[L[91
M7$)5') ]D/W*,T6)AG]^<N-MT--5%$K"%'FC)33'2[.HE@OCY/+PVB.ZI(3/
M1.3VX\O9B07T3<,9AW2B?>JAI*U/9++;,JJ2^R.W'KY#-7*I[&J4QX-M^_V*
MKFH'"DH'O6$=>6O9%M6#2<&ZVK:3S^K0@$[.F(GGM%V-!-Y&Z?M!K)8VG8F1
M:Y;54:X_7#&SE9V.QE+5[H@IO^7@B/2-KJK"4-38G=E* Z$#FB(& +B9FZ.Z
M HM%:?EYJRKQV"'&"0?G97VYBI\@^9?C$5)'<**)LSTF&[,\Z+0#P*DPP5W;
M;A:P$:]QT&U'NWMIR:E!4F*\I*LH48M&)-'SXS#QTBWL?9!0CHV&/U&FZR*#
M-_LU42:.55<Z)[PR$;(YKQ/9-F/7OR"G>;:<V#1;-K>0/\M&F?06F2*&4+65
M6G-V$M ;,U5HI/HI@GH9.S+G?DX9=&$5/<>/O3;D5>WEVI><V[.>PM2<=(WS
M7S*,D3_4-?J-);8L6JH.J&Y\:&L9FLQ(8%A!;ST=9"_Z'51YG&CIPYRFFRUS
MC=QG37/W^$/GHRYE^]=GR?1_RO\ %QZ-UB7_ ( 7/ELP/_$RA!^3 'I1EAMT
M$=I\? :-7<_G.3:(Y@?#^XM[M$QX@=^Q8]NRGK*RB_KSA0IT<EG7]+Q\0Q,A
MXZ\($Z> MFS4_("C<($#+[[V?_\ J)E"SMN/9,M\8<+N5=4]$\YQM]Q2':"(
M0[ZJ^G,JGR-ZA&J9Q [^QUDCU8+W*21Z-V1&8<((%200(3]UB1V]4O)4]C]_
M[4+LJ!CV#.RH.[, 9/K9/4.^Y!/3IRKMU!*?YI336D ^VXU+\&5/S2&N+-SL
MS3_+USO^-QA/7\&,[??^'&<^"0 6) 4'Q))[ -W[=B?X[]_MV_GO]OYZ=B2%
M )+*&4?Y92 0P'\E2"""/L00?\]0JN.A^@[7VG.(/TQ!BVE>3HI74E7]G9!%
MLE)PX\43>H,'"EC?E$F6K,TP42(--U&JV5-]$U,[)[XQU/W,\-2@^K2=(D6!
M5B<FS1AMW4_=?'1FLJ]_[E4.O=64E4>G0^9R/:D,>A@I\E$MV==.<AA^)+2<
M%E![HW=6^XZLKULZ[]X2!_ !E_8_CKG3ULZ[]X2!_ !E_8_CIT];.N_>$@?P
M 9?V/XZ=/6SKOWA('\ &7]C^.G3ULZ[]X2!_ !E_8_CIT];.N_>$@?P 9?V/
MXZ=/6SKOWA('\ &7]C^.G3ULZ[]X2!_ !E_8_CIU'V?M)#@KV-C[?J-C'2>Q
M?<B!9\S@6H4AO(%W3H]N]%H3[1B[V-NGKUR7V704R27=NEGN5E'"NV\656F(
MLJM%9""R8 S6"KX+$(1XB2I^ F!X!?Q [?;J8HZT]RNZV\Q3VAB*>Q>WC3S!
M\O-?%>S]_(>(['[#J"#:LL0,-:A1!GF@4'8E1IUD)&\<0%B-9FPVKC408:L6
MLN2:MRHK5V[U&D$4M';'5TXPU62PLI^*9))!))*ERI))*FD%S4(_V+YD3.Y'
MW:"K(]YJ%$ 2OD%/B'03<#[>:+5KJC=O[D6[O8*>X%6:@'FQ)RR4,N) S%9$
MA,^?D9!!1>0<).I<E0U,S#@F4E4,AXJ3TFFKV/"\HK+(Y'B%V;3\I55/\G\"
MF^,\'V:KC[->8C9A]FM( J)5/\TF%) 1R5 ) '8]=<F@4.2X2CV0/^06U&\W
MJH/<+1W_ "=QV9F_(DG[]?F[@MN/Q2P)]+N>G@1P%2CBX=WR-"W I:/-RNQU
M "L/6F>[10*B<WW,I"]T=F*97?8CHAJ[VRME_D'_ "OQBI_R#C'CC(_V^*OV
MS=O] ?:7@.IFM22QI0LS:'8EV[L^L :G)[]RVD*!H8_>P %"P ZF#]STT53$
M)%+FJDDE'R#0L!3?\V!'B80J/15;L"8C1Q8"FHT@Q;KKH-'K+"+ELBLJDBII
MHIOKMTDF@J234>PBA/>@-59*D.?R'L1F2GW_ #5F5NX)!K'XHTU_&;JJ.@^R
M,B.E$5E'XLJ4G-U4@A71& #*I&9];.N_>$@?P 9?V/YSIT];.N_>$@?P 9?V
M/XZ=/6SKOWA('\ &7]C^.G3ULZ[]X2!_ !E_8_CIT];.N_>$@?P 9?V/XZ=/
M6SKOWA('\ &7]C^.G3ULZ[]X2!_ !E_8_CIT];.N_>$@?P 9?V/XZ=/6SKOW
MA('\ &7]C^.G3ULZ[]X2!_ !E_8_CIUB73[I]\6%'GMU5:\.@DB" 0TZYN#.
M"P9 MH@F51%$5K!W>#TB:;5KH03:+(Z/=&R&KG"FJ*>-> !6=U 5Z3$G8?9G
MD'%1-V'W:8HJT"$E0ZAP/( ]=[DKX$DIYK3P[GQ]BJZ+3Q_CS5*456[>06CJ
M" S Q0W$+FDLI93B1S>@3\U&IL$ATP-\F0\K*6"0I]H4%ILI ^FJY9JF-)II
MD6&B#M/5F^3T=M\)N--5,=3]MS2?[;E@Q=/Q<L$:88LO8EA-VF#W[A&91^+$
M$Y-$$Z$O,*R";GR0([!V0(W=?%G =E[=F8!B"0#UXT(!:S9H98-I3SLW8R-B
M1%R%FAR'"$FAT88)KFBPXRW3F6J)1B4,.G)8BT?:+MWQ-PN_<IJNEE%=HE$:
M8BR*9!8()%09A,K.V9 A'B%SM2C04#M)G<S"EF[S]U?,T]M/8:6J7\V\S70B
M3T4+=_(TNDYI9^_E5$17+!5 _=&%7 W$M +>9<^H V$=>1!B%1Y)AB0EE$R+
MIL^(1=H.TFFK-O'7SYFT>/ B*.@UTZ:MG"[;=9!+?6;$LQ9B68_'[LQ)8_$9
MFR=R?N?BLS-G^_[+,QGXDDF"$S $R9A6HZA"4 >RE:N O;LU5)6C#[NI(8D'
MMUZUXQ=SEM,F3F?4.X9V+C3%@M%^48DJVG6$VFC!/$R04F^R4GPFQ339:>F]
M'WX6B>C?7[D===,18!YB+@-(6;0), TQ=J+9KA#W46:J+5J >9HJN6\E!'0[
MJP=78.)" 8,0P@)^D1# ]Q(1_:$P? 3_   \?MU^L$ 7K5PI<#65BT;70-R\
MW(.0T$Y5BL1%.'ZJ::2CY<='YP/9JO%$D4DMW*B.RVZ:2>FV^==-<8F7<JJE
MF*IW\%+$JOD>[>()[+Y'[GL!W/W/WZK"J&9@JAG[>3  ,WB.R^1 [GL/L._?
ML/L.IMZV==^\) _@ R_L?R/4NGK9UW[PD#^ #+^Q_'3IZV==^\) _@ R_L?Q
MTZ>MG7?O"0/X ,O['\=.GK9UW[PD#^ #+^Q_'3IZV==^\) _@ R_L?QTZ>MG
M7?O"0/X ,O['\=.GK9UW[PD#^ #+^Q_'3IZV==^\) _@ R_L?QTZQIDEU'(Q
M1 %(;NK Z#+-%F!4,9YQ$%!1-BYTRFX9$!SZPEV;UHNGG.BS9RBJBKIG.N^F
MVN<X\X0#V[@'Q9'7N >SS</-QW_AD=5=&'W5U#*00#U)69"&1F5AW[,I*D=Q
MV/8CL1W!(/\ T/;K!RH9T!.H]K$9M9U*S&)ZJ,%=8Q*N7(U(8]JJ+WT5&*ZA
M2\[>#<*#E4DU&&^&WXF>Z>F[?*>VFN<=)+46K'RJE#5*'[T2I# T5S^2T(=P
M7!#=F8=^S'O%251YJ?&=$$GFOV1YAE83=1^+(&1&"$%?)%/;NH(CV:]M390:
MMF3\Z95"L-!0=7/(4'RH)%I'$I,F-&[YF/XF#!.2((R#1FURDWT.(I%M4\/T
M]'&)!F4AE9@RK!%8$@A,P<9D!![A<XI004?:0=Q,*&;OWR;Q9.Y\6:[LO<^+
M/J4)I=A_!;0@"78CO90%H6 [=>G6%7!J]EI'69<^ZD)\HU5G3_7DF&8>S55B
MOHY8J2UUB:?GR-1FY33<-=S&[S9NOIHJCG137&V((!-428$TG==4T3\5GJ1S
M1-**O8+=7)=;*!17)8,">_0LS.:,Q:ADV<T))<P=/6\2Y_(R>?[;3)\&3\2I
M7[=>[U=O+TJQ._Y"HOTV+/DY6,,>RI%/2HZ4FFB; Q)6)#UX_5M#Y9BDDR)F
M6ZR9%^T33;.G*J.FNF.I^WX^O]OQG>2^'X>,M-??IFOCV[3T6)M=!V6M3[*!
MG^_76=W!5V9U8YRP9BP8Y)F64D$D$YI$SS]_]&9*3\5^W7L9#N@ADK+3P=:%
M+CYR>9-QIR9LN78TTE9D<TSKEJP+2)"=IF"+)MG33+=J\>+((YTURFGK^''W
M<F!):)(":6H+668"+6H! K15[!Z $@.P+ $COV/46)<HSGS,E*3+?D9HQ[LB
M$]RBD_<JO8$_<COU+/6SKOWA('\ &7]C^=Z=/6SKOWA('\ &7]C^.G3ULZ[]
MX2!_ !E_8_CIT];.N_>$@?P 9?V/XZ=/6SKOWA('\ &7]C^.G3ULZ[]X2!_
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MDGV1>U&M9Y/_ '3:MF:M&0@O1F=B6))X266B,24JDYU0GNM)Q03BE%/V=)3
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MHU/T.;>LI(KI2\4YJVD$YCVS$+AO&RTEETC$"K<]+.6OI%-.'O 8M@9'JNE
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MV0;J*J[[))YUO)HEA4EUT2G\84[D62*E_P!@/W\UDI>G[0(0%W_'\F[YP4K
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MUUUUOSE[777&-===>0K6QKKKC'W8UUQCM[&,8QC&,8QC'W8Q_P 8\Y_/\]
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M:=%5U912KABX 8&;E'#HZ$, &! =5+*RLKHZ]THC*Z,RL"9WZI]H_O\ <O\
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ME-M E0TUR*^+XGK.X<A 7A2$KK!F(75Z*:8I8YC83+_F1XOXU,?&>6K ^&Q
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MN3RKH[ET0 'JL4R!17CRX%FH_4B0:C4'3[9KVPOLS'HN7B.S\DXU38#&GYQ
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M[,"RGLP()[$=7AT./;G8L'N<+3(4,O?+OSZW#GR!4,D652 WY$=QV[GKF_U
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M'4RC )MUCQH+<,Y3)2((-$;[HC5D&C9-YJY'#G^\-'U9"%RVBF7*SU>'5I"
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M+\\JEW&##@] "UD$Q;.S)@F9:M0UDQ&O'D;8,BQ*KW<[0=&G\Z FFFOBMC=
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MS5VJLP&6W_A$A70R;INA6\Z3OA&@W"HF=O(N,5>1G,A5P;:%G\-#DEPWW8=
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M!NBY:.VRJB*Z*FNVBB>^VN<?=GRB\(Z9/"\UK&@\:3<=U8=P>Q'_ $(!'^Q
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MCM864<:3%L-8Z2+1/1/4ILWU5=846VW4VB92:9D44S,;YBA'<'/IU2W7C_\
MZJ;(2TLG]OMFK@ CKJ5HCI1'9'G;'H1E/8K?C\E<&&P(_P#=RXKURQ?^Y(N4
M![=NWX2&-VG*W:#^15GQJ6>-S3:0Z.7==6=LKN6:!0D<2<.=M+#T_6); 8W'
MQ+AD[_/8/&(8:W=ME]&:&-+!^.@:Q]M(M70+?\?OO6-ZU)_S1KYX7\CW*VC.
MJE716$0S"'Q02,XA/,) ]E6$A=927M]U5%TZ%4*1V2]4_MHP/Z%P%K'V6@\Q
M6G&C]FD[*OT45JXLS&&[XY/A5I%WC?=.P=%&[HA8P,/-'#A'=-7>0C6A'&^%
MT==L115F8E!X'.G'S@5[J9)Q4]$>.1".Q5<<=>J4%'V6>BR=BM&!ZU'<55V+
M+?Y'N5ONM?E03-H\P?LWN@B3?O\ RJ+_ )4$92;)779+S8A/H%QS+WV\=Q$=
MW4@KBR22^\9P<&R7 /=1Q/\ ?;8;Z?#BR^6VWWIY?L6SC.,[IXSYU0%JUU 6
MKVX_0U  &:W%::[.-J3_ )?#JO;1E;^8UH[IV+$]08EIB+'RD);8!#]U$>2S
MIDY"0!_A-F:<X:%_BLT57[A1VPCV,6@1++'7M8<9."[A<JZ<O]ZWLS\]TX-R
MH7.2JSK.MA8U<J/9@%%2179?53.##%!ZG^!;&=MDP(LCR'@TTC-"OV*)GI6T
M O\ @&-+W>;?W(;5\2!1P;'K2BE:.SAO;W[GN2+9IXK G^2M<LI0=>_BTY34
M@^"=IGL<Z'V!+1C:+\D9CSF6YGBX?, LW] K,]I?K/\ ,FW;_P"0/P;&,S73
M23Y>9Q^;DSKA[]_YO_/A0%^/XCQ^*%7-V^WI59O)1/\ Y0)T= !_PL1_GKC.
M[-=F9BVF9EH)/<VFT4@R4/\ Q*8HDB#]O!0O\#J&+1:SG!Z/2=:KN,-ST4/&
MI0 )_P"-K+U782&0RIY.2Y?[M;!U2=/7,T(OY8FJ]3<99R)XY,LL-B"V[C9$
M#.ZTB!)TRPQHR#L4RYL]\F>*_P#*L<NG1GEV[,D;VDI"4<%:CW1TL[42E#6B
MNQ(>A^+Y,WW^_G\+'[%_MI\6'F&]2>,FDKN^IC,(Q/Y1#^13DSAOX<1J1$(#
M:"Q 9A)SEZVUTWS8>-'&K!_G8@,U>)N-19';8@.PU>[;+Y358V?3)0EZ3$GJ
MH =IA-$@I;^?QEJU25A^0GHO,$)5PW'=WC\=V9H"GM$B24#DS+$#_'F8Q- /
MQH8R+AC)/&,$8K9A44^"/JKXL5%DDRJ;QFG6-CMDU,G)@I8!9;39K/T5&[M]
M.%5)8L];[I._3VV2>B^KK[E,5^B02,Q-53,F&6=%'BL)\8EI\>D@O;UKDGIT
M3@J=@B6H@_%V!L]]BU'-'+V;2]6)[FK[$DFMJ$_WMI6,A9F[FG@I8DCOUY&,
M'L(:O&7 ^I>*V2D.&O \9PVK2RT41(U^N2=.6J#?2P=6ZFOZHR7<M]W*2RK-
MP3?K,]T%7:^V\FE-O;Y30B^5<51X*%;(F=LB9_$ *LTR.^554#QSLT!VD2O4
M!6BJBAW GH;6GY'N-+56[W+=_(T>Z)9V8DO9%JW=U##^G838DE#H@#E4\7OQ
M#="--6S/>N+.2U;-8>%<QR,MFRS>PT7#=N'C[UX#:HHJZ)Y$NW0Y751HX52W
M[9%T5:]U%:O;1>E''DU+:HQSZ7IW_O.B&>$K!NZT2,PP/@O;JUHB>M*.J>M9
M>*L0 B:'UHH[?<>&FCW4CL5JQ=2">I*$1NN-S3-B ('QZ'FGHEN#TD ZO+-:
MNT1;5@T%H-6R:5@ZM6OX!;!B,RNV02<[CFC9BHMLU132UL#,K:'!(;4[4T-W
M[M5Z.E*,Y/W[TI.;T[=A1T1W\F52*S^20F?O/,H2"?\ #-5#A0H'^$%**G?O
MX!W"]@S X@E&[2,RF234K6/&1"52]MAI)3;NM[+7=ET?O&YWRZ_'8.4OSW'H
M83J\=))INGN@Q@F[673:(:Z0DJQ5EDHFK7GJ(4 ?U$M*[)U!_D,NM%TCMV!T
M*+$&@\NIM1W*%W9C.5(IW8D+.L:9Z+V[]B&SUI#N02).TP0A(ZS,\TN^SR\:
M/6#!^0)<8AZWYT;(&Z_L]VX&9_6,R&$D\[6%C5=K@@.8$-63O5PSU?,FKS5#
M#ENDKJ11.XTH N@! *C[.!)G>1[_ .\GH[R;^Z;.[(5+,3%B7BV=B3!BQ:1/
MX'R7P<$?\KIV2B_VT0!7#* !'-H;8^YH-(=JJXN],Q]@[&!WN*ULS79DR>KF
M7*Z.J6MA8;K9PXD)U9NLX2579*&"6[-1#+Q?.]8A$)68DGA;.N2B>(\7S)D^
M LB/\*,0&3N.S'-^P29_CU:U[,RLU:%ENVI6\CW%VNFIJ]P?NQTS31]^X]R+
M3MYJ"/+)X#/9FT9L914G%AEHP1#-FB#JM[.QHBSCX!Q%1##[TK#2VW',XR[<
M@/1ZFV[)<0NJ/<H+-M]D\SHJUK2U%%*U?12KN/(U?4F9-)KW[B@NF+(M5<,K
MC-'R!]:]HK:J(LTHZ(HF$56*A/36]I%.Q!1IUTZ'FZD,C6KXD>;=YP(>7R B
M1R!!87R -ADE160/QAK7=E)ABZ*XAD 63?,<3_\ )7UW"CF W.-]<_<T9MTL
M?=A+7[NV47F96'MF6LY5_N/.^FFRS_?[^=-5JZ&;OY&SM3OY'OU&;M)TI(^M
MY+%)LG9?!(36,44#[!)R19JO;Q"*%[>/VZAK6$V*R#K &]5<8X$N KJ.KM5J
MYL]SLL'?&V\D>-%7+FQ%G:F71YFR++N=U\NU7K!@MNOG9BT_)[_Q(_8>4Z8Z
MH0 "E./T5UXG7L!V;/JO;0A'W]U'HW=V)Z!V 90S=F&D,.Y[%=<)Y=*D?Y6V
M:,X,O]OI03 "]P:UAE 3N- 90'-0/D*:/IE+I!+Y#(#E=6?J6>OC,\*S]DDD
MX;V1A4?@(6))_I5QJK-5RJQ;OG>5'>=M_*8P2.;)G ##(D56A #L\97BM"P^
MX)EJTS\.Y03T60#QHX:ZVFMM&C068-I4S=025]7: ]?;^" <L&#$>7E&3=^\
MT(M<#&;/C QL&CU6<5AQ#-R%>-1K&L+%08H.8XH65!*IMM9]^3C84H>,[,L?
M@_"CZ3>8UQ]RV^,S=$HOBZ*R?N_@0/ "V"?%5 3^T*_&RGA*@!?C(L0 B@=5
MK6J'NM'4GMW8,?(D;#R 8MW\BWSB=98DL=!-22Y)ZQ@: 3R/B%P(BH>*&@=U
MDQ^H89K*RG"*VA\"I%BR"GZJP5]]VKJ-JJ L-,[Y:MQ.V6#5%!MC">.T1:S]
M5!YIZJ1[,229UMEO0,Q/DS/;%CJSL2Y?+!O+O).W$H\W-$8JYI*ODI[=GA[_
M $E1_"B?R='@J@*/?4]OS;O[A$3LT$%]7A57\9- ^118&JSQ7-G+8<BCQ4:<
M,LGB[BPUG+U,F6#"7[S9VLLHLN-8YVWSJV1UTGY'R#@]F#XZ=Q]OW,&J^W'0
M]NP-,^S5IU3<_E[[VJ27HQ,0S#^"1_JC^3_%\R8ZJ/\ 97R3GF*C\1!$F $4
M 7?BZ.Q\8QC"_,N,8QC&,8A]I_=C&/\ C&,?_P"A?_&,><ZX!V'8?P/L.O[_
M )I[(_[',W_C[3_L+QTZ?YI[(_[',W_C[3_L+QTZ?YI[(_[',W_C[3_L+QTZ
M?YI[(_[',W_C[3_L+QTZ?YI[(_[',W_C[3_L+QTZ?YI[(_[',W_C[3_L+QTZ
M?YI[(_[',W_C[3_L+QTZ?YI[(_[',W_C[3_L+QTZ?YI[(_[',W_C[3_L+QTZ
M?YI[(_[',W_C[3_L+QTZ?YI[(_[',W_C[3_L+QTZ?YI[(_[',W_C[3_L+QTZ
M?YI[(_[',W_C[3_L+QTZ?YI[(_[',W_C[3_L+QTZV?H"7VU+ADC7MA2NE'K-
M^Q1#_P"/!,E%-<-56ZV[KTEI)#QU59QE75/\C9JHW3T3_'A33?;.NVKIUR=[
MILV Q/KRO+? 6744GD]-@["KF8T\;NBNX)(D6MDA(,Y]8!JDM-LAK201TE#&
M(]^+,*C570(\05:NOU+)-@_IB:Y=V[0LQ:?(\(>)8>P3.:LN4Q<K&Y!5O9&Q
MQOEL$(K)J0JL[(M%2RP2^/+ OZZ8N63DE/B2NB;<=OXZL2R]RM9?,2\/(>M@
MNB;NC41NN==BK!; Z =]"-+GYS@TO($.(56VP3IZ'%<1P/6-ES8Q>X+1[^MC
M2)YJK"Y&W89P\C[9*385<C6R64D\*;L\6RWT-*WC\GE=UJU4-V./3]'Y^*0"
M;'[JG*S8J"J59)1TNDV5$G9>LK8S)IEWCQ?*2S(Q\?Z]N3AIXRI9>ZSIZ9,[
MMWHF=Z4B*51F>E$AXC,\P^Q8^=ZSK!S)#!.OVYN1:=65X.$6RH)Z,C\Z,S))
MF-.KR$4_:UJ/-#=7A,Q&"*C4TI#M )4>@S?,M7&^J=_I]]:=\V35P!Y',ZK0
M=N/XO?EY36OK^U1R&JT*41Z6?8/76T,U<O>]7(4I8\D8.KUK+G!DN)3EW3:V
M8\7FH&#=AA233DH2<LI5WG:XTLDI [@CX0O.O\9]94Q"%Y(EV*)9$O:J$[Z8
MB\UMB/2+GV.Z;8EA!X%:,("Q-1]BZ%M\.8%DJLJVTPYVVRIBB+IDQSN&T"?&
M?3:\CF]G;YVKC/J">ODX&A( IMX5:\>=1(#I59N_B@\=+G)[6I ^BS;O.&GU
MFHR2O])ZL--(SN?79<_U)3-R7PR EVAY=E5FZP<I@ "5%5)?_DF@& '?/1P6
MOJ<*=/5O)'E.B[5YY U\)))RPC,%&+ID6L<.3D!"/!G;]$$B:T>,]5EG)-%"
M.K-6F/E(-=-6KD.+Y/)GU%6E\2-OJ3A^6X[C**5!=,V/%R$UN@=4KO7*#\;/
M.HLAHBO(<5H[&63!R/TWJOF"#OHI@X_E<W*;$\"1YUMJX]@:%:Z%RM2BJ_97
M]16$OH_#$8A!>EJ4:U^)G%"2-]5XSI&O]M9:*CW-/^/;'8L79^9MAS'+>W<L
M9CL,)$F0J0+#-CFF=B*;1-QZ&N@KNTU!:N([?JL8HGL&A'E4XQN'UEW[LIR4
MAR<^W[NC,=YT11WFJ]8,O[&7+-"LM XSBY[:E?:NB^3F.3OKR,A_$C1AOQI]
MX*AEPC"Q$;U9;"PQ6'Q6U7KKI6EYW.B'._.];0IU*>L8V^+;$X[(YDYNMDU.
M#CD.&HR,E%"@00RE!,0-&2IVQ9MY+H^#:$4'-%4#69CXUE7ZEXK5M*H//3PV
M/B^%AI]4:$9A2W)9-FQLED7)9F+TS=FE%))X>J7;]NL<'U (*X*RGKVZ[5XV
M53G/M2<<E#FG7/1M&+NHCK\E;2=<##N3M4*KK,K:40ERKL;WDM'5=.K(8/CM
M8M["/U(^H(A*YA#"(2&,S$%PX-.@D>01;[MMPD@5@C-[AF@WWSJNJSO-;?&U
MQ^GN&RKR?E5I9]\.?Y&E-.=*D-M=<!SEAV&CT&4KSG*CA+YG++WU:/NR'FN.
MLN,^OW:LJ?3NS/K1IK^$DKR!%*"M7B+&;-HM8SK7='FB?Q2%]BV2VGO6$+DM
M3US!V,GA<B-6D-:QV66A>8F*:6>W'.")W44<;1(K79<TQ:L7)-O'-[.<COP#
MUD$D\^E&LG'.W27QT/):>.XO,Y8NG$Z>2U_4='7V#SHL;;</$RMXJJ0XI8YW
M,VN@\VDK)/@8TI[Z?IF7;R=E)8#E>.PK].HC44@*-.2+\A3/1>]+7&MPU0*-
M7MJAV1M"UI#'>EJ8>$93V>4LQ[&D>BH'L\G?.^U:H1^.P]JN<FK( #0!SQ=2
M7:Q!VZ%#'2[!1\OOL_RST6\[--X9^(G0&@CD^HY[Y @L>0Y#D-C\1N]K_P!P
MQ8'2*E"7RG2U82:TB&].M)M;;6)$FIEX&<*%"RLF*45Y7$8]O!/G52='T=O*
MHR+GHWHTT98^2&$QPHHX0Z%I*9D3=-<JU[)E"W4]>.IP7:5Q9%ER*PPS>3KD
M8N"/%A,<E()F-<S06I$Y3^F<M#;$MI^=LYMJC-9_(K63<CFTV<#Q?0<_TN_'
M+K*%5B'?F1+1=F@&21KIR9Y:%@DZBR-+-XDH\8_4"(CKXSC/E.:XK5'.JP</
M,)QN?5.$XZ"LJI#/?36#4H]2-ZWER<,%/,])4<G;6>?G-5NY@ITQ5[XXT:1W
MIU_9+:%KR) Z&W58SJFG2<%:DA@]%H)5TV&%=1PQ3*^ET6]3K2@]@I;Z)U\E
M%!YC>.#XSD^.Y?(PLRK1JZM&'D9O=EGK3,T[T6K,'=U]EC%SG$W^IY\6SJK'
M!^JIP]\&M9R03':F?D\M$533*^D:\ZL%DB2"TH:8EU.;Q#%]5#,Q9JO.DXJ$
MJB3=:UD-;5?++)?@W%<2M0D),-@SL*!$CY ';Q1B_EN(>E(_1H@H3%+/%65)
MFWR%+L*]\G#K+42>^2F+Z@T<EODR>*'0VKC*8\$V]05UX],VFK2H^JMV30D;
M1N5]<Y[Z7T95E,+KF_"QPQ*,OE\89>0GHUL5=GT/N?:)RT9H95[IQKIWFD9'
M  UWT11NKH>%%,7.NEKP;?35PT8H-UL:;X.?=OKA1/;&NV/^-L?=G'_&?-6E
MUIHT40]TI:KJ2.Q*N[,I(/W'V(^W^.O(X^+Y\&+/4 4ADS1H >X#RBB. 1]B
M RGL1_(^_6:]JOF+WB:/^*D'_P!YY3UKZ>U7S%[Q-'_%2#_[SQTZ>U7S%[Q-
M'_%2#_[SQTZ>U7S%[Q-'_%2#_P"\\=.GM5\Q>\31_P 5(/\ [SQTZ>U7S%[Q
M-'_%2#_[SQTZ>U7S%[Q-'_%2#_[SQTZ>U7S%[Q-'_%2#_P"\\=.GM5\Q>\31
M_P 5(/\ [SQTZ>U7S%[Q-'_%2#_[SQTZ>U7S%[Q-'_%2#_[SQTZ>U7S%[Q-'
M_%2#_P"\\=.GM5\Q>\31_P 5(/\ [SQTZ>U7S%[Q-'_%2#_[SQTZ>U7S%[Q-
M'_%2#_[SQTZ>U7S%[Q-'_%2#_P"\\=.GM5\Q>\31_P 5(/\ [SQTZ>U7S%[Q
M-'_%2#_[SQTZ>U7S%[Q-'_%2#_[SQTZ>U7S%[Q-'_%2#_P"\\=.GM5\Q>\31
M_P 5(/\ [SQTZ>U7S%[Q-'_%2#_[SQTZ>U7S%[Q-'_%2#_[SQTZ>U7S%[Q-'
M_%2#_P"\\=.GM5\Q>\31_P 5(/\ [SQTZ>U7S%[Q-'_%2#_[SQTZ>U7S%[Q-
M'_%2#_[SQTZ>U7S%[Q-'_%2#_P"\\=.GM5\Q>\31_P 5(/\ [SQTZ>U7S%[Q
M-'_%2#_[SQTZ>U7S%[Q-'_%2#_[SQTZ>U7S%[Q-'_%2#_P"\\=.GM5\Q>\31
M_P 5(/\ [SQTZ>U7S%[Q-'_%2#_[SQTZ>U7S%[Q-'_%2#_[SQTZ>U7S%[Q-'
M_%2#_P"\\=.GM5\Q>\31_P 5(/\ [SQTZ>U7S%[Q-'_%2#_[SQTZ>U7S%[Q-
M'_%2#_[SQTZ>U7S%[Q-'_%2#_P"\\=.GM5\Q>\31_P 5(/\ [SQTZ>U7S%[Q
M-'_%2#_[SQTZ>U7S%[Q-'_%2#_[SQTZ>U7S%[Q-'_%2#_P"\\=.GM5\Q>\31
M_P 5(/\ [SQTZ>U7S%[Q-'_%2#_[SQTZ>U7S%[Q-'_%2#_[SQTZ>U7S%[Q-'
M_%2#_P"\\=.GM5\Q>\31_P 5(/\ [SQTZ>U7S%[Q-'_%2#_[SQTZ>U7S%[Q-
M'_%2#_[SQTZ>U7S%[Q-'_%2#_P"\\=.GM5\Q>\31_P 5(/\ [SQTZ>U7S%[Q
M-'_%2#_[SQTZ>U7S%[Q-'_%2#_[SQTZ>U7S%[Q-'_%2#_P"\\=.GM5\Q>\31
M_P 5(/\ [SQTZ>U7S%[Q-'_%2#_[SQTZ>U7S%[Q-'_%2#_[SQTZ>U7S%[Q-'
M_%2#_P"\\=.GM5\Q>\31_P 5(/\ [SQTZW:Y1LVN++"R]W74^AL\:BB@QL3<
MPZ3!I*@.<.&CA5N@]6#/7B;59=-/=1)-?;3=333;;3&==<YPZ=;9>.G3QTZU
M=ZS+3]C7D>%5G,&L1E<JL6(QY+1&41>&2^4"UW#EZ8BU;R.;!9'%&$Y(,&*K
MD<F:!D$7XYB5'-?T1!VT),J6\SIR3 HZ'YE*P@9C3588-5)&8I^+2CJ&>VQ5
M*/\ $2S*X"LKZ)!!#91E'><9>NU%=\\'ILS29K>LAE-8-;-E<]YINME:@::L
M#I""[YDM4MX16!>"7#<LY4D,Y;3C,OC+YM.Z]#Q:9PR-OXZ>,49!K3JZ926/
M;SP<JG,R9FHZ_/!V>5'IX(?_ !BU[Y537JSPEZC'U9)UUH*1#5T\OR/#39\^
MCM.3PIQMOU'^M/E1!;!'0-<L\XTS-GS:;U9U>;OZX$>_S]?$RY5F2LE%6CI6
MJ'$!D+S6PEJ]7QZ5:8,N]9Z^+C%L4P*:F)FX<QFMXX[NU1*)%-E+X5IT2>G)
M76EU",,?/7;$D5<:"$ILBT'8'"6[4D6([*,L^:E+K@"J@OR6/@MID]?VLJ<G
MP_/\VTTL)>=:SR<24*^KMIT4A.9@LW>MM\ZQ^82S>G!;E(M03'OO3#HXK)_H
M^TJ(O7D9,K^T/&0TUJC*J@2^)?:#:29LSRK53<>15E=6PUTQTL9FX1R6G[ZQ
MQ19841=188V(BP)*N"&!1%Q@8C(ASU,@ZQ',-5T,\^2CYYZ8JU%LVCU3<I&I
M27T=F^KI&@9S.;V6YPD>QI)ZVUK:L_VAU\;RK6-6 :",U&FKT0,OU&/I]E7\
M5<]BRZNQFM.[+F,PQ%>KSY3Z3*=%@9:ZDL%95I*X@5#LRT,3-3,P1'-#X-L=
M$.">\VJRJ7"FSILNIAJ4C(Z4P8VDCE]%)O(V&<N--853%:!^[BU,]D\'3U6G
M#+H:92PGI1Q/7)C/5FS6"LC^HI1&..@:>AHD H9^Z-0RL+1.G5F6J-,TSNC/
ME?L^?3H0.'BS+63J-KO(=.GCIT\=.GCIT\=.GCIT\=.GCIT\=.GCIT\=.GCI
MT\=.N.,ZZ=NV 69T$+,SASF%$NT^=J?J!YJ+ :;0U-ZOS2ZGM8[[?H,N":-B
M1B>3,V&?O4W9!FN.DC)$BT6VCJ6*,-.\>'.@FE-&SZLU4/8*=6'B]?U3E&-?
M%@/9QZ\7Q]T"JE+QK9V-%RW;K;M@DQN>)"B7T_F?P([#-NOB31#=[68AIZ:-
M6%$<*D+2S^(H-A$+%&?:%6!('D2!Q_G^)/)'9VT#-5HU=WJ\;"%X-88^Z'H4
MM815G3A-W"92PVI@EH:B0</-VJ*9='87)B[D:09Z4OJ=(NYFAKFQTV[5%2T)
MS3AH\RBY=(F?EO6;TS >J(G8XZT*X]B:4[3$49S["9'9;#$F?A9[9>=P\)J>
MT6<>B*-R$-,F%*TJD]<#*>C.9M(Z;^T)6N*TZJ@ ZCI4."6%$H&5.2_7,[*L
M(9)YW3J]RLQ*YEM5"-7OX^S$I)@-B;VU ,X>G'*2S2L=P6%3"?HS04U<C!6*
MSQ7WPC:@$SH/'C"U/9-V'K>R[1Z4SOM ,P+/'W1+Y=$VS0B]"K782-XR\J)-
M;<CKXL&557R?PT8ZT=M$<<SG_*3UNE,R=)O*^J^GCIT\=.GCIT\=.GCIT\=.
MGCIT\=.GCIT\=.GCIUIIV+,+>BR?/;2F#V1$DD]],!A(7LS%NVTX  ZSLR<O
M*_?*E$5,#&DO=Q)B'W,LE6C\3NXT?(.,ZHJ(+TBCIOSGQ-H2Q\EIT90I8Z9Q
ME)&6?@5HNB4[TMC96*#9/.;RT0%,]="RG3%M+4&>GLXN4=1!9<KZ>5R9S5Y^
M2BLO&A2\RR%HM0)2-"M4U1B7VADA;Z3,FQB[*S8\VGUJ29^^-S1O!2<*JV)3
M.M()F+QL.R@Y_P!<9T!/SA9L]C!E_%E&BXUX/)R-$FNQ9J=RN*-EDQ#RH<'?
M;)A7Y*?4/U+SO&\'HS1'BM\;8^.E:FA*KVSOE>::*:.K-.9E%Z(OJK.= <=.
MX]%N+^G</)\K'30>;0N-%:2FC38/;Y'WG+*_:0/?M))4&$R0J<Y[11PH\395
MFTCL^FD\)2K=7H(KSZFK+0,)HPY*HOHH7'H2-)K"H]:Y104\RTP/P00_*6SY
M]37S<70R"Z>3S\'J$59Z2A+FN%Y/G%5]"1+M7/GXJ\B/CK*MZYQ[I*]#+M,1
MG?8I?^GQORTVKV5;.W%VX^!*P>BS\+OR,BI^27FDK,9MV0/T$H^RW%Q51"++
M=Q0M!WDL$8?O(F<2((DP3Q)TX9.F3A,N(CY?&FKAJHHVR6 @RFS7='8@&%O,
MK,4/1H@0S\6#+2&:X^\R5&G/.XFYE2TO9,4]=/76L_-6\*.O9CA![M52/]*^
MB'?QHH?T7I'V*M9RH$IX>:><T;Q8=QU:OE?7>GCIT\=.GCIT\=.GCIT\=.GC
MIT\=.GCIT\=.L>765;BB;A'?*:R ]ZLEOC&,YT52;*[I[XQMC.N<Z[:XSC&<
M9QG[O^<9Q_QY@Y2U,_&<C>+%*QP;+2< $I2>>CHP# J2K*#V((/;[@CK3C1:
M:\LW'DE-,$=3W[,KU56![=C]P2/L0?\ ;KB!7/=%S5W#.<M;=+;V!.7W,QJT
M3(]94!$FEQ-YJ0H@56$Y(E601ZWBC4))9U*HE+%1HW.@Q80],*@7;4C'DW/J
MZ ?U';CA.?MSWXGB?56IBD]6KD#EGR#L%LXCR&1&M(A72NR.W'$+7-19O1,9
MZ6-G,_G\CH2JQ+4&+%@YC3HXY9^T+6^2V7."_DA.:N/30HMW0;&:_:#3_61J
M1Y?G^,__ -0D8*-VR3:7:]=,0#LOT.[YZ5WKW.:?06L+5N62;R5'!I.N]51W
MI(6]4%F!Z39]DA9+^FH\URW,)S=E_J6O>?+'Q&<-Z_1*O$51KG2&K'3DTYHW
M5Z)*.G-;.U9?MO>.?;L<!BL1GQX.%Y,#VE?8-%LG-(!(P"2TY;QI8*4JUT\H
M=@N^GCL['[5-)8 $CK <=BLB+LY^@SE0,E));&]-%59K5]>"MCC1>*;O'J<
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M/NG'['U3K_J)+N!^VK!?L/M]AU#N?52'?]FS!ZQ_]JK@%0])_P!CL 2 S D
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MU_K>\=.GJGVC^_W+_P H=K_6]XZ=/5/M']_N7_E#M?ZWO'3IZI]H_O\ <O\
MRAVO];WCIT]4^T?W^Y?^4.U_K>\=.GJGVC^_W+_RAVO];WCIT]4^T?W^Y?\
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M%&8 ,R37LBDA5!*J"0H!^P'779JT-J$TL429JY+T*3'C-"[=V*(  BD]E [
M =3KU3[1_?[E_P"4.U_K>\[USIZI]H_O]R_\H=K_ %O>.G3U3[1_?[E_Y0[7
M^M[QTZ>J?:/[_<O_ "AVO];WCIT]4^T?W^Y?^4.U_K>\=.GJGVC^_P!R_P#*
M':_UO>.G3U3[1_?[E_Y0[7^M[QTZ>J?:/[_<O_*':_UO>.G3U3[1_?[E_P"4
M.U_K>\=.GJGVC^_W+_RAVO\ 6]XZ=/5/M']_N7_E#M?ZWO'3IZI]H_O]R_\
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M?;&,YQIK]^V<8SG&/^,^/\]O\GOV'^3V'<_]A]S_ +#[]/\ ]_W( _[D@?\
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M.$,J(G?:<KKBNY='!HZ&6]>$9B 1_$9 %.)A:VM-J]@,TDA*STL#$)&N#BH
MK7,S&R .+<G5-" I!BU)--BS?5E#9L)F]LD%0]]3.K-1H0AGXK)R2:IT/D]L
MVQ]V?/A!<L_F6:]/35C?EP>5XSO1S)[YH]PH6[4MS3\9?&P"B:[L.>;:]:A4
M5?VU,H?(BO7[,N\9&+UC*<PJ =EKZIQEE.9#';!_4:#KD/T$<O\ TBL:C9"(
MM'IB!;1J/NAVT\>E!11H;?,FN(2^&($#;6[=ICE;EF"5,L-.:3(#X&FH\#".
MGD%J00N8";V7-1O/Y+9CYSS'1F2E&');6O'=WDK:EX>NDCR[9\W.<LO"X+2'
M8^^AUTSOJSAYC/&_>=]+0LJ5O(OM1"$.;"1$GYOD>ME&!K"?LH)$9:6L71Y3
MQ&&#)NU.L#,'K,V[6LQ1F2]"XKA['AT;Q(&VZ>]IZ 78N0O[1]]5,O9BV+?I
MXOEF1?)<F[/^COVS=RHV9GASN+0;T..BI+<ASFT<T]D)Q+Q2YI-$V9LNKC"Y
M91HEKMR\(G42H.(E^#W>05=7BM<+'[5VGCY&:^T)*;FC(AU4IV*1CUTDL4A\
MS%3T ZDL@?5KT34])3#!>)2"NR Z+A7ZEI!R#%;)$V9>M&DD%_D1=\V#2)U'
M,3:F9*^,J6?'19JZ6DV74>7AYVJI0!ET<52DT@S)7)?+H.J5#?',\BL]-4!:
M,<U26HCRN-!X.'.15(??L/C6I%GJWE'9!I/DK)A3KR:?:4&GIJY8V#H!0^7K
MA**%XTZ"3V1GXW(8E)Y_+('O(I,:C%/'G A(,K$ERA'-6B;R#Z($&;7)[1RV
M,8&4SOY\?+<R&9-\\]*,?VH1U\5HY7/5+=O)RZYGS!K1RXVM2%9[:9*_)2U\
MI38<P<,KSW?'< ^RM^.VX<FN#R)\9LB\A'0$G6^H)+1"F6>R:9J]%:QGK&SJ
MWA5CC4FR#"9Q<3)F[=D7'GFJ"91BD[RW;FA>Z@\FFCMOLEH\;9U37QI^/*2.
M^=DM-FQ!E>ZAC18AF5BO@74+YJ>W=P/)>Q_%G7[]U=U[,<$':J*S*$<EE= 2
MW@Z.4=>[)-^ZLI!#SG12"M)HX91SWCWVB<R)N@SPQSBF&B!053TQ5/MKB'EB
M3. W99)VH(F5S'L0-A^HDZ$Y![N2T7T+:#VT*=(G4I4XD6BL+U\QN0C/"-E
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M3<A/V$RS/9N<GOS9'7O33GFLN$J:S;32;Z*#Y!G[%GL]0]I=&F.IY-"+#5L
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MNH,?J-EF2SD>Z3V2=LU'+)PNR=_IUT]7;195JYU50WV3S SFU$JR*:36B*Y
M)$Z^/MF?^:5?!#2;=T<SFS*2B$3#N$:88A'9'9>_V+R+&=!_M2?DWA1>SJ'<
M*P#L#5SKG&N&5A(6<9%AW,<@U,&*@@T $PM!,5%8.;W9.YFST9BM7KN2Y,-
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M+]Q*C$AM<449"&0&:$=F)4 %(A%(4T;!-.9JAX-=$5%^H.-S4R(/',</(_\
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MBOOIGSR:;-IC-:#[0U[T/]H/FF!3N.I6"_/I6D8 '[)D]7GP[EPVTKMF5C:
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M3#C4_L$XA&XA'447!DTX;OG:+))PZ09(;;-AK5Z^6RJ[<H(::-VJRF=U=?\
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MZODIK!C9EX3%QAK-YX"4!#H^(FLW830U$@#:/N2.##E(B,AZJ;PDU3V9C79
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M:%>.;;4'S1HBG$_JT1V( =_CO$GQ+*MJ*CJR"C+,:;[&BUP7Q8M!-(UL(D<
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MV?@W B6$'[DJI&5QFIX>YR-?:8123VQ/U]K5N/W.[Y]48/V$9<AEXM^*CK!
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M8OE?4^GCIT\=.GCIUK]*3/5#>0%$837'/Q>*IN<ZA24INJQH[(';3\&F<*E
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M\.[']N!SJ!]@9'-3%V<#L*.N2M,TZT#5E!VE-T0]NLG7%"W)4DO,SRO^<N8
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"_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>35
<FILENAME>g164680g01m08.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g164680g01m08.jpg
M_]C_X  02D9)1@ ! 0(!>0%Y  #_[1:84&AO=&]S:&]P(#,N,  X0DE-! 0
M    %GR^5U8X0DE-! 0       \< 5H  QLE1QP"   "    .$))300E
M   0S<_Z?:C'O@D%<':NKP7#3CA"24T$.@      Y0   !     !       +
M<')I;G1/=71P=70    %     %!S=%-B;V]L 0    !);G1E96YU;0    !)
M;G1E     $-L<FT    /<')I;G13:7AT965N0FET8F]O;      +<')I;G1E
M<DYA;65415A4     0      #W!R:6YT4')O;V93971U<$]B:F,    , %
M<@!O &\ 9@ @ %, 90!T '4 <       "G!R;V]F4V5T=7     !     $)L
M=&YE;G5M    #&)U:6QT:6Y0<F]O9@    EP<F]O9D--64L .$))300[
M  (M    $     $      !)P<FEN=$]U='!U=$]P=&EO;G,    7     $-P
M=&YB;V]L      !#;&)R8F]O;       4F=S36)O;VP      $-R;D-B;V]L
M      !#;G1#8F]O;       3&)L<V)O;VP      $YG='9B;V]L      !%
M;6Q$8F]O;       26YT<F)O;VP      $)C:V=/8FIC     0       %)'
M0D,    #     %)D("!D;W5B0&_@            1W)N(&1O=6) ;^
M      !";" @9&]U8D!OX            $)R9%15;G1&(U)L=
M     $)L9"!5;G1&(U)L=                %)S;'15;G1&(U!X;$!7P
M        "G9E8W1O<D1A=&%B;V]L 0    !09U!S96YU;0    !09U!S
M %!G4$,     3&5F=%5N=$8C4FQT                5&]P(%5N=$8C4FQT
M                4V-L(%5N=$8C4')C0%D            08W)O<%=H96Y0
M<FEN=&EN9V)O;VP     #F-R;W!296-T0F]T=&]M;&]N9P         ,8W)O
M<%)E8W1,969T;&]N9P         -8W)O<%)E8W12:6=H=&QO;F<
M"V-R;W!296-T5&]P;&]N9P      .$))30/M       0 [_^-0 "  $#O_XU
M  (  3A"24T$)@      #@             _@   .$))300-       $
M>#A"24T$&0      !    !XX0DE- _,       D           $ .$))32<0
M       *  $          3A"24T#]0      2  O9F8  0!L9F8 !@
M 0 O9F8  0"AF9H !@       0 R     0!:    !@       0 U     0 M
M    !@       3A"24T#^       <   ____________________________
M_P/H     /____________________________\#Z     #_____________
M________________ ^@     _____________________________P/H   X
M0DE-! @      !     !   "0    D      .$))300>       $     #A"
M24T$&@     #-0    8              3(   (V          $
M                 0             "-@   3(
M 0                         0     0       &YU;&P    "    !F)O
M=6YD<T]B:F,    !        4F-T,0    0     5&]P(&QO;F<
M $QE9G1L;VYG          !"=&]M;&]N9P   3(     4F=H=&QO;F<   (V
M    !G-L:6-E<U9L3',    !3V)J8P    $       5S;&EC90   !(    '
M<VQI8V5)1&QO;F<         !V=R;W5P241L;VYG          9O<FEG:6YE
M;G5M    #$53;&EC94]R:6=I;@    UA=71O1V5N97)A=&5D     %1Y<&5E
M;G5M    "D53;&EC951Y<&4     26UG(     9B;W5N9'-/8FIC     0
M     %)C=#$    $     %1O<"!L;VYG          !,969T;&]N9P
M    0G1O;6QO;F<   $R     %)G:'1L;VYG   "-@    -U<FQ415A4
M 0       &YU;&Q415A4     0       $US9V5415A4     0      !F%L
M=%1A9U1%6%0    !       .8V5L;%1E>'1)<TA434QB;V]L 0    AC96QL
M5&5X=%1%6%0    !       ):&]R>D%L:6=N96YU;0    ]%4VQI8V5(;W)Z
M06QI9VX    '9&5F875L=     EV97)T06QI9VYE;G5M    #T53;&EC959E
M<G1!;&EG;@    =D969A=6QT    "V)G0V]L;W)4>7!E96YU;0   !%%4VQI
M8V5"1T-O;&]R5'EP90    !.;VYE    "71O<$]U='-E=&QO;F<
M"FQE9G1/=71S971L;VYG          QB;W1T;VU/=71S971L;VYG
M  MR:6=H=$]U='-E=&QO;F<      #A"24T$*       #     (_\
M #A"24T$$0       0$ .$))3004       $    !CA"24T$#      ,90
M  $   "@    5P   >   *,@   ,20 8  '_V/_M  Q!9&]B95]#30 "_^X
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M)3<2
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
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M(" @(" @(" @(" @(" @(" @(" @( H\/WAP86-K970@96YD/2)W(C\^_]L
M0P ! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$!_]L 0P$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M_\  $0@!-0(\ P$1  (1 0,1 ?_$ !X  0  !@,!               #! 4'
M" D! @8*_\0 7A   0,$ 0,!!@ '"0L(!@@' 0(#!  %!A$'"!(A,0D3%")!
M4147&3)A<=465UB!D966L=0*&",U-T)2=':SM3-#<I*AP='P)"8V4V)X&B4T
M58*7HK1$1W>%LM+Q_\0 ' $!  (# 0$!              $$ @,%!@<(_\0
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M * 4 H!0"@% * 4 H!0"@% * 4 H!0"@% * 4 H!0"@% * 4 H!0"@% * 4
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M * 4 H!0"@% * 4 H!0"@% * 4 H!0"@% * 4 H!0"@% * 4 H!0"@% * 4
MH!0"@% * 4 H!0"@% * 4 H!0"@% 0'B1VCZ$I!_4HZ- :\_9YM-L6OJ.;:3
MVH_OC>0%ZV5?,J4G9VHD_P 7I0&Q.@% * 4 H!0"@% * 4 H!0"@% * 4 H!
M0"@% * 4 H!0"@% * 4 H!0"@% * 4 H!0"@% * 4 H!0"@% * 4 H!0"@%
M* 4 H!0"@% * 4 H!0"@% * 4 H!0"@% * 4!#<2"1OZ;/\ &GR/^V@->'L]
ME]T'J2 ((1U&YZ/'TW(0=?R[J%NMUCP!L->6M VD!1T=)\A1/T[5'Y0?^EO=
M2"47)=2&B4E'<LI<"E-GL!_S]ZTK7^BGSYV: BQW7'%J"EH4$@A26^PA"@H
M!>BI0<*05:)2 "?E&@: G* 4 H!0"@% * 4 H!0"@% * 4 H!0"@% * 4 H!
M0"@% * 4 H!0"@% * 4 H!0"@% * 4 H!0"@% * 4 H!0"@% * 4 H!0"@%
M* 4 H!0"@% * 4 H!0"@% * AN> #^G7_6\;_BH#7-[.X'X/J:\DZZDL^2-_
M9+[8'G]5 ;#YK@;"-A(V2>Y8VGQ_F@CR%G?RG8\_7UH/7KO/D.]M'[5"X]%W
M5+QOQA@5WZC/>KN5LR/E-+/(>;8SA=QQ.8X$JLF%(AW"-%DW%2.Y3S\0E$9P
M-M+3M6B'Z'TZ]*7)V-\S< <6<HXE^[1./YKAMIOUL:Y#5.<S)J-/:]ZE%]D7
M$KES)(.TMS75K,J.EI]!"'0D!Z]=AD50"@% * 4 H!0"@% * 4 H!0"@% *
M4 H!0"@% * 4!Y/+KKDUML<^9A^/P<HOD<#X.T3+TBR1I"OJEZXJB31' \[)
M87KZCQY QDX)ZA>8>7<BR6WWW@ZS838,2RJ[8C>;V.38U^EFY6E#/O5PK0UC
M4!<B(MY:THD_%)2M'8H(!!V]>N[\1Z]?@C,5!4I"2KM"B-D).T_Q$T!VH!0"
M@% * 4 H!0"@% * 4 H!0"@% * 4 H!0"@% * 4 H!0"@% * 4 H!0"@% *
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M:5!/W4"3Z4!T<D%""L!*TIV5DK".Q._SB"%$C_R* \[<<VQ6SMEV\9-C=H0
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M,XS(;<,I9*%J9>*F@-I!U0?K^'/US_$I_4;[.'VYU]YNR:W<!]:>36W@Q,M
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M,U(\   EGP /Z]T!LAH!0"@% * 4 H!0"@% * 4 H!0"@% * 4 H!0"@% *
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M ;#Z 4 H!0"@% * 4 H!0"@% * 4 H!0"@% * 4 H!0"@% * 4 H!0"@% *
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MT#]/\''H#8U0"@% * 4 H!0"@% * 4 H!0"@% * 4 H!0"@% * 4 H!0"@%
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M_P#A.]?;S^OQ]C0&NGH#V,@ZMTD>1U'99_\ J:C&@-CE * 4 H!0"@% * 4
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MLN-G>>;4Q&!*[==XT&Z1B"-=DR#'7]0DB@-G5 * 4 H!0"@% * 4 H!0"@%
M* 4 H!0"@% * 4 H!0"@% * 4 H!0"@% * 4 H!0"@% * 4 H!0"@% * 4 H
M!0"@% * 4 H!0"@% * 4 H!0"@% * 4 H!0&F3VTM_Y'F=.<CBSB[-8>'WW/
M(%]?O+5ZX:R+EJP7_%K!;EW.[VJ8+);+BQ8I*T-(7%=G,O":>Z*RVIU200,<
MO9;W/(^:.1<A@<Q<IVGDW&./<.QJ;Q[Q+:^D+(>G?C[!\DMM]9>BY];V\KA(
MAW',6%OIA0YEM4):(+ZW"%H+?:'PS_/GZ_,^AR&@)#Q"$H"W>[N"5)4X>Q(*
ME=VB2""E)(![0!K0!($=QKO.^XC2%)3KP4E6OF"AI8)T =*'@#7GS0%C\_X"
MQ+D;D;B/DV^2KDW?N&YF13<9:B/-_!2'<FM\2W7%-Q:D-/J?0&8;19[%M*0L
MJ45*WX#UZ9>9Z(VM*TK^=)!)2H I4V= LJ3H!37_ ,!&OJ=T!KTZ!DH:R3JW
MCLLL,,L=1&3)0AEM+:1N-&/A*0 $CZ#5._P^2?Z@V*//!KM':5E6]!*D C7U
M(6I/RCZD;U]J UR]8OM0NF[HGS3B_ >5KE(>R7DV_P 6U-P;1(CON8U:9#P8
M7DM\2$N+:MK2U)"$!*7'_/8I/;Y#U[S8)C>1V?+++;,CQ^=%NECO4&+=+/=(
M3R)$.XVV:RB1%F1G4?G-.M+2KR 4D]B@%A20!7* 4 H!0"@% * 4 H!0"@%
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M0"@% * 4 H!0"@% * 4 H!0"@% * 4 H!0"@% * 4 H!0"@% * 4 H!0"@%
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M% 0G@"-?57@'[:\^E :]NA9M#>8=7B$#6NH?("H_0J,.*20-#7K0&PZ@% *
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MSI5CQ3&)KMS3B-_ML_-(<^[R9*I,BX_&7;)F9#;S*%*;@%U<QJ%[Q13'"T)
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M!T9N$&0M;<>7'?<;_/0PZAU:0#HJ4EM2E!(/@J(UL$;V* F4.(65A)V4*[5
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MO=BDK?L%WO5AM5ZN%C7W-NA^U3KDTJ7;7RZTDH=A+;<;<#:PK2/E UO>T?\
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M$FQ9)=>J?A#@^]YM-Y&N&:8M;[*A6<6K!8LE#3;%NQV_WS'K#)AJB%E!0F)
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M$'[Z4"1^L;V#^@^: X]^SLI]XGN2 5 G1 /H2/I_W?6@(OKZ4 H!0"@% /\
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M_:[DVE:%=TFQ-38J@ LO@*22(\URY\UX/UMR,P%.H0"I:NQ(]5+"DI ^ZE*
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M]U9<N7S@BQVCD*TVKD2[)G3[9G& P([?Q,2*IE2%WW);9\2A8&PY%]\@:T5
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M!//=*73[)RJ7G4CB##7<KGJN+\V\JMB1-E/7F!*M=X<<'?[DNW.VR78DW_!
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M&][2$^21H'1\:WO[$"2C(2AT*64!?;KY?*M'R25*VH(4?/:#K?G1- 5(*2H
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M 4 H!0"@% * 4!PKT/ZC_50%IN:/\EV>?[(WC_ALJJMWRG_EU?\ ;([G1?\
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MN&65S6'DY2ZVK\U:3YUX._/VK'BCEK*RN:SOY$.,ESBUV[IK;O.5.(3LJ4
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M&"B]WB?:79G=.M[O'!\+B6Z9 U<;Q;Y,"?'OMRM:5VY#]ONHNK#"F&&6%OL
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MLP$0'/GCDL.%E1*D*2?F >O6#+%"4H0E"4I2E"4I2E( 2E*0 $I "0$@#0
M  T !XH#M0"@% * 4 H!0"@% * 4 H!0"@% * 4 H!0"@% * 4 H!0"@% *
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)"[EY(4)% ?_9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>36
<FILENAME>g164680g01m09.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g164680g01m09.jpg
M_]C_X  02D9)1@ ! 0(!>0%Y  #_[19T4&AO=&]S:&]P(#,N,  X0DE-! 0
M    %EB^5R X0DE-! 0       \< 5H  QLE1QP"   "    .$))300E
M   0S<_Z?:C'O@D%<':NKP7#3CA"24T$.@      Y0   !     !       +
M<')I;G1/=71P=70    %     %!S=%-B;V]L 0    !);G1E96YU;0    !)
M;G1E     $-L<FT    /<')I;G13:7AT965N0FET8F]O;      +<')I;G1E
M<DYA;65415A4     0      #W!R:6YT4')O;V93971U<$]B:F,    , %
M<@!O &\ 9@ @ %, 90!T '4 <       "G!R;V]F4V5T=7     !     $)L
M=&YE;G5M    #&)U:6QT:6Y0<F]O9@    EP<F]O9D--64L .$))300[
M  (M    $     $      !)P<FEN=$]U='!U=$]P=&EO;G,    7     $-P
M=&YB;V]L      !#;&)R8F]O;       4F=S36)O;VP      $-R;D-B;V]L
M      !#;G1#8F]O;       3&)L<V)O;VP      $YG='9B;V]L      !%
M;6Q$8F]O;       26YT<F)O;VP      $)C:V=/8FIC     0       %)'
M0D,    #     %)D("!D;W5B0&_@            1W)N(&1O=6) ;^
M      !";" @9&]U8D!OX            $)R9%15;G1&(U)L=
M     $)L9"!5;G1&(U)L=                %)S;'15;G1&(U!X;$!7P
M        "G9E8W1O<D1A=&%B;V]L 0    !09U!S96YU;0    !09U!S
M %!G4$,     3&5F=%5N=$8C4FQT                5&]P(%5N=$8C4FQT
M                4V-L(%5N=$8C4')C0%D            08W)O<%=H96Y0
M<FEN=&EN9V)O;VP     #F-R;W!296-T0F]T=&]M;&]N9P         ,8W)O
M<%)E8W1,969T;&]N9P         -8W)O<%)E8W12:6=H=&QO;F<
M"V-R;W!296-T5&]P;&]N9P      .$))30/M       0 [_^-0 "  $#O_XU
M  (  3A"24T$)@      #@             _@   .$))300-       $
M>#A"24T$&0      !    !XX0DE- _,       D           $ .$))32<0
M       *  $          3A"24T#]0      2  O9F8  0!L9F8 !@
M 0 O9F8  0"AF9H !@       0 R     0!:    !@       0 U     0 M
M    !@       3A"24T#^       <   ____________________________
M_P/H     /____________________________\#Z     #_____________
M________________ ^@     _____________________________P/H   X
M0DE-! @      !     !   "0    D      .$))300>       $     #A"
M24T$&@     #-0    8              2$   '%          $
M                 0             !Q0   2$
M 0                         0     0       &YU;&P    "    !F)O
M=6YD<T]B:F,    !        4F-T,0    0     5&]P(&QO;F<
M $QE9G1L;VYG          !"=&]M;&]N9P   2$     4F=H=&QO;F<   '%
M    !G-L:6-E<U9L3',    !3V)J8P    $       5S;&EC90   !(    '
M<VQI8V5)1&QO;F<         !V=R;W5P241L;VYG          9O<FEG:6YE
M;G5M    #$53;&EC94]R:6=I;@    UA=71O1V5N97)A=&5D     %1Y<&5E
M;G5M    "D53;&EC951Y<&4     26UG(     9B;W5N9'-/8FIC     0
M     %)C=#$    $     %1O<"!L;VYG          !,969T;&]N9P
M    0G1O;6QO;F<   $A     %)G:'1L;VYG   !Q0    -U<FQ415A4
M 0       &YU;&Q415A4     0       $US9V5415A4     0      !F%L
M=%1A9U1%6%0    !       .8V5L;%1E>'1)<TA434QB;V]L 0    AC96QL
M5&5X=%1%6%0    !       ):&]R>D%L:6=N96YU;0    ]%4VQI8V5(;W)Z
M06QI9VX    '9&5F875L=     EV97)T06QI9VYE;G5M    #T53;&EC959E
M<G1!;&EG;@    =D969A=6QT    "V)G0V]L;W)4>7!E96YU;0   !%%4VQI
M8V5"1T-O;&]R5'EP90    !.;VYE    "71O<$]U='-E=&QO;F<
M"FQE9G1/=71S971L;VYG          QB;W1T;VU/=71S971L;VYG
M  MR:6=H=$]U='-E=&QO;F<      #A"24T$*       #     (_\
M #A"24T$$0       0$ .$))3004       $    !CA"24T$#      ,00
M  $   "@    9@   >   +]    ,)0 8  '_V/_M  Q!9&]B95]#30 "_^X
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MN^MGT:FV>_U/3_P7Y]_]KU?]Q\K_ -A[/_()*;Z2
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
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M 0$! 0$!_\  $0@!) '* P$1  (1 0,1 ?_$ !X  0  !P$! 0
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M * 4 H!0"@% * 4 H!0"@% * 4 H!0"@% * 4 H!0"@% * 4 H!0"@% * 4
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M>W<>79UN1Z0_09QED1XLKI=U*DMQ1RX--O7_ !=3:% [(4XAM00M3:0WRY!
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M0"@% * 4 H!0"@% * 4 H!0"@% * 4 H!0"@% * ^3?A_P 378^_X-G#?_\
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M@% * 4 H!0"@% * 4 H!0"@% * 4 H!0"@% * 4 H!0"@% * 4 H!0"@% *
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M2I2G'<=M[CBU*42I2EK4I2E$DE2B3YU#1D:@% * 4 H!0"@% * 4 H!0"@%
M* 4 H!0"@% ?&O8WMMT![CX.EC;W;&.X"/[P2#7.:V^'_P OA&X[%17<JVX+
M;GR./?3BU$^(GT^(?2PEEC5F*I!>C17VV"C4&]E"DIE3K>D.))W:<2\XZA2M
MD,N'9-<S>K%4LK6ZW[EGP,LZ4V3J(U%Z-]1L>:S*]XSK-=-2-1[?C64Y*_*@
M2K1;(>;+<M+HE.L)6W$184"/"46U-+:4E#;BP>5=89>?P<I))O93]?KUWG3"
MS-.LVN S)<\>0Q$CL/NJ'=QYAE#+J]SW(<<0IP*.Q4%@D=ZV0^GL/D'U"@&P
M^0?4* ;#Y!]0H!L/D'U"@&P^0?4* ;#Y!]0H!L/D'U"@&P^0?4* ;#Y!]0H!
ML/D'U"@&P^0?4* ;#Y!]0H!L/D'U"@&P^0?4* ;#Y!]0H!L/D'U"@&P^0?4*
M ;#Y!]0H!L/D'U"@&P^0?4* ;#Y!]0H!L/D'U"@&P^0?4* ;#Y!]0H!L/D'U
M"@&P^0?4* ;#Y!]0H!L/D'U"@&P^0?4* ;#Y!]0H!L/D'U"@&P^0?4* TZ](
M&!\2_J)[#_V>3?</_KT"@,^Z3DG2O37<_HZ?X;M^K_R:MM"+)>",DT** 4 H
M!0"@% * 4 H!0"@% * 4 H!0"@% * ^->@3;;IM_]GRDCMYDQUGM\M<IO/:[
M6W43_;X[]M#<<X^,O9'+SHKL-OSST>6-6Z<KU1R(-0)UOFIC1Y<BUW:PY9?9
M<2XQ$28LM#<AEUE)0\EAQQ!4I3:2K8'+5+>'JJ^AJKK5*V5:_P#[-+;YV3SI
MM,B0+?GG4MT2NV^^ZDX_C^5Y=;I48YQCDV;#AV-JW7EMEAIZ6[ZJ\+JIB'X%
MP6MMH>/(4E+21V/2&7@WYF)TKNM?CQ769T%LT?U2U6Z+XGC>K0HD</\ (K\<
M,QFFO&"R2I7B<.7)1*CON2:V9/IT H!0"@% * 4 H!0"@% * 4 H!0"@% *
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MQZB2L I_%Y.WY.):&QFP1N5K]E.V^X)\R /?0/)]?'NC.6D[J?Q6Z9I+G;\
M,-"5*(:#W_DU;?93MS\3MWW3L.WGMVH19+P\3)OC-_UA]:?\Z%'C-_UA]:?\
MZ %YO8^T/\2?\Z _+WZ1'K:ZFM)/3+=%/3GIYJG=L>T>U'D:#IS7#HC%N>ME
MY3DVK%XL.5^LNR$^NO>/CL=E4I,=3!;8;24%"MUEYT\/[)>NSALV.SS\;<?/
M]0GC-_UA]:?\Z%'C-_UA]:?\Z >,W_6'UI_SH!XS?]8?6G_.@./_ *;GJ"U;
MZ:.A++M5-$\SE87G<#-\1M,3(H#49UZ+;KB]/3-C$RVW8Z77TM-@*6TK8I[$
M#?D(^66VFWKQ-"-8NM?J2L'H&]->J6S:J7B/KS>(^'JGYY&:MCMRFNS[U.C3
MT.1G&TPP7(S2$N'PFQLGDDI\ZY.4JT3VV32Y'91C:U;*ZK?/*COR_1U>]%CJ
MYGFN?0CT^:KZF9/(RW/,LQ#X3R'(90BMOW:8I^0WXKB8J4,LJ:2@!24M#?8D
M%0]HS6DGG6F6U/U]<_.Y'%)T2SMMJFG=T=.%ZT7G?H:I\IV0)*%%*$GL4*45
MGVDI4M2D EP \4\4D@';]799+8<RO0H*0A04%A24J"QY*! (4//LH'<=SV-
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MFI2G%E=:,FSC 4&DA0V.R>W(*V/%.XW'F$JW3WW/;<D[T'6\G4 H!0"@% *
M4 H!0"@% * 4 H!0"@% * 4 H!0"@% * 4 H!0"@% * 4!8>J&G6+ZN:?9;I
MIFL1^=BF:6:38K]#C2WH$B1;Y?'QFV9D;_A$9P\4\7F2'&R I!"@" -'HGHQ
M] H+*8[&8]2$2*RRQ'B18'4;JPAB)'C,H8CL1VTWOC'9990AI#;*4)"!Q(V
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M\=:4K8]^R4NGU3AYKJAL*UW0.Z3Y'V3N.Z0>_8=^^Y^7?E[]@!,H!0"@% *
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M#SY!MR,IXN]MO#W"=N1/?84!$%K)]A:B DJ <!;<400/:9]6#GA]^ZTG?<
M=R0'7AU?K* O*YI25J!6A1*4IV4DCWMLK9+Q!.WYQ>[0.X.QXBA>5<_*GC3]
MW/2XX21S"2@[*#1$A?'L>3B$L<D.GMLD<F]BH]_9H0A1(YE;@65-H44I2RE2
ME#;8$/MJ9\1M8)W(3V '< CV@)[;GB+(YM[H Y-H<"R.7=)6DM)6D]NPY >>
MX)% 3Z 4 H!0"@% * 4 H!0"@% * 4 H!0"@% * 4 H!0"@% * 4 H!0"@%
M* X-^EP@:QY=JWT[8;HGHEA&H.;/6C*[E:<UB3[=:-:\4N$;(<,9AV[%LL8U
MLT4S73?#;Q!F7V1?\UL#6HEH];M,>V77&WFW9,62(]EJ^>3I;K9F;7](?3C9
M^C&Z93@3N>Z+R+5J5=;-/P(C \%TPUBR&[Q(]XEW.!F\S$$VFSZE2;9$0V[
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MXPVI#[SB0@*==W*U%MM )4KDE/9( ^_0"@% * 4 H!0"@% * 4 H!0"@% *
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M<67E%6[A4>R12ZZ 4 H!0"@% * 4 H!0"@% * 4 H!0"@% * 4 H!0"@% *
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M[Z]#A!3S*/5(UP?DOQ$ND$[O/8J4?^]JKE;*IW!9;3X9]D)YG<A)!'8]CND
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M-9\:SZQ&X6_U&*J%X5GM<UMU(6[S6ZT7%?FT["4NJ97;\?[S>>2/T?4** 4
MH!0"@% * 4 H!0"@% * 4 H!0"@% * 4 H!0&@?I)[)AV0]).J-FSV?I?;L7
MG2<)1<7]9;;?+QI]LO,[(&#>+;C2DWMWC)0P8;L12=I?#?\ T9)!];>N!S[]
M"W=L=-VZGL1PVVZ03,>QF_Z;JMF>Z,8_FECPS*TWS&)\R9%(S*3(FMS;/(CF
M"]&B!MME6P>W<[TSZH19O@DN-5OYKU._;("6PD;[ J !&W$ D!(^5*1V2?>
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MM^D""H'^LI1]] >!E XGOR2DH"M^_%6^X\MO,[[@#OMOOM0$*([;:DJ2#ND
M#?8^3:&AW(W[(; &Q'FH_P!(T!/H!0"@% * 4 H!0"@% * 4 H!0"@% * 4
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M+DXK65?\4E&-*&5^C_)+AE.!7RYG)9%\@2LDDNV:-<;K$N=\LMC4$"%%O1B
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MU"&VZAZ09JW:F;9?,+R%%RM]UR*UQ6C;)K4J)9W FX7)+3[;*8DB"X0F2TM
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M[3R_ CORGIH0R/SC;JU%=>.A](8RSQG:.KG-*2<W)W[IIM:U,K)*];G]"?\
MR.W/MV?\2BTU:#)*O>=U+!P</ 247BQ<8S6%KO5DVIRDDZ-I['6_1SX,U11F
MZ+HPMB7@5MPDP#%<=FJ<M4V=<&[@]/4M;Z@ZJ<\TZ'5+!::9 X+2MQ?H,#Z=
M[MK$EB)O#P]2\G5MNE77#J\[NN67'Q^F?54\71NS]%6&THZ9IF/).*U%WBPJ
M0PU'$4()*#;3A*DW5-J5%<.AVFK^D^%#$W+F+LM-YOUU,M4=<5DJOEXE7-UE
M#3KKJ@W']94TT0XH\6T\E*[D[^GM Q=!P,2$VW7%Q&E]R3K-M?E&-7?-*BR1
M^7ZB[0P>T-*6D0CJ)X>'%QDX.7^/#C&M(MJ-:?BV[W5,EF5;_=00M'+8!/9:
MD\1WW*T]FU*3N0I7LGW;BON0=<9IN]<EX4M7)=>'P<14PZI>J5[6_K9M(_6%
M#V=D<U;^$%;I2L;C8)<)*%*VY$@;'<#L*[$S2>^G77H%R5(*D\>2@!MN$H02
M1OOS+J@0D [IV!WV[@'>A2(O+1^F6]B0-_90$'MNE14\0I2B?8"=O<%'<[T!
M4)5ND*(X]MR#MV_MV)';W[$C]>U 2 _R/8I(0EQ3@3LL;)44I =Y(;2L^:DJ
M!V[@D;;D" /N*7Q265 A*MP5<0E2VT;%8*D%?+Q]DIWW*$I\P2H.NLZ^F[B5
ME * 4 H!0%'*)2ETC8\H[B!N?Z7%2DC^\^?OV\J YY>BW;4UTN/-K&Q3K)K3
M]1SVZ'_^Z$3KU?S,^=3;*567!)0CL2G;;JGI[<$)DL6V0B*(]_CJ7+9:N]]Q
MV&E]M!]B6B:],C'VHT=Q>R%"USMLKQ\M_P#K>;)0U)6SS24D+6M0*4A(\]O<
ME"5$;;%200=M@I6V]"*CNMO^BKH4HI!_.;$\5>'NCB%%Q: 3XZ&RDI*"?S0*
MBKWCB$D!5!:O'UH8NP[5+!LRS/5+!\8N(G93I)=['9]08)B.1W(-UO6.0LJL
MK)DN;N2R[9;G;I =6XXC9W@ULE%+]<?DBI>G@_+>]IEEG?BH*5R4'' H[;=N
M1* 1V'9LH\NU"DV@% * 4 H!0"@% * 4 H!0"@% * 4 H!0"@% * ENK+:"H
M;;[I2-^X!6H)!(W25 $[E*3R5MLGN10&&-1,TU:L,MAC3S36QYTVNSSY<A5R
MS)6*JC7N/<L28AV1/B6.Z"5'F6J[WZY.7R.E4>&_:XMM=B+?D*696_OZ?/5
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M#+;/J1G.18_EF+XI;;%<,AO#4#&W;C'%I5>KG:HS<F.^@.O!R7'1X6Z0XE1
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M_).N]*E6_+H_KCU3YIH_CVE6/,Z5NY1K#J=@%ZR>?B\3([?8[/B+F)XBW?\
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M8_\ D_1>&?'F6YI+U#]5M^SOJ!M$1C"]>,=P.(6X=ZQ^+^ =@Q'4AV[W1A[
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MM*''WIXGCL?E.X)W/F"-NVU 3* 4 H!0"@% * 4 H!0"@% * 4 H!0"@% *
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M$6^XS8:GVF4NK8?4E:U$ AW4>/IPX<$.\EPX9\=[KM=\S!V+>CQZ<L9U,O\
MJ7(Q")?7Y'X+,XI9+I'9EVS"F\78E1X;5F0IE,E3*ER4R/#GR)C<61%B/01%
M5';V=U'RW6]^MJ=:CO9UV>OS;_5*4,V:/=)N@.@=TO=ZTCT\M.$W+(VI"+V_
M9U2&TW!R5<$W21)?9<><:5+>FI2X]*X>.^$I0\M:0!3NU7;UU>U]YSUE6M8Y
MU:K:NW;M>9]U>C-ED:[1]=[C-F3[S9M/9FG&.6MT-.V^R0;WD$&_9%<HC:V?
M':N-YD6JRQ)CJ'_!]1M$1MME"B^MXL.*==JX+?7YJ]OD1-5LTW1K.]^OFQG"
MNA10"@% * D.['^WDE.X\]B#N*PY--JF2?.E2TSX*OJE^SGEZ,!:G.FN\E1W
M*===<4#]24Y]<@!_<*SKO<O7Y#23:6QOW-C^IL$:/YI(9<?0_"@1)(6RY>&E
MM>%/C.%;:K*R]<20@$\8;;SA/Z3*AO6XMM5=K[/[,NEJ[[==;EF9PLCR9%J@
MR4*YB3%CR"O9Q)67F&G.2DNI2ZD^T!Q=2'   L<MZT4^K0%#+4$E1 W5X9/
M#=;A!   W!+:4J7S '+OND[T!BS#(JX^8ZFNN:=IQ,3KU9W7,N1*BR$ZA^!8
M[3$9N9C1F&G8KD%AINPI\=;CJFK.RI2E-\0 ,NMJY)W(V)4K=)VY)[]@KCV"
MMMNW<@;;DGO0$R@% * 4 H!0"@% * 4 H!0"@% * 4 H!0"@% * 4 H!0"@%
M * 4 H!0"@% * 4 H!0"@% * 4!++8*0D*4 #OY[D_JY'N!_8: F#L /DH"
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MZV?QJ ?'?Z1/I$Z4?:ZV?QJ ?'?Z1/I$Z4?:ZV?QJ ?'?Z1/I$Z4?:ZV?QJ
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M@% * 4 H!0"@% * 4 H!0"@% * 4 H!0"@% * 4 H!0"@% * 4 H!0"@% *
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MP[--)L'7CN2/VM,9AF!AF7YIC[T$-37I/CK4X-0_)6W^WCU3F\S]%M=@* 4
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7% * 4 H!0"@% * 4 H!0"@% * 4!_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>37
<FILENAME>g164680g01m11.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g164680g01m11.jpg
M_]C_X  02D9)1@ ! 0(!>0%Y  #_[2 :4&AO=&]S:&]P(#,N,  X0DE-! 0
M    '_Z^@9 X0DE-! 0       \< 5H  QLE1QP"   "    .$))300E
M   0S<_Z?:C'O@D%<':NKP7#3CA"24T$.@      Y0   !     !       +
M<')I;G1/=71P=70    %     %!S=%-B;V]L 0    !);G1E96YU;0    !)
M;G1E     $-L<FT    /<')I;G13:7AT965N0FET8F]O;      +<')I;G1E
M<DYA;65415A4     0      #W!R:6YT4')O;V93971U<$]B:F,    , %
M<@!O &\ 9@ @ %, 90!T '4 <       "G!R;V]F4V5T=7     !     $)L
M=&YE;G5M    #&)U:6QT:6Y0<F]O9@    EP<F]O9D--64L .$))300[
M  (M    $     $      !)P<FEN=$]U='!U=$]P=&EO;G,    7     $-P
M=&YB;V]L      !#;&)R8F]O;       4F=S36)O;VP      $-R;D-B;V]L
M      !#;G1#8F]O;       3&)L<V)O;VP      $YG='9B;V]L      !%
M;6Q$8F]O;       26YT<F)O;VP      $)C:V=/8FIC     0       %)'
M0D,    #     %)D("!D;W5B0&_@            1W)N(&1O=6) ;^
M      !";" @9&]U8D!OX            $)R9%15;G1&(U)L=
M     $)L9"!5;G1&(U)L=                %)S;'15;G1&(U!X;$!7P
M        "G9E8W1O<D1A=&%B;V]L 0    !09U!S96YU;0    !09U!S
M %!G4$,     3&5F=%5N=$8C4FQT                5&]P(%5N=$8C4FQT
M                4V-L(%5N=$8C4')C0%D            08W)O<%=H96Y0
M<FEN=&EN9V)O;VP     #F-R;W!296-T0F]T=&]M;&]N9P         ,8W)O
M<%)E8W1,969T;&]N9P         -8W)O<%)E8W12:6=H=&QO;F<
M"V-R;W!296-T5&]P;&]N9P      .$))30/M       0 [_^-0 "  $#O_XU
M  (  3A"24T$)@      #@             _@   .$))300-       $
M>#A"24T$&0      !    !XX0DE- _,       D           $ .$))32<0
M       *  $          3A"24T#]0      2  O9F8  0!L9F8 !@
M 0 O9F8  0"AF9H !@       0 R     0!:    !@       0 U     0 M
M    !@       3A"24T#^       <   ____________________________
M_P/H     /____________________________\#Z     #_____________
M________________ ^@     _____________________________P/H   X
M0DE-! @      !     !   "0    D      .$))300>       $     #A"
M24T$&@     #-0    8              1<   &2          $
M                 0             !D@   1<
M 0                         0     0       &YU;&P    "    !F)O
M=6YD<T]B:F,    !        4F-T,0    0     5&]P(&QO;F<
M $QE9G1L;VYG          !"=&]M;&]N9P   1<     4F=H=&QO;F<   &2
M    !G-L:6-E<U9L3',    !3V)J8P    $       5S;&EC90   !(    '
M<VQI8V5)1&QO;F<         !V=R;W5P241L;VYG          9O<FEG:6YE
M;G5M    #$53;&EC94]R:6=I;@    UA=71O1V5N97)A=&5D     %1Y<&5E
M;G5M    "D53;&EC951Y<&4     26UG(     9B;W5N9'-/8FIC     0
M     %)C=#$    $     %1O<"!L;VYG          !,969T;&]N9P
M    0G1O;6QO;F<   $7     %)G:'1L;VYG   !D@    -U<FQ415A4
M 0       &YU;&Q415A4     0       $US9V5415A4     0      !F%L
M=%1A9U1%6%0    !       .8V5L;%1E>'1)<TA434QB;V]L 0    AC96QL
M5&5X=%1%6%0    !       ):&]R>D%L:6=N96YU;0    ]%4VQI8V5(;W)Z
M06QI9VX    '9&5F875L=     EV97)T06QI9VYE;G5M    #T53;&EC959E
M<G1!;&EG;@    =D969A=6QT    "V)G0V]L;W)4>7!E96YU;0   !%%4VQI
M8V5"1T-O;&]R5'EP90    !.;VYE    "71O<$]U='-E=&QO;F<
M"FQE9G1/=71S971L;VYG          QB;W1T;VU/=71S971L;VYG
M  MR:6=H=$]U='-E=&QO;F<      #A"24T$*       #     (_\
M #A"24T$$0       0$ .$))3004       $    !CA"24T$#      5Z
M  $   "@    ;P   >   - @   5S  8  '_V/_M  Q!9&]B95]#30 "_^X
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M/^A_YFD
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
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M 0$! ?_  !$( 1H!E@,!$0 "$0$#$0'_Q  ?   ! P4! 0$
M @<( 0,%!@D$"@O_Q !?$  ! P,# P(# @<,!@0*!@L! @,$!081  <2""$Q
M$T$4(E$580D6(S)Q@9$7&$)58I*AL<'1TO D)5*3E-,SE>'Q-T-35G)V@J*R
MLPHU-D6UPB<T1U=C<W6#HZ34_\0 &P$! 0$! 0$! 0            $" P0%
M!@?_Q ! $0 ! P(#!@0%!  & @ & P !  (1 R$$,4$%$E%A<? B@9&A!A.Q
MP=$4,N'Q!Q4C0E)B)'(6)3."HN(T0]+_V@ , P$  A$#$0 _ /OXT1&B*A(^
MN.^.V/[?I[ZP6F3XB/7\H; G@FUF;F69$;O:3)NB"S%V]=DB\5ETI^P/AZ:Q
M5'6YV0"A?P3[$IGAR#B'N" 58!]+,%B*AI!H>35@LB?$"#EG802>7OS.(I,!
MDML+S>(X\)D96E>*?NYM[ HENW!,O*FMTFZXKD^WIS#KKK-:@QJ:Y5WGJ>&D
MN+<2FGMF2I8R..&SDK2DW]+7:]](TWE],EKA!)!!@S SSMP]%/U%(@.!&ZZ2
M"=01-KC(01/&PO;8+=O:W+I>J<:AUJ+5)-#5!16&(CJRY3G*G#148#4E"PDA
MR1!<0^D$ X5X!R!QK4JU,"6ELW$R"1<"./3WE;;5822"(M,W D ^7&_%>RCW
M31+@?K,>C55BHR;=J;E'K4>.ZHN4^IM)2MR'(20 '4(6E12.0 4#[ZQ5IXBG
M2IO=3<-]H<TD$%S<I'&]B+7Z+8J4S,1$6RGS,^D'CPMZ8=:I]3,U5,J4:::;
M.D4V:B/)"UQIT=+:I$1]M)RE]E#K:B@C*0M/UR)+Q2W]UTAI_P!IS%M<[S;W
M0/9E;.\<HL"2?._E*S3*_4;2OOWY?G.+2KLHCND @>.WU&#[ZQ3=4=3:XMS$
M^*QSU!,A"028L%52N)')U*,GY!RS^TD94/;OCO[ZW+^ _'NIV5YWE.)"CSRI
M7%''U2V"E(*W.!  ;6&\J"_?L#W&J XF3RL)(O:.\SDJ7- &4CB!.=ISL9CD
M1FM,M6_[6OIJM.VE=%/K;5OU:=0:K(ISJ'DP*S!<4)-.F(6.SK(+:0M*"E9:
M>X.*[Z[5\'7I[F^*E$U&RT6N" 9N")$B1F) UOR^:PSND.@B>7/IT(!XVLUI
MZI]BQ)7"<W.H,5YN>[3?6EJFQH2:I'??@2H#M3>933?5@2DE,Y"WN$=;3GK*
M!3\GI9L?:%.D7.I57C>?XB9( #3 D-/&.)-LB5C]32)L0+"UP9OG,Z<.$W4B
MHJ_5;*@YS;*@&5@Y4X@(0"XI62%\U\UH4C"5-E! R2=>'<+#!))BX/>8R/.<
MET#P?/(VCUE>A 4 >1R>1().>W;'_=JK<@Y&4O1%&?J#WBOBP*EM[8>U%H4R
M]=T=SI5P"WJ?<%7<H=LTBB6G%@2[FN.X)T9N1.<CP/M6D1HE.A1TNSGYRP9D
M1+)629V&=O=839?>7=:NWS<>TV^%C6_9]^42VX%YTJIV+7W[CM&Z[3GSGZ0J
MHPA4(46J4:5#JS#L%^GSGYZE.-*=8F+:(T[[T]$4K62HA7(DX60.^?E'C/L%
M8_. \'1%>T1&B(T1&B(T1&B(T1&B(T1&B(T1&B(T1&B(T1&B(T1&B(T1&B(T
M1&B(T1&B(T1&B(T1&B(T1&B(T1&B(T1&B*W@*R/?D3^KL#[?Y[:R' DC4$C\
M>?)0W!Z%<P^H.@R8N_J]M8K$E5(ZH$[?&K*;:<,1+FW\^>_=+2W$)+<<S[?H
M5 BR"Y@/HF.MDG.-?I]F8RE2PS:M2?F8(5S2!.]+ZC &&+>%IAL$Q!/!>&O@
MWU2X-_94W=_(>%IO>#?B=,[)CZ4W<])7N=9:8\Z*UTB;;;KTNV9I1R*7:_(D
MMV8_#Y((D+CVG3*=/ 3R*%/+9QR)&OLMK8.L^A7W6-?C\1AWOM.[3;3WJX=E
M!>_(\#?(KQ?+<S>IDDB@'-ME)= X$6TB)6:HMTW!$O.[H:[EJUGT6]]R=H(-
M^7K3)AIDJ-!>VHAS&@JLJ<1]D*G3B(JY+(2&S^24$YR..(;@Q28_Y;*E6EA'
MFG3<WPN>:Y WFR) 8+ WM.JDODC?+=YXWCP\,YWM-B<AZIWNGRX[PH0W?:VY
MICF\--E;VU]B7<DZ[&X,M4-<6&V:@J=(B2C62S\P3)CNI0\IO(5GOKS;4&!J
M8?9KWO\ D.&#:3293#AOFH2;S MD")@P# 7H87AKMP&IXHDFY\,96)O?@!,@
MIN:3=-:V<IVYVY%(N>ORHMD=1]P3MT[-FUU=4"K)K5+I4>94GHCI>=95!#JI
M4!Y#23*<BM@)(0!JX7#87&.9A&L8T5L*?D5RUK8Q#3);(=PR;(OQ"C=YK2Z3
M(>2YH,B#(R(@WUUF(66BWE=]2O';N+N7O1<]ATZ_MM=Q-R$P8ETKH 7(>K]*
M5:E/C25",\RBDV[(8?,!"D^H^N4SZ3RG2@[?AL+2IXAM##4JS\/7I4 YS&NW
M@)^:X@R7.));;*"XY KJ*I;NA]1[9:Y^=I)L)M/EZ\="8WBWCNW\6:?7[MJ5
M I<+:.J7!0:^]>LC;U=UU)B^[CHT"XGW%0 Y77$V]2:!4'J2I*E2DUX._"95
MS5ZFX+9E/YSMP2[&,9N-I-KPPTJ;BR 6BF"YSY># TR &?U!,7N&DS,3XB X
MR9=I L;$$2IP5[=>Y[6Z5HNY%;7'JU]2MNJ2B(U!"F(]P7M<,&+3Z*U3DO-!
M:4U6M5**AM"F<):=2\6TH;*4?FZE'#LVG5HL %!E>-##!#G-D<P0#Y77H!<^
MDUXGQ-$1(@Y:S&5[1Y*(&TLZZ.E3<^UJ%N':,FV[0WHHMGV;)J+%>;KS<[>Z
MEUM+$VZ:@J' ALTV/=<"ZZA.J3LG^)F4K64L%6OMXDT-H80NHU:;ZV%=4J#=
M8]LT7L)%(!UG5'.IMAPU!%I /G:U])_B8Z'@ C>&<YG@ #E(%]=&X?HVYZND
MRI2I4FW%;+W!?>]=O[AO4JU52-P+=V^K^[^X]!NB[*9(D?&L3'Z0^\NHMJC1
MT+<H[XE-*2(;6>U?$[/.-Q W'_J6-FF35=\ASOD4X;N V<6 SO M)!DR8.:-
M"HZ@"8+9.0;O1-[@ 1P@F<[9KM':;L*30:7(I[XD4URG4\T^4ET/(EPO@(IC
MRFW\D2&GVN#C3P"0XVI*N(SK\77<75'3GO.)M$$N)(C2#IH;+WMID #(=9@0
M(U]M%LZ5!0R/8X_7KBNC1NB)F\JNBTH'=:*K6=JVSD5RLWA:>Y4>9?5PV7?5
MF28,299-KV[0X,W<FNUE52:?@S[<:I:Z0*E2)3#K,YQ,7EP]/EIV%#_'2=?6
M.G24S/0Y<4FX]Q[IKVX#=_U/<V]=OZ'=%LWG?-7HTS\8]GQ6IT*BM4BA4&ET
MNGVB%U-I<U^EI;>6N0ZJ2M]2EG177B3-SW_>?%=102@*(<*?4RM()/%*B,A2
MBD<E?1821E63C)T16A.:2D\Y*$N9&$J4$K4>^1P=5E*%#NE2@.W<=M$ZVZ\U
M[(CZ7T%:'4.H."%-N(=1WSD!:,I)!&",G!['&B*S.D+96UP44E07R)&6@ /E
M+B>Q^9?%L%"@L%?;MG1.^^*9NJ]0^R=%EQJ;4MW-OX<Z36$T%J(N[Z*[)^W4
MK)=I4AIB:Z]$D!7-AU$P-(C.!IM2PI>-$3T07O7:#@4I2%(:4T5%*LM% "5!
MQ)4'>:DK6'<X6E22/H"+VZ(C1$:(C1$:(C1$:(C1$:(C1$:(C1$:(C1$:(C1
M$:(C1$:(C1$:(K;JE);6I(*B$D@ @$_7!/8'&<$]M$41[MZD+I@7[<FWVVVT
M-Q;J5"S8])?NJH1Z_2[:IU(^VV),FGQFI$V/*74I2XT1U:D-1FFPLH!EJ)(#
MOO\ F/<(>0.0\R>$QEJ/=.ILSNY WCM9%VTRFU6B%JL5.VZS;]:$=NHT6OT-
MY$6J4V1Z"WVG51G5%U$EET(E-+9^5)(&B:?;A]0GHT1&B(T1&B(T14XC.<=]
M9W6S,7F9OFBQ\FD4N7,AU"5 B/SJ?ZWP,MUAM<B)\0$A[X=U22MDNA"0LMJ2
M5!(!)&MR0" 3!S'%4$C(D2O,;=H2W:B\NE4];E5;#-268C!5.:2@MAN8KAF2
M V2@![GA)*?!QK8JU&@ /< TR()D'D=/*%Q^6TN<7 >(F<O%)U_GCU6.E63:
MDR-,ARK>HS\.H*CKFQWJ?%6S*7%;#49;Z%,E+BV&P&V5*!+: $I( QHZO4,;
MU0F 0).0)G7G]^:OR:41N-C.(M/%68=%MZU8RH='H].I<5]T+$:G0F(K16HA
M"E\&$-@GL.2L9/;OJDOK[K7.)#6&))@ 21%^F4:Y!9+118^KN@M:YK0W."X@
M1QOF> XIGMVMHJ)N'3GK>9FN6Q$N&IQ)EWN46GPDR+LIT12?4I-9?+8<5$E)
M 9=<65**/E! &O3@\8_#$56P\TS_ *;2;,)_W  CS^EY%#6UJPPXI_+-1E2I
MO@$&*8F)R).6M[9PO=6-D+3KM]4.]*M#BSW;>LF19D*CRXL>5 13Y%6I52^(
M90^TL(?:12FHX4C!X**>P.#&XS$;SGLJ.#7O+W";%[KDF,RYQ)&?*%FM1H?(
M93W&FMO-_P!0_N#6.$B"3FV!ED3Q,N/.LJTZTS!14:!2)[5.2/L]$NFQ'TT]
M.$E+<5+K2@PCY4 I;X <$@#Y1CD,17IN=%1[7$$.(<?%PGC&85-"D]I=NM\6
MZ6>%O@#?W < 8@C6;<LZ]0Z1)C18<JGPGXL-45R-&>CLN,1W(*BY!<884DM-
MJBK(6P4)26RE!004(*> J.#B0\AQD$S!.]G?G:5IH<T" "T:"]C[:0(.?.5Y
M9U H%:2TBJT^%5DQI*)D=,V*T^(\I(6$R6RZA7IO *4 XGYP"0#CMKH*M>G>
MG5=3EN[X3F+<#RTY*FK3J?MI@P;VGEK.662R#5#HR::[2&Z;!:ICPD-N4Y$5
ME,)QN4MQV2A44(#*VY+CSSCP*"'5NN*7R4M6>4U)DO<7:.F71%A/(6UM9::0
M!9H:.$0"8SCSY=%[(D*-!CQX41#4:+%:;8C1F EMIEEI 0TTTVE*4I;0A*4(
M2D!*4@!(  &IXBXN+I)N9'\H7B8(O82,N'&+:V7M  'R@ 'OVU5571%S,_"6
MV;<]T638<RU]F;FW;<I50N"GUP69=$FVKBH]KW-%IT"O02(BVGZO1+DBQDQ:
MS2PZA#[,)L+"D]M%#S!(Y<[9</7I9:CT'7%!O+='=JX9\"E4:ZJ;;EL6R;9%
MVRZS6;"HE,4X6+1_%Z8PR+:I3$@&2IJ.IU#\Q;A*BO))(N3K]N]!U*ZF)P I
M&2/)1[I;XIY941DA"B00@]Q^;]#HJN16]]E;!UOJ1O.ZJIM?NWO36(-O4J@W
MQ0;.B3YULV_6"Z9D.>N3]IPDHK*Z>?AY<2(@I^'4V7"5X *6,COR_CZRNA73
M/,VSF;54L;2TV30[1ASI]/3;\]J3'JMOU6*XA%4I%7BRGY#L:I17R/7:]9P<
M5-K!PO4  R0&>^_RGAN+T5TZ:Q*4IB$[3IXES4$)5#9]!0<?"SGB6VRM84,*
M04\P?EU55P/-!VOIVV5U/4_;B]J@W.H->V[=ZCW-KX,NW(M@2+U>JU0NI=,5
M(#]1K%+BO3&Q> 0)#YAHE.H6VX6]%)R/03J=!I<29TY2N\ME,P(ULV_%I<M=
M0IL2WZ%%IU1<<+JZC 8IK*(<XN'NY\7']-\N?PUN*)[YT5]UK&[6[5A;+6TQ
M>6Y%TT^T;:75Z=0TU2IF2F&JK55THIL1Q<2/*?YR5-/-,,I:)ER%-1&B9+["
M%D6H[?=2.T&Z-8<MZQ+XBW'6FJ9*J#L.+3:W%<;B1VX*W):E5*E0H_R&8VL(
M2Z,MO-)2%*2OB21/8.0GCQS3VF420 K\Y?!/C"D#BE3A/8HRKL@]P%E([A9T
M10TOSK;L"R[QF;?0+7W*ORZFJD[;D%BS[6<ETVK7)"C"=7*%!K#DIJ*JK4"$
MM#E6:4A/PKOJM@K4R=%)'(W_ +'?J!=25VIW'H.[-D4&_K8DR)-"N.GL3X"I
M49<24VEP'U8\V.M2BQ-C.\F)3 )2TZVI(4K&=%4Y&B(T1&B(T1&B*VYRX_(2
ME14D A(5Y4 <@X&"/)]O.B+R+=?0KPE1R H#D<#/L.WL,JQX3DG1%<:*PI*5
MK/(K4O&2H%!0>(RHY3C(/;(R"/OT17W5E#:EI ) &,G &2 5'ZA()40.ZL8'
M<C1%@Q6(;LA,%-2B?'Y0I<!N0T)J&G0I'J&/ZOK!')Q)2%IRD)#@_-QHB]Z7
MG ZAM+BEI*%D91R"RVKTBDN$\O4_AJ2!D8/WZ)WWWHF>ZB]R;BVEVCNV^K5H
MS=<K5&;HJ8T60U+D0XK56N.D42?6Y[$!*YKM.MRG5&5<-09B)+SD*F2$-I4M
M0!(H=;:=4]^5+=/;.T6=R]O=Z*??]P.4BOTRT;8K-)JEETT4:IU,W/\ %&*U
M%328DN#'IDB/57!*4Y4(Q:22%X)W_?>N5I73%]2DLN*3^<D9'<C.".V1XR.V
M?;1%S^ZK=V;^LVZ[6H[-]U_:?;>;;S]3JFX=#L]BZ5JN-NIN,)MR6X[R^RF4
MTT-36Y8:7\2ZXID'"-._RAMG;+OS6W](>Y&XE]-WW%N2X*M?-G4:J4ANQ=PZ
MU;;=LSKICS(+LFLMB$@X?BTJ2&8[$X(09 <)"0$$Z*#K.E\Y&:FJZ0&UD^,=
M_P#M^[ZZ*KB=U;V]9]\]05S1+@O"U=C)E!HENQXUQ5>)<(K.XT.9&J[J6TK@
M)^RWZ52%,NQP!FH RGDK"4%DEWW"FOIF/2#UOK"GET63XTS8NUV8%M4FV(,"
MK7#2X;E#B3HU(N5FGU1:';GA,U)")_I5]9,D.S$^IZR)"DJ+88R0&1/%3"T5
M1HB-$1HB-$1HB-$5M)5E6 ".1]\8_P _W:P2X380)OR'GP11\WPW2K>UTG;V
MKL,QG[4JU\4ZUKRD.-J4Y28=<:<8IE00H$>FVBI):9?</RA+R>6!W'FJ/W2"
MYT D VDR<N=[#*WFOL;,V<<>Y]-H.^*;ZK.!%."_K#9(;G,9)G=T>H^L6I<M
M^FF4N/5+?V\M>CL2RI/%RH7[=,U+=%HK,D*(:;9CNM.R2KN"HC.O [:K:.)K
M8?>'^F !:Y<X6;:;SIGE<$K]GL;X)_7-P5'%LJ4F;1=5QU*H2&C]!@"XXBLU
MKHWK-.[H8(O 61M&L]0])NFB*W&8M6M6K78;\JJ&CL&'4;.=CL_$X6X5E%1A
MC!:>Y)+Q6CDT"-=ZN(JL:*K0PM/A<U@(@D&)WB28O$0#>UUY]K8;X7?3JXC8
M[Z].IA(PW^L]KOG.K/+6N8!D"!-]")B%FZ9U7;652HNTL2*W"=:HUPW# G52
MC3($:KTVW6UR:L[35O +E-Q8[2GE%*4\VDY2-?.I_$F&H..&JRU[1!W@1O1!
M+AT#AS$P>*^=6^ MM?Y<[:@I-?1H8K!X2KNO#G4ZN.>*>&8Z 0/FDM OURA9
MK;+J6L/<V?3:5;?VLV]7J([<-ON5.DRZ9'K](B_#AZ?2GI0"9;2#,9<*F_X!
MY$8SKZ]#:%+$ET&\,(D;LM<!!O>X(BV0GBO)MCX3VKL1NVJ>(PY!^'\9A,!C
MMUP>*-?'-+Z(<YGA,D%IX/\ "8-AH>_>ZV[]@/W)<= C6[2[&LFU45IR77E<
MY5VUE9E.BAPN*P82$-,L-!T)+KTF2AM((!UX\1BZHK8IS2QM.BUCG%PNXE@(
M#=277X^*W-?9^"=A;,VV/\OQ3,55VA4KBE2% >&G2>UQ-:M_TIEH)X N)U3<
M=276!<NVEAT>9MM:K=<O21:K5Y733JBLQXUF4670I-0BFLJYI'V@)25H;A%0
M4\Q GNK  03C_.&LI@D&HYH:]UCNL:YKG'>(-B8D3_M!G)?H/@;_  VI[<K[
M1.+JBE1H.;0PXWFMJ8FNZJ]O^D""'-:*9:]PD!U1D&\G=+BZO:9M]NKN-:=Z
MQZ@+9LFQ=M;P15*/2)527"@7.+YD7!4:VN.#\+#@Q[>IJ67%X3Q,IPDY5CE6
MV_AJ6.J80D^ ,(+03 +W@N=I%@!SL<U\/#_!57';*.TL/N#_ ,['X)S7U6M<
MZOAFT7,ITFN,N&Z^H]^[< - N0%-B!)34(T>;'<#K,A*7&G$X*%MN .-+21@
M<5-J0I)\X/?Z:_0TZC7L:]IEKA(&8(-P9D1(C3U!A?SO$T7T*SZ;VEKFG=((
M@APL1&<@@@VS671V!'T)_LU&_P"[_P!C]D2]:1<V?PD!OF7:&V]!V_W;O/;F
MNW%<M1I:+:L.@M5ZN[D-NQ(RE4IQE2"[%I=&;2[.GRVW&4M)DMAQP<DZ(4VW
MX/*@RK3N'<FVZ^44V](D"ES*Q2*SM^U:MT3(TF3)#%;E5]3\F7<M-?>Y-!1>
M6TS)2IL#(.2@UB>!]N[6U75112M.0<N$H!'+ "G1WY@8_)I2 0!@CMW!SHJN
M>>^['3';6YM6J%Q;O77MG?-P"FOW?3;'K=5CJJ34=E4>FS*]"@QI;#3SL?DT
MA2TLNO("5*Y<0=.'??7\HI-]+%)M:C;14J+9;5)3;;U5KDZFS*347JJ*PU,J
M3[OVS4I\E2I3U8J XN5(2#ZK4A):PE*$I!!WJGTK++;\9YJ1CX1V,\U("P"V
M6G  Z%I5A'%37-*BKL$E601HBY"7G3^CVG1+FLF@;Q5MZEJ=KB(^U\J[Z]&V
ML<J\V=-0:%/FL1O3A0)M7E/-/1VIR6&0XH)+;302"DC.<\KVSN??CST76ZUF
M?1I<5M#+$1EN#3F&X,904Q!,>*AHQ62GY2PTA+265)[*0 /X.BNIZVUMU38=
M1(V@?VSK4#?)=$3M[4DM09XKW(1')\E]IJDHAEI*I":Q\:IM=*=B 2H\I")4
M=;;C <23OST/D;^2T':O?G:W<R]X=#VJG6M5:>U:U:J%Q)1$=I=S1$QY5O,T
M(PH+\6*Y,I,Y$^I1ZE)PMJ)*I[#9XF0@*NFOVY?=2Q.F1//2U^49F<K*2KBL
M.,IX<PMQM)0D)"B?B4.?G]P6F4%*@E'_ $G%9/YO>*J#ETWGTH;5WQN-3:O=
M\6W;NO:?*J]SI@&?.D6O7:O0UT>7<<1R/%E-VQ5IM.D1WI\IE;;BY?INNH*U
M+*B2,]#Y3V!GPY*0O3-2*-0=E-OZ5;L.B0J%&MRGFF,T"H/52G*BO,I=9D,U
M"0I3\OXIM29#CSQ]5;KBRL!7;3V4'>O?%/A+=+24'F$#)))4E(P!CN5X& 5
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MV(T@\#Z%-YQB[1YCWN5N##"$->F&TI;XI2$  )"$@ )QC 'CM^C6H %\SD.
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M/[?E[GQW_P"S5&[J#ZR?L/JLD.M!!CD!Y_G3E$JZ[L_N*Z,*LBY!\P5E-*D
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M2H5'C,R55)JW')1E<65H#N//O7W07'URX>7'A/*%T[DI2IE25G"26\G*P/\
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MUVO7,G::FMUZYZ5%HE?J:)?"55J5!CS(L.%/=20N0S&8G/M-!9*D-E" >+:
MG6Z_4#.T1ESYJ;S>/U7HLWK%M_;Z@TZUK,VII=N6[26BU3J/2Y/PL&,A9"W
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MXN+5YSDJ&/&//Z]4G*'./&2?X1K8F0-(F#Q2.:_]I7\X_P!^LR3F2?-;@#(
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M+Z9R4HI. .'$>^,=_'U]_P"_OH6DQX8&1R)ZZ?:=4:8)),9D#0D])L$DI5[
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M 4$CZXS[ZTB;>]ND_8#;JC/7%>MXS[>H<<H2]4:E/C1F4K<*DMM(YCDXZXH
M(;0%*/? [:*0#F ?)8:Q.FCIRW0I[M4L&^YES06)#D9Y^E5*+($9U)4$HEM@
M>I'</$A25I!![#.-$W6\!Z#3ONZ<=GH4VN*3_KBXLA6%#U6#A0 S@E/<=^W8
M:) X1TM](5X="FUH\U>XC_\ W6!_^71-T<)ZW^LI*NA+:Q6/]:W <?5UG^Q.
MB  9"$G]XCM:""FK5\ >1ZK/?]?'^S16!P2ST*;7$ &K7 <9Q^6:]\?R?NT2
M!P0.A3:Y.<5:X1GSAYK_  ZLD9$A0@', ]4'H4VN5C-6N$X\9>:_PZ$DYF4
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M2TM4E*U53B [P7\ EIQ4HH6I+*0I2RE/<<<3CZ+&SO@ $YF!()UF#<$9VB9
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M8AH1Q(<8E.I0-.^X^Z:6&=LHCJ+&+_A='&$E*E?GJ2%DH+G91"@<H;"B$A"
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MB[S ^PE5;WTW@0$ ;A70D)Y)0159'JMA3;3;A]5M;(<5),9J3(PVT%2G7EI
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M%(25ZXXC:=-V)%6@:VY2HBC3=4(-1X#8WGG>,&28 ,#T V:,B+7=)BPSG*.
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MX<(PD')[=_'<9T2+Y VSZ'*\D7N3)RXV7.29^&+WB>D+*;7IC;(=(PN0XHD
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E$1HB-$1HB-$1HB-$1HB-$1HB-$1HB-$1HB-$1HB-$1HB-$7_V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>38
<FILENAME>g164680g01m12.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g164680g01m12.jpg
M_]C_X  02D9)1@ ! 0(!>0%Y  #_[1A"4&AO=&]S:&]P(#,N,  X0DE-! 0
M    &":^88(X0DE-! 0       \< 5H  QLE1QP"   "    .$))300E
M   0S<_Z?:C'O@D%<':NKP7#3CA"24T$.@      Y0   !     !       +
M<')I;G1/=71P=70    %     %!S=%-B;V]L 0    !);G1E96YU;0    !)
M;G1E     $-L<FT    /<')I;G13:7AT965N0FET8F]O;      +<')I;G1E
M<DYA;65415A4     0      #W!R:6YT4')O;V93971U<$]B:F,    , %
M<@!O &\ 9@ @ %, 90!T '4 <       "G!R;V]F4V5T=7     !     $)L
M=&YE;G5M    #&)U:6QT:6Y0<F]O9@    EP<F]O9D--64L .$))300[
M  (M    $     $      !)P<FEN=$]U='!U=$]P=&EO;G,    7     $-P
M=&YB;V]L      !#;&)R8F]O;       4F=S36)O;VP      $-R;D-B;V]L
M      !#;G1#8F]O;       3&)L<V)O;VP      $YG='9B;V]L      !%
M;6Q$8F]O;       26YT<F)O;VP      $)C:V=/8FIC     0       %)'
M0D,    #     %)D("!D;W5B0&_@            1W)N(&1O=6) ;^
M      !";" @9&]U8D!OX            $)R9%15;G1&(U)L=
M     $)L9"!5;G1&(U)L=                %)S;'15;G1&(U!X;$!7P
M        "G9E8W1O<D1A=&%B;V]L 0    !09U!S96YU;0    !09U!S
M %!G4$,     3&5F=%5N=$8C4FQT                5&]P(%5N=$8C4FQT
M                4V-L(%5N=$8C4')C0%D            08W)O<%=H96Y0
M<FEN=&EN9V)O;VP     #F-R;W!296-T0F]T=&]M;&]N9P         ,8W)O
M<%)E8W1,969T;&]N9P         -8W)O<%)E8W12:6=H=&QO;F<
M"V-R;W!296-T5&]P;&]N9P      .$))30/M       0 [_^-0 "  $#O_XU
M  (  3A"24T$)@      #@             _@   .$))300-       $
M>#A"24T$&0      !    !XX0DE- _,       D           $ .$))32<0
M       *  $          3A"24T#]0      2  O9F8  0!L9F8 !@
M 0 O9F8  0"AF9H !@       0 R     0!:    !@       0 U     0 M
M    !@       3A"24T#^       <   ____________________________
M_P/H     /____________________________\#Z     #_____________
M________________ ^@     _____________________________P/H   X
M0DE-! @      !     !   "0    D      .$))300>       $     #A"
M24T$&@     #-0    8              +D   &4          $
M                 0             !E    +D
M 0                         0     0       &YU;&P    "    !F)O
M=6YD<T]B:F,    !        4F-T,0    0     5&]P(&QO;F<
M $QE9G1L;VYG          !"=&]M;&]N9P   +D     4F=H=&QO;F<   &4
M    !G-L:6-E<U9L3',    !3V)J8P    $       5S;&EC90   !(    '
M<VQI8V5)1&QO;F<         !V=R;W5P241L;VYG          9O<FEG:6YE
M;G5M    #$53;&EC94]R:6=I;@    UA=71O1V5N97)A=&5D     %1Y<&5E
M;G5M    "D53;&EC951Y<&4     26UG(     9B;W5N9'-/8FIC     0
M     %)C=#$    $     %1O<"!L;VYG          !,969T;&]N9P
M    0G1O;6QO;F<   "Y     %)G:'1L;VYG   !E     -U<FQ415A4
M 0       &YU;&Q415A4     0       $US9V5415A4     0      !F%L
M=%1A9U1%6%0    !       .8V5L;%1E>'1)<TA434QB;V]L 0    AC96QL
M5&5X=%1%6%0    !       ):&]R>D%L:6=N96YU;0    ]%4VQI8V5(;W)Z
M06QI9VX    '9&5F875L=     EV97)T06QI9VYE;G5M    #T53;&EC959E
M<G1!;&EG;@    =D969A=6QT    "V)G0V]L;W)4>7!E96YU;0   !%%4VQI
M8V5"1T-O;&]R5'EP90    !.;VYE    "71O<$]U='-E=&QO;F<
M"FQE9G1/=71S971L;VYG          QB;W1T;VU/=71S971L;VYG
M  MR:6=H=$]U='-E=&QO;F<      #A"24T$*       #     (_\
M #A"24T$$0       0$ .$))3004       $    "CA"24T$#      .#P
M  $   "@    20   >   (C@   -\P 8  '_V/_M  Q!9&]B95]#30 "_^X
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M^CGGZT]*:\UN-@M:0UU887.!W&NUKO3W_P!'VN];_P #]13I
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M                             /_A/KMH='1P.B\O;G,N861O8F4N8V]M
M+WAA<"\Q+C O #P_>'!A8VME="!B96=I;CTB[[N_(B!I9#TB5S5-,$UP0V5H
M:4AZ<F53>DY48WIK8SED(C\^"CQX.GAM<&UE=&$@>&UL;G,Z>#TB861O8F4Z
M;G,Z;65T82\B('@Z>&UP=&L](D%D;V)E(%A-4"!#;W)E(#4N,RUC,#$Q(#8V
M+C$T-38V,2P@,C Q,B\P,B\P-BTQ-#HU-CHR-R @(" @(" @(CX*(" @/')D
M9CI21$8@>&UL;G,Z<F1F/2)H='1P.B\O=W=W+G<S+F]R9R\Q.3DY+S R+S(R
M+7)D9BUS>6YT87@M;G,C(CX*(" @(" @/')D9CI$97-C<FEP=&EO;B!R9&8Z
M86)O=70](B(*(" @(" @(" @(" @>&UL;G,Z>&UP/2)H='1P.B\O;G,N861O
M8F4N8V]M+WAA<"\Q+C O(CX*(" @(" @(" @/'AM<#I#<F5A=&5$871E/C(P
M,C$M,3 M,C94,3DZ,#,Z-3@K,#4Z,S \+WAM<#I#<F5A=&5$871E/@H@(" @
M(" @(" \>&UP.D-R96%T;W)4;V]L/DUI8W)O<V]F=,*N(%=O<F0@,C Q-CPO
M>&UP.D-R96%T;W)4;V]L/@H@(" @(" @(" \>&UP.DUO9&EF>41A=&4^,C R
M,2TQ,"TR-E0Q.3HT.#HP-2LP-3HS,#PO>&UP.DUO9&EF>41A=&4^"B @(" @
M(" @(#QX;7 Z365T861A=&%$871E/C(P,C$M,3 M,C94,3DZ-#@Z,#4K,#4Z
M,S \+WAM<#I-971A9&%T841A=&4^"B @(" @(#PO<F1F.D1E<V-R:7!T:6]N
M/@H@(" @(" \<F1F.D1E<V-R:7!T:6]N(')D9CIA8F]U=#TB(@H@(" @(" @
M(" @("!X;6QN<SIP9&8](FAT=' Z+R]N<RYA9&]B92YC;VTO<&1F+S$N,R\B
M/@H@(" @(" @(" \<&1F.E!R;V1U8V5R/DUI8W)O<V]F=,*N(%=O<F0@,C Q
M-CPO<&1F.E!R;V1U8V5R/@H@(" @(" \+W)D9CI$97-C<FEP=&EO;CX*(" @
M(" @/')D9CI$97-C<FEP=&EO;B!R9&8Z86)O=70](B(*(" @(" @(" @(" @
M>&UL;G,Z>&UP34T](FAT=' Z+R]N<RYA9&]B92YC;VTO>&%P+S$N,"]M;2\B
M"B @(" @(" @(" @('AM;&YS.G-T179T/2)H='1P.B\O;G,N861O8F4N8V]M
M+WAA<"\Q+C O<U1Y<&4O4F5S;W5R8V5%=F5N=",B"B @(" @(" @(" @('AM
M;&YS.G-T4F5F/2)H='1P.B\O;G,N861O8F4N8V]M+WAA<"\Q+C O<U1Y<&4O
M4F5S;W5R8V52968C(CX*(" @(" @(" @/'AM<$U-.DEN<W1A;F-E240^>&UP
M+FEI9#I"13 P.3<X.38W,S9%0S$Q03%#-D%!-4(V0S(Y,#A!13PO>&UP34TZ
M26YS=&%N8V5)1#X*(" @(" @(" @/'AM<$U-.D1O8W5M96YT240^>&UP+F1I
M9#I#,3%",$(X0S8V,S9%0S$Q03%#-D%!-4(V0S(Y,#A!13PO>&UP34TZ1&]C
M=6UE;G1)1#X*(" @(" @(" @/'AM<$U-.D]R:6=I;F%L1&]C=6UE;G1)1#YX
M;7 N9&ED.D,Q,4(P0CA#-C8S-D5#,3%!,4,V04$U0C9#,CDP.$%%/"]X;7!-
M33I/<FEG:6YA;$1O8W5M96YT240^"B @(" @(" @(#QX;7!-33I(:7-T;W)Y
M/@H@(" @(" @(" @(" \<F1F.E-E<3X*(" @(" @(" @(" @(" @/')D9CIL
M:2!R9&8Z<&%R<V54>7!E/2)297-O=7)C92(^"B @(" @(" @(" @(" @(" @
M(#QS=$5V=#IA8W1I;VX^<V%V960\+W-T179T.F%C=&EO;CX*(" @(" @(" @
M(" @(" @(" @/'-T179T.FEN<W1A;F-E240^>&UP+FEI9#I#,3%",$(X0S8V
M,S9%0S$Q03%#-D%!-4(V0S(Y,#A!13PO<W1%=G0Z:6YS=&%N8V5)1#X*(" @
M(" @(" @(" @(" @(" @/'-T179T.G=H96X^,C R,2TQ,"TR-E0Q.3HT.#HP
M,2LP-3HS,#PO<W1%=G0Z=VAE;CX*(" @(" @(" @(" @(" @(" @/'-T179T
M.G-O9G1W87)E06=E;G0^061O8F4@4&AO=&]S:&]P($-3-B H5VEN9&]W<RD\
M+W-T179T.G-O9G1W87)E06=E;G0^"B @(" @(" @(" @(" @(" @(#QS=$5V
M=#IC:&%N9V5D/B\\+W-T179T.F-H86YG960^"B @(" @(" @(" @(" @(#PO
M<F1F.FQI/@H@(" @(" @(" @(" @(" \<F1F.FQI(')D9CIP87)S951Y<&4]
M(E)E<V]U<F-E(CX*(" @(" @(" @(" @(" @(" @/'-T179T.F%C=&EO;CYS
M879E9#PO<W1%=G0Z86-T:6]N/@H@(" @(" @(" @(" @(" @(" \<W1%=G0Z
M:6YS=&%N8V5)1#YX;7 N:6ED.D)$,# Y-S@Y-C<S-D5#,3%!,4,V04$U0C9#
M,CDP.$%%/"]S=$5V=#II;G-T86YC94E$/@H@(" @(" @(" @(" @(" @(" \
M<W1%=G0Z=VAE;CXR,#(Q+3$P+3(V5#$Y.C0X.C U*S U.C,P/"]S=$5V=#IW
M:&5N/@H@(" @(" @(" @(" @(" @(" \<W1%=G0Z<V]F='=A<F5!9V5N=#Y!
M9&]B92!0:&]T;W-H;W @0U,V("A7:6YD;W=S*3PO<W1%=G0Z<V]F='=A<F5!
M9V5N=#X*(" @(" @(" @(" @(" @(" @/'-T179T.F-H86YG960^+SPO<W1%
M=G0Z8VAA;F=E9#X*(" @(" @(" @(" @(" @/"]R9&8Z;&D^"B @(" @(" @
M(" @(" @(#QR9&8Z;&D@<F1F.G!A<G-E5'EP93TB4F5S;W5R8V4B/@H@(" @
M(" @(" @(" @(" @(" \<W1%=G0Z86-T:6]N/F-O;G9E<G1E9#PO<W1%=G0Z
M86-T:6]N/@H@(" @(" @(" @(" @(" @(" \<W1%=G0Z<&%R86UE=&5R<SYF
M<F]M(&%P<&QI8V%T:6]N+W9N9"YA9&]B92YP:&]T;W-H;W @=&\@:6UA9V4O
M97!S9CPO<W1%=G0Z<&%R86UE=&5R<SX*(" @(" @(" @(" @(" @/"]R9&8Z
M;&D^"B @(" @(" @(" @(" @(#QR9&8Z;&D@<F1F.G!A<G-E5'EP93TB4F5S
M;W5R8V4B/@H@(" @(" @(" @(" @(" @(" \<W1%=G0Z86-T:6]N/F1E<FEV
M960\+W-T179T.F%C=&EO;CX*(" @(" @(" @(" @(" @(" @/'-T179T.G!A
M<F%M971E<G,^8V]N=F5R=&5D(&9R;VT@87!P;&EC871I;VXO=FYD+F%D;V)E
M+G!H;W1O<VAO<"!T;R!I;6%G92]E<'-F/"]S=$5V=#IP87)A;65T97)S/@H@
M(" @(" @(" @(" @(" \+W)D9CIL:3X*(" @(" @(" @(" @(" @/')D9CIL
M:2!R9&8Z<&%R<V54>7!E/2)297-O=7)C92(^"B @(" @(" @(" @(" @(" @
M(#QS=$5V=#IA8W1I;VX^<V%V960\+W-T179T.F%C=&EO;CX*(" @(" @(" @
M(" @(" @(" @/'-T179T.FEN<W1A;F-E240^>&UP+FEI9#I"13 P.3<X.38W
M,S9%0S$Q03%#-D%!-4(V0S(Y,#A!13PO<W1%=G0Z:6YS=&%N8V5)1#X*(" @
M(" @(" @(" @(" @(" @/'-T179T.G=H96X^,C R,2TQ,"TR-E0Q.3HT.#HP
M-2LP-3HS,#PO<W1%=G0Z=VAE;CX*(" @(" @(" @(" @(" @(" @/'-T179T
M.G-O9G1W87)E06=E;G0^061O8F4@4&AO=&]S:&]P($-3-B H5VEN9&]W<RD\
M+W-T179T.G-O9G1W87)E06=E;G0^"B @(" @(" @(" @(" @(" @(#QS=$5V
M=#IC:&%N9V5D/B\\+W-T179T.F-H86YG960^"B @(" @(" @(" @(" @(#PO
M<F1F.FQI/@H@(" @(" @(" @(" \+W)D9CI397$^"B @(" @(" @(#PO>&UP
M34TZ2&ES=&]R>3X*(" @(" @(" @/'AM<$U-.D1E<FEV961&<F]M(')D9CIP
M87)S951Y<&4](E)E<V]U<F-E(CX*(" @(" @(" @(" @/'-T4F5F.FEN<W1A
M;F-E240^>&UP+FEI9#I"1# P.3<X.38W,S9%0S$Q03%#-D%!-4(V0S(Y,#A!
M13PO<W12968Z:6YS=&%N8V5)1#X*(" @(" @(" @(" @/'-T4F5F.F1O8W5M
M96YT240^>&UP+F1I9#I#,3%",$(X0S8V,S9%0S$Q03%#-D%!-4(V0S(Y,#A!
M13PO<W12968Z9&]C=6UE;G1)1#X*(" @(" @(" @(" @/'-T4F5F.F]R:6=I
M;F%L1&]C=6UE;G1)1#YX;7 N9&ED.D,Q,4(P0CA#-C8S-D5#,3%!,4,V04$U
M0C9#,CDP.$%%/"]S=%)E9CIO<FEG:6YA;$1O8W5M96YT240^"B @(" @(" @
M(#PO>&UP34TZ1&5R:79E9$9R;VT^"B @(" @(#PO<F1F.D1E<V-R:7!T:6]N
M/@H@(" @(" \<F1F.D1E<V-R:7!T:6]N(')D9CIA8F]U=#TB(@H@(" @(" @
M(" @("!X;6QN<SID8STB:'1T<#HO+W!U<FPN;W)G+V1C+V5L96UE;G1S+S$N
M,2\B/@H@(" @(" @(" \9&,Z9F]R;6%T/FEM86=E+V5P<V8\+V1C.F9O<FUA
M=#X*(" @(" @/"]R9&8Z1&5S8W)I<'1I;VX^"B @(" @(#QR9&8Z1&5S8W)I
M<'1I;VX@<F1F.F%B;W5T/2(B"B @(" @(" @(" @('AM;&YS.G!H;W1O<VAO
M<#TB:'1T<#HO+VYS+F%D;V)E+F-O;2]P:&]T;W-H;W O,2XP+R(^"B @(" @
M(" @(#QP:&]T;W-H;W Z0V]L;W)-;V1E/C0\+W!H;W1O<VAO<#I#;VQO<DUO
M9&4^"B @(" @(#PO<F1F.D1E<V-R:7!T:6]N/@H@(" \+W)D9CI21$8^"CPO
M>#IX;7!M971A/@H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @( H\
M/WAP86-K970@96YD/2)W(C\^_]L 0P ! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!_]L
M0P$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$!_\  $0@ NP&8 P$1  (1 0,1 ?_$ !X
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M^6;0A2Y5,_D4BL?:6I/>J/+AK9X)06^WNU[7A?#<)@*(ITQ6!93:QN?$XBH
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MR.SW>1"WAV'W.=K<8P.(8NS_ $UW.P\ZA6J1>LE[(9ME60&,C'#@BHC-+=7
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MAT5>&'(8C18;@9+:HSR$/)/J)+BEN>7E.*=)47"=>QX3@<-PW 4<%@VEF'H
M,IM>XO>&AHU<1-]R8).H7@..\6QG'.+XSB'$:HK8S%5JF(Q%5MA4K/><Q@6
M$PT 6:/"5<XL(43SW>_/'/'GGD>W!\']^NQT76DR(.GD%U^5:^X*^..._A7
M 2.!RDG@]H*A]SYT-S)UZVT06;E!.7<$V/GSU45+:4\<<^.0/R /V   X_VT
M1=]$31%3>69-3XA22;Z^G(KJN&IKYF6XS)?2T'%A Y;B-//>2>.4MJ ^^H:=
M2I#*=W$BQO(W&H]/%4:BT^D^5MUI)ZT/C98+TI[HU^WF/[=3]T8<S'(EZY?0
M9C]*AE<J0\Q\M\K9Q(SJO3#)(="5)7R.2/?7M^#]C1Q/!?FJV(JX=P>YHIM#
M'B& '63$SIJ%PZN(=3>6AK3I>XN?#:/*)W6S7:+JHVOW7I]OIM=D<>->YQ1X
M[9LXX:^Z^8BS+RMBSU0');M8W"6MEQ\QTNH?#2D_K>\@<Z\KC^'5\'6>R'!M
M*HYI>XM(<T.(D0XP7" 9W]^2QQ<V2!\0!%H(.^N@ZM=9-SI;%?"ESY+J&8T*
M,_+D/.$!#3$=I3SKBR2 $H0A2B20 !KAK):(=M?BB9YG2>K1YZZV]]!.RV\>
M^/2;'J17SY\3%]F9=WB5U!S5AF:MV=;7%A&H-P*B',1'?D8M;2D-I+$%3NG7
MKU**F]H^OW?C+\BV\K<8W?K=YYEMT^;A;N;O8[+V13ML-JHU9M=<W^*9/&M7
M907>5)W&CT6'/Q2TMJ6NS?=+J&VF5*>B*_6!]2'4YMEC?1/O/OGN[@&?[5=5
M(V^HLSIVMOZ[;VSVNN]T-G[W="AR&ON8MC)C6U!1OXW,@7[=F6%-5+SUIWH$
M3R17WZJ.JO<K$<-VBSCIS.W6:X'>]06R.W6Z.?KO(-S&I:;/=]MLMK;'&<;K
M(+[K<_([)K-IK*K)Z2(N/IKW9+B7I4B A1%C*KKTW9RSJ5S?%*3*F,$VQP_J
M>=Z7HWX_M!.M<(M;N%6+K)LJVW6;FH=I,RMLN6E.)T28#E)/:1"K)<QN=9,I
M(^&J*ZFS^YW6)<]0F_F'L;D8=O3@.P^,Q:.Q93MU48$F^WSO*J%=1<(K\C@6
M4P)J\4KYD$Y)+4V9+<Z<] *$OPU %#.P'SMURM^RO[T7;W;S[W].5WG&Y$+%
M$;L0,]WKQ=NNHTK8Q9E["\_RC&L:JC)05N2/EHU7!CV,]/ZR2L/2>Q*E]H*K
M!+.>L_JJVGR#+\)>SO;S=O($4. U-M?T6",UF&;,[I;A9JY2UF-2+:#-?1EB
M8N.I<M)$6>MB=&?9CHG-LB44@BS4VBZA-Q<9INJNLWOM:[.KCI??=MI>28W0
MQ,77E>,R,'5G,-L4S+\B%7VK$%IZ(Z@/*0X]Z:N>">'T]^M$5A(7Q7&),9=A
M(Z9-VJVLC8)AV[=A.EV.-^G7[49G8P:6NR]U"'O4>?1:SV&9&/LC\11&(EI4
MII0&I.GC^T_92_EI_(5R(/Q(,<L<CQEN-M-GBMKLURO)L*Q/>-]ZIC8U<7N(
MU<VUNT_ACCHM8D!ENOF18T]U'IR9<9QE !X5JJK'K8#XD67RMV\FVIW;BQ\D
MR[):3;+.-J\1QFNB4MC#P++XVYN2Y-D>22Y,A3;59C6%4&+V<AV0/F77'7FF
M&UKF#TR=>NRRGV4Z[H.\NY^WN#-[+YYB6.[O8IE>;[8;A7C]4]C^5XOBKP1(
MG+9B.*L:9^T94U,J(LY(5(ARFGE]O!X)R]^NM?!;#M$4-MI+?/:5<'W!(X)\
M>> !Y\#SHBP%^)G3BXZ)^H.&]N'0[81E8]239&6Y1;2J.@,*KR?'K6QQ*TMZ
MXIEUT+<*/6C U2$'UDKR1?IJ 4@:(M2'P$(TF?D>]]VF]P>@C4^W^%X5'VGP
M/*LAS*JBL5N=[F9# S*QM;AI,*--_"LAC[?P8<)YZ0*/$:^PL5*E35I!3?J?
M#TU^UE]+[3CB&1R4*[6^4]J0VA02V>"/) "EH40/'"2!XXY)5?.YNC\5C>[#
MNLO>C%B,=QSI[V*SG*-K9D*\V\R.6<US+'-H;'<!$%C<Z ^Y4T%W?6M;*C4=
M+.KE(D5\94AV2W\Q&]4BM#2?%.ZTJS$8=3E$G:BSSC??$>F;.-HKRKPZQCU&
MVL;J%RFPI9--E]8FV>.1O8I#@&0S,:E0$V;KJ6PE';J&=A[Q^Z+9STN=>MM8
M]+EANGU'Q)4[*<'WBS[9;);3:S![VZ@7]IAF33J"+?5F.U7XI/@1+-N'Z[["
MW'DPW%%M3A YU47;HQWDQ/?3K#ZT\XPV+DT2F75[!5:&\KQNUQ2U^8KL+>:D
M$U%RQ&G)CE2P6)"F@V^GE39*1IUU[HMJ:>.!Q[?_ 'HBYT1-$31$T1-$31$T
M1-$31$T1-$31%#<Y^GSQY/\ /Q_PZA,;$^2*4ENJ0"OO2TAOA;BU\@):3]3B
MCP?LD'@C6+GAK<Q@?^W75O(XEA<X 7DCX=_;UCS/)4O79GCUM/75UMS7S)[8
M27(C+Y5(1W!PI*F^.4I*&U+//LE*C[>=:Z-5M1[QG:8;FAIN(/C:+@6O/K')
MQ&#KT:3*CZ3F-J/RAQ$-)B8D'P)N-CR5,;G[K8]MI0(LK3U[.UGR$5V-8S4(
M^:OLEO'PM,.LIX8_6ONOJY4J2M"8T-IMV1(=0TVI0X^(Q+6DM#O 1_<=-I\X
MN#Z*4<.7;:?J)L!O>8 B((WY65L]MMKL@MLF1NWO (MCN _$*,<QV,L2L?VV
MJI#K+JJRI4>42[M\QF?Q*]4"I]P2XT,IB]WJ:<+1<ZH^I4$YJ9 &TAS3:?+6
M\R1Y\RI7:&"FPY1\0<2 29L03:USL"/AU5=[NBW>QQ5148W9Y _-E5TISY$-
M!+0@7,":4N*<6@?2E@E*1Y">#Y!40KTLKBT-)G<7L"#86@2/(GE-^3PIN%=6
M+ZM:G38V88XQF^%PU(C4B-9@SI*N5C4^390H\J5 E5KSC3B3%F! ?0EM;:05
M]BB/J*E%/'N#Y]AKGT72(N!$P?"T^_+VUZ_&T:=&NX,?3J6 S4R8B38 BV@)
MO:1K>*EUN7$31$T1-$31%!?;0ZWV.)"T*4.Y!"5)4.?V5!0(*3]QQ^_[:A<6
MB1,S:#!^:#Y?QU986[__  ^>E#J>R^)G6]6UL3,\EA53=+%L'[6X@J8K6G"X
MB,ENNF16^U*B>"4D\$CGC7=8'C_$<#A^XPU4-IESGP69CF=K)S#6QT.@]=-5
M@>X%PDF!IRL/,_+Q65V,XE1X?1X]C-!#^2IL7JZ^DI8:'%+3#KJR&U A1_46
M2Z[Z$1EN.E;JUK*1]94H]VNHJXE]:H][KNJO+GD0!),D@28!-X'L%O%FY=A$
M3X6@;?(!>;NC@[6Y>W&<;>OVUE0L9IB]SC+]S3K#=K6,W$%Z"[,KUJ!2B4PA
MY2V5$$!8!/C6*BPLW#^'#T\9CA.W6*8W2,;96&VM!88I59E@5)1UF1W&*7FW
M%[M=DM!D#S4,&U@W6+9#8?,_/>M(1;-0;)M[U8B0HBJS..B#;O+(>RZX5[D>
M*WVR^WEAM%79'4+CJGY5MG?8*G!;O#<K96"+6KD1V8-U&$A7K0,FKX=I'6"E
MUA\G75NI/@J(VL^'IBV'3=I1N%NSN3O;C&PN/G&]H-O<_% O \6B#")>W$:=
M.I8U4@9);Q<,L)](S(N'Y+*8TZ61$*WE*TZ^2GKS]S;Y+(3/^F7;',\ J=M:
MF@@8)BE-N?M=NE$K,(JZVDKG[G:C<3']S:=EV#!C-0FT3,BQV*N>OT _(;X;
M+J>UI32P]OD%>?,Z\_.ZM!<="F"VFZMEG*,VS>!A%]N[C?4!DFSL%=;^AEUN
M]BD..S79,]+5%79-)D6M?69/8U:)/HR\EK85@EQE+;C#I-QT-NAZJ_\ LQLG
MB^RM?FD3'GYUE(SG<S</=6_LIQ;=E3<AW'RNRRFU0>Q"/4CQ'K%,6&VH+^5@
MQ(T=#A2SRHB\O;#82HVDVPRW;#$LCNH,3);W<G)D9"1'-K2W6YMQ<Y!:3*LE
MHL%RKMKI^37)>:<;82TPTX'@E7<18B8-\-7&L.VQR?:&?O?N7E6#W<N-D$*/
M/@XY$M*?-8]NU?Q<W:O681GVV0M7#*9;KMLY+9?;6[&+*&UI["+(;"NE.BQO
M;S>;#+K-\ISC(-_F[I&XV=Y (+%_/_%,:>Q6-\G$@L-PH;%34O*8K8P;7Z0Y
M#CCA(()UK\OYYJB9W0=ME-IKFCDW^5&+<;$X1L+*4'(?<SBV#VU9<P)[9#:>
MZTERZN.F3R0TVSW)2V"2HD6OZ1\._?S*]UJ'#WK>\V\V!PS<C*<ZA*KL[Q[(
M,=?BY#1.U[B<5QI=<UEM;;S)#SC\F-;J51,O2+!QB8^EU#2"+./-OAY;0Y/D
MU[N! =LZ;/)+>TJ<4R&"MEB7B#6S]'D>/UM-#D)9+J\:R2FR6QI,KK7O7CV5
M=)[4-,NLLN(G/Q]DW]//RZ\?!8S=(?1]O_@'4/M[FFY$BZI=L-D-OMS<*P#&
M)V>4.8TP?RVUA1JZ+AL:HK(-K'QBNH_G!&DY:LV<<IBU(C*4PJ4IU%NM_IZO
M1;K-5$T1:R?B]P+&V^'SU'0JN*9$P5N +86FA=RF7 +6Y>(2'KJDQN,V^[>7
ME"A*+>%7.M^D\]"C]P4E/#A.CUU;YK'/X36X2\PN=VXKW4OF^_#M;CN"OBLS
M+I<?Z=3CCTAW(HKTF'.D083>6OV;D-R+(;[UIJDPVG2"F4@Z==>R+=TAI*DI
M*BM0Y/(7XY)':>0  01R01]*N>1X(T18-YA\./I:SK?:?U!9+BEW.RRXG,75
M]C1R.8-N;_*8U ]BK.8V^%J0NOE94G&Y+]*JX2MIYR"Z4.I6XAIQLBM[COPE
M^C?&<-S_  B%C6:RZ_/CB[9M+3.K>PR+"X&#2U3\(J=OKAX>OB]7B$U;DFAC
M,ID&*ZZOU''TGM"+SOHGKZ]<EE_L%T];:=-6VE3M3M;7SX&,5<FPL77[6P7:
MWES<V\MR?;WU[;NMH?LKFTF.NR9LU:4%UUQ12A X (L<-E4A'7IUK)2/?&>G
M/R?*N!@\G@<GR0/MSR?WZ(L_4GD _P#/?1%SHB:(FB)HB:(FB(2![D#^.BAG
M:/6?LN.1^8_U&BOF@(//'V_YXT1<Z(N#SXXXX^_.B>2YT6/Q_P#C[J7D**2T
M 0.Y92"?S(_[_P #I!.FVOEU]RF8-C/%R ,O/QG:/=>99OEN(^X5H;[&7E+6
MXWZC24I;4HJ<3R 4)X[BDD!?;VA0)UIKNHLIN?6=E: 8)<  ?&;$<_NL_C:0
MZF Z"# !<Z"=!&\:;#0V6LG$>IO#Z_<K.F<=W)PO<W)C)KZFBP#"L;CMY)D=
MPXS95;<!IR/:REU3%;9J2FVL)+9BML*]20N.@*6/(T^,T*F+K4,%48^J "YO
MPO/=_IEL/EL.B01!GFO68D5,9PW!L/#.(X48>HYS\7BFAE"J"PD!D DOFX<Z
M(9( (-LL]J]H;)J\=W2W5D1[G=&U84W"9:<#M+M[2O(0A>,XNDCTRI2.U%O<
MA E6"B&F_0C)X>]!AL*VH.]JYN\,& ZP\(&G@-A-Y*Z*OB&TVBE3@"#F)U<=
M9YQ>>1-HB5D@B$TE94D<=S:4]R"0KA(X2D$<)[$)Y#:0 $ GLX[EE7:, 8 &
M@6M<>\VN%UAE[C),$:B1,Z_4^-EV;@L-DD%U7/)^MQ2AR?<@$\?V_D.,*C&U
M'!SA<"!!(5IL%*<I=?F949##;:^]/=SV>F!R.T)Y!/ X'!) Y/WX&JU@;I/J
MLC\3B\DDF9O:YG3G]K*-K)$T1-$31$T1<$!0X//OSXT1<^VD :"%" 8G;1<%
M()!^X_YYU('(?)5<ZJ*$64$*2!VA1Y^G@$?F$D#P#]_?GDZ(NORS?(/U<@J(
M/(]U.I=Y\#[+0.W[<>#R?.B+DL-_5V@H*SW%23Y[OLH=P4 0?(('@@:(N2RV
M>[@%/=P3VD@<@\\@>W)^_C@_<:(@9:2>X( / !(\ \$'DI'"221SSV\_OT10
M4PVDA(Y</84]A*_*0EM+12. .$K2D=P^Y)(XY\$48LH( \@IY[% _4@'CD))
M!\$#@\\GC[^W!$##845 *[CSY*UGW_<5$?TT1=?EV_/@CGCGCA/L>?=(2?X^
M>#[$:(ACME7?]7=_F5R"5C[)5R""!^[@_F3HB".V%=_'+G';ZA"._M'(">X)
M!*0%$ $\ '^.B+E3"%<%142".#R >WE)*.0!]"B@=P^_)\_D10&X++9)"G5=
MW'<E:^]"NUWU4<H4"D%'[ *0DE!/<5+X6":*=T1-$6&G7+;X]&Z=MSZ>X9W*
MMY5S1PFJ_$]D\QKL'WHR%3>1XWZ@VZOK2TI$P9L1]R"NRD1+%OBO,AHJ;?<!
M4ZZZE0VOU_'L-25K9^%1C6X,+?'J#NFL9ZK,:V*L< VTA8W3=66]T'=;.D[A
MQ;7.H^72<?KJ3)\AKJ?$K2@_11EN=.F%]5M6625++K[Y9GC?W^FW4B8(JWV,
M?^"W]25<)X)1QV\CP0."0 D\CCD\<<<ZJ*+HB:(FB+ /9C_SZ]:O_MGIS_\
M@\G1%GTC]D?S_P!SHB[:(FB)HB:(FB)HBAN)*NT!03[^YX)]N./ST105CTDD
MJ4".#]2EA"1QQ^T5'V_> 3^?'W*$@:D!=4/]R"6NUTC@DMN)6@CD^QY!\C[$
M<^?'MH@<T_I(/D0II)*N%#]GCV^X5S]_[:*J$^LH[3R$@D@DDC@\?3_Z??Q]
M2DCS[^_% )TNH7!NMNNNHG%+>7>3),#RO&ZBNO:^!&O9\&O5$?P7)<ADH2^'
M/F)S5C7/QZUU+2DI"H:'524I/ZI$A9*1TN*QIHU<N9HN+1)]#(D?.++$U&"
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M;12;QX$_*/W6?K:NY/@$<$CS]^#[^P_VT57?1$T1-$31$T4,[1ZS]DT4^/\
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M:F8K"WW TY-7$@@]C:B7),Z-':0"Z\\AM*E!3;6>]K2*=R!(+[20-,I-R1
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MBXPL(62VEI2/.M]\>M8!4D_*JM5HJU*=%N2G3<<CR"*KPX0>\,EDB+!@#;F
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M@'M"B>$I'T@BUM6GPP]N+GJ7S_J:G[T;\NWVZ#1J,YPI.9--X1>X6FJGU#.
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MS^0_K_?1$[S^0_K_ 'T1.\_D/Z_WT1.\_D/Z_P!]$3O/Y#^O]]$3O/Y#^O\
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MVI,.1'0Q(0EYI:0(]50>N2J-<1+CC*EK4I++A="2$\N+[7$I#JN/K;1WI6A
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:B:(FB)HB:(FB)HB:(FB)HB:(FB)HB:(O_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>39
<FILENAME>g164680g01m13.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g164680g01m13.jpg
M_]C_X  02D9)1@ ! 0(!>0%Y  #_[2#J4&AO=&]S:&]P(#,N,  X0DE-! 0
M    (,Z^@Y@X0DE-! 0       \< 5H  QLE1QP"   "    .$))300E
M   0S<_Z?:C'O@D%<':NKP7#3CA"24T$.@      Y0   !     !       +
M<')I;G1/=71P=70    %     %!S=%-B;V]L 0    !);G1E96YU;0    !)
M;G1E     $-L<FT    /<')I;G13:7AT965N0FET8F]O;      +<')I;G1E
M<DYA;65415A4     0      #W!R:6YT4')O;V93971U<$]B:F,    , %
M<@!O &\ 9@ @ %, 90!T '4 <       "G!R;V]F4V5T=7     !     $)L
M=&YE;G5M    #&)U:6QT:6Y0<F]O9@    EP<F]O9D--64L .$))300[
M  (M    $     $      !)P<FEN=$]U='!U=$]P=&EO;G,    7     $-P
M=&YB;V]L      !#;&)R8F]O;       4F=S36)O;VP      $-R;D-B;V]L
M      !#;G1#8F]O;       3&)L<V)O;VP      $YG='9B;V]L      !%
M;6Q$8F]O;       26YT<F)O;VP      $)C:V=/8FIC     0       %)'
M0D,    #     %)D("!D;W5B0&_@            1W)N(&1O=6) ;^
M      !";" @9&]U8D!OX            $)R9%15;G1&(U)L=
M     $)L9"!5;G1&(U)L=                %)S;'15;G1&(U!X;$!7P
M        "G9E8W1O<D1A=&%B;V]L 0    !09U!S96YU;0    !09U!S
M %!G4$,     3&5F=%5N=$8C4FQT                5&]P(%5N=$8C4FQT
M                4V-L(%5N=$8C4')C0%D            08W)O<%=H96Y0
M<FEN=&EN9V)O;VP     #F-R;W!296-T0F]T=&]M;&]N9P         ,8W)O
M<%)E8W1,969T;&]N9P         -8W)O<%)E8W12:6=H=&QO;F<
M"V-R;W!296-T5&]P;&]N9P      .$))30/M       0 [_^-0 "  $#O_XU
M  (  3A"24T$)@      #@             _@   .$))300-       $
M>#A"24T$&0      !    !XX0DE- _,       D           $ .$))32<0
M       *  $          3A"24T#]0      2  O9F8  0!L9F8 !@
M 0 O9F8  0"AF9H !@       0 R     0!:    !@       0 U     0 M
M    !@       3A"24T#^       <   ____________________________
M_P/H     /____________________________\#Z     #_____________
M________________ ^@     _____________________________P/H   X
M0DE-! @      !     !   "0    D      .$))300>       $     #A"
M24T$&@     #-0    8              *4   (K          $
M                 0             "*P   *4
M 0                         0     0       &YU;&P    "    !F)O
M=6YD<T]B:F,    !        4F-T,0    0     5&]P(&QO;F<
M $QE9G1L;VYG          !"=&]M;&]N9P   *4     4F=H=&QO;F<   (K
M    !G-L:6-E<U9L3',    !3V)J8P    $       5S;&EC90   !(    '
M<VQI8V5)1&QO;F<         !V=R;W5P241L;VYG          9O<FEG:6YE
M;G5M    #$53;&EC94]R:6=I;@    UA=71O1V5N97)A=&5D     %1Y<&5E
M;G5M    "D53;&EC951Y<&4     26UG(     9B;W5N9'-/8FIC     0
M     %)C=#$    $     %1O<"!L;VYG          !,969T;&]N9P
M    0G1O;6QO;F<   "E     %)G:'1L;VYG   "*P    -U<FQ415A4
M 0       &YU;&Q415A4     0       $US9V5415A4     0      !F%L
M=%1A9U1%6%0    !       .8V5L;%1E>'1)<TA434QB;V]L 0    AC96QL
M5&5X=%1%6%0    !       ):&]R>D%L:6=N96YU;0    ]%4VQI8V5(;W)Z
M06QI9VX    '9&5F875L=     EV97)T06QI9VYE;G5M    #T53;&EC959E
M<G1!;&EG;@    =D969A=6QT    "V)G0V]L;W)4>7!E96YU;0   !%%4VQI
M8V5"1T-O;&]R5'EP90    !.;VYE    "71O<$]U='-E=&QO;F<
M"FQE9G1/=71S971L;VYG          QB;W1T;VU/=71S971L;VYG
M  MR:6=H=$]U='-E=&QO;F<      #A"24T$*       #     (_\
M #A"24T$$0       0$ .$))3004       $    !CA"24T$#      6N
M  $   "@    ,    >   %H    6G  8  '_V/_B#%A)0T-?4%)/1DE,10 !
M 0  #$A,:6YO A   &UN=')21T(@6%E:( ?.  ( "0 & #$  &%C<W!-4T94
M     $E%0R!S4D="               !  #VU@ !     -,M2% @(
M                                                        $6-P
M<G0   %0    ,V1E<V,   &$    ;'=T<'0   'P    %&)K<'0   ($
M%')865H   (8    %&=865H   (L    %&)865H   )     %&1M;F0   )4
M    <&1M9&0   +$    B'9U960   -,    AG9I97<   /4    )&QU;6D
M  /X    %&UE87,   0,    )'1E8V@   0P    #')44D,   0\   (#&=4
M4D,   0\   (#&)44D,   0\   (#'1E>'0     0V]P>7)I9VAT("AC*2 Q
M.3DX($AE=VQE='0M4&%C:V%R9"!#;VUP86YY  !D97-C         !)S4D="
M($E%0S8Q.38V+3(N,0              $G-21T(@245#-C$Y-C8M,BXQ
M
M  !865H@        \U$  0    $6S%A96B                      6%E:
M(        &^B   X]0   Y!865H@        8ID  +>%   8VEA96B
M   DH   #X0  +;/9&5S8P         6245#(&AT=' Z+R]W=W<N:65C+F-H
M               6245#(&AT=' Z+R]W=W<N:65C+F-H
M                                             &1E<V,
M+DE%0R V,3DV-BTR+C$@1&5F875L="!21T(@8V]L;W5R('-P86-E("T@<U)'
M0@              +DE%0R V,3DV-BTR+C$@1&5F875L="!21T(@8V]L;W5R
M('-P86-E("T@<U)'0@                            !D97-C
M "Q2969E<F5N8V4@5FEE=VEN9R!#;VYD:71I;VX@:6X@245#-C$Y-C8M,BXQ
M               L4F5F97)E;F-E(%9I97=I;F<@0V]N9&ET:6]N(&EN($E%
M0S8Q.38V+3(N,0                                  =FEE=P
M$Z3^ !1?+@ 0SQ0  ^W,  03"P #7)X    !6%E:(       3 E6 %    !7
M'^=M96%S          $                        "CP    )S:6<@
M $-25"!C=7)V        !      %  H #P 4 !D '@ C "@ +0 R #< .P!
M $4 2@!/ %0 60!> &, : !M '( =P!\ ($ A@"+ )  E0": )\ I "I *X
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MW"@-*#\H<2BB*-0I!BDX*6LIG0
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
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M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_P  1" "G C$# 1$
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M)Z?,&!-)\4_J(W#:VX@[3;%;+YC>Y#M'N7NYDRX^^3S^-N5.V^11:-R!B=_
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M9#*6IR1<UV.O2U5<2>ZXM2U.M1QP2.T)X&A(K-=^_68P@V"MLI;)4."I0X)
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M&@&@&@&@&@&@&@&@&@&@&@&@&@.M;G8?T21P25#@@<>P*>>\\_FE*@///'W
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M[=6HI7P'6YK"(JUJT)7'LL.;B>?E79^D.M#B3]965*89*N]3RAR$^./6[>"
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M'@@ +/!Y!YY3[C\] ?:W_%F/K[OY!'CD']_(2!^KQH-Y%1T T T T T T T
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M3#M@M]PK=3-4TV7@L.%">> +AYMS^ZF2"/T$\_D![@^WCW'C_G\] <M - -
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MG0IW%'@DI)*O!!5]A[>>/'[O[= ?&T%/<5>ZB/ /( 'MQS[>/''VXT!VZ :
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MY*6\6SL.>#]!6F"4A7'MSP>.= 93-'L;2%<@\<\<$^/W Z [/43^9_S5?V:
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M:BX8-?&8:?>=D2I$B$W&:9#<9Y275.A#G8?3*]"GDMNLGIPI< A[HS=RJM6
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M)!X/ /G\M ??G(_CZ_<\'@%7;^15V\]H)\ GP= !+CDJ <2>SW(/CG_J@_\
M6'W'N- <C(:!X[@5?]7D<C]H)\?G^S0'(/(()') 2%\^."D_=/GSH#[ZJ#['
MD?F."/WGGQ_SQH#ZEQ"O8C[_ ''V\?Z] <WN.T>4^ /N/M_^?W??C0'E[O\
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M^'U*?30DO$CU),\I2\^I7;R$#C0&2[/IQ4J2LE/<M:AW>2KMX[E#[!)'! '
M'G@: B[>?;UK='"9F,(FJK)CCT*SJ;(-I?:B6]-+;L:Q<R*H]DJ"9;#8E1U@
MI?:*D'P?($6[+;*V6&LV4S,%U4F4Y>S+2JQVK4^[C6/2)L*"W8JJHTI2DH,V
M9%=L&F^T)AJEOM,J'>XI01&]_41!DW$=:;"UJ'85!I/:D> /(2CM!)24<\*
M\#RK[G0'K5,CI[>5^5%82 .2>P**CQ^7TD _<\ >2- <'7FW$(*"%)4H=Q*0
M>4%)/ !\<J4$^^@.,9YO@_S>>/)\%2B3R"GCP4\ >_M[<^- =XE,DH2%<ESG
MM\'@]IX/GV]_Z>1Q[Z HV05U3?0'*RTAQ+**IUI:XDQE$AA;C*TN-]S+@*%J
M2L)*>1]*@"/;0'L@L--.<-M);"4)0A*2 A#:4)2EMM">$I0G@ ) ''!T!5=
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M]S68>3[,L\.7A_\ <?Q=]N_\BF_^H/?[FD/)]F)X<O#_ .X_B[[=_P"13?\
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#@/_9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>40
<FILENAME>g164680g01m14.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g164680g01m14.jpg
M_]C_X  02D9)1@ ! 0(!>0%Y  #_[1864&AO=&]S:&]P(#,N,  X0DE-! 0
M    %?J^5B8X0DE-! 0       \< 5H  QLE1QP"   "    .$))300E
M   0S<_Z?:C'O@D%<':NKP7#3CA"24T$.@      Y0   !     !       +
M<')I;G1/=71P=70    %     %!S=%-B;V]L 0    !);G1E96YU;0    !)
M;G1E     $-L<FT    /<')I;G13:7AT965N0FET8F]O;      +<')I;G1E
M<DYA;65415A4     0      #W!R:6YT4')O;V93971U<$]B:F,    , %
M<@!O &\ 9@ @ %, 90!T '4 <       "G!R;V]F4V5T=7     !     $)L
M=&YE;G5M    #&)U:6QT:6Y0<F]O9@    EP<F]O9D--64L .$))300[
M  (M    $     $      !)P<FEN=$]U='!U=$]P=&EO;G,    7     $-P
M=&YB;V]L      !#;&)R8F]O;       4F=S36)O;VP      $-R;D-B;V]L
M      !#;G1#8F]O;       3&)L<V)O;VP      $YG='9B;V]L      !%
M;6Q$8F]O;       26YT<F)O;VP      $)C:V=/8FIC     0       %)'
M0D,    #     %)D("!D;W5B0&_@            1W)N(&1O=6) ;^
M      !";" @9&]U8D!OX            $)R9%15;G1&(U)L=
M     $)L9"!5;G1&(U)L=                %)S;'15;G1&(U!X;$!7P
M        "G9E8W1O<D1A=&%B;V]L 0    !09U!S96YU;0    !09U!S
M %!G4$,     3&5F=%5N=$8C4FQT                5&]P(%5N=$8C4FQT
M                4V-L(%5N=$8C4')C0%D            08W)O<%=H96Y0
M<FEN=&EN9V)O;VP     #F-R;W!296-T0F]T=&]M;&]N9P         ,8W)O
M<%)E8W1,969T;&]N9P         -8W)O<%)E8W12:6=H=&QO;F<
M"V-R;W!296-T5&]P;&]N9P      .$))30/M       0 [_^-0 "  $#O_XU
M  (  3A"24T$)@      #@             _@   .$))300-       $
M>#A"24T$&0      !    !XX0DE- _,       D           $ .$))32<0
M       *  $          3A"24T#]0      2  O9F8  0!L9F8 !@
M 0 O9F8  0"AF9H !@       0 R     0!:    !@       0 U     0 M
M    !@       3A"24T#^       <   ____________________________
M_P/H     /____________________________\#Z     #_____________
M________________ ^@     _____________________________P/H   X
M0DE-! @      !     !   "0    D      .$))300>       $     #A"
M24T$&@     #-0    8              +D   (0          $
M                 0             "$    +D
M 0                         0     0       &YU;&P    "    !F)O
M=6YD<T]B:F,    !        4F-T,0    0     5&]P(&QO;F<
M $QE9G1L;VYG          !"=&]M;&]N9P   +D     4F=H=&QO;F<   (0
M    !G-L:6-E<U9L3',    !3V)J8P    $       5S;&EC90   !(    '
M<VQI8V5)1&QO;F<         !V=R;W5P241L;VYG          9O<FEG:6YE
M;G5M    #$53;&EC94]R:6=I;@    UA=71O1V5N97)A=&5D     %1Y<&5E
M;G5M    "D53;&EC951Y<&4     26UG(     9B;W5N9'-/8FIC     0
M     %)C=#$    $     %1O<"!L;VYG          !,969T;&]N9P
M    0G1O;6QO;F<   "Y     %)G:'1L;VYG   "$     -U<FQ415A4
M 0       &YU;&Q415A4     0       $US9V5415A4     0      !F%L
M=%1A9U1%6%0    !       .8V5L;%1E>'1)<TA434QB;V]L 0    AC96QL
M5&5X=%1%6%0    !       ):&]R>D%L:6=N96YU;0    ]%4VQI8V5(;W)Z
M06QI9VX    '9&5F875L=     EV97)T06QI9VYE;G5M    #T53;&EC959E
M<G1!;&EG;@    =D969A=6QT    "V)G0V]L;W)4>7!E96YU;0   !%%4VQI
M8V5"1T-O;&]R5'EP90    !.;VYE    "71O<$]U='-E=&QO;F<
M"FQE9G1/=71S971L;VYG          QB;W1T;VU/=71S971L;VYG
M  MR:6=H=$]U='-E=&QO;F<      #A"24T$*       #     (_\
M #A"24T$$0       0$ .$))3004       $    "CA"24T$#      +Y
M  $   "@    .    >   &D    +R  8  '_V/_M  Q!9&]B95]#30 "_^X
M#D%D;V)E &2      ?_; (0 # @(" D(# D)#!$+"@L1%0\,# \5&!,3%1,3
M&!$,# P,# P1# P,# P,# P,# P,# P,# P,# P,# P,# P,# $-"PL-#@T0
M#@X0% X.#A04#@X.#A01# P,# P1$0P,# P,#!$,# P,# P,# P,# P,# P,
M# P,# P,# P,# P,_\  $0@ . "@ P$B  (1 0,1 ?_=  0 "O_$ 3\   $%
M 0$! 0$!          ,  0($!08'" D*"P$  04! 0$! 0$          0 "
M P0%!@<("0H+$  !! $# @0"!0<&" 4###,!  (1 P0A$C$%05%A$R)Q@3(&
M%)&AL4(C)!52P6(S-'*"T4,')9)3\.'Q8W,U%J*R@R9$DU1D1<*C=#87TE7B
M9?*SA,/3=>/S1B>4I(6TE<34Y/2EM<75Y?569G:&EJ:VQM;F]C='5V=WAY>G
MM\?7Y_<1  (" 0($! ,$!08'!P8%-0$  A$#(3$2!$%187$B$P4R@9$4H;%"
M(\%2T? S)&+A<H*20U,58W,T\24&%J*R@P<F-<+21)-4HQ=D154V=&7B\K.$
MP]-UX_-&E*2%M)7$U.3TI;7%U>7U5F9VAI:FML;6YO8G-T=79W>'EZ>WQ__:
M  P# 0 "$0,1 #\ ]$Q<NSJ(S<=P^S&IQH)K?-K"1])T,]&NSTW,MK].V]5O
ML=G3^HX/IYF3<S)M?797?9ZC=HIOM;#7-]OO8Q+IS'NS.M557-;<ZX>X-<34
MYU3/3WLLKJJL_1^G=['V*-F+GT=2Z:<K-.6UUP
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
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M 0$! 0'_P  1" "[ A8# 1$  A$! Q$!_\0 '@ !  $#!0$
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MD+2I"O*5)*2/V*!!_P!1T!Q(C,MA 2G@-A*4#DD)"?;M'V]SSQX_9H#GT T
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M^XZIX'ZB )^=N//P^N1+TB0IE(1QV-M,K<<)'<L%*20WQ[<#@DD<\_0D#ZM
M<R9+C@"T%!':H! *3WK*$J0.X?JD<GD??SP/'&@.'YM_E0X3RE1*0E)X6C]4
M%2B2/"@5<I'E(T!%%N&YZGQF>F]7GG_D9[R _D2,SJ?(_P#E/VY\Z EJ]7M(
M"E)2D>?//<>2?'Y?QU$J8F_ '$^\$%)]1(21W*[R$A*/;DGP!P2/)/[_  #H
MZ=[2^2B>;[\? <C3AX_604A1"C]PKCNXX' _5*/M]^3J*:=U1SE=^ .E,MX,
M1XQWY\6,^6')*6G7F4.B*TI#3TU3;JTD1([KS"'7^/2;+B0M0*T@V!HU:-*3
M""Y$0NV04890^T$/ QD26OE0I95+"V5!XEKOX1WK_P"K3SH.N???/D;%W$13
M$F2S,B?*QDO_ #$I3[09C&.E8DE]U2O295%<2E+Z72E+7)+O'&@X3E;RY>&1
MV$S.[L4VZAY*E=J.WMX6$)*5KY'(],K'J)6" 6U)(\*&@/-:R""Y,D5:+2L?
MM(3(=FUS<J.JQC)])+B'7827"^AI[A?:I3:4E*FRE7DZ#ON_?$] RU>Y=#8[
M%O K;"3Z8+:U#@G@>@VHI6HD>5 GG@G0&JIRE=GI@$.H*D*3P[RD))]3Z3V\
M>1V#R%'D<Z W5\]F>)*V),>4AA]4=2HZT.(;=; #C3BD*4$OH4?Z5I1"FB0D
MI&@/1T T T T T T!POJ6E *"$\JX4HCDI3VJ/*4^Q42  #^9^_&@. 2"5(3
MW)!6V7"%#ZDD\$-D#QSQW<@^?'Y#0'80OO""%<]R2> /!X_,^XX_+[_P.@.3
M[GR#^SQX_P#'6=/[FY6O&_FOEPX UUH!H!H!H!H!H!H!H!H!H!H!H!H!H!H!
MH"V6Z6Y]'M-@>1[AY0J2W0XK >L+/Y"([835MLIY*(T-G^ED+/("6VU)4L\<
M+2%<AZ] _GE_$^,3D1Y;%[X]9&_+&0;@8E<[:Q:S&LO_ $8N=JLEPJVHGH3C
MN-XWF4)@7K\L71DR\8R[&Y:7E.*8$JQ>C]@,8H =^=B5K0#0$./3O_CE_B-_
MZ._1K_W+FV@)@1(4 D\$I*W&QPGE1*>0%<?D"#]AR/N>= 64VTYOKW/<]64O
M-W%\Y142^04C'<;1\@RN,Y_6C64D2;$(20DNK61SSR.C%3IIHIX4IN&W+:\E
MG]C"A_$VTFVX3?7QS>L3T1?5/'IIX]NP<?N[?'^K7)1D_P#[/Z&YN3[#]P_N
MU<&N@&@&@&@&@&@&@&@&@&@&@&@&@&@&@(ROBX1)]GT.;M5]1&$FR1E&P%JC
MBE?RAV-%I^H;;*SFVK6+Q.Z1?-X]%AO7,^N6@Q),-E;<PF,7@ *#^%G;0)F"
M;BN,9=79.Z]E-<D.Q]EW=EW64KIXI6V_62"#>/+7W\SV/_X[@5&*1Z0.G'EZ
M]!VN^5NO(D<W1F&MVTW$LV)%[&^3P/*)*96-,?/Y''^7H[%Q#F/0BAPR[^(\
MUZU6PI"Q(G>BTI*@> !\Y]!NCUQVL?;*RP6QWC4K(+C(K;"<:R+&K)IZBLEY
M5D+<S'=S)LNNC-O,1,,%3-B25);CHM'G&(ZW$I3H#S:[<7X@GR>-NX\[O!+C
MO9O';PQ%O23VGK#/7W,5:R7'\N[X/J1<%B%S)7:VP<2B,64GL*BEOD/3K^']
M3(3:^\ZG+/XPFT7_ "E<6P3'+:'TI[P1L,:P:UF6C-I2?I=7F1,MU2V&%0I(
M<2UZ;2 M*DD@'GV ^@/DKX42 ION!':.5<^4G@\GQR/'@^"?RU3X=Z9NM&^*
M)4Q$3-]>DKY&#_5GM#U);G[997CNS.\4? <FLE1W*N=^&E!8BMR6E/Q#)Y<4
ME4IH+C<I0"DK]1!Y'CV]@VGV?A54O&P&[);\TU?%+NZ6DHC69S,JZ\5**&I;
M<)K-*-5?C]85C(#:C$]R<:I\?KLYSQK,)M;C]5!MYJ:M,)RSMHT!EN=8JX6H
M),R0E;Y;3^J5]OL!QQ;;B8&+CU5;-A^ZPH25.]-TW-5K*;?"K(M2ZW2G7&]E
M90H\;^9AK\0S87??=AS;&TZ?;,U=_+.8[,[CR#8O06Z_9K>*G9J\HRB.&PKN
MO<*N:C&\CIBE*G>Z)+CME!DE0Y"Q@#'Z=/B67OJ?C6X&25B]N<OW2D[8/5PK
MX0K9<#8SJDQ+"7*UW_G'XCAMM>V6Q->PS9-_-(E5UC(4E*RAY;OOOZ JC)=F
M_B'6E?N_AMFYD:J#/L$ZA6,5K\8MJR#65F5Y_;]3$M3N8.NLN3G(T^AO=B&<
M79KUMKB6,.Q*G&4(25!PM]K1;U,P^A_#NM3&-Q]Z/^4ID,JTPE<AVOP.I7$@
M"KBPX^:YNJA=QJP8<^:?:_P>R,/@W29[32Q9P@6U+"5K<$K7DK<\OOZ<"P%G
MLAU4T62[Z3\+V^G/[MSLWWDS#%]_Y&5/-QK#;_.-TL>O<9P*CH5J=BRK>GVJ
M%GB-:W91FX=/:U5?,C*=^=DJ COP*,L-JOB:Y;B]O'?SW+J=F766%9BM.]+I
M472*:\_PQ-,LY?+CQT!W*:BJD;=(?77K1&$MM3B5*[5%(._>??=CJU.TGQ*<
M>VOK78N9[C/6<4HQV-C'XA1.WT!,7$6&\7N),QZ.IE^NCYHJ;+RP*=5(EUAC
MM1@%)T"Z1R_@DXZ&, W<V[VLS.LWK6EW-[K>+/\ *W'D/%YEZLO7:U^&[%Y/
M]%%<=;E+89 2&T*X[1SH.^G?S,T= - - - - - =68HI:!''_6M$>>#]+B5*
M_AVI5W?DGN/GC@PE5-VH>2OX:3^2*FTK3.5L^=M;21U]4-#U';C[T[$TFP&Y
M$?"<=P7(7\MWKA.0S)5*IYX_]RP9"TE0D+F);LDIK@I"D--QYBE%$AKGV=BP
M]CP\+&QMKWJO@JHPJ*&E[S$>ZE3#5EE-6=W:45PZJJJ]V86[+G2^3XMY)64\
MK*0J$9*4H]=2%K+20LA)1W+0$I+H3]DNGE79_4YX/.O%Q*DG\-M<YCE])Y9L
MU<:9<>.5ET[>1Z('"S^[D_O)'_'WU%-*4.\Q/F5-^K@: : : : : : : : :
M : : : : : : \BXH:B_K)M/<0(UC6V$=R-,AS&6Y$=]EU!0M#K+B5(<2H'E
M25 @D#G0$#VS^99 ]\5#=S&I^0LLU3>]EE#K<:DYY84\MRK:Z:L!M8A9VZB5
M1J+R'"LX[*HUR]8H=3&C_42NK4R1&;Z77R]9:722<2US>AIIWX?8W5/7R6Z.
MYR*2U.G1X[S-'CSE:S>7:V''$N)K*IRSAIES%)$9@R6@\XWW([F1)Y%3NU@%
MW*HX55F6,6,G(Q/721X=S"D/VC<%;K<@P&V7E*E)BNL2(TA;04$OQGD_U%!(
M$6W3H\E7QE/B-DA8/_)WZ-E*)3P$I-/FQ ]SR4I!2O\ )7Y:BIPI5W^8[ZEG
M3$9*93ZIQ/2_!66K)0=U,E?QC",@MHCBD6"XD>LIO2 +PMKN4Q50?31[J6S*
MF-2G@D%7H-N?Y).M,&CWE5*JLG+JB95*OSS\^12I[N5W,3-OIWZU)AV*1,6Q
M>AH([8:35UL1A:4?JF4E'?)=!/D^H^X\?)/A0_(:5UNNIMNTN.D]OJ56'2N>
MOC>?.>T5=P../8<<?P]M9I1/-M^9<V(62D\#RD\<?F!_'4E:7+J3T;\O+\FU
MQ3@1RA([OOR#X_AX]_XZE0W?Z?7N2*W4LN#TUY\OR=1R6MIE;JP.$-.._2DE
M9],GN2AOR5'@?;GR1^[6:J;KC26EX3Q71S/&QI2DTFVYE)^*5WPUZ^9@7U,?
M$#P+IOK\)L+/$<ZR).8YO486&ZO&;(_(R;&8B*7"XMD-R'W"KT:^,TI2ITI3
M;39(5SKV?9_LU;8ZU7C4X*II;H<I[U33W4T\E/[JG$+J<NU;33LZRWG+U4)<
M;7;Y+BC,+$=R*3-"ING:M4.,H:+RK*GGUK96H N(;5+:;2HCV^DJ]QKS,2G<
MQ,2C/<KJHE.4]VITRGJG%G"G-6-Z*MZBBK_*FFKAFD\M,S!3J^Z[+CI:W+@X
M!-Q*/:'<;!<4MMFY7>[WY%F;&\>*[?[G8Y);0A14G%,.W"Q/<$*8[W54\')'
M5-AJO6X*%N/2W76>18>K^,=@&17.V-CCNV>:SL"RO&=R;W+9ZF8";/&H.*S^
MG9&/Y.TE,M429C=A6;ZL3YY0\)T/Y1IAR,'U*0(G\\N?/A_ [^Y[C?Q7*&QP
M#+K;'L$N+G(\4I),^?8$0XF+0+*1,D+HZBP=<E&<)%A3Q'Y:%QXSK/?VH<<0
M3J091]*/7=MMU:R,MAX)49'7.8A'A29$ZYB,,UMM"FR)D%JRJGV'WE>@N?!E
M,"/+3'E(2TEQUI"74$@6(J?B%Y)7LY9N?G&,XA7[-0[W.\8QBCK\A2=W+&VP
MW)8N+0TG'):&8SAO)\ME:VS(;%:TM"WE*0L*T[\HGYCQX]]\#S+OXN.UD*'.
M%9MEN-+MZ]M=;9Q7X]4U#Q_+78-W*@X[>2DSEE#K[M'+97)AIDL)X*D*5QQH
M#MX9\5;%LIP"KS9>R&Z3*)4W <:E(BMT<F&<\SZC@W5)BT&4;)'KJL43FD1)
MBTMLI24%\M+)2!#:6??? R&Z2NL6LZKKC=9W&Z=VIQG!588W6.ST]EL]+NGL
MPKL@K;2,DJ;C2J2ZQ*;6+4VXMIQ;:G6UJ0I)(DS<:65IY5P% E*PD\I"A[@'
M[C_TT!R: : PLZN]FMM-P\8E9MN)NCE>R4?;BNF2V]S,:S/]$H]'!L'8*YZ+
MD2%JJ;./,7!B16(=DPLJD.MMQ@N1):;4$V[[Z\.)9SH[V9V6?LG-T\&ZG,[Z
MF;.O@PE0+>\S9J72T[&4U%?D$9:,9J6(L"))LL?NZFPA6$I@O/P)S*61VME6
MD1\AZ$DK,5IQM@I*VTL@I0E'*![*0KGD GD*Y\C]8!8T!N57LD$ K0/MVG@I
MX4E8X5[\!2>2/ZP)"N1QH#?\DWPE() 2/I"0$]JC[K!'D*(\?EQH")K<EL?^
MV8Z<&N3VJZ-=XEJYX\E.:59''CZ2>?*N>?[M 2NJ+;0["5'MX6I15]0]SW*(
MY)\#W5P/'N!SQ1T4U5)M7^?#OZB9MF\HX&-&]O5+MCL?CD[)LFO*\PX:WHKR
M6+*O<4S.0PXJ'#DI1)=>CO6,D(AQ#\NZ/F7$I?+*"IQ/;@;'7C-*BTO.'#XJ
M6HMKE%XD]39]@KVB%#>:6=WJ[7<+AZEU< W+Q'<"FB6E%<07W)S G-UB+*"]
M9M1'5$QY$J)$DR'FC(92V^$N *2AU 7PL*2,<;"JP,1X=?[EK=)])2;2::F-
M'U.;;=GJV7'>#4H:II;LTG*NU*5I6:LS&SJSZTL0Z5+W;6ERG#\ER).XIOY4
M>W@K@UM%51\972,O0Y=Q:OQ:M-]8O9#$--3RID-VR:C6#[;H37N#69R=Z=_Q
MYT?M'\0;!-R,Z&(7.(Y!MW2760]1>-X+G>5RZJ-BV56?3%NC/VHW+@N2%RFC
M3O,WU5*=I4RN]%E 9E2D.M+;2ET)^E_&(SY\/J4GDGQ-]HZQO>&VQW$<RS3%
M=C-U\:VSSG,L>9@_@A5>PHB)%] 7,E1W;6H;MWUXS!=CH6W8VD*4J$ZN)&1*
M= O7TP]9.WW5-9[J0L J[B##VSNUT\>SM&66$9%%?R'*\:8MZZ&7#)9B/6F&
M6Z&'I3269)"$1W5OLS(L4#P=M^NS:G.SU$R;=JTP'&^G/*9%)E6093&=81/C
M,95:8LUD=;5H:7:/T5I9TS[=9,3%6W(#Q984MZ.\AL#KQOB+]&]@T_+A[Q52
MVX$F!%=;52Y<W9/39TG(H*(<.L7CXFV3S;^,Y$Q,:@,R7(GX5,<F_+)BK40G
MZ?CO[E,5_P 2OIJE[J5^W+F4-PJ;**F+88;GLGYE%%F#LRI1;.UM0R8QF_-U
M493R[5;K+8KC$D.34Q6T=Q RGV6ZE-G-^1D;6U>:Q<L?Q%58G($-5UM7.PV[
M9AR15/ANW@P79,.RBLN28,V.EZ-)907&WE)4DD"_C:E*"N[CD*\<?Y)\I)_:
M1H#DT T T T!H3QQX/W]OV G_P ./WG0%$YQE\/#\:M+Z4A<E,-GLBPX_;\W
M96,Q7RU5604K!#DZPF.L1&4 ?2X\%KX;2LZTPZ'752DXO,N82IAMN,DE]M2M
M<*F7I/5N,K.;Y=)ZJFMKL2E4-,Y+NUM2,LR.2N]RV8R26U7DI':[7Q%N .BM
MI8HC4]4E1[FX%>R@DK[E*MM&*W2E3.ZGNTZK=S3?-N\ZMO2#/"B7XSUM9<ED
MN1=1+1!3P> D$$'@\\D'GGWY''Y^>?.N**JG,Y::7GQC.W;V.;CZB?S'^OQ_
MLUNK)+@#=H!H!H!H!H!H!H!H!H!H!H!H!H!H!H!H!H#Y[=NO2>^+7NE/R%I\
M28F[%A&PV9:L;D,OKQA_IGQ&?VULV/0#;5VE3.1D)0N==(E)DKLJX%5HME.@
M,V.JKI(R/=W=VVW$Q=N,]%R;HLZH^G/*84S*IU&_92=WLBV+GXC BEM!37UQ
MK<-S@6=[$"95(Y91%=KP?4$@8 8=\,_JOCYOMS9R\SJ-OZVND.JI<KHLG;M<
MNV/QRMONJAS'L-HEO0F(6;VDW'=\\'C7-^\S&9L++"K.?(C+4[ ++OAWT!77
MP\-J,QV<^*9\0W"\ZW<R7>N]B;%=)DUW-,LA0(-S*:L&,V?:AO-US347T839
M]".4)Y])/"B2>=0JE5,:..^^)I6Y2YWT[UXQ8F'R]*LEW/P7#4#UJVA:FY_D
M20.X)<2XY78PRZ#RDMOSD6[BT*Y*3%96GQQK:F::*J[W^%.--8>36D>9C5G3
MXOK'+5\.9?@> !^6LBRR1U0\M07QV\@'@$>4>2 5IY!*3Q[C^'GW XFGE$J[
M0W[D%15QPK[_ $\<^_ZH)_B>=![O=BJ\U*=,G%[<?P=WDGC@@*^XY_F"/V?\
M?GH0FG-T^_EZ'"IK@]Y/)'(3^: H'N"5>_!X'(U2M63UF)\R9_*X]2BK_':*
M\##-[7U]FU G0;*)&L(T68B)-@2FI=;/CH>;<]"6Q,:2]$E)"7&'T%3:QVJ&
MNC QJL-*)5JE:>CGEJ^5C&K9*L>K)-3*E64.6YC-1*SC*')6;3*%,(3R%)4T
MUV\ =H[4#A0X]R3]7))Y\#VUFW+;XMOS9JJ70E0[.E*EKFK?0M7FNUNVNX.3
M8;>YKAE)DE_MM9SK7!+6WKFI<K'+*^IY%#;3JE3X4EIVRJWYM<_VCA:8_"TC
MM8<$$\/Q;P\>$9EI,:Z-^E_&:P55%LQA5;!7$O:P5\>!WM)K\F7B4B\K6TJ7
MP(EBUM[@85& 0A)QBH\ Q#W!&?K?Z?;J;7.C7I?5-_$E;,86S(_#I5:MUJ"J
M.VY$?6\\[%D*0\EAX!2REMU]IPM)+H;4E*@"(R]%?O/YEP]KM@]GMH9][9[8
M8)CV&2LJ=5)OW**&F(+)]"E.N-NL E#:%27%2 $I2DO+<6 2X="2D972#TVV
M5WE>13]H<0GW&=MRQE$MV"H?/KL)")<^465N%F)*DR(\9^1)AHCO//--NK65
MH!T!OB=)O3C4U[%5"VDQ"/5MRJIYMIJO2XA3U8BP$21)<<6XZXZRFSL4+E/K
M6I7S;P4H]_@#DB=*W3M&V_M-KX6U.*1L#LK*KMY.,,QUMPG[6I2E-38MO)<#
MS,R$RVRW">8=0Y&:;:0@A*4@!9Z(N!MQM#MEM,Q/B;<8=18FS9M5<6QCTT9+
M)FM5?SAK4OGN[WOES83E*><*G'%R775*4M:E$"[$< -  DD*7W<C@A165$$?
ML[N![^./.@.?0#0$>'Q1(N('HTW3EY>YDK;$>[V@D8^G%:B!D5H_GD?>3!9.
MW<->/VRFZ:WJK'/(^,P;^#=+_#)-&N<S-4W&+BM!W/??4Q*^"[M1DVW.UNY<
MC.J+/*S-)5EMYC$DY-2XOC-=(Q7;O;RBPO"HM/4XO,FLNBOIZQL6UG-<;LI\
MM:4.H]&$SR'\>3MWS)NXB"AA ('<>Y2BDDA2E*)4H<DD!1Y/:3X]N!H#LZ :
M B2W)_QSG3?_ *&6\G_WG5: E>4VE2U*5PHA X' \<<@]Q!^H$'V4"/R&JNE
MNJ54TN"\;S\N##LMZ,M>EXG-%C-U.G+;#=ZHD4V68S4/PI:)7JH9JZYI9D2X
MZXRY;JQ']1Z2T%^K'<6L%IT!P$J XZL':<3 <TU9Q9MW2<QXO50^9Z>Q>TZ]
ME2:H56OQ.IRD[).?AGB5[@6VV&X%4QJS&:>!":@H7$8DLP8;,T14J*FHCDQI
MA$A]F.A089+KBU!E#:2I125'/%Q*\6MUXCFJJ)O.FEW$YQS.7:MLJV[&>/6D
MJH5#2F%NY0GDH>2M-]66%ZH>CC:?JJ310]S9N8QJ^IJKZEDP<:OD5E?>8_D*
MZTW5-=0I4*PBR6IQKH91,89BV\1+"TU]C%#KP=S.8MO@GPYNFS#KFRGRH68Y
MO4RK+=NUIL.S[*)&1XA@KN^6Y8W:W.8Q&K]"(NM8RG,FXM@\X[*FOH88;B,O
MHC+E(D!\N&EBCY?PI^C^+$SZ!BF.9CM_4;GSZ"1GV.XCFMQ$J,EJL?I9]!^C
MLN!9.6C3=--8M9MA-:A&+/\ Q-UN=!GPWT,]H%^M@^C_ &>Z;<CW#RC;2'=Q
MY6Y @Q["):VR[6NJJ6'E&=YG4T&.Q?3:-?2PLLW/S>\6TZN3(1,O7UB0&4L-
MM 4['Z'=E&$;QNOR<UN'M^(%12Y<];9%\R["QV@R*\S.HQRA=$1G\)IX^19'
M>V;+;HE2?7M'0J44I:"!"^_K]C'S>GX7.V>8XXR_M/D60;<;D5V36N24>92;
M-ZS74N9'>[A7N1JAM!KMAR+"3N3DL9J2AMST:R0F TVE/]* A9PIZ7.?%/A3
M=.=%@6V6.9*K)LCS3;2MNFJ+/7[A;-FU;9,X\_?SVF4M>FAJ:Q(D5:XS@"7Z
M-YZN6KAP+2)+K=$'1=9]*\G=.TR#<6QW!L<_D8E"K5SD<)Q[&,*JY531TT59
M0V3':BR>$1^U3<1*$M-.N)).@ZD@:4A/)'')X^W'@> /X: W: : : : ZTLN
M>F@-$!9?8Y4>> VEQ+CP/'L5M(6VD^P6M)/CG13+X1/.=%]7RD=]]Y%AV&O\
M)VXZSW+7A6UEC(;;*?#%UN&ZV4R>>?I>C8;"EN5Z0.Y*;^3-"NUZI:.MU6\.
ME[J2JK23;4_ E%ITK=^BC(5*5'/3DK/3CJE.LO*^S<7TW2Z'#RI*D*': DI]
M12T?2#P%)[U=RN.5D@J]AK!W<\HC1=.'R*4T*EMW;<Y]6_.^>IV>%?Y7^H:%
MS=J(<S-HR[[]0-2!H!H!H!H!H!H!H!H!H!H!H!H!H!H!H#0@$$'R"""/V'P=
M 0<54'H<>ZNIO3%'O-^57M9G-?BK. S<^RC_  02,IE8/=;J3*JN958?C+D:
MHQ[%%S)LMVQ<BBPDMUB5EF2M1"SZ/+KG^5TSU)O'833I'>$J"0 CN2"4\D)<
M^H\DAQI"&RD_2>WN4E1.@-$PD=J XHK4VX'$J('">SN#:0E7< $)(0".%<)'
MU<DG0$/O3OQ_[9/XCB>]7*>GGHX*@HA0^J!FI3VGQP"GA1'V^PU3#4*\WJ;X
MYY0K$XCA*V266G&>2CS)&]L?^D-CF^X25=Z,DR)VHJ'% ]J<<Q18J("XSAX4
MJ-;.1I-T/ZH=G.]G*%<GHQ/A5%'^*EY9N^?C'YDSI:Q*9NE+RSMEP[N7I>EM
MLM+=/D)XX !43R>/  Y/!]^/8?NUG1354XM/6%YO(5UTT+>J;26<*7X4YOP+
M0[K9W6XAA%K=V04U7>B4RI:K$4SD=L=Q<<58.M.(C(:2.XK<2$CR>1[ZM331
M-2JK5+72+<_D:X.S>T-N:7LO9?ZNM_[NJM86)GFJ:KN,VE>$^$&/O1?O%5;J
M;</2ZNYD9,8]K?.OSW\CBY*I;";^PB1F$S(S#3;#<*.B, E2EK6VI*^.% G"
MBMU51"2WFMZ9E2U/2+Y\D>S[:PJ]E6#AUX*P\6C P:,3#2:=.+N4^\OE6MY1
ME/5MF<*4_2E:5$E384DCP"".1QSY X\^?/Y^3J\\+WCH>!N2IG.\1QOG;Y'3
M=L7/2=$=M*WT(6$!P.!KUQX;2M24E00HGE12"0 >/MJ50ZLTH546?KY.?2^9
M:BO"FE5U5JF4JFJ&W&M2F/!:D:75.>L*;^C(VPB8Y&XS#$%7:JZ;<JC.UJ\\
MH?DX_J/,I#,D3Q%1/="EM1ZIVS=?;,)QW7M[#A[ F_ZBNJRJ:55*<_ZNIO*?
M[):U=24*4H^X]B;1^D\-O^MVS:Z=U4_$]DIK3G>IKB*D\FHFS3C@UG+M5,W"
M_1JF3F\6B89:H*5N'\C(MW[M2_P^,DIO?Q)IM L0>!.4WP/FBZ>  0/)Q]WW
MV-NWI][B;K41&^XB+1&46\[?+;?[BK:MIQ,"JMX6+M./7@[]*I;P:L2IX;:5
MDW2TVE*62XD7O7W"ZC6>I_I[O]H(6[=[C=<[A4.3C.*295=A%E9R=XZRRS%^
MQOZWU',>L*_!V93MY*R2._0W./-_A->8TMJ:XK)V[OUCQ7+F<*<U)7NXRS\<
MM']K%C^BV3ULXK:T]Q!P;=_)[%C9NUA;P8[OW<2,=Q^VW=E;BQCC,_!)DTR%
M-,5^'JR)J<J+Q&>,^J_JM@A$9SX]\B7F[S?,MPV/B&26=R'MV\.WWI]T9O5)
M@.:X$K";ZOO-N(.+2ZG:"1E^&HC5"4E.%U5:QE-10VEB TRU*R 6++MDE3J(
M\E?OA=]R.^X,V/AB?\JJ,WNY$ZH(&=O7\BVA6,B^R^1(9A.9&XVTW=T^+5[B
M1'7107&4.5\^N(CR_644I".-2.A0.S,KK$P>@ZT+2- W$R;*TSXEMM7;Y]2O
MEI>06V1_+V>-XICC\H0[/'*&L?,R'9LN--SBI392E# *@[U[[N6:W!ZI_B.;
M-TCU]N:B(SAIM&J2=FL':&N,W&X\?+;*O,N!1,VJF<BEW50Q#D.0I#C*8;"G
MI;*U)(2H"V W.^)!N;68!U);;XQE5A;WTW'(UCC4BI748H:;#9\B/.R>!C2Y
M CM2,@I;(38M>ZI4>=*A-LJ6$^= 9G=('6!U [K=7&1[.[B*6SC5/BN96MK3
MRMOX^.NXX]5G!DXN!D+$J0N;87#>06TNW@+0VW438ZZR,MYM@N:=]]^@)FXW
M/825%1[CSR... D >?/D *Y/N5<^V@.QH!H"-?XL^/MY/T([TUSDFL3';MMI
M+*RB7%G/IZFTK,=WBP#(["AM+*J;=LX42X@5TN M^O#<MM4IIQ#K24J<2!8'
MX.]]@5WM[O"S@^(XMB+5;F%-$MXF,;B9=GZ7I0Q^%\NY.E98$2JN0J,IM;$>
M.2V^PM#KBBM1T7GW8*;^<=%KYOE!,E\XB*SR]PE*#PXXXXAM*$I]0N+<6HA(
M#;;2EK5SP.U1)X!.@+8/;_;0,"@[MPL3YRJ=9UN.'\:B%%M/I7_EK:+#6AQ2
M7G:Y_P#H9@02&'!VK()'('2A]1VR=@Q428>YN%2&;ZZ>QNG=;OX*DV%_&4$O
MT\;ASER<V5)Y: X/<D!7*AR!'UN+(0[\9CIQ<2" GHUWD3W*'""/TSJ3WA7L
MI)!^WL??@: EB4_V]RPV5K2%#TP1W**>[A(// 40!P"0//O[Z%:JH49IS]N#
MXF"O5'U9;J[%TE-9X?TUYSN0]:9;6X\]'K94-28E?-64O7"T0E29/H-)'*>]
MM*?_ (BD ZX=I>+2DZ*-Z:GD[S>&E$\\H/JO8/L+9_:RK]YME&SNG#=<5*'"
M:6K2LFYAIPDX,K,!S2XR6.Z9^#W>*\-^NV;=^$X'%*2"4'Y1UU2%^.2%#Z1[
M^?&M]G6(L-^]353J;2<2DTHR;YGB^T-CP]AVFK PL:C'H2WO>4)[K>]4FE.<
M;J<JSF58C:Z\>L+=_IVWQV:H\4-*G;VYK(5EF<<TZKG(I3S^<8[0^E%C.2HK
MCL(U5E8I1^%HF3H\OLEOL!AI/?N</?F^YZEKNF'X@VZ=O=1'-U'8^YF-Y%M#
MGFXEE"VGP:S<R/:C(\;WQI\ QO!KN(VY)<L7LGQS()MI7)+34EEC#;9Y2%L@
MN@/+G].EO-WY%L,:^)QOCFE599@FEJL*>@=:&+;8HVSR3$K:+D]GLCEE;TTR
MHJ4O35QA^E%#'W5RQ^_=@-RG&K4T#33+E?%E2 $_;CQ^3;Z7U,ROAF]7.XO5
MMMGF65[IU#5-D]788I,9HX=.Y5-8[ SC!,=RES''Y!DOF9/H;27-K9GK)CSX
MB666I45IU)Y Q4W/^(#U0;?WL>FMJ'"*^5$WSW;Q>=%:J+.VB7%/ANYNP6"8
MUM_2S"8RE9);5N[F1VD6T4T6WF,64X&"VV^M :\N^UX\C(S?/XBF6[/;H9UM
M] V/L,IJL%1%-MD M'8CS[[>U6$;LVS$6(F*I+HB4N8*A10ASEZ? =8(!Y
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MU.(](*3WE+@4KZ2#H,^^_,Z-WU+=.V%Q+BJ:W(PEAS$J:;8OXS5VD-^QC5U
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MG4MU).RY=^)M=;M>G>23C)0HYRT[WT/J29KVXZ&6VPA++* E*$(2E"#]O3;
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MH4%D@*2EIE2D^"YX&@[[[Z&U,%U/!+_) 0 I ["DI/DI+GS _:D ) Y(]R%
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M)Y!'!(((\@_<: Y- - - - - - - - - - - =5^8U'6E#G=W+2I2>T<@]I
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M( [B>//'O_$:SPJF[--6;R?%*%+!RZV T T T T T T T T T T T T T T
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M[7Q9N9).0)()/C@\\?ST5*62^8-^I T T T T T T T T T T T T T T T
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MDCUD?M_EI+X/T^X-2ZD#GA1^_@?;^>I!H'4G[*_?QX_U$Z$M1P\T_D<NA T
MT T T T!@G\1C V]QNDG=;$"AER1.D;?65>9&=-[:)BVE3N?A%O5SXN<NH>;
MQZRK[*JBS*F2MHEZR9CQ6BV\^AU(9J,\K:>MM9\S#WX1E[=O0^HW LEGWD^Y
MV_SK$XD]=KO8O>Z"H7F%TN01%U.0?+L,US0B63#<B TMQ;<AIY*P%]R=$YNA
MRCG\Y^GJ34L_]7]_UE>YY/)))_<.?8>X]CYT!RZ : B2W)_QSG3?_H9;R?\
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MA0&:57A)XX4?R">2?MSH"6UI25H2I)Y!'/Y'SYX(/D'@^0?(]CYT!R: : :
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MF8=U+;^9Z.A<: : : : : : : : : : : : : : : : : : : : : : : :
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M$)6E&:502%]H'(XY[>!QYYX'OJ5\5+JIO2LVLAWQ)=$J2D>2$E1*B.>?)_\
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MD[V]>9TT^AR:T T T T T T T T T T T T T T T T T T T T T T T T
MT T!QNCEIT<%7+:QV@\$\I(X!^Q/MS]M ?*1\.KI*Z@-O>N3#]Q+78+,]HMH
MFK'/NRNR^_MMQ[2%(D8S<1:6;(RG)94F5215.NM1&XU(B.TI+OHE'RY[0!]7
M>@&@(<>G?_'+_$;_ -'?HU_[ES;0$QJ?8?N']V@-= - - - - - ;0221VD
M'W\>?VZ U42!X'=^P?\ YT!M')__ *Q_'C_9H1"Y^;^X\_Y _F/]F@A<_-_<
MV);(4I1\<\\>WCG[>_GW_9[:JG4ZHB$IT=_'NPJ?PV3E)];Y<_-LZ#D<=ZN]
MLKY)((!X)/W)43^7G@?G[>-:*N+)?EI)^JXP]9B"E.$YG?W>C:X<^,Y>*.PE
M)2E)#/:!S]/([0//)X \D_M)Y\<\ZSWFY^%MR^GGEGX<S5I)PG,:\2B,KPC'
M<U@3*O**"#=0)C996U,C,N+2.>6W6U*22EQE8"VU)(4A20H'D#5MYQ95*-)Z
MZ2%BXM'[6[2UP2B(^ZZQQ,'<_P"G5G#YC=O53\KHF8KK3]5G>&RW(^4XLIL$
M,BXCGOCY%3M'AKY=YL*92L.+]1+02;85"KQJ:ZXM3K*UF&[V\N9OC?JK;O9_
MLW^AJP*\;9,3&JKQ,7=HJ6$L1;KA-2I23J:;3;3LD8)]</4IG6R,O:2LRZN:
MW)AY!?8P:[<3#*\1Y=I,KLC@3&$9+418SH9]2/'D,28\54:,9$QCMC^HLE7T
M&S4;![FJMXWNZMYTO#Q*IB*8?NVM&[RW*2W9/U3]&;-[&]J^PMIVFO:\*G&>
M'B.G"J>ONY3HW5*5552NW;<2RL3L[:R69N#8W,8CHC-RJUE_TFT--M^HX.Y]
MUM#*4-);D2/5?;"$I2$.)''C7A8R2Q:TFJE-FLFH4<;QGK,R?ENVX-.!M>T8
M5-6]31BUP[ZU.K-YQ)7.LCE(8/C,=2VTFU6RM7LCN.O+ZRYWRDQ+S"KS'L>?
MOJ9FUV:SG;W-U4V5H:2&?P;)9":RGG0I#B!95<FUC_4!QH/D6Y^!UC[T3:#<
M6ZL;2UL+298;:8TVEVC:H*)FBV\VYHL&QI^FB)>>#]A+J:9,BZF.E+KCI:;[
M>$IY!3QX\K/0G<B$J805#A1Y*OR[N?)'MP"?(!\@: [.@.%:A_2#GR0.!_#6
M6,IH:[A9DK-=5\R)3<921\9CIP)4GAOHQWC[CS[?],JH^?L/'GCG\M=&%AU4
M[+55#AM9K65;3-^A,_NTFZ7&_P!+^O E:<D+[OH2E2>!P2 ??V'^S\^=<F#O
MUTM_M^*I1+63=[D.EYJJA*%FWG%SA7,6VA3C@:;0@$K6LI0A('N5*40$@?<D
MC6BHK=DY?!-_8C=K_P L/S92]IN!AM0$?C.1U$/OY*/^=(<_5/!_Z@ND*Y\<
M'CSP.-;K9L2O#ET.JEMIRF[J+77SLIOF88FU8&#4J,3&H6(U+5-7]K<+U6J^
MIAIN=UP56%[][2;'T&VF=YB]NDBT5$R6LK9+5+#77,J<8?$QU'RZH4<H+MFZ
MXMLQX[S"T!2E@:]K9?9-=6RXF*\3!PUAI+==XH:^.6IAM?MZ3D95;1LS:?O:
MFZIB'&2F*;Z<<I9D4SBNX69(#N2Y&G':QQQSB@QA93(45@B6B9<N<NJ:=;4"
MEIKL[%D]BOJYUX]=*P<2I40Z75ORK;TZPUFVKIK3P-L&K#JH;EOXXFIINV><
M>%M&]2X-!@F,XRD_@U2PTHAKU9DDE^>\0XHK4_,?*Y#CG*N0>\'A/!)2>-5J
MQ*ZLWY6X\/+\YZ1AJ/AI3OHKSET7\%<QQPWVJ4 LDDA?:5G[ J'[@../[^=4
M[1+W)<-:ZKC_ !,W\D<BU!(X)0>?8<#^'L/V?^FA'PO)4OP1O:]CR$@\^PXY
M^WOY_;XTEO-R'12^72/L<H(/M]CP?WZ$;BXOT^PT+))*$-"1H#0D#W('[] .
MY(!/(X'OY&@- M))2% D<\@'GC@))_D%I/\ _H: W: : <@>YXT!IW)Y Y')
M!('Y@<<G^'(T!KH!H!H!H!H!H!H!H!H!H!H!H!H!H!H!H!H!H!H!H!H"''IW
M_P <O\1O_1WZ-?\ N7-M 3&I]A^X?W: UT T T T T T T T T T T T T T
M!Y%@VT]ZK+Z XTII/>DH"@H*)24$$<%*ASW<\C[<>^K*4MY<8CC:3-T+:*GL
M]26XUO.<N<V>FD2^29##U\[(YR_G^V5WMCN=48!4O9WMX[=8S)HVK8&Q.:5S
MD?)75/-N^A65P07YS#'IH<;C$NI4@<"50ZEO*%-41=)6F9X>AYN-^H,;].X^
M%L>S54TX6TUTT.G]K2JJ:=632H23;=H=^1+MM='LX> 8O$N;2!=6D:IB,3K2
MKAIKZV;):90AV1!A)^F/&<4"I#8\))/[M5=F]3V*L3WS6*W+Q*::VTYEU).9
M\=2O]05(BOBE],_5_P!3%;MGBO319[80,5:_31K=A.?5-;.N)#$Q.)C#TXA/
MFM+74N19+.02;=YE:''VTP4 DM) $<>^_(]#X6?1CN'T:;;;@8AG]-7U]AD^
M8L7T=^MS:VS)JP2(+*9$M35@I35'Z;Z5,,P87$<M-H7P>?(G2_EGW#CYDK[
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M0O%<(MX6]3-1GJ:Z=W+2YIF=[MM)-IBTV!4Y!":S:A>F5MG9W$;'H<:?$:L
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M0:'&LPLOQ"!2L1&TH8CH@A2F_192EM)Y*$CDZ S5T T T T T T T T T T
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MO:D>R1XY(\#W/N?X_?0&O _(: : : : : : : : : : : : : : : : : :
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AYY[4\\<<\#G@\$CV]B0#Q[>!^6@-P 'L /W: : : __9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>41
<FILENAME>g164680g01m16.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g164680g01m16.jpg
M_]C_X  02D9)1@ ! 0(!>0%Y  #_[2 (4&AO=&]S:&]P(#,N,  X0DE-! 0
M    '^R^@7(X0DE-! 0       \< 5H  QLE1QP"   "    .$))300E
M   0S<_Z?:C'O@D%<':NKP7#3CA"24T$.@      Y0   !     !       +
M<')I;G1/=71P=70    %     %!S=%-B;V]L 0    !);G1E96YU;0    !)
M;G1E     $-L<FT    /<')I;G13:7AT965N0FET8F]O;      +<')I;G1E
M<DYA;65415A4     0      #W!R:6YT4')O;V93971U<$]B:F,    , %
M<@!O &\ 9@ @ %, 90!T '4 <       "G!R;V]F4V5T=7     !     $)L
M=&YE;G5M    #&)U:6QT:6Y0<F]O9@    EP<F]O9D--64L .$))300[
M  (M    $     $      !)P<FEN=$]U='!U=$]P=&EO;G,    7     $-P
M=&YB;V]L      !#;&)R8F]O;       4F=S36)O;VP      $-R;D-B;V]L
M      !#;G1#8F]O;       3&)L<V)O;VP      $YG='9B;V]L      !%
M;6Q$8F]O;       26YT<F)O;VP      $)C:V=/8FIC     0       %)'
M0D,    #     %)D("!D;W5B0&_@            1W)N(&1O=6) ;^
M      !";" @9&]U8D!OX            $)R9%15;G1&(U)L=
M     $)L9"!5;G1&(U)L=                %)S;'15;G1&(U!X;$!7P
M        "G9E8W1O<D1A=&%B;V]L 0    !09U!S96YU;0    !09U!S
M %!G4$,     3&5F=%5N=$8C4FQT                5&]P(%5N=$8C4FQT
M                4V-L(%5N=$8C4')C0%D            08W)O<%=H96Y0
M<FEN=&EN9V)O;VP     #F-R;W!296-T0F]T=&]M;&]N9P         ,8W)O
M<%)E8W1,969T;&]N9P         -8W)O<%)E8W12:6=H=&QO;F<
M"V-R;W!296-T5&]P;&]N9P      .$))30/M       0 [_^-0 "  $#O_XU
M  (  3A"24T$)@      #@             _@   .$))300-       $
M>#A"24T$&0      !    !XX0DE- _,       D           $ .$))32<0
M       *  $          3A"24T#]0      2  O9F8  0!L9F8 !@
M 0 O9F8  0"AF9H !@       0 R     0!:    !@       0 U     0 M
M    !@       3A"24T#^       <   ____________________________
M_P/H     /____________________________\#Z     #_____________
M________________ ^@     _____________________________P/H   X
M0DE-! @      !     !   "0    D      .$))300>       $     #A"
M24T$&@     #-0    8              ;(   )#          $
M                 0             "0P   ;(
M 0                         0     0       &YU;&P    "    !F)O
M=6YD<T]B:F,    !        4F-T,0    0     5&]P(&QO;F<
M $QE9G1L;VYG          !"=&]M;&]N9P   ;(     4F=H=&QO;F<   )#
M    !G-L:6-E<U9L3',    !3V)J8P    $       5S;&EC90   !(    '
M<VQI8V5)1&QO;F<         !V=R;W5P241L;VYG          9O<FEG:6YE
M;G5M    #$53;&EC94]R:6=I;@    UA=71O1V5N97)A=&5D     %1Y<&5E
M;G5M    "D53;&EC951Y<&4     26UG(     9B;W5N9'-/8FIC     0
M     %)C=#$    $     %1O<"!L;VYG          !,969T;&]N9P
M    0G1O;6QO;F<   &R     %)G:'1L;VYG   "0P    -U<FQ415A4
M 0       &YU;&Q415A4     0       $US9V5415A4     0      !F%L
M=%1A9U1%6%0    !       .8V5L;%1E>'1)<TA434QB;V]L 0    AC96QL
M5&5X=%1%6%0    !       ):&]R>D%L:6=N96YU;0    ]%4VQI8V5(;W)Z
M06QI9VX    '9&5F875L=     EV97)T06QI9VYE;G5M    #T53;&EC959E
M<G1!;&EG;@    =D969A=6QT    "V)G0V]L;W)4>7!E96YU;0   !%%4VQI
M8V5"1T-O;&]R5'EP90    !.;VYE    "71O<$]U='-E=&QO;F<
M"FQE9G1/=71S971L;VYG          QB;W1T;VU/=71S971L;VYG
M  MR:6=H=$]U='-E=&QO;F<      #A"24T$*       #     (_\
M #A"24T$$0       0$ .$))3004       $    !CA"24T$#      5U@
M  $   "@    >    >   .$    5N@ 8  '_V/_M  Q!9&]B95]#30 "_^X
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M)?2D"ZU1X'3.B=0<X4,M # _=932P$.+F^W=1N_,1W] Z8W+KQO2M=ZK7/\
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MG_).3_5_B$3IIFAW]<_D:A]<_P"2<G^K_$+0Q?S<?)KS^<^;_]'O.@\
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
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M*3E$15-4<W1VE)6SM$9'8V2#A(:(H\+#T^+_Q  = 0$  P$  P$!
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M>57Z=8B!O[3ZK)'Q!.ES^>JFOY&>57Z=80-_:?5$?$$Z7/YZJ:_D9Y5?IUA
MW]I]41\03I<_GJIK^1GE5^G6$#?VGU1'Q!.ES^>JFOY&>57Z=80-_:?5$?$$
MZ7/YZJ:_D9Y5?IUA W]I]41\03I<_GJIK^1GE5^G6$#?VGU1'Q!.ES^>JFOY
M&>57Z=80-_:?5$?$$Z7/YZJ:_D9Y5?IUA W]I]41\03I<_GJIK^1GE5^G6$#
M?VGU1'Q!.ES^>JFOY&>57Z=80-_:?5$?$$Z7/YZJ:_D9Y5?IUA W]I]47P;
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M^EF")571-[$/6EI.6]3$@D*OFKF6%I!2D@MH%6$K2"3<J L>)M;!%.WT2^Q
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M,TFTTJ0P3]X2+C972]/3UZ7M10,(N9B$"T+T:/SP\CWSV-/PMF!L@@7O-3/
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MNY]!;,,_F^8<@FT=M=49GE!2Z1LT^PS#T-4>7=!UY6E(367N!2G(]4>]2,+
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M_P"41]N$G:SM*A'7@_)"3V^>D_0<1KQ<M/\ : \3Y?=( -S'42OG7D<0@?\
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M%(8C7_:P_P"]]ZK(W]A]$?$HVI^?2-YY@?\ U7I$^P:X@O,4=AS]H>=$!DP
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M<,/Y>>V7]>_^]@?PK23M/:5.C-G,51%Z@CK7UU %N?\ )[/#NQ9OM[[:$_\
MB,6XL<$_]/D>"L-8V)VW[:5D=1X9)I.:^8&\G_=#&_*'/OQO_+WVT-/?XU:7
MPOX%;XOK'^Z1WY<4V,U:^N+5%&DW%AO#7NQ7^7/MF/\ /XW][!_@4?&:3>GR
MG^$)E&:%?JU^'XP#O4!?P) Q ]N_;+_2,8\#@GP9OW+88;LW=D>$>:F&9U>7
M_P"Z"+/<%ZGNU!'KQ;^7?ME_7X_]W!'>&4XJ1A&1\>>QW\9\"IT9FUXN]IW&
MZ?Z:?H*<1_+OVR%??XO'6P\M^KV;<EOJMI+J'<8.Z9_#.$W^Z77/_#T;ZQ]F
M-/Y=>V7^D8G_ -G^%6]WO[OO52,R*\4;_#T98=GZP/>^NF*?R\]LS_GL6W_E
M#L^#P6ON6P;=IWYS2O8GOW1*X_X;B_ZZ,1_+OVS_ *[&[</^%/<C=VE2?NB5
MM_PY%^MO_JXM_+OVP_KM([<+^%;>Y;]4=CO1-_N@5?\ \+1G]9/V8K_+OVT_
MTC2.W#_@3W ^H.[U4J,P:O5J9G$ =ZK>VWU8K_+OVS_K\>=DX4]S%'T9O+N?
MORE,(KNK5<9M$#_G _9H,3_+KVS_ *_'[<&]*&6".94_1F;3SLY":^[NJ?\
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M5ESDLNLJEN2(YP"_ A/#AQL2;<\5_EU[8G_/8\;=?!\-7SWK=O1V"6@AC;6
MC\)\]B656=2:GX0= [+#V"P[.0Q7^7/MH:C&Q\Y&M@T$D3\M<I._8$/1F#?5
M9UMD]LA*JK:I=X_[9NIX:;P%M.](/?CIPO;CVR+&DXV/-?UL+:=C"%UX70^
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MHZ)UC6G523%>V16B?!4@7%K]@ MZ 0?'A>][8M[_ $RGZ9M/_+'W*&M<'"'
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M,$YR42X]AM*5ND-H40G>*DFRUD!M! ).^X39*+;Q/FVOI@BJ$8V?DI6;FR;
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MO'(P1&"(P1<D.E>^_?19_C;=EW\P<]<0;=;?$*[+N^P_P*ZWXE47'OHD/O\
M]*S^-^VL?S R Q MUN\2K.N/LL_<:LM[9G\;?HK_ .DWG5_=#SWQ*J/F'V7^
M 72G!$8(C!%JOM9R6)?RPGM6HS[S)V?I=E_+)E5\^JK+*"RVCIO,Y3*()R)<
MD48UF51%<RLPL0XVE;"(:"@(IV,=:0(U*"4ESSSY)/>L)[&L?GA2^RA&9GY^
M9E59FC6,[D]3YFR%FMY504HG\@HE4+%3NE*:F$70%&T9+XZ;*E#$-%S.-^#5
M;C\7U2 WU/GD'#S[JVS\UIA26>&T12$DV;\ZZISRJ"NY7M:R7-GX<H.:2>@Y
M=3V7DV@J0J.K: F672I;3L+/H)=-0\!+Y=,8*:S::IFJTQ4QB5-.N%I)1([X
MZUY+8-SAG&;4FV<ZMK7:HZ0BJ:VJ20TU5M44W4.0D)(\B9U,EP3$QBI*_6D/
MLYRJ'BJ7F"G%HA(N K128YO?ZF;/;[!<</PGGOV*5N)(.DGRKJ7:9S(R E\F
MS%:@J6H6CHVDIO$Y#[1=/.3&LY]-:\ED\D$Y?G>7$ME$@IUA%,RAV3UK&O2:
MG(EJ(F[L+4<;#,'R8BU(E&UCGYE#E/LQ;8E?9PU'F33>U&C-M^L<EXZFJ-9H
MW+N$@\E,[,],L4Y<FGZ.@JJEL?2,ORIE]"U$N<5+/X2H6IQ/IM,D+FL-*(B
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M0(,2XTDKNT$$:/I()OI!/#X&7&?"(HMQFF>K9;2[90ZV'2X@DAQQ(5N)=>4
M=U;H2EQP#>%U6N=<>D8S0>@.C=)=_P")Q<30QB@@AT/8\N+IUL2X$ZSB)F1F
M.5_\Z:D@$W'&](@"IV3M *XM[7F9><$KSTG$I=J:IJ?E\G*ET=!RMY4%!O,M
MM%Y$2TAMLB.<7$J\GLLIN$D<!O'^H_\ V=_8?\GO27L$W2NF\/H;$TXX;7D:
M8SH9V*&.P1K'#.E8#L4.:0X@U%*U"[6ZOPS($323:P)B0#;?3@NL^1TXJBH<
MKZ!FU;-J;J6-IR =FX>W!$NQ)939^);1YB7'DD+-B2;W(!TQ_/[V\TGH[1?R
ML]-]%:'AX?YKP=(TQF$,-F"<$-8?@@81^CP1!&JP;H61  ),&T09)F-LFU1>
M+&A66EI2I+UA8=:ALJM_DT+(2XL&XL-U1W2.)TMS/Y_TACX>*>FV83=7#P>D
M\%F&* :I#3+0"6G^R !7?,MC7;>(GA6G&+00?):C95-MP&UEM12^&"E04QIW
M*&H8UU !0N.,GGD E=P0"ZXTPTI=[$A(-U<,>]^UG]">PEM7\PZ77];_ ,22
M:$1!&>V;+R+@?=4$F+R:U-(,10>BW-4%I=5UEBHH:\Y&J2"%$=FHMKIZ<>D:
M. [16ZO]<^\UH*Y[ERX)C$>3]03$?6-Z\FTRIVVRX=. %]=+^]\7 U*FUH&W
MPM-_%==" 8WB>3"?::(N-!IZ_5>UN0Q.O<UB@&W/T0")VGGGR$ , %)N=;Z:
M>OG;LQ!(<(%(K7LRG:IZX[?(%3H05FPL+"Y)]^.( U8<X<!F"B92D( TN3II
M[CL]Q@27'8!6O)VQ15M4U)I3P&ZDUWU3C+14JY&EO;I;P/M^J!+1K4K0 \9W
M;)6K!6=WF.95Q;;OH+!0%]>%M+ZVOQM86M;OP +CO[HYC); 307[H]4TTRI*
MB24_)/,]H[L:88+'2;0;<A;X+2W$#C4 &V\1G":2D@W-N'V8V)UH !OS:=JZ
MW.!$";^J9;;)UTM^SZL2UI!D]W(4L;4$VC*XMXA-C<";:[P(MV=_[>WNX:D@
M@  S)SH!L'B2>)6TS0#MRBIC*-]S694K32ED$6 UX_9Z<1!B>N,XF)5L.CJB
M1!IV1/=;;Q3Z$! ]_<D_LPO%.?(#U)*V)UJ#R%AW 9#S3#3961PMWW^KZ.=L
M5)@2@&9$BM//A,55S;0D#= L>79I[FVGM.,B=8QV3LZL]JBY@5)ZJ<+#\(WS
M(00M)TX]_P!F-,-I#VDQG;>"-BUPFD/:2*5S&PIU*2HCA:X&N.I=2;2D)'*_
M=]6"D4(.PA2H05Z@::7OI@M=86VVWY;[Y2G@WNBUK  GE]7;@C!JD$U,CFO.
M2J0VI>H&EQ>YM@NF?*F8G:KBEL#LL. '#!2I]P]H]OV8*6W'$>*8W#VCV_9B
MFN-A[O5!0@["%,D%9  -SZQWXKJ'=VGT0#/(=^X7KR4\RUP &IL5$\O1_HZ\
M^/.Y .JFAJ;"P%CNF\FF4\(3Z4! L./,]OZNSZR22YYY\E!,\!8<]ZJP4*5+
M*U<+>F_U X"NWS74&$[.N?3FFU7%"4I^5KW#V=G#CRUMV#&K6QYQ/4)V9FV6
M2V0EE;A)%AJ;7)%]>6AP#A %X FU.TA;D@7SMO5Y:9W;$@<!PY_M]%APQF<@
M.O;.^@M,"Z 02<R>[FI^Y.)0I?"WIO\ 9B2TDGKM.5XZS'%;AP $[!W_ (3P
M4BR$) XD WMP) [^0X<KXD"H%XD5FX$[304V'(A#G%)BHBQ,7O)J<XVJ)3@*
M!<&QM?0<.=M;:VQKKPQHKQMD2(KLFFVBLW"DAQ.<Q,TRN-EDLXL:#@G@--;=
MIY:=W+&3G Q$KL9A@@7K/B=UAW!*N.7!2-.X>LW/9X>G'7A ^[; ,5-MYSV;
M-RZ6L :T&20*S$;1ELC,[)B\"B$BY(\+Z^_IQH2[>,@*]V9YVH,-@$0#O($F
M3M@#/<("4>7YI4D\=!]!MV\/KQJV8$WWKH8/A&0%@+7OV^$JUNNDW2";\S>_
M'L/?S^GME74%E%-[W'9<D\2.SCSQTX8^ 3 !FH,$U-]V7&%9K)J!,TI>\;#3
MR4:W4HWD#>!&NH38W -M=;ZC2WMQ),Q:E*3OI>W!=F'A=A,G9%*"6TBE-R4+
MR1Q"KG72Q^DC&C?E&7XKK8PZL"($CSV;TNXH*.\-!;GQ%O7QY8LM6@@0=OHE
ME.7\T7U'/AI?CZ>SA8]N-M'/QDCZI\1S3B"M<<QHC=[R._T2J;W5<WU5[4W^
MO%M%_P#'LW/CLYE7/_@,2?ZO_J*Z$9;_ /<33_\ ]!1])Q]6^R?]!:'P?^\5
M^%]+_P!(Z5_M#X!>XQ[&O&HP1&"(P1<D.E>^_?19_C;=EW\P<]<0;=;?$*[+
MN^P_P*ZWXE47'OHD/O\ ]*S^-^VL?S R Q MUN\2K.N/LL_<:LM[9G\;?HK_
M .DWG5_=#SWQ*J/F'V7^ 72G!$8(C!%@7:1R3:VA<I:EREC9Y&R"4U3$4^J:
MQDNZH1,1+Y-/Y9.XB5K*VU7AIE\&IA8H&X7#NN-D%*B#![$5\JS+V>3MVE)?
M)JE<IZDY:N)@*JIZ&ETMB6*KIJ(ERI>B0O/Q<*\_+85@**PJ6+A7%I2EM2]P
M "46F-#]'_'R"8TO+JIS?J&L,N<J93F9+LEZ*CI5(X5%&N9F0$UE$;%1LRA(
M!F+GSLCE,WBH"1&9./B$:4VL[[C2% E>>Y,[/6R-M,Y"R+*O+Z%VN9E4F5.5
M\#)9!"4A,<J,JH6+F]*R8AIN4Q\_@*4AIHB(B(,"'<F<+$,1J%!#S3J'>L4L
MEC?LYX7[EN C)>C49@U?F>B30Z*QKNBZ?H"IIHM:W5QM,TO$U#%R:"2TYO--
M&&B:GG,1UZ4]>XJ*0AU;B&@,$6D-&='%"RN(H*E:^S.F^8V263;.:J,H<K9K
M)9!!PU-'-:FJIHV.5,9Q 2]B93PTS2-<593---QSRV865SEWK&W8EB'>:)X<
MY;^.07K<C=AZH<M:WR=J:O<X)QFA)]FK+BH\K<A9''2:221^GZ=JB54S3\RF
M%2S63P,+&5?4**5HJFZ6AIE.W(HB ^&XIY+DQG$5%*"G5LIP[$,<>>RO7XKQ
M72(-AB/R=2Y92%0.8@(&\4J7UM"74&R>I0%+.\H=7?>*E V)&/Q3\O;9]A\(
MGY1TWHDC/_PFGV7@NG6E^ UC8UB'Q-J@#AMN"!GDN<K+2EI;4N^]N-@I*M[=
M\Q-DI)%@FQ!W0 G>)/,W^2,8'WG0Y@5T70ZDU^:F6R<@3:B]4T0.P&O&)=UH
M,T$@P2:$U&6Z\K4[.!#=%[36S5F+%)#4FJJ S"R0G,8[YL/"/5"B05A3X>6?
M-08N+I>80D.5D;T6]#L)!7$"WZ!T6!I7L]T[T=B@'"^GLTXBCC&%AC1WZC73
M+IQL(D026,<20&RO):'AN&!C"A+\4N%?V0*SPFUIF%N&&PI9W^#J$#@;I;2G
M^!4 1H2D!0&I (O;ACT#268AQ&Z,9&CX3F^['Q#5U##*1JMH:Q;M7(_!>UY+
MK9UGJ)XSG%:3E:IM3$@GT3"1D\D,JFL9 +"H",C8"&B'X57R5+WG65%8W +-
ME03O D:G'NF@_E*]M?9_!PM"Z)TO'9HONAAD86E:6QH:/A.LW"Q6L$@?*0+Y
M@+9E1>(IF+0<SLD4O,9!>I2VVD(#02$-I2VVV&VT);0D;H"=P"R;#1-B$"R1
M<#3U[$Q\/3]-Q>EM,=B'I''+G8KW@NJ\2[](_P#2&3<ETGL4N:ZM01D)''(1
M>TF84R&DG?WB$MFQ=-[(2&[K:ZSB0'%^8"$D!6BK  XYL?"P<4NT+1@YVEZ?
MC8>,XD 8>LQP!+GMF) I()L%+,)^MK?"6M$4(-ZD5M,4M61F%J)LPJ%6U]M*
M9M-@KE%79E0M&4[$$$)?D>7,J^"E/,#AU3DTCHYM*T*4A:F5'S5)(Q[Q[8'W
M/17LG@/+2_HWHG2-$TEH));B8F.7L:T&"0& $D@1((!!IWN,L#9LW*8 FM16
MN[+KC<UEM;B0DZE( ))O=*;!(![ #;E:^E\>C:+B-=@!H#@0]SC(@&0!U_@N
M?"PW->XN:/E@;_B)&6^^V8S5Q::*> '#NOR]G=?&CYS( FEYFNP%=($2;[3V
MQY_<( 82"DZ@ZZ"UN/K[L5 H:C(YV$[MX5@)W<5,A!6;#TGL&) U?B=U#.54
M]O/AVIM" @:<0#?7CX<+GV]FF!=K&)@93R?11:IJ28IX ;*<4VTPI1!-@-=+
MZBQU-M>_CB[,,DR2V(FIYYZETLT=[QK!S ()J\--J4,;OQ!5P0C^0FVE_#3B
M;^W7%<8ZC03;6 I!K!RW9_>$PV%SRT$:P!)/ZH ($ B<R,N% FF6E!1.EBGM
M[2#BV$QSOB$008DQ,0NIF \']4TV[;7 O'-$VA!!Y:CA?P[;8OJ_%JR)WGGO
M6K,-TDQ2HN*VJ-R90T203;=YZB_A;TXV;A.'Q$L@B/F$W^Y;!AH3$5\-XB4Z
ME(W;"U_3IKVV_;K@' NU9@UO:G"5=H.L (@SG:Y[\[F9DQ"D;:*E"X!'/L].
MG#V]F+"AR/ALK3K6HPW"M",I](KO\BGDHW!O'D;"VO'T7O\ ;XXT<UVKK&+5
MK45R%HI4[C6 %8-=K5BDTV;;Y[23M3#3961PMWW^KZ.=L8DP)5P,R*>/W30G
MS5S;0  E(UY6X:<>_MMI])Q2N(8$3D"3;;LX_=)D O= -3,32PG*8H%,EM0(
M)'L/9X8LW">""8[=RU&"X$&6F-A,]X":::45I)M;7GW'Z\;-:003EZ+9K':P
MMGX%/(2$CD#Z?4-/<XT6NJX9=X]5*A!61II<7Y::7]-L% !D#,D1UF!U)Q("
M;#@.[!;MPG"2:GC/4,Y_#BPGS^ -CI?E[,%<-,C;>*G.DP*3ZIU#8'&P M8:
M^VPY8<\PM8K3,]JGZM1[/;]F%D3&X>T>W[,4UQL/=ZJ10@["%,D%1  .O*VH
M]&*ZAW=I]$BYR&>W<*7ZDZRU:P \Y5KD\1?M'8.=O7C7FW.?X9JU#4V$P*P=
MTWDWV[4^A 0+<SQ/OR'+TGB<!2G/.ZW8%4F> L.>]5X*=1VSO'JI TM0! X^
MO"ZO[IYV=O//%7%&XD^<0?#ZSIIZM>VPM=HC)V^!!W 5F,S&[)=WNSN[_12I
M2I7 :>_9^S%]<;]XBHXY*"TBY&Z]>P*ZM,E(!58&W+C]'[!C.E!($7!!J<Y@
M=E3U25N&.DF)FQG+*)/6FT-J5HD:=Y[-/'#5)K(,SMK6MAOR2#R1GMV65:UI
M!LD&X '#3OY^SEB6?I#+1-Q\0( ,WBM(MW;%I$")(DTB 3 VTN1?.DW43BP4
MB_&Q'B2.7TGLQH_#=A .=&J"30U,@"@M?+8KM8YUH_5VY.VQO%[E0%0W1<Z
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M,$1@B,$1@B,$1@BY?](P J8Y-CF8/,0B_<_0E_7C\7_+R/\ X$9_OO1*9?\
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M\3$S"91*R IR*CX]R*B7U*&\5+O>Q!'A.G>D\;I;2C4. <: N.K$   DP
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M[!*-W>)\X74O<L..\0?E!()2 20+8-T?%>[7+3%..RM(J!MSO,QT8;6!K0X
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M(FFV]P7Y\#[^C3$N.L8 GQ-^ZOFH:TDSG%IL/,[2FFV2H\B-+'B/H[_MXX
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MLIEQ&=M[P2I7 $XC5.[M'JK0=A[%*I0;X'N%M.)]_'UXU+'"X,1&47,FQ %
M;$U"T!FT3<DF3:D3!SBXC.Z@=4DZ \A]-\5-HS+6]Q,ULI#':P^$_,X]1%%
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MP/#B>/$CEV>CMQLW1\+W&N7M]Z 8:3\4DUO7/FRUP\0$B32@@@6G.^45\TL
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MQ&(8T@UI3S&Q3ACXJTD7W2$Z$I2BX(O>UN?/W]-K<,;&($9FVZPG:?6D+8V
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MK=:,,TR%]M3MMMRV+U#39'G <!Z3?ZM>7IX8X!&,?>"NI3:!,@$5(O/DNL5
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M;MQ\?!*NN$BR;<^>OK%[:7QW@T%H %-O93/A<UDSTG#H:U@U&TQG>G? B %
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MT4OO:]N++H:TP !S??XH4Y9.Z+7]SKV#]6(BO"R[F AC0:$!(K.\HJ[>&EN
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MM$KBWN.O\?.M%OJS@@Q/S3VWWQ21L2+JNL0I1X7W;>"$D:^D_:<;:'_23/\
M:#JJ5V8S!] ?-_=NF^P';&[O75'*?_>\I7_DMCV@X^G/9S^A]$^R?%?,'M)3
MIOI#_;?]#5D3'G%X-&"(P1&"+DATKWW[Z+/\;;LN_F#GKB#;K;XA79=WV'^!
M76_$JBX]]$A]_P#I6?QOVUC^8&0&(%NMWB59UQ]EG[C5EO;,_C;]%?\ TF\Z
MO[H>>^)51\P^R_P"Z4X(C!$8(N=W2'R?*294GD]%YX.9X2G+Z1YQ4[/XFL<F
M'40[%%3R70L<B23S,6.@VXVJ931H>B7F%SFEY8Z_)XU34;,)A*H7_96"<\\]
MBP?LJYB316569U#SVM,R:JH[,C,3-'+K9!JS,>2UY,*VK:DON>=5 *GU13&G
M(2($F9F40\W3M9U0N$5.I6@+:G$P2&XA2VTSESOK6@X*/$;KG=Q]:RM1J3F;
M695&[&.1M)2&JTYF[,U.YYQN>\L<I:JI0NBVY'055TZ)9,)J[)$PL2:ZG44P
MU)8:!F A:FAHU$6N*B8?K+%/7//E;T4W1Q9H4)3^7>R]0DVV\MI>+K)-&4M3
M;FS]4>3]&0-%RF?NP+<&*0<J)C9VELZ:AY6^YY+#Q$VS(<C4IAD-QD:XXVX0
M2FT7CGF5ME3^R-M/RC;!SKS:F6T3F%-<O:JRDRUD, 8FE\J/(JUBY54&9\RC
MLLWH24T_]TDCD=--U+)TMU,(IMR-9GT;NSJ(5*UMPBT\>SCR,AL0=M+[O FV
M\U(S6A<%+JCSFV>=B'9&RSE]62K:(V=('.R&SDA)K2<\IQW+XT]LW9]9//3B
M:S.;P4KEQ3F'F%7](Q=&IAZC0JJ9+/Y;4[43N;[\+ %(OGMM7.?N&>:'92)S
MCLGD3DLX[ $XF#6:6R%2>75?YX5W\%[,%12C:\HG->G)O*I-D96<DD.6DEH^
MFY+#3NBJ?9RZK-FITU73+=!TQ.7G9Y0\GF-31B9U!TI"U'-YCNVTB)V]E*G@
MEHK(.P3'7$]\",IKMQMF2.8R^H<K(R95)-*AA8Z!S*5#03LHER&8$*B*$+"&
MHB6(2TN'AFNK:9=><B(DH0E#L0XI-D?B_P"7<_\ P3@_[[T.#L_P/I';-)I;
M,F=G'I<ZE,P>%+D@7D$1790+4(#=;:05;Q0VTDG>WC>R3K^"=?D]ECSQ\NXY
M^#H:L_X-H/BWA,WE>M_KB_S@UO8[SLCJ503<W'&UO >YQEB"<;&FWOL2FTZY
MONW=JZ7.AHFT'B:FG=ZV3K:=Q-N^_L&,'$$TV1XJHG/\!L3#3>\;\@?;I[^]
MC+2 )SFV9M%<AMV]4+9ECQ]%<4)W1X^_IYW.*F29.=>I7YY[TVQP5XCZ,=&!
M9W$>"[=$L_BWP*;;Y^CZ\7Q,NOR6S[CAYE3H3O*M[\O9AAB2>KS[MJG#$N/#
MLJ*E.ALI2%<B;>R_H[<:D0 :5[8VQ:*=\56Q @>&<$"I\AON3*K0-Y5K7[L0
MK88EQRIYCM.Y7!I&[J>8]_1]/JP.[GGKXK9T4&SN]2<\A89J8)WC;WXCU^&"
M-!)H8I?N\U<FF>K2#SX=VNNGJU/JQDYTT%N_[O%"9  B,MO7E7G>TS\L>!Q?
M ^<_9/B%I@?.?LGQ"<2-XVX8ZEU)Q"-T#MM;W[^W!79\W ?=YJ5*=\[OI]6"
MNZTQ/,><<RG$I"0 .7/OL1[<%;";\6L:$@P.=UADI$)WU 7MV^&"Z.>Q7!I&
MZ!;@/:??G@B81\H>GZ#@I%G</,)A'RAZ?H.*O^4]7B%"F"=X[O;[^_ =I QF
MWYASDB>;9T L%$\=+V\.P VU-KFUR --1S2.?%6RI0#,TGD9"PVDU=;;W!<Z
MJ^C]?:>6H&ER;>//X[.,TC<.L[?N\;G("7$(VXXCQ7U(NH#M('K."W5S;;TN
M- !?[.6ITOV<./ 6#:3>DP2;5B<S,4[S5=#1!'$<\^*H2+J2#P) /I.-30'@
M5T*\,,VL!P'U:_2=3S[,9YQ=SJ2<IH8-=XIW16K1)#G&DB@D @=AWCF'QJ0.
MW%%U)C_):=OCS]5K6]SC02#?Q)DFNSZM<H%BJ7RKU 0!0?K"NM3>=BB<3<BW
M$><? >_+'0]UQN'49GT4X;#)D96I7OX#KW)99%R0=+<;'OUL>ZVF.9_S#AYE
M=FJ1<9C,;4JZY86'#B3X>^M\>0D&F0N:VFPN8D\2=D4Z#AN$G,3 I>VV*#?0
M?6)(2^)]YN[_ +E7W'[?_+_^R4==W=3J3P'  #F<:+NO%*9#;LIL\?&WOODG
ME>WH ]_>^"LE.)  MW7Y\]3X8Z@*3<4UCLVB+U,5'JH:V*"I/5Y\5]<<W$WM
MJ;>&O.X/O[<"9=4[I@T%;B)GS[NYC3&4Q)L1&ZO.Q*#@+\>>-EUI)SY:O'!;
MML. \$NZZ4C='+T=]_;W:>G&S1#1PGMJL"V7N/[6X=E<\Z6G(RE+[VM[W_9B
MRZ&M-@,N<_,H4NR0+?KUO[.[NQ$5X67<P$,:#>$BL[RB>VWT#&3C))X> 5E0
MX[N(]]>)]7;;4\,;LES6C( =MO7JDUA=V")8W( 5/ D=^214HJ)418GEV<A[
M,#$TLKF)I90N.!(L-56T[K^_OKC=E6":-!-<R9--Y\!=:-/P@#?)V5[SX9["
MI?>UO>^!J;1N5P(H$J\L()OIH-== =.6O'[<;L)+0T9$]M3X*(J3M'#*HONW
M;I2BG;MWX"Y)N;GV#A^O3LT%+1;5!%-IBL5\*<#TL:0 (KLI4[ZQ]T"BM[KZ
M257N+#C[]WA;A;'1HXA]@*&@,Y<US,KR 86X#=;-SCXSMOGG"MKZ@I#BAP*M
M/0 /JQIH7](X?VV^)6NE4Z.</V'>#EUBRE_WNJ4_Y*8^@X^F/9_^B=$^P?WB
MOE;VD_IG3?\ :#]T+(N/,KP:,$1@B,$7)#I7OOWT6?XVW9=_,'/7$&W6WQ"N
MR[OL/\"NM^)5%Q[Z)#[_ /2L_C?MK'\P,@,0+=;O$JSKC[+/W&K+>V9_&WZ*
M_P#I-YU?W0\]\2JCYA]E_@%MSGK(LZ*@R]G4FR!KVF,MLR9@\VU*JWJ^D'JZ
MEL@A5.[\<^U3SD[D\-'1Z&U.?!HC7(N7,+MUT"\VD(P1<H,\,@MK;(K+"L\_
M,PNE2V@O)\OI8B>3-NGLJ,CWZ=6J*CH2 =0J@T4E#0LVAX:+C67FH0Q\.\S"
M@(1$W3O%UGN^[G)1L]>9YE=3-F* SDE^3].M9[9@4SFC7+_E,:JNJ8HD9>PD
M_D<<M,5(8R9TJF=3V&E\^7+G6C.3!1K<"[&EQ<+!PC6ZT"E9\4TR^VMIUMMY
MI1(+;B$K;4.]*@4GU8(OJ8=A"6DI892EG_(I2V@!K2UVP$V0;:73;3!%\1"P
MS:W'&X=A#CNCJT-(2MP<PM02"J_/>)OSP10HELO;4E:(&#0M)WDJ3#,A25<=
MX$(N#?6XUOK@B=X<,$4"8:&0XMY$.REYT6<=2T@..#31:PG>4/-3Q)X#L&"(
M;A89E;CC4.RTX\K?=6VTA"W%:^<M24@K5YRM5$G4]N"+G1MZZ3?*2VG^T^9/
M#3A'9<6Q^+_EW_R(P_\ ?6B?^SZ17)I5@,H\UHSN%10;: K&O"_6J/OISQ\M
MZ08;T+OT70> @S=>L@#7!FHC.*5YG)-A&X .W6P%K:#WY8PQS^GQ]V-B?O$^
M:ZB+7J)KUCLI12M-;Z@>?#7E;4GV^GUWJT2-TUVF+=5>:1$"YR\\AQB^7<;D
MA 0+#GQ[\'W'!;-! J(W<^==J<8^2?\ C'Z!B<//J\UNRQX^B;1P/C]F-%OA
MY]7FIVT;Y[A:_?[^]L:, @G.8ZJ+9HF3LKSZ9VHG>KW$CAV6]'/WMV8T6H(M
MF!UP(O%,\J;%4A!6;7T&OOX^!Q+0":^$[+;^U6'ELGLW[P"=RN#2-T:6M:W>
M=?V]^)=&5LAY]=-YZ@KMB3&R,Y_#B2:!3!.\0!X^_;QX8JMFB212V8GLWJY-
M,]6D'GP[M==/5J?5C)SIH+=_W>*$R !$9;>O*O.]A'$^'UC!ESP\PC?F'7X%
M,M#>5;N/TC'0R_ +HPP 3  ILWA7%"-T#MM;W[^W&JV4J4%9L/'U$?7;!2#!
MYKSSM3S: FP N -21[\^7IP6K0;G/+(<]P4^YO62-!?V6/#!:-^8)MI&Z!;@
M/:??GAR5LF$?*'I^@X(F$?*'I^@XJ_Y3U>(4BSN'F%-;>TM>_+]F,V_,.<E
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M8?X%=;\2J+CWT2'W_P"E9_&_;6/Y@9 8@6ZW>)5G7'V6?N-66]LS^-OT5_\
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M:X9AQ7G.,L*26FW#JM"0KG@BO6"(P1&"(P1&"(P1&"+G+MX??S*/_D7,S_\
M'\ML?BOY>O\ (;#_ -]:'_[3I!8:1\AX'R6DH25.)M:Q6X.^X?<[QVC'REBC
MXNA3_P#3:"/^:3Y+UUPG&?L#B=EJ["KDE.Z.6IOX\OJQKI'\_C?[1_[Q73D#
MM$IMD I-P#YQY=PQ#+'CSXK5ECQ]$XV  ; #7EX#%UT,L>/HID)*CIRM?&C
M()SF.JBT:).5-O-MI\31.A&X +6O].FO=C1:MB*;:\>&7"D;%6A"ED<P-#>]
MK=GO]>) X7%S'5U[=Q6@M6(D7YI.9I:DQ"N#:0!P'*QMV7Q9QOE40+&Q!I?M
MRC)7::N@Y ;)I6?O4P25$ =OA[ZD8ISSSO6@SI-.S?SM5R::W!<\;6X6]SS^
MGNS>>X[>.6[;Q%T)H!$>9K7FV280 2;B^GUC$,)F)I%NL*6@$UV>B8:3=1L
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MTX<>['6:?JF2 :7)],JC9@EHM>EIF:?C^"1=>24GC;B3PT&NFAXGN&-0#-H
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M_B3,K_TAEQC\7_+N ?8G!G_7>A_^SZ17/C5<SG-:CANZ@ --]0('_P ZN_L
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M8(M MM)0>J3*91\Y(D>9.Y<%*A:-RYWMZX!OO@ZC2UL?C'Y=O\B<'_?>A_\
ML^D%1[02TD5! OMJM44#=N1QWW?_ ,*X/H^DX^7=(HSH:/\ 1M"[W">V?19P
M-8TNZ#VQX*8>?J>-SPYWL<21^FQ\_P!,\1P,]E5=C 2X136G.!M\DXRVE*3<
M:DZZZ<N'ZN_$S&0/$;8KE> M',:#;+KZXB#WQ=,)25* '#G;WTL+X$S)S/9O
MYX[D  !@9SPV^6Y7%IH(%R-;^_N>8QD\Q0;YISOLI,96YOOX>J<:0%[V]<VM
M;7MO]F+X30\'6R.P9]2VPF-<#K"8.TCP(3"64WL+VO<ZXV&&T9>7A"V&&P3
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M5K!!+HDP(H#4D@#?D)-Z\$HKSC=6I&MSB1@8((()$$$ .%Q;?U+5N)C @:H
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M.?VSY/LPVJ>S,H6+IVAZ]GT+#T7/8N<Y(S1;:6H2!I%B</PB97'NO/SVFIW
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MJ3PK%7MD/)W.#(^FX*C,P6,G1(:?HJE*=D\TRZEDQEU23N,I]E<L1&U2'Y5
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MN"'X[,5V)BDM#F@:Y+(+ (@@T!DBH,F1DH-*ZH!H10;:4F; 9',&EE5M@J6
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MT.%;ZW&PEQ40MY0B51&]URWD!;BU$JQ7$<YV*,4XC]:9(#C$B8)$R(,'YJ\
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MKV'Q@JWQ#@!)%S86'B./H)]/TC5; 10*WDE:@2>) T\<2VXXCQ4@20-IA5*
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M7_9:(>+S=F=/0[+L< V_.HRGW8<AQUF\\_=38HVY7MS7O6>=A&.CJ4S!V"(
MS[+S,F%S2V/*Q>8%&TXS**AR*A*9IW)Z>S&#FT:Q%.Q<QED^CU(IJ<M3]EJ9
M/5] 0$U;;;6Y&MM/-0<N8N)S[(V<5OCM+3J9S.M,N8694W,I.W"R+-9+$SB7
MH-V%C^LF67;+;J68=YR(:WVVD*<2IM*@\7-X7-S^/_EP8#[$L?K .;TUH@#8
M-CH>GU/?0;"M&MUKF!;A4>,GK6'VTK)"2@BQ*-ZXW5!*BG?3S /X*K*!&O$8
M^6\=^N>B6&&QHVB GBZ+4.V*]62L<.#$[>V8&763X)MMG=21JL$$HY!*R!92
MA_+"; I3P!)/?B=):6XN,UK!B:V(YPQ)(+#8M K21/?==.$YK&.:8DN)DF+@
M"(V4\I5:4N)4HA>Z5(""I'^4M>Y0%@W"5**B1J=>S3&>'B=-L^%G26+AZ/ G
M #:01!%(F<P13:C6L:Z0T=\S<F<ZUL>*?0A"BEU8"G$).X%C>;ZS= 0YN6L5
M(()!)N%*OI;7MT=XT?'^D!@&(<#$PG@$CWCL2^(3!APCKW4CMPW!S3+0 TCK
M V@<*J5*4[H0$))-^L64@K6E0.\E2B#<%1W[G>X  #%<+2'86CZ5HK2?\)=K
M:_U/A,T-SS(RN'MV"DUW<*$6RF9$P4TF'W@@$H4&]4)4VE0*E"Q6;@W-ODV
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M'70#'26P1)!I-KDYGJL(ZUY%N 1!):1L'UO.-LT@SF5;GR;6"K::\?4=;<.
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M%UW?&BCIVW]_<]N)U#NYZE;4=N[U$H;MKFY/[?MQJ!W#T'FM9_#GBE'BKAO
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MB?"8IU+O=L^?[S67_P#R!#_]-S'[;T4(T#1AL9YE?S_]LO\ *?IG_P!8_P
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MQ'Q*JW5D%T)(4%E;@N2H(2D-M  W3OJ(!58A(!/ 8Z&]'G#Q\'#>9&-#WB:
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M/+VE)A&&PM$-<[H//HWLGH^#C=(M86 CV9$_*)#7, L?QN:U6OO7[\@0+U\
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MV'^!76_$JBX]]$A]_P#I6?QOVUC^8&0&(%NMWB59UQ]EG[C5EO;,_C;]%?\
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M/-P(ZE"$FP_A3Z2/KUQ<:%BM$%HI3Y1Y. [EH.C\&*](,_NXGF^4B_?>4.L
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MW!<W"?AAK686&'0UCFB3J@F),S63*ZFZ3B"*QF3)J1P,>.Q,-[-^4AWKTBP
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M*[U5!V0=GQ)LK+V3 A)6=Y<?\E) *B3$< 2!J<1^9]"_JFG>29/&B?RIZ?\
M]::5_P 5WJJ/BA;/925C+R4%.Z%W"X_Y) (-O*0;6(Y:8?F;0C_FXW"#Y)_*
MKI__ %II7_%=ZKR$+L=9.-U?447%4')ETR_)J78D<.F)CD.,S,/U,U5#KH,2
M+-NP$7(NHUMUK#A%E#%AT/H8MACA7(&IC:3;=)H8.G\K/: -#1TEC\?>/UJ.
M::_%?X:']HRO5C8\V=E;RE9;RHFY4M1B(P@%9W]28FUO.TUM:V+?FG0OZKP]
M%4^U?M":_G32A(%L5XM2;YQ7>JQL<[.I('[F\JN1O6ZZ-/FWM?\ [9X=^*GH
MC0I_F6GB1/[A3^5GM%_K;3/^,_\ B7T;'.SJ1<9;RHCM#T:1[(G#\T:%_4-[
M1_ G\K/:+_6VF?\ &?\ Q*-6QEL[+45?N;RH7M_WZ-' =\1B1T3H7]4!N$?P
M^04_RQ]I&T'2FED;?>O/F51\2_9U_P VTI_\M&?^L8G\TZ%_5>'HI'MG[3?Z
MTTL;O>XGDHW-C+9Q0DDY:2DJ2 3_  \< !<ZZ1&MN[UXT;T9H6KJ'";%3)O)
M!S W\E6=[;>U!PPP=+:7JR:>]Q,[W,BTT&6]0_$UV<FTN+&6<F4"D%39>C0%
MK%E(2HKB=T;MA;VWQFWHK1&O!]VW5FL4/$&)'BI_EC[1OPG8;NE-*(((U78C
MR*=<C;LS)6:<HJ7-#Y?R*E%MM0Z)*F,AH9AM86AF#7'1+T&TE=U%?5P[B$ D
MDV38\!CR#<-F$T,89:+;IRZEZR=(TK2GXF/IF(<3'Q,1Y<\DDN$TDDDD\3W0
MLE=8CCO#@5=]@;$VXZ'CV8LH504% %)!!L01WBX]A!P1?<$1@BY(=*]]^^BS
M_&V[+OY@YZX@VZV^(5V7=]A_@5UOQ*HN/?1(??\ Z5G\;]M8_F!D!B!;K=XE
M6=<?99^XU=98N7LQ$8W$OPS40N"<,0PXZUON0RG6WV3$0J@V2(A32EP:@VM*
MS!J4VM10\I*I55?&[[B-Z]]T7OH>',#@>WOP15X(C!$8(C!$8(C!$8(C!%\*
MD@@$@$WL";7L+GU#4]V"+5[,;:\R%RRS'A\L*LKEB758%4JU-&TRV:QLEIN(
MK6.<E]'PM7U!!0C\GI2)J.,W&Y*S.HN#>F!?ARPE27FE*3Z<]J+9>"N6B2H+
M)6K^$!"BY:PWE$)2#8C=20""@)(.N")O!$8(C!$8(L:YJ9F4+E'2D;7&8E0P
MU-TU+%0S+T<\'''GXR.?$- R^"A66W8F-CHZ(4EB#@X1MR*B7U);9;6L@$BP
M)#;:^SC$9?S;,@UT8.GJ?G\OI*;RZ8R:?0%70=3S4J5)I!]QT9+FJG<GDU"5
M&6RT2[RB-1K#-N#7!$]*=M'9SGE!5+FA!U_!HIFB(V5RBI1'RV:RZH)7-YTI
M;4IE;]-1<"U/#,YE$(=AI= MP9?BXMIZ&8;6ZTM(B?/NHG/-?(]2B1ME[/;N
M6D9FP:S6FE(*J&*&BX-^2SYBL6JVC4P9AZ471*Y>FJ$U+$M1\([#2=$M\M>A
M(I$0VRIE:5XE/O6:LI<UZ"SGI:&KG+>?M5#346_'RXQ"6GX6*@9I*8KR.92F
M9R^+99C99,Y?$)4Q&0$<TQ%L+ #C(N#@G//W+*6"(P1?"0 22  "23V 7/J&
MN"+SM4U%)*7D$WJ2H)I!2>14]+YA.9U-8]]$/ RV52N!?C9G&QKSBDI1#0L$
MV\\XHFR0 KE?!%K'-=LS9[DV6F6^;<16RYI26;\$)EETJ1R6=3V;U1*V(1F,
MBYE+I#*(.+F;LOEL#%LQDTC1"^3P;3[2XEQM*V[D[U76&V;LZT)3M$U7,Z_A
MXJ19AR%=54@_3<MF=1OQ]*L-MNQM3.PDF@XIZ7R*!;?2N/FT:AJ!@PE0B'&R
MD@)&W=U[$4]=;8NSOEQ$TQ#U-F!")35DC@ZL@(J404RGT.S248M#4+5,]BI/
M#1$-(I$\^ZAD3>9N0T#UAW%/;P."+9V53""FL/"3*71#$9 3&':CX.,86E;4
M3"1;"'X9]EULJ;?0\RM+B5I58MJ21Q&"*\8(C!%!$JW&BNX 04J))(L$D$D6
MN2H#Y('$V&"+6+-O:OR*R1J:#I3,2LC*9Z]*X6>Q\+"2F;3<4[3\RC8B6PU1
MU9$2F$BH>FI"_&0\3#MSB<JA8'K8=Y/6W8<*2FW(/EQW&FQ)U5M@;/E$9AP6
M5E3UQ#PE61<53D'&+AY?,(^02285A$LP=&P%25-"0CLED$;5#T5"FGX>;Q<*
M[,7W&D0J7%NMI44=OIQ4D3M>Y#P&:Z,DXJMT(KMVIX>C'B8"9*IJ#KB,@X:.
M@*%BJJ$'\ PE63"6Q+$; T_$1C<SBTOL=3#N*?:"HGQCA24[^'.6:FJ7:ZV?
MJ(S3A\GZBKF&E];*G4CIZ,0B7S-V02:IZJ:@HJG*<J.IX>$7()+4=2PT? /2
M*2S2.AIC,FHR%5"0[GE+>]*<\U6T8<;/!:3<@:*!U)('#M(/JP15X(C!%2NY
M2H#CNJM<V%[&USR\>6"+5"9;7^04HS/<R>F-<-PU;HJ"$I)Y:);-7:>@:MCF
MTNP=,1]5"!-/P$_BVRDL2A^-;C7 I&ZT20"Y[$4\KVO,A)UFB[D[ 5S#+K5$
MXB::;2J F;,AB:F@4(<C:>EM3O0:9%,*AA6UH7$R>&C'(U@*NXR#PB1SSV[$
M4=([8.S_ %Y7$RRYIBO(2,J.7IJ!0,5+YG+I)-D4HI]-5(I^H(R$:DU0/2!<
M+$B<)E<7$*@>H>\H#80LB4YYY[DWE5M79#YU5=,Z,RXK)N<5#+H.+FK++\OF
MLMAYY)Y5&-RR/GM(QDR@H>"J>40<:ZW"1$SD#L;!M/.)0X\-X#!%M'@B,$1@
MBPSG'G+EKD)0-09GYN5=*:*HJD9>[,IW/YQ$]0RPVPX6H?JF$?PL=&S%XH1#
M0$.E;\0JR&6U*(!)SX<A>&S<VJ<F,C%R*'S(JSX+B:DD\95,N@I?*IQ/8V%I
M27=0B95+-(230$4_)J6@''F6HN?3!#,OAW' AV(2H$ AV_?OY]5::^VQ]G7+
M.94Q+JKK^$0[54@EE6P45+8*9SJ70-)3Y]<#*ZJJ682B#BH"G:>F$0V[#PDX
MGCT% NN-.(0\2A0!$Q6NU]L_Y?UU+\NJJKN'@*DCON>1UD/+YI'RF2BKE,)I
M9NI9Y"0;LGIQZH514.),B;14,8X/-^3[X<3O$Y"L]<[;^S5EK6D;058YBP4L
MG4IF4!))O%JETVB*<E4[FH:5+9-.:HAH%R12R<QR'FW&99%1C44XT5.):W4*
M()3;ESU;UMY!/LQ4'"Q,.ZV_#Q,.S$,/M*2MIYE]M+K3C:T@)6VMM:5(4-%)
M((XX(F<$1@BPWFGG3EKE NFE9@U?**;76E62*AJ:@XZ(!C9W4M0Q\/+Y3+I?
M @F(B778F):#O4MJ2VP5NNJ0ALJ2\U$@SNNL89C;8.064=8O4-75;B55#+X>
M6Q=0;DJG$PDE(0D\>4U)XFL9_+X*(E=)P\T>0LP"I[%0:7Q;JB4BZ2GJZ^3X
M#BFIWM=Y 2#-&'R;G-=0K-;Q$XIZF(AI$NFD53\OJ*KT,.TK3$ZJ=N#53TFJ
M2HS%PAD<GF$<Q,)D(ACR5ASK4;R?N3OW**'VNL@H_-IO))FN&37;M4QM )'D
M,T%.NUI RQ4ZBZ*A*H,&*=B*O8E;3D4Y3Z8Y4S0EM]'D]VEH!.,SS?GT,E%[
M7.1&8.9CF4=,UPW,:K\LJB52Q*I;,X.4SR;4*LMUG**<J*(AFI144XI9:'$U
M!+95$Q3\H>AXIF+;;,*_N$6TD.H*9;4F]E)WKD6)OKO$6%BKB1Q%['7!%-@B
MH4ZVA6ZI:4J(*K$@'=3Q.O(<\$6'W\Z\L7<U59*0E82>+S/%-KJYVD86*1$3
M*'DC$0(0QD<VRI9@D%TV;;B.K6\+%"58)3GF_ALLK4[GEE:G-6:Y-OU?*$YA
MR*BT5[.:=6^>ME=*+<B$IG$Q64%F7A*H9]UM,0XA:X=!<L$><"+PM![8VSSF
M5&5#!TOF##..4M(HZIII$SB F=/PK]+2QUUF853(HJ<0<)"SZ20S\.ZTN:RM
M41 A8"0]<BY%?\F=IW)W/V-F\)EI4CLUC9+"0$UBH"82B92&9.R2:++<!4$#
M"S>&A'YA(8]24*A)M"-.2^*#B"P^O>O@BV,APH-W5;?4M95;2Y"BE)]*$I^K
M3!%/@B,$7)#I7OOWT6?XVW9=_,'/7$&W6WQ"NR[OL/\  KK?B51<>^B0^_\
MTK/XW[:Q_,#(#$"W6[Q*LZX^RS]QJ["8E51@B,$1@B,$1@B,$1@B,$1@B7=O
MUB.0T*A8G?"=XV!'R=PD+5^&+)%^&"+\].TK.9'3M)],!DM4ZQ#9[9_YHT--
M=GZ1Q$-$+J',*75ILU[..6F5<RH:S"GXV#I7-NC:Y^$5ROKT4I$P4=-YEY&T
MM3I<\\T1?H)DC;K4IE[3]P\U!0C3P)N0\U#--NI4KBI27$J25$ D@Z8(KK@B
M,$1@B,$6G.W'G%E%D/DC'9EYRTQ"5G(Z>GDBC*9IJ)@FHQR.KMJ.0*6=A5/
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MX1XA]EDQ5T%D1SFHS[03LMEO\.*QEFM767^3.UKF#7&><7"2J@JYZ/;+REJ
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MATKWW[Z+/\;;LN_F#GKB#;K;XA79=WV'^!76_$JBX]]$A]_^E9_&_;6/Y@9
M8@6ZW>)5G7'V6?N-783$JJ,$1@B,$1@B,$1@B,$1@B,$1@B\U-*6I^:S:7SJ
M82.41<WEJ W+IS$RR"B9K )*W%;DOCWF%Q4$ MQ2UEAU 5UBM+DDD5\A0L-J
M#A)7OFYNLH/FIL6ROSK$6*K_ /?"OB+'!$S@B,$1@B,$5BGDBE,_93!SJ52R
M<0&BEP<V@8:8PA4%7"O)8IIYDN"VBBB^F"*R-431[,!&2J&I.GX&53#=^$)=
M#2.6M0,>I"5(;$P@FH5,-%,AM2DA#[;MDD@6!.")J'I6G(*7&20DAD\+)'V]
MR*E$)*H-F4/IZL(W7I<VPB$<;4E*4*2MI0W$I3:PM@B6%*TPS)C3?W.2=--N
M-J2NG6Y5 HD10D!=A*TPPEZ6'#=3B##G>=W#:]S@G!7^4P,)+66X&7P,++)?
M"LI:A(&!8;A8-AH[J@EB'90VPTE/ I:0E-[Z<\$5XP1&"(P101(!:4""4D@*
M /RDGB@@@@I<_P F0=+*ORP1>/BZ4IN82N#I^;TW))A)F%-+8E,=*X*+ED*[
M#G?AC"0;\.Y#MF%*0EM24)58@(*0%8(IYA25/3J&AX:<T]))I P3S41 0<SE
M4''0TO>8W2VN$AXIAUN$4@I06UPZ4*1:R2+6P1$QIJGIJ] 1,WD$IFC\LB$O
MR]R92R"C52]U( *Y:N+8>7!]6FQ0I@MK'!)&"+TC* %C=!2E*E!("0A&Z4C3
MC=8'*_ \,$3F"(P11/)*T;H)%U)N00--X$WN#=-OE#F+C!%Y2<4W()O%RZ*F
M]-R6:QDH>#LLCIE*8&.?@(GBAV =BF77X1858];#K;4G4@DV!(A^F:;BIE 3
MV.I^3S"?2LN-2Z<O2V#B9G!(?\]:H68/,JBV@7 -X,/-[J?.%P#<BI52M.+F
M[52O2.3*J9AE<'#5)\'PBIV(%]3:W&$30L&-2A:R$*;0\$J;41;<4O!%.JG*
M<B9M"U!&2&5Q$]@$*AH2?1<M@W)Q!,J6-]N#F3K"XUJ'B"H!:&GT-FYWDV)P
M1>JWD@7*@!:][BUAQ-^SOX8(C>3KYR=..HT\>STX(C>2>"@?2,$5*UI"%*ND
MBQ U%B;:)XZD\+ W."+R3M+TV[,TU$_3\D54#*-UF?O2R#5-X=*KCJ6IDIA4
MP:200G<0^!R(P15-4W(69NY4$-)I2W/XAE+;DZ;ET(B;Q#8)_@HJ9(9$:[#!
M0T;6\I*>( -[D7R&IR0R^8Q<Y@9')X&<S"R8^;0<N@X2/F(XI:BXMAA$5&)%
MR4%]U=^_!$2ZGZ?E49'1\FD,JE<?,H@/3**ET#!P;\R?*;J>F+D*RR]%+024
MER(6ZH+T)O@B]?@B,$1@BL<=#0T;#.04;"LQ<)%A3"X6*8:=AWVMT!,+$P[J
M'6HED W_ (9)3>]Q<8(K;,Z8D,_1#IGDFE<[3 /IB)>W-I;"3%,O=0A(#\*F
M-8>3!QOG )?82A2= #@B^3"G)#-8B71<YI^5S:,DSBS*GX^70<8]+7$ %,5+
MG8IAUV&>3P2Y#+:7<:$<<$\^?$9\5]BJ8D,?,82<QTCE4?.($*,NFT=+82+C
MY7I=34#%/L+BH)*K748=U &O/!%'%TI3L=-&IQ'R"41DX:;ZM$W?E<#$31I
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M@;.^W\.&W+(!K?3)66\2+$_?GB1I?LP1?!LZ[?@-QMQT^#J;C)26@W)!)O\
M#/,@$]X!P15?%XV__P"?-(?[%I=_C."(^+QM_P#\^:0_V+2[_&<$1\7C;_\
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M*HGRV8KC8SRCJH*+;>*'-]:RF. GN_&U/&$6!,M\X]LN:[7TLE]29J9B4]G
MO:_G\BF>5T5\.Q=-Q^5L+7DG@Z9@(N0MRDRV7R*)H-49%PLS$Q/EJ8Z)BW%)
M,&E&%8KSU">K.-Z4)D"UI^_ORRR@?L&@2HEQ2R0HI0 B^\ VEV(ZM6]S4IM2
M=]-O,4+$GE*+E!TKWW[Z+/\ &V[+OY@YZX@VZV^(5V7=]A_@5UOQ*HN/?1(?
M?_I6?QOVUC^8&0&(%NMWB59UQ]EG[C5V$Q*JM/\ .C;"RNR,K6<475,+F'-)
MG3=#0V:=8/4=EK7-;R>C<O9G&S^7PE45E.Z9D,REE,RQN.I"HE]9,XF&;1*I
M3'Q[JPU#K42+8"7UW3$S@Y!,X:?2Y+%2RZ#FL@#DRA&536#F"&EPSS+3K@+K
M;R'T&'"=U;C@<1NDI*<$]>>;[%AVD]J?)>LJU7E[(ZM/W20LQK64)@HR!CI<
MR[%4#43M+5 B'F$P2U"Q"$3EAV%@G4*>3,0VIV#+C9"L$2F:>U;E%E34+]'5
M%.IU%5DIF5HE],4I3D]K"H)W,YV\%RRGY/)Y%"14;,JEBH1*IHB20C2XY,H"
MIFI@0*%.X(LE929QTIG+))A.Z;9J"5JD<XCZ=G\@J^GIS2=322=RY3:(B FT
MCGD) S&#>;+K:AUL.A+B%I6V5)(."+W$?4<H@I@U+XN=2J$F#G5M-0+\PAT1
M:U/@[B6X4N)?>==(LRA"2I8"B!I?!%#!5/(IA$.)@I[*XM]E+KSC,+,X.+6V
MRT'&5J6RQ$*>8;AB J)6\@!"@L*4-VX(O!Y59[9;YSQN8,#EQ4#-1JRQJ^)H
M.JX^"2ZJ5P=6P4JE$XF$JAXQ0#,4]"P,_EKCO4K6A!B$H-EI4E, SMZ^?%%Y
MC-O:7RMR@J6 I:J9C.USJ(E,)/IH9+3,]J2 I"01DS1(Y?4U<QTG@XN#HZ01
MLR=B85B;3YR$@GS 3)Y#I1+(I34HON<&T'162#%'&L(>LYW,JXG<9(Z7IBA:
M-J"O:JFT5+)5%SB>(AY'2,'-YC$P<I@H9X1\S;81"L1JI?#]8%1S#;CGGG@G
M/,>2RHW5,K3))/4$V=,A@YM+X2-81/T.R1^'+\&F9=3&0<S;@XJ%F+#"UKB)
M?%I9B&O(X]IUA"H=5R$BIL+[:)F&JJG'F(M3-02!UN5LPT1'O-3> =3 PT2A
M#S3T8XEU;4,PZ5;K#L2I"76TCJW5%1L18SS>SYROR5H:)S"K"I6F:9AU1J!%
MRE+D^<)EM/S.III$-P4N$1$/L2>0R2:5#, A5H>52Z8QSZD0C*E)<\\\$IM[
M*[.>!FJ]I):]I:<R*55(Q.82&EDW@X&80)FKS<LBTF8P+<<U#Q<)'*8<AXQ]
ME]IQF$=ZIU(=U0=P'!%Z"(G<LAX-N:O3*7P\I<1O0\>]%(3"O @K6IMY>ZRZ
MA:!O0JVWU(=1O*23NW!%X^J\V\O:-I*I*OFM42M<FI.11-1SD2V+9FD8S*V6
M%/[[$! *B8^*6\A)3!-PS+SD2^IMEM*UK""1:V-[>61J(2:3>I87,^@)?)J#
MB,RU#,;*BO:#>G5(PK ?C)C33-2R.6OU&\PTIMV(@Y2W$100XV&V2I8!B=W/
M5S?*Y9FIS:'RIJF-H&%D=2ICWLR:!CLSZ:#<-&EIRC8!F'7'1\:X89'P3Y"Y
M$LL1$/,0U$-1H>@W$I=96@3SSV(K)LW;6V2FU'%YCP64D]CYW$Y53Z'INKD1
M\AFTE1#1D6Y,40$5+ES6$A1-I1,Q*8YZ636"ZZ#C(=@NLO+2L*)%FO,BO:/R
MMHN?UY7<X@J=I&F9=%3:?3J.=0Q"2Z703*XB(B'W%6(;2AL[P3=9!LG4@@BQ
M=&;0664%DY1&=<PG,5*Z S#<RO\ N:FD=+(Y,3&(S@G<CD%$-O0):1%PKTUC
M:CDS3[,0EIV4LQ8=CPTIITI)S^&SB%FZ314',VD3"!BH>-@WVB&WX9]J+AW2
ME>Y=AY@N,*;06U@%#KB@XIYMP[S0 ;OQYYVJ-X/ISR<E?-Q'X*?ZH^S!2C<1
M^"G^J/LP1&XC\%/]4?9@B-Q'X*?ZH^S!$;B/P4_U1]F"(W$?@I_JC[,$1N(_
M!3_5'V8(C<1^"G^J/LP1&XC\%/\ 5'V8(C<1^"G^J/LP1&XC\%/]4?9@B-Q'
MX*?ZH^S!$;B/P4_U1]F"(W$?@I_JC[,$1N(_!3_5'V8(C<1^"G^J/LP1&XC\
M%/\ 5'V8(C<1^"G^J/LP1&XC\%/]4?9@B-Q'X*?ZH^S!$;B/P4_U1]F"(W$?
M@I_JC[,$1N(_!3_5'V8(C<1^"G^J/LP1&XC\%/\ 5'V8(C<1^"G^J/LP1&XC
M\%/]4?9@B-Q'X*?ZH^S!$;B/P4_U1]F"(W$?@I_JC[,$1N(_!3_5'V8(C<1^
M"G^J/LP1&XC\%/\ 5'V8(C<1^"G^J/LP1&XC\%/]4?9@B-Q'X*?ZH^S!$;B/
MP4_U1]F"(W$?@I_JC[,$0$I!N$I! L" +@7O:]KVOK;A?7!%Y"KZDE-%R*?5
M;4$<S**=I61S:I9W,G26X672.12]4RF<9%+M9MB'AH9]Y82AQ1:97N6((!.9
MYYVKGGDQTH6R]G743=/R2+K^EF9E1,YS(IJ>Y@T!5=$4?6M%4Y94]J.E*GJ6
M52Z3SB62V&4(Q]Z%C.L7"!*TMN;Y."<\U[^M;&T)M6Y'YDQ66_W"SE^H93FS
ME[-<U*/K.6R.9N4C&TS+XIF#BHF+JDPOP%*YDZEU"VY3,8^'F3["NL;AE(\[
M!.2LV"K**=+9^Z2F/.<\D;:$UE>ZX^0'"P$![>4ZM"TN-,((42Y_DE$@X(KL
M[-9 E#RWIE+4HAW8>!BBX]#CR=Y\@L045OJ3U*EI4GJVWMPZC=;(U)%A/*3:
M1R;SD@:^FE+3N#;A,MLQJ@RDJ:.GL*J1>25732(4S6 AWYJB%3%PK;<0PM#\
M.M;#U[M@[M\$45:[3&2M%5B[EW,JLET=7'[GL[S7:I*5(7.9S'4-(RAN.G4L
M@)>V]%1RG'%LL0C,&AQV*?<4E 5YRDD7O*3S#HBHJ5I2OE32621FMY'*Y_(4
MU F%D$X7+9E"LQ33,5"353$PAXMLQ:T1,&]U;T+$..0JFDJ2"XOX>7X);AV<
M[U[")JNFY:4*F50R>7!4/#OH7$3.%A6W(.,4H0CC:XIUI"S$+ *%!*M\7W"0
M<$7+?I4GS$3KHN%#<W1TM^RV I'6%*RK+[/1S>2I:4A2%-K;4A2+I(.FEKP;
M=;?$*[+N^P[P*Z]XE47'OHD/O_TK/XW[:Q_,#(#$"W6[Q*LZX^RS]QJ["8E5
M7#C:DV6<[LW\[-J>/E^769"H[-.3T%EYE%F+3^=R*)RRDE#RBAI+#QT1F?0,
MNJ%V-KR6P>8$VK.,F=+3.AZFE<]D$4F31;+,#.9LER+[16,]U:5Y,RG5ZYQW
M\.*Q_5^R5M<9CYKL1M?9>T\30^;E .9:UW0\71")9!9*9=5)+:L\E,RK]539
MD4K6D^FT$_+WY/E3"4!1K]-S!V#F,3_#1$ J4\]M_NWPE(C8ESO"5,57D52]
M=UY'9;T9+*?S(B*DI:(A\N\PHJMXC,G,ZK8*6S5V"F<!-8R8//RZGJGDD1%3
M2+FJF86.B)5)$.13@\\B>U!7G*^Y;5'(;.7+>I<DMH1-'JS>S*E$US!F^;M(
MPL^D4GG\3&UU(H>GJ?BJ6G%31\'3\8FBH*$;EJ)9&U3#NM2UQP2F-B#YBVTH
MMOLH*PS8C9J)/FAES):<FM22Z;U:]&T>AQ<CD4"N;" IVC*@GZGW&IY64/ )
M7&S29RQ#4L<<<#,,SU;1>><]:+4*N=C>K,PLVYCFO-J8D;M4S#:NR[K&!JR.
MBX29SV1Y(Y4PT&J52^1+C(E*I*[4\?&3N"G4IE @VXR'2TJ.ZY*TVB/&<O3[
M]Z*[M; =24Y#YE.9?9MT7EY4==RF:R--5TCD%2]/3B3L368LQ\S<5&2RH)5,
M9RN-84_!O/PTUE75HBXJ(0Z8Q#:T2G//.U>@V&<J,S=FB6QN5]?2:1S:8YFY
MAYL9E1LPH:FETM1]&RN2QTAI*FD1L)&556D9&S>L:5D]*SE+D7/8J8L.OQ3,
MP=>CV(^*B'/=U9\?).>:>G%67.W(/-RN\T\^:4@:53&T1M,P61$AJ?,UZ=R1
MJ I3*;+I^I7J_P NHF41,>BI8J>U!!3^H8"DG)3+(B3IF=?1,9-HZ4(@%.Q!
M">:6IX7I4]:5VO,H,P\^T4Q$O;.K%2U$G*'-NF,OI^UFY,J,F.2&9U?.4Y"L
MSBIH^GY_($1=/&5R.2S>#JRD(6KJKI&=4YN4]*7?+'II".>S>.>U)F/PO&V(
MWY[5[_:$V?ZZS/BMG>GYQ3\KS<HW):D,V*ZG\#5D1+&)=F%G-),L(++[*BGZ
MHIV9NORV92NKFJSS#FTT=C!,I-*IA)&%1Q?;CF0TV1MK-*<UR]8VS!&SUH<\
MA)IO7-NL]E6&V69/E+&5/(J1@<LX"CMDG*',R0S.H91(H+:)FN6U.;153YB0
M68-334L2(P[U7U%EG-Y?#YAU' R*J9+03]$P:WX*80,AF"FS9:U!OX#AE2RN
M^DT/&FS9ZPO0Y0;+6;><NS3F%-Y50,ORHE^:D?7;^5M&)C8,2FG*>VELVFUU
MM4T+*YAUL+ M9;;/D9 T#1LB=E<G;A&X"J9/3L'!22I85+A3S?QS6.<ZLNJB
MV<*9AZ(S-I&E\]JQ%"Y[2:A)'5D_@(">9HUS4$U@Z=R>S3B(&9RIZ03VL(*0
MP4FDC,KI^,5/LLU0;3M&RN6R6:1TQA![?NS/W3!3GG/P73>K=F2,J+)C9+R6
M12T)/\O<J)C2]35[3LSF*6V9U"4514=#R6E8QJ-B2)K 32<3@-S.&>7%P"68
M )F"(EI81B#/J>'K^,V1:70_1UYB2W+^0T/2]'TQ2<UG62\#0^8]3TI,97*)
MZ]/*BS88J6I8=F+A!UJZ=IVC(=,'3<M4Z8" 4^N%IZ&@ A%I41/;MYSYR65*
MSV%JWA)YFQ3$E,^S H^O6,L:>I6O*_S.F=3U#0677P_"/9ET1+I14\?$0,OD
MX;@6II 1LM:$\CX1U<MC8R("$-I<\\YJ>?5>4F.Q=M/26O<XZ0RXF$DH_*^K
M):,I\J*[@XQB*FV6&2U>58W7N9C<'3BYF@1,WE4V9BX.0-E),8J<AM81!LJ3
MASM[T6QF4N3V;>R]G+.*AAH;]U'+^O,N<H,M):*6D$JI%^EUT;/S(9.Y&2)N
M+BHIZ64]24]FLRF$:\XEUIJ"$*2N(=2<1SZ;>LT2V^_/HO2](5LW9W[1F7,/
M+<HJ^DDLC)#)JA?A\N:IIIR?TM6M8QT*S#4G.)I%-5'3GP<[1T2Y$S.4.QHG
M<LAYBJ#G<1(X^.D\%N")IEGS;FVPO2YP;-<QK^A]E?):82Z35GECES7M S7-
M2#>0U*)-,J<R=R_G<THR$;IQZ.F[T;!OYJT]0+<=(HN/F#"95'Q#<;$3%B&<
M49//W6A+[N>=RR?L;94SK)3(JF<OI]*Y=3TP8GV:%4/4M)/(Q(:41F!FQ6N8
M$#2\C$O9AI<U)J9E-52ZG)7!2J%A9=+X24)899"5-V)SSSWRMJL$1@B,$1@B
M,$1@B,$1@B,$1@B,$1@B,$1@B,$1@B,$1@B,$1@B,$1@B,$1@B,$1@B,$1@B
M,$1@B,$1@B,$1@B,$1@B,$1@B,$6+,XY5,Y]E=FC(I+2\GK><SK+RK95**-J
M.*7!4W5<RF=.3:!@:;G\>B[D%)IW$NMRR;O,@J8ET4^\D%2U DYY^Y?EPR.V
M6-H^850K+?+#(C:RRGR>F616=E'9^Y,;2-:T]F'D/3=3Q]&*@J'IS95G\XFD
M97DODJ:H0(9F-1$P,OCY*S!?"D,Z&TI0YYV(/+FA_$7R7DZ?V,MI2$V?,G*0
MR[V>,TLOHNBNCSS\R@K"GXQQN'C8G/&95S Q#<1!.HJ IBHVJWV(R<2B*;ZN
M%5 NM1#!97YHBO#@?NYV(*;\^>;0O<UYT8]=P#.T[%4ADI7/ET#LR;+,^R24
MS5-31*(?:4DIDR\R*HDS+57(8BZZA@R]#SF-F3;@>2UN)?4VD)Q*;0(I%[CO
MSZ]N2N^<N3.V6F(VD\J)7D'G'4TTS@VI=F3.N09B2R*IYZD86A*:D\BA:Y:F
ML>[4K<WA)BW'P\6N,E</*YDLK2HJ"KI."*WYU;,&TI%4M7U%S79BGM<TM7FV
M;M UJBH!*Y]6TPI^5SVBY9 4%4DLH.79I97TY$LSN8L"#;J&MTU#)J80VN8-
MR01:&5DG.PKPV7.Q-M!4["[/U1YC;.F9M19IN]'YGUD@Y5K,0W,9A1F:D!6U
M2.4% U7,/NRBV685VB8U<!3\PEC,9O!R'3Y<\@(2T49VV&9YW4-#X^OJ/9/S
M7E=:90SW:KV1=H/:LH2!V0,G:)RT@Z"K2&;E.2V84AH6I957$LJBC$5_2#<5
M44TK"84=-X2K7);-(J"5*VH]F+,3*"V(KD!]^7:IDTKYTRC8H6^CKVGJ^DL\
MEFTC0]:9CU;3'1#S>C*/G$154[CVF-JJ'KJI8[+V7-3.4SB#ET_S!H2DXR7P
M4%/YA+EQ[,5#KBDS2.4]UR)2U]F?BM\=K27UC*,@^@NE.8B)HSF%*]OGH_Y?
M7L/.WO*)TS6D%D%FQ"U.F;Q!6ZMZ9?"[,4(QUQU:UO)4M2BM2E&#0 ;V^(5V
M?K4CX']PY/7DN]N)5%P >Z-OI-\L,WMIRJ]E'I"<KLF\L-HK:8S)VDXB@YYL
M\RZMII*ZAS'8D4OCX2+J";1D0_$^32JEJ>A4F%\FAR["Q+J&&TQ ;;BL1 N<
MS8SWU]"%N'X<#6828 )@9"-OCY!7H;'?3I6&]TL&3.]8;V[LDTJ$WY[H4I2@
MF_"ZB;<23B/C_9[_ +DU\'ZA[!ZJD[&_3FE8</2NY,%8-PL[)%)[P-@F]^-]
MT > MA\?[/>FO@_4/8/XD#8VZ<T&XZ5W)@$DF_Q2*3O<VN?_ #1ZAA\?[/>F
MO@_4/8/XE3\33IR[@_OK>3%TIW1_V)%)Z)N#N^%P#;NP^/\ 9[TU\'ZA[!_$
MA6QITY2Q972MY+J'G\=D>DC\L67R_E#0]HTP^/\ 9[TU\'ZA[!_$A.QITY:
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#?__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>42
<FILENAME>g164680g01m17.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g164680g01m17.jpg
M_]C_X  02D9)1@ ! 0(!>0%Y  #_[1K24&AO=&]S:&]P(#,N,  X0DE-! 0
M    &K:^:#@X0DE-! 0       \< 5H  QLE1QP"   "    .$))300E
M   0S<_Z?:C'O@D%<':NKP7#3CA"24T$.@      Y0   !     !       +
M<')I;G1/=71P=70    %     %!S=%-B;V]L 0    !);G1E96YU;0    !)
M;G1E     $-L<FT    /<')I;G13:7AT965N0FET8F]O;      +<')I;G1E
M<DYA;65415A4     0      #W!R:6YT4')O;V93971U<$]B:F,    , %
M<@!O &\ 9@ @ %, 90!T '4 <       "G!R;V]F4V5T=7     !     $)L
M=&YE;G5M    #&)U:6QT:6Y0<F]O9@    EP<F]O9D--64L .$))300[
M  (M    $     $      !)P<FEN=$]U='!U=$]P=&EO;G,    7     $-P
M=&YB;V]L      !#;&)R8F]O;       4F=S36)O;VP      $-R;D-B;V]L
M      !#;G1#8F]O;       3&)L<V)O;VP      $YG='9B;V]L      !%
M;6Q$8F]O;       26YT<F)O;VP      $)C:V=/8FIC     0       %)'
M0D,    #     %)D("!D;W5B0&_@            1W)N(&1O=6) ;^
M      !";" @9&]U8D!OX            $)R9%15;G1&(U)L=
M     $)L9"!5;G1&(U)L=                %)S;'15;G1&(U!X;$!88AS
M        "G9E8W1O<D1A=&%B;V]L 0    !09U!S96YU;0    !09U!S
M %!G4$,     3&5F=%5N=$8C4FQT                5&]P(%5N=$8C4FQT
M                4V-L(%5N=$8C4')C0%D            08W)O<%=H96Y0
M<FEN=&EN9V)O;VP     #F-R;W!296-T0F]T=&]M;&]N9P         ,8W)O
M<%)E8W1,969T;&]N9P         -8W)O<%)E8W12:6=H=&QO;F<
M"V-R;W!296-T5&]P;&]N9P      .$))30/M       0 [_^-0 "  $#O_XU
M  (  3A"24T$)@      #@             _@   .$))300-       $
M>#A"24T$&0      !    !XX0DE- _,       D           $ .$))32<0
M       *  $          3A"24T#]0      2  O9F8  0!L9F8 !@
M 0 O9F8  0"AF9H !@       0 R     0!:    !@       0 U     0 M
M    !@       3A"24T#^       <   ____________________________
M_P/H     /____________________________\#Z     #_____________
M________________ ^@     _____________________________P/H   X
M0DE-! @      !     !   "0    D      .$))300>       $     #A"
M24T$&@     #-0    8              2$   )G          $
M                 0             "9P   2$
M 0                         0     0       &YU;&P    "    !F)O
M=6YD<T]B:F,    !        4F-T,0    0     5&]P(&QO;F<
M $QE9G1L;VYG          !"=&]M;&]N9P   2$     4F=H=&QO;F<   )G
M    !G-L:6-E<U9L3',    !3V)J8P    $       5S;&EC90   !(    '
M<VQI8V5)1&QO;F<         !V=R;W5P241L;VYG          9O<FEG:6YE
M;G5M    #$53;&EC94]R:6=I;@    UA=71O1V5N97)A=&5D     %1Y<&5E
M;G5M    "D53;&EC951Y<&4     26UG(     9B;W5N9'-/8FIC     0
M     %)C=#$    $     %1O<"!L;VYG          !,969T;&]N9P
M    0G1O;6QO;F<   $A     %)G:'1L;VYG   "9P    -U<FQ415A4
M 0       &YU;&Q415A4     0       $US9V5415A4     0      !F%L
M=%1A9U1%6%0    !       .8V5L;%1E>'1)<TA434QB;V]L 0    AC96QL
M5&5X=%1%6%0    !       ):&]R>D%L:6=N96YU;0    ]%4VQI8V5(;W)Z
M06QI9VX    '9&5F875L=     EV97)T06QI9VYE;G5M    #T53;&EC959E
M<G1!;&EG;@    =D969A=6QT    "V)G0V]L;W)4>7!E96YU;0   !%%4VQI
M8V5"1T-O;&]R5'EP90    !.;VYE    "71O<$]U='-E=&QO;F<
M"FQE9G1/=71S971L;VYG          QB;W1T;VU/=71S971L;VYG
M  MR:6=H=$]U='-E=&QO;F<      #A"24T$*       #     (_\
M #A"24T$$0       0$ .$))3004       $    !#A"24T$#      0H
M  $   "@    2P   >   (R@   0A  8  '_V/_M  Q!9&]B95]#30 "_^X
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M<1O0+GP&]3R22)#?0O':>77;/^DG/U?N !_:E_N:7M;Z-\[6Z.T]9;XLL,/
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MW!+;?0
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
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M,4%189'P Q(3<8%2H;'!T00B4]+A\10R8G*2!4*B([+B!G."PC-#8Q4D_]H
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MM#Y8FC;:F:?VMED#%DIR/++^0H@)CO)D;)G174D6#;:7E ]ZEP)4WNWRGJ0
MAPE1L2[$4D.KU5WHJM,7DEP>3@E\).Y22V[2&HEDY2^&TZ9K6JRSA6:6HD*R
M6W+$%^:MUJ3!B08#A1)D3ELL+D//RE@(6[(<='/PD;NI<$&KRK.;FM+ #DLX
M9C<XZ,*3-P%H*J_6#)[S4N9CCL;';YF+2TD"!SR:>;%-Q>LQ@U:V,YE,+F,E
M^07G5.O+<=+I0HN%:$K&#LK;"2:BEC3LMD5G&>1DYF1SJTS-BXDJ>]6[Q/3T
M3;';IOZ-GG?;Z3#)_'Q#L_VY_P#)98?HS([G^MZO#0JGMHF0Y<J17SXJ7-*-
M3F!XRNF,M29,O"KN#6PF75(;4M^PD2VF6T)]HK> 2E)V"?0-B=V%@S@3J\N=
M+N\DKL-N  &<B3S(<2JQD>KB95)C',B(W%/:$'R/HR>/Q@1" ?B 3M\3QKA?
MI[_JG'AN/01?*M3C60DD^A;3J3_R;8_[)QYHMDQ(.[4U/_-<B-XF)S.?Y2CU
M>OO?0VA_^KK+_9N+POT]_P!5&-C-8\)?K[JY^K=[]HK3][K+_9N.H$;"8UT5
M]^__ !/RJZJ;4[4^AJ\4IZR!>5]1BJG>:!!:MHS=HI]P.A#Q9C-N=UW@2I3?
M.$$C92% #C)%7%2\P&8U=GY2H6HZUO$4A(Z-*HH[%Q=C)3R#K]GD"+*CS-.7
M+!^? ]$W-A);R%UR36B2[):16-H2B506;*WN5=^S)<F.H!:<<5'^LB 8LT[*
M\Q)V%I$\T!>D,[N9!D9"8F09X)Z_ZX_,4O/3!I4&YSABU[DXKR)YUZDC+K7F
M8T>2EM,D34JK6D+GR%E1"Y#B"D<O*9V F:V,+^5<++Y"2+W=Y. P%'/7FU 2
MJ0SW)LKSZ#35DC#KBM8H5STP6I3^2W3PB28\4I0MVT\8>\5)CI<6M*O96%)0
M4H/+QCAAWDSU?%^U=9)O"7L(I%\S,@%JAY,S]7K+U9R'[26@^CT;8]/H_P"*
M>[B</]N?_-9W;R?XDH]6<A^TMI^]MC_LG#A_MS_YIN"\_P 2M?5Z[^T]M^]E
MB?\ _3XO"-P[_F48]GNB]5GU6OOM/8_O?8_[)QZ>'M+^Z'U4XAO/\?HK>U@H
MK1Z_Q]UJGMGD,Z>Z?0UN1JZ9-;;FQ<3JXTZ*3&0-EL2"8R@K=04R?(E1,X)M
M%KM*DFJ3<"#<H=I$2 QL-DI/=5Q*RHL51>K.0_:6T_#6V._X?TIQYCLYG\O4
MSZ^^M[HO/\8EKZN7GVIMOWMG_P"Q\.'^W-__ '1@.QT)?I.JOG$=6\_PO'Z*
MBJ\1EK8I;)B:U(6B[C*EM1)KLEUA_P .P@+1(1+'.A?,E?)U!]VY=QK9RG/"
MW!9.U,+A[1*ZDST)O.-5.U]HO.E-266--BHSWIS]FXMS(G''C8(:;?[E;Z'#
M%W;:3R^%+ 1N.0) Z3J:X2%ESJ\9Y"IP-OA29MY.M:_M"9?4U:ZBJTJ$6,XA
M".=WUCGR7V6GC(=;])6 E63<A1W2EIN8BL VVB@G<;,V<VS9J7U=[Y49Q*?0
M$L)-9<0S3 I?92ECI1V@\^0M,F'I]*8DLMLQ&%+5?LMQX0<#J@8[*$1''VUG
M_C;K*Y?M;=]R@ 0CD7>3[V%U3IF1RYJTQ*M&E2LS)^E50F;3LOSBU19SZ&Y0
M\B+"KT.-1;5UR2J.E2'%N.N15+V#2BGFW]K;=7,K8\8.S#N0!ETEO0VO6=5'
M>>Z<287E89,\V)$\***>K.0C_D6TZ?\ @VQ_/X3^/B</]O)Y_P"ZJF[-P35_
MRE;'',BZ_J-: ?$5E@=OP>$Z[?#?K\>/5POT]_U77CPW'*+Y5<FFM#<Q\6UE
M;>I[1OQFGD-B#WE=+B.RW5910O.".W(2KO'R N<II(.R&%<J0V%)&3L3+-I5
MYO2ZK<T'M,,V!>8-]MK6\ZYJF?5Z]^T-I^]UE_LW''A?I[_JN+'#^!^5'J]>
M_:&T'_U=9?[*>'"_3W_5&.'\3\J/5G(?M+:?O;8_[)QGA_MS_P":;HO/\2CU
M9R'[2VG[VV/^R<.'^W/_ )IN"\_Q*/5G(?M+:?O;8_[)PX?[<_\ FFX+S_$H
M]6LA'4TMH0.I_4VQ_P!DX</]O0SZ>\? INW$]82W5'J]>G_D*T'T^C[+I_\
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MY(J77'&'7E.%I2U5J5)4J+&:4M159,9U#6M9ASL+AP3:H8B U"[ @&[$-7#
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M<>DN(9;*NJ@!MQK=%P^WW\,%>-'(;\4[-XO:9&H\J34[S+5[2K \DI,1R25
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M )Y=A^+APX.R%>+M.W%FE<>-'BH[J,RVPV5%7(TA*$\QV!/*D ;G8;GZ.-
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M]&Y,Z@=BU$FO@5-EXZ5#9L9Q>MG4U[D"$P]+#_B$1X+"^YCL(6&T-(#82$[
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M'L;D6JX.0TB*"Q>FRV%25PF7[.0AIM4>,TAD,^DY+;26VT-H0A"0@ <$( !
M%E-/YI/B79MTYQ632/5$:T4<=R4977+>L4O\ENW4-T?,Z%,[EL066TK3T <W
M(5UV%ISR(YR\Y3O7,0BI-ST(-K!B9C"9DI%:Z%X-<-YVS+58I&?6T2\OE-/(
M27)T/N"T82E-K#03W"$K(&QW/QWXCFFM77(8+9DN6PK4F\=>:K;&^R9I]C=_
M4W(R'-KB#07,Z_I<8N;F#+QROO)X(D3&(K%6Q.6^AM2D(2_.<9 43L>"H@$\
M+FK6\CFZM#3?1K#-+499ZI19S4C,[N==S5SIHF.MRI:5%4*.L)YF*Z,LN.1X
MP!2WWRPC?RXEH,Y&^E>^R8ME:J !O"T@U#-UHPM9><Z/L08I-QKT7J)E&59-
M91Y]_)JW?'QG*FA8N<OD92["J84NJ,>9$+IBHD1+5N?&=2V\TIONE!/%=[&M
MU4"_%\)9$+-.?(FM'!KSL,K92&!V'-(*Z+$@HG9:JMC>FW7HJK."VU9LY).I
MK2<W)1'@M(9:3:45?-9;C(C!"QW:/K2&VT.ME.OJ@A=C,SG5IRE5\;)UJ4[X
MEV+M(L0L&+*M%PH1KZ%=U41QVHCL53T#(6,F9@)7 KHLJ?&3;QFPE=D_->0S
M];0X&ST+HPUS)\3Z+O==C[32Z>DO-S<IA"PBVC-A%B3ZR5!FJL\C&32'Y-?9
MU\^))#5OLIMAYEQDHZ*;4DG@C U?"9\B,9S/17SICIW0:4XE38+C*Y2J6E2Z
MW&7/D]]+6X^Z[(<YDMM-L-(+KJU):9;::0"4H2$A(!62LO@B."(X(C@B."(X
M(C@B."(X(C@B."*)9Q_>GDG_ (@MO_47^.FR_..GB%PVE8N7DFO!7%-:>X<X
MD[%&)8L=]PD[>@X84 I1"4D@D GH"0=CQF/\\7[CXE=-G^2%[M7+Y%3.WIKV
MC4O4*MH)F#Y7$PO5/+<(?TPKL1R0Y-6XGCU0B>]F=CDR$.5Q;KAS2YJ7&6(S
ML="VF7E.%/&5H'Q([_/QE56=A7U3%I_2ZOR7/=*\QH\V]4,&RJ50B1C<>#95
MV95;\]B[AVTBW365U2%0Y26V;*3'GE'<!3 6\V%-:O1Q1YW:SY)_KOJI.C=E
M-K$BERJ-1S,-5F$W()+=?'9@1$1Y#[C$>O\ $KM+<H<C.,*EUL61$[S9"75%
M0X*N+;GY,SOFKE[/O;.QCM,TN=JT[K9T#)L2KFY\2LR"3";@6+5K7JFX_+-E
M!7+8;A2TEHRVE$3JXJ4W+CMNI*.""='MLNK6W!;=E;6O5S4K,=2L8SY_#\BJ
ML+>KHK&881$EQZ%=Y)8+MOC,:5*6XBWD8^]M%DSX:U,.*!+@9=):22_#6N17
MN+@B."(X(C@B."(X(C@B."(X(J>UC_N%CI]XU!P+;^&=1_)QTV8!,P\QWNN4
M=V/_ *@>95OH^8G_ #4_F''-9BJ>9\5MP7=5OJCD%CCFG><754A3UC4XW;38
M 2 5&0S%=4VZ$]>8,*V<*=B5!&W*>O!%\_Y6G\:\RGLTVSECFDQ&5XW>W&62
M(69YC$JK&P8JXME#D2X=?:LP&2F<ZZEAA+++9ZMJ;4@%'%L^@\:K@86('A7
M,[=]U;/-M'D&MJL/OFM3+;,ZVOML5SBMT8EX_8WRW7I[-E+CREY5);:$Q>3I
MA;2*EE]Q$=N*A*FU..CA<]O*\\K<A@RS9>U[_7NMQ=/&G6HVN\S.NSS37'KQ
M?.Z3-7^*YE3,295<=0KV?CIL:F9(DVKU? LF8]2AMMQV;(<;%BL%.RSU$>5
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MPE5-A+DY%*>GP:Q,14"/ II#332*AJ)#46(ST5@2@ %NR'7O;X*C/FG;L_\
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MT;:"/:0C>:$C=]T^\*L&L>IE=RULX?Z'[1_3O8]C'[)L8O\ 3B@BB)AA.R,
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M(-3.WEKXQAF5YSC.IM!!P3&^T_K/BLJ= CT+F:6.E>)1<?\ 5A.&5UPE,;)
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M$I[H\MILO@>7>$)YP/H"B0/HX*I6/F?@/^OB&G6'Q"*H]1NF2:5*]_KOY_\
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M)WQ'3KZH[?8'Q7!K2S3AB7&GLX1C#4R%'5$B26Z6O0['C*Y@IEE:6 I#9"E
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MRE94=1)G)WK7*GT%0[!"&@E:=O"^R%.>T=SY[@? 8O[L%L4$WD)WR7-6,9P
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M>6,(.CZM-(+73V]N8[<2XS)-A%0N.\F--QC''6>_85SI=+:XA05I(24D@E)
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M+;2;3;E9HLDF59;J%G^%6]QE%EE&-T^D[VGNEV2M,O3X;]GD*<EKW,]NEO,
M..P$5*H,#QB"I+:VISJ>BCO1%$+;27:KWV2\&3=!>5&$[A=;.G,<UZX[,,IK
MU\U8I,-N[G)=(:R3C!QN==SI5HU%NYU!$E7U72V$T!V55QWW&U*!Y@U,<DL
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M\$30,DU4 V]1X"=M^GK% 5MU_P +FZ_?XD[AF?1%MZS:K#RP2O(^/K!!Z_\
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M<DKCG]$#)=5R=C@]< ?>,B@@C_SOC^/RX$06$Y?;Q40<BU:'M)P: 4CS)R.
M1]_8'_?I]/% @O+]1Y'GZ35EJV?<A.2ZL;C?!J[;Z,B@]?H^=[^!$%YUT"BR
MO)=5@I*58+7H4?F)]8X(*O=M\[\9'T_'K"(;";*C&>6BFJZU:@Y)JNE:>?!:
M]*MO92<C@GF\_<3N21^#\Y-#VO\ $Z^RH%7I*=W1QYK?UFU7/3U#@?@R"#O_
M .EP:'M?XE5H>U_B5J<BU8(_O%@#X%>104I_'O\ #?;C&T80%CO&3!FM%IP6
MH1#O!XGK_;@:J/Y9D&J3F-7J)&#5@:536*5E.20"1O$=!'57D?(_ ;D]!QV]
MG +&(F$AF #R9P]Q!$V-DEY/:'<@"3&9-H)Y%LS.M[=@>0:K)PO#6V\%KE1T
M8KC^SGK%!)7M4Q4I ]K]KOMN/<.OO/#; ",@5<O)K>MKN?)EK8ONS9I,W+[:
M=3(9%JH.HP>"/^D$+^=QQG<,SZ+JCUDU5/E@\ GX>L$'^+VOCMQ1,S8"^9[F
M"(]9-6!U.!P?PY!!V_\ 2'&FA[7^)6FA[7^)0<EU74-O42N&_P#A9%!0/W7-
M_%[^(0+(G/(^J$0BU\&;O+K R/5=.Y&"51V!Z>LT$[]-]MN;C)>QNMRDKCF/
M161CTNYFUR'[VN:JYZEJYHC4IJ8A*.G*0\T2CKU'+YC;Z>+S469DR/%+BI4E
MEA/.0VJ2XEIM1\B@*60"H =.O3I[N,1[2& .2'H 3;BNNSV6TVT0AV>SBB-/
M<A)-'!85YI F\K#W:D6E>I+Q*6@J2QN^0-N2. O=Q84>7V=R>@]QXQ#MH8B)
M@;Q]UB#(TM.-ME)K>T]DV^Q??V>T#5$4,4A83($/<]%L[:U[+S;#UBRU)<.[
M;"G6D.*V_:AM9"U;'H=@?IW/'0;79AP\!D:F8JQ$\#1W61[+[1MMF=OL]GM.
M'L_S&&&+=B(%I:VT.R0V-_#KFU.RYS4<<CI2EQ3:%$-H*B0EPI) "3Y;[G\?
M#B[, SA(J2[<@!(S-TS:!9OV;V/;^UB+:P;./<V(WHH888O> G/W6)-W-C>U
M8MG./Y+C\'(8=E'36SC(;COS5HBN..,/+94 'E)YO;;5RE)/,-MOHS%MMG#"
M(B9$.-8GFWBB]EV^TC.[L8X3*+<$$08&PPL2*4*DSEM ;0SWLZ,TAU: D]\T
MGOBZHM(2THJZ^VI&ZAN/+;SWXQL_:((R&(G2<OKDS.]%G\-MX7_TXXMV<7ND
MB%AO38 !Q?RLET1;U[KS3#-C!<E%!4B.F2RMQ2>79:N[0KG6E(W/1(VV!)'&
M^+LR6$0>C SE4L39;W!E#['[2!O'9[00%HG,)  - Y#3<"XTMELBXJPX8Z[.
M!XGE27&?$LAQ*2/8/=%?>#FW]X&^VWWIQMGVFP+ ^/UHGX?;UX49$YB&)BU6
M+66JN-67$O46-!A:5ES4' @IT*2I""WF-1WB-O(.<PV4-]PH$'RVXZ@T(+ @
M4N,]37&*&H(=BW68]>2N-*4*2D\J3N =R =]QP1?/O4O5S4^+VD;'3S'IMM!
MQ*FQC%+B8Y5XBQ>,EZWDW!FJL)JY;3T)A$:N 0M##G4J(W\N*#+*P8]7G7Z+
ME$2"9G!BVO5TY1^V16IL*./8XA<U];E%@B+C5L[*@N-V#+5L]32I<R*RI3U<
M4OLEUN,]S*4VI*E%*B0#88]-561&Q<SLG*T2]!BX4ZQ#M,M9YJ6O ,;PRUDM
MU_C_ $U>N2X;<2L;@S'(9<[A7UZ2'G6R4=VGYI'7W!+6K?I,THB+TNM-!==C
M?=?YD<[3&L_REYL*3Q.04.%ZCW=#9XPQB$D0FL1H8LB98VBLI!$9N<AED%IA
M1(4LAL@'@QGA(Z\Z*;\3VU=ILUN$KJJU8/;2D/U$C(9VEV05]'355!D>5R%V
MM8Y*IZ+)WDM5$F/!;4IV=(6VH2'XJ%([EI)"G"LA/$6A&9.UE[^*@F5=MW(G
MZ>HD8?@\^)8Y!=->JJ;";7R6L@JX.9HQ"X9>#;A]&RWGB'8B7%+(:/>;\^Z.
M'UU/N#6\@H8BU6>P64MGU8JPU=M*G3 G0K+%+:GRI LZZMJ%O1'TV62U=E$K
M)=-$?2I*7UQTSXE@7 !WD0NN;#D(%E+OTVL7D,<3&E,7?/*>2AE1V[JZH5A=
M9F%&],D7Q8C6]M5/1UBOG6%E>1(31KFN=:8[;545OOOO1]@L*0E8)*8F^9!W
MJ:93YSG5B)V=LP[7^:U\;$9<# 354V4Q;FR8M)EO7R7UX[&H9-O76K$1DK6W
M)><9'-$DJ2.4H3WBN8@5OKA/!Y)OQ&UI:)N/A@KIT9[1CVJLJ BOQ.T3C[B'
MJA[+),JO9#F0T\.#(MV'*;O?&1V77991%D-(>0\I#B2E"0E:IK3S3>NHPD:%
MK2*/+TFQ7K<)3R$\J?/H=AY';Z.,PDD%YS*[+QSDN99%I_IK:9Q0MLR*[&M9
MKMW-6'&BMR1@Z\MM::^E5Z1N6G8(G1<A*E )$*HEH)!4"=>TF(@3G[H[VQZX
MH  3(2E<]*&WPE@JMO\ MG.8?695G<JH]8\.EWN8#"8M?*8BR9.(Z;PH4?(+
ME!4ER1,=LKXV)@J985!5 \(M4ID.;\ ).92M<WYT,Z2FN)C.])YT%@ 83?G-
MK9V+G>]MMB/W5^WBES78579/.HEV:UU\B1D,R'C5G<*KHL/O>^9W4S"[J45A
M"Y"U,J  *N";\5_<%8=!VNZQ_().(Y+B=GCV2PZJQNI$)Z="EQU5L:HA6\1Y
M,MA0;;>G1YJ$HC<I6TM#@43MN:WK;;9ULL5XAG(<Z=:E==..UU3:AZBPL&CX
MQ;5"9]>W+A3[-YMI,Q]Q@2"S%86ELRFT()^O,.N$<JB6TCSB0QDD8X:T%%KC
MM@2,:O<GH6\/MLL5C\FTG6LUAZ#!8K*BOFHB$(YSSR7/;2I"0GF4-]U#;;AK
M7>@C,[199X=+^BI?&^WC=4%E=,Y[C-K<+LKFUGT==1,(?768G63$1@Z%PX[[
MDN>OO0HQGPP%!"OKJ>F]9GP=ZRL%' GWYK/$BE.HL:=]UE94L5LY-VQLE?Q0
MY3@^F\J522<B@4%7;VUG!A&4XG(8E/;)E5JE&=!<9:?==BJ4VZ'BTI*DM]"9
M17?)H:SIX/9;0%TGH.VJRY66,Z3BUO9P,4MH[.:WB'(41ND:R#*[['*-F)"4
MKO[8LNTT@25,AONVNY?V<4HI%9^:;\0%<7[R#@[?92?)NV?0U..5%S7XK?V;
ME]B<3+H\..AI1AU\O,Z?"N^L7V"\IB.TJX8N)BV&7_"U\>2X0I2.7B;0;I(D
M2"&N<TMQM,N:HC-OGIS+ 383G9T3/(VHM7H9FD!E+,#(<F5+[KQ#$PQGVZ'(
M6Y+*9,8KCJ+,J+)BJY5=""GV23MZ-B^[M<=G$'=N?.H/A-6$ M)B+N88SZBV
M3X*0T5_K9(UQR^DR#$J2#HQ!Q:C?PW+(UF7;NUR>7*?:MH<ZK[L)9BQ8R6G6
MU\_52_COMY]:UX+HK=RZ2[$QJ^>8=7#D-U%DMB8VR7E1'40WU-2DM(W4Z6%
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MG@--6Y'AN8TEQ':L:B\RK4&ILH;S8+4F).OKF/,:=0?-MUAQ32OB"?B>->T
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M'%Q@LKYOKAB_,"MTD;<7B>S"9]EA+V&&(EF$YQAB6%O(LN8]E]K<&'VN.&K
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MVVW]Q_+Z.#07G71-T]JDZ8O?.=Z!=ZV ;#$M/Q\-LHMA^:HW_CXD(@_N) L
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MC^(U]9U1Z6UF)!.&Z>[CR/K/:[C[Q]#]/P<&@O.NB;IE[U*>Z%U].:V>0Q+
M/H_71;?@Z>AQ^+@T':.NBFY:8N<OJCTUK;L=\2P$_?RBVW_$:@[^[R'\O&8@
M),01:X?T\UU+6>OE"JLSJQUD7D.F1G8Y@R5(S3O8@1D=JE+CAQG(DEAW]2AS
M  CH1MN"?, <>SV6& P[7>)_^.-P!0>[.8:X5M7CC)WA8\3W<Q4WW4E-6AZ8
MUHZ?K/T^]G;E_7/:]-AL-OU']PZ#Z.G'E:"\ZZ+T;I[1R^NNBR;K6D[[XAI^
M>8 ']=%KU \@?U'\OHX-!>==$W3VJ/9?6U8-CK&00<2T_(.^X]9[0@[^?_)/
M7@T%YUT4GH1V4<=$>DM8_P#)/3_^$]I[O+_DGW;G\?!H+SKHGO8<VC?-G29E
MW5B/(>E,83IPS)D<G?R&LBL$//=TD);[QQ-.%K[M("4<Q/*  G8</<[1R^B,
M;AE'Z9WVI1Z0UBV*?5+3_E/F/6>TV/WQZ)Z\&@O.NB3%@RCO=:"9J^-]L/T]
M&Y!/ZYK/J4[[$_J3[MSM\-SP:"\ZZ).Z'^,7HDMBG5*XB.P+7!--+&"\$AZ)
M-R"?)CNA)"DAQEVG4VL)(! 4D@$ \&@O.7T29J ;)B,ZYU2EJ5JZPTVPSANG
M;3+*4I::1DMFEMM*$A"4H2*@!*4I 2     -MAP:"\Y?1)W <A&/*N-5DS=8
M "1A^GF^Q_[I;/\ #Y5(_BV_!P:"\ZZ('<2&40GS:VTFMKI%)=U9FQ_"2\)T
MVE1N9I?<2,BLWFN=AU+S*N[<JE)YFG4)<;.VZ%I"DD$ \7W+^X?*M-@*-4TG
MABE(L=9-@CU2T]Y>@Y?6:U"?+E\O1>WS?9\OF]/+IP]R\Y?\5-T=D="7\'/*
MTXKN+'6-)4I.):?\RNJOUSV@YR-OG$5.Y\AY[^7$:"\ZZ*,:, ^$7F&L#WVK
M4V>LBEH6K#=/ I"PI*_6>TYDJ#:V0H'T.#S):<6@'?<)41OL3P:"\ZZ*[I#E
MWMF/3"38R"W%CK&#N,3T_!^/K/:;^0'GZ)^"4C[P'PX-!VC+5RDW=AE&TJ29
MI(]):R) VQ+3\A.Y2GUHM=M^OE^I/OW/NX-!>==%1O4D.4,7@0V:YFRUB44[
MX7IWNDCD5ZS6FZ/=ND^ANFP)\MN#07G71-TM^:0_3=RGE-;&QUC&ZAB6GX4$
M[ ^L]KY?#I4[_P ?X>#07G713WBT@9O_ '#O,AJ2YIM-9M^F)Z?;GH?USVW4
M'SW_ %+/^^_!H+SKHM->!?(E^X!_LMQ-U@224XAIZ"I7,2,FLP2K8#?^Y/F0
M "?>  >#0=HZZ++&X6V1VU3=<1]3;V [6W. :8VU>[MWL*QO9TR*YMML5L/4
MZVU$ ="1N-O/@T%YR^B .9@6V1"^\,*Z++: K5:MB1Z^NP;32# BH2S&AQ,@
ML8\9AI)W2VRRU4I;;2#U 2D#?KMOQ3N&TY#Y<=,JS!A"&N<MDV ET3@9^L*B
M5*Q'3XJ)"B3DUF3S#R.YJ?/Z?/B-!VCKHH7-0,H_3&5UBSX_6'<'U1T^W  '
MZY[3H$GF3M^I/N5U'P/4=>#07G71)W#*/*E,*+5R?K"M)YL1T]5UYO:R:T(W
MWWW_ +D]3O\ 3U/!H+SU'_$HUX'01#O(D'K9@N2;#6+F_O1T\]HI)_7-:]>4
M;)\ZL^0  Z>X#W#A[AM.3>$*NZP/NC,GR>H"4^DM9-]_5/ -]MM_6BT\M]]O
M[D^1)W/Q/!H+SKHI,6"3BD=O1:^/UAW)]4=/MR% GUGM-R% !6_ZD_M@ #\0
M.O!H+SKHD[AE'Z:87!8,_6$@).(Z?$!(0 <FLR E))"0#4[<H))V\MR>#07G
M71)W#*/E==(76+7Q^L+:3W>(:>H_S<FM![^OS:D'^,?'@T':.NB 3H,H@.\-
M:;#<%IZ1UC6KVL1T]5S$$_KFM=SUWWZU9\O/RZ;</<O.7_%4@M09DTP:9:5]
MB30&M4*M4Q=;@>F<!5@^J3.5$OY\=4N0KHI^26J=)>=5[UK*E'X\/<-IR;PA
M48B@$L(_35*)P](ZQD[^J6G^^P&_K/:>2?(?W)]V_3X<&@O.NB>]A+"/#T7!
MU_5IYIQE[#-.G&GDN(=;7DEDI#B'?V5*TFH(4ES]N#T5[^#07G+Z*-@,HUQ@
MJU5J8S$2LP736%%C)[N/&B9#81V&4$=4MMM4R4(2=AN$I&Y\^#0=HRU<J(7L
M MI%65ADE?I;6?8 8=IZ-M]OUS6NPWZG8>AQMN>N_P#[N(1 Q8DX'[*[I%#D
M /,#1O*8,IL]8SC-ZA>'Z?H:%+9-J[K);0*#2HCG.A %0 $D  C?J /AQUV(
MV9BA!,1)B# ?E)L=P#:<19>IND!Y&1DTQB#>*M2K)'@=IK,,,PSP^+8-X1&*
M8^&E+R>W"UD5,5 #B_11! 3T2-SML.I(!XSM((1M(G-IQ+O.R0=^:CQ$LS@"
MI$J48$O8:2P4Q],ZTIZC%L"4?@<JMMO_ -)/YN,M!>==%6>3 8B$^8"QZ;UK
M5T]4L _A1;'^(5 /!H+SKHK#"Q=WZ-ZH],:UCRQ/ !_TFN/_ &3P:"\ZZ+I*
MXYCT6PN=;/\ )3 /PY-<?ZZG@T%YUT25QS'HL+NM;@DD8E@"B.O*,HM@3][]
M2>OWCP:#M'O^5)7','N8>*LC'I%])K6W<DA5T"S*E=Y'JY;TV(E&PY"E]]B.
MX5'<\R>[V'391Z[9BW7]TDB\_8> Y*)W)3N0>8[GJ.FQV]W\G&7%X487!9*B
M1LD'\7E\-MN*C"X9!92-^I4=]^HWZ#KY;>>WW^"2%P[ED[>]6WWCMQDA[2.5
M%5D)3L.@/T[#KQ0&#>*(V'P'XAQ41L/@/Q#B,+AD$1L/@/Q#@PN&015!K$I2
M:/' DD ZA8#T!V_[M*8?FZ<;A)#M*3='$EQC SCZ_D)K6LU;R/F)_P U/YAQ
ME2*IYGQ6W!=A"!8.H1P1A<,@C@C"X9!'!&%PR".",+AD$<$87#((X(PN&01P
M1A<,@C@C"X9!'!&%PR"XDDMJ)/4>1^'EQB D@N7GZ(P% !T52:3)3Z)O^@_O
MZS8?@]9K?I][V$]/+V1\..WM$43B9I#X=W2B,+@K@V'P'XAQS%!R"J-A\!^(
M<5%G@HPN&01P1A<,@C@C"X9!'!&%PR".",+AD$<$87#(+1/S-_?L>OX^(?,>
M(551ZC #(]*O=^O@GRWV)QC(>NQZ;\>K8%H=KCLXP<0PE@O,9D/?Y%1F@S;6
MB9KEF6'WVG%?4Z,UF)T=CANIC60LRK7)LHG3'F+:D?H6QM":KXS33R7B$I4I
M:N4J.^WE%O/5I\N2]##LCFP;E>_<K*U%GS:W LRL*^2]$G0L5NI<.4PM2'H\
MIBKE.LOM+2I!2XVZA*TJ"DD*2#S#SXJD0#&0H;,%\G,>U2[1>DV%8UJRJ)GE
MOCU_2X]46<#4C4TYW#GY7DCX$3)*^-99"WZ#IH3&ZY-<G)L?:==>9C*\*$B2
MJY>?*V[#$S"\@WW!GR-+*OJMTI97=MG7N_K[N74XWIA 5BD&,];)M;,.NVCT
MRT]%M/5J8F?)Q^"C<&3'JI^;O3)B5"+XIE]/? >5W/OOK*]4&-YTJ:@<G:QS
M,T(72+V^<XGX_:9%#CZ?NLXBG&XMWCLE%W59-EUM?A2)$?!TNY%+@;4[JB)#
M2IN1-/").'I=I+2'DRZ9JS-;)IO(3JP#R>JZ SH"*B3RKY7F4Y.G"?VV-7Z&
MOJ8^0P=,F;O,\>H<HPU-;7Y%(0B/:V5M DU<]FPS&K@3ID1%670[(R?'81[Q
MQSOI"6T!1L#*VNN9,_&O:&F[/#1Z.':WG)G:2J/$.W!G=YD(S.\RFFQ&KN<3
M5=1(.0R[N;B-5(C8RIQ^)&HJO(J1$A=C9LA<1UZ_LTQWG>5FRE;E2JTOJ/ G
MG.;F@$UDGWC7D!(.':0L#2JYM-)U,[>6M]++J(,_#=/;B4BABY-=&BL8C,>T
MJ[2S$*#!I)-MJ1$16W42/RJL@EK,0B:XB,*]MPDEK#4\&MK+3N:0B0L8R-<'
M9GH>05J:+=H?4/.=1,IN+V^QNTI(6DD_)86!X=-M')U-,A9.[!3$R.+-M9RC
M=J8C$.384&I6GO%L&/W( ,?NY=_=*8\^C!V8,7L/V#7O=*BC4?MFZP6F1XQA
M]+"TCL;?-TU\Z)91EY5+K,.B3I$IKT/E,)%Z7Y=TVU'"@N'8U:7WN\#<5ONS
MN5(:8 YT(E8UO478IK:[=6HSF.W&42:S3*J1C+4.'8XI9S[Z!D>16,VNEO"V
MQEU^P#3=!$DQDK=:=AS9#\825)GM&.I1H%;:2M/+SN7,[0RFW3Q)?U)4:R'M
MI:HU6H-##=L,%M16PW:]^PQEV^8TTL)693=+(E5;9#'D7EM8(9PQG*YTN4[&
MMW(T]+;J$O4JG'WV1KXOZW:YS?)+O1I!VZCI, /UDI)8=N?4J).S&H,C1^-)
MTS17JLKJQ?O6Z75E=MJ%:80RC2QEC(&GT.U;5:F9>(4O+8\.9.KV%/1HS[KB
M9I[L?*WT/*R0N:TU+2+6X$B<EZ'T?[06H.K%KJ%C$?':J!D>EU-/ILR4MVW%
M6K586=Y"K*RL<4XTL8])QNE@9<X$K[ST=F6,OMJ[U]X(M]/.QITMG)Y&EMA8
MD CJ!)\1<P9VJ07)F/.F0=OO-G*+T_BM!C5:TTW,KY$'(V;:PDKRW$Z*)=ZB
M0&?$9%AT2)48W87%?B\N;:741<:V8D"#76S+2D*BZ>ZSL&'Z6E71GZ+6.W5G
M4^@CYDR=+:B#>651C]7A=]+R*/E5;)LJ^MDJRN>ZW+#$K'&%3'):F3Z%0[4I
M9E(M$RG"THC0F@&7E))GNUQK"G4%6(4,W2O*;N8TS%>R&GGYG:Z>1U5]7<V\
ME4.G8MD/1[%]F F-(BIR%XLO*"UV$H(2T2,+AE)N;=><G9+L-[=FI&5Y=64+
MF'XI3U;TIBFLY5W.B5+R)LB$9)O8"KC.*FTD4D=U)"H;../O*CDJ-N%)W458
M/(#FW.FK5=_:$[1N;:.U6#6=.WAUQ!NF52K^U=+E@TB*TXREQ^FJ8V15-DN
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M6G%Z#T:N(F$NO360!$<B-J*T15,!GNU,I7[26RDI"O: WZ\$W0S,-=_>FE_
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MO-8N,3=;L<>;HH3RG<F@HM75"S0C*7[6,TXCQ.SA9@*;C)*O() V/D;N$N]
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MU>_Z%D5:9+U@HI$J,I3J"%%"9B5=%K.P/%W"9-RK,V"YY2MZ3$]ZLV.+7S+
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MT5&(A\.[5Z*PK*?#JX<BPFNMQ(4*/*E3GY"N5#,2 GO)#Q5[DH1NHGW)!XP
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M-S;V9%9<9JH2G'6TIE2ULM!:7!S=".+NPW!'H'(GC+%7B@-K:2M(24J1S)(
MZI(W21^#;;Z.)%"*M4CQ \%7-'+7.JGU&.V1Z5;=/U[G^/&,BX].Q W=K(?_
M !Q^ 7GWHGAF6,4VN8W<M.HQ1:(L4FN69:SC,LML'LNQ6GQA[#IUDX]B=6BO
MFO2S/K*Q1Y8U@\ASNWGD *6VGE)(''FW8;ATE5=VMOMUR5I9U42;K"\NIZ]"
M53[3'+>#"0=DI\5,KI,=@%1Z %YQ()\P.O7KQ6%PR1?/2-V,ID#3W#0N_O[O
M-JZ+BE3.;?L$08M51Q9C<G(ZZ!)@-,*Y71WC.[RBIQKV.;8]*H!)I= V$Z];
MZ&3O$+?LU:TOB50U#5A 6W96AL,L&22QZT8].R&DEUE.TP'0J,FMK(LU/0)#
M25=VVLAU0X*&$,0 'YT>U_$=%FS[*.K%>JW?Q=Z2PN9F>:.MAZ^G.(3B,W(\
M/L\<@H0ITI+<"-77'<-= A4A83L7%<5\.0$K_#&MI7/AQ4[R;O6=*7*,0>SG
MVC6E9'4Q%RH4*1-:LFY]E?./64R>W$R=A"&Y;2]G833=E7+1*>9:EAQ/<J6M
M#"%<2^3W9\^ER;D7?S=ZL:L#.?T3=J3I;F6D#]39V#5G=80_2XK$ML69N[-;
M-CF;&'F))LYDH*6&'VK8+D1U/%M$];@'M.(1LMR\Y=&77=%"*V64PI(="X=7
M=>:5:M:A=G+1&LQY5A77L&NF/Y"W*M)3%@U'FA\QV3*4L27%LI=;2%.JYQRI
M ZC;@FZ"PE+P$SGWJ$Y!V2M48-7(:Q"5,AV+ME7H:<]8+ %ND./MQKAA"^^)
M29-IWD@@ <SJBOSZ\%-T7-;-CF'Q>5R[VG90U4K*NW=PQ^776_CX3D!;F0SR
M%US>,^&GQ&BX\4M"9;CO5]-E+5WBNH'!-T7#PMU>PP=*6]!-:\_L[JRS2MEU
M$%Z@N6*2G7D4EQ<>Y:PBII:6:[X5T NFYCS9;?F&>\#WS]^";HN\GR;D'5=Y
M1H=VB*K&+A^3-MX]W0JR#)+K/(EW.F/W.(.8C<5D7 6*Z*I4SQ+$IV(M+C+:
MUM^%3+:YGW.";H8@ //-L:*NJ[2[6G5A.9Y+A=1DM+@L3/,BJHN'1;M]I5K*
ML=)M)*NNR2AEV"TQS7TV5UN5$RFD@Q;29/F,!<UM:306?*8SYW7&VT+D8(HI
M2D9L<9#S-HD*LKTN^RSK0<8ESH=Q/L<\FY/F\.9>/7DI3UIBMCH2]A5:PMM3
MJ(R(ASYJNLVXH;"42'%V" '%J/$L(Z%Z'$9MG>M<,N"X:PY.XZ2FUXH[H=!-
M8I,!VAG4#LBY&:R+6^SR5DLE3&3X_.U)B9'7UH@\XYC48NVF ^AQ#0AN0U1H
MW.S(5O-V%F8'F!/U6V!J!-[-66INT1TLU#QG4O3K3D"PI<.QC$:[(\]HV9,I
M<&+D6-=_4T[<:;S]RMO)6I$:U<CMK()K%=Z!WG5NAW89!&=Y$EB:6 WLV#V.
MX-JSK#HGVD\RUDO\CQ%3U+6ILY:JZX8MW(D:112J;PR(SJ%.KD(?,CHY'2VV
MPVL(=0"I1)T]=7:[[ N<4$9+O<[6MU!'TFZ;;[LY:FW,N@M:S3U6/R(=?)I2
MX]D[TN6B3)DP7Y=SW9<6VRW,+#PV;6%J+@4I&_3A9XTQI;:._HX<3AZ3M-UI
MH_,&RCIWN>S+KO<Q+6IGWRIU-36\*-B,=^W>4'<>DQY3UN)Z2H!UT3'6V6>?
M<AI.PV3N!%U$(N$\'R]$MT1T[S^EU?Q/"G/2%7@^(XI R?*:9I^6J##S&,V[
M4Q8#,DJ[F0W.;4W<F.A2D M@+2%'AY:[_6Y00BC,WO7TOY.,+GFF?4O0[M'9
MAJEE]U2-R:VM>M\K:BSH=VN*S.QVYQ55=6-K=[\R^_9GK[UR*$M,0G$]^RE2
MQN98:V\^C=R;H)H'.'W#O:W1+<H[-.J%7:6J*JBEY?IY+J8L*#AJ<GDQVDY!
M+P]^I?R K<<]D0[8,.J!W[TN+FD%X FSF'-?!Y%QZ%1G#@"DA*VU\++5*]7M
M#-7;#23L^8UBD62]?:<XGC^.6L&OM.[J53JO$8E.5S62ZRN3#BRF5D36GFY3
M3@0XPDKVXKD+!V9+/-KJ#.88SE6UZ*D[[LQ=HK-KS(ADM:TFOM*K*JZS89N'
MGZ&W7+KF6*,H;D.N2Y C/MK4CQ2TH:=ZH2>AXBH@+S$N?3'FU+UPM.R3KS,1
MF%9.\?<0%^G);##MTTW27]:;2IF8]0B-S=\EZ U"<9;+OZ7B*&S)5SG8M[D(
M>7>];M.%Z=[.6.9RYJ1JD[83I[>%X<!CNG;<Q<Q8C2K]I-O?Q0%D-S1C\CN:
MAM\A:4%K9H[*/#7UE]D,(L #@BZN'C:O.4[LYZ[-7,FTB8CWL_T+18SE5ZYD
M#\J5FG@LGO[2;;5<=;S:5J<@V%<T69:VVU+:="VR&T\5P\PXN$A<_5L%R.SB
M-"QO)>WQF1R<4354]F?M"T;[5H[C0NK2SQNHQNPGO6Y?EQJFCS_+[AJ&A(DQ
M0ZIVFN*1DLJ/A2W%?"P5,LA<+%PTC94=;UH;,@@D@@5%^(YW$2O#KTWBNANJ
M,CL\X)IOEDF><@K-4$VMX7+EQN3)P]B[MIIKQ+96%.,J@O0F1'2H)*4(05<J
M5'C.Y#8 &)-!:")2Q>W)=&#4$L!;</OW.O/SG93U]7:7\5=C9KC-7$Q]JP?N
MD/U=I"7E%?8X_P!U&6I4E<BDKV'>[\1N&/K;+/,-SQ1"!0"X%F;KXNL1PM#$
M0&-9!B#234OYI!6]G3M.551=,.^E[BPDB/670DWA=9OVD6DB2[<PF$O,ER2E
MAUHI,U: XD*:4@H2D'4M7V<Q?I_,VT-2>AD PK8*66"5%QH^S;VIX*<<<9D6
M(O66+.!Z4M+Y<JNI(;LMQ3"$-LNLO1'T1E[,%@/-*60VH<J03"+" 0>1!'A6
MQ;@$>\'WF#B8EB")2#SESG-+J#LU=H:!'D2;N)=9'6QI#+-WB,S*NZC9,XEB
MP:-I&$=(W/>R&7U>,<2MT("5H]@$YW0;!B" O3NBX=S>G7U7TG[.F'6F!:0X
M'AU[%1"N:*G$:;#[X21'"GGG4,AX>RLH2XE .Q/G]/%W8;ADJKXY$?X*?W(_
MDXFY#=WGU1:.I2$*(2D'IU  /F.&Y#<#SGW%%%<V]G$<CVV'ZA6IZ >8@N$?
MQD_C/'39@;PE:#_D%RVA(=B1[IH6O39@JBWI]AJT-EQ2,5Q<)0@;J(-/#/*!
M[]SUV) /O/", Q%P+Z8)L8B8022[0E[9B:\V2NW%H%!RRVPV=<Y1&ET603<4
ML;V1A61,8@WDD!E4B13-Y4N"*5^SV2IMN,W+)==V:0.8@<<]V&X3PTW<NV\;
MSWZ*O7$=7=.<UQ*NS:BS&@DXW:08-C%L56<%AI,6R83*A"277MV'7&5)66W2
MVYT/L[@@-V&K#[]R;QO*E7K=B[KT9AG(J3Q#S"9+3"+*$IZ5&*.?O6&B]S+:
MY/K@>0"@H'-S$=1=V&X(YO.97:-D5);QI4BGN:R>U"4H2WX<Z+*;B%KVG$R'
M([CB6E)0%**7-B!N2 .&[#<,E23,.3UTXUSA.DNL6G^K[-]+T_R:'E4+&L@L
M\9N)D$ER/%NJQ8;F0P]RA#JF%^R5M$M$@A*B0>)NPFR[N607$K'MQT>KJYN*
M !((CBHC@B_*O_U2U5-WM9V1ZJ52W&2Q)6H]SXO'Z!'>6]S'9@!YV!7D,OA$
MA]I*D E V22?,#C]%_T\7VFV 9P&<O*RQO/HNT'Y0<3X\M8*O^PIVJ=&+W47
M%,5UMT(SWL]Z3:&8Q$E:-X39XI=V>*R[M84U9YMET]JK;5*NW76!Z/4]#4S'
M=4LM/K.Q'C_J?LVU/M43Q&(F)WF)$F1%W*K.:,;*X,TB]+,&-S.%Z;[>_P!5
MNQVXP.[TCT/T=UOSE%^Y%BW^60<&NZ"G9PUB1'5D2:Z18PVY<IV9 +D:.M,5
MII1="DN$#?CA^!CA ,=2'8/)Z6>![E  [@EVJ9\GI.G(='^=O;>^J#Z7]K?L
MJV>B%_V'M;J)S"<7[_!<O72-J5A<JAI4)9LS(;C)4U :AJ:?L$G:.[%)2>=Y
M/*/L?TKV6/9[4;3>(!#;H! ,P7OER:9FRT*3^O6S+Z#ZK?\ 4VX(^IWP 3S$
M:I9F-]]]]GX0WWV3O]/0?>''ROZJ"/:]H#411 \Q$77&*?\ **QKE^@5'[$/
M\T_Z^/EP_P!W[CY+*J#6+^X6-_\ E!P#_32FXV*1<O,+E'9^_P#]"KA1\Q/^
M:G\PXBS%4\SXKREJUH*QJKJIB636=I<P<:H\7R&BL&J&ZL:>=-DVDN$\EI]R
MN>9<=A!EAQ*VEDH*SY;\%V9ZZOY9K<:+KQS.-.;?"HD./C."8C>43%9)??[\
MORE=Y"2A:FUJD(=<'Z9?=65A:E$DG<$KJS7DJ)PSLR:FXKJ#E^=Q\NBT\[5I
M4][.G:&/":EXI8+>YJB3BAE0Y3"VDQ]FIR)S10[("G^4*7PUJ6KU  ]LZ@S%
MTJZDRDE5IAKCIS;YK3X4K&\VJ=1,@AWTG,,VFLM7%9)=5&%P)E7"@)C7)+<=
M;D1$=Z,B.M:$A">4#A/I;Y*J.R= =6AB%IH?'BXDY@%_FJ<@G9RY9O,7\2 ]
M=M7<J&Q1.1'DNVG?MEEF09B.ZCD<BN?IPUK76JA>8[QB)&O2][ G ]ES)',I
MU3VEU;V%R<=REO2RLYGA(I<@S^,AO)WY$=3!;8;94RZU$=8*EO,V4M2SND<-
M:UDK5^8:_7V:^%UW9TUP@8UENEIK,-3B6:SL(EV.4>G9*K6J8QZCHJNV;AU"
MZMQ#[TAZL6(KXEMJ2@MD<NW%[M=5QW8IBKF\3K]?.:LW4?LZVMY-U.F8U#IT
MMY3BV,PZ9H27*B4F\Q^:92;&3,8CO*8D[ALM2^ZD;+2 \@@;!*8D[UGY2;/#
M 82["C.#TNJY\6I)5W2]DO5)K2K4"@EZB7";S/)V2WEAB/I.!-H+*=<H@1V3
M;7[E0BQ+K(@)*7Z[PJ6"LE$=7OBZB0'(!63V7M"LWTGRC,<CR6)744&^Q_%Z
M?T3'RNTS2;,MZ5E34BW>MKB.R]#C2FN2/%K4%+$=* M*4E1'!)V^64KK_N?=
M8.[).Q&XWV.Q(Z#H2-QO\=NG&(*'F?)55/I/_<F__P"?>;_Z37/'3VBHY0^!
M13+*JUZYQS(*N [':L)U7:U\5R:R)$-J38QU--KE1U@HD1@M3?.@A25)YFR#
MOL<B@Y2RET2>KK?,+YAL=EW7"P@WF+PC4:98GD5% Q6_KZK,+7)V7X[U["FV
MEKC4:[KTHQJ/Z*:G5T.G1^DGGYZU.IY(S2G+]FY6OCY+-938O9?6P,U7-9R*
M?ZSL39=#OHF+3\UM+/3>HR>YRFGNFKI=%F%<_?52F)D6*:)BMBH99L2N1W:4
M[$.IW!Y2> .?.A?#+O7+<B<L).1.T,1;FX\:Q^7V6=3ZC&ZC'H5#B]\[1JR"
M#6Y,QE]UBV4(<GS%2(F0V=O&:>792'T+0Y:P7U%N2\T5[NI6>*UT^5<J^2C&
MC-6LJ8TN5RVW9ZU<%%@UT-1G<TR_"9E/=1<:R!%=%Q)Z="BJC26(4V%7(G(6
M^A7L/R3)(<3WA0-R.(NP>5&;R%#=BSJ*YOH[KSJ/)9R+)\?TZL')$>^KFL-3
M<2F:RC-A'1'AWK]JBN"K6W@NA3S2S&CEL;!MSH3P6F?5HGY43_C/99R^'GV&
MRIV11I&%UU-1W>51PXM=A:ZCXY5O5$*Y"'06UL(0^U-1WJ5 R*^,LI))(*-3
MN[[3]W%5TU$T@UMM[G%\99L8>I^F,><BSS)_*;J%19'D,A%D@UN,.+J:!$9S
M&*H,*FR(JSW]B^X8;RU,$\$G0S$\KB,7-)9KZ$,I"6D)Y0D)2$\HZA( VY1\
M0/(?1Q#3K#XA55)J+_?1I6/<,W.P_P"B^0_[[\>C8TVW_:B\%YR 3!B9V=JY
M6Z4()W*03OS;[#??;;?\73C@O0L[#X#J /+W#RX(L%"#N"E)!\^@Z^_K\?+@
MBQR( WY1T&WE[O/;\?!%ILUT]@>SU'0=/X^"+4M1U[ M)/F!ND=.;;?\>PW^
M]OP1:NP83XV?B1W@>7=+K+;B3RG=.Z5I4#R[>SN.GNX(NH89 Y4M-I2/)*4@
M ?>   'T;;<$6X0D @)&Q^C@BQW:-MN4;$[D;>_@BP&6@00VD$)Y 0!N$D[[
M;_#?@BP66=CNV@@@A0*001L000>A!&XV/3@BX,QH4=(0Q%880G;E0TRVVA.W
M-Y)0 D?.5Y#S)/GP1=DAH;!* -N@Z#H-DC8? ;(3Y?X(^'!%OW:.OL)ZDD]/
M,GS)^D\$7),6*WSE$=E)6D)<4EM 4M*!LE*E !2@D=$@D@>[;@BVV:WW[L;C
MWE(/T<$6$ML]$I;2!UZ<H Z[D\$70MH*>4H24^6Q VX(N28D5"BM$=E*U?.4
MEM*5*V&PYE  JV'0;D[<$73N6MP>[1N"H@\HWW4"E1W^)!()^'!$%IO;JA.P
M&P&PZ ;; #\ _$."+3E9!W#8!Y0D$)'1((( Z]!N ?OC@BR$LD[!M(WV'S1^
MU^;Y? ^7P_'P1= A"0 $I 'D !TZ[_G)/W^O!%R1'CL)4&F6FDE2EJ#;:4!2
MUG=:B$@;J4?G*/4^\\$6=FMTGNQNC?E/*-T[[ [?#?8?BX(L\K:E \@YMB 2
M!T!'4>?3?8?BX(CN6M]^[3OL1OM[B "/O$ #[PX(MN[1L!R)V3U2-O+;J-OO
M>[X<$1W:.HY4]1L>GF//@B.[1N3R)W( )VZ[#J!]X<$6 TV-]D)',=U;#;<@
M;;GX]."+(;;!!"$@I\CMY;>6W^_T<$6_!%S=_8U?@_\ 2'!%%,X_O1R/_P 1
M6O\ Z@OC>S_,.</^^%<=K;^T^:08#OZ@X;R_.]5<8Y3L5 *]"Q.4J">O*#L5
M>[E!WZ<2/\QZ> 38_D'[8?!?/6B[ M/(5K!D><V%S<Y)D^I6=9WA5"O*KQ&%
MUTNZJDP\>L)..(?,#QT&6ZJ0[(7'4IEX)> *QURNY8DRF2XI(Y=\EY3RGZG)
MJ[08G08SI<QA%;1N8#IMCV64:;!,5NPR+%J*SA7EU$7/J+.L4_)L);3BYDR&
M[)=CMJ(2TZ$JX<UEC?*7.L[QW"X-)1.H^IS]J2.[B3<3)**EM(V%.XU?9@,E
M<M5^%5!GL,,0(;U"B5'EM%^,VW,JY\.*IA*^\A[I2G@C.7:8M=K"UH<FC>07
MN+L%]EG4CL^L:@IU)F-3!E+='%1$9NXUO#D.5%:F%+M%L1*6GCQ7+,H4Z\A;
M4B0LK)DR'G>99*SU;K5R]4=G[229I99ZM..MU4>LSC4F^S&AB5#266(M39J;
M+#,AM*$)3)"DK4L)'4$>[H"@DX 82\]8D]5Z6X*I.J0$J*2GJ"1YGW?_ $>,
M[OZHLT79*@I(4/(CAN_JBS4<7C-?$'ZK]V,^T1VK'^S[;]GF%C4R[THS"XO[
M(9%=1*I#;<VM7#AK81+;=9E;OK!6A22  %$'S'TO8?:/PV\03"8O[H07+2F1
M?=25X6W+ .&F#.YJO("HJ+FJOG4YV"/JILAFD1(Q;2^984:X[46RG935N/16
MFMG9+Z_#2H\2Q<DJ6MCDG,E+;(0E"=D[<>L^V[*,[T1$41MBA.\>I<SH%G>+
M.X/63#R%LB'JG4=A'ZIFIJ6W(PO2R7*MJA%58SY&6L,/OPXTIZ;%"1"O6FN=
MF7W#;1AH868_,W(W"$ 4^W;.;DW4.!+O6_!K5=XT>ECS&ATS3+G7U/\ ^J7:
MD1,N1EVGFCRK/)L+?P)RVB9:Q D.XVY7/,%E#43(H<1F?'EQH$I,E^%/,MQR
M8B8Z]'2T@ZA]OA@<P11!NR(G.1QU)3>/:D7%1-VE.M* V7.OKE]1S[).JW8I
M[),;136)BCCY:QG&1Y E%#8&TB^ LG8BV4F4-T.+ !1NE9&VRO>./D>T1G:[
M6/:&(Q;\1B!))81$D"<[WD)J.7+WDB=EM;+S>XL<_61)V2E/*KHD#J 3Y>_W
M$_'C@S>*.+QF%4.L1'H+'3L/9U"P [>\#URJ#U\]C]'3W=>.FSV9VA+6 G"4
MS8:7=ZQ%'  7!,[ )G.ZU6\%(*4@J Z#IS >[R(_U<<B'DY'*2N]"#2=X \7
M6"RT2E1;05)24I40"0DD$@'X$@$^[H.)NXQ9_1:WA>,T!AI.P2VD<OS=AY==
M^GPZ]>&[-WBS'@S)O#M#-9#38)(0D$@@G;J0?,'XC?K]_KY\-W]44\?HCB\9
MA'<M=/K:>A!'0="/(CX$>X\-UO[HL_HCB\9A94VVHA2D))!W!(!((.X(^G?K
MPW?U19IO"\9A'=HYN;E3S;@[[==QT'XNOXSPW<8L_HCB\9A8+39&Q0DCRV(W
M'GOU'OZ]?O\ 7W<-W]468]$>&\9A8[AG??NT;[D[\HWW4-E'[Y'0GWCH>&[^
MJ+,6]/M8CPWC,+/=-[!/(G8>0VZ#R]WX!PW;'BSZ77(XO&806FSYH2?OC[_\
MI_&>&[^J+-'%XS"3\Q#2AUV! Z>X;>7X?(#\'"$-G]NZJKB_0JJLTG_N/?G8
M],[S?<;=?[Y;@C\_\?'7;P$%KQ"0_(&4J3\4<,[AOH^N15NA"!Y)'EMY#R!W
MV_'UXY;OZHLU-X7C-:]TWU]A/7;?IY[#8;_>'0?1TX;K_P!T6?T3>%XS"P&&
M1L0VC<$D'E&X*O,CX$^\^_AN_JBS^F=]J.+QF$%ADG<M-D_$I!/GOY[?'K]_
MAN_JBS1X;QF$=PSU^MHZ[D^R.I/F3]_W\-W&*^OT1Q>,P@,,@[AI .VVX2 =
MOAT]WT<-W&*ZOT3>':&: RTG?9M W.YV &YVVW/T[=/O<-W&*4J_1-X7C,+(
M::"BH-I"E!(4H ;J""2@$^_E*E$;^1)^)X;OZHL_HCB\9A9(YATW3]!Z _B_
MW\^$4)+-4(XO&852:BD#(M*O<?74DCW@G&<AZ]?+SX]&PABW=JQ/N[**(S/7
MRNE55H2"93(8EG-9>"M[CS[OZHLU'%XS".&[^J+-'%XS".&[^J+-'%XS"//A
MN_JBS^B.+QF%KR)^'\9_EXK&\]WHCB\9A'*D>[^,_P O!C>>[T1Q>,PMN)N_
MJBS1Q>,PCAN_JBS1Q>,PCAN_JBS1Q>,PCAN_JBS1Q>,PCAN_JBS1Q>,PCSX;
MOZHL_HCB\9A:\B?A_&?Y>*QO/=Z(XO&81RI'N_C/\O!C>>[T1Q>,PMN)N_JB
MS1Q>,PCSX;OZHL_HCB\9A:\B?A_&?Y>*QO/=Z(XO&860D [@?QG@WZCW>B.+
MQF%GB;OZHLT<7C,(X;OZHLT<7C,(X;OZHLT<7C,(\^&[^J+/Z(XO&86O(GX?
MQG^7BL;SW>B.+QF$<J1[OXS_ "\&-Y[O1'%XS"VXF[^J+-'%XS"" >AX;OZH
ML_HCB\9A:\B?A_&?Y>*QO/=Z(XO&860D [@?QG@WZCW>B.+QF%GB;OZHLT<7
MC,(X;OZHLT<7C,(X;OZHLT<7C,(X;OZHLT<7C,(X;OZHLT<7C,(X;OZHLT<7
MC,(X;OZHLT<7C,+1P H.YV'3Z/?QF*$M**)^;Y2T'01 &H/.8ZJ+YH4G$<C3
MS).])9@['<[&(Z/=UVVZ'\'';8PDQP0U)B%'M/)[>M%G>@+N* U;*?@FS38!
M6"82%;'?#\>!!Z[D5<3;[^R1MO\ #IY<7:PD1Q@N&B-XFYD]]Z"*&3, >08
M2\FP4Y6PRYOWC2%\P*3S)"MTJ()!W\P2E)(\N@^ XY;OZHL_HM.+QF%LIIM0
MV4A) '+L0".7X;?#Z.&[^J+/Z(XO&86.Z:(V*$D;;;;=-OAM\.&[C%=7QE.J
M;PO&81W+0  ;2 !L!L-@/@![APW?U12Q^B;PO&86R4(1OR)"=SN=AMN?B?I^
MGAN_JBS^B.+QF%MQ0&M)YS5<&A=5K<8!<VEC*GQM5=1:)J2Z745E0SITNOB
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3AAPA! [R?%=(1NAG)Q)<YK__V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>43
<FILENAME>g164680g01m18.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g164680g01m18.jpg
M_]C_X  02D9)1@ ! 0(!>0%Y  #_[1@N4&AO=&]S:&]P(#,N,  X0DE-! 0
M    &!*^86(X0DE-! 0       \< 5H  QLE1QP"   "    .$))300E
M   0S<_Z?:C'O@D%<':NKP7#3CA"24T$.@      Y0   !     !       +
M<')I;G1/=71P=70    %     %!S=%-B;V]L 0    !);G1E96YU;0    !)
M;G1E     $-L<FT    /<')I;G13:7AT965N0FET8F]O;      +<')I;G1E
M<DYA;65415A4     0      #W!R:6YT4')O;V93971U<$]B:F,    , %
M<@!O &\ 9@ @ %, 90!T '4 <       "G!R;V]F4V5T=7     !     $)L
M=&YE;G5M    #&)U:6QT:6Y0<F]O9@    EP<F]O9D--64L .$))300[
M  (M    $     $      !)P<FEN=$]U='!U=$]P=&EO;G,    7     $-P
M=&YB;V]L      !#;&)R8F]O;       4F=S36)O;VP      $-R;D-B;V]L
M      !#;G1#8F]O;       3&)L<V)O;VP      $YG='9B;V]L      !%
M;6Q$8F]O;       26YT<F)O;VP      $)C:V=/8FIC     0       %)'
M0D,    #     %)D("!D;W5B0&_@            1W)N(&1O=6) ;^
M      !";" @9&]U8D!OX            $)R9%15;G1&(U)L=
M     $)L9"!5;G1&(U)L=                %)S;'15;G1&(U!X;$!7P
M        "G9E8W1O<D1A=&%B;V]L 0    !09U!S96YU;0    !09U!S
M %!G4$,     3&5F=%5N=$8C4FQT                5&]P(%5N=$8C4FQT
M                4V-L(%5N=$8C4')C0%D            08W)O<%=H96Y0
M<FEN=&EN9V)O;VP     #F-R;W!296-T0F]T=&]M;&]N9P         ,8W)O
M<%)E8W1,969T;&]N9P         -8W)O<%)E8W12:6=H=&QO;F<
M"V-R;W!296-T5&]P;&]N9P      .$))30/M       0 [_^-0 "  $#O_XU
M  (  3A"24T$)@      #@             _@   .$))300-       $
M>#A"24T$&0      !    !XX0DE- _,       D           $ .$))32<0
M       *  $          3A"24T#]0      2  O9F8  0!L9F8 !@
M 0 O9F8  0"AF9H !@       0 R     0!:    !@       0 U     0 M
M    !@       3A"24T#^       <   ____________________________
M_P/H     /____________________________\#Z     #_____________
M________________ ^@     _____________________________P/H   X
M0DE-! @      !     !   "0    D      .$))300>       $     #A"
M24T$&@     #-0    8              .L   &I          $
M                 0             !J0   .L
M 0                         0     0       &YU;&P    "    !F)O
M=6YD<T]B:F,    !        4F-T,0    0     5&]P(&QO;F<
M $QE9G1L;VYG          !"=&]M;&]N9P   .L     4F=H=&QO;F<   &I
M    !G-L:6-E<U9L3',    !3V)J8P    $       5S;&EC90   !(    '
M<VQI8V5)1&QO;F<         !V=R;W5P241L;VYG          9O<FEG:6YE
M;G5M    #$53;&EC94]R:6=I;@    UA=71O1V5N97)A=&5D     %1Y<&5E
M;G5M    "D53;&EC951Y<&4     26UG(     9B;W5N9'-/8FIC     0
M     %)C=#$    $     %1O<"!L;VYG          !,969T;&]N9P
M    0G1O;6QO;F<   #K     %)G:'1L;VYG   !J0    -U<FQ415A4
M 0       &YU;&Q415A4     0       $US9V5415A4     0      !F%L
M=%1A9U1%6%0    !       .8V5L;%1E>'1)<TA434QB;V]L 0    AC96QL
M5&5X=%1%6%0    !       ):&]R>D%L:6=N96YU;0    ]%4VQI8V5(;W)Z
M06QI9VX    '9&5F875L=     EV97)T06QI9VYE;G5M    #T53;&EC959E
M<G1!;&EG;@    =D969A=6QT    "V)G0V]L;W)4>7!E96YU;0   !%%4VQI
M8V5"1T-O;&]R5'EP90    !.;VYE    "71O<$]U='-E=&QO;F<
M"FQE9G1/=71S971L;VYG          QB;W1T;VU/=71S971L;VYG
M  MR:6=H=$]U='-E=&QO;F<      #A"24T$*       #     (_\
M #A"24T$$0       0$ .$))3004       $    !3A"24T$#      -^P
M  $   "@    6    >   *4    -WP 8  '_V/_M  Q!9&]B95]#30 "_^X
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M_2:N4S]MR?#;7'W/5E)3@EO6<*I]N=G5G]'L%A=M#K(:=S*/2VT/]MW^%O\
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MN8X/M!(W"-1/M)VAC?=_45E))2E1S.F'*L<
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M  #_X3Z[:'1T<#HO+VYS+F%D;V)E+F-O;2]X87 O,2XP+P \/WAP86-K970@
M8F5G:6X](N^[OR(@:60](E<U33!-<$-E:&E(>G)E4WI.5&-Z:V,Y9"(_/@H\
M>#IX;7!M971A('AM;&YS.G@](F%D;V)E.FYS.FUE=&$O(B!X.GAM<'1K/2)!
M9&]B92!835 @0V]R92 U+C,M8S Q,2 V-BXQ-#4V-C$L(#(P,3(O,#(O,#8M
M,30Z-38Z,C<@(" @(" @("(^"B @(#QR9&8Z4D1&('AM;&YS.G)D9CTB:'1T
M<#HO+W=W=RYW,RYO<F<O,3DY.2\P,B\R,BUR9&8M<WEN=&%X+6YS(R(^"B @
M(" @(#QR9&8Z1&5S8W)I<'1I;VX@<F1F.F%B;W5T/2(B"B @(" @(" @(" @
M('AM;&YS.GAM<#TB:'1T<#HO+VYS+F%D;V)E+F-O;2]X87 O,2XP+R(^"B @
M(" @(" @(#QX;7 Z0W)E871E1&%T93XR,#(Q+3$P+3(V5#$Y.C S.C4X*S U
M.C,P/"]X;7 Z0W)E871E1&%T93X*(" @(" @(" @/'AM<#I#<F5A=&]R5&]O
M;#Y-:6-R;W-O9G3"KB!7;W)D(#(P,38\+WAM<#I#<F5A=&]R5&]O;#X*(" @
M(" @(" @/'AM<#I-;V1I9GE$871E/C(P,C$M,3 M,C94,C Z,3(Z,SDK,#4Z
M,S \+WAM<#I-;V1I9GE$871E/@H@(" @(" @(" \>&UP.DUE=&%D871A1&%T
M93XR,#(Q+3$P+3(V5#(P.C$R.C,Y*S U.C,P/"]X;7 Z365T861A=&%$871E
M/@H@(" @(" \+W)D9CI$97-C<FEP=&EO;CX*(" @(" @/')D9CI$97-C<FEP
M=&EO;B!R9&8Z86)O=70](B(*(" @(" @(" @(" @>&UL;G,Z<&1F/2)H='1P
M.B\O;G,N861O8F4N8V]M+W!D9B\Q+C,O(CX*(" @(" @(" @/'!D9CI0<F]D
M=6-E<CY-:6-R;W-O9G3"KB!7;W)D(#(P,38\+W!D9CI0<F]D=6-E<CX*(" @
M(" @/"]R9&8Z1&5S8W)I<'1I;VX^"B @(" @(#QR9&8Z1&5S8W)I<'1I;VX@
M<F1F.F%B;W5T/2(B"B @(" @(" @(" @('AM;&YS.GAM<$U-/2)H='1P.B\O
M;G,N861O8F4N8V]M+WAA<"\Q+C O;6TO(@H@(" @(" @(" @("!X;6QN<SIS
M=$5V=#TB:'1T<#HO+VYS+F%D;V)E+F-O;2]X87 O,2XP+W-4>7!E+U)E<V]U
M<F-E179E;G0C(@H@(" @(" @(" @("!X;6QN<SIS=%)E9CTB:'1T<#HO+VYS
M+F%D;V)E+F-O;2]X87 O,2XP+W-4>7!E+U)E<V]U<F-E4F5F(R(^"B @(" @
M(" @(#QX;7!-33I);G-T86YC94E$/GAM<"YI:60Z.38Y,C$S04,V03,V14,Q
M,4$Q0S9!035"-D,R.3 X044\+WAM<$U-.DEN<W1A;F-E240^"B @(" @(" @
M(#QX;7!-33I$;V-U;65N=$E$/GAM<"YD:60Z.3,Y,C$S04,V03,V14,Q,4$Q
M0S9!035"-D,R.3 X044\+WAM<$U-.D1O8W5M96YT240^"B @(" @(" @(#QX
M;7!-33I/<FEG:6YA;$1O8W5M96YT240^>&UP+F1I9#HY,SDR,3-!0S9!,S9%
M0S$Q03%#-D%!-4(V0S(Y,#A!13PO>&UP34TZ3W)I9VEN86Q$;V-U;65N=$E$
M/@H@(" @(" @(" \>&UP34TZ2&ES=&]R>3X*(" @(" @(" @(" @/')D9CI3
M97$^"B @(" @(" @(" @(" @(#QR9&8Z;&D@<F1F.G!A<G-E5'EP93TB4F5S
M;W5R8V4B/@H@(" @(" @(" @(" @(" @(" \<W1%=G0Z86-T:6]N/G-A=F5D
M/"]S=$5V=#IA8W1I;VX^"B @(" @(" @(" @(" @(" @(#QS=$5V=#II;G-T
M86YC94E$/GAM<"YI:60Z.3,Y,C$S04,V03,V14,Q,4$Q0S9!035"-D,R.3 X
M044\+W-T179T.FEN<W1A;F-E240^"B @(" @(" @(" @(" @(" @(#QS=$5V
M=#IW:&5N/C(P,C$M,3 M,C94,C Z,3(Z,S<K,#4Z,S \+W-T179T.G=H96X^
M"B @(" @(" @(" @(" @(" @(#QS=$5V=#IS;V9T=V%R94%G96YT/D%D;V)E
M(%!H;W1O<VAO<"!#4S8@*%=I;F1O=W,I/"]S=$5V=#IS;V9T=V%R94%G96YT
M/@H@(" @(" @(" @(" @(" @(" \<W1%=G0Z8VAA;F=E9#XO/"]S=$5V=#IC
M:&%N9V5D/@H@(" @(" @(" @(" @(" \+W)D9CIL:3X*(" @(" @(" @(" @
M(" @/')D9CIL:2!R9&8Z<&%R<V54>7!E/2)297-O=7)C92(^"B @(" @(" @
M(" @(" @(" @(#QS=$5V=#IA8W1I;VX^<V%V960\+W-T179T.F%C=&EO;CX*
M(" @(" @(" @(" @(" @(" @/'-T179T.FEN<W1A;F-E240^>&UP+FEI9#HY
M-3DR,3-!0S9!,S9%0S$Q03%#-D%!-4(V0S(Y,#A!13PO<W1%=G0Z:6YS=&%N
M8V5)1#X*(" @(" @(" @(" @(" @(" @/'-T179T.G=H96X^,C R,2TQ,"TR
M-E0R,#HQ,CHS.2LP-3HS,#PO<W1%=G0Z=VAE;CX*(" @(" @(" @(" @(" @
M(" @/'-T179T.G-O9G1W87)E06=E;G0^061O8F4@4&AO=&]S:&]P($-3-B H
M5VEN9&]W<RD\+W-T179T.G-O9G1W87)E06=E;G0^"B @(" @(" @(" @(" @
M(" @(#QS=$5V=#IC:&%N9V5D/B\\+W-T179T.F-H86YG960^"B @(" @(" @
M(" @(" @(#PO<F1F.FQI/@H@(" @(" @(" @(" @(" \<F1F.FQI(')D9CIP
M87)S951Y<&4](E)E<V]U<F-E(CX*(" @(" @(" @(" @(" @(" @/'-T179T
M.F%C=&EO;CYC;VYV97)T960\+W-T179T.F%C=&EO;CX*(" @(" @(" @(" @
M(" @(" @/'-T179T.G!A<F%M971E<G,^9G)O;2!A<'!L:6-A=&EO;B]V;F0N
M861O8F4N<&AO=&]S:&]P('1O(&EM86=E+V5P<V8\+W-T179T.G!A<F%M971E
M<G,^"B @(" @(" @(" @(" @(#PO<F1F.FQI/@H@(" @(" @(" @(" @(" \
M<F1F.FQI(')D9CIP87)S951Y<&4](E)E<V]U<F-E(CX*(" @(" @(" @(" @
M(" @(" @/'-T179T.F%C=&EO;CYD97)I=F5D/"]S=$5V=#IA8W1I;VX^"B @
M(" @(" @(" @(" @(" @(#QS=$5V=#IP87)A;65T97)S/F-O;G9E<G1E9"!F
M<F]M(&%P<&QI8V%T:6]N+W9N9"YA9&]B92YP:&]T;W-H;W @=&\@:6UA9V4O
M97!S9CPO<W1%=G0Z<&%R86UE=&5R<SX*(" @(" @(" @(" @(" @/"]R9&8Z
M;&D^"B @(" @(" @(" @(" @(#QR9&8Z;&D@<F1F.G!A<G-E5'EP93TB4F5S
M;W5R8V4B/@H@(" @(" @(" @(" @(" @(" \<W1%=G0Z86-T:6]N/G-A=F5D
M/"]S=$5V=#IA8W1I;VX^"B @(" @(" @(" @(" @(" @(#QS=$5V=#II;G-T
M86YC94E$/GAM<"YI:60Z.38Y,C$S04,V03,V14,Q,4$Q0S9!035"-D,R.3 X
M044\+W-T179T.FEN<W1A;F-E240^"B @(" @(" @(" @(" @(" @(#QS=$5V
M=#IW:&5N/C(P,C$M,3 M,C94,C Z,3(Z,SDK,#4Z,S \+W-T179T.G=H96X^
M"B @(" @(" @(" @(" @(" @(#QS=$5V=#IS;V9T=V%R94%G96YT/D%D;V)E
M(%!H;W1O<VAO<"!#4S8@*%=I;F1O=W,I/"]S=$5V=#IS;V9T=V%R94%G96YT
M/@H@(" @(" @(" @(" @(" @(" \<W1%=G0Z8VAA;F=E9#XO/"]S=$5V=#IC
M:&%N9V5D/@H@(" @(" @(" @(" @(" \+W)D9CIL:3X*(" @(" @(" @(" @
M/"]R9&8Z4V5Q/@H@(" @(" @(" \+WAM<$U-.DAI<W1O<GD^"B @(" @(" @
M(#QX;7!-33I$97)I=F5D1G)O;2!R9&8Z<&%R<V54>7!E/2)297-O=7)C92(^
M"B @(" @(" @(" @(#QS=%)E9CII;G-T86YC94E$/GAM<"YI:60Z.34Y,C$S
M04,V03,V14,Q,4$Q0S9!035"-D,R.3 X044\+W-T4F5F.FEN<W1A;F-E240^
M"B @(" @(" @(" @(#QS=%)E9CID;V-U;65N=$E$/GAM<"YD:60Z.3,Y,C$S
M04,V03,V14,Q,4$Q0S9!035"-D,R.3 X044\+W-T4F5F.F1O8W5M96YT240^
M"B @(" @(" @(" @(#QS=%)E9CIO<FEG:6YA;$1O8W5M96YT240^>&UP+F1I
M9#HY,SDR,3-!0S9!,S9%0S$Q03%#-D%!-4(V0S(Y,#A!13PO<W12968Z;W)I
M9VEN86Q$;V-U;65N=$E$/@H@(" @(" @(" \+WAM<$U-.D1E<FEV961&<F]M
M/@H@(" @(" \+W)D9CI$97-C<FEP=&EO;CX*(" @(" @/')D9CI$97-C<FEP
M=&EO;B!R9&8Z86)O=70](B(*(" @(" @(" @(" @>&UL;G,Z9&,](FAT=' Z
M+R]P=7)L+F]R9R]D8R]E;&5M96YT<R\Q+C$O(CX*(" @(" @(" @/&1C.F9O
M<FUA=#YI;6%G92]E<'-F/"]D8SIF;W)M870^"B @(" @(#PO<F1F.D1E<V-R
M:7!T:6]N/@H@(" @(" \<F1F.D1E<V-R:7!T:6]N(')D9CIA8F]U=#TB(@H@
M(" @(" @(" @("!X;6QN<SIP:&]T;W-H;W ](FAT=' Z+R]N<RYA9&]B92YC
M;VTO<&AO=&]S:&]P+S$N,"\B/@H@(" @(" @(" \<&AO=&]S:&]P.D-O;&]R
M36]D93XT/"]P:&]T;W-H;W Z0V]L;W)-;V1E/@H@(" @(" \+W)D9CI$97-C
M<FEP=&EO;CX*(" @/"]R9&8Z4D1&/@H\+W@Z>&UP;65T83X*(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @
M(" @(" @(" @(" @(" @(" @(" @(" */#]X<&%C:V5T(&5N9#TB=R(_/O_;
M $,  0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! ?_; $,! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M ?_  !$( .X!K@,!$0 "$0$#$0'_Q  >   !! (# 0               P<(
M"0($!08* ?_$ &<0   %!  # @8+# 8#"P8/  $" P0%  8'$0@2(1,Q%")!
M4;&R"14R,S=A<7)S=8$6(S8X0G>1H;.TM<$80U)VPO 7)=4D-#568F5T@I+1
M\28H596VX1E$1E-78V:&HJ.DI</3U/_$ !P! 0 " P$! 0             !
M P(%!@@'!/_$ %41  (  P,(!@4("0$$!PD!   ! A$A S%!!%%A<8&QP? %
M!A(RD:$S-7.RT0<3(C9R=+/A%#1"4G6"M,+Q(Q5#8I(74U1CDZ+2%B1$98.C
MP]/BY/_:  P# 0 "$0,1 #\ ]_% % :RPG Y0 XD*8Q  0T&A*(B.Q$!\4XB
M!!_5UH!MYO*5EPB]PM9:][3BE[0B4IRZTW<ZP;K6_%'.HF60E4E5-,62QTE"
M)N'9D0.=,X)\PD\8.;]4ESH/K'+N-Y6Q@R3'W[;#RP2-C/5;Q9R[!Q;R34I@
M(=9>426.S323.)2G5,J4I1, & !,4*$35\^%^?\ ,[+9=ZVKD& :719EPP]T
M0#_G%G,04BUE(YR!#"0W8O&:JR!^4Q1 P%4$2CL! !Z4XDG:Z C]Q#YFG,&V
M3(WW'8QN[)D="LW,C,L;/>6NT?QT<R14<.GIRW3-P35RFFDF812;.5%]@&DQ
MI+'B]UP(B3OLA5V6UBR#S!+<).;T[*N)E#O(]^2?Q(*XI3ZB)8@RC0+\,Y(+
MH7*(''LQ(F!M"/=1<UGO&&-,<^:7,V<G.\?L_ W5.V.XX9<OKW7:EF15^7=$
MMY[%J2\!#SCN69M"%"1O1B616(C"O7YD6)ES D0?&$YB$%SSSQ(G)RJ\<*3G
MM=S<E/0/A)\7%@QF%,0YY 9%>RLRW7AFT;=%4L>W=1S[-E\P=B0KR7%9X1 C
M.$D[B;N9KP95PHV91CTR17!A *+#X\7O9+NG^;NS)Y_'<TDY[(':Q(2(NG'^
M,\CY0M6],S,L*8MN.W%+48QF6+B<6??M[24K8B]QS<*1]:<4VL>7AD+F<BVB
M)I^V T"YDVB9G1G//B0FO.ZNGX/A@/S@WB1C,UMKW9K6I=&.+SQM-$@KZL2^
M&S1E/P3E:,:3C!V"C-R[CGD9+1+YLZ82#=V=FX0$ZB:Y@(;0FDY8XK'-=SK.
MFV#QEV#?U\PUDM6TG&?=-;,K>%LS\FI$,XB9@HNX9"VTW;,PR1W"OA[B/5?-
MR"B0!9F3$1 XB6G//F1-3EB<I;W&3@Z4@6$Y<.0+>L)&9N"5MR ;WE-1$0YG
M'D5('CUE62?ABP'2.X3$$S (B(&(!B 8VJ$T?GS/G8=W;<2>#G=X+6&US'CQ
M>]$D3+#:A+KB3S'9I(>%*J"R*MX5HK8>W$ 1-I'2@B!=#0<1K+TX].&&S+=D
M[D-F2R;@:0D_$VW*MK;N.'E7+.3FGQ(UFD\*@Y,+,A7)Q!0SH$M@0_*(G "T
M Z4-Q*X.GYV6M:%S#8,G<<)'*RLS"M;GBU7\;'MFX.W+MPD50#H(HM5".%3J
M% $D3%54 I="(>9]M#B6P?D%=%G8V7[#N=V^))D8HQ%QQ+\ZAX=DK(R?9%1<
M"5RJS9(JO%BD,!4VB*[@WWI)0Y4^=0&RMKCRX7[F=Y&299HL%*)Q>\@F-Q7(
MZNB$2@/"+A8(O(L6\L#PR#A(XG!!90 +]_.)2%,1,Y@#F[1MYTCH7?F<\;C#
M_2=C>VY3-<>LS+)14?C^7MGGEHO0*+RC22G)6*BUV[8.AT0=%=* "A6R"Y@"
M@(V85]D)QADFRK7OZ_TE\ 6_D6+BI?&BF7;HL&/?WK'R9C)E=1L7"W-+/&J9
M%N5(1DTV*O,<I"HB8I])_'/SX8$*J6KX:7YU'UDN+/AXMYU<;&X,\8OB'UH&
M3"Y6<I=T&U7A"NG!F[0DD0[SF0666(=)$3  .-""8;+H1,U6M%?GXJFO\MIS
MQ4\/S1I:DLYS=C5M&7N4$[1=+7A#@WN!0ZPHE/&'[?LWI3.-(%.FIR .RF'M
M Y:"<[MN^GBOC@-Y \<N%KGN20M^$G@E"P>4T\2W#*,'$:I'P-T.F";N/"1$
M'1EO:Z164\ 9.DTQ%5^4R/(4"B8!"<]SUDSRF'H03B;F*!B'Z=0WU#X]_*(Z
M&A(O0!0!0!_G_.Z K;]D-XF;\P/BI9EC@DVPO&XDWBZ%ZH6S*S4+9D1%BDN_
M>/EHUA())R#A'F:QB"Y!*Y<'Y_% FA$-M7*;K*B:NQG27F=.S?F6^KGMCAP@
M;4RW/8W9Y L.<O"[+\@3QC&>"3M;%KJ\(B,6-.1YT&R5P3C'LI!D9DF[?LS*
MHMBMC' Q8U.YZ]:O_P 9B4[I8J]I.CQDTU.Z5,\B:?#Y?MT7_P /V*,B7*FH
M:Y+GQU:D_)MDT#-E).0D85LNJJ@V=E;^!*2JVW;=%0PD0!T5,3F*4#FGG'?.
M=V-XGSGW)5S4E=>:6(\]CDNZKRL25L2\\>W?9$):]QR,/=WM&HHYAKL>W&PA
M7S5S"24DU$CIU:DV0Z2JB2Z942=HDF81 &?X\\ZP2-(.RE'>]E =^?IWT!&W
MB2X@D>'FU(2Y5[3G[W>7)>T'8L);EM+P3.2?RMP)R*K/3FX9.*C6R:01S@%%
MW+Q,AN4O*78C0<R(MO\ V22"@VLNPF\*Y-C\@0][6O8JF.UI.P%)1W(7>Q&0
MA7C6?3NH;2%HHV 3N/")M!1$W*42;,4*:<,\Z?#:)J>VZ>?-/F_&8]UL\5SN
M5G[ M>[<3WGCF;R1-S$+!,YZ6LB6.!H9B5\X=JJ6E<MP($;G3-REYE2J"??W
MO0;%SK&;3\&^ A,<9V-;>XB)'AKFU)B-OEK8QK]CGCI!LG!SC-(%3+0T>]47
M()Y<I$3*%;G3(*A!\3F$!T#HY-9\:WJ<JI8Y]6CD9GB_L: PS:F<92,GVUIW
M9--X5! Z#0CV/<.)MU!%6>"=T#9)JFNU.Y55%QHK82& HG,!!AJ?^6MQ"<ZK
MGX[-@TUP^R#VVU2;/;*Q?D;)<1-Y&A\5V7,6R:UH^-ONZY1RLU73MQY<,Y%H
M+,XLY *YD%3D9*J;3;KJ*IJ%*EK\63C=GNP\:[Q^\&\2,3F9S?-ON[8N?'&0
M,9/6"-[V!>81Q)J&9S"+Q:%F 6BW+V.D8>53CGP,WC!\N@JX9/$N?[V&Y'..
MCFNDZS8/&'85_7[;MCQ[:68?=C"Y=N:TY^4-'-(6<@L-7Y:>/+A?MEU713%2
ME)^[T1A.<@ X91CE<QBB=N592M=\N::)7N\B>B>IJ<]U-><:V?\ 9#+11EH>
MU+'QO?61;OEY_/$0U@81U:<*92/X>\E2.++QGBS-UST'!NF;VXF9%H>.8OW$
M\[CQ6<^U92HFVS<_YYH3CGOD]6[4<Z^XX4'J]KQ&/<+Y:R-=\W8;;)4Y9D5'
M0$+,V5;;U1PW:I7">YYF':^V;MPU= SBX]5X_<)))KMVRR+A!0\<X\RTW;1L
M?Y<S^&=T;BXCI*.PBWS7;6)<@W>W4B7,T]LQ)*'MBZX9@Q;+N7ZDLQO"1A$4
M#M$VZX*))KJJG,0#)%.0Q35///#A<'\=-*RS3NP7Y-GBSCPQU>=O6_<.26H<
M/Z=[HQSJPF64KOQ\W?7<VDA*5-2);05TS!^5,YR)B5SV"HG.4"IB/2HQQ\7_
M (>D45[2UCJS/%MPYP;B::2^><71CBV7:+2Y$G-XP:*D(X5Z)-7_ &[LG8+J
M"("":@%5.40Y4^NZD4I5:-.//+.3<\4_#XP3M,7F<,:$+?',>TU#79#$&Y$3
M+=@56&$SG3PA%A!,10[8O/LHFV A0#:6;QOX;OVY$86U9T9=N;,<[@Y[*-%V
MCJ-C[[@XY-ZRCW"R"AQ31N<YU6L,X. $=.VRZ9-=F8*<X\\UO(GSX4VS)EM5
M14%0!,<W*8P%$P ',&P$1  #N((@3>QV8#?8)-R@"@"@"@"@,!3(8W,("(ZU
MWCK0#ON = .P[^^@*D<_<*UX.,HY]N_&UA@]97M"8'NAZ1*4;).+\G;(RHZN
M*[(IPYEURHF=DM\J)8MH\=-6'*5NT(Z;M2%13$-3YNTK2==:X;S KA+*T.EB
M*>CGN0,^SV;H*R'+NUP1CK74O!K)-+/DPCYX6K>>D&)#.B1[4[Z&*=,B:CY,
M@='///YMD\<%JS:MY,/A%L6][1LK),C<=NO,>*7YDJ[+OMVT9(6+J0M:*EU2
MA'M'B$6]D8]-9,Q#+F1:/%4.4^M[V%!LEK6?'\J/.<[B:XLIL\S9.QU?MZM;
MOC8&#M>XH)TA!M(ETU+.J.RK,%DVJ90600*B3D74$3B.Q$U.>>:DCM9DM&1O
M[%]_67$KHI2=SVO-0C%P\$P- <2+%=NB90R9NB93J!S:Z\H" B(= !KGAS3/
MF(RW]P\7K<W"O8.$(^0@V]T6Y&6"PE72RCIM"">VE6 NC-@:ME3\JI6A@+SD
M*D"@EYSE :<\\OQJ1*DMF:G^.4-)GWV/BU^(?+V;;[R&W;*Q=]8CLVR+&E(N
M8D&ERVQ/VP[N5VXEUT"I!#O6XN)...DW?A)METDG2;MBJD)DC"93V?XXG-90
MX3;SSOP=8=X?<D1U@!,6WD?AVD,G0UJ+O8&S+DL;$N7K1N>YX^&19QK9Q%_=
M/8]NO% AVS)!D27?NX,J[1BHJ]3$2FI.CHJ44I8>5VE5=[.S_![Q,XV8VC8F
M"U<8W-BC!G$["YPP-;]_W'/P<G;5CS6,\OVO=F+'$A&P,Z<82T+QR V7QTZ<
M(O5F=HF6MU\ M;=BU51*6&[3?2N-U=$B3^$\ 9,8+\0^1,RR%JM<J\0XH-G\
M58AWZ]L6;"0-@M;%MF+8O7Y$Y"6<(-F1Y)_+=@U[5Z[41;-&B21$Q$+3?3GQ
MWLB?AO@KC,IR6&9S-F.[:G(#"V)I3#LM:]VQ#Q9Q]U\7=TJLM-Q#-RS:MG<6
MZ8+MC-7S=4XG$5#>,7E.)?''GPV(2GNKX-[5<_BQHIOV+G)<*O%#9"=CRD(:
M*FK47ME>]+JLN"MV&>W(K,QSULVMZ/7/.)-VI^S<0AG$887!2J$DBG"@=>7P
MEO./Q_P<<0]SR&1["C+8Q[9=L6SE1*X8G)<RA.J7-)O8^VTV*"$5!SC!Z$K;
MZKD.S]MGMRN#&;E$B[)< $@B)3FL)S\L*4SS3OGG9J)^QO<44DXGYFX'N-UI
M9>U;>B(ULI>T],L)*6@KI2G!=F(-HQ,/;$>]03,D@QB85R5HJ($,NN72E"?#
M<Y_"FS3,<V4]C]SM=D!%XYG%L3VM;EJS]^7K#9$@7TFK>TQ+WG'N02MN99N8
MIJ#6/2=NCL9213DW/MG#I@D2.1$P  2_/G1@[Z:SK6?L!9]>V=8Z3*Q; QKQ
M#2=ZX[L+&,O@^UYR;BXJU!B75@Y/N#)%YIVW!$80ZUD3<XZBHZ53$D$DD"+!
MW*OEDN=226.>?+\\XE6;P5TI^=_@E.AV/*/L=&2E+V4>8H0M$EB6E>>,;PL:
MU75Z7'9KB>8V5BA_B-S:UQ3L)!R#A@*;-\UN"(FQ<S0KN17+(0RQC&.#\\_#
MR^$R).>U>&JZC\JWU+#N&G!\]B'AU;XMEB0[><7+>3Q\U@I><E8N.D[NEIF7
M,V;RT^ZE9%V5NK*]F=^8J""HAV[:(CFP)LDQDELUS?DO%N==]8&1O8Z^)Z;P
MAB3#MO2^-Y-"V.&Y/$L^NI<TE;A&-WMII^]6GU)6,M%Y=%U6^YC5&+1K;R\E
M$QJ;Y%=VLDXWV:HQE<G=*4JR5+WC>I+?-G)WWPQWGPXV;'Y(-;<!>5\1_$FX
MR&@QAK2NF[HF6@Y*')&-4;O6MN"E+F0!@1 RR+QA;<Z#%83>#M"D5.J1+Q?*
MVN[P,G2<]"PU>6V]Z)LEB_@&SWD^Q+5R(>V+>AWU^V]<\//6%<US7MCAC:K&
M0O>2FB2;*&A(TDA-1,@@J5<;>E?N8D7"AD%UUV1P,W 8I-+,G.^]9I7JBEY$
MOY#ADRI8<*_P^A#0TI%Y,XC,9W_;UQP*TJJM&15KI6[)7$>XDY%HH:)!$]M'
M;1YE)>:7=@Z %5TSFH99]=*?F_@7*))&3\&3$>844P QO..M?I'OZT!N4 4
M4 4!PLO;D%<#%S&3D4REXUZ0R;R/D4$WC)VD80$4G39<#HKICH/$5(8O0.E
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MXMQYQ _ZE3?JZT!,+NH H H H!!1 IQ$P&$@CH1$OG >_P W4.@]![QH!0A
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MQ_'0!VIP'8D$0'0:+UZB/>(_)OI0 "IQWK1P[MAT#>NH?*&]"'DH#,ICF'N
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M3 &MFZ=U L=#E^>C>2T(83D*82B43% 1*/>&PWH?C"@,J * * * * * * *
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MX#X.0H%1 A>E <RFP;MRI-VZ23=NER)HH()%1213(02D33(ER 4A0T % .4
M    H"-UA*<W$MFE+7O%L6.GS;V)_$>#O6@UH.FMF[N^@YY\1U\L!K']U?'%
M+#^E,U 5)%_*^</\JKM,-O #)YN#;+'@" Z-EW&10-S)@'/]UL:)2B!SE'0A
ML=E =:ZZ[ZF"YZ^"(>&O-LV7_P"1[N?F$Y0$!*FJ8NP'\O1.<.G30>+H=CO8
M]VJQC4I:6WXR)):<)'X5W+]3L_W\*FSQV<25=%JXHG\E[I3YQOVBE6$"U %
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M#"(]D0-% 3CSSB3W* %*!0[@  #O'H'R[']= ?: * * * * * * * * * *
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M]KU&TT;6D;79-H*Z;>N=X2<:N7+Q9>WYAE*(),NQ$I$TUBME4%53"8R9E2*
MFIR<AI@NV_ ASI+;^6L>%'M@11(X,@+DB2?A/@J2J: KB7[X=,RI""8#B ;
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M'E*8>_7,)2E-RE$0T(CS%*&Q .8==1H!'PX ,(&14 N@$IP$!*(CT$@[T('
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MW;\6>0BQ8EC2L7AFR8K($CD5'!614M?>VW;&!+0$YC &Z&7///B.<'<'DZ4
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M H"6G"1^%=R_4[/]_"K+/'9Q)5T6KBB?R7NE/G&_:*580+4 4 4 4 4 4 4
MBX]X6^C/ZHU,-ZUK>8Q]R+[,6YGASXV?QO.(O\[EZ_QAU7M?Y,?J5DOW6'W8
MSRWU]]?6_MK3WR+0>7R=/08M=/D#2AMF[L?^<T<TH4W=)&:7OA?M]4>O?^G]
M7FJZTBAB34+>B<Z/_!';69^0_'"T.N(["70>N1;6\WDF6W?U\G_A7-]:;.)]
M7NFW1I=&Y:FIUID\<Y85E\3:] VD$737124YOI#)'=@K5)[<TSW:$][+]&7U
M@KP\>KC8H#X8 $I@'N$H@/R"'7]5 >=OB?=6M:7$I-1F&<RY7E,N*YGCKV'&
MUK6K8A+6M+(EW13*SDEYZ[[D34>)LW<8*)3-09.T2 <3%4 ^@ 0]<F]5?&\O
MCL).YFEHVTE>+DKFZTHF/3N-5/P<432I4" \#G;)I)*%%<1T9,A2&[R !=!0
ME75Y?ENWD5>,^P^(6]K>MFWL&6I;$TWE95PUR%)/[C8VS<;&TG2!49&.M62D
M(Y^FV=3*0J-'3G1%$$#F,GXP@(!SSRAN<BX.S@Z1Q+,8_P 9VFW5Q%:UPV7#
M69)7LV*W=1=]6#)6E(/5);VO,B1U;#UR@]$ 0YII/M@3%(YZ<R(V*E%S*EV!
M,K">-'^,\)XVQ?*O$)1]:-C6_;,L])SE0<NF$8W;2(LQ 2JD;&<>$ Q%3QTD
M"HE-U+0DC]P^8ZM?&W$7Q(05KM'31@K;.&7*Y7<@\DG!UW!;Y 3J.GBRRABB
M<IME+RAY=:$ H)2WDQ+I_!JX^X/_ ";E>@= #_5SSN#R!YJ IQ7]_6^E4]<U
M4Q]Y[-R E6("@)&\,/PBC]6./26K8+GKX(AWPZ^#+)TO<!]GH"LR12@(G\7_
M ,&S7Z\9>HO6PZ.]-#_-N1RW6OU;:?;7X496P3R_1)?NZ-=G8^CAU+W4?(\D
MOM-:W0FN7O#Y0]-8%K[EI[2/<9E_J_I!_P %",G[ZUKB63<(7X#2_P!<*>@U
M<UTWZ3)_9/WD?4NJ/ZME?M_[42VK2'7A0!0!0!0!0!0!0'GWRB_O2QN+&\LM
M7_C;(\];L?F*Z8:12+9\'+8X=8=:1'+;TJW*Z9@+^?-(*&<+*J/ 7+V9-@.@
MU$U-9ZR4^"U8[R&DYYOHT;I24_/QEFJ7OV/,Q-Q6;:L]!-_!(29M^)DXEKX.
M1GX/'/F*+EFCX*GXC;LD%$R=@3Q4M<@="U),I4.TT D=8A# 4>81'ET %$?=
M"( /V:'?F#0CWA0 *R8&Y>;KH1^+IY-_VM=0#RA0"1UB*% 2B;EYM".A#8;U
M_P!_D\] 1BQHH8_$)G<#?D1UHE+UWXO8K"'V]>OG\U .SE;X/;H^J5O4-0%2
M9?ROG#_*J[3#;P!E58"@):<)'X5W+]3L_P!_"K+/'9Q)5T6KBB?R7NE/G&_:
M*580+4 4 4 4 4 4 4 BX]X6^C/ZHU,-ZUK>8Q]R+[,6YGASXV?QO.(O\[EZ
M_P 8=5[7^3'ZE9+]UA]V,\M]??7UO[:T]\BR'>/S1]8E=-D7<MMGXB-$^YLA
MX"B7OA?M]4:R*A^.%O\ &/PA^<2U_P",MJTW6CZN=.?P[+OZ>T-EU>]>=#_?
MLF_&1[M">]E^C+ZP5X8/6QL4!\$= (^8!']% 42<4#5]Q RV8UHJU\-VS(8A
MRB,*M=]PMTFU\L8JV+=-<)KB7>-7<3)'7D9-5@QA#(N'1&PD.L"1S@!0$:4T
MJUI@IS7CC3XVTX G%[@POBZ9?MW:#J2LN&=+(/W"KAWVBC-(3J.5EA,HJH<X
M<Y3G,)A Q1$1'="1\B]P?('HH#[0!0$3L<G*?BFXDR%V)D[0P@)PUW<HWXH/
MR^*(#0$C+I#5M7& ]X6Y*@/V1SR@*<5_?UOI5/7-5,?>>S<@)5B H"1O##\(
MH_5CCTEJV"YZ^"(=\.O@RR=+W ?9Z K,D4H")_%_\&S7Z\9>HO6PZ.]-#_-N
M1RW6OU;:?;7X496P3R_1)?NZ-=G8^CAU+W4?(\DOM-:W0FN7O#Y0]-8%K[EI
M[2/<9E_J_I!_P4(R?OK6N)9-PA?@-+_7"GH-7-=-^DR?V3]Y'U+JC^K97[?^
MU$MJTAUX4 4 4 4 4 4 4!Y\^/>WE"98GKYELYQ^2K1MK(5H*R6#+E/-(1L"
M=!51^[M!F%N<T=(#+L$52'2G&+A=J4O:.7!0T-"(FZ;,'=*^F=9YUPQ+S<42
ML;.XRQ_,PT:UAHF5LZW'\=$,C)G:1;)W$M5FT>V,E]Z,@S1.1NF*>B"1,.7I
M0D[_ $!'OB5SY:?#=BN[\J74*SY.VH9Z_C;=8B!I:X'S1DY>^UL:@ "JLHJW
M:KK*B0HE01;K+J"5,AAH#HF1N)-M9]DXOGX:U9&Y[ARL@S>VQ:K1P@DZ4;DA
M"3\JNHY4,5(YHMBL0IB%4^^'43  #=!I\G?JP5;KQZL89'BLGX^@+_CD%XYC
M.,0>BT?"4KAD9 YTG:+@2B).9LLFHFH8HB4!*/6G #+8;FXB?SYGUY"R3.3:
MIMK4;'79+D72(ND@J"B1CD$0 Y?RB[V'<.AH!\,K" X]NG7DB5@^WD-0%29?
MROG#_*J[3#;P!E58"@):<)'X5W+]3L_W\*LL\=G$E71:N*)_)>Z4^<;]HI5A
M M0!0!0!0!0!0!0"+CWA;Z,_JC4PWK6MYC'W(OLQ;F>'/C9_&\XB_P [EZ_Q
MAU7M?Y,?J5DOW6'W8SRWU]]?6_MK3WR+(=X_-'UB5TV1=RVV?B(T3[FR'@*)
M>^%^WU1K(J'XX6_QC\(?G$M?^,MJTW6CZN=.?P[+OZ>T-EU>]>=#_?LF_&1[
MM">]E^C+ZP5X8/6QL4!B;?*;7?RCKY==//Z!H"EOC'NG"%DY;7N7)W#Q<EQ*
M%;-X1E+Q,#%/U+TN)9RW4B'R3-&70<W"A'F%1-1B[C3B)>8QC@0H (ATYHJ-
MUS>>HM2QHX4>6%9[ETS5C#.8")<&CW# L89IVC=$R;95@F)BL%6X""0M2&$I
M#!R]0"A-Z7*T2>/@AU* * * B5C(A@XJN)A3E$2*VIAE(@AUVHDUO0QRCYN4
MJZ8_];XAJ7?L6Y$+B][)'W28#VU<9R]2FMR6,'DZ#'O!#I4$E.2_OZWTJGKF
MJF/O/9N0$JQ 4!(WAA^$4?JQQZ2U;!<]?!$.^'7P99.E[@/L] 5F2*4!$_B_
M^#9K]>,O47K8='>FA_FW(Y;K7ZMM/MK\*,K8)Y?HDOW=&NSL?1PZE[J/D>27
MVFM;H37+WA\H>FL"U]RT]I'N,R_U?T@_X*$9/WUK7$LFX0OP&E_KA3T&KFNF
M_29/[)^\CZEU1_5LK]O_ &HEM6D.O"@"@"@"@"@"@"@*@LM8,R9:V3<K6WCX
M<8W#!Y6G+JS4>1OJ-E5I^P92<;!$W2Y8K,P,TD$T&YBC LUA[5$>T I!(;8.
M>92\PYO,J;E)3\)NXLAP' 1EK84Q7;D,]7DHN$L.V(QA(NB&2<OVS.(:HI/'
M")P Z"SDI 640. &1.<4C  EU0*Y?X'<H",G$KPPV'Q,VV:W[U+--EV<1<S"
M EH:6<1RL2\N:%6A7#\R2.TW1TFZQBD36*)0(*A0T5<^P&NN;A!F'UIXXMNV
M,DR4$XQ)&,8JP95U'H2SN,;GMLEMSYGJK@>9^M+(I)K@=4 \'.D3DT&PH,Q)
M#%>,8W%..+;Q\Q<N)!I!QH,%G;PI17>J+J'5?+JI%$"E\,7554,4HZ)SZ#H%
M -+AFW(6W,XYQ;048TC&K@;:7509I=B0ZAVZACJ*%V.U##XQC?KWWQ=37GT?
M'.!Z,KAK'UU?'%KC_P#A-4@J3+^5\X?Y57:8;> ,JK 4!+3A(_"NY?J=G^_A
M5EGCLXDJZ+5Q1/Y+W2GSC?M%*L(%J * * * * * * 1<>\+?1G]4:F&]:UO,
M8^Y%]F+<SPY\;/XWG$7^=R]?XPZKVO\ )C]2LE^ZP^[&>6^OOKZW]M:>^19#
MO'YH^L2NFR+N6VS\1&B?<V0\!1+WPOV^J-9%0_'"W^,?A#\XEK_QEM6FZT?5
MSIS^'9=_3VALNKWKSH?[]DWXR/=H3WLOT9?6"O#!ZV-B@/ANH"'Q#Y=>3S^3
MY: IVS[BO#$;G&]\SS7%9(V]D6-C%C1UC/GMN2C*V3Q[,ZR<?"Q4H!EHY5_L
MHKJI$%=43%%(P#JA#2?,_*[RE1-SD62X3N)>\<38]N=Z=59Y.VG#R;M1;E Z
M[ATU24[9=, *5-0= IR    &Z!3GGGP)'D#H  ([$ #KY_CH#[0!0$7<;:+Q
M*\1)@*',:'Q*4QM=>7P"X_\ OU\OV5+OV0[D0KGK>]C^W4 %MNY"@&@"W)8
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M;AB@A8X(Z=6>IR2LPR\%2\&DSR*)2HOA>I<K@7:0 FX[3M2>*8*D9JSHJY_
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M6N)9-PA?@-+_ %PIZ#5S73?I,G]D_>1]2ZH_JV5^W_M1+:M(=>% % % % %
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MC1,_9H*"JC'JNW"KL8Y)4>JJ; %@:D4T '*D @  (  '7<4?#'GKZSA/W$E
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M]')>([?+&1S:/?R,K%W+D6VX*8BV",JHFQ,[DXQ^Z9(*K*I DJL55-1-0A#
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MQ",8 @YY^U*#5'9A M&V[W.1C%'%$YQ.;SL<6V;2MZSHT(BV8MI#1@/IB2\
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/<FDFD7E3(4A?, 4,C__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>44
<FILENAME>g164680g01m19.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g164680g01m19.jpg
M_]C_X  02D9)1@ ! 0(!>0%Y  #_[1G\4&AO=&]S:&]P(#,N,  X0DE-! 0
M    &>"^9B0X0DE-! 0       \< 5H  QLE1QP"   "    .$))300E
M   0S<_Z?:C'O@D%<':NKP7#3CA"24T$.@      Y0   !     !       +
M<')I;G1/=71P=70    %     %!S=%-B;V]L 0    !);G1E96YU;0    !)
M;G1E     $-L<FT    /<')I;G13:7AT965N0FET8F]O;      +<')I;G1E
M<DYA;65415A4     0      #W!R:6YT4')O;V93971U<$]B:F,    , %
M<@!O &\ 9@ @ %, 90!T '4 <       "G!R;V]F4V5T=7     !     $)L
M=&YE;G5M    #&)U:6QT:6Y0<F]O9@    EP<F]O9D--64L .$))300[
M  (M    $     $      !)P<FEN=$]U='!U=$]P=&EO;G,    7     $-P
M=&YB;V]L      !#;&)R8F]O;       4F=S36)O;VP      $-R;D-B;V]L
M      !#;G1#8F]O;       3&)L<V)O;VP      $YG='9B;V]L      !%
M;6Q$8F]O;       26YT<F)O;VP      $)C:V=/8FIC     0       %)'
M0D,    #     %)D("!D;W5B0&_@            1W)N(&1O=6) ;^
M      !";" @9&]U8D!OX            $)R9%15;G1&(U)L=
M     $)L9"!5;G1&(U)L=                %)S;'15;G1&(U!X;$!80Z8
M        "G9E8W1O<D1A=&%B;V]L 0    !09U!S96YU;0    !09U!S
M %!G4$,     3&5F=%5N=$8C4FQT                5&]P(%5N=$8C4FQT
M                4V-L(%5N=$8C4')C0%D            08W)O<%=H96Y0
M<FEN=&EN9V)O;VP     #F-R;W!296-T0F]T=&]M;&]N9P         ,8W)O
M<%)E8W1,969T;&]N9P         -8W)O<%)E8W12:6=H=&QO;F<
M"V-R;W!296-T5&]P;&]N9P      .$))30/M       0 [_^-0 "  $#O_XU
M  (  3A"24T$)@      #@             _@   .$))300-       $
M>#A"24T$&0      !    !XX0DE- _,       D           $ .$))32<0
M       *  $          3A"24T#]0      2  O9F8  0!L9F8 !@
M 0 O9F8  0"AF9H !@       0 R     0!:    !@       0 U     0 M
M    !@       3A"24T#^       <   ____________________________
M_P/H     /____________________________\#Z     #_____________
M________________ ^@     _____________________________P/H   X
M0DE-! @      !     !   "0    D      .$))300>       $     #A"
M24T$&@     #-0    8              6(   )D          $
M                 0             "9    6(
M 0                         0     0       &YU;&P    "    !F)O
M=6YD<T]B:F,    !        4F-T,0    0     5&]P(&QO;F<
M $QE9G1L;VYG          !"=&]M;&]N9P   6(     4F=H=&QO;F<   )D
M    !G-L:6-E<U9L3',    !3V)J8P    $       5S;&EC90   !(    '
M<VQI8V5)1&QO;F<         !V=R;W5P241L;VYG          9O<FEG:6YE
M;G5M    #$53;&EC94]R:6=I;@    UA=71O1V5N97)A=&5D     %1Y<&5E
M;G5M    "D53;&EC951Y<&4     26UG(     9B;W5N9'-/8FIC     0
M     %)C=#$    $     %1O<"!L;VYG          !,969T;&]N9P
M    0G1O;6QO;F<   %B     %)G:'1L;VYG   "9     -U<FQ415A4
M 0       &YU;&Q415A4     0       $US9V5415A4     0      !F%L
M=%1A9U1%6%0    !       .8V5L;%1E>'1)<TA434QB;V]L 0    AC96QL
M5&5X=%1%6%0    !       ):&]R>D%L:6=N96YU;0    ]%4VQI8V5(;W)Z
M06QI9VX    '9&5F875L=     EV97)T06QI9VYE;G5M    #T53;&EC959E
M<G1!;&EG;@    =D969A=6QT    "V)G0V]L;W)4>7!E96YU;0   !%%4VQI
M8V5"1T-O;&]R5'EP90    !.;VYE    "71O<$]U='-E=&QO;F<
M"FQE9G1/=71S971L;VYG          QB;W1T;VU/=71S971L;VYG
M  MR:6=H=$]U='-E=&QO;F<      #A"24T$*       #     (_\
M #A"24T$$0       0$ .$))3004       $    !#A"24T$#      /R@
M  $   "@    70   >   *Y@   /K@ 8  '_V/_M  Q!9&]B95]#30 "_^X
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MWEC6M&I:]OK.;_9>W=_;4'+<S.4^">M_@NR8Q$6'/&3</SW?YQ1&Y5G[[O\
M.*#74Y[RP^P-UL+A]%O[SFIB6;_T8(;VW<G^4?ZRNZ73%6EMD9%I_/=]Y_O4
MVY5O^D=]Y5<<)PE00VVY5G[[OO*D,NP?GN^\JEJ%*0A04WAEO_?/WE2&78/S
MC]Y6>'%.+-82X0EU&YSN[C]Y4VYCB1[CR.Y62;=0)1JW6&" 2)&L'Q[IIB%4
M7__0]0.-CEQ<:F%SOI$M$GXJIA5B^[(L?4&4M<::JG,;!#?IVM=MW;+7/^A]
M!7;214\M&X[3#08DQQ*I=-?3B]&JM?\ HJ:JC8^3NV@
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
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M 0$! 0$! 0$! 0$! ?_  !$( 5X"70,!$0 "$0$#$0'_Q  ?    !@,! 0$
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MLOKA/U5V9_W;L'_![/\ ].>=*%XK1B+!S(Q%=&91^'*A_3_Q8(_^5/B-J/\
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M'[11A_O*O)-R9^+B"P%&OZ;^*_\ TG<1/]=LS?\ B6#]4=G?]W[!_P )@?\
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MEOLQ!^JMA_U+96__ &^ 3_X)J7OL3^\Q?]XK\ZW_ -*>?/\ GQFG_6.L'_\
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MO1\;"_88DHKW!13<S!"%2I$^"!=4J)(93I>ZBA0&]Q<*.GNTQ3VW#&-LN,D
M$[JF!U RR+Y>A4NSD(Q$DL0\NUGU:[2>-ZX_YVRU4J3FBJM.NR$O1GBA8<99
M;"P%%2/")22; Z%.O[Q"#[6.%[)0G VW&0I*4E0Q$/ ))<!G9I+V$UHXZ4+
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M.3J,>8TAZX/M;8MW$)3!!XM!=K0-)<2[FJA,MJ5JI15V[6\_+_#?;N"')2
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M0IRTN'+GK<,9:]5\S'',Z;55/ORWT5&A3*=4(S)4IVTY)"9R;7)=BDW0YN@
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MN)4K4@@89W2""&40Q$V&D:C)ZK8NS8.(E05A))*5)<#F 0<F9G@B#,O.LAV
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M5*?0!R 7#15=>/B8R@,)! , M8J8/T<'2CBJ;4&8#%3?BO)ITJ08[<O7PW5
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MPI@?Z-,GIF>)M7)8H91:V]>+//27LS @Z5![,R]P"1<WWTZV/R_0MCJMH3N
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M8*$,#I;U:E)GVE"^OM?K;#\AS/R^M("=U4G*\W,TLMH2%   7/P\L5J5;[P
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M(=(O,<2_*_#.*5FEW(O<@:6.NFFX]VGX[X=WV'B@A"47@I9_$:Z"7R:I5%*
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M$TF+FO,*2F8/&0@7\5'M*">MB.H )T.AU'2T/=+U-HG/6\OQUO%)N'3/EF_
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M).7E4=P1P@_49]?R,L<!,_2^&?$>@9@:<\)N-+;#BT*L.52T@E0%N8:W(.A
M\R3B^U_9>'VUV1C!>"C'Q1ADI7B("U)@PE10M0+:!P6RBI>S\0X2V2HI22Y
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M,@-H(2.7'B&QC V+ 4C$PL->*20E92DJ2'(#$[A<P8$L]<EM>VKQBI6+BJQ
M[^^M[J<."; V#-\G+Q.S6SP9X*9AS'4V<M1,VYKCV:-(0V]-:\6P*I"BE+D)
M2DJ.D=0&MNIQZU^C/V=/;&UIQ=JV9.T825A8&-AE: D*<-O(4D!P]Y FP;G<
M7&"=XI.XX(]T[I-]" 0UK-D7OPU74'JA/DSWR?$G/.O*<))4M3RBI2E*.JBH
MG7FW\],?7N'A)P<-&'A@)2A*4D !(BWNB&:S6;*:YQ;#>(";F6UO(N2_YM2R
MU_9!6O,+6-S?IAH0@+?<2Y(<[H<_>?+-JJ+4H.$DCW<KO(YO2LRE/,EPI"E)
M!Y3;V@+Z@&UTWUVMOAN+AX:L=TI3W(^\D !!.;@!B#Q@MXIA*_[.4K][%(++
M7*A=F)+AH:'>ITX)Q8\3,C<ZHOEFERD2*6II04MM;\M@V=6$D>WS*2CG'M $
MV(-K?/OZ7NZ*L##V)", KQL).(< )05)4M*5!1022%.000YEW$5ZY^C!.)AK
MQ<3:EJQ4X:,1>&,8E824H)!3O@ %*I!!>+N]/N'Q;RY'?JN3^)/#;+V;Z!&F
MRHJ),,RZ!G*D JLV8->C)4X_&";+"*LM]!(  *1RXZGV=[$VSLO9\$=FXJ^S
MTJP\-2T[.%8>%B$I"E=YAI0@*WB224J"I,Y5RWMCVQA=M8ZSM_\ VY:5K2E6
MTE.,M 22$A!6M;;H  B+"T9N<%<F<1&79W [.S-9J(%T\.<YOT^@YR958J(H
M\L\U&S7^\ .>ER  "::I2KXZ,[7M&PK"MMPEH4?>5MF!O8F$K4XT=]@DB&4G
M$0,\47KF-B6LX:L+"Q%## ([@E@P#@)#A*@<[$@$L [USK>6JWEBI2J1F2D5
M2@U6/=M^E5*&F!(;6#I)>8F)<E>JW%@N'(4DW!%Q;'3X7:6SXR0I!0I*AO)4
MDI(-V]X+(4#?BV50E(!;< :X(;J\W$C*UYH@(Z#IR@>\)%_A8FV+J5X:A#$6
MY_\ .:1D_@3Y_6E".QRGFL!V %OT.]_POBO49)FP>.9X6U]XGE</2TTE/LZ#
MJ=O?^6$S'(_*A(#).;F>A^EJ5VP+#0;*Z#L<2$>\1D 8_P!FI0D$*) )B6XU
MG<]S\SAE-8:#P%9%I*KDA.M_W1U\_P <-.]>-0)?D6SX6J/? LD#URHOX!.A
M %^MMO/;IAH620(DC7ZU(XU'B*+^ICN/E_#$H28@\V)J%SP\!\P_C-#P2#]4
M:>5Q]V$:6Z4_?X3SCUUZUM#B1L$CS"2/NPK?Q#S^E-.\;@GI]!7OC#N/D<.W
MC^(>!_RTC'0^!K1SK_O*_P!(_GAKG4^)J7<3IYGZT<4>5)5IH+ZFP^)Z#SZ8
ME4 $DLD1<B/(&HA<<Q4RY,C2TY(D5S*F4HF<LPC,+$.JL2*.UF)5(I+M.,UI
MP4Y]Q$=$"KR$N(CU1E)D0&XCJ#8/D'F]HQ5C%3AXFTXF$DX94AL4X0Q%[PLL
M*2IT#]TEEA;@'<)%I"?=<)22X?W0=U@3F&#G/+@3*U0.$V6:G,H%7S#-FFE9
MKJ-4@QJ%1WFU2X>8*>U4U3:6)2B"F#&D,P6VE)L@^O-)_P"" Q5Q=LVA*L0)
M6O>P0E1*U**-Q326(8D!3#,I)<.!2!%B3=P  "72[YCA-IYTVH7!.G5--)9-
M2KT!537 =+LNF(]7=;J<^="5183K3Y?_ )P0$P_'?00H-M.H)I\5M0EN6<3M
M=8);#3[KP-X%F!"B20G=)+!R +@J/NAV&D&X9VR!ARXN9'F3:G-3>%U+I4"H
M1HC4Y=0JS<2+'8K\>'"KU.>:JZ(KDAJ,XF6M,1^,/$;=B(<ER">1+;BEA!JK
M[5Q5*2H!82-XG<*MU0W<R%!+"2Q.8)8S5M&&D@C<2269T@D,1<F<\A)L!6-;
MX#12Y46F\T5!UV+$ILQN,FG5%A+#,YQE$EJ;(JE%IC466PIPJ9:F+AN+"2E#
M9N&RJ.TU+W2!B)"U*2-Y2"[.RD[N(H$'4.S/J:<K!N9+,2V\PX2(8O$&]-&9
MPPR31Z=/FTZN5RHUF)'J\F-'DQ(:6G'Z%(#$AM?A$A2)?.%L'][E) )Q.G:\
M52P"" 2 ^^HN#G;]TEKM+NU)W0LY+!PX:7MH7>3-0DMC,=4"O#2F"E?U_$!0
M>4[[D>T!_P!:Q!TQL DW!Z$3?A8AF@3PJQN']T Y$M=KLT?#>M!BL$99HD8%
MVIS3,?W"1(L 1T*2HW ZCMWZ*26,LXB&$N((&=CR% 1((!,OF7 8R6:XGED"
M12/-1RW^CFF GE)NVI*-KD@<FH/G?37>^&;.DX<XRMX$N7][,:MHW7A4J\3
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MAH0!T^Q/9+V6P?9?L_!Q5X:4J5AI$)0X"@+MA81"IL9@R216)C[07+GE=FS
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M<'M7$P5C!VE'<XQ4D((6^!C'/N<1TNI@YPEA.(F=T+2E2@A0[J273HWO#0$
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MWE@[9V78-J7M&VXZ^V,4XBE80V@X>TC#"E$H2@(4@I2B&$D,(F=Q*PE"4@L
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MK4X*R089S!%PSG1V=V9R"(J1&8<4$A2B0#S:CJ>NWGY:$#?3'IFU)"L,8>(
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M;4$NAP.E* VT4*;"VGO]Z/'F&[_?]X'3%<QS%QZG6&RIA,'=,$E^>9Z>)#M
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M>6M#V89"DEEAA#(NN# =O[*Y:3R.<F_-?0;6]CV$[4 O'PPI3^Z%>\3O%R8
M+?*X-SM*1A8(9" @,QW8<S)DAN>MIJ@^?N($;,>8'ZF['?1!90668Y=NM:$[
M<Q-S8ZD_O$=<=EV7V>=E "!N6)    (D0<\Y;/C4&*A+$[@$"^G373(ORJNV
M:\WF6\XILAAIF_A(!L&P+[=3IO>]B3H-,;.-ALV_.ZRI /%\F86%W8<\]0&]
MN@#F+7D_26T&L%5G,ADDCQ%FVZN8@G6XU'M;W U'4XSMIVY"$G<(3!L.0>=;
M7,DZ"GJ<!W9WN'X9E@[7+2_.F!5J@HHYE+*C:U[DFW47OOON+F_NQR.U;8I:
MR5+)<F^>0.NC= P@U45CXHWO>-BVN<Y,T1;F[5'50JRP2 XH;7'-\M/U]ES3
M*E:O?A/,3ZM6>K:,:?>4>@?0 0]KGXFR$_(>.A*2?^ML??[MK89>X\>/CZZ5
M&5K4943UU,>.?$:-26MQ:]5J*K=\1%2CF?Z5,PT%WZUA<]SIMY8:PTI6$P)O
MQYT<CI2=P#[(.NNIPJKGF?C34ETA_4TKM)2F_* +6M;IOMVPCEQ)L?)JN(PT
M,?=%_I1YH<R==3W^8P]),N3"2==*EW4Z"CC+%]2#K\S^OUKLW>5J?&C=3H(]
M=>M*#,?I;2]@!J>FM[^?N\AU-XZGQI2#E'%N?KI70GT&8I#?$_F%_:R8!<7L
M/\K#T.F_SOTQC=L%1^SS_?19O[+^$_+C35!4$/GPT\6MPCK^FECP^N9H8**U
M+.O>POIO[M_(?/!2?=!86GU>N7'\H9FJN0XF6LO4X2&83K;]0??944H4\EU+
M(0X!<+\-*U.)!O;< XY_M=]Z';220<R+!W'T:']"_1]LZ,?;E;P<L 2<O=U.
M6;\Y+BE/T!,VUO,U+S+3ZAXKD2!%A@27E*L^^'@VV;G0K2S<%2?K :WTQ'V0
M??)?1RY&?Q%LM7SJ/V\V%>!M()$*6H 1H[0^3W;,UTR0"E023?E2FY\[$'J>
MN.DK@![J1P^)_.M^"G533TT_2:/HP\%*MFRET]S,G$K-E5I?#K@MDMGE,S./
M%'-KJH.5:8VRE1=,&/))JE;D)!3&I,28XJWACF*0NT9P.?Y7-)'H0>C0]Z.'
M"A,?.E2&;.-O$NI/<0N.&?GD?U[-7$.MM^L5$*<79T4NDAURE4&$JS<6FPVF
MFT(P4 ,_-ZO $ILG3ZH %^@MVVO@I:RP446D/I:86\;E 2JXVTL=1YW'N/VX
M:O[JO\)^!I0'(&I:N3F?9*YU2S-+1&<D-RI]1,1]$Q,9"FT2K%F8T7""LJ39
M(4B^@UMCA_8Q(VK8.TL7-&T8X!SC%6[\=2V?"MI6&R1!@ @\0 QXL"8#AVI*
MRE,52Z$''(,:,JZR%174))*KW^K87.O,>I[:C$7LILH[3]H,7!(!"5E37^Z;
MM$Q X 7O5Q,7=!>!/D+F6CYQK5?^*&<O#$LE]1!YN8E0)TYA:]AKTW%^IUQ]
M.]B;-B)*$A+;H"0X(@!HBPT9G\:YS%VHJ*P(DAK"2<R]A-V&5<^<\YJ6](D+
M2I>A-E7)-MKC?O\ (X]%P,':$(24ABP+^1$" (U!ZQFXI*C8,9 RZZS?X!YK
MW7:KXX4 J]]QI8D^6G4ZC77?OC9PL,G=!!@!\B3G9VX:F7L*JJ#.-7>.,</(
M0=#4;S2203OKYVM?X:8TT888!K,\SXR?B!RIM(CWU?UW&%IR?O#K\#1/D3V^
MT_G@J3<3IYGZUD]I;X?CBSD.9^"::G[RNOQ%%@D#8?B?F=<)3P +"DC!4%>6
M'8?(81AH/ 4KG4^)K7R'N/M_+#.[X^7YT_O.'G^5'&%*O:YM_ _EB2FI)<!X
M) (X6^$4HMZVOKO^.*]"OO'UE6T,K-MK'K?IWM@IIN?Z^>=&0RK0]/A^>"GA
M; !K!K_E6X-V %]O+^."E[SAY_E1QM"B+7N=-^GE^?0??"Q)R=S''EX\-6!#
MBE,&&@Z==?'QH\TT?WM?@/EUZ]OOMAX&:F+EK#Y/+Z/QX1T?,!!)'(F_E>PT
MOK_C^>*^+M)P<=.! "QP8..3>?Q:E225!W)</J[ \;<_K5H_19AIJE?S[PPD
M*"HW%;AQFJA1&G/['Z>I,!C,N5E$:GQE5.EKA1[7NY(6.52EF_*^UB1LJ-EV
MO#!"\#:<-1(8MOO@8KEF &%BJ5$P&>*TL. 03]Y)3U<$'0N0>-\ZK0Y3#%=D
M,O<R'8KBVW$6L;I44FXMOI>PMOCJDXY*4Q!2&.8+2/CEK:!68;EV!>0\ D_4
M]:P]1OT3K^/O/WX.]/'^8_2BB+L0V(2D#< )T-B00 1J+V%[::"QQ,C$3BWO
MR+^HU^E +\##SK=WR.MK]),X4\.H6?,U(HM1JS='C)AO/NN%UEIR0ZTFZ8<9
M3RT,I>43S$N%)/<C4YVW[5]E3O(05%V8 F'N8L\EM3I3D@$AV 'B7L#E?R\I
MP8X Y;>9E.Q<VEU<2NKI[RP849MN(T!8M)4\'IT]8_9);:'A*<U4LC;(_7VV
M.QV+)W]]VB6W2&#20PSX5.UH-^;\(U^!SS4\K<#J-6H^9)"JE5*.FDE]FG*K
M#M)1)?+02IXOQ42UK05H5_5@V5758$I.&+[?VHB=CA1;]]S%_N- )F7'2G2
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M201E<:C,-:Q.GC3@XR9#@9=S,U5LNI4K)^<8K>8\KR ;H33Y22\_%64DI2]
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MA4-[PW7YBTS,C%5OI)4HAQ'(V:+V/"(K'C-EM&5^*_$C+Z4@-TK.F8Z9'(T
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MNM#V?[.4O&^V]KOM2<1)7A#%$ EPE1W F7 *9RR8FNNP1]FPVPAW8W6]W0N
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MY>0I9CQ 2"4@Z@_$&XV_#R\KA4H A]1EGST'%N0MIC"PQ9 %+S$<:"W4??\
MK7OM<W.$"U@W.GCT)=LM')9V#MU.GH>NN=+;,:XV%SK\/>;]?EMO;%@+0\VZ
MW&>5^G"GA*2J0D >?)^/E2K'95<7[B^UK7M:Y&I_1PX+1.0M>?,Y\-!I1NIW
MG"0 ",X\RTM;\S2]%C)%B4@FXWOI:UMK:Z#3[L1E2===8Y9YPW&:L*6# ,2
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MK?\ /M;L!B4D6>6<=+3Z#7BGX<$:S(UUZ\/'5<IZFZ+%^EGTI5/D@BFLJO[
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M] (<BYU^IX"*YY<0?:G2KF]U'4];D;X]DV1(0,/=&ZR/!B1GP^EHK'Q%*&\
M3 CP%5WK#)*R;:]_=UTZ7WO;[,;N$5+"7),,7@6-HS#A\F@52Q%'(F[AR\9_
M+RIDR([A4HW-_:WN=1?;[K^[6^+"0  PCX\7U^'*EW<R!(G/E\#%X$4A/"U]
M[VUU.][&_?$Z"6,F_P"?S-+7F'JN>9^-%$7T@7(&MS]XQ(J!&A.H=TY&D!-^
M)^)%$E[#W_GAF^K7R'TJ9*04AQ?B=36K!OJU\A]*7<3IYGZT,&^K7R'THW$Z
M>9^M;;H\OE_##MX^E)^E-8_B5X*H\R6SN@7_ %J-;=_/MU& !.ENN;Q=W8@\
MF84PE6;\K<F%OA>^IL)2G4 ##V&@ GAS\LZ2E%E39(!2%7 W O?:^_SQ2)+F
M3<PYZ=/6E)+\/4_7HPO2@8K2T7*$DG]ZVHTTO;7K\\)O*$@F.-+D_P"1]>?"
MD23%*/J^SKTOI_#OYC73$J<11@D^-_IPL):]- 'X1X:C(YM6D#07O>POJ?SP
M_>.I\:L!*6$-U->C8>X8F%AR%0UD%$;$C$*KGF?C12BRZE5^;6QZW_'[!\SA
MB$@?> -X+1U<:9GE4.&5/))X%OSYQ?033TR?3G,PYLRQ18K05+J=?H]+92+7
M><F3DP@?/]LE2NU]/?3V[&[C"QB%[B$X:EG+= 2%>#$<'?1ZO8:=Y0]T$N \
M29!B^7*9J7O26J(JG'WBJ\VI*@UF^MTEM;9NA<:DNM18Q!'[KK32&TVM<( '
M7'/>RO>HV3 )<!6%A*W3JI()<=2,]*CQU;RE;Q)<J!S&K^4Q<#2H:CBU_P!;
M6Z[]<=/MB4H*5H&ZHDNH&[@Y6$16:E:DD[JB 3;)AXN#S(/&LTQ@\;\HM?0$
M ]?=>^OOZZ8KA2U""789F2P)BK12D27@!VS_ *UD[ 2G4( ]PL>OQZ:>9^&%
M=:3)/GD"3$N+:W/*ADFT<WUY_ YZM682 !H-+=!TP.6^\3&MZ>P&0\*\6A#A
MNM*5'N0,&\0()@6<^%&Z-!-*,."U<'V0;'4[ZWL/E@$ .75RM.>O+\JB)X !
MK7U9S=\QTIR0V&DBX0F][7MT.A^>$IQE*B;@L'NSB/,O2RF(PGZMA[K?GB-S
M^+_P?YJF8?W9\5 ^(Y"BKT9)W2+V!'6X\N^^WZ+"5"7-@6OHS? ZGJZA*56#
M*'4]'R\&Y4EOMN(.A-CU&H\Q;I^N^)MU.@\*@WUV*BQ:>!'KPYBL42"AVR20
MGM?8>[3W7WOIA-Q.:1IY-\#2[RLBP/$2+2 'DQSBG/#F7%N8VMM??X^77XXC
M]Y(+.!=A'+D\@/>E=3!E"[@D,Y>S:QIRS-.^BU%5/J5,FI40J#-A2$D&Q BO
MH<2!;78$ C77Y96TX"<08@Q$@NE202YN"+]3&FM",;$WDC?+;PTL_)ZF;T@X
M31XGU2H,-I9CUZFTFO-$"P*JK2HDQXC7<O+7<@ZG:VPQ^PEJ.!AH))&&I>$E
MXC#Q%(3Y 0<FM%6ML2E*B4@I< QQ SUX6O4'%GJ0-!U(N+6L18>\_ACJ<3$Q
M$I 2LI >W"?4YU4PE+S+ZYN2?.*+E(UN!YZ8J=XO\1IYN<YOK6X) :Y19*]4
MW&AL=R??OITVP[?4P$N_0@N,H$EC_6G)=TW9QX$S]#Q@T>8AL(CKE.A*5M@A
M*#?]I<6N+VN1>^W>^(W,.Y#$@O;(?"!PT>M0(0+) IFU4GD*]2K74'4Z V^>
M 9',NY,_O*$WR'HTZU,D)0M]+J@$H; \0; G?7;4^_W]L3\3EK3D7%O6GYT5
MF29,Z4&T%3RU7#"-_#!_N@;;Z;;D]\,@R20"6;FPST+NV8?(5HX)80T,>LD^
M8^E.ZH3X^4*"W&04KJ#L=*G6TV"BLV',>O,#\S<],,V7#*4D[2>\S=;D-,EF
M:UGFP-)MN^E381*6+EHAA=Q:YOY5<?T.<HTZ@9:S=Z06<B B)&FPJ.](2%*@
MLTE!749*.?1<EV2DPXJD:K2 !??'#>TNUJQ,<;'LZB$+*0M(=E)*F:)9Y/(Z
MBM_L9'>(WL<=X0(*I<SP#%N3,2=#R=]([B$]Q-XTRLZ9WJRT,R$R9,&CLE;A
MH]"BK)HE-#A/*J6^E)DS64V$62\4&_*<=W[-['^KMB^S;.D(20'#,E2R&4HW
M,F)N!QCH4J*)22GD6\!Q:2W$N3-,,QYIG/3:Q/:E2&U5!Q35_%5XBXB25-L*
M4#<M@@623;2VVF.OP-AV; 4,3 P,/#6J5J2"ZM27)EG?26I"M:B-Y3@J#NUB
M<^$AX'SJ,*WF>-]!B$EI"Y:5EPGE'UR/:6%#6Y%]R;G%C&/= E!*8>"PX:.2
M\WUDFK>)N 0 (#W&LO\ !S?*J_URJ%86@N$@W*@3>Y-[#Y] ;&]MMN9VS:L4
MK4#B%I#%IZ,['T(JHI;.1  \>9SX$^1J,:I+O<$W&HO?706WWOH-K^>^,=12
M') >[>-QI/J*SEJ+&6<Q/IN9^51Y/DCF/M&Y!UOU/?KI>UO+:PQ26HDJG[KA
MN(!\?#(U06HE3/G+D\O'YL,Z;RG%W/M'<_?BO4S Y#PHREQ9(!5H;] .GD,(
MPT'@*6]9$ [@'WB^(MY5W]<K56(!O7J0 H'E!L;V%@3[CIK\1[\ 47#DL\SE
M2SE?+G5@. G!N;QDSS&H+2'!3J>E%3K"F'6TS%PPM)]5CQU$+?4J_(I48/<H
M)(.F,CVBVI6S;*K$V51PE,91E!G/^O0UO]C[+O@C:1WA(+*7E(8O$RU^A:IP
M],W@#0N G$[+]+RJMYK+6<LB4/.,&FRRXY(IJI8?BU*'S/I#Z5L2H?.VDW)2
M\HG0@XQ/9+M\;1BKP=OQ#CK(*4G$.\ H@[K2 [\(APU7]N[.A\##" D.=T$,
MP-S/X3^<U55AE1(%SN";#2P(TWZ^1&_6]L=GBX1NA3!S8A_&2P%XTK(2A:"
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MB;3N_+Y36@P$=4W_ .T3B=R[N9Z?"G49:9" >4 =K7UVT^8W[_'$>,$]UBD
MD]VN2UPE7.':.=  WDP'<>9^?SXU8[CPM;59R)!*?;C</<K)<.O[-3L)+Z1<
M;62YU[Z;#'->S2$XN!CXB@%$X^*=XW=V&?\ #QLXL]6MNM8LR;M/+R^=1''4
MKG O>^_G^OLZ8U0M1Q5I))2"IAD&"B/AZBL_9P#O1JW"'^0I?]5Y@$G90&EB
M+7'7746O?SWVPLB,H)+R><>.30XRLH#JL_K+0UZXAM*0TA(2AL$K4-+FW4@&
MQZ6)PQSE!;0:EF!.=RSS LU6TX2"92+N\AHL_FY:U-J9U[7-O=;#197+YBK5
M,N6!XA2?JW(()Z!-_P!?E@.7+YFBD24AQV08[9*_$4/#L;D"VP'D==!TOT(P
M;0HH#H.[8MS;X\9M::L88#B ;RSZCTS@7L*>&:74T'*T:ELCED2;%?*+%1L"
M;V&HZ#]#"[,2M2=Y3R"7:S@Y"Y:2W&'!K0"0!$;QWCE9QEU-\V:KC^A-E*!D
MK*&?..^:'FX%-B4FITZFNR;)M#AH5,K$EM2K6+LD"*PH&ZD^RGOCS[VTQMJV
MKMK"V?9\0G .YO8:)39#%PDV 4>;F:M]F)Q%*"E.22SD9:9LS2^K!B*X:\?>
M(56XC\5L\YWK,UV:[F"N.R(ZE$J2W3$NDQ($6]@@P6K0KI]FS9N"K4^M=D]G
M[-L'96RG9L).%B]TC?6G[RB;E7%37:\9!NIW$0-V0 [SD()MRX=*@DU^11T3
MC""5.3X?@>*>4+;YOK)"K;JN;];=+XZ##PDXP3WHWF+L3<"P=X@V8_(VMU.0
M&?'GYW(8\:B#-L9F%&B.KE>-,D%3CK:2%)0A8*K&QTL2//S[+BD8(4,(% ;(
MD/Z>^;>+5(3H"0EWY-EQGY/4)5IU)5??307MIT&]QUT_CC#VG%]T@JU.I>Y;
M/AXZ536H[IF[GE/&UHE]+S&51+04\Z$@&Z@%"_D+ ;:D:8Y['(.] =CGP,_+
M1Q-4EE6]<@AINX?YVZ<*8-0>\59;03SCVC:QT_CY7\[8R)+N2;W(CDWEG;.F
ME1-STRUI <4I-[:&QVTM;M;#2A!DI%-*0<K=/A11 \4Z>=]!TWOMK?$>\K,^
M0H!< C/UZ\JW "XL #?0VM@"U.',9P*6E)IFX).IW'N'8G^'QQ(ONW@-R9^9
M#_7SJZ,'!S0D#,L[7S+^=*\.*K0D&XU^_33K[N_7%!>(7(!N#'A/+*>; %BO
M=H!^Z(X>%Z<D9I77V4G0C:PZD]M#?;3$2MHQD89PDXBDH+DI%M3QG,/;I2K
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M+&7Z3D_+$.,_E"B5AMVLT5Z)](?2U2:IKTX2Y,;,\I]FH3%O0EMHD%Q*'$(
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M!,Y>S!4ZAQ K3.8_YP(]03*6Q!RB[3Y:41'62GET4XYS@K))?Q_)OG0 T"S
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M;3V?LX*E)P@'M?FX AB^8O:]<M^*'!7-7H_9VC&O49-7I42>)#!=2YZG5XI
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M\I5ZPC?H=V8N)AX2%+Q5IPT!@5+(2D;T220TL&>7I&)+ %180'+RY@9B[;S
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M<0U,0ZF&PR\9C3Q6IUYI;JU++\+LW9\+#P$KQ%'$PT-B*OWBW"L11WG@K3)
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M+BW;VC0F0X"5\XU!L5$#0WQB=@>V79W:6"K&WTDI*IW5ZJ!(_9IF.&4F:4[
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MMOM?94X .Z,A\!>3$^($1232,C,Q::J=-:;6Z8T9]^0X@\R7U!(2TD) OR7
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M:U2ZHT6Z$:-ZP\IN2W.;_92DP6ZLE@@D!!TQZ#V8M.UX8.U'O2R27!006O\
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MGXE'HD_,_ TI2EBV\^4'Z5B[%4D73H/UWN._N&$*US[Q#>/!Q</D^6L4.#8
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MW>JVZOI.28?Z%V@WHB\A(  2+)45^Y2EAPV\BL A.PM8 ))&#=PQ!+WB1=H
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MIVT^8VUQ7Q &/*)>?@YS;*-:LOEZ]<*>$6$RS1'UD#QI$BUBI5^6^PU%A8]
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MS*_&KKZ6E*:\5E,)AD.2$) \5L%!YD+YD+',%)5<C'#]L]KX>,6!@P),OPW
M',\+5U_8Y^TH)>6;(D,1+ACP:P!EZ9O%FDQ:<_33(;89DU2G"J.'P7&(KKZR
M&T)262WR>(I*G.5-DZGV; 8K=FCO2%@0% ZR"X)D%H:(-K/5+MK9QA8@ CW@
M2-7N+FV4![O9X#F1)C9F<L0.%EEMY@1W'%M-N*(NX&'%*:<%[76XVNVA%NG2
M*Q8NV63@,0UGD9#CG?(!# 9EP7>V0!$MPGH+W(]#=AJHTO.[TH-MRDR: V^D
MN-BZDBNZA("4I!).B4I'EBLG$!*G,0U\WX<ISJIMH;N[#[]P\#<;(GF/C-?6
MIC=KS>A@HH8**&"BA@HH8**KGZ2_ B@^D?P.XC\&\Q*7&8S=1EQJ554\RI%"
MS!$*)V7Z] 4"%L3*16(\.<P^@A0<: -T*4"4&QRJ /0%](;-/$SA]6.$/%U
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MF(H[RQB8()8 #=0D?=$,W.985Q&W^^D;Q=PUP_W3H'AV>-"]<=\PMH=S?F=
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MXBQ $I+"<I+=22&^,14APD)2"E+&6F(;4Q\KB\N>'%*' I0ND$*[W U-KWW
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MA(1XS2 0.8E8%R<.PMFV3$&_M" M205 E1#%+D'H+19LK]5L6S;/BX0&*C?
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M-1N=3XFLTI(-B;DCW=#86Z>>)T)"1&?K.?&H4,[-?-V;US^;S3P%;$;--=S
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MG\<(7=(>[Z?2HU*() AOI6>'5'0P45NY$GI]I_/"&0>1I^^>'KK0  VVUW^
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MFW7W/[U@QN&!XQ/FX<'P=ZFP[EXF )=V#^0].2EU1A#\58>"6S>Z"LI!-M-
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M$>%LV@VO%&H394X!8V!M;S%B-3[O/;&/BN!DTP^IDGG:.E5"6! %\I/,VL8
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MO6H1NI9+ EF,&<F<V>V32UJ:%""'Z"ECQ9LE$9U0Y9:E*;<78GEB*427 "=
MHD$=[7QI^R>TX^S^U.+V*% =EE9(P2D;Q(E)[UCC%R!=<1E6;M&&A;E8]Y1=
M@3K<D:^5V%0UG:(>5_V"GE*K).BA8G0@Z"UB"1L;W.QQ].["4J3A@AV2$B38
M""^<;M[UAXF!AIWF2275F3G&=[<\M*JQF!AP.N<@MSG4$>9N.HL;?"V-X (
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M-D;9AM>/AKI6E*$WLH]M=>OD/,?;B795*6#WI<N0+)SBT?4>-1A3D@%M"9Z
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M6Z!(_P!_)=*O&!O?&%B=C8V(M>(%$$X>%AC="DA\,XA#D+<I.^ 4N"+.7>K
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M)6'&#4<OU*3",]CU.&[3*54Z:!2(PC<C#5YD6>6I?B)*4%%@FXP]79./W@Q
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M+A,(SB[!P'BPF7<$64=DKPBQ%B"8.4ZV#'($OF\GUU6GY<CO1:$$O55=A+K
M"2J)<>TFGI5=+H-R"2+VN1T.*G9_9VUXJQON0+02 [&[RPN1.M:&W]I;-AI.
MXSQ$Y$.Y*>! (R:[4S"5J67%%3CBG"XM:U%2EJ5J2HG>Q.@\OEUN%L6%LR05
M@%0:7N<G,B3Q^1KE<7:\7:"2DD@=(ZL2XN2YNQFO  -M.N+H 'RY:<N?TJH_
MQ?KSOYTIQGG$VL;:#IJ-";7_ $?/#5>Z"0-2VI )\R!X#2G0"G($!7)G,9_/
M*CXD6^JGVU:*< 3SD$[%1-Q[]\9F+CX^(?=26%ON_4Y\!SIYQ20T0][F+OND
MN>)CK6+SO*"A)(0K52 3RJ/^<+W*NMS[^V$P\?'PKX;P_P"ZD])L+1QH[T@6
M9@6 SZG-\X:&%ZT/O?U4I3<Z'R-]K#R[:$FYQ9[_ &AR>[N9@ L1G<<. T<4
MJ,7)QHUQ\R&N6HH7@M,9MQ*5>(@I(4 3M;7W'KU)PSOL>24$C>MNAC)=GL;\
MFDU=P\0PUH$06],<BQ>STU):FH\EZ(\CGCO*.F@L=.5257N "18"U[ '2]W%
MXXCC9\^L\Y TNAV>PD.W/AF[/G=Z1TQG8;CD62.:GR@2AY*;\AU U%[:[[6U
MN+;IZ]>IH'[K"9;+0-E$<0<GL-<!]AY#^7IQY O_ 'I*4 GP[#2YZW.A)-K7
MT&N''(CFPU!X#C DVU%6/CGDX^<3X%H>B]$S#,RA45PY329D4 AZ,\>5*K'4
MMF]D6UT3:]Q;77"* 4'22DW]W*[6%K2[/=J!< B#G %QF;V.8;K4]98XX4[)
M.:,K9OH14VU3%MM5"FILE3E,J" W(C*W*U)22INY);<]I-B<<_VSV(OM/9^_
MPW6I.\K> +J9[RFUS<$@/D*LIQ.Z4E221 !%W9G:'TFP)T,N+^4 X/9+XH9#
MI_I,9"+LV68=,AU@1DI2NH4]Q8B,5-QA Y5SZ1) I\E"A=:&U^)?P4C&5[*]
MHXNP;4=@QS[JGW3+!0+[HT+.IR1H^G5=GXG?)25 $Q-M&9X<EIXNSO7%K-=!
MJ&2*DE$:=X[<^G1Y\=Y/MK5'E(*9$:6P24-RHCWB1E-V%PQS6"B3CU3 QAC!
MBDI(40H6#@N"[,Q9X?0UN-\\_P"HT\^=0K4H0*E**/:5<DV( !)-P-A;?IKY
M8UD8>\EQ)(/1I\>N1RH(+.+.'+V_.VHR.E,J9$Y2H@$$@W)-['<;[IT%K_G>
MACH@ACR&H/.X>]M:1X=^OU'Q^5@US34>LF04D+ON"0"1Y:BP-SC$Q\%RHY@%
M[N+QS/'@;V0A@6S?,!B6F?KTTVLMJ+ER 2=/:!(MI?36QWL==ACG=J@.[W?*
MV1SODYCK4"B "Y(Y7Z4M1T)2 $BPN3^/WXPL4N-[/RM^5,;=5&8'FH \/*E^
M&I12!I<W&VNZNOP_6EJRR8&1OT:IS]Q/,_.I'IT"EN0T/3*BX)!2E*H[:0HI
M .VHN3YGH;[8HX@$_42 +ZF+ 6?A2D/< $GF8&4SHP%.N/)I+*&/57'$-L)(
M=0$GG=7;115H;7M:]P ?CC$V@^Z6+W.=\CJ=3J2PIR"/=O%QKQ\=2S"P9Z>W
M,]2FHB$.+1*FL"8\ZA1!2PNQ#*-?V9!T/+;0B^,/'#'-R.+@'E<Y&QT#-6D@
MNFUR^<&0;<HAXE\G67T.QJ>VDV\%(2H"PN; $*3L;:;WUZZ7QF8DIX3>PY^?
MG%!SS>Y:]Q<C-C\Z<4 \H;4=DK0?D;XJ*MB<C\12&W5/Q%/Q97XS;P%T2FDI
M22+A) %P=^FEC\,8V*S".IOX6G-IDN+U,"P()/NOU MTX<J<, 6*;$CV>4&_
MU0>@ T ^'OQ1Q#)X#Q#.U(J[1*3,\3KJ/SJ6.&M'<S%7FX:W6VF%QU"1(?4J
MT=I"K+=LDA0'A@D(3:^@!YK8SENVBN3'3C$7)\!-2;'LZ\90)<@QK,V:T9-?
MI5U9V8,BY+RLQ&HU*.:J[&?%,:K];5X5-AEQHN 4^DQ^4/!%^0.R^==T@Z<N
M*"[J!T,#D6&4MS.4UM'#Q,)+ P 0S.2XD/+2^=F!J)J7(I+[S%4=B+14'7YB
MGA&1XGAO*25N.V>!Y4FP\- T3LG?%'$M%P(<P01YZ7<&]JHB7+1)EKOS#YB<
MLP"U6HX 51A]O-*TRVB2:(5>.X4.W/TQ8J02.6]M+:&W<8=L;/BOIA_A'X\C
M YB^=97:@4>XN2.]>_\ ^7+-#\+MJ]?0]CU*O**&"BA@HH8**&"BA@HH8**&
M"BA@HH8**&"BO#L?<<%%48](JD_Y246I(IR)1=BE *'%,3$*0"D!A84AMU-B
M>9"@>8ZG7;@>T<-0]J]CQ"6PR<-R;#W"+N8=BS19M;:5K;=)<&X(SL8Z"'8G
MQJK]!*86:'J>IX-)DLO);9:;0'4&U_ZPA"18@DDJ)]HZW/6WVFO=[>P%@MA>
MX2Q&0)DWRGF*E& C$!*@3I>-'$<+]9I+S?%"BYS#F000K8!13K?2Q'7RZ=<>
MW^RNTKQL(%9!($$1!L?!B.#YBL/;<).&%*3D203,\0W*189Q53LVQ2'G@E'U
M2>6^MM2-3O[A?7'H^P8RL0J0I0*0( C@',/#=>#5C))4HA3D7G-^1]:2]0U4
M8ZP#8 $ZDGI<F]K_ !^[MC1"B%,T!P +Q\:0@$R""^C\7O<7+<*;C[)3;IMK
MOKUZ;'^&F)1B*.>N0MZO]"*0C2?5YU^,:.G/QDK))%U$:&^EK6T[$?J^F)P2
M)#C@_H4W<3! ,,\V+WY'JQ\TGPE]OO\ RP=YP_YF\M\-R84W='X3XC_-6L;"
M^_7%\6'(4_RK1XP_O(^8_/"TS?&8/KK7GBC^^GYIPW<3IYFFNC))?+GXUOYA
MW'SPT!,.G$XV;_PTUBWW<KSXW;Y5K4$\PO8:'OH2.W;:UK=?=A-J!Q,(A(EN
M$?T;.Y9AJ[90$*WE MO#PSX_3*\K=-K*H:8K+9\%<25ZV^]9"DNLFW[,I((.
MH()N38VML<<;M?9^T8RBE(5+I-P[V^5FXUUVQ]H;-@@;[,&<AA 8V,];^%2?
M1<WY6J3*XF9LMTZIMWDR'I,9EN#*8CI_L$M/-V6\[>Q)-BKYXX3MOL+V@['_
M &O9&(I!)WU=YAJQI)<OO$#+Y<^KV?M+V8[52,-6"^(  2G%W3O!@8"0)DWY
MP*W5+(N5:^U1DY"JSHJ&872ABAU3D1ZM8$D*D7Y[:>SS'70W.IQ+V![4=OX
M*>VL5*P@DD)PAA.$AR W 6?G6=VEV-@NK]7,@+@ _M)4^9L1ROY,FN\,\S9:
M2LUV$_$?:EB.PGD6IAX<A(=3(1= 3S:@\VNENHQTB_;WV?[0_8[4AE [KC$
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MCW&(^*25K20G( BP>2.$DSYT(1BX+[C 9[R7?4\+$/\ (BMB6N=(4G4*5;F
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M>4&1$JM.;08JE@)94893_OA=A0[12E;=\HJ0E!<J=@ '2(93*<F"9)L*3O\
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MVUN/EB0A"@PS=A)DQQ9B/$/S:,98:;<)/7YTZG8S.989F0%H%4;OXL--DDZ
ME21\S8;XAP"O ++L9<DVS8-)ZNW&3-BH[W=)+[M@,W.I=QZ+BV61\RU?(6::
M?F.E+>BU"C2&E^&+I\9E'LOLE!T6U(27/%1LXM9.Y $.V[%@[9A*0M(/>(4
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M=FQ2ZED3DHIU: +>B7I'ES,O-^U!E2WKL^#9R,E \,WT^MJ1>Q.Y(U &$V7
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M6']VD9J_F-2[HXCJ?K67B*\OM_/%CO%69/A\[U5W$\?&MP41H#^OU]FFV&'
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M0/S.I]^N5B((U(YGKH=/C9JHX@[U1*]XYABW3\O&G1#>L !8WMOVV-KDF_\
M#L+4UX8)SNXFSN.4S4F&M6$&20'#%P##V#ZO>X+7ISQ9!;6EQ&A2A3?*1<'F
M3:Y3U-B;'OWMAN)A(8P7O!N+@6>XMQ,S2M<@BQC/BUW#<7JU7HV*<<1G(A)
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M^9>L0LDC;4C[?CB7=2183F /*I*W..A T-^OP_7QZ=[1A1)'Y?2!3 5 $J/
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MBW!_![].E%TK*7P1:QO>X[<IV_#"$.#P46&4D#YT$07R*M!FD<JW)<(D)<T
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MY>7^'QN<2@N(NVECKG#_  /2,F7,ZWG^O3E6&(:2A@HHE(0N_P"ST^WY=O\
M'KAY=)(!9VD\>+>FUI0VG0?U?A:W&:UG0'W'$A@'D:2MK*U*(O;?\1^>*P43
MNVEWZ5&I( ) T^-*373_ *P_#"BZN?R%, A1T:C6V%J>@KVM\%(0"SY6HDL
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M"D)/B0Y*3MH+GV3IOF[+VAB=BK"=I*D@*S> ((E[RW@UJ[57:FSXH&ZQ) !
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M:#IO\R!]HQA8V&ZB+S+1/7FU1_O;N3D^5O&=7F\TXXL@K'M$7Z[ZW[7WUO\
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MRZCE+,%*K\&!4YM)ERJ5*:E,,5*F/N0JA3G'$W"7X\MIQ#H)YD*0I!VPJDJ
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M/<_E@_>"'@ALN/+2H@6FMJ3R I V)^_7]7P=VF!,>M*/7A7O.3H;6.A]Q^.
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ME3&%RY=2CLTNJQYT:*I*W*:5^"Z2D*(3<N/9Q*1NN51$@DG5X#.(CG2!G&]
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M=FY?+^670F7(AHE_-B^<&SY4G\H'0?(8<W$GP^E(#(!:X%AKRK3<^7R'Y80
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MOE[+M#97Q#H<O*7$K//%7+F9Z%G&33\STG-/$68]+S68E23'6EN!4?&,<Q?
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M1#4XK(+ ",YX'5HHFM !TO\ 6MK\<(DWX$@<A1WR\V\&^M ,KT-[C0_N[?+
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MR)#JWN8-V!4&FT1T)2LVTUY4WL$VQE]O(7LVSX6+AE(4I2<SF0- <^-JN(4
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M6BAX7UL7/KE*[_V\S_8</.W80!.[B1P3_GI.Z/XC_,?I6D\,:V+GUND6&O\
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MK38(#+M3KSC5K:^RI\GX7 .,+'VI:503]YGTL(#Q<>HK11MF"0Y1B1/W4RQ
M$[\?+(5B_P"CCPZIL=;S63LO701<&155IL+D^RZM?,2!^\;'90(TQ!BK5BF2
MXXN"_BH<XU-2'M/9B[86*"8#A%SJ=\GP^4R?PERCEBA+S%&I>7:1$:6FC*6A
MN.V>8@5.Q*E,E1M=5@HJM<ZZXLC9TC"PR27(48Z:@^3>-8G:NVI7W&ZE28Q3
+9/[VXW[QLWK+_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>45
<FILENAME>g164680g01m20.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g164680g01m20.jpg
M_]C_X  02D9)1@ ! 0(!>0%Y  #_[2$P4&AO=&]S:&]P(#,N,  X0DE-! 0
M    (12^A&@X0DE-! 0       \< 5H  QLE1QP"   "    .$))300E
M   0S<_Z?:C'O@D%<':NKP7#3CA"24T$.@      Y0   !     !       +
M<')I;G1/=71P=70    %     %!S=%-B;V]L 0    !);G1E96YU;0    !)
M;G1E     $-L<FT    /<')I;G13:7AT965N0FET8F]O;      +<')I;G1E
M<DYA;65415A4     0      #W!R:6YT4')O;V93971U<$]B:F,    , %
M<@!O &\ 9@ @ %, 90!T '4 <       "G!R;V]F4V5T=7     !     $)L
M=&YE;G5M    #&)U:6QT:6Y0<F]O9@    EP<F]O9D--64L .$))300[
M  (M    $     $      !)P<FEN=$]U='!U=$]P=&EO;G,    7     $-P
M=&YB;V]L      !#;&)R8F]O;       4F=S36)O;VP      $-R;D-B;V]L
M      !#;G1#8F]O;       3&)L<V)O;VP      $YG='9B;V]L      !%
M;6Q$8F]O;       26YT<F)O;VP      $)C:V=/8FIC     0       %)'
M0D,    #     %)D("!D;W5B0&_@            1W)N(&1O=6) ;^
M      !";" @9&]U8D!OX            $)R9%15;G1&(U)L=
M     $)L9"!5;G1&(U)L=                %)S;'15;G1&(U!X;$!88AS
M        "G9E8W1O<D1A=&%B;V]L 0    !09U!S96YU;0    !09U!S
M %!G4$,     3&5F=%5N=$8C4FQT                5&]P(%5N=$8C4FQT
M                4V-L(%5N=$8C4')C0%D            08W)O<%=H96Y0
M<FEN=&EN9V)O;VP     #F-R;W!296-T0F]T=&]M;&]N9P         ,8W)O
M<%)E8W1,969T;&]N9P         -8W)O<%)E8W12:6=H=&QO;F<
M"V-R;W!296-T5&]P;&]N9P      .$))30/M       0 [_^-0 "  $#O_XU
M  (  3A"24T$)@      #@             _@   .$))300-       $
M>#A"24T$&0      !    !XX0DE- _,       D           $ .$))32<0
M       *  $          3A"24T#]0      2  O9F8  0!L9F8 !@
M 0 O9F8  0"AF9H !@       0 R     0!:    !@       0 U     0 M
M    !@       3A"24T#^       <   ____________________________
M_P/H     /____________________________\#Z     #_____________
M________________ ^@     _____________________________P/H   X
M0DE-! @      !     !   "0    D      .$))300>       $     #A"
M24T$&@     #-0    8              *@   )G          $
M                 0             "9P   *@
M 0                         0     0       &YU;&P    "    !F)O
M=6YD<T]B:F,    !        4F-T,0    0     5&]P(&QO;F<
M $QE9G1L;VYG          !"=&]M;&]N9P   *@     4F=H=&QO;F<   )G
M    !G-L:6-E<U9L3',    !3V)J8P    $       5S;&EC90   !(    '
M<VQI8V5)1&QO;F<         !V=R;W5P241L;VYG          9O<FEG:6YE
M;G5M    #$53;&EC94]R:6=I;@    UA=71O1V5N97)A=&5D     %1Y<&5E
M;G5M    "D53;&EC951Y<&4     26UG(     9B;W5N9'-/8FIC     0
M     %)C=#$    $     %1O<"!L;VYG          !,969T;&]N9P
M    0G1O;6QO;F<   "H     %)G:'1L;VYG   "9P    -U<FQ415A4
M 0       &YU;&Q415A4     0       $US9V5415A4     0      !F%L
M=%1A9U1%6%0    !       .8V5L;%1E>'1)<TA434QB;V]L 0    AC96QL
M5&5X=%1%6%0    !       ):&]R>D%L:6=N96YU;0    ]%4VQI8V5(;W)Z
M06QI9VX    '9&5F875L=     EV97)T06QI9VYE;G5M    #T53;&EC959E
M<G1!;&EG;@    =D969A=6QT    "V)G0V]L;W)4>7!E96YU;0   !%%4VQI
M8V5"1T-O;&]R5'EP90    !.;VYE    "71O<$]U='-E=&QO;F<
M"FQE9G1/=71S971L;VYG          QB;W1T;VU/=71S971L;VYG
M  MR:6=H=$]U='-E=&QO;F<      #A"24T$*       #     (_\
M #A"24T$$0       0$ .$))3004       $    "#A"24T$#      6_0
M  $   "@    +    >   %*    6X0 8  '_V/_B#%A)0T-?4%)/1DE,10 !
M 0  #$A,:6YO A   &UN=')21T(@6%E:( ?.  ( "0 & #$  &%C<W!-4T94
M     $E%0R!S4D="               !  #VU@ !     -,M2% @(
M                                                        $6-P
M<G0   %0    ,V1E<V,   &$    ;'=T<'0   'P    %&)K<'0   ($
M%')865H   (8    %&=865H   (L    %&)865H   )     %&1M;F0   )4
M    <&1M9&0   +$    B'9U960   -,    AG9I97<   /4    )&QU;6D
M  /X    %&UE87,   0,    )'1E8V@   0P    #')44D,   0\   (#&=4
M4D,   0\   (#&)44D,   0\   (#'1E>'0     0V]P>7)I9VAT("AC*2 Q
M.3DX($AE=VQE='0M4&%C:V%R9"!#;VUP86YY  !D97-C         !)S4D="
M($E%0S8Q.38V+3(N,0              $G-21T(@245#-C$Y-C8M,BXQ
M
M  !865H@        \U$  0    $6S%A96B                      6%E:
M(        &^B   X]0   Y!865H@        8ID  +>%   8VEA96B
M   DH   #X0  +;/9&5S8P         6245#(&AT=' Z+R]W=W<N:65C+F-H
M               6245#(&AT=' Z+R]W=W<N:65C+F-H
M                                             &1E<V,
M+DE%0R V,3DV-BTR+C$@1&5F875L="!21T(@8V]L;W5R('-P86-E("T@<U)'
M0@              +DE%0R V,3DV-BTR+C$@1&5F875L="!21T(@8V]L;W5R
M('-P86-E("T@<U)'0@                            !D97-C
M "Q2969E<F5N8V4@5FEE=VEN9R!#;VYD:71I;VX@:6X@245#-C$Y-C8M,BXQ
M               L4F5F97)E;F-E(%9I97=I;F<@0V]N9&ET:6]N(&EN($E%
M0S8Q.38V+3(N,0                                  =FEE=P
M$Z3^ !1?+@ 0SQ0  ^W,  03"P #7)X    !6%E:(       3 E6 %    !7
M'^=M96%S          $                        "CP    )S:6<@
M $-25"!C=7)V        !      %  H #P 4 !D '@ C "@ +0 R #< .P!
M $4 2@!/ %0 60!> &, : !M '( =P!\ ($ A@"+ )  E0": )\ I "I *X
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M+&XLHBS7+0PM
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
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MV?NUR^<M9=G-/K0!\6C%F\J.WJ.<+]M.$9J%GL+"K _Y(>UW#EC%-SVJ_M&
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M%D)IWX<8"7M;MVBO*T3R):3@DSY4J9+*96*:F:A"E3):S@PIE":Y&%2B4*2
MYIHK3<=DE2SO$)0HH6L*"E*"<"E (4D$N5L&J ,0)R:.H<+<(/#B_(<GU/D
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M6Q<J2M"9<M$E9"Y&]4LS9@064E20 D$%L!9SUQIKDNVYYLA"YB%J4HK 4%E
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MP3[EVLP@5M1U]Y<5^WI>\NT3 4B7)3+L\Q PO*MDL*5;$%:I:$3):$KD)0M
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M1(LX$[W^4^T9LJE5^_U"4*6_&D$N1@DJ[3IEW;<<M E)D2@@(PA(4KF@@!0
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MHK-?-04I#49*4AFRB*\+YO>;_,K,M 2 E"4 AADY4DGI)+OUL(P]B*M\LQW
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MSQ_>T)UI46&^II 0B9NR5$$8N:4*3@!8Y#"<B68=N^F6ZXY2$IF+E!6%)+D
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MS8A8R6)*L' Q-4#&6RXE$UOYKAXO58K\2I"I<J:HA)"4'FH0:%U*=QS0W"K
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M99B;+(,N8!BPM6G. H_ 5ITCLC!MTM4R>E4LJ"2ISASZA3*K%SEGK'9[L7U
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M9?JBF7-0K=B=.FYE2BHVA4Z27<,$C"H@DU(2!0Q;-O.YY<M4V6M FLD#+S2
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M,A+JTO\ 8M)="B%'CRU8L)F#"M""EFPE*69F9FJ^KQ*AT52I;N[E:LPS:Z,
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MSY((1V]O\5;B?L5D:N$Y2<DHU'F T)!:O2/:7=XHN6E88E34R4020"D$G,D
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MH1MG9E6N7(,J8TV8F6A*4(QG$"0HY$( !<EJ]9?;S-E)\NRJGJ4'2C&5%:R
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M5)$O!S04%20,9"<2J!P1ZK$:T)TMXW$NQ6<35**F(22%$,"2V%RX<U9CID&
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MM$6J:/W=2O"<2F07&F))X=9C2'VQR%G7/6[9JS3%3!+4I.]5C4'+XB&<: D
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MI*NT.(:!\9Q"O)!2D@<@'4%H4!+(U40!\?9P]SQ\WVMO02[#/LJ#6;A207
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M][W[^2[.)8FRY>YWBDRT DI5B*0 U010ZLT;OUV_WM)INUO[:KW2]MM7V4F
M[:JVL=S&:O,$U2F!)4'' P8IG)86E*H?B>\>/^]* 7SJ(VZT$!2)1!"G J[
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M:CU]E)6 /"K+-;A:<45DI0R^4/*">>!SP,S:3DMO#9SZZS*EVNS+!(5*K,
MR4@/4<06J0V47V/:RRS,*)SRUN [\T$L!5LJYZ9DTCNABSFI,=B0PZAUA]I#
MK3K;B5-K0M(4@I4"0H+!!2I)*2"#SKYI.EK0I8+XDD@A0((;1J$=N6HCJ4+3
M,2E:2X6G$"-0:T[QUZ1R0^HI'EY^8/'EQZ^GT_1^'X_'5):BH%_:7S^7[8J4
ME5 ]>IO=U:B-)NKKKZZ=.BW#%Y/O7FT6KFRDR328G"4B7E5^[& /AUU6VH.A
MM15PJ0\E++8(45$:LG6B5*!!4"H:!B0>&>>8IVTCJ-F-D+WVPM0LETR"5I("
MIDPX):='Q*H30%@Y--7CIFV;]M/U/];^ZDG;SHWZ7VG<8@OI%AGN>3Y+$*GC
M+5P'KE49+D..M3?"VF&75K<![> > <*1/F3%J*4XDN1U<7;B[=#C+3Z9>')C
M8=C)$N;M9;,)F)!W<I:5*):H2$%V!?I$;5=2_55[1?I*Q4;@Y9M'MSNG@D%L
M/Y&_@4FP9FTB?F>*_,9=9$A41*U=I>:2I* .YSM').)>ELM%S2M_*DFU(6<2
MD@$823D0')X ZT%1%=C-D>3W:FU*L)ORT6.U35K39I,^6@%042485%921D&-
M2#4"-4K/]DE;-4NT<G(%[+YQ/W/9;2TG$X;L-5<X_P!OSY"IRG@^F$VH<.+[
M/$\SPGG6=L]>\F^U 3T*LC$X@L%NAB6Z1J.@FIBY1.0?;#9B5,MFS5EEWU9E
M)"I2TS4RUD%U'$$@A@EF(Z0:$1FOHRZUO::]<5 ]N;BFR^V&R&U$M<KZG;3<
M!RRG6-\VV/WIZLA(9,A4?N(2J6XE+"P"6R5>6NUM%FN>4$),R8M>%+[OWN6#
M9ZNVE!'GU,J^;*I:;=(3)F()3-EJ+E"QYR:#-*@1E5LZQBSJ ]K7UF=$&X<7
M&>JCIUH[G"K&4&ZS<#!9,EJFM8X4>Y=8ZXA*$3BGYWN$WPG4GS/"?/7;;/<G
M=T;3253+)>02M(.)*\(4A3"BTJ+D'($4(<ZQSEZ7_;K*MD6<J"2Q#>=0U!%<
MO9II';#T=^TEZ:>M2B;D[692B+EL5I*[G +U;4'*J\  +=1"4YQ-C \_XQ%*
MV^4D<^1UQ%][)7E<TQ8M4DB2%J2F<D/+.$D JH<+@..B-_8[YLMK "5@3"E)
M*"6+E() S<@EF8%].&_B'D.)24^:>[A1^*?+RY'PY\Q^$:YHC=4.?!O<.#?.
MD;5"L8<=/L>.7JZ+H'T/ESY>GT_<T.1TZ>$(QGN"4G#LA4\NK2V:R:"JW[_D
MYIM+2^18=B2LQ0HGQ0A)('T^6I[%YX\YR1D0[OH=#37I.48UN\PY,U"<JC7H
MRRTCE8*EH8K0^&N"6Q6P^TU??\FI'@)[5P"L!7NZ@?F%7![>!Y<'BMM?&IWH
M_G$$YZGB/#I$4L7F)J#0MAR-.![CH*UC(*?L4^?/D//Z?+UUC_/SG&5$=(0T
MA#2$-(0TA$"> 2/@"=(1\N5:,0H\B7+6U'BQFUNOR'G$M--,,H+DF0XMPA"6
M64I*E+)XX!Y(^(!RPS-! !RPS-!&CUW[2+I3H[694N9Y+LW8,ER(],HZ.PMJ
MU3S1*7$LSHR2RZ$$$*6@E//D"=9XNRUD [L $.'4 69_GIC*^BS#E\^'5'S/
MW3?I-_Z97O\ HK;_ -C3\FVO]6/63#Z),^1#]TWZ3?\ IE>_Z*V_]G3\FVO]
M6/63#Z)-^1#]TWZ3?^F5[_HK;_V=/R;:_P!6/63#Z)-^1#]TWZ3?^F5[_HK;
M_P!G3\FVO]6/63#Z)-^1#]TWZ3?^F5[_ **V_P#9T_)MK_5CUDP^B3?D0_=-
M^DW_ *97O^BMO_9T_)MK_5CUDP^B3?D1!7M..DX D9C?*(!( Q6WY)^@?-^.
MGY-M?ZL>L#[G,/HDP?PCZ-)[23I4N[.+5HSN55NS7F8\:5=TMC5UZGGU)0VA
M<V0D,H)6H DG@#S/IJ\75;5)*A+! ?6I S8-[VBPR#Q9LW&O1E\]4;R1+./8
M,0Y41UE^-,:;?C/LN)=:>:=2EQ#C:T%25-J00H+![2"G@\GRU$X*2H!OM82"
M&+ODQU/:>Z(BEL3Z,W2Y9_9E'U=2Q;#2$-(0TA#2$4W?\FOSX\O7T_X^[JBL
MCW=](JG,=8]\833**MWFHHG]O&.AU5;\F!1',H)#R;?MY\,\$"+W?9?.(YUL
MT &[RK"DG$>=D1S7(9R'KP)Z>&HF%KP;%7 >:W]85]G1DS1FQ/V1_P"U_L5K
M5I^U_:/PC9JS1U_$14U=%\-(0TA$CB_#0I9X^:"?/R_%^/TTA%H93G.-X526
M.2YA=56,X[5QG)<^YN9\># C1VAW.//R7W$-,MI2"D]ZN[O\@#I".G'-_:)[
MT=5>47&S_LV-O1EK,)YZMR?J<SN)(K=I<9=4LLR#C*EH4]EDR*E+JFO=6U15
MN^$I"U)"CI%*G)QGF W:['J:,R],?LQ<!VYRAO>GJ&R:UZE>I*Q=1.M=Q,_)
ML8%-+[U.)BX=1RNZ%2UT/N#,8,,)<*4A9/)TBK!W^?GC':0Q6ICJ:\%PH99*
M2AA*4I0E*4E ;0$@!*$#@('H!SI"/IZ0BC(=#+2W" H) \B0D$D@#DJ\@/NG
M05_=6#$T2'.@XM6. FP05<$,I!5Y<K3R$@?.*CSQSS]CQY$:K3I[OWQ?NIV0
MEGV^%?G*)G9C/8H!;))].U:2>?P ^8^G5(J)%H)8RR =64/A'7EU(9!=8%U-
M=/>Z#F&9WEN(T6)[FTUNO!<9EY-*JK.Z;J$U7OD:$"MB-(\%XE2B HI\_(:J
M'(;3/FUTST/A&+."Y2WKJX[=<_;HPC0W?C)<J:W1S;+MR8NYE/LIE<K*KW$*
M2MDS,?R==\S@.-HQRP55IDQIB:VOLT6B)R"LM19BD+>0>3JGMC(0"J6I3-J#
MJU,J/[&XQAO$T=3V:RM@,JI\<W<C6-0>GI*KF2F]GQKO [6GQ].<2W9P<14P
MFBB79(LXLA+M@J2S(D$A*TG2(WZ#H,NO6H/N#U(C+;NRG4CA6 ;2RZQO=JP3
MF>SVWUGU01V[>UFY!.^0=]MG).<5E8AQ\F)D#^TDO="N9BUO@2K"*VMID^\)
M:4$59CV9-3W/J^=7ZXSMTQ;5;LL8)U 4F%8_:8AL[N5OKNE9JQ[=&#<1=Q[?
M!+_:O;;'ZAVD?D+7.AK7*Q^\CMB7($A'A1U*5P 0ASBX<YT-'>G#-VJXJ^D:
M+X;AG4538KTL8_@^V^\^)W&U6$=&V/NM3HV2NMI@T<^GB;Z,.K??345L2'*B
M91%ELOA^7<5P8D1$MPI$/FIZ/G^$*BI'\'H>HBIZM=+YW%QK(MGL$Q29NO/W
M4>>R;:G>;))=="RFS;OX>[[6716<+N)$8S6G&*F%C+K\..XTI46(J3&2^P5O
M(4*12K$FC T=_@VE,]8^;B>"]5^=9(PYDSNYTB;DF/U+-,Y%K+!5%:;;V>UL
M),FKLKU^0BLCN2+A4A,N.6S:&:0M"OG$:0 )XU>G[Z'NZ.DG(6S^P>[%U9[:
M8)(H]U<6VGA0<(J<ICR)5S4+6*O%9<:[C.3/'$L07+A7(>#@3W!!20DC2*CY
MS^/R<^B,4;BV.XF"XU;5FZLW= YE31]MJK9ANFO)OO=%#1FD"';*RIMJ:VMY
M=A$"EM/RVY#DJ M)!!2=(/I\#^[V/QCTJX\X7(-8#WGM@1RM2R2HNJC-E?<3
MZJ))*N/X7/XD5BYM(0TA#2$042!R!W'Z.>-(HHD"GMZP/C[(XOO*@HI4RI/'
MQY)3Q_VNSM)^X#S]'.JTX]WQ=O8\6@K+L!WBO5SG,:V=2/53M'TH;:7VZF]F
M45F)XW5H=3"3+F,)FW\_L4J-4TL192_.LI93VLQF6RKS[E%*$E2<>UVB7998
M6^-P["A!JP#Y^T<<Q'0[,[.WGM3>2+LL%F>:5I2I>\1@2'#J45J0 P(88@2<
MJY>%[K*]H5U6^UUWSJ]AM@L7R6LVXMKTUN(;=4+JWI%NV9/@_53GDV.ZB(RQ
M&CJ$I]J0XS55C1*I#SRPE:N:"Y]Y+4A),E)+@#GT+US3E1]'<,7KZRN38.Y.
M32S2KSVBM$J:K=!:E3)!04A@"D*D*M%%%P'!)- X+'TL^RY]C#M?T14E3N'N
M$(&X?45.KVW960NQO'I\'D2F.^558TATJ2M;86IAZY>89D2AR66VF7?!UM)5
MW_1@@[H6E88K5B$L&@=A5B2*%OW_ !CE&Y5+5M/-F6&YTFZ;JE8Y*$H5O%VF
M6%*2F:294E2$J2 TNI22RB6K>?M0O:\;*>SQQF1C45Z+N+U%W51X^,[95<YA
M)Q]J8CF-DN?R@EQ6.U/*TO1H+K;MM;H2@0("VEJ?1] V9V:F7W-0F9ALEF"N
M>2-X214)'.05))\Y0.H"7))'P6;;I5E+KE&T327Q)F&42"PJFK<YJ4<@C$(\
MBG2ITY=<OM@NHS=/>QQJNC45S=S[;-=R;RO=IL#K[9N$KY(Q;&DM,&393X49
M344549"GX\8M3;I]OO2IW8[;;-738K)+DR)J9=J"!+Q"6LJ6M"0%3"DK( Q$
M$N=<-7 /UGD4Y<=JKAO:T63::4N\MG;':52;!9 N1*W=@3.4F3*"Y<E:U%,M
ME$K(4<U,7)V6Z>=_>I/V0/41D^!9Q@3PH+28PUFF(RXS:1EU0VXN,UDN*7,1
MA:I0::1XL93)2RIGA$EIIQ#K;7GL7Q>MQVJ9* 5:4))=*BB4[94(5D_-+:!N
M!]K;3[&\GG+?<]GGW,J3=5LF(Q"U2D6FU*"SSE!04+*BOF+  9B&!CV3]-75
M1T^=:FTJ,HVWNJK*JB="3!RG$; LKLL?DR&E)E4]]6/@K#:UI=:8?6TJ+-0A
M2HCSC8\OH5AO88;/:I,]4B:O!-9).-,Q8"F< &AH%#FDY/5O!^V&PUKV6M]L
MNJ]9)ER;)-FV:7:6"I=HERUJ0B8D(6L J2 LR\>-(/.#U'G[]IM[$EJ>_==0
M71C#%??PO'O,CVD@*>ANNO,+7)=L<+?;\,(F \J^322TH@!A:#P1Z%V$Y1)4
M@R[-M))-IDEDR+1-F84EV2$3"A"B%<"00K7*/AM];.R9DQ2KJG?29Q+B0$F4
M6!J4JF*2&?CED[4&"O9J^V[R_82YK>GGK'^5K'#Z^P;QN!FMP74Y3@\EAT0U
M1,LC*2Z9%7"4DMNS&GU2(3;94^R4 J&QVSY+C:T3+YN6<E9MF*U"SIERY:0B
M:\Q*,:YX"B H#%A254H#2,"Q;:V>RSI=@FI,Q<DID3L*EO*6@F6L'%* )"DM
MFRB"06+GMI]HO[;[83I7P%JEV8OZ#>/>?+J)JPQ>MQFZ@VU#CT2<T%Q[O)+.
M 9C3(9:7X[58A*ISP00ZAA)[M>:;VFJN!:A>4E4A*9BD'> @D@L[)"BQ+L10
MN[EVCU'R:\GEJV_F(,JT"R6;"%"9@1.).;8%39-&SYVK-K'FFZ2>BSJQ]LWO
MW9[S;RY'D-?M4S<)?RK<JV][%:J&'E.+QC;N))7';6\L)\%?N9,&$@H,EQ+I
M"%<Y)EKM\Q<Z5.Q(F**T<PA(2JJ4N6)-7R[!E'HO;#:+97DSNRS6+9ZS2I=[
M2I")$Q4M4P+F3Y2$HF3E(FRUI2"O$M2L12*(03F/<'T]=./3]T3;1LX/MO1U
M&#8?C%2[87]Y-+$:38)B,%5A=Y);/]A><X2[(>><=*&$J(3V-)''36&R6B6E
M"42BO$H)%4CG')P[O4 /J[1Y$VDVOO7:ZVKM%[VQ4U9 2E+,A* XPI2E*4I/
MI$ $YD9OY/O:U>W>.Y1RKI:Z)97O]%:NR,6RS=^"E<IS(B^^8S]1@;:&G&Y4
M&4X#"<N6WENNK4D16/#=;D+^MW#L79S9Y=IOJ:B9C25"RA"F0DU3BFH4'+#)
ME)#YLY'!6^]DW3:;-.NE:Y,^0L*WH*B5* #L%AL(-0?96-9-HO8G];>1=)SF
M_P!=UT2%ETJ,B[Q_:.XCHB9U<8LEGWAZ?*<D.-I@V;K12JOI9L9F5)X)?5'[
MV"]\KY0+OL87/E[/*^CJDJYRD)QI)!<A.,I<C)3/6E2#'M?DC_\ :(O&SW?9
M+LOTI7+F(1*$Z:E"D@J 2,6&R*(*B:%\A4@,^Z?LVO;!9+TS2JWIRZJ8-F-O
M:.P;QRKR.1!?AY)M\XET,^Y9!7O1VWI%5&6#W.*4W+C\*;2RZA*1K@96T]N5
MNK/,DX%2THEJFXT%9*$A*E-@ &)0=G+/FT=%RG<BDN_I:[]V26+PM5N0;;-D
MH0BRRU*M#SE)Q6FT2P6*V"TI -63I'J9SC">GCK!V;<K<GA8QNOMGG%6F96S
MD-L3(ST:4@*9M*>6$*<CR6@H*;?9+:VW$E!4%I4D?1+CO2];*J5:++:UIFD!
M0W9 2H:A3*(4*L00X/2T>+KVN*;<ELFV2^[&;'-DS"B8B<,92L.&.Z*B"<P0
M^A%&;QM=>/LS>HGV96XT3J/Z;\CR*YVKJ+1FSJ\VHC(:R';Z2XYP*;*HK+RS
M*IG0M+#,]7B5KG*8]@B.7/"5Z?N/:ZY^4"SINBWV63=UN$@(4HE5H$]24,I<
MJ5@EAB05%!62G/S&,?';PNFTW%,5;)4\SY)F*4,*0@(25.D++J;"D@. ]*\Y
MQ'=;[+_VW6!=2:*797J%D5>WN]KC3<.CR&;.BP,6W!D)0E CQG9ABIK\C60D
MBH6IU$M2C[A*DD]@^7;>\F=JN0FT7?:%6RSJ"E%*))0N7J A&]6I:<R0*)%:
MIK'1W%M7(M+2I\O=K!2RU+)"B0QJ$ 5!%>ULR/1 B:%(;(0H^(V%I(Y6D@@$
M<K2"V.X>8Y<'((/D#KY.C>5$Q&[*6#%0)X:=_1TYQVHPJ;"JA[ 'ZV);@SF*
MRGEA'=X?K]]QP/+GT!].>>?3Z-562!1.+.GCT9O[XH=6K['^>DQCW<!YJ/AV
M1394V-7QV:J6MRPG0%6<**R&_G/.0&/WV9'\OWYD?/6!P GC4]F("TN'&; M
MGH"YU-".P%X@M*<:5,6)! +/UNW'5FS=Z1SL$=8DXE1/1YL:P9>KXI:E0H*Z
MZ')264D*BPG25QV2/G(:<(*!\WGRXU6TLM9IAZ"<2L\R6#N,GRK"RIW:0'!8
M#(,*OHYJ.O.IB^ IP #PO@/X:1J&)XCW.?R?^NG2$.YS^3_UTZ0AW.?R?^NG
M2$.YS^3_ -=.D(=SG\G_ *X_JTA$GB+(^Q ^:3R3Y#@'U\O+[H\_ZFG3P@?B
M/?\ /5&D7M!<BL\?Z/\ ?"RK9C]9-^I%Z(S81EI;<0W+EQ6'_ 4E2E^&XRIQ
MI0*05H6KX$ZRKLD_3;3*EE6!U.[/YM>C-N([6C(DR1-4640$C%E6E6+TKDX/
M9E'FL@V,2+$C1V66$LM1FF4-AMKM"$)! *>T!7!\P5A2D_P5#7T'ZK+!X$=3
MOG73,QL]\K]6,O2'R<L^DC*.5\LM?Q4?D1_5J_'*_5^V*[Y7ZI/>/"'RRU]"
M/R-_U:8Y7ZN&_5^J3WCPA\LM?0C\C?\ 5ICE?JX;]7ZI/>/"'RRU]"/R-_U:
M8Y7ZN&_5^J3WCPA\LM?0C\C?]6F.5^KAOU?JD]X\(?++7T(_(W_5ICE?JX;]
M7ZI/>/"'RRU]"/R-_P"T'^@ZH52R"-WF.,-^H5,I-*^<V5=!' FV$:1#E,26
MH3S+C3O<V\TVEL@H5P7"GM(/GYK2I';QR"/A/9U2T2U/+<YYL]&S%1EU^^+R
M1/2[!!.@8YT/CQ/"D>E'V=UQ8WW2!LE.LIC]B]&QM-6B7*=,F6]&@2G(T0O2
M@MTO.):92A;BNU*QVD\=O!^=WP4"W3BE&$*6"SD@$U)\UQ6M>HYQI[0C!,P@
MXF!<LU/D'X :[S]SG\G_ *Z=:^((=SG\G_KITA#N<_D_]=.D(=SG\G_KITA#
MN<_D_P#73I")'%J"%=R.T<>9[@>/N\ >>K5^:8N2'4!TB,.(6_\ MM-M!.3"
M,<<0ZESY,:3BBEF4 4&R(]Y%L1YF*4^%X/+G(\];%*P;$S)=R7)&,<WT:4?7
ML X:J8@_3R74P30,<&>;UJ0S=7;&8D+45'A')!)^R_"/7C@>O\WKK6(-2.E_
MGV1LUH; I]11N+=,5.YS^3_UTZDA$%.+2"I2  !R2IQ( 'TDGR ^[I"*"I+@
M05!L*4D=RBDK4V1YD=B@CN<\N.2E/J3P#QI".LOJK]J'M!L7E:=C=K<?ONI?
MJFN4^[46PVT:6[Z\K)#Y+4>PW"M88DUN!T;3Q29DRY6B4RSW.-P7>TC2*$]N
ME/FG;&MV*= G4CUF7E=N1[2'<!,##FI35KCO1UM59SH6WM,QW^-"1N%E#3L>
M;FU@@%M4R*AB%7B2A22VXWR@H!]>EQ1JZ9:1W'85MKB&VV-U.'[?XQ1X=B](
MTU'K:3'ZZ'608T=EOPTM(9BMMI'<.%+6!WJ6.[NY)Y16+V;86A7=V \$=I*^
M5A(_@E2B>03R?( _#G@>:$<@K6 26^ /CW _S#2$4')*T-J6E"5%/!X*NT$$
M@$<\'SX^Q''F>!\>11Z@$@ O7IIX]O1%%D)22.<0U,LSQKE&GG67O4O;K;,T
M%,\MC,,]=^0Z41Y+2)D!C@.6UEV)=0[X<&+\Q;S))8=D,N'['@Y$B65E2M);
M$Z@EZ!WZRXX1U6R]U_3+6BU3DA4BS'&N4H$"82" G%E0UHYIUD=1[>0W*"&O
MJVW 4$,-H4X<VR#E:T#^%_CI25@\\J;#8/EY#61HV'@XHVO%@6:/IHLE@'_(
M@/\ 6.>K@>(RR:)_JBN4\GZM\^'D>.[-<@*>?N_X^>!]WCR^'GJU20H$-A?5
MD^,458["I) LJ99(8*)46/42Q^3D\=BG0WNW,O8F3;7Y!<R["YH5IN:"9:S'
MYD^?1S%'QFGY<QUZ1(<@OIX \7YK*TD@!0UCKEX&+O6M&^->KM?A\XVHNDV1
M:;1+YR5T9@&)=C51))J_-JVCD#<_-]I-M]TV:^+N'A>.Y@S7O.2:]K(*R+9-
M1'B4I6ZP'D* [P E?84]Z/FJ)\B8BSTRZ?GP]C1R4LJ,I0+"H!3FU2SG++0D
MF@B^8M)$J(,>%7--1(4..Q#B0HC'@18L9E*6FX\=AE*DM,-H2E#82@EI ("N
M  $/"GOC5O=?K,Z=]D,U<V_W(SB?59)%A8Y+L*Z#AN8WT*OC9O=RJ##7+ZZH
M<?L:6J7E&00':*C:LK*(Y96TIBO::<D2F$J&FGSVQ0D4]NM:]'0:5X9Q\"5U
MX]+L/&J?)9&>WZJ^W>S),R%'VSW1D9/B\/;^W729S9YWB,?#WLDV\HL8M?=*
MZ\R#-:C'JBM5)CEV:U[[$+SYR]\4S^2/GH/:#')M.M?9+%G<BBY9E\5R159G
M;8_3Q< I,VW)L["KH<4P?*[K(;2JQ7#YTROI*F-GE)\J7<=NPQBL@V--)FY*
MU(LEQ(SY^>$5#T?M:N6;1BN!U'='W49N3?8+G6/PKBUV^R557A=[F>&6DFAR
MQL8)#W*E66'9-,IOJ=L(3&/+=G*576SXEQ:],I >8<CK<13/1P>U\_EXWHP>
M_P :S;':3)L*FMS<5MZU*Z68PSX$1^OY BOQ6G&X[P8<:2#&<:Y;4SV*2.""
M$5^>$7J8!*DDN\)2VE)2&Q\\I^Q[E**E%('EP23SY]W.D(QKE.QNUF:9!69=
MD^"XK=Y92+8549#9TD.;95_NKGB1_=WWT+4DLJ*RTKU;4KN3P=(:O^_Y'1&3
M8T),8\H5PGSX;2D)0!QP.!Y\<#Z..?C]Q#Y^?GKCG:0AI"&D(Q3F^ZC6&3$0
M1@VX&4*<94[[UB=/5V,1!2#RPMZ;>5I2^?@V4>9]%:H0&+U&OSV=7MBY("BS
M@/Q^>KOCKFZ@.LKJU]TL:#IAZ$-W<RR9QIYF'DNZUGA6%X;7R#\QN8] A95<
MVEQ'0HE:&T.UJO+@I(5QK63YLZJ9,I1-0"6;*I9FI1BYZA'87/8[MYLRWVU$
MI (=,LD*.3@*2ZL+/B"4@G10K'15FWLB?:G>T3W2B9UUN[MXCMQB(>28V-5<
M]W(1CE4IQ*G:ZAQ&$FOI(*UH2$_*#LZ7(6OAR0I]7(.,JSVBTH&]4' PLH\Y
MJN&'- >O377+[>.4/8S92ZK+(V6L@_*>X!M,Z1C6E5HJ"J8+7)6C$0V06*:N
M8[Z>EKH3Z=O9H;;.O;)[.YEN?G<V,W&R?+J./C5GN/ECB$'A4A^]O,9JJVM#
MG/9$K76&6P0XN,Z_WNJVE@L:9*0D$)4HAU%\N(S  >@>KE](^([7;>W]M3.>
M^IZ_HP)$I"94F4E <5(L\F65$ 4)!8Y822(U3ZLM^O;$;OP[';SHYZ2H?3_6
MV33T%6[VZ><8C;9?':E*4TB;CU)5.6]+CKJX[BO&ESHF13(ZE%R#(8=0AU/5
M75^2TVC%>/U@0KS5J4E"L.$IQA*"H^:V$G 1]DG/YS,G6A2E"2@B4YP+S)2Y
M (< @D5- ICGPZXNF3]C69_N)N(=Y/:)[XO9E=3KIS(KS#<%OKVVLLGL)$E4
MZ:G(]R;Q?OZ(=A*=<581J:LK+)T.+8CVS$8AG736_;*39$;NZY6 H#;Q:1NP
M$J ',4C&I)2X%4 <%-6U-B,PO-#@OD:ZU!R%2^1/ Y@>KS:G93;39#;VAVOV
MBQ:AP/!L3K$T^.8]CM<W"KZF$E7<M#2&SXKKDETJD39+SCDF7+4Y+>=7)=<=
M5\^M5NM%MG39\^89LRTK4M:U,,2EFI"4@)2 [)"0D %@ (VB\,V3*DRP)9D2
MT2W34JW: GG&ATXDGC01AKJKZ)-ANL+ 7,0WJQF+</QDNFBRN*@U^3XS*<2
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MFK @$ !Q'G[:2XKEF)GBQ6Z5:9#J$M"Y<T3%2JA+E11B<-7#J'*F!'4/U?\
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MQN]=L4FU"@RD*5/"/F^^<^3@![>2?7STM"<"U.H*J7(#!PPIFX/'WQ2S**T
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M5CCR"5)! Y\^>2GT^GR.SW*L&+FD="JU?3L[->CIY"C(ES9<V3/QS&P%,I6
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*:0AI"&D(:0C_V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>46
<FILENAME>g164680g1027213408166.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g164680g1027213408166.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1"  4 &D# 2(  A$! Q$!_\0
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M\.:MK@T\E;F>U0;%(R..YZ'ZX.,]:J?\+V\._P!AV>K"PU P3W)M9AM3-NX
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M)'14T6\C$S1*1G!4Y"XZ8 7KQ70_M$2S3>'?"<MQ#Y,S^:TD7]QBD>5_ \4
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I#IZ444 2WVDZ;J9C.H:?:7?EYV?:(5DVYZXR..@_*K>T>@_*BB@#_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>47
<FILENAME>g164680g22s22.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g164680g22s22.jpg
M_]C_X  02D9)1@ ! 0(!>0%Y  #_[0_64&AO=&]S:&]P(#,N,  X0DE-! 0
M    #[J^0"8X0DE-! 0      &$< 5H  QLE1QP"   "[.@< E  "')R,C,P
M-S(X' (% $!-:6-R;W-O9G0@5V]R9" M(%)O:79A;G0@(%)E<V%L92!37S$@
M3V-T;V)E<B R-2 R,#(Q(#<P,'!M($-L96%N #A"24T$)0      $)!L'%$,
M7319@<_3R_-/]!$X0DE-!#H      .4    0     0      "W!R:6YT3W5T
M<'5T    !0    !0<W138F]O; $     26YT965N=6T     26YT90    !#
M;')M    #W!R:6YT4VEX=&5E;D)I=&)O;VP     "W!R:6YT97).86UE5$58
M5     $       ]P<FEN=%!R;V]F4V5T=7!/8FIC    # !0 '( ;P!O &8
M( !3 &4 = !U '        IP<F]O9E-E='5P     0    !";'1N96YU;0
M  QB=6EL=&EN4')O;V8    )<')O;V9#35E+ #A"24T$.P     "+0   !
M   !       2<')I;G1/=71P=71/<'1I;VYS    %P    !#<'1N8F]O;
M    0VQB<F)O;VP      %)G<TUB;V]L      !#<FY#8F]O;       0VYT
M0V)O;VP      $QB;'-B;V]L      !.9W1V8F]O;       16UL1&)O;VP
M     $EN=')B;V]L      !"8VMG3V)J8P    $       !21T)#     P
M  !29" @9&]U8D!OX            $=R;B!D;W5B0&_@            0FP@
M(&1O=6) ;^            !"<F1456YT1B-2;'0               !";&0@
M56YT1B-2;'0               !2<VQT56YT1B-0>&Q 5_R;P         IV
M96-T;W)$871A8F]O; $     4&=0<V5N=6T     4&=0<P    !09U!#
M $QE9G15;G1&(U)L=                %1O<"!5;G1&(U)L=
M     %-C;"!5;G1&(U!R8T!9            $&-R;W!7:&5N4')I;G1I;F=B
M;V]L      YC<F]P4F5C=$)O='1O;6QO;F<         #&-R;W!296-T3&5F
M=&QO;F<         #6-R;W!296-T4FEG:'1L;VYG          MC<F]P4F5C
M=%1O<&QO;F<      #A"24T#[0      $ .__C4  @ " [_^-0 "  (X0DE-
M!"8       X             /X   #A"24T$#0      !    '@X0DE-!!D
M      0    >.$))30/S       )           ! #A"24TG$       "@ !
M          (X0DE- _4      $@ +V9F  $ ;&9F  8       $ +V9F  $
MH9F:  8       $ ,@    $ 6@    8       $ -0    $ +0    8
M  $X0DE- _@      '   /____________________________\#Z     #_
M____________________________ ^@     ________________________
M_____P/H     /____________________________\#Z   .$))300(
M   0     0   D    )      #A"24T$'@      !      X0DE-!!H
M S4    &               N   "70         !
M      $              ET    N                      $
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M     0      "6AO<GI!;&EG;F5N=6T    /15-L:6-E2&]R>D%L:6=N
M!V1E9F%U;'0    )=F5R=$%L:6=N96YU;0    ]%4VQI8V5697(
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
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M 0$! 0$! 0$! 0$! 0$! 0$! ?_  !$( "X"70,!$0 "$0$#$0'_Q  >  $
M 04! 0$!            !@0%!P@) P(* ?_$ #D0  $$ 0,!!@8" @$# P4
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MEOOU6S=1U]7)!/?$B]]H;$,=H]CM%8WMC$=]]XGCL#&;;1CXH8MLMX]MLU^
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M))>&EY\G.SPYA7IR8XOBB'.OD\<B9H'5YV-1:4S"K -1MH+4\/C4/=NTWK<
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MZQ@^UODG'N8=\5TX4O@RWJ=*/5R <\?8G1$M8RT(:HX$9 6',[(BZTB;BV#
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M.>UM079"(_\ V!S_ +MSCSI-2R(\>#8BUZ]1\JR5V =H)&(H$$QF+T&/C<;
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MRO+\H(6RL.4<P<E!G.(2&SH6,3NP9>V1^(Y+*P1B!\TB6<SF5^:?+O<GLS^
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M'5\4DNC%/5>EE0XWAGB);AP#V@X:?@.KXI)=&*>J]+*AQO#/$2W#@'M!PT_
M=7Q22Z,4]5Z65#C>&>(EN' /:#AI^ ZOBDET8IZKTLJ'&\,\1+<. >T'#3\!
MU?%)+HQ3U7I94.-X9XB6X< ]H.&GX#J^*271BGJO2RH<;PSQ$MPX![0<-/P'
M5\4DNC%/5>EE0XWAGB);AP#V@X:?@.KXI)=&*>J]+*AQO#/$2W#@'M!PT_ =
M7Q22Z,4]5Z65#C>&>(EN' /:#AI^ ZOBDET8IZKTLJ'&\,\1+<. >T'#3\!U
M?%)+HQ3U7I94.-X9XB6X< ]H.&GX#J^*271BGJO2RH<;PSQ$MPX![0<-/P'5
M\4DNC%/5>EE0XWAGB);AP#V@X:?@.KXI)=&*>J]+*AQO#/$2W#@'M!PT_ =7
MQ22Z,4]5Z65#C>&>(EN' /:#AI^ ZOBDET8IZKTLJ'&\,\1+<. >T'#3\!U?
M%)+HQ3U7I94.-X9XB6X< ]H.&GX#J^*271BGJO2RH<;PSQ$MPX![0<-/P'5\
M4DNC%/5>EE0XWAGB);AP#V@X:WZXW59G3]<[Q+,YC(<LCQ,K]_@-W%;;;/$V
MF&R'VN[\CO\ ^+[?X_4^X_[MLMMOIX_+\<NA\/D/V?)B#.SW)B?-S:R9G-&T
MKG_$Y?\ :,J<IF9CPP#-SL[]T%W8::-S27N^XST@2D$RE+Z#(KGK '6.)E[_
M '.RC#(P/MR-UI$;#;9MTC>#1GM(X[3U<#5%!R#18;C&DW(=0>\)F7!'V7@H
MJ[X9\;WI "36KUQ@[C14P:%_9SFQ1[7)^>EM=3PED68,):V82%IG,:EKN1-1
ML@;$QHTG&&BXQHS^Y(8O"?IW-/3*7,K .X'<7A(_86P@TI09("86!#I97-=Z
M^<3 UQ8D=MB  X&X<6,JYKX-"K B<?D$6%0=6/L 60[$:-;MP[AX/<$]]X/2
M' D9*0"N&O'((=CL@$0)Z/<1AY%RC 2UGUDI0\@:@Y9X=A4AED"VF']'G4FA
MQEYL3BDEFL>D!Z./1P%P'(LU(W']QADI27MO*2G<+X_4]7H] 3$H0P'C&].5
MYQ_P'.WQDXQ4I^JD)4V@4(=M3Q(FB^8A&\VE""CY[@N9,HEE4SI(GBW9[-R*
M(PCB-0->D A>.0XPJ9C9B,&@!N4V-9T].!U(3%YO#88('F9U,I(4;1")1VRI
M^RC4%3=XPH$O+SQ06 :EB"[[(GT7M9O$^B+@DK^5SV)F2!(Z&%1N8L0UBV9#
M8K9$<!N'SD3';9@\+F$>A=M@6/\ *%&:(:RP$J';B2A0)FVS#$W[!P16Z2\-
M.,\P6+.))58THX.!+TCI-=4W*T55Q')3!%*ZFR:C4\AFT5F2".3;!ZSW;OXR
MT>EFD0<@&QDLD]*@D4-X/2*'H=7 EQ-H<O8BEGOXD85D+B8@[&?!4K$LQI61
M:Q8S@-VCUA&Z8:3!"GSD["K!0;\=,2\&>R-L7 @#29+8N"$/F1'.DZ*W4;FU
M4ZRO:<\5:.LB=8V/+XN<?2G(C61A[N.L>S8W&S1BFI9_>*O+R2#QJ9"(1)RD
M*E.R94,1D4>*/4\D&K19==@T;-4GT4H[2=QUACW2479\(N-(]1@JS@QY#(*;
MCAR-8XVM;^24-RBF$J0! ((AG/<D8'!&S&;RP.YK>')@Z^* #S^/%HR^"*8C
M\"*^[<0N...3Q3&KQ>*S^H(K0CISL6DVSM2I86^6(QV(XN]C>SE+!HZ5PR=&
M454Y"728B&QDL0:A!"#(C[^M6MUPLXW/%C[M2"EDG\BDAN7KDV5E6H/+!)-(
MY]G:)HS!RK";-B-<O'M@K/95EO ',:31)E3F39-%$\91?$??[TJL1X?4 @_B
M)':+2==6%N(\_&-GULV^1$F#$3F1.Q(U(I\"?SQR%M&4A)Z8(3,=*K+'RV1M
MI.OB;P*;$6[9PB3]/UTJ?/:(J@A8F5KO(DDM8&2F"N4B_EC^"F^>$6?PO'?^
M/2*X"?\ B,E'POY?L/EWQ7W=;[;ODTG*9%!)?Q#HB:QZFXN4 S40)X^C_P",
MI_\ H5S755Y2%M-HRA#,=FT@K6PHF?*.4XJAD!1?'B95\B.>ED$G.&QHON]-
M351.KI /G12O#CK3^T;E$36BSM^%FLTA=BRS O+9H:)R&;U[M MHE)"A\M(G
MI]T2';UC!E'*BA/=,RN#^X.)DER1=0@16J<\8:BL.T@ET2!O8S&R8]&6<,&G
MX1>=Y5FWWBK(^O*,01&/5O8T4C)L>[.+_>%D308A_-X-V#,SN_8#1[9J3V]_
M77O4#/<$>+\E%RX*8@LE5%S1\-?DVC.X;J$X"-Q,]QM!F/@>8BPV*M8 =["3
M:RU[&ZW4BD?)F!XE<F,=XAQ>#,J"U&ON%X;RZKEF(51]>"P<# *-I;(VE9RY
M6=PM_/;,LRR),+E2H^1"OY-U,; E\FEIW% 9+#P]F/D)LJ+8,GB39DR;HL!V
6#0HLMZ(FB)HB:(FB)HB:(FB)HB__V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>48
<FILENAME>g164680g23s23.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g164680g23s23.jpg
M_]C_X  02D9)1@ ! 0(!>0%Y  #_[1I84&AO=&]S:&]P(#,N,  X0DE-! 0
M    &CR^9Q8X0DE-! 0      &$< 5H  QLE1QP"   "[.@< E  "')R,C,P
M-S(X' (% $!-:6-R;W-O9G0@5V]R9" M(%)O:79A;G0@(%)E<V%L92!37S$@
M3V-T;V)E<B R-2 R,#(Q(#<P,'!M($-L96%N #A"24T$)0      $)!L'%$,
M7319@<_3R_-/]!$X0DE-!#H      .4    0     0      "W!R:6YT3W5T
M<'5T    !0    !0<W138F]O; $     26YT965N=6T     26YT90    !#
M;')M    #W!R:6YT4VEX=&5E;D)I=&)O;VP     "W!R:6YT97).86UE5$58
M5     $       ]P<FEN=%!R;V]F4V5T=7!/8FIC    # !0 '( ;P!O &8
M( !3 &4 = !U '        IP<F]O9E-E='5P     0    !";'1N96YU;0
M  QB=6EL=&EN4')O;V8    )<')O;V9#35E+ #A"24T$.P     "+0   !
M   !       2<')I;G1/=71P=71/<'1I;VYS    %P    !#<'1N8F]O;
M    0VQB<F)O;VP      %)G<TUB;V]L      !#<FY#8F]O;       0VYT
M0V)O;VP      $QB;'-B;V]L      !.9W1V8F]O;       16UL1&)O;VP
M     $EN=')B;V]L      !"8VMG3V)J8P    $       !21T)#     P
M  !29" @9&]U8D!OX            $=R;B!D;W5B0&_@            0FP@
M(&1O=6) ;^            !"<F1456YT1B-2;'0               !";&0@
M56YT1B-2;'0               !2<VQT56YT1B-0>&Q :V            IV
M96-T;W)$871A8F]O; $     4&=0<V5N=6T     4&=0<P    !09U!#
M $QE9G15;G1&(U)L=                %1O<"!5;G1&(U)L=
M     %-C;"!5;G1&(U!R8T!9            $&-R;W!7:&5N4')I;G1I;F=B
M;V]L      YC<F]P4F5C=$)O='1O;6QO;F<         #&-R;W!296-T3&5F
M=&QO;F<         #6-R;W!296-T4FEG:'1L;VYG          MC<F]P4F5C
M=%1O<&QO;F<      #A"24T#[0      $ .__C4  @ " [_^-0 "  (X0DE-
M!"8       X             /X   #A"24T$#0      !    '@X0DE-!!D
M      0    >.$))30/S       )           ! #A"24TG$       "@ !
M          (X0DE- _4      $@ +V9F  $ ;&9F  8       $ +V9F  $
MH9F:  8       $ ,@    $ 6@    8       $ -0    $ +0    8
M  $X0DE- _@      '   /____________________________\#Z     #_
M____________________________ ^@     ________________________
M_____P/H     /____________________________\#Z   .$))300(
M   0     0   D    )      #A"24T$'@      !      X0DE-!!H
M S4    &              #Q   "4P         !
M      $              E,   #Q                      $
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M     0      "6AO<GI!;&EG;F5N=6T    /15-L:6-E2&]R>D%L:6=N
M!V1E9F%U;'0    )=F5R=$%L:6=N96YU;0    ]%4VQI8V5697)T06QI9VX
M   '9&5F875L=     MB9T-O;&]R5'EP965N=6T    115-L:6-E0D=#;VQO
M<E1Y<&4     3F]N90    ET;W!/=71S971L;VYG          IL969T3W5T
M<V5T;&]N9P         ,8F]T=&]M3W5T<V5T;&]N9P         +<FEG:'1/
M=71S971L;VYG       X0DE-!"@       P    "/_         X0DE-!!$
M      $! #A"24T$%       !     0X0DE-! P     #[P    !    H
M $$   '@  !YX   #Z  &  !_]C_[0 ,061O8F5?0TT  O_N  Y!9&]B90!D
M@     '_VP"$  P(" @)" P)"0P1"PH+$14/# P/%1@3$Q43$Q@1# P,# P,
M$0P,# P,# P,# P,# P,# P,# P,# P,# P,# P!#0L+#0X-$ X.$!0.#@X4
M% X.#@X4$0P,# P,$1$,# P,# P1# P,# P,# P,# P,# P,# P,# P,# P,
M# P,#/_  !$( $$ H ,!(@ "$0$#$0'_W0 $  K_Q $_   !!0$! 0$! 0
M       #  $"! 4&!P@)"@L!  $% 0$! 0$!          $  @,$!08'" D*
M"Q   00! P($ @4'!@@% PPS 0 "$0,$(1(Q!4%181,B<8$R!A21H;%"(R05
M4L%B,S1R@M%#!R624_#A\6-S-1:BLH,F1)-49$7"HW0V%])5XF7RLX3#TW7C
M\T8GE*2%M)7$U.3TI;7%U>7U5F9VAI:FML;6YO8W1U=G=X>7I[?'U^?W$0 "
M @$"! 0#! 4&!P<&!34!  (1 R$Q$@1!46%Q(A,%,H&1%*&Q0B/!4M'P,R1B
MX7*"DD-3%6-S-/$E!A:BLH,')C7"TD235*,79$55-G1EXO*SA,/3=>/S1I2D
MA;25Q-3D]*6UQ=7E]59F=H:6IK;&UN;V)S='5V=WAY>GM\?_V@ , P$  A$#
M$0 _ *?7?K+]8J>N]2IIZED5U595K*ZVN #6M<0UC?;^:J/_ #J^LW_EKD_Y
MX_\ (KO<_P"H/0,O.R<NY^4+<BU]M@;:T-W..YVQOI'VH'_C<?5S]_+_ .W6
M_P#I%)3Q/_.KZS?^6F3_ )P_\BM?$ROK3D?5[)ZK^U<SUV;[,2H/;%E6.6#-
M=M</5>[](_T?2_[B7^I_@UO_ /C<?5S]_+_[=;_Z14+_ *C_ %9Q!5;?E9U6
MV:J'"Z7#<'N=54*J'O;O;ZN]K$E.6\?66EUXM^L&19Z'J,BH.'Z:F_%Q+ZG;
MV?S7Z_5MO9_Z*4OLWUQLR#53URYI-NUK'EQ#:W6WXU3CD^FVNVYOV2UUM+&^
MI_Z+T1]5/JLVVMK>IYOJ9 !86Y/TA?&W=8VG8W[7L;_.N_3[%9KZ!]7\CIV+
M@T]0R#C9+G7XKF6L;9::7.N?;Z_H^H[T;+/4>_Z:2GG;K/K955?9_P X+'FI
MEUM3&[B;&4549MQW;=E#_0RV>RS_  JQO^=7UF_\M<G_ #A_Y%=O5]2/J]F5
M#*JS<[(KR YXM^TAP?O]EKMSJO=ZFS9;_43?^-Q]7/W\O_MUO_I%)3Q/_.KZ
MS?\ EID_YP_\BI5?6GZS&ZL'JF207L!&X<%S?Y*[3_QN/JY^_E_]NM_](IV_
MXNOJZU[7!^7+7!P_2MY!G_0I*>(S>N==9G93&]3S&M;?:UK1D6@ ![PUH]Z#
M^W^O_P#EIF_^Q%O_ )-=_=_B\^KMM]MKGY>ZQ[GNBUL2
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
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M 0$! 0$! 0$!_\  $0@ :@$% P$1  (1 0,1 ?_$ !X  0 !!0 # 0
M       ' 04&" D#! H"_\0 9Q    8! @("!Q$(# H&"P   0(#! 4&!P 1
M"!()(1,4%189,908(D%14U9889&2DY;1T]36X5)55W&!E:'5"A<:(R0F,C4V
M=)>Q)2<T5'.SM+;#\"E%1X6BP3A#1$AB8V1W@H3Q_\0 '0$! 0 !!0$!
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M1!%%H0SA39,!-IEGF<ND^C?OW0H<O&2?0=/3[ 9G+.+;?^EOZ7BK7QKC^H9
MJV799>C5N^.5<?8H>R*<='6&*1E>UGJ*G*Y26C2+ W=*BGVN=<H@@=0NPZ5H
M=%==1]-(4X*3Z:YGJ'I(TX1'D?TTG3+3$\ZJL8@Z?V1C'DEWD&VPZNK*,XU5
M,54GSED4PKH-U$]SIJ*D*!P_D[[Z \ KT_S,"D_&1V_43'AK735=,G<!<$J9
M5["HTDG,.\+%8@7>BUE&2/9WD<Y!$YA;O6R&RBS=8$U2$Y1,0-P 5:_FJ[1]
M!A0_&3ITC?0?SSZ=(CU]^R".E BGKJ-DK_5X^08N%6KUB\Q\S;.FKE XIK(.
M$%71%45DE"F(HF<I3%, @( (:E:_FK[1]!B$4R*T=O?'J?NACI,OPE4[XBQ_
MTS2HX+[>^)E\='4>^'[H8Z3+\)5.^(L?],TJ."^WOAE\='4>^'[H8Z3+\)5.
M^(L?],TJ."^WOAE\='4>^*?NA;I,NO;)=. 1]'O%8"/N]N"/_/IZM:G174:=
M0,/\:.HQFG%#TN72"2V)N$[(L5Q"62EV#(./\A/+6E2VD9#Q<H]@<L6JO1KQ
M1DLU>\BZ42P:M3'(J!3]B PEYA,(Y1D @D!2Z [TFF= 1F1OU]A&E8=+STE'
MLN<I#Z'4ZA@V'TNN(_NZM(RP,G1Y0H:&I!!\U (KX7GI*/9<93\JA?U1I$V;
M7RCVZX>%YZ2CV7&4_*H7]4:0V;7RCVZX>%YZ2CV7&4_*H7]4:0V;7RCVZX\B
M/2X])<Z71;-N+;*RJ[A9-!!)->%.HJJL<$TDR%[D")CG.8I2E -Q,(!MUZT\
M2L_%/10'+Z8Q 2*T<K3<:9]''/HCI_9[5TN%/Q]-S,_TD,1'Y?K6-D\N6#AW
M=7" :Y+C:*HS0D>WUBN(=.+/)=H.$'181)R>44*H4A$!./*%-00"K6H'BC6E
M::[XOB'*A'$A9)'H.77$78RS5TR^4^$C)G&#7^+V^$H>-)%PT6@'3N,"T61G
M&K1K><F:^S"%Y7D;!.)5NC)*D$>P&(L)A#D-M:*^-_\ $1B2DBHQCC4TTUT^
MGT1GV&\K=)GD_!.+\\VCI3(;#<%F&VV2E4*%R+*ILY6;GJS(IQCMHW,UKRC8
MQE7"R/8@YP'D5*)MNO916F+7]$0%*:$UT\<@=8)^O36-5LO\=/2J8'X@IKAY
MRCQHW6MV"NV1K 3%E5E(9Q66C9YV!1">[<;PYS*11FCA)V8Y %0J0B EYBB&
MJ*[S7T4B*!)! *4[R%$]II3+VKE&XN;LC](QA+"$)G:2Z7:FV2M72%L$OC:/
M@9@3R.135E9)K*L*P*];(BY=(.UDFQ@4,0I55"@([;ZAJ,\5!YA[&*!PJHC/
M4Y[QH?-GZ8Y9^%XZ2?V7.4Q]OMJ%#?\ )W'ZM4:#?EKQC/9M[WL!WIK6G14F
MIAX7GI*/9<93\JA?U1JPV;7RCVZX>%YZ2CV7&4_*H7]4:0V;7RCVZX>%YZ2C
MV7&4_*H7]4:0V;7RCVZX>%YZ2CV7&4_*H7]4:0V;?E_H[X^OS]C\\2^=^);A
M:R9<,[9,L62[-$Y>=P<=+V([0[IG$DKL0Z(Q1%HU:I]A*X765ZR"83G,(FVT
MB&@R"@JF\;_I\\?*[T[(_P#2?\1OCV[8H^_4/C[Q:X/I>D C^+\FM(G,*H:
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MW(X0X0HXF=Z+2K=-NZXOC*&:-;I0WR=78+V1@TFW20H&>(H Q650(114Q3E
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MHFBS',)4R!SJ*&.HJ?F44.90YA%X$7G&?O3,;SELC3CBHZ:4TSI33=$Y]*U
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MY7[TV-?F\5W+/M:Y5D6?8=F2%H-.WFYXV_:*IIE3BF)53#U'%I*0E)# (4L
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M?T_+I4]'4.Z&,<#V=\.4?NQ_3\NE3T=0[H8QP/9WPY1^[']/RZ5/1U#NAC'
M]G?%0 0'81$=PW]P0]/?Q[_\^@^%D:;SI^BK@1 J!!RK2E:Y=^^D?=/^QA__
M $-\OAZ6='G^ZL&/I^V/H!KP/E3%+;DAEE9S8R%/[5P\3Q^F.SV538*H*>/7
MK2.W+/CYXPCI$,&Y*M_%OE6?@H>/<Q<@M7S-EUK)7&*ANPUR*04YFSZ5;N4^
M51(X!V1$@FVW*!BB!A^4+QW%O;:UKS<_9MA3\Y)OX'&IAIA:FUT0VA0"@D@X
M2#YZ:#,C],.1#W07(Y<SDSN[=R\U_;"L>VK.;G$3MGS<S@F9<NS\R^WC1A-
MMMU*M?@D*X1I+YF7,7K?B_C=4OUWK@OZ,[^#_=FT^/Y.Y]B/6/NJ_<^_\4+L
M_MG_ &Q4.&;,8>*OQ?QNJ7I@/W[]K3^C2_?]V;3_ &=W[$/NJ_<^_P#%"[/[
M9_VQD51P)F&LVBOV%2L1KHD'+Q\H9N6XT]$5P9.4UQ2!4TR<$Q4 @E XD-R[
M[[#ML.YE>3B_;$RP^;KVHH,NMNX0PYGLUA5*X"!7#2I!IG0'2.-MKW37N?[6
MLBTK,3RJW895/R4U*)>YVE8;7,L.,I644&()VF(C&BM*5SJ-P&%CR@EG[,64
MY+$K)]3,W0,Y4;7429)J#:5;P,ZV:HK=SITCX4T7[=9HDLFL9@8AP R1DP 1
M,'8&[JWY%J6E.+N?:ZF+28<EGV$M+!2TX %8'BT %^*#4MJ J,LH\>F>4WD(
M5<&Z%UY;EKNJQ;ER;2D[6LNU7$ER4=M"3=><0B8DDO''+J;?*5@/X@HI4%>+
MA.<P]_M$%+PE;C\(+(X9KV(KOB5G GRM2UK:JWO2O;$S.+SIUNU^VSK@ )-D
MXTK= F_( AK>-W8OBR\U+-W*MI-FMV=-2*&MFHN@32E*=6I\, *UPI& 82"0
MK.@X*:O]R.3DE.6E,\N]S%7SGKXV+>MZ>0RI-D!5BM);EI$2>V#@2G"5J=+Q
M6XHA!&$5-WBLFV:OXM6Q[ 8.?1)7N*Y#&CQLRRQCYO7EG"XD%&VNHY) KM_-
MK"0IGIW,@8O6IV 2<_,.:;M7P:L\RC-R;;;*I!V27A;*4**U>+,%(0ES:C55
M7,).:4H!H-I,WWY(IZ]3-XK0Y>+D3@8O7*7D:=>9FG)Y#+:\;UF-/&=+,O+(
MJ4L[.5*J %050).JN;Z]F;*V3ZWDF'HL?6W5;K%$@VC5>^4Z0$7E)9-VJ;\3
MEE&@<CI9N58$12$4BCR"JH/GAX&U+CWZGIYF=;NI:K:F&95 ;YNMPE4HC"%?
M 0#C(K@J"/@E1K6/5KB\MWN?[JW4M*[<[RMW7M)JTY^W)MQYAXL$,VV\MU4M
ML]HZ26DK+>U2Y59\8-H^#$\W:4;WA:VY"E>%^%?YMN]?&&FIV7RA39.F-951
M@C'.K9&U=9P!D)A9% JB":CTZ#1Q^_)=8<H\O-W2O1,&9G%W#M<6E.-!I;JV
MR6$K+>!QT,[)1"E )4G"L%"@#B(,= L/E2Y-+#;LJ[LK[HV[35R+#M!4Y(2,
MHVXS;#TJ)EV;9L>:M OG%*-N.E#BDMI6XR"FB30C*H?B$XDZ=,XLC:+BVG0V
M+\<5Z'K:]2?SV-929F692&3M2J-G65!]%JV1-5<#E:%[&@8X&%-41-S:S=B\
MH<JN21*7/M!$G*L-,&65*AQQ;:/QN%_8(+>W22%'"NA()"J9\5.6Y[F>V9.]
MDU;G+38TW>F\=HS5H,6I+6I/RLE*OE>TLQ#EFMS#K#Z;-4ELI#JOOH;IB:R*
M<46R5G2KQ>/(K$./^\5I0,DW:ZILE<G5!['2T#;9(CLE5D6J+]DFX;-6G9F"
MBRG.*J:G9$DT5"@.M$W<O[+-R;=G72MJ51+3TQ-X"VZXEQ+RPL,.A*&\2 FJ
M,\MXPFL<HU?;W.]K3=X9V^7*_=&WG;=NY9-BEYMG83<G/V4TM"+28<*W @K6
M6ED!(I@\92\P8PNSW/XR^3&^'JBPQOCW*KDTE9*4M;L>SI"R3YHFC+]HR2RZ
M+EJQ<K@HHV;H]C[62.5,%#B05!X^9NAR@EV;%GW6M62E9]>TF)54KM4%Q22'
M,#BV<:0H^,$@@)T WGMEA<K'N<T25V5WPY6+KW@O!=5HRUG6NQ/35GI,LTXL
MR>UE6G]BX\RT4MNN.I<#JD%1"<6&,.R#4\LW?#F&\6IT!BP6Q6G82+2Y[W3E
MTY?NX\!T44V@2:)FG:Y0Y1YUU^?K,')XM;6<N+?J9LZS9(W4M-"I#;C&EEQ0
M<VRE*!"<"<% <SB54@4I6.:NWRZ\@EAWSOG>A7*]==]N]:K-4B4#V!R4-GRR
M9?"70XL/[3#B!#; 2-RLJ:_^9FS'ML->B]]]_P"EU1'T/:FO'Z?7X]_'X]<1
M_1G?L?[LVG^SN?1@K3A'?_NJO<_ 9\J%VAT&<&(><4,4\S+F+UOQ?QNJ7Z[T
M_HTOW_=FT_V=W[$/NJ_<^_\ %"[/[9_VP\S-F+< [WHSKWZ^^^H[;^@&W=O?
M^_5_HSOU_=FU/V5S/H^#%/NJO<^@$GE1NQ05SYX#G33('VSC53I%^%'-EK@>
M%A&'@8%12#QE=V<D1W?:)&BDX<Y4M#U$J8R5B:@Z(=LNF<56_94B'$4CG*J4
MQ0^O.0U?@G=-^R[PMNV;/F?<?,L\TO:I0M/BXTX1A*DA*DU.8--T?FU[I*\M
MB<H7*C:MY;G6C*V]8DS)64W+VA(KVLNZMF09;>2A82*EMQ*D'(Z$T%33F.'!
M)Q$;CO7*GX^K_&CC'ZW#^G;Y/:O"FPOEO[I<>!&R9XZ2ZAT@G/S<!%?,2<0_
MK<J?]J.,OK;IX4V%\M_=+[HGO1/^05#S$G$/ZW*G_:CC+ZVZ>%-A?+?W2^Z'
MO1/^05#S$G$/ZW*G_:CC+ZVZ>%-A?+?W2^Z'O1/^05#S$G$/ZW*G_:CC'ZVZ
M>%-A?+?W2^Z'O1/^05 ."7B' 0'O;J?4(#L.4L8;#L.^W]+_ $?R>T.^VL3>
MJP]TXH:$$-D&H-=X4.L&N8RUBILJ?20=@K(C6OFW".H]DSGQF6G U%P'(<,G
M"D2#QC6FU?QY:$;+1PM].=MA14"T0<D;))T&=G4<H$=JRQ&_9CNA,J/GA#;J
M;:+MMVC,VB+;M NS;N.8;\0M/(H06G$J942@@D#"442<-*91R*F[14T&3*-X
M10@*J2DBE%)HD44!45S&9RC DLW=+,7#\MB!UE29DD)2YQ%S3N\AQ!55Q>XE
M6&9E9MH6*FS9"W:PBG*5PNT!(1.X#G!0OB#<;.XW/43J0PG PXR)<2U&5;1>
M/&X@(\=:34 @I%":@FAC#96L4*06W58EXL1..@H $@810"E<S0UT%*QA69;)
MTDN?,&5/ 66;&TN57JUHE;8>5G\VTN5L-B?20I&0;V%X^OKA*091"B798E(R
M!3-%#J& YA-K=2+]S;.GG;0E'$,/.LM-%+3*FVD;(4*VVTC"DN:J!!%1PRC%
MR6M-UM""PLA*JDJ&:M.@'+SZ91I5YB3B'];E3_M1QE];M<Z;U6$23ST9DG)E
M8&9^GB=YJ:#2-HJRI]1KS=0Z.[*'F).(?UN5/^U'&7UMU/"FPOEO[I?=&/O1
M/^05#S$G$/ZW*G_:CC+ZVZ>%-A?+?W2^Z'O1/^05#S$G$/ZW*G_:CC+ZVZ>%
M-A?+?W2^Z'O1/^05#S$G$/ZW*G_:CC+ZVZ>%-A?+?W2^Z'O1/^05%!X(^(@?
M%6ZH([#XLHXQZM^OUW>UIX56$-)RIPJ--DYP\QXQDFR9X5!85G3=70Y_SC[.
M_P!CG8FNV)>$[*L'>6,>PDGV9W<BV1CK!7["D+0:S"H <[J DY)JD<5$C_O*
MJQ%N78XDY3%$?%^4:T92T+7E795W:(1));4K"I/C!Q:J>,."AYHYVSV'9=E2
M'DE"RJN$\*99]GHC3?I+'3E'C,R\1)PNF0J]=$I"+*%( ][$./\ )*8 \9A-
MMXA'Q@("(#]3<CS32N3VP2IM"B4SE2I(45?AC^9)J<@ !0B@&4?F7[H)]]'*
MO>9*7G$H2J2PH2M24@F3E@31)&I45$:%6H(J#H?W0??YVX^%/\NO3=@P=6&C
M_A_G'C/.ICR[OKJ[X=T'W^=N/A3_ "Z;"7\@UZO\X<ZF/+N^NKOC/L:U=QD2
MU-*RXN\+32NTESDFK3(.VD051(G,1LJLV364!5P;E20 2["<P (@ CKB;9G6
MK(D79M%F/SZFZ5EY)I#CY23FL)40 E"<2E$$4!!I'-W>LYVWK3:L]VVI6R4N
MI72:M%]QJ6QA)*&U+34A3BAA3XI%2:D5K$S9VX:;5@IS'Q,KD2I6RT2#Q@V)
M4JC)2DG/-T)-D+YB]4:=JHB=NNB*1$A(8YSJ.$2E+L(ZZ_=B^$A>9+S[-CSL
MA),H=5S^>;;:E5K9<0VXC:5 *T5)6*B@SQ4H([;?7D^M.YCDO*3%O6;:5H3#
MS;0LZSYI^:G&$/,;=MXMI2VK"04I2D%17M $B@-8WIF&,OWR[-,>0U8L[6U/
M63Z33CYAK+1*J<9'M%';E^L1VDFHFUY$E"D5[$8AU3)HE,94Y0/R]HW@N_9=
MGN6I,S4FJ2;?2P79=;3X#KB@&T!2"?'4224FA%#4T3'7[)NK>FV[7:L.3D+3
M:M)]M^80Q,JF6"EB69VCC[C;BA@;72N*AIB" ,0J<2/2\CD1DWA*S<EF4(Y<
MLI9\C$3:S"/<,U!2<D>NR-S(-C(J$/V4JZB1DP  .7FZ@WR9ZR MI*IFSTKF
M$-K:96\P'74/4V9;02I2L9(PFA.M,5*QQ7O5;Z4S3XD[3V,H^6)ITM33C+#S
M2MFZ7W$)(0EMT+*U+P!"*5KFHY5>L66S'[/&DA.S#8K7*-7C[;#+)/G0E8Q<
MBZ,V2&0#SH)*(B45%B%*8 3 1 1$>4-E9EL2-JNVPW+2I2NQ)YZSYEM2$$N/
MM)QT:\2M%$A*<68.M,XY2V;NVM835WGYR;JS>*09M.64W,N(V4L^\II*E$')
M22BJB 0,S2F0GZ?X/9R#QPAE-3.6+7M6?K/&,0JSGI8ZTQ,L&W;3F%8 +(AE
M) I1[&"9A3*)QVYA#<==5E;_ ,G-6S[R)NU:[4XA#;CN.692&&'%[,3#@SPL
M$FH77Q10E,=XG>2RT9&[B;R&^-@.V<ZIYJ65+STPI4S,LI4ZY+- #$N80T E
M2<8Q+!HH X1XV_!ED@U?:.)"_P!#A;O(U8USC<8RMJ.TMSN [5.^34%)7E:-
M7J[1$ZZ#!=P58Q-N82;ZR5RAV.F<<:;LBTIBSF)T6>_;#,HE4DB:V@;( 11:
MFPM02IT8DUUKE&+?)1;YD6W7K=L>5M9^S/?AF[[]J*;M-^2+2G4JP*"6VW5H
M25H96M2RD$5J8K4.#*\6JK8^L#C*N/*V\R>D8U.KMAL,DQEI57M\\:FV3!-N
MJB"JSPH))@)_/"<OC$VL9_E#LR2G;4E!85J3;=D$\_FI25:>9:1@#I6 7$K*
M4MG$JB:IH:[HME<D]LVG9UAS[MY;&D';P'#9DE-6C-,S4PK;F72A.$[,*6[X
MB$*4JN1*CB &N2N/[#%Y-?8KML^SJ4Q%V)[6IJ1F)!PG$0[^/551<J/': .#
M@V!5$Q"G33'F$R?5Z.NX)M*2>L9%N2,FY/LORK,W*LLLCG+[;M%("$*J"LH4
M%45AH*::QT V+/2]XG[N6K:*;.F92?7(3C\T^M$O+/-.;)S&^7'?O86#0H0=
M02#G$YY@X6)_#E,BKC,Y@Q[-(V")0G:S$PDW)+R=@B7"HH$?QJ2C-(JC<#AN
M<RBI!Y2B(!OX^M7?OM)W@M"8L^7N_:<LN4==EIUZ9EFTL2C[:2K9/+&/"X2#
M1(2<ZYC..Y7MY-K0NE9,O:T]>JQYM$]*(F[.EI6==6_-L.' AYI(2"INM"5*
M(J#DD9"-1AD'VX[/'&V_5^_*#^D3"(_E'7?0PP=66B>.$9]5!U;H\NYS,;IA
MTC<0XLCM->N*=T'W^=N/A3_+IL)?R#7JPYS,>7=]=7? 'STPE SMSMS%'J64
M ?'Z @8!T+#(SV39IG0I%*C,5\QSB"8F*C[^Z/&3HM0KF,CGF#H1O!(UCGCT
MM\E))1O!SV*0?)<^';Z<W8W;A/F-^W'< YC<B@;CMYWK\0  !U:^7K^(;\,K
M<.!.?O<*!- *6>P<@*4J5$JIKE6/U(]S"M2N2.R%E1*C:%K9DE61GGB$U422
M$CQ4U)(2 *DYQQK[LRX?]:R7I#N_=C_QO[M=2V:/BB/H3&KCV#NBO=J7^^DC
MY<[^>TV:/BB&-7'L'=#NU+_?21\N=_/:;-'Q1#&KCV#NAW:E_OI(^7._GM-F
MCXHAC5Q[!W0[M2_WTD?+G?SVFS1\40QJX]@[H!,RX_\ 6DEZ/B?._0Z_16]W
M]'7H4( )PC+VWPQJX_1W1L7PJ8%R1Q6YNI^':?,/F 3CH7-FL[U\[+$4RI,!
M*O/6B9<'6!)LRC&?,)15.4%W:C9J0XJ+E#6UFYAB3EUON(2<*:I0"0I9) "4
MZU4=,LAF1I!:RG,UH*Y"E2<)(TID:'*ARS-(Z_P_0WL/V^.*FJ2V7<N3>&^&
MNSTVD)3N.JQWV9 NECN[<CADHTAR+(L&</'-3=TGSHZ1Q%H8B9 *L8#&X7W[
M)9DU)E&@]-!Q>S4M6%"&RK(J(&:@$T43AKB\4%,:6W5@00BJUBM%+PI%#GI0
M[QGG3/T<2\YU8<39AR)C:"N,]9XBG6:1A8^=D6<O7'\BU:G $UGT'(J)O8UX
M4INQ.6RY"B59,YB!V,Q=<[+*#[#3RVT(4XA*RA)Q8"0*I*@ %9Z9:<<XUL1P
MI4*44 :A06#YCG3?T\=T13W:E_OI(^7._GM:^S1\41,:N/8.Z'=J7^^DCY<[
M^>TV:/BB&-7'L'=#NU+_ 'TD?+G?SVFS1\40QJX]@[H=VI?[Z2/ESOY[39H^
M*(8U<>P=T.[4O]])'RYW\]ILT?%$,:N/8.Z*A,RX@;:4D=P*.W\.=#U^,/&J
M.V^WM:A0@5\1.:5:CS=\4$D@DZ$99#7*NXFGUFHC[Y_V*VX<.N"C,QW3A=R<
MN?GQ2G<*G6,4H5&O[% RAC"!?1VWVW$1\8Z\\O: +0:H /P=.0 'YROY=4<3
M.DEQ%?BG_P"ZHBSI*8Z0<<9>6U46+U9)1Q7>55)LL=,VU8B>HIB)& 0 2\@[
M"(@(;#L;<-?8G(_,,(Y/K"0MQI"@B;)"W4)4DF;?6$E)H %)WT)&4?EE[H&5
MFG.5>\BT2SY0I<D X&G A=)"762@A+@-%IP5"@*[A6HT3[C2OWLD/)'/S&O2
M^=RHU?EQ_P PWW1XUS&<^2/_ *MW^##N-*_>R0#_ /4<_,_+^+3G<KN?ESYI
MAONAS&<^2O\ ZMW^#'NQD7)HR,<HI&ORD(_:**&,S<B!")KD,8PB*1.4  .L
M=A$/&&WHZ;\S+*9>2EUA16RZ -JVNI+:J98@DFIRKB&N6H.K+2DVB8EE&5>&
M"89<5]Y<)#2'$[17C(;("4GQB/&%04TI6.J+O)6.2\>,9?'\HU6J"M(BX-A<
M>T5Y&*@+&MCPD2PDSE*V6*)XR9%(BBIB\C50AE#"04Q,7Q!NR;6/)@JS66'$
MSR;1<F'I NH;?FI)-HK?>0 %I4H.H .'$"H @5TCZ5<MJPCRTIMIUUIRS'['
MEY9BU3*K?DY&?-CJEY>;K@<"%,3)(6XH!*,"%4!3B$VTS*\%1KC@>N6_,$7<
MKRT#+*-HR>T566CXB!L\(Y3J\))SY4A;N$#2J*#D$E')Q9* F!@2W !ZY:5B
MS%HV?>><LZ[\Q9]EK38BI.QE(0T[,34H^A4W,LRNTJDEM2DD@??$BM":QVZR
M+QRUCVE<R2M2\LO:MM-^$IM2\:,;LM+2D_)EJSY69M)2$H6TJ:&VP*42R%I!
MH<X]S$=LH-*I2K&<RU$V5:6BLPQUL[M69X=N6QRZTH$:G$5M(H,'C.5$Q'"<
MXY36(8X@8CDHJE#6-N2=IVC:@=E;&=E$,O6"NST2TBWC7+,<V6ZZ_.I6"RME
M.,+810I(*"/%I&5U[0L2R;(+,[>)BU%S,M>QBU3-VFZ64STP9Q$IS.SDM+8F
M&)PJ0X9M6T"JA8<-0J.<_%-,1MHK'#>RKC@TLM5<-QL%.H1[=1<T;*(R#@QF
M*^Q![&X3((&Y>H1*)=NH0UZW<IE<E/7O>G$F73.WA<F97;+0DS#*VV\+K9"P
M5!)422K?05-*1X/RDS#%I6?<%,CM9HV9=26DYUJ5ERI3$QSAVC"P?&0XDD*3
M@!*L@0<XN%DLT6;@QPW3VBQG5LKV:;;8).OD0<=T&T4LP1[5>+H CSD0<J%Y
M$U!+LH;<H;@)A#;2DH\.4*\-H*0E%G3=W9"59G%+:#2WD$AUIHE9&- !*@0:
MA.>L;NT)UO\ HENE9C(6[:MG7KM&>F;/4R\F81*!I*6G7&VVTC X4 @)!"U&
MA"L2J['Y.I&#LXVXO$58<SMZW /L<,S3M#C2/4,@,[?$UD(M.!B&!T2+&9+2
M"#7F4*W%L9$S@1/V,X#KJ-CVG>*[EG*NK+6 J>FVK87S>T)@H-ENV>].;=4P
M_,EQ2 X&W"<!% I*/$J*1WF\-B71OI:OAS/7I;LZSWKNM&:LB42XBW6+7E;,
M<8;LZ6E%,HHPX^VRNH(!074J)3G&<8TXEJ30X+A-ITM&5R:KR%;F8JW33JO$
M?6K&TP\F7O<:=:2 MCK,%XU0[9\= P=C%(!6ZC)D$.+M>Z%I6G-WWM)EV;EI
MU4VS,24LW-I;D;7ET-I#\JML.)2\ET8T)S)(.21F(YV[W*!8]C2?)G94U*2D
MS((DIB6M*:>LYN8M2P)IR8<,E-(F<-&5R_WM]:2E=4@J-5"IT9RC+TN.#*]3
MD::.2L@2UPFGL1G%*2E%U7K9Y*&>MY$&:'-'KF7;;D4[* G RQNR% Q=A]+L
M5F?>584ZS:;=D62Q(LLOW<++2<"FV5-*;"U*+J$MN  )2K"2FM0%$'QJ\+]E
M,(O+9LW9!MZWIFTYIZ4O@A^:=+J''MNT\E*,;:L>%6+:U4DKJ<M+EQ13D9;*
M3PNQ]=<#*NZMA&/A+"BR17.I$2Z,BHH>/>@"?[TN!!YC)F\]RB @/CVPN4P[
M(VE?5V<PRS,[>*8FY-Q;J 7VE(-5)3B*<!41AX@U-*QK<I<RW:UE\G4M(XGW
M[-N?+RMH(ET/*7*3;+^-;3R5-E-30ZBN0(-*1I\$1*;!O%/A-Z/\#>!_P0#W
M!_)KO_.I<$A4PP/,^R!7HUZH\J3*3:AG*/5.9JV\/_RI%.XTK][)#R1S\SJ\
M\E?E$O\ M+7=%YC.?)'_ -6[_!@>(E +N6,?E,'6&S-UM^/<4A#J\8 .WY>K
M><[EOE#&_,3#1SI4#*F_7(BASRK$5)SB02)1X$ T)0Z$C+)1*FPGQ=:$@&@!
MK6D<\>EM@)QS'<'7:L-+..Q8?OI%!1C7BH$-^W#<# 4_(B(D,8I@,!3" ["!
M@\Z.OE^_CK:KYVZ4N)*:R!J%H+0',&4T2M(\;-)SQ&E-./ZB^YC0IKDCL=*@
MH'GUJ&BT*0K.;60H@^+12B:99C(:QQN"K6;T:[-_FB1ZO<;]>NJ;9K>XT/,X
MD_7[4UCZ!C]=Z]E];LW^:)+Z/IMFO*M^NGOA#O7LOK=F_P T27T?3;->5;]=
M/?"'>O9?6[-_FB2^CZ;9KRK?KI[X0[U[+ZW9O\T27T?3;->5;]=/?" 5>R[_
M -'9S\D1);_[/J%UJGXUOA\-.AUT/" -,XWQX&N+W('!;+9![GX/J^3(++$=
M7:Y<&=^JLL_,UKT/-%EG"$4JW2370[=7*@JZ3!3L:YF+0JA#E+RZXVT91J>0
MD":"%- J;+:Q4*R&\T(H37$,XBT!Q)"E82#4*Z2,.FFASJ#77=2.QTKTKF$\
MMY;XF*S=*)D["N$\QRV*;Q"7/"L++P]X&X8O*T4Y9\O:8F>-I])L2+<;)%(5
M$"F4#8A1UP@LEYIIA;3B)MYI#S0;?<1AP.T\9()I][HH@9T"\@(VZF"D(HM+
MB@E2:D).$*ID*BF8KG2N6\:<)>-?*<AQ.\4N8<XP-!G:]!7NS'?0\8K$OA>$
MCFK)K&M7,BHFU*561>I,RNWJH% 3KK'$>O<==BD$(E)1B74\TI2$44K&G(UK
MA J!D,O2<SK&X2,*$H  "1N%,\\SZ2>N-6N]>R^MV;_-$E]'UO-LUY5OUT]\
M6'>O9?6[-_FB2^CZ;9KRK?KI[X0[U[+ZW9O\T27T?3;->5;]=/?"'>O9?6[-
M_FB2^CZ;9KRK?KI[X0[U[+ZW9O\ -$E]'TVS7E6_73WPBAJO9MO.UV;W'J'_
M  1)>+\K?V@U"ZUN<:.XU<3H==\4$C0T_P CZ>,??#^Q7F#^/X*,R)2#)VQ5
M/GU^<B;QLLV4.GWI0  <I%B$$Q!$! #% 0'80W$=>=WK5BM!LA25#FZ:%*@H
M?#7J1OTCC)^FT;I3\6*YUSQ*UX'HX4.^/IX?P4(\>++NX>*=+GY>=9S'M%U3
M[%Y0YE%43'-L!0 -S#L   =0!K@T3$PVRA+;[S:05T2AU:4C(Z!*@!' N2<H
MZXMQV5EG%J0C$MQAI:S2E*J4DDTH-3N'"/5[V:WZWX3\U,/H^L>>SGRN9_7N
M_;C#F$C\BE/V9G[$.]FMCXZ_"#_W2P^CZ<]G/E<S^O=^W#F$C\BE/V9G[$.]
MFM\Q?XOPG6;8?\%,.L-AZO\ )_%K-,W-E*ZS4P:)RJ\X:9C3QHAD)&J?P*4S
M6D'\&9TKI\"*][-;_>_XO0?680'_  2PZPZ^H?X/U^,?'J"<F\2OPJ9_%I/X
M]W6FOPM8U%R$A0?@4I\,C\F9T\?+X$4"L5OS@=[T'L)A 0[DL-A#8.H0[7ZP
M]K6/.YO"H\ZF*@I(.V<R.(9_"@;/D L4D9,>*O269'YB^".@=0X17O9K>P_Q
M?A/& ?S2P\6P]7^3ZS5-S6 ?A,Q\$_VSGQ#^E&/O?(5<_ I3A^3,Z>+E\#3H
MTC\'K5< P;5^$#=38=HI@&X;&ZAV0\6LDS<UA/X3,?F?VSG%'Z48)D9+'^1R
MN863^#LYGQ\SXD?@*U7-P'O?A-]R=?<IAOXM_'V#T^O\>M,3<UB6.<S%,)--
MLY2M59_"AS"1V2#S*4K]ZSYNS7X1WX(\XUFM\F_>]![[AU]R6&_\K;Q]K[^+
MJ_%K6YW-5'X3,?G?VSGQ5?I= ZHHD)'#^12FB3^3LZXDY_ Z3UF/P2LUL=MZ
M_"#Y\WCBF ^(X@'_ +/Z =6M)N;FJ)'.9B@34??G-:G/X6O3 R$C3\BE-4_[
M,SQ'Z$!K%;$1WKT&.QC;;Q+ =NL0_P W]+JUD)N;J/PF8^!7\<YJ3F?A:G?%
M19\@=9*4-%.TK+,FGWH_H0-6:WR&'O?A-]RAOW)8;[=?5OVOJHFYJI'.9BF$
M&FV<UP'/X4'9"1 !$E* E2@2)9FI%3E\#2*][-;#Q5^##_NEA]'U@J<FQAI-
M3(\4?V[OVHJI"1J?P*4U/^S,_8AWLUSUOPGYJ8?1]8\]G/E<S^O=^W$YA(_(
MI3]F9^Q#O9KGK?A/S4P^CZS1.39)K-3)R\N[Q'Z4.82/R*4_9F?L1Z[RIU9V
M5J#JM0#D$43D1!Q#1RP)$,J90Q$P4;&[&4QS&.8I=@$YC&$-Q$1TENNJJM3C
MBE$IJHK45'Q!J2:G0;]T;UA"&4I;90EIL))#;:0A )422$I 2"3F:#,QZ/>-
M2O6?5OB_$_1-8;5WRKGKJ[XUZGB>LP[QJ3ZSZM\7XGZ)IMG?*N>NKOA4\3UF
M'>-2?6?5OB_$_1--L[Y5SUU=\*GB>LP[QJ3ZSZM\7XGZ)IMG?*N>NKOA4\3U
MF'>-2?6?5OB_$_1--L[Y5SUU=\*GB>LP[QJ3ZSZM\7XGZ)JAUVOXUS0_GJX'
MIA4\3UF'>-2?6?5OB_$_1-3:N^4<]=7?"IXGK,> :/2_._Q0J_7OO_@")_\
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F45#)MDDR&.(  "82B;8 #?8 UIJ4I1JI14>*B2>LP))U)/GC_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>49
<FILENAME>g164680g24s24.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g164680g24s24.jpg
M_]C_X  02D9)1@ ! 0(!>0%Y  #_[1H^4&AO=&]S:&]P(#,N,  X0DE-! 0
M    &B*^9I X0DE-! 0      &$< 5H  QLE1QP"   "[.@< E  "')R,C,P
M-S(X' (% $!-:6-R;W-O9G0@5V]R9" M(%)O:79A;G0@(%)E<V%L92!37S$@
M3V-T;V)E<B R-2 R,#(Q(#<P,'!M($-L96%N #A"24T$)0      $)!L'%$,
M7319@<_3R_-/]!$X0DE-!#H      .4    0     0      "W!R:6YT3W5T
M<'5T    !0    !0<W138F]O; $     26YT965N=6T     26YT90    !#
M;')M    #W!R:6YT4VEX=&5E;D)I=&)O;VP     "W!R:6YT97).86UE5$58
M5     $       ]P<FEN=%!R;V]F4V5T=7!/8FIC    # !0 '( ;P!O &8
M( !3 &4 = !U '        IP<F]O9E-E='5P     0    !";'1N96YU;0
M  QB=6EL=&EN4')O;V8    )<')O;V9#35E+ #A"24T$.P     "+0   !
M   !       2<')I;G1/=71P=71/<'1I;VYS    %P    !#<'1N8F]O;
M    0VQB<F)O;VP      %)G<TUB;V]L      !#<FY#8F]O;       0VYT
M0V)O;VP      $QB;'-B;V]L      !.9W1V8F]O;       16UL1&)O;VP
M     $EN=')B;V]L      !"8VMG3V)J8P    $       !21T)#     P
M  !29" @9&]U8D!OX            $=R;B!D;W5B0&_@            0FP@
M(&1O=6) ;^            !"<F1456YT1B-2;'0               !";&0@
M56YT1B-2;'0               !2<VQT56YT1B-0>&Q 5_R;P         IV
M96-T;W)$871A8F]O; $     4&=0<V5N=6T     4&=0<P    !09U!#
M $QE9G15;G1&(U)L=                %1O<"!5;G1&(U)L=
M     %-C;"!5;G1&(U!R8T!9            $&-R;W!7:&5N4')I;G1I;F=B
M;V]L      YC<F]P4F5C=$)O='1O;6QO;F<         #&-R;W!296-T3&5F
M=&QO;F<         #6-R;W!296-T4FEG:'1L;VYG          MC<F]P4F5C
M=%1O<&QO;F<      #A"24T#[0      $ .__C4  @ " [_^-0 "  (X0DE-
M!"8       X             /X   #A"24T$#0      !    '@X0DE-!!D
M      0    >.$))30/S       )           ! #A"24TG$       "@ !
M          (X0DE- _4      $@ +V9F  $ ;&9F  8       $ +V9F  $
MH9F:  8       $ ,@    $ 6@    8       $ -0    $ +0    8
M  $X0DE- _@      '   /____________________________\#Z     #_
M____________________________ ^@     ________________________
M_____P/H     /____________________________\#Z   .$))300(
M   0     0   D    )      #A"24T$'@      !      X0DE-!!H
M S4    &              %@   "70         !
M      $              ET   %@                      $
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M     0      "6AO<GI!;&EG;F5N=6T    /15-L:6-E2&]R>D%L:6=N
M!V1E9F%U;'0    )=F5R=$%L:6=N96YU;0    ]%4VQI8V5697)T06QI9VX
M   '9&5F875L=     MB9T-O;&]R5'EP965N=6T    115-L:6-E0D=#;VQO
M<E1Y<&4     3F]N90    ET;W!/=71S971L;VYG          IL969T3W5T
M<V5T;&]N9P         ,8F]T=&]M3W5T<V5T;&]N9P         +<FEG:'1/
M=71S971L;VYG       X0DE-!"@       P    "/_         X0DE-!!$
M      $! #A"24T$%       !     0X0DE-! P     #Z(    !    H
M %T   '@  "N8   #X8 &  !_]C_[0 ,061O8F5?0TT  O_N  Y!9&]B90!D
M@     '_VP"$  P(" @)" P)"0P1"PH+$14/# P/%1@3$Q43$Q@1# P,# P,
M$0P,# P,# P,# P,# P,# P,# P,# P,# P,# P!#0L+#0X-$ X.$!0.#@X4
M% X.#@X4$0P,# P,$1$,# P,# P1# P,# P,# P,# P,# P,# P,# P,# P,
M# P,#/_  !$( %T H ,!(@ "$0$#$0'_W0 $  K_Q $_   !!0$! 0$! 0
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M-9:7L9N?#^\VZ2YH\5JWY%>/67T
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
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M6')V@;&TM;:WUM@D)28R<Z&RN,$90E-7D]'2U-4*)S4V4O$T1V)T=;/A_\0
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MJ)H(7TS:AX$;1$)HHWM8^5KBX;)MA\72UO4^&<OM'0;3TT.TK<VCG3?D'/\
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M,RYQ\V*XI7*<?1^EC[42+&?],^:3;5]LJO['^F?_ & ;-&,K4X]HDJK,%O\
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MFHK#O7;9-55LIXZB8N/O%\K*6G:ZYL&Q,#0+&_)#2T].?T$+(K0Q0#8&R!#
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MZO[8KR[)NK;0:%6-:E(#C8L&0&]=.(3+Z'F!7M6DH1&T.BS0<*S&-"8G:R;
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MS^F?\CT\_4WY5OV*=^]8=_YA>0=CO\?/_2JOD5]473^A)>4T.R]"L(YQ::K
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M)EX,TT<VDDH@^^V88ZHLV\(GA$\(GA%\CWN+_KM)G^._@/\ S-S?S]3=D_\
M*QG\'Q_^9B:\>QK]L7?O^&_RZ1?68Z< UY(V?LY,Q+4:L]NPEUUSOM$"L%E,
M,DUTU_7?:.""3;&F/UVVQC7'PSGS\LKV%1[QOM_+?8&FQW_D5M%M]6D-W72'
M0!LEA(3",,%CD!DI=@K6ZPN1:R6LX8& (TI"QFO9#XD!.$(E(LTMEOJU#0GV
MJZ6!15JVLR'HP>/3QUBL21B<,K713&%R10:3L&9H:X*'Y_JF'EBACZ2$$0Q[
MD4<O_8W@M79")GO7^> .6$E>A 4;6I1.U/GMI;@"K#@K1BIC3";$97GPR0<:
M"69G,F::!QS; DXB(L#HC6L.^A^Q[4IK!%5F$7)39FF61*+2)>7SX0J&>5A'
M.O,6;;131;[;;SB$1?/KIO\ )G.=?"G$^ ^OW'JL1/6\!6<-9 \KM#]U5XNA
M\UG7D<NORKH%E&OTW<$)E0C5%](<V6KB;$],D&B91N\Q+)0-6&A.<:BQ[P.N
MO@@ X97&O=\?Q[R55-=S'\.IBE/-(O3>,%_SFOB33OLR#GUNKZ6A.UR_*>2T
M_4T%EBZB2TU]9G[8_*)XR;<C@,38A J2UGWY?#/[_-9$F^>68/GKKJ3G<@D\
MSF3>PU1#]7Z%1;-K3L6.PJB_8/G3B]M5U>B#<J^P+C*2X1@-QL(*N*JG6F5Z
MN*3^?I%<3-(>YBY[7ZPO9MD]8U>/#B>N2Q^X^_SS/?<G.ZE7I$?,M(XY%%HO
M32^YZ9#M61:%=X;E<$O1OR"\X.75Y+T=K8:#4]=J1OT2!HJ;+E*"!$.QT''@
M:*T>P;^O'KR5.?&UNX>'(\]=5#%=:>ORRW)]*RBZRW=ONAR'DEDL(4<M.<BU
M+NU"-&=F6I[6'B19./7>]=081@R$NMK4_=W.2:,ZW(PCW?IE?/+U0?+SU%CS
M.AS)X9W7.T8\M8]-;!UQ?W-;;0+$Q&8O:TWJECUM5(WHWKV#<3XW![NU.3Z.
M155OKZ\<.1) NK%EOQR*P=*?FZB+"?"]NN/.WJ-05 '.-O1MEQA,=0S[^GHN
M[S<2&N)[,G,VF6">N:]??'1-?1,W54+5D<)B99O#P&&:[HVLEBK* FOWWZ-<
MC?#Z?/ZI<ZZV&>G.^?#7GDME7'2::72MR:'"W'KLUVZGO]N[6'IF S[;J%PQ
M;Q]U+(, Y<+#;OSR-:*4&/+"LU%QG3X?';8BE+PB?X/Z_P#%X11\[O$(%\J_
M--%-BD976K76R!V19^SF5"$&F$59:QW8?FC71EL?(;<T>JN(*O.Q99))MS_H
M##S?$BJ+3^B1(U?K/V'KMQG88 ]-.Q]&Z!>72]2*5F':7ULLUA9RKJDC4+]-
M8=-B-H $B2'>32*& <6<K;'U2?!4SY7T+J?LDM]2Z9R:K6WG'$;G^'WT$$SV
M>/8:U.[1:,A^"*;$'R3G;2(*X*K(##&HEJ/4+,O&KXII\MA4H;6 G7_GD)R)
M[K]75T)N-",CH3?,'.^7Q^*SGF7%.3\<Y;4;<*O%*MT/X:=L7VCL]^.CL/3G
MJ49)3&!6+;TIYC9T0HA(A^[C4Y.%KB?2&.%6K6@"C#06W77Q*Q<;[7"X-@-,
M[Y#CQ&1\N*=I]FN2\UI=^&>6Q!@UA^&3'=:L)'8$LQ-R#W7WR$ *JIEYK"V6
M$MGG7:4'=%6F8<X\<LD1.^\>T>"R N0.9 'V^.GRU47=;[;[/]C4^T>O&^ )
MZ[SRX_ADT]^NZ;W:PN*3# U:0]ZVW7#\\7)&72"\2JVCO"Z&TUWGA&Y220EA
M]B$4H_.8+@6Y 6[\N7IQ[N"7RMR=F"",_AD?'ADHK]SO47O/8I/>AMT%SQ)G
M;3_P_.2Q1/J)ZWHP'JQPL:]\,;!T?HE@[XHZ,)C;"ED)*>]<CJF*/,8DE:DC
M!A4OG//ARMSOQORY:ZH"1EG;:O:^N@TM:Y&5S?+*QT6#]<X)[M<HNOO:SH?M
M55T:M=ZC^K^ @>RINF6#F9"N1CV-2X72F=&ZSUVPUMI$:+8I5A59O!2PAZZU
M'+7[C0X@E?#3+E].C946-KCB00#GH,P.%M1P)OP&65]][1[<4N7W:TZ_^&TA
MZV)*K]2(FMT];.G56[@=1D$L$'Y6?-5;K7:1U B%9G8<<=7BN6B6KF#DQ98F
MUR&.TS50 $#W@+WOK86&1RN;&]AJ=?/K>M>ZHQEF]VH8?PV?;NR.1>P>B+)P
MMGXI7QBKGL$[Y:0$K;,@G3/!K!?J%*%7QX);!I-NV ^25<&640*U-O#[62P
M!NW._',:YD >[?A<D<2;7MR+Y[S#DV#W%!#_  _O= PP+W)](W; NN\O8JW;
MO:/^QFVB ?9":JS G,&$,O[/*ASG6K?:UUXF616(PV,@:W^7ID;'Y\?(H #;
M,"]SF=+ VYZVR&1STS%_UT3\3_TN%(]BEML+[VEL6/Q /4G#6EVNL]#I-BKC
M)=#ZT:L9RE;=I7\J5"&6GV>%LDV)S-)D $T9,Q7R*#=A('K8'G?^G(:^F6P;
MC*]PZPM?]4D>-[Z$]UM%EAON%ZO=A-[.51Z'W3L@P/XI'K /&37:7:S JW<1
M:_Z]IL6C<D]LDA!KNI"VR)Q@,RRDD:G!?)7I0"89XY<\CU]?AWY+&UL\LQ?Q
MX>9O<]V?@NGO'M-R.INRCU?KLT7KI_Q>T<=B<=[M7*^.+QND#T!+L[N-('Z_
M>,NVMD$QO"QKV$25*EG'E*P/84YD>PDMURTMRY7XZ'.R6(N#E<!PXW&O"^>9
M.>@ROE88=6?Q%*8*\Y]BA<QXR&<3^+-W*FL K%WOF6I[AG::=VI5'=85W$UG
M:79A\D3X&+4F95).Q8@J%JLUK T!/AF7><^/CKG\,^&65E -;W&0(L+ZVUS%
MAF/>L?UADNRJ?M7[>74SA =*J,.Y&GXG/M=3-U5.]9N[M, 5HP#VF+G.:=%[
M6PX91QC5^CUW$2?@+(RG[<5PZ5QDH'U&/>'Q]/QXY<%D0!Z BQ&I/',FU@;9
M _JW&=SMN_#WIGL)1>#/T_LQT 'I'1R.]^Q#>!ZO?06. .JL^PVV>OH\LQZ/
MSV'>17%]?3:"&MB#08DUT!A7 ?:HU-Z^RAMP%LAZV%SYFY5Y?"B>$3PB>$3P
MB_$G^IR?[C;_ -G/A%\DGX0G]W2!_O/Z9_R/3S]3?E6_8IW[UAW_ )A>0=CO
M\?/_ $JKY%?0-^(@@4/O4#K^CA;37$2I<E>!+^B8WQ1YG"NQJ2$TEGFTSI&"
MN!9?;GQMS9AE:,T41VV+&6KRY]/RRO8 2-"1X9*9?6,3(/K=P +;2N1R!\5Y
M<+MI3M@=ZG'M%2$6F=*QNL-9K)$&ORXPHW7L6 .P&!\B&E09TFW*'4VR' :V
M4Y^$7C;]V?\ !G_B\(JL<GL8%8]?V+IJ@?VD$6X=Y^X0UJN&VINU@CZYTF65
M<,D!'GV+R;!!N'IH1K&+++-"//-IJ1\<E3]!\!]%AO?.FU(:B\TL)_$JU<12
MC6YR"G]A0R5=TN:I:D6V75VGHF]0L4^W0;%F/%:K*@4(?)Y\NX8Y>^F,XRX^
M'C\#_53N/A;KY*$#.[^M64C70CTU.DJ^(J:0RE(YMQZ.MRM'.6I*%8QF*?1+
MA6%6AB=BV.1I]M!3+)]S4)9\/Y9 ,/GGES (ZS^* \O/YV(.O#GKF,BIT5W^
ME&VWUI<K_7Y,AGMDO34-:+L*9(HZ=R^N+T=@=DL*]75:=L1$CM1%<!"?JE;Q
M8Q63V"O2/%?U9-H8B?+JWPOQX+N>Q] K;%KRG67E].LLS)HY+K3GN""S4_5%
M:4=@H02I+5@V_-[%8OVVLDS[9]6!P5(TA\5%8EPS9C6[L597N^6:QOFW5G![
MVCFJ. (Z)06E7Z<<"5 J?[= K3,2S<X7W9%M2JW09M@(K-U6SF3N)X64>K=;
M1"[VPB(AW@V"9]<_'\$MWCAEEWWS!(RMXFXR4.6?JL@K#<RR>K'$&O0$<-GF
MJ2Z4@B6S6@S-^[*BGTH1#+E,?S[:M*R1:+:6S9(EBT/JL1Y[:(EG!BU,[<._
M+3.W0O8Y9CA#EKRRMG?CI?777.XY&ZS!9V@1J9QO73U>K@5Z82=O+' ?@$I)
M:1;?NSI+$'5+!MSHP,QE<3YB&76R4I49%<QEWJRVMC<*8.8AUMG;OM>V6=K\
M=1GW$J\?/F$3:ATEI$B@K$3*I5T^*M#1ZQCUZ,M0$1HD'CU&"UC@58DU!BTU
M#$UTT@TQ@:#&,1ZE!H.&0RY+,/"J>$3PB>$3PB>$3PB>$3PB>$6$6._)*Q9J
M%5&,+>1GT=HZ35V<!28<LC8(JZQM)D3AB/IL*HUD3J6,X<AV\49DHL@T&VT^
M=(]B*EBWH(93[U2MO6[#6I[=DGV<GALA*F&O@C+:NI>BLB=)-I3AT8XE=6!9
M:$2'QQDXAW(VTS_J.CE\?0IUXK5]1?=XV_N_P^&?/):+4ZC?O7CV[6+^K6BW
MVUJ@L+.N,J"%.!R7A'W/-.F=Z:0,T<226$Z@+@QVS(@^H2V>*NRDF2_@;"_G
MPX9BUQ?\0KLV:X&XL3H,N/$7:+7UN;Z 6N17OUTXZUO5;]%NH=CFI(E90>@O
ML*,_Z[[@):^<A!1Z/N-+H&= ]8#8JPE7H:^*Y7J0WMJ(ICBSS%&VEK#;E<2
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MIR!(6/J'](A2NETW#B**3?")X1/")X1?(][B_P"NTF?X[^ _\S<W\_4W9/\
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MK]2XW6%1TP](PST?-%K3C=6#4B-?R)3/66+'L=CB99(-2#V(JT*X<AX WM]
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ME')("$FDTR7N+'-]7,>N,ZZ_IG?;77;XXW</J)**KIZ^.(R^Q3PU!!V@R[)
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MPQLHC.W=[3OTS)FU!VF,:XFY9(8Q#&>XXV+U.L73FW))VKH=.OJQ5ROBYN_
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M_="L_2Z/4+8RHJL\F4;>S<G2:?M.IJ+ZH63]H-PN5TP9DO*YYCCQR]<['O\
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M_J<G^XV_]G/A%\DGX0G]W2!_O/Z9_P CT\_4WY5OV*=^]8=_YA>0=CO\?/\
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M>.0<\6Y5)FMR836V.)E7SHT:O:C55+%?RISK#/:"CA25A9L>14:I/E/ C#,
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M/=UR)#NMJC5&DH5G6'1AGLT"F\$36]*M;5QM7XI]CGZ=>2<>'QUTU[M<K@Z
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M6<:ZO,![G[@T&TY9+(*8 VM%=EUJR^>P3ID>O-=3)R<+R1&L#>V9+*CP1]4
M0?[JVD7EUQZZR336V1U.FG#/(:#4'7Q/HWN?36VSC==\F_Y/[O*I6.%'';+-
MD&,;\MWFF;P]/M0\Y$F^\DNQ:#EFC&P1Y^7:OOOM#(99Y;+4ZW^OGRMR4!)R
M XWO8C+0ZZG+AGD+VT,O)_8-U8/V>-MJ1\]&7^VKFC NJ.8);@E ZY0X^S5'
MHZ891[HJ*"%WWE-K]NJ%O9! %XA=Q.&\P@HMTUL? 'J_')4&]\CK8'GSU\_0
M]RYRFP\,Z:?0E[/6KNFX'LYU )8BM ""=\,\S%?]V&95MH7\S?JH2Y]V#4'
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M/?&]DD;W1R1N:]CV.+7L>TAS7L<TAS7-< 6N!!! (((4<UKVN8]H<UP+7-<
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M3/GF?PVGG)C!<[,<;0V.)@-F1L:P9-"]:I*6&BIH:2G8&0P1MC8WC8:N<?\
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MNG2)2.=!2)+"6N(.-ECB-@'^1>R(S"#.15427S\2^&QUH=]Q+A1U3.ZJB2V
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ML<$3'/EED9%'&T>\^21P8QC1_P SG$- YE=B][6,<][@UC&E[G'0-:"XN/<
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MTTTM/.QT4\$CX9HW6VHY(W%CV.L2+M<"#8D7"[2.1DL;)8W!T<C&R,<-',>
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M#I9"B$83]GY@HH!8ROD#D$Q/F&7474;0;>;[7 FWT]Q<[9VVS55FL,$(T44
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M86T8V+UUJIY6[N7<L#LGO^2) C,I_K7V:QA.G=IK4<KP,>I3ZOJA:%U=*"U
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MB/&(K+9:,O2KERW8-.L1CBK8%*M?O@2,!2'II@Z0XG3.F<:$:Q?)'H\3?Q0
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M%N,=SFV3OX@(%(\[QS9FE4597P!%P5"S-&PA%F5QF13.\(TNQ1>90HI<-.Y
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MTS\NVLFF-<Z[:YSC./ESC]/TR13]X1/")_7^O\_^#PB>$3PB>$3PB>$3^O\
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!V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>50
<FILENAME>g164680g25s25.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g164680g25s25.jpg
M_]C_X  02D9)1@ ! 0(!>0%Y  #_[13J4&AO=&]S:&]P(#,N,  X0DE-! 0
M    %,Z^4R8X0DE-! 0      &$< 5H  QLE1QP"   "[.@< E  "')R,C,P
M-S(X' (% $!-:6-R;W-O9G0@5V]R9" M(%)O:79A;G0@(%)E<V%L92!37S$@
M3V-T;V)E<B R-2 R,#(Q(#<P,'!M($-L96%N #A"24T$)0      $)!L'%$,
M7319@<_3R_-/]!$X0DE-!#H      .4    0     0      "W!R:6YT3W5T
M<'5T    !0    !0<W138F]O; $     26YT965N=6T     26YT90    !#
M;')M    #W!R:6YT4VEX=&5E;D)I=&)O;VP     "W!R:6YT97).86UE5$58
M5     $       ]P<FEN=%!R;V]F4V5T=7!/8FIC    # !0 '( ;P!O &8
M( !3 &4 = !U '        IP<F]O9E-E='5P     0    !";'1N96YU;0
M  QB=6EL=&EN4')O;V8    )<')O;V9#35E+ #A"24T$.P     "+0   !
M   !       2<')I;G1/=71P=71/<'1I;VYS    %P    !#<'1N8F]O;
M    0VQB<F)O;VP      %)G<TUB;V]L      !#<FY#8F]O;       0VYT
M0V)O;VP      $QB;'-B;V]L      !.9W1V8F]O;       16UL1&)O;VP
M     $EN=')B;V]L      !"8VMG3V)J8P    $       !21T)#     P
M  !29" @9&]U8D!OX            $=R;B!D;W5B0&_@            0FP@
M(&1O=6) ;^            !"<F1456YT1B-2;'0               !";&0@
M56YT1B-2;'0               !2<VQT56YT1B-0>&Q 5T            IV
M96-T;W)$871A8F]O; $     4&=0<V5N=6T     4&=0<P    !09U!#
M $QE9G15;G1&(U)L=                %1O<"!5;G1&(U)L=
M     %-C;"!5;G1&(U!R8T!9            $&-R;W!7:&5N4')I;G1I;F=B
M;V]L      YC<F]P4F5C=$)O='1O;6QO;F<         #&-R;W!296-T3&5F
M=&QO;F<         #6-R;W!296-T4FEG:'1L;VYG          MC<F]P4F5C
M=%1O<&QO;F<      #A"24T#[0      $ .__C4  @ " [_^-0 "  (X0DE-
M!"8       X             /X   #A"24T$#0      !    '@X0DE-!!D
M      0    >.$))30/S       )           ! #A"24TG$       "@ !
M          (X0DE- _0      !( -0    $ +0    8       $X0DE- _<
M     !P  /____________________________\#Z   .$))300(       0
M     0   D    )      #A"24T$'@      !      X0DE-!!H      S4
M   &              #4   !I0         !
M  $              :4   #4                      $
M            $     $       !N=6QL     @    9B;W5N9'-/8FIC
M 0       %)C=#$    $     %1O<"!L;VYG          !,969T;&]N9P
M        0G1O;6QO;F<   #4     %)G:'1L;VYG   !I0    9S;&EC97-6
M;$QS     4]B:F,    !       %<VQI8V4    2    !W-L:6-E241L;VYG
M          =G<F]U<$E$;&]N9P         &;W)I9VEN96YU;0    Q%4VQI
M8V5/<FEG:6X    -875T;T=E;F5R871E9     !4>7!E96YU;0    I%4VQI
M8V54>7!E     $EM9R     &8F]U;F1S3V)J8P    $       !28W0Q
M!     !4;W @;&]N9P          3&5F=&QO;F<          $)T;VUL;VYG
M    U     !29VAT;&]N9P   :4    #=7)L5$585     $       !N=6QL
M5$585     $       !-<V=E5$585     $       9A;'1486=415A4
M 0      #F-E;&Q497AT27-(5$U,8F]O; $    (8V5L;%1E>'1415A4
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M971L;VYG       X0DE-!"@       P    "/_         X0DE-!!$
M  $! #A"24T$%       !     (X0DE-! P     "M<    !    H    %$
M  '@  "7X   "KL &  !_]C_[0 ,061O8F5?0TT  ?_N  Y!9&]B90!D@
M  '_VP"$  P(" @)" P)"0P1"PH+$14/# P/%1@3$Q43$Q@1# P,# P,$0P,
M# P,# P,# P,# P,# P,# P,# P,# P,# P!#0L+#0X-$ X.$!0.#@X4% X.
M#@X4$0P,# P,$1$,# P,# P1# P,# P,# P,# P,# P,# P,# P,# P,# P,
M#/_  !$( %$ H ,!(@ "$0$#$0'_W0 $  K_Q $_   !!0$! 0$! 0
M   #  $"! 4&!P@)"@L!  $% 0$! 0$!          $  @,$!08'" D*"Q
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M /2LCIF%?C48KJ]E&
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
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M>WZ<\Y^%%$TDSJJG(DDF0RBBBABD33(0!,<YSF$"E(4H"8QC" % !$1  S]
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M_4-JGXCC)#,8QC&1:=;7Y)_GA^Y\N7^"0S4=Z-0?T5#H]>0>73;O?V_]8<H
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MQPJYN KRR[>84VISMREU-@%BI.K79Q#K*/%!<M55AI"3)MZD0RAQ>G'PB8I
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M 'A$0 W;VAXA#VAG)"R=3_R_4XX>_3^FK9OS>?\ 5?GQ\9.J!V_8WX?=^_\
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M5)+QB1R91/L0+PRNEM.3K(8V;U-K.8CA?Q$J+"5H=6D&0RE?3!*!DA:NXI9
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?N5;.[U@ % "E       /(   [  ![@ /(,\XQG__V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>51
<FILENAME>g164680g26s26.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g164680g26s26.jpg
M_]C_X  02D9)1@ ! 0(!>0%Y  #_[1/.4&AO=&]S:&]P(#,N,  X0DE-! 0
M    $[*^4$(X0DE-! 0      &$< 5H  QLE1QP"   "[.@< E  "')R,C,P
M-S(X' (% $!-:6-R;W-O9G0@5V]R9" M(%)O:79A;G0@(%)E<V%L92!37S$@
M3V-T;V)E<B R-2 R,#(Q(#<P,'!M($-L96%N #A"24T$)0      $)!L'%$,
M7319@<_3R_-/]!$X0DE-!#H      .4    0     0      "W!R:6YT3W5T
M<'5T    !0    !0<W138F]O; $     26YT965N=6T     26YT90    !#
M;')M    #W!R:6YT4VEX=&5E;D)I=&)O;VP     "W!R:6YT97).86UE5$58
M5     $       ]P<FEN=%!R;V]F4V5T=7!/8FIC    # !0 '( ;P!O &8
M( !3 &4 = !U '        IP<F]O9E-E='5P     0    !";'1N96YU;0
M  QB=6EL=&EN4')O;V8    )<')O;V9#35E+ #A"24T$.P     "+0   !
M   !       2<')I;G1/=71P=71/<'1I;VYS    %P    !#<'1N8F]O;
M    0VQB<F)O;VP      %)G<TUB;V]L      !#<FY#8F]O;       0VYT
M0V)O;VP      $QB;'-B;V]L      !.9W1V8F]O;       16UL1&)O;VP
M     $EN=')B;V]L      !"8VMG3V)J8P    $       !21T)#     P
M  !29" @9&]U8D!OX            $=R;B!D;W5B0&_@            0FP@
M(&1O=6) ;^            !"<F1456YT1B-2;'0               !";&0@
M56YT1B-2;'0               !2<VQT56YT1B-0>&Q 5T            IV
M96-T;W)$871A8F]O; $     4&=0<V5N=6T     4&=0<P    !09U!#
M $QE9G15;G1&(U)L=                %1O<"!5;G1&(U)L=
M     %-C;"!5;G1&(U!R8T!9            $&-R;W!7:&5N4')I;G1I;F=B
M;V]L      YC<F]P4F5C=$)O='1O;6QO;F<         #&-R;W!296-T3&5F
M=&QO;F<         #6-R;W!296-T4FEG:'1L;VYG          MC<F]P4F5C
M=%1O<&QO;F<      #A"24T#[0      $ .__C4  @ " [_^-0 "  (X0DE-
M!"8       X             /X   #A"24T$#0      !    '@X0DE-!!D
M      0    >.$))30/S       )           ! #A"24TG$       "@ !
M          (X0DE- _0      !( -0    $ +0    8       $X0DE- _<
M     !P  /____________________________\#Z   .$))300(       0
M     0   D    )      #A"24T$'@      !      X0DE-!!H      S4
M   &              #4   !I0         !
M  $              :4   #4                      $
M            $     $       !N=6QL     @    9B;W5N9'-/8FIC
M 0       %)C=#$    $     %1O<"!L;VYG          !,969T;&]N9P
M        0G1O;6QO;F<   #4     %)G:'1L;VYG   !I0    9S;&EC97-6
M;$QS     4]B:F,    !       %<VQI8V4    2    !W-L:6-E241L;VYG
M          =G<F]U<$E$;&]N9P         &;W)I9VEN96YU;0    Q%4VQI
M8V5/<FEG:6X    -875T;T=E;F5R871E9     !4>7!E96YU;0    I%4VQI
M8V54>7!E     $EM9R     &8F]U;F1S3V)J8P    $       !28W0Q
M!     !4;W @;&]N9P          3&5F=&QO;F<          $)T;VUL;VYG
M    U     !29VAT;&]N9P   :4    #=7)L5$585     $       !N=6QL
M5$585     $       !-<V=E5$585     $       9A;'1486=415A4
M 0      #F-E;&Q497AT27-(5$U,8F]O; $    (8V5L;%1E>'1415A4
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M971L;VYG       X0DE-!"@       P    "/_         X0DE-!!$
M  $! #A"24T$%       !     (X0DE-! P     ";P    !    H    %$
M  '@  "7X   ":  &  !_]C_[0 ,061O8F5?0TT  ?_N  Y!9&]B90!D@
M  '_VP"$  P(" @)" P)"0P1"PH+$14/# P/%1@3$Q43$Q@1# P,# P,$0P,
M# P,# P,# P,# P,# P,# P,# P,# P,# P!#0L+#0X-$ X.$!0.#@X4% X.
M#@X4$0P,# P,$1$,# P,# P1# P,# P,# P,# P,# P,# P,# P,# P,# P,
M#/_  !$( %$ H ,!(@ "$0$#$0'_W0 $  K_Q $_   !!0$! 0$! 0
M   #  $"! 4&!P@)"@L!  $% 0$! 0$!          $  @,$!08'" D*"Q
M 00! P($ @4'!@@% PPS 0 "$0,$(1(Q!4%181,B<8$R!A21H;%"(R054L%B
M,S1R@M%#!R624_#A\6-S-1:BLH,F1)-49$7"HW0V%])5XF7RLX3#TW7C\T8G
ME*2%M)7$U.3TI;7%U>7U5F9VAI:FML;6YO8W1U=G=X>7I[?'U^?W$0 " @$"
M! 0#! 4&
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
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M6;QKI.&DY%CE=!'"V4'KA+S?+5,3-UP
M      *JT_SK$/X:]R_F/U$+5
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M;IVX39R#))GZ(6OI%UU0:)B'R;"ARN>QJ49^5<A4BX(^*AY?=')S9U
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MD$:XHU;/HUTZ>I%.3$FE.F7N:N[ I\UL6AZDG,Q%FI^V;58WECEGN+_L>O\
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MJG9JBLD^6Y#ZB=)IHL[1%13IRGE'N8R[=)1$N>Q,GP;W9O0
M                    !KLW:K](.I\H)'A_/<4I+UVI<:IK1]*LY+8/V#6M
M&P:JTMQ8%&,;7=,ZT8SC+!76LPX:Q>89HYL*+$QL%:/B(7*;DXIZFW=0:QK6
MRI6NOU2H(Y90;2AVV8J2J,.I&8AG< [58+&+(PCZ*+A@[8OTW.#H=_+.DH8R
MF<UU"FUJB5&N46K1+6*JM3A(RNP,0B3&6S"(B&J3)@U(4_B\6$4$2%\1NYC&
MQDYLY,;.16<W221ZU2!4DDTBYZ;%S-DJ9"DQG.>1^HL=\X+C'?/;&/Q%K
M                               -9[=TQ?L=:6I^CL^$E7G:Y?J$RK[^
MW6?C"VY [1UC>]3P"3QLWK\YL%7?"<IK=>JW0\?*Q=+A+)+9O-3B89&PZ\B9
M"39;,("JM/\ .L0_AKW+^8_40M4
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M@]/Z[JVNHB6Z<EPD9..JL8C%M7SXG(K42!'3E-'W*+$1QY93Y]^"]\?MR+J
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MQM2W6^4BVGE=\G8QSMJS44_6G0,KC!Q>N
M      #5LL&TJ%LCJTJSVN]T5R4D(SD51JDC/Q[[83:Y4F%K>H(> M^@V&N$
MX]*K2E=GK9B2LLU<WF$B-74V[RIXUXQNX/M)@*JT_P ZM#^&O<OYC]1"U0
M                               &NAO^/WK$\X-M7/BWN?4&@5,[8J^N
MYN)O[EKL2%W-OV;T/ W*K5AY4XVGQZ.JI:<KS=@P?6&5V8I+/4GD:]^SA\/&
M2+G80@',PG7(-:W^K6-B/%QV)Y-DY\4:G-&;)8?I,5UL)94;>E^;AODQ2F,G
MX?=W'?\ X_@*JT_SJV^?]6O<_=VSW_RC]1?_ +^[\?<+5
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MRVO(:R$U%5]/X@XPO(?4:2L3F'J\S--9/S7'^$X?.%TED_\ J<)Y)[Q>V
M                                "JM/\ZQ#^&O<OYC]1"U0
M                           %5:?YUB'\->Y?S'ZB%J@
M                     @%U*=F[\TWQ>LFSM 3]5K<]4)VH/K*_L<8\EWCB
MJN[7!Q,I&UMB@GEL67?(R*A"/9!9-!FF0QRI+G/C!)-;0V59M;ZG<; KNK+Q
MNJP,F$,NEKW7'J MMG%) S5-R>,Q99B"A\89E6.\<%<R:&?1TCX2PHIX2&J'
MXX[LNV[^L3*3MVX[;<XYO8GIV6V-:5W;V:=ZXG&ZG(?42YI6,^QUFLS/#%$_
M^#J>E.6Z_F_XB)B?>%[8                                  Z^5B(J
M=8.(J;C(^9BW>"8=1LJR;2+!SA)4BR>'#-VDLW6PFLFFJ3"B9L$53(H7L8I<
MXYY2E(7!2%P4I<8*4I<8*4I<8[8QC&.V,8QCW8QC';&/P%5J>?\ IJD,?ZMB
MY9_L_P H_4?]\_O]W[O?:F                           K?ZIO4,K'31
MXJV#D+/U6:N4FI*-*E3(.+9-'K%Q<9E)?U)]I#.;!75V==RY2*63>1SAW(-T
M#9.UCW1\83SF7@=RWJW.GB5I?E33H6;KT+M:O/WAH>PL64;(LIFMV"7I]E(1
MHPF[$W3C3V.ORJL+G,P[<JQ!V*KW*#PZ[=*78      "JM/\ZQ#^&O<OYC]1
M"U0!U<W.0E9B9"?LDQ%5^"B6JKZ5FIN0:143&,D"Y.N\D))^LW9LFJ),9.JX
M<K)I)EQDQSXQCN/O&R4=,QS"7AW[*5B95FUD8R4C72#Z.D8]\@1RR?L'K515
ML\9.VZJ3AJZ;JJ(+H*$52.=,Q39YH                        U?OZ6=^
M61'?^NFO\?[SO,#7#M?5+YG<!>FGT@*?Q=V<77D+9J#OK8=J;IP$!+9LLE6>
M3-^CF,5+GF(U\9Q7UFKI8CZ)[E:/<Y*9=,YDT\E_I4PCM5_#13Y?.,KO(YFY
M6SC&"XRJLW34/G!<=L8QDQLYQC&,8QCMVQ@=H     KJZA7-*W</X#6IZ+4*
MC:+'L!]=W)EKY,O8*KQL#KJMI6:>1R^8&364L4NV728UIEE3!';W"A,IJX+X
M1(]QR+JL#QOKW)*VQ-E:5J4UY5+[(PU>@).RV)BC98>/D\L&L)'(*23]=H=]
MY!B)(>9G">3Y+C'<4>DZBFD,=3E'D7FE<B/T5%X3673YIO\ 0%L3TG%[D-TZ
M[M[6,]7^JO2?)4@X&3<Y>8+Y)3HX1SG!SEQF?/M@^)OP_P C_EUV7])&"N3O
M5FTI9N/.YJ]J"(Y+L]HS.NK/&T)TTT#L>.<H6AW&KI1*J#Y:)RDT4*Z,3)5S
M_=3S][/X#2II][Z@+WIJ<J^.FQ(7EI-[*V)NC6%HI$)+5"]R9'E7RN]6V9C,
MJLR.5JUDC^@F>1RJOD.BDP5)$I<&QG9AZ1/5&U5Q2X'<9>-'*.%Y*XY%PT=?
M<2-33TAL.T33:K--B2?JZ3(LWCSF6KE>A9^J,73Q'!FL260C61_!DZ1,VU>V
M#XFY_P!'^1_RZ[+^DCKFG63XF.W;YIBI<GV_H*A$_277&K9R#5WDQ?%D[)8T
M3X7*9?P,<GNQGW?L'8^V#XF_#_(_Y==E_20]L'Q-^'^1_P NNR_I(>V#XF_#
M_(_Y==E_20]L'Q-^'^1_RZ[+^DA[8/B;\/\ (_Y==E_20]L'Q-^'^1_RZ[+^
MDA[8/B;\/\C_ )==E_20]L'Q-^'^1_RZ[+^DA[8/B;\/\C_EUV7])#VP?$WX
M?Y'_ "Z[+^DCHK!UJN%=39H2-F2WY L'4@QB6[N5T#L1DW7DY-<K:.8)*KQA
M"'=O7!BHMD"YRHLJ;!"%R;/8=[[8/B;C_1_D?^[_ "==E_20]L'Q-^'^1_RZ
M[+^DA[8/B;\/\C_EUV7])#VP?$WX?Y'_ "Z[+^DA[8/B;\/\C_EUV7])#VP?
M$WX?Y'_+KLOZ2'M@^)OP_P C_EUV7])#VP?$WX?Y'_+KLOZ2'M@^)OP_R/\
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M#XFYQC/V?Y'^_'?MGCKLOOC^S./5/NR'M@^)OP_R/^779?TD/;!\3?A_D?\
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MAGB[^%S9-6[)MVKYZ2A73IJR=&AIN5ISN9B4W35%TWCW[9!R3SDSYS+0
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ES48B$;2-BDY9]'UV&1,9&&KD<X:P40CG*4;'-4_NBT,   '_V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>52
<FILENAME>g164680g30a01.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g164680g30a01.jpg
M_]C_X  02D9)1@ ! 0(!>0%Y  #_[1<Z4&AO=&]S:&]P(#,N,  X0DE-! 0
M    %QZ^61@X0DE-!"4      !                      .$))300Z
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M8F]O;       0W)N0V)O;VP      $-N=$-B;V]L      !,8FQS8F]O;
M    3F=T=F)O;VP      $5M;$1B;V]L      !);G1R8F]O;       0F-K
M9T]B:F,    !        4D="0P    ,     4F0@(&1O=6) ;^
M  !'<FX@9&]U8D!OX            $)L("!D;W5B0&_@            0G)D
M5%5N=$8C4FQT                0FQD(%5N=$8C4FQT
M4G-L=%5N=$8C4'AL0'+            *=F5C=&]R1&%T86)O;VP!     %!G
M4'-E;G5M     %!G4',     4&=00P    !,969T56YT1B-2;'0
M      !4;W @56YT1B-2;'0               !38VP@56YT1B-0<F- 60
M         !!C<F]P5VAE;E!R:6YT:6YG8F]O;      .8W)O<%)E8W1";W1T
M;VUL;VYG          QC<F]P4F5C=$QE9G1L;VYG          UC<F]P4F5C
M=%)I9VAT;&]N9P         +8W)O<%)E8W14;W!L;VYG       X0DE- ^T
M     ! #O_XU  (  @.__C4  @ ".$))300F       .             #^
M   X0DE-! T       0    >.$))3009       $    'CA"24T#\P
M"0           0 X0DE-)Q        H  0         ".$))30/U      !(
M "]F9@ ! &QF9@ &       ! "]F9@ ! *&9F@ &       ! #(    ! %H
M   &       ! #4    ! "T    &       !.$))30/X      !P  #_____
M________________________ ^@     ____________________________
M_P/H     /____________________________\#Z     #_____________
M________________ ^@  #A"24T$"       $     $   )    "0      X
M0DE-!!X       0     .$))300:      ,U    !@             !(@
M!+T          0                         !              2]   !
M(@                     !                         !     !
M    ;G5L;     (    &8F]U;F1S3V)J8P    $       !28W0Q    !
M  !4;W @;&]N9P          3&5F=&QO;F<          $)T;VUL;VYG   !
M(@    !29VAT;&]N9P  !+T    &<VQI8V5S5FQ,<P    %/8FIC     0
M    !7-L:6-E    $@    =S;&EC94E$;&]N9P         '9W)O=7!)1&QO
M;F<         !F]R:6=I;F5N=6T    ,15-L:6-E3W)I9VEN    #6%U=&]'
M96YE<F%T960     5'EP965N=6T    *15-L:6-E5'EP90    !);6<@
M!F)O=6YD<T]B:F,    !        4F-T,0    0     5&]P(&QO;F<
M     $QE9G1L;VYG          !"=&]M;&]N9P   2(     4F=H=&QO;F<
M  2]     W5R;%1%6%0    !        ;G5L;%1%6%0    !        37-G
M951%6%0    !       &86QT5&%G5$585     $       YC96QL5&5X=$ES
M2%1-3&)O;VP!    "&-E;&Q497AT5$585     $       EH;W)Z06QI9VYE
M;G5M    #T53;&EC94AO<GI!;&EG;@    =D969A=6QT    "79E<G1!;&EG
M;F5N=6T    /15-L:6-E5F5R=$%L:6=N    !V1E9F%U;'0    +8F=#;VQO
M<E1Y<&5E;G5M    $453;&EC94)'0V]L;W)4>7!E     $YO;F4    )=&]P
M3W5T<V5T;&]N9P         *;&5F=$]U='-E=&QO;F<         #&)O='1O
M;4]U='-E=&QO;F<         "W)I9VAT3W5T<V5T;&]N9P      .$))300H
M       ,     C_P        .$))3001       ! 0 X0DE-!!0       0
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M!0$! 0$! 0         !  (#! 4&!P@)"@L0  $$ 0,"! (%!P8(!0,,,P$
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MD;OW+;'76?HO\'^CW_I/T:?ZE.]0TV9!F]S;G.)Y]46%UW]KU,G,
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
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MQE:LB2A.CH)=U4V+FA-C/% !)28:%.*R<5=[)64BL;626W?'FJQZV+/B&_G
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M#?DMHK&')!ZI!@5S=WI=K"T6]UH33_.^.Y-(/&UL>+I_(-;GF1_9X'"+>O9
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M/@HY,/:J_D6R1??'#B]M ]U<0V\8R\TBQCPWC@L?!1ECX UTBEW51S8@?/\
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ML.(I)\MYB@N:N=8KJK*O%EG,K37,<95Y(R\385TM,T#51J-J(Y6'E=N LHX
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MW:8!W/5N,!PHDR1G9*'D7ARI1X'+(Z7<Q6]UNW*A[.ZBDL[R-LE7MKA2D@8
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MC50RB#@ _2K8[H]TGH(Z']@>A'1;F"^DV4TIFVDU6V!$6M;6ZI<MJ>U6JH6
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M631%LO,2A(EC&19)&353.]>EC8V/CRN5U09L6C<$T$XYB"S$ *"20HSA03G
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MBZEI73"Y33HZC@5(AFV?S^N\U-.%'%AIZ4CCDT@[FJ?#MY!2=1?P->1X\JA
M\NB (ZQ.2WJ <.)(6X4>B^),!7./6Q(ID'IJ!UHX\>P2#U\-\<./$#!./>=+
M#XL-N^>)OW__ &OGCG.K?TM/D6G?_P -O7MQ[XOZ*'[)*\MNHZ0KF\W2@NEF
M.5M0$<R;'8]4D'?8(QGE;)>NEBCL4).#G#RDY&9&(M]?A!-V4/(RQ$$?NBP<
M]L@6L-613_.=3;28[6BBN 9<=N%RCMCL7)/#!\C&8YP/2W4/K4.-[YCNGLX
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18NQ8X&<<!R    '@  *__]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>53
<FILENAME>g164680g54t55.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g164680g54t55.jpg
M_]C_X  02D9)1@ ! 0(!>0%Y  #_[1Y@4&AO=&]S:&]P(#,N,  X0DE-! 0
M    'D2^=T@X0DE-! 0      "T< 5H  QLE1QP!6@ #&R5'' (   (  !P"
M!0 11&5R;6%V871N4&EP96QI;F4 .$))300E       0SH?@&]7R+2=3]N,J
MJSH Y#A"24T$.@      Y0   !     !       +<')I;G1/=71P=70    %
M     %!S=%-B;V]L 0    !);G1E96YU;0    !);G1E     $-L<FT    /
M<')I;G13:7AT965N0FET8F]O;      +<')I;G1E<DYA;65415A4     0
M    #W!R:6YT4')O;V93971U<$]B:F,    , %  <@!O &\ 9@ @ %, 90!T
M '4 <       "G!R;V]F4V5T=7     !     $)L=&YE;G5M    #&)U:6QT
M:6Y0<F]O9@    EP<F]O9D--64L .$))300[      (M    $     $
M !)P<FEN=$]U='!U=$]P=&EO;G,    7     $-P=&YB;V]L      !#;&)R
M8F]O;       4F=S36)O;VP      $-R;D-B;V]L      !#;G1#8F]O;
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M(%5N=$8C4')C0%D            08W)O<%=H96Y0<FEN=&EN9V)O;VP
M#F-R;W!296-T0F]T=&]M;&]N9P         ,8W)O<%)E8W1,969T;&]N9P
M       -8W)O<%)E8W12:6=H=&QO;F<         "V-R;W!296-T5&]P;&]N
M9P      .$))30/M       0 [_^-0 "  (#O_XU  (  CA"24T$)@
M#@             _@   .$))300-       $    'CA"24T$&0      !
M !XX0DE- _,       D           $ .$))32<0       *  $
M 3A"24T#]0      2  O9F8  0!L9F8 !@       0 O9F8  0"AF9H !@
M     0 R     0!:    !@       0 U     0 M    !@       3A"24T#
M^       <   _____________________________P/H     /__________
M__________________\#Z     #_____________________________ ^@
M    _____________________________P/H   X0DE-! @      !     !
M   "0    D      .$))300>       $     #A"24T$&@     #-0    8
M             3$   G;          $                          0
M           )VP   3$                      0
M       0     0       &YU;&P    "    !F)O=6YD<T]B:F,    !
M    4F-T,0    0     5&]P(&QO;F<          $QE9G1L;VYG
M  !"=&]M;&]N9P   3$     4F=H=&QO;F<   G;    !G-L:6-E<U9L3',
M   !3V)J8P    $       5S;&EC90   !(    '<VQI8V5)1&QO;F<
M    !V=R;W5P241L;VYG          9O<FEG:6YE;G5M    #$53;&EC94]R
M:6=I;@    UA=71O1V5N97)A=&5D     %1Y<&5E;G5M    "D53;&EC951Y
M<&4     26UG(     9B;W5N9'-/8FIC     0       %)C=#$    $
M %1O<"!L;VYG          !,969T;&]N9P          0G1O;6QO;F<   $Q
M     %)G:'1L;VYG   )VP    -U<FQ415A4     0       &YU;&Q415A4
M     0       $US9V5415A4     0      !F%L=%1A9U1%6%0    !
M   .8V5L;%1E>'1)<TA434QB;V]L 0    AC96QL5&5X=%1%6%0    !
M   ):&]R>D%L:6=N96YU;0    ]%4VQI8V5(;W)Z06QI9VX    '9&5F875L
M=     EV97)T06QI9VYE;G5M    #T53;&EC959E<G1!;&EG;@    =D969A
M=6QT    "V)G0V]L;W)4>7!E96YU;0   !%%4VQI8V5"1T-O;&]R5'EP90
M  !.;VYE    "71O<$]U='-E=&QO;F<         "FQE9G1/=71S971L;VYG
M          QB;W1T;VU/=71S971L;VYG          MR:6=H=$]U='-E=&QO
M;F<      #A"24T$*       #     (_\        #A"24T$$0       0$
M.$))3004       $    !#A"24T$#      3P     $   "@    $P   >
M ".@   3I  8  '_V/_B#%A)0T-?4%)/1DE,10 ! 0  #$A,:6YO A   &UN
M=')21T(@6%E:( ?.  ( "0 & #$  &%C<W!-4T94     $E%0R!S4D="
M           !  #VU@ !     -,M2% @(
M                                    $6-P<G0   %0    ,V1E<V,
M  &$    ;'=T<'0   'P    %&)K<'0   ($    %')865H   (8    %&=8
M65H   (L    %&)865H   )     %&1M;F0   )4    <&1M9&0   +$
MB'9U960   -,    AG9I97<   /4    )&QU;6D   /X    %&UE87,   0,
M    )'1E8V@   0P    #')44D,   0\   (#&=44D,   0\   (#&)44D,
M  0\   (#'1E>'0     0V]P>7)I9VAT("AC*2 Q.3DX($AE=VQE='0M4&%C
M:V%R9"!#;VUP86YY  !D97-C         !)S4D="($E%0S8Q.38V+3(N,0
M            $G-21T(@245#-C$Y-C8M,BXQ
M                                          !865H@        \U$
M 0    $6S%A96B                      6%E:(        &^B   X]0
M Y!865H@        8ID  +>%   8VEA96B         DH   #X0  +;/9&5S
M8P         6245#(&AT=' Z+R]W=W<N:65C+F-H               6245#
M(&AT=' Z+R]W=W<N:65C+F-H
M                         &1E<V,         +DE%0R V,3DV-BTR+C$@
M1&5F875L="!21T(@8V]L;W5R('-P86-E("T@<U)'0@              +DE%
M0R V,3DV-BTR+C$@1&5F875L="!21T(@8V]L;W5R('-P86-E("T@<U)'0@
M                          !D97-C         "Q2969E<F5N8V4@5FEE
M=VEN9R!#;VYD:71I;VX@:6X@245#-C$Y-C8M,BXQ               L4F5F
M97)E;F-E(%9I97=I;F<@0V]N9&ET:6]N(&EN($E%0S8Q.38V+3(N,0
M                            =FEE=P      $Z3^ !1?+@ 0SQ0  ^W,
M  03"P #7)X    !6%E:(       3 E6 %    !7'^=M96%S          $
M                       "CP    )S:6<@     $-25"!C=7)V
M!      %  H #P 4 !D '@ C "@ +0 R #< .P!  $4 2@!/ %0 60!> &,
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M#F0.?PZ;#K8.
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
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MP>$B)$56DO$4%24R-#5#E18C,T)B8V1R)C9$1G1UA(6BHZ3#Q'."@[.T_]H
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MPE#"1OT]"M&V(#C %\0\@FP@ .B\@Q#GK+VYQH8-<1JCA"!'H]8[?T4;3'3
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M&G'3DBQ-&AV7-N"AW,4Z6WSX#3XVS-Q_.=!(C#VC (/=".;X:%RO;&R_'%A
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M1-$31$T1-$31%Y(6'^J%=R+BB1_RA;$&W"1;&]MBF.=2 N*%4WWJ(%<49.X
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MDRXM:R!D<9O9'(L^13M[:3D>9)Q3"+B;.UW9>W$"-F)'%.,6X9EC)BFK5A_
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M2 S,3I<@F1L_P2<3+5.9<[7"^\UK?O%.P0XB[MOQ.C.<38[':0+ \VY+!:3
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M$ERQ[8%5R4TMS)U"PPFKFC*^N HK4)$F=20Q=RKSYDR?+ERWWX<=UMX&)O\
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MX)4-<8:=2IX0J,^CZB7UT_Q6_P#[8TK!<E0UQAIU*OA"HTYUI[R7UT<^QO\
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2FB)HB:(FB)HB:(FB)HB:(O_9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>54
<FILENAME>g164680g56s66.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g164680g56s66.jpg
M_]C_X  02D9)1@ ! 0(!>0%Y  #_[1> 4&AO=&]S:&]P(#,N,  X0DE-! 0
M    %V2^68@X0DE-! 0      "T< 5H  QLE1QP!6@ #&R5'' (   (  !P"
M!0 11&5R;6%V871N4&EP96QI;F4 .$))300E       0SH?@&]7R+2=3]N,J
MJSH Y#A"24T$.@      Y0   !     !       +<')I;G1/=71P=70    %
M     %!S=%-B;V]L 0    !);G1E96YU;0    !);G1E     $-L<FT    /
M<')I;G13:7AT965N0FET8F]O;      +<')I;G1E<DYA;65415A4     0
M    #W!R:6YT4')O;V93971U<$]B:F,    , %  <@!O &\ 9@ @ %, 90!T
M '4 <       "G!R;V]F4V5T=7     !     $)L=&YE;G5M    #&)U:6QT
M:6Y0<F]O9@    EP<F]O9D--64L .$))300[      (M    $     $
M !)P<FEN=$]U='!U=$]P=&EO;G,    7     $-P=&YB;V]L      !#;&)R
M8F]O;       4F=S36)O;VP      $-R;D-B;V]L      !#;G1#8F]O;
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M(%5N=$8C4')C0%D            08W)O<%=H96Y0<FEN=&EN9V)O;VP
M#F-R;W!296-T0F]T=&]M;&]N9P         ,8W)O<%)E8W1,969T;&]N9P
M       -8W)O<%)E8W12:6=H=&QO;F<         "V-R;W!296-T5&]P;&]N
M9P      .$))30/M       0 [_^-0 "  (#O_XU  (  CA"24T$)@
M#@             _@   .$))300-       $    'CA"24T$&0      !
M !XX0DE- _,       D           $ .$))32<0       *  $
M 3A"24T#]0      2  O9F8  0!L9F8 !@       0 O9F8  0"AF9H !@
M     0 R     0!:    !@       0 U     0 M    !@       3A"24T#
M^       <   _____________________________P/H     /__________
M__________________\#Z     #_____________________________ ^@
M    _____________________________P/H   X0DE-! @      !     !
M   "0    D      .$))300>       $     #A"24T$&@     #-0    8
M             ]T   G:          $                          0
M           )V@   ]T                      0
M       0     0       &YU;&P    "    !F)O=6YD<T]B:F,    !
M    4F-T,0    0     5&]P(&QO;F<          $QE9G1L;VYG
M  !"=&]M;&]N9P   ]T     4F=H=&QO;F<   G:    !G-L:6-E<U9L3',
M   !3V)J8P    $       5S;&EC90   !(    '<VQI8V5)1&QO;F<
M    !V=R;W5P241L;VYG          9O<FEG:6YE;G5M    #$53;&EC94]R
M:6=I;@    UA=71O1V5N97)A=&5D     %1Y<&5E;G5M    "D53;&EC951Y
M<&4     26UG(     9B;W5N9'-/8FIC     0       %)C=#$    $
M %1O<"!L;VYG          !,969T;&]N9P          0G1O;6QO;F<   /=
M     %)G:'1L;VYG   )V@    -U<FQ415A4     0       &YU;&Q415A4
M     0       $US9V5415A4     0      !F%L=%1A9U1%6%0    !
M   .8V5L;%1E>'1)<TA434QB;V]L 0    AC96QL5&5X=%1%6%0    !
M   ):&]R>D%L:6=N96YU;0    ]%4VQI8V5(;W)Z06QI9VX    '9&5F875L
M=     EV97)T06QI9VYE;G5M    #T53;&EC959E<G1!;&EG;@    =D969A
M=6QT    "V)G0V]L;W)4>7!E96YU;0   !%%4VQI8V5"1T-O;&]R5'EP90
M  !.;VYE    "71O<$]U='-E=&QO;F<         "FQE9G1/=71S971L;VYG
M          QB;W1T;VU/=71S971L;VYG          MR:6=H=$]U='-E=&QO
M;F<      #A"24T$*       #     (_\        #A"24T$$0       0$
M.$))3004       $    !#A"24T$#      ,WP    $   "@    /P   >
M '8@   ,PP 8  '_V/_M  Q!9&]B95]#30 "_^X #D%D;V)E &2      ?_;
M (0 # @(" D(# D)#!$+"@L1%0\,# \5&!,3%1,3&!$,# P,# P1# P,# P,
M# P,# P,# P,# P,# P,# P,# P,# $-"PL-#@T0#@X0% X.#A04#@X.#A01
M# P,# P1$0P,# P,#!$,# P,# P,# P,# P,# P,# P,# P,# P,# P,_\
M$0@ /P"@ P$B  (1 0,1 ?_=  0 "O_$ 3\   $% 0$! 0$!          ,
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MX'<2_P#/.[=K_P!:_P &MJ7>'XK/RNBX&5FU9MT
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
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M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_P  1" #M ET# 1$  A$! Q$!_\0
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MWEF8BI[(=QV.Q(V_)\$9S&4L):=4M6)<RW[-:"G9<^K-(0:U.8E@)N3LYWB
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M1(5-/7G,&>,>U/5*>DLL<WY!TCA-!IGG50_QY^DA7+!3P5#%U>3Q?E3$$Y6
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M>5$W-D]BW%[+LD<DR:A5DJP9+Q,@TD7^=H8ZQ ^;G?+&UDS73.:3$"0YS0\
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MO'<+G336W.M0TS#.97.D?(9FP$22B0DAA:XM.P2%?R50,ID&1UP(Y,.0&LB
MC?+S@-: &ACGC0Y1U<- ^0U:GX*AJB2?#=&J]:J\BKW2BE#U?Z^S,I$RGSY]
M\67GSVIA&9,%CE6N8W5Y-?@K-I=(;CM1&0CTEIX6N'&P/M.BM-XKN3S6&V*M
MMD4^.<VTRRQM/PV-Y6-9))[NWQQ,X1$,#BXRM:1('.N\ Z,XZ)C6%DD1<R<.
MC=&3+S$]2X#G/(6CF!=T ;O;2!SS^*YS7OO(/4UKM'F^HFCT+XB/"&?.E]2(
M&SY<(;<H=GIM;G%B+XV*^R+69H;H6O0Y9'<9O[A*U$-27_EWVF]R]G]W#Y+
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MP-Y?#Y"Z0. D<YTCB]WI>Q\,1PU2*(NKLN$R-(Y^9IY7.,IUHA[O[M@-U]D
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MR.WGV._7X?#SUWZ=BJ2S0)WU&CK0'0Z\]]=$D'6]:ZD;"C$A[[/U*R7* 0I
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M#ZZ&M [ZK1AWHOR&824-#HL>;,K@")5G/P>%7Y9]VKOV.16'*W7QV^>_6CP
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MK]>]">4^BG*E2:33D7+??2T5!5M?%+&%%E0;/.R'20-ZN*+92P[9JI3AL41
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M&BT!RQ0 A&3*ACS,P*B0HE%%3Y<*;%AD'XR(DJ3$E,,/+=CNI019S"+'!_\
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M^1'Q]%V(^ >J? J'OFJV3T0<[%=ZG\0/T>&ME,M"Z"U9*3+A='M(]B^&AM5
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M_M>%61KLS4+SA&Q,898C/[QXY)@;,(PUN4$/,'9 O= YKF,$QD GB[A-QU_
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M+4N QV4LMMWZF-=(37BL3L'4@;+(W26)8(BR":Y=EC?;GW[[AG^7&?V25_\
M-S(+6E03U_1/?MKNG,Y?E7J%%IE5@#;:S;8A:(B(XD])!DFA),TLC&L*3XAU
M*VAX2! &M+ V1V,=)1RD1+<H%H7%U'CBU=QS^%LE4IU(XK0M,F#6N]X=#*(Y
M)B]LPGA<"V.!D<8,%DMGD;(P!\'TI[#^(?X=L-@.*X/;-PGG<_FK-O#/PL^.
MDDDC.,BOU'W*E%D%C'NQUYCFR6K]FQ<<S(XIDF.JR4YR^+)0MT7EWQ1B'DWB
M];J/6:E'[L))-N].DCWXHJTS@JM;U7H,J\SI$VOEB(!O:475Z",AZLK^FE0R
M!1,*:]9L-D,9[2I.%</7J92LW.12;R3HWLBLR0:_],QUV1SH)98!TN.8QGO+
MN4M?+R/=8WWACBW^$JM[9^/<KG.#LQ+[.;M0LX0AGBL7,56R _\ W6Q'@*\<
M&1IU<D[KP_'/9F_E,?B"Q7J&Q79B+(>&J?[)IW+C([UK<P5HMSUK)R:VEUUL
M]8!H%;KGXJ35D$RHXLC&GS?OS@ ]F*J4$%.MQ)<W['(X0!L?!%3BNGC)H^++
M<=JV;4CJP#VS3QP$GF\>S&?#D;(\E\$;6\T$6FN?U;#!RO\ B&S?L5SG%V/L
M^Q+"6\-A8\-5BRY=#-1QMO)-:WPW8_%V@ZW5EK5^6ODK,DHBR%QKIH:X+)<A
MDK?D4F/G 7VOC?M^JO?=^R+*UK6_H9G_ &_ZYO[=?=^]K[-?9O[=ZW]OV:WK
M>YK@2RBD&]I5I$@6E6];TE2H4M:4J^S^+:D:GHVK6M_9O:=+1M6OXM*3]OVZ
M@[T=:!UT)&P#Y;&QL?#8WZA2-;&P2-C8!Y21Y@.(< 2.Q+7:[Z/94K\O4_V_
M79W>5^B^C<^LC!FZD)/(MP@LF9&&P5QG--D8\2"4&/BZ6O2AC,&FD)LD^Q*@
MEW9!MG<M! II?#%3C*N_.GB*_1L":W([$>'$7LC:6G4@8R2-T5(CPFLIR/=8
M#F2ETK>;Q)N^^U[-^P;*0>SEOLLX9XAQ+Z&"K1<<>]W&12VYFRL+ZKIIJUB.
MUGVD7'V,]7KQXR2*Q19%CY! ZM3YG2>)?&[78K@_&[% :C2#!IR#)U=:?H+-
M:<N%<?9?K I\3-D QDF,S]3%#R$0>L=5!MD NQH<PWH'8.<.POME]XMN;EFA
MKIIBQWOM00O:;==P=6B=&]T$;@/$BC>V(QU8[$'*QTP@L?6,?'W\ C<9A(Y>
M![+Y8J5!EB+^0YPWX'MPF4C?'EKD=V"+(6H99/<[EJK-9;9S%K%Y)DL\% Y'
M&; ]QCXV>V^?)B]MJK2X=;K[)3;EAK&]P)J#QAU3%R6]6R'YG,CH#L)5@*#6
MR$,L-W"@M.')L26Z_P"YP_MDU0#<Q7!97@;(?>:IY'">8EMLO@>;,T;"PSR1
MMD9+%X<;73/:_>,9QW_ 2'\2F7@',O;/E,C)3#<9EP+-=V.HL$F#;'E*W\IH
MVK+9QCJ=MU6>G:$]E[<?7GA8S7X?$?C=ICU9+O8QZ=,6JJ/OMR+M47Y,",Q7
MZVTN?9'VQ&]FZV*4RZ/M01B07E6 _ L)=L59&S+1PQX,POMEY:V\LS[-JLXA
MUVH7,:V"N.>P1%_6KQ<ICLP-,KIYV6)1%8$PFFR<_'_\ IERY;P-:<9,/F(H
MW18'-QQ699,EE'MKXICKO_Z?E;@>RUA\A+#2BQN-L8VD^YBW47X^E;WTUS7X
MG]@OIB;PSKO/!E'<X?(%,CAL-%8>?OFOI7UU@6P:?L$N!;[!,;ER:5;)!A@1
M60Z71$R4+(Z<-&MLXDQWM(L7Y7X3*T8J)PIB#(VBLYU[47O B;*9GQVIY ]]
M*R91'6AW$^2.3<TW$O9-Q3_";C>&Z5?VB<%\26^(6>T!EQ]J>9^5BCX<+KO\
ML?;DI-QT5G#8RNZ"'B##QTI+N6O\MZO!:JEF/H= ./#>QBN7T8=V*PU2Q=.A
MUV Q=30 3+A"R!M#?_CNL,_-MMN.I1^&U,F1XP^(0FMR9\,4)BR61L7?L/'D
MHL71CS$T-C)LKL;=FKL+(I)@.I:">I T'O 8V20.D9'&UPC;\T\=6>$KG&'$
M5K@3'Y#%<(3Y2Q)@,?E+#;-ZMCW.'ALED:-M87<[X())+$U:NZ*M/<NS126Y
MI'4@WM*M(DBDKVG>D*5"EK2E7V;^ZI2-3V]K3K?V;VG2T;5K[=:6G>_MUD3O
M1UH'70D; /EL;&Q\-C?J%J@UL<P);L; (:2-]0'%K@TD= 2UP!Z\I[+CK-Y1
M\7Y3AKY7N'+M(>]%#30_:8C#?_Y=H3K\6;'2XT]\ES1G6X:9W-WOF;?+<B3]
MM%7=.K6;Y!)B_:QN;DS6-T<_'-'IK1_Z$=WMVT\F-:"P28X\]IY8\M>2XF?[
MH@XR_@G#:'C>S_B\N9[,;5"R#/([?$Q/V()2U\?C\5/_ *YK\4Q^#A(&S5P^
MFPL:,?KG;N1_&)+=/Z*0YOV6G-T.:;(.5&+7YX2J0D!5T<O'AM#@QV$>+!WM
MK<0$VB?89JT7Z4,M+<I@; U91-OF<5[6ILGD'X_+5!1?-(:K:\L-5G@FE*UG
MAPS-GFA.W"$B2P\MO&.T'>''[S'D^ .-/X(J7"/#%;BK@;./XCKX^JW-S9&M
MD,Q,[(-X@I2V'V;V/L8ZG=CY6NR =6QL#7<-PVL.Z*2W9_E-V8.M\S^*:3I?
MG>)SGLW,85R!U&P1.QD(P]D,Q.N#]>+-"B91XE%.P['#U&7&"L:$ A<:->W&
M;>Z'2'7&W5,ME<;[39:7#[,?E\<RY#4L,R[VM;"U]QT$PBDD=(R9EAG(60CP
MH8VLO$6S%X1::VD\%\5_PBU,][3YN*>!>*[&!R&;QLW E62Q)=FK8*/(TGW*
ME9E6?'S8NP9VS7Y#<R%N63AUKL(VZZ^V8YK9OA<\^Z)SWG';HG8K?7K5V SW
M8T7ZBR.LOYPL@&W[J51A.#KP>BER0=P\\%B!9[0\2TPB -DQ=RWY4R0ZU"R7
ML\HY>CC,@S.VX+64ER<DEMK)O>;,$G@PL$=VPV1\3YG1-CD8V, ,A>P.>]Q+
M8]6_BFXCX(XDXPX8G]G6$R.'X.I\&T:>"DL8XX?%9*D+^1G][X?QDU2O=AQ\
M=J:U5EGMN+K%Z"R88888V26*0^UK#,X5[D]?^B&NR=/IQJL^#_$M>I<BN4WA
M%NW327:_5GH/C+,.M+ZH#K@*L1%E4(,IN%^Z+$J%2.6T_;>A:MU&K@.BC>@>
M?U]?EY=?)?,?D.GF?R /U\NG7>XBYCZR[=;^FQ>6VCI;/1@%"^(]Y[H8.7;[
M%P#O=K 57H_CWOETM-5>ZCS'F=6IJB\"XUG\>.7JL%=PIRY!RD+O<^&V0@(@
M^7SZ_@1^OUK: =_EO\Q^RJMSSV1ZIYSYOXW4:)UL-Q,!P+X9WB#HG&X-@Z5Q
M>@5KH%AN'+9,L[:KM3.C<KZ!TGO53?LH$?RIRE<5,U@X(6@A''Z<OMKIY0:[
M: !\M]N@^/KV\OC\%)'5W3?4Z[^O76CZ'?4$*V7;.V7#KUYJ\KL?IN51.ETW
MXO7D?E%?\.H5S2(#1SBN]@X\>J%@:"DJ7&[43-VH5-=[4UT5VT, 9 *3^46
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MO?:T,&:J0_HP.QRN8%Y1.Y+B+H\L'#'OOU^'3N>^M#IKOV&O,[4'U\CY=?\
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MB7@C<>8VCH+L01<2Y)P9$1;@;U88V>BS94R-,;8&0>Q\NGX?A^Q4] 1KKO\
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MG>3TT[5>5<I2_68/(>=E;3'V*L_0JW71=6@']7PU5E/4U<\M:B@0769I:&
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M/=5Y'3DHF5MT7,"TFP$*\JH2=!K=;B+]VH3@EB/T(](^5K9PZ>T_1]R@<?\
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M&=U7Q[+J4UH2!T+:L$EFS/&Q=8_JL;^1)?L@K_\ #SJR^+D^JQOY$E^R"O\
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MCM-LL,H0VVA*$ZUJ(HHX8XX88V111,;'%%&UK(XXV -8QC&@-8QK0&M:T -
M   "KN7+>0MV;]^U8NWKL\MJY<MS26;5JU8D=+/8LV)G/EGGFE<Z2665[I)'
MN<][BXDK46>5<PC.QI$?G-%9?AS;21B/-5("V[%(7G2TW2='<3 TMF7;DNN)
MLTAO:73J%J037*3O>LLQB\8TM<W'T0YC[,C'"K "V2X"+;VD1[#[0)%APZS
MZD+@LU)QAQ9*R6.7B?B&2.>#$59V/S.1<R:MP^6G UY6FR0^'"EC3BHG LQY
M:#4;$1M;2$"!JT'&5ZNB1H$"%@QA@<*&@QA@H4-A-)8B0!P^&TS$A0XK"$,Q
MXT=IMEEM*4-H2G6M9=0PPUXHX*\4<$$+&QQ0Q,;'%%&P::R.-@#6,:  UK0
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M>A]?7U_P>HZ?'2CD/P';S\CKK\OM#X^6M]%Z0OX@/EXW,D#@QHL66Q!#EX3
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M$,*_T=[(;VG?VIUK[R=Z5M/WD[W]U2M;JU\_Q/\ E>*ROT6'_M_&+?M\[_\
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M$%>>.*_#$ZM8 =X%BMJMX\'<RN_;^$=LDW'J, AP<+'"!@+5\LLV.:8$MIT
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MB">)]>RV&9T<LF/N^!(_W3(UF^/4E(>&RQ&6";/\7XE7N)<KHW*09RX'!=&
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M ?TL]_T(UA1Z?$_L5EL*4PB81,(F$3")A$PB81,(F$4!<5L_);%:/043F0N
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M)A$PB81,(F$3")A$PB81,(F$3")A%BY00+.D_.31 N9+_P#IO^M2A\21)_\
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M3]OWE:ULBRGYA ?KP/\ M.%^_P (GYA ?KP/^TX7[_")^80'Z\#_ +3A?O\
M")^80'Z\#_M.%^_PB?F$!^O _P"TX7[_  B?F$!^O _[3A?O\(GYA ?KP/\
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+3")A$PB81,(O_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>55
<FILENAME>g164680g58s99.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g164680g58s99.jpg
M_]C_X  02D9)1@ ! 0(!>0%Y  #_[1AL4&AO=&]S:&]P(#,N,  X0DE-! 0
M    &%"^8B0X0DE-! 0      "T< 5H  QLE1QP!6@ #&R5'' (   (  !P"
M!0 11&5R;6%V871N4&EP96QI;F4 .$))300E       0SH?@&]7R+2=3]N,J
MJSH Y#A"24T$.@      Y0   !     !       +<')I;G1/=71P=70    %
M     %!S=%-B;V]L 0    !);G1E96YU;0    !);G1E     $-L<FT    /
M<')I;G13:7AT965N0FET8F]O;      +<')I;G1E<DYA;65415A4     0
M    #W!R:6YT4')O;V93971U<$]B:F,    , %  <@!O &\ 9@ @ %, 90!T
M '4 <       "G!R;V]F4V5T=7     !     $)L=&YE;G5M    #&)U:6QT
M:6Y0<F]O9@    EP<F]O9D--64L .$))300[      (M    $     $
M !)P<FEN=$]U='!U=$]P=&EO;G,    7     $-P=&YB;V]L      !#;&)R
M8F]O;       4F=S36)O;VP      $-R;D-B;V]L      !#;G1#8F]O;
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M(%5N=$8C4')C0%D            08W)O<%=H96Y0<FEN=&EN9V)O;VP
M#F-R;W!296-T0F]T=&]M;&]N9P         ,8W)O<%)E8W1,969T;&]N9P
M       -8W)O<%)E8W12:6=H=&QO;F<         "V-R;W!296-T5&]P;&]N
M9P      .$))30/M       0 [_^-0 "  (#O_XU  (  CA"24T$)@
M#@             _@   .$))300-       $    'CA"24T$&0      !
M !XX0DE- _,       D           $ .$))32<0       *  $
M 3A"24T#]0      2  O9F8  0!L9F8 !@       0 O9F8  0"AF9H !@
M     0 R     0!:    !@       0 U     0 M    !@       3A"24T#
M^       <   _____________________________P/H     /__________
M__________________\#Z     #_____________________________ ^@
M    _____________________________P/H   X0DE-! @      !     !
M   "0    D      .$))300>       $     #A"24T$&@     #-0    8
M             [    G:          $                          0
M           )V@   [                       0
M       0     0       &YU;&P    "    !F)O=6YD<T]B:F,    !
M    4F-T,0    0     5&]P(&QO;F<          $QE9G1L;VYG
M  !"=&]M;&]N9P   [      4F=H=&QO;F<   G:    !G-L:6-E<U9L3',
M   !3V)J8P    $       5S;&EC90   !(    '<VQI8V5)1&QO;F<
M    !V=R;W5P241L;VYG          9O<FEG:6YE;G5M    #$53;&EC94]R
M:6=I;@    UA=71O1V5N97)A=&5D     %1Y<&5E;G5M    "D53;&EC951Y
M<&4     26UG(     9B;W5N9'-/8FIC     0       %)C=#$    $
M %1O<"!L;VYG          !,969T;&]N9P          0G1O;6QO;F<   .P
M     %)G:'1L;VYG   )V@    -U<FQ415A4     0       &YU;&Q415A4
M     0       $US9V5415A4     0      !F%L=%1A9U1%6%0    !
M   .8V5L;%1E>'1)<TA434QB;V]L 0    AC96QL5&5X=%1%6%0    !
M   ):&]R>D%L:6=N96YU;0    ]%4VQI8V5(;W)Z06QI9VX    '9&5F875L
M=     EV97)T06QI9VYE;G5M    #T53;&EC959E<G1!;&EG;@    =D969A
M=6QT    "V)G0V]L;W)4>7!E96YU;0   !%%4VQI8V5"1T-O;&]R5'EP90
M  !.;VYE    "71O<$]U='-E=&QO;F<         "FQE9G1/=71S971L;VYG
M          QB;W1T;VU/=71S971L;VYG          MR:6=H=$]U='-E=&QO
M;F<      #A"24T$*       #     (_\        #A"24T$$0       0$
M.$))3004       $    !#A"24T$#      -S     $   "@    /    >
M '"    -L  8  '_V/_M  Q!9&]B95]#30 "_^X #D%D;V)E &2      ?_;
M (0 # @(" D(# D)#!$+"@L1%0\,# \5&!,3%1,3&!$,# P,# P1# P,# P,
M# P,# P,# P,# P,# P,# P,# P,# $-"PL-#@T0#@X0% X.#A04#@X.#A01
M# P,# P1$0P,# P,#!$,# P,# P,# P,# P,# P,# P,# P,# P,# P,_\
M$0@ / "@ P$B  (1 0,1 ?_=  0 "O_$ 3\   $% 0$! 0$!          ,
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MVN>ZQWI^B_W_ *-:
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
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M6<(9.+XKN<LLD\+XX5/B.LV[[+P_-0""C1L-R8=?8(ZLCXC$&WR90V)QC C
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M8+<7/-@Y87-Y;MIYN/$@Y"9C*UX8_8)#C$T,T[0:\G>AO7CY'\A^3_.#C/\
M66Q/@QR0UWN_95H)%MLS39\(QBFBX TCLB GI%(P\^7=JXG!KQR QL-1S%#G
M%Q;Q=058R30'LB4X3#8'A7.?VGL<5X2[BJ/O<^.JT+1L96XZ:&:&""6FUH,,
MC&S?O")'M\1H$ABC<]S%NU=R%3W!F.MPV)O#9/)-'R5H@Q[7/>V7F(>'<OP]
M >4DMYG!H=0^_>+4&BO.F79[_P"$O+#EIHJ/\;=&ZWU\;T9KZ?$F^<PA$.B
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ML69)#%5;"BC];6_%$2B)1$HB41*(E$2B)1%R2W%TN6L=/\LBW&Y[IS9TBA,
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MI%T_765%-"N91BFHX:8MG#IY]1^OK_)5-(#AS ENQS!KN4D>8#B' $C8!+7
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MY[FL:PES0>WL^R3VC5./H_9A/PIDF<<36HZL.##89))O%8966XK<<KZ$F,\
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MQP53SRO:PLE>][8XY7OYK>>_F\U0>X^OY%%+U*)1$HB41*(N?7)O\-GHT/\
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MG)!5JUH&15JE:,%SA!6ABC=+)+.]KIYI9'V7W:.]8,O@J'[.MFN25'[?XN:
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M#_()ALTB=0CT=5"Q9JV?#H ZDC]D#[^$1.*+O#;<.W<&L!K=^H\6S>/5WD@
M=OO_ %Y;_BH)<1U[;/4CN?0G7777IY;5[2H(0D0)^'%RR0PA\]3LFA)XJC&'
M!T7>V>.5U6"4QC<MCN2F>-KIY=X '^%L,LKX88*6QSQE4JM>-5NKCGH&WGOU
M:3U7;KO]N_\ Z% _;_T_PU).R3H#9WH=A\AO9U]ZJ>X/>]P8V,.<YP8SFY&
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M%&TTG4BG^Q%WS2)A0\><F0=GRY1ZPS8H)(/<W:SU=HU;-7"SC'"S]?7]?-5
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MSQ@-D+:",!1$BR'6,OH^1'% UYG7I]?GT/Z_CN5PCUZAJ;BAHS63;0ZO&1K
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M :^0LP,K7GPOG+(FR/PQ="YN'F9E.QO<C/\ '%_C\]\Y5["OA-.Y&?XXO_2
M]\Y418C*H2,D[=]&7).5#6LAB<J#N"(.6R(6<8)$L1+'-X(*MR/:1Q%M@XR7
M9NT;]:#I-%;P<[I8VK'M5VVZUBJ]\L3+,$L#I*\KH9XVRL+"^&5OQ1R-#B62
M-ZL< 1V6QQ&2EPV5QF7@KTK<V+OU,A%5R52*_CK,E.Q'89!>HSAT-NG,Z,1V
M:TH,<T+GQNZ.*T#XN]&#"^,>T ^SQVY]KR]V&AIN)H@GY7,$'7L:/DRJF;C
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M?-%JRY'!X3.8_.9[(9#.R9#'Y&5CJ%%S-"L &Z<01R0&!@]V8ROIEA@%B?\
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M#W/FAE8.DFMM; R-SGMD#SN5K8Y0QS?U-N <XF&PIAL-MR9F\5,RD_)S+1T
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M7UJTC$5:BRK D-Q.Z=@6PY _*K&;)/EKO#4Y6$M&:K5#(7A'E6RN3EQFLX4
M[WV\NGU&_P!=%0X : V>^]_4@=OI_'[AM=52I2B)1$HB41*(E$2B)1$HB41*
M(E$2B)1$HB41*(E$2B)1$HB41*(E$2B)1$HB41*(E$2B)1$HB41*(E$2B)1$
MHB41*(E$2B)1$HB41*(E$2B)1$HB41*(E$2B)1$HB41*(E$2B)1$HB41*(E$
M2B)1$HB41*(E$2B)1$HB41*(E$2B)1$HB41*(E$2B)1$HB41*(E$2B)1$HB4
M1*(E$2B)1$HB41*(E$2B)1$HB41*(E$2B)1$HB41*(E$2B)1$HB41*(E$2B)
%1$HB_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>56
<FILENAME>g164680g60t85.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g164680g60t85.jpg
M_]C_X  02D9)1@ ! 0(!>0%Y  #_[1)J4&AO=&]S:&]P(#,N,  X0DE-! 0
M    $DZ^1H8X0DE-! 0      !T< @   @  ' (% !%$97)M879A=&Y0:7!E
M;&EN90 X0DE-!"4      !#'- ,3M+S*?1(K>LP9,P[D.$))300Z      #E
M    $     $       MP<FEN=$]U='!U=     4     4'-T4V)O;VP!
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M;       0W)N0V)O;VP      $-N=$-B;V]L      !,8FQS8F]O;
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M;G5M     %!G4',     4&=00P    !,969T56YT1B-2;'0
M  !4;W @56YT1B-2;'0               !38VP@56YT1B-0<F- 60
M     !!C<F]P5VAE;E!R:6YT:6YG8F]O;      .8W)O<%)E8W1";W1T;VUL
M;VYG          QC<F]P4F5C=$QE9G1L;VYG          UC<F]P4F5C=%)I
M9VAT;&]N9P         +8W)O<%)E8W14;W!L;VYG       X0DE- ^T
M ! #O_XU  (  0.__C4  @ !.$))300F       .             #^    X
M0DE- _(       H  /_______P  .$))300-       $    'CA"24T$&0
M    !    !XX0DE- _,       D           $ .$))32<0       *  $
M         3A"24T#]0      2  O9F8  0!L9F8 !@       0 O9F8  0"A
MF9H !@       0 R     0!:    !@       0 U     0 M    !@
M 3A"24T#^       <   _____________________________P/H     /__
M__________________________\#Z     #_________________________
M____ ^@     _____________________________P/H   X0DE-! @
M !     !   "0    D      .$))300>       $     #A"24T$&@     #
M00    8              K4   G:    !@!G #8 , !T #@ -0    $
M                     0             )V@   K4
M     0                         0     0       &YU;&P    "
M!F)O=6YD<T]B:F,    !        4F-T,0    0     5&]P(&QO;F<
M     $QE9G1L;VYG          !"=&]M;&]N9P   K4     4F=H=&QO;F<
M  G:    !G-L:6-E<U9L3',    !3V)J8P    $       5S;&EC90   !(
M   '<VQI8V5)1&QO;F<         !V=R;W5P241L;VYG          9O<FEG
M:6YE;G5M    #$53;&EC94]R:6=I;@    UA=71O1V5N97)A=&5D     %1Y
M<&5E;G5M    "D53;&EC951Y<&4     26UG(     9B;W5N9'-/8FIC
M 0       %)C=#$    $     %1O<"!L;VYG          !,969T;&]N9P
M        0G1O;6QO;F<   *U     %)G:'1L;VYG   )V@    -U<FQ415A4
M     0       &YU;&Q415A4     0       $US9V5415A4     0
M!F%L=%1A9U1%6%0    !       .8V5L;%1E>'1)<TA434QB;V]L 0    AC
M96QL5&5X=%1%6%0    !       ):&]R>D%L:6=N96YU;0    ]%4VQI8V5(
M;W)Z06QI9VX    '9&5F875L=     EV97)T06QI9VYE;G5M    #T53;&EC
M959E<G1!;&EG;@    =D969A=6QT    "V)G0V]L;W)4>7!E96YU;0   !%%
M4VQI8V5"1T-O;&]R5'EP90    !.;VYE    "71O<$]U='-E=&QO;F<
M    "FQE9G1/=71S971L;VYG          QB;W1T;VU/=71S971L;VYG
M      MR:6=H=$]U='-E=&QO;F<      #A"24T$*       #     (_\
M     #A"24T$$0       0$ .$))3004       $     SA"24T$#      '
ML@    $   "@    +    >   %*    'E@ 8  '_V/_M  Q!9&]B95]#30 "
M_^X #D%D;V)E &2      ?_; (0 # @(" D(# D)#!$+"@L1%0\,# \5&!,3
M%1,3&!$,# P,# P1# P,# P,# P,# P,# P,# P,# P,# P,# P,# $-"PL-
M#@T0#@X0% X
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
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M+MXMT\FH!;Q[#?4$@%M<X!(&?N/F=7&R[?IR,_QGO_XFD6!_%7Z$\WPOF/\
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MEM*LE=QL9Z6I5ZDHT%KN!?79A0?[19_U(R"*\<O@JP92&P0K%B5*Y4)C8G#
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M@XQ(U#9L-BJ!JP 4HSDD8SD =C&1J<9R);>B?=M<WO4]Z67'Q7'3OSWR8W.
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M]-0"LS=VC:@BUZ5Q,JOB1>&"9[P)NK57/V=B0/FPY)"X:7,10A5:0$P$*3
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MSYJX,6KO=T9N3O>P3.4)OL1@ZZ@*2R%P%V&C+WG(&-A^EME)?+$#(*'9A@C
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MO('?._ISPX)*<<<\<<\\<_,<F[SWVW!0@L=BJ#X1,X1!^R(%4?L)A=MW9L
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MM5IY''N%EMJ\A2&LK>M?'34ZGQ[EB=AF5I?34HUW)WJL\;!?;8C NPL 7*L
M0BD'4-V25#2"X[\:GMWO<=]"R.(4TRO"EK2^/<Y Z/%VT_<1:R8EX>JJP*OD
MKHE9G=?HMHB9M-2S#4AB#1S%BB43;!QHPZX=.%U'">A_5>!E^,CWGCWU>IK9
M>U"[U/ZA=5:F*?*=UI%*JY#J7+,RXZ$DW(I.:P7T<7EGU[4W,K :[>X)J >^
M\Y&)N+^._P ZS;RSY+KNH[+>@7MB(F;*G<WXBSEP]C0N2VO9TOLXE'P3YVS'
MN7XV.*2S0)$@JR:?N'0]1ZFW11732X\3U/E5\OF6W5!A5K577N,.R4U)2'8
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MVN^H*H\>EE&WC8V-7FIO(29+PH"^-O8;:SN!@LM5C!A@>W&I."6(R#F=XO\
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MYC0&>\<34.#YYT-&ROCB0,VR)7CEUH>9RR<GE<@G=K,FZPGR.GB=\[9W:O\
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M59E/1(DFON8:M;8PP1@L2,$8/1/W'7\2PA.#0LS*XO.R\2C92;0AG(AT,EQ
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MR<O1:K5RLTZ[;**](]]<;FMCJKJKNJV "Q58A7 .0' (# 'L!@0#V.YT$@$
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M?2V!0S^S)< $$GV)N3U]B.L_ .<D8.+=QWVWY&EDQL& Q_T35!"656(EL@L
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M$GJ74T67[BL E!L1D D?'6>B?VEG*QM:L[JAHFQ*BGT1LN"G4ORB99"3XR2
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M'B^@C]U&J?9N[6<)31H:'(K" JB6:W].X?+OOMMK>UMN#4Z5,P/'H/IM%AO
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M<_L1C[ZV)_\ (I?WJ.BO4-?RZV6ED5^5J7S-=T1[_B-9P6;PJ1I?(%2<(*Q
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MX<6-'QZ9.$QV1_=RV5^R$S R+=_G<:5$QI1MRR5\KU-?34Y!'IEE]E.3DW(
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MM\U=U(LXU_%HX[<<V-JEG'K2NODU,5.EH*%CA<$,5;88,'E%M@R;(U:(4+'
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MB"YY\NHB^?FS1,N6(E'%UO/WJ?CI2M5!KKJJ0,S&M4N:]BSD V/98[%VPH^
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KS^6.<?L!\ ?L,"3KF>0C$1B(Q$8B,1&(C$1B(Q$8B,1&(C$1B(Q$8B?_V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>57
<FILENAME>g164680g64e02.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g164680g64e02.jpg
M_]C_X  02D9)1@ ! 0(!>0%Y  #_[1; 4&AO=&]S:&]P(#,N,  X0DE-! 0
M    %J2^5Y8X0DE-! 0      !T< @   @  ' (% !%$97)M879A=&Y0:7!E
M;&EN90 X0DE-!"4      !#'- ,3M+S*?1(K>LP9,P[D.$))300Z      #E
M    $     $       MP<FEN=$]U='!U=     4     4'-T4V)O;VP!
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M;       0W)N0V)O;VP      $-N=$-B;V]L      !,8FQS8F]O;
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M;G5M     %!G4',     4&=00P    !,969T56YT1B-2;'0
M  !4;W @56YT1B-2;'0               !38VP@56YT1B-0<F- 60
M     !!C<F]P5VAE;E!R:6YT:6YG8F]O;      .8W)O<%)E8W1";W1T;VUL
M;VYG          QC<F]P4F5C=$QE9G1L;VYG          UC<F]P4F5C=%)I
M9VAT;&]N9P         +8W)O<%)E8W14;W!L;VYG       X0DE- ^T
M ! #O_XU  (  0.__C4  @ !.$))300F       .             #^    X
M0DE- _(       H  /_______P  .$))300-       $    'CA"24T$&0
M    !    !XX0DE- _,       D           $ .$))32<0       *  $
M         3A"24T#]0      2  O9F8  0!L9F8 !@       0 O9F8  0"A
MF9H !@       0 R     0!:    !@       0 U     0 M    !@
M 3A"24T#^       <   _____________________________P/H     /__
M__________________________\#Z     #_________________________
M____ ^@     _____________________________P/H   X0DE-! @
M !     !   "0    D      .$))300>       $     #A"24T$&@     #
M00    8              ^H   G:    !@!G #8 - !E #  ,@    $
M                     0             )V@   ^H
M     0                         0     0       &YU;&P    "
M!F)O=6YD<T]B:F,    !        4F-T,0    0     5&]P(&QO;F<
M     $QE9G1L;VYG          !"=&]M;&]N9P   ^H     4F=H=&QO;F<
M  G:    !G-L:6-E<U9L3',    !3V)J8P    $       5S;&EC90   !(
M   '<VQI8V5)1&QO;F<         !V=R;W5P241L;VYG          9O<FEG
M:6YE;G5M    #$53;&EC94]R:6=I;@    UA=71O1V5N97)A=&5D     %1Y
M<&5E;G5M    "D53;&EC951Y<&4     26UG(     9B;W5N9'-/8FIC
M 0       %)C=#$    $     %1O<"!L;VYG          !,969T;&]N9P
M        0G1O;6QO;F<   /J     %)G:'1L;VYG   )V@    -U<FQ415A4
M     0       &YU;&Q415A4     0       $US9V5415A4     0
M!F%L=%1A9U1%6%0    !       .8V5L;%1E>'1)<TA434QB;V]L 0    AC
M96QL5&5X=%1%6%0    !       ):&]R>D%L:6=N96YU;0    ]%4VQI8V5(
M;W)Z06QI9VX    '9&5F875L=     EV97)T06QI9VYE;G5M    #T53;&EC
M959E<G1!;&EG;@    =D969A=6QT    "V)G0V]L;W)4>7!E96YU;0   !%%
M4VQI8V5"1T-O;&]R5'EP90    !.;VYE    "71O<$]U='-E=&QO;F<
M    "FQE9G1/=71S971L;VYG          QB;W1T;VU/=71S971L;VYG
M      MR:6=H=$]U='-E=&QO;F<      #A"24T$*       #     (_\
M     #A"24T$$0       0$ .$))3004       $    !CA"24T$#      ,
M"     $   "@    0    >   '@    +[  8  '_V/_M  Q!9&]B95]#30 "
M_^X #D%D;V)E &2      ?_; (0 # @(" D(# D)#!$+"@L1%0\,# \5&!,3
M%1,3&!$,# P,# P1# P,# P,# P,# P,# P,# P,# P,# P,# P,# $-"PL-
M#@T0#@X0% X.#A04#@X.#A01# P,# P1$0P,# P,#!$,# P,# P,# P,# P,
M# P,# P,# P,# P,# P,_\  $0@ 0 "@ P$B  (1 0,1 ?_=  0 "O_$ 3\
M  $% 0$! 0$!          ,  0($!08'" D*"P$  04! 0$! 0$
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MVAU8MH<6G9M=/ZMZOT/7HVN_0_Z#TU<
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
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M4/P,'T,'X"'T'B+A6:-'! (X:MUR%527*19%-4A5VYBG06 IRF %43D(=)0
M]Z9BE,02B4! B\CMVZB:B2B"*B2J9D54CI$,FJD<# =)0ABB4Z9P,8#$, E,
M!C (#ZCQ%Y(HHMTDD&Z2:""*9$D442%22223*!2)I)D I$TR% "D(4H%*4
M   ].(HKU_%Z3MF87;(K:-GAZCH+8K2SKYU<[3E]J=(B_9OW16ETH$M7K3&F
MDQ9)L9@["5;FEXA=]#R(N8U^[:K$7=9;EU!Q7.*)D>7UEA4,ZS.JPE*H]9CA
M74:05:KT>A%Q4>BX>+.7SHZ+-NF5P^?.G4@_7%5X_=.7:ZRZA%FRC-HL=LHJ
MU;*G9J"JT.H@D<[54Q#)F4;&,4104%,YTQ.D)3"0QBB/M,("1<WL)Z^OL+Z^
MX3>OM#U]PAZ";U]/\PA]!'\1#Z"/IQ%PJ,VBQVRBK5LJ=FH*K0ZB"1SM53$,
MF91L8Q1%!04SG3$Z0E,)#&*(^TP@)%6OR3\1,9\K&5-;ZFEH4?(Y_*3$M3K3
ME>N:?B]R@UK'%?H.QM4+5E5KJ4TYBY^) C&6B7SMU'NTTD%#-RKH(JD(I-R+
M&,PPC-,_Q_)Z?&4_.LMJ[&FT.NM!<O20%>8()MTF:4C*+OI9XLX!(JTE(2#Y
MW(RKPRKZ3=.WBRJYR*1BLV9'2CXK5L5ZJD1!5X5!(KI5!,1,FBHX @+'2(81
M,1,QQ(41$2@ B/$7.)""/J)"B/J4?42@(^I?\H^OIZ^I?4?:/XAZ_3TXBX56
M;1<4!7:MUA:K X;"J@DH+=<H&*"Z G*/R5@*<Y043]IP Q@ WH8?4BYO83U$
M?87U$P'$?:'J)P^@&'Z?Y@#\#?B'^P\1>)D43%$ADDS$$ADQ(8A1**9P]#D$
MHAZ"0X"(&*(>TP?B \15QUWQ,Q#=+OA][TV G9YYX\6Q.^YA6&]WN<)G+&[L
M56CBOVVPYK!SL=1[G/U!VS*\IDC;(*86JSIP^7AA:'>N14(K$BS:&=$?&:MA
M?$1,V(\%!(71&YS <Z!' E^<5$QP YD@.!#& #"41#UXBC.3Q;.Y79JMO[B%
M43U6HYY;LICK(TD'S0'F?W6=JUGF*U.QJ"Y(V>9H6*G0DQ!J2C5RYK[W]*'A
MEV1)V:(_(I4   1$  !-Z>X0  $?0/0/4?Q'T#Z!Z_@'TXBX5FK5PHW67;-U
MU6BAEFBJR*:BC58R9DC*MSG*8R*ADCG3,=,2F%,YB"/M,("11AD^*9WB;6]-
ML^AEHQ33-.NVQ7N0>R4A+REET*_R)7]@G)&0DW#ER8"I(1\-#QZ1TX^#KL1#
MP,4V:1D8U;ID4K<1.(G$3B)Q$XB<1.(G$3B)Q$XB<1.(G$3B)Q$XB<1.(G$3
MB)Q$XB<1?@@!@$I@ 2F 0$!#U 0$/00$/]P$/H(<3S\UH5Q;(9FJ[#ID7GKY
MJ34L]@T-&PROJ+%;)/YG M"O6![%07;A143H5G6\[1S1-X9=,K5I/7M*X)D5
MDX$BI-9Z,LE6PF4RO&\F7# YZO+6N@#K]7-&W]G'(0L.R;&*F@Q&68&Z,\<U
MBOL1VI0[QPTIN0^A/A&5QX8[D7HDY!R+T;.]H=4N/PV4RT_%JMB1VR(,QAF9
MO%ASP?5XJ%&8=3ZT(9NTS;0*]JE$J^A59992$M44A)-4G21FTA'KB)T)"'EF
MA_11C-0<DB[AYJ/6 J\?*L7C)<I54#E"193&V<1D+>-N-:+%.9T3RP]4<C=!
MT4\+QVD@L1.9/!(/9DAD9(W;7!,??KY.E6OU7$P68Q(T/'3)&[NV2&5A[QS0
MR!\,T;O:CE8]C@'-*S?O O8G$3B)Q$XB<1.(G$3B)Q$XB<1.(G$3B)Q$XB<1
M.(G$3B)Q$XB<1.(G$3B)Q$XB<1.(G$3B)Q$XB<1.(G$3B)Q$XB<1.(G$3B)Q
M$XB<1.(G$3B)Q$XB<1.(G$3B)Q$XB<1.(G$3B)Q$XB<1.(G$3B)Q$XB<1.(G
M$6G>]L9#*_,W3]<*@LWALMMWC]>I-R8HE04R3R+9VG&M21$X>@%BZW<XIIK,
ML/N*4BM1,X5]_M HPJ]NCD);K3H8_*T[<N_U?FJ[,;<)\OS<5F)MU^CYUBX[
MUI>[T.#UCD7IB]'<@/3RJG4Y-A(RX'HS-7#0Y+&&%FSJ7(Y#BW(\/#[.W3YV
M<#NXD7-C/=@6_N( _P#R^0^2\R_FJV8?V65*\A46*LA:*^!A_8;1FR0$>XMT
M2B'L02OE:N0G,I(7:.0[M,NN1\<;8'M9KBL$<%H><E_C3I!%4LZ\WRX*S(RE
M,X[<<=;H@:CH2.4%BW@L\ZN=C$\CEDGKG^Q2S[6&2U7WY,BS%=CKD([-%^M=
MV72WXFJW?0M2Q.(G$3B)Q$XB<1.(G$3B)Q$XB<1.(G$3B)Q$XB<1.(G$3B)Q
M$XB<1.(G$3B)Q$XB<1.(G$3B)Q$XB<1.(G$3B)Q$XB<1.(G$3B)Q$XB<1.(G
M$3B)Q$XB<1.(G$3B)Q$XB<1.(G$3B)Q$XB<1.(M!6EZIL$-\4^#IR/D6[;4.
MQZE3(B.@6&A;":HTF-K5=Q):?S:VY+"Y=)9(22N9M.=TUG;[?>(MC*7CR RM
MPG:AT2B4;/T+M#I!ZALG]'7?W]]]^WW[T=ZT".XSF.,5VR"9A>Y^C!T;D'3U
M:>'CJ:(]=G!SHWEY;TQ2,!E9OUZU8$XB<1.(G$5'M/CZ_;_**7QNQL3C7=R\
M1+=3[*Z((>C[[%;9%"'C _9 4W3>"LNAR#-43B("58R?RS)>XVBOUHI[_JLP
MW#E<1>HS#W$POC=&._\ :\*W;<WWCI) [;$;Q^3M<6]+/&.1T7B.Q8PLQA<6
M]G9/B6:Q^8Q4;W ]VN@RN9D#"TM+(I@3[6CW6<Q2GDIXI1M,T!^Y87Z&;O,^
MMEA8>A9JI[=B]C7K:MZAA4^K65B[Y4F]WKQCF,DLW5CS',Y8NA%?=<*SUK'M
MQV1+6S6J1FQ^3K2[\*X(#)C\I3LMULU[\(FCD&M^#.'-/5TN71O2GQJ@,YF\
M?2+H<1E?5>0<=L1Z\2ICLS!7SV!G@=Y>L8QMFNPGL&VJDD;VCI>Q2O@6FRFC
MTMRWN#5K$ZGGLV\SS7(!K[BH1EZ@4&JCB1CDU !0*W<H=[$7JGK']QEZK9H@
MRI_M17*:<BY%BHL7>8ZD]\V(R5=F3PUE^BZ7'6'/:R*4CMZU1FCFQ]YHT&W*
MLX Z"TF!X+)2Y&FYMMC8<G0G?C\K7;^C%>@:PNDC!T?5[D,D-ZF3W=4M0D^U
MU 3AV@6Z3B)Q$XB<1.(G$3B)Q$XB<1.(G$3B)Q$XB<1.(G$3B)Q$XB<1.(G$
M3B)Q$XB<1.(G$3B)Q$XB<1.(G$3B)Q$XB<1.(G$3B)Q$XB<1.(G$3B)Q$XB<
M113JFYXYAS*%D=ATVE9JRL<D$1!.;E8(^"3EI  3,J@R^W+)&7*U(JDJ_<%
M6T>BJFL^6;I'*<?!>RF.QC8GY"[7IMF?X<1L2MC#W#6PWJ(V&@@O=^BP$%Q
M.U(N/<1Y/RV6U!QC 9;/34:_K5R/%TI[CJT&R&OF\%C@PR%KFPL)\29S7-B:
M]S2!**"Z+E%%RV52<-W"2:Z"Z*A545D52 HDJDJ03$424(8ITU"&$IRF Q1$
M! >]P(< YI!:0""""""-@@CL01W!'8A1][7,<YCVN8]CBU['@M<US20YKFD
MM<T@@@@$$$$;6N36_B3YMD'E 'C#,TN3D[ E8<!K3F28W[*V$^[>^1-C/5:B
MZJ&63UQB=+T&,KLG\MY?'5+KTRK6:^5[.*MG#9@X)V33.C?6>O>NCH]GI^_K
MZO/X=/[UZ!'4]4,ALRBX)>D5?5@8C%H?G3:\<$.V2/#]7/EOK[]I>5\^O$A-
ML\=)ZZW>@WFHN!8-8JFZ',2=L>3J5U5@7F>1$54GDKIM>GS9Q?&T%:\\9V>K
MS4A4IV,C)AU(1Z[4MB\JPW3?B3^)6=5)W;&VEL;NV;PM"L38*DRF'\3(Q&A,
M:E9H4C&X#%A35[*&;W.(U@]$+.C>U<V5+;V];4A%T'JE??W[*X- <6R$LUU
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MFS)JV:()E*DW;HHD(F7;Q\8QD4;(F2Y=K(V-C8UN>S3&M:QH:UK6,OM8T
M-8UK6CLUH  4#L^E/E%RS8MV*?#)9[4\MB>23T=\#EDDFGD=+(]\LO'))9'O
M>YSG22R/D>XESWN<2XQIJ/P\<ZU;5+)I$QJFOQ4/>#X,I?<TBQRM_6+>IXY3
MOZR9RH\MEMRZS[!!KA*E16GWM0TRN2,R5 OS'B*RBRRF_:T,:U@WIK0T%SG/
M<0T:!<]Y<YSM>;G$N<>[B223SR60S2/D<V-KY'O>_P *-D+"Y[R\],4360Q-
M!=ID<,<<3&@-8QH"P_!_A6^._CU<*G<*/)VD'% LT-.4AA^K^0P!(F+K]4UZ
MGQ=9FINF9?6;7?6R43LLV5Q8+_8++<7JE<J2SJQ*N6T^XL=WW_%6EQ)<7:)=
MLDGMHD@D@ @;/<:((T3H;T1Y5?X8.7TRIM,VK>S[Y%Y,F;(Y:5S-M.4!. LU
MUQG/\NR^L7.QR),Z+9Y%P\IV04Q&9JPSB5%6L#,]N8UB/L:;*09CHD]AHG>N
M^AW\NY)T/B2?CM5<X.>YX8UH+BX1@O+&@G88"][I"UH]D=3W/T!U.<=DR$R^
M'SC;&W7ZY(V+1#26BZ;0]6FFZDK7S,6UBSSRC?>6D,UC2%K)7",2ZT:06B9)
MNY<NG*M1*FP;.VDJ49HU=_ >7Q^[6_/SWW^[?NUV5>MO;\VS0:1K<FB3&&=9
M_.;Z@X>* "&>(2"TQ:C%?I[X.GCY8[&SG9+2]H<-8YW.R,5$.W&62HP;VRGT
MT9I&M6.:RZ2N%4@9(NJV)Q(U:L6"'K\I+MXV=EF+^5(^</V^^]#\.^O+\=]_
M/S\_+MV3K;UA_A1@  >'N3H.FANR3(9-DCK/MZZB= -]E6=H_@MD><[X7R2J
M$S=XG3W,1 U*Q/T7\ #*Y9[7,JJN81>=VIN%<!>2JK)Q2*QHL:4CIO,0F@,G
M[V"EHVOV2SUV9?N ^?\ Q)5KG ZTQK=;WTEYWMQ(WU.=^B"&C6O9 WMVW&,[
M!X!'O=1US)[1LFAUG(-#T?R%F'%3SZ1K?V:[YEY2ST9I6L4C0XJZT:SQT;/,
M=-DM!;42_P!$7B+O5Z/8S,XBRQ<E(28@/_#O_G_/[_,G=)Z2-[Z0' AH <-C
MV2T^T"T DD-/42#U:ZW6$TWQ5SW5+P:^STK;&4N8OC>7[/$/HM*/ GC!Y!I>
M2%"*";V'?N1_2EW1+%VDQG0F>UD3-(PT1)B66*_</Q[[_P =?'R_N[(' #70
MTGVO:)=LAS>D#LX-TT[<W30>HGJ+FZ:-<MU^%9=9#2)*L9]KLO0O&F^6YYI.
MGA&7"-^\B7O4E6];AGDHQKC[$I= D^R6O\"UK-JB=?J5=BH*LQ2<[E%MLD/^
MLLV]GI/F';&@![)&CU$NZMAV]=NDAW43MO2 [(? =$YVWLG$D;61-C#H'0^&
M_P 61TSI_$9*V1L?3$(9(Y1+([Q(/!9'--.S_#-I$D]U_4<$E9.B;AIMDS2W
M.E%+!&UBF2\CCKSQ\<Y/'2KAIG-Y6:)9*Z\?(6Q93*2=4O"-6LMKO+6<KERH
M%PL-#D UL C0\B1W/GOJ ) ) [:V 0/<?:5(S$7,;*TL9V;))&"^0 OZG2M8
M^5C'R-:>D1ET4;VM )8\F89GXM^(>I9=9,ON.R7N%N5ASZ#\II=P\BWZLF_F
M](\N=];:Y<5Y5\A1\[AG<=0*[6J]6(.;A:C46EODK);),,[SR,B*]"K72.#G
M;&]!K&C8T=,8U@)'4[1/3W[G_@,]Z=EB<21N>6L@J5FE\8B)93IUZK'N:)I]
M/>(27@2. .B#[1:S8OUB\:T0Y9XO;C1[OXD>.=FI'A[#7/'']=\A)'?*([T-
M?8[M#YS;J]7-CL#M\^R2$:_KMMWW@R,7=T)*Y+EEF=RL;E\_E/E&*O>&$L=)
M_9:YC#]_4]LCF]ON_-NV?=V\]KTLJO?4GN[:(*]BM5?W'B>-;AN30=+"1N/5
M&82/!]C;.SBX!;WNL7F3B)Q$XB<14T\@H=W-J;ZC&IBK,Q7CE4;77B%+[S&L
MU)N6D7&L^POH(^\)^"CA*)0$Q3 !B@)@ .U>:B=+BKX8-RQUWV(>V_S]75F#
M]_C1,T?<>ZBW-JTEKB6?; TNLU\;/D*30-GU_% 9.@0#[Q=J0$?<0"N7R&EV
MC"(P#R<B# 5CFU[J\E8'A!]PJ8[M#-M0KK\\Q1 #1D*>Q531'P@!O0M"16*
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MJN6YA7-LKUXJ]Y+5Z4^<5-[46=YKLQ%S%98R*4R[K'SVL*_92K%Y3_)_S_\
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M1B86&9A-S2[]_P %4N)#0?)H+6C[@7.=K[S[3B>^SWUO0"N!Q46A%U/VB_\
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M\E8G(\[C9Z(WV'0T>QMJE"-Y&2)L!WE+CKA*2!&A%CSL!JD[1K E/N5#N6*
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M_P 50AB$]QBB $7DHJDD*8*J)IBJH"20*'*05%3 (E33]PA[U# 4P@0OJ80
M1 /H/$7)Q$XBXDED7!/F(+)+)^OI[TE"*$]?0!]/<03%]?00'T]?P$!_ 0XB
M\P4()S)@<@J$*0QR 8!.0J@F AC% ?<4IQ(<""( !A(;T]?:/H1:>)3R4\PY
M?XC=DPFA)-[%DM.M.>)3L) 5W-9RI5G.Y.O4:5M,UI]Y3N)M"I-W?1MHOTU7
M*^]B8IZ_E:AEL=$U"5J-NG[C)UV/+0\CWV=[W\NPT/B"??HC+U1AC6^$TNZ'
M@OZI _J+]M=^ET M#0WI#'-+'.V>LM,6XGJ+$G$5>_+5[J4;XL>24CAZ$DYV
M9A@^M/,I;PJ*KF;6T1M0YY:G$A&R+9XJYFC3Y&'Z(;$:.3.)'[,B#=;W_+,1
M:"'-E\@&M7MT9'V_R@FH.%JGDS_PIWNC2/F:P@-2\JOU-\.)7#6$A%Z19[GJ
M'ZO1EMF]BIZ5.V"ZVW([+,06TSR[:/C&ZU7I=QZ=#6MD ZV=M[N!!]D-.]!W
M;R!:-D]6O1((1&PQEI>]K'.;U2F2)P,S)&.)BCB=U]+)08RX,CDBCZGR-G(^
MGA/YGRT_F@4%?87Y@$]?8"GM#W@3U^OM]WK[?7Z^GIZ_7K5YU ]9EY"2\A]%
M:O*M.U]"*S#/V;"1EW%969V5N-QTTWZ4A"0-CFY!!@ @!!3L;&OR?N,40CA(
M!CE?OW\_^(_=^[[M$W.:!K3VNWK8:']MM:[1ZFM'8N+#HD=3'$$L+'.]+<0&
M&MOCS>B""98#9&E6E5A-[2C":C5+-1$FIQ#T]2KW.4I*I"B/M%=J@(@)BE$N
MHR9\*?$6?^KR+:[SOMX=Z":J ?QL/KZ\^X UWV(1RP&MD>%99H %+E$5&R_9
M'^J9_&Y##-C.AW#\K:Q+PTZ'7$QQ[M"ER^4R#T:CW#/K,W!W7;Q5YZI3K;Z>
MJT38HMU$R"91, @4XM7:ORS^@B0_M,'U .]]NM%<JV:DS>J&U!+7E;V[LF8Z
M-VM]MZ<='W'171L1E+>#RV,S-!_A7L3D*>2IR=_8LTK$=F!QUK8$D;=CWC8/
MFHC\6;U+7?%:FE;7R3S1J*62R_4 !4IG'WA9E+/Z):I%9+WF420L$M7W-AC#
M*?1Q&2C1PD91-0IQU^"M/M8VN)WAURJ'T;P![^MTI'U9WD;) FDA=*PG])CV
MD$@J2>D#$UL5RG(NQL+HL'EC!G^/[:0S[$SU>'+XZ!KM!KGTJUV.E8#?T+%>
M5C@TM(5B.W"A2C78\^1U;*=#SA9P9B>Y5&<@F4DF(@M$2KQ@L6&FFQR_M)NX
M66!E*LU2?MI.F:*A/VBAVTPF2=A\QC<HUHD%&[7L/B.BV>%D@,\#P>SF3P^)
M"]I[%CR"M?EJ(R>,OX\N,9MU9X&2CLZ&5["(IFD=P^&7HE8X=VO8".X7H83H
M:VKX[G.@O6P,)>RU6,<V2+#T]86W-$OT;<8%0"B(%7@;2REX=P4!'V+L5"_B
M'9.0XQN'S>3QK'^)#5N2LJS=_P _2>?%HV1O1+;-1\,[3[VR K'A,@<IB<??
M>WPY;-:-UB+_ *FVT>';@/W.@LLEA</<YA"EGM.MHG$3B)Q$XB<1.(G$3B)Q
M$XB<1.(G$3B)Q$XB<1.(G$3B)Q$XB<1.(G$3B)Q$XB<1.(G$3B)Q$XB<1.(G
M$3B)Q$XB<1.(G$3B)Q$XB<18?=G%_;1"2F<1%/FIX7R)%VMVL<U6(@D8*+@7
M"Z3^!JUN>*OBN"M$T6AXU%NHBJX6.]3.@FBXP6#:# :C('R=0V+$DD3.C1V0
MZ**9Q<#T@-+ ""3U @ ZS+29F.LUV"J8RY<\9@?%ELA:QM85RUY>]MBGC,K*
MZ8/$89$:S6.:Y[C,TL:U]+]^M?Q"8F"JBF1YOBSB4<7> ;3?ZOW*<M[HL*JX
M]%DI%G;Z71&<?7G2WRV\],QSU[,1K!0[ADDQ]JLFTC>7GY9'%7.-J8Y\CK4+
M9O#FDF=X1=HAXGAKM9"XZ$TK'.DC9MS T^VWEO,<EZ::]/'NXY@.*&P_*TX[
M7J68MY:3U5T@#FS19/#8.*"E([4=RU#+-:@A<7PMATZQ%/!9;RQ]I??0/'CW
M>T/=Z:]I(![O3Z^@?<B;T#U]?0/</T_W'\>V_7F_?7Q?_P#>6_Y%2[UKTCZ'
M_(7"=]MG\K,[W^\Z_(OM^&^WWK5WYR83K%ITCR L;KQ:C/)&R:5C66UKQHLD
MKGL'LU1RNPUMG=OU_P R;_I';O'RZ8+,VNY2=>NC'R"JME@")($C'LA*)V'.
MZO$!M&[T.L=^D[#7=@XCMIQ;LM#M;VUI<!KV"=B<0$=+39C]HQ'KC@FTULQC
M('1+) 2^*.4AQZH8W2QM+1X+GAS(OL=<^)+I6VG@+I1-1+E :?F$I9*Z^E*K
M.T%@XRGS3\/KK2+-3)T7,4N2&/DE5V.VI,8EI8)9O% O%ZA=K+H)8Z.95=KM
MK[AO6];T-^?<'>]]]$[+=#0&6;P=L\+_ *N+Q".H,+_"9U](>7/#@_K$AZBQ
MSP7Q-CB<R-D8Y9XM_$*\=<TP*@9G39Z:1-X@:-#4*=F[)%NYKQ8\EO(DN&T;
M0*[;_M,JN[E,UIEM+8/(VNO(=:94BF;'2J$P0;1</GL8]HL1[DG[R5,&<9%Y
MT>,]6C/&EO5M<9XAE#[8Y#(YWQ$G:5,2,I+:&AGMOP*C/9?=4A?(Y]FMN=>0
M]9M1;5&!56#13&@LJSRI?:T6U?>/W=O\D'O^(^&E4$=320.D%NQW((&M['4T
M]_> YOP+?,6I\J,V>Z%YJ>/1DO&6^2,;7G>*7*T^6==A8>V25:5SK6)BV5+&
M\_6EK;'+Y/!RDXJZF/)+08*%^WW3)Y!AF9HFVDE/TEG5%0=_>!YGOO[MZ[ G
MOK0]VSW(&RL20R73[;YP1&R+X7>(>8L>W93JU6V2RLJFW<YAXR1GA_*Y[>\$
ML$RSL<G+Q4BYW-S8'TEE<5^D8.5FM#9:&W4?E@966AB'7;6]Z[[&M'9\NYV-
M:.SKN2-: )@GR"R.W:GI'DZ>T8G->0R\5KVXUQYFT6SKTG*1[J^>(F30GAMI
M,4PMLM#LF5/K"Q=-JT?<XYU]EH&I:!?[6"L6O'WF>B*G7;7W=_Q_S]VNVO?M
M5=T^ST_[HZO/9=L[WOM^'3VZ>G?M]2[?S&P/R>U&4\?7J%#O>CS6/8E,YW"I
M/J?E5LJE@\JHVP85.1.A6Z6N\FXL=$RNZM86R$7VW.7%.UNH'JDT2$M%7=R[
M&(O=/P_S_BJ.Z>H]));L])< UQ;OL2T.<&DCN0'. /8./FK:^4M"\NKAY (/
M,GT/9:9E+!EX;P9(_.Y.AQT%)M;COVRPOEE-2'ZQ0$Q,FFJKA@Y\\8OFKEG^
M@SNV4S7$'=F9H.(XJ+6*/DEYT4S5*/C4[>]7MGE WFVT#3<H96'"SU>SYHR\
M+]/M,<^VJHM%FE[1T&<\@JZVLDY>XN$85@E7&GLV4LT0/:8,][@WK<&$EG40
MTD@$MV=$D@ $C7F!H^[W+U3QUQ<GBJO,M4696UY)'MB=)7;(X1/<^1L;&.?$
M&N)=&P!Q.XQ^BLS?TORM\'8S8HQU/VZF^)D9?,G@*!;Z7/9Y59^*I;71?'+/
M-?GK?,Z%(ECUM#UG/5%(O$9X):+C*\>O:8P5;LM)L] FW57N+PPD@D-.] [V
M9)''JWV)/5O8[:('F"LEVR^TVFZ21DDD=>5LA:) \/ER%ZTX3%[0UTCG6"_J
MBVSPWQM)\02 4<\I=$^(5JF/^+M]\(;%M]KU^='RE+MED:*UY[H<UX_Q/E5J
M$)X2OK])Y^0:;,LU:C&ZP-0G:TL[@9YK^EIF(D))@_1D'-AUOV=ZT//[]#J_
M=U;Z??K6^^UY91$'ZAZRP,B!,G229?"9XY;T]O#\;Q/"W[7A='7[?4MD<=:)
M/8_/BHZ-H&"ZIH%AS75JAG]+?R>:>7=*J&(OUJG66]_M5*FR>(&79M8Z:U?S
M$[+#,;UM4ZM-QY!D*G%,VDA4(=>[\WTG?7U=]>73\-@ G[M^[?W#NO2!CS"_
MO:;8U(6%QB\#L7&,.#6NEVY@:TZ]D2'NYK/:&_\ ZQ>).(G$3B)Q%$+#_7NU
M_P#:'/\ _P STOB+I?)Q@Z>83HS^/2.O*U&';Z-#I)%$RZDSF,JPT*)3;@'U
M^T*R%9;I(^GU^8H4/P$>U.<8YV)NN8"7UXA<C \S)1D9<C#==^HO@:!\?O\
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M1^>0QM!@SZJ;V%<3O%SAU4'S=B[A?-1T?>V B>B.PUZH#[PNB<_ R[<#SF(
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M'_\ \2L_E5^_\4R?\._E1^3CG_Y?_?7_ .7_ *_]/KS[<'ZHSO\ X<[[M_\
M6?N_'X=T_( _MIZ/_P#XE9_*)_Q3)_P[^5'Y..?K_P#O7_\ /IS[<'ZHSO\
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MHD=KWOBXEZ/<5(V?+9'*<WR,7M-$'B0X]D@\NC(YJN9(M._2%#CE=CAU>%8
M+7+6VO2EZ4,I7EH\>J8?T:86PWPY:N)@AI6YX=@=%R# V&V\BUS -.S7*\C(
M"&^+7<0YIJ=Y*?!KTWR!V^3UV2\GHZ07F6]63D%K%G31C+ : B8^).W9-Z4Z
MKL(RC4$&!$H9%)F+]LT*BG(R4D^36DG/=N*>FW#\:X_!A(>)20QUC:\%E/)N
M?7#9YI9FEYO1V9WR$R$S$O$;G=1BBBC+8F?.O)_1#D^1YQ^9GY0V62;U8S.M
M8Y@F<Z&..-W2:<E:)K-,U$/#,C6Z\2663JE=MB#Q2S<H%^7;_(M$"IE3*1+R
MQ\G 3(!2^T/8136E"E] _ /3T#T#T#T#T[CWY7Y3OU4N,/V=DNX=Q0DGW[(P
MP/?\?\5U7\F,<#L6N0#MKMRKDVM?@<L1O]RXA\4:%Z% F@^2Z?M,)@$OE;Y&
M&$1'T^AA5TM3U /3Z!^'U'Z?4>K^5^0[[QG%3O\ ]3^,#7GY:Q0UY_X*AXQ1
MUH7N1#\.4\BV?Q)R9)0WBK3Q _LU'R<2$WX"7R?W-02>@^OH3[1>%P_Z?M 8
M1#\1]0 0J.7W>V\3Q1VOOXGQ\;_'IQ[?[M*W\EZ?NR/)!_\ U/G7?_RON7C_
M ,+%< 2B37_)TGM+[0+_ ,1NJ*@/IZ_M&^T6!83&]!^HF$?P ?3U]1&OY76C
MYX7B9V2?_NQB&_N]FLW0'NUK[CL*IXU7[:RO(VZ&M#D&4/[SUV'$G]_]ZU >
M9GP<]GWG;'V@YOL%><5MU6Z_%D4VNZZ!:+P5]&(+HNRKRP5F?^?&![TQCDAD
M % @J)?(3  $W:>#^FW!<>P,>-RF$LMM,M69B,%0QM2@8Y7-<PMA-NL62C1\
M0B/VR 2XDG7(>9>B#,Y[-NR&.R]=U<U8(0<U<OV;P?&'AVY15G!B'4#&WQ!K
MV@0!I;@(+PZ\;HQ.*<3&0T^Z3<:V;$+.Z,W>ZC+D=)(D(HNVEM(=VB30$QRF
M,F*;E,4RF]I *'T[BMCFW*)3,V'-7:,$KW$U\8]F)@+7.+@UT&+94A=[M[8=
MD;.UUZ'B?'HQ&Z7$U+DS&M'CY%K\G,' #;FS9%UJ5IWL@AX(WI6(B(.%K[)*
M-@(B+A(Y  *BPB(]I&LD2@   )-62**"8     1, ]  /]NC,UB>S(9;$TL\
MKN[I)I'RR$GS)>]SG']Y6_BAB@8(X8HX8VC38XF-C8T?<&L :!^ 7:=B61.(
MG$3B)Q$XB<1:K3>2>)(>1F29MC7B0QM=G>VQY:+U.HY5/432\(M.CR[6DVZY
MS%:'&9 *Q).X%12PWF[Z/>,AC+]GC10^8V?89425D:^[S_=^'^>WW]_WWAOL
M;ZAW<?8V!^@W?4[9'<]73'V)<>L#1&G;4NHK$XBBO=)Z'J^*:]9+#<;)GD%!
M9E>Y:8OM,8IREQI4:PK$HY>6JHQBL/84Y.TP""9Y2O1QH"<!],-6;7]#R?S?
ML2Y%\Z8;YIDQG\G<:9OFV-*I9*?Y47/Q,H;'7=#T:Z0/DG!QGB?'>-OCQL^B
MI/9QYI]\M3IYIVD+8G8;%<Z*1GJ-UJ#92X0F21<_$5]WQV/^._A]W_#WZN'3
MT..QU=30![75TZ>7$>R6Z!#027!P)'2UP+BWZ?4Q4%-,50*542%%0I1$2E4$
MH>\"B/U$H&]0 1^HAZ#U%:H%K$VZE?(?1FCBMS\&G#YAG[)L_F"PX,K"E^N.
MFF_24&,9,2;H6 "4"B,LUB7GN,7T9B41,!5( UIP._NZNW8'OMH\B2TZWW:=
M;;TN=/O%1.(G$6#Z!G-2TV#"!ML<9TBW=)241)LW*\;8*U--@-]AL%8GF)T9
M. G6!C&,TDXUP@X(4RB"AE&RRZ"OEMTZ]Z+P;#"X!P?&]KBR:"5OZ$T$K"'Q
M2L/=KV$$=P=M)!U68PN.SM45,C!XC62-GK3QO?!<HVH]F&Y0MQ%EBG;A)W'/
M ]CQLM)<QSV.UMT+R<\GZGYJ1WBQHM12L] 7;24;7+[*1\?6K3881HWEYR&T
M5W*-9 :O8':L1%NXN6A8!C%KO%HQZ^1B8J692<.$.JYK.5^2LP5NL)J;F/9!
M;>UL,\T;622LMND:[P)GED;HY(HF1N)8YX8Q[7M/"\/S[GV.]*D'H]S>-;?P
MSX[$%'+V(8*&1NU(V6KE3.26(Y_L^Z]U:M+7LU:<-=\KZ\TK:U:U#8IK:YT[
M7T2OP0 ?Q !_'\0]?Q#T'_\ 4/H/_3B*E\[3[3XNS4KH.0P<E:L,F7[J:U'"
MX%JH\EZ0]?+&=3.FX=%(@)E2++'7D[SDK(A$)Y0[NR4=)M:S/X.W1J6O/@Y7
MV\?$^?%2.=+>Q<0+I*SWGJDNXR,>XDF2S1;ILAZY:W3,713]0J9.AS^K7PW)
M+<&/Y;5ABJ8#EMR1L=;+0Q-$=;!<LLN_1<U@9!B.1RN<^FUL5'+.?CA#<QEK
MJA;ZO?ZS"7.ESL;9:M8X]"4A)V(<D=Q\BQ<E]R:R"Q!_$!]R:R)P(NV7(JW<
M)I+I*)DW]>Q!;@BLUI6303,$D4L9ZF/8[R(/]Q!TYK@6N <"!SW)8V_A[]O%
MY2I/0R-&=]>W3LQF.:":,Z<Q[3\-.:X$LD86O8YS'-<<C[,O"G$6$Z)G=1U2
MIR5+N\426@Y$4%@ BR[*1C))BL1W%3L%*LU$9&#L,(^21D82<BW#62BI!!!V
MR<)+)E-WOQN3NXBY%>H3&&Q%U-[M;)%+%(TLFKV(7AT5BM/&713UY6OBFC<Y
MCVEITO'?H5<G5DIW(A+#)TNUMS)(Y&.#XIX)6%LD%B&0-DAGB<V6*1K7L<UP
M!4!T?1KEDELB,7WN4-,MIUV6+QG=G""#*/T<P$,=K1-"*V(C'5S9&C9,WV<Z
M1&D!IS9!>7K2$=-)2M782*_C*.9ISYWCL(@?79XV=X\USI)<6"0'9'&EQ=+:
MP;WGVPXOL8E[FPVG2P&&W)HJ60N8JW%A\[(9FSO\/#9PM#(\AV);1R'2&QUL
MPQH]DM#*^38TS56QS":I%;+H<I2G$3B)Q$XB<1.(G$3B)Q$XBJ18_.WQ,J6J
M*XG8MF@XS4$+)%U!:IJ0]K6<IV.959(1L6=^V@%H@%G"T@S3^:,A]G1.MZ.%
MDO8I[)E6]'W,;F(;GJV#GEQ+JLMUMP3T@TU8 ]TLPC=9;/IC8WGI\+K(&VM.
MQN*3\XXI6RAPL^9@CR@LQU#4,5HN%F5S&LB,C8'0]3G2,&_$Z6DZ<1HZMOT-
M4K3B)Q$XB<1.(G$3B)Q$XB<1.(G$3B)Q$XBXG#A!J@LZ=+)-FS9)1=PX<*$1
M0001(*BJRRRABII)))E,=10YBD(0HF,(% 1ZYK7/<UC&N>]S@UK6@N<YSCIK
M6M&R7$D   DDZ'=4<YK6ESB&M:"YSG$!K6@;))/8 #N2>P'<K71L'GK&A(-:
M+XXQ/WF6^>4=,H:V(1,C8ZX^7:J"@]/G%4A7+&?V5:,5 22$U$R55QV 5^EQ
MV2MJI"R6WUNEA^+MAEYE:L17IV^)1X=B&LL<KR(UU--F%P?#@*CMCQ+62:ZQ
M&TA[:#HW"5MN"QO).;FT>'U*<>%H/$>8Y]R&9V.X3A"XZ#1>=T29V\[OZOC<
M1XLEIS710S.G;X#L<S?PPT/2IX-+\I[C8%91\V5;FJ,=94W5T=1;L"F=05HT
M&MI1,51JJ\]3$>Y5@;"I0+E,/LMXT#6@.L\5CV3RV<Y)7]0LLAXOQ@/#X^)X
M&:5@M=/Z$O(<QUFYE[1'Z33+X,1+F0R&!WA-F6//#^!S>M<:9)S7FC6N9+Z1
M.6487PX]Q)ZH^%\4F8^CB(&NT8LADXI[LH#)VX['W&>,Z^,=B>-Q)J<>,R?-
MF*N>-BLZ$NVH]:2<4IJ0XJ A5')8P%Z^F*IC*F"*4:^]8YU3^Y0YC#XF8S&Q
MFN64*334 ;5<*L(=6 .P('=&XN_?V"WOW\R5KY^5<GLC*"QR+.S-S;S)F629
M:^YF5D(Z2[(L,_1=/2 T>L-DTT!HTT *3OQ_'O<M HHO&$8GI;5TST'(\WN:
M+P#?:!L=+KTJX,8P"'SDWCN/4=H.2^OJFZ;KI.4C>ATE2' #![,=D+V(EDFQ
M=NQCY)@1,ZG*^OX[2-.9.(RUL['#8<R4/8X$AS2"0L=^)F4B@AR31>BK$.JL
MMDSBJX'8?6\0N-=[7 .:^$L<UP#FD. (II:/AFY6D\-,8?JN^^.DL0HBC'YQ
MKM["E+*>I1 DA675A3D09@)0#['7[-7"@41(FHF0?3O3-<Q.1<3FN-XJW([]
M.]B76^*97>R2_P!;XU/CJT\Q)V9<C0R!>1^<#QV6RI9WE6)B$.,Y)9EK,&F8
M_E&.PW/,6T  "-E?F>/S5JI T#38L7>QP9LF,L/=8>.,>=V6&]T=L^@ZO$-R
M^A7E%N.<IV Z9!*  ?-/)*B7="1,8@&,=0ODS%N#G 2D3,90HDQGC?%KO?%<
MSY;QB<GV*O((*'),6W>]!^5J8YF3#0>P_P"1WNT072'IV?6/2!EX=-SWHI]&
M_*H1WDN\<?R#AN7>1_U6+@Y#!A&N(V23=;&" &P:/;0[Y:^7?F97_-4[1+=]
MIJCFA2=&B86K*P;7/E&S>3A("6>(V/*8>?L5!FI20<2[@'"[U2PQ5D:BP<(&
M"'48L6LFI?Z,W,^1TZ_*JWI6QD47AV)*D=+'6I<>Z.G)-$2Z1MN"%QF="[UC
MQJ!<QQ,<L),7AMW%3_2^]"O$,;:X#D/]&^SD;5QS6Y/)9//TGY9EB]&R6/U2
M>;#S9.K'3BFB%1E/+0%Q:9(K =,ZP_?1$^/>F:0_9SDAE";ITBN5VQTKSLO!
M]RMT>L40,A)UKQISB38XW4W)!]'+95A;:5)-%@(+R$*N!RDCD?$. XQ[9LYE
M\GS7(1$.$-(.9CVO&NS<EEZ[(82TC6Z/&7L<=NCLGLY:.QZ5?29?ADI\5QF%
M]&>(G88WMQL#*60EB<TM<RRW$6I<QD8WM/=N8YA*\ EDE8=V"T#7Q5B; @B7
M:])T3:4DTTR!4Y*4;T+)VI$P I&;7+<W0K,%*Q:292I(,KVXO"J9 ,!GB@G,
M8=R.5OH@1\=Q&)X\QHZ66:U<WLJ&@:!^U,DZU-7D'O=C68YGEJ, #4'=Q[UU
M[I<]E<GGI)'&22*S/ZKCW/<=N!Q] 5XK+">_3D7WW[V3(2238NKU&J4>';5Z
MEUFOU& 9% C.$K$-'0,0U*!2D &\=%MFK-$ *4I?\-$OT* ?@ =&[=VY?G?9
MO6[-VR_N^Q;GEL3/[D^U+,Y[W=R3W<>Y*W=:K5I0MKTZT%6!@TR&M#'!$T>7
MLQQ-:P=A[@%D/>9>A.(G$3B)Q$XB<1.(G$3B)Q$XB<1.(G$3B*CN"^ &'X2"
MCA-:QZ7/-+G&7>K6_06])1N%+E8IDS8 K!V+/J;0Y)Y*6-NR3#2;=95I^\:[
M\Q9'4[-<&AP:EKOL!VT"3Y#??7F=;([#0)T.Y !)W<7DL;&0S37O>"&,#R7A
MC2'2!OB/:!&WH8YQ8QQ>YC6F20NO%U%:G$3B)Q$XBB%A_KW:_P#M#G__ )GI
M?$4O<1.(G$3B*,];SPNE4QW"-'_Z"L\<[8V6BVDB0++U2\5];[=6IY-/U 5V
M[9\7[-+,!,"4O!/)6&=>YI(N"'\.1I^NUG1-?X4['-GJS@;=7M0GK@E _M-:
M[V9&>4D3I(S[+RM%R+##.8R2K'-ZI?ADAO8F^&]3\?EJ;O&HW&CS>QDH\.S#
ML-LTY;%63<4[P?'(=$^\REM9MY'?H*T1CU_5[[5S*_.6JE[KRWV&RP)E1 #.
M&J#TOVN&D/:5.8@'L5,MP%K((&-7'V_7:S97L\*=CG0VH"=F"U$>F:+?O:'>
MU&_RDB<R0=GA4XWFQGL7';DA]4OUYIL?F,>7=3L=EZ3_  ;],N[%\;)1XE6;
M0;:I2UK<>XIV$R=WM6^3B*GEQSVXX/9YO8<%A'5CJ5@?K3FT>/D8*29;&Z7-
M\R4TW'FRITF4+J92@9W8ZL51G ZHFFJ9?]'W@S>:D([8J6,3-+D,5$^>O*\R
MY'$1_P#3$[Z[F/:?9CO :=- "V.^ 0>BSTR/Z7C,SB^74*O&>7VXJ&1I0LJ<
M6YI8#B:,;!TU\!R9[ Z6UQXG4='(%LMSCKBT,\;$B2K#.5"VO)].90+RD7^K
MSBMDBU)B+AT9=FA93,VRZ[20*\K#I5"?CGD0_:O(R;8/XYL]AI1D]C9)!J]:
M.$$]I5R="ZV)U:W!(9V&2.,2,$Q:"6O#H'$2L=&X.9*QS Z-[7,> YI B>8X
MMR+ RW(LMA[]1M&PVM8M.K2/HB61C)8#%?C:^G/%9ADBL5)H9WQ6J\L4\#Y(
MI6/=*/>Y:!.(L6NU)JFC5:9I5W@V-CJ\^T,SE8F03,9%=/WE516253,FX9/F
M3A-%Y&R3)9O(1C]!L_CW+9XW073]="_<QEN"_0L25;=9XDAFC(#FG1!:X$%L
MD;VDLEBD:Z*6-SHY&/8YS3YKE.KD*TU.Y"RQ6G9T2Q2#;7#8(((TYCV. ?'(
MPM?&]K7QN:]K7"M%7N]O\?;)#Y9M<X^M&<3[]M"9!ODP<IW@/72A4(G+]J>E
M(FW:7,YS$8T[052MXS10!"+F!8WP4_UIE-NA2Y)5GR^"KQU,I7C=/FN.P ]'
MAL&YLM@F$ESZ/G)=QH+Y<9[4L'B8X'U2-U;MS V8L9F9GVL=/(R'$9V777UO
M/3%B\T\ -9<WIE/(D-BR.VQ3^'D->N7 Z%J6IQ$XB<1.(G$3B)Q%X**)I)G5
M5.1))(AE%%%#%(FFF0HF.<YS"!2$(4!,8QA I2@(B( '5 )( !))   V23V
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M(%SY95,D@I[W<@Q^%:8>)5)8; !;)R3)-B?FI"1IQQT#'2U,'&[9#75W6<D
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M\3F;L/=E,);EJ C>R;-!EKP(]#?5?BI$#76UA(!BY]\6KPP;:"?-8ZW7*TV
M;$A56*M,SZR6R.FYITX3:-6E?5A&SQW.G=O%2-&9(QDY5>.!!-JFM[BB:61^
MA_FKJ R$M;'4XS3???%>RE2G8@JQC<DUB.P]C8&1MTZ1TKVLC!'6YI[*%/\
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M+V&$3V@E\F+N2ESSS+*\1YSPJ0M=B<RZBS]/!<EJW<?D:[==FXO*9&*)SFM
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M)C= #I9 UOP4\IX=8D4R)(^1F])))E B::;C(")ID*'H4A"%R "E*4   *4
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M/P^8^J?>W7_W<U'\H=-_I7FQ\?D?HFC\/F/JOPVMP %,):YJ(F !]H#D.F@
MCZ?0!']5?H C_O\ [<V/C\C]$T?A\Q]5JF^';Y:6S1+/86MKT/6MB*KX\8+>
M-ECG6>SLXGB'EQ:[!K+3;,:C4:Q2FKBGLJTC!UZ*+G<HH\4JZ$ QD""DZLK]
M],W'IZ=[/5U$$:)&M @^7W['OW[]:]K+TQ> UP>?'\5P,?;I\'H86OZCKI=U
M];>G;RX=R(^D&6_D;K=>4W>W*%KNH@">44%N8I\?T]-03EM^D*"<B:E3*95
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M4R;?O[_(_P"&MIH_#YCZ]EVGWMU_]W-1_*'3?Z5YL?'Y'Z)H_#YCZI][=?\
MW<U'\H=-_I7FQ\?D?HFC\/F/JGWMU_\ =S4?RATW^E>;'Q^1^B:/P^8^J?>W
M7_W<U'\H=-_I7FQ\?D?HFC\/F/JNM6W.F-Y=A K1&F)R\HPE)2/8FR#4/G.H
M^%7BFTJZ3$*D*?RV2\Y$IJ@8Y3B9\D)"G %!(W^/R/T31^'S'U^"[+[VZ_\
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MWZ8?R%YT>*J%::5.O2<JN].9S#,I6_I Z=O:"2-CVB6@@$..FZ(T=Z:2[W$
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M'8)V">PT0-@V4XJ)Q$XB<15"D/#VK2'D,AO)K_?4(X-$B=HD,A2_50:!+;5
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7$XB<1.(G$3B)Q$XB<1.(G$3B)Q%__]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>58
<FILENAME>g164680g68z96.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g164680g68z96.jpg
M_]C_X  02D9)1@ ! 0(!>0%Y  #_[0_B4&AO=&]S:&]P(#,N,  X0DE-! 0
M    #\:^0#@X0DE-! 0      !T< @   @  ' (% !%$97)M879A=&Y0:7!E
M;&EN90 X0DE-!"4      !#'- ,3M+S*?1(K>LP9,P[D.$))300Z      #E
M    $     $       MP<FEN=$]U='!U=     4     4'-T4V)O;VP!
M $EN=&5E;G5M     $EN=&4     0VQR;0    ]P<FEN=%-I>'1E96Y":71B
M;V]L      MP<FEN=&5R3F%M951%6%0    !       /<')I;G10<F]O9E-E
M='5P3V)J8P    P 4 !R &\ ;P!F "  4P!E '0 =0!P       *<')O;V93
M971U<     $     0FQT;F5N=6T    ,8G5I;'1I;E!R;V]F    "7!R;V]F
M0TU92P X0DE-!#L      BT    0     0      $G!R:6YT3W5T<'5T3W!T
M:6]N<P   !<     0W!T;F)O;VP      $-L8G)B;V]L      !29W--8F]O
M;       0W)N0V)O;VP      $-N=$-B;V]L      !,8FQS8F]O;
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M;G5M     %!G4',     4&=00P    !,969T56YT1B-2;'0
M  !4;W @56YT1B-2;'0               !38VP@56YT1B-0<F- 60
M     !!C<F]P5VAE;E!R:6YT:6YG8F]O;      .8W)O<%)E8W1";W1T;VUL
M;VYG          QC<F]P4F5C=$QE9G1L;VYG          UC<F]P4F5C=%)I
M9VAT;&]N9P         +8W)O<%)E8W14;W!L;VYG       X0DE- ^T
M ! #O_XU  (  0.__C4  @ !.$))300F       .             #^    X
M0DE- _(       H  /_______P  .$))300-       $    'CA"24T$&0
M    !    !XX0DE- _,       D           $ .$))32<0       *  $
M         3A"24T#]0      2  O9F8  0!L9F8 !@       0 O9F8  0"A
MF9H !@       0 R     0!:    !@       0 U     0 M    !@
M 3A"24T#^       <   _____________________________P/H     /__
M__________________________\#Z     #_________________________
M____ ^@     _____________________________P/H   X0DE-! @
M !     !   "0    D      .$))300>       $     #A"24T$&@     #
M00    8              +    G:    !@!G #8 . !Z #D -@    $
M                     0             )V@   +
M     0                         0     0       &YU;&P    "
M!F)O=6YD<T]B:F,    !        4F-T,0    0     5&]P(&QO;F<
M     $QE9G1L;VYG          !"=&]M;&]N9P   +      4F=H=&QO;F<
M  G:    !G-L:6-E<U9L3',    !3V)J8P    $       5S;&EC90   !(
M   '<VQI8V5)1&QO;F<         !V=R;W5P241L;VYG          9O<FEG
M:6YE;G5M    #$53;&EC94]R:6=I;@    UA=71O1V5N97)A=&5D     %1Y
M<&5E;G5M    "D53;&EC951Y<&4     26UG(     9B;W5N9'-/8FIC
M 0       %)C=#$    $     %1O<"!L;VYG          !,969T;&]N9P
M        0G1O;6QO;F<   "P     %)G:'1L;VYG   )V@    -U<FQ415A4
M     0       &YU;&Q415A4     0       $US9V5415A4     0
M!F%L=%1A9U1%6%0    !       .8V5L;%1E>'1)<TA434QB;V]L 0    AC
M96QL5&5X=%1%6%0    !       ):&]R>D%L:6=N96YU;0    ]%4VQI8V5(
M;W)Z06QI9VX    '9&5F875L=     EV97)T06QI9VYE;G5M    #T53;&EC
M959E<G1!;&EG;@    =D969A=6QT    "V)G0V]L;W)4>7!E96YU;0   !$
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
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M(" @(" @(" @(" @(" @(" @(" */#]X<&%C:V5T(&5N9#TB=R(_/O_; $,
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! ?_; $,! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! ?_
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M=W:I;$W&D<@&'VUL;@P0:1Y>7C&Q)/+:&(K=+BLF]\NKWUN9@/LET T T T
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MKD[2F5,C0S?.:B)8Z[B(BG)RIZOLK"AVL-+ B:W I>[[R!UOT T T T T T
MT!\K\8<.B=IYXCN3V0B6@"A87B'B?,DG))@<V*74.21X!!$41([.<41XN3/3
M#&;E DCW5JT>?USHE(-J5RHSMVD2VJU;2[@:]X\S5Q%,/L20(/1/>13T'$."
M=J1V%J08VBSH0XV2I3FN)Q5=;FA:JC%\>U:*]$QJ^FYGM)C%,1 QI&I<>#@,
MXL3;;$M >U3Q!>+BSAF.C\XN<RD"M&=3$,%@>)8TN".2)JM#.2:8; U=;B58
M6H@HJV<X75)-[0E9;<+RMX1N*>2;ZMM[DM8FL#I#@QD_Q$9-X@\NQQ/-#BU1
M(T/V32%[BU^BPI8VN,!P(DEG9<<2  D-'CL+"[UL?A=Y0Z.EU\R,EFH]2.5P
MD&68*I'EK'N!&6+%$6EO&FEXHCT2GV(*03?(4:(R<_!,D'%3F/(AFN&EI*Z.
M$AOHA7"@OCE!-L,5,\ BU\QMO3T[J[KB*-3>-;-=EV ^DO0#0#0#0#0#0&!2
MK94J(ODA.CM7[ZN^!&%E+82V[EU3>4W1YQHL6D]JUM5=N7[EVJFBU;M4U7*[
ME5--&V]6^VV@/BH!^&3E( <,Y7D6G0BT9$)YASC%'2>"X0"II4R7(1H]9(X]
M'-V7,D!8N>*T*J5@-H8'5.YMX@+-VW<G4FNN+LE;;%Q/< W&RCS'XI<,!4HQ
M<)'F1!5(0#DUEB)Q?-:+&$+O4RB%QG"T-'\2#)C4&8QRP-7U1(9GI>S!Z40B
M,*;))3BCJT/4U1M;&G-]4@?NKSVXLJ;(Z4&L9%)(E:R[X]24819$C' BP;!
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MKB8?H1IZ;U3K<LNZ%9NWTH[]*C2?/N^/742M\3=WV$CRF+I.+9'_  V7D1F
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M>:B!;2MK2;(K&]X"-WKA7-+A>M;-LXOC8@7+Y+N%**^"M+C6\M,@R9CY+-A
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M@KZLP?1_4W=%_P N*^_F%^$#'RA/CKC;HI3&/#%*4Q6$\6J-'^@WR:R1\?\
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MC\M/NT(UI\OP:[)8.YV_NZ/RT^[0NAGW^BI7>W;\7[NCR?R4_;O^&@^C_=_
MIW.W]W1^6GW:&0[G;^[H_+3[M#%GZ7[2^_VK:=7L":::8P+=J=MJ=N?BG?DV
MVVVVY>;P_P"/Q:VL9E\_P0XTMG9_83[U-Y=9FH: : : : : : : : : : :
<: : : : : : : : : : : : : : : : : __V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>59
<FILENAME>g164680g83e66.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g164680g83e66.jpg
M_]C_X  02D9)1@ ! 0(!>0%Y  #_[1R 4&AO=&]S:&]P(#,N,  X0DE-! 0
M    '&2^<F@X0DE-! 0      &D< 5H  QLE1QP!6@ #&R5'' (   *\K!P"
M4  (<G(Q-3$Q.#$< @4 0$UI8W)O<V]F="!7;W)D("T@4F]I=F%N=" @4F5S
M86QE(%-?,2!/8W1O8F5R(#(U(#(P,C$@-S P<&T@0VQE86X .$))300E
M   0X.\F9G[YXFH<=@QF;\O<F#A"24T$.@      Y0   !     !       +
M<')I;G1/=71P=70    %     %!S=%-B;V]L 0    !);G1E96YU;0    !)
M;G1E     $-L<FT    /<')I;G13:7AT965N0FET8F]O;      +<')I;G1E
M<DYA;65415A4     0      #W!R:6YT4')O;V93971U<$]B:F,    , %
M<@!O &\ 9@ @ %, 90!T '4 <       "G!R;V]F4V5T=7     !     $)L
M=&YE;G5M    #&)U:6QT:6Y0<F]O9@    EP<F]O9D--64L .$))300[
M  (M    $     $      !)P<FEN=$]U='!U=$]P=&EO;G,    7     $-P
M=&YB;V]L      !#;&)R8F]O;       4F=S36)O;VP      $-R;D-B;V]L
M      !#;G1#8F]O;       3&)L<V)O;VP      $YG='9B;V]L      !%
M;6Q$8F]O;       26YT<F)O;VP      $)C:V=/8FIC     0       %)'
M0D,    #     %)D("!D;W5B0&_@            1W)N(&1O=6) ;^
M      !";" @9&]U8D!OX            $)R9%15;G1&(U)L=
M     $)L9"!5;G1&(U)L=                %)S;'15;G1&(U!X;$!8QYW
M        "G9E8W1O<D1A=&%B;V]L 0    !09U!S96YU;0    !09U!S
M %!G4$,     3&5F=%5N=$8C4FQT                5&]P(%5N=$8C4FQT
M                4V-L(%5N=$8C4')C0%D            08W)O<%=H96Y0
M<FEN=&EN9V)O;VP     #F-R;W!296-T0F]T=&]M;&]N9P         ,8W)O
M<%)E8W1,969T;&]N9P         -8W)O<%)E8W12:6=H=&QO;F<
M"V-R;W!296-T5&]P;&]N9P      .$))30/M       0 [_^-0 "  (#O_XU
M  (  CA"24T$)@      #@             _@   .$))30/R       *  #_
M______\  #A"24T$#0      !    '@X0DE-!!D       0    >.$))30/S
M       )           ! #A"24TG$       "@ !          (X0DE- _4
M     $@ +V9F  $ ;&9F  8       $ +V9F  $ H9F:  8       $ ,@
M  $ 6@    8       $ -0    $ +0    8       $X0DE- _@      '
M /____________________________\#Z     #_____________________
M________ ^@     _____________________________P/H     /______
M______________________\#Z   .$))300(       0     0   D    )
M     #A"24T$'@      !      X0DE-!!H      S4    &
M   T   "<0         !                          $
M G$    T                      $                         $
M  $       !N=6QL     @    9B;W5N9'-/8FIC     0       %)C=#$
M   $     %1O<"!L;VYG          !,969T;&]N9P          0G1O;6QO
M;F<    T     %)G:'1L;VYG   "<0    9S;&EC97-6;$QS     4]B:F,
M   !       %<VQI8V4    2    !W-L:6-E241L;VYG          =G<F]U
M<$E$;&]N9P         &;W)I9VEN96YU;0    Q%4VQI8V5/<FEG:6X    -
M875T;T=E;F5R871E9     !4>7!E96YU;0    I%4VQI8V54>7!E     $EM
M9R     &8F]U;F1S3V)J8P    $       !28W0Q    !     !4;W @;&]N
M9P          3&5F=&QO;F<          $)T;VUL;VYG    -     !29VAT
M;&]N9P   G$    #=7)L5$585     $       !N=6QL5$585     $
M  !-<V=E5$585     $       9A;'1486=415A4     0      #F-E;&Q4
M97AT27-(5$U,8F]O; $    (8V5L;%1E>'1415A4     0      "6AO<GI!
M;&EG;F5N=6T    /15-L:6-E2&]R>D%L:6=N    !V1E9F%U;'0    )=F5R
M=$%L:6=N96YU;0    ]%4VQI8V5697)T06QI9VX    '9&5F875L=     MB
M9T-O;&]R5'EP965N=6T    115-L:6-E0D=#;VQO<E1Y<&4     3F]N90
M  ET;W!/=71S971L;VYG          IL969T3W5T<V5T;&]N9P         ,
M8F]T=&]M3W5T<V5T;&]N9P         +<FEG:'1/=71S971L;VYG       X
M0DE-!"@       P    "/_         X0DE-!!$       $! #A"24T$%
M    !     4X0DE-! P     $<4    !    H     T   '@   88   $:D
M&  !_]C_X@Q824-#7U!23T9)3$4  0$   Q(3&EN;P(0  !M;G1R4D="(%A9
M6B 'S@ "  D !@ Q  !A8W-P35-&5     !)14,@<U)'0@
M 0  ]M8  0    #3+4A0("
M                         !%C<')T   !4    #-D97-C   !A    &QW
M='!T   !\    !1B:W!T   "!    !1R6%E:   "&    !1G6%E:   "+
M !1B6%E:   "0    !1D;6YD   "5    '!D;61D   "Q    (AV=65D   #
M3    (9V:65W   #U    "1L=6UI   #^    !1M96%S   $#    "1T96-H
M   $,     QR5%)#   $/   " QG5%)#   $/   " QB5%)#   $/   " QT
M97AT     $-O<'ER:6=H=" H8RD@,3DY."!(97=L971T+5!A8VMA<F0@0V]M
M<&%N>0  9&5S8P         2<U)'0B!)14,V,3DV-BTR+C$
M !)S4D="($E%0S8Q.38V+3(N,0
M                                6%E:(        /-1  $    !%LQ8
M65H@                     %A96B        !OH@  ./4   .06%E:(
M     &*9  "WA0  &-I865H@        )*    ^$  "VSV1E<V,
M%DE%0R!H='1P.B\O=W=W+FEE8RYC:               %DE%0R!H='1P.B\O
M=W=W+FEE8RYC:
M              !D97-C         "Y)14,@-C$Y-C8M,BXQ($1E9F%U;'0@
M4D="(&-O;&]U<B!S<&%C92 M('-21T(              "Y)14,@-C$Y-C8M
M,BXQ($1E9F%U;'0@4D="(&-O;&]U<B!S<&%C92 M('-21T(
M                9&5S8P         L4F5F97)E;F-E(%9I97=I;F<@0V]N
M9&ET:6]N(&EN($E%0S8Q.38V+3(N,0              +%)E9F5R96YC92!6
M:65W:6YG($-O;F1I=&EO;B!I;B!)14,V,3DV-BTR+C$
M                 '9I97<      !.D_@ 47RX $,\4  /MS  $$PL  UR>
M     5A96B       $P)5@!0    5Q_G;65A<P         !
M             H\    "<VEG(     !#4E0@8W5R=@        0     !0 *
M  \ %  9 !X (P H "T ,@ W #L 0 !% $H 3P!4 %D 7@!C &@ ;0!R '<
M? "! (8 BP"0 )4 F@"? *0 J0"N +( MP"\ ,$ Q@#+ -  U0#; .  Y0#K
M /  ]@#[ 0$!!P$- 1,!&0$? 24!*P$R 3@!/@%% 4P!4@%9 6 !9P%N 74!
M? &# 8L!D@&: :$!J0&Q ;D!P0') =$!V0'A >D!\@'Z @,"# (4 AT")@(O
M C@"00)+ E0"70)G G$">@*$ HX"F *B JP"M@+! LL"U0+@ NL"
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M                                     /_A0"1H='1P.B\O;G,N861O
M8F4N8V]M+WAA<"\Q+C O #P_>'!A8VME="!B96=I;CTB[[N_(B!I9#TB5S5-
M,$UP0V5H:4AZ<F53>DY48WIK8SED(C\^"CQX.GAM<&UE=&$@>&UL;G,Z>#TB
M861O8F4Z;G,Z;65T82\B('@Z>&UP=&L](D%D;V)E(%A-4"!#;W)E(#4N,RUC
M,#$Q(#8V+C$T-38V,2P@,C Q,B\P,B\P-BTQ-#HU-CHR-R @(" @(" @(CX*
M(" @/')D9CI21$8@>&UL;G,Z<F1F/2)H='1P.B\O=W=W+G<S+F]R9R\Q.3DY
M+S R+S(R+7)D9BUS>6YT87@M;G,C(CX*(" @(" @/')D9CI$97-C<FEP=&EO
M;B!R9&8Z86)O=70](B(*(" @(" @(" @(" @>&UL;G,Z>&UP/2)H='1P.B\O
M;G,N861O8F4N8V]M+WAA<"\Q+C O(CX*(" @(" @(" @/'AM<#I#<F5A=&5$
M871E/C(P,C$M,3 M,C94,3DZ,#0Z,C,K,#4Z,S \+WAM<#I#<F5A=&5$871E
M/@H@(" @(" @(" \>&UP.D-R96%T;W)4;V]L/D%D;V)E(%!H;W1O<VAO<"!#
M4S8@*%=I;F1O=W,I/"]X;7 Z0W)E871O<E1O;VP^"B @(" @(" @(#QX;7 Z
M36]D:69Y1&%T93XR,#(Q+3$P+3(V5#$Y.C,R.C4Y*S U.C,P/"]X;7 Z36]D
M:69Y1&%T93X*(" @(" @(" @/'AM<#I-971A9&%T841A=&4^,C R,2TQ,"TR
M-E0Q.3HS,CHU.2LP-3HS,#PO>&UP.DUE=&%D871A1&%T93X*(" @(" @/"]R
M9&8Z1&5S8W)I<'1I;VX^"B @(" @(#QR9&8Z1&5S8W)I<'1I;VX@<F1F.F%B
M;W5T/2(B"B @(" @(" @(" @('AM;&YS.G!D9CTB:'1T<#HO+VYS+F%D;V)E
M+F-O;2]P9&8O,2XS+R(^"B @(" @(" @(#QP9&8Z4')O9'5C97(^06-R;V)A
M="!$:7-T:6QL97(@,3 N,"XP("A7:6YD;W=S*3PO<&1F.E!R;V1U8V5R/@H@
M(" @(" \+W)D9CI$97-C<FEP=&EO;CX*(" @(" @/')D9CI$97-C<FEP=&EO
M;B!R9&8Z86)O=70](B(*(" @(" @(" @(" @>&UL;G,Z9&,](FAT=' Z+R]P
M=7)L+F]R9R]D8R]E;&5M96YT<R\Q+C$O(CX*(" @(" @(" @/&1C.G1I=&QE
M/@H@(" @(" @(" @(" \<F1F.D%L=#X*(" @(" @(" @(" @(" @/')D9CIL
M:2!X;6PZ;&%N9STB>"UD969A=6QT(CY-:6-R;W-O9G0@5V]R9" M(%)O:79A
M;G0@(%)E<V%L92!37S$@3V-T;V)E<B R-2 R,#(Q(#<P,'!M($-L96%N+F1O
M8W@\+W)D9CIL:3X*(" @(" @(" @(" @/"]R9&8Z06QT/@H@(" @(" @(" \
M+V1C.G1I=&QE/@H@(" @(" @(" \9&,Z8W)E871O<CX*(" @(" @(" @(" @
M/')D9CI397$^"B @(" @(" @(" @(" @(#QR9&8Z;&D^<G(Q-3$Q.#$\+W)D
M9CIL:3X*(" @(" @(" @(" @/"]R9&8Z4V5Q/@H@(" @(" @(" \+V1C.F-R
M96%T;W(^"B @(" @(" @(#QD8SIF;W)M870^:6UA9V4O97!S9CPO9&,Z9F]R
M;6%T/@H@(" @(" \+W)D9CI$97-C<FEP=&EO;CX*(" @(" @/')D9CI$97-C
M<FEP=&EO;B!R9&8Z86)O=70](B(*(" @(" @(" @(" @>&UL;G,Z>&UP34T]
M(FAT=' Z+R]N<RYA9&]B92YC;VTO>&%P+S$N,"]M;2\B"B @(" @(" @(" @
M('AM;&YS.G-T179T/2)H='1P.B\O;G,N861O8F4N8V]M+WAA<"\Q+C O<U1Y
M<&4O4F5S;W5R8V5%=F5N=",B"B @(" @(" @(" @('AM;&YS.G-T4F5F/2)H
M='1P.B\O;G,N861O8F4N8V]M+WAA<"\Q+C O<U1Y<&4O4F5S;W5R8V52968C
M(CX*(" @(" @(" @/'AM<$U-.DEN<W1A;F-E240^>&UP+FEI9#HQ13DU,C<V
M,38U,S9%0S$Q.39%-$9!-4$Y-C<X1$4W-#PO>&UP34TZ26YS=&%N8V5)1#X*
M(" @(" @(" @/'AM<$U-.D1O8W5M96YT240^>&UP+F1I9#HV0C(R0D$X1C0P
M,S9%0S$Q.39%-$9!-4$Y-C<X1$4W-#PO>&UP34TZ1&]C=6UE;G1)1#X*(" @
M(" @(" @/'AM<$U-.D]R:6=I;F%L1&]C=6UE;G1)1#YX;7 N9&ED.C9",C)"
M03A&-# S-D5#,3$Y-D4T1D$U03DV-SA$13<T/"]X;7!-33I/<FEG:6YA;$1O
M8W5M96YT240^"B @(" @(" @(#QX;7!-33I(:7-T;W)Y/@H@(" @(" @(" @
M(" \<F1F.E-E<3X*(" @(" @(" @(" @(" @/')D9CIL:2!R9&8Z<&%R<V54
M>7!E/2)297-O=7)C92(^"B @(" @(" @(" @(" @(" @(#QS=$5V=#IA8W1I
M;VX^<V%V960\+W-T179T.F%C=&EO;CX*(" @(" @(" @(" @(" @(" @/'-T
M179T.FEN<W1A;F-E240^>&UP+FEI9#HV0C(R0D$X1C0P,S9%0S$Q.39%-$9!
M-4$Y-C<X1$4W-#PO<W1%=G0Z:6YS=&%N8V5)1#X*(" @(" @(" @(" @(" @
M(" @/'-T179T.G=H96X^,C R,2TQ,"TR-E0Q.3HR.3HQ,RLP-3HS,#PO<W1%
M=G0Z=VAE;CX*(" @(" @(" @(" @(" @(" @/'-T179T.G-O9G1W87)E06=E
M;G0^061O8F4@4&AO=&]S:&]P($-3-B H5VEN9&]W<RD\+W-T179T.G-O9G1W
M87)E06=E;G0^"B @(" @(" @(" @(" @(" @(#QS=$5V=#IC:&%N9V5D/B\\
M+W-T179T.F-H86YG960^"B @(" @(" @(" @(" @(#PO<F1F.FQI/@H@(" @
M(" @(" @(" @(" \<F1F.FQI(')D9CIP87)S951Y<&4](E)E<V]U<F-E(CX*
M(" @(" @(" @(" @(" @(" @/'-T179T.F%C=&EO;CYS879E9#PO<W1%=G0Z
M86-T:6]N/@H@(" @(" @(" @(" @(" @(" \<W1%=G0Z:6YS=&%N8V5)1#YX
M;7 N:6ED.C%$.34R-S8Q-C4S-D5#,3$Y-D4T1D$U03DV-SA$13<T/"]S=$5V
M=#II;G-T86YC94E$/@H@(" @(" @(" @(" @(" @(" \<W1%=G0Z=VAE;CXR
M,#(Q+3$P+3(V5#$Y.C,R.C4Y*S U.C,P/"]S=$5V=#IW:&5N/@H@(" @(" @
M(" @(" @(" @(" \<W1%=G0Z<V]F='=A<F5!9V5N=#Y!9&]B92!0:&]T;W-H
M;W @0U,V("A7:6YD;W=S*3PO<W1%=G0Z<V]F='=A<F5!9V5N=#X*(" @(" @
M(" @(" @(" @(" @/'-T179T.F-H86YG960^+SPO<W1%=G0Z8VAA;F=E9#X*
M(" @(" @(" @(" @(" @/"]R9&8Z;&D^"B @(" @(" @(" @(" @(#QR9&8Z
M;&D@<F1F.G!A<G-E5'EP93TB4F5S;W5R8V4B/@H@(" @(" @(" @(" @(" @
M(" \<W1%=G0Z86-T:6]N/F-O;G9E<G1E9#PO<W1%=G0Z86-T:6]N/@H@(" @
M(" @(" @(" @(" @(" \<W1%=G0Z<&%R86UE=&5R<SYF<F]M(&%P<&QI8V%T
M:6]N+W9N9"YA9&]B92YP:&]T;W-H;W @=&\@:6UA9V4O97!S9CPO<W1%=G0Z
M<&%R86UE=&5R<SX*(" @(" @(" @(" @(" @/"]R9&8Z;&D^"B @(" @(" @
M(" @(" @(#QR9&8Z;&D@<F1F.G!A<G-E5'EP93TB4F5S;W5R8V4B/@H@(" @
M(" @(" @(" @(" @(" \<W1%=G0Z86-T:6]N/F1E<FEV960\+W-T179T.F%C
M=&EO;CX*(" @(" @(" @(" @(" @(" @/'-T179T.G!A<F%M971E<G,^8V]N
M=F5R=&5D(&9R;VT@87!P;&EC871I;VXO=FYD+F%D;V)E+G!H;W1O<VAO<"!T
M;R!I;6%G92]E<'-F/"]S=$5V=#IP87)A;65T97)S/@H@(" @(" @(" @(" @
M(" \+W)D9CIL:3X*(" @(" @(" @(" @(" @/')D9CIL:2!R9&8Z<&%R<V54
M>7!E/2)297-O=7)C92(^"B @(" @(" @(" @(" @(" @(#QS=$5V=#IA8W1I
M;VX^<V%V960\+W-T179T.F%C=&EO;CX*(" @(" @(" @(" @(" @(" @/'-T
M179T.FEN<W1A;F-E240^>&UP+FEI9#HQ13DU,C<V,38U,S9%0S$Q.39%-$9!
M-4$Y-C<X1$4W-#PO<W1%=G0Z:6YS=&%N8V5)1#X*(" @(" @(" @(" @(" @
M(" @/'-T179T.G=H96X^,C R,2TQ,"TR-E0Q.3HS,CHU.2LP-3HS,#PO<W1%
M=G0Z=VAE;CX*(" @(" @(" @(" @(" @(" @/'-T179T.G-O9G1W87)E06=E
M;G0^061O8F4@4&AO=&]S:&]P($-3-B H5VEN9&]W<RD\+W-T179T.G-O9G1W
M87)E06=E;G0^"B @(" @(" @(" @(" @(" @(#QS=$5V=#IC:&%N9V5D/B\\
M+W-T179T.F-H86YG960^"B @(" @(" @(" @(" @(#PO<F1F.FQI/@H@(" @
M(" @(" @(" \+W)D9CI397$^"B @(" @(" @(#PO>&UP34TZ2&ES=&]R>3X*
M(" @(" @(" @/'AM<$U-.D1E<FEV961&<F]M(')D9CIP87)S951Y<&4](E)E
M<V]U<F-E(CX*(" @(" @(" @(" @/'-T4F5F.FEN<W1A;F-E240^>&UP+FEI
M9#HQ1#DU,C<V,38U,S9%0S$Q.39%-$9!-4$Y-C<X1$4W-#PO<W12968Z:6YS
M=&%N8V5)1#X*(" @(" @(" @(" @/'-T4F5F.F1O8W5M96YT240^>&UP+F1I
M9#HV0C(R0D$X1C0P,S9%0S$Q.39%-$9!-4$Y-C<X1$4W-#PO<W12968Z9&]C
M=6UE;G1)1#X*(" @(" @(" @(" @/'-T4F5F.F]R:6=I;F%L1&]C=6UE;G1)
M1#YX;7 N9&ED.C9",C)"03A&-# S-D5#,3$Y-D4T1D$U03DV-SA$13<T/"]S
M=%)E9CIO<FEG:6YA;$1O8W5M96YT240^"B @(" @(" @(#PO>&UP34TZ1&5R
M:79E9$9R;VT^"B @(" @(#PO<F1F.D1E<V-R:7!T:6]N/@H@(" @(" \<F1F
M.D1E<V-R:7!T:6]N(')D9CIA8F]U=#TB(@H@(" @(" @(" @("!X;6QN<SIP
M:&]T;W-H;W ](FAT=' Z+R]N<RYA9&]B92YC;VTO<&AO=&]S:&]P+S$N,"\B
M/@H@(" @(" @(" \<&AO=&]S:&]P.D-O;&]R36]D93XT/"]P:&]T;W-H;W Z
M0V]L;W)-;V1E/@H@(" @(" \+W)D9CI$97-C<FEP=&EO;CX*(" @/"]R9&8Z
M4D1&/@H\+W@Z>&UP;65T83X*(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @
M(" @(" */#]X<&%C:V5T(&5N9#TB=R(_/O_; $,  0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! ?_; $,! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! ?_  !$( #("70,!$0 "$0$#
M$0'_Q  >  $  @(# 0$!            !P@%!@,$"0$""O_$ $<0   & 0$#
M"@4" P,*!P$   $" P0%!@< "!$2$Q05%AA6E)?3U@DA5%65TM07(C$C0? D
M)C(S46%QD<'A-D92=H&'H;'_Q  : 0$! 0 # 0               0(#!@<%
M_\0 .Q$  0$$!P8#" (" 04       $" Q'1$B%14V&1DA,Q05*A\ 1Q@10B
M(V)CHK'!X?$%!S(&0D-R@O_:  P# 0 "$0,1 #\ _OXT T T!7[:8VC*=LMX
MQ'*-VB;-/1:ENHM'80U0CT).?D['D6WPU)K3%DT<NV*!Q<SLZP14,HY3*FD<
MZF\>#A%N[M*B*JP3?*M>A&F(-O/9URU .996V?PSF&&0+%BZ2I>5.:5"VM+Q
M5D(-W,0J<<Y=K)OS(,K+ NRN8UR[:F1E&X<J"G&0@*D/5$7T7M26@VF=GLU9
ME+D7,^.#56$DPA9>P!:XD8N.E3"8I8]T[!R*:3HPD/PI&'B-PF$-X (Z$@MG
M>[\U$9%VW,(JWJ2HS63=NU(J5A8QU9$31O5<4YV /9&LHA*GD"$<1B46F=5P
MX13.*8@/\AB;S@+""(MN[=PMKJ_KA6;6YVM\#*M8QY5L@5R^HO[Q4Z"Y-39R
M'EPAIFY+\C#*2X@_2*U:*EXEQ. J*G1*8R"2HAPZ$,VMM1[.2$;8IA;-F-4X
MNI224/9GYK9$\V@Y1991NBQD50<"5NY47241(F?<)E"&('S*(: [F/=H#'>4
M+[=<?TR05F'U'A*E87TRU!!>OR47=&KAY#.(:2075(^(9%N<5C 0A2")0*8^
M_> $VZ : : : : P5HL+"HUJ?M,H"PQM<AI*<?@W3!5P+.*9K/7((IB8H'5%
M%$X)D$Q0,;<&\ ^8 >9U/^+ELUV:!&P2U?RI1&R]5IM\BD[G5&\;TU2;Q.LZ
M[$6>.=-Y5ZP/'(R3YN5^5=T@Z;HF%;FYR (Z%5()'&"^><O4NN7:?V>!CJI+
M#F;'1(Z\.A85)V>TQ149]\5<C8[*-4YQPN7*;I0C8Z1!$Q5S D(<8@&A(*NY
M(F10VB<$N75N9-\N4!9U06QW=T03LT88]8:IFX%'$SN<;F21#[DS'5$H H($
MW\0@&@@MF_=B=.V;2&&:CAZ9SPZO$/+8PA8YS(JV6NN"3K5V1L8"&;Q_1XK"
M[=G6$J)&Z>]05# 40#YZ VK#^4JWFS&5*RO3R2*=8OD&WGX0DLUYC)%8NC*%
M2!XT$Z@MU]Z9A,D8XF)\@-N-O  )(T T T T T T!63::VI:9LNPU'E+76[I
M;GN1;M'8_JE?HD4UEYJ1L4FBLNU0!N[?QR)$C)H*;U#+_(W" %'>&@(6Q9\3
M'9:RC-0$ G:7M&DK#!O91JED1JWJA49*.MJ]*>U9<SYW\[&A.MSH\S0!9)5(
M2*).#@< TCWN*J*G=6Z*5EFG&T?@5I)6R'=9>Q\WE:(S-(7)@M:(HCJM,B*@
M@=U+I&< 9H@58P(F44 "@J()CN.( (A^0VD<!#'U&6#,&/0C;Z[484Q\-GBR
MM[,]16(W5;0ZAG  \6(N<J)BI;^%00(.XVX-(R[R!'&>]L3'.SO9*W 76MY%
MD6<[S%1]:JS4G<O4ZPUDY%O$L'-@FB*)(-P<OW2")$&H.W7"?E10Y(#' $K+
M7(+)N$47")N-)=)-9(^X0XDU2 <AMP[A#B*8!W#\_G\] <N@&@&@&@&@&@//
M6\?$DPICW,5BQ%8ZME!(*G<ZMCZQW]I5D7M$B+9=&1GM;BWDDWDCOR&D2%*D
M18(P4$UCD*JH0HB8!4KW+O15R_B"^M=I+>)]MG9NR_17]^@LF5N(CH1DM(V:
M-LDO&1DU56*4NZA".K"P%XJ:.0<OVBB3914W"J)B% >,W" *BIO-^:;3&SZ^
M7J#5EF7'3MS?T0<4I!O:8I92SHF<':%5AR)N#"\(9TDHW**8" KIG2#><HE
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M1'^-G0-=R/#E090,'$OB1X2Z-A9V-![(H.I9?D4#N6HI/&L49BB[,J9RH7E
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M<[.?D#F+V9I%,<ED*#5G5)CM34/N=G/R!S%[,TBF.2R%!JSJDQVIJ'W.SGY
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MS$;DFM\T80T)%+N9-[*-I$73D"KMVS5%3FI!I*,6DBJPW;DKQK7HN[,Q./\
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M%I= - - - - - - - - - - - - - - - - - - - - - - - - - - - -
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MSO[EYH60V[F]8U)W_98SKS3.]5?_ "S'UM/9W]R\T+(;=S>,:D'7FF=ZJ_\
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MH"3] - - - - - - - - - - 4\V]U':6R?EY1B=PFY+  *1VAE". 'G*/\
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MS.J-L<MXUPL+=PQ&V2"(V%DYO(69\_4(ZJDG'1DFHP$6Y =L)IN*I>%0AB&
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MR\;U-3&S=W;&EF0ZKUGN[!?B(_\ ;Z;1Y>-ZFIC9N[MC2S(=5ZSW=@OQ$?\
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"_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>60
<FILENAME>g164680g83n58.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g164680g83n58.jpg
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M            !@<$!0@! @,)"O_$ #X0  $#!  "" ,&! 8#  ,   4#! 8
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M0*!0*!0*!04_.M!Z@V8.D@N=P<=(VLL/@Y0:S>.BJ3_,_&A38&!)#"K1^V*
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M>AL1<EKVM-I"OE"2,>5#'T X-E,#YTB4.2.Q*J;UTKISG?SQ%Z6O_2VO]E0
MA-!\LE;(W"+N6K76H=N[^=<! S,W+%T,G62D9!N!RMHJ_A4:<#ER\QS?$(D_
MESJ09EI451L(N.V*]^/\T7Y12@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4
M"@4"@4&I/?V,S_M;_P#ZJM!MJ!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0
M*!0*!0*!0*!0<;'^)20L]_R'30YKKP>VCY+7@Y-S)2,\[>.YS@<U(9W&-H["
MS()I=KDY^1;=K&V6"SBUE7.;5K?)7$S,U,1C/,3]3&$I"<6NLY,/L^C(F=2)
M0A*$(C$F B.HNG,Y,*CY:860CCFY/ 0V<"@T%E1>1"943C4@C# :V4D8<6H>
MC:1@M])^/:\\QRC9OC5U<A&Y%((VPEIID&#XYHGG<9*"(BG+"NN\-BQ2&&R[
MQ+!\&-'F"[<4L@J)4N"/*H@CW9I8@&9DR3^J/J_JZ^)O33M+89\8>O1T*=R^
M0QK8 101D(N>#/XXB/=BAYF'YS=C(G+PN3'!V8%\"0=*#<"A,?(WQ!OE'DH]
MWFO8-<O[HZSI-1%Z_7VV!?C#TN"66<$WDH0B:&1EOEL.T5*JPC,G'=4%MUG0
MZ1))/-^H3&Z\#NRF:&(KX3LC@K'1J[V0L"PP>+B_YVC%Z]OS#2O^-O2XJ)%)
MD2QEC,3&R9D?,OB"AN?<Q,"!CTI?O39) VM'W5E8Y*@982&CAD]*3Z:Q)D!C
MY(K&Y0/"B^D]>GO2])W7#$YXK/H3/2RXU,9D!F&VX-BBDYR=6<HZ_ETBB*)'
M+/-%"Z2I-(/B^5;6QSQ:J+Y(8K+8IV5R$9^9^II[^+#+D[KS27MT4\6&7)W7
MFDO;H'BPRY.Z\TE[= \6&7)W7FDO;H'BPRY.Z\TE[= \6&7)W7FDO;H)/+9$
M=$0QY(8M&+2P]\J.S%1U8RV -'#@F[9M<5BIYPV>X"0HI-WF4.D4!Q5ZU#L7
MRXX.7?X-ACH.<8_Q1F2XK63_ "UI@1:SW=A;3SR81&:B3VM628SM'Y28QV0D
MV<;D<R#2'-@LQ$W"PS-BB5'GFA PW:#QA(\9_=IC6:_UN(IQ)NR4A5 3B#6U
MA;O&H.;$I>:* Q^8=-0BPRRS<R^(PYJ^E&)WNL(P$Q-S*XN6RF+%W$9S*4@T
MCP%EOI7?'LWCS$[NJ:*4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@I(CHP,ZG
MYS8PN:[)BQB3K1QQ(QL9DK=C'S:L78I#!F3X8Y%/LNBX]+!F[LW<(6<(]/3U
M5+]>@@[3A&UHQ+O)0S-[!0F^3Z/O0T]O)TG$PC:<7&S8*&9LRSH8O8^FB#V/
M-@SM_.V\O.%1Y[-,L6>JC@ZPXE?Q]>]T5"\%.O63R;#R9:3N]?'R(!R#UZWD
M)'$$U["U''M8MC4@S>7=$SLO168&CV!Q<EU7I-\*+FVI0Y'PY!@*C/$[<8K\
M1XRG4QX4=4S4LB<(VDS$JFP:AU'@DY=LJN$0B^<.<"[7<-'?R'SX'.S98T([
M.D[%7"[@(=$K+.<EQ,1,WX[QQ[E33K@F;%YDP&G)'\YHT7F5>Y05,B?3?2=\
M<X?B7#X47D*2;A%@P.N@)HB;=2N-.Q:"KY)AD+B $XXDLJDA/VQWBM)G^*UZ
MWO*>'>"C4DF&+#SQ;8)%8@&GL;-E,I(T;$#,:V0*B864 ;X,0S4;'F+EA!XQ
M@FK"QT8(?&9/W#E\Z6DDIS-E_;%5\[7\5TTK3.Z^!<(#0:%R<,%S?*(DWDWE
M+]R0<8NG;HY,"121GGBF>"2"6%G18F[<8-T$46[?!2R*"::6&&-BQC[^YMJ/
M"9MSI?R2?[B@>$S;G2_DD_W% \)FW.E_))_N*!X3-N=+^23_ '% \)FW.E_)
M)_N*!X3-N=+^23_<4&YV'K,#L[7976<E=%DH^;9C&!-4.[P8/G+08_8/[M%,
MU4';98>2R'XL3(QXV=CRXAT_$D&SAB\<)9AK&NH .(6(A3!N5RG"#S ?-H^0
MD!5NL1;%A35VS&MU%!P\:V4%,V[UPF@P^5Q3QMG;IROU,>@E1CI-QF=6MV3H
M2 [6P?VEV!I98BNE99VP*J,'6 FT4E$*>1M!5).]DP1..3F;LWB/5R?).)85
M)#G[ FD*=C1,7O/NWN>JZ+6MC:V-K=%L;6M:W^EK6Z+6_P#Y:BO- H% H% H
M% H% H% H% H% H% H% H% H% H% H% H-2>_L9G_:W_ /U5:#;4"@4"@4"@
M4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@_-_BYV3MN,;"E S7TU
M.1IO&^'(AL(:W'2[541&(RUO(9,U;F#5]FQ<\WD#%% 8TP7#MW(]OD@BKBY5
M2N[Q<)F9F;FKQ$3K$;SK<=$<QXTY='&#\ABD+F+9"9$C!5L9'%8\9&P$I+H?
M%HVU3P^79 HOUU#)C)MD=,GY&N5'I $(T2NNX+L!,U%U>F-\Z;7]7TXS"O%M
MM.^S-?8,D=>LH_/0NV 8.,.3;S-2-'!W$OH?1T?D&W+_ ".#YB\!X2&4YMA(
M-T.:DY*:?0)TM@Z#M):H6_O$:Z]<16<=VLU_QG[.[291@O'8[+G##8<G;RV2
M,R^"8=X#E7&7N_0D3$0@SFF&%II0\+KMOF,7-HO'TT75!Q:V+(Z_7-YDB=M9
M^-YC?CO._GM#54]E6S=*6V#*10 &XE <L5#"H^]($DF8*[/))A8D](M&.2Q9
MPJBZ=NDFS7!FS2<-V"2S_-JJ1=EB;B^6J\1I5]:AY)K[5%/$:5?6H>2:^U0/
M$:5?6H>2:^U0/$:5?6H>2:^U0/$:5?6H>2:^U0/$:5?6H>2:^U0/$:5?6H>2
M:^U0/$:5?6H>2:^U0/$:5?6H>2:^U0/$:5?6H>2:^U06=)S!YOKAT5"&HF"D
M[H$PQ$G)ODLE$V!TOBT:,79A%HY8KNF]G[Q+X(IL]8*E'.2 M%\RS=XN40X'
M?<3&^1C22+$&3Y !ILWMN^ZI(WUQ#W$NBL6AH744QC!63P8INF.MTDR,)F\J
ME"KO6I#8+LL '1ERQCS(^3(1EF9G]U8N->)GXY[3MUJ+D\=MDP:8EQ>Y&PJ.
MQAQ(57\?(@8V_DQ56(L7&P'UT!PB#F)V=()&8T C18>5/QZ+%,6 3=YU\#$"
M(8+4N+J:GQV[1,S[IB79[9RW>-V[MHNDY:ND4G+9R@IBJ@X;KIXJHKHJX7RP
M4253RQ434PO?'/#*V6-[VO:]&GVH% H% H% H% H% H% H% H% H% H%!%CD
M&A4G?,2DDA\6D),7;&PPB<CXDL^'6Q6LXQLQ=OVCAPTMBO:R^-FZB?0M:REN
MC.W6H5'#',:[U_(5TG)^#0XXY0L6LBX,1D*371L?0Q:G;)*O62ZB=C3;'%N6
MMAE:Q%#'%%Y\9.UL;!X5UUKYPO('*\$AJSF6(+M94X5C 11>3-G.+7!RWD"N
M;')0R@XP9,L%T2.3E-7%HUQ4QRLW2M@2HXA[I:]@*"L=71@\/16B&;M2)K)1
MH*FK%\W^66;[..J8,K9A,WN>>6;O(;=M=SEEEDM?.][WN5L"C)FQC)-BR:MF
M;) ._20:-$$FS9!+Y5;H3101QP22PMTWZ,,,<<;=-^BU!C=RXMR9K]ZWNT#N
M7%N3-?O6]V@=RXMR9K]ZWNT#N7%N3-?O6]V@=RXMR9K]ZWNT#N7%N3-?O6]V
M@=RXMR9K]ZWNT#N7%N3-?O6]V@=RXMR9K]ZWNT#N7%N3-?O6]V@S#$9CTACS
M^)G@HTU&2@Q0,2 E6:) 60%+(?+*L'C-W@JBY;*(?T\TUL,[98_Y_;;IH*OS
MX;]#JLQ@];5$*<-1+HF]:X.0K=RHNX-KC7)JY5PXLHX.I&7 4*L7;&U2#8FH
M&#YO4E[BV%VY*CC^_G?_ )PFTHUM )NW>M)C#H[*&Q%=BY>HGA;4HFNJ-;.V
M3'K6>)J]5)NS(E&F*&'50R:EC#=1/-$L2P="HSC75-,,,$\,$T\,4TT\<<$T
M\,;888886MCCAACC:V....-K6QQM:UK6M:UK6M:BO:@4"@4"@4"@4"@4"@4"
M@4"@4"@4"@4$5D\[A$)[+[YS**Q'MMYV>%[SR$0 [7?_ ,G^!%]JO&GS[S^H
MG_AFGQ5OZF'\G\V/2$JH,9X\9CF;L@0=-F#!@V7>/GSQ=)JS9LVJ6:[ET[<K
MYX(MVS='#-9==;/!)%+#-13/'#&][!DT&I/?V,S_ +6__P"JK0;:@4"@4"@4
M"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4''&P(\7CN[9].36D#F
M](ML#3T,@,=1 -H,7< 'D>-[!>2N$&!<ZD4>:"@$]3E,>?Y'6ZC@,16#.F4T
M6&( XOF0)O.\3&G:^N_B-I<^CM6\7FOH*$UVS?RN2!HQI^*2=0M')\DW(VV$
MVUJ&TN8TT!?OR(^0/XQ'T4BVZAY114,].RUJP;LC8<P]P<#R5,14?SXB)F>_
M'B[8C77'%6?@^Q!A-?:Z"X+5?%8RUJ/=35R(QD4TDXN$>".1A$CM;8APS@W;
M%YNV",M@SV1M ;U-;&0W9NA8%(<7.^F?8K/.,U.FD,\A&.+0ULJ1IMFVV8[$
MI3*23(TX:S7/!N($-.*K3CH.^C)=UM0FQ9M%>'='9SIO>#:SUO9L*?81J3J3
MR;(?.M"9ZU?\QUG%7554:\NR]: I=&-83,#+G,@>*"Y7MQ&+.I/(7<J.JP)2
M62)S!?G9$2(EC1;X497'(-'1TD\.69I-TBB^;M)2]&D#[3,<Q)>;=>Y0.TS'
M,27FW7N4#M,QS$EYMU[E [3,<Q)>;=>Y0.TS',27FW7N4#M,QS$EYMU[E [3
M,<Q)>;=>Y0.TS',27FW7N4#M,QS$EYMU[E [3,<Q)>;=>Y0.TS',27FW7N4#
MM,QS$EYMU[E!>&LG#EP$>YNEEUU+%5<<<W"BBN=L+-&5[8VR4RRRMC;*^5[6
MM?HZ;WOT=-[T'")D;MY7;.YS>Z->[->0&30R"L4[ZW*E)< %1L'NUZD$#"XO
M'+CRYMBM%E\)-NL0*NXFDBCKN6C6K1R&<Q*/LC-3>=*K_P"K_&)Z<M9KS5>S
M4H;%IN.+3M"1!I?M&.PH&TBTGBC=2)K2W;1T,>B<9GQ=8GJF)+164J,!D(G:
M4B;GW$%TP!0D P.V'O7H^MM]-YQF)GF<WC?/<.AY:;E^OV;DW 2&NL@ZZ<>&
MAG]Y=_B1(T4+NU>M<9]$H--+(-U'"X)PI(8L,<.R05^^'J% KH68(&M%S4"@
M4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@U)[^QF?]K?_P#55H-M0*!0*!0*!0*!
M0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*#Q>_1:][_ .5K7O\ =0<OQCB_
MTQ,(9H><@WYYP(XBY3E$-=MLP:R1:Q-#M=-\O(F%UKY!!8UZ(N-?$55%FZ9
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M+<Y:_<M[5 [Z1;G+7[EO:H'?2+<Y:_<M[5 [Z1;G+7[EO:H'?2+<Y:_<M[5
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M9/9(+<KG6A+Z<Q[=7[M<K1-<5^JPD@*1_-&9DL@!!TSD)D1$B+Z/ 68V7XP
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MY?F=OV% \6L.0Y?F=OV% \6L.0Y?F=OV% \6L.0Y?F=OV% \6L.0Y?F=OV%
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M*!0*!0:D]_8S/^UO_P#JJT&VH% H% H% H% H% H% H% H% H% H% H% H%
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M<W\0>Z=JPW=P\'#R9%O"8B,X=CDV28M8+F(:#]M;U/:^/K35O)AKJ<'FQ&+
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"_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>61
<FILENAME>g164680g84a55.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g164680g84a55.jpg
M_]C_X  02D9)1@ ! 0(!>0%Y  #_[1BN4&AO=&]S:&]P(#,N,  X0DE-! 0
M    &)*^8I X0DE-! 0      &D< 5H  QLE1QP!6@ #&R5'' (   *\K!P"
M4  (<G(Q-3$Q.#$< @4 0$UI8W)O<V]F="!7;W)D("T@4F]I=F%N=" @4F5S
M86QE(%-?,2!/8W1O8F5R(#(U(#(P,C$@-S P<&T@0VQE86X .$))300E
M   0X.\F9G[YXFH<=@QF;\O<F#A"24T$.@      Y0   !     !       +
M<')I;G1/=71P=70    %     %!S=%-B;V]L 0    !);G1E96YU;0    !)
M;G1E     $-L<FT    /<')I;G13:7AT965N0FET8F]O;      +<')I;G1E
M<DYA;65415A4     0      #W!R:6YT4')O;V93971U<$]B:F,    , %
M<@!O &\ 9@ @ %, 90!T '4 <       "G!R;V]F4V5T=7     !     $)L
M=&YE;G5M    #&)U:6QT:6Y0<F]O9@    EP<F]O9D--64L .$))300[
M  (M    $     $      !)P<FEN=$]U='!U=$]P=&EO;G,    7     $-P
M=&YB;V]L      !#;&)R8F]O;       4F=S36)O;VP      $-R;D-B;V]L
M      !#;G1#8F]O;       3&)L<V)O;VP      $YG='9B;V]L      !%
M;6Q$8F]O;       26YT<F)O;VP      $)C:V=/8FIC     0       %)'
M0D,    #     %)D("!D;W5B0&_@            1W)N(&1O=6) ;^
M      !";" @9&]U8D!OX            $)R9%15;G1&(U)L=
M     $)L9"!5;G1&(U)L=                %)S;'15;G1&(U!X;$!8
M        "G9E8W1O<D1A=&%B;V]L 0    !09U!S96YU;0    !09U!S
M %!G4$,     3&5F=%5N=$8C4FQT                5&]P(%5N=$8C4FQT
M                4V-L(%5N=$8C4')C0%D            08W)O<%=H96Y0
M<FEN=&EN9V)O;VP     #F-R;W!296-T0F]T=&]M;&]N9P         ,8W)O
M<%)E8W1,969T;&]N9P         -8W)O<%)E8W12:6=H=&QO;F<
M"V-R;W!296-T5&]P;&]N9P      .$))30/M       0 [_^-0 "  (#O_XU
M  (  CA"24T$)@      #@             _@   .$))30/R       *  #_
M______\  #A"24T$#0      !    '@X0DE-!!D       0    >.$))30/S
M       )           ! #A"24TG$       "@ !          (X0DE- _4
M     $@ +V9F  $ ;&9F  8       $ +V9F  $ H9F:  8       $ ,@
M  $ 6@    8       $ -0    $ +0    8       $X0DE- _@      '
M /____________________________\#Z     #_____________________
M________ ^@     _____________________________P/H     /______
M______________________\#Z   .$))300(       0     0   D    )
M     #A"24T$'@      !      X0DE-!!H      S4    &
M  #,   "60         !                          $
M ED   #,                      $                         $
M  $       !N=6QL     @    9B;W5N9'-/8FIC     0       %)C=#$
M   $     %1O<"!L;VYG          !,969T;&]N9P          0G1O;6QO
M;F<   #,     %)G:'1L;VYG   "60    9S;&EC97-6;$QS     4]B:F,
M   !       %<VQI8V4    2    !W-L:6-E241L;VYG          =G<F]U
M<$E$;&]N9P         &;W)I9VEN96YU;0    Q%4VQI8V5/<FEG:6X    -
M875T;T=E;F5R871E9     !4>7!E96YU;0    I%4VQI8V54>7!E     $EM
M9R     &8F]U;F1S3V)J8P    $       !28W0Q    !     !4;W @;&]N
M9P          3&5F=&QO;F<          $)T;VUL;VYG    S     !29VAT
M;&]N9P   ED    #=7)L5$585     $       !N=6QL5$585     $
M  !-<V=E5$585     $       9A;'1486=415A4     0      #F-E;&Q4
M97AT27-(5$U,8F]O; $    (8V5L;%1E>'1415A4     0      "6AO<GI!
M;&EG;F5N=6T    /15-L:6-E2&]R>D%L:6=N    !V1E9F%U;'0    )=F5R
M=$%L:6=N96YU;0    ]%4VQI8V5697)T06QI9VX    '9&5F875L=     MB
M9T-O;&]R5'EP965N=6T    115-L:6-E0D=#;VQO<E1Y<&4     3F]N90
M  ET;W!/=71S971L;VYG          IL969T3W5T<V5T;&]N9P         ,
M8F]T=&]M3W5T<V5T;&]N9P         +<FEG:'1/=71S971L;VYG       X
M0DE-!"@       P    "/_         X0DE-!!$       $! #A"24T$%
M    !     4X0DE-! P     #?,    !    H    #8   '@  !E0   #=<
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M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
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M]T0KO!_%S^(B"K"F>R$HYX_Y3-?ZED$Y]_.<92=02,9\_;S]\8^V<<\O]%W
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M6WO3^7JYD8/ITTQB/K6@7T([^PO+>Y(]@DCM<_$5;OP=<#^SO86_YXGCW_\
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MG-974>YCE79T)($D,BEHYHF((66)WC8@@,2"!O-M<P7<2S6TJRQMT93T/>K
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M6EOS!6N;EP>SC&^>1<&29P"4B1V 9N56P/Z+_%[UEV*<B=<[M1#ZEW(2ID(
MGY[@VOKR8YG"&DP1\@^\[7Y@ES.&T5Z9+?2^ZMEN)EY(A]08V%T7BFVU K;W
M?):WA]%3S#ZO.<X_9,23&Y) [)R<[!'=B0-4X6^D.QUDQV6J"+3M28A4;F*V
M=VQV B=R3#*3L(978,<=G*[-R+N7QG"L84G.%)5C&4JQG&<9QG'G&<9Q[9QG
M'OC./;..;972*YXI3BE42QV6OT^!E[3:IJ+KM;@8\F5FIV:.'C8F*C0VE/E'
M'GEN-#"BCM(4XZ\ZXE"$8SG.>58()KJ:*WMH9)[B>18H884:2661R%1(XT!9
MV9B %4$DUY=TC1I)&5$0%F=B%55'4DG  'B:\J7Q!OC1VG9;TWJ3J7(R=+UU
MA1$9.[:2EZ,N=U9\K9?;JK;J6C:?7"$^5-G+2/:9-E365_@3*R02?I/@?Z)K
M;3Q#JG$R1W=^.66#2\K)9VC;%3<L"4NYUR,H.:VC;FQVY"R+H6L<3/,6M].9
MHX?LM<?9EDZY[,'TD0XR#A9#MGE!Y3H'$&E9Z38$#'/FIJ6,0P,*,T1(2<E(
M%N^E+3+#2'BC#BGW/2VEM+C[SSF,8]:EXQGM;&.%&9C'%%$I9F8A$CC4=68E
M55% ).2%4#WUJ2\SL  79C@ 9)8[GP)+;[$;Y]M;M.M/P>)5VK(W;WAO@'7'
M3X##4J1 24E&1=UD0%)PXG$P?*>N*IJ"L9PAL5]J3L3V5_)Q% D90OG(N(/I
M5C%R='X/L7U[59&,:3QQRR6<;@G)ACCQ-=E-N9@T=N!DF5U!%;/8\-OR"YU2
M865L &*%T24@@_:9LI$2?L@AI.[E!Q66<9W]T?I-DS1_PJ.J;5^L*6TARFTY
M:$D!(0E;:LI3*3,B6XQ<+0,EWUJ09;+!5(H=2L+ PZ)E#:M1N^$=2OPFM_2A
MQ4--M\EHM.6>)[@=,Q6\2AK6!\'#):6]U*< /ALD92/4X(3]4X>T[ZP_1[@Q
MN(_4SM@2."3G,CQ*,[#!%1I8.NG;CM:2F9[H=E+&N!?>04G4.N2F *V$C"\+
M:'=%$'%J Y8GC#6"L05I,<1^NJ;<=];B\>WT@<*\,!H.!^&8&N%!3],ZL&>9
MSN"RHS->/')DDJUS:*-U^KA<!:OZ#U'4"'U?47Y"<FTM\! /[IV$2L-QD1RG
M'[YK(S674;KOJ5([M3UA7WI4?T*38;(PJT3_ ,]&/<EB1G%&JCG5JQA:DQ+<
M>/A6,80PA/ZO-$UCCKBO7"POM9NQ"VQM;1_J5KR].5H;;LQ*!XS&5O%C69M=
M&TVS [&TB+#_ *R4=K)G.<\TG,5Z#[/*!W"LD,>$X3C&,8PG&,)QC&/&,8^V
M,8^V,8_9X\?NYJ77K63I_'\?Q[?EQ2N?/V_=_;]OV?L\>?.?[<YXI7'%*<4I
MQ2G\?Q_CGBE/X_C]G]W%*9_;^WW_ &8^^?MC[??S]O[/RXI5NV:H52ZQJX>X
M5F M,4YY]<;88@"9!SG*?3E6!I <AE*_'_.E&%XS[X5C/OR[L[^^T^87%A>7
M5E.N,36D\MO(,=/3B9&QN=LXW/C5.6&*="DT4<J'(*2(KJ<['9@1TK"*]_#I
MTQ,2+=HU7*6S1ET"=^JC)RB2YWT(1_OELEN-*,24%EM7NVB EX-*/&?3C]G1
M]*^EGB.TC^JZO'9\0V++R20ZA#&)FC[U^L1IRR<PV9KF"Y)\<[U@KGAJPE)D
MMC+8S#=9('8J#USR,VWL1X]]^N]5VK]G/B6]/$8$O@<5W/TP$WEHE\K!+NP0
M8A*,X7\R3:&=LRWLL97DEV;C[R$A&/EY/9:SE>,R(/HRXSQ]4DDX+UJ0@K'(
M5&G22D[!06%KC..0126$C$Y[-CM5F7XATK/:*NK6BYRP!,X0#][ ,A/B2)@-
M\MC>NJ7JWX8GQ/L$NZHE4]2^STAAU3M0- CH :<FUJS\UM^JH)&JMNPI_P!:
MG"*>?#6=S.<DR(><I4/G,IJ7TA_1WR?I%/UGX<0KRW22/.88<>B5NBK7-IZ!
M&%NDFML86)QLPM3;Z'KN?JY^H7QSF,J$YFV)!C!"2C;8QLK]6(V(K3+VOZ-]
M@^G=@Q';6J:UU@TIP:N[&KN'Y.D6''ZZFFF)3Y3:HN4=:0I686;' E/#;KC+
M!(S6"5=8X9XRT/BN#M-.N0+A%#7&GS\L=W 3@%C%TDB!..VA9XMP&*L2M:WJ
M&E7FFL%GC_9DD)-&,Q/UV#9]%B!CE=0W0[[&H^ZY]GMS]5;Z-L'3-Q+KLEA0
M[4U#.Y<+J]LCF',JS$6F"4ZV++ KPMU+3BODR$<MY9<0< 9ALMN_U[AW2.);
M)K'5K19X_2,,P]"ZM9"#^UMI@.:)]AD>DD@')*KJ60T+*^NK"42VTI0[<Z=8
MW P.5U)PP[@3C!/,A'VA[).A/Q+=2]U81N!=P-K_ '=%!)>L.N#SDNHDVVDI
M2_.4H]Y#&9N&4YGR^+E"):(6I+1XZF%B'F_*?&GT?ZIPC-V_I7VCRN1;ZA&F
M#&23RPWB*6$$W<K9,4V,QL&YHTZ1I6M6^IIR$B&Z4#G@8_:_XXB<<Z^(^VN?
M2'>=E?- K-4XI3BE.*5%NR])ZGW&[37]H4. NSVO;0'=*4[.#*?77;1'J2L.
M8CU(<:RDAEQMEW#;OS1UO#C/.,K=&86VI78V_K**W#K>TZWF#"8P.R!#M-R0
M3;3I,7(1QXDM$2++#WADC($H &4H9S*$$MM*84XWASYB5*QKLW73?NSX"4KV
MU^P-9.C<P D%$Q5!U7)5.'.,'D0S'+5<A9K9%O+F9E; GTX@,.=7HH!U]XK+
M1F<,LM3TZ>L=/';Q]M1C.,]V#X[CV_?WU:B.BSZ*3NFHYV6.IS;FKMGZW:D_
MT07C-?SL:^W&[8EEC?I)E4FW$8M:8Y<>DF/_ !!4?@SZL/!.!AX^_P##;[_R
MZU/GS\O/7\V+IGLN2?:A*]O2$J=(@;]V)VC27@]8$'[*KUT[#4;<5?,*)MY-
M];A9$&D6K<D_:H,=%1"=DP18BNR#[*XE,V:\^_?O\/A]U!Y&=ON'XGK@C.U*
MU]T3LM9V1%[(LNU8R;,"M6L[01%L0FQ9EXI[7=7VS6UM%6S:&X-D6D\B;5LQ
MJ2^M+.4W%KAE!, /M&MD!1CI[2>G78C\>M!L?G_3STKMV[J.[6]=(PDJ5V01
M5:'M&  JE:KL:%-6&:OTL-+P9\<]-VH2*CWZU,#@F94<6ME[Z;):GA\-_)6\
M3Z@,8SX_G3'=U[QG;OR-^['D5^M;=1]I46NZZL]7V9 0.W_Y/)>J;5FKW157
M]FQF6V7#L4O/-"1MPK08]N /"#'<*?=FH.0;$RPX$XRO#V0VP.X=VY]^_JZ^
MP>&[O)R23W]_L]G7K5<K?2<R"-N1Y>SFY@JVZWW!07"':8*"ZT_M>3US(N3K
MS4?,CQZLQ:Z$O#T6 !&A'+EL?2YB6 $#OSX^O\@/PJ,;>_/SSY\/76:=.@<U
M2HU6K**P<JMUN#@%')8R.DS,/&#1V2L,9=?^GP1D;+V&<OO9:]>&\NN9QA:E
M2-@*N3BE.*4XI3BE.*4XI3BE.*4XI3BE.*4XI3BE.*4XI3BE.*4XI3BE1[L7
M4FJMOQ8<)MC6>OMGPT<:B3CXG8E,KEUC 9)M"VVY 0"R1TD*,8AMQQM)++3;
M^&W'&\.>A:L94K&S9^I-/:HV-']O]BV&[%1.GJ>)0]<:\B:_!2%+UL/<)&MU
M5URBU*FTIFYR4]8I/\)CVFC)J=0"@U\6)# CU('&'ST_'PZ^K&U.G=U(Z=2<
M[#XD^W.]7;K";ZS;,S)1M<UG"UR4UR7)2QU9OND2]9SE6>OHOU$S8 8:ZU."
M?:'N0CF53$]$)>&FL*<8DS'WDNM)4JLQFO.J=6F6-90FL=*04E<J;*^FKPNN
M*B"%8**B1;+EPRVX^"1%EP#DHIDLF,-<4*49E!7TKSJ<N)4J[QM1:%Q9F-K1
M^K-3.W6%B'(8+8<=1J@];8Z%!#6"J&!M(L6J9'CQ@,. )C!SD#M#96(EE+2E
M-Y;=WD=U.O?W_"K!U?K#J1,T>/G]:Z<TC$5'>L95M@Y! U92ZS_* .RX'<JM
M-ST!F! (F)&(,4'8 %RX;Y\'*I;/1@4YO#F%//GXU7I.J=9-06"R;K)H^H:1
M<Y"1A8:W;+BJ/60KQ(2%SGHF%B [!8X2'S9S%3D[)Q+.<GDNM../-&%J2.RL
MAMXGWD_B:> ^ ]O@*NB=U;H^V7B(O-EUUJNS;*JHS3T%;IVI5*8O-=$SZLLN
MQ<](@$3T2QCUKRTL8L=&,J7E&<94KRZT]?Q/JJZ*W%4&LCE1=0C:?7Q):8D9
M R.K8<+$CR5A/SA^7.*$C&QVC9@W*4.R)+K;AQ&4X<*<7XQG"E65):-Z^6Z.
M"KTOI_3=FB:O8#+%'0<C0*5,QU>M4H\\;(3@<83$DC1,_(ODOEFR3+ \@8Z0
M\^^\XMU:E*>?N_(? 55/Y#M*XBCH+&H-78A)2M0M,DX?&OZGB*D:=6RR)"O5
M,Z/_  CZ0NM01Q91L-!$,N1<66202"*P\\XM2E?16E=-JO)FSU:EUFK94A'*
MB#]A*HE65>#8E0J051A=KS%9GB(]824!K#>/6.L1"!E-Y90E&%*Z$)U_T/60
M'XNN:3U) 1A41(5\F/A=<4Z+!(@98\F5E(1\4&&88>B)*4,+DCXUQM01AY1!
MA#+A#SCBE*[%<T5I&GQ<)"5+3NK*O#5J=Q:*Y$5W7U3A8R LN,93BPPH$;$#
M"Q<XG"E8Q+ M,'XQG.,$8XI5[5VJU>H OQ=3K<!5XPF0/ER8ZNP\=" D2LJ0
MLN4DWQ(T<8=V0DBW%E'FN-J),(6MXAUQQ6594K%7N5TBU)W4I 5:V#F3A+)6
MTR3]$O4$ZK,I59"30,DI;D8Z\W&SD4:H,3$I%'H0X0RQC,?(11R63V<5JVCV
MNKP"*XYD>/F,$R$\T3-C)Y2>5T8JHD1OM*,!E.&&M\2<,:?Q-:I#><\4\ <V
MEW$?VEN\G+SYC)"2QN4021O@D+Z#QOAQX]>W'1C>W3BT9CMB0?XK3#S7&*KL
MVNLE$U&PH_7<:962MO#D).?)1G)4#+?),;RAUT%<@ EH]_D^JZ)?:0_+<+SP
MMD1W48_8OCH"3O&XW/(^&P"06 !KYVXAX7U3AR?DO(NTMG8K;WT0)MYQU )Z
MQ2A<DPR8;(/*7CQ(<VNBGQ?=D: S#ZWWNN7VGJ)G(X($R\\HR_T8/REM/T)A
M2TYLD**G&,XB)%_!HS*<ICC\,M,QV<SHO%EQ9<EO?E[JU& )=C/"N.[+9D0#
M?#D,!Z*L?16MGX5^D.]TDQV6JF2_TX'E60DO=VB]/1=CF>)3TC=N=5R$? 5*
M]%E#[[=:=J;.UWJO6E^CKK/;&JLM;8\B(=1D.($BF</*BYY+V6RXNPD9\I;A
M2QV3$I2IQ:,)RGU;_#K6GW-Q!;6\ZS//$\H*$$(JX]&3?*N2<!".;J<8%=CM
M.*]$O[ZSL+&[2ZFO()+A#$05C6,9*3 D/',>Z)E#=^,5E!>+Q5-;5*?O=YG8
MZLU.L1A,O.34J^V,& "(TMUYUUU:L)RKTI]+;:?4MQ?AM"5*5C',]9V=S?W4
M%G9PR7%U<R+%##$I9Y)'.%4 >L[DX &22 ,UGY98X(WEE=4CC4L[,0  /6?E
MXFO%E\2#XF-V[D6<ND4LF2J/7>OR7_<M:2ZX(?>BPW\_3VFYH;4G+J,+0DF$
MK[N<B1.,-%E(=ETH=$^M. OH]L^%+=;R\6*ZUV>/]K<$!TLE91S6UF3D*?2(
MFN,<TV"BD195^::SKDNI/V41:*S1O10'!E(R.>7?TAU*+D!<@GT]Q@QU]ZZ[
M:[/['C-8Z@K!%AL!V</G%JPX/!UN)2ZAHF>LLI\MQF)B1,K\K><2LDMW+04<
M*;($#".[EKFOZ9PY82:CJMP(+="51<\TMQ*5+""VBR&EE<#95*JJDO(R(K,N
M*L[*YU"<06Z<SG',>B(H(!>1AGE4>)R3L%!) K?)%*ZC?";:$J=*A!NV??F7
M&0"M(0N3HJBRQ;/H^@80*DYRM--J5G"HP#ZFYRK25YDS(<%8V&>*3MQ+])(E
MO+ZX/"W \),A:5Q&]W$K9,C,YC6X)&_:2E;2(D")9G#9VY/T?H.(8$_2&KOA
M<*I81L>@& >S'=RJ3(V#S%%-6BOKSV$[@683:G>G8LP2 E_ZZN:-K)N8NN5T
M=W/K0*2."XH&+SA&<-$)!49.DI\_7SZ7L*;Q@[WCS0N%8'TGZ/\ 3H1)R]G<
M\07D?:SW#*<%X5D57ER02K3<L"[=G;,N&J[BT:\U)Q<ZW._*#S1V,3 (F2#A
MBI*C(&"%RY!W=2,5GO3*+3M=P0M:H]:AZM!!IPEF.A@F0V<JQC"<O$*;3ATL
MI>,8^:66X\4]G]9UY>??G)-0U*_U6Y>[U&[N+VYD.6FN)&D;_E7)PB#N1 J*
M-E4"ME@MX;:,101)%&O144*/:<;D^)))/>:NOEE5:G%*<4IQ2G%*<4IQ2G%*
M<4J,-C[!E:4Y6!(&F'WF4L4XQ&.1D9)"@/Q<>M.5$3A7SV"5+!$\)2[E+24)
M4M/S'FD^5<O+&&PN9I8+O5+73I%MY)X$G!9[IH_^IA0,K%CXC/< "2 <K9:/
M=WMI>:@(ITL+%5^L7OU::2UCEDR(H99T4I%)*=D#')WPIZ&OVFYAU>0K8YX"
MQXJ60\W*6)^08:BX@YMG+K8ZU/L,9>^H]*T,+6H?+B48REO+GEK/.](ON/!K
M\NF:QP_:7NG7M_?'3-5T-YRMAI=O$K6[:O#/VF;FX9E3]E)$HD$H02+V2FR>
M&:[O;"RT72]2U!YK>22]DB02K;21*"6"1(7,3$X#/R 94+S.>6KL9>9(::('
M>:('?;0\P^PXEUE]EQ.%MO-.(SE#C;B%86VM&<I6C.%)SG&>;R05)5@5920R
MD$$$'!!!W!!V(.X-471XG>.1&CDC9DDC=2CHZ$JZ.K ,K*P*LK %2"" 17UQ
MGQ^S/MG'O^_'C_''WQ^_D5YKC^/S_C^/;QCBE8G[WZ;:;WKAZ6/B,T^^)S\\
M*^U%#49-)-;_ %F'I5II*!9E#:\)SE1;?UJ$)](IPJL_,QN_#7'_ !!PR5AA
MN!>Z:=I-,OLS6Y0XYA S$O;,1_V1[,G^TBD&QQ&H:+9:@"SIV-P-UN(<+)S;
MX+@8$@R?WO2\&6HKK_:WL3U!BW-,=W:<UVXZC6!":\J\E1[-AL4%$O*0RP+*
MYF<K1*-M)RA3<);2,$9=;:17K?E(F!E=!@TSACC=QJO!MV>%.+H#]8_1AE,$
M4TRJ79[<Q <H)!)GLU("\[7%F.?FK"/<:AI(-OJT(U+37RGUCE#LJDX DYSC
MO^S)C? CE)&#C/VU^&I3)W7CW;+X?5EQN'0,@V3)V*@QI!$K<M:?*3@J00(,
M3C\<D8N(:<Q^+0$V.W<JT/ADLQ$U&N$R<?N7#/T@W<%\O#''%N=*UM"L<%\X
M6.TO^8E(R[)F&.24C]E<0N;.X;F5#"X6-\5J.B1O$=0TA_K-H<L\*DM)">K
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M."IYA6KB9K4]OVG8F$A^T+<O*5_O,2 ,=^^<9SW5Z4HSX^"X[1%:&<U$;/\
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M,RVG&?;&5N8]2\J2E*$Y4O*4X4I/U%=W-IIEE-=7#I;6=E;M)(V%CCBAA0G
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M]$+$X:_ *H;&'()!>5&!9F!"&"!'YDSY>5JJ+P;;<,7US97%OSZC93-#+-<
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M-0C@Z\H?\,5EDNMY8P")C#DGN]7YD^?748W!]OMZ =_?MXC;QS5!O71[:+6
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M#RL 6W!4\A<&/-9K30-.LY=390UQ*3;V$9QGG88>4 A=E&1MXL!Z0-9[],-
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M]2X;U;5+VUUI]1L);."SN[&S0Z,B2LW:_I2X*%DG?;LO33))(#DXJ;L>_O\
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MJ[.P1,[7EXM-*LXD>%]578LJ,F(0:+N,*^V_F)M :"B$./SS\L>?Z#$^?/\
M3 JNG];]+Q#8,!(S\W&.7#=$9L>!#E+:&J3G=A5[3PM('A(=Z8'?E)Y+.NJ"
M58#H[+TE./YB)VQ%GJ"&,^0&W3U_//YU!&=O.V]65$].M*1SQNM(G86P1ZTN
MH4U.PM+ 7B!&B[O%QM#QIZM6N]"@P3%^'9F:M34P1#<%9*S3K/(U=\HV#/E
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MM"OX&>;6K">1[-B??O\ CZO5M3V_EY\^JNS:]<]F:G4[.32YKLM/3)1O9>G
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MOEJ[6";C7<[-^F"S&Y62U>-IE5*)_!?T?'+,B.MIUV9-R%@%%5+C[H_?TO\
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M-W]'O%]L=_J$T%Y"O_&%,N1T.0T:GKN0/$YU/5E$>N:7)O\ ME:)B#@X)Y?
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MP)2F,EF8DLOC+PHG"L"FJ\.II=]J#&P&L:,^JZ;I=JD4#+>0:A*Z6=X$QRW
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MJ%ZM(G7_ -+,&?CD@EEN81,I9;@\B.*C4B^?Q8W#N$M!W^L >S!SFH\/5O\
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MB %DYAZ0& :TCAW3K_1+$6FJW\6J7%O(R6DL8D8QVXR(Q<S2<IN)0,9(3 (
M+/@$;?:?3ZU0*O!4NGQ(<'6:U&#1,-$A-_)'$!%:]#:4XQXRIU2O4Z^\M2G2
M"7''G%...+5G"RRO-(\LC%Y'8LS$Y))_ = .X  ;"LLS,[%F.68DDGQ/G8=P
MVK#+O1K6;.A-9]B:/66;=L'J_=Q=D"5G(C)9=JI*,L)OM=CD.-.Y:EG(L9B<
MB"66GS6I2#&_#F7)!;&.9#3)8^:>SG8)#?1]CSG'+'.#F"5CL<*^QW"X8\Y"
M@D7%K)RF2(MRK.ACYLX"L00I/_#D\K=W*3G;<4O2.\);MOMV9MU$-6KK-3H"
M, "_$(O#!-OO!J&9%PG^G0@N/>AVGB C@<O.,H%2%]2*MZ2]87+M:T%>*M?N
M-,URQ<Z3P[=0.D,H>,7.IQXD648*]M;/"Y5E;GAFMI(GY#VJNN0L=2OM":5[
M*;L+FXAD@E8*CD02#!4%E)C<, Z/&5=6 WP"#(G8\&_;28B]7ZZ<&;B#)5EF
MZ2'U"FW4 -+2KT)3Z$MJCQ%)6LIM3R72BL"M--X2G+F=1USC!>)^(7X"X?CE
MD2%@NHZC".TM0L)59X25QR16S'E9R2DTRJB%0%9[B^X7U*UT2WUN>2&*.ZDV
MMI6*7)CDWCE7(Y7+@,Q0'G52K$$DA<+.W-)U9  Z[UMJ>)_#-[T8D,JO[5JW
MK#N=;DEJ2I(CI\:XR]-+F"%9R=#2>"@6F%Y3EI+JE8Q]$<&Z''I>F?5A^STI
M(BK128*W#X!EN&#9Y22.8N,%CT) S7'N(^/6X?O+72=,MX]2NGEC%[;-S,@C
M9A^P7LR#]:D!]$[]F,%@3Z-9*Z+[(;DL4%;],[&IL!&=NZ%5DS$;7K'+/5NH
M[1BG&,XB[=%RL>!,+%9>>PEFPQP@CRXXWUY;RR-\[(=*\L;6.1+F"9I--EE*
M&2-0\D+ [QLCLG=DH6.ZXR3Z)?H<866&WN3'-!'/'&\D+\CSVSLH9X9.5RG.
MA/*#S'.-\'(KS=]Z=Z=SK;L4FF=J$V&D(",R3#:V$&>A=?($0]X8D8)L,DF/
MMK"%^K#%D)E)\EMQ;C"#V<IR,WNFD6VG0P=KI_))S+AIR0\N<;JY(#1]<F,*
M@)&Z]6&Q6L5JL8,'*Q( 9\\SY.,@L%RO3)4$#IX[Y+=A-.Z9F-S"]<]7']2Z
MH3(VVOPY;-*K/;:1WY0:['4AZXVJ<L1E_!B-(64L4*+,:(AZE;Y$J;F).( A
M7!PG#Y6*\6]S<"$W,JW;A4=AVAL1;REI.S15,>9U4E]V>,<BJQ;+8KQ'(X0R
ML)S@,06:(1,Q;"* HYU&^SL   21G J,*/U/UE:M:S]THT];[W#7:+C(.F&6
M:B.05]IUO!VH!3+ \'4:I>;1&VL=^,);.BU-S+62<D.19 T>6&^7RN][(LJQ
MR+%&R,7<!U,;(T+.,R-&O(,C?*8&%;)5JDS.&4. O*26"MZ# IS+ABO,,'()
MP1@=*O43HSIVM1MBG+!L&T6B-+U%N(Z""#3JJ1E:[L.@$Q(H1DJ[JW?EYA!Q
MLK/2HFMV&7CIJ-<=(%FH;YHB5.4CJ,[LJI&B$3VX?(DP\<O.6 $MM$Q(Y3AU
M4H=N5L;5'UF0D!553SQY)YB"CYR 'C0Y&/M 8.Q!WJ .Q/4BOZ%HQUA"W?6K
M+=*G)U("T5%NQZA7(/.VB+'DLFU>)I&YKWL 9N!**'%.:O='I1+K/S9)C#:&
MVAW[BVOGN) IMV5) Y5RDQ!Y#R@,TEO%%EE!QV<D@!VSD[5(I^T?!C*AN8JW
MI_N_WBT2J<C&.S+X.01WUL2^%WOOX@]UD8>"%@5[3T"$2R'*7#;)LA$-5T%I
M6$/L5"_+$D)F>/%:2AMNOYC;8()A+(RT0 SRCVM?UVUTB,,[,(+MN8K';*K=
MHQZ&2'*HBD[EP8R<D^F1RFQOHK)02&[*;KR1C/-DG[2851W^EE<D]6KT:9\>
M<^/M^7\><_G]L><^,>WG/CSG3*PU<<4IQ2G%*<4IQ2H)[#[ZJ?7G7<C=;&\T
M_(+2X'6*_AS"3+#.*1G+ C#>%8<^E8SE#\D5^J@8;&<>KY[PS3VR<*\,WW%6
MK0Z=:*RQY$EY=<N8[2V!]*1CTYVW6).KN>G*KLMAJ.H0Z;;-/*<G=8HP<-))
M@D*/ #JQ[AM]HJ#J4N]PLW6W6]GVYL,Q2NXW:Z&)_ HY_&$2>EM+3>/!$D^-
MGTNPMBN0>6PHH!WY3\?!)0MT!A3WS,_1^F:?::Q=VFBZ9&%X1X5D199!NFL:
MO!L%#?\ 70VSY>60<PDGR!(>7EK1)YY+2*6[F8'4]1!Y 3AK6U<G.5VY7DV
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M<[;==A@=,"IBU1M?O9V8O,;4]4V385XL# D^ U&P0D9'U>!B;BS@2U+E6&0
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M$6F:%8ZBEU'>#4++3VBNVF1PY[222XE61)<<LR.A61"5;K6/3284C,+7%Y-
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M*/\ U_C]W*->*?Q]L8^V,8_+^S[_ 'SQ2G%*<4KG&/.?'G&/WYSXQ_?GBE?
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MY]^2M[>([R)=W*22)V;NL\JN\>,<CL'#,F-N4DKC;%28HR #&A"G*@HI"GQ
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M%<[A%53TKH?#NBP\/Z1;:=%RLZ+VEU*!CM[J0 S2DX!*Y CCYLE84C4DE<U
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M-IQA*$XQCG*G=Y':21VDD=BSN[%G=F.69F8EF8DDDDDD[DUL8 4!5   P
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#7__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>62
<FILENAME>g164680g84w55.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g164680g84w55.jpg
M_]C_X  02D9)1@ ! 0(!>0%Y  #_[27T4&AO=&]S:&]P(#,N,  X0DE-! 0
M    )=B^EH@X0DE-! 0      &D< 5H  QLE1QP!6@ #&R5'' (   *\K!P"
M4  (<G(Q-3$Q.#$< @4 0$UI8W)O<V]F="!7;W)D("T@4F]I=F%N=" @4F5S
M86QE(%-?,2!/8W1O8F5R(#(U(#(P,C$@-S P<&T@0VQE86X .$))300E
M   0X.\F9G[YXFH<=@QF;\O<F#A"24T$.@      Y0   !     !       +
M<')I;G1/=71P=70    %     %!S=%-B;V]L 0    !);G1E96YU;0    !)
M;G1E     $-L<FT    /<')I;G13:7AT965N0FET8F]O;      +<')I;G1E
M<DYA;65415A4     0      #W!R:6YT4')O;V93971U<$]B:F,    , %
M<@!O &\ 9@ @ %, 90!T '4 <       "G!R;V]F4V5T=7     !     $)L
M=&YE;G5M    #&)U:6QT:6Y0<F]O9@    EP<F]O9D--64L .$))300[
M  (M    $     $      !)P<FEN=$]U='!U=$]P=&EO;G,    7     $-P
M=&YB;V]L      !#;&)R8F]O;       4F=S36)O;VP      $-R;D-B;V]L
M      !#;G1#8F]O;       3&)L<V)O;VP      $YG='9B;V]L      !%
M;6Q$8F]O;       26YT<F)O;VP      $)C:V=/8FIC     0       %)'
M0D,    #     %)D("!D;W5B0&_@            1W)N(&1O=6) ;^
M      !";" @9&]U8D!OX            $)R9%15;G1&(U)L=
M     $)L9"!5;G1&(U)L=                %)S;'15;G1&(U!X;$!8J2<
M        "G9E8W1O<D1A=&%B;V]L 0    !09U!S96YU;0    !09U!S
M %!G4$,     3&5F=%5N=$8C4FQT                5&]P(%5N=$8C4FQT
M                4V-L(%5N=$8C4')C0%D            08W)O<%=H96Y0
M<FEN=&EN9V)O;VP     #F-R;W!296-T0F]T=&]M;&]N9P         ,8W)O
M<%)E8W1,969T;&]N9P         -8W)O<%)E8W12:6=H=&QO;F<
M"V-R;W!296-T5&]P;&]N9P      .$))30/M       0 [_^-0 "  (#O_XU
M  (  CA"24T$)@      #@             _@   .$))30/R       *  #_
M______\  #A"24T$#0      !    '@X0DE-!!D       0    >.$))30/S
M       )           ! #A"24TG$       "@ !          (X0DE- _4
M     $@ +V9F  $ ;&9F  8       $ +V9F  $ H9F:  8       $ ,@
M  $ 6@    8       $ -0    $ +0    8       $X0DE- _@      '
M /____________________________\#Z     #_____________________
M________ ^@     _____________________________P/H     /______
M______________________\#Z   .$))300(       0     0   D    )
M     #A"24T$'@      !      X0DE-!!H      S4    &
M  $,   ";@         !                          $
M FX   $,                      $                         $
M  $       !N=6QL     @    9B;W5N9'-/8FIC     0       %)C=#$
M   $     %1O<"!L;VYG          !,969T;&]N9P          0G1O;6QO
M;F<   $,     %)G:'1L;VYG   ";@    9S;&EC97-6;$QS     4]B:F,
M   !       %<VQI8V4    2    !W-L:6-E241L;VYG          =G<F]U
M<$E$;&]N9P         &;W)I9VEN96YU;0    Q%4VQI8V5/<FEG:6X    -
M875T;T=E;F5R871E9     !4>7!E96YU;0    I%4VQI8V54>7!E     $EM
M9R     &8F]U;F1S3V)J8P    $       !28W0Q    !     !4;W @;&]N
M9P          3&5F=&QO;F<          $)T;VUL;VYG   !#     !29VAT
M;&]N9P   FX    #=7)L5$585     $       !N=6QL5$585     $
M  !-<V=E5$585     $       9A;'1486=415A4     0      #F-E;&Q4
M97AT27-(5$U,8F]O; $    (8V5L;%1E>'1415A4     0      "6AO<GI!
M;&EG;F5N=6T    /15-L:6-E2&]R>D%L:6=N    !V1E9F%U;'0    )=F5R
M=$%L:6=N96YU;0    ]%4VQI8V5697)T06QI9VX    '9&5F875L=     MB
M9T-O;&]R5'EP965N=6T    115-L:6-E0D=#;VQO<E1Y<&4     3F]N90
M  ET;W!/=71S971L;VYG          IL969T3W5T<V5T;&]N9P         ,
M8F]T=&]M3W5T<V5T;&]N9P         +<FEG:'1/=71S971L;VYG       X
M0DE-!"@       P    "/_         X0DE-!!$       $! #A"24T$%
M    !     <X0DE-! P     &SD    !    H    $4   '@  "!8   &QT
M&  !_]C_X@Q824-#7U!23T9)3$4  0$   Q(3&EN;P(0  !M;G1R4D="(%A9
M6B 'S@ "  D !@ Q  !A8W-P35-&5     !)14,@<U)'0@
M 0  ]M8  0    #3+4A0("
M                         !%C<')T   !4    #-D97-C   !A    &QW
M='!T   !\    !1B:W!T   "!    !1R6%E:   "&    !1G6%E:   "+
M !1B6%E:   "0    !1D;6YD   "5    '!D;61D   "Q    (AV=65D   #
M3    (9V:65W   #U    "1L=6UI   #^    !1M96%S   $#    "1T96-H
M   $,     QR5%)#   $/   " QG5%)#   $/   " QB5%)#   $/   " QT
M97AT     $-O<'ER:6=H=" H8RD@,3DY."!(97=L971T+5!A8VMA<F0@0V]M
M<&%N>0  9&5S8P         2<U)'0B!)14,V,3DV-BTR+C$
M !)S4D="($E%0S8Q.38V+3(N,0
M                                6%E:(        /-1  $    !%LQ8
M65H@                     %A96B        !OH@  ./4   .06%E:(
M     &*9  "WA0  &-I865H@        )*    ^$  "VSV1E<V,
M%DE%0R!H='1P.B\O=W=W+FEE8RYC:               %DE%0R!H='1P.B\O
M=W=W+FEE8RYC:
M              !D97-C         "Y)14,@-C$Y-C8M,BXQ($1E9F%U;'0@
M4D="(&-O;&]U<B!S<&%C92 M('-21T(              "Y)14,@-C$Y-C8M
M,BXQ($1E9F%U;'0@4D="(&-O;&]U<B!S<&%C92 M('-21T(
M                9&5S8P         L4F5F97)E;F-E(%9I97=I;F<@0V]N
M9&ET:6]N(&EN($E%0S8Q.38V+3(N,0              +%)E9F5R96YC92!6
M:65W:6YG($-O;F1I=&EO;B!I;B!)14,V,3DV-BTR+C$
M                 '9I97<      !.D_@ 47RX $,\4  /MS  $$PL  UR>
M     5A96B       $P)5@!0    5Q_G;65A<P         !
M             H\    "<VEG(     !#4E0@8W5R=@        0     !0 *
M  \ %  9 !X (P H "T ,@ W #L 0 !% $H 3P!4 %D 7@!C &@ ;0!R '<
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M"&U@;;EN$FYK;L1O'F]X;]%P*W"&<.!Q.G&5<?!R2W*F<P
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
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M;Q]R[MOUI[!4U=$GGR:=)+/FW%;!JJ^CM9]U,GTMH*GDQ(U3%BEFF/(G'".
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MW?GO[%3W#ZC:>ZRZ^Q*IZAYS<\?L/1Y3D>2P)L:WA2L>P?>^=E,>("$!LH]
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M'4U_?T<F18IC>5V1/CG!EQ'^C$7L1Q4$CR.[Q)W_ $#Z/N-1BH_4^+G.YS
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M?AFT61L9Y>"#D=U0E(B>>!DF1;1B.=\D[F\(OS\:"GX(ET&(8[2'DZ2DIZH
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ML/@K9@X>M%4O+@X:$MD=ZIN.>Y[A<+[5%GR3 Z"5SG!PWR26>UV_\+@=-?:
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M;%PZK8)SG2%CN(QAIY']C0A>JHU.YSFJB<+@L1XEP/!Y)!BE1(>SC+FTM/\
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M]>$C&^B-L,HP"5W?Z+E3SN?#_&E?AD\$57--48?G E8'WD8S][LW/O8C5P!
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M5"]1\J,V,TUN0%6B->=I$>?/+SX(H+SSJ>W5S6SHCEE6.'3Z7$]W:2S%5/-
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M*$UP=ES9XI)>\LH3H!2P;!D1RL$LN,V2)YH95&BFCJQ_:JNU\/?I(\%X[68
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M[T:GR3TYLU$:Z6YJM:GH-8B\F](GI$%?35E5-(ZCP##8Y*IS':.D; '.[>8
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M[C<MN21K:][673_TA,-PG#./C2X12TE'",+HS+!2,9'&V6\@NYD8LUY:&@W
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MRJ\(OA?*\_?K/C'*8B_9/%[:!S=O8!8W)\.]8$X/47_MVD'F0Z_,#GW[WT\
MN;\2>0)Q_P!IUGR__9S^%_1^4^7\'&GZ\I_[I_=Z[3[S;X_ J/U+/_?M]SMN
M7/S[-94V/Z=:R^W9P6/FMQ#%4BR.NF/''1\5T^1%-Z@(+SO.QR-D/^%&C>TJ
MJGP+S\K2MQ:*HB#(69) ]KP]Y:XM+3<9=--=^M]E=TF&/AD+I9 ]A:X%C<S0
M;CG9VH%K^];Y[CIGV=NJFSJ#XLX0;.#*@&**WNFE8.6!P7/&[[0^$C$?W,7Z
M*GG5LW%:YKFN[:Y:X.%V1\C>QLP:*\_5U)_=D&UKA[K^TWUVYKSJ[M>P"VRP
M2'(M:[?W<24^XLI<'$L:AXE165A+FOCS+&)6>N\P'E:&'$.XTHCVO<(#RN17
MJJ+T[#_27BD^6%U%1M;$QIFF<]S&,C!:PN(M8$EP  %LQ YK1ZW@C#8S)/\
M:*M[Y7N[.(!KB7N#WY;G4@ '4ZV',C6C^R\Z4XO3G[5G<[:D>8S<@3:;8F-D
M[9,VMBPY5A9YC68F*QJ)3(SW""E.N5*1IA*OK>D,;FHYI'.M.*^*:O&N'(3+
M3Q1Q5.(21A['$W^RNS @$!WK:'4[7T6Q8/P528*VGQ>.HF?-('PF*0M+6YX_
M6 L+W;J->FRS_!AN09Y[7[<2NR.:;"VNZ4Z225V%6,B+-O,>%G PQ(5Q.<UI
M&ODJB'D^Z]G(^V/W<-55Y-E<^^8Y6WT:+7(&]SOKW:=RV86 +@+VTU^/4<]M
M-.:W:0(0:V%%@1N_W>''%&"A'N(]!A&T;.\CU5[W=K45SG*KG+RJJJKKUV5"
M[>B)HB:(FB)HB:(FB)HB:(FB)HBI]C4U=O')%M*Z%8QBHK2@FQ@R1$:J*BH]
MA6/:Y%15\*BIJMDDD;@Z-[V.!N',<6D'J"""H+0X6< 1T(NL,=X/9U](F]C#
MER[:#&@61T?Q<T40=/8B<].'/$>$T2-=XYY[?GY^FMLPKCKBC!RT4F*U!C;_
M +*9YEC(&P(>3H.G318VIP?#JJYEIF9B+9FC*X;[6TY]%KU-[ 7IH)ES;86>
M9\'$_P"_Q-# >]_)%<O;=*3WQC59PQ$1O*>5YYXUO(]-O$7V4Q.HZ%U2=/M6
M4@6_^C8L^.M^X%8<\)4!DS=K,(_[L$7Y?O;CGRZ:<EGYLY[-OH^V22,?%=HJ
M"?;1NWB[R(#;JS*K41$<4LU",<O*<\]B>57[]:3BW'W%.,%WVG%)V1N_V,#N
MQC&^P98Z@VWM;87U67I\&PZFL8Z9A</WWC,X\N>FG6U]]5FS5TM/21QQ*>K@
M5D4348*/ B BB&U/"-8P+&-:B)]$36HR2RS.+Y9'R.<;ESW%Q)ZDDG59)K6L
M%FM#0+Z-  UWT"J>O-5)HB:(FB)HB:(FB)HB:(FB)HB:(FB)HB:(FB)HB:(F
MB)HB:(FB)HB:(FB)HB:(FB)HB:(FB)HBZ\N7%@QCS)L@$2)&$\TF5)*P$< 1
MM5Y"F,1S1B&QJ*Y[WN:UK4555$U(!)  ))-@ +DGH -247E1]KO[0OI]MIE7
MMOTY@K\GW8Q?)CS[G<^@'%2BKI9A"#,KHTN,U'WUNDF- *V2,CA0Y$4@VJXW
M/-S-^CSA?I"?A.)\01NPBGP[$F8F)J9C8*VM #<T<LHR/CC>^.%_:.)<,@L+
M$D97"/3_ (UZ.H\7P[!9&XO-B>&_JQM-5R.J*2A(>[LY&1'.PEK)9V=E8,/:
MW=]T*=/8Y2NJCJ(%NSDG43NYF]CA S5*TV*3\@+#O#W4DLQUE.L:KM9-B5)8
MX8PHR$:P4@C2^FC5$]-;/Q1B_!!K78-PI4X?5XA@KC2XNVFE9,^CD;HR.8!S
MBV6X<'$ZZ:G5:KA.#\8T]!#C'$U!64-%C8^UX1+/"^*.K@=ZSY('$ .CLYA;
M8[$&Q!N=WFXW4KL)L6@J'.=PJ2ELX407I4"RTF7KH[&-:-6P1N=((YS>..[A
MSOGK$X;P[C6,#M*##ZBHC+B#,&6A#N8,ALT?)>6(\08-A!+*^OIZ>0 'L2\&
M4@ZBS!KWZVW[PL'L^]K3M+3>L# \,R7+C(CD#.GJ.CK^]/"*44A%F*Q?GW,:
MOCZZWF@]%.,SY75M334;3]Y@/;2#74 L.6X^>BTFO]*F"T]VT<%35NURN($3
M+CK>Y.NFGO6+X?:A=2&<Y931,#V_H6PY-K$BNH:RKG9%(L1$D#8Z/]H*!'1"
M%8Y6J5$X&OQ)\O.R2>C+A^@HYI*_%)>T;$]S9GOC@8QP:2#V>;UP#;U;@GVV
M6MQ^DKB"OK(&4&%1]D^5C3&UCY7/:YX%L^49?5/WAWGDMI^_FZ5KC0,%I) C
M5'X70)DFR<PCF/">,*O[X##-X^(9)KE=PJ*OHIPOE>/S\_2#XPQ'AZ+!<#H)
MI:>EQLX@ZIK87F.1S*-U/''"Q[2"W/\ :3*X-(+LC==#;ZFX1P@8C#5USF R
MT7V<B$@/:UTK9'.S#7,&Y,NUC<Z&RM'99-PJ7.*R2)UK;8'DXY83F,\DB& P
MQO>"0U[E>@2B*WTW(G:CV/<G'*ZY=Z%1Z0\'XPPZH)Q7$N">(FU<-1-,^2IH
MX9X8WR0U+)'.=V,C)69';!T;W@W6R\13X'7X%.R1M/38UA[HG1M8&QR/82&N
MB+0&YVN:20=;$ ^.9N0.F"I+8U;&9+LPULTM='>)ID--''(Z,/TW(J/[S(QO
M;_?<\?77V_'E,C \V:7M#B#:S20'&_<+KDK\P8XM%W!I+1U< ;;\[_S"AG;7
M:"!'QRQD[A5M+D]]EUM(R>X%8XW6QQP)EFQCC5HXJ,,Q!Q511HY>'.XY<G/.
MK^MK,\S13%\44$;88RV5[BYK#H\N-M7:&PT'>K:EIRQCG36?),\RONP-RN?:
M[;"^VUR3KKI=1)G6S/1A=3I$+.MG\' :,;M))GX2"''(]CNY",E AHA6<ISW
M_)41?IJ\IYL=:QCZ6KG<'"X;%4@N MLX9M-.5]-3H5:3.PK.YE1#$TM-B98"
M!H-"#EUWL"+ZZ;V6J/K ZUL8S7"\BZ=]NMN*O'<2QF_K*ZDM5/[DONF+ST5K
M8U6,(DCQ)'H]H&N1KE$YI%14<G-_Q?Z :GTC<('#ZK'W4$^(R4M8^00_:,A9
M)VN4ESO6>= [H=!W6G!/Z0E/Z,^-!BT'#WZSCH(ZRA;&Z<T[9>VB=%G&5A+0
MV]VBVOM50V]]I16X;@^'8I8['XK?3,4HHE*RXESV.D2&QD5/417QG.&C^>>Q
M'<(OG]&MOX>]"M3@.!X;@[.(9WMP^D@IC(V#LQ)V+ S/E$E@3:_FZTWB7TV0
M<18_BN.2<.-A?B5;-5]GVHD[+MG9L@>YH<0.ME-6'>UAJYF14--.V6KX5;9V
ML"M.^CGMDSQ).DBBL)%AK':DA['E:_TF_&1J*UGQ*FKJN]%4\--45$>,]H^.
M)\H$T98QV1I<0Y^;2X%@=AST5C1>E*FFJ:>G=@YCCFD9'FC>'.;G<&@AN76Q
M-R-[!?KVSVY5+D/L_MSJNNH\HA_:%AC?KR)^,RX$4$5#G.YYI9&HR-^4:%J$
M<K5Y=V<IWHBZ1P]A[X\8I3-/3E@,H<(ZEKG7[&0: $:CN]Q%PNRX+613U\#6
MQ3L#@XYI("QMLIW+K#7XZK6!8>W ZD]KX-'M]B6Q]5%QW#\9H:2!.OJVU)-M
M8T&MC1VVY/3B+%8&>C$,)@7N$@WM[7N^>MQP[T?89B-,VLFQ=C))G/<Z-CXR
M&$O)#;EUR0" 21<GI=:'C?%M;08E54T.%ODCBD<!(_.W,+WN#E(L==+Z;;+'
M?*/:[]5.1W,R^H]K:O&)5W#/ OQ46.W X.00Y#%15L8C(B .9BKZ@I+6H5%7
MGN5%5-9"#T;8%!-'/^N#G8[-;/%8D:BXS6Y>.]]0+8B3C3%9HWQ_J=V5[2+V
MEN =PTY.FE] +'K=7;6^V!ZL[O'H&SDC:K&JG%LH$/&I(HV(6-;(..<,<23*
M#)=$8B3'L13E>KN5<CG$7CE4M\6X%P$4M95R8V72LCD>TNFC=J 7-:!F%P-@
M!I\E[8=Q3BKIJ>E;@Y;&Y[&G(R0%K38%QN-P-2?:MAL1V1_9$8(H\ 95K0L&
M]2F5PR+&8UCE145%['<<_153]_7&VMI6.:<\CFM(&S?6 W&G,A=%)E+38-!(
MTU.AZ\MNEKGN6/Y\ W+><SWH<SE(Y5*VV[6D5R\J1&JY%:BJJJB<<HGC]&ME
M;B&%!K1=C0 +-[(&W<3;4W)Z^*UY]%B1<3<GUB;]I8'7QO8@:;>Q<7XO]RO_
M -5(7_\ G'\OYW]?/UU5^L<*_B9_R1].OA[%3]AQ+OZV[4_57+B>%[AP;J-(
MDR20([%7UC%FI-:YG'YGH*O#E7]/")]^K6LKL,D@<UC0]Q&C0P,(.ESF'ARO
ML KJDI:]DS72.RM&Y+\^QVL2=_AOKLLF\(P>ZS+,\5J!YJ+'9H[R'85=HZLA
M$:&UA*\D!KAF*-A$>=6\L[E5R)\+576 :^ESL+H'%K7-<YIE(S &Y;>VEUFB
MV;*X,ELX@@'(-"1OIO8Z_B%K&WJZ$?:HS-X;..'<0N32\VRRZ%CLVNWECUGV
MFP(YMDDAU*R8A*N.D.,5$8X:#&]J 1>Y437;\-XAX*&'L<[#,HIH8^W+J7.&
MN):P@2%MGG,X$BXO>]ES:OPKBDUI$6)"T\CC$P3EIR@.?8L!]4!K3?2VE@%0
M3^RU]KS(?&+(E6120BNDQ7EWO&]T8ZB(!Q@.62JC(H2E&KF<.5A7MY[7+SZ_
MTNX#LZU"+.%B/L;=1<&Q&4'< VM:XOO9>)X?XP-KXA<BUKU#C:]QOK;0]VA(
M4O\ L1-F-\W==V\.<Y@P\]^S <AVNW?N9^3-LIK<FFMN:FL@,4A'FNHB6.)R
MFMDL<X(6PXQ$X11HF(XWQ3 IL!I*>@I^QDK'1U=*!$&M[%LEI7'3]FXVM:X+
M@=5L>"X+Q/A]7!+BU69:-\,CF1]L9 2Y@ .6]@6DCE?=;HJ/_P!,MG/_ +EN
M.?\ QZ/7(.=O#XW^BW+]VW^(_ #ZK;%HJ4T1-$31$T1-$31$T1-$31$T1-$7
MQ>[A>$15X7M15\*O'CE?IROS^[4&]C;>VGBI%KB^U]?!4^K)9DB(ZVCQXTOU
M2IZ460Z2+T4>J!=ZKAB7O>SA7M[>&KX1RIJWI753HKU<<44V=XRPR&1F0'U#
MF+&&[FZN&70W )&J]ZEM,V4BEDDEARL(=*P1OS%HSC*'/%FNN ;ZC6P71 6_
M??6$>1"BCQUL*,L":.0BS"S']_O0R1T3N&P:=O:]5X5>%:KE5R-\6/Q!U?41
MR00MPX0Q&GG;)>>29V82L?%8Y6MT+77%_>![/90"@IY(YI78@9Y140.CM"R
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M.AD?'%A(+XW6]2GB%BWOZZ;Z>ZP%@SACB*K8'R8J[(]H<V\TFM[V-A8'3OL
MI!A^P'W^HZR==[@;^8AB]/55TV;865597!'0P@BE([TBG8%HD>Y$'WHO<U'J
MK4<O#76%7Z1J&KBEI*/!W/EJ6F*,%K+ESP6CU6AQ) -[=PV5]1\(5%%4T];5
MXJ1'32LFD]9S6Y&.!(<YQ  .H)VL;66<7L8IVQ6'=)MMCVY^5457E%;NSGX3
MQK^R) D'@+;O6MG,$5[4,&=$0<E"M;PJD5JKW(O&N<1TO$$V)F2GP^K;&^GI
MW -BS6/9MOZP&AON-Q?6ZW;&<3X>GJQ*_$*1Q$,0O]H!U:VW(VN+6Z^U9F9E
ML9[.C+<AL<EL<SQ"#-M#NDSAP,H6/'+*(O)#J)CT1KR+Y>J<<KY75U18YZ0*
M.GCIH::L='&+,STV8AHV%R-A9:+6X)P'65,E5-448EEN7Y*@!I=LYUKVN>?*
M]BJCA_1GT#9LLI,3LZ;)'0NU920LK>5P4<O#5>BG8O"KXY1%3YIJBKXQXZH\
MAJNWI@^^3/2@9M-1]T[;\BJJ7@[@>K+OLS::H+ ,P;4!Q UM<9O#6W+7=6KO
M=M![.SI'PYN[NY-5$;4T]M !#C#LI-O(GVQ'N+#B#@-D*R0KO0>1["HHU&-R
MD16(NO*EXEXXQN4T%-4S%T['-($8BLP@AQ+[ C2^HU^)5U)PMP9A;162TL $
M#F/N7F3U@06^I<YM;:&X[M@HX=[>+HACL:,#,V*QC$:-@Z2,U$:U$1K6HXZ(
MB(G"(GR1/":M_P"KGB5Q),$5R3<F4;W.^E[GYE9+^F.!#05#K ?P$ "W?R&R
MQ%WC]K'T%;FYGCTL^VWO-&0[+K,K:PV_Q^?D=M/I[>CL*6$&<9ZD9'DBB3PS
M7D<Y7B48E16N768H>".)::"<7=VP'9T[&U3A#&V1DK)7%H_>!<TM &A!*Q]7
MQ3@<TL0$K1'</F<8 Y[RQ\98T$G2X#@Z]]#;PV#=+O4M[/KJPKL@F;=[/8W'
MFXR8([6ILMMZ9TX(I2.]WDI[K%*-1&[7(U>Y'<M7E-:UBF"<281*R*KJ)6]H
M+L<*MX:=2+:N&H^1[UF:/&,&KXS+3-$@:[*0(+N!MS !M=2;O/NCTT]..+AW
M#Q_8BD/> L Q:HD7!(-)Z4LC7*TKK18C%BHU&KPYB]RKPC?/&O7 \!Q7'ZT4
M#L1$;"QSWEU29/5:;&S [UC?QMOU5GCO$5!@5":[[')*0]K&-;"6#,=1=Y
M'G98MO\ ;#%3]JV?BK]$[LCX3A.>/",7CZ>/U_HUN@]$3^>+M!Y_L2;?S6B#
MTN1G;"7?\U6I?>UHD6]=:1![)4 Y%A!EQ6S370B$ ^1'>%AU58RJ]1*]'HBN
M7E$1/EKW9Z)7-RWQMX:""0V$@6O<VL[33N[]52?2U'>XP8.YDNDU.W^$W^.B
MOKV(3VXWL/G^U]@'[0O:#<6SS6;E;(8Q MUST$<A@I(:QJOD1YE1+*]G*HP,
ML(F(T0F-34_2)@7ZGKZ21E1VL-53-C9&7$OC-*R.-Q+239KR06]-1R70.&N+
MV<7"JJ!AYH'4G8Q!HN6.:YKK%KB!J WU@+[[DW*E2C_],MG/_N6XY_\ 'H]<
MZMK?N ]U_JMK_='B?D/HML6I4)HB:(FB)HB:(FB)HB:(FB)HBHN1WD3&J*UO
MISNV+50I$POE$5S0C<]&-Y\*]ZHC6I]55$3SKRGF9!#+-(<K(F.>XGD&BY5S
M1TLE;54])$+R5$K(F>+W 7/<!J>X+3YN5C=9O9N)"W4S>*DR; KS0,;IB$<Z
MNJ*R41I45T8G+"3BL1GO!58U4558B<)ROS]C?I"QNL=5TN'U!HJ&60@B(Y99
M&,NUI=( '6(UR@@:ZKMV'^CCA6AK:7$ZK#8L2Q>D@,+*NL F9&YQ#I## Z\+
M;/ +),KGBV]G$*X8M>"$ 4:($$>.!B,"$*-$(;&_)K&,1&M:GW(G'W\KKG;S
M)(YSWNSN<22YQ)))W))!))[S^%M]#F@  6 %@T !HM:P %@ +6  %N5ESJ%R
MK\Q_O\*O^G4@6 \^?.@5)=J?O>PV^%D03T5%1S4X3CPY$3CZ_7ZIX_KQJG*X
M$D$"]S?F+]#X?,]RJS-( ()VWZCKUZ]YZ++GILSNC&R?@DH:0+MQ7V<,A"-4
M-Q&5K!E<#GCM/&=VL*%>55JM(U51RHG>/1EB&'C"WX<Q^2M$TDTK7V':9K-!
M:>=FAM_%<<](^%UOVF'%K]I1%C:;0:T\@NX-<-;M?J6NTUTMH;9>(B)X1.$^
MY-=37+DT1-$31%UWS(@BM 25'&9_'8%YQ,*[GY=HW.1[N?IPBZ(NQHB:(BJB
M)RJHB)\U7PB?OZ(ORTC'\]CV/[>.>UR.XY3E.>%7CE/*<_-/*:(OUHB:(FB)
MHB:(FB)HB:(FB)HB?U_T_P##^OG1$T1-$31$T1-$31$T1-$31$T1-$31%1LA
M"IZ.U"EN2@4D"2S[:"H6EK$<%Z+-&Z0BA1\9.2M4J*Q%8BN3M1=5,!+V@-SD
MN%F:G-K]VPUUVT4.(:TEQ#0 27$@  ;FYTTWUT7G]ZI>KBLKRWNRG3?(LYY;
MN2&HSG=(<F18Y/FUCZZC;1T!F(^02+[R=\5A8W@CRNBUXT$C2D[CP?P0V-D>
M.\1-C8V)AFI:&0!L4# ,WVBIS: V <&.\7ZZ+BG&7'#I9),#X?<^221_83U<
M1+GRN(L8:?*"2+FQ<TW<;@:#7+[V>'1C=;.K(W@W'(T&:Y/0DK(&*.09W451
M/DP[ I;8BJ1"7,@L*.Y[6\^Z-]07JN>]Z:UGC_C2FQQ[,)PW*ZBHY\[JEKK&
M>1C71@1M%BV%H)M< N-C86"V'@+@Z? V/Q/$B[[?619>P.H@C>YKSG)O>8EH
MS?P[7U(6TNWM:^CK)EK:38M= A >:1,F%8"+'8QJKWE*16L8Q/'*JJ)QKF2Z
M6M/,S>7>N9FF59-E6%U6[>RX[65'CH,(K"FAP.]S12H,VOBV+PD:#\\L@8HH
MW+S+DQQ\D2/BH%];]=_=KH.F_>#R.D(V-U;Y3FI\?Z4[#*(\7-*HT3*<0>\3
MBT+#']WD1O>@'+"D5\=".]UF!.5X!N>-#(/L:UK\-]/<>9Z^X70D7OUMM:UK
M'4[:6O\ S4Q2/9I;AQ*,,^MW$A&OXR2[ 56Z.<,=LU8XUC-#*]9R-D&*)H)!
M5$B-8C/+T;VZ6V[MOCY^5K!-=+6WU\.7X^U8WVTO<_96GD=/&X 5Q&#F>14>
M0Y5D:)[_ "WX\QLF*" 0X'*V95@EM?./#0_:172Q.[73#.4">A\=/-NFYWO:
MR;;[?F=;_/I92KG,K$]V,52FQR<W#=CMLHSW,L!QQOFVTYKC!C3+#P);3)\J
MF"D$AU8S*M;"]2=.>CSL$V?/G9"/@-"==?:+Z6]JX^FGJ S+8+(L;A;AER5V
MV.6P1BQ>#*8PA(\1\Q 1IXXQ"M>".GJ(KU8BM(Q$>+O8J.4HO:XL387',D:?
MC?V#FL[NLGJLVHV6V&S#=6=C$/=*=BT*/)KL4:'N>>7+X0"R9GNTA($02N1\
MJ0HW^DSSV*JIJXCX&HN+ZBDH,6PZCJ*>609)*Z".5L=[#,P/U+M= "+E6\O$
M;L%BJ:BDJ9FRQ1N+XJ:1S7R6!NTVTOUOJ+Z:KSPVW[(#ZAUCLJMM]D<!QB(G
M(H<(H;2V<!'JO:@TC,AM<_Y(BH/XEXY377,/]$. 83314K*^.EI8FD,@IHXH
M(F 6N&M!('?8#E[>?S^D'$:R1TC,-DFD>=9'O?(YVW1I(/6^FZB#-/:%>U*Z
MB:\=32X)EYZLLV)8"BX=MA;6<1Q(Q/5!WO= E=X454[FD?V.3\[G67I^&N"<
M+>9),3B,@8YA+ZJ/0$"Y :;@[[:_)6<^-\48@WLX\+>UI<'@&&33*=+W N+]
M=#TZ;@O94SO:4Y/*W%9U'FLL5P05;3?@H3.,9;$M&VJED-EQ::L82">-$%#0
M"D=("H4>K6B3E'ZT?BW^B,+Z;]4 U,GKB<0RD,TL6ND>YKLSB;BS>0UM<!;/
M@(XCDCF&(]G3-NWLL\8<_+8^JUK7 - ZGF;6TNMG^]G3EE.\VVN2X)9[OY#!
M^W8XFM]"!"96-/',R0)DB./LE&BN>/@@4E-5R*G*_#YP.#8_3X/B--71X7!)
M]G>39SW%[FEI:;$W:'6.ARZ?*\QC ZC%L/J:&3$IX_M# V[&-:P$$.%VBSBT
MD:M#Q?2YY+S?=(FS&&=6.Z6Z>SN*[HLHLJVSFSE<4^*D-39-3Q;*16I;4TE+
M&.950@.9$:7& 42D;V>JU5?KL>(>D.;#:6CJZC W"&NC+X7"I:#:P(:YO9DC
M0]=M"M"J?0Q601QRRXPTLE +3V+G'P-Y>0/@5L<;['F]=V^KOA6CY\\)AKW^
M?K\[EO/ZTYUA#Z7Q^[@I&^]6/9H(E:#T1&^N-6'=3'7WS>;>U93=,OL_L.Z=
M;VXRS,<X@9V^;!6MCQY54RGJX7JD8YY"C?82FFD+V]HW.<WM55X3E=:IQ1Q_
M4\0T\-/#2"@9$_M'/;-VCWZ6 S9&96]1K?WK;.&. Z;AZ>:>2J-<Z5F0-?'V
M;&ZW+LN=]W=]^9]D[[_]+O31U!X/(VDW(H\?^SIY W<2/!E@@6T8\%I%%90G
M-(A>!"(5KGHBC4;W(Y>%76J4..XGAU2RKIZJ02LO8N.8$.%B"#U6WU&%T%5
M^GEIHS&\ . ;8Z&XL=_/@M<<?V.?LUV1@SW7;I,.1/\ LH$I^;PTCFLVJG=
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MY"VRXV=)LII)!&=\1[#"<5ZN<BH]&ZZQ4TV!/IH8<2J<.EHZ.,M@:^9A-B
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M+S2_LE?KJW!Z5>F3#ML=J[B?CF6[Z7,VFG9#6G?&G5^,UL=9%J&-)$YA8Y;
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MTL@L_MJ6*4'?5N9MVG6YRD$\RO'B&7&N(*2"CEXDQVA93_V9H*^:G/(>N&N
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&1$T1?__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>63
<FILENAME>g164680g88l67.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g164680g88l67.jpg
M_]C_X  02D9)1@ ! 0(!>0%Y  #_[2K:4&AO=&]S:&]P(#,N,  X0DE-! 0
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M,    7     $-P=&YB;V]L      !#;&)R8F]O;       4F=S36)O;VP
M   $-R;D-B;V]L      !#;G1#8F]O;       3&)L<V)O;VP      $YG='
M9B;V]L      !%;6Q$8F]O;       26YT<F)O;VP      $)C:V=/8FIC
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M]P(%5N=$8C4FQT                4V-L(%5N=$8C4')C0%D
M 08W)O<%=H96Y0<FEN=&EN9V)O;VP     #F-R;W!296-T0F]T=&]M;&]N9P
M         ,8W)O<%)E8W1,969T;&]N9P         -8W)O<%)E8W12:6=H=&
MQO;F<         "V-R;W!296-T5&]P;&]N9P      .$))30/M       0 %
MVUWP !  ( 7;7?  $  CA"24T$)@      #@             _@   .$))30
M0-       $    >#A"24T$&0      !    !XX0DE- _,       D
M    $ .$))32<0       *  $          CA"24T#]0      2  O9F8  0
M!L9F8 !@       0 O9F8  0"AF9H !@       0 R     0!:    !@
M   0 U     0 M    !@       3A"24T#^       <   ______________
M_______________P/H     /____________________________\#Z
M#_____________________________ ^@     ______________________
M_______P/H   X0DE-! @      !     !   "0    D      .$))300>
M     $     #A"24T$&@     #-0    8              7(   $(
M    $                          0             !"    7(
M               0                         0     0       &YU;&
MP    "    !F)O=6YD<T]B:F,    !        4F-T,0    0     5&]P(&
MQO;F<          $QE9G1L;VYG          !"=&]M;&]N9P   7(     4F
M=H=&QO;F<   $(    !G-L:6-E<U9L3',    !3V)J8P    $       5S;&
MEC90   !(    '<VQI8V5)1&QO;F<         !V=R;W5P241L;VYG
M    9O<FEG:6YE;G5M    #$53;&EC94]R:6=I;@    UA=71O1V5N97)A=&
M5D     %1Y<&5E;G5M    "D53;&EC951Y<&4     26UG(     9B;W5N9'
M-/8FIC     0       %)C=#$    $     %1O<"!L;VYG          !,96
M9T;&]N9P          0G1O;6QO;F<   %R     %)G:'1L;VYG   !"
M-U<FQ415A4     0       &YU;&Q415A4     0       $US9V5415A4
M   0      !F%L=%1A9U1%6%0    !       .8V5L;%1E>'1)<TA434QB;V
M]L 0    AC96QL5&5X=%1%6%0    !       ):&]R>D%L:6=N96YU;0
M]%4VQI8V5(;W)Z06QI9VX    '9&5F875L=     EV97)T06QI9VYE;G5M
M  #T53;&EC959E<G1!;&EG;@    =D969A=6QT    "V)G0V]L;W)4>7!E96
MYU;0   !%%4VQI8V5"1T-O;&]R5'EP90    !.;VYE    "71O<$]U='-E=&
MQO;F<         "FQE9G1/=71S971L;VYG          QB;W1T;VU/=71S97
M1L;VYG          MR:6=H=$]U='-E=&QO;F<      #A"24T$*       #
M    (_\        #A"24T$$0       0$ .$))3004       $     SA"24
MT$#      @+     $   !R    H    5@  -<    @$  8  '_V/_B#%A)0T
M-?4%)/1DE,10 ! 0  #$A,:6YO A   &UN=')21T(@6%E:( ?.  ( "0 & #
M$  &%C<W!-4T94     $E%0R!S4D="               !  #VU@ !     -
M,M2% @(
M          $6-P<G0   %0    ,V1E<V,   &$    ;'=T<'0   'P    %&
M)K<'0   ($    %')865H   (8    %&=865H   (L    %&)865H   )
M  %&1M;F0   )4    <&1M9&0   +$    B'9U960   -,    AG9I97<
M/4    )&QU;6D   /X    %&UE87,   0,    )'1E8V@   0P    #')44D
M,   0\   (#&=44D,   0\   (#&)44D,   0\   (#'1E>'0     0V]P>7
M)I9VAT("AC*2 Q.3DX($AE=VQE='0M4&%C:V%R9"!#;VUP86YY  !D97-C
M       !)S4D="($E%0S8Q.38V+3(N,0              $G-21T(@245#-C
M$Y-C8M,BXQ
M                !865H@        \U$  0    $6S%A96B
M          6%E:(        &^B   X]0   Y!865H@        8ID  +>%
M 8VEA96B         DH   #X0  +;/9&5S8P         6245#(&AT=' Z+R
M]W=W<N:65C+F-H               6245#(&AT=' Z+R]W=W<N:65C+F-H
M                                                           &
M1E<V,         +DE%0R V,3DV-BTR+C$@1&5F875L="!21T(@8V]L;W5R('
M-P86-E("T@<U)'0@              +DE%0R V,3DV-BTR+C$@1&5F875L="
M!21T(@8V]L;W5R('-P86-E("T@<U)'0@
M!D97-C         "Q2969E<F5N8V4@5FEE=VEN9R!#;VYD:71I;VX@:6X@24
M5#-C$Y-C8M,BXQ               L4F5F97)E;F-E(%9I97=I;F<@0V]N9&
MET:6]N(&EN($E%0S8Q.38V+3(N,0
M  =FEE=P      $Z3^ !1?+@ 0SQ0  ^W,  03"P #7)X    !6%E:(
M  3 E6 %    !7'^=M96%S          $                        "CP
M    )S:6<@     $-25"!C=7)V        !      %  H #P 4 !D '@ C "
M@ +0 R #< .P!  $4 2@!/ %0 60!> &, : !M '( =P!\ ($ A@"+ )  E0
M": )\ I "I *X L@"W +P P0#& ,L T #5 -L X #E .L \ #V /L! 0$' 0
MT!$P$9 1\!)0$K 3(!. $^ 44!3 %2 5D!8 %G 6X!=0%\ 8,!BP&2 9H!H0
M&I ;$!N0'! <D!T0'9 >$!Z0'R ?H" P(, A0"'0(F B\". )! DL"5 )= F
M<"<0)Z H0"C@*8 J("K *V L$"RP+5 N "ZP+U P #"P,6 R$#+0,X T,#3P
M-: V8#<@-^ XH#E@.B ZX#N@/' ],#X /L _D$!@03!" $+00[!$@$501C!'
M$$?@2,!)H$J 2V!,0$TP3A!/ $_@4-!1P%*P4Z!4D%6 5G!7<%A@66!:8%M0
M7%!=4%Y07V!@8&%@8G!C<&2 99!FH&>P:,!IT&KP; !M$&XP;U!P<'&0<K!S
MT'3P=A!W0'A@>9!ZP'OP?2!^4'^ @+"!\(,@A&"%H(;@B"")8(J@B^"-((YP
MC["1 ))0DZ"4\)9 EY"8\)I FZ"<\)Y0G["A$*)PH]"E0*:@J!"I@*K@K%"M
MP*\PL+"R(+.0M1"VD+@ N8"[ +R OA"_D,$@PJ#$,,7 QU#(X,IPS #-D,\P
MT-#28-0 U:#70-C@VI#<,-W@WX#A,.+@Y)#F0.?PZ;#K8.T@[N#PD/)0]!#U
MX/>@^6#[,/SP_L$ D0)A!#$&$0?A";$+D0UQ#U$1,1,1%/$6T1C!&J$<D1Z!
M('$B8211)D$H02HQ+#$N,3 Q,C$T,38Q.#$Z03Q1/E% 84)Q1)%&H4BQ2M%,
MX4\!42%3055A5X%9L5O17@%@,6)A9)%FP6CQ:R%M86^A<=%T$791>)%ZX7TA
M?W&!L80!AE&(H8KQC5&/H9(!E%&6L9D1FW&=T:!!HJ&E$:=QJ>&L4:[!L4&S
ML;8QN*&[(;VAP"'"H<4AQ['*,<S!SU'1X=1QUP'9D=PQWL'A8>0!YJ'I0>OA
M[I'Q,?/A]I'Y0?OQ_J(!4@02!L()@@Q"#P(1PA2"%U(:$ASB'[(B<B52*"(J
M\BW2,*(S@C9B.4(\(C\"0?)$TD?"2K)-HE"24X)6@EER7')?<F)R97)H<FMR
M;H)Q@G22=Z)ZLGW"@-*#\H<2BB*-0I!BDX*6LIG2G0*@(J-2IH*ILJSRL"*S
M8K:2N=*]$L!2PY+&XLHBS7+0PM02UV+:LMX2X6+DPN@BZW+NXO)"]:+Y$OQR
M_^,#4P;#"D,-LQ$C%*,8(QNC'R,BHR8S*;,M0S#3-&,W\SN#/Q-"LT932>--
M@U$S5--8<UPC7]-C<V<C:N-NDW)#=@-YPWUS@4.% XC#C(.04Y0CE_.;PY^3
MHV.G0ZLCKO.RT[:SNJ.^@\)SQE/*0\XSTB/6$]H3W@/B ^8#Z@/N _(3]A/Z
M(_XD C0&1 ID#G02E!:D&L0>Y",$)R0K5"]T,Z0WU#P$0#1$=$BD3.11)%54
M6:1=Y&(D9G1JM&\$<U1WM'P$@%2$M(D4C721U)8TFI2?!*-TI]2L1+#$M32Y
MI+XDPJ3'),NDT"34I-DTW<3B5.;DZW3P!/24^33]U0)U!Q4+M1!E%049M1YE
M(Q4GQ2QU,34U]3JE/V5$)4CU3;52A5=57"5@]67%:I5O=71%>25^!8+UA]6,
MM9&EEI6;A:!UI66J9:]5M%6Y5;Y5PU7(9<UETG77A=R5X:7FQ>O5\/7V%?LV
M %8%=@JF#\84]AHF'U8DEBG&+P8T-CEV/K9$!DE&3I93UEDF7G9CUFDF;H9S
MUGDV?I:#]HEFCL:4-IFFGQ:DAJGVKW:T]KIVO_;%=LKVT(;6!MN6X2;FMNQ&
M\>;WAOT7 K<(9PX'$Z<95Q\')+<J9S 7-=<[AT%'1P=,QU*'6%=>%V/G:;=O
MAW5G>S>!%X;GC,>2IYB7GG>D9ZI7L$>V-[PGPA?(%\X7U!?:%^ 7YB?L)_(W
M^$?^6 1X"H@0J!:X'-@C""DH+T@U>#NH0=A("$XX5'A:N&#H9RAM>'.X>?B
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M[<_VW____M  Q!9&]B95]#30 "_^X #D%D;V)E &2
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M                _^% (6AT=' Z+R]N<RYA9&]B92YC;VTO>&%P+S$N,"\
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M 0$! 0$! 0$!_\  $0@!>P$/ P$1  (1 0,1 ?_$ !X   $#!0$!
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M/]>%\?\ ;\?KZX833_8/^,_,']<(*.V=_P"?VQ^7\CQ_V\.?'].. )X:!?\
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M5/Q$X '<G  SJ3D: #7)QOG.=>,K<XDB>I&U^7EY<YU0;>L1?IPWF(W) !M
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M<G@0+$WWW@W,8VY6JI9=2RLJ6VH00L24*$0029 %Y!M-P 9Q(WQ3Y#/?;O\
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MQ)/#F+<HQ>QC'?T/D/E@;^7EVTPITS:?<?EZ_/IA>X43L)Y@P?A?ZZ8( /<
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M@(&/FO5YG49SVAK6,M0:EVJJUM,MH,R&4I96HF82TGNEN+<7X$H*E$V!P^%
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M,P_$>\)+*3TA>5/+3A3[SRSU<7%_(<H98&M!;T  O+>6DK5'XR5Z+\DI$'8
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M.<>&G]>7KG37'!@O_0/^/U]"\X'B'_[>G<Y.1IL?OY_/@DQ8_6W/E;?"1_\
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MGAM3/%YI;RR$%*U0>!38P+3(!OUCRQ6NS^<.5N5U5=7*0$TS[Z2M(@!M*4N
M6O("M*;2; 8<"AW!!K]/8J=.ZU1G5+1A]M3+S;C:NEQ#K:QU(<0KX5).QTT(
M/#A+@6E*FSX")%C?>29Z[3M&)^BJF:ZG;J:=1<9<&I!((,=1,@@[_+;&X\0G
M/P Y.N"K^7?/X<+)O>Y]/KZVP[B?P?!7ZX7C*R<(&<ZYSL,9/IL!VVU[< )$
MB;?7U:,$&9T? GYG +RM<(&NYR?M^&G;?;NA,[\<$'^CX*_7ZC #JMPV.PW)
M..^=P<'49\OEPLFQFX$"WU;>WQP1_8/97ZXJ\3_L'EN?UGA+_0X^_P /C@@_
MT?\ F_7%EP)="DJ:PI0P5IQU# (!!()&.V0<;'3.<DJ*3.XWB2 3U\K>V-;C
M27 H*; U)*2H A6D_> 5N)'(B-\9,B1(EK\26Z])6 E.'%!+1;&H;\%A+;*F
MT*)4A"FR$*&0<@'C-3BM)$D3(MM/XH,ZKVFXGGOALS04S!!0PDJMXE>)1M()
M/$F)VF23?%OQ2  $ #;OL.P^OT_#C7).Y^OJ/;RA[!N- OT/SF<+QE?Y <Y/
M<@J.-!G]?CPEXB;3/U]<^>"_]'P5^N#XI)QT)VVQJ#^(TX+^OE^4_GA9/] _
MX_7YX0=.<>&/MW_KYZ8X+_0_?!XOZ!_QQ>CO*#R,MI&JL=M.A6OX?CZ'@QBH
M$I(T@3QB.,[P?+;IC"ZG====,8"/KG3A/HS<](O]>>'.A7]/GL.G[8 4YG4Z
M'? 1D_AP&>&_7;UC!W9DRGSVFW.^"%.^@]<)S^'EVX#SO;ASZ;'X8 A5X3T_
M38_/E@=3N>Q[:A.H_/UX-P.&W^,!;5Q3TX<//!*G.Q[Z A&<'<YQC4\ GC[R
M=YV ^IVB-C03^'Y<=_? "G?/'T3_ "' ;<S\[>O^>N#NU#\)'U?]_<X67-\Y
MSG(^'']#_+A9.T0!L;29WZ^^$[HR24WXSP]SY874[DG.-#C0'RTUSC./IPEQ
M$$SL3,6]+?#"]TK;1\KQ\\(J<!T(VQG"<GYYR> =?GMTM'UQ. -D;)X=-O/V
MP0IP[D:;9"3K]-N R-I][[C8&9^@,&A7+Y8'4[YZY\D;?;.>"#/3S,SM[1\;
MX.[5_3<^7IQP0MW.I./0(S^7 9BV_7!H5R^6$5.'OMC<)W]-/SX+_P".76_R
MP:#81/MO]>6$%N9&=>W^$:?09Q\B/+?C(#H#ONH";>^_' 4*F"DS]<?,7O%H
M.$5.9(ZB?HC?<?,8[^?;3A"(]^<\^(]XCIR.#0KD>LP+CUO'/%)4Z=S_ /CV
M_P!^#I]>^^#0J/NVX[1AB/:6N*+:_)J[*M4J55ZM3632$3F**RA^<U%<K$$/
M2 V76RIL(!86&2IU7C)2E"@I7$5G+Z:;+*EUUMQQ">[UI9 4H)+J 2$FZMX@
M7,P!>W0/X7Y4_FO;;**.FJJ2CJ5IK%4[M<LMTZW4T51W;96$K2E6H]XG7"!W
M9)4"D8R*M?%38E\OV*4B11J=48-+J$B#+;82^F%(<CQV(,TA3B(R4QG$N+4V
MOJ:6D!9R%)X<FHO2)0DI2\ 2E284$%((3:P4 1)&QF1;'(^U>8564]IJ+*D/
ML/E_,'D5E2V"II\![NW"TIQ*%:5+)*5P-0 *1$2^(4L 9))[C'SSN/H,8R<'
M)SP]2 09)D3Y1,02;$R-XM-R;XG-)L8)YB#^5Q]'H&HYIW$VU!;MB*YU3JMX
M+U0"0#[G16WBIQ;XP4D55V.:<TPL@OQU3W4)6B&X.&E:\&F2@&%N#2!))TWU
M*,C:# (W)C[H)53>V>;-9?EJZ1"IJZ]"VTI!(*&)"77%P;)4 6DBTE1(G0J&
MC:J[#= JU!;>!EU*Z8,J5#!"5FDQ:+#*I"QN&1/:BH;((+CC;B$=7A.]+%#N
MBA6D*&I2],3"B+$P.0$>A(&*,Q7T]/V1J*1+J14U-<I!:"H7W.A*BK2+A,I2
M-1B]@8G#S<JGT*MM]IE>76:S52\V0"MLN2"M)*2.H!:3U(.,+1A0TX?TEZ9N
M)@"][ ^FW2\]!MCH78\MKR*E[I6LH*TN1<H6#XDQN(GI(O&'-*E]A@XTT& <
MZX) !TQG&>' !%B;7WW,QQ\YX_M:=!X),#C%A/6 .AZS@=;WG^"?Z<$>?N<&
MA7+Y?K@E:\Y)P -R$Y&V3Z:9/E@:CA4@?B._4QY"]O,^N H/%.WOOY_#WQ#;
MVMN9//>PXMC/<C+>9NF95:=S-?KD.02U%;31K,54J#+]^;A3@V\U5!UQ(?A#
M]Z.@1$NH.3P1<_"XY$\C/P!D1U;U!>0$]T@K)UZ@?[42/PG\6T6(ZXBU1/:]
MYY?^"W,ZBRJ)7JI[23U5CT7EE;4:R:DE*E5AB$W%J3JEL,TZ1&IOB3)KJG9;
M*7%,(9<+87D+QV]SSVG;AY#;>^&P?>[MU.E1J-4-HT$3($&1X8%YN-C)XF>'
MLPW_ 'SS$Y+VI6>9E$J=N<QX"9EN7Q3*I3#2I";AH4IR%(G)A^(ZVVS5XR8M
M5:$=^1';$TL-O++))Q,B1%QU-S<'>WI?8>KMCO'&4*6A25P4K!$>(2"3>/%$
MB+08F9P_H4Z =?D,).<G77@X_O\ EC=W:A;3MPM;XX/4YC^+7RPG7Y:<%YZ>
M9D>?/ZF<&A7+Y?7 ^V %.^?;3 1OV[;<'E\9V^OT\C0H6B.EL+J<WR,Y\D_?
M.."+\?<[^6WU?!W:KG3Y[>_I^>%U.C8[ZG1(U^VOSX.<R.&YVY]/G@T*X)WO
MPOU^>,B,I9>0%9.>KLG;H)[:[C@-KDP!\]K_ %OOMA"@Q<6\QSZ'RQB^AQG.
M<DD9TTSMMZ*[9R3IP1M?CU_7\][G#G0K^WW/I^'_ !UP =]/,=62<#Y](U^A
M^?"^OO\ M&%T*XQ[D_D,'77I.1J2<8USWSIMY$?U2.OD/UXFXD&QZX-!Z?']
M/KC@ D:#4$8\L$G34=7F?4>6W!&_[_.3^7/ 4*X:3ZD?_LG!)SW/EN,9.=L)
M/T. 3KY<!$\3\/TPFA7]ON?_ $X R.PR-"<Y&N-"" =-M--/IP 1QD\[_*?C
MZX-"_P"W_D?_ $X))T(UQE6NAQL1I_3T&VI?G[C](_+"Z%;#29YDS/2$GR^I
MP@25'&#G7<@#MW&?U]B#SOY?7&/2V]\&A<?AWO<\?^F^Q^CBHG.@&1Y@ZZ'Y
M'R/S[:Z<+]?7UYX-"O[?<_I@94<$ 9P1IDC;SVU/IVP3N D&=^'7]?WZX30O
M^WW/_IQ2,XZ3W QKGYC(&Q]=AP08B>7[^_/\[DT*_M]S_P"G! 5NG;4;@Z::
M@$@@@YQG<>NV4"UAYW)'GO:8ZV\L9=VJ.!OPDVZVCXSYR(P)$M2'?=8S9D2@
MD*Z KPFF H9"Y;Q0L,I4,E"$)=><2,H:*<J#RDH':HDHA+>J%N*D =!)\2P"
M/"+2+D",1.:9K2Y4V%/J*G5 ]VPW'>+(M)"M.A$D2I1'& HVP!"EN95+J#V5
M9RS#0B/'P=0D*(=E=0U"G/>6@K&0VC4<6%G*:1H J2751!*U$ F#/A201/KU
M.*-4]J<R>42P6Z1N;)2E#BX.VI;B5!4?VH3\<!4*4C)BU*0%) Z6Y;;4F.D9
MP>KI3'EJ."2E1ED G*@L821W*:)P>%"FC_4A:C>!8I65")!MX21Q!O@INU.9
MM*EXMU+9,Z5MA"XM(0MI*0DVCQ(6 3.G< L37$O)BS&?=GUE8:6' ]&D8'40
MP_T-GQ D=2F7V67?A66TNM)\4P57EKU+*E>-J\*0#.\ *!)T&1 !)!D &9 N
MF5YS2YH"EL]U4)3J53N'QD<5-J TN)F(@A8_&E.+\R'%GL.Q)T>--C.A'BQI
M32)##OAN)<1ULNI6VLH<0EQ 4GX7$I4G!3I&K2%#2I*2D@$I4F>,@$**KBTB
M-Q(X'$^PY44[B'V'5L.H^ZZTM;3B2I)0J%(\8U(*@L C4"4F03AJN:-M2J@S
M&KT%@RDTV([%J,)L*,C]WN+2\9$1M."ZY%=0'5MI/BEA*O=T+=Z4%K5L+=0E
M:#XFI(&Q,7M  F8CC[XHO;/(JK,6&J^C,U=#J64I)#CB)UJT& =:%#4!NHR
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M_P#XHVL3>^T29(GF<(=.?XDZ9W4G7R['\1]N#P\S[?OA=*=H^!^!_*<(G/\
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M)D]VG7J6+QO#VV_;6]H*@5"A6A>S#-_T2YF&IL*E2H:57%5*14GELPO<ZNA
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M(]N"3S//?ZY#VP=W??EP/"V\QMPWMRV06>Y\NV=OKW\_/;@D\S[G"A)/$6Z
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M&FKN"2!_W&H\IYSPMCO.LJ! .,>9 USG&NI/IC?.#WX=6%Y!]%6^$GXX@N[
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M/,J,UU+:2&84"'+G2WBAB+&??<;:4&-Y'D)_3\_+&#VBG;6\\L(:;25+7!,
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ML]VES0.M=G\PH&ZE]ZC#E(XV5MN.*<;+<'!CW)%54 S1:MS"J5;A-6S%J<J
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M4AQM0<0I22,A%M[]-OG??:]L; DQJ E) *3((4DW!!$C8BX(WL<4JJ$-J4Q
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M);?:64.LK+:E!#K:@4N(7"DJ!U#<8OE0U&1\]=/7;&?3.OSXQPY@P0$^?W>
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MI;RY*5TF1+FPWX[+C#@@RE55+N$NH"5/GQX;^Y'Y>FV(%K(7$N(2JL"F-2'
M@*AQ&EQ:W$MF2"DD@I!V)5PB,OG1(YO7C>UI4;E_=/,Z;R]M.\JO:"Z=3K>=
MMQTQ[2YD<L8%>A6S.H,Q"KNE-VC8_,FSF953CH]W5?+KZ6DM XG3D2DI:+^8
MY93*=99?2T_4I0ZEM]M+K14F+*4A:3!_JC<&*95=LJBJJG6LLR/M174E!F5=
ME;C]'EJNX6]EF8-TE6FF=0Z._2DTM8P%$ $NZ@+2.EYL5KF[SLJ')^KP+2YH
M63-IEHJA7]1;6ILM]RI.2KGLFHW#'H%4BS/>7J:W'H%:H9E.)!69Z$NE*O$
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MG.P^V^3W[\&,IG>\;<;R)GWX[XH!.H/GNK.0#_L=M,@DZ:\&$]9PBH:XQO\
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M1 5)UXT+J&T*+8*G'0)+322M8G;6!X6P>"G5(2?ZL2=+D];4MBI4A%'1&?\
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M[X?M>FQ7XE9BQ>:+<6OU:FM<R+&I\9U^F6S>$>E_NZ-7H$"M-4Z6RU5&*F/
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MD+;6A0)"DJ204J!(4FZ9@'%XMM]04$)"LA74$@**L:DG&=\Z]_/@QL!4;:C
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M,]3CK[8;U2_E]</28])&(Y>:US;%3#""ZP=:'"%!"VTO!E?A$J"_%*4FT3<
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MZ9:-LJ5%2W1J%0VO=A3XD1""XY#9<?6X^0ZEXS5%)0A0 :"=)2D""JW\Q0,
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M/SN.1O\ R&WT^?ZV.GSX,' [6%[]>$?N./+"QY:?K]?AP86QGF3;W,S@^?\
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M /GM)Y?$&8QJ$7!1''Q'15J<I\D(\$2V2LJSL$A9UW&#J#OQJ%0P3I#S143
M <3)/ 1,WX<^&-QI*M*.\53O)0?Q%M4&YO)&XO>WOON$J"DA22% @?$"""-=
M04Y!U!QKY[<;L:""+&QY&QCB.@N>(XR.1W_EKO\ +&O??UX,)M)C>PF..\?*
M1["1A#[;?AM]_IOL#DDPLR3,7'+;@(M$VZ#J.%MUYIA)6ZXAM R5+6I*$I &
M<DJ( _1X0D 22 .9,#W. )*B D%1FP3)-S8<8,^?YG5M5ZAR'0S'JT!YX_PM
M-RV5*/3N D+ZC_#KOC?L<:TOL+5I2\TI5[!Q)-IFP/"#C>NDJD)"U4[R4GBI
MM0&PXD7\O*(F,;;(4,I4%).3U D@C'F,@C4$:ZC3MQMQH-I%QT,CF8B^QYGC
MYD$'(S@8UUS@_P"FWG]>#!$\!L=B.?$<!PX1O,8JV_7]?]N#!MM/P$'UGEM8
MD>V,&HQC+B/-)&5E.4:X^-)"DC(TR2,?K/&;:M*TGAL?(V.-C*^[<2NX WXV
M@S8@S8VM,;R,14YGV=(K2?\ A$-E]Q0;*%N-LEQ[^\#;0\12 M:PE8;22<K2
MK'<\2[-#4UA=-.VI:6T%:X5 (!!.YN?#RN.,8PS;M+DG9Y=&K-74MJJ5*33$
M,J=6D )#CA[M*BVV-:0M8(D*B#?#$69'C2YDV'6Q'1)C0Y35/DRTH4M3TAIZ
M$1&=?20'6X\R4LA)4KXE$I*"\>)#)*M\5K'VFM<;8IP5(2ZN6TJ3I&@38_=3
M^*;0+!.*=_$3(LN3E#CV59(Q4UM?4M..O4K94\T"%++^E)44ZB=,I2E*M2M9
MDB7UB6_#CHF4ZH2D5FFSFQ$JE*DMM+8+R6TLM34N+ 0T&H82VVEIDJ:<0 IY
M2CQ::MU-2PX[5::<%"C2/I6G5I25*"D7U]XHWWN#X=L<2R]FK:S&G3EA?J5C
MND5C :6B'%JT+;64E22VDF$J78*25@ F,1 N*Y97+JN3F;=J46+(ALU=J%:\
M*(.FI1S_ !/SJFGQ7HTQIC!C)9;\%DY#A:ZRL4%7:.J4JG2\RAZEHW3]H"EE
M)JR% I4LD*4E0$ B^J8-L1>>9Y6Y/VFJ:-"G?M26W&"%!*@@.($%#B)A2 92
MI*?O"?#..<O.^:I5FXJJT:BJ$\BENT^F!2*M,4Y*2VY[G-@-H,R!X3KS:DRI
M9\-UV)%6E(4LJ+^E[0T2,V74M4898=0E#0 4B'"CQJL"-R0((3<\3:^=F>T3
M%;IR>HS*HK:Y!;73M):?JBXIT!99 2TIUM;2B=:WU)2H@!($ F1G)BT'7&J:
MN:PE8AM*+?B,I!:2NH2Z@E(02H(<85-5&:4DI4EEMD83CI#6NJ17UKM0AL(0
MXI/A!.R0A&HR!]\)*B(-U7 QZ!RN@504#=,\I+CA<+T:9#:C=(N 0M*21*=H
M"9L<3ZHL942"TA23UN9<7YY5MD;#I3T@^OV$6^K4X>2?"!,@1OTWG;&FH7WC
MA@R!X4@$GCZS,;3O$2!C;9]/4;;^6O?C3C1>1^6_P^O6<#UV^Y.OF/37&I \
MN#"Q[W$7GU'('_%H!((.QSKC QY'7.Q/GY>O!A#$\8X\3[[;VGX8!(!U[?<8
MWSD]]!YG4=^#!YS:W[=-NOE@C.!H,Z:; ?A_MZ\&%'ETM:))L-YGK>_('"(^
M_;_7';S'!A#T^O;I\<(_3(R!GSP#^N_T/!A3SBUMB8VZW]+0!'7"!^OKYG[
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M!4I"T@77 )2H>)9&@R"(D:X[(7(B1H;3#KLL.D*D/N,-(0TE*E'J:8DJ))6
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M4?$09"8,F^TWO)G<P+8=(8  '?0#.F!N0?KZ: =].&6(XFUKQTX1$[</C )
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MTW)VO/N=C-L:\^9&>_KG7'^F^2>&YM$;1?E&W[SR!ZX<8)(0"HJ  '43G
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MG0H@S%Y[Y3'<((QWT!SG(^>VMTD-N$;A"R/,))'R\L;&$ZG6003+S:5#H5)
M$3YC$/NKJ&=,J^+/?74_G^/',UF5GF2HF_$F?6;[GGQQV%-D)%K) ^ _3XG
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MN!<\AO'MZ 1@@YQOH==NV1KVSH?J1H>Y@N9$P+D3;<].OI8[8X"E*-SW1)N
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M(9CT05OWR2\4MLH?FOJ::B^(HA/C  /+3U:((&^G%VRU:?\ 1:!K=1:2J)V
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MP<#MN==0.,@1%R#PY#<\^)W//A/$PCU!"O#_ .80HH ('Q8)!)SG?&-L;CA
MHA4R9!"DVWTF9V'+_.%C4%)O<00.7&W'>PP\]4YZ\K+.G6?:MS7C2J;<MRQ8
M::?277^N64J92%2Y@0%(I\,*20F3.4PTLD);4M1">+ZK.,OIS2,5%4VW452&
MRVTI4+(*02M0_ B).I6E/6^*/1]B>T^;TV;9IEN3U=3EN6N.?::M#7\H%*R
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ML7%EPNIU*:<:4"4E#FD*"H!/B0I2%)A0\04J8B1L-7<DE+$%8405$*/22!D
M'3!UT QH#\N-2R -P(BY,03;A?:?WQL)X=23L=K;CSZBQC?#S^S[7?WQ88BJ
M42[1:G,IR6R<AJ(A85"2#DX"F<D#_#GOMQT3(W_M&6L*F2V"T3QE!B3QN"(L
M)QS;.V?L^8OP+.$/#@ ')(@=.9XG:XP^.NF-M\DDGY?[_P AQ+XB#YSO>_'X
M\R9XG:-\B)I);USHO&1K_ K.H TV^O!C6]_MJZ1P_N'Q\\8HV.0#J,#UW.P\
MCVSIMY\&,\-7S9</[JID<XZ'*@M_N251V>E&0% G ?6/KDD:<5_M&O31MIX*
M>23PC2E7'?<C8&<6KLJDFN>7N$TY2#M92P+<ON^=_/##?AKG0?4YSMKY_?)X
MIH MQGG)];F-N6_"V+]SPO/73^>NG;S&/4?/@,C:WF18 <+&-IXVG:;*?KCM
M;\K1BE:EI+("%K0IQ0=4TM*7&D%I:DEL*T*E.I;94[AQ4<.>\!B26A'7B-)/
MBL+F!$G>UR )( )$D"3"KXUN=YH/=%(78#7)2-2@%**01JT"5!$I*R G4D$J
M%XJ4L]:OC40@'I!Z?#;0AIIMM!)"&6&FVV8[>2EEEMMEO"&T@*M142I1 F+0
M83 @)3))  \,?TCRD::0RV&T3"9,J(*EK4HJ6M9$$K6LJ6M1$J4HDF3)E%8K
M18M&@(4,+538ZW<C53BT=2UGU)).?7RXZ/ER-%#2IB(8;D=2D$_$G'+,V/>9
ME6*!U#[0X$W.P48!B.1M\K8Y/FPR54FFOG5+$Y8)/8O->$@:8'Q*( SY_3B-
M[0HU425$2$.IF\0%6G$MV664U[B(/C95$V^[<D"WG\YPQ 4M/6$' 6DH4G)*
M7&U:EM8SKKA3:T%+C+H0\RMI]MMU-*0L(G<A0(4F3I(,BXD7Y'<$ [XOCS27
M4@&4K2H+;6G=M:3(4)F?Z5)NE:"4J!!(-II3BTK4ZV6R'%I3U=*7%-@]"5+2
MVM:4J5JH +Z5)(60A3A9;0Q)"%2F/Q6B+\9%MN/.VXS3JTC6$A<>(()*9G=)
M(!@B#!$IG228U&L@@G)R==2//788QZ^O"B\$2  9 ,Q!\C)@V'E&%Q4 >DX^
MOGKV.NV,'8_GPA(),"9 CCQN3<1O ZV!&%M'7A]3UY;C?<8D?:E'HU:M>TIM
M4I5-J,JEM-S*9(G0(LQZFS&W'4HET]]]I;T.2D A+\=2'4C.%=N.AT"&GJ*B
M6XVA:D-I6VI:$J4A2;!2"H$H4(W3!'3',LQJZRCS#-&*6KJJ=NI4MBI;8?>9
M14LJTE33Z&U)2\T3<MNA23()3-\=\3DG)&F-=-,;'&!CT_EWD<0ACY^IYG<>
MQ,QPG%&3@9TQG)\AV(P,>@\^VYX,)@C0Y'KD =_,[D ^0V.F^G!A>-_;ZVCX
M'<8._?/G@X(^V,_G_(PH%CM[Q:#PVX3SM)!&#W/V_G\N_P#4Z\&$VWZ=;']C
MP(][@:#">WD1G.IR=Q\]1CRSP8(N/KB>-@?,6^.!G&<$DZ@:Y\R-,G/Y@ 9&
M,G@PF*A@9/F=<9U[?0^H!\M=^#"@3M/(GS-OU^'7&L:HE$8JLNN,TFF,UJ<R
MTQ-J[<"(W4Y<:.GH88E3T,IE/L,)^%EIUU2&QD(2!GC6&F@XIT-MAU8"5NA"
M0XI*;)"E@:E!(V!) X8=*K:Q=,U1.5=2NC9<6MFD6\XJE9<607'6Z=2RRVMP
M_?6E(4HW4HX\^O:JNM,?FO;]*+H!IEMAT(Z@-*E*\7) ())5$!2KXB,$# XH
M_:U^*JB:! "6G%*GFI2=)@#@ =[W)&+=V59/V>K= B7&T R-M*IVF+@6V&W'
M&/:EW-F.V"X#\ "@3H=,C4YSG7^+STXK:%VG:_&8&XD[>^VYBPQ9[I)FQY\M
MA$]23'PQTU3O!I#(90MM+KZ74L(2H)4Z6V7)#A*M4H::89=?D.K(:CL-NN+4
MAI*SPX:0X^K0T ;$J5<)0@0"M9MI2F9)GH+[MZFI:IFRX\H@$A*$@$K=<79+
M:$R2IQ9@!,23), &(X<SKV,F&Q"3)5[C3F'4Q&U*Z2N1*=7(GSEH)*@Y,D*5
MX:5J4[&@MPX!?>1#0XK7F-6E033,F6& 4H!)\:O_ )CL7'B,Q8"/%"23C3EE
M$XE3M:^F*NM6%NFQ#3:0.Y82;F&T )4=5UZC=.F/3WDQ#-/Y56%$P4EBVJ<.
MG!!"E-=>IWUZNX.P(SOQU&A1W='2H%@EAL#_ (@\A\L<XK%]Y5U"Y'B><-RJ
M9U$$QP!L#))XVWPVOM9Q_$Y+UN4G/BTZJT":E1R EMBJQB_D #1316D[@@]N
M(_M$G5E%8?Z$)<X_@4#-@3];X?9 O1FM*";*4IK:;+!3[29\L0KY>WKX5,5!
M==!BOKC3&@5+4F'48B'6XTU" %*"78\F73)A;;6M,"<^^U&DS8T1*:'E]2E;
M3E(\H):?$H6HB&G@1I4=]*20 L18"=@,7/,:1QM]G,*=!544TI=:3O44JO\
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MXE#I&3C&!Z:6Y=?;"B/&XV@7%@I8 %N<QYFYYC[H:9=*3.EM94KHE)40)F3
MN8(&Y/+Z&+3C)AVO;D5*>@1Z%2FNG_*406 K(['JSD9^W';6AI:;3R;0/9(&
M./N76M<25+63N0#J)_S.]_/#4^TS$,SD/S/"$]3L2U:E/93W+T%DR6L>7Q(
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M#K3B M#B%(49"@H$6D  S<<),#&>]6*3'CJDOU&"TPA#[BGERF/#\.,A2WU
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MP_?O(+F15>8-^U:A.EFBS*)1X5&DNRU/^_J0)$J0I32$MM!II :05>+UD]:
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MK]8^G!A1N.I'SPCL?D>#!/U];^N$-0#WQ^>,\& ;'H)'F2!BA6F<>GKY^?\
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!V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>64
<FILENAME>g164680g91u88.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g164680g91u88.jpg
M_]C_X  02D9)1@ ! 0(!>0%Y  #_[0]\4&AO=&]S:&]P(#,N,  X0DE-! 0
M    #V"^.38X0DE-! 0      &$< 5H  QLE1QP"   "/_L< E  "')R,34Q
M,3@Q' (% $!-:6-R;W-O9G0@5V]R9" M(%)O:79A;G0@(%)E<V%L92!37S$@
M3V-T;V)E<B R-2 R,#(Q(#<P,'!M($-L96%N #A"24T$)0      $+X;_6OW
M@EC8\+PX'?S5YI,X0DE-!#H      /<    0     0      "W!R:6YT3W5T
M<'5T    !0    !0<W138F]O; $     26YT965N=6T     26YT90    !#
M;')M    #W!R:6YT4VEX=&5E;D)I=&)O;VP     "W!R:6YT97).86UE5$58
M5     H 00!D &\ 8@!E "  4 !$ $8       ]P<FEN=%!R;V]F4V5T=7!/
M8FIC    # !0 '( ;P!O &8 ( !3 &4 = !U '        IP<F]O9E-E='5P
M     0    !";'1N96YU;0    QB=6EL=&EN4')O;V8    )<')O;V9#35E+
M #A"24T$.P     "+0   !     !       2<')I;G1/=71P=71/<'1I;VYS
M    %P    !#<'1N8F]O;       0VQB<F)O;VP      %)G<TUB;V]L
M  !#<FY#8F]O;       0VYT0V)O;VP      $QB;'-B;V]L      !.9W1V
M8F]O;       16UL1&)O;VP      $EN=')B;V]L      !"8VMG3V)J8P
M  $       !21T)#     P    !29" @9&]U8D!OX            $=R;B!D
M;W5B0&_@            0FP@(&1O=6) ;^            !"<F1456YT1B-2
M;'0               !";&0@56YT1B-2;'0               !2<VQT56YT
M1B-0>&Q 6"4O          IV96-T;W)$871A8F]O; $     4&=0<V5N=6T
M    4&=0<P    !09U!#     $QE9G15;G1&(U)L=                %1O
M<"!5;G1&(U)L=                %-C;"!5;G1&(U!R8T!9
M$&-R;W!7:&5N4')I;G1I;F=B;V]L      YC<F]P4F5C=$)O='1O;6QO;F<
M        #&-R;W!296-T3&5F=&QO;F<         #6-R;W!296-T4FEG:'1L
M;VYG          MC<F]P4F5C=%1O<&QO;F<      #A"24T#[0      $ ._
M_C4  @ " [_^-0 "  (X0DE-!"8       X             /X   #A"24T$
M#0      !    '@X0DE-!!D       0    >.$))30/S       )
M   ! #A"24TG$       "@ !          (X0DE- _4      $@ +V9F  $
M;&9F  8       $ +V9F  $ H9F:  8       $ ,@    $ 6@    8
M  $ -0    $ +0    8       $X0DE- _@      '   /______________
M______________\#Z     #_____________________________ ^@
M_____________________________P/H     /______________________
M______\#Z   .$))300(       0     0   D    )      #A"24T$'@
M    !      X0DE-!!H      S4    &               O   "80
M   !                          $              F$    O
M              $                         $     $       !N=6QL
M     @    9B;W5N9'-/8FIC     0       %)C=#$    $     %1O<"!L
M;VYG          !,969T;&]N9P          0G1O;6QO;F<    O     %)G
M:'1L;VYG   "80    9S;&EC97-6;$QS     4]B:F,    !       %<VQI
M8V4    2    !W-L:6-E241L;VYG          =G<F]U<$E$;&]N9P
M   &;W)I9VEN96YU;0    Q%4VQI8V5/<FEG:6X    -875T;T=E;F5R871E
M9     !4>7!E96YU;0    I%4VQI8V54>7!E     $EM9R     &8F]U;F1S
M3V)J8P    $       !28W0Q    !     !4;W @;&]N9P          3&5F
M=&QO;F<          $)T;VUL;VYG    +P    !29VAT;&]N9P   F$    #
M=7)L5$585     $       !N=6QL5$585     $       !-<V=E5$585
M  $       9A;'1486=415A4     0      #F-E;&Q497AT27-(5$U,8F]O
M; $    (8V5L;%1E>'1415A4     0      "6AO<GI!;&EG;F4
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M                                  #_X4 A:'1T<#HO+VYS+F%D;V)E
M+F-O;2]X87 O,2XP+P \/WAP86-K970@8F5G:6X](N^[OR(@:60](E<U33!-
M<$-E:&E(>G)E4WI.5&-Z:V,Y9"(_/@H\>#IX;7!M971A('AM;&YS.G@](F%D
M;V)E.FYS.FUE=&$O(B!X.GAM<'1K/2)!9&]B92!835 @0V]R92 U+C,M8S Q
M,2 V-BXQ-#4V-C$L(#(P,3(O,#(O,#8M,30Z-38Z,C<@(" @(" @("(^"B @
M(#QR9&8Z4D1&('AM;&YS.G)D9CTB:'1T<#HO+W=W=RYW,RYO<F<O,3DY.2\P
M,B\R,BUR9&8M<WEN=&%X+6YS(R(^"B @(" @(#QR9&8Z1&5S8W)I<'1I;VX@
M<F1F.F%B;W5T/2(B"B @(" @(" @(" @('AM;&YS.GAM<#TB:'1T<#HO+VYS
M+F%D;V)E+F-O;2]X87 O,2XP+R(^"B @(" @(" @(#QX;7 Z0W)E871E1&%T
M93XR,#(Q+3$P+3(V5#$Y.C T.C(S*S U.C,P/"]X;7 Z0W)E871E1&%T93X*
M(" @(" @(" @/'AM<#I#<F5A=&]R5&]O;#Y04V-R:7!T-2YD;&P@5F5R<VEO
M;B U+C(N,CPO>&UP.D-R96%T;W)4;V]L/@H@(" @(" @(" \>&UP.DUO9&EF
M>41A=&4^,C R,2TQ,"TR-E0Q.3HR.3HU-RLP-3HS,#PO>&UP.DUO9&EF>41A
M=&4^"B @(" @(" @(#QX;7 Z365T861A=&%$871E/C(P,C$M,3 M,C94,3DZ
M,CDZ-3<K,#4Z,S \+WAM<#I-971A9&%T841A=&4^"B @(" @(#PO<F1F.D1E
M<V-R:7!T:6]N/@H@(" @(" \<F1F.D1E<V-R:7!T:6]N(')D9CIA8F]U=#TB
M(@H@(" @(" @(" @("!X;6QN<SIP9&8](FAT=' Z+R]N<RYA9&]B92YC;VTO
M<&1F+S$N,R\B/@H@(" @(" @(" \<&1F.E!R;V1U8V5R/D%C<F]B870@1&ES
M=&EL;&5R(#$P+C N," H5VEN9&]W<RD\+W!D9CI0<F]D=6-E<CX*(" @(" @
M/"]R9&8Z1&5S8W)I<'1I;VX^"B @(" @(#QR9&8Z1&5S8W)I<'1I;VX@<F1F
M.F%B;W5T/2(B"B @(" @(" @(" @('AM;&YS.F1C/2)H='1P.B\O<'5R;"YO
M<F<O9&,O96QE;65N=',O,2XQ+R(^"B @(" @(" @(#QD8SIT:71L93X*(" @
M(" @(" @(" @/')D9CI!;'0^"B @(" @(" @(" @(" @(#QR9&8Z;&D@>&UL
M.FQA;F<](G@M9&5F875L="(^36EC<F]S;V9T(%=O<F0@+2!2;VEV86YT("!2
M97-A;&4@4U\Q($]C=&]B97(@,C4@,C R,2 W,#!P;2!#;&5A;BYD;V-X/"]R
M9&8Z;&D^"B @(" @(" @(" @(#PO<F1F.D%L=#X*(" @(" @(" @/"]D8SIT
M:71L93X*(" @(" @(" @/&1C.F-R96%T;W(^"B @(" @(" @(" @(#QR9&8Z
M4V5Q/@H@(" @(" @(" @(" @(" \<F1F.FQI/G)R,34Q,3@Q/"]R9&8Z;&D^
M"B @(" @(" @(" @(#PO<F1F.E-E<3X*(" @(" @(" @/"]D8SIC<F5A=&]R
M/@H@(" @(" @(" \9&,Z9F]R;6%T/FEM86=E+V5P<V8\+V1C.F9O<FUA=#X*
M(" @(" @/"]R9&8Z1&5S8W)I<'1I;VX^"B @(" @(#QR9&8Z1&5S8W)I<'1I
M;VX@<F1F.F%B;W5T/2(B"B @(" @(" @(" @('AM;&YS.GAM<$U-/2)H='1P
M.B\O;G,N861O8F4N8V]M+WAA<"\Q+C O;6TO(@H@(" @(" @(" @("!X;6QN
M<SIS=$5V=#TB:'1T<#HO+VYS+F%D;V)E+F-O;2]X87 O,2XP+W-4>7!E+U)E
M<V]U<F-E179E;G0C(@H@(" @(" @(" @("!X;6QN<SIS=%)E9CTB:'1T<#HO
M+VYS+F%D;V)E+F-O;2]X87 O,2XP+W-4>7!E+U)E<V]U<F-E4F5F(R(^"B @
M(" @(" @(#QX;7!-33I);G-T86YC94E$/GAM<"YI:60Z-# P13@T,4$S-C,V
M14,Q,4(Y1#@X,T$P-T8V03-$,$,\+WAM<$U-.DEN<W1A;F-E240^"B @(" @
M(" @(#QX;7!-33I$;V-U;65N=$E$/GAM<"YD:60Z,T4P13@T,4$S-C,V14,Q
M,4(Y1#@X,T$P-T8V03-$,$,\+WAM<$U-.D1O8W5M96YT240^"B @(" @(" @
M(#QX;7!-33I/<FEG:6YA;$1O8W5M96YT240^>&UP+F1I9#HS13!%.#0Q03,V
M,S9%0S$Q0CE$.#@S03 W1C9!,T0P0SPO>&UP34TZ3W)I9VEN86Q$;V-U;65N
M=$E$/@H@(" @(" @(" \>&UP34TZ2&ES=&]R>3X*(" @(" @(" @(" @/')D
M9CI397$^"B @(" @(" @(" @(" @(#QR9&8Z;&D@<F1F.G!A<G-E5'EP93TB
M4F5S;W5R8V4B/@H@(" @(" @(" @(" @(" @(" \<W1%=G0Z86-T:6]N/G-A
M=F5D/"]S=$5V=#IA8W1I;VX^"B @(" @(" @(" @(" @(" @(#QS=$5V=#II
M;G-T86YC94E$/GAM<"YI:60Z,T4P13@T,4$S-C,V14,Q,4(Y1#@X,T$P-T8V
M03-$,$,\+W-T179T.FEN<W1A;F-E240^"B @(" @(" @(" @(" @(" @(#QS
M=$5V=#IW:&5N/C(P,C$M,3 M,C94,3DZ,CDZ-3$K,#4Z,S \+W-T179T.G=H
M96X^"B @(" @(" @(" @(" @(" @(#QS=$5V=#IS;V9T=V%R94%G96YT/D%D
M;V)E(%!H;W1O<VAO<"!#4S8@*%=I;F1O=W,I/"]S=$5V=#IS;V9T=V%R94%G
M96YT/@H@(" @(" @(" @(" @(" @(" \<W1%=G0Z8VAA;F=E9#XO/"]S=$5V
M=#IC:&%N9V5D/@H@(" @(" @(" @(" @(" \+W)D9CIL:3X*(" @(" @(" @
M(" @(" @/')D9CIL:2!R9&8Z<&%R<V54>7!E/2)297-O=7)C92(^"B @(" @
M(" @(" @(" @(" @(#QS=$5V=#IA8W1I;VX^<V%V960\+W-T179T.F%C=&EO
M;CX*(" @(" @(" @(" @(" @(" @/'-T179T.FEN<W1A;F-E240^>&UP+FEI
M9#HS1C!%.#0Q03,V,S9%0S$Q0CE$.#@S03 W1C9!,T0P0SPO<W1%=G0Z:6YS
M=&%N8V5)1#X*(" @(" @(" @(" @(" @(" @/'-T179T.G=H96X^,C R,2TQ
M,"TR-E0Q.3HR.3HU-RLP-3HS,#PO<W1%=G0Z=VAE;CX*(" @(" @(" @(" @
M(" @(" @/'-T179T.G-O9G1W87)E06=E;G0^061O8F4@4&AO=&]S:&]P($-3
M-B H5VEN9&]W<RD\+W-T179T.G-O9G1W87)E06=E;G0^"B @(" @(" @(" @
M(" @(" @(#QS=$5V=#IC:&%N9V5D/B\\+W-T179T.F-H86YG960^"B @(" @
M(" @(" @(" @(#PO<F1F.FQI/@H@(" @(" @(" @(" @(" \<F1F.FQI(')D
M9CIP87)S951Y<&4](E)E<V]U<F-E(CX*(" @(" @(" @(" @(" @(" @/'-T
M179T.F%C=&EO;CYC;VYV97)T960\+W-T179T.F%C=&EO;CX*(" @(" @(" @
M(" @(" @(" @/'-T179T.G!A<F%M971E<G,^9G)O;2!A<'!L:6-A=&EO;B]V
M;F0N861O8F4N<&AO=&]S:&]P('1O(&EM86=E+V5P<V8\+W-T179T.G!A<F%M
M971E<G,^"B @(" @(" @(" @(" @(#PO<F1F.FQI/@H@(" @(" @(" @(" @
M(" \<F1F.FQI(')D9CIP87)S951Y<&4](E)E<V]U<F-E(CX*(" @(" @(" @
M(" @(" @(" @/'-T179T.F%C=&EO;CYD97)I=F5D/"]S=$5V=#IA8W1I;VX^
M"B @(" @(" @(" @(" @(" @(#QS=$5V=#IP87)A;65T97)S/F-O;G9E<G1E
M9"!F<F]M(&%P<&QI8V%T:6]N+W9N9"YA9&]B92YP:&]T;W-H;W @=&\@:6UA
M9V4O97!S9CPO<W1%=G0Z<&%R86UE=&5R<SX*(" @(" @(" @(" @(" @/"]R
M9&8Z;&D^"B @(" @(" @(" @(" @(#QR9&8Z;&D@<F1F.G!A<G-E5'EP93TB
M4F5S;W5R8V4B/@H@(" @(" @(" @(" @(" @(" \<W1%=G0Z86-T:6]N/G-A
M=F5D/"]S=$5V=#IA8W1I;VX^"B @(" @(" @(" @(" @(" @(#QS=$5V=#II
M;G-T86YC94E$/GAM<"YI:60Z-# P13@T,4$S-C,V14,Q,4(Y1#@X,T$P-T8V
M03-$,$,\+W-T179T.FEN<W1A;F-E240^"B @(" @(" @(" @(" @(" @(#QS
M=$5V=#IW:&5N/C(P,C$M,3 M,C94,3DZ,CDZ-3<K,#4Z,S \+W-T179T.G=H
M96X^"B @(" @(" @(" @(" @(" @(#QS=$5V=#IS;V9T=V%R94%G96YT/D%D
M;V)E(%!H;W1O<VAO<"!#4S8@*%=I;F1O=W,I/"]S=$5V=#IS;V9T=V%R94%G
M96YT/@H@(" @(" @(" @(" @(" @(" \<W1%=G0Z8VAA;F=E9#XO/"]S=$5V
M=#IC:&%N9V5D/@H@(" @(" @(" @(" @(" \+W)D9CIL:3X*(" @(" @(" @
M(" @/"]R9&8Z4V5Q/@H@(" @(" @(" \+WAM<$U-.DAI<W1O<GD^"B @(" @
M(" @(#QX;7!-33I$97)I=F5D1G)O;2!R9&8Z<&%R<V54>7!E/2)297-O=7)C
M92(^"B @(" @(" @(" @(#QS=%)E9CII;G-T86YC94E$/GAM<"YI:60Z,T8P
M13@T,4$S-C,V14,Q,4(Y1#@X,T$P-T8V03-$,$,\+W-T4F5F.FEN<W1A;F-E
M240^"B @(" @(" @(" @(#QS=%)E9CID;V-U;65N=$E$/GAM<"YD:60Z,T4P
M13@T,4$S-C,V14,Q,4(Y1#@X,T$P-T8V03-$,$,\+W-T4F5F.F1O8W5M96YT
M240^"B @(" @(" @(" @(#QS=%)E9CIO<FEG:6YA;$1O8W5M96YT240^>&UP
M+F1I9#HS13!%.#0Q03,V,S9%0S$Q0CE$.#@S03 W1C9!,T0P0SPO<W12968Z
M;W)I9VEN86Q$;V-U;65N=$E$/@H@(" @(" @(" \+WAM<$U-.D1E<FEV961&
M<F]M/@H@(" @(" \+W)D9CI$97-C<FEP=&EO;CX*(" @(" @/')D9CI$97-C
M<FEP=&EO;B!R9&8Z86)O=70](B(*(" @(" @(" @(" @>&UL;G,Z<&AO=&]S
M:&]P/2)H='1P.B\O;G,N861O8F4N8V]M+W!H;W1O<VAO<"\Q+C O(CX*(" @
M(" @(" @/'!H;W1O<VAO<#I#;VQO<DUO9&4^-#PO<&AO=&]S:&]P.D-O;&]R
M36]D93X*(" @(" @/"]R9&8Z1&5S8W)I<'1I;VX^"B @(#PO<F1F.E)$1CX*
M/"]X.GAM<&UE=&$^"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @
M"CP_>'!A8VME="!E;F0](G<B/S[_VP!#  $! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_
MVP!# 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_P  1"  O ET# 1$  A$! Q$!_\0
M'@ !  $%  ,!              $%!@<("0,$"@+_Q !7$  ! P," 0<%"P8*
M!P<%   % P0& 0('  @1%Q@A,5B7U@D2$Q1!%18F459787&!E98G-D:1H? *
M&B5'9G6QML'1(S)597:&QADD-T5(A^%G=X6F\?_$ !H! 0$  P$!
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MI?0#TG>VW;L_;$&3W F%W;,LS-#BC5SBZ#K-R3"2,1 R1,GR2@.ZQVT/#8^
M'F6Z]JB1-D##M7MBZ QE8@!1P>TS:S&'@$C&]MF!0#^*AW\>C+X-B''XQW'P
M16U6PH'#.64?16&#"5BZ]I!DSO1;O*+KT<IJ>F4\X#Q#-HVU,*6BQX-MGP )
M-P8:N&A9<;A['K$E$A#I5RLX%QIZVCR3@&/76>O%568U1LWO4=N;ZIUN75K>
M%XJ_XE4D.V';7+@;F,RG;WA&1QQXS"CW8$YBJ"E [EA'+E+H\R6'/02S11H!
MN55J&;WI51%U55]2L0])?Q RZ"! XN'&QV-!A4>CX5F@.#@P8]H)#BA[6RB;
M9B-&L$6[)BS;IVT30;-44D4K*4MLLMMI2F@*KH!H!H!H!H!H!H!H!H# <W@6
M>#<F(DX5N 80:-.+6=!\87Q%'92J.N18MT'EUQU^<9NGOKKY-P^MM4;)T;6N
M*-+*WIHVWW;V&Y!EE$;D%;:1[VJ5IE\5=[*,JB.1R8XN>:VF6U551M$2I,%%
M="VN/QT1M.N+MT/'ASKA5+O];AR!1'_5IT5XTK)N/#C[:5IPKK*EFV:K[]OR
MDP97*)V$NFJ.M"*8QW/7</-W7B*\:\*<,"1"O&O7PI\)NOZ.GH]FE+-LU7W[
M?E+@RF4X&2*XPW/V\?.W8":<*\*\<"1"GFUKU4Z9-T5ZNOCQ_5PM+-<U:T_:
M&O)S&#*93@0FF+]T%;JVTW7B:W4IQ\WD#B%:TI\=:4DWG</BKQI]NE+-<U:[
MPUY"8,I']HFCV$WWTUN2AV1?/2IY2*I[SH??)T6M'JT=LPO [CB3.ZM:6NU!
M5)95]8VK6E:47N0HG6M.%+M2EFV:K[]KR%P93*<"%3=X\W*,+4[WV[@"SL4O
M\Q.YU@F&-Z*7TMK=6RRY646VW7>;2MU;;>-WFTK7API7A:6:YJUH^T->2-9%
M9E<HCK583%7#;6A')[N2KZEPW= *>Z=/.'?D*AE?7[?0^GXL_A1_WFGH*T6X
MH^?_ **M+^/FUXZ4LUS5K1]H:\E])<&4JE.!$YEN*CLRMRUP%QO@Q^B<M<4:
MW!E<18\3*6N;N'FM[F%\QHZHO=YUOFI52I?7SJ<+:\::E+-LU7W[7D)@RF43
MLH7AR6[HNU8+^G\@42\3='[=6EFV:M=X:\A<&4RFOV$NNX<ENZ'M5B^X*)>)
MM2EFV:K[]KR#!E,IP,CDMW0]JP7]F HE_C)JZ4LVS5??M^48,IE.!DCDMW1=
MJP7[?Y@HC^O\Y?9I2S;-5]^UY!@RD/VFOV$W#DLW1=JT9W!1'Q+JTLUS5KO#
M7D&#*93@9')9NB[5HSN"B/B32EFN:M=X:\FJZP8,IE.!D<EFZ+M6C.X*(^)=
M*6;9JUWAKR#!E,KP,CDLW1=JT9W!1'Q+I2S;-5[PUY+V5C!E,KP,CDLW1=JT
M9W!1'Q)J4LVS5??M>08,IE>!D<EFZ+M6C.X*(^)=6EFN:M=X:L^Y;'<,&4RO
M R.2S=%VK1G<%$?$NB2LUKFJK_[#?DO#2]@RF4X&1R6;HNU:,[@HCXETI9KF
MK7>&O(,&4RKM3#/CR')9NB[5HSN"B/B74I9MFJ^_;\O/J&#*93@9')9NB[5H
MSN"B/B75I9MFK7>&O(,&4RG R.2S=%VK1G<%$?$FE+-<U7O#?7_)LQ.K>,&4
MRG R.2S=%VK1G<%$?$FE+-<U:[PUY!@RF5X&1R6;HNU:,[@HCXDTI9KFK7>&
MO(,&4RG R.2S=%VK1G<%$?$FI2S;-5]^UY!@RF4X&1R6;HNU:,[@HCXDU:6;
M9JUWAKR#!E,IP,CDLW1=JT9W!1'Q)J4LVS5??M>08,IE.!D<EFZ+M6C.X*(^
M)-6EFN:M=X:_+&#*93@9')9NB[5HSN"B/B34I9MFJ^_:Q]C=O&#*97@9')9N
MB[5HSN"B/B72EFV:J[_OM?' \!@RF5X&1R6;HNU:,[@HCXDU:6:YJUWAK\L8
M,IE>!D<EFZ+M6C.X*(^)=*6:YJUWAKR#!E,KP,CDLW1=JT9W!1'Q+I2S7-6N
M\->08,IE>!D<EFZ+M6C.X*(^)-*6:YJUWAK\L8,IE.!D<EFZ+M6C.X*(^)=2
MEFV:K[]K%V-^X8,IE.!D<EFZ+M6C.X*(>)=6EFV:K[]O3_3=U8P93*<#(Y+-
MT7:M&>S^8&(_;^DOM_9I2S7-6N\->39XC!E,KP,_(<EFZ+M6C.X*(>)=*6:Y
MJO>&]/\ 1=4L@,&4RO R.2S=%VK1G<%$/$NE+-LU7O#>[V-F/2\8,IE.!D<E
MFZ+M6C.X*(^)-*6:YHUWAKR7M08,IE.!D<EFZ+M6C.X*(^)-*6:YJUWAKR#!
ME,IP,CDLW1=JT9W!1'Q+J4LVJFJ^_:\B#!E,IP,CDLW1=JT9W!1'Q)JTLUS5
MK3]H:\G,8,IE>!D<EFZ+M6C.X*(^)-*6:YJUH^T->2.X8,IE.!D<EFZ+M6C.
MX*(^)=2EFV:K[]KR#!E,IP,CDLW1=JT9W!1'Q)JTLVS5KO#7D&#*93@9')9N
MB[5HSN"B/B34I9MFJ^_:ZOY+Z!@RF4X&1R6;HNU:,[@HCXDTI9MFJ^_:\@P9
M3*<#(Y+-T7:M&=P41\2:M+-JYJUWAI/P*,&4RG R.2S=%VK1G<%$?$FE+-<U
M:[PU^6,&4RG R.2S=%VK1G<%$?$FE+-<U:[PUY!@RF5X&1R6;HNU:,[@HCXD
MTI9KFK7>&O)>/4P93*\#(Y+-T7:M&=P41\2Z4LVS5KO#7D&#*97@9')9NB[5
MHSN"B/B32EFN:M=X:\@P93*\#(Y+-T7:M&=P41\2Z4LVS5<6<-8[?W-V\8,I
ME>!DCDLW1=JT9U_,#$.KXOSE_;T:4LUKFBU?\0W"W^6NZ5#!E,KP,D\EFZ+M
M6C.X*(^)=2EFV:K[]ORC!E,IP,CDLW1=JT9W!1'Q+JTLVS5K3]H:\D-XP93*
M<#(Y+-T7:M&=P41\2ZE+-LU7W[7D&#*97@9')9NB[5HSN"B/B32EFV:K[]K'
MV-V\8,IE>!D<EFZ+M6C.X*(^)-5)6:Q?-56S[0W#@O8,&4RO R.2S=%VK1G<
M%$?$NE+-<U:[PUY!@RF4X&1R6;HNU:,[@HCXDTI9KFK7>&O(,&4RG R.2S=%
MVK1G<%$?$NE+-H_95T?:&H<%[1@RF4X&1R6;HNU:,[@HCXDTI9KFK7>&O(,&
M4RG R.2S=%VK1G<%$?$FE+-<U:QYPWBL_<&#*93@9')9NB[5HSN"B/B74I9M
MFJ^_:\@P93*<#(Y+-T7:M&=P41\2:M+-<U:[PU^6,&4RO R.2S=%VK1G<%$?
M$FE+-<U:[PUY!@RF5X&1R6;HNU:,[@HCXEU*6;9JOOVO(,&4RG R.2S=%VK1
MG<%$?$NK2S:'V5=/VAN/! 8,IE>!D<EFZ+V;K1G<#$?$M-%E9K5-5ZYPVOX$
M&#*93@9%,6;HO;NM%U_]@8CXE_?^U2S;-5ZI=OQ97Q&#*93@9OOJ0S7CL#.H
MZ"78Y"GR&1CEY-PY0/-XD/AEB U1NT3;C*B1KY^W5N;KI.G%7UR]JJU'=$;D
M[;6]EU^F4:8::?)R:R;+G8*MJV]7K%ZHE3D<ZI]9DRC2)[36$KX*YT')^O6Z
MHOS6LR/GHRX_WQ7^4==;DHUAW.[O;I%9J!VA6CQC\U065QY)8(9ODV7F.'F+
M-0V3',,S3^)/>5ELV<BFL6QF_LHY196O%DT:MZ5/C\%+!T53%'E!\5L5UD7H
M:/B]LGE#8#MPV%3&)A,JIY@B8F9;B)5'8L]W'*'3\MQGB5G,(QC;<4/R!*Y.
MU0E>2) &>P#W 0&1Z./R$@49,X]5_?;2C2ZR-7RW/@CR/2MR/W:4B^%:XW/Q
MJ5.3XUW=O,%;Q9!EF*;G7.4L[2#$^6L7@^3?=SD9O!I3.(MF4E6 1 5@XX'6
MA[W'T=>0J'O#$K:G(#$9^U&$Y4#H2]SO5Y'1IQK#=HOCJN>F-R0UZXQ74[%!
MR&[FV87,S7E$,,R ]C+>/A9[ =LT> Y4+Y)$[E9[C_/>5Y3A^*)N0I*=*"7F
MW>/ \1(#'2I$]8]BCZ7Y<>.$QT>M?^Z;I:]6*/A?63%IBL'Q3;HBY%@G4^)5
M 9Q%-S<CD6(,(3&4Y+?Y\D4O6$9/VOS-HZC%SX/8QMRSCC>[#$HU "D)L&,V
MSA#$^0G\V>E+[G<.79-:*M4K2Z]&)5ZX57@-&C&^%KK=53SU5J[HYXTAM+!^
MZ'(XX,PA<FFE^:<*E +V*YU7CYE&:!H4P?XYBM34';O+ET%;V#&309O5$(D"
M..DR*]7L5'[GHN*"Q@Z/PKJ08H>+XN?R7'K2V[L'#\^R3<)M4<988;D4I3!3
M!.IN)O,0&0NWJ$8_6P-&V,<*#I:TQR)BH\^\D:I@<3&VS-<VT+6N!#X .9-&
M=EC7?36.O&^R->Q/ VFR]MGBQ/>G9DX!@&'/BE=K>2WC7(-F+(Z[MY8:28<I
M%7KJ4. *K>Z<VHHV7BW+UY<7HS2NJE?ZK;=PH-84,B[R<RR#&T1$N=V&.(\F
MUQ3&\I2NW#<C@+^L@0%R"W(:XDM/<;U:J,ZE6C!%Y)A3)P%5M5;J!R%Z#M-:
M]\P4844WTQ4=CNR;3?=J5@LVC$)/9VD@O&"!_(\"]'/97'S3''P.*8I7,#GB
M\<81MZ:%!XQ(9.BU=7'FS2RQTJ[MGC!8KNL74[6(:MKMZO\ CU./"@OOVD$,
MRE+R>2MU,32BL+B#'%;3D@JY)2@07FBR1*33>&!<=>_]::J11LV:FDHD&<22
M(M7-YQ.!.B=5K-7%=X>[&=3-D\DR=*MO$0)Y=#ST--$W9P<ZMR1<ZNDY,>/*
M.&PHVK4KCC$<BH/+LK$W@RV68YBLJM9J)VG1MCZBE]Y(HC_@[=\1XQQO-L-
M- - - - - - - - - - - - - - - - - - - - - - - - - - - - - -
M- - - - - - - - - - - - - - - - - - - - - - - - - - - - - -
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MGG^V:_-'UC7-$]^GY8I_"5G?MV<-^KCPY>E:5_;A[_\ GMT^KJYY&SZ,K_\
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MXS1*<[X-%S6=MF;";L99/X;*!S<"0B3QF]ATR,@Q]3D/*$S3Z)'B4?:AC1(
ML8*)M%"=JC5W<S7;IIBFTN@&@&@&@&@&@&@&@&@&@&@&@&@&@--?* ;=IGNN
MVFY4P-C\M& DMG*<6L%$YB[*L8ZVJ#F("1.O=!T$#'R:5%68IPDWJV$NZW.;
MT;%*))77K)^N8SAB:SJ2EVT:5EA6E5&$16HLJRCD::93&L7JD#R3Z;MSJ:RL
MA)JRC;:,X*MJJ,HJ-(U%666EJL4^9#^+G[T/;E;;!T]?POROT]/_ -FOKX?O
M771_X_,\C.>I)..C^*NK5'&<U]79WEIOVI5=?^FE8_BZ&]#I_*MM?Z?9[[\K
M\/9_]&NFOMX\./\ ;HG]OS*N1G.R3ZW_ +6JISGP'U=G;OXTV?KE?RZJH51'
M\7/WG_.MM@_%V5_BX=/Y&O9[/B]G#VO\?F>0G&R3_,Y#ZNSI_P#&FVV5T_\
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MGAQ[*5RKT+-799W)(:Y,DEHXZ:HNW3-PK?=1N@Y'570OOF(;7K: /10(ZV4
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M,&7BC\N;/R:3DC$DD1HF\5O6>ECA8@07X)I7N/0HHII@9!T T T T T T T
+T T T T T T!_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>65
<FILENAME>g164680g92k66.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g164680g92k66.jpg
M_]C_X  02D9)1@ ! 0(!>0%Y  #_[1=,4&AO=&]S:&]P(#,N,  X0DE-! 0
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M    %P    !#<'1N8F]O;       0VQB<F)O;VP      %)G<TUB;V]L
M  !#<FY#8F]O;       0VYT0V)O;VP      $QB;'-B;V]L      !.9W1V
M8F]O;       16UL1&)O;VP      $EN=')B;V]L      !"8VMG3V)J8P
M  $       !21T)#     P    !29" @9&]U8D!OX            $=R;B!D
M;W5B0&_@            0FP@(&1O=6) ;^            !"<F1456YT1B-2
M;'0               !";&0@56YT1B-2;'0               !2<VQT56YT
M1B-0>&Q 6"]<0         IV96-T;W)$871A8F]O; $     4&=0<V5N=6T
M    4&=0<P    !09U!#     $QE9G15;G1&(U)L=                %1O
M<"!5;G1&(U)L=                %-C;"!5;G1&(U!R8T!9
M$&-R;W!7:&5N4')I;G1I;F=B;V]L      YC<F]P4F5C=$)O='1O;6QO;F<
M        #&-R;W!296-T3&5F=&QO;F<         #6-R;W!296-T4FEG:'1L
M;VYG          MC<F]P4F5C=%1O<&QO;F<      #A"24T#[0      $ ._
M_C4  @ " [_^-0 "  (X0DE-!"8       X             /X   #A"24T$
M#0      !    '@X0DE-!!D       0    >.$))30/S       )
M   ! #A"24TG$       "@ !          (X0DE- _4      $@ +V9F  $
M;&9F  8       $ +V9F  $ H9F:  8       $ ,@    $ 6@    8
M  $ -0    $ +0    8       $X0DE- _@      '   /______________
M______________\#Z     #_____________________________ ^@
M_____________________________P/H     /______________________
M______\#Z   .$))300(       0     0   D    )      #A"24T$'@
M    !      X0DE-!!H      S4    &              "Q   "8@
M   !                          $              F(   "Q
M              $                         $     $       !N=6QL
M     @    9B;W5N9'-/8FIC     0       %)C=#$    $     %1O<"!L
M;VYG          !,969T;&]N9P          0G1O;6QO;F<   "Q     %)G
M:'1L;VYG   "8@    9S;&EC97-6;$QS     4]B:F,    !       %<VQI
M8V4    2    !W-L:6-E241L;VYG          =G<F]U<$E$;&]N9P
M   &;W)I9VEN96YU;0    Q%4VQI8V5/<FEG:6X    -875T;T=E;F5R871E
M9     !4>7!E96YU;0    I%4VQI8V54>7!E     $EM9R     &8F]U;F1S
M3V)J8P    $       !28W0Q    !     !4;W @;&]N9P          3&5F
M=&QO;F<          $)T;VUL;VYG    L0    !29VAT;&]N9P   F(    #
M=7)L5$585     $       !N=6QL5$585     $       !-<V=E5$585
M  $       9A;'1486=415A4     0      #F-E;&Q497AT27-(5$U,8F]O
M; $    (8V5L;%1E>'1415A4     0      "6AO<GI!;&EG;F5N=6T    /
M15-L:6-E2&]R>D%L:6=N    !V1E9F%U;'0    )=F5R=$%L:6=N96YU;0
M  ]%4VQI8V5697)T06QI9VX    '9&5F875L=     MB9T-O;&]R5'EP965N
M=6T    115-L:6-E0D=#;VQO<E1Y<&4     3F]N90    ET;W!/=71S971L
M;VYG          IL969T3W5T<V5T;&]N9P         ,8F]T=&]M3W5T<V5T
M;&]N9P         +<FEG:'1/=71S971L;VYG       X0DE-!"@       P
M   "/_         X0DE-!!$       $! #A"24T$%       !     0X0DE-
M! P     #)X    !    H    "X   '@  !60   #(( &  !_]C_[0 ,061O
M8F5?0TT  O_N  Y!9&]B90!D@     '_VP"$  P(" @)" P)"0P1"PH+$14/
M# P/%1@3$Q43$Q@1# P,# P,$0P,# P,# P,# P,# P,# P,# P,# P,# P,
M# P!#0L+#0X-$ X.$!0.#@X4% X.#@X4$0P,# P,$1$,# P,# P1# P,# P,
M# P,# P,# P,# P,# P,# P,# P,#/_  !$( "X H ,!(@ "$0$#$0'_W0 $
M  K_Q $_   !!0$! 0$! 0         #  $"! 4&!P@)"@L!  $% 0$! 0$!
M          $  @,$!08'" D*"Q   00! P($ @4'!@@% PPS 0 "$0,$(1(Q
M!4%181,B<8$R!A21H;%"(R054L%B,S1R@M%#!R624_#A\6-S-1:BLH,F1)-4
M9$7"HW0V%])5XF7RLX3#TW7C\T8GE*2%M)7$U.3TI;7%U>7U5F9VAI:FML;6
MYO8W1U=G=X>7I[?'U^?W$0 " @$"! 0#! 4&!P<&!34!  (1 R$Q$@1!46%Q
M(A,%,H&1%*&Q0B/!4M'P,R1BX7*"DD-3%6-S-/$E!A:BLH,')C7"TD235*,7
M9$55-G1EXO*SA,/3=>/S1I2DA;25Q-3D]*6UQ=7E]59F=H:6IK;&UN;V)S='
M5V=WAY>GM\?_V@ , P$  A$#$0 _ /54D#+S<3!I]?,N915(;ZEAVMEQVM&X
MH%_6NG5.94RYN1D7$-JQZ7-?8XN'J#:W=[6>G^D]2S95L1$2=@56T^H]+S+,
MM[\4W!EY:ZRQN993L< *?T.,*KJO;6WU?^$>@U]-ZKOBQEOIESCKU"P[?9Z?
MM_5VN?[_ 'U^I9[+?TJZ!5/VC7!/HWZ :>FZ228VC^4@IH],Z?GLR_6R_5K:
MP'8W
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
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MT_ D0E=BL]'A\0H8)2=#ER8T-G."@]8W8V5R=X:6LL;_Q  = 0$  04! 0$
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M$G%J_)BIC**%]BH[[([;)G$>'"ZR6BCER)Z&"-'9)4;&61MSR 47@G2,DGL
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MP'$:_P /258EHA_5TP8FLD#'FL7Q!8C5]'E5,V9(+E3"0,\O[TP>^<]A@[[
MG[=.^]4/+>+SFF\6AE5\;X_P]7V#3.6+ZVYNDK?KV:#G<;W:Q3U>5,0;-AVM
M/H294=1  62"(EX;G4*6.<R9!!4ZIY>F,]]N7?;Z_P!_SZ5S4?%FND4A2(F7
MQG"VENBA2FUTD;+D]E"Y8L<AD>:LS:%=XUH,'C)A"72(KC>'13LS[UU5,T 5
M$V[1\LT77</*A'7'7)  &0<?7/KY8[U*7A1X_;SGE_<"7W"T-1V$;@E'B J/
MV,OLI?):;JQK%8ZV>#EH^2HE,2C+0JZKJKANSCGDVS.1T@CZX5.8VE1@C.1T
M./[CN?K_ ,U!RY>)WQ(YHA:74,05S&^+['=;]@.2+=*7E=OD)Q XVRI8K3&N
M*E9OCN#IN#J64T"55P:6B7,!8F#2/=MEXZ165<&69QGY>F__ !Z>M,;[YP,@
MG&^0-MLY S^O4&I4YGX\,K</W%K<\96B$QW.8?AJOPI,HYR^N#NO7)E,9IOM
MDIMJN<@ T]6)DHN(6CR"X02>1#-L5")$ 06FG24:)Q^7EW.* 9 QUW[>0S@;
M_P S\JL\X\7C)\\\CAQGP[X^L\(N[I+1S+S&;IF&27/D?B2OO#C4EH<8K$ED
M0?L32E386F9>'7;BRB7KQLQ;RKANW,Y9\QC_ +QY?+[@'%"-MB,[^O0 ^8VZ
MCZ=#N!V8WQ@+:[/40>X*I$6LP;XX_*G"/\QOFMKEY#(W$=;^&Y)EPZP*V."*
M9>4K<[3W5JGRRSBBJ(PS]A'I$-)G.F6?UH1CSSOC;;8 G)^HZ ^?3>LBG!9Q
M!9$XG\0CF*[8ZJ^-8>P6:R,*)"P=VE;E,NJW6YAY7%)6V>OI=1:0<K(RL5(.
MFL1%KV%NE$JL%'$H1\HY9MW\_FWU^N.V\?S^;U+S2E-*4TI32E-*4TI32E-*
M4TI32E-*4TI4+_$.RAD7#/!IG')>)9AW 9%K,)7CU668,(&3?-'\K=ZQ!JBR
M8VAL\KJ[M9E)NF[;XRV4CTUEB+..0B8J$5(ZC^^<?EOOZ;^58>J9XHG$I@>N
M9(8Y6@IW*EN;9S<XTK5/SNM3,=9+QZUJN%DLDVAQDF1X>*%<Z2XA+JZ:K.<1
MS5?A7\5)UY\YG)VR-F,.ZVC?R^6_Z[?//]ZD@9&#GS*[]<XP#RGRSGO\Q5>Y
MJ\8C+C*O\2T'0\/TJAVJE\.E[RCA^>MMQL5P5FK#3,?T.]V!I),J9CZ9H#.6
MK4/;Y9TM3IO(\58RNH*%^(1:499EG4*SZ?SO_P >=1C;))&^#A<XZ^9'D=OS
M!V-QKQXO5SQ\[R #_"^-+,QH4=ERM"PJN;9"0O,SD?#O"=)<4$I:25);&#06
MG#W:DHIQ3JOD\9!6864?UR?=4ENSL"+-JW[XVZD;].O0=!OWHHSW(W'4= 3C
MSR6W!QCS )QD_K(OBJ9JHE\I.(WF%\-J9$N=.;'E&L'EC),ZRQ[?[WB;+>7<
M61LT^D,$5F#FX=>!H5;0M2<-.GL;->P2KF/@G4=$Q3NQS4@ [YP/EOU4=,^I
M/TQWVMYB/Q3<WFJ>-%+9!XQLU_RQCKA,<M)>U920H& JQ8<E8$RUEZYRLG<8
MW$S^P0,M,)8X")&I.FUJ33OLBC5X5\SCHUS+2<9/3??&#C;Y=.N 2,T( )!/
M0GT)W & >N._38'."0*OEBCQ5;UEBYXJ)'\/$1!8SO-EX:*?8)N7R9(C=H>;
MXE(.RO89U 5=OCP\)8*Y7I*N&\Z8=6Z%5FH*2CI>.C@,NHT;S_/I_._Y4Y3Y
M[X)(P 1CKG?/F<8R,=]R*KSMXD5XQ_GF[81IN+*+)HUVUU/%322L&4GT+D5_
M>LA5&1L4!;HG&K/'T^G(XIKRC9%*SV<;$5\W(C+N&\&Z2AUB.([]O7?>HQMG
M[;;''7?/7<;8_45X&.>,_.N,>!;A!REE%:C9'S1Q)OHTCVS9,R#&XSQC6B6*
M!F[HBXG[95\01Z,&P:PT66+B8O[$OW/Q1PA'/;/+<III>:8!)QY9&>I]-JHC
M*WBHY;;-<E8ZQIA['Y\QU;%+S-#*<6R8^L^,4<2.J$,[7\CL9Z$I!C65G)71
M!W36K)F@W:JCZ&36DD0=BQ3?P?S_ +J>7;.<;XW!^OY;_P#6](SGBT9D95N2
MAHO&.(9*UMJ?]G6<LRRU*REC6R<3#K/)*MU-CA#&[0ZN(R'="U&>2GB/ ?)+
M)&B2-$A6%48^9.YZ=LG^=_GFJGQ_XL&1WQL:P=CQOAJ0>RD/B*NVR6;9L?QT
MY)7O*%!=VUO;JO35,:&!UB.$58BA<;0O,-7=?,H].VAY-O&BLZC?/;'EW_G3
M\_2F!ON=L]O+'7?J2?7UJC(GQA;9=*/3\SHXI4K,!&77-57G<<U_(<)8I>?-
MC*HL9!)_9#NL=K.H6MS,HN:2J\E#R+%P\JY_M ]*L3EB"3_/W_GZTZ9[G;L1
MY]/ICJ-^U=?-GB;<0T?5&-AQ\WP,C;4<:W"R/XZG9H;Y.Q6Q59W?$43'K6B6
M)B2,M\;96,->797,68T0QB3@Z>NVUA31:$TI@9VR1\L'./+)SOW_ "J<?#5Q
MV6[-W$!.\-DUBF*@[IC&!FK!EZ>A[D]G:_#PC]VR2Q!.5U9>H0BDTURI%?%)
MY--VG#J0C9FDD4LD#CS$E1OWQG]NNV<_\UDKTI32E-*4TI32E-*4TI32E-*4
MTI32E-*58C-/#'@3B*&OFS9C"N9$/51D!KRDZ5Z"D4$LB5M)D:JL7C-0$G[<
MA47:)S'272 "*$,7II4@D9P>O6K9$QQP/P)+33$(/!\&E74\?_:VLM7D'%(P
M*./G3!MCHLK%-WC=.*2KCQK'HPI5$6Y$W":)-CJ&V,IDDD]SG/UZU$KB5P1X
M;T+@_(%O!YC+$\=D-5FZ>7[&\/1K?.SBL)=F$RO'5^LV2+MD+*-$;,[(O(QT
M'"MW,8LZ</H]Q%/2@[)&/G]S0$YSUQ\^XQU!![;;]OG54XCP!X?O#A^3+AYF
M'=0G,CMJ<3*E?D+^UB(JPNZ^VR8_O#.<!.$CX&LP+!ADFV/Y& AFK-F1J[=J
M)-45R(G$)H222?T^7["J8X@>!K@DR9DO&=NG,IU?&#"A6&*(6B008A:MIZQ5
MK-!,OJH%M%AK4C?X21DLDR7)96D-9T$%6\H[8QS*$?S4H_D&?R]>@_MWJ06W
MZG[]<8SL1O@=_+?-2ZO-1X)\G6G&.9K^UPG;;5$R\? XPO<S*0;EPYF:U/FD
M8>&CGOK2-I]S6;4)Y6%CGQ9$*_8S&DXU!E*F%P*HW&1N//MV/Y8-5G"T?ADG
M*C*X>@8S'$K4,;W5E>YNCQSYD[8TZ\P^2GV3&4_+,D7AU8F6890@I&T$.],E
MY4]%NU#$_P F53*J,^N-L9SC;&.ORV^56QC<=<!OPS'TK%1V#S1+"8@JQC=^
MUFXH[(DY4<E(9<@82O."28I+R4)D]-M<VS-$RJZ,X"+@Y!*8A!?GWQUZ;]/3
MK4[^N2#\\$'/Y9WJ.U;/X7M_RH[9HX_HD;><6R.5[4XL5CK\M58V#EL+\5$F
MTNDTM.R"[&*<2$-Q*6R;L5<=.U5UC2ECF96OF392S\KB-LX],_VV/G^],GS/
M_8'Z@#Z 5*FF<''!R@\H.0J/AG&RCBJ+_:'']DAT3O6K(SN<<6UB]C52/5V+
MYI'V)ZZL%;1<$=LJY*N59"O(QKE0R@S_ 'J*EQI2FE*:4II2J8M[>WNH-PC1
MI."B+$8Z0M7UDBWLQ%)I@;=8JS&/D8MRH<Y.B9B/$P(;J8IP^[I2K,? >*SI
M_P!XN%/_ "XM_P#]>_+??M]-N^E*? >*OVR+A3?ZXXM_]E]#O[_+V'YO+8>N
MY_GZ?*E/@/%7O_\ :+A3;_\ 3BW_ /U[_;^S3^?SI_.]*? >*O\ TB84_P#+
MBW]?Q_\ 3WIM]-/Y\OE3Z_I]NG_/K3X#Q5_Z1,)_^7%P_=_[??MW_HTI5H)>
MD\::^9ZM,1V0J$E5VL V0LKAK!2K*H.6X2T@J9@M57\_+R4E/BF8522,8_A.
M1L9JU<23<G15WWV^63Y^>!GY?6H\_,_SKC]<]ZG60# 4H'$IC@4 .8I1(4QM
MOO"4HF.)0$=Q HF,(!T$P]]*FOUI2FE*:4JP_$]=L;XSP#E7).7*4AD3'6/Z
M?*W&TTY:"@K(:;C8! 7ZK5O#695"#>NQ%(#-B2+AN@"Q2F,LF( 8%!G( ZDX
M'SJQ$GQ#\ 497J[8K!-X,BXZ B+3%UY*2@*L#JL1]0FX:&M==BF@1RBL02*L
MDG Q;J)CRI(K2SV+201667:B94C.<#J>WH?[5X[WB\X'XA05Y1[BV.I)Z7!6
MB)NRK6B'A)EK9+HY8L8*+A6[E6VGD36]JZ=J(K5M!@:91653=J2B:A2OY^U1
M@[[>O]R3MM7=ROQ!<%^"X?&-\E*I29!GQ%SB_P!BIVFT*KOC7"51BUK::5D9
M,K9F50RA(\KDK]ZX5<#(D1$?SR8G3?S^8_2IP2#CH <YZ =/38YZ=\^M6QQW
MQA^&C>\9?;PGY#ZC$V&7K)['5['3J.UFT;599-=S6D9Z+CF4@UDII]+M%7+!
MXW7D@-))BHB[]80W*I@C&WR_XJ[L7Q/>']-6%12,N^!W=FQB#:(:.TXVM!+5
M9&QS*<'Z&OO#,"N6;5Y/ORQ<@E#*E0+)N%&KT"N#')I3!\CY=^H[?2O<E>+C
M@CQ3(,4GN3L14R3</9:BM2M B(QXDI6+ G$R<$H+%LFLTCXZS2!6/D+"DP+,
M.C)) +M0X"H 3T!/R!^WS]*I3AHXEN#;/-DN%#QA!T2N9 BKQ<I&<H;NL5"*
ML<Q+4*P+UQ]D,K2&!VA)F5<@1RSFE5S33=F];'>ILCN"IB_F_P#/T)J-^_R\
MQ\LU0M_XSN$>3S'Q1XKN.*OMI;^'#!5BOUSGIBATF;B<@U.BQ![Q=,<4V8FG
MIW$W+4Q?X.K.0$TE%0C";FHI4'1E//<MW?'\_@[_ #%2 3C<;G'7IY$^74X[
M[&K;1?B <-L+"^EM?"7?,87I_7<.V7&&*).E81?6++$3E2Y2K3%ZN/Y&E7RP
MTHGDW1E-OG:=CLE<4J4@VD)E^FR.;U*K_OZ>=3@@[$=P2,C &<YR <=0.N<X
M'6K@3/%%18N0Q/!K<!V55^(Q_*9;>T3"BU'P@PO-4B<<.81;(^1J_>)6]LL<
MHU*5>6Z#3B+%4[PY6NDQ.(LVJ"[XLF5DJ ,[D@#N3GOG&P!.=LX./G4_\6RL
M5/8\J,_"T>:QK'V"#8SJ=#LE92IUCJRLPD61=0]@K* >5$3C1RY63EFJ9E2E
M?@N8%UP-YIU15?:4II2J>M2%G<P,@A39"&B[(<B01C^?CG<K$MS@ND987C!B
M^C73@IFX+$3!)Z@)53)G,)BE,0RE62^ \5?^D7"FVW^C>W]_<?\ V^'V_P !
MJ<^@_/\ >HP?,_E^U/@/%7_I%PIV[_DXM_4?_P"?#M\_\=8_+^?SS^=3]?T_
M:GP'BK_TB84^@_DXM_?ZA]O=O^6E/KC[?W%/@/%7T_[Q<*?4?R;V\/\ _?#W
M'OV^FE*X^ \5G^D7"?U_[M[?^\/_ $^#^G^SJ/R'Y[_/K^5/K^G[59^VTKC7
M>9,I$C!Y#H*4.R9.2S[N.@Y:)JXM3O"&,TEJ_)3LXZF9!4@"+1:./'+MR?=%
M\W*83Z;^0'R)/ZT_G\QBITMBN"MT"NU$5G144P<JMTCH(*+@0 541046<'12
M.IS&32.NL8A1 IE5! 3"I7VTI32E>=+1$3/1[B)G(N.F8IV"8.XR69-I&/=
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MU"IPWD=OGL,8_08^0]*KEWQ@\ T<XOSQWE3![9QBF0A5;L]/\ *I OJ[9F]
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MH!*"=P;^PGJU3QX1_77$D\8019%1V91JHLU.H)FZ48&^>GKT_G\Z 5'E]?\
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M B@"5L<X.164'GTJ,G?IOCL.W3'E]*L!*^$%P\R+J:M2%ORHQRK;U<WDON3
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MI9F8] J@$DGL ,U#,J@LQ"@;DL0 !YDG85B"O'B6Y$RM>YG%W 5A%YG=]7'
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M-<7%BRY;LBXQSXK8XJPS;Z=CQGKG8Z[9( KM8S@6/GD<IQZ+5D)A2:&CW!"
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MC5(2JAS(P"?"2 3U-6V=73%/$-(E+EWAZN;",JT+*3"-BN#4Y(^/:MTP6<(
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MD$'U]>G>JPL8O,C?8Y.>^#@['/TZ;8JN:]F>-?JIMIQH,:HH.P.4Q%9J B(
M'F (%43 1[G$HE+UZB&J\5\C8#CD/3*G(SG;/4@8.3\L]:HRV3+^ \R@C (P
M3MG QL>_;;N>M7H162<I$705(L@J0ITU$Q Y#D,&X"40Z" A\NO4.O8-7P*D
M#&^<[Y Z^OY'.W7;?-8\\RD C!&Y!\\GK_8[]<@],;!?AD^*70L-8Z:8&XAG
MTM'0L Y6&CW<B#B4:,HMTH*@P$P0@G79MF"@F%BY #(%0,)#@!@VUP7VB^S6
M_P!0U&36M!B28W #75FI5',J@*9(NBN7&"R['/IO70>&^)K>WMULM0=H_#.(
MIB"5Y3T1M\KRXP"=L>O7+T'BD<"HB ?E]JX;^XD>@ =-^HBWZ:Y9_P#AYQC_
M /\ "O.N/PK]/\W0]C6V?^(=&_\ W\/GU/[?EUJ@:GXH5#R;DN4J>',+YBR]
MC^OG=(6'+5%@T9* CG;6,7DP10B3G2E7X.$T2HM1;EYG!W"!R%Y#:N+S@*]T
MS3X[K5M2TW3+R8*\&EW<I2YDC:0(7+#,:!<DD-N #G%4X=>@NKAHK6WN;F%"
M0]W"@:)6 )Y<$AF/0;=R-JF5C#B$PCG6 8.JC<:[)C."_8JTZ<=1["V-GD<L
MLUEH::ITBL$JUD(]PW70?L7#,12.BIS 8@<PZK?:1J&GR21W-M(%C"DSHC26
MSI(H9'2=5,;(ZL"K!MP165ANH+A5:.1<MD<C$+("I(960GF# @Y!&:N!;L<4
M6^0H5RW5>)G((%TW/PMTWY&AE4R*IE Z;<R/F)&37635;G$S==-0Z:Z2A#"7
M6-JXKX3>+L>6->%<S5/@WRU>FFUBASF9E1])-LW*3UK)&*V%$CIP@\01=D%X
M5P4'*1%^452@?2E>I*2M*H4>,E-2-7ID4HY%$7\F[B:['J.W:B[H41=.E&;<
M[ERL+ER*?.*JR@KK"!C"H;7EG1!S.RHN<99@HSY9) S5:&WGN7\.V@FN),%O
M#@B>5^48RW)&K-RC(R<8&=S4#;UXKW ]C6XRE/NN7$8,8]Y*QC2TK13U:DV.
M6K[I!C98RK6AL5:.GG=<>NF[.9!B=1%JZ5\D%E#IJ<N+FUO38'*37 3!8!R"
M8W9" ZHXR'*$_%CITZ[5NUE[->,=1M8[JSTIIO$6-VMA(BWD$<ZE[>2YMF*R
M0)<(I>'GP749P!BL3WB(^.I"LXICC+@;L+&?E[!%&<V7,7I3J-:PBY57;DB*
MPR=$*5>P"DD9PM(.2&;QQ5VADDUEN<@:]K7%4<<?@Z8XDD=26GP2(QG&$!V+
M]R3L!ZUUGV=>P^XN;A]1XTMY+>WMY0MOI/,!)=E0K&6X=">6WR>4(IYI.5PW
M*"#6LJV:REFEY*QSKU>5FYV2>S$O).S HZD922<J/7[UR<"@!EG3E55=8P%#
MF.<3   (!KG,DC2.SR,69VYF8XRSL<L3MC<Y(P-L]!N3]9VEI#;00VT$8B@M
MXDABB798HHU"(B^05 %4=OIM=>&J8G*42);!L/0 V'KOMV#MMM^&_77C'?'S
MQG'I]=NOVQTJ_"J.WET(_7'Y8Z^55VUI6Y ,*/L ;"7N'N/;V'L/M^W;4[=-
M\X\P>G7L3\^^._>O?,H_RDD#IUSUZ[8SGITS^5=1]3.4IOS6P;;B')MUZ" [
M;?/\/?\ :(Z'?S/3Y'SVSTV'UKR"I[]LD;#?TZCKU\OM5M9RKE*!N9'V-]X"
M &W?KT#Z=PV^>V^HQ\]]Q^8_7/Z# KRT8(V'7?';8D;XV_*I1^']QK/^ 7,C
MVZ&HT+<JM;&[2!M@.&J1;+%PWJR*KOZU)^695LZ3((G<,P,1!^F3RE1WY1#.
MZ%K'](N"QB66.;E20G(D0=RC;_,CN!N<[5R_VF< #CG2EMDO9[2[LFDGM '/
MNTTQ3 CN(B<,I( 1Q\29VQUK?&Q;D^E9EH-9R3CZ<8V"J6N*:2L8_8N$G!0(
MY1(H=JX\LQO(>M#F,W=ME.51%=,Y#E 0UUZ&:.XB2:)@\<BAE8'.Q&<?,=".
MQKX'U+3KS2;ZYTZ_@>WNK65XI8Y%*D,C%>89 RC8RK#8@Y%7 U5JQII2FE*=
MN^E*UM_$Q\5FR1=EG^'_ (8Y\L4G"J+Q-^RE%JD4?JR:9CH/JY4'(<Z39-H<
M!0D9I/S%#K%5:LN4 ,N3O?L[]F<-W!#KG$,1>*7$EEI[@@,G5;BY&Q*MUCBR
M,@<S=A6@<1\3O"[6.G. ZY6>Y4@D'!!CBZ_$#LS8.#L/.M;"\9 2:.'5@M\X
M_EIF354<.7D@]<2DS*N3!L==PZ=JKNW*@CL!W#E4P@&VYA !V[ZHM;"$10Q1
M6\2*%CABC1% V_"B@*,G?8'O\ZT'EGNY2[LTC$Y:1F+'&^Y8[DCIZ8&QS5@)
M+.$FHJ8L7$MFZ(";D4=',JJ(;= ,4FR91W !'8P@(B)>P!JU?4&)(1%'3&3G
M'3.VPZ=,=@#UQ5VE@@7+N6Z]!@8&3MT.?+N.A[UU&F;IU)3=W',7*8; )2"=
M 0+N&_*)><!, =.NP"/R[A"W\@/Q*I!ZX)![[]SGK@YQMOG-2UA&P&"P.,*<
M@C&^#^GKC.VU7BJF1(.TF!NB<S&1V ?1.C% Q^7](4#@(E5V'<=BB!@#EY@
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M)N40( JE$R>_*(G)OL)B!ON(!S;B8NX;!W#?;6ILK Y((!SC(*CUP2,^?<=
M,9WKN&8WYN1E?E)V0@G).0#C._EG]:E2CB;(G -+\,G&M59#%F::G8'(2<4+
M),\Q"0-I+&*KOZ':D7:1E(ZT,F*CQ=H_12#TC^-5=L1%1HF8VPI;3:&;#5XY
M+>[BEQ^'+*KE2?#<;D.%+8(P0RG&_7DDVJZ=[15XHX&O(-6T&_M>9768B*>X
MM%E54O+8K\,EN\@C#QL2'C<*YPVVY;P2<8^/N-;"L-E*G"C%39#'B[Q2E7:3
MB3J-C; 4'+-<I1!55@Z(=)Y&/1(!5VJY"F$%TUB%Z;IFI0ZG:I<1'#?AEC)^
M*-QU4CR[@^7J#7QGQKP?J'!>MSZ3>@R1C_$L[P(RQ7=NWX74D8YUW25 3RNI
M_P I4F86LC6HTTI32E=&4DX^%C7\Q+/&\=%QC1P_D'[M4J+5FS:I&6<.%U3B
M!4TDDB&.<QAV  'WU[1'E=(XU9Y)&"(BC+,S'"J -R23@"H9E52S$*J@EB3@
M #<DGR K4Q\0;Q5L@9ELT_B_ MBDJ1B&*<KQ;BQ0KA:/L=\.B)D73HT@@=-Q
M'0BJA3E9MFJA%G*!2KK* "@DU],<!^S*STZWAU37K=+O4)5$B6DJAH+0-NG,
MAV>7&"W,,*3BN7\0<4SW$DEI8.8K=&Y6F0E7EVWY3U5<Y QU SCRP2V_($16
MSJGD'*SZ57,9<[4J@K.UU51$YEW*RAC"!CFW$ZBQA,<VXB(B.X]?>:"U3D"J
M.4<J1QK@*N"   .55QT '0]ABM2B@DG;F+;$Y,CG).X)ZG).^^<CKUJR[S-T
MVJ<WH8YBU3W';S147/\ /<V_(4!V[@ B #V$=6;7\A8\J@;#<[DC<;>1VWZ_
MW-X+%% +$L?(;#??&QWW)&-\BOK'9PE4U"A(Q;5TEN *&;&,@J4-QW$A3<Q#
M"/\ K& /??4K?OGXT5LGML<#H!ZX&_UJ6L58$ABNQ()W&^^X!R0.O;?YU>NL
MW*$M2/-'K\CDA?SS);8KA'H/7D$=CDWW #DY@'80U>Q3I*#RMANO+T(Z>@V_
M88JPEA>$@L,KT##H2,['OOMG/8GK4JN%SB#M/"YG"D9FJQ%7BM;>JHSL&5R9
MLWLU6E$19ST"Z$H@4Y'#4X.F1E=T6TPSC7QBB9H00PG%7#]OQ-HMYI4Y"-*
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M66X" GPE,B0!W."=FB!.) ZB!.8P%YA#?EYA HB(;CMWL?Y_/Y^NU;^?]_\
M1JZV)\//.,9_#<3'$[#QDQ1)2.4?\/O#\[41F:?3:E--Q!K?+PW^]'V;)EHB
MEBK"*Q%H^HQCKX9'%,].[<EQPM'N96FOE5D4NMO;?BC1,E?%D'X7E=<$9R$4
ME5W)-;E)K]OHVGPZ=PQ+/#//'!-J^M<I@O+J?E$GN-J?_4MK"U<\I"D/=2IX
MKGDY5KT)CPJ."&Q6&4F;?B!C;:ZL[EIB!QQ-O70T"BS5A=(/K1*4>$CCQRL"
M>RNFC=U*LDWJT:9V55PV:-U%U!&DVB:;(S&2W61"2R0N3X43,<N8U&.7G."P
MR1GH!FKF+VD\86\$<=KJLEK.J11S7\*CWZ\BMU*6T=Y-)X@G%NC,D3%!)RD*
MSL%4#1HSQ"U!OQ+YXCJ#5XZG4>)S#D2!J%8B0<%80]<@;7)PL,V0!TNX< 88
M]@@JN*JJ@BY56V$ , !R34N0:A>)%&L4*W$T<:KE55%8HO<GHN3UW#=L5]X\
M(>]/PSP_+?7,EY?3Z38W%U<RE3)+<3VT<LK$JJJ1SR%5P .55ZD&JEJL("OE
M?FQVV*'4/D  /RW'?;?IU]@V#5@-]]\#OVW&WKYY[;^=;:% '48 .^<9Z[C/
M;/Z^FTEZM5/.!,/+^Z !UY=M]]O<.N^X]?Q#?VU.?/IY#OOW_?MV%47D"Y)(
M&W4?D !L3^F^*O.QH?,B4P-^_0!V#Y=Q#KTWVW'^WKKURY/?ID^>3DXW_O\
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M4Y!Z" _/KJ59D8.N0P(Z9Z9[^GG7ET1E96Q@G)SON?\ @XJ;U:G$;%!Q\NB
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M(',NV<CE/-D[C89 W\^^XK7K(9G&<;J_7;? _7/TWQO41.81'??6'(SUK,#
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M&.7K'C)VM3HB9:S$X_CYMC3)69A!?-V9WZK-Q)'CU%5TVY6X*@N"#LP(F3;
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M(QA=I2+R*ICEW%E<S;RJ6F9+ ,YVGL&'JI*2LTRW\[RWD850@*'<\Q)%85@
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MSOV" ;;C]-M_\!KZUQ@=3C(P-\-]-O+^;&N09_3[9\MSG()SG<5$7*555@[
MXD$DC#&RZHN4E@*/(FZ5W.Y1,/4 $R@&5+O^D50P!T(.L)=PE)68$E&/,,9V
MR3D$['J=L=NQ.U9JTF$D>/\ .JX;?/X0 ",]1Z]!M\A:T>X[=MQVU;U>=.N_
MKT_O_!Z]>-*C;?8[@Y[].V-^N<[=?K7T* " "&PCN.^_;\/W;"'?K^W7G!)(
MW P,$?S[[C;[T) Q^@[=^F?3R^H[WCQ'5UI"9+.K)&*QBQ,9$QB[$6>" E*!
M=PV$$BB(J"'0!V 1 0U?64)>3Q"#RJ3@G8%NF 3Y9/GZ=*L;V;EC,8(+.!G!
MR0O?.QV]=L_6I3==Q]^4.WL(^X]O8?IWVUEST_\ F)W/4#H._<>O3/6L8#Y
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M[A[A:VT_2KB^L-*01QP6-K+-'$?#11&@4$@\OP[NV 7))8DDU ^WN1<*&13
M_FJ'\LA! P'%4QO+!/E, &*<3CR\I@ Q3=! !WU8[A@H!#<W)C'4@X'PG_-G
M;![X[FMQYT6(R!U,?(7YP5*<N"0P/0CE(;(.^>8>57#XN>&X].XD<,85Q?5I
MD;5=\5X E'=8,HJ[E#Y#N%>8*6-N1-4"';'4ER+*J-C\I6R@K?> O0,YJ>G"
M'4K2TM8B'DMK1GCR2?&=?\38[[D;CY[[5RSA/BMM0X5UW7-9O8FMK+6>((8[
MHX6-=/M9V%KNH/,!$P4-N6'+YYK?>QC OZMC7'M8E! 9.N4>IP,B)3<Y1?Q$
M#'Q[P2G_ ,X!<-U! W^<'7WUUV%"D,2'JD:(?FJ@'\Q7P3J,Z7.H7US'M'<7
MEU/'D8/)+.\B9';X6&W:JXU4JSK\*'\M,ZG*8_(0Q^0@;G-RE$W*4/<QMMBA
M[B(:#<^7J>GUI6AIQRY5L>9>*#*UZLE7<T]ZXL+N#90;ULZ:ND8JN.%XI@LN
M5VFFHHHZ10%R94I03,"Q>01  $?M+@33;;2N&M/M(+J.['A"XFEB='42SJ'9
M 4)QRDXY3@[$GO7$N(+F6[U2XEDB:+#&-$8,#R(2JG<#.1OMMD[&H&Y&K0V:
MNKMVY1._9G%XS*'03J)E$%$>O852;@ @'40 .HZVBYB,T6W5,%?4[C&?4'Z;
M8%8^VE$4P'13E23V)V!Z@;'^V>E0V53.B<Z2B9DU"")3D.42F(8@B!BF =A*
M8HAL/O\ T#K!D$'<GKC&>A\O7?MM^N<VI!Z#&>XP>P(/U_48KX:]5ZZ5R7N'
M3?OT'WZ:@G S\OUJ#W&^XZ^6Y\L>8^8^5=MLU7=N46K5(RSA=0J2*29=SJ'.
M(@0I ^>X]1'8  -Q$"@(Z*"V H)+'"C.<]M_L?,9.3Z>"0H)8X"[L1MUW.3M
MU)R#Y9%3:IT#]FJ['11MA<))&5='#J!W3A0ZRX .P;E3,?RR[]1(0NX]!$<]
M;Q^'$L9Z@98CNQ.3MY D@'OD8!.!6$FD\29GQCH%SV4 _P [=]P*J8QN0AC?
MJE$P_P!(CMOL'38>^VWN(>_MV"AF(.%&?F%'3;N1CI]CD5Y +84=6VW[<Q^@
MV.1ON/R.U)P9<+-UX68V(Q_'5DDQQ#2+\U_1R#+-%G^/JJRGZ4S:V&K5YRB8
M&J3I-@@C%OII^*AIJ0(Y;LVJ3=)@LE\T<3\1V?$KSZI<W/A:"0MB^FVTBQZC
M<-;W3M:W5PK*2R\[-(L:8$480LQ/.IV465Y8ZC::?I^F\^NVI>YMM7NHWDL8
M8+FT)NX864E(F*<L'/+S&20.BH/@>I3QV2*^WDGEK<OYU:7KMM83^3(2ZTZ1
M=33QXLR5BI<<%1KMR1\G&MG[5ZL9=F50(YD,,Y="5-N*A]?DTVX:..U2.%8;
MBS:#3)[*\B2)5\598?Z[(H*&1HV1>5N4NXD50<D52AU>U69[Z22X,]I>QW.K
MV^HV$TEP\C(T,_\ X;B>3Q1"DL<C<R\PAC]W=SRH28F<2$0O!<.TZ]BBW6N4
M*ZY!@@I2UPG5YF0LJ(J+H^EL1+*4[NMNAD&?DQC&/52+*J.4Q,H;RB"M?202
MZO-/IZG39M5ATMXYQ$%LH+:19(WYK>2V/+<9B8LTDH(0@@@9VLK:4:-#!J?@
MZS#H<VK1S6_B\^I7-U (948W4-T&DM,2J HB*B0/S<X**S8PUI:._-%4E&2!
MCIN&JSE2731\@X=#B<Q#*+ 4RJ1BF3 %4@,) 3#D#?5M8S6<5][KI$LO#]]!
M(O\ 4(Y[@W&G77NPP$YHU!42.VTC, %+$G)&;S4H+Z6P%[K<</$FFW4#1Z;-
M! +75;,W3*S2!79B_(B',2HV75 %Y029/<&SV&D,\0D8T85&RRLC6K-"U6N3
M[PB$/*612*<*1P*_>$RJ"7I5555$5?5E0W52;*@!N7SJLN9GNY[O2M(,-V8K
MP:-<E[N^27PYWDCYF*S$!N95&1S!LXQ531+=WM_<;/3=;UU'L$GM#KEER6&E
MM"TMLBS<D?-;Q\R!'D9E^%XL \^*F+Q#U^<Q<PE\J<2U4^&5UVT@ZE6:9@^S
MN7DN]<N'OIUVC9B9JEZ&%;L%G3U^LF54H'*/. BJ8=>I^)X-.T]5X7M-0UVY
M2X\6X]ZTY)9@),!9BP9N=E<*,L!@=QUJ[T?V?S\3:\8.+]4T7A.RGLV2VF34
MW@M0;=2[6Z@HOAJ\?/A5SESD[FJ5OO#PIE#';RK</N*+*CC._-(=S(6>9F8Y
M\PL,8[B6+L&-I,91K*1#:%=.##-1J()+^I9*E5$X"4-7<FHV6JV#?^+I[&[N
M7M&Y-$O;6Z@$,I8NB,D#J',@"J#S; X[&L=8V&K<*\0QS\ C4]/AL=2\(\3Z
M1>6-PUQ#$1#+-;S7*,(DCP\@YD',0&88(Q57!'X=CFF729LN:KMBVSM(PS(M
M+H.,7+1TS:GC'@+_ !6P/U3N7TB@;E B<6J )-Q$3*J&/K2QQ)Q%:K/;Q6%A
MHNE-;BTM;.SL&C:*+!YC[Y*!.S/U +$#U(S74]9T/@G6A93G5M?XJXA%[)J6
MJ:OKFL17 N9V*E8DTR#-M%'$1AG55+@\I 7:KO9@X"[?:N*B&S1B:X5JIPL"
MWC7:%;4\Q6"A)]@@8%CRE0;&!K,%EW"HO^906WI5$T?++]PIM5=/X@@$+P:S
M)K=\A_PQ%;:FMO;B' )BDB:)VD+-N6+@@8QTVQVHZ).ELJ\/VG"^F2DO(UU>
M:$]UJ#W#2$B:VO4N(DMEC3X!&L+ DL2=]J;XN<H<.K_)C#!66F-B>9\0H$8Q
M^WU'CF[*32=6!JZD(\:Q%+M)%6=<-BIN)$6 %!%!$RK=90Q3' L\/7\CW>I6
M&CZM8Z//(4>"WOS&9Y%D#<@CGD"JWAJ!S9)&3GEZFO7$7#]W;Z-H?$NM\/ZG
MQ'I,,DT5[<:6TXLXGMGC$XNK:$N\2SN^(R0K<HR)/+P>$GADX4\E8Z?8[JF>
M[5E08E^YE+]49)1K!NV[F5E%7:S6:J;5,C%F7U*:K<5&::A 72./FE<$$"T!
MQ#/9"_T6\CT75KN.6Y2^N1#!,9))V8NW-&.0_BR&7 R,C!%7VI<,37T^C<8V
M-OQ-PEIMU:V#:%:^\7D"P6]A%&D21-<,TZ[*.9)&)Y6V!4[VGX2/"WR3@CCS
M+E2[Y7J-TQGCJN3;W%\2U>"C> EK&B:+0":A%5%#M6$%"/)!CZX@BG(K.D%$
MBHE3.4_+--X>:QU>2Z:6)XE$C0(-G5I3T*9V55R =^OI7TEQG[78N)N K?0H
M-/NK2]GEM8M1F<<]M+%: /SI/@>)+/,D<A0X*<KYR3MA.D^%*)RKD:<A[G/(
M-LC9 SRWH$X[D=G#]K9;KD%M5G4@Z34W4648OI45EDA,!U!1,ES%$P"&CR6C
MW&K-;2N5DFOC [G\2F24H3C<Y!.=\Y.!W-?2D.N6VD<&P:E9V(GLK'AC^I0A
M  CQ6E@)U0$?A!$8&03@$GIM6S).X%F+;QC</U/G,+SJ>%N&#&;&2QKF*.M+
MMBU6LS)"N(MH*9C4W!D'Z:3B,!(C,&:#HX,5EW#Y5@[%GKI4EHTVIVB26K^Z
MV$'B6]TLI ,WPJ8W3/Q @9QC.5SG!Q7QW:ZY!8\%<07-MK=O_6>*=3-MJFAR
MV2R.+(&>474%P5YHCS28)YRGQJH0,G-64[6=KE]-*5:7/&+T,TX:R?BE5VG&
MGO\ 1;54FDN=LDZ-#/+!"/HIO+()*E,7SV"CL'"8EV. DV*8!'?60TJ^.F:G
M8:@%\3W.[M[EH^8J)5AE21HR1V<+RGYU;W<'O-M/;\W+XT,D8; /*70J&P>Z
MDY'J*T',O8MMN$\FW;$MY;MFUMH<T>%FDFBX.6BBIFS=^S=LUPV!1K(1CQE(
MMA$ ."+I,JA2J <H?<&C:M::WIEEJUGSFWO(O$CYQRLI5BDB,,=4D5T)W!"Y
M&017"[VTFL+N:TFY?$B)4X((*D<RL,XP"I#=L9JTTM$1\VR6CY%!-PV6  $A
MMMRB'Z*B9NY5"FW$I@'F VW4 WWR#(L@(D!((/GY>@..HW& !5!'>-N9#RGL
M<@;;Y!\P<'U&V#YQ[GL*222IUH%VB\;B(F*W=&%%P0.@\OF<HD4V#H4.4HB'
M41$1UC)+%USX1# '\)P"!GSS@G[D[YK)17RD?XH(.,97) \SC;&<9WZ; ;=*
M._)=<A.*?P@P;#U.*R0$_$!YM]OV;>^J/ND_,,)G.WXARC)],G/[^55O>X?_
M -0 =0,98_/?O\\U75=PN[45(M87B:*)! PLV9O,44 !W AEQY2D*/8W*7F#
MV-[ZN([!L@RL%'=1G?).03T&<9'4G\C;R7R _P"&"QQ^([ '';&^_3'3Y;8D
M#'1S2+:(L6#=-LU;DY$DTP  Z=Q$.PF,/4PCU,;KOK)J%C4(FRC&!O@ CSZY
M/GZG(JP+-(2['XCG?S^AVQVP?(;XKO  @ ;C].W;ML'3V^8CWT)!+8'F>O7K
MDG/?R Z4P0!GY=-QTP,C'U)ZUEK\,''?&RRD;MFSA1@<?SK%N'V!L36]67X2
MW5<G2;RZ1DX\K-P+DS9-8OD.#' $S*+ 4H<PB/(_:7?\)3-9Z/Q'/?V\D:B\
MA>RMEF8J^4P9&88!Y=UQY>5;?PQ;ZLOC7FGK!(C$PLL\C( 1AOP@$''8_/%2
M5Q5E.ZW[B@R0GQE\0N7<-9^H<Y)H8TQMCN-<R-47;,:[)*2!JW$)LU"3PL_+
M<NFB)VRC221116%0QU3%#4M6TZRL^'+!N%M&T[5-&O((S?ZE>LBWB2M.@19V
M+@V_."JMC="2 2 *R]K-/-J,XU2]N;:]A=O MX Q@9>0YY% (?&[;[$<I^>2
MK&<WX@N<\5Q%6FF-<QG7[+)248]SC)G&&RVYQVC(/$&<ZUQL@B+"M7*RPI&H
MI'4<F2AU7:CPJ!5DTR%YW>1<+:=>/-&\UW-"B.--0>)8BZ**6B:[)YIK>&0G
M( S)@+GESG8H7U2YA5"$B20L#<M\,_A9.&$&,*[KC&3\.<XS4^\<X*Q;BZEP
M5%J]/A0B()L9(B\E'M).4D7BZAG$C+RTB\16=2$M+/5%G\D]<*'5=.UU53CN
M;IJM]>W&H7,EU<N7ED/R5$ PD<:]$CC4!408"J !64@@CMXUBB&%'4G=F8]6
M8]69CN2=R:K@*73BB!BU.M 8! 0$(*+ 0$!W 0$&NX" ]0$.H#JTJM4+K;@3
M+>%,F2N6>$-O5G,5D1ZX<9>P+;I1: HLO8%D#BWR72WS5%8E4M1UTTD+.R;M
MPCK*W5!XLD20;E6-C'M9[>8SV/)RRDFXMG8K$S$'$T> >23( <#9QN=QFMSM
M=9TS5M/CTSB<W"RV**NEZU:QK/>10*0#I]VC%3<VH4EK=BW/;D<JDH<5B2R9
MQ)>-BYX@\D5#&V%(>2B&D2[1DJ6YKL>[IM99!99F.@W54NCXS8MO)8*L6'F7
MCY0Y'2;Z0?QZC-NC&H&/A)[OB(W<R06R,G*08V4%(P'8(4DR/$YX^5F[\S%=
MN45T_3M ]D(T.PN=1UB:*5G4I>)/(MW<2&WBDF2YM$#>ZFWN?%A1!E2B)(')
M=JUD<C85RQPT9!7Q;FBGR5&NL<PC9-2'D@3-YT9)(BHQ?LW"!U$';1<"*H@N
M@H8A735RW/RJH*%#G5[97-E.T5S$T4@ ;E.,%6&Q4YW&<@XZ8-?6'#VOZ5Q%
MI\>I:/>1WMF9)(O%CY@5EBV='1L%'4%6PPSRLI488$5Y5IL$_*$#[@( /00#
M?<0__MMOMUZ] WZZL@"#GML<'?OCJ.OD=L_+I6R@AA@#Z'KT&?F/YWWDA6+8
M"()[*;[  =^P;AT_$.W[/<>_H@YQU&0!OW_X+>0[_2FZ%@>AVP-MSMC)[9'G
MW[XJ\3&]@5,/SPEV -MS==P#?[H;_B'N []-2&/_ +3L3GH#G?IT)[?/?IFK
M-[-&)8C<'L-LXZ]"/(_;UKRI>\ H0VRGMON)MA /Z@_$?^<$G&^"?S&1\_+&
M-B-^H->XK:./ &//Z_7<G([#K5BK19BJE5'S=]^8-M^V_0>@[#O]>O\ 6.AQ
MOT&#TZYW\^N/[X],7JICKL,C![DCJ2 >@]<]NV,1JM<R42*_>ZB @ ;]@'W[
M[B(]QVV#;\>GG)Z'8#IWSUR=MMNGK7F1C@#;&/7YY[]3UK8F_P"C?5('+GB:
MR,=B!N4U,IR$B=/J!B@_F%FZ*A@Z!RJD,J!!#?H!O;70^"(0$O9L;EHT#>F"
MQ'W/\Z5\F?\ Q(7Y:7AS3A)D*MY=M&#MN4A#$>F"!GU]#6TYK?:^7::4II2L
M)7C5<+MFR]AZLYFJ"K,ZV#"663M<.H5%!Q)5B>3A$G<JV<B0#.',&:(0,=HJ
M<?,9+JJ([';>6IUKV2<26^CZS+IUVK<FL>!!!*.9A%<(TGAJ5!P%E,I',,<K
M $]:U'B[3);RR6XA8 V?B22(2!SQL%YF![E>0;$[C.,D8K4Q 0W[=3!U -A#
M_?\ 3V#^O7U3@XZC Z$@@X_N.XZG[XKE0(R=NHW P1MM\_3RZ^IJA;?0HBVD
M\U?=I)IE$J+]$I><Q0WV3<$[*I@8!V$?O$ 1$HAOTMI[9)AG 5B,!AON,;$=
M^O0YQOOTJM!<M"<?B0[E3U'4;$#;;L,=1V%6"D</VMFH8&J;612Z@11!8$SG
MV =A,DH "01^[TYQZ[AN.V^L>UE.OX0''4L#CJ?(Y.WS[5?I>0MN25[8(Z 8
M_P V1Y]=_2NHTQ/<G2@$.P3:%$0W.Y7(7E !'<=B <1'EZ@'01$-%LYVQD =
MB2<#?&3WZ?EGUKV]W"I.'SC?X5SDD=]\^>_S\LU>:G8IC8!4DA)J$E))(0,B
M42;-6YPV$#E2-N*BI.FQC[@!@W H==[R"S6/E>0\S@C Z+GOCSV.<G;/0^5C
M/>M(.6,<JGKOECG_ +QC_JKN@&VX>_S'?;MTZ_3MN&WX:O">G8'J!CMYCU[
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M '.V &8_ZG=L^>2<=*^0+J?7O:)Q8WA">]U'5;UUM(2Q(M[<NS1QKU6*"VA
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M<+ 8Q Z;B5-/<3]-]PY@ ?8>G65LIR03A1OU(Z?GG&PVWZ^=0][  0"7.<8
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M$V*T40L@W1="J[23%%8-L9<76H6T.J7&H:JW"G$<<3*D-O: 65Q;1!G@8QP
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M;<4GBW6#J"P&V@CA2"WB9N=Q&NY+MTYF8DX'3..U=<T/2AI%F+8R"1V=I)'
MPI8_Z1DX &*F:K4ZLO-(V1:M5]:Q-@$&\^K#1RDT@ IF2$$90[87R0"D8R8@
M1<H"F8Q/T1$!U47$XB, GF$+?BA$CB)M\[QAN0[[[CKO65,:%@Y1"XZ.5',-
ML;-C(VVZ]-JJ#5&O=-*4TI32E-*5K2?]($X.LMY;)B'B&Q%1W-Q;XWK5RKF4
MTX1)):P,*YZB-GZY,"T$Q%Y"*B5B6<CHC;SG+162143;G366.EI?%VF7%VEO
M=6\9D\!)4F"#XPAY71O_ '*N'! !/Q# KZ+]@O&6EZ)+JVB:K>K:?U&XL[C3
M3-D0/<*)(+B+G&1'+*IMBI;"LL3 L"JAM5.N68" 3=3<# 7J [;[^X=?KV[]
MQWUS0@CZ=#V^A_.OL&.7 &-]N_Y _3H>VV-MZO/#6SD*42*\W;<.80-W[#V
M>X=?V_7498=!Y8[8^?0@;]NOVJ[60?7&,G],]"!Y'KL.V*K=&Z&*'\H)0V
M'F-^W??]NX]_;0?+/GOCIUQMOY??N*D@'RZ]Q^??R&?[UUGMP$X"'G";OW'8
M-Q[;]?P^7;\-3GRV['?K]MOWZU)"CH=@/+Y]>AZ?/<FK;35I+RF$RHB/WAZ#
MN =Q#<-]Q]^GR =]1UV/3IMU/GGI^M4F?&PP?KU._3UQTP?[FJ0J5,R+FZZQ
M>.\6568N]SGE%214!"("N[<BBD958YC'.1!LW23*)EG+I5%N3< .J',&]S;6
MT]U*(8(GDD8$JB?B]3Z#;<G ^XK"ZOK&G:-92ZCJ=W%9VL0_Q)ICRH.8X
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MHJ+XKU5$%0362 Y2EVN.?77X?;0+K6[FYLY+-;01SQ03K! J@)#;-,CO"B*
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MU3-YRJD:/V9907#5PHDJ4AR=2\P (:MI&H+I=Y'=-"LW(''(2%/QJ1S*<8#
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MP![_ % .FX:9)SOT!SV[;'8[[G&WH>N*8&PQY$9WVSN-^FPS\\@=ZY#OM[]
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MII2J/D<?TB6GXVTR56A'ECB'!'<;-+,$!D6CI, *FX2<@4%/.3   BAQ,8@
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M13 J:2**1"IIID*!2$*!2@   :HLS.S.Q+,Q+,S$EF9CDDD[DDDDD[D[U[
M        P !L  -@ .@KLZBIII2FE*:4II2FE*:4II2OFJDDNF9)=)-9(X"4
MZ:I"J)G*/<#$. E, ^X" AJ02I!4D$;@@D$'S!&XJ&56!5@&4[$, 01Y$'8U
MXTE5ZU,)-D)>O0<HBR'=FE(13%XFUZ@/^3$<(*%0#< $03 H"(!OKRZK(<R
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M%3J5+'2E-*4TI32E-*4TI32E-*4TI32E-*5&>W<*N.+B_3D7KJQL5C6":GI
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M?;ITZUQ\7;?J+_PI_P![IX39QE=NOXL#Z\N*CQD\F^P_>OT66;&,4H$6W,(
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MU'H'OTTJ/K]/Y\S^=<"(?ZW4>FV_N #].FP#V 1W'?I[,#&,#'EVJ<]>O?\
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M$L<@ 8\M\CESOTZDY[^IQ21%5=AG)ZY.W7&?GTWZ'..]9+O?;?V[[]=Q'?\
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MV_;Z;>XO'3R;[#]ZGP6'=?NVWRP*X&$5-OS"W'<2B.XF,!A+V$0%$.H>P=0
M>H==/&3R;[#]Z>"V,9 ^I(]=L#MZU^0@UR[<AFQ _P!43@.P=@W!$-^P?( V
M#ITT\=/)OL/WJ/!?IE<=AD_M7[&&<_SB [#T$14Z=0'MY?[-]/'3R;[#]Z>
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FJC(P8@C. H&^!T)\MN]58U* @X.6)V.>H'7(&^U=W5.JE-*5_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>66
<FILENAME>g164680g96s96.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g164680g96s96.jpg
M_]C_X  02D9)1@ ! 0(!>0%Y  #_[2'Z4&AO=&]S:&]P(#,N,  X0DE-! 0
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M=%!R;V]F4V5T=7!/8FIC    # !0 '( ;P!O &8 ( !3 &4 = !U '
M  IP<F]O9E-E='5P     0    !";'1N96YU;0    QB=6EL=&EN4')O;V8
M   )<')O;V9#35E+ #A"24T$.P     "+0   !     !       2<')I;G1/
M=71P=71/<'1I;VYS    %P    !#<'1N8F]O;       0VQB<F)O;VP
M %)G<TUB;V]L      !#<FY#8F]O;       0VYT0V)O;VP      $QB;'-B
M;V]L      !.9W1V8F]O;       16UL1&)O;VP      $EN=')B;V]L
M  !"8VMG3V)J8P    $       !21T)#     P    !29" @9&]U8D!OX
M         $=R;B!D;W5B0&_@            0FP@(&1O=6) ;^
M  !"<F1456YT1B-2;'0               !";&0@56YT1B-2;'0
M      !2<VQT56YT1B-0>&Q >0            IV96-T;W)$871A8F]O; $
M    4&=0<V5N=6T     4&=0<P    !09U!#     $QE9G15;G1&(U)L=
M             %1O<"!5;G1&(U)L=                %-C;"!5;G1&(U!R
M8T!9            $&-R;W!7:&5N4')I;G1I;F=B;V]L      YC<F]P4F5C
M=$)O='1O;6QO;F<         #&-R;W!296-T3&5F=&QO;F<         #6-R
M;W!296-T4FEG:'1L;VYG          MC<F]P4F5C=%1O<&QO;F<      #A"
M24T#[0      $ .__C4  @ " [_^-0 "  (X0DE-!"8       X
M    /X   #A"24T#\@      "@  ________   X0DE-! T       0    >
M.$))3009       $    'CA"24T#\P      "0           0 X0DE-)Q
M      H  0         !.$))30/U      !( "]F9@ ! &QF9@ &       !
M "]F9@ ! *&9F@ &       ! #(    ! %H    &       ! #4    ! "T
M   &       !.$))30/X      !P  #_____________________________
M ^@     _____________________________P/H     /______________
M______________\#Z     #_____________________________ ^@  #A"
M24T$"       $     $   )    "0      X0DE-!!X       0     .$))
M300:      ,U    !@             ".   "=L          0
M               !              G;   ".                      !
M                         !     !        ;G5L;     (    &8F]U
M;F1S3V)J8P    $       !28W0Q    !     !4;W @;&]N9P
M3&5F=&QO;F<          $)T;VUL;VYG   ".     !29VAT;&]N9P  "=L
M   &<VQI8V5S5FQ,<P    %/8FIC     0      !7-L:6-E    $@    =S
M;&EC94E$;&]N9P         '9W)O=7!)1&QO;F<         !F]R:6=I;F5N
M=6T    ,15-L:6-E3W)I9VEN    #6%U=&]'96YE<F%T960     5'EP965N
M=6T    *15-L:6-E5'EP90    !);6<@    !F)O=6YD<T]B:F,    !
M    4F-T,0    0     5&]P(&QO;F<          $QE9G1L;VYG
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M;&5F=$]U='-E=&QO;F<         #&)O='1O;4]U='-E=&QO;F<
M"W)I9VAT3W5T<V5T;&]N9P      .$))300H       ,     C_P
M.$))3001       ! 0 X0DE-!!0       0    #.$))300,     !=,
M 0   *     D   !X   0X   !<P !@  ?_8_^(,6$E#0U]04D]&24Q%  $!
M   ,2$QI;F\"$   ;6YT<E)'0B!865H@!\X  @ )  8 ,0  86-S<$U31E0
M    245#('-21T(               $  /;6  $     TRU(4" @
M                                                       18W!R
M=    5     S9&5S8P   80   !L=W1P=    ?     48FMP=    @0    4
M<EA96@   A@    49UA96@   BP    48EA96@   D     49&UN9    E0
M  !P9&UD9    L0   "(=G5E9    TP   "&=FEE=P   ]0    D;'5M:0
M _@    4;65A<P  ! P    D=&5C:   !#     ,<E120P  !#P   @,9U12
M0P  !#P   @,8E120P  !#P   @,=&5X=     !#;W!Y<FEG:'0@*&,I(#$Y
M.3@@2&5W;&5T="U086-K87)D($-O;7!A;GD  &1E<V,         $G-21T(@
M245#-C$Y-C8M,BXQ               2<U)'0B!)14,V,3DV-BTR+C$
M
M %A96B        #S40 !     1;,6%E:(                     !865H@
M        ;Z(  #CU   #D%A96B        !BF0  MX4  !C:6%E:(
M "2@   /A   ML]D97-C         !9)14,@:'1T<#HO+W=W=RYI96,N8V@
M             !9)14,@:'1T<#HO+W=W=RYI96,N8V@
M                                            9&5S8P         N
M245#(#8Q.38V+3(N,2!$969A=6QT(%)'0B!C;VQO=7(@<W!A8V4@+2!S4D="
M               N245#(#8Q.38V+3(N,2!$969A=6QT(%)'0B!C;VQO=7(@
M<W!A8V4@+2!S4D="                             &1E<V,
M+%)E9F5R96YC92!6:65W:6YG($-O;F1I=&EO;B!I;B!)14,V,3DV-BTR+C$
M             "Q2969E<F5N8V4@5FEE=VEN9R!#;VYD:71I;VX@:6X@245#
M-C$Y-C8M,BXQ                                  !V:65W       3
MI/X %%\N !#/%  #[<P !!,+  -<G@    %865H@      !,"58 4    %<?
MYVUE87,          0                        */     G-I9R
M0U)4(&-U<G8        $      4 "@ / !0 &0 > ", *  M #( -P [ $
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M,4HQ@C&Z,?(R*C)C,ILRU#,-,T8
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
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M(" @(" @(" @(" @(" @(" @(" @( H\/WAP86-K970@96YD/2)W(C\^_]L
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MJSP&L3;HZ-W3@>H@ONAE1+"F$UEM=W5W/H/[K>%7/YN7-YLYLLZ!B() X$@
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M>VG (QI81B0\JZ9MFO2(TQ)Z_L>5SANVJR&307NSY-OIK&G!$^^J'2%P:GY
M7<N//7P*N(CLSKN-:0K2PJ<J%V@1AT2KLTX#& P$O#Z[B':%1?D/\'BS 5NJ
M&9/)+2BAYJ1!U _85['),Q7B\,#A(SN!T2W;8*Q)XI<73>7MNB^R6$\A->W
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M>) X4SRSY49QG&>2_(#.,XSWXS<UC?J\,X^$GISZ/C[O[^[J?,?0OV1T7O\
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M\[:&YLZ+A1D^0&%@T/&BD7@)^^/CX_B:LG*%@0"3,#-+!006C,0,H@$D*2Q
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M8+AM_P##<*N8\]MM!X5^<]D9V=^?3QQ%^OMK_GO_ &_+T_;GY5_:]S\-@O\
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M38Q,6KKK<?#W+C6 C7;4-U=R[;@VKC6SC0K@C,;&F?-J8Y)/J?:36ZZ\)\7
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M[L*;^/I[O#O\/E^3T9[^[N[F41(58/,#3:=>7#GN-YF:C;0=O^':1PG>.>A
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MW?'W]XJ(&@UXP!OP/\03N#RI!\TZDB.,'G!GU]T["*K[>MGOQA=7/Z_;-O\
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MJH">ID=A^=FF,*2XF1@)F4MOM']I;6Y&_#-$\8G2N>-PPPEY+0<N&PN!Q,D
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M'_Q=#^?7RLPYCOJY'^BW<?"GG 4I])T/^3_G=#T_)Z>F8<QWTR/]%NX^%/.
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MH1QN*>./9F5.1UCA'KUWWGU\(&@XR3\]G+!! &12D@L<P+L\D,S!3+1"!%@
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MY! F-*O(BZFD$.C0&Y7>63*QM3/O@!FSD./T&*D$:%2"&&X(,@C4:SKK/""
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M;S7NW,JH7*H%B% S%GESBX_L>JK% 28(3;<RC[21D[S<R9A$X+4L0C;D/?\
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M*/.>D<'O]\ ?83V\JA($1!XF9W.^D ?S_G^<<3.5.._OXS\@N[XL>1FQ\_\
MPUC'C^S_ &>/5/3G0IB.F.BIXGYQP?LUZ\G3CJ?X5HD&-=1&NWB=-SK[>(KG
MB=RHQCQXT<@L8QC'?G-,V/C'Z\]^8W\7Z^_'H[_CZGSWT+N>F.BO_P#1P?\
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M9WI""N"K*PXQ%0T>:E<''4Z4*#G+=G&!+F8YS\?'Q_"O/"R-3!C,8VUU@3K
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M%7%3MD/"K<:+)LFSD>%MR%U"2=O5D5%M7;=@)54W%%B3%[J6R@?X,S$:",Q
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M1&>2D@U%CXHLH1>R%51C'AX0*V]SA&+(>C6S20P(*D@J1&4R25RP L,3YH
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MNP"SQC649-J-7;B%TDA3[HNK7]=Q!*.++O-'M/Q'A^9J@D$$$@KJ"-"#,S/
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MCQ!O,C5]F8D\QYF6>\E'#37DA><G/VT?GQBKSI!I?PF)P:JIQ)CDAF<I2@!
M_L)ADA2K: B841>F3XW->6N]_I2G2E.E*=*4Z4ITI3I2G2E.E*=*4Z4ITI3I
#2O_9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>67
<FILENAME>g164680g97s97.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g164680g97s97.jpg
M_]C_X  02D9)1@ ! 0(!>0%Y  #_[1SF4&AO=&]S:&]P(#,N,  X0DE-! 0
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M=%!R;V]F4V5T=7!/8FIC    # !0 '( ;P!O &8 ( !3 &4 = !U '
M  IP<F]O9E-E='5P     0    !";'1N96YU;0    QB=6EL=&EN4')O;V8
M   )<')O;V9#35E+ #A"24T$.P     "+0   !     !       2<')I;G1/
M=71P=71/<'1I;VYS    %P    !#<'1N8F]O;       0VQB<F)O;VP
M %)G<TUB;V]L      !#<FY#8F]O;       0VYT0V)O;VP      $QB;'-B
M;V]L      !.9W1V8F]O;       16UL1&)O;VP      $EN=')B;V]L
M  !"8VMG3V)J8P    $       !21T)#     P    !29" @9&]U8D!OX
M         $=R;B!D;W5B0&_@            0FP@(&1O=6) ;^
M  !"<F1456YT1B-2;'0               !";&0@56YT1B-2;'0
M      !2<VQT56YT1B-0>&Q >0            IV96-T;W)$871A8F]O; $
M    4&=0<V5N=6T     4&=0<P    !09U!#     $QE9G15;G1&(U)L=
M             %1O<"!5;G1&(U)L=                %-C;"!5;G1&(U!R
M8T!9            $&-R;W!7:&5N4')I;G1I;F=B;V]L      YC<F]P4F5C
M=$)O='1O;6QO;F<         #&-R;W!296-T3&5F=&QO;F<         #6-R
M;W!296-T4FEG:'1L;VYG          MC<F]P4F5C=%1O<&QO;F<      #A"
M24T#[0      $ .__C4  @ " [_^-0 "  (X0DE-!"8       X
M    /X   #A"24T#\@      "@  ________   X0DE-! T       0    >
M.$))3009       $    'CA"24T#\P      "0           0 X0DE-)Q
M      H  0         !.$))30/U      !( "]F9@ ! &QF9@ &       !
M "]F9@ ! *&9F@ &       ! #(    ! %H    &       ! #4    ! "T
M   &       !.$))30/X      !P  #_____________________________
M ^@     _____________________________P/H     /______________
M______________\#Z     #_____________________________ ^@  #A"
M24T$"       $     $   )    "0      X0DE-!!X       0     .$))
M300:      ,U    !@             $B0  "=P          0
M               !              G<   $B0                     !
M                         !     !        ;G5L;     (    &8F]U
M;F1S3V)J8P    $       !28W0Q    !     !4;W @;&]N9P
M3&5F=&QO;F<          $)T;VUL;VYG   $B0    !29VAT;&]N9P  "=P
M   &<VQI8V5S5FQ,<P    %/8FIC     0      !7-L:6-E    $@    =S
M;&EC94E$;&]N9P         '9W)O=7!)1&QO;F<         !F]R:6=I;F5N
M=6T    ,15-L:6-E3W)I9VEN    #6%U=&]'96YE<F%T960     5'EP965N
M=6T    *15-L:6-E5'EP90    !);6<@    !F)O=6YD<T]B:F,    !
M    4F-T,0    0     5&]P(&QO;F<          $QE9G1L;VYG
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M;&5F=$]U='-E=&QO;F<         #&)O='1O;4]U='-E=&QO;F<
M"W)I9VAT3W5T<V5T;&]N9P      .$))300H       ,     C_P
M.$))3001       ! 0 X0DE-!!0       0    $.$))300,     !(W
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MTW7C\T:4I(6TE<34Y/2EM<75Y?569G:&EJ:VQM;F]B<W1U=G=X>7I[?'_]H
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M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
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M 0$! 0'_P  1" $7 EX# 1$  A$! Q$!_\0 '@ !  (!!0$!
M  8'!0$#! @*"0+_Q !K$  " @(! @$&!PH&"PL(! \$!0,& 0('  @1$A,4
M%1=5"18A4925U!DQ4E>1E]'2T]88(D%889(:(R0R0E-4EJ*QU0HS5F)Q<X2A
MLL'7-#=R@8*D\/$E0T1GX28U-CA'2&5UA8:CQ,:V_\0 ' $!  (" P$
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M/!OH[^P-E_RJA]QK'??=OVIN/UZI^WQO[O+Y/W,=W/=?]['<[W#?GIY)S_\
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M4.EW9B?<\<;6T1*T27"XC1F"M2>*65PD]G&#%VB*2BP:,!,0T)598T=BXC<
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MVVQX9VSX^V_D4J9%W+>J,$\.:CIZ@CR9P3/&#\A*SD?N^37DWY3(56KZ,U@
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MI]"'OJYV0ST3C",&$F@V?5C ^246$[<L<:7:,>0W&"A--I(<>:SY>F)@*>L
M.M8WM8GS$\K^7E?LU2QD'49GZF2A2Q(7GU@.9%KCG;D;7TS4:AG<DC:L5O,A
MZF- 9/E*KS(:BUQK'"D)ER-Y1"G77R=(ULNVX>,>3KK#X>&.F*WOBMRN)Y#F
MOZI\X^3LTXDG(!WY-F!DW)^W,<^3?[0Y_+J(T[7C$^U7 RG1!R/*H(FXRL6P
M0; 9.D%0:G/0JNJUD'@KVF -K(3*XCKWG-XR9!5SR3!"D(0**<(LY2V2XQO:
M]AC=@OZMQF;X\P>3<U %L@G$<:RWQD+SH"06<O93(W,N<L!B7[1<IR8DR>"C
MT@6 0,:H54<8$Z!J +!7U$, ;(3>7<9D)!&)K&.<+(3-O 9#KI/#O/+M')KM
M+MG:01!V*HL0191R([#V=HN;'R7U699223))<@JQ+M<@VNI-^8-A<'D;"XY:
MXWGZ)O8]*?B!!O8XZW&YC3^KAMB=*O&2Q11$Z?W-F+5?&0T:K=(=9,8TU9,(
MM8L1&$><=3+'JY8@VMSQYJ/)V<R /E/G.L^.P+W?#,J6N;<2P8@\_A656)_V
M0?(-9P!"A50 !*TRA:*JAG@6" +@PX%HY6V,DP@0#PQQAPD[:ZYGC'TCCFVU
MQF3&V<8ZR%46   '(  "P\PMV?NU L[$EF9BW,DDDL1V$D]MOEO;7&"JM66B
MQB+JY7P H<$9B&"3KA18M2RAV!>8X8!XXH\$FAB'$9UUQB8H4<F3RIH(]]<!
M5'(*H [  .5R"?)Y2 ?G /DUDR2$DEW)-KDLQ)L"!<D^12P'F!('(G4=22<9
M7 LHM,%5G#-+&0 ?GU.%ANFCM4&7!@!\!8<;%9\8!C\M# BHQ]F<)V#28IM"
M]9)(J8V)*X$BX/(7&5R0;BXRYL0>T&_,&^K'6HB #\5 Q!7K-BQCZJE2#BV!
M&(()Q(L+6L,^VQ5J^*RMK890OAKX;-VR>2@C^?6B#*H=6I^Y,<&Y4><)5@T)
M.\><RR@ C#9QO#!#'K)L5!=@ %NQ:W98<R?+V#^ 'F&JUXCE8U+',JBK<V8E
MCBH!-OA,2/("Q/:3K?4B5PD)>S3 JLA$Z#MEI080T6FV"%F@(QP^=(=-HY=U
M&T8.DN,:2Z@> ><X@QYK&0%L" +&Q! 'FL#]'E\W+LT;B E7+W%T()-QULBI
MO_M=:WZW/MYZV7956K->=-7\B1+6$PC2S/S&.H8:=>&%O.]</&6\VN@T,8\N
MA#8\^;&,ZS8E-FD\[Y4G6&*JK%K!5!9B;  "[%CY/.2?WZ*)'=0F3.Q5$ N6
M)-D51Y>8LH'FY#EK$;C\>$V[U3*LK$US7I=+#K'*G!W;")&;\R;5A&9N)G>*
M RR"FE[^;(QO(UCE-DTR1MY[;%DRM9<P+]@N 6)O>W86!/S\^W4KS<.^4G#+
M8?".)=4 QM?M$9"]GP>KV<M9,>G4T*-7 +5:R)$@*G9)81T:J"-*:5G;))ZN
M.,735<43MG?,Y0F(9ILYVS))MGQZS@G+JKU3=>J.1\XY<C\HU@R2G(EY#F K
M$LQR [%;GU@/(#>WDUJ/BHL+.>0-$@,N%?!# 8EQ0 3V!0N;:R'! $EZZ;'A
MB'Z:2&0B;RZ13Z_W1B/;&VN^74+'X)=0 3RR /, GM -KV\O;H1*L8OF(G8E
M0<@C,E@Q ["5N 3Y.R^L#5)^+KVL,N5/AIUD5.7A\!UC5 +"QW#ZA6-A7BIB
M&.@^?69=:LB)@$,=O)/@4Q?M*"1Y&L<N<*8W!9,6#$@L "&*,5-SY<64@'R$
M<M2D$\3".3BHRH+(Q8%4E0/8+?JAT8$BPN#UAY-<IE6>.T:$F0^J5<= ER98
MY1(JP 2.+/"-+Z8U&5AKYY)#\C;S1[3!BR'3Z2;0Z><S+Y&PJ@4W5<5NUL00
M+#M  [;>87\@UA7G=QC)(7:R7S8$B_)2Q(Y7YV)L.W7)9@T-8P4EME]5#:M"
M"*LE),!5QL#2',9S0Q OFDAP3-LSB@8L3%T&V=2XXC"R(M]=)I,9(0$$A03=
M5)L";W)4>>]B2!VV)UA>,RL%,C*H$C@%BJA<5#L.P8W4!CV7 !YC4@5*E*1>
M,K1KERE4)KMH(N5!C +QM-I-Y-]!A XXAH==I=Y)-M8H]<9DWWVSCRMLYSD
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M:Q$LN1K 1R4!:VF=2)8F!B<I88ZDF-C?#A1. <7C!*!"0A&=HY8S(]B+R-Q
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M0;$M^*VD6N1!X%9*Q=ZDD*7.4MKTI:)(P4(C:0A'4F,APX48BUC$&&-A:P(
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MO;B7M.<T2J\F5=O=0 #.3>/JE3C[WQG7$%'O2;-> ?HM(EA(J#-=UB55P]4
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MQ[G1SQ(VW>\:P ;)E:>RM]>,V([>1;7:V+-M:(2RMV9BRQSWR H6  RC(RN
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MKMY_SQO?_AIT_/-T7]"WKZM1_P"NUG\W^[^E;?ZVH_TVG]C[]Z'_  Z[>?\
M/"]_^&G0?EFZ+CLHMZ^K4?\ KM/S?[OZ3M_K*C_3:?V/OWH?\.NWG_/"]_\
MAIT_/-T7]"WKZM1_Z[3\W^[^E;?ZRH_TVG]C[]Z'_#KMY_SPO?\ X:=/SS=&
M/0]Z^K4?^OT_-_N_I6W^LJ/]-I_8^_>A_P .NWG_ #QO?_AIT_/-T8]#WKZM
M1_Z_3\W^[^E;?ZRH_P!-I_8^_>A_PZ[>?\\;W_X:=/SS=%_0MZ^K4?\ KM/
M#=_2=O\ 65'^FT_L??O0_P"'7;S_ )XWO_PTZ?GFZ+^A;U]6H_\ 7:?F_P!W
M]*V_UE1_IM0EM\!IW9ISI5\]ZX$(G@\,39$MEVDCCDSXYS#MOOQU%XR:8\/.
M8UQG&F<^1G;R]=]=>1@_*EL-1$LJT>[*K7Q#P4H8C]:PK&Y'R7-SVVM8GA*O
MH]54<[T[U%+(\=@YB:5E5CS*$M$MV46RL" 38G($#&_<2.Z__AGP;_G1<_\
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MAJD O&Y+M&Q X=E)F!E+$M=08S8  CD;6(YRE&VNQ(EC"Q1SHN7&R=13%:7
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M3+<JXB<#.Q/="QC ,1=2"!+<\P>1O>U]97IC-7O9&B:IC+!,E'<+SOQ606#
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M@^YP5LG?6O@;02@RI_04$"DRX$K+(^[..@<DQ"X)Q2S(%?FQ%B'+A#R'818
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M?MW3OZ?1AZX^[T\%!Z>?JP]_I[)8_?V_U;K]NZ=_3Z,/7'W>G@H/3S]6'O\
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MSC2/77&,8J\(*M#:FI-GI([6$<6S;;-87O8S5M-5U3V[+R5#L1VDZO'1.@D
M-97](J^7M::?I'O5-F>?/N7;*V@H(^WLAI(E'D46&H'R#V@+K0CE5T7GGN=X
M@-UCDR$PJ/._(;J&(C.NV(MRP+P\L^9Q8]LZ[;B!F+/.:Z^3K/%G;;;.W1=*
M'@ESK=EZ/;HA(S2IV>BIWQO<A)*&&F"L>8#2)*!^J; "BHZ(KP[;7T@Z3;3(
M!U2F\UFZ0L1V"6'>I-Q/#[ RT\M+(0.K*C=;7G-[ZJ#\*KV722VO/=ESIR1P
MZ07Z.%R"BO-GCV5[R9_M =M4^FS2HC)?_JI/.DK"?[P-@3+&5$/[;T2J?R=]
M*AP$Z.[50[FB924$]+ 2X%\GI9<0M1&H[;!)4[7B52K-YWO%3TRZ.31Q;MN-
M3+23RB&CWBBFG%'-*W*."KB=GDVZKD/**.66>FG:RP5;S'@+\P/NAG?-][^%
MASO^<6P_Z_3/'KO?@5T2_P##NT_4XO9UI#I!O@_^]:[]\[G^OXM\]]?NAG?-
M_.PYV_.+8?MG3P*Z)?\ AW:?J<7LZ>$.^?M6NY_XA^7\#_+E^X:T^Z&=\W\[
M#G?\XMB^V=/ KHE_X=VGZG%[.GA#OG[5K;?_ ([W_C?3[H9WS?SL.=_E_P#O
M%L/VSY/_ %=9\"NB7_AW:/J4/LZ'I#OG+_M6N\W_ +1)]_\ /Y!I]T,[YOYV
M'._YQ;#]LZQX%=$O_#NT_4XO9T\(=\N/^U:[S?W[_NOS_H?.2+:U^Z&=\W\[
M#G?\XMAQ_P#YG3P)Z)?^'=I^IQ>SIX0[Y?\ ^U:WL\M1)V]G9>WVW/VZT^Z&
M=\W\[#G?\XMB^V=/ KHEV>#NT_4X?YXWT\(=\[>^M=Y?^_?]]P3_  /\N6M?
MNAG?-_.PYV^;_P XMA^V?]?W^G@5T2_\.[3Y_P#V.'V?L[-/"#>_VK7?6)/O
MUI]T,[YOYV'._P"<6P_;.G@5T2_\.[3]3A]G3PAWS]JUP\W]H?Y?EL?N_AI]
MT,[YOYV'._YQ;#]LZ>!71+_P[M/U.+V=8\(M\_:M=RO>]0_+EY3>_P#"XYW^
M73[H9WR_SL.=_P#U<BV'_5Z9CIX%=$O_  [M/U.'V=9\(=\_:M=Z]_OOK7[H
M9WS8^]W8<[_^OD6P_;,]/ KHE_X=VGZG%[.AZ0[Y^U:[]U0X_J-/NAG?-_.P
MYV^;_P XMA^V?]?W^L^!71+_ ,.[1]2A]G3PAWR__P!JUWUA_O\ Q?6GW0SO
MF_G8<[_G%L7VSH.A71(?_P#.[1]2A/\ -=#TAWSG_P!JUWUB0?UY:U^Z&=\W
M\[#G?[WXQ;#]L_Z_O]/ KHE_X=VCZE#[.L'I#OG[5K_W5#_?\OS<N>GW0SOF
M_G8<[?+_ />+8?MGR?\ JZQX%=$N7_\ ;NT_4X?9^_Y-9\(=\_:M=]8?[_Y\
MM:?=#.^;^=ASO^<6Q?;.G@5T2_\ #NT_4XO9T\(=\_:M=YN<[_U/X'EU</ W
M<_\ ".]Q'*=5XFX_[H^=R7ME-QI,;-R#9=ER!./X2M[&YEC*VV@5)P\;DD;8
M\92-\0@B:3'%BCR\=NW1WH1L]!/7U?1_:5BA7JJ*.$/+*W*.&,%;-)(UE%^0
M%V:RJQ%L.];_ %$BQ1[I79,>9[HDQ4>5FL>2C[>0',@:]DO&%C;\<\?5&D'-
MW]^85M*(N97:[/F#JU6IGIIG=B]=,"]YI-B6)LDY.HL6^ UT&\2Y?%""(/#'
M\WU^VP5M94U2+'1I/*TB4M+#'%3TZ'DD,2*!U44!<C=W(+N2[,3W^FZ25%/!
M%"8>.T:!6FFGD>65OTG=B#S9KFPZJ@A5 4 ">>U@[W0)](F_4ZU.\<7Q\GT5
MU?X53^B1>L?V=/:N?[H$^D3?J=.\<7Q\GT5T\*I_1(O6/[.GM8.]T"?2)OU.
MG>.+X^3Z*Z>%4_HD7K']G3VL'>Z!/I$WZG3O'%\?)]%=/"J?T2+UC^SI[6#O
M= GTB;]3IWCB^/D^BNGA5/Z)%ZQ_9T]K!WN@3Z1-^IT[QQ?'R?173PJG]$B]
M8_LZ>U@[W0)](F_4Z=XXOCY/HKIX53^B1>L?V=/:P=[H$^D3?J=.\<7Q\GT5
MT\*I_1(O6/[.GM7/]T"?2)OU.G>.+X^3Z*Z>%4_HD7K']G3VL'>Z!/I$WZG3
MO'%\?)]%=/"J?T2+UC^SI[6#O= GTB;]3IWCB^/D^BNGA5/Z)%ZQ_9T]K!WN
M@3Z1-^IT[QQ?'R?173PJG]$B]8_LZ>U@[W0)](F_4Z=XXOCY/HKIX53^B1>L
M?V=/:P=[H$^D3?J=.\<7Q\GT5T\*I_1(O6/[.GM8.]T"?2)OU.G>.+X^3Z*Z
M>%4_HD7K']G3VL'>Z!/I$WZG3O'%\?)]%=/"J?T2+UC^SI[6#O= GTF;]3IW
MCB^/D^BNGA5/Z)%ZQ_9T]K!WN@3Z1-^IT[QQ?'R?173PJG]$B]8_LZ>U@[W0
M)](F_4Z=XXOCY/HKIX53^B1>L?V=/:P=[H$^D3?J=.\<7Q\GT5T\*I_1(O6/
M[.GM8.]T"?2)OU.G>.+X^3Z*Z>%4_HD7K']G3VL'>Z!/I$WZG3O'%\?)]%=/
M"J?T2+UC^SI[6#O= GTB;]3IWCB^/D^BNGA5/Z)%ZQ_9T]K!WN@3Z1-^IT[Q
MQ?'R?173PJG]$B]8_LZ>U@[W0)](F_4Z=XXOCY/HKIX53^B1>L?V=/:P=[H$
M^D3?J=.\<7Q\GT5T\*I_1(O6/[.GM8.]T"?2)OU.G>.+X^3Z*Z>%4_HD7K']
MG3VL'>Z!/I$WZG3O'%\?)]%=/"J?T2+UC^SI[6#O= GTB;]3IWCB^/D^BNGA
M5/Z)%ZQ_9T]K!WN@3Z1-^IT[QQ?'R?173PJG]$B]8_LZ>U@[W0)](F_4Z=XX
MOCY/HKIX53^B1>L?V=/:P=[H$^D3?J=.\<7Q\GT5T\*I_1(O6/[.GM8.]T"?
M2)OU.G>.+X^3Z*Z>%4_HD7K']G3VL'>Z!/I$WZG3O'%\?)]%=/"J?T2+UC^S
MI[6#O= GTB;]3IWCB^/D^BNGA5/Z)%ZQ_9T]K!WN@3Z1-^IT[QQ?'R?173PJ
MG]$B]8_LZ>U@[W0)](F_4Z=XXOCY/HKIX53^B1>L?V=/:P=[H$^D3?J=.\<7
MQ\GT5T\*I_1(O6/[.GM8.]T"?2)OU.G>.+X^3Z*Z>%4_HD7K']G3VL'>Z!/I
M$WZG3O'%\?)]%=/"J?T2+UC^SI[6#O= GTB;]3IWCB^/D^BNGA5/Z)%ZQ_9T
M]K!WN@3Z1-^IT[QQ?'R?173PJG]$B]8_LZ>U@[W0)](F_4Z=XXOCY/HKIX53
M^B1>L?V=/:P=[H$^D3?J=.\<7Q\GT5T\*I_1(O6/[.GM8.]T"?2)OU.G>.+X
M^3Z*Z>%4_HD7K']G3VL'>Z!/I$WZG3O'%\?)]%=/"J?T2+UC^SI[6#O= GTB
M;]3IWCB^/D^BNGA5/Z)%ZQ_9T]K!WN@3Z1-^IT[QQ?'R?173PJG]$B]8_LZ>
MU@[W0)](F_4Z=XXOCY/HKIX53^B1>L?V=/:P=[H$^D3?J=.\<7Q\GT5T\*I_
M1(O6/[.GM8.]T"?2)OU.G>.+X^3Z*Z>%4_HD7K']G7(&Y1-GDSIE4+KX:9V\
M<$39^]MKCP^73^GJ+;)$!<3R=OZJ_+\NIQ]*)G)!I(ARO_>/YQ_L_+J%GA8Y
MOY?/3LM/2>*."FJ?<U9O_& O'-6X8=B!C:1Y\8V"'BI.<D;C!28D$+OKL0N?
M2-A0Q]=R/WGVM)8SCN>]12A)/TZ+: S0.8B.<<^YRI-$S\G2BA=5O'7$B<D?
MA#OLL$HSV7HW-3F2'GP]QZ0E(ZN,3K\&:EV6GEIITC8-&^Z5*2,!-M:7Z(]^
M'?[R=QORDK[9^V-'&YY9,U4Z/76$N+,Q7M'X\1J6L5>ORQS!&.I5Q C1B>S$
M8@"AG#C1![$8+(![MT)Z#;=N.VR](ND<Y@VI#*88N-W/')' Q2:HJ9P0Z0B0
M-%&D;QR,R,Q<+@'\U_*5^4[>-HWF'HAT/I14;W(L'=-1W.:R6&:J59*>DHJ4
M@QR5!A9)YI9DEACCE11&7$C1=7D7?CWU]J'(M63]YM6,=4FU;Z33X9U^I .8
M5.9X-&+*H6&B10(F;))J3#.=7V6YLN8]X 9LI93ASX^R3]">A72?;ZF;HA4K
M#64H('#FJWA,H4\..K@KBT\<<Q4A)XPECE(.,J&,].I_RE_E)Z$[K10?E H7
MJ-NK2&?BTM#%4+!DO%FH*O:PM)--3!U:2DFXK$81,:9I5F'H<6,P'2U<X5%0
MG*VP(C-:</MY8Y@!X\9094&_^'"0/+'-%M_A:;ZY_EZ\&DC>&22*52DL3O'(
MC"S(Z,5=6'D*L""/(1KZFAFBJ(HIX766&>-)H94.2212*'C=".15T8,I':"#
MK'6JJUV\5MW3[<F L%9LBTI0\2LX-"062XV+:$@8B+?'AG7;3;QTWUSK+#)K
MI-#O'+'IOK935,]'40U5+*\%13R++#+&Q5XY$-U92/,>T'D1<$$$C55;1TNX
MTE10UT$=325<3P5%/*H:.6*0%65@?.#<$696 92& (\#OPCW:&1V;]RMEX_
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MUTTUVVVQC.&945G=E1%4LS,0JJJB[,S&P"@ DDD  7/+0 D@ $DD   DDGL
MMVDG^@^?V"?!N=E G:GQ7BP6\ >3FWD<((ZZ%;:QS2U13G&I2V@@$:YWTTU7
M[[:EV.87;S;)]G,>9C 4Z>;3YZZ9=)6WZOX5.[#;*-F2F7F!._P7JW7ES?X,
M(872+R*TD@/::"D%-'=@#-( 7/ZH[1&#\GZ5N3-<W("V[605WEK?FANY5DU:
MI\2X'5;L1286C^VWVP:!1Q,3@H(7@=;IJ:,756LP:2L;6,XU&7+Y@)<?'-/Q
M;5&T#98895JZO=\IA$RM%3T>WTQD)B1RT#U-9.7,LO#26*F1)U&3R1E5R$K#
M6.RF"*C"I<%7DGJ)<>NPM(L4,87!,F225FB:P5&#&.=W'%EJYEX>S0Z9-.$^
M-O\ Q<V';C%CASUR.M\@5Y_-:(]R"1=9MZSJNP\U"BWE(.R!@0<4N6;4:7K-
M5&\L6"$AC)$0P-L,9%;/M%\;96YWM:QUSFWSQT]3Q9;%!#4*5()#EX741\@;
M9DA;FP%[D@:Z8J>(>[N:\VGE+-<+I5PY6<5"P669;8>.G9]%'W/65PU"@-=%
MN1!B:OQB$(K9R*AR%3ML(<5!HWR1!F33$547,F)1Y2K/9XR8[XJ0N1(NL8"F
MW)B">=]<F:G;A"L 82QP)(L899E$S"\@9PH4D23,6 )!52 ,;<I*\X][V-R+
ME*A<6=<<,BY%6UJT@L.(([-;-:<Z[L9>" K*R-#EW-@+#:\!F'ZFCA0[3,SL
M./0-RKS%B31UGC,2P($@1P8LG"&I,(:_;VP=HL;\Q8N-5K-MMHLEC.31-)&5
MG*1<5:$5110; BU2%Q)L5ZM[1ZS%D3][JB\H$]8)OM@IZ;DRMFQV8YUQ$5&^
MH!MOXX)NP%F W(JK"#8&LR\BP*C-8FDVXNPRU16!VXRNP:285@D54+LBRKUB
M8R&C+QE\A=3R7B 'F?(%!"MJ*-MCPNT@A25X6!0).N,HCE$9C/77FXB+"Z\R
M6=V4LAY3KC'N)KG'W:%'2@+F+9.-NW_7C_D975['0])U;F93PH,]AS':&V*X
MWL.*[5.1E%*<0R-5"^\3UPIA/ @*-8:FCJ%CI, ^44&$@5DY,5A!O=L20J2!
M",@'*DV4DZPD]&\^X<5HBD]7Q8FD22S+G4%3>-2RIF\+2+=28LP+L IMX2O=
MPC_COC9*:\OE7.(YFNFUN:Y:<>Z<BKN#]1.4Y*+ _8AP-ZW,]WD]FP;&6O0L
M'NNDNDIQ.S*%XRTMQG9(@2Z7F?,W3B"&TN&1 *Y?W8.-V\YOEK7,E)'-4.$@
MD IH^&N$I@:J+0<7!25; >.*Y8IRL!B5!C7!$/=MFX4PCF2*S0;[(H-N1-IS
MN,9>--@]^,JE@$*K@ULN:V0W\;E#U_L],D@UK<H6EFP.:2FFH,<,8.ZLT,P:
MY7QES'PK8+;%5)82"2^7+$]:QQPM.K.W\.1:;AFS>)L)N.&XSY%V<8-"8<<!
MD7!PN W%)I=DZ[RJP:S7GOWPK6[<I"4"A;V@KC>+9@JY$&Y#5-;-6J=7)[45
MB3@K2.@\E%G$V'51:::GL,,-)J;2)W"946JU)!+ O*$CR,?,2<12RHN1\3XN
M4DL0R*UD0Y7V0NVN%(5"L4!EE,:S<C"T+*CR/PQ_:@980,"Z2,I,CC"VS9JA
MWQFL;&4HVOS!E5.1;4]XM<MW_%2E3G=OQ;W+UFL>LZL*\8X95:OV-WPOJX.8
M/(]; H,T/&XVK=@57')6'CK225S)21FB+-& ;Q5 6ZAC=5<P@DD7!N(U(>Y)
M=L"H#P562&-)U6.=F&,]')):3$$.Z+48@*2K<N,RF("0)*;WOMA0-6EXY'4!
M"/EWH/C#Q"C>^H6/(O"(%@Q8H]G_ "/&TG4T63G-LE(PUCWS#(MAV6SN%U8T
M(D$K"!=Y% 8 ?W2MB9(0Q892Y%8^.0;CE;ED$.HO+MBDE8H&8JV0_M#IFL-2
MR8'"'$-**97  \O6Q9[:K*IWAIWQ9#<:_&*"OC 'NVHC/@L&_/GB/<%9Q*XM
MK:P::JS:I&B@;YMV9PC&6[$M))LB* T:!QE6J4FXDL2PNAA#EELL;.6%BF(.
M1())Q.)%QK)DVYT4*858!25F6J:)%?)JA8E0W60MCP[$  $!@UM6=S !W6S\
MV$$THNW>R36L"Z"+J2-QMB0S7XKW3%G$V;72ZH3%%X*L&]8UJC(BNNT89FM=
MGW(@3:WZ'JR85/&NI?@X@!4$=SU9 PN\BXN6*8DJ5!">3/6O3-0"E D6/N@R
M$EI3+8=>+AFT<3Y1!<^(N:EAF+9<(ZI5,Q[WLVI9371MIGY56H:)86QBXOC3
M;@K,S+FNS!VEJSCWC MLM//XB5>JJZD5A2VI>\%)(:#:.)DMB+I4UN>!+&4+
M&Q(PX%VF<.3?K%.$+*H&0(YV:S'98;6(S(JQ\!GF4 B;NNRTT11$/./BK4,6
M=G;AE"H#%<D&^2%WW1@5@I3'RO-J')4R'J&P-N!8GKNZ1J1/CWXVE2W)4UKC
MDAKX;563XM7'30K6SQ'TV)$33B <D5ME*B7D4R5FAN7MXPY D"*_P>JW/*Z
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MNJ[IW.BVYXA0UT,]/W:AFCJ)*:6E%28GIU,M,%A/=?P8"V,A2J'HYN#O.DO
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M"2'$#ML!(DLGK(TLYJA083(UVB?<RRV-?8;37*X]K=<A:O:]8G:Q$]7KVID
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MUH+,\+C&K*]J8I1.&8*IHZ!/)6+3FD0^RX0@J.3SQ1DJS=8+D5'FL3VFR@D
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MB!*1R%8*^H&KU@4DKJQHI6C%QSJA#=()2K&V4<DB#D, (BF(=W"C*(L%!<J
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M+1-JZ:],'-5DOZB]L-?*9:6(X*PZ5MZG"L(D"KUP&64I!)AS+2QS2"1V>Z@
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MR.LA93>T9LO&CE(!X>1L8P$#EU4=4#'EJR+<W6)8)(8GB6-E"CBC)NYYH$+
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M=HUQU1L6YTDIAG@1)5 9E%13N5#7MD4E90;<\2<L2I(YB_!^Y1]]_P")8?\
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MH3^4-BG)N(7#C ^(]%2PT\,98^F]2Z& 8JPEB#'K8GB-)#&OD-D!EN2 QMV
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M1B&:GD9@" 2L1(!%B 2UP""01V$=NHKT;W%%*)6Q(A8,45YU4LI!5BH0 LI
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M[+9(WM5JS.^^TUJDJ3>[Z5U55@GS8'+,I2F3EVDT:!+DT*?">8B2Y/HF12W
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MH!1#VHIQNJ\AU18<NS65<]M==L8P8=AK?'[X-<L,2KQ'5<!:# IF,8D+!0'
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M._=/\3-_P>WIX+5GI%-_S?=Z>RIS[Q6?E*^S]._=/\3-_P 'MZ>"U9Z13?\
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M'7%5G9412S,0JJH+,S,;!5 N222   22;#7<W=(U9W941%9W=V"JB*"69F)
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M-D=HR67A7X>6+L =6CQOPWW*HN#^5Z0_M!FUK<NJ^74FC/ER[6&VM%86M?\
MCRK.Y#WSI\5][>(M<):_9Z16J44KW<;6N>I)+%K-)+;'#4+#(A8YDJ5)FD9B
M!B7!D/P,K,JLBJ1?,J&UKS5%$]53R)&.&JL)%6GB2,,0W#81  R<-B&=)7D#
M!0@=DY:R_$/;Q?5%EY1M5Y+8Q[7CBJ;CZJK#.4;K<F%23$\A<NV .N,'C [,
MS I+7[55(AK%%L4Q43>LTB-I*O"P>TE%3N&D9R;/%PU!E=RJF25L2Q/,JK*
MW,CF ;7)C45L3) D(7Q4_&D;N>*-9'$4"YA + ,R273DK @NM^0H5%VB]Q%7
MHLNE'M+*CW-N-7$]D#%YFOA:<ZK5W@CA*CE*P/$B5<JL+BT<>68!9>URD.V(
MUK8 ^!O!%%Z"/KK2U"IU&*.<0WCI""BPPI8&Y 8M&P$@&:@@W\VX^X44DOCH
MQ-&N;(330JPD>IJ9 QY!F14F0F)F,;LK K<W-T-.#>6V'"W#%>L([F[V2A<S
M/[XZ3S\T6.NV?>FGIN6U*%"'RNFB L.C%.-<ZZ+N+JRGTU6B%UJ6SNE<'K,^
MXP2F&%6R=HYF<@S.KX%9551*O6N ZBV79=<BHYZRU5,M54NF,4<U.D2L*9)(
M^()*=V9J=B4Q;A.?@_"L^ 8V%=1=O?=W$ $(RO[-U8@P*I\<KB/SA?U8')=6
M5H>-0['QBGK, HH?'K]X?7+IKIRJH%7V +9UH^@8X96RQB)8=SU5K&0E@%S8
M3.!*H$>486P$;$JX$J@,,@W:S!;>[-NN2L"HA+\.,TT3&%RTQ6=W))F10\?]
MG8NG5*VLB%\OP+Q'S/0N3J;33#[8AX_T*Y=Y@Y 0[66^6A(K:M>:N8G?%U/#
MY$<10+;<RN:+E\9_R4(,Q/8QL^$J_-9HIH;;H:ZS!%,DB(2RQ^-FD7)V )FE
M:-!(U@Y<3!I.9-X1ER<%HU=132PRR!8WE/ IX7X<*,RBFIUFD,2C*,1M3E82
M0 %J6$=BA"R)UV^]PAUCN=F3\CO$;K%E5%\:S1\DW+:LHEK7N#YQL]U+<T2
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M&=(94R+.T4>)>61O'"/&0YEBZ@L 1BPMS(Q))UK25-))4P2&-5C2>;,1T\*
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M3IE!K]6X>N:,M%=>S:\V."""@S8(8]LMC#9V4?%UV&BY"N7QQ'V:EH9[L[)
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MLQ<1(SD#C-T++)@*"LRJLQ%7$3;K$$BQ57("E83D_5&%C,@[3YR00P61VVI
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M/6TIX)7:C<E5IZ5FQ9XWO@2Q4.Q 4WLAMYOTB"4O\,<QRUKO1SQX\11&&>-
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M0[A+7SKQ=FP4(W#C)5ZJC$2CN2""\L;^(D"16J!V][/^!7'P??$7,3#G'F9
MRX\';:VI=D?9B+7JDI6"EQ,&>L;32.>)];MYUT12);$7'DQ8O' ,:FG;9ZZI
MTLWR'IUNNTIL^T315[1&FERX;3U4LC*R1DQDKP*4+(5GD*=661G2)$&N^] N
MB]3^3+9-\;I!OM/4;=W0M7 (A,M/1Q1JZ/(JRJ'[JKW>)6I85DO+%$D3SRRG
M7D3^$([N&/>5W'VGDS7!(E,6ZZU;CE.1OC.ZVH*IIL!;RZ:[R::&-9Y27+'6
M.66+5@>3@??T?S6NOT9T.Z.1=&-CIMO4J]0UZBNE46$M7*%XA%P"4C"K#$2
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M7;K:[!9:P&8NF"KK0_4A0.)Z"MP&%/$&S"D'+(C-\2V;2 E2V)Q=V91:RDW
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M\3S[UG;$VTV7C_#2/<T -\+$8V.;@C'@XV.7(C@1?*<>?PFRD*^JY^,!!S+
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M)=?0^0.0A8%I,UCI5OE.2C06B,=.QDM''=,>[,E\8YV#T0VVI&L4A,4V!20
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M[B_U>/3OU2?J3_03WFG@QN/QE)ZR7E\_B?Y7T]EUB_RA3])*^Q=._5)^I/\
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M$Q%PLG#9C&S $J' + $BX!U954591,J5E+/2LX+()XGBS L"5S R ) -KV)
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M:5@.99; $E"&!R3*)5)YVN3*.PD>8GE>V3;"IC5)+LP D#HRXR83NUK@$*!
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M%IU4>*BT.L8)%@MMRY)35=*,K1U]]<)XX:QQA8[#8VH=>-U$FB" 7KSYF7D
MP%8P'6A.5PMD)8%F>15 "JS'JQLS$ VY"Q)L+FVI"QX=4H7$OXU0A")%"\C%
MF9(P>).B(I87!)9@%).*M/P@PVJ!B52.+GLSB>BD6!!K;MR5X8MI&XZ2\G&U
M:W86A% (RU==<;1DJ"+&/<2#PL$1U@>IMT=O88:OZIX<3$X$KE< ,(Q(5:P(
M6RGF"0]Q?$*RN91[.<P)IT"B4*P3FQ0S&%72Y!8/(  0A0 VS,BM&LU)[W85
M+!OO8.([&LJJ&P84-;*-9:\TFA7[\T6S@.%M A&\A@5N1?JF43$MBW\_BJ$1
MMI9HFVNM=EGW: 3E$P16L7#*>7&: ''D3=U) M\#F3?JZI&UE@@2H1I'3)(R
MCK=NYHZK$N;J/$R#K$VS&/9UA@UW?T$S5%,X.%.0AME%.M7)C\9UY58W!XYJ
M22@6,YXMS:E226P,Y%E^&%A5K1]ET[M66.%8#4)2^RDX%<"I;@R#%'D8,"A$
M:"-BP# 9&T@  Y7')BI#&9VDJP4U4/7D2&,J,PTSM,H0X,V !B)+-S"L+J'5
MD%AS]TS.O<4);W:./CF%FM7-_)?#E8J5*T>V+TLFD73D]2*P,RF1/7T<>*SQ
MFU/9R+*\VDW8Z8S  * 5G*^?=)6(2/&2S321*J7;X#R $V!:V,9O92;^0 \J
M>X%>I:&.8*B4T-0\DI5+"2*%B!DRI?.90H9U&)L6+#GUJD[[.4\7<BR;T->)
MPCF!8S6HO4;<SE\B!IQGV^OTB X$5M*,.^=W3N2IX#' *=E\7UJ<T802P%;2
M&;ZW=TF>6 $'(@8DRF\4+!2 ?A%ZB,&RDJ 0 QO;=&TP&+ 3$U/86+ 4X(FJ
M4=P<?@K'22$7;K,W,IR M9WWQG$<?<CVFG\2.(V_&U&LCRS"WUN+1X$UE#)Y
M835M="GM,5=M%D4MW7$S2:;(ZY)8LJ'*/4)%,\S8%-;N:L)21DB:\:,S<0A
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MPML5BTW6)W)XRE:8(,L:-Y@@29O6(H4A'8LTB*%!8EDE2(7"@M8EPW($A00
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MZKQ0YF'.4KCX;5Q8(.X7L6U[*JZ<%LJLU4&<+"R[WR ?$*.R#&DV+N9[C73
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M;RA3.(Z2'9:36*RRK=@?/N,$:8BL1\B#(MN/5:9K:ZSL5(QQ6YU>*WL5&-C
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MB16E>=4XI"AIB2)5<@G .64YPD!RH!:+JL2HM ;?W ]IA[OC]PZ7(+F:$R)
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MC*&5"<FH8USDIC2QO(SEXI8S.PFJ.]G8AP%RUV=<6\FI^>^3:JPHZUIM8*I
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M/DBU6$%SR60?  TFO,AX(I$=:T,**0A="5P++@#P\2O#^!8K9CUF!D)L3(2
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ML0V\[,619H1(7#4W6K!6LJG&%.T3;9L54<S)X"%7$M5DE<5:9!;!RIGOJVQ
M!N"0\8:B@9LB#?JWO@UPJQH!UD;'E$O63%P2UF -M23=:N-"BLJJ<B,<UQ9G
MFD+=1URYS.,9,XR N2,5!UGS^T;C(T:OCPM+NJEK*)!7%9ZMV!"?HIKZ;F2O
M1P[S3IB=//,$G.U_7GEPQ0E::DJRU<RUBLA,VD:6,A1=QBJJ"&%[*)EMV'M6
M>12>VUB""+Z@NXSJ7.,3<1WD8,I(R=Z=S8!AR#TL14&XY,&R#$:F'%/!*?A]
M616*Q9'4U-*$=9FK)2ZK+08W;YC@LQPL"JB"M5ZN#Q":Z@"5VK5U&@CVW+:S
M@DN#S#II10"$8JS8$-U2% R8W) 5550!R"JJJ!SM>YU545;5+"21%$H*VD!<
MG%%L%8R.[.;]8N[LYY*"% &H$#V:\2JZM5ZJN,N0@]*F4'U5IHY7RMDSNN \
M8"UQ_#(0EF7DLD1?$-+<!Q,%QBHAD*;HU6L5ATJ[$!21!%0%P$L5((N"HC"L
M+@BZ\)".5B0;BQMJX[E4&220B(F4,LBXG%D=IV=",KA7[HD4V(8*1BP89:V7
M?9S0K!JVF8WOEJ5Q90[.KM]CWLZ4IW;$ET64E=:D324^KF! J6^W'E2+C'K8
M*'='ZJT3UJ5+6)94.QJ2-LB7ER;(.V0+.'5%922ILIX:FRA0MK+BO5UE=SF3
M$"*GQCPX2<-L8S&TK1LH#B[+QI!=RY:^3Y.,M;!_95Q6UA:A,WW(1R@Q2ZKR
MA+*\2QKZE7'J#ERNDH:]L/6X3]@APN:[K($2_.>MH9,(X-V4JY,*#U@T<1O=
MI".L%!8616652J]7LM,]LBQ'5YD #0;G4 J0L(<,KL^#92.K0,&?KXWO31@A
M%5;9&V3$ZQ7)W:DSM/*,-[I5SQ40+9<J3:N6QI(R2F%G@H-IX\LB5*'KX;A8
M5[1T+ (\46$[)8<]:,RW-A33S5"?$E*6E$B/@&=&E\I?AE"J^46ZG8,2"Q.1
M'5U*&O5*?@RQ\0QQRI3D6 0S)*KL3\+(\6Y^$K!5&*MXS79$#BZF 7FU\B>J
MH#+3;X$0K$Y@.$7L(/7UA"D2!3)()Z4#"0(5-@^+4F30G?;RLZZ:YVUSL")
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M/<B?N[T\(=@_;FS_ .9T7O\ 3O5NEB1ME?VW/]BJ>WM-KQ"Y\W[M/X*_<_\
MS;^>_P SW(?[N=/"'8/VYL_^9T7O].]>Z?LW</WT55_/A<O)I_!7[G_YM_/?
MYGN0_P!W>GA#L'[<V?\ S.B]_IWKW/\ 9NX?4JKW6G\%?N?_ )M_/?YGN0_W
M<Z>$.P?MS9_\SHO?Z=ZMT_9FX\^S^PU7E\WBOX>?3^"OW/\ \V_GO\SW(G[N
M=/"'8/VYL_\ F=%[_3O5NEN>V;A;L_\ 8:FQ//E_=?)ST_@K]S_\V_GO\SW(
M?[N=/"'8/VYL_P#F=%[_ $[U[IR_[-W _-15/\N%\GS_ +M<6?MD[DA=L:$]
MO?.(^VVOE:ZS\2WZ';.OCG'E8Q)7]<YU\<9QXXQX>.,X\?DZFN^[(XNF\[4X
MO:Z[A2,+^;E,>?R:J>BK8B%EHZN)B+A9*::,D=G(.@)%P1<"UQ;MMK9_@V]Q
M7X@N:_Y?_P!5=Z_D_P#Y#_\ /^3J7?K9OVMMGU^E][JKN>HY^(G /:>#)V_O
M3S#]_/LMST_@W=Q/X@^:OS5WK_8/6>_.S_M7;>7^.I?Y<74NYJGT>H[/B)?/
M_N7_ /37H4^">[$2^)4N.XOE^ND+N3K*&0'0*R[!E%9T.K%:[CFN3P3(XYU]
MHM$6=X(X988C%%<SF"3?29\R"%\CZ>=*5W&3O1M\P>B@8-5S1,&CJIUL4C1U
M)#P0'F2"4DFYBXB1VYO;*(Q#CRJ1(XLBL"#&IO<D'F&<&Q!YJO+EDP'VTZ\U
MUR^G333IIITTU2G/O$P_,U$!J1"ZL-?0+_QE<]0;>%Z:E+'I%^KUF;KY<:B'
M2C3.$*YJDB)B%E\C++:.;7(LI&,TSQ"9 A"FTD;V87!"2*S C_:4%?W\^5];
M-)4&FE,@:1;Q31WC-F!DB=%8<P#BY5[$_HW[0-=%(_@_N2\)6P3/FB&QRR+J
MY- N9C$;J['84=RIHI\MGT=K[6JU ?\ "?$?%7'Y.LE7?@P.<79R<A>+'DJ4
MO2[AE((,^7); WLS*Z7RN&4@PQ1Q\U87S8JP;$\KWWAR5EI<.;@D'FBM&Y'#
MQ:-KK4SSR\GC)7AJ&5ER6:UKL=M2H-'"9R&LBDDL"!?=X 0V$XM@X8E15."]
M<2CXDR!&*$Y9T.HJE;$81>$NJ:\P!:B2P'0K%\EHF4"\@OFN9 ^%#B@DB\@L
M2BJIL $%@!>VH2;K&Y8B \D<Q78=2I#RF*H-\B2JS2,P)8M(1DS6+-*N%NSZ
MQ4.F\V4NY7@=W!RI2H*3N_5::0.F;"*.ZQF<H/\ 41)7H-+VXS:@B3"B][79
M?3DD4[/D)^-A,!7YPTC1K,KR9"5 MP "6&=Y6 5>NV0N27;J\Y&Y8U5.XI*]
M+)'$4-/(9+$FP4\*T"W=QPEX9M81H0Y A7K%Z:*[ ^5F*8Z2R<NI;JZ.M::Y
ME5YRNCTIAK:P5N]&\Q![1V"M7P05/9.8[[+R/7 2:FYA4"T^IJ!8E340&QI:
M30RE3E*)&+*]C;$DJYE'61U >9^(H*$#%  " PV5W>G5QA3&) CQAE)S"J\8
MISU)(F+)3Q<)R)5N9')R4E6Y6GP?W(L[8_9CS.1OH9MQ_L1?UTY07)1X]6MO
M#;^4'+2=.<WCEKD'&C*2D-+/<[[H$R.1SPID9 +MB^=P2$F\YY\.\@_O&Q:$
MGGB2"HC.!9W 8J0JD$L[\0!0%I +&0K$><2YI4+<+D%L_& D5(XR5# L]UPN
M;ACM<O'&O,"3D-@UX[T7KZ")37&*NFF&,?ZK*Q7JV'B 1NI,;5B$D^O8MQXZ
M2^:U&4QE. 30#[-$9R6XOAIGCE$A*6X81L18G%0HL""5N5S-I,;DCAEKRG5J
M:^.>G:$+-<RF1<WN$R=G-RK!9+!^$N<7$ 4,)@A$"][.MW7%:=--.FFG333I
MIITTTZ::=--.FFG333IIITTTZ::=--.FFG333IIITTTZ::=--.FFG333IIIT
MTTZ::=--.FFG333IIITTTZ::=--.FFG333IIITTTZ::=--.FFG333IIITTTZ
M::=--<]=_O\ O_S6W_;TZA)>PMY_*+^0_*-70?#/^Z?YC7;GKH6O6M.FFG33
M3IIITTTZ::=--.FFG333IIITTTZ::=--.FFG337'+EGA&FE&&V,(TCVVA%TD
MBAVFD^]KIYV??2*/7.?#.V^VW\77&<ZZ[[>&FTT56=5=Q&I(#.0S!1Y3906)
MMV #F;7L.8KE=TC=XXVF=5)2)652[>1<G*JHOVDGD+D FP-!M:E>7)T[ U;C
M>:?;Q\,'KO(BCQX^;ABUR9GR8X]?XNN/'.<_+MMG;;;;;/9X*_;:>-8HY2%7
MR\*6['RL>H+ECS)L/FUT*JVO>ZR=ZB>F+.Y^.I\57]%$'&-D4<@.WRDEB2<=
M[/K=[IQ]/6_;.K>^M!\<?52^QK7[P[MZ(?74_O=/9];O=6/IZW[9T[ZT/QQ]
M5+[&G>'=O1#ZZG][I[/K=[IQ]/6_;.G?6A^./JI?8T[P[MZ(?74_O=/9];O=
M6/IZW[9T[ZT/QQ]5+[&G>'=O1#ZZG][I[/K=[IQ]/6_;.G?6A^./JI?8T[P[
MMZ(?74_O=/9];O=6/IZW[9T[ZT/QQ]5+[&G>'=O1#ZZG][I[/K=[JQ]/6_;.
MG?6A^./JI?8T[P[MZ(?74_O=/9];O=./IZW[9T[ZT'QQ]5+[&G>'=O1#ZZG]
M[I[/K=[JQ]/6_;.G?6A^./JI?8T[P[MZ(?74_O=/9];O=6/IZW[9T[ZT/QQ]
M5+[&G>'=O1#ZZG][I[/K=[IQC_IZW_N,ST[ZT'QQ/_E2_P!4&G>'=O1#ZZG]
M[I[/K=[JQ]/6_;.G?6A^./JI?8T[P[MZ(?74_O=/9];O=6/IZW[9T[ZT/QQ]
M5+[&G>'=O1#ZZG][I[/K=[JQ]/6_;.G?6A^./JI?8T[P[MZ(?74_O=/9];O=
M6/IZW[9T[ZT/QQ]5+[&G>'=O1#ZZG][I[/K=[IQ]/6_;.G?6A^./JI?8T[P[
MMZ(?74_O=/9];O=6/IZW[9T[ZT/QQ]5+[&G>'=O1#ZZG][I[/K=[JQ]/6_;.
MG?6A^./JI?8T[P[MZ(?74_O=/9];O=6/IZW[9T[ZT/QQ]5+[&G>'=O1#ZZG]
M[I[/K=[JQ]/6_;.G?6A^./JI?8T[P[MZ(?74_O=/9];O=./IZSY/^7^[/]7C
MUGOK0<_'GU4W/_E_SMIWAW;T0^NI_>Z>SZW>ZL?3UOVSK'?6A^./JI?8T[P[
MMZ(?74_O=/9];O=6/IZW[9T[ZT/QQ]5+[&G>'=O1#ZZG][I[/K=[JQ]/6_;.
MG?6A^./JI?8T[P[MZ(?74_O=/9];O=./IZW[9T[ZT/QQ]5+[&G>'=O1#ZZG]
M[I[/K=[JQ]/6_;.G?6A^./JI?8T[P[MZ(?74_O=/9];O=.,_]/6_]YG3OK0?
M'$?^5+_1-.\.[>B'UU/[W3V?6[W3CZ>M^V=.^M#\<?52^QIWAW;T0^NI_>Z>
MSZW>ZL?3UOR?T?\ EG3OK0<_''U4O/Y?@:=X=V]$/KJ?WNGL^MWNK'T];]LZ
M=]:'XX^JE]C3O#NWHA]=3^]T]GUN]TX^GK?MG3OK0_''U4OL:=X=V]$/KJ?W
MNGL^MWNK'T];]LZ=]:'XX^JE]C3O#NWHA]=3^]T]GUN]TX^GK?MG3OK0_''U
M4OL:=X=V]$/KJ?WNGL^MWNK'T];]LZ=]:'XX^JE]C3O#NWHA]=3^]T]GUN]U
M8^GK?MG3OK0_''U4OL:=X=V]$/KJ?WNGL^MWNG'T];]LZ=]:#XX^JE]C3O#N
MWHA]=3^]T]GUN]U8^GK?MG3OK0_''U4OL:=X=V]$/KJ?WNGL^MWNK'T];]LZ
M=]:'XX^JE]C3O#NWHA]=3^]T]GUN]U8^GK?MG3OK0_''U4OL:=X=V]$/KJ?W
MNGL^MWNK'T];]LZ=]:'XX^JE]C3O#NWHA]=3^]T]GUN]U8^GK?MG3OK0_''U
M4OL:=X=V]$/KJ?WNGL^MWNG'T];]LZ=]:'XX^JE]C3O#NWHA]=3^]T]GUN]U
M8^GK?MG3OK0_''U4OL:=X=V]$/KJ?WNGL^MWNG'T];]LZ=]:'XX^JE]C3O#N
MWHA]=3^]T]GUN]TX_P"7T];]L\?^KIWUH/CC\W"E]BWVZ=X=V]$/KJ?WNGL^
MMWNG'T];]LZ=]:'XX^JE]C3O#NWHA]=3^]T]GUN]TX^GK?MG3OK0_''U4OL:
M=X=V]$/KJ?WNGL^MWNK'T];]LZ=]:'XX^JE]C3O#NWHA]=3^]T]GUN]U8^GK
M?MG3OK0_''U4OL:=X=V]$/KJ?WNGL^MWNG'T];]LZ=]:'XX^JE]C3O#NWHA]
M=3^]T]GUN]U8^GK?MG3OK0_''U4OL:=X=V]$/KJ?WNGL^MWNK'T];]LZ=]:'
MXX^JE]C3O#NWHA]=3^]T]GUN]TX^GK?MG3OK0?''U4OL:=X=V]$/KJ?WNGL^
MMWNG'T]9\O\ [Y_K\.L]]:#X\^JFY?\ +_E?3O#NWHA]=3^]T]GUN]U8^GK?
MR?\ EG6.^M!\<?52_P ?@:=X=V]$/KJ?WNGL^MWNK'T];]LZ=]:'XX^JE]C3
MO#NWHA]=3^]T]GUN]TX^GK?MG3OK0_''U4OL:=X=V]$/KJ?WNGL^MWNK'T];
M]LZ=]:'XX^JE]C3O#NWHA]=3^]UR@Z':HI=MI%?DZYCVUQG!R[/R^5KG']Z9
MX_+C&<_-\_R]1;=*$BPF\H_[J7S'_P"'JR+8]T5B6I2!B1_>P'G<>:778OKJ
M6O1=4*\YRB*?LZ9Q+46G+MM2E;K[!,H.$2<?TYE'X><7W'D1AI.L$:CYSKZ;
M6JR#;;BOTWBF-K0X\L4VW-P[,5@CJ]TJHMJI9E#P+*CS5]7&;VDI*".TCQ-;
MJ5%2]+22$$)4LP*ZZU4](U>IFV_9*&;?:ZG<Q5302)3[702BV45?NTH:".=+
M@R4=''7[A$&5I*-48,>'A7W5-]=IYKIP+1/+SC;14'QU?N3=X-<^&<Q26(KD
MKBW0O.OCG7,VE4"\YY/EXBB\KR=)&3HU%95H][K;=LK[A0[<&^44Z;=N96_;
M8U3VO:YM<U\'IK/=CN/1C;;FX@3:-TWDH+?!-8V\[()"#RR%#%<"^*WQ$%Y"
MD[[*XB*+XXV[9.3VXL>TL2YVAY&XT*9>3C.<#":YO5U5QE;YQC&DASH$3/E9
MQ)+%C7RM]NB'0VHE5:WPAVU&-C)'-0;DD?\ M/:CHI2H\H2)V\P/DIJ&Z=4:
M,\*]&M[Q%S''%N&QU#>=8EGK-WII'Y=4355*C$]:6,+<_$+FSX:;OB[=;@31
MN8^TGC:D6$?QWBA:$7G41@-Y<D>ARECHXV": 3;PRX@-!GG&GQ'OM%)OKKG/
M7JNU_DKZ*[U2K6;9TDK*N!N6<2TA*-8$I(AC#QR*""T<BJZW&2K>VNIG\HFY
MQ5$E'5[/'05T(#34-8LT-0B$E1*EI&BGIW96$=5323TSD$)*Q4@4Y_9$O<'^
M(/AOZRNW^V.N1'Y%-G/_ -\[GV>2.E[?+_W?9YM3_.%7^@4?TI_;^W3^R)>X
M/\0?#?UE=O\ ;'6?S*;/^V=S]72^[_';\FGYPJ_E_8*/Z<W/YNM_73^R)>X+
M\0?#?UE=O]L=/S*;/^V-S]72_+_\/YOMT_.%7^@4?TIO;T_LB7N#_$'PW]97
M;_;'3\RFS_MG<_54O;ZO[/MT_.%7^@4?TYN0\QZ]K_<>1\C^R)>X/\0?#?UE
M=O\ ;'3\RFS>7>=S]72^[T_.%N'H%']*;V]/[(E[@_Q!\-_65V_VQT_,ILW[
M9W/U=+[O3\X5?Z!1_-E->WT]/[(E[@OQ!\-_65V_VQT_,ILW[8W/U=+[O3\X
M5?Z!1W_WYO;T_LB7N#_$'PW]97;_ &QT_,ILW[8W/R]L=+[O3\X6X>@4?TI_
M;UK_ &1+W!>/_F#X;\/_ .)7;Q_+ZW_[NGYE-G_;.Y^6_BZ7]W_=_P =9_.%
M7_L^D^G-[7X^76G]D2]P7X@^&_K*[?[8Z?F4V;R;SN?JZ7W>L?G"K_0*/Z<W
M9]+[?LT_LB7N#_$'PW]97;_;'3\RFS?MG<_5TON]/SA5_H%']*?V^>G]D2]P
M?X@^&_K*[?[8Z?F4V;]L[GZNE]WI^<+</0*/Z4_MZ?V1+W!_B#X;^LKM_MCI
M^939OVQN?JZ7W>GYPMP] H_I3^WI_9$O<%^(/AOZRNW^V.GYE-F_;.Y^KI?=
MZ?G"K_+04A^0/-?_ /S.G]D2]P?X@^&_K*[?[8Z?F4V?]L;GZNE]UI^<+</0
M*/Z4_M_SUK_9$O<%^(/AOZRNW^U^GYE-GY_]L[G\GBZ7[?%_C^;\X5?Y:"D^
MG-[1_'/6G]D2]P?X@^&_K*[?[8ZQ^939_P!L;E;_ /#I?X_W?V?;I^<*O] H
M[_[T]O\ _/\ K^[69KO^Z!.Y^VOTM6K';;Q4^L=C:@(T*165>C&39PT*B"7+
M@!86VTI!9A<T4$$.FN=I))-=<?+GQZJG_(UL--#-4U&^[A#3P1O--+(E(J1Q
M1J7=W8QV544%F/F\G+G./I]N<KI%%MM-)+(RI'&C3LSR,<555#7)9B  .=_+
MKU%\8$\BF\?5$[EM?6E'))J0,VXIZ?(;/6TSHO3)!"964Q*,+.B4ZR:+YF.\
MWFV)(TYPT(PQ$(\7@->M$E;4IMSSR4*2LE++4A!/+$IQ6614550RV,BI:\:L
MJ,692Q].IC4&GB:K6-*ED!F2$DQHYYE%+%BP2^):]F(+"P( GG6IJ_3IIITT
MTZ::=--.FFG333IIITTTZ::=--.FFG333IIITTTZ::=--.FFG333IIITTTZ:
M:=--.FFG333IIITTTZ::=--.FFG333IIITTTZ::=--.FFG333IIITTTZ::=-
M-.FFG333IIITTTZ::=--.FFG333IIITTTZ::ZY<EMGW(MVBX(IC<^O!0IP[-
MS-=$\^XK>OT]H06*BI-98PYQ(KN7(,R]EYQO#MJ95:>M:M0]PWK:JFZ<_M\4
M%!1G>JR*.=C,]-M-',H:*HJXE1YZRIC86EHZ!9([1'J5-7+%$^<,54AZIN\]
M3NNXKT;V^>6EC6".LZ0;A Q2>EH)VD2FV^CE4AH=PW5HIKSIXRBH(9YHS%53
MT,HZU=U/>[PWV()*QQ94*0/8;=A)&2@XYKQ(]>15FO\ G98!6-A::B'R!Y9$
MQ%R!BC+SV324<PQA*'I/":5V+HST-W?IM-4[G55IIZ7C%9]PJ%:>:HG(#,D$
M9>,.(U*AV:1(X@R)&KD,B=1Z:?E$Z/\ Y-:>CV6AVY*JN[F#TVTTCQTE-1TE
MV5):J;"0Q<9UDX:)#++,R222E 5DDZW\"?#(56[WA73N9^-H^,@'Q@H %U46
M*1TD5EG;Z1B9LP+!8M*6JM]I(\3.A2CHQ,2:3EA0 :D'#\_O?Y)JJBHY*O:-
MP.Y/ K/)1RP"&>1$!+=SM'+*LDH Y0LJ%S=4=GQ1^I]&?R^4&Y;C!0;_ +2-
MGCJ94ABW""K[IIH9)"!'W:DL,#P0DE<JA6E"9!Y(TB#RK]LL9QG&,XSC.,X\
M<9Q\N,XS][.,_P N,]>/Z^A==:.ZGM3XG[NN+VW&O*"4:?:08O>KVJ$:+9_3
M'<L6-8&R8O;R9<:8FC@RP6YET$:01:Q3XUEC&)'Y_HYTCW+HSN$==M\K!<E%
M52EB(*N$'G%*HY7L6X<H&<3$E38LK=>Z1]&Z'I)1=SU(X-7!E)MVXQ(IJMOJ
M" .)"S#KQ/95J:9R8:J,<.53967P)]R? -S[8^:+QPO>Q_-NJ>UD&B,CQMZ*
MX4SZZE)W8.^VNFVX39;,,>+MO'%)F&?3,L,.^<QZ_8FR;O2[[M='NM&Q,%7$
M' :V<;@E987MR$D,@:-P+C)38L+,?!3'4T\]505T:Q;AM]0U+61KEPS*BI)'
M/"6ZS4U7!)#5TQ:SF&9%D"RK(JT5URNI?CR<^VP\GX\OG=-/F^?[K_/Y_DTZ
M:SITUCM\O+Y#_4:=-9_]?+^/W:=-8']3Y/Q_'G?M\NG33YOMY?T^?3II]_/^
M'_IITUG\?B^G333IIITUC[3^/F&G33GR^T&W_7^8TZ:S^/Q^/ZZ=-/Q^/Y:=
M-8O^/QV#Y3_Z^E#X(+LD(I82WNTY)6;C6IP')GAA.9!C2= @/'W@)OTT4NN=
MXFEA$FE$K6?)TR)7Y2&FFT^7@.X'C'Y0^DB59DZ/TC!Z:-AWQD4W6:5"&6E!
M!L8X6 :8&X:4*A X39=DV>"2F9*VYCF%S 1R9%9;&0$BX9@2%([$-_TN7H!^
M-EE]]L?I._Z>O(^X*/T:+Z(UV7OKN7IM1ZPZ?&RR^^V/TG?]/3N"C]&B^CIW
MUW+TVH]8=/C99??;'Z3O^GIW#1^C1?0'S?C^/;IWUW+TVH]8=/C99??;'Z3O
M^GIW!1^C1?1T[Z[EZ;4>L.GQLLOOMC])W_3T[AH_1HOH#3OKN7IM1ZPZ?&RR
M^^V/TG?]/3N&C/\ [M%] #^6G?7<O3:CUAT^-EE]]L?I._Z>G<-'Z-%] :=]
M=R]-J/6'3XV67WVQ^D[_ *>G<%'Z-%]'3OKN7IM1ZPZ?&RR^^V/TG?\ 3T[@
MH_1HOHZ=]=R]-J/6'3XV67WVQ^D[_IZ=PT?HT7T!IWUW+TVH]8=/C99??;'Z
M3O\ IZ=PT?9W-%] ?S[=.^NY>FU'K#I\;++[[8_2=_T].X:/T:+Z T[Z[EZ;
M4>L.GQLLOOMC])W_ $].X*/T:+Z.G?7<O3:CUAT^-EE]]L?I._Z>G<%'Z-%]
M'3OKN7IM1ZPZ?&RR^^V/TG?]/3N"C]&B^CIWUW+TVH]8=/C99??;'Z3O^GIW
M!1^C1?1T[Z[EZ;4>L.GQLLOOMC])W_3T[@H_1HOHZ=]=R]-J/6'3XV67WVQ^
MD[_IZ=P4?HT7T=.^NY>FU'K#I\;++[[8_2=_T].X*/T:+Z(T[Z[EZ;4>L.GQ
MLLOOMC])W_3T[@H_1HOHZ=]=R]-J/6'3XV67WVQ^D[_IZ=PT?HT7T!IWUW+T
MVH]8=/C99??;'Z3O^GIW!1^C1?1T[Z[EZ;4>L.GQLLOOMC])W_3T[@H_1XOH
MC3OKN7IM1ZPZ?&RR^^V/TG?]/3N&C]&B^@-.^NY>FU'K#I\;++[[8_2=_P!/
M3N"C]&B^CIWUW+TVH]8=/C99??;'Z3O^GIW#1^C1?0'X/[].^NY>FU'K#I\;
M++[[8_2=_P!/3N&C]&B^@-.^NY>FU'K#I\;++[[8_2=_T].X*/T:+Z(T[Z[E
MZ;4>L.GQLLOOMC])W_3T[@H_1HOHZ=]=R]-J/6'3XV67WVQ^D[_IZ=PT?HT7
MT!IWUW+TVH]8=/C99??;'Z3O^GIW#1G_ -VB^@!_+3OKN7IM1ZPZ?&RR^^V/
MTG?]/3N"C]&B^B-.^NY>FU'K#I\;++[[8_2=_P!/3N"C]&B^B-.^NY>FU'K#
MI\;++[[8_2=_T].X*/T:+Z(T[Z[EZ;4>L.GQLLOOMC])W_3T[@H_1HOHZ=]=
MR]-J/6'3XV67WVQ^D[_IZ=PT?HT7T!IWUW+TVH]8=/C99??;'Z3O^GIW#1^C
M1?0&G?7<O3:CUAT^-EE]]L?I._Z>G<-'Z-%]$?C\?/IWUW+TVH]8=/C99??;
M'Z3O^GIW!1^C1?1&G?7<O3:CUAT^-EE]]L?I&_Z>G<%'Z-%]$#3OKN7IM1ZP
MZ?&RR^^V/TG?]/3N"C]&B^B-.^NY>FU'K#I\;++[[8_2=_T].X*/T:+Z(T[Z
M[EZ;4>L.GQLLOOMC])W_ $].X*/T:+Z(T[Z[EZ;4>L.GQLLOOMC])W_3T[@H
M_1HOHZ=]=R]-J/6'3XV67WVQ^D[_ *>G<-'Z-%] :=]=R]-J/6'3XV67WVQ^
MD[_IZ=PT?HT7T!IWUW+TVH]8=/C99??;'Z3O^GIW!1^C1?1T[Z[EZ;4>L.GQ
MLLOOMC])W_3T[@H_1HOHZ=]=R]-J/6'3XV67WVQ^D[_IZ=P4?HT7T=.^NY>F
MU'K#I\;++[[8_2=_T].X*/T:+Z(T[Z[EZ;4>L.GQLLOOMC])W_3T[@H_1HOH
MC3OKN7IM1ZPZ?&RR^^V/TG?]/3N"C]&B^B-.^NY>FU'K#KF!6FQ;R[8W<L-L
M8CSG&,D29^7RM,>/R?T9S^7J+T-(!<4\7;;X \QU;#NFXLQ!K*@C$G^\/G&L
MGVT1^MJ.\Y,)\)6G,5]N/(,Q6=L2;[UZ9Q/7>.Q,2>&/&);QK7ZB%KKKC$7G
MXR9]-?+(DWWXKI">%60[<O*/::&DH0MK 3B(5%>]O(9-PGJGYW.)52>J+=BZ
M(CC[;4;N_.;?MSW#=&<VN:5JAJ7:DN.5H=GI:"(@=4NKN+ER3\*.XEG6.(_A
M8X[[W#*I&/&4[JK646<]=*U7X02T >OUQ[&MUA(W8+JI;@-931AQB9<D(3?,
M#$D::0R^T[!%4;K^2YJ'891'N2Q55.X218I.,*YIZB#BW41R5-*Y",S+U9ER
M902P^;^E4U'L7Y;AN?2F$R[.\U%5H\L331"E;:TI*2IX05C+#15\5Y%5'.5-
M)BCN &VOA8^X#MPYLGXH'X@<);I<D7KJ6QW) #-"*/7#80]5E=+:3""Y:S>G
M1D'P"Z;$QI==2=<[#S-)HMY?DOV+?]F7=&W6&:DHYA"*>DG=69JA&;BU"1AG
M$0P*HSD*9NJ>L(E(A^6[I1T3Z1'9%V*HIMQKZ;NDU>X4T;!$I)%C$5)),T:<
M<F0-*J NM. X.+3L#Z&.%A&R_ASB<!^="S>@\:44-TR'*B.@8-AJNKA8FPFP
M22P&1%&:33QE0RRQ$:28ECDWTWQMGP?=WBDW;=)($:*!]QK7AC92C1Q-4RF-
M&0@%"J%058 J18@$$#ZEZ/QSQ;#LD53(LU3'M&VQU$RR+*LLZ4<*RR+*K,LB
MR2!F$BLRN"&#$&YLSKCM<OKS ?[H?X=70R<$\Z@#11,SM7O'5CFTCUTV)'7^
M8=5Z63?7&,RSX]8-Q]MY<[;Y&'%CUSB.#&N/?_R*[F[1[QM$C$I$T%=3@DFQ
MFRAJ%%^Q;QP, +#)G)NS:\9_*+1K3;[M.Y)U1N=!5;?4@"P:;;9(ZJB<GEUC
M!5[@CDW8K'"OP4Y><WB3B6_<Z<AUWBKB]''8[W:]FFB)-*W2HHS,I4C*Q,\R
M-K$Q4I0M!4RAB;O(>P&CWU'S%'MO/)%%O[5N>Y46T44VX[A*8*2FX?%E$<LQ
M7C2QP1VB@225RTLJ* J,1E<V )'5:.DGKZF*DI4XD\V?#0NB!N'&\KG)V5%L
MB.UV87M;M(&IOS!VP\U<$IZS9.1JPI&K%Q-:*ZW::G>J!R16&35)H)*U48L/
M'%HM:@1N'"<+/(K/,%/W@EQ/$/)#I)OKJ;7T@VK>):B"AGD:HI4CDGIZFDK*
M&HCBE+".4PUU/3R-&Y1@)$5D!6Q8$@'8K=JK:!(Y:F-!%,S)'+%/3U$;NELD
MSIY)5#@$=5B"1\$&Q.J#QIOG;.N--L[8SG&=<:YSMC./'QQG'AXXSCPSXX\/
M'Y,_-US-QYQ_'7'_ "6-QR/(]OF_'DYZE%2IC^[,3%=?B7;F U^PV<C#5XCK
MH_J>KJ#'C>2 VPL5811NB\ G(*D4B9JX+UC6J CF) XLNO4U<-(B23%\7GAI
MUX<4L[<6HE6&(%84D95+NH>1@(XEN\KHBLPMA@DJ'*1A2RQR2G*1(QA$C.]C
M(R@G$'% 2S'JJ">6I@PX(Y@4"V YKQ_85H53K5!N%F+/'C#'0UKE*53#QZU:
MRD31Z!PVS9ZKD4139U)F&)R7O!&*.5-!JIO.V2M"D=;#(U1/64U.L;%VFGH!
M(:V.,*"6--PI!(1= 0%#%F -S4%:@D9Z>15BCIY92P"B..K*BF=R6L!-FF /
M6L2Q 4,5AERI[VA6I[3+)$!&^KC$A4TC4.DME6ZFB[>3-J"^KC!JB;08SG^(
M8J9&ARX^6*??'R];=+50UM-%50%S#.BR1F6*6"3!NPO#.D<T1/ZLD:,/*NJ9
MX)*>:2"4+Q(V*M@Z2KD.W&2-F1QYF1F4^0ZC.==L8UVSKG&NWCY.V<9QC;R?
MDSY.?O9\,_)GP^]_+UL?O[/)JKG^[7:NK=E7<';^.*QRRL140"BW->[:U5G:
M^:^%*.<]7UQLP1.25U=N?(*&R$:!ME9P.==5/ES2Q:^CZS:30;2=<J.E>R4M
M=4;=)-5O64LD4=2E/M6ZU:0O-$DT2R3TM%- ,HY%;^\L 3>UC;EXMCW&:FBK
M$2G6GF5WB>:MHH#(L;M&]HYIXY.JZ,OP1<@6N"+\BN=D7<3:4=9L2^MU )3:
MN-&_,8,]AY8XIJTR[BU.T%227NT!V*YK#*E6V3@X96@8V6!7"_-VDA4Y+R,3
MF&,_2W9*>:H@>:J>6FKH]L=8-MW&H#[A*C2BC@:"ED2IGCB1I)TIVD,* &2V
M2W1;'N,L<4BQPJLU,]:O%JZ6(K2HP3NB59)E,43.0L;2!0YOC>S6ZF9UVQC7
M.==L8VQXZYSC.,;8\<X\=?'[^/'&<>./'Y<9QUV6X\^N(\E_/S[.W4M1T*Y6
M5%=+.BKK-E7^.E:QU>&X\']PUI8Y>KJTI)9S2;::Q>L7C4!<)#IY9$\LVV^D
M688")(M::LI:>:EIYIXXYJZ22*DB8]>>2*%YY%C O?"*-W8FR@"Q-RH-T=//
M*D\L<;-'3(KSN  L2NZQH6)(^$[!5 NQ)N!96(B/6SJCG^.?S'[Q^"Z:SITT
MTZ:Q_P!?P3;E_(=G/EKZA?!E]D,W<_R5\>[VMESP?QLQ&G?8FCVT@O%GBQ$8
MOI \FWAB0'73:!C;)(O+VB4[#J_$<AZ,8+T?IKTF&R47<E*X[YUJ,(K$Y4L!
MNCU1'ZQ(*0 V!D!DZRQ%6Y+;J/NB3B2#Q,9N;CD[=H3S$#D7^2P_2N/73##"
M-#$./#$../%'#!!#'I%###%IB.*&**/&ND<4>FNND<>FNNFFFN-=<8QC&.O
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MQJ9<<WM"N);L#=KJ$+Z79<I SP$]B9+9BQ5XVY^#6(&9 DC%6""P4!FXB1$
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MRAE1+9ELF"]4D"P8DDC&ZW84K0R-++$985X4D<)D)=HVDE)$2J41FZX5FN5
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M[<$U]+3C\N@PG*T@[G(P8NDQ,\!4N1<5=W)8L4<*6&/- 2O#BD+%2X-QQ1<
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MN<DJ ;8@VL&*S$&X")W/% JF8M&5D,D[91(6*X'X?=BV9BH;)A?(H&E(KGM
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MUH%<:]:HU($"O-.I[:)C(Y E5#4M:P63Y9*UT>]DH@C0%HU8$I&H"K<Y%%4
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M=)4$KS2PB!Y261($_P!=(YEXK:.3&DLJ.8K1^*7)E_0QNOPK]0A<@UL6 ;M
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M#KAL**,=53!U@T=@RFX;%&4\S>^"I\N*J.P#23OH;/(M5U"LH)1P%*92*X
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M1(T[3;D<-6YCVUAA9AWX)8?@@&UC#L#-2.JHS0E2Q"J2MLC8-87Y7X@!\XD
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MBS.E-<KZTQR]>L@E"92O@W)/9M&)$8@( 8\>,[S$E$S100QZXSG>3?7&/O\
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M2NL@(ZV2,W*/%ABRD=?-I7.-R[EK@&QMDW*HE4\2GC> AKIA*L9RG#H<D=2
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MZI Q50<3B3F@!-VZW9:9JJE%=^X4C2.9CGPZ@"&I.:LQ9Y",P9 .%)=5*H,
M2<I/#V?<.K[_ ,4,<V9EM9J'4:*(I1,HZ.Q.LR7@ZTS/JX]SHRK)+E9NBL]W
M$V?,ZE.FBFF/0P3["$;#2SY[DA#Q78EHT0*&P)986)4\U)&+.,BA7M4'R7K.
MXU#15 P7":24LRF551JE,67JR!&R2(X"0/:SD7'(2BY]I50O#RP,6MQN\"1Y
M:&%\AJ06]7C4IKTWK2RH-;(O/EK4UBFV+0+RA]%+)R<G&)>-S(@L;ZIM$TWI
M4=BQ9[%B^ QQ#E0C,#CES4$6+$ DD#LM"/<)8D15CB++&(3(<RS1*[.J$9X"
MS-?)5#'%03;+*PK!P;7[#RU7^8B+!81K%6UX2M>MT7T)HGC$%*-)*U#)LE(>
MVFO2.=3<BNYJE9J],Q%&$TDWUE@Q-M-H0TJRY,&4  6C(M<D@%HV=<KV;!EN
M /-?5253I3O3!$*2,6+93*UR% N(Y4C?'$%1)&]B3Y#;5<73ML=.G'-=L4\H
MV(NP\PTAMQ[$!:UU0-K]%KKE1$AP+52Q*ABUA*47G#;9#687T"ZTVO?,UD+V
MV(T8KZWIV+3.)23*ACLP4A%8!;*0N0"\WQ! =R2QY@BZ*M1$IHV@0+3RK-=&
MD#2NI+7<9X%FY(7*DQQ\D%AB;DO7$]8Y IJBAN=V$->4-:DRC@"(TBG*BJ#$
M)@$N))DBEDP(9Z#&*=(/F W(\DNPI0Q&=)M+GB5T"&^*E#R/;@00"?,;6-K'
MS$:U8IWAE,J6S(D',<AQ%920+]HRN+W%P+@CEKKQ'V0T4A@E;6*^\AVEJB74
M>OAG,I*@#M)4^.+30K94JX3 @J:@7>$4^B::GL]((F['6R/\[FQ:ZHHTE'<:
M$J6DD8J$4$X#JQLC*IL@%@4/.USFUS?&VX=SE =4BAC61I7*KQ".)-'+')(,
MY&-R)>0OBN"@+S;+#M_@_P#BBT($]>NEKO\ ;!40-&K($YQ587$;\><;5ZU(
MJAQZ?A#6%0[%$(3;";*R+*@W=N;(K2%&LM@5@ZW6+4,3J%=I&"A%!)4'"-65
M$ZJ@6!;(FV18*2;*!J2[M4([/''#&6,KD .R\:9T>24!W8AB$"* 0JJS "[$
MZDJ_LHXX7*FZJ.T7HC#SB.T<1,SRS49#(P"XU:E5BPVLDK9#CS]N99I(STH^
M738*=XX<DS+]X)QAA9"CC (R?G$\1)*DD.J*S$E>;'#(GLNS&W9J)W.=BI*1
M]2HCJ% #  Q/*Z1VRMPP)< !8A447N"3QN).VRV5>T<G:WQZN9<=OZK9>/Z3
M5U3C8^9?4K9>+A;6WGR/B/4F227(UB$70+S+#R(9%D>2;6UXUBCBF0T[JTO$
M8%&5D10U[(SNQ/P%*W# !<I"/UM9J*V.2.#@HRS)(DTLC+8&1(HXUMXQPW-"
MQ(2(&X\6#?7.W[/U)FVF[KESE%YL6A54JR:FZ<?0167CY&16B55-(A7T4.),
M+'-6]I#7%<U4/CI+'9=]F,6TJ#->=R VO+(W5"/<1V=%*D(0$&(ZG,K9C=N?
MP<<=\G'P*>!+,TB6XQ*2N) T@+2G(D2<E?)!BME^%E&+AV.U1CQLWJ-8M=B'
M=1<7J*%62W,ZK*W!E3XHYEXOK)SS *#).\,XW,SEB^R#%KO(4L62 #P1:&"'
MX>C4QE59@PB6-2;6ND<T:ENJ>WC,6(%[@6[.<H]TD$RR/&A4U#S.%RRM)/33
M.%N]KCN952_*S'*_*W-L?8S0K>P962SWB\/+JVL@=Q8VAB)1)M3+(O3)ZJ&:
M16M:='59!HJ8B7U?=?JGC'W'TD<:^:L>VC>,U$CDL[NSE@Y9A&;L%50<<,+8
M*%MC;R_"YZ)NLT8"1Q1)$J-&L8,P(1F:0CB<7BW,C%\L[@]7FG5U@7/P>/$;
MD<8*6S6W4 9-%7HP)DW&+!?HH)XZXWXSLD(ZL_C\A.)/94G$U'-GF%711*&J
M\[U",N4-CE$F#0Q&PR:P&(!6,BQCCC;D8R 6$2&X Q(..()&I+O%0MR$CN6+
M$Y3@DB:6=+LLP9@C3RBQ8AE89W90VKHY-[:*]R99Y[$1<;A6H&@O' EF0(=:
MQ(JLFG$UF?6JC[%S.ZXW;+<KV5F;X,PB9*\,X-@HB?'43;!%LE.LCY%F6_#R
M"XV;A,SI<LI86+&^)%QK6@K7@C"".-RIF,;OQ,D[HC6.6V,BJUPBVS5B#>QY
M\J;F^#ZXRF\[Y5UO6=(MZ\6L#]%HFJB%Q78PQAGKU%%38D]S<;+!B4432U!,
MV@"1JQ$ .@(R$8%2:",\\WO=2!9,<EL S+ABYL"H+AB%) (Y$;(WBH  $<7Z
M88WFR*O>ZH_%RB6YR*Q% 6 )%K@Z3?!]<;2D@R;7R^R@J:]M752<U=QFS3 !
MS\8C\8G00*&/'Q*D=0P%&S9S*N"O#J\]I8N3)D\@9HP"\:&,F^<G)2H!$9 !
MC$9%C':QL6* !"Q)QM8!WWFL1P8;LV3,&G5B1,902RS EA<(')+A57K7!)D5
M*[&^-Z5=ZA?(K5<[ XJTP!LF+/'4'F6;!.=;#4.\3(ZK2O:ZM1:VW9<J35EL
MI!#4URL+Q]8X1&WKJ:4<:.CY.Q0WZV#7(+D<RF2A<R $*BRJ+6!O"7=9Y8I(
MBD:+("/%\1,5;AA@5$F,A;A@EI%=LF<WYBV?NO:!3[_(_7V&\\@R4=_9K#;I
MN/@RJR&A'=7$D<RV2Z,8JU\:"(FI41DXL9KTC9-L[<1K)(!Y%L*O+TJ27#.^
M!9F,8QQNY!;GCGS//FW5N;6Y6C%N4L(0I'%Q4C2/C$.7*QW$8QSX8Q! -DNV
M*Y$];*M9O@]..IDL:3'(G((HVY3(MIHM7<:*@VY12ZBK%[$U.NH R7=XF&H"
M[1?8-E^[@;1W9H@BPH3E>B6LT$=@.)(!<DXB( FR $J(\;@( #:_6;F+\KAO
M$P8MP8B2 HR:=B!>4D!VE+XDRDE,L.JMU-C>:ONRNE/B*%M/?>0X%O'V]3)5
MI-9ZL4LF84_DICR<"RQ"?6"ME;%HV8Y4V)@DV6GMJ^M3K,E#QBDY.FU&C&/K
MR6CPL+H1>-S(#S0D,2;,5()4 'L-ZUW.11*.##>;B!F'$! DA6$CE( P55R0
M.&"N2WFMSQ^SVK*F:9Y6.0^1:J\34%1Q?HV4R5"8F>C@U2K5)BL\VVJ;(4,Y
MT+2ZXRF= #C,ES1?YQ1,$&02%-D4J@@K)(A"".ZX7P"(A6S(P&00$L+$$<K#
M43N3LK(\,,BM*TX5N+82F220-U9%)"F1@%)*LIZP)YZY/''9]0.+47)J"J6*
MV+HN1Z9)0(FZ[2J)K-3JWIK:/5N:_9$M8 ;FO$V]J*W6O;.4_-BE6JBI/.'^
MMC6Z.DCC615+#B)A<8JRKUK8LJ@EAD;,Q8\@>V]\3;C-.\#R*A,$@EQ)D9)'
M'#ODC.RJIX8NL8069AV6M'JIV/<?5;2RYTN%V8DVO+61F1-I4@L1RN"^&3#-
MPX%=8#BCQF7A"L^&Q."R9\LGI# DXTD4H2*T4:DG)R6O?X [3$38!;#^Y7R<
M[L3S-Q.3=)I,/%Q*$*%0.(?@+4J.;.3:U2_+E;%0+ $&V.&N 5'"[!P8JMUK
ML@I=(XZXU0J[%I6]1:E1.*SKZ93D*N9'7TQS#8/7D-N(4UL);AJ<.(MV(+V(
MC*G+MB@$))#NPPCC4-C9$C+E%&*J3;,B[$FP'/MOKU-6U2JAHXXR)9IG9"]Y
M)9Q$)'8.[!;\%2%0*H)-A:P%^=7ZU-.FFG333IIKGKO]_P!_^:V_[>G4'[!\
M_P#0ZNA^$>=NJ?-YQYP==AK]0JWR563*K:!9Y@2)A#@S 2IESE&Z6D:&IK%7
MVPV=2T[](PA@8*6@F^LXA4.FV/+CS)%)TVAKJC;ZA*FF8!U#HZ.HDBFAD4I-
M!/$UTE@FC+1RQN"K*3V&Q'I>Y[92;O1R458C-$[1R))&[15%/40N):>JI9T(
MDIZJFE598)HR&CD4'F+@TR)?>3N(=,*.7J^[Y$J8>,1+>9N.J\2\:;A:8\(_
M:9QG7AB+ K<11:^)MBH:M_5V>^DS$E72(I(56.7:AV[=3Q=JGAH*I^<FT5\Z
M01ASVC;MQG98)8B?@4];)!4Q@K&LE809==?3<]XV(<#?:6HW2ACLL._[5225
M,[1@<N_&STD<E5!4"W7J]LAJJ&8AYI(=L4K3ZG2#N"X+L^FVR/E_C<Z6/QP0
M%\<D(S0+?7Q\J)@H,.':+I],XSB0<X0>>/.,XWCUSC/6E/L6\TQM-M6X(#\%
M^Y)VB<>0QRHC1R*?(R.RGR$ZY*FZ3]'*P$TV^[3(1\./N^F2:,^59H'D6:%Q
M^DDL:.IY%0=0Z]=W?;=QZO8'.^7*BRE60;3DIZ:?\?+#KC&?)CTRAINCQI#F
M:3.L4<A(T _E[8S)-'IC;?7:H^B^_P!:Z)%M=5$KFRS5B"AI_E/'K#!$;"Y(
M5F:P-E)Y:U:SIET9HRR'=Z6KG4&])M;-NU;>]@.X]N6JJ%N>63QJ@YEG4 D>
M</X0_P"%-YOY^2N^&^W3BSE"A\6L]9U]EM[&IO1[C=EV^-HY5\<(P4D5>1%:
M[9U*#@)+,81:ZZDG:B$D+<>X="OR?[/LDL6Y[UN6WUVY1V>"".IA-)1..8<%
MV#5$Z]JR.J)&2<8BZK+KS3I%T@WKI*CT4=!6;5L3&TT#HQW'=4OSCK6B#14=
M"Q^'1PRS352V6JGBA::CD^!^>+N3MLYVVX[OFVVV<YVVS4;#G.<YSXYSG.5_
MCG.<_+G.?ESGKUWOCM_IU']9@]O7 =QU0 "TE0 +  02  "WDPL !RL/)V6\
MFGLMY-_%U>_\T;!_L_IWQV_TZC^M0^WIW)5<_P"S5'+_ .#)]O5Y?=I[+>3?
MQ=7O_-&P?[/Z=\=O].H_K,'MZ=QU7HM1ZF3V-/9;R;^+J]_YHV#_ &?T[X[?
MZ=1_68/;UGN2J]&J/4R>SI[+>3?Q=7O_ #1L'^S^G?';_3J/ZS![>L=R57/^
MS5'J9.7_  _O_'-[+>3?Q=7O_-&P?[/Z=\=O].H_K,'MZ=R50Y]S5 ^>&3V?
MGMI[+>3?Q=7O_-&P?[/Z=\=O].H_K,'MZSW)5>C5'J9/9T]EO)OXNKW_ )HV
M#_9_3OCM_IU']9A]O3N2K]&J/4R>SI[+>3?Q<WO_ #1L'^SNG?';_3J/ZS#[
M>G<E5Z+4'_R9/9T]EO)OXNKW_FC8/]G].^&W^G4?UJ#V]8[DJNSN:H^;@R>S
M\VGLMY-_%U>_\T;!_L_IWQV_TZC^LP>WIW'5>C5'J9/9M^_MUMR<9\D1>'G>
M/[O'Y7CY/G*H^T\KP\/'R?* QX^'CCQ\/'P_EZD*^A:^-92-;MM40FWSV?4&
M@G0C.&5;]@:-UYCM(NH\X!\W+SZV_9SR%G[U#N>?_P"EW?V'K/=M'Z73>OB]
MO6.')\6Y^9&T]G/(7_ .Y_YKN_Y/O_\ V'^3IW;1^ETWKXO;U@1R?J/]%C_0
M?CRZ]#7P278G-3@ANZ/EU%*-:VHY$'$E9;A[0DUU,3'N,;>#Q"=<30-WD.\P
M->BEBBV!1[E,_P"W[NP=U_D73[I2*EVV/;Y0U/&P-?/&UQ-*I#+3(PY&.(@-
M*02'ELG(1,'YW;*/ "IE4AV!X2D6*J>1<@\[L.2_[//GD+?>/KRW7,Z=--.F
MFG335+\\\<LN3:4H2)QDI;-)R7Q+>AAW[ U6NF'H7)-8M;>#T]>M;DCF%(U3
M,1?G"Z>*0Z<>$C<6&20N"J:,R(% !(DB>S$@6CE1R+@$@D*0.1YFQY<QL4LP
M@E9V+!6AGB. !;QL+QKR+*" S D9#D"1<@ ]&1.S+GJO2TJ6M\EY]-0\/UE$
M66;RG=(%D7)0'']Q4760X36DGW>R5KD.]6 -^Y<J.3./GF@WDFX6>MZA3\Q:
M0HYU*8RFZQ*I)E>W%".KD]0R,LCL&)66-AYKJEN5;<J1Q('@^%4.PM3QDF$S
M1M%8\98TDAB0HJO#,I)YMC)*#Q:]V4\QX;IS+,VJ\Z[6TE1%P1\DVB9NAXW:
MW?M1M[ZN)&*#C:CBS:/(N'.6UQR4,"NB9QR$+,:Z=&&/F,F%HYKJ69;9$'QC
MEEC+TSLJD1H#EPI018#K@DDEB)/N=-9@B.#@+'@1@-,L5;&KLKS2$%>/ P8L
MY\60%4!1KFV/LKYGU4B*ZI?\Q*<#5S=[6].4;2HQ8VRDCN!"T83V"QT'DZ(/
M50DO_$T:W7-7-DVSQ^+$'LE,J=/::R>DF( 63EU,EXKKD5,_Z31RCD)([=4W
MX8 QQ0B,>Y4N1:2$%[R8/P(VP5A2FV*30$Y-'4$V<6XI)#<213)VW9YR65JG
M.)M"NY-8'6KRV?&Z[W',-YFK7,_;[R#1XV>VJ-@O ("K?&O(JO)8"*.!,VNY
M$ZY>3"[=RQY-)(<3F'(.39NXS*RP.ER%(%EC<$X\F>X'6;5:[C +@1M&N&"<
M.**\>=/5Q2E;N";O-"UBW66*S$8J#G.XKMCY=Y3O-D?U1O6(L'+;%)3K<YOE
MV1/^/YF7;[R5Q2+5$U725QDGF5$7JX@<AEVOUT(V&E(90QIBRTJ&>25132RN
MS*5YAL&9W4QDP21!0JJ007?B%[W'/D;+>-'74\$2(Z2=4J)$2*)EF JX:@R-
M(SJX811F$1XE2 IS + 1:;M9Y[TL5V83,JG;:DZY$-MNM'L?+W(:O%N%8!\S
M"#Z.+'5Z&NGKR^L&7VDO4"4A1>;%$54HETW(<H=7H$R>'<T^;$LKH9,L&ED&
M0(EY%EC&(!>,J+2,"@'$ZJ%;!7TF$:XR1R+#P^,E-"W#(-,>4;RL'+B*568-
M$F,EQ#D\A.67=J'+QMD7?&RS)9ZW#:FC&]%!<D<F,#N9$C/E57=D0]D2LPM<
M5W/'-,!/XZ3J]+-9Q[.F>EAM&"Q0+&O)D*67(9N"H8ESQ)"9E+AES##J\-1P
MU4,P9206 Y:B:^F"L8XV#F-1"#! %IG$)C<HRGQG&D(E9C&F#*"JLW,1%-V7
M<R@L)="K>@P Z*X?GN+<*^WZ&P6D"EJ.&:Q9$S.:)*,81OA#QI8M53R=Y*P<
M;W*89CHIS 4<9 4<P)ZZV8Q%F$D@=@@A5E)M?FL;6.5SE8@?"U:VYTQ6XC?)
M14"-3##PT:0U+HP&9 Z\R9($ '#N"U[:EQ';AW))=V:2FVRH;5DL]J:D)=\D
M<G!D51<IMO<.=1ZJ,L3),,SU&U8Y+XR5,S +G6V"6*DE@*I#LKJ\SS/N>H6Z
MK(F-R5+/+=0&J"B * <<9(@2'4C @7ZK:J%=1-9I(G+XJK!8("'+)1\20LS8
MAA)!,5!B=6XMS:[C4'J?9OSTH<H'A5GJ@AJRW,"@#=;Z_;LZ;4&EE[2+.>N0
MR!\9U-8R]/+X/Y3C-0[+$@)6>0AB&SAZ:983B*UHYP0<U!#,0>(Q*JS4K$+:
M) ;\&3JV )D!+,<B;GW*C8.HB<HT:@KP45975*Y!G>:1EL*B$ALFMPCBJ *!
MD1NSCFIDCG6/+4E4ZC<;L:\*O3\J\HMAV_+0O'-AK@/.;%H6H3L ;!9[<T16
M)JHUB:YKQ526V49N_LY4LHV>Y)BMBZKXL@ 2RD-+@R\8D@$%F*MB <2H8$MV
M0.XTJM=8V:\ZODU/ I6FXJ.U(%#L&1$5D5KKF'9"J(.M<G<=P'SWR*_KUAX>
MY;%X^.6UI/NQR<QL.HQ=UIC-I'5I-ERR&0(JO-*_R)R3BVZD:Z%&M$_'6?1B
MX5>)5EU1!/(RM%+PR%4FY:Q="<>0!&)623/ES(B-CCRUZ.KI(4=*BG,H+MA9
M4)$<@!?FQ%F5XH>'8\@TO,7ZU'O.S_GZ:P7791;%L%28@-%"I=#RW8X3GRY=
MRAQ[8^/Y7V+)Q+>-(SE%"J[I!8H;,=R,@8&-V"6IHZ-66N=EU+4LY9[.,2"%
M'%:[!9$:/+*)[$(I5LC(I)(544\ME=QI L64;&12&9C3QD(6AF24+A4175I)
M%9<! X"AG>21039O-7;YW!7OBKA>H5>SU,"W4?C<]+97\=YO"'4;D6-1214%
MD0GM*YR&4\5+RTUDV)8NUX'(WE&K9T-UK6&5KC9V305#Q0HCH'2,JS&21?&6
M3%@2LA8 JURP$AN+2+=\J*:LHXIZF1XG,<LP9$,44GB2TI>-@'A",0R6"LT-
M@0\4EHRM.^P;GPAC4W<U+%8JF?,MJ^--&:<N\BA"WY%@[N :I;?R8QTJS+>E
M+U ;:FHT"E('<0',1*)2QR B4(A@:N!4=0X@CBN60S2@./'E6D.)P N@55#@
M\A<!5MM=UT@$JB4J5IX^'*M-"3"W]D5XH%,B\4MC([LYB*V<K=F<M(X>SCFY
M?7R<L+LKY%MS$?9.Q+L7*/*-;$ED'X2XZH=3O\+%>M>,!K!0K\AY!M:M$*(/
MJSWOD]F(LXMO!&FTEW).%-W$CV(NTLJ_]U&BN" Q5HW5V"@<\\LPXYP.XTA<
M!8FAB'6 2"!R/[1-))#9F4%)HFA1FOU>$$$9C)UOV?M-[D&\/(L87*"B+:XR
MW.>O3:WOD9?/2HF_%_/-(&6KO,A%P9'M%WY%J?,+LH"!435;)ZZKJ7UY7J;Q
MWZ&>EJ3Q,95&9?'QD@P#1SI86!^&[I,Q%BC9*N2I&-83<*)3%>!SPQ&'\5">
M+C-2RW;F#>..*2G56+"1,79E>26^0L':#RFN(?9X_?I-%#IK?("J^XY$Y 'A
M(J#7E7B"XTA0/(6IM*@,BL5RK\D!1"-:_9*S@JVE*ST3U197TD!J249<-ELQ
M>ZM)(.J9(6C )#"ZJD@ZRLMW*E65FU%-QIVPXT;%D2*S+!";2K#41RN0&C8B
M1I(3U7C<\,,'1D2]8_P'^XB-'$)\>5&6I2RK061@GY4=)&]D;(* XH29DRL;
M/A:TZ;[T76-4XKI8U:#.+*='' ;5-O3T1+>'<=0!82"Y"Y%965F*H8U)<PM_
M=BQ6R@DFXQ**3L'=*(MSA8JI? /3JRH'E$KA8TJHA:4EE<%R   1(LC@71Q=
MP1RK2.::RH.M#IA1]&G+?+7)!<7KG6O/7[#F'E6P\.*A&$D2I;*_<KN8'5DY
M/6JPI(A6G%E$'*DD5'KY&5T4$J3*,R4\;++\+%F:65H@#U5R996,H4<C%'?D
M5OJ3U4$M-(PC192M/3P@XYJBT].E0Q49,$1J=4@9V!*SR8\U<"\+3PT[$O?+
M?(%#K?'91W(M/X86$KG);6KEN[)Q_<N1&+^P,+/74C!DDLL%5M-?@H=S'@=L
MTKVO+]MP10U0,V;7A;.5T$=Y$A%FNMVC>0LQ95)#8.H1P"P91V #6M'4J8J>
M&5Y@L,E2V2!9,4EBA5$6-V570R(YFB)571V%R7.J5X8[6N4>.G'&X3ME2CZY
M6+RHY1:/@W;HFV L4W#%KX< XW!@(J8,-E4C+W"IL;R.U;IG-C,S:R6=.'8O
M]C<4PTLD9C!*%5=968,V098FB$8!0!EL03(S*S'(E+L3K:J=P@G$S*DJN\+4
MZH57AD/4).9R1(2CW4J(E5U4",+(0EM1RZ=JW-SBY6JPK2*.?*S*Y$@WL[3D
MN^B6*X5>]<[\<<EI:Z:EVI;JLU&/CJA4^;CQ;!)%?*W:Q050]CK&R0F=<#AJ
M:9G9AAS,H+-))DR/-&ZK;!E0(B<,#QBN N2@$@2BKZ58T1EE 40D1B"$I')%
M2RPM(&$JR2\663C&YBDC))CDR&1B2GMF[@C0V/&C"\6*9=6>)JD86PDMMC4*
MWO.$F-J9M-7;^PJ##5K6A^&D\*YZL*XX;U.*W-QRW%9<;2M5<<13SF\9D:RQ
M*2V3 &8@)U7Q)*B$68&,KDP8JUR-6-6T@(G$27>H<!>%&S+2CQOC(5D 5S4M
M=#Q5<QK964!2?H%P;4[91>*:=4KP6J-LZ,(P0^=*>W:KL0;-6$ZH:%B\B&.,
ME"3S !&3QKTZN0T<C*)!7T?JY(OW85=(D5R"R@@E2S#M-N; $V%@391?L518
M#B:J2.6HEDB#"-V!4,JJ?@@$XH2%!8$@9,UB,G=KL;7ZMUKZ=--.FFG333II
MITTTZ::=--.FFG333IIITTTZ::=--.FFG333IIITTTZ::=--.FFG333IIITT
MTZ::YZ_Q\]OX?XK;^3Q_P]/Z<=0?L'S_ -#JZ#X9_P!T_P QKMSUT+7K6G33
M4><U&J6/>.2PUBO/9(L>3%(Y2K6F\>N/'PUCV.&GVTQCQS\FN<8^7/5\-54T
M]Q!43P \R(9I(KGSG!EO^_6K44-%66[KHZ6JQ^#W13PSX_-Q4:W[M9!8H4I!
M=04RM<H"USG;418$, +KMG&,9VU'$BBBQG.,8QG.-,9\,8Q_)U"2669B\TDD
MKGM>1V=C\[,2?MU;#!#3H(X(8H(QV1PQI&@\G)$"J.7F&LCU7JW3IIITTTZ:
M:=--.FFG333IIITTTZ::=--<)B?"L!)/(\K,(L69-L:8\K?;/CC7337'WO*W
MWVUTQG;.-=<[>.^VNN,YQ9#$TTJ1+;)VL">P>4D_( ">7,VL.>J:B=*:"6>2
MY2)"Q"B[&W(*!R%V) %R ";D@7.NL;UFQ?L)3R\>'C_%@@QOKF,:#&<^1#'\
MN/'P\?'??PQF3?.V^?O^&.Y4L,5+$L2>3F[6(+L>UC_("_(  :\SKJN>OJ&G
MEY7Y1QAKK%&"2J+?S7NQL,F)-A>PP^!YL_>T_P!+3Y_#\+^GK8S7S_8?NUIX
M-YOM'WZT]'FQ_@?Z6OZW3-?/]A^[3!O-]H^_3T>;/^!_I:_K=,U\_P!A^[3!
MO-]H^_3T>;[_ )'^EK_+_P"UTR7S_8?NTP;S?:/OUKZ-/X>/D?)_Z6G\G_M=
M,U\_V'[M,&\WVC[]:>CS?@?Z6OZW]/3-?/\ 8?NTP;S?:/OUKZ/-^!_)X_WV
MGWO#Q_"^;IFOG^P_=I@WF^T??IZ/-\F?(^_][^-I_)_[73-?/]A^[3!O-]H^
M_3(TV/\  _D\?[[7[WWO'^^__#TS7S_8=,&\WVC[]:^BS_XO[W_&T_6Z9KY_
ML/W:8-YOM'WZ_/H\WX'^EK^M_1TS7S_8?NTP;S?:/OT]'FS_ ('^EK^MTS7S
M_8?NTP;S?:/OUKZ/-\G\3[^?#'\;3[_];^GIFOG^P_=I@WF^T??K7 L^?EQI
M_I:?K=,U\_V'[M,&\WVC[]:>C3>/AY'R_P#I:?R?^UTS7S_8?NTP;S?:/OTP
M--G[VGS?X6G\OWO\+IFOG^P_=I@WF^T??IZ-/\O\3[WW_P"-I^MTS7S_ &'[
MM,&\WVC[]/1IO'P\CY?_ $M/Y?\ VNF:^?[#]VF#>;[1]^GH\WCX>1][Q_PM
M/Y/O_P"%TS7S_8?NTP;S?:/OT]&G^7^)][[_ /&T_6Z9KY_L/W:8-YOM'WZ8
M&FS][3_2T_H_XW]..F:^?[#]VF#>;[1]^M/1YOP/]+7];IFOG^P_=I@WF^T?
M?K7T:;QSCR/O?+G^-I][^MTS7S_8=,&\WVC[]:>CS9_P/]+7];IFOG^P_=I@
MWF^T??IZ/-^!_I:_K?T=,U\_V'[M,&\WVC[]:X&FS][3YO\ "T_E^]_A=,U\
M_P!A^[3!O-]H^_3(TV/'QT^]_P ;3^C_ (W]./R_\O3-?/\ 8=,&\WVC[],#
M3Y^]I_+X?WVGW_O_ (73-?/]A^[3!O-]H^_3 TV?O:?Z6G]/_&_HSTS7S_8?
MNTP;S?:/OUIZ/-^!_I:_K=,U\_V'[M,&\WVC[]:X'FSGPQI_I:?K=,U\_P!A
M^[3!O-]H^_6GH\WX'^EK^M_1TS7S_8?NTP;S?:/OUKZ-/X>/D?)_Z6G_ "?A
M=,U\_P!A^[3!O-]H^_6GH\WX'W_^-K^MTS7S_8?NTP;S?:/OT]'F_ _TM?UN
MF:^?[#]VF#>;[1]^M<C38^_I_I:?K=,U\_V'[M,&\WVC[]/1IO'P\CY<_P#&
MT^?P_"^?IFOG^P_=I@WF^T??IZ/-X^'D?+X^']]I]_\ K=,U\_V'[M,&\WVC
M[]:>CS?@?Z6OZW]'3-?/]A^[3!O-]H^_6OHT_P O\3[WCX_QM/Y/O_X7]/3-
M?/\ 8?NTP;S?:/OUIZ/-^!_I:_K=,U\_V'[M,&\WVC[]/1YOP/\ 2U_6_IZ9
MKY_L/W:8-YOM'WZ>CS?@?Z6G\GR_/\W3-?/]ATP;S?:/OUKZ--X>/D?)_P"E
MI_+CQ_"^;IFOG^P_=I@WF^T??ID:?'W]/O?\;3^C_C?TXZ9KY_L/W:8-YOM'
MWZT]'F_ _P!+7];^GIFOG^P_=I@WF^T??K7T:?Q\/(^7_P!+3^7/A^%\_3-?
M/]A^[3!O-]H^_6GH\WX'^EK^MTS7S_8?NTP;S?:/OUKZ/-X>/D?)X^']]I]_
M^MTS7S_8?NTP;S?:/OUIZ/-^!_I:?I_HSTS7S_8=,&\WVC[]:^C39\/XGW_O
M?QM/Z?\ C?T=,U\_V'[M,&\WVC[]:>CS?@?Z6O\ +_[73-?/]A^[3!O-]H^_
M6N!YL_>T_P!+3Y_#\+^GIFOG^P_=I@WF^T??K3T>;/\ @?Z6OZW3-?/]A^[3
M!O-]H^_3T>;\#[__ !M?UNF:^?[#]VF#>;[1]^M?1I_P/Y/'^^T^]\F?POZ<
M=,U\_P!A^[3!O-]H^_3T:?\  _TM/G\/POGSTS7S_8?NTP;S?:/OT]&G_ ^_
MC&?[[3[V<^&/\+IFOG^P_=I@WF^T??KF@C2^=W\=/#'F]L?WVN?E\K3YML9_
;[NH2,MASMS\WR'S@ZOIXW+D ?HGRCSCY=?_9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>68
<FILENAME>g164680g98s98.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g164680g98s98.jpg
M_]C_X  02D9)1@ ! 0(!>0%Y  #_[1H$4&AO=&]S:&]P(#,N,  X0DE-! 0
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M=%!R;V]F4V5T=7!/8FIC    # !0 '( ;P!O &8 ( !3 &4 = !U '
M  IP<F]O9E-E='5P     0    !";'1N96YU;0    QB=6EL=&EN4')O;V8
M   )<')O;V9#35E+ #A"24T$.P     "+0   !     !       2<')I;G1/
M=71P=71/<'1I;VYS    %P    !#<'1N8F]O;       0VQB<F)O;VP
M %)G<TUB;V]L      !#<FY#8F]O;       0VYT0V)O;VP      $QB;'-B
M;V]L      !.9W1V8F]O;       16UL1&)O;VP      $EN=')B;V]L
M  !"8VMG3V)J8P    $       !21T)#     P    !29" @9&]U8D!OX
M         $=R;B!D;W5B0&_@            0FP@(&1O=6) ;^
M  !"<F1456YT1B-2;'0               !";&0@56YT1B-2;'0
M      !2<VQT56YT1B-0>&Q >0            IV96-T;W)$871A8F]O; $
M    4&=0<V5N=6T     4&=0<P    !09U!#     $QE9G15;G1&(U)L=
M             %1O<"!5;G1&(U)L=                %-C;"!5;G1&(U!R
M8T!9            $&-R;W!7:&5N4')I;G1I;F=B;V]L      YC<F]P4F5C
M=$)O='1O;6QO;F<         #&-R;W!296-T3&5F=&QO;F<         #6-R
M;W!296-T4FEG:'1L;VYG          MC<F]P4F5C=%1O<&QO;F<      #A"
M24T#[0      $ .__C4  @ " [_^-0 "  (X0DE-!"8       X
M    /X   #A"24T#\@      "@  ________   X0DE-! T       0    >
M.$))3009       $    'CA"24T#\P      "0           0 X0DE-)Q
M      H  0         !.$))30/U      !( "]F9@ ! &QF9@ &       !
M "]F9@ ! *&9F@ &       ! #(    ! %H    &       ! #4    ! "T
M   &       !.$))30/X      !P  #_____________________________
M ^@     _____________________________P/H     /______________
M______________\#Z     #_____________________________ ^@  #A"
M24T$"       $     $   )    "0      X0DE-!!X       0     .$))
M300:      ,U    !@             $F@  "=H          0
M               !              G:   $F@                     !
M                         !     !        ;G5L;     (    &8F]U
M;F1S3V)J8P    $       !28W0Q    !     !4;W @;&]N9P
M3&5F=&QO;F<          $)T;VUL;VYG   $F@    !29VAT;&]N9P  "=H
M   &<VQI8V5S5FQ,<P    %/8FIC     0      !7-L:6-E    $@    =S
M;&EC94E$;&]N9P         '9W)O=7!)1&QO;F<         !F]R:6=I;F5N
M=6T    ,15-L:6-E3W)I9VEN    #6%U=&]'96YE<F%T960     5'EP965N
M=6T    *15-L:6-E5'EP90    !);6<@    !F)O=6YD<T]B:F,    !
M    4F-T,0    0     5&]P(&QO;F<          $QE9G1L;VYG
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M;&5F=$]U='-E=&QO;F<         #&)O='1O;4]U='-E=&QO;F<
M"W)I9VAT3W5T<V5T;&]N9P      .$))300H       ,     C_P
M.$))3001       ! 0 X0DE-!!0       0    #.$))300,      ]5
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MTW7C\T:4I(6TE<34Y/2EM<75Y?569G:&EJ:VQM;F]B<W1U=G=X>7I[?'_]H
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MAC0YF.'LJ :0T.VBNMSW;G_O/5#ZT8V?GD=0N#G6TR/0F6;/I.^SMD[;*_\
M"[/YZK_BES?4;L/T+O1VL;Z<GZ0D;ZMNEMEJE]FI",NO99#*)BX^6NDOL?3?
MJ]]8OJYEX]'3NGY_KVT5MJ8S(+FWO#&[=SA>VI]UGM_2/K6ZOGXAK@._<'S_
M 'FE>B_4/ZY9&43T?JCW7Y+6EV'D.^E8U@FRFYWYU]3/TC;?
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
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M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_P  1" $; ET# 1$
M A$! Q$!_\0 'P !   & P$!              $&!P@)"@,$!0(+_\0 =1
M  8"  ,#!0<,"@H)#@X# 0(#! 4&  <($2$)$C$3%!5!40H687&!D? 9(E)6
M6)25H;'1U-87&#)"4U>2H\'3&B,D.')WDY>RX24F,S0U56*$\2<V0T1%1F-D
M@H.6N-+5-V5S='5VA8:8HK.TM<*VQ<;_Q  = 0$  04! 0$
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M_5HTJQ'/4U-,C+3C:_V\M:5]$.=,Y%$SF343,4Y#D,)3D.40,4Y#%$#%,4P
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M8,6B"[A99PJDB0J39%1RX4,=8Z:2:+=NDJY=.%E$FS-JDL[=K(-45EB2 20
M"22  !<DG(  9DDZ"A( ))L!F2= .9K6YXY^W*BX)Q,:WX4&\7;)9$RS!_L^
M2 SNCQJO,R*@5I@F9%2^/$^8F))NU6=&262,1*.V'$N47Y/38?L\MS==G%3:
M,B&$FSBAK^44/S!S2GY]B02@BM3)Q)*;HCV4H7!<.: ?[/TNTY:$!0K6IVEN
M#:&[+.XN6V+S8[W8UP,D5_89%9T5@V,;O%CXAB'DXZ#BDA /-XF':,8ML4"D
M;M$B% H>K8CLQD!MAM#2!P0D"_6HC-1ZR2>9K3...N*WG%E:B=2;V!N=T#(
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MU_7CQ=E:;%(D@VBJ8 HU,S?E,G*%F&BB;AL^@"1H.EYYB];.V+J)2=).VKA
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MM=Q>8Z5DG\]I1MF2A2%V6*T.%!YCB/JY&OT1.$'B\U'QEZ?KFW-36!&7B9E
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M+M%AE3Z?-@]H';]XJ+Y'B+9<+^'/AD.J],<!GKQ''CU\.-^^EM,K\=<^/4/
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M>VGCSZ^WPZ^SV\P]OJ\/#EBFM\]#P[M>OX5E"[-'7*,E:;QM!^W(H%98M:Q
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MA[;[LAKH9DEY702@M#RR4=&M5DMI;#:UV!<8W#4\XA(E]OK54"XD]V0:+?\
M9GHM?CU'DGLV)*=%DVV_689BDHY?6]F8[9CM&*CT%%Y8@MM@I('=*7)R'(MM
M-E_Q8F^MQ4VP"<X>A/\ 0PJ4NZU0G%:)B.G>7"6JP;.]$4?F,%?TIZ*?2&-L
M( PC$W;[388R-]2B-[&H+8"$S&QD536/FHGH%U.?-F)N') 9K=PC=@?L[8\;
M&73BEN#O3=?D$4G:&N:PW82FSG#54A#IA.2+\CNN4MR8I@4!FHQM,FD(&;2D
M=$NRJ)$Y;,VB::);B-A]0R+JR0T#_9"?G.#KN@'4$C.NWL88M5E/K*$G,(2
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MVUOQ]E\LNK,#C3&7P\/NH"-.J^ATZO@*8X^S7V6Y\>>7*HN#IVFV=_-K:7U
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M/'*P-^7"V?CK8\2!4=M["UCG<]HXGWWMJ*9.=]<K:=?W4%N>AMQUXW/'/0V
M%,#C8:7\GK)[3QXB\^.IZQKU#ART\+A@VTTOIV]0[<^WKH=1KKGESRUTR.9!
M[>%,:?9]0U]O.F@S-N%Q:PM[K^ TUU8R OPRSUZJ6&=N/ 9:>!\3[*9-+\<K
M=IZK:VM3([<AVD9<]!8^[G3LY:_5K?J[.NJ#\4D*,UHF9=$*)EJA;:O9.\4
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M*V-_<ZMY5:;2XG-8BL8&]AUK2-D@W$/K3N=?7,U,*H4>8=TQ4=PJ]XH /?*
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M 0$!$!#ED D&X-B,P1J#SI7RFDDD1--)--)-(@)I$3(4A$R   !$RE "D(
M  4H      <@#))))))))N23<D\SS/7332OHQ"& Q3%*8IRB4X&* @<H@("4
MP" @8H@(@(#S 0$0\!R--*5\)HHHIIHHHI)(I  )))ID333 / $R% "D /4!
M0  ]62222222=23<GM)H !D!8<A7V)"&'F8I3#X<Q* CR]G4,BE?6*4Q2F*4
MQ2F*5J8>ZDGJ@4/A=8\S>37O5Y6,'[T1CJS">1'EZQ*,RY[H]>[WS\AZB&=9
M]$Z09V,+-KIBQDCG\YUTG_\ )S[JL/Z)[?A6F]G;QH/CKWUC4R+]8OIEVCAG
MGP[Z4R>?F^0I7T0QDSE4(8Q#D,!R'((E.0Y1YE,4P" E,40 0, @("',!YY%
M@1:P(Y6!'+LZJ5M\>Y@;WLN[VKBI86_9VPK/6*-3=4LJQ3K%=;)-5:$6LTU=
M57TA$5Z2DW,3&O12K+5H+QDS17\V5.@*GDE#$-QKTIQHL=O"2Q%C,N/NRU.O
M-LMH=6&DLA*5N)2%J3=U2K*40% &UZR&"3O7)-@  3?6_P!5;>PB  (B(  !
MS$1Z  !XB(^H SCM9%8>[YV<G#AO+B8N_%\/%CMTY#Q4U P=?J.Y*])5/1^Z
MK)0[1IX^R]:V*41L;JB6R,K=^DE*O0BKC3HG8DF:Y!7'DJX9LVRWU^RU*F.A
M]E+H?3G!-N_@FE=]\0EAX==K4]:KR2FP[?JIM(ZR@W*TB\L#ZDS4)JFK0\?(
MV61DE)>TSEQC+4]EY9)*1>.1<J.U'*E78;BX2*KOC6G$QJ38&S-NR6NN*#7T
M?KB:K3>PUPD=K.OH5!:I2:^HR+U-T$#(6A)<9VPKSXVIL\GR)NVK5FT S(RE
M6A;W[+SA_P!Y;2W;.S?$]Q&:_0XE*=J[4&^M,ZXV;JZM5#:57UQ2Y6&JM4L#
M*2UE-7ULI*U"0L*LDA VV(>2<;(RCEKYNS*06ZU_=2LK4'"QE;A8>NPK4K&'
M@8N/A8ED4ZJI6D9%M$6+!J51<ZBRA6[5!)(#K***G @&4.<XB85*U[?=,]:8
MRW )19]8A D*IQ*T5RR7[H"J*$O1MF1#YH4_+O%27%PT<JE >Z<[! 1 1(40
MZ/Z+W5(VB>1?YKN&2 H7RNA^,M)/6+* Y;QJT]^9WCXUH:YW_*^69-KYBX'/
MGR]E8E,JYVMS^TTIBE,?#7C2LYGN?IRHCQIWY @\B/N&VZME_8*:>R=0OR@(
M>'1=DB8.H"'+F'@(#SCTH)"MG&CG=.)1E#AF69*>7)1OD>RKS'Y__=.NFJ=3
M6XYGSZ.L"YUZ_LY5LM?/M'F]Z?3\V+Z9'N\,_&^?U53SURY6ST)%M<\LNS/,
MTQY[NR_M^ZIUZM?#JMIY[:8''MR[+#PSO3+*^7(7[0,O'X7M3)\^-+VRTL+\
M/NRRX\<Z9&O(\CU^XC/GU:B]-=;\/KX<;C/ARU-,&Q-C8\0/9\?-J@DZ6OIF
M#;[CQ[..8!8]FNG'SJ>OVSSUROY^KM(M3'+W#/V\NX::\*'JUSR]MN5QPURO
MVTQJ.T4&=\NK/.]M1;Q'V4R?/GVT'#*V7/(=5M._W4R.=[YY>P#+J^W2HTN<
M]+VRZ[]6IN;$\.H%CN^RU3J.8[=? <>/VTR +:DD@6]U[=7CRYT%^S//LZLS
MW]_:63GS'@1\?;3O\Y]77]],7\V\V[[=_!<\,^'4#U_',VRYYL<S?+QR S[#
MJ/A>H&6G$'A89:$_8,]=!3([3EKD"#GV9]PSYG6X]1[.WG?V@=MAI9DCWY]W
MGPOK4WYY6&>=^_F;YZYY:4R<N'9X<.Z@(]U[ZYCCU]N=,=O?RJ?O\V]M?::A
MTCIJIF$BB1BG3.4>1B'(;OE,4?48I@ 0$/ 0#(MKQZN%[#JOR^JJ2+W(.N7L
ML>VWOXUC(XKJ.6I;;EI=DW!&"V$B6]17DR<FZ+J767+98\G+^UIA'V9"621;
ME[ODH\[ W<(19,,^S?1=CXQW9&!TBPJ9A21A4L7NK_14)$9PW^<>EB%DJ6;[
M[J7;$D&OSV],^S"MFMN\5Z-O<@8THXU!(39'^FK69K0_HIZ*>F1NMBVXPM@V
M"5)%6T\_5T'IZOCY!R^$.G/J'+QYYT2N4 Z#+349"VF5KZ<<\JCX#X_!]/SC
MXB/P@&*GB,^8X_;ISZ^L4\.7CX_'[?'K^< ^#IBAX=O+S;MI[/I^+Z<NO4/6
MJ:C[/I^3_4'Y,4\^?/U&'AS]@=>?XQ\/@'P$/E]>*CX>>';Q[<\C7L0["+<^
ME96R3K&I4NJ0DG;K[<I4%/1-/ID$B#F<GWY2!Y1;S=$2-8V/1 7<U-/(R$CB
M*R,FT14T^.8PS@>'N374*?=*D1X41L@.S9SUQ'BM7R!<4"IQ9NEEA#KZ_P F
MTHCTVR&RV(;98]"P/#QNKD*+DF2I"E,P839'K,Q\"UD-((2A)*>F?6TPA06\
MFL8=2[?[B2T]Q"SECU9#1,MPK-Q95BH\.EU3023:TR#7=>:V(ELBD#R\%L^T
MK/)&Q6J:14F8)>9ESL5X*4AX.O-H_BV*;$Q=H&79>*/*3CTMQ4F3B3%RD/.)
M2$QTL+5N*A1FT-QX[9*' RTE72)<6XI7Z)8#A4'9O"8&"88V6X&'1TL,I6=Y
MQ>:ENO.J_I/R'EN//*L$J<<40E(L!LB\+W;Y]G_Q"LHYC<KXZX;[TX3(5Y6M
MSIIQ5<*Z /[>:-V6P%S2U8XINC=S87U6D%R_7'AVX\R!R?%?1_M#AJE*:CC$
MHXO9V#=:[<-Z,H!X*MJ&TNI&F^36]2Z@\;'K^O2LOE*V3KO948E-ZZOM+OT,
MN4IT9>E6F#M,8J0Q0,4R3^#?/FJA3%$# )51 2CS#IGCWXTF,HHDQWXZQJA]
MIQI0X9I<2DC/+2KEP=#>IO7<(-4E'#E=%N@D43JK+J$123(4.9C***&*0A0
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MQA^&[AUTJFZ3+,7S<LEL15L14OEA@M:TV6@5A61 >^5NO*[*C3I', $.M'G
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M2+@D UBO8CA[##\I^?#8BQ5EJ3(>D,M,1W4K"%-OO.+2TTM*R$*2X4J2H@$
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M#BMJ0VI]XM-O/*WG766&FF&77WGWFFFFEK6!6HQG&8^"L,.NL29DB9*;@8?
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M2<Q,G!R#%9VBW>*LU%&$LX6:.BM')4GB#<%43(G5$-Y@LZ+&&)PL0Z9$'%X
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M]?Y'4<;_ $7@ACWVZK^W[JG>3K<CAQZN5_A7$.M[N'C7G?R*M#?Z+@?IT\<
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MQ2F*4Q2F*4Q2F*4Q2F*4Q2F*4Q2F*4Q2H" & 2F #%, @8H@ @("'(0$!Z"
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M5R5J&8#CJG' "0% &U9"4)1H.TG4^>JLB  !0 I0 "@         <@  #H
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M4Q2F*4Q2F*4Q2F*4Q2F*4Q2F*4Q2F*4Q2F*4Q2F*4Q2F*4Q2I2/./ .< *B
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MOLZ!Z_R9&Z+:#P^[/D;"WLI?._;[>V^7/G3OF^R-\@B&38<AX7\_5E44[QO
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MG\GJ_+RYY<N.8YWN.SVZ>-6ZAY-0/WA_Y)OS8RYC@=?#NI[2>_6GDU/X,_\
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MW9::S<K-7\_66CQ$_<<-W<K%(.4C\@,)5D5ER*D/R$![IR@/(0'EU#+@:=4
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M<!DH<-=,ASU(N1>75]$<+\F[VS0Z)!FD9K0>Q]N0"U[M3^QM:Y<FM:FN)!S
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MZPINH)221N@#> S*KVW@+\0=Z_,9WMD*I'HG@HUI/W[63&UR]XLI3,^'B[;
M@TJ69*FV"I\1$.27AZOKZR1=P93\[>:LA)QC1Y$J-X<D_-0FPXUF^BTZ,+JP
M9N(8_+;C2E-(8:SQ%B.YT_\ I#;N'+W5NR6U,J0TP[NJ4E7SRA"XZB%]/9N
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M)NK'W *0C)!B@P >\\4>B#/Q6U^UR=IQ!0W"5$1#+ZB5O!U3BGNC&6ZA 2E
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M.1V/_0VT?['#>[_VEX\M>-/JF>G.G^T?9O7P_N*J_']M6/D+VE_2N!_M)_\
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M"O0/&2+JVH=2!:Y5A38 N;#,XC;,D ==2/Y3$Q1LG8MA1SL$XZZ2; DY#".
M!/8"=!3ZI_-^3!7]A:/\F8PD!3W\O/)B<H 82 ?WI]T3@4Q3"7GS # /+D("
M+Y!XU]W\:'=X $I_!3=P"2 ;?A&]B00#H2#RI_.9F6"OQ,8W22 K\.N[I( )
M%_P1:X!!M>]B#7Q]5"F.7/\ 89C?#G_U].OU3Y_BZ^S)^06/^L[W^Z4?\0J!
M_*;E'_\ @V/U?\NN?\(KT5>TKMJ#ALU7T*"+IXU1?-&RULDTG#IBX0%RW>MT
M5*>51=HNW 5T7*13HJH@*I#F( FRRGT'8>M#CB-KMY#3BFG%IPYA2&W4*W%M
M.*&)$(<0NR%(40I*CND Y5D+_E(8JVXVTYL&4.O-(>9;7B\E+CK+B.D;>;0K
M!@I;+C8*T.H"D+3\Y)*<ZZ:':=S[E4B#;23)PNH(@FBA=GJJI^11,;N$3J1C
M'$I2F,(% 1[I1-X .7%^@B(VDK<VI<0A-KJ7A;:4BY %U*Q$ 7) %SJ0*LH_
ME+SG%I0WL4RXM5PE",<>6M1 )(2E.$$FP!)L- 3H*YR=IE:%&QWJ>BD5&2??
M$[PEQD#-2 00 PF<!4!2+W1'D;O'#NCXB&4'T&04N!I6UA2Z;6;.&LAPWTL@
MXEO&_"PSX56/Y26)*:4^G89*F4WWGAC+Y:&[:]W!@^X+$V-U"QKK%[3Z<.!S
M$TK'G!(GE%1+>'8@FGWR)]]02U,P$)Y11-/O&$"]\Y"\^\8H#</H'C @':AT
M%1W4@X4V"I5BJPOB.9W4DV&=@3H#5L?RF9BKD;&,$)3O*MCKIW4W2G>41A!
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MG(9Y5\_50IC^)F-_].G7ZI_%^/V=9^06/^L[W^Z4?\0I_.:E_J;'_P!_.?\
M"*^_JG\YW 5_858 D8YDRK#>'?DC'(4ACD*I[T^Z*A"J$,8@#W@*<AA  , C
M'R#Q=XI_&AW> "BG\%-[P220%$?A&X!((!M8D$#0U/\ .9F6"OQ+9W22 O\
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M;TE2YR)KQE&5NEE'T$M:/?/$MV[21FA:.HTT8G85I!TZ=RV%$DX[*DQ7IAQ
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M(DI40%5\_P"%*8;P'&UEKUA3>)[.+E,!:F'7\$2O%/76BZ@.*:8<Q'\"I=6
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MF/6'OI_X4_NT,=GZ' ?TE<0/[5=APW([!N#HR[@&K<C-J"[ERJ#9HF8YR-D
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MQ_BAJ/WJY_2L?*'MM^L>(_WV_P"'3Y*O1W^J6$_LG/XM/VIW#CT_ZD-1Z?\
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,ZWU,4IBE,4IBE?_9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>69
<FILENAME>g164680g99s99.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g164680g99s99.jpg
M_]C_X  02D9)1@ ! 0(!>0%Y  #_[1?44&AO=&]S:&]P(#,N,  X0DE-! 0
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M=%!R;V]F4V5T=7!/8FIC    # !0 '( ;P!O &8 ( !3 &4 = !U '
M  IP<F]O9E-E='5P     0    !";'1N96YU;0    QB=6EL=&EN4')O;V8
M   )<')O;V9#35E+ #A"24T$.P     "+0   !     !       2<')I;G1/
M=71P=71/<'1I;VYS    %P    !#<'1N8F]O;       0VQB<F)O;VP
M %)G<TUB;V]L      !#<FY#8F]O;       0VYT0V)O;VP      $QB;'-B
M;V]L      !.9W1V8F]O;       16UL1&)O;VP      $EN=')B;V]L
M  !"8VMG3V)J8P    $       !21T)#     P    !29" @9&]U8D!OX
M         $=R;B!D;W5B0&_@            0FP@(&1O=6) ;^
M  !"<F1456YT1B-2;'0               !";&0@56YT1B-2;'0
M      !2<VQT56YT1B-0>&Q >&2G\         IV96-T;W)$871A8F]O; $
M    4&=0<V5N=6T     4&=0<P    !09U!#     $QE9G15;G1&(U)L=
M             %1O<"!5;G1&(U)L=                %-C;"!5;G1&(U!R
M8T!9            $&-R;W!7:&5N4')I;G1I;F=B;V]L      YC<F]P4F5C
M=$)O='1O;6QO;F<         #&-R;W!296-T3&5F=&QO;F<         #6-R
M;W!296-T4FEG:'1L;VYG          MC<F]P4F5C=%1O<&QO;F<      #A"
M24T#[0      $ .__C4  @ " [_^-0 "  (X0DE-!"8       X
M    /X   #A"24T#\@      "@  ________   X0DE-! T       0    >
M.$))3009       $    'CA"24T#\P      "0           0 X0DE-)Q
M      H  0         !.$))30/U      !( "]F9@ ! &QF9@ &       !
M "]F9@ ! *&9F@ &       ! #(    ! %H    &       ! #4    ! "T
M   &       !.$))30/X      !P  #_____________________________
M ^@     _____________________________P/H     /______________
M______________\#Z     #_____________________________ ^@  #A"
M24T$"       $     $   )    "0      X0DE-!!X       0     .$))
M300:      ,U    !@             "Q   "9T          0
M               !              F=   "Q                      !
M                         !     !        ;G5L;     (    &8F]U
M;F1S3V)J8P    $       !28W0Q    !     !4;W @;&]N9P
M3&5F=&QO;F<          $)T;VUL;VYG   "Q     !29VAT;&]N9P  "9T
M   &<VQI8V5S5FQ,<P    %/8FIC     0      !7-L:6-E    $@    =S
M;&EC94E$;&]N9P         '9W)O=7!)1&QO;F<         !F]R:6=I;F5N
M=6T    ,15-L:6-E3W)I9VEN    #6%U=&]'96YE<F%T960     5'EP965N
M=6T    *15-L:6-E5'EP90    !);6<@    !F)O=6YD<T]B:F,    !
M    4F-T,0    0     5&]P(&QO;F<          $QE9G1L;VYG
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M;&5F=$]U='-E=&QO;F<         #&)O='1O;4]U='-E=&QO;F<
M"W)I9VAT3W5T<V5T;&]N9P      .$))300H       ,     C_P
M.$))3001       ! 0 X0DE-!!0       0    #.$))300,      TE
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MTW7C\T:4I(6TE<34Y/2EM<75Y?569G:&EJ:VQM;F]B<W1U=G=X>7I[?'_]H
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M!_BR1<OW3]H=R_ZNXM]]F0_#8VZYV^VRK*L
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
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M 0$! 0$! 0$! 0$!_\  $0@ K@)= P$1  (1 0,1 ?_$ !X  0 !!0 # 0
M           !!08'" D#! H"_\0 <!   0,# @$#"PT*!@L,!@L !@0%!P(#
M"  !"1$86!46%QDA55>6E]76$A,4&C%!49&5TM/4UU-687&!DI.AL? B)28V
M4L$G*#4W18>4IJ?1Y HS-#A"1D=E9J7#X3)#8W6$\2,D5&1G=X:RM+;%_\0
M' $! 0 " P$!              $&!P,$!0((_\0 5Q$  0$$ 0\(!P4$"0($
M!P    $" P0%%P81$A,4%E%459&2E-'3U"%24U9AE:'2%3%!I-7A\'&!D['!
M!S)BQ"0S-(2BQ>+C\2(E1'.#HR,U149D=:7_V@ , P$  A$#$0 _ /OXT T
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M R>4\B3!<,9(@(I$V0;3 <=MRE:,E>'K1+:L+('@5QDF <M#U,Q.%T3"NMB
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MN7RAJ-V$?R 874NA^&)+$'APC['J=G.A/9?3"42X"=*[L1V+C"L67FY4GO,
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ML2&AH625'A&RHW5LX=^^/JMFC@K9J1&; Q]O36F0)W"-"-9*N-;NCJ=)P1N
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MG&CR;4Q'EB7"XCC)--Z";&+K<,S1&;!D.-P8CDR>,D J$22%9%9I.2#AC>D
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MU?H VZT T T T T T T T T T T T T T T T T T T T T T T T T T T
MT T T T T T T T T T T T T T T T T T T T T T T T T T T T T T
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MAFT@;1)+*0!"DO>Q0D=V@=J(6I0AL.RQ)?KJL56Z;]L#1!DG/B*!<OQ&(MR
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M]+6,M0-;I<0I72PA7J61:MMI%"IK7H71'1?JHW6-BU&XI?7D:JQ?N 95T T
MT T T T T T T T T T T T T T T T T T T T T T T T T T T T T T
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MDT"'U4C1V_5QN\(6 F$[:H6>KM*CV,2474FUA0!=A[G/#,3R0;QQ(K@[T/;
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MR_LD8MK32LHU616K&M7L4K^I#HGV693[O]DL_P#A_GB0^<?=_#K1]=</9]V
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MG_CB0^<=!8,<UG138.RU*G<Y9*/]^3X3$A\XZ5UPBP8YK.BFP=EJ5/>DL_\
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M.FPGGX2]WB =NYR]UJ?.[^+^4>EFO9]?>+0QA:SIL(Y^$O=X@'Y*?/2/2S7
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MFY'W.H=S>PZ.3OL<#;2B*BC9+,,E6%RI7(#&T=:C+0H V#D[!8@FG,YT.I;
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M)MMM\&W)KD. : : : : : : : : : : : : : : : : : : : : : : : :
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MCUAZO+;7K-RY;]3ZBNJG=0K55CLBUJ.^'"_Z2]!,?P(?BOT*-?XQ?#-5"3
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MS64HTM*A3<V3V=J.M9I@7PVG+:&\+.==A4+^5>+RMHW8%43."EBW'G 2J9%
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MR>KL?GW/H^30$]2%/<_AV/P_P[GP[_\ LO@Y- .I"GN_P['=WY>Y5<Y/?_\
M9?A_?W@(ZD*?NEC\ZY]%H#Z,J?<V_%M^S78//)T T T T T T T T T T T
MT!BF7(3CF<F1E89&:GA<G&B*R6C3D-&9M'A2-DEEG>1[JP/&<=D0J7L:M0/$
M;^P+JFM[2T.#(]NK2OH4H%ZE/< ND" P^+PL7CN/Q]O%0D,94 Z,#K7170A:
M&=LL4IT:.QZ[7=OW?46Z-M[JA3>OJU5ZJXI5W[ZF[=NU@7;H#7R'\68+@9[>
M".+@Q4QO+PRHA?V6Z&)T9;,0@W."QV0!(2F-B4B21^"HW-<I7)@D&L#PK94>
=QZZ&C;V$BV3@;!Z : : : : : : : : : : _]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>70
<FILENAME>d164680ds1_htm.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version="1.0" encoding="utf-8"?>
<xbrl
  xmlns="http://www.xbrl.org/2003/instance"
  xmlns:country="http://xbrl.sec.gov/country/2021"
  xmlns:dei="http://xbrl.sec.gov/dei/2021"
  xmlns:iso4217="http://www.xbrl.org/2003/iso4217"
  xmlns:link="http://www.xbrl.org/2003/linkbase"
  xmlns:roiv="http://roivant.com/20210630"
  xmlns:srt="http://fasb.org/srt/2021-01-31"
  xmlns:us-gaap="http://fasb.org/us-gaap/2021-01-31"
  xmlns:utr="http://www.xbrl.org/2009/utr"
  xmlns:xbrldi="http://xbrl.org/2006/xbrldi"
  xmlns:xlink="http://www.w3.org/1999/xlink"
  xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
    <link:schemaRef xlink:href="roiv-20210630.xsd" xlink:type="simple"/>
    <context id="P04_01_2020To03_31_2021">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001635088</identifier>
        </entity>
        <period>
            <startDate>2020-04-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="P04_01_2019To03_31_2020">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001635088</identifier>
        </entity>
        <period>
            <startDate>2019-04-01</startDate>
            <endDate>2020-03-31</endDate>
        </period>
    </context>
    <context id="P04_01_2020To06_30_2020">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001635088</identifier>
        </entity>
        <period>
            <startDate>2020-04-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="P04_01_2021To06_30_2021">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001635088</identifier>
        </entity>
        <period>
            <startDate>2021-04-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="PAsOn03_31_2021">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001635088</identifier>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="PAsOn03_31_2020">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001635088</identifier>
        </entity>
        <period>
            <instant>2020-03-31</instant>
        </period>
    </context>
    <context id="PAsOn06_30_2021">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001635088</identifier>
        </entity>
        <period>
            <instant>2021-06-30</instant>
        </period>
    </context>
    <context id="P01_01_2021To03_31_2021">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001635088</identifier>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="PAsOn05_31_2019">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001635088</identifier>
        </entity>
        <period>
            <instant>2019-05-31</instant>
        </period>
    </context>
    <context id="P01_01_2020To01_31_2020">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001635088</identifier>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-01-31</endDate>
        </period>
    </context>
    <context id="P05_01_2021To05_01_2021">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001635088</identifier>
        </entity>
        <period>
            <startDate>2021-05-01</startDate>
            <endDate>2021-05-01</endDate>
        </period>
    </context>
    <context id="P05_01_2021To05_31_2021">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001635088</identifier>
        </entity>
        <period>
            <startDate>2021-05-01</startDate>
            <endDate>2021-05-31</endDate>
        </period>
    </context>
    <context id="PAsOn09_30_2020">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001635088</identifier>
        </entity>
        <period>
            <instant>2020-09-30</instant>
        </period>
    </context>
    <context id="PAsOn05_31_2021">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001635088</identifier>
        </entity>
        <period>
            <instant>2021-05-31</instant>
        </period>
    </context>
    <context id="PAsOn05_01_2021">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001635088</identifier>
        </entity>
        <period>
            <instant>2021-05-01</instant>
        </period>
    </context>
    <context id="PAsOn07_31_2020">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001635088</identifier>
        </entity>
        <period>
            <instant>2020-07-31</instant>
        </period>
    </context>
    <context id="PAsOn07_31_2021">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001635088</identifier>
        </entity>
        <period>
            <instant>2021-07-31</instant>
        </period>
    </context>
    <context id="PAsOn04_30_2020">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001635088</identifier>
        </entity>
        <period>
            <instant>2020-04-30</instant>
        </period>
    </context>
    <context id="PAsOn03_31_2019">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001635088</identifier>
        </entity>
        <period>
            <instant>2019-03-31</instant>
        </period>
    </context>
    <context id="PAsOn06_30_2020">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001635088</identifier>
        </entity>
        <period>
            <instant>2020-06-30</instant>
        </period>
    </context>
    <context id="P01_01_2021To03_31_2021_ArbutusBiopharmaCorporationMemberdeiLegalEntityAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001635088</identifier>
            <segment>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">roiv:ArbutusBiopharmaCorporationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="P05_01_2018To06_30_2020_GenevantSciencesLtdMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001635088</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">roiv:GenevantSciencesLtdMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-05-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="P08_25_2020To09_30_2020_ImmunovantSciencesLtdMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis_RestrictedStockMemberusgaapAwardTypeAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001635088</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">roiv:ImmunovantSciencesLtdMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-08-25</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="P08_25_2020To09_30_2020_CommonStockMemberusgaapStatementEquityComponentsAxis_ImmunovantINCMemberusgaapBusinessAcquisitionAxis_UnderwrittenPublicOfferingMemberusgaapSubsidiarySaleOfStockAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001635088</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">roiv:ImmunovantINCMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">roiv:UnderwrittenPublicOfferingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-08-25</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="P08_25_2020To09_30_2020_CommonStockMemberusgaapStatementEquityComponentsAxis_UnderwrittenPublicOfferingMemberusgaapSubsidiarySaleOfStockAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001635088</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">roiv:UnderwrittenPublicOfferingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-08-25</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="P04_01_2019To03_31_2020_SumitovantMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001635088</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">roiv:SumitovantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-04-01</startDate>
            <endDate>2020-03-31</endDate>
        </period>
    </context>
    <context id="P04_01_2019To03_31_2020_EmployeeStockOptionMemberusgaapAwardTypeAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001635088</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-04-01</startDate>
            <endDate>2020-03-31</endDate>
        </period>
    </context>
    <context id="P04_01_2019To03_31_2020_MaximumMembersrtRangeAxis_MeasurementInputExpectedTermMemberusgaapMeasurementInputTypeAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001635088</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputExpectedTermMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-04-01</startDate>
            <endDate>2020-03-31</endDate>
        </period>
    </context>
    <context id="P04_01_2019To03_31_2020_MeasurementInputExpectedTermMemberusgaapMeasurementInputTypeAxis_MinimumMembersrtRangeAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001635088</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputExpectedTermMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-04-01</startDate>
            <endDate>2020-03-31</endDate>
        </period>
    </context>
    <context id="P04_01_2019To03_31_2020_SumitomoMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001635088</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">roiv:SumitomoMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-04-01</startDate>
            <endDate>2020-03-31</endDate>
        </period>
    </context>
    <context id="P04_01_2019To03_31_2020_FairValueInputsLevel3MemberusgaapFairValueByFairValueHierarchyLevelAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001635088</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-04-01</startDate>
            <endDate>2020-03-31</endDate>
        </period>
    </context>
    <context id="P04_01_2019To03_31_2020_ResearchAndDevelopmentExpenseMemberusgaapIncomeStatementLocationAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001635088</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-04-01</startDate>
            <endDate>2020-03-31</endDate>
        </period>
    </context>
    <context id="P04_01_2019To03_31_2020_GeneralAndAdministrativeExpenseMemberusgaapIncomeStatementLocationAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001635088</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-04-01</startDate>
            <endDate>2020-03-31</endDate>
        </period>
    </context>
    <context id="P04_01_2019To03_31_2020_TwoThousandFifteenEquityIncentivePlanMemberusgaapPlanNameAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001635088</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">roiv:TwoThousandFifteenEquityIncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-04-01</startDate>
            <endDate>2020-03-31</endDate>
        </period>
    </context>
    <context id="P04_01_2019To03_31_2020_SubsidiaryEquityIncentivePlanMemberusgaapPlanNameAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001635088</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">roiv:SubsidiaryEquityIncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-04-01</startDate>
            <endDate>2020-03-31</endDate>
        </period>
    </context>
    <context id="P04_01_2019To03_31_2020_LiabilityInstrumentsMeasuredAtFairValueMemberusgaapBalanceSheetLocationAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001635088</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">roiv:LiabilityInstrumentsMeasuredAtFairValueMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-04-01</startDate>
            <endDate>2020-03-31</endDate>
        </period>
    </context>
    <context id="P04_01_2019To03_31_2020_USsrtStatementGeographicalAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001635088</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-04-01</startDate>
            <endDate>2020-03-31</endDate>
        </period>
    </context>
    <context id="P04_01_2019To03_31_2020_CHsrtStatementGeographicalAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001635088</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:CH</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-04-01</startDate>
            <endDate>2020-03-31</endDate>
        </period>
    </context>
    <context id="P04_01_2019To03_31_2020_BMsrtStatementGeographicalAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001635088</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:BM</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-04-01</startDate>
            <endDate>2020-03-31</endDate>
        </period>
    </context>
    <context id="P04_01_2019To03_31_2020_OtherMembersrtStatementGeographicalAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001635088</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">roiv:OtherMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-04-01</startDate>
            <endDate>2020-03-31</endDate>
        </period>
    </context>
    <context id="P04_01_2019To03_31_2020_DermavantSciencesLtdMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001635088</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">roiv:DermavantSciencesLtdMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-04-01</startDate>
            <endDate>2020-03-31</endDate>
        </period>
    </context>
    <context id="P04_01_2019To03_31_2020_ArbutusBiopharmaCorporationMemberdeiLegalEntityAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001635088</identifier>
            <segment>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">roiv:ArbutusBiopharmaCorporationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-04-01</startDate>
            <endDate>2020-03-31</endDate>
        </period>
    </context>
    <context id="P04_01_2019To03_31_2020_SioGeneTherapiesIncMemberdeiLegalEntityAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001635088</identifier>
            <segment>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">roiv:SioGeneTherapiesIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-04-01</startDate>
            <endDate>2020-03-31</endDate>
        </period>
    </context>
    <context id="P04_01_2019To03_31_2020_PerformanceOptionsMemberusgaapAwardTypeAxis_TwoThousandFifteenEquityIncentivePlanMemberusgaapPlanNameAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001635088</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">roiv:PerformanceOptionsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">roiv:TwoThousandFifteenEquityIncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-04-01</startDate>
            <endDate>2020-03-31</endDate>
        </period>
    </context>
    <context id="P04_01_2019To03_31_2020_RedeemableNoncontrollingInterestMemberusgaapStatementClassOfStockAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001635088</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">roiv:RedeemableNoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-04-01</startDate>
            <endDate>2020-03-31</endDate>
        </period>
    </context>
    <context id="P04_01_2019To03_31_2020_AdditionalPaidInCapitalMemberusgaapStatementEquityComponentsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001635088</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-04-01</startDate>
            <endDate>2020-03-31</endDate>
        </period>
    </context>
    <context id="P04_01_2019To03_31_2020_EmployeeStockOptionMemberusgaapAwardTypeAxis_TwoThousandFifteenEquityIncentivePlanMemberusgaapPlanNameAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001635088</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">roiv:TwoThousandFifteenEquityIncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-04-01</startDate>
            <endDate>2020-03-31</endDate>
        </period>
    </context>
    <context id="P04_01_2019To03_31_2020_NoncontrollingInterestMemberusgaapStatementEquityComponentsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001635088</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-04-01</startDate>
            <endDate>2020-03-31</endDate>
        </period>
    </context>
    <context id="P04_01_2019To03_31_2020_CommonStockMemberusgaapStatementEquityComponentsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001635088</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-04-01</startDate>
            <endDate>2020-03-31</endDate>
        </period>
    </context>
    <context id="P04_01_2019To03_31_2020_AccumulatedOtherComprehensiveIncomeMemberusgaapStatementEquityComponentsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001635088</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-04-01</startDate>
            <endDate>2020-03-31</endDate>
        </period>
    </context>
    <context id="P04_01_2019To03_31_2020_RetainedEarningsMemberusgaapStatementEquityComponentsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001635088</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-04-01</startDate>
            <endDate>2020-03-31</endDate>
        </period>
    </context>
    <context id="P04_01_2020To03_31_2021_ProteovantSciencesIncMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001635088</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">roiv:ProteovantSciencesIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-04-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="P04_01_2020To03_31_2021_SoftwareDevelopmentMemberusgaapPropertyPlantAndEquipmentByTypeAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001635088</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:SoftwareDevelopmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-04-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="P04_01_2020To03_31_2021_FurnitureAndFixturesMemberusgaapPropertyPlantAndEquipmentByTypeAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001635088</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:FurnitureAndFixturesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-04-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="P04_01_2020To03_31_2021_EquipmentMemberusgaapPropertyPlantAndEquipmentByTypeAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001635088</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:EquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-04-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="P04_01_2020To03_31_2021_ComputerEquipmentMemberusgaapPropertyPlantAndEquipmentByTypeAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001635088</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ComputerEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-04-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="P04_01_2020To03_31_2021_SumitovantMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001635088</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">roiv:SumitovantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-04-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="P04_01_2020To03_31_2021_EmployeeStockOptionMemberusgaapAwardTypeAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001635088</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-04-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="P04_01_2020To03_31_2021_PerformanceOptionsMemberusgaapAwardTypeAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001635088</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">roiv:PerformanceOptionsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-04-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="P04_01_2020To03_31_2021_MaximumMembersrtRangeAxis_MeasurementInputExpectedTermMemberusgaapMeasurementInputTypeAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001635088</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputExpectedTermMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-04-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="P04_01_2020To03_31_2021_MeasurementInputExpectedTermMemberusgaapMeasurementInputTypeAxis_MinimumMembersrtRangeAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001635088</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputExpectedTermMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-04-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="P04_01_2020To03_31_2021_SumitomoMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001635088</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">roiv:SumitomoMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-04-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="P04_01_2020To03_31_2021_LeaseholdImprovementsMemberusgaapPropertyPlantAndEquipmentByTypeAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001635088</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LeaseholdImprovementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-04-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="P04_01_2020To03_31_2021_CommonStockAwardsMemberusgaapAwardTypeAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001635088</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">roiv:CommonStockAwardsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-04-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="P04_01_2020To03_31_2021_PerformanceRestrictedStockUnitsMemberusgaapAwardTypeAxis_PerformanceRestrictedStockUnitsPlanMemberusgaapPlanNameAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001635088</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">roiv:PerformanceRestrictedStockUnitsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">roiv:PerformanceRestrictedStockUnitsPlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-04-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="P04_01_2020To03_31_2021_CappedValueAppreciationRightsMemberusgaapAwardTypeAxis_TwoThousandFifteenEquityIncentivePlanMemberusgaapPlanNameAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001635088</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">roiv:CappedValueAppreciationRightsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">roiv:TwoThousandFifteenEquityIncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-04-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="P04_01_2020To03_31_2021_PerformanceOptionsMemberusgaapAwardTypeAxis_TwoThousandFifteenEquityIncentivePlanMemberusgaapPlanNameAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001635088</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">roiv:PerformanceOptionsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">roiv:TwoThousandFifteenEquityIncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-04-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="P04_01_2020To03_31_2021_RestrictedStockUnitsRSUMemberusgaapAwardTypeAxis_TwoThousandFifteenEquityIncentivePlanMemberusgaapPlanNameAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001635088</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">roiv:TwoThousandFifteenEquityIncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-04-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="P04_01_2020To03_31_2021_EmployeeStockOptionMemberusgaapAwardTypeAxis_TwoThousandFifteenEquityIncentivePlanMemberusgaapPlanNameAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001635088</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">roiv:TwoThousandFifteenEquityIncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-04-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="P04_01_2020To03_31_2021_FairValueInputsLevel3MemberusgaapFairValueByFairValueHierarchyLevelAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001635088</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-04-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="P04_01_2020To03_31_2021_ResearchAndDevelopmentExpenseMemberusgaapIncomeStatementLocationAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001635088</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-04-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="P04_01_2020To03_31_2021_GeneralAndAdministrativeExpenseMemberusgaapIncomeStatementLocationAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001635088</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-04-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="P04_01_2020To03_31_2021_ArbutusBiopharmaCorporationMemberdeiLegalEntityAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001635088</identifier>
            <segment>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">roiv:ArbutusBiopharmaCorporationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-04-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="P04_01_2020To03_31_2021_CappedValueAppreciationRightsMemberusgaapAwardTypeAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001635088</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">roiv:CappedValueAppreciationRightsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-04-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="P04_01_2020To03_31_2021_PerformanceRestrictedStockUnitsMemberusgaapAwardTypeAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001635088</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">roiv:PerformanceRestrictedStockUnitsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-04-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="P04_01_2020To03_31_2021_RestrictedStockUnitsRSUMemberusgaapAwardTypeAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001635088</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-04-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="P04_01_2020To03_31_2021_TwoThousandFifteenEquityIncentivePlanMemberusgaapPlanNameAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001635088</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">roiv:TwoThousandFifteenEquityIncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-04-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="P04_01_2020To03_31_2021_SubsidiaryEquityIncentivePlanMemberusgaapPlanNameAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001635088</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">roiv:SubsidiaryEquityIncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-04-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="P04_01_2020To03_31_2021_LiabilityInstrumentsMeasuredAtFairValueMemberusgaapBalanceSheetLocationAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001635088</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">roiv:LiabilityInstrumentsMeasuredAtFairValueMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-04-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="P04_01_2020To03_31_2021_USsrtStatementGeographicalAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001635088</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-04-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="P04_01_2020To03_31_2021_CHsrtStatementGeographicalAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001635088</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:CH</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-04-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="P04_01_2020To03_31_2021_BMsrtStatementGeographicalAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001635088</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:BM</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-04-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="P04_01_2020To03_31_2021_OtherMembersrtStatementGeographicalAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001635088</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">roiv:OtherMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-04-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="P04_01_2020To03_31_2021_MinimumMembersrtRangeAxis_StateAndLocalJurisdictionMemberusgaapIncomeTaxAuthorityAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001635088</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:StateAndLocalJurisdictionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-04-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="P04_01_2020To03_31_2021_MaximumMembersrtRangeAxis_StateAndLocalJurisdictionMemberusgaapIncomeTaxAuthorityAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001635088</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:StateAndLocalJurisdictionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-04-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="P04_01_2020To03_31_2021_RoivantEquityRepurchaseMemberusgaapShareRepurchaseProgramAxis_SumitomoTransactionAgreementMemberusgaapTypeOfArrangementAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001635088</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ShareRepurchaseProgramAxis">roiv:RoivantEquityRepurchaseMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">roiv:SumitomoTransactionAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-04-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="P04_01_2020To03_31_2021_MinimumMembersrtRangeAxis_USsrtStatementGeographicalAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001635088</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-04-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="P04_01_2020To03_31_2021_MaximumMembersrtRangeAxis_USsrtStatementGeographicalAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001635088</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-04-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="P04_01_2020To03_31_2021_PerformanceRestrictedStockUnitsPlanMemberusgaapPlanNameAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001635088</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">roiv:PerformanceRestrictedStockUnitsPlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-04-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="P04_01_2020To03_31_2021_SioGeneTherapiesIncMemberdeiLegalEntityAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001635088</identifier>
            <segment>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">roiv:SioGeneTherapiesIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-04-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="P04_01_2020To03_31_2021_ImmunovantINCMemberusgaapBusinessAcquisitionAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001635088</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">roiv:ImmunovantINCMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-04-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="P04_01_2020To03_31_2021_DatavantHoldingsIncMemberdeiLegalEntityAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001635088</identifier>
            <segment>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">roiv:DatavantHoldingsIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-04-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="P04_01_2020To03_31_2021_AdditionalPaidInCapitalMemberusgaapStatementEquityComponentsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001635088</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-04-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="P04_01_2020To03_31_2021_SubscriptionsReceivablesMemberusgaapStatementEquityComponentsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001635088</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">roiv:SubscriptionsReceivablesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-04-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="P04_01_2020To03_31_2021_NoncontrollingInterestMemberusgaapStatementEquityComponentsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001635088</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-04-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="P04_01_2020To03_31_2021_GenevantSciencesLtdMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001635088</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">roiv:GenevantSciencesLtdMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-04-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="P04_01_2020To03_31_2021_ConvertibleNotesPayableMemberusgaapShortTermDebtTypeAxis_ImmunovantSciencesLtdMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001635088</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">roiv:ImmunovantSciencesLtdMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ShortTermDebtTypeAxis">us-gaap:ConvertibleNotesPayableMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-04-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="P04_01_2020To03_31_2021_ConvertibleNotesPayableMemberusgaapShortTermDebtTypeAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001635088</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ShortTermDebtTypeAxis">us-gaap:ConvertibleNotesPayableMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-04-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="P04_01_2020To03_31_2021_ConvertibleNotesPayableMemberusgaapShortTermDebtTypeAxis_ImmunovantINCMemberusgaapBusinessAcquisitionAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001635088</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">roiv:ImmunovantINCMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ShortTermDebtTypeAxis">us-gaap:ConvertibleNotesPayableMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-04-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="P04_01_2020To03_31_2021_SiliconTherapeuticsMemberusgaapBusinessAcquisitionAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001635088</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">roiv:SiliconTherapeuticsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-04-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="P04_01_2020To03_31_2021_RedeemableNoncontrollingInterestMemberusgaapStatementClassOfStockAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001635088</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">roiv:RedeemableNoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-04-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="P04_01_2020To03_31_2021_CommonStockMemberusgaapStatementEquityComponentsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001635088</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-04-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="P04_01_2020To03_31_2021_AccumulatedOtherComprehensiveIncomeMemberusgaapStatementEquityComponentsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001635088</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-04-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="P04_01_2020To03_31_2021_RetainedEarningsMemberusgaapStatementEquityComponentsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001635088</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-04-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="P04_01_2020To03_31_2021_ImmunovantINCMemberusgaapBusinessAcquisitionAxis_WarrantMemberusgaapStatementEquityComponentsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001635088</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">roiv:ImmunovantINCMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-04-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="P03_01_2020To03_31_2020_CytovantScienceHkLtdMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis_SeriesA1PreferredStockMemberusgaapStatementClassOfStockAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001635088</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">roiv:CytovantScienceHkLtdMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">roiv:SeriesA1PreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-03-01</startDate>
            <endDate>2020-03-31</endDate>
        </period>
    </context>
    <context id="P03_01_2021To03_31_2021_SiliconTherapeuticsMemberusgaapBusinessAcquisitionAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001635088</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">roiv:SiliconTherapeuticsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-03-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="P03_01_2021To03_31_2021_SinovantIncMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001635088</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">roiv:SinovantIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-03-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="P03_01_2021To03_31_2021_FirstTrancheMemberusgaapRestructuringPlanAxis_SiliconTherapeuticsMemberusgaapBusinessAcquisitionAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001635088</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">roiv:SiliconTherapeuticsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RestructuringPlanAxis">roiv:FirstTrancheMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-03-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="P03_01_2021To03_31_2021_SecondTrancheMemberusgaapRestructuringPlanAxis_SiliconTherapeuticsMemberusgaapBusinessAcquisitionAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001635088</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">roiv:SiliconTherapeuticsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RestructuringPlanAxis">roiv:SecondTrancheMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-03-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="P12_01_2020To12_31_2020_ProteovantSciencesIncMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001635088</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">roiv:ProteovantSciencesIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-12-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="P12_01_2019To12_31_2019_SumitomoMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001635088</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">roiv:SumitomoMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-12-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="P08_01_2019To08_31_2019_DermavantSciencesLtdMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001635088</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">roiv:DermavantSciencesLtdMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-08-01</startDate>
            <endDate>2019-08-31</endDate>
        </period>
    </context>
    <context id="P05_01_2020To05_31_2020_ImmunovantSciencesLtdMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis_RestrictedStockMemberusgaapAwardTypeAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001635088</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">roiv:ImmunovantSciencesLtdMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-05-01</startDate>
            <endDate>2020-05-31</endDate>
        </period>
    </context>
    <context id="P05_01_2012To05_31_2012_DermavantSciencesLtdMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001635088</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">roiv:DermavantSciencesLtdMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2012-05-01</startDate>
            <endDate>2012-05-31</endDate>
        </period>
    </context>
    <context id="P07_01_2021To07_31_2021_DatavantMemberusgaapBusinessAcquisitionAxis_SubsequentEventMemberusgaapSubsequentEventTypeAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001635088</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">roiv:DatavantMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2021-07-31</endDate>
        </period>
    </context>
    <context id="P01_01_2021To01_31_2021_ProteovantSciencesIncMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001635088</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">roiv:ProteovantSciencesIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-01-31</endDate>
        </period>
    </context>
    <context id="P07_01_2020To07_31_2020_GenevantSciencesLtdMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001635088</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">roiv:GenevantSciencesLtdMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-07-01</startDate>
            <endDate>2020-07-31</endDate>
        </period>
    </context>
    <context id="P01_01_2020To01_31_2020_DermavantSciencesLtdMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001635088</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">roiv:DermavantSciencesLtdMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-01-31</endDate>
        </period>
    </context>
    <context id="P01_01_2020To01_31_2020_SinovantIncMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001635088</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">roiv:SinovantIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-01-31</endDate>
        </period>
    </context>
    <context id="P04_01_2018To04_30_2018_GenevantSciencesLtdMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001635088</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">roiv:GenevantSciencesLtdMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-04-01</startDate>
            <endDate>2018-04-30</endDate>
        </period>
    </context>
    <context id="P11_01_2020To11_30_2020_AffivantSciencesMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001635088</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">roiv:AffivantSciencesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-11-01</startDate>
            <endDate>2020-11-30</endDate>
        </period>
    </context>
    <context id="P11_01_2020To11_30_2020_FirstProductTargetsEachOfCertainSpecifiedAdditionalMoleculartargetsMemberROIVMilestoneEventsAxis_MaximumMembersrtRangeAxis_ProteovantSciencesIncMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001635088</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">roiv:ProteovantSciencesIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="roiv:MilestoneEventsAxis">roiv:FirstProductTargetsEachOfCertainSpecifiedAdditionalMoleculartargetsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-11-01</startDate>
            <endDate>2020-11-30</endDate>
        </period>
    </context>
    <context id="P11_01_2020To11_30_2020_FirstProductFirstProductForEachMolecularTargetCoveredByIntellectualPropertyMemberROIVMilestoneEventsAxis_MaximumMembersrtRangeAxis_ProteovantSciencesIncMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001635088</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">roiv:ProteovantSciencesIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="roiv:MilestoneEventsAxis">roiv:FirstProductFirstProductForEachMolecularTargetCoveredByIntellectualPropertyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-11-01</startDate>
            <endDate>2020-11-30</endDate>
        </period>
    </context>
    <context id="P11_01_2020To11_30_2020_AffivantSciencesMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis_MaximumMembersrtRangeAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001635088</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">roiv:AffivantSciencesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-11-01</startDate>
            <endDate>2020-11-30</endDate>
        </period>
    </context>
    <context id="P11_01_2020To11_30_2020_FirstProductTargetsTargetingEachOfTwoSpecifiedInitialTargetsMemberROIVMilestoneEventsAxis_MaximumMembersrtRangeAxis_ProteovantSciencesIncMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001635088</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">roiv:ProteovantSciencesIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="roiv:MilestoneEventsAxis">roiv:FirstProductTargetsTargetingEachOfTwoSpecifiedInitialTargetsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-11-01</startDate>
            <endDate>2020-11-30</endDate>
        </period>
    </context>
    <context id="P11_01_2020To11_30_2020_ProteovantSciencesIncMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001635088</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">roiv:ProteovantSciencesIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-11-01</startDate>
            <endDate>2020-11-30</endDate>
        </period>
    </context>
    <context id="P09_01_2019To09_30_2019_CommonStockMemberusgaapStatementEquityComponentsAxis_HealthSciencesMemberusgaapBusinessAcquisitionAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001635088</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">roiv:HealthSciencesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-09-01</startDate>
            <endDate>2019-09-30</endDate>
        </period>
    </context>
    <context id="P09_01_2019To09_30_2019_HealthSciencesMemberusgaapBusinessAcquisitionAxis_SeriesA1PreferredStockMemberusgaapStatementClassOfStockAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001635088</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">roiv:HealthSciencesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">roiv:SeriesA1PreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-09-01</startDate>
            <endDate>2019-09-30</endDate>
        </period>
    </context>
    <context id="P09_01_2019To09_30_2019_HealthSciencesMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis_ImmunovantINCMemberusgaapBusinessAcquisitionAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001635088</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">roiv:ImmunovantINCMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">roiv:HealthSciencesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-09-01</startDate>
            <endDate>2019-09-30</endDate>
        </period>
    </context>
    <context id="P04_01_2020To04_30_2020_CommonStockMemberusgaapStatementEquityComponentsAxis_ImmunovantINCMemberusgaapBusinessAcquisitionAxis_UnderwrittenPublicOfferingMemberusgaapSubsidiarySaleOfStockAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001635088</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">roiv:ImmunovantINCMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">roiv:UnderwrittenPublicOfferingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-04-01</startDate>
            <endDate>2020-04-30</endDate>
        </period>
    </context>
    <context id="P04_01_2020To04_30_2020_CommonStockMemberusgaapStatementEquityComponentsAxis_UnderwrittenPublicOfferingMemberusgaapSubsidiarySaleOfStockAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001635088</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">roiv:UnderwrittenPublicOfferingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-04-01</startDate>
            <endDate>2020-04-30</endDate>
        </period>
    </context>
    <context id="P04_01_2020To12_31_2020_ArbutusBiopharmaCorporationMemberdeiLegalEntityAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001635088</identifier>
            <segment>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">roiv:ArbutusBiopharmaCorporationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-04-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="P12_27_2019To12_27_2019_SumitomoMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001635088</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">roiv:SumitomoMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-12-27</startDate>
            <endDate>2019-12-27</endDate>
        </period>
    </context>
    <context id="P12_26_2019To12_26_2019_RoivantEquityRepurchaseMemberusgaapShareRepurchaseProgramAxis_SumitomoTransactionAgreementMemberusgaapTypeOfArrangementAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001635088</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ShareRepurchaseProgramAxis">roiv:RoivantEquityRepurchaseMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">roiv:SumitomoTransactionAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-12-26</startDate>
            <endDate>2019-12-26</endDate>
        </period>
    </context>
    <context id="P09_29_2017To09_29_2017_ArbutusBiopharmaCorporationMemberdeiLegalEntityAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001635088</identifier>
            <segment>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">roiv:ArbutusBiopharmaCorporationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2017-09-29</startDate>
            <endDate>2017-09-29</endDate>
        </period>
    </context>
    <context id="P05_01_2021To05_01_2021_SubsequentEventMemberusgaapSubsequentEventTypeAxis_SumitomoPharmaceuticalsCoLtdMemberusgaapBusinessAcquisitionAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001635088</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">roiv:SumitomoPharmaceuticalsCoLtdMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-05-01</startDate>
            <endDate>2021-05-01</endDate>
        </period>
    </context>
    <context id="P07_31_2020To07_31_2020_GenevantSciencesLtdMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001635088</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">roiv:GenevantSciencesLtdMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-07-31</startDate>
            <endDate>2020-07-31</endDate>
        </period>
    </context>
    <context id="P07_31_2020To07_31_2020_ArbutusBiopharmaCorporationMemberdeiLegalEntityAxis_GenevantSciencesLtdMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001635088</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">roiv:GenevantSciencesLtdMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">roiv:ArbutusBiopharmaCorporationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-07-31</startDate>
            <endDate>2020-07-31</endDate>
        </period>
    </context>
    <context id="PAsOn03_31_2020_FairValueInputsLevel1MemberusgaapFairValueByFairValueHierarchyLevelAxis_FairValueMeasurementsRecurringMemberusgaapFairValueByMeasurementFrequencyAxis_MoneyMarketFundsMemberusgaapFairValueByAssetClassAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001635088</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-03-31</instant>
        </period>
    </context>
    <context id="PAsOn03_31_2020_FairValueMeasurementsRecurringMemberusgaapFairValueByMeasurementFrequencyAxis_MoneyMarketFundsMemberusgaapFairValueByAssetClassAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001635088</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-03-31</instant>
        </period>
    </context>
    <context id="PAsOn03_31_2020_CytovantScienceHkLtdMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis_SeriesA1PreferredStockMemberusgaapStatementClassOfStockAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001635088</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">roiv:CytovantScienceHkLtdMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">roiv:SeriesA1PreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-03-31</instant>
        </period>
    </context>
    <context id="PAsOn03_31_2020_CommonStockMemberusgaapFairValueByAssetClassAxis_FairValueInputsLevel1MemberusgaapFairValueByFairValueHierarchyLevelAxis_FairValueMeasurementsRecurringMemberusgaapFairValueByMeasurementFrequencyAxis_SioGeneTherapiesIncMemberdeiLegalEntityAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001635088</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">roiv:SioGeneTherapiesIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-03-31</instant>
        </period>
    </context>
    <context id="PAsOn03_31_2020_CommonStockMemberusgaapFairValueByAssetClassAxis_FairValueMeasurementsRecurringMemberusgaapFairValueByMeasurementFrequencyAxis_SioGeneTherapiesIncMemberdeiLegalEntityAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001635088</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">roiv:SioGeneTherapiesIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-03-31</instant>
        </period>
    </context>
    <context id="PAsOn03_31_2020_ArbutusBiopharmaCorporationMemberdeiLegalEntityAxis_CommonStockMemberusgaapFairValueByAssetClassAxis_FairValueInputsLevel1MemberusgaapFairValueByFairValueHierarchyLevelAxis_FairValueMeasurementsRecurringMemberusgaapFairValueByMeasurementFrequencyAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001635088</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">roiv:ArbutusBiopharmaCorporationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-03-31</instant>
        </period>
    </context>
    <context id="PAsOn03_31_2020_ArbutusBiopharmaCorporationMemberdeiLegalEntityAxis_CommonStockMemberusgaapFairValueByAssetClassAxis_FairValueMeasurementsRecurringMemberusgaapFairValueByMeasurementFrequencyAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001635088</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">roiv:ArbutusBiopharmaCorporationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-03-31</instant>
        </period>
    </context>
    <context id="PAsOn03_31_2020_ArbutusBiopharmaCorporationMemberdeiLegalEntityAxis_ConvertiblePreferredStockMemberusgaapFairValueByAssetClassAxis_FairValueInputsLevel2MemberusgaapFairValueByFairValueHierarchyLevelAxis_FairValueMeasurementsRecurringMemberusgaapFairValueByMeasurementFrequencyAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001635088</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:ConvertiblePreferredStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">roiv:ArbutusBiopharmaCorporationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-03-31</instant>
        </period>
    </context>
    <context id="PAsOn03_31_2020_ArbutusBiopharmaCorporationMemberdeiLegalEntityAxis_ConvertiblePreferredStockMemberusgaapFairValueByAssetClassAxis_FairValueMeasurementsRecurringMemberusgaapFairValueByMeasurementFrequencyAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001635088</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:ConvertiblePreferredStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">roiv:ArbutusBiopharmaCorporationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-03-31</instant>
        </period>
    </context>
    <context id="PAsOn03_31_2020_FairValueInputsLevel1MemberusgaapFairValueByFairValueHierarchyLevelAxis_FairValueMeasurementsRecurringMemberusgaapFairValueByMeasurementFrequencyAxis_OtherInvestmentCompaniesMemberusgaapFairValueByAssetClassAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001635088</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:OtherInvestmentCompaniesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-03-31</instant>
        </period>
    </context>
    <context id="PAsOn03_31_2020_FairValueMeasurementsRecurringMemberusgaapFairValueByMeasurementFrequencyAxis_OtherInvestmentCompaniesMemberusgaapFairValueByAssetClassAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001635088</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:OtherInvestmentCompaniesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-03-31</instant>
        </period>
    </context>
    <context id="PAsOn03_31_2020_MaximumMembersrtRangeAxis_MeasurementInputOptionVolatilityMemberusgaapMeasurementInputTypeAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001635088</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputOptionVolatilityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-03-31</instant>
        </period>
    </context>
    <context id="PAsOn03_31_2020_MeasurementInputOptionVolatilityMemberusgaapMeasurementInputTypeAxis_MinimumMembersrtRangeAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001635088</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputOptionVolatilityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-03-31</instant>
        </period>
    </context>
    <context id="PAsOn03_31_2020_MaximumMembersrtRangeAxis_MeasurementInputRiskFreeInterestRateMemberusgaapMeasurementInputTypeAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001635088</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputRiskFreeInterestRateMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-03-31</instant>
        </period>
    </context>
    <context id="PAsOn03_31_2020_MeasurementInputRiskFreeInterestRateMemberusgaapMeasurementInputTypeAxis_MinimumMembersrtRangeAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001635088</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputRiskFreeInterestRateMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-03-31</instant>
        </period>
    </context>
    <context id="PAsOn03_31_2020_FairValueInputsLevel1MemberusgaapFairValueByFairValueHierarchyLevelAxis_FairValueMeasurementsRecurringMemberusgaapFairValueByMeasurementFrequencyAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001635088</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-03-31</instant>
        </period>
    </context>
    <context id="PAsOn03_31_2020_FairValueInputsLevel2MemberusgaapFairValueByFairValueHierarchyLevelAxis_FairValueMeasurementsRecurringMemberusgaapFairValueByMeasurementFrequencyAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001635088</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-03-31</instant>
        </period>
    </context>
    <context id="PAsOn03_31_2020_FairValueMeasurementsRecurringMemberusgaapFairValueByMeasurementFrequencyAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001635088</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-03-31</instant>
        </period>
    </context>
    <context id="PAsOn03_31_2020_FairValueInputsLevel3MemberusgaapFairValueByFairValueHierarchyLevelAxis_FairValueMeasurementsRecurringMemberusgaapFairValueByMeasurementFrequencyAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001635088</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-03-31</instant>
        </period>
    </context>
    <context id="PAsOn03_31_2020_ResearchAndDevelopmentExpenseMemberusgaapIncomeStatementLocationAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001635088</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-03-31</instant>
        </period>
    </context>
    <context id="PAsOn03_31_2020_EmployeeRelatedExpensesMemberusgaapIncomeStatementLocationAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001635088</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">roiv:EmployeeRelatedExpensesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-03-31</instant>
        </period>
    </context>
    <context id="PAsOn03_31_2020_ProfessionalServicesExpensesMemberusgaapIncomeStatementLocationAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001635088</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">roiv:ProfessionalServicesExpensesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-03-31</instant>
        </period>
    </context>
    <context id="PAsOn03_31_2020_OtherGeneralAndAdministrativeExpensesMemberusgaapIncomeStatementLocationAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001635088</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">roiv:OtherGeneralAndAdministrativeExpensesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-03-31</instant>
        </period>
    </context>
    <context id="PAsOn03_31_2020_ArbutusBiopharmaCorporationMemberdeiLegalEntityAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001635088</identifier>
            <segment>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">roiv:ArbutusBiopharmaCorporationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-03-31</instant>
        </period>
    </context>
    <context id="PAsOn03_31_2020_SioGeneTherapiesIncMemberdeiLegalEntityAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001635088</identifier>
            <segment>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">roiv:SioGeneTherapiesIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-03-31</instant>
        </period>
    </context>
    <context id="PAsOn03_31_2020_OtherInvestmentCompaniesMemberusgaapInvestmentTypeAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001635088</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:OtherInvestmentCompaniesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-03-31</instant>
        </period>
    </context>
    <context id="PAsOn03_31_2020_NovaquestMemberusgaapTypeOfArrangementAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001635088</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">roiv:NovaquestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-03-31</instant>
        </period>
    </context>
    <context id="PAsOn03_31_2020_EmployeeMembersrtTitleOfIndividualAxis_SumitomoMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001635088</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">roiv:EmployeeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">roiv:SumitomoMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-03-31</instant>
        </period>
    </context>
    <context id="PAsOn03_31_2021_FairValueMeasurementsRecurringMemberusgaapFairValueByMeasurementFrequencyAxis_MoneyMarketFundsMemberusgaapFairValueByAssetClassAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001635088</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="PAsOn03_31_2021_FairValueInputsLevel1MemberusgaapFairValueByFairValueHierarchyLevelAxis_FairValueMeasurementsRecurringMemberusgaapFairValueByMeasurementFrequencyAxis_MoneyMarketFundsMemberusgaapFairValueByAssetClassAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001635088</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="PAsOn03_31_2021_PerformanceRestrictedStockUnitsPlanMemberusgaapPlanNameAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001635088</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">roiv:PerformanceRestrictedStockUnitsPlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="PAsOn03_31_2021_TwoThousandFifteenEquityIncentivePlanMemberusgaapPlanNameAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001635088</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">roiv:TwoThousandFifteenEquityIncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="PAsOn03_31_2021_SpecialReserveMemberusgaapAwardTypeAxis_TwoThousandFifteenEquityIncentivePlanMemberusgaapPlanNameAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001635088</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">roiv:SpecialReserveMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">roiv:TwoThousandFifteenEquityIncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="PAsOn03_31_2021_FairValueMeasurementsRecurringMemberusgaapFairValueByMeasurementFrequencyAxis_OtherInvestmentCompaniesMemberusgaapFairValueByAssetClassAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001635088</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:OtherInvestmentCompaniesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="PAsOn03_31_2021_FairValueInputsLevel1MemberusgaapFairValueByFairValueHierarchyLevelAxis_FairValueMeasurementsRecurringMemberusgaapFairValueByMeasurementFrequencyAxis_OtherInvestmentCompaniesMemberusgaapFairValueByAssetClassAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001635088</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:OtherInvestmentCompaniesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="PAsOn03_31_2021_ArbutusBiopharmaCorporationMemberdeiLegalEntityAxis_ConvertiblePreferredStockMemberusgaapFairValueByAssetClassAxis_FairValueMeasurementsRecurringMemberusgaapFairValueByMeasurementFrequencyAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001635088</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:ConvertiblePreferredStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">roiv:ArbutusBiopharmaCorporationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="PAsOn03_31_2021_ArbutusBiopharmaCorporationMemberdeiLegalEntityAxis_ConvertiblePreferredStockMemberusgaapFairValueByAssetClassAxis_FairValueInputsLevel2MemberusgaapFairValueByFairValueHierarchyLevelAxis_FairValueMeasurementsRecurringMemberusgaapFairValueByMeasurementFrequencyAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001635088</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:ConvertiblePreferredStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">roiv:ArbutusBiopharmaCorporationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="PAsOn03_31_2021_ArbutusBiopharmaCorporationMemberdeiLegalEntityAxis_CommonStockMemberusgaapFairValueByAssetClassAxis_FairValueMeasurementsRecurringMemberusgaapFairValueByMeasurementFrequencyAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001635088</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">roiv:ArbutusBiopharmaCorporationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="PAsOn03_31_2021_ArbutusBiopharmaCorporationMemberdeiLegalEntityAxis_CommonStockMemberusgaapFairValueByAssetClassAxis_FairValueInputsLevel1MemberusgaapFairValueByFairValueHierarchyLevelAxis_FairValueMeasurementsRecurringMemberusgaapFairValueByMeasurementFrequencyAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001635088</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">roiv:ArbutusBiopharmaCorporationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="PAsOn03_31_2021_CommonStockMemberusgaapFairValueByAssetClassAxis_FairValueMeasurementsRecurringMemberusgaapFairValueByMeasurementFrequencyAxis_SioGeneTherapiesIncMemberdeiLegalEntityAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001635088</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">roiv:SioGeneTherapiesIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="PAsOn03_31_2021_CommonStockMemberusgaapFairValueByAssetClassAxis_FairValueInputsLevel1MemberusgaapFairValueByFairValueHierarchyLevelAxis_FairValueMeasurementsRecurringMemberusgaapFairValueByMeasurementFrequencyAxis_SioGeneTherapiesIncMemberdeiLegalEntityAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001635088</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">roiv:SioGeneTherapiesIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="PAsOn03_31_2021_MaximumMembersrtRangeAxis_MeasurementInputOptionVolatilityMemberusgaapMeasurementInputTypeAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001635088</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputOptionVolatilityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="PAsOn03_31_2021_MeasurementInputOptionVolatilityMemberusgaapMeasurementInputTypeAxis_MinimumMembersrtRangeAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001635088</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputOptionVolatilityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="PAsOn03_31_2021_MeasurementInputRiskFreeInterestRateMemberusgaapMeasurementInputTypeAxis_MinimumMembersrtRangeAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001635088</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputRiskFreeInterestRateMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="PAsOn03_31_2021_MaximumMembersrtRangeAxis_MeasurementInputRiskFreeInterestRateMemberusgaapMeasurementInputTypeAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001635088</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputRiskFreeInterestRateMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="PAsOn03_31_2021_FairValueMeasurementsRecurringMemberusgaapFairValueByMeasurementFrequencyAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001635088</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="PAsOn03_31_2021_FairValueInputsLevel2MemberusgaapFairValueByFairValueHierarchyLevelAxis_FairValueMeasurementsRecurringMemberusgaapFairValueByMeasurementFrequencyAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001635088</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="PAsOn03_31_2021_FairValueInputsLevel1MemberusgaapFairValueByFairValueHierarchyLevelAxis_FairValueMeasurementsRecurringMemberusgaapFairValueByMeasurementFrequencyAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001635088</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="PAsOn03_31_2021_CHsrtStatementGeographicalAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001635088</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:CH</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="PAsOn03_31_2021_USsrtStatementGeographicalAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001635088</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="PAsOn03_31_2021_GBsrtStatementGeographicalAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001635088</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:GB</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="PAsOn03_31_2021_TaxAuthorityInOtherJurisdictionsMembersrtStatementGeographicalAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001635088</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">roiv:TaxAuthorityInOtherJurisdictionsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="PAsOn03_31_2021_StateAndLocalJurisdictionMemberusgaapIncomeTaxAuthorityAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001635088</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:StateAndLocalJurisdictionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="PAsOn03_31_2021_MeasurementInputDiscountRateMemberusgaapMeasurementInputTypeAxis_MinimumMembersrtRangeAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001635088</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputDiscountRateMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="PAsOn03_31_2021_MaximumMembersrtRangeAxis_MeasurementInputDiscountRateMemberusgaapMeasurementInputTypeAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001635088</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputDiscountRateMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="PAsOn03_31_2021_FairValueInputsLevel3MemberusgaapFairValueByFairValueHierarchyLevelAxis_FairValueMeasurementsRecurringMemberusgaapFairValueByMeasurementFrequencyAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001635088</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="PAsOn03_31_2021_ArbutusBiopharmaCorporationMemberdeiLegalEntityAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001635088</identifier>
            <segment>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">roiv:ArbutusBiopharmaCorporationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="PAsOn03_31_2021_ResearchAndDevelopmentExpenseMemberusgaapIncomeStatementLocationAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001635088</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="PAsOn03_31_2021_EmployeeRelatedExpensesMemberusgaapIncomeStatementLocationAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001635088</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">roiv:EmployeeRelatedExpensesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="PAsOn03_31_2021_ProfessionalServicesExpensesMemberusgaapIncomeStatementLocationAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001635088</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">roiv:ProfessionalServicesExpensesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="PAsOn03_31_2021_OtherGeneralAndAdministrativeExpensesMemberusgaapIncomeStatementLocationAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001635088</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">roiv:OtherGeneralAndAdministrativeExpensesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="PAsOn03_31_2021_EmployeeStockOptionMemberusgaapAwardTypeAxis_TwoThousandFifteenEquityIncentivePlanMemberusgaapPlanNameAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001635088</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">roiv:TwoThousandFifteenEquityIncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="PAsOn03_31_2021_PerformanceOptionsMemberusgaapAwardTypeAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001635088</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">roiv:PerformanceOptionsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="PAsOn03_31_2021_SumitomoMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001635088</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">roiv:SumitomoMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="PAsOn03_31_2021_NovaquestMemberusgaapTypeOfArrangementAxis_RegulatoryMilestoneMemberusgaapTransactionTypeAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001635088</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TransactionTypeAxis">roiv:RegulatoryMilestoneMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">roiv:NovaquestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="PAsOn03_31_2021_CommercialMilestoneMemberusgaapTransactionTypeAxis_NovaquestMemberusgaapTypeOfArrangementAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001635088</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TransactionTypeAxis">roiv:CommercialMilestoneMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">roiv:NovaquestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="PAsOn03_31_2021_RestrictedStockUnitsRSUMemberusgaapAwardTypeAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001635088</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="PAsOn03_31_2021_ImmunovantINCMemberusgaapBusinessAcquisitionAxis_WarrantMemberusgaapStatementEquityComponentsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001635088</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">roiv:ImmunovantINCMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="PAsOn03_31_2021_OtherInvestmentCompaniesMemberusgaapInvestmentTypeAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001635088</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:OtherInvestmentCompaniesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="PAsOn03_31_2021_SioGeneTherapiesIncMemberdeiLegalEntityAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001635088</identifier>
            <segment>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">roiv:SioGeneTherapiesIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="PAsOn03_31_2021_DatavantHoldingsIncMemberdeiLegalEntityAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001635088</identifier>
            <segment>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">roiv:DatavantHoldingsIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="PAsOn03_31_2021_DermavantSciencesLtdMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis_RevisionOfPriorPeriodReclassificationAdjustmentMembersrtRestatementAxis_SubsequentEventMemberusgaapSubsequentEventTypeAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001635088</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RestatementAxis">srt:RevisionOfPriorPeriodReclassificationAdjustmentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">roiv:DermavantSciencesLtdMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="PAsOn03_31_2021_CappedValueAppreciationRightsMemberusgaapAwardTypeAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001635088</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">roiv:CappedValueAppreciationRightsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="PAsOn03_31_2021_PerformanceRestrictedStockUnitsMemberusgaapAwardTypeAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001635088</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">roiv:PerformanceRestrictedStockUnitsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="PAsOn03_31_2021_CommonStockAwardsMemberusgaapAwardTypeAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001635088</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">roiv:CommonStockAwardsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="PAsOn03_31_2021_GenevantSciencesLtdMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001635088</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">roiv:GenevantSciencesLtdMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="PAsOn03_31_2021_ConvertibleNotesPayableMemberusgaapShortTermDebtTypeAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001635088</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ShortTermDebtTypeAxis">us-gaap:ConvertibleNotesPayableMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="PAsOn03_31_2021_ProteovantSciencesIncMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001635088</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">roiv:ProteovantSciencesIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="PAsOn03_31_2021_SiliconTherapeuticsMemberusgaapBusinessAcquisitionAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001635088</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">roiv:SiliconTherapeuticsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="PAsOn03_31_2021_NovaquestMemberusgaapTypeOfArrangementAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001635088</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">roiv:NovaquestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="PAsOn03_31_2021_EmployeeMembersrtTitleOfIndividualAxis_SumitomoMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001635088</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">roiv:EmployeeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">roiv:SumitomoMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2020_ArbutusBiopharmaCorporationMemberdeiLegalEntityAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001635088</identifier>
            <segment>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">roiv:ArbutusBiopharmaCorporationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2020_ProteovantSciencesIncMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001635088</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">roiv:ProteovantSciencesIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="PAsOn11_30_2020_ProteovantSciencesIncMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001635088</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">roiv:ProteovantSciencesIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-11-30</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2019_SumitomoMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001635088</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">roiv:SumitomoMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2019_MaximumMembersrtRangeAxis_SumitomoMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001635088</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">roiv:SumitomoMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2019_EmployeeMembersrtTitleOfIndividualAxis_SumitomoMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001635088</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">roiv:EmployeeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">roiv:SumitomoMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_27_2019_SumitomoMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001635088</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">roiv:SumitomoMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-27</instant>
        </period>
    </context>
    <context id="PAsOn12_26_2019_RoivantEquityRepurchaseMemberusgaapShareRepurchaseProgramAxis_SumitomoTransactionAgreementMemberusgaapTypeOfArrangementAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001635088</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ShareRepurchaseProgramAxis">roiv:RoivantEquityRepurchaseMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">roiv:SumitomoTransactionAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-26</instant>
        </period>
    </context>
    <context id="PAsOn09_30_2020_CommonStockMemberusgaapStatementEquityComponentsAxis_ImmunovantINCMemberusgaapBusinessAcquisitionAxis_UnderwrittenPublicOfferingMemberusgaapSubsidiarySaleOfStockAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001635088</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">roiv:ImmunovantINCMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">roiv:UnderwrittenPublicOfferingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-09-30</instant>
        </period>
    </context>
    <context id="PAsOn09_30_2020_ImmunovantSciencesLtdMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001635088</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">roiv:ImmunovantSciencesLtdMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-09-30</instant>
        </period>
    </context>
    <context id="PAsOn09_30_2019_HealthSciencesMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis_ImmunovantINCMemberusgaapBusinessAcquisitionAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001635088</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">roiv:ImmunovantINCMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">roiv:HealthSciencesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-09-30</instant>
        </period>
    </context>
    <context id="PAsOn09_30_2019_HealthSciencesMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001635088</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">roiv:HealthSciencesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-09-30</instant>
        </period>
    </context>
    <context id="PAsOn09_30_2019_CommonStockMemberusgaapStatementEquityComponentsAxis_HealthSciencesMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001635088</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">roiv:HealthSciencesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-09-30</instant>
        </period>
    </context>
    <context id="PAsOn08_31_2018_NovaquestMemberusgaapTypeOfArrangementAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001635088</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">roiv:NovaquestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-08-31</instant>
        </period>
    </context>
    <context id="PAsOn08_31_2018_CommercialMilestoneMemberusgaapTransactionTypeAxis_NovaquestMemberusgaapTypeOfArrangementAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001635088</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TransactionTypeAxis">roiv:CommercialMilestoneMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">roiv:NovaquestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-08-31</instant>
        </period>
    </context>
    <context id="PAsOn08_31_2018_NovaquestMemberusgaapTypeOfArrangementAxis_RegulatoryMilestoneMemberusgaapTransactionTypeAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001635088</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TransactionTypeAxis">roiv:RegulatoryMilestoneMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">roiv:NovaquestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-08-31</instant>
        </period>
    </context>
    <context id="PAsOn05_31_2020_ImmunovantINCMemberusgaapBusinessAcquisitionAxis_WarrantMemberusgaapStatementEquityComponentsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001635088</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">roiv:ImmunovantINCMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-05-31</instant>
        </period>
    </context>
    <context id="PAsOn05_31_2020_ImmunovantSciencesLtdMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001635088</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">roiv:ImmunovantSciencesLtdMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-05-31</instant>
        </period>
    </context>
    <context id="PAsOn05_31_2019_PrimeRateMemberusgaapVariableRateAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001635088</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:VariableRateAxis">us-gaap:PrimeRateMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-05-31</instant>
        </period>
    </context>
    <context id="PAsOn05_31_2012_DermavantSciencesLtdMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001635088</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">roiv:DermavantSciencesLtdMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2012-05-31</instant>
        </period>
    </context>
    <context id="PAsOn05_14_2021_DermavantSciencesLtdMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis_RevenueInterestPurchaseAndSaleAgreementMemberusgaapTypeOfArrangementAxis_SubsequentEventMemberusgaapSubsequentEventTypeAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001635088</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">roiv:DermavantSciencesLtdMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">roiv:RevenueInterestPurchaseAndSaleAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-05-14</instant>
        </period>
    </context>
    <context id="PAsOn05_14_2021_CreditFacilityMemberusgaapDebtInstrumentAxis_DermavantSciencesLtdMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis_SubsequentEventMemberusgaapSubsequentEventTypeAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001635088</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">roiv:CreditFacilityMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">roiv:DermavantSciencesLtdMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-05-14</instant>
        </period>
    </context>
    <context id="PAsOn05_14_2021_DermavantSciencesLtdMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis_SubsequentEventMemberusgaapSubsequentEventTypeAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001635088</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">roiv:DermavantSciencesLtdMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-05-14</instant>
        </period>
    </context>
    <context id="PAsOn01_31_2021_ProteovantSciencesIncMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001635088</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">roiv:ProteovantSciencesIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-01-31</instant>
        </period>
    </context>
    <context id="PAsOn07_31_2020_GenevantSciencesLtdMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001635088</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">roiv:GenevantSciencesLtdMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-07-31</instant>
        </period>
    </context>
    <context id="PAsOn07_31_2020_DatavantHoldingsIncMemberdeiLegalEntityAxis_SeriesBPreferredStockMemberusgaapStatementClassOfStockAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001635088</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesBPreferredStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">roiv:DatavantHoldingsIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-07-31</instant>
        </period>
    </context>
    <context id="PAsOn07_31_2020_SeriesBPreferredStockMemberusgaapStatementClassOfStockAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001635088</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesBPreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-07-31</instant>
        </period>
    </context>
    <context id="PAsOn04_30_2020_CommonStockMemberusgaapStatementEquityComponentsAxis_ImmunovantINCMemberusgaapBusinessAcquisitionAxis_UnderwrittenPublicOfferingMemberusgaapSubsidiarySaleOfStockAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001635088</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">roiv:ImmunovantINCMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">roiv:UnderwrittenPublicOfferingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-04-30</instant>
        </period>
    </context>
    <context id="PAsOn04_30_2020_DatavantHoldingsIncMemberdeiLegalEntityAxis_SeriesBPreferredStockMemberusgaapStatementClassOfStockAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001635088</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesBPreferredStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">roiv:DatavantHoldingsIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-04-30</instant>
        </period>
    </context>
    <context id="PAsOn02_29_2020_MaximumMembersrtRangeAxis_RoivantEquityRepurchaseMemberusgaapShareRepurchaseProgramAxis_SumitomoTransactionAgreementMemberusgaapTypeOfArrangementAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001635088</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ShareRepurchaseProgramAxis">roiv:RoivantEquityRepurchaseMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">roiv:SumitomoTransactionAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-02-29</instant>
        </period>
    </context>
    <context id="PAsOn01_31_2020_SinovantIncMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001635088</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">roiv:SinovantIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-01-31</instant>
        </period>
    </context>
    <context id="PAsOn10_31_2018_NovaquestMemberusgaapTypeOfArrangementAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001635088</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">roiv:NovaquestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-10-31</instant>
        </period>
    </context>
    <context id="PAsOn06_30_2021_FairValueMeasurementsRecurringMemberusgaapFairValueByMeasurementFrequencyAxis_MoneyMarketFundsMemberusgaapFairValueByAssetClassAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001635088</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-06-30</instant>
        </period>
    </context>
    <context id="PAsOn06_30_2021_FairValueInputsLevel1MemberusgaapFairValueByFairValueHierarchyLevelAxis_FairValueMeasurementsRecurringMemberusgaapFairValueByMeasurementFrequencyAxis_MoneyMarketFundsMemberusgaapFairValueByAssetClassAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001635088</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-06-30</instant>
        </period>
    </context>
    <context id="PAsOn06_30_2021_TwoThousandFifteenEquityIncentivePlanMemberusgaapPlanNameAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001635088</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">roiv:TwoThousandFifteenEquityIncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-06-30</instant>
        </period>
    </context>
    <context id="PAsOn06_30_2021_PerformanceRestrictedStockUnitsPlanMemberusgaapPlanNameAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001635088</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">roiv:PerformanceRestrictedStockUnitsPlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-06-30</instant>
        </period>
    </context>
    <context id="PAsOn06_30_2021_FairValueMeasurementsRecurringMemberusgaapFairValueByMeasurementFrequencyAxis_OtherInvestmentCompaniesMemberusgaapFairValueByAssetClassAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001635088</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:OtherInvestmentCompaniesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-06-30</instant>
        </period>
    </context>
    <context id="PAsOn06_30_2021_FairValueInputsLevel1MemberusgaapFairValueByFairValueHierarchyLevelAxis_FairValueMeasurementsRecurringMemberusgaapFairValueByMeasurementFrequencyAxis_OtherInvestmentCompaniesMemberusgaapFairValueByAssetClassAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001635088</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:OtherInvestmentCompaniesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-06-30</instant>
        </period>
    </context>
    <context id="PAsOn06_30_2021_ArbutusBiopharmaCorporationMemberdeiLegalEntityAxis_ConvertiblePreferredStockMemberusgaapFairValueByAssetClassAxis_FairValueMeasurementsRecurringMemberusgaapFairValueByMeasurementFrequencyAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001635088</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:ConvertiblePreferredStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">roiv:ArbutusBiopharmaCorporationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-06-30</instant>
        </period>
    </context>
    <context id="PAsOn06_30_2021_ArbutusBiopharmaCorporationMemberdeiLegalEntityAxis_ConvertiblePreferredStockMemberusgaapFairValueByAssetClassAxis_FairValueInputsLevel2MemberusgaapFairValueByFairValueHierarchyLevelAxis_FairValueMeasurementsRecurringMemberusgaapFairValueByMeasurementFrequencyAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001635088</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:ConvertiblePreferredStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">roiv:ArbutusBiopharmaCorporationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-06-30</instant>
        </period>
    </context>
    <context id="PAsOn06_30_2021_ArbutusBiopharmaCorporationMemberdeiLegalEntityAxis_CommonStockMemberusgaapFairValueByAssetClassAxis_FairValueMeasurementsRecurringMemberusgaapFairValueByMeasurementFrequencyAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001635088</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">roiv:ArbutusBiopharmaCorporationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-06-30</instant>
        </period>
    </context>
    <context id="PAsOn06_30_2021_ArbutusBiopharmaCorporationMemberdeiLegalEntityAxis_CommonStockMemberusgaapFairValueByAssetClassAxis_FairValueInputsLevel1MemberusgaapFairValueByFairValueHierarchyLevelAxis_FairValueMeasurementsRecurringMemberusgaapFairValueByMeasurementFrequencyAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001635088</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">roiv:ArbutusBiopharmaCorporationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-06-30</instant>
        </period>
    </context>
    <context id="PAsOn06_30_2021_CommonStockMemberusgaapFairValueByAssetClassAxis_FairValueMeasurementsRecurringMemberusgaapFairValueByMeasurementFrequencyAxis_SioGeneTherapiesIncMemberdeiLegalEntityAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001635088</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">roiv:SioGeneTherapiesIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-06-30</instant>
        </period>
    </context>
    <context id="PAsOn06_30_2021_CommonStockMemberusgaapFairValueByAssetClassAxis_FairValueInputsLevel1MemberusgaapFairValueByFairValueHierarchyLevelAxis_FairValueMeasurementsRecurringMemberusgaapFairValueByMeasurementFrequencyAxis_SioGeneTherapiesIncMemberdeiLegalEntityAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001635088</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">roiv:SioGeneTherapiesIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-06-30</instant>
        </period>
    </context>
    <context id="PAsOn06_30_2021_SpecialReserveMemberusgaapAwardTypeAxis_TwoThousandFifteenEquityIncentivePlanMemberusgaapPlanNameAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001635088</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">roiv:SpecialReserveMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">roiv:TwoThousandFifteenEquityIncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-06-30</instant>
        </period>
    </context>
    <context id="PAsOn06_30_2021_FairValueMeasurementsRecurringMemberusgaapFairValueByMeasurementFrequencyAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001635088</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-06-30</instant>
        </period>
    </context>
    <context id="PAsOn06_30_2021_FairValueInputsLevel2MemberusgaapFairValueByFairValueHierarchyLevelAxis_FairValueMeasurementsRecurringMemberusgaapFairValueByMeasurementFrequencyAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001635088</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-06-30</instant>
        </period>
    </context>
    <context id="PAsOn06_30_2021_FairValueInputsLevel1MemberusgaapFairValueByFairValueHierarchyLevelAxis_FairValueMeasurementsRecurringMemberusgaapFairValueByMeasurementFrequencyAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001635088</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-06-30</instant>
        </period>
    </context>
    <context id="PAsOn06_30_2021_MaximumMembersrtRangeAxis_MeasurementInputDiscountRateMemberusgaapMeasurementInputTypeAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001635088</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputDiscountRateMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-06-30</instant>
        </period>
    </context>
    <context id="PAsOn06_30_2021_MeasurementInputDiscountRateMemberusgaapMeasurementInputTypeAxis_MinimumMembersrtRangeAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001635088</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputDiscountRateMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-06-30</instant>
        </period>
    </context>
    <context id="PAsOn06_30_2021_FairValueInputsLevel3MemberusgaapFairValueByFairValueHierarchyLevelAxis_FairValueMeasurementsRecurringMemberusgaapFairValueByMeasurementFrequencyAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001635088</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-06-30</instant>
        </period>
    </context>
    <context id="PAsOn06_30_2021_ArbutusBiopharmaCorporationMemberdeiLegalEntityAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001635088</identifier>
            <segment>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">roiv:ArbutusBiopharmaCorporationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-06-30</instant>
        </period>
    </context>
    <context id="PAsOn06_30_2021_ResearchAndDevelopmentExpenseMemberusgaapIncomeStatementLocationAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001635088</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-06-30</instant>
        </period>
    </context>
    <context id="PAsOn06_30_2021_EmployeeRelatedExpensesMemberusgaapIncomeStatementLocationAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001635088</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">roiv:EmployeeRelatedExpensesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-06-30</instant>
        </period>
    </context>
    <context id="PAsOn06_30_2021_ProfessionalServicesExpensesMemberusgaapIncomeStatementLocationAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001635088</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">roiv:ProfessionalServicesExpensesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-06-30</instant>
        </period>
    </context>
    <context id="PAsOn06_30_2021_OtherGeneralAndAdministrativeExpensesMemberusgaapIncomeStatementLocationAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001635088</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">roiv:OtherGeneralAndAdministrativeExpensesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-06-30</instant>
        </period>
    </context>
    <context id="PAsOn06_30_2021_SioGeneTherapiesIncMemberdeiLegalEntityAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001635088</identifier>
            <segment>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">roiv:SioGeneTherapiesIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-06-30</instant>
        </period>
    </context>
    <context id="PAsOn06_30_2021_DatavantHoldingsIncMemberdeiLegalEntityAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001635088</identifier>
            <segment>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">roiv:DatavantHoldingsIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-06-30</instant>
        </period>
    </context>
    <context id="PAsOn06_30_2021_OtherInvestmentCompaniesMemberusgaapInvestmentTypeAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001635088</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:OtherInvestmentCompaniesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-06-30</instant>
        </period>
    </context>
    <context id="PAsOn06_30_2021_NovaquestMemberusgaapTypeOfArrangementAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001635088</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">roiv:NovaquestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-06-30</instant>
        </period>
    </context>
    <context id="PAsOn06_30_2021_EmployeeMembersrtTitleOfIndividualAxis_SumitomoMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001635088</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">roiv:EmployeeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">roiv:SumitomoMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-06-30</instant>
        </period>
    </context>
    <context id="P04_01_2021To06_30_2021_PerformanceOptionsMemberusgaapAwardTypeAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001635088</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">roiv:PerformanceOptionsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="P04_01_2021To06_30_2021_CommonStockAwardsMemberusgaapAwardTypeAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001635088</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">roiv:CommonStockAwardsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="P04_01_2021To06_30_2021_PerformanceRestrictedStockUnitsMemberusgaapAwardTypeAxis_PerformanceRestrictedStockUnitsPlanMemberusgaapPlanNameAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001635088</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">roiv:PerformanceRestrictedStockUnitsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">roiv:PerformanceRestrictedStockUnitsPlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="P04_01_2021To06_30_2021_CappedValueAppreciationRightsMemberusgaapAwardTypeAxis_TwoThousandFifteenEquityIncentivePlanMemberusgaapPlanNameAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001635088</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">roiv:CappedValueAppreciationRightsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">roiv:TwoThousandFifteenEquityIncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="P04_01_2021To06_30_2021_PerformanceOptionsMemberusgaapAwardTypeAxis_TwoThousandFifteenEquityIncentivePlanMemberusgaapPlanNameAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001635088</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">roiv:PerformanceOptionsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">roiv:TwoThousandFifteenEquityIncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="P04_01_2021To06_30_2021_RestrictedStockUnitsRSUMemberusgaapAwardTypeAxis_TwoThousandFifteenEquityIncentivePlanMemberusgaapPlanNameAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001635088</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">roiv:TwoThousandFifteenEquityIncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="P04_01_2021To06_30_2021_EmployeeStockOptionMemberusgaapAwardTypeAxis_TwoThousandFifteenEquityIncentivePlanMemberusgaapPlanNameAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001635088</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">roiv:TwoThousandFifteenEquityIncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="P04_01_2021To06_30_2021_FairValueInputsLevel3MemberusgaapFairValueByFairValueHierarchyLevelAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001635088</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="P04_01_2021To06_30_2021_ResearchAndDevelopmentExpenseMemberusgaapIncomeStatementLocationAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001635088</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="P04_01_2021To06_30_2021_GeneralAndAdministrativeExpenseMemberusgaapIncomeStatementLocationAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001635088</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="P04_01_2021To06_30_2021_ArbutusBiopharmaCorporationMemberdeiLegalEntityAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001635088</identifier>
            <segment>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">roiv:ArbutusBiopharmaCorporationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="P04_01_2021To06_30_2021_PerformanceRestrictedStockUnitsMemberusgaapAwardTypeAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001635088</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">roiv:PerformanceRestrictedStockUnitsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="P04_01_2021To06_30_2021_CappedValueAppreciationRightsMemberusgaapAwardTypeAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001635088</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">roiv:CappedValueAppreciationRightsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="P04_01_2021To06_30_2021_SubsidiaryEquityIncentivePlanMemberusgaapPlanNameAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001635088</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">roiv:SubsidiaryEquityIncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="P04_01_2021To06_30_2021_PerformanceRestrictedStockUnitsPlanMemberusgaapPlanNameAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001635088</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">roiv:PerformanceRestrictedStockUnitsPlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="P04_01_2021To06_30_2021_SioGeneTherapiesIncMemberdeiLegalEntityAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001635088</identifier>
            <segment>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">roiv:SioGeneTherapiesIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="P04_01_2021To06_30_2021_AdditionalPaidInCapitalMemberusgaapStatementEquityComponentsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001635088</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="P04_01_2021To06_30_2021_NoncontrollingInterestMemberusgaapStatementEquityComponentsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001635088</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="P04_01_2021To06_30_2021_AccumulatedOtherComprehensiveIncomeMemberusgaapStatementEquityComponentsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001635088</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="P04_01_2021To06_30_2021_RetainedEarningsMemberusgaapStatementEquityComponentsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001635088</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="P04_01_2021To06_30_2021_TransitionServicesAndStrategicCooperationAgreementMemberROIVAgreementAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001635088</identifier>
            <segment>
                <xbrldi:explicitMember dimension="roiv:AgreementAxis">roiv:TransitionServicesAndStrategicCooperationAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="P04_01_2021To06_30_2021_SumitomoMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001635088</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">roiv:SumitomoMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="P04_01_2021To06_30_2021_AssetPurchaseAgreementMemberROIVAgreementAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001635088</identifier>
            <segment>
                <xbrldi:explicitMember dimension="roiv:AgreementAxis">roiv:AssetPurchaseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="P04_01_2020To06_30_2020_FairValueInputsLevel3MemberusgaapFairValueByFairValueHierarchyLevelAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001635088</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-04-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="P04_01_2020To06_30_2020_ResearchAndDevelopmentExpenseMemberusgaapIncomeStatementLocationAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001635088</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-04-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="P04_01_2020To06_30_2020_GeneralAndAdministrativeExpenseMemberusgaapIncomeStatementLocationAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001635088</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-04-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="P04_01_2020To06_30_2020_EmployeeStockOptionMemberusgaapAwardTypeAxis_TwoThousandFifteenEquityIncentivePlanMemberusgaapPlanNameAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001635088</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">roiv:TwoThousandFifteenEquityIncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-04-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="P04_01_2020To06_30_2020_PerformanceOptionsMemberusgaapAwardTypeAxis_TwoThousandFifteenEquityIncentivePlanMemberusgaapPlanNameAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001635088</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">roiv:PerformanceOptionsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">roiv:TwoThousandFifteenEquityIncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-04-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="P04_01_2020To06_30_2020_SubsidiaryEquityIncentivePlanMemberusgaapPlanNameAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001635088</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">roiv:SubsidiaryEquityIncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-04-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="P04_01_2020To06_30_2020_RestrictedStockUnitsRSUMemberusgaapAwardTypeAxis_TwoThousandFifteenEquityIncentivePlanMemberusgaapPlanNameAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001635088</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">roiv:TwoThousandFifteenEquityIncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-04-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="P04_01_2020To06_30_2020_CappedValueAppreciationRightsMemberusgaapAwardTypeAxis_TwoThousandFifteenEquityIncentivePlanMemberusgaapPlanNameAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001635088</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">roiv:CappedValueAppreciationRightsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">roiv:TwoThousandFifteenEquityIncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-04-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="P04_01_2020To06_30_2020_PerformanceRestrictedStockUnitsMemberusgaapAwardTypeAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001635088</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">roiv:PerformanceRestrictedStockUnitsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-04-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="P04_01_2020To06_30_2020_SioGeneTherapiesIncMemberdeiLegalEntityAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001635088</identifier>
            <segment>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">roiv:SioGeneTherapiesIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-04-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="P04_01_2020To06_30_2020_ArbutusBiopharmaCorporationMemberdeiLegalEntityAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001635088</identifier>
            <segment>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">roiv:ArbutusBiopharmaCorporationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-04-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="P04_01_2020To06_30_2020_DatavantHoldingsIncMemberdeiLegalEntityAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001635088</identifier>
            <segment>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">roiv:DatavantHoldingsIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-04-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="P04_01_2020To06_30_2020_AdditionalPaidInCapitalMemberusgaapStatementEquityComponentsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001635088</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-04-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="P04_01_2020To06_30_2020_NoncontrollingInterestMemberusgaapStatementEquityComponentsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001635088</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-04-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="P04_01_2020To06_30_2020_AccumulatedOtherComprehensiveIncomeMemberusgaapStatementEquityComponentsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001635088</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-04-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="P04_01_2020To06_30_2020_RetainedEarningsMemberusgaapStatementEquityComponentsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001635088</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-04-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="P04_01_2020To06_30_2020_TransitionServicesAndStrategicCooperationAgreementMemberROIVAgreementAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001635088</identifier>
            <segment>
                <xbrldi:explicitMember dimension="roiv:AgreementAxis">roiv:TransitionServicesAndStrategicCooperationAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-04-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="PAsOn06_30_2020_EmployeeMembersrtTitleOfIndividualAxis_SumitomoMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001635088</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">roiv:EmployeeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">roiv:SumitomoMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-06-30</instant>
        </period>
    </context>
    <context id="PAsOn07_31_2021_ProteovantSciencesIncMemberusgaapBusinessAcquisitionAxis_SubsequentEventMemberusgaapSubsequentEventTypeAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001635088</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">roiv:ProteovantSciencesIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-07-31</instant>
        </period>
    </context>
    <context id="P05_01_2021To05_31_2021_RevenueInterestPurchaseAndSaleAgreementMemberusgaapFinancialInstrumentAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001635088</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">roiv:RevenueInterestPurchaseAndSaleAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-05-01</startDate>
            <endDate>2021-05-31</endDate>
        </period>
    </context>
    <context id="PAsOn05_31_2021_AssetPurchaseAgreementMemberROIVAgreementAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001635088</identifier>
            <segment>
                <xbrldi:explicitMember dimension="roiv:AgreementAxis">roiv:AssetPurchaseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-05-31</instant>
        </period>
    </context>
    <context id="PAsOn09_29_2017_ArbutusBiopharmaCorporationMemberdeiLegalEntityAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001635088</identifier>
            <segment>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">roiv:ArbutusBiopharmaCorporationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2017-09-29</instant>
        </period>
    </context>
    <context id="P03_31_2021To03_31_2021_SumitomoMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001635088</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">roiv:SumitomoMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-03-31</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="P05_14_2021To05_14_2021_CreditFacilityMemberusgaapDebtInstrumentAxis_DermavantSciencesLtdMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis_SubsequentEventMemberusgaapSubsequentEventTypeAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001635088</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">roiv:CreditFacilityMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">roiv:DermavantSciencesLtdMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-05-14</startDate>
            <endDate>2021-05-14</endDate>
        </period>
    </context>
    <context id="PAsOn03_31_2019_FairValueInputsLevel3MemberusgaapFairValueByFairValueHierarchyLevelAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001635088</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-03-31</instant>
        </period>
    </context>
    <context id="PAsOn03_31_2019_RedeemableNoncontrollingInterestMemberusgaapStatementClassOfStockAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001635088</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">roiv:RedeemableNoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-03-31</instant>
        </period>
    </context>
    <context id="PAsOn03_31_2019_CommonStockMemberusgaapStatementEquityComponentsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001635088</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-03-31</instant>
        </period>
    </context>
    <context id="PAsOn03_31_2019_AdditionalPaidInCapitalMemberusgaapStatementEquityComponentsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001635088</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-03-31</instant>
        </period>
    </context>
    <context id="PAsOn03_31_2019_SubscriptionsReceivablesMemberusgaapStatementEquityComponentsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001635088</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">roiv:SubscriptionsReceivablesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-03-31</instant>
        </period>
    </context>
    <context id="PAsOn03_31_2019_AccumulatedOtherComprehensiveIncomeMemberusgaapStatementEquityComponentsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001635088</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-03-31</instant>
        </period>
    </context>
    <context id="PAsOn03_31_2019_RetainedEarningsMemberusgaapStatementEquityComponentsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001635088</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-03-31</instant>
        </period>
    </context>
    <context id="PAsOn03_31_2019_NoncontrollingInterestMemberusgaapStatementEquityComponentsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001635088</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-03-31</instant>
        </period>
    </context>
    <context id="PAsOn03_31_2020_RedeemableNoncontrollingInterestMemberusgaapStatementClassOfStockAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001635088</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">roiv:RedeemableNoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-03-31</instant>
        </period>
    </context>
    <context id="PAsOn03_31_2020_CommonStockMemberusgaapStatementEquityComponentsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001635088</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-03-31</instant>
        </period>
    </context>
    <context id="PAsOn03_31_2020_AdditionalPaidInCapitalMemberusgaapStatementEquityComponentsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001635088</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-03-31</instant>
        </period>
    </context>
    <context id="PAsOn03_31_2020_SubscriptionsReceivablesMemberusgaapStatementEquityComponentsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001635088</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">roiv:SubscriptionsReceivablesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-03-31</instant>
        </period>
    </context>
    <context id="PAsOn03_31_2020_AccumulatedOtherComprehensiveIncomeMemberusgaapStatementEquityComponentsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001635088</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-03-31</instant>
        </period>
    </context>
    <context id="PAsOn03_31_2020_RetainedEarningsMemberusgaapStatementEquityComponentsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001635088</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-03-31</instant>
        </period>
    </context>
    <context id="PAsOn03_31_2020_NoncontrollingInterestMemberusgaapStatementEquityComponentsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001635088</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-03-31</instant>
        </period>
    </context>
    <context id="PAsOn03_31_2020_FairValueInputsLevel3MemberusgaapFairValueByFairValueHierarchyLevelAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001635088</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-03-31</instant>
        </period>
    </context>
    <context id="PAsOn03_31_2020_EmployeeStockOptionMemberusgaapAwardTypeAxis_TwoThousandFifteenEquityIncentivePlanMemberusgaapPlanNameAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001635088</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">roiv:TwoThousandFifteenEquityIncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-03-31</instant>
        </period>
    </context>
    <context id="PAsOn03_31_2020_RestrictedStockUnitsRSUMemberusgaapAwardTypeAxis_TwoThousandFifteenEquityIncentivePlanMemberusgaapPlanNameAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001635088</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">roiv:TwoThousandFifteenEquityIncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-03-31</instant>
        </period>
    </context>
    <context id="PAsOn03_31_2020_PerformanceOptionsMemberusgaapAwardTypeAxis_TwoThousandFifteenEquityIncentivePlanMemberusgaapPlanNameAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001635088</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">roiv:PerformanceOptionsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">roiv:TwoThousandFifteenEquityIncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-03-31</instant>
        </period>
    </context>
    <context id="PAsOn03_31_2020_CappedValueAppreciationRightsMemberusgaapAwardTypeAxis_TwoThousandFifteenEquityIncentivePlanMemberusgaapPlanNameAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001635088</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">roiv:CappedValueAppreciationRightsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">roiv:TwoThousandFifteenEquityIncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-03-31</instant>
        </period>
    </context>
    <context id="PAsOn03_31_2020_PerformanceRestrictedStockUnitsMemberusgaapAwardTypeAxis_PerformanceRestrictedStockUnitsPlanMemberusgaapPlanNameAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001635088</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">roiv:PerformanceRestrictedStockUnitsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">roiv:PerformanceRestrictedStockUnitsPlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-03-31</instant>
        </period>
    </context>
    <context id="PAsOn03_31_2020_CommonStockAwardsMemberusgaapAwardTypeAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001635088</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">roiv:CommonStockAwardsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-03-31</instant>
        </period>
    </context>
    <context id="PAsOn03_31_2021_PerformanceRestrictedStockUnitsMemberusgaapAwardTypeAxis_PerformanceRestrictedStockUnitsPlanMemberusgaapPlanNameAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001635088</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">roiv:PerformanceRestrictedStockUnitsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">roiv:PerformanceRestrictedStockUnitsPlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="PAsOn03_31_2021_CappedValueAppreciationRightsMemberusgaapAwardTypeAxis_TwoThousandFifteenEquityIncentivePlanMemberusgaapPlanNameAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001635088</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">roiv:CappedValueAppreciationRightsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">roiv:TwoThousandFifteenEquityIncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="PAsOn03_31_2021_PerformanceOptionsMemberusgaapAwardTypeAxis_TwoThousandFifteenEquityIncentivePlanMemberusgaapPlanNameAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001635088</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">roiv:PerformanceOptionsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">roiv:TwoThousandFifteenEquityIncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="PAsOn03_31_2021_RestrictedStockUnitsRSUMemberusgaapAwardTypeAxis_TwoThousandFifteenEquityIncentivePlanMemberusgaapPlanNameAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001635088</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">roiv:TwoThousandFifteenEquityIncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="PAsOn03_31_2021_RedeemableNoncontrollingInterestMemberusgaapStatementClassOfStockAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001635088</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">roiv:RedeemableNoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="PAsOn03_31_2021_CommonStockMemberusgaapStatementEquityComponentsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001635088</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="PAsOn03_31_2021_AdditionalPaidInCapitalMemberusgaapStatementEquityComponentsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001635088</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="PAsOn03_31_2021_SubscriptionsReceivablesMemberusgaapStatementEquityComponentsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001635088</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">roiv:SubscriptionsReceivablesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="PAsOn03_31_2021_AccumulatedOtherComprehensiveIncomeMemberusgaapStatementEquityComponentsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001635088</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="PAsOn03_31_2021_RetainedEarningsMemberusgaapStatementEquityComponentsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001635088</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="PAsOn03_31_2021_NoncontrollingInterestMemberusgaapStatementEquityComponentsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001635088</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="PAsOn03_31_2021_FairValueInputsLevel3MemberusgaapFairValueByFairValueHierarchyLevelAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001635088</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="PAsOn06_30_2021_PerformanceRestrictedStockUnitsMemberusgaapAwardTypeAxis_PerformanceRestrictedStockUnitsPlanMemberusgaapPlanNameAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001635088</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">roiv:PerformanceRestrictedStockUnitsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">roiv:PerformanceRestrictedStockUnitsPlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-06-30</instant>
        </period>
    </context>
    <context id="PAsOn06_30_2021_CappedValueAppreciationRightsMemberusgaapAwardTypeAxis_TwoThousandFifteenEquityIncentivePlanMemberusgaapPlanNameAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001635088</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">roiv:CappedValueAppreciationRightsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">roiv:TwoThousandFifteenEquityIncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-06-30</instant>
        </period>
    </context>
    <context id="PAsOn06_30_2021_PerformanceOptionsMemberusgaapAwardTypeAxis_TwoThousandFifteenEquityIncentivePlanMemberusgaapPlanNameAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001635088</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">roiv:PerformanceOptionsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">roiv:TwoThousandFifteenEquityIncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-06-30</instant>
        </period>
    </context>
    <context id="PAsOn06_30_2021_RestrictedStockUnitsRSUMemberusgaapAwardTypeAxis_TwoThousandFifteenEquityIncentivePlanMemberusgaapPlanNameAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001635088</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">roiv:TwoThousandFifteenEquityIncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-06-30</instant>
        </period>
    </context>
    <context id="PAsOn06_30_2021_EmployeeStockOptionMemberusgaapAwardTypeAxis_TwoThousandFifteenEquityIncentivePlanMemberusgaapPlanNameAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001635088</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">roiv:TwoThousandFifteenEquityIncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-06-30</instant>
        </period>
    </context>
    <context id="PAsOn06_30_2021_CommonStockAwardsMemberusgaapAwardTypeAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001635088</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">roiv:CommonStockAwardsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-06-30</instant>
        </period>
    </context>
    <context id="PAsOn06_30_2021_RedeemableNoncontrollingInterestMemberusgaapStatementClassOfStockAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001635088</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">roiv:RedeemableNoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-06-30</instant>
        </period>
    </context>
    <context id="PAsOn06_30_2021_CommonStockMemberusgaapStatementEquityComponentsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001635088</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-06-30</instant>
        </period>
    </context>
    <context id="PAsOn06_30_2021_AdditionalPaidInCapitalMemberusgaapStatementEquityComponentsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001635088</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-06-30</instant>
        </period>
    </context>
    <context id="PAsOn06_30_2021_SubscriptionsReceivablesMemberusgaapStatementEquityComponentsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001635088</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">roiv:SubscriptionsReceivablesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-06-30</instant>
        </period>
    </context>
    <context id="PAsOn06_30_2021_AccumulatedOtherComprehensiveIncomeMemberusgaapStatementEquityComponentsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001635088</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-06-30</instant>
        </period>
    </context>
    <context id="PAsOn06_30_2021_RetainedEarningsMemberusgaapStatementEquityComponentsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001635088</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-06-30</instant>
        </period>
    </context>
    <context id="PAsOn06_30_2021_NoncontrollingInterestMemberusgaapStatementEquityComponentsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001635088</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-06-30</instant>
        </period>
    </context>
    <context id="PAsOn06_30_2021_FairValueInputsLevel3MemberusgaapFairValueByFairValueHierarchyLevelAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001635088</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-06-30</instant>
        </period>
    </context>
    <context id="PAsOn06_30_2020_RedeemableNoncontrollingInterestMemberusgaapStatementClassOfStockAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001635088</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">roiv:RedeemableNoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-06-30</instant>
        </period>
    </context>
    <context id="PAsOn06_30_2020_CommonStockMemberusgaapStatementEquityComponentsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001635088</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-06-30</instant>
        </period>
    </context>
    <context id="PAsOn06_30_2020_AdditionalPaidInCapitalMemberusgaapStatementEquityComponentsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001635088</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-06-30</instant>
        </period>
    </context>
    <context id="PAsOn06_30_2020_SubscriptionsReceivablesMemberusgaapStatementEquityComponentsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001635088</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">roiv:SubscriptionsReceivablesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-06-30</instant>
        </period>
    </context>
    <context id="PAsOn06_30_2020_AccumulatedOtherComprehensiveIncomeMemberusgaapStatementEquityComponentsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001635088</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-06-30</instant>
        </period>
    </context>
    <context id="PAsOn06_30_2020_RetainedEarningsMemberusgaapStatementEquityComponentsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001635088</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-06-30</instant>
        </period>
    </context>
    <context id="PAsOn06_30_2020_NoncontrollingInterestMemberusgaapStatementEquityComponentsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001635088</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-06-30</instant>
        </period>
    </context>
    <context id="PAsOn06_30_2020_FairValueInputsLevel3MemberusgaapFairValueByFairValueHierarchyLevelAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001635088</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-06-30</instant>
        </period>
    </context>
    <unit id="Unit_USD">
        <measure>iso4217:USD</measure>
    </unit>
    <unit id="Unit_shares">
        <measure>shares</measure>
    </unit>
    <unit id="Unit_EUR">
        <measure>iso4217:EUR</measure>
    </unit>
    <unit id="Unit_pure">
        <measure>pure</measure>
    </unit>
    <unit id="Unit_Year">
        <measure>utr:Year</measure>
    </unit>
    <unit id="Unit_CAD">
        <measure>iso4217:CAD</measure>
    </unit>
    <unit id="Unit_Day">
        <measure>utr:Day</measure>
    </unit>
    <unit id="Unit_Segment">
        <measure>roiv:Segment</measure>
    </unit>
    <unit id="Unit_USD_per_Share">
        <divide>
            <unitNumerator>
                <measure>iso4217:USD</measure>
            </unitNumerator>
            <unitDenominator>
                <measure>shares</measure>
            </unitDenominator>
        </divide>
    </unit>
    <dei:AmendmentFlag contextRef="P04_01_2021To06_30_2021">false</dei:AmendmentFlag>
    <dei:EntityRegistrantName contextRef="P04_01_2021To06_30_2021" id="hidden28317344">Roivant Sciences Ltd.</dei:EntityRegistrantName>
    <us-gaap:DebtInstrumentMeasurementInput
      contextRef="PAsOn06_30_2021_MaximumMembersrtRangeAxis_MeasurementInputDiscountRateMemberusgaapMeasurementInputTypeAxis"
      decimals="2"
      id="hidden28229201"
      unitRef="Unit_pure">0.12</us-gaap:DebtInstrumentMeasurementInput>
    <us-gaap:DebtInstrumentMeasurementInput
      contextRef="PAsOn06_30_2021_MeasurementInputDiscountRateMemberusgaapMeasurementInputTypeAxis_MinimumMembersrtRangeAxis"
      decimals="2"
      id="hidden28229202"
      unitRef="Unit_pure">0.11</us-gaap:DebtInstrumentMeasurementInput>
    <dei:EntityCentralIndexKey contextRef="P04_01_2021To06_30_2021">0001635088</dei:EntityCentralIndexKey>
    <us-gaap:DebtInstrumentTerm
      contextRef="P05_14_2021To05_14_2021_CreditFacilityMemberusgaapDebtInstrumentAxis_DermavantSciencesLtdMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis_SubsequentEventMemberusgaapSubsequentEventTypeAxis"
      id="hidden28230199">P5Y</us-gaap:DebtInstrumentTerm>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="PAsOn06_30_2021"
      decimals="INF"
      id="hidden28228642"
      unitRef="Unit_USD_per_Share">0.0000001</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="PAsOn03_31_2021"
      decimals="INF"
      unitRef="Unit_USD_per_Share">0.0000001</us-gaap:CommonStockParOrStatedValuePerShare>
    <dei:DocumentType contextRef="P04_01_2021To06_30_2021">S-1</dei:DocumentType>
    <dei:EntityFilerCategory contextRef="P04_01_2021To06_30_2021">Non-accelerated Filer</dei:EntityFilerCategory>
    <dei:EntitySmallBusiness contextRef="P04_01_2021To06_30_2021">true</dei:EntitySmallBusiness>
    <dei:EntityEmergingGrowthCompany contextRef="P04_01_2021To06_30_2021">true</dei:EntityEmergingGrowthCompany>
    <dei:EntityExTransitionPeriod contextRef="P04_01_2021To06_30_2021">true</dei:EntityExTransitionPeriod>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="PAsOn03_31_2021"
      decimals="-3"
      unitRef="Unit_USD">2055044000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="PAsOn03_31_2020"
      decimals="-3"
      unitRef="Unit_USD">2183207000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:RestrictedCashCurrent
      contextRef="PAsOn03_31_2021"
      decimals="-3"
      unitRef="Unit_USD">77701000</us-gaap:RestrictedCashCurrent>
    <us-gaap:RestrictedCashCurrent
      contextRef="PAsOn03_31_2020"
      decimals="-3"
      unitRef="Unit_USD">2275000</us-gaap:RestrictedCashCurrent>
    <us-gaap:OtherAssetsCurrent
      contextRef="PAsOn03_31_2021"
      decimals="-3"
      unitRef="Unit_USD">54250000</us-gaap:OtherAssetsCurrent>
    <us-gaap:OtherAssetsCurrent
      contextRef="PAsOn03_31_2020"
      decimals="-3"
      unitRef="Unit_USD">33763000</us-gaap:OtherAssetsCurrent>
    <us-gaap:AssetsCurrent
      contextRef="PAsOn03_31_2021"
      decimals="-3"
      unitRef="Unit_USD">2186995000</us-gaap:AssetsCurrent>
    <us-gaap:AssetsCurrent
      contextRef="PAsOn03_31_2020"
      decimals="-3"
      unitRef="Unit_USD">2219245000</us-gaap:AssetsCurrent>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="PAsOn03_31_2021"
      decimals="-3"
      unitRef="Unit_USD">14749000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="PAsOn03_31_2020"
      decimals="-3"
      unitRef="Unit_USD">8962000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:OperatingLeaseRightOfUseAsset
      contextRef="PAsOn03_31_2021"
      decimals="-3"
      unitRef="Unit_USD">62279000</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:OperatingLeaseRightOfUseAsset
      contextRef="PAsOn03_31_2020"
      decimals="-3"
      unitRef="Unit_USD">64970000</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:RestrictedCashNoncurrent
      contextRef="PAsOn03_31_2021"
      decimals="-3"
      unitRef="Unit_USD">8931000</us-gaap:RestrictedCashNoncurrent>
    <us-gaap:RestrictedCashNoncurrent
      contextRef="PAsOn03_31_2020"
      decimals="-3"
      unitRef="Unit_USD">83770000</us-gaap:RestrictedCashNoncurrent>
    <us-gaap:InvestmentsFairValueDisclosure
      contextRef="PAsOn03_31_2021"
      decimals="-3"
      unitRef="Unit_USD">188978000</us-gaap:InvestmentsFairValueDisclosure>
    <us-gaap:InvestmentsFairValueDisclosure
      contextRef="PAsOn03_31_2020"
      decimals="-3"
      unitRef="Unit_USD">93445000</us-gaap:InvestmentsFairValueDisclosure>
    <us-gaap:LongTermInvestments
      contextRef="PAsOn03_31_2021"
      decimals="-3"
      unitRef="Unit_USD">100563000</us-gaap:LongTermInvestments>
    <us-gaap:LongTermInvestments
      contextRef="PAsOn03_31_2020"
      decimals="-3"
      unitRef="Unit_USD">0</us-gaap:LongTermInvestments>
    <us-gaap:OtherAssetsNoncurrent
      contextRef="PAsOn03_31_2021"
      decimals="-3"
      unitRef="Unit_USD">27197000</us-gaap:OtherAssetsNoncurrent>
    <us-gaap:OtherAssetsNoncurrent
      contextRef="PAsOn03_31_2020"
      decimals="-3"
      unitRef="Unit_USD">6659000</us-gaap:OtherAssetsNoncurrent>
    <us-gaap:Assets
      contextRef="PAsOn03_31_2021"
      decimals="-3"
      unitRef="Unit_USD">2589692000</us-gaap:Assets>
    <us-gaap:Assets
      contextRef="PAsOn03_31_2020"
      decimals="-3"
      unitRef="Unit_USD">2477051000</us-gaap:Assets>
    <us-gaap:AccountsPayableCurrent
      contextRef="PAsOn03_31_2021"
      decimals="-3"
      unitRef="Unit_USD">20550000</us-gaap:AccountsPayableCurrent>
    <us-gaap:AccountsPayableCurrent
      contextRef="PAsOn03_31_2020"
      decimals="-3"
      unitRef="Unit_USD">10306000</us-gaap:AccountsPayableCurrent>
    <us-gaap:AccruedLiabilitiesCurrent
      contextRef="PAsOn03_31_2021"
      decimals="-3"
      unitRef="Unit_USD">76936000</us-gaap:AccruedLiabilitiesCurrent>
    <us-gaap:AccruedLiabilitiesCurrent
      contextRef="PAsOn03_31_2020"
      decimals="-3"
      unitRef="Unit_USD">68621000</us-gaap:AccruedLiabilitiesCurrent>
    <us-gaap:OperatingLeaseLiabilityCurrent
      contextRef="PAsOn03_31_2021"
      decimals="-3"
      unitRef="Unit_USD">12313000</us-gaap:OperatingLeaseLiabilityCurrent>
    <us-gaap:OperatingLeaseLiabilityCurrent
      contextRef="PAsOn03_31_2020"
      decimals="-3"
      unitRef="Unit_USD">7839000</us-gaap:OperatingLeaseLiabilityCurrent>
    <roiv:DeferredConsiderationLiabilityCurrent
      contextRef="PAsOn03_31_2021"
      decimals="-3"
      unitRef="Unit_USD">100000000</roiv:DeferredConsiderationLiabilityCurrent>
    <roiv:DeferredConsiderationLiabilityCurrent
      contextRef="PAsOn03_31_2020"
      decimals="-3"
      unitRef="Unit_USD">0</roiv:DeferredConsiderationLiabilityCurrent>
    <us-gaap:OtherLiabilitiesCurrent
      contextRef="PAsOn03_31_2021"
      decimals="-3"
      unitRef="Unit_USD">9162000</us-gaap:OtherLiabilitiesCurrent>
    <us-gaap:OtherLiabilitiesCurrent
      contextRef="PAsOn03_31_2020"
      decimals="-3"
      unitRef="Unit_USD">5352000</us-gaap:OtherLiabilitiesCurrent>
    <us-gaap:LiabilitiesCurrent
      contextRef="PAsOn03_31_2021"
      decimals="-3"
      unitRef="Unit_USD">218961000</us-gaap:LiabilitiesCurrent>
    <us-gaap:LiabilitiesCurrent
      contextRef="PAsOn03_31_2020"
      decimals="-3"
      unitRef="Unit_USD">92118000</us-gaap:LiabilitiesCurrent>
    <roiv:LiabilityInstrumentsMeasuredAtFairValue
      contextRef="PAsOn03_31_2021"
      decimals="-3"
      unitRef="Unit_USD">67893000</roiv:LiabilityInstrumentsMeasuredAtFairValue>
    <roiv:LiabilityInstrumentsMeasuredAtFairValue
      contextRef="PAsOn03_31_2020"
      decimals="-3"
      unitRef="Unit_USD">102373000</roiv:LiabilityInstrumentsMeasuredAtFairValue>
    <us-gaap:OperatingLeaseLiabilityNoncurrent
      contextRef="PAsOn03_31_2021"
      decimals="-3"
      unitRef="Unit_USD">62384000</us-gaap:OperatingLeaseLiabilityNoncurrent>
    <us-gaap:OperatingLeaseLiabilityNoncurrent
      contextRef="PAsOn03_31_2020"
      decimals="-3"
      unitRef="Unit_USD">64452000</us-gaap:OperatingLeaseLiabilityNoncurrent>
    <us-gaap:LongTermDebtFairValue
      contextRef="PAsOn03_31_2021"
      decimals="-3"
      unitRef="Unit_USD">150100000</us-gaap:LongTermDebtFairValue>
    <us-gaap:LongTermDebtFairValue
      contextRef="PAsOn03_31_2020"
      decimals="-3"
      unitRef="Unit_USD">89100000</us-gaap:LongTermDebtFairValue>
    <us-gaap:LongTermDebtNoncurrent
      contextRef="PAsOn03_31_2021"
      decimals="-3"
      unitRef="Unit_USD">170280000</us-gaap:LongTermDebtNoncurrent>
    <us-gaap:LongTermDebtNoncurrent
      contextRef="PAsOn03_31_2020"
      decimals="-3"
      unitRef="Unit_USD">108592000</us-gaap:LongTermDebtNoncurrent>
    <us-gaap:OtherLiabilitiesNoncurrent
      contextRef="PAsOn03_31_2021"
      decimals="-3"
      unitRef="Unit_USD">8169000</us-gaap:OtherLiabilitiesNoncurrent>
    <us-gaap:OtherLiabilitiesNoncurrent
      contextRef="PAsOn03_31_2020"
      decimals="-3"
      unitRef="Unit_USD">821000</us-gaap:OtherLiabilitiesNoncurrent>
    <us-gaap:Liabilities
      contextRef="PAsOn03_31_2021"
      decimals="-3"
      unitRef="Unit_USD">527687000</us-gaap:Liabilities>
    <us-gaap:Liabilities
      contextRef="PAsOn03_31_2020"
      decimals="-3"
      unitRef="Unit_USD">368356000</us-gaap:Liabilities>
    <us-gaap:RedeemableNoncontrollingInterestEquityCarryingAmount
      contextRef="PAsOn03_31_2021"
      decimals="-3"
      unitRef="Unit_USD">22491000</us-gaap:RedeemableNoncontrollingInterestEquityCarryingAmount>
    <us-gaap:RedeemableNoncontrollingInterestEquityCarryingAmount
      contextRef="PAsOn03_31_2020"
      decimals="-3"
      unitRef="Unit_USD">22491000</us-gaap:RedeemableNoncontrollingInterestEquityCarryingAmount>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="PAsOn03_31_2020"
      decimals="INF"
      unitRef="Unit_USD_per_Share">0.0000001</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="PAsOn03_31_2021"
      decimals="INF"
      unitRef="Unit_USD_per_Share">0.0000001</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="PAsOn03_31_2020"
      decimals="INF"
      unitRef="Unit_shares">100000000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="PAsOn03_31_2021"
      decimals="INF"
      unitRef="Unit_shares">100000000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="PAsOn03_31_2021"
      decimals="INF"
      unitRef="Unit_shares">222669799</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:CommonStockSharesIssued
      contextRef="PAsOn03_31_2021"
      decimals="INF"
      unitRef="Unit_shares">222669799</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="PAsOn03_31_2020"
      decimals="INF"
      unitRef="Unit_shares">214879058</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:CommonStockSharesIssued
      contextRef="PAsOn03_31_2020"
      decimals="INF"
      unitRef="Unit_shares">214879058</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockValue
      contextRef="PAsOn03_31_2021"
      decimals="-3"
      unitRef="Unit_USD">0</us-gaap:CommonStockValue>
    <us-gaap:CommonStockValue
      contextRef="PAsOn03_31_2020"
      decimals="-3"
      unitRef="Unit_USD">0</us-gaap:CommonStockValue>
    <us-gaap:AdditionalPaidInCapital
      contextRef="PAsOn03_31_2021"
      decimals="-3"
      unitRef="Unit_USD">3814805000</us-gaap:AdditionalPaidInCapital>
    <us-gaap:AdditionalPaidInCapital
      contextRef="PAsOn03_31_2020"
      decimals="-3"
      unitRef="Unit_USD">3143739000</us-gaap:AdditionalPaidInCapital>
    <roiv:SubscriptionsReceivable
      contextRef="PAsOn03_31_2021"
      decimals="-3"
      unitRef="Unit_USD">-100000000</roiv:SubscriptionsReceivable>
    <roiv:SubscriptionsReceivable
      contextRef="PAsOn03_31_2020"
      decimals="-3"
      unitRef="Unit_USD">0</roiv:SubscriptionsReceivable>
    <us-gaap:RetainedEarningsAccumulatedDeficit
      contextRef="PAsOn03_31_2021"
      decimals="-3"
      unitRef="Unit_USD">-1918462000</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:RetainedEarningsAccumulatedDeficit
      contextRef="PAsOn03_31_2020"
      decimals="-3"
      unitRef="Unit_USD">-1109228000</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax
      contextRef="PAsOn03_31_2021"
      decimals="-3"
      unitRef="Unit_USD">1445000</us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax
      contextRef="PAsOn03_31_2020"
      decimals="-3"
      unitRef="Unit_USD">-2349000</us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:StockholdersEquity
      contextRef="PAsOn03_31_2021"
      decimals="-3"
      unitRef="Unit_USD">1797788000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="PAsOn03_31_2020"
      decimals="-3"
      unitRef="Unit_USD">2032162000</us-gaap:StockholdersEquity>
    <us-gaap:MinorityInterest
      contextRef="PAsOn03_31_2021"
      decimals="-3"
      unitRef="Unit_USD">241726000</us-gaap:MinorityInterest>
    <us-gaap:MinorityInterest
      contextRef="PAsOn03_31_2020"
      decimals="-3"
      unitRef="Unit_USD">54042000</us-gaap:MinorityInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="PAsOn03_31_2021"
      decimals="-3"
      unitRef="Unit_USD">2039514000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="PAsOn03_31_2020"
      decimals="-3"
      unitRef="Unit_USD">2086204000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:LiabilitiesAndStockholdersEquity
      contextRef="PAsOn03_31_2021"
      decimals="-3"
      unitRef="Unit_USD">2589692000</us-gaap:LiabilitiesAndStockholdersEquity>
    <us-gaap:LiabilitiesAndStockholdersEquity
      contextRef="PAsOn03_31_2020"
      decimals="-3"
      unitRef="Unit_USD">2477051000</us-gaap:LiabilitiesAndStockholdersEquity>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="P04_01_2020To03_31_2021"
      decimals="-3"
      unitRef="Unit_USD">23795000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="P04_01_2019To03_31_2020"
      decimals="-3"
      unitRef="Unit_USD">67689000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <roiv:OperatingCosts
      contextRef="P04_01_2020To03_31_2021"
      decimals="-3"
      unitRef="Unit_USD">2057000</roiv:OperatingCosts>
    <roiv:OperatingCosts
      contextRef="P04_01_2019To03_31_2020"
      decimals="-3"
      unitRef="Unit_USD">1131000</roiv:OperatingCosts>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="P04_01_2020To03_31_2021"
      decimals="-3"
      unitRef="Unit_USD">832758000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="P04_01_2019To03_31_2020"
      decimals="-3"
      unitRef="Unit_USD">263217000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:GeneralAndAdministrativeExpense
      contextRef="P04_01_2020To03_31_2021"
      decimals="-3"
      unitRef="Unit_USD">259878000</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:GeneralAndAdministrativeExpense
      contextRef="P04_01_2019To03_31_2020"
      decimals="-3"
      unitRef="Unit_USD">335766000</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:OperatingExpenses
      contextRef="P04_01_2020To03_31_2021"
      decimals="-3"
      unitRef="Unit_USD">1094693000</us-gaap:OperatingExpenses>
    <us-gaap:OperatingExpenses
      contextRef="P04_01_2019To03_31_2020"
      decimals="-3"
      unitRef="Unit_USD">600114000</us-gaap:OperatingExpenses>
    <us-gaap:OperatingIncomeLoss
      contextRef="P04_01_2020To03_31_2021"
      decimals="-3"
      unitRef="Unit_USD">-1070898000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="P04_01_2019To03_31_2020"
      decimals="-3"
      unitRef="Unit_USD">-532425000</us-gaap:OperatingIncomeLoss>
    <us-gaap:GainLossOnInvestments
      contextRef="P04_01_2020To03_31_2021"
      decimals="-3"
      unitRef="Unit_USD">95533000</us-gaap:GainLossOnInvestments>
    <us-gaap:GainLossOnInvestments
      contextRef="P04_01_2019To03_31_2020"
      decimals="-3"
      unitRef="Unit_USD">-136005000</us-gaap:GainLossOnInvestments>
    <roiv:GainLossOnFairValueOfDebtAndLiabilityInstruments
      contextRef="P04_01_2020To03_31_2021"
      decimals="-3"
      unitRef="Unit_USD">-29845000</roiv:GainLossOnFairValueOfDebtAndLiabilityInstruments>
    <roiv:GainLossOnFairValueOfDebtAndLiabilityInstruments
      contextRef="P04_01_2019To03_31_2020"
      decimals="-3"
      unitRef="Unit_USD">13722000</roiv:GainLossOnFairValueOfDebtAndLiabilityInstruments>
    <roiv:DeconsolidationAndConsolidationOnGainOrLossOfConsolidatedEntity
      contextRef="P04_01_2020To03_31_2021"
      decimals="-3"
      unitRef="Unit_USD">115364000</roiv:DeconsolidationAndConsolidationOnGainOrLossOfConsolidatedEntity>
    <roiv:DeconsolidationAndConsolidationOnGainOrLossOfConsolidatedEntity
      contextRef="P04_01_2019To03_31_2020"
      decimals="-3"
      unitRef="Unit_USD">107344000</roiv:DeconsolidationAndConsolidationOnGainOrLossOfConsolidatedEntity>
    <us-gaap:OtherNonoperatingIncomeExpense
      contextRef="P04_01_2020To03_31_2021"
      decimals="-3"
      unitRef="Unit_USD">-8701000</us-gaap:OtherNonoperatingIncomeExpense>
    <us-gaap:OtherNonoperatingIncomeExpense
      contextRef="P04_01_2019To03_31_2020"
      decimals="-3"
      unitRef="Unit_USD">-13622000</us-gaap:OtherNonoperatingIncomeExpense>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments
      contextRef="P04_01_2020To03_31_2021"
      decimals="-3"
      unitRef="Unit_USD">-898547000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments
      contextRef="P04_01_2019To03_31_2020"
      decimals="-3"
      unitRef="Unit_USD">-560986000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="P04_01_2020To03_31_2021"
      decimals="-3"
      unitRef="Unit_USD">1686000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="P04_01_2019To03_31_2020"
      decimals="-3"
      unitRef="Unit_USD">7124000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest
      contextRef="P04_01_2020To03_31_2021"
      decimals="-3"
      unitRef="Unit_USD">-900233000</us-gaap:IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest
      contextRef="P04_01_2019To03_31_2020"
      decimals="-3"
      unitRef="Unit_USD">-568110000</us-gaap:IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTax
      contextRef="P04_01_2020To03_31_2021"
      decimals="-3"
      unitRef="Unit_USD">0</us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTax>
    <us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTax
      contextRef="P04_01_2019To03_31_2020"
      decimals="-3"
      unitRef="Unit_USD">1578426000</us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTax>
    <us-gaap:ProfitLoss
      contextRef="P04_01_2020To03_31_2021"
      decimals="-3"
      unitRef="Unit_USD">-900233000</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="P04_01_2019To03_31_2020"
      decimals="-3"
      unitRef="Unit_USD">1010316000</us-gaap:ProfitLoss>
    <us-gaap:NetIncomeLossAttributableToNoncontrollingInterest
      contextRef="P04_01_2020To03_31_2021"
      decimals="-3"
      unitRef="Unit_USD">-90999000</us-gaap:NetIncomeLossAttributableToNoncontrollingInterest>
    <us-gaap:NetIncomeLossAttributableToNoncontrollingInterest
      contextRef="P04_01_2019To03_31_2020"
      decimals="-3"
      unitRef="Unit_USD">-190193000</us-gaap:NetIncomeLossAttributableToNoncontrollingInterest>
    <us-gaap:NetIncomeLoss
      contextRef="P04_01_2020To03_31_2021"
      decimals="-3"
      unitRef="Unit_USD">-809234000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="P04_01_2019To03_31_2020"
      decimals="-3"
      unitRef="Unit_USD">1200509000</us-gaap:NetIncomeLoss>
    <us-gaap:IncomeLossFromContinuingOperations
      contextRef="P04_01_2020To03_31_2021"
      decimals="-3"
      unitRef="Unit_USD">809234000</us-gaap:IncomeLossFromContinuingOperations>
    <us-gaap:IncomeLossFromContinuingOperations
      contextRef="P04_01_2019To03_31_2020"
      decimals="-3"
      unitRef="Unit_USD">519394000</us-gaap:IncomeLossFromContinuingOperations>
    <us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity
      contextRef="P04_01_2020To03_31_2021"
      decimals="-3"
      unitRef="Unit_USD">0</us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity>
    <us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity
      contextRef="P04_01_2019To03_31_2020"
      decimals="-3"
      unitRef="Unit_USD">1719903000</us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity>
    <us-gaap:NetIncomeLoss
      contextRef="P04_01_2020To03_31_2021"
      decimals="-3"
      unitRef="Unit_USD">-809234000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="P04_01_2019To03_31_2020"
      decimals="-3"
      unitRef="Unit_USD">1200509000</us-gaap:NetIncomeLoss>
    <us-gaap:IncomeLossFromContinuingOperationsPerBasicAndDilutedShare
      contextRef="P04_01_2020To03_31_2021"
      decimals="2"
      unitRef="Unit_USD_per_Share">-3.76</us-gaap:IncomeLossFromContinuingOperationsPerBasicAndDilutedShare>
    <us-gaap:IncomeLossFromContinuingOperationsPerBasicAndDilutedShare
      contextRef="P04_01_2019To03_31_2020"
      decimals="2"
      unitRef="Unit_USD_per_Share">-2.72</us-gaap:IncomeLossFromContinuingOperationsPerBasicAndDilutedShare>
    <us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicAndDilutedShare
      contextRef="P04_01_2020To03_31_2021"
      decimals="0"
      unitRef="Unit_USD_per_Share">0</us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicAndDilutedShare>
    <us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicAndDilutedShare
      contextRef="P04_01_2019To03_31_2020"
      decimals="2"
      unitRef="Unit_USD_per_Share">7.85</us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicAndDilutedShare>
    <us-gaap:EarningsPerShareBasicAndDiluted
      contextRef="P04_01_2020To03_31_2021"
      decimals="2"
      unitRef="Unit_USD_per_Share">-3.76</us-gaap:EarningsPerShareBasicAndDiluted>
    <us-gaap:EarningsPerShareBasicAndDiluted
      contextRef="P04_01_2019To03_31_2020"
      decimals="2"
      unitRef="Unit_USD_per_Share">5.13</us-gaap:EarningsPerShareBasicAndDiluted>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="P04_01_2020To03_31_2021"
      decimals="0"
      unitRef="Unit_shares">215312273</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="P04_01_2019To03_31_2020"
      decimals="0"
      unitRef="Unit_shares">219036630</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="P04_01_2020To03_31_2021"
      decimals="0"
      unitRef="Unit_shares">215312273</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="P04_01_2019To03_31_2020"
      decimals="0"
      unitRef="Unit_shares">219036630</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:ProfitLoss
      contextRef="P04_01_2020To03_31_2021"
      decimals="-3"
      unitRef="Unit_USD">-900233000</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="P04_01_2019To03_31_2020"
      decimals="-3"
      unitRef="Unit_USD">1010316000</us-gaap:ProfitLoss>
    <us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax
      contextRef="P04_01_2020To03_31_2021"
      decimals="-3"
      unitRef="Unit_USD">3826000</us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax>
    <us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax
      contextRef="P04_01_2019To03_31_2020"
      decimals="-3"
      unitRef="Unit_USD">-5536000</us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTax
      contextRef="P04_01_2020To03_31_2021"
      decimals="-3"
      unitRef="Unit_USD">3826000</us-gaap:OtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTax
      contextRef="P04_01_2019To03_31_2020"
      decimals="-3"
      unitRef="Unit_USD">-5536000</us-gaap:OtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest
      contextRef="P04_01_2020To03_31_2021"
      decimals="-3"
      unitRef="Unit_USD">-896407000</us-gaap:ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest
      contextRef="P04_01_2019To03_31_2020"
      decimals="-3"
      unitRef="Unit_USD">1004780000</us-gaap:ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest
      contextRef="P04_01_2020To03_31_2021"
      decimals="-3"
      unitRef="Unit_USD">-90967000</us-gaap:ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest>
    <us-gaap:ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest
      contextRef="P04_01_2019To03_31_2020"
      decimals="-3"
      unitRef="Unit_USD">-190862000</us-gaap:ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest>
    <us-gaap:ComprehensiveIncomeNetOfTax
      contextRef="P04_01_2020To03_31_2021"
      decimals="-3"
      unitRef="Unit_USD">-805440000</us-gaap:ComprehensiveIncomeNetOfTax>
    <us-gaap:ComprehensiveIncomeNetOfTax
      contextRef="P04_01_2019To03_31_2020"
      decimals="-3"
      unitRef="Unit_USD">1195642000</us-gaap:ComprehensiveIncomeNetOfTax>
    <us-gaap:TemporaryEquityCarryingAmountIncludingPortionAttributableToNoncontrollingInterests
      contextRef="PAsOn03_31_2019_RedeemableNoncontrollingInterestMemberusgaapStatementClassOfStockAxis"
      decimals="-3"
      unitRef="Unit_USD">50130000</us-gaap:TemporaryEquityCarryingAmountIncludingPortionAttributableToNoncontrollingInterests>
    <us-gaap:SharesOutstanding
      contextRef="PAsOn03_31_2019_CommonStockMemberusgaapStatementEquityComponentsAxis"
      decimals="INF"
      unitRef="Unit_shares">213555119</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="PAsOn03_31_2019_CommonStockMemberusgaapStatementEquityComponentsAxis"
      decimals="-3"
      unitRef="Unit_USD">0</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="PAsOn03_31_2019_AdditionalPaidInCapitalMemberusgaapStatementEquityComponentsAxis"
      decimals="-3"
      unitRef="Unit_USD">3024172000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="PAsOn03_31_2019_SubscriptionsReceivablesMemberusgaapStatementEquityComponentsAxis"
      decimals="-3"
      unitRef="Unit_USD">0</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="PAsOn03_31_2019_AccumulatedOtherComprehensiveIncomeMemberusgaapStatementEquityComponentsAxis"
      decimals="-3"
      unitRef="Unit_USD">2518000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="PAsOn03_31_2019_RetainedEarningsMemberusgaapStatementEquityComponentsAxis"
      decimals="-3"
      unitRef="Unit_USD">-2309737000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="PAsOn03_31_2019_NoncontrollingInterestMemberusgaapStatementEquityComponentsAxis"
      decimals="-3"
      unitRef="Unit_USD">170216000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="PAsOn03_31_2019"
      decimals="-3"
      unitRef="Unit_USD">887169000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <roiv:IssuanceOfSubsidiaryCommonSharesNetValue
      contextRef="P04_01_2019To03_31_2020_AdditionalPaidInCapitalMemberusgaapStatementEquityComponentsAxis"
      decimals="-3"
      unitRef="Unit_USD">59052000</roiv:IssuanceOfSubsidiaryCommonSharesNetValue>
    <roiv:IssuanceOfSubsidiaryCommonSharesNetValue
      contextRef="P04_01_2019To03_31_2020_NoncontrollingInterestMemberusgaapStatementEquityComponentsAxis"
      decimals="-3"
      unitRef="Unit_USD">58606000</roiv:IssuanceOfSubsidiaryCommonSharesNetValue>
    <roiv:IssuanceOfSubsidiaryCommonSharesNetValue
      contextRef="P04_01_2019To03_31_2020"
      decimals="-3"
      unitRef="Unit_USD">117658000</roiv:IssuanceOfSubsidiaryCommonSharesNetValue>
    <roiv:IssuanceOfSubsidiaryCommonSharesToTheCompanyValue
      contextRef="P04_01_2019To03_31_2020_AdditionalPaidInCapitalMemberusgaapStatementEquityComponentsAxis"
      decimals="-3"
      unitRef="Unit_USD">-9962000</roiv:IssuanceOfSubsidiaryCommonSharesToTheCompanyValue>
    <roiv:IssuanceOfSubsidiaryCommonSharesToTheCompanyValue
      contextRef="P04_01_2019To03_31_2020_NoncontrollingInterestMemberusgaapStatementEquityComponentsAxis"
      decimals="-3"
      unitRef="Unit_USD">9962000</roiv:IssuanceOfSubsidiaryCommonSharesToTheCompanyValue>
    <roiv:PurchaseOfSubsidiaryCommonSharesValue
      contextRef="P04_01_2019To03_31_2020_AdditionalPaidInCapitalMemberusgaapStatementEquityComponentsAxis"
      decimals="-3"
      unitRef="Unit_USD">62913000</roiv:PurchaseOfSubsidiaryCommonSharesValue>
    <roiv:PurchaseOfSubsidiaryCommonSharesValue
      contextRef="P04_01_2019To03_31_2020_NoncontrollingInterestMemberusgaapStatementEquityComponentsAxis"
      decimals="-3"
      unitRef="Unit_USD">2631000</roiv:PurchaseOfSubsidiaryCommonSharesValue>
    <roiv:PurchaseOfSubsidiaryCommonSharesValue
      contextRef="P04_01_2019To03_31_2020"
      decimals="-3"
      unitRef="Unit_USD">65544000</roiv:PurchaseOfSubsidiaryCommonSharesValue>
    <us-gaap:TemporaryEquityStockIssuedDuringPeriodValueNewIssues
      contextRef="P04_01_2019To03_31_2020_RedeemableNoncontrollingInterestMemberusgaapStatementClassOfStockAxis"
      decimals="-3"
      unitRef="Unit_USD">27491000</us-gaap:TemporaryEquityStockIssuedDuringPeriodValueNewIssues>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalIncreaseInCarryingAmountOfRedeemablePreferredStock
      contextRef="P04_01_2019To03_31_2020_RedeemableNoncontrollingInterestMemberusgaapStatementClassOfStockAxis"
      decimals="-3"
      unitRef="Unit_USD">55130000</us-gaap:AdjustmentsToAdditionalPaidInCapitalIncreaseInCarryingAmountOfRedeemablePreferredStock>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalIncreaseInCarryingAmountOfRedeemablePreferredStock
      contextRef="P04_01_2019To03_31_2020_AdditionalPaidInCapitalMemberusgaapStatementEquityComponentsAxis"
      decimals="-3"
      unitRef="Unit_USD">77777000</us-gaap:AdjustmentsToAdditionalPaidInCapitalIncreaseInCarryingAmountOfRedeemablePreferredStock>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalIncreaseInCarryingAmountOfRedeemablePreferredStock
      contextRef="P04_01_2019To03_31_2020"
      decimals="-3"
      unitRef="Unit_USD">77777000</us-gaap:AdjustmentsToAdditionalPaidInCapitalIncreaseInCarryingAmountOfRedeemablePreferredStock>
    <roiv:IssuanceOfSubsidiaryWarrants
      contextRef="P04_01_2019To03_31_2020_NoncontrollingInterestMemberusgaapStatementEquityComponentsAxis"
      decimals="-3"
      unitRef="Unit_USD">907000</roiv:IssuanceOfSubsidiaryWarrants>
    <roiv:IssuanceOfSubsidiaryWarrants
      contextRef="P04_01_2019To03_31_2020"
      decimals="-3"
      unitRef="Unit_USD">907000</roiv:IssuanceOfSubsidiaryWarrants>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="P04_01_2019To03_31_2020_AdditionalPaidInCapitalMemberusgaapStatementEquityComponentsAxis"
      decimals="-3"
      unitRef="Unit_USD">875000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="P04_01_2019To03_31_2020_NoncontrollingInterestMemberusgaapStatementEquityComponentsAxis"
      decimals="-3"
      unitRef="Unit_USD">532000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="P04_01_2019To03_31_2020"
      decimals="-3"
      unitRef="Unit_USD">1407000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="P04_01_2019To03_31_2020_CommonStockMemberusgaapStatementEquityComponentsAxis"
      decimals="INF"
      unitRef="Unit_shares">26952143</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="P04_01_2019To03_31_2020_AdditionalPaidInCapitalMemberusgaapStatementEquityComponentsAxis"
      decimals="-3"
      unitRef="Unit_USD">999193000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="P04_01_2019To03_31_2020"
      decimals="-3"
      unitRef="Unit_USD">999193000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <roiv:RepurchaseOfCommonSharesAndOtherEquityInstrumentsShares
      contextRef="P04_01_2019To03_31_2020_CommonStockMemberusgaapStatementEquityComponentsAxis"
      decimals="INF"
      unitRef="Unit_shares">25625933</roiv:RepurchaseOfCommonSharesAndOtherEquityInstrumentsShares>
    <roiv:RepurchaseOfCommonSharesAndOtherEquityInstrumentsValue
      contextRef="P04_01_2019To03_31_2020_AdditionalPaidInCapitalMemberusgaapStatementEquityComponentsAxis"
      decimals="-3"
      unitRef="Unit_USD">990014000</roiv:RepurchaseOfCommonSharesAndOtherEquityInstrumentsValue>
    <roiv:RepurchaseOfCommonSharesAndOtherEquityInstrumentsValue
      contextRef="P04_01_2019To03_31_2020"
      decimals="-3"
      unitRef="Unit_USD">990014000</roiv:RepurchaseOfCommonSharesAndOtherEquityInstrumentsValue>
    <us-gaap:GainOrLossOnSaleOfStockInSubsidiary
      contextRef="P04_01_2019To03_31_2020_NoncontrollingInterestMemberusgaapStatementEquityComponentsAxis"
      decimals="-3"
      unitRef="Unit_USD">-43398000</us-gaap:GainOrLossOnSaleOfStockInSubsidiary>
    <us-gaap:GainOrLossOnSaleOfStockInSubsidiary
      contextRef="P04_01_2019To03_31_2020"
      decimals="-3"
      unitRef="Unit_USD">-43398000</us-gaap:GainOrLossOnSaleOfStockInSubsidiary>
    <roiv:IssuanceOfEquityBySubsidiaryUponBusinessCombinationAndRecapitalization
      contextRef="P04_01_2019To03_31_2020_AdditionalPaidInCapitalMemberusgaapStatementEquityComponentsAxis"
      decimals="-3"
      unitRef="Unit_USD">69379000</roiv:IssuanceOfEquityBySubsidiaryUponBusinessCombinationAndRecapitalization>
    <roiv:IssuanceOfEquityBySubsidiaryUponBusinessCombinationAndRecapitalization
      contextRef="P04_01_2019To03_31_2020_NoncontrollingInterestMemberusgaapStatementEquityComponentsAxis"
      decimals="-3"
      unitRef="Unit_USD">35307000</roiv:IssuanceOfEquityBySubsidiaryUponBusinessCombinationAndRecapitalization>
    <roiv:IssuanceOfEquityBySubsidiaryUponBusinessCombinationAndRecapitalization
      contextRef="P04_01_2019To03_31_2020"
      decimals="-3"
      unitRef="Unit_USD">104686000</roiv:IssuanceOfEquityBySubsidiaryUponBusinessCombinationAndRecapitalization>
    <roiv:IssuanceOfEquityBySubsidiaryToTheCompanyUponBusinessCombinationAndRecapitalization
      contextRef="P04_01_2019To03_31_2020_AdditionalPaidInCapitalMemberusgaapStatementEquityComponentsAxis"
      decimals="-3"
      unitRef="Unit_USD">-2559000</roiv:IssuanceOfEquityBySubsidiaryToTheCompanyUponBusinessCombinationAndRecapitalization>
    <roiv:IssuanceOfEquityBySubsidiaryToTheCompanyUponBusinessCombinationAndRecapitalization
      contextRef="P04_01_2019To03_31_2020_NoncontrollingInterestMemberusgaapStatementEquityComponentsAxis"
      decimals="-3"
      unitRef="Unit_USD">2559000</roiv:IssuanceOfEquityBySubsidiaryToTheCompanyUponBusinessCombinationAndRecapitalization>
    <roiv:ConversionOfSubsidiaryConvertiblePromissoryNotes
      contextRef="P04_01_2019To03_31_2020_AdditionalPaidInCapitalMemberusgaapStatementEquityComponentsAxis"
      decimals="-3"
      unitRef="Unit_USD">21928000</roiv:ConversionOfSubsidiaryConvertiblePromissoryNotes>
    <roiv:ConversionOfSubsidiaryConvertiblePromissoryNotes
      contextRef="P04_01_2019To03_31_2020_NoncontrollingInterestMemberusgaapStatementEquityComponentsAxis"
      decimals="-3"
      unitRef="Unit_USD">11159000</roiv:ConversionOfSubsidiaryConvertiblePromissoryNotes>
    <roiv:ConversionOfSubsidiaryConvertiblePromissoryNotes
      contextRef="P04_01_2019To03_31_2020"
      decimals="-3"
      unitRef="Unit_USD">33087000</roiv:ConversionOfSubsidiaryConvertiblePromissoryNotes>
    <roiv:IssuanceOfEquityInstruments
      contextRef="P04_01_2019To03_31_2020_AdditionalPaidInCapitalMemberusgaapStatementEquityComponentsAxis"
      decimals="-3"
      unitRef="Unit_USD">24842000</roiv:IssuanceOfEquityInstruments>
    <roiv:IssuanceOfEquityInstruments
      contextRef="P04_01_2019To03_31_2020"
      decimals="-3"
      unitRef="Unit_USD">24842000</roiv:IssuanceOfEquityInstruments>
    <roiv:SettlementOfLiabilityClassifiedInstruments
      contextRef="P04_01_2019To03_31_2020_AdditionalPaidInCapitalMemberusgaapStatementEquityComponentsAxis"
      decimals="-3"
      unitRef="Unit_USD">13119000</roiv:SettlementOfLiabilityClassifiedInstruments>
    <roiv:SettlementOfLiabilityClassifiedInstruments
      contextRef="P04_01_2019To03_31_2020"
      decimals="-3"
      unitRef="Unit_USD">13119000</roiv:SettlementOfLiabilityClassifiedInstruments>
    <roiv:DeconsolidationOfSubsidiary
      contextRef="P04_01_2019To03_31_2020_NoncontrollingInterestMemberusgaapStatementEquityComponentsAxis"
      decimals="-3"
      unitRef="Unit_USD">-46483000</roiv:DeconsolidationOfSubsidiary>
    <roiv:DeconsolidationOfSubsidiary
      contextRef="P04_01_2019To03_31_2020"
      decimals="-3"
      unitRef="Unit_USD">-46483000</roiv:DeconsolidationOfSubsidiary>
    <roiv:CapitalContributionsToSubsidiaries
      contextRef="P04_01_2019To03_31_2020_AdditionalPaidInCapitalMemberusgaapStatementEquityComponentsAxis"
      decimals="-3"
      unitRef="Unit_USD">-4699000</roiv:CapitalContributionsToSubsidiaries>
    <roiv:CapitalContributionsToSubsidiaries
      contextRef="P04_01_2019To03_31_2020_NoncontrollingInterestMemberusgaapStatementEquityComponentsAxis"
      decimals="-3"
      unitRef="Unit_USD">4699000</roiv:CapitalContributionsToSubsidiaries>
    <roiv:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationRequisiteServicePeriodRecognitionShares
      contextRef="P04_01_2019To03_31_2020_CommonStockMemberusgaapStatementEquityComponentsAxis"
      decimals="INF"
      unitRef="Unit_shares">-2271</roiv:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationRequisiteServicePeriodRecognitionShares>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="P04_01_2019To03_31_2020_AdditionalPaidInCapitalMemberusgaapStatementEquityComponentsAxis"
      decimals="-3"
      unitRef="Unit_USD">79103000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="P04_01_2019To03_31_2020_NoncontrollingInterestMemberusgaapStatementEquityComponentsAxis"
      decimals="-3"
      unitRef="Unit_USD">43469000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="P04_01_2019To03_31_2020"
      decimals="-3"
      unitRef="Unit_USD">122572000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent
      contextRef="P04_01_2019To03_31_2020_AccumulatedOtherComprehensiveIncomeMemberusgaapStatementEquityComponentsAxis"
      decimals="-3"
      unitRef="Unit_USD">-4867000</us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent>
    <us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent
      contextRef="P04_01_2019To03_31_2020_NoncontrollingInterestMemberusgaapStatementEquityComponentsAxis"
      decimals="-3"
      unitRef="Unit_USD">-669000</us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent>
    <us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent
      contextRef="P04_01_2019To03_31_2020"
      decimals="-3"
      unitRef="Unit_USD">-5536000</us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent>
    <us-gaap:ProfitLoss
      contextRef="P04_01_2019To03_31_2020_RetainedEarningsMemberusgaapStatementEquityComponentsAxis"
      decimals="-3"
      unitRef="Unit_USD">1200509000</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="P04_01_2019To03_31_2020_NoncontrollingInterestMemberusgaapStatementEquityComponentsAxis"
      decimals="-3"
      unitRef="Unit_USD">-190193000</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="P04_01_2019To03_31_2020"
      decimals="-3"
      unitRef="Unit_USD">1010316000</us-gaap:ProfitLoss>
    <us-gaap:TemporaryEquityCarryingAmountIncludingPortionAttributableToNoncontrollingInterests
      contextRef="PAsOn03_31_2020_RedeemableNoncontrollingInterestMemberusgaapStatementClassOfStockAxis"
      decimals="-3"
      unitRef="Unit_USD">22491000</us-gaap:TemporaryEquityCarryingAmountIncludingPortionAttributableToNoncontrollingInterests>
    <us-gaap:SharesOutstanding
      contextRef="PAsOn03_31_2020_CommonStockMemberusgaapStatementEquityComponentsAxis"
      decimals="INF"
      unitRef="Unit_shares">214879058</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="PAsOn03_31_2020_CommonStockMemberusgaapStatementEquityComponentsAxis"
      decimals="-3"
      unitRef="Unit_USD">0</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="PAsOn03_31_2020_AdditionalPaidInCapitalMemberusgaapStatementEquityComponentsAxis"
      decimals="-3"
      unitRef="Unit_USD">3143739000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="PAsOn03_31_2020_SubscriptionsReceivablesMemberusgaapStatementEquityComponentsAxis"
      decimals="-3"
      unitRef="Unit_USD">0</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="PAsOn03_31_2020_AccumulatedOtherComprehensiveIncomeMemberusgaapStatementEquityComponentsAxis"
      decimals="-3"
      unitRef="Unit_USD">-2349000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="PAsOn03_31_2020_RetainedEarningsMemberusgaapStatementEquityComponentsAxis"
      decimals="-3"
      unitRef="Unit_USD">-1109228000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="PAsOn03_31_2020_NoncontrollingInterestMemberusgaapStatementEquityComponentsAxis"
      decimals="-3"
      unitRef="Unit_USD">54042000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="PAsOn03_31_2020"
      decimals="-3"
      unitRef="Unit_USD">2086204000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="P04_01_2020To03_31_2021_RedeemableNoncontrollingInterestMemberusgaapStatementClassOfStockAxis"
      decimals="-3"
      unitRef="Unit_USD">0</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="P04_01_2020To03_31_2021_CommonStockMemberusgaapStatementEquityComponentsAxis"
      decimals="INF"
      unitRef="Unit_shares">7202917</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="P04_01_2020To03_31_2021_CommonStockMemberusgaapStatementEquityComponentsAxis"
      decimals="-3"
      unitRef="Unit_USD">0</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="P04_01_2020To03_31_2021_AdditionalPaidInCapitalMemberusgaapStatementEquityComponentsAxis"
      decimals="-3"
      unitRef="Unit_USD">301744000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="P04_01_2020To03_31_2021_SubscriptionsReceivablesMemberusgaapStatementEquityComponentsAxis"
      decimals="-3"
      unitRef="Unit_USD">0</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="P04_01_2020To03_31_2021_AccumulatedOtherComprehensiveIncomeMemberusgaapStatementEquityComponentsAxis"
      decimals="-3"
      unitRef="Unit_USD">0</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="P04_01_2020To03_31_2021_RetainedEarningsMemberusgaapStatementEquityComponentsAxis"
      decimals="-3"
      unitRef="Unit_USD">0</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="P04_01_2020To03_31_2021_NoncontrollingInterestMemberusgaapStatementEquityComponentsAxis"
      decimals="-3"
      unitRef="Unit_USD">0</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="P04_01_2020To03_31_2021"
      decimals="-3"
      unitRef="Unit_USD">301744000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <roiv:IssuanceOfSubsidiaryCommonSharesNetValue
      contextRef="P04_01_2020To03_31_2021_AdditionalPaidInCapitalMemberusgaapStatementEquityComponentsAxis"
      decimals="-3"
      unitRef="Unit_USD">324995000</roiv:IssuanceOfSubsidiaryCommonSharesNetValue>
    <roiv:IssuanceOfSubsidiaryCommonSharesNetValue
      contextRef="P04_01_2020To03_31_2021_SubscriptionsReceivablesMemberusgaapStatementEquityComponentsAxis"
      decimals="-3"
      unitRef="Unit_USD">-100000000</roiv:IssuanceOfSubsidiaryCommonSharesNetValue>
    <roiv:IssuanceOfSubsidiaryCommonSharesNetValue
      contextRef="P04_01_2020To03_31_2021_NoncontrollingInterestMemberusgaapStatementEquityComponentsAxis"
      decimals="-3"
      unitRef="Unit_USD">231102000</roiv:IssuanceOfSubsidiaryCommonSharesNetValue>
    <roiv:IssuanceOfSubsidiaryCommonSharesNetValue
      contextRef="P04_01_2020To03_31_2021"
      decimals="-3"
      unitRef="Unit_USD">456097000</roiv:IssuanceOfSubsidiaryCommonSharesNetValue>
    <roiv:IssuanceOfSubsidiaryCommonSharesToTheCompanyValue
      contextRef="P04_01_2020To03_31_2021_AdditionalPaidInCapitalMemberusgaapStatementEquityComponentsAxis"
      decimals="-3"
      unitRef="Unit_USD">-11692000</roiv:IssuanceOfSubsidiaryCommonSharesToTheCompanyValue>
    <roiv:IssuanceOfSubsidiaryCommonSharesToTheCompanyValue
      contextRef="P04_01_2020To03_31_2021_NoncontrollingInterestMemberusgaapStatementEquityComponentsAxis"
      decimals="-3"
      unitRef="Unit_USD">11692000</roiv:IssuanceOfSubsidiaryCommonSharesToTheCompanyValue>
    <roiv:ExerciseOfSubsidiaryStockOptionsAndVestingOfSubsidiaryRestrictedStockUnits
      contextRef="P04_01_2020To03_31_2021_AdditionalPaidInCapitalMemberusgaapStatementEquityComponentsAxis"
      decimals="-3"
      unitRef="Unit_USD">522000</roiv:ExerciseOfSubsidiaryStockOptionsAndVestingOfSubsidiaryRestrictedStockUnits>
    <roiv:ExerciseOfSubsidiaryStockOptionsAndVestingOfSubsidiaryRestrictedStockUnits
      contextRef="P04_01_2020To03_31_2021_NoncontrollingInterestMemberusgaapStatementEquityComponentsAxis"
      decimals="-3"
      unitRef="Unit_USD">385000</roiv:ExerciseOfSubsidiaryStockOptionsAndVestingOfSubsidiaryRestrictedStockUnits>
    <roiv:ExerciseOfSubsidiaryStockOptionsAndVestingOfSubsidiaryRestrictedStockUnits
      contextRef="P04_01_2020To03_31_2021"
      decimals="-3"
      unitRef="Unit_USD">907000</roiv:ExerciseOfSubsidiaryStockOptionsAndVestingOfSubsidiaryRestrictedStockUnits>
    <roiv:DeconsolidationOfSubsidiary
      contextRef="P04_01_2020To03_31_2021_NoncontrollingInterestMemberusgaapStatementEquityComponentsAxis"
      decimals="-3"
      unitRef="Unit_USD">-3054000</roiv:DeconsolidationOfSubsidiary>
    <roiv:DeconsolidationOfSubsidiary
      contextRef="P04_01_2020To03_31_2021"
      decimals="-3"
      unitRef="Unit_USD">-3054000</roiv:DeconsolidationOfSubsidiary>
    <roiv:ConsolidationOfUnconsolidatedEntity
      contextRef="P04_01_2020To03_31_2021_NoncontrollingInterestMemberusgaapStatementEquityComponentsAxis"
      decimals="-3"
      unitRef="Unit_USD">9178000</roiv:ConsolidationOfUnconsolidatedEntity>
    <roiv:ConsolidationOfUnconsolidatedEntity
      contextRef="P04_01_2020To03_31_2021"
      decimals="-3"
      unitRef="Unit_USD">9178000</roiv:ConsolidationOfUnconsolidatedEntity>
    <roiv:RepurchaseOfEquityAwards
      contextRef="P04_01_2020To03_31_2021_AdditionalPaidInCapitalMemberusgaapStatementEquityComponentsAxis"
      decimals="-3"
      unitRef="Unit_USD">-113000</roiv:RepurchaseOfEquityAwards>
    <roiv:RepurchaseOfEquityAwards
      contextRef="P04_01_2020To03_31_2021"
      decimals="-3"
      unitRef="Unit_USD">-113000</roiv:RepurchaseOfEquityAwards>
    <roiv:CapitalContributionsToSubsidiaries
      contextRef="P04_01_2020To03_31_2021_AdditionalPaidInCapitalMemberusgaapStatementEquityComponentsAxis"
      decimals="-3"
      unitRef="Unit_USD">-1642000</roiv:CapitalContributionsToSubsidiaries>
    <roiv:CapitalContributionsToSubsidiaries
      contextRef="P04_01_2020To03_31_2021_NoncontrollingInterestMemberusgaapStatementEquityComponentsAxis"
      decimals="-3"
      unitRef="Unit_USD">1642000</roiv:CapitalContributionsToSubsidiaries>
    <roiv:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationRequisiteServicePeriodRecognitionShares
      contextRef="P04_01_2020To03_31_2021_CommonStockMemberusgaapStatementEquityComponentsAxis"
      decimals="INF"
      unitRef="Unit_shares">587824</roiv:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationRequisiteServicePeriodRecognitionShares>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="P04_01_2020To03_31_2021_AdditionalPaidInCapitalMemberusgaapStatementEquityComponentsAxis"
      decimals="-3"
      unitRef="Unit_USD">57252000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="P04_01_2020To03_31_2021_NoncontrollingInterestMemberusgaapStatementEquityComponentsAxis"
      decimals="-3"
      unitRef="Unit_USD">27706000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="P04_01_2020To03_31_2021"
      decimals="-3"
      unitRef="Unit_USD">84958000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent
      contextRef="P04_01_2020To03_31_2021_AccumulatedOtherComprehensiveIncomeMemberusgaapStatementEquityComponentsAxis"
      decimals="-3"
      unitRef="Unit_USD">3794000</us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent>
    <us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent
      contextRef="P04_01_2020To03_31_2021_NoncontrollingInterestMemberusgaapStatementEquityComponentsAxis"
      decimals="-3"
      unitRef="Unit_USD">32000</us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent>
    <us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent
      contextRef="P04_01_2020To03_31_2021"
      decimals="-3"
      unitRef="Unit_USD">3826000</us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent>
    <us-gaap:ProfitLoss
      contextRef="P04_01_2020To03_31_2021_RetainedEarningsMemberusgaapStatementEquityComponentsAxis"
      decimals="-3"
      unitRef="Unit_USD">-809234000</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="P04_01_2020To03_31_2021_NoncontrollingInterestMemberusgaapStatementEquityComponentsAxis"
      decimals="-3"
      unitRef="Unit_USD">-90999000</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="P04_01_2020To03_31_2021"
      decimals="-3"
      unitRef="Unit_USD">-900233000</us-gaap:ProfitLoss>
    <us-gaap:TemporaryEquityCarryingAmountIncludingPortionAttributableToNoncontrollingInterests
      contextRef="PAsOn03_31_2021_RedeemableNoncontrollingInterestMemberusgaapStatementClassOfStockAxis"
      decimals="-3"
      unitRef="Unit_USD">22491000</us-gaap:TemporaryEquityCarryingAmountIncludingPortionAttributableToNoncontrollingInterests>
    <us-gaap:SharesOutstanding
      contextRef="PAsOn03_31_2021_CommonStockMemberusgaapStatementEquityComponentsAxis"
      decimals="INF"
      unitRef="Unit_shares">222669799</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="PAsOn03_31_2021_CommonStockMemberusgaapStatementEquityComponentsAxis"
      decimals="-3"
      unitRef="Unit_USD">0</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="PAsOn03_31_2021_AdditionalPaidInCapitalMemberusgaapStatementEquityComponentsAxis"
      decimals="-3"
      unitRef="Unit_USD">3814805000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="PAsOn03_31_2021_SubscriptionsReceivablesMemberusgaapStatementEquityComponentsAxis"
      decimals="-3"
      unitRef="Unit_USD">-100000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="PAsOn03_31_2021_AccumulatedOtherComprehensiveIncomeMemberusgaapStatementEquityComponentsAxis"
      decimals="-3"
      unitRef="Unit_USD">1445000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="PAsOn03_31_2021_RetainedEarningsMemberusgaapStatementEquityComponentsAxis"
      decimals="-3"
      unitRef="Unit_USD">-1918462000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="PAsOn03_31_2021_NoncontrollingInterestMemberusgaapStatementEquityComponentsAxis"
      decimals="-3"
      unitRef="Unit_USD">241726000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="PAsOn03_31_2021"
      decimals="-3"
      unitRef="Unit_USD">2039514000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:ProfitLoss
      contextRef="P04_01_2020To03_31_2021"
      decimals="-3"
      unitRef="Unit_USD">-900233000</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="P04_01_2019To03_31_2020"
      decimals="-3"
      unitRef="Unit_USD">1010316000</us-gaap:ProfitLoss>
    <us-gaap:ResearchAndDevelopmentInProcess
      contextRef="P04_01_2020To03_31_2021"
      decimals="-3"
      unitRef="Unit_USD">351523000</us-gaap:ResearchAndDevelopmentInProcess>
    <us-gaap:ResearchAndDevelopmentInProcess
      contextRef="P04_01_2019To03_31_2020"
      decimals="-3"
      unitRef="Unit_USD">16405000</us-gaap:ResearchAndDevelopmentInProcess>
    <us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax
      contextRef="P04_01_2020To03_31_2021"
      decimals="-3"
      unitRef="Unit_USD">3826000</us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax>
    <us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax
      contextRef="P04_01_2019To03_31_2020"
      decimals="-3"
      unitRef="Unit_USD">-5536000</us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax>
    <us-gaap:ShareBasedCompensation
      contextRef="P04_01_2020To03_31_2021"
      decimals="-3"
      unitRef="Unit_USD">84958000</us-gaap:ShareBasedCompensation>
    <us-gaap:ShareBasedCompensation
      contextRef="P04_01_2019To03_31_2020"
      decimals="-3"
      unitRef="Unit_USD">122572000</us-gaap:ShareBasedCompensation>
    <us-gaap:GainLossOnSaleOfBusiness
      contextRef="P04_01_2020To03_31_2021"
      decimals="-3"
      unitRef="Unit_USD">0</us-gaap:GainLossOnSaleOfBusiness>
    <us-gaap:GainLossOnSaleOfBusiness
      contextRef="P04_01_2019To03_31_2020"
      decimals="-3"
      unitRef="Unit_USD">1985949000</us-gaap:GainLossOnSaleOfBusiness>
    <us-gaap:GainLossOnInvestments
      contextRef="P04_01_2020To03_31_2021"
      decimals="-3"
      unitRef="Unit_USD">95533000</us-gaap:GainLossOnInvestments>
    <us-gaap:GainLossOnInvestments
      contextRef="P04_01_2019To03_31_2020"
      decimals="-3"
      unitRef="Unit_USD">-136005000</us-gaap:GainLossOnInvestments>
    <roiv:GainLossOnFairValueOfDebtAndLiabilityInstruments
      contextRef="P04_01_2020To03_31_2021"
      decimals="-3"
      unitRef="Unit_USD">-29845000</roiv:GainLossOnFairValueOfDebtAndLiabilityInstruments>
    <roiv:GainLossOnFairValueOfDebtAndLiabilityInstruments
      contextRef="P04_01_2019To03_31_2020"
      decimals="-3"
      unitRef="Unit_USD">13722000</roiv:GainLossOnFairValueOfDebtAndLiabilityInstruments>
    <roiv:GainOrLossOnDeconsolidationOfSubsidiary
      contextRef="P04_01_2020To03_31_2021"
      decimals="-3"
      unitRef="Unit_USD">115364000</roiv:GainOrLossOnDeconsolidationOfSubsidiary>
    <roiv:GainOrLossOnDeconsolidationOfSubsidiary
      contextRef="P04_01_2019To03_31_2020"
      decimals="-3"
      unitRef="Unit_USD">107344000</roiv:GainOrLossOnDeconsolidationOfSubsidiary>
    <us-gaap:IncomeLossFromEquityMethodInvestments
      contextRef="P04_01_2020To03_31_2021"
      decimals="-3"
      unitRef="Unit_USD">-3750000</us-gaap:IncomeLossFromEquityMethodInvestments>
    <us-gaap:IncomeLossFromEquityMethodInvestments
      contextRef="P04_01_2019To03_31_2020"
      decimals="-3"
      unitRef="Unit_USD">-21386000</us-gaap:IncomeLossFromEquityMethodInvestments>
    <us-gaap:OtherNoncashIncomeExpense
      contextRef="P04_01_2020To03_31_2021"
      decimals="-3"
      unitRef="Unit_USD">-13152000</us-gaap:OtherNoncashIncomeExpense>
    <us-gaap:OtherNoncashIncomeExpense
      contextRef="P04_01_2019To03_31_2020"
      decimals="-3"
      unitRef="Unit_USD">-31821000</us-gaap:OtherNoncashIncomeExpense>
    <us-gaap:IncreaseDecreaseInAccountsPayableTrade
      contextRef="P04_01_2020To03_31_2021"
      decimals="-3"
      unitRef="Unit_USD">3752000</us-gaap:IncreaseDecreaseInAccountsPayableTrade>
    <us-gaap:IncreaseDecreaseInAccountsPayableTrade
      contextRef="P04_01_2019To03_31_2020"
      decimals="-3"
      unitRef="Unit_USD">6598000</us-gaap:IncreaseDecreaseInAccountsPayableTrade>
    <us-gaap:IncreaseDecreaseInAccruedLiabilities
      contextRef="P04_01_2020To03_31_2021"
      decimals="-3"
      unitRef="Unit_USD">9225000</us-gaap:IncreaseDecreaseInAccruedLiabilities>
    <us-gaap:IncreaseDecreaseInAccruedLiabilities
      contextRef="P04_01_2019To03_31_2020"
      decimals="-3"
      unitRef="Unit_USD">14845000</us-gaap:IncreaseDecreaseInAccruedLiabilities>
    <us-gaap:IncreaseDecreaseInDeferredLiabilities
      contextRef="P04_01_2020To03_31_2021"
      decimals="-3"
      unitRef="Unit_USD">100000000</us-gaap:IncreaseDecreaseInDeferredLiabilities>
    <us-gaap:IncreaseDecreaseInDeferredLiabilities
      contextRef="P04_01_2019To03_31_2020"
      decimals="-3"
      unitRef="Unit_USD">0</us-gaap:IncreaseDecreaseInDeferredLiabilities>
    <roiv:IncreaseDecreaseInOperatingLeaseLiabilities
      contextRef="P04_01_2020To03_31_2021"
      decimals="-3"
      unitRef="Unit_USD">-5497000</roiv:IncreaseDecreaseInOperatingLeaseLiabilities>
    <roiv:IncreaseDecreaseInOperatingLeaseLiabilities
      contextRef="P04_01_2019To03_31_2020"
      decimals="-3"
      unitRef="Unit_USD">-8419000</roiv:IncreaseDecreaseInOperatingLeaseLiabilities>
    <us-gaap:IncreaseDecreaseInOtherOperatingCapitalNet
      contextRef="P04_01_2020To03_31_2021"
      decimals="-3"
      unitRef="Unit_USD">35542000</us-gaap:IncreaseDecreaseInOtherOperatingCapitalNet>
    <us-gaap:IncreaseDecreaseInOtherOperatingCapitalNet
      contextRef="P04_01_2019To03_31_2020"
      decimals="-3"
      unitRef="Unit_USD">-2272000</us-gaap:IncreaseDecreaseInOtherOperatingCapitalNet>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities
      contextRef="P04_01_2020To03_31_2021"
      decimals="-3"
      unitRef="Unit_USD">-552138000</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities
      contextRef="P04_01_2019To03_31_2020"
      decimals="-3"
      unitRef="Unit_USD">-758750000</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:ProceedsFromDivestitureOfBusinesses
      contextRef="P04_01_2020To03_31_2021"
      decimals="-3"
      unitRef="Unit_USD">0</us-gaap:ProceedsFromDivestitureOfBusinesses>
    <us-gaap:ProceedsFromDivestitureOfBusinesses
      contextRef="P04_01_2019To03_31_2020"
      decimals="-3"
      unitRef="Unit_USD">1772191000</us-gaap:ProceedsFromDivestitureOfBusinesses>
    <us-gaap:CashDivestedFromDeconsolidation
      contextRef="P04_01_2020To03_31_2021"
      decimals="-3"
      unitRef="Unit_USD">19085000</us-gaap:CashDivestedFromDeconsolidation>
    <us-gaap:CashDivestedFromDeconsolidation
      contextRef="P04_01_2019To03_31_2020"
      decimals="-3"
      unitRef="Unit_USD">20049000</us-gaap:CashDivestedFromDeconsolidation>
    <roiv:CashAcquiredUponConsolidationOfUnconsolidatedEntity
      contextRef="P04_01_2020To03_31_2021"
      decimals="-3"
      unitRef="Unit_USD">21439000</roiv:CashAcquiredUponConsolidationOfUnconsolidatedEntity>
    <roiv:CashAcquiredUponConsolidationOfUnconsolidatedEntity
      contextRef="P04_01_2019To03_31_2020"
      decimals="-3"
      unitRef="Unit_USD">0</roiv:CashAcquiredUponConsolidationOfUnconsolidatedEntity>
    <roiv:PaymentsToAcquireInvestmentsInUnconsolidatedEntities
      contextRef="P04_01_2020To03_31_2021"
      decimals="-3"
      unitRef="Unit_USD">28250000</roiv:PaymentsToAcquireInvestmentsInUnconsolidatedEntities>
    <roiv:PaymentsToAcquireInvestmentsInUnconsolidatedEntities
      contextRef="P04_01_2019To03_31_2020"
      decimals="-3"
      unitRef="Unit_USD">36300000</roiv:PaymentsToAcquireInvestmentsInUnconsolidatedEntities>
    <us-gaap:PaymentsToAcquireMarketableSecurities
      contextRef="P04_01_2020To03_31_2021"
      decimals="-3"
      unitRef="Unit_USD">0</us-gaap:PaymentsToAcquireMarketableSecurities>
    <us-gaap:PaymentsToAcquireMarketableSecurities
      contextRef="P04_01_2019To03_31_2020"
      decimals="-3"
      unitRef="Unit_USD">32076000</us-gaap:PaymentsToAcquireMarketableSecurities>
    <us-gaap:ProceedsFromSaleAndMaturityOfMarketableSecurities
      contextRef="P04_01_2020To03_31_2021"
      decimals="-3"
      unitRef="Unit_USD">0</us-gaap:ProceedsFromSaleAndMaturityOfMarketableSecurities>
    <us-gaap:ProceedsFromSaleAndMaturityOfMarketableSecurities
      contextRef="P04_01_2019To03_31_2020"
      decimals="-3"
      unitRef="Unit_USD">16440000</us-gaap:ProceedsFromSaleAndMaturityOfMarketableSecurities>
    <us-gaap:PaymentsToAcquireBusinessesNetOfCashAcquired
      contextRef="P04_01_2020To03_31_2021"
      decimals="-3"
      unitRef="Unit_USD">0</us-gaap:PaymentsToAcquireBusinessesNetOfCashAcquired>
    <us-gaap:PaymentsToAcquireBusinessesNetOfCashAcquired
      contextRef="P04_01_2019To03_31_2020"
      decimals="-3"
      unitRef="Unit_USD">500000</us-gaap:PaymentsToAcquireBusinessesNetOfCashAcquired>
    <us-gaap:PaymentsToAcquirePropertyPlantAndEquipment
      contextRef="P04_01_2020To03_31_2021"
      decimals="-3"
      unitRef="Unit_USD">5806000</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
    <us-gaap:PaymentsToAcquirePropertyPlantAndEquipment
      contextRef="P04_01_2019To03_31_2020"
      decimals="-3"
      unitRef="Unit_USD">4916000</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
    <us-gaap:NetCashProvidedByUsedInInvestingActivities
      contextRef="P04_01_2020To03_31_2021"
      decimals="-3"
      unitRef="Unit_USD">-31702000</us-gaap:NetCashProvidedByUsedInInvestingActivities>
    <us-gaap:NetCashProvidedByUsedInInvestingActivities
      contextRef="P04_01_2019To03_31_2020"
      decimals="-3"
      unitRef="Unit_USD">1694790000</us-gaap:NetCashProvidedByUsedInInvestingActivities>
    <us-gaap:ProceedsFromIssuanceOfCommonStock
      contextRef="P04_01_2020To03_31_2021"
      decimals="-3"
      unitRef="Unit_USD">0</us-gaap:ProceedsFromIssuanceOfCommonStock>
    <us-gaap:ProceedsFromIssuanceOfCommonStock
      contextRef="P04_01_2019To03_31_2020"
      decimals="-3"
      unitRef="Unit_USD">999193000</us-gaap:ProceedsFromIssuanceOfCommonStock>
    <us-gaap:PaymentsForRepurchaseOfEquity
      contextRef="P04_01_2020To03_31_2021"
      decimals="-3"
      unitRef="Unit_USD">113000</us-gaap:PaymentsForRepurchaseOfEquity>
    <us-gaap:PaymentsForRepurchaseOfEquity
      contextRef="P04_01_2019To03_31_2020"
      decimals="-3"
      unitRef="Unit_USD">990014000</us-gaap:PaymentsForRepurchaseOfEquity>
    <us-gaap:ProceedsFromIssuanceOfDebt
      contextRef="P04_01_2020To03_31_2021"
      decimals="-3"
      unitRef="Unit_USD">0</us-gaap:ProceedsFromIssuanceOfDebt>
    <us-gaap:ProceedsFromIssuanceOfDebt
      contextRef="P04_01_2019To03_31_2020"
      decimals="-3"
      unitRef="Unit_USD">101567000</us-gaap:ProceedsFromIssuanceOfDebt>
    <roiv:ProceedsFromIssuanceOfSubsidiaryCommonSharesNet
      contextRef="P04_01_2020To03_31_2021"
      decimals="-3"
      unitRef="Unit_USD">455756000</roiv:ProceedsFromIssuanceOfSubsidiaryCommonSharesNet>
    <roiv:ProceedsFromIssuanceOfSubsidiaryCommonSharesNet
      contextRef="P04_01_2019To03_31_2020"
      decimals="-3"
      unitRef="Unit_USD">117658000</roiv:ProceedsFromIssuanceOfSubsidiaryCommonSharesNet>
    <roiv:ProceedsFromIssuanceOfEquityBySubsidiaryUponBusinessCombinationAndRecapitalization
      contextRef="P04_01_2020To03_31_2021"
      decimals="-3"
      unitRef="Unit_USD">0</roiv:ProceedsFromIssuanceOfEquityBySubsidiaryUponBusinessCombinationAndRecapitalization>
    <roiv:ProceedsFromIssuanceOfEquityBySubsidiaryUponBusinessCombinationAndRecapitalization
      contextRef="P04_01_2019To03_31_2020"
      decimals="-3"
      unitRef="Unit_USD">105930000</roiv:ProceedsFromIssuanceOfEquityBySubsidiaryUponBusinessCombinationAndRecapitalization>
    <roiv:PurchaseOfSubsidiaryCommonShares
      contextRef="P04_01_2020To03_31_2021"
      decimals="-3"
      unitRef="Unit_USD">0</roiv:PurchaseOfSubsidiaryCommonShares>
    <roiv:PurchaseOfSubsidiaryCommonShares
      contextRef="P04_01_2019To03_31_2020"
      decimals="-3"
      unitRef="Unit_USD">-65544000</roiv:PurchaseOfSubsidiaryCommonShares>
    <roiv:ProceedsFromIssuanceOfSubsidiaryConvertibleAndRedeemablePreferredStockNet
      contextRef="P04_01_2020To03_31_2021"
      decimals="-3"
      unitRef="Unit_USD">0</roiv:ProceedsFromIssuanceOfSubsidiaryConvertibleAndRedeemablePreferredStockNet>
    <roiv:ProceedsFromIssuanceOfSubsidiaryConvertibleAndRedeemablePreferredStockNet
      contextRef="P04_01_2019To03_31_2020"
      decimals="-3"
      unitRef="Unit_USD">28455000</roiv:ProceedsFromIssuanceOfSubsidiaryConvertibleAndRedeemablePreferredStockNet>
    <roiv:PaymentsForPurchaseOfSubsidiaryConvertibleAndRedeemablePreferredStock
      contextRef="P04_01_2020To03_31_2021"
      decimals="-3"
      unitRef="Unit_USD">0</roiv:PaymentsForPurchaseOfSubsidiaryConvertibleAndRedeemablePreferredStock>
    <roiv:PaymentsForPurchaseOfSubsidiaryConvertibleAndRedeemablePreferredStock
      contextRef="P04_01_2019To03_31_2020"
      decimals="-3"
      unitRef="Unit_USD">132907000</roiv:PaymentsForPurchaseOfSubsidiaryConvertibleAndRedeemablePreferredStock>
    <roiv:ProceedsFromSubsidiaryDebtFinancingsNet
      contextRef="P04_01_2020To03_31_2021"
      decimals="-3"
      unitRef="Unit_USD">0</roiv:ProceedsFromSubsidiaryDebtFinancingsNet>
    <roiv:ProceedsFromSubsidiaryDebtFinancingsNet
      contextRef="P04_01_2019To03_31_2020"
      decimals="-3"
      unitRef="Unit_USD">83781000</roiv:ProceedsFromSubsidiaryDebtFinancingsNet>
    <roiv:RepaymentOfLongTermDebtAndConvertibleDebtBySubsidiary
      contextRef="P04_01_2020To03_31_2021"
      decimals="-3"
      unitRef="Unit_USD">0</roiv:RepaymentOfLongTermDebtAndConvertibleDebtBySubsidiary>
    <roiv:RepaymentOfLongTermDebtAndConvertibleDebtBySubsidiary
      contextRef="P04_01_2019To03_31_2020"
      decimals="-3"
      unitRef="Unit_USD">32063000</roiv:RepaymentOfLongTermDebtAndConvertibleDebtBySubsidiary>
    <us-gaap:PaymentsOfStockIssuanceCosts
      contextRef="P04_01_2020To03_31_2021"
      decimals="-3"
      unitRef="Unit_USD">286000</us-gaap:PaymentsOfStockIssuanceCosts>
    <us-gaap:PaymentsOfStockIssuanceCosts
      contextRef="P04_01_2019To03_31_2020"
      decimals="-3"
      unitRef="Unit_USD">3082000</us-gaap:PaymentsOfStockIssuanceCosts>
    <roiv:PaymentForDebtMaintenanceFeeBySubsidiary
      contextRef="P04_01_2020To03_31_2021"
      decimals="-3"
      unitRef="Unit_USD">0</roiv:PaymentForDebtMaintenanceFeeBySubsidiary>
    <roiv:PaymentForDebtMaintenanceFeeBySubsidiary
      contextRef="P04_01_2019To03_31_2020"
      decimals="-3"
      unitRef="Unit_USD">-300000</roiv:PaymentForDebtMaintenanceFeeBySubsidiary>
    <us-gaap:ProceedsFromStockOptionsExercised
      contextRef="P04_01_2020To03_31_2021"
      decimals="-3"
      unitRef="Unit_USD">907000</us-gaap:ProceedsFromStockOptionsExercised>
    <us-gaap:ProceedsFromStockOptionsExercised
      contextRef="P04_01_2019To03_31_2020"
      decimals="-3"
      unitRef="Unit_USD">1407000</us-gaap:ProceedsFromStockOptionsExercised>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities
      contextRef="P04_01_2020To03_31_2021"
      decimals="-3"
      unitRef="Unit_USD">456264000</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities
      contextRef="P04_01_2019To03_31_2020"
      decimals="-3"
      unitRef="Unit_USD">214081000</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect
      contextRef="P04_01_2020To03_31_2021"
      decimals="-3"
      unitRef="Unit_USD">-127576000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect
      contextRef="P04_01_2019To03_31_2020"
      decimals="-3"
      unitRef="Unit_USD">1150121000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="PAsOn03_31_2020"
      decimals="-3"
      unitRef="Unit_USD">2269252000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="PAsOn03_31_2019"
      decimals="-3"
      unitRef="Unit_USD">1119131000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="PAsOn03_31_2021"
      decimals="-3"
      unitRef="Unit_USD">2141676000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="PAsOn03_31_2020"
      decimals="-3"
      unitRef="Unit_USD">2269252000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability
      contextRef="P04_01_2020To03_31_2021"
      decimals="-3"
      unitRef="Unit_USD">5491000</us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability>
    <us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability
      contextRef="P04_01_2019To03_31_2020"
      decimals="-3"
      unitRef="Unit_USD">56025000</us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability>
    <roiv:OperatingLeaseRightOfUseAssetsAndAmountsReclassifiedFromOtherLiabilitiesToOperatingLeaseLiabilities
      contextRef="P04_01_2020To03_31_2021"
      decimals="-3"
      unitRef="Unit_USD">0</roiv:OperatingLeaseRightOfUseAssetsAndAmountsReclassifiedFromOtherLiabilitiesToOperatingLeaseLiabilities>
    <roiv:OperatingLeaseRightOfUseAssetsAndAmountsReclassifiedFromOtherLiabilitiesToOperatingLeaseLiabilities
      contextRef="P04_01_2019To03_31_2020"
      decimals="-3"
      unitRef="Unit_USD">43026000</roiv:OperatingLeaseRightOfUseAssetsAndAmountsReclassifiedFromOtherLiabilitiesToOperatingLeaseLiabilities>
    <roiv:SubscriptionReceivableRelatedToIssuanceOfSubsidiaryCommonShares
      contextRef="P04_01_2020To03_31_2021"
      decimals="-3"
      unitRef="Unit_USD">100000000</roiv:SubscriptionReceivableRelatedToIssuanceOfSubsidiaryCommonShares>
    <roiv:SubscriptionReceivableRelatedToIssuanceOfSubsidiaryCommonShares
      contextRef="P04_01_2019To03_31_2020"
      decimals="-3"
      unitRef="Unit_USD">0</roiv:SubscriptionReceivableRelatedToIssuanceOfSubsidiaryCommonShares>
    <roiv:ConversionOfSubsidiaryConvertiblePromissoryNotesToCommonShares
      contextRef="P04_01_2020To03_31_2021"
      decimals="-3"
      unitRef="Unit_USD">0</roiv:ConversionOfSubsidiaryConvertiblePromissoryNotesToCommonShares>
    <roiv:ConversionOfSubsidiaryConvertiblePromissoryNotesToCommonShares
      contextRef="P04_01_2019To03_31_2020"
      decimals="-3"
      unitRef="Unit_USD">32500000</roiv:ConversionOfSubsidiaryConvertiblePromissoryNotesToCommonShares>
    <roiv:OtherNonCashTransactions
      contextRef="P04_01_2020To03_31_2021"
      decimals="-3"
      unitRef="Unit_USD">-960000</roiv:OtherNonCashTransactions>
    <roiv:OtherNonCashTransactions
      contextRef="P04_01_2019To03_31_2020"
      decimals="-3"
      unitRef="Unit_USD">3601000</roiv:OtherNonCashTransactions>
    <us-gaap:IncomeTaxesPaidNet
      contextRef="P04_01_2020To03_31_2021"
      decimals="-3"
      unitRef="Unit_USD">4076000</us-gaap:IncomeTaxesPaidNet>
    <us-gaap:IncomeTaxesPaidNet
      contextRef="P04_01_2019To03_31_2020"
      decimals="-3"
      unitRef="Unit_USD">4936000</us-gaap:IncomeTaxesPaidNet>
    <us-gaap:InterestPaidNet
      contextRef="P04_01_2020To03_31_2021"
      decimals="-3"
      unitRef="Unit_USD">2017000</us-gaap:InterestPaidNet>
    <us-gaap:InterestPaidNet
      contextRef="P04_01_2019To03_31_2020"
      decimals="-3"
      unitRef="Unit_USD">12158000</us-gaap:InterestPaidNet>
    <us-gaap:BusinessDescriptionAndBasisOfPresentationTextBlock contextRef="P04_01_2020To03_31_2021">&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Note 1&#x2014;Description of Business and Liquidity &lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;(A) Description of Business &lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Roivant Sciences Ltd., inclusive of its consolidated subsidiaries (the &#x201c;Company&#x201d; or &#x201c;RSL&#x201d;), aims to improve health by rapidly delivering innovative medicines and technologies to patients. The Company does this by building biotech and healthcare technology companies (&#x201c;Vants&#x201d;) and deploying technology to drive greater efficiency in research and development and commercialization.&#160;In addition to biopharmaceutical subsidiaries, the Company also builds technology Vants focused on improving the process of developing and commercializing medicines. The Company was founded on April&#160;7, 2014 as a Bermuda exempted limited company. &lt;/div&gt;&lt;/div&gt; &lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;The Company has determined that it has one operating and reporting segment as it allocates resources and assesses financial performance on a consolidated basis. The Company&#x2019;s subsidiaries are wholly owned subsidiaries and majority-owned or controlled subsidiaries. Refer to Note 3, &#x201c;Investments&#x201d; for further discussion of the Company&#x2019;s investments in unconsolidated entities. &lt;/div&gt;&lt;/div&gt; &lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;(B) Liquidity &lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;The Company has incurred significant losses and negative cash flows from operations since its inception. As of March&#160;31, 2021, the Company had cash and cash equivalents of approximately $2.1&#160;billion and its accumulated deficit was approximately $1.9&#160;billion. For the years ended March&#160;31, 2021 and 2020, the Company incurred losses from continuing operations of $900.2&#160;million and $568.1&#160;million, respectively. The Company has historically financed its operations primarily through the sale of equity securities, sale of subsidiary interests, debt financings and revenue generated from licensing and collaboration arrangements. The Company has not generated any revenues to date from the sale of its product candidates and does not anticipate generating any revenues from the sale of its product candidates unless and until it successfully completes development and obtains regulatory approval to market its product candidates. Management expects to incur additional losses in the future to fund its operations and conduct product research and development and recognizes the need to raise additional capital to fully implement its business plan. &lt;/div&gt;&lt;/div&gt; &lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;The Company intends to raise such additional capital through the issuance of equity securities, debt financings or other sources in order to further implement its business plan. However, if such financing is not available at adequate levels, the Company will need to reevaluate its operating plan and may be required to delay the development of its product candidates or take other steps to conserve capital. The Company expects its existing cash and cash equivalents will be sufficient to fund its committed operating expenses and capital expenditure requirements for at least the next 12 months from the date of issuance of these consolidated financial statements. &lt;/div&gt;&lt;/div&gt;</us-gaap:BusinessDescriptionAndBasisOfPresentationTextBlock>
    <us-gaap:NumberOfOperatingSegments
      contextRef="P04_01_2020To03_31_2021"
      decimals="0"
      unitRef="Unit_Segment">1</us-gaap:NumberOfOperatingSegments>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="PAsOn03_31_2021"
      decimals="-8"
      unitRef="Unit_USD">2100000000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:RetainedEarningsAccumulatedDeficit
      contextRef="PAsOn03_31_2021"
      decimals="-8"
      unitRef="Unit_USD">-1900000000</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:NetIncomeLossAttributableToRedeemableNoncontrollingInterest
      contextRef="P04_01_2020To03_31_2021"
      decimals="-5"
      unitRef="Unit_USD">900200000</us-gaap:NetIncomeLossAttributableToRedeemableNoncontrollingInterest>
    <us-gaap:NetIncomeLossAttributableToRedeemableNoncontrollingInterest
      contextRef="P04_01_2019To03_31_2020"
      decimals="-5"
      unitRef="Unit_USD">568100000</us-gaap:NetIncomeLossAttributableToRedeemableNoncontrollingInterest>
    <us-gaap:SignificantAccountingPoliciesTextBlock contextRef="P04_01_2020To03_31_2021">&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Note 2&#x2014;Summary of Significant Accounting Policies &lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;(A) Basis of Presentation and Principles of Consolidation &lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;The Company&#x2019;s fiscal year ends on March&#160;31, and its fiscal quarters end on June&#160;30, September&#160;30, and December 31. &lt;/div&gt;&lt;/div&gt; &lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;The accompanying audited consolidated financial statements and notes thereto have been prepared in accordance with accounting principles generally accepted in the United States (&#x201c;U.S. GAAP&#x201d;). &lt;/div&gt;&lt;/div&gt; &lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Any references in these notes to applicable accounting guidance are meant to refer to the authoritative U.S. GAAP as found in the Accounting Standards Codification (&#x201c;ASC&#x201d;) and Accounting Standards Updates &lt;/div&gt;&lt;/div&gt; &lt;div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;(&#x201c;ASU&#x201d;) of the Financial Accounting Standards Board (&#x201c;FASB&#x201d;). The consolidated financial statements include the accounts of RSL and the subsidiaries in which it has a controlling financial interest, most often through a majority voting interest. All intercompany balances and transactions have been eliminated in consolidation. &lt;/div&gt;&lt;/div&gt; &lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;For consolidated entities where the Company owns or is exposed to less than 100% of the economics, the Company records net loss attributable to noncontrolling interests in its consolidated statements of operations equal to the percentage of the economic or ownership interest retained in the respective operations by the noncontrolling parties. The Company presents noncontrolling interests as a component of shareholders&#x2019; equity on its consolidated balance sheets. &lt;/div&gt;&lt;/div&gt; &lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;The Company accounts for changes in its ownership interest in its subsidiaries while control is retained as equity transactions. The carrying amount of the noncontrolling interest is adjusted to reflect the change in RSL&#x2019;s ownership interest in the subsidiary. Any difference between the fair value of the consideration received or paid and the amount by which the noncontrolling interest is adjusted is recognized within shareholders&#x2019; equity attributable to RSL. &lt;/div&gt;&lt;/div&gt; &lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Additionally, the Company concluded that the disposition of RSL&#x2019;s ownership interests in Myovant Sciences Ltd. (&#x201c;Myovant&#x201d;), Urovant Sciences Ltd. (&#x201c;Urovant&#x201d;), Enzyvant Therapeutics Ltd. (&#x201c;Enzyvant&#x201d;), Altavant Sciences Ltd. (&#x201c;Altavant&#x201d;), and Spirovant Sciences Ltd. (&#x201c;Spirovant&#x201d;) (collectively, the &#x201c;Sumitovant Vants&#x201d;), pursuant to the transaction agreement entered into with Sumitomo Dainippon Pharma Co., Ltd. (&#x201c;Sumitomo&#x201d;) on October&#160;31, 2019 (the &#x201c;Sumitomo Transaction Agreement&#x201d;) that closed on December&#160;27, 2019 (the &#x201c;Sumitomo Transaction&#x201d;), met the requirements to be presented as discontinued operations. As such, results relating to the transferred interests prior to disposition are classified as discontinued operations in prior period consolidated financial statements. See Note 5, &#x201c;Sumitomo Transaction Agreement&#x201d; and Note 6, &#x201c;Discontinued Operations&#x201d; for further discussion. Certain prior year amounts were reclassified to conform to current year presentation. &lt;/div&gt;&lt;/div&gt; &lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;In April 2012, the Jumpstart Our Business Startups Act of 2012 (the &#x201c;JOBS Act&#x201d;) was enacted. Section&#160;107(b) of the JOBS Act provides that an emerging growth company can take advantage of an extended transition period for complying with new or revised accounting standards. Thus, an emerging growth company can delay the adoption of certain accounting standards until those standards would otherwise apply to private companies. The Company has irrevocably elected not to avail itself of this extended transition period, and, as a result, the Company will adopt new or revised accounting standards on the relevant dates on which adoption of such standards is required for other public companies. &lt;/div&gt;&lt;/div&gt;  &lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;(B) Use of Estimates &lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;The preparation of financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the amounts reported in the financial statements and accompanying notes. The Company regularly evaluates estimates and assumptions related to assets, liabilities, costs, expenses, contingent liabilities, share-based compensation and research and development costs. The Company bases its estimates and assumptions on historical experience and on various other factors that it believes to be reasonable under the circumstances, the results of which form the basis for making judgments about the carrying values of assets and liabilities that are not readily apparent from other sources. Actual results could differ from those estimates. &lt;/div&gt;&lt;/div&gt; &lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;Additionally, the Company assessed the impact that the &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;COVID-19&lt;/div&gt; pandemic has had on its operations and financial results as of March&#160;31, 2021 and through the issuance of these consolidated financial statements. The Company&#x2019;s analysis was informed by the facts and circumstances as they were known to the Company. This assessment considered the impact &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;COVID-19&lt;/div&gt; may have on financial estimates and assumptions that affect the reported amounts of assets and liabilities and expenses. &lt;/div&gt; &lt;div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;(C) Risks and Uncertainties &lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;The Company is subject to risks common to companies in the biopharmaceutical industry including, but not limited to, uncertainties related to commercialization of products, regulatory approvals, dependence on key products, dependence on third-party service providers, such as contract research organizations, and protection of intellectual property rights. &lt;/div&gt;&lt;/div&gt; &lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;(D) Concentrations of Credit Risk &lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Financial instruments that potentially subject the Company to concentration of credit risk include cash and cash equivalents. The Company maintains cash deposits and cash equivalents in highly-rated, federally-insured financial institutions in excess of federally insured limits. The Company has established guidelines relative to diversification and maturities to maintain safety and liquidity. The Company has not experienced any credit losses related to these financial instruments and does not believe that it is exposed to any significant credit risk related to these instruments. &lt;/div&gt;&lt;/div&gt; &lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;(E) Cash, Cash Equivalents, and Restricted Cash &lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Cash and cash equivalents include cash deposits in banks and all highly liquid investments that are readily convertible to cash. The Company considers all highly liquid investments purchased with original maturities of three months or less to be cash equivalents. &lt;/div&gt;&lt;/div&gt; &lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;Restricted cash classified as a current asset consists of the amount held in escrow relating to the Sumitomo Transaction (see Note 5, &#x201c;Sumitomo Transaction Agreement&#x201d;) and the legally restricted &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;non-interest&lt;/div&gt; bearing deposit account relating to the Company&#x2019;s corporate credit card program. Restricted cash classified as a long-term asset consists of restricted deposit accounts related to irrevocable standby letters of credit. &lt;/div&gt; &lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Cash as reported in the accompanying consolidated statements of cash flows includes the aggregate amounts of cash, cash equivalents, and restricted cash as presented on the accompanying consolidated balance sheets as follows (in thousands): &lt;/div&gt;&lt;/div&gt; &lt;div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 76%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;"&gt;
&lt;tr style="font-size: 0px;"&gt;
&lt;td style="width: 62%;"/&gt;
&lt;td style="width: 8%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="width: 8%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;March&#160;31,&#160;2021&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;March&#160;31,&#160;2020&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Cash and cash equivalents&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;2,055,044&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;2,183,207&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Restricted cash&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;86,632&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;86,045&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Cash, cash equivalents and restricted cash&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;2,141,676&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;2,269,252&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt; &lt;/tr&gt; &lt;/table&gt;  &lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;(F) Trade Receivables, Net &lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;The Company monitors the financial performance and creditworthiness of its customers so that it can properly assess and respond to changes in customer credit profiles. The Company reserves against trade receivables for estimated losses that may arise from a customer&#x2019;s inability to pay and any amounts determined to be uncollectible are written off against the reserve when it is probable that the receivable will not be collected. The reserve amount for estimated losses was de minimis as of March&#160;31, 2021 and 2020. Trade receivables, net is included in &#x201c;Other current assets&#x201d; on the accompanying consolidated balance sheets. &lt;/div&gt;&lt;/div&gt; &lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;(G) Contingencies &lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;The Company may be, from time to time, a party to various disputes and claims arising from normal business activities. The Company continually assesses any litigation or other claims it may confront to determine if an unfavorable outcome would lead to a probable loss or reasonably possible loss which could be estimated. The Company accrues for all contingencies at the earliest date at which the Company deems it probable that a liability has been incurred and the amount of such liability can be reasonably estimated. If the estimate of a probable loss &lt;/div&gt;&lt;/div&gt; &lt;div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;is a range and no amount within the range is more likely than another, the Company accrues the minimum of the range. In the cases where the Company believes that a reasonably possible loss exists, the Company discloses the facts and circumstances of the litigation, including an estimable range, if possible. &lt;/div&gt;&lt;/div&gt; &lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;(H) Property and Equipment &lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Property and equipment, consisting primarily of computers, equipment, furniture and fixtures, software, and leasehold improvements, is recorded at cost, less accumulated depreciation. Maintenance and repairs that do not improve or extend the lives of the respective assets are expensed to operations as incurred. Upon disposal, retirement or sale, the related cost and accumulated depreciation is removed from the accounts and any resulting gain or loss is included in the results of operations. Depreciation of property and equipment is recorded using the straight-line method over the estimated useful lives of the related assets once the asset has been placed in service. Leasehold improvements are amortized using the straight-line method over the estimated useful life or remaining lease term, whichever is shorter. The following table provides the range of estimated useful lives used for each asset type: &lt;/div&gt;&lt;/div&gt;  &lt;div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 100%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;"&gt;
&lt;tr style="font-size: 0px;"&gt;
&lt;td style="width: 33%; font-family: &amp;quot;Times New Roman&amp;quot;;"/&gt;
&lt;td style="width: 1%; vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"/&gt;
&lt;td style="width: 66%; font-family: &amp;quot;Times New Roman&amp;quot;;"/&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt; &lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt; border-bottom: 1pt solid rgb(0, 0, 0); display: table-cell; line-height: normal;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Property and Equipment&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt; &lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt; border-bottom: 1pt solid rgb(0, 0, 0); display: table-cell; line-height: normal;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Estimated Useful Life&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Computers&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;3  years&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Equipment&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;5  years&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Furniture and fixtures&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;7  years&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Software&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;3  years&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Leasehold improvements&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;Lesser of estimated useful life or remaining lease term&lt;/td&gt; &lt;/tr&gt; &lt;/table&gt;  &lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;The Company reviews the recoverability of all long-lived assets, including the related useful lives, whenever events or changes in circumstances indicate that the carrying amount of a long-lived asset might not be recoverable. Recoverability is measured by comparison of the book values of the assets to the future net undiscounted cash flows that the assets are expected to generate. If such assets are considered to be impaired, the impairment to be recognized is measured by the amount by which the book value of the assets exceed their fair value, which is measured based on the projected discounted future net cash flows arising from the assets. &lt;/div&gt;&lt;/div&gt; &lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;(I) Investments &lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;For investments in entities over which the Company has significant influence but do not meet the requirements for consolidation and for which the Company has not elected the fair value option, the Company applies the equity method of accounting with the Company&#x2019;s share of the underlying income or loss of such entities reported in &#x201c;Other expense, net&#x201d; on the consolidated statements of operations. The Company applies the equity method to investments in common stock and to other investments in entities that have risk and reward characteristics that are substantially similar to an investment in the investee&#x2019;s common stock. &lt;/div&gt;&lt;/div&gt; &lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Investments in equity securities may also be accounted for using (i)&#160;the fair value option if elected, (ii)&#160;fair value through earnings if fair value is readily determinable or (iii)&#160;for equity investments without readily determinable fair values, the measurement alternative to measure at cost adjusted for any impairment and observable price changes, as applicable. The election to use the measurement alternative is made for each eligible investment. &lt;/div&gt;&lt;/div&gt; &lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;The Company has elected the fair value option to account for certain investments over which the Company has significant influence. The Company believes the fair value option best reflects the underlying economics of the investment. See Note 3, &#x201c;Investments.&#x201d; &lt;/div&gt;&lt;/div&gt; &lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;(J) Research and Development Expenses &lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Research and development (&#x201c;R&amp;amp;D&#x201d;) costs are expensed as incurred. Preclinical and clinical study costs are accrued over the service periods specified in the contracts and adjusted as necessary based upon an ongoing &lt;/div&gt;&lt;/div&gt; &lt;div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;review of the level of effort and costs actually incurred. Payments for a product license prior to regulatory approval of the product and payments for milestones achieved prior to regulatory approval of the product are expensed in the period incurred as R&amp;amp;D. Milestone payments made in connection with regulatory approvals are capitalized and amortized to cost of revenue over the remaining useful life of the asset. R&amp;amp;D costs primarily consist of the intellectual property and R&amp;amp;D materials acquired and expenses from third parties who conduct R&amp;amp;D activities on behalf of the Company. &lt;/div&gt;&lt;/div&gt; &lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;The Company evaluates &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;in-licensed&lt;/div&gt; agreements for &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;in-process&lt;/div&gt; research and development projects (&#x201c;IPR&amp;amp;D&#x201d;) to determine if it meets the definition of a business and thus should be accounted for as a business combination. If the &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;in-licensed&lt;/div&gt; agreement for IPR&amp;amp;D does not meet the definition of a business and the assets have not reached technological feasibility and therefore have no alternative future use, the Company expenses payments made under such license agreements as R&amp;amp;D expense in its consolidated statements of operations. The Company initially recognizes contingent consideration in an asset acquisition at fair value. The carrying value of contingent consideration is subsequently adjusted when the contingency is resolved and is paid or becomes payable. &lt;/div&gt;  &lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;(K) General and Administrative Expenses &lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;General and administrative (&#x201c;G&amp;amp;A&#x201d;) expenses consist primarily of employee-related expenses for G&amp;amp;A personnel, including those responsible for the identification and acquisition or &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;in-license&lt;/div&gt; of new drug candidates as well as for overseeing Vant operations and facilitating the use of the Company&#x2019;s platform and technologies at Vants. G&amp;amp;A expenses also consist of legal and accounting fees, consulting services and other operating costs relating to corporate matters and daily operations. G&amp;amp;A expenses include costs incurred relating to the identification, acquisition or &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;in-license&lt;/div&gt; and technology transfer of promising drug candidates along with costs incurred relating to the integration of new technologies. &lt;/div&gt; &lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;(L) Income Taxes &lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Deferred tax assets and liabilities are recognized for the future tax consequences attributable to differences between the financial statement carrying amounts of existing assets and liabilities and the respective tax bases. Deferred tax assets and liabilities are measured using enacted tax rates expected to apply to taxable income in the years in which those temporary differences are expected to be recovered or settled. The effect on deferred tax assets and liabilities of a change in tax rates is recognized in income in the period that includes the enactment date. A valuation allowance is recorded when, after consideration of all positive and negative evidence, it is not more likely than not that the Company&#x2019;s deferred tax assets will be realizable. If the Company determines that it would be able to realize its deferred tax assets in the future in excess of its net recorded amount, the Company would make an adjustment to the deferred tax asset valuation allowance, which would reduce the provision for income taxes. &lt;/div&gt;&lt;/div&gt; &lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;When uncertain tax positions exist, the Company recognizes the tax benefit of tax positions to the extent that the benefit will more likely than not be realized. The determination as to whether the tax benefit will more likely than not be realized is based upon the technical merits of the tax position as well as consideration of the available facts and circumstances. &lt;/div&gt;&lt;/div&gt; &lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;(M) Share-Based Compensation &lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Share-based awards to employees, directors, and consultants, including stock options, restricted stock units, performance options and capped value appreciation rights, are measured at fair value on the date of the grant and that fair value is recognized as share-based compensation expense in the Company&#x2019;s consolidated statements of operations over the requisite service period of the respective award. The estimated fair value of awards that contain performance conditions is expensed when the Company concludes that it is probable that the performance condition will be achieved. The Company may grant awards with graded-vesting features. When such awards have only service vesting requirements, the Company elected to record share-based compensation &lt;/div&gt;&lt;/div&gt; &lt;div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;expense on a straight-line basis. If awards with graded-vesting features contain performance or market conditions, then the Company records share-based compensation expense using the accelerated attribution method. &lt;/div&gt;&lt;/div&gt; &lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;The Company measures the fair value of its stock options that only have service vesting requirements or performance-based options without market conditions using the Black-Scholes option pricing model. For performance-based awards with market conditions, the Company determines the fair value of the awards as of the grant date using a Monte Carlo simulation model. &lt;/div&gt;&lt;/div&gt; &lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;Certain assumptions need to be made with respect to utilizing the Black-Scholes option pricing model, including the expected life of the award, volatility of the underlying shares, the risk-free interest rate and the fair value of the Company&#x2019;s common shares. Since the Company has no option exercise history, it has generally elected to estimate the expected life of an award based upon the &#x201c;simplified method&#x201d; with the continued use of this method extended until such time the Company has sufficient exercise history. The risk-free interest rate is based on the rates paid on securities issued by the U.S. Treasury with a term approximating the expected life of the equity award. The expected share price volatility for the Company&#x2019;s common shares is estimated by taking the average historical price volatility for industry peers. The Company accounts for &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;pre-vesting&lt;/div&gt; award forfeitures when they occur. &lt;/div&gt; &lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;As part of the valuation of share-based compensation under the Black-Scholes option pricing model, it is necessary for the Company to estimate the fair value of its common shares for RSL and privately held Vants. Given the absence of a public trading market, and in accordance with the American Institute of Certified Public Accountants&#x2019; Practice Guide, Valuation of Privately-Held-Company Equity Securities Issued as Compensation, the Company exercises reasonable judgment and considers numerous objective and subjective factors to determine its best estimate of the fair value of its common shares. The estimation of the fair value of the common shares considers factors including the following: the prices of the Company&#x2019;s common shares sold to investors in arm&#x2019;s length transactions, the estimated present value of the Company&#x2019;s future cash flows; the Company&#x2019;s business, financial condition and results of operations; the Company&#x2019;s forecasted operating performance; the illiquid nature of the Company&#x2019;s common shares; industry information such as market size and growth; market capitalization of comparable companies and the estimated value of transactions such companies have engaged in; and macroeconomic conditions. &lt;/div&gt;&lt;/div&gt;  &lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;(N) Fair Value Measurements &lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;The Company utilizes fair value measurement guidance prescribed by accounting standards to value its financial instruments. The guidance establishes a fair value hierarchy for financial instruments measured at fair value that distinguishes between assumptions based on market data (observable inputs) and the Company&#x2019;s own assumptions (unobservable inputs). Observable inputs are inputs that market participants would use in pricing the asset or liability based on market data obtained from sources independent of the Company. Unobservable inputs are inputs that reflect the Company&#x2019;s assumptions about the inputs that market participants would use in pricing the asset or liability, and are developed based on the best information available in the circumstances. Fair value is defined as the exchange price, or exit price, representing the amount that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants at the reporting date. As a basis for considering market participant assumptions in fair value measurements, the guidance establishes a three-tier fair value hierarchy that distinguishes among the following: &lt;/div&gt;&lt;/div&gt; &lt;div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;"&gt;
&lt;tr style="page-break-inside: avoid;"&gt;
&lt;td style="width: 5%;"&gt;&#160;&lt;/td&gt;
&lt;td style="width: 3%; vertical-align: top;;text-align:left;"&gt;&#x2022;&lt;/td&gt;
&lt;td style="width: 1%; vertical-align: top;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: top;;text-align:left;"&gt; &lt;div style="text-align: left; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"&gt;Level &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;1-Valuations&lt;/div&gt; are based on unadjusted quoted prices in active markets for identical assets or liabilities that the Company has the ability to access. &lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; &lt;div style="clear: both; max-height: 0px;"/&gt; &lt;div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;"&gt;
&lt;tr style="page-break-inside: avoid;"&gt;
&lt;td style="width: 5%;"&gt;&#160;&lt;/td&gt;
&lt;td style="width: 3%; vertical-align: top;;text-align:left;"&gt;&#x2022;&lt;/td&gt;
&lt;td style="width: 1%; vertical-align: top;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: top;;text-align:left;"&gt; &lt;div style="text-align: left; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"&gt;Level &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;2-Valuations&lt;/div&gt; are based on quoted prices for similar assets or liabilities in active markets, quoted prices for identical or similar assets or liabilities in markets that are not active and models for which all significant inputs are observable, either directly or indirectly. &lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; &lt;div style="clear: both; max-height: 0px;"/&gt; &lt;div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;"&gt;
&lt;tr style="page-break-inside: avoid;"&gt;
&lt;td style="width: 5%;"&gt;&#160;&lt;/td&gt;
&lt;td style="width: 3%; vertical-align: top;;text-align:left;"&gt;&#x2022;&lt;/td&gt;
&lt;td style="width: 1%; vertical-align: top;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: top;;text-align:left;"&gt; &lt;div style="text-align: left; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"&gt;Level &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;3-Valuations&lt;/div&gt; are based on inputs that are unobservable (supported by little or no market activity) and significant to the overall fair value measurement. &lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; &lt;div style="clear: both; max-height: 0px;"/&gt; &lt;div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;To the extent the valuation is based on models or inputs that are less observable or unobservable in the market, the determination of fair value requires more judgment. Accordingly, the degree of judgment exercised by the Company in determining fair value is greatest for instruments categorized in Level&#160;3. A financial instrument&#x2019;s level within the fair value hierarchy is based on the lowest level of any input that is significant to the fair value measurement. &lt;/div&gt;&lt;/div&gt; &lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;The Company&#x2019;s financial instruments include shares of common stock of Arbutus Biopharma Corporation (&#x201c;Arbutus&#x201d;); shares of Arbutus&#x2019;s Series A participating convertible preferred shares (&#x201c;Arbutus Preferred Shares&#x201d;); shares of common stock of Sio Gene Therapies Inc. (&#x201c;Sio&#x201d;); liability instruments issued, including options granted to Sumitomo (the &#x201c;Sumitomo Options&#x201d;) to purchase all, or 75% in one case, of RSL&#x2019;s ownership interests in certain subsidiaries under the Sumitomo Transaction Agreement; deferred consideration liability; its investments in other entities; cash and cash equivalents consisting of money market funds; accounts payable; and long-term debt. &lt;/div&gt;&lt;/div&gt; &lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;The shares of Arbutus and Sio common stock and investments in common stock with a readily determinable fair value are classified as Level&#160;1, and their fair value is determined based upon quoted market prices in an active market. The Arbutus Preferred Shares held by the Company are classified as Level&#160;2 as the fair value of such preferred shares is determined based upon the quoted market price of Arbutus common stock into which such preferred shares are convertible. The liability instruments issued, including the Sumitomo Options, are classified as Level&#160;3 within the fair value hierarchy as the assumptions and estimates used in the valuations are unobservable in the market. Cash, accounts payable, and deferred consideration liability are stated at their respective historical carrying amounts, which approximate fair value due to their short-term nature. The deferred consideration liability is based on a fixed monetary amount, and payment is based solely on the passage of time. Money market funds are included in Level&#160;1 of the fair value hierarchy and are valued at the closing price reported by an actively traded exchange. The carrying value of long-term debt issued by Dermavant Sciences Ltd. (together with its wholly owned subsidiaries, &#x201c;Dermavant&#x201d;), which is stated at amortized cost, approximates fair value&#160;based on current interest rates for similar types of borrowings and therefore is included in Level&#160;2 of the fair value hierarchy. Long-term debt issued by Dermavant for which the fair value option has been elected is included in Level&#160;3 of the fair value hierarchy as the assumptions and estimates used in the valuation are unobservable in the market. &lt;/div&gt;&lt;/div&gt;  &lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;(O) Foreign Currency &lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Assets and liabilities of foreign operations are translated using exchange rates in effect at the balance sheet date and their results of operations are translated using average exchange rates for the year. Certain transactions of the Company and its subsidiaries are denominated in currencies other than their functional currency. Adjustments resulting from the translation of the financial statements of the Company&#x2019;s foreign functional currency subsidiaries into U.S. dollars are excluded from the determination of net loss and are accumulated in a separate component of shareholders&#x2019; equity. Foreign exchange transaction gains and losses are included in &#x201c;Other expense, net&#x201d; in the Company&#x2019;s statements of operations. &lt;/div&gt;&lt;/div&gt; &lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;(P) Revenue Recognition &lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;The Company recognizes revenue when its customer obtains control of promised goods or services, in an amount that reflects the consideration which the Company expects to receive in exchange for those goods or services. To determine revenue recognition for its arrangements, the Company performs the following five steps: (i)&#160;identify the contract(s) with a customer; (ii)&#160;identify the performance obligations in the contract; (iii)&#160;determine the transaction price; (iv)&#160;allocate the transaction price to the performance obligations in the contract; and (v)&#160;recognize revenue when or as the Company satisfies a performance obligation. &lt;/div&gt;&lt;/div&gt; &lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;The Company applies significant judgment when evaluating whether contractual obligations represent distinct performance obligations, allocating transaction price to performance obligations within a contract, determining &lt;/div&gt;&lt;/div&gt; &lt;div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;when performance obligations have been met, assessing the recognition and future reversal of variable consideration, and determining and applying appropriate methods of measuring progress for performance obligations satisfied over time. These judgments are discussed in more detail below. &lt;/div&gt;&lt;/div&gt; &lt;div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;"&gt;
&lt;tr style="page-break-inside: avoid;"&gt;
&lt;td style="width: 5%;"&gt;&#160;&lt;/td&gt;
&lt;td style="width: 3%; vertical-align: top;;text-align:left;"&gt;&#x2022;&lt;/td&gt;
&lt;td style="width: 1%; vertical-align: top;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: top;;text-align:left;"&gt; &lt;div style="text-align: left; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"&gt;&lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;Licenses of intellectual property:&lt;/div&gt;&lt;/div&gt; If the licenses to intellectual property are determined to be distinct from the other performance obligations identified in the arrangement, the Company recognizes revenues from &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;non-refundable,&lt;/div&gt; upfront fees allocated to the license when the license is transferred to the licensee and the licensee is able to use and benefit from the license. For licenses that are not distinct from other promises, the Company applies judgment to assess the nature of the combined performance obligation to determine whether the combined performance obligation is satisfied over time or at a point in time and, if over time, the appropriate method of measuring progress for purposes of recognizing revenue from &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;non-refundable,&lt;/div&gt; upfront fees. The Company evaluates the measure of progress each reporting period and, if necessary, adjusts the related revenue recognition accordingly. &lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; &lt;div style="clear: both; max-height: 0px;"/&gt; &lt;div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;"&gt;
&lt;tr style="page-break-inside: avoid;"&gt;
&lt;td style="width: 5%;"&gt;&#160;&lt;/td&gt;
&lt;td style="width: 3%; vertical-align: top;;text-align:left;"&gt;&#x2022;&lt;/td&gt;
&lt;td style="width: 1%; vertical-align: top;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: top;;text-align:left;"&gt; &lt;div style="text-align: left; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"&gt;&lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;Milestone payments: &lt;/div&gt;&lt;/div&gt;At the inception of each arrangement that includes research, development or regulatory milestone payments, the Company&lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt; &lt;/div&gt;&lt;/div&gt;evaluates whether the milestones are considered probable of being reached and estimates the amount to be included in the transaction price using the most likely amount method. If it is probable that a significant revenue reversal would not occur, the associated milestone value is included in the transaction price. Milestone payments that are not within the control of the Company or the licensee, such as regulatory approvals, are not considered probable of being achieved until those approvals are received. The transaction price is then allocated to each performance obligation on a relative standalone selling price basis, for which the Company recognizes revenue as or when the performance obligations under the contract are satisfied. At the end of each subsequent reporting period, the Company &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;re-evaluates&lt;/div&gt; the probability of achievement of such development milestones and any related constraint, and if necessary, adjusts its estimate of the overall transaction price on a cumulative &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;catch-up&lt;/div&gt; basis in earnings in the period of the adjustment. &lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; &lt;div style="clear: both; max-height: 0px;"/&gt; &lt;div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;"&gt;
&lt;tr style="page-break-inside: avoid;"&gt;
&lt;td style="width: 5%;"&gt;&#160;&lt;/td&gt;
&lt;td style="width: 3%; vertical-align: top;;text-align:left;"&gt;&#x2022;&lt;/td&gt;
&lt;td style="width: 1%; vertical-align: top;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: top;;text-align:left;"&gt; &lt;div style="text-align: left; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"&gt;&lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;Royalties and commercial milestone payments: &lt;/div&gt;&lt;/div&gt;For arrangements that include sales-based royalties, including commercial milestone payments&lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt; &lt;/div&gt;&lt;/div&gt;based on a &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;pre-specified&lt;/div&gt; level of sales, the Company recognizes revenue at the later of (i)&#160;when the related sales occur, or (ii)&#160;when the performance obligation to which some or all of the royalty has been allocated has been satisfied (or partially satisfied). Achievement of these royalties and commercial milestones may solely depend upon performance of the licensee. &lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; &lt;div style="clear: both; max-height: 0px;"/&gt; &lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Revenue is also generated by certain technology-focused Vants from subscription and service-based fees recognized for the use of certain technology developed by these Vants. Subscription revenue is recognized ratably over the contract period. &lt;/div&gt;&lt;/div&gt;  &lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;(Q) Recently Adopted Accounting Pronouncements &lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;In June 2016, the FASB issued ASU &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;No.&#160;2016-13,&lt;/div&gt; &#x201c;Financial Instruments-Credit Losses (Topic 326): Measurement of Credit Losses on Financial Instruments&#x201d; (&#x201c;ASU &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;No.&#160;2016-13&#x201d;),&lt;/div&gt; which requires the measurement and recognition of expected credit losses for financial assets held at amortized cost. ASU &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;No.&#160;2016-13&lt;/div&gt; replaces the existing incurred loss impairment model with an expected loss model that requires the use of forward-looking information to calculate credit loss estimates. It also eliminates the concept of other-than-temporary impairment and requires credit losses on &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;available-for-sale&lt;/div&gt;&lt;/div&gt; debt securities to be recorded through an allowance for credit losses instead of as a reduction in the amortized cost basis of the securities. ASU &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;No.&#160;2016-13&lt;/div&gt; is effective for fiscal years beginning after December&#160;15, 2019 and interim periods within those fiscal years. The adoption of ASU &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;No.&#160;2016-13&lt;/div&gt; on April&#160;1, 2020 did not have a material impact on the Company&#x2019;s consolidated financial statements. &lt;/div&gt; &lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;(R) Recently Issued Accounting Pronouncements Not Yet Adopted &lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;In August 2020, the FASB issued ASU &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;No.&#160;2020-06,&lt;/div&gt; &#x201c;Debt&#x2014;Debt with Conversion and Other Options (Subtopic &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;470-20)&lt;/div&gt; and Derivatives and Hedging&#x2014;Contracts in Entity&#x2019;s Own Equity (Subtopic &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;815-40):&lt;/div&gt; Accounting for &lt;/div&gt; &lt;div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;Convertible Instruments and Contracts in an Entity&#x2019;s Own Equity&#x201d; (&#x201c;ASU &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;No.&#160;2020-06&#x201d;).&lt;/div&gt; ASU &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;No.&#160;2020-06&lt;/div&gt; will simplify the accounting for convertible instruments by reducing the number of accounting models for convertible debt instruments and convertible preferred stock. Limiting the accounting models will result in fewer embedded conversion features being separately recognized from the host contract as compared with current GAAP. ASU &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;No.&#160;2020-06&lt;/div&gt; also removes certain settlement conditions that are required for equity contracts to qualify for the derivatives scope exception, which will permit more equity contracts to qualify for it. Either a modified retrospective transition method or a fully retrospective transition method is permissible for the adoption of this standard. Update &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;No.&#160;2020-06&lt;/div&gt; is effective for fiscal years beginning after December&#160;15, 2021, including interim periods within those fiscal years. Early adoption is permitted no earlier than the fiscal year beginning after December&#160;15, 2020. The adoption of ASU &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;No.&#160;2020-06&lt;/div&gt; is not expected to have a material impact on the Company&#x2019;s consolidated financial statements. &lt;/div&gt; </us-gaap:SignificantAccountingPoliciesTextBlock>
    <us-gaap:BasisOfAccountingPolicyPolicyTextBlock contextRef="P04_01_2020To03_31_2021">&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;(A) Basis of Presentation and Principles of Consolidation &lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;The Company&#x2019;s fiscal year ends on March&#160;31, and its fiscal quarters end on June&#160;30, September&#160;30, and December 31. &lt;/div&gt;&lt;/div&gt; &lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;The accompanying audited consolidated financial statements and notes thereto have been prepared in accordance with accounting principles generally accepted in the United States (&#x201c;U.S. GAAP&#x201d;). &lt;/div&gt;&lt;/div&gt; &lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Any references in these notes to applicable accounting guidance are meant to refer to the authoritative U.S. GAAP as found in the Accounting Standards Codification (&#x201c;ASC&#x201d;) and Accounting Standards Updates &lt;/div&gt;&lt;/div&gt; &lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;(&#x201c;ASU&#x201d;) of the Financial Accounting Standards Board (&#x201c;FASB&#x201d;). The consolidated financial statements include the accounts of RSL and the subsidiaries in which it has a controlling financial interest, most often through a majority voting interest. All intercompany balances and transactions have been eliminated in consolidation. &lt;/div&gt;&lt;/div&gt; &lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;For consolidated entities where the Company owns or is exposed to less than 100% of the economics, the Company records net loss attributable to noncontrolling interests in its consolidated statements of operations equal to the percentage of the economic or ownership interest retained in the respective operations by the noncontrolling parties. The Company presents noncontrolling interests as a component of shareholders&#x2019; equity on its consolidated balance sheets. &lt;/div&gt;&lt;/div&gt; &lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;The Company accounts for changes in its ownership interest in its subsidiaries while control is retained as equity transactions. The carrying amount of the noncontrolling interest is adjusted to reflect the change in RSL&#x2019;s ownership interest in the subsidiary. Any difference between the fair value of the consideration received or paid and the amount by which the noncontrolling interest is adjusted is recognized within shareholders&#x2019; equity attributable to RSL. &lt;/div&gt;&lt;/div&gt; &lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Additionally, the Company concluded that the disposition of RSL&#x2019;s ownership interests in Myovant Sciences Ltd. (&#x201c;Myovant&#x201d;), Urovant Sciences Ltd. (&#x201c;Urovant&#x201d;), Enzyvant Therapeutics Ltd. (&#x201c;Enzyvant&#x201d;), Altavant Sciences Ltd. (&#x201c;Altavant&#x201d;), and Spirovant Sciences Ltd. (&#x201c;Spirovant&#x201d;) (collectively, the &#x201c;Sumitovant Vants&#x201d;), pursuant to the transaction agreement entered into with Sumitomo Dainippon Pharma Co., Ltd. (&#x201c;Sumitomo&#x201d;) on October&#160;31, 2019 (the &#x201c;Sumitomo Transaction Agreement&#x201d;) that closed on December&#160;27, 2019 (the &#x201c;Sumitomo Transaction&#x201d;), met the requirements to be presented as discontinued operations. As such, results relating to the transferred interests prior to disposition are classified as discontinued operations in prior period consolidated financial statements. See Note 5, &#x201c;Sumitomo Transaction Agreement&#x201d; and Note 6, &#x201c;Discontinued Operations&#x201d; for further discussion. Certain prior year amounts were reclassified to conform to current year presentation. &lt;/div&gt;&lt;/div&gt; &lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;In April 2012, the Jumpstart Our Business Startups Act of 2012 (the &#x201c;JOBS Act&#x201d;) was enacted. Section&#160;107(b) of the JOBS Act provides that an emerging growth company can take advantage of an extended transition period for complying with new or revised accounting standards. Thus, an emerging growth company can delay the adoption of certain accounting standards until those standards would otherwise apply to private companies. The Company has irrevocably elected not to avail itself of this extended transition period, and, as a result, the Company will adopt new or revised accounting standards on the relevant dates on which adoption of such standards is required for other public companies. &lt;/div&gt;&lt;/div&gt; </us-gaap:BasisOfAccountingPolicyPolicyTextBlock>
    <us-gaap:UseOfEstimates contextRef="P04_01_2020To03_31_2021">&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;(B) Use of Estimates &lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;The preparation of financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the amounts reported in the financial statements and accompanying notes. The Company regularly evaluates estimates and assumptions related to assets, liabilities, costs, expenses, contingent liabilities, share-based compensation and research and development costs. The Company bases its estimates and assumptions on historical experience and on various other factors that it believes to be reasonable under the circumstances, the results of which form the basis for making judgments about the carrying values of assets and liabilities that are not readily apparent from other sources. Actual results could differ from those estimates. &lt;/div&gt;&lt;/div&gt; &lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;Additionally, the Company assessed the impact that the &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;COVID-19&lt;/div&gt; pandemic has had on its operations and financial results as of March&#160;31, 2021 and through the issuance of these consolidated financial statements. The Company&#x2019;s analysis was informed by the facts and circumstances as they were known to the Company. This assessment considered the impact &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;COVID-19&lt;/div&gt; may have on financial estimates and assumptions that affect the reported amounts of assets and liabilities and expenses. &lt;/div&gt; &lt;div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;</us-gaap:UseOfEstimates>
    <us-gaap:UnusualRisksAndUncertaintiesTextBlock contextRef="P04_01_2020To03_31_2021">&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;(C) Risks and Uncertainties &lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;The Company is subject to risks common to companies in the biopharmaceutical industry including, but not limited to, uncertainties related to commercialization of products, regulatory approvals, dependence on key products, dependence on third-party service providers, such as contract research organizations, and protection of intellectual property rights. &lt;/div&gt;&lt;/div&gt;</us-gaap:UnusualRisksAndUncertaintiesTextBlock>
    <us-gaap:ConcentrationRiskCreditRisk contextRef="P04_01_2020To03_31_2021">&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;(D) Concentrations of Credit Risk &lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Financial instruments that potentially subject the Company to concentration of credit risk include cash and cash equivalents. The Company maintains cash deposits and cash equivalents in highly-rated, federally-insured financial institutions in excess of federally insured limits. The Company has established guidelines relative to diversification and maturities to maintain safety and liquidity. The Company has not experienced any credit losses related to these financial instruments and does not believe that it is exposed to any significant credit risk related to these instruments. &lt;/div&gt;&lt;/div&gt;</us-gaap:ConcentrationRiskCreditRisk>
    <us-gaap:CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy contextRef="P04_01_2020To03_31_2021">&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;(E) Cash, Cash Equivalents, and Restricted Cash &lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Cash and cash equivalents include cash deposits in banks and all highly liquid investments that are readily convertible to cash. The Company considers all highly liquid investments purchased with original maturities of three months or less to be cash equivalents. &lt;/div&gt;&lt;/div&gt; &lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;Restricted cash classified as a current asset consists of the amount held in escrow relating to the Sumitomo Transaction (see Note 5, &#x201c;Sumitomo Transaction Agreement&#x201d;) and the legally restricted &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;non-interest&lt;/div&gt; bearing deposit account relating to the Company&#x2019;s corporate credit card program. Restricted cash classified as a long-term asset consists of restricted deposit accounts related to irrevocable standby letters of credit. &lt;/div&gt; &lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Cash as reported in the accompanying consolidated statements of cash flows includes the aggregate amounts of cash, cash equivalents, and restricted cash as presented on the accompanying consolidated balance sheets as follows (in thousands): &lt;/div&gt;&lt;/div&gt; &lt;div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 76%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;"&gt;
&lt;tr style="font-size: 0px;"&gt;
&lt;td style="width: 62%;"/&gt;
&lt;td style="width: 8%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="width: 8%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;March&#160;31,&#160;2021&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;March&#160;31,&#160;2020&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Cash and cash equivalents&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;2,055,044&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;2,183,207&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Restricted cash&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;86,632&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;86,045&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Cash, cash equivalents and restricted cash&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;2,141,676&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;2,269,252&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; </us-gaap:CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy>
    <us-gaap:ScheduleOfCashAndCashEquivalentsTableTextBlock contextRef="P04_01_2020To03_31_2021">&lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Cash as reported in the accompanying consolidated statements of cash flows includes the aggregate amounts of cash, cash equivalents, and restricted cash as presented on the accompanying consolidated balance sheets as follows (in thousands): &lt;/div&gt;&lt;/div&gt; &lt;div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 76%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;"&gt;
&lt;tr style="font-size: 0px;"&gt;
&lt;td style="width: 62%;"/&gt;
&lt;td style="width: 8%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="width: 8%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;March&#160;31,&#160;2021&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;March&#160;31,&#160;2020&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Cash and cash equivalents&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;2,055,044&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;2,183,207&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Restricted cash&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;86,632&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;86,045&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Cash, cash equivalents and restricted cash&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;2,141,676&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;2,269,252&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; </us-gaap:ScheduleOfCashAndCashEquivalentsTableTextBlock>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="PAsOn03_31_2021"
      decimals="-3"
      unitRef="Unit_USD">2055044000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="PAsOn03_31_2020"
      decimals="-3"
      unitRef="Unit_USD">2183207000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:RestrictedCash
      contextRef="PAsOn03_31_2021"
      decimals="-3"
      unitRef="Unit_USD">86632000</us-gaap:RestrictedCash>
    <us-gaap:RestrictedCash
      contextRef="PAsOn03_31_2020"
      decimals="-3"
      unitRef="Unit_USD">86045000</us-gaap:RestrictedCash>
    <roiv:CashAndCashEquivalentsAndRestrictedCash
      contextRef="PAsOn03_31_2021"
      decimals="-3"
      unitRef="Unit_USD">2141676000</roiv:CashAndCashEquivalentsAndRestrictedCash>
    <roiv:CashAndCashEquivalentsAndRestrictedCash
      contextRef="PAsOn03_31_2020"
      decimals="-3"
      unitRef="Unit_USD">2269252000</roiv:CashAndCashEquivalentsAndRestrictedCash>
    <us-gaap:TradeAndOtherAccountsReceivablePolicy contextRef="P04_01_2020To03_31_2021">&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;(F) Trade Receivables, Net &lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;The Company monitors the financial performance and creditworthiness of its customers so that it can properly assess and respond to changes in customer credit profiles. The Company reserves against trade receivables for estimated losses that may arise from a customer&#x2019;s inability to pay and any amounts determined to be uncollectible are written off against the reserve when it is probable that the receivable will not be collected. The reserve amount for estimated losses was de minimis as of March&#160;31, 2021 and 2020. Trade receivables, net is included in &#x201c;Other current assets&#x201d; on the accompanying consolidated balance sheets. &lt;/div&gt;&lt;/div&gt;</us-gaap:TradeAndOtherAccountsReceivablePolicy>
    <us-gaap:CommitmentsAndContingenciesPolicyTextBlock contextRef="P04_01_2020To03_31_2021">&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;(G) Contingencies &lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;The Company may be, from time to time, a party to various disputes and claims arising from normal business activities. The Company continually assesses any litigation or other claims it may confront to determine if an unfavorable outcome would lead to a probable loss or reasonably possible loss which could be estimated. The Company accrues for all contingencies at the earliest date at which the Company deems it probable that a liability has been incurred and the amount of such liability can be reasonably estimated. If the estimate of a probable loss &lt;/div&gt;&lt;/div&gt; &lt;div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;is a range and no amount within the range is more likely than another, the Company accrues the minimum of the range. In the cases where the Company believes that a reasonably possible loss exists, the Company discloses the facts and circumstances of the litigation, including an estimable range, if possible.</us-gaap:CommitmentsAndContingenciesPolicyTextBlock>
    <us-gaap:PropertyPlantAndEquipmentPolicyTextBlock contextRef="P04_01_2020To03_31_2021">&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;(H) Property and Equipment &lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Property and equipment, consisting primarily of computers, equipment, furniture and fixtures, software, and leasehold improvements, is recorded at cost, less accumulated depreciation. Maintenance and repairs that do not improve or extend the lives of the respective assets are expensed to operations as incurred. Upon disposal, retirement or sale, the related cost and accumulated depreciation is removed from the accounts and any resulting gain or loss is included in the results of operations. Depreciation of property and equipment is recorded using the straight-line method over the estimated useful lives of the related assets once the asset has been placed in service. Leasehold improvements are amortized using the straight-line method over the estimated useful life or remaining lease term, whichever is shorter. The following table provides the range of estimated useful lives used for each asset type: &lt;/div&gt;&lt;/div&gt;  &lt;div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 100%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;"&gt;
&lt;tr style="font-size: 0px;"&gt;
&lt;td style="width: 33%; font-family: &amp;quot;Times New Roman&amp;quot;;"/&gt;
&lt;td style="width: 1%; vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"/&gt;
&lt;td style="width: 66%; font-family: &amp;quot;Times New Roman&amp;quot;;"/&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt; &lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt; border-bottom: 1pt solid rgb(0, 0, 0); display: table-cell; line-height: normal;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Property and Equipment&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt; &lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt; border-bottom: 1pt solid rgb(0, 0, 0); display: table-cell; line-height: normal;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Estimated Useful Life&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Computers&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;3  years&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Equipment&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;5  years&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Furniture and fixtures&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;7  years&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Software&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;3  years&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Leasehold improvements&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;Lesser of estimated useful life or remaining lease term&lt;/td&gt; &lt;/tr&gt; &lt;/table&gt;  &lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;The Company reviews the recoverability of all long-lived assets, including the related useful lives, whenever events or changes in circumstances indicate that the carrying amount of a long-lived asset might not be recoverable. Recoverability is measured by comparison of the book values of the assets to the future net undiscounted cash flows that the assets are expected to generate. If such assets are considered to be impaired, the impairment to be recognized is measured by the amount by which the book value of the assets exceed their fair value, which is measured based on the projected discounted future net cash flows arising from the assets. &lt;/div&gt;&lt;/div&gt;</us-gaap:PropertyPlantAndEquipmentPolicyTextBlock>
    <roiv:ScheduleOfPropertyPlantAndEquipmentEstimatedUsefulLivesTableTextBlock contextRef="P04_01_2020To03_31_2021">The following table provides the range of estimated useful lives used for each asset type: &lt;div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 100%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;"&gt;
&lt;tr style="font-size: 0px;"&gt;
&lt;td style="width: 33%; font-family: &amp;quot;Times New Roman&amp;quot;;"/&gt;
&lt;td style="width: 1%; vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"/&gt;
&lt;td style="width: 66%; font-family: &amp;quot;Times New Roman&amp;quot;;"/&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt; &lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt; border-bottom: 1pt solid rgb(0, 0, 0); display: table-cell; line-height: normal;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Property and Equipment&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt; &lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt; border-bottom: 1pt solid rgb(0, 0, 0); display: table-cell; line-height: normal;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Estimated Useful Life&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Computers&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;3  years&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Equipment&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;5  years&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Furniture and fixtures&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;7  years&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Software&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;3  years&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Leasehold improvements&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;Lesser of estimated useful life or remaining lease term&lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; </roiv:ScheduleOfPropertyPlantAndEquipmentEstimatedUsefulLivesTableTextBlock>
    <us-gaap:PropertyPlantAndEquipmentUsefulLife contextRef="P04_01_2020To03_31_2021_ComputerEquipmentMemberusgaapPropertyPlantAndEquipmentByTypeAxis">P3Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>
    <us-gaap:PropertyPlantAndEquipmentUsefulLife contextRef="P04_01_2020To03_31_2021_EquipmentMemberusgaapPropertyPlantAndEquipmentByTypeAxis">P5Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>
    <us-gaap:PropertyPlantAndEquipmentUsefulLife contextRef="P04_01_2020To03_31_2021_FurnitureAndFixturesMemberusgaapPropertyPlantAndEquipmentByTypeAxis">P7Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>
    <us-gaap:PropertyPlantAndEquipmentUsefulLife contextRef="P04_01_2020To03_31_2021_SoftwareDevelopmentMemberusgaapPropertyPlantAndEquipmentByTypeAxis">P3Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>
    <us-gaap:PropertyPlantAndEquipmentEstimatedUsefulLives contextRef="P04_01_2020To03_31_2021_LeaseholdImprovementsMemberusgaapPropertyPlantAndEquipmentByTypeAxis">Lesser of estimated useful life or remaining lease term</us-gaap:PropertyPlantAndEquipmentEstimatedUsefulLives>
    <us-gaap:InvestmentPolicyTextBlock contextRef="P04_01_2020To03_31_2021">&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;(I) Investments &lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;For investments in entities over which the Company has significant influence but do not meet the requirements for consolidation and for which the Company has not elected the fair value option, the Company applies the equity method of accounting with the Company&#x2019;s share of the underlying income or loss of such entities reported in &#x201c;Other expense, net&#x201d; on the consolidated statements of operations. The Company applies the equity method to investments in common stock and to other investments in entities that have risk and reward characteristics that are substantially similar to an investment in the investee&#x2019;s common stock. &lt;/div&gt;&lt;/div&gt; &lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Investments in equity securities may also be accounted for using (i)&#160;the fair value option if elected, (ii)&#160;fair value through earnings if fair value is readily determinable or (iii)&#160;for equity investments without readily determinable fair values, the measurement alternative to measure at cost adjusted for any impairment and observable price changes, as applicable. The election to use the measurement alternative is made for each eligible investment. &lt;/div&gt;&lt;/div&gt; &lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;The Company has elected the fair value option to account for certain investments over which the Company has significant influence. The Company believes the fair value option best reflects the underlying economics of the investment. See Note 3, &#x201c;Investments.&#x201d; &lt;/div&gt;&lt;/div&gt;</us-gaap:InvestmentPolicyTextBlock>
    <us-gaap:ResearchAndDevelopmentExpensePolicy contextRef="P04_01_2020To03_31_2021">&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;(J) Research and Development Expenses &lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Research and development (&#x201c;R&amp;amp;D&#x201d;) costs are expensed as incurred. Preclinical and clinical study costs are accrued over the service periods specified in the contracts and adjusted as necessary based upon an ongoing &lt;/div&gt;&lt;/div&gt; &lt;div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;review of the level of effort and costs actually incurred. Payments for a product license prior to regulatory approval of the product and payments for milestones achieved prior to regulatory approval of the product are expensed in the period incurred as R&amp;amp;D. Milestone payments made in connection with regulatory approvals are capitalized and amortized to cost of revenue over the remaining useful life of the asset. R&amp;amp;D costs primarily consist of the intellectual property and R&amp;amp;D materials acquired and expenses from third parties who conduct R&amp;amp;D activities on behalf of the Company. &lt;/div&gt;&lt;/div&gt; &lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;The Company evaluates &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;in-licensed&lt;/div&gt; agreements for &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;in-process&lt;/div&gt; research and development projects (&#x201c;IPR&amp;amp;D&#x201d;) to determine if it meets the definition of a business and thus should be accounted for as a business combination. If the &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;in-licensed&lt;/div&gt; agreement for IPR&amp;amp;D does not meet the definition of a business and the assets have not reached technological feasibility and therefore have no alternative future use, the Company expenses payments made under such license agreements as R&amp;amp;D expense in its consolidated statements of operations. The Company initially recognizes contingent consideration in an asset acquisition at fair value. The carrying value of contingent consideration is subsequently adjusted when the contingency is resolved and is paid or becomes payable. &lt;/div&gt; </us-gaap:ResearchAndDevelopmentExpensePolicy>
    <roiv:GeneralAndAdministrativeExpensesPolicyTextBlock contextRef="P04_01_2020To03_31_2021">&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;(K) General and Administrative Expenses &lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;General and administrative (&#x201c;G&amp;amp;A&#x201d;) expenses consist primarily of employee-related expenses for G&amp;amp;A personnel, including those responsible for the identification and acquisition or &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;in-license&lt;/div&gt; of new drug candidates as well as for overseeing Vant operations and facilitating the use of the Company&#x2019;s platform and technologies at Vants. G&amp;amp;A expenses also consist of legal and accounting fees, consulting services and other operating costs relating to corporate matters and daily operations. G&amp;amp;A expenses include costs incurred relating to the identification, acquisition or &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;in-license&lt;/div&gt; and technology transfer of promising drug candidates along with costs incurred relating to the integration of new technologies. &lt;/div&gt;</roiv:GeneralAndAdministrativeExpensesPolicyTextBlock>
    <us-gaap:IncomeTaxPolicyTextBlock contextRef="P04_01_2020To03_31_2021">&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;(L) Income Taxes &lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Deferred tax assets and liabilities are recognized for the future tax consequences attributable to differences between the financial statement carrying amounts of existing assets and liabilities and the respective tax bases. Deferred tax assets and liabilities are measured using enacted tax rates expected to apply to taxable income in the years in which those temporary differences are expected to be recovered or settled. The effect on deferred tax assets and liabilities of a change in tax rates is recognized in income in the period that includes the enactment date. A valuation allowance is recorded when, after consideration of all positive and negative evidence, it is not more likely than not that the Company&#x2019;s deferred tax assets will be realizable. If the Company determines that it would be able to realize its deferred tax assets in the future in excess of its net recorded amount, the Company would make an adjustment to the deferred tax asset valuation allowance, which would reduce the provision for income taxes. &lt;/div&gt;&lt;/div&gt; &lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;When uncertain tax positions exist, the Company recognizes the tax benefit of tax positions to the extent that the benefit will more likely than not be realized. The determination as to whether the tax benefit will more likely than not be realized is based upon the technical merits of the tax position as well as consideration of the available facts and circumstances. &lt;/div&gt;&lt;/div&gt;</us-gaap:IncomeTaxPolicyTextBlock>
    <us-gaap:ShareBasedCompensationOptionAndIncentivePlansPolicy contextRef="P04_01_2020To03_31_2021">&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;(M) Share-Based Compensation &lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Share-based awards to employees, directors, and consultants, including stock options, restricted stock units, performance options and capped value appreciation rights, are measured at fair value on the date of the grant and that fair value is recognized as share-based compensation expense in the Company&#x2019;s consolidated statements of operations over the requisite service period of the respective award. The estimated fair value of awards that contain performance conditions is expensed when the Company concludes that it is probable that the performance condition will be achieved. The Company may grant awards with graded-vesting features. When such awards have only service vesting requirements, the Company elected to record share-based compensation &lt;/div&gt;&lt;/div&gt; &lt;div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;expense on a straight-line basis. If awards with graded-vesting features contain performance or market conditions, then the Company records share-based compensation expense using the accelerated attribution method. &lt;/div&gt;&lt;/div&gt; &lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;The Company measures the fair value of its stock options that only have service vesting requirements or performance-based options without market conditions using the Black-Scholes option pricing model. For performance-based awards with market conditions, the Company determines the fair value of the awards as of the grant date using a Monte Carlo simulation model. &lt;/div&gt;&lt;/div&gt; &lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;Certain assumptions need to be made with respect to utilizing the Black-Scholes option pricing model, including the expected life of the award, volatility of the underlying shares, the risk-free interest rate and the fair value of the Company&#x2019;s common shares. Since the Company has no option exercise history, it has generally elected to estimate the expected life of an award based upon the &#x201c;simplified method&#x201d; with the continued use of this method extended until such time the Company has sufficient exercise history. The risk-free interest rate is based on the rates paid on securities issued by the U.S. Treasury with a term approximating the expected life of the equity award. The expected share price volatility for the Company&#x2019;s common shares is estimated by taking the average historical price volatility for industry peers. The Company accounts for &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;pre-vesting&lt;/div&gt; award forfeitures when they occur. &lt;/div&gt; &lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;As part of the valuation of share-based compensation under the Black-Scholes option pricing model, it is necessary for the Company to estimate the fair value of its common shares for RSL and privately held Vants. Given the absence of a public trading market, and in accordance with the American Institute of Certified Public Accountants&#x2019; Practice Guide, Valuation of Privately-Held-Company Equity Securities Issued as Compensation, the Company exercises reasonable judgment and considers numerous objective and subjective factors to determine its best estimate of the fair value of its common shares. The estimation of the fair value of the common shares considers factors including the following: the prices of the Company&#x2019;s common shares sold to investors in arm&#x2019;s length transactions, the estimated present value of the Company&#x2019;s future cash flows; the Company&#x2019;s business, financial condition and results of operations; the Company&#x2019;s forecasted operating performance; the illiquid nature of the Company&#x2019;s common shares; industry information such as market size and growth; market capitalization of comparable companies and the estimated value of transactions such companies have engaged in; and macroeconomic conditions. &lt;/div&gt;&lt;/div&gt; </us-gaap:ShareBasedCompensationOptionAndIncentivePlansPolicy>
    <us-gaap:FairValueMeasurementPolicyPolicyTextBlock contextRef="P04_01_2020To03_31_2021">&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;(N) Fair Value Measurements &lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;The Company utilizes fair value measurement guidance prescribed by accounting standards to value its financial instruments. The guidance establishes a fair value hierarchy for financial instruments measured at fair value that distinguishes between assumptions based on market data (observable inputs) and the Company&#x2019;s own assumptions (unobservable inputs). Observable inputs are inputs that market participants would use in pricing the asset or liability based on market data obtained from sources independent of the Company. Unobservable inputs are inputs that reflect the Company&#x2019;s assumptions about the inputs that market participants would use in pricing the asset or liability, and are developed based on the best information available in the circumstances. Fair value is defined as the exchange price, or exit price, representing the amount that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants at the reporting date. As a basis for considering market participant assumptions in fair value measurements, the guidance establishes a three-tier fair value hierarchy that distinguishes among the following: &lt;/div&gt;&lt;/div&gt; &lt;div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;"&gt;
&lt;tr style="page-break-inside: avoid;"&gt;
&lt;td style="width: 5%;"&gt;&#160;&lt;/td&gt;
&lt;td style="width: 3%; vertical-align: top;;text-align:left;"&gt;&#x2022;&lt;/td&gt;
&lt;td style="width: 1%; vertical-align: top;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: top;;text-align:left;"&gt; &lt;div style="text-align: left; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"&gt;Level &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;1-Valuations&lt;/div&gt; are based on unadjusted quoted prices in active markets for identical assets or liabilities that the Company has the ability to access. &lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; &lt;div style="clear: both; max-height: 0px;"/&gt; &lt;div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;"&gt;
&lt;tr style="page-break-inside: avoid;"&gt;
&lt;td style="width: 5%;"&gt;&#160;&lt;/td&gt;
&lt;td style="width: 3%; vertical-align: top;;text-align:left;"&gt;&#x2022;&lt;/td&gt;
&lt;td style="width: 1%; vertical-align: top;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: top;;text-align:left;"&gt; &lt;div style="text-align: left; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"&gt;Level &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;2-Valuations&lt;/div&gt; are based on quoted prices for similar assets or liabilities in active markets, quoted prices for identical or similar assets or liabilities in markets that are not active and models for which all significant inputs are observable, either directly or indirectly. &lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; &lt;div style="clear: both; max-height: 0px;"/&gt; &lt;div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;"&gt;
&lt;tr style="page-break-inside: avoid;"&gt;
&lt;td style="width: 5%;"&gt;&#160;&lt;/td&gt;
&lt;td style="width: 3%; vertical-align: top;;text-align:left;"&gt;&#x2022;&lt;/td&gt;
&lt;td style="width: 1%; vertical-align: top;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: top;;text-align:left;"&gt; &lt;div style="text-align: left; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"&gt;Level &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;3-Valuations&lt;/div&gt; are based on inputs that are unobservable (supported by little or no market activity) and significant to the overall fair value measurement. &lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; &lt;div style="clear: both; max-height: 0px;"/&gt; &lt;div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;To the extent the valuation is based on models or inputs that are less observable or unobservable in the market, the determination of fair value requires more judgment. Accordingly, the degree of judgment exercised by the Company in determining fair value is greatest for instruments categorized in Level&#160;3. A financial instrument&#x2019;s level within the fair value hierarchy is based on the lowest level of any input that is significant to the fair value measurement. &lt;/div&gt;&lt;/div&gt; &lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;The Company&#x2019;s financial instruments include shares of common stock of Arbutus Biopharma Corporation (&#x201c;Arbutus&#x201d;); shares of Arbutus&#x2019;s Series A participating convertible preferred shares (&#x201c;Arbutus Preferred Shares&#x201d;); shares of common stock of Sio Gene Therapies Inc. (&#x201c;Sio&#x201d;); liability instruments issued, including options granted to Sumitomo (the &#x201c;Sumitomo Options&#x201d;) to purchase all, or 75% in one case, of RSL&#x2019;s ownership interests in certain subsidiaries under the Sumitomo Transaction Agreement; deferred consideration liability; its investments in other entities; cash and cash equivalents consisting of money market funds; accounts payable; and long-term debt. &lt;/div&gt;&lt;/div&gt; &lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;The shares of Arbutus and Sio common stock and investments in common stock with a readily determinable fair value are classified as Level&#160;1, and their fair value is determined based upon quoted market prices in an active market. The Arbutus Preferred Shares held by the Company are classified as Level&#160;2 as the fair value of such preferred shares is determined based upon the quoted market price of Arbutus common stock into which such preferred shares are convertible. The liability instruments issued, including the Sumitomo Options, are classified as Level&#160;3 within the fair value hierarchy as the assumptions and estimates used in the valuations are unobservable in the market. Cash, accounts payable, and deferred consideration liability are stated at their respective historical carrying amounts, which approximate fair value due to their short-term nature. The deferred consideration liability is based on a fixed monetary amount, and payment is based solely on the passage of time. Money market funds are included in Level&#160;1 of the fair value hierarchy and are valued at the closing price reported by an actively traded exchange. The carrying value of long-term debt issued by Dermavant Sciences Ltd. (together with its wholly owned subsidiaries, &#x201c;Dermavant&#x201d;), which is stated at amortized cost, approximates fair value&#160;based on current interest rates for similar types of borrowings and therefore is included in Level&#160;2 of the fair value hierarchy. Long-term debt issued by Dermavant for which the fair value option has been elected is included in Level&#160;3 of the fair value hierarchy as the assumptions and estimates used in the valuation are unobservable in the market. &lt;/div&gt;&lt;/div&gt; </us-gaap:FairValueMeasurementPolicyPolicyTextBlock>
    <us-gaap:ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock contextRef="P04_01_2020To03_31_2021">&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;(O) Foreign Currency &lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Assets and liabilities of foreign operations are translated using exchange rates in effect at the balance sheet date and their results of operations are translated using average exchange rates for the year. Certain transactions of the Company and its subsidiaries are denominated in currencies other than their functional currency. Adjustments resulting from the translation of the financial statements of the Company&#x2019;s foreign functional currency subsidiaries into U.S. dollars are excluded from the determination of net loss and are accumulated in a separate component of shareholders&#x2019; equity. Foreign exchange transaction gains and losses are included in &#x201c;Other expense, net&#x201d; in the Company&#x2019;s statements of operations. &lt;/div&gt;&lt;/div&gt;</us-gaap:ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock>
    <us-gaap:RevenueFromContractWithCustomerPolicyTextBlock contextRef="P04_01_2020To03_31_2021">&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;(P) Revenue Recognition &lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;The Company recognizes revenue when its customer obtains control of promised goods or services, in an amount that reflects the consideration which the Company expects to receive in exchange for those goods or services. To determine revenue recognition for its arrangements, the Company performs the following five steps: (i)&#160;identify the contract(s) with a customer; (ii)&#160;identify the performance obligations in the contract; (iii)&#160;determine the transaction price; (iv)&#160;allocate the transaction price to the performance obligations in the contract; and (v)&#160;recognize revenue when or as the Company satisfies a performance obligation. &lt;/div&gt;&lt;/div&gt; &lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;The Company applies significant judgment when evaluating whether contractual obligations represent distinct performance obligations, allocating transaction price to performance obligations within a contract, determining &lt;/div&gt;&lt;/div&gt; &lt;div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;when performance obligations have been met, assessing the recognition and future reversal of variable consideration, and determining and applying appropriate methods of measuring progress for performance obligations satisfied over time. These judgments are discussed in more detail below. &lt;/div&gt;&lt;/div&gt; &lt;div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;"&gt;
&lt;tr style="page-break-inside: avoid;"&gt;
&lt;td style="width: 5%;"&gt;&#160;&lt;/td&gt;
&lt;td style="width: 3%; vertical-align: top;;text-align:left;"&gt;&#x2022;&lt;/td&gt;
&lt;td style="width: 1%; vertical-align: top;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: top;;text-align:left;"&gt; &lt;div style="text-align: left; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"&gt;&lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;Licenses of intellectual property:&lt;/div&gt;&lt;/div&gt; If the licenses to intellectual property are determined to be distinct from the other performance obligations identified in the arrangement, the Company recognizes revenues from &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;non-refundable,&lt;/div&gt; upfront fees allocated to the license when the license is transferred to the licensee and the licensee is able to use and benefit from the license. For licenses that are not distinct from other promises, the Company applies judgment to assess the nature of the combined performance obligation to determine whether the combined performance obligation is satisfied over time or at a point in time and, if over time, the appropriate method of measuring progress for purposes of recognizing revenue from &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;non-refundable,&lt;/div&gt; upfront fees. The Company evaluates the measure of progress each reporting period and, if necessary, adjusts the related revenue recognition accordingly. &lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; &lt;div style="clear: both; max-height: 0px;"/&gt; &lt;div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;"&gt;
&lt;tr style="page-break-inside: avoid;"&gt;
&lt;td style="width: 5%;"&gt;&#160;&lt;/td&gt;
&lt;td style="width: 3%; vertical-align: top;;text-align:left;"&gt;&#x2022;&lt;/td&gt;
&lt;td style="width: 1%; vertical-align: top;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: top;;text-align:left;"&gt; &lt;div style="text-align: left; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"&gt;&lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;Milestone payments: &lt;/div&gt;&lt;/div&gt;At the inception of each arrangement that includes research, development or regulatory milestone payments, the Company&lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt; &lt;/div&gt;&lt;/div&gt;evaluates whether the milestones are considered probable of being reached and estimates the amount to be included in the transaction price using the most likely amount method. If it is probable that a significant revenue reversal would not occur, the associated milestone value is included in the transaction price. Milestone payments that are not within the control of the Company or the licensee, such as regulatory approvals, are not considered probable of being achieved until those approvals are received. The transaction price is then allocated to each performance obligation on a relative standalone selling price basis, for which the Company recognizes revenue as or when the performance obligations under the contract are satisfied. At the end of each subsequent reporting period, the Company &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;re-evaluates&lt;/div&gt; the probability of achievement of such development milestones and any related constraint, and if necessary, adjusts its estimate of the overall transaction price on a cumulative &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;catch-up&lt;/div&gt; basis in earnings in the period of the adjustment. &lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; &lt;div style="clear: both; max-height: 0px;"/&gt; &lt;div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;"&gt;
&lt;tr style="page-break-inside: avoid;"&gt;
&lt;td style="width: 5%;"&gt;&#160;&lt;/td&gt;
&lt;td style="width: 3%; vertical-align: top;;text-align:left;"&gt;&#x2022;&lt;/td&gt;
&lt;td style="width: 1%; vertical-align: top;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: top;;text-align:left;"&gt; &lt;div style="text-align: left; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"&gt;&lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;Royalties and commercial milestone payments: &lt;/div&gt;&lt;/div&gt;For arrangements that include sales-based royalties, including commercial milestone payments&lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt; &lt;/div&gt;&lt;/div&gt;based on a &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;pre-specified&lt;/div&gt; level of sales, the Company recognizes revenue at the later of (i)&#160;when the related sales occur, or (ii)&#160;when the performance obligation to which some or all of the royalty has been allocated has been satisfied (or partially satisfied). Achievement of these royalties and commercial milestones may solely depend upon performance of the licensee. &lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; &lt;div style="clear: both; max-height: 0px;"/&gt; &lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Revenue is also generated by certain technology-focused Vants from subscription and service-based fees recognized for the use of certain technology developed by these Vants. Subscription revenue is recognized ratably over the contract period. &lt;/div&gt;&lt;/div&gt; </us-gaap:RevenueFromContractWithCustomerPolicyTextBlock>
    <us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock contextRef="P04_01_2020To03_31_2021">&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;(Q) Recently Adopted Accounting Pronouncements &lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;In June 2016, the FASB issued ASU &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;No.&#160;2016-13,&lt;/div&gt; &#x201c;Financial Instruments-Credit Losses (Topic 326): Measurement of Credit Losses on Financial Instruments&#x201d; (&#x201c;ASU &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;No.&#160;2016-13&#x201d;),&lt;/div&gt; which requires the measurement and recognition of expected credit losses for financial assets held at amortized cost. ASU &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;No.&#160;2016-13&lt;/div&gt; replaces the existing incurred loss impairment model with an expected loss model that requires the use of forward-looking information to calculate credit loss estimates. It also eliminates the concept of other-than-temporary impairment and requires credit losses on &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;available-for-sale&lt;/div&gt;&lt;/div&gt; debt securities to be recorded through an allowance for credit losses instead of as a reduction in the amortized cost basis of the securities. ASU &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;No.&#160;2016-13&lt;/div&gt; is effective for fiscal years beginning after December&#160;15, 2019 and interim periods within those fiscal years. The adoption of ASU &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;No.&#160;2016-13&lt;/div&gt; on April&#160;1, 2020 did not have a material impact on the Company&#x2019;s consolidated financial statements. &lt;/div&gt;</us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock>
    <roiv:NewAccountingPronouncementsNotYetAdoptedPolicyTextBlock contextRef="P04_01_2020To03_31_2021">&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;(R) Recently Issued Accounting Pronouncements Not Yet Adopted &lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;In August 2020, the FASB issued ASU &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;No.&#160;2020-06,&lt;/div&gt; &#x201c;Debt&#x2014;Debt with Conversion and Other Options (Subtopic &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;470-20)&lt;/div&gt; and Derivatives and Hedging&#x2014;Contracts in Entity&#x2019;s Own Equity (Subtopic &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;815-40):&lt;/div&gt; Accounting for &lt;/div&gt; &lt;div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;Convertible Instruments and Contracts in an Entity&#x2019;s Own Equity&#x201d; (&#x201c;ASU &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;No.&#160;2020-06&#x201d;).&lt;/div&gt; ASU &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;No.&#160;2020-06&lt;/div&gt; will simplify the accounting for convertible instruments by reducing the number of accounting models for convertible debt instruments and convertible preferred stock. Limiting the accounting models will result in fewer embedded conversion features being separately recognized from the host contract as compared with current GAAP. ASU &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;No.&#160;2020-06&lt;/div&gt; also removes certain settlement conditions that are required for equity contracts to qualify for the derivatives scope exception, which will permit more equity contracts to qualify for it. Either a modified retrospective transition method or a fully retrospective transition method is permissible for the adoption of this standard. Update &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;No.&#160;2020-06&lt;/div&gt; is effective for fiscal years beginning after December&#160;15, 2021, including interim periods within those fiscal years. Early adoption is permitted no earlier than the fiscal year beginning after December&#160;15, 2020. The adoption of ASU &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;No.&#160;2020-06&lt;/div&gt; is not expected to have a material impact on the Company&#x2019;s consolidated financial statements. &lt;/div&gt; </roiv:NewAccountingPronouncementsNotYetAdoptedPolicyTextBlock>
    <us-gaap:InvestmentsAndOtherNoncurrentAssetsTextBlock contextRef="P04_01_2020To03_31_2021">&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Note 3&#x2014;Investments &lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;(A) Investments Measured at Fair Value &lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;&lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;Investment in Arbutus &lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;RSL owns 16,013,540 shares of common stock of Arbutus and 1,164,000 Arbutus Preferred Shares that are mandatorily convertible into shares of Arbutus common stock on October&#160;18, 2021 subject to conversion earlier upon a sale, merger or other transaction considered a fundamental change of control of Arbutus. The Arbutus Preferred Shares are &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;non-voting&lt;/div&gt; and are convertible into common shares of Arbutus based on the subscription price plus 8.75% per annum, compounded annually, divided by a conversion price of $7.13 per share (which represented a 15% premium to the closing price of $6.20 per share on September&#160;29, 2017). RSL&#x2019;s investments in Arbutus have been measured using the fair value option. Due to the Company&#x2019;s significant influence over operating and financial policies, Arbutus is considered a related party of the Company. &lt;/div&gt; &lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;After conversion of the Arbutus Preferred Shares into common shares, based on the number of Arbutus&#x2019;s common shares outstanding on October&#160;2, 2017, the Company would hold&#160;49.90%&#160;of Arbutus&#x2019;s common shares. In addition, the Company agreed to a four-year standstill to not acquire greater than 49.99% of common shares or securities convertible into common shares of Arbutus. &lt;/div&gt;&lt;/div&gt; &lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;At March&#160;31, 2021 and 2020, the aggregate fair value of the Company&#x2019;s investment in Arbutus was $129.4&#160;million and $39.2&#160;million, respectively, with the Company recognizing an unrealized gain on its investments in Arbutus of $90.2&#160;million and an unrealized loss of $99.9&#160;million in the accompanying consolidated statements of operations for the years ended March&#160;31, 2021 and 2020, respectively. The fair value of the common stock and preferred shares held by the Company was determined using the closing price of Arbutus&#x2019;s common stock on March&#160;31, 2021 and 2020 of $3.33 and $1.01, respectively. &lt;/div&gt;&lt;/div&gt; &lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"&gt;&lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;Investment in Sio &lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Following the completion of Sio&#x2019;s underwritten public offering in February 2020, RSL&#x2019;s ownership interest fell below 50.0%. As such, the Company no longer has a controlling financial interest in Sio. Accordingly, the Company deconsolidated Sio in February 2020. Due to the Company&#x2019;s significant influence over operating and financial policies, Sio remains a related party of the Company following deconsolidation. As the Company still has the ability to exercise significant influence over the operating and financial policies of Sio, the Company has determined that its retained interest represents an equity method investment after the date of deconsolidation. Upon deconsolidation, the retained interest was recorded at fair market value based on the closing price of Sio&#x2019;s common stock. The Company recognized a gain on deconsolidation of $107.3&#160;million in the accompanying consolidated statements of operations for the year ended March&#160;31, 2020. The fair value option was elected to continuously remeasure the investment to fair value each reporting period after the initial measurement. &lt;/div&gt;&lt;/div&gt; &lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;At March&#160;31, 2021 and 2020, the fair value of the Company&#x2019;s investment in Sio was $48.5&#160;million&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt; &lt;/div&gt;&lt;/div&gt;and&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt; &lt;/div&gt;&lt;/div&gt;$45.3&#160;million, respectively, with the Company recognizing an unrealized gain on its investment in Sio of &lt;/div&gt; &lt;div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;$3.2&#160;million and an unrealized loss of $31.6&#160;million in the accompanying consolidated statements of operations for the years ended March&#160;31, 2021 and 2020, respectively. The fair value of common shares held by the Company was determined using the closing price of Sio&#x2019;s common stock on March&#160;31, 2021 and 2020 of $2.61 and $2.44, respectively. &lt;/div&gt;&lt;/div&gt; &lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"&gt;&lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;Other Investment &lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;The Company holds an additional equity investment that is measured using the fair value option. The fair value of this investment was $11.1&#160;million and $8.9&#160;million as of March&#160;31, 2021 and 2020, respectively. &lt;/div&gt;&lt;/div&gt; &lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;(B) Investment Accounted for Using Measurement Alternative &lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;&lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;Investment in Datavant &lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;In April 2020, Datavant Holdings, Inc. (&#x201c;Datavant&#x201d;) completed an initial round of a Series B equity raise by which 13,411,311 Series B preferred shares were issued in April 2020 for gross proceeds of $27.2&#160;million, including 1,065,234 Series B preferred shares issued and sold to RSL for a total purchase price of $2.5&#160;million and 1,800,253 Series B shares issued relating to the conversion of certain liability instruments. As a result of this transaction, along with a restructuring of Datavant&#x2019;s equity classes, RSL no longer controls Datavant. As such, the Company deconsolidated Datavant as of April 2020. Due to the Company&#x2019;s significant influence over operating and financial policies, Datavant remains a related party of the Company following deconsolidation. Upon deconsolidation, the Company recorded its investment in Datavant based on the fair value of Datavant preferred shares held of $99.0&#160;million. The Company accounts for its investment in Datavant using the measurement alternative to fair value. The investment will be remeasured upon future observable price changes in orderly transactions or upon impairment, if any. The Company recognized a gain on deconsolidation of $86.5&#160;million in the accompanying consolidated statements of operations for the year ended March&#160;31, 2021. In July 2020, Datavant issued and sold 639,140 Series B preferred shares to RSL at a price consistent with that of the initial round of Datavant&#x2019;s Series B equity raise. At March&#160;31, 2021, the carrying value of the Company&#x2019;s investment in Datavant was $100.6&#160;million. &lt;/div&gt;&lt;/div&gt; </us-gaap:InvestmentsAndOtherNoncurrentAssetsTextBlock>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="PAsOn03_31_2020_ArbutusBiopharmaCorporationMemberdeiLegalEntityAxis"
      decimals="0"
      unitRef="Unit_shares">16013540</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="PAsOn03_31_2021_ArbutusBiopharmaCorporationMemberdeiLegalEntityAxis"
      decimals="0"
      unitRef="Unit_shares">16013540</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:PreferredStockSharesOutstanding
      contextRef="PAsOn03_31_2020_ArbutusBiopharmaCorporationMemberdeiLegalEntityAxis"
      decimals="0"
      unitRef="Unit_shares">1164000</us-gaap:PreferredStockSharesOutstanding>
    <us-gaap:PreferredStockSharesOutstanding
      contextRef="PAsOn03_31_2021_ArbutusBiopharmaCorporationMemberdeiLegalEntityAxis"
      decimals="0"
      unitRef="Unit_shares">1164000</us-gaap:PreferredStockSharesOutstanding>
    <roiv:AnnualCompoundedConversionRateForPreferredShare
      contextRef="P04_01_2020To03_31_2021_ArbutusBiopharmaCorporationMemberdeiLegalEntityAxis"
      decimals="4"
      unitRef="Unit_pure">0.0875</roiv:AnnualCompoundedConversionRateForPreferredShare>
    <roiv:ConversionPrice
      contextRef="PAsOn03_31_2021_ArbutusBiopharmaCorporationMemberdeiLegalEntityAxis"
      decimals="2"
      unitRef="Unit_USD_per_Share">7.13</roiv:ConversionPrice>
    <roiv:PremiumOnConversionPricePercentage
      contextRef="P09_29_2017To09_29_2017_ArbutusBiopharmaCorporationMemberdeiLegalEntityAxis"
      decimals="2"
      unitRef="Unit_pure">0.15</roiv:PremiumOnConversionPricePercentage>
    <roiv:ClosingPricePerShare
      contextRef="PAsOn09_29_2017_ArbutusBiopharmaCorporationMemberdeiLegalEntityAxis"
      decimals="2"
      unitRef="Unit_USD_per_Share">6.20</roiv:ClosingPricePerShare>
    <roiv:OwnershipInterestPercentage
      contextRef="PAsOn12_31_2020_ArbutusBiopharmaCorporationMemberdeiLegalEntityAxis"
      decimals="4"
      unitRef="Unit_pure">0.4990</roiv:OwnershipInterestPercentage>
    <roiv:MaximumAllowedOwnershipInterestPercentage
      contextRef="P04_01_2020To12_31_2020_ArbutusBiopharmaCorporationMemberdeiLegalEntityAxis"
      decimals="4"
      unitRef="Unit_pure">0.4999</roiv:MaximumAllowedOwnershipInterestPercentage>
    <us-gaap:InvestmentsFairValueDisclosure
      contextRef="PAsOn03_31_2021_ArbutusBiopharmaCorporationMemberdeiLegalEntityAxis"
      decimals="-5"
      unitRef="Unit_USD">129400000</us-gaap:InvestmentsFairValueDisclosure>
    <us-gaap:InvestmentsFairValueDisclosure
      contextRef="PAsOn03_31_2020_ArbutusBiopharmaCorporationMemberdeiLegalEntityAxis"
      decimals="-5"
      unitRef="Unit_USD">39200000</us-gaap:InvestmentsFairValueDisclosure>
    <us-gaap:UnrealizedGainLossOnInvestments
      contextRef="P04_01_2020To03_31_2021_ArbutusBiopharmaCorporationMemberdeiLegalEntityAxis"
      decimals="-5"
      unitRef="Unit_USD">90200000</us-gaap:UnrealizedGainLossOnInvestments>
    <us-gaap:UnrealizedGainLossOnInvestments
      contextRef="P04_01_2019To03_31_2020_ArbutusBiopharmaCorporationMemberdeiLegalEntityAxis"
      decimals="-5"
      unitRef="Unit_USD">99900000</us-gaap:UnrealizedGainLossOnInvestments>
    <us-gaap:SharePrice
      contextRef="PAsOn03_31_2021_ArbutusBiopharmaCorporationMemberdeiLegalEntityAxis"
      decimals="2"
      unitRef="Unit_USD_per_Share">3.33</us-gaap:SharePrice>
    <us-gaap:SharePrice
      contextRef="PAsOn03_31_2020_ArbutusBiopharmaCorporationMemberdeiLegalEntityAxis"
      decimals="2"
      unitRef="Unit_USD_per_Share">1.01</us-gaap:SharePrice>
    <us-gaap:DeconsolidationGainOrLossAmount
      contextRef="P04_01_2019To03_31_2020_SioGeneTherapiesIncMemberdeiLegalEntityAxis"
      decimals="-5"
      unitRef="Unit_USD">107300000</us-gaap:DeconsolidationGainOrLossAmount>
    <us-gaap:InvestmentsFairValueDisclosure
      contextRef="PAsOn03_31_2021_SioGeneTherapiesIncMemberdeiLegalEntityAxis"
      decimals="-5"
      unitRef="Unit_USD">48500000</us-gaap:InvestmentsFairValueDisclosure>
    <us-gaap:InvestmentsFairValueDisclosure
      contextRef="PAsOn03_31_2020_SioGeneTherapiesIncMemberdeiLegalEntityAxis"
      decimals="-5"
      unitRef="Unit_USD">45300000</us-gaap:InvestmentsFairValueDisclosure>
    <us-gaap:UnrealizedGainLossOnInvestments
      contextRef="P04_01_2020To03_31_2021_SioGeneTherapiesIncMemberdeiLegalEntityAxis"
      decimals="-5"
      unitRef="Unit_USD">3200000</us-gaap:UnrealizedGainLossOnInvestments>
    <us-gaap:UnrealizedGainLossOnInvestments
      contextRef="P04_01_2019To03_31_2020_SioGeneTherapiesIncMemberdeiLegalEntityAxis"
      decimals="-5"
      unitRef="Unit_USD">31600000</us-gaap:UnrealizedGainLossOnInvestments>
    <us-gaap:SharePrice
      contextRef="PAsOn03_31_2021_SioGeneTherapiesIncMemberdeiLegalEntityAxis"
      decimals="2"
      unitRef="Unit_USD_per_Share">2.61</us-gaap:SharePrice>
    <us-gaap:SharePrice
      contextRef="PAsOn03_31_2020_SioGeneTherapiesIncMemberdeiLegalEntityAxis"
      decimals="2"
      unitRef="Unit_USD_per_Share">2.44</us-gaap:SharePrice>
    <us-gaap:InvestmentsFairValueDisclosure
      contextRef="PAsOn03_31_2021_OtherInvestmentCompaniesMemberusgaapInvestmentTypeAxis"
      decimals="-5"
      unitRef="Unit_USD">11100000</us-gaap:InvestmentsFairValueDisclosure>
    <us-gaap:InvestmentsFairValueDisclosure
      contextRef="PAsOn03_31_2020_OtherInvestmentCompaniesMemberusgaapInvestmentTypeAxis"
      decimals="-5"
      unitRef="Unit_USD">8900000</us-gaap:InvestmentsFairValueDisclosure>
    <roiv:PreferredStockSharesIssuedAndSoldToCompanyDuringPeriodShares
      contextRef="PAsOn04_30_2020"
      decimals="INF"
      unitRef="Unit_shares">13411311</roiv:PreferredStockSharesIssuedAndSoldToCompanyDuringPeriodShares>
    <roiv:ProceedsFromIssuanceOfPreferredStockAndPreferenceStocks
      contextRef="PAsOn04_30_2020_DatavantHoldingsIncMemberdeiLegalEntityAxis_SeriesBPreferredStockMemberusgaapStatementClassOfStockAxis"
      decimals="-5"
      unitRef="Unit_USD">27200000</roiv:ProceedsFromIssuanceOfPreferredStockAndPreferenceStocks>
    <roiv:PreferredStockSharesIssuedAndSoldToCompanyDuringPeriodShares
      contextRef="PAsOn04_30_2020_DatavantHoldingsIncMemberdeiLegalEntityAxis_SeriesBPreferredStockMemberusgaapStatementClassOfStockAxis"
      decimals="0"
      unitRef="Unit_shares">1065234</roiv:PreferredStockSharesIssuedAndSoldToCompanyDuringPeriodShares>
    <roiv:PreferredStockPurchased
      contextRef="PAsOn04_30_2020_DatavantHoldingsIncMemberdeiLegalEntityAxis_SeriesBPreferredStockMemberusgaapStatementClassOfStockAxis"
      decimals="-5"
      unitRef="Unit_USD">2500000</roiv:PreferredStockPurchased>
    <us-gaap:ConvertiblePreferredStockSharesIssuedUponConversion
      contextRef="PAsOn04_30_2020_DatavantHoldingsIncMemberdeiLegalEntityAxis_SeriesBPreferredStockMemberusgaapStatementClassOfStockAxis"
      decimals="0"
      unitRef="Unit_shares">1800253</us-gaap:ConvertiblePreferredStockSharesIssuedUponConversion>
    <us-gaap:InvestmentsFairValueDisclosure
      contextRef="PAsOn03_31_2021_DatavantHoldingsIncMemberdeiLegalEntityAxis"
      decimals="-5"
      unitRef="Unit_USD">99000000.0</us-gaap:InvestmentsFairValueDisclosure>
    <us-gaap:DeconsolidationGainOrLossAmount
      contextRef="P04_01_2020To03_31_2021_DatavantHoldingsIncMemberdeiLegalEntityAxis"
      decimals="-5"
      unitRef="Unit_USD">86500000</us-gaap:DeconsolidationGainOrLossAmount>
    <roiv:PreferredStockSharesIssuedAndSoldToCompanyDuringPeriodShares
      contextRef="PAsOn07_31_2021"
      decimals="INF"
      unitRef="Unit_shares">639140</roiv:PreferredStockSharesIssuedAndSoldToCompanyDuringPeriodShares>
    <us-gaap:LongTermInvestments
      contextRef="PAsOn03_31_2021_DatavantHoldingsIncMemberdeiLegalEntityAxis"
      decimals="-5"
      unitRef="Unit_USD">100600000</us-gaap:LongTermInvestments>
    <roiv:AssetAcquisitionsAndLicenseAgreementsDisclosureTextBlock contextRef="P04_01_2020To03_31_2021">&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Note 4&#x2014;Asset Acquisitions and License Agreements &lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;During the years ended March&#160;31, 2021 and 2020, the Company, directly or indirectly through Vants, completed the following key asset acquisitions and license agreements. The Company evaluated the below agreements, except the collaboration and license agreement entered into between Dermavant and Japan Tobacco Inc. that is evaluated separately below, and determined that the acquired assets did not meet the definition of a business as substantially all the fair value of the assets acquired were concentrated in a single asset or group of similar assets and/or the acquired assets were not capable of producing outputs due to the lack of an assembled workforce and early stage of development and thus, each transaction was accounted for as an asset acquisition. &lt;/div&gt;&lt;/div&gt; &lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;The Company then evaluated whether each &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;in-process&lt;/div&gt; research and development asset had an alternative future use and concluded it did not. As a result, the Company recorded the consideration attributable to &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;in-process&lt;/div&gt; research and development under the below agreements as research and development expense in the accompanying consolidated statements of operations for the years ended March&#160;31, 2021 and 2020. &lt;/div&gt; &lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;Dermavant &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;In August 2018, Dermavant acquired the worldwide rights (other than with respect to certain rights in China) to tapinarof, an investigational therapeutic aryl hydrocarbon receptor modulating agent for the treatment of psoriasis and atopic dermatitis, from GlaxoSmithKline Intellectual Property Development Ltd. and Glaxo Group Limited (collectively &#x201c;GSK&#x201d;) pursuant to an asset purchase agreement (the &#x201c;GSK Agreement&#x201d;). GSK previously acquired rights to a predecessor formulation of tapinarof from Welichem Biotech Inc. (&#x201c;Welichem&#x201d;) pursuant to an asset &lt;/div&gt;&lt;/div&gt; &lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;purchase agreement between GSK and Welichem entered into in May 2012 (the &#x201c;Welichem Agreement&#x201d;). Under the GSK Agreement, Dermavant made an upfront payment of &#xa3;150.0&#160;million (approximately $191 million) and agreed to a contingent payment of &#xa3;100.0&#160;million (approximately $133 million) upon the first approval of an NDA by the FDA for a product that contains tapinarof. Dermavant assumed responsibility for all obligations under the Welichem Agreement, including payment of up to C$180.0&#160;million (approximately $137 million) in potential development and commercial milestones. The purchase was funded in part by a $117.5&#160;million borrowing from NovaQuest &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Co-Investment&lt;/div&gt; Fund VIII, L.P. (&#x201c;NovaQuest&#x201d;), an affiliate of NovaQuest Capital Management, LLC, as described in Note 8, &#x201c;Long-Term Debt.&#x201d; In connection with the GSK Agreement, Dermavant and GSK have entered into a clinical manufacturing and supply agreement for tapinarof pursuant to which Dermavant will obtain supply of tapinarof for clinical trials on a cost-plus basis. In May 2019, Dermavant achieved a development and regulatory milestone under the GSK Agreement, which resulted in a C$30.0&#160;million (approximately $23 million) milestone payment that Dermavant subsequently paid to Welichem in August 2019. The milestone payment was recorded as research and development expense in the accompanying consolidated statements of operations for the year ended March&#160;31, 2020. &lt;/div&gt; &lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;In January 2020, Dermavant entered into a collaboration and license agreement with Japan Tobacco Inc. (&#x201c;JT&#x201d;) for exclusive rights to develop, register, and market tapinarof in Japan for the treatment of dermatological diseases and conditions, including psoriasis and atopic dermatitis. In conjunction with this agreement, JT executed an exclusive license agreement with its subsidiary, Torii Pharmaceutical Co., Ltd., for &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;co-development&lt;/div&gt; and commercialization of tapinarof in Japan. Under the terms of the license agreement, Dermavant received a nonrefundable, upfront payment of $60.0&#160;million in January 2020 and may receive up to $53.0&#160;million upon the achievement of certain development milestones for tapinarof for the treatment of psoriasis and atopic dermatitis. In addition, Dermavant will have the right to receive royalties based on product sales of tapinarof in the indications. &lt;/div&gt; &lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;The Company evaluated the collaboration and license agreement and concluded that JT is a customer. The Company&#x2019;s performance obligations under the agreement are the following: (i)&#160;an exclusive license to JT of the right to develop, register and market tapinarof in Japan and (ii)&#160;the associated transfer to JT of technology and &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;know-how&lt;/div&gt; related to the license. The Company determined that the monetary value of participation in the Joint Steering Committee under the agreement was immaterial in the context of the contract and therefore was disregarded when identifying the performance obligations. The Company determined that the exclusive license is not capable of being distinct from the associated technology transfer because the customer cannot benefit from or utilize the license without the technology and &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;know-how&lt;/div&gt; transfer and as such does not have standalone value as JT cannot benefit from the exclusive license without the associated technology and &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;know-how&lt;/div&gt; transfer. Accordingly, the Company concluded that these performance obligations should be combined into a single performance obligation. &lt;/div&gt; &lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;Based on management&#x2019;s evaluation, the &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;non-refundable,&lt;/div&gt; &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;up-front&lt;/div&gt; payment of $60.0&#160;million constituted the amount of consideration to be included in the transaction price. The remaining $53.0&#160;million of consideration related to potential development and regulatory approval milestones constitutes variable consideration and has not been recognized because of the inherent uncertainty of the occurrence of the future events and because it is highly susceptible to factors outside of the Company&#x2019;s control. Any consideration related to potential royalty payments will be recognized when the related sales occur, since these amounts have been determined to relate predominantly to the license granted to JT and therefore are recognized at the later of when the performance obligations are satisfied or the related sales occur.&#160;The Company will &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;re-evaluate&lt;/div&gt; the transaction price in each reporting period and as uncertain events are resolved or other changes in circumstances occur. Upon transfer of the technology and &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;know-how&lt;/div&gt; related to the license, the Company recognized the $60.0&#160;million &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;non-refundable&lt;/div&gt; upfront payment as license revenue in the accompanying consolidated statements of operations for the year ended March&#160;31, 2020. &lt;/div&gt; &lt;div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;  &lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;Genevant &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;In July 2020, RSL increased its investment in Genevant Sciences Ltd. (&#x201c;Genevant&#x201d;) as part of a recapitalization transaction (the &#x201c;Recapitalization&#x201d;). Genevant, an entity focused on the discovery, development, and commercialization of a broad range of &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;RNA-based&lt;/div&gt; therapeutics enabled by Arbutus&#x2019; proprietary lipid nanoparticle and ligand conjugate delivery technologies, was created in April 2018 as part of an agreement between RSL and Arbutus. As part of the initial transaction entered into in April 2018, RSL contributed $38.7&#160;million in cash, including transaction costs, for an equity ownership interest in Genevant. Prior to the Recapitalization, RSL accounted for its investment in Genevant under the equity method of accounting as it had determined that it was not the primary beneficiary of Genevant since it did not have the power to direct its most significant activities. Additionally, RSL made additional investments in the form of promissory notes issued by Genevant amounting to $20.1&#160;million aggregate principal amount outstanding (the &#x201c;Genevant Outstanding Notes&#x201d;) prior to the Recapitalization. RSL applied its share of losses relating to its equity method investment in Genevant against the Company&#x2019;s carrying value of its investment in Genevant&#x2019;s common shares and against the carrying value of the Genevant Outstanding Notes. The carrying value of RSL&#x2019;s investment in Genevant was reduced to zero prior to the Recapitalization. &lt;/div&gt; &lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Pursuant to the Recapitalization, the following transactions were completed: &lt;/div&gt;&lt;/div&gt; &lt;div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;"&gt;
&lt;tr style="page-break-inside: avoid;"&gt;
&lt;td style="width: 5%;"&gt;&#160;&lt;/td&gt;
&lt;td style="width: 3%; vertical-align: top;;text-align:left;"&gt;&#x2022;&lt;/td&gt;
&lt;td style="width: 1%; vertical-align: top;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: top;;text-align:left;"&gt; &lt;div style="text-align: left; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Genevant issued 74,272,043 common shares to RSL for an aggregated purchase price of $20.5&#160;million; &lt;/div&gt;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; &lt;div style="clear: both; max-height: 0px;"/&gt; &lt;div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;"&gt;
&lt;tr style="page-break-inside: avoid;"&gt;
&lt;td style="width: 5%;"&gt;&#160;&lt;/td&gt;
&lt;td style="width: 3%; vertical-align: top;;text-align:left;"&gt;&#x2022;&lt;/td&gt;
&lt;td style="width: 1%; vertical-align: top;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: top;;text-align:left;"&gt; &lt;div style="text-align: left; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;$15.1&#160;million aggregate principal amount of the Genevant Outstanding Notes were converted into 54,526,549 common shares; and &lt;/div&gt;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; &lt;div style="clear: both; max-height: 0px;"/&gt; &lt;div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;"&gt;
&lt;tr style="page-break-inside: avoid;"&gt;
&lt;td style="width: 5%;"&gt;&#160;&lt;/td&gt;
&lt;td style="width: 3%; vertical-align: top;;text-align:left;"&gt;&#x2022;&lt;/td&gt;
&lt;td style="width: 1%; vertical-align: top;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: top;;text-align:left;"&gt; &lt;div style="text-align: left; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Genevant issued 9,057,566 common shares to Arbutus for an aggregated purchase price of $2.5&#160;million. &lt;/div&gt;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; &lt;div style="clear: both; max-height: 0px;"/&gt; &lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Following the Recapitalization, RSL held an 82.9% controlling interest in Genevant. &lt;/div&gt;&lt;/div&gt; &lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Concurrent with the Recapitalization, the composition of Genevant&#x2019;s Board of Directors was restructured to include two directors designated by RSL and one director who is a senior officer of Genevant. &lt;/div&gt;&lt;/div&gt; &lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;As a result of the Recapitalization and changes to the &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;bye-laws,&lt;/div&gt; RSL determined that it controls the most significant activities of Genevant and is the primary beneficiary of Genevant following the Recapitalization. As such, RSL began consolidating Genevant into the Company&#x2019;s consolidated financial statements from the date of the Recapitalization. The Company evaluated the acquired set of assets and activities and determined that the acquired set did not meet the definition of a business and thus the transaction was not considered a business combination. &lt;/div&gt; &lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;The transactions completed as part of the Recapitalization represent an acquisition achieved in stages, which required the remeasurement of RSL&#x2019;s previously held interest in Genevant. As such, RSL&#x2019;s investments in Genevant were remeasured to fair value of $28.8&#160;million, also resulting in a gain of $28.8&#160;million in the accompanying consolidated statements of operations for the year ended March&#160;31, 2021. Along with the fair value of noncontrolling interests in Genevant of $9.2&#160;million and cash paid of $20.5&#160;million for common shares of Genevant as part of the Recapitalization, total consideration paid was $58.5&#160;million. Of this amount, $41.4&#160;million was attributed to &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;in-process&lt;/div&gt; research and development, which was determined by the Company to have not reached technological feasibility and therefore have no alternative future use. Accordingly, the Company recorded $41.4&#160;million as research and development expense in the accompanying consolidated statements of operations for the year ended March&#160;31, 2021. &lt;/div&gt; &lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;Proteovant &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;In November 2020, Proteovant Sciences, Inc. (formerly known as Pharmavant 5, Inc.) (&#x201c;ProteoVant&#x201d;) entered into a stock purchase agreement to acquire Oncopia Therapeutics, Inc. (&#x201c;Oncopia&#x201d;), a preclinical biotechnology &lt;/div&gt;&lt;/div&gt;  &lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;company developing small molecule protein degraders primarily against certain oncology targets. Upfront proceeds to Oncopia&#x2019;s shareholders were $105.0&#160;million, prior to certain adjustments in accordance with the terms of the agreement. Proteovant is also obligated to make future development and commercial milestone payments of up to $100.0&#160;million for the first product targeting each of the two specified initial targets, and up to $51.0&#160;million for the first product targeting each of certain specified additional molecular targets. Additionally, the Company&#x2019;s investments in promissory notes issued by Oncopia for an aggregate principal amount of $11.5&#160;million were settled through either conversion to equity or cancellation. &lt;/div&gt;&lt;/div&gt; &lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;Oncopia&#x2019;s intellectual property was developed by the University of Michigan laboratory run by Oncopia&#x2019;s &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;co-founder&lt;/div&gt; (the &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#x201c;Co-Founder&#x201d;).&lt;/div&gt; In connection with Proteovant&#x2019;s acquisition, Oncopia amended and restated its existing license agreements with the University of Michigan. Under the new license agreement, Oncopia will be obligated to make future development and commercial milestone payments of up to $8.6&#160;million for the first product for each molecular target covered by intellectual property included in the agreement, in addition to paying tiered royalties on net sales ranging from &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;low-&lt;/div&gt; to &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;mid-single&lt;/div&gt; digits, subject to certain adjustments. &lt;/div&gt; &lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;The &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Co-Founder&#x2019;s&lt;/div&gt; lab at the University of Michigan had been providing &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;on-going&lt;/div&gt; discovery and optimization services to Oncopia under a sponsored research agreement (the &#x201c;SRA&#x201d;). Immediately after closing the acquisition, Oncopia extended the SRA through at least December&#160;31, 2023, and expanded the potential molecular targets to be pursued under the SRA. As revised, Oncopia is obligated to pay the University of Michigan approximately $15.5&#160;million under the SRA. &lt;/div&gt; &lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;Lastly, in connection with the acquisition of Oncopia, the &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Co-Founder&lt;/div&gt; entered into an agreement with the Company to serve as a consultant. In exchange for these services, the Company has agreed to grant the &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Co-Founder&lt;/div&gt; RSL restricted stock units for which the majority will vest upon achievement of development milestones for products directed to targets for which no milestones are payable to Oncopia shareholders and the remaining portion will be subject to time-based service requirements. All of these restricted stock units are subject to a liquidity requirement to vest. The Company will also make a cash payment to the &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Co-Founder&lt;/div&gt; upon achievement of development milestones for each such product. &lt;/div&gt; &lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;During the year ended March&#160;31, 2021, the Company recorded $116.5&#160;million, relating to the net upfront cash payment of $101.2&#160;million, settlement of promissory notes receivable, including accrued interest, of $11.9&#160;million, and fair value of future contingent consideration payments of $3.4&#160;million, as research and development expense in the accompanying consolidated statements of operations. &lt;/div&gt;&lt;/div&gt; &lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;In December 2020, RSL, Proteovant and SK, Inc. (formerly known as SK Holdings Co., Ltd.) (&#x201c;SK&#x201d;) entered into a subscription agreement (the &#x201c;Subscription Agreement&#x201d;) pursuant to which SK agreed to make a $200.0&#160;million equity investment in Proteovant, representing an ownership interest of 40.0% on the closing date. In January 2021, in accordance with the terms of the Subscription Agreement, SK made the first payment of $100.0&#160;million to Proteovant. A second $100.0&#160;million payment is expected to be made by SK to Proteovant on or about July&#160;12, 2021, the date six months from the closing date. The second $100.0&#160;million payment is classified as a subscription receivable in the accompanying consolidated balance sheets and consolidated statements of shareholders&#x2019; equity and redeemable noncontrolling interest as of March&#160;31, 2021. &lt;/div&gt;&lt;/div&gt; &lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;Affivant &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;In November 2020, RSL and its indirect subsidiary Affivant Sciences GmbH (&#x201c;Affivant&#x201d;) entered into a licensing and strategic collaboration agreement with Affimed N.V. (&#x201c;Affimed&#x201d;) to develop and commercialize novel innate cell engagers for multiple cancer targets in exchange for consideration that includes $40.0&#160;million in upfront cash and &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;pre-paid&lt;/div&gt; R&amp;amp;D funding and $20.0&#160;million of newly issued shares in RSL. Affimed could receive further short-term proceeds in the form of option fees contingent on the commencement of additional programs contemplated under the agreement. Affimed is eligible to receive up to an additional approximately $2.0&#160;billion in milestones over time upon achievement of specified development, regulatory and commercial milestones, as well as tiered royalties on net sales. &lt;/div&gt; &lt;div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;  &lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;Acquisition of Silicon Therapeutics &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;In March 2021, the Company completed the acquisition of the business of Silicon Therapeutics, LLC (&#x201c;SiTX&#x201d;), a physics-driven computational drug discovery company, for total consideration of approximately $450.0&#160;million, with additional cash payments payable subject to the satisfaction of certain regulatory and commercial milestones. This acquisition did not include one of SiTX&#x2019;s subsidiaries, Silicon SWAT, Inc. Approximately $350.0&#160;million of the consideration was payable primarily in the Company&#x2019;s common stock at or near closing of the acquisition (the &#x201c;First Tranche&#x201d;). At closing of the acquisition, the Company issued 7,316,583 common shares and paid approximately $14.0&#160;million in cash, net of cash received, to SiTX after giving effect to certain transaction adjustments and holdbacks. The remainder of the First Tranche is expected to be paid in a combination of common shares and cash as certain holdbacks are released. Approximately $100.0&#160;million (the &#x201c;Second Tranche Consideration&#x201d;) is payable to SiTX on the earlier of (x)&#160;approximately 30 to 60 days following the public listing of the Company&#x2019;s common shares, in either cash or common shares (at the Company&#x2019;s election), and (y) 12 months following the closing of the acquisition, in cash. &lt;/div&gt;&lt;/div&gt; &lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;The transaction was accounted for as an asset acquisition as substantially all of the fair value of the assets acquired were concentrated in a single asset, IPR&amp;amp;D related to the computational drug discovery platform that designs and develops small molecule therapeutics. For accounting purposes, the fair value of consideration transferred was $402.4&#160;million, consisting of $281.7&#160;million relating to the fair value of common shares issued upfront and expected to be issued shortly thereafter; $105.1&#160;million relating to the fair value of liabilities due to the sellers, including the Second Tranche Consideration, future contingent consideration payments, and closing consideration to be paid in cash; and cash of $15.6&#160;million paid at closing. Of this amount, $399.6&#160;million was attributed to IPR&amp;amp;D, which was determined to have no alternative future use. Accordingly, the Company recorded $399.6&#160;million as research and development expense in the accompanying consolidated statement of operations for the year ended March&#160;31, 2021. &lt;/div&gt;&lt;/div&gt; &lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;In connection with the transaction, the vesting of certain outstanding SiTX share-based compensation awards held by employees of SiTX was discretionarily accelerated at closing. As a result, the Company recorded share-based compensation expense of $23.5&#160;million in the accompanying consolidated statements of operations for the year ended March&#160;31, 2021. &lt;/div&gt;&lt;/div&gt; &lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;In addition, certain share-based compensation awards of SiTX were exchanged with restricted common stock of the Company, subject to certain service-based vesting requirements, with a fair value of $22.6&#160;million. Of this amount, $15.6 million was attributed to precombination service and therefore included in the total fair value of consideration transferred. Refer to Note 11, &#x201c;Share-Based Compensation,&#x201d; for additional detail regarding this restricted common stock. &lt;/div&gt;&lt;/div&gt; </roiv:AssetAcquisitionsAndLicenseAgreementsDisclosureTextBlock>
    <roiv:UpfrontCashPayments
      contextRef="P05_01_2012To05_31_2012_DermavantSciencesLtdMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis"
      decimals="-5"
      unitRef="Unit_EUR">150000000.0</roiv:UpfrontCashPayments>
    <roiv:UpfrontCashPayments
      contextRef="P05_01_2012To05_31_2012_DermavantSciencesLtdMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis"
      decimals="-6"
      unitRef="Unit_USD">191000000</roiv:UpfrontCashPayments>
    <roiv:BusinessCollaborationContingentMilestonePayment
      contextRef="P05_01_2012To05_31_2012_DermavantSciencesLtdMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis"
      decimals="-5"
      unitRef="Unit_EUR">100000000.0</roiv:BusinessCollaborationContingentMilestonePayment>
    <roiv:BusinessCollaborationContingentMilestonePayment
      contextRef="P05_01_2012To05_31_2012_DermavantSciencesLtdMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis"
      decimals="-6"
      unitRef="Unit_USD">133000000</roiv:BusinessCollaborationContingentMilestonePayment>
    <roiv:FutureDevelopmentAndCommercialMilestonePayments
      contextRef="P05_01_2012To05_31_2012_DermavantSciencesLtdMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis"
      decimals="-5"
      unitRef="Unit_CAD">180000000.0</roiv:FutureDevelopmentAndCommercialMilestonePayments>
    <roiv:FutureDevelopmentAndCommercialMilestonePayments
      contextRef="P05_01_2012To05_31_2012_DermavantSciencesLtdMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis"
      decimals="-6"
      unitRef="Unit_USD">137000000</roiv:FutureDevelopmentAndCommercialMilestonePayments>
    <us-gaap:LongTermDebt
      contextRef="PAsOn05_31_2012_DermavantSciencesLtdMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis"
      decimals="-5"
      unitRef="Unit_USD">117500000</us-gaap:LongTermDebt>
    <roiv:MilestonePayment
      contextRef="P08_01_2019To08_31_2019_DermavantSciencesLtdMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis"
      decimals="-5"
      unitRef="Unit_CAD">30000000.0</roiv:MilestonePayment>
    <roiv:MilestonePayment
      contextRef="P08_01_2019To08_31_2019_DermavantSciencesLtdMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis"
      decimals="-6"
      unitRef="Unit_USD">23000000</roiv:MilestonePayment>
    <roiv:NonRefundableUpfrontPaymentReceived
      contextRef="P01_01_2020To01_31_2020_DermavantSciencesLtdMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis"
      decimals="-5"
      unitRef="Unit_USD">60000000.0</roiv:NonRefundableUpfrontPaymentReceived>
    <roiv:PotentialMilestonePaymentReceivable
      contextRef="P01_01_2020To01_31_2020_DermavantSciencesLtdMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis"
      decimals="-5"
      unitRef="Unit_USD">53000000.0</roiv:PotentialMilestonePaymentReceivable>
    <roiv:NonRefundableUpfrontPaymentReceived
      contextRef="P01_01_2020To01_31_2020_DermavantSciencesLtdMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis"
      decimals="-5"
      unitRef="Unit_USD">60000000.0</roiv:NonRefundableUpfrontPaymentReceived>
    <roiv:PotentialMilestonePaymentReceivable
      contextRef="P01_01_2020To01_31_2020_DermavantSciencesLtdMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis"
      decimals="-5"
      unitRef="Unit_USD">53000000.0</roiv:PotentialMilestonePaymentReceivable>
    <us-gaap:RevenueRecognitionMilestoneMethodRevenueRecognized
      contextRef="P04_01_2019To03_31_2020_DermavantSciencesLtdMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis"
      decimals="-5"
      unitRef="Unit_USD">60000000.0</us-gaap:RevenueRecognitionMilestoneMethodRevenueRecognized>
    <us-gaap:PaymentsToAcquireEquityMethodInvestments
      contextRef="P04_01_2018To04_30_2018_GenevantSciencesLtdMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis"
      decimals="-5"
      unitRef="Unit_USD">38700000</us-gaap:PaymentsToAcquireEquityMethodInvestments>
    <us-gaap:ProceedsFromNotesPayable
      contextRef="P05_01_2018To06_30_2020_GenevantSciencesLtdMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis"
      decimals="-5"
      unitRef="Unit_USD">20100000</us-gaap:ProceedsFromNotesPayable>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="P07_31_2020To07_31_2020_GenevantSciencesLtdMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis"
      decimals="INF"
      unitRef="Unit_shares">74272043</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="P07_31_2020To07_31_2020_GenevantSciencesLtdMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis"
      decimals="-5"
      unitRef="Unit_USD">20500000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:DebtConversionOriginalDebtAmount1
      contextRef="P07_31_2020To07_31_2020_GenevantSciencesLtdMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis"
      decimals="-5"
      unitRef="Unit_USD">15100000</us-gaap:DebtConversionOriginalDebtAmount1>
    <us-gaap:DebtConversionConvertedInstrumentSharesIssued1
      contextRef="P07_31_2020To07_31_2020_GenevantSciencesLtdMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis"
      decimals="INF"
      unitRef="Unit_shares">54526549</us-gaap:DebtConversionConvertedInstrumentSharesIssued1>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="P07_31_2020To07_31_2020_ArbutusBiopharmaCorporationMemberdeiLegalEntityAxis_GenevantSciencesLtdMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis"
      decimals="INF"
      unitRef="Unit_shares">9057566</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="P07_31_2020To07_31_2020_ArbutusBiopharmaCorporationMemberdeiLegalEntityAxis_GenevantSciencesLtdMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis"
      decimals="-5"
      unitRef="Unit_USD">2500000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <roiv:PercentageOfControllingInterestHeld
      contextRef="PAsOn07_31_2020_GenevantSciencesLtdMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis"
      decimals="3"
      unitRef="Unit_pure">0.829</roiv:PercentageOfControllingInterestHeld>
    <us-gaap:InvestmentsInAffiliatesSubsidiariesAssociatesAndJointVenturesFairValueDisclosure
      contextRef="PAsOn03_31_2021_GenevantSciencesLtdMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis"
      decimals="-5"
      unitRef="Unit_USD">28800000</us-gaap:InvestmentsInAffiliatesSubsidiariesAssociatesAndJointVenturesFairValueDisclosure>
    <us-gaap:GainLossOnInvestments
      contextRef="P04_01_2020To03_31_2021_GenevantSciencesLtdMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis"
      decimals="-5"
      unitRef="Unit_USD">28800000</us-gaap:GainLossOnInvestments>
    <us-gaap:EquityMethodInvestmentsFairValueDisclosure
      contextRef="PAsOn03_31_2021_GenevantSciencesLtdMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis"
      decimals="-5"
      unitRef="Unit_USD">9200000</us-gaap:EquityMethodInvestmentsFairValueDisclosure>
    <us-gaap:PaymentsToAcquireInterestInSubsidiariesAndAffiliates
      contextRef="P04_01_2020To03_31_2021_GenevantSciencesLtdMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis"
      decimals="-5"
      unitRef="Unit_USD">20500000</us-gaap:PaymentsToAcquireInterestInSubsidiariesAndAffiliates>
    <us-gaap:BusinessCombinationConsiderationTransferred1
      contextRef="P07_01_2020To07_31_2020_GenevantSciencesLtdMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis"
      decimals="-5"
      unitRef="Unit_USD">58500000</us-gaap:BusinessCombinationConsiderationTransferred1>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="P04_01_2020To03_31_2021_GenevantSciencesLtdMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis"
      decimals="-5"
      unitRef="Unit_USD">41400000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="P04_01_2020To03_31_2021_GenevantSciencesLtdMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis"
      decimals="-5"
      unitRef="Unit_USD">41400000</us-gaap:ResearchAndDevelopmentExpense>
    <roiv:PaymentForUpfrontPayments
      contextRef="PAsOn11_30_2020_ProteovantSciencesIncMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis"
      decimals="-5"
      unitRef="Unit_USD">105000000.0</roiv:PaymentForUpfrontPayments>
    <roiv:MilestonePayment
      contextRef="P01_01_2021To01_31_2021_ProteovantSciencesIncMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis"
      decimals="-5"
      unitRef="Unit_USD">100000000.0</roiv:MilestonePayment>
    <roiv:FutureDevelopmentAndCommercialMilestonePayments
      contextRef="P11_01_2020To11_30_2020_FirstProductTargetsEachOfCertainSpecifiedAdditionalMoleculartargetsMemberROIVMilestoneEventsAxis_MaximumMembersrtRangeAxis_ProteovantSciencesIncMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis"
      decimals="-5"
      unitRef="Unit_USD">51000000.0</roiv:FutureDevelopmentAndCommercialMilestonePayments>
    <us-gaap:DebtConversionOriginalDebtAmount1
      contextRef="P11_01_2020To11_30_2020_ProteovantSciencesIncMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis"
      decimals="-5"
      unitRef="Unit_USD">11500000</us-gaap:DebtConversionOriginalDebtAmount1>
    <roiv:FutureDevelopmentAndCommercialMilestonePayments
      contextRef="P11_01_2020To11_30_2020_FirstProductFirstProductForEachMolecularTargetCoveredByIntellectualPropertyMemberROIVMilestoneEventsAxis_MaximumMembersrtRangeAxis_ProteovantSciencesIncMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis"
      decimals="-5"
      unitRef="Unit_USD">8600000</roiv:FutureDevelopmentAndCommercialMilestonePayments>
    <roiv:PaymentUnderSponsoredResearchAgreement
      contextRef="P11_01_2020To11_30_2020_ProteovantSciencesIncMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis"
      decimals="-5"
      unitRef="Unit_USD">15500000</roiv:PaymentUnderSponsoredResearchAgreement>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="P04_01_2020To03_31_2021_ProteovantSciencesIncMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis"
      decimals="-5"
      unitRef="Unit_USD">116500000</us-gaap:ResearchAndDevelopmentExpense>
    <roiv:UpfrontCashPayments
      contextRef="P04_01_2020To03_31_2021_ProteovantSciencesIncMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis"
      decimals="-5"
      unitRef="Unit_USD">101200000</roiv:UpfrontCashPayments>
    <us-gaap:RepaymentOfNotesReceivableFromRelatedParties
      contextRef="P04_01_2020To03_31_2021_ProteovantSciencesIncMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis"
      decimals="-5"
      unitRef="Unit_USD">11900000</us-gaap:RepaymentOfNotesReceivableFromRelatedParties>
    <us-gaap:BusinessCombinationContingentConsiderationLiability
      contextRef="PAsOn03_31_2021_ProteovantSciencesIncMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis"
      decimals="-5"
      unitRef="Unit_USD">3400000</us-gaap:BusinessCombinationContingentConsiderationLiability>
    <us-gaap:EquityMethodInvestmentUnderlyingEquityInNetAssets
      contextRef="PAsOn12_31_2020_ProteovantSciencesIncMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis"
      decimals="-5"
      unitRef="Unit_USD">200000000.0</us-gaap:EquityMethodInvestmentUnderlyingEquityInNetAssets>
    <us-gaap:SubsidiaryOrEquityMethodInvesteeCumulativePercentageOwnershipAfterAllTransactions
      contextRef="P12_01_2020To12_31_2020_ProteovantSciencesIncMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis"
      decimals="3"
      unitRef="Unit_pure">0.400</us-gaap:SubsidiaryOrEquityMethodInvesteeCumulativePercentageOwnershipAfterAllTransactions>
    <us-gaap:StockholdersEquityNoteSubscriptionsReceivable
      contextRef="PAsOn01_31_2021_ProteovantSciencesIncMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis"
      decimals="-5"
      unitRef="Unit_USD">100000000.0</us-gaap:StockholdersEquityNoteSubscriptionsReceivable>
    <roiv:FutureDevelopmentAndCommercialMilestonePayments
      contextRef="P11_01_2020To11_30_2020_FirstProductTargetsTargetingEachOfTwoSpecifiedInitialTargetsMemberROIVMilestoneEventsAxis_MaximumMembersrtRangeAxis_ProteovantSciencesIncMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis"
      decimals="-5"
      unitRef="Unit_USD">100000000.0</roiv:FutureDevelopmentAndCommercialMilestonePayments>
    <us-gaap:StockholdersEquityNoteSubscriptionsReceivable
      contextRef="PAsOn03_31_2021"
      decimals="-5"
      unitRef="Unit_USD">100000000.0</us-gaap:StockholdersEquityNoteSubscriptionsReceivable>
    <roiv:UpfrontCashPayments
      contextRef="P11_01_2020To11_30_2020_AffivantSciencesMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis"
      decimals="-5"
      unitRef="Unit_USD">40000000.0</roiv:UpfrontCashPayments>
    <roiv:StockIssuedDuringPeriodValue
      contextRef="P11_01_2020To11_30_2020_AffivantSciencesMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis"
      decimals="-5"
      unitRef="Unit_USD">20000000.0</roiv:StockIssuedDuringPeriodValue>
    <roiv:FutureDevelopmentAndCommercialMilestonePayments
      contextRef="P11_01_2020To11_30_2020_AffivantSciencesMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis_MaximumMembersrtRangeAxis"
      decimals="-8"
      unitRef="Unit_USD">2000000000.0</roiv:FutureDevelopmentAndCommercialMilestonePayments>
    <us-gaap:BusinessCombinationConsiderationTransferred1
      contextRef="P03_01_2021To03_31_2021_SiliconTherapeuticsMemberusgaapBusinessAcquisitionAxis"
      decimals="-5"
      unitRef="Unit_USD">450000000.0</us-gaap:BusinessCombinationConsiderationTransferred1>
    <us-gaap:BusinessCombinationConsiderationTransferredLiabilitiesIncurred
      contextRef="P03_01_2021To03_31_2021_FirstTrancheMemberusgaapRestructuringPlanAxis_SiliconTherapeuticsMemberusgaapBusinessAcquisitionAxis"
      decimals="-5"
      unitRef="Unit_USD">350000000.0</us-gaap:BusinessCombinationConsiderationTransferredLiabilitiesIncurred>
    <us-gaap:BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued
      contextRef="P03_01_2021To03_31_2021_SiliconTherapeuticsMemberusgaapBusinessAcquisitionAxis"
      decimals="INF"
      unitRef="Unit_shares">7316583</us-gaap:BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued>
    <us-gaap:PaymentsToAcquireBusinessesNetOfCashAcquired
      contextRef="P03_01_2021To03_31_2021_SiliconTherapeuticsMemberusgaapBusinessAcquisitionAxis"
      decimals="-5"
      unitRef="Unit_USD">14000000.0</us-gaap:PaymentsToAcquireBusinessesNetOfCashAcquired>
    <us-gaap:BusinessCombinationConsiderationTransferredLiabilitiesIncurred
      contextRef="P03_01_2021To03_31_2021_SecondTrancheMemberusgaapRestructuringPlanAxis_SiliconTherapeuticsMemberusgaapBusinessAcquisitionAxis"
      decimals="-5"
      unitRef="Unit_USD">100000000.0</us-gaap:BusinessCombinationConsiderationTransferredLiabilitiesIncurred>
    <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet
      contextRef="PAsOn03_31_2021_SiliconTherapeuticsMemberusgaapBusinessAcquisitionAxis"
      decimals="-5"
      unitRef="Unit_USD">402400000</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet>
    <us-gaap:BusinessAcquisitionEquityInterestIssuedOrIssuableValueAssigned
      contextRef="PAsOn03_31_2021_SiliconTherapeuticsMemberusgaapBusinessAcquisitionAxis"
      decimals="-5"
      unitRef="Unit_USD">281700000</us-gaap:BusinessAcquisitionEquityInterestIssuedOrIssuableValueAssigned>
    <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccountsPayable
      contextRef="PAsOn03_31_2021_SiliconTherapeuticsMemberusgaapBusinessAcquisitionAxis"
      decimals="-5"
      unitRef="Unit_USD">105100000</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccountsPayable>
    <us-gaap:PaymentsToAcquireBusinessesNetOfCashAcquired
      contextRef="P04_01_2020To03_31_2021_SiliconTherapeuticsMemberusgaapBusinessAcquisitionAxis"
      decimals="-5"
      unitRef="Unit_USD">15600000</us-gaap:PaymentsToAcquireBusinessesNetOfCashAcquired>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="P04_01_2020To03_31_2021_SiliconTherapeuticsMemberusgaapBusinessAcquisitionAxis"
      decimals="-5"
      unitRef="Unit_USD">399600000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="P04_01_2020To03_31_2021_SiliconTherapeuticsMemberusgaapBusinessAcquisitionAxis"
      decimals="-5"
      unitRef="Unit_USD">399600000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ShareBasedCompensation
      contextRef="P04_01_2020To03_31_2021_SiliconTherapeuticsMemberusgaapBusinessAcquisitionAxis"
      decimals="-5"
      unitRef="Unit_USD">23500000</us-gaap:ShareBasedCompensation>
    <roiv:FairValueOfCommonShares
      contextRef="PAsOn03_31_2021_SiliconTherapeuticsMemberusgaapBusinessAcquisitionAxis"
      decimals="-5"
      unitRef="Unit_USD">22600000</roiv:FairValueOfCommonShares>
    <roiv:FairValueOfRestrictedStock
      contextRef="P04_01_2020To03_31_2021_SiliconTherapeuticsMemberusgaapBusinessAcquisitionAxis"
      decimals="-5"
      unitRef="Unit_USD">15600000</roiv:FairValueOfRestrictedStock>
    <roiv:TransactionAgreementDisclosureTextBlock contextRef="P04_01_2020To03_31_2021">&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt; text-indent: 0px;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Note 5&#x2014;Sumitomo Transaction Agreement &lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt; text-indent: 0px;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;On December&#160;27, 2019 (the &#x201c;Sumitomo Closing Date&#x201d;), RSL and Sumitomo completed the transactions contemplated by the Sumitomo Transaction Agreement. Pursuant to the Sumitomo Transaction Agreement, RSL transferred its entire ownership interest in Myovant, Urovant, Enzyvant, Altavant, and Spirovant to a newly formed, wholly-owned entity (&#x201c;Sumitovant&#x201d;). &lt;/div&gt;&lt;/div&gt; &lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt; text-indent: 0px;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;RSL&#x2019;s ownership interest in Sumitovant was then transferred to Sumitomo, such that following the Sumitomo Closing Date, Sumitovant and its subsidiaries, including the Sumitovant Vants, were each directly or indirectly owned by Sumitomo. Additionally, in connection with the Sumitomo Transaction Agreement, RSL (i)&#160;granted Sumitomo options to purchase all, or in the case of Dermavant, 75%, of RSL&#x2019;s ownership interests in six other subsidiaries (Dermavant, Genevant, Lysovant Sciences Ltd. (&#x201c;Lysovant&#x201d;), Metavant Sciences Ltd. (&#x201c;Metavant&#x201d;), Roivant Asia Cell Therapy Holdings Ltd. (&#x201c;Cytovant Parent&#x201d;), and Sinovant Sciences HK Limited (&#x201c;Sinovant&#x201d;)), &lt;/div&gt;&lt;div style="display:inline;"&gt;(ii) (a) transferred the proprietary technology platform DrugOme to Sumitomo (for which RSL retains a perpetual royalty free license for internal use) and (b) licensed the Digital Innovation technology platform to Sumitomo (for which both parties retain ongoing access) and (iii)&#160; &lt;/div&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;transferred 26,952,143 common shares of RSL to Sumitomo. On the Sumitomo Closing Date, the Company received approximately $2.9&#160;billion in cash, resulting in a gain of $2.0&#160;billion after taking into account all of the components of the transaction. &lt;/div&gt;&lt;/div&gt; &lt;div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0px;"&gt;&lt;div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Additionally, on the Sumitomo Closing Date, $75.0&#160;million of the consideration was deposited into a segregated escrow account for the purpose of fulfilling indemnification obligations of RSL that may become due to Sumitomo. Upon the expiration of the escrow period, being 18 months from the Sumitomo Closing Date, any remaining escrow funds will be disbursed to RSL. As of March&#160;31, 2021, the Company does not believe that a reasonably possible loss of the funds in the escrow account exists. As such, the full escrow amount of $75.0&#160;million was recorded by the Company as restricted cash on the accompanying consolidated balance sheets as of March&#160;31, 2021. In connection with the Sumitomo Transaction, RSL&#x2019;s board of directors approved a repurchase of RSL&#x2019;s equity securities for up to $1.0&#160;billion of the proceeds received from Sumitomo. Refer to Note 10, &#x201c;Shareholders&#x2019; Equity and Redeemable Noncontrolling Interest&#x201d; for further detail. &lt;/div&gt;&lt;/div&gt; &lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;In conjunction with the Sumitomo Transaction, certain employees of the Company became employees of Sumitovant or its subsidiaries. The Company issued certain instruments with an aggregate fair value of $39.1&#160;million to these employees, of which $24.8&#160;million was classified within shareholders&#x2019; equity and $14.3&#160;million was classified as a liability. The liability classified awards were subsequently surrendered and exchanged for cash and other newly issued equity as part of the repurchase in March 2020. The remaining instruments vest based on the achievement of time-based, performance or liquidity event requirements. As of March&#160;31, 2021 and 2020, there were 1,865,416 and 1,880,980 outstanding instruments, respectively, held by Sumitovant employees for which aggregate fair value was recorded against the gain on sale of business. &lt;/div&gt;&lt;/div&gt; &lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;In June 2021, RSL completed a transaction with Sumitomo pursuant to which Sumitomo terminated its existing options to acquire RSL&#x2019;s equity interests in certain of its subsidiaries. See Note 19, &#x201c;Subsequent Events&#x201d; for additional information. &lt;/div&gt;&lt;/div&gt; </roiv:TransactionAgreementDisclosureTextBlock>
    <roiv:PercentageOfGrantedOptionToPurchaseOwnershipInterest
      contextRef="P12_27_2019To12_27_2019_SumitomoMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis"
      decimals="2"
      unitRef="Unit_pure">0.75</roiv:PercentageOfGrantedOptionToPurchaseOwnershipInterest>
    <roiv:SaleOfStockNumberOfShareIssuedInTransaction
      contextRef="PAsOn12_31_2019_SumitomoMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis"
      decimals="INF"
      unitRef="Unit_shares">26952143</roiv:SaleOfStockNumberOfShareIssuedInTransaction>
    <us-gaap:SaleOfStockConsiderationReceivedOnTransaction
      contextRef="P04_01_2019To03_31_2020_SumitomoMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis"
      decimals="-8"
      unitRef="Unit_USD">2900000000</us-gaap:SaleOfStockConsiderationReceivedOnTransaction>
    <us-gaap:GainOrLossOnSaleOfStockInSubsidiary
      contextRef="P04_01_2019To03_31_2020_SumitomoMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis"
      decimals="-8"
      unitRef="Unit_USD">2000000000.0</us-gaap:GainOrLossOnSaleOfStockInSubsidiary>
    <us-gaap:EscrowDeposit
      contextRef="PAsOn12_27_2019_SumitomoMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis"
      decimals="-5"
      unitRef="Unit_USD">75000000.0</us-gaap:EscrowDeposit>
    <us-gaap:RestrictedCash
      contextRef="PAsOn03_31_2021_SumitomoMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis"
      decimals="-5"
      unitRef="Unit_USD">75000000.0</us-gaap:RestrictedCash>
    <us-gaap:StockRepurchaseProgramAuthorizedAmount1
      contextRef="PAsOn12_31_2019_MaximumMembersrtRangeAxis_SumitomoMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis"
      decimals="-8"
      unitRef="Unit_USD">1000000000.0</us-gaap:StockRepurchaseProgramAuthorizedAmount1>
    <roiv:AggregateFairValueOfEquityAndLiabilityInstrumentsIssued
      contextRef="PAsOn12_31_2019_EmployeeMembersrtTitleOfIndividualAxis_SumitomoMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis"
      decimals="-5"
      unitRef="Unit_USD">39100000</roiv:AggregateFairValueOfEquityAndLiabilityInstrumentsIssued>
    <us-gaap:DeferredCompensationEquity
      contextRef="PAsOn12_31_2019_EmployeeMembersrtTitleOfIndividualAxis_SumitomoMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis"
      decimals="-5"
      unitRef="Unit_USD">24800000</us-gaap:DeferredCompensationEquity>
    <us-gaap:DeferredCompensationLiabilityCurrent
      contextRef="PAsOn12_31_2019_EmployeeMembersrtTitleOfIndividualAxis_SumitomoMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis"
      decimals="-5"
      unitRef="Unit_USD">14300000</us-gaap:DeferredCompensationLiabilityCurrent>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber
      contextRef="PAsOn03_31_2021_EmployeeMembersrtTitleOfIndividualAxis_SumitomoMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis"
      decimals="INF"
      unitRef="Unit_shares">1865416</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber
      contextRef="PAsOn03_31_2020_EmployeeMembersrtTitleOfIndividualAxis_SumitomoMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis"
      decimals="INF"
      unitRef="Unit_shares">1880980</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber>
    <us-gaap:DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock contextRef="P04_01_2020To03_31_2021">&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Note 6&#x2014;Discontinued Operations &lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;As a result of the Sumitomo Transaction Agreement, see Note 5, &#x201c;Sumitomo Transaction Agreement,&#x201d; the financial results of the Sumitovant Vants are presented as &#x201c;Income from discontinued operations, net of tax&#x201d; in the accompanying consolidated statements of operations for the year ended March&#160;31, 2020. There were no operating results from discontinued operations for the year ended March&#160;31, 2021. &lt;/div&gt;&lt;/div&gt; &lt;div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;The following table presents components of discontinued operations included in &#x201c;Income from discontinued operations, net of tax&#x201d; for the year ended March&#160;31, 2020 (in thousands). &lt;/div&gt;&lt;/div&gt; &lt;div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 92%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;"&gt;
&lt;tr style="font-size: 0px;"&gt;
&lt;td style="width: 85%;"/&gt;
&lt;td style="width: 5%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Year Ended&lt;br/&gt; March&#160;31,&#160;2020&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Operating expenses:&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Research and development&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;265,452&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;General and administrative&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;119,885&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 5em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Total operating expenses&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;385,337&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Loss from operations&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;(385,337&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Gain on sale of business&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;(1,985,949&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Interest income&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;(2,305&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Interest expense&lt;div style="font-size: 85%; vertical-align: top;;display:inline;;font-size:9.4px"&gt;(1)&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;13,733&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Other expense&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;8,866&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Income from discontinued operations before income taxes&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;1,580,318&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Income tax expense&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;1,892&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Income from discontinued operations, net of tax&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;1,578,426&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Loss from discontinued operations before income taxes attributable to noncontrolling interests&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;(141,783&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Income from discontinued operations before income taxes attributable to Roivant Sciences Ltd.&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;1,722,101&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Income from discontinued operations before income taxes&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;1,580,318&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; &lt;div style="clear: both; max-height: 0px;"/&gt; &lt;div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;"&gt;
&lt;tr style="page-break-inside: avoid;"&gt;
&lt;td style="width: 4%; vertical-align: top;;text-align:left;"&gt;&lt;div style="font-size: 85%; vertical-align: top;;display:inline;;font-size:9.4px"&gt;(1)&lt;/div&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: top;;text-align:left;"&gt; &lt;div style="text-align: left; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"&gt;Interest expense consists of interest payments related to outstanding debt held by Myovant and Urovant as well as the associated &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;non-cash&lt;/div&gt; amortization of debt discounts and issuance costs. &lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;/table&gt;  &lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;In the accompanying consolidated statements of cash flows, the cash flows from discontinued operations are not separately classified. The significant cash flow items from discontinued operations were as follows (in thousands): &lt;/div&gt;&lt;/div&gt; &lt;div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 68%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;"&gt;
&lt;tr style="font-size: 0px;"&gt;
&lt;td style="width: 78%;"/&gt;
&lt;td style="width: 8%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Year Ended&lt;br/&gt; March&#160;31,&#160;2020&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Gain on sale of business&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;(1,985,949&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Share-based compensation&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;54,821&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;Acquired &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;in-process&lt;/div&gt; research and development&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;16,405&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; </us-gaap:DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock>
    <us-gaap:ScheduleOfDisposalGroupsIncludingDiscontinuedOperationsIncomeStatementBalanceSheetAndAdditionalDisclosuresTextBlock contextRef="P04_01_2020To03_31_2021">&lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;The following table presents components of discontinued operations included in &#x201c;Income from discontinued operations, net of tax&#x201d; for the year ended March&#160;31, 2020 (in thousands). &lt;/div&gt;&lt;/div&gt; &lt;div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 92%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;"&gt;
&lt;tr style="font-size: 0px;"&gt;
&lt;td style="width: 85%;"/&gt;
&lt;td style="width: 5%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Year Ended&lt;br/&gt; March&#160;31,&#160;2020&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Operating expenses:&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Research and development&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;265,452&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;General and administrative&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;119,885&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 5em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Total operating expenses&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;385,337&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Loss from operations&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;(385,337&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Gain on sale of business&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;(1,985,949&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Interest income&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;(2,305&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Interest expense&lt;div style="font-size: 85%; vertical-align: top;;display:inline;;font-size:9.4px"&gt;(1)&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;13,733&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Other expense&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;8,866&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Income from discontinued operations before income taxes&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;1,580,318&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Income tax expense&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;1,892&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Income from discontinued operations, net of tax&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;1,578,426&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Loss from discontinued operations before income taxes attributable to noncontrolling interests&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;(141,783&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Income from discontinued operations before income taxes attributable to Roivant Sciences Ltd.&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;1,722,101&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Income from discontinued operations before income taxes&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;1,580,318&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; &lt;div style="clear: both; max-height: 0px;"/&gt; &lt;div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;"&gt;
&lt;tr style="page-break-inside: avoid;"&gt;
&lt;td style="width: 4%; vertical-align: top;;text-align:left;"&gt;&lt;div style="font-size: 85%; vertical-align: top;;display:inline;;font-size:9.4px"&gt;(1)&lt;/div&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: top;;text-align:left;"&gt; &lt;div style="text-align: left; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"&gt;Interest expense consists of interest payments related to outstanding debt held by Myovant and Urovant as well as the associated &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;non-cash&lt;/div&gt; amortization of debt discounts and issuance costs. &lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; </us-gaap:ScheduleOfDisposalGroupsIncludingDiscontinuedOperationsIncomeStatementBalanceSheetAndAdditionalDisclosuresTextBlock>
    <roiv:DisposalGroupIncludingDiscontinuedOperationResearchAndDevelopmentExpense
      contextRef="P04_01_2019To03_31_2020"
      decimals="-3"
      unitRef="Unit_USD">265452000</roiv:DisposalGroupIncludingDiscontinuedOperationResearchAndDevelopmentExpense>
    <us-gaap:DisposalGroupIncludingDiscontinuedOperationGeneralAndAdministrativeExpense
      contextRef="P04_01_2019To03_31_2020"
      decimals="-3"
      unitRef="Unit_USD">119885000</us-gaap:DisposalGroupIncludingDiscontinuedOperationGeneralAndAdministrativeExpense>
    <us-gaap:DisposalGroupIncludingDiscontinuedOperationOperatingExpense
      contextRef="P04_01_2019To03_31_2020"
      decimals="-3"
      unitRef="Unit_USD">385337000</us-gaap:DisposalGroupIncludingDiscontinuedOperationOperatingExpense>
    <us-gaap:DisposalGroupIncludingDiscontinuedOperationOperatingIncomeLoss
      contextRef="P04_01_2019To03_31_2020"
      decimals="-3"
      unitRef="Unit_USD">-385337000</us-gaap:DisposalGroupIncludingDiscontinuedOperationOperatingIncomeLoss>
    <roiv:DisposalGroupIncludingDiscontinuedOperationGainLossOnSaleOfBusiness
      contextRef="P04_01_2019To03_31_2020"
      decimals="-3"
      unitRef="Unit_USD">1985949000</roiv:DisposalGroupIncludingDiscontinuedOperationGainLossOnSaleOfBusiness>
    <us-gaap:DisposalGroupIncludingDiscontinuedOperationInterestIncome
      contextRef="P04_01_2019To03_31_2020"
      decimals="-3"
      unitRef="Unit_USD">2305000</us-gaap:DisposalGroupIncludingDiscontinuedOperationInterestIncome>
    <us-gaap:DisposalGroupIncludingDiscontinuedOperationInterestExpense
      contextRef="P04_01_2019To03_31_2020"
      decimals="-3"
      unitRef="Unit_USD">13733000</us-gaap:DisposalGroupIncludingDiscontinuedOperationInterestExpense>
    <us-gaap:DisposalGroupIncludingDiscontinuedOperationOtherExpense
      contextRef="P04_01_2019To03_31_2020"
      decimals="-3"
      unitRef="Unit_USD">8866000</us-gaap:DisposalGroupIncludingDiscontinuedOperationOtherExpense>
    <us-gaap:DiscontinuedOperationIncomeLossFromDiscontinuedOperationBeforeIncomeTax
      contextRef="P04_01_2019To03_31_2020"
      decimals="-3"
      unitRef="Unit_USD">1580318000</us-gaap:DiscontinuedOperationIncomeLossFromDiscontinuedOperationBeforeIncomeTax>
    <us-gaap:DiscontinuedOperationTaxEffectOfDiscontinuedOperation
      contextRef="P04_01_2019To03_31_2020"
      decimals="-3"
      unitRef="Unit_USD">1892000</us-gaap:DiscontinuedOperationTaxEffectOfDiscontinuedOperation>
    <us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTax
      contextRef="P04_01_2019To03_31_2020"
      decimals="-3"
      unitRef="Unit_USD">1578426000</us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTax>
    <us-gaap:DiscontinuedOperationIncomeLossFromDiscontinuedOperationDuringPhaseOutPeriodBeforeIncomeTaxAttributableToNoncontrollingInterest
      contextRef="P04_01_2019To03_31_2020"
      decimals="-3"
      unitRef="Unit_USD">-141783000</us-gaap:DiscontinuedOperationIncomeLossFromDiscontinuedOperationDuringPhaseOutPeriodBeforeIncomeTaxAttributableToNoncontrollingInterest>
    <us-gaap:DiscontinuedOperationIncomeLossFromDiscontinuedOperationDuringPhaseOutPeriodBeforeIncomeTaxAttributableToParent
      contextRef="P04_01_2019To03_31_2020"
      decimals="-3"
      unitRef="Unit_USD">1722101000</us-gaap:DiscontinuedOperationIncomeLossFromDiscontinuedOperationDuringPhaseOutPeriodBeforeIncomeTaxAttributableToParent>
    <us-gaap:DiscontinuedOperationIncomeLossFromDiscontinuedOperationDuringPhaseOutPeriodBeforeIncomeTax
      contextRef="P04_01_2019To03_31_2020"
      decimals="-3"
      unitRef="Unit_USD">1580318000</us-gaap:DiscontinuedOperationIncomeLossFromDiscontinuedOperationDuringPhaseOutPeriodBeforeIncomeTax>
    <roiv:ScheduleOfDisposalGroupsIncludingDiscontinuedCondensedConsolidatedStatementsOfCashFlowsTableTextBlock contextRef="P04_01_2020To03_31_2021">The significant cash flow items from discontinued operations were as follows (in thousands):
&lt;table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 68%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;"&gt;
&lt;tr style="font-size: 0px;"&gt;
&lt;td style="width: 78%;"/&gt;
&lt;td style="width: 8%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Year Ended&lt;br/&gt; March&#160;31,&#160;2020&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Gain on sale of business&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;(1,985,949&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Share-based compensation&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;54,821&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;Acquired &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;in-process&lt;/div&gt; research and development&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;16,405&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; </roiv:ScheduleOfDisposalGroupsIncludingDiscontinuedCondensedConsolidatedStatementsOfCashFlowsTableTextBlock>
    <roiv:DisposalGroupIncludingDiscontinuedOperationGainLossOnSaleOfBusiness
      contextRef="P04_01_2019To03_31_2020"
      decimals="-3"
      unitRef="Unit_USD">1985949000</roiv:DisposalGroupIncludingDiscontinuedOperationGainLossOnSaleOfBusiness>
    <roiv:DisposalGroupIncludingDiscontinuedOperationShareBasedCompensation
      contextRef="P04_01_2019To03_31_2020"
      decimals="-3"
      unitRef="Unit_USD">54821000</roiv:DisposalGroupIncludingDiscontinuedOperationShareBasedCompensation>
    <roiv:DisposalGroupIncludingDiscontinuedOperationResearchAndDevelopmentInProcess
      contextRef="P04_01_2019To03_31_2020"
      decimals="-3"
      unitRef="Unit_USD">16405000</roiv:DisposalGroupIncludingDiscontinuedOperationResearchAndDevelopmentInProcess>
    <us-gaap:SupplementalBalanceSheetDisclosuresTextBlock contextRef="P04_01_2020To03_31_2021">&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Note 7&#x2014;Balance Sheet Components &lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;(A) Other Current Assets &lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Other current assets at March&#160;31, 2021 and 2020 consisted of the following (in thousands): &lt;/div&gt;&lt;/div&gt; &lt;div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 76%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;"&gt;
&lt;tr style="font-size: 0px;"&gt;
&lt;td style="width: 62%;"/&gt;
&lt;td style="width: 11%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="width: 11%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;March&#160;31,&#160;2021&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;March&#160;31,&#160;2020&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Prepaid expenses&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;39,544&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;16,344&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Receivables for value added tax (VAT) paid&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;807&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;5,978&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Note receivable&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;5,000&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Trade receivables, net&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;11,222&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;3,669&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Income tax receivable&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;1,803&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;632&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Other&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;874&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;2,140&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Total other current assets&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;54,250&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;33,763&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt; &lt;/tr&gt; &lt;/table&gt;  &lt;div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;(B) Accrued Expenses &lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Accrued expenses at March&#160;31, 2021 and 2020 consisted of the following (in thousands): &lt;/div&gt;&lt;/div&gt; &lt;div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 76%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;"&gt;
&lt;tr style="font-size: 0px;"&gt;
&lt;td style="width: 62%;"/&gt;
&lt;td style="width: 11%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="width: 11%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;March&#160;31,&#160;2021&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;March&#160;31,&#160;2020&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Research and development expenses&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;20,755&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;21,607&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Compensation-related expenses&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;38,552&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;29,113&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Professional services expenses&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;10,267&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;5,135&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Other general and administrative expenses&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;7,362&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;12,766&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Total accrued expenses&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;76,936&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;68,621&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt; &lt;/tr&gt; &lt;/table&gt;  &lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;(C) Other Current Liabilities &lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Other current liabilities at March&#160;31, 2021 and 2020 consisted of the following (in thousands): &lt;/div&gt;&lt;/div&gt; &lt;div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 76%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;"&gt;
&lt;tr style="font-size: 0px;"&gt;
&lt;td style="width: 62%;"/&gt;
&lt;td style="width: 13%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="width: 13%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;March&#160;31,&#160;2021&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;March&#160;31,&#160;2020&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Deferred revenue&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;5,918&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;3,621&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Income tax payable&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;207&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;1,497&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Other&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;3,037&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;234&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Total other current liabilities&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;9,162&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;5,352&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt; &lt;/tr&gt; &lt;/table&gt;  </us-gaap:SupplementalBalanceSheetDisclosuresTextBlock>
    <us-gaap:ScheduleOfOtherCurrentAssetsTableTextBlock contextRef="P04_01_2020To03_31_2021">&lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Other current assets at March&#160;31, 2021 and 2020 consisted of the following (in thousands): &lt;/div&gt;&lt;/div&gt; &lt;div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 76%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;"&gt;
&lt;tr style="font-size: 0px;"&gt;
&lt;td style="width: 62%;"/&gt;
&lt;td style="width: 11%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="width: 11%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;March&#160;31,&#160;2021&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;March&#160;31,&#160;2020&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Prepaid expenses&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;39,544&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;16,344&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Receivables for value added tax (VAT) paid&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;807&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;5,978&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Note receivable&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;5,000&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Trade receivables, net&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;11,222&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;3,669&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Income tax receivable&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;1,803&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;632&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Other&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;874&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;2,140&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Total other current assets&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;54,250&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;33,763&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; </us-gaap:ScheduleOfOtherCurrentAssetsTableTextBlock>
    <us-gaap:PrepaidExpenseCurrent
      contextRef="PAsOn03_31_2021"
      decimals="-3"
      unitRef="Unit_USD">39544000</us-gaap:PrepaidExpenseCurrent>
    <us-gaap:PrepaidExpenseCurrent
      contextRef="PAsOn03_31_2020"
      decimals="-3"
      unitRef="Unit_USD">16344000</us-gaap:PrepaidExpenseCurrent>
    <us-gaap:ValueAddedTaxReceivable
      contextRef="PAsOn03_31_2021"
      decimals="-3"
      unitRef="Unit_USD">807000</us-gaap:ValueAddedTaxReceivable>
    <us-gaap:ValueAddedTaxReceivable
      contextRef="PAsOn03_31_2020"
      decimals="-3"
      unitRef="Unit_USD">5978000</us-gaap:ValueAddedTaxReceivable>
    <us-gaap:NotesAndLoansReceivableNetCurrent
      contextRef="PAsOn03_31_2021"
      decimals="-3"
      unitRef="Unit_USD">0</us-gaap:NotesAndLoansReceivableNetCurrent>
    <us-gaap:NotesAndLoansReceivableNetCurrent
      contextRef="PAsOn03_31_2020"
      decimals="-3"
      unitRef="Unit_USD">5000000</us-gaap:NotesAndLoansReceivableNetCurrent>
    <us-gaap:AccountsReceivableNetCurrent
      contextRef="PAsOn03_31_2021"
      decimals="-3"
      unitRef="Unit_USD">11222000</us-gaap:AccountsReceivableNetCurrent>
    <us-gaap:AccountsReceivableNetCurrent
      contextRef="PAsOn03_31_2020"
      decimals="-3"
      unitRef="Unit_USD">3669000</us-gaap:AccountsReceivableNetCurrent>
    <us-gaap:IncomeTaxesReceivable
      contextRef="PAsOn03_31_2021"
      decimals="-3"
      unitRef="Unit_USD">1803000</us-gaap:IncomeTaxesReceivable>
    <us-gaap:IncomeTaxesReceivable
      contextRef="PAsOn03_31_2020"
      decimals="-3"
      unitRef="Unit_USD">632000</us-gaap:IncomeTaxesReceivable>
    <us-gaap:OtherAssetsMiscellaneousCurrent
      contextRef="PAsOn03_31_2020"
      decimals="-3"
      unitRef="Unit_USD">2140000</us-gaap:OtherAssetsMiscellaneousCurrent>
    <us-gaap:OtherAssetsCurrent
      contextRef="PAsOn03_31_2021"
      decimals="-3"
      unitRef="Unit_USD">54250000</us-gaap:OtherAssetsCurrent>
    <us-gaap:OtherAssetsCurrent
      contextRef="PAsOn03_31_2020"
      decimals="-3"
      unitRef="Unit_USD">33763000</us-gaap:OtherAssetsCurrent>
    <us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock contextRef="P04_01_2020To03_31_2021">&lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Accrued expenses at March&#160;31, 2021 and 2020 consisted of the following (in thousands): &lt;/div&gt;&lt;/div&gt; &lt;div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 76%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;"&gt;
&lt;tr style="font-size: 0px;"&gt;
&lt;td style="width: 62%;"/&gt;
&lt;td style="width: 11%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="width: 11%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;March&#160;31,&#160;2021&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;March&#160;31,&#160;2020&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Research and development expenses&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;20,755&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;21,607&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Compensation-related expenses&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;38,552&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;29,113&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Professional services expenses&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;10,267&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;5,135&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Other general and administrative expenses&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;7,362&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;12,766&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Total accrued expenses&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;76,936&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;68,621&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; </us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock>
    <us-gaap:AccruedLiabilitiesCurrent
      contextRef="PAsOn03_31_2021_ResearchAndDevelopmentExpenseMemberusgaapIncomeStatementLocationAxis"
      decimals="-3"
      unitRef="Unit_USD">20755000</us-gaap:AccruedLiabilitiesCurrent>
    <us-gaap:AccruedLiabilitiesCurrent
      contextRef="PAsOn03_31_2020_ResearchAndDevelopmentExpenseMemberusgaapIncomeStatementLocationAxis"
      decimals="-3"
      unitRef="Unit_USD">21607000</us-gaap:AccruedLiabilitiesCurrent>
    <us-gaap:AccruedLiabilitiesCurrent
      contextRef="PAsOn03_31_2021_EmployeeRelatedExpensesMemberusgaapIncomeStatementLocationAxis"
      decimals="-3"
      unitRef="Unit_USD">38552000</us-gaap:AccruedLiabilitiesCurrent>
    <us-gaap:AccruedLiabilitiesCurrent
      contextRef="PAsOn03_31_2020_EmployeeRelatedExpensesMemberusgaapIncomeStatementLocationAxis"
      decimals="-3"
      unitRef="Unit_USD">29113000</us-gaap:AccruedLiabilitiesCurrent>
    <us-gaap:AccruedLiabilitiesCurrent
      contextRef="PAsOn03_31_2021_ProfessionalServicesExpensesMemberusgaapIncomeStatementLocationAxis"
      decimals="-3"
      unitRef="Unit_USD">10267000</us-gaap:AccruedLiabilitiesCurrent>
    <us-gaap:AccruedLiabilitiesCurrent
      contextRef="PAsOn03_31_2020_ProfessionalServicesExpensesMemberusgaapIncomeStatementLocationAxis"
      decimals="-3"
      unitRef="Unit_USD">5135000</us-gaap:AccruedLiabilitiesCurrent>
    <us-gaap:AccruedLiabilitiesCurrent
      contextRef="PAsOn03_31_2021_OtherGeneralAndAdministrativeExpensesMemberusgaapIncomeStatementLocationAxis"
      decimals="-3"
      unitRef="Unit_USD">7362000</us-gaap:AccruedLiabilitiesCurrent>
    <us-gaap:AccruedLiabilitiesCurrent
      contextRef="PAsOn03_31_2020_OtherGeneralAndAdministrativeExpensesMemberusgaapIncomeStatementLocationAxis"
      decimals="-3"
      unitRef="Unit_USD">12766000</us-gaap:AccruedLiabilitiesCurrent>
    <us-gaap:AccruedLiabilitiesCurrent
      contextRef="PAsOn03_31_2021"
      decimals="-3"
      unitRef="Unit_USD">76936000</us-gaap:AccruedLiabilitiesCurrent>
    <us-gaap:AccruedLiabilitiesCurrent
      contextRef="PAsOn03_31_2020"
      decimals="-3"
      unitRef="Unit_USD">68621000</us-gaap:AccruedLiabilitiesCurrent>
    <us-gaap:OtherCurrentLiabilitiesTableTextBlock contextRef="P04_01_2020To03_31_2021">&lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Other current liabilities at March&#160;31, 2021 and 2020 consisted of the following (in thousands): &lt;/div&gt;&lt;/div&gt; &lt;div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 76%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;"&gt;
&lt;tr style="font-size: 0px;"&gt;
&lt;td style="width: 62%;"/&gt;
&lt;td style="width: 13%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="width: 13%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;March&#160;31,&#160;2021&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;March&#160;31,&#160;2020&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Deferred revenue&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;5,918&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;3,621&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Income tax payable&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;207&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;1,497&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Other&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;3,037&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;234&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Total other current liabilities&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;9,162&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;5,352&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; </us-gaap:OtherCurrentLiabilitiesTableTextBlock>
    <roiv:DeferredRevenueOtherCurrentLiabilities
      contextRef="PAsOn03_31_2021"
      decimals="-3"
      unitRef="Unit_USD">5918000</roiv:DeferredRevenueOtherCurrentLiabilities>
    <roiv:DeferredRevenueOtherCurrentLiabilities
      contextRef="PAsOn03_31_2020"
      decimals="-3"
      unitRef="Unit_USD">3621000</roiv:DeferredRevenueOtherCurrentLiabilities>
    <us-gaap:TaxesPayableCurrent
      contextRef="PAsOn03_31_2021"
      decimals="-3"
      unitRef="Unit_USD">207000</us-gaap:TaxesPayableCurrent>
    <us-gaap:TaxesPayableCurrent
      contextRef="PAsOn03_31_2020"
      decimals="-3"
      unitRef="Unit_USD">1497000</us-gaap:TaxesPayableCurrent>
    <us-gaap:OtherSundryLiabilitiesCurrent
      contextRef="PAsOn03_31_2021"
      decimals="-3"
      unitRef="Unit_USD">3037000</us-gaap:OtherSundryLiabilitiesCurrent>
    <us-gaap:OtherSundryLiabilitiesCurrent
      contextRef="PAsOn03_31_2020"
      decimals="-3"
      unitRef="Unit_USD">234000</us-gaap:OtherSundryLiabilitiesCurrent>
    <us-gaap:OtherLiabilitiesCurrent
      contextRef="PAsOn03_31_2021"
      decimals="-3"
      unitRef="Unit_USD">9162000</us-gaap:OtherLiabilitiesCurrent>
    <us-gaap:OtherLiabilitiesCurrent
      contextRef="PAsOn03_31_2020"
      decimals="-3"
      unitRef="Unit_USD">5352000</us-gaap:OtherLiabilitiesCurrent>
    <us-gaap:LongTermDebtTextBlock contextRef="P04_01_2020To03_31_2021">&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Note 8&#x2014;Long-Term Debt &lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;(A) Long-Term Debt &lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Long-term debt, net consists of the following (in thousands): &lt;/div&gt;&lt;/div&gt; &lt;div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 84%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;"&gt;
&lt;tr style="font-size: 0px;"&gt;
&lt;td style="width: 66%;"/&gt;
&lt;td style="width: 9%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="width: 9%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;March&#160;31,&#160;2021&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;March&#160;31,&#160;2020&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Principal amount&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;171,490&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;110,490&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Less: unamortized debt discount and issuance costs&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;(1,210&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;(1,898&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Total debt, net&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;170,280&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;108,592&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Less: current portion&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Total long-term debt, net&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;170,280&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;108,592&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt; &lt;/tr&gt; &lt;/table&gt;  &lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;Dermavant &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;In May 2019, Dermavant and certain of its subsidiaries entered into a loan and security agreement (the &#x201c;Hercules Loan Agreement&#x201d;) with Hercules Capital, Inc. (&#x201c;Hercules&#x201d;), pursuant to which Dermavant borrowed an aggregate of $20.0&#160;million which bears interest at a variable per annum rate at the greater of (i)&#160;9.95%&#160;or (ii)&#160;the prime rate plus 4.45%. Dermavant is obligated to pay an end of term charge of&#160;$1.4&#160;million with the debt maturing 36 months from closing, subject to extension with the achievement of a clinical milestone. Dermavant is obligated to make monthly payments of accrued interest for the first 15 months after closing (the &#x201c;Interest-only Period&#x201d;), followed by monthly installments of principal and interest through the maturity date, subject to extension upon certain milestone achievements. In January 2020, the Interest-only Period was extended through June 2021 upon Dermavant&#x2019;s receipt of net proceeds from equity or debt financings, capital contributions, and proceeds from business development or similar transaction of at least $110.0&#160;million. In July 2020, the clinical milestone was achieved and the term loan maturity was extended to June&#160;1, 2023 and the Interest-only Period was further extended through December 2021. As of March&#160;31, 2021 and March&#160;31, 2020, an aggregate principal amount of $20.0&#160;million and end of term charge of $1.4&#160;million remained outstanding. In May 2021, Dermavant repaid all amounts outstanding under the Hercules Loan Agreement using the proceeds from the $40.0&#160;million Credit Facility entered into by Dermavant and certain of its subsidiaries in May 2021. Refer to Note 19, &#x201c;Subsequent Events&#x201d; for additional detail. &lt;/div&gt;&lt;/div&gt; &lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;In connection with Dermavant&#x2019;s acquisition of tapinarof from GSK, Dermavant and NovaQuest &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Co-Investment&lt;/div&gt; Fund VIII, L.P. (&#x201c;NovaQuest&#x201d;) entered into a funding agreement (the &#x201c;NovaQuest Agreement&#x201d;). Pursuant to the NovaQuest Agreement, Dermavant borrowed $100.0&#160;million in August 2018 and $17.5&#160;million in October 2018 in exchange for an obligation to make certain variable future payments calculated as a function of the achievement of regulatory and commercial milestones or events of termination. The aggregate maximum amount of regulatory milestone payments that Dermavant could be required to make under the NovaQuest Agreement is $440.6&#160;million, and the maximum aggregate amount of commercial milestone payments is $141.0&#160;million. In some circumstances, Dermavant may be able to offset certain of the regulatory milestone payments with up to $88.1&#160;million of the commercial milestone payments. At issuance, the Company concluded that certain features of the long-term debt would be considered derivatives that would require bifurcation. In lieu of bifurcating various features in the agreement, the Company has elected the fair value option for this financial instrument and will record the changes in the fair value within the statements of operations at the end of each reporting period. Direct costs and fees related to the debt issued under the NovaQuest Agreement were recognized in earnings. As of March&#160;31, 2021 and 2020, the fair value of the debt was $150.1&#160;million and $89.1&#160;million, respectively. Refer to Note 15, &#x201c;Fair Value Measurements&#x201d; for additional details regarding the fair value measurement. &lt;/div&gt; &lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;(B) Debt Maturities &lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Annual maturities, including the end of term charge, of debt outstanding as of&#160;March&#160;31, 2021&#160;are as follows (in thousands). Long-term debt held by Dermavant for which the fair value option has been elected is excluded from the below as the repayment terms are variable. &lt;/div&gt;&lt;/div&gt; &lt;div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 68%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;"&gt;
&lt;tr style="font-size: 0px;"&gt;
&lt;td style="width: 85%; font-family: &amp;quot;Times New Roman&amp;quot;;"/&gt;
&lt;td style="width: 6%; vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"/&gt;
&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;;"/&gt;
&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;;"/&gt;
&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;;"/&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt; &lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt; border-bottom: 1pt solid rgb(0, 0, 0); display: table-cell; line-height: normal;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Years Ending March&#160;31,&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;2022&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;3,129&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;2023&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;13,306&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;2024&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;4,955&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;2025&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;2026&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Thereafter&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Total&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;21,390&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; </us-gaap:LongTermDebtTextBlock>
    <us-gaap:ScheduleOfDebtTableTextBlock contextRef="P04_01_2020To03_31_2021">&lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Long-term debt, net consists of the following (in thousands): &lt;/div&gt;&lt;/div&gt; &lt;div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 84%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;"&gt;
&lt;tr style="font-size: 0px;"&gt;
&lt;td style="width: 66%;"/&gt;
&lt;td style="width: 9%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="width: 9%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;March&#160;31,&#160;2021&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;March&#160;31,&#160;2020&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Principal amount&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;171,490&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;110,490&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Less: unamortized debt discount and issuance costs&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;(1,210&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;(1,898&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Total debt, net&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;170,280&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;108,592&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Less: current portion&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Total long-term debt, net&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;170,280&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;108,592&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; </us-gaap:ScheduleOfDebtTableTextBlock>
    <roiv:DebtInstrumentAmount
      contextRef="PAsOn03_31_2021"
      decimals="-3"
      unitRef="Unit_USD">171490000</roiv:DebtInstrumentAmount>
    <roiv:DebtInstrumentAmount
      contextRef="PAsOn03_31_2020"
      decimals="-3"
      unitRef="Unit_USD">110490000</roiv:DebtInstrumentAmount>
    <us-gaap:DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet
      contextRef="PAsOn03_31_2021"
      decimals="-3"
      unitRef="Unit_USD">1210000</us-gaap:DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet>
    <us-gaap:DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet
      contextRef="PAsOn03_31_2020"
      decimals="-3"
      unitRef="Unit_USD">1898000</us-gaap:DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet>
    <us-gaap:LongTermDebt
      contextRef="PAsOn03_31_2021"
      decimals="-3"
      unitRef="Unit_USD">170280000</us-gaap:LongTermDebt>
    <us-gaap:LongTermDebt
      contextRef="PAsOn03_31_2020"
      decimals="-3"
      unitRef="Unit_USD">108592000</us-gaap:LongTermDebt>
    <us-gaap:LongTermDebtCurrent
      contextRef="PAsOn03_31_2021"
      decimals="-3"
      unitRef="Unit_USD">0</us-gaap:LongTermDebtCurrent>
    <us-gaap:LongTermDebtCurrent
      contextRef="PAsOn03_31_2020"
      decimals="-3"
      unitRef="Unit_USD">0</us-gaap:LongTermDebtCurrent>
    <us-gaap:LongTermDebtNoncurrent
      contextRef="PAsOn03_31_2021"
      decimals="-3"
      unitRef="Unit_USD">170280000</us-gaap:LongTermDebtNoncurrent>
    <us-gaap:LongTermDebtNoncurrent
      contextRef="PAsOn03_31_2020"
      decimals="-3"
      unitRef="Unit_USD">108592000</us-gaap:LongTermDebtNoncurrent>
    <us-gaap:DebtInstrumentFaceAmount
      contextRef="PAsOn05_31_2019"
      decimals="-5"
      unitRef="Unit_USD">20000000.0</us-gaap:DebtInstrumentFaceAmount>
    <us-gaap:LongTermDebtPercentageBearingVariableInterestRate
      contextRef="PAsOn05_31_2019"
      decimals="4"
      unitRef="Unit_pure">0.0995</us-gaap:LongTermDebtPercentageBearingVariableInterestRate>
    <us-gaap:LongTermDebtPercentageBearingVariableInterestRate
      contextRef="PAsOn05_31_2019_PrimeRateMemberusgaapVariableRateAxis"
      decimals="4"
      unitRef="Unit_pure">0.0445</us-gaap:LongTermDebtPercentageBearingVariableInterestRate>
    <us-gaap:DebtInstrumentFeeAmount
      contextRef="PAsOn05_31_2019"
      decimals="-5"
      unitRef="Unit_USD">1400000</us-gaap:DebtInstrumentFeeAmount>
    <roiv:ProceedsFromSaleOfDebtAndEquitySecurities
      contextRef="P01_01_2020To01_31_2020"
      decimals="-5"
      unitRef="Unit_USD">110000000.0</roiv:ProceedsFromSaleOfDebtAndEquitySecurities>
    <us-gaap:DebtInstrumentFaceAmount
      contextRef="PAsOn03_31_2021"
      decimals="-5"
      unitRef="Unit_USD">20000000.0</us-gaap:DebtInstrumentFaceAmount>
    <us-gaap:DebtInstrumentFeeAmount
      contextRef="PAsOn03_31_2020"
      decimals="-5"
      unitRef="Unit_USD">1400000</us-gaap:DebtInstrumentFeeAmount>
    <us-gaap:ProceedsFromLinesOfCredit
      contextRef="P05_01_2021To05_31_2021"
      decimals="-5"
      unitRef="Unit_USD">40000000.0</us-gaap:ProceedsFromLinesOfCredit>
    <us-gaap:DebtInstrumentFaceAmount
      contextRef="PAsOn08_31_2018_NovaquestMemberusgaapTypeOfArrangementAxis"
      decimals="-5"
      unitRef="Unit_USD">100000000.0</us-gaap:DebtInstrumentFaceAmount>
    <us-gaap:DebtInstrumentFaceAmount
      contextRef="PAsOn10_31_2018_NovaquestMemberusgaapTypeOfArrangementAxis"
      decimals="-5"
      unitRef="Unit_USD">17500000</us-gaap:DebtInstrumentFaceAmount>
    <roiv:MaximumMilestonePaymentObligation
      contextRef="PAsOn03_31_2021_NovaquestMemberusgaapTypeOfArrangementAxis_RegulatoryMilestoneMemberusgaapTransactionTypeAxis"
      decimals="-5"
      unitRef="Unit_USD">440600000</roiv:MaximumMilestonePaymentObligation>
    <roiv:MaximumMilestonePaymentObligation
      contextRef="PAsOn03_31_2021_CommercialMilestoneMemberusgaapTransactionTypeAxis_NovaquestMemberusgaapTypeOfArrangementAxis"
      decimals="-5"
      unitRef="Unit_USD">141000000.0</roiv:MaximumMilestonePaymentObligation>
    <roiv:MaximumMilestonePaymentOffsetAmount
      contextRef="PAsOn03_31_2021_NovaquestMemberusgaapTypeOfArrangementAxis_RegulatoryMilestoneMemberusgaapTransactionTypeAxis"
      decimals="-5"
      unitRef="Unit_USD">88100000</roiv:MaximumMilestonePaymentOffsetAmount>
    <us-gaap:DebtInstrumentFairValue
      contextRef="PAsOn03_31_2021_NovaquestMemberusgaapTypeOfArrangementAxis"
      decimals="-5"
      unitRef="Unit_USD">150100000</us-gaap:DebtInstrumentFairValue>
    <us-gaap:DebtInstrumentFairValue
      contextRef="PAsOn03_31_2020_NovaquestMemberusgaapTypeOfArrangementAxis"
      decimals="-5"
      unitRef="Unit_USD">89100000</us-gaap:DebtInstrumentFairValue>
    <srt:ContractualObligationFiscalYearMaturityScheduleTableTextBlock contextRef="P04_01_2020To03_31_2021">&lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Annual maturities, including the end of term charge, of debt outstanding as of&#160;March&#160;31, 2021&#160;are as follows (in thousands). Long-term debt held by Dermavant for which the fair value option has been elected is excluded from the below as the repayment terms are variable. &lt;/div&gt;&lt;/div&gt; &lt;div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 68%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;"&gt;
&lt;tr style="font-size: 0px;"&gt;
&lt;td style="width: 85%; font-family: &amp;quot;Times New Roman&amp;quot;;"/&gt;
&lt;td style="width: 6%; vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"/&gt;
&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;;"/&gt;
&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;;"/&gt;
&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;;"/&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt; &lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt; border-bottom: 1pt solid rgb(0, 0, 0); display: table-cell; line-height: normal;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Years Ending March&#160;31,&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;2022&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;3,129&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;2023&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;13,306&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;2024&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;4,955&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;2025&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;2026&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Thereafter&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Total&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;21,390&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; </srt:ContractualObligationFiscalYearMaturityScheduleTableTextBlock>
    <us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths
      contextRef="PAsOn03_31_2021"
      decimals="-3"
      unitRef="Unit_USD">3129000</us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths>
    <us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo
      contextRef="PAsOn03_31_2021"
      decimals="-3"
      unitRef="Unit_USD">13306000</us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo>
    <us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree
      contextRef="PAsOn03_31_2021"
      decimals="-3"
      unitRef="Unit_USD">4955000</us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree>
    <us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour
      contextRef="PAsOn03_31_2021"
      decimals="-3"
      unitRef="Unit_USD">0</us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour>
    <us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive
      contextRef="PAsOn03_31_2021"
      decimals="-3"
      unitRef="Unit_USD">0</us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive>
    <us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalAfterYearFive
      contextRef="PAsOn03_31_2021"
      decimals="-3"
      unitRef="Unit_USD">0</us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalAfterYearFive>
    <roiv:LongTermDebtExcludingDebtWithFairValueOption
      contextRef="PAsOn03_31_2021"
      decimals="-3"
      unitRef="Unit_USD">21390000</roiv:LongTermDebtExcludingDebtWithFairValueOption>
    <us-gaap:RelatedPartyTransactionsDisclosureTextBlock contextRef="P04_01_2020To03_31_2021">&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Note 9&#x2014;Related Party Transactions &lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Transition Services Agreement and Strategic Cooperation Agreement with Sumitomo &lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Concurrently with the Sumitomo Transaction Agreement, (i)&#160;RSL, Sumitomo and Sumitovant entered into a transition services agreement, whereby each of the parties thereto agreed to provide certain services to one another at cost for a period of time following the Sumitomo Closing Date and (ii)&#160;RSL and Sumitomo entered into a strategic cooperation agreement relating to certain ongoing technology-related collaborations between the parties. Pursuant to the terms of the transition services agreement and strategic cooperation agreement, RSL billed Sumitovant $1.4&#160;million and $0.2&#160;million, net of amounts billed by Sumitovant to RSL, respectively, during the years ended March&#160;31, 2021 and 2020 for costs incurred on behalf of Sumitovant, which were recorded as offsets to the general and administrative expenses initially charged. Additionally, during the years ended March&#160;31, 2021 and 2020, the Company paid Sumitomo a $1.0&#160;million access fee pursuant to the strategic cooperation agreement. &lt;/div&gt;&lt;/div&gt;</us-gaap:RelatedPartyTransactionsDisclosureTextBlock>
    <us-gaap:CostsAndExpensesRelatedParty
      contextRef="P04_01_2020To03_31_2021_SumitovantMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis"
      decimals="-5"
      unitRef="Unit_USD">1400000</us-gaap:CostsAndExpensesRelatedParty>
    <us-gaap:CostsAndExpensesRelatedParty
      contextRef="P04_01_2019To03_31_2020_SumitovantMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis"
      decimals="-5"
      unitRef="Unit_USD">200000</us-gaap:CostsAndExpensesRelatedParty>
    <us-gaap:RelatedPartyTransactionAmountsOfTransaction
      contextRef="P04_01_2019To03_31_2020_SumitomoMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis"
      decimals="-5"
      unitRef="Unit_USD">1000000.0</us-gaap:RelatedPartyTransactionAmountsOfTransaction>
    <us-gaap:RelatedPartyTransactionAmountsOfTransaction
      contextRef="P04_01_2020To03_31_2021_SumitomoMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis"
      decimals="-5"
      unitRef="Unit_USD">1000000.0</us-gaap:RelatedPartyTransactionAmountsOfTransaction>
    <us-gaap:StockholdersEquityNoteDisclosureTextBlock contextRef="P04_01_2020To03_31_2021">&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Note 10&#x2014;Shareholders&#x2019; Equity and Redeemable Noncontrolling Interest &lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;(A) Sumitomo Transaction Agreement and Roivant Equity Repurchase &lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;In December 2019, RSL and Sumitomo completed the transactions contemplated by the Sumitomo Transaction Agreement; see Note 5, &#x201c;Sumitomo Transaction Agreement.&#x201d; Pursuant to the Sumitomo Transaction Agreement, &lt;/div&gt;&lt;/div&gt; &lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;RSL issued 26,952,143 common shares to Sumitomo at closing at a price per share of $37.10 for allocated net proceeds of approximately $999.2&#160;million, after offering expenses incurred. In connection with the Sumitomo Closing Date, RSL&#x2019;s board of directors approved a repurchase of up to $1.0&#160;billion of the Company&#x2019;s equity securities using the proceeds received from Sumitomo. &lt;/div&gt;&lt;/div&gt; &lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;In February 2020, the Company launched &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;one-time&lt;/div&gt; offers to purchase up to $1.0&#160;billion of issued and outstanding equity securities of the Company (the &#x201c;Roivant Equity Repurchase&#x201d;). The offers included (i) an offer to repurchase up to approximately 11.23% of the common stock held by each holder (and its affiliates) of the Company&#x2019;s common stock as of December 26, 2019, at a price per share of $37.10 representing fair value of the common stock, (ii) an offer to purchase vested stock options whose fair market value (as determined as of December 27, 2019) was less than or equal to the fair market value of approximately 11.23% of the earliest-granted of such holder&#x2019;s outstanding vested and unvested stock options, at a purchase price equal to such vested option&#x2019;s fair market value, and (iii) an offer to holders of performance restricted stock units (&#x201c;pRSUs&#x201d;) to surrender 100% of their existing pRSUs in exchange for newly issued performance stock options and capped value appreciation rights. The offer to the holders of pRSUs included an offer by the Company to immediately purchase approximately 11.23% of the newly issued performance stock options and capped value appreciation rights for cash. The Company additionally entered into an agreement with the Company&#x2019;s Founder to repurchase a portion of his common stock held and exchange his pRSUs for performance stock options and capped value appreciation rights. A summary of payments made during the year ended March&#160;31, 2020 relating to the purchase of equity securities by the Company is as follows (in thousands): &lt;/div&gt; &lt;div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 68%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;"&gt;
&lt;tr style="font-size: 0px;"&gt;
&lt;td style="width: 79%;"/&gt;
&lt;td style="width: 11%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Cash&#160;Payment&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Common stock&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;950,722&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Other equity instruments&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;39,292&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Total cash paid&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;990,014&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt; &lt;/tr&gt; &lt;/table&gt;  &lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;(B) Consolidated Vant Equity Transactions &lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;Cytovant Sciences HK Limited &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;In March 2020, Cytovant Sciences HK Limited (&#x201c;Cytovant&#x201d;), a subsidiary of the Company, issued and sold 20,085,301 Series &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;A-1&lt;/div&gt; preference shares at a purchase price of $&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;1.17&lt;/div&gt; per share to third party investors for aggregate net proceeds of $22.5&#160;million after deducting offering costs. The preferred stock is convertible into ordinary shares of Cytovant at any time at the option of the investor, or automatically upon a qualified initial public offering (&#x201c;Qualified IPO&#x201d;) as defined in the subscription agreement. If a Qualified IPO is not completed within five years of the initial investment, Series A preference shareholders can force a sale or liquidation of Cytovant. The Series &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;A-1&lt;/div&gt; preference shares are classified as redeemable noncontrolling interest in the accompanying consolidated balance sheets and consolidated statements of shareholders&#x2019; equity and redeemable noncontrolling interest as the Company can be obligated to repurchase the Series A-1 preference shares upon the occurrence of certain contingent events outside the Company&#x2019;s control. No dividends shall accrue or be payable on the convertible and redeemable preferred stock unless otherwise determined by the board of directors of Cytovant. The Company did not accrete changes in the redemption value as of March&#160;31, 2021 as the Company considers the events leading to a redemption of the convertible and redeemable preferred stock as not probable. &lt;/div&gt; &lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;Immunovant &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;In September 2019, Immunovant Sciences Ltd. (&#x201c;ISL&#x201d;) entered into a share exchange agreement (the &#x201c;Share Exchange Agreement&#x201d;) with Health Sciences Acquisitions Corporation (&#x201c;HSAC&#x201d;), and in December 2019, ISL and HSAC completed the transactions contemplated by the Share Exchange Agreement (the &#x201c;Business Combination&#x201d;). At closing, HSAC acquired 100% of the issued and outstanding common shares of ISL in exchange for 42,080,376 shares of HSAC&#x2019;s common stock issued to HSAC, ISL, and the shareholders of ISL (together, the &#x201c;Sellers&#x201d;) and 10,000 shares of HSAC Series A preferred shares issued to RSL. Additionally, as &lt;/div&gt;&lt;/div&gt; &lt;div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;  &lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;part of its initial public offering in May 2019, HSAC issued common stock warrants, which are classified in equity. Upon completion of the Business Combination, 11,500,000 warrants were outstanding for the purchase of &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;one-half&lt;/div&gt; of one share of common stock (an aggregate of 5,750,000 common shares) at a price of $11.50 per whole share. Upon closing, ISL became a wholly owned subsidiary of HSAC and HSAC was renamed &#x201c;Immunovant, Inc.&#x201d; The Business Combination was accounted for as a reverse recapitalization and HSAC was treated as the &#x201c;acquired&#x201d; company for accounting purposes. Accordingly, for accounting purposes, the Business Combination was treated as the equivalent of ISL issuing equity for the net assets of HSAC, accompanied by a recapitalization. Immunovant, Inc. received $111.0&#160;million in cash as a result of the Business Combination, consisting of the funds held in HSAC&#x2019;s trust account. The proceeds included $5.1&#160;million related to common shares purchased by RSL. &lt;/div&gt; &lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;The sellers were entitled to receive an additional 20,000,000 shares of Immunovant, Inc.&#x2019;s common stock (the &#x201c;Earnout Shares&#x201d;) if the volume-weighted average price of Immunovant, Inc.&#x2019;s shares equaled or exceeded the following prices for any 20 trading days within any 30 &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;trading-day&lt;/div&gt; period (the &#x201c;Trading Period&#x201d;) following the closing of the Business Combination: &lt;/div&gt; &lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt; margin-left: 4%;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;(i) during any Trading Period prior to March&#160;31, 2023, 10,000,000 Earnout Shares upon the achievement of a volume-weighted average price of at least $17.50 per share; and &lt;/div&gt;&lt;/div&gt; &lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt; margin-left: 4%;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;(ii) during any Trading Period prior to March&#160;31, 2025, 10,000,000 Earnout Shares upon the achievement of a volume-weighted average price of at least $31.50 per share. &lt;/div&gt;&lt;/div&gt; &lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;In May 2020 and September 2020, Immunovant, Inc. achieved the first earnout milestone and second earnout milestone, respectively, under the Share Exchange Agreement and, as a result, all of the 20,000,000 earnout shares of Immunovant, Inc.&#x2019;s common stock were issued to former stockholders of ISL, including 17,547,938 shares of common stock issued to RSL. In addition, upon the achievement of the first earnout milestone and second earnout milestone and pursuant to the restricted stock agreement entered into between HSAC and Health Sciences Holdings, LLC (the &#x201c;Sponsor&#x201d;), all of the 1,800,000 shares of the Sponsor&#x2019;s restricted shares vested and are no longer subject to forfeiture. &lt;/div&gt;&lt;/div&gt; &lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Immediately prior to the closing of the Business Combination, as described above, ISL&#x2019;s convertible promissory notes were automatically converted into an aggregate of 7,156,495 common shares of ISL, which were then exchanged for an aggregate of 3,499,995 shares of Immunovant, Inc. common stock upon the closing of transactions contemplated by the Share Exchange Agreement. The conversion of ISL&#x2019;s convertible promissory notes resulted in an increase to equity by $&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;35.6&#160;&lt;/div&gt;million, the carrying amount of the convertible promissory notes. The conversion included a convertible promissory note held by RSL for $2.5&#160;million. &lt;/div&gt;&lt;/div&gt; &lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;In April 2020, Immunovant, Inc. completed an underwritten public offering of 9,613,365 shares of its common stock, including 1,034,483 shares of common stock purchased by RSL, at a price of $14.50 per share for net proceeds to Immunovant, Inc. of approximately $131.0&#160;million, after deducting underwriting discounts and commissions and offering expenses. The proceeds included $15.0&#160;million received from RSL. &lt;/div&gt;&lt;/div&gt; &lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;In May 2020, Immunovant, Inc.&#x2019;s 11,500,000 outstanding warrants became exercisable for an aggregate of 5,750,000 shares of Immunovant, Inc.&#x2019;s common stock at a price of $11.50 per share. An aggregate of 11,438,290 outstanding warrants were exercised for an aggregate of 5,719,145 shares of Immunovant, Inc.&#x2019;s common stock at a price of $11.50 per share, for net proceeds of approximately $65.8&#160;million. The remaining 61,710 warrants were cancelled. &lt;/div&gt;&lt;/div&gt; &lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;In September 2020, Immunovant, Inc. completed an underwritten public offering of 6,060,606 shares of its common stock, including 380,000 shares of common stock purchased by RSL, at a price of $33.00 per share for net proceeds to Immunovant, Inc. of approximately $188.1&#160;million, after deducting underwriting discounts and commissions and offering expenses. The proceeds included $12.5&#160;million received from RSL. &lt;/div&gt;&lt;/div&gt;  &lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;Sinovant &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Sinovant, a subsidiary of the Company, previously issued and sold preferred stock convertible into ordinary shares of Sinovant at any time at the option of the investors or automatically upon a qualified initial public offering (&#x201c;Qualified IPO&#x201d;) as defined in the subscription agreement relating to the sale of the preferred stock. The convertible preferred stock was redeemable at the option of the investor if a Qualified IPO was not completed within five years of the initial investment and was payable in cash equal to the investment amount plus an annualized return of 12%. As such events are not within the control of the Company, the preferred stock was previously classified as redeemable noncontrolling interest in the accompanying consolidated balance sheets and consolidated statements of shareholders&#x2019; equity and redeemable noncontrolling interest. No dividends accrued or were payable on the convertible preferred stock. In January 2020, Sinovant&#x2019;s parent company, Roivant China Holdings Ltd. (&#x201c;RCHL&#x201d;), purchased all preferred stock of Sinovant held by third parties at a purchase price of $12.26 per preferred share for an aggregate purchase price of $132.9&#160;million. Consideration paid in excess of the carrying value for the repurchase of redeemable noncontrolling interest of $77.8&#160;million is considered a deemed dividend. See Note 18, &#x201c;Earnings per Common Share&#x201d; for resulting impact to earnings per share. &lt;/div&gt;&lt;/div&gt; </us-gaap:StockholdersEquityNoteDisclosureTextBlock>
    <us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction
      contextRef="P12_27_2019To12_27_2019_SumitomoMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis"
      decimals="0"
      unitRef="Unit_shares">26952143</us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction>
    <us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction
      contextRef="P12_01_2019To12_31_2019_SumitomoMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis"
      decimals="0"
      unitRef="Unit_shares">26952143</us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="P04_01_2019To03_31_2020_CommonStockMemberusgaapStatementEquityComponentsAxis"
      decimals="0"
      unitRef="Unit_shares">26952143</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:SaleOfStockPricePerShare
      contextRef="PAsOn12_26_2019_RoivantEquityRepurchaseMemberusgaapShareRepurchaseProgramAxis_SumitomoTransactionAgreementMemberusgaapTypeOfArrangementAxis"
      decimals="2"
      unitRef="Unit_USD_per_Share">37.10</us-gaap:SaleOfStockPricePerShare>
    <us-gaap:SharesIssuedPricePerShare
      contextRef="PAsOn12_31_2019_SumitomoMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis"
      decimals="2"
      unitRef="Unit_USD_per_Share">37.10</us-gaap:SharesIssuedPricePerShare>
    <us-gaap:SaleOfStockConsiderationReceivedOnTransaction
      contextRef="P12_01_2019To12_31_2019_SumitomoMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis"
      decimals="-5"
      unitRef="Unit_USD">999200000</us-gaap:SaleOfStockConsiderationReceivedOnTransaction>
    <us-gaap:StockRepurchaseProgramAuthorizedAmount1
      contextRef="PAsOn12_31_2019_MaximumMembersrtRangeAxis_SumitomoMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis"
      decimals="-8"
      unitRef="Unit_USD">1000000000.0</us-gaap:StockRepurchaseProgramAuthorizedAmount1>
    <us-gaap:StockRepurchaseProgramAuthorizedAmount1
      contextRef="PAsOn02_29_2020_MaximumMembersrtRangeAxis_RoivantEquityRepurchaseMemberusgaapShareRepurchaseProgramAxis_SumitomoTransactionAgreementMemberusgaapTypeOfArrangementAxis"
      decimals="-8"
      unitRef="Unit_USD">1000000000.0</us-gaap:StockRepurchaseProgramAuthorizedAmount1>
    <us-gaap:TreasuryStockAcquiredRepurchaseAuthorization contextRef="P04_01_2020To03_31_2021_RoivantEquityRepurchaseMemberusgaapShareRepurchaseProgramAxis_SumitomoTransactionAgreementMemberusgaapTypeOfArrangementAxis">The offers included (i) an offer to repurchase up to approximately 11.23% of the common stock held by each holder (and its affiliates) of the Company&#x2019;s common stock as of December 26, 2019, at a price per share of $37.10 representing fair value of the common stock, (ii) an offer to purchase vested stock options whose fair market value (as determined as of December 27, 2019) was less than or equal to the fair market value of approximately 11.23% of the earliest-granted of such holder&#x2019;s outstanding vested and unvested stock options, at a purchase price equal to such vested option&#x2019;s fair market value, and (iii) an offer to holders of performance restricted stock units (&#x201c;pRSUs&#x201d;) to surrender 100% of their existing pRSUs in exchange for newly issued performance stock options and capped value appreciation rights. The offer to the holders of pRSUs included an offer by the Company to immediately purchase approximately 11.23% of the newly issued performance stock options and capped value appreciation rights for cash.</us-gaap:TreasuryStockAcquiredRepurchaseAuthorization>
    <roiv:PercentageSharesOfCommonStockOfferedToBeRepurchased
      contextRef="P12_26_2019To12_26_2019_RoivantEquityRepurchaseMemberusgaapShareRepurchaseProgramAxis_SumitomoTransactionAgreementMemberusgaapTypeOfArrangementAxis"
      decimals="4"
      unitRef="Unit_pure">0.1123</roiv:PercentageSharesOfCommonStockOfferedToBeRepurchased>
    <us-gaap:ScheduleOfStockholdersEquityTableTextBlock contextRef="P04_01_2020To03_31_2021">A summary of payments made during the year ended March&#160;31, 2020 relating to the purchase of equity securities by the Company is as follows (in thousands):
&lt;table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 68%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;"&gt;
&lt;tr style="font-size: 0px;"&gt;
&lt;td style="width: 79%;"/&gt;
&lt;td style="width: 11%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Cash&#160;Payment&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Common stock&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;950,722&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Other equity instruments&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;39,292&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Total cash paid&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;990,014&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; </us-gaap:ScheduleOfStockholdersEquityTableTextBlock>
    <us-gaap:PaymentsForRepurchaseOfCommonStock
      contextRef="P04_01_2019To03_31_2020"
      decimals="-3"
      unitRef="Unit_USD">950722000</us-gaap:PaymentsForRepurchaseOfCommonStock>
    <us-gaap:PaymentsForRepurchaseOfOtherEquity
      contextRef="P04_01_2019To03_31_2020"
      decimals="-3"
      unitRef="Unit_USD">39292000</us-gaap:PaymentsForRepurchaseOfOtherEquity>
    <us-gaap:PaymentsForRepurchaseOfEquity
      contextRef="P04_01_2019To03_31_2020"
      decimals="-3"
      unitRef="Unit_USD">990014000</us-gaap:PaymentsForRepurchaseOfEquity>
    <us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction
      contextRef="P03_01_2020To03_31_2020_CytovantScienceHkLtdMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis_SeriesA1PreferredStockMemberusgaapStatementClassOfStockAxis"
      decimals="0"
      unitRef="Unit_shares">20085301</us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction>
    <us-gaap:SharesIssuedPricePerShare
      contextRef="PAsOn03_31_2020_CytovantScienceHkLtdMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis_SeriesA1PreferredStockMemberusgaapStatementClassOfStockAxis"
      decimals="2"
      unitRef="Unit_USD_per_Share">1.17</us-gaap:SharesIssuedPricePerShare>
    <us-gaap:SaleOfStockConsiderationReceivedOnTransaction
      contextRef="P03_01_2020To03_31_2020_CytovantScienceHkLtdMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis_SeriesA1PreferredStockMemberusgaapStatementClassOfStockAxis"
      decimals="-5"
      unitRef="Unit_USD">22500000</us-gaap:SaleOfStockConsiderationReceivedOnTransaction>
    <us-gaap:BusinessAcquisitionPercentageOfVotingInterestsAcquired
      contextRef="PAsOn09_30_2019_HealthSciencesMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis_ImmunovantINCMemberusgaapBusinessAcquisitionAxis"
      decimals="2"
      unitRef="Unit_pure">1</us-gaap:BusinessAcquisitionPercentageOfVotingInterestsAcquired>
    <us-gaap:BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued
      contextRef="P09_01_2019To09_30_2019_CommonStockMemberusgaapStatementEquityComponentsAxis_HealthSciencesMemberusgaapBusinessAcquisitionAxis"
      decimals="0"
      unitRef="Unit_shares">42080376</us-gaap:BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued>
    <us-gaap:BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued
      contextRef="P09_01_2019To09_30_2019_HealthSciencesMemberusgaapBusinessAcquisitionAxis_SeriesA1PreferredStockMemberusgaapStatementClassOfStockAxis"
      decimals="0"
      unitRef="Unit_shares">10000</us-gaap:BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued>
    <us-gaap:ClassOfWarrantOrRightOutstanding
      contextRef="PAsOn09_30_2019_HealthSciencesMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis"
      decimals="0"
      unitRef="Unit_shares">11500000</us-gaap:ClassOfWarrantOrRightOutstanding>
    <us-gaap:ClassOfWarrantOrRightOutstanding
      contextRef="PAsOn09_30_2019_CommonStockMemberusgaapStatementEquityComponentsAxis_HealthSciencesMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis"
      decimals="0"
      unitRef="Unit_shares">5750000</us-gaap:ClassOfWarrantOrRightOutstanding>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="PAsOn09_30_2019_HealthSciencesMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis"
      decimals="2"
      unitRef="Unit_USD_per_Share">11.50</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:PaymentsForProceedsFromBusinessesAndInterestInAffiliates
      contextRef="P09_01_2019To09_30_2019_HealthSciencesMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis_ImmunovantINCMemberusgaapBusinessAcquisitionAxis"
      decimals="-5"
      unitRef="Unit_USD">111000000.0</us-gaap:PaymentsForProceedsFromBusinessesAndInterestInAffiliates>
    <us-gaap:BusinessAcquisitionEquityInterestIssuedOrIssuableValueAssigned
      contextRef="PAsOn09_30_2019_HealthSciencesMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis_ImmunovantINCMemberusgaapBusinessAcquisitionAxis"
      decimals="-5"
      unitRef="Unit_USD">5100000</us-gaap:BusinessAcquisitionEquityInterestIssuedOrIssuableValueAssigned>
    <us-gaap:WeightedAverageNumberOfSharesContingentlyIssuable
      contextRef="P04_01_2020To03_31_2021_ImmunovantINCMemberusgaapBusinessAcquisitionAxis"
      decimals="0"
      unitRef="Unit_shares">20000000</us-gaap:WeightedAverageNumberOfSharesContingentlyIssuable>
    <roiv:EarnOutSharesTermsDescription contextRef="P04_01_2020To03_31_2021">(i) during any Trading Period prior to March&#160;31, 2023, 10,000,000 Earnout Shares upon the achievement of a volume-weighted average price of at least $17.50 per share; and  (ii) during any Trading Period prior to March&#160;31, 2025, 10,000,000 Earnout Shares upon the achievement of a volume-weighted average price of at least $31.50 per share. </roiv:EarnOutSharesTermsDescription>
    <us-gaap:CommonStockSharesIssued
      contextRef="PAsOn05_31_2020_ImmunovantSciencesLtdMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis"
      decimals="0"
      unitRef="Unit_shares">20000000</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockSharesIssued
      contextRef="PAsOn09_30_2020_ImmunovantSciencesLtdMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis"
      decimals="0"
      unitRef="Unit_shares">20000000</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockSharesIssued
      contextRef="PAsOn09_30_2020"
      decimals="0"
      unitRef="Unit_shares">17547938</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockSharesIssued
      contextRef="PAsOn05_31_2021"
      decimals="0"
      unitRef="Unit_shares">17547938</us-gaap:CommonStockSharesIssued>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod
      contextRef="P05_01_2020To05_31_2020_ImmunovantSciencesLtdMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis_RestrictedStockMemberusgaapAwardTypeAxis"
      decimals="0"
      unitRef="Unit_shares">1800000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod
      contextRef="P08_25_2020To09_30_2020_ImmunovantSciencesLtdMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis_RestrictedStockMemberusgaapAwardTypeAxis"
      decimals="0"
      unitRef="Unit_shares">1800000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod>
    <us-gaap:DebtConversionConvertedInstrumentSharesIssued1
      contextRef="P04_01_2020To03_31_2021_ConvertibleNotesPayableMemberusgaapShortTermDebtTypeAxis_ImmunovantINCMemberusgaapBusinessAcquisitionAxis"
      decimals="0"
      unitRef="Unit_shares">7156495</us-gaap:DebtConversionConvertedInstrumentSharesIssued1>
    <us-gaap:DebtConversionConvertedInstrumentSharesIssued1
      contextRef="P04_01_2020To03_31_2021_ConvertibleNotesPayableMemberusgaapShortTermDebtTypeAxis_ImmunovantSciencesLtdMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis"
      decimals="0"
      unitRef="Unit_shares">3499995</us-gaap:DebtConversionConvertedInstrumentSharesIssued1>
    <us-gaap:DebtInstrumentConvertibleCarryingAmountOfTheEquityComponent
      contextRef="PAsOn03_31_2021_ConvertibleNotesPayableMemberusgaapShortTermDebtTypeAxis"
      decimals="-5"
      unitRef="Unit_USD">35600000</us-gaap:DebtInstrumentConvertibleCarryingAmountOfTheEquityComponent>
    <us-gaap:DebtConversionConvertedInstrumentSharesIssued1
      contextRef="P04_01_2020To03_31_2021_ConvertibleNotesPayableMemberusgaapShortTermDebtTypeAxis"
      decimals="-5"
      unitRef="Unit_shares">2500000</us-gaap:DebtConversionConvertedInstrumentSharesIssued1>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="P04_01_2020To04_30_2020_CommonStockMemberusgaapStatementEquityComponentsAxis_ImmunovantINCMemberusgaapBusinessAcquisitionAxis_UnderwrittenPublicOfferingMemberusgaapSubsidiarySaleOfStockAxis"
      decimals="0"
      unitRef="Unit_shares">9613365</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="P04_01_2020To04_30_2020_CommonStockMemberusgaapStatementEquityComponentsAxis_UnderwrittenPublicOfferingMemberusgaapSubsidiarySaleOfStockAxis"
      decimals="0"
      unitRef="Unit_shares">1034483</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:SaleOfStockPricePerShare
      contextRef="PAsOn04_30_2020_CommonStockMemberusgaapStatementEquityComponentsAxis_ImmunovantINCMemberusgaapBusinessAcquisitionAxis_UnderwrittenPublicOfferingMemberusgaapSubsidiarySaleOfStockAxis"
      decimals="2"
      unitRef="Unit_USD_per_Share">14.50</us-gaap:SaleOfStockPricePerShare>
    <us-gaap:ProceedsFromIssuanceOfCommonStock
      contextRef="P04_01_2020To04_30_2020_CommonStockMemberusgaapStatementEquityComponentsAxis_ImmunovantINCMemberusgaapBusinessAcquisitionAxis_UnderwrittenPublicOfferingMemberusgaapSubsidiarySaleOfStockAxis"
      decimals="-5"
      unitRef="Unit_USD">131000000.0</us-gaap:ProceedsFromIssuanceOfCommonStock>
    <us-gaap:ProceedsFromIssuanceOfCommonStock
      contextRef="P04_01_2020To04_30_2020_CommonStockMemberusgaapStatementEquityComponentsAxis_UnderwrittenPublicOfferingMemberusgaapSubsidiarySaleOfStockAxis"
      decimals="-5"
      unitRef="Unit_USD">15000000.0</us-gaap:ProceedsFromIssuanceOfCommonStock>
    <roiv:ClassOfWarrantOrRightExercisable
      contextRef="PAsOn05_31_2020_ImmunovantINCMemberusgaapBusinessAcquisitionAxis_WarrantMemberusgaapStatementEquityComponentsAxis"
      decimals="0"
      unitRef="Unit_shares">11500000</roiv:ClassOfWarrantOrRightExercisable>
    <us-gaap:ClassOfWarrantOrRightOutstanding
      contextRef="PAsOn05_31_2020_ImmunovantINCMemberusgaapBusinessAcquisitionAxis_WarrantMemberusgaapStatementEquityComponentsAxis"
      decimals="0"
      unitRef="Unit_shares">5750000</us-gaap:ClassOfWarrantOrRightOutstanding>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="PAsOn05_31_2020_ImmunovantINCMemberusgaapBusinessAcquisitionAxis_WarrantMemberusgaapStatementEquityComponentsAxis"
      decimals="2"
      unitRef="Unit_USD_per_Share">11.50</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <roiv:ClassOfWarrantOrRightExercisable
      contextRef="PAsOn03_31_2021_ImmunovantINCMemberusgaapBusinessAcquisitionAxis_WarrantMemberusgaapStatementEquityComponentsAxis"
      decimals="0"
      unitRef="Unit_shares">11438290</roiv:ClassOfWarrantOrRightExercisable>
    <roiv:ClassOfWarrantOrRightExercisable
      contextRef="PAsOn03_31_2021_ImmunovantINCMemberusgaapBusinessAcquisitionAxis_WarrantMemberusgaapStatementEquityComponentsAxis"
      decimals="0"
      unitRef="Unit_shares">11438290</roiv:ClassOfWarrantOrRightExercisable>
    <us-gaap:ClassOfWarrantOrRightOutstanding
      contextRef="PAsOn03_31_2021_ImmunovantINCMemberusgaapBusinessAcquisitionAxis_WarrantMemberusgaapStatementEquityComponentsAxis"
      decimals="0"
      unitRef="Unit_shares">5719145</us-gaap:ClassOfWarrantOrRightOutstanding>
    <us-gaap:ClassOfWarrantOrRightOutstanding
      contextRef="PAsOn03_31_2021_ImmunovantINCMemberusgaapBusinessAcquisitionAxis_WarrantMemberusgaapStatementEquityComponentsAxis"
      decimals="0"
      unitRef="Unit_shares">5719145</us-gaap:ClassOfWarrantOrRightOutstanding>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="PAsOn03_31_2021_ImmunovantINCMemberusgaapBusinessAcquisitionAxis_WarrantMemberusgaapStatementEquityComponentsAxis"
      decimals="2"
      unitRef="Unit_USD_per_Share">11.50</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="PAsOn03_31_2021_ImmunovantINCMemberusgaapBusinessAcquisitionAxis_WarrantMemberusgaapStatementEquityComponentsAxis"
      decimals="2"
      unitRef="Unit_USD_per_Share">11.50</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:ProceedsFromIssuanceOfWarrants
      contextRef="P04_01_2020To03_31_2021_ImmunovantINCMemberusgaapBusinessAcquisitionAxis_WarrantMemberusgaapStatementEquityComponentsAxis"
      decimals="-5"
      unitRef="Unit_USD">65800000</us-gaap:ProceedsFromIssuanceOfWarrants>
    <us-gaap:AdjustmentOfWarrantsGrantedForServices
      contextRef="P04_01_2020To03_31_2021_ImmunovantINCMemberusgaapBusinessAcquisitionAxis_WarrantMemberusgaapStatementEquityComponentsAxis"
      decimals="-3"
      unitRef="Unit_USD">61710000</us-gaap:AdjustmentOfWarrantsGrantedForServices>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="P08_25_2020To09_30_2020_CommonStockMemberusgaapStatementEquityComponentsAxis_ImmunovantINCMemberusgaapBusinessAcquisitionAxis_UnderwrittenPublicOfferingMemberusgaapSubsidiarySaleOfStockAxis"
      decimals="0"
      unitRef="Unit_shares">6060606</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="P08_25_2020To09_30_2020_CommonStockMemberusgaapStatementEquityComponentsAxis_UnderwrittenPublicOfferingMemberusgaapSubsidiarySaleOfStockAxis"
      decimals="0"
      unitRef="Unit_shares">380000</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:SaleOfStockPricePerShare
      contextRef="PAsOn09_30_2020_CommonStockMemberusgaapStatementEquityComponentsAxis_ImmunovantINCMemberusgaapBusinessAcquisitionAxis_UnderwrittenPublicOfferingMemberusgaapSubsidiarySaleOfStockAxis"
      decimals="2"
      unitRef="Unit_USD_per_Share">33.00</us-gaap:SaleOfStockPricePerShare>
    <us-gaap:ProceedsFromIssuanceOfCommonStock
      contextRef="P08_25_2020To09_30_2020_CommonStockMemberusgaapStatementEquityComponentsAxis_ImmunovantINCMemberusgaapBusinessAcquisitionAxis_UnderwrittenPublicOfferingMemberusgaapSubsidiarySaleOfStockAxis"
      decimals="-5"
      unitRef="Unit_USD">188100000</us-gaap:ProceedsFromIssuanceOfCommonStock>
    <us-gaap:ProceedsFromIssuanceOfCommonStock
      contextRef="P08_25_2020To09_30_2020_CommonStockMemberusgaapStatementEquityComponentsAxis_UnderwrittenPublicOfferingMemberusgaapSubsidiarySaleOfStockAxis"
      decimals="-5"
      unitRef="Unit_USD">12500000</us-gaap:ProceedsFromIssuanceOfCommonStock>
    <us-gaap:InvestmentCompanyInternalRateOfReturnSinceInception
      contextRef="P03_01_2021To03_31_2021_SinovantIncMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis"
      decimals="2"
      unitRef="Unit_pure">0.12</us-gaap:InvestmentCompanyInternalRateOfReturnSinceInception>
    <us-gaap:PreferredStockRedemptionPricePerShare
      contextRef="PAsOn01_31_2020_SinovantIncMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis"
      decimals="2"
      unitRef="Unit_USD_per_Share">12.26</us-gaap:PreferredStockRedemptionPricePerShare>
    <us-gaap:PaymentsForRepurchaseOfRedeemableConvertiblePreferredStock
      contextRef="P01_01_2020To01_31_2020_SinovantIncMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis"
      decimals="-5"
      unitRef="Unit_USD">132900000</us-gaap:PaymentsForRepurchaseOfRedeemableConvertiblePreferredStock>
    <us-gaap:PaymentsForRepurchaseOfRedeemableNoncontrollingInterest
      contextRef="P01_01_2020To01_31_2020_SinovantIncMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis"
      decimals="-5"
      unitRef="Unit_USD">77800000</us-gaap:PaymentsForRepurchaseOfRedeemableNoncontrollingInterest>
    <us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock contextRef="P04_01_2020To03_31_2021">&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Note 11&#x2014;Share-Based Compensation &lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;(A) RSL 2015 Equity Incentive Plan &lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;As of March&#160;31, 2021, 22,800,000 of the Company&#x2019;s common shares (the &#x201c;Share Reserve&#x201d;) are reserved for issuance under the RSL Amended and Restated 2015 Equity Incentive Plan (the &#x201c;RSL 2015 EIP&#x201d;). At March&#160;31, 2021, a total of 10,296,392 common shares are available for future grants under the RSL 2015 EIP. The Company&#x2019;s employees, directors, and consultants are eligible to receive nonstatutory and incentive stock options, stock appreciation rights, restricted stock awards, restricted stock unit awards, and other stock awards under the RSL 2015 EIP. &lt;/div&gt;&lt;/div&gt; &lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;As of March&#160;31, 2021, an aggregate of 26,558,238 of the Company&#x2019;s common shares (the &#x201c;Special Reserve&#x201d;) were reserved for the granting under RSL 2015 EIP of performance stock options (&#x201c;Performance Options&#x201d;) and capped value appreciation rights (&#x201c;CVARs&#x201d;) to the Company&#x2019;s employees, directors and consultants. At March&#160;31, 2021, there are no common shares available for future grant under the Special Reserve. &lt;/div&gt;&lt;/div&gt; &lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;Stock Options &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;For the years ended March&#160;31, 2021 and 2020, the Company recorded share-based compensation expense related to stock options issued under the RSL 2015 EIP to employees and directors of approximately $32.3&#160;million and $31.8&#160;million, respectively, and was included in research and development and general and administrative expenses in the accompanying consolidated statements of operations. &lt;/div&gt;&lt;/div&gt; &lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;At March&#160;31, 2021, total unrecognized compensation expense related to &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;non-vested&lt;/div&gt; stock options was approximately $70.8&#160;million and is expected to be recognized over the remaining weighted-average service period of 2.96 years. &lt;/div&gt; &lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;The Company estimated the fair value of each stock option on the date of grant using the Black-Scholes closed form option-pricing model applying the weighted average assumptions in the following table. &lt;/div&gt;&lt;/div&gt; &lt;div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 76%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;"&gt;
&lt;tr style="font-size: 0px;"&gt;
&lt;td style="width: 73%;"/&gt;
&lt;td style="width: 9%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="width: 8%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="6" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Years&#160;Ended&#160;March&#160;31,&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Assumptions&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&#160;2021&#160;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&#160;2020&#160;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Expected stock price volatility&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;74.84&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;%&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;66.47&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;%&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Expected risk free interest rate&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;0.43&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;%&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;2.27&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;%&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Expected term, in years&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;6.25&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;6.72&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Expected dividend yield&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;%&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;%&#160;&lt;/td&gt; &lt;/tr&gt; &lt;/table&gt;  &lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;A summary of stock option activity and data under the RSL 2015 EIP for the year ended March&#160;31, 2021 is as follows: &lt;/div&gt;&lt;/div&gt; &lt;div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 92%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;"&gt;
&lt;tr style="font-size: 0px;"&gt;
&lt;td style="width: 48%;"/&gt;
&lt;td style="width: 7%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="width: 7%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="width: 7%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="width: 7%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Number of&lt;br/&gt; Stock&lt;br/&gt; Options&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Weighted&lt;br/&gt; Average&lt;br/&gt; Exercise&lt;br/&gt; Price&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Weighted&lt;br/&gt; Average Grant&lt;br/&gt; Date&#160;Fair&#160;Value&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Weighted&lt;br/&gt; Average&lt;br/&gt; Remaining&lt;br/&gt; Contractual&#160;Life&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Stock options outstanding at March&#160;31, 2020&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;8,176,814&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;24.52&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;16.53&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;7.93&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Granted&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;1,482,604&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;38.71&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;25.37&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Forfeited/Canceled&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;(270,047&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;29.89&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;19.85&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Stock options outstanding at March&#160;31, 2021&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;9,389,371&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;26.61&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;17.90&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;7.26&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Stock options exercisable at March&#160;31, 2021&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;5,533,848&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;21.52&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;14.95&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;6.49&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt; &lt;/table&gt;  &lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;At March&#160;31, 2021 and 2020, there were 5,533,848 and 4,123,953 vested stock options, respectively. Additional information regarding stock options is set forth below (in thousands, except per share data). &lt;/div&gt;&lt;/div&gt; &lt;div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 84%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 8pt; border-collapse: collapse; border-spacing: 0px;"&gt;
&lt;tr style="font-size: 0px;"&gt;
&lt;td style="width: 78%;"/&gt;
&lt;td style="width: 4%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="width: 4%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="6" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Years&#160;Ended&#160;March&#160;31,&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2021&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2020&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Grant date fair value of stock options vested&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;25,711&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;33,789&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Weighted-average grant date fair value per share of stock options granted&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;25.37&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;20.63&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt; &lt;/table&gt;  &lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;Restricted Stock Units &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;Restricted stock units will vest upon the achievement of both time-based service requirements and liquidity requirements on or before the grant expiration date. Restricted stock units expire eight years after the date of grant. During the year ended March&#160;31, 2021, the Company recorded no share-based compensation expense related to these restricted stock units as the liquidity event requirement had not been met and was deemed not probable of being met. At March&#160;31, 2021, there was approximately $83.8&#160;million of unrecognized compensation expense related to &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;non-vested&lt;/div&gt; restricted stock units. The Company will recognize the expense upon achievement of both the time-based service requirement and liquidity requirements through the requisite service period. &lt;/div&gt; &lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;A summary of restricted stock units under the RSL 2015 EIP is as follows: &lt;/div&gt;&lt;/div&gt; &lt;div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 76%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;"&gt;
&lt;tr style="font-size: 0px;"&gt;
&lt;td style="width: 58%;"/&gt;
&lt;td style="width: 12%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="width: 12%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Number of&lt;br/&gt; Restricted&#160;Stock&lt;br/&gt; Units&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Weighted&#160;Average&lt;br/&gt; Grant Date Fair&lt;br/&gt; Value&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Non-vested&lt;/div&gt; balance at March&#160;31, 2020&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;1,008,175&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;32.50&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Granted&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;1,454,199&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;39.19&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Forfeited&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;(169,636&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;36.36&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Non-vested&lt;/div&gt; balance at March&#160;31, 2021&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;2,292,738&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;36.53&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt; &lt;/table&gt;  &lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;Performance Options &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;Performance Options will vest upon the achievement of both time-based service requirements and liquidity requirements on or before the grant expiration date of March&#160;31, 2026. During the year ended March&#160;31, 2021, the Company recorded no share-based compensation expense related to these Performance Options as the liquidity event requirement had not been met and was deemed not probable of being met. At March&#160;31, 2021, there was approximately $337.8&#160;million of unrecognized compensation expense related to &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;non-vested&lt;/div&gt; &lt;/div&gt;  &lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Performance Options. The Company will recognize the expense upon achievement of both the time-based service requirement and liquidity requirements through the requisite service period. &lt;/div&gt;&lt;/div&gt; &lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;The Company estimated the fair value of each Performance Option on the date of grant using the Black-Scholes closed form option-pricing model applying the weighted average assumptions in the following table. &lt;/div&gt;&lt;/div&gt; &lt;div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 68%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;"&gt;
&lt;tr style="font-size: 0px;"&gt;
&lt;td style="width: 70%;"/&gt;
&lt;td style="width: 22%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Year&#160;Ended&#160;March&#160;31,&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Assumptions&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2020&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Expected stock price volatility&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;73.60&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;%&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Expected risk free interest rate&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;0.62&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;%&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Expected term&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;6 years&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Expected dividend yield&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;%&#160;&lt;/td&gt; &lt;/tr&gt; &lt;/table&gt;  &lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;A summary of Performance Option activity and data under the RSL 2015 EIP for the year ended March&#160;31, 2021 is as follows: &lt;/div&gt;&lt;/div&gt; &lt;div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 92%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;"&gt;
&lt;tr style="font-size: 0px;"&gt;
&lt;td style="width: 76%;"/&gt;
&lt;td style="width: 4%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="width: 4%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="width: 4%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="width: 4%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Number of&lt;br/&gt; Options&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Weighted&lt;br/&gt; Average&lt;br/&gt; Exercise&#160;Price&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Weighted&lt;br/&gt; Average Grant&lt;br/&gt; Date&#160;Fair&#160;Value&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Weighted&lt;br/&gt; Average&lt;br/&gt; Remaining&lt;br/&gt; Contractual&#160;Life&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Performance Options outstanding at March&#160;31, 2020&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;14,518,870&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;38.97&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;23.78&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;6.00&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Granted&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Forfeited&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;(93,207&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;46.38&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;22.18&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Performance Options outstanding at March&#160;31, 2021&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;14,425,663&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;38.93&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;23.42&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;5.00&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt; &lt;/table&gt;  &lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;No Performance Options were exercisable at March&#160;31, 2021. &lt;/div&gt;&lt;/div&gt; &lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;CVARs &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;CVARs will vest upon the achievement of both time-based service requirements and liquidity requirements on or before the grant expiration date of March 31, 2026. At settlement, each CVAR pays in common shares the excess of (a) the lesser of (i) the fair market value of a common share as of the settlement date or (ii) the cap of $37.10, over (b) the hurdle price of either $18.70 or $33.63, as applicable to each grant. During the year ended March&#160;31, 2021, the Company recorded no share-based compensation expense related to these CVARs as the liquidity event requirement had not been met and was deemed not probable of being met. At March&#160;31, 2021, there was approximately $23.0&#160;million of unrecognized compensation expense related to &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;non-vested&lt;/div&gt; CVARs. The Company will recognize the expense upon achievement of both the time-based service requirement and liquidity requirements through the requisite service period. &lt;/div&gt; &lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;A summary of CVARs under the RSL 2015 EIP is as follows: &lt;/div&gt;&lt;/div&gt; &lt;div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 76%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;"&gt;
&lt;tr style="font-size: 0px;"&gt;
&lt;td style="width: 56%;"/&gt;
&lt;td style="width: 13%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="width: 13%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Number&#160;of&#160;CVARs&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Weighted&#160;Average&lt;br/&gt; Grant Date Fair&lt;br/&gt; Value&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Non-vested&lt;/div&gt; balance at March&#160;31, 2020&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;11,088,658&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;2.07&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Granted&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Forfeited&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Non-vested&lt;/div&gt; balance at March&#160;31, 2021&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;11,088,658&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;2.07&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt; &lt;/table&gt;   &lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;(B) RSL 2015 Restricted Stock Unit Plan &lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Under the Amended and Restated RSL 2015 Restricted Stock Unit Plan (the &#x201c;pRSU Plan&#x201d;), as of March&#160;31, 2021, there are 200,000 of the Company&#x2019;s common shares reserved for issuance in connection with pRSUs that may be granted to employees, officers, directors and consultants of the Company under the pRSU Plan. The pRSUs expire eight years after the date of grant. At March&#160;31, 2021, none of the Company&#x2019;s common shares were reserved for future grants under this plan. &lt;/div&gt;&lt;/div&gt; &lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;As part of the Roivant Equity Repurchase, 17,044,465 existing pRSUs were surrendered and exchanged for newly issued Performance Options and CVARs issued under an amended and restated RSL 2015 EIP (see above), of which approximately 11.23% were then immediately purchased by the Company, during the year ended March&#160;31, 2020. Refer to Note 10, &#x201c;Shareholders&#x2019; Equity and Redeemable Noncontrolling Interest&#x201d; for additional detail regarding the Roivant Equity Repurchase. &lt;/div&gt;&lt;/div&gt; &lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;A summary of pRSU activity under the pRSU Plan is as follows: &lt;/div&gt;&lt;/div&gt; &lt;div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 76%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;"&gt;
&lt;tr style="font-size: 0px;"&gt;
&lt;td style="width: 64%;"/&gt;
&lt;td style="width: 10%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="width: 10%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Number&#160;of&lt;br/&gt; pRSUs&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Weighted&#160;Average&lt;br/&gt; Grant Date Fair&lt;br/&gt; Value&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Non-vested&lt;/div&gt; balance at March&#160;31, 2020&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;266,845&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;13.92&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Granted&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Forfeited&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;(66,845&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;13.92&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Non-vested&lt;/div&gt; balance at March&#160;31, 2021&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;200,000&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;13.92&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt; &lt;/table&gt;  &lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;These pRSUs will vest to the extent certain performance criteria are achieved and certain liquidity conditions are satisfied within specified years of the grant date, provided that the recipient has provided continued service through such date. As of&#160;March&#160;31, 2021, the performance conditions had not been met and were deemed not probable of being met. During the year ended March&#160;31, 2021, the Company recorded&#160;no share-based compensation expense related to these pRSUs. During the year ended March&#160;31, 2020, the Company recorded $12.3&#160;million of share-based compensation expense relating to cash payments made for the purchase of a portion of the Performance Options and CVARs issued in replacement of pRSUs. At March&#160;31, 2021, there was approximately $2.8&#160;million of unrecognized compensation expense related to &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;non-vested&lt;/div&gt; pRSUs. The Company will recognize the expense upon achievement of the performance and liquidity conditions through the requisite service period. &lt;/div&gt; &lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;(C) RSL Restricted Common Stock &lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;A summary of RSL restricted common stock activity as of March&#160;31, 2021 is as follows: &lt;/div&gt;&lt;/div&gt; &lt;div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 76%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;"&gt;
&lt;tr style="font-size: 0px;"&gt;
&lt;td style="width: 64%;"/&gt;
&lt;td style="width: 10%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="width: 10%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Number&#160;of&lt;br/&gt; Restricted&lt;br/&gt; Common&lt;br/&gt; Stock&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Weighted&#160;Average&lt;br/&gt; Grant Date Fair&lt;br/&gt; Value&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Non-vested&lt;/div&gt; balance at March&#160;31, 2020&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Granted&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;587,824&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;38.50&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Vested&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Forfeited&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Non-vested&lt;/div&gt; balance at March&#160;31, 2021&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;587,824&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;38.50&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt; &lt;/table&gt;  &lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;For the year ended March&#160;31, 2021, the Company recorded share-based compensation expense of $0.1&#160;million in relation to the RSL restricted common stock. At March&#160;31, 2021, total unrecognized compensation expense related to &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;non-vested&lt;/div&gt; restricted common stock was approximately $6.9&#160;million and is expected to be recognized over the remaining weighted-average service period of 3.39 years. $15.6&#160;million of the fair value associated with these restricted common stock was attributed to precombination service. Refer to Note 4, &#x201c;Asset Acquisitions and License Agreements.&#x201d; &lt;/div&gt;  &lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;(D) Subsidiary Equity Incentive Plans &lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;Certain wholly owned and majority-owned or controlled subsidiaries of RSL adopt their own equity incentive plan (&#x201c;EIP&#x201d;). Each EIP is generally structured so that the applicable subsidiary, and its affiliates&#x2019; employees, directors, officers and consultants are eligible to receive &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;non-qualified&lt;/div&gt; and incentive stock options, stock appreciation rights, restricted share awards, restricted stock unit awards, and other share awards under their respective EIP. Standard option grants have time-based vesting requirements, generally vesting over a period of four years with a contractual term of ten years. Such time-based stock options use the Black-Scholes option pricing model. The grant date fair value of awards subject to market conditions is estimated using a Monte Carlo valuation model. For the years ended March&#160;31, 2021 and 2020, the Company recorded share-based compensation expense of $29.1&#160;million and $22.1&#160;million, respectively, in relation to subsidiary EIPs. &lt;/div&gt; &lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;(E) Share-Based Compensation Expense &lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Share-based compensation expense from continuing operations was as follows (in thousands): &lt;/div&gt;&lt;/div&gt; &lt;div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 76%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;"&gt;
&lt;tr style="font-size: 0px;"&gt;
&lt;td style="width: 74%;"/&gt;
&lt;td style="width: 5%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="width: 5%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="6" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Years Ended&lt;br/&gt; March&#160;31,&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2021&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2020&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Share-based compensation expense recognized as:&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;R&amp;amp;D expenses&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;22,637&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;7,738&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;G&amp;amp;A expenses&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;62,321&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;60,013&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Total&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;84,958&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;67,751&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt; &lt;/tr&gt; &lt;/table&gt;  &lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;The classification of share-based compensation expense between R&amp;amp;D and G&amp;amp;A expenses in the accompanying consolidated statements of operations is consistent with the classification of grantee&#x2019;s salary expense. &lt;/div&gt;&lt;/div&gt; </us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock>
    <us-gaap:CommonStockCapitalSharesReservedForFutureIssuance
      contextRef="PAsOn03_31_2021_TwoThousandFifteenEquityIncentivePlanMemberusgaapPlanNameAxis"
      decimals="INF"
      unitRef="Unit_shares">22800000</us-gaap:CommonStockCapitalSharesReservedForFutureIssuance>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant
      contextRef="PAsOn03_31_2021_TwoThousandFifteenEquityIncentivePlanMemberusgaapPlanNameAxis"
      decimals="INF"
      unitRef="Unit_shares">10296392</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant>
    <us-gaap:CommonStockCapitalSharesReservedForFutureIssuance
      contextRef="PAsOn03_31_2021_SpecialReserveMemberusgaapAwardTypeAxis_TwoThousandFifteenEquityIncentivePlanMemberusgaapPlanNameAxis"
      decimals="INF"
      unitRef="Unit_shares">26558238</us-gaap:CommonStockCapitalSharesReservedForFutureIssuance>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant
      contextRef="PAsOn03_31_2021_SpecialReserveMemberusgaapAwardTypeAxis_TwoThousandFifteenEquityIncentivePlanMemberusgaapPlanNameAxis"
      decimals="INF"
      unitRef="Unit_shares">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="P04_01_2020To03_31_2021_TwoThousandFifteenEquityIncentivePlanMemberusgaapPlanNameAxis"
      decimals="INF"
      unitRef="Unit_USD">32300000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="P04_01_2019To03_31_2020_TwoThousandFifteenEquityIncentivePlanMemberusgaapPlanNameAxis"
      decimals="INF"
      unitRef="Unit_USD">31800000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions
      contextRef="PAsOn03_31_2021_TwoThousandFifteenEquityIncentivePlanMemberusgaapPlanNameAxis"
      decimals="-5"
      unitRef="Unit_USD">70800000</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1 contextRef="P04_01_2020To03_31_2021_TwoThousandFifteenEquityIncentivePlanMemberusgaapPlanNameAxis">P2Y11M15D</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1>
    <us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock contextRef="P04_01_2020To03_31_2021">&lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;The Company estimated the fair value of each stock option on the date of grant using the Black-Scholes closed form option-pricing model applying the weighted average assumptions in the following table. &lt;/div&gt;&lt;/div&gt; &lt;div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 76%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;"&gt;
&lt;tr style="font-size: 0px;"&gt;
&lt;td style="width: 73%;"/&gt;
&lt;td style="width: 9%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="width: 8%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="6" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Years&#160;Ended&#160;March&#160;31,&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Assumptions&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&#160;2021&#160;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&#160;2020&#160;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Expected stock price volatility&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;74.84&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;%&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;66.47&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;%&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Expected risk free interest rate&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;0.43&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;%&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;2.27&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;%&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Expected term, in years&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;6.25&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;6.72&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Expected dividend yield&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;%&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;%&#160;&lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; </us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate
      contextRef="P04_01_2020To03_31_2021_EmployeeStockOptionMemberusgaapAwardTypeAxis"
      decimals="4"
      unitRef="Unit_pure">0.7484</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate
      contextRef="P04_01_2019To03_31_2020_EmployeeStockOptionMemberusgaapAwardTypeAxis"
      decimals="4"
      unitRef="Unit_pure">0.6647</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
      contextRef="P04_01_2020To03_31_2021_EmployeeStockOptionMemberusgaapAwardTypeAxis"
      decimals="4"
      unitRef="Unit_pure">0.0043</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
      contextRef="P04_01_2019To03_31_2020_EmployeeStockOptionMemberusgaapAwardTypeAxis"
      decimals="4"
      unitRef="Unit_pure">0.0227</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1 contextRef="P04_01_2020To03_31_2021_EmployeeStockOptionMemberusgaapAwardTypeAxis">P6Y3M</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1 contextRef="P04_01_2019To03_31_2020_EmployeeStockOptionMemberusgaapAwardTypeAxis">P6Y8M19D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
      contextRef="P04_01_2020To03_31_2021_EmployeeStockOptionMemberusgaapAwardTypeAxis"
      decimals="2"
      unitRef="Unit_pure">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
      contextRef="P04_01_2019To03_31_2020_EmployeeStockOptionMemberusgaapAwardTypeAxis"
      decimals="2"
      unitRef="Unit_pure">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>
    <us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock contextRef="P04_01_2020To03_31_2021">&lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;A summary of stock option activity and data under the RSL 2015 EIP for the year ended March&#160;31, 2021 is as follows: &lt;/div&gt;&lt;/div&gt; &lt;div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 92%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;"&gt;
&lt;tr style="font-size: 0px;"&gt;
&lt;td style="width: 48%;"/&gt;
&lt;td style="width: 7%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="width: 7%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="width: 7%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="width: 7%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Number of&lt;br/&gt; Stock&lt;br/&gt; Options&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Weighted&lt;br/&gt; Average&lt;br/&gt; Exercise&lt;br/&gt; Price&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Weighted&lt;br/&gt; Average Grant&lt;br/&gt; Date&#160;Fair&#160;Value&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Weighted&lt;br/&gt; Average&lt;br/&gt; Remaining&lt;br/&gt; Contractual&#160;Life&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Stock options outstanding at March&#160;31, 2020&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;8,176,814&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;24.52&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;16.53&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;7.93&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Granted&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;1,482,604&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;38.71&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;25.37&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Forfeited/Canceled&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;(270,047&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;29.89&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;19.85&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Stock options outstanding at March&#160;31, 2021&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;9,389,371&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;26.61&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;17.90&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;7.26&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Stock options exercisable at March&#160;31, 2021&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;5,533,848&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;21.52&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;14.95&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;6.49&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; </us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="PAsOn03_31_2020_EmployeeStockOptionMemberusgaapAwardTypeAxis_TwoThousandFifteenEquityIncentivePlanMemberusgaapPlanNameAxis"
      decimals="INF"
      unitRef="Unit_shares">8176814</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
      contextRef="PAsOn03_31_2020_EmployeeStockOptionMemberusgaapAwardTypeAxis_TwoThousandFifteenEquityIncentivePlanMemberusgaapPlanNameAxis"
      decimals="2"
      unitRef="Unit_USD_per_Share">24.52</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <roiv:ShareBasedCompensationArrangementByShareBasedPaymentAwardWeightedAverageGrantDateFairValue
      contextRef="PAsOn03_31_2020_EmployeeStockOptionMemberusgaapAwardTypeAxis_TwoThousandFifteenEquityIncentivePlanMemberusgaapPlanNameAxis"
      decimals="2"
      unitRef="Unit_USD_per_Share">16.53</roiv:ShareBasedCompensationArrangementByShareBasedPaymentAwardWeightedAverageGrantDateFairValue>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2 contextRef="P04_01_2019To03_31_2020_EmployeeStockOptionMemberusgaapAwardTypeAxis_TwoThousandFifteenEquityIncentivePlanMemberusgaapPlanNameAxis">P7Y11M4D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
      contextRef="P04_01_2020To03_31_2021_EmployeeStockOptionMemberusgaapAwardTypeAxis_TwoThousandFifteenEquityIncentivePlanMemberusgaapPlanNameAxis"
      decimals="INF"
      unitRef="Unit_shares">1482604</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
      contextRef="P04_01_2020To03_31_2021_EmployeeStockOptionMemberusgaapAwardTypeAxis_TwoThousandFifteenEquityIncentivePlanMemberusgaapPlanNameAxis"
      decimals="2"
      unitRef="Unit_USD_per_Share">38.71</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="P04_01_2020To03_31_2021_EmployeeStockOptionMemberusgaapAwardTypeAxis_TwoThousandFifteenEquityIncentivePlanMemberusgaapPlanNameAxis"
      decimals="2"
      unitRef="Unit_USD_per_Share">25.37</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod
      contextRef="P04_01_2020To03_31_2021_EmployeeStockOptionMemberusgaapAwardTypeAxis_TwoThousandFifteenEquityIncentivePlanMemberusgaapPlanNameAxis"
      decimals="INF"
      unitRef="Unit_shares">270047</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice
      contextRef="P04_01_2020To03_31_2021_EmployeeStockOptionMemberusgaapAwardTypeAxis_TwoThousandFifteenEquityIncentivePlanMemberusgaapPlanNameAxis"
      decimals="2"
      unitRef="Unit_USD_per_Share">29.89</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedWeightedAverageGrantDateFairValue
      contextRef="P04_01_2020To03_31_2021_EmployeeStockOptionMemberusgaapAwardTypeAxis_TwoThousandFifteenEquityIncentivePlanMemberusgaapPlanNameAxis"
      decimals="2"
      unitRef="Unit_USD_per_Share">19.85</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="PAsOn03_31_2021_EmployeeStockOptionMemberusgaapAwardTypeAxis_TwoThousandFifteenEquityIncentivePlanMemberusgaapPlanNameAxis"
      decimals="INF"
      unitRef="Unit_shares">9389371</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
      contextRef="PAsOn03_31_2021_EmployeeStockOptionMemberusgaapAwardTypeAxis_TwoThousandFifteenEquityIncentivePlanMemberusgaapPlanNameAxis"
      decimals="2"
      unitRef="Unit_USD_per_Share">26.61</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <roiv:ShareBasedCompensationArrangementByShareBasedPaymentAwardWeightedAverageGrantDateFairValue
      contextRef="PAsOn03_31_2021_EmployeeStockOptionMemberusgaapAwardTypeAxis_TwoThousandFifteenEquityIncentivePlanMemberusgaapPlanNameAxis"
      decimals="2"
      unitRef="Unit_USD_per_Share">17.90</roiv:ShareBasedCompensationArrangementByShareBasedPaymentAwardWeightedAverageGrantDateFairValue>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2 contextRef="P04_01_2020To03_31_2021_EmployeeStockOptionMemberusgaapAwardTypeAxis_TwoThousandFifteenEquityIncentivePlanMemberusgaapPlanNameAxis">P7Y3M3D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber
      contextRef="PAsOn03_31_2021_EmployeeStockOptionMemberusgaapAwardTypeAxis_TwoThousandFifteenEquityIncentivePlanMemberusgaapPlanNameAxis"
      decimals="INF"
      unitRef="Unit_shares">5533848</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice
      contextRef="PAsOn03_31_2021_EmployeeStockOptionMemberusgaapAwardTypeAxis_TwoThousandFifteenEquityIncentivePlanMemberusgaapPlanNameAxis"
      decimals="2"
      unitRef="Unit_USD_per_Share">21.52</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice>
    <roiv:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExcercisableWeightedAverageGrantDateFairValue
      contextRef="P04_01_2020To03_31_2021_EmployeeStockOptionMemberusgaapAwardTypeAxis_TwoThousandFifteenEquityIncentivePlanMemberusgaapPlanNameAxis"
      decimals="2"
      unitRef="Unit_USD_per_Share">14.95</roiv:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExcercisableWeightedAverageGrantDateFairValue>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1 contextRef="P04_01_2020To03_31_2021_EmployeeStockOptionMemberusgaapAwardTypeAxis_TwoThousandFifteenEquityIncentivePlanMemberusgaapPlanNameAxis">P6Y5M26D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares
      contextRef="P04_01_2020To03_31_2021_TwoThousandFifteenEquityIncentivePlanMemberusgaapPlanNameAxis"
      decimals="INF"
      unitRef="Unit_shares">5533848</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares
      contextRef="P04_01_2019To03_31_2020_TwoThousandFifteenEquityIncentivePlanMemberusgaapPlanNameAxis"
      decimals="INF"
      unitRef="Unit_shares">4123953</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares>
    <roiv:ScheduleOfSharebasedPaymentArrangementFairValueOfVestedStockOptionTableTextBlock contextRef="P04_01_2020To03_31_2021">Additional information regarding stock options is set forth below (in thousands, except per share data).
&lt;table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 84%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 8pt; border-collapse: collapse; border-spacing: 0px;"&gt;
&lt;tr style="font-size: 0px;"&gt;
&lt;td style="width: 78%;"/&gt;
&lt;td style="width: 4%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="width: 4%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="6" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Years&#160;Ended&#160;March&#160;31,&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2021&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2020&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Grant date fair value of stock options vested&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;25,711&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;33,789&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Weighted-average grant date fair value per share of stock options granted&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;25.37&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;20.63&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; </roiv:ScheduleOfSharebasedPaymentArrangementFairValueOfVestedStockOptionTableTextBlock>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1
      contextRef="P04_01_2020To03_31_2021"
      decimals="-3"
      unitRef="Unit_USD">25711000</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1
      contextRef="P04_01_2019To03_31_2020"
      decimals="-3"
      unitRef="Unit_USD">33789000</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue
      contextRef="P04_01_2020To03_31_2021"
      decimals="2"
      unitRef="Unit_USD_per_Share">25.37</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue
      contextRef="P04_01_2019To03_31_2020"
      decimals="2"
      unitRef="Unit_USD_per_Share">20.63</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod contextRef="P04_01_2020To03_31_2021_RestrictedStockUnitsRSUMemberusgaapAwardTypeAxis">P8Y</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="P04_01_2020To03_31_2021_RestrictedStockUnitsRSUMemberusgaapAwardTypeAxis"
      decimals="INF"
      unitRef="Unit_USD">0</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions
      contextRef="PAsOn03_31_2021_RestrictedStockUnitsRSUMemberusgaapAwardTypeAxis"
      decimals="-5"
      unitRef="Unit_USD">83800000</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions>
    <us-gaap:ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock contextRef="P04_01_2020To03_31_2021">&lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;A summary of restricted stock units under the RSL 2015 EIP is as follows: &lt;/div&gt;&lt;/div&gt; &lt;div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 76%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;"&gt;
&lt;tr style="font-size: 0px;"&gt;
&lt;td style="width: 58%;"/&gt;
&lt;td style="width: 12%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="width: 12%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Number of&lt;br/&gt; Restricted&#160;Stock&lt;br/&gt; Units&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Weighted&#160;Average&lt;br/&gt; Grant Date Fair&lt;br/&gt; Value&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Non-vested&lt;/div&gt; balance at March&#160;31, 2020&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;1,008,175&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;32.50&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Granted&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;1,454,199&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;39.19&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Forfeited&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;(169,636&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;36.36&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Non-vested&lt;/div&gt; balance at March&#160;31, 2021&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;2,292,738&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;36.53&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; </us-gaap:ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber
      contextRef="PAsOn03_31_2020_RestrictedStockUnitsRSUMemberusgaapAwardTypeAxis_TwoThousandFifteenEquityIncentivePlanMemberusgaapPlanNameAxis"
      decimals="INF"
      unitRef="Unit_shares">1008175</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue
      contextRef="PAsOn03_31_2020_RestrictedStockUnitsRSUMemberusgaapAwardTypeAxis_TwoThousandFifteenEquityIncentivePlanMemberusgaapPlanNameAxis"
      decimals="2"
      unitRef="Unit_USD_per_Share">32.50</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod
      contextRef="P04_01_2020To03_31_2021_RestrictedStockUnitsRSUMemberusgaapAwardTypeAxis_TwoThousandFifteenEquityIncentivePlanMemberusgaapPlanNameAxis"
      decimals="INF"
      unitRef="Unit_shares">1454199</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="P04_01_2020To03_31_2021_RestrictedStockUnitsRSUMemberusgaapAwardTypeAxis_TwoThousandFifteenEquityIncentivePlanMemberusgaapPlanNameAxis"
      decimals="2"
      unitRef="Unit_USD_per_Share">39.19</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod
      contextRef="P04_01_2020To03_31_2021_RestrictedStockUnitsRSUMemberusgaapAwardTypeAxis_TwoThousandFifteenEquityIncentivePlanMemberusgaapPlanNameAxis"
      decimals="INF"
      unitRef="Unit_shares">169636</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedWeightedAverageGrantDateFairValue
      contextRef="P04_01_2020To03_31_2021_RestrictedStockUnitsRSUMemberusgaapAwardTypeAxis_TwoThousandFifteenEquityIncentivePlanMemberusgaapPlanNameAxis"
      decimals="2"
      unitRef="Unit_USD_per_Share">36.36</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber
      contextRef="PAsOn03_31_2021_RestrictedStockUnitsRSUMemberusgaapAwardTypeAxis_TwoThousandFifteenEquityIncentivePlanMemberusgaapPlanNameAxis"
      decimals="INF"
      unitRef="Unit_shares">2292738</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue
      contextRef="PAsOn03_31_2021_RestrictedStockUnitsRSUMemberusgaapAwardTypeAxis_TwoThousandFifteenEquityIncentivePlanMemberusgaapPlanNameAxis"
      decimals="2"
      unitRef="Unit_USD_per_Share">36.53</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="P04_01_2020To03_31_2021_PerformanceOptionsMemberusgaapAwardTypeAxis"
      decimals="INF"
      unitRef="Unit_USD">0</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions
      contextRef="PAsOn03_31_2021_PerformanceOptionsMemberusgaapAwardTypeAxis"
      decimals="-5"
      unitRef="Unit_USD">337800000</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions>
    <us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock contextRef="P04_01_2020To03_31_2021_PerformanceOptionsMemberusgaapAwardTypeAxis">&lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;The Company estimated the fair value of each Performance Option on the date of grant using the Black-Scholes closed form option-pricing model applying the weighted average assumptions in the following table. &lt;/div&gt;&lt;/div&gt; &lt;div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 68%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;"&gt;
&lt;tr style="font-size: 0px;"&gt;
&lt;td style="width: 70%;"/&gt;
&lt;td style="width: 22%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Year&#160;Ended&#160;March&#160;31,&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Assumptions&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2020&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Expected stock price volatility&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;73.60&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;%&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Expected risk free interest rate&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;0.62&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;%&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Expected term&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;6 years&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Expected dividend yield&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;%&#160;&lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; </us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate
      contextRef="P04_01_2020To03_31_2021_PerformanceOptionsMemberusgaapAwardTypeAxis"
      decimals="4"
      unitRef="Unit_pure">0.7360</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
      contextRef="P04_01_2020To03_31_2021_PerformanceOptionsMemberusgaapAwardTypeAxis"
      decimals="4"
      unitRef="Unit_pure">0.0062</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1 contextRef="P04_01_2020To03_31_2021_PerformanceOptionsMemberusgaapAwardTypeAxis">P6Y</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
      contextRef="P04_01_2020To03_31_2021_PerformanceOptionsMemberusgaapAwardTypeAxis"
      decimals="2"
      unitRef="Unit_pure">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>
    <us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock contextRef="P04_01_2020To03_31_2021_PerformanceOptionsMemberusgaapAwardTypeAxis">&lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;A summary of Performance Option activity and data under the RSL 2015 EIP for the year ended March&#160;31, 2021 is as follows: &lt;/div&gt;&lt;/div&gt; &lt;div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 92%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;"&gt;
&lt;tr style="font-size: 0px;"&gt;
&lt;td style="width: 76%;"/&gt;
&lt;td style="width: 4%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="width: 4%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="width: 4%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="width: 4%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Number of&lt;br/&gt; Options&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Weighted&lt;br/&gt; Average&lt;br/&gt; Exercise&#160;Price&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Weighted&lt;br/&gt; Average Grant&lt;br/&gt; Date&#160;Fair&#160;Value&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Weighted&lt;br/&gt; Average&lt;br/&gt; Remaining&lt;br/&gt; Contractual&#160;Life&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Performance Options outstanding at March&#160;31, 2020&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;14,518,870&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;38.97&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;23.78&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;6.00&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Granted&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Forfeited&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;(93,207&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;46.38&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;22.18&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Performance Options outstanding at March&#160;31, 2021&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;14,425,663&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;38.93&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;23.42&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;5.00&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; </us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="PAsOn03_31_2020_PerformanceOptionsMemberusgaapAwardTypeAxis_TwoThousandFifteenEquityIncentivePlanMemberusgaapPlanNameAxis"
      decimals="INF"
      unitRef="Unit_shares">14518870</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
      contextRef="PAsOn03_31_2020_PerformanceOptionsMemberusgaapAwardTypeAxis_TwoThousandFifteenEquityIncentivePlanMemberusgaapPlanNameAxis"
      decimals="2"
      unitRef="Unit_USD_per_Share">38.97</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <roiv:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageGrantDateFairValue
      contextRef="PAsOn03_31_2020_PerformanceOptionsMemberusgaapAwardTypeAxis_TwoThousandFifteenEquityIncentivePlanMemberusgaapPlanNameAxis"
      decimals="2"
      unitRef="Unit_USD_per_Share">23.78</roiv:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageGrantDateFairValue>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2 contextRef="P04_01_2019To03_31_2020_PerformanceOptionsMemberusgaapAwardTypeAxis_TwoThousandFifteenEquityIncentivePlanMemberusgaapPlanNameAxis">P6Y</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
      contextRef="P04_01_2020To03_31_2021_PerformanceOptionsMemberusgaapAwardTypeAxis_TwoThousandFifteenEquityIncentivePlanMemberusgaapPlanNameAxis"
      decimals="INF"
      unitRef="Unit_shares">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
      contextRef="P04_01_2020To03_31_2021_PerformanceOptionsMemberusgaapAwardTypeAxis_TwoThousandFifteenEquityIncentivePlanMemberusgaapPlanNameAxis"
      decimals="0"
      unitRef="Unit_USD_per_Share">0</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="P04_01_2020To03_31_2021_PerformanceOptionsMemberusgaapAwardTypeAxis_TwoThousandFifteenEquityIncentivePlanMemberusgaapPlanNameAxis"
      decimals="0"
      unitRef="Unit_USD_per_Share">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod
      contextRef="P04_01_2020To03_31_2021_PerformanceOptionsMemberusgaapAwardTypeAxis_TwoThousandFifteenEquityIncentivePlanMemberusgaapPlanNameAxis"
      decimals="INF"
      unitRef="Unit_shares">93207</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice
      contextRef="P04_01_2020To03_31_2021_PerformanceOptionsMemberusgaapAwardTypeAxis_TwoThousandFifteenEquityIncentivePlanMemberusgaapPlanNameAxis"
      decimals="2"
      unitRef="Unit_USD_per_Share">46.38</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice>
    <roiv:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeitedInPeriodWeightedAverageGrantDateFairValue
      contextRef="P04_01_2020To03_31_2021_PerformanceOptionsMemberusgaapAwardTypeAxis_TwoThousandFifteenEquityIncentivePlanMemberusgaapPlanNameAxis"
      decimals="2"
      unitRef="Unit_USD_per_Share">22.18</roiv:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeitedInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="PAsOn03_31_2021_PerformanceOptionsMemberusgaapAwardTypeAxis_TwoThousandFifteenEquityIncentivePlanMemberusgaapPlanNameAxis"
      decimals="INF"
      unitRef="Unit_shares">14425663</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
      contextRef="PAsOn03_31_2021_PerformanceOptionsMemberusgaapAwardTypeAxis_TwoThousandFifteenEquityIncentivePlanMemberusgaapPlanNameAxis"
      decimals="2"
      unitRef="Unit_USD_per_Share">38.93</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <roiv:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageGrantDateFairValue
      contextRef="PAsOn03_31_2021_PerformanceOptionsMemberusgaapAwardTypeAxis_TwoThousandFifteenEquityIncentivePlanMemberusgaapPlanNameAxis"
      decimals="2"
      unitRef="Unit_USD_per_Share">23.42</roiv:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageGrantDateFairValue>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2 contextRef="P04_01_2020To03_31_2021_PerformanceOptionsMemberusgaapAwardTypeAxis_TwoThousandFifteenEquityIncentivePlanMemberusgaapPlanNameAxis">P5Y</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardExpirationDate contextRef="P04_01_2020To03_31_2021_CappedValueAppreciationRightsMemberusgaapAwardTypeAxis">2026-03-31</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardExpirationDate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardDescription contextRef="P04_01_2020To03_31_2021_CappedValueAppreciationRightsMemberusgaapAwardTypeAxis">each CVAR pays in common shares the excess of (a) the lesser of (i) the fair market value of a common share as of the settlement date or (ii) the cap of $37.10, over (b) the hurdle price of either $18.70 or $33.63, as applicable to each grant.</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardDescription>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="P04_01_2020To03_31_2021_CappedValueAppreciationRightsMemberusgaapAwardTypeAxis"
      decimals="INF"
      unitRef="Unit_USD">0</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized
      contextRef="PAsOn03_31_2021_CappedValueAppreciationRightsMemberusgaapAwardTypeAxis"
      decimals="-5"
      unitRef="Unit_USD">23000000.0</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized>
    <us-gaap:ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock contextRef="P04_01_2020To03_31_2021_CappedValueAppreciationRightsMemberusgaapAwardTypeAxis">&lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;A summary of CVARs under the RSL 2015 EIP is as follows: &lt;/div&gt;&lt;/div&gt; &lt;div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 76%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;"&gt;
&lt;tr style="font-size: 0px;"&gt;
&lt;td style="width: 56%;"/&gt;
&lt;td style="width: 13%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="width: 13%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Number&#160;of&#160;CVARs&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Weighted&#160;Average&lt;br/&gt; Grant Date Fair&lt;br/&gt; Value&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Non-vested&lt;/div&gt; balance at March&#160;31, 2020&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;11,088,658&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;2.07&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Granted&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Forfeited&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Non-vested&lt;/div&gt; balance at March&#160;31, 2021&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;11,088,658&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;2.07&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; </us-gaap:ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber
      contextRef="PAsOn03_31_2020_CappedValueAppreciationRightsMemberusgaapAwardTypeAxis_TwoThousandFifteenEquityIncentivePlanMemberusgaapPlanNameAxis"
      decimals="INF"
      unitRef="Unit_shares">11088658</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue
      contextRef="PAsOn03_31_2020_CappedValueAppreciationRightsMemberusgaapAwardTypeAxis_TwoThousandFifteenEquityIncentivePlanMemberusgaapPlanNameAxis"
      decimals="2"
      unitRef="Unit_USD_per_Share">2.07</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod
      contextRef="P04_01_2020To03_31_2021_CappedValueAppreciationRightsMemberusgaapAwardTypeAxis_TwoThousandFifteenEquityIncentivePlanMemberusgaapPlanNameAxis"
      decimals="INF"
      unitRef="Unit_shares">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="P04_01_2020To03_31_2021_CappedValueAppreciationRightsMemberusgaapAwardTypeAxis_TwoThousandFifteenEquityIncentivePlanMemberusgaapPlanNameAxis"
      decimals="0"
      unitRef="Unit_USD_per_Share">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod
      contextRef="P04_01_2020To03_31_2021_CappedValueAppreciationRightsMemberusgaapAwardTypeAxis_TwoThousandFifteenEquityIncentivePlanMemberusgaapPlanNameAxis"
      decimals="INF"
      unitRef="Unit_shares">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedWeightedAverageGrantDateFairValue
      contextRef="P04_01_2020To03_31_2021_CappedValueAppreciationRightsMemberusgaapAwardTypeAxis_TwoThousandFifteenEquityIncentivePlanMemberusgaapPlanNameAxis"
      decimals="0"
      unitRef="Unit_USD_per_Share">0</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber
      contextRef="PAsOn03_31_2021_CappedValueAppreciationRightsMemberusgaapAwardTypeAxis_TwoThousandFifteenEquityIncentivePlanMemberusgaapPlanNameAxis"
      decimals="INF"
      unitRef="Unit_shares">11088658</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue
      contextRef="PAsOn03_31_2021_CappedValueAppreciationRightsMemberusgaapAwardTypeAxis_TwoThousandFifteenEquityIncentivePlanMemberusgaapPlanNameAxis"
      decimals="2"
      unitRef="Unit_USD_per_Share">2.07</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue>
    <us-gaap:CommonStockCapitalSharesReservedForFutureIssuance
      contextRef="PAsOn03_31_2021_PerformanceRestrictedStockUnitsPlanMemberusgaapPlanNameAxis"
      decimals="INF"
      unitRef="Unit_shares">200000</us-gaap:CommonStockCapitalSharesReservedForFutureIssuance>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod contextRef="P04_01_2020To03_31_2021_PerformanceRestrictedStockUnitsPlanMemberusgaapPlanNameAxis">P8Y</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod>
    <roiv:SharebasedCompensationArrangementBySharebasedPaymentAwardAggregateRepurchasePrice
      contextRef="P04_01_2020To03_31_2021_PerformanceRestrictedStockUnitsPlanMemberusgaapPlanNameAxis"
      decimals="0"
      unitRef="Unit_USD">17044465</roiv:SharebasedCompensationArrangementBySharebasedPaymentAwardAggregateRepurchasePrice>
    <roiv:ShareBasedCompensationRightToRepurchasePercentage
      contextRef="P04_01_2020To03_31_2021_PerformanceRestrictedStockUnitsPlanMemberusgaapPlanNameAxis"
      decimals="4"
      unitRef="Unit_pure">0.1123</roiv:ShareBasedCompensationRightToRepurchasePercentage>
    <us-gaap:ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock contextRef="P04_01_2020To03_31_2021_PerformanceRestrictedStockUnitsMemberusgaapAwardTypeAxis">&lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;A summary of pRSU activity under the pRSU Plan is as follows: &lt;/div&gt;&lt;/div&gt; &lt;div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 76%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;"&gt;
&lt;tr style="font-size: 0px;"&gt;
&lt;td style="width: 64%;"/&gt;
&lt;td style="width: 10%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="width: 10%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Number&#160;of&lt;br/&gt; pRSUs&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Weighted&#160;Average&lt;br/&gt; Grant Date Fair&lt;br/&gt; Value&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Non-vested&lt;/div&gt; balance at March&#160;31, 2020&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;266,845&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;13.92&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Granted&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Forfeited&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;(66,845&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;13.92&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Non-vested&lt;/div&gt; balance at March&#160;31, 2021&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;200,000&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;13.92&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; </us-gaap:ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber
      contextRef="PAsOn03_31_2020_PerformanceRestrictedStockUnitsMemberusgaapAwardTypeAxis_PerformanceRestrictedStockUnitsPlanMemberusgaapPlanNameAxis"
      decimals="INF"
      unitRef="Unit_shares">266845</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue
      contextRef="PAsOn03_31_2020_PerformanceRestrictedStockUnitsMemberusgaapAwardTypeAxis_PerformanceRestrictedStockUnitsPlanMemberusgaapPlanNameAxis"
      decimals="2"
      unitRef="Unit_USD_per_Share">13.92</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod
      contextRef="P04_01_2020To03_31_2021_PerformanceRestrictedStockUnitsMemberusgaapAwardTypeAxis_PerformanceRestrictedStockUnitsPlanMemberusgaapPlanNameAxis"
      decimals="INF"
      unitRef="Unit_shares">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="P04_01_2020To03_31_2021_PerformanceRestrictedStockUnitsMemberusgaapAwardTypeAxis_PerformanceRestrictedStockUnitsPlanMemberusgaapPlanNameAxis"
      decimals="0"
      unitRef="Unit_USD_per_Share">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod
      contextRef="P04_01_2020To03_31_2021_PerformanceRestrictedStockUnitsMemberusgaapAwardTypeAxis_PerformanceRestrictedStockUnitsPlanMemberusgaapPlanNameAxis"
      decimals="INF"
      unitRef="Unit_shares">66845</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedWeightedAverageGrantDateFairValue
      contextRef="P04_01_2020To03_31_2021_PerformanceRestrictedStockUnitsMemberusgaapAwardTypeAxis_PerformanceRestrictedStockUnitsPlanMemberusgaapPlanNameAxis"
      decimals="2"
      unitRef="Unit_USD_per_Share">13.92</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber
      contextRef="PAsOn03_31_2021_PerformanceRestrictedStockUnitsMemberusgaapAwardTypeAxis_PerformanceRestrictedStockUnitsPlanMemberusgaapPlanNameAxis"
      decimals="INF"
      unitRef="Unit_shares">200000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue
      contextRef="PAsOn03_31_2021_PerformanceRestrictedStockUnitsMemberusgaapAwardTypeAxis_PerformanceRestrictedStockUnitsPlanMemberusgaapPlanNameAxis"
      decimals="2"
      unitRef="Unit_USD_per_Share">13.92</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="P04_01_2020To03_31_2021_PerformanceRestrictedStockUnitsMemberusgaapAwardTypeAxis"
      decimals="INF"
      unitRef="Unit_USD">12300000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized
      contextRef="PAsOn03_31_2021_PerformanceRestrictedStockUnitsMemberusgaapAwardTypeAxis"
      decimals="-5"
      unitRef="Unit_USD">2800000</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized>
    <us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock contextRef="P04_01_2020To03_31_2021_CommonStockAwardsMemberusgaapAwardTypeAxis">&lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;A summary of RSL restricted common stock activity as of March&#160;31, 2021 is as follows: &lt;/div&gt;&lt;/div&gt; &lt;div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 76%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;"&gt;
&lt;tr style="font-size: 0px;"&gt;
&lt;td style="width: 64%;"/&gt;
&lt;td style="width: 10%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="width: 10%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Number&#160;of&lt;br/&gt; Restricted&lt;br/&gt; Common&lt;br/&gt; Stock&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Weighted&#160;Average&lt;br/&gt; Grant Date Fair&lt;br/&gt; Value&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Non-vested&lt;/div&gt; balance at March&#160;31, 2020&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Granted&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;587,824&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;38.50&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Vested&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Forfeited&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Non-vested&lt;/div&gt; balance at March&#160;31, 2021&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;587,824&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;38.50&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; </us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber
      contextRef="PAsOn03_31_2020_CommonStockAwardsMemberusgaapAwardTypeAxis"
      decimals="INF"
      unitRef="Unit_shares">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod
      contextRef="P04_01_2020To03_31_2021_CommonStockAwardsMemberusgaapAwardTypeAxis"
      decimals="INF"
      unitRef="Unit_shares">587824</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="P04_01_2020To03_31_2021_CommonStockAwardsMemberusgaapAwardTypeAxis"
      decimals="2"
      unitRef="Unit_USD_per_Share">38.50</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod
      contextRef="P04_01_2020To03_31_2021_CommonStockAwardsMemberusgaapAwardTypeAxis"
      decimals="INF"
      unitRef="Unit_shares">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue
      contextRef="P04_01_2020To03_31_2021_CommonStockAwardsMemberusgaapAwardTypeAxis"
      decimals="0"
      unitRef="Unit_USD_per_Share">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod
      contextRef="P04_01_2020To03_31_2021_CommonStockAwardsMemberusgaapAwardTypeAxis"
      decimals="INF"
      unitRef="Unit_shares">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue
      contextRef="P04_01_2020To03_31_2021_CommonStockAwardsMemberusgaapAwardTypeAxis"
      decimals="0"
      unitRef="Unit_USD_per_Share">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber
      contextRef="PAsOn03_31_2021_CommonStockAwardsMemberusgaapAwardTypeAxis"
      decimals="INF"
      unitRef="Unit_shares">587824</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue
      contextRef="PAsOn03_31_2021_CommonStockAwardsMemberusgaapAwardTypeAxis"
      decimals="2"
      unitRef="Unit_USD_per_Share">38.50</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="P04_01_2020To03_31_2021_CommonStockAwardsMemberusgaapAwardTypeAxis"
      decimals="INF"
      unitRef="Unit_USD">100000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized
      contextRef="PAsOn03_31_2021_CommonStockAwardsMemberusgaapAwardTypeAxis"
      decimals="-5"
      unitRef="Unit_USD">6900000</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1 contextRef="P04_01_2020To03_31_2021_CommonStockAwardsMemberusgaapAwardTypeAxis">P3Y4M20D</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1>
    <us-gaap:RestrictedInvestmentsAtFairValue
      contextRef="PAsOn03_31_2021_CommonStockAwardsMemberusgaapAwardTypeAxis"
      decimals="-5"
      unitRef="Unit_USD">15600000</us-gaap:RestrictedInvestmentsAtFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1 contextRef="P04_01_2020To03_31_2021_SubsidiaryEquityIncentivePlanMemberusgaapPlanNameAxis">P4Y</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1 contextRef="P04_01_2020To03_31_2021_SubsidiaryEquityIncentivePlanMemberusgaapPlanNameAxis">P10Y</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="P04_01_2020To03_31_2021_SubsidiaryEquityIncentivePlanMemberusgaapPlanNameAxis"
      decimals="INF"
      unitRef="Unit_USD">29100000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="P04_01_2019To03_31_2020_SubsidiaryEquityIncentivePlanMemberusgaapPlanNameAxis"
      decimals="INF"
      unitRef="Unit_USD">22100000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock contextRef="P04_01_2020To03_31_2021">&lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Share-based compensation expense from continuing operations was as follows (in thousands): &lt;/div&gt;&lt;/div&gt; &lt;div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 76%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;"&gt;
&lt;tr style="font-size: 0px;"&gt;
&lt;td style="width: 74%;"/&gt;
&lt;td style="width: 5%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="width: 5%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="6" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Years Ended&lt;br/&gt; March&#160;31,&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2021&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2020&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Share-based compensation expense recognized as:&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;R&amp;amp;D expenses&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;22,637&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;7,738&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;G&amp;amp;A expenses&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;62,321&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;60,013&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Total&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;84,958&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;67,751&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; </us-gaap:ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="P04_01_2020To03_31_2021_ResearchAndDevelopmentExpenseMemberusgaapIncomeStatementLocationAxis"
      decimals="-3"
      unitRef="Unit_USD">22637000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="P04_01_2019To03_31_2020_ResearchAndDevelopmentExpenseMemberusgaapIncomeStatementLocationAxis"
      decimals="-3"
      unitRef="Unit_USD">7738000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="P04_01_2020To03_31_2021_GeneralAndAdministrativeExpenseMemberusgaapIncomeStatementLocationAxis"
      decimals="-3"
      unitRef="Unit_USD">62321000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="P04_01_2019To03_31_2020_GeneralAndAdministrativeExpenseMemberusgaapIncomeStatementLocationAxis"
      decimals="-3"
      unitRef="Unit_USD">60013000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="P04_01_2020To03_31_2021"
      decimals="-3"
      unitRef="Unit_USD">84958000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="P04_01_2019To03_31_2020"
      decimals="-3"
      unitRef="Unit_USD">67751000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:IncomeTaxDisclosureTextBlock contextRef="P04_01_2020To03_31_2021">&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Note 12&#x2014;Income Taxes &lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;The loss before income taxes and the related expense/(benefit) are as follows (in thousands): &lt;/div&gt;&lt;/div&gt; &lt;div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 76%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;"&gt;
&lt;tr style="font-size: 0px;"&gt;
&lt;td style="width: 70%;"/&gt;
&lt;td style="width: 5%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="width: 5%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="6" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Years Ended March&#160;31,&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2021&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2020&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Loss before income taxes:&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;United States&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;(212,921&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;(69,264&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Switzerland&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;(424,494&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;(355,422&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Bermuda&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;(227,471&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;(105,604&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Other&lt;div style="font-size: 85%; vertical-align: top;;display:inline;;font-size:9.4px"&gt;(1)&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;(33,661&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;(30,696&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 5em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Total loss before income taxes&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;(898,547&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;(560,986&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; &lt;div style="clear: both; max-height: 0px;"/&gt; &lt;div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;"&gt;
&lt;tr style="page-break-inside: avoid;"&gt;
&lt;td style="width: 4%; vertical-align: top;;text-align:left;"&gt;&lt;div style="font-size: 85%; vertical-align: top;;display:inline;;font-size:9.4px"&gt;(1)&lt;/div&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: top;;text-align:left;"&gt; &lt;div style="text-align: left; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Primarily Greater China and United Kingdom activity &lt;/div&gt;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;/table&gt;  &lt;div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 76%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;"&gt;
&lt;tr style="font-size: 0px;"&gt;
&lt;td style="width: 74%;"/&gt;
&lt;td style="width: 7%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="width: 7%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="6" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Years&#160;Ended&#160;March&#160;31,&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&#160;&#160;&#160;2021&#160;&#160;&#160;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&#160;&#160;&#160;2020&#160;&#160;&#160;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Current taxes:&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;United States&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;1,365&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;6,327&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Switzerland&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Bermuda&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Other&lt;div style="font-size: 85%; vertical-align: top;;display:inline;;font-size:9.4px"&gt;(1)&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;321&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;797&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 5em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Total current tax expense&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;1,686&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;7,124&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size: 1pt;"&gt;
&lt;td style="height: 6pt; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height: 6pt; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height: 6pt; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Deferred taxes:&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;United States&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Switzerland&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Bermuda&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Other&lt;div style="font-size: 85%; vertical-align: top;;display:inline;;font-size:9.4px"&gt;(1)&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 5em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Total deferred tax benefit&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 7em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Total income tax expense&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;1,686&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;7,124&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; &lt;div style="clear: both; max-height: 0px;"/&gt; &lt;div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;"&gt;
&lt;tr style="page-break-inside: avoid;"&gt;
&lt;td style="width: 4%; vertical-align: top;;text-align:left;"&gt;&lt;div style="font-size: 85%; vertical-align: top;;display:inline;;font-size:9.4px"&gt;(1)&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: top;;text-align:left;"&gt; &lt;div style="text-align: left; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Primarily Greater China, United States state and local and United Kingdom activity &lt;/div&gt;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;/table&gt;  &lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;A reconciliation of income tax provision/(benefit) computed at the Bermuda statutory rate to income tax expense reflected in the consolidated financial statements is as follows (in thousands, except percentages): &lt;/div&gt;&lt;/div&gt; &lt;div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 92%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;"&gt;
&lt;tr style="font-size: 0px;"&gt;
&lt;td style="width: 59%;"/&gt;
&lt;td style="width: 6%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="width: 6%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="width: 5%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="width: 6%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="6" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Year Ended March&#160;31,&lt;br/&gt; 2021&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&#160;&lt;/td&gt;
&lt;td colspan="6" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Year Ended&lt;br/&gt; March&#160;31, 2020&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Income tax benefit at Bermuda statutory rate&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;%&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;%&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Foreign rate differential&lt;div style="font-size: 85%; vertical-align: top;;display:inline;;font-size:9.4px"&gt;(1)&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;(150,778&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;16.78&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;%&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;(74,922&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;13.36&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;%&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Permanent disallowed IPR&amp;amp;D&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;111,432&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;(12.40&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)%&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;%&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Nondeductible changes in the fair value of investments and loss from equity method investment&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;(22,472&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;2.50&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;%&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;20,840&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;(3.72&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)%&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Nontaxable (loss) gain on deconsolidation of business&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;(16,438&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;1.83&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;%&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;29,041&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;(5.18&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)%&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Permanent adjustments&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;2,923&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;(0.33&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)%&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;(20,395&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;3.64&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;%&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;R&amp;amp;D tax credits&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;(10,555&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;1.17&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;%&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;(5,990&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;1.07&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;%&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Rate changes&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;2,443&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;(0.27&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)%&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;(29,238&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;5.21&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;%&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Valuation allowance&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;85,046&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;(9.46&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)%&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;87,677&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;(15.63&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)%&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Other&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;85&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;(0.01&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)%&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;111&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;(0.02&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)%&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Total income tax expense&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;1,686&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;(0.19&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)%&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;7,124&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;(1.27&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)%&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; &lt;div style="clear: both; max-height: 0px;"/&gt; &lt;div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;"&gt;
&lt;tr style="page-break-inside: avoid;"&gt;
&lt;td style="width: 4%; vertical-align: top;;text-align:left;"&gt;&lt;div style="font-size: 85%; vertical-align: top;;display:inline;;font-size:9.4px"&gt;(1)&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: top;;text-align:left;"&gt; &lt;div style="text-align: left; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Primarily related to operations in Switzerland, the United Kingdom, and other jurisdictions with statutory tax rates different than the Bermuda rate. &lt;/div&gt;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;/table&gt;  &lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;The Company&#x2019;s effective tax rates were (0.19)% and (1.27)% for the years ended March&#160;31, 2021 and 2020, respectively, driven by the Company&#x2019;s jurisdictional earnings by location and a valuation allowance that eliminates the Company&#x2019;s global net deferred tax assets. &lt;/div&gt;&lt;/div&gt; &lt;div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;  &lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Deferred taxes reflect the tax effects of the differences between the amounts recorded as assets and liabilities for financial reporting purposes and the comparable amounts recorded for income tax purposes. Significant components of the deferred tax assets (liabilities) at March&#160;31, 2021 and 2020 are as follows (in thousands): &lt;/div&gt;&lt;/div&gt;  &lt;div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 76%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;"&gt;
&lt;tr style="font-size: 0px;"&gt;
&lt;td style="width: 62%;"/&gt;
&lt;td style="width: 12%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="width: 12%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;March&#160;31,&#160;2021&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;March&#160;31,&#160;2020&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Deferred tax assets&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Research tax credits&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;19,063&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;6,303&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Intangible assets&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;50,564&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;43,626&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Net operating loss&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;202,906&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;116,619&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Share-based compensation&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;26,623&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;18,413&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Lease liabilities&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;16,638&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;17,194&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Other&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;7,303&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;7,060&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 5em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Subtotal&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;323,097&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;209,215&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Valuation allowance&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;(303,287&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;(187,831&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size: 1pt;"&gt;
&lt;td style="height: 6pt; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height: 6pt; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height: 6pt; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Deferred tax liabilities&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Depreciation&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;(1,214&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;(1,833&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"&gt;&lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Right-of-use&lt;/div&gt;&lt;/div&gt; assets&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;(13,908&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;(15,409&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Other&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;(4,688&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;(4,142&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Total deferred tax assets (liabilities)&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt; &lt;/tr&gt; &lt;/table&gt;  &lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;The Company has Federal net operating losses in Switzerland, the United States, the United Kingdom and other jurisdictions in the amount of $1,181.1&#160;million, $122.2&#160;million, $28.6&#160;million, and $75.8&#160;million, respectively. The Switzerland net operating losses will expire in varying amounts between March&#160;31, 2025 and March&#160;31, 2028. The United States net operating losses can be carried forward indefinitely with utilization limited to 80% of future taxable income for tax years beginning on or after January&#160;1, 2021, while the United Kingdom and other net operating losses can be carried forward indefinitely as well, with an annual limitation on utilization. The Company has generated net operating losses from United States state and local jurisdictions in the amount of $69.7&#160;million which will expire in varying amounts between March 31, 2035 and March 31, 2041. The Company has generated $19.1&#160;million of research tax credit carryforwards primarily in the United States, which will expire in varying amounts between March 31, 2035 and March 31, 2041. &lt;/div&gt;&lt;/div&gt; &lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;The Company assesses the realizability of the deferred tax assets at each balance sheet date based on available positive and negative evidence in order to determine the amount which is more likely than not to be realized and record a valuation allowance as necessary. Due to the Company&#x2019;s cumulative loss position which provides significant negative evidence difficult to overcome, the Company has recorded a valuation allowance of $303.3&#160;million as of March&#160;31, 2021, representing the portion of the deferred tax asset that is not more likely than not to be realized. The amount of the deferred tax asset considered realizable could be adjusted for future factors that would impact the assessment of the objective and subjective evidence of the Company. For the period April&#160;1, 2020 through March&#160;31, 2021, the valuation allowance increased by $115.5&#160;million primarily as a result of corresponding increases in our global net operating losses, as well as our Research Tax Credits. For the period April&#160;1, 2019 through March&#160;31, 2020, the valuation allowance decreased by $168.0&#160;million primarily as a result of the Sumitomo Transaction and the deconsolidation of Sio. The Company will continue to assess the realizability of deferred tax assets at each balance sheet date in order to determine the amount, if any, required for a valuation allowance. &lt;/div&gt;&lt;/div&gt; &lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;There are outside basis differences related to the Company&#x2019;s investment in subsidiaries for which no deferred taxes have been recorded as these would not be subject to tax on repatriation as Bermuda has no tax regime for Bermuda exempted limited companies, and the United Kingdom tax regime relating to company distributions and sales generally provides for exemption from tax for most overseas profits, subject to certain exceptions. &lt;/div&gt;&lt;/div&gt; &lt;div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; The Company is subject to tax and is required to file United States, United Kingdom, and Switzerland federal income tax returns, as well as income tax returns in various state, local, and foreign jurisdictions. The Company is subject to tax examinations for tax years ended March&#160;31, 2018 and forward in major taxing jurisdictions. Tax audits and examinations can involve complex issues, interpretations and judgments. The resolution of matters may span multiple years particularly if subject to litigation or negotiation. The Company believes it has appropriately recorded its tax position using reasonable estimates and assumptions, however, the potential tax benefits may impact the results of operations or cash flows in the period of resolution, settlement or when the statutes of limitations expire. There are no unrecognized tax benefits recorded as of March&#160;31, 2021 and 2020.</us-gaap:IncomeTaxDisclosureTextBlock>
    <us-gaap:ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock contextRef="P04_01_2020To03_31_2021">&lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;The loss before income taxes and the related expense/(benefit) are as follows (in thousands): &lt;/div&gt;&lt;/div&gt; &lt;div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 76%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;"&gt;
&lt;tr style="font-size: 0px;"&gt;
&lt;td style="width: 70%;"/&gt;
&lt;td style="width: 5%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="width: 5%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="6" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Years Ended March&#160;31,&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2021&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2020&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Loss before income taxes:&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;United States&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;(212,921&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;(69,264&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Switzerland&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;(424,494&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;(355,422&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Bermuda&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;(227,471&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;(105,604&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Other&lt;div style="font-size: 85%; vertical-align: top;;display:inline;;font-size:9.4px"&gt;(1)&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;(33,661&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;(30,696&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 5em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Total loss before income taxes&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;(898,547&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;(560,986&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; &lt;div style="clear: both; max-height: 0px;"/&gt; &lt;div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;"&gt;
&lt;tr style="page-break-inside: avoid;"&gt;
&lt;td style="width: 4%; vertical-align: top;;text-align:left;"&gt;&lt;div style="font-size: 85%; vertical-align: top;;display:inline;;font-size:9.4px"&gt;(1)&lt;/div&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: top;;text-align:left;"&gt; &lt;div style="text-align: left; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Primarily Greater China and United Kingdom activity &lt;/div&gt;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;/table&gt;
&lt;table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 76%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;"&gt;
&lt;tr style="font-size: 0px;"&gt;
&lt;td style="width: 74%;"/&gt;
&lt;td style="width: 7%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="width: 7%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="6" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Years&#160;Ended&#160;March&#160;31,&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&#160;&#160;&#160;2021&#160;&#160;&#160;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&#160;&#160;&#160;2020&#160;&#160;&#160;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Current taxes:&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;United States&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;1,365&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;6,327&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Switzerland&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Bermuda&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Other&lt;div style="font-size: 85%; vertical-align: top;;display:inline;;font-size:9.4px"&gt;(1)&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;321&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;797&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 5em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Total current tax expense&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;1,686&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;7,124&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size: 1pt;"&gt;
&lt;td style="height: 6pt; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height: 6pt; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height: 6pt; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Deferred taxes:&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;United States&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Switzerland&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Bermuda&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Other&lt;div style="font-size: 85%; vertical-align: top;;display:inline;;font-size:9.4px"&gt;(1)&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 5em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Total deferred tax benefit&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 7em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Total income tax expense&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;1,686&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;7,124&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; &lt;div style="clear: both; max-height: 0px;"/&gt; &lt;div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;"&gt;
&lt;tr style="page-break-inside: avoid;"&gt;
&lt;td style="width: 4%; vertical-align: top;;text-align:left;"&gt;&lt;div style="font-size: 85%; vertical-align: top;;display:inline;;font-size:9.4px"&gt;(1)&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: top;;text-align:left;"&gt; &lt;div style="text-align: left; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Primarily Greater China, United States state and local and United Kingdom activity &lt;/div&gt;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; </us-gaap:ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments
      contextRef="P04_01_2020To03_31_2021_USsrtStatementGeographicalAxis"
      decimals="-3"
      unitRef="Unit_USD">-212921000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments
      contextRef="P04_01_2019To03_31_2020_USsrtStatementGeographicalAxis"
      decimals="-3"
      unitRef="Unit_USD">-69264000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments
      contextRef="P04_01_2020To03_31_2021_CHsrtStatementGeographicalAxis"
      decimals="-3"
      unitRef="Unit_USD">-424494000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments
      contextRef="P04_01_2019To03_31_2020_CHsrtStatementGeographicalAxis"
      decimals="-3"
      unitRef="Unit_USD">-355422000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments
      contextRef="P04_01_2020To03_31_2021_BMsrtStatementGeographicalAxis"
      decimals="-3"
      unitRef="Unit_USD">-227471000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments
      contextRef="P04_01_2019To03_31_2020_BMsrtStatementGeographicalAxis"
      decimals="-3"
      unitRef="Unit_USD">-105604000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments
      contextRef="P04_01_2020To03_31_2021_OtherMembersrtStatementGeographicalAxis"
      decimals="-3"
      id="Fact_28229787"
      unitRef="Unit_USD">-33661000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments
      contextRef="P04_01_2019To03_31_2020_OtherMembersrtStatementGeographicalAxis"
      decimals="-3"
      id="Fact_28229788"
      unitRef="Unit_USD">-30696000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments
      contextRef="P04_01_2020To03_31_2021"
      decimals="-3"
      unitRef="Unit_USD">-898547000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments
      contextRef="P04_01_2019To03_31_2020"
      decimals="-3"
      unitRef="Unit_USD">-560986000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments>
    <us-gaap:CurrentIncomeTaxExpenseBenefit
      contextRef="P04_01_2020To03_31_2021_USsrtStatementGeographicalAxis"
      decimals="-3"
      unitRef="Unit_USD">1365000</us-gaap:CurrentIncomeTaxExpenseBenefit>
    <us-gaap:CurrentIncomeTaxExpenseBenefit
      contextRef="P04_01_2019To03_31_2020_USsrtStatementGeographicalAxis"
      decimals="-3"
      unitRef="Unit_USD">6327000</us-gaap:CurrentIncomeTaxExpenseBenefit>
    <us-gaap:CurrentIncomeTaxExpenseBenefit
      contextRef="P04_01_2020To03_31_2021_CHsrtStatementGeographicalAxis"
      decimals="-3"
      unitRef="Unit_USD">0</us-gaap:CurrentIncomeTaxExpenseBenefit>
    <us-gaap:CurrentIncomeTaxExpenseBenefit
      contextRef="P04_01_2019To03_31_2020_CHsrtStatementGeographicalAxis"
      decimals="-3"
      unitRef="Unit_USD">0</us-gaap:CurrentIncomeTaxExpenseBenefit>
    <us-gaap:CurrentIncomeTaxExpenseBenefit
      contextRef="P04_01_2020To03_31_2021_BMsrtStatementGeographicalAxis"
      decimals="-3"
      unitRef="Unit_USD">0</us-gaap:CurrentIncomeTaxExpenseBenefit>
    <us-gaap:CurrentIncomeTaxExpenseBenefit
      contextRef="P04_01_2019To03_31_2020_BMsrtStatementGeographicalAxis"
      decimals="-3"
      unitRef="Unit_USD">0</us-gaap:CurrentIncomeTaxExpenseBenefit>
    <us-gaap:CurrentIncomeTaxExpenseBenefit
      contextRef="P04_01_2020To03_31_2021_OtherMembersrtStatementGeographicalAxis"
      decimals="-3"
      id="Fact_28229485"
      unitRef="Unit_USD">321000</us-gaap:CurrentIncomeTaxExpenseBenefit>
    <us-gaap:CurrentIncomeTaxExpenseBenefit
      contextRef="P04_01_2019To03_31_2020_OtherMembersrtStatementGeographicalAxis"
      decimals="-3"
      id="Fact_28229486"
      unitRef="Unit_USD">797000</us-gaap:CurrentIncomeTaxExpenseBenefit>
    <us-gaap:CurrentIncomeTaxExpenseBenefit
      contextRef="P04_01_2020To03_31_2021"
      decimals="-3"
      unitRef="Unit_USD">1686000</us-gaap:CurrentIncomeTaxExpenseBenefit>
    <us-gaap:CurrentIncomeTaxExpenseBenefit
      contextRef="P04_01_2019To03_31_2020"
      decimals="-3"
      unitRef="Unit_USD">7124000</us-gaap:CurrentIncomeTaxExpenseBenefit>
    <us-gaap:DeferredIncomeTaxExpenseBenefit
      contextRef="P04_01_2020To03_31_2021_USsrtStatementGeographicalAxis"
      decimals="-3"
      unitRef="Unit_USD">0</us-gaap:DeferredIncomeTaxExpenseBenefit>
    <us-gaap:DeferredIncomeTaxExpenseBenefit
      contextRef="P04_01_2019To03_31_2020_USsrtStatementGeographicalAxis"
      decimals="-3"
      unitRef="Unit_USD">0</us-gaap:DeferredIncomeTaxExpenseBenefit>
    <us-gaap:DeferredIncomeTaxExpenseBenefit
      contextRef="P04_01_2020To03_31_2021_CHsrtStatementGeographicalAxis"
      decimals="-3"
      unitRef="Unit_USD">0</us-gaap:DeferredIncomeTaxExpenseBenefit>
    <us-gaap:DeferredIncomeTaxExpenseBenefit
      contextRef="P04_01_2019To03_31_2020_CHsrtStatementGeographicalAxis"
      decimals="-3"
      unitRef="Unit_USD">0</us-gaap:DeferredIncomeTaxExpenseBenefit>
    <us-gaap:DeferredIncomeTaxExpenseBenefit
      contextRef="P04_01_2020To03_31_2021_BMsrtStatementGeographicalAxis"
      decimals="-3"
      unitRef="Unit_USD">0</us-gaap:DeferredIncomeTaxExpenseBenefit>
    <us-gaap:DeferredIncomeTaxExpenseBenefit
      contextRef="P04_01_2019To03_31_2020_BMsrtStatementGeographicalAxis"
      decimals="-3"
      unitRef="Unit_USD">0</us-gaap:DeferredIncomeTaxExpenseBenefit>
    <us-gaap:DeferredIncomeTaxExpenseBenefit
      contextRef="P04_01_2020To03_31_2021_OtherMembersrtStatementGeographicalAxis"
      decimals="-3"
      unitRef="Unit_USD">0</us-gaap:DeferredIncomeTaxExpenseBenefit>
    <us-gaap:DeferredIncomeTaxExpenseBenefit
      contextRef="P04_01_2019To03_31_2020_OtherMembersrtStatementGeographicalAxis"
      decimals="-3"
      unitRef="Unit_USD">0</us-gaap:DeferredIncomeTaxExpenseBenefit>
    <us-gaap:DeferredIncomeTaxExpenseBenefit
      contextRef="P04_01_2020To03_31_2021"
      decimals="-3"
      unitRef="Unit_USD">0</us-gaap:DeferredIncomeTaxExpenseBenefit>
    <us-gaap:DeferredIncomeTaxExpenseBenefit
      contextRef="P04_01_2019To03_31_2020"
      decimals="-3"
      unitRef="Unit_USD">0</us-gaap:DeferredIncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="P04_01_2020To03_31_2021"
      decimals="-3"
      unitRef="Unit_USD">1686000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="P04_01_2019To03_31_2020"
      decimals="-3"
      unitRef="Unit_USD">7124000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock contextRef="P04_01_2020To03_31_2021">&lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;A reconciliation of income tax provision/(benefit) computed at the Bermuda statutory rate to income tax expense reflected in the consolidated financial statements is as follows (in thousands, except percentages): &lt;/div&gt;&lt;/div&gt; &lt;div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 92%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;"&gt;
&lt;tr style="font-size: 0px;"&gt;
&lt;td style="width: 59%;"/&gt;
&lt;td style="width: 6%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="width: 6%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="width: 5%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="width: 6%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="6" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Year Ended March&#160;31,&lt;br/&gt; 2021&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&#160;&lt;/td&gt;
&lt;td colspan="6" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Year Ended&lt;br/&gt; March&#160;31, 2020&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Income tax benefit at Bermuda statutory rate&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;%&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;%&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Foreign rate differential&lt;div style="font-size: 85%; vertical-align: top;;display:inline;;font-size:9.4px"&gt;(1)&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;(150,778&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;16.78&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;%&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;(74,922&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;13.36&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;%&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Permanent disallowed IPR&amp;amp;D&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;111,432&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;(12.40&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)%&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;%&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Nondeductible changes in the fair value of investments and loss from equity method investment&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;(22,472&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;2.50&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;%&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;20,840&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;(3.72&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)%&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Nontaxable (loss) gain on deconsolidation of business&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;(16,438&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;1.83&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;%&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;29,041&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;(5.18&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)%&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Permanent adjustments&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;2,923&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;(0.33&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)%&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;(20,395&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;3.64&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;%&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;R&amp;amp;D tax credits&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;(10,555&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;1.17&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;%&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;(5,990&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;1.07&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;%&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Rate changes&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;2,443&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;(0.27&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)%&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;(29,238&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;5.21&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;%&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Valuation allowance&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;85,046&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;(9.46&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)%&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;87,677&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;(15.63&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)%&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Other&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;85&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;(0.01&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)%&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;111&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;(0.02&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)%&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Total income tax expense&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;1,686&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;(0.19&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)%&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;7,124&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;(1.27&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)%&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; &lt;div style="clear: both; max-height: 0px;"/&gt; &lt;div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;"&gt;
&lt;tr style="page-break-inside: avoid;"&gt;
&lt;td style="width: 4%; vertical-align: top;;text-align:left;"&gt;&lt;div style="font-size: 85%; vertical-align: top;;display:inline;;font-size:9.4px"&gt;(1)&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: top;;text-align:left;"&gt; &lt;div style="text-align: left; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Primarily related to operations in Switzerland, the United Kingdom, and other jurisdictions with statutory tax rates different than the Bermuda rate. &lt;/div&gt;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; </us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock>
    <us-gaap:IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate
      contextRef="P04_01_2020To03_31_2021"
      decimals="-3"
      unitRef="Unit_USD">0</us-gaap:IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate>
    <us-gaap:IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate
      contextRef="P04_01_2019To03_31_2020"
      decimals="-3"
      unitRef="Unit_USD">0</us-gaap:IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate>
    <us-gaap:IncomeTaxReconciliationForeignIncomeTaxRateDifferential
      contextRef="P04_01_2020To03_31_2021"
      decimals="-3"
      id="Fact_28229520"
      unitRef="Unit_USD">-150778000</us-gaap:IncomeTaxReconciliationForeignIncomeTaxRateDifferential>
    <us-gaap:EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential
      contextRef="P04_01_2020To03_31_2021"
      decimals="4"
      id="Fact_28229521"
      unitRef="Unit_pure">0.1678</us-gaap:EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential>
    <us-gaap:IncomeTaxReconciliationForeignIncomeTaxRateDifferential
      contextRef="P04_01_2019To03_31_2020"
      decimals="-3"
      id="Fact_28229522"
      unitRef="Unit_USD">-74922000</us-gaap:IncomeTaxReconciliationForeignIncomeTaxRateDifferential>
    <us-gaap:EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential
      contextRef="P04_01_2019To03_31_2020"
      decimals="4"
      id="Fact_28229523"
      unitRef="Unit_pure">0.1336</us-gaap:EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential>
    <us-gaap:IncomeTaxReconciliationNondeductibleExpenseResearchAndDevelopment
      contextRef="P04_01_2020To03_31_2021"
      decimals="-3"
      unitRef="Unit_USD">111432000</us-gaap:IncomeTaxReconciliationNondeductibleExpenseResearchAndDevelopment>
    <us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseResearchAndDevelopment
      contextRef="P04_01_2020To03_31_2021"
      decimals="4"
      unitRef="Unit_pure">-0.1240</us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseResearchAndDevelopment>
    <us-gaap:IncomeTaxReconciliationNondeductibleExpense
      contextRef="P04_01_2020To03_31_2021"
      decimals="-3"
      unitRef="Unit_USD">-22472000</us-gaap:IncomeTaxReconciliationNondeductibleExpense>
    <us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpense
      contextRef="P04_01_2020To03_31_2021"
      decimals="4"
      unitRef="Unit_pure">0.0250</us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpense>
    <us-gaap:IncomeTaxReconciliationNondeductibleExpense
      contextRef="P04_01_2019To03_31_2020"
      decimals="-3"
      unitRef="Unit_USD">20840000</us-gaap:IncomeTaxReconciliationNondeductibleExpense>
    <us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpense
      contextRef="P04_01_2019To03_31_2020"
      decimals="4"
      unitRef="Unit_pure">-0.0372</us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpense>
    <us-gaap:IncomeTaxReconciliationDispositionOfBusiness
      contextRef="P04_01_2020To03_31_2021"
      decimals="-3"
      unitRef="Unit_USD">-16438000</us-gaap:IncomeTaxReconciliationDispositionOfBusiness>
    <us-gaap:EffectiveIncomeTaxRateReconciliationDispositionOfBusiness
      contextRef="P04_01_2020To03_31_2021"
      decimals="4"
      unitRef="Unit_pure">-0.0183</us-gaap:EffectiveIncomeTaxRateReconciliationDispositionOfBusiness>
    <us-gaap:IncomeTaxReconciliationDispositionOfBusiness
      contextRef="P04_01_2019To03_31_2020"
      decimals="-3"
      unitRef="Unit_USD">29041000</us-gaap:IncomeTaxReconciliationDispositionOfBusiness>
    <us-gaap:EffectiveIncomeTaxRateReconciliationDispositionOfBusiness
      contextRef="P04_01_2019To03_31_2020"
      decimals="4"
      unitRef="Unit_pure">0.0518</us-gaap:EffectiveIncomeTaxRateReconciliationDispositionOfBusiness>
    <roiv:IncomeTaxReconciliationPermanentAdjustments
      contextRef="P04_01_2020To03_31_2021"
      decimals="-3"
      unitRef="Unit_USD">2923000</roiv:IncomeTaxReconciliationPermanentAdjustments>
    <roiv:EffectiveIncomeTaxReconciliationPermanentDifferences
      contextRef="P04_01_2020To03_31_2021"
      decimals="4"
      unitRef="Unit_pure">-0.0033</roiv:EffectiveIncomeTaxReconciliationPermanentDifferences>
    <roiv:IncomeTaxReconciliationPermanentAdjustments
      contextRef="P04_01_2019To03_31_2020"
      decimals="-3"
      unitRef="Unit_USD">-20395000</roiv:IncomeTaxReconciliationPermanentAdjustments>
    <roiv:EffectiveIncomeTaxReconciliationPermanentDifferences
      contextRef="P04_01_2019To03_31_2020"
      decimals="4"
      unitRef="Unit_pure">0.0364</roiv:EffectiveIncomeTaxReconciliationPermanentDifferences>
    <us-gaap:IncomeTaxReconciliationTaxCreditsResearch
      contextRef="P04_01_2020To03_31_2021"
      decimals="-3"
      unitRef="Unit_USD">10555000</us-gaap:IncomeTaxReconciliationTaxCreditsResearch>
    <us-gaap:EffectiveIncomeTaxRateReconciliationTaxCreditsResearch
      contextRef="P04_01_2020To03_31_2021"
      decimals="4"
      unitRef="Unit_pure">-0.0117</us-gaap:EffectiveIncomeTaxRateReconciliationTaxCreditsResearch>
    <us-gaap:IncomeTaxReconciliationTaxCreditsResearch
      contextRef="P04_01_2019To03_31_2020"
      decimals="-3"
      unitRef="Unit_USD">5990000</us-gaap:IncomeTaxReconciliationTaxCreditsResearch>
    <us-gaap:EffectiveIncomeTaxRateReconciliationTaxCreditsResearch
      contextRef="P04_01_2019To03_31_2020"
      decimals="4"
      unitRef="Unit_pure">-0.0107</us-gaap:EffectiveIncomeTaxRateReconciliationTaxCreditsResearch>
    <us-gaap:IncomeTaxReconciliationChangeInEnactedTaxRate
      contextRef="P04_01_2020To03_31_2021"
      decimals="-3"
      unitRef="Unit_USD">2443000</us-gaap:IncomeTaxReconciliationChangeInEnactedTaxRate>
    <us-gaap:EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate
      contextRef="P04_01_2020To03_31_2021"
      decimals="4"
      unitRef="Unit_pure">-0.0027</us-gaap:EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate>
    <us-gaap:IncomeTaxReconciliationChangeInEnactedTaxRate
      contextRef="P04_01_2019To03_31_2020"
      decimals="-3"
      unitRef="Unit_USD">-29238000</us-gaap:IncomeTaxReconciliationChangeInEnactedTaxRate>
    <us-gaap:EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate
      contextRef="P04_01_2019To03_31_2020"
      decimals="4"
      unitRef="Unit_pure">0.0521</us-gaap:EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate>
    <us-gaap:IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance
      contextRef="P04_01_2020To03_31_2021"
      decimals="-3"
      unitRef="Unit_USD">85046000</us-gaap:IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance>
    <us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance
      contextRef="P04_01_2020To03_31_2021"
      decimals="4"
      unitRef="Unit_pure">0.0946</us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance>
    <us-gaap:IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance
      contextRef="P04_01_2019To03_31_2020"
      decimals="-3"
      unitRef="Unit_USD">87677000</us-gaap:IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance>
    <us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance
      contextRef="P04_01_2019To03_31_2020"
      decimals="4"
      unitRef="Unit_pure">0.1563</us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance>
    <us-gaap:IncomeTaxReconciliationOtherAdjustments
      contextRef="P04_01_2020To03_31_2021"
      decimals="-3"
      unitRef="Unit_USD">85000</us-gaap:IncomeTaxReconciliationOtherAdjustments>
    <us-gaap:EffectiveIncomeTaxRateReconciliationOtherAdjustments
      contextRef="P04_01_2020To03_31_2021"
      decimals="4"
      unitRef="Unit_pure">0.0001</us-gaap:EffectiveIncomeTaxRateReconciliationOtherAdjustments>
    <us-gaap:IncomeTaxReconciliationOtherAdjustments
      contextRef="P04_01_2019To03_31_2020"
      decimals="-3"
      unitRef="Unit_USD">111000</us-gaap:IncomeTaxReconciliationOtherAdjustments>
    <us-gaap:EffectiveIncomeTaxRateReconciliationOtherAdjustments
      contextRef="P04_01_2019To03_31_2020"
      decimals="4"
      unitRef="Unit_pure">0.0002</us-gaap:EffectiveIncomeTaxRateReconciliationOtherAdjustments>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="P04_01_2020To03_31_2021"
      decimals="-3"
      unitRef="Unit_USD">1686000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:EffectiveIncomeTaxRateContinuingOperations
      contextRef="P04_01_2020To03_31_2021"
      decimals="4"
      unitRef="Unit_pure">-0.0019</us-gaap:EffectiveIncomeTaxRateContinuingOperations>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="P04_01_2019To03_31_2020"
      decimals="-3"
      unitRef="Unit_USD">7124000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:EffectiveIncomeTaxRateContinuingOperations
      contextRef="P04_01_2019To03_31_2020"
      decimals="4"
      unitRef="Unit_pure">-0.0127</us-gaap:EffectiveIncomeTaxRateContinuingOperations>
    <us-gaap:EffectiveIncomeTaxRateContinuingOperations
      contextRef="P04_01_2020To03_31_2021"
      decimals="4"
      unitRef="Unit_pure">-0.0019</us-gaap:EffectiveIncomeTaxRateContinuingOperations>
    <us-gaap:EffectiveIncomeTaxRateContinuingOperations
      contextRef="P04_01_2019To03_31_2020"
      decimals="4"
      unitRef="Unit_pure">-0.0127</us-gaap:EffectiveIncomeTaxRateContinuingOperations>
    <us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock contextRef="P04_01_2020To03_31_2021">Significant components of the deferred tax assets (liabilities) at March&#160;31, 2021 and 2020 are as follows (in thousands): &lt;div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 76%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;"&gt;
&lt;tr style="font-size: 0px;"&gt;
&lt;td style="width: 62%;"/&gt;
&lt;td style="width: 12%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="width: 12%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;March&#160;31,&#160;2021&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;March&#160;31,&#160;2020&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Deferred tax assets&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Research tax credits&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;19,063&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;6,303&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Intangible assets&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;50,564&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;43,626&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Net operating loss&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;202,906&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;116,619&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Share-based compensation&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;26,623&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;18,413&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Lease liabilities&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;16,638&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;17,194&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Other&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;7,303&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;7,060&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 5em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Subtotal&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;323,097&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;209,215&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Valuation allowance&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;(303,287&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;(187,831&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size: 1pt;"&gt;
&lt;td style="height: 6pt; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height: 6pt; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td colspan="4" style="height: 6pt; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Deferred tax liabilities&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Depreciation&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;(1,214&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;(1,833&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"&gt;&lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Right-of-use&lt;/div&gt;&lt;/div&gt; assets&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;(13,908&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;(15,409&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Other&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;(4,688&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;(4,142&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Total deferred tax assets (liabilities)&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; </us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock>
    <us-gaap:DeferredTaxAssetsTaxCreditCarryforwardsResearch
      contextRef="PAsOn03_31_2021"
      decimals="-3"
      unitRef="Unit_USD">19063000</us-gaap:DeferredTaxAssetsTaxCreditCarryforwardsResearch>
    <us-gaap:DeferredTaxAssetsTaxCreditCarryforwardsResearch
      contextRef="PAsOn03_31_2020"
      decimals="-3"
      unitRef="Unit_USD">6303000</us-gaap:DeferredTaxAssetsTaxCreditCarryforwardsResearch>
    <us-gaap:DeferredTaxAssetsGoodwillAndIntangibleAssets
      contextRef="PAsOn03_31_2021"
      decimals="-3"
      unitRef="Unit_USD">50564000</us-gaap:DeferredTaxAssetsGoodwillAndIntangibleAssets>
    <us-gaap:DeferredTaxAssetsGoodwillAndIntangibleAssets
      contextRef="PAsOn03_31_2020"
      decimals="-3"
      unitRef="Unit_USD">43626000</us-gaap:DeferredTaxAssetsGoodwillAndIntangibleAssets>
    <us-gaap:DeferredTaxAssetsOperatingLossCarryforwards
      contextRef="PAsOn03_31_2021"
      decimals="-3"
      unitRef="Unit_USD">202906000</us-gaap:DeferredTaxAssetsOperatingLossCarryforwards>
    <us-gaap:DeferredTaxAssetsOperatingLossCarryforwards
      contextRef="PAsOn03_31_2020"
      decimals="-3"
      unitRef="Unit_USD">116619000</us-gaap:DeferredTaxAssetsOperatingLossCarryforwards>
    <us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost
      contextRef="PAsOn03_31_2021"
      decimals="-3"
      unitRef="Unit_USD">26623000</us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost>
    <us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost
      contextRef="PAsOn03_31_2020"
      decimals="-3"
      unitRef="Unit_USD">18413000</us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost>
    <roiv:DeferredTaxAssetsLeaseLiabilities
      contextRef="PAsOn03_31_2021"
      decimals="-3"
      unitRef="Unit_USD">16638000</roiv:DeferredTaxAssetsLeaseLiabilities>
    <roiv:DeferredTaxAssetsLeaseLiabilities
      contextRef="PAsOn03_31_2020"
      decimals="-3"
      unitRef="Unit_USD">17194000</roiv:DeferredTaxAssetsLeaseLiabilities>
    <us-gaap:DeferredTaxAssetsOther
      contextRef="PAsOn03_31_2021"
      decimals="-3"
      unitRef="Unit_USD">7303000</us-gaap:DeferredTaxAssetsOther>
    <us-gaap:DeferredTaxAssetsOther
      contextRef="PAsOn03_31_2020"
      decimals="-3"
      unitRef="Unit_USD">7060000</us-gaap:DeferredTaxAssetsOther>
    <us-gaap:DeferredTaxAssetsGross
      contextRef="PAsOn03_31_2021"
      decimals="-3"
      unitRef="Unit_USD">323097000</us-gaap:DeferredTaxAssetsGross>
    <us-gaap:DeferredTaxAssetsGross
      contextRef="PAsOn03_31_2020"
      decimals="-3"
      unitRef="Unit_USD">209215000</us-gaap:DeferredTaxAssetsGross>
    <us-gaap:DeferredTaxAssetsValuationAllowance
      contextRef="PAsOn03_31_2021"
      decimals="-3"
      unitRef="Unit_USD">303287000</us-gaap:DeferredTaxAssetsValuationAllowance>
    <us-gaap:DeferredTaxAssetsValuationAllowance
      contextRef="PAsOn03_31_2020"
      decimals="-3"
      unitRef="Unit_USD">187831000</us-gaap:DeferredTaxAssetsValuationAllowance>
    <roiv:DeferredTaxLiabilitiesDepreciation
      contextRef="PAsOn03_31_2021"
      decimals="-3"
      unitRef="Unit_USD">1214000</roiv:DeferredTaxLiabilitiesDepreciation>
    <roiv:DeferredTaxLiabilitiesDepreciation
      contextRef="PAsOn03_31_2020"
      decimals="-3"
      unitRef="Unit_USD">1833000</roiv:DeferredTaxLiabilitiesDepreciation>
    <roiv:DeferredTaxLiabilitiesRightOfUseAssets
      contextRef="PAsOn03_31_2021"
      decimals="-3"
      unitRef="Unit_USD">13908000</roiv:DeferredTaxLiabilitiesRightOfUseAssets>
    <roiv:DeferredTaxLiabilitiesRightOfUseAssets
      contextRef="PAsOn03_31_2020"
      decimals="-3"
      unitRef="Unit_USD">15409000</roiv:DeferredTaxLiabilitiesRightOfUseAssets>
    <us-gaap:DeferredTaxLiabilitiesOther
      contextRef="PAsOn03_31_2021"
      decimals="-3"
      unitRef="Unit_USD">4688000</us-gaap:DeferredTaxLiabilitiesOther>
    <us-gaap:DeferredTaxLiabilitiesOther
      contextRef="PAsOn03_31_2020"
      decimals="-3"
      unitRef="Unit_USD">4142000</us-gaap:DeferredTaxLiabilitiesOther>
    <us-gaap:DeferredTaxAssetsLiabilitiesNet
      contextRef="PAsOn03_31_2021"
      decimals="-3"
      unitRef="Unit_USD">0</us-gaap:DeferredTaxAssetsLiabilitiesNet>
    <us-gaap:DeferredTaxAssetsLiabilitiesNet
      contextRef="PAsOn03_31_2020"
      decimals="-3"
      unitRef="Unit_USD">0</us-gaap:DeferredTaxAssetsLiabilitiesNet>
    <us-gaap:OperatingLossCarryforwards
      contextRef="PAsOn03_31_2021_CHsrtStatementGeographicalAxis"
      decimals="-5"
      unitRef="Unit_USD">1181100000</us-gaap:OperatingLossCarryforwards>
    <us-gaap:OperatingLossCarryforwards
      contextRef="PAsOn03_31_2021_USsrtStatementGeographicalAxis"
      decimals="-5"
      unitRef="Unit_USD">122200000</us-gaap:OperatingLossCarryforwards>
    <us-gaap:OperatingLossCarryforwards
      contextRef="PAsOn03_31_2021_GBsrtStatementGeographicalAxis"
      decimals="-5"
      unitRef="Unit_USD">28600000</us-gaap:OperatingLossCarryforwards>
    <us-gaap:OperatingLossCarryforwards
      contextRef="PAsOn03_31_2021_TaxAuthorityInOtherJurisdictionsMembersrtStatementGeographicalAxis"
      decimals="-5"
      unitRef="Unit_USD">75800000</us-gaap:OperatingLossCarryforwards>
    <roiv:PercentageOfFutureTaxableIncome
      contextRef="P04_01_2020To03_31_2021_USsrtStatementGeographicalAxis"
      decimals="2"
      unitRef="Unit_pure">0.80</roiv:PercentageOfFutureTaxableIncome>
    <us-gaap:OperatingLossCarryforwards
      contextRef="PAsOn03_31_2021_StateAndLocalJurisdictionMemberusgaapIncomeTaxAuthorityAxis"
      decimals="-5"
      unitRef="Unit_USD">69700000</us-gaap:OperatingLossCarryforwards>
    <us-gaap:OperatingLossCarryforwardsExpirationDate contextRef="P04_01_2020To03_31_2021_MinimumMembersrtRangeAxis_StateAndLocalJurisdictionMemberusgaapIncomeTaxAuthorityAxis">2035-03-31</us-gaap:OperatingLossCarryforwardsExpirationDate>
    <us-gaap:OperatingLossCarryforwardsExpirationDate contextRef="P04_01_2020To03_31_2021_MaximumMembersrtRangeAxis_StateAndLocalJurisdictionMemberusgaapIncomeTaxAuthorityAxis">2041-03-31</us-gaap:OperatingLossCarryforwardsExpirationDate>
    <us-gaap:TaxCreditCarryforwardAmount
      contextRef="PAsOn03_31_2021_USsrtStatementGeographicalAxis"
      decimals="-5"
      unitRef="Unit_USD">19100000</us-gaap:TaxCreditCarryforwardAmount>
    <us-gaap:TaxCreditCarryforwardExpirationDate contextRef="P04_01_2020To03_31_2021_MinimumMembersrtRangeAxis_USsrtStatementGeographicalAxis">2035-03-31</us-gaap:TaxCreditCarryforwardExpirationDate>
    <us-gaap:TaxCreditCarryforwardExpirationDate contextRef="P04_01_2020To03_31_2021_MaximumMembersrtRangeAxis_USsrtStatementGeographicalAxis">2041-03-31</us-gaap:TaxCreditCarryforwardExpirationDate>
    <us-gaap:DeferredTaxAssetsValuationAllowance
      contextRef="PAsOn03_31_2021"
      decimals="-5"
      unitRef="Unit_USD">303300000</us-gaap:DeferredTaxAssetsValuationAllowance>
    <us-gaap:ValuationAllowanceDeferredTaxAssetChangeInAmount
      contextRef="P04_01_2020To03_31_2021"
      decimals="-5"
      unitRef="Unit_USD">115500000</us-gaap:ValuationAllowanceDeferredTaxAssetChangeInAmount>
    <us-gaap:ValuationAllowanceDeferredTaxAssetChangeInAmount
      contextRef="P04_01_2019To03_31_2020"
      decimals="-5"
      unitRef="Unit_USD">168000000.0</us-gaap:ValuationAllowanceDeferredTaxAssetChangeInAmount>
    <us-gaap:UnrecognizedTaxBenefits
      contextRef="PAsOn03_31_2020"
      decimals="-6"
      unitRef="Unit_USD">0</us-gaap:UnrecognizedTaxBenefits>
    <us-gaap:UnrecognizedTaxBenefits
      contextRef="PAsOn03_31_2021"
      decimals="-6"
      unitRef="Unit_USD">0</us-gaap:UnrecognizedTaxBenefits>
    <us-gaap:LesseeOperatingLeasesTextBlock contextRef="P04_01_2020To03_31_2021">&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Note 13&#x2014;Leases &lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;The Company&#x2019;s operating leases consist primarily of real estate leases, including those entered into by certain wholly owned and majority-owned or controlled subsidiaries of RSL. The Company determines if an agreement is or contains a lease at inception. Leases with an initial term of 12 months or less are not recorded on the balance sheet. For real estate leases, the Company&#160;elected the expedient to account for lease and &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;non-lease&lt;/div&gt; components as a single component. &lt;/div&gt; &lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Right-of-use&lt;/div&gt;&lt;/div&gt; (&#x201c;ROU&#x201d;) assets represent the Company&#x2019;s right to use an underlying asset for the lease term and lease liabilities represent the Company&#x2019;s obligation to make lease payments arising from the lease. ROU assets and liabilities are based on the estimated present value of fixed lease payments over the expected lease term and are recognized at the lease commencement date. &lt;/div&gt; &lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;As most of the Company&#x2019;s leases do not provide an implicit rate, the Company uses an estimated incremental borrowing rate in determining the present value of fixed lease payments based on information available at the lease commencement date. The Company&#x2019;s incremental borrowing rates are determined based on the term of the lease, the economic environment of the lease, and the effect of collateralization. Certain leases include one or more renewal options, generally for the same period as the initial term of the lease. The exercise of lease renewal options is generally at the Company&#x2019;s sole discretion and, as such, the Company typically determines that exercise of these renewal options is not reasonably certain. As a result, the Company does not include the renewal option period in the expected lease term and the associated lease payments are not included in the measurement of the ROU asset and lease liability. Certain leases also contain termination options with an associated penalty. Generally, the Company is reasonably certain not to exercise these options and as such, they are not included in the determination of the expected lease term. The Company recognizes operating lease expense on a straight-line basis over the lease term. &lt;/div&gt;&lt;/div&gt; &lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Leases generally provide for payments of nonlease components, such as common area maintenance, real estate taxes and other costs associated with the leased property. For lease agreements entered into or modified after April&#160;1, 2019, the Company accounts for lease components and nonlease components together as a single lease component and, as such, includes fixed payments of nonlease components in the measurement of the ROU assets and lease liabilities. Variable lease payments, such as periodic adjustments for inflation, reimbursement of real estate taxes, any variable common area maintenance and any other variable costs associated with the leased property are expensed as incurred as variable lease costs and are not recorded on the balance sheet. &lt;/div&gt;&lt;/div&gt; &lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;The Company&#x2019;s lease agreements do not contain any material residual value guarantees or material restrictions or covenants. &lt;/div&gt;&lt;/div&gt; &lt;div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;The components of operating lease expense for the Company were as follows (in thousands): &lt;/div&gt;&lt;/div&gt; &lt;div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 68%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;"&gt;
&lt;tr style="font-size: 0px;"&gt;
&lt;td style="width: 70%;"/&gt;
&lt;td style="width: 6%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="width: 6%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="6" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Years&#160;Ended&#160;March&#160;31,&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2021&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2020&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Operating lease cost&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;11,931&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;11,515&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Short-term lease cost&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;237&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;872&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Variable lease cost&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;704&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;379&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Total operating lease cost&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;12,872&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;12,766&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt; &lt;/tr&gt; &lt;/table&gt;  &lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Information related to the Company&#x2019;s operating lease ROU assets and operating lease liabilities was as follows (in thousands, except periods and percentages): &lt;/div&gt;&lt;/div&gt; &lt;div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 68%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 8pt; border-collapse: collapse; border-spacing: 0px;"&gt;
&lt;tr style="font-size: 0px;"&gt;
&lt;td style="width: 72%;"/&gt;
&lt;td style="width: 6%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="width: 6%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="6" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;During the Year&lt;br/&gt; Ended March&#160;31,&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2021&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2020&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Cash paid for operating lease liabilities&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;8,830&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;8,108&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Operating lease ROU assets obtained in exchange for operating lease liabilities&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;5,491&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;56,025&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; &lt;div style="clear: both; max-height: 0px;"/&gt; &lt;div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 84%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;"&gt;
&lt;tr style="font-size: 0px;"&gt;
&lt;td style="width: 66%;"/&gt;
&lt;td style="width: 15%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="width: 14%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;March&#160;31,&#160;2021&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;March&#160;31,&#160;2020&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Weighted average remaining lease term (in years)&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;9.6&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;10.2&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Weighted average discount rate&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;7.1&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;%&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;7.1&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;%&#160;&lt;/td&gt; &lt;/tr&gt; &lt;/table&gt;  &lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;As of March&#160;31, 2021, maturities of operating lease liabilities were as follows (in thousands): &lt;/div&gt;&lt;/div&gt; &lt;div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 68%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;"&gt;
&lt;tr style="font-size: 0px;"&gt;
&lt;td style="width: 83%; font-family: &amp;quot;Times New Roman&amp;quot;;"/&gt;
&lt;td style="width: 9%; vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"/&gt;
&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;;"/&gt;
&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;;"/&gt;
&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;;"/&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt; &lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt; border-bottom: 1pt solid rgb(0, 0, 0); display: table-cell; line-height: normal;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Years Ending March&#160;31,&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;2022&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;13,386&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;2023&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;11,814&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;2024&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;11,718&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;2025&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;9,734&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;2026&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;8,617&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Thereafter&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;51,674&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Total lease payments&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;106,943&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Less: present value adjustment&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;(29,348&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Less: tenant improvement allowance&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;(2,898&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Total&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;74,697&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt; &lt;/tr&gt; &lt;/table&gt;  </us-gaap:LesseeOperatingLeasesTextBlock>
    <us-gaap:LeaseCostTableTextBlock contextRef="P04_01_2020To03_31_2021">&lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;The components of operating lease expense for the Company were as follows (in thousands): &lt;/div&gt;&lt;/div&gt; &lt;div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 68%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;"&gt;
&lt;tr style="font-size: 0px;"&gt;
&lt;td style="width: 70%;"/&gt;
&lt;td style="width: 6%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="width: 6%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="6" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Years&#160;Ended&#160;March&#160;31,&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2021&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2020&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Operating lease cost&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;11,931&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;11,515&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Short-term lease cost&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;237&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;872&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Variable lease cost&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;704&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;379&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Total operating lease cost&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;12,872&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;12,766&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; </us-gaap:LeaseCostTableTextBlock>
    <us-gaap:OperatingLeaseCost
      contextRef="P04_01_2020To03_31_2021"
      decimals="-3"
      unitRef="Unit_USD">11931000</us-gaap:OperatingLeaseCost>
    <us-gaap:OperatingLeaseCost
      contextRef="P04_01_2019To03_31_2020"
      decimals="-3"
      unitRef="Unit_USD">11515000</us-gaap:OperatingLeaseCost>
    <us-gaap:ShortTermLeaseCost
      contextRef="P04_01_2020To03_31_2021"
      decimals="-3"
      unitRef="Unit_USD">237000</us-gaap:ShortTermLeaseCost>
    <us-gaap:ShortTermLeaseCost
      contextRef="P04_01_2019To03_31_2020"
      decimals="-3"
      unitRef="Unit_USD">872000</us-gaap:ShortTermLeaseCost>
    <us-gaap:VariableLeaseCost
      contextRef="P04_01_2020To03_31_2021"
      decimals="-3"
      unitRef="Unit_USD">704000</us-gaap:VariableLeaseCost>
    <us-gaap:VariableLeaseCost
      contextRef="P04_01_2019To03_31_2020"
      decimals="-3"
      unitRef="Unit_USD">379000</us-gaap:VariableLeaseCost>
    <us-gaap:LeaseCost
      contextRef="P04_01_2020To03_31_2021"
      decimals="-3"
      unitRef="Unit_USD">12872000</us-gaap:LeaseCost>
    <us-gaap:LeaseCost
      contextRef="P04_01_2019To03_31_2020"
      decimals="-3"
      unitRef="Unit_USD">12766000</us-gaap:LeaseCost>
    <us-gaap:LeasesOfLesseeDisclosureTextBlock contextRef="P04_01_2020To03_31_2021">&lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Information related to the Company&#x2019;s operating lease ROU assets and operating lease liabilities was as follows (in thousands, except periods and percentages): &lt;/div&gt;&lt;/div&gt; &lt;div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 68%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 8pt; border-collapse: collapse; border-spacing: 0px;"&gt;
&lt;tr style="font-size: 0px;"&gt;
&lt;td style="width: 72%;"/&gt;
&lt;td style="width: 6%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="width: 6%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="6" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;During the Year&lt;br/&gt; Ended March&#160;31,&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2021&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2020&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Cash paid for operating lease liabilities&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;8,830&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;8,108&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Operating lease ROU assets obtained in exchange for operating lease liabilities&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;5,491&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;56,025&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; &lt;div style="clear: both; max-height: 0px;"/&gt; &lt;div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 84%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;"&gt;
&lt;tr style="font-size: 0px;"&gt;
&lt;td style="width: 66%;"/&gt;
&lt;td style="width: 15%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="width: 14%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;March&#160;31,&#160;2021&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;March&#160;31,&#160;2020&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Weighted average remaining lease term (in years)&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;9.6&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;10.2&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Weighted average discount rate&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;7.1&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;%&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;7.1&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;%&#160;&lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; </us-gaap:LeasesOfLesseeDisclosureTextBlock>
    <us-gaap:OperatingLeasePayments
      contextRef="P04_01_2020To03_31_2021"
      decimals="-3"
      unitRef="Unit_USD">8830000</us-gaap:OperatingLeasePayments>
    <us-gaap:OperatingLeasePayments
      contextRef="P04_01_2019To03_31_2020"
      decimals="-3"
      unitRef="Unit_USD">8108000</us-gaap:OperatingLeasePayments>
    <us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability
      contextRef="P04_01_2020To03_31_2021"
      decimals="-3"
      unitRef="Unit_USD">5491000</us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability>
    <us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability
      contextRef="P04_01_2019To03_31_2020"
      decimals="-3"
      unitRef="Unit_USD">56025000</us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability>
    <us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1 contextRef="PAsOn03_31_2021">P9Y7M6D</us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1>
    <us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1 contextRef="PAsOn03_31_2020">P10Y2M12D</us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1>
    <us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent
      contextRef="PAsOn03_31_2021"
      decimals="3"
      unitRef="Unit_pure">0.071</us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent>
    <us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent
      contextRef="PAsOn03_31_2020"
      decimals="3"
      unitRef="Unit_pure">0.071</us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent>
    <us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock contextRef="P04_01_2020To03_31_2021">&lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;As of March&#160;31, 2021, maturities of operating lease liabilities were as follows (in thousands): &lt;/div&gt;&lt;/div&gt; &lt;div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 68%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;"&gt;
&lt;tr style="font-size: 0px;"&gt;
&lt;td style="width: 83%; font-family: &amp;quot;Times New Roman&amp;quot;;"/&gt;
&lt;td style="width: 9%; vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"/&gt;
&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;;"/&gt;
&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;;"/&gt;
&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;;"/&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt; &lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt; border-bottom: 1pt solid rgb(0, 0, 0); display: table-cell; line-height: normal;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Years Ending March&#160;31,&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;2022&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;13,386&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;2023&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;11,814&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;2024&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;11,718&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;2025&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;9,734&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;2026&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;8,617&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Thereafter&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;51,674&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Total lease payments&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;106,943&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Less: present value adjustment&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;(29,348&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Less: tenant improvement allowance&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;(2,898&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Total&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;74,697&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; </us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths
      contextRef="PAsOn03_31_2021"
      decimals="-3"
      unitRef="Unit_USD">13386000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearTwo
      contextRef="PAsOn03_31_2021"
      decimals="-3"
      unitRef="Unit_USD">11814000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearTwo>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearThree
      contextRef="PAsOn03_31_2021"
      decimals="-3"
      unitRef="Unit_USD">11718000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearThree>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFour
      contextRef="PAsOn03_31_2021"
      decimals="-3"
      unitRef="Unit_USD">9734000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFour>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFive
      contextRef="PAsOn03_31_2021"
      decimals="-3"
      unitRef="Unit_USD">8617000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFive>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive
      contextRef="PAsOn03_31_2021"
      decimals="-3"
      unitRef="Unit_USD">51674000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue
      contextRef="PAsOn03_31_2021"
      decimals="-3"
      unitRef="Unit_USD">106943000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue>
    <roiv:OperatingLeaseLiabilityPresentValueAdjustments
      contextRef="PAsOn03_31_2021"
      decimals="-3"
      unitRef="Unit_USD">29348000</roiv:OperatingLeaseLiabilityPresentValueAdjustments>
    <roiv:LesseeOperatingLeaseLiabilityTenantImprovementAllowance
      contextRef="PAsOn03_31_2021"
      decimals="-3"
      unitRef="Unit_USD">2898000</roiv:LesseeOperatingLeaseLiabilityTenantImprovementAllowance>
    <us-gaap:OperatingLeaseLiability
      contextRef="PAsOn03_31_2021"
      decimals="-3"
      unitRef="Unit_USD">74697000</us-gaap:OperatingLeaseLiability>
    <us-gaap:CommitmentsAndContingenciesDisclosureTextBlock contextRef="P04_01_2020To03_31_2021">&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Note 14&#x2014;Commitments and Contingencies &lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;(A) Significant Agreements &lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;The Company, primarily through its subsidiaries has entered into commitments under various asset acquisition and license agreements including those described in Note 4, &#x201c;Asset Acquisitions and License Agreements.&#x201d; Additionally, the Company through its subsidiaries enters into agreements with contract service providers to assist in the performance of its R&amp;amp;D activities. Expenditures to contract research organizations and contract manufacturing organizations represent significant costs in the clinical development of its product candidates. Subject to required notice periods and certain obligations under binding purchase orders, the Company can elect to discontinue the work under these agreements at any time. The Company expects to enter into additional collaborative research, contract research, manufacturing, and supplier agreements in the future, which may require upfront payments and long-term commitments of capital resources. &lt;/div&gt;&lt;/div&gt; &lt;div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;(B) Loss Contingencies &lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;The Company may be, from time to time, a party to various disputes and claims arising from normal business activities. The Company accrues for loss contingencies when available information indicates that it is probable that a liability has been incurred and the amount of such loss can be reasonably estimated, and if the Company believes that a reasonably possible loss exists, the Company discloses the facts and circumstances of the litigation or claim, including an estimable range, if possible. The Company is currently not involved in any legal proceedings with a probable and estimable material loss. &lt;/div&gt;&lt;/div&gt; &lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;(C) Intellectual Property Agreements &lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;As of March&#160;31, 2021, the Company did not have any ongoing material financial commitments, other than pursuant to various asset acquisition and license agreements including those described in Note 4, &#x201c;Asset Acquisitions and License Agreements.&#x201d; &lt;/div&gt;&lt;/div&gt; &lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;(D) &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;COVID-19&lt;/div&gt; Pandemic &lt;/div&gt;&lt;/div&gt; &lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;The Company has been actively monitoring the impact of the &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;COVID-19&lt;/div&gt; pandemic on its employees and business. Based on guidance issued by federal, state and local authorities, the Company transitioned to a remote work model for its employees in March 2020 and its workforce continues to primarily work remotely. &lt;/div&gt; &lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;The &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;COVID-19&lt;/div&gt; pandemic has had a variable impact on clinical trials by disrupting certain study sites. In the conduct of business activities, the Company continues to take actions designed to protect the safety and well-being of its patients and employees. Although some of the Company&#x2019;s clinical development timelines have been impacted by delays related to the &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;COVID-19&lt;/div&gt; pandemic, the Company has not experienced material financial impacts on its business and operations as a result of the &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;COVID-19&lt;/div&gt; pandemic. However, the impact on the Company&#x2019;s future results will largely depend on future developments related to &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;COVID-19,&lt;/div&gt; which are highly uncertain and cannot be predicted with confidence, such as the emergence of new variants, the ultimate duration and spread of the outbreak, the continuing impact of the &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;COVID-19&lt;/div&gt; pandemic on financial markets and the global economy, travel restrictions and social distancing in the United States and other countries, business closures or business disruptions and the effectiveness of actions taken in the United States and other countries to contain, treat, and prevent the disease, including the availability and effectiveness of vaccines. &lt;/div&gt; </us-gaap:CommitmentsAndContingenciesDisclosureTextBlock>
    <us-gaap:FairValueDisclosuresTextBlock contextRef="P04_01_2020To03_31_2021">&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Note 15&#x2014;Fair Value Measurements &lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Recurring Fair Value Measurements &lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;The following table sets forth the Company&#x2019;s assets and liabilities that are measured at fair value on a recurring basis as of&#160;March&#160;31, 2021 and 2020, by level, within the fair value hierarchy (in thousands): &lt;/div&gt;&lt;/div&gt; &lt;div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 100%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 8pt; border-collapse: collapse; border-spacing: 0px;"&gt;
&lt;tr style="font-size: 0px;"&gt;
&lt;td style="width: 42%;"/&gt;
&lt;td style="width: 1%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="width: 1%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="width: 1%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="width: 1%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="width: 1%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="width: 1%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="width: 1%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="width: 1%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&#160;&lt;/td&gt;
&lt;td colspan="14" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;As of March&#160;31, 2021&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&#160;&lt;/td&gt;
&lt;td colspan="14" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;As of March&#160;31, 2020&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Level&#160;1&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Level&#160;2&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Level&#160;3&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Balance&#160;as&#160;of&lt;br/&gt; March&#160;31,&lt;br/&gt; 2021&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Level&#160;1&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Level&#160;2&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Level&#160;3&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Balance&#160;as&#160;of&lt;br/&gt; March&#160;31,&lt;br/&gt; 2020&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Assets:&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Money market funds&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;1,420,597&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;1,420,597&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;1,874,662&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;1,874,662&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Investment in Sio common shares&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;48,487&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;48,487&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;45,329&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;45,329&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Investment in Arbutus common shares&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;53,325&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;53,325&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;16,174&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;16,174&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Investment in Arbutus convertible preferred shares&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;76,037&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;76,037&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;23,062&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;23,062&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Other investments&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;11,129&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;11,129&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;8,880&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;8,880&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Total assets at fair value&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;1,533,538&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;76,037&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;1,609,575&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;1,945,045&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;23,062&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;1,968,107&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Liabilities:&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Debt held by Dermavant with NovaQuest&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;150,100&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;150,100&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;89,100&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;89,100&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Liability instruments measured at fair value&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;67,893&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;67,893&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;102,373&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;102,373&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Total liabilities at fair value&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;217,993&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;217,993&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;191,473&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;191,473&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt; &lt;/tr&gt; &lt;/table&gt;  &lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;There were no transfers of assets between Level&#160;1 and Level&#160;2 of the fair value measurement hierarchy that occurred during the years ended March&#160;31, 2021 and 2020. &lt;/div&gt;&lt;/div&gt; &lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;Level&#160;3 Disclosures &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;The Company measures its Level&#160;3 liabilities, including debt issued by Dermavant to NovaQuest and the Sumitomo Options, at fair value based on significant inputs not observable in the market, which causes them to be classified as a Level&#160;3 measurement within the fair value hierarchy. The valuation of the Level&#160;3 liabilities uses assumptions and estimates the Company believes would be made by a market participant in making the same valuation. The Company assesses these assumptions and estimates on an ongoing basis as additional data impacting the assumptions and estimates are obtained. Changes in the fair value related to updated assumptions and estimates are recorded within the statements of operations at the end of each reporting period. &lt;/div&gt;&lt;/div&gt; &lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;The fair value of Level&#160;3 liabilities may change significantly as additional data are obtained, impacting the Company&#x2019;s assumptions regarding probabilities of potential scenarios used to estimate fair value. In evaluating this information, considerable judgment is required to interpret the data used to develop the assumptions and estimates. Accordingly, the use of different market assumptions and/or different valuation techniques may have a material effect on the estimated fair value amounts, and such changes could materially impact the Company&#x2019;s results of operations in future periods. &lt;/div&gt;&lt;/div&gt; &lt;div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;The changes in fair value of the Level&#160;3 liabilities during the&#160;years ended March&#160;31, 2021 and 2020 were as follows (in thousands): &lt;/div&gt;&lt;/div&gt; &lt;div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 68%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;"&gt;
&lt;tr style="font-size: 0px;"&gt;
&lt;td style="width: 83%; font-family: &amp;quot;Times New Roman&amp;quot;;"/&gt;
&lt;td style="width: 7%; vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"/&gt;
&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;;"/&gt;
&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;;"/&gt;
&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;;"/&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Balance at March&#160;31, 2019&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;103,628&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Issuance of liability instruments measured at fair value&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;101,567&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Changes in fair value of debt and liability instruments, included in net loss&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;(13,722&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Balance at March&#160;31, 2020&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;191,473&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Changes in fair value of debt and liability instruments, included in net loss&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;29,845&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Liability instruments disposed due to deconsolidation of subsidiary&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;(3,325&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Balance at March&#160;31, 2021&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;217,993&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt; &lt;/tr&gt; &lt;/table&gt;  &lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Debt issued by Dermavant to NovaQuest &lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;The fair value of the debt instrument as of&#160;March&#160;31, 2021 and 2020 represents the fair value of amounts payable to NovaQuest using a Monte Carlo simulation model under the income approach determined by using probability assessments of the expected future payments through 2032 and applying discount rates ranging from 6% to 17%. The future payments are based on significant inputs that are not observable in the market which are subject to remeasurement at each reporting date. The estimates of fair value may not be indicative of the amounts that could ultimately be paid by Dermavant to NovaQuest. &lt;/div&gt;&lt;/div&gt; &lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Sumitomo Options &lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;The fair value of the options to acquire the Company&#x2019;s interest in Dermavant, Genevant, Lysovant, Metavant, Cytovant Parent, and Sinovant (collectively, the &#x201c;Option Vants&#x201d;) granted to Sumitomo under the Sumitomo Transaction Agreement as of March&#160;31, 2021 and 2020 was calculated using significant unobservable inputs including the following: &lt;/div&gt;&lt;/div&gt; &lt;div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 84%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;"&gt;
&lt;tr style="font-size: 0px;"&gt;
&lt;td style="width: 55%;"/&gt;
&lt;td style="width: 7%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td style="width: 6%; vertical-align: bottom;"/&gt;
&lt;td/&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="3" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Range&#160;or&#160;Point&#160;Estimate&#160;Used&lt;/div&gt;&lt;/div&gt;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; padding-bottom: 1pt;"&gt; &lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt; border-bottom: 1pt solid rgb(0, 0, 0); display: table-cell; line-height: normal;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Input&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;As&#160;of&#160;March&#160;31,&#160;2021&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;As&#160;of&#160;March&#160;31,&#160;2020&lt;/div&gt;&lt;/div&gt;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Time to expiration (in years)&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:center;"&gt;3.59&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:center;"&gt;0.49&#160;-&#160;4.59&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Risk-free rate&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:center;"&gt;0.52%&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:center;"&gt;0.15%&#160;-&#160;0.35%&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Volatility&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:center;"&gt;&lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;89.0%&#160;-&#160;95.0%&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:center;"&gt;&lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;91.0%&#160;-&#160;110.0%&lt;/div&gt;&lt;/td&gt; &lt;/tr&gt; &lt;/table&gt;  &lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;As of March&#160;31, 2021 and 2020, the fair value of the Sumitomo Options was $62.4&#160;million and $95.9&#160;million, respectively. Sumitomo Options are included in &#x201c;Liability instruments measured at fair value&#x201d; in the accompanying consolidated balance sheets. &lt;/div&gt;&lt;/div&gt; &lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;In June 2021, the Company completed a transaction with Sumitomo pursuant to which Sumitomo terminated all of its existing options to acquire the Company&#x2019;s equity interests in certain subsidiaries. See Note 19, &#x201c;Subsequent Events&#x201d; for additional information. &lt;/div&gt;&lt;/div&gt; </us-gaap:FairValueDisclosuresTextBlock>
    <us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock contextRef="P04_01_2020To03_31_2021">&lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;The following table sets forth the Company&#x2019;s assets and liabilities that are measured at fair value on a recurring basis as of&#160;March&#160;31, 2021 and 2020, by level, within the fair value hierarchy (in thousands): &lt;/div&gt;&lt;/div&gt; &lt;div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 100%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 8pt; border-collapse: collapse; border-spacing: 0px;"&gt;
&lt;tr style="font-size: 0px;"&gt;
&lt;td style="width: 42%;"/&gt;
&lt;td style="width: 1%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="width: 1%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="width: 1%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="width: 1%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="width: 1%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="width: 1%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="width: 1%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="width: 1%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&#160;&lt;/td&gt;
&lt;td colspan="14" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;As of March&#160;31, 2021&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&#160;&lt;/td&gt;
&lt;td colspan="14" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;As of March&#160;31, 2020&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Level&#160;1&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Level&#160;2&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Level&#160;3&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Balance&#160;as&#160;of&lt;br/&gt; March&#160;31,&lt;br/&gt; 2021&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Level&#160;1&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Level&#160;2&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Level&#160;3&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Balance&#160;as&#160;of&lt;br/&gt; March&#160;31,&lt;br/&gt; 2020&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Assets:&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Money market funds&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;1,420,597&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;1,420,597&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;1,874,662&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;1,874,662&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Investment in Sio common shares&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;48,487&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;48,487&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;45,329&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;45,329&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Investment in Arbutus common shares&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;53,325&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;53,325&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;16,174&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;16,174&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Investment in Arbutus convertible preferred shares&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;76,037&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;76,037&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;23,062&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;23,062&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Other investments&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;11,129&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;11,129&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;8,880&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;8,880&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Total assets at fair value&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;1,533,538&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;76,037&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;1,609,575&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;1,945,045&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;23,062&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;1,968,107&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Liabilities:&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Debt held by Dermavant with NovaQuest&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;150,100&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;150,100&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;89,100&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;89,100&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Liability instruments measured at fair value&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;67,893&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;67,893&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;102,373&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;102,373&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Total liabilities at fair value&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;217,993&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;217,993&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;191,473&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;191,473&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; </us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="PAsOn03_31_2021_FairValueInputsLevel1MemberusgaapFairValueByFairValueHierarchyLevelAxis_FairValueMeasurementsRecurringMemberusgaapFairValueByMeasurementFrequencyAxis_MoneyMarketFundsMemberusgaapFairValueByAssetClassAxis"
      decimals="-3"
      unitRef="Unit_USD">1420597000</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="PAsOn03_31_2021_FairValueMeasurementsRecurringMemberusgaapFairValueByMeasurementFrequencyAxis_MoneyMarketFundsMemberusgaapFairValueByAssetClassAxis"
      decimals="-3"
      unitRef="Unit_USD">1420597000</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="PAsOn03_31_2020_FairValueInputsLevel1MemberusgaapFairValueByFairValueHierarchyLevelAxis_FairValueMeasurementsRecurringMemberusgaapFairValueByMeasurementFrequencyAxis_MoneyMarketFundsMemberusgaapFairValueByAssetClassAxis"
      decimals="-3"
      unitRef="Unit_USD">1874662000</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="PAsOn03_31_2020_FairValueMeasurementsRecurringMemberusgaapFairValueByMeasurementFrequencyAxis_MoneyMarketFundsMemberusgaapFairValueByAssetClassAxis"
      decimals="-3"
      unitRef="Unit_USD">1874662000</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:InvestmentsFairValueDisclosure
      contextRef="PAsOn03_31_2021_CommonStockMemberusgaapFairValueByAssetClassAxis_FairValueInputsLevel1MemberusgaapFairValueByFairValueHierarchyLevelAxis_FairValueMeasurementsRecurringMemberusgaapFairValueByMeasurementFrequencyAxis_SioGeneTherapiesIncMemberdeiLegalEntityAxis"
      decimals="-3"
      unitRef="Unit_USD">48487000</us-gaap:InvestmentsFairValueDisclosure>
    <us-gaap:InvestmentsFairValueDisclosure
      contextRef="PAsOn03_31_2021_CommonStockMemberusgaapFairValueByAssetClassAxis_FairValueMeasurementsRecurringMemberusgaapFairValueByMeasurementFrequencyAxis_SioGeneTherapiesIncMemberdeiLegalEntityAxis"
      decimals="-3"
      unitRef="Unit_USD">48487000</us-gaap:InvestmentsFairValueDisclosure>
    <us-gaap:InvestmentsFairValueDisclosure
      contextRef="PAsOn03_31_2020_CommonStockMemberusgaapFairValueByAssetClassAxis_FairValueInputsLevel1MemberusgaapFairValueByFairValueHierarchyLevelAxis_FairValueMeasurementsRecurringMemberusgaapFairValueByMeasurementFrequencyAxis_SioGeneTherapiesIncMemberdeiLegalEntityAxis"
      decimals="-3"
      unitRef="Unit_USD">45329000</us-gaap:InvestmentsFairValueDisclosure>
    <us-gaap:InvestmentsFairValueDisclosure
      contextRef="PAsOn03_31_2020_CommonStockMemberusgaapFairValueByAssetClassAxis_FairValueMeasurementsRecurringMemberusgaapFairValueByMeasurementFrequencyAxis_SioGeneTherapiesIncMemberdeiLegalEntityAxis"
      decimals="-3"
      unitRef="Unit_USD">45329000</us-gaap:InvestmentsFairValueDisclosure>
    <us-gaap:InvestmentsFairValueDisclosure
      contextRef="PAsOn03_31_2021_ArbutusBiopharmaCorporationMemberdeiLegalEntityAxis_CommonStockMemberusgaapFairValueByAssetClassAxis_FairValueInputsLevel1MemberusgaapFairValueByFairValueHierarchyLevelAxis_FairValueMeasurementsRecurringMemberusgaapFairValueByMeasurementFrequencyAxis"
      decimals="-3"
      unitRef="Unit_USD">53325000</us-gaap:InvestmentsFairValueDisclosure>
    <us-gaap:InvestmentsFairValueDisclosure
      contextRef="PAsOn03_31_2021_ArbutusBiopharmaCorporationMemberdeiLegalEntityAxis_CommonStockMemberusgaapFairValueByAssetClassAxis_FairValueMeasurementsRecurringMemberusgaapFairValueByMeasurementFrequencyAxis"
      decimals="-3"
      unitRef="Unit_USD">53325000</us-gaap:InvestmentsFairValueDisclosure>
    <us-gaap:InvestmentsFairValueDisclosure
      contextRef="PAsOn03_31_2020_ArbutusBiopharmaCorporationMemberdeiLegalEntityAxis_CommonStockMemberusgaapFairValueByAssetClassAxis_FairValueInputsLevel1MemberusgaapFairValueByFairValueHierarchyLevelAxis_FairValueMeasurementsRecurringMemberusgaapFairValueByMeasurementFrequencyAxis"
      decimals="-3"
      unitRef="Unit_USD">16174000</us-gaap:InvestmentsFairValueDisclosure>
    <us-gaap:InvestmentsFairValueDisclosure
      contextRef="PAsOn03_31_2020_ArbutusBiopharmaCorporationMemberdeiLegalEntityAxis_CommonStockMemberusgaapFairValueByAssetClassAxis_FairValueMeasurementsRecurringMemberusgaapFairValueByMeasurementFrequencyAxis"
      decimals="-3"
      unitRef="Unit_USD">16174000</us-gaap:InvestmentsFairValueDisclosure>
    <us-gaap:InvestmentsFairValueDisclosure
      contextRef="PAsOn03_31_2021_ArbutusBiopharmaCorporationMemberdeiLegalEntityAxis_ConvertiblePreferredStockMemberusgaapFairValueByAssetClassAxis_FairValueInputsLevel2MemberusgaapFairValueByFairValueHierarchyLevelAxis_FairValueMeasurementsRecurringMemberusgaapFairValueByMeasurementFrequencyAxis"
      decimals="-3"
      unitRef="Unit_USD">76037000</us-gaap:InvestmentsFairValueDisclosure>
    <us-gaap:InvestmentsFairValueDisclosure
      contextRef="PAsOn03_31_2021_ArbutusBiopharmaCorporationMemberdeiLegalEntityAxis_ConvertiblePreferredStockMemberusgaapFairValueByAssetClassAxis_FairValueMeasurementsRecurringMemberusgaapFairValueByMeasurementFrequencyAxis"
      decimals="-3"
      unitRef="Unit_USD">76037000</us-gaap:InvestmentsFairValueDisclosure>
    <us-gaap:InvestmentsFairValueDisclosure
      contextRef="PAsOn03_31_2020_ArbutusBiopharmaCorporationMemberdeiLegalEntityAxis_ConvertiblePreferredStockMemberusgaapFairValueByAssetClassAxis_FairValueInputsLevel2MemberusgaapFairValueByFairValueHierarchyLevelAxis_FairValueMeasurementsRecurringMemberusgaapFairValueByMeasurementFrequencyAxis"
      decimals="-3"
      unitRef="Unit_USD">23062000</us-gaap:InvestmentsFairValueDisclosure>
    <us-gaap:InvestmentsFairValueDisclosure
      contextRef="PAsOn03_31_2020_ArbutusBiopharmaCorporationMemberdeiLegalEntityAxis_ConvertiblePreferredStockMemberusgaapFairValueByAssetClassAxis_FairValueMeasurementsRecurringMemberusgaapFairValueByMeasurementFrequencyAxis"
      decimals="-3"
      unitRef="Unit_USD">23062000</us-gaap:InvestmentsFairValueDisclosure>
    <us-gaap:InvestmentsFairValueDisclosure
      contextRef="PAsOn03_31_2021_FairValueInputsLevel1MemberusgaapFairValueByFairValueHierarchyLevelAxis_FairValueMeasurementsRecurringMemberusgaapFairValueByMeasurementFrequencyAxis_OtherInvestmentCompaniesMemberusgaapFairValueByAssetClassAxis"
      decimals="-3"
      unitRef="Unit_USD">11129000</us-gaap:InvestmentsFairValueDisclosure>
    <us-gaap:InvestmentsFairValueDisclosure
      contextRef="PAsOn03_31_2021_FairValueMeasurementsRecurringMemberusgaapFairValueByMeasurementFrequencyAxis_OtherInvestmentCompaniesMemberusgaapFairValueByAssetClassAxis"
      decimals="-3"
      unitRef="Unit_USD">11129000</us-gaap:InvestmentsFairValueDisclosure>
    <us-gaap:InvestmentsFairValueDisclosure
      contextRef="PAsOn03_31_2020_FairValueInputsLevel1MemberusgaapFairValueByFairValueHierarchyLevelAxis_FairValueMeasurementsRecurringMemberusgaapFairValueByMeasurementFrequencyAxis_OtherInvestmentCompaniesMemberusgaapFairValueByAssetClassAxis"
      decimals="-3"
      unitRef="Unit_USD">8880000</us-gaap:InvestmentsFairValueDisclosure>
    <us-gaap:InvestmentsFairValueDisclosure
      contextRef="PAsOn03_31_2020_FairValueMeasurementsRecurringMemberusgaapFairValueByMeasurementFrequencyAxis_OtherInvestmentCompaniesMemberusgaapFairValueByAssetClassAxis"
      decimals="-3"
      unitRef="Unit_USD">8880000</us-gaap:InvestmentsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="PAsOn03_31_2021_FairValueInputsLevel1MemberusgaapFairValueByFairValueHierarchyLevelAxis_FairValueMeasurementsRecurringMemberusgaapFairValueByMeasurementFrequencyAxis"
      decimals="-3"
      unitRef="Unit_USD">1533538000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="PAsOn03_31_2021_FairValueInputsLevel2MemberusgaapFairValueByFairValueHierarchyLevelAxis_FairValueMeasurementsRecurringMemberusgaapFairValueByMeasurementFrequencyAxis"
      decimals="-3"
      unitRef="Unit_USD">76037000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="PAsOn03_31_2021_FairValueMeasurementsRecurringMemberusgaapFairValueByMeasurementFrequencyAxis"
      decimals="-3"
      unitRef="Unit_USD">1609575000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="PAsOn03_31_2020_FairValueInputsLevel1MemberusgaapFairValueByFairValueHierarchyLevelAxis_FairValueMeasurementsRecurringMemberusgaapFairValueByMeasurementFrequencyAxis"
      decimals="-3"
      unitRef="Unit_USD">1945045000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="PAsOn03_31_2020_FairValueInputsLevel2MemberusgaapFairValueByFairValueHierarchyLevelAxis_FairValueMeasurementsRecurringMemberusgaapFairValueByMeasurementFrequencyAxis"
      decimals="-3"
      unitRef="Unit_USD">23062000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="PAsOn03_31_2020_FairValueMeasurementsRecurringMemberusgaapFairValueByMeasurementFrequencyAxis"
      decimals="-3"
      unitRef="Unit_USD">1968107000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:DebtInstrumentFairValue
      contextRef="PAsOn03_31_2021_FairValueInputsLevel3MemberusgaapFairValueByFairValueHierarchyLevelAxis_FairValueMeasurementsRecurringMemberusgaapFairValueByMeasurementFrequencyAxis"
      decimals="-3"
      unitRef="Unit_USD">150100000</us-gaap:DebtInstrumentFairValue>
    <us-gaap:DebtInstrumentFairValue
      contextRef="PAsOn03_31_2021_FairValueMeasurementsRecurringMemberusgaapFairValueByMeasurementFrequencyAxis"
      decimals="-3"
      unitRef="Unit_USD">150100000</us-gaap:DebtInstrumentFairValue>
    <us-gaap:DebtInstrumentFairValue
      contextRef="PAsOn03_31_2020_FairValueInputsLevel3MemberusgaapFairValueByFairValueHierarchyLevelAxis_FairValueMeasurementsRecurringMemberusgaapFairValueByMeasurementFrequencyAxis"
      decimals="-3"
      unitRef="Unit_USD">89100000</us-gaap:DebtInstrumentFairValue>
    <us-gaap:DebtInstrumentFairValue
      contextRef="PAsOn03_31_2020_FairValueMeasurementsRecurringMemberusgaapFairValueByMeasurementFrequencyAxis"
      decimals="-3"
      unitRef="Unit_USD">89100000</us-gaap:DebtInstrumentFairValue>
    <us-gaap:DerivativeInstrumentsNotDesignatedAsHedgingInstrumentsLiabilityAtFairValue
      contextRef="PAsOn03_31_2021_FairValueInputsLevel3MemberusgaapFairValueByFairValueHierarchyLevelAxis_FairValueMeasurementsRecurringMemberusgaapFairValueByMeasurementFrequencyAxis"
      decimals="-3"
      unitRef="Unit_USD">67893000</us-gaap:DerivativeInstrumentsNotDesignatedAsHedgingInstrumentsLiabilityAtFairValue>
    <us-gaap:DerivativeInstrumentsNotDesignatedAsHedgingInstrumentsLiabilityAtFairValue
      contextRef="PAsOn03_31_2021_FairValueMeasurementsRecurringMemberusgaapFairValueByMeasurementFrequencyAxis"
      decimals="-3"
      unitRef="Unit_USD">67893000</us-gaap:DerivativeInstrumentsNotDesignatedAsHedgingInstrumentsLiabilityAtFairValue>
    <us-gaap:DerivativeInstrumentsNotDesignatedAsHedgingInstrumentsLiabilityAtFairValue
      contextRef="PAsOn03_31_2020_FairValueInputsLevel3MemberusgaapFairValueByFairValueHierarchyLevelAxis_FairValueMeasurementsRecurringMemberusgaapFairValueByMeasurementFrequencyAxis"
      decimals="-3"
      unitRef="Unit_USD">102373000</us-gaap:DerivativeInstrumentsNotDesignatedAsHedgingInstrumentsLiabilityAtFairValue>
    <us-gaap:DerivativeInstrumentsNotDesignatedAsHedgingInstrumentsLiabilityAtFairValue
      contextRef="PAsOn03_31_2020_FairValueMeasurementsRecurringMemberusgaapFairValueByMeasurementFrequencyAxis"
      decimals="-3"
      unitRef="Unit_USD">102373000</us-gaap:DerivativeInstrumentsNotDesignatedAsHedgingInstrumentsLiabilityAtFairValue>
    <us-gaap:LiabilitiesFairValueDisclosure
      contextRef="PAsOn03_31_2021_FairValueInputsLevel3MemberusgaapFairValueByFairValueHierarchyLevelAxis_FairValueMeasurementsRecurringMemberusgaapFairValueByMeasurementFrequencyAxis"
      decimals="-3"
      unitRef="Unit_USD">217993000</us-gaap:LiabilitiesFairValueDisclosure>
    <us-gaap:LiabilitiesFairValueDisclosure
      contextRef="PAsOn03_31_2021_FairValueMeasurementsRecurringMemberusgaapFairValueByMeasurementFrequencyAxis"
      decimals="-3"
      unitRef="Unit_USD">217993000</us-gaap:LiabilitiesFairValueDisclosure>
    <us-gaap:LiabilitiesFairValueDisclosure
      contextRef="PAsOn03_31_2020_FairValueInputsLevel3MemberusgaapFairValueByFairValueHierarchyLevelAxis_FairValueMeasurementsRecurringMemberusgaapFairValueByMeasurementFrequencyAxis"
      decimals="-3"
      unitRef="Unit_USD">191473000</us-gaap:LiabilitiesFairValueDisclosure>
    <us-gaap:LiabilitiesFairValueDisclosure
      contextRef="PAsOn03_31_2020_FairValueMeasurementsRecurringMemberusgaapFairValueByMeasurementFrequencyAxis"
      decimals="-3"
      unitRef="Unit_USD">191473000</us-gaap:LiabilitiesFairValueDisclosure>
    <us-gaap:FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock contextRef="P04_01_2020To03_31_2021">&lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;The changes in fair value of the Level&#160;3 liabilities during the&#160;years ended March&#160;31, 2021 and 2020 were as follows (in thousands): &lt;/div&gt;&lt;/div&gt; &lt;div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 68%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;"&gt;
&lt;tr style="font-size: 0px;"&gt;
&lt;td style="width: 83%; font-family: &amp;quot;Times New Roman&amp;quot;;"/&gt;
&lt;td style="width: 7%; vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"/&gt;
&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;;"/&gt;
&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;;"/&gt;
&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;;"/&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Balance at March&#160;31, 2019&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;103,628&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Issuance of liability instruments measured at fair value&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;101,567&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Changes in fair value of debt and liability instruments, included in net loss&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;(13,722&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Balance at March&#160;31, 2020&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;191,473&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Changes in fair value of debt and liability instruments, included in net loss&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;29,845&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Liability instruments disposed due to deconsolidation of subsidiary&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;(3,325&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Balance at March&#160;31, 2021&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;217,993&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; </us-gaap:FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue
      contextRef="PAsOn03_31_2019_FairValueInputsLevel3MemberusgaapFairValueByFairValueHierarchyLevelAxis"
      decimals="-3"
      unitRef="Unit_USD">103628000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue>
    <roiv:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityDisposedDueToDeconsolidationOfSubsidiary
      contextRef="P04_01_2019To03_31_2020_FairValueInputsLevel3MemberusgaapFairValueByFairValueHierarchyLevelAxis"
      decimals="-3"
      unitRef="Unit_USD">101567000</roiv:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityDisposedDueToDeconsolidationOfSubsidiary>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings
      contextRef="P04_01_2019To03_31_2020_FairValueInputsLevel3MemberusgaapFairValueByFairValueHierarchyLevelAxis"
      decimals="-3"
      unitRef="Unit_USD">-13722000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue
      contextRef="PAsOn03_31_2020_FairValueInputsLevel3MemberusgaapFairValueByFairValueHierarchyLevelAxis"
      decimals="-3"
      unitRef="Unit_USD">191473000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings
      contextRef="P04_01_2020To03_31_2021_FairValueInputsLevel3MemberusgaapFairValueByFairValueHierarchyLevelAxis"
      decimals="-3"
      unitRef="Unit_USD">29845000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings>
    <roiv:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityDisposedDueToDeconsolidationOfSubsidiary
      contextRef="P04_01_2020To03_31_2021_FairValueInputsLevel3MemberusgaapFairValueByFairValueHierarchyLevelAxis"
      decimals="-3"
      unitRef="Unit_USD">-3325000</roiv:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityDisposedDueToDeconsolidationOfSubsidiary>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue
      contextRef="PAsOn03_31_2021_FairValueInputsLevel3MemberusgaapFairValueByFairValueHierarchyLevelAxis"
      decimals="-3"
      unitRef="Unit_USD">217993000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue>
    <us-gaap:DebtInstrumentMeasurementInput
      contextRef="PAsOn03_31_2021_MeasurementInputDiscountRateMemberusgaapMeasurementInputTypeAxis_MinimumMembersrtRangeAxis"
      decimals="INF"
      unitRef="Unit_pure">0.06</us-gaap:DebtInstrumentMeasurementInput>
    <us-gaap:DebtInstrumentMeasurementInput
      contextRef="PAsOn03_31_2021_MaximumMembersrtRangeAxis_MeasurementInputDiscountRateMemberusgaapMeasurementInputTypeAxis"
      decimals="INF"
      unitRef="Unit_pure">0.17</us-gaap:DebtInstrumentMeasurementInput>
    <us-gaap:FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock contextRef="P04_01_2020To03_31_2021">&lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;The fair value of the options to acquire the Company&#x2019;s interest in Dermavant, Genevant, Lysovant, Metavant, Cytovant Parent, and Sinovant (collectively, the &#x201c;Option Vants&#x201d;) granted to Sumitomo under the Sumitomo Transaction Agreement as of March&#160;31, 2021 and 2020 was calculated using significant unobservable inputs including the following: &lt;/div&gt;&lt;/div&gt; &lt;div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 84%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;"&gt;
&lt;tr style="font-size: 0px;"&gt;
&lt;td style="width: 55%;"/&gt;
&lt;td style="width: 7%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td style="width: 6%; vertical-align: bottom;"/&gt;
&lt;td/&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="3" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Range&#160;or&#160;Point&#160;Estimate&#160;Used&lt;/div&gt;&lt;/div&gt;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; padding-bottom: 1pt;"&gt; &lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt; border-bottom: 1pt solid rgb(0, 0, 0); display: table-cell; line-height: normal;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Input&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;As&#160;of&#160;March&#160;31,&#160;2021&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;As&#160;of&#160;March&#160;31,&#160;2020&lt;/div&gt;&lt;/div&gt;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Time to expiration (in years)&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:center;"&gt;3.59&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:center;"&gt;0.49&#160;-&#160;4.59&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Risk-free rate&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:center;"&gt;0.52%&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:center;"&gt;0.15%&#160;-&#160;0.35%&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Volatility&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:center;"&gt;&lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;89.0%&#160;-&#160;95.0%&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:center;"&gt;&lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;91.0%&#160;-&#160;110.0%&lt;/div&gt;&lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; </us-gaap:FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock>
    <roiv:AlternativeInvestmentExpectedTerm contextRef="P04_01_2020To03_31_2021_MaximumMembersrtRangeAxis_MeasurementInputExpectedTermMemberusgaapMeasurementInputTypeAxis">P3Y7M2D</roiv:AlternativeInvestmentExpectedTerm>
    <roiv:AlternativeInvestmentExpectedTerm contextRef="P04_01_2020To03_31_2021_MeasurementInputExpectedTermMemberusgaapMeasurementInputTypeAxis_MinimumMembersrtRangeAxis">P3Y7M2D</roiv:AlternativeInvestmentExpectedTerm>
    <roiv:AlternativeInvestmentExpectedTerm contextRef="P04_01_2019To03_31_2020_MeasurementInputExpectedTermMemberusgaapMeasurementInputTypeAxis_MinimumMembersrtRangeAxis">P0Y5M26D</roiv:AlternativeInvestmentExpectedTerm>
    <roiv:AlternativeInvestmentExpectedTerm contextRef="P04_01_2019To03_31_2020_MaximumMembersrtRangeAxis_MeasurementInputExpectedTermMemberusgaapMeasurementInputTypeAxis">P4Y7M2D</roiv:AlternativeInvestmentExpectedTerm>
    <us-gaap:AlternativeInvestmentMeasurementInput
      contextRef="PAsOn03_31_2021_MaximumMembersrtRangeAxis_MeasurementInputRiskFreeInterestRateMemberusgaapMeasurementInputTypeAxis"
      decimals="INF"
      unitRef="Unit_pure">0.0052</us-gaap:AlternativeInvestmentMeasurementInput>
    <us-gaap:AlternativeInvestmentMeasurementInput
      contextRef="PAsOn03_31_2021_MeasurementInputRiskFreeInterestRateMemberusgaapMeasurementInputTypeAxis_MinimumMembersrtRangeAxis"
      decimals="INF"
      unitRef="Unit_pure">0.0052</us-gaap:AlternativeInvestmentMeasurementInput>
    <us-gaap:AlternativeInvestmentMeasurementInput
      contextRef="PAsOn03_31_2020_MeasurementInputRiskFreeInterestRateMemberusgaapMeasurementInputTypeAxis_MinimumMembersrtRangeAxis"
      decimals="INF"
      unitRef="Unit_pure">0.0015</us-gaap:AlternativeInvestmentMeasurementInput>
    <us-gaap:AlternativeInvestmentMeasurementInput
      contextRef="PAsOn03_31_2020_MaximumMembersrtRangeAxis_MeasurementInputRiskFreeInterestRateMemberusgaapMeasurementInputTypeAxis"
      decimals="INF"
      unitRef="Unit_pure">0.0035</us-gaap:AlternativeInvestmentMeasurementInput>
    <us-gaap:AlternativeInvestmentMeasurementInput
      contextRef="PAsOn03_31_2021_MeasurementInputOptionVolatilityMemberusgaapMeasurementInputTypeAxis_MinimumMembersrtRangeAxis"
      decimals="INF"
      unitRef="Unit_pure">0.890</us-gaap:AlternativeInvestmentMeasurementInput>
    <us-gaap:AlternativeInvestmentMeasurementInput
      contextRef="PAsOn03_31_2021_MaximumMembersrtRangeAxis_MeasurementInputOptionVolatilityMemberusgaapMeasurementInputTypeAxis"
      decimals="INF"
      unitRef="Unit_pure">0.950</us-gaap:AlternativeInvestmentMeasurementInput>
    <us-gaap:AlternativeInvestmentMeasurementInput
      contextRef="PAsOn03_31_2020_MeasurementInputOptionVolatilityMemberusgaapMeasurementInputTypeAxis_MinimumMembersrtRangeAxis"
      decimals="INF"
      unitRef="Unit_pure">0.910</us-gaap:AlternativeInvestmentMeasurementInput>
    <us-gaap:AlternativeInvestmentMeasurementInput
      contextRef="PAsOn03_31_2020_MaximumMembersrtRangeAxis_MeasurementInputOptionVolatilityMemberusgaapMeasurementInputTypeAxis"
      decimals="INF"
      unitRef="Unit_pure">1.100</us-gaap:AlternativeInvestmentMeasurementInput>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1
      contextRef="P04_01_2020To03_31_2021_LiabilityInstrumentsMeasuredAtFairValueMemberusgaapBalanceSheetLocationAxis"
      decimals="-5"
      unitRef="Unit_USD">62400000</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1
      contextRef="P04_01_2019To03_31_2020_LiabilityInstrumentsMeasuredAtFairValueMemberusgaapBalanceSheetLocationAxis"
      decimals="-5"
      unitRef="Unit_USD">95900000</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1>
    <us-gaap:DefinedContributionPlanTextBlock contextRef="P04_01_2020To03_31_2021">&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Note 16&#x2014;Defined Contribution Plan &lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;The Company and certain of its subsidiaries sponsor defined contribution plans pursuant to Section&#160;401(k) of the U.S. Internal Revenue Code. Employee contributions are voluntary and subject to the maximum allowable under federal tax regulations. For the years ended March&#160;31, 2021 and 2020, the Company recorded total expense for employer matching contributions of $1.7&#160;million and $1.7&#160;million, respectively. &lt;/div&gt;&lt;/div&gt;</us-gaap:DefinedContributionPlanTextBlock>
    <us-gaap:DefinedContributionPlanEmployerDiscretionaryContributionAmount
      contextRef="P04_01_2020To03_31_2021"
      decimals="-5"
      unitRef="Unit_USD">1700000</us-gaap:DefinedContributionPlanEmployerDiscretionaryContributionAmount>
    <us-gaap:DefinedContributionPlanEmployerDiscretionaryContributionAmount
      contextRef="P04_01_2019To03_31_2020"
      decimals="-5"
      unitRef="Unit_USD">1700000</us-gaap:DefinedContributionPlanEmployerDiscretionaryContributionAmount>
    <us-gaap:OtherOperatingIncomeAndExpenseTextBlock contextRef="P04_01_2020To03_31_2021">&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Note 17&#x2014;Other Expense, Net &lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Other expense, net from continuing operations was as follows (in thousands): &lt;/div&gt;&lt;/div&gt; &lt;div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 76%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;"&gt;
&lt;tr style="font-size: 0px;"&gt;
&lt;td style="width: 74%;"/&gt;
&lt;td style="width: 6%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="width: 6%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="6" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Years Ended March&#160;31,&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2021&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2020&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Loss from equity method investment&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;3,750&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;21,386&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Interest income&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;(1,418&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;(17,990&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Interest expense&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;2,809&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;7,683&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Other expense&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;3,560&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;2,543&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Total&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;8,701&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;13,622&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; </us-gaap:OtherOperatingIncomeAndExpenseTextBlock>
    <us-gaap:ScheduleOfOtherOperatingCostAndExpenseByComponentTextBlock contextRef="P04_01_2020To03_31_2021">&lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Other expense, net from continuing operations was as follows (in thousands): &lt;/div&gt;&lt;/div&gt; &lt;div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 76%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;"&gt;
&lt;tr style="font-size: 0px;"&gt;
&lt;td style="width: 74%;"/&gt;
&lt;td style="width: 6%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="width: 6%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="6" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Years Ended March&#160;31,&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2021&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2020&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Loss from equity method investment&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;3,750&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;21,386&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Interest income&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;(1,418&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;(17,990&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Interest expense&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;2,809&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;7,683&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Other expense&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;3,560&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;2,543&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Total&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;8,701&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:right;"&gt;13,622&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; </us-gaap:ScheduleOfOtherOperatingCostAndExpenseByComponentTextBlock>
    <us-gaap:IncomeLossFromEquityMethodInvestments
      contextRef="P04_01_2020To03_31_2021"
      decimals="-3"
      unitRef="Unit_USD">-3750000</us-gaap:IncomeLossFromEquityMethodInvestments>
    <us-gaap:IncomeLossFromEquityMethodInvestments
      contextRef="P04_01_2019To03_31_2020"
      decimals="-3"
      unitRef="Unit_USD">-21386000</us-gaap:IncomeLossFromEquityMethodInvestments>
    <us-gaap:InterestIncomeOther
      contextRef="P04_01_2020To03_31_2021"
      decimals="-3"
      unitRef="Unit_USD">1418000</us-gaap:InterestIncomeOther>
    <us-gaap:InterestIncomeOther
      contextRef="P04_01_2019To03_31_2020"
      decimals="-3"
      unitRef="Unit_USD">17990000</us-gaap:InterestIncomeOther>
    <us-gaap:InterestExpense
      contextRef="P04_01_2020To03_31_2021"
      decimals="-3"
      unitRef="Unit_USD">2809000</us-gaap:InterestExpense>
    <us-gaap:InterestExpense
      contextRef="P04_01_2019To03_31_2020"
      decimals="-3"
      unitRef="Unit_USD">7683000</us-gaap:InterestExpense>
    <roiv:OtherIncomeExpense
      contextRef="P04_01_2020To03_31_2021"
      decimals="-3"
      unitRef="Unit_USD">-3560000</roiv:OtherIncomeExpense>
    <roiv:OtherIncomeExpense
      contextRef="P04_01_2019To03_31_2020"
      decimals="-3"
      unitRef="Unit_USD">-2543000</roiv:OtherIncomeExpense>
    <us-gaap:OtherOperatingIncomeExpenseNet
      contextRef="P04_01_2020To03_31_2021"
      decimals="-3"
      unitRef="Unit_USD">-8701000</us-gaap:OtherOperatingIncomeExpenseNet>
    <us-gaap:OtherOperatingIncomeExpenseNet
      contextRef="P04_01_2019To03_31_2020"
      decimals="-3"
      unitRef="Unit_USD">-13622000</us-gaap:OtherOperatingIncomeExpenseNet>
    <us-gaap:EarningsPerShareTextBlock contextRef="P04_01_2020To03_31_2021">&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Note 18&#x2014;Earnings per Common Share &lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;The computations of the numerator to derive the basic and diluted earnings per share amounts presented on the face of the accompanying consolidated statements of operations are as follows (in thousands): &lt;/div&gt;&lt;/div&gt; &lt;div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 92%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;"&gt;
&lt;tr style="font-size: 0px;"&gt;
&lt;td style="width: 75%;"/&gt;
&lt;td style="width: 3%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="width: 3%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="6" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Years Ended March&#160;31,&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2021&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2020&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Loss from continuing operations, net of tax&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;(900,233&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;(568,110&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Net loss from continuing operations, net of tax, attributable to noncontrolling interest&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;(90,999&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;(48,716&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Loss from continuing operations, net of tax, attributable to Roivant Sciences Ltd.&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;(809,234&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;)&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;(519,394&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;)&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Deemed dividend on repurchase of redeemable noncontrolling interest relating to subsidiary convertible and redeemable preferred stock&lt;div style="font-size: 85%; vertical-align: top;;display:inline;;font-size:9.4px"&gt;(1)&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;(77,777&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Basic and diluted loss from continuing operations, net of tax, attributable to Roivant Sciences Ltd.&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;$&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;(809,234&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;)&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;$&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;(597,171&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;)&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Income from discontinued operations, net of tax&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;1,578,426&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Net loss from discontinued operations, net of tax, attributable to noncontrolling interest&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;(141,477&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Net income from discontinued operations, net of tax, attributable to Roivant Sciences Ltd.&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;$&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#x2014;&#160;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;$&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;1,719,903&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Basic and diluted income from discontinued operations, net of tax&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;1,719,903&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Basic and diluted net (loss) income attributable to Roivant Sciences&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;$&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;(809,234&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;)&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;$&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;1,122,732&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; &lt;div style="clear: both; max-height: 0px;"/&gt; &lt;div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;"&gt;
&lt;tr style="page-break-inside: avoid;"&gt;
&lt;td style="width: 4%; vertical-align: top;;text-align:left;"&gt;&lt;div style="font-size: 85%; vertical-align: top;;display:inline;;font-size:9.4px"&gt;(1)&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: top;;text-align:left;"&gt; &lt;div style="text-align: left; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Consideration paid in excess of carrying value for the repurchase of redeemable noncontrolling interest relating to subsidiary convertible and redeemable preferred stock of $77.8&#160;million is considered a deemed dividend and, for purposes of calculating net loss per share, increases the loss from continuing operations, net of tax, attributable to Roivant Sciences Ltd. for the year ended March&#160;31, 2020. See Note 10, &#x201c;Shareholders&#x2019; Equity and Redeemable Noncontrolling Interest.&#x201d; &lt;/div&gt;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;/table&gt;  &lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Basic net (loss) income per common share is computed by dividing net (loss) income attributable to Roivant Sciences Ltd. by the weighted-average number of common stock outstanding during the period. Diluted net (loss) income per common share is computed by dividing the net income (loss) attributable to Roivant Sciences Ltd. by the diluted weighted-average number of common stock outstanding during the period. &lt;/div&gt;&lt;/div&gt; &lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;For periods of loss from continuing operations, diluted loss per share is calculated similar to basic loss per share as the effect of including all potentially dilutive common share equivalents is anti-dilutive. All outstanding common stock equivalents have been excluded from the computation of diluted loss per share because their &lt;/div&gt;&lt;/div&gt; &lt;div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;effect was anti-dilutive due to the loss from continuing operations. Refer to Note 11, &#x201c;Share-Based Compensation&#x201d; and Note 5, &#x201c;Sumitomo Transaction Agreement&#x201d; for additional detail regarding outstanding common stock equivalents. &lt;/div&gt;&lt;/div&gt; </us-gaap:EarningsPerShareTextBlock>
    <us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock contextRef="P04_01_2020To03_31_2021">&lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;The computations of the numerator to derive the basic and diluted earnings per share amounts presented on the face of the accompanying consolidated statements of operations are as follows (in thousands): &lt;/div&gt;&lt;/div&gt; &lt;div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 92%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;"&gt;
&lt;tr style="font-size: 0px;"&gt;
&lt;td style="width: 75%;"/&gt;
&lt;td style="width: 3%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="width: 3%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="6" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Years Ended March&#160;31,&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2021&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2020&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Loss from continuing operations, net of tax&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;(900,233&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;(568,110&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Net loss from continuing operations, net of tax, attributable to noncontrolling interest&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;(90,999&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;(48,716&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Loss from continuing operations, net of tax, attributable to Roivant Sciences Ltd.&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;(809,234&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;)&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;(519,394&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;)&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Deemed dividend on repurchase of redeemable noncontrolling interest relating to subsidiary convertible and redeemable preferred stock&lt;div style="font-size: 85%; vertical-align: top;;display:inline;;font-size:9.4px"&gt;(1)&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;(77,777&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Basic and diluted loss from continuing operations, net of tax, attributable to Roivant Sciences Ltd.&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;$&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;(809,234&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;)&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;$&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;(597,171&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;)&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Income from discontinued operations, net of tax&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;1,578,426&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Net loss from discontinued operations, net of tax, attributable to noncontrolling interest&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;(141,477&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Net income from discontinued operations, net of tax, attributable to Roivant Sciences Ltd.&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;$&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#x2014;&#160;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;$&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;1,719,903&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Basic and diluted income from discontinued operations, net of tax&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;1,719,903&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Basic and diluted net (loss) income attributable to Roivant Sciences&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;$&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;(809,234&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;)&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;$&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;1,122,732&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; &lt;div style="clear: both; max-height: 0px;"/&gt; &lt;div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;"&gt;
&lt;tr style="page-break-inside: avoid;"&gt;
&lt;td style="width: 4%; vertical-align: top;;text-align:left;"&gt;&lt;div style="font-size: 85%; vertical-align: top;;display:inline;;font-size:9.4px"&gt;(1)&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: top;;text-align:left;"&gt; &lt;div style="text-align: left; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Consideration paid in excess of carrying value for the repurchase of redeemable noncontrolling interest relating to subsidiary convertible and redeemable preferred stock of $77.8&#160;million is considered a deemed dividend and, for purposes of calculating net loss per share, increases the loss from continuing operations, net of tax, attributable to Roivant Sciences Ltd. for the year ended March&#160;31, 2020. See Note 10, &#x201c;Shareholders&#x2019; Equity and Redeemable Noncontrolling Interest.&#x201d; &lt;/div&gt;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; </us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock>
    <us-gaap:IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest
      contextRef="P04_01_2020To03_31_2021"
      decimals="-3"
      unitRef="Unit_USD">-900233000</us-gaap:IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest
      contextRef="P04_01_2019To03_31_2020"
      decimals="-3"
      unitRef="Unit_USD">-568110000</us-gaap:IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:IncomeLossFromContinuingOperationsAttributableToNoncontrollingEntity
      contextRef="P04_01_2020To03_31_2021"
      decimals="-3"
      unitRef="Unit_USD">-90999000</us-gaap:IncomeLossFromContinuingOperationsAttributableToNoncontrollingEntity>
    <us-gaap:IncomeLossFromContinuingOperationsAttributableToNoncontrollingEntity
      contextRef="P04_01_2019To03_31_2020"
      decimals="-3"
      unitRef="Unit_USD">-48716000</us-gaap:IncomeLossFromContinuingOperationsAttributableToNoncontrollingEntity>
    <us-gaap:IncomeLossFromContinuingOperations
      contextRef="P04_01_2020To03_31_2021"
      decimals="-3"
      unitRef="Unit_USD">809234000</us-gaap:IncomeLossFromContinuingOperations>
    <us-gaap:IncomeLossFromContinuingOperations
      contextRef="P04_01_2019To03_31_2020"
      decimals="-3"
      unitRef="Unit_USD">519394000</us-gaap:IncomeLossFromContinuingOperations>
    <us-gaap:PreferredStockDividendsAndOtherAdjustments
      contextRef="P04_01_2019To03_31_2020"
      decimals="-3"
      unitRef="Unit_USD">77777000</us-gaap:PreferredStockDividendsAndOtherAdjustments>
    <roiv:BasicAndDilutedLossFromContinuingOperationsNetOfTax
      contextRef="P04_01_2020To03_31_2021"
      decimals="-3"
      unitRef="Unit_USD">-809234000</roiv:BasicAndDilutedLossFromContinuingOperationsNetOfTax>
    <roiv:BasicAndDilutedLossFromContinuingOperationsNetOfTax
      contextRef="P04_01_2019To03_31_2020"
      decimals="-3"
      unitRef="Unit_USD">-597171000</roiv:BasicAndDilutedLossFromContinuingOperationsNetOfTax>
    <us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTax
      contextRef="P04_01_2020To03_31_2021"
      decimals="-3"
      unitRef="Unit_USD">0</us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTax>
    <us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTax
      contextRef="P04_01_2019To03_31_2020"
      decimals="-3"
      unitRef="Unit_USD">1578426000</us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTax>
    <us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToNoncontrollingInterest
      contextRef="P04_01_2019To03_31_2020"
      decimals="-3"
      unitRef="Unit_USD">-141477000</us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToNoncontrollingInterest>
    <us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity
      contextRef="P04_01_2020To03_31_2021"
      decimals="-3"
      unitRef="Unit_USD">0</us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity>
    <us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity
      contextRef="P04_01_2019To03_31_2020"
      decimals="-3"
      unitRef="Unit_USD">1719903000</us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity>
    <roiv:BasicAndDilutedIncomeFromDiscontinuedOperationsNetOfTax
      contextRef="P04_01_2019To03_31_2020"
      decimals="-3"
      unitRef="Unit_USD">1719903000</roiv:BasicAndDilutedIncomeFromDiscontinuedOperationsNetOfTax>
    <roiv:BasicAndDilutedNetLossIncome
      contextRef="P04_01_2020To03_31_2021"
      decimals="-3"
      unitRef="Unit_USD">-809234000</roiv:BasicAndDilutedNetLossIncome>
    <roiv:BasicAndDilutedNetLossIncome
      contextRef="P04_01_2019To03_31_2020"
      decimals="-3"
      unitRef="Unit_USD">1122732000</roiv:BasicAndDilutedNetLossIncome>
    <us-gaap:PreferredStockDividendsAndOtherAdjustments
      contextRef="P04_01_2019To03_31_2020"
      decimals="-5"
      unitRef="Unit_USD">77800000</us-gaap:PreferredStockDividendsAndOtherAdjustments>
    <us-gaap:SubsequentEventsTextBlock contextRef="P04_01_2020To03_31_2021">&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Note 19&#x2014;Subsequent Events &lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;The Company has evaluated subsequent events for appropriate disclosures through June 30, 2021, the date that the consolidated financial statements were available to be issued. All subsequent events requiring recognition as of March&#160;31, 2021 have been incorporated in these financial statements. &lt;/div&gt;&lt;/div&gt; &lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;Option Vants Transaction &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;On May&#160;1, 2021, the Company entered into an Asset Purchase Agreement with Sumitomo and its subsidiary Sumitomo Pharmaceuticals (Suzhou) Co., Ltd. (&#x201c;SPC&#x201d;) (the &#x201c;Asset Purchase Agreement&#x201d;). The transactions contemplated by the Asset Purchase Agreement closed in June 2021. Pursuant to the Asset Purchase Agreement: (i)&#160;Sumitomo terminated all of its existing options to acquire the Company&#x2019;s equity interests in the Option Vants; (ii)&#160;the Company transferred and assigned to SPC all of its intellectual property, development and commercialization rights for (a)&#160;lefamulin in Mainland China, Taiwan, Hong Kong, and Macau (collectively &#x201c;Greater China&#x201d;), (b) vibegron in Mainland China, (c)&#160;rodatristat ethyl in Greater China and South Korea and &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;(d)&#160;RVT-802&lt;/div&gt; in Greater China and South Korea; (iii)&#160;we will receive a $5.0&#160;million cash payment; and (iv)&#160;Sumitomo entered into an agreement with the Company to pursue future collaborations with Genevant. &lt;/div&gt; &lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;Dermavant &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;On May&#160;14, 2021, Dermavant entered into a $160.0&#160;million revenue interest purchase and sale agreement (the &#x201c;RIPSA&#x201d;) for its investigational product tapinarof with three institutional investors. Under the terms of the RIPSA, the participants purchased a capped single-digit revenue interest in net sales of tapinarof for all dermatological indications in the United States in exchange for $160.0&#160;million in committed funding to be paid to Dermavant, subject to approval of tapinarof by the FDA. &lt;/div&gt;&lt;/div&gt; &lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Dermavant concurrently entered into a $40.0&#160;million senior secured credit facility (the &#x201c;Credit Facility&#x201d;) with one of the institutional investors. The Credit Facility has a &lt;span style="-sec-ix-hidden:hidden28230199"&gt;five&lt;/span&gt;-year maturity and bears an interest rate of 10% per annum. In connection with the funding of the Credit Facility, Dermavant issued to the institutional investor a warrant to purchase 1,199,072 common shares of Dermavant at an exercise price of $0.01 per common share. &lt;/div&gt;&lt;/div&gt; &lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;The proceeds from the Credit Facility were used to repay all amounts outstanding under the loan and security agreement with Hercules, with the remainder of net proceeds used for working capital and general corporate purposes. The Company reclassified $3.1&#160;million on the consolidated balance sheets as of March&#160;31, 2021 from current to long-term given that Dermavant had the intent and ability to refinance the short-term obligation on a long-term basis after March&#160;31, 2021 and before the financial statements were issued. &lt;/div&gt;&lt;/div&gt; &lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;Datavant&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;/div&gt; &lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;In June 2021, Datavant and CIOX Health, LLC entered into a definitive agreement to merge the two companies. &lt;/div&gt;&lt;/div&gt; &lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;The merger closed on July 27, 2021. At closing, Roivant received approximately $320 million in cash. &lt;/div&gt;&lt;/div&gt;</us-gaap:SubsequentEventsTextBlock>
    <roiv:BusinessAcquisitionCostOfAcquiredEntityAdjustmentPaidInCash
      contextRef="P05_01_2021To05_01_2021_SubsequentEventMemberusgaapSubsequentEventTypeAxis_SumitomoPharmaceuticalsCoLtdMemberusgaapBusinessAcquisitionAxis"
      decimals="-5"
      unitRef="Unit_USD">5000000.0</roiv:BusinessAcquisitionCostOfAcquiredEntityAdjustmentPaidInCash>
    <roiv:RevenueInterestPurchaseAndSaleAgreementAmount
      contextRef="PAsOn05_14_2021_DermavantSciencesLtdMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis_RevenueInterestPurchaseAndSaleAgreementMemberusgaapTypeOfArrangementAxis_SubsequentEventMemberusgaapSubsequentEventTypeAxis"
      decimals="-5"
      unitRef="Unit_USD">160000000.0</roiv:RevenueInterestPurchaseAndSaleAgreementAmount>
    <roiv:RevenueInterestPurchaseAndSaleAgreementCommittedFundToBePaid
      contextRef="PAsOn05_14_2021_DermavantSciencesLtdMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis_RevenueInterestPurchaseAndSaleAgreementMemberusgaapTypeOfArrangementAxis_SubsequentEventMemberusgaapSubsequentEventTypeAxis"
      decimals="-5"
      unitRef="Unit_USD">160000000.0</roiv:RevenueInterestPurchaseAndSaleAgreementCommittedFundToBePaid>
    <us-gaap:DebtInstrumentFaceAmount
      contextRef="PAsOn05_14_2021_CreditFacilityMemberusgaapDebtInstrumentAxis_DermavantSciencesLtdMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis_SubsequentEventMemberusgaapSubsequentEventTypeAxis"
      decimals="-5"
      unitRef="Unit_USD">40000000.0</us-gaap:DebtInstrumentFaceAmount>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="PAsOn05_14_2021_CreditFacilityMemberusgaapDebtInstrumentAxis_DermavantSciencesLtdMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis_SubsequentEventMemberusgaapSubsequentEventTypeAxis"
      decimals="2"
      unitRef="Unit_pure">0.10</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:ClassOfWarrantOrRightOutstanding
      contextRef="PAsOn05_14_2021_DermavantSciencesLtdMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis_SubsequentEventMemberusgaapSubsequentEventTypeAxis"
      decimals="INF"
      unitRef="Unit_shares">1199072</us-gaap:ClassOfWarrantOrRightOutstanding>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="PAsOn05_14_2021_DermavantSciencesLtdMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis_SubsequentEventMemberusgaapSubsequentEventTypeAxis"
      decimals="INF"
      unitRef="Unit_USD_per_Share">0.01</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:LongTermDebtNoncurrent
      contextRef="PAsOn03_31_2021_DermavantSciencesLtdMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis_RevisionOfPriorPeriodReclassificationAdjustmentMembersrtRestatementAxis_SubsequentEventMemberusgaapSubsequentEventTypeAxis"
      decimals="-5"
      unitRef="Unit_USD">3100000</us-gaap:LongTermDebtNoncurrent>
    <us-gaap:BusinessCombinationConsiderationTransferred1
      contextRef="P07_01_2021To07_31_2021_DatavantMemberusgaapBusinessAcquisitionAxis_SubsequentEventMemberusgaapSubsequentEventTypeAxis"
      decimals="-6"
      unitRef="Unit_USD">320000000</us-gaap:BusinessCombinationConsiderationTransferred1>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="PAsOn06_30_2021"
      decimals="-3"
      unitRef="Unit_USD">1996733000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="PAsOn03_31_2021"
      decimals="-3"
      unitRef="Unit_USD">2055044000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:RestrictedCashCurrent
      contextRef="PAsOn06_30_2021"
      decimals="-3"
      unitRef="Unit_USD">2711000</us-gaap:RestrictedCashCurrent>
    <us-gaap:RestrictedCashCurrent
      contextRef="PAsOn03_31_2021"
      decimals="-3"
      unitRef="Unit_USD">77701000</us-gaap:RestrictedCashCurrent>
    <us-gaap:OtherAssetsCurrent
      contextRef="PAsOn06_30_2021"
      decimals="-3"
      unitRef="Unit_USD">58165000</us-gaap:OtherAssetsCurrent>
    <us-gaap:OtherAssetsCurrent
      contextRef="PAsOn03_31_2021"
      decimals="-3"
      unitRef="Unit_USD">54250000</us-gaap:OtherAssetsCurrent>
    <us-gaap:AssetsCurrent
      contextRef="PAsOn06_30_2021"
      decimals="-3"
      unitRef="Unit_USD">2057609000</us-gaap:AssetsCurrent>
    <us-gaap:AssetsCurrent
      contextRef="PAsOn03_31_2021"
      decimals="-3"
      unitRef="Unit_USD">2186995000</us-gaap:AssetsCurrent>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="PAsOn06_30_2021"
      decimals="-3"
      unitRef="Unit_USD">15550000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="PAsOn03_31_2021"
      decimals="-3"
      unitRef="Unit_USD">14749000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:OperatingLeaseRightOfUseAsset
      contextRef="PAsOn06_30_2021"
      decimals="-3"
      unitRef="Unit_USD">65163000</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:OperatingLeaseRightOfUseAsset
      contextRef="PAsOn03_31_2021"
      decimals="-3"
      unitRef="Unit_USD">62279000</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:RestrictedCashNoncurrent
      contextRef="PAsOn06_30_2021"
      decimals="-3"
      unitRef="Unit_USD">8933000</us-gaap:RestrictedCashNoncurrent>
    <us-gaap:RestrictedCashNoncurrent
      contextRef="PAsOn03_31_2021"
      decimals="-3"
      unitRef="Unit_USD">8931000</us-gaap:RestrictedCashNoncurrent>
    <us-gaap:InvestmentsFairValueDisclosure
      contextRef="PAsOn06_30_2021"
      decimals="-3"
      unitRef="Unit_USD">180359000</us-gaap:InvestmentsFairValueDisclosure>
    <us-gaap:InvestmentsFairValueDisclosure
      contextRef="PAsOn03_31_2021"
      decimals="-3"
      unitRef="Unit_USD">188978000</us-gaap:InvestmentsFairValueDisclosure>
    <us-gaap:LongTermInvestments
      contextRef="PAsOn06_30_2021"
      decimals="-3"
      unitRef="Unit_USD">100563000</us-gaap:LongTermInvestments>
    <us-gaap:LongTermInvestments
      contextRef="PAsOn03_31_2021"
      decimals="-3"
      unitRef="Unit_USD">100563000</us-gaap:LongTermInvestments>
    <us-gaap:OtherAssetsNoncurrent
      contextRef="PAsOn06_30_2021"
      decimals="-3"
      unitRef="Unit_USD">26520000</us-gaap:OtherAssetsNoncurrent>
    <us-gaap:OtherAssetsNoncurrent
      contextRef="PAsOn03_31_2021"
      decimals="-3"
      unitRef="Unit_USD">27197000</us-gaap:OtherAssetsNoncurrent>
    <us-gaap:Assets
      contextRef="PAsOn06_30_2021"
      decimals="-3"
      unitRef="Unit_USD">2454697000</us-gaap:Assets>
    <us-gaap:Assets
      contextRef="PAsOn03_31_2021"
      decimals="-3"
      unitRef="Unit_USD">2589692000</us-gaap:Assets>
    <us-gaap:AccountsPayableCurrent
      contextRef="PAsOn06_30_2021"
      decimals="-3"
      unitRef="Unit_USD">15014000</us-gaap:AccountsPayableCurrent>
    <us-gaap:AccountsPayableCurrent
      contextRef="PAsOn03_31_2021"
      decimals="-3"
      unitRef="Unit_USD">20550000</us-gaap:AccountsPayableCurrent>
    <us-gaap:AccruedLiabilitiesCurrent
      contextRef="PAsOn06_30_2021"
      decimals="-3"
      unitRef="Unit_USD">73788000</us-gaap:AccruedLiabilitiesCurrent>
    <us-gaap:AccruedLiabilitiesCurrent
      contextRef="PAsOn03_31_2021"
      decimals="-3"
      unitRef="Unit_USD">76936000</us-gaap:AccruedLiabilitiesCurrent>
    <us-gaap:OperatingLeaseLiabilityCurrent
      contextRef="PAsOn06_30_2021"
      decimals="-3"
      unitRef="Unit_USD">12055000</us-gaap:OperatingLeaseLiabilityCurrent>
    <us-gaap:OperatingLeaseLiabilityCurrent
      contextRef="PAsOn03_31_2021"
      decimals="-3"
      unitRef="Unit_USD">12313000</us-gaap:OperatingLeaseLiabilityCurrent>
    <roiv:DeferredConsiderationLiabilityCurrent
      contextRef="PAsOn06_30_2021"
      decimals="-3"
      unitRef="Unit_USD">100000000</roiv:DeferredConsiderationLiabilityCurrent>
    <roiv:DeferredConsiderationLiabilityCurrent
      contextRef="PAsOn03_31_2021"
      decimals="-3"
      unitRef="Unit_USD">100000000</roiv:DeferredConsiderationLiabilityCurrent>
    <us-gaap:OtherLiabilitiesCurrent
      contextRef="PAsOn06_30_2021"
      decimals="-3"
      unitRef="Unit_USD">8301000</us-gaap:OtherLiabilitiesCurrent>
    <us-gaap:OtherLiabilitiesCurrent
      contextRef="PAsOn03_31_2021"
      decimals="-3"
      unitRef="Unit_USD">9162000</us-gaap:OtherLiabilitiesCurrent>
    <us-gaap:LiabilitiesCurrent
      contextRef="PAsOn06_30_2021"
      decimals="-3"
      unitRef="Unit_USD">209158000</us-gaap:LiabilitiesCurrent>
    <us-gaap:LiabilitiesCurrent
      contextRef="PAsOn03_31_2021"
      decimals="-3"
      unitRef="Unit_USD">218961000</us-gaap:LiabilitiesCurrent>
    <roiv:LiabilityInstrumentsMeasuredAtFairValue
      contextRef="PAsOn06_30_2021"
      decimals="-3"
      unitRef="Unit_USD">5906000</roiv:LiabilityInstrumentsMeasuredAtFairValue>
    <roiv:LiabilityInstrumentsMeasuredAtFairValue
      contextRef="PAsOn03_31_2021"
      decimals="-3"
      unitRef="Unit_USD">67893000</roiv:LiabilityInstrumentsMeasuredAtFairValue>
    <us-gaap:OperatingLeaseLiabilityNoncurrent
      contextRef="PAsOn06_30_2021"
      decimals="-3"
      unitRef="Unit_USD">65263000</us-gaap:OperatingLeaseLiabilityNoncurrent>
    <us-gaap:OperatingLeaseLiabilityNoncurrent
      contextRef="PAsOn03_31_2021"
      decimals="-3"
      unitRef="Unit_USD">62384000</us-gaap:OperatingLeaseLiabilityNoncurrent>
    <us-gaap:LongTermDebtFairValue
      contextRef="PAsOn06_30_2021"
      decimals="-3"
      unitRef="Unit_USD">155200000</us-gaap:LongTermDebtFairValue>
    <us-gaap:LongTermDebtFairValue
      contextRef="PAsOn03_31_2021"
      decimals="-3"
      unitRef="Unit_USD">150100000</us-gaap:LongTermDebtFairValue>
    <us-gaap:LongTermDebtNoncurrent
      contextRef="PAsOn06_30_2021"
      decimals="-3"
      unitRef="Unit_USD">186350000</us-gaap:LongTermDebtNoncurrent>
    <us-gaap:LongTermDebtNoncurrent
      contextRef="PAsOn03_31_2021"
      decimals="-3"
      unitRef="Unit_USD">170280000</us-gaap:LongTermDebtNoncurrent>
    <us-gaap:OtherLiabilitiesNoncurrent
      contextRef="PAsOn06_30_2021"
      decimals="-3"
      unitRef="Unit_USD">8188000</us-gaap:OtherLiabilitiesNoncurrent>
    <us-gaap:OtherLiabilitiesNoncurrent
      contextRef="PAsOn03_31_2021"
      decimals="-3"
      unitRef="Unit_USD">8169000</us-gaap:OtherLiabilitiesNoncurrent>
    <us-gaap:Liabilities
      contextRef="PAsOn06_30_2021"
      decimals="-3"
      unitRef="Unit_USD">474865000</us-gaap:Liabilities>
    <us-gaap:Liabilities
      contextRef="PAsOn03_31_2021"
      decimals="-3"
      unitRef="Unit_USD">527687000</us-gaap:Liabilities>
    <us-gaap:CommitmentsAndContingencies
      contextRef="PAsOn06_30_2021"
      unitRef="Unit_USD"
      xsi:nil="true"/>
    <us-gaap:CommitmentsAndContingencies
      contextRef="PAsOn03_31_2021"
      unitRef="Unit_USD"
      xsi:nil="true"/>
    <us-gaap:RedeemableNoncontrollingInterestEquityCarryingAmount
      contextRef="PAsOn06_30_2021"
      decimals="-3"
      unitRef="Unit_USD">22491000</us-gaap:RedeemableNoncontrollingInterestEquityCarryingAmount>
    <us-gaap:RedeemableNoncontrollingInterestEquityCarryingAmount
      contextRef="PAsOn03_31_2021"
      decimals="-3"
      unitRef="Unit_USD">22491000</us-gaap:RedeemableNoncontrollingInterestEquityCarryingAmount>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="PAsOn03_31_2021"
      decimals="INF"
      unitRef="Unit_shares">100000000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="PAsOn06_30_2021"
      decimals="INF"
      unitRef="Unit_shares">100000000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesIssued
      contextRef="PAsOn03_31_2021"
      decimals="INF"
      unitRef="Unit_shares">222669799</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="PAsOn06_30_2021"
      decimals="INF"
      unitRef="Unit_shares">222669799</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="PAsOn03_31_2021"
      decimals="INF"
      unitRef="Unit_shares">222669799</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:CommonStockSharesIssued
      contextRef="PAsOn06_30_2021"
      decimals="INF"
      unitRef="Unit_shares">222669799</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockValue
      contextRef="PAsOn06_30_2021"
      decimals="-3"
      unitRef="Unit_USD">0</us-gaap:CommonStockValue>
    <us-gaap:CommonStockValue
      contextRef="PAsOn03_31_2021"
      decimals="-3"
      unitRef="Unit_USD">0</us-gaap:CommonStockValue>
    <us-gaap:AdditionalPaidInCapital
      contextRef="PAsOn06_30_2021"
      decimals="-3"
      unitRef="Unit_USD">3824974000</us-gaap:AdditionalPaidInCapital>
    <us-gaap:AdditionalPaidInCapital
      contextRef="PAsOn03_31_2021"
      decimals="-3"
      unitRef="Unit_USD">3814805000</us-gaap:AdditionalPaidInCapital>
    <roiv:SubscriptionsReceivable
      contextRef="PAsOn06_30_2021"
      decimals="-3"
      unitRef="Unit_USD">-100000000</roiv:SubscriptionsReceivable>
    <roiv:SubscriptionsReceivable
      contextRef="PAsOn03_31_2021"
      decimals="-3"
      unitRef="Unit_USD">-100000000</roiv:SubscriptionsReceivable>
    <us-gaap:RetainedEarningsAccumulatedDeficit
      contextRef="PAsOn06_30_2021"
      decimals="-3"
      unitRef="Unit_USD">-2000645000</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:RetainedEarningsAccumulatedDeficit
      contextRef="PAsOn03_31_2021"
      decimals="-3"
      unitRef="Unit_USD">-1918462000</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax
      contextRef="PAsOn06_30_2021"
      decimals="-3"
      unitRef="Unit_USD">-1207000</us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax
      contextRef="PAsOn03_31_2021"
      decimals="-3"
      unitRef="Unit_USD">1445000</us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:StockholdersEquity
      contextRef="PAsOn06_30_2021"
      decimals="-3"
      unitRef="Unit_USD">1723122000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="PAsOn03_31_2021"
      decimals="-3"
      unitRef="Unit_USD">1797788000</us-gaap:StockholdersEquity>
    <us-gaap:MinorityInterest
      contextRef="PAsOn06_30_2021"
      decimals="-3"
      unitRef="Unit_USD">234219000</us-gaap:MinorityInterest>
    <us-gaap:MinorityInterest
      contextRef="PAsOn03_31_2021"
      decimals="-3"
      unitRef="Unit_USD">241726000</us-gaap:MinorityInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="PAsOn06_30_2021"
      decimals="-3"
      unitRef="Unit_USD">1957341000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="PAsOn03_31_2021"
      decimals="-3"
      unitRef="Unit_USD">2039514000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:LiabilitiesAndStockholdersEquity
      contextRef="PAsOn06_30_2021"
      decimals="-3"
      unitRef="Unit_USD">2454697000</us-gaap:LiabilitiesAndStockholdersEquity>
    <us-gaap:LiabilitiesAndStockholdersEquity
      contextRef="PAsOn03_31_2021"
      decimals="-3"
      unitRef="Unit_USD">2589692000</us-gaap:LiabilitiesAndStockholdersEquity>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="P04_01_2021To06_30_2021"
      decimals="-3"
      unitRef="Unit_USD">7735000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="P04_01_2020To06_30_2020"
      decimals="-3"
      unitRef="Unit_USD">1576000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <roiv:OperatingCosts
      contextRef="P04_01_2021To06_30_2021"
      decimals="-3"
      unitRef="Unit_USD">742000</roiv:OperatingCosts>
    <roiv:OperatingCosts
      contextRef="P04_01_2020To06_30_2020"
      decimals="-3"
      unitRef="Unit_USD">180000</roiv:OperatingCosts>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="P04_01_2021To06_30_2021"
      decimals="-3"
      unitRef="Unit_USD">78626000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="P04_01_2020To06_30_2020"
      decimals="-3"
      unitRef="Unit_USD">58734000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:GeneralAndAdministrativeExpense
      contextRef="P04_01_2021To06_30_2021"
      decimals="-3"
      unitRef="Unit_USD">82754000</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:GeneralAndAdministrativeExpense
      contextRef="P04_01_2020To06_30_2020"
      decimals="-3"
      unitRef="Unit_USD">57115000</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:OperatingExpenses
      contextRef="P04_01_2021To06_30_2021"
      decimals="-3"
      unitRef="Unit_USD">162122000</us-gaap:OperatingExpenses>
    <us-gaap:OperatingExpenses
      contextRef="P04_01_2020To06_30_2020"
      decimals="-3"
      unitRef="Unit_USD">116029000</us-gaap:OperatingExpenses>
    <us-gaap:OperatingIncomeLoss
      contextRef="P04_01_2021To06_30_2021"
      decimals="-3"
      unitRef="Unit_USD">-154387000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="P04_01_2020To06_30_2020"
      decimals="-3"
      unitRef="Unit_USD">-114453000</us-gaap:OperatingIncomeLoss>
    <us-gaap:GainLossOnInvestments
      contextRef="P04_01_2021To06_30_2021"
      decimals="-3"
      unitRef="Unit_USD">-8619000</us-gaap:GainLossOnInvestments>
    <us-gaap:GainLossOnInvestments
      contextRef="P04_01_2020To06_30_2020"
      decimals="-3"
      unitRef="Unit_USD">41148000</us-gaap:GainLossOnInvestments>
    <roiv:GainLossOnFairValueOfDebtAndLiabilityInstruments
      contextRef="P04_01_2021To06_30_2021"
      decimals="-3"
      unitRef="Unit_USD">-4585000</roiv:GainLossOnFairValueOfDebtAndLiabilityInstruments>
    <roiv:GainLossOnFairValueOfDebtAndLiabilityInstruments
      contextRef="P04_01_2020To06_30_2020"
      decimals="-3"
      unitRef="Unit_USD">-17125000</roiv:GainLossOnFairValueOfDebtAndLiabilityInstruments>
    <roiv:EquityInterestOptionToThirdPartyPurchaserGainOnTermination
      contextRef="P04_01_2021To06_30_2021"
      decimals="-3"
      unitRef="Unit_USD">66472000</roiv:EquityInterestOptionToThirdPartyPurchaserGainOnTermination>
    <roiv:EquityInterestOptionToThirdPartyPurchaserGainOnTermination
      contextRef="P04_01_2020To06_30_2020"
      decimals="-3"
      unitRef="Unit_USD">0</roiv:EquityInterestOptionToThirdPartyPurchaserGainOnTermination>
    <roiv:GainOrLossOnDeconsolidationOfSubsidiary
      contextRef="P04_01_2021To06_30_2021"
      decimals="-3"
      unitRef="Unit_USD">0</roiv:GainOrLossOnDeconsolidationOfSubsidiary>
    <roiv:GainOrLossOnDeconsolidationOfSubsidiary
      contextRef="P04_01_2020To06_30_2020"
      decimals="-3"
      unitRef="Unit_USD">86516000</roiv:GainOrLossOnDeconsolidationOfSubsidiary>
    <us-gaap:OtherNonoperatingIncomeExpense
      contextRef="P04_01_2021To06_30_2021"
      decimals="-3"
      unitRef="Unit_USD">134000</us-gaap:OtherNonoperatingIncomeExpense>
    <us-gaap:OtherNonoperatingIncomeExpense
      contextRef="P04_01_2020To06_30_2020"
      decimals="-3"
      unitRef="Unit_USD">-2842000</us-gaap:OtherNonoperatingIncomeExpense>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
      contextRef="P04_01_2021To06_30_2021"
      decimals="-3"
      unitRef="Unit_USD">-100985000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
      contextRef="P04_01_2020To06_30_2020"
      decimals="-3"
      unitRef="Unit_USD">-6756000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="P04_01_2021To06_30_2021"
      decimals="-3"
      unitRef="Unit_USD">93000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="P04_01_2020To06_30_2020"
      decimals="-3"
      unitRef="Unit_USD">1221000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:ProfitLoss
      contextRef="P04_01_2021To06_30_2021"
      decimals="-3"
      unitRef="Unit_USD">-101078000</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="P04_01_2020To06_30_2020"
      decimals="-3"
      unitRef="Unit_USD">-7977000</us-gaap:ProfitLoss>
    <us-gaap:NetIncomeLossAttributableToNoncontrollingInterest
      contextRef="P04_01_2021To06_30_2021"
      decimals="-3"
      unitRef="Unit_USD">-18895000</us-gaap:NetIncomeLossAttributableToNoncontrollingInterest>
    <us-gaap:NetIncomeLossAttributableToNoncontrollingInterest
      contextRef="P04_01_2020To06_30_2020"
      decimals="-3"
      unitRef="Unit_USD">-4734000</us-gaap:NetIncomeLossAttributableToNoncontrollingInterest>
    <us-gaap:NetIncomeLoss
      contextRef="P04_01_2021To06_30_2021"
      decimals="-3"
      unitRef="Unit_USD">-82183000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="P04_01_2020To06_30_2020"
      decimals="-3"
      unitRef="Unit_USD">-3243000</us-gaap:NetIncomeLoss>
    <us-gaap:EarningsPerShareBasicAndDiluted
      contextRef="P04_01_2021To06_30_2021"
      decimals="2"
      unitRef="Unit_USD_per_Share">-0.37</us-gaap:EarningsPerShareBasicAndDiluted>
    <us-gaap:EarningsPerShareBasicAndDiluted
      contextRef="P04_01_2020To06_30_2020"
      decimals="2"
      unitRef="Unit_USD_per_Share">-0.02</us-gaap:EarningsPerShareBasicAndDiluted>
    <us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted
      contextRef="P04_01_2021To06_30_2021"
      decimals="0"
      unitRef="Unit_shares">222081975</us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted>
    <us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted
      contextRef="P04_01_2020To06_30_2020"
      decimals="0"
      unitRef="Unit_shares">214879058</us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted>
    <us-gaap:ProfitLoss
      contextRef="P04_01_2021To06_30_2021"
      decimals="-3"
      unitRef="Unit_USD">-101078000</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="P04_01_2020To06_30_2020"
      decimals="-3"
      unitRef="Unit_USD">-7977000</us-gaap:ProfitLoss>
    <us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax
      contextRef="P04_01_2021To06_30_2021"
      decimals="-3"
      unitRef="Unit_USD">-2439000</us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax>
    <us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax
      contextRef="P04_01_2020To06_30_2020"
      decimals="-3"
      unitRef="Unit_USD">-820000</us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTax
      contextRef="P04_01_2021To06_30_2021"
      decimals="-3"
      unitRef="Unit_USD">-2439000</us-gaap:OtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTax
      contextRef="P04_01_2020To06_30_2020"
      decimals="-3"
      unitRef="Unit_USD">-820000</us-gaap:OtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest
      contextRef="P04_01_2021To06_30_2021"
      decimals="-3"
      unitRef="Unit_USD">-103517000</us-gaap:ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest
      contextRef="P04_01_2020To06_30_2020"
      decimals="-3"
      unitRef="Unit_USD">-8797000</us-gaap:ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest
      contextRef="P04_01_2021To06_30_2021"
      decimals="-3"
      unitRef="Unit_USD">-18682000</us-gaap:ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest>
    <us-gaap:ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest
      contextRef="P04_01_2020To06_30_2020"
      decimals="-3"
      unitRef="Unit_USD">-4700000</us-gaap:ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest>
    <us-gaap:ComprehensiveIncomeNetOfTax
      contextRef="P04_01_2021To06_30_2021"
      decimals="-3"
      unitRef="Unit_USD">-84835000</us-gaap:ComprehensiveIncomeNetOfTax>
    <us-gaap:ComprehensiveIncomeNetOfTax
      contextRef="P04_01_2020To06_30_2020"
      decimals="-3"
      unitRef="Unit_USD">-4097000</us-gaap:ComprehensiveIncomeNetOfTax>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="PAsOn03_31_2021_RedeemableNoncontrollingInterestMemberusgaapStatementClassOfStockAxis"
      decimals="-3"
      unitRef="Unit_USD">22491000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:SharesOutstanding
      contextRef="PAsOn03_31_2021_CommonStockMemberusgaapStatementEquityComponentsAxis"
      decimals="INF"
      unitRef="Unit_shares">222669799</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="PAsOn03_31_2021_CommonStockMemberusgaapStatementEquityComponentsAxis"
      decimals="-3"
      unitRef="Unit_USD">0</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="PAsOn03_31_2021_AdditionalPaidInCapitalMemberusgaapStatementEquityComponentsAxis"
      decimals="-3"
      unitRef="Unit_USD">3814805000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="PAsOn03_31_2021_SubscriptionsReceivablesMemberusgaapStatementEquityComponentsAxis"
      decimals="-3"
      unitRef="Unit_USD">-100000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="PAsOn03_31_2021_AccumulatedOtherComprehensiveIncomeMemberusgaapStatementEquityComponentsAxis"
      decimals="-3"
      unitRef="Unit_USD">1445000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="PAsOn03_31_2021_RetainedEarningsMemberusgaapStatementEquityComponentsAxis"
      decimals="-3"
      unitRef="Unit_USD">-1918462000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="PAsOn03_31_2021_NoncontrollingInterestMemberusgaapStatementEquityComponentsAxis"
      decimals="-3"
      unitRef="Unit_USD">241726000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="PAsOn03_31_2021"
      decimals="-3"
      unitRef="Unit_USD">2039514000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <roiv:IssuanceOfSubsidiaryWarrants
      contextRef="P04_01_2021To06_30_2021_AdditionalPaidInCapitalMemberusgaapStatementEquityComponentsAxis"
      decimals="-3"
      unitRef="Unit_USD">2051000</roiv:IssuanceOfSubsidiaryWarrants>
    <roiv:IssuanceOfSubsidiaryWarrants
      contextRef="P04_01_2021To06_30_2021_NoncontrollingInterestMemberusgaapStatementEquityComponentsAxis"
      decimals="-3"
      unitRef="Unit_USD">24000</roiv:IssuanceOfSubsidiaryWarrants>
    <roiv:IssuanceOfSubsidiaryWarrants
      contextRef="P04_01_2021To06_30_2021"
      decimals="-3"
      unitRef="Unit_USD">2075000</roiv:IssuanceOfSubsidiaryWarrants>
    <roiv:CapitalContributionsToSubsidiaries
      contextRef="P04_01_2021To06_30_2021_AdditionalPaidInCapitalMemberusgaapStatementEquityComponentsAxis"
      decimals="-3"
      unitRef="Unit_USD">-2973000</roiv:CapitalContributionsToSubsidiaries>
    <roiv:CapitalContributionsToSubsidiaries
      contextRef="P04_01_2021To06_30_2021_NoncontrollingInterestMemberusgaapStatementEquityComponentsAxis"
      decimals="-3"
      unitRef="Unit_USD">2973000</roiv:CapitalContributionsToSubsidiaries>
    <roiv:CapitalContributionsToSubsidiaries
      contextRef="P04_01_2021To06_30_2021"
      decimals="-3"
      unitRef="Unit_USD">0</roiv:CapitalContributionsToSubsidiaries>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="P04_01_2021To06_30_2021_AdditionalPaidInCapitalMemberusgaapStatementEquityComponentsAxis"
      decimals="-3"
      unitRef="Unit_USD">11091000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="P04_01_2021To06_30_2021_NoncontrollingInterestMemberusgaapStatementEquityComponentsAxis"
      decimals="-3"
      unitRef="Unit_USD">8178000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="P04_01_2021To06_30_2021"
      decimals="-3"
      unitRef="Unit_USD">19269000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent
      contextRef="P04_01_2021To06_30_2021_AccumulatedOtherComprehensiveIncomeMemberusgaapStatementEquityComponentsAxis"
      decimals="-3"
      unitRef="Unit_USD">-2652000</us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent>
    <us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent
      contextRef="P04_01_2021To06_30_2021_NoncontrollingInterestMemberusgaapStatementEquityComponentsAxis"
      decimals="-3"
      unitRef="Unit_USD">213000</us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent>
    <us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent
      contextRef="P04_01_2021To06_30_2021"
      decimals="-3"
      unitRef="Unit_USD">-2439000</us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent>
    <us-gaap:ProfitLoss
      contextRef="P04_01_2021To06_30_2021_RetainedEarningsMemberusgaapStatementEquityComponentsAxis"
      decimals="-3"
      unitRef="Unit_USD">-82183000</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="P04_01_2021To06_30_2021_NoncontrollingInterestMemberusgaapStatementEquityComponentsAxis"
      decimals="-3"
      unitRef="Unit_USD">-18895000</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="P04_01_2021To06_30_2021"
      decimals="-3"
      unitRef="Unit_USD">-101078000</us-gaap:ProfitLoss>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="PAsOn06_30_2021_RedeemableNoncontrollingInterestMemberusgaapStatementClassOfStockAxis"
      decimals="-3"
      unitRef="Unit_USD">22491000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:SharesOutstanding
      contextRef="PAsOn06_30_2021_CommonStockMemberusgaapStatementEquityComponentsAxis"
      decimals="INF"
      unitRef="Unit_shares">222669799</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="PAsOn06_30_2021_CommonStockMemberusgaapStatementEquityComponentsAxis"
      decimals="-3"
      unitRef="Unit_USD">0</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="PAsOn06_30_2021_AdditionalPaidInCapitalMemberusgaapStatementEquityComponentsAxis"
      decimals="-3"
      unitRef="Unit_USD">3824974000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="PAsOn06_30_2021_SubscriptionsReceivablesMemberusgaapStatementEquityComponentsAxis"
      decimals="-3"
      unitRef="Unit_USD">-100000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="PAsOn06_30_2021_AccumulatedOtherComprehensiveIncomeMemberusgaapStatementEquityComponentsAxis"
      decimals="-3"
      unitRef="Unit_USD">-1207000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="PAsOn06_30_2021_RetainedEarningsMemberusgaapStatementEquityComponentsAxis"
      decimals="-3"
      unitRef="Unit_USD">-2000645000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="PAsOn06_30_2021_NoncontrollingInterestMemberusgaapStatementEquityComponentsAxis"
      decimals="-3"
      unitRef="Unit_USD">234219000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="PAsOn06_30_2021"
      decimals="-3"
      unitRef="Unit_USD">1957341000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="PAsOn03_31_2020_RedeemableNoncontrollingInterestMemberusgaapStatementClassOfStockAxis"
      decimals="-3"
      unitRef="Unit_USD">22491000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:SharesOutstanding
      contextRef="PAsOn03_31_2020_CommonStockMemberusgaapStatementEquityComponentsAxis"
      decimals="INF"
      unitRef="Unit_shares">214879058</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="PAsOn03_31_2020_CommonStockMemberusgaapStatementEquityComponentsAxis"
      decimals="-3"
      unitRef="Unit_USD">0</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="PAsOn03_31_2020_AdditionalPaidInCapitalMemberusgaapStatementEquityComponentsAxis"
      decimals="-3"
      unitRef="Unit_USD">3143739000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="PAsOn03_31_2020_SubscriptionsReceivablesMemberusgaapStatementEquityComponentsAxis"
      decimals="-3"
      unitRef="Unit_USD">0</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="PAsOn03_31_2020_AccumulatedOtherComprehensiveIncomeMemberusgaapStatementEquityComponentsAxis"
      decimals="-3"
      unitRef="Unit_USD">-2349000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="PAsOn03_31_2020_RetainedEarningsMemberusgaapStatementEquityComponentsAxis"
      decimals="-3"
      unitRef="Unit_USD">-1109228000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="PAsOn03_31_2020_NoncontrollingInterestMemberusgaapStatementEquityComponentsAxis"
      decimals="-3"
      unitRef="Unit_USD">54042000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="PAsOn03_31_2020"
      decimals="-3"
      unitRef="Unit_USD">2086204000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <roiv:IssuanceOfSubsidiaryCommonSharesNetValue
      contextRef="P04_01_2020To06_30_2020_AdditionalPaidInCapitalMemberusgaapStatementEquityComponentsAxis"
      decimals="-3"
      unitRef="Unit_USD">104581000</roiv:IssuanceOfSubsidiaryCommonSharesNetValue>
    <roiv:IssuanceOfSubsidiaryCommonSharesNetValue
      contextRef="P04_01_2020To06_30_2020_NoncontrollingInterestMemberusgaapStatementEquityComponentsAxis"
      decimals="-3"
      unitRef="Unit_USD">76599000</roiv:IssuanceOfSubsidiaryCommonSharesNetValue>
    <roiv:IssuanceOfSubsidiaryCommonSharesNetValue
      contextRef="P04_01_2020To06_30_2020"
      decimals="-3"
      unitRef="Unit_USD">181180000</roiv:IssuanceOfSubsidiaryCommonSharesNetValue>
    <roiv:IssuanceOfSubsidiaryCommonSharesToTheCompanyValue
      contextRef="P04_01_2020To06_30_2020_AdditionalPaidInCapitalMemberusgaapStatementEquityComponentsAxis"
      decimals="-3"
      unitRef="Unit_USD">-6342000</roiv:IssuanceOfSubsidiaryCommonSharesToTheCompanyValue>
    <roiv:IssuanceOfSubsidiaryCommonSharesToTheCompanyValue
      contextRef="P04_01_2020To06_30_2020_NoncontrollingInterestMemberusgaapStatementEquityComponentsAxis"
      decimals="-3"
      unitRef="Unit_USD">6342000</roiv:IssuanceOfSubsidiaryCommonSharesToTheCompanyValue>
    <roiv:IssuanceOfSubsidiaryCommonSharesToTheCompanyValue
      contextRef="P04_01_2020To06_30_2020"
      decimals="-3"
      unitRef="Unit_USD">0</roiv:IssuanceOfSubsidiaryCommonSharesToTheCompanyValue>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="P04_01_2020To06_30_2020_AdditionalPaidInCapitalMemberusgaapStatementEquityComponentsAxis"
      decimals="-3"
      unitRef="Unit_USD">36000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="P04_01_2020To06_30_2020_NoncontrollingInterestMemberusgaapStatementEquityComponentsAxis"
      decimals="-3"
      unitRef="Unit_USD">27000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="P04_01_2020To06_30_2020"
      decimals="-3"
      unitRef="Unit_USD">63000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <roiv:DeconsolidationOfSubsidiary
      contextRef="P04_01_2020To06_30_2020_NoncontrollingInterestMemberusgaapStatementEquityComponentsAxis"
      decimals="-3"
      unitRef="Unit_USD">-3054000</roiv:DeconsolidationOfSubsidiary>
    <roiv:DeconsolidationOfSubsidiary
      contextRef="P04_01_2020To06_30_2020"
      decimals="-3"
      unitRef="Unit_USD">-3054000</roiv:DeconsolidationOfSubsidiary>
    <roiv:RepurchaseOfEquityAwards
      contextRef="P04_01_2020To06_30_2020_AdditionalPaidInCapitalMemberusgaapStatementEquityComponentsAxis"
      decimals="-3"
      unitRef="Unit_USD">-113000</roiv:RepurchaseOfEquityAwards>
    <roiv:RepurchaseOfEquityAwards
      contextRef="P04_01_2020To06_30_2020"
      decimals="-3"
      unitRef="Unit_USD">-113000</roiv:RepurchaseOfEquityAwards>
    <roiv:CapitalContributionsToSubsidiaries
      contextRef="P04_01_2020To06_30_2020_AdditionalPaidInCapitalMemberusgaapStatementEquityComponentsAxis"
      decimals="-3"
      unitRef="Unit_USD">-149000</roiv:CapitalContributionsToSubsidiaries>
    <roiv:CapitalContributionsToSubsidiaries
      contextRef="P04_01_2020To06_30_2020_NoncontrollingInterestMemberusgaapStatementEquityComponentsAxis"
      decimals="-3"
      unitRef="Unit_USD">149000</roiv:CapitalContributionsToSubsidiaries>
    <roiv:CapitalContributionsToSubsidiaries
      contextRef="P04_01_2020To06_30_2020"
      decimals="-3"
      unitRef="Unit_USD">0</roiv:CapitalContributionsToSubsidiaries>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="P04_01_2020To06_30_2020_AdditionalPaidInCapitalMemberusgaapStatementEquityComponentsAxis"
      decimals="-3"
      unitRef="Unit_USD">9285000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="P04_01_2020To06_30_2020_NoncontrollingInterestMemberusgaapStatementEquityComponentsAxis"
      decimals="-3"
      unitRef="Unit_USD">4993000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="P04_01_2020To06_30_2020"
      decimals="-3"
      unitRef="Unit_USD">14278000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent
      contextRef="P04_01_2020To06_30_2020_AccumulatedOtherComprehensiveIncomeMemberusgaapStatementEquityComponentsAxis"
      decimals="-3"
      unitRef="Unit_USD">-854000</us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent>
    <us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent
      contextRef="P04_01_2020To06_30_2020_NoncontrollingInterestMemberusgaapStatementEquityComponentsAxis"
      decimals="-3"
      unitRef="Unit_USD">34000</us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent>
    <us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent
      contextRef="P04_01_2020To06_30_2020"
      decimals="-3"
      unitRef="Unit_USD">-820000</us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent>
    <us-gaap:ProfitLoss
      contextRef="P04_01_2020To06_30_2020_RetainedEarningsMemberusgaapStatementEquityComponentsAxis"
      decimals="-3"
      unitRef="Unit_USD">-3243000</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="P04_01_2020To06_30_2020_NoncontrollingInterestMemberusgaapStatementEquityComponentsAxis"
      decimals="-3"
      unitRef="Unit_USD">-4734000</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="P04_01_2020To06_30_2020"
      decimals="-3"
      unitRef="Unit_USD">-7977000</us-gaap:ProfitLoss>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="PAsOn06_30_2020_RedeemableNoncontrollingInterestMemberusgaapStatementClassOfStockAxis"
      decimals="-3"
      unitRef="Unit_USD">22491000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:SharesOutstanding
      contextRef="PAsOn06_30_2020_CommonStockMemberusgaapStatementEquityComponentsAxis"
      decimals="INF"
      unitRef="Unit_shares">214879058</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="PAsOn06_30_2020_CommonStockMemberusgaapStatementEquityComponentsAxis"
      decimals="-3"
      unitRef="Unit_USD">0</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="PAsOn06_30_2020_AdditionalPaidInCapitalMemberusgaapStatementEquityComponentsAxis"
      decimals="-3"
      unitRef="Unit_USD">3251037000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="PAsOn06_30_2020_SubscriptionsReceivablesMemberusgaapStatementEquityComponentsAxis"
      decimals="-3"
      unitRef="Unit_USD">0</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="PAsOn06_30_2020_AccumulatedOtherComprehensiveIncomeMemberusgaapStatementEquityComponentsAxis"
      decimals="-3"
      unitRef="Unit_USD">-3203000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="PAsOn06_30_2020_RetainedEarningsMemberusgaapStatementEquityComponentsAxis"
      decimals="-3"
      unitRef="Unit_USD">-1112471000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="PAsOn06_30_2020_NoncontrollingInterestMemberusgaapStatementEquityComponentsAxis"
      decimals="-3"
      unitRef="Unit_USD">134398000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="PAsOn06_30_2020"
      decimals="-3"
      unitRef="Unit_USD">2269761000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:ProfitLoss
      contextRef="P04_01_2021To06_30_2021"
      decimals="-3"
      unitRef="Unit_USD">-101078000</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="P04_01_2020To06_30_2020"
      decimals="-3"
      unitRef="Unit_USD">-7977000</us-gaap:ProfitLoss>
    <us-gaap:ShareBasedCompensation
      contextRef="P04_01_2021To06_30_2021"
      decimals="-3"
      unitRef="Unit_USD">19269000</us-gaap:ShareBasedCompensation>
    <us-gaap:ShareBasedCompensation
      contextRef="P04_01_2020To06_30_2020"
      decimals="-3"
      unitRef="Unit_USD">14278000</us-gaap:ShareBasedCompensation>
    <us-gaap:GainLossOnInvestments
      contextRef="P04_01_2021To06_30_2021"
      decimals="-3"
      unitRef="Unit_USD">-8619000</us-gaap:GainLossOnInvestments>
    <us-gaap:GainLossOnInvestments
      contextRef="P04_01_2020To06_30_2020"
      decimals="-3"
      unitRef="Unit_USD">41148000</us-gaap:GainLossOnInvestments>
    <roiv:GainLossOnFairValueOfDebtAndLiabilityInstruments
      contextRef="P04_01_2021To06_30_2021"
      decimals="-3"
      unitRef="Unit_USD">-4585000</roiv:GainLossOnFairValueOfDebtAndLiabilityInstruments>
    <roiv:GainLossOnFairValueOfDebtAndLiabilityInstruments
      contextRef="P04_01_2020To06_30_2020"
      decimals="-3"
      unitRef="Unit_USD">-17125000</roiv:GainLossOnFairValueOfDebtAndLiabilityInstruments>
    <roiv:GainOrLossOnDeconsolidationOfSubsidiary
      contextRef="P04_01_2021To06_30_2021"
      decimals="-3"
      unitRef="Unit_USD">0</roiv:GainOrLossOnDeconsolidationOfSubsidiary>
    <roiv:GainOrLossOnDeconsolidationOfSubsidiary
      contextRef="P04_01_2020To06_30_2020"
      decimals="-3"
      unitRef="Unit_USD">86516000</roiv:GainOrLossOnDeconsolidationOfSubsidiary>
    <roiv:GainOnTerminationOfEquityInterestOptions
      contextRef="P04_01_2021To06_30_2021"
      decimals="-3"
      unitRef="Unit_USD">61472000</roiv:GainOnTerminationOfEquityInterestOptions>
    <roiv:GainOnTerminationOfEquityInterestOptions
      contextRef="P04_01_2020To06_30_2020"
      decimals="-3"
      unitRef="Unit_USD">0</roiv:GainOnTerminationOfEquityInterestOptions>
    <us-gaap:IncomeLossFromEquityMethodInvestments
      contextRef="P04_01_2021To06_30_2021"
      decimals="-3"
      unitRef="Unit_USD">0</us-gaap:IncomeLossFromEquityMethodInvestments>
    <us-gaap:IncomeLossFromEquityMethodInvestments
      contextRef="P04_01_2020To06_30_2020"
      decimals="-3"
      unitRef="Unit_USD">-3750000</us-gaap:IncomeLossFromEquityMethodInvestments>
    <us-gaap:OtherNoncashIncomeExpense
      contextRef="P04_01_2021To06_30_2021"
      decimals="-3"
      unitRef="Unit_USD">-838000</us-gaap:OtherNoncashIncomeExpense>
    <us-gaap:OtherNoncashIncomeExpense
      contextRef="P04_01_2020To06_30_2020"
      decimals="-3"
      unitRef="Unit_USD">-3307000</us-gaap:OtherNoncashIncomeExpense>
    <us-gaap:IncreaseDecreaseInAccountsPayableTrade
      contextRef="P04_01_2021To06_30_2021"
      decimals="-3"
      unitRef="Unit_USD">-6343000</us-gaap:IncreaseDecreaseInAccountsPayableTrade>
    <us-gaap:IncreaseDecreaseInAccountsPayableTrade
      contextRef="P04_01_2020To06_30_2020"
      decimals="-3"
      unitRef="Unit_USD">7501000</us-gaap:IncreaseDecreaseInAccountsPayableTrade>
    <us-gaap:IncreaseDecreaseInAccruedLiabilities
      contextRef="P04_01_2021To06_30_2021"
      decimals="-3"
      unitRef="Unit_USD">-7340000</us-gaap:IncreaseDecreaseInAccruedLiabilities>
    <us-gaap:IncreaseDecreaseInAccruedLiabilities
      contextRef="P04_01_2020To06_30_2020"
      decimals="-3"
      unitRef="Unit_USD">-15982000</us-gaap:IncreaseDecreaseInAccruedLiabilities>
    <roiv:IncreaseDecreaseInOperatingLeaseLiabilities
      contextRef="P04_01_2021To06_30_2021"
      decimals="-3"
      unitRef="Unit_USD">-1957000</roiv:IncreaseDecreaseInOperatingLeaseLiabilities>
    <roiv:IncreaseDecreaseInOperatingLeaseLiabilities
      contextRef="P04_01_2020To06_30_2020"
      decimals="-3"
      unitRef="Unit_USD">-1769000</roiv:IncreaseDecreaseInOperatingLeaseLiabilities>
    <us-gaap:IncreaseDecreaseInOtherOperatingCapitalNet
      contextRef="P04_01_2021To06_30_2021"
      decimals="-3"
      unitRef="Unit_USD">-3709000</us-gaap:IncreaseDecreaseInOtherOperatingCapitalNet>
    <us-gaap:IncreaseDecreaseInOtherOperatingCapitalNet
      contextRef="P04_01_2020To06_30_2020"
      decimals="-3"
      unitRef="Unit_USD">3736000</us-gaap:IncreaseDecreaseInOtherOperatingCapitalNet>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities
      contextRef="P04_01_2021To06_30_2021"
      decimals="-3"
      unitRef="Unit_USD">-141170000</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities
      contextRef="P04_01_2020To06_30_2020"
      decimals="-3"
      unitRef="Unit_USD">-111167000</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:CashDivestedFromDeconsolidation
      contextRef="P04_01_2021To06_30_2021"
      decimals="-3"
      unitRef="Unit_USD">0</us-gaap:CashDivestedFromDeconsolidation>
    <us-gaap:CashDivestedFromDeconsolidation
      contextRef="P04_01_2020To06_30_2020"
      decimals="-3"
      unitRef="Unit_USD">19085000</us-gaap:CashDivestedFromDeconsolidation>
    <roiv:PaymentsToAcquireInvestmentsInUnconsolidatedEntities
      contextRef="P04_01_2021To06_30_2021"
      decimals="-3"
      unitRef="Unit_USD">0</roiv:PaymentsToAcquireInvestmentsInUnconsolidatedEntities>
    <roiv:PaymentsToAcquireInvestmentsInUnconsolidatedEntities
      contextRef="P04_01_2020To06_30_2020"
      decimals="-3"
      unitRef="Unit_USD">6250000</roiv:PaymentsToAcquireInvestmentsInUnconsolidatedEntities>
    <us-gaap:PaymentsToAcquirePropertyPlantAndEquipment
      contextRef="P04_01_2021To06_30_2021"
      decimals="-3"
      unitRef="Unit_USD">2339000</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
    <us-gaap:PaymentsToAcquirePropertyPlantAndEquipment
      contextRef="P04_01_2020To06_30_2020"
      decimals="-3"
      unitRef="Unit_USD">306000</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
    <us-gaap:NetCashProvidedByUsedInInvestingActivities
      contextRef="P04_01_2021To06_30_2021"
      decimals="-3"
      unitRef="Unit_USD">-2339000</us-gaap:NetCashProvidedByUsedInInvestingActivities>
    <us-gaap:NetCashProvidedByUsedInInvestingActivities
      contextRef="P04_01_2020To06_30_2020"
      decimals="-3"
      unitRef="Unit_USD">-25641000</us-gaap:NetCashProvidedByUsedInInvestingActivities>
    <roiv:ProceedsFromIssuanceOfSubsidiaryCommonSharesNet
      contextRef="P04_01_2021To06_30_2021"
      decimals="-3"
      unitRef="Unit_USD">0</roiv:ProceedsFromIssuanceOfSubsidiaryCommonSharesNet>
    <roiv:ProceedsFromIssuanceOfSubsidiaryCommonSharesNet
      contextRef="P04_01_2020To06_30_2020"
      decimals="-3"
      unitRef="Unit_USD">181180000</roiv:ProceedsFromIssuanceOfSubsidiaryCommonSharesNet>
    <roiv:ProceedsFromSubsidiaryDebtFinancingsNet
      contextRef="P04_01_2021To06_30_2021"
      decimals="-3"
      unitRef="Unit_USD">36400000</roiv:ProceedsFromSubsidiaryDebtFinancingsNet>
    <roiv:ProceedsFromSubsidiaryDebtFinancingsNet
      contextRef="P04_01_2020To06_30_2020"
      decimals="-3"
      unitRef="Unit_USD">0</roiv:ProceedsFromSubsidiaryDebtFinancingsNet>
    <roiv:RepaymentOfLongTermDebtAndConvertibleDebtBySubsidiary
      contextRef="P04_01_2021To06_30_2021"
      decimals="-3"
      unitRef="Unit_USD">21590000</roiv:RepaymentOfLongTermDebtAndConvertibleDebtBySubsidiary>
    <roiv:RepaymentOfLongTermDebtAndConvertibleDebtBySubsidiary
      contextRef="P04_01_2020To06_30_2020"
      decimals="-3"
      unitRef="Unit_USD">0</roiv:RepaymentOfLongTermDebtAndConvertibleDebtBySubsidiary>
    <roiv:PaymentForDebtMaintenanceFeeBySubsidiary
      contextRef="P04_01_2021To06_30_2021"
      decimals="-3"
      unitRef="Unit_USD">-4600000</roiv:PaymentForDebtMaintenanceFeeBySubsidiary>
    <roiv:PaymentForDebtMaintenanceFeeBySubsidiary
      contextRef="P04_01_2020To06_30_2020"
      decimals="-3"
      unitRef="Unit_USD">0</roiv:PaymentForDebtMaintenanceFeeBySubsidiary>
    <us-gaap:PaymentsForRepurchaseOfEquity
      contextRef="P04_01_2021To06_30_2021"
      decimals="-3"
      unitRef="Unit_USD">0</us-gaap:PaymentsForRepurchaseOfEquity>
    <us-gaap:PaymentsForRepurchaseOfEquity
      contextRef="P04_01_2020To06_30_2020"
      decimals="-3"
      unitRef="Unit_USD">113000</us-gaap:PaymentsForRepurchaseOfEquity>
    <us-gaap:ProceedsFromStockOptionsExercised
      contextRef="P04_01_2021To06_30_2021"
      decimals="-3"
      unitRef="Unit_USD">0</us-gaap:ProceedsFromStockOptionsExercised>
    <us-gaap:ProceedsFromStockOptionsExercised
      contextRef="P04_01_2020To06_30_2020"
      decimals="-3"
      unitRef="Unit_USD">63000</us-gaap:ProceedsFromStockOptionsExercised>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities
      contextRef="P04_01_2021To06_30_2021"
      decimals="-3"
      unitRef="Unit_USD">10210000</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities
      contextRef="P04_01_2020To06_30_2020"
      decimals="-3"
      unitRef="Unit_USD">181130000</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect
      contextRef="P04_01_2021To06_30_2021"
      decimals="-3"
      unitRef="Unit_USD">-133299000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect
      contextRef="P04_01_2020To06_30_2020"
      decimals="-3"
      unitRef="Unit_USD">44322000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="PAsOn03_31_2021"
      decimals="-3"
      unitRef="Unit_USD">2141676000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="PAsOn03_31_2020"
      decimals="-3"
      unitRef="Unit_USD">2269252000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="PAsOn06_30_2021"
      decimals="-3"
      unitRef="Unit_USD">2008377000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="PAsOn06_30_2020"
      decimals="-3"
      unitRef="Unit_USD">2313574000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability
      contextRef="P04_01_2021To06_30_2021"
      decimals="-3"
      unitRef="Unit_USD">4579000</us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability>
    <us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability
      contextRef="P04_01_2020To06_30_2020"
      decimals="-3"
      unitRef="Unit_USD">555000</us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability>
    <roiv:IssuanceOfSubsidiaryWarrantInConnectionWithDebtFinancing
      contextRef="P04_01_2021To06_30_2021"
      decimals="-3"
      unitRef="Unit_USD">2075000</roiv:IssuanceOfSubsidiaryWarrantInConnectionWithDebtFinancing>
    <roiv:IssuanceOfSubsidiaryWarrantInConnectionWithDebtFinancing
      contextRef="P04_01_2020To06_30_2020"
      decimals="-3"
      unitRef="Unit_USD">0</roiv:IssuanceOfSubsidiaryWarrantInConnectionWithDebtFinancing>
    <roiv:DeferredOfferingAndFinancingCostsIncludedInAccountsPayableAndAccruedExpenses
      contextRef="P04_01_2021To06_30_2021"
      decimals="-3"
      unitRef="Unit_USD">4999000</roiv:DeferredOfferingAndFinancingCostsIncludedInAccountsPayableAndAccruedExpenses>
    <roiv:DeferredOfferingAndFinancingCostsIncludedInAccountsPayableAndAccruedExpenses
      contextRef="P04_01_2020To06_30_2020"
      decimals="-3"
      unitRef="Unit_USD">0</roiv:DeferredOfferingAndFinancingCostsIncludedInAccountsPayableAndAccruedExpenses>
    <us-gaap:BusinessDescriptionAndBasisOfPresentationTextBlock contextRef="P04_01_2021To06_30_2021">&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt; text-indent: 0px;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Note 1&#x2014;Description of Business and Liquidity&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;(A) Description of Business &lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Roivant Sciences Ltd. (inclusive of its consolidated subsidiaries, the &#x201c;Company&#x201d; or &#x201c;RSL&#x201d;), aims to improve health by rapidly delivering innovative medicines and technologies to patients. The Company does this by building biotech and healthcare technology companies (&#x201c;Vants&#x201d;) and deploying technology to drive greater efficiency in research and development and commercialization. In addition to biopharmaceutical subsidiaries, the Company also builds technology Vants focused on improving the process of developing and commercializing medicines. The Company was founded on April&#160;7, 2014 as a Bermuda exempted limited company. &lt;/div&gt;&lt;/div&gt; &lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;The Company has determined that it has one operating and reporting segment as it allocates resources and assesses financial performance on a consolidated basis. The Company&#x2019;s subsidiaries are wholly owned subsidiaries and majority-owned or controlled subsidiaries. Refer to Note 3, &#x201c;Investments&#x201d; for further discussion of the Company&#x2019;s investments in unconsolidated entities&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;.&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;(B) Liquidity &lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;The Company has incurred significant losses and negative cash flows from operations since its inception. As of June&#160;30, 2021, the Company had cash and cash equivalents of approximately $2.0&#160;billion and its accumulated deficit was approximately $2.0&#160;billion. For the three months ended June&#160;30, 2021 and 2020, the Company incurred net losses of $101.1&#160;million and $8.0&#160;million, respectively. The Company has historically financed its operations primarily through the sale of equity securities, sale of subsidiary interests, debt financings and revenue generated from licensing and collaboration arrangements. The Company has not generated any revenues to date from the sale of its product candidates and does not anticipate generating any revenues from the sale of its product candidates unless and until it successfully completes development and obtains regulatory approval to market its product candidates. Management expects to incur additional losses in the future to fund its operations and conduct product research and development and recognizes the need to raise additional capital to fully implement its business plan. &lt;/div&gt;&lt;/div&gt; &lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;The Company intends to raise such additional capital through the issuance of equity securities, debt financings or other sources in order to further implement its business plan. However, if such financing is not available at adequate levels, the Company will need to reevaluate its operating plan and may be required to delay the development of its product candidates or take other steps to conserve capital. The Company expects its existing cash and cash equivalents will be sufficient to fund its committed operating expenses and capital expenditure requirements for at least the next 12 months from the date of issuance of these condensed consolidated financial statements. &lt;/div&gt;&lt;/div&gt;</us-gaap:BusinessDescriptionAndBasisOfPresentationTextBlock>
    <us-gaap:NumberOfOperatingSegments
      contextRef="P01_01_2021To03_31_2021"
      decimals="INF"
      unitRef="Unit_Segment">1</us-gaap:NumberOfOperatingSegments>
    <us-gaap:NumberOfOperatingSegments
      contextRef="P04_01_2021To06_30_2021"
      decimals="INF"
      unitRef="Unit_Segment">1</us-gaap:NumberOfOperatingSegments>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="PAsOn06_30_2021"
      decimals="-8"
      unitRef="Unit_USD">2000000000.0</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:RetainedEarningsAccumulatedDeficit
      contextRef="PAsOn06_30_2021"
      decimals="-8"
      unitRef="Unit_USD">-2000000000.0</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:ProfitLoss
      contextRef="P04_01_2021To06_30_2021"
      decimals="-5"
      unitRef="Unit_USD">-101100000</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="P04_01_2020To06_30_2020"
      decimals="-5"
      unitRef="Unit_USD">-8000000.0</us-gaap:ProfitLoss>
    <us-gaap:SignificantAccountingPoliciesTextBlock contextRef="P04_01_2021To06_30_2021">&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Note 2&#x2014;Summary of Significant Accounting Policies &lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;(A) Basis of Presentation and Principles of Consolidation &lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;The Company&#x2019;s fiscal year ends on March&#160;31, and its fiscal quarters end on June&#160;30, September&#160;30, and December 31. &lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;The accompanying unaudited condensed consolidated financial statements have been prepared in accordance with accounting principles generally accepted in the United States (&#x201c;U.S. GAAP&#x201d;) for interim financial information and follow the requirements of the Securities and Exchange Commission (&#x201c;SEC&#x201d;) for interim financial reporting. Accordingly, these unaudited condensed consolidated financial statements do not include all of the information and &lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt; &lt;/div&gt; &lt;div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0px;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;disclosures required by U.S. GAAP for complete financial statements as certain footnotes or other financial information that are normally required by U.S. GAAP can be condensed or omitted. The unaudited condensed consolidated financial statements have been prepared on the same basis as the audited consolidated financial statements. &lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;These unaudited condensed consolidated financial statements should be read in conjunction with the Company&#x2019;s audited consolidated financial statements and notes thereto for the fiscal year ended March&#160;31, 2021 issued on June&#160;30, 2021. The unaudited condensed consolidated balance sheet at March&#160;31, 2021 has been derived from the audited consolidated financial statements at that date. In the opinion of management, the unaudited condensed consolidated financial statements include all normal and recurring adjustments that are considered necessary to present fairly the financial position of the Company and its results of operations and cash flows for the interim periods presented. Certain prior year amounts were reclassified to conform to current year presentation. Operating results for the three months ended June&#160;30, 2021 are not necessarily indicative of the results that may be expected for the fiscal year ending March&#160;31, 2022, for any other interim period, or for any other future year. &lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Any references in these notes to applicable accounting guidance are meant to refer to the authoritative U.S. GAAP as found in the Accounting Standards Codification (&#x201c;ASC&#x201d;) and Accounting Standards Updates (&#x201c;ASU&#x201d;) of the Financial Accounting Standards Board (&#x201c;FASB&#x201d;). The unaudited condensed consolidated financial statements include the accounts of RSL and the subsidiaries in which it has a controlling financial interest, most often through a majority voting interest. All intercompany balances and transactions have been eliminated in consolidation. &lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;For consolidated entities where the Company owns or is exposed to less than 100% of the economics, the Company records net loss attributable to noncontrolling interests in its unaudited condensed consolidated statements of operations equal to the percentage of the economic or ownership interest retained in the respective operations by the noncontrolling parties. The Company presents noncontrolling interests as a component of shareholders&#x2019; equity on its unaudited condensed consolidated balance sheets. &lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;The Company accounts for changes in its ownership interest in its subsidiaries while control is retained as equity transactions. The carrying amount of the noncontrolling interest is adjusted to reflect the change in RSL&#x2019;s ownership interest in the subsidiary. Any difference between the fair value of the consideration received or paid and the amount by which the noncontrolling interest is adjusted is recognized within shareholders&#x2019; equity attributable to RSL. &lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;There have been no significant changes in the Company&#x2019;s accounting policies from those disclosed in the Company&#x2019;s audited consolidated financial statements for the fiscal year ended March&#160;31, 2021 issued on June&#160;30, 2021. &lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;In April 2012, the Jumpstart Our Business Startups Act of 2012 (the &#x201c;JOBS Act&#x201d;) was enacted. Section&#160;107(b) of the JOBS Act provides that an emerging growth company can take advantage of an extended transition period for complying with new or revised accounting standards. Thus, an emerging growth company can delay the adoption of certain accounting standards until those standards would otherwise apply to private companies. The Company has irrevocably elected not to avail itself of this extended transition period, and, as a result, the Company will adopt new or revised accounting standards on the relevant dates on which adoption of such standards is required for other public companies. &lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt; &lt;/div&gt;  &lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt; text-indent: 0px;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;(B) Use of Estimates &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;The preparation of financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the amounts reported in the financial statements and accompanying notes. The Company regularly evaluates estimates and assumptions related to assets, liabilities, costs, expenses,&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;  &lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0px;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;contingent liabilities, share-based compensation and research and development costs. The Company bases its estimates and assumptions on historical experience and on various other factors that it believes to be reasonable under the circumstances, the results of which form the basis for making judgments about the carrying values of assets and liabilities that are not readily apparent from other sources. Actual results could differ from those estimates. &lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;Additionally, the Company assessed the impact that the &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;COVID-19&lt;/div&gt; pandemic has had on its operations and financial results as of June&#160;30, 2021 and through the issuance of these condensed consolidated financial statements. The Company&#x2019;s analysis was informed by the facts and circumstances as they were known to the Company. This assessment considered the impact &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;COVID-19&lt;/div&gt; may have on financial estimates and assumptions that affect the reported amounts of assets and liabilities and expenses. &lt;/div&gt;&lt;/div&gt;  &lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt; text-indent: 0px;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;(C) Risks and Uncertainties &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;The Company is subject to risks common to companies in the biopharmaceutical industry including, but not limited to, uncertainties related to commercialization of products, regulatory approvals, dependence on key products, dependence on third-party service providers, such as contract research organizations, and protection of intellectual property rights. &lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt; &lt;/div&gt; &lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt; text-indent: 0px;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;(D) Concentrations of Credit Risk &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Financial instruments that potentially subject the Company to concentration of credit risk include cash and cash equivalents. The Company maintains cash deposits and cash equivalents in highly-rated, federally-insured financial institutions in excess of federally insured limits. The Company has established guidelines relative to diversification and maturities to maintain safety and liquidity. The Company has not experienced any credit losses related to these financial instruments and does not believe that it is exposed to any significant credit risk related to these instruments. &lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt; &lt;/div&gt; &lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;(E) Cash, Cash Equivalents, and Restricted Cash &lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Cash and cash equivalents include cash deposits in banks and all highly liquid investments that are readily convertible to cash. The Company considers all highly liquid investments purchased with original maturities of three months or less to be cash equivalents. &lt;/div&gt;&lt;/div&gt; &lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;Restricted cash classified as a current asset consists of legally restricted &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;non-interest&lt;/div&gt; bearing deposit accounts relating to the Company&#x2019;s corporate credit card programs. Restricted cash classified as a long-term asset consists of restricted deposit accounts related to irrevocable standby letters of credit. As of March&#160;31, 2021, restricted cash classified as a current asset included $75.0&#160;million held in escrow for the purpose of fulfilling certain indemnification obligations. The full escrow amount of $75.0&#160;million was disbursed to the Company in June 2021. See Note 4, &#x201c;Sumitomo Transaction Agreement&#x201d; for additional information. &lt;/div&gt; &lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Cash as reported in the condensed consolidated statements of cash flows includes the aggregate amounts of cash, cash equivalents, and restricted cash as presented on the condensed consolidated balance sheets as follows (in thousands): &lt;/div&gt;&lt;/div&gt; &lt;div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;width:76%;"&gt;
&lt;tr style="font-size: 0px;"&gt;
&lt;td style="width: 64%;"/&gt;
&lt;td style="width: 7%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="width: 7%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;June&#160;30,&#160;2021&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;March&#160;31,&#160;2021&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top; width: 64%;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Cash and cash equivalents&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 7%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;1,996,733&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 7%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;2,055,044&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top; width: 64%;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Restricted cash&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 7%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;11,644&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 7%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;86,632&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; width: 64%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 7%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 7%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top; width: 64%;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Cash, cash equivalents and restricted cash&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 7%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;2,008,377&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 7%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;2,141,676&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; width: 64%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 7%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 7%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt; &lt;/tr&gt; &lt;/table&gt;
&lt;table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 76%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px; text-indent: 0px;"&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td/&gt; &lt;/tr&gt; &lt;/table&gt; &lt;div style="clear: both; max-height: 0px; text-indent: 0px;"/&gt; &lt;div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0px;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;  &lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0px;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;(F) Contingencies &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;The Company may be, from time to time, a party to various disputes and claims arising from normal business activities. The Company continually assesses any litigation or other claims it may confront to determine if an unfavorable outcome would lead to a probable loss or reasonably possible loss which could be estimated. The Company accrues for all contingencies at the earliest date at which the Company deems it probable that a liability has been incurred and the amount of such liability can be reasonably estimated. If the estimate of a probable loss is a range and no amount within the range is more likely than another, the Company accrues the minimum of the range. In the cases where the Company believes that a reasonably possible loss exists, the Company discloses the facts and circumstances of the litigation, including an estimable range, if possible&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;.&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt; text-indent: 0px;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;(G) Investments &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;For investments in entities over which the Company has significant influence but do not meet the requirements for consolidation and for which the Company has not elected the fair value option, the Company applies the equity method of accounting with the Company&#x2019;s share of the underlying income or loss of such entities reported in &#x201c;Other (income) expense, net&#x201d; on the condensed consolidated statements of operations. The Company applies the equity method to investments in common stock and to other investments in entities that have risk and reward characteristics that are substantially similar to an investment in the investee&#x2019;s common stock. &lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Investments in equity securities may also be accounted for using (i)&#160;the fair value option if elected, (ii)&#160;fair value through earnings if fair value is readily determinable or (iii)&#160;for equity investments without readily determinable fair values, the measurement alternative to measure at cost adjusted for any impairment and observable price changes, as applicable. The election to use the measurement alternative is made for each eligible investment. &lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt; &lt;/div&gt; &lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;The Company has elected the fair value option to account for certain investments over which the Company has significant influence. The Company believes the fair value option best reflects the underlying economics of the investment. See Note 3, &#x201c;Investments.&#x201d; &lt;/div&gt;&lt;/div&gt; &lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;(H) Research and Development&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;Expenses &lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;Research and development (&#x201c;R&amp;amp;D&#x201d;) costs are expensed as incurred. Preclinical and clinical study costs are accrued over the service periods specified in the contracts and adjusted as necessary based upon an ongoing &lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;review &lt;/div&gt;of the &lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;level &lt;/div&gt;of &lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;effort &lt;/div&gt;and costs&lt;/div&gt; actually incurred. Payments for a product license prior to regulatory approval of the product and payments for milestones achieved prior to regulatory approval of the product are expensed in the period incurred as R&amp;amp;D. Milestone payments made in connection &lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;with &lt;/div&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;regulatory &lt;/div&gt;approvals are capitalized and amortized to cost of revenue over the remaining useful life of the asset. R&amp;amp;D costs primarily consist of the intellectual property and R&amp;amp;D materials acquired and expenses from third parties who conduct R&amp;amp;D activities on behalf of the &lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;Company&lt;/div&gt;.&lt;/div&gt; &lt;/div&gt;&lt;/div&gt; &lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;The Company evaluates &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;in-licensed&lt;/div&gt; agreements for &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;in-process&lt;/div&gt; research and development projects (&#x201c;IPR&amp;amp;D&#x201d;) to determine if it meets the definition of a business and thus should be accounted for as a business combination. If the &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;in-licensed&lt;/div&gt; agreement for IPR&amp;amp;D does not meet the definition of a business and the assets have not reached technological feasibility and therefore have no alternative future use, the Company expenses payments made under such license agreements as R&amp;amp;D expense in its condensed consolidated statements of operations. The Company initially recognizes contingent consideration in an asset acquisition at fair value. The carrying value of contingent consideration is subsequently adjusted when the contingency is resolved and is paid or becomes payable. &lt;/div&gt;&lt;/div&gt; &lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0px;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;(I) Fair Value Measurements &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;The Company utilizes fair value measurement guidance prescribed by accounting standards to value its financial instruments. The guidance establishes a fair value hierarchy for financial instruments measured at fair value that distinguishes between assumptions based on market data (observable inputs) and the Company&#x2019;s own assumptions (unobservable inputs). Observable inputs are inputs that market participants would use in pricing the asset or liability based on market data obtained from sources independent of the Company. Unobservable inputs are inputs that reflect the Company&#x2019;s assumptions about the inputs that market participants would use in pricing the asset or liability, and are developed based on the best information available in the circumstances. Fair value is defined as the exchange price, or exit price, representing the amount that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants at the reporting date. As a basis for considering market participant assumptions in fair value measurements, the guidance establishes a three-tier fair value hierarchy that distinguishes among the following: &lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0px;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px; text-indent: 0px;;width:100%;"&gt;
&lt;tr style="page-break-inside: avoid;"&gt;
&lt;td style="width: 4%;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="width: 4%; vertical-align: top;;text-align:left;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#x2022;&lt;/div&gt;&lt;/td&gt;
&lt;td style="width: 1%; vertical-align: top;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: top;;text-align:left;"&gt; &lt;div style="text-align: left; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;Level &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;1-Valuations&lt;/div&gt; are based on unadjusted quoted prices in active markets for identical assets or liabilities that the Company has the ability to access. &lt;/div&gt;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; &lt;div style="clear: both; max-height: 0px; text-indent: 0px;"/&gt; &lt;div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0px;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px; text-indent: 0px;;width:100%;"&gt;
&lt;tr style="page-break-inside: avoid;"&gt;
&lt;td style="width: 4%;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="width: 4%; vertical-align: top;;text-align:left;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#x2022;&lt;/div&gt;&lt;/td&gt;
&lt;td style="width: 1%; vertical-align: top;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: top;;text-align:left;"&gt; &lt;div style="text-align: left; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;Level &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;2-Valuations&lt;/div&gt; are based on quoted prices for similar assets or liabilities in active markets, quoted prices for identical or similar assets or liabilities in markets that are not active and models for which all significant inputs are observable, either directly or indirectly. &lt;/div&gt;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; &lt;div style="clear: both; max-height: 0px; text-indent: 0px;"/&gt; &lt;div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0px;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px; text-indent: 0px;;width:100%;"&gt;
&lt;tr style="page-break-inside: avoid;"&gt;
&lt;td style="width: 4%;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="width: 4%; vertical-align: top;;text-align:left;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#x2022;&lt;/div&gt;&lt;/td&gt;
&lt;td style="width: 1%; vertical-align: top;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: top;;text-align:left;"&gt; &lt;div style="text-align: left; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;Level &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;3-Valuations&lt;/div&gt; are based on inputs that are unobservable (supported by little or no market activity) and significant to the overall fair value measurement. &lt;/div&gt;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; &lt;div style="clear: both; max-height: 0px; text-indent: 0px;"/&gt; &lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;To the extent the valuation is based on models or inputs that are less observable or unobservable in the market, the determination of fair value requires more judgment. Accordingly, the degree of judgment exercised by the Company in determining fair value is greatest for instruments categorized in Level&#160;3. A financial instrument&#x2019;s level within the fair value hierarchy is based on the lowest level of any input that is significant to the fair value measurement. &lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;The Company&#x2019;s financial instruments include shares of common stock of Arbutus Biopharma Corporation (&#x201c;Arbutus&#x201d;); shares of Arbutus&#x2019;s Series A participating convertible preferred shares (&#x201c;Arbutus Preferred Shares&#x201d;); shares of common stock of Sio Gene Therapies Inc. (&#x201c;Sio&#x201d;); liability instruments issued; deferred consideration liability; its investments in other entities; cash and cash equivalents consisting of money market funds; accounts payable; and long-term debt. &lt;/div&gt;&lt;/div&gt; &lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;The shares of Arbutus and Sio common stock and investments in common stock with a readily determinable fair value are classified as Level&#160;1, and their fair value is determined based upon quoted market prices in an active market. The Arbutus Preferred Shares held by the Company are classified as Level&#160;2 as the fair value of such preferred shares is determined based upon the quoted market price of Arbutus common stock into which such preferred shares are convertible. The liability instruments issued are classified as Level&#160;3 within the fair value hierarchy as the assumptions and estimates used in the valuations are unobservable in the market. Cash, accounts payable, and deferred consideration liability are stated at their respective historical carrying amounts, which approximate fair value due to their short-term nature. The deferred consideration liability is based on a fixed monetary amount, and payment is based solely on the passage of time. Money market funds are included in &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Level-1&lt;/div&gt; of the fair value hierarchy and are valued at the closing price reported by an actively traded exchange. The carrying value of long-term debt issued by Dermavant Sciences Ltd. (together with its wholly owned subsidiaries, &#x201c;Dermavant&#x201d;), which is stated at amortized cost, approximates fair value based on current interest rates for similar types of borrowings and therefore is included in Level&#160;2 of the fair value hierarchy. Long-term debt issued by Dermavant for which the fair value option has been elected is included in Level&#160;3 of the fair value hierarchy as the assumptions and estimates used in the valuation are unobservable in the market. &lt;/div&gt;&lt;/div&gt;  &lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0px;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;(J) Recently Adopted Accounting Pronouncements &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;In August 2020, the FASB issued ASU &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;No.&#160;2020-06,&lt;/div&gt; &#x201c;Debt&#x2014;Debt with Conversion and Other Options (Subtopic &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;470-20)&lt;/div&gt; and Derivatives and Hedging&#x2014;Contracts in Entity&#x2019;s Own Equity (Subtopic &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;815-40):&lt;/div&gt; Accounting for Convertible Instruments and Contracts in an Entity&#x2019;s Own Equity&#x201d; (&#x201c;ASU &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;No.&#160;2020-06&#x201d;).&lt;/div&gt; ASU &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;No.&#160;2020-06&lt;/div&gt; will simplify the accounting for convertible instruments by reducing the number of accounting models for convertible debt instruments and convertible preferred stock. Limiting the accounting models will result in fewer embedded conversion features being separately recognized from the host contract as compared with current U.S. GAAP. ASU &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;No.&#160;2020-06&lt;/div&gt; also removes certain settlement conditions that are required for equity contracts to qualify for the derivatives scope exception, which will permit more equity contracts to qualify for it. Either a modified retrospective transition method or a fully retrospective transition method is permissible for the adoption of this standard. Update &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;No.&#160;2020-06&lt;/div&gt; is effective for fiscal years beginning after December&#160;15, 2021, including interim periods within those fiscal years. The early-adoption of ASU &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;No.&#160;2020-06&lt;/div&gt; on April&#160;1, 2021 did not have a material impact on the Company&#x2019;s unaudited condensed consolidated financial statements. &lt;/div&gt;</us-gaap:SignificantAccountingPoliciesTextBlock>
    <us-gaap:BasisOfAccountingPolicyPolicyTextBlock contextRef="P04_01_2021To06_30_2021">&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;(A) Basis of Presentation and Principles of Consolidation &lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;The Company&#x2019;s fiscal year ends on March&#160;31, and its fiscal quarters end on June&#160;30, September&#160;30, and December 31. &lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;The accompanying unaudited condensed consolidated financial statements have been prepared in accordance with accounting principles generally accepted in the United States (&#x201c;U.S. GAAP&#x201d;) for interim financial information and follow the requirements of the Securities and Exchange Commission (&#x201c;SEC&#x201d;) for interim financial reporting. Accordingly, these unaudited condensed consolidated financial statements do not include all of the information and &lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt; &lt;/div&gt; &lt;div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0px;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;disclosures required by U.S. GAAP for complete financial statements as certain footnotes or other financial information that are normally required by U.S. GAAP can be condensed or omitted. The unaudited condensed consolidated financial statements have been prepared on the same basis as the audited consolidated financial statements. &lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;These unaudited condensed consolidated financial statements should be read in conjunction with the Company&#x2019;s audited consolidated financial statements and notes thereto for the fiscal year ended March&#160;31, 2021 issued on June&#160;30, 2021. The unaudited condensed consolidated balance sheet at March&#160;31, 2021 has been derived from the audited consolidated financial statements at that date. In the opinion of management, the unaudited condensed consolidated financial statements include all normal and recurring adjustments that are considered necessary to present fairly the financial position of the Company and its results of operations and cash flows for the interim periods presented. Certain prior year amounts were reclassified to conform to current year presentation. Operating results for the three months ended June&#160;30, 2021 are not necessarily indicative of the results that may be expected for the fiscal year ending March&#160;31, 2022, for any other interim period, or for any other future year. &lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Any references in these notes to applicable accounting guidance are meant to refer to the authoritative U.S. GAAP as found in the Accounting Standards Codification (&#x201c;ASC&#x201d;) and Accounting Standards Updates (&#x201c;ASU&#x201d;) of the Financial Accounting Standards Board (&#x201c;FASB&#x201d;). The unaudited condensed consolidated financial statements include the accounts of RSL and the subsidiaries in which it has a controlling financial interest, most often through a majority voting interest. All intercompany balances and transactions have been eliminated in consolidation. &lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;For consolidated entities where the Company owns or is exposed to less than 100% of the economics, the Company records net loss attributable to noncontrolling interests in its unaudited condensed consolidated statements of operations equal to the percentage of the economic or ownership interest retained in the respective operations by the noncontrolling parties. The Company presents noncontrolling interests as a component of shareholders&#x2019; equity on its unaudited condensed consolidated balance sheets. &lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;The Company accounts for changes in its ownership interest in its subsidiaries while control is retained as equity transactions. The carrying amount of the noncontrolling interest is adjusted to reflect the change in RSL&#x2019;s ownership interest in the subsidiary. Any difference between the fair value of the consideration received or paid and the amount by which the noncontrolling interest is adjusted is recognized within shareholders&#x2019; equity attributable to RSL. &lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;There have been no significant changes in the Company&#x2019;s accounting policies from those disclosed in the Company&#x2019;s audited consolidated financial statements for the fiscal year ended March&#160;31, 2021 issued on June&#160;30, 2021. &lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;In April 2012, the Jumpstart Our Business Startups Act of 2012 (the &#x201c;JOBS Act&#x201d;) was enacted. Section&#160;107(b) of the JOBS Act provides that an emerging growth company can take advantage of an extended transition period for complying with new or revised accounting standards. Thus, an emerging growth company can delay the adoption of certain accounting standards until those standards would otherwise apply to private companies. The Company has irrevocably elected not to avail itself of this extended transition period, and, as a result, the Company will adopt new or revised accounting standards on the relevant dates on which adoption of such standards is required for other public companies. &lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt; &lt;/div&gt; </us-gaap:BasisOfAccountingPolicyPolicyTextBlock>
    <us-gaap:UseOfEstimates contextRef="P04_01_2021To06_30_2021">&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt; text-indent: 0px;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;(B) Use of Estimates &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;The preparation of financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the amounts reported in the financial statements and accompanying notes. The Company regularly evaluates estimates and assumptions related to assets, liabilities, costs, expenses,&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0px;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;contingent liabilities, share-based compensation and research and development costs. The Company bases its estimates and assumptions on historical experience and on various other factors that it believes to be reasonable under the circumstances, the results of which form the basis for making judgments about the carrying values of assets and liabilities that are not readily apparent from other sources. Actual results could differ from those estimates. &lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;Additionally, the Company assessed the impact that the &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;COVID-19&lt;/div&gt; pandemic has had on its operations and financial results as of June&#160;30, 2021 and through the issuance of these condensed consolidated financial statements. The Company&#x2019;s analysis was informed by the facts and circumstances as they were known to the Company. This assessment considered the impact &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;COVID-19&lt;/div&gt; may have on financial estimates and assumptions that affect the reported amounts of assets and liabilities and expenses. &lt;/div&gt;&lt;/div&gt; </us-gaap:UseOfEstimates>
    <us-gaap:UnusualRisksAndUncertaintiesTextBlock contextRef="P04_01_2021To06_30_2021">&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt; text-indent: 0px;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;(C) Risks and Uncertainties &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;The Company is subject to risks common to companies in the biopharmaceutical industry including, but not limited to, uncertainties related to commercialization of products, regulatory approvals, dependence on key products, dependence on third-party service providers, such as contract research organizations, and protection of intellectual property rights. &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:UnusualRisksAndUncertaintiesTextBlock>
    <us-gaap:ConcentrationRiskCreditRisk contextRef="P04_01_2021To06_30_2021">&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt; text-indent: 0px;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;(D) Concentrations of Credit Risk &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Financial instruments that potentially subject the Company to concentration of credit risk include cash and cash equivalents. The Company maintains cash deposits and cash equivalents in highly-rated, federally-insured financial institutions in excess of federally insured limits. The Company has established guidelines relative to diversification and maturities to maintain safety and liquidity. The Company has not experienced any credit losses related to these financial instruments and does not believe that it is exposed to any significant credit risk related to these instruments. &lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt; &lt;/div&gt;</us-gaap:ConcentrationRiskCreditRisk>
    <us-gaap:CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy contextRef="P04_01_2021To06_30_2021">&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;(E) Cash, Cash Equivalents, and Restricted Cash &lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Cash and cash equivalents include cash deposits in banks and all highly liquid investments that are readily convertible to cash. The Company considers all highly liquid investments purchased with original maturities of three months or less to be cash equivalents. &lt;/div&gt;&lt;/div&gt; &lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;Restricted cash classified as a current asset consists of legally restricted &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;non-interest&lt;/div&gt; bearing deposit accounts relating to the Company&#x2019;s corporate credit card programs. Restricted cash classified as a long-term asset consists of restricted deposit accounts related to irrevocable standby letters of credit. As of March&#160;31, 2021, restricted cash classified as a current asset included $75.0&#160;million held in escrow for the purpose of fulfilling certain indemnification obligations. The full escrow amount of $75.0&#160;million was disbursed to the Company in June 2021. See Note 4, &#x201c;Sumitomo Transaction Agreement&#x201d; for additional information. &lt;/div&gt; &lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Cash as reported in the condensed consolidated statements of cash flows includes the aggregate amounts of cash, cash equivalents, and restricted cash as presented on the condensed consolidated balance sheets as follows (in thousands): &lt;/div&gt;&lt;/div&gt; &lt;div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;width:76%;"&gt;
&lt;tr style="font-size: 0px;"&gt;
&lt;td style="width: 64%;"/&gt;
&lt;td style="width: 7%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="width: 7%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;June&#160;30,&#160;2021&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;March&#160;31,&#160;2021&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top; width: 64%;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Cash and cash equivalents&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 7%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;1,996,733&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 7%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;2,055,044&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top; width: 64%;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Restricted cash&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 7%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;11,644&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 7%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;86,632&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; width: 64%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 7%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 7%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top; width: 64%;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Cash, cash equivalents and restricted cash&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 7%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;2,008,377&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 7%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;2,141,676&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; width: 64%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 7%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 7%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; </us-gaap:CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy>
    <us-gaap:EscrowDeposit
      contextRef="PAsOn03_31_2021"
      decimals="-5"
      unitRef="Unit_USD">75000000.0</us-gaap:EscrowDeposit>
    <roiv:ProceedsFromReleaseOfEscrowDeposit
      contextRef="PAsOn06_30_2021"
      decimals="-5"
      unitRef="Unit_USD">75000000.0</roiv:ProceedsFromReleaseOfEscrowDeposit>
    <us-gaap:ScheduleOfCashAndCashEquivalentsTableTextBlock contextRef="P04_01_2021To06_30_2021">&lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Cash as reported in the condensed consolidated statements of cash flows includes the aggregate amounts of cash, cash equivalents, and restricted cash as presented on the condensed consolidated balance sheets as follows (in thousands): &lt;/div&gt;&lt;/div&gt; &lt;div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;width:76%;"&gt;
&lt;tr style="font-size: 0px;"&gt;
&lt;td style="width: 64%;"/&gt;
&lt;td style="width: 7%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="width: 7%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;June&#160;30,&#160;2021&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;March&#160;31,&#160;2021&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top; width: 64%;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Cash and cash equivalents&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 7%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;1,996,733&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 7%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;2,055,044&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top; width: 64%;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Restricted cash&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 7%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;11,644&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 7%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;86,632&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; width: 64%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 7%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 7%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top; width: 64%;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Cash, cash equivalents and restricted cash&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 7%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;2,008,377&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 7%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;2,141,676&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; width: 64%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 7%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 7%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; </us-gaap:ScheduleOfCashAndCashEquivalentsTableTextBlock>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="PAsOn06_30_2021"
      decimals="-3"
      unitRef="Unit_USD">1996733000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="PAsOn03_31_2021"
      decimals="-3"
      unitRef="Unit_USD">2055044000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:RestrictedCash
      contextRef="PAsOn06_30_2021"
      decimals="-3"
      unitRef="Unit_USD">11644000</us-gaap:RestrictedCash>
    <us-gaap:RestrictedCash
      contextRef="PAsOn03_31_2021"
      decimals="-3"
      unitRef="Unit_USD">86632000</us-gaap:RestrictedCash>
    <roiv:CashAndCashEquivalentsAndRestrictedCash
      contextRef="PAsOn06_30_2021"
      decimals="-3"
      unitRef="Unit_USD">2008377000</roiv:CashAndCashEquivalentsAndRestrictedCash>
    <roiv:CashAndCashEquivalentsAndRestrictedCash
      contextRef="PAsOn03_31_2021"
      decimals="-3"
      unitRef="Unit_USD">2141676000</roiv:CashAndCashEquivalentsAndRestrictedCash>
    <us-gaap:CommitmentsAndContingenciesPolicyTextBlock contextRef="P04_01_2021To06_30_2021">&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0px;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;(F) Contingencies &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;The Company may be, from time to time, a party to various disputes and claims arising from normal business activities. The Company continually assesses any litigation or other claims it may confront to determine if an unfavorable outcome would lead to a probable loss or reasonably possible loss which could be estimated. The Company accrues for all contingencies at the earliest date at which the Company deems it probable that a liability has been incurred and the amount of such liability can be reasonably estimated. If the estimate of a probable loss is a range and no amount within the range is more likely than another, the Company accrues the minimum of the range. In the cases where the Company believes that a reasonably possible loss exists, the Company discloses the facts and circumstances of the litigation, including an estimable range, if possible&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;.&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:CommitmentsAndContingenciesPolicyTextBlock>
    <us-gaap:InvestmentPolicyTextBlock contextRef="P04_01_2021To06_30_2021">&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt; text-indent: 0px;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;(G) Investments &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;For investments in entities over which the Company has significant influence but do not meet the requirements for consolidation and for which the Company has not elected the fair value option, the Company applies the equity method of accounting with the Company&#x2019;s share of the underlying income or loss of such entities reported in &#x201c;Other (income) expense, net&#x201d; on the condensed consolidated statements of operations. The Company applies the equity method to investments in common stock and to other investments in entities that have risk and reward characteristics that are substantially similar to an investment in the investee&#x2019;s common stock. &lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Investments in equity securities may also be accounted for using (i)&#160;the fair value option if elected, (ii)&#160;fair value through earnings if fair value is readily determinable or (iii)&#160;for equity investments without readily determinable fair values, the measurement alternative to measure at cost adjusted for any impairment and observable price changes, as applicable. The election to use the measurement alternative is made for each eligible investment. &lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt; &lt;/div&gt; &lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;The Company has elected the fair value option to account for certain investments over which the Company has significant influence. The Company believes the fair value option best reflects the underlying economics of the investment. See Note 3, &#x201c;Investments.&#x201d; &lt;/div&gt;&lt;/div&gt;</us-gaap:InvestmentPolicyTextBlock>
    <us-gaap:ResearchAndDevelopmentExpensePolicy contextRef="P04_01_2021To06_30_2021">&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;(H) Research and Development&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;Expenses &lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;Research and development (&#x201c;R&amp;amp;D&#x201d;) costs are expensed as incurred. Preclinical and clinical study costs are accrued over the service periods specified in the contracts and adjusted as necessary based upon an ongoing &lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;review &lt;/div&gt;of the &lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;level &lt;/div&gt;of &lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;effort &lt;/div&gt;and costs&lt;/div&gt; actually incurred. Payments for a product license prior to regulatory approval of the product and payments for milestones achieved prior to regulatory approval of the product are expensed in the period incurred as R&amp;amp;D. Milestone payments made in connection &lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;with &lt;/div&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;regulatory &lt;/div&gt;approvals are capitalized and amortized to cost of revenue over the remaining useful life of the asset. R&amp;amp;D costs primarily consist of the intellectual property and R&amp;amp;D materials acquired and expenses from third parties who conduct R&amp;amp;D activities on behalf of the &lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;Company&lt;/div&gt;.&lt;/div&gt; &lt;/div&gt;&lt;/div&gt; &lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;The Company evaluates &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;in-licensed&lt;/div&gt; agreements for &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;in-process&lt;/div&gt; research and development projects (&#x201c;IPR&amp;amp;D&#x201d;) to determine if it meets the definition of a business and thus should be accounted for as a business combination. If the &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;in-licensed&lt;/div&gt; agreement for IPR&amp;amp;D does not meet the definition of a business and the assets have not reached technological feasibility and therefore have no alternative future use, the Company expenses payments made under such license agreements as R&amp;amp;D expense in its condensed consolidated statements of operations. The Company initially recognizes contingent consideration in an asset acquisition at fair value. The carrying value of contingent consideration is subsequently adjusted when the contingency is resolved and is paid or becomes payable. &lt;/div&gt;&lt;/div&gt;</us-gaap:ResearchAndDevelopmentExpensePolicy>
    <us-gaap:FairValueMeasurementPolicyPolicyTextBlock contextRef="P04_01_2021To06_30_2021">&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0px;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;(I) Fair Value Measurements &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;The Company utilizes fair value measurement guidance prescribed by accounting standards to value its financial instruments. The guidance establishes a fair value hierarchy for financial instruments measured at fair value that distinguishes between assumptions based on market data (observable inputs) and the Company&#x2019;s own assumptions (unobservable inputs). Observable inputs are inputs that market participants would use in pricing the asset or liability based on market data obtained from sources independent of the Company. Unobservable inputs are inputs that reflect the Company&#x2019;s assumptions about the inputs that market participants would use in pricing the asset or liability, and are developed based on the best information available in the circumstances. Fair value is defined as the exchange price, or exit price, representing the amount that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants at the reporting date. As a basis for considering market participant assumptions in fair value measurements, the guidance establishes a three-tier fair value hierarchy that distinguishes among the following: &lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0px;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px; text-indent: 0px;;width:100%;"&gt;
&lt;tr style="page-break-inside: avoid;"&gt;
&lt;td style="width: 4%;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="width: 4%; vertical-align: top;;text-align:left;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#x2022;&lt;/div&gt;&lt;/td&gt;
&lt;td style="width: 1%; vertical-align: top;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: top;;text-align:left;"&gt; &lt;div style="text-align: left; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;Level &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;1-Valuations&lt;/div&gt; are based on unadjusted quoted prices in active markets for identical assets or liabilities that the Company has the ability to access. &lt;/div&gt;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; &lt;div style="clear: both; max-height: 0px; text-indent: 0px;"/&gt; &lt;div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0px;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px; text-indent: 0px;;width:100%;"&gt;
&lt;tr style="page-break-inside: avoid;"&gt;
&lt;td style="width: 4%;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="width: 4%; vertical-align: top;;text-align:left;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#x2022;&lt;/div&gt;&lt;/td&gt;
&lt;td style="width: 1%; vertical-align: top;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: top;;text-align:left;"&gt; &lt;div style="text-align: left; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;Level &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;2-Valuations&lt;/div&gt; are based on quoted prices for similar assets or liabilities in active markets, quoted prices for identical or similar assets or liabilities in markets that are not active and models for which all significant inputs are observable, either directly or indirectly. &lt;/div&gt;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; &lt;div style="clear: both; max-height: 0px; text-indent: 0px;"/&gt; &lt;div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0px;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px; text-indent: 0px;;width:100%;"&gt;
&lt;tr style="page-break-inside: avoid;"&gt;
&lt;td style="width: 4%;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="width: 4%; vertical-align: top;;text-align:left;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#x2022;&lt;/div&gt;&lt;/td&gt;
&lt;td style="width: 1%; vertical-align: top;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: top;;text-align:left;"&gt; &lt;div style="text-align: left; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;Level &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;3-Valuations&lt;/div&gt; are based on inputs that are unobservable (supported by little or no market activity) and significant to the overall fair value measurement. &lt;/div&gt;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; &lt;div style="clear: both; max-height: 0px; text-indent: 0px;"/&gt; &lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;To the extent the valuation is based on models or inputs that are less observable or unobservable in the market, the determination of fair value requires more judgment. Accordingly, the degree of judgment exercised by the Company in determining fair value is greatest for instruments categorized in Level&#160;3. A financial instrument&#x2019;s level within the fair value hierarchy is based on the lowest level of any input that is significant to the fair value measurement. &lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;The Company&#x2019;s financial instruments include shares of common stock of Arbutus Biopharma Corporation (&#x201c;Arbutus&#x201d;); shares of Arbutus&#x2019;s Series A participating convertible preferred shares (&#x201c;Arbutus Preferred Shares&#x201d;); shares of common stock of Sio Gene Therapies Inc. (&#x201c;Sio&#x201d;); liability instruments issued; deferred consideration liability; its investments in other entities; cash and cash equivalents consisting of money market funds; accounts payable; and long-term debt. &lt;/div&gt;&lt;/div&gt; &lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;The shares of Arbutus and Sio common stock and investments in common stock with a readily determinable fair value are classified as Level&#160;1, and their fair value is determined based upon quoted market prices in an active market. The Arbutus Preferred Shares held by the Company are classified as Level&#160;2 as the fair value of such preferred shares is determined based upon the quoted market price of Arbutus common stock into which such preferred shares are convertible. The liability instruments issued are classified as Level&#160;3 within the fair value hierarchy as the assumptions and estimates used in the valuations are unobservable in the market. Cash, accounts payable, and deferred consideration liability are stated at their respective historical carrying amounts, which approximate fair value due to their short-term nature. The deferred consideration liability is based on a fixed monetary amount, and payment is based solely on the passage of time. Money market funds are included in &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Level-1&lt;/div&gt; of the fair value hierarchy and are valued at the closing price reported by an actively traded exchange. The carrying value of long-term debt issued by Dermavant Sciences Ltd. (together with its wholly owned subsidiaries, &#x201c;Dermavant&#x201d;), which is stated at amortized cost, approximates fair value based on current interest rates for similar types of borrowings and therefore is included in Level&#160;2 of the fair value hierarchy. Long-term debt issued by Dermavant for which the fair value option has been elected is included in Level&#160;3 of the fair value hierarchy as the assumptions and estimates used in the valuation are unobservable in the market. &lt;/div&gt;&lt;/div&gt; </us-gaap:FairValueMeasurementPolicyPolicyTextBlock>
    <us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock contextRef="P04_01_2021To06_30_2021">&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0px;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;(J) Recently Adopted Accounting Pronouncements &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;In August 2020, the FASB issued ASU &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;No.&#160;2020-06,&lt;/div&gt; &#x201c;Debt&#x2014;Debt with Conversion and Other Options (Subtopic &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;470-20)&lt;/div&gt; and Derivatives and Hedging&#x2014;Contracts in Entity&#x2019;s Own Equity (Subtopic &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;815-40):&lt;/div&gt; Accounting for Convertible Instruments and Contracts in an Entity&#x2019;s Own Equity&#x201d; (&#x201c;ASU &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;No.&#160;2020-06&#x201d;).&lt;/div&gt; ASU &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;No.&#160;2020-06&lt;/div&gt; will simplify the accounting for convertible instruments by reducing the number of accounting models for convertible debt instruments and convertible preferred stock. Limiting the accounting models will result in fewer embedded conversion features being separately recognized from the host contract as compared with current U.S. GAAP. ASU &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;No.&#160;2020-06&lt;/div&gt; also removes certain settlement conditions that are required for equity contracts to qualify for the derivatives scope exception, which will permit more equity contracts to qualify for it. Either a modified retrospective transition method or a fully retrospective transition method is permissible for the adoption of this standard. Update &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;No.&#160;2020-06&lt;/div&gt; is effective for fiscal years beginning after December&#160;15, 2021, including interim periods within those fiscal years. The early-adoption of ASU &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;No.&#160;2020-06&lt;/div&gt; on April&#160;1, 2021 did not have a material impact on the Company&#x2019;s unaudited condensed consolidated financial statements. &lt;/div&gt;</us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock>
    <us-gaap:InvestmentsAndOtherNoncurrentAssetsTextBlock contextRef="P04_01_2021To06_30_2021">&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Note 3&#x2014;Investments &lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;(A) Investments Measured at Fair Value &lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt; margin-left: 4%;"&gt;&lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;Investment in Arbutus &lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;RSL owns 16,013,540 shares of common stock of Arbutus and 1,164,000 Arbutus Preferred Shares that are mandatorily convertible into shares of Arbutus common stock on October&#160;18, 2021 subject to conversion earlier upon a sale, merger or other transaction considered a fundamental change of control of Arbutus. The Arbutus Preferred Shares are &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;non-voting&lt;/div&gt; and are convertible into common shares of Arbutus based on the subscription price plus 8.75% per annum, compounded annually, divided by a conversion price of $7.13 per share (which represented a 15% premium to the closing price of $6.20 per share on September&#160;29, 2017). The fair value option was elected to continuously remeasure the investment to fair value each reporting period after the initial measurement. Due to the Company&#x2019;s significant influence over operating and financial policies, Arbutus is considered a related party of the Company. &lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;At June&#160;30, 2021, RSL held 32% of issued and outstanding shares of Arbutus, including the conversion of the Arbutus Preferred Shares held by RSL into common shares. &lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="text-indent: 4%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;At June&#160;30, 2021 and March&#160;31, 2021, the aggregate fair value of the &lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;RSL&lt;/div&gt; investment in Arbutus was $117.7&#160;million and $129.4&#160;million, respectively, with the Company recognizing an unrealized loss on its investments in Arbutus of $11.7&#160;million and an unrealized gain of $31.5&#160;million in the accompanying condensed consolidated statements of operations for the three months ended June&#160;30, 2021 and 2020, respectively. The fair value of the common stock and preferred shares held by the Company was determined using the closing price of Arbutus&#x2019;s common stock on June&#160;30, 2021 and March&#160;31, 2021 of $3.03 and $3.33, respectively&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;.&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt; margin-left: 4%;"&gt;&lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;Investment in Sio &lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Following the completion of Sio&#x2019;s underwritten public offering in February 2020, RSL&#x2019;s ownership interest fell below &lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;50.0&lt;/div&gt;%. As such, the Company no longer has a controlling financial interest in Sio. Accordingly, the Company deconsolidated Sio in February 2020. Due to the Company&#x2019;s significant influence over operating and financial policies, Sio remains a related party of the Company following deconsolidation. As the Company still has the ability to exercise significant influence over the operating and financial policies of Sio, the Company has determined that its retained interest represents an equity method investment after the date of deconsolidation. Upon deconsolidation, the retained interest was recorded at fair market value based on the closing price of Sio&#x2019;s common stock. The fair value option was elected to continuously remeasure the investment to fair value each reporting period after the initial measurement. At June&#160;30, 2021, RSL held 27% of Sio&#x2019;s issued and outstanding common shares. &lt;/div&gt;&lt;/div&gt; &lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;At June&#160;30, 2021 and March&#160;31, 2021, the fair value of the Company&#x2019;s investment in Sio was $50.7&#160;million and $48.5&#160;million, respectively, with the Company recognizing unrealized gains on its investment in Sio of &lt;/div&gt;&lt;/div&gt;  &lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0px;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;$2.2&#160;million and $7.1&#160;million in the accompanying condensed consolidated statements of operations for the three months ended June&#160;30, 2021 and 2020, respectively. The fair value of common shares held by the Company was determined using the closing price of Sio&#x2019;s common stock on June&#160;30, 2021 and March&#160;31, 2021 of $2.73 and $2.61, respectively. &lt;/div&gt;&lt;/div&gt; &lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt; margin-left: 4%;"&gt;&lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;Other Investment &lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;The Company holds an additional equity investment that is measured using the fair value option. The fair value of this investment was $11.9&#160;million and $11.1&#160;million as of June&#160;30, 2021 and March&#160;31, 2021, respectively. &lt;/div&gt;&lt;/div&gt; &lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;(B) Investment Accounted for Using Measurement Alternative &lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt; margin-left: 4%;"&gt;&lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;Investment in Datavant &lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;In April 2020, Datavant Holdings, Inc. (&#x201c;Datavant&#x201d;) completed an initial round of a Series B equity raise by which 13,411,311 Series B preferred shares were issued in April 2020 for gross proceeds of $27.2&#160;million, including 1,065,234 Series B preferred shares issued and sold to RSL for a total purchase price of $2.5&#160;million and 1,800,253 Series B shares issued relating to the conversion of certain liability instruments. As a result of this transaction, along with a restructuring of Datavant&#x2019;s equity classes, RSL no longer controls Datavant. As such, the Company deconsolidated Datavant as of April 2020. Due to the Company&#x2019;s significant influence over operating and financial policies, Datavant remains a related party of the Company following deconsolidation. Upon deconsolidation, the Company recorded its investment in Datavant based on the fair value of Datavant preferred shares held of $99.0&#160;million. The Company accounts for its investment in Datavant using the measurement alternative to fair value. The investment will be remeasured upon future observable price changes in orderly transactions or upon impairment, if any. The Company recognized a gain on deconsolidation of $86.5&#160;million in the accompanying condensed consolidated statements of operations for the three months ended June&#160;30, 2020. In July 2020, Datavant issued and sold 639,140 Series B preferred shares to RSL at a price consistent with that of the initial round of Datavant&#x2019;s Series B equity raise. At June&#160;30, 2021 and March&#160;31, 2021, the carrying value of the Company&#x2019;s investment in Datavant was $100.6&#160;million. &lt;/div&gt;&lt;/div&gt; &lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;In June 2021, Datavant and CIOX Health, LLC entered into a definitive agreement to merge the two companies, subject to regulatory approvals. See Note 14, &#x201c;Subsequent Events&#x201d; for additional information. &lt;/div&gt;&lt;/div&gt; </us-gaap:InvestmentsAndOtherNoncurrentAssetsTextBlock>
    <roiv:CommonStockOwnedBalanceSharesOfArbutus
      contextRef="PAsOn03_31_2021"
      decimals="0"
      unitRef="Unit_shares">16013540</roiv:CommonStockOwnedBalanceSharesOfArbutus>
    <roiv:CommonStockOwnedBalanceSharesOfArbutus
      contextRef="PAsOn06_30_2021"
      decimals="0"
      unitRef="Unit_shares">16013540</roiv:CommonStockOwnedBalanceSharesOfArbutus>
    <roiv:PreferredStockOwnedBalanceSharesOfArbutus
      contextRef="PAsOn03_31_2021"
      decimals="0"
      unitRef="Unit_shares">1164000</roiv:PreferredStockOwnedBalanceSharesOfArbutus>
    <roiv:PreferredStockOwnedBalanceSharesOfArbutus
      contextRef="PAsOn06_30_2021"
      decimals="0"
      unitRef="Unit_shares">1164000</roiv:PreferredStockOwnedBalanceSharesOfArbutus>
    <roiv:AnnualCompoundedConversionRateForPreferredShare
      contextRef="P01_01_2021To03_31_2021_ArbutusBiopharmaCorporationMemberdeiLegalEntityAxis"
      decimals="4"
      unitRef="Unit_pure">0.0875</roiv:AnnualCompoundedConversionRateForPreferredShare>
    <roiv:AnnualCompoundedConversionRateForPreferredShare
      contextRef="P04_01_2021To06_30_2021_ArbutusBiopharmaCorporationMemberdeiLegalEntityAxis"
      decimals="4"
      unitRef="Unit_pure">0.0875</roiv:AnnualCompoundedConversionRateForPreferredShare>
    <roiv:ConversionPrice
      contextRef="PAsOn03_31_2021_ArbutusBiopharmaCorporationMemberdeiLegalEntityAxis"
      decimals="2"
      unitRef="Unit_USD_per_Share">7.13</roiv:ConversionPrice>
    <roiv:ConversionPrice
      contextRef="PAsOn06_30_2021_ArbutusBiopharmaCorporationMemberdeiLegalEntityAxis"
      decimals="2"
      unitRef="Unit_USD_per_Share">7.13</roiv:ConversionPrice>
    <roiv:PremiumOnConversionPricePercentage
      contextRef="P09_29_2017To09_29_2017_ArbutusBiopharmaCorporationMemberdeiLegalEntityAxis"
      decimals="2"
      unitRef="Unit_pure">0.15</roiv:PremiumOnConversionPricePercentage>
    <roiv:ClosingPricePerShare
      contextRef="PAsOn09_29_2017_ArbutusBiopharmaCorporationMemberdeiLegalEntityAxis"
      decimals="2"
      unitRef="Unit_USD_per_Share">6.20</roiv:ClosingPricePerShare>
    <us-gaap:EquityMethodInvestmentOwnershipPercentage
      contextRef="PAsOn06_30_2021_ArbutusBiopharmaCorporationMemberdeiLegalEntityAxis"
      decimals="2"
      unitRef="Unit_pure">0.32</us-gaap:EquityMethodInvestmentOwnershipPercentage>
    <us-gaap:InvestmentsFairValueDisclosure
      contextRef="PAsOn06_30_2021_ArbutusBiopharmaCorporationMemberdeiLegalEntityAxis"
      decimals="-5"
      unitRef="Unit_USD">117700000</us-gaap:InvestmentsFairValueDisclosure>
    <us-gaap:InvestmentsFairValueDisclosure
      contextRef="PAsOn03_31_2021_ArbutusBiopharmaCorporationMemberdeiLegalEntityAxis"
      decimals="-5"
      unitRef="Unit_USD">129400000</us-gaap:InvestmentsFairValueDisclosure>
    <us-gaap:UnrealizedGainLossOnInvestments
      contextRef="P04_01_2021To06_30_2021_ArbutusBiopharmaCorporationMemberdeiLegalEntityAxis"
      decimals="-5"
      unitRef="Unit_USD">-11700000</us-gaap:UnrealizedGainLossOnInvestments>
    <us-gaap:UnrealizedGainLossOnInvestments
      contextRef="P04_01_2020To06_30_2020_ArbutusBiopharmaCorporationMemberdeiLegalEntityAxis"
      decimals="-5"
      unitRef="Unit_USD">31500000</us-gaap:UnrealizedGainLossOnInvestments>
    <us-gaap:SharePrice
      contextRef="PAsOn06_30_2021_ArbutusBiopharmaCorporationMemberdeiLegalEntityAxis"
      decimals="2"
      unitRef="Unit_USD_per_Share">3.03</us-gaap:SharePrice>
    <us-gaap:SharePrice
      contextRef="PAsOn03_31_2021_ArbutusBiopharmaCorporationMemberdeiLegalEntityAxis"
      decimals="2"
      unitRef="Unit_USD_per_Share">3.33</us-gaap:SharePrice>
    <roiv:OwnershipInterestPercentage
      contextRef="PAsOn06_30_2021_SioGeneTherapiesIncMemberdeiLegalEntityAxis"
      decimals="2"
      unitRef="Unit_pure">0.27</roiv:OwnershipInterestPercentage>
    <us-gaap:InvestmentsFairValueDisclosure
      contextRef="PAsOn06_30_2021_SioGeneTherapiesIncMemberdeiLegalEntityAxis"
      decimals="-5"
      unitRef="Unit_USD">50700000</us-gaap:InvestmentsFairValueDisclosure>
    <us-gaap:InvestmentsFairValueDisclosure
      contextRef="PAsOn03_31_2021_SioGeneTherapiesIncMemberdeiLegalEntityAxis"
      decimals="-5"
      unitRef="Unit_USD">48500000</us-gaap:InvestmentsFairValueDisclosure>
    <us-gaap:UnrealizedGainLossOnInvestments
      contextRef="P04_01_2021To06_30_2021_SioGeneTherapiesIncMemberdeiLegalEntityAxis"
      decimals="-5"
      unitRef="Unit_USD">2200000</us-gaap:UnrealizedGainLossOnInvestments>
    <us-gaap:UnrealizedGainLossOnInvestments
      contextRef="P04_01_2020To06_30_2020_SioGeneTherapiesIncMemberdeiLegalEntityAxis"
      decimals="-5"
      unitRef="Unit_USD">7100000</us-gaap:UnrealizedGainLossOnInvestments>
    <us-gaap:SharePrice
      contextRef="PAsOn06_30_2021_SioGeneTherapiesIncMemberdeiLegalEntityAxis"
      decimals="2"
      unitRef="Unit_USD_per_Share">2.73</us-gaap:SharePrice>
    <us-gaap:SharePrice
      contextRef="PAsOn03_31_2021_SioGeneTherapiesIncMemberdeiLegalEntityAxis"
      decimals="2"
      unitRef="Unit_USD_per_Share">2.61</us-gaap:SharePrice>
    <us-gaap:InvestmentsFairValueDisclosure
      contextRef="PAsOn06_30_2021_OtherInvestmentCompaniesMemberusgaapInvestmentTypeAxis"
      decimals="-5"
      unitRef="Unit_USD">11900000</us-gaap:InvestmentsFairValueDisclosure>
    <us-gaap:InvestmentsFairValueDisclosure
      contextRef="PAsOn03_31_2021_OtherInvestmentCompaniesMemberusgaapInvestmentTypeAxis"
      decimals="-5"
      unitRef="Unit_USD">11100000</us-gaap:InvestmentsFairValueDisclosure>
    <roiv:PreferredStockSharesIssuedAndSoldToCompanyDuringPeriodShares
      contextRef="PAsOn07_31_2020_SeriesBPreferredStockMemberusgaapStatementClassOfStockAxis"
      decimals="INF"
      unitRef="Unit_shares">13411311</roiv:PreferredStockSharesIssuedAndSoldToCompanyDuringPeriodShares>
    <roiv:ProceedsFromIssuanceOfPreferredStockAndPreferenceStocks
      contextRef="PAsOn07_31_2020_DatavantHoldingsIncMemberdeiLegalEntityAxis_SeriesBPreferredStockMemberusgaapStatementClassOfStockAxis"
      decimals="-5"
      unitRef="Unit_USD">27200000</roiv:ProceedsFromIssuanceOfPreferredStockAndPreferenceStocks>
    <roiv:PreferredStockSharesIssuedAndSoldToCompanyDuringPeriodShares
      contextRef="PAsOn07_31_2020_DatavantHoldingsIncMemberdeiLegalEntityAxis_SeriesBPreferredStockMemberusgaapStatementClassOfStockAxis"
      decimals="0"
      unitRef="Unit_shares">1065234</roiv:PreferredStockSharesIssuedAndSoldToCompanyDuringPeriodShares>
    <roiv:PreferredStockPurchased
      contextRef="PAsOn04_30_2020_DatavantHoldingsIncMemberdeiLegalEntityAxis_SeriesBPreferredStockMemberusgaapStatementClassOfStockAxis"
      decimals="-5"
      unitRef="Unit_USD">2500000</roiv:PreferredStockPurchased>
    <us-gaap:ConvertiblePreferredStockSharesIssuedUponConversion
      contextRef="PAsOn04_30_2020_DatavantHoldingsIncMemberdeiLegalEntityAxis_SeriesBPreferredStockMemberusgaapStatementClassOfStockAxis"
      decimals="0"
      unitRef="Unit_shares">1800253</us-gaap:ConvertiblePreferredStockSharesIssuedUponConversion>
    <us-gaap:InvestmentsFairValueDisclosure
      contextRef="PAsOn06_30_2021_DatavantHoldingsIncMemberdeiLegalEntityAxis"
      decimals="-5"
      unitRef="Unit_USD">99000000.0</us-gaap:InvestmentsFairValueDisclosure>
    <us-gaap:DeconsolidationGainOrLossAmount
      contextRef="P04_01_2020To06_30_2020_DatavantHoldingsIncMemberdeiLegalEntityAxis"
      decimals="-5"
      unitRef="Unit_USD">86500000</us-gaap:DeconsolidationGainOrLossAmount>
    <roiv:PreferredStockSharesIssuedAndSoldToCompanyDuringPeriodShares
      contextRef="PAsOn07_31_2020"
      decimals="INF"
      unitRef="Unit_shares">639140</roiv:PreferredStockSharesIssuedAndSoldToCompanyDuringPeriodShares>
    <us-gaap:LongTermInvestments
      contextRef="PAsOn06_30_2021_DatavantHoldingsIncMemberdeiLegalEntityAxis"
      decimals="-5"
      unitRef="Unit_USD">100600000</us-gaap:LongTermInvestments>
    <us-gaap:LongTermInvestments
      contextRef="PAsOn03_31_2021_DatavantHoldingsIncMemberdeiLegalEntityAxis"
      decimals="-5"
      unitRef="Unit_USD">100600000</us-gaap:LongTermInvestments>
    <roiv:TransactionAgreementDisclosureTextBlock contextRef="P04_01_2021To06_30_2021">&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt; text-indent: 0px;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Note 4&#x2014;Sumitomo Transaction Agreement &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;On December&#160;27, 2019 (the &#x201c;Sumitomo Closing Date&#x201d;), RSL and Sumitomo Dainippon Pharma Co., Ltd. (&#x201c;Sumitomo&#x201d;) completed the transactions contemplated by the transaction agreement by and between RSL and Sumitomo, dated as of October&#160;31, 2019 (the &#x201c;Sumitomo Transaction Agreement&#x201d;). Pursuant to the Sumitomo Transaction Agreement, RSL transferred its entire ownership interest in Myovant Sciences Ltd., Urovant Sciences Ltd., Enzyvant Therapeutics Ltd., Altavant Sciences Ltd. and Spirovant Sciences Ltd. (collectively, the &#x201c;Sumitovant Vants&#x201d;) to a newly formed, wholly-owned entity (&#x201c;Sumitovant&#x201d;). &lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;RSL&#x2019;s ownership interest in Sumitovant was then transferred to Sumitomo, such that following the Sumitomo Closing Date, Sumitovant and its subsidiaries, including the Sumitovant Vants, were each directly or indirectly owned by Sumitomo. Additionally, in connection with the Sumitomo Transaction Agreement, RSL (i)&#160;granted Sumitomo options to purchase all, or in the case of Dermavant, 75%, of RSL&#x2019;s ownership interests in six other subsidiaries (Dermavant, Genevant Sciences Ltd. (&#x201c;Genevant&#x201d;), Lysovant Sciences Ltd., Metavant Sciences Ltd., Roivant Asia Cell Therapy Holdings Ltd., and Sinovant Sciences HK Limited (collectively, the &#x201c;Option Vants&#x201d;)), &lt;/div&gt;&lt;div style="display:inline;"&gt;(ii) (a) transferred the proprietary technology platform DrugOme to Sumitomo (for which RSL retains a perpetual royalty free license for internal use) and (b) licensed the Digital Innovation technology platform to Sumitomo (for which both parties retain ongoing access) and (iii)&#160;&lt;/div&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;transferred 26,952,143 common shares of RSL to Sumitomo. On the Sumitomo Closing Date, the Company received approximately $2.9&#160;billion&lt;/div&gt;&lt;/div&gt; &lt;div style="text-indent: 0px; margin-bottom: 1em; margin-top: 1em"/&gt; &lt;div style="text-indent: 0px; margin-bottom: 1em; margin-top: 1em"/&gt; &lt;div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0px;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;  &lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0px;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;in cash. Additionally, $75.0&#160;million was deposited into a segregated escrow account for the purpose of fulfilling indemnification obligations of RSL that may become due to Sumitomo. The full escrow amount of $75.0&#160;million was disbursed to the Company in June 2021.&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;In connection with the Sumitomo Transaction, RSL&#x2019;s board of directors approved an exchange and offer to repurchase RSL equity securities for up to $&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;1.0 &lt;/div&gt;billion of the proceeds received from Sumitomo. &lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Concurrently with the Sumitomo Transaction Agreement, (i)&#160;RSL, Sumitomo and Sumitovant entered into a transition services agreement, whereby each of the parties thereto agreed to provide certain services to one another at cost for a period of time following the Sumitomo Closing Date and (ii)&#160;RSL and Sumitomo entered into a strategic cooperation agreement relating to certain ongoing technology-related collaborations between the parties. Pursuant to the terms of the transition services agreement and strategic cooperation agreement, RSL billed Sumitovant $0.3&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;million and $0.4&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;million, net of amounts billed by Sumitovant to RSL, during the three months ended June&#160;30, 2021 and 2020, respectively, for costs incurred on behalf of Sumitovant, which were recorded as offsets to the general and administrative expenses initially charged. The period for certain services provided under the Transition Services Agreement expired in December 2020. &lt;/div&gt;&lt;/div&gt;  &lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;In conjunction with the Sumitomo Transaction, certain employees of the Company became employees of Sumitovant or its subsidiaries. The Company issued certain instruments to these employees that vest based on the achievement of time-based, performance or liquidity event requirements. As of June&#160;30, 2021 and 2020, there were 1,863,451 and 1,873,480 outstanding instruments, respectively, held by Sumitovant employees for which aggregate fair value was recorded against the gain on sale of business. &lt;/div&gt;&lt;/div&gt; &lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;In May 2021, the Company entered into an Asset Purchase Agreement with Sumitomo and its subsidiary Sumitomo Pharmaceuticals (Suzhou) Co., Ltd. (&#x201c;SPC&#x201d;) (the &#x201c;Asset Purchase Agreement&#x201d;). The transactions contemplated by the Asset Purchase Agreement closed in June 2021. Pursuant to the Asset Purchase Agreement: (i)&#160;Sumitomo terminated all of its existing options to acquire the Company&#x2019;s equity interests in the Option Vants (the &#x201c;Sumitomo Options&#x201d;); (ii) the Company transferred and assigned to SPC all of its intellectual property, development and commercialization rights for (a)&#160;lefamulin in Mainland China, Taiwan, Hong Kong, and Macau (collectively &#x201c;Greater China&#x201d;), (b) vibegron in Mainland China, (c)&#160;rodatristat ethyl in Greater China and South Korea and &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;(d)&#160;RVT-802&lt;/div&gt; in Greater China and South Korea; (iii)&#160;Sumitomo agreed to pay the Company $5.0&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;million in cash; and (iv)&#160;Sumitomo entered into an agreement with the Company to pursue future collaborations with Genevant. The Company received the cash payment, net of certain withholding taxes, in August 2021. The Company recorded a gain on the termination of the Sumitomo Options of $66.5&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;million, consisting of the fair value of the Sumitomo Options on the date of termination and the expected cash payment, in the accompanying condensed consolidated statements of operations for the three months ended June&#160;30, 2021. &lt;/div&gt; </roiv:TransactionAgreementDisclosureTextBlock>
    <roiv:PercentageOfGrantedOptionToPurchaseOwnershipInterest
      contextRef="P03_31_2021To03_31_2021_SumitomoMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis"
      decimals="2"
      unitRef="Unit_pure">0.75</roiv:PercentageOfGrantedOptionToPurchaseOwnershipInterest>
    <roiv:SaleOfStockNumberOfShareIssuedInTransaction
      contextRef="PAsOn12_31_2019_SumitomoMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis"
      decimals="0"
      unitRef="Unit_shares">26952143</roiv:SaleOfStockNumberOfShareIssuedInTransaction>
    <roiv:SaleOfStockConsiderationCashReceivedOnTransaction
      contextRef="PAsOn12_31_2019_SumitomoMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis"
      decimals="-8"
      unitRef="Unit_USD">2900000000</roiv:SaleOfStockConsiderationCashReceivedOnTransaction>
    <us-gaap:EscrowDeposit
      contextRef="PAsOn12_31_2019_SumitomoMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis"
      decimals="-5"
      unitRef="Unit_USD">75000000.0</us-gaap:EscrowDeposit>
    <us-gaap:RestrictedCash
      contextRef="PAsOn12_31_2019_SumitomoMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis"
      decimals="-5"
      unitRef="Unit_USD">75000000.0</us-gaap:RestrictedCash>
    <roiv:StockOfferToRepurchaseDuringPeriodValueOfTheProceedsReceivedFromTransactionAgreement
      contextRef="P04_01_2021To06_30_2021_SumitomoMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis"
      decimals="-8"
      unitRef="Unit_USD">1000000000.0</roiv:StockOfferToRepurchaseDuringPeriodValueOfTheProceedsReceivedFromTransactionAgreement>
    <roiv:AgreementRelatedBilledAmountForCostsIncurredOnBehalfOfSubsidiarynetOfAmountsBilledBySubsidiary
      contextRef="P04_01_2021To06_30_2021_TransitionServicesAndStrategicCooperationAgreementMemberROIVAgreementAxis"
      decimals="-5"
      unitRef="Unit_USD">300000</roiv:AgreementRelatedBilledAmountForCostsIncurredOnBehalfOfSubsidiarynetOfAmountsBilledBySubsidiary>
    <roiv:AgreementRelatedBilledAmountForCostsIncurredOnBehalfOfSubsidiarynetOfAmountsBilledBySubsidiary
      contextRef="P04_01_2020To06_30_2020_TransitionServicesAndStrategicCooperationAgreementMemberROIVAgreementAxis"
      decimals="-5"
      unitRef="Unit_USD">400000</roiv:AgreementRelatedBilledAmountForCostsIncurredOnBehalfOfSubsidiarynetOfAmountsBilledBySubsidiary>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber
      contextRef="PAsOn06_30_2021_EmployeeMembersrtTitleOfIndividualAxis_SumitomoMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis"
      decimals="0"
      unitRef="Unit_shares">1863451</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber
      contextRef="PAsOn06_30_2020_EmployeeMembersrtTitleOfIndividualAxis_SumitomoMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis"
      decimals="0"
      unitRef="Unit_shares">1873480</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber>
    <roiv:AssetPurchaseTransactionConsiderationReceivedInCash
      contextRef="PAsOn05_31_2021_AssetPurchaseAgreementMemberROIVAgreementAxis"
      decimals="-5"
      unitRef="Unit_USD">5000000.0</roiv:AssetPurchaseTransactionConsiderationReceivedInCash>
    <roiv:EquityInterestOptionToThirdPartyPurchaserGainOnTermination
      contextRef="P04_01_2021To06_30_2021_AssetPurchaseAgreementMemberROIVAgreementAxis"
      decimals="-5"
      unitRef="Unit_USD">66500000</roiv:EquityInterestOptionToThirdPartyPurchaserGainOnTermination>
    <us-gaap:SupplementalBalanceSheetDisclosuresTextBlock contextRef="P04_01_2021To06_30_2021">&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Note 5&#x2014;Balance Sheet Components &lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;(A) Other Current Assets &lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Other current assets at June&#160;30, 2021 and March&#160;31, 2021 consisted of the following (in thousands): &lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0px;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 76%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px; text-indent: 0px;"&gt;
&lt;tr style="font-size: 0px;"&gt;
&lt;td style="width: 64%;"/&gt;
&lt;td style="width: 10%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="width: 10%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;June&#160;30,&#160;2021&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;March&#160;31,&#160;2021&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size: 0px;"&gt;
&lt;td style="width: 75%;"/&gt;
&lt;td style="width: 7%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="width: 6%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top; width: 75%;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Prepaid expenses&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 7%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;44,941&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 6%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;39,544&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top; width: 75%;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Trade receivables, net&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 7%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;3,416&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 6%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;11,222&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top; width: 75%;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Income tax receivable&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 7%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;1,993&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 6%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;1,803&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size: 0px;"&gt;
&lt;td style="width: 75%;"/&gt;
&lt;td style="width: 7%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="width: 6%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt; &lt;/tr&gt;
&lt;tr style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; break-inside: avoid;"&gt;
&lt;td style="vertical-align: top; background-color: rgb(255, 255, 255); width: 75%;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Other&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgb(255, 255, 255); width: 7%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(255, 255, 255);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(255, 255, 255);;text-align:right;"&gt;7,815&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(255, 255, 255);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgb(255, 255, 255); width: 6%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(255, 255, 255);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(255, 255, 255);;text-align:right;"&gt;1,681&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(255, 255, 255);"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; background-color: rgb(204, 238, 255); width: 75%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgb(204, 238, 255); width: 7%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="background-color: rgb(204, 238, 255);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgb(204, 238, 255); width: 6%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="background-color: rgb(204, 238, 255);"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top; background-color: rgb(204, 238, 255); width: 75%;"&gt; &lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.26in; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Total other current assets&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgb(204, 238, 255); width: 7%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;"&gt;58,165&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgb(204, 238, 255); width: 6%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;"&gt;54,250&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; background-color: rgb(255, 255, 255); width: 75%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgb(255, 255, 255); width: 7%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgb(255, 255, 255);"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgb(255, 255, 255);"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="background-color: rgb(255, 255, 255);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgb(255, 255, 255); width: 6%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgb(255, 255, 255);"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgb(255, 255, 255);"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="background-color: rgb(255, 255, 255);"&gt;&#160;&lt;/td&gt; &lt;/tr&gt; &lt;/table&gt;  &lt;div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"/&gt; &lt;div style="clear: both; max-height: 0px;"/&gt; &lt;div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;(B) Accrued Expenses &lt;/div&gt;&lt;/div&gt;  &lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Accrued expenses at June&#160;30, 2021 and March&#160;31, 2021 consisted of the following (in thousands): &lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0px;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 76%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px; text-indent: 0px;"&gt;
&lt;tr style="font-size: 0px;"&gt;
&lt;td style="width: 64%;"/&gt;
&lt;td style="width: 10%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="width: 10%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;June&#160;30,&#160;2021&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;March&#160;31,&#160;2021&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size: 0px;"&gt;
&lt;td style="width: 64%;"/&gt;
&lt;td style="width: 10%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="width: 10%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top; width: 64%;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Research and development expenses&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 10%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;28,347&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 10%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;20,755&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top; width: 64%;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Compensation-related expenses&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 10%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;15,242&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 10%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;38,552&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top; width: 64%;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Professional services expenses&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 10%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;16,489&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 10%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;10,267&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top; width: 64%;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Other general and administrative expenses&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 10%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;13,710&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 10%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;7,362&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; width: 64%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 10%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 10%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top; width: 64%;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Total accrued expenses&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 10%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;73,788&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 10%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;76,936&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; width: 64%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 10%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 10%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt; &lt;/tr&gt; &lt;/table&gt;  &lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;(C) Other Current Liabilities &lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Other current liabilities at June&#160;30, 2021 and March&#160;31, 2021 consisted of the following (in thousands): &lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0px;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 76%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px; text-indent: 0px;"&gt;
&lt;tr style="font-size: 0px;"&gt;
&lt;td style="width: 64%;"/&gt;
&lt;td style="width: 12%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="width: 12%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;June&#160;30,&#160;2021&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;March&#160;31,&#160;2021&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size: 0px;"&gt;
&lt;td style="width: 64%;"/&gt;
&lt;td style="width: 12%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="width: 12%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top; width: 64%;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Deferred revenue&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 12%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;3,777&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 12%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;5,918&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top; width: 64%;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Income tax payable&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 12%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;199&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 12%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;207&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top; width: 64%;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Other&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 12%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;4,325&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 12%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;3,037&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; width: 64%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 12%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 12%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top; width: 64%;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Total other current liabilities&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 12%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;8,301&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 12%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;9,162&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; width: 64%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 12%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 12%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; </us-gaap:SupplementalBalanceSheetDisclosuresTextBlock>
    <us-gaap:ScheduleOfOtherCurrentAssetsTableTextBlock contextRef="P04_01_2021To06_30_2021">&lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Other current assets at June&#160;30, 2021 and March&#160;31, 2021 consisted of the following (in thousands): &lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0px;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 76%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px; text-indent: 0px;"&gt;
&lt;tr style="font-size: 0px;"&gt;
&lt;td style="width: 64%;"/&gt;
&lt;td style="width: 10%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="width: 10%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;June&#160;30,&#160;2021&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;March&#160;31,&#160;2021&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size: 0px;"&gt;
&lt;td style="width: 75%;"/&gt;
&lt;td style="width: 7%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="width: 6%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top; width: 75%;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Prepaid expenses&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 7%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;44,941&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 6%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;39,544&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top; width: 75%;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Trade receivables, net&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 7%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;3,416&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 6%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;11,222&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top; width: 75%;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Income tax receivable&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 7%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;1,993&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 6%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;1,803&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size: 0px;"&gt;
&lt;td style="width: 75%;"/&gt;
&lt;td style="width: 7%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="width: 6%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt; &lt;/tr&gt;
&lt;tr style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; break-inside: avoid;"&gt;
&lt;td style="vertical-align: top; background-color: rgb(255, 255, 255); width: 75%;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Other&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgb(255, 255, 255); width: 7%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(255, 255, 255);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(255, 255, 255);;text-align:right;"&gt;7,815&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(255, 255, 255);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgb(255, 255, 255); width: 6%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(255, 255, 255);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(255, 255, 255);;text-align:right;"&gt;1,681&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(255, 255, 255);"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; background-color: rgb(204, 238, 255); width: 75%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgb(204, 238, 255); width: 7%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="background-color: rgb(204, 238, 255);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgb(204, 238, 255); width: 6%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="background-color: rgb(204, 238, 255);"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top; background-color: rgb(204, 238, 255); width: 75%;"&gt; &lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.26in; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Total other current assets&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgb(204, 238, 255); width: 7%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;"&gt;58,165&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgb(204, 238, 255); width: 6%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;"&gt;54,250&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; background-color: rgb(255, 255, 255); width: 75%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgb(255, 255, 255); width: 7%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgb(255, 255, 255);"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgb(255, 255, 255);"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="background-color: rgb(255, 255, 255);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgb(255, 255, 255); width: 6%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgb(255, 255, 255);"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgb(255, 255, 255);"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="background-color: rgb(255, 255, 255);"&gt;&#160;&lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; </us-gaap:ScheduleOfOtherCurrentAssetsTableTextBlock>
    <us-gaap:PrepaidExpenseCurrent
      contextRef="PAsOn06_30_2021"
      decimals="-3"
      unitRef="Unit_USD">44941000</us-gaap:PrepaidExpenseCurrent>
    <us-gaap:PrepaidExpenseCurrent
      contextRef="PAsOn03_31_2021"
      decimals="-3"
      unitRef="Unit_USD">39544000</us-gaap:PrepaidExpenseCurrent>
    <us-gaap:AccountsReceivableNetCurrent
      contextRef="PAsOn06_30_2021"
      decimals="-3"
      unitRef="Unit_USD">3416000</us-gaap:AccountsReceivableNetCurrent>
    <us-gaap:AccountsReceivableNetCurrent
      contextRef="PAsOn03_31_2021"
      decimals="-3"
      unitRef="Unit_USD">11222000</us-gaap:AccountsReceivableNetCurrent>
    <us-gaap:IncomeTaxesReceivable
      contextRef="PAsOn06_30_2021"
      decimals="-3"
      unitRef="Unit_USD">1993000</us-gaap:IncomeTaxesReceivable>
    <us-gaap:IncomeTaxesReceivable
      contextRef="PAsOn03_31_2021"
      decimals="-3"
      unitRef="Unit_USD">1803000</us-gaap:IncomeTaxesReceivable>
    <us-gaap:OtherAssetsMiscellaneousCurrent
      contextRef="PAsOn06_30_2021"
      decimals="-3"
      unitRef="Unit_USD">7815000</us-gaap:OtherAssetsMiscellaneousCurrent>
    <us-gaap:OtherAssetsMiscellaneousCurrent
      contextRef="PAsOn03_31_2021"
      decimals="-3"
      unitRef="Unit_USD">1681000</us-gaap:OtherAssetsMiscellaneousCurrent>
    <us-gaap:OtherAssetsCurrent
      contextRef="PAsOn06_30_2021"
      decimals="-3"
      unitRef="Unit_USD">58165000</us-gaap:OtherAssetsCurrent>
    <us-gaap:OtherAssetsCurrent
      contextRef="PAsOn03_31_2021"
      decimals="-3"
      unitRef="Unit_USD">54250000</us-gaap:OtherAssetsCurrent>
    <us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock contextRef="P04_01_2021To06_30_2021">&lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Accrued expenses at June&#160;30, 2021 and March&#160;31, 2021 consisted of the following (in thousands): &lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0px;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 76%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px; text-indent: 0px;"&gt;
&lt;tr style="font-size: 0px;"&gt;
&lt;td style="width: 64%;"/&gt;
&lt;td style="width: 10%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="width: 10%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;June&#160;30,&#160;2021&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;March&#160;31,&#160;2021&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size: 0px;"&gt;
&lt;td style="width: 64%;"/&gt;
&lt;td style="width: 10%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="width: 10%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top; width: 64%;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Research and development expenses&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 10%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;28,347&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 10%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;20,755&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top; width: 64%;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Compensation-related expenses&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 10%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;15,242&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 10%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;38,552&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top; width: 64%;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Professional services expenses&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 10%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;16,489&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 10%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;10,267&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top; width: 64%;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Other general and administrative expenses&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 10%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;13,710&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 10%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;7,362&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; width: 64%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 10%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 10%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top; width: 64%;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Total accrued expenses&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 10%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;73,788&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 10%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;76,936&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; width: 64%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 10%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 10%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; </us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock>
    <us-gaap:AccruedLiabilitiesCurrent
      contextRef="PAsOn06_30_2021_ResearchAndDevelopmentExpenseMemberusgaapIncomeStatementLocationAxis"
      decimals="-3"
      unitRef="Unit_USD">28347000</us-gaap:AccruedLiabilitiesCurrent>
    <us-gaap:AccruedLiabilitiesCurrent
      contextRef="PAsOn03_31_2021_ResearchAndDevelopmentExpenseMemberusgaapIncomeStatementLocationAxis"
      decimals="-3"
      unitRef="Unit_USD">20755000</us-gaap:AccruedLiabilitiesCurrent>
    <us-gaap:AccruedLiabilitiesCurrent
      contextRef="PAsOn06_30_2021_EmployeeRelatedExpensesMemberusgaapIncomeStatementLocationAxis"
      decimals="-3"
      unitRef="Unit_USD">15242000</us-gaap:AccruedLiabilitiesCurrent>
    <us-gaap:AccruedLiabilitiesCurrent
      contextRef="PAsOn03_31_2021_EmployeeRelatedExpensesMemberusgaapIncomeStatementLocationAxis"
      decimals="-3"
      unitRef="Unit_USD">38552000</us-gaap:AccruedLiabilitiesCurrent>
    <us-gaap:AccruedLiabilitiesCurrent
      contextRef="PAsOn06_30_2021_ProfessionalServicesExpensesMemberusgaapIncomeStatementLocationAxis"
      decimals="-3"
      unitRef="Unit_USD">16489000</us-gaap:AccruedLiabilitiesCurrent>
    <us-gaap:AccruedLiabilitiesCurrent
      contextRef="PAsOn03_31_2021_ProfessionalServicesExpensesMemberusgaapIncomeStatementLocationAxis"
      decimals="-3"
      unitRef="Unit_USD">10267000</us-gaap:AccruedLiabilitiesCurrent>
    <us-gaap:AccruedLiabilitiesCurrent
      contextRef="PAsOn06_30_2021_OtherGeneralAndAdministrativeExpensesMemberusgaapIncomeStatementLocationAxis"
      decimals="-3"
      unitRef="Unit_USD">13710000</us-gaap:AccruedLiabilitiesCurrent>
    <us-gaap:AccruedLiabilitiesCurrent
      contextRef="PAsOn03_31_2021_OtherGeneralAndAdministrativeExpensesMemberusgaapIncomeStatementLocationAxis"
      decimals="-3"
      unitRef="Unit_USD">7362000</us-gaap:AccruedLiabilitiesCurrent>
    <us-gaap:AccruedLiabilitiesCurrent
      contextRef="PAsOn06_30_2021"
      decimals="-3"
      unitRef="Unit_USD">73788000</us-gaap:AccruedLiabilitiesCurrent>
    <us-gaap:AccruedLiabilitiesCurrent
      contextRef="PAsOn03_31_2021"
      decimals="-3"
      unitRef="Unit_USD">76936000</us-gaap:AccruedLiabilitiesCurrent>
    <us-gaap:OtherCurrentLiabilitiesTableTextBlock contextRef="P04_01_2021To06_30_2021">&lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Other current liabilities at June&#160;30, 2021 and March&#160;31, 2021 consisted of the following (in thousands): &lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0px;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 76%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px; text-indent: 0px;"&gt;
&lt;tr style="font-size: 0px;"&gt;
&lt;td style="width: 64%;"/&gt;
&lt;td style="width: 12%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="width: 12%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;June&#160;30,&#160;2021&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;March&#160;31,&#160;2021&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size: 0px;"&gt;
&lt;td style="width: 64%;"/&gt;
&lt;td style="width: 12%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="width: 12%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top; width: 64%;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Deferred revenue&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 12%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;3,777&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 12%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;5,918&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top; width: 64%;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Income tax payable&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 12%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;199&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 12%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;207&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top; width: 64%;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Other&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 12%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;4,325&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 12%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;3,037&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; width: 64%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 12%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 12%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top; width: 64%;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Total other current liabilities&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 12%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;8,301&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 12%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;9,162&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; width: 64%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 12%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 12%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; </us-gaap:OtherCurrentLiabilitiesTableTextBlock>
    <roiv:DeferredRevenueOtherCurrentLiabilities
      contextRef="PAsOn06_30_2021"
      decimals="-3"
      unitRef="Unit_USD">3777000</roiv:DeferredRevenueOtherCurrentLiabilities>
    <roiv:DeferredRevenueOtherCurrentLiabilities
      contextRef="PAsOn03_31_2021"
      decimals="-3"
      unitRef="Unit_USD">5918000</roiv:DeferredRevenueOtherCurrentLiabilities>
    <us-gaap:TaxesPayableCurrent
      contextRef="PAsOn06_30_2021"
      decimals="-3"
      unitRef="Unit_USD">199000</us-gaap:TaxesPayableCurrent>
    <us-gaap:TaxesPayableCurrent
      contextRef="PAsOn03_31_2021"
      decimals="-3"
      unitRef="Unit_USD">207000</us-gaap:TaxesPayableCurrent>
    <us-gaap:OtherSundryLiabilitiesCurrent
      contextRef="PAsOn06_30_2021"
      decimals="-3"
      unitRef="Unit_USD">4325000</us-gaap:OtherSundryLiabilitiesCurrent>
    <us-gaap:OtherSundryLiabilitiesCurrent
      contextRef="PAsOn03_31_2021"
      decimals="-3"
      unitRef="Unit_USD">3037000</us-gaap:OtherSundryLiabilitiesCurrent>
    <us-gaap:OtherLiabilitiesCurrent
      contextRef="PAsOn06_30_2021"
      decimals="-3"
      unitRef="Unit_USD">8301000</us-gaap:OtherLiabilitiesCurrent>
    <us-gaap:OtherLiabilitiesCurrent
      contextRef="PAsOn03_31_2021"
      decimals="-3"
      unitRef="Unit_USD">9162000</us-gaap:OtherLiabilitiesCurrent>
    <us-gaap:LongTermDebtTextBlock contextRef="P04_01_2021To06_30_2021">&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Note 6&#x2014;Long-Term Debt and Loan Commitment &lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;(A) Long-Term Debt &lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Long-term debt, net consists of the following (in thousands): &lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0px;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 84%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px; text-indent: 0px;"&gt;
&lt;tr style="font-size: 0px;"&gt;
&lt;td style="width: 68%;"/&gt;
&lt;td style="width: 8%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="width: 8%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;June&#160;30,&#160;2021&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;March&#160;31,&#160;2021&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size: 0px;"&gt;
&lt;td style="width: 68%;"/&gt;
&lt;td style="width: 8%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="width: 8%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top; width: 68%;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Principal amount&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 8%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;195,200&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 8%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;170,100&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top; width: 68%;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Exit fee / end of term charge&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 8%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;5,000&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 8%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;1,390&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top; width: 68%;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Less: unamortized debt discount and issuance costs&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 8%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;(13,850&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 8%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;(1,210&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; width: 68%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 8%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 8%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top; width: 68%;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Total debt, net&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 8%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;186,350&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 8%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;170,280&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top; width: 68%;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Less: current portion&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 8%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 8%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; width: 68%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 8%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 8%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top; width: 68%;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Total long-term debt, net&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 8%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;186,350&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 8%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;170,280&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; width: 68%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 8%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 8%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt; &lt;/tr&gt; &lt;/table&gt;  &lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt; margin-left: 2%;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;Dermavant &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;In May 2019, Dermavant entered into a loan and security agreement (the &#x201c;Hercules Loan Agreement&#x201d;) with Hercules Capital, Inc. (&#x201c;Hercules&#x201d;), pursuant to which Dermavant borrowed an aggregate of&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;$&lt;/div&gt;20.0&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;million, which bore interest at a variable per annum rate at the greater of (i) &lt;/div&gt;9.95&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;% or (ii)&#160;the prime rate plus &lt;/div&gt;4.45&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;%. Dermavant was also obligated to pay an end of term charge of $&lt;/div&gt;1.4&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;million. Following the achievement of certain milestones, the term loan maturity was extended to June&#160;1, 2023 with interest-only monthly payments through December 2021. All amounts outstanding under the Hercules Loan Agreement were repaid in May 2021 using the proceeds from a $&lt;/div&gt;40.0&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;million senior secured credit facility (the &#x201c;Credit Facility&#x201d;) entered into by Dermavant and certain of its subsidiaries in May 2021 with XYQ Luxco S.A.R.L (&#x201c;XYQ Luxco&#x201d;), as lender, and U.S. Bank National Association, as collateral agent. The Credit Facility has a &lt;/div&gt;five-year&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt; maturity and bears an interest rate of &lt;/div&gt;10.0&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;% per annum. Interest is payable quarterly in arrears on the last day of each calendar quarter through the maturity date. A lump sum principal payment is due on the maturity date.&#160;&lt;/div&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Dermavant is also obligated to pay an exit fee of $5.0&#160;million. The exit fee can be reduced to $4.0&#160;million upon achievement of certain equity milestones defined in the agreement, which are not deemed likely as of June&#160;30, 2021. In connection with the &lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0px;"&gt;&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;funding of the Credit Facility, Dermavant issued a warrant to XYQ Luxco to purchase &lt;/div&gt;1,199,072&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt; common shares of Dermavant at an exercise price of $&lt;/div&gt;0.01&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt; per common share.&lt;/div&gt;&lt;/div&gt; &lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;In connection with Dermavant&#x2019;s acquisition of tapinarof from GlaxoSmithKline Intellectual Property Development Ltd. and Glaxo Group Limited (collectively &#x201c;GSK&#x201d;) pursuant to an asset purchase agreement (the &#x201c;GSK Agreement&#x201d;), Dermavant and NovaQuest &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Co-Investment&lt;/div&gt; Fund VIII, L.P. (&#x201c;NovaQuest&#x201d;) entered into a funding agreement (the &#x201c;NovaQuest Agreement&#x201d;). Pursuant to the NovaQuest Agreement, Dermavant borrowed $100.0&#160;million in August 2018 and $17.5&#160;million in October 2018 in exchange for an obligation to make certain variable future payments calculated as a function of the achievement of regulatory and commercial milestones or events of termination. The aggregate maximum amount of regulatory milestone payments that Dermavant could be required to make under the NovaQuest Agreement is $440.6&#160;million, and the maximum aggregate amount of commercial milestone payments is $141.0&#160;million. In some circumstances, Dermavant may be able to offset certain of the regulatory milestone payments with up to $88.1&#160;million of the commercial milestone payments. At issuance, the Company concluded that certain features of the long-term debt would be considered derivatives that would require bifurcation. In lieu of bifurcating various features in the agreement, the Company has elected the fair value option for this financial instrument and will record the changes in the fair value within the statements of operations at the end of each reporting period. Direct costs and fees related to the debt issued under the NovaQuest Agreement were recognized in earnings. As of June&#160;30, 2021 and March&#160;31, 2021, the fair value of the debt was $155.2&#160;million and $150.1&#160;million, respectively. Refer to Note 11, &#x201c;Fair Value Measurements&#x201d; for additional details regarding the fair value measurement. &lt;/div&gt; &lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;(B) Loan Commitment &lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;In May 2021, Dermavant, as seller, entered into a $160.0&#160;million revenue interest purchase and sale agreement (the &#x201c;RIPSA&#x201d;) for its investigational product tapinarof with XYQ Luxco, NovaQuest &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Co-Investment&lt;/div&gt; Fund XVII, L.P., an affiliate of NovaQuest Capital Management, LLC, and MAM Tapir Lender, LLC, an affiliate of Marathon Asset Management, L.P. (collectively, the &#x201c;Purchasers&#x201d;), together with U.S. Bank National Association, as collateral agent. Under the terms of the RIPSA, the Purchasers procured a capped single-digit revenue interest in net sales of tapinarof for all dermatological indications in the United States in exchange for $160.0&#160;million in committed funding to be paid to Dermavant, conditional based on the approval of tapinarof by the FDA. The agreement will be canceled if funding has not occurred by July 2023. Dermavant acquired the worldwide rights to tapinarof (other than with respect to certain rights in China) in August 2018 pursuant to the GSK Agreement. Dermavant intends to use the RIPSA proceeds for the payment of certain &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;one-time&lt;/div&gt; milestone obligations that become payable upon the approval and commercialization of tapinarof for the treatment of psoriasis in the United States as well as for other general corporate purposes. &lt;/div&gt; </us-gaap:LongTermDebtTextBlock>
    <us-gaap:ScheduleOfDebtTableTextBlock contextRef="P04_01_2021To06_30_2021">&lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Long-term debt, net consists of the following (in thousands): &lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0px;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 84%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px; text-indent: 0px;"&gt;
&lt;tr style="font-size: 0px;"&gt;
&lt;td style="width: 68%;"/&gt;
&lt;td style="width: 8%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="width: 8%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;June&#160;30,&#160;2021&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;March&#160;31,&#160;2021&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size: 0px;"&gt;
&lt;td style="width: 68%;"/&gt;
&lt;td style="width: 8%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="width: 8%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top; width: 68%;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Principal amount&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 8%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;195,200&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 8%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;170,100&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top; width: 68%;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Exit fee / end of term charge&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 8%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;5,000&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 8%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;1,390&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top; width: 68%;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Less: unamortized debt discount and issuance costs&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 8%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;(13,850&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 8%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;(1,210&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; width: 68%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 8%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 8%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top; width: 68%;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Total debt, net&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 8%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;186,350&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 8%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;170,280&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top; width: 68%;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Less: current portion&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 8%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 8%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; width: 68%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 8%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 8%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top; width: 68%;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Total long-term debt, net&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 8%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;186,350&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 8%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;170,280&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; width: 68%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 8%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 8%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; </us-gaap:ScheduleOfDebtTableTextBlock>
    <us-gaap:DebtInstrumentCarryingAmount
      contextRef="PAsOn06_30_2021"
      decimals="-3"
      unitRef="Unit_USD">195200000</us-gaap:DebtInstrumentCarryingAmount>
    <us-gaap:DebtInstrumentCarryingAmount
      contextRef="PAsOn03_31_2021"
      decimals="-3"
      unitRef="Unit_USD">170100000</us-gaap:DebtInstrumentCarryingAmount>
    <roiv:DebtInstrumentExitFeeAndEndOfTermCharge
      contextRef="PAsOn06_30_2021"
      decimals="-3"
      unitRef="Unit_USD">5000000</roiv:DebtInstrumentExitFeeAndEndOfTermCharge>
    <roiv:DebtInstrumentExitFeeAndEndOfTermCharge
      contextRef="PAsOn03_31_2021"
      decimals="-3"
      unitRef="Unit_USD">1390000</roiv:DebtInstrumentExitFeeAndEndOfTermCharge>
    <us-gaap:DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet
      contextRef="PAsOn06_30_2021"
      decimals="-3"
      unitRef="Unit_USD">13850000</us-gaap:DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet>
    <us-gaap:DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet
      contextRef="PAsOn03_31_2021"
      decimals="-3"
      unitRef="Unit_USD">1210000</us-gaap:DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet>
    <us-gaap:LongTermDebt
      contextRef="PAsOn06_30_2021"
      decimals="-3"
      unitRef="Unit_USD">186350000</us-gaap:LongTermDebt>
    <us-gaap:LongTermDebt
      contextRef="PAsOn03_31_2021"
      decimals="-3"
      unitRef="Unit_USD">170280000</us-gaap:LongTermDebt>
    <us-gaap:LongTermDebtCurrent
      contextRef="PAsOn06_30_2021"
      decimals="-3"
      unitRef="Unit_USD">0</us-gaap:LongTermDebtCurrent>
    <us-gaap:LongTermDebtCurrent
      contextRef="PAsOn03_31_2021"
      decimals="-3"
      unitRef="Unit_USD">0</us-gaap:LongTermDebtCurrent>
    <us-gaap:LongTermDebtNoncurrent
      contextRef="PAsOn06_30_2021"
      decimals="-3"
      unitRef="Unit_USD">186350000</us-gaap:LongTermDebtNoncurrent>
    <us-gaap:LongTermDebtNoncurrent
      contextRef="PAsOn03_31_2021"
      decimals="-3"
      unitRef="Unit_USD">170280000</us-gaap:LongTermDebtNoncurrent>
    <us-gaap:DebtInstrumentFaceAmount
      contextRef="PAsOn05_31_2019"
      decimals="-5"
      unitRef="Unit_USD">20000000.0</us-gaap:DebtInstrumentFaceAmount>
    <us-gaap:LongTermDebtPercentageBearingVariableInterestRate
      contextRef="PAsOn05_31_2019"
      decimals="4"
      unitRef="Unit_pure">0.0995</us-gaap:LongTermDebtPercentageBearingVariableInterestRate>
    <us-gaap:LongTermDebtPercentageBearingVariableInterestRate
      contextRef="PAsOn05_31_2019_PrimeRateMemberusgaapVariableRateAxis"
      decimals="4"
      unitRef="Unit_pure">0.0445</us-gaap:LongTermDebtPercentageBearingVariableInterestRate>
    <us-gaap:DebtInstrumentFeeAmount
      contextRef="PAsOn05_31_2019"
      decimals="-5"
      unitRef="Unit_USD">1400000</us-gaap:DebtInstrumentFeeAmount>
    <us-gaap:ProceedsFromLinesOfCredit
      contextRef="P05_01_2021To05_01_2021"
      decimals="-5"
      unitRef="Unit_USD">40000000.0</us-gaap:ProceedsFromLinesOfCredit>
    <us-gaap:DebtInstrumentTerm contextRef="P05_01_2021To05_01_2021">P5Y</us-gaap:DebtInstrumentTerm>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="PAsOn05_01_2021"
      decimals="3"
      unitRef="Unit_pure">0.100</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <roiv:DebtInstrumentExitFeeAndEndOfTermCharge
      contextRef="PAsOn05_31_2019"
      decimals="-2"
      unitRef="Unit_USD">5000.0</roiv:DebtInstrumentExitFeeAndEndOfTermCharge>
    <us-gaap:DebtInstrumentFeeAmount
      contextRef="PAsOn06_30_2021"
      decimals="-2"
      unitRef="Unit_USD">4000.0</us-gaap:DebtInstrumentFeeAmount>
    <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight
      contextRef="PAsOn05_31_2021"
      decimals="0"
      unitRef="Unit_shares">1199072</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="PAsOn05_31_2021"
      decimals="2"
      unitRef="Unit_USD_per_Share">0.01</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:DebtInstrumentFaceAmount
      contextRef="PAsOn08_31_2018_NovaquestMemberusgaapTypeOfArrangementAxis"
      decimals="-5"
      unitRef="Unit_USD">100000000.0</us-gaap:DebtInstrumentFaceAmount>
    <us-gaap:DebtInstrumentFaceAmount
      contextRef="PAsOn10_31_2018_NovaquestMemberusgaapTypeOfArrangementAxis"
      decimals="-5"
      unitRef="Unit_USD">17500000</us-gaap:DebtInstrumentFaceAmount>
    <roiv:MaximumMilestonePaymentObligation
      contextRef="PAsOn08_31_2018_NovaquestMemberusgaapTypeOfArrangementAxis_RegulatoryMilestoneMemberusgaapTransactionTypeAxis"
      decimals="-5"
      unitRef="Unit_USD">440600000</roiv:MaximumMilestonePaymentObligation>
    <roiv:MaximumMilestonePaymentObligation
      contextRef="PAsOn08_31_2018_CommercialMilestoneMemberusgaapTransactionTypeAxis_NovaquestMemberusgaapTypeOfArrangementAxis"
      decimals="-5"
      unitRef="Unit_USD">141000000.0</roiv:MaximumMilestonePaymentObligation>
    <roiv:MaximumMilestonePaymentOffsetAmount
      contextRef="PAsOn08_31_2018_NovaquestMemberusgaapTypeOfArrangementAxis_RegulatoryMilestoneMemberusgaapTransactionTypeAxis"
      decimals="-5"
      unitRef="Unit_USD">88100000</roiv:MaximumMilestonePaymentOffsetAmount>
    <us-gaap:DebtInstrumentFairValue
      contextRef="PAsOn06_30_2021_NovaquestMemberusgaapTypeOfArrangementAxis"
      decimals="-5"
      unitRef="Unit_USD">155200000</us-gaap:DebtInstrumentFairValue>
    <us-gaap:DebtInstrumentFairValue
      contextRef="PAsOn03_31_2021_NovaquestMemberusgaapTypeOfArrangementAxis"
      decimals="-5"
      unitRef="Unit_USD">150100000</us-gaap:DebtInstrumentFairValue>
    <us-gaap:SecuritiesPurchasedUnderAgreementsToResellIncrease
      contextRef="P05_01_2021To05_31_2021_RevenueInterestPurchaseAndSaleAgreementMemberusgaapFinancialInstrumentAxis"
      decimals="-5"
      unitRef="Unit_USD">160000000.0</us-gaap:SecuritiesPurchasedUnderAgreementsToResellIncrease>
    <roiv:MinimumAmountOfAnnualNetSalesToQualifyUnderRevenueInterestPurchaseAgreementContingentThreshold
      contextRef="P05_01_2021To05_31_2021_RevenueInterestPurchaseAndSaleAgreementMemberusgaapFinancialInstrumentAxis"
      decimals="-5"
      unitRef="Unit_USD">160000000.0</roiv:MinimumAmountOfAnnualNetSalesToQualifyUnderRevenueInterestPurchaseAgreementContingentThreshold>
    <us-gaap:StockholdersEquityNoteDisclosureTextBlock contextRef="P04_01_2021To06_30_2021">&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt; text-indent: 0px;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Note 7&#x2014;Shareholders&#x2019; Equity and Redeemable Noncontrolling Interest &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt; text-indent: 0px;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;Business Combination Agreement &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;On May&#160;1, 2021, the Company entered into a Business Combination Agreement (the &#x201c;Business Combination Agreement&#x201d;) with Montes Archimedes Acquisition Corporation (&#x201c;MAAC&#x201d;) and Rhine Merger Sub, Inc. (&#x201c;Merger Sub&#x201d;). MAAC was incorporated in Delaware on July&#160;6, 2020 and was formed as a blank check company for the purpose of effecting a merger, share exchange, asset acquisition, stock purchase, recapitalization, reorganization or similar business combination with one or more businesses. Pursuant to the Business Combination Agreement, and assuming a favorable vote by MAAC&#x2019;s stockholders at a special meeting of MAAC&#x2019;s stockholders convened for purposes of approving the transactions contemplated by the Business Combination Agreement (the &#x201c;Business Combination&#x201d;), and the satisfaction or waiver of all other closing conditions pursuant to the Business Combination Agreement, Merger Sub will merge with and into MAAC, with MAAC surviving the merger as the Company&#x2019;s wholly owned subsidiary. &lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;For financial accounting and reporting purposes, MAAC will be treated as the acquired company. Accordingly, because MAAC does not represent a business for accounting purposes and its primary asset &lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0px;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;represents cash and cash equivalents, the Business Combination will be treated as an equity contribution in exchange for the issuance of RSL shares. The net assets of MAAC will be stated at historical cost, with no goodwill or other intangible assets recorded. RSL will be deemed both the accounting predecessor and the successor SEC registrant, which means that the Company&#x2019;s financial statements for previous periods will be disclosed in the Company&#x2019;s future periodic reports filed with the SEC. &lt;/div&gt;&lt;/div&gt;&lt;/div&gt; </us-gaap:StockholdersEquityNoteDisclosureTextBlock>
    <us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock contextRef="P04_01_2021To06_30_2021">&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Note 8&#x2014;Share-Based Compensation &lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;(A) RSL 2015 Equity Incentive Plan &lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;As of June&#160;30, 2021, 22,800,000 of the Company&#x2019;s common shares (the &#x201c;Share Reserve&#x201d;) are reserved for issuance under the RSL Amended and Restated 2015 Equity Incentive Plan (the &#x201c;RSL 2015 EIP&#x201d;). At June&#160;30, 2021, a total of 786,125 common shares are available for future grants under the RSL 2015 EIP. The Company&#x2019;s employees, directors, and consultants are eligible to receive nonstatutory and incentive stock options, stock appreciation rights, restricted stock awards, restricted stock unit awards, and other stock awards under the RSL 2015 EIP. &lt;/div&gt;&lt;/div&gt; &lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;As of June&#160;30, 2021, an aggregate of 26,558,238 of the Company&#x2019;s common shares (the &#x201c;Special Reserve&#x201d;) are reserved for the granting under RSL 2015 EIP of performance stock options (&#x201c;Performance Options&#x201d;) and capped value appreciation rights (&#x201c;CVARs&#x201d;) to the Company&#x2019;s employees, directors and consultants. At June&#160;30, 2021, there are no common shares available for future grant under the Special Reserve. &lt;/div&gt;&lt;/div&gt; &lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt; margin-left: 2%;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;Stock Options &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;During the three months ended June&#160;30, 2021 and 2020, the Company recorded share-based compensation expense related to stock options issued under the RSL 2015 EIP to employees and directors of approximately $10.3&#160;million and $7.8&#160;million, respectively, and was included in research and development and general and administrative expenses in the accompanying condensed consolidated statements of operations. &lt;/div&gt;&lt;/div&gt; &lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;A summary of stock option activity and data under the RSL 2015 EIP for the three months ended June&#160;30, 2021 is as follows: &lt;/div&gt;&lt;/div&gt; &lt;div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;width:76%;"&gt;
&lt;tr style="font-size: 0px;"&gt;
&lt;td style="width: 65%;"/&gt;
&lt;td style="width: 8%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="width: 8%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Number&#160;of&lt;br/&gt; Stock&lt;br/&gt; Options&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Weighted&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Average&lt;br/&gt; Exercise&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;Price&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top; width: 65%;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Stock options outstanding at March&#160;31, 2021&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 8%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;9,389,371&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 8%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;26.61&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top; width: 65%;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Granted&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 8%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;3,798,605&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 8%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;29.26&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top; width: 65%;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Forfeited&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 8%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;(106,428&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 8%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;30.27&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; width: 65%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 8%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 8%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top; width: 65%;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Stock options outstanding at June&#160;30, 2021&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 8%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;13,081,548&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 8%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;27.35&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; width: 65%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 8%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 8%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;  &lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt; margin-left: 2%;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;Restricted Stock Units &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Restricted stock units will generally vest upon the achievement of both time-based service requirements and liquidity requirements on or before the grant expiration date. Certain restricted stock units have also been granted that will vest upon the achievement of development milestones and liquidity requirements. As of June&#160;30, 2021, the liquidity event requirement had not been met and was deemed not probable of being met. During the three months ended June&#160;30, 2021 and 2020, the Company recorded no share-based compensation expense related to these restricted stock units. The Company will recognize the expense upon achievement of both the time-based service requirement and liquidity requirements through the requisite &lt;/div&gt;&lt;/div&gt; &lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0in;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;service period.&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;A summary of restricted stock units under the RSL 2015 EIP is as follows: &lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;width:68%;"&gt;
&lt;tr style="font-size: 0px;"&gt;
&lt;td style="width: 77%;"/&gt;
&lt;td style="width: 10%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Number&#160;of&lt;br/&gt; Restricted&#160;Stock&lt;br/&gt; Units&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top; width: 77%;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Non-vested&lt;/div&gt; balance at March&#160;31, 2021&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 10%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;2,292,738&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top; width: 77%;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Granted&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 10%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;5,939,340&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top; width: 77%;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Forfeited&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 10%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;(119,285&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; width: 77%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 10%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top; width: 77%;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Non-vested&lt;/div&gt; balance at June&#160;30, 2021&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 10%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;8,112,793&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; width: 77%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 10%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;  Performance OptionsPerformance Options will vest upon the achievement of both time-based service requirements and liquidity requirements on or before the grant expiration date of March&#160;31, 2026. As of June&#160;30, 2021, the liquidity event requirement had not been met and was deemed not probable of being met. During the three months ended June&#160;30, 2021 and 2020, the Company recorded no share-based compensation expense related to these Performance Options. The Company will recognize the expense upon achievement of both the time-based service requirement and liquidity requirements through the requisite service period. &lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;A summary of Performance Option activity and data under the RSL 2015 EIP for the three months ended June&#160;30, 2021 is as follows: &lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0px;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 84%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px; text-indent: 0px;"&gt;
&lt;tr style="font-size: 0px;"&gt;
&lt;td style="width: 70%;"/&gt;
&lt;td style="width: 6%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="width: 6%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Number of&lt;br/&gt; Performance&lt;br/&gt; Options&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Weighted&lt;br/&gt; Average&lt;br/&gt; Exercise&#160;Price&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size: 0px;"&gt;
&lt;td style="width: 70%;"/&gt;
&lt;td style="width: 6%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="width: 6%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top; width: 70%;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Performance Options outstanding at March&#160;31, 2021&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 6%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;14,425,663&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 6%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;38.93&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top; width: 70%;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Granted&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 6%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 6%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top; width: 70%;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Forfeited&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 6%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 6%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; width: 70%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 6%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 6%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top; width: 70%;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Performance Options outstanding at June&#160;30, 2021&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 6%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;14,425,663&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 6%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;38.93&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; width: 70%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 6%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 6%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt; &lt;/tr&gt; &lt;/table&gt;  &lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt; margin-left: 2%;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;CVARs &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;CVARs will vest upon the achievement of both time-based service requirements and liquidity requirements on or before the grant expiration date of March&#160;31, 2026. At settlement, each CVAR pays the excess in shares of (a)&#160;the lesser of (i)&#160;the fair market value of a common share as of the settlement date or (ii)&#160;the cap of $&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;37.10&lt;/div&gt;, over (b)&#160;the hurdle price of either $&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;18.70 &lt;/div&gt;or $&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;33.63&lt;/div&gt;, as applicable to each grant. As of June&#160;30, 2021, the liquidity event requirement had not been met and was deemed not probable of being met. During the three months ended June&#160;30, 2021 and 2020, the Company recorded no share-based compensation expense related to these CVARs. The Company will recognize the expense upon achievement of both the time-based service requirement and liquidity requirements through the requisite service period&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;.&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;  &lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;A summary of CVARs under the RSL 2015 EIP is as follows: &lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0px;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 68%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px; text-indent: 0px;"&gt;
&lt;tr style="font-size: 0px;"&gt;
&lt;td style="width: 81%;"/&gt;
&lt;td style="width: 4%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Number of&lt;br/&gt; CVARs&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size: 0px;"&gt;
&lt;td style="width: 81%;"/&gt;
&lt;td style="width: 4%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top; width: 81%;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Non-vested&lt;/div&gt; balance at March&#160;31, 2021&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 4%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;11,088,658&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top; width: 81%;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Granted&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 4%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top; width: 81%;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Forfeited&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 4%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; width: 81%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 4%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top; width: 81%;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Non-vested&lt;/div&gt; balance at June&#160;30, 2021&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 4%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;11,088,658&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; width: 81%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 4%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt; &lt;/tr&gt; &lt;/table&gt;  &lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0px;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;(B) RSL 2015 Restricted Stock Unit Plan &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Under the Amended and Restated RSL 2015 Restricted Stock Unit Plan (the &#x201c;pRSU Plan&#x201d;), as of June&#160;30, 2021, there are 200,000 of the Company&#x2019;s common shares reserved for the granting under the pRSU Plan of restricted stock units (&#x201c;Performance RSUs&#x201d;) to the Company&#x2019;s employees, officers, directors and consultants. The Performance RSUs expire eight years after the date of grant. At June&#160;30, 2021, there are no common shares available for future grants under this plan.&#160;&lt;/div&gt;&lt;/div&gt;  &lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;A summary of Performance RSU activity under the pRSU Plan is as follows: &lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0px;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 68%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px; text-indent: 0px;"&gt;
&lt;tr style="font-size: 0px;"&gt;
&lt;td style="width: 81%;"/&gt;
&lt;td style="width: 8%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Number of&lt;br/&gt; Performance&lt;br/&gt; RSUs&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size: 0px;"&gt;
&lt;td style="width: 85%;"/&gt;
&lt;td style="width: 6%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Non-vested&lt;/div&gt; balance at March&#160;31, 2021&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;200,000&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; break-inside: avoid;"&gt;
&lt;td style="vertical-align: top; background-color: rgb(255, 255, 255);"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Granted&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgb(255, 255, 255);"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(255, 255, 255);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(255, 255, 255);;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(255, 255, 255);"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top; background-color: rgb(204, 238, 255);"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Forfeited&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; background-color: rgb(255, 255, 255);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgb(255, 255, 255);"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgb(255, 255, 255);"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgb(255, 255, 255);"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="background-color: rgb(255, 255, 255);"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; break-inside: avoid;"&gt;
&lt;td style="vertical-align: top; background-color: rgb(255, 255, 255);"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Non-vested&lt;/div&gt; balance at June&#160;30, 2021&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgb(255, 255, 255);"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(255, 255, 255);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(255, 255, 255);;text-align:right;"&gt;200,000&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(255, 255, 255);"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; background-color: rgb(255, 255, 255);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgb(255, 255, 255);"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgb(255, 255, 255);"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgb(255, 255, 255);"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="background-color: rgb(255, 255, 255);"&gt;&#160;&lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; These Performance RSUs will vest to the extent certain performance criteria are achieved and certain liquidity conditions are satisfied within specified years of the grant date, provided that the recipient has provided continued service through such date. As of June&#160;30, 2021, the performance conditions had not been met and were deemed not probable of being met. During the three months ended June&#160;30, 2021 and 2020, the Company recorded no share-based compensation expense related to these Performance RSUs. The Company will recognize the expense upon achievement of the performance and liquidity conditions through the requisite service period. &lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;(C) RSL Restricted Common Stock &lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;A summary of RSL restricted common stock activity as of June&#160;30, 2021 is as follows: &lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0px;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 68%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px; text-indent: 0px;"&gt;
&lt;tr style="font-size: 0px;"&gt;
&lt;td style="width: 78%;"/&gt;
&lt;td style="width: 11%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Number of&lt;br/&gt; Restricted&lt;br/&gt; Common&#160;Stock&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size: 0px;"&gt;
&lt;td style="width: 83%;"/&gt;
&lt;td style="width: 8%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Non-vested&lt;/div&gt; balance at March&#160;31, 2021&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;587,824&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Granted&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Forfeited&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Non-vested&lt;/div&gt; balance at June&#160;30, 2021&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;587,824&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt; &lt;/tr&gt; &lt;/table&gt;  &lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;For the three months ended June&#160;30, 2021, the Company recorded share-based compensation expense of $0.8&#160;million in relation to the RSL restricted common stock. The RSL restricted common stock will vest upon the achievement of time-based service requirements. &lt;/div&gt;&lt;/div&gt;  &lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;(D) Subsidiary Equity Incentive Plans &lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;Certain wholly owned and majority-owned or controlled subsidiaries of RSL adopt their own equity incentive plan (&#x201c;EIP&#x201d;). Each EIP is generally structured so that the applicable subsidiary, and its affiliates&#x2019; employees, directors, officers and consultants are eligible to receive &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;non-qualified&lt;/div&gt; and incentive stock options, stock appreciation rights, restricted share awards, restricted stock unit awards, and other share awards under their respective EIP. Standard option grants have time-based vesting requirements, generally vesting over a period of four years with a contractual term of ten years. Such time-based stock options use the Black-Scholes option pricing model. The grant date fair value of awards subject to market conditions is estimated using a Monte Carlo valuation model. For the three months ended June&#160;31, 2021 and 2020, the Company recorded share-based compensation expense of $8.2&#160;million and $6.5&#160;million, respectively, in relation to subsidiary EIPs. &lt;/div&gt; (E) Share-Based Compensation Expense &lt;div style="text-indent: 4%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt; padding-top: 0pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Share-based compensation expense was as follows (in thousands): &lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0px; padding-top: 0pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 76%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px; text-indent: 0px;"&gt;
&lt;tr style="font-size: 0px;"&gt;
&lt;td style="width: 74%;"/&gt;
&lt;td style="width: 5%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="width: 5%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td colspan="6" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Three&#160;Months&#160;Ended&lt;br/&gt; June&#160;30,&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2021&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2020&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top; font-size: 10pt;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; padding-top: 0pt; line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Share-based compensation expense recognized as:&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size: 0px;"&gt;
&lt;td style="width: 80%;"/&gt;
&lt;td style="width: 4%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="width: 4%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; padding-top: 0pt; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;R&amp;amp;D expenses&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;1,615&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;1,119&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; padding-top: 0pt; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;G&amp;amp;A expenses&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;17,654&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;13,159&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); padding-top: 0pt; line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); padding-top: 0pt; line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); padding-top: 0pt; line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); padding-top: 0pt; line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; padding-top: 0pt; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Total&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;19,269&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;14,278&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); padding-top: 0pt; line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); padding-top: 0pt; line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); padding-top: 0pt; line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); padding-top: 0pt; line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; &lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px; text-indent: 0px;;display:inline;"&gt;The classification of share-based compensation expense between R&amp;amp;D and G&amp;amp;A expenses in the accompanying condensed consolidated statements of operations is consistent with the classification of grantee&#x2019;s salary expense.&lt;/div&gt;&lt;/div&gt;</us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock>
    <us-gaap:CommonStockCapitalSharesReservedForFutureIssuance
      contextRef="PAsOn06_30_2021_TwoThousandFifteenEquityIncentivePlanMemberusgaapPlanNameAxis"
      decimals="INF"
      unitRef="Unit_shares">22800000</us-gaap:CommonStockCapitalSharesReservedForFutureIssuance>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant
      contextRef="PAsOn06_30_2021_TwoThousandFifteenEquityIncentivePlanMemberusgaapPlanNameAxis"
      decimals="INF"
      unitRef="Unit_shares">786125</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant>
    <roiv:CommonSharesReservedForPerformanceOptionsAndCappedValueAppreciationRights
      contextRef="PAsOn06_30_2021_SpecialReserveMemberusgaapAwardTypeAxis_TwoThousandFifteenEquityIncentivePlanMemberusgaapPlanNameAxis"
      decimals="INF"
      unitRef="Unit_shares">26558238</roiv:CommonSharesReservedForPerformanceOptionsAndCappedValueAppreciationRights>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant
      contextRef="PAsOn06_30_2021_SpecialReserveMemberusgaapAwardTypeAxis_TwoThousandFifteenEquityIncentivePlanMemberusgaapPlanNameAxis"
      decimals="INF"
      unitRef="Unit_shares">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="P04_01_2021To06_30_2021_EmployeeStockOptionMemberusgaapAwardTypeAxis_TwoThousandFifteenEquityIncentivePlanMemberusgaapPlanNameAxis"
      decimals="INF"
      unitRef="Unit_USD">10300000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="P04_01_2020To06_30_2020_EmployeeStockOptionMemberusgaapAwardTypeAxis_TwoThousandFifteenEquityIncentivePlanMemberusgaapPlanNameAxis"
      decimals="INF"
      unitRef="Unit_USD">7800000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock contextRef="P04_01_2021To06_30_2021">&lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;A summary of stock option activity and data under the RSL 2015 EIP for the three months ended June&#160;30, 2021 is as follows: &lt;/div&gt;&lt;/div&gt; &lt;div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;width:76%;"&gt;
&lt;tr style="font-size: 0px;"&gt;
&lt;td style="width: 65%;"/&gt;
&lt;td style="width: 8%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="width: 8%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Number&#160;of&lt;br/&gt; Stock&lt;br/&gt; Options&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Weighted&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Average&lt;br/&gt; Exercise&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;Price&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top; width: 65%;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Stock options outstanding at March&#160;31, 2021&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 8%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;9,389,371&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 8%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;26.61&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top; width: 65%;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Granted&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 8%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;3,798,605&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 8%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;29.26&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top; width: 65%;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Forfeited&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 8%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;(106,428&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 8%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;30.27&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; width: 65%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 8%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 8%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top; width: 65%;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Stock options outstanding at June&#160;30, 2021&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 8%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;13,081,548&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 8%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;27.35&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; width: 65%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 8%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 8%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt; </us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="PAsOn03_31_2021_EmployeeStockOptionMemberusgaapAwardTypeAxis_TwoThousandFifteenEquityIncentivePlanMemberusgaapPlanNameAxis"
      decimals="INF"
      unitRef="Unit_shares">9389371</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
      contextRef="PAsOn03_31_2021_EmployeeStockOptionMemberusgaapAwardTypeAxis_TwoThousandFifteenEquityIncentivePlanMemberusgaapPlanNameAxis"
      decimals="2"
      unitRef="Unit_USD_per_Share">26.61</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
      contextRef="P04_01_2021To06_30_2021_EmployeeStockOptionMemberusgaapAwardTypeAxis_TwoThousandFifteenEquityIncentivePlanMemberusgaapPlanNameAxis"
      decimals="INF"
      unitRef="Unit_shares">3798605</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
      contextRef="P04_01_2021To06_30_2021_EmployeeStockOptionMemberusgaapAwardTypeAxis_TwoThousandFifteenEquityIncentivePlanMemberusgaapPlanNameAxis"
      decimals="2"
      unitRef="Unit_USD_per_Share">29.26</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod
      contextRef="P04_01_2021To06_30_2021_EmployeeStockOptionMemberusgaapAwardTypeAxis_TwoThousandFifteenEquityIncentivePlanMemberusgaapPlanNameAxis"
      decimals="INF"
      unitRef="Unit_shares">106428</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice
      contextRef="P04_01_2021To06_30_2021_EmployeeStockOptionMemberusgaapAwardTypeAxis_TwoThousandFifteenEquityIncentivePlanMemberusgaapPlanNameAxis"
      decimals="2"
      unitRef="Unit_USD_per_Share">30.27</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="PAsOn06_30_2021_EmployeeStockOptionMemberusgaapAwardTypeAxis_TwoThousandFifteenEquityIncentivePlanMemberusgaapPlanNameAxis"
      decimals="INF"
      unitRef="Unit_shares">13081548</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
      contextRef="PAsOn06_30_2021_EmployeeStockOptionMemberusgaapAwardTypeAxis_TwoThousandFifteenEquityIncentivePlanMemberusgaapPlanNameAxis"
      decimals="2"
      unitRef="Unit_USD_per_Share">27.35</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="P04_01_2020To06_30_2020_RestrictedStockUnitsRSUMemberusgaapAwardTypeAxis_TwoThousandFifteenEquityIncentivePlanMemberusgaapPlanNameAxis"
      decimals="INF"
      unitRef="Unit_USD">0</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="P04_01_2021To06_30_2021_RestrictedStockUnitsRSUMemberusgaapAwardTypeAxis_TwoThousandFifteenEquityIncentivePlanMemberusgaapPlanNameAxis"
      decimals="INF"
      unitRef="Unit_USD">0</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock contextRef="P04_01_2021To06_30_2021">&lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;A summary of restricted stock units under the RSL 2015 EIP is as follows: &lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;width:68%;"&gt;
&lt;tr style="font-size: 0px;"&gt;
&lt;td style="width: 77%;"/&gt;
&lt;td style="width: 10%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Number&#160;of&lt;br/&gt; Restricted&#160;Stock&lt;br/&gt; Units&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top; width: 77%;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Non-vested&lt;/div&gt; balance at March&#160;31, 2021&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 10%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;2,292,738&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top; width: 77%;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Granted&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 10%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;5,939,340&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top; width: 77%;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Forfeited&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 10%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;(119,285&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; width: 77%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 10%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top; width: 77%;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Non-vested&lt;/div&gt; balance at June&#160;30, 2021&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 10%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;8,112,793&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; width: 77%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 10%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt; </us-gaap:ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber
      contextRef="PAsOn03_31_2021_RestrictedStockUnitsRSUMemberusgaapAwardTypeAxis_TwoThousandFifteenEquityIncentivePlanMemberusgaapPlanNameAxis"
      decimals="INF"
      unitRef="Unit_shares">2292738</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod
      contextRef="P04_01_2021To06_30_2021_RestrictedStockUnitsRSUMemberusgaapAwardTypeAxis_TwoThousandFifteenEquityIncentivePlanMemberusgaapPlanNameAxis"
      decimals="INF"
      unitRef="Unit_shares">5939340</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod
      contextRef="P04_01_2021To06_30_2021_RestrictedStockUnitsRSUMemberusgaapAwardTypeAxis_TwoThousandFifteenEquityIncentivePlanMemberusgaapPlanNameAxis"
      decimals="INF"
      unitRef="Unit_shares">119285</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber
      contextRef="PAsOn06_30_2021_RestrictedStockUnitsRSUMemberusgaapAwardTypeAxis_TwoThousandFifteenEquityIncentivePlanMemberusgaapPlanNameAxis"
      decimals="INF"
      unitRef="Unit_shares">8112793</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="P04_01_2021To06_30_2021_PerformanceOptionsMemberusgaapAwardTypeAxis_TwoThousandFifteenEquityIncentivePlanMemberusgaapPlanNameAxis"
      decimals="INF"
      unitRef="Unit_USD">0</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="P04_01_2020To06_30_2020_PerformanceOptionsMemberusgaapAwardTypeAxis_TwoThousandFifteenEquityIncentivePlanMemberusgaapPlanNameAxis"
      decimals="INF"
      unitRef="Unit_USD">0</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock contextRef="P04_01_2021To06_30_2021_PerformanceOptionsMemberusgaapAwardTypeAxis">&lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;A summary of Performance Option activity and data under the RSL 2015 EIP for the three months ended June&#160;30, 2021 is as follows: &lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0px;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 84%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px; text-indent: 0px;"&gt;
&lt;tr style="font-size: 0px;"&gt;
&lt;td style="width: 70%;"/&gt;
&lt;td style="width: 6%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="width: 6%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Number of&lt;br/&gt; Performance&lt;br/&gt; Options&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Weighted&lt;br/&gt; Average&lt;br/&gt; Exercise&#160;Price&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size: 0px;"&gt;
&lt;td style="width: 70%;"/&gt;
&lt;td style="width: 6%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="width: 6%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top; width: 70%;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Performance Options outstanding at March&#160;31, 2021&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 6%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;14,425,663&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 6%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;38.93&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top; width: 70%;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Granted&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 6%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 6%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top; width: 70%;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Forfeited&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 6%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 6%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; width: 70%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 6%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 6%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top; width: 70%;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Performance Options outstanding at June&#160;30, 2021&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 6%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;14,425,663&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 6%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;38.93&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; width: 70%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 6%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 6%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; </us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="PAsOn03_31_2021_PerformanceOptionsMemberusgaapAwardTypeAxis_TwoThousandFifteenEquityIncentivePlanMemberusgaapPlanNameAxis"
      decimals="INF"
      unitRef="Unit_shares">14425663</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
      contextRef="PAsOn03_31_2021_PerformanceOptionsMemberusgaapAwardTypeAxis_TwoThousandFifteenEquityIncentivePlanMemberusgaapPlanNameAxis"
      decimals="2"
      unitRef="Unit_USD_per_Share">38.93</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
      contextRef="P04_01_2021To06_30_2021_PerformanceOptionsMemberusgaapAwardTypeAxis_TwoThousandFifteenEquityIncentivePlanMemberusgaapPlanNameAxis"
      decimals="INF"
      unitRef="Unit_shares">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
      contextRef="P04_01_2021To06_30_2021_PerformanceOptionsMemberusgaapAwardTypeAxis_TwoThousandFifteenEquityIncentivePlanMemberusgaapPlanNameAxis"
      decimals="0"
      unitRef="Unit_USD_per_Share">0</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod
      contextRef="P04_01_2021To06_30_2021_PerformanceOptionsMemberusgaapAwardTypeAxis_TwoThousandFifteenEquityIncentivePlanMemberusgaapPlanNameAxis"
      decimals="INF"
      unitRef="Unit_shares">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice
      contextRef="P04_01_2021To06_30_2021_PerformanceOptionsMemberusgaapAwardTypeAxis_TwoThousandFifteenEquityIncentivePlanMemberusgaapPlanNameAxis"
      decimals="0"
      unitRef="Unit_USD_per_Share">0</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="PAsOn06_30_2021_PerformanceOptionsMemberusgaapAwardTypeAxis_TwoThousandFifteenEquityIncentivePlanMemberusgaapPlanNameAxis"
      decimals="INF"
      unitRef="Unit_shares">14425663</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
      contextRef="PAsOn06_30_2021_PerformanceOptionsMemberusgaapAwardTypeAxis_TwoThousandFifteenEquityIncentivePlanMemberusgaapPlanNameAxis"
      decimals="2"
      unitRef="Unit_USD_per_Share">38.93</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="P04_01_2020To06_30_2020_CappedValueAppreciationRightsMemberusgaapAwardTypeAxis_TwoThousandFifteenEquityIncentivePlanMemberusgaapPlanNameAxis"
      decimals="INF"
      unitRef="Unit_USD">0</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="P04_01_2021To06_30_2021_CappedValueAppreciationRightsMemberusgaapAwardTypeAxis_TwoThousandFifteenEquityIncentivePlanMemberusgaapPlanNameAxis"
      decimals="INF"
      unitRef="Unit_USD">0</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock contextRef="P04_01_2021To06_30_2021_CappedValueAppreciationRightsMemberusgaapAwardTypeAxis">&lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;A summary of CVARs under the RSL 2015 EIP is as follows: &lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0px;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 68%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px; text-indent: 0px;"&gt;
&lt;tr style="font-size: 0px;"&gt;
&lt;td style="width: 81%;"/&gt;
&lt;td style="width: 4%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Number of&lt;br/&gt; CVARs&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size: 0px;"&gt;
&lt;td style="width: 81%;"/&gt;
&lt;td style="width: 4%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top; width: 81%;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Non-vested&lt;/div&gt; balance at March&#160;31, 2021&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 4%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;11,088,658&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top; width: 81%;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Granted&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 4%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top; width: 81%;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Forfeited&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 4%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; width: 81%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 4%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top; width: 81%;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Non-vested&lt;/div&gt; balance at June&#160;30, 2021&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 4%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;11,088,658&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; width: 81%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 4%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; </us-gaap:ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber
      contextRef="PAsOn03_31_2021_CappedValueAppreciationRightsMemberusgaapAwardTypeAxis_TwoThousandFifteenEquityIncentivePlanMemberusgaapPlanNameAxis"
      decimals="INF"
      unitRef="Unit_shares">11088658</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod
      contextRef="P04_01_2021To06_30_2021_CappedValueAppreciationRightsMemberusgaapAwardTypeAxis_TwoThousandFifteenEquityIncentivePlanMemberusgaapPlanNameAxis"
      decimals="INF"
      unitRef="Unit_shares">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod
      contextRef="P04_01_2021To06_30_2021_CappedValueAppreciationRightsMemberusgaapAwardTypeAxis_TwoThousandFifteenEquityIncentivePlanMemberusgaapPlanNameAxis"
      decimals="INF"
      unitRef="Unit_shares">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber
      contextRef="PAsOn06_30_2021_CappedValueAppreciationRightsMemberusgaapAwardTypeAxis_TwoThousandFifteenEquityIncentivePlanMemberusgaapPlanNameAxis"
      decimals="INF"
      unitRef="Unit_shares">11088658</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber>
    <us-gaap:CommonStockCapitalSharesReservedForFutureIssuance
      contextRef="PAsOn06_30_2021_PerformanceRestrictedStockUnitsPlanMemberusgaapPlanNameAxis"
      decimals="INF"
      unitRef="Unit_shares">200000</us-gaap:CommonStockCapitalSharesReservedForFutureIssuance>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod contextRef="P04_01_2021To06_30_2021_PerformanceRestrictedStockUnitsPlanMemberusgaapPlanNameAxis">P8Y</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod>
    <us-gaap:ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock contextRef="P04_01_2021To06_30_2021_PerformanceRestrictedStockUnitsMemberusgaapAwardTypeAxis">&lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;A summary of Performance RSU activity under the pRSU Plan is as follows: &lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0px;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 68%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px; text-indent: 0px;"&gt;
&lt;tr style="font-size: 0px;"&gt;
&lt;td style="width: 81%;"/&gt;
&lt;td style="width: 8%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Number of&lt;br/&gt; Performance&lt;br/&gt; RSUs&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size: 0px;"&gt;
&lt;td style="width: 85%;"/&gt;
&lt;td style="width: 6%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Non-vested&lt;/div&gt; balance at March&#160;31, 2021&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;200,000&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; break-inside: avoid;"&gt;
&lt;td style="vertical-align: top; background-color: rgb(255, 255, 255);"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Granted&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgb(255, 255, 255);"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(255, 255, 255);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(255, 255, 255);;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(255, 255, 255);"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top; background-color: rgb(204, 238, 255);"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Forfeited&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; background-color: rgb(255, 255, 255);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgb(255, 255, 255);"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgb(255, 255, 255);"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgb(255, 255, 255);"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="background-color: rgb(255, 255, 255);"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; break-inside: avoid;"&gt;
&lt;td style="vertical-align: top; background-color: rgb(255, 255, 255);"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Non-vested&lt;/div&gt; balance at June&#160;30, 2021&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgb(255, 255, 255);"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(255, 255, 255);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(255, 255, 255);;text-align:right;"&gt;200,000&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(255, 255, 255);"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; background-color: rgb(255, 255, 255);"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgb(255, 255, 255);"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgb(255, 255, 255);"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; background-color: rgb(255, 255, 255);"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="background-color: rgb(255, 255, 255);"&gt;&#160;&lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; </us-gaap:ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber
      contextRef="PAsOn03_31_2021_PerformanceRestrictedStockUnitsMemberusgaapAwardTypeAxis_PerformanceRestrictedStockUnitsPlanMemberusgaapPlanNameAxis"
      decimals="INF"
      unitRef="Unit_shares">200000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod
      contextRef="P04_01_2021To06_30_2021_PerformanceRestrictedStockUnitsMemberusgaapAwardTypeAxis_PerformanceRestrictedStockUnitsPlanMemberusgaapPlanNameAxis"
      decimals="INF"
      unitRef="Unit_shares">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod
      contextRef="P04_01_2021To06_30_2021_PerformanceRestrictedStockUnitsMemberusgaapAwardTypeAxis_PerformanceRestrictedStockUnitsPlanMemberusgaapPlanNameAxis"
      decimals="INF"
      unitRef="Unit_shares">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber
      contextRef="PAsOn06_30_2021_PerformanceRestrictedStockUnitsMemberusgaapAwardTypeAxis_PerformanceRestrictedStockUnitsPlanMemberusgaapPlanNameAxis"
      decimals="INF"
      unitRef="Unit_shares">200000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="P04_01_2020To06_30_2020_PerformanceRestrictedStockUnitsMemberusgaapAwardTypeAxis"
      decimals="INF"
      unitRef="Unit_USD">0</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="P04_01_2021To06_30_2021_PerformanceRestrictedStockUnitsMemberusgaapAwardTypeAxis"
      decimals="INF"
      unitRef="Unit_USD">0</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock contextRef="P04_01_2021To06_30_2021_CommonStockAwardsMemberusgaapAwardTypeAxis">&lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;A summary of RSL restricted common stock activity as of June&#160;30, 2021 is as follows: &lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0px;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 68%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px; text-indent: 0px;"&gt;
&lt;tr style="font-size: 0px;"&gt;
&lt;td style="width: 78%;"/&gt;
&lt;td style="width: 11%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Number of&lt;br/&gt; Restricted&lt;br/&gt; Common&#160;Stock&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size: 0px;"&gt;
&lt;td style="width: 83%;"/&gt;
&lt;td style="width: 8%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Non-vested&lt;/div&gt; balance at March&#160;31, 2021&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;587,824&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Granted&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Forfeited&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Non-vested&lt;/div&gt; balance at June&#160;30, 2021&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;587,824&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; </us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber
      contextRef="PAsOn03_31_2021_CommonStockAwardsMemberusgaapAwardTypeAxis"
      decimals="INF"
      unitRef="Unit_shares">587824</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod
      contextRef="P04_01_2021To06_30_2021_CommonStockAwardsMemberusgaapAwardTypeAxis"
      decimals="INF"
      unitRef="Unit_shares">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod
      contextRef="P04_01_2021To06_30_2021_CommonStockAwardsMemberusgaapAwardTypeAxis"
      decimals="INF"
      unitRef="Unit_shares">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber
      contextRef="PAsOn06_30_2021_CommonStockAwardsMemberusgaapAwardTypeAxis"
      decimals="INF"
      unitRef="Unit_shares">587824</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="P04_01_2021To06_30_2021_CommonStockAwardsMemberusgaapAwardTypeAxis"
      decimals="INF"
      unitRef="Unit_USD">800000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1 contextRef="P04_01_2021To06_30_2021_SubsidiaryEquityIncentivePlanMemberusgaapPlanNameAxis">P4Y</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1 contextRef="P04_01_2021To06_30_2021_SubsidiaryEquityIncentivePlanMemberusgaapPlanNameAxis">P10Y</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="P04_01_2021To06_30_2021_SubsidiaryEquityIncentivePlanMemberusgaapPlanNameAxis"
      decimals="INF"
      unitRef="Unit_USD">8200000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="P04_01_2020To06_30_2020_SubsidiaryEquityIncentivePlanMemberusgaapPlanNameAxis"
      decimals="INF"
      unitRef="Unit_USD">6500000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock contextRef="P04_01_2021To06_30_2021">&lt;div style="text-indent: 4%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt; padding-top: 0pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Share-based compensation expense was as follows (in thousands): &lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0px; padding-top: 0pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 76%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px; text-indent: 0px;"&gt;
&lt;tr style="font-size: 0px;"&gt;
&lt;td style="width: 74%;"/&gt;
&lt;td style="width: 5%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="width: 5%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td colspan="6" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Three&#160;Months&#160;Ended&lt;br/&gt; June&#160;30,&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2021&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2020&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top; font-size: 10pt;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; padding-top: 0pt; line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Share-based compensation expense recognized as:&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size: 0px;"&gt;
&lt;td style="width: 80%;"/&gt;
&lt;td style="width: 4%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="width: 4%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; padding-top: 0pt; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;R&amp;amp;D expenses&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;1,615&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;1,119&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; padding-top: 0pt; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;G&amp;amp;A expenses&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;17,654&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;13,159&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); padding-top: 0pt; line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); padding-top: 0pt; line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); padding-top: 0pt; line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); padding-top: 0pt; line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; padding-top: 0pt; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Total&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;19,269&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;14,278&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); padding-top: 0pt; line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); padding-top: 0pt; line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); padding-top: 0pt; line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); padding-top: 0pt; line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; </us-gaap:ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="P04_01_2021To06_30_2021_ResearchAndDevelopmentExpenseMemberusgaapIncomeStatementLocationAxis"
      decimals="-3"
      unitRef="Unit_USD">1615000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="P04_01_2020To06_30_2020_ResearchAndDevelopmentExpenseMemberusgaapIncomeStatementLocationAxis"
      decimals="-3"
      unitRef="Unit_USD">1119000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="P04_01_2021To06_30_2021_GeneralAndAdministrativeExpenseMemberusgaapIncomeStatementLocationAxis"
      decimals="-3"
      unitRef="Unit_USD">17654000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="P04_01_2020To06_30_2020_GeneralAndAdministrativeExpenseMemberusgaapIncomeStatementLocationAxis"
      decimals="-3"
      unitRef="Unit_USD">13159000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="P04_01_2021To06_30_2021"
      decimals="-3"
      unitRef="Unit_USD">19269000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="P04_01_2020To06_30_2020"
      decimals="-3"
      unitRef="Unit_USD">14278000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:IncomeTaxDisclosureTextBlock contextRef="P04_01_2021To06_30_2021">&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt; text-indent: 0px; line-height: 12pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Note 9&#x2014;Income Taxes &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="text-indent: 4%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt; line-height: 12pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;The Company&#x2019;s effective tax rate for the three months ended June&#160;30, 2021 and 2020 was&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; letter-spacing: 0px; top: 0px; line-height: 10pt;;display:inline;"&gt;(0.1)&lt;/div&gt;&lt;div style="font-size: 10pt; line-height: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; letter-spacing: 0px; top: 0px; line-height: 10pt;;display:inline;"&gt;% and (18.1)&lt;/div&gt;&lt;/div&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;%, respectively, and is driven by the Company&#x2019;s jurisdictional earnings by location and a valuation allowance that eliminates the Company&#x2019;s global net deferred tax assets. However, for the three months ended June&#160;30, 2020, the effective tax rate was also favorably impacted by the &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;non-taxable&lt;/div&gt; gains associated with the deconsolidation of subsidiary and changes in fair value of investments. &lt;/div&gt;&lt;/div&gt; &lt;div style="text-indent: 4%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt; line-height: 12pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;The Company assesses the realizability of its deferred tax assets at each balance sheet date based on available positive and negative evidence in order to determine the amount which is more likely than not to be realized and records a valuation allowance as necessary. &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:IncomeTaxDisclosureTextBlock>
    <us-gaap:EffectiveIncomeTaxRateContinuingOperations
      contextRef="P04_01_2021To06_30_2021"
      decimals="3"
      unitRef="Unit_pure">-0.001</us-gaap:EffectiveIncomeTaxRateContinuingOperations>
    <us-gaap:EffectiveIncomeTaxRateContinuingOperations
      contextRef="P04_01_2020To06_30_2020"
      decimals="3"
      unitRef="Unit_pure">-0.181</us-gaap:EffectiveIncomeTaxRateContinuingOperations>
    <us-gaap:CommitmentsAndContingenciesDisclosureTextBlock contextRef="P04_01_2021To06_30_2021">&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt; text-indent: 0px; line-height: 12pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Note 10&#x2014;Commitments and Contingencies &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt; text-indent: 0px; line-height: 12pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;(A) Significant Agreements &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="text-indent: 4%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt; line-height: 12pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;The Company, primarily through its subsidiaries, has entered into commitments under various asset acquisition and license agreements. Additionally, the Company, through its subsidiaries, enters into agreements with contract service providers to assist in the performance of its R&amp;amp;D activities. Expenditures to contract research organizations and contract manufacturing organizations represent significant costs in the clinical development of its product candidates. Subject to required notice periods and certain obligations under binding purchase orders, the Company can elect to discontinue the work under these agreements at any time. The Company expects to enter into additional collaborative research, contract research, manufacturing, and supplier agreements in the future, which may require upfront payments and long-term commitments of capital resources. &lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt; text-indent: 0px; line-height: 12pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;(B) Loss Contingencies &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="text-indent: 4%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt; line-height: 12pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;The Company may be, from time to time, a party to various disputes and claims arising from normal business activities. The Company accrues for loss contingencies when available information indicates that it is probable that a liability has been incurred and the amount of such loss can be reasonably estimated, and if the Company believes that a reasonably possible loss exists, the Company discloses the facts and circumstances of the litigation or claim, including an estimable range, if possible. The Company is currently not involved in any legal proceedings with a probable and estimable material loss. &lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt; text-indent: 0px; line-height: 12pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;(C) Intellectual Property Agreements &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;As of June&#160;30, 2021, the Company did not have any ongoing material financial commitments, other than pursuant to various asset acquisition and license agreements. &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0px;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;(D) &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;COVID-19&lt;/div&gt; Pandemic &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;The Company has been actively monitoring the impact of the &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;COVID-19&lt;/div&gt; pandemic on its employees and business. Based on guidance issued by federal, state and local authorities, the Company transitioned to a remote work model for its employees in March 2020 and its workforce continues to primarily work remotely. &lt;/div&gt;&lt;/div&gt;&lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;The &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;COVID-19&lt;/div&gt; pandemic has had a variable impact on clinical trials by disrupting certain study sites. In the conduct of business activities, the Company continues to take actions designed to protect the safety and well-being of its patients and employees. Although some of the Company&#x2019;s clinical development timelines have been impacted by delays related to the &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;COVID-19&lt;/div&gt; pandemic, the Company has not experienced material financial impacts on its business and operations as a result of the &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;COVID-19&lt;/div&gt; pandemic. However, the impact on the Company&#x2019;s future results will largely depend on future developments related to &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;COVID-19,&lt;/div&gt; which are highly uncertain and cannot be predicted with confidence, such as the emergence of new variants, the ultimate duration and spread of the outbreak, the continuing impact of the &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;COVID-19&lt;/div&gt; pandemic on financial markets and the global economy, travel restrictions and social distancing in the United States and other countries, business closures or business disruptions and the effectiveness of actions taken in the United States and other countries to contain, treat, and prevent the disease, including the availability and effectiveness of vaccines. &lt;/div&gt;&lt;/div&gt;</us-gaap:CommitmentsAndContingenciesDisclosureTextBlock>
    <us-gaap:FairValueDisclosuresTextBlock contextRef="P04_01_2021To06_30_2021">&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Note 11&#x2014;Fair Value Measurements &lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Recurring Fair Value Measurements &lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;The following table sets forth the Company&#x2019;s assets and liabilities that are measured at fair value on a recurring basis as of June&#160;30, 2021 and March&#160;31, 2021, by level, within the fair value hierarchy (in thousands): &lt;/div&gt;&lt;/div&gt; &lt;div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;width:100%;"&gt;
&lt;tr style="font-size: 0px;"&gt;
&lt;td style="width: 30%;"/&gt;
&lt;td style="width: 1%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="width: 1%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="width: 1%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="width: 1%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="width: 1%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="width: 1%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="width: 1%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="width: 1%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="14" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;As of June&#160;30, 2021&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="14" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;As of March&#160;31, 2021&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Level&#160;1&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Level&#160;2&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Level&#160;3&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Balance as&lt;br/&gt; of&#160;June&#160;30,&lt;br/&gt; 2021&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Level&#160;1&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Level&#160;2&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Level&#160;3&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Balance as&lt;br/&gt; of&#160;March&#160;31,&lt;br/&gt; 2021&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top; width: 30%;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Assets:&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 1%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 1%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 1%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 1%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 1%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 1%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 1%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 1%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top; width: 30%;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Money market funds&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 1%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;1,340,662&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 1%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 1%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 1%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;1,340,662&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 1%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;1,420,597&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 1%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 1%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 1%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;1,420,597&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top; width: 30%;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Investment in Sio common shares&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 1%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;50,716&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 1%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 1%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 1%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;50,716&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 1%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;48,487&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 1%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 1%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 1%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;48,487&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top; width: 30%;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Investment in Arbutus common shares&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 1%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;48,521&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 1%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 1%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 1%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;48,521&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 1%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;53,325&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 1%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 1%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 1%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;53,325&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top; width: 30%;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Investment in Arbutus convertible preferred shares&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 1%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 1%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;69,187&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 1%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 1%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;69,187&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 1%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 1%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;76,037&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 1%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 1%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;76,037&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top; width: 30%;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Other investment&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 1%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;11,935&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 1%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 1%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 1%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;11,935&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 1%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;11,129&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 1%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 1%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 1%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;11,129&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; width: 30%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 1%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 1%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 1%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 1%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 1%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 1%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 1%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 1%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top; width: 30%;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Total assets at fair value&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 1%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;1,451,834&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 1%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;69,187&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 1%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 1%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;1,521,021&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 1%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;1,533,538&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 1%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;76,037&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 1%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 1%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;1,609,575&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; width: 30%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 1%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 1%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 1%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 1%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 1%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 1%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 1%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 1%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top; width: 30%;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Liabilities:&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 1%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 1%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 1%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 1%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 1%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 1%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 1%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 1%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top; text-indent: 0px; width: 30%;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Debt issued by Dermavant to NovaQuest&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; text-indent: 0px; width: 1%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; text-indent: 0px;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;$&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; text-indent: 0px;;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; text-indent: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; text-indent: 0px; width: 1%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; text-indent: 0px;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;$&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; text-indent: 0px;;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; text-indent: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; text-indent: 0px; width: 1%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; text-indent: 0px;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;$&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; text-indent: 0px;;text-align:right;"&gt;155,200&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; text-indent: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; text-indent: 0px; width: 1%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; text-indent: 0px;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;$&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; text-indent: 0px;;text-align:right;"&gt;155,200&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; text-indent: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; text-indent: 0px; width: 1%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; text-indent: 0px;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;$&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; text-indent: 0px;;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; text-indent: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; text-indent: 0px; width: 1%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; text-indent: 0px;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;$&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; text-indent: 0px;;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; text-indent: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; text-indent: 0px; width: 1%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; text-indent: 0px;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;$&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; text-indent: 0px;;text-align:right;"&gt;150,100&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; text-indent: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; text-indent: 0px; width: 1%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; text-indent: 0px;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;$&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; text-indent: 0px;;text-align:right;"&gt;150,100&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; text-indent: 0px;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top; width: 30%;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Liability instruments measured at fair value&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 1%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 1%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 1%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;5,906&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 1%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;5,906&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 1%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 1%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 1%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;67,893&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 1%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;67,893&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; width: 30%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 1%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 1%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 1%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 1%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 1%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 1%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 1%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 1%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top; width: 30%;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Total liabilities at fair value&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 1%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 1%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 1%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;161,106&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 1%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;161,106&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 1%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 1%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 1%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;217,993&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 1%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;217,993&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; width: 30%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 1%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 1%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 1%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 1%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 1%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 1%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 1%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 1%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;  &lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;There were no transfers of assets between Level&#160;1 and Level&#160;2 of the fair value measurement hierarchy that occurred during the three months ended June&#160;30, 2021. &lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 2%;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;Level&#160;3 Disclosures &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;The Company measures its Level&#160;3 liabilities at fair value based on significant inputs not observable in the market, which causes them to be classified as a Level&#160;3 measurement within the fair value hierarchy. The valuation of the Level&#160;3 liabilities uses assumptions and estimates the Company believes would be made by a market participant in making the same valuation. The Company assesses these assumptions and estimates on an ongoing basis as additional data impacting the assumptions and estimates are obtained. Changes in the fair value related to updated assumptions and estimates are recorded within the statements of operations at the end of each reporting period. &lt;/div&gt;&lt;/div&gt; &lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;The fair value of Level&#160;3 liabilities may change significantly as additional data are obtained, impacting the Company&#x2019;s assumptions regarding probabilities of potential scenarios used to estimate fair value. In evaluating this information, considerable judgment is required to interpret the data used to develop the assumptions and estimates. Accordingly, the use of different market assumptions and/or different valuation techniques may have a material effect on the estimated fair value amounts, and such changes could materially impact the Company&#x2019;s results of operations in future periods. &lt;/div&gt;&lt;/div&gt; &lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;The changes in fair value of the Level&#160;3 liabilities during the three months ended June&#160;30, 2021 and 2020 were as follows (in thousands): &lt;/div&gt;&lt;/div&gt; &lt;div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;width:68%;"&gt;
&lt;tr style="font-size: 0px;"&gt;
&lt;td style="width: 83%; font-family: &amp;quot;Times New Roman&amp;quot;;"/&gt;
&lt;td style="width: 7%; vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"/&gt;
&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;;"/&gt;
&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;;"/&gt;
&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;;"/&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top; width: 83%;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Balance at March&#160;31, 2020&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 7%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;191,473&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top; width: 83%;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Changes in fair value of debt and liability instruments, included in net loss&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 7%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;17,125&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top; width: 83%;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Liability instruments disposed due to deconsolidation of subsidiary&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 7%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;(3,325&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; width: 83%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 7%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top; width: 83%;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Balance at June&#160;30, 2020&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 7%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;205,273&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; width: 83%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 7%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="vertical-align: top; line-height: 5pt; font-size: 5pt; width: 83%;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 5pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: 5pt;"&gt;&lt;div style="font-size: 5pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; line-height: 5pt; font-size: 5pt; width: 7%;"&gt;&lt;div style="font-size: 5pt; line-height: 5pt;"&gt;&lt;div style="font-size: 5pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; line-height: 5pt; font-size: 5pt;"&gt;&lt;div style="font-size: 5pt; line-height: 5pt;"&gt;&lt;div style="font-size: 5pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; line-height: 5pt; font-size: 5pt;;text-align:right;"&gt;&lt;div style="font-size: 5pt; line-height: 5pt;"&gt;&lt;div style="font-size: 5pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; line-height: 5pt; font-size: 5pt;"&gt;&lt;div style="font-size: 5pt; line-height: 5pt;"&gt;&lt;div style="font-size: 5pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top; width: 83%;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Balance at March&#160;31, 2021&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 7%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;217,993&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top; width: 83%;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Changes in fair value of debt and liability instruments, included in net loss&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 7%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;4,585&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top; width: 83%;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Termination of DSP Options&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 7%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;(61,472&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; width: 83%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 7%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top; width: 83%;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Balance at June&#160;30, 2021&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 7%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;161,106&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; width: 83%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 7%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;   &lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Debt issued by Dermavant to NovaQuest &lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;The fair value of the debt instrument as of June&#160;30, 2021 and March&#160;31, 2021 represents the fair value of amounts payable to NovaQuest using a Monte Carlo simulation model under the income approach determined by using probability assessments of the expected future payments through 2032 and applying discount rates ranging from &lt;span style="-sec-ix-hidden:hidden28229202"&gt;11&lt;/span&gt;% to &lt;span style="-sec-ix-hidden:hidden28229201"&gt;12&lt;/span&gt;%. The future payments are based on significant inputs that are not observable in the market which are subject to remeasurement at each reporting date. The estimates of fair value may not be indicative of the amounts that could ultimately be paid by Dermavant to NovaQuest. &lt;/div&gt;&lt;/div&gt; &lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Sumitomo Options &lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;In June 2021, the Company completed a transaction with Sumitomo pursuant to which the Sumitomo Options were terminated, resulting in the extinguishment of the related liability. As of the termination date, the fair value of the Sumitomo Options was &lt;/div&gt;&lt;/div&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;$61.5&#160;million, and as of March&#160;31, 2021, the fair value was $62.4&#160;million. See Note 4, &#x201c;Sumitomo Transaction Agreement&#x201d; for additional information. &lt;/div&gt;&lt;/div&gt; </us-gaap:FairValueDisclosuresTextBlock>
    <us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock contextRef="P04_01_2021To06_30_2021">&lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;The following table sets forth the Company&#x2019;s assets and liabilities that are measured at fair value on a recurring basis as of June&#160;30, 2021 and March&#160;31, 2021, by level, within the fair value hierarchy (in thousands): &lt;/div&gt;&lt;/div&gt; &lt;div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;width:100%;"&gt;
&lt;tr style="font-size: 0px;"&gt;
&lt;td style="width: 30%;"/&gt;
&lt;td style="width: 1%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="width: 1%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="width: 1%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="width: 1%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="width: 1%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="width: 1%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="width: 1%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="width: 1%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="14" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;As of June&#160;30, 2021&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="14" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;As of March&#160;31, 2021&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Level&#160;1&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Level&#160;2&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Level&#160;3&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Balance as&lt;br/&gt; of&#160;June&#160;30,&lt;br/&gt; 2021&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Level&#160;1&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Level&#160;2&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Level&#160;3&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Balance as&lt;br/&gt; of&#160;March&#160;31,&lt;br/&gt; 2021&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top; width: 30%;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Assets:&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 1%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 1%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 1%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 1%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 1%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 1%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 1%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 1%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top; width: 30%;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Money market funds&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 1%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;1,340,662&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 1%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 1%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 1%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;1,340,662&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 1%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;1,420,597&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 1%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 1%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 1%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;1,420,597&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top; width: 30%;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Investment in Sio common shares&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 1%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;50,716&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 1%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 1%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 1%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;50,716&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 1%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;48,487&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 1%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 1%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 1%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;48,487&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top; width: 30%;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Investment in Arbutus common shares&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 1%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;48,521&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 1%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 1%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 1%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;48,521&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 1%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;53,325&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 1%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 1%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 1%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;53,325&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top; width: 30%;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Investment in Arbutus convertible preferred shares&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 1%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 1%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;69,187&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 1%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 1%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;69,187&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 1%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 1%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;76,037&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 1%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 1%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;76,037&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top; width: 30%;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Other investment&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 1%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;11,935&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 1%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 1%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 1%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;11,935&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 1%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;11,129&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 1%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 1%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 1%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;11,129&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; width: 30%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 1%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 1%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 1%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 1%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 1%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 1%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 1%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 1%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top; width: 30%;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Total assets at fair value&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 1%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;1,451,834&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 1%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;69,187&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 1%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 1%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;1,521,021&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 1%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;1,533,538&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 1%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;76,037&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 1%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 1%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;1,609,575&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; width: 30%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 1%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 1%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 1%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 1%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 1%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 1%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 1%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 1%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top; width: 30%;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Liabilities:&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 1%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 1%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 1%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 1%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 1%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 1%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 1%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 1%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top; text-indent: 0px; width: 30%;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Debt issued by Dermavant to NovaQuest&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; text-indent: 0px; width: 1%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; text-indent: 0px;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;$&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; text-indent: 0px;;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; text-indent: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; text-indent: 0px; width: 1%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; text-indent: 0px;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;$&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; text-indent: 0px;;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; text-indent: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; text-indent: 0px; width: 1%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; text-indent: 0px;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;$&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; text-indent: 0px;;text-align:right;"&gt;155,200&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; text-indent: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; text-indent: 0px; width: 1%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; text-indent: 0px;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;$&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; text-indent: 0px;;text-align:right;"&gt;155,200&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; text-indent: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; text-indent: 0px; width: 1%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; text-indent: 0px;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;$&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; text-indent: 0px;;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; text-indent: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; text-indent: 0px; width: 1%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; text-indent: 0px;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;$&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; text-indent: 0px;;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; text-indent: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; text-indent: 0px; width: 1%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; text-indent: 0px;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;$&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; text-indent: 0px;;text-align:right;"&gt;150,100&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; text-indent: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; text-indent: 0px; width: 1%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; text-indent: 0px;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;$&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; text-indent: 0px;;text-align:right;"&gt;150,100&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; text-indent: 0px;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top; width: 30%;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Liability instruments measured at fair value&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 1%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 1%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 1%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;5,906&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 1%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;5,906&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 1%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 1%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 1%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;67,893&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 1%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;67,893&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; width: 30%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 1%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 1%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 1%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 1%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 1%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 1%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 1%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 1%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top; width: 30%;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Total liabilities at fair value&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 1%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 1%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 1%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;161,106&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 1%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;161,106&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 1%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 1%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 1%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;217,993&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 1%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;217,993&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; width: 30%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 1%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 1%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 1%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 1%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 1%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 1%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 1%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 1%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt; </us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="PAsOn06_30_2021_FairValueInputsLevel1MemberusgaapFairValueByFairValueHierarchyLevelAxis_FairValueMeasurementsRecurringMemberusgaapFairValueByMeasurementFrequencyAxis_MoneyMarketFundsMemberusgaapFairValueByAssetClassAxis"
      decimals="-3"
      unitRef="Unit_USD">1340662000</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="PAsOn06_30_2021_FairValueMeasurementsRecurringMemberusgaapFairValueByMeasurementFrequencyAxis_MoneyMarketFundsMemberusgaapFairValueByAssetClassAxis"
      decimals="-3"
      unitRef="Unit_USD">1340662000</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="PAsOn03_31_2021_FairValueInputsLevel1MemberusgaapFairValueByFairValueHierarchyLevelAxis_FairValueMeasurementsRecurringMemberusgaapFairValueByMeasurementFrequencyAxis_MoneyMarketFundsMemberusgaapFairValueByAssetClassAxis"
      decimals="-3"
      unitRef="Unit_USD">1420597000</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="PAsOn03_31_2021_FairValueMeasurementsRecurringMemberusgaapFairValueByMeasurementFrequencyAxis_MoneyMarketFundsMemberusgaapFairValueByAssetClassAxis"
      decimals="-3"
      unitRef="Unit_USD">1420597000</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:InvestmentsFairValueDisclosure
      contextRef="PAsOn06_30_2021_CommonStockMemberusgaapFairValueByAssetClassAxis_FairValueInputsLevel1MemberusgaapFairValueByFairValueHierarchyLevelAxis_FairValueMeasurementsRecurringMemberusgaapFairValueByMeasurementFrequencyAxis_SioGeneTherapiesIncMemberdeiLegalEntityAxis"
      decimals="-3"
      unitRef="Unit_USD">50716000</us-gaap:InvestmentsFairValueDisclosure>
    <us-gaap:InvestmentsFairValueDisclosure
      contextRef="PAsOn06_30_2021_CommonStockMemberusgaapFairValueByAssetClassAxis_FairValueMeasurementsRecurringMemberusgaapFairValueByMeasurementFrequencyAxis_SioGeneTherapiesIncMemberdeiLegalEntityAxis"
      decimals="-3"
      unitRef="Unit_USD">50716000</us-gaap:InvestmentsFairValueDisclosure>
    <us-gaap:InvestmentsFairValueDisclosure
      contextRef="PAsOn03_31_2021_CommonStockMemberusgaapFairValueByAssetClassAxis_FairValueInputsLevel1MemberusgaapFairValueByFairValueHierarchyLevelAxis_FairValueMeasurementsRecurringMemberusgaapFairValueByMeasurementFrequencyAxis_SioGeneTherapiesIncMemberdeiLegalEntityAxis"
      decimals="-3"
      unitRef="Unit_USD">48487000</us-gaap:InvestmentsFairValueDisclosure>
    <us-gaap:InvestmentsFairValueDisclosure
      contextRef="PAsOn03_31_2021_CommonStockMemberusgaapFairValueByAssetClassAxis_FairValueMeasurementsRecurringMemberusgaapFairValueByMeasurementFrequencyAxis_SioGeneTherapiesIncMemberdeiLegalEntityAxis"
      decimals="-3"
      unitRef="Unit_USD">48487000</us-gaap:InvestmentsFairValueDisclosure>
    <us-gaap:InvestmentsFairValueDisclosure
      contextRef="PAsOn06_30_2021_ArbutusBiopharmaCorporationMemberdeiLegalEntityAxis_CommonStockMemberusgaapFairValueByAssetClassAxis_FairValueInputsLevel1MemberusgaapFairValueByFairValueHierarchyLevelAxis_FairValueMeasurementsRecurringMemberusgaapFairValueByMeasurementFrequencyAxis"
      decimals="-3"
      unitRef="Unit_USD">48521000</us-gaap:InvestmentsFairValueDisclosure>
    <us-gaap:InvestmentsFairValueDisclosure
      contextRef="PAsOn06_30_2021_ArbutusBiopharmaCorporationMemberdeiLegalEntityAxis_CommonStockMemberusgaapFairValueByAssetClassAxis_FairValueMeasurementsRecurringMemberusgaapFairValueByMeasurementFrequencyAxis"
      decimals="-3"
      unitRef="Unit_USD">48521000</us-gaap:InvestmentsFairValueDisclosure>
    <us-gaap:InvestmentsFairValueDisclosure
      contextRef="PAsOn03_31_2021_ArbutusBiopharmaCorporationMemberdeiLegalEntityAxis_CommonStockMemberusgaapFairValueByAssetClassAxis_FairValueInputsLevel1MemberusgaapFairValueByFairValueHierarchyLevelAxis_FairValueMeasurementsRecurringMemberusgaapFairValueByMeasurementFrequencyAxis"
      decimals="-3"
      unitRef="Unit_USD">53325000</us-gaap:InvestmentsFairValueDisclosure>
    <us-gaap:InvestmentsFairValueDisclosure
      contextRef="PAsOn03_31_2021_ArbutusBiopharmaCorporationMemberdeiLegalEntityAxis_CommonStockMemberusgaapFairValueByAssetClassAxis_FairValueMeasurementsRecurringMemberusgaapFairValueByMeasurementFrequencyAxis"
      decimals="-3"
      unitRef="Unit_USD">53325000</us-gaap:InvestmentsFairValueDisclosure>
    <us-gaap:InvestmentsFairValueDisclosure
      contextRef="PAsOn06_30_2021_ArbutusBiopharmaCorporationMemberdeiLegalEntityAxis_ConvertiblePreferredStockMemberusgaapFairValueByAssetClassAxis_FairValueInputsLevel2MemberusgaapFairValueByFairValueHierarchyLevelAxis_FairValueMeasurementsRecurringMemberusgaapFairValueByMeasurementFrequencyAxis"
      decimals="-3"
      unitRef="Unit_USD">69187000</us-gaap:InvestmentsFairValueDisclosure>
    <us-gaap:InvestmentsFairValueDisclosure
      contextRef="PAsOn06_30_2021_ArbutusBiopharmaCorporationMemberdeiLegalEntityAxis_ConvertiblePreferredStockMemberusgaapFairValueByAssetClassAxis_FairValueMeasurementsRecurringMemberusgaapFairValueByMeasurementFrequencyAxis"
      decimals="-3"
      unitRef="Unit_USD">69187000</us-gaap:InvestmentsFairValueDisclosure>
    <us-gaap:InvestmentsFairValueDisclosure
      contextRef="PAsOn03_31_2021_ArbutusBiopharmaCorporationMemberdeiLegalEntityAxis_ConvertiblePreferredStockMemberusgaapFairValueByAssetClassAxis_FairValueInputsLevel2MemberusgaapFairValueByFairValueHierarchyLevelAxis_FairValueMeasurementsRecurringMemberusgaapFairValueByMeasurementFrequencyAxis"
      decimals="-3"
      unitRef="Unit_USD">76037000</us-gaap:InvestmentsFairValueDisclosure>
    <us-gaap:InvestmentsFairValueDisclosure
      contextRef="PAsOn03_31_2021_ArbutusBiopharmaCorporationMemberdeiLegalEntityAxis_ConvertiblePreferredStockMemberusgaapFairValueByAssetClassAxis_FairValueMeasurementsRecurringMemberusgaapFairValueByMeasurementFrequencyAxis"
      decimals="-3"
      unitRef="Unit_USD">76037000</us-gaap:InvestmentsFairValueDisclosure>
    <us-gaap:InvestmentsFairValueDisclosure
      contextRef="PAsOn06_30_2021_FairValueInputsLevel1MemberusgaapFairValueByFairValueHierarchyLevelAxis_FairValueMeasurementsRecurringMemberusgaapFairValueByMeasurementFrequencyAxis_OtherInvestmentCompaniesMemberusgaapFairValueByAssetClassAxis"
      decimals="-3"
      unitRef="Unit_USD">11935000</us-gaap:InvestmentsFairValueDisclosure>
    <us-gaap:InvestmentsFairValueDisclosure
      contextRef="PAsOn06_30_2021_FairValueMeasurementsRecurringMemberusgaapFairValueByMeasurementFrequencyAxis_OtherInvestmentCompaniesMemberusgaapFairValueByAssetClassAxis"
      decimals="-3"
      unitRef="Unit_USD">11935000</us-gaap:InvestmentsFairValueDisclosure>
    <us-gaap:InvestmentsFairValueDisclosure
      contextRef="PAsOn03_31_2021_FairValueInputsLevel1MemberusgaapFairValueByFairValueHierarchyLevelAxis_FairValueMeasurementsRecurringMemberusgaapFairValueByMeasurementFrequencyAxis_OtherInvestmentCompaniesMemberusgaapFairValueByAssetClassAxis"
      decimals="-3"
      unitRef="Unit_USD">11129000</us-gaap:InvestmentsFairValueDisclosure>
    <us-gaap:InvestmentsFairValueDisclosure
      contextRef="PAsOn03_31_2021_FairValueMeasurementsRecurringMemberusgaapFairValueByMeasurementFrequencyAxis_OtherInvestmentCompaniesMemberusgaapFairValueByAssetClassAxis"
      decimals="-3"
      unitRef="Unit_USD">11129000</us-gaap:InvestmentsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="PAsOn06_30_2021_FairValueInputsLevel1MemberusgaapFairValueByFairValueHierarchyLevelAxis_FairValueMeasurementsRecurringMemberusgaapFairValueByMeasurementFrequencyAxis"
      decimals="-3"
      unitRef="Unit_USD">1451834000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="PAsOn06_30_2021_FairValueInputsLevel2MemberusgaapFairValueByFairValueHierarchyLevelAxis_FairValueMeasurementsRecurringMemberusgaapFairValueByMeasurementFrequencyAxis"
      decimals="-3"
      unitRef="Unit_USD">69187000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="PAsOn06_30_2021_FairValueMeasurementsRecurringMemberusgaapFairValueByMeasurementFrequencyAxis"
      decimals="-3"
      unitRef="Unit_USD">1521021000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="PAsOn03_31_2021_FairValueInputsLevel1MemberusgaapFairValueByFairValueHierarchyLevelAxis_FairValueMeasurementsRecurringMemberusgaapFairValueByMeasurementFrequencyAxis"
      decimals="-3"
      unitRef="Unit_USD">1533538000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="PAsOn03_31_2021_FairValueInputsLevel2MemberusgaapFairValueByFairValueHierarchyLevelAxis_FairValueMeasurementsRecurringMemberusgaapFairValueByMeasurementFrequencyAxis"
      decimals="-3"
      unitRef="Unit_USD">76037000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="PAsOn03_31_2021_FairValueMeasurementsRecurringMemberusgaapFairValueByMeasurementFrequencyAxis"
      decimals="-3"
      unitRef="Unit_USD">1609575000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:DebtInstrumentFairValue
      contextRef="PAsOn06_30_2021_FairValueInputsLevel3MemberusgaapFairValueByFairValueHierarchyLevelAxis_FairValueMeasurementsRecurringMemberusgaapFairValueByMeasurementFrequencyAxis"
      decimals="-3"
      unitRef="Unit_USD">155200000</us-gaap:DebtInstrumentFairValue>
    <us-gaap:DebtInstrumentFairValue
      contextRef="PAsOn06_30_2021_FairValueMeasurementsRecurringMemberusgaapFairValueByMeasurementFrequencyAxis"
      decimals="-3"
      unitRef="Unit_USD">155200000</us-gaap:DebtInstrumentFairValue>
    <us-gaap:DebtInstrumentFairValue
      contextRef="PAsOn03_31_2021_FairValueInputsLevel3MemberusgaapFairValueByFairValueHierarchyLevelAxis_FairValueMeasurementsRecurringMemberusgaapFairValueByMeasurementFrequencyAxis"
      decimals="-3"
      unitRef="Unit_USD">150100000</us-gaap:DebtInstrumentFairValue>
    <us-gaap:DebtInstrumentFairValue
      contextRef="PAsOn03_31_2021_FairValueMeasurementsRecurringMemberusgaapFairValueByMeasurementFrequencyAxis"
      decimals="-3"
      unitRef="Unit_USD">150100000</us-gaap:DebtInstrumentFairValue>
    <us-gaap:DerivativeInstrumentsNotDesignatedAsHedgingInstrumentsLiabilityAtFairValue
      contextRef="PAsOn06_30_2021_FairValueInputsLevel3MemberusgaapFairValueByFairValueHierarchyLevelAxis_FairValueMeasurementsRecurringMemberusgaapFairValueByMeasurementFrequencyAxis"
      decimals="-3"
      unitRef="Unit_USD">5906000</us-gaap:DerivativeInstrumentsNotDesignatedAsHedgingInstrumentsLiabilityAtFairValue>
    <us-gaap:DerivativeInstrumentsNotDesignatedAsHedgingInstrumentsLiabilityAtFairValue
      contextRef="PAsOn06_30_2021_FairValueMeasurementsRecurringMemberusgaapFairValueByMeasurementFrequencyAxis"
      decimals="-3"
      unitRef="Unit_USD">5906000</us-gaap:DerivativeInstrumentsNotDesignatedAsHedgingInstrumentsLiabilityAtFairValue>
    <us-gaap:DerivativeInstrumentsNotDesignatedAsHedgingInstrumentsLiabilityAtFairValue
      contextRef="PAsOn03_31_2021_FairValueInputsLevel3MemberusgaapFairValueByFairValueHierarchyLevelAxis_FairValueMeasurementsRecurringMemberusgaapFairValueByMeasurementFrequencyAxis"
      decimals="-3"
      unitRef="Unit_USD">67893000</us-gaap:DerivativeInstrumentsNotDesignatedAsHedgingInstrumentsLiabilityAtFairValue>
    <us-gaap:DerivativeInstrumentsNotDesignatedAsHedgingInstrumentsLiabilityAtFairValue
      contextRef="PAsOn03_31_2021_FairValueMeasurementsRecurringMemberusgaapFairValueByMeasurementFrequencyAxis"
      decimals="-3"
      unitRef="Unit_USD">67893000</us-gaap:DerivativeInstrumentsNotDesignatedAsHedgingInstrumentsLiabilityAtFairValue>
    <us-gaap:LiabilitiesFairValueDisclosure
      contextRef="PAsOn06_30_2021_FairValueInputsLevel3MemberusgaapFairValueByFairValueHierarchyLevelAxis_FairValueMeasurementsRecurringMemberusgaapFairValueByMeasurementFrequencyAxis"
      decimals="-3"
      unitRef="Unit_USD">161106000</us-gaap:LiabilitiesFairValueDisclosure>
    <us-gaap:LiabilitiesFairValueDisclosure
      contextRef="PAsOn06_30_2021_FairValueMeasurementsRecurringMemberusgaapFairValueByMeasurementFrequencyAxis"
      decimals="-3"
      unitRef="Unit_USD">161106000</us-gaap:LiabilitiesFairValueDisclosure>
    <us-gaap:LiabilitiesFairValueDisclosure
      contextRef="PAsOn03_31_2021_FairValueInputsLevel3MemberusgaapFairValueByFairValueHierarchyLevelAxis_FairValueMeasurementsRecurringMemberusgaapFairValueByMeasurementFrequencyAxis"
      decimals="-3"
      unitRef="Unit_USD">217993000</us-gaap:LiabilitiesFairValueDisclosure>
    <us-gaap:LiabilitiesFairValueDisclosure
      contextRef="PAsOn03_31_2021_FairValueMeasurementsRecurringMemberusgaapFairValueByMeasurementFrequencyAxis"
      decimals="-3"
      unitRef="Unit_USD">217993000</us-gaap:LiabilitiesFairValueDisclosure>
    <us-gaap:FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock contextRef="P04_01_2021To06_30_2021">&lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;The changes in fair value of the Level&#160;3 liabilities during the three months ended June&#160;30, 2021 and 2020 were as follows (in thousands): &lt;/div&gt;&lt;/div&gt; &lt;div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;width:68%;"&gt;
&lt;tr style="font-size: 0px;"&gt;
&lt;td style="width: 83%; font-family: &amp;quot;Times New Roman&amp;quot;;"/&gt;
&lt;td style="width: 7%; vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"/&gt;
&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;;"/&gt;
&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;;"/&gt;
&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;;"/&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top; width: 83%;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Balance at March&#160;31, 2020&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 7%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;191,473&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top; width: 83%;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Changes in fair value of debt and liability instruments, included in net loss&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 7%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;17,125&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top; width: 83%;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Liability instruments disposed due to deconsolidation of subsidiary&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 7%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;(3,325&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; width: 83%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 7%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top; width: 83%;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Balance at June&#160;30, 2020&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 7%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;205,273&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; width: 83%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 7%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="vertical-align: top; line-height: 5pt; font-size: 5pt; width: 83%;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 5pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: 5pt;"&gt;&lt;div style="font-size: 5pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; line-height: 5pt; font-size: 5pt; width: 7%;"&gt;&lt;div style="font-size: 5pt; line-height: 5pt;"&gt;&lt;div style="font-size: 5pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; line-height: 5pt; font-size: 5pt;"&gt;&lt;div style="font-size: 5pt; line-height: 5pt;"&gt;&lt;div style="font-size: 5pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; line-height: 5pt; font-size: 5pt;;text-align:right;"&gt;&lt;div style="font-size: 5pt; line-height: 5pt;"&gt;&lt;div style="font-size: 5pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; line-height: 5pt; font-size: 5pt;"&gt;&lt;div style="font-size: 5pt; line-height: 5pt;"&gt;&lt;div style="font-size: 5pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top; width: 83%;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Balance at March&#160;31, 2021&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 7%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;217,993&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top; width: 83%;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Changes in fair value of debt and liability instruments, included in net loss&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 7%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;4,585&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top; width: 83%;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Termination of DSP Options&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 7%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;(61,472&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; width: 83%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 7%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top; width: 83%;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Balance at June&#160;30, 2021&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 7%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;161,106&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; width: 83%;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; width: 7%;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt; </us-gaap:FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue
      contextRef="PAsOn03_31_2020_FairValueInputsLevel3MemberusgaapFairValueByFairValueHierarchyLevelAxis"
      decimals="-3"
      unitRef="Unit_USD">191473000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings
      contextRef="P04_01_2020To06_30_2020_FairValueInputsLevel3MemberusgaapFairValueByFairValueHierarchyLevelAxis"
      decimals="-3"
      unitRef="Unit_USD">17125000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings>
    <roiv:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityDisposedDueToDeconsolidationOfSubsidiary
      contextRef="P04_01_2020To06_30_2020_FairValueInputsLevel3MemberusgaapFairValueByFairValueHierarchyLevelAxis"
      decimals="-3"
      unitRef="Unit_USD">-3325000</roiv:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityDisposedDueToDeconsolidationOfSubsidiary>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue
      contextRef="PAsOn06_30_2020_FairValueInputsLevel3MemberusgaapFairValueByFairValueHierarchyLevelAxis"
      decimals="-3"
      unitRef="Unit_USD">205273000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue
      contextRef="PAsOn03_31_2021_FairValueInputsLevel3MemberusgaapFairValueByFairValueHierarchyLevelAxis"
      decimals="-3"
      unitRef="Unit_USD">217993000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings
      contextRef="P04_01_2021To06_30_2021_FairValueInputsLevel3MemberusgaapFairValueByFairValueHierarchyLevelAxis"
      decimals="-3"
      unitRef="Unit_USD">4585000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements
      contextRef="P04_01_2021To06_30_2021_FairValueInputsLevel3MemberusgaapFairValueByFairValueHierarchyLevelAxis"
      decimals="-3"
      unitRef="Unit_USD">-61472000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue
      contextRef="PAsOn06_30_2021_FairValueInputsLevel3MemberusgaapFairValueByFairValueHierarchyLevelAxis"
      decimals="-3"
      unitRef="Unit_USD">161106000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue>
    <roiv:EquityInterestOptionToThirdPartyPurchaser
      contextRef="PAsOn03_31_2021"
      decimals="-5"
      unitRef="Unit_USD">61500000</roiv:EquityInterestOptionToThirdPartyPurchaser>
    <roiv:EquityInterestOptionToThirdPartyPurchaser
      contextRef="PAsOn06_30_2021"
      decimals="-5"
      unitRef="Unit_USD">62400000</roiv:EquityInterestOptionToThirdPartyPurchaser>
    <us-gaap:OtherOperatingIncomeAndExpenseTextBlock contextRef="P04_01_2021To06_30_2021">&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0px;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Note 12&#x2014;Other (Income) Expense, Net &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Other (income) expense, net was as follows (in thousands): &lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0px;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 76%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px; text-indent: 0px;"&gt;
&lt;tr style="font-size: 0px;"&gt;
&lt;td style="width: 75%;"/&gt;
&lt;td style="width: 7%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="width: 7%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td colspan="6" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Three&#160;Months&#160;Ended&lt;br/&gt; June&#160;30,&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2021&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2020&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size: 0px;"&gt;
&lt;td style="width: 80%;"/&gt;
&lt;td style="width: 6%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="width: 5%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Loss from equity method investment&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;3,750&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Interest income&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;(71&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;(621&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Interest expense&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;2,513&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;791&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Other income&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;(2,576&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;(1,078&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Total&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;(134&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;2,842&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; </us-gaap:OtherOperatingIncomeAndExpenseTextBlock>
    <us-gaap:ScheduleOfOtherOperatingCostAndExpenseByComponentTextBlock contextRef="P04_01_2021To06_30_2021">&lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Other (income) expense, net was as follows (in thousands): &lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0px;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 76%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px; text-indent: 0px;"&gt;
&lt;tr style="font-size: 0px;"&gt;
&lt;td style="width: 75%;"/&gt;
&lt;td style="width: 7%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="width: 7%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td colspan="6" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Three&#160;Months&#160;Ended&lt;br/&gt; June&#160;30,&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2021&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2020&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 1pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size: 0px;"&gt;
&lt;td style="width: 80%;"/&gt;
&lt;td style="width: 6%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="width: 5%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Loss from equity method investment&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;3,750&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Interest income&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;(71&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;(621&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Interest expense&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;2,513&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;791&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Other income&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;(2,576&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;(1,078&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Total&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;(134&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;2,842&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; </us-gaap:ScheduleOfOtherOperatingCostAndExpenseByComponentTextBlock>
    <us-gaap:IncomeLossFromEquityMethodInvestments
      contextRef="P04_01_2021To06_30_2021"
      decimals="-3"
      unitRef="Unit_USD">0</us-gaap:IncomeLossFromEquityMethodInvestments>
    <us-gaap:IncomeLossFromEquityMethodInvestments
      contextRef="P04_01_2020To06_30_2020"
      decimals="-3"
      unitRef="Unit_USD">-3750000</us-gaap:IncomeLossFromEquityMethodInvestments>
    <us-gaap:InterestIncomeOther
      contextRef="P04_01_2021To06_30_2021"
      decimals="-3"
      unitRef="Unit_USD">71000</us-gaap:InterestIncomeOther>
    <us-gaap:InterestIncomeOther
      contextRef="P04_01_2020To06_30_2020"
      decimals="-3"
      unitRef="Unit_USD">621000</us-gaap:InterestIncomeOther>
    <us-gaap:InterestExpense
      contextRef="P04_01_2021To06_30_2021"
      decimals="-3"
      unitRef="Unit_USD">2513000</us-gaap:InterestExpense>
    <us-gaap:InterestExpense
      contextRef="P04_01_2020To06_30_2020"
      decimals="-3"
      unitRef="Unit_USD">791000</us-gaap:InterestExpense>
    <roiv:OtherIncomeExpense
      contextRef="P04_01_2021To06_30_2021"
      decimals="-3"
      unitRef="Unit_USD">2576000</roiv:OtherIncomeExpense>
    <roiv:OtherIncomeExpense
      contextRef="P04_01_2020To06_30_2020"
      decimals="-3"
      unitRef="Unit_USD">1078000</roiv:OtherIncomeExpense>
    <us-gaap:OtherOperatingIncomeExpenseNet
      contextRef="P04_01_2021To06_30_2021"
      decimals="-3"
      unitRef="Unit_USD">134000</us-gaap:OtherOperatingIncomeExpenseNet>
    <us-gaap:OtherOperatingIncomeExpenseNet
      contextRef="P04_01_2020To06_30_2020"
      decimals="-3"
      unitRef="Unit_USD">-2842000</us-gaap:OtherOperatingIncomeExpenseNet>
    <us-gaap:EarningsPerShareTextBlock contextRef="P04_01_2021To06_30_2021">&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Note 13&#x2014;Net Loss per Common Share &lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Basic net loss per common share is computed by dividing net loss attributable to Roivant Sciences Ltd. by the weighted-average number of common stock outstanding during the period. Diluted net loss per common share is computed by dividing the net loss attributable to Roivant Sciences Ltd. by the diluted weighted-average number of common stock outstanding during the period. &lt;/div&gt;&lt;/div&gt; &lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;For periods of loss, diluted loss per share is calculated similar to basic loss per share as the effect of including all potentially dilutive common share equivalents is anti-dilutive. All outstanding common stock equivalents have been excluded from the computation of diluted loss per share because their effect was anti-dilutive due to the net loss. Refer to Note 8, &#x201c;Share-Based Compensation&#x201d; and Note 4, &#x201c;Sumitomo Transaction Agreement&#x201d; for additional detail regarding outstanding common stock equivalents. &lt;/div&gt;&lt;/div&gt;</us-gaap:EarningsPerShareTextBlock>
    <us-gaap:SubsequentEventsTextBlock contextRef="P04_01_2021To06_30_2021">&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Note 14&#x2014;Subsequent Events &lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt; margin-left: 2%;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;Proteovant &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;In July 2021, Proteovant Sciences, Inc. (&#x201c;Proteovant&#x201d;) received the second $100.0&#160;million payment due under a subscription agreement entered into with SK, Inc. (&#x201c;SK&#x201d;) in December 2020 pursuant to which SK agreed to make a $200.0&#160;million equity investment in Proteovant, representing an ownership interest of 40.0% on the closing date. The second $100.0&#160;million payment was classified as a subscription receivable in the accompanying condensed consolidated balance sheets and condensed consolidated statements of shareholders&#x2019; equity and redeemable noncontrolling interest as of June&#160;30, 2021.&lt;/div&gt;&lt;/div&gt; &lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt; margin-left: 2%; text-indent: 0px;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;Datavant &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;In July 2021, Datavant closed its merger with CIOX Health, LLC. At closing, RSL received approximately $320&#160;million in cash and a minority equity stake in the combined company.&lt;/div&gt;&lt;/div&gt;</us-gaap:SubsequentEventsTextBlock>
    <roiv:SubscriptionsReceivable
      contextRef="PAsOn07_31_2021_ProteovantSciencesIncMemberusgaapBusinessAcquisitionAxis_SubsequentEventMemberusgaapSubsequentEventTypeAxis"
      decimals="-5"
      unitRef="Unit_USD">-100000000.0</roiv:SubscriptionsReceivable>
    <us-gaap:EquityMethodInvestments
      contextRef="PAsOn07_31_2021_ProteovantSciencesIncMemberusgaapBusinessAcquisitionAxis_SubsequentEventMemberusgaapSubsequentEventTypeAxis"
      decimals="-5"
      unitRef="Unit_USD">200000000.0</us-gaap:EquityMethodInvestments>
    <us-gaap:EquityMethodInvestmentOwnershipPercentage
      contextRef="PAsOn07_31_2021_ProteovantSciencesIncMemberusgaapBusinessAcquisitionAxis_SubsequentEventMemberusgaapSubsequentEventTypeAxis"
      decimals="3"
      unitRef="Unit_pure">0.400</us-gaap:EquityMethodInvestmentOwnershipPercentage>
    <roiv:SubscriptionsReceivable
      contextRef="PAsOn06_30_2021"
      decimals="-5"
      unitRef="Unit_USD">-100000000.0</roiv:SubscriptionsReceivable>
    <us-gaap:BusinessCombinationConsiderationTransferred1
      contextRef="P07_01_2021To07_31_2021_DatavantMemberusgaapBusinessAcquisitionAxis_SubsequentEventMemberusgaapSubsequentEventTypeAxis"
      decimals="-6"
      unitRef="Unit_USD">320000000</us-gaap:BusinessCombinationConsiderationTransferred1>
    <link:footnoteLink
      xlink:role="http://www.xbrl.org/2003/role/link"
      xlink:type="extended">
        <link:loc
          xlink:href="#Fact_28229485"
          xlink:label="Fact_28229485"
          xlink:type="locator"/>
        <link:footnote id="FN_95030" xlink:label="FN_95030" xlink:role="http://www.xbrl.org/2003/role/footnote" xlink:type="resource" xml:lang="en-US">Primarily Greater China, United States state and local and United Kingdom activity</link:footnote>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fact_28229485"
          xlink:to="FN_95030"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Fact_28229486"
          xlink:label="Fact_28229486"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fact_28229486"
          xlink:to="FN_95030"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Fact_28229520"
          xlink:label="Fact_28229520"
          xlink:type="locator"/>
        <link:footnote id="FN_95032" xlink:label="FN_95032" xlink:role="http://www.xbrl.org/2003/role/footnote" xlink:type="resource" xml:lang="en-US">Primarily related to operations in Switzerland, the United Kingdom, and other jurisdictions with statutory tax rates different than the Bermuda rate. </link:footnote>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fact_28229520"
          xlink:to="FN_95032"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Fact_28229521"
          xlink:label="Fact_28229521"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fact_28229521"
          xlink:to="FN_95032"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Fact_28229522"
          xlink:label="Fact_28229522"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fact_28229522"
          xlink:to="FN_95032"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Fact_28229523"
          xlink:label="Fact_28229523"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fact_28229523"
          xlink:to="FN_95032"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Fact_28229787"
          xlink:label="Fact_28229787"
          xlink:type="locator"/>
        <link:footnote id="FN_95031" xlink:label="FN_95031" xlink:role="http://www.xbrl.org/2003/role/footnote" xlink:type="resource" xml:lang="en-US">Primarily Greater China and United Kingdom activity</link:footnote>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fact_28229787"
          xlink:to="FN_95031"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Fact_28229788"
          xlink:label="Fact_28229788"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fact_28229788"
          xlink:to="FN_95031"
          xlink:type="arc"/>
    </link:footnoteLink>
</xbrl>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>71
<FILENAME>R1.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm139997750974264">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Cover<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_CoverAbstract', window );"><strong>Cover [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentType', window );">Document Type</a></td>
<td class="text">S-1<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_AmendmentFlag', window );">Amendment Flag</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityRegistrantName', window );">Entity Registrant Name</a></td>
<td class="text">Roivant Sciences Ltd.<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityCentralIndexKey', window );">Entity Central Index Key</a></td>
<td class="text">0001635088<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityFilerCategory', window );">Entity Filer Category</a></td>
<td class="text">Non-accelerated Filer<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntitySmallBusiness', window );">Entity Small Business</a></td>
<td class="text">true<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityEmergingGrowthCompany', window );">Emerging Growth Company</a></td>
<td class="text">true<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityExTransitionPeriod', window );">Entity Ex Transition Period</a></td>
<td class="text">true<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AmendmentFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AmendmentFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CoverAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Cover page.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CoverAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentType">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentType</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:submissionTypeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCentralIndexKey">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCentralIndexKey</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:centralIndexKeyItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityEmergingGrowthCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate if registrant meets the emerging growth company criteria.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityEmergingGrowthCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityExTransitionPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate if an emerging growth company has elected not to use the extended transition period for complying with any new or revised financial accounting standards.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Securities Act<br> -Number 7A<br> -Section B<br> -Subsection 2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityExTransitionPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFilerCategory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFilerCategory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:filerCategoryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityRegistrantName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityRegistrantName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntitySmallBusiness">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicates that the company is a Smaller Reporting Company (SRC).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntitySmallBusiness</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>72
<FILENAME>R2.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm139997756168120">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Condensed Consolidated Balance Sheets - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Jun. 30, 2021</div></th>
<th class="th"><div>Mar. 31, 2021</div></th>
<th class="th"><div>Mar. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsCurrentAbstract', window );"><strong>Current assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and cash equivalents</a></td>
<td class="nump">$ 1,996,733<span></span>
</td>
<td class="nump">$ 2,055,044<span></span>
</td>
<td class="nump">$ 2,183,207<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestrictedCashCurrent', window );">Restricted cash</a></td>
<td class="nump">2,711<span></span>
</td>
<td class="nump">77,701<span></span>
</td>
<td class="nump">2,275<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherAssetsCurrent', window );">Other current assets</a></td>
<td class="nump">58,165<span></span>
</td>
<td class="nump">54,250<span></span>
</td>
<td class="nump">33,763<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsCurrent', window );">Total current assets</a></td>
<td class="nump">2,057,609<span></span>
</td>
<td class="nump">2,186,995<span></span>
</td>
<td class="nump">2,219,245<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentNet', window );">Property and equipment, net</a></td>
<td class="nump">15,550<span></span>
</td>
<td class="nump">14,749<span></span>
</td>
<td class="nump">8,962<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseRightOfUseAsset', window );">Operating lease right-of-use assets</a></td>
<td class="nump">65,163<span></span>
</td>
<td class="nump">62,279<span></span>
</td>
<td class="nump">64,970<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestrictedCashNoncurrent', window );">Restricted cash, net of current portion</a></td>
<td class="nump">8,933<span></span>
</td>
<td class="nump">8,931<span></span>
</td>
<td class="nump">83,770<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentsFairValueDisclosure', window );">Investments measured at fair value</a></td>
<td class="nump">180,359<span></span>
</td>
<td class="nump">188,978<span></span>
</td>
<td class="nump">93,445<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermInvestments', window );">Long-term investment</a></td>
<td class="nump">100,563<span></span>
</td>
<td class="nump">100,563<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherAssetsNoncurrent', window );">Other assets</a></td>
<td class="nump">26,520<span></span>
</td>
<td class="nump">27,197<span></span>
</td>
<td class="nump">6,659<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Assets', window );">Total assets</a></td>
<td class="nump">2,454,697<span></span>
</td>
<td class="nump">2,589,692<span></span>
</td>
<td class="nump">2,477,051<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrentAbstract', window );"><strong>Current liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsPayableCurrent', window );">Accounts payable</a></td>
<td class="nump">15,014<span></span>
</td>
<td class="nump">20,550<span></span>
</td>
<td class="nump">10,306<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccruedLiabilitiesCurrent', window );">Accrued expenses</a></td>
<td class="nump">73,788<span></span>
</td>
<td class="nump">76,936<span></span>
</td>
<td class="nump">68,621<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityCurrent', window );">Operating lease liabilities</a></td>
<td class="nump">12,055<span></span>
</td>
<td class="nump">12,313<span></span>
</td>
<td class="nump">7,839<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_roiv_DeferredConsiderationLiabilityCurrent', window );">Deferred consideration liability</a></td>
<td class="nump">100,000<span></span>
</td>
<td class="nump">100,000<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherLiabilitiesCurrent', window );">Other current liabilities</a></td>
<td class="nump">8,301<span></span>
</td>
<td class="nump">9,162<span></span>
</td>
<td class="nump">5,352<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrent', window );">Total current liabilities</a></td>
<td class="nump">209,158<span></span>
</td>
<td class="nump">218,961<span></span>
</td>
<td class="nump">92,118<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_roiv_LiabilityInstrumentsMeasuredAtFairValue', window );">Liability instruments measured at fair value</a></td>
<td class="nump">5,906<span></span>
</td>
<td class="nump">67,893<span></span>
</td>
<td class="nump">102,373<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityNoncurrent', window );">Operating lease liabilities, noncurrent</a></td>
<td class="nump">65,263<span></span>
</td>
<td class="nump">62,384<span></span>
</td>
<td class="nump">64,452<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebtNoncurrent', window );">Long-term debt</a></td>
<td class="nump">186,350<span></span>
</td>
<td class="nump">170,280<span></span>
</td>
<td class="nump">108,592<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherLiabilitiesNoncurrent', window );">Other liabilities</a></td>
<td class="nump">8,188<span></span>
</td>
<td class="nump">8,169<span></span>
</td>
<td class="nump">821<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Liabilities', window );">Total liabilities</a></td>
<td class="nump">474,865<span></span>
</td>
<td class="nump">527,687<span></span>
</td>
<td class="nump">368,356<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingencies', window );">Commitments and Contingencies</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RedeemableNoncontrollingInterestEquityCarryingAmount', window );">Redeemable noncontrolling interest</a></td>
<td class="nump">22,491<span></span>
</td>
<td class="nump">22,491<span></span>
</td>
<td class="nump">22,491<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityAbstract', window );"><strong>Shareholders' equity:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockValue', window );">Common shares</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdditionalPaidInCapital', window );">Additional paid-in capital</a></td>
<td class="nump">3,824,974<span></span>
</td>
<td class="nump">3,814,805<span></span>
</td>
<td class="nump">3,143,739<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_roiv_SubscriptionsReceivable', window );">Subscription receivable</a></td>
<td class="num">(100,000)<span></span>
</td>
<td class="num">(100,000)<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RetainedEarningsAccumulatedDeficit', window );">Accumulated deficit</a></td>
<td class="num">(2,000,645)<span></span>
</td>
<td class="num">(1,918,462)<span></span>
</td>
<td class="num">(1,109,228)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax', window );">Accumulated other comprehensive (loss) income</a></td>
<td class="num">(1,207)<span></span>
</td>
<td class="nump">1,445<span></span>
</td>
<td class="num">(2,349)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Shareholders' equity attributable to Roivant Sciences Ltd.</a></td>
<td class="nump">1,723,122<span></span>
</td>
<td class="nump">1,797,788<span></span>
</td>
<td class="nump">2,032,162<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MinorityInterest', window );">Noncontrolling interests</a></td>
<td class="nump">234,219<span></span>
</td>
<td class="nump">241,726<span></span>
</td>
<td class="nump">54,042<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Total shareholders' equity</a></td>
<td class="nump">1,957,341<span></span>
</td>
<td class="nump">2,039,514<span></span>
</td>
<td class="nump">2,086,204<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesAndStockholdersEquity', window );">Total liabilities, redeemable noncontrolling interest and shareholders' equity</a></td>
<td class="nump">$ 2,454,697<span></span>
</td>
<td class="nump">$ 2,589,692<span></span>
</td>
<td class="nump">$ 2,477,051<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_roiv_DeferredConsiderationLiabilityCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Deferred consideration liability current.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">roiv_DeferredConsiderationLiabilityCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>roiv_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_roiv_LiabilityInstrumentsMeasuredAtFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Liability instruments measured at fair value.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">roiv_LiabilityInstrumentsMeasuredAtFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>roiv_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_roiv_SubscriptionsReceivable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Subscriptions receivable.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">roiv_SubscriptionsReceivable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>roiv_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsPayableCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Accumulated change in equity from transactions and other events and circumstances from non-owner sources, net of tax effect, at period end. Excludes Net Income (Loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners. Includes foreign currency translation items, certain pension adjustments, unrealized gains and losses on certain investments in debt and equity securities, other than temporary impairment (OTTI) losses related to factors other than credit losses on available-for-sale and held-to-maturity debt securities that an entity does not intend to sell and it is not more likely than not that the entity will be required to sell before recovery of the amortized cost basis, as well as changes in the fair value of derivatives related to the effective portion of a designated cash flow hedge.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(4))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=d3e637-108580<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(3))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14A<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669686-108580<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(ii)<br> -URI http://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=d3e681-108580<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdditionalPaidInCapital">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of excess of issue price over par or stated value of stock and from other transaction involving stock or stockholder. Includes, but is not limited to, additional paid-in capital (APIC) for common and preferred stock.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (g)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=121322162&amp;loc=SL121327923-165333<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdditionalPaidInCapital</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Assets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(11))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(12))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 9: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 14: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI http://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8906-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Assets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6801-107765<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.9)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 15: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI http://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 20: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6676-107765<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3044-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6676-107765<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingencies">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.25)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03.(a),19)<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03.17)<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 450<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=121557415&amp;loc=d3e14326-108349<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingencies</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentsFairValueDisclosure">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value portion of investment securities, including, but not limited to, marketable securities, derivative financial instruments, and investments accounted for under the equity method.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123874694&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentsFairValueDisclosure</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Liabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19-26)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8906-108599<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI http://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 20: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Liabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesAndStockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(23))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(25))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(32))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesAndStockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI http://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 20: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.21)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebtNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after unamortized (discount) premium and debt issuance costs of long-term debt classified as noncurrent and excluding amounts to be repaid within one year or the normal operating cycle, if longer. Includes, but not limited to, notes payable, bonds payable, debentures, mortgage loans and commercial paper. Excludes capital lease obligations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.22)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebtNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The total amount of investments that are intended to be held for an extended period of time (longer than one operating cycle).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.12)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MinorityInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which is directly or indirectly attributable to that ownership interest in subsidiary equity which is not attributable to the parent (that is, noncontrolling interest, previously referred to as minority interest).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(24))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.31)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 10: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MinorityInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as current.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseRightOfUseAsset">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's right to use underlying asset under operating lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseRightOfUseAsset</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherAssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of current assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.8)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherAssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherAssetsNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of noncurrent assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.17)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherAssetsNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities classified as other, due within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6904-107765<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6911-107765<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherLiabilitiesNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities classified as other, due after one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.24)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherLiabilitiesNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(14))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 360<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=124429447&amp;loc=SL124453093-239630<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(13))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 6: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RedeemableNoncontrollingInterestEquityCarryingAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>As of the reporting date, the aggregate carrying amount of all noncontrolling interests which are redeemable by the (parent) entity (1) at a fixed or determinable price on a fixed or determinable date, (2) at the option of the holder of the noncontrolling interest, or (3) upon occurrence of an event that is not solely within the control of the (parent) entity. This item includes noncontrolling interest holder's ownership (or holders' ownership) regardless of the type of equity interest (common, preferred, other) including all potential organizational (legal) forms of the investee entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 480<br> -SubTopic 10<br> -Section S99<br> -Paragraph 3A<br> -Subparagraph (16)(c)<br> -URI http://asc.fasb.org/extlink&amp;oid=122040564&amp;loc=SL6540498-122764<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 480<br> -SubTopic 10<br> -Section S99<br> -Paragraph 3A<br> -Subparagraph 15<br> -URI http://asc.fasb.org/extlink&amp;oid=122040564&amp;loc=SL6540498-122764<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 480<br> -SubTopic 10<br> -Section S99<br> -Paragraph 3A<br> -Subparagraph (12)(c)<br> -URI http://asc.fasb.org/extlink&amp;oid=122040564&amp;loc=SL6540498-122764<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 480<br> -SubTopic 10<br> -Section S99<br> -Paragraph 3A<br> -Subparagraph 14<br> -URI http://asc.fasb.org/extlink&amp;oid=122040564&amp;loc=SL6540498-122764<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RedeemableNoncontrollingInterestEquityCarryingAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestrictedCashCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash restricted as to withdrawal or usage, classified as current. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=123431023&amp;loc=SL98516268-108586<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6676-107765<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestrictedCashCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestrictedCashNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash restricted as to withdrawal or usage, classified as noncurrent. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6812-107765<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(17))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=123431023&amp;loc=SL98516268-108586<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 954<br> -SubTopic 210<br> -Section 45<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=120413173&amp;loc=SL116631458-115580<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestrictedCashNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetainedEarningsAccumulatedDeficit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cumulative amount of the reporting entity's undistributed earnings or deficit.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(3))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (g)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=121322162&amp;loc=SL121327923-165333<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(4))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(i)<br> -URI http://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RetainedEarningsAccumulatedDeficit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 4.E)<br> -URI http://asc.fasb.org/extlink&amp;oid=122038336&amp;loc=d3e74512-122707<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(31))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of stockholders' equity (deficit), net of receivables from officers, directors, owners, and affiliates of the entity, attributable to both the parent and noncontrolling interests. Amount excludes temporary equity. Alternate caption for the concept is permanent equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=124436220&amp;loc=d3e21930-107793<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 45<br> -Paragraph 23<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124436220&amp;loc=d3e21914-107793<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22644-107794<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124442411-227067<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 10<br> -Section 65<br> -Paragraph 4<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=122640432&amp;loc=SL121648383-210437<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 105<br> -SubTopic 10<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=124434974&amp;loc=SL124442142-165695<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 105<br> -SubTopic 10<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=124434974&amp;loc=SL124442142-165695<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 16<br> -URI http://asc.fasb.org/extlink&amp;oid=123454820&amp;loc=SL4568740-111683<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=123482062&amp;loc=SL123482106-238011<br><br>Reference 11: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 45<br> -Paragraph 5<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124436220&amp;loc=d3e21711-107793<br><br>Reference 13: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 14: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6450520&amp;loc=d3e32583-110901<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 65<br> -Paragraph 8<br> -Subparagraph (d)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=123459177&amp;loc=SL121830611-158277<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 45<br> -Paragraph 17<br> -URI http://asc.fasb.org/extlink&amp;oid=118261656&amp;loc=d3e32136-110900<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 65<br> -Paragraph 8<br> -Subparagraph (d)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=123459177&amp;loc=SL121830611-158277<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (f)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (f)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=121322162&amp;loc=SL121327923-165333<br><br>Reference 21: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4I<br> -URI http://asc.fasb.org/extlink&amp;oid=120409616&amp;loc=SL4590271-111686<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (f)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 45<br> -Paragraph 20<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=118261656&amp;loc=d3e32211-110900<br><br>Reference 24: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -URI http://asc.fasb.org/extlink&amp;oid=123454820&amp;loc=SL4568447-111683<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (f)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=121322162&amp;loc=SL121327923-165333<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=121322162&amp;loc=SL121327923-165333<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 848<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Publisher FASB<br> -Subparagraph (a)(3)(iii)(03)<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>73
<FILENAME>R3.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm139997864374744">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Condensed Consolidated Balance Sheets (Parenthetical) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Jun. 30, 2021</div></th>
<th class="th"><div>Mar. 31, 2021</div></th>
<th class="th"><div>Mar. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebtFairValue', window );">Long term debt accounted under fair value option</a></td>
<td class="nump">$ 155,200<span></span>
</td>
<td class="nump">$ 150,100<span></span>
</td>
<td class="nump">$ 89,100<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Common stock, par or stated value per share</a></td>
<td class="nump">$ 0.0000001<span></span>
</td>
<td class="nump">$ 0.0000001<span></span>
</td>
<td class="nump">$ 0.0000001<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesAuthorized', window );">Common stock, shares authorized</a></td>
<td class="nump">100,000,000,000<span></span>
</td>
<td class="nump">100,000,000,000<span></span>
</td>
<td class="nump">100,000,000,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Common stock, shares issued</a></td>
<td class="nump">222,669,799<span></span>
</td>
<td class="nump">222,669,799<span></span>
</td>
<td class="nump">214,879,058<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Common stock, shares outstanding</a></td>
<td class="nump">222,669,799<span></span>
</td>
<td class="nump">222,669,799<span></span>
</td>
<td class="nump">214,879,058<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of common stock.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The maximum number of common shares permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebtFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The fair value amount of long-term debt whether such amount is presented as a separate caption or as a parenthetical disclosure. Additionally, this element may be used in connection with the fair value disclosures required in the footnote disclosures to the financial statements. The element may be used in both the balance sheet and disclosure in the same submission.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebtFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>74
<FILENAME>R4.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm139997851385560">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Condensed Consolidated Statements of Operations - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2021</div></th>
<th class="th"><div>Jun. 30, 2020</div></th>
<th class="th"><div>Mar. 31, 2021</div></th>
<th class="th"><div>Mar. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenue, net</a></td>
<td class="nump">$ 7,735<span></span>
</td>
<td class="nump">$ 1,576<span></span>
</td>
<td class="nump">$ 23,795<span></span>
</td>
<td class="nump">$ 67,689<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingExpensesAbstract', window );"><strong>Operating expenses:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_roiv_OperatingCosts', window );">Cost of revenues</a></td>
<td class="nump">742<span></span>
</td>
<td class="nump">180<span></span>
</td>
<td class="nump">2,057<span></span>
</td>
<td class="nump">1,131<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">Research and development</a></td>
<td class="nump">78,626<span></span>
</td>
<td class="nump">58,734<span></span>
</td>
<td class="nump">832,758<span></span>
</td>
<td class="nump">263,217<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GeneralAndAdministrativeExpense', window );">General and administrative</a></td>
<td class="nump">82,754<span></span>
</td>
<td class="nump">57,115<span></span>
</td>
<td class="nump">259,878<span></span>
</td>
<td class="nump">335,766<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingExpenses', window );">Total operating expenses</a></td>
<td class="nump">162,122<span></span>
</td>
<td class="nump">116,029<span></span>
</td>
<td class="nump">1,094,693<span></span>
</td>
<td class="nump">600,114<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingIncomeLoss', window );">Loss from operations</a></td>
<td class="num">(154,387)<span></span>
</td>
<td class="num">(114,453)<span></span>
</td>
<td class="num">(1,070,898)<span></span>
</td>
<td class="num">(532,425)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherNonoperatingIncomeExpenseAbstract', window );"><strong>Other income (expense):</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GainLossOnInvestments', window );">Change in fair value of investments</a></td>
<td class="nump">8,619<span></span>
</td>
<td class="num">(41,148)<span></span>
</td>
<td class="num">(95,533)<span></span>
</td>
<td class="nump">136,005<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_roiv_GainLossOnFairValueOfDebtAndLiabilityInstruments', window );">Change in fair value of debt and liability instruments</a></td>
<td class="nump">4,585<span></span>
</td>
<td class="nump">17,125<span></span>
</td>
<td class="nump">29,845<span></span>
</td>
<td class="num">(13,722)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_roiv_EquityInterestOptionToThirdPartyPurchaserGainOnTermination', window );">Gain on termination of Sumitomo Options</a></td>
<td class="num">(66,472)<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_roiv_GainOrLossOnDeconsolidationOfSubsidiary', window );">Gain on deconsolidation of subsidiary</a></td>
<td class="nump">0<span></span>
</td>
<td class="num">(86,516)<span></span>
</td>
<td class="num">(115,364)<span></span>
</td>
<td class="num">(107,344)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_roiv_DeconsolidationAndConsolidationOnGainOrLossOfConsolidatedEntity', window );">Gain on deconsolidation of subsidiary and consolidation of unconsolidated entity</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(115,364)<span></span>
</td>
<td class="num">(107,344)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherNonoperatingIncomeExpense', window );">Other (income) expense, net</a></td>
<td class="num">(134)<span></span>
</td>
<td class="nump">2,842<span></span>
</td>
<td class="nump">8,701<span></span>
</td>
<td class="nump">13,622<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments', window );">Loss from continuing operations before income taxes</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(898,547)<span></span>
</td>
<td class="num">(560,986)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest', window );">Loss before income taxes</a></td>
<td class="num">(100,985)<span></span>
</td>
<td class="num">(6,756)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxExpenseBenefit', window );">Income tax expense</a></td>
<td class="nump">93<span></span>
</td>
<td class="nump">1,221<span></span>
</td>
<td class="nump">1,686<span></span>
</td>
<td class="nump">7,124<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest', window );">Loss from continuing operations, net of tax</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(900,233)<span></span>
</td>
<td class="num">(568,110)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTax', window );">Income from discontinued operations, net of tax</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">1,578,426<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProfitLoss', window );">Net loss</a></td>
<td class="num">(101,078)<span></span>
</td>
<td class="num">(7,977)<span></span>
</td>
<td class="num">(900,233)<span></span>
</td>
<td class="nump">1,010,316<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest', window );">Net loss attributable to noncontrolling interests</a></td>
<td class="num">(18,895)<span></span>
</td>
<td class="num">(4,734)<span></span>
</td>
<td class="num">(90,999)<span></span>
</td>
<td class="num">(190,193)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss attributable to Roivant Sciences Ltd.</a></td>
<td class="num">(82,183)<span></span>
</td>
<td class="num">(3,243)<span></span>
</td>
<td class="num">(809,234)<span></span>
</td>
<td class="nump">1,200,509<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeAmountsAttributableToReportingEntityDisclosuresAbstract', window );"><strong>Amounts attributable to Roivant Sciences Ltd.:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeLossFromContinuingOperations', window );">Loss from continuing operations, net of tax</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(809,234)<span></span>
</td>
<td class="num">(519,394)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity', window );">Income from discontinued operations, net of tax</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">1,719,903<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net (loss) income attributable to Roivant Sciences Ltd.</a></td>
<td class="num">$ (82,183)<span></span>
</td>
<td class="num">$ (3,243)<span></span>
</td>
<td class="num">$ (809,234)<span></span>
</td>
<td class="nump">$ 1,200,509<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasicAndDilutedAbstract', window );"><strong>Basic and diluted net (loss) income per common share:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeLossFromContinuingOperationsPerBasicAndDilutedShare', window );">Basic and diluted loss from continuing operations</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (3.76)<span></span>
</td>
<td class="num">$ (2.72)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicAndDilutedShare', window );">Basic and diluted income from discontinued operations</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">7.85<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasicAndDiluted', window );">Net loss per common share&#8212;basic and diluted</a></td>
<td class="num">$ (0.37)<span></span>
</td>
<td class="num">$ (0.02)<span></span>
</td>
<td class="num">$ (3.76)<span></span>
</td>
<td class="nump">$ 5.13<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasicAndDilutedOtherDisclosuresAbstract', window );"><strong>Basic and diluted weighted average shares outstanding:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic', window );">Basic</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">215,312,273<span></span>
</td>
<td class="nump">219,036,630<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding', window );">Diluted</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">215,312,273<span></span>
</td>
<td class="nump">219,036,630<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted', window );">Weighted average shares outstanding&#8212;basic and diluted</a></td>
<td class="nump">222,081,975<span></span>
</td>
<td class="nump">214,879,058<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_roiv_DeconsolidationAndConsolidationOnGainOrLossOfConsolidatedEntity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Deconsolidation and consolidation on gain or loss of consolidated entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">roiv_DeconsolidationAndConsolidationOnGainOrLossOfConsolidatedEntity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>roiv_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_roiv_EquityInterestOptionToThirdPartyPurchaserGainOnTermination">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Equity interest option to third party purchaser gain on termination.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">roiv_EquityInterestOptionToThirdPartyPurchaserGainOnTermination</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>roiv_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_roiv_GainLossOnFairValueOfDebtAndLiabilityInstruments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Gain Loss on Fair Value of Debt and Liability Instruments</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">roiv_GainLossOnFairValueOfDebtAndLiabilityInstruments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>roiv_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_roiv_GainOrLossOnDeconsolidationOfSubsidiary">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Gain or (loss) on deconsolidation of subsidiary.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">roiv_GainOrLossOnDeconsolidationOfSubsidiary</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>roiv_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_roiv_OperatingCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Operating costs.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">roiv_OperatingCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>roiv_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareBasicAndDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of net income or loss for the period per each share in instances when basic and diluted earnings per share are the same amount and reported as a single line item on the face of the financial statements.  Basic earnings per share is the amount of net income or loss for the period per each share of common stock or unit outstanding during the reporting period.  Diluted earnings per share includes the amount of net income or loss for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=d3e1337-109256<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareBasicAndDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareBasicAndDilutedAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareBasicAndDilutedAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareBasicAndDilutedOtherDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareBasicAndDilutedOtherDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GainLossOnInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of realized and unrealized gain (loss) on investment.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 10<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123581744&amp;loc=d3e27405-111563<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.7(c),9(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br><br>Reference 3: http://www.xbrl.org/2003/role/recommendedDisclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GainLossOnInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GeneralAndAdministrativeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.4)<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GeneralAndAdministrativeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeAmountsAttributableToReportingEntityDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeAmountsAttributableToReportingEntityDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromContinuingOperations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after tax of income (loss) from continuing operations attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 18<br> -URI http://asc.fasb.org/extlink&amp;oid=123454820&amp;loc=SL4613673-111683<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=SL5780133-109256<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.13)<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromContinuingOperations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of income (loss) from continuing operations, including income (loss) from equity method investments, before deduction of income tax expense (benefit), and income (loss) attributable to noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8906-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 940<br> -SubTopic 20<br> -Section 25<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=123384075&amp;loc=d3e41242-110953<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(10))<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(8))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 235<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399901&amp;loc=d3e537907-122884<br><br>Reference 9: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8924-108599<br><br>Reference 10: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(15))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of income (loss) from continuing operations before deduction of income tax expense (benefit) and income (loss) attributable to noncontrolling interest, and addition of income (loss) from equity method investments.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8906-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8924-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after tax of income (loss) from continuing operations including portion attributable to the noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 13: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 19<br> -URI http://asc.fasb.org/extlink&amp;oid=123454820&amp;loc=SL4569616-111683<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123482062&amp;loc=SL123482106-238011<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 17: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8924-108599<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8906-108599<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromContinuingOperationsPerBasicAndDilutedShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) from continuing operations per each basic and diluted share of common stock or unit when the per share amount is the same for both basic and diluted shares.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromContinuingOperationsPerBasicAndDilutedShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after tax of income (loss) from a discontinued operation including the portion attributable to the noncontrolling interest. Includes, but is not limited to, the income (loss) from operations during the phase-out period, gain (loss) on disposal, gain (loss) for reversal of write-down (write-down) to fair value, less cost to sell, and adjustments to a prior period gain (loss) on disposal.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(12))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 45<br> -Paragraph 3B<br> -URI http://asc.fasb.org/extlink&amp;oid=109222160&amp;loc=SL51721525-107759<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 5C<br> -Subparagraph (b)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721675-107760<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 45<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=109222160&amp;loc=d3e957-107759<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=d3e1361-107760<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 45<br> -Paragraph 3A<br> -URI http://asc.fasb.org/extlink&amp;oid=109222160&amp;loc=SL51721523-107759<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 45<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=109222160&amp;loc=d3e1012-107759<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 270<br> -Section 45<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=109227538&amp;loc=d3e44648-109337<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after tax of income (loss) from a discontinued operation attributable to the parent. Includes, but is not limited to, the income (loss) from operations during the phase-out period, gain (loss) on disposal, gain (loss) for reversal of write-down (write-down) to fair value, less cost to sell, and adjustments to a prior period gain (loss) on disposal.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 45<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=109222160&amp;loc=d3e957-107759<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 45<br> -Paragraph 3A<br> -URI http://asc.fasb.org/extlink&amp;oid=109222160&amp;loc=SL51721523-107759<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 45<br> -Paragraph 3B<br> -URI http://asc.fasb.org/extlink&amp;oid=109222160&amp;loc=SL51721525-107759<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=d3e1361-107760<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 5C<br> -Subparagraph (b)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721675-107760<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 5B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721673-107760<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 19<br> -URI http://asc.fasb.org/extlink&amp;oid=123454820&amp;loc=SL4569616-111683<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 45<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=109222160&amp;loc=d3e1012-107759<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicAndDilutedShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Per basic and diluted share amount, after tax, of income (loss) from the day-to-day business activities of the discontinued operation and gain (loss) from the disposal of the discontinued operation, when the per share amount is the same.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicAndDilutedShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB TOPIC 6.I.7)<br> -URI http://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32672-109319<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (h)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 20<br> -Section 45<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123586238&amp;loc=d3e38679-109324<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(9))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123482062&amp;loc=SL123482106-238011<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124452729-227067<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=SL5780133-109256<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669619-108580<br><br>Reference 25: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8924-108599<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669625-108580<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8906-108599<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of Net Income (Loss) attributable to noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669625-108580<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (a)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=SL4573702-111684<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669619-108580<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4J<br> -URI http://asc.fasb.org/extlink&amp;oid=120409616&amp;loc=SL4591551-111686<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124452729-227067<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLossAttributableToNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Generally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Includes selling, general and administrative expense.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingExpensesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingExpensesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The net result for the period of deducting operating expenses from operating revenues.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8924-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8906-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherNonoperatingIncomeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of income (expense) related to nonoperating activities, classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.9)<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherNonoperatingIncomeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherNonoperatingIncomeExpenseAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherNonoperatingIncomeExpenseAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProfitLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The consolidated profit or loss for the period, net of income taxes, including the portion attributable to the noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669619-108580<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=SL4573702-111684<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123482062&amp;loc=SL123482106-238011<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 12: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124452729-227067<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8906-108599<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3000-108585<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 19<br> -URI http://asc.fasb.org/extlink&amp;oid=123454820&amp;loc=SL4569616-111683<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 235<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399901&amp;loc=d3e537907-122884<br><br>Reference 23: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8924-108599<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669625-108580<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 29: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (c)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=SL4573702-111684<br><br>Reference 31: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4J<br> -URI http://asc.fasb.org/extlink&amp;oid=120409616&amp;loc=SL4591551-111686<br><br>Reference 32: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4K<br> -URI http://asc.fasb.org/extlink&amp;oid=120409616&amp;loc=SL4591552-111686<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProfitLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 912<br> -SubTopic 730<br> -Section 25<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6472174&amp;loc=d3e58812-109433<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 985<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6501960&amp;loc=d3e128462-111756<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 730<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6420194&amp;loc=d3e21568-108373<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8906-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 40<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e9031-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e9038-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123351226&amp;loc=SL49130543-203045<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 42<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e9054-108599<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=123351226&amp;loc=SL49130545-203045<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 924<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 11.L)<br> -URI http://asc.fasb.org/extlink&amp;oid=6472922&amp;loc=d3e499488-122856<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 16<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=d3e1505-109256<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Average number of shares or units issued and outstanding that are used in calculating basic and diluted earnings per share (EPS).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=d3e1448-109256<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfSharesOutstandingBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>75
<FILENAME>R5.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm139997755537720">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Condensed Consolidated Statements of Comprehensive Loss - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2021</div></th>
<th class="th"><div>Jun. 30, 2020</div></th>
<th class="th"><div>Mar. 31, 2021</div></th>
<th class="th"><div>Mar. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementOfStockholdersEquityAbstract', window );"><strong>Statement of Stockholders' Equity [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProfitLoss', window );">Net loss</a></td>
<td class="num">$ (101,078)<span></span>
</td>
<td class="num">$ (7,977)<span></span>
</td>
<td class="num">$ (900,233)<span></span>
</td>
<td class="nump">$ 1,010,316<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossTaxAbstract', window );"><strong>Other comprehensive loss:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax', window );">Foreign currency translation adjustment</a></td>
<td class="num">(2,439)<span></span>
</td>
<td class="num">(820)<span></span>
</td>
<td class="nump">3,826<span></span>
</td>
<td class="num">(5,536)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossNetOfTax', window );">Total other comprehensive loss</a></td>
<td class="num">(2,439)<span></span>
</td>
<td class="num">(820)<span></span>
</td>
<td class="nump">3,826<span></span>
</td>
<td class="num">(5,536)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest', window );">Comprehensive loss</a></td>
<td class="num">(103,517)<span></span>
</td>
<td class="num">(8,797)<span></span>
</td>
<td class="num">(896,407)<span></span>
</td>
<td class="nump">1,004,780<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest', window );">Comprehensive loss attributable to noncontrolling interests</a></td>
<td class="num">(18,682)<span></span>
</td>
<td class="num">(4,700)<span></span>
</td>
<td class="num">(90,967)<span></span>
</td>
<td class="num">(190,862)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ComprehensiveIncomeNetOfTax', window );">Comprehensive loss attributable to Roivant Sciences Ltd.</a></td>
<td class="num">$ (84,835)<span></span>
</td>
<td class="num">$ (4,097)<span></span>
</td>
<td class="num">$ (805,440)<span></span>
</td>
<td class="nump">$ 1,195,642<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ComprehensiveIncomeNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income, attributable to parent entity. Excludes changes in equity resulting from investments by owners and distributions to owners.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(24))<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=d3e557-108580<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(26))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669625-108580<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669619-108580<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ComprehensiveIncomeNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income (loss) and other comprehensive income (loss), attributable to noncontrolling interests. Excludes changes in equity resulting from investments by owners and distributions to owners.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669625-108580<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(21))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(25))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4K<br> -URI http://asc.fasb.org/extlink&amp;oid=120409616&amp;loc=SL4591552-111686<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669619-108580<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 21<br> -URI http://asc.fasb.org/extlink&amp;oid=123454820&amp;loc=SL4613674-111683<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(23))<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 20<br> -URI http://asc.fasb.org/extlink&amp;oid=123454820&amp;loc=SL4569643-111683<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income. Excludes changes in equity resulting from investments by owners and distributions to owners.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4K<br> -URI http://asc.fasb.org/extlink&amp;oid=120409616&amp;loc=SL4591552-111686<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669619-108580<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(20))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 19<br> -URI http://asc.fasb.org/extlink&amp;oid=123454820&amp;loc=SL4569616-111683<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669625-108580<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(24))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after tax, before reclassification adjustments of gain (loss) on foreign currency translation adjustments, foreign currency transactions designated and effective as economic hedges of a net investment in a foreign entity and intra-entity foreign currency transactions that are of a long-term-investment nature.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 20<br> -Section 35<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=123602790&amp;loc=d3e30304-110892<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 10<br> -Section 45<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=120253306&amp;loc=d3e28129-110885<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 45<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=118261656&amp;loc=d3e32022-110900<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10A<br> -Subparagraph (a-c)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669646-108580<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=d3e637-108580<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after tax and reclassification adjustments of other comprehensive income (loss).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669619-108580<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124442407-227067<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21463-112644<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 45<br> -Paragraph 17<br> -URI http://asc.fasb.org/extlink&amp;oid=118261656&amp;loc=d3e32136-110900<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(21))<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 55<br> -Paragraph 15<br> -URI http://asc.fasb.org/extlink&amp;oid=124507222&amp;loc=d3e1436-108581<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 45<br> -Paragraph 20<br> -URI http://asc.fasb.org/extlink&amp;oid=118261656&amp;loc=d3e32211-110900<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6450520&amp;loc=d3e32583-110901<br><br>Reference 9: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124442411-227067<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669625-108580<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(23))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(19))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossTaxAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossTaxAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProfitLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The consolidated profit or loss for the period, net of income taxes, including the portion attributable to the noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669619-108580<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=SL4573702-111684<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123482062&amp;loc=SL123482106-238011<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 12: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124452729-227067<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8906-108599<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3000-108585<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 19<br> -URI http://asc.fasb.org/extlink&amp;oid=123454820&amp;loc=SL4569616-111683<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 235<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399901&amp;loc=d3e537907-122884<br><br>Reference 23: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8924-108599<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669625-108580<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 29: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (c)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=SL4573702-111684<br><br>Reference 31: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4J<br> -URI http://asc.fasb.org/extlink&amp;oid=120409616&amp;loc=SL4591551-111686<br><br>Reference 32: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4K<br> -URI http://asc.fasb.org/extlink&amp;oid=120409616&amp;loc=SL4591552-111686<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProfitLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementOfStockholdersEquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementOfStockholdersEquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>76
<FILENAME>R6.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm139997750604376">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Condensed Consolidated Statements of Shareholders' Equity and Redeemable Noncontrolling Interest - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Total</div></th>
<th class="th"><div>Redeemable Noncontrolling Interest [Member]</div></th>
<th class="th"><div>Common Stock [Member]</div></th>
<th class="th"><div>Additional Paid-in Capital [Member]</div></th>
<th class="th"><div>Subscriptions Receivables [Member]</div></th>
<th class="th"><div>AOCI Attributable to Parent [Member]</div></th>
<th class="th"><div>Accumulated Deficit [Member]</div></th>
<th class="th"><div>Noncontrolling Interest [Member]</div></th>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquityCarryingAmountIncludingPortionAttributableToNoncontrollingInterests', window );">Balance, temporary equity at Mar. 31, 2019</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 50,130<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Balance at Mar. 31, 2019</a></td>
<td class="nump">$ 887,169<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 3,024,172<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 2,518<span></span>
</td>
<td class="num">$ (2,309,737)<span></span>
</td>
<td class="nump">$ 170,216<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Balance, shares at Mar. 31, 2019</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">213,555,119<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquityStockIssuedDuringPeriodValueNewIssues', window );">Issuance of subsidiary convertible and redeemable preferred stock, net</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">27,491<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalIncreaseInCarryingAmountOfRedeemablePreferredStock', window );">Purchase of subsidiary convertible and redeemable preferred stock</a></td>
<td class="num">(77,777)<span></span>
</td>
<td class="num">(55,130)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(77,777)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_roiv_IssuanceOfSubsidiaryCommonSharesNetValue', window );">Issuance of subsidiary common shares, net of issuance costs paid</a></td>
<td class="nump">117,658<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">59,052<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">58,606<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_roiv_IssuanceOfSubsidiaryCommonSharesToTheCompanyValue', window );">Issuance of subsidiary common shares to the Company</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(9,962)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">9,962<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_roiv_PurchaseOfSubsidiaryCommonSharesValue', window );">Purchase of subsidiary common shares</a></td>
<td class="num">(65,544)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(62,913)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(2,631)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_roiv_IssuanceOfSubsidiaryWarrants', window );">Issuance of subsidiary warrants</a></td>
<td class="nump">907<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">907<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised', window );">Exercise of subsidiary stock options</a></td>
<td class="nump">1,407<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">875<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">532<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueNewIssues', window );">Issuance of the Company's common shares</a></td>
<td class="nump">999,193<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">999,193<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Issuance of the Company's common shares, net, shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">26,952,143<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_roiv_RepurchaseOfCommonSharesAndOtherEquityInstrumentsValue', window );">Repurchase of common shares and other equity instruments</a></td>
<td class="num">(990,014)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(990,014)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_roiv_RepurchaseOfCommonSharesAndOtherEquityInstrumentsShares', window );">Repurchase of common shares and other equity instruments, shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(25,625,933)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GainOrLossOnSaleOfStockInSubsidiary', window );">Sale of interests in subsidiaries</a></td>
<td class="num">(43,398)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(43,398)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_roiv_IssuanceOfEquityBySubsidiaryUponBusinessCombinationAndRecapitalization', window );">Issuance of equity by subsidiary upon Business Combination and recapitalization</a></td>
<td class="nump">104,686<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">69,379<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">35,307<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_roiv_IssuanceOfEquityBySubsidiaryToTheCompanyUponBusinessCombinationAndRecapitalization', window );">Issuance of equity by subsidiary to the Company upon Business Combination and recapitalization</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(2,559)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,559<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_roiv_ConversionOfSubsidiaryConvertiblePromissoryNotes', window );">Conversion of subsidiary convertible promissory notes</a></td>
<td class="nump">33,087<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">21,928<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">11,159<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_roiv_IssuanceOfEquityInstruments', window );">Issuance of equity instruments</a></td>
<td class="nump">24,842<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">24,842<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_roiv_SettlementOfLiabilityClassifiedInstruments', window );">Settlement in equity of liability-classified instruments</a></td>
<td class="nump">13,119<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">13,119<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_roiv_DeconsolidationOfSubsidiary', window );">Deconsolidation of subsidiary</a></td>
<td class="num">(46,483)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(46,483)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_roiv_CapitalContributionsToSubsidiaries', window );">Cash contributions to majority-owned subsidiaries</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(4,699)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,699<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue', window );">Share-based compensation</a></td>
<td class="nump">122,572<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">79,103<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">43,469<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_roiv_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationRequisiteServicePeriodRecognitionShares', window );">Share-based compensation, shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(2,271)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent', window );">Foreign currency translation adjustment</a></td>
<td class="num">(5,536)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(4,867)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(669)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProfitLoss', window );">Net loss</a></td>
<td class="nump">1,010,316<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,200,509<span></span>
</td>
<td class="num">(190,193)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquityCarryingAmountIncludingPortionAttributableToNoncontrollingInterests', window );">Balance, temporary equity at Mar. 31, 2020</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">22,491<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Balance at Mar. 31, 2020</a></td>
<td class="nump">2,086,204<span></span>
</td>
<td class="nump">22,491<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">3,143,739<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="num">(2,349)<span></span>
</td>
<td class="num">(1,109,228)<span></span>
</td>
<td class="nump">54,042<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Balance, shares at Mar. 31, 2020</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">214,879,058<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_roiv_IssuanceOfSubsidiaryCommonSharesNetValue', window );">Issuance of subsidiary common shares, net of issuance costs paid</a></td>
<td class="nump">181,180<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">104,581<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">76,599<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_roiv_IssuanceOfSubsidiaryCommonSharesToTheCompanyValue', window );">Issuance of subsidiary common shares to the Company</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(6,342)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6,342<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised', window );">Exercise of subsidiary stock options</a></td>
<td class="nump">63<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">36<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">27<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_roiv_DeconsolidationOfSubsidiary', window );">Deconsolidation of subsidiary</a></td>
<td class="num">(3,054)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(3,054)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_roiv_RepurchaseOfEquityAwards', window );">Repurchase of equity awards</a></td>
<td class="num">(113)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(113)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_roiv_CapitalContributionsToSubsidiaries', window );">Cash contributions to majority-owned subsidiaries</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(149)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">149<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue', window );">Share-based compensation</a></td>
<td class="nump">14,278<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">9,285<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,993<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent', window );">Foreign currency translation adjustment</a></td>
<td class="num">(820)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(854)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">34<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProfitLoss', window );">Net loss</a></td>
<td class="num">(7,977)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(3,243)<span></span>
</td>
<td class="num">(4,734)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Balance at Jun. 30, 2020</a></td>
<td class="nump">2,269,761<span></span>
</td>
<td class="nump">22,491<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">3,251,037<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="num">(3,203)<span></span>
</td>
<td class="num">(1,112,471)<span></span>
</td>
<td class="nump">134,398<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Balance, shares at Jun. 30, 2020</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">214,879,058<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquityCarryingAmountIncludingPortionAttributableToNoncontrollingInterests', window );">Balance, temporary equity at Mar. 31, 2020</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">22,491<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Balance at Mar. 31, 2020</a></td>
<td class="nump">2,086,204<span></span>
</td>
<td class="nump">22,491<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">3,143,739<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="num">(2,349)<span></span>
</td>
<td class="num">(1,109,228)<span></span>
</td>
<td class="nump">54,042<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Balance, shares at Mar. 31, 2020</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">214,879,058<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_roiv_IssuanceOfSubsidiaryCommonSharesNetValue', window );">Issuance of subsidiary common shares, net of issuance costs paid</a></td>
<td class="nump">456,097<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">324,995<span></span>
</td>
<td class="num">(100,000)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">231,102<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_roiv_IssuanceOfSubsidiaryCommonSharesToTheCompanyValue', window );">Issuance of subsidiary common shares to the Company</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(11,692)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">11,692<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueNewIssues', window );">Issuance of the Company's common shares</a></td>
<td class="nump">301,744<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">301,744<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Issuance of the Company's common shares, net, shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">7,202,917<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_roiv_ExerciseOfSubsidiaryStockOptionsAndVestingOfSubsidiaryRestrictedStockUnits', window );">Exercise of subsidiary stock options and vesting of subsidiary restricted stock units</a></td>
<td class="nump">907<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">522<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">385<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_roiv_DeconsolidationOfSubsidiary', window );">Deconsolidation of subsidiary</a></td>
<td class="num">(3,054)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(3,054)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_roiv_ConsolidationOfUnconsolidatedEntity', window );">Consolidation of unconsolidated entity</a></td>
<td class="nump">9,178<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">9,178<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_roiv_RepurchaseOfEquityAwards', window );">Repurchase of equity awards</a></td>
<td class="num">(113)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(113)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_roiv_CapitalContributionsToSubsidiaries', window );">Cash contributions to majority-owned subsidiaries</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(1,642)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,642<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue', window );">Share-based compensation</a></td>
<td class="nump">84,958<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">57,252<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">27,706<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_roiv_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationRequisiteServicePeriodRecognitionShares', window );">Share-based compensation, shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">587,824<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent', window );">Foreign currency translation adjustment</a></td>
<td class="nump">3,826<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,794<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">32<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProfitLoss', window );">Net loss</a></td>
<td class="num">(900,233)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(809,234)<span></span>
</td>
<td class="num">(90,999)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquityCarryingAmountIncludingPortionAttributableToNoncontrollingInterests', window );">Balance, temporary equity at Mar. 31, 2021</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">22,491<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Balance at Mar. 31, 2021</a></td>
<td class="nump">2,039,514<span></span>
</td>
<td class="nump">22,491<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">3,814,805<span></span>
</td>
<td class="num">(100,000)<span></span>
</td>
<td class="nump">1,445<span></span>
</td>
<td class="num">(1,918,462)<span></span>
</td>
<td class="nump">241,726<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Balance, shares at Mar. 31, 2021</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">222,669,799<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_roiv_IssuanceOfSubsidiaryWarrants', window );">Issuance of subsidiary warrants</a></td>
<td class="nump">2,075<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,051<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">24<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_roiv_CapitalContributionsToSubsidiaries', window );">Cash contributions to majority-owned subsidiaries</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(2,973)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,973<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue', window );">Share-based compensation</a></td>
<td class="nump">19,269<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">11,091<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">8,178<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent', window );">Foreign currency translation adjustment</a></td>
<td class="num">(2,439)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(2,652)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">213<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProfitLoss', window );">Net loss</a></td>
<td class="num">(101,078)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(82,183)<span></span>
</td>
<td class="num">(18,895)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Balance at Jun. 30, 2021</a></td>
<td class="nump">$ 1,957,341<span></span>
</td>
<td class="nump">$ 22,491<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 3,824,974<span></span>
</td>
<td class="num">$ (100,000)<span></span>
</td>
<td class="num">$ (1,207)<span></span>
</td>
<td class="num">$ (2,000,645)<span></span>
</td>
<td class="nump">$ 234,219<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Balance, shares at Jun. 30, 2021</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">222,669,799<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_roiv_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationRequisiteServicePeriodRecognitionShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Adjustments to Additional Paid in Capital, Share-based Compensation, Requisite Service Period Recognition, Shares</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">roiv_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationRequisiteServicePeriodRecognitionShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>roiv_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_roiv_CapitalContributionsToSubsidiaries">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Capital Contributions To Subsidiaries</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">roiv_CapitalContributionsToSubsidiaries</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>roiv_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_roiv_ConsolidationOfUnconsolidatedEntity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Consolidation of Unconsolidated Entity</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">roiv_ConsolidationOfUnconsolidatedEntity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>roiv_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_roiv_ConversionOfSubsidiaryConvertiblePromissoryNotes">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Conversion of Subsidiary Convertible Promissory Notes</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">roiv_ConversionOfSubsidiaryConvertiblePromissoryNotes</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>roiv_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_roiv_DeconsolidationOfSubsidiary">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Deconsolidation Of Subsidiary</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">roiv_DeconsolidationOfSubsidiary</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>roiv_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_roiv_ExerciseOfSubsidiaryStockOptionsAndVestingOfSubsidiaryRestrictedStockUnits">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Exercise of Subsidiary Stock Options and Vesting of Subsidiary Restricted Stock Units</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">roiv_ExerciseOfSubsidiaryStockOptionsAndVestingOfSubsidiaryRestrictedStockUnits</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>roiv_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_roiv_IssuanceOfEquityBySubsidiaryToTheCompanyUponBusinessCombinationAndRecapitalization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Issuance of Equity by Subsidiary to the Company upon Business Combination and Recapitalization</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">roiv_IssuanceOfEquityBySubsidiaryToTheCompanyUponBusinessCombinationAndRecapitalization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>roiv_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_roiv_IssuanceOfEquityBySubsidiaryUponBusinessCombinationAndRecapitalization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Issuance of Equity by Subsidiary upon Business Combination and Recapitalization</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">roiv_IssuanceOfEquityBySubsidiaryUponBusinessCombinationAndRecapitalization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>roiv_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_roiv_IssuanceOfEquityInstruments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Issuance of Equity Instruments</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">roiv_IssuanceOfEquityInstruments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>roiv_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_roiv_IssuanceOfSubsidiaryCommonSharesNetValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Issuance of Subsidiary Common Shares Net Value</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">roiv_IssuanceOfSubsidiaryCommonSharesNetValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>roiv_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_roiv_IssuanceOfSubsidiaryCommonSharesToTheCompanyValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Issuance of Subsidiary Common Shares to the Company Value</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">roiv_IssuanceOfSubsidiaryCommonSharesToTheCompanyValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>roiv_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_roiv_IssuanceOfSubsidiaryWarrants">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Issuance of Subsidiary Warrants</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">roiv_IssuanceOfSubsidiaryWarrants</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>roiv_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_roiv_PurchaseOfSubsidiaryCommonSharesValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Purchase of Subsidiary Common Shares Value</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">roiv_PurchaseOfSubsidiaryCommonSharesValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>roiv_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_roiv_RepurchaseOfCommonSharesAndOtherEquityInstrumentsShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Repurchase of Common Shares and Other Equity Instruments Shares</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">roiv_RepurchaseOfCommonSharesAndOtherEquityInstrumentsShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>roiv_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_roiv_RepurchaseOfCommonSharesAndOtherEquityInstrumentsValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Repurchase of Common Shares and Other Equity Instruments Value</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">roiv_RepurchaseOfCommonSharesAndOtherEquityInstrumentsValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>roiv_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_roiv_RepurchaseOfEquityAwards">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Repurchase of Equity Awards</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">roiv_RepurchaseOfEquityAwards</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>roiv_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_roiv_SettlementOfLiabilityClassifiedInstruments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Settlement of Liability Classified Instruments</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">roiv_SettlementOfLiabilityClassifiedInstruments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>roiv_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalIncreaseInCarryingAmountOfRedeemablePreferredStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of decrease (increase) in additional paid in capital (APIC) for the increase in carrying amount of redeemable preferred stock.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 480<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 3.C)<br> -URI http://asc.fasb.org/extlink&amp;oid=122040564&amp;loc=d3e177168-122764<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToAdditionalPaidInCapitalIncreaseInCarryingAmountOfRedeemablePreferredStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase to additional paid-in capital (APIC) for recognition of cost for award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 20<br> -Section 55<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=122142933&amp;loc=d3e11149-113907<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5047-113901<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 20<br> -Section 55<br> -Paragraph 13<br> -URI http://asc.fasb.org/extlink&amp;oid=122142933&amp;loc=d3e11178-113907<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 35<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123468992&amp;loc=d3e4534-113899<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GainOrLossOnSaleOfStockInSubsidiary">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of gain (loss) on sale or disposal of equity in securities of subsidiaries.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(b)(9)(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(b)(7)(c))<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(13)(g))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(3)(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GainOrLossOnSaleOfStockInSubsidiary</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after tax and reclassification adjustments of gain (loss) on foreign currency translation adjustments, foreign currency transactions designated and effective as economic hedges of a net investment in a foreign entity and intra-entity foreign currency transactions that are of a long-term-investment nature, attributable to parent entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 20<br> -URI http://asc.fasb.org/extlink&amp;oid=123454820&amp;loc=SL4569643-111683<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (c)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=SL4573702-111684<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 19<br> -URI http://asc.fasb.org/extlink&amp;oid=123454820&amp;loc=SL4569616-111683<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProfitLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The consolidated profit or loss for the period, net of income taxes, including the portion attributable to the noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669619-108580<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=SL4573702-111684<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123482062&amp;loc=SL123482106-238011<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 12: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124452729-227067<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8906-108599<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3000-108585<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 19<br> -URI http://asc.fasb.org/extlink&amp;oid=123454820&amp;loc=SL4569616-111683<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 235<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399901&amp;loc=d3e537907-122884<br><br>Reference 23: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8924-108599<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669625-108580<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 29: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (c)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=SL4573702-111684<br><br>Reference 31: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4J<br> -URI http://asc.fasb.org/extlink&amp;oid=120409616&amp;loc=SL4591551-111686<br><br>Reference 32: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4K<br> -URI http://asc.fasb.org/extlink&amp;oid=120409616&amp;loc=SL4591552-111686<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProfitLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued which are neither cancelled nor held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of new stock issued during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21463-112644<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Equity impact of the value of new stock issued during the period. Includes shares issued in an initial public offering or a secondary public offering.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21463-112644<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Value of stock issued as a result of the exercise of stock options.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.29-31)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of stockholders' equity (deficit), net of receivables from officers, directors, owners, and affiliates of the entity, attributable to both the parent and noncontrolling interests. Amount excludes temporary equity. Alternate caption for the concept is permanent equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=124436220&amp;loc=d3e21930-107793<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 45<br> -Paragraph 23<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124436220&amp;loc=d3e21914-107793<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22644-107794<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124442411-227067<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 10<br> -Section 65<br> -Paragraph 4<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=122640432&amp;loc=SL121648383-210437<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 105<br> -SubTopic 10<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=124434974&amp;loc=SL124442142-165695<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 105<br> -SubTopic 10<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=124434974&amp;loc=SL124442142-165695<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 16<br> -URI http://asc.fasb.org/extlink&amp;oid=123454820&amp;loc=SL4568740-111683<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=123482062&amp;loc=SL123482106-238011<br><br>Reference 11: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 45<br> -Paragraph 5<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124436220&amp;loc=d3e21711-107793<br><br>Reference 13: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 14: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6450520&amp;loc=d3e32583-110901<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 65<br> -Paragraph 8<br> -Subparagraph (d)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=123459177&amp;loc=SL121830611-158277<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 45<br> -Paragraph 17<br> -URI http://asc.fasb.org/extlink&amp;oid=118261656&amp;loc=d3e32136-110900<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 65<br> -Paragraph 8<br> -Subparagraph (d)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=123459177&amp;loc=SL121830611-158277<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (f)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (f)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=121322162&amp;loc=SL121327923-165333<br><br>Reference 21: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4I<br> -URI http://asc.fasb.org/extlink&amp;oid=120409616&amp;loc=SL4590271-111686<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (f)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 45<br> -Paragraph 20<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=118261656&amp;loc=d3e32211-110900<br><br>Reference 24: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -URI http://asc.fasb.org/extlink&amp;oid=123454820&amp;loc=SL4568447-111683<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (f)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=121322162&amp;loc=SL121327923-165333<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=121322162&amp;loc=SL121327923-165333<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 848<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Publisher FASB<br> -Subparagraph (a)(3)(iii)(03)<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TemporaryEquityCarryingAmountIncludingPortionAttributableToNoncontrollingInterests">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying amount, attributable to parent and noncontrolling interests, of an entity's issued and outstanding stock which is not included within permanent equity. Temporary equity is a security with redemption features that are outside the control of the issuer, is not classified as an asset or liability in conformity with GAAP, and is not mandatorily redeemable. Includes any type of security that is redeemable at a fixed or determinable price or on a fixed or determinable date or dates, is redeemable at the option of the holder, or has conditions for redemption which are not solely within the control of the issuer. Includes stock with a put option held by an ESOP and stock redeemable by a holder only in the event of a change in control of the issuer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.27(b))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TemporaryEquityCarryingAmountIncludingPortionAttributableToNoncontrollingInterests</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TemporaryEquityStockIssuedDuringPeriodValueNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Value of new stock classified as temporary equity issued during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TemporaryEquityStockIssuedDuringPeriodValueNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>77
<FILENAME>R7.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm139997862156216">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Condensed Consolidated Statements of Cash Flows - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2021</div></th>
<th class="th"><div>Jun. 30, 2020</div></th>
<th class="th"><div>Mar. 31, 2021</div></th>
<th class="th"><div>Mar. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>Cash flows from operating activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProfitLoss', window );">Net loss</a></td>
<td class="num">$ (101,078)<span></span>
</td>
<td class="num">$ (7,977)<span></span>
</td>
<td class="num">$ (900,233)<span></span>
</td>
<td class="nump">$ 1,010,316<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>Adjustments to reconcile net loss to net cash used in operating activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentInProcess', window );">Acquired in-processresearch and development</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">351,523<span></span>
</td>
<td class="nump">16,405<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax', window );">Unrealized foreign currency translation adjustment</a></td>
<td class="num">(2,439)<span></span>
</td>
<td class="num">(820)<span></span>
</td>
<td class="nump">3,826<span></span>
</td>
<td class="num">(5,536)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensation', window );">Share-based compensation</a></td>
<td class="nump">19,269<span></span>
</td>
<td class="nump">14,278<span></span>
</td>
<td class="nump">84,958<span></span>
</td>
<td class="nump">122,572<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GainLossOnSaleOfBusiness', window );">Gain on sale of business</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="num">(1,985,949)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GainLossOnInvestments', window );">Change in fair value of investments</a></td>
<td class="nump">8,619<span></span>
</td>
<td class="num">(41,148)<span></span>
</td>
<td class="num">(95,533)<span></span>
</td>
<td class="nump">136,005<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_roiv_GainLossOnFairValueOfDebtAndLiabilityInstruments', window );">Change in fair value of debt and liability instruments</a></td>
<td class="nump">4,585<span></span>
</td>
<td class="nump">17,125<span></span>
</td>
<td class="nump">29,845<span></span>
</td>
<td class="num">(13,722)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_roiv_GainOrLossOnDeconsolidationOfSubsidiary', window );">Gain on deconsolidation of subsidiary</a></td>
<td class="nump">0<span></span>
</td>
<td class="num">(86,516)<span></span>
</td>
<td class="num">(115,364)<span></span>
</td>
<td class="num">(107,344)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_roiv_GainOnTerminationOfEquityInterestOptions', window );">Gain on termination of Sumitomo Options</a></td>
<td class="num">(61,472)<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeLossFromEquityMethodInvestments', window );">Loss from equity method investment</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">3,750<span></span>
</td>
<td class="nump">3,750<span></span>
</td>
<td class="nump">21,386<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherNoncashIncomeExpense', window );">Other</a></td>
<td class="nump">838<span></span>
</td>
<td class="nump">3,307<span></span>
</td>
<td class="nump">13,152<span></span>
</td>
<td class="nump">31,821<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract', window );"><strong>Changes in assets and liabilities, net of effects from acquisition and divestiture:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccountsPayableTrade', window );">Accounts payable</a></td>
<td class="num">(6,343)<span></span>
</td>
<td class="nump">7,501<span></span>
</td>
<td class="nump">3,752<span></span>
</td>
<td class="nump">6,598<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccruedLiabilities', window );">Accrued expenses</a></td>
<td class="num">(7,340)<span></span>
</td>
<td class="num">(15,982)<span></span>
</td>
<td class="nump">9,225<span></span>
</td>
<td class="nump">14,845<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInDeferredLiabilities', window );">Deferred consideration liability</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">100,000<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_roiv_IncreaseDecreaseInOperatingLeaseLiabilities', window );">Operating lease liabilities</a></td>
<td class="num">(1,957)<span></span>
</td>
<td class="num">(1,769)<span></span>
</td>
<td class="num">(5,497)<span></span>
</td>
<td class="num">(8,419)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOtherOperatingCapitalNet', window );">Other</a></td>
<td class="nump">3,709<span></span>
</td>
<td class="num">(3,736)<span></span>
</td>
<td class="num">(35,542)<span></span>
</td>
<td class="nump">2,272<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivities', window );">Net cash used in operating activities</a></td>
<td class="num">(141,170)<span></span>
</td>
<td class="num">(111,167)<span></span>
</td>
<td class="num">(552,138)<span></span>
</td>
<td class="num">(758,750)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract', window );"><strong>Cash flows from investing activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromDivestitureOfBusinesses', window );">Proceeds from sale of business, net of cash disposed</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">1,772,191<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashDivestedFromDeconsolidation', window );">Cash disposed upon deconsolidation of subsidiary</a></td>
<td class="nump">0<span></span>
</td>
<td class="num">(19,085)<span></span>
</td>
<td class="num">(19,085)<span></span>
</td>
<td class="num">(20,049)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_roiv_CashAcquiredUponConsolidationOfUnconsolidatedEntity', window );">Cash acquired upon consolidation of unconsolidated entity</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">21,439<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_roiv_PaymentsToAcquireInvestmentsInUnconsolidatedEntities', window );">Investments in unconsolidated entities</a></td>
<td class="nump">0<span></span>
</td>
<td class="num">(6,250)<span></span>
</td>
<td class="num">(28,250)<span></span>
</td>
<td class="num">(36,300)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireMarketableSecurities', window );">Purchase of marketable securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="num">(32,076)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities', window );">Maturity of marketable securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">16,440<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired', window );">Acquisitions, net of cash acquired</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="num">(500)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment', window );">Purchase of property and equipment</a></td>
<td class="num">(2,339)<span></span>
</td>
<td class="num">(306)<span></span>
</td>
<td class="num">(5,806)<span></span>
</td>
<td class="num">(4,916)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivities', window );">Net cash used in investing activities</a></td>
<td class="num">(2,339)<span></span>
</td>
<td class="num">(25,641)<span></span>
</td>
<td class="num">(31,702)<span></span>
</td>
<td class="nump">1,694,790<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract', window );"><strong>Cash flows from financing activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfCommonStock', window );">Proceeds from issuance of the Company's common shares, net</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">999,193<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsForRepurchaseOfEquity', window );">Repurchase of equity awards</a></td>
<td class="nump">0<span></span>
</td>
<td class="num">(113)<span></span>
</td>
<td class="num">(113)<span></span>
</td>
<td class="num">(990,014)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfDebt', window );">Proceeds from issuance of liability instruments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">101,567<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_roiv_ProceedsFromIssuanceOfSubsidiaryCommonSharesNet', window );">Proceeds from issuance of subsidiary common shares, net of issuance costs paid</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">181,180<span></span>
</td>
<td class="nump">455,756<span></span>
</td>
<td class="nump">117,658<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_roiv_ProceedsFromIssuanceOfEquityBySubsidiaryUponBusinessCombinationAndRecapitalization', window );">Proceeds from issuance of equity by subsidiary upon Business Combination and recapitalization</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">105,930<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_roiv_PurchaseOfSubsidiaryCommonShares', window );">Purchase of subsidiary common shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="num">(65,544)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_roiv_ProceedsFromIssuanceOfSubsidiaryConvertibleAndRedeemablePreferredStockNet', window );">Proceeds from issuance of subsidiary convertible and redeemable preferred stock, net</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">28,455<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_roiv_PaymentsForPurchaseOfSubsidiaryConvertibleAndRedeemablePreferredStock', window );">Purchase of subsidiary convertible and redeemable preferred stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="num">(132,907)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_roiv_ProceedsFromSubsidiaryDebtFinancingsNet', window );">Proceeds from subsidiary debt financings, net of financing costs paid</a></td>
<td class="nump">36,400<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">83,781<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_roiv_RepaymentOfLongTermDebtAndConvertibleDebtBySubsidiary', window );">Repayment of long-term debt by subsidiary</a></td>
<td class="num">(21,590)<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="num">(32,063)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsOfStockIssuanceCosts', window );">Offering costs paid</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(286)<span></span>
</td>
<td class="num">(3,082)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_roiv_PaymentForDebtMaintenanceFeeBySubsidiary', window );">Payment of deferred offering and loan origination costs</a></td>
<td class="num">(4,600)<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="num">(300)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromStockOptionsExercised', window );">Proceeds from exercise of subsidiary stock options</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">63<span></span>
</td>
<td class="nump">907<span></span>
</td>
<td class="nump">1,407<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivities', window );">Net cash provided by financing activities</a></td>
<td class="nump">10,210<span></span>
</td>
<td class="nump">181,130<span></span>
</td>
<td class="nump">456,264<span></span>
</td>
<td class="nump">214,081<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect', window );">Net change in cash, cash equivalents and restricted cash</a></td>
<td class="num">(133,299)<span></span>
</td>
<td class="nump">44,322<span></span>
</td>
<td class="num">(127,576)<span></span>
</td>
<td class="nump">1,150,121<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents', window );">Cash, cash equivalents and restricted cash at beginning of period</a></td>
<td class="nump">2,141,676<span></span>
</td>
<td class="nump">2,269,252<span></span>
</td>
<td class="nump">2,269,252<span></span>
</td>
<td class="nump">1,119,131<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents', window );">Cash, cash equivalents and restricted cash at end of period</a></td>
<td class="nump">2,008,377<span></span>
</td>
<td class="nump">2,313,574<span></span>
</td>
<td class="nump">2,141,676<span></span>
</td>
<td class="nump">2,269,252<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract', window );"><strong>Non-cash investing and financing activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability', window );">Operating lease right-of-use assets obtained and exchanged for operating lease liabilities</a></td>
<td class="nump">4,579<span></span>
</td>
<td class="nump">555<span></span>
</td>
<td class="nump">5,491<span></span>
</td>
<td class="nump">56,025<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_roiv_OperatingLeaseRightOfUseAssetsAndAmountsReclassifiedFromOtherLiabilitiesToOperatingLeaseLiabilities', window );">Operating lease right-of-use assets and operating lease liabilities, including amounts reclassified from other current liabilities and other liabilities to operating lease liabilities, recognized upon the adoption of ASC 842, Leases, on April 1, 2019</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">43,026<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_roiv_IssuanceOfSubsidiaryWarrantInConnectionWithDebtFinancing', window );">Issuance of subsidiary warrant in connection with debt financing</a></td>
<td class="nump">2,075<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_roiv_DeferredOfferingAndFinancingCostsIncludedInAccountsPayableAndAccruedExpenses', window );">Deferred offering and financing costs included in accounts payable and accrued expenses</a></td>
<td class="nump">$ 4,999<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_roiv_OtherNonCashTransactions', window );">Other</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(960)<span></span>
</td>
<td class="nump">3,601<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NoncashInvestingAndFinancingItemsAbstract', window );"><strong>Supplemental disclosure of noncash activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_roiv_ConversionOfSubsidiaryConvertiblePromissoryNotesToCommonShares', window );">Conversion Of Subsidiary Convertible Promissory Notes To Common Shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">32,500<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_roiv_SubscriptionReceivableRelatedToIssuanceOfSubsidiaryCommonShares', window );">Subscription Receivable Related To Issuance Of Subsidiary Common Shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">100,000<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SupplementalCashFlowInformationAbstract', window );"><strong>Supplemental disclosure of cash paid:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxesPaidNet', window );">Income taxes paid</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,076<span></span>
</td>
<td class="nump">4,936<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InterestPaidNet', window );">Interest paid</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,017<span></span>
</td>
<td class="nump">$ 12,158<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_roiv_CashAcquiredUponConsolidationOfUnconsolidatedEntity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Cash Acquired Upon Consolidation of Unconsolidated Entity</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">roiv_CashAcquiredUponConsolidationOfUnconsolidatedEntity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>roiv_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_roiv_ConversionOfSubsidiaryConvertiblePromissoryNotesToCommonShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Conversion of subsidiary convertible promissory notes to common shares.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">roiv_ConversionOfSubsidiaryConvertiblePromissoryNotesToCommonShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>roiv_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_roiv_DeferredOfferingAndFinancingCostsIncludedInAccountsPayableAndAccruedExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Deferred offering and financing costs included in accounts payable and accrued expenses.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">roiv_DeferredOfferingAndFinancingCostsIncludedInAccountsPayableAndAccruedExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>roiv_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_roiv_GainLossOnFairValueOfDebtAndLiabilityInstruments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Gain Loss on Fair Value of Debt and Liability Instruments</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">roiv_GainLossOnFairValueOfDebtAndLiabilityInstruments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>roiv_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_roiv_GainOnTerminationOfEquityInterestOptions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Gain on termination of equity interest options.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">roiv_GainOnTerminationOfEquityInterestOptions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>roiv_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_roiv_GainOrLossOnDeconsolidationOfSubsidiary">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Gain or (loss) on deconsolidation of subsidiary.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">roiv_GainOrLossOnDeconsolidationOfSubsidiary</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>roiv_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_roiv_IncreaseDecreaseInOperatingLeaseLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Increase decrease in operating lease liabilities</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">roiv_IncreaseDecreaseInOperatingLeaseLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>roiv_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_roiv_IssuanceOfSubsidiaryWarrantInConnectionWithDebtFinancing">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Issuance of subsidiary warrant in connection with debt financing.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">roiv_IssuanceOfSubsidiaryWarrantInConnectionWithDebtFinancing</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>roiv_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_roiv_OperatingLeaseRightOfUseAssetsAndAmountsReclassifiedFromOtherLiabilitiesToOperatingLeaseLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Operating Lease Right of Use Assets and Amounts Reclassified from Other Liabilities to Operating Lease Liabilities</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">roiv_OperatingLeaseRightOfUseAssetsAndAmountsReclassifiedFromOtherLiabilitiesToOperatingLeaseLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>roiv_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_roiv_OtherNonCashTransactions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Other Non Cash Transactions</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">roiv_OtherNonCashTransactions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>roiv_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_roiv_PaymentForDebtMaintenanceFeeBySubsidiary">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Payment for Debt Maintenance Fee by Subsidiary</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">roiv_PaymentForDebtMaintenanceFeeBySubsidiary</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>roiv_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_roiv_PaymentsForPurchaseOfSubsidiaryConvertibleAndRedeemablePreferredStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Payments for Purchase of Subsidiary Convertible and Redeemable Preferred Stock</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">roiv_PaymentsForPurchaseOfSubsidiaryConvertibleAndRedeemablePreferredStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>roiv_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_roiv_PaymentsToAcquireInvestmentsInUnconsolidatedEntities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Payments to Acquire Investments in Unconsolidated Entities</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">roiv_PaymentsToAcquireInvestmentsInUnconsolidatedEntities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>roiv_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_roiv_ProceedsFromIssuanceOfEquityBySubsidiaryUponBusinessCombinationAndRecapitalization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Proceeds from Issuance of Equity by Subsidiary Upon Business Combination and Recapitalization</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">roiv_ProceedsFromIssuanceOfEquityBySubsidiaryUponBusinessCombinationAndRecapitalization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>roiv_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_roiv_ProceedsFromIssuanceOfSubsidiaryCommonSharesNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Proceeds from Issuance of Subsidiary Common Shares Net</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">roiv_ProceedsFromIssuanceOfSubsidiaryCommonSharesNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>roiv_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_roiv_ProceedsFromIssuanceOfSubsidiaryConvertibleAndRedeemablePreferredStockNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Proceeds from Issuance of Subsidiary Convertible and Redeemable Preferred Stock Net</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">roiv_ProceedsFromIssuanceOfSubsidiaryConvertibleAndRedeemablePreferredStockNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>roiv_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_roiv_ProceedsFromSubsidiaryDebtFinancingsNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Proceeds from Subsidiary Debt Financings Net</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">roiv_ProceedsFromSubsidiaryDebtFinancingsNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>roiv_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_roiv_PurchaseOfSubsidiaryCommonShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Purchase of Subsidiary Common Shares</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">roiv_PurchaseOfSubsidiaryCommonShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>roiv_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_roiv_RepaymentOfLongTermDebtAndConvertibleDebtBySubsidiary">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Repayment of Long Term Debt and Convertible Debt by Subsidiary</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">roiv_RepaymentOfLongTermDebtAndConvertibleDebtBySubsidiary</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>roiv_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_roiv_SubscriptionReceivableRelatedToIssuanceOfSubsidiaryCommonShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Subscription Receivable Related To Issuance Of Subsidiary Common Shares.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">roiv_SubscriptionReceivableRelatedToIssuanceOfSubsidiaryCommonShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>roiv_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3521-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3044-108585<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=123431023&amp;loc=SL98516268-108586<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; excluding effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 230<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=123444420&amp;loc=d3e33268-110906<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3521-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashDivestedFromDeconsolidation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Reduction in cash due to no longer including the former subsidiary's cash in the consolidated entity's cash.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3213-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashDivestedFromDeconsolidation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GainLossOnInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of realized and unrealized gain (loss) on investment.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 10<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123581744&amp;loc=d3e27405-111563<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.7(c),9(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br><br>Reference 3: http://www.xbrl.org/2003/role/recommendedDisclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GainLossOnInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GainLossOnSaleOfBusiness">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of gain (loss) from sale and disposal of integrated set of activities and assets capable of being conducted and managed for purpose of providing return in form of dividend, lower cost, or other economic benefit to investor, owner, member and participant.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=SL4582445-111684<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GainLossOnSaleOfBusiness</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromEquityMethodInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of income (loss) for proportionate share of equity method investee's income (loss).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(12))<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(10))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(13)(f))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (g)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=109237563&amp;loc=d3e33749-111570<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromEquityMethodInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxesPaidNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of cash paid during the current period to foreign, federal, state, and local authorities as taxes on income, net of any cash received during the current period as refunds for the overpayment of taxes.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123431023&amp;loc=d3e4297-108586<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxesPaidNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccountsPayableTrade">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Change in recurring obligations of a business that arise from the acquisition of merchandise, materials, supplies and services used in the production and sale of goods and services.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccountsPayableTrade</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccruedLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the aggregate amount of expenses incurred but not yet paid.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccruedLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInDeferredLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Change during the period in carrying value for all deferred liabilities due within one year or operating cycle.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInDeferredLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOperatingCapitalAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOtherOperatingCapitalNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in operating assets after deduction of operating liabilities classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOtherOperatingCapitalNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestPaidNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash paid for interest, excluding capitalized interest, classified as operating activity. Includes, but is not limited to, payment to settle zero-coupon bond for accreted interest of debt discount and debt instrument with insignificant coupon interest rate in relation to effective interest rate of borrowing attributable to accreted interest of debt discount.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123431023&amp;loc=d3e4297-108586<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 17<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3367-108585<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3536-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestPaidNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3521-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3521-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInInvestingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3536-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3521-108585<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NoncashInvestingAndFinancingItemsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NoncashInvestingAndFinancingItemsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after tax, before reclassification adjustments of gain (loss) on foreign currency translation adjustments, foreign currency transactions designated and effective as economic hedges of a net investment in a foreign entity and intra-entity foreign currency transactions that are of a long-term-investment nature.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 20<br> -Section 35<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=123602790&amp;loc=d3e30304-110892<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 10<br> -Section 45<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=120253306&amp;loc=d3e28129-110885<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 45<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=118261656&amp;loc=d3e32022-110900<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10A<br> -Subparagraph (a-c)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669646-108580<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=d3e637-108580<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherNoncashIncomeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of income (expense) included in net income that results in no cash inflow (outflow), classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherNoncashIncomeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsForRepurchaseOfEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow to reacquire common and preferred stock.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3291-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsForRepurchaseOfEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsOfStockIssuanceCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow for cost incurred directly with the issuance of an equity security.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3291-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsOfStockIssuanceCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow associated with the acquisition of a business, net of the cash acquired from the purchase.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3213-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquireMarketableSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash outflow for purchase of marketable security.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=124260329&amp;loc=d3e26853-111562<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquireMarketableSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3213-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquirePropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromDivestitureOfBusinesses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow associated with the amount received from the sale of a portion of the company's business, for example a segment, division, branch or other business, during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 12<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3179-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromDivestitureOfBusinesses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from the additional capital contribution to the entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow during the period from additional borrowings in aggregate debt. Includes proceeds from short-term and long-term debt.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow associated with the aggregate amount received by the entity through sale or maturity of marketable securities  (held-to-maturity or available-for-sale) during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow from exercise of option under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=SL79508275-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProfitLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The consolidated profit or loss for the period, net of income taxes, including the portion attributable to the noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669619-108580<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=SL4573702-111684<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123482062&amp;loc=SL123482106-238011<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 12: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124452729-227067<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8906-108599<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3000-108585<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 19<br> -URI http://asc.fasb.org/extlink&amp;oid=123454820&amp;loc=SL4569616-111683<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 235<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399901&amp;loc=d3e537907-122884<br><br>Reference 23: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8924-108599<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669625-108580<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 29: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (c)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=SL4573702-111684<br><br>Reference 31: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4J<br> -URI http://asc.fasb.org/extlink&amp;oid=120409616&amp;loc=SL4591551-111686<br><br>Reference 32: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4K<br> -URI http://asc.fasb.org/extlink&amp;oid=120409616&amp;loc=SL4591552-111686<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProfitLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentInProcess">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of purchased research and development assets that are acquired in a business combination have no alternative future use and are therefore written off in the period of acquisition.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentInProcess</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase in right-of-use asset obtained in exchange for operating lease liability.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 55<br> -Paragraph 53<br> -URI http://asc.fasb.org/extlink&amp;oid=123414884&amp;loc=SL77918982-209971<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=123408670&amp;loc=SL77918686-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of noncash expense for share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SupplementalCashFlowInformationAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SupplementalCashFlowInformationAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>78
<FILENAME>R8.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm139997750719176">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Description of Business and Liquidity<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2021</div></th>
<th class="th"><div>Mar. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract', window );"><strong>Organization, Consolidation and Presentation of Financial Statements [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock', window );">Description of Business and Liquidity</a></td>
<td class="text"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt; text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Note 1&#8212;Description of Business and Liquidity</div></div></div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">(A) Description of Business </div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Roivant Sciences Ltd. (inclusive of its consolidated subsidiaries, the &#8220;Company&#8221; or &#8220;RSL&#8221;), aims to improve health by rapidly delivering innovative medicines and technologies to patients. The Company does this by building biotech and healthcare technology companies (&#8220;Vants&#8221;) and deploying technology to drive greater efficiency in research and development and commercialization. In addition to biopharmaceutical subsidiaries, the Company also builds technology Vants focused on improving the process of developing and commercializing medicines. The Company was founded on April&#160;7, 2014 as a Bermuda exempted limited company. </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The Company has determined that it has one operating and reporting segment as it allocates resources and assesses financial performance on a consolidated basis. The Company&#8217;s subsidiaries are wholly owned subsidiaries and majority-owned or controlled subsidiaries. Refer to Note 3, &#8220;Investments&#8221; for further discussion of the Company&#8217;s investments in unconsolidated entities<div style="letter-spacing: 0px; top: 0px;;display:inline;">.</div></div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">(B) Liquidity </div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The Company has incurred significant losses and negative cash flows from operations since its inception. As of June&#160;30, 2021, the Company had cash and cash equivalents of approximately $2.0&#160;billion and its accumulated deficit was approximately $2.0&#160;billion. For the three months ended June&#160;30, 2021 and 2020, the Company incurred net losses of $101.1&#160;million and $8.0&#160;million, respectively. The Company has historically financed its operations primarily through the sale of equity securities, sale of subsidiary interests, debt financings and revenue generated from licensing and collaboration arrangements. The Company has not generated any revenues to date from the sale of its product candidates and does not anticipate generating any revenues from the sale of its product candidates unless and until it successfully completes development and obtains regulatory approval to market its product candidates. Management expects to incur additional losses in the future to fund its operations and conduct product research and development and recognizes the need to raise additional capital to fully implement its business plan. </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The Company intends to raise such additional capital through the issuance of equity securities, debt financings or other sources in order to further implement its business plan. However, if such financing is not available at adequate levels, the Company will need to reevaluate its operating plan and may be required to delay the development of its product candidates or take other steps to conserve capital. The Company expects its existing cash and cash equivalents will be sufficient to fund its committed operating expenses and capital expenditure requirements for at least the next 12 months from the date of issuance of these condensed consolidated financial statements. </div></div><span></span>
</td>
<td class="text"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Note 1&#8212;Description of Business and Liquidity </div></div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">(A) Description of Business </div></div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Roivant Sciences Ltd., inclusive of its consolidated subsidiaries (the &#8220;Company&#8221; or &#8220;RSL&#8221;), aims to improve health by rapidly delivering innovative medicines and technologies to patients. The Company does this by building biotech and healthcare technology companies (&#8220;Vants&#8221;) and deploying technology to drive greater efficiency in research and development and commercialization.&#160;In addition to biopharmaceutical subsidiaries, the Company also builds technology Vants focused on improving the process of developing and commercializing medicines. The Company was founded on April&#160;7, 2014 as a Bermuda exempted limited company. </div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The Company has determined that it has one operating and reporting segment as it allocates resources and assesses financial performance on a consolidated basis. The Company&#8217;s subsidiaries are wholly owned subsidiaries and majority-owned or controlled subsidiaries. Refer to Note 3, &#8220;Investments&#8221; for further discussion of the Company&#8217;s investments in unconsolidated entities. </div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">(B) Liquidity </div></div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The Company has incurred significant losses and negative cash flows from operations since its inception. As of March&#160;31, 2021, the Company had cash and cash equivalents of approximately $2.1&#160;billion and its accumulated deficit was approximately $1.9&#160;billion. For the years ended March&#160;31, 2021 and 2020, the Company incurred losses from continuing operations of $900.2&#160;million and $568.1&#160;million, respectively. The Company has historically financed its operations primarily through the sale of equity securities, sale of subsidiary interests, debt financings and revenue generated from licensing and collaboration arrangements. The Company has not generated any revenues to date from the sale of its product candidates and does not anticipate generating any revenues from the sale of its product candidates unless and until it successfully completes development and obtains regulatory approval to market its product candidates. Management expects to incur additional losses in the future to fund its operations and conduct product research and development and recognizes the need to raise additional capital to fully implement its business plan. </div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The Company intends to raise such additional capital through the issuance of equity securities, debt financings or other sources in order to further implement its business plan. However, if such financing is not available at adequate levels, the Company will need to reevaluate its operating plan and may be required to delay the development of its product candidates or take other steps to conserve capital. The Company expects its existing cash and cash equivalents will be sufficient to fund its committed operating expenses and capital expenditure requirements for at least the next 12 months from the date of issuance of these consolidated financial statements. </div></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for the business description and basis of presentation concepts.  Business description describes the nature and type of organization including but not limited to organizational structure as may be applicable to holding companies, parent and subsidiary relationships, business divisions, business units, business segments, affiliates and information about significant ownership of the reporting entity.  Basis of presentation describes the underlying basis used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -URI http://asc.fasb.org/topic&amp;trid=2122369<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -URI http://asc.fasb.org/topic&amp;trid=2122149<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -URI http://asc.fasb.org/topic&amp;trid=2134479<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>79
<FILENAME>R9.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm139997751068696">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2021</div></th>
<th class="th"><div>Mar. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SignificantAccountingPoliciesTextBlock', window );">Summary of Significant Accounting Policies</a></td>
<td class="text"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Note 2&#8212;Summary of Significant Accounting Policies </div></div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">(A) Basis of Presentation and Principles of Consolidation </div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The Company&#8217;s fiscal year ends on March&#160;31, and its fiscal quarters end on June&#160;30, September&#160;30, and December 31. </div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The accompanying unaudited condensed consolidated financial statements have been prepared in accordance with accounting principles generally accepted in the United States (&#8220;U.S. GAAP&#8221;) for interim financial information and follow the requirements of the Securities and Exchange Commission (&#8220;SEC&#8221;) for interim financial reporting. Accordingly, these unaudited condensed consolidated financial statements do not include all of the information and </div></div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"> </div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">disclosures required by U.S. GAAP for complete financial statements as certain footnotes or other financial information that are normally required by U.S. GAAP can be condensed or omitted. The unaudited condensed consolidated financial statements have been prepared on the same basis as the audited consolidated financial statements. </div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">These unaudited condensed consolidated financial statements should be read in conjunction with the Company&#8217;s audited consolidated financial statements and notes thereto for the fiscal year ended March&#160;31, 2021 issued on June&#160;30, 2021. The unaudited condensed consolidated balance sheet at March&#160;31, 2021 has been derived from the audited consolidated financial statements at that date. In the opinion of management, the unaudited condensed consolidated financial statements include all normal and recurring adjustments that are considered necessary to present fairly the financial position of the Company and its results of operations and cash flows for the interim periods presented. Certain prior year amounts were reclassified to conform to current year presentation. Operating results for the three months ended June&#160;30, 2021 are not necessarily indicative of the results that may be expected for the fiscal year ending March&#160;31, 2022, for any other interim period, or for any other future year. </div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Any references in these notes to applicable accounting guidance are meant to refer to the authoritative U.S. GAAP as found in the Accounting Standards Codification (&#8220;ASC&#8221;) and Accounting Standards Updates (&#8220;ASU&#8221;) of the Financial Accounting Standards Board (&#8220;FASB&#8221;). The unaudited condensed consolidated financial statements include the accounts of RSL and the subsidiaries in which it has a controlling financial interest, most often through a majority voting interest. All intercompany balances and transactions have been eliminated in consolidation. </div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">For consolidated entities where the Company owns or is exposed to less than 100% of the economics, the Company records net loss attributable to noncontrolling interests in its unaudited condensed consolidated statements of operations equal to the percentage of the economic or ownership interest retained in the respective operations by the noncontrolling parties. The Company presents noncontrolling interests as a component of shareholders&#8217; equity on its unaudited condensed consolidated balance sheets. </div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The Company accounts for changes in its ownership interest in its subsidiaries while control is retained as equity transactions. The carrying amount of the noncontrolling interest is adjusted to reflect the change in RSL&#8217;s ownership interest in the subsidiary. Any difference between the fair value of the consideration received or paid and the amount by which the noncontrolling interest is adjusted is recognized within shareholders&#8217; equity attributable to RSL. </div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">There have been no significant changes in the Company&#8217;s accounting policies from those disclosed in the Company&#8217;s audited consolidated financial statements for the fiscal year ended March&#160;31, 2021 issued on June&#160;30, 2021. </div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">In April 2012, the Jumpstart Our Business Startups Act of 2012 (the &#8220;JOBS Act&#8221;) was enacted. Section&#160;107(b) of the JOBS Act provides that an emerging growth company can take advantage of an extended transition period for complying with new or revised accounting standards. Thus, an emerging growth company can delay the adoption of certain accounting standards until those standards would otherwise apply to private companies. The Company has irrevocably elected not to avail itself of this extended transition period, and, as a result, the Company will adopt new or revised accounting standards on the relevant dates on which adoption of such standards is required for other public companies. </div></div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"> </div>  <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt; text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">(B) Use of Estimates </div></div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The preparation of financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the amounts reported in the financial statements and accompanying notes. The Company regularly evaluates estimates and assumptions related to assets, liabilities, costs, expenses,</div></div></div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>  <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">contingent liabilities, share-based compensation and research and development costs. The Company bases its estimates and assumptions on historical experience and on various other factors that it believes to be reasonable under the circumstances, the results of which form the basis for making judgments about the carrying values of assets and liabilities that are not readily apparent from other sources. Actual results could differ from those estimates. </div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">Additionally, the Company assessed the impact that the <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">COVID-19</div> pandemic has had on its operations and financial results as of June&#160;30, 2021 and through the issuance of these condensed consolidated financial statements. The Company&#8217;s analysis was informed by the facts and circumstances as they were known to the Company. This assessment considered the impact <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">COVID-19</div> may have on financial estimates and assumptions that affect the reported amounts of assets and liabilities and expenses. </div></div>  <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt; text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">(C) Risks and Uncertainties </div></div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The Company is subject to risks common to companies in the biopharmaceutical industry including, but not limited to, uncertainties related to commercialization of products, regulatory approvals, dependence on key products, dependence on third-party service providers, such as contract research organizations, and protection of intellectual property rights. </div></div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"> </div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt; text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">(D) Concentrations of Credit Risk </div></div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Financial instruments that potentially subject the Company to concentration of credit risk include cash and cash equivalents. The Company maintains cash deposits and cash equivalents in highly-rated, federally-insured financial institutions in excess of federally insured limits. The Company has established guidelines relative to diversification and maturities to maintain safety and liquidity. The Company has not experienced any credit losses related to these financial instruments and does not believe that it is exposed to any significant credit risk related to these instruments. </div></div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"> </div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">(E) Cash, Cash Equivalents, and Restricted Cash </div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Cash and cash equivalents include cash deposits in banks and all highly liquid investments that are readily convertible to cash. The Company considers all highly liquid investments purchased with original maturities of three months or less to be cash equivalents. </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">Restricted cash classified as a current asset consists of legally restricted <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-interest</div> bearing deposit accounts relating to the Company&#8217;s corporate credit card programs. Restricted cash classified as a long-term asset consists of restricted deposit accounts related to irrevocable standby letters of credit. As of March&#160;31, 2021, restricted cash classified as a current asset included $75.0&#160;million held in escrow for the purpose of fulfilling certain indemnification obligations. The full escrow amount of $75.0&#160;million was disbursed to the Company in June 2021. See Note 4, &#8220;Sumitomo Transaction Agreement&#8221; for additional information. </div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Cash as reported in the condensed consolidated statements of cash flows includes the aggregate amounts of cash, cash equivalents, and restricted cash as presented on the condensed consolidated balance sheets as follows (in thousands): </div></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;width:76%;">
<tr style="font-size: 0px;">
<td style="width: 64%;"/>
<td style="width: 7%; vertical-align: bottom;"/>
<td/>
<td/>
<td/>
<td style="width: 7%; vertical-align: bottom;"/>
<td/>
<td/>
<td/> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">June&#160;30,&#160;2021</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">March&#160;31,&#160;2021</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top; width: 64%;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Cash and cash equivalents</div></div> </td>
<td style="vertical-align: bottom; width: 7%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">1,996,733</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 7%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">2,055,044</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; width: 64%;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Restricted cash</div></div> </td>
<td style="vertical-align: bottom; width: 7%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">11,644</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 7%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">86,632</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 64%;">&#160;</td>
<td style="vertical-align: bottom; width: 7%;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom; width: 7%;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top; width: 64%;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Cash, cash equivalents and restricted cash</div></div> </td>
<td style="vertical-align: bottom; width: 7%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">2,008,377</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 7%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">2,141,676</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 64%;">&#160;</td>
<td style="vertical-align: bottom; width: 7%;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom; width: 7%;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td> </tr> </table>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 76%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px; text-indent: 0px;">
<tr style="font-size: 1px;">
<td/> </tr> </table> <div style="clear: both; max-height: 0px; text-indent: 0px;"/> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div>  <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">(F) Contingencies </div></div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The Company may be, from time to time, a party to various disputes and claims arising from normal business activities. The Company continually assesses any litigation or other claims it may confront to determine if an unfavorable outcome would lead to a probable loss or reasonably possible loss which could be estimated. The Company accrues for all contingencies at the earliest date at which the Company deems it probable that a liability has been incurred and the amount of such liability can be reasonably estimated. If the estimate of a probable loss is a range and no amount within the range is more likely than another, the Company accrues the minimum of the range. In the cases where the Company believes that a reasonably possible loss exists, the Company discloses the facts and circumstances of the litigation, including an estimable range, if possible<div style="letter-spacing: 0px; top: 0px;;display:inline;">.</div></div></div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt; text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">(G) Investments </div></div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">For investments in entities over which the Company has significant influence but do not meet the requirements for consolidation and for which the Company has not elected the fair value option, the Company applies the equity method of accounting with the Company&#8217;s share of the underlying income or loss of such entities reported in &#8220;Other (income) expense, net&#8221; on the condensed consolidated statements of operations. The Company applies the equity method to investments in common stock and to other investments in entities that have risk and reward characteristics that are substantially similar to an investment in the investee&#8217;s common stock. </div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Investments in equity securities may also be accounted for using (i)&#160;the fair value option if elected, (ii)&#160;fair value through earnings if fair value is readily determinable or (iii)&#160;for equity investments without readily determinable fair values, the measurement alternative to measure at cost adjusted for any impairment and observable price changes, as applicable. The election to use the measurement alternative is made for each eligible investment. </div></div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"> </div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The Company has elected the fair value option to account for certain investments over which the Company has significant influence. The Company believes the fair value option best reflects the underlying economics of the investment. See Note 3, &#8220;Investments.&#8221; </div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">(H) Research and Development<div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div>Expenses </div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">Research and development (&#8220;R&amp;D&#8221;) costs are expensed as incurred. Preclinical and clinical study costs are accrued over the service periods specified in the contracts and adjusted as necessary based upon an ongoing <div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">review </div>of the <div style="letter-spacing: 0px; top: 0px;;display:inline;">level </div>of <div style="letter-spacing: 0px; top: 0px;;display:inline;">effort </div>and costs</div> actually incurred. Payments for a product license prior to regulatory approval of the product and payments for milestones achieved prior to regulatory approval of the product are expensed in the period incurred as R&amp;D. Milestone payments made in connection <div style="letter-spacing: 0px; top: 0px;;display:inline;">with </div><div style="letter-spacing: 0px; top: 0px;;display:inline;">regulatory </div>approvals are capitalized and amortized to cost of revenue over the remaining useful life of the asset. R&amp;D costs primarily consist of the intellectual property and R&amp;D materials acquired and expenses from third parties who conduct R&amp;D activities on behalf of the <div style="letter-spacing: 0px; top: 0px;;display:inline;">Company</div>.</div> </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">The Company evaluates <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">in-licensed</div> agreements for <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">in-process</div> research and development projects (&#8220;IPR&amp;D&#8221;) to determine if it meets the definition of a business and thus should be accounted for as a business combination. If the <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">in-licensed</div> agreement for IPR&amp;D does not meet the definition of a business and the assets have not reached technological feasibility and therefore have no alternative future use, the Company expenses payments made under such license agreements as R&amp;D expense in its condensed consolidated statements of operations. The Company initially recognizes contingent consideration in an asset acquisition at fair value. The carrying value of contingent consideration is subsequently adjusted when the contingency is resolved and is paid or becomes payable. </div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">(I) Fair Value Measurements </div></div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The Company utilizes fair value measurement guidance prescribed by accounting standards to value its financial instruments. The guidance establishes a fair value hierarchy for financial instruments measured at fair value that distinguishes between assumptions based on market data (observable inputs) and the Company&#8217;s own assumptions (unobservable inputs). Observable inputs are inputs that market participants would use in pricing the asset or liability based on market data obtained from sources independent of the Company. Unobservable inputs are inputs that reflect the Company&#8217;s assumptions about the inputs that market participants would use in pricing the asset or liability, and are developed based on the best information available in the circumstances. Fair value is defined as the exchange price, or exit price, representing the amount that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants at the reporting date. As a basis for considering market participant assumptions in fair value measurements, the guidance establishes a three-tier fair value hierarchy that distinguishes among the following: </div></div></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px; text-indent: 0px;;width:100%;">
<tr style="page-break-inside: avoid;">
<td style="width: 4%;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="width: 4%; vertical-align: top;;text-align:left;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#8226;</div></td>
<td style="width: 1%; vertical-align: top;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">Level <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">1-Valuations</div> are based on unadjusted quoted prices in active markets for identical assets or liabilities that the Company has the ability to access. </div></div> </td> </tr> </table> <div style="clear: both; max-height: 0px; text-indent: 0px;"/> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px; text-indent: 0px;;width:100%;">
<tr style="page-break-inside: avoid;">
<td style="width: 4%;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="width: 4%; vertical-align: top;;text-align:left;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#8226;</div></td>
<td style="width: 1%; vertical-align: top;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">Level <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">2-Valuations</div> are based on quoted prices for similar assets or liabilities in active markets, quoted prices for identical or similar assets or liabilities in markets that are not active and models for which all significant inputs are observable, either directly or indirectly. </div></div> </td> </tr> </table> <div style="clear: both; max-height: 0px; text-indent: 0px;"/> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px; text-indent: 0px;;width:100%;">
<tr style="page-break-inside: avoid;">
<td style="width: 4%;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="width: 4%; vertical-align: top;;text-align:left;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#8226;</div></td>
<td style="width: 1%; vertical-align: top;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">Level <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">3-Valuations</div> are based on inputs that are unobservable (supported by little or no market activity) and significant to the overall fair value measurement. </div></div> </td> </tr> </table> <div style="clear: both; max-height: 0px; text-indent: 0px;"/> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">To the extent the valuation is based on models or inputs that are less observable or unobservable in the market, the determination of fair value requires more judgment. Accordingly, the degree of judgment exercised by the Company in determining fair value is greatest for instruments categorized in Level&#160;3. A financial instrument&#8217;s level within the fair value hierarchy is based on the lowest level of any input that is significant to the fair value measurement. </div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The Company&#8217;s financial instruments include shares of common stock of Arbutus Biopharma Corporation (&#8220;Arbutus&#8221;); shares of Arbutus&#8217;s Series A participating convertible preferred shares (&#8220;Arbutus Preferred Shares&#8221;); shares of common stock of Sio Gene Therapies Inc. (&#8220;Sio&#8221;); liability instruments issued; deferred consideration liability; its investments in other entities; cash and cash equivalents consisting of money market funds; accounts payable; and long-term debt. </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">The shares of Arbutus and Sio common stock and investments in common stock with a readily determinable fair value are classified as Level&#160;1, and their fair value is determined based upon quoted market prices in an active market. The Arbutus Preferred Shares held by the Company are classified as Level&#160;2 as the fair value of such preferred shares is determined based upon the quoted market price of Arbutus common stock into which such preferred shares are convertible. The liability instruments issued are classified as Level&#160;3 within the fair value hierarchy as the assumptions and estimates used in the valuations are unobservable in the market. Cash, accounts payable, and deferred consideration liability are stated at their respective historical carrying amounts, which approximate fair value due to their short-term nature. The deferred consideration liability is based on a fixed monetary amount, and payment is based solely on the passage of time. Money market funds are included in <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">Level-1</div> of the fair value hierarchy and are valued at the closing price reported by an actively traded exchange. The carrying value of long-term debt issued by Dermavant Sciences Ltd. (together with its wholly owned subsidiaries, &#8220;Dermavant&#8221;), which is stated at amortized cost, approximates fair value based on current interest rates for similar types of borrowings and therefore is included in Level&#160;2 of the fair value hierarchy. Long-term debt issued by Dermavant for which the fair value option has been elected is included in Level&#160;3 of the fair value hierarchy as the assumptions and estimates used in the valuation are unobservable in the market. </div></div>  <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">(J) Recently Adopted Accounting Pronouncements </div></div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;">In August 2020, the FASB issued ASU <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">No.&#160;2020-06,</div> &#8220;Debt&#8212;Debt with Conversion and Other Options (Subtopic <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">470-20)</div> and Derivatives and Hedging&#8212;Contracts in Entity&#8217;s Own Equity (Subtopic <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">815-40):</div> Accounting for Convertible Instruments and Contracts in an Entity&#8217;s Own Equity&#8221; (&#8220;ASU <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">No.&#160;2020-06&#8221;).</div> ASU <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">No.&#160;2020-06</div> will simplify the accounting for convertible instruments by reducing the number of accounting models for convertible debt instruments and convertible preferred stock. Limiting the accounting models will result in fewer embedded conversion features being separately recognized from the host contract as compared with current U.S. GAAP. ASU <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">No.&#160;2020-06</div> also removes certain settlement conditions that are required for equity contracts to qualify for the derivatives scope exception, which will permit more equity contracts to qualify for it. Either a modified retrospective transition method or a fully retrospective transition method is permissible for the adoption of this standard. Update <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">No.&#160;2020-06</div> is effective for fiscal years beginning after December&#160;15, 2021, including interim periods within those fiscal years. The early-adoption of ASU <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">No.&#160;2020-06</div> on April&#160;1, 2021 did not have a material impact on the Company&#8217;s unaudited condensed consolidated financial statements. </div><span></span>
</td>
<td class="text"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Note 2&#8212;Summary of Significant Accounting Policies </div></div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">(A) Basis of Presentation and Principles of Consolidation </div></div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The Company&#8217;s fiscal year ends on March&#160;31, and its fiscal quarters end on June&#160;30, September&#160;30, and December 31. </div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The accompanying audited consolidated financial statements and notes thereto have been prepared in accordance with accounting principles generally accepted in the United States (&#8220;U.S. GAAP&#8221;). </div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Any references in these notes to applicable accounting guidance are meant to refer to the authoritative U.S. GAAP as found in the Accounting Standards Codification (&#8220;ASC&#8221;) and Accounting Standards Updates </div></div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">(&#8220;ASU&#8221;) of the Financial Accounting Standards Board (&#8220;FASB&#8221;). The consolidated financial statements include the accounts of RSL and the subsidiaries in which it has a controlling financial interest, most often through a majority voting interest. All intercompany balances and transactions have been eliminated in consolidation. </div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">For consolidated entities where the Company owns or is exposed to less than 100% of the economics, the Company records net loss attributable to noncontrolling interests in its consolidated statements of operations equal to the percentage of the economic or ownership interest retained in the respective operations by the noncontrolling parties. The Company presents noncontrolling interests as a component of shareholders&#8217; equity on its consolidated balance sheets. </div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The Company accounts for changes in its ownership interest in its subsidiaries while control is retained as equity transactions. The carrying amount of the noncontrolling interest is adjusted to reflect the change in RSL&#8217;s ownership interest in the subsidiary. Any difference between the fair value of the consideration received or paid and the amount by which the noncontrolling interest is adjusted is recognized within shareholders&#8217; equity attributable to RSL. </div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Additionally, the Company concluded that the disposition of RSL&#8217;s ownership interests in Myovant Sciences Ltd. (&#8220;Myovant&#8221;), Urovant Sciences Ltd. (&#8220;Urovant&#8221;), Enzyvant Therapeutics Ltd. (&#8220;Enzyvant&#8221;), Altavant Sciences Ltd. (&#8220;Altavant&#8221;), and Spirovant Sciences Ltd. (&#8220;Spirovant&#8221;) (collectively, the &#8220;Sumitovant Vants&#8221;), pursuant to the transaction agreement entered into with Sumitomo Dainippon Pharma Co., Ltd. (&#8220;Sumitomo&#8221;) on October&#160;31, 2019 (the &#8220;Sumitomo Transaction Agreement&#8221;) that closed on December&#160;27, 2019 (the &#8220;Sumitomo Transaction&#8221;), met the requirements to be presented as discontinued operations. As such, results relating to the transferred interests prior to disposition are classified as discontinued operations in prior period consolidated financial statements. See Note 5, &#8220;Sumitomo Transaction Agreement&#8221; and Note 6, &#8220;Discontinued Operations&#8221; for further discussion. Certain prior year amounts were reclassified to conform to current year presentation. </div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">In April 2012, the Jumpstart Our Business Startups Act of 2012 (the &#8220;JOBS Act&#8221;) was enacted. Section&#160;107(b) of the JOBS Act provides that an emerging growth company can take advantage of an extended transition period for complying with new or revised accounting standards. Thus, an emerging growth company can delay the adoption of certain accounting standards until those standards would otherwise apply to private companies. The Company has irrevocably elected not to avail itself of this extended transition period, and, as a result, the Company will adopt new or revised accounting standards on the relevant dates on which adoption of such standards is required for other public companies. </div></div>  <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">(B) Use of Estimates </div></div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The preparation of financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the amounts reported in the financial statements and accompanying notes. The Company regularly evaluates estimates and assumptions related to assets, liabilities, costs, expenses, contingent liabilities, share-based compensation and research and development costs. The Company bases its estimates and assumptions on historical experience and on various other factors that it believes to be reasonable under the circumstances, the results of which form the basis for making judgments about the carrying values of assets and liabilities that are not readily apparent from other sources. Actual results could differ from those estimates. </div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">Additionally, the Company assessed the impact that the <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">COVID-19</div> pandemic has had on its operations and financial results as of March&#160;31, 2021 and through the issuance of these consolidated financial statements. The Company&#8217;s analysis was informed by the facts and circumstances as they were known to the Company. This assessment considered the impact <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">COVID-19</div> may have on financial estimates and assumptions that affect the reported amounts of assets and liabilities and expenses. </div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">(C) Risks and Uncertainties </div></div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The Company is subject to risks common to companies in the biopharmaceutical industry including, but not limited to, uncertainties related to commercialization of products, regulatory approvals, dependence on key products, dependence on third-party service providers, such as contract research organizations, and protection of intellectual property rights. </div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">(D) Concentrations of Credit Risk </div></div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Financial instruments that potentially subject the Company to concentration of credit risk include cash and cash equivalents. The Company maintains cash deposits and cash equivalents in highly-rated, federally-insured financial institutions in excess of federally insured limits. The Company has established guidelines relative to diversification and maturities to maintain safety and liquidity. The Company has not experienced any credit losses related to these financial instruments and does not believe that it is exposed to any significant credit risk related to these instruments. </div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">(E) Cash, Cash Equivalents, and Restricted Cash </div></div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Cash and cash equivalents include cash deposits in banks and all highly liquid investments that are readily convertible to cash. The Company considers all highly liquid investments purchased with original maturities of three months or less to be cash equivalents. </div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">Restricted cash classified as a current asset consists of the amount held in escrow relating to the Sumitomo Transaction (see Note 5, &#8220;Sumitomo Transaction Agreement&#8221;) and the legally restricted <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-interest</div> bearing deposit account relating to the Company&#8217;s corporate credit card program. Restricted cash classified as a long-term asset consists of restricted deposit accounts related to irrevocable standby letters of credit. </div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Cash as reported in the accompanying consolidated statements of cash flows includes the aggregate amounts of cash, cash equivalents, and restricted cash as presented on the accompanying consolidated balance sheets as follows (in thousands): </div></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 76%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="font-size: 0px;">
<td style="width: 62%;"/>
<td style="width: 8%; vertical-align: bottom;"/>
<td/>
<td/>
<td/>
<td style="width: 8%; vertical-align: bottom;"/>
<td/>
<td/>
<td/> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">March&#160;31,&#160;2021</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">March&#160;31,&#160;2020</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Cash and cash equivalents</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">2,055,044</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">2,183,207</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Restricted cash</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">86,632</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">86,045</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;">&#160;</td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Cash, cash equivalents and restricted cash</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">2,141,676</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">2,269,252</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;">&#160;</td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td> </tr> </table>  <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">(F) Trade Receivables, Net </div></div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The Company monitors the financial performance and creditworthiness of its customers so that it can properly assess and respond to changes in customer credit profiles. The Company reserves against trade receivables for estimated losses that may arise from a customer&#8217;s inability to pay and any amounts determined to be uncollectible are written off against the reserve when it is probable that the receivable will not be collected. The reserve amount for estimated losses was de minimis as of March&#160;31, 2021 and 2020. Trade receivables, net is included in &#8220;Other current assets&#8221; on the accompanying consolidated balance sheets. </div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">(G) Contingencies </div></div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The Company may be, from time to time, a party to various disputes and claims arising from normal business activities. The Company continually assesses any litigation or other claims it may confront to determine if an unfavorable outcome would lead to a probable loss or reasonably possible loss which could be estimated. The Company accrues for all contingencies at the earliest date at which the Company deems it probable that a liability has been incurred and the amount of such liability can be reasonably estimated. If the estimate of a probable loss </div></div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">is a range and no amount within the range is more likely than another, the Company accrues the minimum of the range. In the cases where the Company believes that a reasonably possible loss exists, the Company discloses the facts and circumstances of the litigation, including an estimable range, if possible. </div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">(H) Property and Equipment </div></div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Property and equipment, consisting primarily of computers, equipment, furniture and fixtures, software, and leasehold improvements, is recorded at cost, less accumulated depreciation. Maintenance and repairs that do not improve or extend the lives of the respective assets are expensed to operations as incurred. Upon disposal, retirement or sale, the related cost and accumulated depreciation is removed from the accounts and any resulting gain or loss is included in the results of operations. Depreciation of property and equipment is recorded using the straight-line method over the estimated useful lives of the related assets once the asset has been placed in service. Leasehold improvements are amortized using the straight-line method over the estimated useful life or remaining lease term, whichever is shorter. The following table provides the range of estimated useful lives used for each asset type: </div></div>  <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="font-size: 0px;">
<td style="width: 33%; font-family: &quot;Times New Roman&quot;;"/>
<td style="width: 1%; vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/>
<td style="width: 66%; font-family: &quot;Times New Roman&quot;;"/> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; white-space: nowrap;"> <div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt; border-bottom: 1pt solid rgb(0, 0, 0); display: table-cell; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">Property and Equipment</div></div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;"> <div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt; border-bottom: 1pt solid rgb(0, 0, 0); display: table-cell; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">Estimated Useful Life</div></div></div> </td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Computers</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">3  years</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Equipment</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">5  years</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Furniture and fixtures</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">7  years</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Software</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">3  years</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Leasehold improvements</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">Lesser of estimated useful life or remaining lease term</td> </tr> </table>  <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The Company reviews the recoverability of all long-lived assets, including the related useful lives, whenever events or changes in circumstances indicate that the carrying amount of a long-lived asset might not be recoverable. Recoverability is measured by comparison of the book values of the assets to the future net undiscounted cash flows that the assets are expected to generate. If such assets are considered to be impaired, the impairment to be recognized is measured by the amount by which the book value of the assets exceed their fair value, which is measured based on the projected discounted future net cash flows arising from the assets. </div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">(I) Investments </div></div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">For investments in entities over which the Company has significant influence but do not meet the requirements for consolidation and for which the Company has not elected the fair value option, the Company applies the equity method of accounting with the Company&#8217;s share of the underlying income or loss of such entities reported in &#8220;Other expense, net&#8221; on the consolidated statements of operations. The Company applies the equity method to investments in common stock and to other investments in entities that have risk and reward characteristics that are substantially similar to an investment in the investee&#8217;s common stock. </div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Investments in equity securities may also be accounted for using (i)&#160;the fair value option if elected, (ii)&#160;fair value through earnings if fair value is readily determinable or (iii)&#160;for equity investments without readily determinable fair values, the measurement alternative to measure at cost adjusted for any impairment and observable price changes, as applicable. The election to use the measurement alternative is made for each eligible investment. </div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The Company has elected the fair value option to account for certain investments over which the Company has significant influence. The Company believes the fair value option best reflects the underlying economics of the investment. See Note 3, &#8220;Investments.&#8221; </div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">(J) Research and Development Expenses </div></div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Research and development (&#8220;R&amp;D&#8221;) costs are expensed as incurred. Preclinical and clinical study costs are accrued over the service periods specified in the contracts and adjusted as necessary based upon an ongoing </div></div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">review of the level of effort and costs actually incurred. Payments for a product license prior to regulatory approval of the product and payments for milestones achieved prior to regulatory approval of the product are expensed in the period incurred as R&amp;D. Milestone payments made in connection with regulatory approvals are capitalized and amortized to cost of revenue over the remaining useful life of the asset. R&amp;D costs primarily consist of the intellectual property and R&amp;D materials acquired and expenses from third parties who conduct R&amp;D activities on behalf of the Company. </div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">The Company evaluates <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">in-licensed</div> agreements for <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">in-process</div> research and development projects (&#8220;IPR&amp;D&#8221;) to determine if it meets the definition of a business and thus should be accounted for as a business combination. If the <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">in-licensed</div> agreement for IPR&amp;D does not meet the definition of a business and the assets have not reached technological feasibility and therefore have no alternative future use, the Company expenses payments made under such license agreements as R&amp;D expense in its consolidated statements of operations. The Company initially recognizes contingent consideration in an asset acquisition at fair value. The carrying value of contingent consideration is subsequently adjusted when the contingency is resolved and is paid or becomes payable. </div>  <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">(K) General and Administrative Expenses </div></div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;">General and administrative (&#8220;G&amp;A&#8221;) expenses consist primarily of employee-related expenses for G&amp;A personnel, including those responsible for the identification and acquisition or <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">in-license</div> of new drug candidates as well as for overseeing Vant operations and facilitating the use of the Company&#8217;s platform and technologies at Vants. G&amp;A expenses also consist of legal and accounting fees, consulting services and other operating costs relating to corporate matters and daily operations. G&amp;A expenses include costs incurred relating to the identification, acquisition or <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">in-license</div> and technology transfer of promising drug candidates along with costs incurred relating to the integration of new technologies. </div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">(L) Income Taxes </div></div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Deferred tax assets and liabilities are recognized for the future tax consequences attributable to differences between the financial statement carrying amounts of existing assets and liabilities and the respective tax bases. Deferred tax assets and liabilities are measured using enacted tax rates expected to apply to taxable income in the years in which those temporary differences are expected to be recovered or settled. The effect on deferred tax assets and liabilities of a change in tax rates is recognized in income in the period that includes the enactment date. A valuation allowance is recorded when, after consideration of all positive and negative evidence, it is not more likely than not that the Company&#8217;s deferred tax assets will be realizable. If the Company determines that it would be able to realize its deferred tax assets in the future in excess of its net recorded amount, the Company would make an adjustment to the deferred tax asset valuation allowance, which would reduce the provision for income taxes. </div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">When uncertain tax positions exist, the Company recognizes the tax benefit of tax positions to the extent that the benefit will more likely than not be realized. The determination as to whether the tax benefit will more likely than not be realized is based upon the technical merits of the tax position as well as consideration of the available facts and circumstances. </div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">(M) Share-Based Compensation </div></div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Share-based awards to employees, directors, and consultants, including stock options, restricted stock units, performance options and capped value appreciation rights, are measured at fair value on the date of the grant and that fair value is recognized as share-based compensation expense in the Company&#8217;s consolidated statements of operations over the requisite service period of the respective award. The estimated fair value of awards that contain performance conditions is expensed when the Company concludes that it is probable that the performance condition will be achieved. The Company may grant awards with graded-vesting features. When such awards have only service vesting requirements, the Company elected to record share-based compensation </div></div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">expense on a straight-line basis. If awards with graded-vesting features contain performance or market conditions, then the Company records share-based compensation expense using the accelerated attribution method. </div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The Company measures the fair value of its stock options that only have service vesting requirements or performance-based options without market conditions using the Black-Scholes option pricing model. For performance-based awards with market conditions, the Company determines the fair value of the awards as of the grant date using a Monte Carlo simulation model. </div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">Certain assumptions need to be made with respect to utilizing the Black-Scholes option pricing model, including the expected life of the award, volatility of the underlying shares, the risk-free interest rate and the fair value of the Company&#8217;s common shares. Since the Company has no option exercise history, it has generally elected to estimate the expected life of an award based upon the &#8220;simplified method&#8221; with the continued use of this method extended until such time the Company has sufficient exercise history. The risk-free interest rate is based on the rates paid on securities issued by the U.S. Treasury with a term approximating the expected life of the equity award. The expected share price volatility for the Company&#8217;s common shares is estimated by taking the average historical price volatility for industry peers. The Company accounts for <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">pre-vesting</div> award forfeitures when they occur. </div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">As part of the valuation of share-based compensation under the Black-Scholes option pricing model, it is necessary for the Company to estimate the fair value of its common shares for RSL and privately held Vants. Given the absence of a public trading market, and in accordance with the American Institute of Certified Public Accountants&#8217; Practice Guide, Valuation of Privately-Held-Company Equity Securities Issued as Compensation, the Company exercises reasonable judgment and considers numerous objective and subjective factors to determine its best estimate of the fair value of its common shares. The estimation of the fair value of the common shares considers factors including the following: the prices of the Company&#8217;s common shares sold to investors in arm&#8217;s length transactions, the estimated present value of the Company&#8217;s future cash flows; the Company&#8217;s business, financial condition and results of operations; the Company&#8217;s forecasted operating performance; the illiquid nature of the Company&#8217;s common shares; industry information such as market size and growth; market capitalization of comparable companies and the estimated value of transactions such companies have engaged in; and macroeconomic conditions. </div></div>  <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">(N) Fair Value Measurements </div></div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The Company utilizes fair value measurement guidance prescribed by accounting standards to value its financial instruments. The guidance establishes a fair value hierarchy for financial instruments measured at fair value that distinguishes between assumptions based on market data (observable inputs) and the Company&#8217;s own assumptions (unobservable inputs). Observable inputs are inputs that market participants would use in pricing the asset or liability based on market data obtained from sources independent of the Company. Unobservable inputs are inputs that reflect the Company&#8217;s assumptions about the inputs that market participants would use in pricing the asset or liability, and are developed based on the best information available in the circumstances. Fair value is defined as the exchange price, or exit price, representing the amount that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants at the reporting date. As a basis for considering market participant assumptions in fair value measurements, the guidance establishes a three-tier fair value hierarchy that distinguishes among the following: </div></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;">Level <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">1-Valuations</div> are based on unadjusted quoted prices in active markets for identical assets or liabilities that the Company has the ability to access. </div> </td> </tr> </table> <div style="clear: both; max-height: 0px;"/> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;">Level <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">2-Valuations</div> are based on quoted prices for similar assets or liabilities in active markets, quoted prices for identical or similar assets or liabilities in markets that are not active and models for which all significant inputs are observable, either directly or indirectly. </div> </td> </tr> </table> <div style="clear: both; max-height: 0px;"/> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;">Level <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">3-Valuations</div> are based on inputs that are unobservable (supported by little or no market activity) and significant to the overall fair value measurement. </div> </td> </tr> </table> <div style="clear: both; max-height: 0px;"/> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">To the extent the valuation is based on models or inputs that are less observable or unobservable in the market, the determination of fair value requires more judgment. Accordingly, the degree of judgment exercised by the Company in determining fair value is greatest for instruments categorized in Level&#160;3. A financial instrument&#8217;s level within the fair value hierarchy is based on the lowest level of any input that is significant to the fair value measurement. </div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The Company&#8217;s financial instruments include shares of common stock of Arbutus Biopharma Corporation (&#8220;Arbutus&#8221;); shares of Arbutus&#8217;s Series A participating convertible preferred shares (&#8220;Arbutus Preferred Shares&#8221;); shares of common stock of Sio Gene Therapies Inc. (&#8220;Sio&#8221;); liability instruments issued, including options granted to Sumitomo (the &#8220;Sumitomo Options&#8221;) to purchase all, or 75% in one case, of RSL&#8217;s ownership interests in certain subsidiaries under the Sumitomo Transaction Agreement; deferred consideration liability; its investments in other entities; cash and cash equivalents consisting of money market funds; accounts payable; and long-term debt. </div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The shares of Arbutus and Sio common stock and investments in common stock with a readily determinable fair value are classified as Level&#160;1, and their fair value is determined based upon quoted market prices in an active market. The Arbutus Preferred Shares held by the Company are classified as Level&#160;2 as the fair value of such preferred shares is determined based upon the quoted market price of Arbutus common stock into which such preferred shares are convertible. The liability instruments issued, including the Sumitomo Options, are classified as Level&#160;3 within the fair value hierarchy as the assumptions and estimates used in the valuations are unobservable in the market. Cash, accounts payable, and deferred consideration liability are stated at their respective historical carrying amounts, which approximate fair value due to their short-term nature. The deferred consideration liability is based on a fixed monetary amount, and payment is based solely on the passage of time. Money market funds are included in Level&#160;1 of the fair value hierarchy and are valued at the closing price reported by an actively traded exchange. The carrying value of long-term debt issued by Dermavant Sciences Ltd. (together with its wholly owned subsidiaries, &#8220;Dermavant&#8221;), which is stated at amortized cost, approximates fair value&#160;based on current interest rates for similar types of borrowings and therefore is included in Level&#160;2 of the fair value hierarchy. Long-term debt issued by Dermavant for which the fair value option has been elected is included in Level&#160;3 of the fair value hierarchy as the assumptions and estimates used in the valuation are unobservable in the market. </div></div>  <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">(O) Foreign Currency </div></div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Assets and liabilities of foreign operations are translated using exchange rates in effect at the balance sheet date and their results of operations are translated using average exchange rates for the year. Certain transactions of the Company and its subsidiaries are denominated in currencies other than their functional currency. Adjustments resulting from the translation of the financial statements of the Company&#8217;s foreign functional currency subsidiaries into U.S. dollars are excluded from the determination of net loss and are accumulated in a separate component of shareholders&#8217; equity. Foreign exchange transaction gains and losses are included in &#8220;Other expense, net&#8221; in the Company&#8217;s statements of operations. </div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">(P) Revenue Recognition </div></div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The Company recognizes revenue when its customer obtains control of promised goods or services, in an amount that reflects the consideration which the Company expects to receive in exchange for those goods or services. To determine revenue recognition for its arrangements, the Company performs the following five steps: (i)&#160;identify the contract(s) with a customer; (ii)&#160;identify the performance obligations in the contract; (iii)&#160;determine the transaction price; (iv)&#160;allocate the transaction price to the performance obligations in the contract; and (v)&#160;recognize revenue when or as the Company satisfies a performance obligation. </div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The Company applies significant judgment when evaluating whether contractual obligations represent distinct performance obligations, allocating transaction price to performance obligations within a contract, determining </div></div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">when performance obligations have been met, assessing the recognition and future reversal of variable consideration, and determining and applying appropriate methods of measuring progress for performance obligations satisfied over time. These judgments are discussed in more detail below. </div></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Licenses of intellectual property:</div></div> If the licenses to intellectual property are determined to be distinct from the other performance obligations identified in the arrangement, the Company recognizes revenues from <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-refundable,</div> upfront fees allocated to the license when the license is transferred to the licensee and the licensee is able to use and benefit from the license. For licenses that are not distinct from other promises, the Company applies judgment to assess the nature of the combined performance obligation to determine whether the combined performance obligation is satisfied over time or at a point in time and, if over time, the appropriate method of measuring progress for purposes of recognizing revenue from <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-refundable,</div> upfront fees. The Company evaluates the measure of progress each reporting period and, if necessary, adjusts the related revenue recognition accordingly. </div> </td> </tr> </table> <div style="clear: both; max-height: 0px;"/> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Milestone payments: </div></div>At the inception of each arrangement that includes research, development or regulatory milestone payments, the Company<div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;"> </div></div>evaluates whether the milestones are considered probable of being reached and estimates the amount to be included in the transaction price using the most likely amount method. If it is probable that a significant revenue reversal would not occur, the associated milestone value is included in the transaction price. Milestone payments that are not within the control of the Company or the licensee, such as regulatory approvals, are not considered probable of being achieved until those approvals are received. The transaction price is then allocated to each performance obligation on a relative standalone selling price basis, for which the Company recognizes revenue as or when the performance obligations under the contract are satisfied. At the end of each subsequent reporting period, the Company <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">re-evaluates</div> the probability of achievement of such development milestones and any related constraint, and if necessary, adjusts its estimate of the overall transaction price on a cumulative <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">catch-up</div> basis in earnings in the period of the adjustment. </div> </td> </tr> </table> <div style="clear: both; max-height: 0px;"/> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Royalties and commercial milestone payments: </div></div>For arrangements that include sales-based royalties, including commercial milestone payments<div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;"> </div></div>based on a <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">pre-specified</div> level of sales, the Company recognizes revenue at the later of (i)&#160;when the related sales occur, or (ii)&#160;when the performance obligation to which some or all of the royalty has been allocated has been satisfied (or partially satisfied). Achievement of these royalties and commercial milestones may solely depend upon performance of the licensee. </div> </td> </tr> </table> <div style="clear: both; max-height: 0px;"/> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Revenue is also generated by certain technology-focused Vants from subscription and service-based fees recognized for the use of certain technology developed by these Vants. Subscription revenue is recognized ratably over the contract period. </div></div>  <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">(Q) Recently Adopted Accounting Pronouncements </div></div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;">In June 2016, the FASB issued ASU <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">No.&#160;2016-13,</div> &#8220;Financial Instruments-Credit Losses (Topic 326): Measurement of Credit Losses on Financial Instruments&#8221; (&#8220;ASU <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">No.&#160;2016-13&#8221;),</div> which requires the measurement and recognition of expected credit losses for financial assets held at amortized cost. ASU <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">No.&#160;2016-13</div> replaces the existing incurred loss impairment model with an expected loss model that requires the use of forward-looking information to calculate credit loss estimates. It also eliminates the concept of other-than-temporary impairment and requires credit losses on <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">available-for-sale</div></div> debt securities to be recorded through an allowance for credit losses instead of as a reduction in the amortized cost basis of the securities. ASU <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">No.&#160;2016-13</div> is effective for fiscal years beginning after December&#160;15, 2019 and interim periods within those fiscal years. The adoption of ASU <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">No.&#160;2016-13</div> on April&#160;1, 2020 did not have a material impact on the Company&#8217;s consolidated financial statements. </div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">(R) Recently Issued Accounting Pronouncements Not Yet Adopted </div></div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;">In August 2020, the FASB issued ASU <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">No.&#160;2020-06,</div> &#8220;Debt&#8212;Debt with Conversion and Other Options (Subtopic <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">470-20)</div> and Derivatives and Hedging&#8212;Contracts in Entity&#8217;s Own Equity (Subtopic <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">815-40):</div> Accounting for </div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Convertible Instruments and Contracts in an Entity&#8217;s Own Equity&#8221; (&#8220;ASU <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">No.&#160;2020-06&#8221;).</div> ASU <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">No.&#160;2020-06</div> will simplify the accounting for convertible instruments by reducing the number of accounting models for convertible debt instruments and convertible preferred stock. Limiting the accounting models will result in fewer embedded conversion features being separately recognized from the host contract as compared with current GAAP. ASU <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">No.&#160;2020-06</div> also removes certain settlement conditions that are required for equity contracts to qualify for the derivatives scope exception, which will permit more equity contracts to qualify for it. Either a modified retrospective transition method or a fully retrospective transition method is permissible for the adoption of this standard. Update <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">No.&#160;2020-06</div> is effective for fiscal years beginning after December&#160;15, 2021, including interim periods within those fiscal years. Early adoption is permitted no earlier than the fiscal year beginning after December&#160;15, 2020. The adoption of ASU <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">No.&#160;2020-06</div> is not expected to have a material impact on the Company&#8217;s consolidated financial statements. </div> <span></span>
</td>
</tr>
</table>
<div style="display: none;"><table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SignificantAccountingPoliciesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for all significant accounting policies of the reporting entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=123372394&amp;loc=d3e18726-107790<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -URI http://asc.fasb.org/topic&amp;trid=2122369<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SignificantAccountingPoliciesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table></div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>80
<FILENAME>R10.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm139997751312040">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Investments<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2021</div></th>
<th class="th"><div>Mar. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentsAllOtherInvestmentsAbstract', window );"><strong>Investments, All Other Investments [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentsAndOtherNoncurrentAssetsTextBlock', window );">Investments</a></td>
<td class="text"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Note 3&#8212;Investments </div></div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">(A) Investments Measured at Fair Value </div></div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt; margin-left: 4%;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Investment in Arbutus </div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;">RSL owns 16,013,540 shares of common stock of Arbutus and 1,164,000 Arbutus Preferred Shares that are mandatorily convertible into shares of Arbutus common stock on October&#160;18, 2021 subject to conversion earlier upon a sale, merger or other transaction considered a fundamental change of control of Arbutus. The Arbutus Preferred Shares are <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-voting</div> and are convertible into common shares of Arbutus based on the subscription price plus 8.75% per annum, compounded annually, divided by a conversion price of $7.13 per share (which represented a 15% premium to the closing price of $6.20 per share on September&#160;29, 2017). The fair value option was elected to continuously remeasure the investment to fair value each reporting period after the initial measurement. Due to the Company&#8217;s significant influence over operating and financial policies, Arbutus is considered a related party of the Company. <div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">At June&#160;30, 2021, RSL held 32% of issued and outstanding shares of Arbutus, including the conversion of the Arbutus Preferred Shares held by RSL into common shares. </div></div></div> <div style="text-indent: 4%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">At June&#160;30, 2021 and March&#160;31, 2021, the aggregate fair value of the <div style="letter-spacing: 0px; top: 0px;;display:inline;">RSL</div> investment in Arbutus was $117.7&#160;million and $129.4&#160;million, respectively, with the Company recognizing an unrealized loss on its investments in Arbutus of $11.7&#160;million and an unrealized gain of $31.5&#160;million in the accompanying condensed consolidated statements of operations for the three months ended June&#160;30, 2021 and 2020, respectively. The fair value of the common stock and preferred shares held by the Company was determined using the closing price of Arbutus&#8217;s common stock on June&#160;30, 2021 and March&#160;31, 2021 of $3.03 and $3.33, respectively<div style="letter-spacing: 0px; top: 0px;;display:inline;">.</div></div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt; margin-left: 4%;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Investment in Sio </div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Following the completion of Sio&#8217;s underwritten public offering in February 2020, RSL&#8217;s ownership interest fell below <div style="letter-spacing: 0px; top: 0px;;display:inline;">50.0</div>%. As such, the Company no longer has a controlling financial interest in Sio. Accordingly, the Company deconsolidated Sio in February 2020. Due to the Company&#8217;s significant influence over operating and financial policies, Sio remains a related party of the Company following deconsolidation. As the Company still has the ability to exercise significant influence over the operating and financial policies of Sio, the Company has determined that its retained interest represents an equity method investment after the date of deconsolidation. Upon deconsolidation, the retained interest was recorded at fair market value based on the closing price of Sio&#8217;s common stock. The fair value option was elected to continuously remeasure the investment to fair value each reporting period after the initial measurement. At June&#160;30, 2021, RSL held 27% of Sio&#8217;s issued and outstanding common shares. </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">At June&#160;30, 2021 and March&#160;31, 2021, the fair value of the Company&#8217;s investment in Sio was $50.7&#160;million and $48.5&#160;million, respectively, with the Company recognizing unrealized gains on its investment in Sio of </div></div>  <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0px;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">$2.2&#160;million and $7.1&#160;million in the accompanying condensed consolidated statements of operations for the three months ended June&#160;30, 2021 and 2020, respectively. The fair value of common shares held by the Company was determined using the closing price of Sio&#8217;s common stock on June&#160;30, 2021 and March&#160;31, 2021 of $2.73 and $2.61, respectively. </div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt; margin-left: 4%;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Other Investment </div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The Company holds an additional equity investment that is measured using the fair value option. The fair value of this investment was $11.9&#160;million and $11.1&#160;million as of June&#160;30, 2021 and March&#160;31, 2021, respectively. </div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">(B) Investment Accounted for Using Measurement Alternative </div></div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt; margin-left: 4%;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Investment in Datavant </div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">In April 2020, Datavant Holdings, Inc. (&#8220;Datavant&#8221;) completed an initial round of a Series B equity raise by which 13,411,311 Series B preferred shares were issued in April 2020 for gross proceeds of $27.2&#160;million, including 1,065,234 Series B preferred shares issued and sold to RSL for a total purchase price of $2.5&#160;million and 1,800,253 Series B shares issued relating to the conversion of certain liability instruments. As a result of this transaction, along with a restructuring of Datavant&#8217;s equity classes, RSL no longer controls Datavant. As such, the Company deconsolidated Datavant as of April 2020. Due to the Company&#8217;s significant influence over operating and financial policies, Datavant remains a related party of the Company following deconsolidation. Upon deconsolidation, the Company recorded its investment in Datavant based on the fair value of Datavant preferred shares held of $99.0&#160;million. The Company accounts for its investment in Datavant using the measurement alternative to fair value. The investment will be remeasured upon future observable price changes in orderly transactions or upon impairment, if any. The Company recognized a gain on deconsolidation of $86.5&#160;million in the accompanying condensed consolidated statements of operations for the three months ended June&#160;30, 2020. In July 2020, Datavant issued and sold 639,140 Series B preferred shares to RSL at a price consistent with that of the initial round of Datavant&#8217;s Series B equity raise. At June&#160;30, 2021 and March&#160;31, 2021, the carrying value of the Company&#8217;s investment in Datavant was $100.6&#160;million. </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">In June 2021, Datavant and CIOX Health, LLC entered into a definitive agreement to merge the two companies, subject to regulatory approvals. See Note 14, &#8220;Subsequent Events&#8221; for additional information. </div></div> <span></span>
</td>
<td class="text"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Note 3&#8212;Investments </div></div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">(A) Investments Measured at Fair Value </div></div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Investment in Arbutus </div></div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;">RSL owns 16,013,540 shares of common stock of Arbutus and 1,164,000 Arbutus Preferred Shares that are mandatorily convertible into shares of Arbutus common stock on October&#160;18, 2021 subject to conversion earlier upon a sale, merger or other transaction considered a fundamental change of control of Arbutus. The Arbutus Preferred Shares are <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-voting</div> and are convertible into common shares of Arbutus based on the subscription price plus 8.75% per annum, compounded annually, divided by a conversion price of $7.13 per share (which represented a 15% premium to the closing price of $6.20 per share on September&#160;29, 2017). RSL&#8217;s investments in Arbutus have been measured using the fair value option. Due to the Company&#8217;s significant influence over operating and financial policies, Arbutus is considered a related party of the Company. </div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">After conversion of the Arbutus Preferred Shares into common shares, based on the number of Arbutus&#8217;s common shares outstanding on October&#160;2, 2017, the Company would hold&#160;49.90%&#160;of Arbutus&#8217;s common shares. In addition, the Company agreed to a four-year standstill to not acquire greater than 49.99% of common shares or securities convertible into common shares of Arbutus. </div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">At March&#160;31, 2021 and 2020, the aggregate fair value of the Company&#8217;s investment in Arbutus was $129.4&#160;million and $39.2&#160;million, respectively, with the Company recognizing an unrealized gain on its investments in Arbutus of $90.2&#160;million and an unrealized loss of $99.9&#160;million in the accompanying consolidated statements of operations for the years ended March&#160;31, 2021 and 2020, respectively. The fair value of the common stock and preferred shares held by the Company was determined using the closing price of Arbutus&#8217;s common stock on March&#160;31, 2021 and 2020 of $3.33 and $1.01, respectively. </div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Investment in Sio </div></div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Following the completion of Sio&#8217;s underwritten public offering in February 2020, RSL&#8217;s ownership interest fell below 50.0%. As such, the Company no longer has a controlling financial interest in Sio. Accordingly, the Company deconsolidated Sio in February 2020. Due to the Company&#8217;s significant influence over operating and financial policies, Sio remains a related party of the Company following deconsolidation. As the Company still has the ability to exercise significant influence over the operating and financial policies of Sio, the Company has determined that its retained interest represents an equity method investment after the date of deconsolidation. Upon deconsolidation, the retained interest was recorded at fair market value based on the closing price of Sio&#8217;s common stock. The Company recognized a gain on deconsolidation of $107.3&#160;million in the accompanying consolidated statements of operations for the year ended March&#160;31, 2020. The fair value option was elected to continuously remeasure the investment to fair value each reporting period after the initial measurement. </div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">At March&#160;31, 2021 and 2020, the fair value of the Company&#8217;s investment in Sio was $48.5&#160;million<div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"> </div></div>and<div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"> </div></div>$45.3&#160;million, respectively, with the Company recognizing an unrealized gain on its investment in Sio of </div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">$3.2&#160;million and an unrealized loss of $31.6&#160;million in the accompanying consolidated statements of operations for the years ended March&#160;31, 2021 and 2020, respectively. The fair value of common shares held by the Company was determined using the closing price of Sio&#8217;s common stock on March&#160;31, 2021 and 2020 of $2.61 and $2.44, respectively. </div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Other Investment </div></div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The Company holds an additional equity investment that is measured using the fair value option. The fair value of this investment was $11.1&#160;million and $8.9&#160;million as of March&#160;31, 2021 and 2020, respectively. </div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">(B) Investment Accounted for Using Measurement Alternative </div></div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Investment in Datavant </div></div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">In April 2020, Datavant Holdings, Inc. (&#8220;Datavant&#8221;) completed an initial round of a Series B equity raise by which 13,411,311 Series B preferred shares were issued in April 2020 for gross proceeds of $27.2&#160;million, including 1,065,234 Series B preferred shares issued and sold to RSL for a total purchase price of $2.5&#160;million and 1,800,253 Series B shares issued relating to the conversion of certain liability instruments. As a result of this transaction, along with a restructuring of Datavant&#8217;s equity classes, RSL no longer controls Datavant. As such, the Company deconsolidated Datavant as of April 2020. Due to the Company&#8217;s significant influence over operating and financial policies, Datavant remains a related party of the Company following deconsolidation. Upon deconsolidation, the Company recorded its investment in Datavant based on the fair value of Datavant preferred shares held of $99.0&#160;million. The Company accounts for its investment in Datavant using the measurement alternative to fair value. The investment will be remeasured upon future observable price changes in orderly transactions or upon impairment, if any. The Company recognized a gain on deconsolidation of $86.5&#160;million in the accompanying consolidated statements of operations for the year ended March&#160;31, 2021. In July 2020, Datavant issued and sold 639,140 Series B preferred shares to RSL at a price consistent with that of the initial round of Datavant&#8217;s Series B equity raise. At March&#160;31, 2021, the carrying value of the Company&#8217;s investment in Datavant was $100.6&#160;million. </div></div> <span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentsAllOtherInvestmentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentsAllOtherInvestmentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentsAndOtherNoncurrentAssetsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire  disclosure for investments and other noncurrent assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentsAndOtherNoncurrentAssetsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>81
<FILENAME>R11.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm139997748021256">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Asset Acquisitions and License Agreements<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationsAbstract', window );"><strong>Business Combinations [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_roiv_AssetAcquisitionsAndLicenseAgreementsDisclosureTextBlock', window );">Asset Acquisitions and License Agreements</a></td>
<td class="text"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Note 4&#8212;Asset Acquisitions and License Agreements </div></div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">During the years ended March&#160;31, 2021 and 2020, the Company, directly or indirectly through Vants, completed the following key asset acquisitions and license agreements. The Company evaluated the below agreements, except the collaboration and license agreement entered into between Dermavant and Japan Tobacco Inc. that is evaluated separately below, and determined that the acquired assets did not meet the definition of a business as substantially all the fair value of the assets acquired were concentrated in a single asset or group of similar assets and/or the acquired assets were not capable of producing outputs due to the lack of an assembled workforce and early stage of development and thus, each transaction was accounted for as an asset acquisition. </div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">The Company then evaluated whether each <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">in-process</div> research and development asset had an alternative future use and concluded it did not. As a result, the Company recorded the consideration attributable to <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">in-process</div> research and development under the below agreements as research and development expense in the accompanying consolidated statements of operations for the years ended March&#160;31, 2021 and 2020. </div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Dermavant </div></div></div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">In August 2018, Dermavant acquired the worldwide rights (other than with respect to certain rights in China) to tapinarof, an investigational therapeutic aryl hydrocarbon receptor modulating agent for the treatment of psoriasis and atopic dermatitis, from GlaxoSmithKline Intellectual Property Development Ltd. and Glaxo Group Limited (collectively &#8220;GSK&#8221;) pursuant to an asset purchase agreement (the &#8220;GSK Agreement&#8221;). GSK previously acquired rights to a predecessor formulation of tapinarof from Welichem Biotech Inc. (&#8220;Welichem&#8221;) pursuant to an asset </div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">purchase agreement between GSK and Welichem entered into in May 2012 (the &#8220;Welichem Agreement&#8221;). Under the GSK Agreement, Dermavant made an upfront payment of &#163;150.0&#160;million (approximately $191 million) and agreed to a contingent payment of &#163;100.0&#160;million (approximately $133 million) upon the first approval of an NDA by the FDA for a product that contains tapinarof. Dermavant assumed responsibility for all obligations under the Welichem Agreement, including payment of up to C$180.0&#160;million (approximately $137 million) in potential development and commercial milestones. The purchase was funded in part by a $117.5&#160;million borrowing from NovaQuest <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">Co-Investment</div> Fund VIII, L.P. (&#8220;NovaQuest&#8221;), an affiliate of NovaQuest Capital Management, LLC, as described in Note 8, &#8220;Long-Term Debt.&#8221; In connection with the GSK Agreement, Dermavant and GSK have entered into a clinical manufacturing and supply agreement for tapinarof pursuant to which Dermavant will obtain supply of tapinarof for clinical trials on a cost-plus basis. In May 2019, Dermavant achieved a development and regulatory milestone under the GSK Agreement, which resulted in a C$30.0&#160;million (approximately $23 million) milestone payment that Dermavant subsequently paid to Welichem in August 2019. The milestone payment was recorded as research and development expense in the accompanying consolidated statements of operations for the year ended March&#160;31, 2020. </div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">In January 2020, Dermavant entered into a collaboration and license agreement with Japan Tobacco Inc. (&#8220;JT&#8221;) for exclusive rights to develop, register, and market tapinarof in Japan for the treatment of dermatological diseases and conditions, including psoriasis and atopic dermatitis. In conjunction with this agreement, JT executed an exclusive license agreement with its subsidiary, Torii Pharmaceutical Co., Ltd., for <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">co-development</div> and commercialization of tapinarof in Japan. Under the terms of the license agreement, Dermavant received a nonrefundable, upfront payment of $60.0&#160;million in January 2020 and may receive up to $53.0&#160;million upon the achievement of certain development milestones for tapinarof for the treatment of psoriasis and atopic dermatitis. In addition, Dermavant will have the right to receive royalties based on product sales of tapinarof in the indications. </div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">The Company evaluated the collaboration and license agreement and concluded that JT is a customer. The Company&#8217;s performance obligations under the agreement are the following: (i)&#160;an exclusive license to JT of the right to develop, register and market tapinarof in Japan and (ii)&#160;the associated transfer to JT of technology and <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">know-how</div> related to the license. The Company determined that the monetary value of participation in the Joint Steering Committee under the agreement was immaterial in the context of the contract and therefore was disregarded when identifying the performance obligations. The Company determined that the exclusive license is not capable of being distinct from the associated technology transfer because the customer cannot benefit from or utilize the license without the technology and <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">know-how</div> transfer and as such does not have standalone value as JT cannot benefit from the exclusive license without the associated technology and <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">know-how</div> transfer. Accordingly, the Company concluded that these performance obligations should be combined into a single performance obligation. </div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">Based on management&#8217;s evaluation, the <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-refundable,</div> <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">up-front</div> payment of $60.0&#160;million constituted the amount of consideration to be included in the transaction price. The remaining $53.0&#160;million of consideration related to potential development and regulatory approval milestones constitutes variable consideration and has not been recognized because of the inherent uncertainty of the occurrence of the future events and because it is highly susceptible to factors outside of the Company&#8217;s control. Any consideration related to potential royalty payments will be recognized when the related sales occur, since these amounts have been determined to relate predominantly to the license granted to JT and therefore are recognized at the later of when the performance obligations are satisfied or the related sales occur.&#160;The Company will <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">re-evaluate</div> the transaction price in each reporting period and as uncertain events are resolved or other changes in circumstances occur. Upon transfer of the technology and <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">know-how</div> related to the license, the Company recognized the $60.0&#160;million <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-refundable</div> upfront payment as license revenue in the accompanying consolidated statements of operations for the year ended March&#160;31, 2020. </div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>  <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Genevant </div></div></div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;">In July 2020, RSL increased its investment in Genevant Sciences Ltd. (&#8220;Genevant&#8221;) as part of a recapitalization transaction (the &#8220;Recapitalization&#8221;). Genevant, an entity focused on the discovery, development, and commercialization of a broad range of <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">RNA-based</div> therapeutics enabled by Arbutus&#8217; proprietary lipid nanoparticle and ligand conjugate delivery technologies, was created in April 2018 as part of an agreement between RSL and Arbutus. As part of the initial transaction entered into in April 2018, RSL contributed $38.7&#160;million in cash, including transaction costs, for an equity ownership interest in Genevant. Prior to the Recapitalization, RSL accounted for its investment in Genevant under the equity method of accounting as it had determined that it was not the primary beneficiary of Genevant since it did not have the power to direct its most significant activities. Additionally, RSL made additional investments in the form of promissory notes issued by Genevant amounting to $20.1&#160;million aggregate principal amount outstanding (the &#8220;Genevant Outstanding Notes&#8221;) prior to the Recapitalization. RSL applied its share of losses relating to its equity method investment in Genevant against the Company&#8217;s carrying value of its investment in Genevant&#8217;s common shares and against the carrying value of the Genevant Outstanding Notes. The carrying value of RSL&#8217;s investment in Genevant was reduced to zero prior to the Recapitalization. </div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Pursuant to the Recapitalization, the following transactions were completed: </div></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Genevant issued 74,272,043 common shares to RSL for an aggregated purchase price of $20.5&#160;million; </div></div> </td> </tr> </table> <div style="clear: both; max-height: 0px;"/> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">$15.1&#160;million aggregate principal amount of the Genevant Outstanding Notes were converted into 54,526,549 common shares; and </div></div> </td> </tr> </table> <div style="clear: both; max-height: 0px;"/> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Genevant issued 9,057,566 common shares to Arbutus for an aggregated purchase price of $2.5&#160;million. </div></div> </td> </tr> </table> <div style="clear: both; max-height: 0px;"/> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Following the Recapitalization, RSL held an 82.9% controlling interest in Genevant. </div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Concurrent with the Recapitalization, the composition of Genevant&#8217;s Board of Directors was restructured to include two directors designated by RSL and one director who is a senior officer of Genevant. </div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">As a result of the Recapitalization and changes to the <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">bye-laws,</div> RSL determined that it controls the most significant activities of Genevant and is the primary beneficiary of Genevant following the Recapitalization. As such, RSL began consolidating Genevant into the Company&#8217;s consolidated financial statements from the date of the Recapitalization. The Company evaluated the acquired set of assets and activities and determined that the acquired set did not meet the definition of a business and thus the transaction was not considered a business combination. </div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">The transactions completed as part of the Recapitalization represent an acquisition achieved in stages, which required the remeasurement of RSL&#8217;s previously held interest in Genevant. As such, RSL&#8217;s investments in Genevant were remeasured to fair value of $28.8&#160;million, also resulting in a gain of $28.8&#160;million in the accompanying consolidated statements of operations for the year ended March&#160;31, 2021. Along with the fair value of noncontrolling interests in Genevant of $9.2&#160;million and cash paid of $20.5&#160;million for common shares of Genevant as part of the Recapitalization, total consideration paid was $58.5&#160;million. Of this amount, $41.4&#160;million was attributed to <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">in-process</div> research and development, which was determined by the Company to have not reached technological feasibility and therefore have no alternative future use. Accordingly, the Company recorded $41.4&#160;million as research and development expense in the accompanying consolidated statements of operations for the year ended March&#160;31, 2021. </div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Proteovant </div></div></div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">In November 2020, Proteovant Sciences, Inc. (formerly known as Pharmavant 5, Inc.) (&#8220;ProteoVant&#8221;) entered into a stock purchase agreement to acquire Oncopia Therapeutics, Inc. (&#8220;Oncopia&#8221;), a preclinical biotechnology </div></div>  <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">company developing small molecule protein degraders primarily against certain oncology targets. Upfront proceeds to Oncopia&#8217;s shareholders were $105.0&#160;million, prior to certain adjustments in accordance with the terms of the agreement. Proteovant is also obligated to make future development and commercial milestone payments of up to $100.0&#160;million for the first product targeting each of the two specified initial targets, and up to $51.0&#160;million for the first product targeting each of certain specified additional molecular targets. Additionally, the Company&#8217;s investments in promissory notes issued by Oncopia for an aggregate principal amount of $11.5&#160;million were settled through either conversion to equity or cancellation. </div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">Oncopia&#8217;s intellectual property was developed by the University of Michigan laboratory run by Oncopia&#8217;s <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">co-founder</div> (the <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">&#8220;Co-Founder&#8221;).</div> In connection with Proteovant&#8217;s acquisition, Oncopia amended and restated its existing license agreements with the University of Michigan. Under the new license agreement, Oncopia will be obligated to make future development and commercial milestone payments of up to $8.6&#160;million for the first product for each molecular target covered by intellectual property included in the agreement, in addition to paying tiered royalties on net sales ranging from <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">low-</div> to <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">mid-single</div> digits, subject to certain adjustments. </div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">The <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">Co-Founder&#8217;s</div> lab at the University of Michigan had been providing <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">on-going</div> discovery and optimization services to Oncopia under a sponsored research agreement (the &#8220;SRA&#8221;). Immediately after closing the acquisition, Oncopia extended the SRA through at least December&#160;31, 2023, and expanded the potential molecular targets to be pursued under the SRA. As revised, Oncopia is obligated to pay the University of Michigan approximately $15.5&#160;million under the SRA. </div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">Lastly, in connection with the acquisition of Oncopia, the <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">Co-Founder</div> entered into an agreement with the Company to serve as a consultant. In exchange for these services, the Company has agreed to grant the <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">Co-Founder</div> RSL restricted stock units for which the majority will vest upon achievement of development milestones for products directed to targets for which no milestones are payable to Oncopia shareholders and the remaining portion will be subject to time-based service requirements. All of these restricted stock units are subject to a liquidity requirement to vest. The Company will also make a cash payment to the <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">Co-Founder</div> upon achievement of development milestones for each such product. </div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">During the year ended March&#160;31, 2021, the Company recorded $116.5&#160;million, relating to the net upfront cash payment of $101.2&#160;million, settlement of promissory notes receivable, including accrued interest, of $11.9&#160;million, and fair value of future contingent consideration payments of $3.4&#160;million, as research and development expense in the accompanying consolidated statements of operations. </div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">In December 2020, RSL, Proteovant and SK, Inc. (formerly known as SK Holdings Co., Ltd.) (&#8220;SK&#8221;) entered into a subscription agreement (the &#8220;Subscription Agreement&#8221;) pursuant to which SK agreed to make a $200.0&#160;million equity investment in Proteovant, representing an ownership interest of 40.0% on the closing date. In January 2021, in accordance with the terms of the Subscription Agreement, SK made the first payment of $100.0&#160;million to Proteovant. A second $100.0&#160;million payment is expected to be made by SK to Proteovant on or about July&#160;12, 2021, the date six months from the closing date. The second $100.0&#160;million payment is classified as a subscription receivable in the accompanying consolidated balance sheets and consolidated statements of shareholders&#8217; equity and redeemable noncontrolling interest as of March&#160;31, 2021. </div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Affivant </div></div></div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;">In November 2020, RSL and its indirect subsidiary Affivant Sciences GmbH (&#8220;Affivant&#8221;) entered into a licensing and strategic collaboration agreement with Affimed N.V. (&#8220;Affimed&#8221;) to develop and commercialize novel innate cell engagers for multiple cancer targets in exchange for consideration that includes $40.0&#160;million in upfront cash and <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">pre-paid</div> R&amp;D funding and $20.0&#160;million of newly issued shares in RSL. Affimed could receive further short-term proceeds in the form of option fees contingent on the commencement of additional programs contemplated under the agreement. Affimed is eligible to receive up to an additional approximately $2.0&#160;billion in milestones over time upon achievement of specified development, regulatory and commercial milestones, as well as tiered royalties on net sales. </div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>  <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Acquisition of Silicon Therapeutics </div></div></div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">In March 2021, the Company completed the acquisition of the business of Silicon Therapeutics, LLC (&#8220;SiTX&#8221;), a physics-driven computational drug discovery company, for total consideration of approximately $450.0&#160;million, with additional cash payments payable subject to the satisfaction of certain regulatory and commercial milestones. This acquisition did not include one of SiTX&#8217;s subsidiaries, Silicon SWAT, Inc. Approximately $350.0&#160;million of the consideration was payable primarily in the Company&#8217;s common stock at or near closing of the acquisition (the &#8220;First Tranche&#8221;). At closing of the acquisition, the Company issued 7,316,583 common shares and paid approximately $14.0&#160;million in cash, net of cash received, to SiTX after giving effect to certain transaction adjustments and holdbacks. The remainder of the First Tranche is expected to be paid in a combination of common shares and cash as certain holdbacks are released. Approximately $100.0&#160;million (the &#8220;Second Tranche Consideration&#8221;) is payable to SiTX on the earlier of (x)&#160;approximately 30 to 60 days following the public listing of the Company&#8217;s common shares, in either cash or common shares (at the Company&#8217;s election), and (y) 12 months following the closing of the acquisition, in cash. </div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The transaction was accounted for as an asset acquisition as substantially all of the fair value of the assets acquired were concentrated in a single asset, IPR&amp;D related to the computational drug discovery platform that designs and develops small molecule therapeutics. For accounting purposes, the fair value of consideration transferred was $402.4&#160;million, consisting of $281.7&#160;million relating to the fair value of common shares issued upfront and expected to be issued shortly thereafter; $105.1&#160;million relating to the fair value of liabilities due to the sellers, including the Second Tranche Consideration, future contingent consideration payments, and closing consideration to be paid in cash; and cash of $15.6&#160;million paid at closing. Of this amount, $399.6&#160;million was attributed to IPR&amp;D, which was determined to have no alternative future use. Accordingly, the Company recorded $399.6&#160;million as research and development expense in the accompanying consolidated statement of operations for the year ended March&#160;31, 2021. </div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">In connection with the transaction, the vesting of certain outstanding SiTX share-based compensation awards held by employees of SiTX was discretionarily accelerated at closing. As a result, the Company recorded share-based compensation expense of $23.5&#160;million in the accompanying consolidated statements of operations for the year ended March&#160;31, 2021. </div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">In addition, certain share-based compensation awards of SiTX were exchanged with restricted common stock of the Company, subject to certain service-based vesting requirements, with a fair value of $22.6&#160;million. Of this amount, $15.6 million was attributed to precombination service and therefore included in the total fair value of consideration transferred. Refer to Note 11, &#8220;Share-Based Compensation,&#8221; for additional detail regarding this restricted common stock. </div></div> <span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_roiv_AssetAcquisitionsAndLicenseAgreementsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Asset acquisitions and license agreements disclosure.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">roiv_AssetAcquisitionsAndLicenseAgreementsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>roiv_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>82
<FILENAME>R12.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm139997754906776">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Sumitomo Transaction Agreement<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2021</div></th>
<th class="th"><div>Mar. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_roiv_TransactionAgreementAbstract', window );"><strong>Transaction Agreement [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_roiv_TransactionAgreementDisclosureTextBlock', window );">Sumitomo Transaction Agreement</a></td>
<td class="text"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt; text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Note 4&#8212;Sumitomo Transaction Agreement </div></div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">On December&#160;27, 2019 (the &#8220;Sumitomo Closing Date&#8221;), RSL and Sumitomo Dainippon Pharma Co., Ltd. (&#8220;Sumitomo&#8221;) completed the transactions contemplated by the transaction agreement by and between RSL and Sumitomo, dated as of October&#160;31, 2019 (the &#8220;Sumitomo Transaction Agreement&#8221;). Pursuant to the Sumitomo Transaction Agreement, RSL transferred its entire ownership interest in Myovant Sciences Ltd., Urovant Sciences Ltd., Enzyvant Therapeutics Ltd., Altavant Sciences Ltd. and Spirovant Sciences Ltd. (collectively, the &#8220;Sumitovant Vants&#8221;) to a newly formed, wholly-owned entity (&#8220;Sumitovant&#8221;). </div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">RSL&#8217;s ownership interest in Sumitovant was then transferred to Sumitomo, such that following the Sumitomo Closing Date, Sumitovant and its subsidiaries, including the Sumitovant Vants, were each directly or indirectly owned by Sumitomo. Additionally, in connection with the Sumitomo Transaction Agreement, RSL (i)&#160;granted Sumitomo options to purchase all, or in the case of Dermavant, 75%, of RSL&#8217;s ownership interests in six other subsidiaries (Dermavant, Genevant Sciences Ltd. (&#8220;Genevant&#8221;), Lysovant Sciences Ltd., Metavant Sciences Ltd., Roivant Asia Cell Therapy Holdings Ltd., and Sinovant Sciences HK Limited (collectively, the &#8220;Option Vants&#8221;)), </div><div style="display:inline;">(ii) (a) transferred the proprietary technology platform DrugOme to Sumitomo (for which RSL retains a perpetual royalty free license for internal use) and (b) licensed the Digital Innovation technology platform to Sumitomo (for which both parties retain ongoing access) and (iii)&#160;</div><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">transferred 26,952,143 common shares of RSL to Sumitomo. On the Sumitomo Closing Date, the Company received approximately $2.9&#160;billion</div></div> <div style="text-indent: 0px; margin-bottom: 1em; margin-top: 1em"/> <div style="text-indent: 0px; margin-bottom: 1em; margin-top: 1em"/> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div>  <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0px;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">in cash. Additionally, $75.0&#160;million was deposited into a segregated escrow account for the purpose of fulfilling indemnification obligations of RSL that may become due to Sumitomo. The full escrow amount of $75.0&#160;million was disbursed to the Company in June 2021.<div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">In connection with the Sumitomo Transaction, RSL&#8217;s board of directors approved an exchange and offer to repurchase RSL equity securities for up to $<div style="letter-spacing: 0px; top: 0px;;display:inline;">1.0 </div>billion of the proceeds received from Sumitomo. </div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Concurrently with the Sumitomo Transaction Agreement, (i)&#160;RSL, Sumitomo and Sumitovant entered into a transition services agreement, whereby each of the parties thereto agreed to provide certain services to one another at cost for a period of time following the Sumitomo Closing Date and (ii)&#160;RSL and Sumitomo entered into a strategic cooperation agreement relating to certain ongoing technology-related collaborations between the parties. Pursuant to the terms of the transition services agreement and strategic cooperation agreement, RSL billed Sumitovant $0.3<div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div>million and $0.4<div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div>million, net of amounts billed by Sumitovant to RSL, during the three months ended June&#160;30, 2021 and 2020, respectively, for costs incurred on behalf of Sumitovant, which were recorded as offsets to the general and administrative expenses initially charged. The period for certain services provided under the Transition Services Agreement expired in December 2020. </div></div>  <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">In conjunction with the Sumitomo Transaction, certain employees of the Company became employees of Sumitovant or its subsidiaries. The Company issued certain instruments to these employees that vest based on the achievement of time-based, performance or liquidity event requirements. As of June&#160;30, 2021 and 2020, there were 1,863,451 and 1,873,480 outstanding instruments, respectively, held by Sumitovant employees for which aggregate fair value was recorded against the gain on sale of business. </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">In May 2021, the Company entered into an Asset Purchase Agreement with Sumitomo and its subsidiary Sumitomo Pharmaceuticals (Suzhou) Co., Ltd. (&#8220;SPC&#8221;) (the &#8220;Asset Purchase Agreement&#8221;). The transactions contemplated by the Asset Purchase Agreement closed in June 2021. Pursuant to the Asset Purchase Agreement: (i)&#160;Sumitomo terminated all of its existing options to acquire the Company&#8217;s equity interests in the Option Vants (the &#8220;Sumitomo Options&#8221;); (ii) the Company transferred and assigned to SPC all of its intellectual property, development and commercialization rights for (a)&#160;lefamulin in Mainland China, Taiwan, Hong Kong, and Macau (collectively &#8220;Greater China&#8221;), (b) vibegron in Mainland China, (c)&#160;rodatristat ethyl in Greater China and South Korea and <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">(d)&#160;RVT-802</div> in Greater China and South Korea; (iii)&#160;Sumitomo agreed to pay the Company $5.0<div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div>million in cash; and (iv)&#160;Sumitomo entered into an agreement with the Company to pursue future collaborations with Genevant. The Company received the cash payment, net of certain withholding taxes, in August 2021. The Company recorded a gain on the termination of the Sumitomo Options of $66.5<div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div>million, consisting of the fair value of the Sumitomo Options on the date of termination and the expected cash payment, in the accompanying condensed consolidated statements of operations for the three months ended June&#160;30, 2021. </div> <span></span>
</td>
<td class="text"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt; text-indent: 0px;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Note 5&#8212;Sumitomo Transaction Agreement </div></div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt; text-indent: 0px;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">On December&#160;27, 2019 (the &#8220;Sumitomo Closing Date&#8221;), RSL and Sumitomo completed the transactions contemplated by the Sumitomo Transaction Agreement. Pursuant to the Sumitomo Transaction Agreement, RSL transferred its entire ownership interest in Myovant, Urovant, Enzyvant, Altavant, and Spirovant to a newly formed, wholly-owned entity (&#8220;Sumitovant&#8221;). </div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt; text-indent: 0px;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">RSL&#8217;s ownership interest in Sumitovant was then transferred to Sumitomo, such that following the Sumitomo Closing Date, Sumitovant and its subsidiaries, including the Sumitovant Vants, were each directly or indirectly owned by Sumitomo. Additionally, in connection with the Sumitomo Transaction Agreement, RSL (i)&#160;granted Sumitomo options to purchase all, or in the case of Dermavant, 75%, of RSL&#8217;s ownership interests in six other subsidiaries (Dermavant, Genevant, Lysovant Sciences Ltd. (&#8220;Lysovant&#8221;), Metavant Sciences Ltd. (&#8220;Metavant&#8221;), Roivant Asia Cell Therapy Holdings Ltd. (&#8220;Cytovant Parent&#8221;), and Sinovant Sciences HK Limited (&#8220;Sinovant&#8221;)), </div><div style="display:inline;">(ii) (a) transferred the proprietary technology platform DrugOme to Sumitomo (for which RSL retains a perpetual royalty free license for internal use) and (b) licensed the Digital Innovation technology platform to Sumitomo (for which both parties retain ongoing access) and (iii)&#160; </div><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">transferred 26,952,143 common shares of RSL to Sumitomo. On the Sumitomo Closing Date, the Company received approximately $2.9&#160;billion in cash, resulting in a gain of $2.0&#160;billion after taking into account all of the components of the transaction. </div></div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0px;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Additionally, on the Sumitomo Closing Date, $75.0&#160;million of the consideration was deposited into a segregated escrow account for the purpose of fulfilling indemnification obligations of RSL that may become due to Sumitomo. Upon the expiration of the escrow period, being 18 months from the Sumitomo Closing Date, any remaining escrow funds will be disbursed to RSL. As of March&#160;31, 2021, the Company does not believe that a reasonably possible loss of the funds in the escrow account exists. As such, the full escrow amount of $75.0&#160;million was recorded by the Company as restricted cash on the accompanying consolidated balance sheets as of March&#160;31, 2021. In connection with the Sumitomo Transaction, RSL&#8217;s board of directors approved a repurchase of RSL&#8217;s equity securities for up to $1.0&#160;billion of the proceeds received from Sumitomo. Refer to Note 10, &#8220;Shareholders&#8217; Equity and Redeemable Noncontrolling Interest&#8221; for further detail. </div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">In conjunction with the Sumitomo Transaction, certain employees of the Company became employees of Sumitovant or its subsidiaries. The Company issued certain instruments with an aggregate fair value of $39.1&#160;million to these employees, of which $24.8&#160;million was classified within shareholders&#8217; equity and $14.3&#160;million was classified as a liability. The liability classified awards were subsequently surrendered and exchanged for cash and other newly issued equity as part of the repurchase in March 2020. The remaining instruments vest based on the achievement of time-based, performance or liquidity event requirements. As of March&#160;31, 2021 and 2020, there were 1,865,416 and 1,880,980 outstanding instruments, respectively, held by Sumitovant employees for which aggregate fair value was recorded against the gain on sale of business. </div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">In June 2021, RSL completed a transaction with Sumitomo pursuant to which Sumitomo terminated its existing options to acquire RSL&#8217;s equity interests in certain of its subsidiaries. See Note 19, &#8220;Subsequent Events&#8221; for additional information. </div></div> <span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_roiv_TransactionAgreementAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Transaction Agreement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">roiv_TransactionAgreementAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>roiv_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_roiv_TransactionAgreementDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Transaction Agreement Disclosure.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">roiv_TransactionAgreementDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>roiv_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>83
<FILENAME>R13.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm139997756282584">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Balance Sheet Components<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2021</div></th>
<th class="th"><div>Mar. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract', window );"><strong>Organization, Consolidation and Presentation of Financial Statements [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SupplementalBalanceSheetDisclosuresTextBlock', window );">Balance Sheet Components</a></td>
<td class="text"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Note 5&#8212;Balance Sheet Components </div></div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">(A) Other Current Assets </div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Other current assets at June&#160;30, 2021 and March&#160;31, 2021 consisted of the following (in thousands): </div></div></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 76%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px; text-indent: 0px;">
<tr style="font-size: 0px;">
<td style="width: 64%;"/>
<td style="width: 10%; vertical-align: bottom;"/>
<td/>
<td/>
<td/>
<td style="width: 10%; vertical-align: bottom;"/>
<td/>
<td/>
<td/> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 1pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">June&#160;30,&#160;2021</div></div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">March&#160;31,&#160;2021</div></div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td> </tr>
<tr style="font-size: 0px;">
<td style="width: 75%;"/>
<td style="width: 7%; vertical-align: bottom;"/>
<td/>
<td/>
<td/>
<td style="width: 6%; vertical-align: bottom;"/>
<td/>
<td/>
<td/> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top; width: 75%;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Prepaid expenses</div></div> </td>
<td style="vertical-align: bottom; width: 7%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">44,941</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 6%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">39,544</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; width: 75%;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Trade receivables, net</div></div> </td>
<td style="vertical-align: bottom; width: 7%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">3,416</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 6%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">11,222</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top; width: 75%;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Income tax receivable</div></div> </td>
<td style="vertical-align: bottom; width: 7%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">1,993</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 6%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">1,803</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-size: 0px;">
<td style="width: 75%;"/>
<td style="width: 7%; vertical-align: bottom;"/>
<td/>
<td/>
<td/>
<td style="width: 6%; vertical-align: bottom;"/>
<td/>
<td/>
<td/> </tr>
<tr style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; break-inside: avoid;">
<td style="vertical-align: top; background-color: rgb(255, 255, 255); width: 75%;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Other</div></div> </td>
<td style="vertical-align: bottom; background-color: rgb(255, 255, 255); width: 7%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(255, 255, 255);">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(255, 255, 255);;text-align:right;">7,815</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(255, 255, 255);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(255, 255, 255); width: 6%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(255, 255, 255);">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(255, 255, 255);;text-align:right;">1,681</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(255, 255, 255);">&#160;</td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; background-color: rgb(204, 238, 255); width: 75%;">&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255); width: 7%;">&#160;&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="background-color: rgb(204, 238, 255);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255); width: 6%;">&#160;&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="background-color: rgb(204, 238, 255);">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; background-color: rgb(204, 238, 255); width: 75%;"> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.26in; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Total other current assets</div></div> </td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255); width: 7%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);">$</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;">58,165</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255); width: 6%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);">$</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;">54,250</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);">&#160;</td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; background-color: rgb(255, 255, 255); width: 75%;">&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(255, 255, 255); width: 7%;">&#160;&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="background-color: rgb(255, 255, 255);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(255, 255, 255); width: 6%;">&#160;&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="background-color: rgb(255, 255, 255);">&#160;</td> </tr> </table>  <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"/> <div style="clear: both; max-height: 0px;"/> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div> <div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;;"><div style="font-weight:bold;display:inline;">(B) Accrued Expenses </div></div>  <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Accrued expenses at June&#160;30, 2021 and March&#160;31, 2021 consisted of the following (in thousands): </div></div></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 76%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px; text-indent: 0px;">
<tr style="font-size: 0px;">
<td style="width: 64%;"/>
<td style="width: 10%; vertical-align: bottom;"/>
<td/>
<td/>
<td/>
<td style="width: 10%; vertical-align: bottom;"/>
<td/>
<td/>
<td/> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 1pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">June&#160;30,&#160;2021</div></div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">March&#160;31,&#160;2021</div></div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td> </tr>
<tr style="font-size: 0px;">
<td style="width: 64%;"/>
<td style="width: 10%; vertical-align: bottom;"/>
<td/>
<td/>
<td/>
<td style="width: 10%; vertical-align: bottom;"/>
<td/>
<td/>
<td/> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top; width: 64%;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Research and development expenses</div></div> </td>
<td style="vertical-align: bottom; width: 10%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">28,347</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 10%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">20,755</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; width: 64%;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Compensation-related expenses</div></div> </td>
<td style="vertical-align: bottom; width: 10%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">15,242</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 10%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">38,552</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top; width: 64%;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Professional services expenses</div></div> </td>
<td style="vertical-align: bottom; width: 10%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">16,489</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 10%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">10,267</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; width: 64%;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Other general and administrative expenses</div></div> </td>
<td style="vertical-align: bottom; width: 10%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">13,710</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 10%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">7,362</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 64%;">&#160;</td>
<td style="vertical-align: bottom; width: 10%;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom; width: 10%;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top; width: 64%;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Total accrued expenses</div></div> </td>
<td style="vertical-align: bottom; width: 10%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">73,788</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 10%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">76,936</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 64%;">&#160;</td>
<td style="vertical-align: bottom; width: 10%;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom; width: 10%;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td> </tr> </table>  <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">(C) Other Current Liabilities </div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Other current liabilities at June&#160;30, 2021 and March&#160;31, 2021 consisted of the following (in thousands): </div></div></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 76%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px; text-indent: 0px;">
<tr style="font-size: 0px;">
<td style="width: 64%;"/>
<td style="width: 12%; vertical-align: bottom;"/>
<td/>
<td/>
<td/>
<td style="width: 12%; vertical-align: bottom;"/>
<td/>
<td/>
<td/> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 1pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">June&#160;30,&#160;2021</div></div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">March&#160;31,&#160;2021</div></div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td> </tr>
<tr style="font-size: 0px;">
<td style="width: 64%;"/>
<td style="width: 12%; vertical-align: bottom;"/>
<td/>
<td/>
<td/>
<td style="width: 12%; vertical-align: bottom;"/>
<td/>
<td/>
<td/> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top; width: 64%;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Deferred revenue</div></div> </td>
<td style="vertical-align: bottom; width: 12%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">3,777</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 12%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">5,918</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; width: 64%;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Income tax payable</div></div> </td>
<td style="vertical-align: bottom; width: 12%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">199</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 12%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">207</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top; width: 64%;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Other</div></div> </td>
<td style="vertical-align: bottom; width: 12%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">4,325</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 12%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">3,037</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 64%;">&#160;</td>
<td style="vertical-align: bottom; width: 12%;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom; width: 12%;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; width: 64%;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Total other current liabilities</div></div> </td>
<td style="vertical-align: bottom; width: 12%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">8,301</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 12%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">9,162</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 64%;">&#160;</td>
<td style="vertical-align: bottom; width: 12%;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom; width: 12%;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td> </tr> </table> <span></span>
</td>
<td class="text"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Note 7&#8212;Balance Sheet Components </div></div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">(A) Other Current Assets </div></div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Other current assets at March&#160;31, 2021 and 2020 consisted of the following (in thousands): </div></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 76%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="font-size: 0px;">
<td style="width: 62%;"/>
<td style="width: 11%; vertical-align: bottom;"/>
<td/>
<td/>
<td/>
<td style="width: 11%; vertical-align: bottom;"/>
<td/>
<td/>
<td/> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">March&#160;31,&#160;2021</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">March&#160;31,&#160;2020</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: bottom;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Prepaid expenses</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">$</td>
<td style="vertical-align: bottom;;text-align:right;">39,544</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">$</td>
<td style="vertical-align: bottom;;text-align:right;">16,344</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Receivables for value added tax (VAT) paid</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">807</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">5,978</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Note receivable</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">5,000</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Trade receivables, net</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">11,222</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">3,669</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Income tax receivable</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">1,803</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">632</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Other</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">874</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">2,140</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;">&#160;</td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Total other current assets</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">54,250</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">33,763</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;">&#160;</td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td> </tr> </table>  <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">(B) Accrued Expenses </div></div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Accrued expenses at March&#160;31, 2021 and 2020 consisted of the following (in thousands): </div></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 76%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="font-size: 0px;">
<td style="width: 62%;"/>
<td style="width: 11%; vertical-align: bottom;"/>
<td/>
<td/>
<td/>
<td style="width: 11%; vertical-align: bottom;"/>
<td/>
<td/>
<td/> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">March&#160;31,&#160;2021</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">March&#160;31,&#160;2020</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: bottom;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Research and development expenses</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">$</td>
<td style="vertical-align: bottom;;text-align:right;">20,755</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">$</td>
<td style="vertical-align: bottom;;text-align:right;">21,607</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Compensation-related expenses</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">38,552</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">29,113</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Professional services expenses</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">10,267</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">5,135</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Other general and administrative expenses</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">7,362</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">12,766</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;">&#160;</td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Total accrued expenses</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">76,936</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">68,621</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;">&#160;</td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td> </tr> </table>  <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">(C) Other Current Liabilities </div></div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Other current liabilities at March&#160;31, 2021 and 2020 consisted of the following (in thousands): </div></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 76%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="font-size: 0px;">
<td style="width: 62%;"/>
<td style="width: 13%; vertical-align: bottom;"/>
<td/>
<td/>
<td/>
<td style="width: 13%; vertical-align: bottom;"/>
<td/>
<td/>
<td/> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">March&#160;31,&#160;2021</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">March&#160;31,&#160;2020</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Deferred revenue</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">5,918</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">3,621</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Income tax payable</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">207</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">1,497</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Other</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">3,037</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">234</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;">&#160;</td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Total other current liabilities</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">9,162</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">5,352</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;">&#160;</td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td> </tr> </table>  <span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SupplementalBalanceSheetDisclosuresTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for supplemental balance sheet disclosures, including descriptions and amounts for assets, liabilities, and equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -URI http://asc.fasb.org/topic&amp;trid=2122208<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SupplementalBalanceSheetDisclosuresTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>84
<FILENAME>R14.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm139997755081224">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Long Term Debt and Loan Commitment<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2021</div></th>
<th class="th"><div>Mar. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtDisclosureAbstract', window );"><strong>Debt Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebtTextBlock', window );">Long Term Debt</a></td>
<td class="text"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Note 6&#8212;Long-Term Debt and Loan Commitment </div></div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">(A) Long-Term Debt </div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Long-term debt, net consists of the following (in thousands): </div></div></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 84%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px; text-indent: 0px;">
<tr style="font-size: 0px;">
<td style="width: 68%;"/>
<td style="width: 8%; vertical-align: bottom;"/>
<td/>
<td/>
<td/>
<td style="width: 8%; vertical-align: bottom;"/>
<td/>
<td/>
<td/> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 1pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">June&#160;30,&#160;2021</div></div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">March&#160;31,&#160;2021</div></div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td> </tr>
<tr style="font-size: 0px;">
<td style="width: 68%;"/>
<td style="width: 8%; vertical-align: bottom;"/>
<td/>
<td/>
<td/>
<td style="width: 8%; vertical-align: bottom;"/>
<td/>
<td/>
<td/> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top; width: 68%;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Principal amount</div></div> </td>
<td style="vertical-align: bottom; width: 8%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">195,200</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 8%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">170,100</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; width: 68%;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Exit fee / end of term charge</div></div> </td>
<td style="vertical-align: bottom; width: 8%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">5,000</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 8%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">1,390</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top; width: 68%;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Less: unamortized debt discount and issuance costs</div></div> </td>
<td style="vertical-align: bottom; width: 8%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(13,850</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom; width: 8%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(1,210</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 68%;">&#160;</td>
<td style="vertical-align: bottom; width: 8%;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom; width: 8%;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; width: 68%;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Total debt, net</div></div> </td>
<td style="vertical-align: bottom; width: 8%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">186,350</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 8%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">170,280</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top; width: 68%;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Less: current portion</div></div> </td>
<td style="vertical-align: bottom; width: 8%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 8%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 68%;">&#160;</td>
<td style="vertical-align: bottom; width: 8%;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom; width: 8%;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; width: 68%;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Total long-term debt, net</div></div> </td>
<td style="vertical-align: bottom; width: 8%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">186,350</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 8%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">170,280</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 68%;">&#160;</td>
<td style="vertical-align: bottom; width: 8%;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom; width: 8%;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td> </tr> </table>  <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt; margin-left: 2%;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Dermavant </div></div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">In May 2019, Dermavant entered into a loan and security agreement (the &#8220;Hercules Loan Agreement&#8221;) with Hercules Capital, Inc. (&#8220;Hercules&#8221;), pursuant to which Dermavant borrowed an aggregate of<div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">$</div>20.0<div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;million, which bore interest at a variable per annum rate at the greater of (i) </div>9.95<div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">% or (ii)&#160;the prime rate plus </div>4.45<div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">%. Dermavant was also obligated to pay an end of term charge of $</div>1.4<div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;million. Following the achievement of certain milestones, the term loan maturity was extended to June&#160;1, 2023 with interest-only monthly payments through December 2021. All amounts outstanding under the Hercules Loan Agreement were repaid in May 2021 using the proceeds from a $</div>40.0<div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;million senior secured credit facility (the &#8220;Credit Facility&#8221;) entered into by Dermavant and certain of its subsidiaries in May 2021 with XYQ Luxco S.A.R.L (&#8220;XYQ Luxco&#8221;), as lender, and U.S. Bank National Association, as collateral agent. The Credit Facility has a </div>five-year<div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"> maturity and bears an interest rate of </div>10.0<div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">% per annum. Interest is payable quarterly in arrears on the last day of each calendar quarter through the maturity date. A lump sum principal payment is due on the maturity date.&#160;</div><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Dermavant is also obligated to pay an exit fee of $5.0&#160;million. The exit fee can be reduced to $4.0&#160;million upon achievement of certain equity milestones defined in the agreement, which are not deemed likely as of June&#160;30, 2021. In connection with the </div></div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0px;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">funding of the Credit Facility, Dermavant issued a warrant to XYQ Luxco to purchase </div>1,199,072<div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"> common shares of Dermavant at an exercise price of $</div>0.01<div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"> per common share.</div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">In connection with Dermavant&#8217;s acquisition of tapinarof from GlaxoSmithKline Intellectual Property Development Ltd. and Glaxo Group Limited (collectively &#8220;GSK&#8221;) pursuant to an asset purchase agreement (the &#8220;GSK Agreement&#8221;), Dermavant and NovaQuest <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">Co-Investment</div> Fund VIII, L.P. (&#8220;NovaQuest&#8221;) entered into a funding agreement (the &#8220;NovaQuest Agreement&#8221;). Pursuant to the NovaQuest Agreement, Dermavant borrowed $100.0&#160;million in August 2018 and $17.5&#160;million in October 2018 in exchange for an obligation to make certain variable future payments calculated as a function of the achievement of regulatory and commercial milestones or events of termination. The aggregate maximum amount of regulatory milestone payments that Dermavant could be required to make under the NovaQuest Agreement is $440.6&#160;million, and the maximum aggregate amount of commercial milestone payments is $141.0&#160;million. In some circumstances, Dermavant may be able to offset certain of the regulatory milestone payments with up to $88.1&#160;million of the commercial milestone payments. At issuance, the Company concluded that certain features of the long-term debt would be considered derivatives that would require bifurcation. In lieu of bifurcating various features in the agreement, the Company has elected the fair value option for this financial instrument and will record the changes in the fair value within the statements of operations at the end of each reporting period. Direct costs and fees related to the debt issued under the NovaQuest Agreement were recognized in earnings. As of June&#160;30, 2021 and March&#160;31, 2021, the fair value of the debt was $155.2&#160;million and $150.1&#160;million, respectively. Refer to Note 11, &#8220;Fair Value Measurements&#8221; for additional details regarding the fair value measurement. </div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">(B) Loan Commitment </div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;">In May 2021, Dermavant, as seller, entered into a $160.0&#160;million revenue interest purchase and sale agreement (the &#8220;RIPSA&#8221;) for its investigational product tapinarof with XYQ Luxco, NovaQuest <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">Co-Investment</div> Fund XVII, L.P., an affiliate of NovaQuest Capital Management, LLC, and MAM Tapir Lender, LLC, an affiliate of Marathon Asset Management, L.P. (collectively, the &#8220;Purchasers&#8221;), together with U.S. Bank National Association, as collateral agent. Under the terms of the RIPSA, the Purchasers procured a capped single-digit revenue interest in net sales of tapinarof for all dermatological indications in the United States in exchange for $160.0&#160;million in committed funding to be paid to Dermavant, conditional based on the approval of tapinarof by the FDA. The agreement will be canceled if funding has not occurred by July 2023. Dermavant acquired the worldwide rights to tapinarof (other than with respect to certain rights in China) in August 2018 pursuant to the GSK Agreement. Dermavant intends to use the RIPSA proceeds for the payment of certain <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">one-time</div> milestone obligations that become payable upon the approval and commercialization of tapinarof for the treatment of psoriasis in the United States as well as for other general corporate purposes. </div> <span></span>
</td>
<td class="text"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Note 8&#8212;Long-Term Debt </div></div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">(A) Long-Term Debt </div></div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Long-term debt, net consists of the following (in thousands): </div></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 84%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="font-size: 0px;">
<td style="width: 66%;"/>
<td style="width: 9%; vertical-align: bottom;"/>
<td/>
<td/>
<td/>
<td style="width: 9%; vertical-align: bottom;"/>
<td/>
<td/>
<td/> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">March&#160;31,&#160;2021</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">March&#160;31,&#160;2020</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Principal amount</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">171,490</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">110,490</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Less: unamortized debt discount and issuance costs</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(1,210</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(1,898</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Total debt, net</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">170,280</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">108,592</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Less: current portion</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Total long-term debt, net</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">170,280</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">108,592</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;">&#160;</td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td> </tr> </table>  <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Dermavant </div></div></div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">In May 2019, Dermavant and certain of its subsidiaries entered into a loan and security agreement (the &#8220;Hercules Loan Agreement&#8221;) with Hercules Capital, Inc. (&#8220;Hercules&#8221;), pursuant to which Dermavant borrowed an aggregate of $20.0&#160;million which bears interest at a variable per annum rate at the greater of (i)&#160;9.95%&#160;or (ii)&#160;the prime rate plus 4.45%. Dermavant is obligated to pay an end of term charge of&#160;$1.4&#160;million with the debt maturing 36 months from closing, subject to extension with the achievement of a clinical milestone. Dermavant is obligated to make monthly payments of accrued interest for the first 15 months after closing (the &#8220;Interest-only Period&#8221;), followed by monthly installments of principal and interest through the maturity date, subject to extension upon certain milestone achievements. In January 2020, the Interest-only Period was extended through June 2021 upon Dermavant&#8217;s receipt of net proceeds from equity or debt financings, capital contributions, and proceeds from business development or similar transaction of at least $110.0&#160;million. In July 2020, the clinical milestone was achieved and the term loan maturity was extended to June&#160;1, 2023 and the Interest-only Period was further extended through December 2021. As of March&#160;31, 2021 and March&#160;31, 2020, an aggregate principal amount of $20.0&#160;million and end of term charge of $1.4&#160;million remained outstanding. In May 2021, Dermavant repaid all amounts outstanding under the Hercules Loan Agreement using the proceeds from the $40.0&#160;million Credit Facility entered into by Dermavant and certain of its subsidiaries in May 2021. Refer to Note 19, &#8220;Subsequent Events&#8221; for additional detail. </div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">In connection with Dermavant&#8217;s acquisition of tapinarof from GSK, Dermavant and NovaQuest <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">Co-Investment</div> Fund VIII, L.P. (&#8220;NovaQuest&#8221;) entered into a funding agreement (the &#8220;NovaQuest Agreement&#8221;). Pursuant to the NovaQuest Agreement, Dermavant borrowed $100.0&#160;million in August 2018 and $17.5&#160;million in October 2018 in exchange for an obligation to make certain variable future payments calculated as a function of the achievement of regulatory and commercial milestones or events of termination. The aggregate maximum amount of regulatory milestone payments that Dermavant could be required to make under the NovaQuest Agreement is $440.6&#160;million, and the maximum aggregate amount of commercial milestone payments is $141.0&#160;million. In some circumstances, Dermavant may be able to offset certain of the regulatory milestone payments with up to $88.1&#160;million of the commercial milestone payments. At issuance, the Company concluded that certain features of the long-term debt would be considered derivatives that would require bifurcation. In lieu of bifurcating various features in the agreement, the Company has elected the fair value option for this financial instrument and will record the changes in the fair value within the statements of operations at the end of each reporting period. Direct costs and fees related to the debt issued under the NovaQuest Agreement were recognized in earnings. As of March&#160;31, 2021 and 2020, the fair value of the debt was $150.1&#160;million and $89.1&#160;million, respectively. Refer to Note 15, &#8220;Fair Value Measurements&#8221; for additional details regarding the fair value measurement. </div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">(B) Debt Maturities </div></div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Annual maturities, including the end of term charge, of debt outstanding as of&#160;March&#160;31, 2021&#160;are as follows (in thousands). Long-term debt held by Dermavant for which the fair value option has been elected is excluded from the below as the repayment terms are variable. </div></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 68%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="font-size: 0px;">
<td style="width: 85%; font-family: &quot;Times New Roman&quot;;"/>
<td style="width: 6%; vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/>
<td style="font-family: &quot;Times New Roman&quot;;"/>
<td style="font-family: &quot;Times New Roman&quot;;"/>
<td style="font-family: &quot;Times New Roman&quot;;"/> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; white-space: nowrap;"> <div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt; border-bottom: 1pt solid rgb(0, 0, 0); display: table-cell; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">Years Ending March&#160;31,</div></div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">2022</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">3,129</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">2023</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">13,306</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">2024</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">4,955</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">2025</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">2026</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Thereafter</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Total</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">21,390</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;">&#160;</td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td> </tr> </table> <span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebtTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for long-term debt.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -URI http://asc.fasb.org/topic&amp;trid=2208564<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebtTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>85
<FILENAME>R15.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm139997750713016">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Shareholders' Equity and Redeemable Noncontrolling Interest<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2021</div></th>
<th class="th"><div>Mar. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityNoteDisclosureTextBlock', window );">Shareholders' Equity and Redeemable Noncontrolling Interest</a></td>
<td class="text"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt; text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Note 7&#8212;Shareholders&#8217; Equity and Redeemable Noncontrolling Interest </div></div></div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt; text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Business Combination Agreement </div></div></div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">On May&#160;1, 2021, the Company entered into a Business Combination Agreement (the &#8220;Business Combination Agreement&#8221;) with Montes Archimedes Acquisition Corporation (&#8220;MAAC&#8221;) and Rhine Merger Sub, Inc. (&#8220;Merger Sub&#8221;). MAAC was incorporated in Delaware on July&#160;6, 2020 and was formed as a blank check company for the purpose of effecting a merger, share exchange, asset acquisition, stock purchase, recapitalization, reorganization or similar business combination with one or more businesses. Pursuant to the Business Combination Agreement, and assuming a favorable vote by MAAC&#8217;s stockholders at a special meeting of MAAC&#8217;s stockholders convened for purposes of approving the transactions contemplated by the Business Combination Agreement (the &#8220;Business Combination&#8221;), and the satisfaction or waiver of all other closing conditions pursuant to the Business Combination Agreement, Merger Sub will merge with and into MAAC, with MAAC surviving the merger as the Company&#8217;s wholly owned subsidiary. </div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">For financial accounting and reporting purposes, MAAC will be treated as the acquired company. Accordingly, because MAAC does not represent a business for accounting purposes and its primary asset </div></div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">represents cash and cash equivalents, the Business Combination will be treated as an equity contribution in exchange for the issuance of RSL shares. The net assets of MAAC will be stated at historical cost, with no goodwill or other intangible assets recorded. RSL will be deemed both the accounting predecessor and the successor SEC registrant, which means that the Company&#8217;s financial statements for previous periods will be disclosed in the Company&#8217;s future periodic reports filed with the SEC. </div></div></div> <span></span>
</td>
<td class="text"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Note 10&#8212;Shareholders&#8217; Equity and Redeemable Noncontrolling Interest </div></div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">(A) Sumitomo Transaction Agreement and Roivant Equity Repurchase </div></div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">In December 2019, RSL and Sumitomo completed the transactions contemplated by the Sumitomo Transaction Agreement; see Note 5, &#8220;Sumitomo Transaction Agreement.&#8221; Pursuant to the Sumitomo Transaction Agreement, </div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">RSL issued 26,952,143 common shares to Sumitomo at closing at a price per share of $37.10 for allocated net proceeds of approximately $999.2&#160;million, after offering expenses incurred. In connection with the Sumitomo Closing Date, RSL&#8217;s board of directors approved a repurchase of up to $1.0&#160;billion of the Company&#8217;s equity securities using the proceeds received from Sumitomo. </div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">In February 2020, the Company launched <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">one-time</div> offers to purchase up to $1.0&#160;billion of issued and outstanding equity securities of the Company (the &#8220;Roivant Equity Repurchase&#8221;). The offers included (i) an offer to repurchase up to approximately 11.23% of the common stock held by each holder (and its affiliates) of the Company&#8217;s common stock as of December 26, 2019, at a price per share of $37.10 representing fair value of the common stock, (ii) an offer to purchase vested stock options whose fair market value (as determined as of December 27, 2019) was less than or equal to the fair market value of approximately 11.23% of the earliest-granted of such holder&#8217;s outstanding vested and unvested stock options, at a purchase price equal to such vested option&#8217;s fair market value, and (iii) an offer to holders of performance restricted stock units (&#8220;pRSUs&#8221;) to surrender 100% of their existing pRSUs in exchange for newly issued performance stock options and capped value appreciation rights. The offer to the holders of pRSUs included an offer by the Company to immediately purchase approximately 11.23% of the newly issued performance stock options and capped value appreciation rights for cash. The Company additionally entered into an agreement with the Company&#8217;s Founder to repurchase a portion of his common stock held and exchange his pRSUs for performance stock options and capped value appreciation rights. A summary of payments made during the year ended March&#160;31, 2020 relating to the purchase of equity securities by the Company is as follows (in thousands): </div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 68%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="font-size: 0px;">
<td style="width: 79%;"/>
<td style="width: 11%; vertical-align: bottom;"/>
<td/>
<td/>
<td/> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Cash&#160;Payment</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Common stock</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">950,722</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Other equity instruments</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">39,292</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;">&#160;</td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Total cash paid</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">990,014</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;">&#160;</td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td> </tr> </table>  <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">(B) Consolidated Vant Equity Transactions </div></div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Cytovant Sciences HK Limited </div></div></div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;">In March 2020, Cytovant Sciences HK Limited (&#8220;Cytovant&#8221;), a subsidiary of the Company, issued and sold 20,085,301 Series <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">A-1</div> preference shares at a purchase price of $<div style="letter-spacing: 0px; top: 0px;;display:inline;">1.17</div> per share to third party investors for aggregate net proceeds of $22.5&#160;million after deducting offering costs. The preferred stock is convertible into ordinary shares of Cytovant at any time at the option of the investor, or automatically upon a qualified initial public offering (&#8220;Qualified IPO&#8221;) as defined in the subscription agreement. If a Qualified IPO is not completed within five years of the initial investment, Series A preference shareholders can force a sale or liquidation of Cytovant. The Series <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">A-1</div> preference shares are classified as redeemable noncontrolling interest in the accompanying consolidated balance sheets and consolidated statements of shareholders&#8217; equity and redeemable noncontrolling interest as the Company can be obligated to repurchase the Series A-1 preference shares upon the occurrence of certain contingent events outside the Company&#8217;s control. No dividends shall accrue or be payable on the convertible and redeemable preferred stock unless otherwise determined by the board of directors of Cytovant. The Company did not accrete changes in the redemption value as of March&#160;31, 2021 as the Company considers the events leading to a redemption of the convertible and redeemable preferred stock as not probable. </div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Immunovant </div></div></div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">In September 2019, Immunovant Sciences Ltd. (&#8220;ISL&#8221;) entered into a share exchange agreement (the &#8220;Share Exchange Agreement&#8221;) with Health Sciences Acquisitions Corporation (&#8220;HSAC&#8221;), and in December 2019, ISL and HSAC completed the transactions contemplated by the Share Exchange Agreement (the &#8220;Business Combination&#8221;). At closing, HSAC acquired 100% of the issued and outstanding common shares of ISL in exchange for 42,080,376 shares of HSAC&#8217;s common stock issued to HSAC, ISL, and the shareholders of ISL (together, the &#8220;Sellers&#8221;) and 10,000 shares of HSAC Series A preferred shares issued to RSL. Additionally, as </div></div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>  <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">part of its initial public offering in May 2019, HSAC issued common stock warrants, which are classified in equity. Upon completion of the Business Combination, 11,500,000 warrants were outstanding for the purchase of <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">one-half</div> of one share of common stock (an aggregate of 5,750,000 common shares) at a price of $11.50 per whole share. Upon closing, ISL became a wholly owned subsidiary of HSAC and HSAC was renamed &#8220;Immunovant, Inc.&#8221; The Business Combination was accounted for as a reverse recapitalization and HSAC was treated as the &#8220;acquired&#8221; company for accounting purposes. Accordingly, for accounting purposes, the Business Combination was treated as the equivalent of ISL issuing equity for the net assets of HSAC, accompanied by a recapitalization. Immunovant, Inc. received $111.0&#160;million in cash as a result of the Business Combination, consisting of the funds held in HSAC&#8217;s trust account. The proceeds included $5.1&#160;million related to common shares purchased by RSL. </div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">The sellers were entitled to receive an additional 20,000,000 shares of Immunovant, Inc.&#8217;s common stock (the &#8220;Earnout Shares&#8221;) if the volume-weighted average price of Immunovant, Inc.&#8217;s shares equaled or exceeded the following prices for any 20 trading days within any 30 <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">trading-day</div> period (the &#8220;Trading Period&#8221;) following the closing of the Business Combination: </div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt; margin-left: 4%;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">(i) during any Trading Period prior to March&#160;31, 2023, 10,000,000 Earnout Shares upon the achievement of a volume-weighted average price of at least $17.50 per share; and </div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt; margin-left: 4%;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">(ii) during any Trading Period prior to March&#160;31, 2025, 10,000,000 Earnout Shares upon the achievement of a volume-weighted average price of at least $31.50 per share. </div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">In May 2020 and September 2020, Immunovant, Inc. achieved the first earnout milestone and second earnout milestone, respectively, under the Share Exchange Agreement and, as a result, all of the 20,000,000 earnout shares of Immunovant, Inc.&#8217;s common stock were issued to former stockholders of ISL, including 17,547,938 shares of common stock issued to RSL. In addition, upon the achievement of the first earnout milestone and second earnout milestone and pursuant to the restricted stock agreement entered into between HSAC and Health Sciences Holdings, LLC (the &#8220;Sponsor&#8221;), all of the 1,800,000 shares of the Sponsor&#8217;s restricted shares vested and are no longer subject to forfeiture. </div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Immediately prior to the closing of the Business Combination, as described above, ISL&#8217;s convertible promissory notes were automatically converted into an aggregate of 7,156,495 common shares of ISL, which were then exchanged for an aggregate of 3,499,995 shares of Immunovant, Inc. common stock upon the closing of transactions contemplated by the Share Exchange Agreement. The conversion of ISL&#8217;s convertible promissory notes resulted in an increase to equity by $<div style="letter-spacing: 0px; top: 0px;;display:inline;">35.6&#160;</div>million, the carrying amount of the convertible promissory notes. The conversion included a convertible promissory note held by RSL for $2.5&#160;million. </div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">In April 2020, Immunovant, Inc. completed an underwritten public offering of 9,613,365 shares of its common stock, including 1,034,483 shares of common stock purchased by RSL, at a price of $14.50 per share for net proceeds to Immunovant, Inc. of approximately $131.0&#160;million, after deducting underwriting discounts and commissions and offering expenses. The proceeds included $15.0&#160;million received from RSL. </div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">In May 2020, Immunovant, Inc.&#8217;s 11,500,000 outstanding warrants became exercisable for an aggregate of 5,750,000 shares of Immunovant, Inc.&#8217;s common stock at a price of $11.50 per share. An aggregate of 11,438,290 outstanding warrants were exercised for an aggregate of 5,719,145 shares of Immunovant, Inc.&#8217;s common stock at a price of $11.50 per share, for net proceeds of approximately $65.8&#160;million. The remaining 61,710 warrants were cancelled. </div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">In September 2020, Immunovant, Inc. completed an underwritten public offering of 6,060,606 shares of its common stock, including 380,000 shares of common stock purchased by RSL, at a price of $33.00 per share for net proceeds to Immunovant, Inc. of approximately $188.1&#160;million, after deducting underwriting discounts and commissions and offering expenses. The proceeds included $12.5&#160;million received from RSL. </div></div>  <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Sinovant </div></div></div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Sinovant, a subsidiary of the Company, previously issued and sold preferred stock convertible into ordinary shares of Sinovant at any time at the option of the investors or automatically upon a qualified initial public offering (&#8220;Qualified IPO&#8221;) as defined in the subscription agreement relating to the sale of the preferred stock. The convertible preferred stock was redeemable at the option of the investor if a Qualified IPO was not completed within five years of the initial investment and was payable in cash equal to the investment amount plus an annualized return of 12%. As such events are not within the control of the Company, the preferred stock was previously classified as redeemable noncontrolling interest in the accompanying consolidated balance sheets and consolidated statements of shareholders&#8217; equity and redeemable noncontrolling interest. No dividends accrued or were payable on the convertible preferred stock. In January 2020, Sinovant&#8217;s parent company, Roivant China Holdings Ltd. (&#8220;RCHL&#8221;), purchased all preferred stock of Sinovant held by third parties at a purchase price of $12.26 per preferred share for an aggregate purchase price of $132.9&#160;million. Consideration paid in excess of the carrying value for the repurchase of redeemable noncontrolling interest of $77.8&#160;million is considered a deemed dividend. See Note 18, &#8220;Earnings per Common Share&#8221; for resulting impact to earnings per share. </div></div> <span></span>
</td>
</tr>
</table>
<div style="display: none;"><table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityNoteDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for shareholders' equity comprised of portions attributable to the parent entity and noncontrolling interest, including other comprehensive income. Includes, but is not limited to, balances of common stock, preferred stock, additional paid-in capital, other capital and retained earnings, accumulated balance for each classification of other comprehensive income and amount of comprehensive income.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=SL123496158-112644<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=SL123496158-112644<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 14<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=SL123496171-112644<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 14<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=SL123496171-112644<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=SL123496189-112644<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (g)<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=SL123496158-112644<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -URI http://asc.fasb.org/topic&amp;trid=2208762<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=SL123496189-112644<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (h)<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=SL123496158-112644<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=SL123496171-112644<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=SL123496189-112644<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 16<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=SL123496180-112644<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (i)<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=SL123496158-112644<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(e)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityNoteDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table></div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>86
<FILENAME>R16.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm139997755920984">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Share-Based Compensation<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2021</div></th>
<th class="th"><div>Mar. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract', window );"><strong>Share-based Payment Arrangement [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock', window );">Share-Based Compensation</a></td>
<td class="text"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Note 8&#8212;Share-Based Compensation </div></div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">(A) RSL 2015 Equity Incentive Plan </div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">As of June&#160;30, 2021, 22,800,000 of the Company&#8217;s common shares (the &#8220;Share Reserve&#8221;) are reserved for issuance under the RSL Amended and Restated 2015 Equity Incentive Plan (the &#8220;RSL 2015 EIP&#8221;). At June&#160;30, 2021, a total of 786,125 common shares are available for future grants under the RSL 2015 EIP. The Company&#8217;s employees, directors, and consultants are eligible to receive nonstatutory and incentive stock options, stock appreciation rights, restricted stock awards, restricted stock unit awards, and other stock awards under the RSL 2015 EIP. </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">As of June&#160;30, 2021, an aggregate of 26,558,238 of the Company&#8217;s common shares (the &#8220;Special Reserve&#8221;) are reserved for the granting under RSL 2015 EIP of performance stock options (&#8220;Performance Options&#8221;) and capped value appreciation rights (&#8220;CVARs&#8221;) to the Company&#8217;s employees, directors and consultants. At June&#160;30, 2021, there are no common shares available for future grant under the Special Reserve. </div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt; margin-left: 2%;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Stock Options </div></div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">During the three months ended June&#160;30, 2021 and 2020, the Company recorded share-based compensation expense related to stock options issued under the RSL 2015 EIP to employees and directors of approximately $10.3&#160;million and $7.8&#160;million, respectively, and was included in research and development and general and administrative expenses in the accompanying condensed consolidated statements of operations. </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">A summary of stock option activity and data under the RSL 2015 EIP for the three months ended June&#160;30, 2021 is as follows: </div></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;width:76%;">
<tr style="font-size: 0px;">
<td style="width: 65%;"/>
<td style="width: 8%; vertical-align: bottom;"/>
<td/>
<td/>
<td/>
<td style="width: 8%; vertical-align: bottom;"/>
<td/>
<td/>
<td/></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Number&#160;of<br/> Stock<br/> Options</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="margin-top: 0px; margin-bottom: 0px; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Weighted&#160;</div></div></div><div style="margin-top: 0px; margin-bottom: 0px; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Average<br/> Exercise<div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div>Price</div></div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top; width: 65%;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Stock options outstanding at March&#160;31, 2021</div></div></td>
<td style="vertical-align: bottom; width: 8%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">9,389,371</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 8%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">26.61</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; width: 65%;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Granted</div></div></td>
<td style="vertical-align: bottom; width: 8%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">3,798,605</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 8%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">29.26</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top; width: 65%;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Forfeited</div></div></td>
<td style="vertical-align: bottom; width: 8%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(106,428</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom; width: 8%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">30.27</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 65%;">&#160;</td>
<td style="vertical-align: bottom; width: 8%;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom; width: 8%;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; width: 65%;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Stock options outstanding at June&#160;30, 2021</div></div></td>
<td style="vertical-align: bottom; width: 8%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">13,081,548</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 8%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">27.35</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 65%;">&#160;</td>
<td style="vertical-align: bottom; width: 8%;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom; width: 8%;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td></tr></table>  <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt; margin-left: 2%;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Restricted Stock Units </div></div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Restricted stock units will generally vest upon the achievement of both time-based service requirements and liquidity requirements on or before the grant expiration date. Certain restricted stock units have also been granted that will vest upon the achievement of development milestones and liquidity requirements. As of June&#160;30, 2021, the liquidity event requirement had not been met and was deemed not probable of being met. During the three months ended June&#160;30, 2021 and 2020, the Company recorded no share-based compensation expense related to these restricted stock units. The Company will recognize the expense upon achievement of both the time-based service requirement and liquidity requirements through the requisite </div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0in;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">service period.</div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">A summary of restricted stock units under the RSL 2015 EIP is as follows: </div></div></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;width:68%;">
<tr style="font-size: 0px;">
<td style="width: 77%;"/>
<td style="width: 10%; vertical-align: bottom;"/>
<td/>
<td/>
<td/></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Number&#160;of<br/> Restricted&#160;Stock<br/> Units</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top; width: 77%;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">Non-vested</div> balance at March&#160;31, 2021</div></td>
<td style="vertical-align: bottom; width: 10%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">2,292,738</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; width: 77%;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Granted</div></div></td>
<td style="vertical-align: bottom; width: 10%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">5,939,340</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top; width: 77%;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Forfeited</div></div></td>
<td style="vertical-align: bottom; width: 10%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(119,285</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 77%;">&#160;</td>
<td style="vertical-align: bottom; width: 10%;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; width: 77%;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">Non-vested</div> balance at June&#160;30, 2021</div></td>
<td style="vertical-align: bottom; width: 10%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">8,112,793</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; width: 77%;">&#160;</td>
<td style="vertical-align: bottom; width: 10%;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td></tr></table>  Performance OptionsPerformance Options will vest upon the achievement of both time-based service requirements and liquidity requirements on or before the grant expiration date of March&#160;31, 2026. As of June&#160;30, 2021, the liquidity event requirement had not been met and was deemed not probable of being met. During the three months ended June&#160;30, 2021 and 2020, the Company recorded no share-based compensation expense related to these Performance Options. The Company will recognize the expense upon achievement of both the time-based service requirement and liquidity requirements through the requisite service period. <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">A summary of Performance Option activity and data under the RSL 2015 EIP for the three months ended June&#160;30, 2021 is as follows: </div></div></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 84%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px; text-indent: 0px;">
<tr style="font-size: 0px;">
<td style="width: 70%;"/>
<td style="width: 6%; vertical-align: bottom;"/>
<td/>
<td/>
<td/>
<td style="width: 6%; vertical-align: bottom;"/>
<td/>
<td/>
<td/> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 1pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Number of<br/> Performance<br/> Options</div></div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Weighted<br/> Average<br/> Exercise&#160;Price</div></div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td> </tr>
<tr style="font-size: 0px;">
<td style="width: 70%;"/>
<td style="width: 6%; vertical-align: bottom;"/>
<td/>
<td/>
<td/>
<td style="width: 6%; vertical-align: bottom;"/>
<td/>
<td/>
<td/> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top; width: 70%;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Performance Options outstanding at March&#160;31, 2021</div></div> </td>
<td style="vertical-align: bottom; width: 6%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">14,425,663</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 6%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">38.93</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; width: 70%;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Granted</div></div> </td>
<td style="vertical-align: bottom; width: 6%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 6%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top; width: 70%;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Forfeited</div></div> </td>
<td style="vertical-align: bottom; width: 6%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 6%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 70%;">&#160;</td>
<td style="vertical-align: bottom; width: 6%;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom; width: 6%;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; width: 70%;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Performance Options outstanding at June&#160;30, 2021</div></div> </td>
<td style="vertical-align: bottom; width: 6%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">14,425,663</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 6%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">38.93</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 70%;">&#160;</td>
<td style="vertical-align: bottom; width: 6%;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom; width: 6%;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td> </tr> </table>  <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt; margin-left: 2%;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">CVARs </div></div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">CVARs will vest upon the achievement of both time-based service requirements and liquidity requirements on or before the grant expiration date of March&#160;31, 2026. At settlement, each CVAR pays the excess in shares of (a)&#160;the lesser of (i)&#160;the fair market value of a common share as of the settlement date or (ii)&#160;the cap of $<div style="letter-spacing: 0px; top: 0px;;display:inline;">37.10</div>, over (b)&#160;the hurdle price of either $<div style="letter-spacing: 0px; top: 0px;;display:inline;">18.70 </div>or $<div style="letter-spacing: 0px; top: 0px;;display:inline;">33.63</div>, as applicable to each grant. As of June&#160;30, 2021, the liquidity event requirement had not been met and was deemed not probable of being met. During the three months ended June&#160;30, 2021 and 2020, the Company recorded no share-based compensation expense related to these CVARs. The Company will recognize the expense upon achievement of both the time-based service requirement and liquidity requirements through the requisite service period<div style="letter-spacing: 0px; top: 0px;;display:inline;">.</div></div></div>  <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">A summary of CVARs under the RSL 2015 EIP is as follows: </div></div></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 68%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px; text-indent: 0px;">
<tr style="font-size: 0px;">
<td style="width: 81%;"/>
<td style="width: 4%; vertical-align: bottom;"/>
<td/>
<td/>
<td/> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 1pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Number of<br/> CVARs</div></div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td> </tr>
<tr style="font-size: 0px;">
<td style="width: 81%;"/>
<td style="width: 4%; vertical-align: bottom;"/>
<td/>
<td/>
<td/> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top; width: 81%;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">Non-vested</div> balance at March&#160;31, 2021</div> </td>
<td style="vertical-align: bottom; width: 4%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">11,088,658</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; width: 81%;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Granted</div></div> </td>
<td style="vertical-align: bottom; width: 4%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top; width: 81%;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Forfeited</div></div> </td>
<td style="vertical-align: bottom; width: 4%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 81%;">&#160;</td>
<td style="vertical-align: bottom; width: 4%;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; width: 81%;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">Non-vested</div> balance at June&#160;30, 2021</div> </td>
<td style="vertical-align: bottom; width: 4%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">11,088,658</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; width: 81%;">&#160;</td>
<td style="vertical-align: bottom; width: 4%;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td> </tr> </table>  <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">(B) RSL 2015 Restricted Stock Unit Plan </div></div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Under the Amended and Restated RSL 2015 Restricted Stock Unit Plan (the &#8220;pRSU Plan&#8221;), as of June&#160;30, 2021, there are 200,000 of the Company&#8217;s common shares reserved for the granting under the pRSU Plan of restricted stock units (&#8220;Performance RSUs&#8221;) to the Company&#8217;s employees, officers, directors and consultants. The Performance RSUs expire eight years after the date of grant. At June&#160;30, 2021, there are no common shares available for future grants under this plan.&#160;</div></div>  <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">A summary of Performance RSU activity under the pRSU Plan is as follows: </div></div></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 68%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px; text-indent: 0px;">
<tr style="font-size: 0px;">
<td style="width: 81%;"/>
<td style="width: 8%; vertical-align: bottom;"/>
<td/>
<td/>
<td/> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 1pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Number of<br/> Performance<br/> RSUs</div></div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td> </tr>
<tr style="font-size: 0px;">
<td style="width: 85%;"/>
<td style="width: 6%; vertical-align: bottom;"/>
<td/>
<td/>
<td/> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">Non-vested</div> balance at March&#160;31, 2021</div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">200,000</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; break-inside: avoid;">
<td style="vertical-align: top; background-color: rgb(255, 255, 255);"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Granted</div></div> </td>
<td style="vertical-align: bottom; background-color: rgb(255, 255, 255);">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(255, 255, 255);">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(255, 255, 255);;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(255, 255, 255);">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; background-color: rgb(204, 238, 255);"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Forfeited</div></div> </td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255);">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);">&#160;</td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; background-color: rgb(255, 255, 255);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(255, 255, 255);">&#160;&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="background-color: rgb(255, 255, 255);">&#160;</td> </tr>
<tr style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; break-inside: avoid;">
<td style="vertical-align: top; background-color: rgb(255, 255, 255);"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">Non-vested</div> balance at June&#160;30, 2021</div> </td>
<td style="vertical-align: bottom; background-color: rgb(255, 255, 255);">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(255, 255, 255);">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(255, 255, 255);;text-align:right;">200,000</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(255, 255, 255);">&#160;</td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; background-color: rgb(255, 255, 255);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(255, 255, 255);">&#160;&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="background-color: rgb(255, 255, 255);">&#160;</td> </tr> </table> These Performance RSUs will vest to the extent certain performance criteria are achieved and certain liquidity conditions are satisfied within specified years of the grant date, provided that the recipient has provided continued service through such date. As of June&#160;30, 2021, the performance conditions had not been met and were deemed not probable of being met. During the three months ended June&#160;30, 2021 and 2020, the Company recorded no share-based compensation expense related to these Performance RSUs. The Company will recognize the expense upon achievement of the performance and liquidity conditions through the requisite service period. <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">(C) RSL Restricted Common Stock </div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">A summary of RSL restricted common stock activity as of June&#160;30, 2021 is as follows: </div></div></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 68%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px; text-indent: 0px;">
<tr style="font-size: 0px;">
<td style="width: 78%;"/>
<td style="width: 11%; vertical-align: bottom;"/>
<td/>
<td/>
<td/> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 1pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Number of<br/> Restricted<br/> Common&#160;Stock</div></div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td> </tr>
<tr style="font-size: 0px;">
<td style="width: 83%;"/>
<td style="width: 8%; vertical-align: bottom;"/>
<td/>
<td/>
<td/> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">Non-vested</div> balance at March&#160;31, 2021</div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">587,824</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Granted</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Forfeited</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">Non-vested</div> balance at June&#160;30, 2021</div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">587,824</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td> </tr> </table>  <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">For the three months ended June&#160;30, 2021, the Company recorded share-based compensation expense of $0.8&#160;million in relation to the RSL restricted common stock. The RSL restricted common stock will vest upon the achievement of time-based service requirements. </div></div>  <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">(D) Subsidiary Equity Incentive Plans </div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;">Certain wholly owned and majority-owned or controlled subsidiaries of RSL adopt their own equity incentive plan (&#8220;EIP&#8221;). Each EIP is generally structured so that the applicable subsidiary, and its affiliates&#8217; employees, directors, officers and consultants are eligible to receive <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-qualified</div> and incentive stock options, stock appreciation rights, restricted share awards, restricted stock unit awards, and other share awards under their respective EIP. Standard option grants have time-based vesting requirements, generally vesting over a period of four years with a contractual term of ten years. Such time-based stock options use the Black-Scholes option pricing model. The grant date fair value of awards subject to market conditions is estimated using a Monte Carlo valuation model. For the three months ended June&#160;31, 2021 and 2020, the Company recorded share-based compensation expense of $8.2&#160;million and $6.5&#160;million, respectively, in relation to subsidiary EIPs. </div> (E) Share-Based Compensation Expense <div style="text-indent: 4%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt; padding-top: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Share-based compensation expense was as follows (in thousands): </div></div></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0px; padding-top: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 76%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px; text-indent: 0px;">
<tr style="font-size: 0px;">
<td style="width: 74%;"/>
<td style="width: 5%; vertical-align: bottom;"/>
<td/>
<td/>
<td/>
<td style="width: 5%; vertical-align: bottom;"/>
<td/>
<td/>
<td/> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 1pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td colspan="6" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Three&#160;Months&#160;Ended<br/> June&#160;30,</div></div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 1pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2021</div></div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2020</div></div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top; font-size: 10pt;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; padding-top: 0pt; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Share-based compensation expense recognized as:</div></div></div> </td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td> </tr>
<tr style="font-size: 0px;">
<td style="width: 80%;"/>
<td style="width: 4%; vertical-align: bottom;"/>
<td/>
<td/>
<td/>
<td style="width: 4%; vertical-align: bottom;"/>
<td/>
<td/>
<td/> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; padding-top: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">R&amp;D expenses</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">1,615</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">1,119</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; padding-top: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">G&amp;A expenses</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">17,654</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">13,159</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); padding-top: 0pt; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); padding-top: 0pt; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); padding-top: 0pt; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); padding-top: 0pt; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; padding-top: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Total</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">19,269</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">14,278</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); padding-top: 0pt; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); padding-top: 0pt; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); padding-top: 0pt; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); padding-top: 0pt; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td> </tr> </table> <div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px; text-indent: 0px;;display:inline;">The classification of share-based compensation expense between R&amp;D and G&amp;A expenses in the accompanying condensed consolidated statements of operations is consistent with the classification of grantee&#8217;s salary expense.</div></div><span></span>
</td>
<td class="text"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Note 11&#8212;Share-Based Compensation </div></div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">(A) RSL 2015 Equity Incentive Plan </div></div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">As of March&#160;31, 2021, 22,800,000 of the Company&#8217;s common shares (the &#8220;Share Reserve&#8221;) are reserved for issuance under the RSL Amended and Restated 2015 Equity Incentive Plan (the &#8220;RSL 2015 EIP&#8221;). At March&#160;31, 2021, a total of 10,296,392 common shares are available for future grants under the RSL 2015 EIP. The Company&#8217;s employees, directors, and consultants are eligible to receive nonstatutory and incentive stock options, stock appreciation rights, restricted stock awards, restricted stock unit awards, and other stock awards under the RSL 2015 EIP. </div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">As of March&#160;31, 2021, an aggregate of 26,558,238 of the Company&#8217;s common shares (the &#8220;Special Reserve&#8221;) were reserved for the granting under RSL 2015 EIP of performance stock options (&#8220;Performance Options&#8221;) and capped value appreciation rights (&#8220;CVARs&#8221;) to the Company&#8217;s employees, directors and consultants. At March&#160;31, 2021, there are no common shares available for future grant under the Special Reserve. </div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Stock Options </div></div></div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">For the years ended March&#160;31, 2021 and 2020, the Company recorded share-based compensation expense related to stock options issued under the RSL 2015 EIP to employees and directors of approximately $32.3&#160;million and $31.8&#160;million, respectively, and was included in research and development and general and administrative expenses in the accompanying consolidated statements of operations. </div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">At March&#160;31, 2021, total unrecognized compensation expense related to <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-vested</div> stock options was approximately $70.8&#160;million and is expected to be recognized over the remaining weighted-average service period of 2.96 years. </div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The Company estimated the fair value of each stock option on the date of grant using the Black-Scholes closed form option-pricing model applying the weighted average assumptions in the following table. </div></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 76%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="font-size: 0px;">
<td style="width: 73%;"/>
<td style="width: 9%; vertical-align: bottom;"/>
<td/>
<td/>
<td/>
<td style="width: 8%; vertical-align: bottom;"/>
<td/>
<td/>
<td/> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;&#160;</td>
<td colspan="6" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Years&#160;Ended&#160;March&#160;31,</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 1pt;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Assumptions</div></div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;&#160;2021&#160;&#160;</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;&#160;2020&#160;&#160;</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Expected stock price volatility</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">74.84</td>
<td style="vertical-align: bottom; white-space: nowrap;">%&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">66.47</td>
<td style="vertical-align: bottom; white-space: nowrap;">%&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Expected risk free interest rate</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">0.43</td>
<td style="vertical-align: bottom; white-space: nowrap;">%&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">2.27</td>
<td style="vertical-align: bottom; white-space: nowrap;">%&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Expected term, in years</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">6.25</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">6.72</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Expected dividend yield</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">%&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">%&#160;</td> </tr> </table>  <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">A summary of stock option activity and data under the RSL 2015 EIP for the year ended March&#160;31, 2021 is as follows: </div></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 92%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="font-size: 0px;">
<td style="width: 48%;"/>
<td style="width: 7%; vertical-align: bottom;"/>
<td/>
<td/>
<td/>
<td style="width: 7%; vertical-align: bottom;"/>
<td/>
<td/>
<td/>
<td style="width: 7%; vertical-align: bottom;"/>
<td/>
<td/>
<td/>
<td style="width: 7%; vertical-align: bottom;"/>
<td/>
<td/>
<td/> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Number of<br/> Stock<br/> Options</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Weighted<br/> Average<br/> Exercise<br/> Price</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Weighted<br/> Average Grant<br/> Date&#160;Fair&#160;Value</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Weighted<br/> Average<br/> Remaining<br/> Contractual&#160;Life</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Stock options outstanding at March&#160;31, 2020</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">8,176,814</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">24.52</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">16.53</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">7.93</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Granted</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">1,482,604</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">38.71</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">25.37</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Forfeited/Canceled</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(270,047</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">29.89</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">19.85</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Stock options outstanding at March&#160;31, 2021</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">9,389,371</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">26.61</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">17.90</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">7.26</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Stock options exercisable at March&#160;31, 2021</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">5,533,848</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">21.52</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">14.95</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">6.49</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td> </tr> </table>  <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">At March&#160;31, 2021 and 2020, there were 5,533,848 and 4,123,953 vested stock options, respectively. Additional information regarding stock options is set forth below (in thousands, except per share data). </div></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 84%; font-family: &quot;Times New Roman&quot;; font-size: 8pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="font-size: 0px;">
<td style="width: 78%;"/>
<td style="width: 4%; vertical-align: bottom;"/>
<td/>
<td/>
<td/>
<td style="width: 4%; vertical-align: bottom;"/>
<td/>
<td/>
<td/> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;&#160;</td>
<td colspan="6" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Years&#160;Ended&#160;March&#160;31,</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2021</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2020</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Grant date fair value of stock options vested</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">25,711</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">33,789</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Weighted-average grant date fair value per share of stock options granted</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">25.37</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">20.63</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;">&#160;</td> </tr> </table>  <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Restricted Stock Units </div></div></div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;">Restricted stock units will vest upon the achievement of both time-based service requirements and liquidity requirements on or before the grant expiration date. Restricted stock units expire eight years after the date of grant. During the year ended March&#160;31, 2021, the Company recorded no share-based compensation expense related to these restricted stock units as the liquidity event requirement had not been met and was deemed not probable of being met. At March&#160;31, 2021, there was approximately $83.8&#160;million of unrecognized compensation expense related to <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-vested</div> restricted stock units. The Company will recognize the expense upon achievement of both the time-based service requirement and liquidity requirements through the requisite service period. </div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">A summary of restricted stock units under the RSL 2015 EIP is as follows: </div></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 76%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="font-size: 0px;">
<td style="width: 58%;"/>
<td style="width: 12%; vertical-align: bottom;"/>
<td/>
<td/>
<td/>
<td style="width: 12%; vertical-align: bottom;"/>
<td/>
<td/>
<td/> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Number of<br/> Restricted&#160;Stock<br/> Units</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Weighted&#160;Average<br/> Grant Date Fair<br/> Value</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">Non-vested</div> balance at March&#160;31, 2020</div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">1,008,175</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">32.50</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Granted</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">1,454,199</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">39.19</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Forfeited</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(169,636</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">36.36</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;">&#160;</td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">Non-vested</div> balance at March&#160;31, 2021</div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">2,292,738</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">36.53</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;">&#160;</td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td> </tr> </table>  <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Performance Options </div></div></div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;">Performance Options will vest upon the achievement of both time-based service requirements and liquidity requirements on or before the grant expiration date of March&#160;31, 2026. During the year ended March&#160;31, 2021, the Company recorded no share-based compensation expense related to these Performance Options as the liquidity event requirement had not been met and was deemed not probable of being met. At March&#160;31, 2021, there was approximately $337.8&#160;million of unrecognized compensation expense related to <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-vested</div> </div>  <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Performance Options. The Company will recognize the expense upon achievement of both the time-based service requirement and liquidity requirements through the requisite service period. </div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The Company estimated the fair value of each Performance Option on the date of grant using the Black-Scholes closed form option-pricing model applying the weighted average assumptions in the following table. </div></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 68%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="font-size: 0px;">
<td style="width: 70%;"/>
<td style="width: 22%; vertical-align: bottom;"/>
<td/>
<td/>
<td/> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Year&#160;Ended&#160;March&#160;31,</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 1pt;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Assumptions</div></div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2020</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Expected stock price volatility</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">73.60</td>
<td style="vertical-align: bottom; white-space: nowrap;">%&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Expected risk free interest rate</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">0.62</td>
<td style="vertical-align: bottom; white-space: nowrap;">%&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Expected term</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">6 years</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Expected dividend yield</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">%&#160;</td> </tr> </table>  <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">A summary of Performance Option activity and data under the RSL 2015 EIP for the year ended March&#160;31, 2021 is as follows: </div></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 92%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="font-size: 0px;">
<td style="width: 76%;"/>
<td style="width: 4%; vertical-align: bottom;"/>
<td/>
<td/>
<td/>
<td style="width: 4%; vertical-align: bottom;"/>
<td/>
<td/>
<td/>
<td style="width: 4%; vertical-align: bottom;"/>
<td/>
<td/>
<td/>
<td style="width: 4%; vertical-align: bottom;"/>
<td/>
<td/>
<td/> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Number of<br/> Options</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Weighted<br/> Average<br/> Exercise&#160;Price</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Weighted<br/> Average Grant<br/> Date&#160;Fair&#160;Value</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Weighted<br/> Average<br/> Remaining<br/> Contractual&#160;Life</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Performance Options outstanding at March&#160;31, 2020</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">14,518,870</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">38.97</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">23.78</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">6.00</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Granted</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Forfeited</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(93,207</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">46.38</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">22.18</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Performance Options outstanding at March&#160;31, 2021</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">14,425,663</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">38.93</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">23.42</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">5.00</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td> </tr> </table>  <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">No Performance Options were exercisable at March&#160;31, 2021. </div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">CVARs </div></div></div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;">CVARs will vest upon the achievement of both time-based service requirements and liquidity requirements on or before the grant expiration date of March 31, 2026. At settlement, each CVAR pays in common shares the excess of (a) the lesser of (i) the fair market value of a common share as of the settlement date or (ii) the cap of $37.10, over (b) the hurdle price of either $18.70 or $33.63, as applicable to each grant. During the year ended March&#160;31, 2021, the Company recorded no share-based compensation expense related to these CVARs as the liquidity event requirement had not been met and was deemed not probable of being met. At March&#160;31, 2021, there was approximately $23.0&#160;million of unrecognized compensation expense related to <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-vested</div> CVARs. The Company will recognize the expense upon achievement of both the time-based service requirement and liquidity requirements through the requisite service period. </div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">A summary of CVARs under the RSL 2015 EIP is as follows: </div></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 76%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="font-size: 0px;">
<td style="width: 56%;"/>
<td style="width: 13%; vertical-align: bottom;"/>
<td/>
<td/>
<td/>
<td style="width: 13%; vertical-align: bottom;"/>
<td/>
<td/>
<td/> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Number&#160;of&#160;CVARs</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Weighted&#160;Average<br/> Grant Date Fair<br/> Value</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">Non-vested</div> balance at March&#160;31, 2020</div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">11,088,658</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">2.07</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Granted</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Forfeited</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;">&#160;</td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">Non-vested</div> balance at March&#160;31, 2021</div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">11,088,658</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">2.07</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;">&#160;</td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td> </tr> </table>   <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">(B) RSL 2015 Restricted Stock Unit Plan </div></div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Under the Amended and Restated RSL 2015 Restricted Stock Unit Plan (the &#8220;pRSU Plan&#8221;), as of March&#160;31, 2021, there are 200,000 of the Company&#8217;s common shares reserved for issuance in connection with pRSUs that may be granted to employees, officers, directors and consultants of the Company under the pRSU Plan. The pRSUs expire eight years after the date of grant. At March&#160;31, 2021, none of the Company&#8217;s common shares were reserved for future grants under this plan. </div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">As part of the Roivant Equity Repurchase, 17,044,465 existing pRSUs were surrendered and exchanged for newly issued Performance Options and CVARs issued under an amended and restated RSL 2015 EIP (see above), of which approximately 11.23% were then immediately purchased by the Company, during the year ended March&#160;31, 2020. Refer to Note 10, &#8220;Shareholders&#8217; Equity and Redeemable Noncontrolling Interest&#8221; for additional detail regarding the Roivant Equity Repurchase. </div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">A summary of pRSU activity under the pRSU Plan is as follows: </div></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 76%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="font-size: 0px;">
<td style="width: 64%;"/>
<td style="width: 10%; vertical-align: bottom;"/>
<td/>
<td/>
<td/>
<td style="width: 10%; vertical-align: bottom;"/>
<td/>
<td/>
<td/> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Number&#160;of<br/> pRSUs</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Weighted&#160;Average<br/> Grant Date Fair<br/> Value</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">Non-vested</div> balance at March&#160;31, 2020</div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">266,845</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">13.92</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Granted</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Forfeited</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(66,845</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">13.92</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;">&#160;</td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">Non-vested</div> balance at March&#160;31, 2021</div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">200,000</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">13.92</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;">&#160;</td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td> </tr> </table>  <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">These pRSUs will vest to the extent certain performance criteria are achieved and certain liquidity conditions are satisfied within specified years of the grant date, provided that the recipient has provided continued service through such date. As of&#160;March&#160;31, 2021, the performance conditions had not been met and were deemed not probable of being met. During the year ended March&#160;31, 2021, the Company recorded&#160;no share-based compensation expense related to these pRSUs. During the year ended March&#160;31, 2020, the Company recorded $12.3&#160;million of share-based compensation expense relating to cash payments made for the purchase of a portion of the Performance Options and CVARs issued in replacement of pRSUs. At March&#160;31, 2021, there was approximately $2.8&#160;million of unrecognized compensation expense related to <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-vested</div> pRSUs. The Company will recognize the expense upon achievement of the performance and liquidity conditions through the requisite service period. </div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">(C) RSL Restricted Common Stock </div></div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">A summary of RSL restricted common stock activity as of March&#160;31, 2021 is as follows: </div></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 76%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="font-size: 0px;">
<td style="width: 64%;"/>
<td style="width: 10%; vertical-align: bottom;"/>
<td/>
<td/>
<td/>
<td style="width: 10%; vertical-align: bottom;"/>
<td/>
<td/>
<td/> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Number&#160;of<br/> Restricted<br/> Common<br/> Stock</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Weighted&#160;Average<br/> Grant Date Fair<br/> Value</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">Non-vested</div> balance at March&#160;31, 2020</div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Granted</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">587,824</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">38.50</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Vested</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Forfeited</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;">&#160;</td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">Non-vested</div> balance at March&#160;31, 2021</div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">587,824</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">38.50</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;">&#160;</td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td> </tr> </table>  <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">For the year ended March&#160;31, 2021, the Company recorded share-based compensation expense of $0.1&#160;million in relation to the RSL restricted common stock. At March&#160;31, 2021, total unrecognized compensation expense related to <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-vested</div> restricted common stock was approximately $6.9&#160;million and is expected to be recognized over the remaining weighted-average service period of 3.39 years. $15.6&#160;million of the fair value associated with these restricted common stock was attributed to precombination service. Refer to Note 4, &#8220;Asset Acquisitions and License Agreements.&#8221; </div>  <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">(D) Subsidiary Equity Incentive Plans </div></div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;">Certain wholly owned and majority-owned or controlled subsidiaries of RSL adopt their own equity incentive plan (&#8220;EIP&#8221;). Each EIP is generally structured so that the applicable subsidiary, and its affiliates&#8217; employees, directors, officers and consultants are eligible to receive <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-qualified</div> and incentive stock options, stock appreciation rights, restricted share awards, restricted stock unit awards, and other share awards under their respective EIP. Standard option grants have time-based vesting requirements, generally vesting over a period of four years with a contractual term of ten years. Such time-based stock options use the Black-Scholes option pricing model. The grant date fair value of awards subject to market conditions is estimated using a Monte Carlo valuation model. For the years ended March&#160;31, 2021 and 2020, the Company recorded share-based compensation expense of $29.1&#160;million and $22.1&#160;million, respectively, in relation to subsidiary EIPs. </div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">(E) Share-Based Compensation Expense </div></div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Share-based compensation expense from continuing operations was as follows (in thousands): </div></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 76%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="font-size: 0px;">
<td style="width: 74%;"/>
<td style="width: 5%; vertical-align: bottom;"/>
<td/>
<td/>
<td/>
<td style="width: 5%; vertical-align: bottom;"/>
<td/>
<td/>
<td/> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;&#160;</td>
<td colspan="6" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Years Ended<br/> March&#160;31,</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2021</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2020</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Share-based compensation expense recognized as:</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: bottom;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">R&amp;D expenses</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">$</td>
<td style="vertical-align: bottom;;text-align:right;">22,637</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">$</td>
<td style="vertical-align: bottom;;text-align:right;">7,738</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">G&amp;A expenses</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">62,321</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">60,013</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;">&#160;</td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Total</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">84,958</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">67,751</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;">&#160;</td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td> </tr> </table>  <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The classification of share-based compensation expense between R&amp;D and G&amp;A expenses in the accompanying consolidated statements of operations is consistent with the classification of grantee&#8217;s salary expense. </div></div> <span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -URI http://asc.fasb.org/topic&amp;trid=2228938<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>87
<FILENAME>R17.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm139997750512488">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Related Party Transactions<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsDisclosureTextBlock', window );">Related Party Transactions</a></td>
<td class="text"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Note 9&#8212;Related Party Transactions </div></div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Transition Services Agreement and Strategic Cooperation Agreement with Sumitomo </div></div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Concurrently with the Sumitomo Transaction Agreement, (i)&#160;RSL, Sumitomo and Sumitovant entered into a transition services agreement, whereby each of the parties thereto agreed to provide certain services to one another at cost for a period of time following the Sumitomo Closing Date and (ii)&#160;RSL and Sumitomo entered into a strategic cooperation agreement relating to certain ongoing technology-related collaborations between the parties. Pursuant to the terms of the transition services agreement and strategic cooperation agreement, RSL billed Sumitovant $1.4&#160;million and $0.2&#160;million, net of amounts billed by Sumitovant to RSL, respectively, during the years ended March&#160;31, 2021 and 2020 for costs incurred on behalf of Sumitovant, which were recorded as offsets to the general and administrative expenses initially charged. Additionally, during the years ended March&#160;31, 2021 and 2020, the Company paid Sumitomo a $1.0&#160;million access fee pursuant to the strategic cooperation agreement. </div></div><span></span>
</td>
</tr>
</table>
<div style="display: none;"><table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for related party transactions. Examples of related party transactions include transactions between (a) a parent company and its subsidiary; (b) subsidiaries of a common parent; (c) and entity and its principal owners; and (d) affiliates.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 850<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=6457730&amp;loc=d3e39549-107864<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 850<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=6457730&amp;loc=d3e39549-107864<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 850<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6457730&amp;loc=d3e39549-107864<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 850<br> -URI http://asc.fasb.org/topic&amp;trid=2122745<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 850<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=6457730&amp;loc=d3e39691-107864<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table></div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>88
<FILENAME>R18.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm139997755073560">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Discontinued Operations<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DiscontinuedOperationsAndDisposalGroupsAbstract', window );"><strong>Discontinued Operations and Disposal Groups [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock', window );">Discontinued Operations</a></td>
<td class="text"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Note 6&#8212;Discontinued Operations </div></div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">As a result of the Sumitomo Transaction Agreement, see Note 5, &#8220;Sumitomo Transaction Agreement,&#8221; the financial results of the Sumitovant Vants are presented as &#8220;Income from discontinued operations, net of tax&#8221; in the accompanying consolidated statements of operations for the year ended March&#160;31, 2020. There were no operating results from discontinued operations for the year ended March&#160;31, 2021. </div></div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The following table presents components of discontinued operations included in &#8220;Income from discontinued operations, net of tax&#8221; for the year ended March&#160;31, 2020 (in thousands). </div></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 92%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="font-size: 0px;">
<td style="width: 85%;"/>
<td style="width: 5%; vertical-align: bottom;"/>
<td/>
<td/>
<td/> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Year Ended<br/> March&#160;31,&#160;2020</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Operating expenses:</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Research and development</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">265,452</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">General and administrative</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">119,885</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;">&#160;</td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 5em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Total operating expenses</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">385,337</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;">&#160;</td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Loss from operations</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(385,337</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Gain on sale of business</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(1,985,949</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Interest income</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(2,305</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Interest expense<div style="font-size: 85%; vertical-align: top;;display:inline;;font-size:9.4px">(1)</div></div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">13,733</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Other expense</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">8,866</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;">&#160;</td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Income from discontinued operations before income taxes</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">1,580,318</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Income tax expense</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">1,892</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;">&#160;</td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: bottom;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Income from discontinued operations, net of tax</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">$</td>
<td style="vertical-align: bottom;;text-align:right;">1,578,426</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;">&#160;</td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Loss from discontinued operations before income taxes attributable to noncontrolling interests</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(141,783</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Income from discontinued operations before income taxes attributable to Roivant Sciences Ltd.</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">1,722,101</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;">&#160;</td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Income from discontinued operations before income taxes</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">1,580,318</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;">&#160;</td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td> </tr> </table> <div style="clear: both; max-height: 0px;"/> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 4%; vertical-align: top;;text-align:left;"><div style="font-size: 85%; vertical-align: top;;display:inline;;font-size:9.4px">(1)</div>&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;">Interest expense consists of interest payments related to outstanding debt held by Myovant and Urovant as well as the associated <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-cash</div> amortization of debt discounts and issuance costs. </div> </td> </tr> </table>  <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">In the accompanying consolidated statements of cash flows, the cash flows from discontinued operations are not separately classified. The significant cash flow items from discontinued operations were as follows (in thousands): </div></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 68%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="font-size: 0px;">
<td style="width: 78%;"/>
<td style="width: 8%; vertical-align: bottom;"/>
<td/>
<td/>
<td/> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Year Ended<br/> March&#160;31,&#160;2020</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Gain on sale of business</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(1,985,949</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Share-based compensation</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">54,821</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;">Acquired <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">in-process</div> research and development</div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">16,405</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;">&#160;</td> </tr> </table> <span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DiscontinuedOperationsAndDisposalGroupsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DiscontinuedOperationsAndDisposalGroupsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure related to a disposal group. Includes, but is not limited to, a discontinued operation, disposal classified as held-for-sale or disposed of by means other than sale or disposal of an individually significant component.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -URI http://asc.fasb.org/topic&amp;trid=2155823<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -URI http://asc.fasb.org/subtopic&amp;trid=2122178<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>89
<FILENAME>R19.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm139997754993768">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2021</div></th>
<th class="th"><div>Mar. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureTextBlock', window );">Income Taxes</a></td>
<td class="text"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt; text-indent: 0px; line-height: 12pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Note 9&#8212;Income Taxes </div></div></div></div> <div style="text-indent: 4%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt; line-height: 12pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The Company&#8217;s effective tax rate for the three months ended June&#160;30, 2021 and 2020 was<div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div><div style="font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif; letter-spacing: 0px; top: 0px; line-height: 10pt;;display:inline;">(0.1)</div><div style="font-size: 10pt; line-height: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;, Times, serif; letter-spacing: 0px; top: 0px; line-height: 10pt;;display:inline;">% and (18.1)</div></div><div style="letter-spacing: 0px; top: 0px;;display:inline;">%, respectively, and is driven by the Company&#8217;s jurisdictional earnings by location and a valuation allowance that eliminates the Company&#8217;s global net deferred tax assets. However, for the three months ended June&#160;30, 2020, the effective tax rate was also favorably impacted by the <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-taxable</div> gains associated with the deconsolidation of subsidiary and changes in fair value of investments. </div></div> <div style="text-indent: 4%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt; line-height: 12pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The Company assesses the realizability of its deferred tax assets at each balance sheet date based on available positive and negative evidence in order to determine the amount which is more likely than not to be realized and records a valuation allowance as necessary. </div></div></div><span></span>
</td>
<td class="text"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Note 12&#8212;Income Taxes </div></div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The loss before income taxes and the related expense/(benefit) are as follows (in thousands): </div></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 76%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="font-size: 0px;">
<td style="width: 70%;"/>
<td style="width: 5%; vertical-align: bottom;"/>
<td/>
<td/>
<td/>
<td style="width: 5%; vertical-align: bottom;"/>
<td/>
<td/>
<td/> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;&#160;</td>
<td colspan="6" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Years Ended March&#160;31,</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2021</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2020</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Loss before income taxes:</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">United States</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(212,921</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(69,264</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Switzerland</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(424,494</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(355,422</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Bermuda</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(227,471</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(105,604</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Other<div style="font-size: 85%; vertical-align: top;;display:inline;;font-size:9.4px">(1)</div></div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(33,661</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(30,696</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 5em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Total loss before income taxes</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(898,547</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(560,986</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td> </tr> </table> <div style="clear: both; max-height: 0px;"/> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 4%; vertical-align: top;;text-align:left;"><div style="font-size: 85%; vertical-align: top;;display:inline;;font-size:9.4px">(1)</div>&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Primarily Greater China and United Kingdom activity </div></div> </td> </tr> </table>  <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 76%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="font-size: 0px;">
<td style="width: 74%;"/>
<td style="width: 7%; vertical-align: bottom;"/>
<td/>
<td/>
<td/>
<td style="width: 7%; vertical-align: bottom;"/>
<td/>
<td/>
<td/> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;&#160;</td>
<td colspan="6" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Years&#160;Ended&#160;March&#160;31,</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;&#160;&#160;&#160;2021&#160;&#160;&#160;&#160;</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;&#160;&#160;&#160;2020&#160;&#160;&#160;&#160;</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Current taxes:</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">United States</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">1,365</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">6,327</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Switzerland</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Bermuda</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Other<div style="font-size: 85%; vertical-align: top;;display:inline;;font-size:9.4px">(1)</div></div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">321</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">797</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;">&#160;</td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 5em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Total current tax expense</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">1,686</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">7,124</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;">&#160;</td> </tr>
<tr style="font-size: 1pt;">
<td style="height: 6pt; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td colspan="4" style="height: 6pt; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td colspan="4" style="height: 6pt; font-family: &quot;Times New Roman&quot;;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Deferred taxes:</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">United States</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Switzerland</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Bermuda</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Other<div style="font-size: 85%; vertical-align: top;;display:inline;;font-size:9.4px">(1)</div></div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 5em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Total deferred tax benefit</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;">&#160;</td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 7em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Total income tax expense</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">1,686</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">7,124</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;">&#160;</td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td> </tr> </table> <div style="clear: both; max-height: 0px;"/> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 4%; vertical-align: top;;text-align:left;"><div style="font-size: 85%; vertical-align: top;;display:inline;;font-size:9.4px">(1)</div></td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Primarily Greater China, United States state and local and United Kingdom activity </div></div> </td> </tr> </table>  <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">A reconciliation of income tax provision/(benefit) computed at the Bermuda statutory rate to income tax expense reflected in the consolidated financial statements is as follows (in thousands, except percentages): </div></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 92%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="font-size: 0px;">
<td style="width: 59%;"/>
<td style="width: 6%; vertical-align: bottom;"/>
<td/>
<td/>
<td/>
<td style="width: 6%; vertical-align: bottom;"/>
<td/>
<td/>
<td/>
<td style="width: 5%; vertical-align: bottom;"/>
<td/>
<td/>
<td/>
<td style="width: 6%; vertical-align: bottom;"/>
<td/>
<td/>
<td/> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;&#160;</td>
<td colspan="6" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Year Ended March&#160;31,<br/> 2021</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td colspan="6" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Year Ended<br/> March&#160;31, 2020</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Income tax benefit at Bermuda statutory rate</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">%&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">%&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Foreign rate differential<div style="font-size: 85%; vertical-align: top;;display:inline;;font-size:9.4px">(1)</div></div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(150,778</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">16.78</td>
<td style="vertical-align: bottom; white-space: nowrap;">%&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(74,922</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">13.36</td>
<td style="vertical-align: bottom; white-space: nowrap;">%&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Permanent disallowed IPR&amp;D</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">111,432</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(12.40</td>
<td style="vertical-align: bottom; white-space: nowrap;">)%&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">%&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Nondeductible changes in the fair value of investments and loss from equity method investment</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(22,472</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">2.50</td>
<td style="vertical-align: bottom; white-space: nowrap;">%&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">20,840</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(3.72</td>
<td style="vertical-align: bottom; white-space: nowrap;">)%&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Nontaxable (loss) gain on deconsolidation of business</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(16,438</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">1.83</td>
<td style="vertical-align: bottom; white-space: nowrap;">%&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">29,041</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(5.18</td>
<td style="vertical-align: bottom; white-space: nowrap;">)%&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Permanent adjustments</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">2,923</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(0.33</td>
<td style="vertical-align: bottom; white-space: nowrap;">)%&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(20,395</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">3.64</td>
<td style="vertical-align: bottom; white-space: nowrap;">%&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">R&amp;D tax credits</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(10,555</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">1.17</td>
<td style="vertical-align: bottom; white-space: nowrap;">%&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(5,990</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">1.07</td>
<td style="vertical-align: bottom; white-space: nowrap;">%&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Rate changes</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">2,443</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(0.27</td>
<td style="vertical-align: bottom; white-space: nowrap;">)%&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(29,238</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">5.21</td>
<td style="vertical-align: bottom; white-space: nowrap;">%&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Valuation allowance</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">85,046</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(9.46</td>
<td style="vertical-align: bottom; white-space: nowrap;">)%&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">87,677</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(15.63</td>
<td style="vertical-align: bottom; white-space: nowrap;">)%&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Other</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">85</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(0.01</td>
<td style="vertical-align: bottom; white-space: nowrap;">)%&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">111</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(0.02</td>
<td style="vertical-align: bottom; white-space: nowrap;">)%&#160;</td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: bottom;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Total income tax expense</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">$</td>
<td style="vertical-align: bottom;;text-align:right;">1,686</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">(0.19</td>
<td style="vertical-align: bottom; white-space: nowrap;">)%&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">$</td>
<td style="vertical-align: bottom;;text-align:right;">7,124</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">(1.27</td>
<td style="vertical-align: bottom; white-space: nowrap;">)%&#160;</td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td> </tr> </table> <div style="clear: both; max-height: 0px;"/> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 4%; vertical-align: top;;text-align:left;"><div style="font-size: 85%; vertical-align: top;;display:inline;;font-size:9.4px">(1)</div></td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Primarily related to operations in Switzerland, the United Kingdom, and other jurisdictions with statutory tax rates different than the Bermuda rate. </div></div> </td> </tr> </table>  <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The Company&#8217;s effective tax rates were (0.19)% and (1.27)% for the years ended March&#160;31, 2021 and 2020, respectively, driven by the Company&#8217;s jurisdictional earnings by location and a valuation allowance that eliminates the Company&#8217;s global net deferred tax assets. </div></div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>  <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Deferred taxes reflect the tax effects of the differences between the amounts recorded as assets and liabilities for financial reporting purposes and the comparable amounts recorded for income tax purposes. Significant components of the deferred tax assets (liabilities) at March&#160;31, 2021 and 2020 are as follows (in thousands): </div></div>  <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 76%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="font-size: 0px;">
<td style="width: 62%;"/>
<td style="width: 12%; vertical-align: bottom;"/>
<td/>
<td/>
<td/>
<td style="width: 12%; vertical-align: bottom;"/>
<td/>
<td/>
<td/> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">March&#160;31,&#160;2021</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">March&#160;31,&#160;2020</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Deferred tax assets</div></div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Research tax credits</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">19,063</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">6,303</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Intangible assets</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">50,564</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">43,626</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Net operating loss</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">202,906</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">116,619</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Share-based compensation</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">26,623</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">18,413</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Lease liabilities</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">16,638</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">17,194</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Other</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">7,303</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">7,060</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;">&#160;</td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 5em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Subtotal</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">323,097</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">209,215</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Valuation allowance</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(303,287</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(187,831</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td> </tr>
<tr style="font-size: 1pt;">
<td style="height: 6pt; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td colspan="4" style="height: 6pt; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td colspan="4" style="height: 6pt; font-family: &quot;Times New Roman&quot;;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Deferred tax liabilities</div></div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Depreciation</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(1,214</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(1,833</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">Right-of-use</div></div> assets</div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(13,908</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(15,409</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Other</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(4,688</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(4,142</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Total deferred tax assets (liabilities)</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;">&#160;</td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td> </tr> </table>  <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The Company has Federal net operating losses in Switzerland, the United States, the United Kingdom and other jurisdictions in the amount of $1,181.1&#160;million, $122.2&#160;million, $28.6&#160;million, and $75.8&#160;million, respectively. The Switzerland net operating losses will expire in varying amounts between March&#160;31, 2025 and March&#160;31, 2028. The United States net operating losses can be carried forward indefinitely with utilization limited to 80% of future taxable income for tax years beginning on or after January&#160;1, 2021, while the United Kingdom and other net operating losses can be carried forward indefinitely as well, with an annual limitation on utilization. The Company has generated net operating losses from United States state and local jurisdictions in the amount of $69.7&#160;million which will expire in varying amounts between March 31, 2035 and March 31, 2041. The Company has generated $19.1&#160;million of research tax credit carryforwards primarily in the United States, which will expire in varying amounts between March 31, 2035 and March 31, 2041. </div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The Company assesses the realizability of the deferred tax assets at each balance sheet date based on available positive and negative evidence in order to determine the amount which is more likely than not to be realized and record a valuation allowance as necessary. Due to the Company&#8217;s cumulative loss position which provides significant negative evidence difficult to overcome, the Company has recorded a valuation allowance of $303.3&#160;million as of March&#160;31, 2021, representing the portion of the deferred tax asset that is not more likely than not to be realized. The amount of the deferred tax asset considered realizable could be adjusted for future factors that would impact the assessment of the objective and subjective evidence of the Company. For the period April&#160;1, 2020 through March&#160;31, 2021, the valuation allowance increased by $115.5&#160;million primarily as a result of corresponding increases in our global net operating losses, as well as our Research Tax Credits. For the period April&#160;1, 2019 through March&#160;31, 2020, the valuation allowance decreased by $168.0&#160;million primarily as a result of the Sumitomo Transaction and the deconsolidation of Sio. The Company will continue to assess the realizability of deferred tax assets at each balance sheet date in order to determine the amount, if any, required for a valuation allowance. </div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">There are outside basis differences related to the Company&#8217;s investment in subsidiaries for which no deferred taxes have been recorded as these would not be subject to tax on repatriation as Bermuda has no tax regime for Bermuda exempted limited companies, and the United Kingdom tax regime relating to company distributions and sales generally provides for exemption from tax for most overseas profits, subject to certain exceptions. </div></div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> The Company is subject to tax and is required to file United States, United Kingdom, and Switzerland federal income tax returns, as well as income tax returns in various state, local, and foreign jurisdictions. The Company is subject to tax examinations for tax years ended March&#160;31, 2018 and forward in major taxing jurisdictions. Tax audits and examinations can involve complex issues, interpretations and judgments. The resolution of matters may span multiple years particularly if subject to litigation or negotiation. The Company believes it has appropriately recorded its tax position using reasonable estimates and assumptions, however, the potential tax benefits may impact the results of operations or cash flows in the period of resolution, settlement or when the statutes of limitations expire. There are no unrecognized tax benefits recorded as of March&#160;31, 2021 and 2020.<span></span>
</td>
</tr>
</table>
<div style="display: none;"><table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for income taxes. Disclosures may include net deferred tax liability or asset recognized in an enterprise's statement of financial position, net change during the year in the total valuation allowance, approximate tax effect of each type of temporary difference and carryforward that gives rise to a significant portion of deferred tax liabilities and deferred tax assets, utilization of a tax carryback, and tax uncertainties information.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 21<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32857-109319<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 11.C)<br> -URI http://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330215-122817<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 17<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32809-109319<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB TOPIC 6.I.5.Q1)<br> -URI http://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 14<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32705-109319<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 270<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6424409&amp;loc=d3e44925-109338<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -URI http://asc.fasb.org/topic&amp;trid=2144680<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6424122&amp;loc=d3e41874-109331<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(2))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table></div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>90
<FILENAME>R20.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm139997756219112">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Leases<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LeasesAbstract', window );"><strong>Leases [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeasesTextBlock', window );">Leases</a></td>
<td class="text"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Note 13&#8212;Leases </div></div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;">The Company&#8217;s operating leases consist primarily of real estate leases, including those entered into by certain wholly owned and majority-owned or controlled subsidiaries of RSL. The Company determines if an agreement is or contains a lease at inception. Leases with an initial term of 12 months or less are not recorded on the balance sheet. For real estate leases, the Company&#160;elected the expedient to account for lease and <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-lease</div> components as a single component. </div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">Right-of-use</div></div> (&#8220;ROU&#8221;) assets represent the Company&#8217;s right to use an underlying asset for the lease term and lease liabilities represent the Company&#8217;s obligation to make lease payments arising from the lease. ROU assets and liabilities are based on the estimated present value of fixed lease payments over the expected lease term and are recognized at the lease commencement date. </div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">As most of the Company&#8217;s leases do not provide an implicit rate, the Company uses an estimated incremental borrowing rate in determining the present value of fixed lease payments based on information available at the lease commencement date. The Company&#8217;s incremental borrowing rates are determined based on the term of the lease, the economic environment of the lease, and the effect of collateralization. Certain leases include one or more renewal options, generally for the same period as the initial term of the lease. The exercise of lease renewal options is generally at the Company&#8217;s sole discretion and, as such, the Company typically determines that exercise of these renewal options is not reasonably certain. As a result, the Company does not include the renewal option period in the expected lease term and the associated lease payments are not included in the measurement of the ROU asset and lease liability. Certain leases also contain termination options with an associated penalty. Generally, the Company is reasonably certain not to exercise these options and as such, they are not included in the determination of the expected lease term. The Company recognizes operating lease expense on a straight-line basis over the lease term. </div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Leases generally provide for payments of nonlease components, such as common area maintenance, real estate taxes and other costs associated with the leased property. For lease agreements entered into or modified after April&#160;1, 2019, the Company accounts for lease components and nonlease components together as a single lease component and, as such, includes fixed payments of nonlease components in the measurement of the ROU assets and lease liabilities. Variable lease payments, such as periodic adjustments for inflation, reimbursement of real estate taxes, any variable common area maintenance and any other variable costs associated with the leased property are expensed as incurred as variable lease costs and are not recorded on the balance sheet. </div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The Company&#8217;s lease agreements do not contain any material residual value guarantees or material restrictions or covenants. </div></div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The components of operating lease expense for the Company were as follows (in thousands): </div></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 68%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="font-size: 0px;">
<td style="width: 70%;"/>
<td style="width: 6%; vertical-align: bottom;"/>
<td/>
<td/>
<td/>
<td style="width: 6%; vertical-align: bottom;"/>
<td/>
<td/>
<td/> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;&#160;</td>
<td colspan="6" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Years&#160;Ended&#160;March&#160;31,</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2021</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2020</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Operating lease cost</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">11,931</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">11,515</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Short-term lease cost</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">237</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">872</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Variable lease cost</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">704</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">379</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;">&#160;</td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Total operating lease cost</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">12,872</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">12,766</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;">&#160;</td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td> </tr> </table>  <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Information related to the Company&#8217;s operating lease ROU assets and operating lease liabilities was as follows (in thousands, except periods and percentages): </div></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 68%; font-family: &quot;Times New Roman&quot;; font-size: 8pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="font-size: 0px;">
<td style="width: 72%;"/>
<td style="width: 6%; vertical-align: bottom;"/>
<td/>
<td/>
<td/>
<td style="width: 6%; vertical-align: bottom;"/>
<td/>
<td/>
<td/> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;&#160;</td>
<td colspan="6" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">During the Year<br/> Ended March&#160;31,</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2021</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2020</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Cash paid for operating lease liabilities</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">8,830</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">8,108</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Operating lease ROU assets obtained in exchange for operating lease liabilities</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">5,491</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">56,025</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;">&#160;</td> </tr> </table> <div style="clear: both; max-height: 0px;"/> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 84%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="font-size: 0px;">
<td style="width: 66%;"/>
<td style="width: 15%; vertical-align: bottom;"/>
<td/>
<td/>
<td/>
<td style="width: 14%; vertical-align: bottom;"/>
<td/>
<td/>
<td/> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">March&#160;31,&#160;2021</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">March&#160;31,&#160;2020</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Weighted average remaining lease term (in years)</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">9.6</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">10.2</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Weighted average discount rate</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">7.1</td>
<td style="vertical-align: bottom; white-space: nowrap;">%&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">7.1</td>
<td style="vertical-align: bottom; white-space: nowrap;">%&#160;</td> </tr> </table>  <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">As of March&#160;31, 2021, maturities of operating lease liabilities were as follows (in thousands): </div></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 68%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="font-size: 0px;">
<td style="width: 83%; font-family: &quot;Times New Roman&quot;;"/>
<td style="width: 9%; vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/>
<td style="font-family: &quot;Times New Roman&quot;;"/>
<td style="font-family: &quot;Times New Roman&quot;;"/>
<td style="font-family: &quot;Times New Roman&quot;;"/> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; white-space: nowrap;"> <div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt; border-bottom: 1pt solid rgb(0, 0, 0); display: table-cell; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">Years Ending March&#160;31,</div></div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">2022</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">13,386</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">2023</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">11,814</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">2024</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">11,718</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">2025</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">9,734</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">2026</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">8,617</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Thereafter</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">51,674</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;">&#160;</td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Total lease payments</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">106,943</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Less: present value adjustment</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(29,348</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Less: tenant improvement allowance</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(2,898</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Total</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">74,697</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;">&#160;</td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td> </tr> </table>  <span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeasesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeasesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeasesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for operating leases of lessee. Includes, but is not limited to, description of operating lease and maturity analysis of operating lease liability.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -URI http://asc.fasb.org/subtopic&amp;trid=77888251<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeasesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>91
<FILENAME>R21.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm139997755098424">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Commitments &amp; Contingencies<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2021</div></th>
<th class="th"><div>Mar. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock', window );">Commitments &amp; Contingencies</a></td>
<td class="text"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt; text-indent: 0px; line-height: 12pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Note 10&#8212;Commitments and Contingencies </div></div></div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt; text-indent: 0px; line-height: 12pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">(A) Significant Agreements </div></div></div></div> <div style="text-indent: 4%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt; line-height: 12pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The Company, primarily through its subsidiaries, has entered into commitments under various asset acquisition and license agreements. Additionally, the Company, through its subsidiaries, enters into agreements with contract service providers to assist in the performance of its R&amp;D activities. Expenditures to contract research organizations and contract manufacturing organizations represent significant costs in the clinical development of its product candidates. Subject to required notice periods and certain obligations under binding purchase orders, the Company can elect to discontinue the work under these agreements at any time. The Company expects to enter into additional collaborative research, contract research, manufacturing, and supplier agreements in the future, which may require upfront payments and long-term commitments of capital resources. </div></div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt; text-indent: 0px; line-height: 12pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">(B) Loss Contingencies </div></div></div></div> <div style="text-indent: 4%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt; line-height: 12pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The Company may be, from time to time, a party to various disputes and claims arising from normal business activities. The Company accrues for loss contingencies when available information indicates that it is probable that a liability has been incurred and the amount of such loss can be reasonably estimated, and if the Company believes that a reasonably possible loss exists, the Company discloses the facts and circumstances of the litigation or claim, including an estimable range, if possible. The Company is currently not involved in any legal proceedings with a probable and estimable material loss. </div></div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt; text-indent: 0px; line-height: 12pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">(C) Intellectual Property Agreements </div></div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">As of June&#160;30, 2021, the Company did not have any ongoing material financial commitments, other than pursuant to various asset acquisition and license agreements. </div></div></div><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(D) <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">COVID-19</div> Pandemic </div></div></div><div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">The Company has been actively monitoring the impact of the <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">COVID-19</div> pandemic on its employees and business. Based on guidance issued by federal, state and local authorities, the Company transitioned to a remote work model for its employees in March 2020 and its workforce continues to primarily work remotely. </div></div><div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">The <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">COVID-19</div> pandemic has had a variable impact on clinical trials by disrupting certain study sites. In the conduct of business activities, the Company continues to take actions designed to protect the safety and well-being of its patients and employees. Although some of the Company&#8217;s clinical development timelines have been impacted by delays related to the <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">COVID-19</div> pandemic, the Company has not experienced material financial impacts on its business and operations as a result of the <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">COVID-19</div> pandemic. However, the impact on the Company&#8217;s future results will largely depend on future developments related to <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">COVID-19,</div> which are highly uncertain and cannot be predicted with confidence, such as the emergence of new variants, the ultimate duration and spread of the outbreak, the continuing impact of the <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">COVID-19</div> pandemic on financial markets and the global economy, travel restrictions and social distancing in the United States and other countries, business closures or business disruptions and the effectiveness of actions taken in the United States and other countries to contain, treat, and prevent the disease, including the availability and effectiveness of vaccines. </div></div><span></span>
</td>
<td class="text"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Note 14&#8212;Commitments and Contingencies </div></div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">(A) Significant Agreements </div></div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The Company, primarily through its subsidiaries has entered into commitments under various asset acquisition and license agreements including those described in Note 4, &#8220;Asset Acquisitions and License Agreements.&#8221; Additionally, the Company through its subsidiaries enters into agreements with contract service providers to assist in the performance of its R&amp;D activities. Expenditures to contract research organizations and contract manufacturing organizations represent significant costs in the clinical development of its product candidates. Subject to required notice periods and certain obligations under binding purchase orders, the Company can elect to discontinue the work under these agreements at any time. The Company expects to enter into additional collaborative research, contract research, manufacturing, and supplier agreements in the future, which may require upfront payments and long-term commitments of capital resources. </div></div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">(B) Loss Contingencies </div></div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The Company may be, from time to time, a party to various disputes and claims arising from normal business activities. The Company accrues for loss contingencies when available information indicates that it is probable that a liability has been incurred and the amount of such loss can be reasonably estimated, and if the Company believes that a reasonably possible loss exists, the Company discloses the facts and circumstances of the litigation or claim, including an estimable range, if possible. The Company is currently not involved in any legal proceedings with a probable and estimable material loss. </div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">(C) Intellectual Property Agreements </div></div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">As of March&#160;31, 2021, the Company did not have any ongoing material financial commitments, other than pursuant to various asset acquisition and license agreements including those described in Note 4, &#8220;Asset Acquisitions and License Agreements.&#8221; </div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;">(D) <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">COVID-19</div> Pandemic </div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;">The Company has been actively monitoring the impact of the <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">COVID-19</div> pandemic on its employees and business. Based on guidance issued by federal, state and local authorities, the Company transitioned to a remote work model for its employees in March 2020 and its workforce continues to primarily work remotely. </div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">The <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">COVID-19</div> pandemic has had a variable impact on clinical trials by disrupting certain study sites. In the conduct of business activities, the Company continues to take actions designed to protect the safety and well-being of its patients and employees. Although some of the Company&#8217;s clinical development timelines have been impacted by delays related to the <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">COVID-19</div> pandemic, the Company has not experienced material financial impacts on its business and operations as a result of the <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">COVID-19</div> pandemic. However, the impact on the Company&#8217;s future results will largely depend on future developments related to <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">COVID-19,</div> which are highly uncertain and cannot be predicted with confidence, such as the emergence of new variants, the ultimate duration and spread of the outbreak, the continuing impact of the <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">COVID-19</div> pandemic on financial markets and the global economy, travel restrictions and social distancing in the United States and other countries, business closures or business disruptions and the effectiveness of actions taken in the United States and other countries to contain, treat, and prevent the disease, including the availability and effectiveness of vaccines. </div> <span></span>
</td>
</tr>
</table>
<div style="display: none;"><table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for commitments and contingencies.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 450<br> -URI http://asc.fasb.org/topic&amp;trid=2127136<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 440<br> -URI http://asc.fasb.org/topic&amp;trid=2144648<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 954<br> -SubTopic 440<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6491277&amp;loc=d3e6429-115629<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 440<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123406679&amp;loc=d3e25336-109308<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 440<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123406679&amp;loc=d3e25336-109308<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table></div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>92
<FILENAME>R22.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm139997755088360">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Fair Value Measurements<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2021</div></th>
<th class="th"><div>Mar. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueDisclosuresTextBlock', window );">Fair Value Measurements</a></td>
<td class="text"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Note 11&#8212;Fair Value Measurements </div></div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Recurring Fair Value Measurements </div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The following table sets forth the Company&#8217;s assets and liabilities that are measured at fair value on a recurring basis as of June&#160;30, 2021 and March&#160;31, 2021, by level, within the fair value hierarchy (in thousands): </div></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;width:100%;">
<tr style="font-size: 0px;">
<td style="width: 30%;"/>
<td style="width: 1%; vertical-align: bottom;"/>
<td/>
<td/>
<td/>
<td style="width: 1%; vertical-align: bottom;"/>
<td/>
<td/>
<td/>
<td style="width: 1%; vertical-align: bottom;"/>
<td/>
<td/>
<td/>
<td style="width: 1%; vertical-align: bottom;"/>
<td/>
<td/>
<td/>
<td style="width: 1%; vertical-align: bottom;"/>
<td/>
<td/>
<td/>
<td style="width: 1%; vertical-align: bottom;"/>
<td/>
<td/>
<td/>
<td style="width: 1%; vertical-align: bottom;"/>
<td/>
<td/>
<td/>
<td style="width: 1%; vertical-align: bottom;"/>
<td/>
<td/>
<td/></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;&#160;</td>
<td colspan="14" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">As of June&#160;30, 2021</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;&#160;</td>
<td colspan="14" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">As of March&#160;31, 2021</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Level&#160;1</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Level&#160;2</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Level&#160;3</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Balance as<br/> of&#160;June&#160;30,<br/> 2021</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Level&#160;1</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Level&#160;2</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Level&#160;3</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Balance as<br/> of&#160;March&#160;31,<br/> 2021</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top; width: 30%;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Assets:</div></div></td>
<td style="vertical-align: bottom; width: 1%;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; width: 1%;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; width: 1%;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; width: 1%;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; width: 1%;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; width: 1%;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; width: 1%;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; width: 1%;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; width: 30%;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Money market funds</div></div></td>
<td style="vertical-align: bottom; width: 1%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">1,340,662</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 1%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 1%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 1%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">1,340,662</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 1%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">1,420,597</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 1%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 1%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 1%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">1,420,597</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top; width: 30%;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Investment in Sio common shares</div></div></td>
<td style="vertical-align: bottom; width: 1%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">50,716</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 1%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 1%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 1%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">50,716</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 1%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">48,487</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 1%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 1%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 1%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">48,487</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; width: 30%;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Investment in Arbutus common shares</div></div></td>
<td style="vertical-align: bottom; width: 1%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">48,521</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 1%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 1%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 1%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">48,521</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 1%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">53,325</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 1%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 1%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 1%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">53,325</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top; width: 30%;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Investment in Arbutus convertible preferred shares</div></div></td>
<td style="vertical-align: bottom; width: 1%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 1%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">69,187</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 1%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 1%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">69,187</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 1%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 1%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">76,037</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 1%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 1%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">76,037</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; width: 30%;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Other investment</div></div></td>
<td style="vertical-align: bottom; width: 1%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">11,935</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 1%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 1%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 1%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">11,935</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 1%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">11,129</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 1%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 1%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 1%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">11,129</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 30%;">&#160;</td>
<td style="vertical-align: bottom; width: 1%;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom; width: 1%;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom; width: 1%;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom; width: 1%;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom; width: 1%;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom; width: 1%;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom; width: 1%;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom; width: 1%;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top; width: 30%;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Total assets at fair value</div></div></td>
<td style="vertical-align: bottom; width: 1%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">1,451,834</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 1%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">69,187</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 1%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 1%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">1,521,021</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 1%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">1,533,538</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 1%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">76,037</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 1%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 1%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">1,609,575</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 30%;">&#160;</td>
<td style="vertical-align: bottom; width: 1%;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom; width: 1%;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom; width: 1%;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom; width: 1%;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom; width: 1%;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom; width: 1%;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom; width: 1%;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom; width: 1%;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; width: 30%;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Liabilities:</div></div></td>
<td style="vertical-align: bottom; width: 1%;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; width: 1%;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; width: 1%;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; width: 1%;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; width: 1%;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; width: 1%;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; width: 1%;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; width: 1%;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top; text-indent: 0px; width: 30%;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Debt issued by Dermavant to NovaQuest</div></div></td>
<td style="vertical-align: bottom; text-indent: 0px; width: 1%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">$</div></td>
<td style="vertical-align: bottom; white-space: nowrap; text-indent: 0px;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; text-indent: 0px;">&#160;</td>
<td style="vertical-align: bottom; text-indent: 0px; width: 1%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">$</div></td>
<td style="vertical-align: bottom; white-space: nowrap; text-indent: 0px;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; text-indent: 0px;">&#160;</td>
<td style="vertical-align: bottom; text-indent: 0px; width: 1%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">$</div></td>
<td style="vertical-align: bottom; white-space: nowrap; text-indent: 0px;;text-align:right;">155,200</td>
<td style="vertical-align: bottom; white-space: nowrap; text-indent: 0px;">&#160;</td>
<td style="vertical-align: bottom; text-indent: 0px; width: 1%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">$</div></td>
<td style="vertical-align: bottom; white-space: nowrap; text-indent: 0px;;text-align:right;">155,200</td>
<td style="vertical-align: bottom; white-space: nowrap; text-indent: 0px;">&#160;</td>
<td style="vertical-align: bottom; text-indent: 0px; width: 1%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">$</div></td>
<td style="vertical-align: bottom; white-space: nowrap; text-indent: 0px;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; text-indent: 0px;">&#160;</td>
<td style="vertical-align: bottom; text-indent: 0px; width: 1%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">$</div></td>
<td style="vertical-align: bottom; white-space: nowrap; text-indent: 0px;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; text-indent: 0px;">&#160;</td>
<td style="vertical-align: bottom; text-indent: 0px; width: 1%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">$</div></td>
<td style="vertical-align: bottom; white-space: nowrap; text-indent: 0px;;text-align:right;">150,100</td>
<td style="vertical-align: bottom; white-space: nowrap; text-indent: 0px;">&#160;</td>
<td style="vertical-align: bottom; text-indent: 0px; width: 1%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">$</div></td>
<td style="vertical-align: bottom; white-space: nowrap; text-indent: 0px;;text-align:right;">150,100</td>
<td style="vertical-align: bottom; white-space: nowrap; text-indent: 0px;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; width: 30%;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Liability instruments measured at fair value</div></div></td>
<td style="vertical-align: bottom; width: 1%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 1%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 1%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">5,906</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 1%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">5,906</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 1%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 1%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 1%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">67,893</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 1%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">67,893</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 30%;">&#160;</td>
<td style="vertical-align: bottom; width: 1%;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom; width: 1%;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom; width: 1%;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom; width: 1%;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom; width: 1%;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom; width: 1%;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom; width: 1%;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom; width: 1%;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top; width: 30%;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Total liabilities at fair value</div></div></td>
<td style="vertical-align: bottom; width: 1%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 1%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 1%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">161,106</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 1%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">161,106</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 1%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 1%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 1%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">217,993</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 1%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">217,993</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 30%;">&#160;</td>
<td style="vertical-align: bottom; width: 1%;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom; width: 1%;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom; width: 1%;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom; width: 1%;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom; width: 1%;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom; width: 1%;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom; width: 1%;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom; width: 1%;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td></tr></table>  <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">There were no transfers of assets between Level&#160;1 and Level&#160;2 of the fair value measurement hierarchy that occurred during the three months ended June&#160;30, 2021. </div></div></div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 2%;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Level&#160;3 Disclosures </div></div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The Company measures its Level&#160;3 liabilities at fair value based on significant inputs not observable in the market, which causes them to be classified as a Level&#160;3 measurement within the fair value hierarchy. The valuation of the Level&#160;3 liabilities uses assumptions and estimates the Company believes would be made by a market participant in making the same valuation. The Company assesses these assumptions and estimates on an ongoing basis as additional data impacting the assumptions and estimates are obtained. Changes in the fair value related to updated assumptions and estimates are recorded within the statements of operations at the end of each reporting period. </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The fair value of Level&#160;3 liabilities may change significantly as additional data are obtained, impacting the Company&#8217;s assumptions regarding probabilities of potential scenarios used to estimate fair value. In evaluating this information, considerable judgment is required to interpret the data used to develop the assumptions and estimates. Accordingly, the use of different market assumptions and/or different valuation techniques may have a material effect on the estimated fair value amounts, and such changes could materially impact the Company&#8217;s results of operations in future periods. </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The changes in fair value of the Level&#160;3 liabilities during the three months ended June&#160;30, 2021 and 2020 were as follows (in thousands): </div></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;width:68%;">
<tr style="font-size: 0px;">
<td style="width: 83%; font-family: &quot;Times New Roman&quot;;"/>
<td style="width: 7%; vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/>
<td style="font-family: &quot;Times New Roman&quot;;"/>
<td style="font-family: &quot;Times New Roman&quot;;"/>
<td style="font-family: &quot;Times New Roman&quot;;"/></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top; width: 83%;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Balance at March&#160;31, 2020</div></div></td>
<td style="vertical-align: bottom; width: 7%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">191,473</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; width: 83%;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Changes in fair value of debt and liability instruments, included in net loss</div></div></td>
<td style="vertical-align: bottom; width: 7%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">17,125</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top; width: 83%;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Liability instruments disposed due to deconsolidation of subsidiary</div></div></td>
<td style="vertical-align: bottom; width: 7%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(3,325</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 83%;">&#160;</td>
<td style="vertical-align: bottom; width: 7%;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; width: 83%;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Balance at June&#160;30, 2020</div></div></td>
<td style="vertical-align: bottom; width: 7%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">205,273</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 83%;">&#160;</td>
<td style="vertical-align: bottom; width: 7%;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td></tr>
<tr>
<td style="vertical-align: top; line-height: 5pt; font-size: 5pt; width: 83%;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 5pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: 5pt;"><div style="font-size: 5pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom; line-height: 5pt; font-size: 5pt; width: 7%;"><div style="font-size: 5pt; line-height: 5pt;"><div style="font-size: 5pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap; line-height: 5pt; font-size: 5pt;"><div style="font-size: 5pt; line-height: 5pt;"><div style="font-size: 5pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap; line-height: 5pt; font-size: 5pt;;text-align:right;"><div style="font-size: 5pt; line-height: 5pt;"><div style="font-size: 5pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap; line-height: 5pt; font-size: 5pt;"><div style="font-size: 5pt; line-height: 5pt;"><div style="font-size: 5pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top; width: 83%;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Balance at March&#160;31, 2021</div></div></td>
<td style="vertical-align: bottom; width: 7%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">217,993</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; width: 83%;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Changes in fair value of debt and liability instruments, included in net loss</div></div></td>
<td style="vertical-align: bottom; width: 7%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">4,585</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top; width: 83%;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Termination of DSP Options</div></div></td>
<td style="vertical-align: bottom; width: 7%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(61,472</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 83%;">&#160;</td>
<td style="vertical-align: bottom; width: 7%;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; width: 83%;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Balance at June&#160;30, 2021</div></div></td>
<td style="vertical-align: bottom; width: 7%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">161,106</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 83%;">&#160;</td>
<td style="vertical-align: bottom; width: 7%;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td></tr></table>   <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Debt issued by Dermavant to NovaQuest </div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The fair value of the debt instrument as of June&#160;30, 2021 and March&#160;31, 2021 represents the fair value of amounts payable to NovaQuest using a Monte Carlo simulation model under the income approach determined by using probability assessments of the expected future payments through 2032 and applying discount rates ranging from <span style="-sec-ix-hidden:hidden28229202">11</span>% to <span style="-sec-ix-hidden:hidden28229201">12</span>%. The future payments are based on significant inputs that are not observable in the market which are subject to remeasurement at each reporting date. The estimates of fair value may not be indicative of the amounts that could ultimately be paid by Dermavant to NovaQuest. </div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Sumitomo Options </div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">In June 2021, the Company completed a transaction with Sumitomo pursuant to which the Sumitomo Options were terminated, resulting in the extinguishment of the related liability. As of the termination date, the fair value of the Sumitomo Options was </div></div><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">$61.5&#160;million, and as of March&#160;31, 2021, the fair value was $62.4&#160;million. See Note 4, &#8220;Sumitomo Transaction Agreement&#8221; for additional information. </div></div> <span></span>
</td>
<td class="text"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Note 15&#8212;Fair Value Measurements </div></div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Recurring Fair Value Measurements </div></div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The following table sets forth the Company&#8217;s assets and liabilities that are measured at fair value on a recurring basis as of&#160;March&#160;31, 2021 and 2020, by level, within the fair value hierarchy (in thousands): </div></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 8pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="font-size: 0px;">
<td style="width: 42%;"/>
<td style="width: 1%; vertical-align: bottom;"/>
<td/>
<td/>
<td/>
<td style="width: 1%; vertical-align: bottom;"/>
<td/>
<td/>
<td/>
<td style="width: 1%; vertical-align: bottom;"/>
<td/>
<td/>
<td/>
<td style="width: 1%; vertical-align: bottom;"/>
<td/>
<td/>
<td/>
<td style="width: 1%; vertical-align: bottom;"/>
<td/>
<td/>
<td/>
<td style="width: 1%; vertical-align: bottom;"/>
<td/>
<td/>
<td/>
<td style="width: 1%; vertical-align: bottom;"/>
<td/>
<td/>
<td/>
<td style="width: 1%; vertical-align: bottom;"/>
<td/>
<td/>
<td/> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td colspan="14" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">As of March&#160;31, 2021</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td colspan="14" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">As of March&#160;31, 2020</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Level&#160;1</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Level&#160;2</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Level&#160;3</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Balance&#160;as&#160;of<br/> March&#160;31,<br/> 2021</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Level&#160;1</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Level&#160;2</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Level&#160;3</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Balance&#160;as&#160;of<br/> March&#160;31,<br/> 2020</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">Assets:</div></div> </td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">Money market funds</div></div> </td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">1,420,597</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">1,420,597</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">1,874,662</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">1,874,662</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">Investment in Sio common shares</div></div> </td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">48,487</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">48,487</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">45,329</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">45,329</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">Investment in Arbutus common shares</div></div> </td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">53,325</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">53,325</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">16,174</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">16,174</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">Investment in Arbutus convertible preferred shares</div></div> </td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">76,037</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">76,037</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">23,062</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">23,062</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">Other investments</div></div> </td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">11,129</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">11,129</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">8,880</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">8,880</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;">&#160;</td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">Total assets at fair value</div></div> </td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">1,533,538</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">76,037</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">1,609,575</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">1,945,045</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">23,062</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">1,968,107</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;">&#160;</td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">Liabilities:</div></div> </td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">Debt held by Dermavant with NovaQuest</div></div> </td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">150,100</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">150,100</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">89,100</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">89,100</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">Liability instruments measured at fair value</div></div> </td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">67,893</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">67,893</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">102,373</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">102,373</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;">&#160;</td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">Total liabilities at fair value</div></div> </td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">217,993</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">217,993</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">191,473</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">191,473</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;">&#160;</td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td> </tr> </table>  <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">There were no transfers of assets between Level&#160;1 and Level&#160;2 of the fair value measurement hierarchy that occurred during the years ended March&#160;31, 2021 and 2020. </div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Level&#160;3 Disclosures </div></div></div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The Company measures its Level&#160;3 liabilities, including debt issued by Dermavant to NovaQuest and the Sumitomo Options, at fair value based on significant inputs not observable in the market, which causes them to be classified as a Level&#160;3 measurement within the fair value hierarchy. The valuation of the Level&#160;3 liabilities uses assumptions and estimates the Company believes would be made by a market participant in making the same valuation. The Company assesses these assumptions and estimates on an ongoing basis as additional data impacting the assumptions and estimates are obtained. Changes in the fair value related to updated assumptions and estimates are recorded within the statements of operations at the end of each reporting period. </div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The fair value of Level&#160;3 liabilities may change significantly as additional data are obtained, impacting the Company&#8217;s assumptions regarding probabilities of potential scenarios used to estimate fair value. In evaluating this information, considerable judgment is required to interpret the data used to develop the assumptions and estimates. Accordingly, the use of different market assumptions and/or different valuation techniques may have a material effect on the estimated fair value amounts, and such changes could materially impact the Company&#8217;s results of operations in future periods. </div></div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The changes in fair value of the Level&#160;3 liabilities during the&#160;years ended March&#160;31, 2021 and 2020 were as follows (in thousands): </div></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 68%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="font-size: 0px;">
<td style="width: 83%; font-family: &quot;Times New Roman&quot;;"/>
<td style="width: 7%; vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/>
<td style="font-family: &quot;Times New Roman&quot;;"/>
<td style="font-family: &quot;Times New Roman&quot;;"/>
<td style="font-family: &quot;Times New Roman&quot;;"/> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: bottom;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Balance at March&#160;31, 2019</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">$</td>
<td style="vertical-align: bottom;;text-align:right;">103,628</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Issuance of liability instruments measured at fair value</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">101,567</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Changes in fair value of debt and liability instruments, included in net loss</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(13,722</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Balance at March&#160;31, 2020</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">191,473</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Changes in fair value of debt and liability instruments, included in net loss</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">29,845</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Liability instruments disposed due to deconsolidation of subsidiary</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(3,325</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: bottom;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Balance at March&#160;31, 2021</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">$</td>
<td style="vertical-align: bottom;;text-align:right;">217,993</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;">&#160;</td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td> </tr> </table>  <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Debt issued by Dermavant to NovaQuest </div></div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The fair value of the debt instrument as of&#160;March&#160;31, 2021 and 2020 represents the fair value of amounts payable to NovaQuest using a Monte Carlo simulation model under the income approach determined by using probability assessments of the expected future payments through 2032 and applying discount rates ranging from 6% to 17%. The future payments are based on significant inputs that are not observable in the market which are subject to remeasurement at each reporting date. The estimates of fair value may not be indicative of the amounts that could ultimately be paid by Dermavant to NovaQuest. </div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Sumitomo Options </div></div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The fair value of the options to acquire the Company&#8217;s interest in Dermavant, Genevant, Lysovant, Metavant, Cytovant Parent, and Sinovant (collectively, the &#8220;Option Vants&#8221;) granted to Sumitomo under the Sumitomo Transaction Agreement as of March&#160;31, 2021 and 2020 was calculated using significant unobservable inputs including the following: </div></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 84%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="font-size: 0px;">
<td style="width: 55%;"/>
<td style="width: 7%; vertical-align: bottom;"/>
<td/>
<td style="width: 6%; vertical-align: bottom;"/>
<td/> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;&#160;</td>
<td colspan="3" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Range&#160;or&#160;Point&#160;Estimate&#160;Used</div></div></td> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; white-space: nowrap; padding-bottom: 1pt;"> <div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt; border-bottom: 1pt solid rgb(0, 0, 0); display: table-cell; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">Input</div></div></div> </td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;&#160;</td>
<td style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">As&#160;of&#160;March&#160;31,&#160;2021</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">As&#160;of&#160;March&#160;31,&#160;2020</div></div></td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Time to expiration (in years)</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:center;">3.59</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:center;">0.49&#160;-&#160;4.59</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Risk-free rate</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:center;">0.52%</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:center;">0.15%&#160;-&#160;0.35%</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Volatility</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:center;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">89.0%&#160;-&#160;95.0%</div></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:center;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">91.0%&#160;-&#160;110.0%</div></td> </tr> </table>  <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">As of March&#160;31, 2021 and 2020, the fair value of the Sumitomo Options was $62.4&#160;million and $95.9&#160;million, respectively. Sumitomo Options are included in &#8220;Liability instruments measured at fair value&#8221; in the accompanying consolidated balance sheets. </div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">In June 2021, the Company completed a transaction with Sumitomo pursuant to which Sumitomo terminated all of its existing options to acquire the Company&#8217;s equity interests in certain subsidiaries. See Note 19, &#8220;Subsequent Events&#8221; for additional information. </div></div> <span></span>
</td>
</tr>
</table>
<div style="display: none;"><table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueDisclosuresTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for the fair value of financial instruments (as defined), including financial assets and financial liabilities (collectively, as defined), and the measurements of those instruments as well as disclosures related to the fair value of non-financial assets and liabilities. Such disclosures about the financial instruments, assets, and liabilities would include: (1) the fair value of the required items together with their carrying amounts (as appropriate); (2) for items for which it is not practicable to estimate fair value, disclosure would include: (a) information pertinent to estimating fair value (including, carrying amount, effective interest rate, and maturity, and (b) the reasons why it is not practicable to estimate fair value; (3) significant concentrations of credit risk including: (a) information about the activity, region, or economic characteristics identifying a concentration, (b) the maximum amount of loss the entity is exposed to based on the gross fair value of the related item, (c) policy for requiring collateral or other security and information as to accessing such collateral or security, and (d) the nature and brief description of such collateral or security; (4) quantitative information about market risks and how such risks are managed; (5) for items measured on both a recurring and nonrecurring basis information regarding the inputs used to develop the fair value measurement; and (6) for items presented in the financial statement for which fair value measurement is elected: (a) information necessary to understand the reasons for the election, (b) discussion of the effect of fair value changes on earnings, (c) a description of [similar groups] items for which the election is made and the relation thereof to the balance sheet, the aggregate carrying value of items included in the balance sheet that are not eligible for the election; (7) all other required (as defined) and desired information.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123874694&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueDisclosuresTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table></div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>93
<FILENAME>R23.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm139997755071144">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Defined Contribution Plan<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CompensationAndRetirementDisclosureAbstract', window );"><strong>Retirement Benefits [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedContributionPlanTextBlock', window );">Defined Contribution Plan</a></td>
<td class="text"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Note 16&#8212;Defined Contribution Plan </div></div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The Company and certain of its subsidiaries sponsor defined contribution plans pursuant to Section&#160;401(k) of the U.S. Internal Revenue Code. Employee contributions are voluntary and subject to the maximum allowable under federal tax regulations. For the years ended March&#160;31, 2021 and 2020, the Company recorded total expense for employer matching contributions of $1.7&#160;million and $1.7&#160;million, respectively. </div></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CompensationAndRetirementDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CompensationAndRetirementDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedContributionPlanTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for defined contribution plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 70<br> -URI http://asc.fasb.org/subtopic&amp;trid=2235116<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 70<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=49170846&amp;loc=d3e28014-114942<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedContributionPlanTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>94
<FILENAME>R24.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm139997755069384">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Other (Income) Expense, Net<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2021</div></th>
<th class="th"><div>Mar. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherIncomeAndExpensesAbstract', window );"><strong>Other Income and Expenses [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherOperatingIncomeAndExpenseTextBlock', window );">Other (Income) Expense, Net</a></td>
<td class="text"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Note 12&#8212;Other (Income) Expense, Net </div></div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Other (income) expense, net was as follows (in thousands): </div></div></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 76%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px; text-indent: 0px;">
<tr style="font-size: 0px;">
<td style="width: 75%;"/>
<td style="width: 7%; vertical-align: bottom;"/>
<td/>
<td/>
<td/>
<td style="width: 7%; vertical-align: bottom;"/>
<td/>
<td/>
<td/> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 1pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td colspan="6" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Three&#160;Months&#160;Ended<br/> June&#160;30,</div></div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 1pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2021</div></div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2020</div></div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td> </tr>
<tr style="font-size: 0px;">
<td style="width: 80%;"/>
<td style="width: 6%; vertical-align: bottom;"/>
<td/>
<td/>
<td/>
<td style="width: 5%; vertical-align: bottom;"/>
<td/>
<td/>
<td/> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Loss from equity method investment</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">3,750</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Interest income</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(71</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(621</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Interest expense</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">2,513</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">791</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Other income</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(2,576</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(1,078</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Total</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(134</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">2,842</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td> </tr> </table> <span></span>
</td>
<td class="text"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Note 17&#8212;Other Expense, Net </div></div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Other expense, net from continuing operations was as follows (in thousands): </div></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 76%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="font-size: 0px;">
<td style="width: 74%;"/>
<td style="width: 6%; vertical-align: bottom;"/>
<td/>
<td/>
<td/>
<td style="width: 6%; vertical-align: bottom;"/>
<td/>
<td/>
<td/> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;&#160;</td>
<td colspan="6" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Years Ended March&#160;31,</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2021</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2020</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: bottom;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Loss from equity method investment</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">$</td>
<td style="vertical-align: bottom;;text-align:right;">3,750</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">$</td>
<td style="vertical-align: bottom;;text-align:right;">21,386</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Interest income</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(1,418</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(17,990</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Interest expense</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">2,809</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">7,683</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Other expense</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">3,560</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">2,543</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;">&#160;</td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: bottom;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Total</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">$</td>
<td style="vertical-align: bottom;;text-align:right;">8,701</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">$</td>
<td style="vertical-align: bottom;;text-align:right;">13,622</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;">&#160;</td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td> </tr> </table> <span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherIncomeAndExpensesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherIncomeAndExpensesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherOperatingIncomeAndExpenseTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for other operating income and other operating expense items.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherOperatingIncomeAndExpenseTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>95
<FILENAME>R25.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm139997755033224">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Net Loss per Common Share<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2021</div></th>
<th class="th"><div>Mar. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareAbstract', window );"><strong>Earnings Per Share [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareTextBlock', window );">Net Loss per Common Share</a></td>
<td class="text"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Note 13&#8212;Net Loss per Common Share </div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Basic net loss per common share is computed by dividing net loss attributable to Roivant Sciences Ltd. by the weighted-average number of common stock outstanding during the period. Diluted net loss per common share is computed by dividing the net loss attributable to Roivant Sciences Ltd. by the diluted weighted-average number of common stock outstanding during the period. </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">For periods of loss, diluted loss per share is calculated similar to basic loss per share as the effect of including all potentially dilutive common share equivalents is anti-dilutive. All outstanding common stock equivalents have been excluded from the computation of diluted loss per share because their effect was anti-dilutive due to the net loss. Refer to Note 8, &#8220;Share-Based Compensation&#8221; and Note 4, &#8220;Sumitomo Transaction Agreement&#8221; for additional detail regarding outstanding common stock equivalents. </div></div><span></span>
</td>
<td class="text"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Note 18&#8212;Earnings per Common Share </div></div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The computations of the numerator to derive the basic and diluted earnings per share amounts presented on the face of the accompanying consolidated statements of operations are as follows (in thousands): </div></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 92%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="font-size: 0px;">
<td style="width: 75%;"/>
<td style="width: 3%; vertical-align: bottom;"/>
<td/>
<td/>
<td/>
<td style="width: 3%; vertical-align: bottom;"/>
<td/>
<td/>
<td/> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;&#160;</td>
<td colspan="6" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Years Ended March&#160;31,</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2021</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2020</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Loss from continuing operations, net of tax</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(900,233</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(568,110</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Net loss from continuing operations, net of tax, attributable to noncontrolling interest</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(90,999</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(48,716</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Loss from continuing operations, net of tax, attributable to Roivant Sciences Ltd.</div></div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(809,234</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">)&#160;</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(519,394</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">)&#160;</div></div></td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Deemed dividend on repurchase of redeemable noncontrolling interest relating to subsidiary convertible and redeemable preferred stock<div style="font-size: 85%; vertical-align: top;;display:inline;;font-size:9.4px">(1)</div></div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(77,777</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Basic and diluted loss from continuing operations, net of tax, attributable to Roivant Sciences Ltd.</div></div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">$</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(809,234</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">)&#160;</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">$</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(597,171</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">)&#160;</div></div></td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Income from discontinued operations, net of tax</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">1,578,426</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Net loss from discontinued operations, net of tax, attributable to noncontrolling interest</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(141,477</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Net income from discontinued operations, net of tax, attributable to Roivant Sciences Ltd.</div></div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">$</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#8212;&#160;&#160;</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">$</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">1,719,903</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Basic and diluted income from discontinued operations, net of tax</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">1,719,903</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;">&#160;</td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Basic and diluted net (loss) income attributable to Roivant Sciences</div></div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">$</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(809,234</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">)&#160;</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">$</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">1,122,732</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td> </tr> </table> <div style="clear: both; max-height: 0px;"/> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 4%; vertical-align: top;;text-align:left;"><div style="font-size: 85%; vertical-align: top;;display:inline;;font-size:9.4px">(1)</div></td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Consideration paid in excess of carrying value for the repurchase of redeemable noncontrolling interest relating to subsidiary convertible and redeemable preferred stock of $77.8&#160;million is considered a deemed dividend and, for purposes of calculating net loss per share, increases the loss from continuing operations, net of tax, attributable to Roivant Sciences Ltd. for the year ended March&#160;31, 2020. See Note 10, &#8220;Shareholders&#8217; Equity and Redeemable Noncontrolling Interest.&#8221; </div></div> </td> </tr> </table>  <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Basic net (loss) income per common share is computed by dividing net (loss) income attributable to Roivant Sciences Ltd. by the weighted-average number of common stock outstanding during the period. Diluted net (loss) income per common share is computed by dividing the net income (loss) attributable to Roivant Sciences Ltd. by the diluted weighted-average number of common stock outstanding during the period. </div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">For periods of loss from continuing operations, diluted loss per share is calculated similar to basic loss per share as the effect of including all potentially dilutive common share equivalents is anti-dilutive. All outstanding common stock equivalents have been excluded from the computation of diluted loss per share because their </div></div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">effect was anti-dilutive due to the loss from continuing operations. Refer to Note 11, &#8220;Share-Based Compensation&#8221; and Note 5, &#8220;Sumitomo Transaction Agreement&#8221; for additional detail regarding outstanding common stock equivalents. </div></div> <span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for earnings per share.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=109243012&amp;loc=SL65017193-207537<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -URI http://asc.fasb.org/topic&amp;trid=2144383<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3630-109257<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>96
<FILENAME>R26.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm139997864186936">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Subsequent Events<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2021</div></th>
<th class="th"><div>Mar. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventsTextBlock', window );">Subsequent Events</a></td>
<td class="text"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Note 14&#8212;Subsequent Events </div></div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt; margin-left: 2%;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Proteovant </div></div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">In July 2021, Proteovant Sciences, Inc. (&#8220;Proteovant&#8221;) received the second $100.0&#160;million payment due under a subscription agreement entered into with SK, Inc. (&#8220;SK&#8221;) in December 2020 pursuant to which SK agreed to make a $200.0&#160;million equity investment in Proteovant, representing an ownership interest of 40.0% on the closing date. The second $100.0&#160;million payment was classified as a subscription receivable in the accompanying condensed consolidated balance sheets and condensed consolidated statements of shareholders&#8217; equity and redeemable noncontrolling interest as of June&#160;30, 2021.</div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt; margin-left: 2%; text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Datavant </div></div></div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">In July 2021, Datavant closed its merger with CIOX Health, LLC. At closing, RSL received approximately $320&#160;million in cash and a minority equity stake in the combined company.</div></div><span></span>
</td>
<td class="text"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Note 19&#8212;Subsequent Events </div></div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The Company has evaluated subsequent events for appropriate disclosures through June 30, 2021, the date that the consolidated financial statements were available to be issued. All subsequent events requiring recognition as of March&#160;31, 2021 have been incorporated in these financial statements. </div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Option Vants Transaction </div></div></div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;">On May&#160;1, 2021, the Company entered into an Asset Purchase Agreement with Sumitomo and its subsidiary Sumitomo Pharmaceuticals (Suzhou) Co., Ltd. (&#8220;SPC&#8221;) (the &#8220;Asset Purchase Agreement&#8221;). The transactions contemplated by the Asset Purchase Agreement closed in June 2021. Pursuant to the Asset Purchase Agreement: (i)&#160;Sumitomo terminated all of its existing options to acquire the Company&#8217;s equity interests in the Option Vants; (ii)&#160;the Company transferred and assigned to SPC all of its intellectual property, development and commercialization rights for (a)&#160;lefamulin in Mainland China, Taiwan, Hong Kong, and Macau (collectively &#8220;Greater China&#8221;), (b) vibegron in Mainland China, (c)&#160;rodatristat ethyl in Greater China and South Korea and <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">(d)&#160;RVT-802</div> in Greater China and South Korea; (iii)&#160;we will receive a $5.0&#160;million cash payment; and (iv)&#160;Sumitomo entered into an agreement with the Company to pursue future collaborations with Genevant. </div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Dermavant </div></div></div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">On May&#160;14, 2021, Dermavant entered into a $160.0&#160;million revenue interest purchase and sale agreement (the &#8220;RIPSA&#8221;) for its investigational product tapinarof with three institutional investors. Under the terms of the RIPSA, the participants purchased a capped single-digit revenue interest in net sales of tapinarof for all dermatological indications in the United States in exchange for $160.0&#160;million in committed funding to be paid to Dermavant, subject to approval of tapinarof by the FDA. </div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Dermavant concurrently entered into a $40.0&#160;million senior secured credit facility (the &#8220;Credit Facility&#8221;) with one of the institutional investors. The Credit Facility has a <span style="-sec-ix-hidden:hidden28230199">five</span>-year maturity and bears an interest rate of 10% per annum. In connection with the funding of the Credit Facility, Dermavant issued to the institutional investor a warrant to purchase 1,199,072 common shares of Dermavant at an exercise price of $0.01 per common share. </div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The proceeds from the Credit Facility were used to repay all amounts outstanding under the loan and security agreement with Hercules, with the remainder of net proceeds used for working capital and general corporate purposes. The Company reclassified $3.1&#160;million on the consolidated balance sheets as of March&#160;31, 2021 from current to long-term given that Dermavant had the intent and ability to refinance the short-term obligation on a long-term basis after March&#160;31, 2021 and before the financial statements were issued. </div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Datavant</div></div></div></div> </div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">In June 2021, Datavant and CIOX Health, LLC entered into a definitive agreement to merge the two companies. </div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The merger closed on July 27, 2021. At closing, Roivant received approximately $320 million in cash. </div></div><span></span>
</td>
</tr>
</table>
<div style="display: none;"><table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for significant events or transactions that occurred after the balance sheet date through the date the financial statements were issued or the date the financial statements were available to be issued. Examples include: the sale of a capital stock issue, purchase of a business, settlement of litigation, catastrophic loss, significant foreign exchange rate changes, loans to insiders or affiliates, and transactions not in the ordinary course of business.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 855<br> -URI http://asc.fasb.org/topic&amp;trid=2122774<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 855<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6842918&amp;loc=SL6314017-165662<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table></div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>97
<FILENAME>R27.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm139997851141624">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies (Policies)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2021</div></th>
<th class="th"><div>Mar. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BasisOfAccountingPolicyPolicyTextBlock', window );">Basis of Presentation and Principles of Consolidation</a></td>
<td class="text"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">(A) Basis of Presentation and Principles of Consolidation </div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The Company&#8217;s fiscal year ends on March&#160;31, and its fiscal quarters end on June&#160;30, September&#160;30, and December 31. </div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The accompanying unaudited condensed consolidated financial statements have been prepared in accordance with accounting principles generally accepted in the United States (&#8220;U.S. GAAP&#8221;) for interim financial information and follow the requirements of the Securities and Exchange Commission (&#8220;SEC&#8221;) for interim financial reporting. Accordingly, these unaudited condensed consolidated financial statements do not include all of the information and </div></div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"> </div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">disclosures required by U.S. GAAP for complete financial statements as certain footnotes or other financial information that are normally required by U.S. GAAP can be condensed or omitted. The unaudited condensed consolidated financial statements have been prepared on the same basis as the audited consolidated financial statements. </div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">These unaudited condensed consolidated financial statements should be read in conjunction with the Company&#8217;s audited consolidated financial statements and notes thereto for the fiscal year ended March&#160;31, 2021 issued on June&#160;30, 2021. The unaudited condensed consolidated balance sheet at March&#160;31, 2021 has been derived from the audited consolidated financial statements at that date. In the opinion of management, the unaudited condensed consolidated financial statements include all normal and recurring adjustments that are considered necessary to present fairly the financial position of the Company and its results of operations and cash flows for the interim periods presented. Certain prior year amounts were reclassified to conform to current year presentation. Operating results for the three months ended June&#160;30, 2021 are not necessarily indicative of the results that may be expected for the fiscal year ending March&#160;31, 2022, for any other interim period, or for any other future year. </div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Any references in these notes to applicable accounting guidance are meant to refer to the authoritative U.S. GAAP as found in the Accounting Standards Codification (&#8220;ASC&#8221;) and Accounting Standards Updates (&#8220;ASU&#8221;) of the Financial Accounting Standards Board (&#8220;FASB&#8221;). The unaudited condensed consolidated financial statements include the accounts of RSL and the subsidiaries in which it has a controlling financial interest, most often through a majority voting interest. All intercompany balances and transactions have been eliminated in consolidation. </div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">For consolidated entities where the Company owns or is exposed to less than 100% of the economics, the Company records net loss attributable to noncontrolling interests in its unaudited condensed consolidated statements of operations equal to the percentage of the economic or ownership interest retained in the respective operations by the noncontrolling parties. The Company presents noncontrolling interests as a component of shareholders&#8217; equity on its unaudited condensed consolidated balance sheets. </div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The Company accounts for changes in its ownership interest in its subsidiaries while control is retained as equity transactions. The carrying amount of the noncontrolling interest is adjusted to reflect the change in RSL&#8217;s ownership interest in the subsidiary. Any difference between the fair value of the consideration received or paid and the amount by which the noncontrolling interest is adjusted is recognized within shareholders&#8217; equity attributable to RSL. </div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">There have been no significant changes in the Company&#8217;s accounting policies from those disclosed in the Company&#8217;s audited consolidated financial statements for the fiscal year ended March&#160;31, 2021 issued on June&#160;30, 2021. </div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">In April 2012, the Jumpstart Our Business Startups Act of 2012 (the &#8220;JOBS Act&#8221;) was enacted. Section&#160;107(b) of the JOBS Act provides that an emerging growth company can take advantage of an extended transition period for complying with new or revised accounting standards. Thus, an emerging growth company can delay the adoption of certain accounting standards until those standards would otherwise apply to private companies. The Company has irrevocably elected not to avail itself of this extended transition period, and, as a result, the Company will adopt new or revised accounting standards on the relevant dates on which adoption of such standards is required for other public companies. </div></div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"> </div> <span></span>
</td>
<td class="text"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">(A) Basis of Presentation and Principles of Consolidation </div></div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The Company&#8217;s fiscal year ends on March&#160;31, and its fiscal quarters end on June&#160;30, September&#160;30, and December 31. </div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The accompanying audited consolidated financial statements and notes thereto have been prepared in accordance with accounting principles generally accepted in the United States (&#8220;U.S. GAAP&#8221;). </div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Any references in these notes to applicable accounting guidance are meant to refer to the authoritative U.S. GAAP as found in the Accounting Standards Codification (&#8220;ASC&#8221;) and Accounting Standards Updates </div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">(&#8220;ASU&#8221;) of the Financial Accounting Standards Board (&#8220;FASB&#8221;). The consolidated financial statements include the accounts of RSL and the subsidiaries in which it has a controlling financial interest, most often through a majority voting interest. All intercompany balances and transactions have been eliminated in consolidation. </div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">For consolidated entities where the Company owns or is exposed to less than 100% of the economics, the Company records net loss attributable to noncontrolling interests in its consolidated statements of operations equal to the percentage of the economic or ownership interest retained in the respective operations by the noncontrolling parties. The Company presents noncontrolling interests as a component of shareholders&#8217; equity on its consolidated balance sheets. </div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The Company accounts for changes in its ownership interest in its subsidiaries while control is retained as equity transactions. The carrying amount of the noncontrolling interest is adjusted to reflect the change in RSL&#8217;s ownership interest in the subsidiary. Any difference between the fair value of the consideration received or paid and the amount by which the noncontrolling interest is adjusted is recognized within shareholders&#8217; equity attributable to RSL. </div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Additionally, the Company concluded that the disposition of RSL&#8217;s ownership interests in Myovant Sciences Ltd. (&#8220;Myovant&#8221;), Urovant Sciences Ltd. (&#8220;Urovant&#8221;), Enzyvant Therapeutics Ltd. (&#8220;Enzyvant&#8221;), Altavant Sciences Ltd. (&#8220;Altavant&#8221;), and Spirovant Sciences Ltd. (&#8220;Spirovant&#8221;) (collectively, the &#8220;Sumitovant Vants&#8221;), pursuant to the transaction agreement entered into with Sumitomo Dainippon Pharma Co., Ltd. (&#8220;Sumitomo&#8221;) on October&#160;31, 2019 (the &#8220;Sumitomo Transaction Agreement&#8221;) that closed on December&#160;27, 2019 (the &#8220;Sumitomo Transaction&#8221;), met the requirements to be presented as discontinued operations. As such, results relating to the transferred interests prior to disposition are classified as discontinued operations in prior period consolidated financial statements. See Note 5, &#8220;Sumitomo Transaction Agreement&#8221; and Note 6, &#8220;Discontinued Operations&#8221; for further discussion. Certain prior year amounts were reclassified to conform to current year presentation. </div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">In April 2012, the Jumpstart Our Business Startups Act of 2012 (the &#8220;JOBS Act&#8221;) was enacted. Section&#160;107(b) of the JOBS Act provides that an emerging growth company can take advantage of an extended transition period for complying with new or revised accounting standards. Thus, an emerging growth company can delay the adoption of certain accounting standards until those standards would otherwise apply to private companies. The Company has irrevocably elected not to avail itself of this extended transition period, and, as a result, the Company will adopt new or revised accounting standards on the relevant dates on which adoption of such standards is required for other public companies. </div></div> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_UseOfEstimates', window );">Use of Estimates</a></td>
<td class="text"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt; text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">(B) Use of Estimates </div></div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The preparation of financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the amounts reported in the financial statements and accompanying notes. The Company regularly evaluates estimates and assumptions related to assets, liabilities, costs, expenses,</div></div></div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">contingent liabilities, share-based compensation and research and development costs. The Company bases its estimates and assumptions on historical experience and on various other factors that it believes to be reasonable under the circumstances, the results of which form the basis for making judgments about the carrying values of assets and liabilities that are not readily apparent from other sources. Actual results could differ from those estimates. </div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">Additionally, the Company assessed the impact that the <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">COVID-19</div> pandemic has had on its operations and financial results as of June&#160;30, 2021 and through the issuance of these condensed consolidated financial statements. The Company&#8217;s analysis was informed by the facts and circumstances as they were known to the Company. This assessment considered the impact <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">COVID-19</div> may have on financial estimates and assumptions that affect the reported amounts of assets and liabilities and expenses. </div></div> <span></span>
</td>
<td class="text"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">(B) Use of Estimates </div></div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The preparation of financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the amounts reported in the financial statements and accompanying notes. The Company regularly evaluates estimates and assumptions related to assets, liabilities, costs, expenses, contingent liabilities, share-based compensation and research and development costs. The Company bases its estimates and assumptions on historical experience and on various other factors that it believes to be reasonable under the circumstances, the results of which form the basis for making judgments about the carrying values of assets and liabilities that are not readily apparent from other sources. Actual results could differ from those estimates. </div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">Additionally, the Company assessed the impact that the <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">COVID-19</div> pandemic has had on its operations and financial results as of March&#160;31, 2021 and through the issuance of these consolidated financial statements. The Company&#8217;s analysis was informed by the facts and circumstances as they were known to the Company. This assessment considered the impact <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">COVID-19</div> may have on financial estimates and assumptions that affect the reported amounts of assets and liabilities and expenses. </div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_UnusualRisksAndUncertaintiesTextBlock', window );">Risks and Uncertainties</a></td>
<td class="text"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt; text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">(C) Risks and Uncertainties </div></div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The Company is subject to risks common to companies in the biopharmaceutical industry including, but not limited to, uncertainties related to commercialization of products, regulatory approvals, dependence on key products, dependence on third-party service providers, such as contract research organizations, and protection of intellectual property rights. </div></div></div><span></span>
</td>
<td class="text"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">(C) Risks and Uncertainties </div></div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The Company is subject to risks common to companies in the biopharmaceutical industry including, but not limited to, uncertainties related to commercialization of products, regulatory approvals, dependence on key products, dependence on third-party service providers, such as contract research organizations, and protection of intellectual property rights. </div></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskCreditRisk', window );">Concentrations of Credit Risk</a></td>
<td class="text"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt; text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">(D) Concentrations of Credit Risk </div></div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Financial instruments that potentially subject the Company to concentration of credit risk include cash and cash equivalents. The Company maintains cash deposits and cash equivalents in highly-rated, federally-insured financial institutions in excess of federally insured limits. The Company has established guidelines relative to diversification and maturities to maintain safety and liquidity. The Company has not experienced any credit losses related to these financial instruments and does not believe that it is exposed to any significant credit risk related to these instruments. </div></div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"> </div><span></span>
</td>
<td class="text"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">(D) Concentrations of Credit Risk </div></div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Financial instruments that potentially subject the Company to concentration of credit risk include cash and cash equivalents. The Company maintains cash deposits and cash equivalents in highly-rated, federally-insured financial institutions in excess of federally insured limits. The Company has established guidelines relative to diversification and maturities to maintain safety and liquidity. The Company has not experienced any credit losses related to these financial instruments and does not believe that it is exposed to any significant credit risk related to these instruments. </div></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy', window );">Cash, Cash Equivalents, and Restricted Cash</a></td>
<td class="text"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">(E) Cash, Cash Equivalents, and Restricted Cash </div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Cash and cash equivalents include cash deposits in banks and all highly liquid investments that are readily convertible to cash. The Company considers all highly liquid investments purchased with original maturities of three months or less to be cash equivalents. </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">Restricted cash classified as a current asset consists of legally restricted <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-interest</div> bearing deposit accounts relating to the Company&#8217;s corporate credit card programs. Restricted cash classified as a long-term asset consists of restricted deposit accounts related to irrevocable standby letters of credit. As of March&#160;31, 2021, restricted cash classified as a current asset included $75.0&#160;million held in escrow for the purpose of fulfilling certain indemnification obligations. The full escrow amount of $75.0&#160;million was disbursed to the Company in June 2021. See Note 4, &#8220;Sumitomo Transaction Agreement&#8221; for additional information. </div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Cash as reported in the condensed consolidated statements of cash flows includes the aggregate amounts of cash, cash equivalents, and restricted cash as presented on the condensed consolidated balance sheets as follows (in thousands): </div></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;width:76%;">
<tr style="font-size: 0px;">
<td style="width: 64%;"/>
<td style="width: 7%; vertical-align: bottom;"/>
<td/>
<td/>
<td/>
<td style="width: 7%; vertical-align: bottom;"/>
<td/>
<td/>
<td/> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">June&#160;30,&#160;2021</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">March&#160;31,&#160;2021</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top; width: 64%;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Cash and cash equivalents</div></div> </td>
<td style="vertical-align: bottom; width: 7%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">1,996,733</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 7%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">2,055,044</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; width: 64%;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Restricted cash</div></div> </td>
<td style="vertical-align: bottom; width: 7%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">11,644</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 7%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">86,632</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 64%;">&#160;</td>
<td style="vertical-align: bottom; width: 7%;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom; width: 7%;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top; width: 64%;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Cash, cash equivalents and restricted cash</div></div> </td>
<td style="vertical-align: bottom; width: 7%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">2,008,377</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 7%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">2,141,676</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 64%;">&#160;</td>
<td style="vertical-align: bottom; width: 7%;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom; width: 7%;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td> </tr> </table> <span></span>
</td>
<td class="text"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">(E) Cash, Cash Equivalents, and Restricted Cash </div></div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Cash and cash equivalents include cash deposits in banks and all highly liquid investments that are readily convertible to cash. The Company considers all highly liquid investments purchased with original maturities of three months or less to be cash equivalents. </div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">Restricted cash classified as a current asset consists of the amount held in escrow relating to the Sumitomo Transaction (see Note 5, &#8220;Sumitomo Transaction Agreement&#8221;) and the legally restricted <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-interest</div> bearing deposit account relating to the Company&#8217;s corporate credit card program. Restricted cash classified as a long-term asset consists of restricted deposit accounts related to irrevocable standby letters of credit. </div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Cash as reported in the accompanying consolidated statements of cash flows includes the aggregate amounts of cash, cash equivalents, and restricted cash as presented on the accompanying consolidated balance sheets as follows (in thousands): </div></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 76%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="font-size: 0px;">
<td style="width: 62%;"/>
<td style="width: 8%; vertical-align: bottom;"/>
<td/>
<td/>
<td/>
<td style="width: 8%; vertical-align: bottom;"/>
<td/>
<td/>
<td/> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">March&#160;31,&#160;2021</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">March&#160;31,&#160;2020</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Cash and cash equivalents</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">2,055,044</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">2,183,207</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Restricted cash</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">86,632</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">86,045</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;">&#160;</td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Cash, cash equivalents and restricted cash</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">2,141,676</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">2,269,252</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;">&#160;</td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td> </tr> </table> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TradeAndOtherAccountsReceivablePolicy', window );">Trade Receivables, Net</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">(F) Trade Receivables, Net </div></div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The Company monitors the financial performance and creditworthiness of its customers so that it can properly assess and respond to changes in customer credit profiles. The Company reserves against trade receivables for estimated losses that may arise from a customer&#8217;s inability to pay and any amounts determined to be uncollectible are written off against the reserve when it is probable that the receivable will not be collected. The reserve amount for estimated losses was de minimis as of March&#160;31, 2021 and 2020. Trade receivables, net is included in &#8220;Other current assets&#8221; on the accompanying consolidated balance sheets. </div></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesPolicyTextBlock', window );">Contingencies</a></td>
<td class="text"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">(F) Contingencies </div></div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The Company may be, from time to time, a party to various disputes and claims arising from normal business activities. The Company continually assesses any litigation or other claims it may confront to determine if an unfavorable outcome would lead to a probable loss or reasonably possible loss which could be estimated. The Company accrues for all contingencies at the earliest date at which the Company deems it probable that a liability has been incurred and the amount of such liability can be reasonably estimated. If the estimate of a probable loss is a range and no amount within the range is more likely than another, the Company accrues the minimum of the range. In the cases where the Company believes that a reasonably possible loss exists, the Company discloses the facts and circumstances of the litigation, including an estimable range, if possible<div style="letter-spacing: 0px; top: 0px;;display:inline;">.</div></div></div></div><span></span>
</td>
<td class="text"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">(G) Contingencies </div></div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The Company may be, from time to time, a party to various disputes and claims arising from normal business activities. The Company continually assesses any litigation or other claims it may confront to determine if an unfavorable outcome would lead to a probable loss or reasonably possible loss which could be estimated. The Company accrues for all contingencies at the earliest date at which the Company deems it probable that a liability has been incurred and the amount of such liability can be reasonably estimated. If the estimate of a probable loss </div></div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>is a range and no amount within the range is more likely than another, the Company accrues the minimum of the range. In the cases where the Company believes that a reasonably possible loss exists, the Company discloses the facts and circumstances of the litigation, including an estimable range, if possible.<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock', window );">Property and Equipment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">(H) Property and Equipment </div></div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Property and equipment, consisting primarily of computers, equipment, furniture and fixtures, software, and leasehold improvements, is recorded at cost, less accumulated depreciation. Maintenance and repairs that do not improve or extend the lives of the respective assets are expensed to operations as incurred. Upon disposal, retirement or sale, the related cost and accumulated depreciation is removed from the accounts and any resulting gain or loss is included in the results of operations. Depreciation of property and equipment is recorded using the straight-line method over the estimated useful lives of the related assets once the asset has been placed in service. Leasehold improvements are amortized using the straight-line method over the estimated useful life or remaining lease term, whichever is shorter. The following table provides the range of estimated useful lives used for each asset type: </div></div>  <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="font-size: 0px;">
<td style="width: 33%; font-family: &quot;Times New Roman&quot;;"/>
<td style="width: 1%; vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/>
<td style="width: 66%; font-family: &quot;Times New Roman&quot;;"/> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; white-space: nowrap;"> <div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt; border-bottom: 1pt solid rgb(0, 0, 0); display: table-cell; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">Property and Equipment</div></div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;"> <div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt; border-bottom: 1pt solid rgb(0, 0, 0); display: table-cell; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">Estimated Useful Life</div></div></div> </td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Computers</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">3  years</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Equipment</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">5  years</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Furniture and fixtures</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">7  years</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Software</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">3  years</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Leasehold improvements</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">Lesser of estimated useful life or remaining lease term</td> </tr> </table>  <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The Company reviews the recoverability of all long-lived assets, including the related useful lives, whenever events or changes in circumstances indicate that the carrying amount of a long-lived asset might not be recoverable. Recoverability is measured by comparison of the book values of the assets to the future net undiscounted cash flows that the assets are expected to generate. If such assets are considered to be impaired, the impairment to be recognized is measured by the amount by which the book value of the assets exceed their fair value, which is measured based on the projected discounted future net cash flows arising from the assets. </div></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentPolicyTextBlock', window );">Investments</a></td>
<td class="text"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt; text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">(G) Investments </div></div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">For investments in entities over which the Company has significant influence but do not meet the requirements for consolidation and for which the Company has not elected the fair value option, the Company applies the equity method of accounting with the Company&#8217;s share of the underlying income or loss of such entities reported in &#8220;Other (income) expense, net&#8221; on the condensed consolidated statements of operations. The Company applies the equity method to investments in common stock and to other investments in entities that have risk and reward characteristics that are substantially similar to an investment in the investee&#8217;s common stock. </div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Investments in equity securities may also be accounted for using (i)&#160;the fair value option if elected, (ii)&#160;fair value through earnings if fair value is readily determinable or (iii)&#160;for equity investments without readily determinable fair values, the measurement alternative to measure at cost adjusted for any impairment and observable price changes, as applicable. The election to use the measurement alternative is made for each eligible investment. </div></div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"> </div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The Company has elected the fair value option to account for certain investments over which the Company has significant influence. The Company believes the fair value option best reflects the underlying economics of the investment. See Note 3, &#8220;Investments.&#8221; </div></div><span></span>
</td>
<td class="text"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">(I) Investments </div></div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">For investments in entities over which the Company has significant influence but do not meet the requirements for consolidation and for which the Company has not elected the fair value option, the Company applies the equity method of accounting with the Company&#8217;s share of the underlying income or loss of such entities reported in &#8220;Other expense, net&#8221; on the consolidated statements of operations. The Company applies the equity method to investments in common stock and to other investments in entities that have risk and reward characteristics that are substantially similar to an investment in the investee&#8217;s common stock. </div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Investments in equity securities may also be accounted for using (i)&#160;the fair value option if elected, (ii)&#160;fair value through earnings if fair value is readily determinable or (iii)&#160;for equity investments without readily determinable fair values, the measurement alternative to measure at cost adjusted for any impairment and observable price changes, as applicable. The election to use the measurement alternative is made for each eligible investment. </div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The Company has elected the fair value option to account for certain investments over which the Company has significant influence. The Company believes the fair value option best reflects the underlying economics of the investment. See Note 3, &#8220;Investments.&#8221; </div></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpensePolicy', window );">Research and Development Expenses</a></td>
<td class="text"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">(H) Research and Development<div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div>Expenses </div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">Research and development (&#8220;R&amp;D&#8221;) costs are expensed as incurred. Preclinical and clinical study costs are accrued over the service periods specified in the contracts and adjusted as necessary based upon an ongoing <div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">review </div>of the <div style="letter-spacing: 0px; top: 0px;;display:inline;">level </div>of <div style="letter-spacing: 0px; top: 0px;;display:inline;">effort </div>and costs</div> actually incurred. Payments for a product license prior to regulatory approval of the product and payments for milestones achieved prior to regulatory approval of the product are expensed in the period incurred as R&amp;D. Milestone payments made in connection <div style="letter-spacing: 0px; top: 0px;;display:inline;">with </div><div style="letter-spacing: 0px; top: 0px;;display:inline;">regulatory </div>approvals are capitalized and amortized to cost of revenue over the remaining useful life of the asset. R&amp;D costs primarily consist of the intellectual property and R&amp;D materials acquired and expenses from third parties who conduct R&amp;D activities on behalf of the <div style="letter-spacing: 0px; top: 0px;;display:inline;">Company</div>.</div> </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">The Company evaluates <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">in-licensed</div> agreements for <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">in-process</div> research and development projects (&#8220;IPR&amp;D&#8221;) to determine if it meets the definition of a business and thus should be accounted for as a business combination. If the <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">in-licensed</div> agreement for IPR&amp;D does not meet the definition of a business and the assets have not reached technological feasibility and therefore have no alternative future use, the Company expenses payments made under such license agreements as R&amp;D expense in its condensed consolidated statements of operations. The Company initially recognizes contingent consideration in an asset acquisition at fair value. The carrying value of contingent consideration is subsequently adjusted when the contingency is resolved and is paid or becomes payable. </div></div><span></span>
</td>
<td class="text"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">(J) Research and Development Expenses </div></div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Research and development (&#8220;R&amp;D&#8221;) costs are expensed as incurred. Preclinical and clinical study costs are accrued over the service periods specified in the contracts and adjusted as necessary based upon an ongoing </div></div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">review of the level of effort and costs actually incurred. Payments for a product license prior to regulatory approval of the product and payments for milestones achieved prior to regulatory approval of the product are expensed in the period incurred as R&amp;D. Milestone payments made in connection with regulatory approvals are capitalized and amortized to cost of revenue over the remaining useful life of the asset. R&amp;D costs primarily consist of the intellectual property and R&amp;D materials acquired and expenses from third parties who conduct R&amp;D activities on behalf of the Company. </div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">The Company evaluates <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">in-licensed</div> agreements for <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">in-process</div> research and development projects (&#8220;IPR&amp;D&#8221;) to determine if it meets the definition of a business and thus should be accounted for as a business combination. If the <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">in-licensed</div> agreement for IPR&amp;D does not meet the definition of a business and the assets have not reached technological feasibility and therefore have no alternative future use, the Company expenses payments made under such license agreements as R&amp;D expense in its consolidated statements of operations. The Company initially recognizes contingent consideration in an asset acquisition at fair value. The carrying value of contingent consideration is subsequently adjusted when the contingency is resolved and is paid or becomes payable. </div> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_roiv_GeneralAndAdministrativeExpensesPolicyTextBlock', window );">General and Administrative Expenses</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">(K) General and Administrative Expenses </div></div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;">General and administrative (&#8220;G&amp;A&#8221;) expenses consist primarily of employee-related expenses for G&amp;A personnel, including those responsible for the identification and acquisition or <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">in-license</div> of new drug candidates as well as for overseeing Vant operations and facilitating the use of the Company&#8217;s platform and technologies at Vants. G&amp;A expenses also consist of legal and accounting fees, consulting services and other operating costs relating to corporate matters and daily operations. G&amp;A expenses include costs incurred relating to the identification, acquisition or <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">in-license</div> and technology transfer of promising drug candidates along with costs incurred relating to the integration of new technologies. </div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxPolicyTextBlock', window );">Income Taxes</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">(L) Income Taxes </div></div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Deferred tax assets and liabilities are recognized for the future tax consequences attributable to differences between the financial statement carrying amounts of existing assets and liabilities and the respective tax bases. Deferred tax assets and liabilities are measured using enacted tax rates expected to apply to taxable income in the years in which those temporary differences are expected to be recovered or settled. The effect on deferred tax assets and liabilities of a change in tax rates is recognized in income in the period that includes the enactment date. A valuation allowance is recorded when, after consideration of all positive and negative evidence, it is not more likely than not that the Company&#8217;s deferred tax assets will be realizable. If the Company determines that it would be able to realize its deferred tax assets in the future in excess of its net recorded amount, the Company would make an adjustment to the deferred tax asset valuation allowance, which would reduce the provision for income taxes. </div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">When uncertain tax positions exist, the Company recognizes the tax benefit of tax positions to the extent that the benefit will more likely than not be realized. The determination as to whether the tax benefit will more likely than not be realized is based upon the technical merits of the tax position as well as consideration of the available facts and circumstances. </div></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy', window );">Share-Based Compensation</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">(M) Share-Based Compensation </div></div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Share-based awards to employees, directors, and consultants, including stock options, restricted stock units, performance options and capped value appreciation rights, are measured at fair value on the date of the grant and that fair value is recognized as share-based compensation expense in the Company&#8217;s consolidated statements of operations over the requisite service period of the respective award. The estimated fair value of awards that contain performance conditions is expensed when the Company concludes that it is probable that the performance condition will be achieved. The Company may grant awards with graded-vesting features. When such awards have only service vesting requirements, the Company elected to record share-based compensation </div></div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">expense on a straight-line basis. If awards with graded-vesting features contain performance or market conditions, then the Company records share-based compensation expense using the accelerated attribution method. </div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The Company measures the fair value of its stock options that only have service vesting requirements or performance-based options without market conditions using the Black-Scholes option pricing model. For performance-based awards with market conditions, the Company determines the fair value of the awards as of the grant date using a Monte Carlo simulation model. </div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">Certain assumptions need to be made with respect to utilizing the Black-Scholes option pricing model, including the expected life of the award, volatility of the underlying shares, the risk-free interest rate and the fair value of the Company&#8217;s common shares. Since the Company has no option exercise history, it has generally elected to estimate the expected life of an award based upon the &#8220;simplified method&#8221; with the continued use of this method extended until such time the Company has sufficient exercise history. The risk-free interest rate is based on the rates paid on securities issued by the U.S. Treasury with a term approximating the expected life of the equity award. The expected share price volatility for the Company&#8217;s common shares is estimated by taking the average historical price volatility for industry peers. The Company accounts for <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">pre-vesting</div> award forfeitures when they occur. </div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">As part of the valuation of share-based compensation under the Black-Scholes option pricing model, it is necessary for the Company to estimate the fair value of its common shares for RSL and privately held Vants. Given the absence of a public trading market, and in accordance with the American Institute of Certified Public Accountants&#8217; Practice Guide, Valuation of Privately-Held-Company Equity Securities Issued as Compensation, the Company exercises reasonable judgment and considers numerous objective and subjective factors to determine its best estimate of the fair value of its common shares. The estimation of the fair value of the common shares considers factors including the following: the prices of the Company&#8217;s common shares sold to investors in arm&#8217;s length transactions, the estimated present value of the Company&#8217;s future cash flows; the Company&#8217;s business, financial condition and results of operations; the Company&#8217;s forecasted operating performance; the illiquid nature of the Company&#8217;s common shares; industry information such as market size and growth; market capitalization of comparable companies and the estimated value of transactions such companies have engaged in; and macroeconomic conditions. </div></div> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueMeasurementPolicyPolicyTextBlock', window );">Fair Value Measurements</a></td>
<td class="text"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">(I) Fair Value Measurements </div></div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The Company utilizes fair value measurement guidance prescribed by accounting standards to value its financial instruments. The guidance establishes a fair value hierarchy for financial instruments measured at fair value that distinguishes between assumptions based on market data (observable inputs) and the Company&#8217;s own assumptions (unobservable inputs). Observable inputs are inputs that market participants would use in pricing the asset or liability based on market data obtained from sources independent of the Company. Unobservable inputs are inputs that reflect the Company&#8217;s assumptions about the inputs that market participants would use in pricing the asset or liability, and are developed based on the best information available in the circumstances. Fair value is defined as the exchange price, or exit price, representing the amount that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants at the reporting date. As a basis for considering market participant assumptions in fair value measurements, the guidance establishes a three-tier fair value hierarchy that distinguishes among the following: </div></div></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px; text-indent: 0px;;width:100%;">
<tr style="page-break-inside: avoid;">
<td style="width: 4%;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="width: 4%; vertical-align: top;;text-align:left;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#8226;</div></td>
<td style="width: 1%; vertical-align: top;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">Level <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">1-Valuations</div> are based on unadjusted quoted prices in active markets for identical assets or liabilities that the Company has the ability to access. </div></div> </td> </tr> </table> <div style="clear: both; max-height: 0px; text-indent: 0px;"/> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px; text-indent: 0px;;width:100%;">
<tr style="page-break-inside: avoid;">
<td style="width: 4%;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="width: 4%; vertical-align: top;;text-align:left;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#8226;</div></td>
<td style="width: 1%; vertical-align: top;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">Level <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">2-Valuations</div> are based on quoted prices for similar assets or liabilities in active markets, quoted prices for identical or similar assets or liabilities in markets that are not active and models for which all significant inputs are observable, either directly or indirectly. </div></div> </td> </tr> </table> <div style="clear: both; max-height: 0px; text-indent: 0px;"/> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px; text-indent: 0px;;width:100%;">
<tr style="page-break-inside: avoid;">
<td style="width: 4%;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="width: 4%; vertical-align: top;;text-align:left;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#8226;</div></td>
<td style="width: 1%; vertical-align: top;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">Level <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">3-Valuations</div> are based on inputs that are unobservable (supported by little or no market activity) and significant to the overall fair value measurement. </div></div> </td> </tr> </table> <div style="clear: both; max-height: 0px; text-indent: 0px;"/> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">To the extent the valuation is based on models or inputs that are less observable or unobservable in the market, the determination of fair value requires more judgment. Accordingly, the degree of judgment exercised by the Company in determining fair value is greatest for instruments categorized in Level&#160;3. A financial instrument&#8217;s level within the fair value hierarchy is based on the lowest level of any input that is significant to the fair value measurement. </div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The Company&#8217;s financial instruments include shares of common stock of Arbutus Biopharma Corporation (&#8220;Arbutus&#8221;); shares of Arbutus&#8217;s Series A participating convertible preferred shares (&#8220;Arbutus Preferred Shares&#8221;); shares of common stock of Sio Gene Therapies Inc. (&#8220;Sio&#8221;); liability instruments issued; deferred consideration liability; its investments in other entities; cash and cash equivalents consisting of money market funds; accounts payable; and long-term debt. </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">The shares of Arbutus and Sio common stock and investments in common stock with a readily determinable fair value are classified as Level&#160;1, and their fair value is determined based upon quoted market prices in an active market. The Arbutus Preferred Shares held by the Company are classified as Level&#160;2 as the fair value of such preferred shares is determined based upon the quoted market price of Arbutus common stock into which such preferred shares are convertible. The liability instruments issued are classified as Level&#160;3 within the fair value hierarchy as the assumptions and estimates used in the valuations are unobservable in the market. Cash, accounts payable, and deferred consideration liability are stated at their respective historical carrying amounts, which approximate fair value due to their short-term nature. The deferred consideration liability is based on a fixed monetary amount, and payment is based solely on the passage of time. Money market funds are included in <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">Level-1</div> of the fair value hierarchy and are valued at the closing price reported by an actively traded exchange. The carrying value of long-term debt issued by Dermavant Sciences Ltd. (together with its wholly owned subsidiaries, &#8220;Dermavant&#8221;), which is stated at amortized cost, approximates fair value based on current interest rates for similar types of borrowings and therefore is included in Level&#160;2 of the fair value hierarchy. Long-term debt issued by Dermavant for which the fair value option has been elected is included in Level&#160;3 of the fair value hierarchy as the assumptions and estimates used in the valuation are unobservable in the market. </div></div> <span></span>
</td>
<td class="text"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">(N) Fair Value Measurements </div></div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The Company utilizes fair value measurement guidance prescribed by accounting standards to value its financial instruments. The guidance establishes a fair value hierarchy for financial instruments measured at fair value that distinguishes between assumptions based on market data (observable inputs) and the Company&#8217;s own assumptions (unobservable inputs). Observable inputs are inputs that market participants would use in pricing the asset or liability based on market data obtained from sources independent of the Company. Unobservable inputs are inputs that reflect the Company&#8217;s assumptions about the inputs that market participants would use in pricing the asset or liability, and are developed based on the best information available in the circumstances. Fair value is defined as the exchange price, or exit price, representing the amount that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants at the reporting date. As a basis for considering market participant assumptions in fair value measurements, the guidance establishes a three-tier fair value hierarchy that distinguishes among the following: </div></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;">Level <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">1-Valuations</div> are based on unadjusted quoted prices in active markets for identical assets or liabilities that the Company has the ability to access. </div> </td> </tr> </table> <div style="clear: both; max-height: 0px;"/> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;">Level <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">2-Valuations</div> are based on quoted prices for similar assets or liabilities in active markets, quoted prices for identical or similar assets or liabilities in markets that are not active and models for which all significant inputs are observable, either directly or indirectly. </div> </td> </tr> </table> <div style="clear: both; max-height: 0px;"/> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;">Level <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">3-Valuations</div> are based on inputs that are unobservable (supported by little or no market activity) and significant to the overall fair value measurement. </div> </td> </tr> </table> <div style="clear: both; max-height: 0px;"/> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">To the extent the valuation is based on models or inputs that are less observable or unobservable in the market, the determination of fair value requires more judgment. Accordingly, the degree of judgment exercised by the Company in determining fair value is greatest for instruments categorized in Level&#160;3. A financial instrument&#8217;s level within the fair value hierarchy is based on the lowest level of any input that is significant to the fair value measurement. </div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The Company&#8217;s financial instruments include shares of common stock of Arbutus Biopharma Corporation (&#8220;Arbutus&#8221;); shares of Arbutus&#8217;s Series A participating convertible preferred shares (&#8220;Arbutus Preferred Shares&#8221;); shares of common stock of Sio Gene Therapies Inc. (&#8220;Sio&#8221;); liability instruments issued, including options granted to Sumitomo (the &#8220;Sumitomo Options&#8221;) to purchase all, or 75% in one case, of RSL&#8217;s ownership interests in certain subsidiaries under the Sumitomo Transaction Agreement; deferred consideration liability; its investments in other entities; cash and cash equivalents consisting of money market funds; accounts payable; and long-term debt. </div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The shares of Arbutus and Sio common stock and investments in common stock with a readily determinable fair value are classified as Level&#160;1, and their fair value is determined based upon quoted market prices in an active market. The Arbutus Preferred Shares held by the Company are classified as Level&#160;2 as the fair value of such preferred shares is determined based upon the quoted market price of Arbutus common stock into which such preferred shares are convertible. The liability instruments issued, including the Sumitomo Options, are classified as Level&#160;3 within the fair value hierarchy as the assumptions and estimates used in the valuations are unobservable in the market. Cash, accounts payable, and deferred consideration liability are stated at their respective historical carrying amounts, which approximate fair value due to their short-term nature. The deferred consideration liability is based on a fixed monetary amount, and payment is based solely on the passage of time. Money market funds are included in Level&#160;1 of the fair value hierarchy and are valued at the closing price reported by an actively traded exchange. The carrying value of long-term debt issued by Dermavant Sciences Ltd. (together with its wholly owned subsidiaries, &#8220;Dermavant&#8221;), which is stated at amortized cost, approximates fair value&#160;based on current interest rates for similar types of borrowings and therefore is included in Level&#160;2 of the fair value hierarchy. Long-term debt issued by Dermavant for which the fair value option has been elected is included in Level&#160;3 of the fair value hierarchy as the assumptions and estimates used in the valuation are unobservable in the market. </div></div> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock', window );">Foreign Currency</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">(O) Foreign Currency </div></div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Assets and liabilities of foreign operations are translated using exchange rates in effect at the balance sheet date and their results of operations are translated using average exchange rates for the year. Certain transactions of the Company and its subsidiaries are denominated in currencies other than their functional currency. Adjustments resulting from the translation of the financial statements of the Company&#8217;s foreign functional currency subsidiaries into U.S. dollars are excluded from the determination of net loss and are accumulated in a separate component of shareholders&#8217; equity. Foreign exchange transaction gains and losses are included in &#8220;Other expense, net&#8221; in the Company&#8217;s statements of operations. </div></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock', window );">Revenue Recognition</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">(P) Revenue Recognition </div></div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The Company recognizes revenue when its customer obtains control of promised goods or services, in an amount that reflects the consideration which the Company expects to receive in exchange for those goods or services. To determine revenue recognition for its arrangements, the Company performs the following five steps: (i)&#160;identify the contract(s) with a customer; (ii)&#160;identify the performance obligations in the contract; (iii)&#160;determine the transaction price; (iv)&#160;allocate the transaction price to the performance obligations in the contract; and (v)&#160;recognize revenue when or as the Company satisfies a performance obligation. </div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The Company applies significant judgment when evaluating whether contractual obligations represent distinct performance obligations, allocating transaction price to performance obligations within a contract, determining </div></div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">when performance obligations have been met, assessing the recognition and future reversal of variable consideration, and determining and applying appropriate methods of measuring progress for performance obligations satisfied over time. These judgments are discussed in more detail below. </div></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Licenses of intellectual property:</div></div> If the licenses to intellectual property are determined to be distinct from the other performance obligations identified in the arrangement, the Company recognizes revenues from <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-refundable,</div> upfront fees allocated to the license when the license is transferred to the licensee and the licensee is able to use and benefit from the license. For licenses that are not distinct from other promises, the Company applies judgment to assess the nature of the combined performance obligation to determine whether the combined performance obligation is satisfied over time or at a point in time and, if over time, the appropriate method of measuring progress for purposes of recognizing revenue from <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-refundable,</div> upfront fees. The Company evaluates the measure of progress each reporting period and, if necessary, adjusts the related revenue recognition accordingly. </div> </td> </tr> </table> <div style="clear: both; max-height: 0px;"/> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Milestone payments: </div></div>At the inception of each arrangement that includes research, development or regulatory milestone payments, the Company<div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;"> </div></div>evaluates whether the milestones are considered probable of being reached and estimates the amount to be included in the transaction price using the most likely amount method. If it is probable that a significant revenue reversal would not occur, the associated milestone value is included in the transaction price. Milestone payments that are not within the control of the Company or the licensee, such as regulatory approvals, are not considered probable of being achieved until those approvals are received. The transaction price is then allocated to each performance obligation on a relative standalone selling price basis, for which the Company recognizes revenue as or when the performance obligations under the contract are satisfied. At the end of each subsequent reporting period, the Company <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">re-evaluates</div> the probability of achievement of such development milestones and any related constraint, and if necessary, adjusts its estimate of the overall transaction price on a cumulative <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">catch-up</div> basis in earnings in the period of the adjustment. </div> </td> </tr> </table> <div style="clear: both; max-height: 0px;"/> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Royalties and commercial milestone payments: </div></div>For arrangements that include sales-based royalties, including commercial milestone payments<div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;"> </div></div>based on a <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">pre-specified</div> level of sales, the Company recognizes revenue at the later of (i)&#160;when the related sales occur, or (ii)&#160;when the performance obligation to which some or all of the royalty has been allocated has been satisfied (or partially satisfied). Achievement of these royalties and commercial milestones may solely depend upon performance of the licensee. </div> </td> </tr> </table> <div style="clear: both; max-height: 0px;"/> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Revenue is also generated by certain technology-focused Vants from subscription and service-based fees recognized for the use of certain technology developed by these Vants. Subscription revenue is recognized ratably over the contract period. </div></div> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock', window );">Recently Adopted Accounting Pronouncements</a></td>
<td class="text"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">(J) Recently Adopted Accounting Pronouncements </div></div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;">In August 2020, the FASB issued ASU <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">No.&#160;2020-06,</div> &#8220;Debt&#8212;Debt with Conversion and Other Options (Subtopic <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">470-20)</div> and Derivatives and Hedging&#8212;Contracts in Entity&#8217;s Own Equity (Subtopic <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">815-40):</div> Accounting for Convertible Instruments and Contracts in an Entity&#8217;s Own Equity&#8221; (&#8220;ASU <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">No.&#160;2020-06&#8221;).</div> ASU <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">No.&#160;2020-06</div> will simplify the accounting for convertible instruments by reducing the number of accounting models for convertible debt instruments and convertible preferred stock. Limiting the accounting models will result in fewer embedded conversion features being separately recognized from the host contract as compared with current U.S. GAAP. ASU <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">No.&#160;2020-06</div> also removes certain settlement conditions that are required for equity contracts to qualify for the derivatives scope exception, which will permit more equity contracts to qualify for it. Either a modified retrospective transition method or a fully retrospective transition method is permissible for the adoption of this standard. Update <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">No.&#160;2020-06</div> is effective for fiscal years beginning after December&#160;15, 2021, including interim periods within those fiscal years. The early-adoption of ASU <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">No.&#160;2020-06</div> on April&#160;1, 2021 did not have a material impact on the Company&#8217;s unaudited condensed consolidated financial statements. </div><span></span>
</td>
<td class="text"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">(Q) Recently Adopted Accounting Pronouncements </div></div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;">In June 2016, the FASB issued ASU <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">No.&#160;2016-13,</div> &#8220;Financial Instruments-Credit Losses (Topic 326): Measurement of Credit Losses on Financial Instruments&#8221; (&#8220;ASU <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">No.&#160;2016-13&#8221;),</div> which requires the measurement and recognition of expected credit losses for financial assets held at amortized cost. ASU <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">No.&#160;2016-13</div> replaces the existing incurred loss impairment model with an expected loss model that requires the use of forward-looking information to calculate credit loss estimates. It also eliminates the concept of other-than-temporary impairment and requires credit losses on <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">available-for-sale</div></div> debt securities to be recorded through an allowance for credit losses instead of as a reduction in the amortized cost basis of the securities. ASU <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">No.&#160;2016-13</div> is effective for fiscal years beginning after December&#160;15, 2019 and interim periods within those fiscal years. The adoption of ASU <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">No.&#160;2016-13</div> on April&#160;1, 2020 did not have a material impact on the Company&#8217;s consolidated financial statements. </div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_roiv_NewAccountingPronouncementsNotYetAdoptedPolicyTextBlock', window );">Recently Issued Accounting Pronouncements Not Yet Adopted</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">(R) Recently Issued Accounting Pronouncements Not Yet Adopted </div></div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;">In August 2020, the FASB issued ASU <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">No.&#160;2020-06,</div> &#8220;Debt&#8212;Debt with Conversion and Other Options (Subtopic <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">470-20)</div> and Derivatives and Hedging&#8212;Contracts in Entity&#8217;s Own Equity (Subtopic <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">815-40):</div> Accounting for </div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Convertible Instruments and Contracts in an Entity&#8217;s Own Equity&#8221; (&#8220;ASU <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">No.&#160;2020-06&#8221;).</div> ASU <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">No.&#160;2020-06</div> will simplify the accounting for convertible instruments by reducing the number of accounting models for convertible debt instruments and convertible preferred stock. Limiting the accounting models will result in fewer embedded conversion features being separately recognized from the host contract as compared with current GAAP. ASU <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">No.&#160;2020-06</div> also removes certain settlement conditions that are required for equity contracts to qualify for the derivatives scope exception, which will permit more equity contracts to qualify for it. Either a modified retrospective transition method or a fully retrospective transition method is permissible for the adoption of this standard. Update <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">No.&#160;2020-06</div> is effective for fiscal years beginning after December&#160;15, 2021, including interim periods within those fiscal years. Early adoption is permitted no earlier than the fiscal year beginning after December&#160;15, 2020. The adoption of ASU <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">No.&#160;2020-06</div> is not expected to have a material impact on the Company&#8217;s consolidated financial statements. </div> <span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_roiv_GeneralAndAdministrativeExpensesPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>General and Administrative Expenses, Policy [Text Block]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">roiv_GeneralAndAdministrativeExpensesPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>roiv_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_roiv_NewAccountingPronouncementsNotYetAdoptedPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>New Accounting Pronouncements Not Yet Adopted [Policy Text Block]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">roiv_NewAccountingPronouncementsNotYetAdoptedPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>roiv_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BasisOfAccountingPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for basis of accounting, or basis of presentation, used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BasisOfAccountingPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Entity's cash and cash equivalents accounting policy with respect to restricted balances.  Restrictions may include legally restricted deposits held as compensating balances against short-term borrowing arrangements, contracts entered into with others, or company statements of intention with regard to particular deposits; however, time deposits and short-term certificates of deposit are not generally included in legally restricted deposits.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(1)(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=123431023&amp;loc=d3e4273-108586<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for commitments and contingencies, which may include policies for recognizing and measuring loss and gain contingencies.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 460<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123368208&amp;loc=d3e12565-110249<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 954<br> -SubTopic 450<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6491354&amp;loc=d3e6049-115624<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskCreditRisk">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for credit risk.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e5967-108592<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 825<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=123345438&amp;loc=d3e61044-112788<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskCreditRisk</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueMeasurementPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for fair value measurements of financial and non-financial assets, liabilities and instruments classified in shareholders' equity. Disclosures include, but are not limited to, how an entity that manages a group of financial assets and liabilities on the basis of its net exposure measures the fair value of those assets and liabilities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueMeasurementPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for (1) transactions denominated in a currency other than the reporting enterprise's functional currency, (2) translating foreign currency financial statements that are incorporated into the financial statements of the reporting enterprise by consolidation, combination, or the equity method of accounting, and (3) remeasurement of the financial statements of a foreign reporting enterprise in a hyperinflationary economy.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -URI http://asc.fasb.org/topic&amp;trid=2175825<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for income taxes, which may include its accounting policies for recognizing and measuring deferred tax assets and liabilities and related valuation allowances, recognizing investment tax credits, operating loss carryforwards, tax credit carryforwards, and other carryforwards, methodologies for determining its effective income tax rate and the characterization of interest and penalties in the financial statements.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -URI http://asc.fasb.org/extlink&amp;oid=123427490&amp;loc=d3e32247-109318<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 20<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32847-109319<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 19<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32840-109319<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL116659661-227067<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32639-109319<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=123427490&amp;loc=d3e32280-109318<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 17<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32809-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for investment in financial asset.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(3)(b))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for long-lived, physical asset used in normal conduct of business and not intended for resale. Includes, but is not limited to, work of art, historical treasure, and similar asset classified as collections.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 958<br> -SubTopic 360<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=120429125&amp;loc=d3e99779-112916<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.13(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 958<br> -SubTopic 360<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=120429125&amp;loc=d3e99893-112916<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpensePolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for costs it has incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 730<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6420194&amp;loc=d3e21568-108373<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpensePolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for revenue from contract with customer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 17<br> -URI http://asc.fasb.org/extlink&amp;oid=123351226&amp;loc=SL49130561-203045<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 20<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=123351226&amp;loc=SL49130566-203045<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123351226&amp;loc=SL49130563-203045<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -URI http://asc.fasb.org/topic&amp;trid=49130388<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 20<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123351226&amp;loc=SL49130566-203045<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123351226&amp;loc=SL49130563-203045<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=123372394&amp;loc=d3e18823-107790<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 20<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123351226&amp;loc=SL49130566-203045<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 19<br> -URI http://asc.fasb.org/extlink&amp;oid=123351226&amp;loc=SL49130564-203045<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 20<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123351226&amp;loc=SL49130566-203045<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for award under share-based payment arrangement. Includes, but is not limited to, methodology and assumption used in measuring cost.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b),(f)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5047-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TradeAndOtherAccountsReceivablePolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for accounts receivable.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123577603&amp;loc=d3e4975-111524<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section 50<br> -Paragraph 15<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=123577603&amp;loc=d3e5212-111524<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11B<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123577603&amp;loc=SL6953423-111524<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=123577603&amp;loc=d3e5093-111524<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123577603&amp;loc=d3e5033-111524<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=84159169&amp;loc=d3e10133-111534<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TradeAndOtherAccountsReceivablePolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UnusualRisksAndUncertaintiesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the nature of the unusual risk or uncertainty, if estimable, such as the threat of expropriation of its assets by a foreign government, rapid technological obsolescence in the industry, risk of natural disaster from earthquake or weather events, and availability of or continuation of a labor force at a reasonable cost.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UnusualRisksAndUncertaintiesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UseOfEstimates">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6191-108592<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6161-108592<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6143-108592<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e5967-108592<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6061-108592<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6132-108592<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e5967-108592<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UseOfEstimates</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>98
<FILENAME>R28.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm139997747363240">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies (Tables)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2021</div></th>
<th class="th"><div>Mar. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfCashAndCashEquivalentsTableTextBlock', window );">Schedule of Aggregate Amounts of Cash, Cash Equivalents, and Restricted Cash</a></td>
<td class="text"><div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Cash as reported in the condensed consolidated statements of cash flows includes the aggregate amounts of cash, cash equivalents, and restricted cash as presented on the condensed consolidated balance sheets as follows (in thousands): </div></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;width:76%;">
<tr style="font-size: 0px;">
<td style="width: 64%;"/>
<td style="width: 7%; vertical-align: bottom;"/>
<td/>
<td/>
<td/>
<td style="width: 7%; vertical-align: bottom;"/>
<td/>
<td/>
<td/> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">June&#160;30,&#160;2021</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">March&#160;31,&#160;2021</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top; width: 64%;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Cash and cash equivalents</div></div> </td>
<td style="vertical-align: bottom; width: 7%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">1,996,733</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 7%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">2,055,044</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; width: 64%;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Restricted cash</div></div> </td>
<td style="vertical-align: bottom; width: 7%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">11,644</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 7%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">86,632</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 64%;">&#160;</td>
<td style="vertical-align: bottom; width: 7%;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom; width: 7%;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top; width: 64%;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Cash, cash equivalents and restricted cash</div></div> </td>
<td style="vertical-align: bottom; width: 7%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">2,008,377</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 7%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">2,141,676</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 64%;">&#160;</td>
<td style="vertical-align: bottom; width: 7%;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom; width: 7%;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td> </tr> </table> <span></span>
</td>
<td class="text"><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Cash as reported in the accompanying consolidated statements of cash flows includes the aggregate amounts of cash, cash equivalents, and restricted cash as presented on the accompanying consolidated balance sheets as follows (in thousands): </div></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 76%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="font-size: 0px;">
<td style="width: 62%;"/>
<td style="width: 8%; vertical-align: bottom;"/>
<td/>
<td/>
<td/>
<td style="width: 8%; vertical-align: bottom;"/>
<td/>
<td/>
<td/> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">March&#160;31,&#160;2021</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">March&#160;31,&#160;2020</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Cash and cash equivalents</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">2,055,044</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">2,183,207</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Restricted cash</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">86,632</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">86,045</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;">&#160;</td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Cash, cash equivalents and restricted cash</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">2,141,676</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">2,269,252</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;">&#160;</td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td> </tr> </table> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_roiv_ScheduleOfPropertyPlantAndEquipmentEstimatedUsefulLivesTableTextBlock', window );">Schedule of Estimated Useful Lives Used for Asset Type</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">The following table provides the range of estimated useful lives used for each asset type: <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="font-size: 0px;">
<td style="width: 33%; font-family: &quot;Times New Roman&quot;;"/>
<td style="width: 1%; vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/>
<td style="width: 66%; font-family: &quot;Times New Roman&quot;;"/> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; white-space: nowrap;"> <div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt; border-bottom: 1pt solid rgb(0, 0, 0); display: table-cell; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">Property and Equipment</div></div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;"> <div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt; border-bottom: 1pt solid rgb(0, 0, 0); display: table-cell; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">Estimated Useful Life</div></div></div> </td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Computers</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">3  years</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Equipment</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">5  years</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Furniture and fixtures</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">7  years</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Software</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">3  years</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Leasehold improvements</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">Lesser of estimated useful life or remaining lease term</td> </tr> </table> <span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_roiv_ScheduleOfPropertyPlantAndEquipmentEstimatedUsefulLivesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Schedule Of Property Plant And Equipment Estimated Useful Lives.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">roiv_ScheduleOfPropertyPlantAndEquipmentEstimatedUsefulLivesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>roiv_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfCashAndCashEquivalentsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the components of cash and cash equivalents.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfCashAndCashEquivalentsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>99
<FILENAME>R29.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm139997755063416">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Discontinued Operations (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DiscontinuedOperationsAndDisposalGroupsAbstract', window );"><strong>Discontinued Operations and Disposal Groups [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfDisposalGroupsIncludingDiscontinuedOperationsIncomeStatementBalanceSheetAndAdditionalDisclosuresTextBlock', window );">Summary Of Disposal Groups Including Discontinued Operations Income Statement</a></td>
<td class="text"><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The following table presents components of discontinued operations included in &#8220;Income from discontinued operations, net of tax&#8221; for the year ended March&#160;31, 2020 (in thousands). </div></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 92%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="font-size: 0px;">
<td style="width: 85%;"/>
<td style="width: 5%; vertical-align: bottom;"/>
<td/>
<td/>
<td/> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Year Ended<br/> March&#160;31,&#160;2020</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Operating expenses:</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Research and development</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">265,452</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">General and administrative</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">119,885</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;">&#160;</td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 5em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Total operating expenses</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">385,337</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;">&#160;</td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Loss from operations</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(385,337</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Gain on sale of business</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(1,985,949</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Interest income</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(2,305</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Interest expense<div style="font-size: 85%; vertical-align: top;;display:inline;;font-size:9.4px">(1)</div></div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">13,733</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Other expense</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">8,866</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;">&#160;</td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Income from discontinued operations before income taxes</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">1,580,318</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Income tax expense</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">1,892</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;">&#160;</td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: bottom;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Income from discontinued operations, net of tax</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">$</td>
<td style="vertical-align: bottom;;text-align:right;">1,578,426</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;">&#160;</td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Loss from discontinued operations before income taxes attributable to noncontrolling interests</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(141,783</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Income from discontinued operations before income taxes attributable to Roivant Sciences Ltd.</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">1,722,101</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;">&#160;</td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Income from discontinued operations before income taxes</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">1,580,318</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;">&#160;</td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td> </tr> </table> <div style="clear: both; max-height: 0px;"/> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 4%; vertical-align: top;;text-align:left;"><div style="font-size: 85%; vertical-align: top;;display:inline;;font-size:9.4px">(1)</div>&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;">Interest expense consists of interest payments related to outstanding debt held by Myovant and Urovant as well as the associated <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-cash</div> amortization of debt discounts and issuance costs. </div> </td> </tr> </table> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_roiv_ScheduleOfDisposalGroupsIncludingDiscontinuedCondensedConsolidatedStatementsOfCashFlowsTableTextBlock', window );">Summary of Cash Flows from Discontinued Operations</a></td>
<td class="text">The significant cash flow items from discontinued operations were as follows (in thousands):
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 68%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="font-size: 0px;">
<td style="width: 78%;"/>
<td style="width: 8%; vertical-align: bottom;"/>
<td/>
<td/>
<td/> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Year Ended<br/> March&#160;31,&#160;2020</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Gain on sale of business</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(1,985,949</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Share-based compensation</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">54,821</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;">Acquired <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">in-process</div> research and development</div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">16,405</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;">&#160;</td> </tr> </table> <span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_roiv_ScheduleOfDisposalGroupsIncludingDiscontinuedCondensedConsolidatedStatementsOfCashFlowsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Schedule Of Disposal Groups Including Discontinued Condensed Consolidated Statements Of Cash Flows Table [Text Block]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">roiv_ScheduleOfDisposalGroupsIncludingDiscontinuedCondensedConsolidatedStatementsOfCashFlowsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>roiv_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DiscontinuedOperationsAndDisposalGroupsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DiscontinuedOperationsAndDisposalGroupsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfDisposalGroupsIncludingDiscontinuedOperationsIncomeStatementBalanceSheetAndAdditionalDisclosuresTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of information related to a disposal group. Includes, but is not limited to, a discontinued operation, disposal classified as held-for-sale or disposed of by means other than sale or disposal of an individually significant component.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3A<br> -URI http://asc.fasb.org/extlink&amp;oid=109226691&amp;loc=SL51724579-110230<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=d3e1474-107760<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 5D<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721677-107760<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 45<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=109222160&amp;loc=SL51721533-107759<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 3A<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721659-107760<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4B<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721665-107760<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=109226691&amp;loc=d3e2941-110230<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 5C<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721675-107760<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 10: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=d3e1361-107760<br><br>Reference 11: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 5A<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721671-107760<br><br>Reference 12: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 5B<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721673-107760<br><br>Reference 13: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4A<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721663-107760<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfDisposalGroupsIncludingDiscontinuedOperationsIncomeStatementBalanceSheetAndAdditionalDisclosuresTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>100
<FILENAME>R30.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm139997747369464">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Balance Sheet Components (Tables)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2021</div></th>
<th class="th"><div>Mar. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract', window );"><strong>Organization, Consolidation and Presentation of Financial Statements [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfOtherCurrentAssetsTableTextBlock', window );">Schedule of Other Current Assets</a></td>
<td class="text"><div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Other current assets at June&#160;30, 2021 and March&#160;31, 2021 consisted of the following (in thousands): </div></div></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 76%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px; text-indent: 0px;">
<tr style="font-size: 0px;">
<td style="width: 64%;"/>
<td style="width: 10%; vertical-align: bottom;"/>
<td/>
<td/>
<td/>
<td style="width: 10%; vertical-align: bottom;"/>
<td/>
<td/>
<td/> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 1pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">June&#160;30,&#160;2021</div></div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">March&#160;31,&#160;2021</div></div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td> </tr>
<tr style="font-size: 0px;">
<td style="width: 75%;"/>
<td style="width: 7%; vertical-align: bottom;"/>
<td/>
<td/>
<td/>
<td style="width: 6%; vertical-align: bottom;"/>
<td/>
<td/>
<td/> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top; width: 75%;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Prepaid expenses</div></div> </td>
<td style="vertical-align: bottom; width: 7%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">44,941</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 6%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">39,544</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; width: 75%;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Trade receivables, net</div></div> </td>
<td style="vertical-align: bottom; width: 7%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">3,416</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 6%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">11,222</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top; width: 75%;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Income tax receivable</div></div> </td>
<td style="vertical-align: bottom; width: 7%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">1,993</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 6%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">1,803</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-size: 0px;">
<td style="width: 75%;"/>
<td style="width: 7%; vertical-align: bottom;"/>
<td/>
<td/>
<td/>
<td style="width: 6%; vertical-align: bottom;"/>
<td/>
<td/>
<td/> </tr>
<tr style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; break-inside: avoid;">
<td style="vertical-align: top; background-color: rgb(255, 255, 255); width: 75%;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Other</div></div> </td>
<td style="vertical-align: bottom; background-color: rgb(255, 255, 255); width: 7%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(255, 255, 255);">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(255, 255, 255);;text-align:right;">7,815</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(255, 255, 255);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(255, 255, 255); width: 6%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(255, 255, 255);">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(255, 255, 255);;text-align:right;">1,681</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(255, 255, 255);">&#160;</td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; background-color: rgb(204, 238, 255); width: 75%;">&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255); width: 7%;">&#160;&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="background-color: rgb(204, 238, 255);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255); width: 6%;">&#160;&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="background-color: rgb(204, 238, 255);">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; background-color: rgb(204, 238, 255); width: 75%;"> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.26in; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Total other current assets</div></div> </td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255); width: 7%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);">$</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;">58,165</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255); width: 6%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);">$</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;">54,250</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);">&#160;</td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; background-color: rgb(255, 255, 255); width: 75%;">&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(255, 255, 255); width: 7%;">&#160;&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="background-color: rgb(255, 255, 255);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(255, 255, 255); width: 6%;">&#160;&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="background-color: rgb(255, 255, 255);">&#160;</td> </tr> </table> <span></span>
</td>
<td class="text"><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Other current assets at March&#160;31, 2021 and 2020 consisted of the following (in thousands): </div></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 76%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="font-size: 0px;">
<td style="width: 62%;"/>
<td style="width: 11%; vertical-align: bottom;"/>
<td/>
<td/>
<td/>
<td style="width: 11%; vertical-align: bottom;"/>
<td/>
<td/>
<td/> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">March&#160;31,&#160;2021</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">March&#160;31,&#160;2020</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: bottom;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Prepaid expenses</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">$</td>
<td style="vertical-align: bottom;;text-align:right;">39,544</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">$</td>
<td style="vertical-align: bottom;;text-align:right;">16,344</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Receivables for value added tax (VAT) paid</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">807</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">5,978</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Note receivable</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">5,000</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Trade receivables, net</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">11,222</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">3,669</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Income tax receivable</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">1,803</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">632</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Other</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">874</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">2,140</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;">&#160;</td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Total other current assets</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">54,250</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">33,763</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;">&#160;</td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td> </tr> </table> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock', window );">Schedule of Accrued Expenses</a></td>
<td class="text"><div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Accrued expenses at June&#160;30, 2021 and March&#160;31, 2021 consisted of the following (in thousands): </div></div></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 76%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px; text-indent: 0px;">
<tr style="font-size: 0px;">
<td style="width: 64%;"/>
<td style="width: 10%; vertical-align: bottom;"/>
<td/>
<td/>
<td/>
<td style="width: 10%; vertical-align: bottom;"/>
<td/>
<td/>
<td/> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 1pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">June&#160;30,&#160;2021</div></div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">March&#160;31,&#160;2021</div></div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td> </tr>
<tr style="font-size: 0px;">
<td style="width: 64%;"/>
<td style="width: 10%; vertical-align: bottom;"/>
<td/>
<td/>
<td/>
<td style="width: 10%; vertical-align: bottom;"/>
<td/>
<td/>
<td/> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top; width: 64%;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Research and development expenses</div></div> </td>
<td style="vertical-align: bottom; width: 10%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">28,347</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 10%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">20,755</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; width: 64%;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Compensation-related expenses</div></div> </td>
<td style="vertical-align: bottom; width: 10%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">15,242</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 10%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">38,552</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top; width: 64%;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Professional services expenses</div></div> </td>
<td style="vertical-align: bottom; width: 10%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">16,489</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 10%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">10,267</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; width: 64%;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Other general and administrative expenses</div></div> </td>
<td style="vertical-align: bottom; width: 10%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">13,710</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 10%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">7,362</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 64%;">&#160;</td>
<td style="vertical-align: bottom; width: 10%;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom; width: 10%;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top; width: 64%;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Total accrued expenses</div></div> </td>
<td style="vertical-align: bottom; width: 10%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">73,788</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 10%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">76,936</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 64%;">&#160;</td>
<td style="vertical-align: bottom; width: 10%;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom; width: 10%;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td> </tr> </table> <span></span>
</td>
<td class="text"><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Accrued expenses at March&#160;31, 2021 and 2020 consisted of the following (in thousands): </div></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 76%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="font-size: 0px;">
<td style="width: 62%;"/>
<td style="width: 11%; vertical-align: bottom;"/>
<td/>
<td/>
<td/>
<td style="width: 11%; vertical-align: bottom;"/>
<td/>
<td/>
<td/> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">March&#160;31,&#160;2021</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">March&#160;31,&#160;2020</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: bottom;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Research and development expenses</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">$</td>
<td style="vertical-align: bottom;;text-align:right;">20,755</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">$</td>
<td style="vertical-align: bottom;;text-align:right;">21,607</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Compensation-related expenses</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">38,552</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">29,113</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Professional services expenses</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">10,267</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">5,135</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Other general and administrative expenses</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">7,362</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">12,766</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;">&#160;</td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Total accrued expenses</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">76,936</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">68,621</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;">&#160;</td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td> </tr> </table> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherCurrentLiabilitiesTableTextBlock', window );">Schedule of Other Current Liabilities</a></td>
<td class="text"><div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Other current liabilities at June&#160;30, 2021 and March&#160;31, 2021 consisted of the following (in thousands): </div></div></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 76%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px; text-indent: 0px;">
<tr style="font-size: 0px;">
<td style="width: 64%;"/>
<td style="width: 12%; vertical-align: bottom;"/>
<td/>
<td/>
<td/>
<td style="width: 12%; vertical-align: bottom;"/>
<td/>
<td/>
<td/> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 1pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">June&#160;30,&#160;2021</div></div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">March&#160;31,&#160;2021</div></div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td> </tr>
<tr style="font-size: 0px;">
<td style="width: 64%;"/>
<td style="width: 12%; vertical-align: bottom;"/>
<td/>
<td/>
<td/>
<td style="width: 12%; vertical-align: bottom;"/>
<td/>
<td/>
<td/> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top; width: 64%;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Deferred revenue</div></div> </td>
<td style="vertical-align: bottom; width: 12%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">3,777</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 12%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">5,918</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; width: 64%;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Income tax payable</div></div> </td>
<td style="vertical-align: bottom; width: 12%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">199</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 12%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">207</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top; width: 64%;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Other</div></div> </td>
<td style="vertical-align: bottom; width: 12%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">4,325</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 12%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">3,037</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 64%;">&#160;</td>
<td style="vertical-align: bottom; width: 12%;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom; width: 12%;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; width: 64%;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Total other current liabilities</div></div> </td>
<td style="vertical-align: bottom; width: 12%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">8,301</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 12%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">9,162</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 64%;">&#160;</td>
<td style="vertical-align: bottom; width: 12%;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom; width: 12%;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td> </tr> </table> <span></span>
</td>
<td class="text"><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Other current liabilities at March&#160;31, 2021 and 2020 consisted of the following (in thousands): </div></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 76%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="font-size: 0px;">
<td style="width: 62%;"/>
<td style="width: 13%; vertical-align: bottom;"/>
<td/>
<td/>
<td/>
<td style="width: 13%; vertical-align: bottom;"/>
<td/>
<td/>
<td/> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">March&#160;31,&#160;2021</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">March&#160;31,&#160;2020</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Deferred revenue</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">5,918</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">3,621</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Income tax payable</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">207</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">1,497</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Other</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">3,037</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">234</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;">&#160;</td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Total other current liabilities</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">9,162</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">5,352</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;">&#160;</td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td> </tr> </table> <span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherCurrentLiabilitiesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of other current liabilities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherCurrentLiabilitiesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the components of accrued liabilities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfOtherCurrentAssetsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the carrying amounts of other current assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfOtherCurrentAssetsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>101
<FILENAME>R31.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm139997745882552">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Long Term Debt and Loan Commitment (Tables)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2021</div></th>
<th class="th"><div>Mar. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtDisclosureAbstract', window );"><strong>Debt Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfDebtTableTextBlock', window );">Schedule of Long Term Debt</a></td>
<td class="text"><div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Long-term debt, net consists of the following (in thousands): </div></div></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 84%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px; text-indent: 0px;">
<tr style="font-size: 0px;">
<td style="width: 68%;"/>
<td style="width: 8%; vertical-align: bottom;"/>
<td/>
<td/>
<td/>
<td style="width: 8%; vertical-align: bottom;"/>
<td/>
<td/>
<td/> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 1pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">June&#160;30,&#160;2021</div></div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">March&#160;31,&#160;2021</div></div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td> </tr>
<tr style="font-size: 0px;">
<td style="width: 68%;"/>
<td style="width: 8%; vertical-align: bottom;"/>
<td/>
<td/>
<td/>
<td style="width: 8%; vertical-align: bottom;"/>
<td/>
<td/>
<td/> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top; width: 68%;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Principal amount</div></div> </td>
<td style="vertical-align: bottom; width: 8%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">195,200</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 8%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">170,100</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; width: 68%;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Exit fee / end of term charge</div></div> </td>
<td style="vertical-align: bottom; width: 8%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">5,000</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 8%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">1,390</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top; width: 68%;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Less: unamortized debt discount and issuance costs</div></div> </td>
<td style="vertical-align: bottom; width: 8%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(13,850</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom; width: 8%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(1,210</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 68%;">&#160;</td>
<td style="vertical-align: bottom; width: 8%;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom; width: 8%;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; width: 68%;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Total debt, net</div></div> </td>
<td style="vertical-align: bottom; width: 8%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">186,350</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 8%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">170,280</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top; width: 68%;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Less: current portion</div></div> </td>
<td style="vertical-align: bottom; width: 8%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 8%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 68%;">&#160;</td>
<td style="vertical-align: bottom; width: 8%;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom; width: 8%;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; width: 68%;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Total long-term debt, net</div></div> </td>
<td style="vertical-align: bottom; width: 8%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">186,350</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 8%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">170,280</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 68%;">&#160;</td>
<td style="vertical-align: bottom; width: 8%;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom; width: 8%;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td> </tr> </table> <span></span>
</td>
<td class="text"><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Long-term debt, net consists of the following (in thousands): </div></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 84%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="font-size: 0px;">
<td style="width: 66%;"/>
<td style="width: 9%; vertical-align: bottom;"/>
<td/>
<td/>
<td/>
<td style="width: 9%; vertical-align: bottom;"/>
<td/>
<td/>
<td/> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">March&#160;31,&#160;2021</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">March&#160;31,&#160;2020</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Principal amount</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">171,490</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">110,490</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Less: unamortized debt discount and issuance costs</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(1,210</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(1,898</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Total debt, net</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">170,280</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">108,592</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Less: current portion</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Total long-term debt, net</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">170,280</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">108,592</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;">&#160;</td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td> </tr> </table> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ContractualObligationFiscalYearMaturityScheduleTableTextBlock', window );">Schedule of Company's Annual Payments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text"><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Annual maturities, including the end of term charge, of debt outstanding as of&#160;March&#160;31, 2021&#160;are as follows (in thousands). Long-term debt held by Dermavant for which the fair value option has been elected is excluded from the below as the repayment terms are variable. </div></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 68%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="font-size: 0px;">
<td style="width: 85%; font-family: &quot;Times New Roman&quot;;"/>
<td style="width: 6%; vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/>
<td style="font-family: &quot;Times New Roman&quot;;"/>
<td style="font-family: &quot;Times New Roman&quot;;"/>
<td style="font-family: &quot;Times New Roman&quot;;"/> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; white-space: nowrap;"> <div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt; border-bottom: 1pt solid rgb(0, 0, 0); display: table-cell; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">Years Ending March&#160;31,</div></div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">2022</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">3,129</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">2023</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">13,306</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">2024</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">4,955</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">2025</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">2026</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Thereafter</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Total</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">21,390</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;">&#160;</td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td> </tr> </table> <span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ContractualObligationFiscalYearMaturityScheduleTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of contractual obligation by timing of payment due. Includes, but is not limited to, long-term debt obligation, lease obligation, and purchase obligation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher SEC<br> -Name Regulation S-K (SK)<br> -Number 229<br> -Section 303<br> -Paragraph (a)<br> -Subparagraph (5)<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ContractualObligationFiscalYearMaturityScheduleTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>srt_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfDebtTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of information pertaining to short-term and long-debt instruments or arrangements, including but not limited to identification of terms, features, collateral requirements and other information necessary to a fair presentation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfDebtTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>102
<FILENAME>R32.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm139997755063416">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Shareholders' Equity and Redeemable Noncontrolling Interest (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquityAbstract', window );"><strong>Equity [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfStockholdersEquityTableTextBlock', window );">Shareholders' Equity and Redeemable Non-Controlling Interest</a></td>
<td class="text">A summary of payments made during the year ended March&#160;31, 2020 relating to the purchase of equity securities by the Company is as follows (in thousands):
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 68%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="font-size: 0px;">
<td style="width: 79%;"/>
<td style="width: 11%; vertical-align: bottom;"/>
<td/>
<td/>
<td/> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Cash&#160;Payment</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Common stock</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">950,722</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Other equity instruments</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">39,292</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;">&#160;</td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Total cash paid</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">990,014</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;">&#160;</td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td> </tr> </table> <span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfStockholdersEquityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of changes in the separate accounts comprising stockholders' equity (in addition to retained earnings) and of the changes in the number of shares of equity securities during at least the most recent annual fiscal period and any subsequent interim period presented is required to make the financial statements sufficiently informative if both financial position and results of operations are presented.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21463-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfStockholdersEquityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>103
<FILENAME>R33.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm139997851353576">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Share-Based Compensation (Tables)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2021</div></th>
<th class="th"><div>Mar. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock', window );">Schedule of Fair Value Assumptions</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text"><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The Company estimated the fair value of each stock option on the date of grant using the Black-Scholes closed form option-pricing model applying the weighted average assumptions in the following table. </div></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 76%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="font-size: 0px;">
<td style="width: 73%;"/>
<td style="width: 9%; vertical-align: bottom;"/>
<td/>
<td/>
<td/>
<td style="width: 8%; vertical-align: bottom;"/>
<td/>
<td/>
<td/> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;&#160;</td>
<td colspan="6" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Years&#160;Ended&#160;March&#160;31,</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 1pt;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Assumptions</div></div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;&#160;2021&#160;&#160;</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;&#160;2020&#160;&#160;</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Expected stock price volatility</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">74.84</td>
<td style="vertical-align: bottom; white-space: nowrap;">%&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">66.47</td>
<td style="vertical-align: bottom; white-space: nowrap;">%&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Expected risk free interest rate</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">0.43</td>
<td style="vertical-align: bottom; white-space: nowrap;">%&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">2.27</td>
<td style="vertical-align: bottom; white-space: nowrap;">%&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Expected term, in years</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">6.25</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">6.72</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Expected dividend yield</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">%&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">%&#160;</td> </tr> </table> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock', window );">Summary of Stock Option Activity</a></td>
<td class="text"><div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">A summary of stock option activity and data under the RSL 2015 EIP for the three months ended June&#160;30, 2021 is as follows: </div></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;width:76%;">
<tr style="font-size: 0px;">
<td style="width: 65%;"/>
<td style="width: 8%; vertical-align: bottom;"/>
<td/>
<td/>
<td/>
<td style="width: 8%; vertical-align: bottom;"/>
<td/>
<td/>
<td/></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Number&#160;of<br/> Stock<br/> Options</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="margin-top: 0px; margin-bottom: 0px; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Weighted&#160;</div></div></div><div style="margin-top: 0px; margin-bottom: 0px; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Average<br/> Exercise<div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div>Price</div></div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top; width: 65%;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Stock options outstanding at March&#160;31, 2021</div></div></td>
<td style="vertical-align: bottom; width: 8%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">9,389,371</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 8%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">26.61</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; width: 65%;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Granted</div></div></td>
<td style="vertical-align: bottom; width: 8%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">3,798,605</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 8%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">29.26</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top; width: 65%;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Forfeited</div></div></td>
<td style="vertical-align: bottom; width: 8%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(106,428</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom; width: 8%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">30.27</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 65%;">&#160;</td>
<td style="vertical-align: bottom; width: 8%;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom; width: 8%;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; width: 65%;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Stock options outstanding at June&#160;30, 2021</div></div></td>
<td style="vertical-align: bottom; width: 8%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">13,081,548</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 8%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">27.35</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 65%;">&#160;</td>
<td style="vertical-align: bottom; width: 8%;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom; width: 8%;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td></tr></table> <span></span>
</td>
<td class="text"><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">A summary of stock option activity and data under the RSL 2015 EIP for the year ended March&#160;31, 2021 is as follows: </div></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 92%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="font-size: 0px;">
<td style="width: 48%;"/>
<td style="width: 7%; vertical-align: bottom;"/>
<td/>
<td/>
<td/>
<td style="width: 7%; vertical-align: bottom;"/>
<td/>
<td/>
<td/>
<td style="width: 7%; vertical-align: bottom;"/>
<td/>
<td/>
<td/>
<td style="width: 7%; vertical-align: bottom;"/>
<td/>
<td/>
<td/> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Number of<br/> Stock<br/> Options</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Weighted<br/> Average<br/> Exercise<br/> Price</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Weighted<br/> Average Grant<br/> Date&#160;Fair&#160;Value</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Weighted<br/> Average<br/> Remaining<br/> Contractual&#160;Life</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Stock options outstanding at March&#160;31, 2020</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">8,176,814</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">24.52</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">16.53</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">7.93</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Granted</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">1,482,604</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">38.71</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">25.37</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Forfeited/Canceled</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(270,047</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">29.89</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">19.85</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Stock options outstanding at March&#160;31, 2021</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">9,389,371</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">26.61</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">17.90</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">7.26</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Stock options exercisable at March&#160;31, 2021</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">5,533,848</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">21.52</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">14.95</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">6.49</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td> </tr> </table> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_roiv_ScheduleOfSharebasedPaymentArrangementFairValueOfVestedStockOptionTableTextBlock', window );">Summary of Fair Value of Vested Stock Option</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">Additional information regarding stock options is set forth below (in thousands, except per share data).
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 84%; font-family: &quot;Times New Roman&quot;; font-size: 8pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="font-size: 0px;">
<td style="width: 78%;"/>
<td style="width: 4%; vertical-align: bottom;"/>
<td/>
<td/>
<td/>
<td style="width: 4%; vertical-align: bottom;"/>
<td/>
<td/>
<td/> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;&#160;</td>
<td colspan="6" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Years&#160;Ended&#160;March&#160;31,</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2021</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2020</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Grant date fair value of stock options vested</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">25,711</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">33,789</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Weighted-average grant date fair value per share of stock options granted</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">25.37</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">20.63</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;">&#160;</td> </tr> </table> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock', window );">Summary of Restricted Stock Units</a></td>
<td class="text"><div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">A summary of restricted stock units under the RSL 2015 EIP is as follows: </div></div></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;width:68%;">
<tr style="font-size: 0px;">
<td style="width: 77%;"/>
<td style="width: 10%; vertical-align: bottom;"/>
<td/>
<td/>
<td/></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Number&#160;of<br/> Restricted&#160;Stock<br/> Units</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top; width: 77%;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">Non-vested</div> balance at March&#160;31, 2021</div></td>
<td style="vertical-align: bottom; width: 10%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">2,292,738</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; width: 77%;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Granted</div></div></td>
<td style="vertical-align: bottom; width: 10%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">5,939,340</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top; width: 77%;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Forfeited</div></div></td>
<td style="vertical-align: bottom; width: 10%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(119,285</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 77%;">&#160;</td>
<td style="vertical-align: bottom; width: 10%;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; width: 77%;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">Non-vested</div> balance at June&#160;30, 2021</div></td>
<td style="vertical-align: bottom; width: 10%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">8,112,793</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; width: 77%;">&#160;</td>
<td style="vertical-align: bottom; width: 10%;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td></tr></table> <span></span>
</td>
<td class="text"><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">A summary of restricted stock units under the RSL 2015 EIP is as follows: </div></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 76%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="font-size: 0px;">
<td style="width: 58%;"/>
<td style="width: 12%; vertical-align: bottom;"/>
<td/>
<td/>
<td/>
<td style="width: 12%; vertical-align: bottom;"/>
<td/>
<td/>
<td/> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Number of<br/> Restricted&#160;Stock<br/> Units</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Weighted&#160;Average<br/> Grant Date Fair<br/> Value</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">Non-vested</div> balance at March&#160;31, 2020</div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">1,008,175</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">32.50</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Granted</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">1,454,199</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">39.19</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Forfeited</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(169,636</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">36.36</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;">&#160;</td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">Non-vested</div> balance at March&#160;31, 2021</div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">2,292,738</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">36.53</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;">&#160;</td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td> </tr> </table> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock', window );">Summary of Share-Based Compensation Expense</a></td>
<td class="text"><div style="text-indent: 4%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt; padding-top: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Share-based compensation expense was as follows (in thousands): </div></div></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0px; padding-top: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 76%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px; text-indent: 0px;">
<tr style="font-size: 0px;">
<td style="width: 74%;"/>
<td style="width: 5%; vertical-align: bottom;"/>
<td/>
<td/>
<td/>
<td style="width: 5%; vertical-align: bottom;"/>
<td/>
<td/>
<td/> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 1pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td colspan="6" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Three&#160;Months&#160;Ended<br/> June&#160;30,</div></div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 1pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2021</div></div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2020</div></div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top; font-size: 10pt;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; padding-top: 0pt; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Share-based compensation expense recognized as:</div></div></div> </td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td> </tr>
<tr style="font-size: 0px;">
<td style="width: 80%;"/>
<td style="width: 4%; vertical-align: bottom;"/>
<td/>
<td/>
<td/>
<td style="width: 4%; vertical-align: bottom;"/>
<td/>
<td/>
<td/> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; padding-top: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">R&amp;D expenses</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">1,615</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">1,119</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; padding-top: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">G&amp;A expenses</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">17,654</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">13,159</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); padding-top: 0pt; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); padding-top: 0pt; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); padding-top: 0pt; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); padding-top: 0pt; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; padding-top: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Total</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">19,269</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">14,278</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); padding-top: 0pt; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); padding-top: 0pt; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); padding-top: 0pt; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); padding-top: 0pt; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td> </tr> </table> <span></span>
</td>
<td class="text"><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Share-based compensation expense from continuing operations was as follows (in thousands): </div></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 76%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="font-size: 0px;">
<td style="width: 74%;"/>
<td style="width: 5%; vertical-align: bottom;"/>
<td/>
<td/>
<td/>
<td style="width: 5%; vertical-align: bottom;"/>
<td/>
<td/>
<td/> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;&#160;</td>
<td colspan="6" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Years Ended<br/> March&#160;31,</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2021</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2020</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Share-based compensation expense recognized as:</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: bottom;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">R&amp;D expenses</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">$</td>
<td style="vertical-align: bottom;;text-align:right;">22,637</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">$</td>
<td style="vertical-align: bottom;;text-align:right;">7,738</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">G&amp;A expenses</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">62,321</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">60,013</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;">&#160;</td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Total</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">84,958</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">67,751</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;">&#160;</td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td> </tr> </table> <span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=roiv_PerformanceOptionsMember', window );">Performance Options [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock', window );">Schedule of Fair Value Assumptions</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text"><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The Company estimated the fair value of each Performance Option on the date of grant using the Black-Scholes closed form option-pricing model applying the weighted average assumptions in the following table. </div></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 68%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="font-size: 0px;">
<td style="width: 70%;"/>
<td style="width: 22%; vertical-align: bottom;"/>
<td/>
<td/>
<td/> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Year&#160;Ended&#160;March&#160;31,</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 1pt;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Assumptions</div></div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2020</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Expected stock price volatility</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">73.60</td>
<td style="vertical-align: bottom; white-space: nowrap;">%&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Expected risk free interest rate</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">0.62</td>
<td style="vertical-align: bottom; white-space: nowrap;">%&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Expected term</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">6 years</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Expected dividend yield</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">%&#160;</td> </tr> </table> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock', window );">Summary of Stock Option Activity</a></td>
<td class="text"><div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">A summary of Performance Option activity and data under the RSL 2015 EIP for the three months ended June&#160;30, 2021 is as follows: </div></div></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 84%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px; text-indent: 0px;">
<tr style="font-size: 0px;">
<td style="width: 70%;"/>
<td style="width: 6%; vertical-align: bottom;"/>
<td/>
<td/>
<td/>
<td style="width: 6%; vertical-align: bottom;"/>
<td/>
<td/>
<td/> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 1pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Number of<br/> Performance<br/> Options</div></div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Weighted<br/> Average<br/> Exercise&#160;Price</div></div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td> </tr>
<tr style="font-size: 0px;">
<td style="width: 70%;"/>
<td style="width: 6%; vertical-align: bottom;"/>
<td/>
<td/>
<td/>
<td style="width: 6%; vertical-align: bottom;"/>
<td/>
<td/>
<td/> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top; width: 70%;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Performance Options outstanding at March&#160;31, 2021</div></div> </td>
<td style="vertical-align: bottom; width: 6%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">14,425,663</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 6%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">38.93</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; width: 70%;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Granted</div></div> </td>
<td style="vertical-align: bottom; width: 6%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 6%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top; width: 70%;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Forfeited</div></div> </td>
<td style="vertical-align: bottom; width: 6%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 6%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 70%;">&#160;</td>
<td style="vertical-align: bottom; width: 6%;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom; width: 6%;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; width: 70%;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Performance Options outstanding at June&#160;30, 2021</div></div> </td>
<td style="vertical-align: bottom; width: 6%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">14,425,663</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 6%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">38.93</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 70%;">&#160;</td>
<td style="vertical-align: bottom; width: 6%;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom; width: 6%;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td> </tr> </table> <span></span>
</td>
<td class="text"><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">A summary of Performance Option activity and data under the RSL 2015 EIP for the year ended March&#160;31, 2021 is as follows: </div></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 92%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="font-size: 0px;">
<td style="width: 76%;"/>
<td style="width: 4%; vertical-align: bottom;"/>
<td/>
<td/>
<td/>
<td style="width: 4%; vertical-align: bottom;"/>
<td/>
<td/>
<td/>
<td style="width: 4%; vertical-align: bottom;"/>
<td/>
<td/>
<td/>
<td style="width: 4%; vertical-align: bottom;"/>
<td/>
<td/>
<td/> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Number of<br/> Options</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Weighted<br/> Average<br/> Exercise&#160;Price</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Weighted<br/> Average Grant<br/> Date&#160;Fair&#160;Value</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Weighted<br/> Average<br/> Remaining<br/> Contractual&#160;Life</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Performance Options outstanding at March&#160;31, 2020</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">14,518,870</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">38.97</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">23.78</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">6.00</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Granted</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Forfeited</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(93,207</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">46.38</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">22.18</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Performance Options outstanding at March&#160;31, 2021</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">14,425,663</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">38.93</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">23.42</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">5.00</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td> </tr> </table> <span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=roiv_CappedValueAppreciationRightsMember', window );">CVARs [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock', window );">Summary of Restricted Stock Units</a></td>
<td class="text"><div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">A summary of CVARs under the RSL 2015 EIP is as follows: </div></div></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 68%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px; text-indent: 0px;">
<tr style="font-size: 0px;">
<td style="width: 81%;"/>
<td style="width: 4%; vertical-align: bottom;"/>
<td/>
<td/>
<td/> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 1pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Number of<br/> CVARs</div></div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td> </tr>
<tr style="font-size: 0px;">
<td style="width: 81%;"/>
<td style="width: 4%; vertical-align: bottom;"/>
<td/>
<td/>
<td/> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top; width: 81%;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">Non-vested</div> balance at March&#160;31, 2021</div> </td>
<td style="vertical-align: bottom; width: 4%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">11,088,658</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; width: 81%;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Granted</div></div> </td>
<td style="vertical-align: bottom; width: 4%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top; width: 81%;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Forfeited</div></div> </td>
<td style="vertical-align: bottom; width: 4%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 81%;">&#160;</td>
<td style="vertical-align: bottom; width: 4%;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; width: 81%;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">Non-vested</div> balance at June&#160;30, 2021</div> </td>
<td style="vertical-align: bottom; width: 4%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">11,088,658</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; width: 81%;">&#160;</td>
<td style="vertical-align: bottom; width: 4%;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td> </tr> </table> <span></span>
</td>
<td class="text"><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">A summary of CVARs under the RSL 2015 EIP is as follows: </div></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 76%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="font-size: 0px;">
<td style="width: 56%;"/>
<td style="width: 13%; vertical-align: bottom;"/>
<td/>
<td/>
<td/>
<td style="width: 13%; vertical-align: bottom;"/>
<td/>
<td/>
<td/> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Number&#160;of&#160;CVARs</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Weighted&#160;Average<br/> Grant Date Fair<br/> Value</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">Non-vested</div> balance at March&#160;31, 2020</div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">11,088,658</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">2.07</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Granted</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Forfeited</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;">&#160;</td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">Non-vested</div> balance at March&#160;31, 2021</div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">11,088,658</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">2.07</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;">&#160;</td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td> </tr> </table> <span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=roiv_PerformanceRestrictedStockUnitsMember', window );">Performance RSU [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock', window );">Summary of Restricted Stock Units</a></td>
<td class="text"><div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">A summary of Performance RSU activity under the pRSU Plan is as follows: </div></div></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 68%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px; text-indent: 0px;">
<tr style="font-size: 0px;">
<td style="width: 81%;"/>
<td style="width: 8%; vertical-align: bottom;"/>
<td/>
<td/>
<td/> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 1pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Number of<br/> Performance<br/> RSUs</div></div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td> </tr>
<tr style="font-size: 0px;">
<td style="width: 85%;"/>
<td style="width: 6%; vertical-align: bottom;"/>
<td/>
<td/>
<td/> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">Non-vested</div> balance at March&#160;31, 2021</div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">200,000</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; break-inside: avoid;">
<td style="vertical-align: top; background-color: rgb(255, 255, 255);"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Granted</div></div> </td>
<td style="vertical-align: bottom; background-color: rgb(255, 255, 255);">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(255, 255, 255);">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(255, 255, 255);;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(255, 255, 255);">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; background-color: rgb(204, 238, 255);"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Forfeited</div></div> </td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255);">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);">&#160;</td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; background-color: rgb(255, 255, 255);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(255, 255, 255);">&#160;&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="background-color: rgb(255, 255, 255);">&#160;</td> </tr>
<tr style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; break-inside: avoid;">
<td style="vertical-align: top; background-color: rgb(255, 255, 255);"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">Non-vested</div> balance at June&#160;30, 2021</div> </td>
<td style="vertical-align: bottom; background-color: rgb(255, 255, 255);">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(255, 255, 255);">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(255, 255, 255);;text-align:right;">200,000</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(255, 255, 255);">&#160;</td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; background-color: rgb(255, 255, 255);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(255, 255, 255);">&#160;&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="background-color: rgb(255, 255, 255);">&#160;</td> </tr> </table> <span></span>
</td>
<td class="text"><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">A summary of pRSU activity under the pRSU Plan is as follows: </div></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 76%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="font-size: 0px;">
<td style="width: 64%;"/>
<td style="width: 10%; vertical-align: bottom;"/>
<td/>
<td/>
<td/>
<td style="width: 10%; vertical-align: bottom;"/>
<td/>
<td/>
<td/> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Number&#160;of<br/> pRSUs</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Weighted&#160;Average<br/> Grant Date Fair<br/> Value</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">Non-vested</div> balance at March&#160;31, 2020</div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">266,845</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">13.92</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Granted</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Forfeited</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(66,845</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">13.92</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;">&#160;</td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">Non-vested</div> balance at March&#160;31, 2021</div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">200,000</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">13.92</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;">&#160;</td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td> </tr> </table> <span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=roiv_CommonStockAwardsMember', window );">RSL Common Share Award</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock', window );">Summary of Stock Option Activity</a></td>
<td class="text"><div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">A summary of RSL restricted common stock activity as of June&#160;30, 2021 is as follows: </div></div></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 68%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px; text-indent: 0px;">
<tr style="font-size: 0px;">
<td style="width: 78%;"/>
<td style="width: 11%; vertical-align: bottom;"/>
<td/>
<td/>
<td/> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 1pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Number of<br/> Restricted<br/> Common&#160;Stock</div></div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td> </tr>
<tr style="font-size: 0px;">
<td style="width: 83%;"/>
<td style="width: 8%; vertical-align: bottom;"/>
<td/>
<td/>
<td/> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">Non-vested</div> balance at March&#160;31, 2021</div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">587,824</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Granted</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Forfeited</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">Non-vested</div> balance at June&#160;30, 2021</div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">587,824</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td> </tr> </table> <span></span>
</td>
<td class="text"><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">A summary of RSL restricted common stock activity as of March&#160;31, 2021 is as follows: </div></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 76%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="font-size: 0px;">
<td style="width: 64%;"/>
<td style="width: 10%; vertical-align: bottom;"/>
<td/>
<td/>
<td/>
<td style="width: 10%; vertical-align: bottom;"/>
<td/>
<td/>
<td/> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Number&#160;of<br/> Restricted<br/> Common<br/> Stock</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Weighted&#160;Average<br/> Grant Date Fair<br/> Value</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">Non-vested</div> balance at March&#160;31, 2020</div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Granted</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">587,824</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">38.50</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Vested</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Forfeited</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;">&#160;</td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">Non-vested</div> balance at March&#160;31, 2021</div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">587,824</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">38.50</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;">&#160;</td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td> </tr> </table> <span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_roiv_ScheduleOfSharebasedPaymentArrangementFairValueOfVestedStockOptionTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Schedule of Share-based Payment Arrangement, Fair Value of Vested Stock Option.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">roiv_ScheduleOfSharebasedPaymentArrangementFairValueOfVestedStockOptionTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>roiv_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of cost recognized for award under share-based payment arrangement by plan. Includes, but is not limited to, related tax benefit.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the changes in outstanding nonvested restricted stock units.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure for stock option plans. Includes, but is not limited to, outstanding awards at beginning and end of year, grants, exercises, forfeitures, and weighted-average grant date fair value.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the significant assumptions used during the year to estimate the fair value of stock options, including, but not limited to: (a) expected term of share options and similar instruments, (b) expected volatility of the entity's shares, (c) expected dividends, (d) risk-free rate(s), and (e) discount for post-vesting restrictions.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=roiv_PerformanceOptionsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=roiv_PerformanceOptionsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=roiv_CappedValueAppreciationRightsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=roiv_CappedValueAppreciationRightsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=roiv_PerformanceRestrictedStockUnitsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=roiv_PerformanceRestrictedStockUnitsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=roiv_CommonStockAwardsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=roiv_CommonStockAwardsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>104
<FILENAME>R34.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm139997744704056">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock', window );">Schedule of Company's net deferred tax assets</a></td>
<td class="text">Significant components of the deferred tax assets (liabilities) at March&#160;31, 2021 and 2020 are as follows (in thousands): <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 76%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="font-size: 0px;">
<td style="width: 62%;"/>
<td style="width: 12%; vertical-align: bottom;"/>
<td/>
<td/>
<td/>
<td style="width: 12%; vertical-align: bottom;"/>
<td/>
<td/>
<td/> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">March&#160;31,&#160;2021</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">March&#160;31,&#160;2020</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Deferred tax assets</div></div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Research tax credits</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">19,063</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">6,303</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Intangible assets</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">50,564</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">43,626</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Net operating loss</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">202,906</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">116,619</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Share-based compensation</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">26,623</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">18,413</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Lease liabilities</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">16,638</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">17,194</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Other</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">7,303</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">7,060</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;">&#160;</td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 5em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Subtotal</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">323,097</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">209,215</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Valuation allowance</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(303,287</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(187,831</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td> </tr>
<tr style="font-size: 1pt;">
<td style="height: 6pt; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td colspan="4" style="height: 6pt; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td colspan="4" style="height: 6pt; font-family: &quot;Times New Roman&quot;;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Deferred tax liabilities</div></div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Depreciation</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(1,214</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(1,833</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">Right-of-use</div></div> assets</div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(13,908</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(15,409</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Other</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(4,688</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(4,142</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Total deferred tax assets (liabilities)</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;">&#160;</td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td> </tr> </table> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock', window );">Reconciliation of Federal Statutory Income Taxes Rate</a></td>
<td class="text"><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">A reconciliation of income tax provision/(benefit) computed at the Bermuda statutory rate to income tax expense reflected in the consolidated financial statements is as follows (in thousands, except percentages): </div></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 92%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="font-size: 0px;">
<td style="width: 59%;"/>
<td style="width: 6%; vertical-align: bottom;"/>
<td/>
<td/>
<td/>
<td style="width: 6%; vertical-align: bottom;"/>
<td/>
<td/>
<td/>
<td style="width: 5%; vertical-align: bottom;"/>
<td/>
<td/>
<td/>
<td style="width: 6%; vertical-align: bottom;"/>
<td/>
<td/>
<td/> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;&#160;</td>
<td colspan="6" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Year Ended March&#160;31,<br/> 2021</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td colspan="6" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Year Ended<br/> March&#160;31, 2020</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Income tax benefit at Bermuda statutory rate</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">%&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">%&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Foreign rate differential<div style="font-size: 85%; vertical-align: top;;display:inline;;font-size:9.4px">(1)</div></div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(150,778</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">16.78</td>
<td style="vertical-align: bottom; white-space: nowrap;">%&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(74,922</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">13.36</td>
<td style="vertical-align: bottom; white-space: nowrap;">%&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Permanent disallowed IPR&amp;D</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">111,432</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(12.40</td>
<td style="vertical-align: bottom; white-space: nowrap;">)%&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">%&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Nondeductible changes in the fair value of investments and loss from equity method investment</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(22,472</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">2.50</td>
<td style="vertical-align: bottom; white-space: nowrap;">%&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">20,840</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(3.72</td>
<td style="vertical-align: bottom; white-space: nowrap;">)%&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Nontaxable (loss) gain on deconsolidation of business</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(16,438</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">1.83</td>
<td style="vertical-align: bottom; white-space: nowrap;">%&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">29,041</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(5.18</td>
<td style="vertical-align: bottom; white-space: nowrap;">)%&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Permanent adjustments</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">2,923</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(0.33</td>
<td style="vertical-align: bottom; white-space: nowrap;">)%&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(20,395</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">3.64</td>
<td style="vertical-align: bottom; white-space: nowrap;">%&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">R&amp;D tax credits</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(10,555</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">1.17</td>
<td style="vertical-align: bottom; white-space: nowrap;">%&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(5,990</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">1.07</td>
<td style="vertical-align: bottom; white-space: nowrap;">%&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Rate changes</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">2,443</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(0.27</td>
<td style="vertical-align: bottom; white-space: nowrap;">)%&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(29,238</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">5.21</td>
<td style="vertical-align: bottom; white-space: nowrap;">%&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Valuation allowance</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">85,046</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(9.46</td>
<td style="vertical-align: bottom; white-space: nowrap;">)%&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">87,677</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(15.63</td>
<td style="vertical-align: bottom; white-space: nowrap;">)%&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Other</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">85</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(0.01</td>
<td style="vertical-align: bottom; white-space: nowrap;">)%&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">111</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(0.02</td>
<td style="vertical-align: bottom; white-space: nowrap;">)%&#160;</td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: bottom;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Total income tax expense</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">$</td>
<td style="vertical-align: bottom;;text-align:right;">1,686</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">(0.19</td>
<td style="vertical-align: bottom; white-space: nowrap;">)%&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">$</td>
<td style="vertical-align: bottom;;text-align:right;">7,124</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;;text-align:right;">(1.27</td>
<td style="vertical-align: bottom; white-space: nowrap;">)%&#160;</td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td> </tr> </table> <div style="clear: both; max-height: 0px;"/> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 4%; vertical-align: top;;text-align:left;"><div style="font-size: 85%; vertical-align: top;;display:inline;;font-size:9.4px">(1)</div></td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Primarily related to operations in Switzerland, the United Kingdom, and other jurisdictions with statutory tax rates different than the Bermuda rate. </div></div> </td> </tr> </table> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock', window );">Schedule of Loss Before Income Taxes and Related Expense/(Benefit)</a></td>
<td class="text"><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The loss before income taxes and the related expense/(benefit) are as follows (in thousands): </div></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 76%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="font-size: 0px;">
<td style="width: 70%;"/>
<td style="width: 5%; vertical-align: bottom;"/>
<td/>
<td/>
<td/>
<td style="width: 5%; vertical-align: bottom;"/>
<td/>
<td/>
<td/> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;&#160;</td>
<td colspan="6" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Years Ended March&#160;31,</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2021</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2020</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Loss before income taxes:</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">United States</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(212,921</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(69,264</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Switzerland</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(424,494</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(355,422</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Bermuda</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(227,471</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(105,604</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Other<div style="font-size: 85%; vertical-align: top;;display:inline;;font-size:9.4px">(1)</div></div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(33,661</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(30,696</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 5em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Total loss before income taxes</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(898,547</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(560,986</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td> </tr> </table> <div style="clear: both; max-height: 0px;"/> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 4%; vertical-align: top;;text-align:left;"><div style="font-size: 85%; vertical-align: top;;display:inline;;font-size:9.4px">(1)</div>&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Primarily Greater China and United Kingdom activity </div></div> </td> </tr> </table>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 76%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="font-size: 0px;">
<td style="width: 74%;"/>
<td style="width: 7%; vertical-align: bottom;"/>
<td/>
<td/>
<td/>
<td style="width: 7%; vertical-align: bottom;"/>
<td/>
<td/>
<td/> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;&#160;</td>
<td colspan="6" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Years&#160;Ended&#160;March&#160;31,</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;&#160;&#160;&#160;2021&#160;&#160;&#160;&#160;</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;&#160;&#160;&#160;2020&#160;&#160;&#160;&#160;</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Current taxes:</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">United States</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">1,365</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">6,327</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Switzerland</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Bermuda</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Other<div style="font-size: 85%; vertical-align: top;;display:inline;;font-size:9.4px">(1)</div></div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">321</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">797</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;">&#160;</td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 5em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Total current tax expense</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">1,686</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">7,124</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;">&#160;</td> </tr>
<tr style="font-size: 1pt;">
<td style="height: 6pt; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td colspan="4" style="height: 6pt; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td colspan="4" style="height: 6pt; font-family: &quot;Times New Roman&quot;;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Deferred taxes:</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">United States</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Switzerland</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Bermuda</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Other<div style="font-size: 85%; vertical-align: top;;display:inline;;font-size:9.4px">(1)</div></div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 5em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Total deferred tax benefit</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;">&#160;</td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 7em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Total income tax expense</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">1,686</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">7,124</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;">&#160;</td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td> </tr> </table> <div style="clear: both; max-height: 0px;"/> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 4%; vertical-align: top;;text-align:left;"><div style="font-size: 85%; vertical-align: top;;display:inline;;font-size:9.4px">(1)</div></td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Primarily Greater China, United States state and local and United Kingdom activity </div></div> </td> </tr> </table> <span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the components of net deferred tax asset or liability recognized in an entity's statement of financial position, including the following: the total of all deferred tax liabilities, the total of all deferred tax assets, the total valuation allowance recognized for deferred tax assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32537-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the reconciliation using percentage or dollar amounts of the reported amount of income tax expense attributable to continuing operations for the year to the amount of income tax expense that would result from applying domestic federal statutory tax rates to pretax income from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32687-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of income before income tax between domestic and foreign jurisdictions.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(1)(Note 1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>105
<FILENAME>R35.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm139997751014776">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Leases (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LeasesAbstract', window );"><strong>Leases [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LeaseCostTableTextBlock', window );">Schedule of Operating Lease Costs</a></td>
<td class="text"><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The components of operating lease expense for the Company were as follows (in thousands): </div></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 68%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="font-size: 0px;">
<td style="width: 70%;"/>
<td style="width: 6%; vertical-align: bottom;"/>
<td/>
<td/>
<td/>
<td style="width: 6%; vertical-align: bottom;"/>
<td/>
<td/>
<td/> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;&#160;</td>
<td colspan="6" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Years&#160;Ended&#160;March&#160;31,</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2021</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2020</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Operating lease cost</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">11,931</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">11,515</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Short-term lease cost</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">237</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">872</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Variable lease cost</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">704</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">379</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;">&#160;</td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Total operating lease cost</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">12,872</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">12,766</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;">&#160;</td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td> </tr> </table> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LeasesOfLesseeDisclosureTextBlock', window );">Summary of Operating Lease ROU Assets and Operating Lease Liabilities</a></td>
<td class="text"><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Information related to the Company&#8217;s operating lease ROU assets and operating lease liabilities was as follows (in thousands, except periods and percentages): </div></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 68%; font-family: &quot;Times New Roman&quot;; font-size: 8pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="font-size: 0px;">
<td style="width: 72%;"/>
<td style="width: 6%; vertical-align: bottom;"/>
<td/>
<td/>
<td/>
<td style="width: 6%; vertical-align: bottom;"/>
<td/>
<td/>
<td/> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;&#160;</td>
<td colspan="6" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">During the Year<br/> Ended March&#160;31,</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2021</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2020</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Cash paid for operating lease liabilities</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">8,830</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">8,108</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Operating lease ROU assets obtained in exchange for operating lease liabilities</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">5,491</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">56,025</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;">&#160;</td> </tr> </table> <div style="clear: both; max-height: 0px;"/> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 84%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="font-size: 0px;">
<td style="width: 66%;"/>
<td style="width: 15%; vertical-align: bottom;"/>
<td/>
<td/>
<td/>
<td style="width: 14%; vertical-align: bottom;"/>
<td/>
<td/>
<td/> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">March&#160;31,&#160;2021</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">March&#160;31,&#160;2020</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Weighted average remaining lease term (in years)</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">9.6</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">10.2</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Weighted average discount rate</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">7.1</td>
<td style="vertical-align: bottom; white-space: nowrap;">%&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">7.1</td>
<td style="vertical-align: bottom; white-space: nowrap;">%&#160;</td> </tr> </table> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock', window );">Schedule of Maturities of Operating Lease Liabilities</a></td>
<td class="text"><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">As of March&#160;31, 2021, maturities of operating lease liabilities were as follows (in thousands): </div></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 68%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="font-size: 0px;">
<td style="width: 83%; font-family: &quot;Times New Roman&quot;;"/>
<td style="width: 9%; vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/>
<td style="font-family: &quot;Times New Roman&quot;;"/>
<td style="font-family: &quot;Times New Roman&quot;;"/>
<td style="font-family: &quot;Times New Roman&quot;;"/> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; white-space: nowrap;"> <div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt; border-bottom: 1pt solid rgb(0, 0, 0); display: table-cell; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">Years Ending March&#160;31,</div></div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">2022</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">13,386</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">2023</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">11,814</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">2024</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">11,718</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">2025</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">9,734</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">2026</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">8,617</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Thereafter</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">51,674</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;">&#160;</td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Total lease payments</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">106,943</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Less: present value adjustment</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(29,348</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Less: tenant improvement allowance</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(2,898</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Total</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">74,697</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;">&#160;</td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td> </tr> </table> <span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeaseCostTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of lessee's lease cost. Includes, but is not limited to, interest expense for finance lease, amortization of right-of-use asset for finance lease, operating lease cost, short-term lease cost, variable lease cost and sublease income.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=123408670&amp;loc=SL77918686-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeaseCostTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeasesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeasesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeasesOfLesseeDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for lessee entity's leasing arrangements including, but not limited to, all of the following: (a.) The basis on which contingent rental payments are determined, (b.) The existence and terms of renewal or purchase options and escalation clauses, (c.) Restrictions imposed by lease agreements, such as those concerning dividends, additional debt, and further leasing.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 840<br> -URI http://asc.fasb.org/topic&amp;trid=2208923<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeasesOfLesseeDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of undiscounted cash flows of lessee's operating lease liability. Includes, but is not limited to, reconciliation of undiscounted cash flows to operating lease liability recognized in statement of financial position.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=123408670&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>106
<FILENAME>R36.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm139997755097640">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Fair Value Measurements (Tables)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2021</div></th>
<th class="th"><div>Mar. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock', window );">Schedule of Assets and Liabilities Measured at Fair Value on a Recurring Basis</a></td>
<td class="text"><div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The following table sets forth the Company&#8217;s assets and liabilities that are measured at fair value on a recurring basis as of June&#160;30, 2021 and March&#160;31, 2021, by level, within the fair value hierarchy (in thousands): </div></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;width:100%;">
<tr style="font-size: 0px;">
<td style="width: 30%;"/>
<td style="width: 1%; vertical-align: bottom;"/>
<td/>
<td/>
<td/>
<td style="width: 1%; vertical-align: bottom;"/>
<td/>
<td/>
<td/>
<td style="width: 1%; vertical-align: bottom;"/>
<td/>
<td/>
<td/>
<td style="width: 1%; vertical-align: bottom;"/>
<td/>
<td/>
<td/>
<td style="width: 1%; vertical-align: bottom;"/>
<td/>
<td/>
<td/>
<td style="width: 1%; vertical-align: bottom;"/>
<td/>
<td/>
<td/>
<td style="width: 1%; vertical-align: bottom;"/>
<td/>
<td/>
<td/>
<td style="width: 1%; vertical-align: bottom;"/>
<td/>
<td/>
<td/></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;&#160;</td>
<td colspan="14" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">As of June&#160;30, 2021</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;&#160;</td>
<td colspan="14" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">As of March&#160;31, 2021</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Level&#160;1</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Level&#160;2</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Level&#160;3</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Balance as<br/> of&#160;June&#160;30,<br/> 2021</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Level&#160;1</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Level&#160;2</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Level&#160;3</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Balance as<br/> of&#160;March&#160;31,<br/> 2021</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top; width: 30%;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Assets:</div></div></td>
<td style="vertical-align: bottom; width: 1%;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; width: 1%;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; width: 1%;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; width: 1%;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; width: 1%;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; width: 1%;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; width: 1%;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; width: 1%;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; width: 30%;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Money market funds</div></div></td>
<td style="vertical-align: bottom; width: 1%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">1,340,662</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 1%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 1%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 1%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">1,340,662</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 1%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">1,420,597</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 1%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 1%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 1%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">1,420,597</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top; width: 30%;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Investment in Sio common shares</div></div></td>
<td style="vertical-align: bottom; width: 1%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">50,716</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 1%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 1%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 1%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">50,716</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 1%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">48,487</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 1%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 1%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 1%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">48,487</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; width: 30%;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Investment in Arbutus common shares</div></div></td>
<td style="vertical-align: bottom; width: 1%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">48,521</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 1%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 1%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 1%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">48,521</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 1%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">53,325</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 1%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 1%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 1%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">53,325</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top; width: 30%;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Investment in Arbutus convertible preferred shares</div></div></td>
<td style="vertical-align: bottom; width: 1%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 1%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">69,187</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 1%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 1%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">69,187</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 1%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 1%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">76,037</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 1%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 1%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">76,037</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; width: 30%;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Other investment</div></div></td>
<td style="vertical-align: bottom; width: 1%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">11,935</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 1%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 1%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 1%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">11,935</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 1%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">11,129</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 1%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 1%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 1%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">11,129</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 30%;">&#160;</td>
<td style="vertical-align: bottom; width: 1%;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom; width: 1%;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom; width: 1%;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom; width: 1%;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom; width: 1%;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom; width: 1%;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom; width: 1%;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom; width: 1%;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top; width: 30%;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Total assets at fair value</div></div></td>
<td style="vertical-align: bottom; width: 1%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">1,451,834</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 1%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">69,187</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 1%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 1%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">1,521,021</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 1%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">1,533,538</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 1%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">76,037</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 1%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 1%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">1,609,575</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 30%;">&#160;</td>
<td style="vertical-align: bottom; width: 1%;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom; width: 1%;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom; width: 1%;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom; width: 1%;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom; width: 1%;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom; width: 1%;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom; width: 1%;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom; width: 1%;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; width: 30%;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Liabilities:</div></div></td>
<td style="vertical-align: bottom; width: 1%;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; width: 1%;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; width: 1%;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; width: 1%;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; width: 1%;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; width: 1%;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; width: 1%;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; width: 1%;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top; text-indent: 0px; width: 30%;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Debt issued by Dermavant to NovaQuest</div></div></td>
<td style="vertical-align: bottom; text-indent: 0px; width: 1%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">$</div></td>
<td style="vertical-align: bottom; white-space: nowrap; text-indent: 0px;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; text-indent: 0px;">&#160;</td>
<td style="vertical-align: bottom; text-indent: 0px; width: 1%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">$</div></td>
<td style="vertical-align: bottom; white-space: nowrap; text-indent: 0px;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; text-indent: 0px;">&#160;</td>
<td style="vertical-align: bottom; text-indent: 0px; width: 1%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">$</div></td>
<td style="vertical-align: bottom; white-space: nowrap; text-indent: 0px;;text-align:right;">155,200</td>
<td style="vertical-align: bottom; white-space: nowrap; text-indent: 0px;">&#160;</td>
<td style="vertical-align: bottom; text-indent: 0px; width: 1%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">$</div></td>
<td style="vertical-align: bottom; white-space: nowrap; text-indent: 0px;;text-align:right;">155,200</td>
<td style="vertical-align: bottom; white-space: nowrap; text-indent: 0px;">&#160;</td>
<td style="vertical-align: bottom; text-indent: 0px; width: 1%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">$</div></td>
<td style="vertical-align: bottom; white-space: nowrap; text-indent: 0px;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; text-indent: 0px;">&#160;</td>
<td style="vertical-align: bottom; text-indent: 0px; width: 1%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">$</div></td>
<td style="vertical-align: bottom; white-space: nowrap; text-indent: 0px;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; text-indent: 0px;">&#160;</td>
<td style="vertical-align: bottom; text-indent: 0px; width: 1%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">$</div></td>
<td style="vertical-align: bottom; white-space: nowrap; text-indent: 0px;;text-align:right;">150,100</td>
<td style="vertical-align: bottom; white-space: nowrap; text-indent: 0px;">&#160;</td>
<td style="vertical-align: bottom; text-indent: 0px; width: 1%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">$</div></td>
<td style="vertical-align: bottom; white-space: nowrap; text-indent: 0px;;text-align:right;">150,100</td>
<td style="vertical-align: bottom; white-space: nowrap; text-indent: 0px;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; width: 30%;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Liability instruments measured at fair value</div></div></td>
<td style="vertical-align: bottom; width: 1%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 1%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 1%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">5,906</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 1%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">5,906</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 1%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 1%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 1%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">67,893</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 1%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">67,893</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 30%;">&#160;</td>
<td style="vertical-align: bottom; width: 1%;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom; width: 1%;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom; width: 1%;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom; width: 1%;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom; width: 1%;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom; width: 1%;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom; width: 1%;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom; width: 1%;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top; width: 30%;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Total liabilities at fair value</div></div></td>
<td style="vertical-align: bottom; width: 1%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 1%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 1%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">161,106</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 1%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">161,106</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 1%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 1%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 1%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">217,993</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 1%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">217,993</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 30%;">&#160;</td>
<td style="vertical-align: bottom; width: 1%;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom; width: 1%;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom; width: 1%;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom; width: 1%;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom; width: 1%;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom; width: 1%;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom; width: 1%;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom; width: 1%;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td></tr></table> <span></span>
</td>
<td class="text"><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The following table sets forth the Company&#8217;s assets and liabilities that are measured at fair value on a recurring basis as of&#160;March&#160;31, 2021 and 2020, by level, within the fair value hierarchy (in thousands): </div></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 8pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="font-size: 0px;">
<td style="width: 42%;"/>
<td style="width: 1%; vertical-align: bottom;"/>
<td/>
<td/>
<td/>
<td style="width: 1%; vertical-align: bottom;"/>
<td/>
<td/>
<td/>
<td style="width: 1%; vertical-align: bottom;"/>
<td/>
<td/>
<td/>
<td style="width: 1%; vertical-align: bottom;"/>
<td/>
<td/>
<td/>
<td style="width: 1%; vertical-align: bottom;"/>
<td/>
<td/>
<td/>
<td style="width: 1%; vertical-align: bottom;"/>
<td/>
<td/>
<td/>
<td style="width: 1%; vertical-align: bottom;"/>
<td/>
<td/>
<td/>
<td style="width: 1%; vertical-align: bottom;"/>
<td/>
<td/>
<td/> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td colspan="14" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">As of March&#160;31, 2021</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td colspan="14" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">As of March&#160;31, 2020</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Level&#160;1</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Level&#160;2</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Level&#160;3</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Balance&#160;as&#160;of<br/> March&#160;31,<br/> 2021</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Level&#160;1</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Level&#160;2</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Level&#160;3</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Balance&#160;as&#160;of<br/> March&#160;31,<br/> 2020</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">Assets:</div></div> </td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">Money market funds</div></div> </td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">1,420,597</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">1,420,597</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">1,874,662</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">1,874,662</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">Investment in Sio common shares</div></div> </td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">48,487</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">48,487</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">45,329</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">45,329</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">Investment in Arbutus common shares</div></div> </td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">53,325</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">53,325</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">16,174</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">16,174</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">Investment in Arbutus convertible preferred shares</div></div> </td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">76,037</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">76,037</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">23,062</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">23,062</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">Other investments</div></div> </td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">11,129</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">11,129</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">8,880</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">8,880</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;">&#160;</td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">Total assets at fair value</div></div> </td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">1,533,538</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">76,037</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">1,609,575</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">1,945,045</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">23,062</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">1,968,107</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;">&#160;</td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">Liabilities:</div></div> </td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">Debt held by Dermavant with NovaQuest</div></div> </td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">150,100</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">150,100</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">89,100</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">89,100</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">Liability instruments measured at fair value</div></div> </td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">67,893</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">67,893</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">102,373</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">102,373</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;">&#160;</td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">Total liabilities at fair value</div></div> </td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">217,993</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">217,993</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">191,473</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">191,473</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;">&#160;</td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td> </tr> </table> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock', window );">Schedule of Fair Value of Unobservable Input Related To Options to Acquire Under Sumitomo Transaction Agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text"><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The fair value of the options to acquire the Company&#8217;s interest in Dermavant, Genevant, Lysovant, Metavant, Cytovant Parent, and Sinovant (collectively, the &#8220;Option Vants&#8221;) granted to Sumitomo under the Sumitomo Transaction Agreement as of March&#160;31, 2021 and 2020 was calculated using significant unobservable inputs including the following: </div></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 84%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="font-size: 0px;">
<td style="width: 55%;"/>
<td style="width: 7%; vertical-align: bottom;"/>
<td/>
<td style="width: 6%; vertical-align: bottom;"/>
<td/> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;&#160;</td>
<td colspan="3" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Range&#160;or&#160;Point&#160;Estimate&#160;Used</div></div></td> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; white-space: nowrap; padding-bottom: 1pt;"> <div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt; border-bottom: 1pt solid rgb(0, 0, 0); display: table-cell; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">Input</div></div></div> </td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;&#160;</td>
<td style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">As&#160;of&#160;March&#160;31,&#160;2021</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">As&#160;of&#160;March&#160;31,&#160;2020</div></div></td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Time to expiration (in years)</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:center;">3.59</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:center;">0.49&#160;-&#160;4.59</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Risk-free rate</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:center;">0.52%</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:center;">0.15%&#160;-&#160;0.35%</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Volatility</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:center;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">89.0%&#160;-&#160;95.0%</div></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:center;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">91.0%&#160;-&#160;110.0%</div></td> </tr> </table> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock', window );">Schedule of change in the fair value of the derivative warrant liabilities</a></td>
<td class="text"><div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The changes in fair value of the Level&#160;3 liabilities during the three months ended June&#160;30, 2021 and 2020 were as follows (in thousands): </div></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;width:68%;">
<tr style="font-size: 0px;">
<td style="width: 83%; font-family: &quot;Times New Roman&quot;;"/>
<td style="width: 7%; vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/>
<td style="font-family: &quot;Times New Roman&quot;;"/>
<td style="font-family: &quot;Times New Roman&quot;;"/>
<td style="font-family: &quot;Times New Roman&quot;;"/></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top; width: 83%;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Balance at March&#160;31, 2020</div></div></td>
<td style="vertical-align: bottom; width: 7%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">191,473</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; width: 83%;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Changes in fair value of debt and liability instruments, included in net loss</div></div></td>
<td style="vertical-align: bottom; width: 7%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">17,125</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top; width: 83%;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Liability instruments disposed due to deconsolidation of subsidiary</div></div></td>
<td style="vertical-align: bottom; width: 7%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(3,325</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 83%;">&#160;</td>
<td style="vertical-align: bottom; width: 7%;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; width: 83%;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Balance at June&#160;30, 2020</div></div></td>
<td style="vertical-align: bottom; width: 7%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">205,273</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 83%;">&#160;</td>
<td style="vertical-align: bottom; width: 7%;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td></tr>
<tr>
<td style="vertical-align: top; line-height: 5pt; font-size: 5pt; width: 83%;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 5pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: 5pt;"><div style="font-size: 5pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom; line-height: 5pt; font-size: 5pt; width: 7%;"><div style="font-size: 5pt; line-height: 5pt;"><div style="font-size: 5pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap; line-height: 5pt; font-size: 5pt;"><div style="font-size: 5pt; line-height: 5pt;"><div style="font-size: 5pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap; line-height: 5pt; font-size: 5pt;;text-align:right;"><div style="font-size: 5pt; line-height: 5pt;"><div style="font-size: 5pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap; line-height: 5pt; font-size: 5pt;"><div style="font-size: 5pt; line-height: 5pt;"><div style="font-size: 5pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top; width: 83%;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Balance at March&#160;31, 2021</div></div></td>
<td style="vertical-align: bottom; width: 7%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">217,993</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; width: 83%;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Changes in fair value of debt and liability instruments, included in net loss</div></div></td>
<td style="vertical-align: bottom; width: 7%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">4,585</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top; width: 83%;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Termination of DSP Options</div></div></td>
<td style="vertical-align: bottom; width: 7%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(61,472</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 83%;">&#160;</td>
<td style="vertical-align: bottom; width: 7%;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; width: 83%;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Balance at June&#160;30, 2021</div></div></td>
<td style="vertical-align: bottom; width: 7%;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">161,106</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 83%;">&#160;</td>
<td style="vertical-align: bottom; width: 7%;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td></tr></table> <span></span>
</td>
<td class="text"><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The changes in fair value of the Level&#160;3 liabilities during the&#160;years ended March&#160;31, 2021 and 2020 were as follows (in thousands): </div></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 68%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="font-size: 0px;">
<td style="width: 83%; font-family: &quot;Times New Roman&quot;;"/>
<td style="width: 7%; vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/>
<td style="font-family: &quot;Times New Roman&quot;;"/>
<td style="font-family: &quot;Times New Roman&quot;;"/>
<td style="font-family: &quot;Times New Roman&quot;;"/> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: bottom;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Balance at March&#160;31, 2019</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">$</td>
<td style="vertical-align: bottom;;text-align:right;">103,628</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Issuance of liability instruments measured at fair value</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">101,567</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Changes in fair value of debt and liability instruments, included in net loss</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(13,722</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Balance at March&#160;31, 2020</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">191,473</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Changes in fair value of debt and liability instruments, included in net loss</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">29,845</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Liability instruments disposed due to deconsolidation of subsidiary</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(3,325</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: bottom;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Balance at March&#160;31, 2021</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">$</td>
<td style="vertical-align: bottom;;text-align:right;">217,993</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;">&#160;</td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td> </tr> </table> <span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of input and valuation technique used to measure fair value and change in valuation approach and technique for each separate class of asset and liability measured on recurring and nonrecurring basis.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)<br> -URI http://asc.fasb.org/extlink&amp;oid=123874694&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the fair value measurement of liabilities using significant unobservable inputs (Level 3), a reconciliation of the beginning and ending balances, separately presenting changes attributable to the following: (1) total gains or losses for the period (realized and unrealized), segregating those gains or losses included in earnings (or changes in net assets), and gains or losses recognized in other comprehensive income (loss) and a description of where those gains or losses included in earnings (or changes in net assets) are reported in the statement of income (or activities); (2) purchases, sales, issues, and settlements (each type disclosed separately); and (3) transfers in and transfers out of Level 3 (for example, transfers due to changes in the observability of significant inputs) by class of liability.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123874694&amp;loc=d3e19207-110258<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=123874694&amp;loc=d3e19279-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of assets and liabilities, including [financial] instruments measured at fair value that are classified in stockholders' equity, if any, that are measured at fair value on a recurring basis. The disclosures contemplated herein include the fair value measurements at the reporting date by the level within the fair value hierarchy in which the fair value measurements in their entirety fall, segregating fair value measurements using quoted prices in active markets for identical assets (Level 1), significant other observable inputs (Level 2), and significant unobservable inputs (Level 3).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123874694&amp;loc=d3e19207-110258<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123874694&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>107
<FILENAME>R37.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm139997851016232">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Other (Income) Expense, Net (Tables)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2021</div></th>
<th class="th"><div>Mar. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherIncomeAndExpensesAbstract', window );"><strong>Other Income and Expenses [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfOtherOperatingCostAndExpenseByComponentTextBlock', window );">Summary of Other (Income) Expense, Net From Continuing Operations</a></td>
<td class="text"><div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Other (income) expense, net was as follows (in thousands): </div></div></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 76%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px; text-indent: 0px;">
<tr style="font-size: 0px;">
<td style="width: 75%;"/>
<td style="width: 7%; vertical-align: bottom;"/>
<td/>
<td/>
<td/>
<td style="width: 7%; vertical-align: bottom;"/>
<td/>
<td/>
<td/> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 1pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td colspan="6" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Three&#160;Months&#160;Ended<br/> June&#160;30,</div></div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 1pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2021</div></div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2020</div></div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td> </tr>
<tr style="font-size: 0px;">
<td style="width: 80%;"/>
<td style="width: 6%; vertical-align: bottom;"/>
<td/>
<td/>
<td/>
<td style="width: 5%; vertical-align: bottom;"/>
<td/>
<td/>
<td/> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Loss from equity method investment</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">3,750</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Interest income</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(71</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(621</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Interest expense</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">2,513</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">791</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Other income</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(2,576</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(1,078</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Total</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(134</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">2,842</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td> </tr> </table> <span></span>
</td>
<td class="text"><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Other expense, net from continuing operations was as follows (in thousands): </div></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 76%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="font-size: 0px;">
<td style="width: 74%;"/>
<td style="width: 6%; vertical-align: bottom;"/>
<td/>
<td/>
<td/>
<td style="width: 6%; vertical-align: bottom;"/>
<td/>
<td/>
<td/> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;&#160;</td>
<td colspan="6" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Years Ended March&#160;31,</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2021</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2020</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: bottom;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Loss from equity method investment</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">$</td>
<td style="vertical-align: bottom;;text-align:right;">3,750</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">$</td>
<td style="vertical-align: bottom;;text-align:right;">21,386</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Interest income</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(1,418</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(17,990</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Interest expense</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">2,809</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">7,683</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Other expense</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">3,560</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">2,543</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;">&#160;</td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: bottom;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Total</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">$</td>
<td style="vertical-align: bottom;;text-align:right;">8,701</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">$</td>
<td style="vertical-align: bottom;;text-align:right;">13,622</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;">&#160;</td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td> </tr> </table> <span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherIncomeAndExpensesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherIncomeAndExpensesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfOtherOperatingCostAndExpenseByComponentTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of each detailed component of other operating costs and expenses that are applicable to sales and revenues, but not included in the cost of sales in the income statement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.3)<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfOtherOperatingCostAndExpenseByComponentTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>108
<FILENAME>R38.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm139997864304824">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Net Loss per Common Share (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock', window );">Schedule of basic and diluted per share of common stock</a></td>
<td class="text"><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The computations of the numerator to derive the basic and diluted earnings per share amounts presented on the face of the accompanying consolidated statements of operations are as follows (in thousands): </div></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 92%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="font-size: 0px;">
<td style="width: 75%;"/>
<td style="width: 3%; vertical-align: bottom;"/>
<td/>
<td/>
<td/>
<td style="width: 3%; vertical-align: bottom;"/>
<td/>
<td/>
<td/> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;&#160;</td>
<td colspan="6" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Years Ended March&#160;31,</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2021</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2020</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 1pt;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Loss from continuing operations, net of tax</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(900,233</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(568,110</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Net loss from continuing operations, net of tax, attributable to noncontrolling interest</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(90,999</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(48,716</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Loss from continuing operations, net of tax, attributable to Roivant Sciences Ltd.</div></div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(809,234</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">)&#160;</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(519,394</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">)&#160;</div></div></td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Deemed dividend on repurchase of redeemable noncontrolling interest relating to subsidiary convertible and redeemable preferred stock<div style="font-size: 85%; vertical-align: top;;display:inline;;font-size:9.4px">(1)</div></div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(77,777</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Basic and diluted loss from continuing operations, net of tax, attributable to Roivant Sciences Ltd.</div></div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">$</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(809,234</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">)&#160;</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">$</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(597,171</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">)&#160;</div></div></td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Income from discontinued operations, net of tax</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">1,578,426</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Net loss from discontinued operations, net of tax, attributable to noncontrolling interest</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(141,477</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Net income from discontinued operations, net of tax, attributable to Roivant Sciences Ltd.</div></div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">$</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#8212;&#160;&#160;</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">$</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">1,719,903</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Basic and diluted income from discontinued operations, net of tax</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">1,719,903</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;">&#160;</td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Basic and diluted net (loss) income attributable to Roivant Sciences</div></div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">$</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(809,234</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">)&#160;</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">$</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">1,122,732</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td> </tr> </table> <div style="clear: both; max-height: 0px;"/> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 4%; vertical-align: top;;text-align:left;"><div style="font-size: 85%; vertical-align: top;;display:inline;;font-size:9.4px">(1)</div></td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Consideration paid in excess of carrying value for the repurchase of redeemable noncontrolling interest relating to subsidiary convertible and redeemable preferred stock of $77.8&#160;million is considered a deemed dividend and, for purposes of calculating net loss per share, increases the loss from continuing operations, net of tax, attributable to Roivant Sciences Ltd. for the year ended March&#160;31, 2020. See Note 10, &#8220;Shareholders&#8217; Equity and Redeemable Noncontrolling Interest.&#8221; </div></div> </td> </tr> </table> <span></span>
</td>
</tr>
</table>
<div style="display: none;"><table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of an entity's basic and diluted earnings per share calculations, including a reconciliation of numerators and denominators of the basic and diluted per-share computations for income from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table></div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>109
<FILENAME>R39.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm139997756285384">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Description of Business and Liquidity - Additional Information (Detail)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="3">3 Months Ended</th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th">
<div>Jun. 30, 2021 </div>
<div>USD ($) </div>
<div>Segment</div>
</th>
<th class="th">
<div>Mar. 31, 2021 </div>
<div>USD ($) </div>
<div>Segment</div>
</th>
<th class="th">
<div>Jun. 30, 2020 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Mar. 31, 2021 </div>
<div>USD ($) </div>
<div>Segment</div>
</th>
<th class="th">
<div>Mar. 31, 2020 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract', window );"><strong>Organization, Consolidation and Presentation of Financial Statements [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NumberOfOperatingSegments', window );">Number of operating and reporting segments | Segment</a></td>
<td class="nump">1<span></span>
</td>
<td class="nump">1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and cash equivalents</a></td>
<td class="nump">$ 1,996,733<span></span>
</td>
<td class="nump">$ 2,055,044<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,055,044<span></span>
</td>
<td class="nump">$ 2,183,207<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RetainedEarningsAccumulatedDeficit', window );">Accumulated deficit</a></td>
<td class="nump">2,000,645<span></span>
</td>
<td class="nump">$ 1,918,462<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,918,462<span></span>
</td>
<td class="nump">1,109,228<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProfitLoss', window );">Net loss</a></td>
<td class="num">$ (101,078)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (7,977)<span></span>
</td>
<td class="num">(900,233)<span></span>
</td>
<td class="nump">1,010,316<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLossAttributableToRedeemableNoncontrollingInterest', window );">Net losses from continuing operations</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 900,200<span></span>
</td>
<td class="nump">$ 568,100<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3044-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6676-107765<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLossAttributableToRedeemableNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of Net Income (Loss) attributable to redeemable noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.19)<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLossAttributableToRedeemableNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NumberOfOperatingSegments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of operating segments. An operating segment is a component of an enterprise: (a) that engages in business activities from which it may earn revenues and incur expenses (including revenues and expenses relating to transactions with other components of the same enterprise), (b) whose operating results are regularly reviewed by the enterprise's chief operating decision maker to make decisions about resources to be allocated to the segment and assess its performance, and (c) for which discrete financial information is available. An operating segment may engage in business activities for which it has yet to earn revenues, for example, start-up operations may be operating segments before earning revenues.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 18<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8672-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NumberOfOperatingSegments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProfitLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The consolidated profit or loss for the period, net of income taxes, including the portion attributable to the noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669619-108580<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=SL4573702-111684<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123482062&amp;loc=SL123482106-238011<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 12: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124452729-227067<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8906-108599<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3000-108585<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 19<br> -URI http://asc.fasb.org/extlink&amp;oid=123454820&amp;loc=SL4569616-111683<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 235<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399901&amp;loc=d3e537907-122884<br><br>Reference 23: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8924-108599<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669625-108580<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 29: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (c)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=SL4573702-111684<br><br>Reference 31: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4J<br> -URI http://asc.fasb.org/extlink&amp;oid=120409616&amp;loc=SL4591551-111686<br><br>Reference 32: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4K<br> -URI http://asc.fasb.org/extlink&amp;oid=120409616&amp;loc=SL4591552-111686<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProfitLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetainedEarningsAccumulatedDeficit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cumulative amount of the reporting entity's undistributed earnings or deficit.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(3))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (g)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=121322162&amp;loc=SL121327923-165333<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(4))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(i)<br> -URI http://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RetainedEarningsAccumulatedDeficit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>110
<FILENAME>R40.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm139997748010472">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies - Additional Information (Detail) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th"><div>Jun. 30, 2021</div></th>
<th class="th"><div>Mar. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_roiv_ScheduleOfAccountingPoliciesLineItems', window );"><strong>Schedule Of Accounting Policies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EscrowDeposit', window );">Escrowed deposit</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 75.0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_roiv_ProceedsFromReleaseOfEscrowDeposit', window );">Proceeds from release of escrow deposit</a></td>
<td class="nump">$ 75.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_roiv_ProceedsFromReleaseOfEscrowDeposit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Proceeds from Release of Escrow Deposit.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">roiv_ProceedsFromReleaseOfEscrowDeposit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>roiv_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_roiv_ScheduleOfAccountingPoliciesLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Schedule Of Accounting Policies [Line Items]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">roiv_ScheduleOfAccountingPoliciesLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>roiv_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EscrowDeposit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The designation of funds furnished by a borrower to a lender to assure future payments of the borrower's real estate taxes and insurance obligations with respect to a mortgaged property. Escrow deposits may be made for a variety of other purposes such as earnest money and contingent payments. This element excludes replacement reserves which are an escrow separately provided for within the US GAAP taxonomy.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03.10)<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 954<br> -SubTopic 440<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=6491277&amp;loc=d3e6429-115629<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EscrowDeposit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>111
<FILENAME>R41.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm139997747442840">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies - Schedule of Aggregate Amounts of Cash, Cash Equivalents, and Restricted Cash (Detail) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Jun. 30, 2021</div></th>
<th class="th"><div>Mar. 31, 2021</div></th>
<th class="th"><div>Mar. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAbstract', window );"><strong>Cash and Cash Equivalents [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and cash equivalents</a></td>
<td class="nump">$ 1,996,733<span></span>
</td>
<td class="nump">$ 2,055,044<span></span>
</td>
<td class="nump">$ 2,183,207<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestrictedCash', window );">Restricted cash</a></td>
<td class="nump">11,644<span></span>
</td>
<td class="nump">86,632<span></span>
</td>
<td class="nump">86,045<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_roiv_CashAndCashEquivalentsAndRestrictedCash', window );">Cash, cash equivalents and restricted cash</a></td>
<td class="nump">$ 2,008,377<span></span>
</td>
<td class="nump">$ 2,141,676<span></span>
</td>
<td class="nump">$ 2,269,252<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_roiv_CashAndCashEquivalentsAndRestrictedCash">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Cash and Cash Equivalents and Restricted Cash</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">roiv_CashAndCashEquivalentsAndRestrictedCash</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>roiv_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3044-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6676-107765<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestrictedCash">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash restricted as to withdrawal or usage. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=123431023&amp;loc=SL98516268-108586<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(1)(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(2))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestrictedCash</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>112
<FILENAME>R42.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm139997755838664">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies - Schedule of Estimated Useful Lives (Detail)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2021</div></th></tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_ComputerEquipmentMember', window );">Computer [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLife', window );">Estimated useful lives</a></td>
<td class="text">3 years<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_EquipmentMember', window );">Equipment [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLife', window );">Estimated useful lives</a></td>
<td class="text">5 years<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_FurnitureAndFixturesMember', window );">Furniture and Fixtures [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLife', window );">Estimated useful lives</a></td>
<td class="text">7 years<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_SoftwareDevelopmentMember', window );">Software [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLife', window );">Estimated useful lives</a></td>
<td class="text">3 years<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LeaseholdImprovementsMember', window );">Leasehold Improvements [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentEstimatedUsefulLives', window );">Estimated useful lives</a></td>
<td class="text">Lesser of estimated useful life or remaining lease term<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentEstimatedUsefulLives">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Describes the periods of time over which an entity anticipates to receive utility from its property, plant and equipment (that is, the periods of time over which an entity allocates the initial cost of its property, plant and equipment).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 35<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=123364984&amp;loc=d3e1205-110223<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentEstimatedUsefulLives</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentUsefulLife">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Useful life of long lived, physical assets used in the normal conduct of business and not intended for resale, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. Examples include, but not limited to, land, buildings, machinery and equipment, office equipment, furniture and fixtures, and computer equipment.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentUsefulLife</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_ComputerEquipmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_ComputerEquipmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_EquipmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_EquipmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_FurnitureAndFixturesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_FurnitureAndFixturesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_SoftwareDevelopmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_SoftwareDevelopmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LeaseholdImprovementsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LeaseholdImprovementsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>113
<FILENAME>R43.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm139997750517320">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Investments - Additional Information (Detail) - USD ($)<br> $ / shares in Units, $ in Thousands</strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="3">3 Months Ended</th>
<th class="th" colspan="1">9 Months Ended</th>
<th class="th" colspan="2">12 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Sep. 29, 2017</div></th>
<th class="th"><div>Jun. 30, 2021</div></th>
<th class="th"><div>Mar. 31, 2021</div></th>
<th class="th"><div>Jun. 30, 2020</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Mar. 31, 2021</div></th>
<th class="th"><div>Mar. 31, 2020</div></th>
<th class="th"><div>Jul. 31, 2021</div></th>
<th class="th"><div>Jul. 31, 2020</div></th>
<th class="th"><div>Apr. 30, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_roiv_InvestmentsLineItems', window );"><strong>Investments [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_roiv_CommonStockOwnedBalanceSharesOfArbutus', window );">Common stock Owned, Balance, Shares of Arbutus</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">16,013,540<span></span>
</td>
<td class="nump">16,013,540<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">16,013,540<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_roiv_PreferredStockOwnedBalanceSharesOfArbutus', window );">Preferred stock Owned, Balance, Shares of Arbutus</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,164,000<span></span>
</td>
<td class="nump">1,164,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,164,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentsFairValueDisclosure', window );">Aggregate fair value investment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 180,359<span></span>
</td>
<td class="nump">$ 188,978<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 188,978<span></span>
</td>
<td class="nump">$ 93,445<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_roiv_PreferredStockSharesIssuedAndSoldToCompanyDuringPeriodShares', window );">Preferred stock issued and sold</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">639,140<span></span>
</td>
<td class="nump">639,140<span></span>
</td>
<td class="nump">13,411,311<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermInvestments', window );">Carrying value of long-term investment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 100,563<span></span>
</td>
<td class="nump">$ 100,563<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 100,563<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Common stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">222,669,799<span></span>
</td>
<td class="nump">222,669,799<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">222,669,799<span></span>
</td>
<td class="nump">214,879,058<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=us-gaap_SeriesBPreferredStockMember', window );">Series B Preferred Stock [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_roiv_InvestmentsLineItems', window );"><strong>Investments [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_roiv_PreferredStockSharesIssuedAndSoldToCompanyDuringPeriodShares', window );">Preferred stock issued and sold</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">13,411,311<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentTypeAxis=us-gaap_OtherInvestmentCompaniesMember', window );">Other Investments [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_roiv_InvestmentsLineItems', window );"><strong>Investments [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentsFairValueDisclosure', window );">Aggregate fair value investment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 11,900<span></span>
</td>
<td class="nump">$ 11,100<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 11,100<span></span>
</td>
<td class="nump">$ 8,900<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_LegalEntityAxis=roiv_ArbutusBiopharmaCorporationMember', window );">Arbutus Biopharma Corporation [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_roiv_InvestmentsLineItems', window );"><strong>Investments [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_roiv_PremiumOnConversionPricePercentage', window );">Premium on the conversion price, percentage</a></td>
<td class="nump">15.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_roiv_AnnualCompoundedConversionRateForPreferredShare', window );">Annual compounded conversion rate for preferred share</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">8.75%<span></span>
</td>
<td class="nump">8.75%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">8.75%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_roiv_ConversionPrice', window );">Conversion price</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 7.13<span></span>
</td>
<td class="nump">$ 7.13<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 7.13<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_roiv_ClosingPricePerShare', window );">Closing price</a></td>
<td class="nump">$ 6.20<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_roiv_OwnershipInterestPercentage', window );">Ownership interest, percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">49.90%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_roiv_MaximumAllowedOwnershipInterestPercentage', window );">Maximum allowed ownership interest percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">49.99%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentsFairValueDisclosure', window );">Aggregate fair value investment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 117,700<span></span>
</td>
<td class="nump">$ 129,400<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 129,400<span></span>
</td>
<td class="nump">39,200<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_UnrealizedGainLossOnInvestments', window );">Unrealized gain (loss) on investments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (11,700)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 31,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 90,200<span></span>
</td>
<td class="nump">$ 99,900<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharePrice', window );">Closing price of common stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3.03<span></span>
</td>
<td class="nump">$ 3.33<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3.33<span></span>
</td>
<td class="nump">$ 1.01<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquityMethodInvestmentOwnershipPercentage', window );">Equity method investment ownership percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">32.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Common stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">16,013,540<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">16,013,540<span></span>
</td>
<td class="nump">16,013,540<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockSharesOutstanding', window );">Preferred stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,164,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,164,000<span></span>
</td>
<td class="nump">1,164,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_LegalEntityAxis=roiv_SioGeneTherapiesIncMember', window );">Sio Gene Therapies Inc [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_roiv_InvestmentsLineItems', window );"><strong>Investments [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_roiv_OwnershipInterestPercentage', window );">Ownership interest, percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">27.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentsFairValueDisclosure', window );">Aggregate fair value investment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 50,700<span></span>
</td>
<td class="nump">$ 48,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 48,500<span></span>
</td>
<td class="nump">$ 45,300<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_UnrealizedGainLossOnInvestments', window );">Unrealized gain (loss) on investments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,200<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">7,100<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3,200<span></span>
</td>
<td class="nump">$ 31,600<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharePrice', window );">Closing price of common stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2.73<span></span>
</td>
<td class="nump">$ 2.61<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2.61<span></span>
</td>
<td class="nump">$ 2.44<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeconsolidationGainOrLossAmount', window );">Gain on deconsolidation</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 107,300<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_LegalEntityAxis=roiv_DatavantHoldingsIncMember', window );">Datavant Holdings, Inc [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_roiv_InvestmentsLineItems', window );"><strong>Investments [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentsFairValueDisclosure', window );">Aggregate fair value investment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 99,000<span></span>
</td>
<td class="nump">$ 99,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 99,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeconsolidationGainOrLossAmount', window );">Gain on deconsolidation</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 86,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">86,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermInvestments', window );">Carrying value of long-term investment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 100,600<span></span>
</td>
<td class="nump">$ 100,600<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 100,600<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_LegalEntityAxis=roiv_DatavantHoldingsIncMember', window );">Datavant Holdings, Inc [Member] | Series B Preferred Stock [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_roiv_InvestmentsLineItems', window );"><strong>Investments [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_roiv_ProceedsFromIssuanceOfPreferredStockAndPreferenceStocks', window );">Gross proceeds from issuance of stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 27,200<span></span>
</td>
<td class="nump">$ 27,200<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_roiv_PreferredStockSharesIssuedAndSoldToCompanyDuringPeriodShares', window );">Preferred stock issued and sold</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,065,234<span></span>
</td>
<td class="nump">1,065,234<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_roiv_PreferredStockPurchased', window );">Total purchase price</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,500<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion', window );">Issued relating to the conversion of certain liability instruments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,800,253<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_roiv_AnnualCompoundedConversionRateForPreferredShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Annual Compunded Conversion Rate for Preferred Share</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">roiv_AnnualCompoundedConversionRateForPreferredShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>roiv_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_roiv_ClosingPricePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Closing Price Per Share.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">roiv_ClosingPricePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>roiv_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_roiv_CommonStockOwnedBalanceSharesOfArbutus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Common stock Owned, Balance, Shares of Arbutus.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">roiv_CommonStockOwnedBalanceSharesOfArbutus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>roiv_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_roiv_ConversionPrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Conversion Price</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">roiv_ConversionPrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>roiv_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_roiv_InvestmentsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Investments [Line Items]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">roiv_InvestmentsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>roiv_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_roiv_MaximumAllowedOwnershipInterestPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Maximum Allowed Ownership Interest Percentage</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">roiv_MaximumAllowedOwnershipInterestPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>roiv_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_roiv_OwnershipInterestPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Ownership Interest Percentage</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">roiv_OwnershipInterestPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>roiv_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_roiv_PreferredStockOwnedBalanceSharesOfArbutus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Preferred stock Owned, Balance, Shares of Arbutus.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">roiv_PreferredStockOwnedBalanceSharesOfArbutus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>roiv_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_roiv_PreferredStockPurchased">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Preferred Stock Purchased</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">roiv_PreferredStockPurchased</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>roiv_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_roiv_PreferredStockSharesIssuedAndSoldToCompanyDuringPeriodShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Preferred Stock Shares Issued And Sold to Company During Period, Shares</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">roiv_PreferredStockSharesIssuedAndSoldToCompanyDuringPeriodShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>roiv_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_roiv_PremiumOnConversionPricePercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Premium on Conversion Price, Percentage</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">roiv_PremiumOnConversionPricePercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>roiv_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_roiv_ProceedsFromIssuanceOfPreferredStockAndPreferenceStocks">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Proceeds from Issuance of Preferred Stock and Preference Stocks.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">roiv_ProceedsFromIssuanceOfPreferredStockAndPreferenceStocks</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>roiv_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued for each share of convertible preferred stock that is converted.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(27))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21475-112644<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 16<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=SL123496180-112644<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21506-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeconsolidationGainOrLossAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of gain (loss) from deconsolidation of subsidiary and derecognition of group of assets constituting transfer of business or nonprofit activity, excluding conveyance of oil and gas mineral rights and transfer of good or service in contract with customer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=SL4582445-111684<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeconsolidationGainOrLossAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityMethodInvestmentOwnershipPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The percentage of ownership of common stock or equity participation in the investee accounted for under the equity method of accounting.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityMethodInvestmentOwnershipPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentsFairValueDisclosure">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value portion of investment securities, including, but not limited to, marketable securities, derivative financial instruments, and investments accounted for under the equity method.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123874694&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentsFairValueDisclosure</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The total amount of investments that are intended to be held for an extended period of time (longer than one operating cycle).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.12)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Price of a single share of a number of saleable stocks of a company.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UnrealizedGainLossOnInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of unrealized gain (loss) on investment.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UnrealizedGainLossOnInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=us-gaap_SeriesBPreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=us-gaap_SeriesBPreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentTypeAxis=us-gaap_OtherInvestmentCompaniesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentTypeAxis=us-gaap_OtherInvestmentCompaniesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LegalEntityAxis=roiv_ArbutusBiopharmaCorporationMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LegalEntityAxis=roiv_ArbutusBiopharmaCorporationMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LegalEntityAxis=roiv_SioGeneTherapiesIncMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LegalEntityAxis=roiv_SioGeneTherapiesIncMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LegalEntityAxis=roiv_DatavantHoldingsIncMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LegalEntityAxis=roiv_DatavantHoldingsIncMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>114
<FILENAME>R44.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm139997737917368">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Asset Acquisitions and License Agreements -Additional Information (Detail)<br> $ in Thousands, &#8364; in Millions, $ in Millions</strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="12">1 Months Ended</th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">12 Months Ended</th>
<th class="th" colspan="1">26 Months Ended</th>
</tr>
<tr>
<th class="th">
<div>Jul. 31, 2020 </div>
<div>USD ($) </div>
<div>shares</div>
</th>
<th class="th">
<div>Mar. 31, 2021 </div>
<div>USD ($) </div>
<div>shares</div>
</th>
<th class="th">
<div>Jan. 31, 2021 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2020 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Nov. 30, 2020 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Jul. 31, 2020 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Jan. 31, 2020 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Aug. 31, 2019 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Aug. 31, 2019 </div>
<div>CAD ($)</div>
</th>
<th class="th">
<div>Apr. 30, 2018 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>May 31, 2012 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>May 31, 2012 </div>
<div>EUR (&#8364;)</div>
</th>
<th class="th">
<div>May 31, 2012 </div>
<div>CAD ($)</div>
</th>
<th class="th">
<div>Jun. 30, 2021 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Jun. 30, 2020 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Mar. 31, 2021 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Mar. 31, 2020 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Jun. 30, 2020 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebt', window );">Long term debt</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 170,280<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 186,350<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 170,280<span></span>
</td>
<td class="nump">$ 108,592<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueNewIssues', window );">Stock issued, value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">301,744<span></span>
</td>
<td class="nump">999,193<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GainLossOnInvestments', window );">Gain (loss) on remeasurement of investment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(8,619)<span></span>
</td>
<td class="nump">$ 41,148<span></span>
</td>
<td class="nump">95,533<span></span>
</td>
<td class="num">(136,005)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">Research and development expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">78,626<span></span>
</td>
<td class="nump">58,734<span></span>
</td>
<td class="nump">832,758<span></span>
</td>
<td class="nump">263,217<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityNoteSubscriptionsReceivable', window );">Subscription receivable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired', window );">Payment to acquire business, net</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensation', window );">Share-based compensation expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 19,269<span></span>
</td>
<td class="nump">$ 14,278<span></span>
</td>
<td class="nump">84,958<span></span>
</td>
<td class="nump">122,572<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=roiv_SiliconTherapeuticsMember', window );">Silicon Therapeutics [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationConsiderationTransferred1', window );">Business combination, consideration transferred</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 450,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">Research and development expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">399,600<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued', window );">Number of shares issued in business combination | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">7,316,583<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired', window );">Payment to acquire business, net</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 14,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">15,600<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet', window );">Business combination, recognized identifiable assets acquired and liabilities assumed, assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">402,400<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">402,400<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionEquityInterestIssuedOrIssuableValueAssigned', window );">Business combination, recognized identifiable assets acquired and liabilities assumed, current liabilities, accounts payable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">281,700<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">281,700<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccountsPayable', window );">Business acquisition, equity interest issued or issuable, value assigned</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">105,100<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">105,100<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensation', window );">Share-based compensation expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">23,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_roiv_FairValueOfCommonShares', window );">Fair value of common shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">22,600<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">22,600<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_roiv_FairValueOfRestrictedStock', window );">Fair value of restricted stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">15,600<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=roiv_SiliconTherapeuticsMember', window );">Silicon Therapeutics [Member] | First Tranche [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationConsiderationTransferredLiabilitiesIncurred', window );">Business combination, consideration transferred, liabilities incurred</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">350,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=roiv_SiliconTherapeuticsMember', window );">Silicon Therapeutics [Member] | Second Tranche [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationConsiderationTransferredLiabilitiesIncurred', window );">Business combination, consideration transferred, liabilities incurred</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=roiv_DermavantSciencesLtdMember', window );">Dermavant Sciences Ltd [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_roiv_UpfrontCashPayments', window );">Net upfront cash payment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 191,000<span></span>
</td>
<td class="nump">&#8364; 150.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_roiv_BusinessCollaborationContingentMilestonePayment', window );">Contingent payment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">133,000<span></span>
</td>
<td class="nump">&#8364; 100.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_roiv_FutureDevelopmentAndCommercialMilestonePayments', window );">Future development and commercial milestone payments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">137,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 180.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebt', window );">Long term debt</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 117,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_roiv_MilestonePayment', window );">Milestone payment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 23,000<span></span>
</td>
<td class="nump">$ 30.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_roiv_NonRefundableUpfrontPaymentReceived', window );">Nonrefundable, upfront payment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 60,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_roiv_PotentialMilestonePaymentReceivable', window );">Nonrefundable, upfront payment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 53,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueRecognitionMilestoneMethodRevenueRecognized', window );">Non-refundable, up-front payment recognized</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 60,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=roiv_GenevantSciencesLtdMember', window );">Genevant Sciences Ltd [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireEquityMethodInvestments', window );">Equity ownership interest, additional cash contribution</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 38,700<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromNotesPayable', window );">Promissory notes issued</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 20,100<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Stock issued | shares</a></td>
<td class="nump">74,272,043<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueNewIssues', window );">Stock issued, value</a></td>
<td class="nump">$ 20,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtConversionOriginalDebtAmount1', window );">Aggregate principal amount of notes converted</a></td>
<td class="nump">$ 15,100<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtConversionConvertedInstrumentSharesIssued1', window );">Notes converted, shares issued | shares</a></td>
<td class="nump">54,526,549<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_roiv_PercentageOfControllingInterestHeld', window );">Percentage controlling interest</a></td>
<td class="nump">82.90%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">82.90%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentsInAffiliatesSubsidiariesAssociatesAndJointVenturesFairValueDisclosure', window );">Investment, fair value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">28,800<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">28,800<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GainLossOnInvestments', window );">Gain (loss) on remeasurement of investment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">28,800<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquityMethodInvestmentsFairValueDisclosure', window );">Fair value of noncontrolling interests</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">9,200<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">9,200<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireInterestInSubsidiariesAndAffiliates', window );">Cash paid for common shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">20,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationConsiderationTransferred1', window );">Business combination, consideration transferred</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 58,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">Research and development expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">41,400<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=roiv_GenevantSciencesLtdMember', window );">Genevant Sciences Ltd [Member] | Arbutus Biopharma Corporation [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Stock issued | shares</a></td>
<td class="nump">9,057,566<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueNewIssues', window );">Stock issued, value</a></td>
<td class="nump">$ 2,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=roiv_ProteovantSciencesIncMember', window );">ProteoVant Sciences, Inc [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_roiv_UpfrontCashPayments', window );">Net upfront cash payment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">101,200<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_roiv_MilestonePayment', window );">Milestone payment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtConversionOriginalDebtAmount1', window );">Aggregate principal amount of notes converted</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 11,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">Research and development expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">116,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_roiv_PaymentForUpfrontPayments', window );">Upfront proceeds</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">105,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_roiv_PaymentUnderSponsoredResearchAgreement', window );">Payment under SRA</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">15,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RepaymentOfNotesReceivableFromRelatedParties', window );">Settlement of promissory notes receivable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">11,900<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationContingentConsiderationLiability', window );">Fair value of future contingent consideration payments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3,400<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3,400<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquityMethodInvestmentUnderlyingEquityInNetAssets', window );">Equity investment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 200,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsidiaryOrEquityMethodInvesteeCumulativePercentageOwnershipAfterAllTransactions', window );">Ownership interest</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">40.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityNoteSubscriptionsReceivable', window );">Subscription receivable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=roiv_ProteovantSciencesIncMember', window );">ProteoVant Sciences, Inc [Member] | First Product First Product for Each Molecular Target Covered by Intellectual Property [Member] | Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_roiv_FutureDevelopmentAndCommercialMilestonePayments', window );">Future development and commercial milestone payments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">8,600<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=roiv_ProteovantSciencesIncMember', window );">ProteoVant Sciences, Inc [Member] | First Product Targets Targeting Each of Two Specified Initial Targets [Member] | Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_roiv_FutureDevelopmentAndCommercialMilestonePayments', window );">Future development and commercial milestone payments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=roiv_ProteovantSciencesIncMember', window );">ProteoVant Sciences, Inc [Member] | First Product Targets Each of Certain Specified Additional MolecularTargets [Member] | Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_roiv_FutureDevelopmentAndCommercialMilestonePayments', window );">Future development and commercial milestone payments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">51,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=roiv_AffivantSciencesMember', window );">Affivant Sciences [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_roiv_UpfrontCashPayments', window );">Net upfront cash payment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">40,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_roiv_StockIssuedDuringPeriodValue', window );">Newly issued shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">20,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=roiv_AffivantSciencesMember', window );">Affivant Sciences [Member] | Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_roiv_FutureDevelopmentAndCommercialMilestonePayments', window );">Future development and commercial milestone payments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_roiv_BusinessCollaborationContingentMilestonePayment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Business Collaboration Contingent Milestone Payment</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">roiv_BusinessCollaborationContingentMilestonePayment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>roiv_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_roiv_FairValueOfCommonShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair Value Of Common Shares</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">roiv_FairValueOfCommonShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>roiv_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_roiv_FairValueOfRestrictedStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair Value Of Restricted Stock</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">roiv_FairValueOfRestrictedStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>roiv_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_roiv_FutureDevelopmentAndCommercialMilestonePayments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Future Development And Commercial Milestone Payments.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">roiv_FutureDevelopmentAndCommercialMilestonePayments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>roiv_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_roiv_MilestonePayment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Milestone Payment</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">roiv_MilestonePayment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>roiv_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_roiv_NonRefundableUpfrontPaymentReceived">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Non Refundable Upfront Payment Received</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">roiv_NonRefundableUpfrontPaymentReceived</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>roiv_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_roiv_PaymentForUpfrontPayments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Payment for upfront payments.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">roiv_PaymentForUpfrontPayments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>roiv_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_roiv_PaymentUnderSponsoredResearchAgreement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Payment under sponsored research agreement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">roiv_PaymentUnderSponsoredResearchAgreement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>roiv_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_roiv_PercentageOfControllingInterestHeld">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of controlling interest held.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">roiv_PercentageOfControllingInterestHeld</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>roiv_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_roiv_PotentialMilestonePaymentReceivable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Potential milestone payment receivable.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">roiv_PotentialMilestonePaymentReceivable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>roiv_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_roiv_StockIssuedDuringPeriodValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Stock Issued During Period</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">roiv_StockIssuedDuringPeriodValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>roiv_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_roiv_UpfrontCashPayments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Upfront Cash Payments</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">roiv_UpfrontCashPayments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>roiv_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionEquityInterestIssuedOrIssuableValueAssigned">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Value of equity interests (such as common shares, preferred shares, or partnership interest) issued or issuable to acquire the entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(4)<br> -URI http://asc.fasb.org/extlink&amp;oid=120321790&amp;loc=d3e6927-128479<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionEquityInterestIssuedOrIssuableValueAssigned</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares of equity interests issued or issuable to acquire entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(4)<br> -URI http://asc.fasb.org/extlink&amp;oid=120321790&amp;loc=d3e6927-128479<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationConsiderationTransferred1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of consideration transferred, consisting of acquisition-date fair value of assets transferred by the acquirer, liabilities incurred by the acquirer, and equity interest issued by the acquirer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 30<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=116859721&amp;loc=d3e6613-128477<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120321790&amp;loc=d3e6927-128479<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 30<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=116859721&amp;loc=d3e6578-128477<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationConsiderationTransferred1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationConsiderationTransferredLiabilitiesIncurred">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities incurred by the acquirer as part of consideration transferred in a business combination.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 30<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=116859721&amp;loc=d3e6578-128477<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 25<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=6911189&amp;loc=d3e6405-128476<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=120321790&amp;loc=d3e6927-128479<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 30<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=116859721&amp;loc=d3e6613-128477<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationConsiderationTransferredLiabilitiesIncurred</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationContingentConsiderationLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of liability recognized arising from contingent consideration in a business combination.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120321790&amp;loc=d3e6927-128479<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 35<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=116859824&amp;loc=d3e6819-128478<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 25<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=6911189&amp;loc=d3e6408-128476<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationContingentConsiderationLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccountsPayable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities incurred for goods and services received that are used in an entity's business and related party payables, assumed at the acquisition date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123413009&amp;loc=d3e4845-128472<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccountsPayable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount recognized as of the acquisition date for the identifiable assets acquired in excess of (less than) the aggregate liabilities assumed.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 10<br> -Section 55<br> -Paragraph 37<br> -URI http://asc.fasb.org/extlink&amp;oid=123455525&amp;loc=d3e2207-128464<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123413009&amp;loc=d3e4845-128472<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtConversionConvertedInstrumentSharesIssued1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of shares issued in exchange for the original debt being converted in a noncash (or part noncash) transaction. "Part noncash" refers to that portion of the transaction not resulting in cash receipts or payments in the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=123431023&amp;loc=d3e4332-108586<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=123431023&amp;loc=d3e4304-108586<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtConversionConvertedInstrumentSharesIssued1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtConversionOriginalDebtAmount1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of the original debt being converted in a noncash (or part noncash) transaction. "Part noncash" refers to that portion of the transaction not resulting in cash receipts or cash payments in the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=123431023&amp;loc=d3e4304-108586<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=123431023&amp;loc=d3e4332-108586<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtConversionOriginalDebtAmount1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityMethodInvestmentUnderlyingEquityInNetAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>This item represents the entity's ownership percentage in the investee multiplied by the investee's total equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityMethodInvestmentUnderlyingEquityInNetAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityMethodInvestmentsFairValueDisclosure">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value portion of investments accounted under the equity method.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 25<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=125513658&amp;loc=d3e32014-111567<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityMethodInvestmentsFairValueDisclosure</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GainLossOnInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of realized and unrealized gain (loss) on investment.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 10<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123581744&amp;loc=d3e27405-111563<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.7(c),9(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br><br>Reference 3: http://www.xbrl.org/2003/role/recommendedDisclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GainLossOnInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentsInAffiliatesSubsidiariesAssociatesAndJointVenturesFairValueDisclosure">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value portion of investments in an entity not consolidated. Includes, but is not limited to, investments in an entity that is affiliated with the reporting entity by means of direct or indirect ownership, an entity in which the reporting entity shares control of the entity with another party or group, an entity which the company has significant influence, but does not have control and subsidiaries that are not required to be consolidated and are accounted for using the equity or cost method.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123874694&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentsInAffiliatesSubsidiariesAssociatesAndJointVenturesFairValueDisclosure</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after unamortized (discount) premium and debt issuance costs, of long-term debt. Includes, but not limited to, notes payable, bonds payable, debentures, mortgage loans and commercial paper. Excludes capital lease obligations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (b)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=123466204&amp;loc=SL6031897-161870<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 55<br> -Paragraph 69C<br> -URI http://asc.fasb.org/extlink&amp;oid=123466577&amp;loc=SL123495737-112612<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(16))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 55<br> -Paragraph 69B<br> -URI http://asc.fasb.org/extlink&amp;oid=123466577&amp;loc=SL123495735-112612<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(16))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1D<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495340-112611<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow associated with the acquisition of a business, net of the cash acquired from the purchase.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3213-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquireEquityMethodInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow associated with the purchase of or advances to an equity method investments, which are investments in joint ventures and entities in which the entity has an equity ownership interest normally of 20 to 50 percent and exercises significant influence.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3213-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquireEquityMethodInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquireInterestInSubsidiariesAndAffiliates">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow associated with the acquisition of or advances to an entity that is related to it but not strictly controlled (for example, an unconsolidated subsidiary, affiliate, and joint venture or equity method investment) or the acquisition of an additional interest in a subsidiary (controlled entity).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3213-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquireInterestInSubsidiariesAndAffiliates</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromNotesPayable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from a borrowing supported by a written promise to pay an obligation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromNotesPayable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RepaymentOfNotesReceivableFromRelatedParties">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from a loan, supported by a promissory note, granted to related parties where one party can exercise control or significant influence over another party; including affiliates, owners or officers and their immediate families, pension trusts, and so forth.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 12<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3179-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RepaymentOfNotesReceivableFromRelatedParties</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 912<br> -SubTopic 730<br> -Section 25<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6472174&amp;loc=d3e58812-109433<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 985<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6501960&amp;loc=d3e128462-111756<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 730<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6420194&amp;loc=d3e21568-108373<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueRecognitionMilestoneMethodRevenueRecognized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of consideration recognized during the period for the milestone or milestones.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueRecognitionMilestoneMethodRevenueRecognized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of noncash expense for share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of new stock issued during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21463-112644<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Equity impact of the value of new stock issued during the period. Includes shares issued in an initial public offering or a secondary public offering.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21463-112644<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityNoteSubscriptionsReceivable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Note received instead of cash as contribution to equity. The transaction may be a sale of capital stock or a contribution to paid-in capital.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=65888546&amp;loc=d3e21300-112643<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityNoteSubscriptionsReceivable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiaryOrEquityMethodInvesteeCumulativePercentageOwnershipAfterAllTransactions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of subsidiary's or equity method investee's stock owned by parent immediately after all stock transactions.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiaryOrEquityMethodInvesteeCumulativePercentageOwnershipAfterAllTransactions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionAxis=roiv_SiliconTherapeuticsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionAxis=roiv_SiliconTherapeuticsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestructuringPlanAxis=roiv_FirstTrancheMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestructuringPlanAxis=roiv_FirstTrancheMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestructuringPlanAxis=roiv_SecondTrancheMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestructuringPlanAxis=roiv_SecondTrancheMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=roiv_DermavantSciencesLtdMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=roiv_DermavantSciencesLtdMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=roiv_GenevantSciencesLtdMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=roiv_GenevantSciencesLtdMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LegalEntityAxis=roiv_ArbutusBiopharmaCorporationMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LegalEntityAxis=roiv_ArbutusBiopharmaCorporationMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=roiv_ProteovantSciencesIncMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=roiv_ProteovantSciencesIncMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_roiv_MilestoneEventsAxis=roiv_FirstProductFirstProductForEachMolecularTargetCoveredByIntellectualPropertyMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">roiv_MilestoneEventsAxis=roiv_FirstProductFirstProductForEachMolecularTargetCoveredByIntellectualPropertyMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_roiv_MilestoneEventsAxis=roiv_FirstProductTargetsTargetingEachOfTwoSpecifiedInitialTargetsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">roiv_MilestoneEventsAxis=roiv_FirstProductTargetsTargetingEachOfTwoSpecifiedInitialTargetsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_roiv_MilestoneEventsAxis=roiv_FirstProductTargetsEachOfCertainSpecifiedAdditionalMoleculartargetsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">roiv_MilestoneEventsAxis=roiv_FirstProductTargetsEachOfCertainSpecifiedAdditionalMoleculartargetsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=roiv_AffivantSciencesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=roiv_AffivantSciencesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>115
<FILENAME>R45.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm139997750839976">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Sumitomo Transaction Agreement - Additional Information (Detail) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1">1 Months Ended</th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2021</div></th>
<th class="th"><div>Dec. 27, 2019</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
<th class="th"><div>Jun. 30, 2021</div></th>
<th class="th"><div>Jun. 30, 2020</div></th>
<th class="th"><div>Mar. 31, 2020</div></th>
<th class="th"><div>May 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_roiv_TransactionAgreementLineItems', window );"><strong>Transaction Agreement [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GainOrLossOnSaleOfStockInSubsidiary', window );">Gain (loss) on sale of stock transactions</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (43,398)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EscrowDeposit', window );">Escrow amount</a></td>
<td class="nump">$ 75,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestrictedCash', window );">Restricted cash</a></td>
<td class="nump">$ 86,632<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 11,644<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">86,045<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_roiv_EquityInterestOptionToThirdPartyPurchaserGainOnTermination', window );">Gain on termination of Sumitomo Options</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">66,472<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_roiv_AgreementAxis=roiv_TransitionServicesAndStrategicCooperationAgreementMember', window );">Transition Services And Strategic Cooperation Agreement [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_roiv_TransactionAgreementLineItems', window );"><strong>Transaction Agreement [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_roiv_AgreementRelatedBilledAmountForCostsIncurredOnBehalfOfSubsidiarynetOfAmountsBilledBySubsidiary', window );">Transition and cooperation agreement billed amount,Net of amounts billed by sumitovant</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">300<span></span>
</td>
<td class="nump">$ 400<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_roiv_AgreementAxis=roiv_AssetPurchaseAgreementMember', window );">Asset Purchase Agreement [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_roiv_TransactionAgreementLineItems', window );"><strong>Transaction Agreement [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_roiv_AssetPurchaseTransactionConsiderationReceivedInCash', window );">Consideration received in cash</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 5,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_roiv_EquityInterestOptionToThirdPartyPurchaserGainOnTermination', window );">Gain on termination of Sumitomo Options</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">66,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=roiv_SumitomoMember', window );">Sumitomo [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_roiv_TransactionAgreementLineItems', window );"><strong>Transaction Agreement [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_roiv_PercentageOfGrantedOptionToPurchaseOwnershipInterest', window );">Percentage of granted option to purchase ownership interest</a></td>
<td class="nump">75.00%<span></span>
</td>
<td class="nump">75.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_roiv_SaleOfStockNumberOfShareIssuedInTransaction', window );">Number of shares transferred</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">26,952,143<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SaleOfStockConsiderationReceivedOnTransaction', window );">Consideration received in transaction</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 999,200<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,900,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GainOrLossOnSaleOfStockInSubsidiary', window );">Gain (loss) on sale of stock transactions</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EscrowDeposit', window );">Escrow amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 75,000<span></span>
</td>
<td class="nump">75,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestrictedCash', window );">Restricted cash</a></td>
<td class="nump">$ 75,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">75,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_roiv_SaleOfStockConsiderationCashReceivedOnTransaction', window );">Sale Of Stock Consideration Cash Received On Transaction</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,900,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_roiv_StockOfferToRepurchaseDuringPeriodValueOfTheProceedsReceivedFromTransactionAgreement', window );">Stock offer to repurchase during period value of the proceeds received from transaction agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=roiv_SumitomoMember', window );">Sumitomo [Member] | Employee [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_roiv_TransactionAgreementLineItems', window );"><strong>Transaction Agreement [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_roiv_AggregateFairValueOfEquityAndLiabilityInstrumentsIssued', window );">Aggregate fair value of issued instruments to employees on transaction</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">39,100<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredCompensationEquity', window );">Deferred compensation equity</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">24,800<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredCompensationLiabilityCurrent', window );">Deferred compensation liability</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">14,300<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber', window );">Outstanding instruments vest based on the achievement of time-based, performance or liquidity event requirements</a></td>
<td class="nump">1,865,416<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,863,451<span></span>
</td>
<td class="nump">1,873,480<span></span>
</td>
<td class="nump">1,880,980<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=roiv_SumitomoMember', window );">Sumitomo [Member] | Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_roiv_TransactionAgreementLineItems', window );"><strong>Transaction Agreement [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockRepurchaseProgramAuthorizedAmount1', window );">Repurchase of RSL's equity securities approved amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_roiv_AggregateFairValueOfEquityAndLiabilityInstrumentsIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate Fair Value of Equity and Liability Instruments Issued</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">roiv_AggregateFairValueOfEquityAndLiabilityInstrumentsIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>roiv_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_roiv_AgreementRelatedBilledAmountForCostsIncurredOnBehalfOfSubsidiarynetOfAmountsBilledBySubsidiary">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Agreement related billed amount for costs incurred on behalf of subsidiary,net of amounts billed by subsidiary.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">roiv_AgreementRelatedBilledAmountForCostsIncurredOnBehalfOfSubsidiarynetOfAmountsBilledBySubsidiary</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>roiv_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_roiv_AssetPurchaseTransactionConsiderationReceivedInCash">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Asset Purchase Transaction Consideration Received In Cash.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">roiv_AssetPurchaseTransactionConsiderationReceivedInCash</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>roiv_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_roiv_EquityInterestOptionToThirdPartyPurchaserGainOnTermination">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Equity interest option to third party purchaser gain on termination.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">roiv_EquityInterestOptionToThirdPartyPurchaserGainOnTermination</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>roiv_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_roiv_PercentageOfGrantedOptionToPurchaseOwnershipInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of granted option to purchase ownership interest.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">roiv_PercentageOfGrantedOptionToPurchaseOwnershipInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>roiv_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_roiv_SaleOfStockConsiderationCashReceivedOnTransaction">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sale Of Stock Consideration Cash Received On Transaction.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">roiv_SaleOfStockConsiderationCashReceivedOnTransaction</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>roiv_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_roiv_SaleOfStockNumberOfShareIssuedInTransaction">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sale Of Stock Number Of Share Issued In Transaction</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">roiv_SaleOfStockNumberOfShareIssuedInTransaction</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>roiv_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_roiv_StockOfferToRepurchaseDuringPeriodValueOfTheProceedsReceivedFromTransactionAgreement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Stock offer to repurchase during period value of the proceeds received from transaction agreement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">roiv_StockOfferToRepurchaseDuringPeriodValueOfTheProceedsReceivedFromTransactionAgreement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>roiv_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_roiv_TransactionAgreementLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Transaction Agreement [Line Items]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">roiv_TransactionAgreementLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>roiv_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredCompensationEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Value of stock issued under share-based plans to employees or officers which is the unearned portion, accounted for under the fair value method.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 35<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123468992&amp;loc=d3e4534-113899<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.30)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredCompensationEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredCompensationLiabilityCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate carrying value as of the balance sheet date of the liabilities for all deferred compensation arrangements payable within one year (or the operating cycle, if longer). Represents currently earned compensation under compensation arrangements that is not actually paid until a later date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 710<br> -SubTopic 10<br> -Section 25<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=6409733&amp;loc=d3e19512-108361<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 710<br> -SubTopic 10<br> -Section 30<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=6409875&amp;loc=d3e20028-108363<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredCompensationLiabilityCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EscrowDeposit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The designation of funds furnished by a borrower to a lender to assure future payments of the borrower's real estate taxes and insurance obligations with respect to a mortgaged property. Escrow deposits may be made for a variety of other purposes such as earnest money and contingent payments. This element excludes replacement reserves which are an escrow separately provided for within the US GAAP taxonomy.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03.10)<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 954<br> -SubTopic 440<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=6491277&amp;loc=d3e6429-115629<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EscrowDeposit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GainOrLossOnSaleOfStockInSubsidiary">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of gain (loss) on sale or disposal of equity in securities of subsidiaries.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(b)(9)(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(b)(7)(c))<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(13)(g))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(3)(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GainOrLossOnSaleOfStockInSubsidiary</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestrictedCash">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash restricted as to withdrawal or usage. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=123431023&amp;loc=SL98516268-108586<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(1)(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(2))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestrictedCash</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SaleOfStockConsiderationReceivedOnTransaction">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Cash received on stock transaction after deduction of issuance costs.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SaleOfStockConsiderationReceivedOnTransaction</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of equity instruments other than options outstanding, including both vested and non-vested instruments.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(ii)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockRepurchaseProgramAuthorizedAmount1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of stock repurchase plan authorized.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockRepurchaseProgramAuthorizedAmount1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_roiv_AgreementAxis=roiv_TransitionServicesAndStrategicCooperationAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">roiv_AgreementAxis=roiv_TransitionServicesAndStrategicCooperationAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_roiv_AgreementAxis=roiv_AssetPurchaseAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">roiv_AgreementAxis=roiv_AssetPurchaseAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=roiv_SumitomoMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=roiv_SumitomoMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_TitleOfIndividualAxis=roiv_EmployeeMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_TitleOfIndividualAxis=roiv_EmployeeMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>116
<FILENAME>R46.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm139997747535416">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Balance Sheet Components - Schedule of Other Current Assets (Detail) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Jun. 30, 2021</div></th>
<th class="th"><div>Mar. 31, 2021</div></th>
<th class="th"><div>Mar. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BalanceSheetRelatedDisclosuresAbstract', window );"><strong>Balance Sheet Related Disclosures [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PrepaidExpenseCurrent', window );">Prepaid expenses</a></td>
<td class="nump">$ 44,941<span></span>
</td>
<td class="nump">$ 39,544<span></span>
</td>
<td class="nump">$ 16,344<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ValueAddedTaxReceivable', window );">Receivables for value added tax (VAT) paid</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">807<span></span>
</td>
<td class="nump">5,978<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NotesAndLoansReceivableNetCurrent', window );">Note receivable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">5,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsReceivableNetCurrent', window );">Trade receivables, net</a></td>
<td class="nump">3,416<span></span>
</td>
<td class="nump">11,222<span></span>
</td>
<td class="nump">3,669<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxesReceivable', window );">Income tax receivable</a></td>
<td class="nump">1,993<span></span>
</td>
<td class="nump">1,803<span></span>
</td>
<td class="nump">632<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherAssetsMiscellaneousCurrent', window );">Other</a></td>
<td class="nump">7,815<span></span>
</td>
<td class="nump">1,681<span></span>
</td>
<td class="nump">2,140<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherAssetsCurrent', window );">Total other current assets</a></td>
<td class="nump">$ 58,165<span></span>
</td>
<td class="nump">$ 54,250<span></span>
</td>
<td class="nump">$ 33,763<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsReceivableNetCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after allowance for credit loss, of right to consideration from customer for product sold and service rendered in normal course of business, classified as current.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=124259787&amp;loc=d3e4428-111522<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(3))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6676-107765<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section 45<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=124259787&amp;loc=d3e4531-111522<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsReceivableNetCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BalanceSheetRelatedDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BalanceSheetRelatedDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxesReceivable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying amount due within one year of the balance sheet date (or one operating cycle, if longer) from tax authorities as of the balance sheet date representing refunds of overpayments or recoveries based on agreed-upon resolutions of disputes.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03.5(c))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03.10)<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.3(a)(4))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxesReceivable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NotesAndLoansReceivableNetCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after allowance for credit loss, of financing receivable, classified as current. Includes, but is not limited to, notes and loan receivable.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=124259787&amp;loc=d3e4428-111522<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section 45<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=124259787&amp;loc=d3e4531-111522<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6676-107765<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(7))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6676-107765<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NotesAndLoansReceivableNetCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherAssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of current assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.8)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherAssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherAssetsMiscellaneousCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of other miscellaneous assets expected to be realized or consumed within one year or operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherAssetsMiscellaneousCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PrepaidExpenseCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of asset related to consideration paid in advance for costs that provide economic benefits within a future period of one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6787-107765<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (g)<br> -URI http://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6676-107765<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 340<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6387103&amp;loc=d3e6435-108320<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 340<br> -SubTopic 10<br> -Section 05<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=123349782&amp;loc=d3e5879-108316<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PrepaidExpenseCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ValueAddedTaxReceivable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying amount as of the balance sheet date of value added taxes due either from customers arising from sales on credit terms, or as previously overpaid to tax authorities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.8)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ValueAddedTaxReceivable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>117
<FILENAME>R47.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm139997755209704">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Balance Sheet Components - Schedule of Accrued Expenses (Detail) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Jun. 30, 2021</div></th>
<th class="th"><div>Mar. 31, 2021</div></th>
<th class="th"><div>Mar. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_roiv_BalanceSheetComponentsLineItems', window );"><strong>Balance Sheet Components [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccruedLiabilitiesCurrent', window );">Total accrued expenses</a></td>
<td class="nump">$ 73,788<span></span>
</td>
<td class="nump">$ 76,936<span></span>
</td>
<td class="nump">$ 68,621<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember', window );">R&amp;D Expenses [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_roiv_BalanceSheetComponentsLineItems', window );"><strong>Balance Sheet Components [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccruedLiabilitiesCurrent', window );">Total accrued expenses</a></td>
<td class="nump">28,347<span></span>
</td>
<td class="nump">20,755<span></span>
</td>
<td class="nump">21,607<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=roiv_EmployeeRelatedExpensesMember', window );">Employee Related Expenses [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_roiv_BalanceSheetComponentsLineItems', window );"><strong>Balance Sheet Components [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccruedLiabilitiesCurrent', window );">Total accrued expenses</a></td>
<td class="nump">15,242<span></span>
</td>
<td class="nump">38,552<span></span>
</td>
<td class="nump">29,113<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=roiv_ProfessionalServicesExpensesMember', window );">Professional Services Expenses [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_roiv_BalanceSheetComponentsLineItems', window );"><strong>Balance Sheet Components [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccruedLiabilitiesCurrent', window );">Total accrued expenses</a></td>
<td class="nump">16,489<span></span>
</td>
<td class="nump">10,267<span></span>
</td>
<td class="nump">5,135<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=roiv_OtherGeneralAndAdministrativeExpensesMember', window );">Other General and Administrative Expenses [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_roiv_BalanceSheetComponentsLineItems', window );"><strong>Balance Sheet Components [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccruedLiabilitiesCurrent', window );">Total accrued expenses</a></td>
<td class="nump">$ 13,710<span></span>
</td>
<td class="nump">$ 7,362<span></span>
</td>
<td class="nump">$ 12,766<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_roiv_BalanceSheetComponentsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Balance Sheet Components [Line Items]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">roiv_BalanceSheetComponentsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>roiv_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=roiv_EmployeeRelatedExpensesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=roiv_EmployeeRelatedExpensesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=roiv_ProfessionalServicesExpensesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=roiv_ProfessionalServicesExpensesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=roiv_OtherGeneralAndAdministrativeExpensesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=roiv_OtherGeneralAndAdministrativeExpensesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>118
<FILENAME>R48.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm139997747304664">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Balance Sheet Components - Schedule of Other Current Liabilities (Detail) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Jun. 30, 2021</div></th>
<th class="th"><div>Mar. 31, 2021</div></th>
<th class="th"><div>Mar. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BalanceSheetRelatedDisclosuresAbstract', window );"><strong>Balance Sheet Related Disclosures [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_roiv_DeferredRevenueOtherCurrentLiabilities', window );">Deferred revenue</a></td>
<td class="nump">$ 3,777<span></span>
</td>
<td class="nump">$ 5,918<span></span>
</td>
<td class="nump">$ 3,621<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TaxesPayableCurrent', window );">Income tax payable</a></td>
<td class="nump">199<span></span>
</td>
<td class="nump">207<span></span>
</td>
<td class="nump">1,497<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherSundryLiabilitiesCurrent', window );">Other</a></td>
<td class="nump">4,325<span></span>
</td>
<td class="nump">3,037<span></span>
</td>
<td class="nump">234<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherLiabilitiesCurrent', window );">Total other current liabilities</a></td>
<td class="nump">$ 8,301<span></span>
</td>
<td class="nump">$ 9,162<span></span>
</td>
<td class="nump">$ 5,352<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_roiv_DeferredRevenueOtherCurrentLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Deferred Revenue Other Current Liabilities</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">roiv_DeferredRevenueOtherCurrentLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>roiv_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BalanceSheetRelatedDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BalanceSheetRelatedDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities classified as other, due within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6904-107765<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6911-107765<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherSundryLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Obligations not otherwise itemized or categorized in the footnotes to the financial statements that are due within one year or operating cycle, if longer, from the balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=99376301&amp;loc=d3e1243-112600<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherSundryLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TaxesPayableCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred and payable for statutory income, sales, use, payroll, excise, real, property and other taxes. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19,20)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TaxesPayableCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>119
<FILENAME>R49.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm139997755121176">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Long Term Debt and Loan Commitment (Detail) - USD ($)<br></strong></div></th>
<th class="th"><div>Jun. 30, 2021</div></th>
<th class="th"><div>Mar. 31, 2021</div></th>
<th class="th"><div>Mar. 31, 2020</div></th>
<th class="th"><div>May 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebtAbstract', window );"><strong>Long-term Debt, Unclassified [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentCarryingAmount', window );">Principal amount</a></td>
<td class="nump">$ 195,200,000<span></span>
</td>
<td class="nump">$ 170,100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_roiv_DebtInstrumentAmount', window );">Principal amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">171,490,000<span></span>
</td>
<td class="nump">$ 110,490,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_roiv_DebtInstrumentExitFeeAndEndOfTermCharge', window );">Exit fee / end of term charge</a></td>
<td class="nump">5,000,000<span></span>
</td>
<td class="nump">1,390,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 5,000.0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet', window );">Less: unamortized debt discount and issuance costs</a></td>
<td class="num">(13,850,000)<span></span>
</td>
<td class="num">(1,210,000)<span></span>
</td>
<td class="num">(1,898,000)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebt', window );">Total debt, net</a></td>
<td class="nump">186,350,000<span></span>
</td>
<td class="nump">170,280,000<span></span>
</td>
<td class="nump">108,592,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebtCurrent', window );">Less: current portion</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebtNoncurrent', window );">Total long term debt, net</a></td>
<td class="nump">$ 186,350,000<span></span>
</td>
<td class="nump">$ 170,280,000<span></span>
</td>
<td class="nump">$ 108,592,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_roiv_DebtInstrumentAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Debt instrument amount.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">roiv_DebtInstrumentAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>roiv_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_roiv_DebtInstrumentExitFeeAndEndOfTermCharge">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Debt instrument exit fee and end of term charge.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">roiv_DebtInstrumentExitFeeAndEndOfTermCharge</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>roiv_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentCarryingAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, before unamortized (discount) premium and debt issuance costs, of long-term debt. Includes, but is not limited to, notes payable, bonds payable, commercial loans, mortgage loans, convertible debt, subordinated debt and other types of debt.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (b)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=123466204&amp;loc=SL6031897-161870<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(16))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(16))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentCarryingAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of unamortized debt discount (premium) and debt issuance costs.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 55<br> -Paragraph 69C<br> -URI http://asc.fasb.org/extlink&amp;oid=123466577&amp;loc=SL123495737-112612<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (b)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=123466204&amp;loc=SL6031897-161870<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1D<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495340-112611<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 55<br> -Paragraph 69B<br> -URI http://asc.fasb.org/extlink&amp;oid=123466577&amp;loc=SL123495735-112612<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=124435984&amp;loc=d3e28555-108399<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after unamortized (discount) premium and debt issuance costs, of long-term debt. Includes, but not limited to, notes payable, bonds payable, debentures, mortgage loans and commercial paper. Excludes capital lease obligations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (b)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=123466204&amp;loc=SL6031897-161870<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 55<br> -Paragraph 69C<br> -URI http://asc.fasb.org/extlink&amp;oid=123466577&amp;loc=SL123495737-112612<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(16))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 55<br> -Paragraph 69B<br> -URI http://asc.fasb.org/extlink&amp;oid=123466577&amp;loc=SL123495735-112612<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(16))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1D<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495340-112611<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebtAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebtAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebtCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after unamortized (discount) premium and debt issuance costs, of long-term debt, classified as current. Includes, but not limited to, notes payable, bonds payable, debentures, mortgage loans and commercial paper. Excludes capital lease obligations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19,20)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebtCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebtNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after unamortized (discount) premium and debt issuance costs of long-term debt classified as noncurrent and excluding amounts to be repaid within one year or the normal operating cycle, if longer. Includes, but not limited to, notes payable, bonds payable, debentures, mortgage loans and commercial paper. Excludes capital lease obligations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.22)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebtNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>120
<FILENAME>R50.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm139997749413624">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Long-Term Debt and Loan Commitment - Additional Information (Detail) - USD ($)<br></strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="2">1 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>May 01, 2021</div></th>
<th class="th"><div>May 31, 2021</div></th>
<th class="th"><div>Jan. 31, 2020</div></th>
<th class="th"><div>Jun. 30, 2021</div></th>
<th class="th"><div>Mar. 31, 2021</div></th>
<th class="th"><div>Mar. 31, 2020</div></th>
<th class="th"><div>May 31, 2019</div></th>
<th class="th"><div>Oct. 31, 2018</div></th>
<th class="th"><div>Aug. 31, 2018</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentFaceAmount', window );">Debt principal amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 20,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 20,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebtPercentageBearingVariableInterestRate', window );">Debt interest rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">9.95%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentFeeAmount', window );">Debt Instrument, Fee Amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 4,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,400,000<span></span>
</td>
<td class="nump">$ 1,400,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_roiv_DebtInstrumentExitFeeAndEndOfTermCharge', window );">Debt Instrument Exit Fee And End Of Term Charge</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,000,000<span></span>
</td>
<td class="nump">1,390,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 5,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_roiv_ProceedsFromSaleOfDebtAndEquitySecurities', window );">Proceed from equity and debt financing</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 110,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromLinesOfCredit', window );">Proceeds from credit facility</a></td>
<td class="nump">$ 40,000,000.0<span></span>
</td>
<td class="nump">$ 40,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Interest rate</a></td>
<td class="nump">10.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentTerm', window );">Debt Instrument, Term</a></td>
<td class="text">5 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight', window );">Class of warrants or rights number of shares called by each warrant or right</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,199,072<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Class of Warrant or Right, Exercise Price per share</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.01<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=roiv_RevenueInterestPurchaseAndSaleAgreementMember', window );">Revenue Interest Purchase and Sale Agreement [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SecuritiesPurchasedUnderAgreementsToResellIncrease', window );">Securities Purchased under Agreements to Resell</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 160,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_roiv_MinimumAmountOfAnnualNetSalesToQualifyUnderRevenueInterestPurchaseAgreementContingentThreshold', window );">Minimum Amount of Annual Net Sales To Qualify Under Revenue Interest Purchase Agreement, Contingent Threshold</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 160,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_VariableRateAxis=us-gaap_PrimeRateMember', window );">Prime Rate [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebtPercentageBearingVariableInterestRate', window );">Debt interest rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4.45%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=roiv_NovaquestMember', window );">NovaQuest Agreement [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentFaceAmount', window );">Debt principal amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 17,500,000<span></span>
</td>
<td class="nump">$ 100,000,000.0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentFairValue', window );">Debt fair value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 155,200,000<span></span>
</td>
<td class="nump">150,100,000<span></span>
</td>
<td class="nump">$ 89,100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=roiv_NovaquestMember', window );">NovaQuest Agreement [Member] | Regulatory Milestone [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_roiv_MaximumMilestonePaymentObligation', window );">Maximum amount required milestone payments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">440,600,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">440,600,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_roiv_MaximumMilestonePaymentOffsetAmount', window );">Possible offset of regulatory milestone payments with commercial milestone</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">88,100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">88,100,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=roiv_NovaquestMember', window );">NovaQuest Agreement [Member] | Commercial Milestone [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_roiv_MaximumMilestonePaymentObligation', window );">Maximum amount required milestone payments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 141,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 141,000,000.0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_roiv_DebtInstrumentExitFeeAndEndOfTermCharge">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Debt instrument exit fee and end of term charge.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">roiv_DebtInstrumentExitFeeAndEndOfTermCharge</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>roiv_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_roiv_MaximumMilestonePaymentObligation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Maximum milestone payment obligation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">roiv_MaximumMilestonePaymentObligation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>roiv_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_roiv_MaximumMilestonePaymentOffsetAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Maximum Milestone Payment Offset Amount</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">roiv_MaximumMilestonePaymentOffsetAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>roiv_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_roiv_MinimumAmountOfAnnualNetSalesToQualifyUnderRevenueInterestPurchaseAgreementContingentThreshold">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Minimum amount of annual net sales to qualify under revenue interest purchase agreement, contingent threshold.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">roiv_MinimumAmountOfAnnualNetSalesToQualifyUnderRevenueInterestPurchaseAgreementContingentThreshold</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>roiv_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_roiv_ProceedsFromSaleOfDebtAndEquitySecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Proceeds from the sale of debt and equity securities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">roiv_ProceedsFromSaleOfDebtAndEquitySecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>roiv_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Exercise price per share or per unit of warrants or rights outstanding.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21475-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of securities into which each warrant or right may be converted. For example, but not limited to, each warrant may be converted into two shares.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentFaceAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Face (par) amount of debt instrument at time of issuance.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495323-112611<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=124435984&amp;loc=d3e28551-108399<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 55<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=114775985&amp;loc=d3e28878-108400<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=124429444&amp;loc=SL124452920-239629<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 55<br> -Paragraph 69C<br> -URI http://asc.fasb.org/extlink&amp;oid=123466577&amp;loc=SL123495737-112612<br><br>Reference 6: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 55<br> -Paragraph 69B<br> -URI http://asc.fasb.org/extlink&amp;oid=123466577&amp;loc=SL123495735-112612<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentFaceAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value portion of debt instrument payable, including, but not limited to, notes payable and loans payable.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 55<br> -Paragraph 69C<br> -URI http://asc.fasb.org/extlink&amp;oid=123466577&amp;loc=SL123495737-112612<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 55<br> -Paragraph 69B<br> -URI http://asc.fasb.org/extlink&amp;oid=123466577&amp;loc=SL123495735-112612<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=123594938&amp;loc=d3e13433-108611<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1D<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495340-112611<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentFeeAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of the fee that accompanies borrowing money under the debt instrument.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.22(b))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentFeeAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentInterestRateStatedPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Contractual interest rate for funds borrowed, under the debt agreement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495323-112611<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.22(a)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentInterestRateStatedPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentTerm">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Period of time between issuance and maturity of debt instrument, in PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentTerm</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebtPercentageBearingVariableInterestRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The interest rate applicable to the portion of the carrying amount of long-term borrowings outstanding as of the balance sheet date, including current maturities, which accrues interest at a rate subject to change from time to time.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.22(a)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebtPercentageBearingVariableInterestRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromLinesOfCredit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow from contractual arrangement with the lender, including but not limited to, letter of credit, standby letter of credit and revolving credit arrangements.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3255-108585<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(f))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromLinesOfCredit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SecuritiesPurchasedUnderAgreementsToResellIncrease">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase from purchase of security purchased under agreement to resell.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 20<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (h)<br> -URI http://asc.fasb.org/extlink&amp;oid=124255953&amp;loc=SL82919244-210447<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SecuritiesPurchasedUnderAgreementsToResellIncrease</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=roiv_RevenueInterestPurchaseAndSaleAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=roiv_RevenueInterestPurchaseAndSaleAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_VariableRateAxis=us-gaap_PrimeRateMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_VariableRateAxis=us-gaap_PrimeRateMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=roiv_NovaquestMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=roiv_NovaquestMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TransactionTypeAxis=roiv_RegulatoryMilestoneMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TransactionTypeAxis=roiv_RegulatoryMilestoneMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TransactionTypeAxis=roiv_CommercialMilestoneMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TransactionTypeAxis=roiv_CommercialMilestoneMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>121
<FILENAME>R51.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm139997755062888">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Long Term Debt and Convertible Notes Payable - Schedule of Company's Annual Payments (Detail)<br> $ in Thousands</strong></div></th>
<th class="th">
<div>Mar. 31, 2021 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebtByMaturityAbstract', window );"><strong>Long-term Debt, Fiscal Year Maturity [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths', window );">2022</a></td>
<td class="nump">$ 3,129<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo', window );">2023</a></td>
<td class="nump">13,306<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree', window );">2024</a></td>
<td class="nump">4,955<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour', window );">2025</a></td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive', window );">2026</a></td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalAfterYearFive', window );">Thereafter</a></td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_roiv_LongTermDebtExcludingDebtWithFairValueOption', window );">Total</a></td>
<td class="nump">$ 21,390<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_roiv_LongTermDebtExcludingDebtWithFairValueOption">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Long Term Debt Excluding Debt With Fair Value Option</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">roiv_LongTermDebtExcludingDebtWithFairValueOption</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>roiv_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebtByMaturityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebtByMaturityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalAfterYearFive">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of long-term debt payable, sinking fund requirement, and other securities issued that are redeemable by holder at fixed or determinable price and date, maturing after fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=123465755&amp;loc=d3e1835-112601<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1E<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495348-112611<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-04(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e24072-122690<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalAfterYearFive</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of long-term debt payable, sinking fund requirement, and other securities issued that are redeemable by holder at fixed or determinable price and date, maturing in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1E<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495348-112611<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-04(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e24072-122690<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=123465755&amp;loc=d3e1835-112601<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of long-term debt payable, sinking fund requirement, and other securities issued that are redeemable by holder at fixed or determinable price and date, maturing in fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1E<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495348-112611<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=123465755&amp;loc=d3e1835-112601<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-04(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e24072-122690<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of long-term debt payable, sinking fund requirement, and other securities issued that are redeemable by holder at fixed or determinable price and date, maturing in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1E<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495348-112611<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=123465755&amp;loc=d3e1835-112601<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-04(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e24072-122690<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of long-term debt payable, sinking fund requirement, and other securities issued that are redeemable by holder at fixed or determinable price and date, maturing in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1E<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495348-112611<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-04(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e24072-122690<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=123465755&amp;loc=d3e1835-112601<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of long-term debt payable, sinking fund requirement, and other securities issued that are redeemable by holder at fixed or determinable price and date, maturing in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1E<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495348-112611<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-04(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e24072-122690<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=123465755&amp;loc=d3e1835-112601<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>122
<FILENAME>R52.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm139997740163880">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Shareholders' Equity and Redeemable Non-Controlling Interest - Additional Information (Detail) - USD ($)<br> $ / shares in Units, $ in Thousands</strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="8">1 Months Ended</th>
<th class="th" colspan="2">12 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Dec. 27, 2019</div></th>
<th class="th"><div>Dec. 26, 2019</div></th>
<th class="th"><div>Mar. 31, 2021</div></th>
<th class="th"><div>Sep. 30, 2020</div></th>
<th class="th"><div>May 31, 2020</div></th>
<th class="th"><div>Apr. 30, 2020</div></th>
<th class="th"><div>Mar. 31, 2020</div></th>
<th class="th"><div>Jan. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
<th class="th"><div>Sep. 30, 2019</div></th>
<th class="th"><div>Mar. 31, 2021</div></th>
<th class="th"><div>Mar. 31, 2020</div></th>
<th class="th"><div>Jun. 30, 2021</div></th>
<th class="th"><div>May 31, 2021</div></th>
<th class="th"><div>Feb. 29, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Warrant exercise price per share</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.01<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_roiv_EarnOutSharesTermsDescription', window );">Earnout shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">(i) during any Trading Period prior to March&#160;31, 2023, 10,000,000 Earnout Shares upon the achievement of a volume-weighted average price of at least $17.50 per share; and  (ii) during any Trading Period prior to March&#160;31, 2025, 10,000,000 Earnout Shares upon the achievement of a volume-weighted average price of at least $31.50 per share. <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Common stock issued</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">222,669,799<span></span>
</td>
<td class="nump">17,547,938<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">214,879,058<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">222,669,799<span></span>
</td>
<td class="nump">214,879,058<span></span>
</td>
<td class="nump">222,669,799<span></span>
</td>
<td class="nump">17,547,938<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfCommonStock', window );">Net proceeds of common stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 999,193<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShortTermDebtTypeAxis=us-gaap_ConvertibleNotesPayableMember', window );">Convertible Notes Payable [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtConversionConvertedInstrumentSharesIssued1', window );">Conversion of stock , share converted</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentConvertibleCarryingAmountOfTheEquityComponent', window );">Carrying amount of the convertible promissory</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 35,600<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 35,600<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember', window );">Common Stock [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Public offering shares of common stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">7,202,917<span></span>
</td>
<td class="nump">26,952,143<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=roiv_UnderwrittenPublicOfferingMember', window );">Underwritten Public Offering [Member] | Common Stock [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Public offering shares of common stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">380,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,034,483<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfCommonStock', window );">Net proceeds of common stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 12,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 15,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=roiv_SumitomoTransactionAgreementMember', window );">Sumitomo Transaction Agreement [Member] | Roivant Equity Repurchase [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_roiv_PercentageSharesOfCommonStockOfferedToBeRepurchased', window );">Offer to repurchase common stock held by each holder</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">11.23%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SaleOfStockPricePerShare', window );">Common stock per share</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 37.10<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TreasuryStockAcquiredRepurchaseAuthorization', window );">Description of share repurchase offer</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">The offers included (i) an offer to repurchase up to approximately 11.23% of the common stock held by each holder (and its affiliates) of the Company&#8217;s common stock as of December 26, 2019, at a price per share of $37.10 representing fair value of the common stock, (ii) an offer to purchase vested stock options whose fair market value (as determined as of December 27, 2019) was less than or equal to the fair market value of approximately 11.23% of the earliest-granted of such holder&#8217;s outstanding vested and unvested stock options, at a purchase price equal to such vested option&#8217;s fair market value, and (iii) an offer to holders of performance restricted stock units (&#8220;pRSUs&#8221;) to surrender 100% of their existing pRSUs in exchange for newly issued performance stock options and capped value appreciation rights. The offer to the holders of pRSUs included an offer by the Company to immediately purchase approximately 11.23% of the newly issued performance stock options and capped value appreciation rights for cash.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_RangeAxis=srt_MaximumMember', window );">Maximum | Sumitomo Transaction Agreement [Member] | Roivant Equity Repurchase [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockRepurchaseProgramAuthorizedAmount1', window );">Equity securities authorized for repurchase</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,000,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=roiv_ImmunovantINCMember', window );">Immunovant, Inc [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfSharesContingentlyIssuable', window );">Earnout shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">20,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=roiv_ImmunovantINCMember', window );">Immunovant, Inc [Member] | Convertible Notes Payable [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtConversionConvertedInstrumentSharesIssued1', window );">Conversion of stock , share converted</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">7,156,495<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=roiv_ImmunovantINCMember', window );">Immunovant, Inc [Member] | Warrant</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightOutstanding', window );">Number of outstanding warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,719,145<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,750,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,719,145<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Warrant exercise price per share</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 11.50<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 11.50<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 11.50<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_roiv_ClassOfWarrantOrRightExercisable', window );">Number of exercisable outstanding warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">11,438,290<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">11,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">11,438,290<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfWarrants', window );">Proceeds of warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 65,800<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentOfWarrantsGrantedForServices', window );">Warrants cancellation</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 61,710<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=roiv_ImmunovantINCMember', window );">Immunovant, Inc [Member] | Underwritten Public Offering [Member] | Common Stock [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SaleOfStockPricePerShare', window );">Common stock per share</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 33.00<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 14.50<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Public offering shares of common stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6,060,606<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">9,613,365<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfCommonStock', window );">Net proceeds of common stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 188,100<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 131,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=roiv_HealthSciencesMember', window );">Health Sciences [Member] | Common Stock [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued', window );">Stock acquired related to business acquisition</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">42,080,376<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=roiv_HealthSciencesMember', window );">Health Sciences [Member] | Series A 1 Preferred Stock [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued', window );">Stock acquired related to business acquisition</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=roiv_SumitomoMember', window );">Sumitomo [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction', window );">Number of shares transferred</a></td>
<td class="nump">26,952,143<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">26,952,143<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesIssuedPricePerShare', window );">Share price</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 37.10<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SaleOfStockConsiderationReceivedOnTransaction', window );">Net proceeds from sale of stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 999,200<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,900,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=roiv_SumitomoMember', window );">Sumitomo [Member] | Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockRepurchaseProgramAuthorizedAmount1', window );">Equity securities authorized for repurchase</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=roiv_CytovantScienceHkLtdMember', window );">Cytovant Science HK Ltd [Member] | Series A 1 Preferred Stock [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction', window );">Number of shares transferred</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">20,085,301<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesIssuedPricePerShare', window );">Share price</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1.17<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1.17<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SaleOfStockConsiderationReceivedOnTransaction', window );">Net proceeds from sale of stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 22,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=roiv_HealthSciencesMember', window );">Health Sciences [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightOutstanding', window );">Number of outstanding warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">11,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Warrant exercise price per share</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 11.50<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=roiv_HealthSciencesMember', window );">Health Sciences [Member] | Common Stock [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightOutstanding', window );">Number of outstanding warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,750,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=roiv_HealthSciencesMember', window );">Health Sciences [Member] | Immunovant, Inc [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionPercentageOfVotingInterestsAcquired', window );">Percentage of common stock acquired related to business acquisition</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">100.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsForProceedsFromBusinessesAndInterestInAffiliates', window );">Cash as a result of the Business Combination</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 111,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionEquityInterestIssuedOrIssuableValueAssigned', window );">Proceeds related to common stock purchase by RSL</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 5,100<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=roiv_ImmunovantSciencesLtdMember', window );">Immunovant Sciences Ltd [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Common stock issued</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">20,000,000<span></span>
</td>
<td class="nump">20,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=roiv_ImmunovantSciencesLtdMember', window );">Immunovant Sciences Ltd [Member] | Restricted Stock [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod', window );">Restricted shares vested</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,800,000<span></span>
</td>
<td class="nump">1,800,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=roiv_ImmunovantSciencesLtdMember', window );">Immunovant Sciences Ltd [Member] | Convertible Notes Payable [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtConversionConvertedInstrumentSharesIssued1', window );">Conversion of stock , share converted</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,499,995<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=roiv_SinovantIncMember', window );">Sinovant Inc [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentCompanyInternalRateOfReturnSinceInception', window );">Annualized return rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">12.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockRedemptionPricePerShare', window );">Preferred stock purchase price per share</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 12.26<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsForRepurchaseOfRedeemableConvertiblePreferredStock', window );">Preferred stock purchase price</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 132,900<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsForRepurchaseOfRedeemableNoncontrollingInterest', window );">Repurchase of redeemable noncontrolling interest</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 77,800<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_roiv_ClassOfWarrantOrRightExercisable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Class of Warrant or Right, Exercisable</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">roiv_ClassOfWarrantOrRightExercisable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>roiv_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_roiv_EarnOutSharesTermsDescription">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Earnout shares terms description.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">roiv_EarnOutSharesTermsDescription</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>roiv_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_roiv_PercentageSharesOfCommonStockOfferedToBeRepurchased">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage Shares of Common Stock Offered To Be Repurchased</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">roiv_PercentageSharesOfCommonStockOfferedToBeRepurchased</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>roiv_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentOfWarrantsGrantedForServices">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Adjustment for noncash service expenses paid for by granting of warrants.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentOfWarrantsGrantedForServices</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionEquityInterestIssuedOrIssuableValueAssigned">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Value of equity interests (such as common shares, preferred shares, or partnership interest) issued or issuable to acquire the entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(4)<br> -URI http://asc.fasb.org/extlink&amp;oid=120321790&amp;loc=d3e6927-128479<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionEquityInterestIssuedOrIssuableValueAssigned</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares of equity interests issued or issuable to acquire entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(4)<br> -URI http://asc.fasb.org/extlink&amp;oid=120321790&amp;loc=d3e6927-128479<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionPercentageOfVotingInterestsAcquired">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of voting equity interests acquired at the acquisition date in the business combination.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=79982066&amp;loc=d3e1392-128463<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionPercentageOfVotingInterestsAcquired</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfStockLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfStockLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Exercise price per share or per unit of warrants or rights outstanding.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21475-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of warrants or rights outstanding.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtConversionConvertedInstrumentSharesIssued1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of shares issued in exchange for the original debt being converted in a noncash (or part noncash) transaction. "Part noncash" refers to that portion of the transaction not resulting in cash receipts or payments in the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=123431023&amp;loc=d3e4332-108586<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=123431023&amp;loc=d3e4304-108586<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtConversionConvertedInstrumentSharesIssued1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentConvertibleCarryingAmountOfTheEquityComponent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The carrying amount of the equity component of convertible debt which may be settled in cash upon conversion.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123466204&amp;loc=SL6031897-161870<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentConvertibleCarryingAmountOfTheEquityComponent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentCompanyInternalRateOfReturnSinceInception">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Rate since inception resulting in zero net present value of cash flows from investment.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 946<br> -SubTopic 205<br> -Section 50<br> -Paragraph 23<br> -URI http://asc.fasb.org/extlink&amp;oid=25866437&amp;loc=d3e10432-115837<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentCompanyInternalRateOfReturnSinceInception</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsForProceedsFromBusinessesAndInterestInAffiliates">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The net cash outflow or inflow associated with the acquisition or sale of a business segment during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsForProceedsFromBusinessesAndInterestInAffiliates</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsForRepurchaseOfRedeemableConvertiblePreferredStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow to reacquire callable preferred stock which is identified as being convertible to another type of financial security.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3291-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsForRepurchaseOfRedeemableConvertiblePreferredStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsForRepurchaseOfRedeemableNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow during the period for redemption of redeemable noncontrolling interests.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3291-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsForRepurchaseOfRedeemableNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockRedemptionPricePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The price per share at which the preferred stock of an entity that has priority over common stock in the distribution of dividends and in the event of liquidation of the entity is redeemed or may be called at. The redemption features of this preferred stock are solely within the control of the issuer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21488-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21475-112644<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21564-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockRedemptionPricePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from the additional capital contribution to the entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfWarrants">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from issuance of rights to purchase common shares at predetermined price (usually issued together with corporate debt).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfWarrants</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SaleOfStockConsiderationReceivedOnTransaction">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Cash received on stock transaction after deduction of issuance costs.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SaleOfStockConsiderationReceivedOnTransaction</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of shares issued or sold by the subsidiary or equity method investee per stock transaction.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SaleOfStockPricePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Per share amount received by subsidiary or equity investee for each share of common stock issued or sold in the stock transaction.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SaleOfStockPricePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of equity-based payment instruments, excluding stock (or unit) options, that vested during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharesIssuedPricePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Per share or per unit amount of equity securities issued.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharesIssuedPricePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of new stock issued during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21463-112644<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockRepurchaseProgramAuthorizedAmount1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of stock repurchase plan authorized.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockRepurchaseProgramAuthorizedAmount1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TreasuryStockAcquiredRepurchaseAuthorization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Description of share repurchase program, including accounting treatment.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=6405834&amp;loc=d3e23285-112656<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 30<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=6405834&amp;loc=d3e23315-112656<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TreasuryStockAcquiredRepurchaseAuthorization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfSharesContingentlyIssuable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Shares issuable for little or no cash consideration upon the satisfaction of certain conditions (contingently issuable shares) are considered outstanding common shares and included in the computation of basic Earnings Per Share as of the date that all necessary conditions have been satisfied (in essence, when issuance of the shares is no longer contingent). Outstanding common shares that are contingently returnable (that is, subject to recall) are treated in the same manner as contingently issuable shares. Contingently issuable shares include shares that (a) will be issued in the future upon the satisfaction of specified conditions, (b) have been placed in escrow and all or part must be returned if specified conditions are not met, or (c) have been issued but the holder must return all or part if specified conditions are not met. The number of contingently issuable shares is determined by relating the portion of time within a reporting period that these shares have been outstanding to the total time in that period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=d3e2646-109256<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfSharesContingentlyIssuable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShortTermDebtTypeAxis=us-gaap_ConvertibleNotesPayableMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShortTermDebtTypeAxis=us-gaap_ConvertibleNotesPayableMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=roiv_UnderwrittenPublicOfferingMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=roiv_UnderwrittenPublicOfferingMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=roiv_SumitomoTransactionAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=roiv_SumitomoTransactionAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareRepurchaseProgramAxis=roiv_RoivantEquityRepurchaseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareRepurchaseProgramAxis=roiv_RoivantEquityRepurchaseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionAxis=roiv_ImmunovantINCMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionAxis=roiv_ImmunovantINCMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_WarrantMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_WarrantMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionAxis=roiv_HealthSciencesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionAxis=roiv_HealthSciencesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=roiv_SeriesA1PreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=roiv_SeriesA1PreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=roiv_SumitomoMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=roiv_SumitomoMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=roiv_CytovantScienceHkLtdMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=roiv_CytovantScienceHkLtdMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=roiv_HealthSciencesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=roiv_HealthSciencesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=roiv_ImmunovantSciencesLtdMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=roiv_ImmunovantSciencesLtdMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_RestrictedStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=roiv_SinovantIncMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=roiv_SinovantIncMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>123
<FILENAME>R53.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm139997747460792">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Shareholders' Equity and Redeemable Non-Controlling Interest - Schedule of payments of equity securities (Detail) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2021</div></th>
<th class="th"><div>Jun. 30, 2020</div></th>
<th class="th"><div>Mar. 31, 2021</div></th>
<th class="th"><div>Mar. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsForRepurchaseOfEquityAbstract', window );"><strong>Payments for Repurchase of Equity [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsForRepurchaseOfCommonStock', window );">Common stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 950,722<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsForRepurchaseOfOtherEquity', window );">Other equity instruments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">39,292<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsForRepurchaseOfEquity', window );">Total cash paid</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 113<span></span>
</td>
<td class="nump">$ 113<span></span>
</td>
<td class="nump">$ 990,014<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsForRepurchaseOfCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow to reacquire common stock during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3291-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsForRepurchaseOfCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsForRepurchaseOfEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow to reacquire common and preferred stock.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3291-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsForRepurchaseOfEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsForRepurchaseOfEquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsForRepurchaseOfEquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsForRepurchaseOfOtherEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash outflow to reacquire equity classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3291-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsForRepurchaseOfOtherEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>124
<FILENAME>R54.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm139997839059704">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Share-Based Compensation - Additional Information (Detail) - USD ($)<br></strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2021</div></th>
<th class="th"><div>Jun. 30, 2020</div></th>
<th class="th"><div>Mar. 31, 2021</div></th>
<th class="th"><div>Mar. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Share-based compensation expense</a></td>
<td class="nump">$ 19,269,000<span></span>
</td>
<td class="nump">$ 14,278,000<span></span>
</td>
<td class="nump">$ 84,958,000<span></span>
</td>
<td class="nump">$ 67,751,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember', window );">RSUs [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Share-based compensation expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod', window );">Grant expiration period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">8 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions', window );">Unrecognized compensation expense related to non-vested stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 83,800,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=roiv_PerformanceOptionsMember', window );">Performance Options [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Share-based compensation expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions', window );">Unrecognized compensation expense related to non-vested stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">337,800,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=roiv_CappedValueAppreciationRightsMember', window );">CVARs [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Share-based compensation expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardExpirationDate', window );">Grant expiration date</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">Mar. 31,  2026<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardDescription', window );">Grant, Description</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">each CVAR pays in common shares the excess of (a) the lesser of (i) the fair market value of a common share as of the settlement date or (ii) the cap of $37.10, over (b) the hurdle price of either $18.70 or $33.63, as applicable to each grant.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized', window );">Unrecognized compensation expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 23,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=roiv_PerformanceRestrictedStockUnitsMember', window );">Performance RSU [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Share-based compensation expense</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">12,300,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized', window );">Unrecognized compensation expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,800,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=roiv_CommonStockAwardsMember', window );">RSL Common Share Award</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Share-based compensation expense</a></td>
<td class="nump">$ 800,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1', window );">Remaining weighted-average service period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">3 years 4 months 20 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized', window );">Unrecognized compensation expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 6,900,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestrictedInvestmentsAtFairValue', window );">Restricted common stock fair value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 15,600,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PlanNameAxis=roiv_TwoThousandFifteenEquityIncentivePlanMember', window );">2015 EIP [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance', window );">Common shares reserved for future issuance</a></td>
<td class="nump">22,800,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">22,800,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant', window );">Common shares available for grant</a></td>
<td class="nump">786,125<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10,296,392<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Share-based compensation expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 32,300,000<span></span>
</td>
<td class="nump">$ 31,800,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions', window );">Unrecognized compensation expense related to non-vested stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 70,800,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1', window );">Remaining weighted-average service period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">2 years 11 months 15 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares', window );">Stock options vested</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,533,848<span></span>
</td>
<td class="nump">4,123,953<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PlanNameAxis=roiv_TwoThousandFifteenEquityIncentivePlanMember', window );">2015 EIP [Member] | Special Reserve [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance', window );">Common shares reserved for future issuance</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">26,558,238<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_roiv_CommonSharesReservedForPerformanceOptionsAndCappedValueAppreciationRights', window );">Common shares reserved for performance options and capped value appreciation rights</a></td>
<td class="nump">26,558,238<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant', window );">Common shares available for grant</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PlanNameAxis=roiv_TwoThousandFifteenEquityIncentivePlanMember', window );">2015 EIP [Member] | RSUs [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Share-based compensation expense</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PlanNameAxis=roiv_TwoThousandFifteenEquityIncentivePlanMember', window );">2015 EIP [Member] | Performance Options [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Share-based compensation expense</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PlanNameAxis=roiv_TwoThousandFifteenEquityIncentivePlanMember', window );">2015 EIP [Member] | CVARs [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Share-based compensation expense</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PlanNameAxis=roiv_TwoThousandFifteenEquityIncentivePlanMember', window );">2015 EIP [Member] | Stock Option [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Share-based compensation expense</a></td>
<td class="nump">10,300,000<span></span>
</td>
<td class="nump">7,800,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1', window );">Grant contractual term</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">6 years 5 months 26 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PlanNameAxis=roiv_SubsidiaryEquityIncentivePlanMember', window );">Subsidiary EIPs [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Share-based compensation expense</a></td>
<td class="nump">$ 8,200,000<span></span>
</td>
<td class="nump">$ 6,500,000<span></span>
</td>
<td class="nump">$ 29,100,000<span></span>
</td>
<td class="nump">$ 22,100,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1', window );">Grant vesting period</a></td>
<td class="text">4 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">4 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1', window );">Grant contractual term</a></td>
<td class="text">10 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">10 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PlanNameAxis=roiv_PerformanceRestrictedStockUnitsPlanMember', window );">pRSU Plan [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance', window );">Common shares reserved for future issuance</a></td>
<td class="nump">200,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">200,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod', window );">Grant expiration period</a></td>
<td class="text">8 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">8 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_roiv_SharebasedCompensationArrangementBySharebasedPaymentAwardAggregateRepurchasePrice', window );">Equity repurchase</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 17,044,465<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_roiv_ShareBasedCompensationRightToRepurchasePercentage', window );">Percentage of share repurchased</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">11.23%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_roiv_CommonSharesReservedForPerformanceOptionsAndCappedValueAppreciationRights">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Common shares reserved for performance options and capped value appreciation rights.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">roiv_CommonSharesReservedForPerformanceOptionsAndCappedValueAppreciationRights</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>roiv_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_roiv_ShareBasedCompensationRightToRepurchasePercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Share based compensation right to repurchase percentage.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">roiv_ShareBasedCompensationRightToRepurchasePercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>roiv_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_roiv_SharebasedCompensationArrangementBySharebasedPaymentAwardAggregateRepurchasePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sharebased Compensation Arrangement By Sharebased Payment Award Aggregate Repurchase Price</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">roiv_SharebasedCompensationArrangementBySharebasedPaymentAwardAggregateRepurchasePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>roiv_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AllocatedShareBasedCompensationExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5047-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.F)<br> -URI http://asc.fasb.org/extlink&amp;oid=122041274&amp;loc=d3e301413-122809<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)(i)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AllocatedShareBasedCompensationExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate number of common shares reserved for future issuance.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.29)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockCapitalSharesReservedForFutureIssuance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cost not yet recognized for nonvested award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (i)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted-average period over which cost not yet recognized is expected to be recognized for award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (i)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cost to be recognized for nonvested award under share-based payment arrangement. Excludes share and unit options.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (i)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cost to be recognized for option under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (i)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestrictedInvestmentsAtFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate value of all restricted investments.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 954<br> -SubTopic 210<br> -Section 45<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=120413173&amp;loc=SL6242262-115580<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 946<br> -SubTopic 320<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.12-12.6(c))<br> -URI http://asc.fasb.org/extlink&amp;oid=122147990&amp;loc=d3e611133-123010<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 954<br> -SubTopic 210<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=120413209&amp;loc=SL6242269-115581<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 946<br> -SubTopic 320<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-12B(Footnote 11(c)))<br> -URI http://asc.fasb.org/extlink&amp;oid=122147990&amp;loc=d3e611197-123010<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestrictedInvestmentsAtFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Period over which grantee's right to exercise award under share-based payment arrangement is no longer contingent on satisfaction of service or performance condition, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Includes, but is not limited to, combination of market, performance or service condition.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardDescription">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Description of terms of share-based payment arrangement. Includes, but is not limited to, type of award or grantee and reason for issuance.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5047-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardDescription</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardExpirationDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Date the equity-based award expires, in YYYY-MM-DD format.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardExpirationDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The difference between the maximum number of shares (or other type of equity) authorized for issuance under the plan (including the effects of amendments and adjustments), and the sum of: 1) the number of shares (or other type of equity) already issued upon exercise of options or other equity-based awards under the plan; and 2) shares (or other type of equity) reserved for issuance on granting of outstanding awards, net of cancellations and forfeitures, if applicable.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Period from grant date that an equity-based award expires, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term for vested portions of options outstanding and currently exercisable or convertible, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of options vested.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=roiv_PerformanceOptionsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=roiv_PerformanceOptionsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=roiv_CappedValueAppreciationRightsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=roiv_CappedValueAppreciationRightsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=roiv_PerformanceRestrictedStockUnitsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=roiv_PerformanceRestrictedStockUnitsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=roiv_CommonStockAwardsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=roiv_CommonStockAwardsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=roiv_TwoThousandFifteenEquityIncentivePlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=roiv_TwoThousandFifteenEquityIncentivePlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=roiv_SpecialReserveMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=roiv_SpecialReserveMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=roiv_SubsidiaryEquityIncentivePlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=roiv_SubsidiaryEquityIncentivePlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=roiv_PerformanceRestrictedStockUnitsPlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=roiv_PerformanceRestrictedStockUnitsPlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>125
<FILENAME>R55.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm139997754942616">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Share-Based Compensation - Schedule of Fair Value Assumptions (Detail)<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2021</div></th>
<th class="th"><div>Mar. 31, 2020</div></th>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember', window );">Stock Option [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate', window );">Expected stock price volatility</a></td>
<td class="nump">74.84%<span></span>
</td>
<td class="nump">66.47%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate', window );">Expected risk free interest rate</a></td>
<td class="nump">0.43%<span></span>
</td>
<td class="nump">2.27%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1', window );">Expected term</a></td>
<td class="text">6 years 3 months<span></span>
</td>
<td class="text">6 years 8 months 19 days<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate', window );">Expected dividend yield</a></td>
<td class="nump">0.00%<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=roiv_PerformanceOptionsMember', window );">Performance Options [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate', window );">Expected stock price volatility</a></td>
<td class="nump">73.60%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate', window );">Expected risk free interest rate</a></td>
<td class="nump">0.62%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1', window );">Expected term</a></td>
<td class="text">6 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate', window );">Expected dividend yield</a></td>
<td class="nump">0.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The estimated dividend rate (a percentage of the share price) to be paid (expected dividends) to holders of the underlying shares over the option's term.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iii)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The risk-free interest rate assumption that is used in valuing an option on its own shares.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iv)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Rate of weighted-average expected volatility for award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(ii)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Expected term of award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(i)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.D.2)<br> -URI http://asc.fasb.org/extlink&amp;oid=122041274&amp;loc=d3e301413-122809<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=roiv_PerformanceOptionsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=roiv_PerformanceOptionsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>126
<FILENAME>R56.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm139997756122248">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Share-Based Compensation - Summary of Stock Option Activity (Detail) - Stock Option [Member] - 2015 EIP [Member] - $ / shares<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2021</div></th>
<th class="th"><div>Mar. 31, 2021</div></th>
<th class="th"><div>Mar. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Stock options outstanding ,Beginning balance</a></td>
<td class="nump">9,389,371<span></span>
</td>
<td class="nump">8,176,814<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross', window );">Options Granted</a></td>
<td class="nump">3,798,605<span></span>
</td>
<td class="nump">1,482,604<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod', window );">Options Forfeited/Canceled</a></td>
<td class="num">(106,428)<span></span>
</td>
<td class="num">(270,047)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Stock options outstanding , Ending balance</a></td>
<td class="nump">13,081,548<span></span>
</td>
<td class="nump">9,389,371<span></span>
</td>
<td class="nump">8,176,814<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber', window );">Stock options exercisable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,533,848<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Weighted average exercise price, Beginning balance</a></td>
<td class="nump">$ 26.61<span></span>
</td>
<td class="nump">$ 24.52<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice', window );">Weighted average exercise price, Granted</a></td>
<td class="nump">29.26<span></span>
</td>
<td class="nump">38.71<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice', window );">Weighted average exercise price,Forfeited/Canceled</a></td>
<td class="nump">30.27<span></span>
</td>
<td class="nump">29.89<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Weighted average exercise price, Ending balance</a></td>
<td class="nump">27.35<span></span>
</td>
<td class="nump">26.61<span></span>
</td>
<td class="nump">$ 24.52<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice', window );">Weighted average exercise price, exercisable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">21.52<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_roiv_ShareBasedCompensationArrangementByShareBasedPaymentAwardWeightedAverageGrantDateFairValue', window );">Weighted Average Grant Date Fair Value, Beginning balance</a></td>
<td class="nump">$ 17.90<span></span>
</td>
<td class="nump">16.53<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue', window );">Weighted average grant date fair value, Granted</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">25.37<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedWeightedAverageGrantDateFairValue', window );">Weighted Average Grant Date Fair Value, Granted</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">19.85<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_roiv_ShareBasedCompensationArrangementByShareBasedPaymentAwardWeightedAverageGrantDateFairValue', window );">Weighted Average Grant Date Fair Value, Ending balance</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">17.90<span></span>
</td>
<td class="nump">$ 16.53<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_roiv_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExcercisableWeightedAverageGrantDateFairValue', window );">Weighted Average Grant Date Fair Value, exercisable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 14.95<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2', window );">Weighted Average Remaining Contractual Life</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">7 years 3 months 3 days<span></span>
</td>
<td class="text">7 years 11 months 4 days<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1', window );">Weighted Average Remaining Contractual Life, exercisable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">6 years 5 months 26 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_roiv_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExcercisableWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Share Based Compensation Arrangement by Share Based Payment Award Options Excercisable Weighted Average Grant Date Fair Value.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">roiv_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExcercisableWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>roiv_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_roiv_ShareBasedCompensationArrangementByShareBasedPaymentAwardWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Share Based Compensation Arrangement By Share Based Payment Award, Weighted Average Grant Date Fair Value</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">roiv_ShareBasedCompensationArrangementByShareBasedPaymentAwardWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>roiv_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of shares into which fully or partially vested stock options outstanding as of the balance sheet date can be currently converted under the option plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iii)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The weighted-average price as of the balance sheet date at which grantees can acquire the shares reserved for issuance on vested portions of options outstanding and currently exercisable under the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iii)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of shares under options that were cancelled during the reporting period as a result of occurrence of a terminating event specified in contractual agreements pertaining to the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Gross number of share options (or share units) granted during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The weighted average grant-date fair value of options granted during the reporting period as calculated by applying the disclosed option pricing methodology.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of options outstanding, including both vested and non-vested options.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)-(ii)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which grantees could have acquired the underlying shares with respect to stock options that were terminated.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term for vested portions of options outstanding and currently exercisable or convertible, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average grant-date fair value of non-vested options forfeited.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term for option awards outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=roiv_TwoThousandFifteenEquityIncentivePlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=roiv_TwoThousandFifteenEquityIncentivePlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>127
<FILENAME>R57.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm139997851160648">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Share-Based Compensation - Summary of Fair Value of Vested Stock Option (Detail) - USD ($)<br> $ / shares in Units, $ in Thousands</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2021</div></th>
<th class="th"><div>Mar. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract', window );"><strong>Share-based Payment Arrangement [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1', window );">Grant date fair value of stock options vested</a></td>
<td class="nump">$ 25,711<span></span>
</td>
<td class="nump">$ 33,789<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue', window );">Weighted-average grant date fair value per share of stock options granted</a></td>
<td class="nump">$ 25.37<span></span>
</td>
<td class="nump">$ 20.63<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value of options vested. Excludes equity instruments other than options, for example, but not limited to, share units, stock appreciation rights, restricted stock.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average grant-date fair value of options vested.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>128
<FILENAME>R58.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm139997751270312">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Share-Based Compensation - Summary of Restricted Stock Units (Detail) - RSUs [Member] - 2015 EIP [Member] - $ / shares<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2021</div></th>
<th class="th"><div>Mar. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber', window );">Non-vested balance, beginning</a></td>
<td class="nump">2,292,738<span></span>
</td>
<td class="nump">1,008,175<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod', window );">Granted</a></td>
<td class="nump">5,939,340<span></span>
</td>
<td class="nump">1,454,199<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod', window );">Forfeited</a></td>
<td class="num">(119,285)<span></span>
</td>
<td class="num">(169,636)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber', window );">Non-vested balance, ending</a></td>
<td class="nump">8,112,793<span></span>
</td>
<td class="nump">2,292,738<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue', window );">Non-vested units, Beginning balance</a></td>
<td class="nump">$ 36.53<span></span>
</td>
<td class="nump">$ 32.50<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue', window );">Weighted Average Grant Date Fair Value,Granted</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">39.19<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedWeightedAverageGrantDateFairValue', window );">Weighted Average Grant Date Fair Value,Forfeited</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">36.36<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue', window );">Non-vested units , Ending balance</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 36.53<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of equity-based payment instruments, excluding stock (or unit) options, that were forfeited during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of grants made during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of non-vested equity-based payment instruments, excluding stock (or unit) options, that validly exist and are outstanding as of the balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(i)-(ii)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The weighted average grant-date fair value of options granted during the reporting period as calculated by applying the disclosed option pricing methodology.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average grant-date fair value of non-vested options forfeited.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average grant-date fair value of non-vested options outstanding.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=roiv_TwoThousandFifteenEquityIncentivePlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=roiv_TwoThousandFifteenEquityIncentivePlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>129
<FILENAME>R59.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm139997744491576">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Share-Based Compensation - Summary of Performance Options Activity (Detail) - Performance Options [Member] - 2015 EIP [Member] - $ / shares<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2021</div></th>
<th class="th"><div>Mar. 31, 2021</div></th>
<th class="th"><div>Mar. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Stock options outstanding ,Beginning balance</a></td>
<td class="nump">14,425,663<span></span>
</td>
<td class="nump">14,518,870<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross', window );">Options Granted</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod', window );">Options Forfeited</a></td>
<td class="nump">0<span></span>
</td>
<td class="num">(93,207)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Stock options outstanding , Ending balance</a></td>
<td class="nump">14,425,663<span></span>
</td>
<td class="nump">14,425,663<span></span>
</td>
<td class="nump">14,518,870<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Weighted average exercise price, Beginning balance</a></td>
<td class="nump">$ 38.93<span></span>
</td>
<td class="nump">$ 38.97<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice', window );">Weighted average exercise price, Granted</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice', window );">Weighted average exercise price, Forfeited</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">46.38<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Weighted average exercise price, Ending balance</a></td>
<td class="nump">38.93<span></span>
</td>
<td class="nump">38.93<span></span>
</td>
<td class="nump">$ 38.97<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_roiv_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageGrantDateFairValue', window );">Weighted average grant date fair value, Beginning balance</a></td>
<td class="nump">$ 23.42<span></span>
</td>
<td class="nump">23.78<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue', window );">Weighted average grant date fair value, Granted</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_roiv_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeitedInPeriodWeightedAverageGrantDateFairValue', window );">Weighted average grant date fair value, Forfeited</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">22.18<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_roiv_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageGrantDateFairValue', window );">Weighted average grant date fair value, Ending balance</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 23.42<span></span>
</td>
<td class="nump">$ 23.78<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2', window );">Performance Options outstanding at March 31, 2020</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">5 years<span></span>
</td>
<td class="text">6 years<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_roiv_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeitedInPeriodWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Share Based Compensation Arrangement By Share Based Payment Award Options Forfeited In Period Weighted Average Grant Date Fair Value</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">roiv_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeitedInPeriodWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>roiv_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_roiv_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Grant Date Fair Value</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">roiv_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>roiv_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of shares under options that were cancelled during the reporting period as a result of occurrence of a terminating event specified in contractual agreements pertaining to the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Gross number of share options (or share units) granted during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The weighted average grant-date fair value of options granted during the reporting period as calculated by applying the disclosed option pricing methodology.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of options outstanding, including both vested and non-vested options.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)-(ii)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which grantees could have acquired the underlying shares with respect to stock options that were terminated.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term for option awards outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=roiv_PerformanceOptionsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=roiv_PerformanceOptionsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=roiv_TwoThousandFifteenEquityIncentivePlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=roiv_TwoThousandFifteenEquityIncentivePlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>130
<FILENAME>R60.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm139997851130936">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Share-Based Compensation - Summary of Capped Value Appreciation Rights (Detail) - CVARs [Member] - 2015 EIP [Member] - $ / shares<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2021</div></th>
<th class="th"><div>Mar. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber', window );">Non-vested balance, beginning</a></td>
<td class="nump">11,088,658<span></span>
</td>
<td class="nump">11,088,658<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod', window );">Granted</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod', window );">Forfeited</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber', window );">Non-vested balance, ending</a></td>
<td class="nump">11,088,658<span></span>
</td>
<td class="nump">11,088,658<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue', window );">Non-vested units, Beginning balance</a></td>
<td class="nump">$ 2.07<span></span>
</td>
<td class="nump">$ 2.07<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue', window );">Weighted average grant date fair value, Granted</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedWeightedAverageGrantDateFairValue', window );">Weighted average grant date fair value, forfeited</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue', window );">Non-vested units , Ending balance</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2.07<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of equity-based payment instruments, excluding stock (or unit) options, that were forfeited during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of grants made during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of non-vested equity-based payment instruments, excluding stock (or unit) options, that validly exist and are outstanding as of the balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(i)-(ii)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The weighted average grant-date fair value of options granted during the reporting period as calculated by applying the disclosed option pricing methodology.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average grant-date fair value of non-vested options forfeited.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average grant-date fair value of non-vested options outstanding.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=roiv_CappedValueAppreciationRightsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=roiv_CappedValueAppreciationRightsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=roiv_TwoThousandFifteenEquityIncentivePlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=roiv_TwoThousandFifteenEquityIncentivePlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>131
<FILENAME>R61.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm139997755794424">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Share-Based Compensation - Summary of Performance Restricted Stock Units (Detail) - Performance RSU [Member] - pRSU Plan [Member] - $ / shares<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2021</div></th>
<th class="th"><div>Mar. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber', window );">Non-vested balance, beginning</a></td>
<td class="nump">200,000<span></span>
</td>
<td class="nump">266,845<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod', window );">Units Granted</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod', window );">Units Forfeited</a></td>
<td class="nump">0<span></span>
</td>
<td class="num">(66,845)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber', window );">Non-vested balance, ending</a></td>
<td class="nump">200,000<span></span>
</td>
<td class="nump">200,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue', window );">Non-vested units, Beginning balance</a></td>
<td class="nump">$ 13.92<span></span>
</td>
<td class="nump">$ 13.92<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue', window );">Units Granted</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedWeightedAverageGrantDateFairValue', window );">Units Forfeited</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">13.92<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue', window );">Non-vested units , Ending balance</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 13.92<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of equity-based payment instruments, excluding stock (or unit) options, that were forfeited during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of grants made during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of non-vested equity-based payment instruments, excluding stock (or unit) options, that validly exist and are outstanding as of the balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(i)-(ii)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The weighted average grant-date fair value of options granted during the reporting period as calculated by applying the disclosed option pricing methodology.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average grant-date fair value of non-vested options forfeited.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average grant-date fair value of non-vested options outstanding.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=roiv_PerformanceRestrictedStockUnitsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=roiv_PerformanceRestrictedStockUnitsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=roiv_PerformanceRestrictedStockUnitsPlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=roiv_PerformanceRestrictedStockUnitsPlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>132
<FILENAME>R62.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm139997755713880">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Share-Based Compensation - Summary of Common Share Award Activity (Detail) - RSL Common Share Award - $ / shares<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2021</div></th>
<th class="th"><div>Mar. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber', window );">Non-vested balance, beginning</a></td>
<td class="nump">587,824<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod', window );">Granted</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">587,824<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod', window );">Vested</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod', window );">Forfeited</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber', window );">Non-vested balance, ending</a></td>
<td class="nump">587,824<span></span>
</td>
<td class="nump">587,824<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue', window );">Weighted Average Grant Date Fair Value, vested</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 38.50<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue', window );">Weighted Average Grant Date Fair Value, vested</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue', window );">Weighted Average Grant Date Fair Value, Forfeited</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue', window );">Weighted Average Grant Date Fair Value, Ending Balance</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 38.50<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of equity-based payment instruments, excluding stock (or unit) options, that were forfeited during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average fair value as of the grant date of equity-based award plans other than stock (unit) option plans that were not exercised or put into effect as a result of the occurrence of a terminating event.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of grants made during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The weighted average fair value at grant date for nonvested equity-based awards issued during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of non-vested equity-based payment instruments, excluding stock (or unit) options, that validly exist and are outstanding as of the balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(i)-(ii)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Per share or unit weighted-average fair value of nonvested award under share-based payment arrangement. Excludes share and unit options.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(i)-(ii)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of equity-based payment instruments, excluding stock (or unit) options, that vested during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The weighted average fair value as of grant date pertaining to an equity-based award plan other than a stock (or unit) option plan for which the grantee gained the right during the reporting period, by satisfying service and performance requirements, to receive or retain shares or units, other instruments, or cash in accordance with the terms of the arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=roiv_CommonStockAwardsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=roiv_CommonStockAwardsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>133
<FILENAME>R63.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm139997982149176">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Share-Based Compensation - Summary of Share-Based Compensation Expense (Detail) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2021</div></th>
<th class="th"><div>Jun. 30, 2020</div></th>
<th class="th"><div>Mar. 31, 2021</div></th>
<th class="th"><div>Mar. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Share-based compensation expense</a></td>
<td class="nump">$ 19,269<span></span>
</td>
<td class="nump">$ 14,278<span></span>
</td>
<td class="nump">$ 84,958<span></span>
</td>
<td class="nump">$ 67,751<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember', window );">R&amp;D Expenses [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Share-based compensation expense</a></td>
<td class="nump">1,615<span></span>
</td>
<td class="nump">1,119<span></span>
</td>
<td class="nump">22,637<span></span>
</td>
<td class="nump">7,738<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_GeneralAndAdministrativeExpenseMember', window );">G&amp;A Expenses [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Share-based compensation expense</a></td>
<td class="nump">$ 17,654<span></span>
</td>
<td class="nump">$ 13,159<span></span>
</td>
<td class="nump">$ 62,321<span></span>
</td>
<td class="nump">$ 60,013<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AllocatedShareBasedCompensationExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5047-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.F)<br> -URI http://asc.fasb.org/extlink&amp;oid=122041274&amp;loc=d3e301413-122809<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)(i)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AllocatedShareBasedCompensationExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_GeneralAndAdministrativeExpenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_GeneralAndAdministrativeExpenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>134
<FILENAME>R64.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm139997868251320">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Discontinued Operations - Summary Of Disposal Groups Including Discontinued Operations Income Statement (Detail) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2021</div></th>
<th class="th"><div>Mar. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_roiv_DisposalGroupIncludingDiscontinuedOperationOperatingExpenseAbstract', window );"><strong>Operating expenses:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_roiv_DisposalGroupIncludingDiscontinuedOperationResearchAndDevelopmentExpense', window );">Research and development</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 265,452<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisposalGroupIncludingDiscontinuedOperationGeneralAndAdministrativeExpense', window );">General and administrative</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">119,885<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisposalGroupIncludingDiscontinuedOperationOperatingExpense', window );">Total operating expenses</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">385,337<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisposalGroupIncludingDiscontinuedOperationOperatingIncomeLoss', window );">Loss from operations</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(385,337)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_roiv_DisposalGroupIncludingDiscontinuedOperationGainLossOnSaleOfBusiness', window );">Gain on sale of business</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(1,985,949)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisposalGroupIncludingDiscontinuedOperationInterestIncome', window );">Interest income</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(2,305)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisposalGroupIncludingDiscontinuedOperationInterestExpense', window );">Interest expense(1)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">13,733<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisposalGroupIncludingDiscontinuedOperationOtherExpense', window );">Other expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">8,866<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DiscontinuedOperationIncomeLossFromDiscontinuedOperationBeforeIncomeTax', window );">Income from discontinued operations before income taxes</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,580,318<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DiscontinuedOperationTaxEffectOfDiscontinuedOperation', window );">Income tax expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,892<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTax', window );">Income from discontinued operations, net of tax</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">1,578,426<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DiscontinuedOperationIncomeLossFromDiscontinuedOperationDuringPhaseOutPeriodBeforeIncomeTaxAttributableToNoncontrollingInterest', window );">Loss from discontinued operations before income taxes attributable to noncontrolling interests</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(141,783)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DiscontinuedOperationIncomeLossFromDiscontinuedOperationDuringPhaseOutPeriodBeforeIncomeTaxAttributableToParent', window );">Income from discontinued operations before income taxes attributable to Roivant Sciences Ltd.</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,722,101<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DiscontinuedOperationIncomeLossFromDiscontinuedOperationDuringPhaseOutPeriodBeforeIncomeTax', window );">Income from discontinued operations before income taxes</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,580,318<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_roiv_DisposalGroupIncludingDiscontinuedOperationGainLossOnSaleOfBusiness">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disposal Group, Including Discontinued Operation, Gain (Loss) on Sale of Business</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">roiv_DisposalGroupIncludingDiscontinuedOperationGainLossOnSaleOfBusiness</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>roiv_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_roiv_DisposalGroupIncludingDiscontinuedOperationOperatingExpenseAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disposal Group, Including Discontinued Operation, Operating Expense [Abstract]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">roiv_DisposalGroupIncludingDiscontinuedOperationOperatingExpenseAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>roiv_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_roiv_DisposalGroupIncludingDiscontinuedOperationResearchAndDevelopmentExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disposal Group Including Discontinued Operation Research And Development Expense</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">roiv_DisposalGroupIncludingDiscontinuedOperationResearchAndDevelopmentExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>roiv_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DiscontinuedOperationIncomeLossFromDiscontinuedOperationBeforeIncomeTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before tax of income (loss) from a discontinued operation. Includes, but is not limited to, the income (loss) from operations during the phase-out period, gain (loss) on disposal, gain (loss) for reversal of write-down (write-down) to fair value, less cost to sell, and adjustments to a prior period gain (loss) on disposal.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 5B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721673-107760<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=d3e1361-107760<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 45<br> -Paragraph 3A<br> -URI http://asc.fasb.org/extlink&amp;oid=109222160&amp;loc=SL51721523-107759<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 45<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=109222160&amp;loc=d3e1012-107759<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(12))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 45<br> -Paragraph 3B<br> -URI http://asc.fasb.org/extlink&amp;oid=109222160&amp;loc=SL51721525-107759<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 45<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=109222160&amp;loc=d3e957-107759<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(14))<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DiscontinuedOperationIncomeLossFromDiscontinuedOperationBeforeIncomeTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DiscontinuedOperationIncomeLossFromDiscontinuedOperationDuringPhaseOutPeriodBeforeIncomeTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before tax of income (loss) from operations classified as a discontinued operation. Excludes gain (loss) on disposal and provision for gain (loss) until its disposal.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 45<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=109222160&amp;loc=d3e957-107759<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 45<br> -Paragraph 3A<br> -URI http://asc.fasb.org/extlink&amp;oid=109222160&amp;loc=SL51721523-107759<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 5B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721673-107760<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DiscontinuedOperationIncomeLossFromDiscontinuedOperationDuringPhaseOutPeriodBeforeIncomeTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DiscontinuedOperationIncomeLossFromDiscontinuedOperationDuringPhaseOutPeriodBeforeIncomeTaxAttributableToNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before tax of income (loss) from operations classified as a discontinued operation attributable to the noncontrolling interest. Excludes gain (loss) on disposal and provision for gain (loss) until its disposal.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DiscontinuedOperationIncomeLossFromDiscontinuedOperationDuringPhaseOutPeriodBeforeIncomeTaxAttributableToNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DiscontinuedOperationIncomeLossFromDiscontinuedOperationDuringPhaseOutPeriodBeforeIncomeTaxAttributableToParent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before tax of income (loss) from operations classified as a discontinued operation attributable to the parent. Excludes gain (loss) on disposal and provision for gain (loss) until its disposal.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 5B<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721673-107760<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DiscontinuedOperationIncomeLossFromDiscontinuedOperationDuringPhaseOutPeriodBeforeIncomeTaxAttributableToParent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DiscontinuedOperationTaxEffectOfDiscontinuedOperation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of tax expense (benefit) related to a discontinued operation. Includes, but is not limited to, tax expense (benefit) related to income (loss) from operations during the phase-out period, tax expense (benefit) related to gain (loss) on disposal, tax expense (benefit) related to gain (loss) for reversal of write-down (write-down) to fair value, less cost to sell, and tax expense (benefit) related to adjustments of a prior period gain (loss) on disposal.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 45<br> -Paragraph 3B<br> -URI http://asc.fasb.org/extlink&amp;oid=109222160&amp;loc=SL51721525-107759<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 20<br> -Section 45<br> -Paragraph 2<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123586238&amp;loc=d3e38679-109324<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 45<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=109222160&amp;loc=d3e1012-107759<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=d3e1361-107760<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 45<br> -Paragraph 3A<br> -URI http://asc.fasb.org/extlink&amp;oid=109222160&amp;loc=SL51721523-107759<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB TOPIC 6.I.7)<br> -URI http://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 5C<br> -Subparagraph (b)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721675-107760<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 5B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721673-107760<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32672-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DiscontinuedOperationTaxEffectOfDiscontinuedOperation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisposalGroupIncludingDiscontinuedOperationGeneralAndAdministrativeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of general and administrative expense attributable to disposal group, including, but not limited to, discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 5B<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721673-107760<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisposalGroupIncludingDiscontinuedOperationGeneralAndAdministrativeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisposalGroupIncludingDiscontinuedOperationInterestExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of interest expense attributable to disposal group, including, but not limited to, discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section S99<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=26872618&amp;loc=d3e7436-122677<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 45<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=109222160&amp;loc=d3e1063-107759<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 5B<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721673-107760<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 45<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=109222160&amp;loc=d3e1060-107759<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisposalGroupIncludingDiscontinuedOperationInterestExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisposalGroupIncludingDiscontinuedOperationInterestIncome">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of interest income attributable to disposal group, including, but not limited to, discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 5B<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721673-107760<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisposalGroupIncludingDiscontinuedOperationInterestIncome</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisposalGroupIncludingDiscontinuedOperationOperatingExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of operating expense attributable to disposal group, including, but not limited to, discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 5B<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721673-107760<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisposalGroupIncludingDiscontinuedOperationOperatingExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisposalGroupIncludingDiscontinuedOperationOperatingIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of operating income (loss) attributable to disposal group, including, but not limited to, discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 5B<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721673-107760<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisposalGroupIncludingDiscontinuedOperationOperatingIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisposalGroupIncludingDiscontinuedOperationOtherExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of other expense attributable to disposal group, including, but not limited to, discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 5B<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721673-107760<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisposalGroupIncludingDiscontinuedOperationOtherExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after tax of income (loss) from a discontinued operation including the portion attributable to the noncontrolling interest. Includes, but is not limited to, the income (loss) from operations during the phase-out period, gain (loss) on disposal, gain (loss) for reversal of write-down (write-down) to fair value, less cost to sell, and adjustments to a prior period gain (loss) on disposal.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(12))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 45<br> -Paragraph 3B<br> -URI http://asc.fasb.org/extlink&amp;oid=109222160&amp;loc=SL51721525-107759<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 5C<br> -Subparagraph (b)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721675-107760<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 45<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=109222160&amp;loc=d3e957-107759<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=d3e1361-107760<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 45<br> -Paragraph 3A<br> -URI http://asc.fasb.org/extlink&amp;oid=109222160&amp;loc=SL51721523-107759<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 45<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=109222160&amp;loc=d3e1012-107759<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 270<br> -Section 45<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=109227538&amp;loc=d3e44648-109337<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>135
<FILENAME>R65.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm139997756263880">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Discontinued Operations - Summary of Cash Flows From Discontinued Operations (Detail)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th">
<div>Mar. 31, 2020 </div>
<div>USD ($)</div>
</th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DiscontinuedOperationsAndDisposalGroupsAbstract', window );"><strong>Discontinued Operations and Disposal Groups [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_roiv_DisposalGroupIncludingDiscontinuedOperationGainLossOnSaleOfBusiness', window );">Gain on sale of business</a></td>
<td class="num">$ (1,985,949)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_roiv_DisposalGroupIncludingDiscontinuedOperationShareBasedCompensation', window );">Share-based compensation</a></td>
<td class="nump">54,821<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_roiv_DisposalGroupIncludingDiscontinuedOperationResearchAndDevelopmentInProcess', window );">Acquired in-processresearch and development</a></td>
<td class="nump">$ 16,405<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_roiv_DisposalGroupIncludingDiscontinuedOperationGainLossOnSaleOfBusiness">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disposal Group, Including Discontinued Operation, Gain (Loss) on Sale of Business</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">roiv_DisposalGroupIncludingDiscontinuedOperationGainLossOnSaleOfBusiness</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>roiv_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_roiv_DisposalGroupIncludingDiscontinuedOperationResearchAndDevelopmentInProcess">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disposal group including discontinued operation research and development in process.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">roiv_DisposalGroupIncludingDiscontinuedOperationResearchAndDevelopmentInProcess</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>roiv_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_roiv_DisposalGroupIncludingDiscontinuedOperationShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disposal group including discontinued operation share based compensation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">roiv_DisposalGroupIncludingDiscontinuedOperationShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>roiv_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DiscontinuedOperationsAndDisposalGroupsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DiscontinuedOperationsAndDisposalGroupsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>136
<FILENAME>R66.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm139997748357560">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Related Party Transactions - Additional Information (Detail) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2021</div></th>
<th class="th"><div>Mar. 31, 2020</div></th>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=roiv_SumitovantMember', window );">Sumitovant [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CostsAndExpensesRelatedParty', window );">Cost incurred and recorded as offsets to general and administrative expenses</a></td>
<td class="nump">$ 1.4<span></span>
</td>
<td class="nump">$ 0.2<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=roiv_SumitomoMember', window );">Sumitomo [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionAmountsOfTransaction', window );">Access fee paid pursuant to strategic cooperation agreement</a></td>
<td class="nump">$ 1.0<span></span>
</td>
<td class="nump">$ 1.0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CostsAndExpensesRelatedParty">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Costs of sales and operating expenses for the period incurred from transactions with related parties.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.2)<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CostsAndExpensesRelatedParty</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionAmountsOfTransaction">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of transactions with related party during the financial reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 850<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=6457730&amp;loc=d3e39549-107864<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 850<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=6457730&amp;loc=d3e39603-107864<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionAmountsOfTransaction</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=roiv_SumitovantMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=roiv_SumitovantMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=roiv_SumitomoMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=roiv_SumitomoMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>137
<FILENAME>R67.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm139997851134808">
<tr>
<th class="tl" colspan="2" rowspan="2"><div style="width: 200px;"><strong>Income Taxes - Schedule of Loss Before Income Taxes by Geographic Region (Detail) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2021</div></th>
<th class="th"><div>Mar. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestmentsAbstract', window );"><strong>Loss before income taxes:</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments', window );">Total loss before income taxes</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">$ (898,547)<span></span>
</td>
<td class="num">$ (560,986)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_StatementGeographicalAxis=country_US', window );">United States [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestmentsAbstract', window );"><strong>Loss before income taxes:</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments', window );">Total loss before income taxes</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">(212,921)<span></span>
</td>
<td class="num">(69,264)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_StatementGeographicalAxis=country_CH', window );">Switzerland [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestmentsAbstract', window );"><strong>Loss before income taxes:</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments', window );">Total loss before income taxes</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">(424,494)<span></span>
</td>
<td class="num">(355,422)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_StatementGeographicalAxis=country_BM', window );">Bermuda [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestmentsAbstract', window );"><strong>Loss before income taxes:</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments', window );">Total loss before income taxes</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">(227,471)<span></span>
</td>
<td class="num">(105,604)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_StatementGeographicalAxis=roiv_OtherMember', window );">Other [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestmentsAbstract', window );"><strong>Loss before income taxes:</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments', window );">Total loss before income taxes</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="num">$ (33,661)<span></span>
</td>
<td class="num">$ (30,696)<span></span>
</td>
</tr>
<tr><td colspan="3"></td></tr>
<tr><td colspan="3"><table class="outerFootnotes" width="100%"><tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[1]</td>
<td style="vertical-align: top;" valign="top">Primarily Greater China and United Kingdom activity</td>
</tr></table></td></tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of income (loss) from continuing operations before deduction of income tax expense (benefit) and income (loss) attributable to noncontrolling interest, and addition of income (loss) from equity method investments.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8906-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8924-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestmentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestmentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementGeographicalAxis=country_US">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementGeographicalAxis=country_US</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementGeographicalAxis=country_CH">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementGeographicalAxis=country_CH</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementGeographicalAxis=country_BM">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementGeographicalAxis=country_BM</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementGeographicalAxis=roiv_OtherMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementGeographicalAxis=roiv_OtherMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>138
<FILENAME>R68.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm139997756228360">
<tr>
<th class="tl" colspan="2" rowspan="2"><div style="width: 200px;"><strong>Income Taxes - Schedule Components of Income Tax Expense (Benefit) (Detail) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2021</div></th>
<th class="th"><div>Jun. 30, 2020</div></th>
<th class="th"><div>Mar. 31, 2021</div></th>
<th class="th"><div>Mar. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract', window );"><strong>Current taxes:</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CurrentIncomeTaxExpenseBenefit', window );">Total current tax expense</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,686<span></span>
</td>
<td class="nump">$ 7,124<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract', window );"><strong>Deferred taxes:</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredIncomeTaxExpenseBenefit', window );">Total deferred tax benefit</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxExpenseBenefit', window );">Income tax provision</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">$ 93<span></span>
</td>
<td class="nump">$ 1,221<span></span>
</td>
<td class="nump">1,686<span></span>
</td>
<td class="nump">7,124<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_StatementGeographicalAxis=country_US', window );">United States [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract', window );"><strong>Current taxes:</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CurrentIncomeTaxExpenseBenefit', window );">Total current tax expense</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,365<span></span>
</td>
<td class="nump">6,327<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract', window );"><strong>Deferred taxes:</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredIncomeTaxExpenseBenefit', window );">Total deferred tax benefit</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_StatementGeographicalAxis=country_CH', window );">Switzerland [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract', window );"><strong>Current taxes:</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CurrentIncomeTaxExpenseBenefit', window );">Total current tax expense</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract', window );"><strong>Deferred taxes:</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredIncomeTaxExpenseBenefit', window );">Total deferred tax benefit</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_StatementGeographicalAxis=country_BM', window );">Bermuda [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract', window );"><strong>Current taxes:</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CurrentIncomeTaxExpenseBenefit', window );">Total current tax expense</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract', window );"><strong>Deferred taxes:</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredIncomeTaxExpenseBenefit', window );">Total deferred tax benefit</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_StatementGeographicalAxis=roiv_OtherMember', window );">Other [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract', window );"><strong>Current taxes:</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CurrentIncomeTaxExpenseBenefit', window );">Total current tax expense</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">321<span></span>
</td>
<td class="nump">797<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract', window );"><strong>Deferred taxes:</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredIncomeTaxExpenseBenefit', window );">Total deferred tax benefit</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr><td colspan="5"></td></tr>
<tr><td colspan="5"><table class="outerFootnotes" width="100%"><tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[1]</td>
<td style="vertical-align: top;" valign="top">Primarily Greater China, United States state and local and United Kingdom activity</td>
</tr></table></td></tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CurrentIncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of current income tax expense (benefit) pertaining to taxable income (loss) from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.7)<br> -URI http://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(1)(Note 1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32639-109319<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.2)<br> -URI http://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CurrentIncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredIncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred income tax expense (benefit) pertaining to income (loss) from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.7)<br> -URI http://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.1)<br> -URI http://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(1)(Note 1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.2)<br> -URI http://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32639-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredIncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB TOPIC 6.I.7)<br> -URI http://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32672-109319<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (h)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 20<br> -Section 45<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123586238&amp;loc=d3e38679-109324<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(9))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementGeographicalAxis=country_US">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementGeographicalAxis=country_US</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementGeographicalAxis=country_CH">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementGeographicalAxis=country_CH</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementGeographicalAxis=country_BM">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementGeographicalAxis=country_BM</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementGeographicalAxis=roiv_OtherMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementGeographicalAxis=roiv_OtherMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>139
<FILENAME>R69.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm139997851490600">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes - Additional Information (Detail) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2021</div></th>
<th class="th"><div>Jun. 30, 2020</div></th>
<th class="th"><div>Mar. 31, 2021</div></th>
<th class="th"><div>Mar. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_roiv_IncomeTaxDisclosureLineItems', window );"><strong>Income Tax Disclosure [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateContinuingOperations', window );">Effective tax rate</a></td>
<td class="num">(0.10%)<span></span>
</td>
<td class="num">(18.10%)<span></span>
</td>
<td class="num">(0.19%)<span></span>
</td>
<td class="num">(1.27%)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsValuationAllowance', window );">Valuation allowance</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 303,287<span></span>
</td>
<td class="nump">$ 187,831<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount', window );">Valuation allowance increase (decrease)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">115,500<span></span>
</td>
<td class="nump">168,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_UnrecognizedTaxBenefits', window );">Unrecognized tax benefits</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_StateAndLocalJurisdictionMember', window );">United States and Local Jurisdiction [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_roiv_IncomeTaxDisclosureLineItems', window );"><strong>Income Tax Disclosure [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwards', window );">Net operating losses</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 69,700<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_RangeAxis=srt_MinimumMember', window );">Minimum | United States and Local Jurisdiction [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_roiv_IncomeTaxDisclosureLineItems', window );"><strong>Income Tax Disclosure [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwardsExpirationDate', window );">Net operating losses expiration date</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">Mar. 31,  2035<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_RangeAxis=srt_MaximumMember', window );">Maximum | United States and Local Jurisdiction [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_roiv_IncomeTaxDisclosureLineItems', window );"><strong>Income Tax Disclosure [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwardsExpirationDate', window );">Net operating losses expiration date</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">Mar. 31,  2041<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_StatementGeographicalAxis=country_CH', window );">Switzerland [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_roiv_IncomeTaxDisclosureLineItems', window );"><strong>Income Tax Disclosure [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwards', window );">Net operating losses</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,181,100<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_StatementGeographicalAxis=country_US', window );">United States [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_roiv_IncomeTaxDisclosureLineItems', window );"><strong>Income Tax Disclosure [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwards', window );">Net operating losses</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 122,200<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_roiv_PercentageOfFutureTaxableIncome', window );">Percentage of future taxable income</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">80.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TaxCreditCarryforwardAmount', window );">Research and development tax credit carryforwards</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 19,100<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_StatementGeographicalAxis=country_US', window );">United States [Member] | Minimum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_roiv_IncomeTaxDisclosureLineItems', window );"><strong>Income Tax Disclosure [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TaxCreditCarryforwardExpirationDate', window );">Research and development tax credit expiration date</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">Mar. 31,  2035<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_StatementGeographicalAxis=country_US', window );">United States [Member] | Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_roiv_IncomeTaxDisclosureLineItems', window );"><strong>Income Tax Disclosure [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TaxCreditCarryforwardExpirationDate', window );">Research and development tax credit expiration date</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">Mar. 31,  2041<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_StatementGeographicalAxis=country_GB', window );">United Kingdom [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_roiv_IncomeTaxDisclosureLineItems', window );"><strong>Income Tax Disclosure [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwards', window );">Net operating losses</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 28,600<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_StatementGeographicalAxis=roiv_TaxAuthorityInOtherJurisdictionsMember', window );">Other Jurisdictions [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_roiv_IncomeTaxDisclosureLineItems', window );"><strong>Income Tax Disclosure [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwards', window );">Net operating losses</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 75,800<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_roiv_IncomeTaxDisclosureLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Income Tax Disclosure [Line Items]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">roiv_IncomeTaxDisclosureLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>roiv_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_roiv_PercentageOfFutureTaxableIncome">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of future taxable income.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">roiv_PercentageOfFutureTaxableIncome</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>roiv_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsValuationAllowance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred tax assets for which it is more likely than not that a tax benefit will not be realized.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32537-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsValuationAllowance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateContinuingOperations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32687-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateContinuingOperations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLossCarryforwards">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of operating loss carryforward, before tax effects, available to reduce future taxable income under enacted tax laws.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32559-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLossCarryforwards</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLossCarryforwardsExpirationDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Expiration date of each operating loss carryforward included in operating loss carryforward, in YYYY-MM-DD format.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32559-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLossCarryforwardsExpirationDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TaxCreditCarryforwardAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of the tax credit carryforward, before tax effects, available to reduce future taxable income under enacted tax laws.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32559-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TaxCreditCarryforwardAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TaxCreditCarryforwardExpirationDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Expiration date of the tax credit carryforward, in YYYY-MM-DD format.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32559-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TaxCreditCarryforwardExpirationDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UnrecognizedTaxBenefits">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of unrecognized tax benefits.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10B<br> -URI http://asc.fasb.org/extlink&amp;oid=123427490&amp;loc=SL37586934-109318<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 15A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=SL6600010-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UnrecognizedTaxBenefits</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in the valuation allowance for a specified deferred tax asset.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32537-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_StateAndLocalJurisdictionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxAuthorityAxis=us-gaap_StateAndLocalJurisdictionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementGeographicalAxis=country_CH">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementGeographicalAxis=country_CH</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementGeographicalAxis=country_US">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementGeographicalAxis=country_US</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementGeographicalAxis=country_GB">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementGeographicalAxis=country_GB</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementGeographicalAxis=roiv_TaxAuthorityInOtherJurisdictionsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementGeographicalAxis=roiv_TaxAuthorityInOtherJurisdictionsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>140
<FILENAME>R70.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm139997754886008">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Income Taxes - Schedule of Deferred Tax Assets (Liabilities) (Detail) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Mar. 31, 2021</div></th>
<th class="th"><div>Mar. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsGrossAbstract', window );"><strong>Deferred tax assets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch', window );">Research tax credits</a></td>
<td class="nump">$ 19,063<span></span>
</td>
<td class="nump">$ 6,303<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsGoodwillAndIntangibleAssets', window );">Intangible assets</a></td>
<td class="nump">50,564<span></span>
</td>
<td class="nump">43,626<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards', window );">Net operating loss</a></td>
<td class="nump">202,906<span></span>
</td>
<td class="nump">116,619<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost', window );">Share-based compensation</a></td>
<td class="nump">26,623<span></span>
</td>
<td class="nump">18,413<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_roiv_DeferredTaxAssetsLeaseLiabilities', window );">Lease liabilities</a></td>
<td class="nump">16,638<span></span>
</td>
<td class="nump">17,194<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsOther', window );">Other</a></td>
<td class="nump">7,303<span></span>
</td>
<td class="nump">7,060<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsGross', window );">Subtotal</a></td>
<td class="nump">323,097<span></span>
</td>
<td class="nump">209,215<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsValuationAllowance', window );">Valuation allowance</a></td>
<td class="num">(303,287)<span></span>
</td>
<td class="num">(187,831)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxLiabilitiesAbstract', window );"><strong>Deferred tax liabilities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_roiv_DeferredTaxLiabilitiesDepreciation', window );">Depreciation</a></td>
<td class="num">(1,214)<span></span>
</td>
<td class="num">(1,833)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_roiv_DeferredTaxLiabilitiesRightOfUseAssets', window );">Right-of-use assets</a></td>
<td class="num">(13,908)<span></span>
</td>
<td class="num">(15,409)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxLiabilitiesOther', window );">Other</a></td>
<td class="num">(4,688)<span></span>
</td>
<td class="num">(4,142)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsLiabilitiesNet', window );">Net Deferred tax assets/(liabilities), net of valuation allowance</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_roiv_DeferredTaxAssetsLeaseLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Deferred tax assets lease liabilities</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">roiv_DeferredTaxAssetsLeaseLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>roiv_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_roiv_DeferredTaxLiabilitiesDepreciation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Deferred Tax Liabilities, Depreciation</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">roiv_DeferredTaxLiabilitiesDepreciation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>roiv_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_roiv_DeferredTaxLiabilitiesRightOfUseAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Deferred tax liabilities right of use assets</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">roiv_DeferredTaxLiabilitiesRightOfUseAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>roiv_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsGoodwillAndIntangibleAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from intangible assets including goodwill.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsGoodwillAndIntangibleAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences and carryforwards.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32537-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsGrossAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsGrossAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsLiabilitiesNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after allocation of valuation allowances and deferred tax liability, of deferred tax asset attributable to deductible differences and carryforwards, without jurisdictional netting.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32537-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsLiabilitiesNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible operating loss carryforwards.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32632-109319<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32621-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsOperatingLossCarryforwards</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsOther">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, before allocation of valuation allowance, of deferred tax asset attributable to deductible temporary differences, classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32621-109319<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32632-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsOther</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible research tax credit carryforwards.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32632-109319<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32559-109319<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32621-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from share-based compensation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32621-109319<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32632-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsValuationAllowance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred tax assets for which it is more likely than not that a tax benefit will not be realized.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32537-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsValuationAllowance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxLiabilitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxLiabilitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxLiabilitiesOther">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred tax liability attributable to taxable temporary differences classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32632-109319<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32621-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxLiabilitiesOther</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>141
<FILENAME>R71.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm139997750668248">
<tr>
<th class="tl" colspan="2" rowspan="2"><div style="width: 200px;"><strong>Income Taxes - Schedule of Effective Income Tax Rate Reconciliation (Detail) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2021</div></th>
<th class="th"><div>Jun. 30, 2020</div></th>
<th class="th"><div>Mar. 31, 2021</div></th>
<th class="th"><div>Mar. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxExpenseBenefitContinuingOperationsIncomeTaxReconciliationAbstract', window );"><strong>Effective Income Tax Rate Reconciliation, Amount [Abstract]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate', window );">Income tax benefit at Bermuda statutory rate</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxReconciliationForeignIncomeTaxRateDifferential', window );">Foreign rate differential</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(150,778)<span></span>
</td>
<td class="num">(74,922)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxReconciliationNondeductibleExpenseResearchAndDevelopment', window );">Permanent disallowed IPR&amp;D</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">111,432<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxReconciliationNondeductibleExpense', window );">Nondeductible changes in the fair value of investments and loss from equity method investment</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(22,472)<span></span>
</td>
<td class="nump">20,840<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxReconciliationDispositionOfBusiness', window );">Nontaxable (loss) gain on deconsolidation of business</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(16,438)<span></span>
</td>
<td class="nump">29,041<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_roiv_IncomeTaxReconciliationPermanentAdjustments', window );">Permanent adjustments</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,923<span></span>
</td>
<td class="num">(20,395)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxReconciliationTaxCreditsResearch', window );">R&amp;D tax credits</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(10,555)<span></span>
</td>
<td class="num">(5,990)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxReconciliationChangeInEnactedTaxRate', window );">Rate changes</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,443<span></span>
</td>
<td class="num">(29,238)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance', window );">Valuation allowance</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">85,046<span></span>
</td>
<td class="nump">87,677<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxReconciliationOtherAdjustments', window );">Other</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">85<span></span>
</td>
<td class="nump">111<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxExpenseBenefit', window );">Income tax provision</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">$ 93<span></span>
</td>
<td class="nump">$ 1,221<span></span>
</td>
<td class="nump">$ 1,686<span></span>
</td>
<td class="nump">$ 7,124<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract', window );"><strong>Effective Income Tax Rate Reconciliation, Percent [Abstract]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential', window );">Foreign rate differential(1)</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">16.78%<span></span>
</td>
<td class="nump">13.36%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseResearchAndDevelopment', window );">Permanent disallowed IPR&amp;D</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(12.40%)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpense', window );">Nondeductible changes in the fair value of investments and loss from equity method investment</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2.50%<span></span>
</td>
<td class="num">(3.72%)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationDispositionOfBusiness', window );">Nontaxable (loss) gain on deconsolidation of business</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1.83%<span></span>
</td>
<td class="num">(5.18%)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_roiv_EffectiveIncomeTaxReconciliationPermanentDifferences', window );">Permanent adjustments</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(0.33%)<span></span>
</td>
<td class="nump">3.64%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsResearch', window );">R&amp;D tax credits</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1.17%<span></span>
</td>
<td class="nump">1.07%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate', window );">Rate changes</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(0.27%)<span></span>
</td>
<td class="nump">5.21%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance', window );">Change in Valuation Allowance</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(9.46%)<span></span>
</td>
<td class="num">(15.63%)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments', window );">Other</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(0.01%)<span></span>
</td>
<td class="num">(0.02%)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateContinuingOperations', window );">Total income tax expense</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">(0.10%)<span></span>
</td>
<td class="num">(18.10%)<span></span>
</td>
<td class="num">(0.19%)<span></span>
</td>
<td class="num">(1.27%)<span></span>
</td>
</tr>
<tr><td colspan="5"></td></tr>
<tr><td colspan="5"><table class="outerFootnotes" width="100%"><tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[1]</td>
<td style="vertical-align: top;" valign="top">Primarily related to operations in Switzerland, the United Kingdom, and other jurisdictions with statutory tax rates different than the Bermuda rate.</td>
</tr></table></td></tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_roiv_EffectiveIncomeTaxReconciliationPermanentDifferences">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Effective Income Tax Reconciliation Permanent Differences</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">roiv_EffectiveIncomeTaxReconciliationPermanentDifferences</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>roiv_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_roiv_IncomeTaxReconciliationPermanentAdjustments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Income Tax Reconciliation Permanent Adjustments</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">roiv_IncomeTaxReconciliationPermanentAdjustments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>roiv_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateContinuingOperations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32687-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateContinuingOperations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to changes in the valuation allowance for deferred tax assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.4)<br> -URI http://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32687-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to changes in the income tax rates.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.4)<br> -URI http://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32687-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationDispositionOfBusiness">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to disposition of a business not qualifying as a discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.4)<br> -URI http://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32687-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationDispositionOfBusiness</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations applicable to statutory income tax expense (benefit) outside of the country of domicile.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32687-109319<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.4)<br> -URI http://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to nondeductible expenses.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32687-109319<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.4)<br> -URI http://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseResearchAndDevelopment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to research and development expense.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32687-109319<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.4)<br> -URI http://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseResearchAndDevelopment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to other adjustments.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32687-109319<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.4)<br> -URI http://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsResearch">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to research tax credit.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.4)<br> -URI http://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32687-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsResearch</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB TOPIC 6.I.7)<br> -URI http://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32672-109319<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (h)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 20<br> -Section 45<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123586238&amp;loc=d3e38679-109324<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(9))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxExpenseBenefitContinuingOperationsIncomeTaxReconciliationAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxExpenseBenefitContinuingOperationsIncomeTaxReconciliationAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to increase (decrease) in the valuation allowance for deferred tax assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32687-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxReconciliationChangeInEnactedTaxRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations, attributable to increase (decrease) in the income tax rates.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -URI http://asc.fasb.org/extlink&amp;oid=123427490&amp;loc=d3e32059-109318<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32687-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxReconciliationChangeInEnactedTaxRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxReconciliationDispositionOfBusiness">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to the disposition of a business not qualifying as a discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32687-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxReconciliationDispositionOfBusiness</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxReconciliationForeignIncomeTaxRateDifferential">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to foreign income tax expense (benefit).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32687-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxReconciliationForeignIncomeTaxRateDifferential</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of income tax expense or benefit for the period computed by applying the domestic federal statutory tax rates to pretax income from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32687-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxReconciliationNondeductibleExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to nondeductible expenses.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32687-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxReconciliationNondeductibleExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxReconciliationNondeductibleExpenseResearchAndDevelopment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to nondeductible research and development expense.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32687-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxReconciliationNondeductibleExpenseResearchAndDevelopment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxReconciliationOtherAdjustments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to other adjustments.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32687-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxReconciliationOtherAdjustments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxReconciliationTaxCreditsResearch">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to research tax credit.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32687-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxReconciliationTaxCreditsResearch</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>142
<FILENAME>R72.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm139997751056344">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Leases - Schedule of Maturities of Operating Lease Liabilities (Detail)<br> $ in Thousands</strong></div></th>
<th class="th">
<div>Mar. 31, 2021 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract', window );"><strong>Maturities of operating lease liabilities [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths', window );">2022</a></td>
<td class="nump">$ 13,386<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo', window );">2023</a></td>
<td class="nump">11,814<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree', window );">2024</a></td>
<td class="nump">11,718<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour', window );">2025</a></td>
<td class="nump">9,734<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive', window );">2026</a></td>
<td class="nump">8,617<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive', window );">Thereafter</a></td>
<td class="nump">51,674<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue', window );">Total lease payments</a></td>
<td class="nump">106,943<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_roiv_OperatingLeaseLiabilityPresentValueAdjustments', window );">Less: present value adjustment</a></td>
<td class="num">(29,348)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_roiv_LesseeOperatingLeaseLiabilityTenantImprovementAllowance', window );">Less: tenant improvement allowance</a></td>
<td class="num">(2,898)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiability', window );">Total</a></td>
<td class="nump">$ 74,697<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_roiv_LesseeOperatingLeaseLiabilityTenantImprovementAllowance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Lessee operating lease liability tenant improvement allowance..</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">roiv_LesseeOperatingLeaseLiabilityTenantImprovementAllowance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>roiv_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_roiv_OperatingLeaseLiabilityPresentValueAdjustments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Operating Lease Liability Present Value Adjustments</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">roiv_OperatingLeaseLiabilityPresentValueAdjustments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>roiv_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=123408670&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease due after fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=123408670&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=123408670&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=123408670&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=123408670&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=123408670&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=123408670&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>143
<FILENAME>R73.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm139997851160648">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Leases - Summary of Operating Lease ROU Assets and Operating Lease Liabilities (Detail) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2021</div></th>
<th class="th"><div>Jun. 30, 2020</div></th>
<th class="th"><div>Mar. 31, 2021</div></th>
<th class="th"><div>Mar. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LeasesAbstract', window );"><strong>Leases [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeasePayments', window );">Cash paid for operating lease liabilities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 8,830<span></span>
</td>
<td class="nump">$ 8,108<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability', window );">Operating lease ROU assets obtained in exchange for operating lease liabilities</a></td>
<td class="nump">$ 4,579<span></span>
</td>
<td class="nump">$ 555<span></span>
</td>
<td class="nump">$ 5,491<span></span>
</td>
<td class="nump">$ 56,025<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1', window );">Weighted average remaining lease term (in years)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">9 years 7 months 6 days<span></span>
</td>
<td class="text">10 years 2 months 12 days<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent', window );">Weighted average discount rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">7.10%<span></span>
</td>
<td class="nump">7.10%<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeasesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeasesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeasePayments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash outflow from operating lease, excluding payments to bring another asset to condition and location necessary for its intended use.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 5<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918643-209977<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=123408670&amp;loc=SL77918686-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeasePayments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average discount rate for operating lease calculated at point in time.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(4)<br> -URI http://asc.fasb.org/extlink&amp;oid=123408670&amp;loc=SL77918686-209980<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 55<br> -Paragraph 53<br> -URI http://asc.fasb.org/extlink&amp;oid=123414884&amp;loc=SL77918982-209971<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining lease term for operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 55<br> -Paragraph 53<br> -URI http://asc.fasb.org/extlink&amp;oid=123414884&amp;loc=SL77918982-209971<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=123408670&amp;loc=SL77918686-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase in right-of-use asset obtained in exchange for operating lease liability.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 55<br> -Paragraph 53<br> -URI http://asc.fasb.org/extlink&amp;oid=123414884&amp;loc=SL77918982-209971<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=123408670&amp;loc=SL77918686-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>144
<FILENAME>R74.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm139997746166856">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Leases - Schedule of Operating Lease Costs (Detail) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2021</div></th>
<th class="th"><div>Mar. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LeaseCostAbstract', window );"><strong>Lease, Cost [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseCost', window );">Operating lease cost</a></td>
<td class="nump">$ 11,931<span></span>
</td>
<td class="nump">$ 11,515<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShortTermLeaseCost', window );">Short-term lease cost</a></td>
<td class="nump">237<span></span>
</td>
<td class="nump">872<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_VariableLeaseCost', window );">Variable lease cost</a></td>
<td class="nump">704<span></span>
</td>
<td class="nump">379<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LeaseCost', window );">Total operating lease cost</a></td>
<td class="nump">$ 12,872<span></span>
</td>
<td class="nump">$ 12,766<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeaseCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lease cost recognized by lessee for lease contract.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=123408670&amp;loc=SL77918686-209980<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 55<br> -Paragraph 53<br> -URI http://asc.fasb.org/extlink&amp;oid=123414884&amp;loc=SL77918982-209971<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeaseCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeaseCostAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeaseCostAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of single lease cost, calculated by allocation of remaining cost of lease over remaining lease term. Includes, but is not limited to, single lease cost, after impairment of right-of-use asset, calculated by amortization of remaining right-of-use asset and accretion of lease liability.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 55<br> -Paragraph 53<br> -URI http://asc.fasb.org/extlink&amp;oid=123414884&amp;loc=SL77918982-209971<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123408670&amp;loc=SL77918686-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShortTermLeaseCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of short-term lease cost, excluding expense for lease with term of one month or less.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123408670&amp;loc=SL77918686-209980<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 55<br> -Paragraph 53<br> -URI http://asc.fasb.org/extlink&amp;oid=123414884&amp;loc=SL77918982-209971<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShortTermLeaseCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_VariableLeaseCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of variable lease cost, excluded from lease liability, recognized when obligation for payment is incurred for finance and operating leases.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=123408670&amp;loc=SL77918686-209980<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 55<br> -Paragraph 53<br> -URI http://asc.fasb.org/extlink&amp;oid=123414884&amp;loc=SL77918982-209971<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_VariableLeaseCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>145
<FILENAME>R75.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm139997750771656">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Fair Value Measurements - Schedule of Assets and Liabilities Measured at Fair Value on a Recurring Basis (Detail) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Jun. 30, 2021</div></th>
<th class="th"><div>Mar. 31, 2021</div></th>
<th class="th"><div>Mar. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentsFairValueDisclosure', window );">Investment</a></td>
<td class="nump">$ 180,359<span></span>
</td>
<td class="nump">$ 188,978<span></span>
</td>
<td class="nump">$ 93,445<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair Value, Recurring [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Assets held in Trust Account</a></td>
<td class="nump">1,521,021<span></span>
</td>
<td class="nump">1,609,575<span></span>
</td>
<td class="nump">1,968,107<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentFairValue', window );">Debt issued by Dermavant to NovaQuest</a></td>
<td class="nump">155,200<span></span>
</td>
<td class="nump">150,100<span></span>
</td>
<td class="nump">89,100<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentsNotDesignatedAsHedgingInstrumentsLiabilityAtFairValue', window );">Liability instruments measured at fair value</a></td>
<td class="nump">5,906<span></span>
</td>
<td class="nump">67,893<span></span>
</td>
<td class="nump">102,373<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesFairValueDisclosure', window );">Total liabilities at fair value</a></td>
<td class="nump">161,106<span></span>
</td>
<td class="nump">217,993<span></span>
</td>
<td class="nump">191,473<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair Value, Recurring [Member] | Fair Value, Inputs, Level 1 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Assets held in Trust Account</a></td>
<td class="nump">1,451,834<span></span>
</td>
<td class="nump">1,533,538<span></span>
</td>
<td class="nump">1,945,045<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair Value, Recurring [Member] | Fair Value, Inputs, Level 2 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Assets held in Trust Account</a></td>
<td class="nump">69,187<span></span>
</td>
<td class="nump">76,037<span></span>
</td>
<td class="nump">23,062<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair Value, Recurring [Member] | Fair Value, Inputs, Level 3 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentFairValue', window );">Debt issued by Dermavant to NovaQuest</a></td>
<td class="nump">155,200<span></span>
</td>
<td class="nump">150,100<span></span>
</td>
<td class="nump">89,100<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentsNotDesignatedAsHedgingInstrumentsLiabilityAtFairValue', window );">Liability instruments measured at fair value</a></td>
<td class="nump">5,906<span></span>
</td>
<td class="nump">67,893<span></span>
</td>
<td class="nump">102,373<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesFairValueDisclosure', window );">Total liabilities at fair value</a></td>
<td class="nump">161,106<span></span>
</td>
<td class="nump">217,993<span></span>
</td>
<td class="nump">191,473<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByAssetClassAxis=us-gaap_MoneyMarketFundsMember', window );">Money Market Funds [Member] | Fair Value, Recurring [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure', window );">Money market funds</a></td>
<td class="nump">1,340,662<span></span>
</td>
<td class="nump">1,420,597<span></span>
</td>
<td class="nump">1,874,662<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByAssetClassAxis=us-gaap_MoneyMarketFundsMember', window );">Money Market Funds [Member] | Fair Value, Recurring [Member] | Fair Value, Inputs, Level 1 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure', window );">Money market funds</a></td>
<td class="nump">1,340,662<span></span>
</td>
<td class="nump">1,420,597<span></span>
</td>
<td class="nump">1,874,662<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByAssetClassAxis=us-gaap_OtherInvestmentCompaniesMember', window );">Other Investment [Member] | Fair Value, Recurring [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentsFairValueDisclosure', window );">Investment</a></td>
<td class="nump">11,935<span></span>
</td>
<td class="nump">11,129<span></span>
</td>
<td class="nump">8,880<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByAssetClassAxis=us-gaap_OtherInvestmentCompaniesMember', window );">Other Investment [Member] | Fair Value, Recurring [Member] | Fair Value, Inputs, Level 1 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentsFairValueDisclosure', window );">Investment</a></td>
<td class="nump">11,935<span></span>
</td>
<td class="nump">11,129<span></span>
</td>
<td class="nump">8,880<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_LegalEntityAxis=roiv_SioGeneTherapiesIncMember', window );">Sio Gene Therapies Inc [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentsFairValueDisclosure', window );">Investment</a></td>
<td class="nump">50,700<span></span>
</td>
<td class="nump">48,500<span></span>
</td>
<td class="nump">45,300<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_LegalEntityAxis=roiv_SioGeneTherapiesIncMember', window );">Sio Gene Therapies Inc [Member] | Common Stock [Member] | Fair Value, Recurring [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentsFairValueDisclosure', window );">Investment</a></td>
<td class="nump">50,716<span></span>
</td>
<td class="nump">48,487<span></span>
</td>
<td class="nump">45,329<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_LegalEntityAxis=roiv_SioGeneTherapiesIncMember', window );">Sio Gene Therapies Inc [Member] | Common Stock [Member] | Fair Value, Recurring [Member] | Fair Value, Inputs, Level 1 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentsFairValueDisclosure', window );">Investment</a></td>
<td class="nump">50,716<span></span>
</td>
<td class="nump">48,487<span></span>
</td>
<td class="nump">45,329<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_LegalEntityAxis=roiv_ArbutusBiopharmaCorporationMember', window );">Arbutus Biopharma Corporation [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentsFairValueDisclosure', window );">Investment</a></td>
<td class="nump">117,700<span></span>
</td>
<td class="nump">129,400<span></span>
</td>
<td class="nump">39,200<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_LegalEntityAxis=roiv_ArbutusBiopharmaCorporationMember', window );">Arbutus Biopharma Corporation [Member] | Common Stock [Member] | Fair Value, Recurring [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentsFairValueDisclosure', window );">Investment</a></td>
<td class="nump">48,521<span></span>
</td>
<td class="nump">53,325<span></span>
</td>
<td class="nump">16,174<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_LegalEntityAxis=roiv_ArbutusBiopharmaCorporationMember', window );">Arbutus Biopharma Corporation [Member] | Common Stock [Member] | Fair Value, Recurring [Member] | Fair Value, Inputs, Level 1 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentsFairValueDisclosure', window );">Investment</a></td>
<td class="nump">48,521<span></span>
</td>
<td class="nump">53,325<span></span>
</td>
<td class="nump">16,174<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_LegalEntityAxis=roiv_ArbutusBiopharmaCorporationMember', window );">Arbutus Biopharma Corporation [Member] | Convertible Preferred Stock [Member] | Fair Value, Recurring [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentsFairValueDisclosure', window );">Investment</a></td>
<td class="nump">69,187<span></span>
</td>
<td class="nump">76,037<span></span>
</td>
<td class="nump">23,062<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_LegalEntityAxis=roiv_ArbutusBiopharmaCorporationMember', window );">Arbutus Biopharma Corporation [Member] | Convertible Preferred Stock [Member] | Fair Value, Recurring [Member] | Fair Value, Inputs, Level 2 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentsFairValueDisclosure', window );">Investment</a></td>
<td class="nump">$ 69,187<span></span>
</td>
<td class="nump">$ 76,037<span></span>
</td>
<td class="nump">$ 23,062<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsFairValueDisclosure">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value portion of probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123874694&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsFairValueDisclosure</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value portion of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsFairValueDisclosure</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value portion of debt instrument payable, including, but not limited to, notes payable and loans payable.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 55<br> -Paragraph 69C<br> -URI http://asc.fasb.org/extlink&amp;oid=123466577&amp;loc=SL123495737-112612<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 55<br> -Paragraph 69B<br> -URI http://asc.fasb.org/extlink&amp;oid=123466577&amp;loc=SL123495735-112612<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=123594938&amp;loc=d3e13433-108611<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1D<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495340-112611<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeInstrumentsNotDesignatedAsHedgingInstrumentsLiabilityAtFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value as of the balance sheet date of derivative instrument not designated as hedging instrument and classified as a liability.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4B<br> -Subparagraph (c)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=125515794&amp;loc=SL5624163-113959<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeInstrumentsNotDesignatedAsHedgingInstrumentsLiabilityAtFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentsFairValueDisclosure">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value portion of investment securities, including, but not limited to, marketable securities, derivative financial instruments, and investments accounted for under the equity method.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123874694&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentsFairValueDisclosure</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesFairValueDisclosure">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value of financial and nonfinancial obligations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123874694&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesFairValueDisclosure</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByAssetClassAxis=us-gaap_MoneyMarketFundsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByAssetClassAxis=us-gaap_MoneyMarketFundsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByAssetClassAxis=us-gaap_OtherInvestmentCompaniesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByAssetClassAxis=us-gaap_OtherInvestmentCompaniesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LegalEntityAxis=roiv_SioGeneTherapiesIncMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LegalEntityAxis=roiv_SioGeneTherapiesIncMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByAssetClassAxis=us-gaap_CommonStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByAssetClassAxis=us-gaap_CommonStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LegalEntityAxis=roiv_ArbutusBiopharmaCorporationMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LegalEntityAxis=roiv_ArbutusBiopharmaCorporationMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByAssetClassAxis=us-gaap_ConvertiblePreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByAssetClassAxis=us-gaap_ConvertiblePreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>146
<FILENAME>R76.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm139997756163192">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Fair Value Measurements - Additional Information (Detail)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th">
<div>Mar. 31, 2021 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Mar. 31, 2020 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Jun. 30, 2021 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_roiv_FairValueDisclosuresLineItems', window );"><strong>Fair Value Disclosures [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1', window );">Fair value of options</a></td>
<td class="nump">$ 25,711<span></span>
</td>
<td class="nump">$ 33,789<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_roiv_EquityInterestOptionToThirdPartyPurchaser', window );">Fair value of options</a></td>
<td class="nump">61,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 62,400<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BalanceSheetLocationAxis=roiv_LiabilityInstrumentsMeasuredAtFairValueMember', window );">Liability Instruments Measured At Fair Value [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_roiv_FairValueDisclosuresLineItems', window );"><strong>Fair Value Disclosures [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1', window );">Fair value of options</a></td>
<td class="nump">$ 62,400<span></span>
</td>
<td class="nump">$ 95,900<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_RangeAxis=srt_MinimumMember', window );">Minimum | Measurement Input, Discount Rate [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_roiv_FairValueDisclosuresLineItems', window );"><strong>Fair Value Disclosures [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentMeasurementInput', window );">Discount rate</a></td>
<td class="nump">0.06<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.11<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_RangeAxis=srt_MaximumMember', window );">Maximum | Measurement Input, Discount Rate [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_roiv_FairValueDisclosuresLineItems', window );"><strong>Fair Value Disclosures [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentMeasurementInput', window );">Discount rate</a></td>
<td class="nump">0.17<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.12<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_roiv_EquityInterestOptionToThirdPartyPurchaser">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Equity interest option to third party purchaser.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">roiv_EquityInterestOptionToThirdPartyPurchaser</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>roiv_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_roiv_FairValueDisclosuresLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair Value Disclosures [Line Items]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">roiv_FairValueDisclosuresLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>roiv_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentMeasurementInput">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Value of input used to measure debt instrument, including, but not limited to, convertible and non-convertible debt.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=123874694&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentMeasurementInput</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:decimalItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value of options vested. Excludes equity instruments other than options, for example, but not limited to, share units, stock appreciation rights, restricted stock.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BalanceSheetLocationAxis=roiv_LiabilityInstrumentsMeasuredAtFairValueMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BalanceSheetLocationAxis=roiv_LiabilityInstrumentsMeasuredAtFairValueMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputDiscountRateMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputDiscountRateMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>147
<FILENAME>R77.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm139997851246328">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Fair Value Measurements - Change in the Fair Value of the Derivative Warrant Liabilities (Detail) - Fair Value, Inputs, Level 3 [Member] - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2021</div></th>
<th class="th"><div>Jun. 30, 2020</div></th>
<th class="th"><div>Mar. 31, 2021</div></th>
<th class="th"><div>Mar. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue', window );">Balance at beginning of period</a></td>
<td class="nump">$ 217,993<span></span>
</td>
<td class="nump">$ 191,473<span></span>
</td>
<td class="nump">$ 191,473<span></span>
</td>
<td class="nump">$ 103,628<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings', window );">Changes in fair value of debt and liability instruments, included in net loss</a></td>
<td class="nump">4,585<span></span>
</td>
<td class="nump">17,125<span></span>
</td>
<td class="nump">29,845<span></span>
</td>
<td class="num">(13,722)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements', window );">Termination of DSP Options</a></td>
<td class="num">(61,472)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_roiv_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityDisposedDueToDeconsolidationOfSubsidiary', window );">Liability instruments disposed due to deconsolidation of subsidiary</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(3,325)<span></span>
</td>
<td class="num">(3,325)<span></span>
</td>
<td class="nump">101,567<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue', window );">Balance at end of period</a></td>
<td class="nump">$ 161,106<span></span>
</td>
<td class="nump">$ 205,273<span></span>
</td>
<td class="nump">$ 217,993<span></span>
</td>
<td class="nump">$ 191,473<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_roiv_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityDisposedDueToDeconsolidationOfSubsidiary">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, disposed due to deconsolidation of subsidiary.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">roiv_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityDisposedDueToDeconsolidationOfSubsidiary</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>roiv_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of gain (loss) recognized in income from liability measured at fair value on recurring basis using unobservable input (level 3).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=123874694&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of settlements of financial instrument classified as a liability measured using unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=123874694&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value of financial instrument classified as a liability measured using unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123874694&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>148
<FILENAME>R78.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm139997755169544">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Fair Value Measurements - Schedule of Fair Value of Unobservable Input Related To Options to Acquire Under Sumitomo Transaction Agreement (Detail)<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2021</div></th>
<th class="th"><div>Mar. 31, 2020</div></th>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputExpectedTermMember', window );">Measurement Input, Expected Term [Member] | Minimum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_roiv_AlternativeInvestmentExpectedTerm', window );">Time to expiration (in years)</a></td>
<td class="text">3 years 7 months 2 days<span></span>
</td>
<td class="text">5 months 26 days<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputExpectedTermMember', window );">Measurement Input, Expected Term [Member] | Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_roiv_AlternativeInvestmentExpectedTerm', window );">Time to expiration (in years)</a></td>
<td class="text">3 years 7 months 2 days<span></span>
</td>
<td class="text">4 years 7 months 2 days<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputRiskFreeInterestRateMember', window );">Risk-free rate | Minimum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AlternativeInvestmentMeasurementInput', window );">Investment</a></td>
<td class="nump">0.0052<span></span>
</td>
<td class="nump">0.0015<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputRiskFreeInterestRateMember', window );">Risk-free rate | Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AlternativeInvestmentMeasurementInput', window );">Investment</a></td>
<td class="nump">0.0052<span></span>
</td>
<td class="nump">0.0035<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputOptionVolatilityMember', window );">Measurement Input, Option Volatility [Member] | Minimum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AlternativeInvestmentMeasurementInput', window );">Investment</a></td>
<td class="nump">0.890<span></span>
</td>
<td class="nump">0.910<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputOptionVolatilityMember', window );">Measurement Input, Option Volatility [Member] | Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AlternativeInvestmentMeasurementInput', window );">Investment</a></td>
<td class="nump">0.950<span></span>
</td>
<td class="nump">1.100<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_roiv_AlternativeInvestmentExpectedTerm">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Alternative investment expected term.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">roiv_AlternativeInvestmentExpectedTerm</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>roiv_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AlternativeInvestmentMeasurementInput">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Value of input used to measure alternative investment.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=123874694&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AlternativeInvestmentMeasurementInput</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:decimalItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputExpectedTermMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputExpectedTermMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputRiskFreeInterestRateMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputRiskFreeInterestRateMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputOptionVolatilityMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputOptionVolatilityMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>149
<FILENAME>R79.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm139997755224232">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Defined Contribution Plan - Additional Information (Detail) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2021</div></th>
<th class="th"><div>Mar. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CompensationAndRetirementDisclosureAbstract', window );"><strong>Retirement Benefits [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedContributionPlanEmployerDiscretionaryContributionAmount', window );">Defined contribution plan, employer matching contribution</a></td>
<td class="nump">$ 1.7<span></span>
</td>
<td class="nump">$ 1.7<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CompensationAndRetirementDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CompensationAndRetirementDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedContributionPlanEmployerDiscretionaryContributionAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of discretionary contributions made by an employer to a defined contribution plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedContributionPlanEmployerDiscretionaryContributionAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>150
<FILENAME>R80.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm139997756281240">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Other (Income) Expense, Net - Summary of Other (Income) Expense, Net From Continuing Operations (Detail) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2021</div></th>
<th class="th"><div>Jun. 30, 2020</div></th>
<th class="th"><div>Mar. 31, 2021</div></th>
<th class="th"><div>Mar. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherIncomeAndExpensesAbstract', window );"><strong>Other (income) expense [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeLossFromEquityMethodInvestments', window );">Loss from equity method investment</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 3,750<span></span>
</td>
<td class="nump">$ 3,750<span></span>
</td>
<td class="nump">$ 21,386<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InterestIncomeOther', window );">Interest income</a></td>
<td class="num">(71)<span></span>
</td>
<td class="num">(621)<span></span>
</td>
<td class="num">(1,418)<span></span>
</td>
<td class="num">(17,990)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InterestExpense', window );">Interest expense</a></td>
<td class="nump">2,513<span></span>
</td>
<td class="nump">791<span></span>
</td>
<td class="nump">2,809<span></span>
</td>
<td class="nump">7,683<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_roiv_OtherIncomeExpense', window );">Other (expense) income</a></td>
<td class="num">(2,576)<span></span>
</td>
<td class="num">(1,078)<span></span>
</td>
<td class="nump">3,560<span></span>
</td>
<td class="nump">2,543<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherOperatingIncomeExpenseNet', window );">Total</a></td>
<td class="num">$ (134)<span></span>
</td>
<td class="nump">$ 2,842<span></span>
</td>
<td class="nump">$ 8,701<span></span>
</td>
<td class="nump">$ 13,622<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_roiv_OtherIncomeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Other Income Expense</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">roiv_OtherIncomeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>roiv_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromEquityMethodInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of income (loss) for proportionate share of equity method investee's income (loss).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(12))<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(10))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(13)(f))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (g)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=109237563&amp;loc=d3e33749-111570<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromEquityMethodInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of the cost of borrowed funds accounted for as interest expense.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6450988&amp;loc=d3e26243-108391<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=124435984&amp;loc=d3e28555-108399<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (210.5-03(11))<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04.9)<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestIncomeOther">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of interest income earned from interest bearing assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestIncomeOther</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherIncomeAndExpensesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherIncomeAndExpensesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherOperatingIncomeExpenseNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The net amount of other operating income and expenses, the components of which are not separately disclosed on the income statement, from items that are associated with the entity's normal revenue producing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherOperatingIncomeExpenseNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>151
<FILENAME>R81.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm139997755399704">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Net Loss per Common Share - Summary of Basic and Diluted Net Income Per Share of Common Stock (Detail) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2021</div></th>
<th class="th"><div>Mar. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareAbstract', window );"><strong>Earnings Per Share [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest', window );">Loss from continuing operations, net of tax</a></td>
<td class="num">$ (900,233)<span></span>
</td>
<td class="num">$ (568,110)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeLossFromContinuingOperationsAttributableToNoncontrollingEntity', window );">Net loss from continuing operations, net of tax, attributable to noncontrolling interest</a></td>
<td class="num">(90,999)<span></span>
</td>
<td class="num">(48,716)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeLossFromContinuingOperations', window );">Loss from continuing operations, net of tax, attributable to Roivant Sciences Ltd.</a></td>
<td class="num">(809,234)<span></span>
</td>
<td class="num">(519,394)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockDividendsAndOtherAdjustments', window );">Deemed dividend on repurchase of redeemable noncontrolling interest relating to subsidiary convertible and redeemable preferred stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(77,777)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_roiv_BasicAndDilutedLossFromContinuingOperationsNetOfTax', window );">Basic and diluted loss from continuing operations, net of tax, attributable to Roivant Sciences Ltd.</a></td>
<td class="num">(809,234)<span></span>
</td>
<td class="num">(597,171)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTax', window );">Income from discontinued operations, net of tax</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">1,578,426<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToNoncontrollingInterest', window );">Net loss from discontinued operations, net of tax, attributable to noncontrolling interest</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(141,477)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity', window );">Net income from discontinued operations, net of tax, attributable to Roivant Sciences Ltd.</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">1,719,903<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_roiv_BasicAndDilutedIncomeFromDiscontinuedOperationsNetOfTax', window );">Basic and diluted income from discontinued operations, net of tax</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,719,903<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_roiv_BasicAndDilutedNetLossIncome', window );">Basic and diluted net (loss) income attributable to Roivant Sciences</a></td>
<td class="num">$ (809,234)<span></span>
</td>
<td class="nump">$ 1,122,732<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_roiv_BasicAndDilutedIncomeFromDiscontinuedOperationsNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Basic and Diluted Income From Discontinued Operations, Net of Tax.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">roiv_BasicAndDilutedIncomeFromDiscontinuedOperationsNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>roiv_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_roiv_BasicAndDilutedLossFromContinuingOperationsNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Basic and Diluted Loss From Continuing Operations, Net of Tax.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">roiv_BasicAndDilutedLossFromContinuingOperationsNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>roiv_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_roiv_BasicAndDilutedNetLossIncome">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Basic and Diluted Net (Loss) Income.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">roiv_BasicAndDilutedNetLossIncome</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>roiv_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromContinuingOperations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after tax of income (loss) from continuing operations attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 18<br> -URI http://asc.fasb.org/extlink&amp;oid=123454820&amp;loc=SL4613673-111683<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=SL5780133-109256<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.13)<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromContinuingOperations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromContinuingOperationsAttributableToNoncontrollingEntity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after tax of income (loss) from continuing operations attributable to the noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -URI http://asc.fasb.org/extlink&amp;oid=123454820&amp;loc=SL4568447-111683<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 19<br> -URI http://asc.fasb.org/extlink&amp;oid=123454820&amp;loc=SL4569616-111683<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromContinuingOperationsAttributableToNoncontrollingEntity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after tax of income (loss) from continuing operations including portion attributable to the noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 13: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 19<br> -URI http://asc.fasb.org/extlink&amp;oid=123454820&amp;loc=SL4569616-111683<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123482062&amp;loc=SL123482106-238011<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 17: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8924-108599<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8906-108599<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after tax of income (loss) from a discontinued operation including the portion attributable to the noncontrolling interest. Includes, but is not limited to, the income (loss) from operations during the phase-out period, gain (loss) on disposal, gain (loss) for reversal of write-down (write-down) to fair value, less cost to sell, and adjustments to a prior period gain (loss) on disposal.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(12))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 45<br> -Paragraph 3B<br> -URI http://asc.fasb.org/extlink&amp;oid=109222160&amp;loc=SL51721525-107759<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 5C<br> -Subparagraph (b)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721675-107760<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 45<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=109222160&amp;loc=d3e957-107759<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=d3e1361-107760<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 45<br> -Paragraph 3A<br> -URI http://asc.fasb.org/extlink&amp;oid=109222160&amp;loc=SL51721523-107759<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 45<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=109222160&amp;loc=d3e1012-107759<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 270<br> -Section 45<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=109227538&amp;loc=d3e44648-109337<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after tax of income (loss) from a discontinued operation attributable to the noncontrolling interest. Includes, but is not limited to, the income (loss) from operations during the phase-out period, gain (loss) on disposal, gain (loss) for reversal of write-down (write-down) to fair value, less cost to sell, and adjustments to a prior period gain (loss) on disposal.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 45<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=109222160&amp;loc=d3e1012-107759<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -URI http://asc.fasb.org/extlink&amp;oid=123454820&amp;loc=SL4568447-111683<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 5B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721673-107760<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=d3e1361-107760<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 19<br> -URI http://asc.fasb.org/extlink&amp;oid=123454820&amp;loc=SL4569616-111683<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 5C<br> -Subparagraph (b)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721675-107760<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 45<br> -Paragraph 3B<br> -URI http://asc.fasb.org/extlink&amp;oid=109222160&amp;loc=SL51721525-107759<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 45<br> -Paragraph 3A<br> -URI http://asc.fasb.org/extlink&amp;oid=109222160&amp;loc=SL51721523-107759<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 45<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=109222160&amp;loc=d3e957-107759<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after tax of income (loss) from a discontinued operation attributable to the parent. Includes, but is not limited to, the income (loss) from operations during the phase-out period, gain (loss) on disposal, gain (loss) for reversal of write-down (write-down) to fair value, less cost to sell, and adjustments to a prior period gain (loss) on disposal.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 45<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=109222160&amp;loc=d3e957-107759<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 45<br> -Paragraph 3A<br> -URI http://asc.fasb.org/extlink&amp;oid=109222160&amp;loc=SL51721523-107759<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 45<br> -Paragraph 3B<br> -URI http://asc.fasb.org/extlink&amp;oid=109222160&amp;loc=SL51721525-107759<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=d3e1361-107760<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 5C<br> -Subparagraph (b)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721675-107760<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 5B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721673-107760<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 19<br> -URI http://asc.fasb.org/extlink&amp;oid=123454820&amp;loc=SL4569616-111683<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 45<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=109222160&amp;loc=d3e1012-107759<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockDividendsAndOtherAdjustments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate value of preferred stock dividends and other adjustments necessary to derive net income apportioned to common stockholders.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=d3e1377-109256<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockDividendsAndOtherAdjustments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>152
<FILENAME>R82.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm139997750768088">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Net Loss per Common Share - Summary of Basic and Diluted Net Income Per Share of Common Stock (Parenthetical) (Detail)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th">
<div>Mar. 31, 2020 </div>
<div>USD ($)</div>
</th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareAbstract', window );"><strong>Earnings Per Share [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockDividendsAndOtherAdjustments', window );">Deemed dividend on repurchase of redeemable noncontrolling interest relating to subsidiary convertible and redeemable preferred stock</a></td>
<td class="nump">$ 77,777<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockDividendsAndOtherAdjustments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate value of preferred stock dividends and other adjustments necessary to derive net income apportioned to common stockholders.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=d3e1377-109256<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockDividendsAndOtherAdjustments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>153
<FILENAME>R83.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm139997839031432">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Subsequent Events - Additional Information (Detail) - USD ($)<br> $ / shares in Units, $ in Thousands</strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1">1 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>May 14, 2021</div></th>
<th class="th"><div>May 01, 2021</div></th>
<th class="th"><div>Jul. 31, 2021</div></th>
<th class="th"><div>Jun. 30, 2021</div></th>
<th class="th"><div>May 31, 2021</div></th>
<th class="th"><div>Mar. 31, 2021</div></th>
<th class="th"><div>Mar. 31, 2020</div></th>
<th class="th"><div>May 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentFaceAmount', window );">Debt principal amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 20,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 20,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Interest rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentTerm', window );">Maturity date</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">5 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Warrants exercise price</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.01<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebtNoncurrent', window );">Long term debt</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 186,350<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">170,280<span></span>
</td>
<td class="nump">$ 108,592<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_roiv_SubscriptionsReceivable', window );">Subscription receivable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">100,000<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=roiv_DermavantSciencesLtdMember', window );">Dermavant Sciences Ltd [Member] | Subsequent Event [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightOutstanding', window );">Warrants issued to purchase common shares</a></td>
<td class="nump">1,199,072<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Warrants exercise price</a></td>
<td class="nump">$ 0.01<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=roiv_DermavantSciencesLtdMember', window );">Dermavant Sciences Ltd [Member] | Subsequent Event [Member] | Credit Facility [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentFaceAmount', window );">Debt principal amount</a></td>
<td class="nump">$ 40,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Interest rate</a></td>
<td class="nump">10.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentTerm', window );">Maturity date</a></td>
<td class="text">5 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=roiv_DermavantSciencesLtdMember', window );">Dermavant Sciences Ltd [Member] | Subsequent Event [Member] | Revenue Interest Purchase and Sale Agreement [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_roiv_RevenueInterestPurchaseAndSaleAgreementAmount', window );">Revenue interest purchase and sale agreement amount</a></td>
<td class="nump">$ 160,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_roiv_RevenueInterestPurchaseAndSaleAgreementCommittedFundToBePaid', window );">Revenue interest purchase and sale agreement committed fund to be paid</a></td>
<td class="nump">$ 160,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=roiv_DermavantSciencesLtdMember', window );">Dermavant Sciences Ltd [Member] | Subsequent Event [Member] | Revision of Prior Period, Reclassification, Adjustment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebtNoncurrent', window );">Long term debt</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3,100<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=roiv_SumitomoPharmaceuticalsCoLtdMember', window );">Sumitomo Pharmaceuticals (Suzhou) Co., Ltd. [Member] | Subsequent Event [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_roiv_BusinessAcquisitionCostOfAcquiredEntityAdjustmentPaidInCash', window );">Business combination, paid in cash</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 5,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=roiv_ProteovantSciencesIncMember', window );">ProteoVant Sciences, Inc [Member] | Subsequent Event [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_roiv_SubscriptionsReceivable', window );">Subscription receivable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquityMethodInvestments', window );">Equity Method Investments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 200,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquityMethodInvestmentOwnershipPercentage', window );">Equity Method Investment, Ownership Percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">40.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=roiv_DatavantMember', window );">Datavant [Member] | Subsequent Event [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationConsiderationTransferred1', window );">Business combination, consideration transferred</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 320,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_roiv_BusinessAcquisitionCostOfAcquiredEntityAdjustmentPaidInCash">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Business Acquisition Cost Of Acquired Entity Adjustment Paid In Cash</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">roiv_BusinessAcquisitionCostOfAcquiredEntityAdjustmentPaidInCash</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>roiv_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_roiv_RevenueInterestPurchaseAndSaleAgreementAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Revenue interest purchase and sale agreement amount.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">roiv_RevenueInterestPurchaseAndSaleAgreementAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>roiv_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_roiv_RevenueInterestPurchaseAndSaleAgreementCommittedFundToBePaid">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Revenue interest purchase and sale agreement committed fund to be paid.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">roiv_RevenueInterestPurchaseAndSaleAgreementCommittedFundToBePaid</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>roiv_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_roiv_SubscriptionsReceivable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Subscriptions receivable.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">roiv_SubscriptionsReceivable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>roiv_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationConsiderationTransferred1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of consideration transferred, consisting of acquisition-date fair value of assets transferred by the acquirer, liabilities incurred by the acquirer, and equity interest issued by the acquirer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 30<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=116859721&amp;loc=d3e6613-128477<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120321790&amp;loc=d3e6927-128479<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 30<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=116859721&amp;loc=d3e6578-128477<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationConsiderationTransferred1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Exercise price per share or per unit of warrants or rights outstanding.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21475-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of warrants or rights outstanding.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentFaceAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Face (par) amount of debt instrument at time of issuance.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495323-112611<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=124435984&amp;loc=d3e28551-108399<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 55<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=114775985&amp;loc=d3e28878-108400<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=124429444&amp;loc=SL124452920-239629<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 55<br> -Paragraph 69C<br> -URI http://asc.fasb.org/extlink&amp;oid=123466577&amp;loc=SL123495737-112612<br><br>Reference 6: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 55<br> -Paragraph 69B<br> -URI http://asc.fasb.org/extlink&amp;oid=123466577&amp;loc=SL123495735-112612<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentFaceAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentInterestRateStatedPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Contractual interest rate for funds borrowed, under the debt agreement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495323-112611<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.22(a)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentInterestRateStatedPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentTerm">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Period of time between issuance and maturity of debt instrument, in PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentTerm</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityMethodInvestmentOwnershipPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The percentage of ownership of common stock or equity participation in the investee accounted for under the equity method of accounting.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityMethodInvestmentOwnershipPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityMethodInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>This item represents the carrying amount on the entity's balance sheet of its investment in common stock of an equity method investee. This is not an indicator of the fair value of the investment, rather it is the initial cost adjusted for the entity's share of earnings and losses of the investee, adjusted for any distributions (dividends) and other than temporary impairment (OTTI) losses recognized.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=109237563&amp;loc=d3e33749-111570<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 25<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8813-108599<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.12)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityMethodInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebtNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after unamortized (discount) premium and debt issuance costs of long-term debt classified as noncurrent and excluding amounts to be repaid within one year or the normal operating cycle, if longer. Includes, but not limited to, notes payable, bonds payable, debentures, mortgage loans and commercial paper. Excludes capital lease obligations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.22)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebtNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=roiv_DermavantSciencesLtdMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=roiv_DermavantSciencesLtdMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=roiv_CreditFacilityMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=roiv_CreditFacilityMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=roiv_RevenueInterestPurchaseAndSaleAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=roiv_RevenueInterestPurchaseAndSaleAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RestatementAxis=srt_RevisionOfPriorPeriodReclassificationAdjustmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RestatementAxis=srt_RevisionOfPriorPeriodReclassificationAdjustmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionAxis=roiv_SumitomoPharmaceuticalsCoLtdMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionAxis=roiv_SumitomoPharmaceuticalsCoLtdMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionAxis=roiv_ProteovantSciencesIncMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionAxis=roiv_ProteovantSciencesIncMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionAxis=roiv_DatavantMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionAxis=roiv_DatavantMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EXCEL
<SEQUENCE>154
<FILENAME>Financial_Report.xlsx
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 Financial_Report.xlsx
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M01B>XG($1U/.@N2 .^$4'CB%7DYWHM>J+LV\,JPP)KL \?&3$THM&BXH29+
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MC#_MI&A7Q'-KU'55KI1(*]7'1=DX8MAF;4+"V"(>&X:1P%:DVS"$D,M=K#4
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M  P?(Q1;A6X %U(6&[$T!W 19R[R(EHQD,-+!<?7TRZ(K0\L3P$)P8FI\N8
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M>PPUM%6+*_9_. )BD![A5G4)@ U00Q>T%F'O=P3$; T24V'=L0-@+,+6)3L
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MBEJEAKNI#]KZNC38JZR5H]SU+?Q:0KG^>M'4:^AVN8[@4]=4Y3KOX<M=#W_
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MW03O>) K@:@2VQ.#Y9FZ%::C<>R;#U(#%32\XJ+MD;\LNVA[.-8XU,5T%19
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MQ&8+JO(!O)]9[ [-#1OH/F$>_P902P,$%     @ N8M=4^V%63$U(P  [)@
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MY&4X+:;;#X!"D,DX ;UPM8LL^H3CZ0#0-DM+D248E&,"$ 3"SR"UA]$X%9!
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MQ#!.>Y2*</$&7:A&0+$+;@A9%7+ $N[H2/0?VJ-QPD&V$,J:P%OP6O2*)D1
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M!L(K(\F;.CZ;%' 2TD3HI&EF8+LX%"998$@)1NM+L L,6#N6R+$M8$N_)H4
M>G0.TZ 2::5 -0C4#!XOJH92WS"#8 ] &17 GO%9CT5^Y^B)Q\@E%ZY:(PP\
MF'*P&T:U1"7[QHR4CXR3XG1'D?28TM# (ODZ'+B*_0+X?MF (]>YY+FF&&#F
M!MAI4&#%;ZDA<A%-&/U$@%P;*M&X##Q&G!D')&LJ!T-=)M,,ED$[1EZXIA?&
MUAUNY-I6R0^F-%2/D-8(P^LRFX9:95N%:6+!$V&+$O\7*!IY]7[YA1]TD7!X
MMN>OL'.EWM3%[B2 1C01*UB[695FHW)I#N8GC/4E,G6Z02Z[X, Y2(QC)',
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MQ1K.>LF>'VHH-#KH.D-D+U=YP8,>$&LLW\BAH-<5USY'P4>=0B42C)S;8MO
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ME/2@JZBVLJ"$JP8H@YB+J2C&YH0L+#HD^(=\AUZ6NR])Y9K'R 0;25*G6Y"
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M0Y*O P>70P7\0ID4&7?:2'4+GE#$.#E3 HHXW1%7,^J++=C[U.D9HI4<AWP
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MAI7FX9<O.OBB!VJAK%#S-#DG=RC]I&6PX7,ZG3 MXX2)8"+8W/-,$O]2:3Z
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MGZ:^HZL^XA-+B.!#+N''_3QUK:$5?$SK6K*,M]IFWNG?"*\E/>Y+XVWG#N*
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M2Y%N"F^_%3F.CH;/JUN1TT%T]GN^%:GG_]##-F.2['Q;VKW]R%O33Y!HTVW
MMZX!-J!3I[.M+QJG&Y+PCJ@$GK,&>.J(%&_8B[8-)++N 4 [_%+&]P:;OIL_
M;/WV G/^S/\DA0=%U(_P,XSZ;?VKERO_8X_#9GOXR0R"9L;M8DI3'!WT3XY[
MX:Z@>G Z][_D0"<' _J/<Y+()-Z ]:F&EN4#,ZA_"W3Y+U!+ P04    " "Y
MBUU3,3!3;8P$  "I#0  &0   'AL+W=O<FMS:&5E=',O<VAE970Q,RYX;6R]
M5]]OVS80?O=?07C!D !:+)'ZF3D!'+?%.JQKD&3=P[ '6CK;1"72(VD[W5^_
M(R4[3N"X+M;VQ3X>[TYWWYT^D<.UTA_-',"2AZ:6YK(_MW9Q,1B8<@X--^=J
M 1)WIDHWW.)2SP9FH8%7WJFI!S0,TT'#A>Q?#;WN1E\-U=+60L*-)F;9-%Q_
MNH9:K2_[47^CN!6SN76*P=5PP6=P!_:/Q8W&U6 ;I1(-2".4)!JFE_U1=#&.
MG;TW^"!@;79DXBJ9*/71+=Y6E_W0)00UE-9%X/BW@C'4M0N$:?S3Q>QO'^D<
M=^5-]#>^=JQEP@V,5?VGJ.S\LI_W2053OJSMK5K_ ET]B8M7JMKX7[+N;,,^
M*9?&JJ9SQ@P:(=M__M#A<(P#[1SHL0ZL<V"^T#8S7]8K;OG54*LUT<X:HSG!
M8^.]L1HA71?OK,9=@7[VZIK77)9 [OS(C%6S4!*D-<.!Q>C.9E!VD:[;2/2%
M2(R\4]+.#7DM*ZCV^(\/^T?T0( !EK6MC6YJNZ8'(_ZZE.>$A0&A(8WV)738
M_1W7Z![M<W^2#MM"S7P\]D*\]WK&I?B7N_$-$&II5"TJWDZSK,B-!H/0MPHU
M)6^$Q-8(7I,[5$+CVD+^&DV,U3C\?Q_(*-YF%/N,XJ_0_,.1?E<62/+C#SF-
MZ,\OA26GHS/RWLY!D_%2:U21D3& &ZVR[)2\57)+L(.P[: '"9M2SK==(26B
M*(R%R@&&0<A4U4A,0L[(J9"H44N#;N;LHO<TUM,X/<1^P45%X 'IT8 A)R2.
M@R*.4&!%D,1Q[U[S"I"X2A K/JG!!$1B>2R(HY1$44 I[;V5I6J 6/ZP8TBB
MH"@8_N8AZ[659D$>):A)\ZAWKRRV6.U#X(0D>1"EB1/B@"9A[_3ZC(S*4B^Q
MXM>;7#>*;?+?$[E;'%JO<<^H8(7?A84;U5TH:1ZP.'-"&&1)TG,C@7M^TG_2
M4'.[FWV4!#2FA.5!DE#LC)J"<1\-1,F 7HD2;1Z-TR#."Q*% 4VS#MT92-!H
M[3+B%9*F<*^,^USL^+$@BT)L!$MIUP+^',83DJ%5GCLA#0J6]D['SP?X-\$G
MHA96P/,IKG=VOF=#7L$4,(,*)W %<@EN@H,L<_ G01'ENT.ZX)_:"2T*=-[@
M%P>,)N@4LFSO=.Y6=D*PMZ%[30J<5+J/98]@CNRK,\<S<!W>*(1?@O*S$$^6
MX3[&:(D"!1Q*AHQQ^\@5^!A-5KS&=O *OVX>_=,/H_LSXJ/D8>:ZD^4]C\<.
M>73(X&X8AB^14$L_V+(T+5XD(:0?DC+:-3G/8D*#* X_0T">=UQQ.$0I.YZ
MOGD#CB(>SS=.0*[%^3Y,/"WC$(J3'+'/$H]G'&Q+Q)(OX!U/."2B"&9Z@'<\
MW:"0YD&*[_3_X)UOWH<]?.-YQO..2WX/WR#7X$#&Q89Q/-<0RN(C^,;SC'\(
M2^B^0]!@YS3<@)[Y2X+!@I?2M@?CK79[#QGYX_?@T;R]Q&"I,R$-J6&*KN%Y
MEO2);B\&[<*JA3];3Y3%D[H7YWB7 NT,<'^J\'7N%NX!V]O9U7]02P,$%
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MFO1B,76RT;?[\L07*:L@(%H/9*UMZ B-WKA/:;IG5II%(RLK\Z.:EC454H)
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MY[XM-2-2@AB,XQTIFG"D3HRB1JK[$ZTH*%(P5>:0*RKGAF85)&=9$1L"6[K
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M1&[3X#2VOFU^L>U<-KLV+&F_D9:*^B2,YC$\;C\5@V%O1-ES ]?FA^I2"_#
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M*>/?J^0JB+ECA&Y#"VUKVTKTFJYL-[!'=:>I2HHMZ9F>7CVT">0GGAF-?!M
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M9PR1D^2 K$N31_?B(5HY;&.R7%9<I)C#BPB7;*4)J,(*C1FL$VL"&MH1UV:
MJPO^>L5D3K5A=K$\HV!\-,X$D&*))H(^-@/M*'%V"M$V<' 2Z"H2MHOM+;L
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M9!B#@'"-T1&7>QP]8K&()0VU=:A ;%\45B-1E5#'$,'H+S27!$:'>L%G;FS
M%2%51\?>7?)7LD865'0A"LQ+&5.$\(@?\9 Y#KZ04Z%P4?)*V)*+.=T61<QS
M./VO+&91<6OJ1N@3*BLG#29"JA=CJG.4T-&1T0%?%/XKE9S3OTV_=#+W:P:5
M\+HY(*!N_1,PG X/Z&W_;HSJ_>L+<J5$ERH^PG0Q?_\V(=N_:/W&FR:^(@?C
M02TN*WP$L T*D!\-1M]Y$QP,GQ6;?P!02P,$%     @ N8M=4\FJX6J@!
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M1%W2 LROC''- VVP_RW\YE]02P,$%     @ N8M=4^@$NF,_!P  D!(  !D
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M5]CP_2/<>+/E;PY+X[W)^7*C9*HL;<#SE<$;<75#!IJ/4+=_ U!+ P04
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MMUD [Y<6''<W[* _83S[&U!+ P04    " "YBUU3^V@359T*  "?*0  &0
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M064VHRB-#HZ97)7D'<EX6(L5SI$>ZZEE*^E0"EFA=M)HL+@<13?I]63@XT/
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M&&)I"<>2M1RM#^#O2\,CMC=\@>[?8?P;4$L#!!0    ( +F+75,9!%-U 0,
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M?.*E'F0XYW5I+N7J+;;U#"S?3);:_<.J\8T3#V:U-K)JP91!58AFY ^M#H\
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M'B8##U3S!C0+(Y>NC=Y(0TW937-Z-E%9![+/)1UIN[ !NH=X^@M02P,$%
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M&(2G:ZVQ2VY$PB2N9_5Z4JX;MRX,O<\*"RD;/;)4W(L4>7F2X-9J,2HL'V7
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M)R67E=!.&LVLV-P,[F:O%Q>T/V[X+L7.]:X9>;(VY@?=?,AO!E,R2"B1>9+
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M05"\3D&3*.#/V1%+G!_;]0;6J)OD0ULG+UL+5 CRYAR_:C<6[A&B,QR0[.$
MN3Q^_/#R'']T-] 54FZ99J2VG(M+:G;X9._"W4XZ!IBZN@2J4"4,9._:U$NZ
M?>OJ"E1IE=MH7S3I%R"0^67JY! .^-KPT8E+6!5CM<!;1,0JI)F7Y@I)KC:7
M.6(B0)G5NQ')H+63ZS8S-T7*PBN=5QO5 -6^ZILXP2\*H0;_[169$Z2V7,&F
M2!D1M3._!)3+JCOR$._+'!2[RPHUEVU"WC]#I@/I-)<I+ ;RQA0+!CO=0D/
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M =63!"QZPB)ZYIC-)D!DX18"!L353(T\G__FY!(HR?,V0QYDQ@9*)F) B[:
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M7X5+<LRJ!_\12EH27I2)#6HR1HH.D.HP3715@=5V*?%TKSNVUBS:H@MI/K.
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M]0MT8%8[NI9.7XH&HD%N#!>%CON^*::H&U;%-5XA;%&;%<;E<BO61BF;-I0
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MD&\A2@F)Y:Z3=3$@_MCM3I-.D_-<,YWBT(L>R7S%/@) RMSM9#O1AK.^DW#
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MGIQ6^(X<46#(H6=D"M"^%* \I_DFT3WHD@V3RUI37O3Q:>=O*^G>5*>EA:+
M)VI/&O59YYX"<0 VC1D^4K^I+$]P!-%PX/<'4><*!>D53H)E5$W<YM:V!0C#
ML9\D@\Z#-"0@7^!#G S\.!YU/DFMFV!W:.FVMW#<N:)&"-1N*+=H0U[4FM)
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MI"2W/%T),I802TLTONR2L9<G1ON)7/*).!M".$M1/HCA^<>%T$[E^2,14B6
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MCC9@?:&460_(P.;Y?OD/4$L#!!0    ( +F+75,>&</3" 0  .4)   9
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MT01JMB;9'N"L!0C> / #N!1<%PI^YSGF+P$FY$WG4O#DTEDPB'C)Y!A"WX7
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MVR?@Q=0;?;7MF&RP>\(D?(GFBGK&MCPVB7HTI^,89N,8?&\<O-;,2Y6)+==
MOB$D8Q]^WG\'N!IW7(W?W4@NF:9"V&@/4/=_N#ELYE2U!OHI<^D>Z1L<)-A[
M6XQ1?]%C[,D.W3"-S2PTS23U(S..S#CQ4S.>PLQ-0KL<$X%B/QE1/Z17QIKJ
M!%/?C9-HWT9:YQKV6-L^Z7NQ.XO"T04J=0+VX%&I[EFU)8?S?^D&-7+P(9BY
M893"\5Y0(V>T7-:-%/=H19@)C?$,2=A-9T:VM7@$2>3&L^10N2>]J[=&N;$/
M# 66,.TMW*UV;YC3]NI^%F\?0)2V3<D5!;@F56^<4+N1[:.BG6C1V(M\)30]
M"^RPH'<82B- ^VLA]-/$&.A>=LO_ %!+ P04    " "YBUU3P70MVM@&  !U
M%P  &0   'AL+W=O<FMS:&5E=',O<VAE970S-BYX;6S56%MSVC@4?O>OT+#;
MG61&!5^QG=M,FK2[V6FVV81VGP466!/;HI),RK_?(]D8 X8P[?9A'\#'DL[]
MG$^2+UZX>)8II0I]R[-"7O92I>9G@X&<I#0GLL_GM("9*1<Y4? J9@,Y%Y0D
MABG/!JYM#P<Y847OZL*,/8BK"UZJC!7T02!9YCD1RW<TXR^7/:>W&GADLU3I
M@<'5Q9S,Z!-5G^</ MX&C92$Y;20C!=(T.EE[]HYNPGT>K/@"Z,OLD4C[<F8
M\V?]<I=<]FQM$,WH1&D)!!X+>D.S3 L",[[6,GN-2LW8IE?2/QC?P9<QD?2&
M9_^P1*67O:B'$CHE9:8>^<L?M/;'&#CAF33_Z*5>:_?0I)2*YS4S6)"SHGJ2
M;W4<CF%P:P;W6 :O9O",HY5EQJU;HLC5A> O2.C5($T3)C:&&[QAA<[BDQ(P
MRX!/77T@3* O)"LINJ=$EH)"BI1$)R,RSJ@\O1@HT*+7#B:UQ'>51'>/1 _=
M\T*E$KTO$IIT\-\<YG?< P(&X%[CH[OR\9U[4.*?9=%'GHV1:[M.ET&'V>^)
M ':GBWW#'*\)N6?D^7OD/4$G)F5&$9^B:RDI1)L4"?K(R)AE3#$J5ZE($%&H
ME2%=]NB13DHA6#%#[XADLBM!A_6/4HJF/(/^U4*4SC,R5@ FJ!0IF+[A^9P4
MR]]^B5PG/ ?[UF9F+3-5"O8105'>LG>J[5VL[16-O6-M+\C2CD-.:),3(QC"
M/$F;.&,T7J*,+FB&H2-4R@IC6$MXRJC0+$MT8B9Y*4&,/#VSKCLT5&.;.JR/
M6CYR4/5TZZ<'@<U(,:':U->76%4.SRRH6KJ$WA3/ +[3$FQ!OR('>[Z-AT,7
M:!-.]WR#:L\[V'=M',3AWK7UO'57+*A4NE,1^/[$.)KP/(=PRQ32(5%@X] 9
M-JRK9SWL1]B/PIW9:GA+]K48EZJ46_)A:0!![9"@AP,/>VZPJ]T,[Y4/PT(Q
M78RP'4VIT.54JUM)&,;8:1F^]1H.L>UMOUJ?H&P$:&J4.@Z.O5WKZF%X.&[<
M-0O#UH@KDC7=L%'K)CV!@R//![HV;3-[$!NL:]'0G@>_".C:[,VE0SO&01A8
M+5 XLV[I&&(F90F1@>ZXI;"-+0BXI#CZBR_(WR7XN*]V@@##SKY!=:^SL5.O
M,U1CPA*"*)4HJ_UA3\?OY!S']K#^WYX;ACB*O?I1A[:-+MOQ[31W"(D!V6VJ
M:QW &(Y!64-U;0/_ ]C<!# C&0C[Q]%R2W#'H'T,7 +34:M> \TC@=#04>@?
M!-AZ_E70/ B+R \ O7:!H1H^"C0/PB+4+W9"?Q=XS/"/@&8G+#:OKH=MB-WF
MZPYHRL.XB"(<1?;.I!E]#3./ T)#QQ!LV]=T;?7FTG@8 0*$'9B9TFP+,763
M'(&96UBX9UT4UY,5\6.(N8&*N_&V7>R%WNKYG:BY@X;[ A!#IX7>FCIP^O6;
MTZ]_].FW?;2=HL\%'TLJ%@99[XIYJ>"LFQ$%(1MQ]&FNKWU2[W77DZ\E _C\
M#/<#@9[*G,$MB:.1((4DU>WP>B:HN<ETX?QA T>;P F&:2CE:_6D5M^%^*Q0
M5.B*@BYMJ@VCWVE!*^KC4O**NJ>JGKU9*C.&'J!Q]8"&]2=65(,G<,4SEUZ
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M<VAE971S+W-H965T,S@N>&ULQ5;;;N,V$'WW5Q!J4-B 8%U\D9W8!C;9733
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M"X0!Z/T-Y^IY8AI>?R%F_P!02P,$%     @ N8M=4UG%QI+T @  H@H  !D
M  !X;"]W;W)K<VAE971S+W-H965T-#(N>&ULO59-3^,P$/TK5DZ[$DOB] M0
M6XGRH44"J:)B]X#VX":3UL*Q@^U0^/<[=MJDJZ4IA\*EL1W/FS=OTID9KI1^
M,DL 2UYS(<TH6%I;G(6A29:0,W.L"I#X)E,Z9Q:W>A&:0@-+O5$NPCB*^F'.
MN S&0W\VU>.A*JW@$J::F#+/F7Z;@%"K44"#S<$]7RRM.PC'PX(M8 ;VH9AJ
MW(4U2LISD(8K231DH^"<GDWHP!GX&[\XK,S6FKA0YDH]N<U-.@HBQP@$)-9!
M,'R\P 4(X9"0Q_,:-*A].L/M]0;]V@>/P<R9@0LE?O/4+D?!24!2R%@I[+U:
M_81U0#V'ERAA_"]9K>]& 4E*8U6^-D8&.9?5D[VNA=@RZ/5W&,1K@]CSKAQY
MEI?,LO%0JQ71[C:BN84/U5LC.2Y=5F96XUN.=G8\J[)!5$9F?"%YQA,F+3E/
M$E5*R^6"3)7@"0=#?I 9?A-I*<#=OC*6HRB0D@<#62G(+:IKR+=+L(R+[\/0
M(COG(TS63"85DW@'$QJ3.R7MTI KF4+Z+T"(8=6QQ9O8)G$KXAW3QZ1#CT@<
MQ;0%KU-KU?%XW1UX%RHO2@N:/-Y!/@?]IP6S6V-V/69G!^94XQ],V[<C,A5.
M>"93<O5<\@*_?$L>;_$ZN;&0FS9GO=I9KS6 )F=EE3/A<O9>JMIQ.N0-F#8M
MC/HUHWX[HR;4_9H.:M#!YVMZ4CL[.9"F[3B]O9J>UHQ.6Y&N2RVY+37XP*_Y
MJUN;CPA,HZ9J1)\O,=TJ4O1 (N\!&NQ5F<8-J;@5:Z8RNV(H\T>4;6H,[7R!
MLDWYH=U#*=L.M+\FT*9,T?;Z<@O89Y=*I.0F+[1Z 1?[Q[[@IO#0_A?HW)0D
M.CB4SNU MV ,MB#LP/ _9(:M6>.PY,8QU[N%$Y)@R\K?"R+<&AMRT L_'!GB
M.W\U0=2G]0!V7HT=S?5J>L-6N^#2H,,,3:/C 2985P-1M;&J\$/(7%D<:?QR
MB4,D:'<!WV=*V<W&.:C'TO%?4$L#!!0    ( +F+75,7L=T)7P<   ,F   9
M    >&PO=V]R:W-H965T<R]S:&5E=#0S+GAM;*U:;6_;-A#^*X2Q 2V0VB*I
M%VM( B1.:B=9L&)IMP_%/C 68PN51)>BDW;8CQ\I*Z8L412;YDMBV<\=[\B[
M>WBDCI\8_U*N*17@6YX5Y<EH+<3FM\FD7*YI3LHQV]!"_O+ >$Z$?.2K2;GA
ME"254)Y-D.>%DYRDQ>CTN/KN S\]9EN1I07]P$&YS7/"OY_3C#V=C.#H^8L_
MT]5:J"\FI\<;LJ)W5'S:?.#R:;+7DJ0Y+<J4%8#3AY/1&?SMQ@^50(7X*Z5/
M9>,S4*[<,_9%/5PE)R-/640SNA1*!9'_'NF,9IG2).WX6BL=[<=4@LW/S]K?
M5\Y+9^Y)26<L^SM-Q/ID-!V!A#Z0;2;^9$\+6CL4*'U+EI757_!48[T16&Y+
MP?):6%J0I\7N/_E63T1# /H] J@60*X"N!; K@)^+>"["@2U0. J$-8"H:M
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MLF[>E/FZ_J7;+"_+/*U?KDC(RET^@/U]D3-*-F_XC^>Z'Q0?_Q]02P,$%
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M5 !^O $<)Y+MS)FX8E*=L&:X59<FX!J@UM=,?=#U1!^SS35L^A]02P,$%
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M7(UE$%9_EM0#04M][JZID*>XOMW*+SG$%$"^SR@5^X$ZRMMOP]D_4$L#!!0
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M50_]!J-[1)A$3R1.K1.97Q_&<1#XMJ&L$#WH*H&'+:(?+5J'(^SRJ:JTOGM
M=Y$(_0M%99G&1 NY17<,RHX6O%'6^E4E]H-7(5E52_T3M90\9[4T9Q>29@:%
MD0\EI3]KLLWJO>T4YM=GYU[/ZUNIUT3TT(FJ9OHG:J90BLVAX8HH4C3K"++:
MFKHK:,/T"H4B2<P4 ;E5BEB='-0L'PYM3+QI(GGH8E6^??=4?H*)T\J7ES&Q
M*N_^Z%4._E7![KH+]O]C8J'\\!R*;<>0FT:BN1.=O:]]YAOV'9PU&5<HIA%@
MO?8 E,C\LW!^H\4Z^P X%UJ+)+M<40(#B!& ]Y$0>G=COBF6'^<G_P%02P,$
M%     @ N8M=4UBUZA6  @  E@8  !D   !X;"]W;W)K<VAE971S+W-H965T
M-3$N>&ULC95M3]LP$,>_BA4A#20@3TT?4!L)J- FC:FBL&F:]L)M+HV%8V>V
MT])OO[,;HFZ$EC>-S[G__?[7.)?Q1JIG70 8\E)RH2=>84QUY?MZ64!)]:6L
M0."=7*J2&@S5RM>5 IHY4<G]* CZ?DF9\-*QVYNI="QKPYF F2*Z+DNJMC?
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MFV,8A?'H?YJ_-V;LQ,:W<\6$)AQRU 67 RR@=E-P%QA9N<FSD ;GF%L6^.$
M91/P?BYQO#2!'6;MIRC]"U!+ P04    " "YBUU3;PB4)0X,  #M/0  &0
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M0E?!Y16*5>4P*3=&;ERW7$J#O=<M,YR_H*P!WJ^D-+N-=5!/]-%?4$L#!!0
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MQ%W^]!NK)T24O3!/2OT_>*IEO1X(EZ7(TUI9>I#&6?67?J\#L:8@[=@54*V
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MV>!#+%[H\2^2$W*5O36-N?X+CKFL-0#K Q<TR94E@B1*L__X/0]$14'::59
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M(#??L/'C!*:RT.X7-DULX$&ZTD:6#9@4E%S43_;:U&$'$%X= 40-(-H'=(\
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MEULQX@*5!N+YFA!^OI$;5$/SY!]02P,$%     @ N8M=4UUX+FPJ P  ]0D
M !D   !X;"]W;W)K<VAE971S+W-H965T-C N>&ULK99M;]HP$,>_RBG:BTVB
MS0/EH1,@0?;4:9U0JW4OIKTPY +6$CNS#:S??F<G9*&#E$E[0V+G_N??W1F?
M1SNI?N@UHH%?>2;TV%L;4[SV?;U<8\[TI2Q0T)=4JIP9&JJ5KPN%+'&B//.C
M(.C[.>/"FXS<W%Q-1G)C,BYPKD!O\IRIQQEF<C?V0F\_<<=7:V,G_,FH8"N\
M1_.EF"L:^;67A.<H-)<"%*9C;QJ^CD,G<!8/''>Z\0XVE(64/^S@)AE[@27"
M#)?&NF#TV&*,668]$<?/RJE7KVF%S?>]]W<N> IFP33&,OO*$[,>>T,/$DS9
M)C-W<O<!JX!ZUM]29MK]PJZR#3Q8;K21>24F@IR+\LE^58EH",C/<4%4":*G
M@OX)0;<2=%V@)9D+ZPTS;#)2<@?*6I,W^^)RX]04#1>VC/=&T5=..C.Y7S.%
M%S-*1 *QS&EW:.;R>P'W965!IA"SHB"#!Y9M$*8%;9@E+\U<W36\?(.&\>P5
MR>*'Z9V&;[>8+U!]IXDH"'OP]F;>G'L!/FB[M![YAL*P,/ZR0IZ5R-$)Y"[<
M2F'6&MZ*!),C^KA='T8M#GS*7YW$:)_$6=3J\>-&7$(WZ%"H47@,J%U^RQ3)
MPV/R YQN7=.N\]=MK>GB[YI.E6)BA?0O-+!XA*;=G#VZZ>F.J02^?2*7<&,P
MU]];@*YJH"L'='4"Z+,4%UO4AM99L(R))79@@2LN!!>K8QN@=-=W[NQ!M)V$
M83 <]GO#D;]M)O8,PP/B7DW<:R5^3XDR1S?7K/?7DL$3J#:+ YI^3=-OI:$#
M*T5^@J?_+$^;Q0'/H.89_',]420GBCDXMYAG&![@#FO<X;FX&\&-[L!LO_GV
M_,>X2Z>#!DYT&0R>,#]C=,![7?->M_)^=;V':-D6%?526-G=" DS""GC"K;V
M'.[ Z4T:7Y];\C#XTRB"_T*5MFS6N%KC'+!&!PO_J;S0L0=[>W'CRN<SA?,;
MC35'M7+W#0U+N1&F[+'U;'VGF;I.[O\Q+R]$=,C3GM.084K2X') IX0J[QCE
MP,C"M>F%--3TW>N:[F6HK %]3Z4T^X%=H+[I37X#4$L#!!0    ( +F+75,[
MGIL/%0,  ,X)   9    >&PO=V]R:W-H965T<R]S:&5E=#8Q+GAM;*666V_:
M,!3'OXH5[6&3*+D  2I @G273NN$BKH]5'TPR8%$36QF&VB__8Z=D(86 E5Y
M(+%S_B>_<XGMP9:+1QD#*/*4I4P.K5BIU:5MRS"&C,HF7P'#)PLN,JIP*):V
M7 F@D1%EJ>TYCF]G-&'6:&#FIF(TX&N5)@RF@LAUEE'Q/(&4;X>6:^TF;I-E
MK/2$/1JLZ!)FH.Y64X$CN_02)1DPF7!&!"R&UMB]#%PC,!9_$MC*RCW1H<PY
M?]2#ZVAH.9H(4@B5=D'QLH$ TE1[0HY_A5.K?*<65N]WWK^9X#&8.940\/1O
M$JEX:/4L$L&"KE-UR[<_H BHH_V%/)7FGVP+6\<BX5HJGA5B),@2EE_I4Y&(
MB@#]'!9XA<![+?"/"%J%H&4"S<E,6%=4T=% \"T1VAJ]Z1N3&Z/&:!*FRSA3
M I\FJ%.C64P%7$PP$1$)>(;=(:G)[P69Y94E?$&F($S'L!#(+4@EDE"A8*9X
M^$CN6*(D^7P%BB;I%Q3N6<_NR/T-9',0#_AHI<?3E++JY"=B$ZDYY,!6&),F
ML\."?Y+S>T?X6^2&,Q5+\I5%$!W0!_5ZUZMQ8&,RRXQZNXQ.O%J//]>L25I.
M@WB.YQX"JI??4(%R]Y!\#Z=5%KAE_+5J"SQ_6^"Q$)0M 3])1>;/I&HWI<]F
M>KRE(B+WO] EN5:0R8<:H'8)U#9 [2- OSF[V& /X7OF--5-TB!S6":,)6QY
MJ %R=[YQIU>ES0C7*/P-[$TUK0?,?+_7[I1F>[2=DK932YLW]W=,E3K87I/.
MF]>^!JNSV&/R2R;_#"9<Q1:0'*'R3U*]M;BH25>W1.N^N[C HB.5[9Y7V9-F
M>ZB]$K5W+NI:)[1!)KLNW+$?8LZ==BLP;JO9]UXAG[+:(^Z7Q/T/]6+0/[?3
M7.=E>W ^V&M!X:%W7K!N96=RWU4@TM!K='UY@L+GJ<S;E1TS [$T!PE)0KYF
M*M\\R]GRL#(V6[3]8IZ?='#!QK:1)(4%2IUF%[]WD1\>\H'B*[/_SKG"W=S<
MQGC@ J$-\/F"<[4;Z!>41[C1?U!+ P04    " "YBUU3"M08X!H#  !$"@
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M\,\&*+L WV^E-*<;2]#^?5G]#5!+ P04    " "YBUU3SP'5_(D"  #'!0
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M'?!PO&?_XKV3EQ4S.%/B)\_L>A0, L@P9Y6P]VKW%1L_5XXO5<+X7]@UL5$
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MQLDO.F2Q;@NM]K$240;6"B+&TW_ZFA7B&@#) .0$H&]<#_ R@'<*:)\!M#-
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MA%6@-5D5UHIJNIQ+<4+26ALU^U#EIO(VT;#2?L:UEF:6&3^]?"@S40#Z3E]
MH0E:FVVR/7) 8H=6L ,I86LGT4>E0"MT\Y71#>-,,U"WZ&8%FC)^:QQ_K%?H
MYMTM>H=8B;[GXJAHN55S7QM&NY*?-3R?:IY@@.<;E7<H).]1@ /B<+]_NSN^
M=O=-9MKT!&UZ@DHO'-!K<Z!-#FB5@Q'5L%4-*]5H0/4)%%"9Y95J9N195[9.
M5:T25RKV/#XOR0PGX=Q_OLQ(WRH)\=GHBC!J":-1PH=2TW+/-F8GN**N\6J)
MY&+A&,=)U,'K6T5A$B1NOKCEBT?Y_C$%SI0R234K]X@+Y02,>TN;;6$RV"'L
MFQ&2)&3F1DQ:Q&04<9U3"1-;8K;(G#%3=Q6UE<L%FO1!DR3H?NB^%4DC,O"E
MIRWF=!3S*QA"Q,_'VL4W[:^<)&':X7-83<DL<O.E+5\ZRO>OSD&ZF-+>:M/+
M;5\C.8QP@MU$LY9H-OYACQLM-.4NJ%EOO3 (\6S:P>J;!7@6D-@-1O"YF.-1
MM)^4'VE]/7)S0=,R V<)QKWU)R9W0=KE=!F2=)J&9(#TXMHA;R^L@[OO6OQ<
MM$DPFH85F)8F8X/'K7&_#BL@W<KE-$O#@0-'SM6?_*7\V]9B(G:3HQHKKXW*
M]?+A#'>/G=,NCO! _2+G.X",7P*#1X_T:_HD2M(>F,N,1,$ U[GVD[\7?\?%
M[-]<[*/;]ZBT=\0./;_Q3,2]:Q1WXQDSJ6/Q+SHQVP:;?F3/2H4X[(P/OIL:
M9UEWEO5 BT/5G&V$-JU>]9B;;ARD-3#S.R'TZ\#V>VU_O_P#4$L#!!0    (
M +F+75,-VULNY04  *X8   9    >&PO=V]R:W-H965T<R]S:&5E=#<Q+GAM
M;+U9;6_;-A#^*X31#@Z0R"+U9F=)@+PX6#9T"Y*V^U#T V/1-EM)=$DJ+_OU
M.\J*Y<@4Y0'%OL26=,_QN>/IGC-S\B3D=[5D3*/G/"O4Z6"I]>IX-%*S)<NI
M\L2*%?!D+F1.-5S*Q4BM)*-I!<JS$?']>)137@S.3JI[M_+L1)0ZXP6[E4B5
M>4[ERP7+Q-/I  ]>;]SQQ5*;&Z.SDQ5=L'NF/ZUN)5R--EY2GK-"<5$@R>:G
M@W-\?$T2 Z@L/G/VI+:^(Q/*@Q#?S<5->CKP#2.6L9DV+BA\/+)+EF7&$_#X
M43L=;-8TP.WOK]ZOJ^ AF >JV*7(_N:I7IX.Q@.4LCDM,WTGGGYC=4"1\3<3
MF:K^HJ?:UA^@6:FTR&LP,,AYL?ZDSW4B]@&0&D!: %C8#@AJ0- &A!V L :$
M;4#< 8AJ0+3O"G$-B*O<KY-59?J*:GIV(L43DL8:O)DOU795:$@P+TQEW6L)
M3SG@]-E-,1,Y0Q_I,U/H"-U#Y:9EQI"8H^E\SJI]1XT1NJ.:H3LV$\6,9YQ6
MU3&\8IKR[ #PG^ZOT/#= 7J'>($^+D6I:)&JDY$&JF;!T:RF=;FF13IH!>B#
M*/12H6F1LM2"G[KQF#@<C"!'FT21UT1=$J?'W\O"0X%_B(A/L(70U?YPWQ:/
M&_Z!2H#CSM6O]X?[CF0$FZH)*G]!A[]]2^,0G>>B+#3Z<OZ@M(0V\M6Q>KA9
M/:Q6#]TUJV'-!U:P.=>(:G3!9%ZF%"E-=:F%?$$2"-E2O?8>5=Y-YWT\@YP\
M;F?39?&&<K2A'#DI0Q>$'E=4E%#*(7V2%9K3S,+OPNWJ"_YJ"VH-BK<H'^'(
M3Y)Q*S2+71)."+''%V_BBYVD;B'YM("0(#A%,] KEJ*;V[M?:+[Z]<K&-][A
M@3$.@PX>R89'XN3QIS"O>PFU^0!-;+:DQ0+Z&O0BO61H3KE$CS0KJ_;&BT>F
M-(BD5@B:%,J$4F@N18[8CY+K%Y0SO13IEITMC&0WG82$"6EE?=>,^..PHZC&
MFV#'?<'".T!-I$/#_@ M8)1 T)%3\Q8JD?%TW:$AW(=2 5S9>O%T;*F=. S:
MI;-K1B9^B.U!3#9!3/:L')I^*^L-L9&<6%8G08OBKM$1\8-)9.>(_48E?2?+
MNI"KGC.3+.5VCK67MYGTHRAJT;3919-)1SW@+3'';IJFO=15;^6'=Y,8ANTD
M6JR.3*[''?1(0X\XZ7V&=V]=D%6+H,7,VI]K+]OKCR,_C-LT+69)G"0=+!MM
MPX&3Y5_0*Z255V#AU2:U:P-]K8-2(WAX;\5;2?'(S5QO':IVA6O2VMTKBPTF
M!+^UFMJLXO'.%NQ:)9B$'>$V8HFCGS1>0/>8L7WG"]RH&7;+6:=<#_&!3;%[
MW'5(=@\*QUXR?F\;]OJ @1?$[UV):.04N_7TO^MZC\,A)E[HOS]PL6OT#_<*
MX/^K]CU\B!?Y]@USXX:!EQ!W3AHYQ6X]_6E#0<\ZV!L']EC=N&'DX;$S5M*H
M,G&K\MZS0X^?H>\%09M3_;O*C0R\.'2]::21;M(CW?M-&#U>L(<3ZZ[TXOPV
M[FT<C<83M\;WC2 ]<-@*DG1LA1L9>00[0V@& .(> "XK]J:/- /+N6M@Z?$W
MG'AAW!%3#Q)'7KQ3F6_#:H8(XAXB.N>:'AQLB8\[Z/<CW7V--#,!<?_L_2@T
MS6!/-H,0>UZQ0MGVX[+'%=#".Q)4'^+T(/&X"SK=8]%)1Q;[%K6\$F^S: :;
MMW<:A2=N0;;/)A<]J%O)<RIY]H(DR^"-3Y$62*R8K-Z62H/OG[C^A\D,U/:P
M$N1/!3>&?_!BD8K\L))A86H2?2LE5RF?K;& 6VZ=XIB]-G.8:@8Q<$?7(O]Z
MZ&,,/%N&1EM'HSF3B^H06Z&9.95:']]L[FX.RB^JX^'6_4M\?(4M]Z?X^-IV
M_YS$QU,26YY ;N%)=18_:BBM3_(_4+G@D(.,S8&>[R50&G)].+Z^T&)5'>8^
M"*U%7GU=,IHR:0S@^5P(_7IA%MC\B^+L7U!+ P04    " "YBUU3?N.)4M,"
M   L"   &0   'AL+W=O<FMS:&5E=',O<VAE970W,BYX;6R-EEUOFS 4AO^*
MA7K12EO!0/BHDDC]T+1)K58U[78Q[<()3O!J,+--TO[['0.E;#');H*-?<[S
MOAC.R70GY+/**=7HI>"EFCFYUM6%ZZI53@NBSD5%2UA9"UD0#5.Y<54E*<F:
MH(*[ON=%;D%8Z<RGS;U[.9^*6G-6TGN)5%T41+Y>42YV,P<[;S<>V";7YH8[
MGU9D0Q=4/U7W$F9NGR5C!2T5$R62=#US+O'%%?9-0+/C&Z,[-1@C8V4IQ+.9
M?,EFCF<444Y7VJ0@<-G2:\JYR00Z?G=)G9YI H?CM^R?&O-@9DD4O1;\.\MT
M/G,2!V5T36JN'\3N,^T,34R^E>"J^46[;J_GH%6MM"BZ8%!0L+*]DI?N00P"
M?#P2X'<!S8-P6U"C\H9H,I]*L4/2[(9L9M!8;:)!'"O-J2RTA%4&<7I^2\&2
M0A_1 LX[JSE%8HWNB*XETPP68/:UHI)H5FY0LQG=,K)DO%T^O:&:,'Z&3A K
MT6,N:D7*3$U=#=H,P5UU.JY:'?Z(CCLBSU& /R#?\_'3X@:=GIS]G<4%9[T]
MO[?G-VF#T;1#)Z)WPALG?.#DQ^52:0DOR<\#V*#'!@TV',&""=_V#-JH21-E
MOI?M' =!$DW=K046]K#P&"RPP=JH: C#"0[ML$D/FQR#A3;8Q *+<6*'13TL
M.@:;V&#1'BR-@Q%C<<^*C[$B&RO>8R41CNVLI&<E!UF/.84*NM94VHC)'G&"
MHWC$7MHCT\-(H0GO7ON*O$)=U=:O--T_1R]*P\!.Q]Y[F?$.\F^I4A<(&H<"
M,MH27E-$LE]0X(P4:[WP]J1\]-,@''FG\*#BX?^0HFE)0 DK*BFVU(A A$./
M(N6*6N5@BYPD'5/S7J"P?_Q@K$!_KUC$893^^^JY@]IO^B@4T@TK%1SU&N*\
M\Q@2R+8UM1,MJJ8=+(6&YM(,<VCG5)H-L+X60K]-3(?I_R#,_P!02P,$%
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ML^Y+]7![-6,<^Y2U+  ).:6<MG$#"0/&G3[B8,-,;(?F"38@1]G P ^S0=K
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M@;( _+Z1TAPF=H.^<9S]#U!+ P04    " "YBUU39)5!RJL#   ;#P  &0
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M/I>F>T5I!<SZ7 B]'5@#93\\^ -02P,$%     @ N8M=4UF4\^U. @  3 4
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MNYN F>;M-@+JVH__2B,])G\L:=V!<09TO]8:#X)ST"W0[!502P,$%     @
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M^O=]9*6J7KP:&+ER[>Q<&FR.W6V&WR^@K $^7TAIM@/[@N:+:/P?4$L#!!0
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M#%UPX/.-M73<A OZA['X U!+ P04    " "YBUU35RBX[2$%  !;%0  &0
M 'AL+W=O<FMS:&5E=',O<VAE970X,RYX;6RU6-MNXS80_17"V ()X,:B?%\D
M!N(XMV*#&NMF]Z'H RV-;78ET2$I>U/TXSN4%$F))5I%=E]L77B&A\/#,Z3.
M]T)^4QL 3;Z'0:0N6ANMMQ\['>5M(&3J3&PAPC<K(4.F\5:N.VHK@?D)* PZ
MKN,,.B'C46MRGCR;R\FYB'7 (YA+HN(P9/)Y"H'87[1HZ^7!9[[>:/.@,SG?
MLC4L0#]NYQ+O.GD4GX<0*2XB(F%UT;JD'^_=H0$D+;YPV*O2-3%#60KQS=S<
M^Q<MQS"" #QM0C#\V\$5!(&)A#R>LJ"MO$\#+%^_1+])!H^#63(%5R+XRGV]
MN6B-6L2'%8L#_5GL[R ;4-_$\T2@DE^RS]HZ+>+%2HLP R.#D$?I/_N>):($
MH-T:@)L!W*: ;@;HO@7T:@"]#-!K"NAG@'Y32H,,,&C:PS ##)L"1AE@U)32
M. .,$SFD\Y=,_HQI-CF78D^D:8W1S$6BH 2-<\XC(_:%EOB6(TY/%O%2P5,,
MD2;7._Q5Y%=RZ?O<*)$%Y#Y*UY/1Y<D,-./!*;9X7,S(R8=3\H%TB-HP"8KP
MB#Q&7*LV/L3K/S8B5BSRU7E'(TW36<?+*$U32FX-I0?V3&BO35S'I17HJ^-H
MA]:B9W;T;W%P1KKU\.MC\ CA3BW\YCAW2^>WQ]#2ROVN.=RI@-\WY4['K]$=
ME&2N2S?7I9N$Z]6$F\%2DZWDD<>WJ$,6BCC253E)P_23,,;9=Q/T>0<'L"MS
M/];J%<=NSK%KY7@?:4#I:R*9ABJEVN'4.7.<7RRYZN4\>M9 #TS'DNMGXM?P
ML,/[Y!F85!8B_9Q(WQKI*Y.2&0^![R ]KL#,H%=%Z28--"Q-"&:#5L_'(.]^
M8.W^DXC6!*<DQ&JWK!++]>! !G0TZ/;?J.4V;38H-QLZ[NA-L[N*:,ZH/W:K
M1S',1S&TCL(XLB?Y5J?;"0_XCBV#JB1>#RL('(K_=G@XG(IF=X?1:M;'*!_)
MZ,@:QM*Q0T&0A<<A\K!*?-(^^?,!PB7(O\B_Y&WUR=]9Q#C.>Q\W$R-7*@:?
M:$&VL?0VN#,BG@A#S&Y:NJHJU/@P970\=H8U<TN=HMPZ/VB)3+-(S=8(+15\
M^K-F!=]=2<#- ;EA'@^,Y328,%IX/OTQIC^EAW[>J_=S6A@Z?9^C3X_@CUHZ
M+3R=OL_4IT?PQUV=%K9.[;[^/LE\!GP2 \F3.W]9AK@_) L6 +E<2X"PH0'0
MHAY0>T%XZ9F_]+PM]ZQ,SRSOV:*V"J,?6.16.#VU6_W_XF<\BVN-3K:*H\3.
MEF@>C/N5E"M*@XUR8>GTIWEZ*@6>')/%BLPE%Y+, ?_\-K[Q J847W$O.6VT
M\13R-QY_S-!M6BBJ ;67@Z.;@]LL0#EG75J7,;=P?-?N^(L8ITV$@LRQVH3,
M@UCC& -%3A;Q/WA*.B57XJQMLGCVWM+H%D7 M1>!::SPB5)&54L>92DW:C*'
M-X^I3=4^,@M:SE"_5E-N::MOM_VY%!K$E[*HVN@6WKO34?B^:_?MYGNN61;)
MLNEZS:$P?-=NV-=/L;'[!] ;X>/P=Y"JOVI_,LMB'1QHZE@45N_:K;Z.19O\
MOH] J@W?FC7KX2.VKDZ0O8/>L1+I%O;NVNW=?/!(K.B].BD,V[4;=O6R\42D
MN \R_4RB<7^G5B!QHU29GD-G[E:=13NE;SKFLR,>S]<\4B2 %0*=LR%&D.F7
MO/1&BVWRF6<I--I-<KD!AK1, WR_$KC*LAOSY2C_GCKY#U!+ P04    " "Y
MBUU3P>4E=D(#  #P$P  #0   'AL+W-T>6QE<RYX;6S=6-%NVC 4_97(G:96
MFAH@:TI60-J0*DW:IDKE86^5(0Y8<IS,,1WT<=^SK]J7S-<."5!?U/5AHPLJ
ML>_).??8OJG=#BJ]%NQVP9@.5KF0U9 LM"[?A6$U6["<5N=%R:1!LD+E5)NN
MFH=5J1A-*R#E(NQU.G&84R[):""7^76NJV!6+*4>DK@)!>[V,1V2;OR6!$YN
M7*1L2.Y.7W];%OKJ5>#N)V].3CIW9U?[\5,+G)'0*WKQ!-'S#JYK,$PZ]DO_
M^O$3<=PBASU?/LGS <N8<']7>#- ._S3MH?1$X2^P[;DL%[QT2 K9+OP$7$!
MHTYS%MQ3,21C*OA4<6!E-.=B[<(]",P*4:A FXHSZ;H0J1X<W'4]*,9:)^>R
M4#:WR^"^I_7C>\"F!P:Y$(W!'G&!T:"D6C,EKTW'/FR#CZ"@;D_6I7$X5W3=
M[5V0EF!O)LFT4"E339HNV81& \$RL*/X? %W790A@%H7N6FDG,X+2:V'#:-N
M&-D9$^(6WM2OV8[V*MM:MPZLFFR:QE#==#*N _K;:DY[6S9ZEFY0\OM"?UB:
MX4C;ASIE-XIE?&7[JZPQ@*EW<75:EF+]7O"YS)D;_),3C@9TPPL6A>(/)AN4
MRLP$F"+!/5.:S[8CWQ4M)VRE-^6TRG#/O1?H^>_.\YQ)IJC8-FUJ_YAG^=F.
MZZWM7WBVOU;V'7M-1I?'[['>SH_;9)0<O\?Z\'+L)E]$2?9?@LGCK,FP/F1L
MG61VSC%--(#SXI!\@=.G:),&TR47FLNZM^!IRN2CXXR1UW1J_IS9T3?/IRRC
M2Z$G#3@D;?LS2_DR3YJG;F BZJ?:]B<87C=N#JLF%Y<I6[%T7'?5?&J;@6F8
MK/4%A'WDVEY^!.,XS(\ AN7!'& <Q\+R_$_CZ:/C<1CFK>]%^BBGCW(<RX>,
M[0?+X^<DYO*/-$FB*(ZQ&1V/O0[&V+S%,?SXU3!OP,#R0*8_FVM\M?$*.5P'
MV)H>JA!LI'@E8B/%YQH0_[P!(TG\JXWE 0:V"ECM0'Y_'J@I/R>*8%4Q;]@;
MC"-)@B%0B_X:C6-D=F+X^-<'>TNB*$G\"&!^!U&$(? VX@CF #Q@2!39?7!O
M/PHW^U38_H]O]!M02P,$%     @ N8M=4Y>*NQS     $P(   L   !?<F5L
M<R\N<F5L<YV2N6[#, Q ?\70GC 'T"&(,V7Q%@3Y 5:B#]@2!8I%G;^OVJ5Q
MD L9>3T\$MP>:4#M.*2VBZD8_1!2:5K5N %(MB6/:<Z10J[4+!XUA]) 1-MC
M0[!:+#Y +AEFM[UD%J=SI%>(7->=I3W;+T]!;X"O.DQQ0FE(2S,.\,W2?S+W
M\PPU1>5*(Y5;&GC3Y?YVX$G1H2)8%II%R=.B':5_'<?VD-/IKV,BM'I;Z/EQ
M:%0*CMQC)8QQ8K3^-8+)#^Q^ %!+ P04    " "YBUU3?C#*/O\%  #T-@
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M)^VBS753EF=AVT=S965Q]Z>MNS^<O?X?4$L#!!0    ( +F+75,T3CM]>@(
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M,^J="?3.J'<FT#NCWIE ;T>]G4!O1[V=0&]'O9U ;T>]G4!O1[V=0&]'O9U
M;Y_\;$*@MZ/>3J"WH]Y.H+>CWDZ@=Z#>0:!WH-Y!H'>@WD&@=Z#>0:!WH-Y!
MH'>@WD&@=Z#>0:!W3'X6)- [4.\@T#M0[R#0NT&]&P*]&]2[(="[0;T; KT;
MU+OY3KV'\?-0AEO/UQJO_YU4CY=SR^WRU^77SLFM<L6YOJ\8GO\"4$L#!!0
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MV?(/_9M?4$L! A0#%     @ N8M=4P=!36*!    L0   !
M ( !     &1O8U!R;W!S+V%P<"YX;6Q02P$"% ,4    " "YBUU3C9@8\>X
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M=V]R:W-H965T<R]S:&5E=#(N>&UL4$L! A0#%     @ N8M=4QOHZ3:^ @
M6 @  !@              ("!>1(  'AL+W=O<FMS:&5E=',O<VAE970S+GAM
M;%!+ 0(4 Q0    ( +F+75.H-E:+A@<  !PA   8              " @6T5
M  !X;"]W;W)K<VAE971S+W-H965T-"YX;6Q02P$"% ,4    " "YBUU3>+3]
M%K(#   Q#   &               @($I'0  >&PO=V]R:W-H965T<R]S:&5E
M=#4N>&UL4$L! A0#%     @ N8M=4[6I57):"P  FSX  !@
M ("!$2$  'AL+W=O<FMS:&5E=',O<VAE970V+GAM;%!+ 0(4 Q0    ( +F+
M75,C<-B>00P  )@X   8              " @:$L  !X;"]W;W)K<VAE971S
M+W-H965T-RYX;6Q02P$"% ,4    " "YBUU3O]3Q*$D'  #.'   &
M        @($8.0  >&PO=V]R:W-H965T<R]S:&5E=#@N>&UL4$L! A0#%
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M+GAM;%!+ 0(4 Q0    ( +F+75,Q,%-MC 0  *D-   9              "
M@1&)  !X;"]W;W)K<VAE971S+W-H965T,3,N>&UL4$L! A0#%     @ N8M=
M4P\6B6[P"   ;1D  !D              ("!U(T  'AL+W=O<FMS:&5E=',O
M<VAE970Q-"YX;6Q02P$"% ,4    " "YBUU3NL$A[ $-  "%)@  &0
M        @('[E@  >&PO=V]R:W-H965T<R]S:&5E=#$U+GAM;%!+ 0(4 Q0
M   ( +F+75.L76=J2@X  +U    9              " @3.D  !X;"]W;W)K
M<VAE971S+W-H965T,38N>&UL4$L! A0#%     @ N8M=4SI&SPNB P  8@@
M !D              ("!M+(  'AL+W=O<FMS:&5E=',O<VAE970Q-RYX;6Q0
M2P$"% ,4    " "YBUU3R:KA:J $  "M"P  &0              @(&-M@
M>&PO=V]R:W-H965T<R]S:&5E=#$X+GAM;%!+ 0(4 Q0    ( +F+75,+4"F"
MZPH  !<?   9              " @62[  !X;"]W;W)K<VAE971S+W-H965T
M,3DN>&UL4$L! A0#%     @ N8M=4^@$NF,_!P  D!(  !D
M ("!AL8  'AL+W=O<FMS:&5E=',O<VAE970R,"YX;6Q02P$"% ,4    " "Y
MBUU3+ <7"8$%  !M%   &0              @('\S0  >&PO=V]R:W-H965T
M<R]S:&5E=#(Q+GAM;%!+ 0(4 Q0    ( +F+75/[:!-5G0H  )\I   9
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M970R-BYX;6Q02P$"% ,4    " "YBUU3U,-!S-HD   >I   &0
M    @(&>\@  >&PO=V]R:W-H965T<R]S:&5E=#(W+GAM;%!+ 0(4 Q0    (
M +F+75.*R,T"UP,  )$*   9              " @:\7 0!X;"]W;W)K<VAE
M971S+W-H965T,C@N>&UL4$L! A0#%     @ N8M=4QG/B[\\!   0 H  !D
M             ("!O1L! 'AL+W=O<FMS:&5E=',O<VAE970R.2YX;6Q02P$"
M% ,4    " "YBUU3>Z7F\Z$$  !A#@  &0              @($P( $ >&PO
M=V]R:W-H965T<R]S:&5E=#,P+GAM;%!+ 0(4 Q0    ( +F+75,FVO8([0,
M /X)   9              " @0@E 0!X;"]W;W)K<VAE971S+W-H965T,S$N
M>&UL4$L! A0#%     @ N8M=4VC[8@R9 @  BP4  !D              ("!
M+"D! 'AL+W=O<FMS:&5E=',O<VAE970S,BYX;6Q02P$"% ,4    " "YBUU3
MH("Z8;H'  #\'@  &0              @('\*P$ >&PO=V]R:W-H965T<R]S
M:&5E=#,S+GAM;%!+ 0(4 Q0    ( +F+75.;5VB%D08  ,H/   9
M      " @>TS 0!X;"]W;W)K<VAE971S+W-H965T,S0N>&UL4$L! A0#%
M  @ N8M=4QX9P],(!   Y0D  !D              ("!M3H! 'AL+W=O<FMS
M:&5E=',O<VAE970S-2YX;6Q02P$"% ,4    " "YBUU3P70MVM@&  !U%P
M&0              @('T/@$ >&PO=V]R:W-H965T<R]S:&5E=#,V+GAM;%!+
M 0(4 Q0    ( +F+75-8(KX#"P,  '@'   9              " @0-& 0!X
M;"]W;W)K<VAE971S+W-H965T,S<N>&UL4$L! A0#%     @ N8M=4\.;OWQ*
M!   (0L  !D              ("!14D! 'AL+W=O<FMS:&5E=',O<VAE970S
M."YX;6Q02P$"% ,4    " "YBUU3"BIJ*(T#   ("P  &0
M@('&30$ >&PO=V]R:W-H965T<R]S:&5E=#,Y+GAM;%!+ 0(4 Q0    ( +F+
M75.@]RL=-P(   ,%   9              " @8I1 0!X;"]W;W)K<VAE971S
M+W-H965T-# N>&UL4$L! A0#%     @ N8M=4W+FGK2H @  ' <  !D
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M=#0U+GAM;%!+ 0(4 Q0    ( +F+75,54!JZ*P,  )()   9
M  " @2YS 0!X;"]W;W)K<VAE971S+W-H965T-#8N>&UL4$L! A0#%     @
MN8M=4\!!7>XR P  I@L  !D              ("!D'8! 'AL+W=O<FMS:&5E
M=',O<VAE970T-RYX;6Q02P$"% ,4    " "YBUU3XQ=<0K<"  !Y!P  &0
M            @('Y>0$ >&PO=V]R:W-H965T<R]S:&5E=#0X+GAM;%!+ 0(4
M Q0    ( +F+75/!<#98'@,  "<*   9              " @>=\ 0!X;"]W
M;W)K<VAE971S+W-H965T-#DN>&UL4$L! A0#%     @ N8M=4Q(]<>V8!0
MJ!<  !D              ("!/( ! 'AL+W=O<FMS:&5E=',O<VAE970U,"YX
M;6Q02P$"% ,4    " "YBUU36+7J%8 "  "6!@  &0              @($+
MA@$ >&PO=V]R:W-H965T<R]S:&5E=#4Q+GAM;%!+ 0(4 Q0    ( +F+75-O
M")0E#@P  .T]   9              " @<*( 0!X;"]W;W)K<VAE971S+W-H
M965T-3(N>&UL4$L! A0#%     @ N8M=4\51\_'F @  W0<  !D
M     ("!!Y4! 'AL+W=O<FMS:&5E=',O<VAE970U,RYX;6Q02P$"% ,4
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M+GAM;%!+ 0(4 Q0    ( +F+75,X4ENM6@,   8*   9              "
M@4JK 0!X;"]W;W)K<VAE971S+W-H965T-3@N>&UL4$L! A0#%     @ N8M=
M4T8@A^SD P  0 \  !D              ("!VZX! 'AL+W=O<FMS:&5E=',O
M<VAE970U.2YX;6Q02P$"% ,4    " "YBUU377@N;"H#  #U"0  &0
M        @('VL@$ >&PO=V]R:W-H965T<R]S:&5E=#8P+GAM;%!+ 0(4 Q0
M   ( +F+75,[GIL/%0,  ,X)   9              " @5>V 0!X;"]W;W)K
M<VAE971S+W-H965T-C$N>&UL4$L! A0#%     @ N8M=4PK4&. : P  1 H
M !D              ("!H[D! 'AL+W=O<FMS:&5E=',O<VAE970V,BYX;6Q0
M2P$"% ,4    " "YBUU3Z5 22AL#  #2"@  &0              @('TO $
M>&PO=V]R:W-H965T<R]S:&5E=#8S+GAM;%!+ 0(4 Q0    ( +F+75-L]A4X
MWP,  ,H,   9              " @4;  0!X;"]W;W)K<VAE971S+W-H965T
M-C0N>&UL4$L! A0#%     @ N8M=4\\!U?R) @  QP4  !D
M ("!7,0! 'AL+W=O<FMS:&5E=',O<VAE970V-2YX;6Q02P$"% ,4    " "Y
MBUU3G;LM1,4"   ]!P  &0              @($<QP$ >&PO=V]R:W-H965T
M<R]S:&5E=#8V+GAM;%!+ 0(4 Q0    ( +F+75/&'T#9=0,  #X,   9
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M970W,2YX;6Q02P$"% ,4    " "YBUU3?N.)4M,"   L"   &0
M    @($VX0$ >&PO=V]R:W-H965T<R]S:&5E=#<R+GAM;%!+ 0(4 Q0    (
M +F+75//T'_D(@,  ( )   9              " @4#D 0!X;"]W;W)K<VAE
M971S+W-H965T-S,N>&UL4$L! A0#%     @ N8M=4VW;7RZ9 @   0<  !D
M             ("!F><! 'AL+W=O<FMS:&5E=',O<VAE970W-"YX;6Q02P$"
M% ,4    " "YBUU3V6-Q4(4&   ;*@  &0              @(%IZ@$ >&PO
M=V]R:W-H965T<R]S:&5E=#<U+GAM;%!+ 0(4 Q0    ( +F+75.0?N8A)0,
M ,H*   9              " @27Q 0!X;"]W;W)K<VAE971S+W-H965T-S8N
M>&UL4$L! A0#%     @ N8M=4V>@][)\ P  1 H  !D              ("!
M@?0! 'AL+W=O<FMS:&5E=',O<VAE970W-RYX;6Q02P$"% ,4    " "YBUU3
M9)5!RJL#   ;#P  &0              @($T^ $ >&PO=V]R:W-H965T<R]S
M:&5E=#<X+GAM;%!+ 0(4 Q0    ( +F+75-9E//M3@(  $P%   9
M      " @1;\ 0!X;"]W;W)K<VAE971S+W-H965T-SDN>&UL4$L! A0#%
M  @ N8M=4UP^]5Q( P  @ H  !D              ("!F_X! 'AL+W=O<FMS
M:&5E=',O<VAE970X,"YX;6Q02P$"% ,4    " "YBUU3/&KE4MT#   =#0
M&0              @($: @( >&PO=V]R:W-H965T<R]S:&5E=#@Q+GAM;%!+
M 0(4 Q0    ( +F+75-N)J9,@@(  "0%   9              " @2X& @!X
M;"]W;W)K<VAE971S+W-H965T.#(N>&UL4$L! A0#%     @ N8M=4U<HN.TA
M!0  6Q4  !D              ("!YP@" 'AL+W=O<FMS:&5E=',O<VAE970X
M,RYX;6Q02P$"% ,4    " "YBUU3P>4E=D(#  #P$P  #0
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:+GAM;%!+!08     6P!; /08  #('0(    !

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>155
<FILENAME>Show.js
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
// Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission.  Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105.
var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0);
e.removeAttribute('id');a.parentNode.appendChild(e)}}
if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'}
e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>156
<FILENAME>report.css
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/* Updated 2009-11-04 */
/* v2.2.0.24 */

/* DefRef Styles */
..report table.authRefData{
	background-color: #def;
	border: 2px solid #2F4497;
	font-size: 1em;
	position: absolute;
}

..report table.authRefData a {
	display: block;
	font-weight: bold;
}

..report table.authRefData p {
	margin-top: 0px;
}

..report table.authRefData .hide {
	background-color: #2F4497;
	padding: 1px 3px 0px 0px;
	text-align: right;
}

..report table.authRefData .hide a:hover {
	background-color: #2F4497;
}

..report table.authRefData .body {
	height: 150px;
	overflow: auto;
	width: 400px;
}

..report table.authRefData table{
	font-size: 1em;
}

/* Report Styles */
..pl a, .pl a:visited {
	color: black;
	text-decoration: none;
}

/* table */
..report {
	background-color: white;
	border: 2px solid #acf;
	clear: both;
	color: black;
	font: normal 8pt Helvetica, Arial, san-serif;
	margin-bottom: 2em;
}

..report hr {
	border: 1px solid #acf;
}

/* Top labels */
..report th {
	background-color: #acf;
	color: black;
	font-weight: bold;
	text-align: center;
}

..report th.void	{
	background-color: transparent;
	color: #000000;
	font: bold 10pt Helvetica, Arial, san-serif;
	text-align: left;
}

..report .pl {
	text-align: left;
	vertical-align: top;
	white-space: normal;
	width: 200px;
	white-space: normal; /* word-wrap: break-word; */
}

..report td.pl a.a {
	cursor: pointer;
	display: block;
	width: 200px;
	overflow: hidden;
}

..report td.pl div.a {
	width: 200px;
}

..report td.pl a:hover {
	background-color: #ffc;
}

/* Header rows... */
..report tr.rh {
	background-color: #acf;
	color: black;
	font-weight: bold;
}

/* Calendars... */
..report .rc {
	background-color: #f0f0f0;
}

/* Even rows... */
..report .re, .report .reu {
	background-color: #def;
}

..report .reu td {
	border-bottom: 1px solid black;
}

/* Odd rows... */
..report .ro, .report .rou {
	background-color: white;
}

..report .rou td {
	border-bottom: 1px solid black;
}

..report .rou table td, .report .reu table td {
	border-bottom: 0px solid black;
}

/* styles for footnote marker */
..report .fn {
	white-space: nowrap;
}

/* styles for numeric types */
..report .num, .report .nump {
	text-align: right;
	white-space: nowrap;
}

..report .nump {
	padding-left: 2em;
}

..report .nump {
	padding: 0px 0.4em 0px 2em;
}

/* styles for text types */
..report .text {
	text-align: left;
	white-space: normal;
}

..report .text .big {
	margin-bottom: 1em;
	width: 17em;
}

..report .text .more {
	display: none;
}

..report .text .note {
	font-style: italic;
	font-weight: bold;
}

..report .text .small {
	width: 10em;
}

..report sup {
	font-style: italic;
}

..report .outerFootnotes {
	font-size: 1em;
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>157
<FILENAME>FilingSummary.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version='1.0' encoding='utf-8'?>
<FilingSummary>
  <Version>3.21.2</Version>
  <ProcessingTime/>
  <ReportFormat>html</ReportFormat>
  <ContextCount>384</ContextCount>
  <ElementCount>576</ElementCount>
  <EntityCount>1</EntityCount>
  <FootnotesReported>true</FootnotesReported>
  <SegmentCount>94</SegmentCount>
  <ScenarioCount>0</ScenarioCount>
  <TuplesReported>false</TuplesReported>
  <UnitCount>9</UnitCount>
  <MyReports>
    <Report instance="d164680ds1.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R1.htm</HtmlFileName>
      <LongName>1001 - Document - Cover</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://roivant.com/role/Cover</Role>
      <ShortName>Cover</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>1</Position>
    </Report>
    <Report instance="d164680ds1.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R2.htm</HtmlFileName>
      <LongName>1002 - Statement - Condensed Consolidated Balance Sheets</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://roivant.com/role/CondensedConsolidatedBalanceSheets</Role>
      <ShortName>Condensed Consolidated Balance Sheets</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>2</Position>
    </Report>
    <Report instance="d164680ds1.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R3.htm</HtmlFileName>
      <LongName>1003 - Statement - Condensed Consolidated Balance Sheets (Parenthetical)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://roivant.com/role/CondensedConsolidatedBalanceSheetsParenthetical</Role>
      <ShortName>Condensed Consolidated Balance Sheets (Parenthetical)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>3</Position>
    </Report>
    <Report instance="d164680ds1.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R4.htm</HtmlFileName>
      <LongName>1004 - Statement - Condensed Consolidated Statements of Operations</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://roivant.com/role/CondensedConsolidatedStatementsOfOperations</Role>
      <ShortName>Condensed Consolidated Statements of Operations</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>4</Position>
    </Report>
    <Report instance="d164680ds1.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R5.htm</HtmlFileName>
      <LongName>1005 - Statement - Condensed Consolidated Statements of Comprehensive Loss</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://roivant.com/role/CondensedConsolidatedStatementsOfComprehensiveLoss</Role>
      <ShortName>Condensed Consolidated Statements of Comprehensive Loss</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>5</Position>
    </Report>
    <Report instance="d164680ds1.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R6.htm</HtmlFileName>
      <LongName>1006 - Statement - Condensed Consolidated Statements of Shareholders' Equity and Redeemable Noncontrolling Interest</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://roivant.com/role/CondensedConsolidatedStatementsOfShareholdersEquityAndRedeemableNoncontrollingInterest</Role>
      <ShortName>Condensed Consolidated Statements of Shareholders' Equity and Redeemable Noncontrolling Interest</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>6</Position>
    </Report>
    <Report instance="d164680ds1.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R7.htm</HtmlFileName>
      <LongName>1007 - Statement - Condensed Consolidated Statements of Cash Flows</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://roivant.com/role/CondensedConsolidatedStatementsOfCashFlows</Role>
      <ShortName>Condensed Consolidated Statements of Cash Flows</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>7</Position>
    </Report>
    <Report instance="d164680ds1.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R8.htm</HtmlFileName>
      <LongName>1008 - Disclosure - Description of Business and Liquidity</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://roivant.com/role/DescriptionOfBusinessAndLiquidity</Role>
      <ShortName>Description of Business and Liquidity</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>8</Position>
    </Report>
    <Report instance="d164680ds1.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R9.htm</HtmlFileName>
      <LongName>1009 - Disclosure - Summary of Significant Accounting Policies</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://roivant.com/role/SummaryOfSignificantAccountingPolicies</Role>
      <ShortName>Summary of Significant Accounting Policies</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>9</Position>
    </Report>
    <Report instance="d164680ds1.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R10.htm</HtmlFileName>
      <LongName>1010 - Disclosure - Investments</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://roivant.com/role/Investments</Role>
      <ShortName>Investments</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>10</Position>
    </Report>
    <Report instance="d164680ds1.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R11.htm</HtmlFileName>
      <LongName>1011 - Disclosure - Asset Acquisitions and License Agreements</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://roivant.com/role/AssetAcquisitionsAndLicenseAgreements</Role>
      <ShortName>Asset Acquisitions and License Agreements</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>11</Position>
    </Report>
    <Report instance="d164680ds1.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R12.htm</HtmlFileName>
      <LongName>1012 - Disclosure - Sumitomo Transaction Agreement</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://roivant.com/role/SumitomoTransactionAgreement</Role>
      <ShortName>Sumitomo Transaction Agreement</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>12</Position>
    </Report>
    <Report instance="d164680ds1.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R13.htm</HtmlFileName>
      <LongName>1013 - Disclosure - Balance Sheet Components</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://roivant.com/role/BalanceSheetComponents</Role>
      <ShortName>Balance Sheet Components</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>13</Position>
    </Report>
    <Report instance="d164680ds1.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R14.htm</HtmlFileName>
      <LongName>1014 - Disclosure - Long Term Debt and Loan Commitment</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://roivant.com/role/LongTermDebtAndLoanCommitment</Role>
      <ShortName>Long Term Debt and Loan Commitment</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>14</Position>
    </Report>
    <Report instance="d164680ds1.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R15.htm</HtmlFileName>
      <LongName>1015 - Disclosure - Shareholders' Equity and Redeemable Noncontrolling Interest</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://roivant.com/role/ShareholdersEquityAndRedeemableNoncontrollingInterest</Role>
      <ShortName>Shareholders' Equity and Redeemable Noncontrolling Interest</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>15</Position>
    </Report>
    <Report instance="d164680ds1.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R16.htm</HtmlFileName>
      <LongName>1016 - Disclosure - Share-Based Compensation</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://roivant.com/role/ShareBasedCompensation</Role>
      <ShortName>Share-Based Compensation</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>16</Position>
    </Report>
    <Report instance="d164680ds1.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R17.htm</HtmlFileName>
      <LongName>1017 - Disclosure - Related Party Transactions</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://roivant.com/role/RelatedPartyTransactions</Role>
      <ShortName>Related Party Transactions</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>17</Position>
    </Report>
    <Report instance="d164680ds1.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R18.htm</HtmlFileName>
      <LongName>1018 - Disclosure - Discontinued Operations</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://roivant.com/role/DiscontinuedOperations</Role>
      <ShortName>Discontinued Operations</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>18</Position>
    </Report>
    <Report instance="d164680ds1.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R19.htm</HtmlFileName>
      <LongName>1019 - Disclosure - Income Taxes</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://roivant.com/role/IncomeTaxes</Role>
      <ShortName>Income Taxes</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>19</Position>
    </Report>
    <Report instance="d164680ds1.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R20.htm</HtmlFileName>
      <LongName>1020 - Disclosure - Leases</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://roivant.com/role/Leases</Role>
      <ShortName>Leases</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>20</Position>
    </Report>
    <Report instance="d164680ds1.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R21.htm</HtmlFileName>
      <LongName>1021 - Disclosure - Commitments &amp; Contingencies</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://roivant.com/role/CommitmentsContingencies</Role>
      <ShortName>Commitments &amp; Contingencies</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>21</Position>
    </Report>
    <Report instance="d164680ds1.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R22.htm</HtmlFileName>
      <LongName>1022 - Disclosure - Fair Value Measurements</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://roivant.com/role/FairValueMeasurements</Role>
      <ShortName>Fair Value Measurements</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>22</Position>
    </Report>
    <Report instance="d164680ds1.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R23.htm</HtmlFileName>
      <LongName>1023 - Disclosure - Defined Contribution Plan</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://roivant.com/role/DefinedContributionPlan</Role>
      <ShortName>Defined Contribution Plan</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>23</Position>
    </Report>
    <Report instance="d164680ds1.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R24.htm</HtmlFileName>
      <LongName>1024 - Disclosure - Other (Income) Expense, Net</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://roivant.com/role/OtherIncomeExpenseNet</Role>
      <ShortName>Other (Income) Expense, Net</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>24</Position>
    </Report>
    <Report instance="d164680ds1.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R25.htm</HtmlFileName>
      <LongName>1025 - Disclosure - Net Loss per Common Share</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://roivant.com/role/NetLossPerCommonShare</Role>
      <ShortName>Net Loss per Common Share</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>25</Position>
    </Report>
    <Report instance="d164680ds1.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R26.htm</HtmlFileName>
      <LongName>1026 - Disclosure - Subsequent Events</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://roivant.com/role/SubsequentEvents</Role>
      <ShortName>Subsequent Events</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>26</Position>
    </Report>
    <Report instance="d164680ds1.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R27.htm</HtmlFileName>
      <LongName>1027 - Disclosure - Summary of Significant Accounting Policies (Policies)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://roivant.com/role/SummaryOfSignificantAccountingPoliciesPolicies</Role>
      <ShortName>Summary of Significant Accounting Policies (Policies)</ShortName>
      <MenuCategory>Policies</MenuCategory>
      <ParentRole>http://roivant.com/role/SummaryOfSignificantAccountingPolicies</ParentRole>
      <Position>27</Position>
    </Report>
    <Report instance="d164680ds1.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R28.htm</HtmlFileName>
      <LongName>1028 - Disclosure - Summary of Significant Accounting Policies (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://roivant.com/role/SummaryOfSignificantAccountingPoliciesTables</Role>
      <ShortName>Summary of Significant Accounting Policies (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://roivant.com/role/SummaryOfSignificantAccountingPolicies</ParentRole>
      <Position>28</Position>
    </Report>
    <Report instance="d164680ds1.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R29.htm</HtmlFileName>
      <LongName>1029 - Disclosure - Discontinued Operations (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://roivant.com/role/DiscontinuedOperationsTables</Role>
      <ShortName>Discontinued Operations (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://roivant.com/role/DiscontinuedOperations</ParentRole>
      <Position>29</Position>
    </Report>
    <Report instance="d164680ds1.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R30.htm</HtmlFileName>
      <LongName>1030 - Disclosure - Balance Sheet Components (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://roivant.com/role/BalanceSheetComponentsTables</Role>
      <ShortName>Balance Sheet Components (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://roivant.com/role/BalanceSheetComponents</ParentRole>
      <Position>30</Position>
    </Report>
    <Report instance="d164680ds1.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R31.htm</HtmlFileName>
      <LongName>1031 - Disclosure - Long Term Debt and Loan Commitment (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://roivant.com/role/LongTermDebtAndLoanCommitmentTables</Role>
      <ShortName>Long Term Debt and Loan Commitment (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://roivant.com/role/LongTermDebtAndLoanCommitment</ParentRole>
      <Position>31</Position>
    </Report>
    <Report instance="d164680ds1.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R32.htm</HtmlFileName>
      <LongName>1032 - Disclosure - Shareholders' Equity and Redeemable Noncontrolling Interest (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://roivant.com/role/ShareholdersEquityAndRedeemableNoncontrollingInterestTables</Role>
      <ShortName>Shareholders' Equity and Redeemable Noncontrolling Interest (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://roivant.com/role/ShareholdersEquityAndRedeemableNoncontrollingInterest</ParentRole>
      <Position>32</Position>
    </Report>
    <Report instance="d164680ds1.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R33.htm</HtmlFileName>
      <LongName>1033 - Disclosure - Share-Based Compensation (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://roivant.com/role/ShareBasedCompensationTables</Role>
      <ShortName>Share-Based Compensation (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://roivant.com/role/ShareBasedCompensation</ParentRole>
      <Position>33</Position>
    </Report>
    <Report instance="d164680ds1.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R34.htm</HtmlFileName>
      <LongName>1034 - Disclosure - Income Taxes (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://roivant.com/role/IncomeTaxesTables</Role>
      <ShortName>Income Taxes (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://roivant.com/role/IncomeTaxes</ParentRole>
      <Position>34</Position>
    </Report>
    <Report instance="d164680ds1.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R35.htm</HtmlFileName>
      <LongName>1035 - Disclosure - Leases (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://roivant.com/role/LeasesTables</Role>
      <ShortName>Leases (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://roivant.com/role/Leases</ParentRole>
      <Position>35</Position>
    </Report>
    <Report instance="d164680ds1.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R36.htm</HtmlFileName>
      <LongName>1036 - Disclosure - Fair Value Measurements (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://roivant.com/role/FairValueMeasurementsTables</Role>
      <ShortName>Fair Value Measurements (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://roivant.com/role/FairValueMeasurements</ParentRole>
      <Position>36</Position>
    </Report>
    <Report instance="d164680ds1.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R37.htm</HtmlFileName>
      <LongName>1037 - Disclosure - Other (Income) Expense, Net (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://roivant.com/role/OtherIncomeExpenseNetTables</Role>
      <ShortName>Other (Income) Expense, Net (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://roivant.com/role/OtherIncomeExpenseNet</ParentRole>
      <Position>37</Position>
    </Report>
    <Report instance="d164680ds1.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R38.htm</HtmlFileName>
      <LongName>1038 - Disclosure - Net Loss per Common Share (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://roivant.com/role/NetLossPerCommonShareTables</Role>
      <ShortName>Net Loss per Common Share (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://roivant.com/role/NetLossPerCommonShare</ParentRole>
      <Position>38</Position>
    </Report>
    <Report instance="d164680ds1.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R39.htm</HtmlFileName>
      <LongName>1039 - Disclosure - Description of Business and Liquidity - Additional Information (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://roivant.com/role/DescriptionOfBusinessAndLiquidityAdditionalInformationDetail</Role>
      <ShortName>Description of Business and Liquidity - Additional Information (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>39</Position>
    </Report>
    <Report instance="d164680ds1.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R40.htm</HtmlFileName>
      <LongName>1040 - Disclosure - Summary of Significant Accounting Policies - Additional Information (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://roivant.com/role/SummaryOfSignificantAccountingPoliciesAdditionalInformationDetail</Role>
      <ShortName>Summary of Significant Accounting Policies - Additional Information (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>40</Position>
    </Report>
    <Report instance="d164680ds1.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R41.htm</HtmlFileName>
      <LongName>1041 - Disclosure - Summary of Significant Accounting Policies - Schedule of Aggregate Amounts of Cash, Cash Equivalents, and Restricted Cash (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://roivant.com/role/SummaryOfSignificantAccountingPoliciesScheduleOfAggregateAmountsOfCashCashEquivalentsAndRestrictedCashDetail</Role>
      <ShortName>Summary of Significant Accounting Policies - Schedule of Aggregate Amounts of Cash, Cash Equivalents, and Restricted Cash (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>41</Position>
    </Report>
    <Report instance="d164680ds1.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R42.htm</HtmlFileName>
      <LongName>1042 - Disclosure - Summary of Significant Accounting Policies - Schedule of Estimated Useful Lives (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://roivant.com/role/SummaryOfSignificantAccountingPoliciesScheduleOfEstimatedUsefulLivesDetail</Role>
      <ShortName>Summary of Significant Accounting Policies - Schedule of Estimated Useful Lives (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>42</Position>
    </Report>
    <Report instance="d164680ds1.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R43.htm</HtmlFileName>
      <LongName>1043 - Disclosure - Investments - Additional Information (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://roivant.com/role/InvestmentsAdditionalInformationDetail</Role>
      <ShortName>Investments - Additional Information (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>43</Position>
    </Report>
    <Report instance="d164680ds1.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R44.htm</HtmlFileName>
      <LongName>1044 - Disclosure - Asset Acquisitions and License Agreements -Additional Information (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://roivant.com/role/AssetAcquisitionsAndLicenseAgreementsAdditionalInformationDetail</Role>
      <ShortName>Asset Acquisitions and License Agreements -Additional Information (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>44</Position>
    </Report>
    <Report instance="d164680ds1.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R45.htm</HtmlFileName>
      <LongName>1045 - Disclosure - Sumitomo Transaction Agreement - Additional Information (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://roivant.com/role/SumitomoTransactionAgreementAdditionalInformationDetail</Role>
      <ShortName>Sumitomo Transaction Agreement - Additional Information (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>45</Position>
    </Report>
    <Report instance="d164680ds1.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R46.htm</HtmlFileName>
      <LongName>1046 - Disclosure - Balance Sheet Components - Schedule of Other Current Assets (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://roivant.com/role/BalanceSheetComponentsScheduleOfOtherCurrentAssetsDetail</Role>
      <ShortName>Balance Sheet Components - Schedule of Other Current Assets (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>46</Position>
    </Report>
    <Report instance="d164680ds1.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R47.htm</HtmlFileName>
      <LongName>1047 - Disclosure - Balance Sheet Components - Schedule of Accrued Expenses (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://roivant.com/role/BalanceSheetComponentsScheduleOfAccruedExpensesDetail</Role>
      <ShortName>Balance Sheet Components - Schedule of Accrued Expenses (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>47</Position>
    </Report>
    <Report instance="d164680ds1.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R48.htm</HtmlFileName>
      <LongName>1048 - Disclosure - Balance Sheet Components - Schedule of Other Current Liabilities (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://roivant.com/role/BalanceSheetComponentsScheduleOfOtherCurrentLiabilitiesDetail</Role>
      <ShortName>Balance Sheet Components - Schedule of Other Current Liabilities (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>48</Position>
    </Report>
    <Report instance="d164680ds1.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R49.htm</HtmlFileName>
      <LongName>1049 - Disclosure - Long Term Debt and Loan Commitment (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://roivant.com/role/LongTermDebtAndLoanCommitmentDetail</Role>
      <ShortName>Long Term Debt and Loan Commitment (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://roivant.com/role/LongTermDebtAndLoanCommitmentTables</ParentRole>
      <Position>49</Position>
    </Report>
    <Report instance="d164680ds1.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R50.htm</HtmlFileName>
      <LongName>1050 - Disclosure - Long-Term Debt and Loan Commitment - Additional Information (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://roivant.com/role/LongTermDebtAndLoanCommitmentAdditionalInformationDetail</Role>
      <ShortName>Long-Term Debt and Loan Commitment - Additional Information (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>50</Position>
    </Report>
    <Report instance="d164680ds1.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R51.htm</HtmlFileName>
      <LongName>1051 - Disclosure - Long Term Debt and Convertible Notes Payable - Schedule of Company's Annual Payments (Detail)</LongName>
      <ReportType>Notes</ReportType>
      <Role>http://roivant.com/role/LongTermDebtAndConvertibleNotesPayableScheduleOfCompanysAnnualPaymentsDetail</Role>
      <ShortName>Long Term Debt and Convertible Notes Payable - Schedule of Company's Annual Payments (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>51</Position>
    </Report>
    <Report instance="d164680ds1.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R52.htm</HtmlFileName>
      <LongName>1052 - Disclosure - Shareholders' Equity and Redeemable Non-Controlling Interest - Additional Information (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://roivant.com/role/ShareholdersEquityAndRedeemableNonControllingInterestAdditionalInformationDetail</Role>
      <ShortName>Shareholders' Equity and Redeemable Non-Controlling Interest - Additional Information (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>52</Position>
    </Report>
    <Report instance="d164680ds1.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R53.htm</HtmlFileName>
      <LongName>1053 - Disclosure - Shareholders' Equity and Redeemable Non-Controlling Interest - Schedule of payments of equity securities (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://roivant.com/role/ShareholdersEquityAndRedeemableNonControllingInterestScheduleOfPaymentsOfEquitySecuritiesDetail</Role>
      <ShortName>Shareholders' Equity and Redeemable Non-Controlling Interest - Schedule of payments of equity securities (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>53</Position>
    </Report>
    <Report instance="d164680ds1.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R54.htm</HtmlFileName>
      <LongName>1054 - Disclosure - Share-Based Compensation - Additional Information (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://roivant.com/role/ShareBasedCompensationAdditionalInformationDetail</Role>
      <ShortName>Share-Based Compensation - Additional Information (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>54</Position>
    </Report>
    <Report instance="d164680ds1.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R55.htm</HtmlFileName>
      <LongName>1055 - Disclosure - Share-Based Compensation - Schedule of Fair Value Assumptions (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://roivant.com/role/ShareBasedCompensationScheduleOfFairValueAssumptionsDetail</Role>
      <ShortName>Share-Based Compensation - Schedule of Fair Value Assumptions (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>55</Position>
    </Report>
    <Report instance="d164680ds1.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R56.htm</HtmlFileName>
      <LongName>1056 - Disclosure - Share-Based Compensation - Summary of Stock Option Activity (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://roivant.com/role/ShareBasedCompensationSummaryOfStockOptionActivityDetail</Role>
      <ShortName>Share-Based Compensation - Summary of Stock Option Activity (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>56</Position>
    </Report>
    <Report instance="d164680ds1.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R57.htm</HtmlFileName>
      <LongName>1057 - Disclosure - Share-Based Compensation - Summary of Fair Value of Vested Stock Option (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://roivant.com/role/ShareBasedCompensationSummaryOfFairValueOfVestedStockOptionDetail</Role>
      <ShortName>Share-Based Compensation - Summary of Fair Value of Vested Stock Option (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>57</Position>
    </Report>
    <Report instance="d164680ds1.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R58.htm</HtmlFileName>
      <LongName>1058 - Disclosure - Share-Based Compensation - Summary of Restricted Stock Units (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://roivant.com/role/ShareBasedCompensationSummaryOfRestrictedStockUnitsDetail</Role>
      <ShortName>Share-Based Compensation - Summary of Restricted Stock Units (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>58</Position>
    </Report>
    <Report instance="d164680ds1.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R59.htm</HtmlFileName>
      <LongName>1059 - Disclosure - Share-Based Compensation - Summary of Performance Options Activity (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://roivant.com/role/ShareBasedCompensationSummaryOfPerformanceOptionsActivityDetail</Role>
      <ShortName>Share-Based Compensation - Summary of Performance Options Activity (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>59</Position>
    </Report>
    <Report instance="d164680ds1.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R60.htm</HtmlFileName>
      <LongName>1060 - Disclosure - Share-Based Compensation - Summary of Capped Value Appreciation Rights (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://roivant.com/role/ShareBasedCompensationSummaryOfCappedValueAppreciationRightsDetail</Role>
      <ShortName>Share-Based Compensation - Summary of Capped Value Appreciation Rights (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>60</Position>
    </Report>
    <Report instance="d164680ds1.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R61.htm</HtmlFileName>
      <LongName>1061 - Disclosure - Share-Based Compensation - Summary of Performance Restricted Stock Units (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://roivant.com/role/ShareBasedCompensationSummaryOfPerformanceRestrictedStockUnitsDetail</Role>
      <ShortName>Share-Based Compensation - Summary of Performance Restricted Stock Units (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>61</Position>
    </Report>
    <Report instance="d164680ds1.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R62.htm</HtmlFileName>
      <LongName>1062 - Disclosure - Share-Based Compensation - Summary of Common Share Award Activity (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://roivant.com/role/ShareBasedCompensationSummaryOfCommonShareAwardActivityDetail</Role>
      <ShortName>Share-Based Compensation - Summary of Common Share Award Activity (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>62</Position>
    </Report>
    <Report instance="d164680ds1.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R63.htm</HtmlFileName>
      <LongName>1063 - Disclosure - Share-Based Compensation - Summary of Share-Based Compensation Expense (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://roivant.com/role/ShareBasedCompensationSummaryOfShareBasedCompensationExpenseDetail</Role>
      <ShortName>Share-Based Compensation - Summary of Share-Based Compensation Expense (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>63</Position>
    </Report>
    <Report instance="d164680ds1.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R64.htm</HtmlFileName>
      <LongName>1064 - Disclosure - Discontinued Operations - Summary Of Disposal Groups Including Discontinued Operations Income Statement (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://roivant.com/role/DiscontinuedOperationsSummaryOfDisposalGroupsIncludingDiscontinuedOperationsIncomeStatementDetail</Role>
      <ShortName>Discontinued Operations - Summary Of Disposal Groups Including Discontinued Operations Income Statement (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>64</Position>
    </Report>
    <Report instance="d164680ds1.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R65.htm</HtmlFileName>
      <LongName>1065 - Disclosure - Discontinued Operations - Summary of Cash Flows From Discontinued Operations (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://roivant.com/role/DiscontinuedOperationsSummaryOfCashFlowsFromDiscontinuedOperationsDetail</Role>
      <ShortName>Discontinued Operations - Summary of Cash Flows From Discontinued Operations (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>65</Position>
    </Report>
    <Report instance="d164680ds1.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R66.htm</HtmlFileName>
      <LongName>1066 - Disclosure - Related Party Transactions - Additional Information (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://roivant.com/role/RelatedPartyTransactionsAdditionalInformationDetail</Role>
      <ShortName>Related Party Transactions - Additional Information (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>66</Position>
    </Report>
    <Report instance="d164680ds1.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R67.htm</HtmlFileName>
      <LongName>1067 - Disclosure - Income Taxes - Schedule of Loss Before Income Taxes by Geographic Region (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://roivant.com/role/IncomeTaxesScheduleOfLossBeforeIncomeTaxesByGeographicRegionDetail</Role>
      <ShortName>Income Taxes - Schedule of Loss Before Income Taxes by Geographic Region (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>67</Position>
    </Report>
    <Report instance="d164680ds1.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R68.htm</HtmlFileName>
      <LongName>1068 - Disclosure - Income Taxes - Schedule Components of Income Tax Expense (Benefit) (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://roivant.com/role/IncomeTaxesScheduleComponentsOfIncomeTaxExpenseBenefitDetail</Role>
      <ShortName>Income Taxes - Schedule Components of Income Tax Expense (Benefit) (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>68</Position>
    </Report>
    <Report instance="d164680ds1.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R69.htm</HtmlFileName>
      <LongName>1069 - Disclosure - Income Taxes - Additional Information (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://roivant.com/role/IncomeTaxesAdditionalInformationDetail</Role>
      <ShortName>Income Taxes - Additional Information (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>69</Position>
    </Report>
    <Report instance="d164680ds1.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R70.htm</HtmlFileName>
      <LongName>1070 - Disclosure - Income Taxes - Schedule of Deferred Tax Assets (Liabilities) (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://roivant.com/role/IncomeTaxesScheduleOfDeferredTaxAssetsLiabilitiesDetail</Role>
      <ShortName>Income Taxes - Schedule of Deferred Tax Assets (Liabilities) (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>70</Position>
    </Report>
    <Report instance="d164680ds1.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R71.htm</HtmlFileName>
      <LongName>1071 - Disclosure - Income Taxes - Schedule of Effective Income Tax Rate Reconciliation (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://roivant.com/role/IncomeTaxesScheduleOfEffectiveIncomeTaxRateReconciliationDetail</Role>
      <ShortName>Income Taxes - Schedule of Effective Income Tax Rate Reconciliation (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>71</Position>
    </Report>
    <Report instance="d164680ds1.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R72.htm</HtmlFileName>
      <LongName>1072 - Disclosure - Leases - Schedule of Maturities of Operating Lease Liabilities (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://roivant.com/role/LeasesScheduleOfMaturitiesOfOperatingLeaseLiabilitiesDetail</Role>
      <ShortName>Leases - Schedule of Maturities of Operating Lease Liabilities (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>72</Position>
    </Report>
    <Report instance="d164680ds1.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R73.htm</HtmlFileName>
      <LongName>1073 - Disclosure - Leases - Summary of Operating Lease ROU Assets and Operating Lease Liabilities (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://roivant.com/role/LeasesSummaryOfOperatingLeaseRouAssetsAndOperatingLeaseLiabilitiesDetail</Role>
      <ShortName>Leases - Summary of Operating Lease ROU Assets and Operating Lease Liabilities (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>73</Position>
    </Report>
    <Report instance="d164680ds1.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R74.htm</HtmlFileName>
      <LongName>1074 - Disclosure - Leases - Schedule of Operating Lease Costs (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://roivant.com/role/LeasesScheduleOfOperatingLeaseCostsDetail</Role>
      <ShortName>Leases - Schedule of Operating Lease Costs (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>74</Position>
    </Report>
    <Report instance="d164680ds1.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R75.htm</HtmlFileName>
      <LongName>1075 - Disclosure - Fair Value Measurements - Schedule of Assets and Liabilities Measured at Fair Value on a Recurring Basis (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://roivant.com/role/FairValueMeasurementsScheduleOfAssetsAndLiabilitiesMeasuredAtFairValueOnARecurringBasisDetail</Role>
      <ShortName>Fair Value Measurements - Schedule of Assets and Liabilities Measured at Fair Value on a Recurring Basis (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>75</Position>
    </Report>
    <Report instance="d164680ds1.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R76.htm</HtmlFileName>
      <LongName>1076 - Disclosure - Fair Value Measurements - Additional Information (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://roivant.com/role/FairValueMeasurementsAdditionalInformationDetail</Role>
      <ShortName>Fair Value Measurements - Additional Information (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>76</Position>
    </Report>
    <Report instance="d164680ds1.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R77.htm</HtmlFileName>
      <LongName>1077 - Disclosure - Fair Value Measurements - Change in the Fair Value of the Derivative Warrant Liabilities (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://roivant.com/role/FairValueMeasurementsChangeInTheFairValueOfTheDerivativeWarrantLiabilitiesDetail</Role>
      <ShortName>Fair Value Measurements - Change in the Fair Value of the Derivative Warrant Liabilities (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>77</Position>
    </Report>
    <Report instance="d164680ds1.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R78.htm</HtmlFileName>
      <LongName>1078 - Disclosure - Fair Value Measurements - Schedule of Fair Value of Unobservable Input Related To Options to Acquire Under Sumitomo Transaction Agreement (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://roivant.com/role/FairValueMeasurementsScheduleOfFairValueOfUnobservableInputRelatedToOptionsToAcquireUnderSumitomoTransactionAgreementDetail</Role>
      <ShortName>Fair Value Measurements - Schedule of Fair Value of Unobservable Input Related To Options to Acquire Under Sumitomo Transaction Agreement (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>78</Position>
    </Report>
    <Report instance="d164680ds1.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R79.htm</HtmlFileName>
      <LongName>1079 - Disclosure - Defined Contribution Plan - Additional Information (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://roivant.com/role/DefinedContributionPlanAdditionalInformationDetail</Role>
      <ShortName>Defined Contribution Plan - Additional Information (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>79</Position>
    </Report>
    <Report instance="d164680ds1.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R80.htm</HtmlFileName>
      <LongName>1080 - Disclosure - Other (Income) Expense, Net - Summary of Other (Income) Expense, Net From Continuing Operations (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://roivant.com/role/OtherIncomeExpenseNetSummaryOfOtherIncomeExpenseNetFromContinuingOperationsDetail</Role>
      <ShortName>Other (Income) Expense, Net - Summary of Other (Income) Expense, Net From Continuing Operations (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://roivant.com/role/OtherIncomeExpenseNetTables</ParentRole>
      <Position>80</Position>
    </Report>
    <Report instance="d164680ds1.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R81.htm</HtmlFileName>
      <LongName>1081 - Disclosure - Net Loss per Common Share - Summary of Basic and Diluted Net Income Per Share of Common Stock (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://roivant.com/role/NetLossPerCommonShareSummaryOfBasicAndDilutedNetIncomePerShareOfCommonStockDetail</Role>
      <ShortName>Net Loss per Common Share - Summary of Basic and Diluted Net Income Per Share of Common Stock (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>81</Position>
    </Report>
    <Report instance="d164680ds1.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R82.htm</HtmlFileName>
      <LongName>1082 - Disclosure - Net Loss per Common Share - Summary of Basic and Diluted Net Income Per Share of Common Stock (Parenthetical) (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://roivant.com/role/NetLossPerCommonShareSummaryOfBasicAndDilutedNetIncomePerShareOfCommonStockParentheticalDetail</Role>
      <ShortName>Net Loss per Common Share - Summary of Basic and Diluted Net Income Per Share of Common Stock (Parenthetical) (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>82</Position>
    </Report>
    <Report instance="d164680ds1.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R83.htm</HtmlFileName>
      <LongName>1083 - Disclosure - Subsequent Events - Additional Information (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://roivant.com/role/SubsequentEventsAdditionalInformationDetail</Role>
      <ShortName>Subsequent Events - Additional Information (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>83</Position>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <LongName>All Reports</LongName>
      <ReportType>Book</ReportType>
      <ShortName>All Reports</ShortName>
    </Report>
  </MyReports>
  <InputFiles>
    <File doctype="S-1" original="d164680ds1.htm">d164680ds1.htm</File>
    <File>d164680dex231.htm</File>
    <File>d164680dex232.htm</File>
    <File>d164680dex51.htm</File>
    <File>d164680dex52.htm</File>
    <File>d164680dex81.htm</File>
    <File>d164680dex82.htm</File>
    <File>roiv-20210630.xsd</File>
    <File>roiv-20210630_cal.xml</File>
    <File>roiv-20210630_def.xml</File>
    <File>roiv-20210630_lab.xml</File>
    <File>roiv-20210630_pre.xml</File>
  </InputFiles>
  <SupplementalFiles>
    <File>g164680g00y01.jpg</File>
    <File>g164680g00y02.jpg</File>
    <File>g164680g00y03.jpg</File>
    <File>g164680g00y06.jpg</File>
    <File>g164680g00y07.jpg</File>
    <File>g164680g00y08.jpg</File>
    <File>g164680g00y09.jpg</File>
    <File>g164680g00y10.jpg</File>
    <File>g164680g00y11.jpg</File>
    <File>g164680g00y14.jpg</File>
    <File>g164680g00y15.jpg</File>
    <File>g164680g00y16.jpg</File>
    <File>g164680g00y17.jpg</File>
    <File>g164680g00y19.jpg</File>
    <File>g164680g00y20.jpg</File>
    <File>g164680g01m01.jpg</File>
    <File>g164680g01m02.jpg</File>
    <File>g164680g01m03.jpg</File>
    <File>g164680g01m04.jpg</File>
    <File>g164680g01m07.jpg</File>
    <File>g164680g01m08.jpg</File>
    <File>g164680g01m09.jpg</File>
    <File>g164680g01m11.jpg</File>
    <File>g164680g01m12.jpg</File>
    <File>g164680g01m13.jpg</File>
    <File>g164680g01m14.jpg</File>
    <File>g164680g01m16.jpg</File>
    <File>g164680g01m17.jpg</File>
    <File>g164680g01m18.jpg</File>
    <File>g164680g01m19.jpg</File>
    <File>g164680g01m20.jpg</File>
    <File>g164680g22s22.jpg</File>
    <File>g164680g23s23.jpg</File>
    <File>g164680g24s24.jpg</File>
    <File>g164680g25s25.jpg</File>
    <File>g164680g26s26.jpg</File>
    <File>g164680g30a01.jpg</File>
    <File>g164680g54t55.jpg</File>
    <File>g164680g56s66.jpg</File>
    <File>g164680g58s99.jpg</File>
    <File>g164680g60t85.jpg</File>
    <File>g164680g64e02.jpg</File>
    <File>g164680g68z96.jpg</File>
    <File>g164680g83e66.jpg</File>
    <File>g164680g83n58.jpg</File>
    <File>g164680g84a55.jpg</File>
    <File>g164680g84w55.jpg</File>
    <File>g164680g88l67.jpg</File>
    <File>g164680g91u88.jpg</File>
    <File>g164680g92k66.jpg</File>
    <File>g164680g96s96.jpg</File>
    <File>g164680g97s97.jpg</File>
    <File>g164680g98s98.jpg</File>
    <File>g164680g99s99.jpg</File>
  </SupplementalFiles>
  <BaseTaxonomies>
    <BaseTaxonomy>http://xbrl.sec.gov/dei/2021</BaseTaxonomy>
    <BaseTaxonomy>http://xbrl.sec.gov/country/2021</BaseTaxonomy>
    <BaseTaxonomy>http://fasb.org/us-gaap/2021-01-31</BaseTaxonomy>
    <BaseTaxonomy>http://fasb.org/srt/2021-01-31</BaseTaxonomy>
  </BaseTaxonomies>
  <HasPresentationLinkbase>true</HasPresentationLinkbase>
  <HasCalculationLinkbase>true</HasCalculationLinkbase>
</FilingSummary>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>JSON
<SEQUENCE>160
<FILENAME>MetaLinks.json
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
{
 "instance": {
  "d164680ds1.htm": {
   "axisCustom": 2,
   "axisStandard": 30,
   "contextCount": 384,
   "dts": {
    "calculationLink": {
     "local": [
      "roiv-20210630_cal.xml"
     ]
    },
    "definitionLink": {
     "local": [
      "roiv-20210630_def.xml"
     ]
    },
    "inline": {
     "local": [
      "d164680ds1.htm"
     ]
    },
    "labelLink": {
     "local": [
      "roiv-20210630_lab.xml"
     ]
    },
    "presentationLink": {
     "local": [
      "roiv-20210630_pre.xml"
     ]
    },
    "schema": {
     "local": [
      "roiv-20210630.xsd"
     ],
     "remote": [
      "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xl-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xlink-2003-12-31.xsd",
      "https://xbrl.sec.gov/dei/2021/dei-2021.xsd",
      "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd",
      "http://www.xbrl.org/2005/xbrldt-2005.xsd",
      "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd",
      "https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd",
      "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd",
      "http://www.xbrl.org/2006/ref-2006-02-27.xsd",
      "https://xbrl.fasb.org/us-gaap/2021/elts/us-types-2021-01-31.xsd",
      "https://xbrl.fasb.org/srt/2021/elts/srt-types-2021-01-31.xsd",
      "https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd",
      "https://xbrl.sec.gov/country/2021/country-2021.xsd",
      "https://xbrl.fasb.org/srt/2021/elts/srt-roles-2021-01-31.xsd",
      "https://xbrl.fasb.org/us-gaap/2021/elts/us-roles-2021-01-31.xsd",
      "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd",
      "https://xbrl.sec.gov/currency/2021/currency-2021.xsd",
      "https://xbrl.sec.gov/exch/2021/exch-2021.xsd",
      "https://xbrl.sec.gov/naics/2021/naics-2021.xsd",
      "https://xbrl.sec.gov/sic/2021/sic-2021.xsd",
      "https://xbrl.sec.gov/stpr/2021/stpr-2021.xsd",
      "http://www.xbrl.org/lrr/arcrole/factExplanatory-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/reference-2009-12-16.xsd"
     ]
    }
   },
   "elementCount": 740,
   "entityCount": 1,
   "hidden": {
    "http://fasb.org/us-gaap/2021-01-31": 5,
    "http://xbrl.sec.gov/dei/2021": 3,
    "total": 8
   },
   "keyCustom": 122,
   "keyStandard": 454,
   "memberCustom": 50,
   "memberStandard": 39,
   "nsprefix": "roiv",
   "nsuri": "http://roivant.com/20210630",
   "report": {
    "R1": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d164680ds1.htm",
      "contextRef": "P04_01_2021To06_30_2021",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "dei:DocumentType",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "document",
     "isDefault": "true",
     "longName": "1001 - Document - Cover",
     "role": "http://roivant.com/role/Cover",
     "shortName": "Cover",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d164680ds1.htm",
      "contextRef": "P04_01_2021To06_30_2021",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "dei:DocumentType",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R10": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d164680ds1.htm",
      "contextRef": "P04_01_2021To06_30_2021",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:InvestmentsAndOtherNoncurrentAssetsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "1010 - Disclosure - Investments",
     "role": "http://roivant.com/role/Investments",
     "shortName": "Investments",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d164680ds1.htm",
      "contextRef": "P04_01_2021To06_30_2021",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:InvestmentsAndOtherNoncurrentAssetsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R11": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d164680ds1.htm",
      "contextRef": "P04_01_2020To03_31_2021",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "roiv:AssetAcquisitionsAndLicenseAgreementsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "1011 - Disclosure - Asset Acquisitions and License Agreements",
     "role": "http://roivant.com/role/AssetAcquisitionsAndLicenseAgreements",
     "shortName": "Asset Acquisitions and License Agreements",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d164680ds1.htm",
      "contextRef": "P04_01_2020To03_31_2021",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "roiv:AssetAcquisitionsAndLicenseAgreementsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R12": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d164680ds1.htm",
      "contextRef": "P04_01_2021To06_30_2021",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "roiv:TransactionAgreementDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "1012 - Disclosure - Sumitomo Transaction Agreement",
     "role": "http://roivant.com/role/SumitomoTransactionAgreement",
     "shortName": "Sumitomo Transaction Agreement",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d164680ds1.htm",
      "contextRef": "P04_01_2021To06_30_2021",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "roiv:TransactionAgreementDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R13": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d164680ds1.htm",
      "contextRef": "P04_01_2021To06_30_2021",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SupplementalBalanceSheetDisclosuresTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "1013 - Disclosure - Balance Sheet Components",
     "role": "http://roivant.com/role/BalanceSheetComponents",
     "shortName": "Balance Sheet Components",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d164680ds1.htm",
      "contextRef": "P04_01_2021To06_30_2021",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SupplementalBalanceSheetDisclosuresTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R14": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d164680ds1.htm",
      "contextRef": "P04_01_2021To06_30_2021",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LongTermDebtTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "1014 - Disclosure - Long Term Debt and Loan Commitment",
     "role": "http://roivant.com/role/LongTermDebtAndLoanCommitment",
     "shortName": "Long Term Debt and Loan Commitment",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d164680ds1.htm",
      "contextRef": "P04_01_2021To06_30_2021",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LongTermDebtTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R15": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d164680ds1.htm",
      "contextRef": "P04_01_2021To06_30_2021",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "1015 - Disclosure - Shareholders' Equity and Redeemable Noncontrolling Interest",
     "role": "http://roivant.com/role/ShareholdersEquityAndRedeemableNoncontrollingInterest",
     "shortName": "Shareholders' Equity and Redeemable Noncontrolling Interest",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d164680ds1.htm",
      "contextRef": "P04_01_2021To06_30_2021",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R16": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d164680ds1.htm",
      "contextRef": "P04_01_2021To06_30_2021",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "1016 - Disclosure - Share-Based Compensation",
     "role": "http://roivant.com/role/ShareBasedCompensation",
     "shortName": "Share-Based Compensation",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d164680ds1.htm",
      "contextRef": "P04_01_2021To06_30_2021",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R17": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d164680ds1.htm",
      "contextRef": "P04_01_2020To03_31_2021",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:RelatedPartyTransactionsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "1017 - Disclosure - Related Party Transactions",
     "role": "http://roivant.com/role/RelatedPartyTransactions",
     "shortName": "Related Party Transactions",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d164680ds1.htm",
      "contextRef": "P04_01_2020To03_31_2021",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:RelatedPartyTransactionsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R18": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d164680ds1.htm",
      "contextRef": "P04_01_2020To03_31_2021",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "1018 - Disclosure - Discontinued Operations",
     "role": "http://roivant.com/role/DiscontinuedOperations",
     "shortName": "Discontinued Operations",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d164680ds1.htm",
      "contextRef": "P04_01_2020To03_31_2021",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R19": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d164680ds1.htm",
      "contextRef": "P04_01_2021To06_30_2021",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:IncomeTaxDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "1019 - Disclosure - Income Taxes",
     "role": "http://roivant.com/role/IncomeTaxes",
     "shortName": "Income Taxes",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d164680ds1.htm",
      "contextRef": "P04_01_2021To06_30_2021",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:IncomeTaxDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R2": {
     "firstAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d164680ds1.htm",
      "contextRef": "PAsOn06_30_2021",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue",
      "reportCount": 1,
      "unitRef": "Unit_USD",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "1002 - Statement - Condensed Consolidated Balance Sheets",
     "role": "http://roivant.com/role/CondensedConsolidatedBalanceSheets",
     "shortName": "Condensed Consolidated Balance Sheets",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d164680ds1.htm",
      "contextRef": "PAsOn06_30_2021",
      "decimals": "-3",
      "lang": null,
      "name": "us-gaap:RestrictedCashCurrent",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_USD",
      "xsiNil": "false"
     }
    },
    "R20": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d164680ds1.htm",
      "contextRef": "P04_01_2020To03_31_2021",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LesseeOperatingLeasesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "1020 - Disclosure - Leases",
     "role": "http://roivant.com/role/Leases",
     "shortName": "Leases",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d164680ds1.htm",
      "contextRef": "P04_01_2020To03_31_2021",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LesseeOperatingLeasesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R21": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d164680ds1.htm",
      "contextRef": "P04_01_2021To06_30_2021",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "1021 - Disclosure - Commitments & Contingencies",
     "role": "http://roivant.com/role/CommitmentsContingencies",
     "shortName": "Commitments & Contingencies",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d164680ds1.htm",
      "contextRef": "P04_01_2021To06_30_2021",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R22": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d164680ds1.htm",
      "contextRef": "P04_01_2021To06_30_2021",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:FairValueDisclosuresTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "1022 - Disclosure - Fair Value Measurements",
     "role": "http://roivant.com/role/FairValueMeasurements",
     "shortName": "Fair Value Measurements",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d164680ds1.htm",
      "contextRef": "P04_01_2021To06_30_2021",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:FairValueDisclosuresTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R23": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d164680ds1.htm",
      "contextRef": "P04_01_2020To03_31_2021",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DefinedContributionPlanTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "1023 - Disclosure - Defined Contribution Plan",
     "role": "http://roivant.com/role/DefinedContributionPlan",
     "shortName": "Defined Contribution Plan",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d164680ds1.htm",
      "contextRef": "P04_01_2020To03_31_2021",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DefinedContributionPlanTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R24": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d164680ds1.htm",
      "contextRef": "P04_01_2021To06_30_2021",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:OtherOperatingIncomeAndExpenseTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "1024 - Disclosure - Other (Income) Expense, Net",
     "role": "http://roivant.com/role/OtherIncomeExpenseNet",
     "shortName": "Other (Income) Expense, Net",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d164680ds1.htm",
      "contextRef": "P04_01_2021To06_30_2021",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:OtherOperatingIncomeAndExpenseTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R25": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d164680ds1.htm",
      "contextRef": "P04_01_2021To06_30_2021",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:EarningsPerShareTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "1025 - Disclosure - Net Loss per Common Share",
     "role": "http://roivant.com/role/NetLossPerCommonShare",
     "shortName": "Net Loss per Common Share",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d164680ds1.htm",
      "contextRef": "P04_01_2021To06_30_2021",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:EarningsPerShareTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R26": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d164680ds1.htm",
      "contextRef": "P04_01_2021To06_30_2021",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SubsequentEventsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "1026 - Disclosure - Subsequent Events",
     "role": "http://roivant.com/role/SubsequentEvents",
     "shortName": "Subsequent Events",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d164680ds1.htm",
      "contextRef": "P04_01_2021To06_30_2021",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SubsequentEventsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R27": {
     "firstAnchor": {
      "ancestors": [
       "us-gaap:SignificantAccountingPoliciesTextBlock",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d164680ds1.htm",
      "contextRef": "P04_01_2021To06_30_2021",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:BasisOfAccountingPolicyPolicyTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "1027 - Disclosure - Summary of Significant Accounting Policies (Policies)",
     "role": "http://roivant.com/role/SummaryOfSignificantAccountingPoliciesPolicies",
     "shortName": "Summary of Significant Accounting Policies (Policies)",
     "subGroupType": "policies",
     "uniqueAnchor": {
      "ancestors": [
       "us-gaap:SignificantAccountingPoliciesTextBlock",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d164680ds1.htm",
      "contextRef": "P04_01_2021To06_30_2021",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:BasisOfAccountingPolicyPolicyTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R28": {
     "firstAnchor": {
      "ancestors": [
       "us-gaap:CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy",
       "ix:continuation",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d164680ds1.htm",
      "contextRef": "P04_01_2021To06_30_2021",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfCashAndCashEquivalentsTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "1028 - Disclosure - Summary of Significant Accounting Policies (Tables)",
     "role": "http://roivant.com/role/SummaryOfSignificantAccountingPoliciesTables",
     "shortName": "Summary of Significant Accounting Policies (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "us-gaap:CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy",
       "ix:continuation",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d164680ds1.htm",
      "contextRef": "P04_01_2021To06_30_2021",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfCashAndCashEquivalentsTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R29": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d164680ds1.htm",
      "contextRef": "P04_01_2020To03_31_2021",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfDisposalGroupsIncludingDiscontinuedOperationsIncomeStatementBalanceSheetAndAdditionalDisclosuresTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "1029 - Disclosure - Discontinued Operations (Tables)",
     "role": "http://roivant.com/role/DiscontinuedOperationsTables",
     "shortName": "Discontinued Operations (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d164680ds1.htm",
      "contextRef": "P04_01_2020To03_31_2021",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfDisposalGroupsIncludingDiscontinuedOperationsIncomeStatementBalanceSheetAndAdditionalDisclosuresTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R3": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d164680ds1.htm",
      "contextRef": "PAsOn06_30_2021",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:LongTermDebtFairValue",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_USD",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "1003 - Statement - Condensed Consolidated Balance Sheets (Parenthetical)",
     "role": "http://roivant.com/role/CondensedConsolidatedBalanceSheetsParenthetical",
     "shortName": "Condensed Consolidated Balance Sheets (Parenthetical)",
     "subGroupType": "parenthetical",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d164680ds1.htm",
      "contextRef": "PAsOn06_30_2021",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:LongTermDebtFairValue",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_USD",
      "xsiNil": "false"
     }
    },
    "R30": {
     "firstAnchor": {
      "ancestors": [
       "us-gaap:SupplementalBalanceSheetDisclosuresTextBlock",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d164680ds1.htm",
      "contextRef": "P04_01_2021To06_30_2021",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfOtherCurrentAssetsTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "1030 - Disclosure - Balance Sheet Components (Tables)",
     "role": "http://roivant.com/role/BalanceSheetComponentsTables",
     "shortName": "Balance Sheet Components (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "us-gaap:SupplementalBalanceSheetDisclosuresTextBlock",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d164680ds1.htm",
      "contextRef": "P04_01_2021To06_30_2021",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfOtherCurrentAssetsTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R31": {
     "firstAnchor": {
      "ancestors": [
       "us-gaap:LongTermDebtTextBlock",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d164680ds1.htm",
      "contextRef": "P04_01_2021To06_30_2021",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfDebtTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "1031 - Disclosure - Long Term Debt and Loan Commitment (Tables)",
     "role": "http://roivant.com/role/LongTermDebtAndLoanCommitmentTables",
     "shortName": "Long Term Debt and Loan Commitment (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "us-gaap:LongTermDebtTextBlock",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d164680ds1.htm",
      "contextRef": "P04_01_2021To06_30_2021",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfDebtTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R32": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d164680ds1.htm",
      "contextRef": "P04_01_2020To03_31_2021",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfStockholdersEquityTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "1032 - Disclosure - Shareholders' Equity and Redeemable Noncontrolling Interest (Tables)",
     "role": "http://roivant.com/role/ShareholdersEquityAndRedeemableNoncontrollingInterestTables",
     "shortName": "Shareholders' Equity and Redeemable Noncontrolling Interest (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d164680ds1.htm",
      "contextRef": "P04_01_2020To03_31_2021",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfStockholdersEquityTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R33": {
     "firstAnchor": {
      "ancestors": [
       "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d164680ds1.htm",
      "contextRef": "P04_01_2020To03_31_2021",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "1033 - Disclosure - Share-Based Compensation (Tables)",
     "role": "http://roivant.com/role/ShareBasedCompensationTables",
     "shortName": "Share-Based Compensation (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d164680ds1.htm",
      "contextRef": "P04_01_2020To03_31_2021",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R34": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "div",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d164680ds1.htm",
      "contextRef": "P04_01_2020To03_31_2021",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "1034 - Disclosure - Income Taxes (Tables)",
     "role": "http://roivant.com/role/IncomeTaxesTables",
     "shortName": "Income Taxes (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "div",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d164680ds1.htm",
      "contextRef": "P04_01_2020To03_31_2021",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R35": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d164680ds1.htm",
      "contextRef": "P04_01_2020To03_31_2021",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LeaseCostTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "1035 - Disclosure - Leases (Tables)",
     "role": "http://roivant.com/role/LeasesTables",
     "shortName": "Leases (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d164680ds1.htm",
      "contextRef": "P04_01_2020To03_31_2021",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LeaseCostTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R36": {
     "firstAnchor": {
      "ancestors": [
       "us-gaap:FairValueDisclosuresTextBlock",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d164680ds1.htm",
      "contextRef": "P04_01_2021To06_30_2021",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "1036 - Disclosure - Fair Value Measurements (Tables)",
     "role": "http://roivant.com/role/FairValueMeasurementsTables",
     "shortName": "Fair Value Measurements (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "us-gaap:FairValueDisclosuresTextBlock",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d164680ds1.htm",
      "contextRef": "P04_01_2021To06_30_2021",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R37": {
     "firstAnchor": {
      "ancestors": [
       "us-gaap:OtherOperatingIncomeAndExpenseTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d164680ds1.htm",
      "contextRef": "P04_01_2021To06_30_2021",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfOtherOperatingCostAndExpenseByComponentTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "1037 - Disclosure - Other (Income) Expense, Net (Tables)",
     "role": "http://roivant.com/role/OtherIncomeExpenseNetTables",
     "shortName": "Other (Income) Expense, Net (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "us-gaap:OtherOperatingIncomeAndExpenseTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d164680ds1.htm",
      "contextRef": "P04_01_2021To06_30_2021",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfOtherOperatingCostAndExpenseByComponentTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R38": {
     "firstAnchor": {
      "ancestors": [
       "us-gaap:EarningsPerShareTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d164680ds1.htm",
      "contextRef": "P04_01_2020To03_31_2021",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "1038 - Disclosure - Net Loss per Common Share (Tables)",
     "role": "http://roivant.com/role/NetLossPerCommonShareTables",
     "shortName": "Net Loss per Common Share (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "us-gaap:EarningsPerShareTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d164680ds1.htm",
      "contextRef": "P04_01_2020To03_31_2021",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R39": {
     "firstAnchor": {
      "ancestors": [
       "us-gaap:NumberOfOperatingSegments",
       "div",
       "div",
       "us-gaap:BusinessDescriptionAndBasisOfPresentationTextBlock",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d164680ds1.htm",
      "contextRef": "P04_01_2021To06_30_2021",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "us-gaap:NumberOfOperatingSegments",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Segment",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "1039 - Disclosure - Description of Business and Liquidity - Additional Information (Detail)",
     "role": "http://roivant.com/role/DescriptionOfBusinessAndLiquidityAdditionalInformationDetail",
     "shortName": "Description of Business and Liquidity - Additional Information (Detail)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "us-gaap:NumberOfOperatingSegments",
       "div",
       "div",
       "us-gaap:BusinessDescriptionAndBasisOfPresentationTextBlock",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d164680ds1.htm",
      "contextRef": "P04_01_2021To06_30_2021",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "us-gaap:NumberOfOperatingSegments",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Segment",
      "xsiNil": "false"
     }
    },
    "R4": {
     "firstAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d164680ds1.htm",
      "contextRef": "P04_01_2021To06_30_2021",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_USD",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "1004 - Statement - Condensed Consolidated Statements of Operations",
     "role": "http://roivant.com/role/CondensedConsolidatedStatementsOfOperations",
     "shortName": "Condensed Consolidated Statements of Operations",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d164680ds1.htm",
      "contextRef": "P04_01_2021To06_30_2021",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_USD",
      "xsiNil": "false"
     }
    },
    "R40": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "us-gaap:CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy",
       "ix:continuation",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d164680ds1.htm",
      "contextRef": "PAsOn03_31_2021",
      "decimals": "-5",
      "first": true,
      "lang": null,
      "name": "us-gaap:EscrowDeposit",
      "reportCount": 1,
      "unitRef": "Unit_USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "1040 - Disclosure - Summary of Significant Accounting Policies - Additional Information (Detail)",
     "role": "http://roivant.com/role/SummaryOfSignificantAccountingPoliciesAdditionalInformationDetail",
     "shortName": "Summary of Significant Accounting Policies - Additional Information (Detail)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "us-gaap:CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy",
       "ix:continuation",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d164680ds1.htm",
      "contextRef": "PAsOn06_30_2021",
      "decimals": "-5",
      "lang": null,
      "name": "roiv:ProceedsFromReleaseOfEscrowDeposit",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_USD",
      "xsiNil": "false"
     }
    },
    "R41": {
     "firstAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d164680ds1.htm",
      "contextRef": "PAsOn06_30_2021",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue",
      "reportCount": 1,
      "unitRef": "Unit_USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "1041 - Disclosure - Summary of Significant Accounting Policies - Schedule of Aggregate Amounts of Cash, Cash Equivalents, and Restricted Cash (Detail)",
     "role": "http://roivant.com/role/SummaryOfSignificantAccountingPoliciesScheduleOfAggregateAmountsOfCashCashEquivalentsAndRestrictedCashDetail",
     "shortName": "Summary of Significant Accounting Policies - Schedule of Aggregate Amounts of Cash, Cash Equivalents, and Restricted Cash (Detail)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfCashAndCashEquivalentsTableTextBlock",
       "us-gaap:CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy",
       "ix:continuation",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d164680ds1.htm",
      "contextRef": "PAsOn06_30_2021",
      "decimals": "-3",
      "lang": null,
      "name": "roiv:CashAndCashEquivalentsAndRestrictedCash",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_USD",
      "xsiNil": "false"
     }
    },
    "R42": {
     "firstAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "ix:continuation",
       "us-gaap:PropertyPlantAndEquipmentPolicyTextBlock",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d164680ds1.htm",
      "contextRef": "P04_01_2020To03_31_2021_ComputerEquipmentMemberusgaapPropertyPlantAndEquipmentByTypeAxis",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PropertyPlantAndEquipmentUsefulLife",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "1042 - Disclosure - Summary of Significant Accounting Policies - Schedule of Estimated Useful Lives (Detail)",
     "role": "http://roivant.com/role/SummaryOfSignificantAccountingPoliciesScheduleOfEstimatedUsefulLivesDetail",
     "shortName": "Summary of Significant Accounting Policies - Schedule of Estimated Useful Lives (Detail)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "ix:continuation",
       "us-gaap:PropertyPlantAndEquipmentPolicyTextBlock",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d164680ds1.htm",
      "contextRef": "P04_01_2020To03_31_2021_ComputerEquipmentMemberusgaapPropertyPlantAndEquipmentByTypeAxis",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PropertyPlantAndEquipmentUsefulLife",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R43": {
     "firstAnchor": {
      "ancestors": [
       "roiv:CommonStockOwnedBalanceSharesOfArbutus",
       "div",
       "us-gaap:InvestmentsAndOtherNoncurrentAssetsTextBlock",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d164680ds1.htm",
      "contextRef": "PAsOn06_30_2021",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "roiv:CommonStockOwnedBalanceSharesOfArbutus",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_shares",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "1043 - Disclosure - Investments - Additional Information (Detail)",
     "role": "http://roivant.com/role/InvestmentsAdditionalInformationDetail",
     "shortName": "Investments - Additional Information (Detail)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "roiv:CommonStockOwnedBalanceSharesOfArbutus",
       "div",
       "us-gaap:InvestmentsAndOtherNoncurrentAssetsTextBlock",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d164680ds1.htm",
      "contextRef": "PAsOn06_30_2021",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "roiv:CommonStockOwnedBalanceSharesOfArbutus",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_shares",
      "xsiNil": "false"
     }
    },
    "R44": {
     "firstAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfDebtTableTextBlock",
       "us-gaap:LongTermDebtTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d164680ds1.htm",
      "contextRef": "PAsOn03_31_2021",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:LongTermDebt",
      "reportCount": 1,
      "unitRef": "Unit_USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "1044 - Disclosure - Asset Acquisitions and License Agreements -Additional Information (Detail)",
     "role": "http://roivant.com/role/AssetAcquisitionsAndLicenseAgreementsAdditionalInformationDetail",
     "shortName": "Asset Acquisitions and License Agreements -Additional Information (Detail)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "div",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d164680ds1.htm",
      "contextRef": "P03_01_2021To03_31_2021_SiliconTherapeuticsMemberusgaapBusinessAcquisitionAxis",
      "decimals": "-5",
      "lang": null,
      "name": "us-gaap:BusinessCombinationConsiderationTransferred1",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_USD",
      "xsiNil": "false"
     }
    },
    "R45": {
     "firstAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d164680ds1.htm",
      "contextRef": "P04_01_2019To03_31_2020",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:GainOrLossOnSaleOfStockInSubsidiary",
      "reportCount": 1,
      "unitRef": "Unit_USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "1045 - Disclosure - Sumitomo Transaction Agreement - Additional Information (Detail)",
     "role": "http://roivant.com/role/SumitomoTransactionAgreementAdditionalInformationDetail",
     "shortName": "Sumitomo Transaction Agreement - Additional Information (Detail)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "div",
       "ix:continuation",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d164680ds1.htm",
      "contextRef": "P04_01_2021To06_30_2021_TransitionServicesAndStrategicCooperationAgreementMemberROIVAgreementAxis",
      "decimals": "-5",
      "lang": null,
      "name": "roiv:AgreementRelatedBilledAmountForCostsIncurredOnBehalfOfSubsidiarynetOfAmountsBilledBySubsidiary",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_USD",
      "xsiNil": "false"
     }
    },
    "R46": {
     "firstAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfOtherCurrentAssetsTableTextBlock",
       "us-gaap:SupplementalBalanceSheetDisclosuresTextBlock",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d164680ds1.htm",
      "contextRef": "PAsOn06_30_2021",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:PrepaidExpenseCurrent",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "1046 - Disclosure - Balance Sheet Components - Schedule of Other Current Assets (Detail)",
     "role": "http://roivant.com/role/BalanceSheetComponentsScheduleOfOtherCurrentAssetsDetail",
     "shortName": "Balance Sheet Components - Schedule of Other Current Assets (Detail)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfOtherCurrentAssetsTableTextBlock",
       "us-gaap:SupplementalBalanceSheetDisclosuresTextBlock",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d164680ds1.htm",
      "contextRef": "PAsOn06_30_2021",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:PrepaidExpenseCurrent",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_USD",
      "xsiNil": "false"
     }
    },
    "R47": {
     "firstAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d164680ds1.htm",
      "contextRef": "PAsOn06_30_2021",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:AccruedLiabilitiesCurrent",
      "reportCount": 1,
      "unitRef": "Unit_USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "1047 - Disclosure - Balance Sheet Components - Schedule of Accrued Expenses (Detail)",
     "role": "http://roivant.com/role/BalanceSheetComponentsScheduleOfAccruedExpensesDetail",
     "shortName": "Balance Sheet Components - Schedule of Accrued Expenses (Detail)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock",
       "ix:continuation",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d164680ds1.htm",
      "contextRef": "PAsOn06_30_2021_ResearchAndDevelopmentExpenseMemberusgaapIncomeStatementLocationAxis",
      "decimals": "-3",
      "lang": null,
      "name": "us-gaap:AccruedLiabilitiesCurrent",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_USD",
      "xsiNil": "false"
     }
    },
    "R48": {
     "firstAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:OtherCurrentLiabilitiesTableTextBlock",
       "ix:continuation",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d164680ds1.htm",
      "contextRef": "PAsOn06_30_2021",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "roiv:DeferredRevenueOtherCurrentLiabilities",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "1048 - Disclosure - Balance Sheet Components - Schedule of Other Current Liabilities (Detail)",
     "role": "http://roivant.com/role/BalanceSheetComponentsScheduleOfOtherCurrentLiabilitiesDetail",
     "shortName": "Balance Sheet Components - Schedule of Other Current Liabilities (Detail)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:OtherCurrentLiabilitiesTableTextBlock",
       "ix:continuation",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d164680ds1.htm",
      "contextRef": "PAsOn06_30_2021",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "roiv:DeferredRevenueOtherCurrentLiabilities",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_USD",
      "xsiNil": "false"
     }
    },
    "R49": {
     "firstAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfDebtTableTextBlock",
       "us-gaap:LongTermDebtTextBlock",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d164680ds1.htm",
      "contextRef": "PAsOn06_30_2021",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:DebtInstrumentCarryingAmount",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "1049 - Disclosure - Long Term Debt and Loan Commitment (Detail)",
     "role": "http://roivant.com/role/LongTermDebtAndLoanCommitmentDetail",
     "shortName": "Long Term Debt and Loan Commitment (Detail)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfDebtTableTextBlock",
       "us-gaap:LongTermDebtTextBlock",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d164680ds1.htm",
      "contextRef": "PAsOn06_30_2021",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:DebtInstrumentCarryingAmount",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_USD",
      "xsiNil": "false"
     }
    },
    "R5": {
     "firstAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d164680ds1.htm",
      "contextRef": "P04_01_2021To06_30_2021",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:ProfitLoss",
      "reportCount": 1,
      "unitRef": "Unit_USD",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "1005 - Statement - Condensed Consolidated Statements of Comprehensive Loss",
     "role": "http://roivant.com/role/CondensedConsolidatedStatementsOfComprehensiveLoss",
     "shortName": "Condensed Consolidated Statements of Comprehensive Loss",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d164680ds1.htm",
      "contextRef": "P04_01_2021To06_30_2021",
      "decimals": "-3",
      "lang": null,
      "name": "us-gaap:OtherComprehensiveIncomeLossNetOfTax",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_USD",
      "xsiNil": "false"
     }
    },
    "R50": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "div",
       "us-gaap:LongTermDebtTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d164680ds1.htm",
      "contextRef": "PAsOn03_31_2021",
      "decimals": "-5",
      "first": true,
      "lang": null,
      "name": "us-gaap:DebtInstrumentFaceAmount",
      "reportCount": 1,
      "unitRef": "Unit_USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "1050 - Disclosure - Long-Term Debt and Loan Commitment - Additional Information (Detail)",
     "role": "http://roivant.com/role/LongTermDebtAndLoanCommitmentAdditionalInformationDetail",
     "shortName": "Long-Term Debt and Loan Commitment - Additional Information (Detail)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "div",
       "us-gaap:LongTermDebtTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d164680ds1.htm",
      "contextRef": "PAsOn05_31_2019",
      "decimals": "4",
      "lang": null,
      "name": "us-gaap:LongTermDebtPercentageBearingVariableInterestRate",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_pure",
      "xsiNil": "false"
     }
    },
    "R51": {
     "firstAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "srt:ContractualObligationFiscalYearMaturityScheduleTableTextBlock",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d164680ds1.htm",
      "contextRef": "PAsOn03_31_2021",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "1051 - Disclosure - Long Term Debt and Convertible Notes Payable - Schedule of Company's Annual Payments (Detail)",
     "role": "http://roivant.com/role/LongTermDebtAndConvertibleNotesPayableScheduleOfCompanysAnnualPaymentsDetail",
     "shortName": "Long Term Debt and Convertible Notes Payable - Schedule of Company's Annual Payments (Detail)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "srt:ContractualObligationFiscalYearMaturityScheduleTableTextBlock",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d164680ds1.htm",
      "contextRef": "PAsOn03_31_2021",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_USD",
      "xsiNil": "false"
     }
    },
    "R52": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "ix:continuation",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d164680ds1.htm",
      "contextRef": "PAsOn05_31_2021",
      "decimals": "2",
      "first": true,
      "lang": null,
      "name": "us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1",
      "reportCount": 1,
      "unitRef": "Unit_USD_per_Share",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "1052 - Disclosure - Shareholders' Equity and Redeemable Non-Controlling Interest - Additional Information (Detail)",
     "role": "http://roivant.com/role/ShareholdersEquityAndRedeemableNonControllingInterestAdditionalInformationDetail",
     "shortName": "Shareholders' Equity and Redeemable Non-Controlling Interest - Additional Information (Detail)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d164680ds1.htm",
      "contextRef": "P04_01_2020To03_31_2021",
      "decimals": null,
      "lang": "en-US",
      "name": "roiv:EarnOutSharesTermsDescription",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R53": {
     "firstAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "ix:continuation",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d164680ds1.htm",
      "contextRef": "P04_01_2019To03_31_2020",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:PaymentsForRepurchaseOfCommonStock",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "1053 - Disclosure - Shareholders' Equity and Redeemable Non-Controlling Interest - Schedule of payments of equity securities (Detail)",
     "role": "http://roivant.com/role/ShareholdersEquityAndRedeemableNonControllingInterestScheduleOfPaymentsOfEquitySecuritiesDetail",
     "shortName": "Shareholders' Equity and Redeemable Non-Controlling Interest - Schedule of payments of equity securities (Detail)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "ix:continuation",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d164680ds1.htm",
      "contextRef": "P04_01_2019To03_31_2020",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:PaymentsForRepurchaseOfCommonStock",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_USD",
      "xsiNil": "false"
     }
    },
    "R54": {
     "firstAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock",
       "ix:continuation",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d164680ds1.htm",
      "contextRef": "P04_01_2021To06_30_2021",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:AllocatedShareBasedCompensationExpense",
      "reportCount": 1,
      "unitRef": "Unit_USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "1054 - Disclosure - Share-Based Compensation - Additional Information (Detail)",
     "role": "http://roivant.com/role/ShareBasedCompensationAdditionalInformationDetail",
     "shortName": "Share-Based Compensation - Additional Information (Detail)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d164680ds1.htm",
      "contextRef": "P04_01_2020To03_31_2021_RestrictedStockUnitsRSUMemberusgaapAwardTypeAxis",
      "decimals": "INF",
      "lang": null,
      "name": "us-gaap:AllocatedShareBasedCompensationExpense",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_USD",
      "xsiNil": "false"
     }
    },
    "R55": {
     "firstAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock",
       "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d164680ds1.htm",
      "contextRef": "P04_01_2020To03_31_2021_EmployeeStockOptionMemberusgaapAwardTypeAxis",
      "decimals": "4",
      "first": true,
      "lang": null,
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_pure",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "1055 - Disclosure - Share-Based Compensation - Schedule of Fair Value Assumptions (Detail)",
     "role": "http://roivant.com/role/ShareBasedCompensationScheduleOfFairValueAssumptionsDetail",
     "shortName": "Share-Based Compensation - Schedule of Fair Value Assumptions (Detail)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock",
       "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d164680ds1.htm",
      "contextRef": "P04_01_2020To03_31_2021_EmployeeStockOptionMemberusgaapAwardTypeAxis",
      "decimals": "4",
      "first": true,
      "lang": null,
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_pure",
      "xsiNil": "false"
     }
    },
    "R56": {
     "firstAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d164680ds1.htm",
      "contextRef": "PAsOn03_31_2021_EmployeeStockOptionMemberusgaapAwardTypeAxis_TwoThousandFifteenEquityIncentivePlanMemberusgaapPlanNameAxis",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber",
      "reportCount": 1,
      "unitRef": "Unit_shares",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "1056 - Disclosure - Share-Based Compensation - Summary of Stock Option Activity (Detail)",
     "role": "http://roivant.com/role/ShareBasedCompensationSummaryOfStockOptionActivityDetail",
     "shortName": "Share-Based Compensation - Summary of Stock Option Activity (Detail)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
       "ix:continuation",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d164680ds1.htm",
      "contextRef": "P04_01_2021To06_30_2021_EmployeeStockOptionMemberusgaapAwardTypeAxis_TwoThousandFifteenEquityIncentivePlanMemberusgaapPlanNameAxis",
      "decimals": "INF",
      "lang": null,
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_shares",
      "xsiNil": "false"
     }
    },
    "R57": {
     "firstAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "ix:continuation",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d164680ds1.htm",
      "contextRef": "P04_01_2020To03_31_2021",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1",
      "reportCount": 1,
      "unitRef": "Unit_USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "1057 - Disclosure - Share-Based Compensation - Summary of Fair Value of Vested Stock Option (Detail)",
     "role": "http://roivant.com/role/ShareBasedCompensationSummaryOfFairValueOfVestedStockOptionDetail",
     "shortName": "Share-Based Compensation - Summary of Fair Value of Vested Stock Option (Detail)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "ix:continuation",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d164680ds1.htm",
      "contextRef": "P04_01_2020To03_31_2021",
      "decimals": "2",
      "lang": null,
      "name": "us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_USD_per_Share",
      "xsiNil": "false"
     }
    },
    "R58": {
     "firstAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d164680ds1.htm",
      "contextRef": "PAsOn03_31_2021_RestrictedStockUnitsRSUMemberusgaapAwardTypeAxis_TwoThousandFifteenEquityIncentivePlanMemberusgaapPlanNameAxis",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber",
      "reportCount": 1,
      "unitRef": "Unit_shares",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "1058 - Disclosure - Share-Based Compensation - Summary of Restricted Stock Units (Detail)",
     "role": "http://roivant.com/role/ShareBasedCompensationSummaryOfRestrictedStockUnitsDetail",
     "shortName": "Share-Based Compensation - Summary of Restricted Stock Units (Detail)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d164680ds1.htm",
      "contextRef": "PAsOn03_31_2020_RestrictedStockUnitsRSUMemberusgaapAwardTypeAxis_TwoThousandFifteenEquityIncentivePlanMemberusgaapPlanNameAxis",
      "decimals": "INF",
      "lang": null,
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_shares",
      "xsiNil": "false"
     }
    },
    "R59": {
     "firstAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d164680ds1.htm",
      "contextRef": "PAsOn03_31_2021_PerformanceOptionsMemberusgaapAwardTypeAxis_TwoThousandFifteenEquityIncentivePlanMemberusgaapPlanNameAxis",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber",
      "reportCount": 1,
      "unitRef": "Unit_shares",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "1059 - Disclosure - Share-Based Compensation - Summary of Performance Options Activity (Detail)",
     "role": "http://roivant.com/role/ShareBasedCompensationSummaryOfPerformanceOptionsActivityDetail",
     "shortName": "Share-Based Compensation - Summary of Performance Options Activity (Detail)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
       "ix:continuation",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d164680ds1.htm",
      "contextRef": "P04_01_2021To06_30_2021_PerformanceOptionsMemberusgaapAwardTypeAxis_TwoThousandFifteenEquityIncentivePlanMemberusgaapPlanNameAxis",
      "decimals": "INF",
      "lang": null,
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_shares",
      "xsiNil": "false"
     }
    },
    "R6": {
     "firstAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d164680ds1.htm",
      "contextRef": "PAsOn03_31_2019_RedeemableNoncontrollingInterestMemberusgaapStatementClassOfStockAxis",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:TemporaryEquityCarryingAmountIncludingPortionAttributableToNoncontrollingInterests",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_USD",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "1006 - Statement - Condensed Consolidated Statements of Shareholders' Equity and Redeemable Noncontrolling Interest",
     "role": "http://roivant.com/role/CondensedConsolidatedStatementsOfShareholdersEquityAndRedeemableNoncontrollingInterest",
     "shortName": "Condensed Consolidated Statements of Shareholders' Equity and Redeemable Noncontrolling Interest",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d164680ds1.htm",
      "contextRef": "PAsOn03_31_2019_RedeemableNoncontrollingInterestMemberusgaapStatementClassOfStockAxis",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:TemporaryEquityCarryingAmountIncludingPortionAttributableToNoncontrollingInterests",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_USD",
      "xsiNil": "false"
     }
    },
    "R60": {
     "firstAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d164680ds1.htm",
      "contextRef": "PAsOn03_31_2021_CappedValueAppreciationRightsMemberusgaapAwardTypeAxis_TwoThousandFifteenEquityIncentivePlanMemberusgaapPlanNameAxis",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber",
      "reportCount": 1,
      "unitRef": "Unit_shares",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "1060 - Disclosure - Share-Based Compensation - Summary of Capped Value Appreciation Rights (Detail)",
     "role": "http://roivant.com/role/ShareBasedCompensationSummaryOfCappedValueAppreciationRightsDetail",
     "shortName": "Share-Based Compensation - Summary of Capped Value Appreciation Rights (Detail)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d164680ds1.htm",
      "contextRef": "PAsOn03_31_2020_CappedValueAppreciationRightsMemberusgaapAwardTypeAxis_TwoThousandFifteenEquityIncentivePlanMemberusgaapPlanNameAxis",
      "decimals": "INF",
      "lang": null,
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_shares",
      "xsiNil": "false"
     }
    },
    "R61": {
     "firstAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d164680ds1.htm",
      "contextRef": "PAsOn03_31_2021_PerformanceRestrictedStockUnitsMemberusgaapAwardTypeAxis_PerformanceRestrictedStockUnitsPlanMemberusgaapPlanNameAxis",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber",
      "reportCount": 1,
      "unitRef": "Unit_shares",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "1061 - Disclosure - Share-Based Compensation - Summary of Performance Restricted Stock Units (Detail)",
     "role": "http://roivant.com/role/ShareBasedCompensationSummaryOfPerformanceRestrictedStockUnitsDetail",
     "shortName": "Share-Based Compensation - Summary of Performance Restricted Stock Units (Detail)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d164680ds1.htm",
      "contextRef": "PAsOn03_31_2020_PerformanceRestrictedStockUnitsMemberusgaapAwardTypeAxis_PerformanceRestrictedStockUnitsPlanMemberusgaapPlanNameAxis",
      "decimals": "INF",
      "lang": null,
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_shares",
      "xsiNil": "false"
     }
    },
    "R62": {
     "firstAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d164680ds1.htm",
      "contextRef": "PAsOn03_31_2021_CommonStockAwardsMemberusgaapAwardTypeAxis",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber",
      "reportCount": 1,
      "unitRef": "Unit_shares",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "1062 - Disclosure - Share-Based Compensation - Summary of Common Share Award Activity (Detail)",
     "role": "http://roivant.com/role/ShareBasedCompensationSummaryOfCommonShareAwardActivityDetail",
     "shortName": "Share-Based Compensation - Summary of Common Share Award Activity (Detail)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d164680ds1.htm",
      "contextRef": "PAsOn03_31_2020_CommonStockAwardsMemberusgaapAwardTypeAxis",
      "decimals": "INF",
      "lang": null,
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_shares",
      "xsiNil": "false"
     }
    },
    "R63": {
     "firstAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock",
       "ix:continuation",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d164680ds1.htm",
      "contextRef": "P04_01_2021To06_30_2021",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:AllocatedShareBasedCompensationExpense",
      "reportCount": 1,
      "unitRef": "Unit_USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "1063 - Disclosure - Share-Based Compensation - Summary of Share-Based Compensation Expense (Detail)",
     "role": "http://roivant.com/role/ShareBasedCompensationSummaryOfShareBasedCompensationExpenseDetail",
     "shortName": "Share-Based Compensation - Summary of Share-Based Compensation Expense (Detail)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock",
       "ix:continuation",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d164680ds1.htm",
      "contextRef": "P04_01_2021To06_30_2021_ResearchAndDevelopmentExpenseMemberusgaapIncomeStatementLocationAxis",
      "decimals": "-3",
      "lang": null,
      "name": "us-gaap:AllocatedShareBasedCompensationExpense",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_USD",
      "xsiNil": "false"
     }
    },
    "R64": {
     "firstAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfDisposalGroupsIncludingDiscontinuedOperationsIncomeStatementBalanceSheetAndAdditionalDisclosuresTextBlock",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d164680ds1.htm",
      "contextRef": "P04_01_2019To03_31_2020",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "roiv:DisposalGroupIncludingDiscontinuedOperationResearchAndDevelopmentExpense",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "1064 - Disclosure - Discontinued Operations - Summary Of Disposal Groups Including Discontinued Operations Income Statement (Detail)",
     "role": "http://roivant.com/role/DiscontinuedOperationsSummaryOfDisposalGroupsIncludingDiscontinuedOperationsIncomeStatementDetail",
     "shortName": "Discontinued Operations - Summary Of Disposal Groups Including Discontinued Operations Income Statement (Detail)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfDisposalGroupsIncludingDiscontinuedOperationsIncomeStatementBalanceSheetAndAdditionalDisclosuresTextBlock",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d164680ds1.htm",
      "contextRef": "P04_01_2019To03_31_2020",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "roiv:DisposalGroupIncludingDiscontinuedOperationResearchAndDevelopmentExpense",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_USD",
      "xsiNil": "false"
     }
    },
    "R65": {
     "firstAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfDisposalGroupsIncludingDiscontinuedOperationsIncomeStatementBalanceSheetAndAdditionalDisclosuresTextBlock",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d164680ds1.htm",
      "contextRef": "P04_01_2019To03_31_2020",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "roiv:DisposalGroupIncludingDiscontinuedOperationGainLossOnSaleOfBusiness",
      "reportCount": 1,
      "unitRef": "Unit_USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "1065 - Disclosure - Discontinued Operations - Summary of Cash Flows From Discontinued Operations (Detail)",
     "role": "http://roivant.com/role/DiscontinuedOperationsSummaryOfCashFlowsFromDiscontinuedOperationsDetail",
     "shortName": "Discontinued Operations - Summary of Cash Flows From Discontinued Operations (Detail)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "ix:continuation",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d164680ds1.htm",
      "contextRef": "P04_01_2019To03_31_2020",
      "decimals": "-3",
      "lang": null,
      "name": "roiv:DisposalGroupIncludingDiscontinuedOperationShareBasedCompensation",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_USD",
      "xsiNil": "false"
     }
    },
    "R66": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "div",
       "us-gaap:RelatedPartyTransactionsDisclosureTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d164680ds1.htm",
      "contextRef": "P04_01_2020To03_31_2021_SumitovantMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis",
      "decimals": "-5",
      "first": true,
      "lang": null,
      "name": "us-gaap:CostsAndExpensesRelatedParty",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "1066 - Disclosure - Related Party Transactions - Additional Information (Detail)",
     "role": "http://roivant.com/role/RelatedPartyTransactionsAdditionalInformationDetail",
     "shortName": "Related Party Transactions - Additional Information (Detail)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "div",
       "us-gaap:RelatedPartyTransactionsDisclosureTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d164680ds1.htm",
      "contextRef": "P04_01_2020To03_31_2021_SumitovantMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis",
      "decimals": "-5",
      "first": true,
      "lang": null,
      "name": "us-gaap:CostsAndExpensesRelatedParty",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_USD",
      "xsiNil": "false"
     }
    },
    "R67": {
     "firstAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d164680ds1.htm",
      "contextRef": "P04_01_2020To03_31_2021",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments",
      "reportCount": 1,
      "unitRef": "Unit_USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "1067 - Disclosure - Income Taxes - Schedule of Loss Before Income Taxes by Geographic Region (Detail)",
     "role": "http://roivant.com/role/IncomeTaxesScheduleOfLossBeforeIncomeTaxesByGeographicRegionDetail",
     "shortName": "Income Taxes - Schedule of Loss Before Income Taxes by Geographic Region (Detail)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock",
       "us-gaap:IncomeTaxDisclosureTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d164680ds1.htm",
      "contextRef": "P04_01_2020To03_31_2021_USsrtStatementGeographicalAxis",
      "decimals": "-3",
      "lang": null,
      "name": "us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_USD",
      "xsiNil": "false"
     }
    },
    "R68": {
     "firstAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "ix:continuation",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d164680ds1.htm",
      "contextRef": "P04_01_2020To03_31_2021",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:CurrentIncomeTaxExpenseBenefit",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "1068 - Disclosure - Income Taxes - Schedule Components of Income Tax Expense (Benefit) (Detail)",
     "role": "http://roivant.com/role/IncomeTaxesScheduleComponentsOfIncomeTaxExpenseBenefitDetail",
     "shortName": "Income Taxes - Schedule Components of Income Tax Expense (Benefit) (Detail)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "ix:continuation",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d164680ds1.htm",
      "contextRef": "P04_01_2020To03_31_2021",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:CurrentIncomeTaxExpenseBenefit",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_USD",
      "xsiNil": "false"
     }
    },
    "R69": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "div",
       "us-gaap:IncomeTaxDisclosureTextBlock",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d164680ds1.htm",
      "contextRef": "P04_01_2021To06_30_2021",
      "decimals": "3",
      "first": true,
      "lang": null,
      "name": "us-gaap:EffectiveIncomeTaxRateContinuingOperations",
      "reportCount": 1,
      "unitRef": "Unit_pure",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "1069 - Disclosure - Income Taxes - Additional Information (Detail)",
     "role": "http://roivant.com/role/IncomeTaxesAdditionalInformationDetail",
     "shortName": "Income Taxes - Additional Information (Detail)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "div",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d164680ds1.htm",
      "contextRef": "P04_01_2020To03_31_2021",
      "decimals": "-5",
      "lang": null,
      "name": "us-gaap:ValuationAllowanceDeferredTaxAssetChangeInAmount",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_USD",
      "xsiNil": "false"
     }
    },
    "R7": {
     "firstAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d164680ds1.htm",
      "contextRef": "P04_01_2021To06_30_2021",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:ProfitLoss",
      "reportCount": 1,
      "unitRef": "Unit_USD",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "1007 - Statement - Condensed Consolidated Statements of Cash Flows",
     "role": "http://roivant.com/role/CondensedConsolidatedStatementsOfCashFlows",
     "shortName": "Condensed Consolidated Statements of Cash Flows",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d164680ds1.htm",
      "contextRef": "P04_01_2020To03_31_2021",
      "decimals": "-3",
      "lang": null,
      "name": "us-gaap:ResearchAndDevelopmentInProcess",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_USD",
      "xsiNil": "false"
     }
    },
    "R70": {
     "firstAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "ix:continuation",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d164680ds1.htm",
      "contextRef": "PAsOn03_31_2021",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:DeferredTaxAssetsTaxCreditCarryforwardsResearch",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "1070 - Disclosure - Income Taxes - Schedule of Deferred Tax Assets (Liabilities) (Detail)",
     "role": "http://roivant.com/role/IncomeTaxesScheduleOfDeferredTaxAssetsLiabilitiesDetail",
     "shortName": "Income Taxes - Schedule of Deferred Tax Assets (Liabilities) (Detail)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "ix:continuation",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d164680ds1.htm",
      "contextRef": "PAsOn03_31_2021",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:DeferredTaxAssetsTaxCreditCarryforwardsResearch",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_USD",
      "xsiNil": "false"
     }
    },
    "R71": {
     "firstAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d164680ds1.htm",
      "contextRef": "P04_01_2020To03_31_2021",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "1071 - Disclosure - Income Taxes - Schedule of Effective Income Tax Rate Reconciliation (Detail)",
     "role": "http://roivant.com/role/IncomeTaxesScheduleOfEffectiveIncomeTaxRateReconciliationDetail",
     "shortName": "Income Taxes - Schedule of Effective Income Tax Rate Reconciliation (Detail)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d164680ds1.htm",
      "contextRef": "P04_01_2020To03_31_2021",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_USD",
      "xsiNil": "false"
     }
    },
    "R72": {
     "firstAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d164680ds1.htm",
      "contextRef": "PAsOn03_31_2021",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "1072 - Disclosure - Leases - Schedule of Maturities of Operating Lease Liabilities (Detail)",
     "role": "http://roivant.com/role/LeasesScheduleOfMaturitiesOfOperatingLeaseLiabilitiesDetail",
     "shortName": "Leases - Schedule of Maturities of Operating Lease Liabilities (Detail)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d164680ds1.htm",
      "contextRef": "PAsOn03_31_2021",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_USD",
      "xsiNil": "false"
     }
    },
    "R73": {
     "firstAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:LeasesOfLesseeDisclosureTextBlock",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d164680ds1.htm",
      "contextRef": "P04_01_2020To03_31_2021",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:OperatingLeasePayments",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "1073 - Disclosure - Leases - Summary of Operating Lease ROU Assets and Operating Lease Liabilities (Detail)",
     "role": "http://roivant.com/role/LeasesSummaryOfOperatingLeaseRouAssetsAndOperatingLeaseLiabilitiesDetail",
     "shortName": "Leases - Summary of Operating Lease ROU Assets and Operating Lease Liabilities (Detail)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:LeasesOfLesseeDisclosureTextBlock",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d164680ds1.htm",
      "contextRef": "P04_01_2020To03_31_2021",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:OperatingLeasePayments",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_USD",
      "xsiNil": "false"
     }
    },
    "R74": {
     "firstAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:LeaseCostTableTextBlock",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d164680ds1.htm",
      "contextRef": "P04_01_2020To03_31_2021",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:OperatingLeaseCost",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "1074 - Disclosure - Leases - Schedule of Operating Lease Costs (Detail)",
     "role": "http://roivant.com/role/LeasesScheduleOfOperatingLeaseCostsDetail",
     "shortName": "Leases - Schedule of Operating Lease Costs (Detail)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:LeaseCostTableTextBlock",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d164680ds1.htm",
      "contextRef": "P04_01_2020To03_31_2021",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:OperatingLeaseCost",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_USD",
      "xsiNil": "false"
     }
    },
    "R75": {
     "firstAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d164680ds1.htm",
      "contextRef": "PAsOn06_30_2021",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:InvestmentsFairValueDisclosure",
      "reportCount": 1,
      "unitRef": "Unit_USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "1075 - Disclosure - Fair Value Measurements - Schedule of Assets and Liabilities Measured at Fair Value on a Recurring Basis (Detail)",
     "role": "http://roivant.com/role/FairValueMeasurementsScheduleOfAssetsAndLiabilitiesMeasuredAtFairValueOnARecurringBasisDetail",
     "shortName": "Fair Value Measurements - Schedule of Assets and Liabilities Measured at Fair Value on a Recurring Basis (Detail)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock",
       "us-gaap:FairValueDisclosuresTextBlock",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d164680ds1.htm",
      "contextRef": "PAsOn06_30_2021_FairValueMeasurementsRecurringMemberusgaapFairValueByMeasurementFrequencyAxis",
      "decimals": "-3",
      "lang": null,
      "name": "us-gaap:AssetsFairValueDisclosure",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_USD",
      "xsiNil": "false"
     }
    },
    "R76": {
     "firstAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "ix:continuation",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d164680ds1.htm",
      "contextRef": "P04_01_2020To03_31_2021",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1",
      "reportCount": 1,
      "unitRef": "Unit_USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "1076 - Disclosure - Fair Value Measurements - Additional Information (Detail)",
     "role": "http://roivant.com/role/FairValueMeasurementsAdditionalInformationDetail",
     "shortName": "Fair Value Measurements - Additional Information (Detail)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "div",
       "ix:continuation",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d164680ds1.htm",
      "contextRef": "PAsOn03_31_2021",
      "decimals": "-5",
      "lang": null,
      "name": "roiv:EquityInterestOptionToThirdPartyPurchaser",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_USD",
      "xsiNil": "false"
     }
    },
    "R77": {
     "firstAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d164680ds1.htm",
      "contextRef": "PAsOn03_31_2021_FairValueInputsLevel3MemberusgaapFairValueByFairValueHierarchyLevelAxis",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue",
      "reportCount": 1,
      "unitRef": "Unit_USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "1077 - Disclosure - Fair Value Measurements - Change in the Fair Value of the Derivative Warrant Liabilities (Detail)",
     "role": "http://roivant.com/role/FairValueMeasurementsChangeInTheFairValueOfTheDerivativeWarrantLiabilitiesDetail",
     "shortName": "Fair Value Measurements - Change in the Fair Value of the Derivative Warrant Liabilities (Detail)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d164680ds1.htm",
      "contextRef": "PAsOn03_31_2019_FairValueInputsLevel3MemberusgaapFairValueByFairValueHierarchyLevelAxis",
      "decimals": "-3",
      "lang": null,
      "name": "us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_USD",
      "xsiNil": "false"
     }
    },
    "R78": {
     "firstAnchor": {
      "ancestors": [
       "roiv:AlternativeInvestmentExpectedTerm",
       "td",
       "tr",
       "table",
       "us-gaap:FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d164680ds1.htm",
      "contextRef": "P04_01_2020To03_31_2021_MeasurementInputExpectedTermMemberusgaapMeasurementInputTypeAxis_MinimumMembersrtRangeAxis",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "roiv:AlternativeInvestmentExpectedTerm",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "1078 - Disclosure - Fair Value Measurements - Schedule of Fair Value of Unobservable Input Related To Options to Acquire Under Sumitomo Transaction Agreement (Detail)",
     "role": "http://roivant.com/role/FairValueMeasurementsScheduleOfFairValueOfUnobservableInputRelatedToOptionsToAcquireUnderSumitomoTransactionAgreementDetail",
     "shortName": "Fair Value Measurements - Schedule of Fair Value of Unobservable Input Related To Options to Acquire Under Sumitomo Transaction Agreement (Detail)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "roiv:AlternativeInvestmentExpectedTerm",
       "td",
       "tr",
       "table",
       "us-gaap:FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d164680ds1.htm",
      "contextRef": "P04_01_2020To03_31_2021_MeasurementInputExpectedTermMemberusgaapMeasurementInputTypeAxis_MinimumMembersrtRangeAxis",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "roiv:AlternativeInvestmentExpectedTerm",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R79": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "div",
       "us-gaap:DefinedContributionPlanTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d164680ds1.htm",
      "contextRef": "P04_01_2020To03_31_2021",
      "decimals": "-5",
      "first": true,
      "lang": null,
      "name": "us-gaap:DefinedContributionPlanEmployerDiscretionaryContributionAmount",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "1079 - Disclosure - Defined Contribution Plan - Additional Information (Detail)",
     "role": "http://roivant.com/role/DefinedContributionPlanAdditionalInformationDetail",
     "shortName": "Defined Contribution Plan - Additional Information (Detail)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "div",
       "us-gaap:DefinedContributionPlanTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d164680ds1.htm",
      "contextRef": "P04_01_2020To03_31_2021",
      "decimals": "-5",
      "first": true,
      "lang": null,
      "name": "us-gaap:DefinedContributionPlanEmployerDiscretionaryContributionAmount",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_USD",
      "xsiNil": "false"
     }
    },
    "R8": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d164680ds1.htm",
      "contextRef": "P04_01_2021To06_30_2021",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:BusinessDescriptionAndBasisOfPresentationTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "1008 - Disclosure - Description of Business and Liquidity",
     "role": "http://roivant.com/role/DescriptionOfBusinessAndLiquidity",
     "shortName": "Description of Business and Liquidity",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d164680ds1.htm",
      "contextRef": "P04_01_2021To06_30_2021",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:BusinessDescriptionAndBasisOfPresentationTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R80": {
     "firstAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d164680ds1.htm",
      "contextRef": "P04_01_2021To06_30_2021",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:IncomeLossFromEquityMethodInvestments",
      "reportCount": 1,
      "unitRef": "Unit_USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "1080 - Disclosure - Other (Income) Expense, Net - Summary of Other (Income) Expense, Net From Continuing Operations (Detail)",
     "role": "http://roivant.com/role/OtherIncomeExpenseNetSummaryOfOtherIncomeExpenseNetFromContinuingOperationsDetail",
     "shortName": "Other (Income) Expense, Net - Summary of Other (Income) Expense, Net From Continuing Operations (Detail)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfOtherOperatingCostAndExpenseByComponentTextBlock",
       "us-gaap:OtherOperatingIncomeAndExpenseTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d164680ds1.htm",
      "contextRef": "P04_01_2021To06_30_2021",
      "decimals": "-3",
      "lang": null,
      "name": "us-gaap:InterestIncomeOther",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_USD",
      "xsiNil": "false"
     }
    },
    "R81": {
     "firstAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d164680ds1.htm",
      "contextRef": "P04_01_2020To03_31_2021",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest",
      "reportCount": 1,
      "unitRef": "Unit_USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "1081 - Disclosure - Net Loss per Common Share - Summary of Basic and Diluted Net Income Per Share of Common Stock (Detail)",
     "role": "http://roivant.com/role/NetLossPerCommonShareSummaryOfBasicAndDilutedNetIncomePerShareOfCommonStockDetail",
     "shortName": "Net Loss per Common Share - Summary of Basic and Diluted Net Income Per Share of Common Stock (Detail)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock",
       "us-gaap:EarningsPerShareTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d164680ds1.htm",
      "contextRef": "P04_01_2020To03_31_2021",
      "decimals": "-3",
      "lang": null,
      "name": "us-gaap:IncomeLossFromContinuingOperationsAttributableToNoncontrollingEntity",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_USD",
      "xsiNil": "false"
     }
    },
    "R82": {
     "firstAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock",
       "us-gaap:EarningsPerShareTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d164680ds1.htm",
      "contextRef": "P04_01_2019To03_31_2020",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:PreferredStockDividendsAndOtherAdjustments",
      "reportCount": 1,
      "unitRef": "Unit_USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "1082 - Disclosure - Net Loss per Common Share - Summary of Basic and Diluted Net Income Per Share of Common Stock (Parenthetical) (Detail)",
     "role": "http://roivant.com/role/NetLossPerCommonShareSummaryOfBasicAndDilutedNetIncomePerShareOfCommonStockParentheticalDetail",
     "shortName": "Net Loss per Common Share - Summary of Basic and Diluted Net Income Per Share of Common Stock (Parenthetical) (Detail)",
     "subGroupType": "parenthetical",
     "uniqueAnchor": null
    },
    "R83": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "div",
       "us-gaap:LongTermDebtTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d164680ds1.htm",
      "contextRef": "PAsOn03_31_2021",
      "decimals": "-5",
      "first": true,
      "lang": null,
      "name": "us-gaap:DebtInstrumentFaceAmount",
      "reportCount": 1,
      "unitRef": "Unit_USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "1083 - Disclosure - Subsequent Events - Additional Information (Detail)",
     "role": "http://roivant.com/role/SubsequentEventsAdditionalInformationDetail",
     "shortName": "Subsequent Events - Additional Information (Detail)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "div",
       "us-gaap:SubsequentEventsTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d164680ds1.htm",
      "contextRef": "PAsOn05_14_2021_DermavantSciencesLtdMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis_SubsequentEventMemberusgaapSubsequentEventTypeAxis",
      "decimals": "INF",
      "lang": null,
      "name": "us-gaap:ClassOfWarrantOrRightOutstanding",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_shares",
      "xsiNil": "false"
     }
    },
    "R9": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d164680ds1.htm",
      "contextRef": "P04_01_2021To06_30_2021",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SignificantAccountingPoliciesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "1009 - Disclosure - Summary of Significant Accounting Policies",
     "role": "http://roivant.com/role/SummaryOfSignificantAccountingPolicies",
     "shortName": "Summary of Significant Accounting Policies",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d164680ds1.htm",
      "contextRef": "P04_01_2021To06_30_2021",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SignificantAccountingPoliciesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    }
   },
   "segmentCount": 94,
   "tag": {
    "country_BM": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "BERMUDA",
        "terseLabel": "Bermuda [Member]"
       }
      }
     },
     "localname": "BM",
     "nsuri": "http://xbrl.sec.gov/country/2021",
     "presentation": [
      "http://roivant.com/role/IncomeTaxesScheduleComponentsOfIncomeTaxExpenseBenefitDetail",
      "http://roivant.com/role/IncomeTaxesScheduleOfLossBeforeIncomeTaxesByGeographicRegionDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "country_CH": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "SWITZERLAND",
        "terseLabel": "Switzerland [Member]"
       }
      }
     },
     "localname": "CH",
     "nsuri": "http://xbrl.sec.gov/country/2021",
     "presentation": [
      "http://roivant.com/role/IncomeTaxesAdditionalInformationDetail",
      "http://roivant.com/role/IncomeTaxesScheduleComponentsOfIncomeTaxExpenseBenefitDetail",
      "http://roivant.com/role/IncomeTaxesScheduleOfLossBeforeIncomeTaxesByGeographicRegionDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "country_GB": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "UNITED KINGDOM",
        "terseLabel": "United Kingdom [Member]"
       }
      }
     },
     "localname": "GB",
     "nsuri": "http://xbrl.sec.gov/country/2021",
     "presentation": [
      "http://roivant.com/role/IncomeTaxesAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "country_US": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "UNITED STATES",
        "terseLabel": "United States [Member]"
       }
      }
     },
     "localname": "US",
     "nsuri": "http://xbrl.sec.gov/country/2021",
     "presentation": [
      "http://roivant.com/role/IncomeTaxesAdditionalInformationDetail",
      "http://roivant.com/role/IncomeTaxesScheduleComponentsOfIncomeTaxExpenseBenefitDetail",
      "http://roivant.com/role/IncomeTaxesScheduleOfLossBeforeIncomeTaxesByGeographicRegionDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "dei_AmendmentFlag": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.",
        "label": "Amendment Flag",
        "terseLabel": "Amendment Flag"
       }
      }
     },
     "localname": "AmendmentFlag",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://roivant.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_CoverAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Cover page.",
        "label": "Cover [Abstract]"
       }
      }
     },
     "localname": "CoverAbstract",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "xbrltype": "stringItemType"
    },
    "dei_DocumentType": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.",
        "label": "Document Type",
        "terseLabel": "Document Type"
       }
      }
     },
     "localname": "DocumentType",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://roivant.com/role/Cover"
     ],
     "xbrltype": "submissionTypeItemType"
    },
    "dei_EntityCentralIndexKey": {
     "auth_ref": [
      "r713"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.",
        "label": "Entity Central Index Key",
        "terseLabel": "Entity Central Index Key"
       }
      }
     },
     "localname": "EntityCentralIndexKey",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://roivant.com/role/Cover"
     ],
     "xbrltype": "centralIndexKeyItemType"
    },
    "dei_EntityDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "All the names of the entities being reported upon in a document. Any legal structure used to conduct activities or to hold assets. Some examples of such structures are corporations, partnerships, limited liability companies, grantor trusts, and other trusts. This item does not include business and geographical segments which are included in the geographical or business segments domains.",
        "label": "Entity [Domain]",
        "terseLabel": "Entity [Domain]"
       }
      }
     },
     "localname": "EntityDomain",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://roivant.com/role/AssetAcquisitionsAndLicenseAgreementsAdditionalInformationDetail",
      "http://roivant.com/role/CommitmentsContingencies",
      "http://roivant.com/role/CondensedConsolidatedBalanceSheets",
      "http://roivant.com/role/CondensedConsolidatedBalanceSheetsParenthetical",
      "http://roivant.com/role/CondensedConsolidatedStatementsOfCashFlows",
      "http://roivant.com/role/CondensedConsolidatedStatementsOfOperations",
      "http://roivant.com/role/FairValueMeasurements",
      "http://roivant.com/role/FairValueMeasurementsAdditionalInformationDetail",
      "http://roivant.com/role/FairValueMeasurementsChangeInTheFairValueOfTheDerivativeWarrantLiabilitiesDetail",
      "http://roivant.com/role/FairValueMeasurementsScheduleOfAssetsAndLiabilitiesMeasuredAtFairValueOnARecurringBasisDetail",
      "http://roivant.com/role/FairValueMeasurementsTables",
      "http://roivant.com/role/IncomeTaxes",
      "http://roivant.com/role/IncomeTaxesAdditionalInformationDetail",
      "http://roivant.com/role/IncomeTaxesScheduleComponentsOfIncomeTaxExpenseBenefitDetail",
      "http://roivant.com/role/IncomeTaxesScheduleOfDeferredTaxAssetsLiabilitiesDetail",
      "http://roivant.com/role/IncomeTaxesScheduleOfEffectiveIncomeTaxRateReconciliationDetail",
      "http://roivant.com/role/IncomeTaxesTables",
      "http://roivant.com/role/InvestmentsAdditionalInformationDetail",
      "http://roivant.com/role/NetLossPerCommonShareTables",
      "http://roivant.com/role/RelatedPartyTransactions",
      "http://roivant.com/role/ShareholdersEquityAndRedeemableNoncontrollingInterest",
      "http://roivant.com/role/SubsequentEvents",
      "http://roivant.com/role/SummaryOfSignificantAccountingPolicies",
      "http://roivant.com/role/SummaryOfSignificantAccountingPoliciesAdditionalInformationDetail",
      "http://roivant.com/role/SummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "domainItemType"
    },
    "dei_EntityEmergingGrowthCompany": {
     "auth_ref": [
      "r713"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate if registrant meets the emerging growth company criteria.",
        "label": "Entity Emerging Growth Company",
        "terseLabel": "Emerging Growth Company"
       }
      }
     },
     "localname": "EntityEmergingGrowthCompany",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://roivant.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntityExTransitionPeriod": {
     "auth_ref": [
      "r732"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate if an emerging growth company has elected not to use the extended transition period for complying with any new or revised financial accounting standards.",
        "label": "Entity Ex Transition Period",
        "terseLabel": "Entity Ex Transition Period"
       }
      }
     },
     "localname": "EntityExTransitionPeriod",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://roivant.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntityFilerCategory": {
     "auth_ref": [
      "r713"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.",
        "label": "Entity Filer Category",
        "terseLabel": "Entity Filer Category"
       }
      }
     },
     "localname": "EntityFilerCategory",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://roivant.com/role/Cover"
     ],
     "xbrltype": "filerCategoryItemType"
    },
    "dei_EntityRegistrantName": {
     "auth_ref": [
      "r713"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.",
        "label": "Entity Registrant Name",
        "terseLabel": "Entity Registrant Name"
       }
      }
     },
     "localname": "EntityRegistrantName",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://roivant.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntitySmallBusiness": {
     "auth_ref": [
      "r713"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicates that the company is a Smaller Reporting Company (SRC).",
        "label": "Entity Small Business",
        "terseLabel": "Entity Small Business"
       }
      }
     },
     "localname": "EntitySmallBusiness",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://roivant.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_LegalEntityAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The set of legal entities associated with a report.",
        "label": "Legal Entity [Axis]",
        "terseLabel": "Legal Entity [Axis]"
       }
      }
     },
     "localname": "LegalEntityAxis",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://roivant.com/role/AssetAcquisitionsAndLicenseAgreementsAdditionalInformationDetail",
      "http://roivant.com/role/CommitmentsContingencies",
      "http://roivant.com/role/CondensedConsolidatedBalanceSheets",
      "http://roivant.com/role/CondensedConsolidatedBalanceSheetsParenthetical",
      "http://roivant.com/role/CondensedConsolidatedStatementsOfCashFlows",
      "http://roivant.com/role/CondensedConsolidatedStatementsOfOperations",
      "http://roivant.com/role/FairValueMeasurements",
      "http://roivant.com/role/FairValueMeasurementsAdditionalInformationDetail",
      "http://roivant.com/role/FairValueMeasurementsChangeInTheFairValueOfTheDerivativeWarrantLiabilitiesDetail",
      "http://roivant.com/role/FairValueMeasurementsScheduleOfAssetsAndLiabilitiesMeasuredAtFairValueOnARecurringBasisDetail",
      "http://roivant.com/role/FairValueMeasurementsTables",
      "http://roivant.com/role/IncomeTaxes",
      "http://roivant.com/role/IncomeTaxesAdditionalInformationDetail",
      "http://roivant.com/role/IncomeTaxesScheduleComponentsOfIncomeTaxExpenseBenefitDetail",
      "http://roivant.com/role/IncomeTaxesScheduleOfDeferredTaxAssetsLiabilitiesDetail",
      "http://roivant.com/role/IncomeTaxesScheduleOfEffectiveIncomeTaxRateReconciliationDetail",
      "http://roivant.com/role/IncomeTaxesTables",
      "http://roivant.com/role/InvestmentsAdditionalInformationDetail",
      "http://roivant.com/role/NetLossPerCommonShareTables",
      "http://roivant.com/role/RelatedPartyTransactions",
      "http://roivant.com/role/ShareholdersEquityAndRedeemableNoncontrollingInterest",
      "http://roivant.com/role/SubsequentEvents",
      "http://roivant.com/role/SummaryOfSignificantAccountingPolicies",
      "http://roivant.com/role/SummaryOfSignificantAccountingPoliciesAdditionalInformationDetail",
      "http://roivant.com/role/SummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "stringItemType"
    },
    "roiv_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationRequisiteServicePeriodRecognitionShares": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Adjustments to Additional Paid in Capital, Share-based Compensation, Requisite Service Period Recognition, Shares",
        "label": "Adjustments to Additional Paid in Capital, Share-based Compensation, Requisite Service Period Recognition, Shares",
        "terseLabel": "Share-based compensation, shares"
       }
      }
     },
     "localname": "AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationRequisiteServicePeriodRecognitionShares",
     "nsuri": "http://roivant.com/20210630",
     "presentation": [
      "http://roivant.com/role/CondensedConsolidatedStatementsOfShareholdersEquityAndRedeemableNoncontrollingInterest"
     ],
     "xbrltype": "sharesItemType"
    },
    "roiv_AffivantSciencesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Affivant Sciences [Member]",
        "label": "Affivant Sciences [Member]",
        "terseLabel": "Affivant Sciences [Member]"
       }
      }
     },
     "localname": "AffivantSciencesMember",
     "nsuri": "http://roivant.com/20210630",
     "presentation": [
      "http://roivant.com/role/AssetAcquisitionsAndLicenseAgreementsAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "roiv_AggregateFairValueOfEquityAndLiabilityInstrumentsIssued": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Aggregate Fair Value of Equity and Liability Instruments Issued",
        "label": "Aggregate Fair Value of Equity and Liability Instruments Issued",
        "terseLabel": "Aggregate fair value of issued instruments to employees on transaction"
       }
      }
     },
     "localname": "AggregateFairValueOfEquityAndLiabilityInstrumentsIssued",
     "nsuri": "http://roivant.com/20210630",
     "presentation": [
      "http://roivant.com/role/SumitomoTransactionAgreementAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "roiv_AgreementAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Agreement [Axis].",
        "label": "Agreement [Axis]"
       }
      }
     },
     "localname": "AgreementAxis",
     "nsuri": "http://roivant.com/20210630",
     "presentation": [
      "http://roivant.com/role/SumitomoTransactionAgreementAdditionalInformationDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "roiv_AgreementDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Agreement [Domain].",
        "label": "Agreement [Domain]"
       }
      }
     },
     "localname": "AgreementDomain",
     "nsuri": "http://roivant.com/20210630",
     "presentation": [
      "http://roivant.com/role/SumitomoTransactionAgreementAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "roiv_AgreementRelatedBilledAmountForCostsIncurredOnBehalfOfSubsidiarynetOfAmountsBilledBySubsidiary": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Agreement related billed amount for costs incurred on behalf of subsidiary,net of amounts billed by subsidiary.",
        "label": "Agreement Related Billed Amount For Costs Incurred On Behalf Of Subsidiary,Net Of Amounts Billed By Subsidiary",
        "terseLabel": "Transition and cooperation agreement billed amount,Net of amounts billed by sumitovant"
       }
      }
     },
     "localname": "AgreementRelatedBilledAmountForCostsIncurredOnBehalfOfSubsidiarynetOfAmountsBilledBySubsidiary",
     "nsuri": "http://roivant.com/20210630",
     "presentation": [
      "http://roivant.com/role/SumitomoTransactionAgreementAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "roiv_AlternativeInvestmentExpectedTerm": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Alternative investment expected term.",
        "label": "Alternative Investment Expected Term",
        "terseLabel": "Time to expiration (in years)"
       }
      }
     },
     "localname": "AlternativeInvestmentExpectedTerm",
     "nsuri": "http://roivant.com/20210630",
     "presentation": [
      "http://roivant.com/role/FairValueMeasurementsScheduleOfFairValueOfUnobservableInputRelatedToOptionsToAcquireUnderSumitomoTransactionAgreementDetail"
     ],
     "xbrltype": "durationItemType"
    },
    "roiv_AnnualCompoundedConversionRateForPreferredShare": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Annual Compunded Conversion Rate for Preferred Share",
        "label": "Annual compounded conversion rate for preferred share",
        "terseLabel": "Annual compounded conversion rate for preferred share"
       }
      }
     },
     "localname": "AnnualCompoundedConversionRateForPreferredShare",
     "nsuri": "http://roivant.com/20210630",
     "presentation": [
      "http://roivant.com/role/InvestmentsAdditionalInformationDetail"
     ],
     "xbrltype": "percentItemType"
    },
    "roiv_ArbutusBiopharmaCorporationMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Arbutus Biopharma Corporation [Member]",
        "label": "Arbutus Biopharma Corporation [Member]",
        "terseLabel": "Arbutus Biopharma Corporation [Member]"
       }
      }
     },
     "localname": "ArbutusBiopharmaCorporationMember",
     "nsuri": "http://roivant.com/20210630",
     "presentation": [
      "http://roivant.com/role/AssetAcquisitionsAndLicenseAgreementsAdditionalInformationDetail",
      "http://roivant.com/role/FairValueMeasurementsScheduleOfAssetsAndLiabilitiesMeasuredAtFairValueOnARecurringBasisDetail",
      "http://roivant.com/role/InvestmentsAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "roiv_AssetAcquisitionsAndLicenseAgreementsDisclosureTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Asset acquisitions and license agreements disclosure.",
        "label": "Asset Acquisitions and License Agreements Disclosure [Text Block]",
        "terseLabel": "Asset Acquisitions and License Agreements"
       }
      }
     },
     "localname": "AssetAcquisitionsAndLicenseAgreementsDisclosureTextBlock",
     "nsuri": "http://roivant.com/20210630",
     "presentation": [
      "http://roivant.com/role/AssetAcquisitionsAndLicenseAgreements"
     ],
     "xbrltype": "textBlockItemType"
    },
    "roiv_AssetPurchaseAgreementMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Asset Purchase Agreement [Member]",
        "terseLabel": "Asset Purchase Agreement [Member]"
       }
      }
     },
     "localname": "AssetPurchaseAgreementMember",
     "nsuri": "http://roivant.com/20210630",
     "presentation": [
      "http://roivant.com/role/SumitomoTransactionAgreementAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "roiv_AssetPurchaseTransactionConsiderationReceivedInCash": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Asset Purchase Transaction Consideration Received In Cash.",
        "label": "Asset Purchase Transaction Consideration Received In Cash",
        "terseLabel": "Consideration received in cash"
       }
      }
     },
     "localname": "AssetPurchaseTransactionConsiderationReceivedInCash",
     "nsuri": "http://roivant.com/20210630",
     "presentation": [
      "http://roivant.com/role/SumitomoTransactionAgreementAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "roiv_BalanceSheetComponentsLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Balance Sheet Components [Line Items]",
        "label": "Balance Sheet Components [Line Items]",
        "terseLabel": "Balance Sheet Components [Line Items]"
       }
      }
     },
     "localname": "BalanceSheetComponentsLineItems",
     "nsuri": "http://roivant.com/20210630",
     "presentation": [
      "http://roivant.com/role/BalanceSheetComponentsScheduleOfAccruedExpensesDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "roiv_BalanceSheetComponentsTable": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Balance Sheet Components [Table]",
        "label": "Balance Sheet Components [Table]",
        "terseLabel": "Balance Sheet Components [Table]"
       }
      }
     },
     "localname": "BalanceSheetComponentsTable",
     "nsuri": "http://roivant.com/20210630",
     "presentation": [
      "http://roivant.com/role/BalanceSheetComponentsScheduleOfAccruedExpensesDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "roiv_BasicAndDilutedIncomeFromDiscontinuedOperationsNetOfTax": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Basic and Diluted Income From Discontinued Operations, Net of Tax.",
        "label": "Basic and Diluted Income From Discontinued Operations, Net of Tax",
        "terseLabel": "Basic and diluted income from discontinued operations, net of tax"
       }
      }
     },
     "localname": "BasicAndDilutedIncomeFromDiscontinuedOperationsNetOfTax",
     "nsuri": "http://roivant.com/20210630",
     "presentation": [
      "http://roivant.com/role/NetLossPerCommonShareSummaryOfBasicAndDilutedNetIncomePerShareOfCommonStockDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "roiv_BasicAndDilutedLossFromContinuingOperationsNetOfTax": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Basic and Diluted Loss From Continuing Operations, Net of Tax.",
        "label": "Basic and Diluted Loss From Continuing Operations, Net of Tax",
        "terseLabel": "Basic and diluted loss from continuing operations, net of tax, attributable to Roivant Sciences Ltd."
       }
      }
     },
     "localname": "BasicAndDilutedLossFromContinuingOperationsNetOfTax",
     "nsuri": "http://roivant.com/20210630",
     "presentation": [
      "http://roivant.com/role/NetLossPerCommonShareSummaryOfBasicAndDilutedNetIncomePerShareOfCommonStockDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "roiv_BasicAndDilutedNetLossIncome": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Basic and Diluted Net (Loss) Income.",
        "label": "Basic and Diluted Net (Loss) Income",
        "terseLabel": "Basic and diluted net (loss) income attributable to Roivant Sciences"
       }
      }
     },
     "localname": "BasicAndDilutedNetLossIncome",
     "nsuri": "http://roivant.com/20210630",
     "presentation": [
      "http://roivant.com/role/NetLossPerCommonShareSummaryOfBasicAndDilutedNetIncomePerShareOfCommonStockDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "roiv_BusinessAcquisitionCostOfAcquiredEntityAdjustmentPaidInCash": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Business Acquisition Cost Of Acquired Entity Adjustment Paid In Cash",
        "label": "Business Acquisition Cost Of Acquired Entity Adjustment Paid In Cash",
        "terseLabel": "Business combination, paid in cash"
       }
      }
     },
     "localname": "BusinessAcquisitionCostOfAcquiredEntityAdjustmentPaidInCash",
     "nsuri": "http://roivant.com/20210630",
     "presentation": [
      "http://roivant.com/role/SubsequentEventsAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "roiv_BusinessCollaborationContingentMilestonePayment": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Business Collaboration Contingent Milestone Payment",
        "label": "Business Collaboration Contingent Milestone Payment",
        "terseLabel": "Contingent payment"
       }
      }
     },
     "localname": "BusinessCollaborationContingentMilestonePayment",
     "nsuri": "http://roivant.com/20210630",
     "presentation": [
      "http://roivant.com/role/AssetAcquisitionsAndLicenseAgreementsAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "roiv_CapitalContributionsToSubsidiaries": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Capital Contributions To Subsidiaries",
        "label": "Capital Contributions To Subsidiaries",
        "terseLabel": "Cash contributions to majority-owned subsidiaries"
       }
      }
     },
     "localname": "CapitalContributionsToSubsidiaries",
     "nsuri": "http://roivant.com/20210630",
     "presentation": [
      "http://roivant.com/role/CondensedConsolidatedStatementsOfShareholdersEquityAndRedeemableNoncontrollingInterest"
     ],
     "xbrltype": "monetaryItemType"
    },
    "roiv_CappedValueAppreciationRightsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Capped Value Appreciation Rights [Member]",
        "label": "Capped Value Appreciation Rights [Member]",
        "terseLabel": "CVARs [Member]"
       }
      }
     },
     "localname": "CappedValueAppreciationRightsMember",
     "nsuri": "http://roivant.com/20210630",
     "presentation": [
      "http://roivant.com/role/ShareBasedCompensationAdditionalInformationDetail",
      "http://roivant.com/role/ShareBasedCompensationSummaryOfCappedValueAppreciationRightsDetail",
      "http://roivant.com/role/ShareBasedCompensationTables"
     ],
     "xbrltype": "domainItemType"
    },
    "roiv_CashAcquiredUponConsolidationOfUnconsolidatedEntity": {
     "auth_ref": [],
     "calculation": {
      "http://roivant.com/role/CondensedConsolidatedStatementsOfCashFlows": {
       "order": 25.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Cash Acquired Upon Consolidation of Unconsolidated Entity",
        "label": "Cash Acquired Upon Consolidation of Unconsolidated Entity",
        "terseLabel": "Cash acquired upon consolidation of unconsolidated entity"
       }
      }
     },
     "localname": "CashAcquiredUponConsolidationOfUnconsolidatedEntity",
     "nsuri": "http://roivant.com/20210630",
     "presentation": [
      "http://roivant.com/role/CondensedConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "roiv_CashAndCashEquivalentsAndRestrictedCash": {
     "auth_ref": [],
     "calculation": {
      "http://roivant.com/role/SummaryOfSignificantAccountingPoliciesScheduleOfAggregateAmountsOfCashCashEquivalentsAndRestrictedCashDetail": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Cash and Cash Equivalents and Restricted Cash",
        "label": "Cash and Cash Equivalents and Restricted Cash",
        "totalLabel": "Cash, cash equivalents and restricted cash"
       }
      }
     },
     "localname": "CashAndCashEquivalentsAndRestrictedCash",
     "nsuri": "http://roivant.com/20210630",
     "presentation": [
      "http://roivant.com/role/SummaryOfSignificantAccountingPoliciesScheduleOfAggregateAmountsOfCashCashEquivalentsAndRestrictedCashDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "roiv_ClassOfWarrantOrRightExercisable": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Class of Warrant or Right, Exercisable",
        "label": "Class of Warrant or Right, Exercisable",
        "terseLabel": "Number of exercisable outstanding warrants"
       }
      }
     },
     "localname": "ClassOfWarrantOrRightExercisable",
     "nsuri": "http://roivant.com/20210630",
     "presentation": [
      "http://roivant.com/role/ShareholdersEquityAndRedeemableNonControllingInterestAdditionalInformationDetail"
     ],
     "xbrltype": "sharesItemType"
    },
    "roiv_ClosingPricePerShare": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Closing Price Per Share.",
        "label": "Closing Price Per Share",
        "terseLabel": "Closing price"
       }
      }
     },
     "localname": "ClosingPricePerShare",
     "nsuri": "http://roivant.com/20210630",
     "presentation": [
      "http://roivant.com/role/InvestmentsAdditionalInformationDetail"
     ],
     "xbrltype": "perShareItemType"
    },
    "roiv_CommercialMilestoneMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Commercial Milestone [Member]",
        "label": "Commercial Milestone [Member]",
        "terseLabel": "Commercial Milestone [Member]"
       }
      }
     },
     "localname": "CommercialMilestoneMember",
     "nsuri": "http://roivant.com/20210630",
     "presentation": [
      "http://roivant.com/role/LongTermDebtAndLoanCommitmentAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "roiv_CommonSharesReservedForPerformanceOptionsAndCappedValueAppreciationRights": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Common shares reserved for performance options and capped value appreciation rights.",
        "label": "Common Shares Reserved For Performance Options And Capped Value Appreciation Rights",
        "terseLabel": "Common shares reserved for performance options and capped value appreciation rights"
       }
      }
     },
     "localname": "CommonSharesReservedForPerformanceOptionsAndCappedValueAppreciationRights",
     "nsuri": "http://roivant.com/20210630",
     "presentation": [
      "http://roivant.com/role/ShareBasedCompensationAdditionalInformationDetail"
     ],
     "xbrltype": "sharesItemType"
    },
    "roiv_CommonStockAwardsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Common Stock Awards [Member]",
        "label": "Common Stock Awards [Member]",
        "terseLabel": "RSL Common Share Award"
       }
      }
     },
     "localname": "CommonStockAwardsMember",
     "nsuri": "http://roivant.com/20210630",
     "presentation": [
      "http://roivant.com/role/ShareBasedCompensationAdditionalInformationDetail",
      "http://roivant.com/role/ShareBasedCompensationSummaryOfCommonShareAwardActivityDetail",
      "http://roivant.com/role/ShareBasedCompensationTables"
     ],
     "xbrltype": "domainItemType"
    },
    "roiv_CommonStockOwnedBalanceSharesOfArbutus": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Common stock Owned, Balance, Shares of Arbutus.",
        "label": "Common stock Owned, Balance, Shares of Arbutus",
        "terseLabel": "Common stock Owned, Balance, Shares of Arbutus"
       }
      }
     },
     "localname": "CommonStockOwnedBalanceSharesOfArbutus",
     "nsuri": "http://roivant.com/20210630",
     "presentation": [
      "http://roivant.com/role/InvestmentsAdditionalInformationDetail"
     ],
     "xbrltype": "sharesItemType"
    },
    "roiv_ComponentsOfIncomeTaxExpenseLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Components Of Income Tax Expense [Line Items]",
        "label": "Components Of Income Tax Expense [Line Items]",
        "terseLabel": "Components Of Income Tax Expense [Line Items]"
       }
      }
     },
     "localname": "ComponentsOfIncomeTaxExpenseLineItems",
     "nsuri": "http://roivant.com/20210630",
     "presentation": [
      "http://roivant.com/role/IncomeTaxesScheduleComponentsOfIncomeTaxExpenseBenefitDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "roiv_ComponentsOfIncomeTaxExpenseTable": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Components Of Income Tax Expense [Table]",
        "label": "Components Of Income Tax Expense [Table]",
        "terseLabel": "Components Of Income Tax Expense [Table]"
       }
      }
     },
     "localname": "ComponentsOfIncomeTaxExpenseTable",
     "nsuri": "http://roivant.com/20210630",
     "presentation": [
      "http://roivant.com/role/IncomeTaxesScheduleComponentsOfIncomeTaxExpenseBenefitDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "roiv_ConsolidationOfUnconsolidatedEntity": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Consolidation of Unconsolidated Entity",
        "label": "Consolidation of Unconsolidated Entity",
        "terseLabel": "Consolidation of unconsolidated entity"
       }
      }
     },
     "localname": "ConsolidationOfUnconsolidatedEntity",
     "nsuri": "http://roivant.com/20210630",
     "presentation": [
      "http://roivant.com/role/CondensedConsolidatedStatementsOfShareholdersEquityAndRedeemableNoncontrollingInterest"
     ],
     "xbrltype": "monetaryItemType"
    },
    "roiv_ConversionOfSubsidiaryConvertiblePromissoryNotes": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Conversion of Subsidiary Convertible Promissory Notes",
        "label": "Conversion of Subsidiary Convertible Promissory Notes",
        "terseLabel": "Conversion of subsidiary convertible promissory notes"
       }
      }
     },
     "localname": "ConversionOfSubsidiaryConvertiblePromissoryNotes",
     "nsuri": "http://roivant.com/20210630",
     "presentation": [
      "http://roivant.com/role/CondensedConsolidatedStatementsOfShareholdersEquityAndRedeemableNoncontrollingInterest"
     ],
     "xbrltype": "monetaryItemType"
    },
    "roiv_ConversionOfSubsidiaryConvertiblePromissoryNotesToCommonShares": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Conversion of subsidiary convertible promissory notes to common shares.",
        "label": "Conversion Of Subsidiary Convertible Promissory Notes To Common Shares"
       }
      }
     },
     "localname": "ConversionOfSubsidiaryConvertiblePromissoryNotesToCommonShares",
     "nsuri": "http://roivant.com/20210630",
     "presentation": [
      "http://roivant.com/role/CondensedConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "roiv_ConversionPrice": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Conversion Price",
        "label": "Conversion Price",
        "terseLabel": "Conversion price"
       }
      }
     },
     "localname": "ConversionPrice",
     "nsuri": "http://roivant.com/20210630",
     "presentation": [
      "http://roivant.com/role/InvestmentsAdditionalInformationDetail"
     ],
     "xbrltype": "perShareItemType"
    },
    "roiv_CreditFacilityMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Credit Facility [Member]",
        "label": "Credit Facility [Member]",
        "terseLabel": "Credit Facility [Member]"
       }
      }
     },
     "localname": "CreditFacilityMember",
     "nsuri": "http://roivant.com/20210630",
     "presentation": [
      "http://roivant.com/role/SubsequentEventsAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "roiv_CytovantScienceHkLtdMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Cytovant Science HK Ltd [Member]",
        "label": "Cytovant Science HK Ltd [Member]",
        "terseLabel": "Cytovant Science HK Ltd [Member]"
       }
      }
     },
     "localname": "CytovantScienceHkLtdMember",
     "nsuri": "http://roivant.com/20210630",
     "presentation": [
      "http://roivant.com/role/ShareholdersEquityAndRedeemableNonControllingInterestAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "roiv_DatavantHoldingsIncMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Datavant Holdings, Inc [Member]",
        "label": "Datavant Holdings, Inc [Member]",
        "terseLabel": "Datavant Holdings, Inc [Member]"
       }
      }
     },
     "localname": "DatavantHoldingsIncMember",
     "nsuri": "http://roivant.com/20210630",
     "presentation": [
      "http://roivant.com/role/InvestmentsAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "roiv_DatavantMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Datavant [Member].",
        "label": "Datavant [Member]"
       }
      }
     },
     "localname": "DatavantMember",
     "nsuri": "http://roivant.com/20210630",
     "presentation": [
      "http://roivant.com/role/SubsequentEventsAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "roiv_DebtInstrumentAmount": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Debt instrument amount.",
        "label": "Debt Instrument Amount",
        "terseLabel": "Principal amount"
       }
      }
     },
     "localname": "DebtInstrumentAmount",
     "nsuri": "http://roivant.com/20210630",
     "presentation": [
      "http://roivant.com/role/LongTermDebtAndLoanCommitmentDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "roiv_DebtInstrumentExitFeeAndEndOfTermCharge": {
     "auth_ref": [],
     "calculation": {
      "http://roivant.com/role/LongTermDebtAndLoanCommitmentDetail": {
       "order": 5.0,
       "parentTag": "us-gaap_LongTermDebt",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Debt instrument exit fee and end of term charge.",
        "label": "Debt Instrument Exit Fee And End Of Term Charge",
        "terseLabel": "Exit fee / end of term charge"
       }
      }
     },
     "localname": "DebtInstrumentExitFeeAndEndOfTermCharge",
     "nsuri": "http://roivant.com/20210630",
     "presentation": [
      "http://roivant.com/role/LongTermDebtAndLoanCommitmentAdditionalInformationDetail",
      "http://roivant.com/role/LongTermDebtAndLoanCommitmentDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "roiv_DeconsolidationAndConsolidationOnGainOrLossOfConsolidatedEntity": {
     "auth_ref": [],
     "calculation": {
      "http://roivant.com/role/CondensedConsolidatedStatementsOfOperations": {
       "order": 19.0,
       "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Deconsolidation and consolidation on gain or loss of consolidated entity.",
        "label": "Deconsolidation and Consolidation on Gain or Loss of Consolidated Entity",
        "negatedLabel": "Gain on deconsolidation of subsidiary and consolidation of unconsolidated entity"
       }
      }
     },
     "localname": "DeconsolidationAndConsolidationOnGainOrLossOfConsolidatedEntity",
     "nsuri": "http://roivant.com/20210630",
     "presentation": [
      "http://roivant.com/role/CondensedConsolidatedStatementsOfOperations"
     ],
     "xbrltype": "monetaryItemType"
    },
    "roiv_DeconsolidationOfSubsidiary": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Deconsolidation Of Subsidiary",
        "label": "Deconsolidation Of Subsidiary",
        "terseLabel": "Deconsolidation of subsidiary"
       }
      }
     },
     "localname": "DeconsolidationOfSubsidiary",
     "nsuri": "http://roivant.com/20210630",
     "presentation": [
      "http://roivant.com/role/CondensedConsolidatedStatementsOfShareholdersEquityAndRedeemableNoncontrollingInterest"
     ],
     "xbrltype": "monetaryItemType"
    },
    "roiv_DeferredConsiderationLiabilityCurrent": {
     "auth_ref": [],
     "calculation": {
      "http://roivant.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 17.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Deferred consideration liability current.",
        "label": "Deferred Consideration Liability Current",
        "terseLabel": "Deferred consideration liability"
       }
      }
     },
     "localname": "DeferredConsiderationLiabilityCurrent",
     "nsuri": "http://roivant.com/20210630",
     "presentation": [
      "http://roivant.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "roiv_DeferredOfferingAndFinancingCostsIncludedInAccountsPayableAndAccruedExpenses": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Deferred offering and financing costs included in accounts payable and accrued expenses.",
        "label": "Deferred Offering And Financing Costs Included In Accounts Payable And Accrued Expenses",
        "terseLabel": "Deferred offering and financing costs included in accounts payable and accrued expenses"
       }
      }
     },
     "localname": "DeferredOfferingAndFinancingCostsIncludedInAccountsPayableAndAccruedExpenses",
     "nsuri": "http://roivant.com/20210630",
     "presentation": [
      "http://roivant.com/role/CondensedConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "roiv_DeferredRevenueOtherCurrentLiabilities": {
     "auth_ref": [],
     "calculation": {
      "http://roivant.com/role/BalanceSheetComponentsScheduleOfOtherCurrentLiabilitiesDetail": {
       "order": 1.0,
       "parentTag": "us-gaap_OtherLiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Deferred Revenue Other Current Liabilities",
        "label": "Deferred Revenue Other Current Liabilities",
        "terseLabel": "Deferred revenue"
       }
      }
     },
     "localname": "DeferredRevenueOtherCurrentLiabilities",
     "nsuri": "http://roivant.com/20210630",
     "presentation": [
      "http://roivant.com/role/BalanceSheetComponentsScheduleOfOtherCurrentLiabilitiesDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "roiv_DeferredTaxAssetsLeaseLiabilities": {
     "auth_ref": [],
     "calculation": {
      "http://roivant.com/role/IncomeTaxesScheduleOfDeferredTaxAssetsLiabilitiesDetail": {
       "order": 6.0,
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Deferred tax assets lease liabilities",
        "label": "Deferred tax assets lease liabilities",
        "terseLabel": "Lease liabilities"
       }
      }
     },
     "localname": "DeferredTaxAssetsLeaseLiabilities",
     "nsuri": "http://roivant.com/20210630",
     "presentation": [
      "http://roivant.com/role/IncomeTaxesScheduleOfDeferredTaxAssetsLiabilitiesDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "roiv_DeferredTaxAssetsLiabilitiesLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Deferred Tax Assets Liabilities [Line Items]",
        "label": "Deferred Tax Assets Liabilities [Line Items]",
        "terseLabel": "Deferred Tax Assets Liabilities [Line Items]"
       }
      }
     },
     "localname": "DeferredTaxAssetsLiabilitiesLineItems",
     "nsuri": "http://roivant.com/20210630",
     "presentation": [
      "http://roivant.com/role/IncomeTaxesScheduleOfDeferredTaxAssetsLiabilitiesDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "roiv_DeferredTaxAssetsLiabilitiesTable": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Deferred Tax Assets Liabilities [Table]",
        "label": "Deferred Tax Assets Liabilities [Table]",
        "terseLabel": "Deferred Tax Assets Liabilities [Table]"
       }
      }
     },
     "localname": "DeferredTaxAssetsLiabilitiesTable",
     "nsuri": "http://roivant.com/20210630",
     "presentation": [
      "http://roivant.com/role/IncomeTaxesScheduleOfDeferredTaxAssetsLiabilitiesDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "roiv_DeferredTaxLiabilitiesDepreciation": {
     "auth_ref": [],
     "calculation": {
      "http://roivant.com/role/IncomeTaxesScheduleOfDeferredTaxAssetsLiabilitiesDetail": {
       "order": 8.0,
       "parentTag": "us-gaap_DeferredTaxAssetsLiabilitiesNet",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Deferred Tax Liabilities, Depreciation",
        "label": "Deferred Tax Liabilities, Depreciation",
        "negatedLabel": "Depreciation"
       }
      }
     },
     "localname": "DeferredTaxLiabilitiesDepreciation",
     "nsuri": "http://roivant.com/20210630",
     "presentation": [
      "http://roivant.com/role/IncomeTaxesScheduleOfDeferredTaxAssetsLiabilitiesDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "roiv_DeferredTaxLiabilitiesRightOfUseAssets": {
     "auth_ref": [],
     "calculation": {
      "http://roivant.com/role/IncomeTaxesScheduleOfDeferredTaxAssetsLiabilitiesDetail": {
       "order": 9.0,
       "parentTag": "us-gaap_DeferredTaxAssetsLiabilitiesNet",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Deferred tax liabilities right of use assets",
        "label": "Deferred tax liabilities right of use assets",
        "negatedLabel": "Right-of-use assets"
       }
      }
     },
     "localname": "DeferredTaxLiabilitiesRightOfUseAssets",
     "nsuri": "http://roivant.com/20210630",
     "presentation": [
      "http://roivant.com/role/IncomeTaxesScheduleOfDeferredTaxAssetsLiabilitiesDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "roiv_DermavantSciencesLtdMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Dermavant Sciences Ltd [Member]",
        "label": "Dermavant Sciences Ltd [Member]",
        "terseLabel": "Dermavant Sciences Ltd [Member]"
       }
      }
     },
     "localname": "DermavantSciencesLtdMember",
     "nsuri": "http://roivant.com/20210630",
     "presentation": [
      "http://roivant.com/role/AssetAcquisitionsAndLicenseAgreementsAdditionalInformationDetail",
      "http://roivant.com/role/SubsequentEventsAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "roiv_DisposalGroupIncludingDiscontinuedOperationGainLossOnSaleOfBusiness": {
     "auth_ref": [],
     "calculation": {
      "http://roivant.com/role/DiscontinuedOperationsSummaryOfDisposalGroupsIncludingDiscontinuedOperationsIncomeStatementDetail": {
       "order": 5.0,
       "parentTag": "us-gaap_DiscontinuedOperationIncomeLossFromDiscontinuedOperationBeforeIncomeTax",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disposal Group, Including Discontinued Operation, Gain (Loss) on Sale of Business",
        "label": "Disposal Group, Including Discontinued Operation, Gain (Loss) on Sale of Business",
        "negatedLabel": "Gain on sale of business"
       }
      }
     },
     "localname": "DisposalGroupIncludingDiscontinuedOperationGainLossOnSaleOfBusiness",
     "nsuri": "http://roivant.com/20210630",
     "presentation": [
      "http://roivant.com/role/DiscontinuedOperationsSummaryOfCashFlowsFromDiscontinuedOperationsDetail",
      "http://roivant.com/role/DiscontinuedOperationsSummaryOfDisposalGroupsIncludingDiscontinuedOperationsIncomeStatementDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "roiv_DisposalGroupIncludingDiscontinuedOperationOperatingExpenseAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disposal Group, Including Discontinued Operation, Operating Expense [Abstract]",
        "label": "Disposal Group, Including Discontinued Operation, Operating Expense [Abstract]",
        "terseLabel": "Operating expenses:"
       }
      }
     },
     "localname": "DisposalGroupIncludingDiscontinuedOperationOperatingExpenseAbstract",
     "nsuri": "http://roivant.com/20210630",
     "presentation": [
      "http://roivant.com/role/DiscontinuedOperationsSummaryOfDisposalGroupsIncludingDiscontinuedOperationsIncomeStatementDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "roiv_DisposalGroupIncludingDiscontinuedOperationResearchAndDevelopmentExpense": {
     "auth_ref": [],
     "calculation": {
      "http://roivant.com/role/DiscontinuedOperationsSummaryOfDisposalGroupsIncludingDiscontinuedOperationsIncomeStatementDetail": {
       "order": 1.0,
       "parentTag": "us-gaap_DisposalGroupIncludingDiscontinuedOperationOperatingExpense",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disposal Group Including Discontinued Operation Research And Development Expense",
        "label": "Disposal Group Including Discontinued Operation Research And Development Expense",
        "terseLabel": "Research and development"
       }
      }
     },
     "localname": "DisposalGroupIncludingDiscontinuedOperationResearchAndDevelopmentExpense",
     "nsuri": "http://roivant.com/20210630",
     "presentation": [
      "http://roivant.com/role/DiscontinuedOperationsSummaryOfDisposalGroupsIncludingDiscontinuedOperationsIncomeStatementDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "roiv_DisposalGroupIncludingDiscontinuedOperationResearchAndDevelopmentInProcess": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disposal group including discontinued operation research and development in process.",
        "label": "Disposal Group Including Discontinued Operation Research and Development In Process",
        "terseLabel": "Acquired in-processresearch and development"
       }
      }
     },
     "localname": "DisposalGroupIncludingDiscontinuedOperationResearchAndDevelopmentInProcess",
     "nsuri": "http://roivant.com/20210630",
     "presentation": [
      "http://roivant.com/role/DiscontinuedOperationsSummaryOfCashFlowsFromDiscontinuedOperationsDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "roiv_DisposalGroupIncludingDiscontinuedOperationShareBasedCompensation": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disposal group including discontinued operation share based compensation.",
        "label": "Disposal Group Including Discontinued Operation Share Based Compensation",
        "terseLabel": "Share-based compensation"
       }
      }
     },
     "localname": "DisposalGroupIncludingDiscontinuedOperationShareBasedCompensation",
     "nsuri": "http://roivant.com/20210630",
     "presentation": [
      "http://roivant.com/role/DiscontinuedOperationsSummaryOfCashFlowsFromDiscontinuedOperationsDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "roiv_EarnOutSharesTermsDescription": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Earnout shares terms description.",
        "label": "Earn Out Shares Terms Description",
        "terseLabel": "Earnout shares"
       }
      }
     },
     "localname": "EarnOutSharesTermsDescription",
     "nsuri": "http://roivant.com/20210630",
     "presentation": [
      "http://roivant.com/role/ShareholdersEquityAndRedeemableNonControllingInterestAdditionalInformationDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "roiv_EffectiveIncomeTaxReconciliationPermanentDifferences": {
     "auth_ref": [],
     "calculation": {
      "http://roivant.com/role/IncomeTaxesScheduleOfEffectiveIncomeTaxRateReconciliationDetail": {
       "order": 15.0,
       "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations",
       "weight": 1.0
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Effective Income Tax Reconciliation Permanent Differences",
        "label": "Effective Income Tax Reconciliation Permanent Differences",
        "terseLabel": "Permanent adjustments"
       }
      }
     },
     "localname": "EffectiveIncomeTaxReconciliationPermanentDifferences",
     "nsuri": "http://roivant.com/20210630",
     "presentation": [
      "http://roivant.com/role/IncomeTaxesScheduleOfEffectiveIncomeTaxRateReconciliationDetail"
     ],
     "xbrltype": "percentItemType"
    },
    "roiv_EffectiveTaxRateReconcilingItemsLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Effective Tax Rate Reconciling Items [Line Items]",
        "label": "Effective Tax Rate Reconciling Items [Line Items]",
        "terseLabel": "Effective Tax Rate Reconciling Items [Line Items]"
       }
      }
     },
     "localname": "EffectiveTaxRateReconcilingItemsLineItems",
     "nsuri": "http://roivant.com/20210630",
     "presentation": [
      "http://roivant.com/role/IncomeTaxesScheduleOfEffectiveIncomeTaxRateReconciliationDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "roiv_EffectiveTaxRateReconcilingItemsTable": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Effective Tax Rate Reconciling Items [Table]",
        "label": "Effective Tax Rate Reconciling Items [Table]",
        "terseLabel": "Effective Tax Rate Reconciling Items [Table]"
       }
      }
     },
     "localname": "EffectiveTaxRateReconcilingItemsTable",
     "nsuri": "http://roivant.com/20210630",
     "presentation": [
      "http://roivant.com/role/IncomeTaxesScheduleOfEffectiveIncomeTaxRateReconciliationDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "roiv_EmployeeMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Employee [Member]",
        "label": "Employee [Member]",
        "terseLabel": "Employee [Member]"
       }
      }
     },
     "localname": "EmployeeMember",
     "nsuri": "http://roivant.com/20210630",
     "presentation": [
      "http://roivant.com/role/SumitomoTransactionAgreementAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "roiv_EmployeeRelatedExpensesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Employee Related Expenses [Member]",
        "label": "Employee Related Expenses [Member]",
        "terseLabel": "Employee Related Expenses [Member]"
       }
      }
     },
     "localname": "EmployeeRelatedExpensesMember",
     "nsuri": "http://roivant.com/20210630",
     "presentation": [
      "http://roivant.com/role/BalanceSheetComponentsScheduleOfAccruedExpensesDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "roiv_EquityInterestOptionToThirdPartyPurchaser": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Equity interest option to third party purchaser.",
        "label": "Equity Interest Option to Third Party Purchaser",
        "terseLabel": "Fair value of options"
       }
      }
     },
     "localname": "EquityInterestOptionToThirdPartyPurchaser",
     "nsuri": "http://roivant.com/20210630",
     "presentation": [
      "http://roivant.com/role/FairValueMeasurementsAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "roiv_EquityInterestOptionToThirdPartyPurchaserGainOnTermination": {
     "auth_ref": [],
     "calculation": {
      "http://roivant.com/role/CondensedConsolidatedStatementsOfOperations": {
       "order": 10.0,
       "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Equity interest option to third party purchaser gain on termination.",
        "label": "Equity Interest Option to Third Party Purchaser Gain On Termination",
        "negatedLabel": "Gain on termination of Sumitomo Options",
        "terseLabel": "Gain on termination of Sumitomo Options"
       }
      }
     },
     "localname": "EquityInterestOptionToThirdPartyPurchaserGainOnTermination",
     "nsuri": "http://roivant.com/20210630",
     "presentation": [
      "http://roivant.com/role/CondensedConsolidatedStatementsOfOperations",
      "http://roivant.com/role/SumitomoTransactionAgreementAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "roiv_ExerciseOfSubsidiaryStockOptionsAndVestingOfSubsidiaryRestrictedStockUnits": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Exercise of Subsidiary Stock Options and Vesting of Subsidiary Restricted Stock Units",
        "label": "Exercise of Subsidiary Stock Options and Vesting of Subsidiary Restricted Stock Units",
        "terseLabel": "Exercise of subsidiary stock options and vesting of subsidiary restricted stock units"
       }
      }
     },
     "localname": "ExerciseOfSubsidiaryStockOptionsAndVestingOfSubsidiaryRestrictedStockUnits",
     "nsuri": "http://roivant.com/20210630",
     "presentation": [
      "http://roivant.com/role/CondensedConsolidatedStatementsOfShareholdersEquityAndRedeemableNoncontrollingInterest"
     ],
     "xbrltype": "monetaryItemType"
    },
    "roiv_FairValueDisclosuresLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fair Value Disclosures [Line Items]",
        "label": "Fair Value Disclosures [Line Items]",
        "terseLabel": "Fair Value Disclosures [Line Items]"
       }
      }
     },
     "localname": "FairValueDisclosuresLineItems",
     "nsuri": "http://roivant.com/20210630",
     "presentation": [
      "http://roivant.com/role/FairValueMeasurementsAdditionalInformationDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "roiv_FairValueDisclosuresTable": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fair Value Disclosures [Table]",
        "label": "Fair Value Disclosures [Table]",
        "terseLabel": "Fair Value Disclosures [Table]"
       }
      }
     },
     "localname": "FairValueDisclosuresTable",
     "nsuri": "http://roivant.com/20210630",
     "presentation": [
      "http://roivant.com/role/FairValueMeasurementsAdditionalInformationDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "roiv_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityDisposedDueToDeconsolidationOfSubsidiary": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, disposed due to deconsolidation of subsidiary.",
        "label": "Fair Value, Measurement With Unobservable Inputs Reconciliation, Recurring Basis, Liability, Disposed Due to Deconsolidation of Subsidiary",
        "terseLabel": "Liability instruments disposed due to deconsolidation of subsidiary"
       }
      }
     },
     "localname": "FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityDisposedDueToDeconsolidationOfSubsidiary",
     "nsuri": "http://roivant.com/20210630",
     "presentation": [
      "http://roivant.com/role/FairValueMeasurementsChangeInTheFairValueOfTheDerivativeWarrantLiabilitiesDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "roiv_FairValueOfCommonShares": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fair Value Of Common Shares",
        "label": "Fair Value Of Common Shares",
        "terseLabel": "Fair value of common shares"
       }
      }
     },
     "localname": "FairValueOfCommonShares",
     "nsuri": "http://roivant.com/20210630",
     "presentation": [
      "http://roivant.com/role/AssetAcquisitionsAndLicenseAgreementsAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "roiv_FairValueOfRestrictedStock": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fair Value Of Restricted Stock",
        "label": "Fair Value Of Restricted Stock",
        "terseLabel": "Fair value of restricted stock"
       }
      }
     },
     "localname": "FairValueOfRestrictedStock",
     "nsuri": "http://roivant.com/20210630",
     "presentation": [
      "http://roivant.com/role/AssetAcquisitionsAndLicenseAgreementsAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "roiv_FirstProductFirstProductForEachMolecularTargetCoveredByIntellectualPropertyMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "First Product First Product for Each Molecular Target Covered by Intellectual Property [Member]",
        "label": "First Product First Product for Each Molecular Target Covered by Intellectual Property [Member]",
        "terseLabel": "First Product First Product for Each Molecular Target Covered by Intellectual Property [Member]"
       }
      }
     },
     "localname": "FirstProductFirstProductForEachMolecularTargetCoveredByIntellectualPropertyMember",
     "nsuri": "http://roivant.com/20210630",
     "presentation": [
      "http://roivant.com/role/AssetAcquisitionsAndLicenseAgreementsAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "roiv_FirstProductTargetsEachOfCertainSpecifiedAdditionalMoleculartargetsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "First Product Targets Each of Certain Specified Additional MolecularTargets [Member]",
        "label": "First Product Targets Each of Certain Specified Additional MolecularTargets [Member]",
        "terseLabel": "First Product Targets Each of Certain Specified Additional MolecularTargets [Member]"
       }
      }
     },
     "localname": "FirstProductTargetsEachOfCertainSpecifiedAdditionalMoleculartargetsMember",
     "nsuri": "http://roivant.com/20210630",
     "presentation": [
      "http://roivant.com/role/AssetAcquisitionsAndLicenseAgreementsAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "roiv_FirstProductTargetsTargetingEachOfTwoSpecifiedInitialTargetsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "First Product Targets Targeting Each of Two Specified Initial Targets [Member]",
        "label": "First Product Targets Targeting Each of Two Specified Initial Targets [Member]",
        "terseLabel": "First Product Targets Targeting Each of Two Specified Initial Targets [Member]"
       }
      }
     },
     "localname": "FirstProductTargetsTargetingEachOfTwoSpecifiedInitialTargetsMember",
     "nsuri": "http://roivant.com/20210630",
     "presentation": [
      "http://roivant.com/role/AssetAcquisitionsAndLicenseAgreementsAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "roiv_FirstTrancheMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "First Tranche [Member]",
        "label": "First Tranche [Member]",
        "terseLabel": "First Tranche [Member]"
       }
      }
     },
     "localname": "FirstTrancheMember",
     "nsuri": "http://roivant.com/20210630",
     "presentation": [
      "http://roivant.com/role/AssetAcquisitionsAndLicenseAgreementsAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "roiv_FutureDevelopmentAndCommercialMilestonePayments": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Future Development And Commercial Milestone Payments.",
        "label": "Future Development And Commercial Milestone Payments",
        "terseLabel": "Future development and commercial milestone payments"
       }
      }
     },
     "localname": "FutureDevelopmentAndCommercialMilestonePayments",
     "nsuri": "http://roivant.com/20210630",
     "presentation": [
      "http://roivant.com/role/AssetAcquisitionsAndLicenseAgreementsAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "roiv_GainLossOnFairValueOfDebtAndLiabilityInstruments": {
     "auth_ref": [],
     "calculation": {
      "http://roivant.com/role/CondensedConsolidatedStatementsOfCashFlows": {
       "order": 5.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      },
      "http://roivant.com/role/CondensedConsolidatedStatementsOfOperations": {
       "order": 8.0,
       "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Gain Loss on Fair Value of Debt and Liability Instruments",
        "label": "Gain Loss on Fair Value of Debt and Liability Instruments",
        "negatedLabel": "Change in fair value of debt and liability instruments"
       }
      }
     },
     "localname": "GainLossOnFairValueOfDebtAndLiabilityInstruments",
     "nsuri": "http://roivant.com/20210630",
     "presentation": [
      "http://roivant.com/role/CondensedConsolidatedStatementsOfCashFlows",
      "http://roivant.com/role/CondensedConsolidatedStatementsOfOperations"
     ],
     "xbrltype": "monetaryItemType"
    },
    "roiv_GainOnTerminationOfEquityInterestOptions": {
     "auth_ref": [],
     "calculation": {
      "http://roivant.com/role/CondensedConsolidatedStatementsOfCashFlows": {
       "order": 9.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Gain on termination of equity interest options.",
        "label": "Gain On Termination Of Equity Interest Options",
        "negatedLabel": "Gain on termination of Sumitomo Options"
       }
      }
     },
     "localname": "GainOnTerminationOfEquityInterestOptions",
     "nsuri": "http://roivant.com/20210630",
     "presentation": [
      "http://roivant.com/role/CondensedConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "roiv_GainOrLossOnDeconsolidationOfSubsidiary": {
     "auth_ref": [],
     "calculation": {
      "http://roivant.com/role/CondensedConsolidatedStatementsOfCashFlows": {
       "order": 6.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      },
      "http://roivant.com/role/CondensedConsolidatedStatementsOfOperations": {
       "order": 11.0,
       "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Gain or (loss) on deconsolidation of subsidiary.",
        "label": "Gain Or Loss On Deconsolidation Of Subsidiary",
        "negatedLabel": "Gain on deconsolidation of subsidiary"
       }
      }
     },
     "localname": "GainOrLossOnDeconsolidationOfSubsidiary",
     "nsuri": "http://roivant.com/20210630",
     "presentation": [
      "http://roivant.com/role/CondensedConsolidatedStatementsOfCashFlows",
      "http://roivant.com/role/CondensedConsolidatedStatementsOfOperations"
     ],
     "xbrltype": "monetaryItemType"
    },
    "roiv_GeneralAndAdministrativeExpensesPolicyTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "General and Administrative Expenses, Policy [Text Block]",
        "label": "General and Administrative Expenses [Policy Text Block]",
        "terseLabel": "General and Administrative Expenses"
       }
      }
     },
     "localname": "GeneralAndAdministrativeExpensesPolicyTextBlock",
     "nsuri": "http://roivant.com/20210630",
     "presentation": [
      "http://roivant.com/role/SummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "roiv_GenevantSciencesLtdMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Genevant Sciences Ltd [Member]",
        "label": "Genevant Sciences Ltd [Member]",
        "terseLabel": "Genevant Sciences Ltd [Member]"
       }
      }
     },
     "localname": "GenevantSciencesLtdMember",
     "nsuri": "http://roivant.com/20210630",
     "presentation": [
      "http://roivant.com/role/AssetAcquisitionsAndLicenseAgreementsAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "roiv_HealthSciencesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "HSAC [Member]",
        "label": "Health Sciences [Member]",
        "terseLabel": "Health Sciences [Member]"
       }
      }
     },
     "localname": "HealthSciencesMember",
     "nsuri": "http://roivant.com/20210630",
     "presentation": [
      "http://roivant.com/role/ShareholdersEquityAndRedeemableNonControllingInterestAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "roiv_ImmunovantINCMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Immunovant INC.",
        "label": "Immunovant INC [Member]",
        "terseLabel": "Immunovant, Inc [Member]"
       }
      }
     },
     "localname": "ImmunovantINCMember",
     "nsuri": "http://roivant.com/20210630",
     "presentation": [
      "http://roivant.com/role/ShareholdersEquityAndRedeemableNonControllingInterestAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "roiv_ImmunovantSciencesLtdMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Immunovant Sciences Ltd [Member]",
        "label": "Immunovant Sciences Ltd [Member]",
        "terseLabel": "Immunovant Sciences Ltd [Member]"
       }
      }
     },
     "localname": "ImmunovantSciencesLtdMember",
     "nsuri": "http://roivant.com/20210630",
     "presentation": [
      "http://roivant.com/role/ShareholdersEquityAndRedeemableNonControllingInterestAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "roiv_IncomeTaxDisclosureLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Income Tax Disclosure [Line Items]",
        "label": "Income Tax Disclosure [Line Items]",
        "terseLabel": "Income Tax Disclosure [Line Items]"
       }
      }
     },
     "localname": "IncomeTaxDisclosureLineItems",
     "nsuri": "http://roivant.com/20210630",
     "presentation": [
      "http://roivant.com/role/IncomeTaxesAdditionalInformationDetail",
      "http://roivant.com/role/IncomeTaxesScheduleOfLossBeforeIncomeTaxesByGeographicRegionDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "roiv_IncomeTaxDisclosureTable": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Income Tax Disclosure [Table]",
        "label": "Income Tax Disclosure [Table]",
        "terseLabel": "Income Tax Disclosure [Table]"
       }
      }
     },
     "localname": "IncomeTaxDisclosureTable",
     "nsuri": "http://roivant.com/20210630",
     "presentation": [
      "http://roivant.com/role/IncomeTaxesAdditionalInformationDetail",
      "http://roivant.com/role/IncomeTaxesScheduleOfLossBeforeIncomeTaxesByGeographicRegionDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "roiv_IncomeTaxReconciliationPermanentAdjustments": {
     "auth_ref": [],
     "calculation": {
      "http://roivant.com/role/IncomeTaxesScheduleOfEffectiveIncomeTaxRateReconciliationDetail": {
       "order": 6.0,
       "parentTag": "us-gaap_IncomeTaxExpenseBenefit",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Income Tax Reconciliation Permanent Adjustments",
        "label": "Income Tax Reconciliation Permanent Adjustments",
        "terseLabel": "Permanent adjustments"
       }
      }
     },
     "localname": "IncomeTaxReconciliationPermanentAdjustments",
     "nsuri": "http://roivant.com/20210630",
     "presentation": [
      "http://roivant.com/role/IncomeTaxesScheduleOfEffectiveIncomeTaxRateReconciliationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "roiv_IncreaseDecreaseInOperatingLeaseLiabilities": {
     "auth_ref": [],
     "calculation": {
      "http://roivant.com/role/CondensedConsolidatedStatementsOfCashFlows": {
       "order": 12.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Increase decrease in operating lease liabilities",
        "label": "Increase Decrease In Operating Lease Liabilities",
        "terseLabel": "Operating lease liabilities"
       }
      }
     },
     "localname": "IncreaseDecreaseInOperatingLeaseLiabilities",
     "nsuri": "http://roivant.com/20210630",
     "presentation": [
      "http://roivant.com/role/CondensedConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "roiv_InvestmentsLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Investments [Line Items]",
        "label": "Investments [Line Items]",
        "terseLabel": "Investments [Line Items]"
       }
      }
     },
     "localname": "InvestmentsLineItems",
     "nsuri": "http://roivant.com/20210630",
     "presentation": [
      "http://roivant.com/role/InvestmentsAdditionalInformationDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "roiv_InvestmentsTable": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Investments [Table]",
        "label": "Investments [Table]",
        "terseLabel": "Investments [Table]"
       }
      }
     },
     "localname": "InvestmentsTable",
     "nsuri": "http://roivant.com/20210630",
     "presentation": [
      "http://roivant.com/role/InvestmentsAdditionalInformationDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "roiv_IssuanceOfEquityBySubsidiaryToTheCompanyUponBusinessCombinationAndRecapitalization": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Issuance of Equity by Subsidiary to the Company upon Business Combination and Recapitalization",
        "label": "Issuance of Equity by Subsidiary to the Company upon Business Combination and Recapitalization",
        "terseLabel": "Issuance of equity by subsidiary to the Company upon Business Combination and recapitalization"
       }
      }
     },
     "localname": "IssuanceOfEquityBySubsidiaryToTheCompanyUponBusinessCombinationAndRecapitalization",
     "nsuri": "http://roivant.com/20210630",
     "presentation": [
      "http://roivant.com/role/CondensedConsolidatedStatementsOfShareholdersEquityAndRedeemableNoncontrollingInterest"
     ],
     "xbrltype": "monetaryItemType"
    },
    "roiv_IssuanceOfEquityBySubsidiaryUponBusinessCombinationAndRecapitalization": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Issuance of Equity by Subsidiary upon Business Combination and Recapitalization",
        "label": "Issuance of Equity by Subsidiary upon Business Combination and Recapitalization",
        "terseLabel": "Issuance of equity by subsidiary upon Business Combination and recapitalization"
       }
      }
     },
     "localname": "IssuanceOfEquityBySubsidiaryUponBusinessCombinationAndRecapitalization",
     "nsuri": "http://roivant.com/20210630",
     "presentation": [
      "http://roivant.com/role/CondensedConsolidatedStatementsOfShareholdersEquityAndRedeemableNoncontrollingInterest"
     ],
     "xbrltype": "monetaryItemType"
    },
    "roiv_IssuanceOfEquityInstruments": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Issuance of Equity Instruments",
        "label": "Issuance of Equity Instruments",
        "terseLabel": "Issuance of equity instruments"
       }
      }
     },
     "localname": "IssuanceOfEquityInstruments",
     "nsuri": "http://roivant.com/20210630",
     "presentation": [
      "http://roivant.com/role/CondensedConsolidatedStatementsOfShareholdersEquityAndRedeemableNoncontrollingInterest"
     ],
     "xbrltype": "monetaryItemType"
    },
    "roiv_IssuanceOfSubsidiaryCommonSharesNetValue": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Issuance of Subsidiary Common Shares Net Value",
        "label": "Issuance of Subsidiary Common Shares Net Value",
        "terseLabel": "Issuance of subsidiary common shares, net of issuance costs paid"
       }
      }
     },
     "localname": "IssuanceOfSubsidiaryCommonSharesNetValue",
     "nsuri": "http://roivant.com/20210630",
     "presentation": [
      "http://roivant.com/role/CondensedConsolidatedStatementsOfShareholdersEquityAndRedeemableNoncontrollingInterest"
     ],
     "xbrltype": "monetaryItemType"
    },
    "roiv_IssuanceOfSubsidiaryCommonSharesToTheCompanyValue": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Issuance of Subsidiary Common Shares to the Company Value",
        "label": "Issuance of Subsidiary Common Shares to the Company Value",
        "terseLabel": "Issuance of subsidiary common shares to the Company"
       }
      }
     },
     "localname": "IssuanceOfSubsidiaryCommonSharesToTheCompanyValue",
     "nsuri": "http://roivant.com/20210630",
     "presentation": [
      "http://roivant.com/role/CondensedConsolidatedStatementsOfShareholdersEquityAndRedeemableNoncontrollingInterest"
     ],
     "xbrltype": "monetaryItemType"
    },
    "roiv_IssuanceOfSubsidiaryWarrantInConnectionWithDebtFinancing": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Issuance of subsidiary warrant in connection with debt financing.",
        "label": "Issuance Of Subsidiary Warrant In Connection With Debt Financing",
        "terseLabel": "Issuance of subsidiary warrant in connection with debt financing"
       }
      }
     },
     "localname": "IssuanceOfSubsidiaryWarrantInConnectionWithDebtFinancing",
     "nsuri": "http://roivant.com/20210630",
     "presentation": [
      "http://roivant.com/role/CondensedConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "roiv_IssuanceOfSubsidiaryWarrants": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Issuance of Subsidiary Warrants",
        "label": "Issuance of Subsidiary Warrants",
        "terseLabel": "Issuance of subsidiary warrants"
       }
      }
     },
     "localname": "IssuanceOfSubsidiaryWarrants",
     "nsuri": "http://roivant.com/20210630",
     "presentation": [
      "http://roivant.com/role/CondensedConsolidatedStatementsOfShareholdersEquityAndRedeemableNoncontrollingInterest"
     ],
     "xbrltype": "monetaryItemType"
    },
    "roiv_LesseeOperatingLeaseLiabilityTenantImprovementAllowance": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Lessee operating lease liability tenant improvement allowance..",
        "label": "Lessee Operating Lease Liability Tenant Improvement Allowance",
        "negatedLabel": "Less: tenant improvement allowance"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityTenantImprovementAllowance",
     "nsuri": "http://roivant.com/20210630",
     "presentation": [
      "http://roivant.com/role/LeasesScheduleOfMaturitiesOfOperatingLeaseLiabilitiesDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "roiv_LiabilityInstrumentsMeasuredAtFairValue": {
     "auth_ref": [],
     "calculation": {
      "http://roivant.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 21.0,
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Liability instruments measured at fair value.",
        "label": "Liability Instruments Measured At Fair Value",
        "terseLabel": "Liability instruments measured at fair value"
       }
      }
     },
     "localname": "LiabilityInstrumentsMeasuredAtFairValue",
     "nsuri": "http://roivant.com/20210630",
     "presentation": [
      "http://roivant.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "roiv_LiabilityInstrumentsMeasuredAtFairValueMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Liability Instruments Measured At Fair Value [Member]",
        "label": "Liability Instruments Measured At Fair Value [Member]",
        "terseLabel": "Liability Instruments Measured At Fair Value [Member]"
       }
      }
     },
     "localname": "LiabilityInstrumentsMeasuredAtFairValueMember",
     "nsuri": "http://roivant.com/20210630",
     "presentation": [
      "http://roivant.com/role/FairValueMeasurementsAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "roiv_LongTermDebtExcludingDebtWithFairValueOption": {
     "auth_ref": [],
     "calculation": {
      "http://roivant.com/role/LongTermDebtAndConvertibleNotesPayableScheduleOfCompanysAnnualPaymentsDetail": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Long Term Debt Excluding Debt With Fair Value Option",
        "label": "Long Term Debt Excluding Debt With Fair Value Option",
        "totalLabel": "Total"
       }
      }
     },
     "localname": "LongTermDebtExcludingDebtWithFairValueOption",
     "nsuri": "http://roivant.com/20210630",
     "presentation": [
      "http://roivant.com/role/LongTermDebtAndConvertibleNotesPayableScheduleOfCompanysAnnualPaymentsDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "roiv_MaximumAllowedOwnershipInterestPercentage": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Maximum Allowed Ownership Interest Percentage",
        "label": "Maximum Allowed Ownership Interest Percentage",
        "terseLabel": "Maximum allowed ownership interest percentage"
       }
      }
     },
     "localname": "MaximumAllowedOwnershipInterestPercentage",
     "nsuri": "http://roivant.com/20210630",
     "presentation": [
      "http://roivant.com/role/InvestmentsAdditionalInformationDetail"
     ],
     "xbrltype": "percentItemType"
    },
    "roiv_MaximumMilestonePaymentObligation": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Maximum milestone payment obligation.",
        "label": "Maximum Milestone Payment Obligation",
        "terseLabel": "Maximum amount required milestone payments"
       }
      }
     },
     "localname": "MaximumMilestonePaymentObligation",
     "nsuri": "http://roivant.com/20210630",
     "presentation": [
      "http://roivant.com/role/LongTermDebtAndLoanCommitmentAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "roiv_MaximumMilestonePaymentOffsetAmount": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Maximum Milestone Payment Offset Amount",
        "label": "Maximum Milestone Payment Offset Amount",
        "terseLabel": "Possible offset of regulatory milestone payments with commercial milestone"
       }
      }
     },
     "localname": "MaximumMilestonePaymentOffsetAmount",
     "nsuri": "http://roivant.com/20210630",
     "presentation": [
      "http://roivant.com/role/LongTermDebtAndLoanCommitmentAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "roiv_MilestoneEventsAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Milestone Events [Axis]",
        "label": "Milestone Events [Axis]",
        "terseLabel": "Milestone Events [Axis]"
       }
      }
     },
     "localname": "MilestoneEventsAxis",
     "nsuri": "http://roivant.com/20210630",
     "presentation": [
      "http://roivant.com/role/AssetAcquisitionsAndLicenseAgreementsAdditionalInformationDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "roiv_MilestoneEventsDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Milestone Events [Domain]",
        "label": "Milestone Events [Domain]",
        "terseLabel": "Milestone Events [Domain]"
       }
      }
     },
     "localname": "MilestoneEventsDomain",
     "nsuri": "http://roivant.com/20210630",
     "presentation": [
      "http://roivant.com/role/AssetAcquisitionsAndLicenseAgreementsAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "roiv_MilestonePayment": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Milestone Payment",
        "label": "Milestone Payment",
        "terseLabel": "Milestone payment"
       }
      }
     },
     "localname": "MilestonePayment",
     "nsuri": "http://roivant.com/20210630",
     "presentation": [
      "http://roivant.com/role/AssetAcquisitionsAndLicenseAgreementsAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "roiv_MinimumAmountOfAnnualNetSalesToQualifyUnderRevenueInterestPurchaseAgreementContingentThreshold": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Minimum amount of annual net sales to qualify under revenue interest purchase agreement, contingent threshold.",
        "label": "Minimum Amount Of Annual Net Sales To Qualify Under Revenue Interest Purchase Agreement Contingent Threshold",
        "terseLabel": "Minimum Amount of Annual Net Sales To Qualify Under Revenue Interest Purchase Agreement, Contingent Threshold"
       }
      }
     },
     "localname": "MinimumAmountOfAnnualNetSalesToQualifyUnderRevenueInterestPurchaseAgreementContingentThreshold",
     "nsuri": "http://roivant.com/20210630",
     "presentation": [
      "http://roivant.com/role/LongTermDebtAndLoanCommitmentAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "roiv_NewAccountingPronouncementsNotYetAdoptedPolicyTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "New Accounting Pronouncements Not Yet Adopted [Policy Text Block]",
        "label": "New Accounting Pronouncements Not Yet Adopted [Policy Text Block]",
        "terseLabel": "Recently Issued Accounting Pronouncements Not Yet Adopted"
       }
      }
     },
     "localname": "NewAccountingPronouncementsNotYetAdoptedPolicyTextBlock",
     "nsuri": "http://roivant.com/20210630",
     "presentation": [
      "http://roivant.com/role/SummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "roiv_NonRefundableUpfrontPaymentReceived": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Non Refundable Upfront Payment Received",
        "label": "Non Refundable Upfront Payment Received",
        "terseLabel": "Nonrefundable, upfront payment"
       }
      }
     },
     "localname": "NonRefundableUpfrontPaymentReceived",
     "nsuri": "http://roivant.com/20210630",
     "presentation": [
      "http://roivant.com/role/AssetAcquisitionsAndLicenseAgreementsAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "roiv_NovaquestMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Novaquest.",
        "label": "Novaquest [Member]",
        "terseLabel": "NovaQuest Agreement [Member]"
       }
      }
     },
     "localname": "NovaquestMember",
     "nsuri": "http://roivant.com/20210630",
     "presentation": [
      "http://roivant.com/role/LongTermDebtAndLoanCommitmentAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "roiv_OperatingCosts": {
     "auth_ref": [],
     "calculation": {
      "http://roivant.com/role/CondensedConsolidatedStatementsOfOperations": {
       "order": 3.0,
       "parentTag": "us-gaap_OperatingExpenses",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Operating costs.",
        "label": "Operating Costs",
        "terseLabel": "Cost of revenues"
       }
      }
     },
     "localname": "OperatingCosts",
     "nsuri": "http://roivant.com/20210630",
     "presentation": [
      "http://roivant.com/role/CondensedConsolidatedStatementsOfOperations"
     ],
     "xbrltype": "monetaryItemType"
    },
    "roiv_OperatingLeaseLiabilityPresentValueAdjustments": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Operating Lease Liability Present Value Adjustments",
        "label": "Operating Lease Liability Present Value Adjustments",
        "negatedLabel": "Less: present value adjustment"
       }
      }
     },
     "localname": "OperatingLeaseLiabilityPresentValueAdjustments",
     "nsuri": "http://roivant.com/20210630",
     "presentation": [
      "http://roivant.com/role/LeasesScheduleOfMaturitiesOfOperatingLeaseLiabilitiesDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "roiv_OperatingLeaseRightOfUseAssetsAndAmountsReclassifiedFromOtherLiabilitiesToOperatingLeaseLiabilities": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Operating Lease Right of Use Assets and Amounts Reclassified from Other Liabilities to Operating Lease Liabilities",
        "label": "Operating Lease Right of Use Assets and Amounts Reclassified from Other Liabilities to Operating Lease Liabilities",
        "terseLabel": "Operating lease right-of-use assets and operating lease liabilities, including amounts reclassified from other current liabilities and other liabilities to operating lease liabilities, recognized upon the adoption of ASC 842, Leases, on April 1, 2019"
       }
      }
     },
     "localname": "OperatingLeaseRightOfUseAssetsAndAmountsReclassifiedFromOtherLiabilitiesToOperatingLeaseLiabilities",
     "nsuri": "http://roivant.com/20210630",
     "presentation": [
      "http://roivant.com/role/CondensedConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "roiv_OtherGeneralAndAdministrativeExpensesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Other General and Administrative Expenses [Member]",
        "label": "Other General and Administrative Expenses [Member]",
        "terseLabel": "Other General and Administrative Expenses [Member]"
       }
      }
     },
     "localname": "OtherGeneralAndAdministrativeExpensesMember",
     "nsuri": "http://roivant.com/20210630",
     "presentation": [
      "http://roivant.com/role/BalanceSheetComponentsScheduleOfAccruedExpensesDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "roiv_OtherIncomeExpense": {
     "auth_ref": [],
     "calculation": {
      "http://roivant.com/role/OtherIncomeExpenseNetSummaryOfOtherIncomeExpenseNetFromContinuingOperationsDetail": {
       "order": 4.0,
       "parentTag": "us-gaap_OtherOperatingIncomeExpenseNet",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Other Income Expense",
        "label": "Other Income Expense",
        "negatedLabel": "Other (expense) income"
       }
      }
     },
     "localname": "OtherIncomeExpense",
     "nsuri": "http://roivant.com/20210630",
     "presentation": [
      "http://roivant.com/role/OtherIncomeExpenseNetSummaryOfOtherIncomeExpenseNetFromContinuingOperationsDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "roiv_OtherMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Other [Member]",
        "label": "Other [Member]",
        "terseLabel": "Other [Member]"
       }
      }
     },
     "localname": "OtherMember",
     "nsuri": "http://roivant.com/20210630",
     "presentation": [
      "http://roivant.com/role/IncomeTaxesScheduleComponentsOfIncomeTaxExpenseBenefitDetail",
      "http://roivant.com/role/IncomeTaxesScheduleOfLossBeforeIncomeTaxesByGeographicRegionDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "roiv_OtherNonCashTransactions": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Other Non Cash Transactions",
        "label": "Other Non Cash Transactions",
        "terseLabel": "Other"
       }
      }
     },
     "localname": "OtherNonCashTransactions",
     "nsuri": "http://roivant.com/20210630",
     "presentation": [
      "http://roivant.com/role/CondensedConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "roiv_OwnershipInterestPercentage": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Ownership Interest Percentage",
        "label": "Ownership Interest Percentage",
        "terseLabel": "Ownership interest, percentage"
       }
      }
     },
     "localname": "OwnershipInterestPercentage",
     "nsuri": "http://roivant.com/20210630",
     "presentation": [
      "http://roivant.com/role/InvestmentsAdditionalInformationDetail"
     ],
     "xbrltype": "percentItemType"
    },
    "roiv_PaymentForDebtMaintenanceFeeBySubsidiary": {
     "auth_ref": [],
     "calculation": {
      "http://roivant.com/role/CondensedConsolidatedStatementsOfCashFlows": {
       "order": 32.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Payment for Debt Maintenance Fee by Subsidiary",
        "label": "Payment for Debt Maintenance Fee by Subsidiary",
        "terseLabel": "Payment of deferred offering and loan origination costs"
       }
      }
     },
     "localname": "PaymentForDebtMaintenanceFeeBySubsidiary",
     "nsuri": "http://roivant.com/20210630",
     "presentation": [
      "http://roivant.com/role/CondensedConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "roiv_PaymentForUpfrontPayments": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Payment for upfront payments.",
        "label": "Payment For Upfront payments",
        "terseLabel": "Upfront proceeds"
       }
      }
     },
     "localname": "PaymentForUpfrontPayments",
     "nsuri": "http://roivant.com/20210630",
     "presentation": [
      "http://roivant.com/role/AssetAcquisitionsAndLicenseAgreementsAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "roiv_PaymentUnderSponsoredResearchAgreement": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Payment under sponsored research agreement.",
        "label": "Payment Under Sponsored Research Agreement",
        "terseLabel": "Payment under SRA"
       }
      }
     },
     "localname": "PaymentUnderSponsoredResearchAgreement",
     "nsuri": "http://roivant.com/20210630",
     "presentation": [
      "http://roivant.com/role/AssetAcquisitionsAndLicenseAgreementsAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "roiv_PaymentsForPurchaseOfSubsidiaryConvertibleAndRedeemablePreferredStock": {
     "auth_ref": [],
     "calculation": {
      "http://roivant.com/role/CondensedConsolidatedStatementsOfCashFlows": {
       "order": 35.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Payments for Purchase of Subsidiary Convertible and Redeemable Preferred Stock",
        "label": "Payments for Purchase of Subsidiary Convertible and Redeemable Preferred Stock",
        "negatedLabel": "Purchase of subsidiary convertible and redeemable preferred stock"
       }
      }
     },
     "localname": "PaymentsForPurchaseOfSubsidiaryConvertibleAndRedeemablePreferredStock",
     "nsuri": "http://roivant.com/20210630",
     "presentation": [
      "http://roivant.com/role/CondensedConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "roiv_PaymentsToAcquireInvestmentsInUnconsolidatedEntities": {
     "auth_ref": [],
     "calculation": {
      "http://roivant.com/role/CondensedConsolidatedStatementsOfCashFlows": {
       "order": 20.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Payments to Acquire Investments in Unconsolidated Entities",
        "label": "Payments to Acquire Investments in Unconsolidated Entities",
        "negatedLabel": "Investments in unconsolidated entities"
       }
      }
     },
     "localname": "PaymentsToAcquireInvestmentsInUnconsolidatedEntities",
     "nsuri": "http://roivant.com/20210630",
     "presentation": [
      "http://roivant.com/role/CondensedConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "roiv_PercentageOfControllingInterestHeld": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of controlling interest held.",
        "label": "Percentage Of Controlling Interest Held",
        "terseLabel": "Percentage controlling interest"
       }
      }
     },
     "localname": "PercentageOfControllingInterestHeld",
     "nsuri": "http://roivant.com/20210630",
     "presentation": [
      "http://roivant.com/role/AssetAcquisitionsAndLicenseAgreementsAdditionalInformationDetail"
     ],
     "xbrltype": "percentItemType"
    },
    "roiv_PercentageOfFutureTaxableIncome": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of future taxable income.",
        "label": "Percentage Of Future Taxable Income",
        "terseLabel": "Percentage of future taxable income"
       }
      }
     },
     "localname": "PercentageOfFutureTaxableIncome",
     "nsuri": "http://roivant.com/20210630",
     "presentation": [
      "http://roivant.com/role/IncomeTaxesAdditionalInformationDetail"
     ],
     "xbrltype": "percentItemType"
    },
    "roiv_PercentageOfGrantedOptionToPurchaseOwnershipInterest": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of granted option to purchase ownership interest.",
        "label": "Percentage of granted option to purchase ownership interest",
        "terseLabel": "Percentage of granted option to purchase ownership interest"
       }
      }
     },
     "localname": "PercentageOfGrantedOptionToPurchaseOwnershipInterest",
     "nsuri": "http://roivant.com/20210630",
     "presentation": [
      "http://roivant.com/role/SumitomoTransactionAgreementAdditionalInformationDetail"
     ],
     "xbrltype": "percentItemType"
    },
    "roiv_PercentageSharesOfCommonStockOfferedToBeRepurchased": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage Shares of Common Stock Offered To Be Repurchased",
        "label": "Percentage Shares of Common Stock Offered To Be Repurchased",
        "terseLabel": "Offer to repurchase common stock held by each holder"
       }
      }
     },
     "localname": "PercentageSharesOfCommonStockOfferedToBeRepurchased",
     "nsuri": "http://roivant.com/20210630",
     "presentation": [
      "http://roivant.com/role/ShareholdersEquityAndRedeemableNonControllingInterestAdditionalInformationDetail"
     ],
     "xbrltype": "percentItemType"
    },
    "roiv_PerformanceOptionsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Performance Options [Member]",
        "label": "Performance Options [Member]",
        "terseLabel": "Performance Options [Member]"
       }
      }
     },
     "localname": "PerformanceOptionsMember",
     "nsuri": "http://roivant.com/20210630",
     "presentation": [
      "http://roivant.com/role/ShareBasedCompensationAdditionalInformationDetail",
      "http://roivant.com/role/ShareBasedCompensationScheduleOfFairValueAssumptionsDetail",
      "http://roivant.com/role/ShareBasedCompensationSummaryOfPerformanceOptionsActivityDetail",
      "http://roivant.com/role/ShareBasedCompensationTables"
     ],
     "xbrltype": "domainItemType"
    },
    "roiv_PerformanceRestrictedStockUnitsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Performance Restricted Stock Units [Member]",
        "label": "Performance Restricted Stock Units [Member]",
        "terseLabel": "Performance RSU [Member]"
       }
      }
     },
     "localname": "PerformanceRestrictedStockUnitsMember",
     "nsuri": "http://roivant.com/20210630",
     "presentation": [
      "http://roivant.com/role/ShareBasedCompensationAdditionalInformationDetail",
      "http://roivant.com/role/ShareBasedCompensationSummaryOfPerformanceRestrictedStockUnitsDetail",
      "http://roivant.com/role/ShareBasedCompensationTables"
     ],
     "xbrltype": "domainItemType"
    },
    "roiv_PerformanceRestrictedStockUnitsPlanMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Performance Restricted Stock Units Plan [Member]",
        "label": "Performance Restricted Stock Units Plan [Member]",
        "terseLabel": "pRSU Plan [Member]"
       }
      }
     },
     "localname": "PerformanceRestrictedStockUnitsPlanMember",
     "nsuri": "http://roivant.com/20210630",
     "presentation": [
      "http://roivant.com/role/ShareBasedCompensationAdditionalInformationDetail",
      "http://roivant.com/role/ShareBasedCompensationSummaryOfPerformanceRestrictedStockUnitsDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "roiv_PotentialMilestonePaymentReceivable": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Potential milestone payment receivable.",
        "label": "Potential Milestone Payment Receivable",
        "terseLabel": "Nonrefundable, upfront payment"
       }
      }
     },
     "localname": "PotentialMilestonePaymentReceivable",
     "nsuri": "http://roivant.com/20210630",
     "presentation": [
      "http://roivant.com/role/AssetAcquisitionsAndLicenseAgreementsAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "roiv_PreferredStockOwnedBalanceSharesOfArbutus": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Preferred stock Owned, Balance, Shares of Arbutus.",
        "label": "Preferred stock Owned, Balance, Shares of Arbutus",
        "terseLabel": "Preferred stock Owned, Balance, Shares of Arbutus"
       }
      }
     },
     "localname": "PreferredStockOwnedBalanceSharesOfArbutus",
     "nsuri": "http://roivant.com/20210630",
     "presentation": [
      "http://roivant.com/role/InvestmentsAdditionalInformationDetail"
     ],
     "xbrltype": "sharesItemType"
    },
    "roiv_PreferredStockPurchased": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Preferred Stock Purchased",
        "label": "Preferred Stock Purchased",
        "terseLabel": "Total purchase price"
       }
      }
     },
     "localname": "PreferredStockPurchased",
     "nsuri": "http://roivant.com/20210630",
     "presentation": [
      "http://roivant.com/role/InvestmentsAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "roiv_PreferredStockSharesIssuedAndSoldToCompanyDuringPeriodShares": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Preferred Stock Shares Issued And Sold to Company During Period, Shares",
        "label": "Preferred Stock Shares Issued And Sold to Company During Period, Shares",
        "terseLabel": "Preferred stock issued and sold"
       }
      }
     },
     "localname": "PreferredStockSharesIssuedAndSoldToCompanyDuringPeriodShares",
     "nsuri": "http://roivant.com/20210630",
     "presentation": [
      "http://roivant.com/role/InvestmentsAdditionalInformationDetail"
     ],
     "xbrltype": "sharesItemType"
    },
    "roiv_PremiumOnConversionPricePercentage": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Premium on Conversion Price, Percentage",
        "label": "Premium on Conversion Price, Percentage",
        "terseLabel": "Premium on the conversion price, percentage"
       }
      }
     },
     "localname": "PremiumOnConversionPricePercentage",
     "nsuri": "http://roivant.com/20210630",
     "presentation": [
      "http://roivant.com/role/InvestmentsAdditionalInformationDetail"
     ],
     "xbrltype": "percentItemType"
    },
    "roiv_ProceedsFromIssuanceOfEquityBySubsidiaryUponBusinessCombinationAndRecapitalization": {
     "auth_ref": [],
     "calculation": {
      "http://roivant.com/role/CondensedConsolidatedStatementsOfCashFlows": {
       "order": 38.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Proceeds from Issuance of Equity by Subsidiary Upon Business Combination and Recapitalization",
        "label": "Proceeds from Issuance of Equity by Subsidiary Upon Business Combination and Recapitalization",
        "terseLabel": "Proceeds from issuance of equity by subsidiary upon Business Combination and recapitalization"
       }
      }
     },
     "localname": "ProceedsFromIssuanceOfEquityBySubsidiaryUponBusinessCombinationAndRecapitalization",
     "nsuri": "http://roivant.com/20210630",
     "presentation": [
      "http://roivant.com/role/CondensedConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "roiv_ProceedsFromIssuanceOfPreferredStockAndPreferenceStocks": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Proceeds from Issuance of Preferred Stock and Preference Stocks.",
        "label": "Proceeds from Issuance of Preferred Stock and Preference Stocks",
        "terseLabel": "Gross proceeds from issuance of stock"
       }
      }
     },
     "localname": "ProceedsFromIssuanceOfPreferredStockAndPreferenceStocks",
     "nsuri": "http://roivant.com/20210630",
     "presentation": [
      "http://roivant.com/role/InvestmentsAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "roiv_ProceedsFromIssuanceOfSubsidiaryCommonSharesNet": {
     "auth_ref": [],
     "calculation": {
      "http://roivant.com/role/CondensedConsolidatedStatementsOfCashFlows": {
       "order": 29.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Proceeds from Issuance of Subsidiary Common Shares Net",
        "label": "Proceeds from Issuance of Subsidiary Common Shares Net",
        "terseLabel": "Proceeds from issuance of subsidiary common shares, net of issuance costs paid"
       }
      }
     },
     "localname": "ProceedsFromIssuanceOfSubsidiaryCommonSharesNet",
     "nsuri": "http://roivant.com/20210630",
     "presentation": [
      "http://roivant.com/role/CondensedConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "roiv_ProceedsFromIssuanceOfSubsidiaryConvertibleAndRedeemablePreferredStockNet": {
     "auth_ref": [],
     "calculation": {
      "http://roivant.com/role/CondensedConsolidatedStatementsOfCashFlows": {
       "order": 36.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Proceeds from Issuance of Subsidiary Convertible and Redeemable Preferred Stock Net",
        "label": "Proceeds from Issuance of Subsidiary Convertible and Redeemable Preferred Stock Net",
        "terseLabel": "Proceeds from issuance of subsidiary convertible and redeemable preferred stock, net"
       }
      }
     },
     "localname": "ProceedsFromIssuanceOfSubsidiaryConvertibleAndRedeemablePreferredStockNet",
     "nsuri": "http://roivant.com/20210630",
     "presentation": [
      "http://roivant.com/role/CondensedConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "roiv_ProceedsFromReleaseOfEscrowDeposit": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Proceeds from Release of Escrow Deposit.",
        "label": "Proceeds from Release of Escrow Deposit",
        "terseLabel": "Proceeds from release of escrow deposit"
       }
      }
     },
     "localname": "ProceedsFromReleaseOfEscrowDeposit",
     "nsuri": "http://roivant.com/20210630",
     "presentation": [
      "http://roivant.com/role/SummaryOfSignificantAccountingPoliciesAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "roiv_ProceedsFromSaleOfDebtAndEquitySecurities": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Proceeds from the sale of debt and equity securities.",
        "label": "Proceeds from Sale of Debt and Equity Securities",
        "terseLabel": "Proceed from equity and debt financing"
       }
      }
     },
     "localname": "ProceedsFromSaleOfDebtAndEquitySecurities",
     "nsuri": "http://roivant.com/20210630",
     "presentation": [
      "http://roivant.com/role/LongTermDebtAndLoanCommitmentAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "roiv_ProceedsFromSubsidiaryDebtFinancingsNet": {
     "auth_ref": [],
     "calculation": {
      "http://roivant.com/role/CondensedConsolidatedStatementsOfCashFlows": {
       "order": 30.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Proceeds from Subsidiary Debt Financings Net",
        "label": "Proceeds from Subsidiary Debt Financings Net",
        "terseLabel": "Proceeds from subsidiary debt financings, net of financing costs paid"
       }
      }
     },
     "localname": "ProceedsFromSubsidiaryDebtFinancingsNet",
     "nsuri": "http://roivant.com/20210630",
     "presentation": [
      "http://roivant.com/role/CondensedConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "roiv_ProfessionalServicesExpensesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Professional Services Expenses [Member]",
        "label": "Professional Services Expenses [Member]",
        "terseLabel": "Professional Services Expenses [Member]"
       }
      }
     },
     "localname": "ProfessionalServicesExpensesMember",
     "nsuri": "http://roivant.com/20210630",
     "presentation": [
      "http://roivant.com/role/BalanceSheetComponentsScheduleOfAccruedExpensesDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "roiv_ProteovantSciencesIncMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "ProteoVant Sciences, Inc [Member].",
        "label": "ProteoVant Sciences, Inc [Member]",
        "terseLabel": "ProteoVant Sciences, Inc [Member]"
       }
      }
     },
     "localname": "ProteovantSciencesIncMember",
     "nsuri": "http://roivant.com/20210630",
     "presentation": [
      "http://roivant.com/role/AssetAcquisitionsAndLicenseAgreementsAdditionalInformationDetail",
      "http://roivant.com/role/SubsequentEventsAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "roiv_PurchaseOfSubsidiaryCommonShares": {
     "auth_ref": [],
     "calculation": {
      "http://roivant.com/role/CondensedConsolidatedStatementsOfCashFlows": {
       "order": 37.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Purchase of Subsidiary Common Shares",
        "label": "Purchase of Subsidiary Common Shares",
        "terseLabel": "Purchase of subsidiary common shares"
       }
      }
     },
     "localname": "PurchaseOfSubsidiaryCommonShares",
     "nsuri": "http://roivant.com/20210630",
     "presentation": [
      "http://roivant.com/role/CondensedConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "roiv_PurchaseOfSubsidiaryCommonSharesValue": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Purchase of Subsidiary Common Shares Value",
        "label": "Purchase of Subsidiary Common Shares Value",
        "negatedLabel": "Purchase of subsidiary common shares"
       }
      }
     },
     "localname": "PurchaseOfSubsidiaryCommonSharesValue",
     "nsuri": "http://roivant.com/20210630",
     "presentation": [
      "http://roivant.com/role/CondensedConsolidatedStatementsOfShareholdersEquityAndRedeemableNoncontrollingInterest"
     ],
     "xbrltype": "monetaryItemType"
    },
    "roiv_RedeemableNoncontrollingInterestMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Redeemable Noncontrolling Interest [Member]",
        "label": "Redeemable Noncontrolling Interest [Member]",
        "terseLabel": "Redeemable Noncontrolling Interest [Member]"
       }
      }
     },
     "localname": "RedeemableNoncontrollingInterestMember",
     "nsuri": "http://roivant.com/20210630",
     "presentation": [
      "http://roivant.com/role/CondensedConsolidatedStatementsOfShareholdersEquityAndRedeemableNoncontrollingInterest"
     ],
     "xbrltype": "domainItemType"
    },
    "roiv_RegulatoryMilestoneMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Regulatory Milestone [Member]",
        "label": "Regulatory Milestone [Member]",
        "terseLabel": "Regulatory Milestone [Member]"
       }
      }
     },
     "localname": "RegulatoryMilestoneMember",
     "nsuri": "http://roivant.com/20210630",
     "presentation": [
      "http://roivant.com/role/LongTermDebtAndLoanCommitmentAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "roiv_RepaymentOfLongTermDebtAndConvertibleDebtBySubsidiary": {
     "auth_ref": [],
     "calculation": {
      "http://roivant.com/role/CondensedConsolidatedStatementsOfCashFlows": {
       "order": 31.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Repayment of Long Term Debt and Convertible Debt by Subsidiary",
        "label": "Repayment of Long Term Debt and Convertible Debt by Subsidiary",
        "negatedLabel": "Repayment of long-term debt by subsidiary"
       }
      }
     },
     "localname": "RepaymentOfLongTermDebtAndConvertibleDebtBySubsidiary",
     "nsuri": "http://roivant.com/20210630",
     "presentation": [
      "http://roivant.com/role/CondensedConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "roiv_RepurchaseOfCommonSharesAndOtherEquityInstrumentsShares": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Repurchase of Common Shares and Other Equity Instruments Shares",
        "label": "Repurchase of Common Shares and Other Equity Instruments Shares",
        "negatedLabel": "Repurchase of common shares and other equity instruments, shares"
       }
      }
     },
     "localname": "RepurchaseOfCommonSharesAndOtherEquityInstrumentsShares",
     "nsuri": "http://roivant.com/20210630",
     "presentation": [
      "http://roivant.com/role/CondensedConsolidatedStatementsOfShareholdersEquityAndRedeemableNoncontrollingInterest"
     ],
     "xbrltype": "sharesItemType"
    },
    "roiv_RepurchaseOfCommonSharesAndOtherEquityInstrumentsValue": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Repurchase of Common Shares and Other Equity Instruments Value",
        "label": "Repurchase of Common Shares and Other Equity Instruments Value",
        "negatedLabel": "Repurchase of common shares and other equity instruments"
       }
      }
     },
     "localname": "RepurchaseOfCommonSharesAndOtherEquityInstrumentsValue",
     "nsuri": "http://roivant.com/20210630",
     "presentation": [
      "http://roivant.com/role/CondensedConsolidatedStatementsOfShareholdersEquityAndRedeemableNoncontrollingInterest"
     ],
     "xbrltype": "monetaryItemType"
    },
    "roiv_RepurchaseOfEquityAwards": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Repurchase of Equity Awards",
        "label": "Repurchase of Equity Awards",
        "terseLabel": "Repurchase of equity awards"
       }
      }
     },
     "localname": "RepurchaseOfEquityAwards",
     "nsuri": "http://roivant.com/20210630",
     "presentation": [
      "http://roivant.com/role/CondensedConsolidatedStatementsOfShareholdersEquityAndRedeemableNoncontrollingInterest"
     ],
     "xbrltype": "monetaryItemType"
    },
    "roiv_RevenueInterestPurchaseAndSaleAgreementAmount": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Revenue interest purchase and sale agreement amount.",
        "label": "Revenue Interest Purchase And Sale Agreement Amount",
        "terseLabel": "Revenue interest purchase and sale agreement amount"
       }
      }
     },
     "localname": "RevenueInterestPurchaseAndSaleAgreementAmount",
     "nsuri": "http://roivant.com/20210630",
     "presentation": [
      "http://roivant.com/role/SubsequentEventsAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "roiv_RevenueInterestPurchaseAndSaleAgreementCommittedFundToBePaid": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Revenue interest purchase and sale agreement committed fund to be paid.",
        "label": "Revenue Interest Purchase And Sale Agreement Committed Fund To Be Paid",
        "terseLabel": "Revenue interest purchase and sale agreement committed fund to be paid"
       }
      }
     },
     "localname": "RevenueInterestPurchaseAndSaleAgreementCommittedFundToBePaid",
     "nsuri": "http://roivant.com/20210630",
     "presentation": [
      "http://roivant.com/role/SubsequentEventsAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "roiv_RevenueInterestPurchaseAndSaleAgreementMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Revenue Interest Purchase And Sale Agreement [Member].",
        "label": "Revenue Interest Purchase And Sale Agreement [Member]",
        "terseLabel": "Revenue Interest Purchase and Sale Agreement [Member]"
       }
      }
     },
     "localname": "RevenueInterestPurchaseAndSaleAgreementMember",
     "nsuri": "http://roivant.com/20210630",
     "presentation": [
      "http://roivant.com/role/LongTermDebtAndLoanCommitmentAdditionalInformationDetail",
      "http://roivant.com/role/SubsequentEventsAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "roiv_RoivantEquityRepurchaseMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Roivant Equity Repurchase [Member]",
        "label": "Roivant Equity Repurchase [Member]",
        "terseLabel": "Roivant Equity Repurchase [Member]"
       }
      }
     },
     "localname": "RoivantEquityRepurchaseMember",
     "nsuri": "http://roivant.com/20210630",
     "presentation": [
      "http://roivant.com/role/ShareholdersEquityAndRedeemableNonControllingInterestAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "roiv_SaleOfStockConsiderationCashReceivedOnTransaction": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sale Of Stock Consideration Cash Received On Transaction.",
        "label": "Sale Of Stock Consideration Cash Received On Transaction"
       }
      }
     },
     "localname": "SaleOfStockConsiderationCashReceivedOnTransaction",
     "nsuri": "http://roivant.com/20210630",
     "presentation": [
      "http://roivant.com/role/SumitomoTransactionAgreementAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "roiv_SaleOfStockNumberOfShareIssuedInTransaction": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sale Of Stock Number Of Share Issued In Transaction",
        "label": "Sale Of Stock Number Of Share Issued In Transaction",
        "terseLabel": "Number of shares transferred"
       }
      }
     },
     "localname": "SaleOfStockNumberOfShareIssuedInTransaction",
     "nsuri": "http://roivant.com/20210630",
     "presentation": [
      "http://roivant.com/role/SumitomoTransactionAgreementAdditionalInformationDetail"
     ],
     "xbrltype": "sharesItemType"
    },
    "roiv_ScheduleOfAccountingPoliciesLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule Of Accounting Policies [Line Items]",
        "label": "Schedule Of Accounting Policies [Line Items]",
        "terseLabel": "Schedule Of Accounting Policies [Line Items]"
       }
      }
     },
     "localname": "ScheduleOfAccountingPoliciesLineItems",
     "nsuri": "http://roivant.com/20210630",
     "presentation": [
      "http://roivant.com/role/SummaryOfSignificantAccountingPoliciesAdditionalInformationDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "roiv_ScheduleOfAccountingPoliciesTable": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule Of Accounting Policies [Table]",
        "label": "Schedule Of Accounting Policies [Table]",
        "terseLabel": "Schedule Of Accounting Policies [Table]"
       }
      }
     },
     "localname": "ScheduleOfAccountingPoliciesTable",
     "nsuri": "http://roivant.com/20210630",
     "presentation": [
      "http://roivant.com/role/SummaryOfSignificantAccountingPoliciesAdditionalInformationDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "roiv_ScheduleOfDisposalGroupsIncludingDiscontinuedCondensedConsolidatedStatementsOfCashFlowsTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule Of Disposal Groups Including Discontinued Condensed Consolidated Statements Of Cash Flows Table [Text Block]",
        "label": "Schedule Of Disposal Groups Including Discontinued Condensed Consolidated Statements Of Cash Flows Table [Text Block]",
        "terseLabel": "Summary of Cash Flows from Discontinued Operations"
       }
      }
     },
     "localname": "ScheduleOfDisposalGroupsIncludingDiscontinuedCondensedConsolidatedStatementsOfCashFlowsTableTextBlock",
     "nsuri": "http://roivant.com/20210630",
     "presentation": [
      "http://roivant.com/role/DiscontinuedOperationsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "roiv_ScheduleOfPropertyPlantAndEquipmentEstimatedUsefulLivesTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule Of Property Plant And Equipment Estimated Useful Lives.",
        "label": "Schedule Of Property Plant And Equipment Estimated Useful Lives [Table Text Block]",
        "terseLabel": "Schedule of Estimated Useful Lives Used for Asset Type"
       }
      }
     },
     "localname": "ScheduleOfPropertyPlantAndEquipmentEstimatedUsefulLivesTableTextBlock",
     "nsuri": "http://roivant.com/20210630",
     "presentation": [
      "http://roivant.com/role/SummaryOfSignificantAccountingPoliciesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "roiv_ScheduleOfSharebasedPaymentArrangementFairValueOfVestedStockOptionTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule of Share-based Payment Arrangement, Fair Value of Vested Stock Option.",
        "label": "Schedule of Share-based Payment Arrangement, Fair Value of Vested Stock Option [Table Text Block]",
        "terseLabel": "Summary of Fair Value of Vested Stock Option"
       }
      }
     },
     "localname": "ScheduleOfSharebasedPaymentArrangementFairValueOfVestedStockOptionTableTextBlock",
     "nsuri": "http://roivant.com/20210630",
     "presentation": [
      "http://roivant.com/role/ShareBasedCompensationTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "roiv_SecondTrancheMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Second Tranche [Member]",
        "label": "Second Tranche [Member]",
        "terseLabel": "Second Tranche [Member]"
       }
      }
     },
     "localname": "SecondTrancheMember",
     "nsuri": "http://roivant.com/20210630",
     "presentation": [
      "http://roivant.com/role/AssetAcquisitionsAndLicenseAgreementsAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "roiv_SeriesA1PreferredStockMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Series A 1 Preferred Stock [Member]",
        "label": "Series A 1 Preferred Stock [Member]",
        "terseLabel": "Series A 1 Preferred Stock [Member]"
       }
      }
     },
     "localname": "SeriesA1PreferredStockMember",
     "nsuri": "http://roivant.com/20210630",
     "presentation": [
      "http://roivant.com/role/ShareholdersEquityAndRedeemableNonControllingInterestAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "roiv_SettlementOfLiabilityClassifiedInstruments": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Settlement of Liability Classified Instruments",
        "label": "Settlement of Liability Classified Instruments",
        "terseLabel": "Settlement in equity of liability-classified instruments"
       }
      }
     },
     "localname": "SettlementOfLiabilityClassifiedInstruments",
     "nsuri": "http://roivant.com/20210630",
     "presentation": [
      "http://roivant.com/role/CondensedConsolidatedStatementsOfShareholdersEquityAndRedeemableNoncontrollingInterest"
     ],
     "xbrltype": "monetaryItemType"
    },
    "roiv_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExcercisableWeightedAverageGrantDateFairValue": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share Based Compensation Arrangement by Share Based Payment Award Options Excercisable Weighted Average Grant Date Fair Value.",
        "label": "Share Based Compensation Arrangement by Share Based Payment Award Options Excercisable Weighted Average Grant Date Fair Value",
        "terseLabel": "Weighted Average Grant Date Fair Value, exercisable"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExcercisableWeightedAverageGrantDateFairValue",
     "nsuri": "http://roivant.com/20210630",
     "presentation": [
      "http://roivant.com/role/ShareBasedCompensationSummaryOfStockOptionActivityDetail"
     ],
     "xbrltype": "perShareItemType"
    },
    "roiv_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeitedInPeriodWeightedAverageGrantDateFairValue": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share Based Compensation Arrangement By Share Based Payment Award Options Forfeited In Period Weighted Average Grant Date Fair Value",
        "label": "Share Based Compensation Arrangement By Share Based Payment Award Options Forfeited In Period Weighted Average Grant Date Fair Value",
        "terseLabel": "Weighted average grant date fair value, Forfeited"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeitedInPeriodWeightedAverageGrantDateFairValue",
     "nsuri": "http://roivant.com/20210630",
     "presentation": [
      "http://roivant.com/role/ShareBasedCompensationSummaryOfPerformanceOptionsActivityDetail"
     ],
     "xbrltype": "perShareItemType"
    },
    "roiv_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageGrantDateFairValue": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Grant Date Fair Value",
        "label": "Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Grant Date Fair Value",
        "periodEndLabel": "Weighted average grant date fair value, Ending balance",
        "periodStartLabel": "Weighted average grant date fair value, Beginning balance"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageGrantDateFairValue",
     "nsuri": "http://roivant.com/20210630",
     "presentation": [
      "http://roivant.com/role/ShareBasedCompensationSummaryOfPerformanceOptionsActivityDetail"
     ],
     "xbrltype": "perShareItemType"
    },
    "roiv_ShareBasedCompensationArrangementByShareBasedPaymentAwardWeightedAverageGrantDateFairValue": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share Based Compensation Arrangement By Share Based Payment Award, Weighted Average Grant Date Fair Value",
        "label": "Share Based Compensation Arrangement By Share Based Payment Award, Weighted Average Grant Date Fair Value",
        "periodEndLabel": "Weighted Average Grant Date Fair Value, Ending balance",
        "periodStartLabel": "Weighted Average Grant Date Fair Value, Beginning balance"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardWeightedAverageGrantDateFairValue",
     "nsuri": "http://roivant.com/20210630",
     "presentation": [
      "http://roivant.com/role/ShareBasedCompensationSummaryOfStockOptionActivityDetail"
     ],
     "xbrltype": "perShareItemType"
    },
    "roiv_ShareBasedCompensationRightToRepurchasePercentage": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share based compensation right to repurchase percentage.",
        "label": "Share Based Compensation Right To Repurchase Percentage",
        "terseLabel": "Percentage of share repurchased"
       }
      }
     },
     "localname": "ShareBasedCompensationRightToRepurchasePercentage",
     "nsuri": "http://roivant.com/20210630",
     "presentation": [
      "http://roivant.com/role/ShareBasedCompensationAdditionalInformationDetail"
     ],
     "xbrltype": "percentItemType"
    },
    "roiv_SharebasedCompensationArrangementBySharebasedPaymentAwardAggregateRepurchasePrice": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sharebased Compensation Arrangement By Sharebased Payment Award Aggregate Repurchase Price",
        "label": "Sharebased Compensation Arrangement By Sharebased Payment Award Aggregate Repurchase Price",
        "terseLabel": "Equity repurchase"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardAggregateRepurchasePrice",
     "nsuri": "http://roivant.com/20210630",
     "presentation": [
      "http://roivant.com/role/ShareBasedCompensationAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "roiv_SiliconTherapeuticsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Silicon Therapeutics",
        "label": "Silicon Therapeutics [Member]",
        "terseLabel": "Silicon Therapeutics [Member]"
       }
      }
     },
     "localname": "SiliconTherapeuticsMember",
     "nsuri": "http://roivant.com/20210630",
     "presentation": [
      "http://roivant.com/role/AssetAcquisitionsAndLicenseAgreementsAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "roiv_SinovantIncMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sinovant Inc [Member]",
        "label": "Sinovant Inc [Member]",
        "terseLabel": "Sinovant Inc [Member]"
       }
      }
     },
     "localname": "SinovantIncMember",
     "nsuri": "http://roivant.com/20210630",
     "presentation": [
      "http://roivant.com/role/ShareholdersEquityAndRedeemableNonControllingInterestAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "roiv_SioGeneTherapiesIncMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sio Gene Therapies Inc [Member]",
        "label": "Sio Gene Therapies Inc [Member]",
        "terseLabel": "Sio Gene Therapies Inc [Member]"
       }
      }
     },
     "localname": "SioGeneTherapiesIncMember",
     "nsuri": "http://roivant.com/20210630",
     "presentation": [
      "http://roivant.com/role/FairValueMeasurementsScheduleOfAssetsAndLiabilitiesMeasuredAtFairValueOnARecurringBasisDetail",
      "http://roivant.com/role/InvestmentsAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "roiv_SpecialReserveMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Special Reserve [Member]",
        "label": "Special Reserve [Member]",
        "terseLabel": "Special Reserve [Member]"
       }
      }
     },
     "localname": "SpecialReserveMember",
     "nsuri": "http://roivant.com/20210630",
     "presentation": [
      "http://roivant.com/role/ShareBasedCompensationAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "roiv_StockIssuedDuringPeriodValue": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Stock Issued During Period",
        "label": "Stock Issued During Period",
        "terseLabel": "Newly issued shares"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodValue",
     "nsuri": "http://roivant.com/20210630",
     "presentation": [
      "http://roivant.com/role/AssetAcquisitionsAndLicenseAgreementsAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "roiv_StockOfferToRepurchaseDuringPeriodValueOfTheProceedsReceivedFromTransactionAgreement": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Stock offer to repurchase during period value of the proceeds received from transaction agreement.",
        "label": "Stock Offer To Repurchase During Period Value Of the Proceeds Received From Transaction Agreement",
        "verboseLabel": "Stock offer to repurchase during period value of the proceeds received from transaction agreement"
       }
      }
     },
     "localname": "StockOfferToRepurchaseDuringPeriodValueOfTheProceedsReceivedFromTransactionAgreement",
     "nsuri": "http://roivant.com/20210630",
     "presentation": [
      "http://roivant.com/role/SumitomoTransactionAgreementAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "roiv_SubscriptionReceivableRelatedToIssuanceOfSubsidiaryCommonShares": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Subscription Receivable Related To Issuance Of Subsidiary Common Shares.",
        "label": "Subscription Receivable Related To Issuance Of Subsidiary Common Shares"
       }
      }
     },
     "localname": "SubscriptionReceivableRelatedToIssuanceOfSubsidiaryCommonShares",
     "nsuri": "http://roivant.com/20210630",
     "presentation": [
      "http://roivant.com/role/CondensedConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "roiv_SubscriptionsReceivable": {
     "auth_ref": [],
     "calculation": {
      "http://roivant.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 28.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Subscriptions receivable.",
        "label": "Subscriptions Receivable",
        "negatedLabel": "Subscription receivable",
        "terseLabel": "Subscription receivable"
       }
      }
     },
     "localname": "SubscriptionsReceivable",
     "nsuri": "http://roivant.com/20210630",
     "presentation": [
      "http://roivant.com/role/CondensedConsolidatedBalanceSheets",
      "http://roivant.com/role/SubsequentEventsAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "roiv_SubscriptionsReceivablesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Subscriptions Receivables [Member]",
        "label": "Subscriptions Receivables [Member]",
        "terseLabel": "Subscriptions Receivables [Member]"
       }
      }
     },
     "localname": "SubscriptionsReceivablesMember",
     "nsuri": "http://roivant.com/20210630",
     "presentation": [
      "http://roivant.com/role/CondensedConsolidatedStatementsOfShareholdersEquityAndRedeemableNoncontrollingInterest"
     ],
     "xbrltype": "domainItemType"
    },
    "roiv_SubsidiaryEquityIncentivePlanMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Subsidiary Equity Incentive Plan [Member]",
        "label": "Subsidiary Equity Incentive Plan [Member]",
        "terseLabel": "Subsidiary EIPs [Member]"
       }
      }
     },
     "localname": "SubsidiaryEquityIncentivePlanMember",
     "nsuri": "http://roivant.com/20210630",
     "presentation": [
      "http://roivant.com/role/ShareBasedCompensationAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "roiv_SumitomoMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sumitomo [Member]",
        "label": "Sumitomo [Member]",
        "terseLabel": "Sumitomo [Member]"
       }
      }
     },
     "localname": "SumitomoMember",
     "nsuri": "http://roivant.com/20210630",
     "presentation": [
      "http://roivant.com/role/RelatedPartyTransactionsAdditionalInformationDetail",
      "http://roivant.com/role/ShareholdersEquityAndRedeemableNonControllingInterestAdditionalInformationDetail",
      "http://roivant.com/role/SumitomoTransactionAgreementAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "roiv_SumitomoPharmaceuticalsCoLtdMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sumitomo Pharmaceuticals Co., Ltd.",
        "label": "Sumitomo Pharmaceuticals Co., Ltd. [Member]",
        "terseLabel": "Sumitomo Pharmaceuticals (Suzhou) Co., Ltd. [Member]"
       }
      }
     },
     "localname": "SumitomoPharmaceuticalsCoLtdMember",
     "nsuri": "http://roivant.com/20210630",
     "presentation": [
      "http://roivant.com/role/SubsequentEventsAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "roiv_SumitomoTransactionAgreementMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sumitomo Transaction Agreement [Member]",
        "label": "Sumitomo Transaction Agreement [Member]",
        "terseLabel": "Sumitomo Transaction Agreement [Member]"
       }
      }
     },
     "localname": "SumitomoTransactionAgreementMember",
     "nsuri": "http://roivant.com/20210630",
     "presentation": [
      "http://roivant.com/role/ShareholdersEquityAndRedeemableNonControllingInterestAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "roiv_SumitovantMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sumitovant.",
        "label": "Sumitovant [Member]",
        "terseLabel": "Sumitovant [Member]"
       }
      }
     },
     "localname": "SumitovantMember",
     "nsuri": "http://roivant.com/20210630",
     "presentation": [
      "http://roivant.com/role/RelatedPartyTransactionsAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "roiv_TaxAuthorityInOtherJurisdictionsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tax Authority In Other Jurisdictions [Member]",
        "label": "Tax Authority In Other Jurisdictions [Member]",
        "terseLabel": "Other Jurisdictions [Member]"
       }
      }
     },
     "localname": "TaxAuthorityInOtherJurisdictionsMember",
     "nsuri": "http://roivant.com/20210630",
     "presentation": [
      "http://roivant.com/role/IncomeTaxesAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "roiv_TaxRatesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tax Rates [Abstract]",
        "label": "Tax Rates [Abstract]"
       }
      }
     },
     "localname": "TaxRatesAbstract",
     "nsuri": "http://roivant.com/20210630",
     "xbrltype": "stringItemType"
    },
    "roiv_TransactionAgreementAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Transaction Agreement.",
        "label": "Transaction Agreement [Abstract]"
       }
      }
     },
     "localname": "TransactionAgreementAbstract",
     "nsuri": "http://roivant.com/20210630",
     "xbrltype": "stringItemType"
    },
    "roiv_TransactionAgreementDisclosureTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Transaction Agreement Disclosure.",
        "label": "Transaction Agreement Disclosure [Text Block]",
        "terseLabel": "Sumitomo Transaction Agreement"
       }
      }
     },
     "localname": "TransactionAgreementDisclosureTextBlock",
     "nsuri": "http://roivant.com/20210630",
     "presentation": [
      "http://roivant.com/role/SumitomoTransactionAgreement"
     ],
     "xbrltype": "textBlockItemType"
    },
    "roiv_TransactionAgreementLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Transaction Agreement [Line Items]",
        "label": "Transaction Agreement [Line Items]",
        "terseLabel": "Transaction Agreement [Line Items]"
       }
      }
     },
     "localname": "TransactionAgreementLineItems",
     "nsuri": "http://roivant.com/20210630",
     "presentation": [
      "http://roivant.com/role/SumitomoTransactionAgreementAdditionalInformationDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "roiv_TransactionAgreementTable": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Transaction Agreement [Table]",
        "label": "Transaction Agreement [Table]",
        "terseLabel": "Transaction Agreement [Table]"
       }
      }
     },
     "localname": "TransactionAgreementTable",
     "nsuri": "http://roivant.com/20210630",
     "presentation": [
      "http://roivant.com/role/SumitomoTransactionAgreementAdditionalInformationDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "roiv_TransitionServicesAndStrategicCooperationAgreementMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Transition Services And Strategic Cooperation Agreement [Member]",
        "terseLabel": "Transition Services And Strategic Cooperation Agreement [Member]"
       }
      }
     },
     "localname": "TransitionServicesAndStrategicCooperationAgreementMember",
     "nsuri": "http://roivant.com/20210630",
     "presentation": [
      "http://roivant.com/role/SumitomoTransactionAgreementAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "roiv_TwoThousandFifteenEquityIncentivePlanMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Two Thousand Fifteen Equity Incentive Plan [Member]",
        "label": "Two Thousand Fifteen Equity Incentive Plan [Member]",
        "terseLabel": "2015 EIP [Member]"
       }
      }
     },
     "localname": "TwoThousandFifteenEquityIncentivePlanMember",
     "nsuri": "http://roivant.com/20210630",
     "presentation": [
      "http://roivant.com/role/ShareBasedCompensationAdditionalInformationDetail",
      "http://roivant.com/role/ShareBasedCompensationSummaryOfCappedValueAppreciationRightsDetail",
      "http://roivant.com/role/ShareBasedCompensationSummaryOfPerformanceOptionsActivityDetail",
      "http://roivant.com/role/ShareBasedCompensationSummaryOfRestrictedStockUnitsDetail",
      "http://roivant.com/role/ShareBasedCompensationSummaryOfStockOptionActivityDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "roiv_UncategorizedAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Uncategorized [Abstract]",
        "label": "Uncategorized [Abstract]"
       }
      }
     },
     "localname": "UncategorizedAbstract",
     "nsuri": "http://roivant.com/20210630",
     "xbrltype": "stringItemType"
    },
    "roiv_UnderwrittenPublicOfferingMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Underwritten Public Offering [Member]",
        "label": "Underwritten Public Offering [Member]",
        "terseLabel": "Underwritten Public Offering [Member]"
       }
      }
     },
     "localname": "UnderwrittenPublicOfferingMember",
     "nsuri": "http://roivant.com/20210630",
     "presentation": [
      "http://roivant.com/role/ShareholdersEquityAndRedeemableNonControllingInterestAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "roiv_UpfrontCashPayments": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Upfront Cash Payments",
        "label": "Upfront Cash Payments",
        "terseLabel": "Net upfront cash payment"
       }
      }
     },
     "localname": "UpfrontCashPayments",
     "nsuri": "http://roivant.com/20210630",
     "presentation": [
      "http://roivant.com/role/AssetAcquisitionsAndLicenseAgreementsAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "srt_ContractualObligationFiscalYearMaturityScheduleTableTextBlock": {
     "auth_ref": [
      "r721"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of contractual obligation by timing of payment due. Includes, but is not limited to, long-term debt obligation, lease obligation, and purchase obligation.",
        "label": "Contractual Obligation, Fiscal Year Maturity [Table Text Block]",
        "terseLabel": "Schedule of Company's Annual Payments"
       }
      }
     },
     "localname": "ContractualObligationFiscalYearMaturityScheduleTableTextBlock",
     "nsuri": "http://fasb.org/srt/2021-01-31",
     "presentation": [
      "http://roivant.com/role/LongTermDebtAndLoanCommitmentTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "srt_MaximumMember": {
     "auth_ref": [
      "r288",
      "r323",
      "r379",
      "r381",
      "r576",
      "r577",
      "r578",
      "r579",
      "r580",
      "r581",
      "r600",
      "r660",
      "r662",
      "r710",
      "r711"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Upper limit of the provided range.",
        "label": "Maximum [Member]",
        "terseLabel": "Maximum"
       }
      }
     },
     "localname": "MaximumMember",
     "nsuri": "http://fasb.org/srt/2021-01-31",
     "presentation": [
      "http://roivant.com/role/AssetAcquisitionsAndLicenseAgreementsAdditionalInformationDetail",
      "http://roivant.com/role/FairValueMeasurementsAdditionalInformationDetail",
      "http://roivant.com/role/FairValueMeasurementsScheduleOfFairValueOfUnobservableInputRelatedToOptionsToAcquireUnderSumitomoTransactionAgreementDetail",
      "http://roivant.com/role/IncomeTaxesAdditionalInformationDetail",
      "http://roivant.com/role/ShareholdersEquityAndRedeemableNonControllingInterestAdditionalInformationDetail",
      "http://roivant.com/role/SumitomoTransactionAgreementAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_MinimumMember": {
     "auth_ref": [
      "r288",
      "r323",
      "r379",
      "r381",
      "r576",
      "r577",
      "r578",
      "r579",
      "r580",
      "r581",
      "r600",
      "r660",
      "r662",
      "r710",
      "r711"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Lower limit of the provided range.",
        "label": "Minimum [Member]",
        "terseLabel": "Minimum"
       }
      }
     },
     "localname": "MinimumMember",
     "nsuri": "http://fasb.org/srt/2021-01-31",
     "presentation": [
      "http://roivant.com/role/FairValueMeasurementsAdditionalInformationDetail",
      "http://roivant.com/role/FairValueMeasurementsScheduleOfFairValueOfUnobservableInputRelatedToOptionsToAcquireUnderSumitomoTransactionAgreementDetail",
      "http://roivant.com/role/IncomeTaxesAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_RangeAxis": {
     "auth_ref": [
      "r288",
      "r323",
      "r366",
      "r379",
      "r381",
      "r576",
      "r577",
      "r578",
      "r579",
      "r580",
      "r581",
      "r600",
      "r660",
      "r662",
      "r710",
      "r711"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by statistical measurement. Includes, but is not limited to, minimum, maximum, weighted average, arithmetic average, and median.",
        "label": "Statistical Measurement [Axis]",
        "terseLabel": "Statistical Measurement [Axis]"
       }
      }
     },
     "localname": "RangeAxis",
     "nsuri": "http://fasb.org/srt/2021-01-31",
     "presentation": [
      "http://roivant.com/role/AssetAcquisitionsAndLicenseAgreementsAdditionalInformationDetail",
      "http://roivant.com/role/FairValueMeasurementsAdditionalInformationDetail",
      "http://roivant.com/role/FairValueMeasurementsScheduleOfFairValueOfUnobservableInputRelatedToOptionsToAcquireUnderSumitomoTransactionAgreementDetail",
      "http://roivant.com/role/IncomeTaxesAdditionalInformationDetail",
      "http://roivant.com/role/LongTermDebtAndLoanCommitmentAdditionalInformationDetail",
      "http://roivant.com/role/ShareholdersEquityAndRedeemableNonControllingInterestAdditionalInformationDetail",
      "http://roivant.com/role/SumitomoTransactionAgreementAdditionalInformationDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_RangeMember": {
     "auth_ref": [
      "r288",
      "r323",
      "r366",
      "r379",
      "r381",
      "r576",
      "r577",
      "r578",
      "r579",
      "r580",
      "r581",
      "r600",
      "r660",
      "r662",
      "r710",
      "r711"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Statistical measurement. Includes, but is not limited to, minimum, maximum, weighted average, arithmetic average, and median.",
        "label": "Statistical Measurement [Domain]",
        "terseLabel": "Statistical Measurement [Domain]"
       }
      }
     },
     "localname": "RangeMember",
     "nsuri": "http://fasb.org/srt/2021-01-31",
     "presentation": [
      "http://roivant.com/role/AssetAcquisitionsAndLicenseAgreementsAdditionalInformationDetail",
      "http://roivant.com/role/FairValueMeasurementsAdditionalInformationDetail",
      "http://roivant.com/role/FairValueMeasurementsScheduleOfFairValueOfUnobservableInputRelatedToOptionsToAcquireUnderSumitomoTransactionAgreementDetail",
      "http://roivant.com/role/IncomeTaxesAdditionalInformationDetail",
      "http://roivant.com/role/LongTermDebtAndLoanCommitmentAdditionalInformationDetail",
      "http://roivant.com/role/ShareholdersEquityAndRedeemableNonControllingInterestAdditionalInformationDetail",
      "http://roivant.com/role/SumitomoTransactionAgreementAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_RestatementAxis": {
     "auth_ref": [
      "r1",
      "r152",
      "r153",
      "r154",
      "r155",
      "r156",
      "r157",
      "r158",
      "r159",
      "r160",
      "r162",
      "r163",
      "r164",
      "r165",
      "r166",
      "r167",
      "r183",
      "r244",
      "r245",
      "r421",
      "r451",
      "r503",
      "r504",
      "r505",
      "r506",
      "r663",
      "r664",
      "r665",
      "r666",
      "r667",
      "r668",
      "r669",
      "r670",
      "r671",
      "r672",
      "r733",
      "r734"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by adjustment to previously issued financial statements. Includes, but is not limited to, adjustment for retrospective application of amendment to accounting standards, other change in accounting principle, correction of error, and other revision.",
        "label": "Revision of Prior Period [Axis]",
        "terseLabel": "Revision of Prior Period [Axis]"
       }
      }
     },
     "localname": "RestatementAxis",
     "nsuri": "http://fasb.org/srt/2021-01-31",
     "presentation": [
      "http://roivant.com/role/SubsequentEventsAdditionalInformationDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_RestatementDomain": {
     "auth_ref": [
      "r1",
      "r152",
      "r153",
      "r154",
      "r155",
      "r156",
      "r157",
      "r158",
      "r159",
      "r160",
      "r162",
      "r163",
      "r164",
      "r165",
      "r166",
      "r167",
      "r183",
      "r244",
      "r245",
      "r421",
      "r451",
      "r503",
      "r504",
      "r505",
      "r506",
      "r663",
      "r664",
      "r665",
      "r666",
      "r667",
      "r668",
      "r669",
      "r670",
      "r671",
      "r672",
      "r733",
      "r734"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Adjustment to previously issued financial statements. Includes, but is not limited to, adjustment for retrospective application of amendment to accounting standards, other change in accounting principle, correction of error, and other revision.",
        "label": "Revision of Prior Period [Domain]",
        "terseLabel": "Revision of Prior Period [Domain]"
       }
      }
     },
     "localname": "RestatementDomain",
     "nsuri": "http://fasb.org/srt/2021-01-31",
     "presentation": [
      "http://roivant.com/role/SubsequentEventsAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_RevisionOfPriorPeriodReclassificationAdjustmentMember": {
     "auth_ref": [
      "r2"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Cumulative increase (decrease) to previously issued financial statements for reclassification. Excludes adjustment for reclassification from amendment to accounting standards.",
        "label": "Revision of Prior Period, Reclassification, Adjustment [Member]",
        "terseLabel": "Revision of Prior Period, Reclassification, Adjustment"
       }
      }
     },
     "localname": "RevisionOfPriorPeriodReclassificationAdjustmentMember",
     "nsuri": "http://fasb.org/srt/2021-01-31",
     "presentation": [
      "http://roivant.com/role/SubsequentEventsAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_SegmentGeographicalDomain": {
     "auth_ref": [
      "r217",
      "r218",
      "r361",
      "r362",
      "r661",
      "r701",
      "r702",
      "r703",
      "r704",
      "r705",
      "r706",
      "r707",
      "r708",
      "r709",
      "r722",
      "r724",
      "r725",
      "r726",
      "r727",
      "r728",
      "r729",
      "r730",
      "r731"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Geographical area.",
        "label": "Geographical [Domain]",
        "terseLabel": "Geographical [Domain]"
       }
      }
     },
     "localname": "SegmentGeographicalDomain",
     "nsuri": "http://fasb.org/srt/2021-01-31",
     "presentation": [
      "http://roivant.com/role/IncomeTaxesAdditionalInformationDetail",
      "http://roivant.com/role/IncomeTaxesScheduleComponentsOfIncomeTaxExpenseBenefitDetail",
      "http://roivant.com/role/IncomeTaxesScheduleOfLossBeforeIncomeTaxesByGeographicRegionDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_StatementGeographicalAxis": {
     "auth_ref": [
      "r217",
      "r218",
      "r361",
      "r362",
      "r661",
      "r692",
      "r701",
      "r702",
      "r703",
      "r704",
      "r705",
      "r706",
      "r707",
      "r708",
      "r709",
      "r722",
      "r723"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by geographical components.",
        "label": "Geographical [Axis]",
        "terseLabel": "Geographical [Axis]"
       }
      }
     },
     "localname": "StatementGeographicalAxis",
     "nsuri": "http://fasb.org/srt/2021-01-31",
     "presentation": [
      "http://roivant.com/role/IncomeTaxesAdditionalInformationDetail",
      "http://roivant.com/role/IncomeTaxesScheduleComponentsOfIncomeTaxExpenseBenefitDetail",
      "http://roivant.com/role/IncomeTaxesScheduleOfLossBeforeIncomeTaxesByGeographicRegionDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_TitleOfIndividualAxis": {
     "auth_ref": [
      "r220",
      "r560"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by title of individual or nature of relationship to individual or group of individuals.",
        "label": "Title of Individual [Axis]",
        "terseLabel": "Title of Individual [Axis]"
       }
      }
     },
     "localname": "TitleOfIndividualAxis",
     "nsuri": "http://fasb.org/srt/2021-01-31",
     "presentation": [
      "http://roivant.com/role/SumitomoTransactionAgreementAdditionalInformationDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_TitleOfIndividualWithRelationshipToEntityDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Title of individual, or nature of relationship to individual or group of individuals.",
        "label": "Title of Individual [Domain]",
        "terseLabel": "Title of Individual [Domain]"
       }
      }
     },
     "localname": "TitleOfIndividualWithRelationshipToEntityDomain",
     "nsuri": "http://fasb.org/srt/2021-01-31",
     "presentation": [
      "http://roivant.com/role/SumitomoTransactionAgreementAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AccountingPoliciesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Accounting Policies [Abstract]"
       }
      }
     },
     "localname": "AccountingPoliciesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_AccountsPayableCurrent": {
     "auth_ref": [
      "r61",
      "r566"
     ],
     "calculation": {
      "http://roivant.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 13.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).",
        "label": "Accounts Payable, Current",
        "terseLabel": "Accounts payable"
       }
      }
     },
     "localname": "AccountsPayableCurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://roivant.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccountsReceivableNetCurrent": {
     "auth_ref": [
      "r29",
      "r49",
      "r221",
      "r222"
     ],
     "calculation": {
      "http://roivant.com/role/BalanceSheetComponentsScheduleOfOtherCurrentAssetsDetail": {
       "order": 4.0,
       "parentTag": "us-gaap_OtherAssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after allowance for credit loss, of right to consideration from customer for product sold and service rendered in normal course of business, classified as current.",
        "label": "Accounts Receivable, after Allowance for Credit Loss, Current",
        "terseLabel": "Trade receivables, net"
       }
      }
     },
     "localname": "AccountsReceivableNetCurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://roivant.com/role/BalanceSheetComponentsScheduleOfOtherCurrentAssetsDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccruedLiabilitiesCurrent": {
     "auth_ref": [
      "r65"
     ],
     "calculation": {
      "http://roivant.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 14.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).",
        "label": "Accrued Liabilities, Current",
        "terseLabel": "Accrued expenses",
        "verboseLabel": "Total accrued expenses"
       }
      }
     },
     "localname": "AccruedLiabilitiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://roivant.com/role/BalanceSheetComponentsScheduleOfAccruedExpensesDetail",
      "http://roivant.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax": {
     "auth_ref": [
      "r52",
      "r85",
      "r86",
      "r87",
      "r642",
      "r668",
      "r672"
     ],
     "calculation": {
      "http://roivant.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 30.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Accumulated change in equity from transactions and other events and circumstances from non-owner sources, net of tax effect, at period end. Excludes Net Income (Loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners. Includes foreign currency translation items, certain pension adjustments, unrealized gains and losses on certain investments in debt and equity securities, other than temporary impairment (OTTI) losses related to factors other than credit losses on available-for-sale and held-to-maturity debt securities that an entity does not intend to sell and it is not more likely than not that the entity will be required to sell before recovery of the amortized cost basis, as well as changes in the fair value of derivatives related to the effective portion of a designated cash flow hedge.",
        "label": "Accumulated Other Comprehensive Income (Loss), Net of Tax",
        "terseLabel": "Accumulated other comprehensive (loss) income"
       }
      }
     },
     "localname": "AccumulatedOtherComprehensiveIncomeLossNetOfTax",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://roivant.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccumulatedOtherComprehensiveIncomeMember": {
     "auth_ref": [
      "r84",
      "r87",
      "r95",
      "r96",
      "r97",
      "r152",
      "r153",
      "r154",
      "r492",
      "r663",
      "r664",
      "r734"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Accumulated increase (decrease) in equity from transactions and other events and circumstances from non-owner sources, attributable to the parent. Excludes net income (loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners.",
        "label": "AOCI Attributable to Parent [Member]",
        "terseLabel": "AOCI Attributable to Parent [Member]"
       }
      }
     },
     "localname": "AccumulatedOtherComprehensiveIncomeMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://roivant.com/role/CondensedConsolidatedStatementsOfShareholdersEquityAndRedeemableNoncontrollingInterest"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AdditionalPaidInCapital": {
     "auth_ref": [
      "r50",
      "r421",
      "r566"
     ],
     "calculation": {
      "http://roivant.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 27.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of excess of issue price over par or stated value of stock and from other transaction involving stock or stockholder. Includes, but is not limited to, additional paid-in capital (APIC) for common and preferred stock.",
        "label": "Additional Paid in Capital",
        "terseLabel": "Additional paid-in capital"
       }
      }
     },
     "localname": "AdditionalPaidInCapital",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://roivant.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AdditionalPaidInCapitalMember": {
     "auth_ref": [
      "r152",
      "r153",
      "r154",
      "r418",
      "r419",
      "r420",
      "r504"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Excess of issue price over par or stated value of the entity's capital stock and amounts received from other transactions involving the entity's stock or stockholders.",
        "label": "Additional Paid-in Capital [Member]",
        "terseLabel": "Additional Paid-in Capital [Member]"
       }
      }
     },
     "localname": "AdditionalPaidInCapitalMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://roivant.com/role/CondensedConsolidatedStatementsOfShareholdersEquityAndRedeemableNoncontrollingInterest"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AdjustmentOfWarrantsGrantedForServices": {
     "auth_ref": [
      "r133"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Adjustment for noncash service expenses paid for by granting of warrants.",
        "label": "Adjustment of Warrants Granted for Services",
        "terseLabel": "Warrants cancellation"
       }
      }
     },
     "localname": "AdjustmentOfWarrantsGrantedForServices",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://roivant.com/role/ShareholdersEquityAndRedeemableNonControllingInterestAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AdjustmentsToAdditionalPaidInCapitalIncreaseInCarryingAmountOfRedeemablePreferredStock": {
     "auth_ref": [
      "r313",
      "r338",
      "r347"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of decrease (increase) in additional paid in capital (APIC) for the increase in carrying amount of redeemable preferred stock.",
        "label": "Adjustments to Additional Paid in Capital, Increase in Carrying Amount of Redeemable Preferred Stock",
        "negatedLabel": "Purchase of subsidiary convertible and redeemable preferred stock"
       }
      }
     },
     "localname": "AdjustmentsToAdditionalPaidInCapitalIncreaseInCarryingAmountOfRedeemablePreferredStock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://roivant.com/role/CondensedConsolidatedStatementsOfShareholdersEquityAndRedeemableNoncontrollingInterest"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue": {
     "auth_ref": [
      "r382",
      "r384",
      "r424",
      "r425"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase to additional paid-in capital (APIC) for recognition of cost for award under share-based payment arrangement.",
        "label": "APIC, Share-based Payment Arrangement, Increase for Cost Recognition",
        "terseLabel": "Share-based compensation"
       }
      }
     },
     "localname": "AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://roivant.com/role/CondensedConsolidatedStatementsOfShareholdersEquityAndRedeemableNoncontrollingInterest"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract]",
        "terseLabel": "Adjustments to reconcile net loss to net cash used in operating activities:"
       }
      }
     },
     "localname": "AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://roivant.com/role/CondensedConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AllocatedShareBasedCompensationExpense": {
     "auth_ref": [
      "r384",
      "r414",
      "r423"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.",
        "label": "Share-based Payment Arrangement, Expense",
        "terseLabel": "Share-based compensation expense"
       }
      }
     },
     "localname": "AllocatedShareBasedCompensationExpense",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://roivant.com/role/ShareBasedCompensationAdditionalInformationDetail",
      "http://roivant.com/role/ShareBasedCompensationSummaryOfShareBasedCompensationExpenseDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AlternativeInvestmentMeasurementInput": {
     "auth_ref": [
      "r512"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Value of input used to measure alternative investment.",
        "label": "Alternative Investment, Measurement Input",
        "terseLabel": "Investment"
       }
      }
     },
     "localname": "AlternativeInvestmentMeasurementInput",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://roivant.com/role/FairValueMeasurementsScheduleOfFairValueOfUnobservableInputRelatedToOptionsToAcquireUnderSumitomoTransactionAgreementDetail"
     ],
     "xbrltype": "decimalItemType"
    },
    "us-gaap_ArrangementsAndNonarrangementTransactionsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations.",
        "label": "Collaborative Arrangement and Arrangement Other than Collaborative [Domain]",
        "terseLabel": "Collaborative Arrangement and Arrangement Other than Collaborative [Domain]"
       }
      }
     },
     "localname": "ArrangementsAndNonarrangementTransactionsMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://roivant.com/role/LongTermDebtAndLoanCommitmentAdditionalInformationDetail",
      "http://roivant.com/role/ShareholdersEquityAndRedeemableNonControllingInterestAdditionalInformationDetail",
      "http://roivant.com/role/SubsequentEventsAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_Assets": {
     "auth_ref": [
      "r146",
      "r204",
      "r208",
      "r214",
      "r242",
      "r274",
      "r275",
      "r276",
      "r277",
      "r278",
      "r279",
      "r280",
      "r281",
      "r282",
      "r283",
      "r284",
      "r486",
      "r494",
      "r520",
      "r564",
      "r566",
      "r617",
      "r639"
     ],
     "calculation": {
      "http://roivant.com/role/CondensedConsolidatedBalanceSheets": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.",
        "label": "Assets",
        "totalLabel": "Total assets"
       }
      }
     },
     "localname": "Assets",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://roivant.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AssetsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Assets [Abstract]",
        "terseLabel": "Assets"
       }
      }
     },
     "localname": "AssetsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://roivant.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AssetsCurrent": {
     "auth_ref": [
      "r32",
      "r34",
      "r80",
      "r146",
      "r242",
      "r274",
      "r275",
      "r276",
      "r277",
      "r278",
      "r279",
      "r280",
      "r281",
      "r282",
      "r283",
      "r284",
      "r486",
      "r494",
      "r520",
      "r564",
      "r566"
     ],
     "calculation": {
      "http://roivant.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 1.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.",
        "label": "Assets, Current",
        "totalLabel": "Total current assets"
       }
      }
     },
     "localname": "AssetsCurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://roivant.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AssetsCurrentAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Assets, Current [Abstract]",
        "terseLabel": "Current assets:"
       }
      }
     },
     "localname": "AssetsCurrentAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://roivant.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AssetsFairValueDisclosure": {
     "auth_ref": [
      "r507"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fair value portion of probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.",
        "label": "Assets, Fair Value Disclosure",
        "terseLabel": "Assets held in Trust Account"
       }
      }
     },
     "localname": "AssetsFairValueDisclosure",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://roivant.com/role/FairValueMeasurementsScheduleOfAssetsAndLiabilitiesMeasuredAtFairValueOnARecurringBasisDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AwardTypeAxis": {
     "auth_ref": [
      "r385",
      "r416"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of award under share-based payment arrangement.",
        "label": "Award Type [Axis]",
        "terseLabel": "Award Type [Axis]"
       }
      }
     },
     "localname": "AwardTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://roivant.com/role/ShareBasedCompensationAdditionalInformationDetail",
      "http://roivant.com/role/ShareBasedCompensationScheduleOfFairValueAssumptionsDetail",
      "http://roivant.com/role/ShareBasedCompensationSummaryOfCappedValueAppreciationRightsDetail",
      "http://roivant.com/role/ShareBasedCompensationSummaryOfCommonShareAwardActivityDetail",
      "http://roivant.com/role/ShareBasedCompensationSummaryOfPerformanceOptionsActivityDetail",
      "http://roivant.com/role/ShareBasedCompensationSummaryOfPerformanceRestrictedStockUnitsDetail",
      "http://roivant.com/role/ShareBasedCompensationSummaryOfRestrictedStockUnitsDetail",
      "http://roivant.com/role/ShareBasedCompensationSummaryOfStockOptionActivityDetail",
      "http://roivant.com/role/ShareBasedCompensationTables",
      "http://roivant.com/role/ShareholdersEquityAndRedeemableNonControllingInterestAdditionalInformationDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_BalanceSheetLocationAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by location on balance sheet (statement of financial position).",
        "label": "Balance Sheet Location [Axis]",
        "terseLabel": "Balance Sheet Location [Axis]"
       }
      }
     },
     "localname": "BalanceSheetLocationAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://roivant.com/role/FairValueMeasurementsAdditionalInformationDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_BalanceSheetLocationDomain": {
     "auth_ref": [
      "r499",
      "r501"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Location in the balance sheet (statement of financial position).",
        "label": "Balance Sheet Location [Domain]",
        "terseLabel": "Balance Sheet Location [Domain]"
       }
      }
     },
     "localname": "BalanceSheetLocationDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://roivant.com/role/FairValueMeasurementsAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_BalanceSheetRelatedDisclosuresAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Balance Sheet Related Disclosures [Abstract]"
       }
      }
     },
     "localname": "BalanceSheetRelatedDisclosuresAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_BasisOfAccountingPolicyPolicyTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for basis of accounting, or basis of presentation, used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS).",
        "label": "Basis of Accounting, Policy [Policy Text Block]",
        "terseLabel": "Basis of Presentation and Principles of Consolidation"
       }
      }
     },
     "localname": "BasisOfAccountingPolicyPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://roivant.com/role/SummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_BusinessAcquisitionAcquireeDomain": {
     "auth_ref": [
      "r378",
      "r380"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Identification of the acquiree in a material business combination (or series of individually immaterial business combinations), which may include the name or other type of identification of the acquiree.",
        "label": "Business Acquisition, Acquiree [Domain]",
        "terseLabel": "Business Acquisition, Acquiree [Domain]"
       }
      }
     },
     "localname": "BusinessAcquisitionAcquireeDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://roivant.com/role/AssetAcquisitionsAndLicenseAgreementsAdditionalInformationDetail",
      "http://roivant.com/role/ShareholdersEquityAndRedeemableNonControllingInterestAdditionalInformationDetail",
      "http://roivant.com/role/SubsequentEventsAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_BusinessAcquisitionAxis": {
     "auth_ref": [
      "r378",
      "r380",
      "r466",
      "r467"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by business combination or series of individually immaterial business combinations.",
        "label": "Business Acquisition [Axis]",
        "terseLabel": "Business Acquisition [Axis]"
       }
      }
     },
     "localname": "BusinessAcquisitionAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://roivant.com/role/AssetAcquisitionsAndLicenseAgreementsAdditionalInformationDetail",
      "http://roivant.com/role/ShareholdersEquityAndRedeemableNonControllingInterestAdditionalInformationDetail",
      "http://roivant.com/role/SubsequentEventsAdditionalInformationDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_BusinessAcquisitionEquityInterestIssuedOrIssuableValueAssigned": {
     "auth_ref": [
      "r477"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Value of equity interests (such as common shares, preferred shares, or partnership interest) issued or issuable to acquire the entity.",
        "label": "Business Acquisition, Equity Interest Issued or Issuable, Value Assigned",
        "terseLabel": "Business combination, recognized identifiable assets acquired and liabilities assumed, current liabilities, accounts payable",
        "verboseLabel": "Proceeds related to common stock purchase by RSL"
       }
      }
     },
     "localname": "BusinessAcquisitionEquityInterestIssuedOrIssuableValueAssigned",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://roivant.com/role/AssetAcquisitionsAndLicenseAgreementsAdditionalInformationDetail",
      "http://roivant.com/role/ShareholdersEquityAndRedeemableNonControllingInterestAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued": {
     "auth_ref": [
      "r477"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares of equity interests issued or issuable to acquire entity.",
        "label": "Business Acquisition, Equity Interest Issued or Issuable, Number of Shares",
        "terseLabel": "Number of shares issued in business combination",
        "verboseLabel": "Stock acquired related to business acquisition"
       }
      }
     },
     "localname": "BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://roivant.com/role/AssetAcquisitionsAndLicenseAgreementsAdditionalInformationDetail",
      "http://roivant.com/role/ShareholdersEquityAndRedeemableNonControllingInterestAdditionalInformationDetail"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_BusinessAcquisitionLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Business Acquisition [Line Items]",
        "terseLabel": "Business Acquisition [Line Items]"
       }
      }
     },
     "localname": "BusinessAcquisitionLineItems",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://roivant.com/role/AssetAcquisitionsAndLicenseAgreementsAdditionalInformationDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_BusinessAcquisitionPercentageOfVotingInterestsAcquired": {
     "auth_ref": [
      "r465"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of voting equity interests acquired at the acquisition date in the business combination.",
        "label": "Business Acquisition, Percentage of Voting Interests Acquired",
        "terseLabel": "Percentage of common stock acquired related to business acquisition"
       }
      }
     },
     "localname": "BusinessAcquisitionPercentageOfVotingInterestsAcquired",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://roivant.com/role/ShareholdersEquityAndRedeemableNonControllingInterestAdditionalInformationDetail"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_BusinessCombinationConsiderationTransferred1": {
     "auth_ref": [
      "r472",
      "r473",
      "r475"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of consideration transferred, consisting of acquisition-date fair value of assets transferred by the acquirer, liabilities incurred by the acquirer, and equity interest issued by the acquirer.",
        "label": "Business Combination, Consideration Transferred",
        "terseLabel": "Business combination, consideration transferred"
       }
      }
     },
     "localname": "BusinessCombinationConsiderationTransferred1",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://roivant.com/role/AssetAcquisitionsAndLicenseAgreementsAdditionalInformationDetail",
      "http://roivant.com/role/SubsequentEventsAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_BusinessCombinationConsiderationTransferredLiabilitiesIncurred": {
     "auth_ref": [
      "r470",
      "r472",
      "r473",
      "r476"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of liabilities incurred by the acquirer as part of consideration transferred in a business combination.",
        "label": "Business Combination, Consideration Transferred, Liabilities Incurred",
        "terseLabel": "Business combination, consideration transferred, liabilities incurred"
       }
      }
     },
     "localname": "BusinessCombinationConsiderationTransferredLiabilitiesIncurred",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://roivant.com/role/AssetAcquisitionsAndLicenseAgreementsAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_BusinessCombinationContingentConsiderationLiability": {
     "auth_ref": [
      "r471",
      "r474",
      "r478"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of liability recognized arising from contingent consideration in a business combination.",
        "label": "Business Combination, Contingent Consideration, Liability",
        "terseLabel": "Fair value of future contingent consideration payments"
       }
      }
     },
     "localname": "BusinessCombinationContingentConsiderationLiability",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://roivant.com/role/AssetAcquisitionsAndLicenseAgreementsAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccountsPayable": {
     "auth_ref": [
      "r469"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of liabilities incurred for goods and services received that are used in an entity's business and related party payables, assumed at the acquisition date.",
        "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Current Liabilities, Accounts Payable",
        "terseLabel": "Business acquisition, equity interest issued or issuable, value assigned"
       }
      }
     },
     "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccountsPayable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://roivant.com/role/AssetAcquisitionsAndLicenseAgreementsAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet": {
     "auth_ref": [
      "r468",
      "r469"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount recognized as of the acquisition date for the identifiable assets acquired in excess of (less than) the aggregate liabilities assumed.",
        "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Net",
        "terseLabel": "Business combination, recognized identifiable assets acquired and liabilities assumed, assets"
       }
      }
     },
     "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://roivant.com/role/AssetAcquisitionsAndLicenseAgreementsAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_BusinessCombinationsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Business Combinations [Abstract]"
       }
      }
     },
     "localname": "BusinessCombinationsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock": {
     "auth_ref": [
      "r27",
      "r151",
      "r197"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for the business description and basis of presentation concepts.  Business description describes the nature and type of organization including but not limited to organizational structure as may be applicable to holding companies, parent and subsidiary relationships, business divisions, business units, business segments, affiliates and information about significant ownership of the reporting entity.  Basis of presentation describes the underlying basis used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS).",
        "label": "Business Description and Basis of Presentation [Text Block]",
        "terseLabel": "Description of Business and Liquidity"
       }
      }
     },
     "localname": "BusinessDescriptionAndBasisOfPresentationTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://roivant.com/role/DescriptionOfBusinessAndLiquidity"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_CashAndCashEquivalentsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cash and Cash Equivalents [Abstract]"
       }
      }
     },
     "localname": "CashAndCashEquivalentsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_CashAndCashEquivalentsAtCarryingValue": {
     "auth_ref": [
      "r28",
      "r56",
      "r135"
     ],
     "calculation": {
      "http://roivant.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 2.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      },
      "http://roivant.com/role/SummaryOfSignificantAccountingPoliciesScheduleOfAggregateAmountsOfCashCashEquivalentsAndRestrictedCashDetail": {
       "order": 1.0,
       "parentTag": "roiv_CashAndCashEquivalentsAndRestrictedCash",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.",
        "label": "Cash and Cash Equivalents, at Carrying Value",
        "terseLabel": "Cash and cash equivalents"
       }
      }
     },
     "localname": "CashAndCashEquivalentsAtCarryingValue",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://roivant.com/role/CondensedConsolidatedBalanceSheets",
      "http://roivant.com/role/DescriptionOfBusinessAndLiquidityAdditionalInformationDetail",
      "http://roivant.com/role/SummaryOfSignificantAccountingPoliciesScheduleOfAggregateAmountsOfCashCashEquivalentsAndRestrictedCashDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashAndCashEquivalentsFairValueDisclosure": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fair value portion of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.",
        "label": "Cash and Cash Equivalents, Fair Value Disclosure",
        "terseLabel": "Money market funds"
       }
      }
     },
     "localname": "CashAndCashEquivalentsFairValueDisclosure",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://roivant.com/role/FairValueMeasurementsScheduleOfAssetsAndLiabilitiesMeasuredAtFairValueOnARecurringBasisDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy": {
     "auth_ref": [
      "r38",
      "r136",
      "r616"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Entity's cash and cash equivalents accounting policy with respect to restricted balances.  Restrictions may include legally restricted deposits held as compensating balances against short-term borrowing arrangements, contracts entered into with others, or company statements of intention with regard to particular deposits; however, time deposits and short-term certificates of deposit are not generally included in legally restricted deposits.",
        "label": "Cash and Cash Equivalents, Restricted Cash and Cash Equivalents, Policy [Policy Text Block]",
        "terseLabel": "Cash, Cash Equivalents, and Restricted Cash"
       }
      }
     },
     "localname": "CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://roivant.com/role/SummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents": {
     "auth_ref": [
      "r129",
      "r135",
      "r140"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.",
        "label": "Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents",
        "periodEndLabel": "Cash, cash equivalents and restricted cash at end of period",
        "periodStartLabel": "Cash, cash equivalents and restricted cash at beginning of period"
       }
      }
     },
     "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://roivant.com/role/CondensedConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect": {
     "auth_ref": [
      "r129",
      "r523"
     ],
     "calculation": {
      "http://roivant.com/role/CondensedConsolidatedStatementsOfCashFlows": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) in cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; excluding effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.",
        "label": "Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Excluding Exchange Rate Effect",
        "totalLabel": "Net change in cash, cash equivalents and restricted cash"
       }
      }
     },
     "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://roivant.com/role/CondensedConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashDivestedFromDeconsolidation": {
     "auth_ref": [
      "r122"
     ],
     "calculation": {
      "http://roivant.com/role/CondensedConsolidatedStatementsOfCashFlows": {
       "order": 19.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Reduction in cash due to no longer including the former subsidiary's cash in the consolidated entity's cash.",
        "label": "Cash Divested from Deconsolidation",
        "negatedLabel": "Cash disposed upon deconsolidation of subsidiary"
       }
      }
     },
     "localname": "CashDivestedFromDeconsolidation",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://roivant.com/role/CondensedConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cash Flow, Noncash Investing and Financing Activities Disclosure [Abstract]",
        "terseLabel": "Non-cash investing and financing activities:"
       }
      }
     },
     "localname": "CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://roivant.com/role/CondensedConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ClassOfStockDomain": {
     "auth_ref": [
      "r143",
      "r146",
      "r172",
      "r173",
      "r174",
      "r176",
      "r178",
      "r186",
      "r187",
      "r188",
      "r242",
      "r274",
      "r278",
      "r279",
      "r280",
      "r283",
      "r284",
      "r321",
      "r322",
      "r326",
      "r330",
      "r520",
      "r714"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share of stock differentiated by the voting rights the holder receives. Examples include, but are not limited to, common stock, redeemable preferred stock, nonredeemable preferred stock, and convertible stock.",
        "label": "Class of Stock [Domain]",
        "terseLabel": "Class of Stock [Domain]"
       }
      }
     },
     "localname": "ClassOfStockDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://roivant.com/role/CondensedConsolidatedBalanceSheets",
      "http://roivant.com/role/CondensedConsolidatedBalanceSheetsParenthetical",
      "http://roivant.com/role/CondensedConsolidatedStatementsOfShareholdersEquityAndRedeemableNoncontrollingInterest",
      "http://roivant.com/role/InvestmentsAdditionalInformationDetail",
      "http://roivant.com/role/ShareholdersEquityAndRedeemableNonControllingInterestAdditionalInformationDetail",
      "http://roivant.com/role/SummaryOfSignificantAccountingPoliciesAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ClassOfStockLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Class of Stock [Line Items]",
        "terseLabel": "Class of Stock [Line Items]"
       }
      }
     },
     "localname": "ClassOfStockLineItems",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://roivant.com/role/ShareholdersEquityAndRedeemableNonControllingInterestAdditionalInformationDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ClassOfWarrantOrRightAxis": {
     "auth_ref": [
      "r350",
      "r383"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of warrant or right issued.",
        "label": "Class of Warrant or Right [Axis]",
        "terseLabel": "Class of Warrant or Right [Axis]"
       }
      }
     },
     "localname": "ClassOfWarrantOrRightAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://roivant.com/role/FairValueMeasurementsScheduleOfAssetsAndLiabilitiesMeasuredAtFairValueOnARecurringBasisDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ClassOfWarrantOrRightDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the class or type of warrant or right outstanding. Warrants and rights represent derivative securities that give the holder the right to purchase securities (usually equity) from the issuer at a specific price within a certain time frame. Warrants are often included in a new debt issue to entice investors by a higher return potential. The main difference between warrants and call options is that warrants are issued and guaranteed by the company, whereas options are exchange instruments and are not issued by the company. Also, the lifetime of a warrant is often measured in years, while the lifetime of a typical option is measured in months.",
        "label": "Class of Warrant or Right [Domain]",
        "terseLabel": "Class of Warrant or Right [Domain]"
       }
      }
     },
     "localname": "ClassOfWarrantOrRightDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://roivant.com/role/FairValueMeasurementsScheduleOfAssetsAndLiabilitiesMeasuredAtFairValueOnARecurringBasisDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1": {
     "auth_ref": [
      "r339"
     ],
     "lang": {
      "en-us": {
       "role": {
        "disclosureGuidance": "Class of Warrant or Right, Exercise Price per share",
        "documentation": "Exercise price per share or per unit of warrants or rights outstanding.",
        "label": "Class of Warrant or Right, Exercise Price of Warrants or Rights",
        "positiveLabel": "Warrants exercise price",
        "verboseLabel": "Warrant exercise price per share"
       }
      }
     },
     "localname": "ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://roivant.com/role/LongTermDebtAndLoanCommitmentAdditionalInformationDetail",
      "http://roivant.com/role/ShareholdersEquityAndRedeemableNonControllingInterestAdditionalInformationDetail",
      "http://roivant.com/role/SubsequentEventsAdditionalInformationDetail"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of securities into which each warrant or right may be converted. For example, but not limited to, each warrant may be converted into two shares.",
        "label": "Class of Warrant or Right, Number of Securities Called by Each Warrant or Right",
        "verboseLabel": "Class of warrants or rights number of shares called by each warrant or right"
       }
      }
     },
     "localname": "ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://roivant.com/role/LongTermDebtAndLoanCommitmentAdditionalInformationDetail"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ClassOfWarrantOrRightOutstanding": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of warrants or rights outstanding.",
        "label": "Class of Warrant or Right, Outstanding",
        "terseLabel": "Number of outstanding warrants",
        "verboseLabel": "Warrants issued to purchase common shares"
       }
      }
     },
     "localname": "ClassOfWarrantOrRightOutstanding",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://roivant.com/role/ShareholdersEquityAndRedeemableNonControllingInterestAdditionalInformationDetail",
      "http://roivant.com/role/SubsequentEventsAdditionalInformationDetail"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_CommitmentsAndContingencies": {
     "auth_ref": [
      "r71",
      "r269",
      "r624",
      "r647"
     ],
     "calculation": {
      "http://roivant.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 22.0,
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur.",
        "label": "Commitments and Contingencies",
        "terseLabel": "Commitments and Contingencies"
       }
      }
     },
     "localname": "CommitmentsAndContingencies",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://roivant.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CommitmentsAndContingenciesDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Commitments and Contingencies Disclosure [Abstract]"
       }
      }
     },
     "localname": "CommitmentsAndContingenciesDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_CommitmentsAndContingenciesDisclosureTextBlock": {
     "auth_ref": [
      "r266",
      "r267",
      "r268",
      "r270",
      "r696"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for commitments and contingencies.",
        "label": "Commitments and Contingencies Disclosure [Text Block]",
        "terseLabel": "Commitments &amp; Contingencies"
       }
      }
     },
     "localname": "CommitmentsAndContingenciesDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://roivant.com/role/CommitmentsContingencies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_CommitmentsAndContingenciesPolicyTextBlock": {
     "auth_ref": [
      "r271",
      "r698"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for commitments and contingencies, which may include policies for recognizing and measuring loss and gain contingencies.",
        "label": "Commitments and Contingencies, Policy [Policy Text Block]",
        "terseLabel": "Contingencies"
       }
      }
     },
     "localname": "CommitmentsAndContingenciesPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://roivant.com/role/SummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_CommonStockCapitalSharesReservedForFutureIssuance": {
     "auth_ref": [
      "r74"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Aggregate number of common shares reserved for future issuance.",
        "label": "Common Stock, Capital Shares Reserved for Future Issuance",
        "terseLabel": "Common shares reserved for future issuance"
       }
      }
     },
     "localname": "CommonStockCapitalSharesReservedForFutureIssuance",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://roivant.com/role/ShareBasedCompensationAdditionalInformationDetail"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_CommonStockMember": {
     "auth_ref": [
      "r152",
      "r153",
      "r504"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Stock that is subordinate to all other stock of the issuer.",
        "label": "Common Stock [Member]",
        "terseLabel": "Common Stock [Member]"
       }
      }
     },
     "localname": "CommonStockMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://roivant.com/role/CondensedConsolidatedStatementsOfShareholdersEquityAndRedeemableNoncontrollingInterest",
      "http://roivant.com/role/FairValueMeasurementsScheduleOfAssetsAndLiabilitiesMeasuredAtFairValueOnARecurringBasisDetail",
      "http://roivant.com/role/ShareholdersEquityAndRedeemableNonControllingInterestAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_CommonStockParOrStatedValuePerShare": {
     "auth_ref": [
      "r47"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Face amount or stated value per share of common stock.",
        "label": "Common Stock, Par or Stated Value Per Share",
        "terseLabel": "Common stock, par or stated value per share"
       }
      }
     },
     "localname": "CommonStockParOrStatedValuePerShare",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://roivant.com/role/CondensedConsolidatedBalanceSheetsParenthetical"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_CommonStockSharesAuthorized": {
     "auth_ref": [
      "r47"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The maximum number of common shares permitted to be issued by an entity's charter and bylaws.",
        "label": "Common Stock, Shares Authorized",
        "terseLabel": "Common stock, shares authorized"
       }
      }
     },
     "localname": "CommonStockSharesAuthorized",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://roivant.com/role/CondensedConsolidatedBalanceSheetsParenthetical"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_CommonStockSharesIssued": {
     "auth_ref": [
      "r47"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.",
        "label": "Common Stock, Shares, Issued",
        "terseLabel": "Common stock issued",
        "verboseLabel": "Common stock, shares issued"
       }
      }
     },
     "localname": "CommonStockSharesIssued",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://roivant.com/role/CondensedConsolidatedBalanceSheetsParenthetical",
      "http://roivant.com/role/ShareholdersEquityAndRedeemableNonControllingInterestAdditionalInformationDetail"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_CommonStockSharesOutstanding": {
     "auth_ref": [
      "r47",
      "r338"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.",
        "label": "Common Stock, Shares, Outstanding",
        "positiveLabel": "Common stock, shares outstanding",
        "terseLabel": "Common stock"
       }
      }
     },
     "localname": "CommonStockSharesOutstanding",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://roivant.com/role/CondensedConsolidatedBalanceSheetsParenthetical",
      "http://roivant.com/role/InvestmentsAdditionalInformationDetail"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_CommonStockValue": {
     "auth_ref": [
      "r47",
      "r566"
     ],
     "calculation": {
      "http://roivant.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 26.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.",
        "label": "Common Stock, Value, Issued",
        "verboseLabel": "Common shares"
       }
      }
     },
     "localname": "CommonStockValue",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://roivant.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CompensationAndRetirementDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Retirement Benefits [Abstract]"
       }
      }
     },
     "localname": "CompensationAndRetirementDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_ComprehensiveIncomeNetOfTax": {
     "auth_ref": [
      "r90",
      "r92",
      "r93",
      "r107",
      "r632",
      "r655"
     ],
     "calculation": {
      "http://roivant.com/role/CondensedConsolidatedStatementsOfComprehensiveLoss": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income, attributable to parent entity. Excludes changes in equity resulting from investments by owners and distributions to owners.",
        "label": "Comprehensive Income (Loss), Net of Tax, Attributable to Parent",
        "totalLabel": "Comprehensive loss attributable to Roivant Sciences Ltd."
       }
      }
     },
     "localname": "ComprehensiveIncomeNetOfTax",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://roivant.com/role/CondensedConsolidatedStatementsOfComprehensiveLoss"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest": {
     "auth_ref": [
      "r90",
      "r92",
      "r106",
      "r484",
      "r485",
      "r498",
      "r631",
      "r654"
     ],
     "calculation": {
      "http://roivant.com/role/CondensedConsolidatedStatementsOfComprehensiveLoss": {
       "order": 5.0,
       "parentTag": "us-gaap_ComprehensiveIncomeNetOfTax",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income (loss) and other comprehensive income (loss), attributable to noncontrolling interests. Excludes changes in equity resulting from investments by owners and distributions to owners.",
        "label": "Comprehensive Income (Loss), Net of Tax, Attributable to Noncontrolling Interest",
        "terseLabel": "Comprehensive loss attributable to noncontrolling interests"
       }
      }
     },
     "localname": "ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://roivant.com/role/CondensedConsolidatedStatementsOfComprehensiveLoss"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest": {
     "auth_ref": [
      "r90",
      "r92",
      "r105",
      "r483",
      "r498",
      "r630",
      "r653"
     ],
     "calculation": {
      "http://roivant.com/role/CondensedConsolidatedStatementsOfComprehensiveLoss": {
       "order": 1.0,
       "parentTag": "us-gaap_ComprehensiveIncomeNetOfTax",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income. Excludes changes in equity resulting from investments by owners and distributions to owners.",
        "label": "Comprehensive Income (Loss), Net of Tax, Including Portion Attributable to Noncontrolling Interest",
        "totalLabel": "Comprehensive loss"
       }
      }
     },
     "localname": "ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://roivant.com/role/CondensedConsolidatedStatementsOfComprehensiveLoss"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ComputerEquipmentMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Long lived, depreciable assets that are used in the creation, maintenance and utilization of information systems.",
        "label": "Computer Equipment [Member]",
        "terseLabel": "Computer [Member]"
       }
      }
     },
     "localname": "ComputerEquipmentMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://roivant.com/role/SummaryOfSignificantAccountingPoliciesScheduleOfEstimatedUsefulLivesDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ConcentrationRiskCreditRisk": {
     "auth_ref": [
      "r191",
      "r637"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for credit risk.",
        "label": "Concentration Risk, Credit Risk, Policy [Policy Text Block]",
        "terseLabel": "Concentrations of Credit Risk"
       }
      }
     },
     "localname": "ConcentrationRiskCreditRisk",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://roivant.com/role/SummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ConvertibleNotesPayableMember": {
     "auth_ref": [
      "r42",
      "r618",
      "r638",
      "r674"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Written promise to pay a note which can be exchanged for a specified quantity of securities (typically common stock), at the option of the issuer or the holder.",
        "label": "Convertible Notes Payable [Member]",
        "terseLabel": "Convertible Notes Payable [Member]"
       }
      }
     },
     "localname": "ConvertibleNotesPayableMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://roivant.com/role/ShareholdersEquityAndRedeemableNonControllingInterestAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ConvertiblePreferredStockMember": {
     "auth_ref": [
      "r321",
      "r322",
      "r326"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Preferred stock that may be exchanged into common shares or other types of securities at the owner's option.",
        "label": "Convertible Preferred Stock [Member]",
        "terseLabel": "Convertible Preferred Stock [Member]"
       }
      }
     },
     "localname": "ConvertiblePreferredStockMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://roivant.com/role/FairValueMeasurementsScheduleOfAssetsAndLiabilitiesMeasuredAtFairValueOnARecurringBasisDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion": {
     "auth_ref": [
      "r45",
      "r46",
      "r333",
      "r339",
      "r343"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares issued for each share of convertible preferred stock that is converted.",
        "label": "Convertible Preferred Stock, Shares Issued upon Conversion",
        "terseLabel": "Issued relating to the conversion of certain liability instruments"
       }
      }
     },
     "localname": "ConvertiblePreferredStockSharesIssuedUponConversion",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://roivant.com/role/InvestmentsAdditionalInformationDetail"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_CostsAndExpensesRelatedParty": {
     "auth_ref": [
      "r113"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Costs of sales and operating expenses for the period incurred from transactions with related parties.",
        "label": "Costs and Expenses, Related Party",
        "terseLabel": "Cost incurred and recorded as offsets to general and administrative expenses"
       }
      }
     },
     "localname": "CostsAndExpensesRelatedParty",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://roivant.com/role/RelatedPartyTransactionsAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CurrentIncomeTaxExpenseBenefit": {
     "auth_ref": [
      "r147",
      "r447",
      "r454",
      "r456"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of current income tax expense (benefit) pertaining to taxable income (loss) from continuing operations.",
        "label": "Current Income Tax Expense (Benefit)",
        "terseLabel": "Total current tax expense"
       }
      }
     },
     "localname": "CurrentIncomeTaxExpenseBenefit",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://roivant.com/role/IncomeTaxesScheduleComponentsOfIncomeTaxExpenseBenefitDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Current Income Tax Expense (Benefit), Continuing Operations [Abstract]",
        "terseLabel": "Current taxes:"
       }
      }
     },
     "localname": "CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://roivant.com/role/IncomeTaxesScheduleComponentsOfIncomeTaxExpenseBenefitDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DebtConversionConvertedInstrumentSharesIssued1": {
     "auth_ref": [
      "r138",
      "r139"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of shares issued in exchange for the original debt being converted in a noncash (or part noncash) transaction. \"Part noncash\" refers to that portion of the transaction not resulting in cash receipts or payments in the period.",
        "label": "Debt Conversion, Converted Instrument, Shares Issued",
        "terseLabel": "Conversion of stock , share converted",
        "verboseLabel": "Notes converted, shares issued"
       }
      }
     },
     "localname": "DebtConversionConvertedInstrumentSharesIssued1",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://roivant.com/role/AssetAcquisitionsAndLicenseAgreementsAdditionalInformationDetail",
      "http://roivant.com/role/ShareholdersEquityAndRedeemableNonControllingInterestAdditionalInformationDetail"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_DebtConversionOriginalDebtAmount1": {
     "auth_ref": [
      "r138",
      "r139"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of the original debt being converted in a noncash (or part noncash) transaction. \"Part noncash\" refers to that portion of the transaction not resulting in cash receipts or cash payments in the period.",
        "label": "Debt Conversion, Original Debt, Amount",
        "terseLabel": "Aggregate principal amount of notes converted"
       }
      }
     },
     "localname": "DebtConversionOriginalDebtAmount1",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://roivant.com/role/AssetAcquisitionsAndLicenseAgreementsAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DebtDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Debt Disclosure [Abstract]"
       }
      }
     },
     "localname": "DebtDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_DebtInstrumentAxis": {
     "auth_ref": [
      "r42",
      "r43",
      "r44",
      "r145",
      "r150",
      "r285",
      "r286",
      "r287",
      "r288",
      "r289",
      "r290",
      "r291",
      "r292",
      "r293",
      "r294",
      "r295",
      "r296",
      "r297",
      "r298",
      "r299",
      "r300",
      "r301",
      "r307",
      "r308",
      "r309",
      "r310",
      "r538",
      "r618",
      "r619",
      "r638"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of debt instrument, including, but not limited to, draws against credit facilities.",
        "label": "Debt Instrument [Axis]",
        "terseLabel": "Debt Instrument [Axis]"
       }
      }
     },
     "localname": "DebtInstrumentAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://roivant.com/role/SubsequentEventsAdditionalInformationDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DebtInstrumentCarryingAmount": {
     "auth_ref": [
      "r44",
      "r304",
      "r619",
      "r638"
     ],
     "calculation": {
      "http://roivant.com/role/LongTermDebtAndLoanCommitmentDetail": {
       "order": 3.0,
       "parentTag": "us-gaap_LongTermDebt",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, before unamortized (discount) premium and debt issuance costs, of long-term debt. Includes, but is not limited to, notes payable, bonds payable, commercial loans, mortgage loans, convertible debt, subordinated debt and other types of debt.",
        "label": "Long-term Debt, Gross",
        "terseLabel": "Principal amount"
       }
      }
     },
     "localname": "DebtInstrumentCarryingAmount",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://roivant.com/role/LongTermDebtAndLoanCommitmentDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DebtInstrumentConvertibleCarryingAmountOfTheEquityComponent": {
     "auth_ref": [
      "r303"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The carrying amount of the equity component of convertible debt which may be settled in cash upon conversion.",
        "label": "Debt Instrument, Convertible, Carrying Amount of Equity Component",
        "terseLabel": "Carrying amount of the convertible promissory"
       }
      }
     },
     "localname": "DebtInstrumentConvertibleCarryingAmountOfTheEquityComponent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://roivant.com/role/ShareholdersEquityAndRedeemableNonControllingInterestAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DebtInstrumentFaceAmount": {
     "auth_ref": [
      "r285",
      "r307",
      "r308",
      "r536",
      "r538",
      "r539"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Face (par) amount of debt instrument at time of issuance.",
        "label": "Debt Instrument, Face Amount",
        "terseLabel": "Debt principal amount"
       }
      }
     },
     "localname": "DebtInstrumentFaceAmount",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://roivant.com/role/LongTermDebtAndLoanCommitmentAdditionalInformationDetail",
      "http://roivant.com/role/SubsequentEventsAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DebtInstrumentFairValue": {
     "auth_ref": [
      "r294",
      "r307",
      "r308",
      "r519"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fair value portion of debt instrument payable, including, but not limited to, notes payable and loans payable.",
        "label": "Debt Instrument, Fair Value Disclosure",
        "terseLabel": "Debt fair value",
        "verboseLabel": "Debt issued by Dermavant to NovaQuest"
       }
      }
     },
     "localname": "DebtInstrumentFairValue",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://roivant.com/role/FairValueMeasurementsScheduleOfAssetsAndLiabilitiesMeasuredAtFairValueOnARecurringBasisDetail",
      "http://roivant.com/role/LongTermDebtAndLoanCommitmentAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DebtInstrumentFeeAmount": {
     "auth_ref": [
      "r68"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "definitionGuidance": "Debt Instrument, Fee Amount",
        "documentation": "Amount of the fee that accompanies borrowing money under the debt instrument.",
        "label": "Debt Instrument, Fee Amount"
       }
      }
     },
     "localname": "DebtInstrumentFeeAmount",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://roivant.com/role/LongTermDebtAndLoanCommitmentAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DebtInstrumentInterestRateStatedPercentage": {
     "auth_ref": [
      "r67",
      "r286"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Contractual interest rate for funds borrowed, under the debt agreement.",
        "label": "Debt Instrument, Interest Rate, Stated Percentage",
        "terseLabel": "Interest rate"
       }
      }
     },
     "localname": "DebtInstrumentInterestRateStatedPercentage",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://roivant.com/role/LongTermDebtAndLoanCommitmentAdditionalInformationDetail",
      "http://roivant.com/role/SubsequentEventsAdditionalInformationDetail"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_DebtInstrumentLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Debt Instrument [Line Items]",
        "terseLabel": "Debt Instrument [Line Items]"
       }
      }
     },
     "localname": "DebtInstrumentLineItems",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://roivant.com/role/LongTermDebtAndLoanCommitmentAdditionalInformationDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DebtInstrumentMeasurementInput": {
     "auth_ref": [
      "r512"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Value of input used to measure debt instrument, including, but not limited to, convertible and non-convertible debt.",
        "label": "Debt Instrument, Measurement Input",
        "terseLabel": "Discount rate"
       }
      }
     },
     "localname": "DebtInstrumentMeasurementInput",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://roivant.com/role/FairValueMeasurementsAdditionalInformationDetail"
     ],
     "xbrltype": "decimalItemType"
    },
    "us-gaap_DebtInstrumentNameDomain": {
     "auth_ref": [
      "r69",
      "r145",
      "r150",
      "r285",
      "r286",
      "r287",
      "r288",
      "r289",
      "r290",
      "r291",
      "r292",
      "r293",
      "r294",
      "r295",
      "r296",
      "r297",
      "r298",
      "r299",
      "r300",
      "r301",
      "r307",
      "r308",
      "r309",
      "r310",
      "r538"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The name for the particular debt instrument or borrowing that distinguishes it from other debt instruments or borrowings, including draws against credit facilities.",
        "label": "Debt Instrument, Name [Domain]",
        "terseLabel": "Debt Instrument, Name [Domain]"
       }
      }
     },
     "localname": "DebtInstrumentNameDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://roivant.com/role/SubsequentEventsAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_DebtInstrumentTable": {
     "auth_ref": [
      "r69",
      "r145",
      "r150",
      "r285",
      "r286",
      "r287",
      "r288",
      "r289",
      "r290",
      "r291",
      "r292",
      "r293",
      "r294",
      "r295",
      "r296",
      "r297",
      "r298",
      "r299",
      "r300",
      "r301",
      "r302",
      "r307",
      "r308",
      "r309",
      "r310",
      "r339",
      "r344",
      "r345",
      "r346",
      "r535",
      "r536",
      "r538",
      "r539",
      "r636"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A table or schedule providing information pertaining to long-term debt instruments or arrangements, including identification, terms, features, collateral requirements and other information necessary to a fair presentation. These are debt arrangements that originally required repayment more than twelve months after issuance or greater than the normal operating cycle of the company, if longer.",
        "label": "Schedule of Long-term Debt Instruments [Table]",
        "terseLabel": "Schedule of Long-term Debt Instruments [Table]"
       }
      }
     },
     "localname": "DebtInstrumentTable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://roivant.com/role/LongTermDebtAndLoanCommitmentAdditionalInformationDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DebtInstrumentTerm": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Period of time between issuance and maturity of debt instrument, in PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.",
        "label": "Debt Instrument, Term",
        "terseLabel": "Maturity date"
       }
      }
     },
     "localname": "DebtInstrumentTerm",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://roivant.com/role/LongTermDebtAndLoanCommitmentAdditionalInformationDetail",
      "http://roivant.com/role/SubsequentEventsAdditionalInformationDetail"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet": {
     "auth_ref": [
      "r292",
      "r305",
      "r307",
      "r308",
      "r537"
     ],
     "calculation": {
      "http://roivant.com/role/LongTermDebtAndLoanCommitmentDetail": {
       "order": 4.0,
       "parentTag": "us-gaap_LongTermDebt",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of unamortized debt discount (premium) and debt issuance costs.",
        "label": "Debt Instrument, Unamortized Discount (Premium) and Debt Issuance Costs, Net",
        "negatedLabel": "Less: unamortized debt discount and issuance costs"
       }
      }
     },
     "localname": "DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://roivant.com/role/LongTermDebtAndLoanCommitmentDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeconsolidationGainOrLossAmount": {
     "auth_ref": [
      "r493"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of gain (loss) from deconsolidation of subsidiary and derecognition of group of assets constituting transfer of business or nonprofit activity, excluding conveyance of oil and gas mineral rights and transfer of good or service in contract with customer.",
        "label": "Deconsolidation, Gain (Loss), Amount",
        "terseLabel": "Gain on deconsolidation"
       }
      }
     },
     "localname": "DeconsolidationGainOrLossAmount",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://roivant.com/role/InvestmentsAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredCompensationEquity": {
     "auth_ref": [
      "r77",
      "r382"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Value of stock issued under share-based plans to employees or officers which is the unearned portion, accounted for under the fair value method.",
        "label": "Deferred Compensation Equity",
        "terseLabel": "Deferred compensation equity"
       }
      }
     },
     "localname": "DeferredCompensationEquity",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://roivant.com/role/SumitomoTransactionAgreementAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredCompensationLiabilityCurrent": {
     "auth_ref": [
      "r364",
      "r365"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Aggregate carrying value as of the balance sheet date of the liabilities for all deferred compensation arrangements payable within one year (or the operating cycle, if longer). Represents currently earned compensation under compensation arrangements that is not actually paid until a later date.",
        "label": "Deferred Compensation Liability, Current",
        "terseLabel": "Deferred compensation liability"
       }
      }
     },
     "localname": "DeferredCompensationLiabilityCurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://roivant.com/role/SumitomoTransactionAgreementAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredIncomeTaxExpenseBenefit": {
     "auth_ref": [
      "r133",
      "r147",
      "r448",
      "r454",
      "r455",
      "r456"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of deferred income tax expense (benefit) pertaining to income (loss) from continuing operations.",
        "label": "Deferred Income Tax Expense (Benefit)",
        "terseLabel": "Total deferred tax benefit"
       }
      }
     },
     "localname": "DeferredIncomeTaxExpenseBenefit",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://roivant.com/role/IncomeTaxesScheduleComponentsOfIncomeTaxExpenseBenefitDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Deferred Income Tax Expense (Benefit), Continuing Operations [Abstract]",
        "terseLabel": "Deferred taxes:"
       }
      }
     },
     "localname": "DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://roivant.com/role/IncomeTaxesScheduleComponentsOfIncomeTaxExpenseBenefitDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DeferredTaxAssetsGoodwillAndIntangibleAssets": {
     "auth_ref": [],
     "calculation": {
      "http://roivant.com/role/IncomeTaxesScheduleOfDeferredTaxAssetsLiabilitiesDetail": {
       "order": 3.0,
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from intangible assets including goodwill.",
        "label": "Deferred Tax Assets, Goodwill and Intangible Assets",
        "terseLabel": "Intangible assets"
       }
      }
     },
     "localname": "DeferredTaxAssetsGoodwillAndIntangibleAssets",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://roivant.com/role/IncomeTaxesScheduleOfDeferredTaxAssetsLiabilitiesDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxAssetsGross": {
     "auth_ref": [
      "r439"
     ],
     "calculation": {
      "http://roivant.com/role/IncomeTaxesScheduleOfDeferredTaxAssetsLiabilitiesDetail": {
       "order": 1.0,
       "parentTag": "us-gaap_DeferredTaxAssetsLiabilitiesNet",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences and carryforwards.",
        "label": "Deferred Tax Assets, Gross",
        "totalLabel": "Subtotal"
       }
      }
     },
     "localname": "DeferredTaxAssetsGross",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://roivant.com/role/IncomeTaxesScheduleOfDeferredTaxAssetsLiabilitiesDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxAssetsGrossAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Deferred Tax Assets, Gross [Abstract]",
        "terseLabel": "Deferred tax assets"
       }
      }
     },
     "localname": "DeferredTaxAssetsGrossAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://roivant.com/role/IncomeTaxesScheduleOfDeferredTaxAssetsLiabilitiesDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DeferredTaxAssetsLiabilitiesNet": {
     "auth_ref": [
      "r441"
     ],
     "calculation": {
      "http://roivant.com/role/IncomeTaxesScheduleOfDeferredTaxAssetsLiabilitiesDetail": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after allocation of valuation allowances and deferred tax liability, of deferred tax asset attributable to deductible differences and carryforwards, without jurisdictional netting.",
        "label": "Deferred Tax Assets, Net",
        "totalLabel": "Net Deferred tax assets/(liabilities), net of valuation allowance"
       }
      }
     },
     "localname": "DeferredTaxAssetsLiabilitiesNet",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://roivant.com/role/IncomeTaxesScheduleOfDeferredTaxAssetsLiabilitiesDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxAssetsOperatingLossCarryforwards": {
     "auth_ref": [
      "r445",
      "r446"
     ],
     "calculation": {
      "http://roivant.com/role/IncomeTaxesScheduleOfDeferredTaxAssetsLiabilitiesDetail": {
       "order": 4.0,
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible operating loss carryforwards.",
        "label": "Deferred Tax Assets, Operating Loss Carryforwards",
        "terseLabel": "Net operating loss"
       }
      }
     },
     "localname": "DeferredTaxAssetsOperatingLossCarryforwards",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://roivant.com/role/IncomeTaxesScheduleOfDeferredTaxAssetsLiabilitiesDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxAssetsOther": {
     "auth_ref": [
      "r445",
      "r446"
     ],
     "calculation": {
      "http://roivant.com/role/IncomeTaxesScheduleOfDeferredTaxAssetsLiabilitiesDetail": {
       "order": 7.0,
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, before allocation of valuation allowance, of deferred tax asset attributable to deductible temporary differences, classified as other.",
        "label": "Deferred Tax Assets, Other",
        "terseLabel": "Other"
       }
      }
     },
     "localname": "DeferredTaxAssetsOther",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://roivant.com/role/IncomeTaxesScheduleOfDeferredTaxAssetsLiabilitiesDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch": {
     "auth_ref": [
      "r444",
      "r445",
      "r446"
     ],
     "calculation": {
      "http://roivant.com/role/IncomeTaxesScheduleOfDeferredTaxAssetsLiabilitiesDetail": {
       "order": 2.0,
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible research tax credit carryforwards.",
        "label": "Deferred Tax Assets, Tax Credit Carryforwards, Research",
        "terseLabel": "Research tax credits"
       }
      }
     },
     "localname": "DeferredTaxAssetsTaxCreditCarryforwardsResearch",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://roivant.com/role/IncomeTaxesScheduleOfDeferredTaxAssetsLiabilitiesDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost": {
     "auth_ref": [
      "r445",
      "r446"
     ],
     "calculation": {
      "http://roivant.com/role/IncomeTaxesScheduleOfDeferredTaxAssetsLiabilitiesDetail": {
       "order": 5.0,
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from share-based compensation.",
        "label": "Deferred Tax Assets, Tax Deferred Expense, Compensation and Benefits, Share-based Compensation Cost",
        "terseLabel": "Share-based compensation"
       }
      }
     },
     "localname": "DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://roivant.com/role/IncomeTaxesScheduleOfDeferredTaxAssetsLiabilitiesDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxAssetsValuationAllowance": {
     "auth_ref": [
      "r440"
     ],
     "calculation": {
      "http://roivant.com/role/IncomeTaxesScheduleOfDeferredTaxAssetsLiabilitiesDetail": {
       "order": 11.0,
       "parentTag": "us-gaap_DeferredTaxAssetsLiabilitiesNet",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of deferred tax assets for which it is more likely than not that a tax benefit will not be realized.",
        "label": "Deferred Tax Assets, Valuation Allowance",
        "negatedLabel": "Valuation allowance",
        "terseLabel": "Valuation allowance"
       }
      }
     },
     "localname": "DeferredTaxAssetsValuationAllowance",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://roivant.com/role/IncomeTaxesAdditionalInformationDetail",
      "http://roivant.com/role/IncomeTaxesScheduleOfDeferredTaxAssetsLiabilitiesDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxLiabilitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Deferred Tax Liabilities, Gross [Abstract]",
        "terseLabel": "Deferred tax liabilities"
       }
      }
     },
     "localname": "DeferredTaxLiabilitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://roivant.com/role/IncomeTaxesScheduleOfDeferredTaxAssetsLiabilitiesDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DeferredTaxLiabilitiesOther": {
     "auth_ref": [
      "r445",
      "r446"
     ],
     "calculation": {
      "http://roivant.com/role/IncomeTaxesScheduleOfDeferredTaxAssetsLiabilitiesDetail": {
       "order": 10.0,
       "parentTag": "us-gaap_DeferredTaxAssetsLiabilitiesNet",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of deferred tax liability attributable to taxable temporary differences classified as other.",
        "label": "Deferred Tax Liabilities, Other",
        "negatedLabel": "Other"
       }
      }
     },
     "localname": "DeferredTaxLiabilitiesOther",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://roivant.com/role/IncomeTaxesScheduleOfDeferredTaxAssetsLiabilitiesDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DefinedContributionPlanEmployerDiscretionaryContributionAmount": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of discretionary contributions made by an employer to a defined contribution plan.",
        "label": "Defined Contribution Plan, Employer Discretionary Contribution Amount",
        "terseLabel": "Defined contribution plan, employer matching contribution"
       }
      }
     },
     "localname": "DefinedContributionPlanEmployerDiscretionaryContributionAmount",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://roivant.com/role/DefinedContributionPlanAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DefinedContributionPlanTextBlock": {
     "auth_ref": [
      "r376",
      "r377"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for defined contribution plan.",
        "label": "Defined Contribution Plan [Text Block]",
        "terseLabel": "Defined Contribution Plan"
       }
      }
     },
     "localname": "DefinedContributionPlanTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://roivant.com/role/DefinedContributionPlan"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_DerivativeInstrumentsNotDesignatedAsHedgingInstrumentsLiabilityAtFairValue": {
     "auth_ref": [
      "r500"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fair value as of the balance sheet date of derivative instrument not designated as hedging instrument and classified as a liability.",
        "label": "Derivative Instruments Not Designated as Hedging Instruments, Liability, at Fair Value",
        "terseLabel": "Liability instruments measured at fair value"
       }
      }
     },
     "localname": "DerivativeInstrumentsNotDesignatedAsHedgingInstrumentsLiabilityAtFairValue",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://roivant.com/role/FairValueMeasurementsScheduleOfAssetsAndLiabilitiesMeasuredAtFairValueOnARecurringBasisDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock": {
     "auth_ref": [
      "r426"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for share-based payment arrangement.",
        "label": "Share-based Payment Arrangement [Text Block]",
        "terseLabel": "Share-Based Compensation"
       }
      }
     },
     "localname": "DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://roivant.com/role/ShareBasedCompensation"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-based Payment Arrangement [Abstract]"
       }
      }
     },
     "localname": "DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_DiscontinuedOperationIncomeLossFromDiscontinuedOperationBeforeIncomeTax": {
     "auth_ref": [
      "r4",
      "r5",
      "r6",
      "r7",
      "r10",
      "r17",
      "r102",
      "r650"
     ],
     "calculation": {
      "http://roivant.com/role/DiscontinuedOperationsSummaryOfDisposalGroupsIncludingDiscontinuedOperationsIncomeStatementDetail": {
       "order": 3.0,
       "parentTag": "us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTax",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before tax of income (loss) from a discontinued operation. Includes, but is not limited to, the income (loss) from operations during the phase-out period, gain (loss) on disposal, gain (loss) for reversal of write-down (write-down) to fair value, less cost to sell, and adjustments to a prior period gain (loss) on disposal.",
        "label": "Discontinued Operation, Income (Loss) from Discontinued Operation, before Income Tax",
        "totalLabel": "Income from discontinued operations before income taxes"
       }
      }
     },
     "localname": "DiscontinuedOperationIncomeLossFromDiscontinuedOperationBeforeIncomeTax",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://roivant.com/role/DiscontinuedOperationsSummaryOfDisposalGroupsIncludingDiscontinuedOperationsIncomeStatementDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DiscontinuedOperationIncomeLossFromDiscontinuedOperationDuringPhaseOutPeriodBeforeIncomeTax": {
     "auth_ref": [
      "r4",
      "r5",
      "r17"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before tax of income (loss) from operations classified as a discontinued operation. Excludes gain (loss) on disposal and provision for gain (loss) until its disposal.",
        "label": "Discontinued Operation, Income (Loss) from Discontinued Operation During Phase-out Period, before Income Tax",
        "terseLabel": "Income from discontinued operations before income taxes"
       }
      }
     },
     "localname": "DiscontinuedOperationIncomeLossFromDiscontinuedOperationDuringPhaseOutPeriodBeforeIncomeTax",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://roivant.com/role/DiscontinuedOperationsSummaryOfDisposalGroupsIncludingDiscontinuedOperationsIncomeStatementDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DiscontinuedOperationIncomeLossFromDiscontinuedOperationDuringPhaseOutPeriodBeforeIncomeTaxAttributableToNoncontrollingInterest": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before tax of income (loss) from operations classified as a discontinued operation attributable to the noncontrolling interest. Excludes gain (loss) on disposal and provision for gain (loss) until its disposal.",
        "label": "Discontinued Operation, Income (Loss) from Discontinued Operation During Phase-out Period, before Income Tax, Attributable to Noncontrolling Interest",
        "terseLabel": "Loss from discontinued operations before income taxes attributable to noncontrolling interests"
       }
      }
     },
     "localname": "DiscontinuedOperationIncomeLossFromDiscontinuedOperationDuringPhaseOutPeriodBeforeIncomeTaxAttributableToNoncontrollingInterest",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://roivant.com/role/DiscontinuedOperationsSummaryOfDisposalGroupsIncludingDiscontinuedOperationsIncomeStatementDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DiscontinuedOperationIncomeLossFromDiscontinuedOperationDuringPhaseOutPeriodBeforeIncomeTaxAttributableToParent": {
     "auth_ref": [
      "r19"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before tax of income (loss) from operations classified as a discontinued operation attributable to the parent. Excludes gain (loss) on disposal and provision for gain (loss) until its disposal.",
        "label": "Discontinued Operation, Income (Loss) from Discontinued Operation During Phase-out Period, before Income Tax, Attributable to Parent",
        "terseLabel": "Income from discontinued operations before income taxes attributable to Roivant Sciences Ltd."
       }
      }
     },
     "localname": "DiscontinuedOperationIncomeLossFromDiscontinuedOperationDuringPhaseOutPeriodBeforeIncomeTaxAttributableToParent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://roivant.com/role/DiscontinuedOperationsSummaryOfDisposalGroupsIncludingDiscontinuedOperationsIncomeStatementDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DiscontinuedOperationTaxEffectOfDiscontinuedOperation": {
     "auth_ref": [
      "r5",
      "r6",
      "r7",
      "r10",
      "r17",
      "r21",
      "r432",
      "r453",
      "r460"
     ],
     "calculation": {
      "http://roivant.com/role/DiscontinuedOperationsSummaryOfDisposalGroupsIncludingDiscontinuedOperationsIncomeStatementDetail": {
       "order": 9.0,
       "parentTag": "us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTax",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of tax expense (benefit) related to a discontinued operation. Includes, but is not limited to, tax expense (benefit) related to income (loss) from operations during the phase-out period, tax expense (benefit) related to gain (loss) on disposal, tax expense (benefit) related to gain (loss) for reversal of write-down (write-down) to fair value, less cost to sell, and tax expense (benefit) related to adjustments of a prior period gain (loss) on disposal.",
        "label": "Discontinued Operation, Tax Effect of Discontinued Operation",
        "terseLabel": "Income tax expense"
       }
      }
     },
     "localname": "DiscontinuedOperationTaxEffectOfDiscontinuedOperation",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://roivant.com/role/DiscontinuedOperationsSummaryOfDisposalGroupsIncludingDiscontinuedOperationsIncomeStatementDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DiscontinuedOperationsAndDisposalGroupsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Discontinued Operations and Disposal Groups [Abstract]"
       }
      }
     },
     "localname": "DiscontinuedOperationsAndDisposalGroupsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_DisposalGroupIncludingDiscontinuedOperationGeneralAndAdministrativeExpense": {
     "auth_ref": [
      "r18"
     ],
     "calculation": {
      "http://roivant.com/role/DiscontinuedOperationsSummaryOfDisposalGroupsIncludingDiscontinuedOperationsIncomeStatementDetail": {
       "order": 2.0,
       "parentTag": "us-gaap_DisposalGroupIncludingDiscontinuedOperationOperatingExpense",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of general and administrative expense attributable to disposal group, including, but not limited to, discontinued operation.",
        "label": "Disposal Group, Including Discontinued Operation, General and Administrative Expense",
        "terseLabel": "General and administrative"
       }
      }
     },
     "localname": "DisposalGroupIncludingDiscontinuedOperationGeneralAndAdministrativeExpense",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://roivant.com/role/DiscontinuedOperationsSummaryOfDisposalGroupsIncludingDiscontinuedOperationsIncomeStatementDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DisposalGroupIncludingDiscontinuedOperationInterestExpense": {
     "auth_ref": [
      "r8",
      "r9",
      "r18",
      "r25"
     ],
     "calculation": {
      "http://roivant.com/role/DiscontinuedOperationsSummaryOfDisposalGroupsIncludingDiscontinuedOperationsIncomeStatementDetail": {
       "order": 7.0,
       "parentTag": "us-gaap_DiscontinuedOperationIncomeLossFromDiscontinuedOperationBeforeIncomeTax",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of interest expense attributable to disposal group, including, but not limited to, discontinued operation.",
        "label": "Disposal Group, Including Discontinued Operation, Interest Expense",
        "terseLabel": "Interest expense(1)"
       }
      }
     },
     "localname": "DisposalGroupIncludingDiscontinuedOperationInterestExpense",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://roivant.com/role/DiscontinuedOperationsSummaryOfDisposalGroupsIncludingDiscontinuedOperationsIncomeStatementDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DisposalGroupIncludingDiscontinuedOperationInterestIncome": {
     "auth_ref": [
      "r18"
     ],
     "calculation": {
      "http://roivant.com/role/DiscontinuedOperationsSummaryOfDisposalGroupsIncludingDiscontinuedOperationsIncomeStatementDetail": {
       "order": 6.0,
       "parentTag": "us-gaap_DiscontinuedOperationIncomeLossFromDiscontinuedOperationBeforeIncomeTax",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of interest income attributable to disposal group, including, but not limited to, discontinued operation.",
        "label": "Disposal Group, Including Discontinued Operation, Interest Income",
        "negatedLabel": "Interest income"
       }
      }
     },
     "localname": "DisposalGroupIncludingDiscontinuedOperationInterestIncome",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://roivant.com/role/DiscontinuedOperationsSummaryOfDisposalGroupsIncludingDiscontinuedOperationsIncomeStatementDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DisposalGroupIncludingDiscontinuedOperationOperatingExpense": {
     "auth_ref": [
      "r18"
     ],
     "calculation": {
      "http://roivant.com/role/DiscontinuedOperationsSummaryOfDisposalGroupsIncludingDiscontinuedOperationsIncomeStatementDetail": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of operating expense attributable to disposal group, including, but not limited to, discontinued operation.",
        "label": "Disposal Group, Including Discontinued Operation, Operating Expense",
        "totalLabel": "Total operating expenses"
       }
      }
     },
     "localname": "DisposalGroupIncludingDiscontinuedOperationOperatingExpense",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://roivant.com/role/DiscontinuedOperationsSummaryOfDisposalGroupsIncludingDiscontinuedOperationsIncomeStatementDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DisposalGroupIncludingDiscontinuedOperationOperatingIncomeLoss": {
     "auth_ref": [
      "r18"
     ],
     "calculation": {
      "http://roivant.com/role/DiscontinuedOperationsSummaryOfDisposalGroupsIncludingDiscontinuedOperationsIncomeStatementDetail": {
       "order": 4.0,
       "parentTag": "us-gaap_DiscontinuedOperationIncomeLossFromDiscontinuedOperationBeforeIncomeTax",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of operating income (loss) attributable to disposal group, including, but not limited to, discontinued operation.",
        "label": "Disposal Group, Including Discontinued Operation, Operating Income (Loss)",
        "terseLabel": "Loss from operations"
       }
      }
     },
     "localname": "DisposalGroupIncludingDiscontinuedOperationOperatingIncomeLoss",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://roivant.com/role/DiscontinuedOperationsSummaryOfDisposalGroupsIncludingDiscontinuedOperationsIncomeStatementDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DisposalGroupIncludingDiscontinuedOperationOtherExpense": {
     "auth_ref": [
      "r18"
     ],
     "calculation": {
      "http://roivant.com/role/DiscontinuedOperationsSummaryOfDisposalGroupsIncludingDiscontinuedOperationsIncomeStatementDetail": {
       "order": 8.0,
       "parentTag": "us-gaap_DiscontinuedOperationIncomeLossFromDiscontinuedOperationBeforeIncomeTax",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of other expense attributable to disposal group, including, but not limited to, discontinued operation.",
        "label": "Disposal Group, Including Discontinued Operation, Other Expense",
        "terseLabel": "Other expense"
       }
      }
     },
     "localname": "DisposalGroupIncludingDiscontinuedOperationOtherExpense",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://roivant.com/role/DiscontinuedOperationsSummaryOfDisposalGroupsIncludingDiscontinuedOperationsIncomeStatementDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock": {
     "auth_ref": [
      "r26",
      "r264"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure related to a disposal group. Includes, but is not limited to, a discontinued operation, disposal classified as held-for-sale or disposed of by means other than sale or disposal of an individually significant component.",
        "label": "Disposal Groups, Including Discontinued Operations, Disclosure [Text Block]",
        "terseLabel": "Discontinued Operations"
       }
      }
     },
     "localname": "DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://roivant.com/role/DiscontinuedOperations"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_EarningsPerShareAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Earnings Per Share [Abstract]"
       }
      }
     },
     "localname": "EarningsPerShareAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_EarningsPerShareBasicAndDiluted": {
     "auth_ref": [
      "r177"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of net income or loss for the period per each share in instances when basic and diluted earnings per share are the same amount and reported as a single line item on the face of the financial statements.  Basic earnings per share is the amount of net income or loss for the period per each share of common stock or unit outstanding during the reporting period.  Diluted earnings per share includes the amount of net income or loss for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.",
        "label": "Earnings Per Share, Basic and Diluted",
        "terseLabel": "Net loss per common share\u2014basic and diluted"
       }
      }
     },
     "localname": "EarningsPerShareBasicAndDiluted",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://roivant.com/role/CondensedConsolidatedStatementsOfOperations"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_EarningsPerShareBasicAndDilutedAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Earnings Per Share, Basic and Diluted [Abstract]",
        "terseLabel": "Basic and diluted net (loss) income per common share:"
       }
      }
     },
     "localname": "EarningsPerShareBasicAndDilutedAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://roivant.com/role/CondensedConsolidatedStatementsOfOperations"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_EarningsPerShareBasicAndDilutedOtherDisclosuresAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Earnings Per Share, Basic and Diluted, Other Disclosures [Abstract]",
        "terseLabel": "Basic and diluted weighted average shares outstanding:"
       }
      }
     },
     "localname": "EarningsPerShareBasicAndDilutedOtherDisclosuresAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://roivant.com/role/CondensedConsolidatedStatementsOfOperations"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_EarningsPerShareTextBlock": {
     "auth_ref": [
      "r180",
      "r181",
      "r182",
      "r184"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for earnings per share.",
        "label": "Earnings Per Share [Text Block]",
        "terseLabel": "Net Loss per Common Share"
       }
      }
     },
     "localname": "EarningsPerShareTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://roivant.com/role/NetLossPerCommonShare"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_EffectiveIncomeTaxRateContinuingOperations": {
     "auth_ref": [
      "r433"
     ],
     "calculation": {
      "http://roivant.com/role/IncomeTaxesScheduleOfEffectiveIncomeTaxRateReconciliationDetail": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.",
        "label": "Effective Income Tax Rate Reconciliation, Percent",
        "terseLabel": "Effective tax rate",
        "totalLabel": "Total income tax expense"
       }
      }
     },
     "localname": "EffectiveIncomeTaxRateContinuingOperations",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://roivant.com/role/IncomeTaxesAdditionalInformationDetail",
      "http://roivant.com/role/IncomeTaxesScheduleOfEffectiveIncomeTaxRateReconciliationDetail"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Effective Income Tax Rate Reconciliation, Percent [Abstract]",
        "terseLabel": "Effective Income Tax Rate Reconciliation, Percent [Abstract]"
       }
      }
     },
     "localname": "EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://roivant.com/role/IncomeTaxesScheduleOfEffectiveIncomeTaxRateReconciliationDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance": {
     "auth_ref": [
      "r433",
      "r457"
     ],
     "calculation": {
      "http://roivant.com/role/IncomeTaxesScheduleOfEffectiveIncomeTaxRateReconciliationDetail": {
       "order": 18.0,
       "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations",
       "weight": 1.0
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to changes in the valuation allowance for deferred tax assets.",
        "label": "Effective Income Tax Rate Reconciliation, Change in Deferred Tax Assets Valuation Allowance, Percent",
        "negatedLabel": "Change in Valuation Allowance"
       }
      }
     },
     "localname": "EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://roivant.com/role/IncomeTaxesScheduleOfEffectiveIncomeTaxRateReconciliationDetail"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate": {
     "auth_ref": [
      "r433",
      "r457"
     ],
     "calculation": {
      "http://roivant.com/role/IncomeTaxesScheduleOfEffectiveIncomeTaxRateReconciliationDetail": {
       "order": 17.0,
       "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations",
       "weight": 1.0
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to changes in the income tax rates.",
        "label": "Effective Income Tax Rate Reconciliation, Change in Enacted Tax Rate, Percent",
        "terseLabel": "Rate changes"
       }
      }
     },
     "localname": "EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://roivant.com/role/IncomeTaxesScheduleOfEffectiveIncomeTaxRateReconciliationDetail"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationDispositionOfBusiness": {
     "auth_ref": [
      "r433",
      "r457"
     ],
     "calculation": {
      "http://roivant.com/role/IncomeTaxesScheduleOfEffectiveIncomeTaxRateReconciliationDetail": {
       "order": 14.0,
       "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations",
       "weight": 1.0
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to disposition of a business not qualifying as a discontinued operation.",
        "label": "Effective Income Tax Rate Reconciliation, Disposition of Business, Percent",
        "negatedLabel": "Nontaxable (loss) gain on deconsolidation of business"
       }
      }
     },
     "localname": "EffectiveIncomeTaxRateReconciliationDispositionOfBusiness",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://roivant.com/role/IncomeTaxesScheduleOfEffectiveIncomeTaxRateReconciliationDetail"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential": {
     "auth_ref": [
      "r433",
      "r457"
     ],
     "calculation": {
      "http://roivant.com/role/IncomeTaxesScheduleOfEffectiveIncomeTaxRateReconciliationDetail": {
       "order": 11.0,
       "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations",
       "weight": 1.0
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations applicable to statutory income tax expense (benefit) outside of the country of domicile.",
        "label": "Effective Income Tax Rate Reconciliation, Foreign Income Tax Rate Differential, Percent",
        "terseLabel": "Foreign rate differential(1)"
       }
      }
     },
     "localname": "EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://roivant.com/role/IncomeTaxesScheduleOfEffectiveIncomeTaxRateReconciliationDetail"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpense": {
     "auth_ref": [
      "r433",
      "r457"
     ],
     "calculation": {
      "http://roivant.com/role/IncomeTaxesScheduleOfEffectiveIncomeTaxRateReconciliationDetail": {
       "order": 13.0,
       "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations",
       "weight": 1.0
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to nondeductible expenses.",
        "label": "Effective Income Tax Rate Reconciliation, Nondeductible Expense, Percent",
        "terseLabel": "Nondeductible changes in the fair value of investments and loss from equity method investment"
       }
      }
     },
     "localname": "EffectiveIncomeTaxRateReconciliationNondeductibleExpense",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://roivant.com/role/IncomeTaxesScheduleOfEffectiveIncomeTaxRateReconciliationDetail"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseResearchAndDevelopment": {
     "auth_ref": [
      "r433",
      "r457"
     ],
     "calculation": {
      "http://roivant.com/role/IncomeTaxesScheduleOfEffectiveIncomeTaxRateReconciliationDetail": {
       "order": 12.0,
       "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations",
       "weight": 1.0
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to research and development expense.",
        "label": "Effective Income Tax Rate Reconciliation, Nondeductible Expense, Research and Development, Percent",
        "terseLabel": "Permanent disallowed IPR&amp;D"
       }
      }
     },
     "localname": "EffectiveIncomeTaxRateReconciliationNondeductibleExpenseResearchAndDevelopment",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://roivant.com/role/IncomeTaxesScheduleOfEffectiveIncomeTaxRateReconciliationDetail"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments": {
     "auth_ref": [
      "r433",
      "r457"
     ],
     "calculation": {
      "http://roivant.com/role/IncomeTaxesScheduleOfEffectiveIncomeTaxRateReconciliationDetail": {
       "order": 19.0,
       "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations",
       "weight": 1.0
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to other adjustments.",
        "label": "Effective Income Tax Rate Reconciliation, Other Adjustments, Percent",
        "negatedLabel": "Other"
       }
      }
     },
     "localname": "EffectiveIncomeTaxRateReconciliationOtherAdjustments",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://roivant.com/role/IncomeTaxesScheduleOfEffectiveIncomeTaxRateReconciliationDetail"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsResearch": {
     "auth_ref": [
      "r433",
      "r457"
     ],
     "calculation": {
      "http://roivant.com/role/IncomeTaxesScheduleOfEffectiveIncomeTaxRateReconciliationDetail": {
       "order": 16.0,
       "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations",
       "weight": 1.0
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to research tax credit.",
        "label": "Effective Income Tax Rate Reconciliation, Tax Credit, Research, Percent",
        "negatedLabel": "R&amp;D tax credits"
       }
      }
     },
     "localname": "EffectiveIncomeTaxRateReconciliationTaxCreditsResearch",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://roivant.com/role/IncomeTaxesScheduleOfEffectiveIncomeTaxRateReconciliationDetail"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized": {
     "auth_ref": [
      "r415"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cost not yet recognized for nonvested award under share-based payment arrangement.",
        "label": "Share-based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Amount",
        "terseLabel": "Unrecognized compensation expense"
       }
      }
     },
     "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://roivant.com/role/ShareBasedCompensationAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1": {
     "auth_ref": [
      "r415"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted-average period over which cost not yet recognized is expected to be recognized for award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.",
        "label": "Share-based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Period for Recognition",
        "terseLabel": "Remaining weighted-average service period"
       }
      }
     },
     "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://roivant.com/role/ShareBasedCompensationAdditionalInformationDetail"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions": {
     "auth_ref": [
      "r415"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cost to be recognized for nonvested award under share-based payment arrangement. Excludes share and unit options.",
        "label": "Share-based Payment Arrangement, Nonvested Award, Excluding Option, Cost Not yet Recognized, Amount",
        "terseLabel": "Unrecognized compensation expense related to non-vested stock"
       }
      }
     },
     "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://roivant.com/role/ShareBasedCompensationAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions": {
     "auth_ref": [
      "r415"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cost to be recognized for option under share-based payment arrangement.",
        "label": "Share-based Payment Arrangement, Nonvested Award, Option, Cost Not yet Recognized, Amount",
        "terseLabel": "Unrecognized compensation expense related to non-vested stock"
       }
      }
     },
     "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://roivant.com/role/ShareBasedCompensationAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_EmployeeStockOptionMember": {
     "auth_ref": [
      "r412"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share-based payment arrangement granting right, subject to vesting and other restrictions, to purchase or sell certain number of shares at predetermined price for specified period of time.",
        "label": "Share-based Payment Arrangement, Option [Member]",
        "terseLabel": "Stock Option [Member]"
       }
      }
     },
     "localname": "EmployeeStockOptionMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://roivant.com/role/ShareBasedCompensationAdditionalInformationDetail",
      "http://roivant.com/role/ShareBasedCompensationScheduleOfFairValueAssumptionsDetail",
      "http://roivant.com/role/ShareBasedCompensationSummaryOfStockOptionActivityDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_EquipmentMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tangible personal property used to produce goods and services.",
        "label": "Equipment [Member]",
        "terseLabel": "Equipment [Member]"
       }
      }
     },
     "localname": "EquipmentMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://roivant.com/role/SummaryOfSignificantAccountingPoliciesScheduleOfEstimatedUsefulLivesDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_EquityAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Equity [Abstract]"
       }
      }
     },
     "localname": "EquityAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_EquityComponentDomain": {
     "auth_ref": [
      "r0",
      "r95",
      "r96",
      "r97",
      "r152",
      "r153",
      "r154",
      "r156",
      "r163",
      "r166",
      "r185",
      "r243",
      "r338",
      "r347",
      "r418",
      "r419",
      "r420",
      "r450",
      "r451",
      "r504",
      "r525",
      "r526",
      "r527",
      "r528",
      "r529",
      "r531",
      "r663",
      "r664",
      "r665",
      "r734"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Components of equity are the parts of the total Equity balance including that which is allocated to common, preferred, treasury stock, retained earnings, etc.",
        "label": "Equity Component [Domain]",
        "terseLabel": "Equity Component [Domain]"
       }
      }
     },
     "localname": "EquityComponentDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://roivant.com/role/CondensedConsolidatedStatementsOfShareholdersEquityAndRedeemableNoncontrollingInterest",
      "http://roivant.com/role/ShareholdersEquityAndRedeemableNonControllingInterestAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_EquityMethodInvestmentOwnershipPercentage": {
     "auth_ref": [
      "r239"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The percentage of ownership of common stock or equity participation in the investee accounted for under the equity method of accounting.",
        "label": "Equity Method Investment, Ownership Percentage",
        "terseLabel": "Equity Method Investment, Ownership Percentage",
        "verboseLabel": "Equity method investment ownership percentage"
       }
      }
     },
     "localname": "EquityMethodInvestmentOwnershipPercentage",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://roivant.com/role/InvestmentsAdditionalInformationDetail",
      "http://roivant.com/role/SubsequentEventsAdditionalInformationDetail"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_EquityMethodInvestmentUnderlyingEquityInNetAssets": {
     "auth_ref": [
      "r241"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "This item represents the entity's ownership percentage in the investee multiplied by the investee's total equity.",
        "label": "Equity Method Investment, Underlying Equity in Net Assets",
        "terseLabel": "Equity investment"
       }
      }
     },
     "localname": "EquityMethodInvestmentUnderlyingEquityInNetAssets",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://roivant.com/role/AssetAcquisitionsAndLicenseAgreementsAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_EquityMethodInvestments": {
     "auth_ref": [
      "r57",
      "r205",
      "r238"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "This item represents the carrying amount on the entity's balance sheet of its investment in common stock of an equity method investee. This is not an indicator of the fair value of the investment, rather it is the initial cost adjusted for the entity's share of earnings and losses of the investee, adjusted for any distributions (dividends) and other than temporary impairment (OTTI) losses recognized.",
        "label": "Equity Method Investments",
        "terseLabel": "Equity Method Investments"
       }
      }
     },
     "localname": "EquityMethodInvestments",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://roivant.com/role/SubsequentEventsAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_EquityMethodInvestmentsFairValueDisclosure": {
     "auth_ref": [
      "r237"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fair value portion of investments accounted under the equity method.",
        "label": "Equity Method Investments, Fair Value Disclosure",
        "terseLabel": "Fair value of noncontrolling interests"
       }
      }
     },
     "localname": "EquityMethodInvestmentsFairValueDisclosure",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://roivant.com/role/AssetAcquisitionsAndLicenseAgreementsAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_EscrowDeposit": {
     "auth_ref": [
      "r623",
      "r697"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The designation of funds furnished by a borrower to a lender to assure future payments of the borrower's real estate taxes and insurance obligations with respect to a mortgaged property. Escrow deposits may be made for a variety of other purposes such as earnest money and contingent payments. This element excludes replacement reserves which are an escrow separately provided for within the US GAAP taxonomy.",
        "label": "Escrow Deposit",
        "terseLabel": "Escrow amount",
        "verboseLabel": "Escrowed deposit"
       }
      }
     },
     "localname": "EscrowDeposit",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://roivant.com/role/SumitomoTransactionAgreementAdditionalInformationDetail",
      "http://roivant.com/role/SummaryOfSignificantAccountingPoliciesAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Abstract]"
       }
      }
     },
     "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]",
        "terseLabel": "Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]"
       }
      }
     },
     "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://roivant.com/role/FairValueMeasurementsScheduleOfAssetsAndLiabilitiesMeasuredAtFairValueOnARecurringBasisDetail",
      "http://roivant.com/role/FairValueMeasurementsScheduleOfFairValueOfUnobservableInputRelatedToOptionsToAcquireUnderSumitomoTransactionAgreementDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable": {
     "auth_ref": [
      "r507",
      "r508",
      "r509",
      "r517"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about asset and liability measured at fair value on recurring and nonrecurring basis.",
        "label": "Fair Value, Recurring and Nonrecurring [Table]",
        "terseLabel": "Fair Value, Recurring and Nonrecurring [Table]"
       }
      }
     },
     "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://roivant.com/role/FairValueMeasurementsScheduleOfAssetsAndLiabilitiesMeasuredAtFairValueOnARecurringBasisDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable": {
     "auth_ref": [
      "r510"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about input and valuation technique used to measure fair value and change in valuation approach and technique for each separate class of asset and liability measured on recurring and nonrecurring basis.",
        "label": "Fair Value Measurement Inputs and Valuation Techniques [Table]",
        "terseLabel": "Fair Value Measurement Inputs and Valuation Techniques [Table]"
       }
      }
     },
     "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://roivant.com/role/FairValueMeasurementsScheduleOfFairValueOfUnobservableInputRelatedToOptionsToAcquireUnderSumitomoTransactionAgreementDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock": {
     "auth_ref": [
      "r510"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of input and valuation technique used to measure fair value and change in valuation approach and technique for each separate class of asset and liability measured on recurring and nonrecurring basis.",
        "label": "Fair Value Measurement Inputs and Valuation Techniques [Table Text Block]",
        "terseLabel": "Schedule of Fair Value of Unobservable Input Related To Options to Acquire Under Sumitomo Transaction Agreement"
       }
      }
     },
     "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://roivant.com/role/FairValueMeasurementsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain": {
     "auth_ref": [
      "r513"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Class of asset.",
        "label": "Asset Class [Domain]",
        "terseLabel": "Asset Class [Domain]"
       }
      }
     },
     "localname": "FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://roivant.com/role/FairValueMeasurementsScheduleOfAssetsAndLiabilitiesMeasuredAtFairValueOnARecurringBasisDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueByAssetClassAxis": {
     "auth_ref": [
      "r507",
      "r517"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by class of asset.",
        "label": "Asset Class [Axis]",
        "terseLabel": "Asset Class [Axis]"
       }
      }
     },
     "localname": "FairValueByAssetClassAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://roivant.com/role/FairValueMeasurementsScheduleOfAssetsAndLiabilitiesMeasuredAtFairValueOnARecurringBasisDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueByFairValueHierarchyLevelAxis": {
     "auth_ref": [
      "r294",
      "r307",
      "r308",
      "r367",
      "r368",
      "r369",
      "r370",
      "r371",
      "r372",
      "r373",
      "r375",
      "r508",
      "r573",
      "r574",
      "r575"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by level within fair value hierarchy and fair value measured at net asset value per share as practical expedient.",
        "label": "Fair Value Hierarchy and NAV [Axis]",
        "terseLabel": "Fair Value Hierarchy and NAV [Axis]"
       }
      }
     },
     "localname": "FairValueByFairValueHierarchyLevelAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://roivant.com/role/FairValueMeasurementsChangeInTheFairValueOfTheDerivativeWarrantLiabilitiesDetail",
      "http://roivant.com/role/FairValueMeasurementsScheduleOfAssetsAndLiabilitiesMeasuredAtFairValueOnARecurringBasisDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueByMeasurementFrequencyAxis": {
     "auth_ref": [
      "r507",
      "r508",
      "r511",
      "r512",
      "r518"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by measurement frequency.",
        "label": "Measurement Frequency [Axis]",
        "terseLabel": "Measurement Frequency [Axis]"
       }
      }
     },
     "localname": "FairValueByMeasurementFrequencyAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://roivant.com/role/FairValueMeasurementsScheduleOfAssetsAndLiabilitiesMeasuredAtFairValueOnARecurringBasisDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueDisclosuresAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair Value Disclosures [Abstract]"
       }
      }
     },
     "localname": "FairValueDisclosuresAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueDisclosuresTextBlock": {
     "auth_ref": [
      "r516"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for the fair value of financial instruments (as defined), including financial assets and financial liabilities (collectively, as defined), and the measurements of those instruments as well as disclosures related to the fair value of non-financial assets and liabilities. Such disclosures about the financial instruments, assets, and liabilities would include: (1) the fair value of the required items together with their carrying amounts (as appropriate); (2) for items for which it is not practicable to estimate fair value, disclosure would include: (a) information pertinent to estimating fair value (including, carrying amount, effective interest rate, and maturity, and (b) the reasons why it is not practicable to estimate fair value; (3) significant concentrations of credit risk including: (a) information about the activity, region, or economic characteristics identifying a concentration, (b) the maximum amount of loss the entity is exposed to based on the gross fair value of the related item, (c) policy for requiring collateral or other security and information as to accessing such collateral or security, and (d) the nature and brief description of such collateral or security; (4) quantitative information about market risks and how such risks are managed; (5) for items measured on both a recurring and nonrecurring basis information regarding the inputs used to develop the fair value measurement; and (6) for items presented in the financial statement for which fair value measurement is elected: (a) information necessary to understand the reasons for the election, (b) discussion of the effect of fair value changes on earnings, (c) a description of [similar groups] items for which the election is made and the relation thereof to the balance sheet, the aggregate carrying value of items included in the balance sheet that are not eligible for the election; (7) all other required (as defined) and desired information.",
        "label": "Fair Value Disclosures [Text Block]",
        "terseLabel": "Fair Value Measurements"
       }
      }
     },
     "localname": "FairValueDisclosuresTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://roivant.com/role/FairValueMeasurements"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_FairValueInputsLevel1Member": {
     "auth_ref": [
      "r294",
      "r367",
      "r368",
      "r373",
      "r375",
      "r508",
      "r573"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Quoted prices in active markets for identical assets or liabilities that the reporting entity can access at the measurement date.",
        "label": "Fair Value, Inputs, Level 1 [Member]",
        "terseLabel": "Fair Value, Inputs, Level 1 [Member]"
       }
      }
     },
     "localname": "FairValueInputsLevel1Member",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://roivant.com/role/FairValueMeasurementsScheduleOfAssetsAndLiabilitiesMeasuredAtFairValueOnARecurringBasisDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueInputsLevel2Member": {
     "auth_ref": [
      "r294",
      "r307",
      "r308",
      "r367",
      "r368",
      "r373",
      "r375",
      "r508",
      "r574"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Inputs other than quoted prices included within level 1 that are observable for an asset or liability, either directly or indirectly, including, but not limited to, quoted prices for similar assets or liabilities in active markets, or quoted prices for identical or similar assets or liabilities in inactive markets.",
        "label": "Fair Value, Inputs, Level 2 [Member]",
        "terseLabel": "Fair Value, Inputs, Level 2 [Member]"
       }
      }
     },
     "localname": "FairValueInputsLevel2Member",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://roivant.com/role/FairValueMeasurementsScheduleOfAssetsAndLiabilitiesMeasuredAtFairValueOnARecurringBasisDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueInputsLevel3Member": {
     "auth_ref": [
      "r294",
      "r307",
      "r308",
      "r367",
      "r368",
      "r369",
      "r370",
      "r371",
      "r372",
      "r373",
      "r375",
      "r508",
      "r575"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing.",
        "label": "Fair Value, Inputs, Level 3 [Member]",
        "terseLabel": "Fair Value, Inputs, Level 3 [Member]"
       }
      }
     },
     "localname": "FairValueInputsLevel3Member",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://roivant.com/role/FairValueMeasurementsChangeInTheFairValueOfTheDerivativeWarrantLiabilitiesDetail",
      "http://roivant.com/role/FairValueMeasurementsScheduleOfAssetsAndLiabilitiesMeasuredAtFairValueOnARecurringBasisDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock": {
     "auth_ref": [
      "r513",
      "r517"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the fair value measurement of liabilities using significant unobservable inputs (Level 3), a reconciliation of the beginning and ending balances, separately presenting changes attributable to the following: (1) total gains or losses for the period (realized and unrealized), segregating those gains or losses included in earnings (or changes in net assets), and gains or losses recognized in other comprehensive income (loss) and a description of where those gains or losses included in earnings (or changes in net assets) are reported in the statement of income (or activities); (2) purchases, sales, issues, and settlements (each type disclosed separately); and (3) transfers in and transfers out of Level 3 (for example, transfers due to changes in the observability of significant inputs) by class of liability.",
        "label": "Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Table Text Block]",
        "terseLabel": "Schedule of change in the fair value of the derivative warrant liabilities"
       }
      }
     },
     "localname": "FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://roivant.com/role/FairValueMeasurementsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_FairValueMeasurementFrequencyDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Measurement frequency.",
        "label": "Measurement Frequency [Domain]",
        "terseLabel": "Measurement Frequency [Domain]"
       }
      }
     },
     "localname": "FairValueMeasurementFrequencyDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://roivant.com/role/FairValueMeasurementsScheduleOfAssetsAndLiabilitiesMeasuredAtFairValueOnARecurringBasisDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueMeasurementPolicyPolicyTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for fair value measurements of financial and non-financial assets, liabilities and instruments classified in shareholders' equity. Disclosures include, but are not limited to, how an entity that manages a group of financial assets and liabilities on the basis of its net exposure measures the fair value of those assets and liabilities.",
        "label": "Fair Value Measurement, Policy [Policy Text Block]",
        "terseLabel": "Fair Value Measurements"
       }
      }
     },
     "localname": "FairValueMeasurementPolicyPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://roivant.com/role/SummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings": {
     "auth_ref": [
      "r514"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of gain (loss) recognized in income from liability measured at fair value on recurring basis using unobservable input (level 3).",
        "label": "Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Gain (Loss) Included in Earnings",
        "verboseLabel": "Changes in fair value of debt and liability instruments, included in net loss"
       }
      }
     },
     "localname": "FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://roivant.com/role/FairValueMeasurementsChangeInTheFairValueOfTheDerivativeWarrantLiabilitiesDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements": {
     "auth_ref": [
      "r515"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of settlements of financial instrument classified as a liability measured using unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing.",
        "label": "Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Settlements",
        "terseLabel": "Termination of DSP Options"
       }
      }
     },
     "localname": "FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://roivant.com/role/FairValueMeasurementsChangeInTheFairValueOfTheDerivativeWarrantLiabilitiesDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue": {
     "auth_ref": [
      "r513"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fair value of financial instrument classified as a liability measured using unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing.",
        "label": "Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability Value",
        "periodEndLabel": "Balance at end of period",
        "periodStartLabel": "Balance at beginning of period"
       }
      }
     },
     "localname": "FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://roivant.com/role/FairValueMeasurementsChangeInTheFairValueOfTheDerivativeWarrantLiabilitiesDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FairValueMeasurementsFairValueHierarchyDomain": {
     "auth_ref": [
      "r294",
      "r307",
      "r308",
      "r367",
      "r368",
      "r369",
      "r370",
      "r371",
      "r372",
      "r373",
      "r375",
      "r573",
      "r574",
      "r575"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Categories used to prioritize the inputs to valuation techniques to measure fair value.",
        "label": "Fair Value Hierarchy and NAV [Domain]",
        "terseLabel": "Fair Value Hierarchy and NAV [Domain]"
       }
      }
     },
     "localname": "FairValueMeasurementsFairValueHierarchyDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://roivant.com/role/FairValueMeasurementsChangeInTheFairValueOfTheDerivativeWarrantLiabilitiesDetail",
      "http://roivant.com/role/FairValueMeasurementsScheduleOfAssetsAndLiabilitiesMeasuredAtFairValueOnARecurringBasisDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueMeasurementsRecurringMember": {
     "auth_ref": [
      "r516",
      "r518"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Frequent fair value measurement. Includes, but is not limited to, fair value adjustment for impairment of asset, liability or equity, frequently measured at fair value.",
        "label": "Fair Value, Recurring [Member]",
        "terseLabel": "Fair Value, Recurring [Member]"
       }
      }
     },
     "localname": "FairValueMeasurementsRecurringMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://roivant.com/role/FairValueMeasurementsScheduleOfAssetsAndLiabilitiesMeasuredAtFairValueOnARecurringBasisDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FinancialInstrumentAxis": {
     "auth_ref": [
      "r232",
      "r233",
      "r234",
      "r235",
      "r236",
      "r247",
      "r248",
      "r249",
      "r250",
      "r251",
      "r252",
      "r253",
      "r254",
      "r255",
      "r302",
      "r336",
      "r502",
      "r570",
      "r571",
      "r572",
      "r573",
      "r574",
      "r575",
      "r576",
      "r577",
      "r578",
      "r579",
      "r580",
      "r581",
      "r582",
      "r583",
      "r584",
      "r585",
      "r586",
      "r587",
      "r588",
      "r589",
      "r590",
      "r591",
      "r592",
      "r593",
      "r594",
      "r595",
      "r596",
      "r597",
      "r598",
      "r599",
      "r714",
      "r715",
      "r716",
      "r717",
      "r718",
      "r719",
      "r720"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of financial instrument.",
        "label": "Financial Instrument [Axis]"
       }
      }
     },
     "localname": "FinancialInstrumentAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://roivant.com/role/LongTermDebtAndLoanCommitmentAdditionalInformationDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock": {
     "auth_ref": [
      "r533"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for (1) transactions denominated in a currency other than the reporting enterprise's functional currency, (2) translating foreign currency financial statements that are incorporated into the financial statements of the reporting enterprise by consolidation, combination, or the equity method of accounting, and (3) remeasurement of the financial statements of a foreign reporting enterprise in a hyperinflationary economy.",
        "label": "Foreign Currency Transactions and Translations Policy [Policy Text Block]",
        "terseLabel": "Foreign Currency"
       }
      }
     },
     "localname": "ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://roivant.com/role/SummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_FurnitureAndFixturesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Equipment commonly used in offices and stores that have no permanent connection to the structure of a building or utilities. Examples include, but are not limited to, desks, chairs, tables, and bookcases.",
        "label": "Furniture and Fixtures [Member]",
        "terseLabel": "Furniture and Fixtures [Member]"
       }
      }
     },
     "localname": "FurnitureAndFixturesMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://roivant.com/role/SummaryOfSignificantAccountingPoliciesScheduleOfEstimatedUsefulLivesDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_GainLossOnInvestments": {
     "auth_ref": [
      "r116",
      "r133",
      "r231"
     ],
     "calculation": {
      "http://roivant.com/role/CondensedConsolidatedStatementsOfCashFlows": {
       "order": 4.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      },
      "http://roivant.com/role/CondensedConsolidatedStatementsOfOperations": {
       "order": 7.0,
       "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of realized and unrealized gain (loss) on investment.",
        "label": "Gain (Loss) on Investments",
        "negatedLabel": "Change in fair value of investments",
        "terseLabel": "Gain (loss) on remeasurement of investment"
       }
      }
     },
     "localname": "GainLossOnInvestments",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://roivant.com/role/AssetAcquisitionsAndLicenseAgreementsAdditionalInformationDetail",
      "http://roivant.com/role/CondensedConsolidatedStatementsOfCashFlows",
      "http://roivant.com/role/CondensedConsolidatedStatementsOfOperations"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_GainLossOnSaleOfBusiness": {
     "auth_ref": [
      "r133",
      "r493"
     ],
     "calculation": {
      "http://roivant.com/role/CondensedConsolidatedStatementsOfCashFlows": {
       "order": 15.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of gain (loss) from sale and disposal of integrated set of activities and assets capable of being conducted and managed for purpose of providing return in form of dividend, lower cost, or other economic benefit to investor, owner, member and participant.",
        "label": "Gain (Loss) on Disposition of Business",
        "negatedLabel": "Gain on sale of business"
       }
      }
     },
     "localname": "GainLossOnSaleOfBusiness",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://roivant.com/role/CondensedConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_GainOrLossOnSaleOfStockInSubsidiary": {
     "auth_ref": [
      "r109",
      "r110",
      "r133",
      "r626",
      "r656"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of gain (loss) on sale or disposal of equity in securities of subsidiaries.",
        "label": "Gain (Loss) on Disposition of Stock in Subsidiary",
        "terseLabel": "Gain (loss) on sale of stock transactions",
        "verboseLabel": "Sale of interests in subsidiaries"
       }
      }
     },
     "localname": "GainOrLossOnSaleOfStockInSubsidiary",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://roivant.com/role/CondensedConsolidatedStatementsOfShareholdersEquityAndRedeemableNoncontrollingInterest",
      "http://roivant.com/role/SumitomoTransactionAgreementAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_GeneralAndAdministrativeExpense": {
     "auth_ref": [
      "r115"
     ],
     "calculation": {
      "http://roivant.com/role/CondensedConsolidatedStatementsOfOperations": {
       "order": 5.0,
       "parentTag": "us-gaap_OperatingExpenses",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line.",
        "label": "General and Administrative Expense",
        "terseLabel": "General and administrative"
       }
      }
     },
     "localname": "GeneralAndAdministrativeExpense",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://roivant.com/role/CondensedConsolidatedStatementsOfOperations"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_GeneralAndAdministrativeExpenseMember": {
     "auth_ref": [
      "r108"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Primary financial statement caption encompassing general and administrative expense.",
        "label": "General and Administrative Expense [Member]",
        "terseLabel": "G&amp;A Expenses [Member]"
       }
      }
     },
     "localname": "GeneralAndAdministrativeExpenseMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://roivant.com/role/ShareBasedCompensationSummaryOfShareBasedCompensationExpenseDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_IncomeAmountsAttributableToReportingEntityDisclosuresAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Income Amounts Attributable to Parent, Disclosures [Abstract]",
        "terseLabel": "Amounts attributable to Roivant Sciences Ltd.:"
       }
      }
     },
     "localname": "IncomeAmountsAttributableToReportingEntityDisclosuresAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://roivant.com/role/CondensedConsolidatedStatementsOfOperations"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncomeLossFromContinuingOperations": {
     "auth_ref": [
      "r111",
      "r134",
      "r157",
      "r158",
      "r160",
      "r161",
      "r175",
      "r178",
      "r482"
     ],
     "calculation": {
      "http://roivant.com/role/CondensedConsolidatedStatementsOfOperations": {
       "order": 18.0,
       "parentTag": "us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after tax of income (loss) from continuing operations attributable to the parent.",
        "label": "Income (Loss) from Continuing Operations, Net of Tax, Attributable to Parent",
        "negatedLabel": "Loss from continuing operations, net of tax",
        "negatedTerseLabel": "Loss from continuing operations, net of tax, attributable to Roivant Sciences Ltd."
       }
      }
     },
     "localname": "IncomeLossFromContinuingOperations",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://roivant.com/role/CondensedConsolidatedStatementsOfOperations",
      "http://roivant.com/role/NetLossPerCommonShareSummaryOfBasicAndDilutedNetIncomePerShareOfCommonStockDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncomeLossFromContinuingOperationsAttributableToNoncontrollingEntity": {
     "auth_ref": [
      "r480",
      "r483"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after tax of income (loss) from continuing operations attributable to the noncontrolling interest.",
        "label": "Income (Loss) from Continuing Operations, Net of Tax, Attributable to Noncontrolling Interest",
        "terseLabel": "Net loss from continuing operations, net of tax, attributable to noncontrolling interest"
       }
      }
     },
     "localname": "IncomeLossFromContinuingOperationsAttributableToNoncontrollingEntity",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://roivant.com/role/NetLossPerCommonShareSummaryOfBasicAndDilutedNetIncomePerShareOfCommonStockDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest": {
     "auth_ref": [
      "r100",
      "r204",
      "r207",
      "r210",
      "r213",
      "r215",
      "r615",
      "r627",
      "r634",
      "r658"
     ],
     "calculation": {
      "http://roivant.com/role/CondensedConsolidatedStatementsOfOperations": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of income (loss) from continuing operations, including income (loss) from equity method investments, before deduction of income tax expense (benefit), and income (loss) attributable to noncontrolling interest.",
        "label": "Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest",
        "totalLabel": "Loss before income taxes"
       }
      }
     },
     "localname": "IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://roivant.com/role/CondensedConsolidatedStatementsOfOperations"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments": {
     "auth_ref": [
      "r204",
      "r207",
      "r210",
      "r213",
      "r215"
     ],
     "calculation": {
      "http://roivant.com/role/CondensedConsolidatedStatementsOfOperations": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of income (loss) from continuing operations before deduction of income tax expense (benefit) and income (loss) attributable to noncontrolling interest, and addition of income (loss) from equity method investments.",
        "label": "Income (Loss) from Continuing Operations before Equity Method Investments, Income Taxes, Noncontrolling Interest",
        "terseLabel": "Total loss before income taxes",
        "totalLabel": "Loss from continuing operations before income taxes"
       }
      }
     },
     "localname": "IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://roivant.com/role/CondensedConsolidatedStatementsOfOperations",
      "http://roivant.com/role/IncomeTaxesScheduleOfLossBeforeIncomeTaxesByGeographicRegionDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestmentsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Income (Loss) from Continuing Operations before Equity Method Investments, Income Taxes, Noncontrolling Interest [Abstract]",
        "terseLabel": "Loss before income taxes:"
       }
      }
     },
     "localname": "IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestmentsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://roivant.com/role/IncomeTaxesScheduleOfLossBeforeIncomeTaxesByGeographicRegionDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest": {
     "auth_ref": [
      "r146",
      "r155",
      "r204",
      "r207",
      "r210",
      "r213",
      "r215",
      "r242",
      "r274",
      "r275",
      "r276",
      "r278",
      "r279",
      "r280",
      "r281",
      "r282",
      "r283",
      "r284",
      "r483",
      "r506",
      "r520"
     ],
     "calculation": {
      "http://roivant.com/role/CondensedConsolidatedStatementsOfOperations": {
       "order": 15.0,
       "parentTag": "us-gaap_ProfitLoss",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after tax of income (loss) from continuing operations including portion attributable to the noncontrolling interest.",
        "label": "Income (Loss) from Continuing Operations, Net of Tax, Including Portion Attributable to Noncontrolling Interest",
        "totalLabel": "Loss from continuing operations, net of tax",
        "verboseLabel": "Loss from continuing operations, net of tax"
       }
      }
     },
     "localname": "IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://roivant.com/role/CondensedConsolidatedStatementsOfOperations",
      "http://roivant.com/role/NetLossPerCommonShareSummaryOfBasicAndDilutedNetIncomePerShareOfCommonStockDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncomeLossFromContinuingOperationsPerBasicAndDilutedShare": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of net income (loss) from continuing operations per each basic and diluted share of common stock or unit when the per share amount is the same for both basic and diluted shares.",
        "label": "Income (Loss) from Continuing Operations, Per Basic and Diluted Share",
        "terseLabel": "Basic and diluted loss from continuing operations"
       }
      }
     },
     "localname": "IncomeLossFromContinuingOperationsPerBasicAndDilutedShare",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://roivant.com/role/CondensedConsolidatedStatementsOfOperations"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTax": {
     "auth_ref": [
      "r4",
      "r5",
      "r6",
      "r7",
      "r10",
      "r21",
      "r24",
      "r461",
      "r650"
     ],
     "calculation": {
      "http://roivant.com/role/CondensedConsolidatedStatementsOfOperations": {
       "order": 17.0,
       "parentTag": "us-gaap_ProfitLoss",
       "weight": 1.0
      },
      "http://roivant.com/role/DiscontinuedOperationsSummaryOfDisposalGroupsIncludingDiscontinuedOperationsIncomeStatementDetail": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after tax of income (loss) from a discontinued operation including the portion attributable to the noncontrolling interest. Includes, but is not limited to, the income (loss) from operations during the phase-out period, gain (loss) on disposal, gain (loss) for reversal of write-down (write-down) to fair value, less cost to sell, and adjustments to a prior period gain (loss) on disposal.",
        "label": "Income (Loss) from Discontinued Operations, Net of Tax, Including Portion Attributable to Noncontrolling Interest",
        "terseLabel": "Income from discontinued operations, net of tax",
        "totalLabel": "Income from discontinued operations, net of tax"
       }
      }
     },
     "localname": "IncomeLossFromDiscontinuedOperationsNetOfTax",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://roivant.com/role/CondensedConsolidatedStatementsOfOperations",
      "http://roivant.com/role/DiscontinuedOperationsSummaryOfDisposalGroupsIncludingDiscontinuedOperationsIncomeStatementDetail",
      "http://roivant.com/role/NetLossPerCommonShareSummaryOfBasicAndDilutedNetIncomePerShareOfCommonStockDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToNoncontrollingInterest": {
     "auth_ref": [
      "r4",
      "r5",
      "r6",
      "r7",
      "r10",
      "r17",
      "r21",
      "r480",
      "r483"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after tax of income (loss) from a discontinued operation attributable to the noncontrolling interest. Includes, but is not limited to, the income (loss) from operations during the phase-out period, gain (loss) on disposal, gain (loss) for reversal of write-down (write-down) to fair value, less cost to sell, and adjustments to a prior period gain (loss) on disposal.",
        "label": "Income (Loss) from Discontinued Operations, Net of Tax, Attributable to Noncontrolling Interest",
        "terseLabel": "Net loss from discontinued operations, net of tax, attributable to noncontrolling interest"
       }
      }
     },
     "localname": "IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToNoncontrollingInterest",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://roivant.com/role/NetLossPerCommonShareSummaryOfBasicAndDilutedNetIncomePerShareOfCommonStockDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity": {
     "auth_ref": [
      "r4",
      "r5",
      "r6",
      "r7",
      "r10",
      "r17",
      "r21",
      "r483"
     ],
     "calculation": {
      "http://roivant.com/role/CondensedConsolidatedStatementsOfOperations": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after tax of income (loss) from a discontinued operation attributable to the parent. Includes, but is not limited to, the income (loss) from operations during the phase-out period, gain (loss) on disposal, gain (loss) for reversal of write-down (write-down) to fair value, less cost to sell, and adjustments to a prior period gain (loss) on disposal.",
        "label": "Income (Loss) from Discontinued Operations, Net of Tax, Attributable to Parent",
        "terseLabel": "Net income from discontinued operations, net of tax, attributable to Roivant Sciences Ltd.",
        "totalLabel": "Income from discontinued operations, net of tax"
       }
      }
     },
     "localname": "IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://roivant.com/role/CondensedConsolidatedStatementsOfOperations",
      "http://roivant.com/role/NetLossPerCommonShareSummaryOfBasicAndDilutedNetIncomePerShareOfCommonStockDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicAndDilutedShare": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Per basic and diluted share amount, after tax, of income (loss) from the day-to-day business activities of the discontinued operation and gain (loss) from the disposal of the discontinued operation, when the per share amount is the same.",
        "label": "Income (Loss) from Discontinued Operations and Disposal of Discontinued Operations, Net of Tax, Per Basic and Diluted Share",
        "terseLabel": "Basic and diluted income from discontinued operations"
       }
      }
     },
     "localname": "IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicAndDilutedShare",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://roivant.com/role/CondensedConsolidatedStatementsOfOperations"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_IncomeLossFromEquityMethodInvestments": {
     "auth_ref": [
      "r101",
      "r133",
      "r202",
      "r238",
      "r625",
      "r649"
     ],
     "calculation": {
      "http://roivant.com/role/CondensedConsolidatedStatementsOfCashFlows": {
       "order": 7.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      },
      "http://roivant.com/role/OtherIncomeExpenseNetSummaryOfOtherIncomeExpenseNetFromContinuingOperationsDetail": {
       "order": 1.0,
       "parentTag": "us-gaap_OtherOperatingIncomeExpenseNet",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of income (loss) for proportionate share of equity method investee's income (loss).",
        "label": "Income (Loss) from Equity Method Investments",
        "negatedLabel": "Loss from equity method investment"
       }
      }
     },
     "localname": "IncomeLossFromEquityMethodInvestments",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://roivant.com/role/CondensedConsolidatedStatementsOfCashFlows",
      "http://roivant.com/role/OtherIncomeExpenseNetSummaryOfOtherIncomeExpenseNetFromContinuingOperationsDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncomeStatementAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Income Statement [Abstract]"
       }
      }
     },
     "localname": "IncomeStatementAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncomeStatementLocationAxis": {
     "auth_ref": [
      "r261",
      "r265"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by location in the income statement.",
        "label": "Income Statement Location [Axis]",
        "terseLabel": "Income Statement Location [Axis]"
       }
      }
     },
     "localname": "IncomeStatementLocationAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://roivant.com/role/BalanceSheetComponentsScheduleOfAccruedExpensesDetail",
      "http://roivant.com/role/ShareBasedCompensationSummaryOfShareBasedCompensationExpenseDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncomeStatementLocationDomain": {
     "auth_ref": [
      "r265"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Location in the income statement.",
        "label": "Income Statement Location [Domain]",
        "terseLabel": "Income Statement Location [Domain]"
       }
      }
     },
     "localname": "IncomeStatementLocationDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://roivant.com/role/BalanceSheetComponentsScheduleOfAccruedExpensesDetail",
      "http://roivant.com/role/ShareBasedCompensationSummaryOfShareBasedCompensationExpenseDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_IncomeTaxAuthorityAxis": {
     "auth_ref": [
      "r435"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by tax jurisdiction.",
        "label": "Income Tax Authority [Axis]",
        "terseLabel": "Income Tax Authority [Axis]"
       }
      }
     },
     "localname": "IncomeTaxAuthorityAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://roivant.com/role/IncomeTaxesAdditionalInformationDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncomeTaxAuthorityDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Agency, division or body classification that levies income taxes, examines tax returns for compliance, or grants exemptions from or makes other decisions pertaining to income taxes.",
        "label": "Income Tax Authority [Domain]",
        "terseLabel": "Income Tax Authority [Domain]"
       }
      }
     },
     "localname": "IncomeTaxAuthorityDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://roivant.com/role/IncomeTaxesAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_IncomeTaxDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Income Tax Disclosure [Abstract]"
       }
      }
     },
     "localname": "IncomeTaxDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncomeTaxDisclosureTextBlock": {
     "auth_ref": [
      "r148",
      "r434",
      "r437",
      "r443",
      "r452",
      "r458",
      "r462",
      "r463",
      "r464"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for income taxes. Disclosures may include net deferred tax liability or asset recognized in an enterprise's statement of financial position, net change during the year in the total valuation allowance, approximate tax effect of each type of temporary difference and carryforward that gives rise to a significant portion of deferred tax liabilities and deferred tax assets, utilization of a tax carryback, and tax uncertainties information.",
        "label": "Income Tax Disclosure [Text Block]",
        "terseLabel": "Income Taxes"
       }
      }
     },
     "localname": "IncomeTaxDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://roivant.com/role/IncomeTaxes"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_IncomeTaxExpenseBenefit": {
     "auth_ref": [
      "r149",
      "r165",
      "r166",
      "r203",
      "r432",
      "r453",
      "r459",
      "r659"
     ],
     "calculation": {
      "http://roivant.com/role/CondensedConsolidatedStatementsOfOperations": {
       "order": 16.0,
       "parentTag": "us-gaap_IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest",
       "weight": -1.0
      },
      "http://roivant.com/role/IncomeTaxesScheduleOfEffectiveIncomeTaxRateReconciliationDetail": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.",
        "label": "Income Tax Expense (Benefit)",
        "terseLabel": "Income tax expense",
        "totalLabel": "Income tax provision"
       }
      }
     },
     "localname": "IncomeTaxExpenseBenefit",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://roivant.com/role/CondensedConsolidatedStatementsOfOperations",
      "http://roivant.com/role/IncomeTaxesScheduleComponentsOfIncomeTaxExpenseBenefitDetail",
      "http://roivant.com/role/IncomeTaxesScheduleOfEffectiveIncomeTaxRateReconciliationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncomeTaxExpenseBenefitContinuingOperationsIncomeTaxReconciliationAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Effective Income Tax Rate Reconciliation, Amount [Abstract]",
        "terseLabel": "Effective Income Tax Rate Reconciliation, Amount [Abstract]"
       }
      }
     },
     "localname": "IncomeTaxExpenseBenefitContinuingOperationsIncomeTaxReconciliationAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://roivant.com/role/IncomeTaxesScheduleOfEffectiveIncomeTaxRateReconciliationDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncomeTaxPolicyTextBlock": {
     "auth_ref": [
      "r94",
      "r430",
      "r431",
      "r437",
      "r438",
      "r442",
      "r449"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for income taxes, which may include its accounting policies for recognizing and measuring deferred tax assets and liabilities and related valuation allowances, recognizing investment tax credits, operating loss carryforwards, tax credit carryforwards, and other carryforwards, methodologies for determining its effective income tax rate and the characterization of interest and penalties in the financial statements.",
        "label": "Income Tax, Policy [Policy Text Block]",
        "terseLabel": "Income Taxes"
       }
      }
     },
     "localname": "IncomeTaxPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://roivant.com/role/SummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance": {
     "auth_ref": [
      "r433"
     ],
     "calculation": {
      "http://roivant.com/role/IncomeTaxesScheduleOfEffectiveIncomeTaxRateReconciliationDetail": {
       "order": 9.0,
       "parentTag": "us-gaap_IncomeTaxExpenseBenefit",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to increase (decrease) in the valuation allowance for deferred tax assets.",
        "label": "Effective Income Tax Rate Reconciliation, Change in Deferred Tax Assets Valuation Allowance, Amount",
        "terseLabel": "Valuation allowance"
       }
      }
     },
     "localname": "IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://roivant.com/role/IncomeTaxesScheduleOfEffectiveIncomeTaxRateReconciliationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncomeTaxReconciliationChangeInEnactedTaxRate": {
     "auth_ref": [
      "r429",
      "r433"
     ],
     "calculation": {
      "http://roivant.com/role/IncomeTaxesScheduleOfEffectiveIncomeTaxRateReconciliationDetail": {
       "order": 8.0,
       "parentTag": "us-gaap_IncomeTaxExpenseBenefit",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations, attributable to increase (decrease) in the income tax rates.",
        "label": "Effective Income Tax Rate Reconciliation, Change in Enacted Tax Rate, Amount",
        "terseLabel": "Rate changes"
       }
      }
     },
     "localname": "IncomeTaxReconciliationChangeInEnactedTaxRate",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://roivant.com/role/IncomeTaxesScheduleOfEffectiveIncomeTaxRateReconciliationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncomeTaxReconciliationDispositionOfBusiness": {
     "auth_ref": [
      "r433"
     ],
     "calculation": {
      "http://roivant.com/role/IncomeTaxesScheduleOfEffectiveIncomeTaxRateReconciliationDetail": {
       "order": 5.0,
       "parentTag": "us-gaap_IncomeTaxExpenseBenefit",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to the disposition of a business not qualifying as a discontinued operation.",
        "label": "Effective Income Tax Rate Reconciliation, Disposition of Business, Amount",
        "terseLabel": "Nontaxable (loss) gain on deconsolidation of business"
       }
      }
     },
     "localname": "IncomeTaxReconciliationDispositionOfBusiness",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://roivant.com/role/IncomeTaxesScheduleOfEffectiveIncomeTaxRateReconciliationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncomeTaxReconciliationForeignIncomeTaxRateDifferential": {
     "auth_ref": [
      "r433"
     ],
     "calculation": {
      "http://roivant.com/role/IncomeTaxesScheduleOfEffectiveIncomeTaxRateReconciliationDetail": {
       "order": 2.0,
       "parentTag": "us-gaap_IncomeTaxExpenseBenefit",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to foreign income tax expense (benefit).",
        "label": "Effective Income Tax Rate Reconciliation, Foreign Income Tax Rate Differential, Amount",
        "terseLabel": "Foreign rate differential"
       }
      }
     },
     "localname": "IncomeTaxReconciliationForeignIncomeTaxRateDifferential",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://roivant.com/role/IncomeTaxesScheduleOfEffectiveIncomeTaxRateReconciliationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate": {
     "auth_ref": [
      "r433"
     ],
     "calculation": {
      "http://roivant.com/role/IncomeTaxesScheduleOfEffectiveIncomeTaxRateReconciliationDetail": {
       "order": 1.0,
       "parentTag": "us-gaap_IncomeTaxExpenseBenefit",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of income tax expense or benefit for the period computed by applying the domestic federal statutory tax rates to pretax income from continuing operations.",
        "label": "Effective Income Tax Rate Reconciliation at Federal Statutory Income Tax Rate, Amount",
        "terseLabel": "Income tax benefit at Bermuda statutory rate"
       }
      }
     },
     "localname": "IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://roivant.com/role/IncomeTaxesScheduleOfEffectiveIncomeTaxRateReconciliationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncomeTaxReconciliationNondeductibleExpense": {
     "auth_ref": [
      "r433"
     ],
     "calculation": {
      "http://roivant.com/role/IncomeTaxesScheduleOfEffectiveIncomeTaxRateReconciliationDetail": {
       "order": 4.0,
       "parentTag": "us-gaap_IncomeTaxExpenseBenefit",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to nondeductible expenses.",
        "label": "Effective Income Tax Rate Reconciliation, Nondeductible Expense, Amount",
        "terseLabel": "Nondeductible changes in the fair value of investments and loss from equity method investment"
       }
      }
     },
     "localname": "IncomeTaxReconciliationNondeductibleExpense",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://roivant.com/role/IncomeTaxesScheduleOfEffectiveIncomeTaxRateReconciliationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncomeTaxReconciliationNondeductibleExpenseResearchAndDevelopment": {
     "auth_ref": [
      "r433"
     ],
     "calculation": {
      "http://roivant.com/role/IncomeTaxesScheduleOfEffectiveIncomeTaxRateReconciliationDetail": {
       "order": 3.0,
       "parentTag": "us-gaap_IncomeTaxExpenseBenefit",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to nondeductible research and development expense.",
        "label": "Effective Income Tax Rate Reconciliation, Nondeductible Expense, Research and Development, Amount",
        "terseLabel": "Permanent disallowed IPR&amp;D"
       }
      }
     },
     "localname": "IncomeTaxReconciliationNondeductibleExpenseResearchAndDevelopment",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://roivant.com/role/IncomeTaxesScheduleOfEffectiveIncomeTaxRateReconciliationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncomeTaxReconciliationOtherAdjustments": {
     "auth_ref": [
      "r433"
     ],
     "calculation": {
      "http://roivant.com/role/IncomeTaxesScheduleOfEffectiveIncomeTaxRateReconciliationDetail": {
       "order": 10.0,
       "parentTag": "us-gaap_IncomeTaxExpenseBenefit",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to other adjustments.",
        "label": "Effective Income Tax Rate Reconciliation, Other Adjustments, Amount",
        "terseLabel": "Other"
       }
      }
     },
     "localname": "IncomeTaxReconciliationOtherAdjustments",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://roivant.com/role/IncomeTaxesScheduleOfEffectiveIncomeTaxRateReconciliationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncomeTaxReconciliationTaxCreditsResearch": {
     "auth_ref": [
      "r433"
     ],
     "calculation": {
      "http://roivant.com/role/IncomeTaxesScheduleOfEffectiveIncomeTaxRateReconciliationDetail": {
       "order": 7.0,
       "parentTag": "us-gaap_IncomeTaxExpenseBenefit",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to research tax credit.",
        "label": "Effective Income Tax Rate Reconciliation, Tax Credit, Research, Amount",
        "negatedLabel": "R&amp;D tax credits"
       }
      }
     },
     "localname": "IncomeTaxReconciliationTaxCreditsResearch",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://roivant.com/role/IncomeTaxesScheduleOfEffectiveIncomeTaxRateReconciliationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncomeTaxesPaidNet": {
     "auth_ref": [
      "r137"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of cash paid during the current period to foreign, federal, state, and local authorities as taxes on income, net of any cash received during the current period as refunds for the overpayment of taxes.",
        "label": "Income Taxes Paid, Net",
        "terseLabel": "Income taxes paid"
       }
      }
     },
     "localname": "IncomeTaxesPaidNet",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://roivant.com/role/CondensedConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncomeTaxesReceivable": {
     "auth_ref": [
      "r76",
      "r623",
      "r648"
     ],
     "calculation": {
      "http://roivant.com/role/BalanceSheetComponentsScheduleOfOtherCurrentAssetsDetail": {
       "order": 5.0,
       "parentTag": "us-gaap_OtherAssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying amount due within one year of the balance sheet date (or one operating cycle, if longer) from tax authorities as of the balance sheet date representing refunds of overpayments or recoveries based on agreed-upon resolutions of disputes.",
        "label": "Income Taxes Receivable, Current",
        "terseLabel": "Income tax receivable"
       }
      }
     },
     "localname": "IncomeTaxesReceivable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://roivant.com/role/BalanceSheetComponentsScheduleOfOtherCurrentAssetsDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInAccountsPayableTrade": {
     "auth_ref": [
      "r132"
     ],
     "calculation": {
      "http://roivant.com/role/CondensedConsolidatedStatementsOfCashFlows": {
       "order": 10.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Change in recurring obligations of a business that arise from the acquisition of merchandise, materials, supplies and services used in the production and sale of goods and services.",
        "label": "Increase (Decrease) in Accounts Payable, Trade",
        "terseLabel": "Accounts payable"
       }
      }
     },
     "localname": "IncreaseDecreaseInAccountsPayableTrade",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://roivant.com/role/CondensedConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInAccruedLiabilities": {
     "auth_ref": [
      "r132"
     ],
     "calculation": {
      "http://roivant.com/role/CondensedConsolidatedStatementsOfCashFlows": {
       "order": 11.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The increase (decrease) during the reporting period in the aggregate amount of expenses incurred but not yet paid.",
        "label": "Increase (Decrease) in Accrued Liabilities",
        "terseLabel": "Accrued expenses"
       }
      }
     },
     "localname": "IncreaseDecreaseInAccruedLiabilities",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://roivant.com/role/CondensedConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInDeferredLiabilities": {
     "auth_ref": [
      "r132"
     ],
     "calculation": {
      "http://roivant.com/role/CondensedConsolidatedStatementsOfCashFlows": {
       "order": 14.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Change during the period in carrying value for all deferred liabilities due within one year or operating cycle.",
        "label": "Increase (Decrease) in Deferred Liabilities",
        "terseLabel": "Deferred consideration liability"
       }
      }
     },
     "localname": "IncreaseDecreaseInDeferredLiabilities",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://roivant.com/role/CondensedConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInOperatingCapitalAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Increase (Decrease) in Operating Capital [Abstract]",
        "terseLabel": "Changes in assets and liabilities, net of effects from acquisition and divestiture:"
       }
      }
     },
     "localname": "IncreaseDecreaseInOperatingCapitalAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://roivant.com/role/CondensedConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncreaseDecreaseInOtherOperatingCapitalNet": {
     "auth_ref": [
      "r132"
     ],
     "calculation": {
      "http://roivant.com/role/CondensedConsolidatedStatementsOfCashFlows": {
       "order": 13.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) in operating assets after deduction of operating liabilities classified as other.",
        "label": "Increase (Decrease) in Other Operating Assets and Liabilities, Net",
        "negatedLabel": "Other"
       }
      }
     },
     "localname": "IncreaseDecreaseInOtherOperatingCapitalNet",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://roivant.com/role/CondensedConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InterestExpense": {
     "auth_ref": [
      "r99",
      "r201",
      "r534",
      "r537",
      "r633"
     ],
     "calculation": {
      "http://roivant.com/role/OtherIncomeExpenseNetSummaryOfOtherIncomeExpenseNetFromContinuingOperationsDetail": {
       "order": 3.0,
       "parentTag": "us-gaap_OtherOperatingIncomeExpenseNet",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of the cost of borrowed funds accounted for as interest expense.",
        "label": "Interest Expense",
        "terseLabel": "Interest expense"
       }
      }
     },
     "localname": "InterestExpense",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://roivant.com/role/OtherIncomeExpenseNetSummaryOfOtherIncomeExpenseNetFromContinuingOperationsDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InterestIncomeOther": {
     "auth_ref": [],
     "calculation": {
      "http://roivant.com/role/OtherIncomeExpenseNetSummaryOfOtherIncomeExpenseNetFromContinuingOperationsDetail": {
       "order": 2.0,
       "parentTag": "us-gaap_OtherOperatingIncomeExpenseNet",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of interest income earned from interest bearing assets classified as other.",
        "label": "Interest Income, Other",
        "negatedLabel": "Interest income"
       }
      }
     },
     "localname": "InterestIncomeOther",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://roivant.com/role/OtherIncomeExpenseNetSummaryOfOtherIncomeExpenseNetFromContinuingOperationsDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InterestPaidNet": {
     "auth_ref": [
      "r127",
      "r130",
      "r137"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash paid for interest, excluding capitalized interest, classified as operating activity. Includes, but is not limited to, payment to settle zero-coupon bond for accreted interest of debt discount and debt instrument with insignificant coupon interest rate in relation to effective interest rate of borrowing attributable to accreted interest of debt discount.",
        "label": "Interest Paid, Excluding Capitalized Interest, Operating Activities",
        "terseLabel": "Interest paid"
       }
      }
     },
     "localname": "InterestPaidNet",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://roivant.com/role/CondensedConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InvestmentCompanyInternalRateOfReturnSinceInception": {
     "auth_ref": [
      "r673"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Rate since inception resulting in zero net present value of cash flows from investment.",
        "label": "Investment Company, Internal Rate of Return since Inception",
        "terseLabel": "Annualized return rate"
       }
      }
     },
     "localname": "InvestmentCompanyInternalRateOfReturnSinceInception",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://roivant.com/role/ShareholdersEquityAndRedeemableNonControllingInterestAdditionalInformationDetail"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_InvestmentPolicyTextBlock": {
     "auth_ref": [
      "r240",
      "r657"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for investment in financial asset.",
        "label": "Investment, Policy [Policy Text Block]",
        "terseLabel": "Investments"
       }
      }
     },
     "localname": "InvestmentPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://roivant.com/role/SummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_InvestmentTypeAxis": {
     "auth_ref": [
      "r676",
      "r677",
      "r678",
      "r679",
      "r680",
      "r681",
      "r682",
      "r683",
      "r684",
      "r686",
      "r687",
      "r688",
      "r689",
      "r690",
      "r691"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of investments.",
        "label": "Investment Type [Axis]",
        "terseLabel": "Investment Type [Axis]"
       }
      }
     },
     "localname": "InvestmentTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://roivant.com/role/InvestmentsAdditionalInformationDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_InvestmentTypeCategorizationMember": {
     "auth_ref": [
      "r676",
      "r677",
      "r678",
      "r679",
      "r680",
      "r681",
      "r682",
      "r683",
      "r684",
      "r686",
      "r687",
      "r688",
      "r689",
      "r690",
      "r691"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Asset obtained to generate income or appreciate in value.",
        "label": "Investments [Domain]",
        "terseLabel": "Investments [Domain]"
       }
      }
     },
     "localname": "InvestmentTypeCategorizationMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://roivant.com/role/InvestmentsAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_InvestmentsAllOtherInvestmentsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Investments, All Other Investments [Abstract]"
       }
      }
     },
     "localname": "InvestmentsAllOtherInvestmentsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_InvestmentsAndOtherNoncurrentAssetsTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire  disclosure for investments and other noncurrent assets.",
        "label": "Investments and Other Noncurrent Assets [Text Block]",
        "terseLabel": "Investments"
       }
      }
     },
     "localname": "InvestmentsAndOtherNoncurrentAssetsTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://roivant.com/role/Investments"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_InvestmentsFairValueDisclosure": {
     "auth_ref": [
      "r507"
     ],
     "calculation": {
      "http://roivant.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 8.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fair value portion of investment securities, including, but not limited to, marketable securities, derivative financial instruments, and investments accounted for under the equity method.",
        "label": "Investments, Fair Value Disclosure",
        "positiveLabel": "Investments measured at fair value",
        "terseLabel": "Aggregate fair value investment",
        "verboseLabel": "Investment"
       }
      }
     },
     "localname": "InvestmentsFairValueDisclosure",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://roivant.com/role/CondensedConsolidatedBalanceSheets",
      "http://roivant.com/role/FairValueMeasurementsScheduleOfAssetsAndLiabilitiesMeasuredAtFairValueOnARecurringBasisDetail",
      "http://roivant.com/role/InvestmentsAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InvestmentsInAffiliatesSubsidiariesAssociatesAndJointVenturesFairValueDisclosure": {
     "auth_ref": [
      "r507"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fair value portion of investments in an entity not consolidated. Includes, but is not limited to, investments in an entity that is affiliated with the reporting entity by means of direct or indirect ownership, an entity in which the reporting entity shares control of the entity with another party or group, an entity which the company has significant influence, but does not have control and subsidiaries that are not required to be consolidated and are accounted for using the equity or cost method.",
        "label": "Investments in Affiliates, Subsidiaries, Associates, and Joint Ventures, Fair Value Disclosure",
        "terseLabel": "Investment, fair value"
       }
      }
     },
     "localname": "InvestmentsInAffiliatesSubsidiariesAssociatesAndJointVenturesFairValueDisclosure",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://roivant.com/role/AssetAcquisitionsAndLicenseAgreementsAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LeaseCost": {
     "auth_ref": [
      "r551",
      "r553"
     ],
     "calculation": {
      "http://roivant.com/role/LeasesScheduleOfOperatingLeaseCostsDetail": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lease cost recognized by lessee for lease contract.",
        "label": "Lease, Cost",
        "totalLabel": "Total operating lease cost"
       }
      }
     },
     "localname": "LeaseCost",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://roivant.com/role/LeasesScheduleOfOperatingLeaseCostsDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LeaseCostAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Lease, Cost [Abstract]"
       }
      }
     },
     "localname": "LeaseCostAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_LeaseCostTableTextBlock": {
     "auth_ref": [
      "r551"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of lessee's lease cost. Includes, but is not limited to, interest expense for finance lease, amortization of right-of-use asset for finance lease, operating lease cost, short-term lease cost, variable lease cost and sublease income.",
        "label": "Lease, Cost [Table Text Block]",
        "terseLabel": "Schedule of Operating Lease Costs"
       }
      }
     },
     "localname": "LeaseCostTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://roivant.com/role/LeasesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_LeaseholdImprovementsMember": {
     "auth_ref": [
      "r259"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Additions or improvements to assets held under a lease arrangement.",
        "label": "Leasehold Improvements [Member]",
        "terseLabel": "Leasehold Improvements [Member]"
       }
      }
     },
     "localname": "LeaseholdImprovementsMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://roivant.com/role/SummaryOfSignificantAccountingPoliciesScheduleOfEstimatedUsefulLivesDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_LeasesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Leases [Abstract]"
       }
      }
     },
     "localname": "LeasesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_LeasesOfLesseeDisclosureTextBlock": {
     "auth_ref": [
      "r540"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for lessee entity's leasing arrangements including, but not limited to, all of the following: (a.) The basis on which contingent rental payments are determined, (b.) The existence and terms of renewal or purchase options and escalation clauses, (c.) Restrictions imposed by lease agreements, such as those concerning dividends, additional debt, and further leasing.",
        "label": "Leases of Lessee Disclosure [Text Block]",
        "terseLabel": "Summary of Operating Lease ROU Assets and Operating Lease Liabilities"
       }
      }
     },
     "localname": "LeasesOfLesseeDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://roivant.com/role/LeasesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock": {
     "auth_ref": [
      "r552"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of undiscounted cash flows of lessee's operating lease liability. Includes, but is not limited to, reconciliation of undiscounted cash flows to operating lease liability recognized in statement of financial position.",
        "label": "Lessee, Operating Lease, Liability, Maturity [Table Text Block]",
        "terseLabel": "Schedule of Maturities of Operating Lease Liabilities"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityMaturityTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://roivant.com/role/LeasesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue": {
     "auth_ref": [
      "r552"
     ],
     "calculation": {
      "http://roivant.com/role/LeasesScheduleOfMaturitiesOfOperatingLeaseLiabilitiesDetail": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease.",
        "label": "Lessee, Operating Lease, Liability, to be Paid",
        "totalLabel": "Total lease payments"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDue",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://roivant.com/role/LeasesScheduleOfMaturitiesOfOperatingLeaseLiabilitiesDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive": {
     "auth_ref": [
      "r552"
     ],
     "calculation": {
      "http://roivant.com/role/LeasesScheduleOfMaturitiesOfOperatingLeaseLiabilitiesDetail": {
       "order": 6.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease due after fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Lessee, Operating Lease, Liability, to be Paid, after Year Five",
        "terseLabel": "Thereafter"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://roivant.com/role/LeasesScheduleOfMaturitiesOfOperatingLeaseLiabilitiesDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths": {
     "auth_ref": [
      "r552"
     ],
     "calculation": {
      "http://roivant.com/role/LeasesScheduleOfMaturitiesOfOperatingLeaseLiabilitiesDetail": {
       "order": 1.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Lessee, Operating Lease, Liability, to be Paid, Year One",
        "terseLabel": "2022"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://roivant.com/role/LeasesScheduleOfMaturitiesOfOperatingLeaseLiabilitiesDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive": {
     "auth_ref": [
      "r552"
     ],
     "calculation": {
      "http://roivant.com/role/LeasesScheduleOfMaturitiesOfOperatingLeaseLiabilitiesDetail": {
       "order": 5.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Lessee, Operating Lease, Liability, to be Paid, Year Five",
        "terseLabel": "2026"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearFive",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://roivant.com/role/LeasesScheduleOfMaturitiesOfOperatingLeaseLiabilitiesDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour": {
     "auth_ref": [
      "r552"
     ],
     "calculation": {
      "http://roivant.com/role/LeasesScheduleOfMaturitiesOfOperatingLeaseLiabilitiesDetail": {
       "order": 4.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Lessee, Operating Lease, Liability, to be Paid, Year Four",
        "terseLabel": "2025"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearFour",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://roivant.com/role/LeasesScheduleOfMaturitiesOfOperatingLeaseLiabilitiesDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree": {
     "auth_ref": [
      "r552"
     ],
     "calculation": {
      "http://roivant.com/role/LeasesScheduleOfMaturitiesOfOperatingLeaseLiabilitiesDetail": {
       "order": 3.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Lessee, Operating Lease, Liability, to be Paid, Year Three",
        "terseLabel": "2024"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearThree",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://roivant.com/role/LeasesScheduleOfMaturitiesOfOperatingLeaseLiabilitiesDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo": {
     "auth_ref": [
      "r552"
     ],
     "calculation": {
      "http://roivant.com/role/LeasesScheduleOfMaturitiesOfOperatingLeaseLiabilitiesDetail": {
       "order": 2.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Lessee, Operating Lease, Liability, to be Paid, Year Two",
        "terseLabel": "2023"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearTwo",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://roivant.com/role/LeasesScheduleOfMaturitiesOfOperatingLeaseLiabilitiesDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeasesTextBlock": {
     "auth_ref": [
      "r554"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for operating leases of lessee. Includes, but is not limited to, description of operating lease and maturity analysis of operating lease liability.",
        "label": "Lessee, Operating Leases [Text Block]",
        "terseLabel": "Leases"
       }
      }
     },
     "localname": "LesseeOperatingLeasesTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://roivant.com/role/Leases"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_Liabilities": {
     "auth_ref": [
      "r64",
      "r146",
      "r209",
      "r242",
      "r274",
      "r275",
      "r276",
      "r278",
      "r279",
      "r280",
      "r281",
      "r282",
      "r283",
      "r284",
      "r487",
      "r494",
      "r495",
      "r520",
      "r564",
      "r565"
     ],
     "calculation": {
      "http://roivant.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 11.0,
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future.",
        "label": "Liabilities",
        "totalLabel": "Total liabilities"
       }
      }
     },
     "localname": "Liabilities",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://roivant.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LiabilitiesAndStockholdersEquity": {
     "auth_ref": [
      "r55",
      "r146",
      "r242",
      "r520",
      "r566",
      "r621",
      "r645"
     ],
     "calculation": {
      "http://roivant.com/role/CondensedConsolidatedBalanceSheets": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.",
        "label": "Liabilities and Equity",
        "totalLabel": "Total liabilities, redeemable noncontrolling interest and shareholders' equity"
       }
      }
     },
     "localname": "LiabilitiesAndStockholdersEquity",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://roivant.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LiabilitiesAndStockholdersEquityAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Liabilities and Equity [Abstract]",
        "verboseLabel": "Liabilities, Redeemable Noncontrolling Interest and Shareholders' Equity"
       }
      }
     },
     "localname": "LiabilitiesAndStockholdersEquityAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://roivant.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LiabilitiesCurrent": {
     "auth_ref": [
      "r66",
      "r146",
      "r242",
      "r274",
      "r275",
      "r276",
      "r278",
      "r279",
      "r280",
      "r281",
      "r282",
      "r283",
      "r284",
      "r487",
      "r494",
      "r495",
      "r520",
      "r564",
      "r565",
      "r566"
     ],
     "calculation": {
      "http://roivant.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 12.0,
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.",
        "label": "Liabilities, Current",
        "totalLabel": "Total current liabilities"
       }
      }
     },
     "localname": "LiabilitiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://roivant.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LiabilitiesCurrentAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Liabilities, Current [Abstract]",
        "terseLabel": "Current liabilities:"
       }
      }
     },
     "localname": "LiabilitiesCurrentAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://roivant.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LiabilitiesFairValueDisclosure": {
     "auth_ref": [
      "r507"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fair value of financial and nonfinancial obligations.",
        "label": "Financial and Nonfinancial Liabilities, Fair Value Disclosure",
        "terseLabel": "Total liabilities at fair value"
       }
      }
     },
     "localname": "LiabilitiesFairValueDisclosure",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://roivant.com/role/FairValueMeasurementsScheduleOfAssetsAndLiabilitiesMeasuredAtFairValueOnARecurringBasisDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LongTermDebt": {
     "auth_ref": [
      "r44",
      "r293",
      "r306",
      "r307",
      "r308",
      "r619",
      "r640"
     ],
     "calculation": {
      "http://roivant.com/role/LongTermDebtAndLoanCommitmentDetail": {
       "order": 2.0,
       "parentTag": "us-gaap_LongTermDebtNoncurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after unamortized (discount) premium and debt issuance costs, of long-term debt. Includes, but not limited to, notes payable, bonds payable, debentures, mortgage loans and commercial paper. Excludes capital lease obligations.",
        "label": "Long-term Debt",
        "terseLabel": "Long term debt",
        "totalLabel": "Total debt, net"
       }
      }
     },
     "localname": "LongTermDebt",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://roivant.com/role/AssetAcquisitionsAndLicenseAgreementsAdditionalInformationDetail",
      "http://roivant.com/role/LongTermDebtAndLoanCommitmentDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LongTermDebtAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Long-term Debt, Unclassified [Abstract]"
       }
      }
     },
     "localname": "LongTermDebtAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_LongTermDebtByMaturityAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Long-term Debt, Fiscal Year Maturity [Abstract]"
       }
      }
     },
     "localname": "LongTermDebtByMaturityAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_LongTermDebtCurrent": {
     "auth_ref": [
      "r63"
     ],
     "calculation": {
      "http://roivant.com/role/LongTermDebtAndLoanCommitmentDetail": {
       "order": 1.0,
       "parentTag": "us-gaap_LongTermDebtNoncurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after unamortized (discount) premium and debt issuance costs, of long-term debt, classified as current. Includes, but not limited to, notes payable, bonds payable, debentures, mortgage loans and commercial paper. Excludes capital lease obligations.",
        "label": "Long-term Debt, Current Maturities",
        "negatedLabel": "Less: current portion"
       }
      }
     },
     "localname": "LongTermDebtCurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://roivant.com/role/LongTermDebtAndLoanCommitmentDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LongTermDebtFairValue": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The fair value amount of long-term debt whether such amount is presented as a separate caption or as a parenthetical disclosure. Additionally, this element may be used in connection with the fair value disclosures required in the footnote disclosures to the financial statements. The element may be used in both the balance sheet and disclosure in the same submission.",
        "label": "Long-term Debt, Fair Value",
        "terseLabel": "Long term debt accounted under fair value option"
       }
      }
     },
     "localname": "LongTermDebtFairValue",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://roivant.com/role/CondensedConsolidatedBalanceSheetsParenthetical"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalAfterYearFive": {
     "auth_ref": [
      "r150",
      "r273",
      "r297"
     ],
     "calculation": {
      "http://roivant.com/role/LongTermDebtAndConvertibleNotesPayableScheduleOfCompanysAnnualPaymentsDetail": {
       "order": 6.0,
       "parentTag": "roiv_LongTermDebtExcludingDebtWithFairValueOption",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of long-term debt payable, sinking fund requirement, and other securities issued that are redeemable by holder at fixed or determinable price and date, maturing after fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Long-Term Debt, Maturity, after Year Five",
        "terseLabel": "Thereafter"
       }
      }
     },
     "localname": "LongTermDebtMaturitiesRepaymentsOfPrincipalAfterYearFive",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://roivant.com/role/LongTermDebtAndConvertibleNotesPayableScheduleOfCompanysAnnualPaymentsDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths": {
     "auth_ref": [
      "r150",
      "r273",
      "r297"
     ],
     "calculation": {
      "http://roivant.com/role/LongTermDebtAndConvertibleNotesPayableScheduleOfCompanysAnnualPaymentsDetail": {
       "order": 1.0,
       "parentTag": "roiv_LongTermDebtExcludingDebtWithFairValueOption",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of long-term debt payable, sinking fund requirement, and other securities issued that are redeemable by holder at fixed or determinable price and date, maturing in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Long-Term Debt, Maturity, Year One",
        "terseLabel": "2022"
       }
      }
     },
     "localname": "LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://roivant.com/role/LongTermDebtAndConvertibleNotesPayableScheduleOfCompanysAnnualPaymentsDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive": {
     "auth_ref": [
      "r150",
      "r273",
      "r297"
     ],
     "calculation": {
      "http://roivant.com/role/LongTermDebtAndConvertibleNotesPayableScheduleOfCompanysAnnualPaymentsDetail": {
       "order": 5.0,
       "parentTag": "roiv_LongTermDebtExcludingDebtWithFairValueOption",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of long-term debt payable, sinking fund requirement, and other securities issued that are redeemable by holder at fixed or determinable price and date, maturing in fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Long-Term Debt, Maturity, Year Five",
        "terseLabel": "2026"
       }
      }
     },
     "localname": "LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://roivant.com/role/LongTermDebtAndConvertibleNotesPayableScheduleOfCompanysAnnualPaymentsDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour": {
     "auth_ref": [
      "r150",
      "r273",
      "r297"
     ],
     "calculation": {
      "http://roivant.com/role/LongTermDebtAndConvertibleNotesPayableScheduleOfCompanysAnnualPaymentsDetail": {
       "order": 4.0,
       "parentTag": "roiv_LongTermDebtExcludingDebtWithFairValueOption",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of long-term debt payable, sinking fund requirement, and other securities issued that are redeemable by holder at fixed or determinable price and date, maturing in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Long-Term Debt, Maturity, Year Four",
        "terseLabel": "2025"
       }
      }
     },
     "localname": "LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://roivant.com/role/LongTermDebtAndConvertibleNotesPayableScheduleOfCompanysAnnualPaymentsDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree": {
     "auth_ref": [
      "r150",
      "r273",
      "r297"
     ],
     "calculation": {
      "http://roivant.com/role/LongTermDebtAndConvertibleNotesPayableScheduleOfCompanysAnnualPaymentsDetail": {
       "order": 3.0,
       "parentTag": "roiv_LongTermDebtExcludingDebtWithFairValueOption",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of long-term debt payable, sinking fund requirement, and other securities issued that are redeemable by holder at fixed or determinable price and date, maturing in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Long-Term Debt, Maturity, Year Three",
        "terseLabel": "2024"
       }
      }
     },
     "localname": "LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://roivant.com/role/LongTermDebtAndConvertibleNotesPayableScheduleOfCompanysAnnualPaymentsDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo": {
     "auth_ref": [
      "r150",
      "r273",
      "r297"
     ],
     "calculation": {
      "http://roivant.com/role/LongTermDebtAndConvertibleNotesPayableScheduleOfCompanysAnnualPaymentsDetail": {
       "order": 2.0,
       "parentTag": "roiv_LongTermDebtExcludingDebtWithFairValueOption",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of long-term debt payable, sinking fund requirement, and other securities issued that are redeemable by holder at fixed or determinable price and date, maturing in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Long-Term Debt, Maturity, Year Two",
        "terseLabel": "2023"
       }
      }
     },
     "localname": "LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://roivant.com/role/LongTermDebtAndConvertibleNotesPayableScheduleOfCompanysAnnualPaymentsDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LongTermDebtNoncurrent": {
     "auth_ref": [
      "r69"
     ],
     "calculation": {
      "http://roivant.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 19.0,
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0
      },
      "http://roivant.com/role/LongTermDebtAndLoanCommitmentDetail": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after unamortized (discount) premium and debt issuance costs of long-term debt classified as noncurrent and excluding amounts to be repaid within one year or the normal operating cycle, if longer. Includes, but not limited to, notes payable, bonds payable, debentures, mortgage loans and commercial paper. Excludes capital lease obligations.",
        "label": "Long-term Debt, Excluding Current Maturities",
        "terseLabel": "Long term debt",
        "totalLabel": "Total long term debt, net",
        "verboseLabel": "Long-term debt"
       }
      }
     },
     "localname": "LongTermDebtNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://roivant.com/role/CondensedConsolidatedBalanceSheets",
      "http://roivant.com/role/LongTermDebtAndLoanCommitmentDetail",
      "http://roivant.com/role/SubsequentEventsAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LongTermDebtPercentageBearingVariableInterestRate": {
     "auth_ref": [
      "r67"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The interest rate applicable to the portion of the carrying amount of long-term borrowings outstanding as of the balance sheet date, including current maturities, which accrues interest at a rate subject to change from time to time.",
        "label": "Long-term Debt, Percentage Bearing Variable Interest, Percentage Rate",
        "terseLabel": "Debt interest rate"
       }
      }
     },
     "localname": "LongTermDebtPercentageBearingVariableInterestRate",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://roivant.com/role/LongTermDebtAndLoanCommitmentAdditionalInformationDetail"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_LongTermDebtTextBlock": {
     "auth_ref": [
      "r311"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for long-term debt.",
        "label": "Long-term Debt [Text Block]",
        "terseLabel": "Long Term Debt"
       }
      }
     },
     "localname": "LongTermDebtTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://roivant.com/role/LongTermDebtAndLoanCommitment"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_LongTermInvestments": {
     "auth_ref": [
      "r57"
     ],
     "calculation": {
      "http://roivant.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 9.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The total amount of investments that are intended to be held for an extended period of time (longer than one operating cycle).",
        "label": "Long-term Investments",
        "terseLabel": "Carrying value of long-term investment",
        "verboseLabel": "Long-term investment"
       }
      }
     },
     "localname": "LongTermInvestments",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://roivant.com/role/CondensedConsolidatedBalanceSheets",
      "http://roivant.com/role/InvestmentsAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_MeasurementInputDiscountRateMember": {
     "auth_ref": [
      "r510"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Measurement input using interest rate to determine present value of future cash flows.",
        "label": "Measurement Input, Discount Rate [Member]",
        "terseLabel": "Measurement Input, Discount Rate [Member]"
       }
      }
     },
     "localname": "MeasurementInputDiscountRateMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://roivant.com/role/FairValueMeasurementsAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_MeasurementInputExpectedTermMember": {
     "auth_ref": [
      "r510"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Measurement input using period financial instrument is expected to be outstanding. Excludes maturity date.",
        "label": "Measurement Input, Expected Term [Member]",
        "terseLabel": "Measurement Input, Expected Term [Member]"
       }
      }
     },
     "localname": "MeasurementInputExpectedTermMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://roivant.com/role/FairValueMeasurementsScheduleOfFairValueOfUnobservableInputRelatedToOptionsToAcquireUnderSumitomoTransactionAgreementDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_MeasurementInputOptionVolatilityMember": {
     "auth_ref": [
      "r510"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Measurement input using rate at which price of option increases (decreases) for given set of returns.",
        "label": "Measurement Input, Option Volatility [Member]",
        "terseLabel": "Measurement Input, Option Volatility [Member]"
       }
      }
     },
     "localname": "MeasurementInputOptionVolatilityMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://roivant.com/role/FairValueMeasurementsScheduleOfFairValueOfUnobservableInputRelatedToOptionsToAcquireUnderSumitomoTransactionAgreementDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_MeasurementInputRiskFreeInterestRateMember": {
     "auth_ref": [
      "r510"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Measurement input using interest rate on instrument with zero risk of financial loss.",
        "label": "Measurement Input, Risk Free Interest Rate [Member]",
        "terseLabel": "Risk-free rate"
       }
      }
     },
     "localname": "MeasurementInputRiskFreeInterestRateMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://roivant.com/role/FairValueMeasurementsScheduleOfFairValueOfUnobservableInputRelatedToOptionsToAcquireUnderSumitomoTransactionAgreementDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_MeasurementInputTypeAxis": {
     "auth_ref": [
      "r510"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of measurement input used to determine value of asset and liability.",
        "label": "Measurement Input Type [Axis]",
        "terseLabel": "Measurement Input Type [Axis]"
       }
      }
     },
     "localname": "MeasurementInputTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://roivant.com/role/FairValueMeasurementsAdditionalInformationDetail",
      "http://roivant.com/role/FairValueMeasurementsScheduleOfFairValueOfUnobservableInputRelatedToOptionsToAcquireUnderSumitomoTransactionAgreementDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_MeasurementInputTypeDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Measurement input used to determine value of asset and liability.",
        "label": "Measurement Input Type [Domain]",
        "terseLabel": "Measurement Input Type [Domain]"
       }
      }
     },
     "localname": "MeasurementInputTypeDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://roivant.com/role/FairValueMeasurementsAdditionalInformationDetail",
      "http://roivant.com/role/FairValueMeasurementsScheduleOfFairValueOfUnobservableInputRelatedToOptionsToAcquireUnderSumitomoTransactionAgreementDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_MinorityInterest": {
     "auth_ref": [
      "r78",
      "r146",
      "r242",
      "r274",
      "r278",
      "r279",
      "r280",
      "r283",
      "r284",
      "r520",
      "r620",
      "r644"
     ],
     "calculation": {
      "http://roivant.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 31.0,
       "parentTag": "us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which is directly or indirectly attributable to that ownership interest in subsidiary equity which is not attributable to the parent (that is, noncontrolling interest, previously referred to as minority interest).",
        "label": "Stockholders' Equity Attributable to Noncontrolling Interest",
        "terseLabel": "Noncontrolling interests"
       }
      }
     },
     "localname": "MinorityInterest",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://roivant.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_MoneyMarketFundsMember": {
     "auth_ref": [
      "r367"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fund that invests in short-term money-market instruments, for example, but not limited to, commercial paper, banker's acceptances, repurchase agreements, government securities, certificates of deposit, and other highly liquid securities.",
        "label": "Money Market Funds [Member]",
        "terseLabel": "Money Market Funds [Member]"
       }
      }
     },
     "localname": "MoneyMarketFundsMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://roivant.com/role/FairValueMeasurementsScheduleOfAssetsAndLiabilitiesMeasuredAtFairValueOnARecurringBasisDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_NetCashProvidedByUsedInFinancingActivities": {
     "auth_ref": [
      "r129"
     ],
     "calculation": {
      "http://roivant.com/role/CondensedConsolidatedStatementsOfCashFlows": {
       "order": 27.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.",
        "label": "Net Cash Provided by (Used in) Financing Activities",
        "totalLabel": "Net cash provided by financing activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInFinancingActivities",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://roivant.com/role/CondensedConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Cash Provided by (Used in) Financing Activities [Abstract]",
        "terseLabel": "Cash flows from financing activities:"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInFinancingActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://roivant.com/role/CondensedConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NetCashProvidedByUsedInInvestingActivities": {
     "auth_ref": [
      "r129"
     ],
     "calculation": {
      "http://roivant.com/role/CondensedConsolidatedStatementsOfCashFlows": {
       "order": 18.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets.",
        "label": "Net Cash Provided by (Used in) Investing Activities",
        "totalLabel": "Net cash used in investing activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInInvestingActivities",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://roivant.com/role/CondensedConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Cash Provided by (Used in) Investing Activities [Abstract]",
        "terseLabel": "Cash flows from investing activities:"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInInvestingActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://roivant.com/role/CondensedConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NetCashProvidedByUsedInOperatingActivities": {
     "auth_ref": [
      "r129",
      "r131",
      "r134"
     ],
     "calculation": {
      "http://roivant.com/role/CondensedConsolidatedStatementsOfCashFlows": {
       "order": 1.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect",
       "weight": 1.0
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.",
        "label": "Net Cash Provided by (Used in) Operating Activities",
        "totalLabel": "Net cash used in operating activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInOperatingActivities",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://roivant.com/role/CondensedConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Cash Provided by (Used in) Operating Activities [Abstract]",
        "terseLabel": "Cash flows from operating activities:"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInOperatingActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://roivant.com/role/CondensedConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NetIncomeLoss": {
     "auth_ref": [
      "r24",
      "r88",
      "r91",
      "r97",
      "r103",
      "r134",
      "r146",
      "r155",
      "r157",
      "r158",
      "r160",
      "r161",
      "r165",
      "r166",
      "r175",
      "r204",
      "r207",
      "r210",
      "r213",
      "r215",
      "r242",
      "r274",
      "r275",
      "r276",
      "r278",
      "r279",
      "r280",
      "r281",
      "r282",
      "r283",
      "r284",
      "r506",
      "r520",
      "r628",
      "r651"
     ],
     "calculation": {
      "http://roivant.com/role/CondensedConsolidatedStatementsOfOperations": {
       "order": 12.0,
       "parentTag": "us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.",
        "label": "Net Income (Loss) Attributable to Parent",
        "totalLabel": "Net loss attributable to Roivant Sciences Ltd.",
        "verboseLabel": "Net (loss) income attributable to Roivant Sciences Ltd."
       }
      }
     },
     "localname": "NetIncomeLoss",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://roivant.com/role/CondensedConsolidatedStatementsOfOperations"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetIncomeLossAttributableToNoncontrollingInterest": {
     "auth_ref": [
      "r88",
      "r91",
      "r97",
      "r165",
      "r166",
      "r489",
      "r497"
     ],
     "calculation": {
      "http://roivant.com/role/CondensedConsolidatedStatementsOfOperations": {
       "order": 13.0,
       "parentTag": "us-gaap_NetIncomeLoss",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of Net Income (Loss) attributable to noncontrolling interest.",
        "label": "Net Income (Loss) Attributable to Noncontrolling Interest",
        "terseLabel": "Net loss attributable to noncontrolling interests"
       }
      }
     },
     "localname": "NetIncomeLossAttributableToNoncontrollingInterest",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://roivant.com/role/CondensedConsolidatedStatementsOfOperations"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetIncomeLossAttributableToRedeemableNoncontrollingInterest": {
     "auth_ref": [
      "r112"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of Net Income (Loss) attributable to redeemable noncontrolling interest.",
        "label": "Net Income (Loss) Attributable to Redeemable Noncontrolling Interest",
        "terseLabel": "Net losses from continuing operations"
       }
      }
     },
     "localname": "NetIncomeLossAttributableToRedeemableNoncontrollingInterest",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://roivant.com/role/DescriptionOfBusinessAndLiquidityAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact.",
        "label": "New Accounting Pronouncements, Policy [Policy Text Block]",
        "terseLabel": "Recently Adopted Accounting Pronouncements"
       }
      }
     },
     "localname": "NewAccountingPronouncementsPolicyPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://roivant.com/role/SummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_NoncashInvestingAndFinancingItemsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Noncash Investing and Financing Items [Abstract]",
        "terseLabel": "Supplemental disclosure of noncash activities:"
       }
      }
     },
     "localname": "NoncashInvestingAndFinancingItemsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://roivant.com/role/CondensedConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NoncontrollingInterestMember": {
     "auth_ref": [
      "r152",
      "r153",
      "r154",
      "r347",
      "r480"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "This element represents that portion of equity (net assets) in a subsidiary not attributable, directly or indirectly, to the parent. A noncontrolling interest is sometimes called a minority interest.",
        "label": "Noncontrolling Interest [Member]",
        "terseLabel": "Noncontrolling Interest [Member]"
       }
      }
     },
     "localname": "NoncontrollingInterestMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://roivant.com/role/CondensedConsolidatedStatementsOfShareholdersEquityAndRedeemableNoncontrollingInterest"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_NotesAndLoansReceivableNetCurrent": {
     "auth_ref": [
      "r29",
      "r30",
      "r48",
      "r221",
      "r222",
      "r622"
     ],
     "calculation": {
      "http://roivant.com/role/BalanceSheetComponentsScheduleOfOtherCurrentAssetsDetail": {
       "order": 3.0,
       "parentTag": "us-gaap_OtherAssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after allowance for credit loss, of financing receivable, classified as current. Includes, but is not limited to, notes and loan receivable.",
        "label": "Financing Receivable, after Allowance for Credit Loss, Current",
        "terseLabel": "Note receivable"
       }
      }
     },
     "localname": "NotesAndLoansReceivableNetCurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://roivant.com/role/BalanceSheetComponentsScheduleOfOtherCurrentAssetsDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NumberOfOperatingSegments": {
     "auth_ref": [
      "r198"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of operating segments. An operating segment is a component of an enterprise: (a) that engages in business activities from which it may earn revenues and incur expenses (including revenues and expenses relating to transactions with other components of the same enterprise), (b) whose operating results are regularly reviewed by the enterprise's chief operating decision maker to make decisions about resources to be allocated to the segment and assess its performance, and (c) for which discrete financial information is available. An operating segment may engage in business activities for which it has yet to earn revenues, for example, start-up operations may be operating segments before earning revenues.",
        "label": "Number of Operating Segments",
        "terseLabel": "Number of operating and reporting segments"
       }
      }
     },
     "localname": "NumberOfOperatingSegments",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://roivant.com/role/DescriptionOfBusinessAndLiquidityAdditionalInformationDetail"
     ],
     "xbrltype": "integerItemType"
    },
    "us-gaap_OperatingExpenses": {
     "auth_ref": [],
     "calculation": {
      "http://roivant.com/role/CondensedConsolidatedStatementsOfOperations": {
       "order": 2.0,
       "parentTag": "us-gaap_OperatingIncomeLoss",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Generally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Includes selling, general and administrative expense.",
        "label": "Operating Expenses",
        "totalLabel": "Total operating expenses"
       }
      }
     },
     "localname": "OperatingExpenses",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://roivant.com/role/CondensedConsolidatedStatementsOfOperations"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingExpensesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Operating Expenses [Abstract]",
        "terseLabel": "Operating expenses:"
       }
      }
     },
     "localname": "OperatingExpensesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://roivant.com/role/CondensedConsolidatedStatementsOfOperations"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_OperatingIncomeLoss": {
     "auth_ref": [
      "r204",
      "r207",
      "r210",
      "r213",
      "r215"
     ],
     "calculation": {
      "http://roivant.com/role/CondensedConsolidatedStatementsOfOperations": {
       "order": 1.0,
       "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The net result for the period of deducting operating expenses from operating revenues.",
        "label": "Operating Income (Loss)",
        "totalLabel": "Loss from operations"
       }
      }
     },
     "localname": "OperatingIncomeLoss",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://roivant.com/role/CondensedConsolidatedStatementsOfOperations"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseCost": {
     "auth_ref": [
      "r544",
      "r553"
     ],
     "calculation": {
      "http://roivant.com/role/LeasesScheduleOfOperatingLeaseCostsDetail": {
       "order": 1.0,
       "parentTag": "us-gaap_LeaseCost",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of single lease cost, calculated by allocation of remaining cost of lease over remaining lease term. Includes, but is not limited to, single lease cost, after impairment of right-of-use asset, calculated by amortization of remaining right-of-use asset and accretion of lease liability.",
        "label": "Operating Lease, Cost",
        "terseLabel": "Operating lease cost"
       }
      }
     },
     "localname": "OperatingLeaseCost",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://roivant.com/role/LeasesScheduleOfOperatingLeaseCostsDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Lessee, Operating Lease, Liability, Payment, Due [Abstract]",
        "terseLabel": "Maturities of operating lease liabilities [Abstract]"
       }
      }
     },
     "localname": "OperatingLeaseLiabilitiesPaymentsDueAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://roivant.com/role/LeasesScheduleOfMaturitiesOfOperatingLeaseLiabilitiesDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_OperatingLeaseLiability": {
     "auth_ref": [
      "r542"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease.",
        "label": "Operating Lease, Liability",
        "terseLabel": "Total"
       }
      }
     },
     "localname": "OperatingLeaseLiability",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://roivant.com/role/LeasesScheduleOfMaturitiesOfOperatingLeaseLiabilitiesDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseLiabilityCurrent": {
     "auth_ref": [
      "r542"
     ],
     "calculation": {
      "http://roivant.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 15.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as current.",
        "label": "Operating Lease, Liability, Current",
        "terseLabel": "Operating lease liabilities"
       }
      }
     },
     "localname": "OperatingLeaseLiabilityCurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://roivant.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseLiabilityNoncurrent": {
     "auth_ref": [
      "r542"
     ],
     "calculation": {
      "http://roivant.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 18.0,
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent.",
        "label": "Operating Lease, Liability, Noncurrent",
        "terseLabel": "Operating lease liabilities, noncurrent"
       }
      }
     },
     "localname": "OperatingLeaseLiabilityNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://roivant.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeasePayments": {
     "auth_ref": [
      "r543",
      "r547"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash outflow from operating lease, excluding payments to bring another asset to condition and location necessary for its intended use.",
        "label": "Operating Lease, Payments",
        "terseLabel": "Cash paid for operating lease liabilities"
       }
      }
     },
     "localname": "OperatingLeasePayments",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://roivant.com/role/LeasesSummaryOfOperatingLeaseRouAssetsAndOperatingLeaseLiabilitiesDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseRightOfUseAsset": {
     "auth_ref": [
      "r541"
     ],
     "calculation": {
      "http://roivant.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 6.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's right to use underlying asset under operating lease.",
        "label": "Operating Lease, Right-of-Use Asset",
        "terseLabel": "Operating lease right-of-use assets"
       }
      }
     },
     "localname": "OperatingLeaseRightOfUseAsset",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://roivant.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent": {
     "auth_ref": [
      "r550",
      "r553"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average discount rate for operating lease calculated at point in time.",
        "label": "Operating Lease, Weighted Average Discount Rate, Percent",
        "terseLabel": "Weighted average discount rate"
       }
      }
     },
     "localname": "OperatingLeaseWeightedAverageDiscountRatePercent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://roivant.com/role/LeasesSummaryOfOperatingLeaseRouAssetsAndOperatingLeaseLiabilitiesDetail"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1": {
     "auth_ref": [
      "r549",
      "r553"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average remaining lease term for operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.",
        "label": "Operating Lease, Weighted Average Remaining Lease Term",
        "terseLabel": "Weighted average remaining lease term (in years)"
       }
      }
     },
     "localname": "OperatingLeaseWeightedAverageRemainingLeaseTerm1",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://roivant.com/role/LeasesSummaryOfOperatingLeaseRouAssetsAndOperatingLeaseLiabilitiesDetail"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_OperatingLossCarryforwards": {
     "auth_ref": [
      "r444"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of operating loss carryforward, before tax effects, available to reduce future taxable income under enacted tax laws.",
        "label": "Operating Loss Carryforwards",
        "terseLabel": "Net operating losses"
       }
      }
     },
     "localname": "OperatingLossCarryforwards",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://roivant.com/role/IncomeTaxesAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLossCarryforwardsExpirationDate": {
     "auth_ref": [
      "r444"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Expiration date of each operating loss carryforward included in operating loss carryforward, in YYYY-MM-DD format.",
        "label": "Operating Loss Carryforwards, Expiration Date",
        "terseLabel": "Net operating losses expiration date"
       }
      }
     },
     "localname": "OperatingLossCarryforwardsExpirationDate",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://roivant.com/role/IncomeTaxesAdditionalInformationDetail"
     ],
     "xbrltype": "dateItemType"
    },
    "us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Organization, Consolidation and Presentation of Financial Statements [Abstract]"
       }
      }
     },
     "localname": "OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_OtherAssetsCurrent": {
     "auth_ref": [
      "r79",
      "r566"
     ],
     "calculation": {
      "http://roivant.com/role/BalanceSheetComponentsScheduleOfOtherCurrentAssetsDetail": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      },
      "http://roivant.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 4.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of current assets classified as other.",
        "label": "Other Assets, Current",
        "terseLabel": "Other current assets",
        "totalLabel": "Total other current assets"
       }
      }
     },
     "localname": "OtherAssetsCurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://roivant.com/role/BalanceSheetComponentsScheduleOfOtherCurrentAssetsDetail",
      "http://roivant.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherAssetsMiscellaneousCurrent": {
     "auth_ref": [],
     "calculation": {
      "http://roivant.com/role/BalanceSheetComponentsScheduleOfOtherCurrentAssetsDetail": {
       "order": 6.0,
       "parentTag": "us-gaap_OtherAssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of other miscellaneous assets expected to be realized or consumed within one year or operating cycle, if longer.",
        "label": "Other Assets, Miscellaneous, Current",
        "terseLabel": "Other"
       }
      }
     },
     "localname": "OtherAssetsMiscellaneousCurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://roivant.com/role/BalanceSheetComponentsScheduleOfOtherCurrentAssetsDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherAssetsNoncurrent": {
     "auth_ref": [
      "r60"
     ],
     "calculation": {
      "http://roivant.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 10.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of noncurrent assets classified as other.",
        "label": "Other Assets, Noncurrent",
        "terseLabel": "Other assets"
       }
      }
     },
     "localname": "OtherAssetsNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://roivant.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent": {
     "auth_ref": [
      "r483",
      "r484",
      "r491"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after tax and reclassification adjustments of gain (loss) on foreign currency translation adjustments, foreign currency transactions designated and effective as economic hedges of a net investment in a foreign entity and intra-entity foreign currency transactions that are of a long-term-investment nature, attributable to parent entity.",
        "label": "Other Comprehensive Income (Loss), Foreign Currency Transaction and Translation Adjustment, Net of Tax, Portion Attributable to Parent",
        "terseLabel": "Foreign currency translation adjustment"
       }
      }
     },
     "localname": "OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://roivant.com/role/CondensedConsolidatedStatementsOfShareholdersEquityAndRedeemableNoncontrollingInterest"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax": {
     "auth_ref": [
      "r83",
      "r85",
      "r521",
      "r522",
      "r524"
     ],
     "calculation": {
      "http://roivant.com/role/CondensedConsolidatedStatementsOfCashFlows": {
       "order": 17.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      },
      "http://roivant.com/role/CondensedConsolidatedStatementsOfComprehensiveLoss": {
       "order": 4.0,
       "parentTag": "us-gaap_OtherComprehensiveIncomeLossNetOfTax",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after tax, before reclassification adjustments of gain (loss) on foreign currency translation adjustments, foreign currency transactions designated and effective as economic hedges of a net investment in a foreign entity and intra-entity foreign currency transactions that are of a long-term-investment nature.",
        "label": "Other Comprehensive Income (Loss), Foreign Currency Transaction and Translation Gain (Loss) Arising During Period, Net of Tax",
        "terseLabel": "Foreign currency translation adjustment",
        "verboseLabel": "Unrealized foreign currency translation adjustment"
       }
      }
     },
     "localname": "OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://roivant.com/role/CondensedConsolidatedStatementsOfCashFlows",
      "http://roivant.com/role/CondensedConsolidatedStatementsOfComprehensiveLoss"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherComprehensiveIncomeLossNetOfTax": {
     "auth_ref": [
      "r89",
      "r92",
      "r95",
      "r96",
      "r98",
      "r104",
      "r338",
      "r525",
      "r530",
      "r531",
      "r629",
      "r652"
     ],
     "calculation": {
      "http://roivant.com/role/CondensedConsolidatedStatementsOfComprehensiveLoss": {
       "order": 3.0,
       "parentTag": "us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after tax and reclassification adjustments of other comprehensive income (loss).",
        "label": "Other Comprehensive Income (Loss), Net of Tax",
        "totalLabel": "Total other comprehensive loss"
       }
      }
     },
     "localname": "OtherComprehensiveIncomeLossNetOfTax",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://roivant.com/role/CondensedConsolidatedStatementsOfComprehensiveLoss"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherComprehensiveIncomeLossTaxAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Other Comprehensive Income (Loss), Tax [Abstract]",
        "terseLabel": "Other comprehensive loss:"
       }
      }
     },
     "localname": "OtherComprehensiveIncomeLossTaxAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://roivant.com/role/CondensedConsolidatedStatementsOfComprehensiveLoss"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_OtherCurrentLiabilitiesTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of other current liabilities.",
        "label": "Other Current Liabilities [Table Text Block]",
        "terseLabel": "Schedule of Other Current Liabilities"
       }
      }
     },
     "localname": "OtherCurrentLiabilitiesTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://roivant.com/role/BalanceSheetComponentsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_OtherExpensesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Other Expenses [Abstract]"
       }
      }
     },
     "localname": "OtherExpensesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_OtherIncomeAndExpensesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Other Income and Expenses [Abstract]",
        "terseLabel": "Other (income) expense [Abstract]",
        "verboseLabel": "Other (Income) Expense, Net [Abstract]"
       }
      }
     },
     "localname": "OtherIncomeAndExpensesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://roivant.com/role/OtherIncomeExpenseNetSummaryOfOtherIncomeExpenseNetFromContinuingOperationsDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_OtherInvestmentCompaniesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Investment in other investment companies (as defined).",
        "label": "Other Investment Companies [Member]",
        "terseLabel": "Other Investments [Member]",
        "verboseLabel": "Other Investment [Member]"
       }
      }
     },
     "localname": "OtherInvestmentCompaniesMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://roivant.com/role/FairValueMeasurementsScheduleOfAssetsAndLiabilitiesMeasuredAtFairValueOnARecurringBasisDetail",
      "http://roivant.com/role/InvestmentsAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_OtherLiabilitiesCurrent": {
     "auth_ref": [
      "r36",
      "r37",
      "r65",
      "r566"
     ],
     "calculation": {
      "http://roivant.com/role/BalanceSheetComponentsScheduleOfOtherCurrentLiabilitiesDetail": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      },
      "http://roivant.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 16.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of liabilities classified as other, due within one year or the normal operating cycle, if longer.",
        "label": "Other Liabilities, Current",
        "terseLabel": "Other current liabilities",
        "totalLabel": "Total other current liabilities"
       }
      }
     },
     "localname": "OtherLiabilitiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://roivant.com/role/BalanceSheetComponentsScheduleOfOtherCurrentLiabilitiesDetail",
      "http://roivant.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherLiabilitiesNoncurrent": {
     "auth_ref": [
      "r70"
     ],
     "calculation": {
      "http://roivant.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 20.0,
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of liabilities classified as other, due after one year or the normal operating cycle, if longer.",
        "label": "Other Liabilities, Noncurrent",
        "terseLabel": "Other liabilities"
       }
      }
     },
     "localname": "OtherLiabilitiesNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://roivant.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherNoncashIncomeExpense": {
     "auth_ref": [
      "r134"
     ],
     "calculation": {
      "http://roivant.com/role/CondensedConsolidatedStatementsOfCashFlows": {
       "order": 8.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of income (expense) included in net income that results in no cash inflow (outflow), classified as other.",
        "label": "Other Noncash Income (Expense)",
        "negatedLabel": "Other"
       }
      }
     },
     "localname": "OtherNoncashIncomeExpense",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://roivant.com/role/CondensedConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherNonoperatingIncomeExpense": {
     "auth_ref": [
      "r117"
     ],
     "calculation": {
      "http://roivant.com/role/CondensedConsolidatedStatementsOfOperations": {
       "order": 20.0,
       "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of income (expense) related to nonoperating activities, classified as other.",
        "label": "Other Nonoperating Income (Expense)",
        "negatedLabel": "Other (income) expense, net"
       }
      }
     },
     "localname": "OtherNonoperatingIncomeExpense",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://roivant.com/role/CondensedConsolidatedStatementsOfOperations"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherNonoperatingIncomeExpenseAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Other Nonoperating Income (Expense) [Abstract]",
        "verboseLabel": "Other income (expense):"
       }
      }
     },
     "localname": "OtherNonoperatingIncomeExpenseAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://roivant.com/role/CondensedConsolidatedStatementsOfOperations"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_OtherOperatingIncomeAndExpenseTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for other operating income and other operating expense items.",
        "label": "Other Operating Income and Expense [Text Block]",
        "verboseLabel": "Other (Income) Expense, Net"
       }
      }
     },
     "localname": "OtherOperatingIncomeAndExpenseTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://roivant.com/role/OtherIncomeExpenseNet"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_OtherOperatingIncomeExpenseNet": {
     "auth_ref": [],
     "calculation": {
      "http://roivant.com/role/OtherIncomeExpenseNetSummaryOfOtherIncomeExpenseNetFromContinuingOperationsDetail": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The net amount of other operating income and expenses, the components of which are not separately disclosed on the income statement, from items that are associated with the entity's normal revenue producing operations.",
        "label": "Other Operating Income (Expense), Net",
        "negatedTotalLabel": "Total"
       }
      }
     },
     "localname": "OtherOperatingIncomeExpenseNet",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://roivant.com/role/OtherIncomeExpenseNetSummaryOfOtherIncomeExpenseNetFromContinuingOperationsDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherSundryLiabilitiesCurrent": {
     "auth_ref": [
      "r65",
      "r272"
     ],
     "calculation": {
      "http://roivant.com/role/BalanceSheetComponentsScheduleOfOtherCurrentLiabilitiesDetail": {
       "order": 3.0,
       "parentTag": "us-gaap_OtherLiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Obligations not otherwise itemized or categorized in the footnotes to the financial statements that are due within one year or operating cycle, if longer, from the balance sheet date.",
        "label": "Other Sundry Liabilities, Current",
        "terseLabel": "Other"
       }
      }
     },
     "localname": "OtherSundryLiabilitiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://roivant.com/role/BalanceSheetComponentsScheduleOfOtherCurrentLiabilitiesDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsForProceedsFromBusinessesAndInterestInAffiliates": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The net cash outflow or inflow associated with the acquisition or sale of a business segment during the period.",
        "label": "Payments for (Proceeds from) Businesses and Interest in Affiliates",
        "terseLabel": "Cash as a result of the Business Combination"
       }
      }
     },
     "localname": "PaymentsForProceedsFromBusinessesAndInterestInAffiliates",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://roivant.com/role/ShareholdersEquityAndRedeemableNonControllingInterestAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsForRepurchaseOfCommonStock": {
     "auth_ref": [
      "r125"
     ],
     "calculation": {
      "http://roivant.com/role/ShareholdersEquityAndRedeemableNonControllingInterestScheduleOfPaymentsOfEquitySecuritiesDetail": {
       "order": 1.0,
       "parentTag": "us-gaap_PaymentsForRepurchaseOfEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash outflow to reacquire common stock during the period.",
        "label": "Payments for Repurchase of Common Stock",
        "terseLabel": "Common stock"
       }
      }
     },
     "localname": "PaymentsForRepurchaseOfCommonStock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://roivant.com/role/ShareholdersEquityAndRedeemableNonControllingInterestScheduleOfPaymentsOfEquitySecuritiesDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsForRepurchaseOfEquity": {
     "auth_ref": [
      "r125"
     ],
     "calculation": {
      "http://roivant.com/role/CondensedConsolidatedStatementsOfCashFlows": {
       "order": 28.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": -1.0
      },
      "http://roivant.com/role/ShareholdersEquityAndRedeemableNonControllingInterestScheduleOfPaymentsOfEquitySecuritiesDetail": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash outflow to reacquire common and preferred stock.",
        "label": "Payments for Repurchase of Equity",
        "negatedLabel": "Repurchase of equity awards",
        "totalLabel": "Total cash paid"
       }
      }
     },
     "localname": "PaymentsForRepurchaseOfEquity",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://roivant.com/role/CondensedConsolidatedStatementsOfCashFlows",
      "http://roivant.com/role/ShareholdersEquityAndRedeemableNonControllingInterestScheduleOfPaymentsOfEquitySecuritiesDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsForRepurchaseOfEquityAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Payments for Repurchase of Equity [Abstract]"
       }
      }
     },
     "localname": "PaymentsForRepurchaseOfEquityAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_PaymentsForRepurchaseOfOtherEquity": {
     "auth_ref": [
      "r125"
     ],
     "calculation": {
      "http://roivant.com/role/ShareholdersEquityAndRedeemableNonControllingInterestScheduleOfPaymentsOfEquitySecuritiesDetail": {
       "order": 2.0,
       "parentTag": "us-gaap_PaymentsForRepurchaseOfEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash outflow to reacquire equity classified as other.",
        "label": "Payments for Repurchase of Other Equity",
        "terseLabel": "Other equity instruments"
       }
      }
     },
     "localname": "PaymentsForRepurchaseOfOtherEquity",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://roivant.com/role/ShareholdersEquityAndRedeemableNonControllingInterestScheduleOfPaymentsOfEquitySecuritiesDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsForRepurchaseOfRedeemableConvertiblePreferredStock": {
     "auth_ref": [
      "r125"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash outflow to reacquire callable preferred stock which is identified as being convertible to another type of financial security.",
        "label": "Payments for Repurchase of Redeemable Convertible Preferred Stock",
        "terseLabel": "Preferred stock purchase price"
       }
      }
     },
     "localname": "PaymentsForRepurchaseOfRedeemableConvertiblePreferredStock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://roivant.com/role/ShareholdersEquityAndRedeemableNonControllingInterestAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsForRepurchaseOfRedeemableNoncontrollingInterest": {
     "auth_ref": [
      "r125"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash outflow during the period for redemption of redeemable noncontrolling interests.",
        "label": "Payments for Repurchase of Redeemable Noncontrolling Interest",
        "terseLabel": "Repurchase of redeemable noncontrolling interest"
       }
      }
     },
     "localname": "PaymentsForRepurchaseOfRedeemableNoncontrollingInterest",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://roivant.com/role/ShareholdersEquityAndRedeemableNonControllingInterestAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsOfStockIssuanceCosts": {
     "auth_ref": [
      "r126"
     ],
     "calculation": {
      "http://roivant.com/role/CondensedConsolidatedStatementsOfCashFlows": {
       "order": 34.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash outflow for cost incurred directly with the issuance of an equity security.",
        "label": "Payments of Stock Issuance Costs",
        "negatedLabel": "Offering costs paid"
       }
      }
     },
     "localname": "PaymentsOfStockIssuanceCosts",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://roivant.com/role/CondensedConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired": {
     "auth_ref": [
      "r120"
     ],
     "calculation": {
      "http://roivant.com/role/CondensedConsolidatedStatementsOfCashFlows": {
       "order": 22.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash outflow associated with the acquisition of a business, net of the cash acquired from the purchase.",
        "label": "Payments to Acquire Businesses, Net of Cash Acquired",
        "negatedLabel": "Acquisitions, net of cash acquired",
        "terseLabel": "Payment to acquire business, net"
       }
      }
     },
     "localname": "PaymentsToAcquireBusinessesNetOfCashAcquired",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://roivant.com/role/AssetAcquisitionsAndLicenseAgreementsAdditionalInformationDetail",
      "http://roivant.com/role/CondensedConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsToAcquireEquityMethodInvestments": {
     "auth_ref": [
      "r120"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash outflow associated with the purchase of or advances to an equity method investments, which are investments in joint ventures and entities in which the entity has an equity ownership interest normally of 20 to 50 percent and exercises significant influence.",
        "label": "Payments to Acquire Equity Method Investments",
        "terseLabel": "Equity ownership interest, additional cash contribution"
       }
      }
     },
     "localname": "PaymentsToAcquireEquityMethodInvestments",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://roivant.com/role/AssetAcquisitionsAndLicenseAgreementsAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsToAcquireInterestInSubsidiariesAndAffiliates": {
     "auth_ref": [
      "r120"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash outflow associated with the acquisition of or advances to an entity that is related to it but not strictly controlled (for example, an unconsolidated subsidiary, affiliate, and joint venture or equity method investment) or the acquisition of an additional interest in a subsidiary (controlled entity).",
        "label": "Payments to Acquire Interest in Subsidiaries and Affiliates",
        "terseLabel": "Cash paid for common shares"
       }
      }
     },
     "localname": "PaymentsToAcquireInterestInSubsidiariesAndAffiliates",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://roivant.com/role/AssetAcquisitionsAndLicenseAgreementsAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsToAcquireMarketableSecurities": {
     "auth_ref": [
      "r230"
     ],
     "calculation": {
      "http://roivant.com/role/CondensedConsolidatedStatementsOfCashFlows": {
       "order": 24.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash outflow for purchase of marketable security.",
        "label": "Payments to Acquire Marketable Securities",
        "negatedLabel": "Purchase of marketable securities"
       }
      }
     },
     "localname": "PaymentsToAcquireMarketableSecurities",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://roivant.com/role/CondensedConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsToAcquirePropertyPlantAndEquipment": {
     "auth_ref": [
      "r121"
     ],
     "calculation": {
      "http://roivant.com/role/CondensedConsolidatedStatementsOfCashFlows": {
       "order": 21.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets.",
        "label": "Payments to Acquire Property, Plant, and Equipment",
        "negatedLabel": "Purchase of property and equipment"
       }
      }
     },
     "localname": "PaymentsToAcquirePropertyPlantAndEquipment",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://roivant.com/role/CondensedConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PlanNameAxis": {
     "auth_ref": [
      "r385",
      "r416"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by plan name for share-based payment arrangement.",
        "label": "Plan Name [Axis]",
        "terseLabel": "Plan Name [Axis]"
       }
      }
     },
     "localname": "PlanNameAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://roivant.com/role/ShareBasedCompensationAdditionalInformationDetail",
      "http://roivant.com/role/ShareBasedCompensationSummaryOfCappedValueAppreciationRightsDetail",
      "http://roivant.com/role/ShareBasedCompensationSummaryOfPerformanceOptionsActivityDetail",
      "http://roivant.com/role/ShareBasedCompensationSummaryOfPerformanceRestrictedStockUnitsDetail",
      "http://roivant.com/role/ShareBasedCompensationSummaryOfRestrictedStockUnitsDetail",
      "http://roivant.com/role/ShareBasedCompensationSummaryOfStockOptionActivityDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_PlanNameDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Plan name for share-based payment arrangement.",
        "label": "Plan Name [Domain]",
        "terseLabel": "Plan Name [Domain]"
       }
      }
     },
     "localname": "PlanNameDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://roivant.com/role/ShareBasedCompensationAdditionalInformationDetail",
      "http://roivant.com/role/ShareBasedCompensationSummaryOfCappedValueAppreciationRightsDetail",
      "http://roivant.com/role/ShareBasedCompensationSummaryOfPerformanceOptionsActivityDetail",
      "http://roivant.com/role/ShareBasedCompensationSummaryOfPerformanceRestrictedStockUnitsDetail",
      "http://roivant.com/role/ShareBasedCompensationSummaryOfRestrictedStockUnitsDetail",
      "http://roivant.com/role/ShareBasedCompensationSummaryOfStockOptionActivityDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_PreferredStockDividendsAndOtherAdjustments": {
     "auth_ref": [
      "r169",
      "r179"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate value of preferred stock dividends and other adjustments necessary to derive net income apportioned to common stockholders.",
        "label": "Preferred Stock Dividends and Other Adjustments",
        "negatedLabel": "Deemed dividend on repurchase of redeemable noncontrolling interest relating to subsidiary convertible and redeemable preferred stock",
        "terseLabel": "Deemed dividend on repurchase of redeemable noncontrolling interest relating to subsidiary convertible and redeemable preferred stock"
       }
      }
     },
     "localname": "PreferredStockDividendsAndOtherAdjustments",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://roivant.com/role/NetLossPerCommonShareSummaryOfBasicAndDilutedNetIncomePerShareOfCommonStockDetail",
      "http://roivant.com/role/NetLossPerCommonShareSummaryOfBasicAndDilutedNetIncomePerShareOfCommonStockParentheticalDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PreferredStockRedemptionPricePerShare": {
     "auth_ref": [
      "r320",
      "r339",
      "r341"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The price per share at which the preferred stock of an entity that has priority over common stock in the distribution of dividends and in the event of liquidation of the entity is redeemed or may be called at. The redemption features of this preferred stock are solely within the control of the issuer.",
        "label": "Preferred Stock, Redemption Price Per Share",
        "terseLabel": "Preferred stock purchase price per share"
       }
      }
     },
     "localname": "PreferredStockRedemptionPricePerShare",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://roivant.com/role/ShareholdersEquityAndRedeemableNonControllingInterestAdditionalInformationDetail"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_PreferredStockSharesOutstanding": {
     "auth_ref": [
      "r46"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Aggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased.",
        "label": "Preferred Stock, Shares Outstanding",
        "terseLabel": "Preferred stock"
       }
      }
     },
     "localname": "PreferredStockSharesOutstanding",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://roivant.com/role/InvestmentsAdditionalInformationDetail"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_PrepaidExpenseCurrent": {
     "auth_ref": [
      "r31",
      "r33",
      "r256",
      "r257"
     ],
     "calculation": {
      "http://roivant.com/role/BalanceSheetComponentsScheduleOfOtherCurrentAssetsDetail": {
       "order": 1.0,
       "parentTag": "us-gaap_OtherAssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of asset related to consideration paid in advance for costs that provide economic benefits within a future period of one year or the normal operating cycle, if longer.",
        "label": "Prepaid Expense, Current",
        "terseLabel": "Prepaid expenses"
       }
      }
     },
     "localname": "PrepaidExpenseCurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://roivant.com/role/BalanceSheetComponentsScheduleOfOtherCurrentAssetsDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PrimeRateMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Interest rate charged by financial institutions to their most creditworthy borrowers.",
        "label": "Prime Rate [Member]",
        "terseLabel": "Prime Rate [Member]"
       }
      }
     },
     "localname": "PrimeRateMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://roivant.com/role/LongTermDebtAndLoanCommitmentAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ProceedsFromDivestitureOfBusinesses": {
     "auth_ref": [
      "r119"
     ],
     "calculation": {
      "http://roivant.com/role/CondensedConsolidatedStatementsOfCashFlows": {
       "order": 26.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash inflow associated with the amount received from the sale of a portion of the company's business, for example a segment, division, branch or other business, during the period.",
        "label": "Proceeds from Divestiture of Businesses",
        "terseLabel": "Proceeds from sale of business, net of cash disposed"
       }
      }
     },
     "localname": "ProceedsFromDivestitureOfBusinesses",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://roivant.com/role/CondensedConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromIssuanceOfCommonStock": {
     "auth_ref": [
      "r123"
     ],
     "calculation": {
      "http://roivant.com/role/CondensedConsolidatedStatementsOfCashFlows": {
       "order": 40.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash inflow from the additional capital contribution to the entity.",
        "label": "Proceeds from Issuance of Common Stock",
        "terseLabel": "Net proceeds of common stock",
        "verboseLabel": "Proceeds from issuance of the Company's common shares, net"
       }
      }
     },
     "localname": "ProceedsFromIssuanceOfCommonStock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://roivant.com/role/CondensedConsolidatedStatementsOfCashFlows",
      "http://roivant.com/role/ShareholdersEquityAndRedeemableNonControllingInterestAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromIssuanceOfDebt": {
     "auth_ref": [
      "r124"
     ],
     "calculation": {
      "http://roivant.com/role/CondensedConsolidatedStatementsOfCashFlows": {
       "order": 39.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash inflow during the period from additional borrowings in aggregate debt. Includes proceeds from short-term and long-term debt.",
        "label": "Proceeds from Issuance of Debt",
        "terseLabel": "Proceeds from issuance of liability instruments"
       }
      }
     },
     "localname": "ProceedsFromIssuanceOfDebt",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://roivant.com/role/CondensedConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromIssuanceOfWarrants": {
     "auth_ref": [
      "r123"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash inflow from issuance of rights to purchase common shares at predetermined price (usually issued together with corporate debt).",
        "label": "Proceeds from Issuance of Warrants",
        "verboseLabel": "Proceeds of warrants"
       }
      }
     },
     "localname": "ProceedsFromIssuanceOfWarrants",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://roivant.com/role/ShareholdersEquityAndRedeemableNonControllingInterestAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromLinesOfCredit": {
     "auth_ref": [
      "r124",
      "r145"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow from contractual arrangement with the lender, including but not limited to, letter of credit, standby letter of credit and revolving credit arrangements.",
        "label": "Proceeds from Lines of Credit",
        "terseLabel": "Proceeds from credit facility"
       }
      }
     },
     "localname": "ProceedsFromLinesOfCredit",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://roivant.com/role/LongTermDebtAndLoanCommitmentAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromNotesPayable": {
     "auth_ref": [
      "r124"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash inflow from a borrowing supported by a written promise to pay an obligation.",
        "label": "Proceeds from Notes Payable",
        "terseLabel": "Promissory notes issued"
       }
      }
     },
     "localname": "ProceedsFromNotesPayable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://roivant.com/role/AssetAcquisitionsAndLicenseAgreementsAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities": {
     "auth_ref": [],
     "calculation": {
      "http://roivant.com/role/CondensedConsolidatedStatementsOfCashFlows": {
       "order": 23.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash inflow associated with the aggregate amount received by the entity through sale or maturity of marketable securities  (held-to-maturity or available-for-sale) during the period.",
        "label": "Proceeds from Sale and Maturity of Marketable Securities",
        "terseLabel": "Maturity of marketable securities"
       }
      }
     },
     "localname": "ProceedsFromSaleAndMaturityOfMarketableSecurities",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://roivant.com/role/CondensedConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromStockOptionsExercised": {
     "auth_ref": [
      "r123",
      "r417"
     ],
     "calculation": {
      "http://roivant.com/role/CondensedConsolidatedStatementsOfCashFlows": {
       "order": 33.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow from exercise of option under share-based payment arrangement.",
        "label": "Proceeds from Stock Options Exercised",
        "terseLabel": "Proceeds from exercise of subsidiary stock options"
       }
      }
     },
     "localname": "ProceedsFromStockOptionsExercised",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://roivant.com/role/CondensedConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProfitLoss": {
     "auth_ref": [
      "r24",
      "r88",
      "r91",
      "r97",
      "r128",
      "r146",
      "r155",
      "r165",
      "r166",
      "r204",
      "r207",
      "r210",
      "r213",
      "r215",
      "r242",
      "r274",
      "r275",
      "r276",
      "r278",
      "r279",
      "r280",
      "r281",
      "r282",
      "r283",
      "r284",
      "r483",
      "r488",
      "r490",
      "r497",
      "r498",
      "r506",
      "r520",
      "r634"
     ],
     "calculation": {
      "http://roivant.com/role/CondensedConsolidatedStatementsOfCashFlows": {
       "order": 2.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      },
      "http://roivant.com/role/CondensedConsolidatedStatementsOfComprehensiveLoss": {
       "order": 2.0,
       "parentTag": "us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest",
       "weight": 1.0
      },
      "http://roivant.com/role/CondensedConsolidatedStatementsOfOperations": {
       "order": 14.0,
       "parentTag": "us-gaap_NetIncomeLoss",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The consolidated profit or loss for the period, net of income taxes, including the portion attributable to the noncontrolling interest.",
        "label": "Net Income (Loss), Including Portion Attributable to Noncontrolling Interest",
        "terseLabel": "Net loss",
        "totalLabel": "Net loss",
        "verboseLabel": "Net loss"
       }
      }
     },
     "localname": "ProfitLoss",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://roivant.com/role/CondensedConsolidatedStatementsOfCashFlows",
      "http://roivant.com/role/CondensedConsolidatedStatementsOfComprehensiveLoss",
      "http://roivant.com/role/CondensedConsolidatedStatementsOfOperations",
      "http://roivant.com/role/CondensedConsolidatedStatementsOfShareholdersEquityAndRedeemableNoncontrollingInterest",
      "http://roivant.com/role/DescriptionOfBusinessAndLiquidityAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentByTypeAxis": {
     "auth_ref": [
      "r59",
      "r260"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of long-lived, physical assets used to produce goods and services and not intended for resale.",
        "label": "Long-Lived Tangible Asset [Axis]",
        "terseLabel": "Long-Lived Tangible Asset [Axis]"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentByTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://roivant.com/role/SummaryOfSignificantAccountingPoliciesScheduleOfEstimatedUsefulLivesDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentEstimatedUsefulLives": {
     "auth_ref": [
      "r258"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Describes the periods of time over which an entity anticipates to receive utility from its property, plant and equipment (that is, the periods of time over which an entity allocates the initial cost of its property, plant and equipment).",
        "label": "Property, Plant and Equipment, Estimated Useful Lives",
        "terseLabel": "Estimated useful lives"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentEstimatedUsefulLives",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://roivant.com/role/SummaryOfSignificantAccountingPoliciesScheduleOfEstimatedUsefulLivesDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Property, Plant and Equipment [Line Items]",
        "terseLabel": "Property, Plant and Equipment [Line Items]"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentLineItems",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://roivant.com/role/SummaryOfSignificantAccountingPoliciesScheduleOfEstimatedUsefulLivesDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentNet": {
     "auth_ref": [
      "r39",
      "r40",
      "r260",
      "r566",
      "r635",
      "r646"
     ],
     "calculation": {
      "http://roivant.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 5.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.",
        "label": "Property, Plant and Equipment, Net",
        "terseLabel": "Property and equipment, net"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentNet",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://roivant.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentPolicyTextBlock": {
     "auth_ref": [
      "r58",
      "r260",
      "r699",
      "r700"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for long-lived, physical asset used in normal conduct of business and not intended for resale. Includes, but is not limited to, work of art, historical treasure, and similar asset classified as collections.",
        "label": "Property, Plant and Equipment, Policy [Policy Text Block]",
        "terseLabel": "Property and Equipment"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://roivant.com/role/SummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentTypeDomain": {
     "auth_ref": [
      "r39",
      "r259"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Listing of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale. Examples include land, buildings, machinery and equipment, and other types of furniture and equipment including, but not limited to, office equipment, furniture and fixtures, and computer equipment and software.",
        "label": "Long-Lived Tangible Asset [Domain]",
        "terseLabel": "Long-Lived Tangible Asset [Domain]"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentTypeDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://roivant.com/role/SummaryOfSignificantAccountingPoliciesScheduleOfEstimatedUsefulLivesDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentUsefulLife": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Useful life of long lived, physical assets used in the normal conduct of business and not intended for resale, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. Examples include, but not limited to, land, buildings, machinery and equipment, office equipment, furniture and fixtures, and computer equipment.",
        "label": "Property, Plant and Equipment, Useful Life",
        "terseLabel": "Estimated useful lives"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentUsefulLife",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://roivant.com/role/SummaryOfSignificantAccountingPoliciesScheduleOfEstimatedUsefulLivesDetail"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_RedeemableNoncontrollingInterestEquityCarryingAmount": {
     "auth_ref": [
      "r314",
      "r315",
      "r316",
      "r317"
     ],
     "calculation": {
      "http://roivant.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 23.0,
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "As of the reporting date, the aggregate carrying amount of all noncontrolling interests which are redeemable by the (parent) entity (1) at a fixed or determinable price on a fixed or determinable date, (2) at the option of the holder of the noncontrolling interest, or (3) upon occurrence of an event that is not solely within the control of the (parent) entity. This item includes noncontrolling interest holder's ownership (or holders' ownership) regardless of the type of equity interest (common, preferred, other) including all potential organizational (legal) forms of the investee entity.",
        "label": "Redeemable Noncontrolling Interest, Equity, Carrying Amount",
        "terseLabel": "Redeemable noncontrolling interest"
       }
      }
     },
     "localname": "RedeemableNoncontrollingInterestEquityCarryingAmount",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://roivant.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RelatedPartyDomain": {
     "auth_ref": [
      "r374",
      "r557",
      "r558"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Related parties include affiliates; other entities for which investments are accounted for by the equity method by the entity; trusts for benefit of employees; and principal owners, management, and members of immediate families. It also may include other parties with which the entity may control or can significantly influence the management or operating policies of the other to an extent that one of the transacting parties might be prevented from fully pursuing its own separate interests.",
        "label": "Related Party [Domain]",
        "terseLabel": "Related Party [Domain]"
       }
      }
     },
     "localname": "RelatedPartyDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://roivant.com/role/AssetAcquisitionsAndLicenseAgreementsAdditionalInformationDetail",
      "http://roivant.com/role/LongTermDebtAndLoanCommitmentAdditionalInformationDetail",
      "http://roivant.com/role/RelatedPartyTransactionsAdditionalInformationDetail",
      "http://roivant.com/role/ShareholdersEquityAndRedeemableNonControllingInterestAdditionalInformationDetail",
      "http://roivant.com/role/SubsequentEventsAdditionalInformationDetail",
      "http://roivant.com/role/SumitomoTransactionAgreementAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_RelatedPartyTransactionAmountsOfTransaction": {
     "auth_ref": [
      "r557",
      "r561"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of transactions with related party during the financial reporting period.",
        "label": "Related Party Transaction, Amounts of Transaction",
        "terseLabel": "Access fee paid pursuant to strategic cooperation agreement"
       }
      }
     },
     "localname": "RelatedPartyTransactionAmountsOfTransaction",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://roivant.com/role/RelatedPartyTransactionsAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RelatedPartyTransactionLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Related Party Transaction [Line Items]",
        "terseLabel": "Related Party Transaction [Line Items]"
       }
      }
     },
     "localname": "RelatedPartyTransactionLineItems",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://roivant.com/role/RelatedPartyTransactionsAdditionalInformationDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_RelatedPartyTransactionsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Related Party Transactions [Abstract]"
       }
      }
     },
     "localname": "RelatedPartyTransactionsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_RelatedPartyTransactionsByRelatedPartyAxis": {
     "auth_ref": [
      "r374",
      "r557",
      "r561",
      "r603",
      "r604",
      "r605",
      "r606",
      "r607",
      "r608",
      "r609",
      "r610",
      "r611",
      "r612",
      "r613",
      "r614"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of related party. Related parties include, but not limited to, affiliates; other entities for which investments are accounted for by the equity method by the entity; trusts for benefit of employees; and principal owners, management, and members of immediate families. It also may include other parties with which the entity may control or can significantly influence the management or operating policies of the other to an extent that one of the transacting parties might be prevented from fully pursuing its own separate interests.",
        "label": "Related Party [Axis]",
        "terseLabel": "Related Party [Axis]"
       }
      }
     },
     "localname": "RelatedPartyTransactionsByRelatedPartyAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://roivant.com/role/AssetAcquisitionsAndLicenseAgreementsAdditionalInformationDetail",
      "http://roivant.com/role/LongTermDebtAndLoanCommitmentAdditionalInformationDetail",
      "http://roivant.com/role/RelatedPartyTransactionsAdditionalInformationDetail",
      "http://roivant.com/role/ShareholdersEquityAndRedeemableNonControllingInterestAdditionalInformationDetail",
      "http://roivant.com/role/SubsequentEventsAdditionalInformationDetail",
      "http://roivant.com/role/SumitomoTransactionAgreementAdditionalInformationDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_RelatedPartyTransactionsDisclosureTextBlock": {
     "auth_ref": [
      "r555",
      "r556",
      "r558",
      "r562",
      "r563"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for related party transactions. Examples of related party transactions include transactions between (a) a parent company and its subsidiary; (b) subsidiaries of a common parent; (c) and entity and its principal owners; and (d) affiliates.",
        "label": "Related Party Transactions Disclosure [Text Block]",
        "terseLabel": "Related Party Transactions"
       }
      }
     },
     "localname": "RelatedPartyTransactionsDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://roivant.com/role/RelatedPartyTransactions"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_RepaymentOfNotesReceivableFromRelatedParties": {
     "auth_ref": [
      "r118"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash inflow from a loan, supported by a promissory note, granted to related parties where one party can exercise control or significant influence over another party; including affiliates, owners or officers and their immediate families, pension trusts, and so forth.",
        "label": "Repayment of Notes Receivable from Related Parties",
        "terseLabel": "Settlement of promissory notes receivable"
       }
      }
     },
     "localname": "RepaymentOfNotesReceivableFromRelatedParties",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://roivant.com/role/AssetAcquisitionsAndLicenseAgreementsAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ResearchAndDevelopmentExpense": {
     "auth_ref": [
      "r427",
      "r601",
      "r712"
     ],
     "calculation": {
      "http://roivant.com/role/CondensedConsolidatedStatementsOfOperations": {
       "order": 4.0,
       "parentTag": "us-gaap_OperatingExpenses",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use.",
        "label": "Research and Development Expense",
        "terseLabel": "Research and development",
        "verboseLabel": "Research and development expense"
       }
      }
     },
     "localname": "ResearchAndDevelopmentExpense",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://roivant.com/role/AssetAcquisitionsAndLicenseAgreementsAdditionalInformationDetail",
      "http://roivant.com/role/CondensedConsolidatedStatementsOfOperations"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ResearchAndDevelopmentExpenseMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Primary financial statement caption in which the reported facts about research and development expense have been included.",
        "label": "Research and Development Expense [Member]",
        "terseLabel": "R&amp;D Expenses [Member]"
       }
      }
     },
     "localname": "ResearchAndDevelopmentExpenseMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://roivant.com/role/BalanceSheetComponentsScheduleOfAccruedExpensesDetail",
      "http://roivant.com/role/ShareBasedCompensationSummaryOfShareBasedCompensationExpenseDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ResearchAndDevelopmentExpensePolicy": {
     "auth_ref": [
      "r427"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for costs it has incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process.",
        "label": "Research and Development Expense, Policy [Policy Text Block]",
        "terseLabel": "Research and Development Expenses"
       }
      }
     },
     "localname": "ResearchAndDevelopmentExpensePolicy",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://roivant.com/role/SummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ResearchAndDevelopmentInProcess": {
     "auth_ref": [],
     "calculation": {
      "http://roivant.com/role/CondensedConsolidatedStatementsOfCashFlows": {
       "order": 16.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of purchased research and development assets that are acquired in a business combination have no alternative future use and are therefore written off in the period of acquisition.",
        "label": "Research and Development in Process",
        "terseLabel": "Acquired in-processresearch and development"
       }
      }
     },
     "localname": "ResearchAndDevelopmentInProcess",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://roivant.com/role/CondensedConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RestrictedCash": {
     "auth_ref": [
      "r140",
      "r616",
      "r641"
     ],
     "calculation": {
      "http://roivant.com/role/SummaryOfSignificantAccountingPoliciesScheduleOfAggregateAmountsOfCashCashEquivalentsAndRestrictedCashDetail": {
       "order": 2.0,
       "parentTag": "roiv_CashAndCashEquivalentsAndRestrictedCash",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash restricted as to withdrawal or usage. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits.",
        "label": "Restricted Cash",
        "terseLabel": "Restricted cash"
       }
      }
     },
     "localname": "RestrictedCash",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://roivant.com/role/SumitomoTransactionAgreementAdditionalInformationDetail",
      "http://roivant.com/role/SummaryOfSignificantAccountingPoliciesScheduleOfAggregateAmountsOfCashCashEquivalentsAndRestrictedCashDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RestrictedCashCurrent": {
     "auth_ref": [
      "r28",
      "r38",
      "r140"
     ],
     "calculation": {
      "http://roivant.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 3.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash restricted as to withdrawal or usage, classified as current. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits.",
        "label": "Restricted Cash, Current",
        "terseLabel": "Restricted cash"
       }
      }
     },
     "localname": "RestrictedCashCurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://roivant.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RestrictedCashNoncurrent": {
     "auth_ref": [
      "r35",
      "r41",
      "r140",
      "r694"
     ],
     "calculation": {
      "http://roivant.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 7.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash restricted as to withdrawal or usage, classified as noncurrent. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits.",
        "label": "Restricted Cash, Noncurrent",
        "terseLabel": "Restricted cash, net of current portion"
       }
      }
     },
     "localname": "RestrictedCashNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://roivant.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RestrictedInvestmentsAtFairValue": {
     "auth_ref": [
      "r675",
      "r685",
      "r693",
      "r695"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate value of all restricted investments.",
        "label": "Restricted Investments, at Fair Value",
        "terseLabel": "Restricted common stock fair value"
       }
      }
     },
     "localname": "RestrictedInvestmentsAtFairValue",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://roivant.com/role/ShareBasedCompensationAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RestrictedStockMember": {
     "auth_ref": [
      "r180"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Stock including a provision that prohibits sale or substantive sale of an equity instrument for a specified period of time or until specified performance conditions are met.",
        "label": "Restricted Stock [Member]",
        "terseLabel": "Restricted Stock [Member]"
       }
      }
     },
     "localname": "RestrictedStockMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://roivant.com/role/ShareholdersEquityAndRedeemableNonControllingInterestAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_RestrictedStockUnitsRSUMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share instrument which is convertible to stock or an equivalent amount of cash, after a specified period of time or when specified performance conditions are met.",
        "label": "Restricted Stock Units (RSUs) [Member]",
        "terseLabel": "RSUs [Member]"
       }
      }
     },
     "localname": "RestrictedStockUnitsRSUMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://roivant.com/role/ShareBasedCompensationAdditionalInformationDetail",
      "http://roivant.com/role/ShareBasedCompensationSummaryOfRestrictedStockUnitsDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_RestructuringPlanAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by individual restructuring plan.",
        "label": "Restructuring Plan [Axis]",
        "terseLabel": "Restructuring Plan [Axis]"
       }
      }
     },
     "localname": "RestructuringPlanAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://roivant.com/role/AssetAcquisitionsAndLicenseAgreementsAdditionalInformationDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_RestructuringPlanDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Identification of the individual restructuring plans.",
        "label": "Restructuring Plan [Domain]",
        "terseLabel": "Restructuring Plan [Domain]"
       }
      }
     },
     "localname": "RestructuringPlanDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://roivant.com/role/AssetAcquisitionsAndLicenseAgreementsAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_RetainedEarningsAccumulatedDeficit": {
     "auth_ref": [
      "r51",
      "r347",
      "r421",
      "r566",
      "r643",
      "r667",
      "r672"
     ],
     "calculation": {
      "http://roivant.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 29.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cumulative amount of the reporting entity's undistributed earnings or deficit.",
        "label": "Retained Earnings (Accumulated Deficit)",
        "negatedLabel": "Accumulated deficit",
        "terseLabel": "Accumulated deficit"
       }
      }
     },
     "localname": "RetainedEarningsAccumulatedDeficit",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://roivant.com/role/CondensedConsolidatedBalanceSheets",
      "http://roivant.com/role/DescriptionOfBusinessAndLiquidityAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RetainedEarningsMember": {
     "auth_ref": [
      "r0",
      "r152",
      "r153",
      "r154",
      "r156",
      "r163",
      "r166",
      "r243",
      "r418",
      "r419",
      "r420",
      "r450",
      "r451",
      "r504",
      "r663",
      "r665"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cumulative amount of the reporting entity's undistributed earnings or deficit.",
        "label": "Retained Earnings [Member]",
        "terseLabel": "Accumulated Deficit [Member]"
       }
      }
     },
     "localname": "RetainedEarningsMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://roivant.com/role/CondensedConsolidatedStatementsOfShareholdersEquityAndRedeemableNoncontrollingInterest"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax": {
     "auth_ref": [
      "r199",
      "r200",
      "r206",
      "r211",
      "r212",
      "r216",
      "r217",
      "r219",
      "r360",
      "r361",
      "r602"
     ],
     "calculation": {
      "http://roivant.com/role/CondensedConsolidatedStatementsOfOperations": {
       "order": 6.0,
       "parentTag": "us-gaap_OperatingIncomeLoss",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise.",
        "label": "Revenue from Contract with Customer, Excluding Assessed Tax",
        "terseLabel": "Revenue, net"
       }
      }
     },
     "localname": "RevenueFromContractWithCustomerExcludingAssessedTax",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://roivant.com/role/CondensedConsolidatedStatementsOfOperations"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RevenueFromContractWithCustomerPolicyTextBlock": {
     "auth_ref": [
      "r142",
      "r352",
      "r353",
      "r354",
      "r355",
      "r356",
      "r357",
      "r358",
      "r359",
      "r363"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for revenue from contract with customer.",
        "label": "Revenue from Contract with Customer [Policy Text Block]",
        "terseLabel": "Revenue Recognition"
       }
      }
     },
     "localname": "RevenueFromContractWithCustomerPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://roivant.com/role/SummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_RevenueRecognitionMilestoneMethodRevenueRecognized": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of consideration recognized during the period for the milestone or milestones.",
        "label": "Revenue Recognition, Milestone Method, Revenue Recognized",
        "terseLabel": "Non-refundable, up-front payment recognized"
       }
      }
     },
     "localname": "RevenueRecognitionMilestoneMethodRevenueRecognized",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://roivant.com/role/AssetAcquisitionsAndLicenseAgreementsAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability": {
     "auth_ref": [
      "r548",
      "r553"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase in right-of-use asset obtained in exchange for operating lease liability.",
        "label": "Right-of-Use Asset Obtained in Exchange for Operating Lease Liability",
        "terseLabel": "Operating lease right-of-use assets obtained and exchanged for operating lease liabilities",
        "verboseLabel": "Operating lease ROU assets obtained in exchange for operating lease liabilities"
       }
      }
     },
     "localname": "RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://roivant.com/role/CondensedConsolidatedStatementsOfCashFlows",
      "http://roivant.com/role/LeasesSummaryOfOperatingLeaseRouAssetsAndOperatingLeaseLiabilitiesDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_SaleOfStockConsiderationReceivedOnTransaction": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Cash received on stock transaction after deduction of issuance costs.",
        "label": "Sale of Stock, Consideration Received on Transaction",
        "terseLabel": "Consideration received in transaction",
        "verboseLabel": "Net proceeds from sale of stock"
       }
      }
     },
     "localname": "SaleOfStockConsiderationReceivedOnTransaction",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://roivant.com/role/ShareholdersEquityAndRedeemableNonControllingInterestAdditionalInformationDetail",
      "http://roivant.com/role/SumitomoTransactionAgreementAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_SaleOfStockNameOfTransactionDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sale of the entity's stock, including, but not limited to, initial public offering (IPO) and private placement.",
        "label": "Sale of Stock [Domain]",
        "terseLabel": "Sale of Stock [Domain]"
       }
      }
     },
     "localname": "SaleOfStockNameOfTransactionDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://roivant.com/role/ShareholdersEquityAndRedeemableNonControllingInterestAdditionalInformationDetail",
      "http://roivant.com/role/SummaryOfSignificantAccountingPoliciesAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of shares issued or sold by the subsidiary or equity method investee per stock transaction.",
        "label": "Sale of Stock, Number of Shares Issued in Transaction",
        "terseLabel": "Number of shares transferred"
       }
      }
     },
     "localname": "SaleOfStockNumberOfSharesIssuedInTransaction",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://roivant.com/role/ShareholdersEquityAndRedeemableNonControllingInterestAdditionalInformationDetail"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_SaleOfStockPricePerShare": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Per share amount received by subsidiary or equity investee for each share of common stock issued or sold in the stock transaction.",
        "label": "Sale of Stock, Price Per Share",
        "terseLabel": "Common stock per share"
       }
      }
     },
     "localname": "SaleOfStockPricePerShare",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://roivant.com/role/ShareholdersEquityAndRedeemableNonControllingInterestAdditionalInformationDetail"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the components of accrued liabilities.",
        "label": "Schedule of Accrued Liabilities [Table Text Block]",
        "terseLabel": "Schedule of Accrued Expenses"
       }
      }
     },
     "localname": "ScheduleOfAccruedLiabilitiesTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://roivant.com/role/BalanceSheetComponentsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable": {
     "auth_ref": [
      "r466",
      "r467"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule reflecting each material business combination (or series of individually immaterial business combinations) completed during the period, including background, timing, and recognized assets and liabilities.",
        "label": "Schedule of Business Acquisitions, by Acquisition [Table]",
        "terseLabel": "Schedule of Business Acquisitions, by Acquisition [Table]"
       }
      }
     },
     "localname": "ScheduleOfBusinessAcquisitionsByAcquisitionTable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://roivant.com/role/AssetAcquisitionsAndLicenseAgreementsAdditionalInformationDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfCashAndCashEquivalentsTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the components of cash and cash equivalents.",
        "label": "Schedule of Cash and Cash Equivalents [Table Text Block]",
        "terseLabel": "Schedule of Aggregate Amounts of Cash, Cash Equivalents, and Restricted Cash"
       }
      }
     },
     "localname": "ScheduleOfCashAndCashEquivalentsTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://roivant.com/role/SummaryOfSignificantAccountingPoliciesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock": {
     "auth_ref": [
      "r413"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of cost recognized for award under share-based payment arrangement by plan. Includes, but is not limited to, related tax benefit.",
        "label": "Share-based Payment Arrangement, Cost by Plan [Table Text Block]",
        "terseLabel": "Summary of Share-Based Compensation Expense"
       }
      }
     },
     "localname": "ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://roivant.com/role/ShareBasedCompensationTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfDebtTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of information pertaining to short-term and long-debt instruments or arrangements, including but not limited to identification of terms, features, collateral requirements and other information necessary to a fair presentation.",
        "label": "Schedule of Debt [Table Text Block]",
        "terseLabel": "Schedule of Long Term Debt"
       }
      }
     },
     "localname": "ScheduleOfDebtTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://roivant.com/role/LongTermDebtAndLoanCommitmentTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock": {
     "auth_ref": [
      "r441"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the components of net deferred tax asset or liability recognized in an entity's statement of financial position, including the following: the total of all deferred tax liabilities, the total of all deferred tax assets, the total valuation allowance recognized for deferred tax assets.",
        "label": "Schedule of Deferred Tax Assets and Liabilities [Table Text Block]",
        "terseLabel": "Schedule of Company's net deferred tax assets"
       }
      }
     },
     "localname": "ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://roivant.com/role/IncomeTaxesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfDisposalGroupsIncludingDiscontinuedOperationsIncomeStatementBalanceSheetAndAdditionalDisclosuresTextBlock": {
     "auth_ref": [
      "r3",
      "r11",
      "r12",
      "r13",
      "r14",
      "r15",
      "r16",
      "r20",
      "r22",
      "r23",
      "r24",
      "r262",
      "r263"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of information related to a disposal group. Includes, but is not limited to, a discontinued operation, disposal classified as held-for-sale or disposed of by means other than sale or disposal of an individually significant component.",
        "label": "Disposal Groups, Including Discontinued Operations [Table Text Block]",
        "terseLabel": "Summary Of Disposal Groups Including Discontinued Operations Income Statement"
       }
      }
     },
     "localname": "ScheduleOfDisposalGroupsIncludingDiscontinuedOperationsIncomeStatementBalanceSheetAndAdditionalDisclosuresTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://roivant.com/role/DiscontinuedOperationsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock": {
     "auth_ref": [
      "r178"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of an entity's basic and diluted earnings per share calculations, including a reconciliation of numerators and denominators of the basic and diluted per-share computations for income from continuing operations.",
        "label": "Schedule of Earnings Per Share, Basic and Diluted [Table Text Block]",
        "terseLabel": "Schedule of basic and diluted per share of common stock"
       }
      }
     },
     "localname": "ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://roivant.com/role/NetLossPerCommonShareTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock": {
     "auth_ref": [
      "r433"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the reconciliation using percentage or dollar amounts of the reported amount of income tax expense attributable to continuing operations for the year to the amount of income tax expense that would result from applying domestic federal statutory tax rates to pretax income from continuing operations.",
        "label": "Schedule of Effective Income Tax Rate Reconciliation [Table Text Block]",
        "terseLabel": "Reconciliation of Federal Statutory Income Taxes Rate"
       }
      }
     },
     "localname": "ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://roivant.com/role/IncomeTaxesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock": {
     "auth_ref": [
      "r507",
      "r508"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of assets and liabilities, including [financial] instruments measured at fair value that are classified in stockholders' equity, if any, that are measured at fair value on a recurring basis. The disclosures contemplated herein include the fair value measurements at the reporting date by the level within the fair value hierarchy in which the fair value measurements in their entirety fall, segregating fair value measurements using quoted prices in active markets for identical assets (Level 1), significant other observable inputs (Level 2), and significant unobservable inputs (Level 3).",
        "label": "Schedule of Fair Value, Assets and Liabilities Measured on Recurring Basis [Table Text Block]",
        "terseLabel": "Schedule of Assets and Liabilities Measured at Fair Value on a Recurring Basis"
       }
      }
     },
     "localname": "ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://roivant.com/role/FairValueMeasurementsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock": {
     "auth_ref": [
      "r147"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of income before income tax between domestic and foreign jurisdictions.",
        "label": "Schedule of Income before Income Tax, Domestic and Foreign [Table Text Block]",
        "terseLabel": "Schedule of Loss Before Income Taxes and Related Expense/(Benefit)"
       }
      }
     },
     "localname": "ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://roivant.com/role/IncomeTaxesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock": {
     "auth_ref": [
      "r398"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the changes in outstanding nonvested restricted stock units.",
        "label": "Schedule of Nonvested Restricted Stock Units Activity [Table Text Block]",
        "terseLabel": "Summary of Restricted Stock Units"
       }
      }
     },
     "localname": "ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://roivant.com/role/ShareBasedCompensationTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfOtherCurrentAssetsTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the carrying amounts of other current assets.",
        "label": "Schedule of Other Current Assets [Table Text Block]",
        "terseLabel": "Schedule of Other Current Assets"
       }
      }
     },
     "localname": "ScheduleOfOtherCurrentAssetsTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://roivant.com/role/BalanceSheetComponentsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfOtherOperatingCostAndExpenseByComponentTextBlock": {
     "auth_ref": [
      "r114"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of each detailed component of other operating costs and expenses that are applicable to sales and revenues, but not included in the cost of sales in the income statement.",
        "label": "Schedule of Other Operating Cost and Expense, by Component [Table Text Block]",
        "terseLabel": "Summary of Other (Income) Expense, Net From Continuing Operations"
       }
      }
     },
     "localname": "ScheduleOfOtherOperatingCostAndExpenseByComponentTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://roivant.com/role/OtherIncomeExpenseNetTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfPropertyPlantAndEquipmentTable": {
     "auth_ref": [
      "r59",
      "r260"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation.",
        "label": "Property, Plant and Equipment [Table]",
        "terseLabel": "Property, Plant and Equipment [Table]"
       }
      }
     },
     "localname": "ScheduleOfPropertyPlantAndEquipmentTable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://roivant.com/role/SummaryOfSignificantAccountingPoliciesScheduleOfEstimatedUsefulLivesDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable": {
     "auth_ref": [
      "r559",
      "r561"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule of quantitative and qualitative information pertaining to related party transactions. Examples of related party transactions include transactions between (a) a parent company and its subsidiary; (b) subsidiaries of a common parent; (c) and entity and its principal owners; and (d) affiliates.",
        "label": "Schedule of Related Party Transactions, by Related Party [Table]",
        "terseLabel": "Schedule of Related Party Transactions, by Related Party [Table]"
       }
      }
     },
     "localname": "ScheduleOfRelatedPartyTransactionsByRelatedPartyTable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://roivant.com/role/RelatedPartyTransactionsAdditionalInformationDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable": {
     "auth_ref": [
      "r385",
      "r416"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about share-based payment arrangement.",
        "label": "Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table]",
        "terseLabel": "Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table]"
       }
      }
     },
     "localname": "ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://roivant.com/role/ShareBasedCompensationAdditionalInformationDetail",
      "http://roivant.com/role/ShareBasedCompensationScheduleOfFairValueAssumptionsDetail",
      "http://roivant.com/role/ShareBasedCompensationSummaryOfCappedValueAppreciationRightsDetail",
      "http://roivant.com/role/ShareBasedCompensationSummaryOfCommonShareAwardActivityDetail",
      "http://roivant.com/role/ShareBasedCompensationSummaryOfPerformanceOptionsActivityDetail",
      "http://roivant.com/role/ShareBasedCompensationSummaryOfPerformanceRestrictedStockUnitsDetail",
      "http://roivant.com/role/ShareBasedCompensationSummaryOfRestrictedStockUnitsDetail",
      "http://roivant.com/role/ShareBasedCompensationSummaryOfShareBasedCompensationExpenseDetail",
      "http://roivant.com/role/ShareBasedCompensationSummaryOfStockOptionActivityDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock": {
     "auth_ref": [
      "r392",
      "r403",
      "r405"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure for stock option plans. Includes, but is not limited to, outstanding awards at beginning and end of year, grants, exercises, forfeitures, and weighted-average grant date fair value.",
        "label": "Share-based Payment Arrangement, Option, Activity [Table Text Block]",
        "terseLabel": "Summary of Stock Option Activity"
       }
      }
     },
     "localname": "ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://roivant.com/role/ShareBasedCompensationTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock": {
     "auth_ref": [
      "r407"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the significant assumptions used during the year to estimate the fair value of stock options, including, but not limited to: (a) expected term of share options and similar instruments, (b) expected volatility of the entity's shares, (c) expected dividends, (d) risk-free rate(s), and (e) discount for post-vesting restrictions.",
        "label": "Schedule of Share-based Payment Award, Stock Options, Valuation Assumptions [Table Text Block]",
        "terseLabel": "Schedule of Fair Value Assumptions"
       }
      }
     },
     "localname": "ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://roivant.com/role/ShareBasedCompensationTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfStockByClassTable": {
     "auth_ref": [
      "r73",
      "r143",
      "r186",
      "r187",
      "r312",
      "r318",
      "r319",
      "r321",
      "r322",
      "r323",
      "r324",
      "r326",
      "r330",
      "r336",
      "r339",
      "r340",
      "r342",
      "r344",
      "r345",
      "r346",
      "r347"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule detailing information related to equity by class of stock. Class of stock includes common, convertible, and preferred stocks which are not redeemable or redeemable solely at the option of the issuer. It also includes preferred stock with redemption features that are solely within the control of the issuer and mandatorily redeemable stock if redemption is required to occur only upon liquidation or termination of the reporting entity.",
        "label": "Schedule of Stock by Class [Table]",
        "terseLabel": "Schedule of Stock by Class [Table]"
       }
      }
     },
     "localname": "ScheduleOfStockByClassTable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://roivant.com/role/ShareholdersEquityAndRedeemableNonControllingInterestAdditionalInformationDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfStockholdersEquityTableTextBlock": {
     "auth_ref": [
      "r338"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of changes in the separate accounts comprising stockholders' equity (in addition to retained earnings) and of the changes in the number of shares of equity securities during at least the most recent annual fiscal period and any subsequent interim period presented is required to make the financial statements sufficiently informative if both financial position and results of operations are presented.",
        "label": "Schedule of Stockholders Equity [Table Text Block]",
        "terseLabel": "Shareholders' Equity and Redeemable Non-Controlling Interest"
       }
      }
     },
     "localname": "ScheduleOfStockholdersEquityTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://roivant.com/role/ShareholdersEquityAndRedeemableNoncontrollingInterestTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_SecuritiesPurchasedUnderAgreementsToResellIncrease": {
     "auth_ref": [
      "r246"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase from purchase of security purchased under agreement to resell.",
        "label": "Securities Purchased under Agreements to Resell, Increase",
        "terseLabel": "Securities Purchased under Agreements to Resell"
       }
      }
     },
     "localname": "SecuritiesPurchasedUnderAgreementsToResellIncrease",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://roivant.com/role/LongTermDebtAndLoanCommitmentAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_SeriesBPreferredStockMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Outstanding nonredeemable series B preferred stock or outstanding series B preferred stock. Classified within stockholders' equity if nonredeemable or redeemable solely at the option of the issuer. Classified within temporary equity if redemption is outside the control of the issuer.",
        "label": "Series B Preferred Stock [Member]",
        "terseLabel": "Series B Preferred Stock [Member]"
       }
      }
     },
     "localname": "SeriesBPreferredStockMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://roivant.com/role/InvestmentsAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ShareBasedCompensation": {
     "auth_ref": [
      "r132"
     ],
     "calculation": {
      "http://roivant.com/role/CondensedConsolidatedStatementsOfCashFlows": {
       "order": 3.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of noncash expense for share-based payment arrangement.",
        "label": "Share-based Payment Arrangement, Noncash Expense",
        "terseLabel": "Share-based compensation",
        "verboseLabel": "Share-based compensation expense"
       }
      }
     },
     "localname": "ShareBasedCompensation",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://roivant.com/role/AssetAcquisitionsAndLicenseAgreementsAdditionalInformationDetail",
      "http://roivant.com/role/CondensedConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1": {
     "auth_ref": [
      "r387"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Period over which grantee's right to exercise award under share-based payment arrangement is no longer contingent on satisfaction of service or performance condition, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Includes, but is not limited to, combination of market, performance or service condition.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Period",
        "terseLabel": "Grant vesting period"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://roivant.com/role/ShareBasedCompensationAdditionalInformationDetail"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardDescription": {
     "auth_ref": [
      "r383",
      "r386"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Description of terms of share-based payment arrangement. Includes, but is not limited to, type of award or grantee and reason for issuance.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Description",
        "terseLabel": "Grant, Description"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardDescription",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://roivant.com/role/ShareBasedCompensationAdditionalInformationDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod": {
     "auth_ref": [
      "r397"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of equity-based payment instruments, excluding stock (or unit) options, that were forfeited during the reporting period.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Forfeited in Period",
        "negatedLabel": "Forfeited",
        "negatedTerseLabel": "Units Forfeited"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://roivant.com/role/ShareBasedCompensationSummaryOfCappedValueAppreciationRightsDetail",
      "http://roivant.com/role/ShareBasedCompensationSummaryOfCommonShareAwardActivityDetail",
      "http://roivant.com/role/ShareBasedCompensationSummaryOfPerformanceRestrictedStockUnitsDetail",
      "http://roivant.com/role/ShareBasedCompensationSummaryOfRestrictedStockUnitsDetail"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue": {
     "auth_ref": [
      "r402"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average fair value as of the grant date of equity-based award plans other than stock (unit) option plans that were not exercised or put into effect as a result of the occurrence of a terminating event.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Forfeitures, Weighted Average Grant Date Fair Value",
        "terseLabel": "Weighted Average Grant Date Fair Value, Forfeited"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://roivant.com/role/ShareBasedCompensationSummaryOfCommonShareAwardActivityDetail"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod": {
     "auth_ref": [
      "r400"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of grants made during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period",
        "terseLabel": "Granted",
        "verboseLabel": "Units Granted"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://roivant.com/role/ShareBasedCompensationSummaryOfCappedValueAppreciationRightsDetail",
      "http://roivant.com/role/ShareBasedCompensationSummaryOfCommonShareAwardActivityDetail",
      "http://roivant.com/role/ShareBasedCompensationSummaryOfPerformanceRestrictedStockUnitsDetail",
      "http://roivant.com/role/ShareBasedCompensationSummaryOfRestrictedStockUnitsDetail"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue": {
     "auth_ref": [
      "r400"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The weighted average fair value at grant date for nonvested equity-based awards issued during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period, Weighted Average Grant Date Fair Value",
        "terseLabel": "Weighted Average Grant Date Fair Value, vested"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://roivant.com/role/ShareBasedCompensationSummaryOfCommonShareAwardActivityDetail"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber": {
     "auth_ref": [
      "r399"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of non-vested equity-based payment instruments, excluding stock (or unit) options, that validly exist and are outstanding as of the balance sheet date.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Number",
        "periodEndLabel": "Non-vested balance, ending",
        "periodStartLabel": "Non-vested balance, beginning"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://roivant.com/role/ShareBasedCompensationSummaryOfCappedValueAppreciationRightsDetail",
      "http://roivant.com/role/ShareBasedCompensationSummaryOfCommonShareAwardActivityDetail",
      "http://roivant.com/role/ShareBasedCompensationSummaryOfPerformanceRestrictedStockUnitsDetail",
      "http://roivant.com/role/ShareBasedCompensationSummaryOfRestrictedStockUnitsDetail"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue": {
     "auth_ref": [
      "r399"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Per share or unit weighted-average fair value of nonvested award under share-based payment arrangement. Excludes share and unit options.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value",
        "periodEndLabel": "Weighted Average Grant Date Fair Value, Ending Balance"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://roivant.com/role/ShareBasedCompensationSummaryOfCommonShareAwardActivityDetail"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod": {
     "auth_ref": [
      "r401"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of equity-based payment instruments, excluding stock (or unit) options, that vested during the reporting period.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Vested in Period",
        "terseLabel": "Restricted shares vested",
        "verboseLabel": "Vested"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://roivant.com/role/ShareBasedCompensationSummaryOfCommonShareAwardActivityDetail",
      "http://roivant.com/role/ShareholdersEquityAndRedeemableNonControllingInterestAdditionalInformationDetail"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue": {
     "auth_ref": [
      "r401"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The weighted average fair value as of grant date pertaining to an equity-based award plan other than a stock (or unit) option plan for which the grantee gained the right during the reporting period, by satisfying service and performance requirements, to receive or retain shares or units, other instruments, or cash in accordance with the terms of the arrangement.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Vested in Period, Weighted Average Grant Date Fair Value",
        "terseLabel": "Weighted Average Grant Date Fair Value, vested"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://roivant.com/role/ShareBasedCompensationSummaryOfCommonShareAwardActivityDetail"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardExpirationDate": {
     "auth_ref": [
      "r388"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Date the equity-based award expires, in YYYY-MM-DD format.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Expiration Date",
        "terseLabel": "Grant expiration date"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardExpirationDate",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://roivant.com/role/ShareBasedCompensationAdditionalInformationDetail"
     ],
     "xbrltype": "dateItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate": {
     "auth_ref": [
      "r410"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The estimated dividend rate (a percentage of the share price) to be paid (expected dividends) to holders of the underlying shares over the option's term.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Dividend Rate",
        "terseLabel": "Expected dividend yield"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://roivant.com/role/ShareBasedCompensationScheduleOfFairValueAssumptionsDetail"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate": {
     "auth_ref": [
      "r411"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The risk-free interest rate assumption that is used in valuing an option on its own shares.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate",
        "terseLabel": "Expected risk free interest rate"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://roivant.com/role/ShareBasedCompensationScheduleOfFairValueAssumptionsDetail"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate": {
     "auth_ref": [
      "r409"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Rate of weighted-average expected volatility for award under share-based payment arrangement.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Weighted Average Volatility Rate",
        "terseLabel": "Expected stock price volatility"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://roivant.com/role/ShareBasedCompensationScheduleOfFairValueAssumptionsDetail"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award [Line Items]",
        "terseLabel": "Share-based Compensation Arrangement by Share-based Payment Award [Line Items]"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://roivant.com/role/ShareBasedCompensationAdditionalInformationDetail",
      "http://roivant.com/role/ShareBasedCompensationScheduleOfFairValueAssumptionsDetail",
      "http://roivant.com/role/ShareBasedCompensationSummaryOfCappedValueAppreciationRightsDetail",
      "http://roivant.com/role/ShareBasedCompensationSummaryOfCommonShareAwardActivityDetail",
      "http://roivant.com/role/ShareBasedCompensationSummaryOfPerformanceOptionsActivityDetail",
      "http://roivant.com/role/ShareBasedCompensationSummaryOfPerformanceRestrictedStockUnitsDetail",
      "http://roivant.com/role/ShareBasedCompensationSummaryOfRestrictedStockUnitsDetail",
      "http://roivant.com/role/ShareBasedCompensationSummaryOfShareBasedCompensationExpenseDetail",
      "http://roivant.com/role/ShareBasedCompensationSummaryOfStockOptionActivityDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber": {
     "auth_ref": [
      "r393",
      "r395"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of equity instruments other than options outstanding, including both vested and non-vested instruments.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Non-Option Equity Instruments, Outstanding, Number",
        "terseLabel": "Outstanding instruments vest based on the achievement of time-based, performance or liquidity event requirements"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://roivant.com/role/SumitomoTransactionAgreementAdditionalInformationDetail"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant": {
     "auth_ref": [
      "r416"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The difference between the maximum number of shares (or other type of equity) authorized for issuance under the plan (including the effects of amendments and adjustments), and the sum of: 1) the number of shares (or other type of equity) already issued upon exercise of options or other equity-based awards under the plan; and 2) shares (or other type of equity) reserved for issuance on granting of outstanding awards, net of cancellations and forfeitures, if applicable.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Available for Grant",
        "terseLabel": "Common shares available for grant"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://roivant.com/role/ShareBasedCompensationAdditionalInformationDetail"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber": {
     "auth_ref": [
      "r396"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of shares into which fully or partially vested stock options outstanding as of the balance sheet date can be currently converted under the option plan.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Number",
        "terseLabel": "Stock options exercisable"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://roivant.com/role/ShareBasedCompensationSummaryOfStockOptionActivityDetail"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice": {
     "auth_ref": [
      "r396"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The weighted-average price as of the balance sheet date at which grantees can acquire the shares reserved for issuance on vested portions of options outstanding and currently exercisable under the stock option plan.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Weighted Average Exercise Price",
        "terseLabel": "Weighted average exercise price, exercisable"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://roivant.com/role/ShareBasedCompensationSummaryOfStockOptionActivityDetail"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod": {
     "auth_ref": [
      "r397"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of shares under options that were cancelled during the reporting period as a result of occurrence of a terminating event specified in contractual agreements pertaining to the stock option plan.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures in Period",
        "negatedLabel": "Options Forfeited",
        "negatedTerseLabel": "Options Forfeited/Canceled"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://roivant.com/role/ShareBasedCompensationSummaryOfPerformanceOptionsActivityDetail",
      "http://roivant.com/role/ShareBasedCompensationSummaryOfStockOptionActivityDetail"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Gross number of share options (or share units) granted during the period.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross",
        "terseLabel": "Options Granted"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://roivant.com/role/ShareBasedCompensationSummaryOfPerformanceOptionsActivityDetail",
      "http://roivant.com/role/ShareBasedCompensationSummaryOfStockOptionActivityDetail"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue": {
     "auth_ref": [
      "r404"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The weighted average grant-date fair value of options granted during the reporting period as calculated by applying the disclosed option pricing methodology.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value",
        "positiveLabel": "Weighted Average Grant Date Fair Value,Granted",
        "terseLabel": "Units Granted",
        "verboseLabel": "Weighted average grant date fair value, Granted"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://roivant.com/role/ShareBasedCompensationSummaryOfCappedValueAppreciationRightsDetail",
      "http://roivant.com/role/ShareBasedCompensationSummaryOfPerformanceOptionsActivityDetail",
      "http://roivant.com/role/ShareBasedCompensationSummaryOfPerformanceRestrictedStockUnitsDetail",
      "http://roivant.com/role/ShareBasedCompensationSummaryOfRestrictedStockUnitsDetail",
      "http://roivant.com/role/ShareBasedCompensationSummaryOfStockOptionActivityDetail"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber": {
     "auth_ref": [
      "r394",
      "r416"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of options outstanding, including both vested and non-vested options.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Number",
        "periodEndLabel": "Stock options outstanding , Ending balance",
        "periodStartLabel": "Stock options outstanding ,Beginning balance"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://roivant.com/role/ShareBasedCompensationSummaryOfPerformanceOptionsActivityDetail",
      "http://roivant.com/role/ShareBasedCompensationSummaryOfStockOptionActivityDetail"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice": {
     "auth_ref": [
      "r393"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price",
        "periodEndLabel": "Weighted average exercise price, Ending balance",
        "periodStartLabel": "Weighted average exercise price, Beginning balance"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://roivant.com/role/ShareBasedCompensationSummaryOfPerformanceOptionsActivityDetail",
      "http://roivant.com/role/ShareBasedCompensationSummaryOfStockOptionActivityDetail"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain": {
     "auth_ref": [
      "r383",
      "r389"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Award under share-based payment arrangement.",
        "label": "Award Type [Domain]",
        "terseLabel": "Award Type [Domain]"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://roivant.com/role/ShareBasedCompensationAdditionalInformationDetail",
      "http://roivant.com/role/ShareBasedCompensationScheduleOfFairValueAssumptionsDetail",
      "http://roivant.com/role/ShareBasedCompensationSummaryOfCappedValueAppreciationRightsDetail",
      "http://roivant.com/role/ShareBasedCompensationSummaryOfCommonShareAwardActivityDetail",
      "http://roivant.com/role/ShareBasedCompensationSummaryOfPerformanceOptionsActivityDetail",
      "http://roivant.com/role/ShareBasedCompensationSummaryOfPerformanceRestrictedStockUnitsDetail",
      "http://roivant.com/role/ShareBasedCompensationSummaryOfRestrictedStockUnitsDetail",
      "http://roivant.com/role/ShareBasedCompensationSummaryOfStockOptionActivityDetail",
      "http://roivant.com/role/ShareBasedCompensationTables",
      "http://roivant.com/role/ShareholdersEquityAndRedeemableNonControllingInterestAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average price at which grantees could have acquired the underlying shares with respect to stock options that were terminated.",
        "label": "Share-based Compensation Arrangements by Share-based Payment Award, Options, Forfeitures in Period, Weighted Average Exercise Price",
        "terseLabel": "Weighted average exercise price, Forfeited",
        "verboseLabel": "Weighted average exercise price,Forfeited/Canceled"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://roivant.com/role/ShareBasedCompensationSummaryOfPerformanceOptionsActivityDetail",
      "http://roivant.com/role/ShareBasedCompensationSummaryOfStockOptionActivityDetail"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options.",
        "label": "Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price",
        "terseLabel": "Weighted average exercise price, Granted"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://roivant.com/role/ShareBasedCompensationSummaryOfPerformanceOptionsActivityDetail",
      "http://roivant.com/role/ShareBasedCompensationSummaryOfStockOptionActivityDetail"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy": {
     "auth_ref": [
      "r385",
      "r390"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for award under share-based payment arrangement. Includes, but is not limited to, methodology and assumption used in measuring cost.",
        "label": "Share-based Payment Arrangement [Policy Text Block]",
        "terseLabel": "Share-Based Compensation"
       }
      }
     },
     "localname": "ShareBasedCompensationOptionAndIncentivePlansPolicy",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://roivant.com/role/SummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_SharePrice": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Price of a single share of a number of saleable stocks of a company.",
        "label": "Share Price",
        "terseLabel": "Closing price of common stock"
       }
      }
     },
     "localname": "SharePrice",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://roivant.com/role/InvestmentsAdditionalInformationDetail"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareRepurchaseProgramAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by share repurchase program.",
        "label": "Share Repurchase Program [Axis]",
        "terseLabel": "Share Repurchase Program [Axis]"
       }
      }
     },
     "localname": "ShareRepurchaseProgramAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://roivant.com/role/ShareholdersEquityAndRedeemableNonControllingInterestAdditionalInformationDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ShareRepurchaseProgramDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the share repurchase program.",
        "label": "Share Repurchase Program [Domain]",
        "terseLabel": "Share Repurchase Program [Domain]"
       }
      }
     },
     "localname": "ShareRepurchaseProgramDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://roivant.com/role/ShareholdersEquityAndRedeemableNonControllingInterestAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod": {
     "auth_ref": [
      "r388"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Period from grant date that an equity-based award expires, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Expiration Period",
        "terseLabel": "Grant expiration period"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://roivant.com/role/ShareBasedCompensationAdditionalInformationDetail"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1": {
     "auth_ref": [
      "r408",
      "r422"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Expected term of award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Term",
        "terseLabel": "Expected term"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://roivant.com/role/ShareBasedCompensationScheduleOfFairValueAssumptionsDetail"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1": {
     "auth_ref": [
      "r416"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average remaining contractual term for vested portions of options outstanding and currently exercisable or convertible, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Weighted Average Remaining Contractual Term",
        "terseLabel": "Grant contractual term",
        "verboseLabel": "Weighted Average Remaining Contractual Life, exercisable"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://roivant.com/role/ShareBasedCompensationAdditionalInformationDetail",
      "http://roivant.com/role/ShareBasedCompensationSummaryOfStockOptionActivityDetail"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedWeightedAverageGrantDateFairValue": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average grant-date fair value of non-vested options forfeited.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Nonvested Options Forfeited, Weighted Average Grant Date Fair Value",
        "positiveLabel": "Weighted Average Grant Date Fair Value, Granted",
        "positiveTerseLabel": "Weighted Average Grant Date Fair Value,Forfeited",
        "terseLabel": "Units Forfeited",
        "verboseLabel": "Weighted average grant date fair value, forfeited"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedWeightedAverageGrantDateFairValue",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://roivant.com/role/ShareBasedCompensationSummaryOfCappedValueAppreciationRightsDetail",
      "http://roivant.com/role/ShareBasedCompensationSummaryOfPerformanceRestrictedStockUnitsDetail",
      "http://roivant.com/role/ShareBasedCompensationSummaryOfRestrictedStockUnitsDetail",
      "http://roivant.com/role/ShareBasedCompensationSummaryOfStockOptionActivityDetail"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average grant-date fair value of non-vested options outstanding.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Option, Nonvested, Weighted Average Exercise Price",
        "periodEndLabel": "Non-vested units , Ending balance",
        "periodStartLabel": "Non-vested units, Beginning balance"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://roivant.com/role/ShareBasedCompensationSummaryOfCappedValueAppreciationRightsDetail",
      "http://roivant.com/role/ShareBasedCompensationSummaryOfPerformanceRestrictedStockUnitsDetail",
      "http://roivant.com/role/ShareBasedCompensationSummaryOfRestrictedStockUnitsDetail"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2": {
     "auth_ref": [
      "r406"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average remaining contractual term for option awards outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Remaining Contractual Term",
        "terseLabel": "Performance Options outstanding at March 31, 2020",
        "verboseLabel": "Weighted Average Remaining Contractual Life"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://roivant.com/role/ShareBasedCompensationSummaryOfPerformanceOptionsActivityDetail",
      "http://roivant.com/role/ShareBasedCompensationSummaryOfStockOptionActivityDetail"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1": {
     "auth_ref": [
      "r391"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fair value of options vested. Excludes equity instruments other than options, for example, but not limited to, share units, stock appreciation rights, restricted stock.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested in Period, Fair Value",
        "terseLabel": "Fair value of options",
        "verboseLabel": "Grant date fair value of stock options vested"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://roivant.com/role/FairValueMeasurementsAdditionalInformationDetail",
      "http://roivant.com/role/ShareBasedCompensationSummaryOfFairValueOfVestedStockOptionDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of options vested.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested, Number of Shares",
        "terseLabel": "Stock options vested"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://roivant.com/role/ShareBasedCompensationAdditionalInformationDetail"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average grant-date fair value of options vested.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested, Weighted Average Grant Date Fair Value",
        "terseLabel": "Weighted-average grant date fair value per share of stock options granted"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://roivant.com/role/ShareBasedCompensationSummaryOfFairValueOfVestedStockOptionDetail"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_SharesIssuedPricePerShare": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Per share or per unit amount of equity securities issued.",
        "label": "Shares Issued, Price Per Share",
        "terseLabel": "Share price"
       }
      }
     },
     "localname": "SharesIssuedPricePerShare",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://roivant.com/role/ShareholdersEquityAndRedeemableNonControllingInterestAdditionalInformationDetail"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_SharesOutstanding": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares issued which are neither cancelled nor held in the treasury.",
        "label": "Shares, Outstanding",
        "periodEndLabel": "Balance, shares",
        "periodStartLabel": "Balance, shares"
       }
      }
     },
     "localname": "SharesOutstanding",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://roivant.com/role/CondensedConsolidatedStatementsOfShareholdersEquityAndRedeemableNoncontrollingInterest"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShortTermDebtTypeAxis": {
     "auth_ref": [
      "r62"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of short-term debt arrangement.",
        "label": "Short-term Debt, Type [Axis]",
        "terseLabel": "Short-term Debt, Type [Axis]"
       }
      }
     },
     "localname": "ShortTermDebtTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://roivant.com/role/ShareholdersEquityAndRedeemableNonControllingInterestAdditionalInformationDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ShortTermDebtTypeDomain": {
     "auth_ref": [
      "r61"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Type of short-term debt arrangement, such as notes, line of credit, commercial paper, asset-based financing, project financing, letter of credit financing.",
        "label": "Short-term Debt, Type [Domain]",
        "terseLabel": "Short-term Debt, Type [Domain]"
       }
      }
     },
     "localname": "ShortTermDebtTypeDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://roivant.com/role/ShareholdersEquityAndRedeemableNonControllingInterestAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ShortTermLeaseCost": {
     "auth_ref": [
      "r545",
      "r553"
     ],
     "calculation": {
      "http://roivant.com/role/LeasesScheduleOfOperatingLeaseCostsDetail": {
       "order": 2.0,
       "parentTag": "us-gaap_LeaseCost",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of short-term lease cost, excluding expense for lease with term of one month or less.",
        "label": "Short-term Lease, Cost",
        "terseLabel": "Short-term lease cost"
       }
      }
     },
     "localname": "ShortTermLeaseCost",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://roivant.com/role/LeasesScheduleOfOperatingLeaseCostsDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_SignificantAccountingPoliciesTextBlock": {
     "auth_ref": [
      "r141",
      "r151"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for all significant accounting policies of the reporting entity.",
        "label": "Significant Accounting Policies [Text Block]",
        "terseLabel": "Summary of Significant Accounting Policies"
       }
      }
     },
     "localname": "SignificantAccountingPoliciesTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://roivant.com/role/SummaryOfSignificantAccountingPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_SoftwareDevelopmentMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Internally developed software for sale, licensing or long-term internal use.",
        "label": "Software Development [Member]",
        "terseLabel": "Software [Member]"
       }
      }
     },
     "localname": "SoftwareDevelopmentMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://roivant.com/role/SummaryOfSignificantAccountingPoliciesScheduleOfEstimatedUsefulLivesDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_StateAndLocalJurisdictionMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Designated tax department of a state or local government entitled to levy and collect income taxes from the entity.",
        "label": "State and Local Jurisdiction [Member]",
        "terseLabel": "United States and Local Jurisdiction [Member]"
       }
      }
     },
     "localname": "StateAndLocalJurisdictionMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://roivant.com/role/IncomeTaxesAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_StatementClassOfStockAxis": {
     "auth_ref": [
      "r45",
      "r46",
      "r47",
      "r143",
      "r146",
      "r172",
      "r173",
      "r174",
      "r176",
      "r178",
      "r186",
      "r187",
      "r188",
      "r242",
      "r274",
      "r278",
      "r279",
      "r280",
      "r283",
      "r284",
      "r321",
      "r322",
      "r326",
      "r330",
      "r338",
      "r520",
      "r714"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by the different classes of stock of the entity.",
        "label": "Class of Stock [Axis]",
        "terseLabel": "Class of Stock [Axis]"
       }
      }
     },
     "localname": "StatementClassOfStockAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://roivant.com/role/CondensedConsolidatedBalanceSheets",
      "http://roivant.com/role/CondensedConsolidatedBalanceSheetsParenthetical",
      "http://roivant.com/role/CondensedConsolidatedStatementsOfShareholdersEquityAndRedeemableNoncontrollingInterest",
      "http://roivant.com/role/InvestmentsAdditionalInformationDetail",
      "http://roivant.com/role/ShareholdersEquityAndRedeemableNonControllingInterestAdditionalInformationDetail",
      "http://roivant.com/role/SummaryOfSignificantAccountingPoliciesAdditionalInformationDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementEquityComponentsAxis": {
     "auth_ref": [
      "r0",
      "r75",
      "r95",
      "r96",
      "r97",
      "r152",
      "r153",
      "r154",
      "r156",
      "r163",
      "r166",
      "r185",
      "r243",
      "r338",
      "r347",
      "r418",
      "r419",
      "r420",
      "r450",
      "r451",
      "r504",
      "r525",
      "r526",
      "r527",
      "r528",
      "r529",
      "r531",
      "r663",
      "r664",
      "r665",
      "r734"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by component of equity.",
        "label": "Equity Components [Axis]",
        "terseLabel": "Equity Components [Axis]"
       }
      }
     },
     "localname": "StatementEquityComponentsAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://roivant.com/role/CondensedConsolidatedStatementsOfShareholdersEquityAndRedeemableNoncontrollingInterest",
      "http://roivant.com/role/ShareholdersEquityAndRedeemableNonControllingInterestAdditionalInformationDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Statement [Line Items]",
        "terseLabel": "Statement [Line Items]"
       }
      }
     },
     "localname": "StatementLineItems",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://roivant.com/role/CommitmentsContingencies",
      "http://roivant.com/role/CondensedConsolidatedBalanceSheets",
      "http://roivant.com/role/CondensedConsolidatedBalanceSheetsParenthetical",
      "http://roivant.com/role/CondensedConsolidatedStatementsOfCashFlows",
      "http://roivant.com/role/CondensedConsolidatedStatementsOfOperations",
      "http://roivant.com/role/CondensedConsolidatedStatementsOfShareholdersEquityAndRedeemableNoncontrollingInterest",
      "http://roivant.com/role/FairValueMeasurements",
      "http://roivant.com/role/FairValueMeasurementsChangeInTheFairValueOfTheDerivativeWarrantLiabilitiesDetail",
      "http://roivant.com/role/FairValueMeasurementsTables",
      "http://roivant.com/role/IncomeTaxes",
      "http://roivant.com/role/IncomeTaxesTables",
      "http://roivant.com/role/NetLossPerCommonShareTables",
      "http://roivant.com/role/RelatedPartyTransactions",
      "http://roivant.com/role/ShareBasedCompensationTables",
      "http://roivant.com/role/ShareholdersEquityAndRedeemableNoncontrollingInterest",
      "http://roivant.com/role/SubsequentEvents",
      "http://roivant.com/role/SubsequentEventsAdditionalInformationDetail",
      "http://roivant.com/role/SummaryOfSignificantAccountingPolicies",
      "http://roivant.com/role/SummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementOfCashFlowsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement of Cash Flows [Abstract]"
       }
      }
     },
     "localname": "StatementOfCashFlowsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementOfFinancialPositionAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement of Financial Position [Abstract]"
       }
      }
     },
     "localname": "StatementOfFinancialPositionAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementOfPartnersCapitalAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement of Partners' Capital [Abstract]"
       }
      }
     },
     "localname": "StatementOfPartnersCapitalAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementOfStockholdersEquityAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement of Stockholders' Equity [Abstract]"
       }
      }
     },
     "localname": "StatementOfStockholdersEquityAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementTable": {
     "auth_ref": [
      "r152",
      "r153",
      "r154",
      "r185",
      "r602"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule reflecting a Statement of Income, Statement of Cash Flows, Statement of Financial Position, Statement of Shareholders' Equity and Other Comprehensive Income, or other statement as needed.",
        "label": "Statement [Table]",
        "terseLabel": "Statement [Table]"
       }
      }
     },
     "localname": "StatementTable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://roivant.com/role/CommitmentsContingencies",
      "http://roivant.com/role/CondensedConsolidatedBalanceSheets",
      "http://roivant.com/role/CondensedConsolidatedBalanceSheetsParenthetical",
      "http://roivant.com/role/CondensedConsolidatedStatementsOfCashFlows",
      "http://roivant.com/role/CondensedConsolidatedStatementsOfOperations",
      "http://roivant.com/role/CondensedConsolidatedStatementsOfShareholdersEquityAndRedeemableNoncontrollingInterest",
      "http://roivant.com/role/FairValueMeasurements",
      "http://roivant.com/role/FairValueMeasurementsChangeInTheFairValueOfTheDerivativeWarrantLiabilitiesDetail",
      "http://roivant.com/role/FairValueMeasurementsTables",
      "http://roivant.com/role/IncomeTaxes",
      "http://roivant.com/role/IncomeTaxesTables",
      "http://roivant.com/role/NetLossPerCommonShareTables",
      "http://roivant.com/role/RelatedPartyTransactions",
      "http://roivant.com/role/ShareBasedCompensationTables",
      "http://roivant.com/role/ShareholdersEquityAndRedeemableNoncontrollingInterest",
      "http://roivant.com/role/SubsequentEvents",
      "http://roivant.com/role/SubsequentEventsAdditionalInformationDetail",
      "http://roivant.com/role/SummaryOfSignificantAccountingPolicies",
      "http://roivant.com/role/SummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StockIssuedDuringPeriodSharesNewIssues": {
     "auth_ref": [
      "r46",
      "r47",
      "r338",
      "r347"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of new stock issued during the period.",
        "label": "Stock Issued During Period, Shares, New Issues",
        "positiveLabel": "Public offering shares of common stock",
        "positiveTerseLabel": "Stock issued",
        "terseLabel": "Issuance of the Company's common shares, net, shares"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodSharesNewIssues",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://roivant.com/role/AssetAcquisitionsAndLicenseAgreementsAdditionalInformationDetail",
      "http://roivant.com/role/CondensedConsolidatedStatementsOfShareholdersEquityAndRedeemableNoncontrollingInterest",
      "http://roivant.com/role/ShareholdersEquityAndRedeemableNonControllingInterestAdditionalInformationDetail"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_StockIssuedDuringPeriodValueNewIssues": {
     "auth_ref": [
      "r46",
      "r47",
      "r338",
      "r347"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Equity impact of the value of new stock issued during the period. Includes shares issued in an initial public offering or a secondary public offering.",
        "label": "Stock Issued During Period, Value, New Issues",
        "terseLabel": "Issuance of the Company's common shares",
        "verboseLabel": "Stock issued, value"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodValueNewIssues",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://roivant.com/role/AssetAcquisitionsAndLicenseAgreementsAdditionalInformationDetail",
      "http://roivant.com/role/CondensedConsolidatedStatementsOfShareholdersEquityAndRedeemableNoncontrollingInterest"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised": {
     "auth_ref": [
      "r75",
      "r338",
      "r347"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Value of stock issued as a result of the exercise of stock options.",
        "label": "Stock Issued During Period, Value, Stock Options Exercised",
        "terseLabel": "Exercise of subsidiary stock options"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodValueStockOptionsExercised",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://roivant.com/role/CondensedConsolidatedStatementsOfShareholdersEquityAndRedeemableNoncontrollingInterest"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockRepurchaseProgramAuthorizedAmount1": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of stock repurchase plan authorized.",
        "label": "Stock Repurchase Program, Authorized Amount",
        "terseLabel": "Equity securities authorized for repurchase",
        "verboseLabel": "Repurchase of RSL's equity securities approved amount"
       }
      }
     },
     "localname": "StockRepurchaseProgramAuthorizedAmount1",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://roivant.com/role/ShareholdersEquityAndRedeemableNonControllingInterestAdditionalInformationDetail",
      "http://roivant.com/role/SumitomoTransactionAgreementAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockholdersEquity": {
     "auth_ref": [
      "r47",
      "r53",
      "r54",
      "r146",
      "r228",
      "r242",
      "r520",
      "r566"
     ],
     "calculation": {
      "http://roivant.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 25.0,
       "parentTag": "us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.",
        "label": "Stockholders' Equity Attributable to Parent",
        "totalLabel": "Shareholders' equity attributable to Roivant Sciences Ltd."
       }
      }
     },
     "localname": "StockholdersEquity",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://roivant.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockholdersEquityAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stockholders' Equity Attributable to Parent [Abstract]",
        "terseLabel": "Shareholders' equity:"
       }
      }
     },
     "localname": "StockholdersEquityAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://roivant.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest": {
     "auth_ref": [
      "r0",
      "r1",
      "r96",
      "r146",
      "r152",
      "r153",
      "r154",
      "r156",
      "r163",
      "r242",
      "r243",
      "r347",
      "r418",
      "r419",
      "r420",
      "r450",
      "r451",
      "r480",
      "r481",
      "r496",
      "r504",
      "r520",
      "r525",
      "r526",
      "r531",
      "r664",
      "r665",
      "r734"
     ],
     "calculation": {
      "http://roivant.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 24.0,
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of stockholders' equity (deficit), net of receivables from officers, directors, owners, and affiliates of the entity, attributable to both the parent and noncontrolling interests. Amount excludes temporary equity. Alternate caption for the concept is permanent equity.",
        "label": "Stockholders' Equity, Including Portion Attributable to Noncontrolling Interest",
        "periodEndLabel": "Balance",
        "periodStartLabel": "Balance",
        "totalLabel": "Total shareholders' equity"
       }
      }
     },
     "localname": "StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://roivant.com/role/CondensedConsolidatedBalanceSheets",
      "http://roivant.com/role/CondensedConsolidatedStatementsOfShareholdersEquityAndRedeemableNoncontrollingInterest"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockholdersEquityNoteDisclosureTextBlock": {
     "auth_ref": [
      "r144",
      "r322",
      "r325",
      "r326",
      "r327",
      "r328",
      "r329",
      "r330",
      "r331",
      "r332",
      "r334",
      "r335",
      "r337",
      "r347",
      "r351"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for shareholders' equity comprised of portions attributable to the parent entity and noncontrolling interest, including other comprehensive income. Includes, but is not limited to, balances of common stock, preferred stock, additional paid-in capital, other capital and retained earnings, accumulated balance for each classification of other comprehensive income and amount of comprehensive income.",
        "label": "Stockholders' Equity Note Disclosure [Text Block]",
        "terseLabel": "Shareholders' Equity and Redeemable Noncontrolling Interest"
       }
      }
     },
     "localname": "StockholdersEquityNoteDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://roivant.com/role/ShareholdersEquityAndRedeemableNoncontrollingInterest"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_StockholdersEquityNoteSubscriptionsReceivable": {
     "auth_ref": [
      "r46",
      "r47",
      "r53",
      "r318"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Note received instead of cash as contribution to equity. The transaction may be a sale of capital stock or a contribution to paid-in capital.",
        "label": "Stockholders' Equity Note, Subscriptions Receivable",
        "terseLabel": "Subscription receivable"
       }
      }
     },
     "localname": "StockholdersEquityNoteSubscriptionsReceivable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://roivant.com/role/AssetAcquisitionsAndLicenseAgreementsAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_SubsequentEventMember": {
     "auth_ref": [
      "r532",
      "r568"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Identifies event that occurred after the balance sheet date but before financial statements are issued or available to be issued.",
        "label": "Subsequent Event [Member]",
        "terseLabel": "Subsequent Event [Member]"
       }
      }
     },
     "localname": "SubsequentEventMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://roivant.com/role/SubsequentEventsAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_SubsequentEventTypeAxis": {
     "auth_ref": [
      "r532",
      "r568"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by event that occurred after the balance sheet date but before financial statements are issued or available to be issued.",
        "label": "Subsequent Event Type [Axis]",
        "terseLabel": "Subsequent Event Type [Axis]"
       }
      }
     },
     "localname": "SubsequentEventTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://roivant.com/role/SubsequentEventsAdditionalInformationDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_SubsequentEventTypeDomain": {
     "auth_ref": [
      "r532",
      "r568"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Event that occurred after the balance sheet date but before financial statements are issued or available to be issued.",
        "label": "Subsequent Event Type [Domain]",
        "terseLabel": "Subsequent Event Type [Domain]"
       }
      }
     },
     "localname": "SubsequentEventTypeDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://roivant.com/role/SubsequentEventsAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_SubsequentEventsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Subsequent Events [Abstract]"
       }
      }
     },
     "localname": "SubsequentEventsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_SubsequentEventsTextBlock": {
     "auth_ref": [
      "r567",
      "r569"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for significant events or transactions that occurred after the balance sheet date through the date the financial statements were issued or the date the financial statements were available to be issued. Examples include: the sale of a capital stock issue, purchase of a business, settlement of litigation, catastrophic loss, significant foreign exchange rate changes, loans to insiders or affiliates, and transactions not in the ordinary course of business.",
        "label": "Subsequent Events [Text Block]",
        "terseLabel": "Subsequent Events"
       }
      }
     },
     "localname": "SubsequentEventsTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://roivant.com/role/SubsequentEvents"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_SubsidiaryOrEquityMethodInvesteeCumulativePercentageOwnershipAfterAllTransactions": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of subsidiary's or equity method investee's stock owned by parent immediately after all stock transactions.",
        "label": "Subsidiary or Equity Method Investee, Cumulative Percentage Ownership after All Transactions",
        "terseLabel": "Ownership interest"
       }
      }
     },
     "localname": "SubsidiaryOrEquityMethodInvesteeCumulativePercentageOwnershipAfterAllTransactions",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://roivant.com/role/AssetAcquisitionsAndLicenseAgreementsAdditionalInformationDetail"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_SubsidiarySaleOfStockAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of sale of the entity's stock.",
        "label": "Sale of Stock [Axis]",
        "terseLabel": "Sale of Stock [Axis]"
       }
      }
     },
     "localname": "SubsidiarySaleOfStockAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://roivant.com/role/ShareholdersEquityAndRedeemableNonControllingInterestAdditionalInformationDetail",
      "http://roivant.com/role/SummaryOfSignificantAccountingPoliciesAdditionalInformationDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_SupplementalBalanceSheetDisclosuresTextBlock": {
     "auth_ref": [
      "r82"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for supplemental balance sheet disclosures, including descriptions and amounts for assets, liabilities, and equity.",
        "label": "Supplemental Balance Sheet Disclosures [Text Block]",
        "terseLabel": "Balance Sheet Components"
       }
      }
     },
     "localname": "SupplementalBalanceSheetDisclosuresTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://roivant.com/role/BalanceSheetComponents"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_SupplementalCashFlowInformationAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Supplemental Cash Flow Information [Abstract]",
        "terseLabel": "Supplemental disclosure of cash paid:"
       }
      }
     },
     "localname": "SupplementalCashFlowInformationAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://roivant.com/role/CondensedConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_TaxCreditCarryforwardAmount": {
     "auth_ref": [
      "r444"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of the tax credit carryforward, before tax effects, available to reduce future taxable income under enacted tax laws.",
        "label": "Tax Credit Carryforward, Amount",
        "terseLabel": "Research and development tax credit carryforwards"
       }
      }
     },
     "localname": "TaxCreditCarryforwardAmount",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://roivant.com/role/IncomeTaxesAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_TaxCreditCarryforwardExpirationDate": {
     "auth_ref": [
      "r444"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Expiration date of the tax credit carryforward, in YYYY-MM-DD format.",
        "label": "Tax Credit Carryforward, Expiration Date",
        "terseLabel": "Research and development tax credit expiration date"
       }
      }
     },
     "localname": "TaxCreditCarryforwardExpirationDate",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://roivant.com/role/IncomeTaxesAdditionalInformationDetail"
     ],
     "xbrltype": "dateItemType"
    },
    "us-gaap_TaxesPayableCurrent": {
     "auth_ref": [
      "r63"
     ],
     "calculation": {
      "http://roivant.com/role/BalanceSheetComponentsScheduleOfOtherCurrentLiabilitiesDetail": {
       "order": 2.0,
       "parentTag": "us-gaap_OtherLiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying value as of the balance sheet date of obligations incurred and payable for statutory income, sales, use, payroll, excise, real, property and other taxes. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).",
        "label": "Taxes Payable, Current",
        "terseLabel": "Income tax payable"
       }
      }
     },
     "localname": "TaxesPayableCurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://roivant.com/role/BalanceSheetComponentsScheduleOfOtherCurrentLiabilitiesDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_TemporaryEquityCarryingAmountIncludingPortionAttributableToNoncontrollingInterests": {
     "auth_ref": [
      "r72",
      "r146",
      "r242",
      "r520"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying amount, attributable to parent and noncontrolling interests, of an entity's issued and outstanding stock which is not included within permanent equity. Temporary equity is a security with redemption features that are outside the control of the issuer, is not classified as an asset or liability in conformity with GAAP, and is not mandatorily redeemable. Includes any type of security that is redeemable at a fixed or determinable price or on a fixed or determinable date or dates, is redeemable at the option of the holder, or has conditions for redemption which are not solely within the control of the issuer. Includes stock with a put option held by an ESOP and stock redeemable by a holder only in the event of a change in control of the issuer.",
        "label": "Temporary Equity, Carrying Amount, Including Portion Attributable to Noncontrolling Interests",
        "periodEndLabel": "Balance, temporary equity",
        "periodStartLabel": "Balance, temporary equity"
       }
      }
     },
     "localname": "TemporaryEquityCarryingAmountIncludingPortionAttributableToNoncontrollingInterests",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://roivant.com/role/CondensedConsolidatedStatementsOfShareholdersEquityAndRedeemableNoncontrollingInterest"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_TemporaryEquityStockIssuedDuringPeriodValueNewIssues": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Value of new stock classified as temporary equity issued during the period.",
        "label": "Temporary Equity, Stock Issued During Period, Value, New Issues",
        "terseLabel": "Issuance of subsidiary convertible and redeemable preferred stock, net"
       }
      }
     },
     "localname": "TemporaryEquityStockIssuedDuringPeriodValueNewIssues",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://roivant.com/role/CondensedConsolidatedStatementsOfShareholdersEquityAndRedeemableNoncontrollingInterest"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_TradeAndOtherAccountsReceivablePolicy": {
     "auth_ref": [
      "r223",
      "r224",
      "r225",
      "r226",
      "r227",
      "r229"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for accounts receivable.",
        "label": "Accounts Receivable [Policy Text Block]",
        "terseLabel": "Trade Receivables, Net"
       }
      }
     },
     "localname": "TradeAndOtherAccountsReceivablePolicy",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://roivant.com/role/SummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_TransactionDomain": {
     "auth_ref": [
      "r81"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Agreement between buyer and seller for the exchange of financial instruments.",
        "label": "Transaction [Domain]",
        "terseLabel": "Transaction [Domain]"
       }
      }
     },
     "localname": "TransactionDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://roivant.com/role/LongTermDebtAndLoanCommitmentAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_TransactionTypeAxis": {
     "auth_ref": [
      "r81"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of agreement between buyer and seller for the exchange of financial instruments.",
        "label": "Transaction Type [Axis]",
        "terseLabel": "Transaction Type [Axis]"
       }
      }
     },
     "localname": "TransactionTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://roivant.com/role/LongTermDebtAndLoanCommitmentAdditionalInformationDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain": {
     "auth_ref": [
      "r232",
      "r233",
      "r234",
      "r235",
      "r236",
      "r302",
      "r336",
      "r502",
      "r570",
      "r571",
      "r572",
      "r573",
      "r574",
      "r575",
      "r576",
      "r577",
      "r578",
      "r579",
      "r580",
      "r581",
      "r582",
      "r583",
      "r584",
      "r585",
      "r586",
      "r587",
      "r588",
      "r589",
      "r590",
      "r591",
      "r592",
      "r593",
      "r594",
      "r595",
      "r596",
      "r597",
      "r598",
      "r599",
      "r714",
      "r715",
      "r716",
      "r717",
      "r718",
      "r719",
      "r720"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Instrument or contract that imposes a contractual obligation to deliver cash or another financial instrument or to exchange other financial instruments on potentially unfavorable terms and conveys a contractual right to receive cash or another financial instrument or to exchange other financial instruments on potentially favorable terms.",
        "label": "Financial Instruments [Domain]"
       }
      }
     },
     "localname": "TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://roivant.com/role/LongTermDebtAndLoanCommitmentAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_TreasuryStockAcquiredRepurchaseAuthorization": {
     "auth_ref": [
      "r348",
      "r349"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Description of share repurchase program, including accounting treatment.",
        "label": "Treasury Stock Acquired, Repurchase Authorization",
        "terseLabel": "Description of share repurchase offer"
       }
      }
     },
     "localname": "TreasuryStockAcquiredRepurchaseAuthorization",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://roivant.com/role/ShareholdersEquityAndRedeemableNonControllingInterestAdditionalInformationDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_TypeOfArrangementAxis": {
     "auth_ref": [
      "r479"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations.",
        "label": "Collaborative Arrangement and Arrangement Other than Collaborative [Axis]",
        "terseLabel": "Collaborative Arrangement and Arrangement Other than Collaborative [Axis]"
       }
      }
     },
     "localname": "TypeOfArrangementAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://roivant.com/role/LongTermDebtAndLoanCommitmentAdditionalInformationDetail",
      "http://roivant.com/role/ShareholdersEquityAndRedeemableNonControllingInterestAdditionalInformationDetail",
      "http://roivant.com/role/SubsequentEventsAdditionalInformationDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_UnrealizedGainLossOnInvestments": {
     "auth_ref": [
      "r133"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of unrealized gain (loss) on investment.",
        "label": "Unrealized Gain (Loss) on Investments",
        "terseLabel": "Unrealized gain (loss) on investments"
       }
      }
     },
     "localname": "UnrealizedGainLossOnInvestments",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://roivant.com/role/InvestmentsAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_UnrecognizedTaxBenefits": {
     "auth_ref": [
      "r428",
      "r436"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of unrecognized tax benefits.",
        "label": "Unrecognized Tax Benefits",
        "terseLabel": "Unrecognized tax benefits"
       }
      }
     },
     "localname": "UnrecognizedTaxBenefits",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://roivant.com/role/IncomeTaxesAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_UnusualRisksAndUncertaintiesTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the nature of the unusual risk or uncertainty, if estimable, such as the threat of expropriation of its assets by a foreign government, rapid technological obsolescence in the industry, risk of natural disaster from earthquake or weather events, and availability of or continuation of a labor force at a reasonable cost.",
        "label": "Unusual Risks and Uncertainties [Table Text Block]",
        "terseLabel": "Risks and Uncertainties"
       }
      }
     },
     "localname": "UnusualRisksAndUncertaintiesTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://roivant.com/role/SummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_UseOfEstimates": {
     "auth_ref": [
      "r189",
      "r190",
      "r192",
      "r193",
      "r194",
      "r195",
      "r196"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles.",
        "label": "Use of Estimates, Policy [Policy Text Block]",
        "terseLabel": "Use of Estimates"
       }
      }
     },
     "localname": "UseOfEstimates",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://roivant.com/role/SummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount": {
     "auth_ref": [
      "r441"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) in the valuation allowance for a specified deferred tax asset.",
        "label": "Valuation Allowance, Deferred Tax Asset, Increase (Decrease), Amount",
        "terseLabel": "Valuation allowance increase (decrease)"
       }
      }
     },
     "localname": "ValuationAllowanceDeferredTaxAssetChangeInAmount",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://roivant.com/role/IncomeTaxesAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ValueAddedTaxReceivable": {
     "auth_ref": [
      "r79"
     ],
     "calculation": {
      "http://roivant.com/role/BalanceSheetComponentsScheduleOfOtherCurrentAssetsDetail": {
       "order": 2.0,
       "parentTag": "us-gaap_OtherAssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying amount as of the balance sheet date of value added taxes due either from customers arising from sales on credit terms, or as previously overpaid to tax authorities.",
        "label": "Value Added Tax Receivable",
        "terseLabel": "Receivables for value added tax (VAT) paid"
       }
      }
     },
     "localname": "ValueAddedTaxReceivable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://roivant.com/role/BalanceSheetComponentsScheduleOfOtherCurrentAssetsDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_VariableLeaseCost": {
     "auth_ref": [
      "r546",
      "r553"
     ],
     "calculation": {
      "http://roivant.com/role/LeasesScheduleOfOperatingLeaseCostsDetail": {
       "order": 3.0,
       "parentTag": "us-gaap_LeaseCost",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of variable lease cost, excluded from lease liability, recognized when obligation for payment is incurred for finance and operating leases.",
        "label": "Variable Lease, Cost",
        "terseLabel": "Variable lease cost"
       }
      }
     },
     "localname": "VariableLeaseCost",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://roivant.com/role/LeasesScheduleOfOperatingLeaseCostsDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_VariableRateAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of variable rate.",
        "label": "Variable Rate [Axis]",
        "terseLabel": "Variable Rate [Axis]"
       }
      }
     },
     "localname": "VariableRateAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://roivant.com/role/LongTermDebtAndLoanCommitmentAdditionalInformationDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_VariableRateDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Interest rate that fluctuates over time as a result of an underlying benchmark interest rate or index.",
        "label": "Variable Rate [Domain]",
        "terseLabel": "Variable Rate [Domain]"
       }
      }
     },
     "localname": "VariableRateDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://roivant.com/role/LongTermDebtAndLoanCommitmentAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_WarrantMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Security that gives the holder the right to purchase shares of stock in accordance with the terms of the instrument, usually upon payment of a specified amount.",
        "label": "Warrant [Member]",
        "terseLabel": "Warrant"
       }
      }
     },
     "localname": "WarrantMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://roivant.com/role/ShareholdersEquityAndRedeemableNonControllingInterestAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding": {
     "auth_ref": [
      "r171",
      "r178"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period.",
        "label": "Weighted Average Number of Shares Outstanding, Diluted",
        "terseLabel": "Diluted"
       }
      }
     },
     "localname": "WeightedAverageNumberOfDilutedSharesOutstanding",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://roivant.com/role/CondensedConsolidatedStatementsOfOperations"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Average number of shares or units issued and outstanding that are used in calculating basic and diluted earnings per share (EPS).",
        "label": "Weighted Average Number of Shares Outstanding, Basic and Diluted",
        "verboseLabel": "Weighted average shares outstanding\u2014basic and diluted"
       }
      }
     },
     "localname": "WeightedAverageNumberOfShareOutstandingBasicAndDiluted",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://roivant.com/role/CondensedConsolidatedStatementsOfOperations"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_WeightedAverageNumberOfSharesContingentlyIssuable": {
     "auth_ref": [
      "r170"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Shares issuable for little or no cash consideration upon the satisfaction of certain conditions (contingently issuable shares) are considered outstanding common shares and included in the computation of basic Earnings Per Share as of the date that all necessary conditions have been satisfied (in essence, when issuance of the shares is no longer contingent). Outstanding common shares that are contingently returnable (that is, subject to recall) are treated in the same manner as contingently issuable shares. Contingently issuable shares include shares that (a) will be issued in the future upon the satisfaction of specified conditions, (b) have been placed in escrow and all or part must be returned if specified conditions are not met, or (c) have been issued but the holder must return all or part if specified conditions are not met. The number of contingently issuable shares is determined by relating the portion of time within a reporting period that these shares have been outstanding to the total time in that period.",
        "label": "Weighted Average Number of Shares, Contingently Issuable",
        "terseLabel": "Earnout shares"
       }
      }
     },
     "localname": "WeightedAverageNumberOfSharesContingentlyIssuable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://roivant.com/role/ShareholdersEquityAndRedeemableNonControllingInterestAdditionalInformationDetail"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_WeightedAverageNumberOfSharesOutstandingBasic": {
     "auth_ref": [
      "r168",
      "r178"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.",
        "label": "Weighted Average Number of Shares Outstanding, Basic",
        "terseLabel": "Basic"
       }
      }
     },
     "localname": "WeightedAverageNumberOfSharesOutstandingBasic",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://roivant.com/role/CondensedConsolidatedStatementsOfOperations"
     ],
     "xbrltype": "sharesItemType"
    }
   },
   "unitCount": 9
  }
 },
 "std_ref": {
  "r0": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "105",
   "URI": "http://asc.fasb.org/extlink&oid=124434974&loc=SL124442142-165695"
  },
  "r1": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "105",
   "URI": "http://asc.fasb.org/extlink&oid=124434974&loc=SL124442142-165695"
  },
  "r10": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "205",
   "URI": "http://asc.fasb.org/extlink&oid=109222650&loc=d3e1361-107760"
  },
  "r100": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(10))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227"
  },
  "r101": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(12))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227"
  },
  "r102": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(14))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227"
  },
  "r103": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(20))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227"
  },
  "r104": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(21))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227"
  },
  "r105": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(22))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227"
  },
  "r106": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(23))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227"
  },
  "r107": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(24))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227"
  },
  "r108": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(4))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227"
  },
  "r109": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(b)(7)(c))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227"
  },
  "r11": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "205",
   "URI": "http://asc.fasb.org/extlink&oid=109222650&loc=d3e1361-107760"
  },
  "r110": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(b)(9)(a))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227"
  },
  "r111": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.13)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227"
  },
  "r112": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.19)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227"
  },
  "r113": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.2)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227"
  },
  "r114": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.3)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227"
  },
  "r115": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.4)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227"
  },
  "r116": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.7(c),9(a))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227"
  },
  "r117": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.9)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227"
  },
  "r118": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3179-108585"
  },
  "r119": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3179-108585"
  },
  "r12": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "205",
   "URI": "http://asc.fasb.org/extlink&oid=109222650&loc=d3e1474-107760"
  },
  "r120": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3213-108585"
  },
  "r121": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3213-108585"
  },
  "r122": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3213-108585"
  },
  "r123": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3255-108585"
  },
  "r124": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3255-108585"
  },
  "r125": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3291-108585"
  },
  "r126": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3291-108585"
  },
  "r127": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3367-108585"
  },
  "r128": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3000-108585"
  },
  "r129": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "24",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3521-108585"
  },
  "r13": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "205",
   "URI": "http://asc.fasb.org/extlink&oid=109222650&loc=SL51721659-107760"
  },
  "r130": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3536-108585"
  },
  "r131": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3536-108585"
  },
  "r132": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3602-108585"
  },
  "r133": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3602-108585"
  },
  "r134": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3602-108585"
  },
  "r135": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3044-108585"
  },
  "r136": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123431023&loc=d3e4273-108586"
  },
  "r137": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123431023&loc=d3e4297-108586"
  },
  "r138": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123431023&loc=d3e4304-108586"
  },
  "r139": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123431023&loc=d3e4332-108586"
  },
  "r14": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "205",
   "URI": "http://asc.fasb.org/extlink&oid=109222650&loc=SL51721663-107760"
  },
  "r140": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123431023&loc=SL98516268-108586"
  },
  "r141": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=123372394&loc=d3e18726-107790"
  },
  "r142": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=123372394&loc=d3e18823-107790"
  },
  "r143": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(d))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r144": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(e)(1))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r145": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(f))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r146": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(g)(1)(ii))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r147": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(h)(1)(Note 1))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r148": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(h)(2))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r149": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(h))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r15": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "205",
   "URI": "http://asc.fasb.org/extlink&oid=109222650&loc=SL51721665-107760"
  },
  "r150": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.12-04(a))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e24072-122690"
  },
  "r151": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "235",
   "URI": "http://asc.fasb.org/topic&trid=2122369"
  },
  "r152": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "23",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124436220&loc=d3e21914-107793"
  },
  "r153": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "24",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124436220&loc=d3e21930-107793"
  },
  "r154": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124436220&loc=d3e21711-107793"
  },
  "r155": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)(2)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22499-107794"
  },
  "r156": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)(3)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22499-107794"
  },
  "r157": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22694-107794"
  },
  "r158": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22694-107794"
  },
  "r159": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=SL124452830-107794"
  },
  "r16": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "205",
   "URI": "http://asc.fasb.org/extlink&oid=109222650&loc=SL51721671-107760"
  },
  "r160": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22583-107794"
  },
  "r161": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22595-107794"
  },
  "r162": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22644-107794"
  },
  "r163": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22644-107794"
  },
  "r164": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22644-107794"
  },
  "r165": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22658-107794"
  },
  "r166": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22663-107794"
  },
  "r167": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 11.M.Q2)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=122038215&loc=d3e31137-122693"
  },
  "r168": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=d3e1448-109256"
  },
  "r169": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=d3e1377-109256"
  },
  "r17": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "205",
   "URI": "http://asc.fasb.org/extlink&oid=109222650&loc=SL51721673-107760"
  },
  "r170": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=d3e2646-109256"
  },
  "r171": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "16",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=d3e1505-109256"
  },
  "r172": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=d3e1252-109256"
  },
  "r173": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=d3e1278-109256"
  },
  "r174": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "55",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=d3e2626-109256"
  },
  "r175": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "60B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=SL5780133-109256"
  },
  "r176": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "60B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=SL5780133-109256"
  },
  "r177": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=d3e1337-109256"
  },
  "r178": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=124432515&loc=d3e3550-109257"
  },
  "r179": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=124432515&loc=d3e3550-109257"
  },
  "r18": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "205",
   "URI": "http://asc.fasb.org/extlink&oid=109222650&loc=SL51721673-107760"
  },
  "r180": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=124432515&loc=d3e3550-109257"
  },
  "r181": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=124432515&loc=d3e3630-109257"
  },
  "r182": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=109243012&loc=SL65017193-207537"
  },
  "r183": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=125512782&loc=d3e3842-109258"
  },
  "r184": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "260",
   "URI": "http://asc.fasb.org/topic&trid=2144383"
  },
  "r185": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "272",
   "URI": "http://asc.fasb.org/extlink&oid=125520817&loc=d3e70191-108054"
  },
  "r186": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "272",
   "URI": "http://asc.fasb.org/extlink&oid=125520817&loc=d3e70229-108054"
  },
  "r187": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "272",
   "URI": "http://asc.fasb.org/extlink&oid=6373374&loc=d3e70434-108055"
  },
  "r188": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "272",
   "URI": "http://asc.fasb.org/extlink&oid=6373374&loc=d3e70478-108055"
  },
  "r189": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e5967-108592"
  },
  "r19": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)",
   "Topic": "205",
   "URI": "http://asc.fasb.org/extlink&oid=109222650&loc=SL51721673-107760"
  },
  "r190": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e5967-108592"
  },
  "r191": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e5967-108592"
  },
  "r192": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6161-108592"
  },
  "r193": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6191-108592"
  },
  "r194": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6061-108592"
  },
  "r195": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6132-108592"
  },
  "r196": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6143-108592"
  },
  "r197": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "275",
   "URI": "http://asc.fasb.org/topic&trid=2134479"
  },
  "r198": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8672-108599"
  },
  "r199": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8736-108599"
  },
  "r2": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "205",
   "URI": "http://asc.fasb.org/extlink&oid=124429488&loc=d3e326-107755"
  },
  "r20": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "205",
   "URI": "http://asc.fasb.org/extlink&oid=109222650&loc=SL51721673-107760"
  },
  "r200": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8736-108599"
  },
  "r201": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8736-108599"
  },
  "r202": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(g)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8736-108599"
  },
  "r203": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(h)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8736-108599"
  },
  "r204": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8736-108599"
  },
  "r205": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8813-108599"
  },
  "r206": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "30",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8906-108599"
  },
  "r207": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "30",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8906-108599"
  },
  "r208": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "30",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8906-108599"
  },
  "r209": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "30",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8906-108599"
  },
  "r21": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5C",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(2)",
   "Topic": "205",
   "URI": "http://asc.fasb.org/extlink&oid=109222650&loc=SL51721675-107760"
  },
  "r210": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "31",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8924-108599"
  },
  "r211": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8933-108599"
  },
  "r212": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8933-108599"
  },
  "r213": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8933-108599"
  },
  "r214": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8933-108599"
  },
  "r215": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8933-108599"
  },
  "r216": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "40",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e9031-108599"
  },
  "r217": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "41",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e9038-108599"
  },
  "r218": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "41",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e9038-108599"
  },
  "r219": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "42",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e9054-108599"
  },
  "r22": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5C",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "205",
   "URI": "http://asc.fasb.org/extlink&oid=109222650&loc=SL51721675-107760"
  },
  "r220": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "310",
   "URI": "http://asc.fasb.org/extlink&oid=124259787&loc=d3e4647-111522"
  },
  "r221": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "310",
   "URI": "http://asc.fasb.org/extlink&oid=124259787&loc=d3e4428-111522"
  },
  "r222": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "310",
   "URI": "http://asc.fasb.org/extlink&oid=124259787&loc=d3e4531-111522"
  },
  "r223": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "310",
   "URI": "http://asc.fasb.org/extlink&oid=123577603&loc=d3e4975-111524"
  },
  "r224": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "310",
   "URI": "http://asc.fasb.org/extlink&oid=123577603&loc=SL6953423-111524"
  },
  "r225": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "310",
   "URI": "http://asc.fasb.org/extlink&oid=123577603&loc=d3e5212-111524"
  },
  "r226": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "310",
   "URI": "http://asc.fasb.org/extlink&oid=123577603&loc=d3e5033-111524"
  },
  "r227": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "310",
   "URI": "http://asc.fasb.org/extlink&oid=123577603&loc=d3e5093-111524"
  },
  "r228": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 4.E)",
   "Topic": "310",
   "URI": "http://asc.fasb.org/extlink&oid=122038336&loc=d3e74512-122707"
  },
  "r229": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "310",
   "URI": "http://asc.fasb.org/extlink&oid=84159169&loc=d3e10133-111534"
  },
  "r23": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5D",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "205",
   "URI": "http://asc.fasb.org/extlink&oid=109222650&loc=SL51721677-107760"
  },
  "r230": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=124260329&loc=d3e26853-111562"
  },
  "r231": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=123581744&loc=d3e27405-111563"
  },
  "r232": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=123581744&loc=d3e27232-111563"
  },
  "r233": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=123581744&loc=SL120269820-111563"
  },
  "r234": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "321",
   "URI": "http://asc.fasb.org/extlink&oid=123583765&loc=SL75117539-209714"
  },
  "r235": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "321",
   "URI": "http://asc.fasb.org/extlink&oid=123583765&loc=SL75117539-209714"
  },
  "r236": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "321",
   "URI": "http://asc.fasb.org/extlink&oid=123583765&loc=SL75117539-209714"
  },
  "r237": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "25",
   "SubTopic": "10",
   "Topic": "323",
   "URI": "http://asc.fasb.org/extlink&oid=125513658&loc=d3e32014-111567"
  },
  "r238": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "323",
   "URI": "http://asc.fasb.org/extlink&oid=109237563&loc=d3e33749-111570"
  },
  "r239": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(1)",
   "Topic": "323",
   "URI": "http://asc.fasb.org/extlink&oid=114001798&loc=d3e33918-111571"
  },
  "r24": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "205",
   "URI": "http://asc.fasb.org/extlink&oid=109222650&loc=SL51721683-107760"
  },
  "r240": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(2)",
   "Topic": "323",
   "URI": "http://asc.fasb.org/extlink&oid=114001798&loc=d3e33918-111571"
  },
  "r241": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(3)",
   "Topic": "323",
   "URI": "http://asc.fasb.org/extlink&oid=114001798&loc=d3e33918-111571"
  },
  "r242": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "323",
   "URI": "http://asc.fasb.org/extlink&oid=114001798&loc=d3e33918-111571"
  },
  "r243": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=122640432&loc=SL121648383-210437"
  },
  "r244": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(e)(3)",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=122640432&loc=SL121648383-210437"
  },
  "r245": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(e)(4)",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=122640432&loc=SL121648383-210437"
  },
  "r246": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(h)",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=124255953&loc=SL82919244-210447"
  },
  "r247": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=124255953&loc=SL82919244-210447"
  },
  "r248": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=124255953&loc=SL82919249-210447"
  },
  "r249": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=124255953&loc=SL82919253-210447"
  },
  "r25": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "20",
   "Topic": "205",
   "URI": "http://asc.fasb.org/extlink&oid=26872618&loc=d3e7436-122677"
  },
  "r250": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "16",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=124255953&loc=SL82919258-210447"
  },
  "r251": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=124255953&loc=SL82919230-210447"
  },
  "r252": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=124269663&loc=SL82922888-210455"
  },
  "r253": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=124269663&loc=SL82922895-210455"
  },
  "r254": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=124269663&loc=SL82922900-210455"
  },
  "r255": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "30",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=121590138&loc=SL82922954-210456"
  },
  "r256": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "05",
   "SubTopic": "10",
   "Topic": "340",
   "URI": "http://asc.fasb.org/extlink&oid=123349782&loc=d3e5879-108316"
  },
  "r257": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "340",
   "URI": "http://asc.fasb.org/extlink&oid=6387103&loc=d3e6435-108320"
  },
  "r258": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "35",
   "SubTopic": "10",
   "Topic": "360",
   "URI": "http://asc.fasb.org/extlink&oid=123364984&loc=d3e1205-110223"
  },
  "r259": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "360",
   "URI": "http://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229"
  },
  "r26": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "SubTopic": "20",
   "Topic": "205",
   "URI": "http://asc.fasb.org/subtopic&trid=2122178"
  },
  "r260": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "360",
   "URI": "http://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229"
  },
  "r261": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "360",
   "URI": "http://asc.fasb.org/extlink&oid=109226691&loc=d3e2941-110230"
  },
  "r262": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "360",
   "URI": "http://asc.fasb.org/extlink&oid=109226691&loc=d3e2941-110230"
  },
  "r263": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "360",
   "URI": "http://asc.fasb.org/extlink&oid=109226691&loc=SL51724579-110230"
  },
  "r264": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "360",
   "URI": "http://asc.fasb.org/topic&trid=2155823"
  },
  "r265": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "420",
   "URI": "http://asc.fasb.org/extlink&oid=6394359&loc=d3e17939-110869"
  },
  "r266": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "440",
   "URI": "http://asc.fasb.org/extlink&oid=123406679&loc=d3e25336-109308"
  },
  "r267": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "440",
   "URI": "http://asc.fasb.org/extlink&oid=123406679&loc=d3e25336-109308"
  },
  "r268": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "440",
   "URI": "http://asc.fasb.org/topic&trid=2144648"
  },
  "r269": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "450",
   "URI": "http://asc.fasb.org/extlink&oid=121557415&loc=d3e14326-108349"
  },
  "r27": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "205",
   "URI": "http://asc.fasb.org/topic&trid=2122149"
  },
  "r270": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "450",
   "URI": "http://asc.fasb.org/topic&trid=2127136"
  },
  "r271": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "460",
   "URI": "http://asc.fasb.org/extlink&oid=123368208&loc=d3e12565-110249"
  },
  "r272": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=99376301&loc=d3e1243-112600"
  },
  "r273": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123465755&loc=d3e1835-112601"
  },
  "r274": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(i))",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756"
  },
  "r275": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(ii))",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756"
  },
  "r276": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(iii)(A))",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756"
  },
  "r277": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(iii))",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756"
  },
  "r278": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(iv))",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756"
  },
  "r279": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(5))",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756"
  },
  "r28": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=124098289&loc=d3e6676-107765"
  },
  "r280": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(4)(i))",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442552-122756"
  },
  "r281": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(4)(iii)(A))",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442552-122756"
  },
  "r282": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(4)(iii)(B))",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442552-122756"
  },
  "r283": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(4)(iv))",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442552-122756"
  },
  "r284": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(5))",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442552-122756"
  },
  "r285": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611"
  },
  "r286": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611"
  },
  "r287": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611"
  },
  "r288": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611"
  },
  "r289": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(e)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611"
  },
  "r29": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=124098289&loc=d3e6676-107765"
  },
  "r290": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(f)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611"
  },
  "r291": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(h)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611"
  },
  "r292": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1D",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495340-112611"
  },
  "r293": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1D",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495340-112611"
  },
  "r294": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1D",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495340-112611"
  },
  "r295": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1E",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495348-112611"
  },
  "r296": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1E",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495348-112611"
  },
  "r297": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1E",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495348-112611"
  },
  "r298": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1F",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495355-112611"
  },
  "r299": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1F",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495355-112611"
  },
  "r3": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Topic": "205",
   "URI": "http://asc.fasb.org/extlink&oid=109222160&loc=SL51721533-107759"
  },
  "r30": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=124098289&loc=d3e6676-107765"
  },
  "r300": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1F",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(1)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495355-112611"
  },
  "r301": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1F",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(2)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495355-112611"
  },
  "r302": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1I",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495371-112611"
  },
  "r303": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466204&loc=SL6031897-161870"
  },
  "r304": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(1)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466204&loc=SL6031897-161870"
  },
  "r305": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(2)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466204&loc=SL6031897-161870"
  },
  "r306": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(3)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466204&loc=SL6031897-161870"
  },
  "r307": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "69B",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466577&loc=SL123495735-112612"
  },
  "r308": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "69C",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466577&loc=SL123495737-112612"
  },
  "r309": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "69E",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466577&loc=SL123495743-112612"
  },
  "r31": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(g)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=124098289&loc=d3e6676-107765"
  },
  "r310": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "69F",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466577&loc=SL123495745-112612"
  },
  "r311": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "470",
   "URI": "http://asc.fasb.org/topic&trid=2208564"
  },
  "r312": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(CFRR 211.02)",
   "Topic": "480",
   "URI": "http://asc.fasb.org/extlink&oid=122040564&loc=d3e177068-122764"
  },
  "r313": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 3.C)",
   "Topic": "480",
   "URI": "http://asc.fasb.org/extlink&oid=122040564&loc=d3e177168-122764"
  },
  "r314": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(12)(c)",
   "Topic": "480",
   "URI": "http://asc.fasb.org/extlink&oid=122040564&loc=SL6540498-122764"
  },
  "r315": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(16)(c)",
   "Topic": "480",
   "URI": "http://asc.fasb.org/extlink&oid=122040564&loc=SL6540498-122764"
  },
  "r316": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "14",
   "Topic": "480",
   "URI": "http://asc.fasb.org/extlink&oid=122040564&loc=SL6540498-122764"
  },
  "r317": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "15",
   "Topic": "480",
   "URI": "http://asc.fasb.org/extlink&oid=122040564&loc=SL6540498-122764"
  },
  "r318": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=65888546&loc=d3e21300-112643"
  },
  "r319": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=d3e21553-112644"
  },
  "r32": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=124098289&loc=d3e6676-107765"
  },
  "r320": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=d3e21564-112644"
  },
  "r321": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496158-112644"
  },
  "r322": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496158-112644"
  },
  "r323": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496158-112644"
  },
  "r324": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496158-112644"
  },
  "r325": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(g)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496158-112644"
  },
  "r326": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(h)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496158-112644"
  },
  "r327": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(i)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496158-112644"
  },
  "r328": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496158-112644"
  },
  "r329": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496171-112644"
  },
  "r33": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=124098289&loc=d3e6787-107765"
  },
  "r330": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496171-112644"
  },
  "r331": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496171-112644"
  },
  "r332": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "16",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496180-112644"
  },
  "r333": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "16",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496180-112644"
  },
  "r334": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496189-112644"
  },
  "r335": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496189-112644"
  },
  "r336": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496189-112644"
  },
  "r337": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496189-112644"
  },
  "r338": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=d3e21463-112644"
  },
  "r339": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=d3e21475-112644"
  },
  "r34": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=124098289&loc=d3e6801-107765"
  },
  "r340": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=d3e21484-112644"
  },
  "r341": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=d3e21488-112644"
  },
  "r342": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=d3e21488-112644"
  },
  "r343": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=d3e21506-112644"
  },
  "r344": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=d3e21506-112644"
  },
  "r345": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=d3e21521-112644"
  },
  "r346": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=d3e21538-112644"
  },
  "r347": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.3-04)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=120397183&loc=d3e187085-122770"
  },
  "r348": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=6405834&loc=d3e23285-112656"
  },
  "r349": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=6405834&loc=d3e23315-112656"
  },
  "r35": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=124098289&loc=d3e6812-107765"
  },
  "r350": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "50",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=6784392&loc=d3e188667-122775"
  },
  "r351": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "505",
   "URI": "http://asc.fasb.org/topic&trid=2208762"
  },
  "r352": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=123351226&loc=SL49130561-203045"
  },
  "r353": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=123351226&loc=SL49130563-203045"
  },
  "r354": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=123351226&loc=SL49130563-203045"
  },
  "r355": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "19",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=123351226&loc=SL49130564-203045"
  },
  "r356": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=123351226&loc=SL49130566-203045"
  },
  "r357": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=123351226&loc=SL49130566-203045"
  },
  "r358": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=123351226&loc=SL49130566-203045"
  },
  "r359": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=123351226&loc=SL49130566-203045"
  },
  "r36": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=124098289&loc=d3e6904-107765"
  },
  "r360": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=123351226&loc=SL49130543-203045"
  },
  "r361": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=123351226&loc=SL49130545-203045"
  },
  "r362": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "91",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=123410239&loc=SL49130690-203046-203046"
  },
  "r363": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "606",
   "URI": "http://asc.fasb.org/topic&trid=49130388"
  },
  "r364": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "25",
   "SubTopic": "10",
   "Topic": "710",
   "URI": "http://asc.fasb.org/extlink&oid=6409733&loc=d3e19512-108361"
  },
  "r365": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "30",
   "SubTopic": "10",
   "Topic": "710",
   "URI": "http://asc.fasb.org/extlink&oid=6409875&loc=d3e20028-108363"
  },
  "r366": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(i)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r367": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(ii)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r368": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(01)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r369": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(02)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r37": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=124098289&loc=d3e6911-107765"
  },
  "r370": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(02)(A)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r371": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(02)(B)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r372": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(02)(C)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r373": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(03)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r374": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(n)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r375": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123450688&loc=d3e4179-114921"
  },
  "r376": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "70",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=49170846&loc=d3e28014-114942"
  },
  "r377": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "SubTopic": "70",
   "Topic": "715",
   "URI": "http://asc.fasb.org/subtopic&trid=2235116"
  },
  "r378": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "80",
   "Subparagraph": "(a)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=65877416&loc=SL14450702-114947"
  },
  "r379": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "80",
   "Subparagraph": "(d)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=65877416&loc=SL14450657-114947"
  },
  "r38": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(1))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r380": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "80",
   "Subparagraph": "(a)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=65877416&loc=SL14450673-114947"
  },
  "r381": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "80",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=35742348&loc=SL14450788-114948"
  },
  "r382": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "35",
   "SubTopic": "10",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=123468992&loc=d3e4534-113899"
  },
  "r383": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5047-113901"
  },
  "r384": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5047-113901"
  },
  "r385": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5047-113901"
  },
  "r386": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r387": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(1)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r388": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(2)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r389": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a),(g)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r39": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(13))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r390": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b),(f)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r391": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r392": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r393": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(i)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r394": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(i)-(ii)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r395": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(ii)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r396": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iii)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r397": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)(3)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r398": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r399": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(i)-(ii)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r4": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Topic": "205",
   "URI": "http://asc.fasb.org/extlink&oid=109222160&loc=d3e957-107759"
  },
  "r40": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(14))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r400": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(iii)(1)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r401": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(iii)(2)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r402": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(iii)(3)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r403": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r404": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)(1)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r405": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r406": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)(1)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r407": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r408": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(i)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r409": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(ii)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r41": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(17))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r410": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(iii)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r411": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(iv)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r412": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(g)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r413": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(h)(1)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r414": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(h)(1)(i)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r415": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(i)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r416": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r417": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=SL79508275-113901"
  },
  "r418": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333"
  },
  "r419": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(f)(1)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333"
  },
  "r42": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(19))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r420": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333"
  },
  "r421": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(g)(2)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333"
  },
  "r422": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 14.D.2)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=122041274&loc=d3e301413-122809"
  },
  "r423": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 14.F)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=122041274&loc=d3e301413-122809"
  },
  "r424": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=122142933&loc=d3e11149-113907"
  },
  "r425": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=122142933&loc=d3e11178-113907"
  },
  "r426": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "718",
   "URI": "http://asc.fasb.org/topic&trid=2228938"
  },
  "r427": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "730",
   "URI": "http://asc.fasb.org/extlink&oid=6420194&loc=d3e21568-108373"
  },
  "r428": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=123427490&loc=SL37586934-109318"
  },
  "r429": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=123427490&loc=d3e32059-109318"
  },
  "r43": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(20))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r430": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=123427490&loc=d3e32247-109318"
  },
  "r431": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=123427490&loc=d3e32280-109318"
  },
  "r432": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32672-109319"
  },
  "r433": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32687-109319"
  },
  "r434": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32705-109319"
  },
  "r435": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32718-109319"
  },
  "r436": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=SL6600010-109319"
  },
  "r437": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32809-109319"
  },
  "r438": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "19",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32840-109319"
  },
  "r439": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32537-109319"
  },
  "r44": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(22))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r440": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32537-109319"
  },
  "r441": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32537-109319"
  },
  "r442": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32847-109319"
  },
  "r443": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "21",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32857-109319"
  },
  "r444": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32559-109319"
  },
  "r445": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32621-109319"
  },
  "r446": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32632-109319"
  },
  "r447": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32639-109319"
  },
  "r448": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32639-109319"
  },
  "r449": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32639-109319"
  },
  "r45": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(27))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r450": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(d)(2)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=123459177&loc=SL121830611-158277"
  },
  "r451": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(d)(3)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=123459177&loc=SL121830611-158277"
  },
  "r452": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB TOPIC 6.I.5.Q1)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817"
  },
  "r453": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB TOPIC 6.I.7)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817"
  },
  "r454": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 6.I.7)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817"
  },
  "r455": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 6.I.Fact.1)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817"
  },
  "r456": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 6.I.Fact.2)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817"
  },
  "r457": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 6.I.Fact.4)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817"
  },
  "r458": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 11.C)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=122134291&loc=d3e330215-122817"
  },
  "r459": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=123586238&loc=d3e38679-109324"
  },
  "r46": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(28))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r460": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=123586238&loc=d3e38679-109324"
  },
  "r461": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "270",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=109227538&loc=d3e44648-109337"
  },
  "r462": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "270",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=6424409&loc=d3e44925-109338"
  },
  "r463": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=6424122&loc=d3e41874-109331"
  },
  "r464": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "740",
   "URI": "http://asc.fasb.org/topic&trid=2144680"
  },
  "r465": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "805",
   "URI": "http://asc.fasb.org/extlink&oid=79982066&loc=d3e1392-128463"
  },
  "r466": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "805",
   "URI": "http://asc.fasb.org/extlink&oid=79982066&loc=d3e1392-128463"
  },
  "r467": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "805",
   "URI": "http://asc.fasb.org/extlink&oid=79982066&loc=d3e1486-128463"
  },
  "r468": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "37",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "805",
   "URI": "http://asc.fasb.org/extlink&oid=123455525&loc=d3e2207-128464"
  },
  "r469": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "805",
   "URI": "http://asc.fasb.org/extlink&oid=123413009&loc=d3e4845-128472"
  },
  "r47": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(29))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r470": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "25",
   "SubTopic": "30",
   "Topic": "805",
   "URI": "http://asc.fasb.org/extlink&oid=6911189&loc=d3e6405-128476"
  },
  "r471": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "25",
   "SubTopic": "30",
   "Topic": "805",
   "URI": "http://asc.fasb.org/extlink&oid=6911189&loc=d3e6408-128476"
  },
  "r472": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "30",
   "SubTopic": "30",
   "Topic": "805",
   "URI": "http://asc.fasb.org/extlink&oid=116859721&loc=d3e6578-128477"
  },
  "r473": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "30",
   "SubTopic": "30",
   "Topic": "805",
   "URI": "http://asc.fasb.org/extlink&oid=116859721&loc=d3e6613-128477"
  },
  "r474": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "35",
   "SubTopic": "30",
   "Subparagraph": "(b)",
   "Topic": "805",
   "URI": "http://asc.fasb.org/extlink&oid=116859824&loc=d3e6819-128478"
  },
  "r475": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(b)",
   "Topic": "805",
   "URI": "http://asc.fasb.org/extlink&oid=120321790&loc=d3e6927-128479"
  },
  "r476": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(b)(3)",
   "Topic": "805",
   "URI": "http://asc.fasb.org/extlink&oid=120321790&loc=d3e6927-128479"
  },
  "r477": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(b)(4)",
   "Topic": "805",
   "URI": "http://asc.fasb.org/extlink&oid=120321790&loc=d3e6927-128479"
  },
  "r478": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(c)(1)",
   "Topic": "805",
   "URI": "http://asc.fasb.org/extlink&oid=120321790&loc=d3e6927-128479"
  },
  "r479": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "808",
   "URI": "http://asc.fasb.org/extlink&oid=6931272&loc=SL5834143-161434"
  },
  "r48": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(3)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r480": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=123454820&loc=SL4568447-111683"
  },
  "r481": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "16",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=123454820&loc=SL4568740-111683"
  },
  "r482": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=123454820&loc=SL4613673-111683"
  },
  "r483": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "19",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=123454820&loc=SL4569616-111683"
  },
  "r484": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=123454820&loc=SL4569643-111683"
  },
  "r485": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "21",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=123454820&loc=SL4613674-111683"
  },
  "r486": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=116870748&loc=SL6758485-165988"
  },
  "r487": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=116870748&loc=SL6758485-165988"
  },
  "r488": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(1)",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684"
  },
  "r489": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(2)",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684"
  },
  "r49": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(3))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r490": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684"
  },
  "r491": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(3)",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684"
  },
  "r492": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c),(3)",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684"
  },
  "r493": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=109239629&loc=SL4582445-111684"
  },
  "r494": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(bb)",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=123419778&loc=d3e5710-111685"
  },
  "r495": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=123419778&loc=d3e5710-111685"
  },
  "r496": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4I",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=120409616&loc=SL4590271-111686"
  },
  "r497": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4J",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=120409616&loc=SL4591551-111686"
  },
  "r498": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4K",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=120409616&loc=SL4591552-111686"
  },
  "r499": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=125515794&loc=SL5618551-113959"
  },
  "r5": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Topic": "205",
   "URI": "http://asc.fasb.org/extlink&oid=109222160&loc=SL51721523-107759"
  },
  "r50": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(30)(a)(1))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r500": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=125515794&loc=SL5624163-113959"
  },
  "r501": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=125515794&loc=SL5624163-113959"
  },
  "r502": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "40",
   "Subparagraph": "(f)",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=123477628&loc=d3e90205-114008"
  },
  "r503": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(b)(2)",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=123482062&loc=SL123482106-238011"
  },
  "r504": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(e)(3)",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=123482062&loc=SL123482106-238011"
  },
  "r505": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(e)(4)",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=123482062&loc=SL123482106-238011"
  },
  "r506": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(f)",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=123482062&loc=SL123482106-238011"
  },
  "r507": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=123874694&loc=d3e19207-110258"
  },
  "r508": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=123874694&loc=d3e19207-110258"
  },
  "r509": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(bb)",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=123874694&loc=d3e19207-110258"
  },
  "r51": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(30)(a)(3))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r510": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(bbb)",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=123874694&loc=d3e19207-110258"
  },
  "r511": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(bbb)(1)",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=123874694&loc=d3e19207-110258"
  },
  "r512": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(bbb)(2)",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=123874694&loc=d3e19207-110258"
  },
  "r513": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=123874694&loc=d3e19207-110258"
  },
  "r514": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=123874694&loc=d3e19207-110258"
  },
  "r515": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=123874694&loc=d3e19207-110258"
  },
  "r516": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=123874694&loc=d3e19207-110258"
  },
  "r517": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=123874694&loc=d3e19279-110258"
  },
  "r518": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=123874694&loc=SL6742756-110258"
  },
  "r519": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "825",
   "URI": "http://asc.fasb.org/extlink&oid=123594938&loc=d3e13433-108611"
  },
  "r52": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(30)(a)(4))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r520": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "825",
   "URI": "http://asc.fasb.org/extlink&oid=123596393&loc=d3e14064-108612"
  },
  "r521": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=120253306&loc=d3e28129-110885"
  },
  "r522": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "35",
   "SubTopic": "20",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=123602790&loc=d3e30304-110892"
  },
  "r523": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "230",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=123444420&loc=d3e33268-110906"
  },
  "r524": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32022-110900"
  },
  "r525": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32136-110900"
  },
  "r526": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Subparagraph": "(a)",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900"
  },
  "r527": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Subparagraph": "(b)",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900"
  },
  "r528": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Subparagraph": "(c)",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900"
  },
  "r529": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Subparagraph": "(d)",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900"
  },
  "r53": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(30))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r530": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900"
  },
  "r531": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=6450520&loc=d3e32583-110901"
  },
  "r532": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=6450520&loc=d3e32618-110901"
  },
  "r533": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "830",
   "URI": "http://asc.fasb.org/topic&trid=2175825"
  },
  "r534": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "835",
   "URI": "http://asc.fasb.org/extlink&oid=6450988&loc=d3e26243-108391"
  },
  "r535": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "835",
   "URI": "http://asc.fasb.org/extlink&oid=124435984&loc=d3e28541-108399"
  },
  "r536": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "835",
   "URI": "http://asc.fasb.org/extlink&oid=124435984&loc=d3e28551-108399"
  },
  "r537": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "835",
   "URI": "http://asc.fasb.org/extlink&oid=124435984&loc=d3e28555-108399"
  },
  "r538": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "835",
   "URI": "http://asc.fasb.org/extlink&oid=124429444&loc=SL124452920-239629"
  },
  "r539": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "30",
   "Topic": "835",
   "URI": "http://asc.fasb.org/extlink&oid=114775985&loc=d3e28878-108400"
  },
  "r54": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(31))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r540": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "840",
   "URI": "http://asc.fasb.org/topic&trid=2208923"
  },
  "r541": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=123391704&loc=SL77918627-209977"
  },
  "r542": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=123391704&loc=SL77918627-209977"
  },
  "r543": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=123391704&loc=SL77918643-209977"
  },
  "r544": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=123408670&loc=SL77918686-209980"
  },
  "r545": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=123408670&loc=SL77918686-209980"
  },
  "r546": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=123408670&loc=SL77918686-209980"
  },
  "r547": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(g)(1)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=123408670&loc=SL77918686-209980"
  },
  "r548": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(g)(2)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=123408670&loc=SL77918686-209980"
  },
  "r549": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(g)(3)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=123408670&loc=SL77918686-209980"
  },
  "r55": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(32))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r550": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(g)(4)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=123408670&loc=SL77918686-209980"
  },
  "r551": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=123408670&loc=SL77918686-209980"
  },
  "r552": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=123408670&loc=SL77918701-209980"
  },
  "r553": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "53",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=123414884&loc=SL77918982-209971"
  },
  "r554": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "SubTopic": "20",
   "Topic": "842",
   "URI": "http://asc.fasb.org/subtopic&trid=77888251"
  },
  "r555": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "850",
   "URI": "http://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864"
  },
  "r556": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "850",
   "URI": "http://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864"
  },
  "r557": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "850",
   "URI": "http://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864"
  },
  "r558": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "850",
   "URI": "http://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864"
  },
  "r559": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "850",
   "URI": "http://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864"
  },
  "r56": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.1)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r560": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "850",
   "URI": "http://asc.fasb.org/extlink&oid=6457730&loc=d3e39599-107864"
  },
  "r561": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "850",
   "URI": "http://asc.fasb.org/extlink&oid=6457730&loc=d3e39603-107864"
  },
  "r562": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "850",
   "URI": "http://asc.fasb.org/extlink&oid=6457730&loc=d3e39691-107864"
  },
  "r563": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "850",
   "URI": "http://asc.fasb.org/topic&trid=2122745"
  },
  "r564": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "852",
   "URI": "http://asc.fasb.org/extlink&oid=124433192&loc=SL2890621-112765"
  },
  "r565": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "852",
   "URI": "http://asc.fasb.org/extlink&oid=124433192&loc=SL2890621-112765"
  },
  "r566": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "852",
   "URI": "http://asc.fasb.org/extlink&oid=84165509&loc=d3e56426-112766"
  },
  "r567": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "855",
   "URI": "http://asc.fasb.org/extlink&oid=6842918&loc=SL6314017-165662"
  },
  "r568": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "855",
   "URI": "http://asc.fasb.org/extlink&oid=6842918&loc=SL6314017-165662"
  },
  "r569": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "855",
   "URI": "http://asc.fasb.org/topic&trid=2122774"
  },
  "r57": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.12)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r570": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(2)(i)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r571": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(2)(ii)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r572": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(3)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r573": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(bb)(1)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r574": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(bb)(2)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r575": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(bb)(3)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r576": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)(1)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r577": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)(2)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r578": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)(3)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r579": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(1)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719"
  },
  "r58": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.13(a))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r580": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(2)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719"
  },
  "r581": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(3)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719"
  },
  "r582": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719"
  },
  "r583": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=66007379&loc=d3e113888-111728"
  },
  "r584": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=109249958&loc=SL34722452-111729"
  },
  "r585": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(1)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=125521744&loc=d3e122625-111746"
  },
  "r586": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(2)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=125521744&loc=d3e122625-111746"
  },
  "r587": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(3)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=125521744&loc=d3e122625-111746"
  },
  "r588": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(4)(i)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=125521744&loc=d3e122625-111746"
  },
  "r589": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(1)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=125521744&loc=d3e122739-111746"
  },
  "r59": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.14)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r590": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(2)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=125521744&loc=d3e122739-111746"
  },
  "r591": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(3)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=125521744&loc=d3e122739-111746"
  },
  "r592": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(4)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=125521744&loc=d3e122739-111746"
  },
  "r593": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(5)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=125521744&loc=d3e122739-111746"
  },
  "r594": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(6)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=125521744&loc=d3e122739-111746"
  },
  "r595": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(7)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=125521744&loc=d3e122739-111746"
  },
  "r596": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(b)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=125521744&loc=d3e122739-111746"
  },
  "r597": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(e)(1)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=125521744&loc=d3e122739-111746"
  },
  "r598": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(e)(2)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=125521744&loc=d3e122739-111746"
  },
  "r599": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(e)(3)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=125521744&loc=d3e122739-111746"
  },
  "r6": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Topic": "205",
   "URI": "http://asc.fasb.org/extlink&oid=109222160&loc=SL51721525-107759"
  },
  "r60": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.17)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r600": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "910",
   "URI": "http://asc.fasb.org/extlink&oid=123353855&loc=SL119991595-234733"
  },
  "r601": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "25",
   "SubTopic": "730",
   "Topic": "912",
   "URI": "http://asc.fasb.org/extlink&oid=6472174&loc=d3e58812-109433"
  },
  "r602": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 11.L)",
   "Topic": "924",
   "URI": "http://asc.fasb.org/extlink&oid=6472922&loc=d3e499488-122856"
  },
  "r603": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(a)",
   "Topic": "932",
   "URI": "http://asc.fasb.org/extlink&oid=123377692&loc=d3e61929-109447"
  },
  "r604": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(b)",
   "Topic": "932",
   "URI": "http://asc.fasb.org/extlink&oid=123377692&loc=d3e61929-109447"
  },
  "r605": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(a)",
   "Topic": "932",
   "URI": "http://asc.fasb.org/extlink&oid=123377692&loc=d3e62059-109447"
  },
  "r606": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(b)",
   "Topic": "932",
   "URI": "http://asc.fasb.org/extlink&oid=123377692&loc=d3e62059-109447"
  },
  "r607": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(a)",
   "Topic": "932",
   "URI": "http://asc.fasb.org/extlink&oid=123377692&loc=d3e62395-109447"
  },
  "r608": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(b)",
   "Topic": "932",
   "URI": "http://asc.fasb.org/extlink&oid=123377692&loc=d3e62395-109447"
  },
  "r609": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "33",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(a)",
   "Topic": "932",
   "URI": "http://asc.fasb.org/extlink&oid=123377692&loc=d3e62479-109447"
  },
  "r61": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.19(a))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r610": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "33",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(b)",
   "Topic": "932",
   "URI": "http://asc.fasb.org/extlink&oid=123377692&loc=d3e62479-109447"
  },
  "r611": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "35A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(a)",
   "Topic": "932",
   "URI": "http://asc.fasb.org/extlink&oid=123377692&loc=SL6807758-109447"
  },
  "r612": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "35A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(b)",
   "Topic": "932",
   "URI": "http://asc.fasb.org/extlink&oid=123377692&loc=SL6807758-109447"
  },
  "r613": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(c)(1)",
   "Topic": "932",
   "URI": "http://asc.fasb.org/extlink&oid=123377692&loc=d3e61872-109447"
  },
  "r614": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(c)(2)",
   "Topic": "932",
   "URI": "http://asc.fasb.org/extlink&oid=123377692&loc=d3e61872-109447"
  },
  "r615": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "25",
   "SubTopic": "20",
   "Topic": "940",
   "URI": "http://asc.fasb.org/extlink&oid=123384075&loc=d3e41242-110953"
  },
  "r616": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(1)(a))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878"
  },
  "r617": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(11))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878"
  },
  "r618": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(13))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878"
  },
  "r619": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(16))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878"
  },
  "r62": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.19)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r620": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(22))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878"
  },
  "r621": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(23))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878"
  },
  "r622": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(7))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878"
  },
  "r623": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03.10)",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878"
  },
  "r624": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03.17)",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878"
  },
  "r625": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04(13)(f))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260"
  },
  "r626": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04(13)(g))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260"
  },
  "r627": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04(15))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260"
  },
  "r628": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04(22))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260"
  },
  "r629": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04(23))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260"
  },
  "r63": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.19,20)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r630": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04(24))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260"
  },
  "r631": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04(25))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260"
  },
  "r632": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04(26))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260"
  },
  "r633": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04.9)",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260"
  },
  "r634": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "235",
   "Subparagraph": "(SX 210.9-05(b)(2))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120399901&loc=d3e537907-122884"
  },
  "r635": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "360",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=124429447&loc=SL124453093-239630"
  },
  "r636": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "470",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=123599511&loc=d3e64711-112823"
  },
  "r637": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "825",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=123345438&loc=d3e61044-112788"
  },
  "r638": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(16))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r639": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(12))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r64": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.19-26)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r640": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(16))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r641": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(2))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r642": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(23)(a)(3))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r643": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(23)(a)(4))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r644": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(24))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r645": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(25))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r646": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(8))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r647": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03.(a),19)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r648": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03.5(c))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r649": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(10))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263"
  },
  "r65": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.20)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r650": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(12))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263"
  },
  "r651": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(18))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263"
  },
  "r652": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(19))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263"
  },
  "r653": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(20))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263"
  },
  "r654": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(21))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263"
  },
  "r655": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(22))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263"
  },
  "r656": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(3)(a))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263"
  },
  "r657": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(3)(b))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263"
  },
  "r658": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(8))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263"
  },
  "r659": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(9))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263"
  },
  "r66": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.21)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r660": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "40",
   "Subparagraph": "(d)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=124506351&loc=SL117782755-158439"
  },
  "r661": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13H",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "40",
   "Subparagraph": "(b)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=124504033&loc=SL117783719-158441"
  },
  "r662": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "29F",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "40",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=124504033&loc=SL117819544-158441"
  },
  "r663": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(e)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641"
  },
  "r664": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(f)(1)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641"
  },
  "r665": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(f)(2)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641"
  },
  "r666": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(g)(1)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641"
  },
  "r667": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(g)(2)(i)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641"
  },
  "r668": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(g)(2)(ii)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641"
  },
  "r669": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(g)(2)(iii)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641"
  },
  "r67": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.22(a)(1))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r670": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(g)(2)(iv)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641"
  },
  "r671": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(h)(1)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641"
  },
  "r672": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(h)(2)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641"
  },
  "r673": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "23",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "205",
   "Topic": "946",
   "URI": "http://asc.fasb.org/extlink&oid=25866437&loc=d3e10432-115837"
  },
  "r674": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.6-04(13))",
   "Topic": "946",
   "URI": "http://asc.fasb.org/extlink&oid=120401414&loc=d3e603758-122996"
  },
  "r675": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-12.6(c))",
   "Topic": "946",
   "URI": "http://asc.fasb.org/extlink&oid=122147990&loc=d3e611133-123010"
  },
  "r676": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-12B(Column B)(Footnote 1))",
   "Topic": "946",
   "URI": "http://asc.fasb.org/extlink&oid=122147990&loc=d3e611197-123010"
  },
  "r677": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-12B(Column B)(Footnote 6))",
   "Topic": "946",
   "URI": "http://asc.fasb.org/extlink&oid=122147990&loc=d3e611197-123010"
  },
  "r678": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-12B(Column B)(Footnote 7))",
   "Topic": "946",
   "URI": "http://asc.fasb.org/extlink&oid=122147990&loc=d3e611197-123010"
  },
  "r679": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-12B(Column C)(Footnote 1))",
   "Topic": "946",
   "URI": "http://asc.fasb.org/extlink&oid=122147990&loc=d3e611197-123010"
  },
  "r68": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.22(b))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r680": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-12B(Column C)(Footnote 6))",
   "Topic": "946",
   "URI": "http://asc.fasb.org/extlink&oid=122147990&loc=d3e611197-123010"
  },
  "r681": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-12B(Column C)(Footnote 7))",
   "Topic": "946",
   "URI": "http://asc.fasb.org/extlink&oid=122147990&loc=d3e611197-123010"
  },
  "r682": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-12B(Column D)(Footnote 1))",
   "Topic": "946",
   "URI": "http://asc.fasb.org/extlink&oid=122147990&loc=d3e611197-123010"
  },
  "r683": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-12B(Column D)(Footnote 6))",
   "Topic": "946",
   "URI": "http://asc.fasb.org/extlink&oid=122147990&loc=d3e611197-123010"
  },
  "r684": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-12B(Column D)(Footnote 7))",
   "Topic": "946",
   "URI": "http://asc.fasb.org/extlink&oid=122147990&loc=d3e611197-123010"
  },
  "r685": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-12B(Footnote 11(c)))",
   "Topic": "946",
   "URI": "http://asc.fasb.org/extlink&oid=122147990&loc=d3e611197-123010"
  },
  "r686": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5D",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-13D(Column B)(Footnote 2))",
   "Topic": "946",
   "URI": "http://asc.fasb.org/extlink&oid=122147990&loc=SL120429264-123010"
  },
  "r687": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5D",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-13D(Column C)(Footnote 2))",
   "Topic": "946",
   "URI": "http://asc.fasb.org/extlink&oid=122147990&loc=SL120429264-123010"
  },
  "r688": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-15(Column A))",
   "Topic": "946",
   "URI": "http://asc.fasb.org/extlink&oid=122147990&loc=d3e611379-123010"
  },
  "r689": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-15(Column B))",
   "Topic": "946",
   "URI": "http://asc.fasb.org/extlink&oid=122147990&loc=d3e611379-123010"
  },
  "r69": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.22)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r690": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-15(Column C))",
   "Topic": "946",
   "URI": "http://asc.fasb.org/extlink&oid=122147990&loc=d3e611379-123010"
  },
  "r691": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-15(Column D))",
   "Topic": "946",
   "URI": "http://asc.fasb.org/extlink&oid=122147990&loc=d3e611379-123010"
  },
  "r692": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "310",
   "Subparagraph": "(SX 210.12-29(Footnote 4))",
   "Topic": "948",
   "URI": "http://asc.fasb.org/extlink&oid=120402547&loc=d3e617274-123014"
  },
  "r693": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "210",
   "Topic": "954",
   "URI": "http://asc.fasb.org/extlink&oid=120413173&loc=SL6242262-115580"
  },
  "r694": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "210",
   "Topic": "954",
   "URI": "http://asc.fasb.org/extlink&oid=120413173&loc=SL116631458-115580"
  },
  "r695": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "210",
   "Topic": "954",
   "URI": "http://asc.fasb.org/extlink&oid=120413209&loc=SL6242269-115581"
  },
  "r696": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "440",
   "Subparagraph": "(a)",
   "Topic": "954",
   "URI": "http://asc.fasb.org/extlink&oid=6491277&loc=d3e6429-115629"
  },
  "r697": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "440",
   "Subparagraph": "(d)",
   "Topic": "954",
   "URI": "http://asc.fasb.org/extlink&oid=6491277&loc=d3e6429-115629"
  },
  "r698": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "450",
   "Topic": "954",
   "URI": "http://asc.fasb.org/extlink&oid=6491354&loc=d3e6049-115624"
  },
  "r699": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "360",
   "Subparagraph": "(d)",
   "Topic": "958",
   "URI": "http://asc.fasb.org/extlink&oid=120429125&loc=d3e99779-112916"
  },
  "r7": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Topic": "205",
   "URI": "http://asc.fasb.org/extlink&oid=109222160&loc=d3e1012-107759"
  },
  "r70": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.24)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r700": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "360",
   "Topic": "958",
   "URI": "http://asc.fasb.org/extlink&oid=120429125&loc=d3e99893-112916"
  },
  "r701": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column B))",
   "Topic": "970",
   "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024"
  },
  "r702": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column C))",
   "Topic": "970",
   "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024"
  },
  "r703": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column D))",
   "Topic": "970",
   "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024"
  },
  "r704": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column E))",
   "Topic": "970",
   "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024"
  },
  "r705": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column F))",
   "Topic": "970",
   "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024"
  },
  "r706": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column G))",
   "Topic": "970",
   "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024"
  },
  "r707": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column H))",
   "Topic": "970",
   "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024"
  },
  "r708": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column I))",
   "Topic": "970",
   "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024"
  },
  "r709": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Footnote 2))",
   "Topic": "970",
   "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024"
  },
  "r71": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.25)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r710": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "310",
   "Subparagraph": "(c)",
   "Topic": "976",
   "URI": "http://asc.fasb.org/extlink&oid=6497875&loc=d3e22274-108663"
  },
  "r711": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "310",
   "Subparagraph": "(b)",
   "Topic": "978",
   "URI": "http://asc.fasb.org/extlink&oid=123360121&loc=d3e27327-108691"
  },
  "r712": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "985",
   "URI": "http://asc.fasb.org/extlink&oid=6501960&loc=d3e128462-111756"
  },
  "r713": {
   "Name": "Regulation 12B",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "b-2"
  },
  "r714": {
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Paragraph": "(a)",
   "Publisher": "SEC",
   "Section": "1402"
  },
  "r715": {
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Paragraph": "(b)",
   "Publisher": "SEC",
   "Section": "1402",
   "Subparagraph": "(1)"
  },
  "r716": {
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Paragraph": "(b)",
   "Publisher": "SEC",
   "Section": "1402",
   "Subparagraph": "(2)"
  },
  "r717": {
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Paragraph": "(b)",
   "Publisher": "SEC",
   "Section": "1402",
   "Subparagraph": "(3)"
  },
  "r718": {
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Paragraph": "(c)",
   "Publisher": "SEC",
   "Section": "1402",
   "Subparagraph": "(2)(i)"
  },
  "r719": {
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Paragraph": "(c)",
   "Publisher": "SEC",
   "Section": "1402",
   "Subparagraph": "(2)(ii)"
  },
  "r72": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.27(b))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r720": {
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Paragraph": "(c)",
   "Publisher": "SEC",
   "Section": "1402",
   "Subparagraph": "(2)(iii)"
  },
  "r721": {
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Paragraph": "(a)",
   "Publisher": "SEC",
   "Section": "303",
   "Subparagraph": "(5)"
  },
  "r722": {
   "Footnote": "2",
   "Name": "Regulation S-X (SX)",
   "Number": "210",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "28"
  },
  "r723": {
   "Footnote": "4",
   "Name": "Regulation S-X (SX)",
   "Number": "210",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "29"
  },
  "r724": {
   "Name": "Regulation S-X (SX)",
   "Number": "210",
   "Paragraph": "Column B",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "28"
  },
  "r725": {
   "Name": "Regulation S-X (SX)",
   "Number": "210",
   "Paragraph": "Column C",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "28"
  },
  "r726": {
   "Name": "Regulation S-X (SX)",
   "Number": "210",
   "Paragraph": "Column D",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "28"
  },
  "r727": {
   "Name": "Regulation S-X (SX)",
   "Number": "210",
   "Paragraph": "Column E",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "28"
  },
  "r728": {
   "Name": "Regulation S-X (SX)",
   "Number": "210",
   "Paragraph": "Column F",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "28"
  },
  "r729": {
   "Name": "Regulation S-X (SX)",
   "Number": "210",
   "Paragraph": "Column G",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "28"
  },
  "r73": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.28,29)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r730": {
   "Name": "Regulation S-X (SX)",
   "Number": "210",
   "Paragraph": "Column H",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "28"
  },
  "r731": {
   "Name": "Regulation S-X (SX)",
   "Number": "210",
   "Paragraph": "Column I",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "28"
  },
  "r732": {
   "Name": "Securities Act",
   "Number": "7A",
   "Publisher": "SEC",
   "Section": "B",
   "Subsection": "2"
  },
  "r733": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(a)(3)(iii)(01)",
   "Topic": "848"
  },
  "r734": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(a)(3)(iii)(03)",
   "Topic": "848"
  },
  "r74": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.29)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r75": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.29-31)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r76": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.3(a)(4))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r77": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.30)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r78": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.31)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r79": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.8)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r8": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Topic": "205",
   "URI": "http://asc.fasb.org/extlink&oid=109222160&loc=d3e1060-107759"
  },
  "r80": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.9)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r81": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=99393222&loc=SL20226052-175313"
  },
  "r82": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "210",
   "URI": "http://asc.fasb.org/topic&trid=2122208"
  },
  "r83": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a-c)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=SL7669646-108580"
  },
  "r84": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=SL7669646-108580"
  },
  "r85": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=d3e637-108580"
  },
  "r86": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=d3e681-108580"
  },
  "r87": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=SL7669686-108580"
  },
  "r88": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=SL7669619-108580"
  },
  "r89": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=SL7669619-108580"
  },
  "r9": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Topic": "205",
   "URI": "http://asc.fasb.org/extlink&oid=109222160&loc=d3e1063-107759"
  },
  "r90": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=SL7669619-108580"
  },
  "r91": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=SL7669625-108580"
  },
  "r92": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=SL7669625-108580"
  },
  "r93": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=d3e557-108580"
  },
  "r94": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124431353&loc=SL116659661-227067"
  },
  "r95": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124431353&loc=SL124442407-227067"
  },
  "r96": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124431353&loc=SL124442411-227067"
  },
  "r97": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124431353&loc=SL124452729-227067"
  },
  "r98": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124507222&loc=d3e1436-108581"
  },
  "r99": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(210.5-03(11))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227"
  }
 },
 "version": "2.1"
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>ZIP
<SEQUENCE>161
<FILENAME>0001193125-21-313597-xbrl.zip
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 0001193125-21-313597-xbrl.zip
M4$L#!!0    ( +F+75-V9Y:'U0(  ,H&   1    9#$V-#8X,&1E>#(S,2YH
M=&VU55UOVC 4?4?B/UQETK1)0 K=N@Y") B!9@H?@K"NCR8QQ!*Q,]L9[7[]
MKA.@TM3VB;X@W\O-/>=<']O.730-7>?.'XS<>LV)@BCT7?]7LW/=:CMV%6+>
M/A: ,YR/'F X\>;A?-FW[N^"R+=<J->PR*-<4^DZH^ GK**'T.];!Y;HM'O;
M^LJX!63/=KQO[>E66V6OQ:DL(W+'>%.+O'N5ZQX<XXW06F15:BNX;BKVEW;;
MS_&69&S_U(U81A7,Z &6(B.(- B#R:QO2;9+$<H9NOYCRC9,@Y$%CCUT'7MA
M=+W$H'U[00IQ.1/DL':#V<A?^/@SBV#I3X)5Y"_]$2S6PS#P8.!Y\_4L"F83
M& ?+Z<</[2\WO15X\]G*?.#8ZS<Y=R[ V;VG$ NND#)H 3JEP'B\+Q03'%>8
M8 J6=,>4ED2;Y$H333-3+[;8A/TAN%S%C/(8.X<Z:0%6C87,P!G/4<;)%BG3
MM*ER$M,N%P=)<LM=-=%PIL@US40A0=)<2 T)8B3UVI3(./W(-RKO=3H-Z%QU
MV@V@CS'--:J2)5VZW=)8*]/ A)*J,\&$J;A0BB9&R4QH"AT@RNA$,G%:UALD
M0(U3\E0!M:]/0 >F4],OQ_[F(\./% E[!MLR3GC,R![.H.5_4YPX#F. [''>
MB5G&OPNF6#E!3\B\98A@Y8C&--M066%?MTOLJWJ-\.2L,*>2"0RER.!'L3_R
MO*E*X1/N%\X#&W_&:BF*7?I*U\91]G'&),\ID:K:90H+*4JEA3K5X51R(G4E
M]E4;M  M1/9*_.\C2;=4&E><9C=FZ(F")[22E5*2,+ZKUXSOO_7\1]2IE0EN
M>X:4*DY[_TRM!>9 O'R+7.0,N[:RP=BN0/NNIH,P=,-PX=C5$M[].+X-_7[7
MI^L)M#!,J2(-\/#61O-Q1MX2?!'8>:S%V:B=[]71.Z':^*K@#7A\8_#U,#GS
M&&&R?,/^ 5!+ P04    " "YBUU3].R9H0 "  ##!   $0   &0Q-C0V.#!D
M97@R,S(N:'1MO93?CYI $,??3?P?)C0Q;:*B7)M>%4G\@2<7JD9)KSZN,. F
ML$MVE[/7O[Z[H.V+Z9/M"\D,7_;[F=EAW%7T-?3<E3]=>.V6&P51Z'O^]Y[S
MT'=<NPEUWKX(P)UM%@>8/<TWX68WL5Y60>1;'K1;6C1'IE!X[B+X!OOH$/H3
MZTP3=1H]]C]19@'):<8F5HZILNJSME=9041&64_Q<C0HU1@N\9$KQ8LFE7*F
M>I+^Q-'P3YR2@N9OHX@6*&&-9]CQ@FBG:1@\K2>6H-E)6[DS7=$JF 41F++
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MUR/W)^\/3$PKU<,3?E"@?F#U_MY3J+NY;ZU[&11FK#*QN;'9%X_8F//-$V?
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M<39K:AS40KH46HD7+- FG->>H.4$$J3KM^82UO!D#'ZYH&EJ(<.B>2Q%T9;
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M(H[29(KVQJ4E)'"JK36+)]'2MK-#P_?U)?*4*4'Z"BVL)A;SN;VS3 @.Y.U
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MO6MSVTB2*/K]1)S_@-#.[+'C4C))O>UNGY!EN5LSMJ4KRMT[]XNB"!3)&H,
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M:6HTV'\]N6;\(T9"K=C5"COT/>6/Y'$D['#+"6[JCNN$=C. N (#B*M&%&:
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MTM'+9,W$S2N6-:\J<I;%%E^N;KXM7[- R\CS/3*HA6UY#%UZ#A?O/_MVC*X
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MCK I$.'W?NG*=Q\MS#R4@:_#$WBM[#-/_(?^?EL'LGQS+06<>",+P.4Y3#H
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MG7(;[H'(5J6DJIU,4L:!H0RD#&:!+(UV,Z@"U#Q' 9*(II0$;$,"=2<!QY#
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M+<)4]-RDVA:%P8X_P"OCB*8OH4P,XJXK;) 7.D4GK\1=J]^2])U$BR-!]D;
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MNDI\E;X8)8PM(IWKDM[7C4>3M^%Q[8VL?\/?H2.T9PZ/=]J*NA<@1TY!_?@
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M$8/-+#'I)Q,["@E/Y7O^B7$5UR5GC.0VQ\ '.G& '&S.G5"3$Y(/2QR@A1H
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M\XU9O$UF\>O'0PN2Y_"YJ4F3I#>G%*IX<M+S^ %.4,7[B0P"90_AT+?ZTG^
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M;R#)TFQZ+-[ @:IJ-F,VXA'O2-8R/D=1AUVIHP.]1H\J\4;ZEH9NR9U:K/#
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M($S/IFV\,"%(+,%2W=YL(>UXB(T+;(S"]2(MUQ/2&4/SWI@P+]>[3 . M30
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M39)J=7N];:\;[@6"%\%UVZOTFBW88E,D+(!S5F'+5BI;J7NR4I/\E_:*F!H
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MB^NPG:'<,$=M>556M3;)PJ6NRLT&3R:6-E'<(_]5.B.(*4V[;N$PZKD]F6C
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MTGALQJ:SOT1'2CA$C--G3I+YLQG<$^+Q2D$N:4[ 8LTN@U-RA&^B*H+B<1]
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M?"+1)ZKON#(T,05V9>^0S>9T$-$FO!Z2\8.KT>W+1GI[X$?P 0D-XF\F3DD
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MS293Y@W8CP2Z8.7UZHHY .#[8!G&HUA[-4F8XG2XOS2Q6CO/W:N>L\][**D
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M379N?0.L7L^?&? ([UGJJCD7]\+Q/CWUK0U7.QJET;T:WL7%SU4;>3',P+*
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MFC8KTZTFE9>Y'Y430]E>97OU)!PI#+!VE=3<" M#@.JF;71S%P_B]2QGBJR
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MV&%#Y]H3SXZNV$[:R0(%HHJ=?!CE*%"UMVO69114BIA/'_M\1'3J1X"FSJ)
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MQ?PLYN?7'KJTH<.F<C$'-7%)>!>(Z"@Z@E9N,D8H,Q%6V"P1RF(&%C/P,,S
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M*]D!,,3=EC@),5]HZ!/,_EB^SAZ0UDI\O,OL%6'?,$QF=AON!DZV2LJ14$$
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MM\<:M1!9ED9R1EA4YLQ.1XW\\GN;%]>BE$X-?FK7-OU!8;OE0(BKN]LXP'G
M>E2,=XQ:,!0\!22KN0Z5)?<<5_A&>,*Q9:I1Q1Y)SN&R('D=6OBP2IALG,KO
M[S_"&'DA0-1N+D^=?:89H<'8M&E//SA-^_(H@]%-#(*\W)>/8$5M"NI;IFH_
MK&Q$0+<$]_Q\8>5:SLOEO/P(YV4!@4NSP_Q/S,P\_YX;E!MPHW?8CB&$)U,]
MF'FF#2_Z??"3WZJ?3)<90]4B_P;:V)/2>UC*_*"]%KYPL.J/%,A0LR,9E]PU
M7J9ZD\)HD4HECMH_Y9FXE8-.@GA8S,<47&WY*"J5T2R:4.542VX<$\J!8;&8
M&)M;9I6)H9R2&T3#[SM4]/"<+63P$1&[C:U52P@COI(YIW5!5Q;+#Z=% >MK
M'7K:%XY^4;@88<Y-7GCP6>R.@:<^F1<"D],S5V24#LUV/3QF9;@R;B2KPHVJ
M%+N/%:)1O>^K77&V@8H7#+_3 NE_H)#^+Q=(_P+I_]6Y05^>=8.F_96/0<;R
MZXC&QP<2L0"ED4H,T=X5C\:S<!PGI='G-'=%/%43&CM/3_>5$%S=T)&$A7W"
M1A\*0C+/';/PXLC,3OQV[L'%$]N%>BU,*__9>*54ZS9MQV4VC9Y9$D+I].2^
MHB9>V*>X>H=H!L%8A(WJVMMQ+' W]!2;?8CT:Y@MIJ;A_:K<]>B!)LQ/=$,?
M+!,A'O86$"8./<%3()1]2_?]ZMVNJS;5L^<T0QAUT=04-6_@;M2NZ BJDPX'
MP3X6]1EVE<A6Q8Y8Q>W'!;/&,5(%5K:T4O!DS%W-E2OICVG"(68NZ.WZ556N
MW?J@=/9X\:H+6'"G.6'Q@W2#OPW7<#R$U.&<?]6Y)XO:B=VQQU6"] 5NPP@Z
MAC^J9#/C=X-K,#QF:[K%_R1--'B$CTR_^[ U<Y]'65S1?:&=UTRS5454TSMX
M\HA>S+OZT\Q14R$E?U<;[).J&Q(X7V8O*+%Y:&#Q$6E>:BD0MLQE//\@M;9E
MR+N-8TWMH?</K2. U3 >@&C-DB"8C.TIQAM4HF-J(A=?SH\!$<*E/$/<SM0@
M9ZER"*1MZY'EC^MU]#/K>PWO,V3HBG&@!>!]Y\E;/=< &%("(J(ZQW2_V*A2
MZKY"E=(\A907*=;17=5Z::RT2LU#%-_OP"J(E)FK*OHV\3PNBG=U?O_<]IL\
M@2W:XX(GT1_UL,& %I^87O*:E1NWI3@2LH[  M4,FW>,LNR/,*QR0(*(R[M#
M.R7TF"ODB$BIV>#)VD/3<C[@&'8,WT%.U+VL806ZQU\*M1@<Q)5^B)(&/7I)
MPA\RI+]*2%29XTWH4_%X$P)5^([3G^*OAW3GJ0BZ,JKBK>PVE]GSF\">Q![I
M2LJNZWEG;4F[:G5H8-7D4HB/=&<D Q'V=&TA+"BX_X&*T?8QI.2M8(W1/B[:
M345L85N]87G,![0+=9"K\]G*>"/P*XEVE)F*KWFAE.N$PPP6PS#!E3M2,F1>
MX(WSCO%X%K;H+J(9,8S!2;)OZTA^X%3FCW!D7!#!VYY)@C?R3NP]^EWJ2-*H
M34_E38T<E(AK6@IQ\PRI6V4=,C^@IX_<O/LY?19J1<VF1_MP+WRRMDSD<[#/
M"RPJG*':70@GDX__V1TQ85=V(H>R!X>>(@;&@% X 1[NP+MCK81(D1P;7L]3
M)2MCZ]0*7A@>D?SI^YK2UP@AD>SE/I[</X+5[39*=DM##V9.9;C@'#F0$)>?
MSP%'$\IR(=*(#;&>SVYFNU.'7%B,)"?K?2 N9C+^3-4^IA_4<V":Z=BI%4\1
MQ5H:FDX7H6F$%SE>V.4=*(H<A,E31+FDD<QI0 5]9Q;%IS(\1$CFJQCBU^FI
M88Q;YFZ%G\!C&;0\R "B;5H/_$H)@]5O/L7HC+G'PD\%]E'\=_99*?@AG3DY
M+&*V8EB\^ J^HU]2[X%S"\W&6D84(<7*1DA"#)>A;^I7.4I?8T"*,P^Q8H,
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M]IP(JBXE>*@]L_I@JX.>H!O'C$FK*!*$"%EA&PD1D]74S:0!J*G"B/I6*>(
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M7/FC8\>Y^YRK"4^R[RK>J#PF9'S-^2#CQ1&.*(NJNY26B)-#5#%##7,TQ2-
MZ)NU\CE1_=(]KJS1LHR1V?S/(5BYL.\?2;Z"-BV@6Y1=Z0;1,^&"78D$T:C<
M+ML5YC(8M1#0MGM%G? ZU6%X$"+P9=NM'$*.;U'8F\ A3T8TW"4\TW?L?G%0
M0*-<R+4M.\+^E8&BJ >Z8\5=)M]2K+A- _4!'2*4K+2,^MIU9IJ_#6\R>FCA
M^.+-L>S:OK]_KM_=P?K=XW/][ER_NRNK\8)K<\X^1\8^X1>"LZE&:-56S*#*
M7G 3P8#:9C81F"9$.NJEC,WJ,9&480NIA*VH+Q #PV1H<?N():/8+6&;)U+O
MCR(!?#BTZHY[R<A]T9,U48XO@^O #MQ%=;BJ1$Y&DE#_%<9H1977<,$PUO=N
M.S!_4/GQ?T!<6=MM>Z4SF3ZU,?^2=^"._A]Q9#\*QW,D 7O3@->J7WS5T:<_
M*4:IQWIR8+)D59G_G<#,M6F;L3-T+ZS(B]JR)^8@T0]Y4HE2]I2-"@\$^12<
MO7R:7X$,DBBK0//(]2I.%BO$VB=>G5NJ*=U8?9;4GOOXBGB4D;":PI]/N[0/
M%C_E6*#YH"N/EL>#6Z"V%!PT7MV/O^3E/1OTJM_62-"\/!HG,V?0^+'2-&N^
M5G+G=MV5N^JJ[=XX@;LL(,";C%)DDZ^DC&<H?FB:@AU=;H2\#!';/V-6Q4?H
M:=N.UA$LH/+P!_;-*/$[$QZZG4ZD+:2)Q6J$ .(R?35H6%9L&K9E+Z0>![*.
M^&'H%L>J%!&JR0FA8&!H:J1<A'WD;?N&BSWC*9)&PWU;:VF@EF9O=+?VL;M5
M&7)<L! 3_4F[IXIR4GG8](>84)05BK0M6#,U?-H@Z\-U6:$+U)P;T[&R14 <
M$R=OVZH"A];,ED<156/B4MGOTVD)S8Y]A#(;+YA7L(O]VPONWY;$I2.GH:D8
MFM((U0DCN[6\P3MC8EW/=ZSK80:O+*L]"3BW!LTUDPQ)LDZB)M6$YNW:.UY\
MIE D0IP\9QK)UK.6PE00FX-WQE0+3,=0'"%$STSU6WIW5@"%>_0TS'8XJHZ]
MU4\ VU=5)F9KZ.=P#OY8 MJ =_XWTM[QNJ-<9MS^!=G$T7GF2X-V\/B&;O>!
MK.SA9S9M>55!K679.-A)Q#B=:/TE5)I12>_;IM>V[C 4^<F'X:1[2-$S:>I5
MW=5$1#'Q&;2B!ZL+Z@4DNH-M[152HSI=BPOFRI)DRV3#,&N,K\ J#2E!*XVN
M5I0MU"YFZDJ&>2$C"!$E(7J B#VUN;57TH^6I)?S5B#)>\7T#J'U9(A6UL_-
MYP5LKV,->)&FH0Y&9I8A=J:&7)>*U]*,!Z%.;:W43THJH(0 V3Y3;>7I=RS3
MCB77'$5E$T4:.+D)X].2NZ)VK4WM.A):IR[8IJRL+T+:]6\_JK@ER__<US0T
MB0NZ&)LD[?(D]>-6B.*"(T4QWE)YW]QQ*CUF7.T,SYLV5N[8D;=Z+Y+'P<&(
M'"D;7@%]"BUQ2YXMIJQTX==HFDH( .$VP5?H$7'B.9CYP0,7P&TXO3X1MNGK
MCPIIP[:RAQJ:*)/Z8/%JDID'750AO.-=Z?J8M*,@WI9U.C@JMF&?[5\U>(N@
MS\83P<X1*;<P<./FI[*<=W#7%!,2H8J<]C2X#',W>IZYZZJ1'L6)I\P;;B.Y
MX7W.2J\D4B)GH8,?$KT^3/M5I2U<Z5Q#KR!$IRL+EJRL'MV)B7Y;\TH2Z^9.
MR0E%FG&85N2"*OZX8H=Y#?]4R(59=GG4H7N2#R#X')$:6GOV5A5) ]6-*V-R
MD,CI\UYQ3X[&/WLA[%'^*#=2$WN1*1#%CD?7:8:ZVO0F,+C2H<H% H!X2?N1
MN]T';SD^\VN,"(+%_0]++*QW\I,4LNDX8.D<I/FNFMAN">K7L)T;HKSR:J9C
M3MBHR0 <4GE!Q.+XV$2@8;ZIDDAE:M[N^S#(57-)G?"$QB)=>%&=T7U,G?BT
M3)*D9ZRF$'=2!/$) #$*[AC6RWD<65DL6;J3:_/,O6'<&WRRK+PGNC"NL^L7
M8L*ATJ;(I=F52.33X;_???]^5^4-EMZ680,:P#Q8?!<_Q6 '\OR%T<H(D\+[
M5)Z:F2S>\LU6"/>#%=W6E[(/T_MEK-?FPF. Y1C@+/N4 R[)N6^>>PCJN4?P
MKE9U/O_T7&,\UQCORFJTWH1X=EZTJ^RL9211[*?W[F2"0#QT X0/F:Z0XSY*
M1'.=T<']6VT?R^[ZQ/'_H> I-9Y@W*S<\.VSE\7BV_]^B3]^^]W+>-@_F8JQ
M:$\0_[HC+%EWY2!1Z<7@.84\8/#)@N%,$^]\ZC63\8AN<-+-W47&Q,@&5G!;
M6N$U]<R<1S$.7X>4^II[L^"%##U!(C/>#E 3]K6R(O@ZA9'&TJ 4BS?U\LT%
MRRJ$ &9]?Q4N#KC-15=?5!T833HCS:>> >*0/^3]E?S8-+P('"(YQ^LT4Z"9
M?@D# !I=E NBE5IT'!ZNW=M/NH(J:%>DBP>P?(8^X5G#O"[UUZI0D8\V]=NU
M@NY'D^#2Y685ZD6WIC,>+^;(/T],%<&8[%A/64)L_5$%167J#TQ-PPZPB."$
MYR#:38AY&"U LJX B^8<"U?QP5J,A&E&D8EV.!!ST:P/6T/92^;>,Y.*1-Z8
MH12_4E\I/%UDHI2' U>JP*I3OSMF#KS3'O:*:]>HN!4*+OJ(+4O34!0[\WF7
MZ,8F#/N(K6/3<YLRWD8',(( PB@ORT%RN!6+"X&$&2437BB\:Y $LD2W4S^K
M?#^@UU,;&BZ<(]'!FKO:BTD&!X+ES.QI&1@N8*,HD0@E9AD \R>UY"P&#-EQ
MRIKN>,;1%CZ3^8D]56WGO<R/-M_ZU&FU%)JQ27>PBX9*R<YY\X0*+7X;MD ;
M*<(Y!N&,*$$(<2CQ/K<%&7YT&1]I6%6F6JIE2!I/ORL%;G>%*-Q)4EZ@_2;"
MU42JS)'U)J(_&2%Q7TN17@'VR"S1<>?@";Z>D)D+7T0F^&6+3B(ZO9=:B=C6
MQ*G'%6,6H9FC^1T3YXR)@JG)6C&SOFBO/$[ZTE$^4V_*399=E>(NZME7HQ*@
M> B*M$9$3$"AG>L$]3?)>KZP!F137KCGJ>?&G-C'#MP=2$]P@/HJTNO4B+T]
M:I:=-[R^HCPOK4*<.)*@!+Z B:$C&=F\^"8KLPG%M#"\&17O6M0=1R*I$Y*P
M]=J4T%^L;YA,^%VS6K:IC!F]JZR.2/!HK6:CYN$8)(3]./=S8V8*!M8GI@A#
M/.(1(XRQZODYZCA=6&A6$A\^_A*;=Z#T^=9K:WHN]3JC9T_JLB)&D#7!PILV
MCU8R9CF= _?PZ0@DZ7.JPQ>Q" ^W.>7VL)*%TF22.QP,%_H@A*&S'WIJ2U5'
M&IU*N:JONCGF$E2_A&?LC14E*@(+T(G9JL@6\K_JE?/HM+294A["[RN0=EE5
M%\%)@5R#K[/:*TQ4SU<U7GS#@K7K6I XJMQ0HE-0&N$2@+]&%V-^*>#F0AP[
MPQDJB4XG\Z-L::-)OF%"])R?G\_/O\P%H1V@PGRR2$DKL\1FE<MWX\YL5]G"
M-'$;XJ1L\B3O>F^5-Y9D1E?C.<<-PE?MJZY^J5GD>]J=&!W[$C!0L'ABW$%$
M9"2%3-_D D\39/B%R8:&/O$LN4<G6T1< GU 0*')OP0GD%@[+@AA12IA![_:
M(%7') 2D.\?D3BF7J^+\9@GV]&#L*3P228H(#O;  ;*)=)ZXROY8X_G[AKS3
MDB/M+;&%+'X>5I=LWQ@I!LZ9JW!VLM,\C0+BQE2*/.5KFY(\LJCPPK:0^G"$
M[ &>1]1RB0@!@O16ZPIP+QZZN6EPQ^G\ME6YM_Z0,T1QS7\K1!-A4FJ<ZX@P
M@5QED=]B]OZ:2N&8^J\WROY_\9NS_U^\I^S___Y?_^> C.^RVF[W-"S-Y?_]
MT\,_X6>Y,'Z61^"^"-Q@@7BF.2![_621I+=_@P'A.]R'<[COPZ_U7_:GY'W_
MQ.]@67:7DZ^!@?WKHGS;UBO]X"I+3W_^;VY@#JOI#WT:7@F<.6$;:A([C/.3
M)RZKC:0V7>K+QX^_.'&M1S/7.O$4-[SU;'Z>\^WOR4N86ZK BMS7NH8<];=V
MK) ;77?> 3<O*Z-]]VZRH2T ,8%R)^J)3_*R$4U1^&^'_]+^20=_N0U>Y%\)
M /9D5_ZB@R(;^FP9SI;A;!ENS3)PU-I"_I>"877;1P%LRRPTJR[X/<BC6.0*
M+A1-N&7?.YN*LZDXFXH_AJD8 U!1B$)8PO5W!HE&W.IY]Y]W_WGW_S%V/Q ,
MDN*@U #*Q111&!K&XH/H#>R[>D<)<XTVS@;A;!#.!N&/81!\8M$J8TB*<L\/
MD_V[LB42A!0MG*W V0J<K< ?PPK4C2OC^@)@=;* !97MHQ:91Q]@- :*441<
M^GN9BW,;PJVT(7QV;D/XUVM#.!]HYP/MCWB@Z5E$N.OM5A0E..LM,.:+:IOA
M];EC@.'ZC$=CSJ"V.?NZ9]-P-@U_$-.PJIB<C/HX=M+0]1Z]7+KBV5B<C<79
M6/P1C 6U3X&WB[G@<[SR>][:?^S.I]>;:@)P&';7T#'G1J6F8$L4;QWUAC)/
MTM%#UD]= MJ41,1 ?55+;K!-A-4+WU+7#^LUD8(U:(SHJGIW@0;'@0&V4#95
MR:K82B=P9_HRD?W[%J318]0]=V P=!7G3OCG5J^K$F:I]KO<0!Y2B1:)F LX
MWXG;H%&,+MXR+R/5=:7ES[TC:\LD>JE#Q(S+VZU8$<X&5\&L\R!C$;P>=>)<
M"7<%TX3:9(P>GJ'IX+KPR&?74S.^^A,BS*MXU ^1C$O'2A[VU$IA;2>Y WJ@
M;/0(0Z,=DR;](H/W8/'4 7KG\+.B^"/2 :KM,(9-GR!WFN8VHL4229$\Y0FP
MO1+% ,=OS-HWA_,GGDQAX/Y)8/^Y5V.^5^/%+,.H4U0D4@$!R@.QR<UW4X0L
M"=MIWLYEK&A.MK@3T+C .V@:9XBUSLT:1DCDQK2A/@9J%?^5TY43742E-FL-
M/.8TE.!="/_@I 24 ?OPN6 @20&P*@_6AT<OT/:,WMN4_RR[%3VJBL-*+VK9
MHPE"E3I'_7HB$A/) :1=)5X0D=&VW.U@$^WR_NV6FVI'_J38I3HX\)= #;I/
MJ[RDJG@%DU.YN^!!32D-S*BB:KD]6N^;T2,**[&J)8.'THT&DQ],CT2D7*VV
MZ!<4!B1MB$%/281.TA;Z>>B.UJKK+VRDLMRR?^+;;,6M2Y[F8#30;K \JS%$
MJ^A<V5;FC<3+62N@.DCN!!+FQF556>>=DN'^),3:26O)"!"6$\(RX3%UZ2:R
MY,Q;D.A77TL"D.V5CY<%8$N\\Y<;=O;$LR.*^^ ):'\R1#.:7GM*U7/!V+X%
MC0=K (SU5<6#Y/D5CPXK4GJ_P7UJ5&K9(IVT!FZ1@J$B/HZZJJHC9AY3]$ZU
MV<E:&%WC(=;DJL4E)EQ<Y&:\%78+G2Q ^TN]#/_M#J:Q1*>=.(3$'M^!+S:Z
M7$R>T0@/J760B:U%!["S*-&F%6XPJ-&Z7-5MR7P<SBY\I*LY:3Y+%M]8"-AK
M)'@;(:$?6N"E:?G7G+Y*"#2^W"37'9X4;35J*H7Y1YQ>;8F7$XK6C.D[$V7F
MC,'S-#PYO379WZ2]+ADD:4I/O#EAQU<VF[,C?E-'_"<AYZDRYV'8,W?*CL,;
M8GXPFY$%8ZPI$Q;%81/,VAOF%3D@,0A&HKJG7++(L>I4!3]@H ;_\%=R/[K8
M!6\-6Z) HEV<^DDJ6)'=/)+>B*Q/4!)%M@X7NPOUCC(;Z47.7OV?_N/K.&.+
M$_/"CE!/J80*BCM@'1F16] 4":^%6GM=*2I;W>82%9,1_"23L3*%*6=QB!_+
MT;,2^<05:& .<E#Q.XD/*D0\JNF)WQ)UC"R2@>6^MEN6I?4^'P@@VA@C4+Z(
M)1+*@_B94+K@?NVZ67?A>;IAR>DTKU>14NV%?RFY@%S:LV0Q"VLKG.VQSUMF
M@%S7E%Q$]B?Q[Q"_'5EEL/XHJ_<R;,->I*Z9HX-\AT'5FEGN)]F":QX*9WSW
MM)%6""7"LF0]T?'.]$D8OX]YQUY5O%*B9)#E-"G,1&Y&*>RAI+*MWU2L#X_$
M2W2@ZBS(&&]T3]:"C\&;FCY]S3F$C*T</D+UJ@^%-5?I=+WCFPLA6^$H".DX
MW)#&4=B&1-+H==#!SE0N846C>8VN7Y'2R=QPVUUW-IX18K>($/O\C!#[UT.(
M?0#W\AU6YEWV+E]#2$R+.AHS(W6RE6;[\(4#\6GV"^'9[%D1A75WB+UC0]1?
MS65U3L6&V[[R8\<Z+K%D=E')**\4I#Q0CS+59BY(PB^-WR:K&Y[>4NZSM$R6
M9!/)G>_GF.JX6#=[%6+:PU-*]"C\]I2^?;!(7B[JD\@I?U&W&3..4>^:]P*!
M=V1L\Z"2);I8TAH>&2U&E0(1.E/4HLFG"0-+EQE8YP6BY23I(HZ4"G1)7G1>
M%H&CV2B9)GFEW 'FTJ=+_GBA,:5GM?Q,QF%H[2>0,0SOE.PNTGMIJJWJ]W"L
MW@BQ(OD[7?CRD@78&V-:)/U(8OQ)^&@EFZ14B*1?*91\YF^(?[51E5QB_=VV
M+/P(]QNJ8AV*OJ6C\'2EH%W;$&/D2/G'C6)R.T_^'![;\;).UXBEC3?Q<B4
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M*T0_WA6\;E%J<AE2!R.I<J?1/DK#S0F3*U7*G))JMM!/>2V2O]?8E %R[*=
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MUL-V>SR!<YE#?[Q(0!NBWJ3(DRAK 6Q?BD7P]W(0DQOHFN)B\_)Z,S+"'M5
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ME="ZCYRT#;1R\W1!,VV;C33Z!NK>2\9Q".U:;/[1X;CI3GEIM!I@X:CR"_'
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M:O7^94%HPX&>:LQ.!6Q\S!+R(OH>? *,8*GGWH+9]TC[?P]0]56&5 2 EY2
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M7$\79&)'UU&2(@5"SCT'-:$QCXJ*<K^T-)EB>R,H@ZOR,(CD&)?L/"#86/9
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M""V5F,Y2Y=QC$+AH+.<48ZA7\^[V)LHYROGH"<7:/0R^0;52:VI- T)I\3E
M=@/ #*K4[.!?0LLJW(0FE"@7>OLY8B^FTH8"5T=4D$-36E=DG&I7M#T:_J!B
M=VG36,!B#I#FFE0LMF-),YN(0D5MULM^0!"^6R((P:M7"'!ODK]K&GTC3RZ[
M:?&]S<647.9&?M!;%M26O$@B<BY@>-XLU2):D[64"4N!B+3/:?)0Q8#W5YC&
M1C SXH/29KX"QULS2GW'R3M50.K^_\@4$V@IRM5 D((H)8%.8;1G;.DLUF?-
M$B=P"E]B#A'I%@N4(9<N,<Q25$U5CSE'J'2?3@4)+Y+U+J,5M5,+[J8@^>C_
M/91V:@F3Q12L5*UW,#D#/2I:O=4.%:=3M86^4QJL4';+Z1P.RT>!2DG7ZV)Q
MG8-[O"/Q%@D.'"# 3<4-#I\F$:7F8%Q?"K?2:[IO_NNH?0C(5&\[93M%.167
M41JBZ*XS#:Q$W $RQ22W8G7G1NB&Y.Q^*RTT6/U^MG=*87[.'CNZ]=@K"KU_
MU&-4#@L1NRP/4LF7@+?+BRZ57U0%+HO\IKJR!@=!.TDR"I^<"PY=@"(QW(C>
M:B>N$YIO-*NZ$8R>"QL"D'1%3+.;DDZ/YMF[$=^"*:R!O+.\GA^L[]1-HEZM
M3KV(7.'XK7P/TB8PIQ!QD%$_X0R[22N.3';X>52,(KG1[\Z^IV*.\65E=W_(
MX_C=1RDIOM'C8/X(>2T@Q;8&T1G%^0R%*4=FT3_!'[&>=7YRK,?[')5Q].=F
M<-;VQC::3"ZYAW=D?W2/%C' 3_(206MP%=#GY32 CG 2UFO2N<7E@5TC!Z!
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M0ZV/*:RJEO'00"2R*^@0J"/U6COGBW(IY7],X5PFP+%L(0&S%]G-NF)1@SP
MMA@.% HW[?R^BYP=ZQ56 8B@B!"2HSWVB)H< 94M)4%.> .]/HF3J,"O6R1
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M+)=BF7HZ5TH=M_Q5$^J33NM6E?9R?V?8.TH* 0L+0!=?%1!@1O\>!74E&>3
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M=)#IP1PR4LB@"/-&Q#02U0WTS6V]%&4YE<114S:-8'$GBK71AYH)'QRXTSD
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M_8_N\3W.W^D;;U4H?#!\3_FQ$I7 2P#@\G]_!IYT4N0:4^5+D4^D071^E4Q
M*>G@>ASF1,<O VS:@'CR[" M""#%U8HE00"8!Q_XK9RVD5J;Z)[".(J29VA+
M4EPQD)3,JHBV).4[!)IV33ZJ!%_S&JCDI/95E_IYE*0:WSN+" 0UD*_X5NH2
M,A&3EF3+']2=IM("<6G<R.V2X5 1]]_Y8=-/.,Y+#*Q*BJ\PD$&V;&@;L@P:
M6U>Z_5 TC4S>VA*)8LP=6XQ JE8CRKQ _+QDU=8+(ADQ6LX"Z7 =*1\,]7<
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M+;E963(Q.\V5&M3Y(E,A,]M\T$.X*,H+SE\M7J%P=&?$J:.%#"I*Q\'9;U#
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MM@R]@ "-@XUCW=F%F8\-[3,W>I5&8R:-2@.1A@IG5JJ@XV\0'A"!U"C HB!
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M &!&]'@D$2Q49>6^RGOI)]+$5(DJM0MZO8^\QZXYW$%OU:.%9_<!DYJV,F8
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M9UX,>PR6(EC.+#6M^<6;>],LL*@QUH->GP&SA"]FISUDH)1UY&[/[%BL'Y>
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MN'(D[CQ4 5_=33*&][J1&_C8=BAM,AZM# _8KV_NX,H&*QJK4!GT0698 W/
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M9769NW=RHQ'LVJAVZCN <R$64& =#@\LBU1G)!<;?55X2C@=159BK?:D9\9
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M@_V@%-Y(VYVXMO'Q-]6\A4F>29Y)OCDDGS5B2W!ZG_PK<>>J!S*@RL('FP)
M:MA3.<-"*+#R[7 1Q3BHAI2"A1Z"2*WFZ.?LT<)8O$6+NYRF2-;,+J<=[G):
MORZG^W)^5@X_M^AMEH\A@RO2@\+7#T0D7XI^0$PFKN>J,9DT2JP\$%M-$>.6
M8RO:SW!0@XYCP^Y/;Y]L^+0Q<%3XWF-K/-*6:MT:+XF?[J1=U/.[!VV.H<&E
MP37Y?W_5??7$&FM#:D4Z>'$LY-%V!FF/WL\IDUB-S![]8KB/5Y5:49Q(DYPC
MT^6O LR.37I\?Y,QNK3,V_Q+PU9__AW4V=6;V]'%\95]0#-3 >.=ZR6Q='9_
M?YU-][?'["-C+.QO=R'.!2U>5J?= S6P.X)_^OTW6^8H;5;,S\EDVK>'HF0L
MT!LKY;,HY G_$&O]82ZZ=0LG-$7WDK#U[)V,>C]5)/&.D?KQ-HUY^?;N^.%%
MJX?\L/LB363_Y-(?_;3[0^^S=N?Y)^SN^X0LVIK !;("@XI2ZFA4$;DVO&"Y
M5@N,_A(&L0PJC=2#JBAKV4:8F3<!]?.F A5%_.J8*1?,SNN!TWG?E8KB=&4T
ME&PCS,R;@/AYN69%$;\ZS#S?"7/S:B-U7GU94:0>=BJ"TP/FYDU"_,MPG,1)
M5%F\[W::[A'M7-38(\HTN ,:O'$# QN=Z*I\ZC9047+L#!M/CKT:DR,+SH,1
M+1)LI37&4;<J&B.[M.J!TK\%WZJ=37)1%<,>1 'S\N8@_CL1B_TDG/2KGG!2
M%;="[P!N!::573@,O$6U9<2P(AA]4981W-]L;7^S]]]UFRP A+<XCV(@WKR_
M63#!1ANQ=/VL#C_2W;6F[MB- _AU++&4S9'WT@NP7C>>@LR\FU(MVQ/MQ5I[
M;:^6U<@8$_<N"1^MC--N.)#YD6O3.U05LJ,RPPM%>:6^8G8 NPLCV)D"E9Q(
M. )L<"KP?5/I.<9X8:15.ZX/.[:#V0R>5X^8B,_VU'B K6%A'UPBOLTW/MMQ
M,):AVJ<U2O>9KE3<CY$ZS_.](4;#WD,$DKHN_4OVO:5BP)/O*M#;OF& U>**
M_UTP(*J9,8AF(B1EC=O8C\$:OHT,[ H$>(4,J5032]W%HB@!0D'<#I(8N):/
M&)O2G7X(O@P<8;GL=0<R@:EE>VKI,+7LA%H^E.31\ZD&!7&15+"_!HA+:M,'
M I8DD02J"0V4MRB$0B/QU<\F4U2%**K+%+6;0A??N$SNDB@FW<K,=*MY$MI3
MZGLY"8.9D=?#&-;0Q"<[PT%!TA0^3U6[.+"_&0)4+U )79O4Z->6U1KVD3K5
M5TWJ:R-\0]S=A?(.VURF[RU\J=-NM]I*!P2(>*!GMHP/>?N(J0LL(!1^I/IL
MYD<82U].7-L5R#. #43&L&MV+T;F8-![>NLFL!?092.D=GB-T%IQ4>=43(/X
M"NK;W]T9G #>->BV1C\Q?S@J?^@Q?]A1=:<?8#\5$GHN67Q(T]CS-AE[K@WH
M'J-)[#"^'Q7?^XSONY*'Z!K1TC#UR1OD3Y..<EX(PP'!X@,]W$MC)L,[D&<"
M!)B<H>-&>3?&Z+IY<..I<>4&WXU_D8>FA<D516%EV!YU=W7QK4!*RK]1%&Z2
M'L&?M?:IWI=+.1"6L*&9ZRO/C]9H2ZX1Y:2A+3G[TU[WU;[J$:?AK?:RV0$*
MZ80 B<HZW0,<'+UOL\"1'NCU$O0!SY5P8P_*I_8 3.1\#K#%BT"7'5RL R!%
MK0.^M^*'2UUZH*C@H,0@S-ULNJ'W#.X&U0WWOT)I(O+[7!GGX>HRA7[>N4=P
MY]-+X/7IX(!SX-;21U12?X&/],T)&Y!&P:&(G)&:(2"_2SO!-J0*GO=NZNFC
M1[&'>8JI &B7C@$?*I>DC8#&GN@ $&RREJ(=]PNLDA/<:G>Y7R#W"WP:/_^4
M(&Z @PHC#,9H,X)N(7U'T-2">8!P ?9G^" KSN'D,_@\%MZ"'"O*+9^R"F!M
ML\B(9(P6( A)X,W!0\L Z8MJGN*>#S17P4?^L7.^F+%#J>]PEGBQ._=D?@P0
MQ[!]>0>,'@ O:.LJ2H/VZP+.^!0W.[$N@L?6K@OK/=)&T.H^9Y./-AS<W"MP
M-R\8/*LMXV,KK>L$O=.M6OT?V>KQN_3MJZW7V@C]P3K]6<\PJ[A;W[%PA-%A
MR[(XK40P2C!*Z+>^_SZ7-L;G8'WXPD;,.'H>WP&':(NYZXL0%/%/[RX-[(,-
M^JKK&_,H"%UQB''V.U?2/[K..7K$])7"=MKM=O=M1:[V@#?ZA2)B78-\CN1;
MPIL5,<Y--QQ)4^3B ]QPYU_DH3RYF_@ %)7Y^AQI:Q<8F*;9%6$@\W"DUOF_
M>!&=4X'_;3 GWZD#FH"*1\<KM!$#Z+WH.'1A$5UT'[\.#7!2.\J+IB*8C/TR
M.+.>[)U7.WSZZ!A3:*^Y[[NY5CP3\WGO U D%:(@GGS\Y]Y?_A[SB:M#JB^T
M]7<+FZ_2S:XFQ/%%,[R4V_?O]O[FE^O8VSE-GZ-D'VCRRJ^7U=.2:X"5?UY>
M_^N2\9+Q\FAX>>G[08*Q:1$#=$44&_%#8/BP$2QKL,DHB$@+O?[XQ^VYU6M;
M!S('GA!M6ZH]/PKLIU2>ZJQ[=*4KZV:\;VO)#0$]=<C?<"C!A3)ADCD.+7=V
M'\V[_/K[N35JIXX"@%XR$7:<A.@#T4.2V3C>%V?2 5M0JFVX#WR@8*CM^ZZ5
M^6?]W.'[K8M;;^T-%IU;;*]7S5[/^\SN^68^X8F2F1AKM.@L^3PC$=JP[> 0
M3C9KA^K-26!)WF%[SS?SVPVJN,.V97R\?'=XQL$HL35*%.<-[/ENM"909!AH
M#DU(&TT+]PT;*_]0#=V_OL"(\@Q$2=/9?S8.B#(?TZ0_D>NPJY@2J>Q_M"6N
M/[T[E[X84W UBA/'I:81]I3R ??9@D1M^"86(96C+2/7+I+V#]38@W[.7$[/
MUAXWK.?& "A[4X./KU@I+'T;VU^HC/0L<Q4O+E(].-)L52.FK +U[)B*((.\
M,8>DW /M< $<H9IA>%#,Y[ #O 53%R3<X>/P30P?3J1TL)>6RJF?B84QEL46
M'O94P//ELHRG[NC'O8+6:/O[VF_ZQX_Y"[]*S*TVWJE^*UCN$6T%.?7.P8O3
M<@='RLJM? [N#U2X/=+^Z/EE<-@!H#-X9*UU2;N*MSZ+%=>QBFZ_DV334KE?
M2@B^H9P.>6"A+NZ1\KI271W5OE'] #J_L560\$$"J[*ZI0HWT_#%#'Y+WVD:
MKFI7Y!/KSEI%> !+K.+6/93(<R7M( (Y(&>FD4G[M(3)1(?BO8M-H.!'L:#_
M+WY9@!:Q (2)\@V:Z;<! 6RJ)E>R0E=9W6'QET^'!/+Q;50J$$*>.P$9 ;^B
MWS];# $12:!^+#67WY7@P).Y8?8:3U)Q&6Q'P487*>IJPT!5&RJ$[PRS]D]Q
M6FN85Q>&P&CA&IRE"O?7W4ZY(I\Z5XEH2OO^\7+$G1<B,M=GKL]<?W]<7\>4
M?BEI7V6FKQ\!SJ BF(YBD]0^()HJ=K07'W-GU+;,M,357^FA=R>I&A>;W8.P
MH+8&T31X0"DT0Q:/'>R2\-[%G+\@(?ECC8P9@&1*:6;3Q3R83X-H#M\4D8M,
MSY;,R)B1,2.K(2/+,Q)7>-G:_D@SX6 =+#8G6E:$BAT(\F6WZUGTXC9%)35-
MJ%9$:YH6,9]B/L5\JH9\*BLH>IQ-H8U%50NV+>>8<Z-"(63)9DMD-C!5#,$#
MY7(&LK,!QQ0SPPI_3_R5R+S,@9+MG<2+"_T];O6+J2U-%,'-H/%H?'GW^X=+
M6!_,4- $5>\;]*VG]B 8M %8CG\E(@3@X<M*#EKR=U-[@!L\SFPLP]2ED!Y&
M)QKA8I-2 A)NLEPE0,U+'C_J2@T!,TQFF,PP:\@PTQ%)C_/+]*EE3^2=%XPQ
ML0V1#?!,A965;XZZAQ3\DY3B>"N^24=D/,7) Q3K>T0AKU&=H/S OW?#LEV*
MWCY<*IFC]8D^SQ!#4M1E";M&26!JP)FRS3^ #HIQ)0D7["+YYE]^W6UW5SQV
MR7P2!GIK>?L6>  TQ !V,1>+F?9Y>DEDA,%">-0$$+X.>J:3V& S Y\FOH_R
M("HR\S+0QC)^D-+/-XLO5> Z!&_ESE+'Z2S5X\Y2]>XLM6?Y4). \Z])!#]$
M$5P2!BX42WLBXKS+GER#JE'V9]_X*'0(R3*U%'V0R_)S+=PN,YEYAN*"=*/V
MV\<?I8>LMV^4F/V(I!(9EZ$]A?/AL(_+0@_#JR"<IV+G3*_^\?+R*EL#1<_7
M*584?U2!L9MD;()U8;?RY[,/TF^U#%R#AI2XOJU?H7IWOI.>>$#)7(JL#0@L
M;7H;?@M;):(QA/TZQY[POQGV5-K?=&1OD2D-\P36CH@ER,E$VKK_=-KXDUQ"
M6>#/1"N+;*KL_*;R#&6MM-%%9(,R$1<Z4X8R".^$GVDAP#-=0!NPM,;I-=B%
M:R"@HT808$--S(K13Z'H_Y*$42)4A!;W__A%J@08V'0R4^>:@"(>$@^\!Q4$
M)\6D=T6V*9UE"KR INY@._%H+FW24Z2,=6/4S=^@X32^-H U9*.L9?=]VH^N
MV/:2LG?D#/ =KQ?V\_2AGD3D%(G4Z4E)@K]'$VT*P]X>!&EUZ9 "&D*0MGY%
M=<I5>YL_$]@Y'BOM4(70Z3[53!Q8!Z%G:L)"%%=ACQ0T:8/;B-I_/@!@53MU
MBH^,P99R1;C23W9/;+!Z Z0^D%_%%SZAI+#M(-&>6!\'5 "3H-]2S#,U$]&*
M.OD<%$] 4!,1(_?4+*$%; TX#5K?WL*$+]@B <9 2S@!G,</XMS_BVPEQ0;J
MJY]O)D-\NO,XPN[Z ,6%9A[9$E$>Q*<?,'Q_CXX8M $VHMN:TP@_#?TC,87N
M.$DS^+.,A93=X10;U75WDKG!E=M;>9-\Y&ZXS2BE].R%4:S>%QM@?<1!2+5'
M=A#%&IO]P+@+ H<>A[<IH@*4A_>3>:27!?:(+@2G9?PIL[4=I"!'#9%2=Y-#
M$ZY(8DT9#2_0Y)S8^B\W[Z^P1S!L**2T$S7;:B:!P:@H(Y)1CC)T!I7!1BPJ
ME/=ND%"323=PHGP_;I0WBZ8EDCC!-NST',T00F2+T,N7%MSAQF [CQ!GU?()
MKP'O;?+ [3PD?/7YC^MWY]9%R00YFMJ6ME(=HTV,4N > S:SP,=Y<EF7U P:
M^-N^(8*]JN4,9UPH!$,1&"RDYAKXEY2]M(Q?TZS8N\1UB'KU,"H0EQ.@CE!X
MID)MY2T)D#+3^724$?6@A6ZQ_3;@\ QU@(<@_*8:=Q--E#>#G3L$:#:Y<D5R
M";X"SU*BE&H&3HE2BL_!S:DUU?K>8FWGUH,U+3_@5:(;?BK0 W\/8" M*T4J
M=<E9R:;NGS/&\4I1F,R)T]DRC 667<6)LP 5,4:F?)VF</GD  +L+.*&0N;\
MDM/K((5%?)-&JF6!UJZB W1-<"V8"$V*T43B"$/4FK%%NQJMJ-^2!AI49_(4
M)S!]&U +VZI'P4RF#^?EJ 4W7 SWB$"+"O2G0**P%Y!.+% F*/5/JUF'NC "
M&6T,13NFFH>4_H<IXUB# (?)18?:=I1>97X#2!/PS31'/2+*BC!0<V!6TC+^
M%3P \$.SQ,]* DSM3 LZRL;$$5]R+GUB,/HIIYCJ7;B<O9TDS1Q2XAM-KBG(
M+=@:YC IJE!JDH\W-9:D%;B$121[ >\GKH-W9Z)R,$UU/$GZM-9WL'\#$6:F
M8&%%"EZUX20%;W,$BP,5Z]L+DIA\8&9*ATA@U.[O:/(B1TK@>=^D)E#<A?:@
MHTLXF&&B52C0W8U)"*"O95440+CT=7AIC"NIYH6XP.\@$@&H-S&5XA!N*^,(
MU;&0V$QNLX*&1$-.@P(YI/PL?1/=@C*LT32,E#FHMX(LRM_ZU6K8AX_88"KU
M5QEXJ,41LYG*U$^_W %=W NPM\>NYVIFM[*E>U Y\03'%%9HWA2*HUP?G1@:
M+\>8%1>ZT3<%FHPN*$)P)/ZI-&PLKTEIH< 8S0*:9B:U-M04#T+!D3%.H%LI
MTX"&&H[AQJA;:SO_*QS=^  O"<)(V_?I\%FX32^2JBZ(<,E%DRM ST6</#(%
MHT*:^)'L:; KYZ /^NHRON;W\CD7:(>ID=JDNY==YIV?7@[9PU;$?476E  _
M0L-Z%92GYLC^LZ!O8>A5.771'QLJ0!&3IUP5U7F25%0O4S+3.&BA7!0YBA/0
MBB#87=N=X[?UXLHW5%A]9=4U*R:^ERIVZ(/P4$O4'@<UHCL=F[T2<0[&I*JL
M&UJ$!34DK#><HV5\AK_K?69 R"VJTA!P]*'<^6X:TTXCRVD$.2\DP4*1P/<U
M1R55:266#J_66(HA93!+@L+5@(Z.?D<[=.>Y?B3#>UCD7!5K3N3RYO7N_IN.
MLX2M2_7M]%AH*"E%#L0_&B;N!$P'/SZB[Z3NC.8J4,,Q,TQG9H,X:2^#):<H
MI32I"J_'47P=8FM_:J)"1V!/3_W "^X6*4_0H\*!^B)0LHOOQ4B3MJ5-8PK[
MHQHPI2N[H7,^%R$HJ52V@;O7Q+5RD$TTE!+94[3$F1K'S-3H<Z8&9VH\ELE7
M<W$$MH0DOS&I9P4U";UL?L3R:2L8:>D!NX8OD>0@B8 :%>;]KM7OM!=$S[A<
M7GJC'HU*X%/;6=%&50)X6FGSRU82A_.N.>_Z!/.N#\A7OJA6VN>4N@-*H6(:
M!9?H,J%RD<4)$+O5WH;:.TSM-:-VQPU5,#>W'36]JV!:*JHS*9XI#XGO%&>I
M1UDH+0[1F1^F^D Q>3'*<C:OOGZ.2CF>V1?+':$W?/MC_NTTLJ8,7-1Y$B\6
MM*%I0'5M45S0;;;19C!*)M*9 CDC'&,AG5EH3@!6_%VHXH'1'%X<A&3NJX.;
M2R=)=:\5E4N]'Q])X\:ZDB22^G'<'G[N!WX6)R>8I;_H]G8Z7]-?Z-A7\5:S
M"U0WCA7'L4KV(KZF8S];@><MO8:%  L!%@*-$ *9YY\Z):QA42MYZVG3J^5@
M@)', U_G8$Y=8"8I)RDREJQH+5KV,C(7.0$NTM^&B:R;@LU,9"LF<A70+81Y
M7V5=J4(5)GO)UX6-9:,[",G#3=Z@5(.[_O+U_XC9_.V[3 F,IR%E!6[-:]:8
MI,Q!3H*#L![23#V$ZEB6TQ'>LH[ %,X4W@P*USW2\O1<STWS:@$OXC!15H0J
M4&$_ U,_4W^#J'\BW-"X%UY"5HBN%BG,7[!+EDNJ +"3X 19 #L)&LD!?O>%
MAP6FJAD'?-775> <8#YQ@F>9WTR*3Y.5S],JLS00F9=:1L(3JCB0S .=-HUE
M$O"@;H*#EL!8^G+B(JM I^9&%^-<AA'&+SRV'YB7,"]I$"]1+H.<@>15NCKM
M(\NST$,BL!2<2KLRI8-:5V09'3K%8\\6QH'J?S=FX!:[/.0@>T:<A<K]B\TA
MQI*2Y4-5F59J:$"M0*@[3Z&>+NNELY%I9^DI]"[898B%V%GT"JL2(BF)JVF[
M$03' TZ#O%<-B=8G\J1!I9U'O.8@I]+T&WWEZ8S)4F:.:M5AJMW"R;#!@^H<
M10T%?BR3FF!$I7;8;"C$.O2T]YF?4,-M,*^C&38GFP6>M!,OK5U$,.7IW=*_
M<WU].P58ID"#,RYG&*T[''4920O/56-!&KNXY84# F77K6OYU0V7D;74%P-7
M+I]OW:G4*50>&^PJB5T/J$JU&P'E(HG3\3+8/@Z+Y0G=L(4*/&@'NNM)WO;7
M"9.[TDW]F1T5^TW(O//-&F4G/XM^=I.N4_A. 6GTEY;YG*:"*>)3H?8?( 6G
MM-/RM#EVFTJAC-]=PQV.WF<G;:)AIB?#DC8:[KF7D/7S"/B17$$BQKP'BNK>
M@UUQT,6E.@XH"M.IE-@"(Y=,'IQ0R25S?3D$JYN55S?95]5(;9/J_.U@CDU9
M48E1Y?Z@%F%W$LVD5SJ2$(^0:[M9%=4PZB&K_=_;<AJS$#;;*%;SEV1B'3NL
MZ"1BCJ4S>V+VU!SVI+5]ZCF G$KQ*+F^2$ ;NZ0P.F  .V3*49-BR8R!&0,S
MAN8PAG*#-\SH+VD9J6E+_>_T["WIAX!M*E\_!%LWF-,HU4 [#,CYHPS44!4!
M,<=@CL$<HRD<(W<<.M1]GJR'K(6O;@G&1,]$ST3?'*+/F^."BJ <Y6K""GDB
M1)AU#L=D7"9])GTF_2:0/OH7T[1[#!!)FP*J&/W%!O" )(9PY%\)>CVOOG[.
M(DAI-+8P3F#)>WDX+L&M!X_3>G# K0?KUWJ0!1D+LA,09#)"+'=I*IKJG3T'
MJ127YM3("3:ZM1?H#L?Q6]G4HG5];ECE94[!G*()G(+,6LHF,I4S:ZYZ[L,B
M,S54QL_;[>MD.?C5 S C-11[\N>3T9A!,(-@!M$<!C$/4%^GX;!Y+J76'0KC
M'K/QI&G"8 BV,N@>:N!%D57@\##F$\PGF$\TBD\4YV50B@U.24;.<(<9Z#[%
MT#4;R*>695PA'</*7(&Y G.%9G"%C8Z(<BI>,)O)4(_>+/4&%G/U;4H.!OUB
M1M-WPQ"GKQ>Z*Q<;^N8KR)#B=X2M]'8?!VMF^;_:O['YNQCG2YL TXM35TAQ
M;!ES*^96S*UVS*W*@^/1!9'545)WC&P6KJZR+$R*=I*L:??.:Z,V#&PMUM,S
M V &P R@(>H*#HA24]*S*F_'$#;.W23LURZ0-&*RN18RJU[,7*FFX1)C,Q^;
M'=6$ZOLCW62I])I\6&$P3J\6J\"5"O=(E&NY@-5/0$<-DB@M7BVW69C-9:S?
MMD&%72RKNO=IBT>>S_K# _'^22-UE14AG!G8%%&,FL"]K.1(O&VVFTZG6SO:
M=*6 GA#X;O.R6=.?(KK&TR#"V T-9W''7MY/PD4 D LG\] 4.F&@R;2/'NFZ
MMX:^%NPK )!>ZBI0+/HGH@7Q%DF)Q_D#_4T%%1!W#02(M*5F51=&RA*MIVT-
M5*!+SYBE"O>8%@/6N\U-4:>)]+I@;4_>I=^P*8,4WXV#G,UB?P(]!+?8[%7O
M/6M>0)=,&\?UPWE =;8S@8#5H[D%(49VYF=L.)U<M#3SL/C.54PP#X\&I<L!
M<0PV?S11F?C K&>N:MBPC"1> '_5$Y<>/Q_8$7>ZHZ;&N"(J'+/KPY%$YH;6
M-(\PEPW-:4K=2HJ=-E2'D521VJ)6VRR$GG+)J<=>8<H*K*KKO].W.UD#D"BP
M7>*5A YC8A7"F"=CCX;W@7GI@^B]G4K:LOJV/HKG?I.%>9R%J%>!0%77)#SI
MU UU.P[J7;..Y3ZCN8FOIK\KVS9&8Z0XO:O4_:3<^*EE7$8K)Z3&,X5[502!
M6\INKW":5.--E1K/I<XWV9BPD%KF%!SWQ'"1'A/O+AUMCP_>O+]2>E<A6>"3
MB!SQ%P"7AG,7UJ*5)77_44X]G/V-BXAP+,#J/__\W9,+XU*Y SKM=H>@(.!A
M!UYYAL_J^1FK7TD':;2,:^5*T%) VZ'(S#2FKM$!=7U/5(I>:A4^Q?/?6S<M
M7$7XZCK^ XI?Y+CV<MN?U._X$"2>H^ZA&#%1^*9Q.&?9RVB<N)[J_(/M 37\
M@(M\DXJYR=6N7:Q.;JU.7F' BAA8N26S&FVG<+-"ZN21!,4V4-*L,U*ZEP]H
MC3VF',,+P.@ZNP,6\P:-*B1ZZG%?_*;F8-[B' 2-HSFE\)?ZM-VX 2D]R,%!
MXT#U[=JW6]DD'?B\-$CQ,AP#F4?&KVXP!RX\$\:55JV0_Z;?TD_E3 .DXE2@
MK/.D34P2)5OAV.2(I/9Y2N=+56D2*MFIF"9W3I..',>Z,]^Z40D5(M,?/,'*
M7/#UQ+2LV,Y @B1*D&I!;0<@9%)%M[@%GYK'I?H C?&DVA55(I]M:XGP:-MJ
M$@5*>X'S1#T@UN#!A[]$R1A4%E>$)&C?2<"1>[3/8'>?0&K^7TP(VH-G/CB_
MSJA-7_2'!$[_Q_7UM6G\UOK2*JD)^58^*$-QD8]-?6((1Q$4@0Y#T+13I4'=
M)#,7[CXPWJ$:-<>Q?U]2=M."G<1.@47I9_-97T%A'AG&-0"D831UYRKL(=-)
MJ?J",E@C\RMI0>DF/JL-9B]0Q22JF!&NQO4S TCY!-(#P>+_3H"W=MH=:ZTI
MQ!5'1Z\X&G+%4?TJCO8@^3>&5FHN^/^)+ YUJS*C6N9M59+TVVY9=<8#@4'Y
M]*IT%(QMF3%C='8)6SV,'A/T_Z;FM?#!SL<>Q5]247&9]B0V"'G5#(E &8S9
MN\E) O*C(*"SSY2$LF5" 4.0)3?)?Z=!\F:=S/IRE4D3..Q'L=!"XI8*Y!_9
M-QYSX\9MT&5HWT6Y\P5[<&GEX;%O_V*<N6^4/,B.E%X!1NP\C\P3.+S\KIT/
M09Y D/8=7B]P-\G;M_#.]*4/,G-/(O#)4Q:A::]5@B]7Z1[P';BRA]9$HIJ/
MS6'UA5GV@)4B1:F_B[B+\GZ?"?UJ(&XQ2X!BU&4 \>!WKZ9P=-.X%>Z#\$WC
M7^@4_=\ :SSPTX_"%HEQAA%R'&9\CZXN?;O_! $ YU8+Y"K1V?B-<>^.Y5T8
MK'W1F:VW$P:.B$. L0!<C*<+<I*4%J4=W 0)H.;_@I11O^]<'SQS](:^_G%[
M/FIW-$=X:C-TJ2NH1"V_Z2;G@.U@0K[NM]KJ&6 ?GJM@@D,:52;(F7N_O$2)
M+K$(+T-\(M(DREO.Y?.?/$^,@S2H0<^AO8O:M**V*^7A2YU4RC:E69%Z1)1I
M^#(N:O2X""CK*@@DOBN]WKA,[A) ],=U/;90-PJJSV0LG(%9$,SDF]1WIX!?
M(>%T)$7U,>CHX!E9G6C,%MNQ:]?0#-A(X!1\*6:1->.:*'#)H2LB%4N@'_#K
M8.:F%IO^1MJ>5@E@BL_A^[+/A6V':-?"DAA).D<IDMOIY,^>!6&<<N34B*=.
M<(EFW&@:D]=<3US([<D9/ :L7_@2\PC4[MDS],-T=ZVN'QA9=J],;FN XE(<
M [/@G"S07PQ2%+H<80O4($NV;!GOI-9I<#V:C!&5/%84- ]EZF3Z;^$-:?@/
MOHADCJ5@/H6]8U 0QDF<9E8[[@3>H3X;R_A!2AT^!/GL4Z(,:A-:2Q1AN*#H
MQPS)C?A&IM)MVEX68,+Q)A2WQ#UA#.X9!]1>-<=(*.XL?:&\P? M:ONH@SQZ
MDLI\[E$"&7Q,Q]2,2@>,%E*$I<Y2Z'E!51F$/6CE18#@JXLKCQ6H[TF9 $##
M?F-/.DH?D/ ]#)'YP)2>/A4FUJH*';6Q["0:7?1UDF99W#VHJV[@E%KW*\<D
MP82N"6-G+>.2W(PZD03SWX@I%I'Q82HQLV 2ZPD.^8Q+W!QHS/, ,P[N50\>
M7][IL/,])B?8. @#'9$T+V"&;BT=MH6M^?3'+(:]#AX4Z"5XDH8-U]0R_H0-
MY3U"Z6FU!2020C0*Z&7@48XTQ"8U@HMLM]*7M.4"' <!0QO"W]/G:1-K]Y[M
M++U=1Q:M2D%+ P!)L"QO8ZME$70J$IV@EU+Y!.VI*LL T\/- ['%,Q7CSRN7
M1A+R7KB>FD@#"*''1KBAG<R D!&K6>3]L,C[!$H3>?V7N:@?^&AO8ZM:Y$^Y
MNY@EXO-A5E1+5?USF.<)Z<4RESD^''B4+^"@G5<8,J!Y4VG*5@+HKP)"4<I1
ME3 KK;[U5E% ."XP),H?H)*)W-M2W*S.O5FSU:Q24^TH=X$ IT=OJ+A[FF0Y
M$G#,2,"((P$<"7@>:CY/R!T&D;_F\V(^Y]F\3XBN'8'N&5*KBJ C5R!8=+D6
M%@/Z2^S.$4]!=:4\.?2L*U[9;9OD[B/>#S^TGX)RHQ6$V^)\,4.7]DCE:8^G
MZ;B^;)11CIJIJ?L\6"^/\=[ "#LO%J9JB2.4^ZE-JG(_Q0&?+  <K2#50>O_
M"NL5/EXNPALH@V%CD5Y_39&>NJGRU[;YN79+J\JT5:ANPR1([=NZ!G/#9@V-
MF;E^,(^?4Q^YS3*KBP&> 6;Y?W\U>/74PAH1U:_G!?4(. 3^]V;YD52W*B"X
M_D1;G:3-EXHZ,Z6ER!->;)0^*O)ND?LIP'PD%JA^?H]\\&_C\.=_E'AA6=#L
MY%+V?[>=)^_V /MC,MON*AI*9JA#-)1XFGMC;;ZQ.MV8<LSM[<Z.SKN?CT);
M8(O5?@I=CGRK1_;9GY&;-T@B, "C-YO\\<^_DI?CE#*=-B*5,1;VM[LP2'RG
M2.*==@\LVNX(_NGWWSR)>JI+R69OPCDY(@^:"TMOK%3CD:_R7OJ)RHI9T_7C
M993Z!-]:EW#WZA^O7[A"D>;)&0IK#LUAM__BG>V.A54&,);9'PX8,*N &9A6
M_V*G@-DCOV1.N(MTP:P71EH#_<NA&>+6IUWK"VS J@PYAMPN5V4=]?F<N5LY
MSGP5J#9'H=)5HVKHJ3M99JVRVNO472/;&VRL49MALP$V_<%N\885UFJSQ:\;
MVE@UG3V.S$&G]C;K_KC R!QV>PR>30+DPAQ=U(9/LI)Y,&ZZN8UEP_GIJ&,.
M^\PP-O+3H6E9M?<=[PT\G;XYZ![&4:JI>TV67"T\+:\V9\1OY)DZ8*URT>??
M5:QZ*=S]-!?=15G#R1WS8!3;%("=R#$9+Q@OGL0+=IT4E?U^Y93]VR &53]8
MB?@U7-6W!AW3ZK!W>2-\K('9[NQ6FVT2?'H GHLN*_NG(]5.Y)BLU#%>,%XP
M7E1-V6^L_[]ZZ7^_8;L2U0,PJ[-NN#EP9O5[9G<T?/$.WS15X3VSK)[9Z[]<
MY6TNA+H7YL4.XLUOV"BHC?0[D6.R\L=XP7C!>%$UHX#5_<.,DFNX]C\R!Q:[
MNC?JM3W+M'HC5OPWQ@(NS.'@Y:8C.U).A;,^/G2PX<RV9_9'G$2X,>XZ-*T.
M@V>S%ZIC]GLO+WS:RL?""FHUV.B6$]T:SC?/!@.S-WQYQDICU3 <E69UWAYU
MLW6!U5Z0B976)G%;1^:C"C3'S<=6-IS7,BMY!BL9#<R^]?(JU,;*I1W!AS76
M^O#01^8M-IQSGEF[CH W"3H=<\0=33;C3L>\V$$+/LZ?J$^@\$2.R7%RQ@O&
M"\:+JN5/L%OEL$G5:I9?.LPW%M\;7V=Y9K7;YL4. GZ-M0G.!N:PS^Z3S?"Y
MZ)F='52B<LBO1MSR.N.0J?.DX7QRQ[7$30*-!>1O,70V"EC3ZNPX.8^=)I6V
M#D[DF&P<,UXP7C!>L-/D9,V 3S(VO" Z 2>)9;:'7&*Q&4)#\V+(U?F/.$FZ
M)B 1FP$G).].Y)BL[C%>,%XP7E3-#& %?X<*OB'B.'3'22S&GH0OP,9\&Q8/
M \_#KK0N#JR64>.+(\^LD3FZX&CI(\7H.YGITUSX6#W3&K A<$H2[T2.R0H?
MXP7C!>-%U0P!C@<<WUSX&KCWPH^-&]N5O@WO_BUV6M6P%5[O0\L;=4QK5/]>
MK'N!3=?L]!@TZZ,H(_/B4-U33MPXZ((4=(($^5.CI7UESED;-; R$#N5<S)F
M,&9L;2+ OZA4ED]H>U*$O\!YIF]GXGNZ0SS7JVS5W6C$15A:HZW4],Y/ZQ3R
M![7'<> YJU!9>9I^SD#^;+U\PWIN#'ACKS[^APA= 6JZ(7SA+2(W CB$1CP-
MI31F\/5I9$@P>QSCWXDOU15U 4,Z[8Y%;1/AA[91O-/R_>[^)@8-O8BO\E[Z
MB6I,\0R :C!UMC4KU^VKL,0.:!JIF6Q!6WK>7#@.+/3W5^U7]+M>F'XOL2QZ
M@2&2.$CYD_J+G80A&-UDS(,.[#KQ]!=CU/OI!^WO48'_P9J>F$?PU_2G[*/2
M^5]M5JG;:U1JO<=A^Z?URK'^'(^PD:<7^>(6/]=NZ9>X@$8O"@6G!HY&S(PV
MK'G\([&@QY9970SP###+__NKP:NG%M:(J'XM^K)R"5U^1%^054!P_8GF8^0'
M+-FBML10[@NE^O.8["T*%@68CR1=U,_O4<3\;1S^_(^2F"DSP)U<RO[OMO/D
MW1Y@?TQFVUU%0\D,U;.&$D]S;ZS--U:G&U,=Y?=V9T?GW;NLT\VPQ6H_A2Y'
MOM4C6X%GK@_&=Y!$8%M';S:9@<^_$HZ\-B?R6O04-#>N.C2'W=H/7]@'8"RS
MOX/.C T$S,"T^KL=';4[-W2)BZUXKY[FNR5?=&=[W][A.1)VU +Y$$G'&"^,
MUX-61T$4]N%A[_(X,%X/6\/R'Y7/66[I=[:#V5R$\!FN9;4&/[X6_#L/70 E
M ,EP$LI?P>^&T@[N?#=MMI[,)R&L ])O06.!\'/IWL.*(*[MP/>E38\^N/$4
M9(6-37(,<0?OI\=;A@:0<2=]G.(,7WP0$>!<;$2 DNX$T--'R!G2I7;%<QFZ
M@0-[DQ&J0$[+V+=;O;$!CJL@BO$.0W4%$?O6Z^];'UP\[EL?[,\!OL>EA^Q;
M9]\Z^];?KO[+?O8*')5]@.QG;\2-5=[/SK?'/G?VN;//G7WNE?&Y+WL1&NQW
MK_]4I+UXW4<OK]5Y&5@J#Z+^8+>8L^,D\(*8?I$S;[0C7]X*P]4 T@+X)1&"
M9YSI,.S3:E\L>;#+_[>A@H'DP/(YY*PD$M4<#Q")WH-81(7[GV;R-M5MV^V?
MWAJI1.GBE@M2T^IW32/]!Z3FSYL=PMU69X3?+FVU-1BNV:W^\]NB$F20%@0;
M%<8TE)._O_J?.+!?_>.6'+L@8Z[@60P;_.UGL26N+(GOU)/;ZKN *<7G4;QF
M>PS5;I1?N"1_Z4^/Z00OC&!5#C]7@@3E(%9[.<:$@:?V#H-8[>4HV;."6"UC
M9?_/"R]1)0>@HB?M."I$Q' ']O+2>0P+0(-CB.W0I:GOM$HDPWO7!N(DX$VD
MC#AV]8*:D CDG#TER#IP 5XPQXAB.HACRV#6+DEW4_G-T4CWP[.H+BU9,HT@
M"8WP2?CBW&TW0F0'$L#73 +/"QYH9QP\W&'PT"I6)NXY>MA[/'K8WU^(K_I+
M']T%QM'#(T8/#14X-&H:,^0X806.RG$+CA,VXL8J'R?D&^/8(,<&.3;(L<&C
MQ@:_A,%=*( 9SJ6-OC9RF46_'#I$N)>6;75:E2''D-OEJGODSC7DN]W*\=WK
MCW_<GEN]MF6<7<]FB1]@VUG3N/;MUIM#,]\#)B)TS<'HY>/IFIBBT3.[]9_=
MO9]FL^T=SS%AS;4)'/16S%U?A,'$.'LG82NK?;LKPDAWLLPZRK@PA_V7S[(\
M,LO8&W1&9L]Z^8"?ID+',KL[:&Y^(*[:7'ZY#JS/YH277W\_MT9M[:0WSB[#
M9",S;" ;[)C=T6Y;)S0).EVSVZ^]7KDWZ)Q=#'8\!(Z5RR8HE_]T9Y'K)3,Q
M-L[^%_YT>LIEQVP/F*MN5)] Z'1JW^%I?VS5:IN=_LL;/1V*LS+/W '/_*S2
ML]<&E)K.+-NF9=6^]&R/CHKV!3LJ-LH2RVQ;NY4EFUCEB<_2JLI$R1,Y9FWF
M)54%8"=R3,8+Q@L>M+L'FZ!?.9O@-HB%=YHV06^T<[6N4> 9FOT1FTP;P=,]
M3'2.+8)*B+X3.29K?HP7C!>,%U6S"&JHZU>OE.1W7WA>8%-W%1=KK>!W+B>I
MESY5IS,RY!I13M)8;TSU(K0W4Q&FW:VPA9?T(X'-KQKNB;', 3MB'H&.97&B
MST8_S,5NQY6Q$EMM%OE%AA'.Q/+.0^F1*INV4VLXD^QTS/8%^V,W5Y,,!YS"
M\DA=YZ[3(5GC; ([53F!)\)"!^9%FRO.-NN9G4'M1[_N#3I]<]#=;6$\1_PJ
M[=H^D6-R9(?Q@O&"\8(C?@>-^#VO+>$A<P&?;%N_;A[ L=2]O<RH&IF#3NT5
MX;W,8!J9PV[M#:B]=(>Z,$<[=LZQ>;!6#G9!#CI!@I,F&BWO*W/.VBB"E8'8
MJ9R3,8,Q8VLCX6\[F+2XRU%3I=E)18AN,QBK/,#-NFA=J ,7)[@-1\MSW5XP
MPJT_>LD\./@W'[OF)!*7%'YV"IP^]=KJMKKE-[@^CG+;$&QM&;=3-P?$XP\;
M\"2<)7:%AQL(W7OI(^2P+3ZFMX#5,97"L8,$@ Q[BY+Y/ AC>#*Y,P#U[  (
M9F'("1PZCHPD A2E$5L(HR06>HW\R5C:4S_P@KL%W6$,MRQQ0_,PB"5LU9%W
MH7#H>P;@=0SKSLQ\^A8!5MA_)6Y$^T, W;B>:\./MU,)NII,@'XCX^S__,^H
MTVF_O7%O_Q_ZT7K[!D'QD= GFPGVV;>#N2M*WU6M9+,5]"/%13[!669C&1IJ
M"M]E!BQO86ZHV"*LR)HMXF+6\&T$YT\[,>JO+2/P\M7CIH-'ND4L?]]JM4L+
MF(7K#B:32,9TW0#W(L:UEU^+NU_?S"<[2@JO]+$,8'=Y0Z#TD"*"5X(YFW@T
M8W *S$6&^@!.$J87O14%&2E. WHBYD5QXBSPEG;>+.[J\Q_7[\XQXX?XWV44
M!;9+K[[\^NXFG7?(DP[7K+=ISL(_::BD1V@MG)GKNU$< O7?RV?..N39>\_'
MLU%!2]GSZ+WAXZ/W>ON;CU?]I5_BJFW"=# >O<>C]WCTWM&NHJ'$Q:/W:GAC
M/'JO5C?&H_>V]Z/RZ+TM34(>O5?G[(D#]9C>Z#9H;O+#J&,.^QSB7Y?\,#2M
M^E<I[@,R'<R-WFV%8NUB1I5C49N"59W^<E@*XTNC3FNTNV#5L&6](%B%H269
M1Y8>1+0:O4H_C2CP% 83&44J"$3QGE#XD; I=#.1\!"&&T9+T0:3OBK">#E.
M4( 71II@90/7NG?CQ?_/WKLV)XY< </?GZKW/Z@FDY3G*9E%8##>R:;*.Y?=
M2>:6\>PF^?24D!JCC)!8M60/^?7ON71++1 VM@$#[JIDQX#4E].GS_V"CUX+
MF%#@;LD7, 7XYX+'F!;#F%PD (QDYO)T-[C%<%G]><<>;D NR0/7K]*;)ZU>
M[<V6LXK=>K J=UYJMAZLR6J]<$L5E5#"Z$,NZAWVM)U[ZGGMN=.I_[/$ZT\R
MT?P^Q*0F'@X%W"X4#^-K?R8-(C@N94^MY[7;0/^T=-7%)1L2I-?KNH[^#TB0
M/RQW?71;G0&^75MJJW_:L%KU]4M3(7!((X"%^@[0@]%/S_Z4I\&S1H+-UOZO
MY-P G'\%H\#W\J\_^"MBT9R0J[T9K5X$.&0^CT)HN?J,U\F^D9J42E\]VXC[
M;34Q>?^\;ZR_([4=^5'F7/EQ(9C.7@F98V"%];Y9[]L.N,BL]\UZWZSWS7K?
M]NUR/5G/@/6^[>&)6>_;7IV8];Y9[YOUOEGOV]9-9BN8#0[8#>?V][_FXR8
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M\;G(@C&:PL\O83INHH-2"3P7)3#P=92/JZ53>L#G5RWG I:F&GV\@FG3A)P
M,.T7JM)%?WZBRELX__&*(%&]0AQ_F%X) H31@"9*L D,O6M-] \VT8<"/2^H
M:)2G(8LAB#R1G\VL@?X #/1GUD!O#?360&\-]-9 O[M'<:#7S!KH]_#$K(%^
MKT[,&NBM@=X:Z*V!_M'L6S>:$ [7/&]-T*N9H =]M^?UK1>CJ7C4>D!CC?,;
M(EYLFA\\R#1?:TCM5P6"%D=-51#ZXHI>^SGU"<<X]?-I%L4.M]^P;21VMXV$
M9]M(W-Q&PC:+V&L'TB>@59D#>D*03L0+W>_&=1*16[?1_KN-3MO6;63=1M9M
M9-U&UFVTNT=QH-?,NHWV\,2LVVBO3LRZC:S;R+J-K-MHZZ:Q&PP'A^LL.O*Z
M#^_5?H@ND(X[.'EX?L(! N:HXYZ=KMEM9IU##R91]4)%S]OSA9C@RY3>YI?Y
M'2I/M="XO7RT-O[:VT2@O^F&_2SK%X%5EP"XHRR=.&D!B_RCP%I/$P'\/33:
M9>#XV-R>_%,(DN[\/F%:M(*&N*6TN!S3/M@U5B1Y%&.C]LKE!<_IX5SJ^A[Y
M,2PL'8TP3046-@;,)/AB=HK,:YW6O?D>[7>$IN26\!E[ZU9V\=D\E'M+C.\(
M)YW<_UX>I/4>'+SWH+<Y$__N#_WHJK'U'ECO@?4>'/HU>[*63>L]V,,3L]Z#
MO3HQZSVPW@/K/;#>@ZV;YA;M!8?K-#CK6L-X0Y<+MX/RG07,HH_)]3IK;KAM
M/0;W)4ME<P$JM/1\H1UTGCK/S[K\G69Z=S-7NS5C-<S0>4"62LMIV +Z!I(T
M=R2@330"%&)SOXC(GS 5692&SC03$D65D)P1F1C%(L@ES1PM#HE++G*J*N7\
MM\@B&4:J-A5\H5HU"">EDE&WMF"P&2Z/A_&>U[$9+C;#9651\F0-KJDM]2LB
MJAI)53\/Z-@,.)TFG1_\+!@KVNG->6$;7%<;XX']72,(Z'(>I7&<7E-#'D)]
M*;@E4#XF'W)6%05,RZ* )9]:%<H_KL05K%?P3J>]%;=@KV?=@M8M:-V"]:?_
M@W3/< 4J#V&- AZH==PZ W?F* [T<EEGX!Z>F'4&[M6)66>@=09:9Z!U!F[=
MY/!%7(FD./3<H4[7/3VS;=T;(-,_=?N#,PN9!E_@2=<=G*TYY6R#1-.2PW6D
M+;%--;G4WC;YX[:IXLJ[;30#'L"H%G(6<NL<U0JJ=Z?,W9VCS*]22<F1&0NL
M.]*T<"W#-"=UMWNG^RZ6;0PZGNMU]SZ ;6/0.>MLHB"R%5IWE31^$5*@JXO<
M^R'0QSB=8E[Y@9/(0;?CGO8>'JUYJ&2@T^^Z'<\RD67PZ?7/W-[)>MF(E34/
M@:!B]8S,CXF>^N$D2B*9HUG@:D<R)39',GIG[N#4DM1E\.EV>^YI?[W2U2'!
MY^BTYPX&&TF@6!8KYS7$RNV%T>79\@COI713.; YMGKZG7W7<^[OVRGI.L+T
MG]PVMW9G#P5@3V2;%B\L7MR*%]:"8@K\O9T3^+^F.8C[Z8+S[\#%?<]MGYVX
M_?U/DMX8A/KMMNMY#P\".%3XG #^]$[7&S]BY?V=9FQ/9)M6KK-X8?'"XL6N
MR?L'ZP;8O6# ]ZG4U;O+5.L#UPB.0"4X;;N#LS7;< \*1KUNQSWI/#R<_) A
M-'!/3A^N5EH_P/XPP">R32O_6;RP>&'Q8M?T BOQKR/(O.SW,_*CS+GRXX**
MCU6]>@Y> 3CKN;WNFB6W0P*0U^V[[?;>YY)N#H$Z70\P:$LQ0-:@<@CD-11#
M[O 61_XPBK%)&IQ1GA5/@>)VSMS!B:4G-[3]=$\[#^]O>; ,Z:3K]OKKC?*W
M8NINT]%??.Q(F6!][++IHVJ'*8LA@#ORLQD1U(7?BZ36)Q)@"M3VP"GLD>?U
MW&Y__[L';Q!"[5.W>V(AM!Q" Y>*JEFAUA+CID['N]>#?6-78>">MFWR]7+[
M@-M?@[AZJ. Y.G'/UM![QCH&]\<"_D2V:1U %B\L7EB\L([! Q3RJU#  (:*
MD@*SA(P&+-QOR>C6=?"Y0T>#LX';.WFXX?%P30:]?ML]&SR\6L#A0JC;/75[
M_2VI ]:LLD\4=U>[U&[.<.#VUT K#I54G+I>QZ9A+F<U[LFV0BZL564GU(<G
MLDVK/5N\L'AA\<):50Y0QK_%JD+.5&H@['\_<.'_Z*S==CLV[OI&:\K ];PU
MAV <%(2ZW0YH25O*NK36E'VBM,J:0K06?E3D5H1/D]K^Y4^#CM=Y^:B+W1=8
M>6[O=.">K+FEP"%!Z&A](+(&F/W1-)[(-JVB;?'"XH7%"VN .4"UX"-(_$=Q
M*N4+%;IRX(*_-;.L4!+8:[M=SXK[-XC[9P"BWLG#J]Y:<7]_^-H3V:85ZRQ>
M6+RP>+%KXK[U%6Q5*4"=P/'S/(N&1>X/8P$OP,*P>$">I7&,CMHH@6&%//@"
M+: TN&=G:Y;V#@I 'D#(6T,7D8.%T-D9P&>]X:M67=AIOOA$MFG%0HL7%B\L
M7NR:NF 5@4UX!Q8T@B]I=.4GN7,11"()8!'O\["U&^K \TT(NH/VF=OI[G^9
MK$T QW,[[;;;:Z^W&=R! .>HX[8!=TY/;$^,;;"[+K"[,"V02ATT6]^9?>Z-
MO+<S$'LJ^[2883%C95T _HNB97V'02S\[$?8S_CEQ/^N5XC[>E:.NAX!V82E
M-UA):C_Y<Y-\?LUK'*9QN B5A:?I[Q+D=Q;3EXP7Y8 WP>+CO_M9Y(.P[OB)
M'\]D) $.F3,#&$M'@/H3.A_\+!CSX70]U^FT.QX5$X8_VHYYFO637?\9] _T
M"+Z(*Y$47"ST#@!58.JLJE\VK<L88@VW&>\QZ8*!B..I'X8PT$_/VL_HLQJ8
M/M>(%4W@^$6>:LK$WP1%EH'V3>X]D'ZC,!__Z S@>.^GB \,R@=CQOY4PK?Z
MK_*GVOZ?+1>FVPW"M%ICO__G9K%8_8Y;6$K-38JXPM][-_1#K#R#!QEYM&JC
M$+.\&]XTOX^SYZ9A%@<#/ /,2GYZUG]VV\ *$?FCZ=VN>'/]$75 GH'@ZA=%
MQ\C45U-$ X'>V@?R\[L1V?\@2V' O$&^PG_6F4N=[*WE*#9_HIU;3W0+Z[.7
M:[6C.-#+A4+9@5Z>PSVQMCVQ?3HQ;E>UL3-[=-J]3DM[B2U>^S9T>>13?63=
M[RA*G'R<%A(T:OEBF?)W]R.Q$9B'XW@U[0.'ZTWM=-W3L[UO?+<)R/1/W?[
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M83XU'X#_HLFB\@\>C*[7Q/^&M.QYI[T05U1:4,R& !60,+A$U2=2 D&#/1R
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M$Q2;94VM(6+'HGGS,N%Z9N@<F_I1Z!12WZ-2["X9S-U#B6OP!(97[3.J+1U
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M(.K;E8E 1--<ZD)'0TP!9H0T.LKX<:QQUQB/"RSD8[\6$8A%,!H8:,M998F
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M <Y=#E;*85\S/Y%<WL_*/_>6?]Z6I@@K_SR0G]WF(IGC:=YINW76H,&WUZG
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M%)E6N:>4CR50KZ*TD-CZX7O$HE^<^@GW<F"UVBCVS%OY561!@06[7[&6KKB
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M^5-MO\]X#Z7N9FAZ$1T8:"=7:13J!\,YI:?W9P,P>=C\4!>V1+T% C_6JA'
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MF0Y%X*,Q]EJ4!:94^A9+MGYIH@75(!:941Y=6^HTDU=#<.6AJG^MHGQT@<P
MC/(9LMABEV@0 DINS]/8>W$KDYN4F<Q$#G\65-DU<=YHDOX+DW2= $B-9=19
M?BG/4O_ZE._*OQA_ 78*Y9=PQ1+?(TP?57XB/S%*TVFNWW+.Y0WLE3@1RNR+
M_%ZS5_%=Z!QGJERG"__7&,C,N)3UFACUU$OCM\I16!:55%7(63^NA/-J:*0&
M,)ARU?&[7'T1!P2J$DENKZ869W!2RH@UG6LUD>FD?:(A=^%G0Q]DLN-/WV,Q
M0QBZ1N_':FMF[29=D)4Y 'DMOXN@(,Y02[=?U"1410&V5Y.\ .OF':LBG5GZ
M?>8T]Y:8 R::"S!=S@<*F PCKDD)AQI)-$U<H0I%*?^-2^-&13/G$OM+@NSB
M9WXPQAS@JDNX%HFH03AB3%)'&9+05%TW@^S"@12!".<@9):9KTAR4PEI'2<W
M%"JF>Q+E"O"Z_CT59\FO4W9[D;BJ\*1Y&@*A^;C48M[29>G^H20$$L(KYE$D
M>BY"Y&BRK$-31/<NPQHU:<+>H1(VZKY_6"P#\;K>2^K<Z"55M1AX5<LG^5*I
MU)]*E5K3C.H4RMHXBY=?M;2HKC[+TR5_=>(TN:06Q\LHRZ).<KM"LAK1:U9/
MV)^P5#\I<]WA)&L+.SWR7QQU7AS]7"I,1F(Z7?[[JC;O= ?MZQ0^NW?;H%5Y
MMJ'RE,6##1F4(-! W"H>P#=V&<.;%S)5=29X VU)6+'?Q]XH1G65LB"L^=HL
M+<CV1A4PJYXT\WNHNBK@"T3].:SG\8-#_J4.G)N'WJ3C:\RM=S/V5#=C,I0;
M/=$IF@:(&) ]:E0*%Y@?K+<7'D4C[/J<) #!3"ICH1G/PP]E,+#TV2.CNZ;,
MU4\RA ;<!+67PF-A>4.U&2@I/:+UT5 M::'52I[F6!P\2= 1#V"04K>#(J:5
M@\B(6WWNM=JG/,10-88^\HW"P(C4@"VL0]7%FE+18K1"QRE**/"O[LG<,0#+
MP-"K+#M(*T(?8@'52@^+X9CKI<!&48S7A]]&$90C7%1 ;AGNU S8LD,)>>=!
MH%M[9U$0@X[]$2PR0M*AKH+X'@@!1.+Y:7NN][9O5&#'FED7V!:1*CQUV_F8
M>B@=S98"3Q^Q,I138P[88D*'63]+0 M8&E &BB1%?V HAGFMC2D7[1IG8JX=
MKW5[[Z+;NV?=WM;M?3M^GBL= EUCKI:F;[=O:<'0:($,%.0=&JN\]M'H!;!*
MHK*E56W]E/3B^!\M=5H72Y:)TLC-IH0F11#$F4MM"2QM!<TELEB&)R/'"NJ>
MV>9G7A1QEH+:D$5NDCE*OGX4&?Q@GNTM!AL_$J?K])9R.HPCH#^!%^/62KU3
M8K1^J'?]1^%G.;)ZY(&1WC0U:&!9IFQJR9/"43SWYOFKXF]E8@TU-*G!59LV
M=A:2-\@,=X,DU9<KE5:RW2Q>'(+4K;>&O>YDE*$>&ARJ&<F;FU^IIB[-6@5W
M%0,-)0I >;-2QVY*'7TK=>RIU!&%/ST#]<SKG_0'[?_G><]61MKU)XKMB9OI
MY]\NWGU\<W&Q30?1#L=RUUKI*@%2J=FE.U1]K4IDUCREZJ=K,?]-41J*@=.K
M[X"%&&%4M1*:R-R4+U6UZ-6Z_D40\?K>YZ"VDI<CE[5&M%@J.<;@EYQ[W>+)
M&99*7?NZ==N)6S\L3?OI"HO3P[#6@^H,BR@NG8X);IB3HPA5%58/HTMG"L+D
MQ"\-[]HIFF:7/G<RH1ZY&85H8;'P+#%:&9FYY$E.5<0345#W/SF-LH@"N9)H
M@BQH67X.R(HH%8H6A8--(G;T1'2KHPEJ/$)U7HHCZO8(0XZ%'^?C@/JDIL"V
M\XC;FV$RD. L-4'/ DA0@L-[."-C/ B$4U1XBB3"/)N=HZ';];)C(+7(, U0
M^!-VVNH&Z2!M9\6E[A-%O1$EPC&/)-KXI^.9!+CZ*'YKQ9%0CIX,_=PW'N<.
MB0EL7]#/@ J,=E5-TW)$_7C96*O6(#!+1X(0!#,)0<7"J OE!R54T0B/J$)J
MB<:-EG.>:\*LJE%CXR]N.8R[+W45TD8D=9DN@<']#D$/B(Y1!XFF $>TI],3
M.9)J4B6B)$FO.!JJ=D=P>8A)T8A#/\K.=4:8,'F0E//C"H,90BS0OR->C%!@
M[R7 E_%LBNQ)1O(XS&"="?<TP 1E<Y, !NS[5[5YC&?'H,FJH.,<C>CZF*.R
M)QH<U1B%;2YO*UBMQ&:4P"0G(F>0P'. 1-P#E'IY2"&^D5\B(%[IKE\=1OF5
M&ZJI,X!]Z=ZSB)% LA#MZ+I4K68=_]+'1##ECM1[QO:I:I],\,@. Y0U%J!G
MFDUM^;X@(9RFUT(7/@=81'\4&GW+,A^QX*1,O(I%[K.%35TIJ;IU!F,<#ZL'
M4)C,D7:XOR\#:@-_RL$+U*01EOK((AX@@H3E!&GM"BBZA'W"=RJ5<6ND6U'$
M!8Q#<&GATN2P2.T0R=2!4Q*H&3]%? #3KH.\=ITET$9J$@+'PUTX4"O#+^!1
MO.E7BO\S>>"T;<WA6\X;'$:97WXGWQR06?),(Z/(>>I0B&GEWZ[H*0?/3#!@
M1Q8!UA08%;$.W*G,.B9S($>DP)D_J1FY,5"$KD5RX($P$!G.9EF0**"M5UIL
M!WCG2(A9M*G1<>VNXPT@U0E#:NAKR!G*)4TB"V&JOM%N;;7<N&XR$1E:I73%
M'M@S[O7QB?YC2?!H3KV,@! 2QG!WFC$*;JAM8:@1<5.@XU$(3!/ 7R=: /A2
MI $MRI^*@HH,(#LQ(_&BR:1@/,530::K/HR%_IL;[R2!^H%H:!KZ/)$YEF9A
M&/F03I%%P5\H;*LE:"EY&(V*)%"DN4[VV4"OJA=ALC9Z4;T3A<0429*GP#_&
MY&I6PAL)$13?QK>(;B)MGHLX3*.IH%Y:>%>NR(4[3S*J@)?8A[6-58-<COU0
M)E$2>Z;J1&!G',W"5 #E:?_R,A.7Y >^!@5#CJ,IVEB_L3N_ZG@$VWI^=C)G
M.U871?75X.T>$6A) M-%(<RB(1]F*5W3K^GT^+>I,H:_4%;HTE_-TW3;KM-I
M=SQ.X#=0BDS%(J%^10 _^++ K&R3^I$1/DU$;E33J@[TNNH_7+8+KVZWR_B*
M0&*$I?@$T7#AT<2=3H3N52_-<$[RD(WQ,G!L'D $"WA(+ H4R3&% OI9KH N
MC3@?!B3)*;J@AH(>_X+$&XCNTU6 +B)J$4=5<PN.$@54[+2]DS+E](:V1<;T
M_?F]WMGPWU^3X?_)UTWSNJL43CM98^&TCBV<MH6[BJ[#@J,Q22%*5&-LXJ.?
M03@03A?4YXCX;NFVIL4CU6,O-3&YH>"VEDJ<W$!]44LE+)6P5.*1J(3$E'CJ
M/>@\[];##8LI:'VHVU7R$NN?%\4D@AVESI$49::QJGSQ62N"7[BO-X?,LZW$
MT@Y+.RSM.!#:H9T<&%6.1B50DI6Q1^4?A,[;U^>L'5YA\/HHY_(U4:;L]NSX
MU<3$$@=+'"QQ.!#BP+9>?Q5SF@.T@+)[R,2,F3PSPZ&#=DLC7\82"4LD+)%8
M-Y$H[=C:F_.Z<K^DM[M;72Z^49I,?<('%>"%G]GF&RYQM)J^")<L%9><)<9N
MM@UD)0!4QFE1NJ:O1>[$_A#;/E,2NMFCP9(82V(LB=E;.23 R#;*>RJ#C&0Z
MRJ\Y""Z-R<^$^> 3[*)$/0.D61I@;<[HS5$1FT7Q.%D4IS:+8D^S*+::N_DU
M#?U959)7QR=0$ &@%-6%82I5EHH!V8@]SK5RZ6F1@_ DEP7>F,$5*+-M+J(/
MGM;I;:-166]H)3EQ0;[D& .C @.A#-FD,P"U+..@Y(]-5\L\D\Z#Z2 /\0CB
M%"^2Q2E&WDT*6(,UR%?&<,;/\S+.X,]$O>[20HL/JO[:;@PQ_]K)>C8W_]K9
M1H8]W<QB^QL9MM.KAF61:1'W5B'3A.@K:P)+%NJH^ULQP&E^%R%]E6$6!X/;
M"/<O^>E9]]EM ZOKRA^/#?[?=AW\WXOY1_3A&&1 _:("E:G2=4VS*+FR23D?
M',=\8S:48A5_'68__.U3&2/GY[4L)?QQ>TOZ>Y&(>HA</65J+;A@A['#//HP
MCT]U&T76YH4_/*ES916Z3B]I 4PMYPBN)ATLSQZCV+>R862S.:+WTO51 &_*
M#MT4]WN:'.]G7T;!!CB*A2\__3J*BUR$C\NSMPK;NUGDUDHMO3N8@G>0XKVN
MNMELCO!9M#DTM'DO_)#/]G.67F:8((T??N!_/HA@[">1G%B4LBBU*DI]X/2Y
MF<49BS.K]X\*56>-(ZE*[OU .1\6B2P2K=R 9QJD$WA2\:XHQIHCB2YMN-2[
M_1A& XZ;>(TIR60S7!D7[ZPB\4SH?-GX)(.3>\RQ\NBO.9"!?&[H?>3:CI@,
MRW5#$JI;&24JZ?O8R/?>X*J^^E.L$9..G!_0,6BDHL]B9SP+LS3PLR&5#0O$
M-(?5<A(R19X!]MSG[%=?'.>I;W"&Y>[I8Z_50V?\ALU;-9]Y!R?<4#3//4-.
M**8*_O'.>I1OU.Z\_"S3+/)E)!6?^V)$"Z\U%WE54*PW,F\[MDUO]P__G,I$
MJ+H341Y)(!$DTRB/S#V%&GM'MW!'_]FA)$&O_[+3^;&>%12*(*+:=?"_BOHC
M'YKJBVUO\>'<8N_7$A.Z/V(U$DH.T?GH5 $/"Z3,W_4[2)LJE(<]0[7[K$%
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MT5/HWQ;8[Y34DP$*/DL?&XJVUKWJT?$2>9UBL)C+8K2%@9Y?+31JTVAT&\N
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M7L5^C/6HYC(89U.>-!CGR*[ EM$T/#E"/52FPYJ^S84R?E^=(]3A%2/Q&UA
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MH>G#OT0?!4[9R-0DR%"0H9O*T$=-1!QD)LC,C4DV[0SI%^HECL9"DM,@0$&
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MTSH%Z?>3][U^D*3@+/UP]>6X_W4M+>1/7I">NTHZ/3OY]-M:%GJMH5M02@_
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MT=^MG?ZA'F'O>ED%1B6Y/1W31NBJ#:6J>F$&,A_K\<LO#7O5&#RB$@<184<
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MW:N9#>_Y &T>LOI4UB5JRG<7<8[M9U_&,7B>U^!G ]7CC:D>KR%*6P\OF@Y
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M3IP\[\;@LYN+ *H)\JJM,XUB &O._#WLZ;9YK^ [15S5I3!\._#V_Y1D![1
M:6)0).')B1Z2NKZ]G?FL:9;9#VE)UC*A(KT0N \W-^]X&/*.CSOO^)3$<1]=
MS'DO?'_[L/GC'GB&B[10T[X-90YFILZIN9X44;=](;[^#GJAK>M_DLXL;SG#
MQ_9K@8XS*MM1TAL6;HA/1QF*D$MN>),=B,O#$HJ!2"#!&=K%JDYGFS0KXO%
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M(0,1TJB)'7"+WL=XXOU6$[WY]^[&[N[^O+6_\[-6=!@WVWN:((1?R,STO/]
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M;(^DB4ZQ753+:"Y!0[1<[@TQ58P,2%@<E$52O!1=.NQ1HE=0HT9N:C<:FL$
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M'F;O)MHP]7L8;J)C!Q1DX) ]T(NHR( M9' ZUT6N?*SKPY4LW@Z_E_J,X^(
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M&V%Z;-".#X:/-FAUGF9#&=73S-/,TVR8HWI=PO.1/WN>9D,8]>9@3@]@_CB
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M"FKOO@KK49"X7)F ?DUNC!P9 "PA$@@R4$S':K3VNC,4UM=C4,WYE(G5+S'
M+6>O/4#8/D>./#@'R&\%3><O6*[:!F5$MS@+Z:Y.P]( N^WE91$:0W.B,@AX
MD4IUD6'Z?<OK$//9U8FIC1"V0:ZJ--R6$L*H8$&W.R+PEL%Q6(<=VMV*-^;@
M4@2VI^-!W(PYU [_FA:D69(\T2K=T?&1UHZ>=AU.W<C/5NN%\(E-\)6#?>E
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M5V']6V4)0W5W'V!R1TS^AR)JJK!,ER0[R%K4C.2@.0S;F) (B=*.R.))@8G
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M84TDKJEUU>9JPN5J4K5&6@&0A.J%!"W++E>=X\?6F9NR%O$B(+([]:-P'9H
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M1N*5Q57-6<9MY6Y8ME*17/O,><B35ZVO7*I\ ++6WG*7SKKD=Z=WBC'6!-^
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MH#&H/$;I4!1C)G:]6"F]X5"+BU9PY8E#B5N4JM^T'5U2Q: G50D:"7H?,FY
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M^U^E+,[U<]5D/-G:<_AW2K^.5SXL,':E0 4X?>8J"WG52=32,E'5E>O379-
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MN0EB\EBOG/E%Y5#PZ.  3 NGA#5N#<VR=73G0R:BW<D@Q2*Q?@>&C'$=)J_
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M[?!?\@4!EHY'IP&$.DU<)M+*<8U[B+<<"?()>1@2RJF[''0+8;/"]@,%4(J
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MIO-SL4K3V:WBVS%AI,0R@)#VG" A$ $.G09\DK&Z4[.NU_G/'^JN5Y5A4$+
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MC>B[/SS;SVZ%M6$-<TF C9(!";2>5&!(Z7S$P[].HS+6PB=8Q\""*Q-[Y-"
M*V^TON*@I[5;V*"4K)2AGC1W)'_<I4>VM/CC#7OD6"%:MM4N$@F"5"7\P0N!
MA8$EM7?D564+\P4+ST=A'"Q4&/L'WUX'\-2\Y,T$P*X/@\-S4$.D-B,Q)OHU
MEYD &#5-++U[9Q&0#,RG'2DS1"LVLCA8ZS=HX:'_5&!1 %;+VN[D69UHG..R
M]4-"P/XFQ<1Y%/Q 7L,&<JL7L4"@^?=0U57  L1(1".2.8O]L;$*9KCF!GBV
MT+'^\C. \M:EVT27[F7KTCTAE^[95FI6^77OS(54ST5-;4A><$TS4SL9N/_*
MYRI;Y$X*+NC 0>$2Z:J:3]L=WKC0&5SEG*OBN1F-^"0JTB9+4YT?JB@R*7#'
MA%QI]!S"B5("1XUS@8[<6O<;B14OZ!\_L<N(@PNY2L>B88?&'>:K@/],X0K>
MD+$T-MC.U2U9.:KJ:\R]JY<N$UP<I8B8VJ?P^QD3P7;,,/D9[@P[%\O/I:,=
MO9"^WR&X226F+6FT'>6#,3'OK9J)^6#_B0]U_:31"_WX152PF\:\6M\PM7$:
MR%23:M;J!T\41)=;N&TS;^NEI"O_2\63U_]KD/WPKP_IR2*CX&'8?UO>WZ?&
M^_O)&2YL50[#:(7$XZWX/#7Q.7>QEW=5U=0/YZ8/Y7G5GF2I4*V1(Y7>ZP$#
MOG<OT>G/YS^<[^_NLIZVY8'-B?E:>M%[_$+>DK$;1Z_I/WNO#O&?_F[_M1V0
M+>:I\WL!SI+XJ,D)?1ZP!:_OZ-ZHUV&JO =/ _C=#U/?4F>%\SUJEK@&1_<V
M$^ZYTVJW?>"XVXJ#&O=]P<?QT!<*W07WQA4(3C$6=* !7>V\__1+U=#K!8N=
M%!YEV@]9+%'(X0.L8P&<WWA./<P&.OG\/^<;Q%?X^Y//_ K2UTK<[!PE=]J[
MECX-7EX.<O+ 7W1,4+QZ9=J;B)SS]L2TF&UW]O[GT_<=[Y?W';[TX\7I^]..
M-XCHU 6ZBH?PXG;-:E:4S^7FFUNY8<'_1F>(CFJ2C^2G[_K?;?1MG]&Y<_'A
MY//I2?^'@XTY>&[1 2A-;)2=\J"Y]-3N 7F? VR+%X\^<GEVUZ(>>0-Z._^_
M],[FL9K/$"%34?2B/;2>P*$E> 334)<[@%MK]T<KCEVGZ[E<HE:O]156;ZN;
MGYEN_NWSR87WZU[_;&-T\UM7@,%56%4UEW$'G/$BR@YC;U7<$U!Q'\B,]889
MXSA0(6$UF5OV,.$5E]H!PQ>P5NO;[1W;.=8 2UIIW'YI?$MC _!2NMZ347A^
M=D*.SNEG^A^=!&FL"U)"$4OD3"WXTN.V[9SR)( ]QRVP9[N!/5M&R\[##;2?
M9L;@)Z-(9WSA5TOOKW20<C_[3W3.78?T;G<@>)X(AF+C$1/W=AAL:^@%, *8
M*O7\$F^1QW0FS$EZA_=P"Q#"&EM?89LM>.&EFUUTQH88-VO9_W;;R^+\.'N2
MK<Q6N;?MNW(S]]EKCL/O;]MB7Z]>W*9O-_HZO1AWL@M+H_;'"9<4=(>I7P)L
MR87UH>_1_4",%H4,J!26M*I:A9L4);:[$[TB*LH2E:03A26A?6-+\M]_/'<%
M^324@FS7N,,T/%_H#LPW!F+S"&2EI9! 3FA9IQX '\,T"E/S<#VIHUX!6,U
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MZYOU!'U<"S%5J#:^\VS51VM=/$GKPOEV* "J%62A"GJ@=<(-;*T*,$EN]FB
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M"2=U"@8_4S-]15>,TS1HY'$,'N_6[=#S&-MB?:V%X#M^']IT),"\UERR)+]
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MH2!U&L@(<G*%OYNG%3@(:U0X1W?&N&CLGERC? =Y(M>L#'<EMXSN9]>.;17
MIP"EX(6$X-$Z5>($&<@Y895(CJ3GG02N^G51;\:\G' QV-S^Y=Y('"5=AM'W
M;.]'[B</V:M5YTI!"MUT85W+30C]&]$ O5(>$&8H4S+/NU&D^54U\"7JF@Z&
M,=Z77=J%G>RE\G+:^I\;[7_NM_YGZW\^3?^S42X*6Q;A4'=.W.<,,,J?R\(1
ML NMUWK'27"O\K.GZAH>+W(-#_9W&Z[A_O%7N(9MJ:/I!'_JZIO;0L=F_)TQ
M/L83M<6.XK3"664?0C6*RV$TSI>-VY_V/.G*;3M1^LKU:C'T6,8H$YW"-S&&
MNS1-2>F7*5ML:4'.1V6OA4R;(-1<V:+FF#K!>9,;=H1FETP[',?;$ F[P+(F
MF?3=8J^MYZ%(=.[U9](6*V\*W.@)O+PC<,_[T_62B*:RF@Z[1J^'0]F;:*GZ
MGBV]3Q>]:+7.SU-'/RCZLK7BUV[%'[16_-.SXI^*MNGOWD/;[!W=,UGP2/&N
M/R7>;>KXI-(WP:-!>V .MKECQ<9"V;CH]W9=/+0Z;W#NVJ\K6H:YT]8!GND#
MG8S +41/<D?JTD,TTB/E3^=&EC>'ME<;6KCEH/8D31J!-?;%Z$-+!$=^6J$%
M:%Z!-=)%J_#C'9#FMI!Q8]!I+<GQDZR#/!6RAIS+("$(OBU@3*,IO!A#L!7.
MA%C:\N5VU[>[_A_O^K>S5@B<;_K/O%SC;_?#?V0<U.X7%C0'_OSE=)Y?A]=I
M8R_H9(S*+TL<:\O"6G70JH-6'6RW$0 M!.K80MB"F1O7+PN5:.26R1J ,Y;I
M$3U>8HLW:1D%@%+0=^PZ59='TV8GN"Q446LZM+JBU15/0U=\9I+I7$(@10@)
MY_B_)&%,%$1@8"O=]"M,PO</MCMU^9&FA@%9)G3EPBX+DID7X_0F]]X)3W/@
MG=NTT@>7/<)ZGM6B8+^Y*-AS3;D?'>C=_GW0V =[;<K]:ZH7V >ZNQ+A26?8
M775&KO45)[%!UD%[N:YFA:3<Y\2S21&':2V5S,HY">ND_U6[ L%O-N#)'<_/
MU+ 0AA+PJD><"];@R (@$8;"P+3I,PA;@3,VOK$CK4.8PR1)KPTG2(.#?1PB
MDTQ:)^0<LGMMC#9ED&:9&'2FH0X7WO$J;=](PS?H?CD.GR$CG4J&>BY/_VS1
MO9<H.9!I-XB'(:@/;S!+LN("#J\6-LWRECRYM;U;VWO]MO>)Z%3:GM<T"0$'
M#)M=3^Y5B%*'3:9,_F0[Y(#<-*)%$3W_6$Y["V%9#X3EL(6P;!^$Y=F?;:_:
MLVVE9]NYZU!6.T_@,%AF?3Y"ZJ6FFP]EJ95> M'"+D!#]YE**SH)JS)&+B[C
MJD3Z;^- -2#A1OUM&]MN=5"K@[;;OOZ8>HD65-^@#*. 6\UE";=[G*L:0-#%
M733?CPZ5S.@0@/9RN4]^M#]FX%^"LGN2-.34(HG41/J+Z>>Y^HCYLP]LV$!3
M&]-H=6ZK<]>O<S\U8[TFHHO^N0L[N_*7-;NKXX +V.BD$-%]=QQ./-O-B;')
M3>/-W+7%)+0ZI-4A#ZI#+J<3RS1CBS,YHE%GU9AVF25>+S.<JCY.)G>%?G+(
M:)LV356ZB1GI*Q(/4AU1&A85IPZGRI(TT5_\J$2SZH?W5-.RZ)I6POEL&*U5
M**U":17*4S!*3 &:]C+230D8>8R*"3270)END7F-42U':UIR[@9AXI SY82\
MP:1 ( V)>+)=/O^7BB>OS^B^83PHLYS1U<*[5N,#HC<F;Y+TF'R3I5,5<<RI
MG*3U(GGP;M$C'P5Y]73]2#JH:*EK[,*H%#3(!MNV!'8F$^LYG 5_K+Q\S&6!
MUZ%M+"C-R$/NC>Z0$ U[--9!B-R;$!9D*LD9F&6I"YAC&$@[2(84,\[ ,:HR
M?1$_W;JV6W:*M.GZQSM%_G'ES.W=.+*P8%5=%W#FQ.N_KK+W=Y'E(2-?YN!;
M]-P-W;6YCH9=.C:B<,@-HY":>7"[]O33'^_.NGNOS ZU\  RTD>9BEL;M]5.
MK79ZJMIIB3)B"V>1\L$%*O'*Q%#!LN<>&!11JRI:5=&JBNU3%1?DQTP*M4!1
M?-8Y[51_O" 8ET[DSU&FI4X8JD'@YQ4GY(/;*J2OF"+&UBG#;VYBOG,>2*6>
M$EUFJ6O2;AF?7U<N'Q/V&I2'I"/LJQH]:*9G";P>MR8M(%R6]#S+*SPP $M)
M,6/,U6@-(3@X+RW/6J5%&V3M9Z4_UDFBO>H-IGF1I9-Q6XW=:MM6VVZAMOTY
M3#]>ZB8F[<'UI-'?IVFWIJ[,7B*U4TZ@E(:(3V7,PV7; ;#"&]/HR<2+P<V+
M@!5SC^M >#75O6Q'^Y+.DXV=]5C7S64\$*+_-/$-KMWHQE:YM<JM56Y;I]PN
MU94.%EF22UU.3A:SBKJED$5Z*(@I5:F/FAVUI'L*1]FU*DR_#]M.I-4NK79I
MM<MSTRYI<AVBCPK[8J)>D,UCNX7MH>(F%7.HV1VHU1:MMFBUQ?9IBXM+[QS<
M"0^5GJL9'CK+0M1$">F"2L2]>:S,7*N/6GW4ZJ.MTT?G4K"2^ \&&*CNV(RS
M/"6(0$N55!7I_FQKF]+AO)B<V;R+Y?NZLT]6J_!;A?^\%;[<%W\_&MWRYW10
MYH5T[T3]$]<J2)<E4T?::^R'$][MG_PB'>A,%F3OL./U=_M['2^%G_IR=]?C
MDO; =6O"W6W')G/O!ML+SI#Y?EY5VM%/+0O7D#.3=,J@;B,*)V%08: [#)4-
MD?X$.-848=4^C=-L,N93"Z5;23E4^!T>@ $^^"F%LZ]+KV1F#B]51O+&/<SC
MC=27A(SJK@(#Q5CG3<8R;FV&ZE_I<<4=L19PE9GZM<6E+?1'@::':>(-RPSA
MA@[_1IBUZU_C'K97;0T)+J4FF*SJL6'5J[@U_]O3H#T-MOTT> .*@1 6?% O
M:"VTBIO' #<4;%Y@VAKIB>@NSM-6E 5SI;!9.6I@5SB9BR($_\K+M$^R"VVO
MOVB_9)1*HR%CF-1K&A0X#;AM8-43&Q7YY@3(:PR/3DM6!;XSC#(UOA9#S9*;
MCH\5.0O4IQ[0M4CF\*'F;.*&<N2#32ZZUDW0TF/HS9;<;#WD9D<MN5E+;M8>
M[>W1ODE'^X>&P_/@SLX5_; [3F]Z"X(\%R%<#/S/1#PR<F>DK2\9$)ZT'QJ1
M81 FU^1R2ATJG?!R4K/'0=9&_*CC9P.G^4ARD816.O>0J@VD(%;3QT'IHQE!
MARV@.]TO]M%R81(1)4C>:JPSIKO.2;CU:FV#-H+YQ@4ZSB48<4XFVS"-PO19
MT[]_FHG >,)J50C4R5099Q(O,E&<B9VXCL1H.):" Q! SD0"-HJ;<].FT?\I
M0U0H,R"^JAQ?R)#S;$G2L0@N;,906 <U:VNKM\RB:ADZ5FM1753L%Q+XG(D,
MUZ+ C2H6"3M#Y:PB['O^YM<N/[]EY6GW?+OGGP8KS_F"S%)3IY -GR;1%%B(
MH./%*9)J?B$E+60)<=I,U!(' "4V6+=]ND@&&3)!F[)JNQ>V*J15(4]#A7R\
M<Z^SBV7)"VU:&SVPQBHC74+N5<[E)ZU.:'5"JQ.>@DY@B$A-%R#\4L>)M%N]
MW>KM5G\26_T/E85H:6[#H:@R7YIC>*QMWR($UH,0>-DB!+8/(?!5(OKPZNR?
M)-=XN %056Q7_.B5"9U;?.'7<QY-\Y3!5)_H%+@.Z=WNC^MOY%N^3>'(+5I#
MXY\;&E]A0SQ>59*S5NHBU5HNBRV7M>Q_N^U_;)Q:K8ORC#1'"Q5;[49W1VR8
M6XPT1P<N_KCL[KW<W>MXBBZFSSV=!&DTS<.DXP@/F6'&T@&N&71V4:C)F RH
M3)=Y8PL-.)ZIXU!Y.[SZNZ\O3G[FO_9>OP HVT&JHRG*4#*X12!%#(>TJO1R
M\X1@EA&Q,0&Y%K=+'@B(59@,!8G5UJX\+ZW5VCM;I@8WP]YYKU5@2\M_]%JC
MY[FJC];H>=+X>&=<-6&6']G,,M9#.AE#:$BTPFNR-P8A%^CZG@^<>N 8FL5T
MZ8"Q7@L$A*'B#!HW=_+I\H@^+D(:%ME(TRCU4Q^6#(-&4-%;84N8E;E+%E!(
MUY)9 \0\B:QW3=83EZ7=D)7DC:=!QK9@:]<\+\74VC7;KNG68M><"9\@DS9P
M/*>U;9ZM"FEMFR=MVRP-PX2YI^@U_D*9N@*+%Q.LV/B(#:C\GH2H0+D &XPI
MAE<).DK8X K]?*CHV1YJXND^,%IJ$1[4^^@)B(YOQEIN:<,Q'N?.Y*,H38,<
MP9NX1X^,$/ AMRN>H+T@QW0 K+TX^9F?'NM"D36$]1'R%/ .U,KU:Z$BZ4Z8
ML;+#@[(PO^)6&6F&^2JF/>]RK 6R*S!>1OE6]#2FMZ&=&;+G$';S509RE-P%
ML-Z]L?&K#LNV'@"\1W?5:3S5$5_+3#AE1,]0V;0-1;7ZMM6WJ]"W[Q8H+D/;
MP55UI$!T7H0Q]P*GF>OL[NZZ3J>FS0XI&NS6PUW^DC][]\:;D+::T@X4G4&:
M00@/H4_PBS"WNH9DY?&L[8;-%@B?%"9@E*4W-&[6ZM=*N+T ,0I0--6QC%_2
M+C8DE4?:4@<NJ![HZ]"WG7\=B8OMD1'&<9FDT)2DI.G;H-8JME5FSTB9M?[G
MEFG'S? _WX<QV:MB88$$0;9"E;W+6X#!LU4IK7WT)#'0IV:/(XP=*&%X\\4>
M*\)!F+I^B6Q\T>=H8$_.DQ\*;4J@)H7Y)Z[Z\/GB1+J #<@;[$;D4ZIX[EX?
M+NQ58O^!I&6@R0]-4D<BE\H-2;.I )R6=J#5O6IZR2O4E::Q3)D?&U29#$YH
MN+7H 93F$W;(_X8)2B]4F4>7/!#])<R+1: &!C-@/$M2!O6W<YZJ>0C>\]T;
M>M^\LF<-\P8<7GKJT#JQ]3=*Z:*@],5!YH9KSCO&(@DGJ>U ,DO.T:KD9Z"2
M6RMOVW7\6JR\4_JO.).J4*U%]VS51VO1/4F+[K/.RX@,B&&6QFAO1%;"W@]]
MY?EVVQ? 7)*14XY&.B?O;JR*"L>*<!G:GV6,\KRAK4#O'NE,581C9/@%9+X
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MRAW39[6,5!9-YTKG9]3%NS=XL;QP%66.E,#/TCR?&64U9__?R]Z!V+D#J'X
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M*SR>-'7W9P9Q\+GN#!3;(F0&3,#V^6W.FF$N4^(X%31W2PG,ZF?I6,EWE;)
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M3@<M6P!IMT8*69OTQ7:]5G,S&R!#-%VTK;VY'<U5T;]&ZDMZ$=/*_H;;VU@
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MBP-;I#(%S<]OE)2HF\0[5DF@O&-461A+\4U0=R=QTTN3+&H^E O-C>?*3OQ
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MFH+N-!5.TN*XHZV$/[(-R 6#50%E,C^<\,M?>UG6VW2LBQFVH&4.K 2?Q;D
M$"!1>3B)4UK7]D[R&X6^F\.'<Y0LNFKFR?O3=^C<+W1-$\R[%L_?+6/PM*27
M%P%8(>;.?N8K-U"(EIP,0>VY"#O 7T'P.%8Z$/<.J&@#-B35@W#5/2SE8D;5
M]=>^A"=CW,FR>OEROIC!648!A%N9QW,.+W8.%X%0S>7M<#=E>@ZZO.8/1,?.
M*MCJ>$+P'WEYWM)"IU5Y7L]VDL\-_%VBX6#C)DC>!G"THJU,K^^K:CSL#<M
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M^BJ#\DL<+1:!G6@"O(?5"U51!-1-RGD,KJIX0"S51-IX.)V9Q#2"6,)@0#M
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M5[AB&2Y8&4 ;'Y1>&JS:NZ[H;@<3321(Z0)L@V7[4"7(8-G>W('?;@NI=2[
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M976J"LD52Z X5^DW_ $<Z!RW7!@&/XIYE6$;'L/+YGAH$!J9U]2S1E-T2B)
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M[[SHL"O 64/M8&URIO)&CU6&+2NU^DX_V-]YV;I^)QS4C,X>51Z3Z2-\#X5
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MI+DR<^?%AFW&[CV+IA1AC%@E=?<AX1CA%R[( JH)M"QLSW;\<74(5.D/LHK
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MN&-!QX8^OWH& FY6YEF/.T;52G"B/(HAY@1H]A3BD\\;,! 7N>Z^-,^9+YO
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M5\$>V^S<JX^\:-[=1G %V]OO<N<@&^IR/#=9R[*J-4+;K)27+T=]D<VX)3%
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MHXM+C,NAL/4V"UM?#(6M=Z^P];Z20D>14/&[)13RZ?VOR==(%KWY= B^NB0
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MR!G%\$.?E_=+5MN.UR\RO*6]C&WHNT+Z2SP-=NG<R=$+,C^";")E;19"6?0
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MC/ZO9U@.L*H/ ZOZ[ "K^NW!J@YGW^'L^SV>?:.#J*_J_^Y$R1QT6(T4J/D
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M])KM-LS3HORILNOX=@I@E08F=+S,_KYK*G"K//QJ=D4KFL4JM!M#)%HPR\R
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MMSRZ5D$6>:T*V..%6:<0J**WTMY6++Z]VPI2+-W$E&Z<E7)!H8>D894GT1(
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MW4Z4O")N9?BN[>@(*&;/Y]5*VH,7LV_K:GZ%LONV@I+CGC(ZE\ZYJ+5>H[%
M<Y8"#)4JN%06]E76K1[UXB25HUYQV >W!>6Q[>VF&L RLTOT,@.A[R:+LD6:
M4LK("3NP8^[!$7L=^BA6TLH7RI'A"IDM:N8:X%I"IS(5-=6]W*;(>]1RL.=I
MWF1\#N*X!W'<@SCNKU-&C568%ZR'J,3R&O.Y*>7ZNL!YK<PRK.)XB6H@U]AN
MZB8T)"2A)Y>-9:-[%A-GDIGY@9RC>"B<?O/B+)T*9NU?J#9E#:;M5;VP 5H]
M$*8-AK;J*+:$:;0?/CV19._D0^!R<*X4E!*HS=U:)[8-:3SL 6W?TIG2@$CH
M=N) 05Y[ PS\U$><F*.;'VU%UVSJ0+J'7+)]@?MAF=@>ELA_AL":W^)1U= *
MK#A[9UFV_KXP&DV<=0D.+G5BQ8%[[TA0-+!:8J)\ A/]\W\6LY/G3\ZY+72.
M8ZJI:/TL*DF *U"F9PL%4'U=7E22F:.0XJA>KZ&*FC(J^H?%;6^%1CG!KNM.
M%%+!X-V_X16*<!QROFWW4YX5-;Y;4'0FTE5+ZCR5WI?L@ISZ=M77B@NT"<8C
M;X93W?3.YL@CX2-^4U@N"NUWJ61P,PK]?^<Q!1,%0G\0"T\" .4@2./Z-:3K
MWZTGFD<#7TY& [^.-0P H<FUA$]HDNKU3JC*&*:66CZ1?/3:QGY?,+I(]TJ7
ML#P)SJY97C''CQX^F"W*6Z-O%=JR53M_#=ZU3<\%A";2%=]T,*Z\AMJ.EU6J
MOSM RW-EHXZ:VGO*.%AE%EC9>2R_I]^'(3Z>G:9Q<-D@=(&G&0*CY6!RZ'%Y
MKT"?CA;EK?5]VK,>S_[ER#+<:7;)O/TE2'AK43J1(Z4 B",45-)9LVTO1:Q
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MR!0<:L$?:_'MT:=?'&K!AUKPQ[(<-UT]-_!]5]7K"SJL)02\+CN5ES*,DN?
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M_0\H/Y,JJ5Y((U*KQYE4R;(\XV1L*Y9G\N9^N06231%C$&  4#+SZ^_9NM$
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M@-P"^,7>=&I:[?SIZTB7:G-"9PBM]7%%3%0PBH6H$4D5*"J@4G>Y3ZAT/<Z
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MZ,8P&E.G9I$<IOS*PLT0%\D>Z=J"'M.)H;"R=^I[5^FL%(NX19,]YA@?LC2
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M%CCT;9,M+P^^(7GWT,\-DYNB1!;X= W-$LKC &3&ZY'YZFZ@R..-T:<F<&C
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M'UM+$H6G)), 9\VZ:=A!14!1<4/*OJ:;B?Y#^/]&T025#+,SB3WL%AB"8:4
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M\(K('AXG.78E13LWF9+&7)H@ <GF1IL34@!Z8,0F@B&7EE%H:6(C+'VA8FP
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MD_ VB//];C+D,>9QUC5W;IMVXWD5H;VZ1DIZ&F>Y;C-&974KAH'J.Z62,O,
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MU7&BXHLA"^W3#9>*G*CX3$ Y]D\/C_QC!Y:*KN6?'IUM,EA>FFAXZ&3#*DQ
M,&R_/MDDX=#9-U>5Z\EBY/M[\CV78,<\=G;,ET:7G!US&X73-95:U@U,RY'A
MVT>G_NO-Q9XU%E:7QA=D>YMZ9,O!Y!/_X+B]<$QVYLSUED4K90>T+#J[],#[
MF:4'G,?=2:I.4EU7[NS Y,!4(PMM Y366)1=BHVQY9]M,H%<"M<X63Q0_KJP
MJDDZ5!<SK4M2X%Q)N.WI"-^'A =_GQD>_+188%>GS<(T6>_1_"78*!_N7HQU
M1=3F*CP5#$%[R;'QU2A)L5D8]=#!%E])-!YB":E^A"6DL*Q4$,?C(/*Z03;
MO/5NJC!M 2MZV2UK.Y@-:<I1Z;KN]Y>E\I&XP,-W"GOH!"F6;D?UB4;J!-AR
M.T&%R@NR3&79$&-(.I/&?CI]ZMV%#<FP3!9V[L'!0)L-;\,>;L->,Q:UGU$A
M:P&$S5WP!USPMKO@SWC!1W ?\3+1%;^YP1ISV&(V16]:#__L!V'J88]JI6]R
M0+F+^ G>S=.PBP-GF/;JC>,PSZR^#+\7K2/P L9)_!^X?6$_-&\DE!.9\8RJ
MGFK4-&L@HPL]4>T-X?V6]_:]\R&WHL!9O\ J QR[?= Z]C@_SC-9<1YFQ)DE
M\R,?KDK+#F )"BA>V&$(]L<I]0'KJ3P((Z^CHN2.6Q#6PPT[6L#*N^,HD#,(
MNEVX941][L)\X+T_OW[KG5]?>%^34=CU3EMGV!NP&XU-N3_5[PO5A-V$0QH(
M"%=?A?DX5=)%<>JXD;01]>,CR\:=/XF>)R4"V$V ,/(Q$/VUUFI(KW0M[W"K
MG#'0HZ%!B(:Q M,%L0"+CP]@LV/$.=HZ;4ZV1&W6#!)66J)EM.Z.@MUUDYL8
M;D:/J#R-0#W6NK24,.GAR:AT&!(7J5F%H,^BH)YEXZ&@\3CC ]8@Q(&R,>!S
M/69@SY%,Y:;8(TT:)SF@,>RUVFDE@(7A"A"$*(GR<DP6#V$Y<D;DL[@+;.P2
M9>IN@(>J;SX<(C'@<8:WI((OO01G+_-]>!0&!YAC?\VN+)QZWPV#"9\'7&D\
MC<Z$WRBZ@L+U=;VIM[W!V&O78&Q#&XP]SLOT<%_.T5]6*P;-%&=02K'%CW?I
M/E]IB5P'PEE25$)^#8A3.!P/83VW*C*B44'Z9C%8$'!"17U)@2#_8&);Y^WV
MN9B2Q^MU1$4-9.2)>=.A&6;>*#W:NN:RSNTG[Z-&$DZ\W?G!)&GM^E,8M/.#
MB=-E@=*\+5%M.S^8V(C="A(XU?$!JN.A4QV7ISI6S"2S;$7F,E>[Z"U/^'-=
M-];IQM[?=:,QPJ'F6@?N6B_D6K^'&UQF7+Z^MIDQE(*2"UR.^C['>1IVQJ+8
MDL8LG39)&STZ:.U\V_5&9#[Y@9)>=UV;+7??GW[?.^Z^+^R^5V11Z\+OA+O\
MRT)N/LFU.Z$>LZ\4B@Y=%=ZR86BV5D7"!0H3VHXG%L=ZWTX74"&  49I>*L-
MA63E[/?#* QRUA*T81AD<XI9WW5MP!R!6@R!ZCH"M7B!Q.KGM2BAA,-^JBJU
M\^@^LUI^Y*[+8NIID#<*?99_#^)QD$[XXK1/?&2B+;_F+@$^D@>/^"H:U[(I
MK]*L>G%Y&L1<NY^-:Z3O,_IZ:1*A[ZLF\'W?^Q![>"?P15^<:/@ ^^+('\;.
MP*HV4ET;R #QGIZPH6J=3_[58#1*0FT#Q-W2;(T=_RXK:[I6HUP-.RH5D)Y-
M@90-??."<VJ5WG@D,HVLE$)84$P)NP,4<J[&4?BM6//4 (Z(K9:('3LBMIB*
ME17;]P!0GLA,7P%&];Q^F@SIGA!]@0O2F.:MK?WZP29"AD$%7JSNHLD>U;_L
M>7_ (*[KYW.<]N=QGN7 29!82N0-ES[W@EPK@-BCQ+NLJ&:N#VAC'U"0@0&M
M8WPNL<"K&+P2ZH,*M7&%%3$P*NY--00]SZ6A:)QACU::0QY_.\Y@>5F&75L[
MP)&$H5. 5L/46GC7P69*-D-14L2JZ6GX#E[H_3G.&D*BZ$V5#K-9:_'.;U)%
M,2\LKL!C.H*K'!$U%63#BYJ.=\F4K(H":?8Q?\^(,@ Q#OG**KU8<V YAJ$W
MG\E 129(1KLH >HQ2B*P%[/M>JAG2GD2I?;5GJ]\K6#(BSF'E!@W';_V^ B6
MQY.W]M&&D[??OUY_/?_T[L.G7[S+?_[^X>N_O?-_G7]Y=^V=?V7#UOL/UQ?G
MOWG_OCS_XEU^>K>$A$_=(.8^\FEOUK7W?4ZQU!IO1GO?]@F%8#0:J-K-/0=+
MK\WSMQO:#=WX]U/J$"RFJ^.J6DZTSEYJSPEN321"Q(8U"CEYJ8=&K<:6?6:K
MIP:NQ^N:]7AU?5R?YW[_0A&P[X)<;1A%?K$G]FF,/@0T65!QH&L%^DB8AXH[
M_?V.[LIH O/*1_5=I=TP4SWZ_%F"F7?^9Y<^7_*O2#;<^;_ \S>_.PS8' RP
M>GS*_96^BVG85:ZW\P8?YBA,Q6R*@')<>7..D:DR0T8H<S8(4I7)5_(3):^7
MGR(%BW)=!X$T4(V3G)^Y5>2Z0&KM\& C\.!CD'Y3^O0PF^RQ*,'?(%[P7X@<
M_!=@!SVFD<,U\'1%1>=OX+FU-3N/?FP?P'^MD\TMP;8TV)RYXIU;7VYQ654-
M]\].-Q<D2Z0VK== ;=J.VFSYI=I8*"U1=IM'*IM?Z*H-2-C88SW^L=U",>3,
MH?PTT7SMGQT[BEE3;_ZUWSIN/WE]2XC\:N]*S-=6237MP_U#AX>UQ MUJ+8C
M7DZJ64\H;81%Z@7+/F2">>TNAB,?#DH.2@Y*:P^E]H(:.RU!]SC<7;'JL32@
MO_9/VHMI<OI,8'?&I)7@R>&/[9,?-Z49W5+.:)-&77]\.CHY\0\.C]>1ZARM
MFM@OI?_5Z7YK(^[NL].UPY;SGCFQ=7VAY.Q,:WSX3BS:I%'7'Y].3T_\T[83
MBYQ8M&JZYL0B)Q:M,Y2<'<@)/%LDFKQ4?%IC.]#Q-@H\K;/]T[6T]9^L&MI.
MEMI"*<%!R9F8-OSPG<2U2:.N/SZML8EI*R6NP\/]D\-UA+:3N-:"9&Z9+.&@
MY*Q7:WNL.JMD(V2I+4/Y[8#2X<':!JFV5\W/ER(]G>VWGRX];1\>'G/6_Z&C
M9(Z2K2>4-L*HY"HVW=>%+PV['G>QW=IZ3:V69 NZ\C(UYJ(C_\@5;*K#FB/_
M^.1H/07!K:R4T-H_<WA82[VX )2C7DX47$\H.6O7JJQ=K@!4$]5L^\<N\K>6
MG?@GK@#4,XHUK@"4*P"U9OS:06EK#%PO6/9Q!:":8JZ/_;,C)_O4(,V1#R,[
MV>?9G'OM_0-GM6AT[K4=\7*RSWI"R5ET5A38N$&QX%N&\ML!I:.#0__L]=.9
MKBLP,&]^X_ZA,V&X$&U'R38-2LZ\L\:'[P*Y'?EXHI]K?:L-NT#N%X2'+I#;
M4;+UAI*S]3@19\U@XPB#@Y*#DH/2ND%IC96*[6UA<NR?GFY@"Q/X-^A$JIR
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M.MM?0!5XES?GI"Q')K<&2LZ4Y.2G-8.-(PP;'QV]E?*3JSO@Y*<U@HTCD^L
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MI*-GV@PG=NK!6/#_9[!R@%,/I 0%VP/6"-_#JG=P#%[G#0)P/$KB75J=$'F
M+$(\T-Q,."53_CQ-(LV7=H@?]F%=/<V7-,;L^C5G?Q<"M99S[X\C6!1+5;.V
MCZ-\NOR<U6R7CD?OE*<''A+G^AUS*&HXBI()84N('/0VB<9Q'J1P14G,1]8
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M%4?D<*3BC 4G#/T* 6HB8R5]\IXB<\6?:<%\,N9P%?""4.@;C*PH[<U: .Y
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M+AM<54CT M";4U).=A^EG9PM*6ZL0(47HJ!4I>=Z:;CV;M\3I6+1!3J.]2,
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M04>".S 6=H^$:03,W>+E\)%[4@);![[,NA!^%^+_CR.%)=,B)HG"T+5FPR&
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M9A98OWG6MZH>X" +]SL!0/<RI6,@=.36'"O;URN[!T(<1R]@*L,APL@\3!4
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M7T<G<OODQ 4Y;':0PX+$HP>@YCI+1U]!97OCG:/'PL3(?[4RR]9(8EJUOV]
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MB^D,I?$H,B=9^ZC!2%;'6#_)\C!G-R.=+D*$2GC%<.5E O1-X[L_&M\G,NJ
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M944+L]UE;#+B6N:-(=\2DU^$?OLB16?D&ZD-MZ]&Y4]']J<*$_:Q9I$.]:=
MXYZD&/A%L@$:RB1'P+,::'!6 86.(V](T;U$@49DTBG&X7&K*03VEUP*G),$
MB_>L"/M";?9+T?7ZNP)V>D?*AI98CJ2EBHX3(/Y#CY ]$:Y4QE8EGXU[HS2D
M&# +I?3]H\LN1( #SI%Z3"<L9_/EAA?FXSD'K$M]'DDXF;%?S>+EFM@5<TW-
M4;*%D9D0V7P:?C.?%IYC\2V&1<*=-$6=T38Y5$%&IXBIJ=D !&I?=\- 6XV
MJ/2LG=M2&B+L6^3=)Y--)<*O+&V\ /II;LX%&=JC]2";:R4BXVVK:[%A4QV&
MG65YV9DN@;$[TUQ)Y5S*%DA)XM*!++K"2[43Q33^^I*N?8-K-93!B"6IS@RW
M^VY5-_/37$:6DR<;64X69&3YW__KKYPHA+Z*$=8 B6]^?G7PBC[+P/19EM"A
MG"B:0,<KD8W@C5<R(CP!^WB&/?3=!J,,OM9_F9]*^WW%>S"V#,OR$9(C!+3U
MVR3LZ0=[%2/ \5\LP.2]^H<.84O @:GZB#85 )S?O+%L!V0Z>,5E)4YFC-5J
M&&O&*N:<NM$*PE:-)>=H>(AD>]IZ)(1X930I2%.ZF<:S"OQ^.&(Y18HR!#J3
MK^1RDXO-2HP$J$D$#O+'5,KJ<:5I(P=2J0C4PT<!7HG=-U5K'IXI_)O2OWCA
MRJ?5C520_@3@'+P!WJRA*!3 D1)'2API60M20M@#-(*T(Z$K !==,_9QQ(+&
MDZ2<+G>%,*7B3(8(&P8Q-I';4K# Y.B,HS..SFP)G3$15T1'=&>WG9KHJ]VR
MF&+'_?:%MMB=#$V[O+Q4JH^BMYH4&4=9'&5QE&4[* N'(EH$XS$$@?I_:2LR
MI1&SR5HZ ]N!W1V)G2SJ-U<B)ZTVNW4N+UHDI?,Z&N1HD*-!VT"#AE1WNZ 6
MNGH1!0=/U;RU$IW\<EE?($&@7;%3(I[XFER9/"6*BM-^-_+XW"5CT)F*4@(2
MK]?#(:RX.LQ++2+6RS5]'T$M,?A>]P&L(WT[)7+YPP&NIGDC859  =50](N3
M.W&:N)H$8([$9GCK-"^,[ TFG!U#RFHP-'&)!"RKSWLID!Q?,"EQZ.I"EY+B
M,L1U)+R&?61F<HDWQT!,2J#+NFERAT[*((W)+N][.'PGZ'[+R@'LQD#?#54V
M%=&X8/ZPW2$R#>D^(??E23I J0*IWDAY J4 $JQOEIJT&?E6YT8B3G%1LGVO
M81;CNNF%6&B#BN0T^&FT+B2YXN-8/I06()DG+S?>2>>U3=T[7;,VM'LA]E2?
M*&U]K#+GE:NR'\TYMIP<Y>2HU<M1@1US(Y7$I2 FM4)!BET\D''N'F7G2<8Y
M!_9X-VDR'MEO23ZZK_M&99P-7F+Z&66)*4RD([<Y@.M/3@W28EC"V6&8_T7I
M6T"%DF'8K<W4>CX3DTMJ6$U2PYE+:MB\I ;'.1WGW$[.J:-^[:K:Q$*[ \6Z
MO/AZ204VG%.S0 I!IJH 83ZF'-L@E58HQ2/96.GB**7T5-+&2^&R:,D8T33=
M,.V.AQB-UJ5>&0JC+BN,UPY7JS5.5"?082Z2HRALF[D_%=&($8<HC)Z-"MJX
MRP&W=LRL];8]M=WXM;HYTXKD/AFA+T[S])93)Z@#FAR/ZI7<YO"3B1-,4M_8
M;Q[Z,ITCNM2P[N0=ZD%6CQ72)K6QH7A]WGV3U8;<^N79'[=4%T?D^(_C/UO"
M?]@VAA'T2!DQ-!\)1Q\9$C4+RM"H'(4@W656+#X.DV32F0]KUWH8C8R9YP]1
M WTK9L@D=I2(GOE1HOLE+#*(I:4@?BD!3RJ?RI:G2KAV3V(T[L5LZ*7@!>?-
M<[3,T;*MHV74+;>@4$4O'2 W==*VWR!K:W)W%V:*@IOLE(X28;$(#\E_51JE
M Z,>1Z9(--8QEB*Q%50R+;UL)'@2V.7II]!W*LF4S)9-&XH<+8.6;EO2%E5.
M-DT9?.^:"N?KKLRS^S.L()GK >7X*JT _.E> $6^=M$/X$T-^WS6 Y&0Q5X)
MT*1PZF)A>!B]1+%+4E<<QO:_PU$0IN+\#CE.4@*DI=*:5<S-T\GYXA W/YA4
MX;L4*V7%ND8<Y9"+3U/<YLVIXV@CB"I #C-]%%S[+NCG5%6OW$7 ]9F['T6X
M5J&K,%\+RP_S%XQHS*&4@HP]::.5C*2H9&--^L;S*->DYQ*314W5KXLJ+LX#
M/[:XN'G;%1=WQ<67G! M559=<7%77'R^J^.*BS?>(%=<?,,#U%907%SS^@<5
M%_]I'8J+-]?G?A'EOGF]KMSWAI7[]NMJ?5,])HS\-XO2]TMN[MS5P'VK%CA:
M'546IH&4X)VK,+CI?]@;<V-#$&Q,"\!JA6PF&D!!OW'%I!KR ==L',DN*-7;
M0 MEJ^![_:.N"N\Z!ZR]=@%KFQ>PMBPI:NWP\WDK_(O8X"K\K[/*R"?W7P"
MU*Y]R5KC=8$8VI)HUZ&<KBW'HEMP<Y/R92B0L5P0F"6H.!0_8Z6&Y/2= 6'K
MY+5_>'#@'QP<['L?<!T]B>&0LG+], 4YI1>0W5,%F D99MT@XD;8EM126$W+
MZ8?8\KAJV!0CC96N:)>!F+*"EN]?><OW5]^4*:FZ)Y)B]/!VV3TC1AXB3+$T
M0BZG<6(&(T^[$^YZQW_1BRLOHB1 &R-5%!20P\_E<$B0%^EY&YP(EITPW&7Y
MAL33IGU/I:(V4%(Q-Q=-5=G&/5U\M :3ROACD[@Y2Y$VX%P)PH*N4C-6CK/N
MQ>E6$:NW4LP#2KL!:SRI5VU+&^UQS5I\V$8.>7_A=5GC)-[3?%$@J=''E\"#
M/+GA< G606 5I.GUD9&.@M"N]&1"?/48>CN<15WLQ^<;B1Y3C$\ 4/QP>DR$
MB.I._=#"/^FCL1;K(8W]E8E3A2")61H)6/V=V*4,T 2++I-EM];!N=UFKF8,
MO1<[B3)(C_J2_UZ[KSN*2LL7*>JQUQ]'D90B0\=^JAAK\.F02TU[:5#4GD9[
M@]1^-CC"A3IFLH+@-@@C$BWOX07[WKFP.60#?F68&G)74U'?A@83+ET"K5>-
M84QI07T%=[7G(QF[4\B*LBE.)AEMI0'@L7*"N_:(%.0W]4SU-<L"))8<";J'
M=[/^A-1]/"=,6R<+ *=/$ZTV\9B)>=O7-;&["5K42O#MC]'C*1:B.AB_+ G7
M];!:1@\KJW<X  R+QX/D@*DG"9GD"Q,@OMQGHL"\3(?K:6Y02A*=.>GN0SIG
M%<JGI?$NM7.6S/B8SEG;=N=<VY^R W*+VOYL);ZZ=B;U[4S*D=>NN<E&-3>Q
MC32NN<D:-S=Q'KL5>NQ.#YS';K;'KI;5<6K7FOORG@=1GUE4<9V#[I6RQ=MB
MR4QKWCBHIEF0:P_D\E==_NK:YJ^Z]D".E#A2XDC)<DB)[@@D8< /;^OS^%Y"
MCK(XRN(HRY90EOJ&0*[UCZ,ACH8X&O(HZ80PJ"'%:UYQQ34A=/3"T8OMI!?E
MY(Q(W2HRLP8YQO382HWD^I';TLISM?)01.B09EZ.1#@2X4C$-I (UTW0T2!'
M@QP-6BL:-$U.YNPTV%1)QC4==$T'7=-!UW30-1U<9M/!(LW#-1UTXI83M^X3
MM\3R0FW\,(P[IZKDW,L/+ALZ@SFI,+.SG1<>E=UJ[PUA5P,=E:U 6.GM2ODE
MK/;8Q<QSK%].X>/'!W^IAME)FG"E%5"YYY$V&CE5S=$.1SN>3CLL^9A+Y U-
MYP'LN% O-'&+*Y#2_>>G*+X4LNC9":J^50FDHV#OL3C%=>%;>E&W:<,:*?4;
MVQ'AY5(7D'^+S^A"G7#KT-_5%T4 RYFP/F(-7&YMUC2-*>U0V0>,'HQ&21A3
M(A$'%M>.@#JB*=.-%560;'(R>G.3M:'"W!T#J/(FI92 UK50R)47ZI_?=938
M46)'B3?=:*;KHF*]?5.FM+$I9BF7U!;.#$&KZY.(I3))+I6R)*I(;H0A1-ZC
MLN=<?;G&DL/FL5)_LU+-D,+#6*WLJZC,QY#+H]_37O,A#1VGEVV!H[;-YIPB
M+U?$PZ_[V,]$RHV6K'%%Q\A"WB_B/9U;PU%H1Z$73Z'9I#C=W\RN0#2C4:*N
M?<)-R$PCX5G:N]0H8AV>:[#H<&\M=S^;'D]4BRS]1,9L\@6+S;)Z:C6K^]K^
M4@7(K:MG$05WZ(=XT;FAY_=63 NX-Z NL0;Z$EPDW;H;RW&G/:O -Q;7TW =
M@6#3%4^=U15:! @NU86]D*9J,T:B%E$"*'LE.!R*PZVQ/D<A)!1E*5*\$8DN
M]I)4&HL7;4^*=W%O.)DT$",7B>F06"Q4 B+>);W>WGN U#?O7W@-K_-4P=7\
MHMCG"5*&*SJ^OB4,6JZ$P687'=\F=+P@!1%([56:Y**6G7>+#JV52N/5XL;-
MGE=NT<(:ENB-0HZI%!&&+DPXVMR0<4ILR;C!2UR47C3M0V8VCS UX4P'":*D
M11F?EU8E"SN<OO$VK MJJ4($B<7PNM3MA;4V^OH?VR95BQ:N3>H<;5)_CSDF
MR+0T];(DB;G[<U-<U7VUPXL#D9(:/8HAZK-*@@7-8Y+FXA"KADG?R/LKH\_9
MTU6OR^KI6I37=CU=%T.',+!'QWM)+]%S$\QS,6='4]?_]6']7Z7"75'^32X#
MO!'OV25MZEH<8\5"&@#8_D3*WW$%ZJJ:I7L.6!U;=>=IJ2]7>YCGFJ7O>]=<
M%+'+):0-$2BN=-6$W32H"QYR1DUGU+2,FM1EQ+[JQI0IE6_N!MR-0((=L36?
M!#[Z[(76%S_(Q&>2_83].QA:Y1+R(.SG>[H<5F-9?)(URLO@F.-,AR)C3SYJ
M$Q+43M,X,CY6&5BD")::3 E/?\7LD'<U'$=Y"(H5V71LLL _[W2LW4O@0N'W
M0G+GZYC+-!F3C-)+[F(-B%@A>'+)^:7H*K_2%(7 C76$J0KK=.O#>TX*T344
MGK[S?9XQ31_)FI.RPN*)(J[SR5%01].Q32Q(5,[+'-1X5'],76*'[\N^26OW
M-8 KVPB' 3>8M*\$Q4G7=BBU2L*3XE2H^5)XPN?N%,QWI9<B-E_ ZJJ%IK[K
M!9(%2G7XZLYMN<X Q]8=6W_9;!WOIK!P31Z^7/]>YN"@H0O+F> K#4R\IG<5
MZ0(5HE(SF:6Q%Q=_+>AU+9TNL<$JH5[QLH=A/,Y*) 666ZP7SF0NJ8N]8#6N
M6Y/CA9XCXUFRN]GDP7<**%=<Z)0;3VL-GHC[- :4$L*F?RX*I_-H/9O_!-0%
M,@]AYS>[C],R+?95-1KGIH>V8T2.$3E&M#Q&9-+F&MF0K4@^6G^LG:;:#M%6
M)9_$[&IG6U]V=Y]B"9S$FZ6=W*-&WJN@U('+J2F..SCN\-*Y@R8(%W^<?UF9
M[1$GG\DKYC$[-O(*>XOU/&(];%@/L3X^DE',MC<.QFDO6EX7(;&8ZF9"8BHM
M]10BI9GTH6XPT@L)LFISH&:DF<,"NAF[G"[AMBEHO!ZF6(22DW!<4.EJ@TK;
M+JATBX)*ER"EE1;0_LNF11&]DY R%,4P@/$!04$+@NP#XH$>!LCG(1'OPPPT
M"0QP._#J@<D7Y"5'6'TM-01C_9@RFX $Y@,OC*D$+G?P53=!6C#M.$;1D$I:
MI@IKYV+GR2"DU))2O^Z&^.4P-N6HX'OKK/:-G-&#T3#@DYL13\5W=>VC+,TZ
M8^P76LGJ'6?86:# R+-HXGU4699F /-@&&1WP7#B>[\E)'-]!'4VZ"6L]ND0
MW3+0I>9Z:)JE9QC.5G_@^U[=&CZF^RS(F/D]:1L+LAU*8Q@4K[ZK[IB./.GW
M819.*P[,V-6N\ /07*;6B5_JENZD8:>8 S ]-#V6"_Y3=W1$)U-*0S]NTQ&*
M'VZ_N<:8O7120V+V=>C*//%Z)>1YG$#)0ZS 9L:+9)L92P'W6M'.IN[:LQK1
MK/&LGZN6K)/V0Q:)$F.33>RDQB;&9_K4"3;W;0<:!YJYWF;]??K^SL.E2<F>
MVV3>!.Q:,Y80QD)%&TW9J!]%X.:V+&A*9RW H](FI(<"F\7_=M]XFN2SH+>'
M1'SN"B[+E? ?90+Y% Q5G?!^OUM!'V?]R3$CG/91 &>!M<4_OVJ_NF_@TH'L
M64:!XC#*CVB+PM1I:JV3SK/D"S&JN@W])RNE,\_YO5(9P^4R2&/5^VLG_?%O
M(%Q=@>!/?Z-1%G^^ +V OMCY8;=\1 LY&W?$2SOB:RPY1$?'*4OF%!MLE\=-
M#L/*R&^*ET[WCT??7_UMI[5;9\UP"++>"/(5RZ0L_6X_A=6S8M#(ZSU,R;XA
MCXA]*NV#(]]K'Y[!/\?'N_=*!.S(;C8A[)&I^5EMG#3C6A5D^P-4Y6^%;>&1
M;+KY-CY"6GOUMQ^>.()]_\CB#6.VC@_\@X.#)Z_MH5M<,&@6,DP=?,1$LM+%
MOE T6B(E=31R$66@XEX*@_Z6;"]U;!\XZNBHXUJBD9,SMX&&7@5Y&G:_:9_5
M]E+2TV-'2!TA74,L6DIHW2:[0K<N?>!H_LP LNQM56S_BOC:='B$J5765.Z(
M>X=\#-+N@%\];/E<Y(NJR3XNM.&SE=50+F@5Y#J@X]]8LNXR[IE@A_.FE6!+
M0DR5Z)OHDTK(R4!%O7*?-!/?T;3MNEIGG#%;K9+D<IU> +%Z/4^NTT,H6N H
MVF("T31%@RN/V?<9J$(G*(UXW.M"EWG1]SF)O<_=/.FHE%_#H#&XV2>ZYG5-
M(9\?6L?[K=,B*\77A=LY7Y_BV:S6EU89'CL#(L> ,8X\Q*P8>W&^5]I%P&4I
MJ0NN@H,-);%$.N):?5:%>,V*39L90><(F2-D3R5D'4?(%BN:&:&%J-E.N.L=
MG_FMX\-U(&@^Y2-ZAZ?^\2P*^PXHU;"ZHM-9*VJW]D_;CU[1'$OZ>Q"/@W0B
M*VK3BE[/6M%AN[(BLYKV:[\%/\U8E"FJPIEL2/ZI> L^3;]QR]'2*Z%4A_.H
MOPC6(HY!1(XB[@N>#])D?,-U7+CIB*=8?(:]?0+)NP#WX8&6BCE_]/:AP.'W
M#V8"YW2_=5 +G-:)?W)RMN[ :6]'3_+SFJ2)S/2N+Z4PH+(&!+D[CJCL="?(
M*'M3JL6.4FQ'!M\4"=L [A0(6#01D&:L9"T\!S=.XCTU'$7)1$GP71&'+Z'[
MW'XS3'42!B5K!#@!"#]4X9R%&T">'ZD/VW"(=;=U3T>JA^3=P%L@';%NB>70
M][U+;GB&$I,E@&%F?:(;K#?)7^H[2ER(P^&P,TXSI;NH5.L+VVD"C9*87SFH
M(,J2TM0=:Z8>]]CLYGCTL@Y,42'QA$L,8]%QPO^A4IC_.BMOAE(?XHGNP&2
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MMV^]I8UC(<=V !O]KA!QU6GQ3="$HL'/8%$;\V0SZMX2-ZVKBM5V$Z[O.WZ
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M"<T_%17X%ERB:>)=&)^+L) <>L^=& R'/O*3_7;;$8-F2Z\3'!S)6#8TY+,
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M5E7S81EA5](XB#)IH%>W?]695H1P4)&@ "6K2^8$]TQ;A(7J"0]/WGXTLRE
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MQ''3Y<6I=:QQ.OI)6)Y5%,+W/@&KCD/@C:^3?#;SO4,8)$^\HVE.HWY-Q B
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M-!>+,-2=[2VV"_ML><L7]M%/;P6!.X6_)W$8Q%5HE!^[&V"600)@ A$/&TP
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MNH5/;&*?M(H0-U%Z>E56_%]QMG-\OW'UGIADDD/XQDB&Z;TR8\58&<;M1%[
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M>00?+B5?M@"I83W!Z-+[ T0CW_O8>M-:#EBQ@CMLPF^&4P5J4@\%O1EF__V
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M]4; 0.CS_YRQA_\+@@CHVCD*:/"L%0-E'/&6V[]RA^UB^#L-J@;LXZ7"<,*
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MI<6 [GI388W&9.AJ5CS6W!T7 S<XI%5Y#Q4/B!R2""K6Q*7H#6,43R0%.49
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MJN6@?566Y:U!0)T2CUYHT=Z'M.DD^/0PAGE8B._?97S_98CO_WCQ_1O0 ZY
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M3<A+@ #RNOJW?TTVI)660T;6^VKG10:4XCZ/#A,SQY)GDS1UT?*HT$<_]6S
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MDF:Q8$_2G/,Z,9H*1KEQ G5#0-NQ$Z]S)PYF$M(RQSFM?P"_]NKCZ-?D0Y0
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M;ZET+:+I@KKG-5+5S#\P4QAXDT,9TB[0KSS]#@J1]&$774\FOC;1(#^O>'Q
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MEJ68IK]X GB?9P8^D%?C-;,)(<K[&P)ZMOLRA"A#B/+>TN>^=.KV8*K)>ZR
MRFB#V98?_= 'M@M+F8H+D)@?DZ@$05>9:+Z$<>J)B1*$ @/-H2MH)MQ?E#D0
M!P[RK=>Y)/ZV!B0L()QFAE%*'<VGF;89E 7%=HG8\97P3!=BM+I8WJW%H$Q
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MZ_8GIN@SM;+1:DMX9M80N"@6;68SPU0^YP2M1-52@5T$=A'8Q0-C%P0)/"5
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M4G/QU=: N\ZXMIGG]QDP2QC;H$Q/DW*VP, 5_#P#D[ JFG*:WFJ;IP#X=2>
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MA<F=%N7:9%"C1X@Y2$;TR3P$Z$,74J5@B7(#(EJ)N /6*YZ3+A+>:'0UU%9
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M^90(1;$0]#Z4EGAUO8,"NZ?JD7)N*,/K+-"K?)+SD(:CB(HC()/HS6]O/+B
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MB\34PB/:"7R[W9."&7?;)G7KY1RSFS(DI'^HLB_RF8DCF/UGQI5GHYE:(^*
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MR<#DC$>B&<H$-Q&A;K<U8H-20<#!%7I+%YO(X)8(-E%/4+0%8=;C%,>@V(V
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MX[YR70V8)?!SU+_-U2*\S[E<.HG.27 N)9*%*^G<)_?",JZ(?V5)+XPCE&]
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MU^XNKBZ_7US>:=_NOYSEN+/4ST/X#=]0(3>T;;9#4^^)?H\3A@Y/],E?SPX
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M%,M SOO0 .P&-R,KOAG9Z$B]R'K]K;W(VN7T(N-E>=FJ+_N*F,6)M"%+K7)
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MN)3J>-E')0=%K%_TE*(&:^3EX4')GIM.6^^.*I*FQ*I[M7D\Y5@UD(W3N7$
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MU'@&<37.R)C F+"."6SI'ZQ7]JNG5W[?IVM]$_5.  P.>[KQW$? 3.OS\Z\
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MG7)#M?U5!)ZW;JK0;>O#%G?U>ITWY]677%:QR6#<TX?C:KMS61-E_8,UT4I
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MWX$S;#9^DJ_M\WLY2Y/%DG/T?<ANM",]1-O+ Z/P)Q'EA,(IH^KURZPO!L@
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MAT5.K_#]_%SJRVD?2"MV@;0R+I"/OC#1#?+D>A8H N_^[CI"6_. )"5Z<C#
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M!C"TF</F<=A_4 E3<AF-9:PTOT=7+2W@@93B#/_JP']DW1^\$#7_P*7"J'>
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M4.VW_]<48#;-?>CF#); ;H>?4F$'BCK@4J-.9[!EK;PA%;)SXMY=_#8\>F,
M109$RFZ\F-]F\1L5-!;N\&A_C*W.J"H+V6S,7$,GKE_!0\GB12E/9/&<4&Q$
MLA>9QDT5]VJXD)=)/5S-RR/7F33"XVG5&"GP_52Y2UX_P10<S+DP/&K)2-;$
MCQAV$JV9@S '80Y2'@?I[. @6;:!3"+JV97/(M88BYZS1,)G]EDOXE!Q#S',
M@#02WQ8Y(?U43SC,0,YV XIUXD13UC5A4]:E3.'"0AAR7:N_F($Q V,&=@(,
MK+N#@:7M6'PC8^R_]\.EZL,XH9GT@>Q;Y[B1>:5:##Q+=T*:JZB<<.JD"PPG
MW]@Z$AOA7+QJ9ON\,A>OQ[EX_S][[]K<-I*D"W\_$?L?$-[I$W8$Q.%%I*CV
MO!-!RW:W9FQ+*ZE[WOGD $E0PC0(< %2,OO7G[Q4%0HW@G>"(B)V>V02!%!9
M67G/)ZM:O&5J\=JKU.)U5JG%.W_%M7@/B:X>/3FNUW4( Y/LP[@RH=G*FCY!
MR-5X-)9N*_/0TU0#D!]#4A5U8&(,O,SPUBC['*!!YL[E31"" W^MTL R2:Q*
M3")4#?5,*B",A4[A-EBP,A6%&U&,'A'G'_U MA*2\F9QW\(.P:S OI9@14VO
MC;?/C"0F*V=<_P5?1$$_\;M/9B(RZX19VG>QUGWMI1T/61GBS)2+[.,7.7+.
MST9HS_#O7M"?36>A\<'Q)W#1V(([,V@ \JF$EA!726B)]]H-M:_H1>[! (!O
M>E&$6H 3>&3%,O"N;'H4MTD\!D$@Q074B9/YW.1"[AV?P#LP8046)159>(.:
MNC=\']U&#]MKU**B#+U83]9?4A$C9P7N9V,'6, WWFKU:NI#[F4+=<"CR0SX
M'N=N@+E(68F+]D]XMA#M:V A' ^\_=W]%SU190?ADS-1-6>,TRT*%1&GQADZ
M%I$Y*MA1K_"@I1YZ$K+G?=1H&F_[4Y1X3TG !.0W0TQ(X._W7/3 O4GP!XHM
M.(0L.*)Y][ <V!E[+FWI$;PD_%;5@ EH'$[GT_P*JH ;VOV3.L&I(T3T0#9.
M(;(O0FP7180%0-J,$.=:8<CU35:HR_:&*;.FL6D7G&03M4*Q4DT1VY&YJ"BX
MG @#<?HX[UAS:5=";RU\T:9,]L4+C:AN)"55<M\>;Y"Q GTK8B2&8^B+&%/V
MD\2P$BG@>-7+RIC8X;V1S8(+R= JU+(R0*_G>!%I3Q3@B$'TX@[*_ G3KG+,
ME*D95W#NS=11-@46W&()PX, IJ*90'";UN*G%9@F@2-D_WM4)1M;]W!F"\L
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MVL8A98NX@B^6A,@Z/\0:6UW^QJS1J373&D)C#5CCO3V9:LY[\Y)R\!?O:C'
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M-#5B:H3VQ(+/;%<?D5;+1G*G#LJ58-RO?/0K:&I5M *%Y1[>C'#H[6=\6P+
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M%<82EY&4;WOO# ;4N.*@E=$+0SN'>LN-Q*3;B;OQS38/B&YKDF7IAD@S[47
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M+2^,CO8W>[I32_M/._"'5OB$ZZ:T0NJ$'Y2XU=YN4X#7Z_43$."5:-[&'-[
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M4^40VQHJ_\2:GSPD/V&SWS(A]IG[:9:G':O:[)U/IC7/+TNSW97U_1K$^"F
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MV.>*O]_BP_$R?>"KO U^GC7E=6VZG-?.,^A2T\Z$$QI^'S2BA9,UX,Q,0 #
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MN?[-5OM/"A%1EN@^68,<C4N-'/72D*->2^,+)_I3$"@*H9H$X(O@'3C9&OL
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M->DX662[P[+:HSJNZY;G-IN%@\ZY.'=H#V<#2DNK,EV"$>"2BHE<@<CK4V6
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MJ;&Z*97V_6I;+D*UR5>@VG)&N KA, 43 9:E7NO7^]Z5YCAYI T3\ /7 GX
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MXH^>&$F_><H^WZ$\^K(?(YR-X87FN,DY\FL&"H,UR]W]%Y NC;;QZ?H62PY
MN(Q\4  OX<]'5S>PATJ B\ZZE0 -O21VMZ4 [8)2@$9S=[4 V[IWE98]T21?
M8MI]I 686*0+^"O2"%4&]Y@V5P9>F#:QN=F<N<,HC(%A&/YPMZ/1JY3OSD+T
M6[&"OR6MX+[EXNR-A6.PJU[W93LT924P"-@9V?-)_TV9XLL,QE[5G2M/:7+#
MK-=Q0/8I-V8>7R1?,>>&TX</R[>;S[UKUMJE@=.KLMGESF97DV%WJ2[C PUW
M$Q\OD]8\;Y^;C<O2E-*<CM8LV]#-8U>AE[5&:;BX\DE?@Z)5\[A>N:K=U8S(
M0EVK"'PRZK9S:79:G6I^9(D\SQT-WSMV==JI;9]/JZ%QKQB1^D2662&\[.C>
M5=CI.#(TC5=K!Q]!AN;0=L5&P]/-YF73O&A52,5':2=O..SH^.WA#-2CRAXN
MGSU<&HS*4UEG91'OU")> _.P:MVZM0,2YFC%"D5VP+ZMK+<I2],6/BEMY'>.
MJ3U)(Z^@[M%T)F5Q1M661&U)$;1C00O2]K9_Z>ZC5NOB"-N/U/\4-P%K)?@;
M=85TMP4FF0S-" TKJI^-#<3V"FO:4]KQ;!-;K56/[79RZU/4C&E_##HE26&/
M8Y$UUB<_&Y;[8LU#Z@;A>SXI7T16L=?K/[TWI"':PO?6$M:-=LLTY'_>O7_S
MU_SFI%:MV<5?QUZUUKG(>%OQ\7O=0#'(0HEO9]J^L(RG .7"?X/<>1-C-1D%
MY%Z=!RE3<5@$ZMF__=7*-R<R>#5A]TMPTEK; 4[5K\= H%I@P$OA!J=8I) ^
MXBC 8KC5W@1DSE""KIY_;RQ"O$U>W'RS-3NI= <N0PD?4T_F:IV9V3%*7=MB
M,(>#1&$X&_-G:[1JKJ:73Z2M4^<J4,UD9 UIE^- =S:P5(9Q: A/(88D8,Q"
M::A_<*W!'V>PV;X+KS]P?60]O(< ,CJ; &N0*>@/;1<M/7<N?_LBXGN&!$FR
MHNTW''XN-Y72+Y ADAQ8-9>").]TCZ"Y]**^N+FT636 5CV"FZ)!5V#0\7?,
M$VYK:9+];:5F!F2%T*HC5 $E5Q7*AS$G,4RJP8*@=6<;S[X+YKL+/L4KKUO>
M4;V&2FAK@B^1_/Y=D?@.+/&=1ZDGLWC2^ER%*<^:"^.4%ZU:9^M]A6_^_E-5
MMW6$,B)PPC^,46#;X,W!'3#U% #W5D)B6T+B#@C\&>A[+<A;;ME0KW6V/H%[
M?Z*A,C+V+T#@5^/3D!9;ABC-$A:2JBL,FEY)2BR"*^UD0Y5N=5LJL^!(3C4\
M'FCK#8VY8[NOO=5QC]: )/!'0=^#6 /-7&O@3SOPAU;XA,3N-AO-]SGE#%O:
MT0R[8$%AVZJI+'V[]%36!DBC5?JJ")4T(SUE"7I3:A/GF.9AE,(/EZ@LJZ!,
M"[--E\UCR#9UCGVJZ7'>NJR)D"K[ME_XU9NL[$V94%:KW<O"5^7-B^&K?OIA
M!P,G_'_LO7MSV[B2/OQ56#XS6W$5K1%U5SPG58J=S/%N$N>-/;/O_C4%B9#%
M&8K4X<6VSJ?_=0,@14K4S2(E4,36V8DM4R#0W>A^T.@+Y63[COY^>;FJ>+LC
M;WG97/X1IM1QPN&A@O]4; %=Q>?C[N$?=$HL!][)?\4X4CQRA<3FA/QBC56U
M9.6\V3-B57/#P _@W(71>9M**RO?SIMJ[MTOR+M+(>4]O ?R9.@;+;UM]/1>
M5YI:M/O(9UF3\_,1RJ4(A0@H,H@HJ:@>GI3?J_55Y\YC"*SG6L\%2NN^Y;[+
M*[*-9JU;Y0(H);NYW2JY,9A/P'B\TFWLU'SVF(*<<2&,WO>+#YU:O9[S5;"J
M 7:>YPY5>C[OXMV_>:Z_G-]^^(7D"8\41[Y75H>%A>#YAY2-WW1@D$T@UZ*P
MNA1262(X)J$4GZ+W@9+D$DFRA)6ZBJ\"ICSVY4;.JI=$+MI?D#$$/+I?SXAR
M@.<E9U&_J3?JN3LX#^@6<8YX8QMJSA"Y<X3.NSHP6YV:JN!<'I_[2HN=LT7,
M.WO@&S6C&@(L(9@]!5!65;$E:I]2D64>PR\IX18\]=A*52I:RF)VU)VE')Z7
M-\5*&F?NII$H5K*DOAFCI;<:;;W3D:8K3-4=.<7'2I;YV(NQDJ44U=()K%2Q
MDF46V4:SULJ]1%&)1+;JL9*G<SFNC95LYQ\KJ9Q8Y6MY5I5U*C=6J?976=>K
M:'GZL7]]:[/!LM<T^N9F=F%[P79HE)\,60V?;#_1MA88JB5C]/C-'X,?IVS"
MR-\O4]O%[3#\3>W&XQ?=[EQQ[H;,9M3D%>QF,P\.8&R 'RA-.Q:9?(^KFL*[
M)B:9(UC&0I-LPVA13\EEG<*:$?H@=39;D%X006ZI/_(LMJT+I<8'UK0'Q4R;
MD3GKF3-RIT 2C?L91=^H$?5]Y/X[<LG[/,+OK%:/]LZZ7+0" AG^FP:+CD D
M-1B618,/\>D% 85@>3"0&&E$9OC83\UNS0 (Z8+-T-X-^=\FH6>"6N,UX['E
MD(4M(+6?C%ZM6\=1?FHV:YVFKO&6D+"GF1H,7-Z<B$EU;<5,E*=KZ%ME7JX&
MHERKJ9:AV&)SLQ^L$'[OW#&TT:RM%E7@!)6W82@3KC*UPMNU<F@L73_@O_!@
M(/K-(HL/*AKZ5B&K8OU0KKK6% A5E3^W5?[$HIK25_YL;ZG\:32+*Z*9U]B'
M!'BH*IHEKN'&8Q<X9=PQ_Y<I+56*KTQLC&ZA.&U2I?C872HKN:CA;2K_L-AJ
MBRJ=K["@LEQ \+=E$#PD-G,,;JJIIR+$=O9.B6M8@-TAP_?W>(I\G!!'.%YC
M:+Y+E;VWP6V)@L@,O=[KZ9UV-1)23AV9DU>(0RRC!Y8QDT%\#X_2J>6?HJIB
ML<\S%EO5CRK2=*9+HQ3IL%+UI<[;-LI6GT<&*3W34CWJ/'H.AK4JY65.95I7
MRBB41V\IZRJ;=<WCY+DLE\K0EM70JLA^B>HV5&29*HI:%0.0!R>?X-[&4 CY
M=/<V<L ,=6]37?1\8$JU#.);B7L;A8UER@:MRCH5.CY5CB%^@(K7<D*F4=?&
M^O9V!:1K0WU[.47ZKN!M02H1Z*;M"?_?N*8C>9FO#METS07H3NV[U#]K% @[
M22R3@DY3QR6><@?')?N%S'T6XLO'G,1&)0I8K-=_OM8BC=+$>2?N)XQV4]>B
M_UQ>7_RRE<D7:^74:-8:/1P_M9A:IYNQGNCCY OP''5]G8QQU%B08UH$5@,D
MB3;Q$"K\(W!'%ZF91\=!'K3]&*7[8$D.A/6__D+6YV4*\O5J;<O)F&>T((]/
ME,>QIPZ$["..\I+;7+/,?UY@IL4#M2D#(@"KJ&/^V>@UF@"X6G^*$B'P!0!M
MP9:'FUG\*.[,>W >[G$V[[N/EXL4BT7>B\827S3$E!KBS8P,W>)S<T]$DM_C
MW)/!E"<J8AX2TH;E6.U"K7?X;?0Z-^K7LQ\/O[-/V>_&]:4NTC0W9,]A+N?F
M0\\-2_MD[X5S!V97,\COPZ2H]TS-SZ[W.<3R]'>^'Z+'8^=R4%G)3\<Z03?J
M=;U>7TV)B[):1;X9\^=WK_VE3%I/K!W?H%EBW3SAUG&X4M!>K&"B(4LPA8P$
M('AS;2BRL7D"'16)B+X.;QU;(^K!3Z8%Y[G ]7B.-XSGAW9 6&)W:F:)Q*68
M[SQ5CK^3Y7O3'5*:WW*>7>1XO[$'QOZLSRB)%*>R,FW'\GW]%4Q'X*#+R12E
MO?/,X;59I?!ENIL4L!(-*5$8LXW W[!(+;-\;<:X4X12DS#)#I9+O""BX0_7
M>L8L!^YK %TV"X'J(%'Z&L6SJ%_W%M$</#UY] E8O7C1V_IB'*J=EC)UUUX>
M+KOVNGJ]U=);G?:J;J+PF@#3HOD69_+GL]P\$#1A/>@KK!EHQ 72H2_VG&DH
M^""KS A^A2="BH>XT()E(0F3Y*V8),R1?.=3,"!#]YE>H@9#C\QHLI2+O7>)
M0N;$>G03W*,>PES V4=G(4PAY=IJQ3R\:FSQS]8:J\4N?^8<@TT!B',ZI:;%
M:12MU-2&\Z3: 6.P8S6#>@WVU1B5C:M]<T'-8;4%@0H8F2> !,&\"$46[46.
M-C !G\'P;ZZ#!/9<V\:WWN'9 B@HT 23)TPOPK40&\@2$ MSL9]@UT6S7+O9
MEY7?B?.DMPB)RI1.94HS@$$$N;. ATJ7/H]TZ4YK2[ITO<!TZ9S&5NG2%<VS
M3:=+\UQ:!I14NG29V*C2I2L2GJ[2I:L5=E-_,^J6QFG8Z>B]UNK!7,6AES.2
M1@Z)/#B2QFC6^M+T*5 1J')G:JD4:-E2H&7002I)2S;C*%L*M Q26K',+'7&
M+)-AK4H*]+N2Y4#+H+@..706=>:\K*9=E3CY609)K<9A5.5U2)0,7)%EJJP.
ME?,L#S!6.<_R'^?SS7F6 5T4$;&M$IY+@)CSZR&MD+%"QI7)!*[*.A4V/E7&
M<^'QRX^L39Q(6(B;7_+^<1KH>^R^-8)%$\O!9EIQ@L+( V7G681EJ(FN7CP9
M(7IZT:\+3 </2_?9TVBE_+$%CV,.%CSIST 'LP]8CE"4F<(;8V):D(ZMYYXM
M#*YGN5J\U]?(FEF\=9V_^'N<!AJW (L:A/GA:,)&JVD#? ?GP]K6@ZG%+A:0
MW2</\P:V-\H[L/DA?\9QM?W; #+^[CZ!^IKNBULZ]^79?O'M&0 [-V#<W)'/
M:-164T0XE1(=^79C!2.ZJXV(/\'>G[QQW928E"5M,&D3>1B\E>?,]0+Q OSC
M3HE!L(\\"DI]%#?7$TP_C_:,!<G#[@T::ZNUG%:D0;+^C$( #NC/N*P(TWT8
M$VIQORZ,^2??%]<%^TC9]S<\^SZ12LX3NT5&>5;6_6XY6MD;E(TJ=,E!#2T7
MV>=\JQ\[-4NZH@&IS"QDJ;=@:92?S%@:)VRM+0*@TK94VI9*VU+Y/M*E;2VL
M%/^=6P'^,[,%*J6K3"Q6*5T5";=3*5W5NE6L[X7/5<CY"2_Z!-W..]SY?#6K
MRA Z$^WZIB:)QU&R2Q[)=J^K]QHM66ZLST0/RR%W>;5K>K-@'AQ-T>S5VM($
M ZDCQ3D8OC\2APYE]W+6/YRX4MH]=;@X#Z&2UZBI_%1U8%.9IV75,F]MOJNL
ME[)>.\A5"+Q6IDN%N:L$T/->I@IR+U\":-6]+RI-] QPQGZM<=5=@P*V>0G<
MH7UNU?6"0K&E26*LRCH5CCW;9,W/(EOL+=F#VU/5W/$Q$_P.,AYO2^FKUXPM
M.5PLB<[F9!$YL!M2.#;DUF'"FVSI8.L24<J2 IB;Q.R<]->I];<(#";$6:R;
M(QT)1@ZIEF"[^RR:,7ET2BP',T%?!.JZ(AQV+:7)X3[<F-M5&/FY]QR4C/@(
MGS/RW\T9K2)1H0&HJS7[*UJ5I837MHGD(B/ACJV;X=Y!< P@^R;),MJUSO9\
M4I2;,2Q!>\8U:,3WW9'%% ;K7LISNS=NZP#^- R%9,Y0+J=#R^%*2(C=<F^Z
M5MR:;N#[-- &(Y[.&:<=?X$OH?(:/'F4'43\6M2#+D8CJE'[&3=J;YQ%H_8D
M%?=OPRY-T_7M_>9/UY9==5K/S/6^O=0>PJ%OF1:F"8M>G'<.<L]ZIJQCHW^2
M/NLWHG3+R\2U 0:Z+XZHZ3(E?[D>S/**?P3'D*@3*1XLHK58U(^2GHGISEB=
M%C!>\!V-\D5:\2)GK#NZ,#2?[KY'/=%KVB<RFK#^M8"KGJ@#$ GG@LZL$=[%
MPOO<1148P*TV'/%PP\33F.L<E@5@KL9CRT:+&;=6333UCEMY+_I[KS3UQGHU
M%#:+A6\ "PG?H#C]0M#ZOT/8EU@'1_";K2*F&+?J+G?AZ>)7Q.T4,0'N1[:#
MX4\)1, .?1IAH";]!_9U!#/Q7_%U+KH*4]]:]!,%5L( "'1Q.L"AFO8 5#+A
M*3&MJ+/V!)"M%H!0BN,F(C)$OJPRA,<Q@YY@;O1W!I;)KCCXS0Y2]I\_^#LY
MYMT1Y2YV;>1C%<QY>V_TL1MZ:UJC,XQ'^$X#A C" <K;F^Y&EP.J GYZI=[(
M\G%3+3F(?T1GF)O%G!YA2J<C']C';.J!;&*]IX00IO:/%OJ\^LE'FXS^OGH8
M@<9#[<7%> 8CL*I-KDEM7D!E48PJB<BQ6@_?):!]_H*=@3H"5.O?@)L3U5'P
MA C2-F70/?1Q:*)]18II-\2S738:W\/BE4E/C[_>U</V[(:"39+Y?-XH #FY
M?QK]K?X?)&>1]##Z"7K43TV/QC9ZZ F%;X-977*/^0D0<_?=5_5]-F"^3X#Y
MV&9D$J,E1483,G- D9]ESPZHCU73MS  OA!B>'I=@2 <Q?\X1\%[0UV@JA3[
M>=BF7\>>.XUJ$C*$ ]B&<*/ _#-Q=1_M'6RN8.*&/N@@_U(5^REKL9_NEF(_
M[>)J_>0T=-5+_72J6@?F_QC8_(1@DQ=Z22-.*2N^G(/ 5;;PT"*<4)6**@W'
MZE+J 14H+$NZVU9,G+@=)_[[8R?%21A8=.JQ%2U/GLBP(U!1RF>+\OGQ7V0Z
MN[Z-=(U_9.VR5YSX_B'A>?IB?U"?(KP?..8M?::V.T//D!@BZ7N\<T"+TX<
MWHM/?!&.HUVB89JQ)[*YQ1.I=YI=6<*YJRH@2\YIF02DJW>;J_7W)0OW5S"U
M3);B-V8I!J>R%'(EM^5I6'[CU_J@-@;FU'(L/T"/]S,]C>;H-/1F8_6:ZPQ-
MRQE)U)(EDDRBZGK=6&T-))DQ4KEG$I46J,@RE5PHN=@J%ZI:F=RXF&4*R0&&
MCY]SGR,.S@MN]%IZORW-V5=)P7[8-3?0V=6[;6F.,0ITEJ$00%76J21#2<;.
MP/.4Y1M.A>@F5!O9Q/>ML<7=(3MU+A[2X 6;7$=7:A@;O^PTU5C0*C8 '_'4
M XQQQ?PI/'40GF<D7#$L-2P1_FKY[$'+9RW&HWSFC(FRS M*10*7K_G$QHAS
M,87:<A;J:N;QIA!J[B]Z)*^WEC^R73_T#HMT7O0?'P1+R9$\+=+H-G(3A',*
MD&>IYT9#U"KE;-& +S0[$W*WL'@^S$>63[S@-/SC@]H;.%CJ $B10X#[#FSO
MG&\4/"H8V#N^QC.W,6<1N1<P[J':X/4O>*D3L6]_>3>D#AU;P27+L52!\.<7
M"%]7@?#ECDM6@? K69=2QKZ>@ZQ5.:):Q<"7C6,J!EY=HFP2J"]KT+"*=C_]
MV(J6)P]S+*&.:4JG8_ ^"? IBW62)'JQB*NZ=YOOZKA;!_7M9\^=WL29]O>Q
MIW')_4/]KY;#BEG=(7*@?C!PS/0HO!C'5QI,W&0YR=W"'W]_\+T@#D#[C;I/
ML+()4F#O(#0?Z "?;0Z=-QIZ/_\ QXL/EV=X[2N]+"T%/AY9ECI]O=')O<G#
MDB@I@'L.QN?AQ0K^0SV;..?>U5!ZG;%<B?E?1]49K49+;_6+5AI*H$YGA(XL
M4,UV6V\U&N6U0LJ^Y&!?/E)O&II$V1:I;,O'K\<]VS2Z>JM[AF>;Z@K4DFTY
MLD 9];;>J:L3CK) VRT0:YJWKN=$5H !4G5YF.O%E_JUUNP5=JAQF17/I#31
MB4T;8S?/)#VF2F(]%#X#B3!,K-'O]KJ @)MZIZ.LWAG)VI+5DT76>B!K=;W3
M7^U$=!R#J-)%)$K2K,@RE5PHN5 YRGMA\[9TV)SE**\-.9<#65?R_O* %.A=
MSN^]?D]OMW(O%'=Z:%Q)83D@4WH786EWZGJ_I["M2GBMSCJ59"C)>$,J=.*M
M(YL2CRU_@JM[C>?(,[W.-PUO:](=;S9[NJR[G8\48KZM=3[J!%9@#6#7MU;.
MP<V]LV)9,[6UO6YY[]JB#T)2'7N^>X!L/'B1]AN( 7Q5NYE8#F$IMB(:^']@
M(-.=:HAUGK'C:H8^V+L0@F2MNC=.6+7NWMBZNWD6K;NW][Q.TGG_YMZK3;*E
M:?=]O&;>BWH5&ZH;)#M^PZ-_&ON,W+E0V?*[MHWK%I<MG]/05<]@KG:V/"<,
M2YGG/ZJ\>96%7:34)2F3_"\ZGM?]3>79GPF'ZT?GL KJ.X>\_!N.#U4ROBQC
M*UJJ9/QSB!:N2#+^YBMEH5WC&V-1*/LC+_1W]/3Y38D >K/3EJ6:MI*-=;)1
M7#K\IBQXO=F0IA>A@IWG8!VJDRU?O('(,1TYJ02 /:Y)_ G2AI4@7M$ )V5
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MA4ZTAQC0)@YR;HCN6L"Y3+HB=^[8,I&7.C\<$([1P6)[>$1ATNR XF%;V(F
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M9@V@JCD+"$Z1//0Q7)IH7]%0:3?$LUTXX4Q#FY^"IZY);3 PL"/9R)8S<J>
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MIZ(@W@\ZPT(*Q25%'^*'R?$>ZL387XE\V42^*#=3U^CK_7I6N9B"I%T=:4J
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M:_NUTDUU<MUB@H[IB5KU/J%4C'BC8]X?EPD<]MP%G@WG7- B.=K/<<5% <9
M2>"G/&I>$=C58%6PB>\0WHW2*E[/]W(8^ 'P&5]IAA[3"Q,V3<N%T6[7NM%V
M7@CK(+R(3A6C[+68R)F7TZ+2<GJN$O@9E11;,=-16[5.J@[4HG\SLE6H-S0
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M1]ZUB\'MR^6>[5LD2PV?\T,\/@LCO>[;[[5WEKBBC]<,1)S"WL%WXQ$-SVQ
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M$T'5E UO149\09"T6&[4$3\0-X8TNG2(;-O ,1]@&\46;C!U0V>YT-# OW=
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M_=(TNNU.WX '+.,#"Z>)8V'#Z>D,B<ISI\(+0NOD=<_:+N1"$;17)Y*$Y01
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MQ"3;"C"RYP'6*122&?>/B<NM?J23*;-X?""4:52<=<03S+_B!),)9IDO*5T
MBJ/V/H;K8X5P/ZX#AQRYL6J4#^^O<PFII=_\;>;D? G#^]_2+PFJS:I$2E?X
M$,!_TN]_'MY_D MLHSA(SA5/6-;[ 3;T_?X+S^]%%4)-80/P/$]<>R(S(*TT
M?0VWJRI'/+9MPIV.,&X$^GT:7K/2+#CC*8AY@C%_O&4,/?%EX1N2LD+D&X>6
M'_&@OJKU,,Q;]2WAPK%5%ZN^A:^O1^7)B?.9@4 "* -4^1,\^Z0DNQC( R'%
MI0(%\X$-^V3 2DIGL"@HO78A9HGA;Z1TF30#PCL.W5%"[0-P-3_P56)+TR<0
MYRC[5EX!A?#S\A$CJ9YD$? QFI>@%Q0W3-KZL\_":.+.TO?#QD571<$[LO02
M]1TC+LH+A\ R=+>8O2V$9K3XQ.+F36>!+\*RT028W@2L<]B=4 IEV#I8$SPY
MK4RK_]7D'J1<E0Q/<NVF!%M"2^(O.9X+#-=CDL_B#4L)SHHDCE7&R(G)%LF%
M0F^3M+R I'!9KJ7*G($Q.B3H*]E@55%!0@9'^>9S N,%V#F6?[AC(<J!6\?/
MC(GL&=!O#4Q,2.^9U(BY@ 5^P$CO!\#-+-=)!9(X$%PH+HK6/19!3J38.&1)
MP8:7W)LB_X'3ZTNQS:4 F9');#_(Y?8J5Z/4O%5".#)P+NQ!$#:&\/MD//CU
MYG&5QK FEM=VJ10U2UBKU.5JPC^3Z0S0%,;&;1)F=8/W^%$RBT!K)AZ'7S#>
M*N5P_[S]<(]_3/5MS&)FOF63G7O/O:X<<9WVY=M1JI#++QI4F>4P:;J#NCEE
M"&8P.,+@.9[(:BGR[E$2E.5@/9_0(/ +/V-.0L2FN0'/3<C,'TF\FMP[/H 3
M/@W9DXL4K9!^),T!9/%)9*[:3);$93E!6G,IO9ME"XNT2WZKLD^?R2=%)NXS
M92."_26<%>X3YD*EI7KS::=N""<)T%A[,<C+S<C_1&8<)K2AP&/>F(.=],=%
MP*( O,F5'V[DEV2]T4G7@:%TD8:P*2J_%(ELTL)104;Y>-DW7<6[/$Y=P[-D
M!)Q)!44# Z)_*40@5B0;_1:QV_&G**:$_W43TS=-*NKN-I_L) O;L=0(D(G$
MG*)S@R84.@FI7,WG\19+\HD%3A;I'D6MDEA\YG@2?"127-$\71W$"$L1)8H6
M001R8Y)+(AJ)KJC$D<C_R-2@A0& ^0YI><;-L^C1_RQSAZ,EVP$6:@G#@4\:
M,-7Y 29O-&JFR;AF#7W3]I*I46"DF^1JZ!!N/7D;5VMW06M^XL;JC(?M4COF
M4R0:D^RQNU2.^2R-#5(ZNF^X_K1>3D=7YW2\@B%PV#ZB8,P)%?+<G(VL2/2K
M -&2I2(N++0B4927=;B$J$%9*.%@V:PND 192+U:>.F9;SQ98* DD8P"@G49
MA%':*V+$/!?V0*$K'MB/ I_N [;HX/X&VPWM9(HVABV;B"C!7&Z2\!#K1&9T
MH.D!B@**\#\2YU%(]U&0"+^=] "2DXV7+?,Y0+AI!99J^DI,:0<86 4;SZ)
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M<FTFO=\A:EQ4-AWQ4*2EEK,'X2,<G6\IXG52\+U8C)'"0EG@&1ZJPZ@UP)]
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M 1W%=X')D:H"6+;IQ,88UO*0!%1]A4/#^"S^ENHI.?5G]*)<9E2")+T!Z;F
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M+U7871\5=JZ:@ZCS_<3ROK$8KQ_<Z?^!W]SQ"P%@T5V5E'Y-X0V$V,,$'I@
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M_^6>:^K^%.]GU&EWWA8,@#\8$IR0F-OWJ*#ZB;Q6#=%468K')B%S"VR4C#S
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MH3K<H!%55]O 9DDKJI-&[=752;W#EQ"IXE=5DUA-\2LQT^.M/&P ;>\]Z5/
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M6I0TDQH/P4C_A3^EFZ1.*=N6^*:6WSTU_BN^SD65-O.MI.,>7"4L,$?JA^W
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M;+K-(C\Y/%XFW&55V9'PLS[HW]];OF&[?NB56!U4=:N6G)*57&(\]HJ[SV[
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M^]%[4U\$6\ZGCMNT,/\.HFV!49O"ZI$F)3)%"5?+,\*9'Z#H(^Z%?X;#2&%
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M#M\P B1DPGFY#S-]R?K,#8%*--JI'R*WE)1I$-^)UH*K%3>7>VW T$-[B=:
M%B=A *Q4$I:_2%D90V4AK21.^$CEE\C,#_/.B7-$WB%;^L-)1 #E+,&?7<>
M;]%.4,UY9[O&MX5DE%;O/RV1B/+@)LF79P H0Y\CM7LA7U')<)3T;R1\.<L*
M5LJU;4USPC;XH26<"< T)JYMN\\^.R<&[H8^/.%?_%S,BM.G[;S.+EU:8G<3
MG*'CB9B(P6U[CJS0>?SUK'5&O\N%Z?>,.4@OD(:'<*2)3\CSX01DP.U4-".]
M<["0K<]]^#CZ*?Y3YM!OA<4T&/TH,Y'R\I1:RWE*D:'5722-U=.NEOV2<J$A
MK+-S[E/>^LWY<H,JO_#:5>77:I;Q3K=UQ^"HA_Z.)H3DBVWBBZV="K^&C4\E
MS4L'_1.4^B7Y[F<%O)]5!^*^76L[=K7*RG4NK<;BJJWUAH?(/=UOTW#%*M:S
MBILB5<S$@8&H0=EY;<7!Q'(,.T3%"[[I@#%AN[Y?+\Y2QBK[8R\%W.4?8-%^
M M#>2G#?.A]TSX''_"([HY6R,^K'>H9:N]-O)N=1JLP!^%/^4 -\S/4I7,N%
M9P1]*]A,(7:1^N$8+L_2O9?3X$KG^6S)<ZVGLGG2>PG]]R%_<-]G07\WN8\!
M7U\.A>Y$^&PEJ^IJW0HXU44="G0$XWEE5M/K*>(H&J:<PAF5)M] 29DR^I=\
MH<KFWY/-7UO%N]/J:YV#V/Q*G-4Z?_4D#IF/IAO(G\PV^WBZ%$[3[Y5+J'Y9
M JJ_*C;5+RL[=%/RVQBRP]PLK?2NZWO(W'&+:T]^8L?-%>>G!( Z'E>YT8[5
M.%B."+:5=;#?B&!IW8^:WXU&^1'JQBI41+ F[*6TB& F\[!NK*>G]4<J(*C8
MT\;YH]R;64X<YGM__X7=B1SFT^ U!7&^BIC-/=R.+6H<ZLM=-HGF#3#EJ:/"
M>?7Q?]8CU'4*9U1J> /EW*IPGC+8]QS.JYW6O(<VZ4J<-3'2=1*'W*;GSD\+
MC0M*Z<ZRL@G'VF8H"ST/2FL<L;9%PYZZ+[1'Q9#;K=O"?D3O>W1T6;X?<A-+
MX=^#Q:D_8?U[X++/[I/^/R'W@W4M6(Z^V<)RY28Y"!.7(%9<PE\*"C-SPA!8
M).]QGS)\@Z4WR")B4$!?J/8Q<QFACZ6A.OL=13B[T3W;!;-P%MJ"$F:NR6T0
MO<#(:&7+,=P9Z%;SN>=B=;[) W(KB L7BR7UX%$[@[C4GPJ=O\^!J+#.658?
MZR\SN7//#1^G<*)NATX*;[%?<$4 HX%G8!ZU%?!TYQ$_GGCNC/T"L'>BFWSC
M<^.-]?W-U#(!?WX6_P&J[5P!F$#X@_Z'C__]1P3"QM\$:F]WHF^*=@V+>\<J
M^E6-,*A7EDZ=N8H[8LB&&/B8'X[_PN)PV"9J:4G+"UAFH2T"-F$0FTHUAYAD
MVG?I+_3>,;[/A'T%UE.,>Q%VT Y%57EHBW5L[',!9[164/.*=@R**=)K[\.9
M!7MV(V];_?A?0SJ W3K$$HGC:9EN+,"3YK :]B(1?>^D\8,M1U@,_WGH^:'$
M7T%IN,;2]5#->R"=I=@30[1/0%*3U H7!+^%EC\EDI2$%'5&B8,\E^PZ9GI!
MROF*!*OE\.G\W>@+"',8V/^PHDCBPW]#..TM:FC $,3&']R'J>697W0O>/D2
M@L "WNBMC.RN,_#ZL8$W6..OO%R.B@AQ"8"RJ9\("1>ZFQQANG0U> 65G3_5
MV**D\W<N>ZO/?\GN.0<.#O*^IS'L$M)IO8T1[R%%/]>/'B>Q0P^U$8^\= .9
M5).613E0I?6PXT*YO=K*9(<5M(W<KDUD!4Z_JF'6B":2W<V:2-;E?M*;C?^S
M<TO*PCXOV_>D/&0'RDH\":N;)MV!8/'N1 <FY_&63*EKQ_P !I'C\_+Z(#6=
M%]11BR=QV>[((8ATD^Q<7.$%DS>HP7OSW!N;--2Z-Z;<#&U^-\EBR8WK!PF.
MO'M!E==U /+U;)MU5 :'O&5+WC*/;AESM% IW+ Q5EGML?:DMY35;&L/+;>B
MT,5@FX96.[??RKL'MKH-%\MMG]6G8"[ZXO/_7MQ>*_.U37ZN9FD*(>0<?1/>
M,5H3$V<;!:\D0B6*Q<Z\)HO(2P#<]T:*M@,HBOY(L@;7;$WBL/@UG6^71*&R
MCT2*88HVY%_H33^+S(Q,^#D.T)3%D*I5(AZP#:( +3J^I[[X^0,V1/QE[(&2
MFW&^YXGT@V-&>B.*$ ]/B!U%B-L3XG).3DVNNS8;47A7$=ZU:H]W15Q]K68Y
M:JW6+ ?5:9;]PVN6)14?K,8#S,H\6Q&X4ZF8\%JLMA%1>DXQ$C;C8"1CG=,3
M]P,,+"P$#38EOYQ,M<W(=E4>YNM7V#X14WB.$#X? 3PB@O0[ ><VALUFA0.O
M3HS\7^ZYINY/$9;DU"J(&I4$XVV7.>TKSG1ZJZ!#V[#?RD^!+>N**V3@BC67
MDDPAPM4RHZL>?+B495Y1^Q4!0Y LN7VKY;T+]#ALET^,%P=FN VXR]<SV97Y
M%U5?IM*-CXH!R[#2D7/@S8A6ACGWRGP[6K]=T,"CP?INO2^R$LX[O*J \RJ=
MMCDL5<3K3UFAI7Q4 H-0?P[$3X<%]95*GZWL*BOAJ&VM-1P=2)M-E\MN]K*-
M.<W^A/,"RVY4&X2MN.9Q'%/AA<*+M7BAS.]CT!4?W$"WZZ$D5A&:6.,DR\M$
MEPK&9Q[L55UL=Y?+E1JO+.X_VO2Z&ZTVS-311KV"SF%5F^1*>SQTTY$]J@FU
M.:?"#(49&VN0A:UWEEOQK"H<BGK8?N'>_53WZE=&UO3^#:+RJRN39+#"B]*:
M0-1B_X$92&*">_W:.NRUYYZ/B"E[5Q-L# $;GV!C^=2C(0Q$GQC8I(79D\DW
M]"#PK'$81 UJOKH6M1JY-RSN&+#G3X%YB5_%VGR!)=Q\HP/; %N*@=XQAE>Z
MD_BM 1  <\/ #W2'WF2&V+V.O@Z[LUQ8[;UETX:VWS:N\KJMF_*=)1UA+]B6
MJ5"K!;I]=#T) FKB@->@Q:"-KS*Y0]TV0M&<P[=@?[J']S0FG%UX6A<-E/AD
M@MUW8&W1FYUZ)-DVF[M82VS!CR_B?=A()X,RF.CX!$HRMM2!5P,B6&^B)R_9
M-:R1OM+,7:>_.@6\8&/.'<:_R^;PE$>)FQ,H&3=R+CCWF!MZZ'/\AN5%!Z*J
MQ?26HCFP:8R^9" QN"?:_ #O&R5-(G#E-^^HSQ$6HH)U0=N(VD-@7XTR^DJ8
M/- MFWG\4?<(3IO ['*! V\C1''T*BP%RWQXPK64$*U$B/:D$$W S02\-ZJ7
MW1V*17(SZZSJY,[-V@ZJLDY":I9;@ZM@/2L ]=A8?OR+!^!U2>H45Y^?BBY"
M;:* /XM>/BG01 )98[>.<<G.)8=*GI#<Z (8C\&!.9K$%GWLA&NN[ "$^&QX
MUCQJE0M?1FT@K]_/,)YDD[PWVAAL*]T8]QVVT^.^?VT D_.)-V(GW/\L,*OT
M5Q;^]/ RYYLTS\WT%MK$L]-NM2Z7$X@S78:BWG@D840#09UFBT> 8GHD!1C5
M#M'\$VS-14V[_K5P2_?_BF_'<MA[@#'I2^BWRFGL=?\OL;J)'\WT;R#8BRXP
MMJ,V2M!NR!VNG&>Z_NIDM492IH$P3\ZJ)?TF23$"->39X9X_M>9XA2*M#323
MUP#\+EH)[%FL*0/=N+97 'C'TW>0.$C?=%:/;LF[@A^Q=23I=Z"$91L[ELN"
M7M=RK&RV@*JH8>N^;TTL3NW8%MB#%Q\BZKNG&X9H^"?40)1?J(G"3Q0D) 5_
M++N_^U/.L2^G8Q8]"0IEP./.I*0T3T&X _:1EC)\&Y$!K@'<"7@5;0:.AC#U
M7#@/]024"%_4M/7R8 TRE]2:FG7NV:^2]%X/])4JTFDK2C%XD/V@+ :Z %/I
M$80L2>2;V[O_C_W&=3N8:NS3IQLP9H.(56GLZ_VG1&NB[L#?HQ:R:^1NQ)[!
MGAS+#IDW+D7%/?J%[$8P1X$"VXO6V#!EC242(3K)8>3P8$,YW.VLXY3 ]0S=
MGXINE6QF 9T@.Y)<"=C7MY@S&@0\XG#$("]7F\(;M:RKJ-EZ&7T@RV19!V_6
MN!T7V1-4]M6.<=#+-?VS_RF( +5S&@NV^"R37S/F0(*87V,_ZR_^VZ0IHFJ#
M6 ,N@',6)I;3'O0&H]9_VOVSC8FF_(2E$^AA^/7#E[NO#^SN([O]_/[#EP_P
MS^<']O7#/V[O'SY\_?">??GCW:?;&W9]<W/WQ^>'V\__8!]OO_Z^F4^I^@!#
M0YC:@_"FWZ-_6AH4),+?N;IGTN1%"S2EP/7(7J@.JD<E*6@\A<^N/6,*;S#Q
MQT23 ^;FS1?=_WNWMDZ @=S-+8>B3D+K_ CZNF-8N@W('MO253.+H^HP^B<7
MD3X]-*U ^ILS7HZ,.X,:UF] ".>XC/2;RA$)L?-4>"DB_VFF\WU+R\PQR/I'
MW+FTQWR-&<F@:S_%Y7+<)F2_3*A#*H;XDM"UB&:B^2FV,! [H&:KG/P_%_$\
MF*+-X@O2&W9<A,PY-N_$J4U/:'QZ7)B.Z >6L5T)F$F,O,E!(RA=,K"-W="#
M4Q/"RY$ .=]@T@]*\P+L%YSE38%BM'T]?!3^C.-N_,4EYJZ\,CGX(1IEL?I^
MDB/C2 IZ%.WTY'+H"?RH4LBC9>I2[W^\:'(/(-:&PA\\]V I:V[#93QR!W:&
MT7+X.ZPN9ISC9M!VAM^(<= YKLDXU14;WX,>R&,$CM"/4$#Q\UTA>^W3K*K0
M]P6F4]B[$R58Y#$0;9GGY_*957R!B'X2Y\240>%)_HDGD,54A+F?-#K!KR--
M2U'?=L/U_ (QC1E14G#.T;LLQ]-EA:]48'P B*,_TC<OV1VH 0O?@CL"BN;?
M4?;[%/[,ZL6+R^7N*)X6AWH&Z7^7#-1!2D)C\W!L6T9:J$XL;X8)498O0N4D
M=/%E7\2CD?YPG7SE[@F4,D1R:7J>9V3N19( <7-]]RY1$-';["&D0(V3FI,8
M',=Q!B:%[O#=4K&)>%OT?M1_8 N>26IKO,L_+N\OV82C4]_&<&;H@?8#2&#K
MSWZLU>"\/U !*%L[1/5!1-X>Y3#">)C6??)]?.+#=Z&04CJNY?N46R"7I+-M
MQ[I.V7?Q)Z=H:4CS&6/$++I42LD#S(HO1D+[8>KZZ;]*5!(C!I]!$06;AFX(
MY!4JD>+R\4U$6.XXT"T4/+KO.H0-NN^'GACJ/79#G)/(J=5#H5:."#SQ.'D^
M8U4<<2-Z1(O7D F08"4 VX7_33S8B0B[QSCMT_C$-$6@?-0P<BG&Q<&AN/,(
M/(/^*(^%ZKH$H-33*5:,"8XR@,Q<(-'4">*ACC0Z;JY[],WD'I[Y$FE*8,&;
M*,<FSI*DU-4-W\;& %,\86PIA-X<KQ 6D5PNRO/(,CJ150J6%H;6BICI-H<F
M)(,?T9)ZYC&+=5SFA\8T>KVBYXT=-BD2EFG$$CGEH%:#FR& 6)C'.*I52$G+
M_^87TDYTT?GJ[$JZTM)DO[@%Y Y"TII"JB *TE8NV3U>?^KA^#C\.P#2H1@T
MLGT68"H&IG;#5OB396)&4"J1.#WQ%+>"VKKM^G+-PF,)-4! 4K=]-_5^G!%(
M-9>Q(K]L!H<HZO%UZ<FPR;36F6YR+!!(U X-]?UG;MOXWX57(/E0+KKP/.AI
M+T+^WO]$5=ZV^)-DP0E# 8@BC##W)L5NQ[$:FO*!**+;]+4_^3_17,EP)@/$
MQ9&\M\G+VNW+UG#^_>SOGSY]R<0_%<#7!@<4L/?OLL81UB)O+T_H$WL!!N*C
MSX%\"HI_;/K:W]S0#]#I_ #";;O2B%..$":3?#L=D7F)M5-\GJBU0EV-%54O
MY0;-\]J1P$XJ5;BH5%E^LMTF*D@/E<8,4S0;?M>E#Z[=E5O:Y#950M2I(O''
M-X/^421$'2B?L-:3=U=2>Q/3QFJ5/#:H3_)8;>,+O]]]?OAPSZZ_WOQV^_N'
M]_CCS?_\<7M_^W![]YG=W'W]LE9+4\ M#-Y<?[K^?/.!W?_VX</# <&X3;E^
M'>%8$.-4>/E*>)[+<+\9%5]S+C7<BTK&%%<^6'@?(X6%\K/#+6TY4_AU$X1'
MPVTVN6HB7*=X;-N.+VC4MU5OSVI[>]:1/UZ#,1_X/^=:796WC]P"0X]A;35!
MH=Y=<6^$+*18X )-*&IH$C4<K;3IUH]F='^Z;T+97]?AMC:X&F@]'*VC)NF<
M#$Y_\?A<M\QH-IE?#_RN; 1+9SC06E?=IJ"X8N[[<T:%7*334W;=LP>W[AT[
M-?2TT7"HNK2?VI"3$SFFTD..UI-#,UTB?ZZT80_CUMDSQVYK5\.AUALT1DE7
M&LQ>S5-*9?I=][YQ$3=)%=!,N4V93 ]>Z =1]="1DTNOW=)&K:[6:^^'8)2:
M4R/Y?R+'5&K.D:LYU[53;_97GOU#]MCECUK;VTEZ[8XV'($X&G9*/-,^3Y"7
M\ZN$85/F4IW*.95A<^)"\Y.E4_>&J&G ?4[C*M&17F6"-#SV?>34M=],$#NA
M&Y4.TEB2.%JQ5#]_FW2A8?N.%W2VU<,VJR(UI-,::JW.55-\S@J[R\%N+^2G
MDQC2:VF]5J<I**[8_-X)P7(,=\99H'\_<E)H#[1A2S'[4\+QC]AS;6KYA-[U
MTF<J0_/12.N/]I,)J#RA-8J7G<@QE29RXG[0;(Y4RKM3ITAB9=R]W^]HPTYC
M$KV/G#[VU4_ LYYT&G;_K'N>GD+[ER-']]Z5UKH::IUNJRD8K^3&'NE"CD:)
M2QO$6-VHA_:Q^W;:/:T[[&OM[DAI^Z>F!I_(,>NBI^2#M4DLN;ZJ_*%5^.V9
M3QXS'O2T5J</VHK*R#Z]Y*Q3.:=2HD^<8]. FD".*'%,ZJX)7^2.<3 '3 WS
M8!J:8W/D]+0G"K%UWQ<7=DVVJ"MGC&KLA]9EJ]5JXU@<AA,Q^%O6%29<?SAB
M_E3'&1Y^./Y+3J6:NV#&$M/G)I_1W#NF!^R'-JZ#,TC$=X[<RNWVNMJPW\<B
M@[UJ5L$2/40H1B/G=F(-(--@:\ZO9[VS,A=7$OGT)+)* U?RN)G4M+=&4-)+
M7"R%VQI\@O^/A+ >!E/7@[<"XW-<!R=A^*&<@.6&032C[L@EKVRW7-EFE;@Z
M!@+;3N'M"4(K(K8!->OK]/K1'_,)CYWS[SB^#G_<5H6^.'*J'0P;$RM5]%<N
M_;W;A/Y6D5^[I74&0^VJ/UA-?T=.0J /=/;3/TZ)NE>1VK5I6LC+=3L[GB?G
M'K:F)VP;"L>6R&WH<RO0[>-%];XV'':T0:<Q)2+'A<F'*_X(9SB5'GB[R2>6
M81U[RZQSD&W#(>B*[=VS92Y4A+9A>20G<DRE<YRX-UADU/@Y/F%./N'3R)&7
M)H[*Q#DY!G@BQU2Z]I%S\,V;/=6)HZO^B:I_8K)Y)3";D-)Y*N?,$9GP+_8#
MR)[0L+GN :8'T[<S_7NTPQ:E [UF:N]ZZ?O:T<?T<PR[K05-P7KH[;2,'+DT
MY4PW#'<VUYT7C+LY;H#"R8./'6;!R1\]$%QSW0MP['HPY3YG$\O1'<,BDT0/
M..6-KAW0G0+0:%,=H'!D[^@U,C@/DZJ[\RW.M*>N&6\& [9 1YG_%# $4KT6
M#X*?I?3+,9^X'NJ7]K/^XJ=H:AH+B<P XXA#=''/*5=#N]_56/3/Q=NSG]9>
MT0(GBP807_8MN*#T\ZA'QN?PQ.O%T.6,HDD?Y2F_JS"C NTWHW"+4<OYM[:2
MTMK=R\X(89RYT,O!,.=.Y<=OTZH!(]T 7JVSJ<<GOY[]#336LPQ<LGM\H#D.
MP"DPA1SYPB\_Z6EB.^Q]6B9 QW+:@]Y@U/I/>WAVP!MNB.'R^]WGAP_W[/KK
MS6^WOW]XCS_>_,\?M_>W#[=WG]G-W=<O:SF_ FYAEN?#]<.'WS]\?F!W']G=
MEP]?KQ&J]P<$Z#::2ATA^M'U4$EA7[AGN2;[B"/R_AG:+T+V#S36:75:[/S6
M,;A(&V(/4\\-'Z?L/3?X;,P]\62W+1]5N/W*FSC_RDD[-&6^X3WG[#,HEZQS
ML86JF,''U^F*8HD2E$4T.$B\&=RVY[J)*3._GK7.Z'>Y,/V>4:+H!5(R"1-*
M?");W9#R ]9^6CO:X9:DD0:KVOK<AX^CG^(_92!P5FS)MW(L^4@:#[?9Y%F>
MUT.NU(&%2G /Y+R@4=]6,;UCR+[X!W<X&LOHV=7-F>58?N")!C_U:DM;1=/E
M+N!2ISGI=0KART@WRD=R*? ]+A*1T'=T[ VM.B.M->@W!?F53-B?/9)I52LI
MY,B)88^M:D]3$FS3D;F.IN$GU_?%]'IWSE%X+#1U.UK*.._U<8C][H)BHU15
M)2F:)"GN@BGWV"VU[5<3C51U]RG3PLU4=QXYCO^>Z)8L<L.@DGFZ+7//NZ!4
M#;71U>YEH$IX'!W!?!09&=0GUP\B"_R4R66@C3!;O-,<74L10@F$<(LA..X'
MC.N>PTWF.KCC;UP$;GQNA)Y(OYUR&X<DL0<OA*?E<+PC)XKAE=8?[*>KM!(?
M3:*:/QR OXW- MBC#D2AJ"93=S1H*V^6\F85$<]G#FH5>K1$$B0Z>NLUM::*
M<!_57?>'VJ"$T7O*'CDZ@7(;3Y\\D9B'FD*II,1&4N(D!,,^&W(HP7"\5;-_
MTIZP41D &VXO:E^6[AGH3C+MT=)M I/N@!I<L6\9E)IE6G8(:]:)$"OLLJUU
M1P.MWVN,U:^H;.]4]FZ1-)@#PDH.$(_[T6L;D%F=:*H*X:9:YRKJJX&,.U5I
MUNYJW4Y/:^]I&)>29DVDIWQI1@ZZ EE6)]JIQ"1K78YVIY@<8TQU6LA93W5:
M4)T6W@R&JM."ZK2@.BU$G19&JM."ZK10FTX+-[]=?_X'P/?V,[M_N+OYUV]W
MG]Y_^'H?=^ #J#_\_ZH)P^OEGVK"4).;4$T8CK8)0[?WX]M5K17:Q:T5,E_;
MY&>UM%JZ\.==W&>CS;QGGOLL!JMV8[HN<EY(EI#HVO/@-2[)39>)1[ZV>VNW
M)FE?_)IVPB?M,[./1/>4XBGR+])U04VK,SZ?6+??7Z/8&^%*NU]VI94.[0KP
M(+[ SMDVRQ_I7283F'X9>S]EOES*%*8O.(7I-B=.N/2ZBG$V/?]I&5TKP#.%
MNE6C;C+[B)#I_?+\(W7%S;YB:J)_0*Z1TZ[_@+O)&Q10$3+N0<4KFV &ITHD
MZ<&]%:MCZL[*O[-WE=U9 XFX<ZH(<4\Y0 TCWY.]K>O98AFDNJWZWI:BK2;=
M5L6TI3)N3S%#T-8=@\N0& 8F61R3M.*89"E9@3MGW>V/T(KF?96:BKC/X^2D
MZI=VMJ9<3 /Q\'AF "H4;"@**E9XA!?30#Q4K+!^=Z)04*&@0D&%@@H%%0HJ
M%*PA"AZPFC=&\,:ZZ_;4'<SW0_3 4?52*O29[3 1N,QRK$ 4/R:)%X?VR%56
MW5YU<XF*H+0QWIS.VJ_YQN$9YR;[/*SP:K>U/C;U;K6.3&8II#H@4FGMOL(G
MA4]E[;S3U48*H92&I<ANOV37/T*]H/;9*<VW>.N8H'*OB\X>(9B_/HY;B.S@
M>3BV+0/^-.$>K*0QN,"26@HK?E3NSGMMK35L:Z-.]\AXDD*J R*5UFX-%3XI
MU5)!22G@->--W5%+ZW<&6K>K))ZB/45[>Z>];DOK]90%K**Y>[96[Z0U*D;/
MJO!LK?BG@I*"DH*2TECJIK&<=]HXG%OK]MH-U5@NE+F@B$\17\V(3T7,3C)B
M=E,PFFSN^KZ%W8)+GE&F.%+)' D'%0[[6G\X.C:.I-#JD&BE];I-#9@I!;.&
M"J:"DN).)0J]KC;L=T /;VK(3/$H17W-IKZ^-APU-6AV""OXZ.S;CZXWX580
M>ISM[^:BPL?TU>450:HX6DUXJH*2DCRE29ZVUNEVM%:O=VQR1V'5(;&JL:GF
M"I]JB$_-12=ED]9/,S@V**DXXTG&&3_S@-G[+[D[-NI14%)04E!24#H-*#5%
M]SVT_=K2AL.>UFVK%!"%5@JM7A_ED0KN?'ET?-$1:]8++V.R;&1DR/E%]! <
M7(PN6IA^M-[LV/8>ER]F*RO@.(ZI,$)AA,((A1$*(Q1&*(Q0&*$P0F&$P@B%
M$95CQ &3' ,UE+7:H:SON<%G8^ZQ;EM,9JU'P*T9#K<:CIT9:(.K@=;I]1OJ
M@ZM%2LG^CGL\\XX&PZ8F]Y\8RAT9PVNWM,Y@J%WU!PK]FG#<X^%XV-JCJ27/
M"NF:BG1];3CL:(-.1V%>$XY[/)AWQ/%]A7LUQST:.0/_;VH7+958TD@OZ(D<
M4V&$P@B%$0HC%$8HC% 8H3!"883""(41"B/VE%@"_^ICFV</:-A<]\":#J9O
M9_KW:(=XK+-XU=3C*>\$,[@#&UXPB5?EJ(P6$T':G0*0YMC]]',,NJVS,0K6
MLP(XC+'\^,.4,]TPW-E<=UYP%(SC!G NW8./<7IIP!\]'%^J>P'.-0VFW.=L
M8CFZ8^!84S_0 SX#^/B7+"_18VDS^? IPKB\XR0KE(%(95WYYLD_!\O3^?AF
M,&(+9)3Y3P$[H/RDQ8/@9ZDDK#&?N!XF8=G/^HN?(JEI[(=ZMLQ@BGMO_?B6
M10RBBWM.M4IH][L:B_ZY>'OVT]HK6N!C\BVCR[X%%Y1^'I.MXG-XXO5Z&+@+
MV5CT45Z&V"K,J"!%+).5UB+'7?ZMK:2T=O>R,T(89R[T<C#,N5/Y\=NT]Y&1
M^Q%>K;.IQR>_GOTM<(VS#%RR>WQ SHN<X@960;[PRT]ZFM@.>Y^6"="QG/:@
M-QBU_M.^.CO@#3<DN^_WN\\/'^[9]=>;WVY___ >?[SYGS]N[V\?;N\^LYN[
MKU_6<GX%W"+@WC]</WSX_</G!W;WD=U<W__&/GZZ^_-^;P#=25&I%J"ODO ?
M70]5%/:%>Y9KLH^>.V/_#.T7(?D'(B&5G=\Z!J>)$A?L8>JYX>.416FKXLDH
M=_5P%U$;Q'[5/9Q_Y:09FC(I^)YS]AD42]:YV$)-'.RL)@XJ4!/31-_9>8=B
MB1*VB,80R5Z#V_9<-TU8Z->SUAG]+A>FWS,:'KU BDUAW8E/C-#S )]),WO+
M,JK;#NQ1VH^PJJW/??@X^BG^4P8"9\61S-2?S4558? CZ4I+AK#\>Q?.4-R7
M(658KOZY]FW$1*7#_D+2-[H_91]M]]EG$^2[=W/NZ0&:E-=&8#U9@<7]GW=+
ME=C8E8-GKR2"7<N%53E-O<?LYK6>>T4-3$GI0C]4D+B32>7:<7\7>T+M,KFL
M(H"5!'!M_A7Z ;D)<;2;QPW7,2S051R@C',DC0MF.88[X_AG_-! 81+ZW(3/
MF1M+$CU?DNR#F"K,AZKCVDJFU)ND;J:Z\\B1.B:ZY;$GW0[)[?:L>Y[N@+RQ
M]+%E$ZG40^Q4UEFPJ_5'0VUTU2IUBTKP' .5?!2!*I <ANL'TAD!=J;U!/+D
MB9\@M0RT$28^=_I-H19%!R70P2VZ)KD?,*Y[#BA5KH,[_L:%Q\CG1N@1\K,I
MMTGE>O! 80/#W0 N%1PY29P/K[3^0!DNBFZ6Z.8/!^!OPP(F>]31$E%TDZ*;
MOC9H=QM#-HH@2C,[_ 6KW/<Y6/:Z8Z85*66A-]9"/UH)TZT=07WQ^%RW3,:_
MS[GC'[WY<=X9@/5QI:3&22&YU(=\ /,+:DY'CN2=UA L[*NF6-B*V^^3$+R0
MGPRW;P];6J_5:0HA*!0O$<6C>)[^_=B1?* -6XK9*TI8"CYXNF-,+9^(X$14
MG]%(ZX]VU^XW(89:MC11Q89'?4REB93"?^M8BO%YDZRCO-SUH^/AYYW>2+OJ
M]_;CHU%LO$;\[42.J93M$Q]9L%BK<.L\<7^A5N$PO+Z&@::&!K&.G*SV2"@F
MG[L^"/C3RW#H85U#>Z1UNKMGEZKT(&5A9"T,*Y8ZIV9A[)VNE)51(_7[1(ZI
M%)V3L1^2.H/"6F=E0#3-@#A:1:I^9L87SS4X-R4U80NZ*%XFZD5M["5"3>A>
MCEPUZM!8@L;4LBGL+P'[OW) =JR.Q@+.4T;^\[*P7]G:1T<DL8CPN,&M)Z (
MDA66 \H6-B@-Q[9E  %-N ?K:0QNI2X=-RJCES+-:"4P&D\+<ZIK!NEAP]6B
M/#ER],=)G>V>UAT,FH+]2E[LC4;NI"2@RG^L/+#,(R>'\Y$VO!IJ5\/FE#(K
M3"_%?+!FX]#S>61"N%G4)]D '(=[SQY<MG?L6E&_<Z6U^D,E$U2\KIQXW=QS
MG^#"3#9^B48?G%[,KM?N:(-!5QL,]],Z1D7L:A3*.I%C*B/X:"-VR,PMQX#+
M\*EK'C+VD^#;;6UP-=!Z5VVE#RD2VCGH+5OHC3D<RT$M2,R$8G,:N' 2!"5!
M4-EFE4+4 $WA1(ZI%*)3X.;<,>O+Q_<WP.*'UPVGV%AP[.\D*9VOM!,I(=4X
M[GTBQU2&R8F+LOMP/K<I^J';#/YJV*X?>EQD4SGDPBT8'*'2<IN7EGOD!+:G
MWC2N-^%6(*GDQM9]G[UCACN;N0YLQS6^U4/[JV)84;NSGP8U2N0TJ5M33KX(
MQOONYZ[CNQZZC/EW0PQ=F>#OOA_JCG&"Y'.E\M-/C#06>Q0KXEC5#+!!U*'$
MRZ'$B^48=FB*,G"]EDUAJZ".856U3? OULMDD="PN>Z!I1I,W\[T[Q$FX.V=
MO6J6]WI"2R/J-I/4Z><81[?&K8+U+#"'+6/Y\8<I1YQS9W/=>4&4Q)(CG^E@
M"^C8E"#@CQY65.A>(-W"/H_RGN!S&NQ-LQPOMYCEO<N \QT&D>=YCJJ[\RW.
MM"<S[\W@BBWPD\Q_"OQ_Q+$7#X*?I43)F(.H1U%B/^LO?HJFIK&<RLP-CSAQ
M%_><DC;M?E=CT3\@;7Y:>T4+PB::^WW9M^""TL^C,(C/X8G7BUGG&6E!'YWE
MH&Z%XBHC(<4T\_P;6CV OGO9&2$\,Y=W.1CFW)_\^&W:C<?(CP>OUMG4XY-?
MS_X&ZME9KA07>WR@LD14ZV 5Y &__*2G">NP=V>9 !W+:0]Z@U'K/YUDV'W%
MM]D0/^EG+"UMRZ#?>^X;GC4/+%#*X3[OO$?=L?Y7Q]\U]B[TX2N@M\LA[J#F
MTWB?=[IO^?@XF 0^^EOIZVND0 :->C_NQ&$'=>.POR,=^.S:,Z;P!A-_-/X;
M6KY%D+EQO;G&SC&RBF#OM-[>"+%+O[7?7H"IQ'0VMG7G&S.FW/C&I%RF_NG>
MW/5TV7?K/;?U9Y31L.P_0_M%2+8!Z.BM3NN2H5"7:[-GW4<S;(9U86"-45PW
MA+5\HEP.FJ@AN@ZQ&?<>N:<Q0Y^CMB"LL]B6T\1D)U 6XA-I\A%8#Y[QX1&/
MNRG48? ^WP+ ZQX;1T@$1QJ#^D!_?[:"*1R!XX,SD!_Q4P"Y-)QB#+Q)OAP!
M+7M:A"#8GW@4/!28,\_PB@B,@+5X#.:'QE0C4*2^YX?COP 66&:MVW84 _<L
M_YN/1W=!WT'HTY[S7V#Q!2VH,LQ?H4]>$TF^YP:?C;DG$*/;%IB1/?-4-U';
M(V.<@X%N,OS4C8G\DET#'&2PY"7!'LH*$(4D2[C'S@%5.3&2"W@:K,G':<%F
M9#$[#0%/;8LXTO"M0%J!)LAL\(F"\MX,JMS*9[Z(9R)+*R8QDSC=&//WN>T^
M:_'B/M@'QI1.J;, ( NX3NX+,M#$HGEXN$!M%H ,@?K('80C3\,4MNKQ)^Z$
M<.C0"2P [@3X"[T>,0C8C63 ZUX*VP[H:[!I&] NR-E%O(.,B,VQH;9F<X[K
MO(F/)#%=3G@ WH3;PKNC<T2C1N6?79%K2T"G'S@PDR?=IF'PA%&$85%%*PWG
MC0I:\2\%MTOK4:'K<E="=J[C0J )1'>^P#*FR!"X#:0/#RRB*G(+O(R)Y8-%
MREX WHP[YF6>*K8G C^0;'O((5$_<OGY[ L@ U:<W?\W1+ET(V7(IT\W&?*4
M3L(L\_;XH^4'@NLD%F7,<!;?6H0$SW31!D@;])\(P?9$.'=G!&Y\J;&4O%OX
MPU4>DS1@O^%L)@1O4/QR0/8>.33P_T#=^&SZX'_@)S$7 NK]H=VZA">!C!C^
M38OH54H5H/>8#&#M'WHM>%SL$V[;%CS H<DJH2=WD'$JP9?T.2SQW<+-VR_L
MAT[GLIU9@9T[G*QZ;TW1(&Z@WQ%'BVDQ741XH0DGED\ AZ?;O87=(ET"%7(/
M+R?^JGC%;&;Y/JF5YZ25#B1>I-\ >@CW# N;)>++W2? 71#3;B"V+%17> <Y
M*A P\.MG>"HAYG9'RIU(74%YQW33)%T&KK2MM89M;=3ITH5DK^\.WW<=OR]S
MFVNN;N$6X-J'A?>(>THVM/9&^T/R,..Y,R"=<%2@-K_<Q2WVBF\ZVFQRUPM?
M[@[[T9[R[QLW=[$"N EO.+0J=:@,%FL6VH'N<#?T[1>A<)**8+M^*LN^@!,5
MLR\A6A>Z0K!S>0E?Y%^^1'^)F16\KYVP-C [/!W%]3G748O66=$"[$_QJ%Q(
M"'W7M@5?ME_$3M=].\,T=3R (5E,Q#X+OQIIEE+H9.@TPUS;B[Q5,J(^(.&&
MMW&WP)"*N,_JZ_$Y?&(NKKUT0#2T?-@5/B,UKHBI$44"6WM\!*F*7Y*_)UQ%
M=,GH%X/-QVA>$=P6^%M6=\\3.H*9')Z8_X##;$U&6<Z4& LY-[)P[MX2GV?G
M"R+_(MH",NHT/A(FZ,*UAC\+<20O>I4*7(0OR<W*19:?> 8]/:5"@PE$2K0>
M*=&23#.J=4R9MFM$GHEHO_#;?4#F'5$,>@B!NU%2WCTY#1Y@0_XD(H__H\_
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MIP")7%)DZ1"P,!$7]JF4V5SIY&N!N(4+GRRW>T?Y\E'*O0L&ITM4DNJ/"DS
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M.Y/\],CY:'N@#5MJ!IIRE=0&?92OI-8&PHD<4UG&"B,41BB,4+Z2(]'L/_.
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M7$R=\)U2Q2":PV3 H][8;G59:TRIZA34M;>G%;6:B-99S,.V<N-\_2R8$G>
M-_<&I3=7EHD67IT%BE7405)Y 0*H=*Y97)H]-A'9VCQ';-7Z*BB?I6?7^DCB
MT,?L#V_)\_,XEY@6'"V8\H6M44"F*!^*U9R9(4&BP,$SSC1.J=41H.=QIG"D
MW>KTLESKY9K7E8E/>*NR5-AF[BT+5'7G95:DJCALD0MC@P&P2L:*DQ9*7$LA
MH.[H08-AOT/KWTDE>4Y*5@%G,MA79S-1.C\6($N& )01<.&U\+U;3V7G%/.N
M'B3-^DKC"@UC)8KG#V\0V8O@)!RO+*I^%,*O]HV5:\$)]EPI0'!$\#^D2YC@
MYZL&/SLF^&E*;/>^Q'8D/5#O\SQ3E;7Y>YYG>M#M9(K=&3C$1+'$&Z%5DY'8
ME"FM08HR@4(WLF+P<PA**$>9<ZUK*9E2]U+$8NY$!<^T[#T3R$AF5>L(N116
MI@B9PEG]*E*92\F27 J4\,:/G.,'L^]JXGJXPZ.;8]"UV+.MZ=_K&1[O4(+?
M>6,VV+&=!J9QBF4]G+SM0=ZSJL9JUV)15[F[Y=Q-..U+U:]4UL"M]$Z5/5/W
MNA_*44VR\#3D#4EE8AF]D+2:&:9&.W>.Y].B^#6]WA8]0LIY@RF76''E33RL
M(\1D-1P$Q; MG#L_;>[I(:7G!I/6XQ\+&Z[Y/M.."$S<BP:#T++^./<%64?P
MU:R"+A)Z4FR8@R"A6I\\S%J1?)MOS/4B-YUA-2'&'! X?"QI=JE,]\PXPFP&
M1Y8.$'9Z6F744E<Q "=63<+NN!W9&A@BTW^'[61JW2BDQI(N#?>+N/M@=9ZG
M]NA@7%;&D?/Q7>7\90D=Z6K[EC\'W\K#S%,ABR8H,(W&^.,*]+ .O)#I01Y3
MM6KV'LD@M.XV$D 2ULL9#AD>((_23LE%86A'6UZI^AT10IGL"LMQMXSE6KFQ
MOR!79TZZ%+;"Q'V&&=:F@<(-+(268X36'D=L/UC[\KH(<DP14,#>!N-#!@VO
M2> T+>NW\!YN/JH/D5)*#6;E([M PPU%)-TB9SP!/PA"Z85AT01? 5R]AP\6
M!4*-GT:IQ:V1<$PE$E,59^1RU3BV#@@96X&7A!&7A* +._<B7UU>$#FMS72V
M*7W(HO8",F#7D$1AO-X.\@+G[&VR= 35GTBQ##%FYK+6R9]]7HG6.;PWR\WM
M3!XI*4@9>0P*$M>([;*D)!(DTM>X?4KR2V56=E8[G/'B DX22J%<$Z6;??@]
M=@ZWHG"6DJ8HHU5@!]=VW3 :4XXDH?@51TVDIP/T0_[IZ.PX2W4L*E?D1^*Z
M7M955A=D[#\;OB\HX1F;4-=37^#&4EJKTYK@?6,#@4<KYZ@-R 08(BI-5,.?
MM+P6(N"L4T!1<(.5$NL.PG4X![X8%D\6)P"1'^@<+LISE:<;.5XL:ROF(0?O
M*F-VCU''J/$M[UM!.=((I_"'B4740'+F[9D*MJQ1I'B4M\M9ZTU QS="S]2#
M@]Z&F'/CX$)%A0LQP,[57JDGNUG9[")_,6<U%^L593E;EIP<<W,?3(9-G!]<
MC(N!)QD$P?5*G2UJBN3HK?JR*-PS5<S&HX91EE:HML<M&G,-N:)%3?$X'O+<
M\7./19$868^&8"L=,5Q1AQW#;@,5=/=D2F:V%M:WTAVGW 0(C96LET_9@<U&
M7A;UCD1VRN*5'Y?!74$(!2@=%RN.Q#WH+1_9H_ 5,2YO['0$BQ>C="7'.1F5
MA<5CK9?/+(P$$\@P[^G#F6U,XME"JGTJUR*Q?*2FJIG)F^6^IMSS9RWKBK%_
MK&79/[)[2MY^57$_;(%+2/D?C>/=A7XZ$R=+@YE4EY$UNJ1("8^K%=N3*($/
M@CHB/4R>JO"(HAX^[N*A_A\>52^L.C?=*6V;-5^)+)^<Z = Y%]8UJ[0!+&:
M+=,2&[2+63D9$)(E$0?\+6O_<B2/$0B'< '=O<>2"9*ERKVV!AE"30'H3*?X
MF[[#+ US&<?M[&]LZ]*O;SNGQ;XTFM!+P$"]I<XCE/Z8&^4O8HZ?YN8X[?3E
MK/^G7E ;*!YWVCEM/_>F9(X0-48[:+UPC3+[Y;*"HE_7EK77N8]T/5'V'/NK
M_@W'O&\3WFQP>+-KPIN[7=NY3_C(A4N90LVV S>,X$L@?R^SHHTTAE""2?I7
MY/MK_=T;[1MRP*-[UE5KUC"WZ]2IUD''JK^0\5\1RM%BO54%NXCW]+'>?S5;
M8W7['33JO& I[_L!%>&O:ZD'PV>K!\,-J0<XN8LX@RM\?X[.K^#V[V_:;^AW
MN3#]+K? D\?H!<K]3L(--6]-^CT#-^1L,UC5=^8Q?*Q^ROY4..^;TD"[M8=8
MROT._J(!9FEFFWRH!T>J&B&NSR@DF8=+@2$R7+%6IV:M%;M8\]6UXIO%\9;3
M@]:8-_>"' ,IES))N% X4:V/WY7UPRT,JS,T;FC<T/CV:;S4RZ#=DJ, I( W
MI&Y(W9#Z?I Z>>H<"[L#S-(9DKLTE65ZG(PIJ'8@59EI[(HV+,&P!,,2-LH2
MO(F=IV_C+YQQ_93A"P^-/'C9@0="QFYE!'/J1>-5<<RZ00:QP*9<%(.J2IB5
MWR\G8^E![V]8J48IS,509IVSZ*5G5>2=+C?,4%\H2)8E=%("BA=3!DI%#B5G
MF69.I<R1E :47+.YG/U-Y [F6UDS;7_=9,E";K_LET.Y*=,M],T&^@12DZBA
M40V3:,LZ5SE">3H@]2R3KN^JE$ 5*N;L?<I!HZ_(AH)Z&H#F+M0GELK^1Z5<
M@0DEH6'?>/F-&\&UE;*6YN'I'\9%_E07>=NXR+?B(C>><:,W&[UYKTQIXQDW
M-&YH?+]IW$G0'=XIM/:U-N!#RRN8*2%/V:I9TJ4L>WQ,]6QF1&MO0<XD.[[P
MB\J5YWI]P0UJ,<H^YC93J@Z/4UX<.:$4]1.]4-5)\D1.:2+0%*P99WK>::9V
M5@KTL'EDW(R&E1I6NC^LM-*[67+(U9JDCW7$P1$Q)1HK3&3;R:Q0A9JOX=_C
MIXV3-7S)\"7#E_:)+U5R(IS E1=Z/BD:L$4F].#4QADVK016BJ/+ DE^W)((
ML,.7F]:+>UFMBYV9ZD;Y&(^5(S78K,<*=X9:T.@TI:866H#<9Z4@G#)=\)HM
M%:\4]N#<A'=+4^1W,U[RBD5%:RCJ]9YC( (P5&9"3A:JJX-<,U")2W1*@4IO
M-A-CC]LC3H"MT]20FOA@I8&%PSRU]I!:8VV%>M1[,FL?PHVQBF[?0@>LRCIS
MK]#,9B*<!#L+X:'R(MAVJS?LK!40THW,H\J9M<<'6PA7>5?9J$%MBA7 "ZMW
M*1\]AI>0@VZ1S^7YN*+-T+,FZ68<6BVMNB6(."MA7M%:V*["43U<RF:\'$9-
MH3I>L2)\H/D*<-)JE$%L45AGC(%5[R9EY%5-V,K]L@!;15*:1%4YCBOKO5 >
M%Y13W#DU#8$+]V6/J.R@W"2J/&78E @VM23KP\EISY0(F@ZHF\+:QG9 /94=
M4*]01$L6K1R]E]S.HG'A\F=G(31Y<@3I3W5S(G88"OMTEL?=J%*&+U@9)DJ3
M5%=WS]=%%0YXV#2,@&9(_^,V2GT>"$FMU=?1ON4DU[D3L26D:B':LAJ"UEAC
MZ"%J,/B??L=NCSKV:;>W7@.LW #&_#G5@:'7M[%7_F!TNM8JFM4P#^.8.O;K
M.9(8!*+=N;@$=U5%"QP>"",G6J@./6I.A^LRD'$K-XY/?8CBJ1!)91+6*Y@@
M>TT8AM4U_RQ/876_;IS5K>9TOSZ)TWT)K'^F_D(.8NEELROJIUCSV! *'*O.
M8;ATE^=;3+01U]GL+=C4C9@Z_J0T]9I:>_]TITYPRPZ5K T:/-=AIKCF>6VM
M&9I\/&^PYB^R'@Q1/DE:GH=@4)A',]0GJZA39[W<8(&N?;K^SLJ]W_"< ;EL
MT<J.9'M1[FO-[>K@VL8XZ]/)<Y5USVG]F\B\7X8;-=7*9B>K=O3G?M:TD7*>
MXSAT/>Y=IR8D87=*FB4<B20*'=FG"?>:R-'CF$W@DRQ2[6MS0 %@Y80[>PE=
M>*1=>5,/P)$Z!=,;,OD'P)P(+Y&MO@ONHD6A 4BL:?:55Z"^KS<@Q-_U437*
M) A+LWDR;R2UH,W& >"<G12@S'W[,&W,QB8BV=)YHD:I"R&W^:1^6]V\Q5;9
M9R,G!5"\54./')0%Z.5=4FI'?5V7CDM;YM['^:'8\U0-@15#BI3?C.??4*5(
M<0GV"V'/M?Q=2^OA2C1YMD NY'C+$0%YA]WM=>UVOU^-3HH"5FIYG;;='8[L
ML\%P/7Z+"E<A+1CY$6!9SHV6D;8I"M8+VMNZB<WN?/06+@V^# ,,.21:H0!S
M%_90!M3O?>8DA*;<GPZ?IC\!Y>O4CBW(L[>%Z:I^>=2YN_;A)0$+6Z M)N&M
M0)M -OU$SZ?4O<L[!23(QR8X_&WYH@*#RL-RF<L;3N4[]Z\?&K@N5MQ4 06=
M33A0VR76P:-6$V[#NL(TDG3L17%2;-A=# T]ML<3EKT3AY?]6I>9[^.[KA>G
MQ^(%US)PNV(0(R7M;;[ZQXE/)*S%6.('90W:NA").9FQ,#R#V[8^'B 5PD>"
MIWQ%M:,&YWX:ZTV M1TZF]DAC97$;O3:!_6W&16JQ%"/J&U8C;'U/.)?\2:[
MW$"L(KK(J@&7EN4ZR.-P7)\%3"64S^S$K0=$)]S/3.*5QS'2)'S$!=#4&>;0
MZ@/*.\523]\7D:*/!SNUX5=6)$/(2RAUAUYWV+.-F;Z(BC<:UN7X)O%64K>:
M;X#WJ_ZB<^^:;N6K1QA7QC[743P*_'6=>U$LL=3H'"4N"]ZF:"5[[23X&JF)
MFAOR#W0JW /S["722,[= 4N^ -V"'@MJNRCSE$!-8=X"/([T'#77'#Z89^GD
M&$16H]:UC',..>-P#"1-_+?(%3-SYB9T0 ^$38]!WP%S/'I00]?\L$%8?VJ-
M/VNBJK[ U$2<7S7BW#<1YSUJ2GO8<>4SR=8_8 8>YYQ^$DX,EC\J+X<]4O.:
MO#:9:4<X+:=+H HU03',RM^-:IA0D[64.09G#-LQJCB4]"@]WP%-H<(,60YQ
M42N#%:)%3JP8@P6;)7;ERTT]$3F1.UTHY1P_EOJ[<*>!]V<J8FMI4&6:>+Z2
MV)E\E#E>V>+K94,5]*>G"2=>XA5*!GB37#+ #*7Q103:>MJ?ETH'1H_9)$J?
MNIJ 845- %_J<U^PN]\VH#&@6>O;7!^P3+_K2$W2V-<N&:H#=J4S3W+&7-V;
M+]7H/(G!K6VF*$ZG;<"*0]\;DTX+UA3^[_B=I7@^2^03Y.)K%_-L5P][DCWU
MGDI**#Q5I6P]7%VE;K7Z ED@+I=J@8"!+09_?]-]\]#"A7LYT>R,_$Z*CRBI
MN'2IRH-!UUHH"<NT_Y=SK_QW2O$8FO,3_^TF^@5[:9Q3")E^XQ%!Q<07_/SE
M=GCTN[@3OM4Y+B+&1C#"(-;6KNT*WNM-X,!!8GU!%Q"AS9>;6$1WR+(89A^#
M>=H$[.H:[-I5[&+P,(J]'AY]#\*&HG9O>ZC]'"6.3;Y:+0[,?_?';83Q6AUK
MN^T^V/Z]4_C/8'#\H*[')=KUSIH3<DANN\:ZX(JC-S9"47N:/^B<G#E_?9:6
M5L_9'D#)YQDI>["J@9R!W"97W2('-[SYQ7GS!19:HU.<K3;R]VHMF56]<Z%4
M&!<VS-RPI)U:U4#NA9FY4<=?C(E_;UVU@$53C'2A)_S-L*.)'-YP/H\\G['_
ME(*AG9?FWE7N\S?_^^TS5]#="I3. &OV.VW[M-VS.]WNL_?WV&/N 'CT#<H\
MAHWN>2]!METP&:VZV2P6]>3]Y9?=T[-=)_J-+/,:E&]@]7PN*2F[(H5G)VR,
M-_7IKP\%_3GQ=/ZS,N+_, ?=1!+SP1WSY<BW(5;B[E'4+IUQ3ZWVAB'$RQN?
M_4YGUQ6%7;2D#)B,*O5T':,'.L8X3*GQUC[K4HTYIU&F&D]3NW3&1BE3>^YY
M:V(\^W>/AQ=XPB0<&3:S8ZL:R#V&01^XIMH4;]B!'-/HJ8:B#$5MC:)VPJ6Y
MP[KZRVC?[P6U\<()-6H2DI\KY/L;/^]U[>&@:W?:;>/*-![?)X*I,[3[_8'=
MZ6T6B8SZW&P'Z*&<TRC0AJ8,36U=A?Z;F9_Z4'LR.3 "VXO_0DTLJ>HYMCHM
MJ]NB8J@>-1W#!N:W 77VDAV_1#!6K<$B,0\CZIXYI_F1W&1?Q(DWHPD*>I<R
M_D9I+FYA< 5MP^&-\)WV5,^SF9R#6OAK1U]??[#8_$SV/(LKWT_M-6,Q=R(>
MU.I[- ^9^OE'SAB[X JXM$#VXE?]^FE-/BV/DRA/X"AL\QY>_K;7;G7Y [A?
MGYKBOG:S\]<*3^BP 3,UB=*9;(N'C9ZQE?"=X&&QU&UXEB8X*X)'A?+?>/S$
M+0Y9".C*\WH/OI6L+1T.:/&HI0 WH\,F]BZM1_>+LW@=&RXY<*<X0]A:>,+'
M<==X6'B+G"M,8X!CQM"Q<'QJH1]9-U'X WZTM>:QL0<@=.#?,(U<GDZ2M\,K
MM=H#)/626#_NP>+$]1)DJJCUR)O0$!)Y*]PZ0HR/"?XKNV=K3 G[4]_B>%PO
M"&?8L?IW)TEP^C*-IHF\^,=)(%+ #D"YR)F)^S#ZT;*NYL*ESAF^FOLZ26D>
MAYQ[K.9$EP;SSL*Q\&E 69S.^+W_$.%,)/"\]6L4W@>>$UB?0AZQLFH#']2D
M"+6D?#^]F7<DSVO-G44XF>#K8;MNZM.Q;QPY<X1;L >POJ0#GI4.Q!=&.$$M
M49W6<>P)"&]X:Z3-2+%^T::Q'6>C3P)LK465L;FDP)5/ .CN%#ZC<TTB(:@Y
M-U-IX;+UV]+V+1GW/ IOY$CV?$JW;*BIUKG#(16^KR"C ,7@.'#:6FI%&MYY
M8WC=GZF#<TG87Z7W)<5Q#C3GN"B0JT5NQF/YYG$@NR:/:8#T7TWOS^7>G\/3
M'6C].1K]I=KR4CV/!O6]&0O?>^#GY[B_-]/;T'2E>I6N5.=RDD,XX7\+X^K.
M;.K_A JW:<AD B\KD.Y?(<Z900VA&4&6K568=;NMP;-W]Q=3>;L[J'WY$\P/
MU'C'<K!-U92=/<?ZC4\4^^1$)WD#B!>(-AEQLDLT]ZU@L.XY<;5;O>=7OQN1
MLD/H_=Y#!T P9H_GWJ/W\_,)*K#;Q)G6\3W)">AJE/&2EW>\,F'*PB&-Y &D
M$!/[X/.A[G*:.?DO!?LDX6D0D+?3NO$W'H8"9@ ECFK%TCEF/%15'JK1< <\
M5*?=30VG6>'*,F-&C :[8R)^-6-UDM5\M!DZP2XF8QK=5R>,7N,(XR-.R XX
M8"MCS*LCR,T@A:VIQ_V!/6B?V;W^RV3=&BFR2\1RD:GO1=5]M=J^YQ33LP>G
M(_OTS*2I'U"QUH$<TZ@R>Z7C5WM!FL&?M])Z[,QNGXWLKBDA.J@R@$,YYY;*
M'<JY5,]R<#YIEFG5L<NL7]ZIS%%ZCJO\$6=Z&4;^X>1T4') %_^IP5X22>6#
MB%E![MZ(21BAW/7OG46L(< TXV6%8>0*G7NX9\V\Z@QZMJ7^ ^;5+_5>\EZK
M>XK?+FRU-1Q5[%9^_$Y/%+,H4PPVZEC32$S^_N:_DM!]4ZD&L%_XFOS@8)9<
MP"J"3'9G330JL0;E4VX-/$ B_7G4 ;+=1[Q/=J,7E 3Z:!/3CY^%M4UL3/4Y
M3 1\5;K?/@9N.!/6M?,37E;5IVI+4;)A+1#URI%Q"$MBL8$,B_@+:^J EI4X
M/PG5/-[]39I8]Y[O6[<B$)@H4'Y A;VR;'T,/,%B;@C*<$S)]E@'@I@HXD1]
M"WAWD*?K%R9/%0I<")2C=[%\O4]^+&<\\P)8.V*]T UCS,R&M\N'U-M!N,$[
M-IY7$R=.E)RD<WF-\O6X+]A"$:)C,4[=Q -P\:GDZ0&$G*$>8R;ZT0UL>^(E
MQPIFL8H<9EGM?ZWBDH<;M-N)M/+3]@-IY5V35F[2RI^15OZ!$P<H??QKGCQ
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MZW6H#A8#XO^5SN2DR32,X*T@&H(P$)87QUC[A/I/F"9Q C_ V_=<S3'C>)H
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MYROO9_4M\Z>%J^8?MGK?)@EJ'S*[_R$"@<X*#/$YXYD7>'$2\=B.9HTXWL8
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M$5=V3H4_1K9S':7P]+GKPNWL>VNOD=W>L'MR/QC*V9E]-MAL+V;CMVVT^^I
MCFG\M@8CC-_V0/RVGP782.B[Y5(J#$@?R'3UH^[0[IUV[?[H^4)\#^VEHY&-
MX_9.AQOV:QN+:3\L)O+9'D[ZBIE8M9:3Y<P>M/O&)CH<U?! CFEL(H,1QB8Z
M,)NH26;0-@I7]L,"V@IDP/@9]NS>I@%CE)EFMWHZE'/N@#K3&%@=RCE-7/O
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M??M^W 9BGRP=Z^Q;=PJ35;P/6<6FP*S$&+KV$#"LVQ^9)+9EV S[!BHF.]1
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MF7@   31K0@0*D*'$+PH$G<B2.$8:9!X *H)\ #:&5X]L 3)$[TDSO9:A;6
M?@E]#4Q('_ E*>Y"O3PN*G05/I1'LZ$@#$ZRXTCTE,T=@*'@EO FZ RJHZC\
M<\A9<W0_](, #G#G^-2JEW"#;RUTA1C'W$!1C/._U-Q+\>13)$OA P'"5]\+
M5\QN1"0QJ8,TBY"=>+'K^/SI B!HB6#<JK(O7LB^?AD!<EU!-?$<J!9H _C6
M5[A1+/FX^C-%B7 AN??OOU\4J..*OU%DFY&X]>)$TEIF;&=45WYKS4V2C!D+
M%_@\ML5AD7)'B//%3<+L(C/Y]*7TAS/^0Y%GN;#?=#9CD9?4OQPPMM^6<^;;
M0)[XK'[P[_A)Q@2 _-YVVBUX$FC!PK_9BNHD/P>"S7 9UG[;;\/CO$^X;9^)
M.*#.*&DD=U"HM($O.7-8XJ>'F_<7UMMNM]4IK& =82=K>#!ZH&H'-S#H\M$R
M@M*K>(YMW(@/K.:.!/K;3K^T6R3OL8!5\7*RK_(K9C,OCDE5.\K5O8%$#OTU
MH :(R/70.X,[".\ @4%*A@GOFW5"[*6:HAP)J WQ9W@JI^).5XH-I2V@#+)P
MF@Q^%^ZU8[=''?NTVZ-;*=[A%WS?>?:^PI4^<'^EJX"[']5>)NXIW]"#USH8
M#>EBX-P%N$X$ZB_KWW!YB_WZZU:;S2^\].7>:*#V5'WIN+GC%<#-&<0+:S*O
M%1OU9JF?.($(T]A?L'I'<MT/8RU#M(;[U+,LEHG82AC^]4%TT_T?29A_E7_Y
MJOZ2,2AX7R=G9[(%,:"3<%!G=:RZ!:Q_\Z-R(9;6H>\S+_87O-.'OEU@E X>
MP)5L1;',VJ\J!4\*F@)9%AAJI\Q/=>;3/V[Q#VO>RY<2)ZIC.ZLO*L9I ^/R
MVDM'10,GAEWA,U)I4MR,2!'XV>TMR%3\4CCA#128''_4!0KO#0?UH)1QQYM%
M+4!+?*ZH6U=)(&8J+T[4WV'OCR:G(D.R,\.@XCY*Q^POL7?KJ"3NC]46D#_K
M>$EXX+ /%G]F*22ON4[Y</)<Q/K;5(LL/W$/BC9S!S+K'2NAYOP.-]O,N$6A
M97]&H7[H*G^ VB_\=I60_4#T@JYDX'*4]G%%IOHU;"B>*.+X7\X,+ E>7>&.
M(]T!,>]%""4@[\ DH/D" &AXY??654NQDUO4!P(Z43YPP%:<"+<B]S@3#J7=
MHR,!E$S8(OSA"ED4&O1$&T?.\5%G>)PC"KZ7EE8[/'?AXNE\#B!=@J\CE.^<
M#JRQLXC1F^"#W67C#[#^+ S$0@Y%  4E@.N>"<$:D(@2!ZN"@/H]]EF1L+2^
MI8 (&[?!NL[)2)(>OV;E":>>.Y5PSZ ^]B+T41#P-:@G6-^41@ &0,];MNG)
MTS$6L,&9%W#AJL8C;&G(YK9H!##\*QCU,C:_;-LZE18M8<>1IW]MC#:%=Y.J
M+^)G!13FG96L\7U7-*K,.%C?N656@ ;P310Z8TK0BD3N( .9,Y>.*>)1\(LW
M 28$O ]XD:-#N8JGK6)=99Y7S\, F_QD2CZ>.+T!4S' 10$I-5]9X>UHBZ(G
M(<"B:=CZC> -PV\LQ_#+20@*SC@7Q^R(K$(S,DEPR1BH#_UQ*?;E$_!>Z5 I
M.'+P91A.@_=*'!9UZ!NGK@N?H>&R*+HD9HBQ^=>#E8Z=95]F[CO2O)KP1]E6
M7S(P&CXA>9.);3<XMMTUL>V]BVV;8*N)9.]#)+N"Q!LT/WI#&EWCA */C!)_
MIJ 28- P@14<4!E.VW_1-2(I[]7XM65E^(BTX0DKZ:@+'UM'XJ?KISAHFYY_
MV'U+RISS4V3S&2QI=WO+X^&6=G#<LGX+[\4=!G^75"FR/!Y2HCQ9CA?&R4F"
M)J9#)ET6> WO ]9],'@,V[$&"".E*/&7PS1!M9(.?1<F;"9FT^OD0PG</_I5
MP5B!7Z-[[,N<+>J@(IE$(1C^Y*#)PECZ5[- =)Q.0(OV5+S#2RC\QYIJ)&C)
M,4^BQ!B)0,6-E<#,7%.G>\B6LSIG_3:98\Z,]>%BV++J.Z_FAET*BLK.1]84
M>"=ZH/6]2YN"? OR[[HCLRJ&I%]S/'4BOML5V?9A3C=UIDS5EFCI/(E"N0_#
M^3R,$HP2+?ARQT+,V(B)T.$)?\SM*5#-"\M9:>;.6L<R%A[B:&Y2LZ,A8'>'
M,@#B'':Y6P+VP\A'_JT[0>^L?$<8:<8WF/CH8>&@@D6V5\3Q!K9LQF YQF2S
MD\OP?BIH@TLT'POQH[ QW@;%1.H."QM!+TKJ)J579Q;9S $L*GLAX'H%NS;0
MVY:;OKSA"OS*E@."\1)?T2A=8]653?A>(WC(2<H7# 1)+!A^#%9Q:&GYH;D+
M;W6].7N.B5=H_D7]S<>82..[J4^/.LS![L.,__"-D;]J'GD8< T+F0[5V0,4
M^AD7V%N1L;-_2S]*T:6(@@+YW#P2=QZ[UB.!<HO/HZ,"UK<XBTHB)E%C6S+$
M51 \?'$;=YW-\6&$JV2$ZN+H"C*'$Q^B$FNF*[$D2_\@Y@]8G#O,'A:^2_1#
M8 N7@W<DZ0'%TUBVJ%X.NI99+SI3%*NH$[WH!OTC5&Y0\NGPJ4",(NZ!C.6?
M:-CE'0K/22U'J4F+R6%7@ARZK8.<CD +N@]3'S-%4NRX!$2-6 (<_Y8*I:0V
MQ/>&7EK\3F"]'<B05Z=E?9R4V")NGAT_22Z9X7:D PR7]9U[RC8KI*Q94>H+
M%849%ZYI' I>#UGBF!Q%^+*J%R,#R90&I7A8Z' E)VOY\FT,"<6I#(CA^970
MQST@Q1)#0,\S>O$X5*0E^%',0D\'+#[X47\P#X$KUDLI:UDM6ES8"S$#G3$C
M>"0?4C$/]"M?Y5H7;OE20?,B0_DL,'%U>9$'# .LW/!+[QB';LI#O3,1#%_*
M69X2I"L<?Q\G-ER.U$_KI!)SNESS!'1Y-*I0P*" )80<A*WA#04**E]?QI!:
MW) PR056G-$07. ?:5#0##"RM:"^*JXGTV;+U\F/:/>8L?<'[[UEG6=A28P.
M8WRY@G,":UE8E)?U@)S%38-N)U5W&32B>T%J(U("\15)9[9,7M TD$5.;2BQ
M;P':<:(.B>FJ8_U^B4OHX$65):Z^GDJUJUJ\Z@(XUL5'A8WFW$:"Y0UM'#?Q
M(6130()DZ4M%EM]GFL$O%D%)TINESZS LVLI)(\QKSA#ON%[QV.=THLT;F&1
MURQ>"CI4G&R]?9>AOJ[B_(*Q())U*SALT00B\>944 E /;QE5&;\PD JF)>^
M)Q?%C.,"=B*.HV%,WP'E)E9  D5EMOPXYC6[*N\ X(KB@X,)>4H(=EZ8JZ"K
MCGORZO0P:Z>GF*;&[3-.CS8K!E3/>OU:LU5_6,F 8SO3SE'011YE<U(B$W,.
M.@"@6)SS#!W3R!U ^D IE<+J#);\!07<LS/^(_-NV!R)9<Z5QBE8OY$Y%59)
M+\BM5/0-J'PK#KJ&)=NWBL9R84BT5M0%'*GT\A\Y_J_((K.'5#Q+4[TD_V.D
MPIO@D*]4UE<A[]&YBLHB;,?>A#5:&<!S*5:5>#,M+V,)#ED\6>;% Q/3.$8-
MD:\,E(6Z ,201N6%*I?2DL+VD"M*RS;0/_[*J>P5?!PMZ%\EG*I8GR119 &D
M^U ^.WGFPJ6[!Y@I+@K+;MX(BL2)A*WDD-41>9G'CS%^J6+G@)2\+"Z O&A?
MKW25U+I%"CX"E,C(PW)\)<ZY=;.0$M;LS DJ&[[:N9>6C/Z,L^CFOXF[-L_%
M_N'DK&?BKJOCKB:ZNJL!0!-=-=%5$UVM.6J(!0R@]WI)I4^^TA5^I'(FY>^@
M&; U4N6H/@:]/AOI0<':%-/&I38:% )5!77GQ4-R)5>'ATFJZZ:W276XV\<T
MV&0JW419;<FZ:=F@S594;'5M4JA)TY.UHN@NPN#,3YGY5W9$K;)7"B4*R\I[
M[NU<\JME(3:7^OQ3."\O0Q<_L4ZUJOSYWN/[34'US,-H#F76@XF#\9Y8NO,
MX(N\W]=-RN'BW&*%\U;%=M!X$%0M:M?ZT.WF*\</4.-3XE*EC.!'QZ70CR#C
M4!Y;'$=D[*1S?.)M1U;0Z 6M\IL J#CT.3U9_)QCTR&LHUO%#AY@"2I;6S.-
M"2\5=<)I@"+@:ZD75WE9R\:C$Y?<CSE\R<./3[%-Y@ITY4W2B*Q4W_LS]<9,
M-'H6=@8C.*9>YU[PBK]3J=R/H(-)B"X!BN6GA?,7WD-X57+61V+F>%P,4'!2
M2H?,38B)P?!LYGRQL],)Z97!6[P3^9L L<B+[5(O@IIZ<RU#7CK&LF8*&!E
M%)'>/N07KN]X,XK=NG VCYQ :HLROL#1#2SLHRLHPO0PTMH?XVYF!(=/,UP%
M%"C@:E[Y6&01:_BEBQ[HHMB<.)X?/T)D5GN0M%0IN7[UX3DG:3E6BC['K'?
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M'"GABUE?JO%B7"R,BXOY"/4]V@N^(>7VRIWTF0.L.5= T)%N_NH+H&XJ<5X
MI\5WE03A8238+J]*',$=WDBZ7?\B2[>DI8)8^I:7=U>S.4?+ *N4F9I\#,JB
ML:'WM9945.7'>:<,"A-5P\"+XS1/T2N\"X!_YT5)6F8G-X+SQ0KI8=@#)VNH
MR_0EHEDLVUAGW5D+C6/U>!...(;/-;49,U,I/9-:.VK]1N4W8UFUEJ77% <E
M+*^H2BNY;HRUAR.W#D_O\Z[868_H7"]\@ LIC,ST2Q4DT/2+JA=4WY'4-'*
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M<N5LBXP/RUSLTH5I&0G9"3#S@*>%!&%P(_OWP?5[8)/*&1)A4+<EDK)U<ZV
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MS_7>SV:I:&4;E#.B'4PY$1WI'%59I7(S FP-RN667> ]+[AGV7?3M@W4&QI
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MZ]DG_/'T']_/K\]OSB\OK-/+;U>-QW1< ]Q*,^(287MS:7V_./G^Z?SF[!-
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MR\E-@1T_+ S7>E*W+NX4[ESUBL":<?JV?%&.%V4=+-*J(3B5Q^Y?I?G<(S#
M^!+F:SO$%&3)A\@57V#I2 IUPRBV!BHQ GN-C0(@_WO5=JM>[I8H$R&>+41^
M"3NM8SGE4P7S:7UXCY4LV2Y)I*$TT=77][/H0,*8#U5]/_8ML76Q$"43_''/
MU7JLQ0%F(RX/D!)Q(L%3LW& ;4V])(+-Z+M1.V2KV2&E!?$)"MCT@^K;#',I
MH%3B0";O <#X![KR<MW;I/>QXDUVP;]8EAHHA#UEQVM:13W<UI,S*:FPCA\A
MK#[07).E<+Y,JS[@*08C&+#Z@-+29M32A8>*+A8V?E0YO OR<"7P"SV6ZF;?
MVM;$]1$%!QJV97@F\552M>@L)%BN^HO.G"M2/Q?WFSGW4?2+)#%B&ZF"_(@:
MD>.G=>Y%L4)";6IK!,S0)X$JY*IIH;&)H55,N.F8A!O30F,W,S],6HU)JS'#
M.M:87W$H7<=OL5UN?FJ:2 J@-A,#KCFI*'U9]A,MVA@-ZR*P1J%H0))9,'.M
M+/6JKXA/69BK4Y9C('W9Y*)LI)M<"EMLRQYH%:^B2H5"JTHJ=\;!J3G+J59'
MQ(KF#[C75"ENM;42:*T4HEX-R =5 DX^3G+9..BQGBN)&*.;Q,^FR5942&G]
M#*XSZ^7$B46[/N4@6-ZL+U;_W>NU?DQ-KL734,59(AL"T@O)_)A02.:.N1XM
M2G7>6IP!W52J0 [M(?0/B""KL#LGV&L"89L[=W;:S%8CXVJ P9KHQ\Q&_T^:
M"4=@$OXS=%?+&$E6;V?MP5?300&P(ZU-:9"!0#ANLZX<)>U0LXTY;N@D$W0"
M8/(- D<<2YIX:NQAUAV _&'"*SOGC2@ZKD< 3NFQ%R.":V"(-+S[S7@L>R7K
MCB2-%/((_.@0@M11P=!Y+WN/:!'T0EM9"2)9T_@M>PZ^E;4F&7/9*YJ:F6#(
M;;DY!!BKRW4'HM)4M6KZ'LDYM'&4>??$?%><%!F0>6FG%!WOT62UW$*8#K%"
ME5 I5,?="E37!IAXE#2@>1]H8@+V4Q8P0Z<:FTZ!C]!R JNUQQ'EWTJ]3R'F
MBV$C!=MU,#MDRO :S)!#%_D]7'18;#&3I?52F U[(R.+P,1<%)5T::(IEJOY
M-X2((J]#? \?S%(';[F@JD^=)0T^$HFXU'$D=$1D"F.E@<!08")!*+IS8WUP
MYJ^Y/CL5#O^ZW&:=8H?2IEV?PN0U1% 0U=M!-L E?9OLXHVZ4,A37Y=@*+5.
M_NSSJI!H"N\UL'$[E49*!E+[-@$/$2' S%#1XCOD)-!KH !UA$M"Y8J58U%2
M)IQ#3,(KE&J\<+V/O\?.@)<7S5+$Y"6T*IV7C5G"(65,$)Y?"R>EU!-!8]P[
M5B-[1F6:%17XB91;H:@LT2M[%]CO?4X)3SF#NHS*Z0)"%FM-\D=PN=E(I*75
M<HIYBI9(1$N:5(8_:1V/B&[3V4=Y&0V62J07:SXW<" :[ NO>LC<2/; G@:B
M,4*I4WP9S0LEC"^3FR2D0XU4<G_0/=L_':LZ]QI3(O:RM*!:;Q*A#2V]' YZ
M&P#1 V7#0H70#Z"!G:FY4B]V6!9F2E\LFE[FHQERH$"::!6))";LE1BS'R*O
M 8,KLOX<URL$)"O&%-!;]651L*=:EXU'%5&<W/9$?H86M9O/A<D?QT4N.WSN
ML2@0*+.S2M)@@@7C9C#&F";-NK)C7[H6#ABA.TY$5A,%ZU5R4C%32!AU:2>1
MD*>GS%_Y?A'<)820@])^OC,\OP=UY5QX%:X0X[*AD+D!65FV5*$RBBS)W!LB
M;1K@) BYH))^%AP685:9Y*L6$K>M&L<+L8AR-+-ST_Z(B0@"U[*F! D,M;3!
MY28U6'L^C_/F5[0O,?,_&GSN B^9<.FCP]L%C87=<C4\K<[P-RG8<;5LZIH^
M_@SD<QC+EG822[-'% F)X\X>&V;F4H?;1>>F.Z5M"ZU78LQ7%OX B/P3<S@5
MKB!J"TNTP MM2;%%^17/R3I@<NE4NSUY#)\SP@5TMN]+3B@2T"B#L)<BU!B
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MM &!3@6,5-<MI/H!\OS:$8[UZF]/\N=](C\[^3;+]+.ULXGV6^42_TAP\*B
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M+Q[%"^.AV6S+X(:&?V>E/9NA]*\E,-EMV]UVQ^Z8P.0;4??7 2:CZ;^DY.Z
M2!L&"19E[;3HWIAS;HU.MS$0>ROG-)AA,*.VOO\7T[MKJPK'/W&'8_]@69G0
MHN+Q)C8.]K!@0>].458^7F]R@:GU-K7>V[7T<YP7IM9[FPN\GE#KK7BHI=CG
M1I9WF5)O4^IMJD!-J;>Y<E/J;6[<E'J;_+SM*V0QI=[;& O9IC,:R)D:%L.;
MGU<87EX7;IBV83U;M:J!W LS;:-VOQBSKNK. ?N.$PJ2!;YU,@U=:<<=B:;*
M.YPCUVK:1\V.W6J;'#F3([>I8#(:\V:SU5,6C3>#1ZZMX*M]=+SME&\*!]\
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M817Q[!N_13M030/Y[L.NPTC.!_GJPBENV1)^J[9)3]\U6MJ:]/026DK3TT>
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M?R]TBX>)Z)KEL7OT2J_<NEWY@DQ.]H6;.L .=+GK))#<DE.97-UP),^:JJ'
M43(0P*. @8_AV+M N&Y%2<S8G2C B*)*'50^J"(V=O9Q!,2BF+.AK:KCZ,WP
M,H?A061%2V#Q!^[ 98DDJI">2 O?(UFUF;;0K2B0%S<=)=.I)[T<JK2EW%5A
MI[W=T&;&OS&ORJM1E<3=;^\-]F5?#]'M5X0-" :BLA&.(D<91<(5$0?B"R+@
MHBH%HT((@A[%%6RM_9M6+P,+G#W('D>GP63B1A'=SRUZ;$2@#>M0,":S*\BJ
MHRE]*-2R>$:APD!TM>,AM=$CQH ?8"$NA8UD\Y4T0S]R8X&@ '$>15@)(!Q+
MP\#G5*B*KZ,/\0Y=(>?$2T0Y&(:;K#&5GT88T$'>+L)+V%YPB#VQ9'C)5EW6
M$;%&,X')Q*5&+A:3W=(KB*/MU(W9HC]BRAM2SB* EOX&3 ##OX*Y8L^O@. H
MIGREEX+>O3LWC($5YSO<;)M[%="&N);P3B[TI:[\XM Y*Z1?YE#-8I!">@XX
MMK94\;NTN$Y%VF4,,&/A@IWY:<$\90-@L"\;3OA\=VHM!6O%#M:M3[PI ]I3
M7*N=XV6V_40O[&I>L+JMMM>]U=;14[;Z'._-T;.<-^KP3Q_/6W1#YL?SZME6
MM4>@/8V::CE76DLD7*W7M'N2)P>=@I6#<VI=M&1Y.8 L/9O:8,U680VY1=>'
M-@9A=@UA/H&>]\A\KAV(1.Y@A#,-G)@P9,TPY!A6_A4_J^2,87!?1)!'XE7S
M;+'^&B_(R;8U1?UT[/*1=4;^17077LHT8#19/\GDX*<'N]9 'QL%O;UIZ/J.
M.V6>=-$B"&4F]?X3U8,G: );R54+#&-]X"DC>67R'U!8<MT4GPO(T1LW"HN+
M.7Y&3]E.BC)Z2@T]148X+0IN&CUEN_24SZ[/0-Z"N)5ZBE%-:J@FHQ1J+ZZ:
M&-F[/MG[8DF^!9:Y#8JLT4N,7K)E>@G[,7:MOR=P)J.5;)=6<N)@X3)E%1FU
MI+Y:PC*PO;A>4HK;\[)X,\2OSAF,\#7"UPC?50O??[IW_ >(X F+[MEDMLD"
M.'/*&ZO-6&T+Q,8<3AO1842'$1VK%ATG_C"$A;\$1F@8H;'U0D/#9B,NC+@P
MXF+5XN**Q:'K_+"^,F?,AD9H&*&Q_4)C#J>-Z#"BPXB.58N.OW,L=/[*?&?,
ML<>JD1U&=FR][)A':B,\C/ PPF/5PN/<8[YU&7+_F2'6E01:C738 *S8!NF@
M8>VZ$?69)>M&2&WNND9(;8F0^L1\EWO6KX$W-&+*B*FM$5,YO#6"R@@J(ZAV
M6U!]91&;!=8-&S(CJ(R@VAI!E<-;(ZB,H#*":K<%U=\8KGW:L+X&DYC]AU=W
M9C'BRHBK31-7)=AKA-9BGOR7ZED;N/08\3*=ME'=.'8UDS>6Z$G[*K,XUD#U
M=4[\,@2.DSI:"R9U !:^'P3#&?QQ'$^\7_X_4$L#!!0    ( +J+75/\8 9"
M-X(  %?0   1    9S$V-#8X,&<P,'DP,2YJ<&?LO 5855N[+[[HE!(0I+ND
MNZ6[NV.QZ(9%2@C275("TBTA*:5T(]T@(0(2DM)<P*U[^^W]G7ON.>=_G_M_
M'EZ8,=[ZO>,=8XXYQEQKS>NIZT\ -&EQ*7$ ! 0DA#N$.P!PO?W(6]'<SMG.
MR=S.GIB5@0G )2PE!PT-N*%'QLU:@7\6 :CX$-H *#P*"7Q( .#F_X<JQ9T,
M;6#HS*N@JQD!QM[E31E,F_R=C.=.]OE6?K-!W)60[!TM;)T5P,[V8.>;(LPM
M3]')6<78SL[Z3D/*UAD$L@7;_#R_/8I8.]Z64>]L52S<;C6$+9QO;?[T"7*4
M-[(!J8IIJOX"^V&@Z&AG9ZH"<@;;*QA; F_8R !%@"/ [N;/%$ ,4 &  ,X
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M!;\!_N2CWYU"_!AYH#'O2K<-"GE7OM4'/)#](V&O;[:;L0[BT\TMY^D-GPF
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M]K5V !$  'G[YC"H/U_#B B/@ 0' PL!!0UYHZ"!!@# 0D) 04#!(" BPCP
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M9I+6(ZR@'5P75I\0M^/-<H6P<8 FT:,NU_U..!+SYK:LKV !9>/"JE!-AV@
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MPPW6 #UVIG$6 6"1+*:0*$7/LXINVM".:T"_8@BVUO-GOI[P^&N*'4R8;6L
M<HXV1F3[[8X&+?UO/J9GS>E[;!@;*8N@IO1%B\K6E82EV!D&@BK^T4SS>6PU
M%3RL+EFUG$_NZ"]F7'$<)E+=2@AY9[T9E]$=\,/V3,0?IQAU^;]ZM=NDGC>\
MR=%F")]+.)>5;(.-+:0@I8$1'B-_JF\)A+ND91E]'&81;]+6[4.P#*?W(9P^
MN>#@72]%NM8QW'L/]7HJ#!?&-U\%H1=&\Z.;RC!<[#S!X&E&#+WRSV$R*[9]
M1YXA)P[.A2'HI;E5+AQ*DF+O$YLBN1900XX&.2I&Y1-GQ*/RCK^\-\>BJ%Z6
MT7P8SE80J)"[_DH+A*Q=Q?/"LSS=^\Q=H (OP;A/CUN&2,C$4H]CQ:!E>KI=
MI>0!Q;<)SQ#%;2>.(I.\T*Q&&:D>6#.IPS0A#=_AG%0U-=@H7*SR*BTX^B7=
M,ONM:T 5 ]F8VX'&5EPU"MKP.<>)Q,;,L[,4<QZV$4930?AFK&H,O.8G6R,R
MO@\5EN$S0V7Z%O!9V+<8S"CGM?GE9UIA9]8$A@YG&00_17B<1YQCC>T8C8+%
MQWV]J;=&E5^]#A)9P8I*WJFZ<H?FP!<>WF^7);7(KTG'W=&BRW4YD[%5)Z]2
M.8"BGNF<_OJJ#=FG_$AR6#(F-BJ-0ZM#A&ZL.S%4>I0EG$Y%OA.W0GH\)]2Q
M1.OY\DB8RW>1ENI 9ICY9-?1W>@!RQ$:+2#M7-S,8.E7BHZ2S,QDO EU7284
MG <CW*4[K_V.!X78<^=DV!M#12 CQJ6@(TVXU7&YR,JTJYHE-*I\]2?RAZST
MKHK[O<=9!-F\D<]A=_=;SIE5.]..\B^,+M5.+3D\F:X!TF"#0[*DEJ+E:\"5
MPR+V9;Y/+_$EO=[B9:3K>0XQT1<!WHE8_#Y+C *K&<I1S..W^:6#V_IA2CN*
MX_D,K&#1;66:!?["SK?8R<;-E!AI"H[Z"5]G86 _?P]2P2P0A3>4W8P^9L!I
M/N27YYJN>/ )>S?]^=0:]O<0IN1U;''*M&F9^7Z(DTJ/H"FIWICMM??'D JZ
MZN;]!OSA'H/2W+.!&.@[J<V&IUF]G"X#7\6"EXIKWF PJPFU@4?E3-1E.Y0H
MX%6BWQO[!A8])?:#@$836A>:\M\BS1L2AA]20.6/2G\F=8P/'K "CHK8/-Y9
MB_[T((@UL&B&'K.S?)KBK=#6*V^% ORCU&6 ;U(ON^W^!YP=4^9W>3R9#V@>
M9T:^ID;$PQTOB<PHT)W9[8[4)GUF%#<9M2 <72(^UVO9PN<U]B8=\-D'>D>0
MN4-^04*9S3XKOFVF:@Y2$;SRT*+45*&U)_T)J+L>ZRU89,PJK*)M50&"\)+A
M,[=2C0EK9724JI]C\$J]*C:-D&K[=P:4REW;O&:'31TJ,/I!BJ)[\ 7\<VB?
MY<)OA00"#&86DM-PU!=D5U"'H=(V:I,-II/6+CB3/)+4,K#Z+>]58KW%E]>C
ME>S2$F2PTD;ME4C4 M0;PW,C10,4 UEQ:@$B[B'N7HWU,KPZ884"3]#9D@:Y
MDU"5( Y<:?UG6G-6P1&/1>J4!B)J!7 $3*)AK"9#]TIE'@#YO$*HE3J"<U9H
M099!*A&,OF$\E\H$K\BE:5^]D"WF@I6->407@FB& J,V2&B)(X&9HI&N91I]
M(,4619;!Z?*DZPL55&MQ>$=2Q5P%>88%-_MNHWQCR4A3UOR4BI7K_E!DL?)&
MMW&$FM0Q4:%G47,VU7?C)^.=.AF,1IB#%=L#2$JD&SCK[R)SNWA%ER7XQMWT
MVSX>CB4$4C:2NAZ@[Q ;Q* *\"&_4/T<KS='$GR4<Q0Y^_P[\:E-R\LCR1&<
MWFL 5F0QKJUT(5/?X[EMCG=RVLL-=O 6#7*$ F]I+(.,RU/[=TAQYNCZGF3&
MD8'ZCTP>,RRU6V?)YK</LY4!P"R=(62=J"6%)&!QLIYPNVT<:%]<QZ_)[J&K
MV(HX46AX7())%VD>.[WI?:;KL'BSO)%YLQ32,W%53(;'KU.KP]5+6 GYC<AH
M<.(<N/Q=.FM5Y(Q#'<F62^(;^:7\A,%-F/%%>UY!/F8$F\@]YE-Q!+(8"= 9
M E+<DOOJCL_:\$[JL[7@.D4"CXL-B9)\[>&$%=+,V?LG,M>7Q/"I<[6.JP6
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M(^.*58!P\<>QE?8&\)@,>RI!4@WBLL-D+J4Z.8J0>6'.#^7(XZ@A)(4Q7P,
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MU=[+HML2^E9B"[_6>5KY(I2T$)F(^  +9&(J :.'4TRS69(3"#<#3SSN[(<
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M.5<8ZYVZHXAS5BM>U4=_0Q&B$!L2CDSD#_Y#94E@.J+QC4Y+:]-F!YYH ZR
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M)7AV["HWLLI*P@OO[ER@SJD!/XY%!"WP V*X86DX"/_SHO[S5B$A"7_"'D%
M_ N3S$08*B)7L VS=5Y\%FSF4BN(]37L70P!W1.;IQAO5272$77J66O=-!F1
MM_4/4S:@4#M<%!,OQH$N#55&X:5#LID&V\T,<_GK1WY#.Z3B+DVE+6E^Y2IG
MJ2!*39JS2E"Q!$4RC6W90\3YXL2P?Q0>?>11,D *0:2_CZ^.+Q!^U2';:ZGT
M7N1WCO-IGL/4F@W?QHV_Z"1V.+4U(;(D;F=S;U3Y',3)R.7O=H,5K?(V7%VQ
M#;PQ@NJ#;,JY&"<2Z2<O*KM)E"&\6^MQ:,Y3=B6):6 4M? L(X]2K*331*0A
M+CG%C$3?@D]E ;>X\$1EIXLI10?RST.(G/'Q\0UKDVT-FA0-8DT_O_6<ZOGS
MDG9KTPE^^4[Z:1'-ZT:/3KZS3BRM^H9).6W3 \)1$<4V%W(S/T(D _?%:641
MF</D&S5G=<1(:UG+5DYWCYLM@PA<4@W+5'9DN=&E[WT-@:A81BZYCDW=G:,$
M!8?C7SL"V5+_4 %=-]]NFJG$#!LZ%Q.&LIW16_1M8J/U[\3,P&CC&F&5+$9%
M/\=N]N4FX]#8FG6Y6*-*5C&E-'D@2)2" DBZB)CG X$4:R3HL*[!5/B(3Z6X
M?!:PA-929ZA&>V8SSP^2AM=>RX&>LFBJ?["(1G DB>OIW>@PE.DP$!:,:$24
M(RN'V,/MC]8F"#>E>F$*7^7W@]QVI'B<;P8B&3LB\;G:<JXL,O=5,R@3CESV
MIBZT?AS".,(& M1$Z]TM[";11[<5;,J<\([_^[%B2(ZH&Q:*5],UEXU9&<MW
MC6LU_6D$$^$1^6X/2DTUX"6DG04\R=&@N7Q5E59K!I^9FKXEMG/56&;@X7C&
M1X;WNM]#]_QA^"8\AIMEUE*"\&GBS]L79MB!E%!1C/"#ONM+6-.+TX6-X.6$
MT:<J/[E/P"SO]-_3M=[.6$MB^5?%[:U/P+CB_F+M'!P_^,];PNW[2@R_IL*%
M3X-6F")S#=GZPQDZ;ARF^L;!Z%U3%M0&O4!DO=KE-^DT YGO9)A[)?(:#E@C
MMECF5 ;R46$#'85_Q-H_2AFJGE:^:8>ARATK-5!K: ;HB 1.\7A-8NX40$'A
ME)5G<J:L\X>8Z"("2'+&^H"F @(I,+Q7K@^S^I(<I=_V[?S<OEM9%5MP_XU@
M]@TV#M"+XO!KAGG04:K:&NV?I>T*&[)5WM<8M8XTV22@I?N11&LM]>>JU*YX
M:YIC+!Z<>DQQE<SG@DONUP_"&<BY6\%W:&A) J*S"7$BW+[F?\L.WI=,831O
M\&'O%F<A&K?9UFR>/"\_>Q[E-O$-,P-JR-9W)?-_87R#,$NGMQ%W>E/+$6)W
MM8DWWY)D6-#O*TE8$2O!_&K1N5_-Z"-;IFS??MR:"3R.@+R3QB>[0Z/I&\?E
MYB:"R1WW^TI>A@Y*2 9IEJM S')N>:SGC68,BRG_.YNC7K_$5,K)=R9;U?B<
MZT?=)E>J*_V>]N4P3<K=1:HGH302R9!?I#%MI'B]'X.T)B$<N(MMQ%"\P:YB
MCX#I/I\I4<Z8XMY8HD,UH">^!]3>@2KUS&JRVW4&WS9"=G==0O\(/7-WNS.\
M(91L79..>EL6+ DXR3'_<+W8V1IE"O@_Q3RMM"^@^'RW0E Q1@=@,XSE@&V$
MB!M]46+F0\0WN#H1)>@Y/'/&?N>&IP:$+B_:HHT"Z36P/3\,%YYQ"9^3T)2Y
MJK#\#)F^,M.VMZ>0NY7E;V!B'G3NBIZ,AP?L1@<JH$24A9'FI+O2#_E$4':B
MH-98[HE_]R_R?O=9SR%>0_(:H>TK\IM8?=&9UM?E#PXO@Y0F,J#Y@PB.TF!5
MP..\UZZ"K)#3RYJ2,E2L_]GW"9!MCYU5:F[/2A]%+-B)A[%UKEM%A^![B=2
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MI46\,*[3UV+99T8EL$]=C:P:Z&]L8%$WC&&F(Z:(I#H7#;>+',&:K,)">:L
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MKYB^G\^^+SEM,]VS!)P%H)=F8[BDATM9IB6A<V(G."G?S)0>]4> 2@D:+*-
MQQ1?<69XV1M8K<$>M=\%!:)0G3ORY[(T/C*A8TUP,X)"H!,Q72;RLT-P@;NN
MN,"#<BION>Q$I^A$1UX4BW&U[E0N/J/FMX#&^^GJ6ZQNA"%7>8O(*<?J0CR\
MA1^YYF9,)19U+#,9;,"J*\'0M*HB[#23;![_,\A.ROE3Y(4MNB2[E=S0D?43
MA68UE<SH6_UT_/1;O7!$KQ8C1=HQ];NOB"[,+"U78!ZMA#UASHSH$,7@6^?7
M,"K [I%BQ.H#IEM5;F.B^;P$SX;%S?4&R4/4L0WX-&O$/I'V,H?#^4=L5.@,
M&@^6B*N":XK4D3(;3B@$#CH<$%4$.@BN']I6!-91Y(RF5J$9P3L Q/=H-( M
MJR!9S]TX.WS)>/!+2ZK=AFA:XH' ILG+)$0JE%:Y:HV+5XF#]IZ?E1%#ZIH
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M+L'(3@;ER%"*= ;JCY;-WX>>J>>*\_,\JMV(8W ,X_&K?; 0X43^) <;<M_
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M0Q#91LB! ,BRQR\ %+> S[7_ 5!+ P04    " "ZBUU3!7:0_,V\ 0#I"0(
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M)3BG/P[_3"!"?'Q"(D(2(B(2"B(B(HJS'1'%3Q/2_QT'/SH 4IS3X O00:P
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MY-2\F4GQJ'5YLIFWE0K.V^?9RDLHZ-($[U#V;GL?4D]?*4$"PF<5E%)]@UZ
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MN\I38FUXM*#$OJ"(F%6UR(9!C>P/LTI2C?KO:S0PE6[+&YC/W!*!/95]FF#
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MJC&H*PS1=B>4Y>#$I$O*S02A,K@\SFC-V1AD:7ILH4>@]98YXP< [GZG_P-
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ML& :*"NJB2\@/ 6\.=((FBC<2.7&1J1A*5T&NF4_(,WN5VZ65!3<5-NR()J
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M8:J6Y1#F0IJ1]I0^6=F.]^RX6']W1Q&"'=:[41:C! AQ.SE?QVZSLD"&'\^
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M88GU$%>-Z=N-A0U'64Z%CW38@;&8(YL LV;D\G29O3$-:UP\84MH+*=;&@
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M]VKTPR^%0-YGP)SG3_H36_ [[W=;EQ\"E1N7?OS3L&AD8^FIW_#7BT?M&_.
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MH2MZ/EQ7N+@SO48Y!UC04,Y)XMK5:FBMKHGHMG*O?-2H</N=W^:#<__:YC-
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M\5YROL81PY-RH;X+-?TR]O4JX,LS0/ ';W+/ZA=^IT8#U0F\<6[X+V^$U#-
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M37WF<&.P?N# %,$F5.2P+/;7UH1-J;Z-)D%9SP(=>9!W,6^&*K '0/5&T50
M,4HJ,)N2DZ@W^!Z]ONI&]IB#ARNHD!O#I:&VLQ58.G-RT<N;^IIM/?Z^RG%9
MG9U$GR33MV:O!/,/KRQR/?H8DM*-3(CI@A]0H"Q(75Z% H_'0GM8:3R];9>I
M(D:E_XKJI(YM]U"^Q,=]D";!589P (6RIGD<@&N9%[:?@05230TG2J:#V<V
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M^1*<@(DQS7%#D?6"AT>/6+U@TQHHL@"DV4*[>GT\7F^+,-1P&PI8,;[+,^(
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MJ@;)'#*AARR#3]Y:4F-G(S.V+).4@JUQ\0"&G_T+[\^JU7E6BI?7YHN=M!1
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M"F7S/-$F8UQ,8)<4&R3%5.%#=DXP2#$^D5U6KNS;EP8DN!.YE][0-]#4B3F
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MDC4==W,A03PX^5M]M]O_9,@ *>=XWS5J7LOUZMY&1ZWJ$IMOU&V15$S5<<Y
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M Q#X#O?S(_&L1\_I+N[4J7DS0;F,>[.^(3@MJ-LEQN7M931'0FTW_BR\E2K
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MX1E2>E$4SN9-)"?$:<7JV.!8BG6P'A$?"7TI$K\UMU07("A%5M1'7A@@AM=
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M3A.(:8[$:I07J;LH"MW)$%(A'K+>;'"J_O4=#K;L;EXX1([ &9TE?/2N2!0
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MS5."FZ;%;,REP?D4W:V#P4=CHA,.JPZ67M?-S9_8QYN"X?$]V2DI$U38P"V
M;?(>Q W7MD(1=+NH(8_.\J'+5E<,W]70XL%_P%3PM+;*7TIKYDJ.&Q#>)_/@
MBEM2<;?\VP#*Y5I[3IP,&<>;>LSA_DGIV=*' -_&" )\=-<8X!7_\^U$\%GE
MXU!86GT8OR^NZOYZ>":5;@< ZAKR*7QG/OJ\<@8GR("12E@W*9/7-6YX74@>
MGGSN&J9N"J1X?PL#Q!!H+:H$K%& 4,)8]'Y(P#6M8(*1M,5YYT3LV#-138GT
M?OT5YO.[(#+(?ZL2N$W,?/3G^9H=$G.1'J/CP>Q-0!34<BH,R#*8I.%'CL2\
M0PTYWXE0)XJUXK17]!06&1Y%BJXI9Q1JU$V+UK"$]4- T<'"[*VWF-'@UA,2
MR\8<8:+GGMA]"F.A 4IX??33QU5&9IHP;*>N)+]/FM,+M'KD./XY?>A0LTJ9
M](%(@/P;'(.I2^=$L%E-:2W)+@N=AV^R;AZL6U#7K"$;@ GU* KR.*^>A\DB
M\N&%)::"VS)4Z5L*JA^(]R;=#4?N]#OJA!&5P-=A0*-\D6)'M2%I:!%=1\#/
M#05F-8#EI4Y> OKZ,E[WY+0 0Y8RV'Y>Q9I.82U89N[80/[;5;VVMS?!VD6@
M$1L64B=BEW<_"2G9)M=@3[98"@H3G5$0 NOIF981LY$6!$3V%R[^8?%(U\H"
M+45O/44*'#UAF#="G7*11EXE(P0QWBL[)[MJ[33>D.:E,":ZCDD!3\@W\;G\
M=M%H&$R^.#*3#@LKY+_W1R JTP[$,9$_DV0$%E,(D(?L%4;IRBF#"A,RC^K3
MNE=LJAP^L:T]UI%\BXWM"6Y_L=D6."@3/6DA=-7*/O2RAK(IYR:J&%6 RWY-
M6)4J1J&F""_(6U?A Q6O8#+B*"J(0M3"*%9H!+SC:$X]#8Z[R?PT&U/*M55;
M4F#,TNE"I,#D_&B 2%3JH5 2P46N2E0\)&=4O?QLYBKJ@4I/4W71,984-QH/
MZJ6'DO%KRH[//P;5*-#IX%W@!%3/2.8$R(#RC&G>I)=!.-(['Y!#I>$+&1#S
M(P,T3P2G6 NPJ,E-L/N))X:5$:3K#4\F<X+7D-.^@[_]33!+@&A[B@;P<.FJ
MXZ<!6SCAU=*X4W(J!>%+-^;TJF^:IHKF/% EY=1G,P]!JWP^*PF/PGK^=RU:
M6K.,^>0X_?Q,\-TT9LAI2S#8L$'(S[TI+N@, L0?8B$S*ZRHW"J2/)B6GSYI
ML![J:_ &))MOI)7.B"# D;/#UD:AY*4S6 S?=\CSPK/2&6RJLJM+4 $Q%.)J
M9H0Q6K#;;^>-!E\0_IK;^T0=J]KKAW4LI;?[(MVRH24NMG;7U0?WC)G\LUG2
M9&]L1B0MA&[&2L@K N1PPX@/I [MF(]HB5P+?  R*L,9-X05:#W&NM#"@B8<
M<$'\8>DW=E]"\-L2M#&J\E&O*SK G3*51S:_[]_"'#_2VV>MOK]VL<].=6]<
MYS=]]90KGWZH+?UW=4[V(>+AIH]#Y/8ME,3&"L,)JZ+NC"29GP$[YM?/J6#N
M\ S;IJSC"\:K=O>B-@2_E1-+5:=TKSX]6>E+,/14ZT:!"[UN,VF/B:P$E4PJ
M*P-W).1^R^[EK3;IH(W*#7\&1]01X42#"*+<I<Q,4J>57:J5R.C8*7_B?3 R
MF6W85SZQZ,DR$5#'OPI4)-<J: /*+SFH5QQ+$GWFUBB;L6KASJ"2\0R*'B)^
M"<?U18#/'VKVSAM\J&DF6'E0_WM3W*]C,<]9XADM@,=*U#,0)_WU(KN&X]#8
M7@]]@E0E-WTN=?]@)X? K$QDZA6VLP6(,YL^NU:CW@ M?U4RJ.(X=<)P-AFK
M&"%$%BY30UX)QD&7&3<'6C!R^F58U81(V':18\!YUE*P<EHT>0#/)='O/W>4
MM,;!95KY6<]/U_LNV7ZV9,X3#FA\^K)LF*NE$UH<E]/$]ZMV=:$P[J=5?8G6
M8_$.MDSO=)XK79[1]5KCZB5M2W%=*&]D)!D&<(^%4>V'=%)*OU'VB&'2[FIN
MNW<X!"=)@5]#%>?7MZ"\(A4%9\]&*ZY,)?9?Y9UG-!$+<@?8&N47S.TS/XIS
M7O+NI12->&!+#YCH(?[+*F%A3OW<.T;*=S((&3'/(U *5EP<E-40@#GY M-X
M%Q_"A*8\8L0T"KL] BC*CR8_V'4W3!/V_K%*PIJ\GXJ0OHO8[R):>4J3K'NR
M\?=##^]KM=+ZC^[J.L%/E4PWA,?%_K", TE!4 R7]K60\@I-PJFHN,6X/5IN
MLL;J.-U9+*1>P>]#E9HY.'!0IS1/XVG9BPVO;P"Q:Q@[AGIY J1G6_TFD$;]
MKV6W[S^T=7DZ+"!3"YU^&9$!5J07)"8Y#V(V0=U9DU&FVA4)Z1GFZ#._/#06
MR=3D-ZD-#SEAD 58):*C3O$&RRM8@&.;$#E/AGH82L&O%D7T2L,Z+)EB7U>;
M5YJ3&\T)/4R@(P5E[%E5*B?,%_*V@^-IFSZVS*EZXXB:YH5Q7$%;Y:[1G$GR
M,I'S\:-:FDQ#4^VJR"N92B(YHLA)$A#X:%1/7J$8"39]D0BUN59(A_78^4AH
M)5TZ$.:S\\&?0]X:MZ*2$8\DBMG[+]>U[18_%&V:(?3D65L^"NTVHY8K?!E,
MZ(VENO0VHMFJL\2+"$FG&?1[HZ+S8(=ZR </E/G-N*)/:"F609J.N^OQAK@2
M!MDU<.9:D FX5-55#!@U\1L[D@X^ 2$3NY4!(D@8;:UZ$'(4X56]VG* D?LZ
M?RMC. [R!X>.WS%,*85.7K_A=B@I.FBB0F5XW@&K:CF96KBI7ZCYW;H,J[Z,
M:*>D,Z_%1(4L@O2U\=VE05+9P*#]D+KU;D-GB6;X,(9(6%MMZN#6X_L58XKL
M)_</@@KZ,+8E@BCL*1.HXVYT54Q8IF %M\&3CXK>";":I63""<1"\(M@'!0)
M]7X$1LV6R/.('UPI*'I*4QU8RZ22Q\N!;7,;K",+CZ0^QJJIT=55R2%6LJ[P
M$MC(2;MI@ H $ AL)RIGBJ&GCK7W^:)"B!^J7_9#$IRR'U+:A*0JJ1'Z6GIZ
MG]!*2A@Q.J'T'1=^F"DKJ"4?!1Z806L)4)Q+CTFQN$&5X&7TW]8%@.)0(+U%
M;DZ3&5UF44H=O7^ZG?PB>.]K+;/*)LV"S@=/>KS<-D"ZEQ!BR/_XY?]?H!D5
MM\87J\2W2EX2X$4@7O; 3:_"4;+YI +;%I2N!4MJLVUI 0*)\KF-@2* 8(V\
M<,:5023@#KPD;,9BUQORX9Z1V=6(K&)<EH7W2?2L>CS;\9$R,2--CK5!')7*
M-F^[U.YC+#I &DF"]'4%].GP'9#H<U.J3$S/;_TM()GZ Q'N;MB@LTP&U0N9
M>L:(*) 3>4C0#<?9>,"Y0\+Y_LQ\^IHFCOBJQD3[ZF85D)("^CG"[!YLQA0$
MFR:1%NQSB1.%5)Z(=!($F^6TA1(D(;M7#UQ-;!(G+&-IG-UK.E;//_([GO'[
M*7NG(G[>=F>P-?O0YA%XSF9G8V<31L1?.[78YOD.(*JH*&S6'[]-95:_>#B%
M1P$IJE!8H>J;02SZX?W:*W;"X:FRV.%#W #(%U@Q@XR4AJ]97;-_U<RKEDP9
M#R0#EL#>6W2UI8L8SEPDEW+H=]7Z?C9JPYWS/+/T;*5UHQ+Z(D8 E"UGB0@;
M-L@@8S_37M[VRKP?5O0M_VIZN*-<^HD:1'\&(]Y.OMP. [X(>O)3:?-3F^]@
MJG92/9W8_(I"HD4TB7KE7E:4C)5YT_E6&%)$#PDED+R&:)XNPE4..T*^41D(
M[_^EI>FO"YP7I/7P\B7B"?.&6(!X92FS($LQQ[FX7ST=!6Y:?JJJ8B@_%1^4
M0V)C-OF8R52.J4%@DJ@;/$A'%.0:U=V7 =V:B0YX!QP]V=T6)<353J+2G9\Q
MR])^FA<)'=.TG?3-FNUJ7BGGCF&EB0X+-<4F2@J-#1(,DP?0./@'B'/Z/@5X
ML%5$5[$NAKR$XI-HBQ+2K:FQRT4N-95EFI?*CV>5"@:GJR@4PI))#./$#3QG
MC.(D%/>@"6T97=U$O2!:50P69V#I8-3Z7!9K/'T;37.=*AJ7\:4G+H%UA$@9
M">G92EI'AC&A3 Q'HU@<Q'$)CLM_V(%S'F8"'.S2)?>>?R%M]P%U+M=W=G7%
M8-B4FFGA?[_ +$SGE[QB4F/F.2UF$(A7S@JOA2I=*;2*>%C<9'Y8G7IVILM;
MH&F7I$HNJ6R?VG4IT,-#@W6?$?D]$H,A<.!OL.?7-%>=66,PY/D1:2:4N,#Z
M_+N)R1BO['KC8%.^+"Y]$F0]A/ILIV=PF]9)D31/3H4*>Z"75\3VYTV?8*Z.
M]AOOVT?D,?U,2>L?CK6:X5//7O5L-;,K)U?EEI1I_O#"/OCCL3BLTB11+:-T
MU-R[M]:3-)X3SQ$PEM[]$5>0]2"_ @_HE76L%X_=[B:!;==M7%S8@0WSF+8\
MS0OZVR 9%TLT:[5"\V<5JDQ5W4RN:1OUU,BHC6<(@$CL-2++QZZRQ.BAJ7?T
M@_E&LRN[A#^K9ZD4V"6OU1I))<NQ)A^62\IPS@5W 0&1S@9F&]E_?!BO1%:)
M+T;]$=;&NU\53DH0)J>=CR2T:.7VP-MX]QV0/Z0>OT=16<J OFX)DYQV]YP(
M(KHMB)/,C3^]O5&\D6XC"B.'!1)>>;>T.T< [X]UO:4/Y,%T"PIS'^3A]W6+
M2'B7BP>(4X=AK]/VR.2YO$/# &)G !<#-=*^S 83QH@*&J.LU0>_*_ IC;=-
MU0P\(GI>'C5K)=BOD3KRA/,=($\*,,;\ZFN7Z1>T[AQ=1$DI%L 5B7]$EW;&
M>=;?>>2KG6&#1Q1>CCE:QEG%;+]DT!&%K8V!C3"8BJJT[9J#.O="K6,@Z]C^
MYZM!5O+=G*0H3XK#,_:QB:-!X_+H)=.F5^M+@EKZA6<G+OVWS<_04GIU4F4Z
M]]%;!V9=6+P4,)C;OA.LKB>V)TWD3+\S%(DNC>X"&T0D_4;C?7]Z 7B9>>QC
M(S)Y_E7]A>;?SRM-M O6R;&_&-$[0&V"X"FA1^YTC(-20LPP]6R"2ZEWH7<Y
MYDN1WU^C0.KK-<-_A6T.L?X=5KI],]A1-D_BA4$[:30$B M?!=8Z3>)'X<&+
ML9+![!GT#?<F]72SDB(?BYX3DCZYKO,"6X&>^X/#,Z<#D[_G=L-X.1JR )%)
MJ\M;!E$17RET)<\V8<A'LJ]TZ#3&Y,,[@]R@?\4)2;W7/=J#,$*QC'.HV^"T
M RE4#')S.@"-B7G/^GSZI;?I.INCA1Z::F0^?PH7,3K[&.=T'SP]L[_1+$:X
M?5_5B@TL3 ;?@5S21K !3)$) \/T%V8?0E*;<>7,]D,K.,)T46.  P4+A6L_
MY69R_0F(8'?)>C_.$1Q,<1TUX6O<^NJ7/A+<K2'VO/:<[1R?87/"/(7LV6%V
M/]LX(/:+^-PM8XL^S/GX>QW5WY@6<<(X8,5BZFM%SO%>?#VO7HI45D[_84>
MD^[K/=<:X_:)5<^'6THI53AGL<*WDJ9Z&3_9R 6O)IED%*Y#PC\-6V@V-\0[
MG%:W',MK]LV^6[15S2)M84'0ZT\X9PDNR/@[O&#HT,NB(%8='(;8LB[<EY:
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MK9PZV?72"W&O"MJBHC+&05E!&3A>@^,JZ[*L4.!L/C4B^E"2.5$9(%1(&@C
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M9BDIS\:'?GG6_E#^K)+5#P:6'^8/Z:4")&5E:5;WN8>X /_0F@_8$ZX7CA3
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M#N @I_[1T@SCT%73X#:J R&( /Z+!,:^(_-#2@R'R8JU<FQ-OY*Q0W-I__C
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M<[SX[<=I8^H.BN-JG1'OZ[))5BCLC?%_1+\2,E_4#J!^L*H^E:Q+Z[Z-7FP
M>/@_1TOXK.B9S4]?M2V$S.B][ U(='\L7%'T'>_M!0UM.*:_;'MORG>[*WVQ
M@=[E1[W7"EF[.M5P/_?YBK;"Y>"OQG3))^O,Q[T-^J^&59J4?6SLAM[=#P$
M5\\YK[7PR,=<?(30>D\BUC"I'_+._LX^T<& O<F\Q&N,3N%MC4_&2L5HK_D3
M)=ZEH<KK>]FB6UT43ZU9CT]OGGND7#_^Q7@BL_#_JB<3$#_?/XCI_7W#?253
M44!KHIKR_RXTBQM"= O=!;)[=GL=_*F;"_OFHHQV'G$;F\DSN9)N)DG':/+(
MDR$*!:#(I[G2E 3H,2 !2,7?\^=+6*V:3[=E>;D!^+Y4*5,]<2HB]XD<K.@.
M/45BTGL]4Q#3O/X R%%51T:I#&MIZ_-9+L[+3MX@@?1-*H?K&(IM@[1Z %YY
M]R+5JV/AL<Y<PP<"@:.;+G3/FKBTY@R0\? D.:9@=::/D)]N__/8Z$N::C^+
M@GV0HH.X&T>HJ46O#%0I"H9N3J4_' QA Y;?S9PES,MY#GNS%0H&@ED^=R*$
MIF"PZ/O42E(?/?ABJ5EICBC)CA[.ZN?&X2"Q5;:?OE-%EXGC,G4ASY_:7#Z]
MFC)6K?9:#B7<]JB>LL0EYFRTYJQ^"98L>9(5=5EP6P"DP[RP&ZD)W!78M#:G
M#,^Z\OL+,#S;<V1Y(QW^9$4SJ[4$J$\5$KL%:E&L'VI+%!JR_-VC@02#I$$,
MNLYGH$ZR(966#&A-UN^O8;Z^^6X36'>J,O<<E&%F?LY$O4 2F78$SDC,(&<P
M/Q2YN$@\K"70WS(W,2W4Z@H94[[JXE+:X9\5,E8!#K&(ZU_]]!SNMHE,?3V3
M]_0;UVF6(:N@ADZ59DDUWZV.6N C=J^DD?^M*Q-,DUJE+1QX<O([\O2R\9^C
MY%&7XQ \]*5;GF_[>F-6T\,KE'/=]]1%_GOG-69UI/V?)>UYOE[W7TO*%DM4
MFEBF.Z =[4S^Q:F?-7W+5]=B5^R?KV!+V?NR]IRB;9&C6+;FZ7TSY+]C0%;
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M>[L$U 2?<L=J?J!.E?/\FX"'LY,O.V5_?&564WQMM.7$@#>U2X).\[G+3E,
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M*1>QR?WHE4Y +#=9_.N97N[+2!) *V2!/:)YR]W:O3.1:JGNZ5>)Q]P: +V
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M[/-'L4=#&5R'$(+"2+D!4TS2;JU%&2[,V[IS/9-08;Z=TIMG%\_HGFD6T,)
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MTK_7WM?MXYK.+7&/1M1XDSQW_)>0)<<7NKFNR*OO_Q/U[BMME\>W6@)=Q5\
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MK:7*54D27*"LB=D*4'^Q*MA\(D.L=W1#O9@<JYK!=+8,&,8(40J&Z#I.VE7
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M1\:%Z\YN>5%J'$QB'\N45\ZQ,\?IU9,C6]8K\%D7&J0D@#=6<4>XSB66-.!
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MY=X09W-DB\4TR>Y2),A$DW@F=961+H>ZSV3Z#'/ER#<9KL$Q#MHH7-Q6. S
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M'I09/@9M,,-^0 ;)N6\7?VRP;6W.,ZD!<FL&<A':/&3:#M=A)=VE6M*X P0
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M9X314ST,_TPE!]CIX8&35^[V-"Q%-#(/$%D=?/6]9\L-"YLPP8S47:OENUD
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MMNY,CMG"V7L./@'U<UD)_8%_>*K<3BW\]!C_O[K[S=EG_P%^O.TWBTO]']4
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M1A6ZCIC>NZ/ ;R$K6X/:WLNJ%N).JS(S+24SR.WQ^X3_J[.W"FL#ZK9%@Z=
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MJV/UW?11H%_)X(RBUZ^TZ6>AC-1>* 7"H-<Q\UP$+@)I_)'#8I* FOP),M+
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MS\>H&>@Z7OU,=)11UV)CL"^.3%MTXV1ZH:]G8* __<<BAY<7ZLF.X@^2!<0
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M$PSBAD A#A!'A,MYQ+Q_CA@,$K."P1V "$E;!Z UA!OBY&(ESOT[]]\=X/F
MJ:O_UV7MX,#]=Y8N"'DWQ']MZ7+Q2)-;&^("<X6#(/)NYUUF^'M7VI!_,JQ_
M[^I<G>$?SS9U=3%E1Q<$T/'B>;CD.8/+UA8L)B(C*L/#*R@M(,TO)"_+RRO-
M*\<C*L CQ\,O+2<C+"-]6;)_-OV+6SD8R/5BN'YS"[YP*_K?<_L'T[^X_?$
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M%WFH_J.NL5J91.3M5994RH<T%6]*9I8G1[W#P\&IJ^P2:B5:#:I4VDKKB#.
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M"C:^O]$*VFTWTXMC#DE36/PR@R^M%N/?+$U6+>B>?G[!*"^:+#@8,F[,(-L
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MJ?0TJ_ OQYZO VZL%&#>(+&VD/=]:1+:B()T.VBVLVVJC?#9*YG<E"PF(])
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M4L->[".A#_Z+N<%V<U)I)?2-/O(W01^;D0R,%AGP/M7;$K$U!>,62F&JIS;
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M[P#$=&[?1TKB R,=% WLZ<0PKH1=8[FZ870"3EPJJBJN-AT;&E0@RCI!\E\
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MS9J8'42GP3'/!EOJBVS*4R:4R7&^;[NLHV>V$LV2('*FH\1ZK&0]*R:&X_O
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M-OUK QB;I(#PJW?^.6U+!DPA0!%6Q%VV&$&+2SKG;F[ZV+>1F.BG(G+5R7[
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M+X.=O7@2GMJW+*%S($J,2&=\+MI[Y#O-Z =*VV.CI=BY<"+2VTB,_/J(^ZS
M48Z:7.:[D-3NWES5^(S.#J2$IY:20@9@ N^QRO,S,VHW;5__=/9E0W IV%)$
MD&B3>CB5!$>9^%>'5F%P-E24,'$P57GB8\GZ3Y2W/$S&_\^&,_ZWC9N<*-<L
M+?CEJC4TPAY_<'3BYS=-B*]>D^-"1%'\V$2 L:#+:T4%I8]JP1LDUJ$$:7Q"
M[6$Y.$M.TZSR)F'(&% #\4=-5/9$'C%R'^G7@G2+FI4'F!3<@0T1VD"Z> :)
MZ*US:=^U.](+F*OSAJJT(\7^#KJY=<*'M*.\J#']X9V_-I:U\$PL"G3 VIC1
M'>M&;?[28O,!N3Z-W[4*Q#Q4)OH\T4M5&<!9DE/WPCL9'C]36_?5!,+>8T_<
M)F#O.X (G=.XO>2<7FQ!#B!M3\Q$N2))"5LMTSKF&(S1;C'J9Q4<^L7$<X'G
M'2!5B6@U*C&K#>F 9)NQ/V2>:-3&/)<C6E1\KFLL.X0/* A(BLB::/KZ(M%W
M]!H3]//@8M.A;O]T\3!@TW;IR YT^"#0Q3\WS_YHWR'V1<VPGE5Z0/]RQ]9J
MK2\J*8(2$FWPF1IQ4/ID-W6B:-.JS(/?.^_$*VNZQ;.CO)MDU&/$*9K!?Z(E
M42()?G1T0C(,19*+J B%@)"H#H56.'^%9M!07EI2;9%OB<,3V43.SN)B7<ZX
M/>,L]_M'G(#,K*0!+#'CABOYK3U,.:$)2B0J3G*WYOWNU_A;M(W<\:(EN_S1
M X&VDW< A3_Q.\#8Z-A IU:8+K7,?*SIW+),)^R+<OE23"I?5I^"D85<%N^<
MPNB*D>P*SRC\0FW/WK?5+W5/UUY:!11GEK.6D ON2F<<=5MVYD2JSE?Q\:>L
M,0Y"J3O-%60S],X=.:HO5/ H5>SX1QW"VD-VBB14<R3\_G9_BQ_*5)(G)A/+
MF#1S4SD^+Z#+"ZHRP;/+49*;AY)9+'19"JN!NQ;U4 ,JM9KOLJ<Z_,(K9?A%
M/FT8@Y5NI$5+KSQU&.3Y:7LM+=N;(#M50B[XS=J0V<\QUEE?&B/+LNF-L(E>
MT\-8./VZ3PE>4P'1KZ O-:ZKZ:YKE8:$&2T*4*G6E[@.WV;+HBQ\'X#A4M2H
M5.99V>W/8T.A#J75S,0ZDB\V,/"P#Z51U5&O/QA$!!(K0&%Z\^85_GP[H3G1
M/VPL#J6'?K$TWBG,>P5/S+=J(U[\._.W^L:%!Y=.@8)[+1!PN'\I!Z)GN+<R
M5YSFF(8U7O([@0+B @EJL@;NIOX.<"EOZ] L'RR8K^H7K1(['B:<@H"L@24*
M;8$&DY@4[ YI_L6"9C7SM*X'G3$WDA ):F6!1TY^V:.^ARZTA2"!1^;X *YZ
M6FWCRLK,*L*<%N31J'#& ?5<JR[M8L<?SE/1[F.<4>7E,KH^8<#(BN 1@3,A
M!)4;%]EA;>><RCN;E$.AN.CTRN]#HW-IZ9V&:1I4K-ATR5T_AMEMLDGB&\7E
MKC@4S%^ V(5]YYSS)& F_1/9EK#JX,K:I]%R;B<%:H6PXXR&.8?S2"X*&BN4
M;O)FVH1<TTEM/0I%#G&W'QP;&KI/JVBD$B4EN"S(#Y,-J%UJZR@?O@6MNY_:
MF29B6\QE+.K-%TQ9H0XIYYPE!R5Z*2ZY- B<*Q NMH).>$O\X;#.G5LL<@>V
MZE*=Q9@[($RS#X>'(\DG@V]90P"V,B*D7XW2O3]=UK^[)L?$,N;6>&EG?W\U
MM1NLIT"S6G!-4CT82$:M#9I92M(LB,:5->^(R"9B\")PVRTF[G3AC1F^Z10E
M09V5"2&8,Y+Q(_>'SM0K\-,PF*?:H*]B+W*-"+'^ ,]]E$7V.21AF,F5"7V6
M'+-VU"CC01>>"L*,2KKQ^XA+;_6D:$V95Y1"2'J,:618DT;DIHC%;K0@Q4()
M$VR2-^9^Z(UC96(#YQ.G&:,>]T74QA*45I1_<L /;1J268%)9#@'.[(-:;L=
MWOKNU\K3$C!^0U=?X'%#HM-/RIF_DI(9SM(M4T!FN$^26LSUZ#CBM:\,'<:E
M1/4.+FO*A\.M3JGP@87(4<W*W]7-5RG1Y2TQ*=06^)E>:TPD9Y%M,L$G@?*[
M^T[H5UEB;8<(R(/C*AUX4Q;^L*[C<P:W$"H4'IQ)$?+W4JUETH<+XL9!/B3P
M?WR-#;P!U4O,,:0UTE+ZXUQ6:+X#;(FX+)[C#5V\5U##W=^0%%LM0S4TX*U/
M/24H#B;!-U$D"'2*%N1'Y7JCZQ*TLJ3AR@ERDWK:1V2*46=_]LN%]8\-[%B@
MZ:T5C%)'$ERC1GZAA_O7I[E%?]<-ECHK'%?$_SC,G"<O(3WC5FDI+RFZ;3<B
MPCK@M!D60_0R9>M>7=(TV2CY%,VJ18;D:2(XBX_Y6FUMW-5O&K\MI>6*$+9@
MD\Y8:)CV7E$F:^K>BA#S<R#*PU.'^2T&)1H\2SC''CYUV>G>*_^25W_=">26
MPOJ1)R;EU&<LK37,C8T S4CYZ@09@*V F>AK&;J>]Y,LV&- \.N42U;+3"M]
M??E,ZJA59&W[>X>28H52:5A^AUZQ;?I$E.7ND*=S;>?0UWR9@X\9+7)XU5@K
M/H*4!:SVL]Y>BOS3M'"I;"0H60IVB+>P%.%>/GEBV^A@])8EK)P\?H\X\%,1
M6',.VL<2X?0-1@&/^ML/9IA(R4C4@C\_\G[4R30SP3!^Z/<H=VL@(-:0JDW7
M,S;P2V5)94+K[,L8=:DY*-XWE,_V0C3FR+'WF_9@^2_UT )'T(P/"=I]1P.2
M?:G1,;V7GS9NV=]")F_;!-TWQ7QY1@R%Z*I25II)27GMB'5Q4@-!7^R%WEW
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M)B9'KT1%1"0>7MX!*NFC;Z)]H,F;EP,1$:$#Z [?2XC*YF1.\,O/-\O CG=
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M^,"3[T<,+_I3B]G/E&1T'K?4]&]?L:M#,AX#_#;\.DN=KW'2Z0*.EWCQP"E
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M(AZ: PP5I.FCA55/<3H[A4/YA(Q*-)T%Q3U*W>> R\G.;WNQV8%7EH6RL@,
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M^>.G+$1W/;Z<\L<_/DV;CR*/[Z3/5R>/.PDIW!T]JIK:&1*7]*TG)0QV2"@
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M >X-$/&'GC.%O--PX4)$3-4<([1A\C2&IUW753(,F77( IO2$?G814$M&(=
M;EAN61\*,I.O*!Q+M%9Z(>9 KI0/-(?9':I?#-_TEQSP ,+9;2/-=.2O",#<
MPPZH+O2"O,G*Z8WR.U@M$&1HPC^OP@\;C6BV=7J.K5>R6O9<*90 D..-VLX/
M1RSY=#B*C@A57$%[?).?_QTW__;#Y.?X;!MR0BBM.W!*Z/^ZX$G*(R0\I'J;
M[N#@.(P?L;3K#XZN<$"7A.>,UX0Y5HC]U%GR41Q_R<*&Y_XD\-Z6"RM9<.)-
M?(T0K1^85Z<D<15^DM!,-,(8B*4L+O%3>YP_/"-YO'>N!H:;.;S\S3@__]H"
M[>4UH/.!Z!T@*K+I;T&O)!,,NR][LQ1?<[F?X15UDLLQ"?TQYCK!!6KSJT33
M"C-E>@< %=.C[G#-*FU&M4ZK,:*\,58,?0)'3C42-@(B$O?? ;EO4BY^Q']?
M>I3G)#=4+T7> =<B@9)OOO66^^(IB/H,#?")<?S)&(0[&#,26(+I0VJ7^UPM
MA#Y->WRWD*9RIJF\/-!5W;9?_,_7/Q^#3#_>$"W3KTDF+_:8GC[=5+N]6.Y!
M[VZN0/Z!K@]7SX&B_7]?;%)$-M&;[P-M;$:>L,]K*$Y-U2O<IXY>KJ[>"/Z3
MIO:!YEV^M1W(;?8^^I ?[>? % #^TJ]M^;M+_YTHN7)=5VNGK]3([[TG>
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M7.U,G_4T0Y%W%\("W4&5?).![B-&*VXBFT5E<-E4\&/"VHWYK(VL)D<.X=%
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MJX=KN,D#QL6^%_2P20NTJ[V6I>?F3B9NH%T!QLP?Q*<-GF%L?T@4SBI9HKI
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M%7O,8K/D342K!H)4"SWNZZ(XTIP</:J0GQ@=ZDT4"7[,KM*H5V7*E(!6N'=
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M0"FL8/DUOU6#CT")OIPA:-Q$\:Q:X1K6$#DD9X+5WVJ"G5TXN0@)S&U1>#V
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M-.IAP6ZX# )\R7VBZ2_4J@SV+B?N9L$","$S7W!!H@2B7B.L>AFRIYY#BV/
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M2/(")PB O0(*C&+^&>IXO'?[G\;G$%BX5PJ.!=Y?G%OZG8EG;M\^1;4F7]X
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MQ99.7_5LB0=GU>G>4R!?$;=9A,S4VTA;M;KIX^*3TJ5A;1,:\I]I2L G0\(
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M!BTX0CTN'HB#YE2075Z>BQ4\R^^_ H 3&77+6]-GT/KG(-.E_<E-,9%@-<J
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MR45CVRN \>;DZ?$)&^P5([0E+!>7EI 7#\R)%!'4CS'[GA*7ELB0"DA.%(S
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M:_D)_]J@;H(\.8 C=35_N I:%$0I-VWV^PW4Y#,B;?F'^"*%4+$2MV5)E/;
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MTTW_'ET<F<,+5\:E:UYBV@E?;^^\XN[J'3MNW2GI_Y^<@*X85MWQ7VWFV%S
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M*V,CXW.A\!/'AYX=$96,&Q =$0FPZ:R<^^K(A(R.L<<Y'APS+"/OD"# U+J
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MW?[KAMFV4TV'5,/02,..F]'Y85C.&W@T3UR):NV?7"W[MH9ZA"#]14;B@OT
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M<2#=.>E)/:6\AIB<NJBB^ANZ7MP:2DN0[8GX<7/+]]J9L[,_-ECFJJ1(*2G
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M$Y'SZ):>9"Y6MV8>IZ>VU\QZE%%JSO(\FV $?X3D0A;O)&5I(;GDHBO%MI[
M!2T7]T<AJAMC5-"V9;.H7['*PKPYOE!VDQVCS?R!_PV8[YA6(,]V\QJ8^6Q^
M<RSL!LH[!HN(["78OUT?WS["3:PF!O+_]7^ZNSFXHYEZV?T@$9DU\H[/SOS:
MCT'#1_\B%1\%4T59,)OW:A8QM.LM.Y9G:7=/KN/88[ZT_TXKQ=Y&@]_0^"0"
M&C_Q>__0!T"7]'H]K:&<^/W'ZE-O;V^];>,)W6%)7QC7UQ_GMHOW?3/PE\PG
MEQ!)'9'%!GRS[](I>N'GV.2&O8=1<R; G"!JWK(Y+\*_G@?O@B SO^>52%#5
M2P+"BR\:].$+:-_O=N"]CPTT.\/Q_ 'J<TLD[4_,L_XHT/@W)T"62#.[:AT@
MW+?+UM+KG/;1XZ8G0%/6^CA;(<P\M-1U].%WT&94C)!Q)NDT[N=Y8YE!T?F\
ME\U"I$HA@ =,QJ3SCTPZ)[6]YCA<(N?[99'"<G5@L0[CP<$R"[[W""CX<VV"
M5G<R+92=!E .D7IX<X<$5CS?LAZ+O>1&"KGPIW=%L,51KJ]F&L;6P4YYS0[K
MHAEOUI@QA=6 ?PQE3]%-ZFMAQ!61Y!5/'[_Y?T >@X$DFS=G)3;O\'>%?J\%
MQN<R7.V[B3?T'9^ ,$$'OS&0X/TG(,E8BTB/@ZK!VD&1NT%/K,,Q?\PU3JY/
ML &#N^9MVDFKUGQ3[9:F3O%0T9K/T5XN8GJ#P%)-:-H%'/==A"*J-/[D]7EU
MR:NBCN9U@V8L7/7A.0@M\7#&(_M<Q+#-<=6</K[8G8K;1!^H4/NS]6M?]9@"
M#RZ#>K 8L9.!3?E!2OIO*24JW0G=R2C;IZ7:SMN[7!)O YP,72*LBYD1^T'2
ML!2XU4WSP^,TZ^20R[4+>XG4"^6IS=/?K6-C'XF)IW%>GX 2R/'8\?'-]'=G
M_1?2C+&.3NBQ^/.[=_^F6P'[>@3'^LG5*9>]S23"N0GSADUZP2,B4;8%,Y;%
M/$X'BU!*$LI.L'^SE*T7V,\:OXJ0 "9Q*E =<MC O_8VV]?6%5K27_%\1RC:
MF&E>WWC?C8 YBBVJ\BTI*:ZLJ-8%:6#!#A=1;:D2DADF)\%?9BDQ0H* "&:_
M+N*$OEN=>OXG/'#AZP?NCP+^1$LD>R;YV/%SM4U\\GN>_??O[G]<EZ"\3X#Q
M^?/A\,S TTJ?N/3L'-ITOH/O^5T%@W^-"!^LFCZ71%NN?[$1:JJZ_HEZ:+B(
M4QH!GFY*#EA( M; HIA1&B51>0L.4QS?)8^%N2.%2LMEMV\$^=;Y^V/AU:5:
MX,C+)8SSU!>XJP3+</%QZ( _L&M?OBY# 0,J#/N-!>[N]AQ^-Q3RHQ1NM%SH
M4S-H=%*(Q^#?+E7I%XSVZQZPIA5EJ,:1.O3O,%*+4#':W:0GV;IBN1["$?&5
M)Z; ,UE<9.TIJXG5'K#L)=":&:;>)^"5J ">:1$+\Z&9><L[Z'3FNCTRR+PT
M$KC6A?WHI4+'0   ]T\TG5>&/E)U[S0];ER]E[J**Y\04&9,.OKQ57OW+21B
MB-0;^8"!"9FR7(W$]7P>)TI?UFQ/QP4%;P6]HH/WS%! N.B7S_TW4KGZ"1C-
MX?Q$?R5?SX912BGA,N^C=]&T\TG8BWT7//TETRO/<,M?9J]BD98A6)*^DR&^
MY/(H_=MH'TQ!+W[^.IQ/7J@<&FL4B]6^:%CH$GD%S5E,,-!V<0C+L6PTTIQY
MG!*IJDJ^MKDAR7BV62/]D:Q+02C"/FQ6+SXS1+75NQB*XPBF4MTZSQII*$$C
M*#5T]!O/I$39\^^6^M7V?#8H1.&>;&N5UUL":70L2.BU$_^"+"VUI3;R@_"N
MF=N0^#=-]-J0E/:ZO&]DUUXJX33R I(QWW)*N&&9R4O_#;N?6=RT3<@$_]C
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M.=N ?:R>+"LMP 1::.QENW0D3/CA*'N%_/I-=D=_.U>#TX+"S3*="EXD#B6
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MCEZNR+>1YA9W$FC?P+KD/4FJQP-:0E)=[WH2RP_W^!4VCP#RX?9Q9:X]IQ2
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M$U5G)^U3U^5<0'$-%\6EF8GX#Z;P;F!VD)%+8^P,^VV0![-YJ4@*HR[>S">
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M<;$&6)W#P9^QAH+&?6;"?]M;<J76-R@NRC.!QNI6&.PPM:J%_2H2$3[8_FC
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MCSM POO2Q5FXC[1^KC"<I=SN6TD8>O[!I# 2GE!5=$^0%1+22#V[S#^O[W;
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M=L#T ,<VKC\89\)X\2+!.\C6);!_=)[+H)S4P-P[7_&5K:DQS-Q_76X P"\
M !& %/0^SAK #=ALO+I;8C/4^5\_<IF,XS. J97?5I8K1![_Y'EWL]>VHA/E
M!<$EUIDA.(78Z5!ZK,L+MR;J60RIY06B!]9V6/ /BI#@5+X!(+GE+A7Z[IU
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M_>QSZ+4F#A:(Y0C#^7>>I!DUY4-ZK3[](JRV'R,PI5@L.)E\%SE$;&>7XVA
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M=9,W(OL(IY6Q5@:AR4_D[R;&!9(.M91V=<[?@ZBH 4OIXQO]7@  WKL3P!M
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M&2*8OA.1\_C?3YX,@_J&SN!][<P1R_X*')V]1+P3FN&3H)SWWR :.  2!!^
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M#+6?QQR"7T#RULHCHFN/+G]^>?U[\;OJJ9IAN%E/:%L($&0NQ%JSDJ-JQ.8
MIG:I9L@5$D@V9,Y"F?YA<J=Q;B=OIZ24RT\(>')JR6*=8N'<[LP?FXX%?546
M%82$A*D/3Q)Q\^&EF"2)!Z*GXMXK:_0HPJZ$61KV,01(%N^X]BN/";P533>T
MA3,;>U)Q2A*CAAL:LV4;!.>;D5 '")_=,QD:JVT5]8>]U&,,\7/Y=]\ \0+3
MHK"3@:?2G-KS3L>Y&;$R@K6(#8-*!).9.^6(X\QSXN&*$<$\G;DKO<76&'=5
MC#\Z(")\@IOO+L8P)L,JP@*LBVIWT(F?CF'VX5$A2\20BO*4:M$EG/69YE?[
M?,8G+%E5LXR?2@A%/<ML;H[QP2G!>^=<FG2UK:"::0A_FQZ"QH("V9+A(&].
M.?.WA H\&]"RK&GL*.DDE*3*YT.9?^N2PS^^MF:7I%_-BDLN9P9#2VN?JOT[
MP3$B/OMZ[C\95E6W^B(<PL<T+#!:-:N0+$-;#[>EY990U CN$[3HAON3U-E3
MCY>JYX[8-*NE@X?? '9?1G^+@CK2Y!A05D8_U7;*'G!R^:%HVGP0)])*<MS0
M#MD98P0-*,W-+ Z8T1C=16=T!]V\&(5_0&=RWER_MM!9L !?5%TU55Z?Y@NN
M+1MXWKYONT.RL#4(K>-V6_)ZDB-2*"(3AQ57J]IU+-A*JOIJ(S*9E?F2B>X\
MJCZ>'/_]*D0A2;*<' 'YII3B'&/<J>ICVB3(0!W*1*^\BT:@%!;W*[[[.]Q!
M):AV-U3I*J6*I476''+,K+F[3H>S:%D2,B]?!Y+43?&1@Z'@,L7VFU&0">!]
M>;W31Y]2'E-;.R3OAR,V3A./0<EL5M>,6N97'"KGA4JB"AV)/__@X;-^'SK[
MA(':XIV:L*%D0/+9<_V<;T7D["8HGE&Y'$:+&%Z,27>MBK>DL:,0&3<";$PJ
MN7(S&2OJ7!;-J8L\RT4>4(RSJY4S^W/Y'GF"1&,7.$J7J=",C3:;@=NEE9$T
M[ >\K5ZL1S\F["H-F9 C[M5)M;=//F5D9R]B,LS>IE7@9F*LYG-7^(0K]PYB
M5,'MY(8XEU.^2@*%$J!7UC_^RZ?R0<EO?)YEHQ)H:;00W6Q5BFG)!]2,JCOR
M>JV=L%U4CD27ZIA]6D;35*[ZP)),L,BA\(!FD3*HF$1K=51UQB8R+V6FP!(F
MW_#WIR:$#@=E4;@J0V_,<%R%U,ZT,RH_P?.?S,<4^QQ] Q)384MJTD49"F,%
M- 61DY&,0\W[M'@0HTY^3'0J#Y39HE(!6/VY;QQ&K7KS6NZ$@JZSC.ZR9."Q
M8*>KWWYZ<[7B)H_V,:3=1K=%<."C!+W#\N'CLER6V0WR_;>=*=ZG-T";IG(?
M_/UR]6F/G&R9)2^33^F0FZ].)^+5CN-M!U^53O>'[=KE/D,_W>7&PSZT1F8_
MC1_:4K$+.N9II+'GN.5]EJM.8I9$9CJG-WB:A6Z!:G)7MS#. 6[?!!3Z#AQ^
M'4/9_M1MV9-O,&V.8?N<I9E6ZWO1.<W"QYP?]0<35K<<QV>;BYE=F!H3JS1C
M<S)S1]\<O5FXY%_X\[9E46BB(99S9$JDB?+J+@Y8H[">+XK"TN;,G32V\ OF
M*A&3V%;A)$PM0DL;DD]DBUM^W/V76C[5O/E@& ->!;W+6+NY/.>8_,GW]>$;
M9>1GF?[(_I6V5@;BI4KCIG"%/R*:B44F7%5A9#&*^6\ &=LQ$EY)^2)9)YEC
M^7BS[FBL.A=4*[I08U.SVSD3Z&S3]A^][_T;Q&-R5G2\Z"KSKZJ6:*+4IGLV
ML1 4<\YA\V3^!-F7_2YQ2J L65-/#U7P&>)Y]D\J1/;(0@YIFEB@E @7L0?&
M\+@Y I%X\9>OC-H-P36&Z8,<L6:$_V5>@QR7L684_UD3Q[C^V/];7+K_0W,-
MHR%%[/"N4PO!\+./A/[THFU(^Q^\O7507$'T+C@0/#@,P74([A+<W1ETL&"#
MNP8([@Z#>W!WM^#N[A \: (!@K-Y/WF[6[5_[%;M>[?.7[?J]JD^Y^O3W]?5
MMSN,64)? X3YI#@,WE=I:J:RUN:**>4?(76IKE8@DTQ__UDO[NMH.S*II<'Z
M ?E$W#CW/"D-=WM#]C!'%C.[]16V/)L M(:0$T,O-R4F33].M/;L\0V@HO_\
M/V[1:VH_J=:I9\%7K#X-UFW1:PZ)Y'Q\=/%FB<2SX2PND^ZF02M@;T)Q, 30
M9='23TR*4/ZJ:]FV?C_L?5>ER<5C7118)6$[/5>O 4(GY5:2A87(G<H\5];=
MF:*^ :Q1 ]\ ^"S,KMRRX]SU=L.'OI$2(_JK?RXFV-+_6Z"FL(2^;]_998Q4
M6#$L-F<JKN6;>2S_\WWOCVRM<,@;8,=OM,2H+7T\)2;NV1#JP'M&MS\0IV_P
MGZ':3]7]@:(^U)$JC>X937OX!FB8W6\IS74W$CJ>W[ "+^W?#7_93S!4XMH[
M4Q!!@YJE:]FPJAV1C3><T4UB9IAE>C).:Z61,*_ CK/? *TQ]U?QA/MQNO_1
M>+89WS17/-_,L'/>L/,+UPAI5=.&/)Z>5@%>C DP/ZZT)?EXFL0FB]E7JZ3K
M?M@Y-2M<T4:A)X-1!=QUJ#OMLI_J^)_I9+2E;E3J%M_$;JK_W%K&:#A!I."T
MP3GA+I<_T];UW+@G%E0A7=[EQ:+QVX;!:%"0$3K^]0W =O,&&+E^%4UI'&'Z
MOX.CXF+A>L&E<L4M6)MT(P;SI696@) *7P[\^S3#&2,A'(EQCG<#,Q:9M,?(
M;,.5EP&)%,5$*MEY[- /GKH:@^)S$ 9 6H8C<)"(R7V)EA^<[;R2Y^N0H"[5
MU8K"W&#H!AMSGY=W7]ER'N([,OO_^$_P_UM+5R3SH%[!-,=?[7&#BY2M1''N
M&R,,TTX+$1$:QE]3OW8^R"^D*9)T3P)PI"H C_*LWP_$Z:38@FXM#&R0!F@0
M"16R+9*^C!,;"[95<?^YCX%9=^VVG2TZ,3.<L,]O &;B-AK54!5(4J)"G"=\
M_B_+($&-J_ 5*X=5G(3N?07!3GFM9,U"D**OO*1.S#1H3AFH- 2].'M-*0+J
M176"<AIQM/S.HZ_M-:-B.KXG2[036@E[U;PCZLGE3:I*)JWD<62#QR(_L.%:
M@!XL-N.I;:,!B_\X5FI5V\'?_T)UR^XM?Q7K+F\I[ODDG/NRYOCUPJK?Q$EM
M_7E[*)6<#YL\#08+DP+L2".YDFCX'[SJ":'O&B8P:.GMP[*@351\"N"PN1 J
M!A6.&%H&!><8.L+_*$ C<7S'*__EP:]MO!^VUGQ>B!&/46\>$Z>"7_4XT#K0
M;ZCHN9 7XGVN373CK9%=*K)32YY=2Z\8_]-E]C^#<40^@("8B:D-K][5AE '
M0I M%4G3'Q@=5Y.[-'M(9]811@A3]%(<P%\ <38)K!.DD4:?>3TP?*';MV-M
MN6@II)8&+[;,A2489-LJ\0EMT#Q,R^).82O9)_ *U5Z$IXA5.#M@'GW93T7^
MO]S4V="T422?:H@9D1_9QNR1EY[DVY4$E(QF8;R#'JGEH7S4+-I5J-41'AY-
M=48#A;['Y9>A';E]=%'7J)#6*'#^0!2^I3&82,/PT;7'F>$3N\O+&FJ&Z77R
M0>&4ST.V$6X8Q)X%A88FC&^_:1]F]+\&MO\9.8(!H_"FP0_(0N]EAS/"KO=9
MH7+ZJNRG*-A]%/9R7[GZ&$JB ;L&5G714%B8>^FZQ/Q^2ID')-9%[3<)P@K(
M%JMM-J4[64(MI#7E$#WR?5W.L%HOGF-[<A-&8@E2<+:['&FRM)( ^[R*:*WC
MV>,+%JOJS'\X-J5CQN9)/RX^3W(&WB=>92?2\8-(E5P)^S6[#O=5OSAG#N.&
M,O'KE[]JEG^.L>0;(P5/[O&9P2"$)V!N2P_!Y: R9I51<N0>9IC<G@P,@DN_
M2&"9N(2CZ46;$:$&N):GQ)0Z[?31V(XQ\*6S/.N,O"A=_,&C7VW3;V;]\ J-
MQ?EH-J8Z[*<98[8O*DIT$$WX=(O/T_&)B<F')VI!HM3HD9,ZN#K>0:8Z<62+
MF6&[U*ZD<\A6347';ZN?SJ7SP5'_P16/(XU5D("Q;;Q;Z\(_T%Z[Z!AM0'8M
MUG[F1[JCSCBYD@()YQKU>/=[_.&3 QI6RG#<]*^I,K?/;X"TXQ?'FQV67/[_
MRBN_SODA?>T/%'0:)@=_J-;W8\*9>+%;]S2?VUK1[):"BJ"ZIGVB_M]O@)8>
MC'*O@5>A_T;]OT_UI!DH[:,#^/O5(A]])7IYG????VD;.'?2(-(6VI\FQ+N'
M,FCC91_OC&M7F;#LL_)#K_X;P.4LBE.L9XB>]NB-B%!=_,J%L^ODJ/V9CJA_
M2CUFEV$ +YRU03^Z_RK53JQK+Y.<1X5VA.5_[LI,X1YJ,5H!067UOX]KXV"^
ML_O.4I2"HST./,\"(J>8])7\4MKU*Q'7-Y<4%P@5-0-OB_UV<>#GK=0J8,21
MCPJWWI'(=1N8YCA,8^"B5RV6F50B_Y5V )IVYH/0"N>)L(=!%"4Y)UC:#N+_
ME^'^ORS;91#_2AYA-YR=AM -/,B0.DJ8GR>1^=6%T)W)^HC<7L%^.5LB80^_
MJ)I?Q36.[U V(IJW[M6[[EC_]LGF5E!UXH%Z"@RD'ZGD[I]PW<R)L#9J]0\M
M1GOZD3$M6YU;GP[?&4X: VP\O,ON+U]7D3,90$QF,C[?VU_4X)8=M<>L5PL/
M3+0NDK,[AHQGPR*SK.NMS)@ESZ_"\>W<_23-,+Y0!3H8( YFW2M$#9&/V *M
MBTWN"RIBT((*OP]4RN)1ZJ103G W3"Y56BO 7?'J>C*3]0*C>$3#%)F+>"//
M0]'&*/UN8@^;+SY4_2B2KDLSLMAQ)<)\^+X#?#9QT1@LQR3^V:AAS>!D1_"(
M>UK I"S1&QG2(N2F)E['-Z7/JG!0-L=<@G:Q\3JA?P>\R4+=PC='A8A3RG/
M-!J,9"Q,':)"K=;,.2)+C5X@]4_6?ZF05-9 EQR5*6"SZ(5(B8H"1NJR#+TR
MM^A)/^H:=[2I&AY6WFOXNK[A2<R%\XZ-<]P!RYA'79#GNE7@F.6&;_BZ]9V!
M9'6^=3Q&%D_>]ZX_8H]0%OQ:$J"Q5G**23.4%J(RP, HCA!GD=J%5R:_&V6.
M7D.@.R^-&4-&B(2 )*,%-3G414+ QF)(46,64.7T$%;-L.41OTYBL5YL*!7E
M^KA'0NH<F[I" '&AR+1PC]@EEEM\>& @OJD4?X>*\,*/*CFM#/G1Y2L834I
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MX=/J^)QV:,-*,J$9K8W$^E;6.]_OF'^)L3WDYBCSA#N$IDTW[\Y9\4@/[12
MM;J2;P"-BA$E#YYR YQUN,LY\J% '*S2EH>U%^X=\&=%UCT]Q9P$Q-92;__.
M<UH6^(M8;\A[7>[09+-0_LB?DR\+[#\^?!2'ZT((5<ZN3F!Z$/VHT*53&=.-
MCU;Z>[NF\"E2MBL @&P&0*6T'37UF/Q _G'Q_LP^:'1T>OS]OGW[&Z"J[]<)
MKN>3[DN3RC/PG;BBIWVC^R#F0CF1=O9 <.T.KEZ/ #EV9&9*!64(A6&+&'X5
M5'RR=ZR!OU\P_C)WP '!S!R@+BD\_:><QCB^ED/ ](3'HR!"N3[]BLU]C<C&
MJ ^)9<=#2+]8<\6TQ"A^VBD-!\B5JELO075 ]0:8/:+1?+)R5Y PJ&5Q^%_,
MH/Z;B2K?(83MWV)\M\H3+5U61W5*_YU2.XDH,()E7;?/TA*.?^J*BNV'OTQB
M1*;BLIY05,DW>6Z3UHE@^_3'.V5_[=U="_47TVNY=W<PMIQ8GVO:O[JGRDPY
M("K+I,W7<2("R%>,I+:YL.;CC1SJ2??WI[WF7?G.O@%MGP@U(P='>'?,6:M:
M CXSK$A)VGV;I"H"N?,F\\8?2CB'E.X3'B^D//XZEV;J(]UBB^<LXBBJ\E8D
MGS377>1G-J.-=!JLO_:='CL^&GH#U+,]FBM[GS?[S7-%:NM[F%=%WQ7GQ8"P
MN)H8:2!/:LQ0,?%=L0MR9(Z=:X''5O\_0?_R_#>E\PWPL&WQNN,;YO]4'?\&
M>)8DZWFEN'VPG51]#O=?$'T#9'?]>@.X&WU[ UP_^X^>G6Z] :8QC]\ V]K_
MWA][B:_LF.2^ =;LOCSW-!#NO 'H7GSYW@"CGB]<_YJ>F/[G1.L4ZPW -O(<
M][UZY_E'C?_+H<,;X-4S_N+OJN4_ESSU;X"\-T FX:\#4>@+ULP,Q0/F&Z#$
M_PW [[7S>MHM_F\B>EBCT*1_2DWD*K?96%]5[K'6<">_\3ZDH[%/:!_CPQS<
M$.CM0,O+@NF7X/>;67EPR,ICFE#[%@:_#Z7"\A;2J''Q%4WJ3&E?X ;'$6^=
MLQ>C<YN.],?+$KD(]ME* 7'6;=7EAF3W+S&/H9YW\:NU*NX[RC<E[X!WL1E9
M/$MN3+=48QO-F<TYS<S\0EO65]*U&Y:9YE'%\E1J%V5N5#$>E;9UTUX[PHV9
M/Z-95MP3'GD&_R0;:C+$!\E,HE."6#X=1O58#9X1'$($B,G;^&-%25^V':@-
MQVKMFC5--[ X6HYYR;.Y WAI\-89";4MH%&8N\V\"D O$*-D!,XB%2.=J63?
M*.UA:SU"&-IN!%>9!O-6D9W.+_1((LI"A9]#O8[28@R?0/7=OHLF[4&'C/"&
M)8WA3A=9Y@D.PXV"X6EI9-9<:1(?9]!Y6" 3ZL[3H;C4[&$2 ),-ZR(SG[M5
MCZIAPC< ZDUEH!%+V7R>"G;4)')GG:4C;3I,?K3IK!Q]+M(<+B#5Q2)-R:-7
MGLH"327>-"%84@$ <%8Z^UXCCS6V:#*^E'0@!/M<=^JZ\XW<1+D^,=/;B9#-
MM,=.D=E;WTHQA"4 P:2$*U!8LC[UM/7\)W-5BQKF'%DQ7IGA7^R8)QA+'JC_
MJGYM[=I3IM@ -E=><]@9DY+>/[G5W9GP$6;(%D"KHYZ?7X>RU[_IH/?J1YS4
MHD#@P=IO0W4B:(Z]&FEJ!#V$<J0P'="O]3IY,LBH'9E9F*P3%UL)E\*C$P^V
M.P,7*JXD33]E%J1O\_S*+>1PB1#UUB5]I0N5)QL]+(E4=>4NJV6< Z42R-FU
MEI'>29O3&QV] =!=*T[ VB0+!56<[%3:'QE(/AL$CV4[CS">M?2S4ALS2G.2
M=5H,IB!RV@UT69CMGCFQ"LE9M1@<8H^Q#HN57>4BX/1CG[0O9%!:11RGPQO\
M[%*ETD:)WJ'!^)G#6-OJDP=B?0; 68@ ?LNMSXV 9KO/&HG3?YK?9$)5M7UX
MX2LSW?*9"_3A/T% 7N0"M_OF7H?:,,*C:&!17D?(.N_+W8:+.QCG>EI\^2-M
M<PK]NSU02&J$D@%40(F$@68X%V!!PQOMGCB/"95B4(I/[,7-373\1>L!^B4W
MA8OE"*#"E(VW\-C)N1<X<DT/:V>*'IJM)@0'Z2]5'K'*$4$@AU]#.!?E59W/
M;=PJ""6&U1XK%D0,7X RMPW/ZFFG8X4F1F,IU87U!=V*&HJVFR+"G0*[)8O)
MM4P2EH6TQ(JKDJ\['>L$:=_RJ$_]*IF#'^(N*%YGA88S)L;)S.,I+#Y1-N@-
MF5D(H).HCR_Y>O](@+NW-J%59!"NZMU52%GMB-\2F /)S"[;"Z9\,%72+;#S
MEF,"<Q[$!M"+#X9UZI@EI6WRRJ 1XXY\(-_ %,6R=$8>I\Z"L3$KU3]OB,D%
MG_:)Z:C_800&O '>>U%+2,9.>HR :8>@: '-D]/W$_. G:"NI,89F<F> )#&
ME# $RHQK$V4:GI9.A_@1&Z9>'//U:\ D,6I?UQHU(9$R[544?IAF2QYIF'8X
MQ*NXO)5$3SL4RC_LE?Y/S9QCH]"L!A]0[$_A)W:!A<"%LB"'N3&2<EE9":VY
MI0 H])_^"Q!'P$8Y%&XD,J^.7"E!T_O=^T2\P"BHZV[?)%6FYV..1F).Q3\
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MIA1X>M*MHG ,E&?,+Z[^DV+D2-<3L4V03'O*7==L819]L-MC3'-Y=M3G7D9
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M\31O>R0A.W)!S@GZ$F-KC?9M/V"3DY*T=->QF%-*RB*!&4WYTN>U45D24D_
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MB]N/  !<XH)/#" #()R/GV\!L"4MH&;@^]*J ,3S;0#.50E@\?C2[GP*$ #
M1D='QT#'QL# QL?"Q,(GQL7&QB4F(R0D)B0DP\>^HI^7?R:$&UA8-W!NX.'@
MX!'AX. 079YPB'Z8X/\W#LY? _#1+X+/0D*@ R#B(R#A(YS/7%04\[P#0?PB
M2A2$*_J91B0  B(R"BH:.@8F%L*_"A$ B$B_A'@ !&0$)$1D1!0T5'04)&R>
M"R$^$C(M 0A%4M.4D,[)EQN5*":[4HH>2*S5:L;#"_/[((W&$*O]>7[7W)F/
M)*?*GU$F3L="MBT7SD\ZJ+L WJL.:!]R6?PBQQ2?%UB3T#&\M)]?VSFR?*!G
MZ1KTM*"N:W3E\(Z\OI5;<&)A_9NQ3T?X $3$BVB1KV)"0T7ANPJ!%D2 ?!&!
M$QTA"K=O#-%E!*U:'S[S ,WF87ZQTMK$YLZ\NPRHEP&@,?*U#5X$D4MJ(:O+
M#P<O_ [AWT? ]$<(YY, ;*0K3'R ..! )P&KJ86!A&*GI<F$?O(;!7YCRT[V
MOECF,1^:2TO&Y*D\^$.=L@>P>]+X!M7..S,=G35@P)CA87!-9;\C2IX*GD9%
M=W-MOWVB/S+ZING T=,S&R5[8'7+5-Q)I)O'(<(Y0">\KZHGTU5RZA[%IX:.
M=L,[C>_[!V"\I79&[X_3VHS>SR-7QXAA!LDQ2M][07YD!+BF:[JF:[JF:[JF
M:[JF:[JFO]#YO,"*-1SN*,3)Z>#,87KY\,9A#K7G=#=UY 1Q<'$"1,3='4W-
M;<%P&C.P%<1!E&[GQ2LZ&HB%*)T^GRJ7JJ,TV!JBX D#:WNJZ9A[VIH+6M")
MBV&*N NYVSO:@^&F-.[V=@[.0NZB=%?.A2[N+]F<=#17*G!;4;JK1T::NZH:
M--)0&)B&CX/GMCD7"$3#S\\!XN7CYP>QTW!S@;@YN2Y^^&^#>(7X^(6X[]#\
M)#HQS(NS",S"4DA+1NXGW$5)E.YGO=S<W#C<>#B@,"M.D*"@X*4;;N[;%QJW
MG3T<X*;NMQV<Z7\X^>5'!NQL#H-<O0^FN2R;FD%=X*)T=)@T?Z*?];)W_ WT
MCPG\[?G2^86VD#0,; H'RUP<8MQ<W*#;(*[;W/PZ($$A+AXA/@$V+CXA'BX1
MSG_1_"<?4)@.%&HGI@HQAT&=H9;PMF<T^E"8Q66N^/_DX*?:OWA0A5I +#W^
M(0IN;B$>WC]'\2?-?_5QT8X6IG#3_\K+GW5_Y9KS7Y+]/VT$QS^U]E\:X4)P
MT0@\?VV$"Z:0!@QJX6(.AOV[[/U%YW\[W(M\J*K^YUYC;\_Y3Y;.<%E7^'^V
M=+Y\L\2I!7:&NL#,P;*N8 <X_;_V0555(06(\T7/\!#["\A51;3!3G_E_A+8
M0:XJYF@*<[YZ12A*]PN%[F\&ES97P0J9FE^ER@(,@[B"+40X_\+]]V87**87
M\P08YBQF#G6X?/D&MJ"QA$'M:4P='>T@YJ:7]IRN#A8_4^#X^S=E<"@-Q-[4
M"LP)=G2V_(7W)W=_JQOGC\K]?U!I9]/_DRI#')SAI@Z7+WC%+MJ( P*Q$.(5
MY..1EA(4X.?AX9>5!H$D03)<@KQ<,EP\DC)2=Z0D?_G^D^F_]^]F#7;X3\/T
M3UK_WLGE4'$SA8$EK2XZEMB/F?N/WU)*:_/3,.M#'"R@;LXLOSS^U>3?NS:W
M-G6P EN(<?XR_,7X[UKL!_>OO?=J[OG'WOYS&,C\Z)9REQWKW[4SYS^80<U=
M["]J\[.I+/ZKIOJ;Z=_<*OY/>L#?3/_F]L?+?U.[_XNH_\'%__:L:&'^>V)S
M=('97:W7%N:<8#OP):#SQ>0&^NL\;F$N9 F%V9O"Q?X\WO_@_J^O,K^Z^;]9
M:WZ)_[[L_Q8)7;W[OUA1P6*\(IS_Q/Z/0?_@7NQR+C98G+]W6/\TI/[WZ1KD
M&N0:Y!KD&N0:Y!KD&N0:Y!KD&N0:Y!KD&N0:Y!KD&N0:Y!KD&N0:Y!KD&N0:
MY!KD&N0:Y!KD&N0:Y!KD&N0:Y!KD&N0:Y!KD&N0:Y!KD&N0:Y!KD&N0:Y!KD
M?QD$\X^_600[6(C2N=&)BYU/ :0!"/^7=.GD_]8'PH_/T:PA&B,AX/_Z'$T'
M@!KP^V,SO_XT$Q4!&04-'0D1 Q/K0L$+#X" A(2(A(*$@H*#@X6.C8N B(**
MA(R/1@L@ *$3DTAJ$A*98I#2.?DR,'+KQI#1 WGY^/7BGV97?AC\3,YT1TI6
M3DM'W\4UMG6>1T;;S-(YH;IF>$3>W (&#^K<9681D ;[!>;D5=6V&5A9N[D'
M!,<EYN;7U8\N7(!37H:%].?@  @_OX1S(=7&O_QF#C(B&@HR*BH&$A(2"@(^
M+0 1)(E$H&GJY(M,%W,1PV<40B+N5E2M^5UB>BEM,Q@)CU]LSB OG[1S7%7;
MT )0Q]P_MYW?HII!)KYC^*\?ECD[$Y"BI,7!"T:7#J!MPYM'=PSX;Q@T*7'L
MQ1A#Q?NCD[,)6^[>K)HL]34E6?B>12?$O6T:"FV!?"4SO".]*WFGP-BT^[+/
M-B&%>>&V+QCS_.-CT]C3RBD;S2?Y]4FB:Z5=U+AFCT\Y0^7!QV[@_(7'3D^%
MQ+I?9#L>QWSK"!@">S\9O$<9E!>[<#<DPI:'\?O9;)E6L\W,?0"LGXN6(</#
MB@</.??&2G)A4K1OOH0EL@J9'SS-0Q)Q^36L) L RZW%<*%X4]-;IT.;JEPP
M])010KPX;*=,OL8E4O>ALH3):=QHUHZ.8VTG3*E ,5 8I*]%VBNWF<W;4US$
M]N28WWM"31[5=-29O4!#$1"@\CH[&8-.7TOE%IT6\?@XB2%BMRX>_Q;9&J[=
M:I_LWDJ7_JWHCE701+-!;RJ#@Z;<A+#%P$M_J4E:.V;,V&E(JUE\Y8:=SUF9
M+T^3WN=U':D"E&9XWFJM?RYY=(\D<DZ/#@V*!J*2/PN.'UA"DI;E331>UH>D
M-1?$G&.VQ/"#3W:B(DZA<ADUP^,#X'?<J^U\V_$\BJ9AP[:6;_JE"Y'=W7/Z
MDKD7>^KJHTMJJRP2N0VY)@\$UPON9D&>/6/*56=)4F4!*%FB9@?RH $1BWPU
MTHH(.%MBRY:4*-^GY "Z5^%>(?VO[)GW,M,BAFT4*%;O!PGKV9)0L"6'DGO[
M2F[?-8[3DIP_5@]/\0?E4[S(WB'&5\O1@A CE^3;9V+P&VZ72;&@!@7I,)"\
M)D  B7X/UPZ]]YA#.OHN\7!1GN7V"T-^01/N>S*\Q\XNL.*7J-0\15OV>%70
MH8/^VMTC&>.;2\2:K*K*B25:9$;O"^+O=0X_K7-?8R)XXMG;/K\"*(Y/"_!-
M$M/ >5!-BY$HP:/REKTTL26A[1891:I628VAD*%TD5!I270$V"J<"')<,[FC
MYG)3EQ-*TL]6S%4;M>8UFU"M0+8V(A,4_C O2*)9OJ@HN5@NO2EV(%LK0L*&
M+H.@AVG]L<H0.1@]@ 6S)#8Z(5-*#URFPR_Q.%$7R3&?2&N5K$9JRLL&(MKA
MF\/^^0T('#-B;7R2$-?L([:#2K&-+_SV!1M;GTNJQ@Y0KBP#S6&(/=LX1="%
MK)(S9D/1?E/.W*3&< CT'@2*TL'PY>FA>C 8PZ(GL1^?0&=2+*B#J(E?,]J-
M#L"+)"P+Z"((AEJSY4]N)W\<8@J9LG\Y6=:X%BE9L"=;)=Q>O@_YD)Y?KAFZ
MF<) ORN:4?$F3E%S NPR5/*<6*%D5*YAY!:))[\Y,PUMV83_4SE,C+P9+4KR
MRJ,]:TV;.M3BG J\6SE*6U-N:LD4VSO+S\NE0F F/0;):\IB#C>+6A1ICA_W
M%FAUZ;WQ+^J-G K9']EZ.KNB2!O]Q@Q#MXV-T2A^""CYX>T-WOP$Q-C0%&W>
M9U*!" @VB+JT;Q)5$PP<D-^VOL7I(6#G$(:ULLG-6CA9\VXK.DQ/T1XIUVB'
M, JKV746QBI^#!KVD7F6SQ:68$"GCFF4 61X'_"%^6MU?)C9N\U-%4+6)60_
M)977V-F2.K=YRSI7P\RSA3E+"B8!]VUJ7$4,UG/WG2+VUJIV8Y=G\IM'2Z7]
MRAPX)]OSB?1N'^B-Z943<\1^]M=+>9H0[Z<NI!=F5(V=5QYFDEWO\IV"X63+
MRW$_?T&]X\F?YK3O<_Z'C76E.<><L&:YP>!^Z:?-FD_6*9^J<X/M[8?J@1V?
MN#'5APKX<1^8+T@UB-Y]6Z^5T[U[;XM0?FVXV,XK2E[QDZ:8 9A<ILH_97DE
M"1%<E- *P)W@[HIZ=#LHJQ%#Z< P6R\J6Z%$V-7FQK#:E$;IFIU'D]C"YZ$;
M=5%&BIG8,2EJYX")9S<F)5J:Q1B%HI.0-:'JE=\2;#2)1@L)3 E?/]<Q38#=
MPF-.!/$ JU4YM..#,9410%(]"C B=O60IT7^L* G$CBYM?%=3E]J99:'Y/AL
MY(ESJ>^E$6@L=%J5.X&K7UF7\X\R)77JU[\Q.Z+)UQL#?6+2>N%E4^7%RQJI
MS89%JS KFNZ[PR7?'*LI1@5Y7NFL'%X@)7GTX*"0G5$P'X"1%(CO2TC;J"W#
MO:JHM=RMA=VU1#]9[]HV'(I=('W3XG$KB_&TFC<Y>1,LG<NX.#+6)2)5D5F@
MWY >1LY>#+=X^,6%J8[8[/GGP%J=(&+B^'[(BD_RAZ5$ H]*)QQ%RPQ'KA6I
M6%8%RQ3-.SV #;JLM%P9Q6$NUIZ.7!9:!U\)7'LSO<[)*.U;>=TYBSB/-<)I
M%U5N3.3L?0XE,#Q0KJ$<JXYC8M'E4<7-&!16TLO1U*25*J.,?&"I^&GM%F&N
M$B/!PH ",X^2!+ ;A$BNH<0=#WR,P,,#N%-\3U1"5S]AFI#;H2CRPY/1+>/H
M+B#%KEQ+Y0QD<TZ-?7&  B,/4DJ@.,HW&E2M8*CS%()U Z*S1;"E4$$[. F?
M'U/F7S67Q3)=E"'6'/G01!F7A@\L< JQ? IK\)_I96/9P%/3%=0A+UCWYS+(
MH4A@!J#C9!4UY(<^C53JPABK6THO5B=YBG\J&J=;R)G>.>+PALNZJ)G5"->X
M*RK?L*R1*)*)PIJ[Q*:<-=BKKXY=WS@V[[9,Z5.K-VK4U<]1H:-F;X&/\7PF
M3A^D2'()F/,#AP XVBSM"2O</2V;;TEG>[*#C_R"I4H .*LUQ$XWD51.--=)
MLEK:D (8B3Z0/TR2I75('V'727XMT <?.7[DL-^QWY4O1YV$KQK#.US#D:[4
M^<U%GB['5&O6)'7S.\+9H)U:V1>4IQX2!%D]5>]8\MKT-108$ #(#4W(,*QR
MG0:IKA<DI7(<B[6V<-'4FEB@803JBW2)@X=G=XA"7BFFV!G?I(_L'3J4(YP.
MCR>D8_<]D]1E+752F^!K"11NM'.=YM"WK?$2QX$\?]S'D(FM8M4K2-"?H"#Z
M0&\O/IKE!I>!/&AMW%]<2PN<RF$TR-Y]MT"_1/5+GZ1@Q,HPGL,T(5-R_KVF
M%:*520K>+MYT=MM'-O#8GG23$]6-NM!FE?U.T#?*JKA)O$Y*\[C>: ;MFUXV
M*FRU><Q:9<7&*N< N8\ 4A)'=*#Z4XNG!F"T@\=]W+'.I D!6:H"C)ID4=9F
ML2W;NAI5*T\;H\D)= 4E   I1)FJ9=UTZRA;8YE1C[I(0V.NZHZ)O,1A8ZJR
MQ:JO=EWI,TQ;-&EJWE1[2?LI%Q!4/H&BO%5YTXI]<B];_%OTT9Z,U*DR@#Q1
M<7!P@'OJO%V* <UV(HHX=FT&87TR!3)TIER$J$#RUY(CM*R(I.]+1WI*#T(-
M$QZHR--1?&.1F3*DM!#J)>=[\"7CO0YYMI:JQ9!E*J9]M-O;9D;&,1\.JZ$
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M.MB\YSRQ3X)HTTU1P2!!;6<)Y:E/U9B'CPM2S-GP;QLDRM@HSIG7O+RGGIG
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MMZ%A3/0D-J2(S%\J<EU2ECOH%&F;7]-YI[7\I?%'LT\SS('?<;G4'DZ?OO0
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M9.,>RP(@L4.RS?H@)D7!FO8 (3[N"S169:Y4+H+'E@@,ZTJ6[YBYE?+"LQE
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M46_V6'G)ZZGWG[S3?6]Z.V60X^2^ZL'$]Q;Q0 -M03DM*NZ^YRN]-TRESW_
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MWNHKP9S([!=DW/V(A?_];'9AN9:%)L[%:E;FHY55 7; )DQ[X6.L=A_J&S^
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M-NB-Z-XUO]H_G ,?@>.;>HW5.J\@SR? DEE4AAK$F*J*ZU:4:&"*&D!:B;)
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M/9@3MWPC/#K,#]QZ>!>HQDF3NF/H*^_(#1Q^)M@G#G$)RJ?/,?V_H8FPX^6
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M%<Q%T=.JFN2AI3,$*^;XG=G7[?*C8YTV8T2)-$9 ATUH@%YJ:-M\N+BJH#!
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M=8V5J/1S\^)RH.*F!U)Q\:)X\+8L*5O:(E>M*I% I$D31_6PXF7!_!D!HOI
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M@FR83"L.-JF4BN61C6JS[0<BVE].2SJ((/24IB89(67:4[:;@T'U #I$,)<
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MK(?V\#1)VGX,]8A]$NIY"7:"AE(NH8$\-]YT")9M"<JMB8D!;LX52;WW4=?
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M@^)2:KAW:AB5(!S;+#A)KNQ!YYQ*VD%)-3?!=K]>?\]_ RAKNM525Z.UL,A
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M4M;@RC1IM5F.J0[TRDZO$;\=RPUGS91$(##!;;9*5R)K,Z->,77 GZ\6IC3
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M$R57]F-G!#COI$B/J\Y%'?L[_[:8O+TBA9@(6V3\R*(5FZ=K(J &<HC.O=I
MK+@ $JM*Y7&S-\O<7SZA^&$]]>1@3C5 4,3.T6=I@^A>V<;? PY%>4Y%(W%5
M0&/3BOQ*,WED]:=&A5UB:FDK,ZJ,J;SVATT_"K-UO1TXYO*NWSSV*F7W.R4^
M/=^HW+J')]\'&:S8>EIH//'=2(0?D2>41U^P?S"P;X@XD%?(.??'3'_4:BFZ
MZT;J.^EYX;-L)N]-#*SW^IZE186\Z#=7"QK3[D1;(;S6TAE/T=8)+)\BNO^]
M-SB\2KO^;&J<1K]*^0>(5>7H:U(5/T/9.HVJ-VIDJ0PY'<Q7>:YOAV\$/]$8
MST%U)2D471@N6K5J@%JO5WI+NG$J0-#N+,7BC&+Z8<FE$1GN)19PT*Y!BH>O
M/FPQWO. /(9G)H=_@)G@C7^ 9SO?]^2<?X"2<-*TV'#@[C&, ,DM7Y##U]S+
M7 (KZI>M4O,_P#H1IMM_$D_)Q[L_42?]5_\ [UP]G^-*_P!7* @=M_<?OD*X
M%MNG+QZV)&N?16//I__')B@\S%GPHY<5CV6L>V[1]?^K"<]-_*6F47+S\'\+
MGO\!WN"@?YL8N/<6=Q/:!7GWB'+_ ]C\ VR 3OX!_DC\5S-U51YYN@^[<MH]
MR)*.22R<.]Q,?#XFB]'I<K-NM6EHU-J>\N^VX7Z[U*Q"RW5>/DO+5:"GYGJ=
M@$X#2BNJ']$K/J?SW"XN #96/V TT]VL6IR#J*Q0T!)X92(1W^9O):HQ]3.&
MX?/BO/8JA<]&D[$XPQ#=RSH?1GT;K!!V[X4GQMJH85A')AZ^;]PX*2<IKR6P
M>..H,*OP5+?T-_2T5'K9^)JV@+&9&8 ZIP[BB#H,FE@86NG%R8@.)@O1AXK>
M,*;[%U\1TOI&%='63DG9T(0=^@50AP;P,1R@ZH'-(F&)D]_+3)^1N.HHR-L,
MYGV_$L;H>0KS.L&[D')O+MH ;-H$.3,,=E(;B:M(FCPNV':#T^=C)$\0C_.<
MT16QX?6 0GH68^&K__,*1OH#G'](<6#3N%]]_<BN8NOK0F9\'[K]^;=H$0.&
M@1-Z8I]FL.$.H8\V3R4AUPZDJ+!6[TBO%,& )$V)//!-GIMW#%64H/ TFM$G
M4-9^81ZZZ994YTYNJ^GZHKN!LV.MS</%I[73W=FEIRKK1R3:ZIVR=2I6E *$
M7GN7F+(^_<=-;G(^U7;D[]:MP:)\3."3VN<)2'NMO"P&7^H_W*>ZUU1CXIHF
M2;%(B.YQ&]/F;VKGT8*;0Z;-\]=[!:UZXX.:'D8!+KWV$?GF\PXSL4K5U$)<
M2G7L9!4.N5GK6%$WPGI )P$'.%4F'M-*\CBXK$"P48VH&88UYJ2L(-W-D<QL
M1U.:'&M']2#LMW].0<%<N"50NHT6\IX;GY'N%MGV-++2F=,ULG"VONSKUM+0
MV-SKK6'#8>"_V"I !W;OHJ]J43,2TY&BEY-MPI.K,5KM'L UI3<?#SO#$C[O
MD?N>DLXGP568AKX?0S;Z19_Z>)X4K/;1/W"<2%?YG!31]47!/W:=M$_P>7@Y
M2*F\I;?^N+/0#OX'""Z858';N&P\[%) :G*^X&YJV&H**V@'B1]W!J'7>J5I
M9I3?Q45->4N-UVRUJAB%ZWV_>?PQKLG]YBER?4J9U8E/R0=EV4<"#'%MU3"1
M_CZ\0!SH86)P43F[[,,V >(SO,>VL_ 74U;L[E$Q!&,ZQ>5)\2#PFW[P?>A"
MT8"Y_W0M^F <R\)S#-"H[9O&$A'^4 .>#^2$P)=N.U@*4.CA9. F5?G8P6W4
MFH7=-:OJUUG?WK5U@J:-5IT=":Y,;9373X[W>HF%B=\"9#EMEI08Z'NZARO?
M=1!IG?_;SXV=<7/R(_LZ9Z;8F>KL&4&']SSMM*VYGQ0IW1/$Y;Y=%HQ+)WK=
MW7%Q0EK;8!>E),U),H7D-.T"2O5L)6-ZK(I(.2U]W6Q//74SR"U-'W@$;&QJ
M= 2U26S-Y;PU- 4*D7=]GMO-ZOV^LB<"-$'%L,WY<_;&Z5[EOD\$L]?-VS7I
MSUM+N>@EB.A9K9G=V/<'5?91M:<S_?HIN?7&3[/^OI0M=@&I.D<G5IN8T TY
MO7(M*F:P^Q^'K?ODUDRZ!@Z\W!(1@AP:)BL1K R1L3#J$2[0"6,<$$%'$ :&
MAJI#79<#BH$=IB_! FS=RT*W7^:'GO EZ+(&<#IQEWO8<FI0)<:$@>WS]]O
M28YAHBZ-/#"Y6*W>=R[] _]71S8.Z[0+3):/N#RKCJ42$'TB&H91+TK0HW,^
M=,%+?3")M0)03I':PJ%_$0J2"2@Q2A&4%G)XA[,/F@-:?^KU@\JX/;4E*V_>
M?ICQ>E>!>3I3@)GD!^4_F+64N6JW"[)9[$:.[NAUE1WG:_2SU<=:K^IM%<.$
M?V]+:"JF<],4<ZA 3X,T,313RU%<[,SR]:S(8,F*3=&FK @1E],30ZYL-E U
M/'W$NF6;59W+,KM2-BW46@4U6"W4#63.?P?A:GM/X^NO6SU:E+(3%&J6*63
M3&$2E>''[R"VVFUIE$?\;'5F=7A\]5,Z<#T0"\F0L%: A-7)F!Y77-0_OKK"
M#*7'!-!0RP& :O;5"&HXDVEL.T#CB:=U<P)>PNZ4K377A8UA>^-M#_L8,B?W
MVLG*\AZL9JWD%Z=(=R^AVG+9,BX[Z<YJ HHK@J"IZ:?S.E5![_M#E:4I)WKB
M_D$F7VJA[HI"#M'NN>-=O'>?%[?X)57NY(O2E)A,,7N<5LI(U:4VD:;Z&XFN
M1[ZWQH\WTEJB8+U+)HWTEF&4X.B6@'?@GW\ OF!<;'9/X3 :7Z\;$;5G\$N0
MR9.KDA&JZ8__TU"V_^6ZE]U%,O#M_O)W0,FU[-#'_H<A)J[D.GFAD7]2.I .
MX3<5J0GHO+ ?_?0XB87V4M@J)E.Y6_&/3VAM4=10P-N'")%U=I%K:FY(96&C
MAP(:RV#C!<(#WKOX(>JJWQ0ZU5;[7:Q+^P*)R9KG_>/]>Z#?GT^;\C#Y=I=#
M4JSTU'RJQPO>?X#_@!9JZ%9"VA0;-&4AT8&<!'I_<I(Q>SH:J>X&#N]N2-*'
MQ5?H5]&3;_QQU0>C?:NYLN3+)X]N//N&_V'KU(AI)+"Y@F 3UK7:BFA@1<KB
M3Y9KH9I?<J1+O'N"EB9QT63M)B'>J-I0OT3;%6-I7D9,/09G%+Q,7OX:%LBQ
M[4E.^&#^7&;YZ),@E)(R6 A]*8#HNA\+LF98BSF(2&(T9FBG>#X#<=6 0I,F
MA?07(51X2$K^D:>@L_>9Z*+/7$!%HD1L?6+O[ 6%I+#\K(I?P>AAY<JRRS))
M/CGVNP^T7SY*V04>E'M!-.V%W]/E'VF Z/FNV6G^X3V:>\ /V ]R2!D!7U+F
MQ.'P^0 ?O(<MPJC3RW2*RI+[%Z?&L2S)Y1"_\**8D:?+[H4(C8JAJRWHV_-G
M*D@VO\+B [^[#T%R[-G7+5)(O]!Y7Z(K5_9\EWPWAXLO:W0)GMG_%O41<QX@
M%+T>("XD]72991O!_OP =20,E_73AV]BZ_+@#XO3_H@9]N/6M+/XKEO!G&2[
MA/R9P!4A]6*1QODS6BSRWWL2J="UP\[?I@6C*GZG1'*2HE )?\FNUQQ/ XHH
M3]N^5(T[).COH*8./%*]\:"6B;Y9S*<,HAOW!7HDB[*X]7F?N26[\DDPIL<'
M1DW;5* NBPBSM\-+<_8)_> , 4 Y5U[]-O5]14&+K8&B.B4+$T;90E4EDQ\]
M3%A2^UD0-?JY757C%:!H_BS[.+)]"3H7W*-J)JD4O#T1B+>82OSFDHW4>02H
M^<O+9X@B?E/9U/4L*^Y6*O"_#T9C EP\POK5$ZN3.U\+-@PEKHF>F&&<"=%\
M5(ZR\'F_&:1X3XJ4_P',:HM:D^Y?I*-F1/*^AO1$'4B/_Z@JF&&_5BX%KSO0
M7IO\ ]R^)G2Y_C^LO754G$^S+CK X&[!'0(,!'=W=R?!@KN[:Y#@[A#<+7AP
M=W>",[B[<_A]WSUG[WW7/?NN=<_]<ZJZJIZJM[K[Z5[K?2=8P.)FHSHH[:-9
MNV,67S>JX43_E[WOQMD[($<ADPPUW8?S-93%=T%0\]XWPT?G/PE&'RZ"99:7
MM)>^O,ZGM2ZW_LU,USB@E::8*RF5/.4C!T+9Z?S!9WDA[PVFD)%JWZ,NT6/\
M9I20(9KH@W3_T[J>'=O ?%YF.O830LLX)9T)11*H:XWR0FUO[7;*QX@(9PA;
M?<>5X=<,RSN =SK73[60]P/F(LGFG9?+@P,6P9,?!3;,:_$$[74G_HLN[>M$
ML[??N1]4?R#RLV*FYKXG^T.K:@)X:Q'I$3GT]U.KRW&?\G'6H_ _)C0NGFP\
M33*2*<<N@XM$/MG[@G;0,-E)&PKVPIT6UQ$OYQ*=.#*>.[>M.XLOD[?$"+PI
M$O_RJKKORR98.Y-=_*SC<)SP#O"ZA;UR4+,ZGD;[QRYTXL7LTKGXGF?GDLA#
MH+/\9 M(<)?#1:0?A01N56W2;U\D87RC'GS<,4;[Y[,"+I[LD??.Q7C'6_M$
M$\]('W,T8);@9C,OXNE?&$EXI_-?HY.<J6];MSEP89\FZ6.:BE[$(>\53&/_
MB1:3='2,0W-'/U,><0R8;A(ELG6A"020*$+QPX.H_?)X+H5UY3.Z0(P_+NCI
M5Z9\]1IBVKG-VLW#]>\;T*U\S[UW;UTLIC4B7+G!7,"@6@W66([5B1!EQWRA
M5NO6<_QO]"--<Z2I: K'WY>F(>TJ3U>M(0XR5#OGA :D>7??4)6G"#=1E@64
M7OY,K8J?(@+JMP<2&Y]T72/%RG"(TY5M?]%8-7G66+8[D*_L0JZY%R>'#F@V
MNB7K9+\#8G"O1Q=4W/CZC(!&7QINNUUW?H71?$U?%*YF%RW#BG98+-5(<G6(
ML5AM&(@>6-/:76E>_N1:U$UH+AW"5IHL7,:8'B>?T]OBHZ9E_H<^UDQ0.@;J
M,P,SG!Z<")?&_- :Y*$8Z:#G!38-APVG>\^=URER_DJ#'ZJ)@;^6.%4=,GXP
M?U%4UD)6<P.+"!]QW]THNJ*C(+D$Q66(W$@B4*NO(V!"2D,*?C?KC*V.X%YT
MT1S1)8]\J4%.V$@WCYY=. )FD.-D=U:D9^?K2OU8OW[5:-AL8\H:YV4?V>E:
MT@>G,CPL)4VHY0LTJC6B"PV+C2L8G2J$2X$N,73^QD2GCXK[IQ Y97">+(_Q
MUDMHZ)"'U]Q; 177/(%GW9)->[PT7=Q/1>(5S= WD+<-9YSOI]2G=\#G&+EL
M8WAFOT]];R=#,]4X(*5.A)(2, +TS%!W24->:J0W_@+?V42]^\G Z9?99-Y&
MS\N#WX1NS5EKQHT:T\_D*TO&AV8^1K+#9QAPM#%M[>A!<1O-V^>3U\K'K5CJ
MT)6BAJM9 Y=\FB4;U* )UU6CR%V/A*SA59L8@B(#=8;$J36O00 99A:O4KGU
M@_#1=5#-T3<;X6N*R?L??ST>Y@D59VWH=--9(31=81,WOP9-H=,ET,!P0BJ^
MW0;4\EX7VP0,I@[#;B+4H)3*$(MYN!68L65?P"L+,V#CTC+DL88F1F((,N+*
M,QB[YP)ZOE0S5F:<VC+:T9%'-51B:U9KBSGFI4. N(8UEI:,'(7PN >4D'43
MSQ5U\M9*MVK/1GXFB-_^#@FQE^<MMRPME1<BM)84S2[5!/V06(TF;O=QIM=#
MX#O)UHOT5;;Z7'6$?_M)97V1P=O2W,I!/*JRW*6'7H@,*L-7!8N[:8)34)G/
M=_#.:RE[=+"[.X4DWV![\NQB+]MB-]W1C$6:K=M<S_!3\*>8OHXIG_R[&(G^
M_GNNAW@99@=@BUS=K=AUN))72T5$F5:I$7XM3T,I!5#11+2$E)\[QA]$1F$S
M=!BCX_&*H_#,?:+#AG'#$ D/,8#G4'JL.2,Y<</8D+V8&<<I.T!389:XE+.&
MPM?<CU)V)"%T>5+NU+G6Q+A),5D\?WO:^X2Z#.%WTTR)IO3<T@+[123D?C77
MRV]EX[DCL=5KV<M7EU^/$KO(<]Z@=:B:/K&L'4<2[LIFZN'G.\#"=X [:_&!
MU%]8)H"K1XW)(=.J]TZQEMDDV8.)ASO9@K(_\;G%?S3LDW1FN;\4D*89 $5
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M%\"'I5SM)ICX3QSQIK!4GI2[G%6SK<;=$XA5$@#'T;_2D,3@:W?7P<.$&,:
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M5Z"=3;2?!OK5UF.%?IM)ZR]>1T.D9]?7HL[9UF9<=?":6(%_:T.@BEK![A4
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MD/>33^J!0Y/.YODLGSAQ>2<T\%[CGFFQN6C!F=1M9KZGMIER,V'J%A@P2R2
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M%0DB(JAXM-'GLR8!X['B$_"^_A(9G3<5*DS2<S3[HRR$P$O2UH#D1E?'5C>
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MY$'/V?$RZ>:1N<3C6!FS2.I_)^$(0Q*:+DF\3(J:-@R-Z]UM0I\QLE>GJD]
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M9:'B#%<FK:4K2H7^E[SUH&B7G!2%SB&/1]MS<_?4"<V.<Z(IHJW%Y;XX;\L
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MR+)2B:-"FB4F2VGD;'+8X;=K_W:7X-_<.HB<LO2ZQAPHKZC[KJJ[OSC3 P%
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M 5=(9-K#.O<SBN'7'M[2C^@' $7Y&'A,?AR.O_^F:6OL\X.3TJEH5$V AF@
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M2-]7"BG)7&)"KJ]TU#Q!P_V^9_,(8ZTZ>4(&/F.[SE5S<Q*&)\2FVJ(>,G:
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MB-NB++#=@.V\?:6VV^,-$GI&]79J.%W(>VQF9FM7-7<7#1I47:C#@JB;*\7
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M :1PB\V\2V$5U(R:P--(;68HND2L=@2 C OJ#N6#(%&8A86WLKV_QZMEEQ-
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M(MZYLQ Z%>BNH? KU4)A%G5Z];@*(=!<93J2C9F'@^S#I0!VD A,F,H\5]L
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M3$WANJMZPW])].F[*F @.RD:\($$65PM6PZ7),\Q)#((BS4G@DQK P @*W0
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M*IET'#4>)8.O.&]N]*7#9\=2"7MS)B;9,3SRK6!0"1X8?HV@C4:5D2B17W@
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MU^9],Z?VWX<'2[&W88Z%7;48KL-F*UN@B"$^S3B_(:[4]C]*@3B+$/O*>S#
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M 7(!<@%R 7(!<@%R 7(!<@%R 7(!<@'R'P;!^_T_HD,\[*49?1EE94Z7 (H
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MTE&?O=9RG>1)L(H5](3)7PS&T\'LODUS"B#!(S<_!1QR^=70KMP)_9QRU*+
ME9"R*N.TJ:#>TL1R_)DV?W$NTE\H08WSR>&<16S9"?U4F>*CT#'9]#HK%\E2
M4-X>^NRGRY:3WN<KHG9C(0%=-^F^K+9RMUJ$9UOSG8/7$]1#V\$- RV"$Z<
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ML<#$Q,%8*S9X.^,;OSMQRIZ_A6+FD7P&$B/*LY@5R\MP:EK<GD*QMCBMP%
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M-??.8XW8M_U(N?+:B- ;4%=_R9AT-E%8,4<OD@)9C@V,F,7BY:[!\2@/ONQ
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MX%W@L(K =8)]<(!<<[<A>I7")>:D1>![B@TH?)?E25"YX*N9^][JP0B1UJT
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M-U"7^B;ZJ ]J6L-.H'54X>1.[>T$!APEWV(G9K,6@F\[)MKU)O"I]I!99)$
M"ZDV$,$/6WI=WL@D[W[85IS?Y9>_Q4@#'T@K3GM(,!OR<ZSG/.;$BOU5G$E4
M8S&K2#3;=H0KC-ME76GK 7]1UE]??Y)<!Y*3,V8P0U[ET=ASS_ /MFV>\WM'
M2H,Q*R\LAGNE(\/_X7LG4F401;DU#JII(^;4-Q)M/F46)M.-)0S,48OX&(F:
M'\U H"@,DKX<58VDIYGRA&"1Z2\[W[]9$UV(1E&+\3<1YE(+IZN!N'\[-#?;
MP:Z2$I[8K=U/6C L(QJF94I:D\ZEQ4*CT,^+&'H-G+B$^#"G/PV QW:V+7\!
M@M:F0=P"=PH#7K%[P;N0N#CX)[),:7+!?!.=>"B:PYK05'1I?F&K1VTA'O=.
MS;LW6W(4PYL-.L@GJ4"5SPCI'YE;=M%Q-:C(R?L]-/]9[)^#R$GX&XK(R2%N
M_>W@,ADJ(Q_7FL5J/T"UQTJQ>;Q]1-0XIK$SJ8COYDUC_%15/@EHC(_9N>QZ
MW=R_DM$R!2YP&8)*1)<$X.M?1?@K@,PR>-4SS 7HA"'-]1SQJCI,QK\C&)XP
MB/N^N!C.F.7T2F3=\D_Z3,U+WN F"7([#Q(-QQ4!-(-1SEV#&?RVW67?'8''
MQR)J$L;CI>^YRP^W(LC2ML:L3 0A9%%T+!;L M55L<>:!>V2S%%:<!KT&QDM
M6$:Z*MK1_ ;K](B_;FZ5[4E? '6,Z+WC^@C81LG0:PG+6Q&F:0Y'OF5NUR3=
M'7=TWMM>6]ME01R]]C;A*-_05#OL0,SX^ZT5,@GST#@8XA\\$S#JEJMD2LS3
M3<>BIA:PE47G&B)EVB!5+FW=)X;T9\ -P7S?>ZN)HIC,CHXPE)-OGAY++ S2
MHD24/P&1@2,R[;'X"6GX]V1Z]=PT1Z;7Y.1$'=#!4@1Q\-_ ?7&D228(DU/3
M""<BU[KAD:T45R-H%=R\YA]$3YQ!#1F&T]OKB&NF'\)F:C[+8(A]I,NIB9%]
MCCI43ZFPV&.J[=.\ZJ<.O.DLDKVR.$US6C;[XR3ZC^GB;W@F+=&NRJI]26A'
M?>*S>DU 2S40B_C6%  %I:IQO7'Q1J 3B2TR'>$WR,(>Y7QLO@9#N%88(.F:
M&-+PG_O%[CJS!V=6<Q[HR&J*EB95X#3K1MF -"Z[8,K% NCZMH?=P/,T4P-J
M9U-%Z T^RHO?3M)9/RW-A_EG"GIWO$D#]9T:.D!<E>FCG6H&V5&'4Q%06/B;
M^5//T]&:U]H3EMTEN,@/()I;>^**''QK9IS:T:*UT-Y22']6AT;BQ U4=58T
MH;;NZ?0GAL(0/I[#VQGXYBC[CYZ$IJJ2IS%&+B#T4.7%(\(TL'4AJIHO@$8Q
M#V(_*&HYN-BBKXR=>$AT1F5GTJ!/9B4@/H[FI=&!GHQZDWX =3CA(A5=3?'@
MT6&I><PG-:?K2QZ,0ZU("3UH>6O^)36O).:8*3%-A6=X?C(^,5M=>OF?T0M?
M<;-3?+@L\>BB[5-_-F ,<M^)Y&_2;B.=@(I;BV4HF[X,'DL #[.4/EE$9%9'
M8=Q'D,6%@'GA"ZK;_B+T5^TEAM0MDQKGS84J-B=#EHP3?^>)MMS*K&<B*>AF
M_.'7P^.VNV4HUESVURAZ%_."A"ASK1WL3UO?:H=L':>'4^*U>6:M4:TB^9>C
M*'*B]VYC?<-[32T.TY <$JTL!#0 3S2FN-]Y:&6+<39J'>F\[?*=I**5=#\J
M!B686?O6/RMWE$A;_B_@,!"$2V[SSI&I7G2S8CQFEP,B$1WC2$T8$;;K_1NZ
M(1G2G]I^Y/LOI'430:;@P'R1Z30CKX+0Y''97N?)L=U*#X\BH7)B$FH40+SO
M>C33.ZJP/9*27E5&]2C%X4*FK4"LE=L9_N!E,!M<\W#\A">(HR>JC,OHF8A@
M5$X<<1!4'XEV\RB),U/=ID,LF[,[ D]=]]@MO31M,D^@EFNFD:(A[5E#):##
M:<H,"5=RG RTF:*,%DVZ+9,;$$U-227@\@H- S!7P(!+)TB@+,;3\C?;4.9:
M:T'Q]1&T/659 D\NER;R(58Q0"H$7MO*2!PH&!M1T]H#Y4Z,#^56$?4;79!
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M9_=/=9#U_TIFNY*^36,$Q+MUE'#D7?W@\E7H;$U7E[HA%7%;2XXX\]V/E(M
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M56 B+(T&@[R&&*8=+G)K*Q=&"C-]^LZS>ZBE/91Y2#P9A:$FIA8(C,AQH#6
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MIZ-6P<4^JU$*)2<D?U&0]*8=]%7AS#U]*C\AQ^%V\J72X:&)F3$PUL$WVH9
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MPH/3TH1%(ZW#1-61$:R/JBI(HVS9.DK%SL74 ;]^^U+#V:$GIBXQ51[PYS,
MJ6T7CRN R^-!L;*'B_2>K^?KPSS _T651 1<03P#BE/E9F4\]4UO/PS &;KS
M[)O^NJAR9RD=X=]D?]4*JUR4AW;W(X(HLO&Z&/.1O:'QP?>X]L]PS=);R!SB
M'OWC=4DAS)_-$<[#2GU. C8'YYX2;'R=.> 1YDH4'1>Z><"I[V[4W,_:4$I
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MSQ4MEZ4Q43?@LRCC;[\5\ 5J2HJSZ+I*VVC6$R06+SJ$QE<!L6APHIJ<:81
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MB\"6JCG7J1N]:0_P-,_7O :=VRLJR(8O]!5!@#E"!):A3,S.FC5@9$2P!!!
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M47:>,F+D 3HM+L*2@Y)/D'$50WY!P]3(J$Y+5#9\3'=8$H"?B'8Q;9+[M$-
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M7J;HHLI@MKYO*9RN'(@41898^T&5<G-6@>%A5Q.J"WUP-;6>Z^3' WQ :MJ
M&$3U6IBTB?8F$P,0Y8DYH:\RI-#^+R8'X(OX$;"O/9OY6=XZU30C<U=Z:5Z+
MF+OPR#M<>ZF^.86H2(8OWD?(RG3U0W:&-"=OSN!(LQ6^\B"-ND.?E,0GBG";
MYIYJT5EM8GJN1N0*@NHOXT1&R 1$:*QZ%==D93S?3_=VY+F;V!18$XDD4-)>
M@5" 2(L85=R'MN=\NLO6K!\D*YHD2\<JY_B987DN$^\84YM6\G4&M,;B<A6G
MKU2F:-;#DA0IK,PI<4Z493J/%]L3QPP.SLK&56:-F:A53U*""5,%W4H 7Q'0
MT0$<WQQEO6+YIE+#6+A(26.JF3Y9O@3F' .A>Y"^\T\OA7[8G9ZK'9QJ.R@=
MZ.5=BWA\'':4L52OV=%(Q3G09"D\L)L#OS%L;RU.?(#\?&5F,8CI;"0?^I)Z
MW=%/7%P5OD(#BX*RF:8]WI.TF_4MY.Z46YL:/1#-=^"T8A1^&#?ZLM$W$D?_
MP^ITFW%"\(-U$3NW%5XC>%28"]9=FZ/#F;2BI:QSQ:A]:J3!5+H9J FQLO,
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M%[N<\O%<J?S5+BM'Z/]N/@KS*T<&+I41@1_?/1I"J%<C+(?5?+2:3P;\G6I
M<BW-C9JE] " IJ0$K92=?O?]+2Y9=*]5J("I$\K7N77SI3NW@-'$>+$36Y3>
ME(<N3BNY)3'/AZ$N<1$)I^W>'!%^-;<2NNX#1^I[!KF]SW\+_QGP6ZK9K>;M
M],6&A',#VLEFGY>Q1%UYO[&_P+<O#]]_'&T=W_2C>JH9@"4%\NHPY3_B%IE0
MUO]M#=QA_%TONR+^'GK*BH;FQ3P*Q[KO%4L23LBZ]@OY1?W"UP,7!\XHU5/#
M/)T.,IV$=Y&\-9YMN+8MM,YJFSO0A%X"/Q;5$BB_S->+-G(:.@,H2CL!Q^%%
MZOV!_\\#RLGKNMLS]^7\AH";XKB\K:6N+Q?COQ75+TOBQ63V1.T-^OW\'K =
MHTDAKV\" ZX/7"M*V2<J+IN)/$R5OS5L'.GD"LHT\>:2^S,,!Q.5XF4.AJ$S
MJ\W#0%F >N^PX+=".T*@UTX"C^NC5Z7.58-6O YMO@DF!IZU5(2Y,4$R0S&!
MQ%V\B24@$#(],Z)5=@&B['%M-F$98]$ ],!+^)-CP*C)\)W@'-,918"]=XM!
M5)32XH>4T&@^-G2P#T_H1 D(328079Q0C(::7E12'K$O?D0F8M8+-R#;H&%F
M;8A?BO-/'LF3G<QGH7R@4UE"'!@" "B7(% #Q 'H&>@ 3$S]#<GED51 O4:0
MA"2HL&I0\$_>;UN5%F%:Z1\%B/V)\;-]_B\3<U_H<7,I &(N^1</[L)5%V]>
MY8S^R;M\G!$ESW]JINO8.FP.416;$34G^'N/^;$6Q$@Q;K<# QXO3D2%Y_@2
M_9+I0NA.\CO^F+FW[^O\XJ^EQ2F,_^"(RY+Q9<<R.L;T^_:&H041A(@F_"I2
MQZ?]$!RYE_[R<(F8=3\F#I/[UUNQ<@>=K>/+D6]T+ KMJ-^VU,3KJ8]Y@#_;
M\N,BL*255/[U#!R+RR4ZM/2D4_[0JUW@<WU[P8OL'&HU_0PP:/@=$S"HFO]]
MX+_]-M+YXB1K#O(Q*V_7]^G#6.>?9X */N) >MQE T?4W_/BS+-OFI?>N'5Q
MV<,HLIC+\V:NM50A7V!>NKI?VCNCWS.DB%$R)TD.C&X7E;'3VE*,X;VYK:90
M@@A?U$ Q;1'P;)Z$A<W#1AP<ACY*4<#>\DNK,%<R9TUDG7-;J@[HI'24EW@K
MGP1PQ10;I"Y O7DV<;HJ8#F?4R?W9ZZT9^C"@@T[+1X1OS'$LF#F;HJX!KF@
MP];)MX?+%TAQFS!*@ZH8&Z,[D]+5>,:2O?AL?8:KI4>557AI9>1$TV4GRE-Y
M)KZ /]##8H.-5"9+\7_:?(D4]-/R5 5;)YX-#<BUEG:;I+4^3:/6]$^"=HU8
MIRBN@J+MA'!(."-6HJWHP[?L:"DE'$37HC"D:MB8(=JKLY+09IB"&HT"/="4
M<-?=V^N__!K%N=(--)C30U;B?1"0VU52 !"%OL4BE] Z+[O5BKO?QO,*^#!M
M<[">[^[[:Q822$2 '7;K91A3<3]:-X &V-QZ>2E?AY9AQI+A9+=Z<Q:JKQ^I
M2]Z'/5L@0-CA_^<&3UPN)9Y$36B][%>&RZ5LC+P+3(;>=]#;VD,XQ/TX=^-"
M$LIF5O,-O9VOI<'*HLLXI(]'!&VC,#IYR;2=0%@WG;;@!TG3>5XNORX.]8]
MY4CM;R+\D>HO1<*&<^(Y2&'((;(]#I25?6VU[*G2J"]90?X.YXZ.B$X %D9?
MM?ILU]:\?7$4_]EHQSZS0938K]/\;QU\>1P?F>X5F3;GBQ>.09T'-!+F&OXG
M<=/@/F:RP#8"$@*XA'8"Y+\-9TJISIJADR2T=W[_A==><2A%'"4D[71S$:@=
MKU"BKQ@8EDKLS=<I[M&?2O"&(&TZM1TP#0(!= E]CW(AV2P<+LI@^](KC>1/
M;=5F2GWOK3X@JR$IMB,S%!65$(Y(N-<4>$H&IV2GE@@4[:B7IY"#P2DR<WN!
M G%:D\B=6OQE9@#DIQO 0L90]$#B#6"VSKX5XF=O$R: ]TW2$+T=/.I) 4G9
MF$]U@A)!:\[62D&;*MFK3,:2KTB(?-)+VVZ/I\<IHVL,\/27L/6C>04VW[1V
MU3BF(KTCRF<^ 7T#!TKRJ_Q*ZXP\W8Z,09C,43;P:AO1;8?@DC\#T$T2\'6$
M*S;;@N3YWZ]^Y*0D\TFX2+V[%+J[[*2C]?29&N8$'AGR >IY!EWY=^2S%-E@
M2\K[AMB\BP>+R]3>E5K7G6;L94;K?];IC/5$70K+I=&_YT3XVZY,-F28&_,5
M_@\>1XM]3^XG((WGSK9N!M#A-9E^,>J]@X[X(,WUJ:U"1A<1NV@F5L5R)HF3
MBW<@;D]2=7LW?X.&Q+3#T)UYM,W1=58DJ=,)C2XN<%CS6D\K<YU&&;*R5>F+
M@I/J3X<QV"\+Z8,!PY'W 6]7J@UT[&558P7G>N<_XF>]LE9Y!JC?2;Y*?$C?
MM9$B1+MLFR5H87(*!5)^1Y-4GJ@UQ-27PTP4%XK!-"N,:;IB+O>B[W8.1(TW
M4=3I^#/CZ\''*/$1F3S(A?=8Z%CHHH#7M?U Q%EMAKC&&[+UZC+\9U0]/4@4
MTI9&[.^7N.*LN18=?%Z6XTI(GXBJ3S(=TI%5[='EY".CUN:YN:CFR/^B)B;1
ME[K @'SPO,+&8!.D>K<)-C)Z".N[NR38KVC7\D5](-.>D-N2(FA!CD"JSWH(
M$JU=+E24#62*"79*9?<F0='6UTXEI@>3=WVF/ME;O26QP."+\&\[G]LPUWXW
MD)R[W=+ZA'V,*A6%30-FUH@F*Z&_R-U1H#NVM 4[0%+9J/$0:(]?<5'V%2>9
MJ?QV?IIA%]=="JX;Y X:C(2U!3(IN+-X8[BM?59QXBMI+@J?7=9/_E3B'D/[
M%7*K8=I)^*& M3^NP(Q",TL]P^EF,=U#NYJ;I(H,</K[-YG(YR^_W/A?TS_^
M&I3)</T]LHL%Y_1T&!D$]B T$4+V;(-J(^R0.G+=M:J,AE=?")+9P'351( W
M7KIZRWFB%?VE3$JCV%S0^?7?4;^0/G%+!Z:4TGX# A" B8#Z#B#45P%XQ?AJ
MEZE^C]8EZK_ODI&KS?SMD:MCU&5);AOGFN7M&X:[@$A1JD]KWVSD-XCEBH3]
MR]A-2>"KPD/<WU4OKQ.V$_#+H??ACX#D3(-+J#YXOM$=O5Z(0%[HT .L0&5N
M>KB KU/;Z;35M752.N-K/Y+;;H*6,71\#-'3@URMREKL]9/HJ2GN[#<D*!S@
M0Z)RA-4+)Z&TB.:()YPNKA)#+_'Q<8XIP(\%-3A4PD5O6_?KK"FOMRD\,QQ\
MT[CY#J9&E.SERENDE8T[%\MY+?:Y.T<1NY.GK\_4@?DRM$QH':S#^6-V5+*9
M=E":=_N:UQ1$Y X-LS2J5"*V>).&0<5S)H>^0]C%7./8>8?=7[R7,W>ORHK5
MZ5*^T.-S-!%3:TQS97SYT@B3LF1V;%\)2:KCY8S1UWZ4POK,L1L&\Z,EE0XG
MPB%?9+V=S9&SI_RLJ.%6*9J;#/G)IX7+E"0N-69Y"K/W4!Z0HG.M+R?1;*DX
MUBPE4 !N$U+]_B\/(]*ZQG\^''B;HEZ. I!C<,A^7?+WXPM(4F<3"(5=HHXD
M17>,KUI^7$H@ 18TUSM)3I>XD+P$I&2'^%_NW=>9H?<KT*M*I<88&&/;__H@
M8_7PHN/1V<K95V[LC:^C0=9-V@RY?;2.6&M]B3E7>+/SFT8IUI\$,9&51QC0
MJF2%5^$]ZA25LIZ@\*"X"H)0)7(WZQ<$\P2YOB[%Q>^IIG!#^T?[MQ^\N9IJ
M! ^8K=XU4T>X(X=DI%IYLO+SFG\U<]6%M:=62BXE(3%+(F)HUA=]^PZBIF<=
M1,K(GA4TD?-4XHN($O1O K:]L06>Z;&6@!;?.\&F[*"O60\%P+6@M*P,YN2T
M\#F..ITYIK35Y!%)>G6D0K;L;%L6JW>+L&3I?C5TD'1!*45@D*2\W^<<]5HL
MQ[C2N+10ZK&31 3#V=! O<EW!&@X-[!O=')6HLL&FN"3]8<IDJMH6_8DA^WF
M5O$]TZ\PGDK(!KJ!O/T=3+.V-2JGB!G_?I9A-$.F"Y\F2MI0J'2Z)BW8!)_>
MG(_.\@LTDV":FW3V0 EXX)I6%"8G _B<()2<@-G\W4Q+T%[0AS8T2%9=,$>=
M=OQ;.NHX&V7ZK2QW.M=AI8'5>M?HP[!I.G=<R:_2T?7H')U&U/WS>9X6%FW2
M:H>?HKENHA@,Z%%=];/N_9)#8EC/ ,GVEK19"D5+D6H^8OKWFA!M8.&H;LD!
M\<,2-9XP3@VEX!W4LI0Z-'7YD]7XJPAT\L\BQA.4>ON_YM<@!S\L+#\.<NK]
MT=4@E.-K66-A8KS_K:I8PF8E(R7M,),Z'VXZDY@P5*O?P<70Y%7YV46+2)%K
M[RTI+HND6EE*1GQV<T\^LV%0')=DHJ6"NJQ#(:K=<C+DL]YLHMY#*'24<Y!<
MTC:'H] 26&LSCFJM5-(N7^I/7,\0)GE&K&9@=J;>O$#7^ 21LK:X8CYYU5VU
M6OEI/&>JN/0G@_D)*%[R@.+V#9.9&1U] X?2:#$M$#UKOA\EW"#C502Y-\A6
MH<7:H<.MB;5X5A^ _(!@!\9\P>-!G*CL\(;LSK^LXS1GCRC88:^>&5?.Y3/M
MQ'NOJ?=B#A.ME1LA']Y//I!9*VL0K(3H^<3NC^M0:M([B\+BW_'+CY?PC.=1
MINVK)28/9Q&"0NWT%-"B):F1F"3/ZQ@1Z$ISV?ELHU0L:%( "O)NR=(5B'J3
MQ?)KN7%9*0H:L=$0:!&:6[T-$1I#"4'_$J_I:VGW;K-="RZOM@V-)%QPZ8D_
M&%BCCAEJZ8IAU+>I[@&F[V,M]B6TWQV?<F<M;4RG;P/HA?1>[TG[H,MQ(;@9
M8F1G85[&QF .RYNB#7Q^\)'I->!<A0ME^GQ1L9GFN@7\9X# T6]&(S\(+_U3
M8^\]G<G:1HG5JX6X]O_W&U"I[%<Q42]I<BI9)N-G@*PGC[I"0TL?7WL[2?OI
M7%C'+L5( 5F7O1$HP'RP[*M/M&C$%ID<_Z_ T9[\HT/]*H&JU0#VHY70'0V:
M] D[1DHK*F9[/GW\%^RV%1]R(C]:ONP@@LRA'RX[UI]$8K?NQ*_'(I]*M]3J
M@SMY0/8?2"&!^[(%',4:U485F':J(PI)O 1I;IDQ8$(-2"D'4E4[6;(L\9N9
MF._A2]EO';9(512;ZOA@%)_BJPPAH';!1\4).66U&2QIT4@;;3/->1[A6X.&
M\R(J%!"&<PFF9 H?QYJ0WUXG/4P!10&(!Z!&L3/LVB]XIQ)G^"JNF%D" 0QH
M5.1DSTB2528-KG+O<HX[IX&5W&BF&8F5'ZB]5Q!9-4#G2U/Z9HR/QXUNX2M)
MBRJ*_VM*]E%$489%<M:OF?E;H"POHWPFFQ[1JX-1B9XWV&TQPL'\P^N97S)B
MCP3#E?H29"J'8^=]N(-9=P1&3G^L$(_/VP.SI]:[M&VZ*&!V(*MR([JJC%*#
M8$,K_Q\PC@0/"QH\4 *G/P?K#^?#]T_*>839Q>J*5CZZ$4U'N^&X8HFG1.AN
MO.;:UXTMRFUKL1;U:_H61%/\+Y.XNB<2.[(2Z\2PB95 L 2EC$.^F$OHAS+F
M(.FDHST1 7R6%*GQO S4-SN%XB]QOS9)8@W12&"=BY-5&U;@G564B#RI^ 5)
M'+\29&^/K?Y=:=SLZP"FXZ_(Z<_7OEZ@41N8.LAT% TKJY*6D&HOHR?\$LFK
MI-3QI:D+ZZK_I:<WWHFKRYB&312-W6(R, 7(%%NH(I6+8&V7!YQWD;<:C_IL
M!]"1G'"CT&P]QJ#\76S/M&R[=FGR?:R-[++A-?/*9<NDG?9O"<=O^_3-*HO7
MQ=[":J,_MZP>F[^0"0E5EQS[#96[/:$35W_JB+%+S1TKV";.G%%3LW>\KZX4
MPE'&I[IB;H+.;C7+?NV_UI5*DPS>#U/5[&\&"4+#8J,^J .J0:-VB5*+(L&M
M::QO?*U16&A((6'TXB %ZBP\KGV(WL::VF/QF,I1_&Q+B@=VXV,$6\6]\7Q*
M#;O<Z%5KV=1J-!+KT9P!+8'A@OX9@GP_Q[JCR[J?P8^W=!\5B#'9_4=\^+8)
M5@&#*LMKO!C:M!8+E>K4988IU5TE&$S,A1MZ30"4>3/\YM9@*'TI.CA08SP3
M&EOL6FC'B=P%V;-7&EI=LEUF'9Y\_!DT2;H.S?U"V<(U95G6"#9"H;]$+2YE
MK/FR71FU-]0.LY^+S+QV,%PXC$0KY ";9MNBVQ8$R@K.<7"-6BJB44^D65D#
M#SVMW,JL-U;-/ZJPZ:55]UEJ2R9ZG+R%+I@;G",F31D?:KM;I:05KM !?]:V
M9^\K&<]E+F<1%-4=#5/35NI1OD6GOZ@63[Z3Q: E(Q#BJ6%M>]6:>T@4U(E3
M_(JC71-9.:LAEPNRAV=CJ#X:?\+=,R!KJ$(OHR!IA&+U[<)4J?!V2^7+231T
M=<IV_2QM+WZ\QOJM@HQFLL/^JE-H51-4 5U5:HE[5<[ZD+]HCW[)*+F+W>J]
ML$&B;?90W^?Z/<DU5QGR.H&00]2A_E"E'(T,=S>BT#!6CS(48L')5S[4Z>]0
MVEQQYM754K.9@U.(^@C$6;.0!:E#:A0-7\00,2QU:3HR/$V0(IPLJ.][2-[P
MM_ ,<'-+QJ?)TQQC['@VK8_2JLMT1MYE.DAW1)+&5 9%PUX%A8EGW7:KN\J_
MJ2X'GH6%#I1,L/,P6V3:I"^BO 4.@NE9RT7SS-#YQB3,/G1_+2F @4;#:L O
M9K^$L5JY1]_H4AJ=4VT)_MI8<VO^8>[P#&ANP1<L/?0"S9=%V LVH:+CL^G,
M994O#>,RX=.66IS^P4P%VX7RXJMIOI<INZC<"DXOS)"CE&S7J(< =URY9G7'
M((TT4>A@Z:8<)NA[Q#)K%RBKLC"7JWTF _@'40JT2&)<3Y-U.%"XGC3OX0^[
M8J[&!9Y3[=H/R?J6%8,!?V7JRE$ "J+R;2#@<B3/1 O<@]YNOD'983F+6]]>
M@?JP>7E@5M#^PLNKFY,CEN$=N]Z7D3^O>4\.TB*RYRYV.?Y@W%5@BUG</5W6
M-EV5W_H7;_CSBU@M#Y .1=!@_>NYGPYI/,3.U/HIO?P9D%;@\Z_7(#6S=2&&
M9T"DJ#6!D_>0^F'\EFW,<N1_/@A%CZ7/*7;B_G3H/?!U"3RX'%[=L@=5-[[G
M*K7):8BK.GYQQ2S& I/WK!3TRR(KS)F;#GN8M&C+"8_2+--0%*WPTJV(;!:J
M*"_2UZ#!SM[&ASS@X#Q^WB_P'^:KG>2^$VICMJWL)[#54BH\7I!3^KU9E_-6
M-%.1SB!C^+.2I<OE#WKA:3S.BP:L?N30ELV)5@-Y!0"-JH'^Z>N8!O\%[*E$
M >E!IV TH9#AISLJTS$T_@2J+[J&>59+UR[]-"')G_XD G  V K7R>_/\^"N
M__YC:TF8/PQI4O3U83_UIU"<D6AQ%U>(XY225+AGV5VXSN*IZ1__/PUJ_(QA
M0=.QFJ"OQ%8^;0EZ,3*Z34%N+QQHPBW.*2^B/?UJ?HR]/Q%I?R]0%$6?K$.F
M$Q ]R.&Y.+,SA&OO2OMKG;D10E3*/ J&8$P>0E)*?KQG)A%5&%8PI\TAH*QT
M)^OBM/+\-:3-#0SWT5M>;G+UE7OY06-%&[H2G%!U]%7DV%97;DDP2=O*4@:B
MF7C!E",[>=P1TE#+=1<L[D"K/Q<9&$X/UC,-)2;/<3;GG&NP3],N.RR-4AA;
MP$)GE]+Q?&_$$V?(@*--RH*N^%U-;_+]RU'4VO4PWD5NA_V5.KJK8UUZ[YJT
MZQ[=\+2UG_>A?K44$Z7J$ZQL&2L.,V5SE"@DLU"BN=-NHK"X[=KVI=3(7&!W
M2X6+YXN,>9?6NPE^7&8[-Q@@7 37WR!;Q,4,]D/#,O:6OZSED<_L *N._5A_
MC/V*I/6K@&XD_<Q-J74:4[@,"U_.\*?5 Z0>)19<T;14KW(UHDO&" 5R<\)T
MUB$::<10U@)B>F:_SWWONUQV;;ZS6&S/5L^JE?1HQAZ;R421V8]WX-A]^&A_
MRLR=E9(_M_#!^\!=\R;G#&J]"='V%VE9F528GS_8.5HFXTW/9/6BTOT6M1X6
MHW!D$.7/<FLW9+D[7@919PO&2@VC>1 _ E8LI[W<\6S6\Z+AG 4?5Q\)KK%A
MXIV*X_P_C+UC=*1MVS3:T<2V;=NVDXX]22:V;3L3>^*D8UL33FS;3B9V9M\/
MWF\_>/>W]M_N/[W6U6<=5<=55:=>(K(HGE7/P28$7:&E-AX_3R-?PM08/&<C
M,=_7Q[#T=D;OSNQEW!%JZQ^3,*LI]%7/K([-ZDEHX/KO+/BQ[%"(L\3D!O6M
M]0!&2K9T.MMB6?5&6DI2M)02"C:086*[=5W^U[7H%1ZS%)K[ N<T$$@[2W2B
MJ1@-ABQ79-I"M9WD!7WKX$J'H':4H&M<?V("H33O6RI[1I-M&0MHI.1[,Z:J
M_-&$[OX=E9%*,U9?>,# '4P&*%A?,I; %;B' R9V%+.>$16MDX'2!)+5-(P%
MA%%0(-1H0XNH(IZ"ZY8TD)OLEH1&60'E1"&CPGYIFI21'80E/KC.2\6]J%T0
MI[E]&<?P'YUA;_]@EU!EFF62+V.10F+R(#C$YPC/;KCW\&O>NI)0-#4&7OR<
M26JFE=\@27(J>Y'SIJ;S;:9@M*)1H8$BI0#T$6D5Q"4W.IZG9:JA%499P\LS
M1I%DI=D=:Y8VQ=N.YF<%!H6FMY01VAO #<(9N-JW-?4WA0-+P/+IY;A_B9Y<
M^6:;9O7FJ )K/%CBD]!0<J)\05\)>D(V9J]8FG0J/A+[42.*B8ETSVY,A(;?
M_:/EJF^(??<M/\M#_@ (19;UFQ#[M%K^1IX;W%*0;Z2,X[37_\LBC0K)(\3O
M0[9> =3334PL@4Q*284$M\O?)@E]^45B @,9[,H,8;(>P]TA1.Y3PZ\X]A@\
M\;ZL:.F"E99VL9GIFF;PS8W@@5PXM,S::N$'6TF=5WL6^\NU!.4-G;L!789:
M4PJZF9PS$F/;BIAAO*K6K#M#N^QJ1KN7E->SU50GVT)LN0C"(8GU/4D=;JCO
MDTUFF=4NE3!0B4J6%J^ GE).U1O;Q32;IT[1:QNXJ&/WPV_&KJ(2[P@179=)
MN-T8'GA8A#E1P.(@#G1#H+-@!XUSO*]6RAW5G6<);0PQZ-+!BI'A![@E277%
M"I%)H<.AY"=UZ1?7TE!7%'& Z&A!2 "*F;R*S--DU*CO_*B1=+*T2D36<Q@B
MYTAQ-+1*$;2NS9ESEX3?/0B/&W%ZCNTG;COFOI7K3/@) L>__;[3'I[ERIIK
M.$OR@U>B@FV+X/,,%]!G:UOQ,.9^Q:$4+P\M,27RL!W_P4Q0$J+."$^H)?NM
MN%.C"EKW,+" Q%LPF4MB ENZ<*;)6X(&"@T'#YLW!N7IR^.Y ^OM- 7[.)\5
M8:0[2R$(9("<G'E).258T!*8.2S>U2ZHP52.J<(K/H]^DDKFP%=.56]F*\41
ML1$2;C:\:OLF ^P$FD]*86IOB-+1R2BT6XI\"R;*!X=UMI%">HR7.&63HL31
M84([7-"4BY.>\P!PAF!_Y8B;;)H:G=_,H#]=6E#Q"J')53N=QLVS-HO7Z_NU
MAU]SG+F; 125'/V&FKSUK*>J_DY?ZPDDI8U@520CU!N#H<C1%G#MLDZ/R FG
MDX73U88<5]:18*FL Z#J\7^)S:B"^PU*YY-+$5-/ L_521&U</[9+)"#-MO4
M0KD6GSJZEI2Z:F\JMN#D(I?,4:'+U3 --2S2SE#U&).0TJFO^9MY;&[,W&\7
M<C0J."Q;&*T%. B!6$#*7X37]DZ&$3:=5B:CK JV00(N3G.F,U+]L/USCRHX
MA0%;*"FN$9/5D7!ML;R[J.N0HKJ9VK.X&HI_/UHN2>HWM'RP/>M140]!X!.Y
MLJT3N9E=BA5B&BW>47:R<NEBS@!K8WCGE'5I:;FQV>5DZ8-! "$8)@LJ;) 8
MOAIPEBZU8:#TW"Y#@OU*3X9?C=4SJDJ#I1,%+_"+BDVS6 INE><P6$02<D&?
MH+6UQVI('F*Q1>90PZ/X\0(& Y/583>ONH3\'EYLRI0)"8YY?O)PW;FR^/!8
MF2TI.@Y-N5G=MLB=\F9QW$(@$IDA,RI39$8^/ \G!J[=^ JW1(Y LBN<I[U@
M?7]%9[M+.J:4DX(++F]"!IL<7$ F1IK#$B_ME_OV,[JJB0HR/#PD2<T1H3LJ
M\P5=_-!P?5.[JD+:I>"-=FI"YK%YA'9+,MV44%=+%6D=6A)PI">;GN X?X>#
M>RA&4QYX557<<32Y. 8 DJL_!VKJ49G+!^Y/R%8Z_8_)$.WYE^[S@934(@=Y
MXNQO]]8%V. 4&!5$W_J[R?3HP!QO],9DY62:ZW5\5)W5Y=!IP./C3$EH]1SD
M->\I'/,YHK)Y% #TO,P9;#$E%)SPR)I5#SU=L5?J,XAF=F"2L^V5&??F)F:3
M9MI:,[SS].ZZ#T9<%7=HA,_66U0V\&C+GKW(@B:40[P(@J#TI/GJN,>D+T;C
M[+F2DE#LX$#5M" :WWP #(08CE6YYR(_,H*8B$)?,:T$#4.P7+1Z0?:<M4.)
MP3@@[XGZ=GXP)Z',>9VCD9C!1B N5<N95]/B5UY@3$6%K*951HFYF@8@QG)
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M)^-C(S,GA">+A8J.9V6/9X1FEQ*&)_9CXO4\R2M@K=LA+=LK#UW@9CQ*?1)
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M7H+UE;=/\!G416EPD1 <+R01#+1SX(JV&[BGQ)+X))>$3&O3%K%-:^!JRI)
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MWFBM3'Q.J#?]UI@[#2?EQU=BK?\'D-*G?#I:Y9OF!/E- WX8RY0IRAF/-OA
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M%BU?D:Z<7N0N$5_YCJY?!BK^ -+(ZE_AS2+Z9/B_7Y.OVZ.^W-E CRC548H
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M\\JSJ9$=\BTO-$.O?<ZM"2&K$2L\PR.A8_3' 9#[<E[@H\V'^\APR3(WZT6
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MZB7K%9U>//@1\ZW0#X!/F7K(A-RG^VCW77DBS[7]>,U9B;NE!YL&S_%\WP\
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MAYR\WS"@4RW:ENPA?(T @G_K2P*PLZ5,I3UPLP .3;====N"AF-Z3+TB#ZZ
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MJ0NH:%/S:610D8J3-D/M&0HZM#;HXCI/B<"L,:8;N&TFVIYG+'P ?_S8 <P
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MU5@ED;-,M17G[:T'7S02"H;.Z*9:)RRV5%+-&ER8_NI!. ?-A>KC"7);576
M%[?0*JZX_4I6Q:H+WF-S^IB;[T#^(N3] [/H4>,3W*27%@P#ZDX)0=@A/'5M
MHP52!O=DCAJ]/&^<MJ\[MU>49V\<A$,WH<2FV>*(J4M:DK.-U_WI[<[6NUK!
MR(!/$2@J;S-AQ?N9X=F[E+3P*B8%'2:;G5Z_K\W)DNS&J>3<; Z;NR40IZXL
MSEDT15E!HW9Z%P]!WLCQV<8EHO._\1Y8\)2OJ>29UWLJ0#EC= $:OC#;NW4'
MJ1IWM;"HGZROI\WUK=<GDA\KFXU.=6 >%EIKMY!P5@# #K;\BJUDS3"VW!=!
M,C]+GCG6P>VQ(PL_Y9JC!F2@C^G=A,X A^QNEG/63,^"\2:V^YK1#F_D5R3_
M7=\7E,>-I%. EX6-+_I^GPGVLZ45B32)M"RCB]H0?9W?3Q9)<>Y^K F\)-HB
M8@QE'&4F!5NY7(D0 ]*N3!A0!$$(R?%MJ\+F,QM>+AZ,:BW;XZR%[J\>]G!<
MX"(HFLYB+"^<!4Y76UJR8OR3M[O. 04HHV4*6(VE<WV" DEX=G/NA6U=;R&2
M\S;GPS*!E0;,OVH'#U62\E)(E0[.1B:U^\#2"KOC3^F"Q&]"< 4C/-9^$^YI
MS2;:1D\ZI^FEFN/EKD:5(J+'-5B4PB0K M85EN/0PZ"%<2)@@'I=^D:N:BRH
MP:WA(1T]C 6:7@V6.![?NPV<XT4A5_5XML-9:])/<>QJ(86:VAR^"Q;WAKO9
M9Z@.,[Z,UVT^"@8*M_X;B39]<_GG?*<-6\5R\2Q4))3FS]2@===I",S@VSFP
M%[C#]1U(@FU#..Q(;AWSMX9;<4Q['.<O/^Z9O7R4>&AZY\3;(Z[4?M^@[_7D
MI]K>>V[>3^80?TZV_^X2"V_].U#W9J<>55:ZR>45-'+WZMFI11^"AI-OL(7\
MIUF#(S4Q^EAJWV2'#"0V/<T9.FQ#Z0#/:?Y WHBBG)U;<,C1R0/%D#RLYI\L
M5L3JR108EH9I)*PY>8E42ZOI0)X;H,5E,^2%VYXN&7E1GGFAMN&>;FYF/ZAA
M;R=:U.R_O%]@WIXQ?1>)"LNOM%U(KP@]7')9R$82&"=%?O<)9=R!.TWYDU0A
M0TTM\RLJ*D,R!WE8F-EAQ'B1WM+G 8'1K<V=^OX'^Z:,;3!G=CA^%G=OR<RI
M"=.O*2'!)D28\UG!G@6<O:.T=(PGLB24<,P-2(E-#3$%I21^D,20#3I_'GT)
ME>:&+9M@%% 3M5ECKRE4!0(D;E4&SCDSE#G!3,F (D(CT)+S?+O>+G%0H#,+
M\%V-Y2OT"?\4TIU"BG1*\'$16!DH$\^["/8&S!:)4C1%Y?Y^TTPH-%#LZP8O
M)2ZAWCZW%Y,M@(\#=)E*8DN<0(:(I@B"U8H>Y*PF?HX3'=.GSO0@Y=[Y89UP
M$L:H7 )GW+=NT!4N/A36) (I 0I'! <I=$E'Q0V=@0JSJB "4_%N=27M#O"'
MG<$OX[;>ZBK.!>LW<B<XW?0#*X1ZSB,$WOC.7HV.##@55B].7MB(Q>./KO/0
M/J45XZF^CWB5<M"'=\&IACB,4F$Z"J>W+Q!<PD$&<&V:M3)FQ8_+5YW1W/Q]
MF\=X@\=CE8UZGD[AKDGL_G-<)<;>;/=;^%)X15;-L0WKWQ()C7"J$@LH*:A
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MIGOTE+__"%NCF59'1HTA-H^MP)@$O/'=U%6G:HE^\'LXO,.^N_-#[0,PHY=
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MN!JA8C.C6)5;MM#8*M1PMJY@P@V/;3I;>7L3J496*:HM%16IHJ>=6WZ"T'7
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M7(X7_^8+S2^2O_A#7UO'D] [M&7]SMBOM;%TG'%<-QY*1F'G66S$<L_-:S
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M_4*_-I(2;LI87SV@GUZ=1*\1#),CQQUH/VQPVEN!O;9T:!"3!B3R$],04X6
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M-J2"LQIP/'B#*ICG,]H;BFNRTBU<08>H\+5S]7O;ZJY'.LP6551WNO3*9&'
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M,?;_=U/JZ:(=$V('G<'=3#_QN^?RV2P%8S;\VB[D*3!N]^X(SKC_"*J[=U'
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M*</3- *1I!B]4F\9-5*IK'?1$J[CE >WZ_AM=-0_J+P0;_PF7ZPX(L:B;BW
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M.;27NP6,&'[PR8;PCW/_!U!+ P04    " "ZBUU3JTRX)B:W 0 ="P( $0
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M[&5F466=2"9")O3<8C%AP[%>O=.DU?Z,"-)#.D1YH'!_.I4# >4L+-[S _4
MT7T'5)400A-PQQC5!YU:(S!SHS:6T$PU0UTHO<:F?\TA6EU*8DH, ?-(;C*H
M.W>)+R&_^O"Y N<X]V' -(EV<CB7/>L[%=>ADQZB\("=.L)S+9=^R^GOA31A
M3A\I4_PGD-G%A1N6DI4;GEL_T:M1Q6K[9F,]@VK$7<:_&B^.RWG.XR6WOK-
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MDF65+<C?A)AKPX^P,CZ ^E7G4K *:AZ'#\>C M4SX=R<V&G&-C&E)@O#51)
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M"B1%G4^<96!D:LYMJG<"T":F.Q?*WA.A-W\A9V7WXS48Y>PXK*_Q6V$NB%4
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M< E_#UW5TOJ>(9%+(7&+FQ,IXLE!!T(0!;;+%$,H?T)[S4(I.^5+*;%4SFY
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MGK[/!](9.(Q3,NH%$W2LJ4%-^!@:11G3TA2SDWOK7*@5.&-KDG'E/?P2XVF
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M8P7O1)F+<T8Y3F"EY466!0G5R)\)KQS9) .A1B@4((!HXBH*:.69"0E>+N;
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MN >O;B[\*(>C&7U&)Z<P7*.@B@31]F%+SSIX]35%(/9H>]PS P&/4_2=D-
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MK8B\W(0J+07EN"5E?""1VFR7*D^3@:XE=5)2%3]-1-A0W$B_VI;XIS>R>4+
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M<FF'FZ\;7;[;ISRAMBYQF7AIQXOE)N+VG#5(WL$B>-)B6O2KM;W6+'"^#VD
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M;QV%[9[H],(8! GK;!T$VU>C]Y]K<IT^X%A1U^/)D"'I2XHE90((DE<#PIL
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MQ'IO@0+.E.P+M< _-]$0%N[)L:GF;=%&N)8HU%,?17A7CLNFAG%)A^1!Q*W
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M?D90\+#UD#C\)ALY*TW;QT2 "(DG:7MBJ",:AP96?]J>FO_(_)JUIN $!B&
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MYN2XS$$[2Y&U1,CY@>^S)EL,3A:O,5<Y^R9<4@%1H <[Y072>^8,'IKDX>4
M#<#E)J'3J Z^.4L%*2VE#&:+>;X$,)E"3GJUAY GA]0I=JZHJ)B&>X4>EAN7
MJ$A/V]K805MBBQ IU%Y4Y.E34GL10&RV,B2H?%4AD_Q<S5J+: -=_+8K%VA!
M^D:=Z*VVSC1NWJ?ZCK@\U -5!'@1$5DW7#I5!W6G(*098I,P\\D)V#!EDGTQ
MU74W>K>W8B)$Q6]AL+-G$Q H-[?T*$%WY[>-#NG6R-RA<:^4 \V" ^)@A^J@
M16!O4?CJ@FW^/(B+WIPDG0/(A-A".OHIRN)>GRTH^4<WD7F1Q)P%:H236$Y%
MJ(:3 UZ?K6&@-9,GELV<W]Z>]YPBM>F=V"O 6R2O8,1:EE>NG,0*F<-8H-<K
M1[GM?9#HZ>M%2).*%C!C"S?><Y,0ZZ/JM:!H%- SGCT8&12;?M4T( O8628M
MF?"Y>J>P^0Z.H+4&?CRVKS4VYN=^ZOB(*\3J!Z4K'@_=^6/]*))B8C$-%[?Q
M>.FGE*(+N_01OD],9=\0FG!-36#.\S*%EM5NW)H-'8C19U"B;3\&<=:<4;\*
M->HI[0WZXAQ=(0-%W?2.BQ'*M:.KM2[VAH8>$9%AO4!TY3/_*;$@WH*"\UL$
M7?ZI6&B_LQI]22K4"0S"]:#>K?Y %^9(0/_E^D/'-"4= 06RN'JV;AMZ7\]?
MSR?E]]5[G?G;,QA@OOVS=)BAAA#:&E;$'Q:M$Y?2U];]%X".Z0O@SI(M16I"
M]NG#;3\MZ'L+_O)0S(YJLN_L)T/_6P8E2.3HW5!N3>T5?E$'O-:]!G'-WQ4,
M)1H&)#<QC%B#=/#PC T>^^J.U,GS#FNE:Z9U+-=]XR=Q4N5C1\&#@'X77N%V
M[=J*]0TD>X=G%5_XLU(E6>;99"ZIT$G<,N GMN_E.=5ZU/7<%RFE8<$<EU#J
M5@@Y/WLXU-Z6<[6'PP1#3IF)_J"-RF<HE6_?KM)8J_7@"$W0@MQZX;O-^LQE
MT14XR]<BAJGA/5R^Q:O:T"^&.>S=C%P #:NX8FL_R'Y_%C;7L+WK:+LRW5QN
M>KBV(!.HJ7I]1KXPXEL9W^4Y\I0A/$DUZ;]$=>)'!2;,@H?:(/UJ\-V[0][&
MQ/1_&.0Z''(^=J7";K \N >(Z"6/+-5/^-^D1A7FSW6K\$Y1@HUU_%1>N^!S
MR]MX6BSV?\L&,5N"$^5M!U0"(+6D+9D'4EK;OZCF7_N-F#(F?@D1_V\M^;MV
MT:BPC73RT,?AFKJ#9S'>NNN/A7^NT4'\V]:FJK:;9-[#<BJE)[+4TE""Q'1F
MGXZ='@H@ZBN^B^:W+N'WF#%) W(5TA&C2]Q[+4B\!XJEJ=-8B.8&)I3R,-_Y
M_/'[Y%@_?4-0P3]\B!$X&+3/BZKXBKX10Y^W)@\\Y0MPWH\=4;6QR)W006(P
M9!X%MK';<X[3:TJ.V]CUO5/4CTF(F+8MGYW.MI%CL8&-6%;#82B>LH[UI>DC
M[VOL*4B7C><51C*O#:TB1J;Z.:UXKEI3AZ:%X0>O$BRO^!]3-C$<^:IA1% C
M#3NU!FR!YY%\11Y<OBO*,45FTJ'FCA5#*/FR/-16<3*?K7?\?#W;,/R<1,I5
MI(DBR)U #QS1KIHT^;+4</#$9-+GIADO $Z(LGFSA06M(95%.6,_MJ"C^K2"
M?(PQN_G@#^O%;;OREGYVFAVF&IH6]8Y&"EDQW"8:)&5IX#U)6-QJ)@U6\-7K
ML8_FFVRVP^ZC0D!'H=<V+E/\?%X-Z5:,@>QG'/X(63W2(P:WD+V[<KYX]^:1
M<S=]*[%:'7D1Q/<44E=\-U \? YQGOLUL\\B!-(,EQ%A6#^'H5%4/Y.LU.=;
M[-SFLN^E1.(ZCV?99KP-;=D*8412^Q&[V^JO99'MP.V<"!',QA%(:?)^O?3A
M:[/9YCL)U<4/L\3\0X&JFRKH8[C+_1 2<5OQJ9JZI'(4"MNY!A=T1;%(35$L
M!(97[QEX5.6B+E%W75-Y)5<J4\7D^VBD9;R,961VW["\,0MX'0#!!5B&BI-Q
MO56!NE\H2N5[Y$R_$$PX";\]RWT!')TA7R21J;Q] ?CR;>DN7#9$J(Z_ ))M
M3L6=G'RH#M!<UMIQV(_#?R3[I*HA%Z3N?+?Z+H9;:B*$ZDO [2(X&%'H<B76
M-BM!A?+I.WIG'#"DW%R3*.6TOGLI*X.?!'-A',<U("/8+$\85@IPNWD)%J]K
ME>;N*:&FH&_)>Z.E*A[6$=^%+.$[)]9SXJ"CFWWD>DC,[[P]G"YBFQN?>P'6
M?AW@%EE;3J)YN3GI'5_H<04R<?K;N%8L:HGB%;^ PM$7!C#>62]O]"<A;ZW#
MT@&V,28F2XE$PD]47;1);RMTH7:>& ($8;PD*5T1&P!EG;5X%VV4FM ?00@/
MH$:76PB!\=\!KM8@96MGQ^Y/B%.+=)J()=#\<G9.U0[R?^*].)&#HDZTW:S9
MZ]*^-/W#JND7NKU8+GWH2;YNEU8*/ 6/O0#(W.$+> *>Q"<NP!^K:]\8.5:2
M()Z><X0R,A &5FQ[;M6VO56X]7CD.*YA[<:=SMNF!Q/[?+5'EK%!?L-6K.C@
M<MQ?($B6JR3\HZ^ECY<+IS)V ;N<"E.>U?<;_W3>.@,Q[T$)QDGJ#Z>(N][O
M2A1I&AE=2%9?!,FH0"#=E-Y[FYMQK?9FH;G!DP[SYR&R/:5H;W32.S)O02E2
M-B J=,__::\TEGA<+RGDZ.\"R<Z,_1@MI4;'GLRLNZBV4G$CWV(?$._.A2&T
M39U(I<X[?V3!&MV?JS4\UT60V/AGDU3I8S+L"\"DX 6 ZQ0.="OMD_S"=.JG
M\M"#=X:R 17V_HQM8@,+NW;U[8G& 5",;5S_-6W9_ M K_Y+MEX+&EU_J)F5
M#D,6>"\PXMD0H>]!7;6NR4%IPM@P8B0T+3#R8VX[^^BW^T@M!=D-\YJJ=BZ]
M W!X4)DY6]T8O55(FMR6\>SWR#CLX'*1B5RN4W0+WM3\&OS4O*TTRQ*%&938
M[??YZA8%MF7132-OD+.+]T*FL6E-9 HN2%^9LH?J1GE6,NX-7SG#D2IP.>^2
M9LV[$IA5,)3:^PURL6:PWN-@8="%+>V$N,SE"#7GK2!P-TTGVI[HK%M_<?VR
MU=I%E ,4,0+:/-V=1=;]QP,;*?MNB"Z\N:/%=J^/U<4-4D$^2;PY5]4FN;\X
M4UTQ8F/P4)U,YTNAT%A#3H^$MW5R>W4ZT!]!-6..I:4#;?1&_RO.8"A_RT!3
MD\!.BHDCS*6Z?B!-4+,&D'_2O':'KC&RYSIH?(<)42UJK*K?V9;0D=XM>-=G
M+1FC)&5U'=X:LF<?J90G2Z\_3\TU:<-:#ALQ>=83?ZK?3H%U=,$2C1YP[.+N
M3NZNI>F]*:TY&:9<!^"1^MC^P<'Y$^+*)[MBHC+#<!A7WFI)L]DR0^4^6'T9
MN-B?DOP-=M:$W.]=[';NZNJN*D(D'1!GD-,/3#:S>WO2"/B4?Q+.P3*SGE T
ME8+XR@;+"A*R5V7"I8D='21OOQJGLLLW!0$K+J<K\LG#9$7M) VP!\V:QU.M
M,T((\!!27:)4G+ +O?/8:!2DMJ)U$649$:QL>]9M@,O:ND2!<H\-5ZJ"J\Z>
MLZWT0ZTO +[V0TA%_#[:#^ME'??R,7<=G46Y15L6U ]F=)ZT>=8B;V!B-HJK
M2U-)\5)FF*63-+'8=L80OTA.D$-J\6\$HA+PN-UZS!^K/KT?F4Q4%3?>1;@Q
MR/7&RVMJ?+4PB0;^3$9"PG[+H:9G>GC PU/O2'@CF7<S\LQ2B0<[1,@# IC(
MM3\45,G+_S=E<&JB^WJW=JKG@2H\.>XT\)XS^^W5S*I(9!4?-A<<%S75 6/1
M"Z"ZCFH,%3RR&#G.PF[]Q.6!U;Z"DT) V1+ 3RS%-+=TATK_-QU#R1M4R[9[
M>&%2=BUE&!&9:RWHA_$+F?S]\\=RS9RO4>5Z#8^.HW:<:T=R.L$)N?YNI?UZ
MH/U@KV,UGKRYS%(P#.3'L]O1_#U8Z[7GV4V<-R ;H3^[&ZW#!I:O<'V;?2Z\
MO(23[XOT+%HP*P.U:8BD 6QY,C\KIZ6+*&QV0$]+/56[,\TJ26[N0IBVZ^QB
MY+:G:N"F-BO-5R"'A1PZK'6J)B492RHDPF@< 4*,CTS$PY1/UQ'@(NH-!,SN
MJJWHC; 9D][Y62+X UT9<%M'94=)VQ$+,YZ5F(681E0%V2V/DOAZ?<K)K+<]
M5MDGKJ5? &(>Q[7N\7L"/MN^>U>_5-X#5<!%!-BHUE[0@):+C2WA[TNSF C*
MZ2O*BYWA<%TR_3&QUR"U6O9WIGQO:1TV$[>V\!<BK1<6PK)-CGYI\BJCZ#AB
MC5JM1$5#%CJ=?RZ@_"7V9!7SZ))JWMQE N./A4@]WVFD'J*1WBZKKL$7$ZY=
M_F9H?:) :S5YG9+?=7C9I\W.*X/"8-$\.A%3XIV%+Q7P#]0QNWXRNX\YC!P"
MGG<_B;GHH+JE=)M74U2;-%5DRC(*6<J)![A6354ND_GI:DLXANSQ&,NWMG+=
MM524MLS8IEO71*GU^%;5.1GG57#8/#_#S>JQNI;(=4UD _NP-$N1W;Q-M@E3
M.*/9XA>UN!<A OL,?*U!(X2Q=&STPW%3<[':W98:5%C4:6JG49FC13/>K[DX
M9H0H*(MCAS=,DV%5117724)B'% 1,;]9F'B[DX+NAILBUN]4TEN ,S^M[IV6
M]M04F$05:*S$$DA494ZK,!,.-+=D=2(3L-K.;X9:Z"(R4B^V/1"$M*V>5BRC
M'JHK"AJ253'IB\6!89DU2.KAS"F$&F_2%$OJ5;#>A)(7GZKNZY6'MPS>M@P%
MRV%>9X;8]Q70R*G+;FSHN-#0KM6"8]V&F@*8WW?<%9/F;>2\=K4=S;6!P^52
MFMUQD)AE;0#"S&"]&[4VEIX@+&5(&V[#8,(SPVQ%7MGNA2B8?,S#7G)F^=J%
MO8QM'1HNG*@ .BWSW-[)5-MAW/3G*3%OD/X6T5CA,AH8&OTZADL@4Y@[/+X$
M4W(KA);>*D-T0*RV4P5.G2(K/!0#O<+^*N_2A8A8"4PR01(M-KTI-EE43?<Q
M+J\Q 24FB9.;/.HJ1H3/& OGS[..+"6UAT*;%(Z);Q+-EN-0VU<V<LO)KR\/
M8=M^<V LY(E=,G7ZN\63WUZO]<.J@U!/G3W'V.>GVCL%>\SY9[]=DP"R&4LV
MJ4X!WQ9%?N\)U [?"W,%^GH9Q=KP$FANX&PS?^'ZDI7_%>*XM%%*/F]Y*&=O
M+8DI2H(R0'F.8160#479G6GE.&$@7F9:L+#XB3:+'T7<LAU_.T0?!-'M\B/F
M+PA0ZRC%7/(9X5']+#,;:[*E"D=-N8/0]\6G0D;@+;H6Z-4QP-&_ASI.X<CV
MK'YFD*DT2M^9#6/OX8>-L'ZHE?M.!\(+8*TZAP_4^GKKJ\OV"T J49,&2_)]
MT]M0MU+,,=*'N!> H/!UP@M@NI97JIWSZ3?WT2(C3\W5ZA2JYQ&>OQW(NQG^
MA9:XI--=[1NXD?56_YH(_?,C]5H51);] H"%^)^/FU+G9B<_2/B7>=V:HE>A
M01,FD,W*2)W:X3E>M8/N-FE!VQ,+6O?18H+Q"YNFR0)2J14O .9V=Y=^RJG_
MWAY+?GYVUPBL^/U-D]+O2C<=5-M2[B\ Q5UNWZL'1)J+!Y^"HX%GEBC2Q(1<
MO]SC6TC.#@<1BM/^#<S>K[/E<6UP:^#[V=;>AIWONA$Q(1R^(/0";>4D*[8)
MZRU[F'36B;!7&7PQ9"T1(^)V-UN!M"U^ \,]G5CN(_3Z9N&;6)[SQZ9G>6U<
M"YBI03AP!U0,F79@>*4%ZXF)$ NJT6&^H/ON>5?1IC;>U&=^.)L--<4JDL$Z
M9FT\YX@:QMNYT.0UTKM.2Z07 -"6+].G0#.K:T&+JXNYTIFGZRTX\GR^>2BW
MV= 5K5EH:G#M%\4;(]O#V!,^^C,_^]VCHOKV=DE)*R)&7M[L[WL.HB0=3PO2
MGTYX'_5HN6D>1P^>E<"=;)7?E;2B];\M1,=#1VR-]&]?KDU,_#NK^^=\$"GH
M+%Q33TK#U""5IW0'_O$55D,POVD.]4-8L)C3H1"?$1#)'2(<_J].?+1;JA',
M', ?5+]VY=0=+ZY*WY8M24$;I(E],X"ZA'A--L)KS[!"P%!3VK3B(Z/R(>F3
M%U^&VBF[38DS!KIY\MN+-I"/((-\E9@@YJA>!262$=F;$\\6UW()([VX12$J
M/ @+$*'>72B?'C\=V\!:OEB#T]U&SB*9U$"=0Z>7PU;@NXO.=HK)+.,X9ES9
MV_*D 7,H\G2*-.VB'@KE_;?,M&Q*?&%D3B=G$<;7<#TM-[NX#K;V%)0W.E6?
MQKY4S"1=V.C)D=BDCH"2TK7FOFP6CT(H*2O2U;%QC=3J50>;3?BD)8LPM1%"
M,W3-U?"P$XHIW_QDFVZS6)&7.ZYRAXM0M)DGT.=V-TS#3C8I+V(D6O1X/\%^
MX"C7+U]<'FD_5 1GJE+3)T/$/#H%N(0^<Y'19TSBXM#YGB N"*>!Q7S7U0=B
MH.A05E?G<%--3XS%@5JJ28B)N4!*2U':V"\_0J-5-!%94"]6DQ>3L?B15OBF
M;=R?@%>].53<M4RZ,06/KVP5-(K]$UEB6 B7%E.7*<2$\A6MP*WYR6T:JP7R
M,L^F#;3UBLB4WP_:(>?XF10;T*?H1!6U.[T2G!0Z3$G2^-DF[/T!''B>V"SU
M\^L9KE V]+&1/H[HSH-O+B0W:4S\V$W%F%:H(+8SOQNV%21)0YZDZ=G+&E]V
M#J_E3@7FH(PQ!/VMK5\@;\/P)A7[LZ:^%X.*\T[UKN.T0!-?4UF!R<8_;BOX
M T1EIU?G+;O<?JIKF3\G=9$)\IW5&S]<*Z;.E'Z]U:@_Z+7VE\HL[O?46GXH
M/,_]3K*^ZKMKPL,"^CYJKL< T>ET_N:IV[\([K ;HM&487C=1I!&30S+L%'Q
M 1QXU/,@Z;0,5)&%C[JK,J9#?;I]93^P&]AE61O;\G/XCEWC2(V!BP/"#GTV
M *S .R5G1;TBZ$Q3;HE$1Q*%"7)1# J84<*_N'?VBGQ-WL N4D-;]'"KYOGA
MLWC1;#*F$XKL3/G]K:!GH7'F-EN4(4X)T<U.;9;I-/SHK%\[\B0Q6FL'"EAX
M[L=]$_?Y5O?Y[HD7[%(^IX6+#9<H]=8CN&N;/3!;,'<I%7Q0R>(7?SPD;+K0
M,)N;ZB D NXYN(',EQ@_G<3&EPF>=T4=](<UUA[?OBNHTOG;A0\]LR:7CR>W
M#,)3R!L#,L+\;Z_#7P#*D56?9%;^ :,?R'ZAY=J@">WC;QBUS86&>: :=Q[.
MU',[= 1C1_WS9?_GZ/A?'%-X]10<][3TD+,KY'OE T^[D7_K\6YIQ&&UEJYP
MNW1MQ?H%T"9P0]]Y!A+L\*2#- OS7/3=_F*7T% A4-6H>M#9^%#5R" ,O^D8
MP0+Z;!M0UKX\OFJ'BR/\3V:I#U#5?*$P5Y_UK=NAD"4_T+FA>D9?'5:[?73I
MQ?,U]-F1CRW%"]KL0C/LA^#"XU&G.,V5&%?&PD*6J$BC#LBH2J%%4[AZ.G^A
MY:^C"N@J<S#*-WKWPY;G<%.A:?L#I+_5]N;GQ-+;;K6*/^4P^&?\<_"CZ:3G
MS>##U 'PS+I"$A_Y=>RWOY(#W.BXO]^E83F.8U.0AKO9M^W9F8H8DRZZ/;Z.
M9FX*T[^2R<2X(Z%Q6GX4]85VG;2S':1CJL,!;[.U.]&+H*OJ?;1W]=C.&A'Q
M'Y=RH*VWU) =65:L,?,9"0D1/>YKAYCW>=Y!^@O_+5*0H$GC?@$0;^7V,/U+
M*L_K/WS/?32+6:@-;>' $:*1R&UPZJE7WZF>6M04])U:0&E\JGQG7LQ&76&&
MW;'Y7MFBB8"2C:M1W8Z$3:Y/ZIU$=4:",Q84%LS%FU36F?U@^B@[+BSTCYL_
M967IHD \G>U[*V<S7Q)V/K@1Y:AW#"2.@#I*Z1^7)&T8XD+BA('NM7&#>[M4
M1DN5)2:4O-_HBINBU5-H2<)3\K\SWSQ^D79;C9=5)6^FGN3UFX1'O]/HT]-5
M_)S]/C5# X="<5L!_PJ+/-H&3BH+TRJ=>(F+I"Q9443>)%ZAB56I_MQZN0*.
M:X'"B#(M(CV-0.='56>O(@4]Z6C=T>'I0= K-A":/I$DX^A8M.^KQ;'P;_*9
M>4:T'#:Q'APILH)A&0H,^Z."4FKO%*BG+M[+#W&TCE+9]4B]XR!X=>C0CCQC
M'X99%V\",$.M75[#SSJ=\:ON16X0,.2EH(9)/*D2I3YY0WL#[7-4/?I+O_,C
M+?"009\%B.*V);DQ"&%L>ND>PU.?]]!R_:7LQ%K(\(2E2A&"NB;,=)K*2.<M
M(0KF*J:??\K-NI_B?ZN;7Z2V9N.JW-CX46.*DM^?85098?Z _^OA?"R^CGK.
M75Q\/N2->@&L8F6:GCS0-A.\WPK3Y-_S;I'J=K_BCO[.7V3R D@JE*02_F!<
M]2$"Y!S+CY%6@PIM1!RTHN?,VK=M'0&7ANOML$!"GR5*3@CHA<=AR7F:2%3%
M5_E<MWKKSL$#C=YG'DY@J^/X(.$M?)?AZUXW1N0W/TGU O#G 4.-Y%U[ 51F
MN'(];V*_W<-3"/GY?=Y)O-)XO-]:R?"#_'@!5(+CY"8JU\CT,W,/R4 V:*#:
MS?MZXZ.W#YT85I6X?S/'G:X0.D)=6&R'MT+N:Y'W.MEE[A8-&Z7N@S6,I_-;
M^CG/;[9=3$UXBI5?$W,B!8=IPRUWNWI\_I!CBL&S2^O7UB&/)0*W>[%$/*&9
MFRG>.Q7YKL#IOWY!E#!VY%$<1^H3WZ.\^F9.%UK#V&\R=_L"N'>U7!2N2W!D
MK=GK^H/)^9/]P>2 /J^APS7YXG)]>9Q_4U((N!W>6%[23=@80E$3?VJ.JYHV
M?YX3I):96,RW$04EAH)*L7<U(>QNB5 X:[:R*F <>;>QK8I-T'J(,VL[/]D_
MSOQ3T?C@;O8C+,BC+V#C;.13$V75RKH3&)3+$8PV3CI=P^B*VH"[NSZZ#'-W
M=+YUYJ"3N]\@;%?K+KAUQ^E;&3^VQWYV5^2^+/>P1!:6#_5GU6ESFH!<?=(T
MV@?6Q_K@C*T\2O)_M9U*O36PZP\=G(2W\_U9D.V&[](?X0,OMB6+[A43/@"=
M_,'J!HBX %#+E@[WYK_^.5VNW*^R0;?,;\\LH0.?]>\DB/EF-JD,_C6\*+1N
MW:'Z;RD#SDW%%3$%_B'S4;O:]Q< (I5B1XOU7=UHMMS=1AC*F7H6_-['L9,;
M28SOS4T)RHW)6 2:D6[WM(Z9C33\^@7ER>(*U)-)C8MJJ"\ ;R8VJ('W.MD6
M)/80X!3Z=F8<0@],')D ?>A]O(CKB ]$[=IKXEZ<K4&*YDMEO[*S!LQ.Q[<$
M391I54FBJ&2569"^%)K8B.(F3S&K,V,#7;B< NX4J]L\F:P 9P#P^'SU9@T
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M-:1ZI7#J!3 ZL]\4:K5TW1PH_'#7!2:%3Z6I.D?UH(V.%>T (TE-\B)>7+P
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M=B-QB!9T%5PA:S@)F(@" .I<O!%Y\59C0Z#S2K1V''0&%&[?>'VI.1:"E]V
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M[RO]^ZS.I/6)G8+JN+F 4G!\B?/>"^ /LA!J]0)H;43[S19(H5.5]J:)B!I
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M:EJ /^)KR7KAC4D1SJNVH_4==JEKFYH$V1WAQV]<2\>"^BKI5KQS($+(</M
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MU5-2_:":51PH4Y/8WWQ:1YR8F)8Y/CPJ(G$QE9!<#;4U/I:9!HW#IB+7$]E
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M.AHW:2\*P"9XM6%S?6M(<GA&F\;5Z,<[E4"6)].RM+>4L%=CU"Y@?[7XKSV
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MRV3PWWO,=RD0BDU[7+)0V+P4N)9T_B+8?8\K.AEI_C75RXM["#6C-">]-+S
M1.F89 6JC?EQ]E"N.)E_$Q>%KN0>"T5,FHRAG,C>VMI:O>WQ%9%ANT&5L;N]
M0*QWIK>#E!4*4*B CR(U5?<V]&=S 7/CV3E<'K)+F3Y8 :0_,&R?+RDRT=^D
M"R8)98F;_K+H'9,B^$12;M$'3AV"(@D[7Y&$,MM71B,X*MNF:$1XND$2%M&$
M3R2G6R[\;-5'R=71YS=E#W>.;W\;.<5K.FB&57]B)7^/HF448>36M6T_]P>
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MJ3B221]1\:H<E]12AWS<E?WIT26\6#F)$;="PS8(QZILP].&+OMP27CX.<_
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M<MB!%A8O[)C)QL/;E,K@?ETC'M(X#R\4II<K=^YX-BUSYAH]9BGFJ^:TFKP
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MZ(E1WN2;:&N9'"7IKZX3$D=M6)A-^DD.<]0C8*'%VFA;ZPCR 7,A[_GGF9K
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M:3R9-)'/;X94DPG=Q^]%5E9I((S*9*LX8[N?\UJ="_J8A2_YH_W+<"X2W>O
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MV$!MGO2JO;K)V%5@1O$<0XD6JPVG4 O=>G59*#MC%IA??#&2.)3>G,6L<J+
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M45FD@A1^%+]656_W2WXY5CO.@T.6^^H:JI,2,X^SG=4UR0SY[30HIAW9-$D
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M*!1.<7'[@$ S47F\^28J<X*O0=5N;2(L]IY.&8B#,'FEMF#<7.B&0YTK8KV
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MY*)GH%Q"<SG"=$^:>V,\X@S$(U-L0O\&Z.CK$XJKQV"&LK#S;B/ 5TQJ4R#
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M]WV_)N<+K]^9>5FKU5!&6E2'IIXHOM]E%HIA\'N "O2*2B_CK[^E+$P46EQ
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MI]414FP<2]AW-^)JV(@G^Z"Z +Z+*$;:+>M$$8N$.1>#Q?%U:ZKY94/K[L9
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M!K(8)"D3>ES[YW*_B2Y:VQ-:'[1*_(!7P/,%9Z ;=\\U,=4L$%/DE@'569T
MXS*%!-EW[6*%U-^@F2TS9S,60_YG^1V(Z(.ZT9I:E7Q5"2)*#]7Q-6AW>_>:
MPOP(%T*.[&/E(YG7U)*M+E%?H$,KX&,^3/O&IE<\H>\'QG#+/DK=P_"5?OC*
MQ)4 $R,YP_DX?P+)&6AW_L89J'"BB;R?+/[\'#6@6YIK!$N]<X:5%?P<K&P\
M ZGJC7MGU2"'OJDQ$M,NJ<.>1O.=5"%@-X.Z!/6>KX.<*GI8]5)?1/V^MG%
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MRFR539O]"_7C=P#4A#DR\&;$-"8(^<M9=GT8-P3_:'<D*Y6LM*.*+Q*8V(Q
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M<H_$E_0_\4U1KC_X""Q*Q>H7FQ:%]?"T<,+@!Q<_7L[NCC\S1GT@,,''!/?
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MQ7^_E_LE4CC\\1M_FX11DE84^R?V?QCT#R[^UA5_URSVZ[;YG^KZ?YZ.0(Y
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MRAVU2Z]Q+HYS&+]GK#QKMMB\"#^U>*,:9XR2^W[VIB"CZUDW^F<4P77*S?M
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M^)A3%"L5*27^%=1'H?76^JLRZUMZP<?+?.RIGV 1%7( 6,^3O\CN.</VS8V
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MD*^4 $*DB>F\N=Q*!*1!*+STR%KRJ(6#BLDV;.$J"4IBFV%;+TM080R-55;
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ML5P&R&_R?4'?_P!2*2Y?^SL;?MYM$. Z7#;N(<"Z;7,>,^*?^YTN#:0']-N
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MQ:ATND9%/FRAA0J9@4<*!@0P6,#XM\*+>3*"GX=*2M /NWR.+JL8F^;.2KN
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M^\'#W5/N^B<(A\'X)"LP8CB?^6QV M41VY&C<KJ@<5(=^W@7SRM_ )ZF1-+
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MT8,LJ22Z\DWRC419=275&0(>/B?V?\'YIF,H*S:Y/XB07F.NI4DJXPM$B<9
M9+I,WC-6AH4$'BJ:!FZCAXBG('M*E9(% KXB "4M1RS9JB@&].#DX& Q[8X?
MUY\3TL\VDDTLTQ U3,4"2G5,W_C_ 'C)+,2J$@VCW3_!_AFK)+I-4"P55(5!
M]\(Q+"@M>&DZ/62L;!GI]K1<0TA55HMVX30D91$15A%7R[226>)/R.T"-NO/
MCE22.";A5R9)6X&Q)OB_Q8S&<F8S'6E F$IE$I0F02B0@EE4H0A-FYCX/\(
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MB F!GD*HGS#/ XH]HXZ3PVDT\T@E4 :P-E75Q9D7*%ZLYN41;K6&_P""4XV
M?Q>(6^2PCV 'CG\=H!/J@@H0KJ,_F7!?2/0?A6D\LG7!(E?YI<-F[;%#YYY?
M5G6S2DT:74=M58VH%'#\4BG36;D>1KR/C)A(# 4HFIN8<L)P+>ZB#+81#>&
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MIGR*T(91@Z(@ !U#0+AI?MT^?0>'>/:.,T*.P)4U*TL&5W(>I!$(+\1#@%@
M1M<.8?J$/1IBH4HP)6Y*FU#B'L54PA0'F @(CSMPX=U@  OKS^3$=[ $@@9N
M@="25&(6@9$* !<;#>P<=---!#M +]UK!<>&!)4C THH2@X)0JK,L(0>\1M:
MUPL("-@TTM8.X=./#%5+./O E]JTVD604A"!W!J-K#IH/R]N#DA24*H!<,@*
M9?K@A1X"(@(WM<1$ &X::!;EPX<\0%<J:K-L*U4(<T4/5">D=;\1 ;VTUXV'
MT:XJ/38E!B&"A<:JC-"%O<UQ"_ -![>S4..O'EH.(4=W.*T"J 790H*.CJ5$
M( &]@$;" #81[PTN/\<L4+D6I@Q"!"B>RK"(;0(@%(4[80 W@M"X (#:PK6T
MTXAV@/<&(%(5'L=YHQ=36G KN>NP\&'3E$Q 1"^E[:WX^C3MOSXA<<:8*/NA
M2F)L<<D KLC$'9?6XC<!]%[WU'@-Q]'/%.> K3FBU?=E"&*>4F:X$/H%P4,(
M%$H& ?*L B8.-R" @<=DHZ#C"54!$);%W2Q2RX;J*AT[[7T,57F5.5I"2%$+
M4P9J>.E:TB(NJSKL'C]ZA$OE2,B.(AJ4XQR1&ZBZ2JQWR96Y4DSG.)0 1+F;
M6JX"ID@H*!L&'K'>354."0]0N1554LVYQ%04%5>=O7,NAJ>29R\!5.8E?Q;\
MKVFDH:H4J9A(.91IY9RI&$2BFK23F*=5=JBJV2%=J[C2$$%%5 -G)JU[//\
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M=(&3Q%PH=9N?9STX<?<1U4,]:9[#W;?44[TC<^:::U<U94E)UR]:5;!LV,C
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M_.3H0X>#42AV7%RXL%^T==GCVB X@*DNI3KB0;V1,5<Z_=W]/<#:[((W"ZE
M0L%[!<. :6U^D!#E;7L"DA45%%=AH,Z\1&8=P'B%[=O;IJ/(0 ?HQ"@Q4U0E
M%13FE'% $R*"PFMQ$=>8!II]%[]W9SQ1;BCN"$0JRMRVPAQ0*<%"G4*'N)P*
M4Y#*$*!A*!E-V6P**% H;LIC"%];!81Q)@N*D H5Q/,+L>@J.^B*!Q<W"T&?
M1Z&Q^?\ FAGWG6RK#,V&IZD).E(VFU:4)3DO,038!J!EUD?#KYF^5:SD6\=R
M34.K0T8LS0,11%07"Q1.F <BQIQV;.'TCN'#%7'JP*N4JBKL41)LR<\JNB8>
M.-%/9.EY%S1]!3;()&E2S,K+5%6 D$C1XQ20,VC6D<4AF50JJMQ(P%V@J )J
MHI)X%?</Z[>5481005(WM]!'$RZZ069DK&YE.\S$0I)S#0Q'46M&P+RH&D>_
MCUT62K5!HVC&KQTYDVQU96-:+JO060516,X0 JB6("L1 S7.Y5IE0)A6+9R-
MS"K6JW,='5:NREEW=#-ZK(_:LNH+L5333B+28RS8$DDT7<A'@B^>L$R@5$Y1
MV0,4-L=2@D@$JA8$M54X50'/&..D(E)110+6V[<%S&$>F$K[( 8V\U-=6UM\
M:XB*H%Y /(O+32^-[&)47%&H-Y=41%8QP-<:9U&-X=:P]O#0.8#8>P+Z>C6V
M+5V!E+DI7"[$EB](D&G"XA:_'T]GR\N-N << LH1C@^U1N+/CB0(0I-3D$VG
MVP37T% 0]%Q"WTX/\V=,RE$^@4/':3[HW^IC8H.W7*MU ?Y[1X=T6QY\];\@
MX8Y7F_W>PCTRT&P1M5JF"ZE*H',8@+5*P 1*.H#Y6@#PX".MN6+1\"/<^W:P
M+MB#[=8VC4D@JG95R=4W63.=I=FS4, B%@ /<A !#B A?4/0&)U)7;9F3=$1
M6*HFXXFI+JA6KUJ(%4M04%2LJUIJIJM8PTM(T_.U0TC9%)F4KFGZ5*W\/22"
MR[4&R";).136?B!BG23>*F&Y1$V$$ Q**6577B;*8C33-;)Q2.,_0S+A642U
M;4Y(&6=@C'$,RJ1F:9II-NBX:HBX)*M=ZZ(S;$.[.FDHJJF4B1L":.E*;6MS
MYP#@W!6N>&7 B+E\6%/RFY'O%%D'_P#SC^L> 8UK'+@.D8\F3 \?I!XL*VMX
M3=>C<LK?^7U^BW?AK38\ATAY,F!X_2#Q85_*;KL^!9<.S[G^C#6FQY#I#R9,
M#Q@\6%+A:3=!W[EE?_Y \.'$,-:;'D.D3R9<'_W'U3V@\6%/RDYMR]Q9?/\
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M2T37&\2S2<D!OT'RJ]-7(;\!-Z8DVW[4S]]]+_TY6,WX3Z\.?@-L_VKMW^N
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MHDCZ_T6FQHL_+/URL#;Q7]W_.*Y/"N[_T/GV$G] XO;\(#7HJ)63F'BDS0-
M9P)"!W+J*A;*CK#.J<NC6Z@-6#9OQEYUJ$=PRO%V+&Z46?Q0^E;@&1VRZ"I6
M9[R-MA\?(C8-IB<&XJ)D'0,.UCH\/8]^_3\Z^R5\3H!BK-+_U5,+$$922_4?
M>O=3O.VL*?\Y_']D,M!T9E6ZS/U>4Q<#$<[ZLC$J$6A)LL$YK,<-%D4O2[;3
M&:ESCO:I4PPNNHBR3^IQU&@,^58^Y^P/>Y7@E>SUS4FEL=K)D/\13>-BG*G:
ML!CV_"#' F^>LL/8+@MF=*XHZW[H7D8-1H84A]9#SA_HU1]ZKM9;$ 5US+G,
M!:,\S=]'I?/H'.:+3C+KWO+X;(I(2(XJ4:LJD88K<95_I26M8_57DM2K5-%/
M=GN0YGV_,5#.[6I:@5"(EB//[T=? O"L=JEO)/,&(B>HI>O?I*8I!UWG>%L8
MZYVC?:'XP--+H]+X)=Z.7J5967 B4B@94*S0;+-,(RQFV#(&MT 8U63=I]]$
MU*&-X2O9;3Z[W@I"]>CYY6(K<1O*HQ"1_^5%;Q.>7>,2;[@K!N_\\S#L*H3G
M']/I509JH0G\O]SL?R1:CU_%OJ>?.1%*^N(LN5V'@-WFDX@,KBF:7*<#2$YY
ML%)NP!P;@-:/+Q@@]^'A7AIR>]V^,U!S0A>2(V=F2=+2+7\?<8 !@(>:$/8I
MPN,[?,P5C770IS@W<;JD4#8ICK+)^XPO;MM>>_^Z$_D_CW^B;EN].Q\H_L>W
M4)0M_"GYMV_]1)6S;?D/1)):$G@-5Q82=AV;(ZI7'[^7WQ&G((^+[9)7QH5?
MQDX]JI8V;B\(B.%-FE$EL.;./CX'EZSRW+F/?D4 ^8%,,.!AWAZCJ_W,A5!J
MT=&J9.@D'B+75TUC'JH[%W=\% :"/S=2$ _.$>%[PJ+.HJJ<5\6F'X0]+IKM
M2++J:)B20,-=]1&'+'%'V>W<+-$ZF$)8BAC,Z:^\TR&MR).N>VM^*LS3SJE?
MHAOX_:)2LT=K?BW]P]U)S%B%9KV61ZH'DX[?B5<Y:P,QY@=H('[EB\2B+QZ#
M7QUB.'7&4R< +?NWPS-I5[$5;96+E[;TO:]E8)KZ"892C@O!'$+H(>A3;#9S
M+YB\3%BGF+ 8^7F0E8M&4'D1<G9N>OR9PAJF^V/E3U)G2AE[F$]&:^[P?P,V
M_JMO=7^G1BCS?\_['TL.9OZ_;H%J_18/U<[=ZO;_1!I]PY-A/\N5UE,C%I9F
M2N*:XA4 *1KE-IAMC3,3( TG$2T  Q2#FQ/<'/Z8U"Y+&06F0<]%39\FK>#K
ML<7]9;=73,R7<)]0>50Z!?\M=N9 "\3WKYVR.Z_=WB!OKG9": LUH?]LA[N'
MJ>-A9O$;4*?ZZO1_YWDM'<KA_D[S?VT,^<(XN?R++%NNU0*?BJ9X["O#<SO'
M[XOO;53Q"AHYJA/=Q)Y\$%Y^-3QP;H;+,N=E,%ZQT]'?+A0]4%33*2LCWJ?%
M58BE+FC>,Z,SG_? D4;$*H;"8#ZUVL8,'TU=N8KB 7U7MK-C&4*Q^=&+][-?
M"8P]WA]G?-@]P-^&Y'-[KTG;G B\2SR4'78O7BD*0891*=\_(ZROTO'R+C7-
MEDN"U2B'R'+5E267YXT(&8-VT+3;RBK;U51Z^+ED#X8?H;'^I$9_4>I\/+OM
MBTFB!4Z*U\(&]8>TS.MKZFW*R*C5D&O-7I_+&GY@8,/%H2 )S2!MX*H] "YR
M"JD-E()@GQ?!@,(P(K;V:EIL;G(Y[:/L/N$Y=:+YKSP]K"R/0?2&)L]N8_XF
MP\Y_&\4?-6Y],?\TI/A?:GS[]UGFR6J'QQXBHD(/](\K#X8$\ X \*ME=4"O
M9EX71)D"("8 JO3B(\;I/Q:]F$&B%,6TYK1+'62=&I-JKKZH34).P\:^MCRJ
M!M$$&T7M9A\CH14FU)@ 34H! '4K)SS>373F-V#QF6IQ-T*G4<:DY+D=2119
M-@FA0K$-DR@I@ 1C[1UQ(%@:?><E$+L8 2\NG^+WBY$U^<::'7G?^%)EN*(V
MM5O8@:9Z6/[;DT-ECT83(;+(LHT<OM)*)V@DW.LW0)2Q2QY,Q5L9D ?%D/3E
MWT$7ISX,E')4CXYS/>S,@^J6"E4%@4B#.1\0D)UB> /"[+EU52\7^<:K2K8T
M)%T#'V"K\ =X_Z@><)@I5L7[YD26$5G^1;<9%Q^V4 %-U5MM]C])I\A9R3Q:
M!E&X'O([V*JC]V>E\^>Y0!K0U#_#C&6E24CBT<,K-R-J8?.P.IL;+:(DCQFW
MR8FB*;NPGQJBVE-XW0^?/5;*'(LP#:JD_=)O#DCV'$J#6>&7TW$ .:O4&$1(
MN69A0N^US[5Y8F+#B&;E@+SJ[6,V$=]B."39))7&5&U%M#*\*6UGW&'L)OK-
M(F:*2K9?R?EGA4IC)Y9@-M+2=?/MKR5$R&ZGH$ %2I&O"KX\M7KU6ATQ&X^@
MP#YD&H84?9W& <"76:56O99R26I6NAOW3;=H]D&/GG1PR1<, 1Y%+39#NW?[
M%4K6ZZ(EF2I#7[-%BH1N'\]<R*2FYA9G*=%38F,7Y-AM9#*-0 LA =O#4D*-
M^SZ7(9AL=08P3%MS8DV6V3RB%P^DJ\8_BA!GOZ]2OK)]S>0$)4(6/9O%;8SF
M[8_M.Y3,XL@(PRFF+X)P1TY-C@1NEPH\Q)O&'*>,Y#S2"-OMVT[]%EP<;0P%
M+:^,\__"E@WU68-[?!S,AS-1W?JO>[2BN4(+!-G>;74)S;0I!$/63-A(5]IH
M%QF2T$A(2 GQK0'!<(5M)N95ZF"\1,0ZS88KA4[>X9\C//98=I\.7=0R'FW<
MD(L+1MP9)8-*I!WV."Q:Q<=7+UM?GQL2QBC%4@@'HC\(.D@=U=X9TU:(CEG5
M(:?<QG!2B+UC2=(A!2'AF24D.T 6JW7E?A>W@?Z7P,_3@"#*[LN^2)#]PTR\
MKRI2B,3$<'%<OJ[/<@H'Y/YB:-N2X:,_10@%!>5\<IA@S+A]53KX"H0$7$9R
M VT1>R:7_$FF3V6E7C_/C3'J#9'0QT_L8U$'N3][9(S.\%Q9!.)7H21/E^!+
M;]DIW]JY2G@0!@EA;K685[&[62$"/P<XB=%9<Y?G-8KPDH.H8"(H?4::HJ_>
MFN<I)@* Q&6KQ$7]<69?)&C9*##.@?A<3_$M6FW#Y%3J^&XV;S(>O]$=JIU-
ME5-E)4![[@P= BIZ,3*T$#'\O"9=BL\5'D[-9A+#F_!T\Q00[QB@,L,QP]$A
M.;L\!QPRH=.:=!16UG,AQ!RXN2D@S)AR"MO,EKTE4J[2/\+<RE_A?9\Q \ @
M)JN%)IZ$=>>WL6A'O2[-2U%;Z/2-)&7%V#7:#@F&89S$EG"WTHA?\0!T*B+Z
M09I 0XJ*=@OH5*9.K"4>0$I^%+YZYP/'+A*=EY.UK-N%(]1U/KH<P!6HZ$%%
M='+P<&9M0*HKJ8.)!E&9D1_A!2W<1*<NKA,=+]0*Z&LHA6>:G#ODZJ:MQ:OI
MO>-*+_SQBY,DX67!LM\:")X9P50*T$RMXM$#J0X!,):9KTTE(DFZ+P!H'YKX
MHBT\5VPYH[C'$![ 0GS+0XSG.&[CTO[/[Q=)ASU)&X9(Y-B"(:R%!38 #. (
MTJE",00W"89 ]V2M .%9<QRD\MN][R/<OY7B2MRV( Q?RYXH3WGA!)>O3S7%
M9II-18I>.]92A,8S15U-2)Y*K'QD]Q#PH./C4]";7Y#G 396L"[WDYB,S+H>
M+]9-<&GC5ZXXDG'I84[G0RV2759%J#,([D(_ FW'L_<V^5I*-F4LX2#82"<-
MC[("7!+BE#+EO.@UTIP1FX[D;B5H6'WC3TKS*$/[>(SJ:;@(#BXXN2GTSN"-
MWZX!*.1XM>%MNC\T-9D(")GF'.I4+=B?@0:[A;P,4YW<QO7$= W40M^R,F;;
M8/Q")?RQA+F@$9=+Y2&]7N.39V/OA=12AJ>H+RC$CY7'&<,*2S+DQQN$!"V>
M4AM9!6=Q>V5+F<:,237<[_NV'![4-U@/>"TTTC\*>$8[6B?'C\Z,NF\ US:/
MF*BFO>F, #B']%XP#KYVSKH6$Y+'G%I)AQ@;;JN2:S0ZZF1$.(0M4O'"V"1%
M#-W9<9'R1/=OWAPL-<'#/8=!M%LO#8(306$<^/='C@7KKM)P_^='K3X\Z"U
M+/4PGP8;0>SJ.!HI?#$ [7JA!?KIY42?>(+?YUVT FS6>;8X] V>NG"7)>'Y
M-WYNUW$E%YB:4J20WI/X/B#6->!!T!CV#5U\V[1^FL"V4<2-0II8V(*4\GC
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MLRIJ@N%J5!M 5J"RP9C37,U2$'6#0Q0 AS\_.@.TB%7SEN=E;Y.Y6_F,YI-
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M504*8"Q4EOT8R/5(M<;S6<6@-(:DU,]0WNS43CEA\X?B>,39P+H$PVFVN<K
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MW'H<FE[.5,?99]U*;(SH8-?'Q\WJ$23</R31D -F4\M+P[^W%3#Z!I1.$N7
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M3H>Z3]0QQ)E O=*[2!%7@ &*))Y1:))>#ZE(P]]%\LU];<D.!P84UHYFOMK
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M'.G.NGT&,;!BS0[#]Q@'XF_=V:($A.-2Y#=XD2DVA)2I&NVEIA"QC],T/"(
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MK[1%TL2JW-7QJ?:://^@\0)9EF=D0K@O4()\;*0NDJ4SU/1"P^384)2LR%B
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MI)(BX5CM !EK9UV(<PM6UT6<  B^$!/?$K6%2'K@37K0]/PC;47$5#SOU,9
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MQ40\]U'%3?#K,+<8_*H:];OX"38VOTX#6ZX%I+_@L !BVQ%B6-3TV'^2/D=
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M>UQ;>P"H5X3MA/,I0(/'$?+9DE44N>2D8_3H'J?8E=G NXQ VQ5IGH#]'C?
M?*T8?1#I4L=4(WZ.K82.? @=X?:;UQJP&4 X[6$$BI3$BNP4BKTD>@M13X :
M-:[66XGRH(C0!<&[G1E<][CKAB&]5^=8CM:$>4F%%O(O64QUB+!K(CI]1DOQ
MB:*']!Y_:1O EMDCA&2*$P)HT."-^JZXT94P9+9O;Y<!@MB.U-:& CQ%(2U7
M[)/>L85*1R>^1)2%M49=@,)%0BNM8;[=@[KPD;?[HMS3B%,#U31.6L(^/##
M/5B-* +E)#V*95VQM*B)'-Z4O  !'&-W<(E#[IU="=X%E,Z3VF0\);N\""<I
MG+;@@6 V!B9"BL5W:.$XIM$_DM#7X+ZY 6&-I@[C,#NUL";4;6J@#[W'6\<
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MV=T<J\G=R>558H!IXW??K97X:K\=I6!;\70!,NP7PWW S)2MI_TG9EJB?1*
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MWCHI/U.JB%N<D\A6P8.C&: "260H6EU(!5YK)YFIZ%:U< N-"C^*=&VA]NO
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M%!S(D<OPU;Y/I*0+$1$6,MCDD61@/6H:NV(!GS\'9?VK)R"V_8>CV)W]MC^
M/P#BEY^C#/[;XIW$J-%C <TFC6,XR.XC&\YHY8)VCT&+G2E3R8^)^'9;QPMP
MT39DHDDI+'<[1>M4]8B:H()VP4,) J[40X5?9H0*Z(R:*O*KY)6%K:2B\1LO
MD<)WE 95KQ0!&7?%%:X">8KN+]C3[H[L&G!4/U3'!\'78.#AMA[7.]- _N_K
MER.\>KOK#Y\*X/C4%0Z6&F8L1CZFUSU7:3H4X1AITA<LVYN]^<+(U"&W[)Y
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M)F(83=8/@3ZA:JT^(),*83YQ(HRT*28O>#ZY*.-M2 Q8:HQ8OC?5^\MW#I!
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M\ L9-Z2*V^)G56XI9@,_#Z-L<U@,*E0D1!7ZPI9+M,&8)&BU(%C(Q%(:CZ"
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M1P\WL);^U=BL@P@A;"'1OZ,6?/T:2>'V]Q@1&=]/D@PK$7@1].+UWX1:3I]
MAU+O%]0XU+KV-TH:2;[X"=CL_RV14%]:>=DY>CB#Y];)(X\;?QF987_63EEY
M86X=EBG=XQ'2_/493BNX1,3MJ[B9VPCWD@<MT7WUE2W#4!(K6>A002FU8!4)
MW;SOIQ_C71/=S+\W#5OQB]@E6>@#\:\'R+2?$.G?M_]]:(C*KL-,YQUM71LO
M]!E+Z)IR3%;^1_GI$4@6CN'^N H9_Y5D,$B.JK]77;9%#4N'V9UK) ^EH+CU
MIG!@X<&[OM(J+S[RZ)?YL/E^99T$"HW\&),5NA'8:EVZ0X%Z6I+99^(1G?,
M3]8^L7BQ(V6F=A^156.)3ZJ,BMIT0?@+3%/$(]HEF[RZG>P5P#!K$YY"AZ\)
M5.6+\1K9,8H!DNV[TVH4B1X0,FTH]SUPK-4[]\-1N'ZUGL/,6.CNB"I>JK:,
M?: 5%0)E*-*N<U&%B\A4/L]X:B?J>4P6)W5D_)S5H.'01L>+#DZH5?9$UY@>
MQ-FPQR,1[3EH9DNL+:M06V^'.LJ-9F->'SQ8G1]#]YJ78W L:^=152KR;*M6
MY6$IHZYC9DZ@XAM)4_SQ'6DNI'XNE^*&.0R=UO/%T4+/&-(3B-4N UA 2 'H
M"[O%53&7U(,K$6X_J )S&#7;NSY=V%RZ1[;[TR>Z?NN?3?D#_>U[C>T^EU"S
MO)"J.S&<XNSUU0 /CD^/ST95G8*2[EH;?% &S9]64:M5MZ^W!\<B!RBSCC&"
M-^XJF3[)"U6J-^0: P'ZFWP_BLM]QCW<(//]H?..X+W_4TO)'(9"*9PBFNK?
M4T-BK^B3BAG8\T;'WD"47Z=JZNF"#==7R/34PL4<476:AJ-)<@#P,)L*D%1>
MND"H#RIN-!:J04O\E>,1V[,B^+*&J>V-RFZ2C:"M\VZ]@P-/JE,L"44JNW'4
M>8JUBDJL"B U&:Q2U.LW-I2F8""MT6!-BX]G\=!K;Y0;C2T5,R7 V3UU45->
MG.-:IQMUX&^L;46.+I"GC(A&JECS)(:7;3':[IB1":#GY\0 ?3_$<FB9D=M.
MW1EA\X*WX<$+885V.LE!A8]!00;<.L0<57N,K,9S;_;2S_LQ:91?2UBLRF17
MU_J_]<@VBKD+)V$#=4I_0ODC0N3]T/>(2SM@LI:^_)&V++AHQPF-+ /U"^./
M6>'-BDN #&?R=4R$J\>771XT5RT(7A @2IY#B&4/*:/BN6;[I:_NY:V7:RYM
M+KV_NH<<.2?8>]-T^=W:9+;AR1]H\XZ(QN\VW!IZ1_+VS:KD ?Y.\R3I7+4^
M^)4*.3CO(-NXAWIMNC]" FH,8I+!SW?*X%#_8@-@(05IUKI#U1\# *;.T!X,
M4X;6L\<8M@AALXW?P4'U*Q."/H&)OMC>%-^&VMF+Q)!$(@B1_LN&VRSX>A]1
M_)FK);>8;;RSU-H*JI]0]<33>3_ON=E"#/YE9N'._A"2THXSA7_N!(^PG%:$
M2M%>&J3[3MFZ$ET>1&KJ"KP<9!MB*^)O*U?EYMM\&D"=8B^:H:US4J"Q820B
MYIR:@^^U'S,D7,'6D3V'DQ1BO^'[9B#^R^@K&2QBM0^\.KZ>)\YLY6IR(DR!
M3OP^<<[5$]%S+>4LNP>\^8G%'UCW]I]K*"<QF:099@Q'#BM-R(N:*T]KNH@S
M',&-%"3OFCO,H)3+4 6M_*Y12H-CUQ8\A*+W2-C%=+NKV--810/4@6=7B[D"
M!>,R6T%.#9<I>(,,]C$Y1TR$[E%\Q_!-C2*C)$,26+C[BO=(T"6(3$O_8)Z&
M<6FT1(MKRA<D9ZA:GPB(:X3P4+8;=!ZY3_+$V;[//* 2MLQ;EC1ZFKC0O=\'
MF^N0I/KZX7>NIZM^SVF_\OJ%</K.KPOA-G'_>,8+F(C?WH7Q?8F6.HFG^?4H
MB?F2,(T'WC+WB;,P+<.P':8/9'H%NQF,%QG7C#O^;/;PZ'V'_P:6FIN5FS[P
M(M3GWZZ3>2*>KSH,3^M_TPHM<94#T@*"\A5[2@ZSI4V^*LP4D(-;S5=C&:(-
M9DS\-4_F57B^EC(/54XX/,IZE.U065=2'IW,^XW"2=R#!_F-+:IOM$/!+@ZQ
M8$,:=D;L7)$<HD(YQJ:#JXKDOK:(IK&H=ZZ":'GGHO;.>YD< ]0C.XO+HIN9
MOH]?5_#YSA5').<D6^S 4Q[.O @V)A:BU-;SE#"3'Z^>4F'">=*PL4>JR@OB
M=5?=5.\['+;R*EM]?G( 8K.KT'X>$4]6CIUF)HK=&#43"/(C@YL)\,P&1[MC
M[J1XP!P]D_(:>?.SV>MS@_8A]>T'J_2U?!"K,(>+><?W6#$53 WE$U;*_N3Z
M=*%*):%^7+/GO#-^1"R(T:8\..UPA^XW%4&C19-+JSP7EGGYI5Y>#J[K ;XI
M:9$JSSS[FL+A(A792$ J ",NF <,Z43*KC/66,1]G><)%]*Q3'O:GK_4]4^^
M);JV_Y.JLLX RCP81@W!@HL%&N2]_?:DM,_MI1Z-6UBS(>B<-04N : [-0
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M<(SBC]862)@M.K-L8AY,',ZJ8A*YK#@(P(N,C(QK@D &XI1^+OP_4$L#!!0
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ML08_(82_T"\F2K*_R4:W=8-ZN/R%A 9U@]A"?G5%.6T$D_H%#3['L?!PARJ
MG<%N%NY@ZPOM?5Q^-G6L'YL1%,2*DI,MS?\/]B-[N#G^Y=)PX?R_4E1AMG^]
M?*!9.+KK6-C^A89K!8;S@;W=E6"*.JJW?S8HC)_DOVS&M(.Z^4HY0FQ_>@KO
MA_&*/\D([UJ#;2P\+CH4IB?8S?T?MNO])/]U.[:EK0S4$>KVFW,)?C!(*_Q:
M0*BA!G5&'#'=H2[PRQ ,_+OCL!SACOP;]8KE1:O[&QW;#='0_H5\44$L/_@0
MZ2RQ ?Q))[@X!?WH/"C$%S-$0']TMBL7+A7^PV$9B+C!3Z<!(.D-G$X%7 -
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M"EQ!OL D "2 78$D.^;7<4=,98N"TU>3P0L>H)08M#N22,>22&, (-:+WLA
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MQ">(V45671H?*DVLVBU*@DBU*S_W@CVS8<)ZV43R4F\E[JU5 Z$4K6QC1$V
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MD)Y"Q6^E01\F1%72+2L*"] *S+,/>9N,CTKDR@_MNSHSG7;YB-PGC,8K$<4
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M\=*)T]W:?M\Y0ED9%1$1^APL_"AWY Y9$)0LH41D= HL0+W1H-ILU3K^5L-
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M"]H$6;-3W\P=VM0;\"F"L]%G&.S-2VC0 G;F=_#*LOC#]F51FM.C>+6LD3?
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MOFJ"O;[5A#LS%^3)?)$$!?;7OZY%K=YZHEF_S^>_3T$"WM7W!,X?8CFR'#X
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MM(,?,YI_GE5EJ)AJVVN,:;,%,>C8%:VZ9>TE,UC*J1[(8,6+J7F<1=-9PYO
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M4!'K"77-:@W3F,8W%O'T2MSX.U6EYUJ# ITNPF9<^-YE0I6G_O2M$&09%,.
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MWCZ%!$Y(\?)8O>*W(LHJ_<F3L\O#%\P]RX_@OCUG0%(0M%-H&"]3PV[H- Y
M%%;B_BLD!%^>6"DY'/;,;;LXU7DCUXJ75<I5M[DA7<]LS.K[[L%0V&.LF(TL
M$.=M-9,LPR!S.<L TP^\$G"Y.IP:PZ5Y^()+K+?)T""0V +71'J=_C(@9-3
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M-Z1LXGN[U2I"?3$F^J:-NX&:\%R(@3Q-K1^ RAJ"L!G/YY?EDBK?8R21;WH
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M&$@YD/)NC+IBI\:3V\$J^$U(D_$S>.9;C4).!L$IP15AHJM]:VDEME*,\OO
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M'[R5_,3?4')(_2/5[67EKZA/L%GSK48R@^2+<3&FH^Y*8M_;C]W:A$B]D^V
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MQK&8BG2WZ N7U$Y(AN"(;[8A.H__HG]952),^:%6N0IZZ)KT4'XAKTO9_">
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MSZ3) +4N .;6'S,,_Z="."Z!=IN9G6VOHH818W"ORH>Q3[XQ]VQ'8ZEB17,
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M<U.KWH%YJM5RS 8$6%^&^+H=E25.;\@MDG+-_#W&U%\N8X04F_74]?"9S]L
M.O_L2LX_3J8D*7^7[>6$@M#(]B[Y,'U;J>9O*XTZXS?:H/\/$V\9U ;W17L'
M"!*<X%(T0'$M4J18(0D>W(J[N]/@6B2X0XL6*%+<6R@N+>[%*>X.[?O\Y[UW
MYGXZG\Z7,WOV7K_99RV>C7ROD '71>U>HB2VY&\U<Y<F?T]/'4\M725UJ^OK
M1_#W]=:+1>BBTZG^GQ#2I0=V]:4W=;1)$3)O]*Y,47C8W5XZ7@9LGXR&V5YU
M6_ ) D8\E-&6)- &G1@G\WQQ72_^ ::O:K;PU/Z[_M8M!/OD_R(-^\'OIIF3
MHCO!II#1:[%-60P1 _5L_A#7%&!,GA/MFQ&4TZI\H<A[CK99D9Z\)97W'0-B
M/^PV=L."R)FLX93;PR2_#_9.J2(5U8JR#_/$IZY?;'N-)F;P#79J1=,B=)/#
M$#BD36\AOC&4C/<XI&)J_P#O-"<2OIZ_[Q*S(DO"7U7(S7WIOL:S<W:)Y5;0
M%?#X*SC(O&GZY:1B@-ZW):>T4$%&X\**^-PQTY2=L QLHBYMCO'R!8I;0FS2
M_P 0"_>SP5!&1OQH5VFA*BS R9#3G6VK;5,V]H%G1_HO+Z(GSU3:OZN:9UIM
M=HS\9WO%FD*)ZA" U'+!: 5"I]Q81(?^OE&&KM4MF-";E[-KY P:HQ+F/X0/
M$FG;>36:_F.P:M]#5/1C3H>XF<C.ZTY!.NW0+0Z BXMZ(PIZ.BPT%%S:1WL@
M+LE_P?UZOOH-ELCL2W-L7D6K@O+-\QWR/^R?FIT\@A9?&[W"JQC]C"JK1)12
MTO'QR[OP2,0R-13!?<(8%]S<QYLW3J:T5\Q(:OJEE@S%?@3$.S,TK"<H?%B]
MPNRU6_7D3K6=.#=_%U'7)+S#^DK"7'BL8=F%D0TL'X/&9!DI(W \1H*=X)@[
M2/UVI5ZTPP-RT>S?9/>H-N=32E;Y5G9;?.0(-_T%0XU$A=S+*A25Y2(/:U>%
M#(@++J.5BV#6MH&VG3*[)QI"#:>?.342@5'(OEZ/RKI0J+(^_FJ4W"M\@K8.
MI##/N\\! 0Z1L\4#I@;VDS1PC3XH:O-[**UO?.I1N$>E4%2BWG7FG@&9D?3M
M"Z'KU;%@DVFG [H.UEGH1)Y':+F#/7A:%K,\Q]7--4"6PXVLE%^73+5D6&PA
MD!1[S;)8R W*PKQ/Y#;]+:KMS9,2$;;M(%H^_36D/W^.];9//[;5F:;SRKPL
MO>9K:0M3L^,O:$2OXHS6B1T@0DXC2T:"]"@<G1$I17O4/)('80SU8<.*DM:L
M('#<>T?WI+DT\6LIZ]LP[2&ZA7++F 65M,&\P@X25U%!17B,Z'FA521U_,BR
MQ\DEKH>=\F<!+U/C%^G:+-4E\6S1/Q;]?XP@9&8@@<D0_UQ"F^!_ %B??61X
M(B>]RL[17V-[!9$P_&)(.HR5$>7L888*&I\@Q=O3$_PK/*8)VI9N>A,@Z*Q4
MHB='BK%T<*K&C,VP*JU,PJ!GERC>+^$$H6=1&:().''JL0X:WMAO1Y=T/"%G
M!J<(F0>95[FICW (__V[=Q?S<.KZ^5*,PU-*^NO5_LK_?OC7W*MI%^^K%I2\
MC*A2LO= X*._QVZ$Q *R&B\IMJ@_)-W9[>\Z:AW_S@Z*C1F=E,](WX.F=992
M(TN=2:R03F 6._0WD.>LAMJLB9#H#XZP>ZTAQ>17&+-+>>E^@PZH_$Y,LK!:
M7FBN?[CT_@['Y(IE>F^RQ-$E.<JLN"P&QH6PF98.+AD4O?4]CM&YI"_0X6\4
M5?8+;K=6IW&W;LP?^4]^< *'21U]+OKL[30)X>:0\1FE1N=ON<$*]VC]P@W:
MVKMOVX23<!/R=US&>\WS)N<CI+4<KV(JRMPST8>\Z[XQ7KQ 3)6<R<"GCZIE
M,448;W18?B/Q)M5H:-=>R\]6T\DCC<4L*>U^$BR?F0O.2]LZ<.H)OO#.MY95
M=A:^KKVS7Y&WPM;>)!P&W<<!9&YD0"2]VP739OB\,\L:-&2ASCY!0D4>] 27
M=FQ= G>F+97!V?7B;.Y1SD\ZUIWOU-Q94@Z[<VSPJD8,0HS>:@FOL_:WU8=\
M3T.B87*2-JIPBDO[[3WZ4%A_<<%O^U4FOGNQV\$L@-O<B,W3B8+T19_%!W.Z
M#@MECJI_K"R]*V#6ZO'Y4X?0CLP6E 7>)]=*.M[MPW5+.D*=]449L2GP+^9K
MOOK/*/'2?ARO;NFK,*,N:-&[))<MP]67R[5+;47*.K,O[7E!T;55@/&) G=A
M@WK7A]<R_ST 1>;7K[O;#E90PML:+>$*>><<K\A"$E;5M-2CM%!6MN!T3)5*
MJ<>A_N&_N%![?]<3T19?I&^5OIBE-R=UF'RT(#18<%Y"H$)+L/C5XT'FEOA!
M$YYRY"R'M=PV)GDJ(T;+48/_\(TG)A(HGE>$_%5QD4ASZL3GQFDP94:1CUGP
M:D+HO^ESW_(YH&+#BI6C9/@S&/9A!%;A]7UV!;#["X),3@MM1$L</%(_US"5
MZ,GU& M[15'+]Y?-&2ZA.!T!2X!0>&8Y@A4D/K@P2/=!$090Q#<F(+N]"#2&
MV *@BFPAZ6V!+;__$+546MJ?DC<:+4K3Y>X$#(WZ2KC=]76VD$5</&A<A-4*
MF!990MI8C4FOGG=)?YCH'"O :E6/F?HTGKJP+'(Z8?;=(SKU4NKZC=NFYYXN
MZU1DQ<!THX'T>!%9+YU2.R,II5CLU\>0-B)"<I[UNHR)B^W,9WTK/&UI5%H,
M[:V)#7KM0E461E+5:FC[WNI#L/VV-+W*GFZG[SEXNJ+J(&..I\,\W:,(E]P^
M.TR"/G@%/=4*^WUX=*',(6!^[KVL@I=CV<>;*?$WDO\ F$K2_P"^+@+_!PC4
MUUG284U/B'^ _YD'\*N$[R6)D(]U"#Q"N4[]>Z/6_5?C>9-B]1M5CUN_!Z<3
MHOHNDPQ:F$9?SW45W9/^+_4G3F*ED:"7Y)@VY<>GH6"6'O;_A?\K720\FWYO
M5.'?UZ#F4&($_L'(R#[[V@FYDU\ 76H0U_(5,.9^._7<H;*&[NV A="A,U+Q
M!^,"YO)6)</J<6$ B0REQA"W)75'TT1^!"5:F>47,U.1Y GOJF6M6,Z(7L[&
M_#F!^W<R-UG;%]!O<"%;WM]C:&[]ER[:?U[>O4G0!ZT%AU_&H#%2BP(J^E>(
M<02"R#F5OI^=HJUDVCPLO3/.,98<5I9E_(R31 R#?T1#4\A:'EB(T<N/\S]
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M$?/U$WRE"[HKZ?F_SA:D+N96GV]*4G.XYE9DRQBQ: V>S+(%H2<@4E) [Q8
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MY&,TO/4YD7H-%S-EG[73!5C,K],:?BH[4JY-F7/)"":7ONP?&BR0<,7$<##
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M6>Q9Q(%L.(!DZ.:PYG=Y"3'D+H-0?V:@9T8I((PU'CS/+)$7-5VBXS,,_)Z
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MV: VH$<;]_EJ:UKMOY#_ -5N7I^%>-2PF2E:5 ^R-HG:4D=TS!]XMV)L<9,
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MNQI'N$,0SEG-Y<@%GT%XZU)BO4W""5YB=JDD2SF@VJ2("@/%,*2+ B\8C83
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MCZKLMO@H%105#395SXI&X1!)D@ 6@1:PD8[#^'.,I:-J0I:E#]K1"E%IPP"
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M0D0;& 8B8]X/T_1A:4RS_< 96F)O-J< 6C: )L#W'G$=K6(\I,X*>1KJ.HM
MN"8OP<O-/4--%M*PL%13*DW/!M(%S$=C%_*<%-+\K'F8L228?(]!-4"$I_)@
ME42!!,$7[$>47O<7F8%GXE1I;D/7IJE3($WU]'O[ZN$\'D6L8@ [9'<GD]OI
MMAIBS=<SH[YY:4X3=^F0U9LL]:=(*7&RE0"@#(FYFP"H,WC;?F ._!@C?Q%
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MM#MH2 "D .<@ 6)SMY]]3=GM[P0,C;/>\/OJ8/W0-?O:#WVC&&K;18<AY4H
M!QYD_2><%+1@HKYJ_E.$?]U/GJR4I0G26F1>P"CE31W3Y[B5>\^6,OL@!PDN
M'Z<3#YY!Q8<IU/MSYU 1TR:>_4>8KSW"GVP4)<2H=S()5:95YF]YGOC(;J=!
M].ZV5:N"K=#<@>&DG7I9IIJXZK< 3=/YIM//G^IPFZ-!^G#T^8I=X@)<F<B(
M&I$#SYBG3;X(,G@1SQ !^OD=O=&(E7+:^NZI!8WLX;5Q,/.7%V<4HEXK"+E
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M\A(^*S.TL'SN[Y:IEE&U59PJ4[G% ;TI *92D;B/\:"I1\R3WQPS:4^[PB
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MDBX,DSPC>GY^N[A60PI'$MW$=^<W\:T3JME%.[I:L1*E*--4.H7M"?;+>T+
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M8]H$@Q/N,Q/..0HV;%P]G44.B2Q$"UPX>_'DU=UQ-LPDXH2AK N#8EW 8DV
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MESV]J [B"N4QRU- '6BOD;/#+K-3P&+[;(F%<JB=FSJJ$DM=O0'>V<DP+R$
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M5_-RV1>;?ICQMPI\5CO5.(UTO&\"*%@YV9<]@O4'X'#ZR8F5M@?]ZM1VN/P
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M%6R$UO?WNA_=!IT9(<#62CMU#VQ"WYZYF DR0G/EX:3G]<5\U+VLB,)/:N:
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M.6#[!64^'1&+NYB5G5 2?]YDG]^ZIQ>:7X \C4_8::L,H7RV8)$R1&X!I>Y
M203\)P=W.Y L"#%T]6A-?XR@-R\;Q8#!W(7QKV&ZU#P5S)N4R:*14G[Y)M "
M1QTS?.FM-51T][JC8\P*C[%__R>$Y-OP;@CT:2>^, @S:NPE\4\D*S;S)^%I
MGM]SCP(D1,VE"$*V#SG[+F(!29! YIHN$2(TRHTH]?&8+-3P;B=(:=@?.O&W
M:4Q,3F=4@1C"YJ3//\I2*F0C>LAL9K^%>,-UPW10=*;-@OK-.3@IG#AU]J!*
MBFBHSMOG*C27+KX[* @(>(MKS>9L1],)6Z^?#BUL>+FM946 O(K&3>5S9_OW
M;.B;X;(J)[M8'-)/PSD@<5*$3/#4W?;7V:9M,RI&N(:%ZW/5-M;<]QJ8URM!
M2HUA3&]P>8 Y@?1"WF5K-JVDM@YLK^DC#%LIU?B;#F2P^.VX%IOB-EII[V6:
M.>@'Q6TD5M^)40,!B Y+LH^.%3WJ%I]H?O82P3)<._,R?/N&G-+^UJ.^;B$!
M4:&G=ZG@T=9D 1%_A$6$F#9X5'@._E+37V 815O@M]>/1&,IV7>&!"E)J.B;
M"PT7-IHS^(1E^Q>$Y([X.F-(?Y!=2BEM?LQ?PG20P7]87(#,[!,4C]U26]'4
M;Z\XTO5\+HV:29$X)8(+R+NZ] V_<X ^0R.D;8?_[HI>'JAI_@,T\BACB/U^
M5[96?#(1.MM@PUGV]9PD@I2KF#(_1 %=;@X:J] X&".F%Q/)NNZ35[4ME$OH
M%?KQ>G,K78E88&+ONV24ZE3=Q\1WRJH+VKQ;KKQ]YS/?59;2]=7FS/90<[=%
M=^DL21*/B):!Y=:<;@[[_;5K18G%($QT*ZQ:A=&)1FL%D0$1[)G"T?[+7["Q
M/.4,5<[=#"25!KL>56$A/]-.HP%YK5NO^3"$;TIV ^81_8L=:RDCMK:2U Y;
M0Y*KE[55_V+'L$M'X4;,KF)(\H+F2_%7:8(,]8@3I6\H8Y 4[)1T"!PKA--V
M>'E)4$^O0\I-.Z+",K13T@O/]/A8V2.-=$+T"^S6*(N<E(T%"64G%##]HQK^
M5H8'Y=/W@ME&EG%W)/\K8/-*F6,_%&],X>/5GA)SV\D&]49#K]I$2&I[+\XY
ML%#CRIJJ<M2HIZ/1*^ZB;H6<A-.$Z/3TF8^9]3,2_,3LK@#+@]78*:+T4NRC
M=VW(,7)9YO8(7A(\RFH,"_>RM'%@P);=DG[OJ.=J:EG!-*04@% )9$8?[=?@
M,I!B/?5"U$1>U5 U;6;&S=H,Z]^O[^T55]521\\._B8D: V]T+<ETQTENE 2
M!N;B=ORH:5)>2JK^#S#._P'VPN5VKX-NWQR$/ V^<ZG:8:P=TQF8@ _D^<0M
M_/V"'\*PQ[=VL+^P;2K=2Y1"@@;(T$,%/(RHOE",[_V:]Q97FCG/C[4!RO=/
M4[]11C"JGKJ51D:2G!#W J;Y<Y.>#;#\HXD+I-X$$>/!](BF1]<Y+0K7EYE>
M2?_AJJ#$TEWJ[ W#ZLE)9D .$"%8&4QFR#;]KQ;I]= U4*0E:J<7D[^JKI5)
M-:/GP'2.JT99=K8&%3 G;K>\M1"%)K\RY (VK8?M9N0C,(;.T)S9=IWYGR!!
M!6ZO>S'>WAP=J;[I%*5A;G_FM"'Q<%]9R@"WY7JT)$<8;JP'_L!#*#?&7H4>
MTG:S]6ID$7="0Y;2)^/V9$Y[A!7@]!"/:'!*6)$8]]?U.I -\)C)3TM#)[:1
M&2B3GZ_ IDN(^JG25Z(\9%CBU8CC.+7!!ZVW+WE3!I",[ZEW*:OYD=IVTI-O
M"@STY[7</)B<8H3547$H&WA(XZ/RI, *C)N-><FOYMA&GL3CNL*1G#F4;!DA
M&18A15& D&9 >"X6_3.>S"M2QB#?,HK)"DKLRK'/SL6]:^L5("74HE"+1A2$
MKPKR8N]EA8[2BXT8%)SU)D?*1IWMD6!)+YRX@?]=S;;^N>L+Q^B:ZC26*2\3
MNXVN959N"4R3HS6L!=9T@N6.XA6+!H\,)UY]BN+NWB/H:L<5(@*)1%8]K^H.
M1<',5):[LZC>-1N&5GW7*=>=KN3\A1J#@/W40+FK<LZ/@X  4 0D7H](W><"
MG.+(Z06\:EC%#$.-/E H+:8(,2N%LG+Y9#E;;<L0".?-!WU_6AGUS:A6HP/*
M%"L:]6E0_R#<Y736!V?;-M36 :<"(K^@BEKRD(C.4=P[N_2*A?@MQ#58'X[-
MKN_/UJH0V-@=)%ECYMQ-)I%"T)?P>152( ?B-F,5CD]QT*;,/J3(=J/AY;?:
M=QKPRP&.T@JT\K$,;A2+%.L@<<>N_.@S_P] =J"B8(AR'3X%>.MZ3[Y)<(>@
MU@L.'U@%XUKBX#CT6F[;6_^9X]Q[-$YP%#Y4^D9^G(/>K]@BD'-_=W7C8FG*
M8'U\4DB @VO&3(S'#M/"_P(MX,9[Q'WQ?%)NX@QL:;1 V*S3*2EHC5GV.G8\
MLP<0,/9GI)_(_:TD5]"(!6I80W%0,9-%3.YLO=<(J@Z.IO47F],3ZRR([6@>
M[.HSW%;G%WX1:V>00@7_>Y%XO:$ : RD/S"'WJ)S MFOGQ;5"3' <^K,MN+;
M$#F4W=DA@;I4WDG6_KB.'GM[6O7?Z<GG^ES8>RWYMS>::'&!2!=$!G&WV4C@
M?V/A]7%(L,R\3S DPR7%.S]_U#>S9]<+?_*V :F:BWOL0UW7;'8\Z)Q'4D&9
MX,[@,?/N>N_2J':<)D'[MU7FLL*B7Z2P@90&'5:1DB442,>?%BRBC9Q-YV11
M -)Q8Z@;V)C#.ZD<==28N/AOZ1/GJP='=XP3MA'6_[]TP5PM=F[W'V#0X$[]
MZ$<W,R $(]WOYD$'R2OJ8"COY)(=&!QZ21\TZ^KPXQAS-F[M_#_788O;?.;6
MTKG\?(]]A.,2A!25A# %6W_.$8E!/:\L#262R&[A=JMUG$5=PIB%7!VRZR!7
M?*XX7:WJ=_EV?DDKI6<#-;Q"]_Q'R02H:PZ"7+^"]IU_B+T-09&9^NW8/C3R
MG%@1)!_[X#;=;WF[T]1]S/!X]C2G+&0Z=W1=IM+\.&LHH:A3 Z$1#A C%Y>C
M8QR)Q<P6_210P&M,5(!08Q262O &3)-QXVT'_G0P:]0556MUU%7 X,(L'"".
MQRW2\>./!!=;A@"IRSH?5'PO> XB2_,#1-6_(D@.Y]"Q63''6PA7LL45'KGW
MC#]U&'IG_=Q#7A\'9T!VT\=!;A;^F& ?_29.0^3Z.-6GL70BN>TWJ"U'/LQY
M%A<X9)/+O=X<C%?.0C;O',Q"KP^%##H0SD:L\RN7(E\R;C<U= 2;.G/6ZDB%
M97XX-7?%[%I$^$LW)".]%L#_ %>"^^_8=:[F>Z>Z4H_QWW0=3R9"P1@_0BAU
M%<#]3GW/\GXE6C\[LG1GYAC9RSS8RBJ<E,(,I#(S.!!,\AAHX0#]GR([8!).
MR89P?_5/W;#EJ.H9\P3.UBQK-/A#&D/N?0%IX\^VHZ0Z31;K#.U&IV8BF>KZ
M 5,B(71%H/Q$GGQVH.$$S9?GQX6R=4V-_#U2@L=8<6,C=J:_].Z/R/:W%2 %
M4+D=/SIK\$7:P8ES)SSP*C2[N4IB<^!R]\8&;YS"ZU<'^Z$\!:%JZ)>*BAM,
M*A 7!,HJ)T&(P72;0[[-Y8;RW3?GT>^5B9Z;ZQ1E^3\ #W1M\G$CW$9GXG/1
M6):BLMHC]<<RCE8FE$ZF?I=]J#N 4( ,R)?]*_+CT@S/"#8!S]@T9_7CD:'
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MM"T!<2'V3C[.N:0U+,<@W?[W'^7!(J\#AQ2Y;=R8<?\R__WKEKY"DHM1=DY
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M6N6Y**HK#EE*,_TV?YC<2LI64SU2] _0C(L(,OWQK0UT=]QLN3RW63=4^I*
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M"I/EC3Y%X74$Q)L?=AXU9SY"M8^?&UB.%/J.OIADC!TU<Z[M5ZF*J.97?CX
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M7_M<YYPYX[D<O_P,P'H@JR +@(&!A7&!<0$ +K^1/G]H 8*"(!8@.RHN5G8
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M>[*,L3DO*N+:1I;V<RO;/RU_?V3FZ!^?5]4QNG+ )Z=M[A20D%_=.;9ZB V
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M[\: N7GR(HPB[&,X&.R?3UYL U  8  P< A_?  K,B(2"LSUHQ51K_266
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M7-^3( @Y["J!.PPD@:OTJ9EN7!X!!D4%3K7VL5H*NR8K$$U,$F5M;,F6@TK
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MWUD>W6G;#4S[+A18\P&0U=H&PZB\0O4.3M407"BKWQGME#KT%;?EP/$@Y(&
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M67AR/_71&O<W[I<].D8/ORQ';:4OJ^<[=A#M*3XWE@R.P,2\3_?BC20#X.[
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MLIXB#JC!QLF:7WSYX,<F39V3.V8;/\!")OJ9O3M G%(U/J!DRZ'A7?FV?6S
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ML _"^RSIDO#Q'Q(FB/2P#>-22!MK:< *7SR?M.7&)4S27/,@5<E67$X:'<Z
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MG>@32S*:(F?LM;(I8&1VR#:7+FUM>L6<QV;B._VA/]W;".G%@(?(K^3$Y0
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M%_=>.BRBH6FB&+&<G2G5W[=76 D=E#!<OR4CHS/NB')[=!_PU@!?[TDF3"Z
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M88;$"-T_[:0.Z!10NMG-GO"N^09F;:/*I]KR)Z15(NQL-P&,*.">*F3A][P
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M3AC'AK4A!PMZA?VDK+?7D[C>NM6G7Y2G]W*PSEK=^'8TD3/K[#*_V3&*B@3
M%4-E#D5E>"#OQF3K38'-R+GP?"M-.&0G^N*N\H(90M-D':2=SF(@UBWQ#-2>
MI4GKX&VK\'#Y;69L'2>^7_T.'F1JS#XW5[AL0X$!U&E=@]H+EO\HQW)Y&4T+
M\PT3PSO=Y(V6[$G%QKKYK<_]WU(OMO35TU++DM?YXUQ]8XO@Y):>+IWHI6VX
M(%+$3$&X<C*[ %8X] 78+0X GNJ(__558<+!>3)/[A@PD*8Q9R>P\072$BE_
M8D\#;70?'(>18$3P2C1$^-S_[@(QHZG0VA3(.K!F;NX#Y)^+>D-U98CP=5 7
MPDJ2.3G8.!;'%<VMG.5)<W1*4>SYA!$RC^O">?WP3I<A "LJQ2)GB4+TMN(M
M0A.&V2SW")RH\^MN8$7*^<GV(;X).U+WC]E_ 1D9:#O0>PH&Y$F^W,)S-:W#
M]ERJF OA)OKY+%)/\DF23GZZXP EEN_)A:M]#G\J'6<0YJ9>;+[A>6R*FM4H
MA^B/N$7!IZQOBNAJGV U)V=_51/D#9K2\Q$1#_U4Q]>NV@HK?''&>^( 6<=$
MX9T8C5D'\_!D0OA3@<C4W3D'^V8X;Y'"EAPQH4?6I3S-<XJZCD4%O<=0^&@^
M])=\Y^"I<9511^,D D)9,P*$6II:P6BJ DYAI-I^2<7:46ERK3DU5Y=)Y["O
MU1!&TA7+#K5U+Q$RXVC/"YV_6  &=O-8UR%Z%5TEG4LET[B68 '@VF),%(4H
MFJKS<NB%L4E(254O3(2PUE^.T61\,8^7NCYT]+),9%'W,*@RL.#[\P3/W/2W
M#SH#3P$@-$,[^S(&W5=&44&8MK\ /?/4ILO[]TI%2-Z@ULNGC[^ ,J_W'X+@
M_5C-U/_5(N2':]XZ6>UW8=(8CG8,\NT-P(9H!B87N@TUIA VC4GF>$XER83C
M;V^ONMLTS@#;1-V#_,V]%Y%)L1^UK!7@"QESE$,!<NV'_Y ?( .2[5GW!.U4
M'J]$)'B0Y==PXB[.U!(S^*4CFQA849SE8J53. IK?]*N.)-*=<SVB%^V@2VE
ML@Y^04_,J&WU(BLX>'Z<XGO#PBM+%R_0&4Z**H'"D0SS0<>Q63(_X;QB"#\4
MN4R0$S;Q=JW\AA&&%F@6]":%9MXWA<R.X;\\NO3M5@U?K7](I=CID34HV[0)
M+[]CX+HB%9$[WSE(MZ0!4@CX!FM((_H/391>0"%9F^RT&MY_&O/4>C;K1"(C
M<04D,$G$A!N],I2KV.($I!DYN?2R/&DS"+M8:D!.D$'T(LH]>8<=DS[YY-FZ
M9%(' I)F#GQ%4U!,JK[2;#]9>L.?>#5\*]5*_M/5T 1+[]B_"@J0SO4ZOR+_
M!V?O%*0+T 4)?HW;MFWW;7]MV\9MV[9MV[9MV[IMV[9U]Y^9G=V-F9B)F'VL
MEWJIC#J5)_-4MBV_?O&[R/U79:S#LE%@]; O_X,FL>3_T>YFY9QFR4:3M/7B
M*%E2U8]6@?P=8@[!!@,*LK.:3Y-ZV.L0Q3"@)K_05$5.F4.I #3*2"I?Y2A^
MW;OQ ;=YY!(4C[-#@\.[*VR/:I.<,[&T4RQP3:#B3=T@4_0"U\474@4E'C1_
MKH.@D8!+]-D(0BPN0S]HQQ-$G9&CR9Q)7>!<O<@-WW&OR,WO#Y)YTH_=8JGM
M&<<MM=WN<=P<99QC].N6I.FXN7M7"V>S_#V.S8;IVAR9-D ,X#[<]#VAFU)*
MC_;4!+$)5H11P^=2B:B+]-(OVQ09T18VPIWM#;N6FT2S12W'4P)_2_W11Y("
ME4+V_Q98MW'P7P+KQJXWPDMF_E-K_SHYM%G8]3IU_A+;[EW7ZHH7)>8*E40;
M/D7!;-/P+T&>PP,"\(5 E,#359( .8"[#C*[Q_L3#!25I\.]V!;!WXK)-\KP
MGO7)#8Q@4&?B[3VA_B+L#X_P"$%]E8B#W@X=![_34>9#+"8-6;_NR&2F_6U(
M^T[[_@'4";!@H]SIS, ^S/ T)?'Z^\][:U=U_FC8R:;2><F:NNMB3<@MO,IU
M8669'$]+_-XR'J,JG%TR0?6E]A_S0*%PD)'2!S"6VLT@$0YZF_:=4QQGY$TT
M]CM"XD$4.0'2PZ'\SB']72KN-#NVUZP/HTW+^Q>@\7B2*&SW3"$YE*I83.'F
M1Z$ZG%;D)FQ0.&B=9!PW/"(/YTR%RU'<7%M-%=G84\@*E5@V4V4JX]C!4Q)E
M*HI^_<FG6Q)DC9C0O]NBC<#8/S. AZDE@QE#5:L>"OAUY5 Z/BFL@^V$30>W
M.??6AWG8C9!V>H^UX=X)/TX8<L'8[NZT!FW#-5VBG;B@HYB?"(;#@I,$08^Y
M&!7HZ?EG>%W5*=S_.618D,[?3B?\O?;CBE#_UI#W4QMSGX([7!EQR(%"^5?^
M4'W +FH,BG=(S23/*_H_@ 0"_I#VA7LNK.JL=>#)85MV)WL8<FW60\R-',I3
MT_[68E*A>D\C6.(&0:FMF*5%;V^;08=%LSTH=' <3$//5@:H#QPY8SA$F,XP
MYRS[FYMPB$*%MA&NQM)0]DMKCJ7^,7N@ P-1/R.L3#H**WZ8>!]:WN@]L/YF
M_R2*%H,ISL52=8JEW\[LP?F36?"J&WG'VGP"D^B1@&TDN^+0HC2.WCNYY0A6
MC>(0F"CI;/6._X2;0I^[.8**Y,HI?9W"I(R30<?*IH158<"ZJ-4.(GG:DGL%
M/24A[44D"?D,($HSX[+Q..KY@S 0]VL9/^EW&FXK<T9"$IDNPDSS0Z[6/X#D
M<B_3I)UZ0"_>)G/0_G0+SF%UQ_V.";/]7^:PEBD\8[_Q:/MEIN\IL$=P0[&W
M A.I<<=,QPC\JM^1RM:!DH6__I!X S=OY#>OY:/C/1YZYW<]WM:M#^L8WE%F
M#'ZU3=ZE1D!03N&5'M.#A)N(.DHGI2IC YE-<BCN^*T&0X%PY(&4.*/,<(89
M$RR_.QB,ZK%%T,#B(21;6I'_YH4MT/G,Q8AS?B"(=WJ\62CM]YJ90;MR#S80
M\.\/-X&O9;./\*2,PY[@+34YQXR4.KJ]J ?+5FKG<H.?=&#HN"'X*I UHH@<
M".Z#7NJ$XZLLQG2_)AHZKQ!-D*8-L#?O*@.<8D0227B.-<7^@X&M0U0N>>(X
MMAB&# 2GR5DE=3&Z)I[EZUK<2(=1*BGDUK*Q-5H$Q?CD8)_,QE&#^?0C167Z
M_-[T8PF;<0J"VYB?"2_1UQP0C-8?G<V+T@>>A7:?)^_9]P+\ *Y&GE$F#)4,
MK7Y=B9*+UH5NX^R0%+41>F1PJ$M"34E"A7WB5FI!]?7!VST%\(J_2YH[I*];
M,O+V?YW?UF!1S]GKF8Z9_M".L5!B<3S"GT!SRF<ZY@H;>PS]Y12C9$INW#[@
M:9]).K$_DQFE)!B39$KD!05YW9,'YQ$X=+ M GJ- #-,@$AIF_:F&PG)LO\
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MJ5,:<08#QDZ'B^"!#<+;%*/)M)]=M'ID_&?\=Z3?KYH$DUT &K"'-@/FX;'
MOE)<=JK7!R1./0A__[=O(RLX[)58 N_H2JL0AVR"":J,T"=6-H^V=!D6"\,Q
M ;<4^8TX0W.I4:3)5#WC#'ZPG&T'7"W8S5:BOE"<I,DK"OBDKC\Q:E)[QL?P
MZ,_8,.?CI@,3-\*#,\:C,MO_/']&#^ (_4%D6KO:__E+,X:>QUXV]1XVNODA
MVZ(J[%>UIS %S<^1B;#]T=;'$ ]I8S?N<MR7HXN=_9LH'B'_\_A);2H3#O6.
M^[RXUK-")5ET440".JN"'PY<A)]'?HG/8(L[+!WAT^?9H-E\;U@9F<*HV:WM
M@O[(AS2QF/,Y-.%D<2K9RHC6'AL(O;HXIXAPN&3D]AE6[GVQYR-5.+/H89>;
M;P<#94*=A$R4E1&.H]<YA90]_-3G$!1=XAHUFI,ZJZ&YAM8 Y<O?0\3$U!X.
M&HP=/:&4$Y) S!Q*O&",_3M/!/23:@04RA-1W _F;55B!//>TFYP3Y+>QW(@
MN:I><-QBO\+08IFPV+4RTJ10>Z?1;OH^-DEI/]K)7@8KLG$!9Q4PD2CI5:EL
M/PD1T*AM*,%UL+&)[BG/^WL5FL<DK/ZP#XNAMML8"]'ZFL#,T0;4W3]*1F62
MDBJOO!S&%!O8H20<+$,K#&>3H_3BPA$GU =;TNY^X'X!LF99FG>BH1%RV#P9
M6\D$3-^:Z=)T M74'$)I1FMW92C]37\06 )#>,)4ZY4]J"EAE4FU-*372\<(
M/\#9N/]:Q!*-QR\V<("/J/0GD8X.2BNZ@/\L?FK6Z$P&GH(QBLP]'Z 7R&YE
M#-*$+(\&!Z9K-L8E&74PZVNX 93.%N5R()/\=N%J57$^<7(\TB?A!H_@-8/>
M6W+W$H'[6S_]72L0D%LD EC0R3F9-TF(>6$,B[\\(BR&O'[<7:\\SG"4^W23
MJ5F\6CR"[".?^//?_<_=8Y2T&&J;IVE6B9IK;%HZ.SLZM41*6AJ%$!K*Z0)L
MOV@LDIWYD9[\$4<V(EEQG!J.]PVV_91[>9C8BYNBL./H.0S65H1CMO2TMP6L
M&YH:46"M;@>SBCM*SH\G&F)2:%T(-=4BP:B:)\6$K4RAZ,\"#:DBAF'[#GB1
MANV_>+E:SCC+Z#13SC.C*<*M@ETWPRM67:(IBH%L8++,DO[.[0@\3"EX&[;3
M$&HM,TBK&S+ !0M3)4"'F_F)N3D*,Q]T/%B]E9]YW&OX'ZX-:]M GHGWQ#9;
MI_ %^93>N_+SWZ6<"'$[O%.YUJ35K1(53LYG1^U:ZEIDZ0A+J@H &A&&4RPY
M(C[!@JHU2_3[XM8<2%.F=70L>0_ZZ3GN 6=O-0)V_.#]I1E?<IWJXD6&\KT]
MA#FNUI[A3FL V<XHFK*N<LIC68Q5],@EMN%-8(KD]0%5V]]2ME#J;E$2N#B+
M%'4KH1*.]+I&-"$Q?5"<Y=XU.*W(LPJ#>FVFZJ\S$\O],CJXDJ>*]F&8DHZH
M+;(I 3HNB+;G6J5>=OS1*'GQ2F[$H-GUX51(U1K9C@BTBL/RAIX*P#*=>2+>
MX!T\*7%#*G7XP:@R<!3G>G-1?=_-S]70<S%K*J$?IJAHJF!$=%M'E<M'7-4%
M0T$$ $.4CE2RXH! ^@?K:YE +A_HJMEOK3DZ&@O6+-,Q1T%L]Z8'4Q)@JVD=
MLZ7MQ'L$RWF;W=IG+(Q+=EFRBDP0L--V_!&FQ[52TU2]B+$FWH?>&UG\O^K*
M]RIRDD.?S-05-T$[,I#>I]ZH.QS?";N_G$UE%)Q$;>ZY<_]^BF9B-"$*%S1F
M?MK>?K >E:>&ARNO&$1%%H%>>OM</*OH:>W(\6^XV3%]28"X"#R8Y7!(-ITE
MOK=X)9BA8T$ '&/R%&=7=?5$=#>WM!E>%4\0&QM[*=F2 QT>N%-$[V-98(&:
M:HY/R>!0% R2N<^OM\99CSGLJW("419UWI*80F81N.YAO)G=^J^<!))C>'Q9
M]W-FBUL_I"313&9N)U0(T",(?VLX?GC1:%_X]NW0=WK.4=$&&)5,N*)RG8!;
MRN5%)]:\WZQ/G5"K?\_98VJ-[2K\F[X'MQ:IC_0P&7>L<D2O]AN_HC!5K\\#
M*I<71IJKP*:J/.5BH+H+DQ:L;U<F-L<WESLWCIM=14[4O\69=K[1;L^\7C%W
M>*I],193:I+R!NTPM+_/3+X(?)G?%OKC$\53?T>;@"[R,L=1I./(8>R,8@AR
MRN.1F0CG">5O?9F"\L8DY51SG^H4_?4C*JM!*T'F^3J+7&2(8#(9K*1SB#&0
MIF]_6V7'1'X9$3FL><:3B\^6K3T@<8 'W,[6X5GUO249$.;_I&=\,X%U_W5<
M\2NT+_X'>/0AP7-)]:T H\J:?D#VRO6!_<(-S:YFT&)H$"$X&/U9L[ZY#@DH
MAZG)#7L06P!9 Q<1D"!'PH>"5'#+^\MG%T$605HOL?#!QA?47BD/-8@QL/^T
M]V+&"&X-13QC3V(K"$&I =#$.D5N4"8/-DCXMK ^SP4C=4@4P'9$RUG1,4&2
M=5U@TFIN8XT9-/$RC0%6UC3+[^0GZ8[YE!9<URJKA*?0I;UE11G2J#K=J3"6
M=AFV:!*FVD@5<Q4%;2\O@&-R#BP33+?0X#6>'%O8=FQC[%W9$%FI#$=S-RF5
MJ1]4+A8SSU^UM-!*#P$FL5XZ4SC((,/P5JL95^A$"A:C#:3,N<O='SG;ZJ\
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M%^EHZ"=E0\[ -E6I_^58PIP I!8 'V%('ZS@(VS.=ZZ0#A ,@@HB!4'( B(
M[NLSID7P_3F/)"$(!H@OA,3/!L\G,IB#F,9Y"Q, V?7QYTL6+?^O]@( A#\
M"" 4 %R!B"CBIA(>(]#^ W!;ZWT'<2+>KOK%S__7Q)O_\]1HNF B)'#VGJ_G
MNEN<DEL^/X:08Z65X[QF]X]RUHG3-P)*"W$BXW4%,:/+KC46-JW-#9Z^\5WC
M.AAL-K%4-C'>";T\-"9PY1A1<4O,XI$U*)S&^F3=5\!Z/'S 6I<3$113W46W
M.EJ-8C1VM"9$9OM#1'..CX&XI'P)>V0Z!*IKKZ@RO>AQ*X98K^WHHK=@0KX'
MCH12-F"(P#A[U"B:79:$$HSLPX*:3D:(!G8[_EB6M1,!<9Z/?>2@:(2R9=;5
M\J 6L<I*TV#WQ?/&*7?W?,)-PBG=P,*]3S(,L534M5,30BWT)<\*5!2O1RM?
MNBE-<B;>7V+$:971ARPW.2SKS R56"X=]Y>V7N6V5[RR@T/<=D([]()#BO&2
M$K'_"/$P(L'(8,]Z>'[@*^3%19W T%ULJ+-)1ON,VR&3AE-#K"E-5E-+?D>[
MZ?YX*6R.ON4*$QUB-1:T=A9'&_(YA*E"L8;<E8?5L'!0V+WV2;U8,=0UDKYD
M"-^;WYG:X0Y,IUV6:6/%>'1IP(2G5X=+A6QL!EZK;I^1L)13RE//WY)26LE9
M" FT%LFPND$"HQ+^"(X?QB')V MJDXF4YG.NJF'.6BM+%KC^!1!KSA@$HW2_
M<---OCAGC6[6]<K<AH=#$L_6EV L%YE9-F9NH2.\8LF9D48H3:TB&PMK:2\K
MI>1R(O\ "2%,T7-J0/XO:@$1UMY/@H+'.G93DA(WSAL+SCKRO?;7+'CO+W^=
MIOVLB2Q_8D]6'Z'_#B'[@&%A'; 72+5_@+*_QW5--]O*&4VHMV.B@*3R.$:U
M0!]7\!<"OYP/OKRV797GH)1WO5."V_H4VO&.OK;F>MRHD6Y@9["W'KQP>(0K
M;WB&C.TFX $^SG?[7"C'6IW.%:\^R=+'2H=(UPFN5\ANEV;;,KG>!F%XJ1Z_
MS,3EX  ,['V#1S:5P4-VTM7#6ICH\+?2.:Y;0U?,>(;.$3VF21_+87@+C9.H
MPR:IP12)5P)B-6C4.#*Q40)+4NV^=%*RS=Q3;^R32;I3Z(@#04LLP@\&03CY
MM-6T2WI:YHR113,V4".W*5-@TK$WRSNK6(=]Y(\K29BHCE"-&.O^6F2LE:8T
M"ZH\S)8<]D%1SJ_J*H4?==FME505GUIA##Z3KZB@PXH')--1(92[C^X@PG4"
MX#\ BB6BF_#FSIJQ'P#30P&QJPP8_Z<9)3),BHSRU]?O@I&_T 4QB ,BO$MK
MTQ*7U*N!FG@?MF4J7/'?)C5N:G=R4K&<XP-V8/\ LH:,<J8</!B1+?BAKN+[
M6V=DD)'-A=4O.+I<H_$KO4F:6(M $F^#] -:Z8;A#)?E? ;;+5T=G%-%JN;C
MCOL9^[F,^7F0Z,EI(\1!2FR]/_)?"YD=MI1CVZ.Y8X86[#465NH7<DY8*XD@
M=,4K6QN(5JS]$%-M^SIX>-!QMCA5,^S-:3 #<0YTX* 7M>5G3<W^\!-9E<V-
ML0JB(F->8^Z/)/F"@'M]YJFUI )__@4,SI'.JX+Z*\*[:;Y D(WZCUQ,U5+:
ME4+C_@H9GMTT-8*K0D!'4CF$VKCJ@;/>1I%4L>UJ*MMBA0=\KL+F.$NY3MQH
M0$A9W5U4'/,H&Y<Q0.E"%,[)VQ#,.^KZ#2!].,(8^UGEF?O\0;/X1FN9AH->
M80A 34F!U19D<DU+%?=PIX"SKHL%7NC#+-$HD,7CG03"P0YMRO/'6^NINI!@
MQZ',#D<,/L"QB31,U*E8)+3]/E*V,E2TNA=T?"5D*07I78Y0AHPP#E/T/3HV
M=Q(69*<W8&1E!]SN-Y1I(=@20%)/;_MM$R%*DNN P9"^O/\#U.+\!'P'UN,+
M<+W+3,LD/2_VB2;2@!2\^4XEER+#A\;TS3]]^/O]^4[XDO=0D7".R'([:Y]5
MN"))_=EI@/?NZPVMVK3.>T1LO2MF"M,2R\SUN4P7-CCN:_*L;&1/&_Z>2P2B
MGL(&CP!NJ'W\>7U]#?ET]?CY^6N?.^%QS-2^M/E$Q35/-DBG\;LYZ3T[*Z5(
M#F6D%P"ZNV9^Z9>G#=^]*<*69EP>;UH2!#!@CIL^W[N9Z_;Q-#I0=GI^9P](
M5V!;?KU5-D(3Y/7P+01/N8?L(=)KA-O'?+@QF.%!61IU&-9MG:TOD6PA7>T-
ML(TQ%QAF!/'J$^%O)5390,AY 1$OW$<1<_>18ZL9*JN(H-R,=DI!3%P+5!(5
M92SMXVIW>G,2QR6,E>-A)*)IV #P5LQN!^5B+F'3]U>&UY=;538)[&JW'5YT
M>3)8CY0)I?\Q2#B\N_Z'?R3NU";J'Z#>C$"O+?4L4N?_J-#]]P5&*!(55-S4
MRW>?CH!Y%NSW#PPT0+Y#C[\[X2G&(71U@7S,/6<I1D,+ LM\)N&]NJ!P60..
M!C;A%)YID:4'3\/&-O*B6S62D")F<D=*="$TT<XZ?8M(E3RW8N?.-\[0@0/F
M)!T,5:,:F$G3F92/\:)]RM,2Z\X TB&0!G@%HB;%'&2;YN#)$AW(4J2QWHS3
M0(<)@M%*9W)C3D,'[D$C7;9DZW"<GJ-.;9F/SE&,KWB%'EJGN24W@4]NS&!Z
M.Z '4T+'M[(?GIIM!I:.?KPFGL8AH\-CQFTQ.%S<NX3J6 ="QV/6;S%(=-*)
M55TVO F&(Q@Y95-7*2P@AD7:7M)"S&-GXR^/J<%F.G+II2F^R7&] &75@,W=
M+_WPK6J<TTY@4=$ $- ]CB3R#A?CF'J1S*RU(CJ;J^CKUN+F>ANK9KJ0D)1,
M(E"5K$T%HL($*1QJ99D0:K]Y^F I6]0(!QRLMB6LC]GR5XZ.]Q&A5US8WBP<
M0W# IJA_8*<, DPH0I:&7+J5YIJ51MYOF0&(HD+)1)&>X0Q[<C4B<$*BG\YR
MULRH]_:OF:[N0Q<-(LM PW^ FOSK$T+YEY?/%J73EE(\H_&\>&7LFNJ'YW6[
MROG_?KPUS9LT @TS 7@GC:-8V^G_ )B*Y\MLC=OI4,KNLGOU(#D(1#;.1,*Q
M_> 2N"!5;]ZDEWVT(/048TV82XG:  !V\ZP_"D8?^@AC.QNFJI< J YG5/@F
MJ9;L\<8 "<115/D,R_'&R[0MPET[[*0U1@7>4+RC1 5X*%I^/!:B\:I]^-&?
M>H7 7^)K\?LDD5@@Y-$.2+5E8/-FAI:M*9J'-4YX]\)P\YKYYN9N]]JGD<Z4
M+,+PABLJE+1ZS!V__63KURQ-6[CD+H0;?8V03A6,HK)/8@M*@_+T?J,J5R#X
ML 7J]A-/[@@SY7H>X:<,E9$<S3)^V;BGPZ=2AVMY%9X2V5VHC,H9WH1'5T1T
M'K.D1XY='^72'''Y4HVA2=")O:*,WN7"Z$@',[5<MO1T&^U<%":%$X\4S "W
MODIASUNJ2:D]RIU:-/:]N2/O/\R^U']QR3O#T?$T;YPTPC._[EF&X1CL<=->
MJ'CII8=&H-(1O>EA&X[>"^,,JA>:<8*G6;5L(DM_[J$\@V1GWWAN8S*UK%"H
MJH+#U^[ADR,HE6&,&&VS.ORZSHH?90JDP+F0-3*>#6[.(>O74<,LZF8/!;*$
M&&B)2;=XS8AC"O*/UFD6#0F0X! :?!5TKB*?:>O^-D-?T\C$67%NQVW3*AV=
MH@7;V0ZW&G9@]E+;%[;NY.Q<HG]=4D"^: D?73Z@(W[.^_/N9;(,Q>( SB8W
M:BL:$,/,Z,V/."2S6#CY!SS3VNK7^TLT6'F4?$3F7#!1O+"/ .F6,W&/3]:N
MY4CI;+4 OYS/L;5TT-%U6<EGZMZ:E=FNCZ\YI!]#6IHG4.7'S!OWZ=5$T@O1
M_MBE?IS$=XP(]^^T^.GI8]7 #2@+/NF(8.E0^5M>9Y/C%F%4F:'1U#XR-LR@
MWB']?.EFU,-M/1J>'&B%0#[./#I#7FZ+1O78LDE0WN3M]!SD4\L,F2[[&IW5
MFRI7H+2FK;Q)C-5$5**6@DQ.-O/,B6HW S;V>G2ZT710JL-ML,[F.I,LWN[A
M\1I4^">$NX>S,[C;>W&+?#T HA5$ _X NS%SZ5P55*0=R'7B#,\(A,#>K6 )
M_X$["7-!KU*D>,<Y29VVY>H_.$?>\ !LJ?NWQZ <HVF)&N4:9<<&.)-$?S#Y
M(+EQ^)4SQ)NH&3V\1P/A&Y#A_2UKNY '+UJ*'I[+,SI,%!X=?\T(G (X60O=
MNFEP@P]4LN5UY.HH.M.MW:+CC)SPN>5(?5SF'%^T8D 2L_:@ ^@601"MC-C?
M<L5L&>WZI"TG14H""2U((OWMM)"1<;CA@RNU+]P['8F.*VD6<?\!=CA'1O4G
M,%$HR&A&O'6(5CJ#\H,HTE0. 'UG@#9EZV%-_?20VU;'.LAM[>*-6V8IO#/]
M-?8CL0X$KCY&<TC]X.M(UM6^GW)P2#VHV,^-NODK%XJTUCP-"7;&*MFG2DC$
M5\W)OTY=C8%N3.ZU81+VZ+':QW'TDQ8]+>J"\=RB2^HK\:X.H/+Q?71VLO*N
M(7T63HT.S=I\L%FP@7H:Z>"^4L4DZ?ZO.\$ X=X?E_*JD!K)D5H$JQ!_+U)A
M=^PZJ[4WW4L[:52Q*N',DW9X:6@F+LDHI_9FO<27LSIR9)&M@NE>+D-*%+'C
M#"DN28L7C#N)R5C4K3!'<O@ I:"!JZ/$%O9Z4-SU/64[(9M;+5O" 2;UP16#
MLS10_;2>Y@WN1Q5?-]BM4"3N8PNF;"O$T#3>_5(R ->@S "XLH5Y.^57O^']
M[#)J(E[J1$1(+^(A:K).C?$TQCI8,@K1F&S(O$B6/+988O)1FV\AE*^<1#25
MB%=@(/&RQEHL<O!@P.H]##H-1J)&\%2X.?&FBE$CFQT<<9CWL(;1W$%[M'!.
M$KQBS328CJ:%!.F'CIRN8.P< P!)6$5N&(_UV J13+T,M>LLTW9F,:L[@?=H
MRU1HSP/B3VAW:TX!'T<LBYOF6;6U8E:IEZJW$$AA:X*0V&W!R>NQAF?$$X]>
ML3<F:G!%:/\^H3 "X_30_ITM620Z[@KG6YH*O(-7)<=B_$5H?N6JB@-%J>O#
M%V&1MAELE(VW*95:S6IGC;6T(T)K5F?^!DFZ^^^+C0U_I*W8LM0L$>5))XL%
MH@PIBE5) 7"!@EW-=S? -_K),XX.&1:WN0OO70]Y_:B_:VO6.[U4S?_@F!!%
M]C#X\HLBG-W$_ ?0G^7ILZ/[_T6TVV4J8&3#[$%6NOR_PLY(<)#_L]MR9HN6
M8,&89,PSGT@%J Q]SO)W3DMEFMMDD8UQ(&5[1[N& 37=9+H+=#2)#@#2!U'1
M*S02K-%_52KO%&>E)62V7%A]=()\>]@DD,2;P<!%.!?+UA \T?4IHSN.@?R1
M>*9.8D7V>%24 >H;WS4VD38#?C.*YY9FK':P/W9F!-7+:"OL$=HG#*P%#)I<
M@TI$.2%>)AM9%$X)KFR-BVD^F@%BJ"_V?F.Z\(L1O?Y)=^&D96"HLO)UH?KE
M.>#]%XV/=EAW(HW*./6=MG(400+KF@QJA%5A5C8THI,6O!. KGAO< Y'T %?
M2X (B-%%WAN[*];+N@_4_XL0L2;W.!Q1@6M1*M;32)0Y'8J2(='-76=F$$=1
M$"G\Y/X'A11SQ3;(#'SQ\,-@X4I>N@J/@.:-ASNJ0AD;1\?UI;(S!HY[/+1E
MQBHBPCDMI/OL%.(?0&BN Z)$0#H:+-792M)'F$2F<Z]]B(3LF'YC=F&"46QA
M'=8XJ)TB4$0B:^=U0<@?ZO:$=4+RI),(L+#S?=$%_"^96'19C&&.5O\ &X@W
MW[TN (AIC\\;E:F^L@.,_W!9E'\ ^>\4P7*(L;6<LEV?%.D"2TID9/YAA0N"
M&A!G_-?CTP_NN,W.>&T74[VW #X<\9RVF_3(P&>9377S^V^R+SOW=65FCV13
M)B/[2]+X5B:V#?^8J:"6<?6U0H'KIMIV=-#0%UPF?W$]IEL-E;,_[JG*";,:
M5G+%#Y^6:NB^I(-W17QL7181$7[J<Q)S(H!#0X-&J5C1HT/CUG.**U;H--.I
M)-1R74V;*,3 C8K".*5'ZD)7,NU"W-7.E\8@M((E8\\PU28[2!<(G/1J8<8:
M[-@_ :HOSMIL!?'&*&!1H=>!T$=WWSQ[6]Z</=C]*X=](W VKMS8(8/C5^WL
MN%&#"D,\3(/"%9 -PUB^5:6,MF+R,2ZWJ<HFPS)A'!E4O>06I)<?(LA4V)@R
M2?1H:EI"NI/B) ZLX]Q?'?XBS1RYA!)!<AG#6(&6IJ5;322C60,DAMK3\U71
M&1UZ1=\,!W*E^R,Y\QL0AJF0L$-O.6Z)W/2NI#B3U2#Y8IH<[LY9;.1*=LC=
M@H&[&YO[=RF.I@[N+;BM6F!;7O/QMDF@.<P\?-.$JUU UJ#A<U$-^(65E9++
M"Q(*A1RP%'ED/6S)9TM1. Y.:/Q4_(+\P(O\1.&-TV/4M#93J'\ !/T/+FUW
M4X)2FIX_:;S+E2H^9IQ_R6]8F= K78Q!#S.BR;I-R"!.V;DP0[1U<JX:36U[
M6K.-<151F)HU<Z3=*7C7PUU@X2R1B%-<%1#(>$K>*B>6A,W=QS?1QK,0D6.!
MFHQOZC;$CO=N/!F8TP,6*(Y3THXM)357-;.0P4H'(.VQ%*.92]MKH-J3)J&"
MH#EBB9H&,T[INF-#.9N1D>IJ.7:)_Y]KY$"^RI!"NLBG;07BX>'ZX9N0?U5)
M  ?[(42"GJN5_P#RC%4XPE_\P4>P=Q<)$!X.:5>7^_,/L*Q&HU(^!%^2]\/6
MNG6#[J%^-GWV0,'+JE(T4B4=$OFRX 7+FCG<UZG0(\E*!YY/NKRD0.0?&N9%
M4!,Z#,YS48W $,55Q94-+\.]Y1C&@BE60;3C&!HH=F0KSEC?D%PO7_IR<-%8
M0EQK*6^^P(H)<4^4TY4*=&03?O)L[.Y@'O@VU4JJF32B1C_0R5X1Y1![U-H^
MX*A19@1F0^H[26.V2D@9((. 0GQ#@H2=+VM3N_P6Y:$'9QHLT265#V9+UR=E
M]#O5M$3:\[O%$:Q'Q-"FYP9Y\[Y2<"6%L30<VM!XY_JRS4"GQ]'D\%%KYC!G
M1F:QE^O!@G7CVRFF:[O#Z,!@&CG1_C7X-SE)0OO"SGV+' QKNN&-A:=ROWH/
M9(MLW6KDCS%2&SRNAOOD-D*)9$WE%ALMFC;7WR<= E*Q'!:P/P<.OR_MB#JS
MM,#_ 1+G0-3NWG0S^(IB*)<*Q*GA.3:RF9MR-TU"YXL/!D60\&0$R8_\$:7^
MC-PH2A,0V#UF]UJ-2[AL[&%@7>"GUMPYF]>(4<6%7B-$LXPD).*%4EDW:G2>
M7W&)E#)"+>V]I8FJ#VY1F\$,FWCYL8</&#'%8>=#* ,OVUG''%^6+2R^N09;
M,4NNRO%U:L>4D&1IU*,A\$OWIF8T!4?JH3@=N777_%7O1A*MH<=:AYK6' 85
MQ]3F9')[#^TB/=?LE@",(+D46&^-A1UY!TR!!^+VHG!$H+R3$ AZ6--B]$5;
M#LGW_AE-_C<(-A0MS166@I.7V<.),O2E,9KN]EM/^&(G+,  O.QW>G>,!H,H
MJ' :E6$6-<K<L_BM(,3$W^1K&\#QK%H\*:ZUN":)@EK8NO<)@)_"V85]6',:
MCGRB9"KKK+&M=/HC_GL66TY-DQE:\1[ "PJ9>+CE$0>@#M)'.9:3)EO&;3CF
MX5B/BUWL>F*8LAB34/0R"UUYHO42&\35FD%72NXD4';!16)8*70UJ'C.&&LC
M!QM1)-@R0T3=46//N7:@?@?EJ]8S"P^8BK@&NF8#+$AQ$4?MERM[PRL8K**,
M2/<X8XGJDV1 #XQ;R6M;M<>T5D!! <3'#_\ 79]5&LE@)4]//U-6Z=JSF6LW
M+?_;F;VBUU"'?P"W\T)JI__3=CLYLF+CA+4N*K9'ZN1.%JG#*"RZ3IYN+OWX
MSM;<3@) I=.A7>&81!*I"X0Y%+"KO]ZRK(:+X!YUOE \I'CKJ\;(T=RQ,9#&
M" "0I2$!P*>E6L+KEH =LU/)T&0_J4F@_2BFD@!;Z/A>=0_.:>_O<\DI>FW)
M?=&F8C^PC6UTGH3X+65W(V!!_2A \4#A+I&HVHV@KI :,P:S5)'Q+L1!)E K
M?-ILY8T!;-#9#?$GZ4!>WX<B0 ;Q@(.CO:/Y3'@J1[,\_@!@A+68,6-DN>26
M>_@V8BU'ME\?[4#O0(9E[L]:_LK8S-H$G[M.2:O_[#SJ_"8X(,,]*..N/HRS
M5>=$.66\-(Z-/3L,2Y+>D58<27GP%IE2RA=8RD0Z?S0K8I.(4JHRW:"B*@=6
MW$,_ZMR'_'[!8(/'HJTA%$4=>-+B#\0)K>&R]1%8P;LA4DJ$!=ALK]GWQLWM
MPSN4;MTX"7I-;7L/:F-QK0;.Z<=O_8?0D<SSA TI1*8-[WQP]8*\>8H <:[[
MXOTD5G_KR6-,)E>H3KX<3SMR')'-QL(C9-?:Q-2U:Y43M34=DQS9;76YI);_
M-[>CUBDLQ#!Z9T^G*!D2&,R8PB@Q%/@-KQEH.$1O3M>EUD[E,9=M^=Y*!,7@
MH1XSL7I=9)%@;(7BM14NLXP_CSXA[.Z(V)B<AM% ETXAI.$_0&K>];0(/>Y]
ME<?NYC4:EZ&^[(9^H>L<A#*:L+C8CU)@/A<BU 82_48<1)4"I$J%7!+B(T^S
M*1-COV5]$DX81+LUS(D#+]V@<OD%D%IM1,WNHDPPA08B49^KQE2A0C8FZ6,H
M=S1APQX\94YN-:5I@(:>'=F;%J]30L:X>M$Z[T@H'+<W6T Q@)&&[ ; ]J@R
MTX/6SX6RM)%-$H!HA*_3K\?DI4'V#R \G$C7E+4[N8F]$*U/BKZT9YXHIH:#
M7B4"$,Z3W-:PBB##X(Q#HB/!OVR^=\-BY] :)W_YFZ&D&2!78)Q!-^\A>AW0
MLD(P;DD]'\.(J/8I>ACSK06:7HI$M1S9;=GDQ!J2K D($"UK9B%8XHQU>6J5
M\S Q82_,IFD:L;;AGU:;9/G17ZZQ(6X.418Y3L+.M):P*JYZZVF$T01!1:+K
M:8\(W"V6 *O]!QB"2A[8*N0SJO&P;&FF46$@3]P\I@_M?&G&M_:-*AE6'5*S
MVM9,.\$'!.66_.Y2!P+Q >$12" T-#W&[Z["GMU!]Q\'*Y,CK6=T%!D>HW-U
M"N7OXP[,,XSW'/2H%JTS*P5T_P![S?J\Z@RWZ.HG36P+I2"#:1H1WBKE8.7-
MQZP2S*<$536F$FS3#_J03-4V C@>T[+:1B-2VK18.ZC*K)=+ VT13-4LILHU
MB@6WY/-?2A<V1MI#DM?3]YX-_Z$W!RME2!:ZSR/'UX[:DQ0,09<+'2P! "@$
M!KE2@I8EE&1G?.A2(>< 92K_YX.#AA0FDQA&K'XPK#5X))(]UD:!^C7H20C#
MUFQ^L)\H _3<C[\4EBI5R9U%6R:SO!I. F03H @9,2D+?534YND8M_T,"C_*
M_>A</PST<<QGKK@/M[W?50C]0\'OPVZ?/^NUI5<2D?13M?W3@K'SM@=^C<\7
MZ/_O+S>8@9^D^M&LV_R2.QJ'-1@@R\X7/R<[2^MF]?AOLYB6Q8'X@O5?E2%,
M+?D(3XJWJX?F/\="4;V^!F7<EZDROR?B._X#*CM7MC^I;\P4S:F\Q@61.) R
ML1_FH_1ME*?FB*SW @("$V==! DY\&-[&QMKH_/]B]Y(5[+>W#1<FO@@04@R
M$=&UD^<D6EQ.>@?3"+^?U96^1 6@Z$KDD=0!9,@,^? #/UKRCV*]ZCJ/?QEP
M:QJBD.X]6>PSPD:2.!"<)U^&M@"BH3SNN:RFC&GM?D/4%0 !SW!0!9#4KL"]
M(<\5M=%N8.Q4I6+A*:@14^)Y:_7L>,\)>F?T0?N@9V7R777J^G2)4I&FC;[A
MW&\\K#NW&/?U=M+HHRB44[X9QS *!E&1F]$Q&JGH4+[67ADNJ9K8WT%:PO<3
M(F#E,%;A(Q/#7<@*< 95>8=\G+)!B('[Z?3($LU,SU0L8<O#2T:FN%IH5^QZ
MVH%^JG)S*V*1?7=]@/*?QE*25J;]]XK6&ET2'&A,)XL?DR7J(%"+^O!F%+3I
MB %B]_/<#6Y ^)A!M5K(=A><3D%#3..B/N% :RM%2@?X!E6<)- !_LH9%&^6
MOI4=RW/LT)+UU&W1QM8).TC@'R XCJZMV;Z9\=J*RD =UX#.3VW3HH(LGK^\
M<CI49H^ &,SS\8)@E\Z;^)O/;UZ]QY2@)?/KE63_.KQUSVU7-'FG';:ME[SU
M:=6D(HGH'P T=QC2+Y?X\?$M&.QG_K:.*R!H2)(\X1\ 7?AN!I?*16IT3^\'
ML7$)25;_]O01'NKU^G%W7/S9=:?RF^M]..B NTPCH,[]06U;Q/SZY<6[FZZP
MI?&*-N(TT&B&B/$<IA#DLV*':]OY0!'D>N& '#WJ";0T'P#Q,U\]/UPUAT+3
M#0U*<'7E;PVFNRH>3M0?4Q-Y@RU6$H5U;40KK<>=J*68/YUW#'I!,_SVG8BS
M,*9^\Y3^L(MYZ!V(ZMHA;'-9N/@:R,S-R\O(@A]@_H#\4I82G4])DUA&PU0K
M\@HIM%6FHUMSPQ*Y4'FQO#'98^/)*[WVREYA)6W14C>U'-91+VA2LO S)2O4
MC,<>O%1,/>]5@:-2R7E5OM*N2D_O0>> C@<V,M6?'@KL6!?0^ 6/E \@T$0L
M\[&Z_O#9%:Q5O(F(D<QUH!S:J:H!@! <VU4FE_QOO@Q0CB1) _Z?"1_:^&94
MWB:[>2/UCR!77 #"IN.797"(0('>(+T=CWR0ER7"LC)R2^87XS%U(?#OQ,;B
MB%9JA)AUG._Y]8V]EPDRH=(VT41?+"IZ>EJ\4EF(8A#I$%5^*8N\ADOVT#T'
M;ZDBJKE2';6"T%9U(MO3-,Z"F';LF"9A3>EP=?4;4O%0IF?+=HC%G:,DQU\L
M*>LY)")(PEY* -KC48=$3N[SENG+@RM>V]>(MP!HE_KVA!Y.-%@3>TCE8>[N
MQ3[AI:M!,AYYG' DD@N CC:(<*FFO':9__XVR% ;<GCMEAA?"3N,M14-6]&C
MZ[94A%-EO9(!'4/E"1 YN2,_4V4,DM53X:OZ5S*N J;DK_QI,[=WLB3O:+)C
M!#H+(NP/WD-$#"9"1*:06.;A:A 3X[0PS_^0)G>H*HH,/G\0#.\T7J1<ELV%
M U ('0=&3 &AY'P V)$/[3D;?Y0AO%GT\J\*II*8,M%X\FJK<_^#LU_#T2>#
M_8 N6^3!L[M.DJS?L')FR&X="W"Y#7<B":!N1#LJM3M#?L3PW[0H^MKG%5J\
MX@Z:(%%'8-^[J]^J(/WI3ZM7O#?Y *"NA.<@7SDXNY"7@NJ;A&U=-%\7D[/>
ML_CI\[(:[&YZZJY5''Z-$TU20KWP1SP]M3$KRY5?1)7=8TB#ZJKPV'/<U@26
M%!1#(]T2.2/4-3.:#"[")X>_U90?M0W[TB0N>$1"L40WBD 0@6[E8A53(MY.
M2>%@<V;&#>(9('7#IN>=%H3\*)<N4C>5^Y9\*=,V(V85.HBY8[J$D!%\U<)0
MU!&()L-]KX?>*E/(RVM(I  ?0Q"W8K4EBU";_JU:N0),7^ONZ,@];0X/7!GJ
M*]>.0: MY8%OCU1GBK6!,]$7A4/_S<> KU8SJV"IE&\Q7RZ8=_"L#\(I@&(Q
M%9%&7G9";#A7BD='T %@VFE$G^D>M-I/[S%1($9^+!U>H@!\K7H$AB%S"JP<
MHZ+1$K?[HDN.I# AC*A@^]NP\4:#FX,%?3K*S+#S# ]!8XX-JYS;$K?@"T.*
M!^Q/&)3$UD0,'%XL6;"L* ^V] 0"PMA:UEZ%PR>-,MHBD:.>D^PGF3WX='O!
M$H]L*-KT)5(J\T$)6)RIDVV,)"M!ZA$)5LX50<#<>UYHM@QF+4QP5,[9 *DM
MM1Y3I68X-AEKJ1VKS,:398CS>'RNRZ.KPX87H(]?EBU:LB7#*-B2[6F1A@)7
M+3/& .9^@"1&*)OY<2"=]8RK;"I;,5)KBYU(JYKK,>@[,K@_*I&UB'AQ)L$!
M<>US>87J,X(9BN2JW(^ $YN.&"ZD6! 8UFA+OC\8"/CUAQ,VI:/+0X "&71R
MH2%$T#?]";[5[6?;1C5;>96]*7>?P78=JSNC<D;KCRX@5RH^[2^)/1OW.[#C
M8"0@HIGK5@<OE1GC' E2B()=(G9,#PH %=O=4E!=R4&3'F9<O#4;/2P!4KA*
M3P_FL,L&2(GZ@R\597(S">(/Y4"V*P"NIYA_EX*Y9#&>G<I?+5FMTQ"*JB"C
MI5ZQC,L3EKBY0@V ,.1/T(7%5V0-&XG)-RX9NTN%K8HB!B77XE(MW\-Q]/\X
M_</!3<>2G-M/1X%'W)/(@CU[ DLGJLW=/OYKY&H(RW\!YZ)#S_J[5,  9(A%
M1KV9X\0A17'M$DTV="0F<:"G)J1S+;5FYKHUP,# Q%3)']2"*'4\0Z#@2(#*
M(RYW&F=R64?G^";QT T3N?8.8 YPC,O<,C!G#UM$2\<9529BJD%-AI<D_TOO
M?"&9:&L\P:JCKF$A(L\5*-"A:(:@7^,/3DCT,/?U#R">MZU P#?/_@S*JV)L
MQQ#Q63/ZGU>DE1\1P29AF0-,HKY<K\.]TGI ELZW5U=:GH.EZ@N-UK/WZT&X
MN:]1/I/WYPO"]B7^\GW,/P!-= S()358>1:'^R7$]@6^4%#MSQS.3\,YPLTO
M!9:OII@&+<!XH\H#,:CA#>@Y2WS+*.[LKUT-;[<49'D3T-C^HN6"M3!]G-G^
M/8>UD]!]\^4QWL4?'9)U%!$3P#&W(%%6BFDK*:*0I)>&!?%(_X7(  *1^E:
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MG)Q&;(&O7X"ZH_^0OA7@Q85%MFJRA0I!TD&GDQL9SL,7O@JGAZ3#*Z'.6;O
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MT=2:"9MX@WL.+\7'=RX[M)9:>J=P-S[-RN2%3+X+[F9I#I=D$^>/N%<&0_K
MT5W[@7&0F@<Y#/CZM G\9Q2B)01P-/+P!N SNH#<4XMAD-6)6//4R]I"+^M&
MB0*;TV;^19QMV6CK[I74HM[>70AX, \C6R7J]Y[$=$W>GB GEJVD-NHS_/CW
M(BVZ2+\6;P3[#@4,.]$#UIHR8G-J@&MC>5P!LXJG?DPX?$EJJI1,0/1E?:26
MH!M<T=P?FB%';3^$/'YX+(U%"KLFHMC1FS\ 17#+#\!9J$>D.*GQ/P :IOZ
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M\4]K">"O:(1.5?U<4[5<M>N@K10!+3W2Z%Y**U\#U8??VR[YM,>;*=5$(Y,
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M> YX= [+*8 EOKVBE!3)QQ176@?VTYT -/CK!G3U+5!*?#YF12(KB9$/]N#
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M2" @2)M;/ES((OS%P4HW<W+V'VA4>\T;PHCHYHO/=_"LT:7R#7)"L?'-BE*
M8HY?C;DV!U<@UZ<_1JP\PH,0X#)[!X^V^/\OPKXZJ._FN_J#N[L[! CN[A9<
M@[N[0] OP=W=W=TMN!/<W=TA!.=]VFEGVD[?_O;_E=G9N;+GGGNN[^-26[H_
M5+<$(4[1O!'OKBG,TJN6\'#"1XB6VYT=W8+*GLDTZ,QQ"W3HK+KP8-^*IJ:#
M,.!+Z415 F0+K00NKSX>I0,<2(@^>!7&51(81K7(O+:=HQ1@[)T_ ?21N'U^
M;ABGR\O3U53Q7-)/H$^8:_,^UTMQ^B)[OM:'Y,M3=> (MTN\_/5@*I5I_T.:
M"%[1Z<KO;LD9V.0$@:MY /;9HYZX%^QX@Y84#>85"Q+FC$:4=<W81/J)X!KH
M;T>+<HK=M?)D^:+KS*L'P-1G$&1."@1Q+<1+F_B\IDGY/I+S5?"63*Y/@E,8
MP:3Z]ZG0JEK%S0K<^5*FS5A6J*.3PU$J*1:SBXB5$9/&AI"@_[0+CZ*^/YL5
M]WY\/BOW+!N6),[Q2#0_MOD!X3$Z/[Y.'] ?3\.N@L03)7>F,+26GIE0GSBQ
M+2-)O=__/1[7=XZ'B3%+='[3/1'>?;;R+FXG338;1UQ)^!MY>E\\126E;IX#
M_'R^:%7NCUF_@*53L35/D#UZH$X:JH[RE%,@DAW= ZSE,@\S+.H<92WM:>Q>
M#,3/B#;&F(9<C'T[EXP7I+(S]G+LE8A%%ER+62Q<F6EQ@9A(?Z3?E\*(>@._
MY%RV#"Q2V\/IO$),"@C_5L4AH,IWO+6$HG+)LJ'B40SB)UTY^?K1-0K3Z>/!
M*]]0'I]4N@8BS79P,&<))NH^XOP$&Y]5@D7VWI0_O&)>M70*B6K/P%^JY=DA
MPMK/#:LMC3W5HPC-5]Z9+=)3*-R67G "#^M7RSMSG3"M_T/#4K8<H)3P)^>K
M4/#M%%:XCNAME5G!UP%343@[[:I8>QR+M]!POSU_S#.>#EUX"=YI''C=K^7C
M-+RE7RSY1Z),;&XK8BO#7'FN)FT1\%WDF)%K\&%.$\['J 9K_Z-VP;'IIHLW
MTTK91)8L8'<:+:FC,5NE<EM]T'WBKI-L''\)P#JO4C:$H?I?RA?^IV"-_W\(
MU@BU>I&GJOW+QK!1?NA#'F0)'5P-#2N8$YOM/%LT1F;F<3;FRB9)&.#7;0%!
MG!3K9:[:M:%&%4Y<'$V:9[&4O=BH\] R7P&%(\CXC;KZIW%=WOAR]=\FT%?4
M!Q=+(=WSY2'A  9JO8Q MJF^T1U:+JZAN)9A?185OACEE#.QT4A-P^CY7+I<
M C0LG:.MTS6[T-JT82+BN"BZ#'-!!+D2I IO9!;6%9[L&T\HTY#LF3$K1].)
MVED%>UW[(*$LG85EW!)_W6$)*3M_VS3I2^X>?KOEH]7L-%-%GW(-,@!;L+-T
MSHA7],M;(K]E*,3TP?*.@/N^AAYT5Z,62A:Y81C#T[\F!18.R3GWPD:2.6*2
MV.+.K;60'"GW"6SA'%&)&,O^QHBD?K[NH*5W=.Z?7IX[_4!  &4)8E<2+T&[
MN=$+%F9<%!">)5OFU->)]PCI*.%%#>/0*^9QK[6-\*&%F:QF3T^.JUG5[_,X
M6=KQB\FSD?T>70KAF$<?I3E-A3&4,QDA-!R*9!$W^T6!9=),!F=G'B#_P]>=
MMGBO@Y\[5J56\3LTK;SKO7/^E3K+-W C6GB5'S#$P_MMF];-9QH?%)L"*8VD
MP'JE2=Y<5C6SKIY *0XNQ6*;) 92WXEJH7Q _L_#H:%!5$K^GSNWSO.V1;@@
MA)(7V#AOE(GKC[/^T2T#H9[.'\<6#D(!KPP?_LNJAGR_CJ]*!EV@Z-2*T7XP
M7J4@NB.T\^JOM:YHQVFT=W6U4Q57MR,<N50X@2<5D!- $(A2_,%O5\BLX*,'
M8^0$X)9W^.W Y7KIB1N'J(]= H71[<5\ . MZKPA8IHPO]%)\IV0!Z][-,B&
M-F*?PZG[JRPFFR>@=$OHC+$G2'#Z31E,:>951AF4B_Z+Y!CY&J5/]VZKNR]]
M#/-T+F/Q3%.O:46VH55UE=*?V;)C;H][I90\T>40Z)X6T*-S\?258@=DH K9
M,D9P$2E7>BO'2GR.Q)(/;#"E[:AF54@6#WA8EX:VB(:&(4'2B94^_+P+8[HQ
M_J=8HP6FR1*WO,6\9EKBBV1QQ,,A\+&[KZ=[W,W8;H=1@ZK]2RXPZ&9<CZ>+
MY9+9M@X'6?@&Z4&\+=\!/<E">;*1/1:FTTLNU=WFK$D^7=J%6CF>%2F!W)I,
M/8T<I)4PQQ+MQP&Q ![]$?@0J]O*$-S8V(H<8^#'DFI[$T-BB5PB9VO12SRB
M2KQD6:&.EO0(O"$&YEZ6%Y.-E;W:]%Q]#;)*&7\/X6D-13$6$B_3F>/"77,2
M;?N!&? )Y.IWXRM6[:/+!A* R\+AI<KW>M&*%28U?G>JUNH;6B3N'4'78S@K
M5ZE6KP*K(TAJ2^"C9,<NKS$B!>$,S?HOW@R*7:S$^@LQQ*YNM?,F&:B)N(>\
MQU>7.CUVG*TK1T?^V/9GROF0K?:V59^E\V,NTA]&HJ8YNSX^PM]VR,V=.)1<
M+@RT/$=$]BUT=KL(/?>[TJ97/Q5"A5;%230Z+,>F^*N?K;NH!PX0!E']UZ\"
MB;PPF#20[WX%>4M#U$ 4F0T\:_B&4<9^:7/V? /X;G?,XUI<S@D ";-W\_>.
MR#Y7X1/PJQ L_!$KSU_=D1\:ASVUN8,[3W^ 7J9TPT108!Y5E_4)H"A+G'EV
M*9.B@R[$B]4*MT7F\V%Z_'[U)[==;:3XSU77\QO%7$09_$X4Y%<TE> ,[*DO
M'(RL"_F[4L@B& 190D*!D#KH?6Q$3.VJ/&V &YL=&R5%U5]"EOLK22/C6.;]
MYKI1%WHVEY #UF,KVC1Y(4M09Z-QNC6EO[1S9M!K<+H'"M_S+D'F)H%SX3VU
MTFA$EW/1$?F;"(&I0C8YC$NZ;H<\(8Q1'JJV4N?SW^[8?B6 >/?7FH_@A_FX
MZ;OW7Q;#'U+^$9T?([9L/S(4MHT9ONE$=_P.L Q;R?H)0'_)HSQA@800A2:]
MEN R@3Y#%U3>/NNB]O&&B-U*_QV!A6[FP@V+UU? .;/^(Q\)Y2I21WSQNGY[
M)!^Y'QQ3-N;V-KVE=&LCV42"/ICQ]#G6B*2+H[8V]94N_B7+AR?6RUG"NB'E
M>\"N9670/.G8FC'+TN"0[/)W[VDP4E2:_IP8=;E=/W]$V RK>(DH@7%H<%S%
MS-"!COI&&0A/ENIPUCE\TS0<%IO3RCT?E1CP]'+M0LU9WAP5:1,((FIQ,SSA
M^KKDGXCU4SG?[A/TO .?E''\H@9BRFV+,,Y!W_JN%]7.:%J8-I-)B1&'?0.D
MTPBI0M&QU.;_));CJ2XX=J/UN_)1,\5R)FY UL>6KZ"XR(*LB@W0EM J79@3
MD[";:]!_N>\9_!,YW@IGH>R^GK&%A@JD=<EJ#JNYX-_*'#2&[SIBT:HBMY]%
M1;U7U!AA<'!'GDP,Z7I(COL**J4+L;@5^A3.)WJ6#> X<P:+#JX-OFQKC2A.
M"W+,1L4C!U"<9LLJ'WN)S-M*"EP-W+Q8P 4C(HX2(VDGOHQ5G#%\-8(JI$>4
M%AIT=(*8>4%Z4NYO0]"*9+"GB(S/*#9^J2J1!6,8^U;"\9#SS$&X8LDXG=PT
MD$E!QQGI^5BZN!V>#_[S5^WL# GIS6#Q=MR)]WL/W8Z"=C6YK5M]]O/;%=)R
M=>I\F7FD5S=4UK&!L-E^RAKC[Y9@-H!I+RS,QX\DM)9T63'N':9GN5L6=\UN
M?+:=<JR'0696%8O JR817QB5>KMT<]FY\O^"#"30VO^3J7#]D?]_T3:;T&9@
MW^G@0(I4V!1I]%$*0HS;=;[9S1JZ=Y>0?7.2K<+ W$2-39**M$);,N4H'QH:
M!HP1VO4<T2]_\U?HK@K'J4I=F5)T:=2C3D789QT5([%-A;#./ =C/U5>$@EP
MMA&^^E^LQMX]1MY&;4TF;=C'&P'TKMB(.OBNZ!'%-FQKX6A: R<HRJ*TT8E)
MWX+EJ0O@<HM*+ML\Q)U6JF(J1E3/1<ZLZEC^9+&V]Q>NV+#/&#$P3&MR5)<G
MQXP?U_%%[W4S]1K!V7$U#\7I_^THU 0<K9#((X,M](W#71H0+U)"S9Z?1W_%
M54V/R<4%(81J7GW/OHO3LZJE'"<W1FNK0U/BT7=:(E/:Z@THD7<MC7>V*D:?
M0SW78;I:H_F"LV#EV 4C9<7;(MC(O(!@WH(?63%OTQ>'%SD,HU:I'L@F9J7*
M;H7XY\O"VR(-P WO>BM 7@8A5K$X>12Q",6ZYLR*8U2W6C97<@=ML>CH*ZH]
MGK0I<4EY0!.B2_$0Z50^;I:3>Q_#.LJ3R;C6N'K KYR27;P\^7?R@I@N_IZ
M>B3V"^[#WI?OLFDK^!RHR?U)\HO*<A&>IA W1.3[7111I@,S VJEH0/Q"POY
M,DWE=>(A#2G:]F8T30)3R"9$B).T:2:IA8[Z*-^#.!;IU*8U\C*"KURVCG$3
M]@PT4X](T>=DD*/FY$P=8(T(?\7HQCE3Q*-_X8N1[PI$_AHL5F]%"6]2Y0'-
M=R)#<GFY3=F?N/_P4^-CH[>I0=)S08N-@B!V36<UG5Z$7#?8^N*?D,)8A^R8
MZXP-$I8!R8F!M+X5=6ZC#A][*QB&8W63;%@;H/B" _V<)7' #9JGX;1)Y@FL
M WSI-80YZ:TA 1Y8'>$.)AEOX(?/A_?S>Q,;-,?ZJC"IZ 98[?H??RF[!794
M0/"J5-WVX <\ H1%FT_RF';!)2R0]M<^$G^E1P^V HHG2$X/[!LTD:W4[DST
MA1#R/K_6NQX\%NX)94.FU7<>R1J7XOP\$?X]N?ZAMV7DPB26'9YYX-AV; 8&
M+L9L!GI//;QMDL>$+& $SN2UY&1WW$F1ZE!6=O0<'V2$2AXUXP8?=/FW#'#%
M"0ZG%H.YV;]?1T2!V8FFB=DCM.8D4 E!FJ[^SH*$E-$T3!U)"'<YS^ B392Z
M:</25L.AM]O%&2A,[34^5;!F5/\QQ3LB%^9XF3D!85BVF4S9-HY 7Q=]J/,\
MPO@#_B9M8[ N4HM ;MO>4!J*IIEEGUP\7%13%0,,,_D@,WGN2]('T5UEW"#2
M$0%*9+7"+Z;@]BZ:H! <C4D=M<SV*L/:2,2:XT!2WLS14DX_VRK^2UM)[.1O
MW/IT)$.>E6=H$KV",4I[<XJJP=,2U1!?(ZJ1RX&..".7:/VAX:^A65CUB?=H
M8Q5W',;^.H9["]@7,N&XZ"PMBT\2KG)@N@WOYH:*3_T:=?G$B508:&@:56Q%
MGK9?W)"1))[TR6>.]MJRO_=@A%7*'^!P9M+-F-')(]E4L0YH$Z6U6?!,GWQ0
M-VGL+:9'[EXQL'-[T[8B2":NDM6XG"R[:0>E<C7))$B#5BU' W54O8FB"W7D
MLRMM5'W;&6QUJACFFQH:FTD!S"#I##)AD/XF$<5&/Q4:2[3NSPO.[N.V2(=K
M]3/E;__%JNFK%J[+,K36\/%PM6A#=]00,J$WRG%M"].'"\O7O/.!O01C>GAX
M8DP[(,18_S9P5D0K=3G[VB!!'2/0JYTGSY@( W:/7) <CE  >##YU:8A]T)"
MY_8,](BW/[]5U_>$QOHKM0M]%<*%0^QS>'S<%" ]3S"5NZET+B/;&+9LQ?L:
M= KZ8PF^*(!3:HYV*?[Z^N2C\;#/'QD71O1*)6KX!;G':7\E(8%OTW_*)QO7
M3GC@48+C"!QL+5?(:Y.I+A<#[>:O8.S0&?/^\G57)8TI",! :LIQO;9><D&9
MK')*E,3E#9PV;^9\  R7K?UNN?YQ\H$E<6D+]VO\M3=MN>K.A;C+)*+A95%T
M+(2</<$6)G;U[5N=*#')[6IHSR<CZ->'%32^U\0[*Q[OBT[_^?W:)>N2L F!
M&?YFC@8H5HE-^P[N02._H.2F]%>K5VQPVSM9'4_K6VQ'E-#*]C"ZK V:HWN\
MNQ,@_QDU>V.'G$"13MONBW5$1;+L=\84YHM-??BQD%.))N=N5M/6V9+VD;A5
MHURJ-2B?W7/R9P'B',*Y/GC"7\:=8E^+R4CYX/).4!<%?;0^Q'NK$K8S+2 "
M.I7OISXX'=AX6@IO_')"E3!WJ2V4%@?<]H-'7K+G_>IWG.]W*Y)-G<R6Y2IE
M+&!)0QIF5ESG<!2T1D@433Z9)081;S2%Q4]2_,;<]<A(A5CK,C%&>!EG275N
M7T+9XY"8M;7W(:?,P)UJD7\H3I]*I%@>\=?OH46/.[;'#MC9S=MU=C6CB8=3
M886X@=>EN %#9_$RTEV#JJ01ILSE#C2J1<.NG2A/]F=I]A#JS=9S*1K>6M9N
M>JN7?Q:< J:M&@/U$<1(,QPI?M_XAVX8W-IM9Y]NLDZA7\3V[6Z=&2X4Z5JS
M-&4/L'##7Y:0=5<L__ W5;L,SI$3":[?0H[0%JWOTBJ@(JDGD]/A7$>GY$K-
M)A5KY]GVL>;EI3,&6VSK4%>?] ]2G%$#Y>A$# NAN[0/#:;R.<X0039' \(L
MD)EQD'WI+S3!-QW\@HFT*H8VM/55*^U#(. L=E(F;.ZW:=JJWF'BK2I23'/M
M^2LDQ..BC8%,+:M?CRCV[##8D_<?O8B._ZF.^_]A43RO[7T"%[0CE_?_AU*-
M)>^R$Y+#Z]_:JPI=-@3B3R#T*@\6<%8FB".L&EK![W]J""<JZUI=>7E.8[A>
MQ^ALJ$,%]];:[5N5=0][Q9/32W^4<+.P50EO:I]N.B_9R289=*)AKH_&+()1
M*]L3P4 &^UE(K$MY<L1^2,%,Y<SO7:3IA[L<RC-=YLU0,MPBT@[9-5\N7\T,
MRVBRA9")^%/Z>?J J]C^1[9I\>"&1VB'V?%(9*VJ5:345RHR^ Z ,<K"=;^\
M,(XU')(3FLYJP$@/G!?.$CIPI<U?HLT"RJ2>(XM-Q:K,B4,78@7"A;\IE3<9
M&_K()C_5BK1-O)9KT$F??BAW(52,6!C3*B2$3YJ1AOZ,CU,%X8QX)@[A6WL:
MU\SZ**-$5[.9HK2@DH^=0TL]8#*$9K,4^$M;,T*'@D05KKMO&!$:.9[='C>B
MMW10A?AK/7*V2Y?!+3U,/T3=!ETBX5);[&2B\H/L)R"EI=2)?+82&C>;4:LI
M(2P6;$% - QS<U:+#H$64Z.3?^9<ITX:=Q%EPR)?JO@'%9]@->RKC;U?6)T%
MB>,U48&TF&.+4*SP_L'-;_=(B;A\KYL\L* I1?N(9(O2OSF)L+2>S\[=8T%'
M-&$J 6X'3S4LD7OW.ACJTZP0=LG1D6)6AX9VS3P0X>\*?I4+S+H42/VAWT7R
MZTG[&!GY4H78&ETNVB=YF\#-#"A*:!C?Y/_2!NY<\1)OF?2DGJ$4V["JVS1R
M%GT"O=OI--L%TZ[<PFC;E.^IUK7@R!$ A**W+WKQMT8>"@Z3#5-7VP-GRGDO
MIR_Q)<R+]HT+Z1M>8GYCAB:2EY=.9ZO?G(MH T!B_Z1?O_MVSKZ[:"]%F[!-
M:83/LT_>-2KDI:5K;]CSYA 5M6^61U6#'?P-&Q?!H6 +&@.I%["WQO%PB%(1
MF-;UW>K\A"66YY+@$91JIY'^(M;4K[4$.T^B_(':GC#.> 7+1W<+@%UG?T<*
M'O@)D:E?:"^&P,H>MT)RQ,>,;V[O/)LF%+\T-[QGTR:+A)W >'-S!Q%&#466
MM.:<,&-JVC22<0W7JTD;\Y?Y8%7%HQ;MG&VC[="VX\J"BYX\*7_.O*!&W&1V
M'WBFPH[52E?"P"C:5U:H)=F_*@W:Z6VLIF% I,*&/K0]2M7@21M%9G+9HHV#
M)05ON.6VAPOUKF1-U)0Z/:<W/DO%,)2M;%_]?2$K@UWGW"B><V>11,6*&X"S
MQ;O#EXA'4#7&;-@JQG:@\:=WA+:>F-];#AIZW!",EA5;0OH*'GPTAPF61[B&
MUM9K"VS6?4'@:]X6153)O$P:KV;$[_[YP3AMDJCJ?CJ-,MU>,/:Z/U;=B_@$
M>A=V&@OV95PQ)A70.WC/<BRA^#%OE>>_TD/!%+*_I]2!VY_%.((_]%+.N;;T
MKV 0.-V6:T3YXD(RY=9TN^LP>?3P':R9G]_$$9LW'#L0?4C?Y'^CP[/I;.9%
M%* "OVK"O6)2#5?#>DI<E4+?P?N62#NAO?2HO<0;J2.3%](B5A0><@KC_7,W
MZ<F,)61W0?^-^7*AS-HLU/I8H)E.K<PYE?OG9#7?82).93$KU)KENNV.L1M,
ME.&MEV+-GOW@Z4IFW9O(6K.ZA*ZL@2R.;/E 5+OUL9W<S8Z4<<[W%J..3(]P
MK:27#O$,F.KJMTG6@>Y&_I0TJ&$[7OONBK'O*O]D3< ]*DJ7L%!-6$>E@98V
M"&GHL $@6]%HDQ$ ^3RZA'S,OKLJ&_UZ^ROXH.:2HCP\V?=Z*AC2Z@-BHHS&
M?G\#"=&ZX[_K&] AG!(7'F58\KMM>T-0Z:3F*.](ZNBL!SL'63_9SF)ARE1<
MZ*F! 40 @K9-R"0YL222I7CW('CFEOLCWQP#T?KZA$-'BV9C2M'8;5,M;GW0
MF1@5U6G59OH^DF&AK&*$&_+ROIRIW]E(4 4U0$K::H21]DV)]"G19'/\$_"\
M6>[Q1'/D7"&*DISM.N';H4_Y_DM:>C"2H\_IB+N5RT[!C%'E[\_0R6'S(.I(
MW,>[3R"XWQ -R<VR'[5TZ]8_9'OM._,>_\]/H'"*;7#6X9TD!E^+I5':81)R
M#WV,.7;"B&XY5QKZ)/77-DEH@W>^.P'W?FC5E4"^-VIK,F^HHV>.+K><KKC;
M1WH1_2:,M*W;G$K,A_<=Y704!+$?\/2:N6AB9+ANKR-YSF>#H-:)OC6WR6<J
MFP>LJDH'T<0!;@#RGR/> CNK^5\>39GOJ<[_M9P_G+"?L>.OQF,8@Y-S/:KH
M1H%;BN:0/"MF,03<I(EE'@!.0-SW:\N-CD8/M.3?]=I4ULYVB$/"<DX^Y?##
M'</"PKK/A%(IV+?9I;W=T*6'3U7U=W2CL#[>U-KI1DFCA+DCCUK;B00%D1BY
M\IKADR1;Y*)EL?2"RR1S*#.K&X-+M :T-H1LE1P<?HU#A.M$H0!>J4H)$XYH
MIM:BA8U>.!.#KY3J!Q+G7,U948*$.;3 I!$'\<PH#.*J8J9NWC'_V #B30,'
M:;BHB+&6@,+2C4ZN>N-WF<C*Q-5Y\C@-"?F9=#2POTW]*@1]#".QN#HS-YMX
MO0_N@2P;&HUP1K8\GT"1FFU64L;X-8?!JDLF$N/XQFXUV10QT9Q@LNMVZ7W@
M"=Y;,H0JQ?GA[G6Y2F*.]JZ2$YT:%#ZYL(OVW(Z+[ :R"/=3^,GDH(]7:UV&
M*23&>+O/7O**(,]:6E1\*"OFS]8.!LOJ9\%D9"B8TD(&U]J?ZNC0F"D"V2[=
M-*?#-!'M#VW>"NAA)E(:"-9JWGE9P\7?$$?7(V&!AC]DJSK;KJHWC2&.,:4X
M<UQLX;<A74+W4,GI,LT("+*KH0/&>L(A/4T&RB$0:T<J-BN$%R7DJD7JJA=
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M'F/5OQMB_!+CQ($_M7@Z5ZB=F;4?7Z)O%16#;,6++!7MVA&*6')DJ+VA;@(
MSG5X)!6%I^W%=3)@-33,XT_,"MCHX2^*[\R,8WP"L(8?W!MZ-([AR8]5+B21
MW%GPPC8VJY3M5G_+Y)P%"P2/L[X9MJ9(J#W)GU97S]8.X+3$('<Z;8@T#=&P
M)&TYB=0B4JIQQ%!G8[>AJ=)G]3^&EQ >U8AL8.#-EY</(=0]L!V;,>]9@3/"
MFL&O^$S]A+9T[VT;U6K8W2[0B7S[1H#':TL2[%-K[*^'F"CH8./88^]"2FZ2
M@3L.F.-:/A6SH+5+<%!N(L#A).D^P <<9GD4X]9\_8N^-%NTMT<;R @VPF7W
MKL?_7EE77VVNBF)2U?D+H=?R9@9"P8,3VAD2%X2@37PW,\,G?.3$$">>4E69
MQ"MV0-0%XJC9$V)<0WK[QZ7S(&.4\7\";K/HP 'XIDJQZIV,KCWA4N5"\65S
M0#& @OX\=\HGCG"X7J[\)4W,J"$)T1!Y#P#K^!+=1#3'<Q>[J<DRV:AU^W,=
MM@_'U5X)Y-#/*28_QP&'^A1!;6V#CB[]H0H+!AHELU6!#9<SB0-$=5G]\M'*
MTIN&!\_/\MS[HE_#>KA9B*%GP ^;>BD3-DA/,ZBNM=2'-WS-UX0<R0A&D,:3
MBF>:15>14ZMA^E4(S3Q4DA'E'S('B2OBPS[2, @4[ [:FCH<?G3OF4B?:5.H
MF$XFD$[V_M(DL&D!T5\M6MDNV@8'!YHUNB77\_^;#L1L:W,KF1 [;(8$+3S1
M R *@@OM&>2K\FJ6)0(@!)Z%XW_W1O?=7@RFJ7,6:Q=U%(WQIBT]@A4,Q$$P
M5&]:L4UY_S2$=69-S^OBUN=IUY0RFL7M3NN:/+XK-4FK1N/6(5.[)3&H">*=
M%P\!?[*J*(\!!"@:^APCLK2>M8>A.;K-O)KIH%7RAD>L"R=.F_/2)RAAH09#
M.*[LL>E)%&%7?SCZ19MH_VT_^ 3HA4N>^>30>#>"43.>3?@.?D)'.?;C.%(8
M&G,IW&OH67K&]-5[MX8)KH5SBG^_,4U\BR?0$D$H>Y%H#JNK(LU>F 0^:@2H
M]&-43E9M7I1N>%LBHGIWSUC^L&!.1'%W!$M%N(IIBSFW)ZP0F>BS9L/ GW(0
M"P27;<5PMZ$?N?TI%X@NNE$P#X@L6&7518#(-H;^SI*OG\4TI)G#[-<SQMK*
M==&9J6\7;GV;<D<T;L]:0&D(J)=0IR-_50K;C8%/BR]K[DXNAW>8".Z-J]"(
MC7C(^<4:T'_#SVV.R.U?853AIG87"H.A_)3!_MMO99HHI84-WQ2TF]G_A,'<
MG!VUERS$$E%9;7WY$Q$Q/^EFD9BVUT8;8*2,1T9**0_?V[1YJKO^!):*7[H&
M.84,2*NUM\S+/R8^W-\3ASHN7]-\.C^TF 2W6\]?OZ17^#=^ MF5"IT]STP?
M:P:M?]^MCN]?:2>O3X0^ 1>_3\#TO/,32'CQ+TD]OW_WGR%6NW]^;_F82\\E
M.4P_3*\TP#[W'_+VC:1:_W/]N)UJA_G/3M,?[J61;GGOXWS;3K<)=\_GTP_N
M**V7U-:Y%Y_ L?5\Q?6'["?0DHUYY/'@\"ZVO#E?<_TA[?_1U/-]NN=!F4WH
M!?83"*\T0#__)^!#\?]H9MSL*>UQ:/.7_X_5JWUT<C]L_SF@&P.*@Y# ^_LG
MH*3,IO8)6'P"?-_%=QK(YM*[#5I] ]3!SF;"/"!03M_UNI(!QY  7_G]G% '
M ]GT#P$QJEFB2=X7Y\#MHK.6![IZ=L,_U="/T'1@><0?VG<70AZ.8$10\ISU
MU63#B&GU?^J[SEU\]PXE;25PT+=FP>UI8PQ7IOV]#B3/MO86AILU,6D5\YGC
M14^\3R QO\#^17+X\]ZHGHQ[XOE3/&#U%GIDG/,J6)ZNJ1)B@5?*TZW]HPYN
MUE6WMKJJ>ARGXDF"&Q30@6P7,RAT2\4<$@3YRZC;01M_I(0[,$>>D$D;F*_)
MF_X$\(B?J:Q7Z,@*<52$=BM,[SY06?X$&S? T+>=1H+?\ES9C%P@:XPER4UU
M_DF8?B&)U\KDM^AC/D$HT,%UJR=>[.YU-2A*6PZ00M#K!>V<-5G.%B=ENVB4
MR]0NK-90/Q=\;>J2+=8CWE6+EE-$+0&@)\VL:]"HG6>*U=?@VH"+;S^U$.:E
MAI[*DT1IC/A&QR.\)0_CHRZPC?-"CXCP.EA2+Y/$N7;KONKO4/'T"MM4]W_@
MN0:BXENS-*V))Q@$>V?:/.I$V,@92-UWA>DK#_><PLW4(/^M8_W%6DEDWMRV
M(4!7\(AE "I7[R!Y_>G*++%@@/*ME('U<DW#QWEO;]?&[9G%R=DAX0#!VXGE
MF](M,1YJ)'-3K,*([ :=X1F$0QDGG[4 PHD]P/&TQ:/1&-"I0((56K2/AF=>
MN,9UL4"9BW"?YC"<D^$:UQ$+>Q)9EL"@D2.$$%76>Y]>Z_\23"T##58FE#);
MZ+D\N)56(PRJI1N%,SH*5OM2;&5''3. ;(,1T()]OH]%&5O"#:-T)E<&)RXN
MQ VCE<Q"$K+!T;#$AZ62"4+,5PS'3V!-MSE?*)8^I,0QJR!DGZ@;_P3$/MB<
M_II;8//3)4N.8=6](5>*V3OS1#E6Z8HW-XH?'9DF:TH(P-L(Z65?\SD3J]-Y
MMLMM-7BN:ZFZD T*$GVCYDJ()6(-"TL36&_E<CHE\D#4M=A;8NQ$XL75F+]H
MXIC&1-!)&G1SO7$]S,\#H"3CK>J 0\=/H)<8([2"WM@IMDIVS%OS0M_C"%U1
M2S5<8WQOGVHX\0BI>$ANP_ND:O=*2'13;']/?L,N$94MZ>YV251G@*!ER51@
MUX2/\0$\R3-C!4[,&__ 28][KZT4!V>^!'GA5)5"*V<1!Z_G+HZ!I5S@ ^:F
ML3"-,P2>J6QG=ZU:O\<<<A!150N;,@(4R$(*JUJ %D7Z]#BR.E-FJT&X >#;
M1DFM[3]Z(UGZ8!?-RR'BSX0!H2D@FV0W45=*B/-M7Y\2_D,/=D?74[VFTZ;L
M(4[VRW(KMO:>W[H4)3!(/V!_H,Q[;=N!D/_4_+&S8/B#"@V"_):DF?J0[*5Z
M6UKXPIPI4<FTRR3XJUES;-^S97W-72.ESHPDV43%C.4'K0\U[ J#@]^0E;-]
MG8J:2IXK+)$WG1U!.@O&83O.$4=F-I7NEI+S7S;CDDG("9!G.=.!N\HT]K@^
M!S-7QVMV#!FG7%65,X[+[P;OB6_Q+5 H=C[^;HGMTN<&D7QK.VH^I')C\S^Z
M_]YLG+OPQ6+.>0>WQ.;--W*VM"I+<IUZ_!A],QO10B$Q+-)I;)$Z'/" 5QIN
ME)E)@4.?E&K%L0FE&3LG]%3W"81 I7'$J4^;7>))9I&?W_U9FFT\DC+[T)7S
M:D_ZS=CT=$LDNUNRCJ>7M0::\R&K\\A68*!4URER?3J[73G5-.U2SO*8FN.<
MDEH@(L< *:N!FW_=T\([>BAM_Z@S(AF5J;J6/ 9+-)V,5<H3;N/9Q_#\SU%]
M..^DKM^=^_:X75I&L,J_:#%9$N@]8\L?JC?@&_KR)3P/# T T.Z)H$>N27C)
M9[XI0P!)!=!O.ZA(!)^ )L?VPRSV#O#O PF ,0102(%G0!E3\C#T]N.K;U;S
MT">PP@;Z>"%/9?_ONX"WJY\B[Y.@Z& A%G,HO-@7YU9SFL FF/OEM-L&,V-1
MJP%Y"R+G3_:4%77K7XA$)?Z91^ 7_< 4X61=+Y\73KE<ICW,#NN(9%6U58=J
MROO/4X5^U+9GFB,D02QQ:4O-Y,@3E*$,HVK:PK?#TQ>?JOO6I[--W4U-G+SL
M/>J/3Y:JB1,[L>55&3484X.V;C.\CPE+E7)(1N<P]8MZ4F68Q59-#05U3!Z3
MCI?4R^.%)L"5F;.%OQ4K$NF<]ICE.YM6AJ5JB36T6TR)F('2(T(#?K45<&L_
M="N8&-H(?R^%O*=YD1]<)X-^=RN_&=4[(!RW^G.G@6,@5W09G_M.\K1$Z<L=
MS!<=7*:82U9[6J/)*^^GJ &4M2"E4%I09U(UI2: 2*5,X8K[PR_N@V+/2]QZ
M;M?V+86PE=2*YQ8Y!;O#1KU03M6*ANMF@'AK4DV@?.N&.%3YY"9+SV!R,6OH
MMTVF?"ES5+69==^.'(9[9AJ!N?@IN8X*.4+*)KAEN>OZ'TP0Q$:>"IC/2.N$
M]E;G]PQXW)&V#^,6\U%'HU)IEU_FA!N#.K/NCO33*HRFTTPT\?P?YYLS,$[7
M[[Z_KE.GM2\$/B[FP.HUQL /=6BOU$ F!Q#;<%2-;HMCPBWRV#O-KZ\A WN/
M8A124:_.U,3]KG&H7T(Z[2N(<K2)/T[:2$\=LD[-IJT"N)#1&:8M _./$&W=
M-":IVM>I8;'1<,30)5*^6&O%V4K>F7B*H9CAD[Y+T'\+9AQ1B7:##BH#PI"D
M>AC]!+:QO&6O-]L/-VCF]6VV(W>DO76*NRKT/;*RV5ND0Q24XQB#7RZ[CLYX
M^N*3!O_Z"4*!G:*/5,T2=S^$MP!,!3XT^N\M\R+^>!#JON-Z&$4 Q'2=._+
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M3SUS.7_5#=@9<'$O'P+?P'L=YBU3W=@$%V29'"-2FT1)35;PN"=7LOHE\;J
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M6A^BPZS$F^"D_8Q?[G74+L']^@QH[;G#>*)]!GB2?'L&E%/T.4!R)J%K%,^
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MF^L66T+#+\KFIE_YE"=Z9_.3N"DCY-/FI5QN?Z$$67<>R 7 +O=[I0R]&T8
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M <GC1S9LMV:H(9/_LE'69([0-P/+9I^_\@R8T1Q8?*C(S',:"TI@NP&'0!'
MA+7PAZ%-26BT:DL*$E.A_:?YV7W"2("P6P&C7C8Z\2.U LE@X")KQ2'M)Y)P
M,V/#C59E6"3FH'X_X6NM)F!01EK+ IJU!?>K:;AN]$K_;T=#U:B4!FN24?,Y
M23F?]KW!*4_\3M!O\RF/4H^[<@NEN\O.(X  B=/=VE YW3D.W,_(-$*^4IH
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M>9J4*Y.HN^RL"^_29RV].UIB OT!Q+BZV@ T0J WYLY]HVI3CF!)>=G4]$I
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MU@O!'S?MQK.L-K5PJ$?Q1MC+E%K4?4^W\V;&3J%(E3I1GTE)$Q.'4 :@0F-
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M=..:5G#%)B'E\ZGINA#^'N4T(.+@G;&+EJ]/$E9)2JU"'UZ#_"C+X3.TCS3
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M_0*]*(+X'T78?V$.RS. X^H1/6B_Y5\0>E$TO83$&!_,7[&F,-L<1SR$<(>
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M!H1HV:\@&-N"W1?',RPX&:]9%+V3MU2HZ=*]36B2A"*T@2DYT+M+;:_]XF<
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M*4-3D^X;UBJ]^\.OK\R2VQK/E]7,YE\]JO[7>JX.&RC7 X)9/YMTE\N3N.3
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MJ\ *9*O#-E;N7'9K,D-\Z6V_&=Y^XE@O+$F%Q,:NK>T@S7X^0G,61G;!4T9
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M7-5,'2 @65W0;["?!D!7)R=++0C4W5G=S-8<QL8$  &N "?8'TL -4 +  %
M >X YQL3=.??VK_<2-E#'?^("-/,W<8>:N-XXQ(V1KO1EE;54_Y9#>%K?7BV
MOV6,_Y>,U9VA-DZ.;M?5O<G+&>KX*PE8DF:NOP>:5FZJ?TI<':7_'#A"_QRH
MF-F[_1ZH64$]?@]D'>QE?@]@=?S3M92YG=4?A?@9($!37DH:=D*XN;:@IK9P
M<C>3<%H _")Y5\=_XTG9_[N>E*L%".P(E;NG:0\%_(6D["VH_XFOZ68/O>$#
MO>PE=,Y3W_YDHWM S*%.KC*F4-/?70&T KK]ZHKKZS_.TC=%@%A"_\D]"-;2
M_\37,K?_R0>ZFDOH_6;CFKLZ.>M80V"3"YLO&T>K7Q7#OA9HPF*2<H)"G1SL
MG1RM_C#!_"6Y#N$O?*Q??$T;*^N_"C!^"6"Q_69?=P["]L\8$-Y<\L$6%]RO
M\TU7,=S(L/_,0#S@C]6'=3.\7I]>-V/2WV/*&Z\'-V.T7W9P-U;W<7^6^=?T
M_T1!.+JY5@!P6%K")/:P(_(?1C\YV<DIOSG<-T=]V/$7A^_FR/8GY\;GCYMK
MV$JZ^D="6+L6_^_+;FJ!^K.B-W$!X"5^OOZ04?ZNT\\QV?45 M_OZ'^F<&UG
M]+MT_TY_X5WKP?V;SC\9_;DQ !S=[:\;['HO139S<G>T</N7=6D.Y?H5YG4S
M_Z61 /_2<0"IWYWY,PS-WXUWDP*RF[V-.<1-VU[E>NG _0T'Z48&N\"'O5!N
M!HHR?_&-8N7JY.[\-Q:RDZN-E<WO75%6Z]I(_88'&V.9ND.=Y"&.$%=3*,3B
M)GIOYU^;.OI/Y6O.M431P8KZ_X/\$=Q=[?]V:[@I_M\YJFY6?[]]()O:0T&F
M5G_C89M#8'80+ZBBFP)(5>77!H7ZB_TW931K)U<?27L;JU^5POF9O,(O]G5U
M+2"6INXW.Q2:!\05^@_JVK_8?U?',+.2=K)W<OU+<?%^&DC)_Q9<AZ'FY'A]
M1H,Z.<-N0VZ0OQ8.W1Y6R'_C8IK=;'7_QL=PO=[0_H5]LX(8?]I=M[/X+N!/
M/M[-)=S/G0>1\&9T/:$_=[9K?0"6U!\%RX*]9&"7"P" ?P",SP"X X"[^G2U
M#<"4M' R@QA+JP+@KW8 V#<C@$7 M=W5#" 8@(F*BHJ&BHF&AHF'@8Z!1X2#
MB8E#=(> @(B X X>Y@W]<?IG@L/"P,#"QL+%QL8EQ,;&)KP^8!/^-,'[[SBX
M>@O 0X4%GX4 1PN QX-#P(.[FH,EBG[5 2<.BQ()[H;^*","  X>$0D9!14-
M'0/N7X5P 'B$7T)< !PB' (\(CP2"C(J$@(F#TR(AX!(@\^%)*EA2D#K$LB-
M3!B=72UUCXY(\YT9#Z]KT(@T"GV,UN[BGKD;'W%.S1,&F5B0A>S[7"@_R2AX
M";)?&]P^YKY\('<_+B^D+KYC?.4PO_[#Q)<C;4N/T(2"AL[)U6,!>1TKS[#$
MPL:NCU^_XP'@X6'1(M[$A(*,Q'<3 @T7/B(L A=: B3NP&C"ZPC>:8[L\M"9
M+;H&Q4AK$9F[\>[1(U\'@,+ ]WX4%D0NB84LF!\*6?H=PG^.X/Z?(5Q- S 1
M;C#Q .* P]IQ%P'<NU^WZ? [19?D(K]S15K50]Q;UU[W8F"Q/2*[J.QI.#>;
MFT^Z(+>QHW(S:OQ\!4@N7GR#_FRC9;Y,5Q8<9B(V'6*?DC1Y&4%N)^ ONN/S
MY4TG@H^E%;B]<=Q/TH.E(<*%-&4@HU2^A/5,6R#OF\ZA>.;94QD"_6\+;>%!
MLA0B1JIU@W.?'DGS/Q.;BS\9>V,GENKI]ZC1?R:\TH-GI\8HU*[AS>C@0_GF
M+ZUSNM:GF&=@^R/[J5-[]]6I!T9XS3@DGV-?6M_SO5?P4=<F\!+E.&SM"N"-
ML>6OX[]CJ7/Y5N<*T(-X!7#JNK1])29NMY[@H^Y2-Q-J[Y9F.)8<C_O-O_YS
M\JF5^*%?8D'Z?#C;X7;'F-U3P63 +=W2+=W2+=W2+=W2+=W2+?W_DJX6'ZQ:
M0Z'.0AP<CF[LIM<?9MG-G1PXO$R=.;C8.3D (N)>SJ;F=A HM1G$RL91E/9;
MZQM::AL+45H=/E5.56=IB+6-@H\K1,M'#63N8V<N:$$K+H8NXB7DY>#L (&:
M4GLYV#NZ"7F)TMXX%X)=7[,Y:*EO5*!VHK0W'Z&I=56!U-).KA!J/G8>-G-.
M+BYJ?GYV+EX^?GXN5FIN3BYN#D[87WXV+EXA/GXA;@'J/XA6#!UV%'&UL!32
ME)'[ PXV$J7](R]/3T]V3QYV)U<K#BY!0<%K-]S<;# --C=O1ZBI%YNCV[V?
M3G[YD8&XF;O:W'P_3GT]-C5S<H>*TM*B4_^%_LC+P?DWT#\6\+?G:^<P;2%I
M5X@I%"(#>XEQ<W)SL7%QLG'S@[@$A3AYA/@>L'#R"?%PBG#\B^8_^7!R!3DY
MV8NIVIB[.KDY64+?5U#K.+E:7->*_R\._E#[%P^J3A8VEM[_$ 7/ R%>@;]&
M\1?-?_4!FT<+4ZCI?\O+7W5_U9KC7XK]?SL)SG^9[;]- DP FP2>OT\"C"D$
M='6R<#>'N/ZGZOU-YW\[7%@]5%7_ZZYQ<.#X)TLWJ*P']+^V=+O^IHU#$^+F
MY.YJ#I'U@#A"[_UK#ZJJ"BG8N,$ZPUOL;R WB6A!7/[._26PM[E)S-G4U>WF
M*U-1VE\HM/]F<&US$ZR0J?E-J2P@KC8>$ L1CK]Q_[,9#,44MD] 7-W$S)T<
MK[^,A%A06[HZ.5";.CO;VYB;7MMS>#A:_%$"Y]^_'$*=J&T<3*T@'!!G-\M?
M>']Q]V^Y<?Q,[O^%I-U,_Y^D;./H!C5UO/["6PPV1^PV-A9"O#)<O'*R/)+\
M?#S\LM)<7))<,IR"O)PRG#R2,E("4I*_?/_%]#_[][2&./Y7R_0O6O_9R?52
M\31UA4A:P1I+[.?._>>OMM):_-2,.C:.%DZ>;DR_//[=Y#^[-K<V=;2"6(AQ
M_#+\Q?COS=A/[M^[]V;O^<=N_V,9R/QL2[GKQOI/\\SQ#V9.YNX.L&S^F"J+
M_]94_9OIO[E5_+_I@'\S_3>W/W\,,;7_'T3]#R[^MW=%"_/?&YNSNZO]S?W:
MPIP#8@^Y!G2#;6Y<?]_'+<R%+)U<'4RA8G]=[W]R_]?O,K_:_#_<:WZ)__VV
M_ULD=/-;".R."A'C%>'X)_9_&?1/+NQ=#NP-%L?O=UC_M*3^]^D6Y!;D%N06
MY!;D%N06Y!;D%N06Y!;D%N06Y!;D%N06Y!;D%N06Y!;D%N06Y!;D%N06Y!;D
M%N06Y!;D%N06Y!;D%N06Y!;D%N06Y!;D%N06Y!;D%N06Y!;D%N06Y'\9!/W/
M?[,(<;00I?6D%1>[F@%( ^#^AW3MY'_J ^[F\3QP</!&"'!XOQ[/TP&@NG[J
M$#("W%\>TP5W\^0=> 0T= R8@@\N+'P4> 0$%'A,#!P<-$0,.+R?#^>A 7"A
M2FJ@X9L2$!(1T[H$DD2CWR%EN,\ME5W];F27[!X=/2.?P --T"(/+[^,G+R"
MEHZNE6=0PIZT+%C;S-+5S3TQ*2>O9M+<.C0LKJ%Q]*.'5^%["TAP;'QN?D%]
M9Q<,^R[<]8. X/X6W!\/!H))'?"N'R&$@(B(BHR&B86.B(0$AT<#@.>21- P
M1<1W"42*SMY%)B"DY8:%@T),(J6Y2'2/CL?,-69TCYY76D8+! Z*S1F?X)/5
M-K=PBXO/S:MY/X9ZAT% #N+^)'B)'QJ2KU/;WO%!/K2N?OGO3^ Y^S$NM#[S
M6=Q,B(RC7)A$[</1>S*7L?KF@V!>*P2YWOD/"M*2<U3)2Z708LX72-N$+@8R
MSB>,[DZSH#V>SP48(=K*O+$\L;R'GF-<-KY"X_)97?&$WTMSO)C]-KAIY"3$
M5)Z[:<0C;;14JXQ/:%*<7;@LSQ4WBVCH'J@:YC*VEDOUE+.]"JH@31^9"'%9
MA6Y]KJO9Z=T)_C(;LDQ7#Q*JK55GWVJ%M(S,46ZD/D9EA1]0NML-,*9;"HAO
M96-U"P3+,[_<+I*H4WXF!RI_L+0<@Y[5J'7J*&G<,0*6_=I:HR=+CM7^!8)D
M/%''&O:41AWXC3QN/&%E;(@2@_TM#E-A?'Y.N0'"1ZL!7L+D>6HAFF8X%"MD
MJ6YX7LDX]M>O.:#LV:K:+ FV&RZU'"W1VCUSPZT'I+PY%WM](".FN"M 6-@1
M[\>)38B^0B%QS;-<AH.O]EJ=:2V\AS_XY")L2R$SU2*VD3GM"3;X,X 2X(&&
M5DET^E8]&B(2&GR6(7W&LXE/>T&,?HP_OK;$8FB)-!&%K.07G;H]?4VVQ%#;
M[!"9V4=; !4=:"!Q:'FM8=B=1[R48.E.4\#.6J"J+!(=;OL^-J]D:KF!4KN^
M*)=F$\#^903;9P1/SQ9%"R"E46J$)P]_)TY+4YG]G6YI;=?S2/![WYQ8C=C"
M48S/*DH;:R4Y-M)MD%3^B>)2N^+M]9S"V.0QE3+9X1@>&:UQENGJ3-:UP<(A
MBKH^Q_3Z+'HI0D*L]FK;9_HQ);0Z#-E$F\9 $R4"8,*@;\JL[-Y+W_L"W%1/
MF>SPFQ3I690[417Z' PT\ Y5AU,'K#):9Z0Z=N8T0!\D:?--9WOO"F-.3.3K
MK\>%^X,[T$,2YA224F+E9%"[\SM]H4IDR1)P/%M^]TN?8L[[&#RJ[ 3'5X]Z
MS]V',]"*_:%,\SZ87AHX>4C15VR^_'RC;4FT9%!KO<!A8+K @@_%<[PA?8+(
MB'($.KZ=4&I!)$LI Y\F6!#Q]>'P0GTW$I&#)UK[L],.)RLD$NGPU, /STI:
M]H<<^PL4C7<E+5E(1>O*V6;WHPH6[)#M4H(R*RP'Y[G)"VR*=[W&<Q[O)SLD
M@HTT, R[YQKZDO0EES&5R]&Z,TP>; +SH@;-\K!FP&-"<=TUHBB,8Z4?_;TN
M6A,JPS>0#F9>HCQX6O<]A7T)>'@%P(F/)^%</,Z-F5O'#!K7K),=I1-NK61/
M;[7T6'\)1GJX-Q-?IK=3A0&/Q@3.J9K,WR&B4#0RD\"0( *V#E?+0(JD4CAG
M!T4=A_#::/2$$9P>6/-!)XL"&^OKR-ULL.*]#<:.>*<_:L0=K-/%>(TG9)89
M%#*CER_SA W:-((>86\B^YIXK=;FJC(;-YII &I"3(@07J&3Y,9Y%0%BE)OZ
M,ZH"X+VSJMR>V@VR-W66,[CGIQ1F5] S&0SLL%T!$M\-%+=BZ7E:$+MG8-NB
MS_>IKKC7$BX64(P3R:Y[]+5(/M&IUN/5A8R]U?.X0S3/FG>F038$QIG0?;W6
M$W(WNN05F- OO'KK.Z&A35_Z[E=Y:=4*)*6CB7OOSC.B<S?8*4KUGNF<II=3
M<M$M\9>7.^;R_CAY4,1*7ON XY4-*Q?^3HAEO1^+'',59I"",C= :!/TN@)5
M-B(+G#.>.9KM;2$=7C@L\/+ENFA;]A<HHH.Z9.]ZKW+8U'-HJ(LYI0Z;6LFS
MSYVJ8W7UM02"VU(CQ8N?\LLWGR+IS(5@ZW)\XJ*)E:O;6P8N/\D7Z@UAS=+P
MIE-">];6?;2T0 DYTM&MG!6C;U5<P2</1%,;LF5\^BHCNY)U'][U@5= DDA;
MK1+)\W:+-0_+42>)$WE6L >T4>-$2+) #[<?O8YK=0M%"I3BAJF'0.PS'&,L
MP!E 4LBY\54&?^K.!.U.<=.'9?81Z=DI"G<,0^V=]:**!]OEC>46A@_4&=R$
MEM: <1=YF<Z?K/#)L-./'/K<>=Q:TT@=$HQ&W0,+I]@HSP#A#([C]PQ"I"@(
MQX7R &BEH!3="*!&J+)7<22#L+31Q,B$8841=]$78&(.Q"9OTH.]E]2BP9OE
MT=LW?7$QU9:-6#[]VS.>V6.$BQZH'@^'[N0J(QVPMHVS]H-.CTJ_=F@ \W2?
MZE"'%.>,4P.AKW)9G3DZ$DEUM-^ZX.D8H=&Q:1B/<*.BQ:<&/\NQLR4SUS D
M2>C9.LVM/\(,\G5R0$D[K796*9$8+FBKK3IUWZB='G\=!EGF7M.PY64R=K7(
M0G^E@'Y'U&F@F[39-@9=+FIZ)K]CS@T*F5B9M/)P?'02_VCJ$T.MX$5$\V2!
M%G42F@Y![$PA7?0(5K4"VE[>UR59Y<F).W")X@;LI:YC#<)OK1M1I;$DF4NU
MC>T[6;D']$;*Y7/1+=X+6SSV/'[ZII9(QAX:4?*TB$[ ;T@+[#O)K^G"5F M
MI.^M\+&::'D*,UQ/79_4B[F9'DV-3VV"V*_2\;GWPU:;DHT:K_4AYX*6XRA9
MQ@6+1RH"$!!FR\K*:G>Y9)I%DAC?F01YJXC 6"RZ;6Z K;?*IV@O.@ZO1V58
M!%QFK;EVQU^/GL=7:D^5/'RBX1/]F6V2V/<+A=Y+#6,-OC?>#1F$#=ID.8SH
M3M*9%HX1*\H'[@*6/J+F9$H_]K8)'EDPU!:=4.B?>K*V$4_&E[)W=;=]F1-0
M&N,CJJS<0'^:XB/W(=ZR$*GT!4T.4^>G$C8DPX$[<^[*(P/:$ZG3V1&+XT'>
MR$PR,IKQ,JZ5$@%OGTKIIK!XY%J$$VC"D</9/6A<KG'X0(4=QS<:HVHTFD@6
MV:"JPUN.9UFJJ%(CBR?>X#:U;66H'O*NH:Y>GBZJ&L2YGLBGRN=!2YK]A'48
M_ %QPK'B.;P4(YUSPPOGQD?#9705X7H96XE2:QWTT9,/]G*A/Q+37<!PMJ;W
M=D2%);3NRNUJ\#3&O<"R85&L2UF98<J'T*89V24+OH)><&\/B,S1:R$HOBJ@
MF%";MFZ%;F_>GPQ%:*:+J :C/G-G:&S(0P[.UJ*3:@X^:@C'+2\K)G*9IM'H
M*XL?L_5\D#'/G!HRR+QCD4%L9Y4QRCO'!M*8^!!"*)N4UDUQHF2MSAXORIC!
M/:>ES?W!&'O'0Q:SKTG':)59ZI6!A&/I>-[N*$.'QON HG4E:DTY\"13H_+S
MR]$[BGQY%4QDE-RQ^=] X*[*H@@?7VL6P95.,FUV(^%[]=IFK80?&HLW2%E/
MBQM9U=AM3+CDP2%/SQQ5K2E&7U+P"'^H*2H4"MIT70:'KFE!CT<"E4"T^AUR
M4Y_ZQCI%Y3M6@K1<<@JB&UQK7[59S4@JD<M \%O4DFOP7!G*9:T_0!&("&@+
M6 ?S,-N*R1U32_5LEC]IZX8[="4*ZC/QOLX5TH5GS5Y"AW\7]0"BV1OP3*=8
M :\,]*I[&3YY*>%B!D,+_'&00>#^<^'=<7HV@RG!?E\B90.J*#V<+([^A/4A
MID1HWZEC1E.-'@4[X['M^_;./M8PV9+J&;(8H]?1FIWAA A*#Q/X@N#A1Y#M
M/"P,.!]ODY],C72(;BQ53$_HM&SUS&EJHGV09LY=4[H__/R=:$*_-9E41N$W
MNO7B=I7Z]36AH$,^0T7KXSY'/1>E[KN\*PTS']^&3  SB'SAHX"B:)I!U%EP
MY+6!)0$8\2V&L90Q=K2?1+'Z7#YJ%5MW80&<'C8LFJPKHTN1N5:AU$<?#!Y9
M2\L3:^6Z%]N])[OO;_32F1)W'&E(J&2O_ 61'A4O'U^/QC@+9','DZ:PC.=S
MYJ/W9/0DU>4;FWX=O/HX8[:%=@PY:]8IS(;-)MV!WTI*I,B"G@VTO!-QL!0@
MEM:\L"HNG\\WQ>*^0/,3A!=KDM;8!/=H;I5,#G,&\_'ZG:NC;&KED#$5EH:V
M[$U6A>9*E#V 9%. >G'']"_D)0S%GDF@6?#QE=(X&E8.YK$%D85]?#'!87]
M;($>6LAE.'&"VVSQ1%)!6OU1(>+.<7DVE@3(<"["W=HV]*B4II@U'33X45;$
M%QB:%:F84*3$9RU?_9P6$;]Y]O[^M^4??/ @>1#=&8?'IH,I8M>I/\=#Y<4B
M?".H%$K]2SS/8(*.':+'@JYJ;WI>J&V"@#F(.*Y?7)M?/<3#%1=_*O[2[_$1
MLOXK7 U5%*[W[^.#)47 GJ#S82O*^YJ0*N!2P 217;G]4U1D"9:EU]\.#S:S
MD8+J[P@2976' CB_HN*]GMHUO/]E2!W;Y\7(8=$:CU;\,%YF":X*M:BXF.XN
M*I]P!"@Z&F"3W%J2&$RP^O5Y)I%&1I@?1"VU0;-%,S3[O: E,0(OKN^1^N'C
M$R,!U8%HVT=>43T.IKBL3W;6N#Y"Q<3#*L*E6A+<.B=RD$:P8O (S]^J8!M[
M<6@$STASX)<$U>O<IU[7\8D+)N@Z.-L<8PE>)9%F;OD*O*R*LY $F46%(VL=
M,!T0U!1OIG_7M'3\@&),AF*9K8%*HWJ0OL_S?:@C.CMABSW0H;PIH"I2@H&/
M/%]1\^2^GLOV,JKMN6_*GKDDM.4]&1D1/S.\)^A+'DT^T;YH(9^LS#%&=J%I
M?IWRR+I.'4WA&V$B62,]% 9K.9S7.J/SNWL2,K.MR5QI;\> [D@L*C7C$1GI
MH ,MP?+[FA&6&8F"T=V&,FH%ELR>#Q*Y=Z7;&PY:SEH^O4,.03:7F("O0),U
M_, -]IGOZ5)R[ZQ0:U5]H!.E67=A)Y8R:^,NRENR$2'D2XYG7:%%.P.&@O95
MU=769S+Z>'MLY\<="V.G6+)IBQ\*/O[DE1\PAL4*CXM1#'XX#4Y6Z)_G=B3Q
MD,L>&E_4;45\CO[9+AT+1;?'Y+ZVY4X/HX?=)2LC>LQC:]M>.RV)^O=]H(/D
M"4G&7(NZF;6G7\2Z4]6Q+&8X](X$AE\:/#9NT&,/LF6!BU<BXT:84""5<RH%
M*!7W!U.83F#:SXCF/&9I*?]2QUE6"%<<;"3.2'0 XGO(QHNEJC-BMJ9U:#B]
MRJ,NE)_O/B?O]*RD.@*RI87SR74OT>EQFH)-0KZD :-2E>8WH/)T[U)TD]/1
M,"T+[H,2,#IJM4DKV$LV(DX\331S5M%\<N602)XV5HUUN[]P0VE)P[V@MIBM
M-@F(+_B%!_6XQ1W$1Y/>YGR9[DTX0ZMVR/_.<\XT=+>*]:0E?X(R/U/7$<^9
M,/#C>$4XE3 !T9-IN_?2:RUJ^$9@;3<F"$0=R"="K\A8GTC)G9&?3\*_-+@-
M$>2L^,JJN2T-O'1Q7GFY;C4 6L6KU"/W6&[1QVH /%M9 Y/H?Z*!?6J)FN-#
MKDBN3Z90)G1T4<X^DW/ 7").>E*4-L&J#68]KG>C8JV/8^MMCFEYF)C[;?RT
MJ]=V^K7]:H#'?D;4^%@S@DIB-&Y_& ?5H$&HS68X?PEQEDH\<W$'P-'(V\Z3
M&]([-><JMPD?3Y-S\.JN\P@Q\ID*FWM[3.=[S=U)H?16X!%A*+&-!HC'-K*R
M-71B;'(_/3O/E;'X?-\7I/X,J9US7JMMKT"ZRYYE,KV'F@ABI$29!2Q]1B2/
M!P]>Z7W$$8^[)B5B2C94]UH=/&!2+$9:C.Y37D)-Y^E8V4*@1F,K%!O&+#6@
MU:#TB#9WTV,SK+;/$SRA5@B?ERD8A<)>#+]!U33C1)FH//=B%8)>#PA,TBS)
M&Y\(*#-P075_Q#Q1-KE)KW?/T@:;K3CI\D[Q((,=Z5T0:X$=:URU4-2T35_&
MO;1WH*'[;&/?\D'GIP.UH!XKUX+[SVNV(Q*/[@HG<B0??8@PVF*5#C>A%QKB
M!/FD-0L4<<&#Z>!#MLTFD11S$.$B;2+$2HQ1&8SE![-+IN<9TDIME&QK;;-#
MZG5HQ?241B=>=*9.Z_%.MR0+%Y*9A;C.M<>)%F;P@;R+<=HKEK&X'YU&&?)D
M+]6#A9#!9BG$BYZMNH162^<'X(C\^UUSC<TB"D!M[!E%6]L$+5#KZP('MP+0
MD9V:%JN*?=RJ)'TZ.K&;4/X'/A<Z=5NTCE5I J'\DH9/!69YE10BIHT.@47@
M5*49X3A@N@D3.J+:.IQC7#W^!'U"CKF&U[O:^?%>?2TW6>+]/B/Y&#0!_,26
M=R M!2&YNJ(2E K[_!Q_8[$RZQ9F1=4/C<!7CX3C8PG46B$STQ[1R(U/'1(Y
M]*'=_9D"+<B J#O9#<E)^.6S65;-8&I\H@^3)W(V=G5C(8)YI[**HQ/]ADO9
M9=8]1LJ*LJ_S-N^0,3"+U3:J&ND3QZ9K8VF52W7;^A0$FDX 5Z6.,D4L<:.&
M\5A1V-#(HD)8FRTTNW$9[=XJ/)(^VA>0U4P+-C3DW^MQ]'KQ-+?HA)!-YG*Q
MGXVBNI6O3518X2./LJ=\WTXZB?HD[]:KUDJ1_'5;[^]E]FHYR7G9.1>ZI3D7
MF,:B>=FS0@Y3"'+U4,-QP *-A00E,DCSE:=M%@H8K,-&'+BMOO"A0]2?>']A
MB-1L+HG_7K)E>#EE2G*[)RWEZ*EEL-=L -EH!@F\Q5*BKU@@VP,N"U$+8DD_
MNJBRAA$%!A,F7SL(8_FHA//*$:%F9P<RA0TQT<BV0M;Z_6K'8F%/8Q7#VO;:
M01JZ(_ C^=E>RCA'S0\]9@%FRB+[VJN%)7F8(OMNGML@=1O&1$S^"3Y,/;\!
M5<R3<2=!M0:#C3B)4ED!+N%$IJ(MNXGN0AH2L,%TYGLC)-'2E;&3^D\<14UG
MF2A\S^(^E;8_*%#O?KZ8+#O_-&IP93S5%:T_<K+AH9H=TV930YITWS3.'1^#
M?6"DP3NCWM+[FD_,@JU ;0)8X:CX.SW&$(1L[4B=OKKC=WIR[,'%*Q1=19L&
MG@X;FR\8HM_-E'3JL#6[;K KJX]K)8+<C1_DSVI^N\M%5T3O<#KVE386T@@F
MY<*J5>OP-)4M:2$2* (J$TG4R<)):?86OZWR-%O4WF"7T"WK;55_H!I1=%=S
M[+0F+^?K\'AL24J!66FV[8F#J&+_5(.:T_/]%QE##\<&A#R--1M&"NME5'G?
M<DR'(B6J".".O:&'8$WKYL17@37QH@UTGS!MV 6]PR/"S6TI!!F)B.P5*[J0
M&W[VIDN(+&-*T1X8F72L?Y(^&??%7';\")/H8[R..TOCZ^P)PCD!3061>7GJ
M&/&0_8K/$<G)RRI--*'ZIDU(8/M@EJS-17FZED\2)CS4>[:KS#L1.>]9K<7&
M!_%6#X?*HPY2<Y$P2#'L[Q/.-C#TSD[Y:ACV[+1MGT<$9@!YSZ ?"^VFV%0U
ME'P?0KX(8A"2>_6I/>0V^OZPFCJ8CD,+W2Z?>(%. %6B*WDB@%JWR-RU:(0/
M93KLW>9ZB $"@>Z$Z]=#H%?_8O&'EO*%A51\I>GTK%*/%2?R0CU'MWVP\20W
ML^4"=Y]HKQQ]S6X<I"&'1D-CEGA"D)%A$4@/E(;.!A 6;WEFPPT7WT^JF+S(
M->0<?JTFEI<V2\)[X$F6TS#"EU8S/JN83@ ''CZ*BPPIHGA5833VC:E22KCD
M?J3-:F9[QSTGPZ$4CV'(C&I;^L+[^BQW3%096=)<1,W>.1K?,OP-7G:," JS
MCOCC/%TF80YZ'3]N[J 2/RTGBCO]!:J,)9O>CV,2ZC\>9U=S*S_5';2(VVP$
M'4:4%JU@)CK()*0C9_*^$U-^'=U6YN>256U&=<\UOHJ!/#U0<4N(AS;?+G[M
M"E#7&H+V>*DY4:7$IT4:R^F+CA2_G<90N7M7O%;MF 6+/"%;?QSP(&'=>6=!
MO5@HTHDQS%=MM/_#&TRU-!$/T8;T%B?&$F[-%KQW0&YFQF)2K+F'KQRU-]#<
M):(YQ+<%%I6>)W2;;R9MYDM_&# >G_>D*]WZT!T# L75Q' 3VY)5U,2*%#[;
M\$B%3IBJ)Y201.J%^O4?WQ6FJ[E(Y)\'+;U+9-UIH:0Q;5+:_5@:<-=FPM\%
MS\<2R.?.8<K8)XO@NR$<:U-)U%YLK=L;J:6F:-5P^2R^VP)9:7;I\5B+4<+&
MQD9#KDW!=#'9@253:(G5P(/P?=_.$F7:F*R81AVT+!GT%4[]MQ@CZ):R]:X-
MD$=PE&YC<WD'&&RVNCGE7]$2-@PWAE2;0I^D:Q%/?JO:Z7EO($9B(X1>UZ+5
M:J[/94]1#P1A?_W.-,>ZDV@9;SK6VZ"H%7;TR(%SO5RJ$EGC;1'<^'R>!IPS
MK:<\L85M&# 0/XYV!92V[/U(>>.,21M<83M/16.VQN!@]+;%XU@HK75?,+XG
M?0PDPD>\H:4]<8A;*!*/Y;ACI*R3XAI3M+316&_B3^<WE:UO7S-6/,\W4HN.
M;**]_9[+UR6Z3(<23/2V:=RWMNFX@CB@A.&[]N$GG^KQB"IO_5XZ'8]1#=[M
MD2<QO0P#FG&-!4R]&;,#5CR)]>3LRIQ@P_0CAKTIK^''][RJ^K1--)@Z*R2D
MR+"2-RQ;9M)\'%[7N-$UHH\CRJ)]0E+.+D;8.#U@N/S.: /LRO"=C]>FK0J-
M:#@B!BZ2,%C1#H=F W.9>A(J?8F/2IG),E8+YU-P[&FR26FG[)^H+;I+A18V
M;WT[I<&296^SM852KFQ(RU1B?.TG&G_%I"L-Y"Y'M1B_5T,_-A^:+_Q]ATU7
M6GF67K56_JCP@;2,C,7  \I&7@5IE=B $9Z1J*\*TFHY3A9'^8D5N&.&H7+K
M\ZL3UM)J OI,0_78SU"M 0WIQCF73=*JPGL?)Q=-L=@RD=V7TQ-A'\G<.3ZG
M:#?(8HMYK,(S2M5CGQQ8XA6]U9UI:O<=[:T/8<RJ$+(CI>:31"<IU\.U'HJ?
MZU ^[=[V3[LGH%YO5?AFEK-U0]LP!$XSX]U##!U,&9I-<K0DU"K?=T0*U''O
M :WNZPF[IZ3<V"?WY)R(?D@7->)I9++C(6C4" 1$[$T)IA%V2[1%_N@LR6X;
MF=$HK1V;I5DJ_HKR+7T;1^\."B>7!".ZAI^%5I3$E%:"IF?02P'65XJEEB.4
MS!G.[L>;T,B'U<*7]^X$,])$^7[VY@?FDV 4SR>N'2,0++U!)::O^S8GXW+T
M(O-8C/'1L/^)Q]U36X&P8930NL9'TAV9>;R,78?&C.%%GV;Z:3\RXSK"!^Z1
M+] ^IR#4<9=]C\P//3KN\*ILIY __#[..&Z/="%)TD/(38*8T8Q69<B<PY#:
MOO8DEKYY/GX33PP6#T;F>GC*TT@@WK/GQ!+G)?+JW<"::7V?HJ/FT2GI#WZX
M/ER^2)'-#V$%0L\P)=D%I)\$OT.(^?8B8@.DXX(4@>/<T/ 5A^B'Z2'=D39E
M=75(P+-5)60U0;QQKS@*M!'YD18@2566X<AS^8ASZBF$S^DP1W7W^VDON@4D
M)$#KL0O!S%'4N)?6AK%%+II?N-%B/Q <A(&%PPP#PT\[OZ4AFJQOU116D*!]
MZQXORW\\V0_GKS5:+<:R&_:&Y?-#%QS=N0)JLX_T>.F!<WXTWB%WJ"NRH@^!
M*P$LWQ\]( V+.*?Q&SR'FKW4G2O6O5,%0-G6 ZTJ&,)]%*8TY;TN.(KCH/P,
M+'K-[R+>NV6BYN9H<,2%T0#H#$J;Z)1*0:B-7_B$!.405#ZB,(U*;6&?;KJ:
MGD3WO22)GS:RZ,,:?:O#UY*"^%K;;2(^<*E<?,KX3R>V077(^.>+W01;F\_2
M]QP2?5=IVFKM$OWT$JU)G&=T?YCL3W0TN;9U02UC5=.#OJL$VPWQ[K_D5MVW
M8_\1W900@6@02Z;,]<*[" O1(N *0 W/O5T@HD@7W6<>,?#B2>CC?M5E?VX7
M4#_>'*W%GNZ+>GO;@/MS!$CTZ!?E^"Q]5X!$P=D3[N++8"JL>F.J6G2 MWI&
MS?<\]6<=I\J]1NX[451[%_[C0[SG0T#?::^+5)KS?:<?8KD;N'M>Y5]=;(SK
M7TVW2;Z$Q& <Q&:.ADE&F@JL^4X74/(/A;$K5'X=;;X3R\!4-A?S?>N%U+)X
M6/-7@DG(A^+8B<Y(F^V!NOI@!ZD.T"J\ T<\4( [O8*ADDX];P E<@-^5:*=
M<*:KW!M%PZ'5YJ +MOE988\U;KTWFE+0E"B@KD;,CE8"!:ZWL"UW;--Y)RU)
M'T92WNV/"!L$P+D^@<*]5F0AR]?QD-CM,FR"[N<65VR]]\6=@Y" )O#JB9BX
MBS:+7[GH]]BM'QF(/DL;CJ95!;[*5,B+3/*5;\[]Y*FB9*1!J40;:=7/5[UT
M7!7@<*#1,[6+KA)&752T$!]/A.:0?E%.Z$"P8KFGBZS%14!-WF3EK8"-5K%.
MG6<9VBJR-51.Q <\+6SF6+)5;,2+S69YFJZD'Z5H_J @P8=]ZQ0?KYBE8;%#
M2VTF[5W-WD%GFDS4S)"0AT@L:,_ _&(>6.([$*2!DE*65\RNFPI 'U>OB\H
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MK,T4*<SCW5:RU4\)9*LF'!#4ZEO[;$#N;="::ZBC1IZ$\:.\FBJ/L.5)S4)
M?(\B(5T5X^-U?2ZTACB$WOMTI3LF +P">LYW"29?+%D[37DS;/J/U9^0J;5+
MSMU)>;AL9#M?T%('89,;+!&NUVHN82CO75/DW9>6:844:OIX]O!0QZE3"=H
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M.H<SC.BH^E65*7'+FFZ "\4K&30II<"U.C21N74%N/\=>WDMP#D-.%$:? 5
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M?UB3G86Y'&:%4*EBZ6=L&;[Z:&\#:[W,[<'QS_/\81^/+E-TBF'ST1>\]NU
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M6Y[;6?,*0'M&LCLX<AXJ?I0G!GXL6+66-Y;M@S%5]=W<A0#[D7P3H6]F+*5
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MN$@7KRY]J*R;>OJHB>X=_W(DW&MYPO@P&=1&+B5ST[[IS:(3]/9+XLQ]KBM
M.<W^F\5J;!^>L$_J*!&P#:X]O:_\*/);86Z0](7#CT^R@J<VS'M][[\$+L<&
M-H^?!R_Z8ZJ>D*L?_1^BVSF\#B[8'CZQU22-;=NVG1.C48/&-D_8V+;3V+9M
MVVQL_/K>Y[OW^WNOF;5G9C][ULH4U.+G5O[ S7EF"KKT](F>2+K0$;_+YG*G
M\"VS:UD\D'ZU.'O_EOO74;1$9 ?>B(A$2^FU(B+,UW;.J>64-*B,?F%9"%D0
M:\W@-Z3A!96HY^>P*XN.RI$4KAZZG],G!ZO;J\4Y1-WMBVS/JJ9UU8&%+_BU
MU.,Z>F:[].0_XP%#[=WR;&#Y2!=V8A \"_/(?(,D7O3VF1F-@.RKQ+TP;4!)
MV['_;D8T/CVL<HOU;^E58'<G-/S;&CN,&Y!2X]/!]XIAAN\H>=]&O@#&QJ8.
M0;V&M"A1^(ZO9N77O%\ Y^B2U&<C#B*2%K^^YTU=J0?0?S&-&__)"!'[3X1#
M@N'?V0B*/J+[:G9_4RN:^$BXL),$8'9Y<V+_H'978*]Z\HG."H%P_#LW"9G?
MN]QU[SW9A"ZH1!P^$:Z,?YW6[<P+:67^=/FXPW0+V395ZGQNBHG]0[3K+:OF
M9/59+['<:.QKX,WT*H#[!7AB$OD" )=+A]WW2H*8'I.&##\HK2Y*Q&ZC!?%H
M>A=]1>V_ ,$WT@AWKA5^#[@N5G%!AU^ OHLV#K]K@\#N+X"T#X9X[UY"$.*'
MJ4-R*1Q$>'JK;"(D2F(2=41F"HF+$(F[85]+A=VRV!?@H+/FQ?>ZG3%J]!4K
M-Z8Z_]^[H^D-^,SG'A\Z'6@<IOH"A'4)>=GT> >/^35C=Y^3";V-MUMB? $R
MA8)SQ/*_ !-94!\J!-OR;C"P,&7XIN!J0O*#@WKH@;XJ8S_B70_ B\F]H4;?
M67Z_\ 'O/I1),FB/Y(6.D78UK_2Q/DU/B,XLTE^-W#FV%PG98*<?Y?6LBU$>
MQH[O;)JY7Q#^Y[UR5I]C+_ZC,PQFO_'!Y7A#FH%N\PG"YZ!*+>/9@PB26E?%
M-_::1L?"M\UB%,8CH8+KXH#988)3N^BBPEB[ZGZ*7QD4.L;YQ^>#]VEV@J1T
M32E\NT^PS9B):TO#R#RV*YCV.^H:[C;NSN;O5,D!$VS.11,34=O=/P&BD9,_
M*W07>=W >2P)(NKIA 1,? &,XJ:]!I;'[6#\+G4CE5[E-_Z)GN>8<:78":%=
M[2\ F>5G7<078(JKKSIOMOO((."S,/IOLB^*WUHW=LY]6DOWA_2BK]A_XRM>
MGEQ;_P*T>":M57[_5Y]Y,%=*@8<SDS"J.Y-HE-3WZ.UD9!2A?V'M_PQPX^!Z
M_T6\KQT^!G;<-5:H;U).]2^_SQTOS]TO '<W_()')Y:Z4&DGQ(<L8</W8I]N
M.GXB\W.32$'#519'@17=N$@GX1(^_W^#3_7K2_CW 3A\? &V$B.%[F*NRWP(
M(V6K5Q0#YG)*&^<55=ANT_IH(4O<^PFO*&TI@3S>^=DFU]%M,;&M0L$_S]:Z
M_WC=H@G=15^7,$:-O\'-$"V8*4$[]%Q(Q+G8EX?;&!I>.SC:\;,#8= 9?MJ9
MNT=4$N@C^.BWIK9[/J3)U[FH2'24EYXN)R:^<%IQ>V;MN*YOG9^8S_S-;OH[
M\2QW[3?G"X//T^$]9!DPT-\_R(TN%T->;Q08HE"-/R+,FA9YRK+U+;R(Y"T+
M;'<YR  '[O ZP:3G=D/&O#_%9L7>=3(#O6 D!4-.D#R#$YEPNE&.)\-3GL<^
M,E52.X02F;T>C:IX"?EN[EUX[=3&A3HH)EY<0EQ2E@Y>U7I<-#>_ @=2S+$\
M)#8[&4*>+ULM85F)9#L$U^)[JEG7*22!T8E@[,!ZS<\!UI?;M$*Q-B[$0#7^
M>J110:LDSC3Q<7J/;?A7&*L3A9J+3F(S/I9OQA?U8_83J<_8]6C!X=2K-U2L
M0>'T/;&:OBIW\H76OFT>@5'JP-G*U#.<87!<%[S0Z00]^#\D)80?*9UY2!S>
M/0S]U:2E"R"M>M#]J.$CK?[\L]-F:SP/6!(M*TNTYRUA/1ZWS-Z18:'G#+E<
MI!F86"PT/!F)(RP\!FH:'R44&?$Y[0[8SZD!EHL1D!$G+#QXN7V 8Y@CV CV
MD;+]*B04#"Y=OFFE_(ZD4EV8HQ3[)TJX:C  @IPQ5O:E] $7 7&C#;+2TF+J
M;)B56NO!GM1P#-3RQ]1(ZX[W+_4*"<!GJ3\;NEERA%+TT"VY[&@"#*Z+2>^B
M^KNXY@XJ\5A;IQ4$E(>G;6O20DQ'4 F:<BWS6+9K)90P[ @A.2UH/?4['W:B
M:OH#5FJ2YG?A3+T7%Q^=GX1TRBZ0(?0Q)!S)XM_5G^2-3,MM$J'0D-%CX<&6
MHNVDE(F6)5II]YH 7MN,</)C, T:4V#R!V@QA"+2$E3644T6?R3@H40Q4*TW
MLI)T"@(H><!QI^PYJ;Q!8Y%EY$P>LL$B(&GB/%_(15@IG?+\\B3X<7S[BAJX
MA*Q$Q/RXJ!1K1@!U"# 7J]1,CJ;83@(64CP>'4R8.(\(\C&BC-8S'OF%.HFT
M5WF[_""%R5&Z3;A8-!<^B+LO\<!C5_+@ )]891"@U\=1WTYMQDB#K-=GTMD-
MQ!ZC)D=OHQ&K(UT490*6S\ZJ!UI%2#-/B4 81V13RZB"S+=;>^:@]-!,U!<"
MK3"$<!.E\Q:F#474[MQFI":-C7)G)(+B6RE<#4[)8(/BD_"&@)I>K#6E4$ %
M3)5-2/W/8D,MDQ6Y0PPK4EH;UCAN/\Y089@SZFD^H2KX4MR-JSS7(Q%+#2Z+
M*VI_6AHNKI][8)CA1V&'UO0-*KFNKI77//A)1YB:$*X)D,BYJ$%FN',1$> '
MB_HRO](A!FCUC6?*IIO!_;\ S'9V7@T;P:=U^X*P-;E:R\B3+>9*W()-"<W1
M:3\M@9-7/KK*$M^]:E4:Z8\.- 13T]B+(!0JZ.L@Z#9-HW\T'KQ#INZ[LP2P
MS\N;#PVO%V>;J?[,L1S@&PM8W%8TU/L")#)^)YR\[MYUA88,0H% 0.G]@T_/
M _AFM&ODSC#C:+0+3:EMEH*L0JPLG(2O-K$NMUY"6UWLZBK!46,C\S,IR<W-
MC,L1%[<+G:II*32O,C'^?,8E,95-@9GVYY4/#Z_K!H< AJ7Y!'])N62Z=8IP
MCM<CJ;5!Z,!0:AS3VI,97BY.1Y4'%7K4 S5DPK<\;]->_YBH'5GS55=$RUA\
ME4:X9F%(]P[+7A( E,@6NKS\^D#043C@'B*8D8MN_=")?.GH<(93=4O^?)R(
M9@\Z.E9%3W+D2F J=NX!4CSJ(CVC]7'P@456_1O.^9BC'W6VYZ1<(W!VLNZA
MF7Z@S;INI9ARB/F0 @[<B7X@$)^%^&^2O6@B7B_8EL62F-./_.FD84/J^Y[$
M]^D]&)V!<&$(C<<R@V/IU'/W:7=_5YJGB+,$_M$>9#\]LCVLDXIAKS!;#!'A
MZ9$/:[: #ZP:.#W2'^_HV9U_ W7I6^;VE3P<*!,=$Q!C,KF#(3&<\-[@[3"Y
MTG(H\T]X#/@_JMHYK/DCEI<Q@SE<RV6;\F.OOP!RRPL+^=\=* 0;%^;'.-NJ
M2I(21#(<!?LOTQEEK"U"I*'K_M"EVT9P5;;MTD#,\+DNP-NB,\B\:0-* 22)
M%#( <.QDEAGNP H-*=ZZ @Y&Y!">=<%)72R5V05$&SM'NC7%DAS=\,BS@J3P
M31RFG^ 6"V>#TL=)%:HR'[PCL>OKD)/3E66_I^6HB8P]$\[7XJ&K,3+&FSHJ
ME(3] >;?(G^O_:A&V\>'FAJ*I$[3F#BI+?"VMM\7MM]5TZ61Z"H_=L%G,++%
M+CLFK)&4*;9A53 1B&O4'.T$%"P@E"G)F"9Q8,.:1O!Z9[<!W[)!+>OBTVU(
M^ HARE&[<8@BSN6@0N@IWE;_<X_P'Q>BOTM]F&[-<RBV"=01@Z=)GA\$A8A.
M_'B5)L-OG5^6QA[+?"FP%NA_.)^W]JQ**=QVM%KNWWR&WA6^K^2@/>L]21TS
MF4JU-@D,5/5[EV)/>9@49_]O_ V$X+C0+E:QF&Q8: *!P-N=(3Y2PF;K_/#^
M!\JQS$LM! 1/.Q_=\HK11E^YW<RW+OR>=0"*J_/-\Q= [&7.UYI?:M=)\;N.
MQEG-K8?X46FPVO'[LA)1S+U0%M71P'.4E,K9?:BM2ZB#IJ-3UGS52!!53Y7F
M_YV[^X^HA:G%YLDZ/8JU"%ZOF!.A=[??5/PO-R'9=8SRV*=;YPMV3(+>%3/Z
M?O2/9QK#D?\C5PKSDRY!4:NGXJ !3*WBO=5F8E(1+GT!_ K^OQ0U-^#MF\DM
M]U$Z5>B1?)E#_)HYK++/T1EQ5^[O?GGOIT*<,! T[0Q+Z@^PW]FZ1@3)S(C_
M=HT^___E287511?SO)\MC3AKQ3AX8@I">+L ^6=AV/^O08+$0EF]C2WJ].%G
M8:S28-GN5-:(P01J)=$NEBQ-\3*;=D,)DC\0CL>89>K+ #-:ZH>NDON3U>.N
M^87*,.Z]--@T$\_6KA)]3DLK@VM<.AJT<J.R9ILFG@J94$C"/<G(@O&'7N7#
M?_!9K]^L_C(P[EFJ ('55<S-BMKRDK/L;ZJ6O]C6?FC_OG,E9Y6E=!/B,%R%
MKRACL(Y>(:IDMN@5_/S#MU*\&M58=5%'Q*OJ-AI[-5&7RYJK+&(H+^\F_:U,
M*_PQJ@@!7.<6PHW*\02U6$8-CT33'L:F,$'7C"EVZT7 AKJBI;"J4L%'6>WN
M5;+@A;.Q3F=.BC1VB:V,/3A!9:2<F0IF.2*]U*9-($%9#:IFQ#+>X2)#8_%Q
MGI&0A-M==0_.C4M^R(A_/3XAA#S;J(V"=91]7H9-GF*K7Q]?H<12?5/%D;(?
M .Z?DFB:"UDJ+&Z:9@?V7?N.Y+FTRBW3TQ1"%C<Y^B%>T,)ZXO6BL5_JGC>'
M'B-)BO3!=!$,A4TB:K+F\;(20Q9K$O(E#"P3!8\5[$B6_XXVB#[WKQ)=7.8D
M#3G#I;*VL%46.#,D)MK1Y5S!H>OKL9XG<D;I[EF;;TR5E965$E TMGY5/=Y)
M>82<+0DR\T>IH05&'Y(G0>RE5HNC$B=.[#1] @X5M]?<)'N^39^9<%U\I+1N
M+8L8MP/= F.>F-/YY6^/:6^C/^ RA_'0]IQZC&K%S5P._?X)4*)U>I'C3<D4
MD(XSM"!JZ%\.Q>:"%L:EAYK)!XY "<A$ZI+-N& H.,[X".I@^3D>N'."+>*G
MQT<N/@VZZ#%!>,_B3?# ;&R$A'%]1+8&&N$(B>L7&+URS'WM4M4\0TX-!-4X
M57L93P1J=-]?=0E;;^J 7/*K+*PB\G593'A\K'Y8+*DRABKE5&ZQ6,#OHPN=
MI -+^[:_F%14.\$8QRY"@ERJZ8P\]&PN28,2_IWUFBCXI]=%\'"C5M/Q=9G+
MF_PG&"K^LEEU_H[4F5.\Q3M(7+7!(IWR:<!$C'$#M!+^ -%HS.._<A(ZB V*
MJT"@^7'?SC>USDF/*,5':G;A7NBKTL^C2$*>,(CX!UI_Y=+S$7J-C1?YS%M5
M6%@9 /)?_2F'=X8$Y9;"\&"@H&T6**?JA@K/!3<@:[,GK^+:"[NLU<8 $:27
MR?B\ I$D6AJL6 _6 "%Z[H'-Q2EN5:L#NX2]0U+"NAGS:MR@8V<VY %%AJW_
MSN-"%1?$.;,SGLI$I7J6V"$5@^.:V>(X5HW.J -\3(@_R!-FFR9/@BT7W4%U
M9)R3"U4]#Y&(B_][%46$G82S^0(YSF0-S&*7Q#B$]KVEO4P:&B 0O41<K,Z=
MP0ZB2]K7:W?GT2KEI0; _ C+IG+&G\5P@DG/$MVW4SV(KV,&*^_%B"Y(_'&3
MSL0BY]7N%#$>*#<?ZTF:Z<]VO5'U<B"J/!F)1OL%$&9-5Q-4@?:8:<16J4=F
M(QF/,JX[86OJ=16+"MAV7L>?0N. ]LG3R(DK]WQ;5\." ;SO8%!0,>C*+QAH
M:F4ZATF3F^#E0<2C[[%* CEQ&>?<R^>1-]+8HA#ED3(76G3")ZWYSRLXU44P
MS<E@"&>HX$4C37+ZG9Y=_B#/\(T^/'G!+F/K<HC@<E+H857>-F@0#VES4R.#
M&5K0;#CUE00R"B]4\98A+\>=BL..5&=2]JU&_91Z9_G12.VH4JRB'&KZK;1U
M2HW:'_^!O)I#_+ ,W<0T_4\1MO\L#,+/6LAZCXM@A,J3[)-27H  Y$5[3JC:
M;DY.!P@"(;K F2_W#L&%QS&39^ Y*UV3,NQ4L$EOGCDRB05XA5Q2.MK[TLH4
MWN=U/&1#)-6DX+75H::U<_&@VJ">'B8*TP:?$?JO^. 3"$?TG8X47Y"9QX4+
MJ;6+"*--)U53#;<NC>9(S8 D;1X29K2,18XCG#(HZ]:-#-X;[AD1K0*N*1 7
M6/HG@*:X8UCOUW-E>F'!+ N#;I>)WBEFJ:L(9##D=V]X?QG8TM8G9)VJSSG9
M<&VX/\FR;(7R+;JLZHLHVU \=W,"U1?9IAR*6WU+$U/4JIH_ Q*4,)[='%Z.
M#2F?Y5</^U?Y"6*Y<U"*CEI$'9I$[L,O<2+WUY_1HQTXJ[)3FTY/>AJ!?6N$
M*8R2A2H%/YZ!*:(C+6'[?6+P_)G-AR&;"XSX^;ZM2YS1<D*9[!!DA*HD;S9F
MS"/J9.W54Y_P0:'-SW)4$W@:P\RF8H*$U/3%<])H/75+0LK//L'!0KTI/4TS
MAGCH!1W</9D9H_7/P-^<J >ND1IR99I1K\L-H[H*/LWS95T"2+C-CUYB?;@A
M#,JGRJBE32(M)%"[2 H<9P;GYZB_O]NES7X!XHNVGXY[_5+L5:!=_L?H;3*-
M<=;X0!A*SSKBB+="J5$E7V2B=ZU3PON#$9/NJ__N)*(2'6@M0LN" L?>T;(L
MTNA9Q5$TN%;'3TA.L=<D-QPKHA[#*%/E0#3S+<A ^PZ)JTJR :9>Y^@(CMZ$
MO![\*.K,FT/ WD.&H@.2RK>86A)1/@,\/,U4G+P>JR[$:S=,\4L*#TAX%!JF
M]<KO&C\F,VYZ]?R(!4I%\ZI.B>?J'BOS@%FE '& 4*[8%?4,?^!:C:NTC35T
M7J'5P- YDH3"?<77-*%)*&.M"G/:R.)&;E1%: ,5:>A#-3%A2_N23/ZRQ%7]
MJD23XT8R<&DZKOL"B"N2Y6Y4QX;^_I!HU?;@ 6,.0 6/ ,->>F^7(545_49!
M3@P+>Y>4R8 1/];,*DWQ9]!1S!'"/L*I9658_ 7F!G4G/LR#(# NV@)Y%8RU
M(%(A?0R*WH>PH6V+'#T-^B-DI)7-X?>CZ6.S]R/V6 [0U];L6^.=")<$:T 3
M>+Q3W65@VS%.44==0H<^M)E>*/FJG/\Y*AJ\BJ:4HT&8E_I =](??>F?3 4Y
MZLJUJ+6L)[TXF#A<9/:RE#(*TWJ!:&*>*B*,TN+EP1C<^2F$T68;P<Z/W>9\
M%*2-<AIHU^*35C@;8[3*I.^CN)0FQZ,Y;7^A3/&-[*58D;WU$Q"<KW!DB%MO
M_"UD(&MY0LM+(V&0[UW;VXCA5&EU6!?2\\)SL$.OD2GR#>&PPEJX>V!'J4N]
MH?L=(\(K$152S)/PXP>B5F]I416 G1ATZLOV#&-UYBZU+E!RIJSE/1.';"4J
M3(=,'7N$WYA%",W@J2&,E0&ES/!NTI!6ETX*+8#R%BN0'#%RX%'P'/N[>._$
MF"VJUN]JQ!R)\+"3%0]K=GEKKQ,+=W>;CFL2Y<+O'L'DN69P0V!O/\?9^U3Q
M>4/!9K&/%3#CX&1N*$0@ S&X#?7&K@ H"VHPLW?4HZ?>G[]PC0W'R9R.=</5
M'R ,K2MF_#'-QV#EG6MKFT7EJ*'M!@&D *4,Y0",? ""Y"%!1=]FZ<> >9@;
MV'BI'PDRB:*0*BDLTM19Q<5!M >)4OW@&F<@-D*@7I(8<-,,$]Z05]P4H=11
M918)_/>M<P!>/NVN\MW83MD**5@B<<*?6D@@FOIAQJQ,C3BF"XO%PAB>O[A0
MV=J1%"<_RMYIH0''4[UZ">023U[ $7!5XH"1X0<,HS 4S?44?XR_L-$S0]TG
M,N.:G2'-P+[[&\I[@=]Y0C_3X+7#%^!S^<3@?6\[OYW3G36O7 :HJ;!JH26S
M\7LA#HK92WVQ7F,K@E+-GF;-6P%T6^1WZII7Z*;8:)J:PH+8<'G!;,'^FEJ4
M"GK*,6.Y?N6T9K@YV F.'>.*W1_GO,Z41D64$0WRF(%+';V)9&NMN] 25;\Q
ML0+\Q4D9DE<(A&M.,F,M& /"(Z:8<A/OCH>.=6GKZO):53FI2EN<1K44:I=?
M#6ZW?./S$U$\JI-I./O=M/#17VW5YAA0O"T^?RLU*5W&36,2XH. W-\DARB
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M0?GXV/ )]+6K1%D]\=X+KGUIOZI'_?BYG:7YRT6'A^H:O1+]>8\7J95)F2^
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M1&#N'^(W'/OEZ9C+PI_Z@ST>ZAU'Q 90XL;BT/LX^!C;3?8HKZ#X_,)0?U9
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MT+!FQO1_W2L_;UB._AEM]T=,JKHT>9U'G<XVW?1-FP^M+4OWX+S@=.^@>W(
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M:U63,1;F0]9$E79F$3\I&PK,+"2Y.2J$?H*:'7F]B2)*MM%TWT>5$; ^+K<
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M9Y!_Y82TK\-OCRD9129X?P'VAN+L[]Z.GB^VGT0;2H[K[XL_6/9\7H9A\K\
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MSFR^/#.SCL_?&5+4^"=?(T,U8?V[4 G MX(&!51'-^)JAAZ_.R)5\G"+;%2
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M0$R6*!/2""ZT41)!M[SF!672EZE9#.6G@AHZZ'OJ+H3P4*)6:B!:9/LX4K5
MLD3,4EYT$UM"7.'>+G=NZA-T%\*Z>W5F(2RSO7*NM5+M+"RGJ[H0(3QV#FV%
MPX6KB1/<IF+O$&)9<EAF]VNC@#)'>YFB7L&^_,PM]U>N= '9W$4O7Y:>%D[[
MN2P+G[HMCU&H.[\'K+NF!?,&Z3BW:8NW+KZ;)./DZ@A\AED&XRTBR0QMFY@1
MY-6-YYI,2>R-9DFJQH%M%B$%V9X/5W03CDRII71*.H8R(SO@ECXD.&S/,NMF
M4U9^>$JK-CTL6<XB#4US,@HRD0W\29FH;:6FS\CLLM)W'TW#S') :-&V+<SM
M<H)!^RZG]_/=MNMR*F;NWG!_(IP/O7&JAS51EITHP:R_#\H3*8/^84&2-1\F
M.QYTLH-3FYT"_6Z*[V$!_#[@/AXUW-LC8X)F4E(!/5G1CB]XS_*2'$(,UZPA
M56JOAG8\ZY_1Y,W^Z3(4RMYL"EWPX[CQ"WT5X)=+_7:R\HT72P43("U9IJL0
MI6&E"WQ]+!.19 L9@1GF0Y13U%TESZ::I:AO0$X -"7%5)-18*>D2),$SRQ4
MCL("Q2TY1<X160$-*:?N^,^?[#5%I#03OHHZ5?YPMOL'TZ>>C$9,%6S]D;^2
MZO=LN1(S-NHED]A0CPA+KKH?=4MQ;<,G6W$.,_H:IT)$WM-7-91SBA%>GR.R
M0*3@V9)<$D4V\MN9IV7N</HPUUL41 H]S7(U':*D8/":)DAP2B770-%$% 8E
M.[&9\ZI>4LITQ1;D*9=8ARUM+=_T< N=3[S8C67[!9C,M?)D)[?<%DA*/?GM
MBNQ4%NB@(A;H4M.OZQ^+:J-?"'"8C9 P.B-Y1KR,(R@&!U.=R/\FQU.F^O,$
MP<4LI3K^G)@9&#Z%D83ARM2T0,1!'37UW4,/II'B$+"L8F0.;3MDLT='R_22
M97''<"0YU:S*T)%V;D4?:G\58\%:7JNH'"L>3F4=4.%6;4C"M,**G1!YE="G
MQ4?]K*&N]^+3C"ZT(>9INHJG&&*VPRE+<YGT6?C5WIT87V@DGL]1Y(^$9LL<
M9)H#7UQI:,_:F"A0]VM+GA.=&!:G:[569/PE+YNGU'R)YZTA(%.J=H@)B4!J
MOC[9OO*&.=@LR_5G]E'N8ZRO7).CV8RF95AEOS3]+#)!JHSTTT_-9U/4:*YZ
M,PHC)N@?C))B#^/0DI&04@!)4,F2P*$-=TEF&0JT2'>0-$\!)65'J8P2(1AE
M-L0;/=:/_:BH3)+8M,G,&HM7YQ=N>^HJLRD)BZ,CFTD];>[0\\73^">AA_H)
M+%!MD4Z(U. 6 EY:+L.)\,!5F)\\U)30"7]8\[,%&;)EY@-I%W $)!.TU+=2
M%;O">(ILR9"P.,$+KT:EPL@\ ]*2\^=@J&2T<L/W<&G8TRNMN$I$[8TS NW8
M2W*%)RRQI=Q@BSP-R'1/IVP(1[7H%II_#SV\(ZY9YI\@F;CKAFF:>^GHAOG
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MRX5PG-$37O;^2E_K>_^[9H]1*LSNI47>RZF [(0]=KH%PHX-Y<1! T%*I*:
M;)HQID@G?2^76$UR6 Q%[,"2C(-M8=P50+SFVAB,3%(..@Y-BS&WS2J0@=T
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M[(0-*PPX*\RHJ!(TCA9RM$'TI'72^:5&QA*(<J:^7D$&?J'Q[OU)U?T@ VP
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MPD-&6SZX4SXJSR+E)B27 \X%U#Q^]SJ ? MM7"J /%7SB/(H,O9DJO&RQ.&
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M,"TZ^+AL16B\.!C>8+<<HDQ.I 0/I&+Q:"""(\MUY(" 328T.TF3']ZCTBU
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MOWCJA_D&%'-S(LEFP=^6M\&4-[6$_ %KCL]5C(A4;@QZ];(?;"J(.J!$PA>
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M\A^3\GKG-\BW'AE/TM>Q?*IQE_J/,P<?75WJ^AYYZ\8?Q= =>9OR!T@N/%7
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ME3OW#N0(B%=R>6!1M#<J18D1#@NV&T#"0]*T/%\="_"X7#.=D.FR/===%K2
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M?6B&BAQG>FR]R0:ET-'RR,S47IH0A=C+OI>6_G(J;[,J>C'3SNC*Y+.Z@^"
MP#6>9%PE6!BWZ7K@21)9OJ[J?^G"_4Z%9BQ(R![N @A3863$")\?&MV&V _7
MW]T-&.'>@%H1%,1?U=4+1K9AD^OB:GTRIV,'X;,P(HQ8B:244RKG\YC:-?=]
MD&WN\=E;)G8B\C':S;;O_PK+$BIO=:')(2D' $=_CUF?>4,I1V,YO+G\/C_)
M]%>)>W]Q$L1_4L(L?CC@73H?%5Q='7S;W(GQ%1.[^(-VY@2E)# S!$F>Y C
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M5J.&4^WR!>%:88J$'/ V"1RF "QJ@;XG'?7"'@&IO#0P /CLJK/H,6J:('"
MI!I^!!45P2$UMAFW>%1T0  *]3K#64_A *OP43LQZF02QR\<L1##=HT$6D6Y
M#,BU<@^6AK5=<#3AF>,T432XH*X!5M022'!$XF])\7[TAE\ 2^)*D A"$ ]J
M;L(>3P)8WPA*8&Y3H 9( :6![E<]6$+ O66"]'%# ,A64K32+"<HQ+9='"[G
MI !%A6 9/AUR@'0(3$(>$QJ/$6QG^&<\.)0H8)D6U(P!(GG0L"?FUP%RZ@1L
M^I79E&D(_-/YLT%,.*T=./#M@$^AX5BS[T9DB_$U&O6S\=C5=41=BH:6VYC[
MY)R48Y.6GU0T>$6..1(*#@*VM#HZ&?7-.6$2^KRLE+:KCIMG).UOB LQ4:"V
M"*_3M1B,=I=U.YF@#FY(5"Q3:K#H?&X2!-2KU+$VO<$:WP\[R[9.[C<INEKN
MXWB*NS<9.367=]?LDJO=:DO:COJJTU<35\'<2)+&YNSQR_82JU/SOI](DZ[8
M3FE59RL*HF%K'F*,P:(;#E+XR#(_5#$-)@(09!LQ8**Q"BF[0>&&%CT"@6;$
MBGFP-3P46\J1<K46&S#_^6T=P*]V-TJQ_+-D!UQ?B9=#JI8<@XX(Q5!")SS"
M'B-3'6'M;!-CDW7::* YN0/\7YR;[[P;-DG_!\MDHQ&'T8J\1(#6<V14U=0"
M\I#J.MXR_??\L82Y\3,X>[,4HMVY->E/94G'4]KL^3OMYMGDS(SV[=*5Y'ZN
MG'&% V(]VLHB:P4%_C)$<E]%LYJ?/T+14NU;N1Y+$"+2!T5$DO14B^$CSI[[
M[MW%G)8DRH$XU.(E@\*.#VM_D.65K[EDNPLI'IHHX%F":O>&KU/9$2:D^.M5
MZ<IX<GT=V<W2L59QAL]>L%K\YCI-(DJSK*,KWRHT)#\7\"?9$N#LT1J9J<&F
M)P&8TG#B"(I@UO"_Y/O5?^G5FDIX+!1RNQ94ZIH=A_-,I;E29&Z$D9ZQ**Y
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MPU';-LI1UDKGW+A)+=L.!D3U<8=_CYP]&JG;K[_M?,5X!WUDU3#\B<(VNHA
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M::[@:A7'<GGI&0\A$H\L[YD0-H'C6BG$5MY6OQ=1*H=R>,M3#^>Z-19 Z$!
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M%,S3TU1,1#,&Z?89@!>/]*W?659A.E8!:-F22S^ILM'1C"RRJJA3H+;$ 2$
M6/'A'T9GI#,Z:Y5NC8>@!=9&"M%"&XR0J1*-R&GO4U14"K8J^<#;,L'7 7[X
M2Y\+[YHW67N&HCH:NFGY#6B-WY'EIY9M.)=T[.4ZF:_V]E?V!JP4\;E%]&DX
M9O7;?YL6&5 F%=CA]?UB3R,[^.7)4V8HLSU*SQ:4-U:=UY4Q[0LYF<O2E-T#
M@48%XQ;H* &D:,@57;%"HNGNGC_=[=OQ-Z*J1DMD.O*Z%3DV!;'V/I^&CR-I
MO@!.K"_2[TQ'R/;ZW<I"HKD>*_CZ&SY_'WDJWSE?_YS&G.7CD9NME<%^W!H^
MFU"S'+9E2J"$:,YV&[]BP@^M/!KHYO6V#VNWQJ^@3+@^D2B8)@]LLKSIF)9^
M5HD%->D-5$GZ,PYA0GP3+O"D+:J#4BWE02Y0[ K)7W.WY_T\!AH:^.N)R*B/
M>.%3MAQ>#R* /7%2$,VDUDY2RV4YL1 :<HK?$->F=.\3%2AUZ;5UML+Q;F15
M?\O_G/?!8*SW^9GZ>3PDWSKJL*Z_=[AHSG6(["(D6N#Q^.K ,+)Y.:PEK-ZG
M$[TWS@^5CV^&L58/V<TR+'@W0ZC/J>:G_&2U9?R*\3:BPMW5BO<%<(ZJIOH"
M;$JWO>/H"W*/O^V@WPY_ 6[ME6R5TA52=E($MLO]0@5OZOYVM7[+8QC6GMQ2
MP<\?+!N%%?(V\=/Z @2/D$V63CA,$)[\I]@7P'>K[0N0G567WE/T_F)U,Z*T
MO9KZ:M+R$5:W@<R43=-+[5TH](^3KB^7VQ^BW:,J=9Z=W^0J#??463Z.J40_
MAMY!Z?[=[CY[AW?_I27\ >>[__G6Z=2[OU]%=Z>N>T?K7/Z\1_77:F';X^$Y
M_7])B?N+YGM\ 7IN-\UHWO"!YGY>T=""'XNE97]B\KOKA>BM/HX-YO]C0,=H
M!\F_'ASAW+_=-"5J'];,?5W2'HCO+AO%^2^CE;>9\/+!R:/_HX1\T=4J!/\3
M>."BHD)Z\/?E/SZ5N/61['D6]D^<U<IGS*9IN _O;!J\I\6.2>77WXC] K1/
MZ]XAU]+3ULD;N\T]&U/]M16V;8SS_[7^O[Z*_,\@DOY(=_M3\(:_'/WW,Z*A
M^,K+6;0N#HUH?37\^4_Z!0_Y_W3 _) O7.RN)<KL=ZP=$L +=S7X(:NO$73^
M$5R,ZK,I:7[[)%'Q'PEN$@6./]\E5R+5*?"+QZ8+SI\D'F0^X+=6RO!'>?R'
M@6U^I+<( NV5F<2%%MVJ$/K7L#OVNJS/YC0?=5$NVPDW'S&8L(7U-+Z97J(!
MDZQ57>4G"L(5<%)@208[!:".G.=B$+)A_:%L6:FO)95V#]=>Z^;JY/.S?IZ]
MKY>X;Q*1J%]=54]39._<DC[+1XHZ\LCV4B\O',A'2K S60C?[.,\*E7A@A0[
MIYK^-SC51<0KF^O$5J+*!V+SW.'0P[<0^%L[;E7>+X X?P+QZ* N$6$Q[!,C
M<Z'GL^'UVS;+B]'OS/SI2V?TWH*1]C]$\A_?6?/G( X2L'GN/W^N_-RO(ML#
M(*^O#NSX#/!\ 3P$EN7*\QE*E$@R24&=)W32V<[WO)H"O_TRH^A<B;304R$2
M>I?!1C#>T<EP!)7[:Z>C>N-#^_*[6BEHV< YN$H<N,^/KA]N+!9HOYVXU0J+
MW$^JF(XNX<R&?P'JXMY?SJ '"'4Y:?'K'7.^ &3HO50+0LD/0Z>OA'R9DY&T
M;!G3D-PC8_Z%X%U? ,+6'E6BAU)!0Y\^I2\ W6I]73O%&YB2UH/XWQ-O>Z6G
M$17_(_P_7P 4R+?Q/V434L^40H>[_@-A!YDY[=;OF3KU@N<G?E<HD!YQ1;S^
MPFIQH(^IYQAP'[^;Q4/A+-N,*L,>(\;F/JY+-Y;H(5E&)13-%72J7UC[U%01
M7DP$ECR] KV5B"L._07/RG2O*Q@)7P"??B/N715U2XU$05*1NU@G'AM.VY0N
M^;8+N#9[%>[H8G>B)?HM47"N^U=,_8B-/,5\FJ,W2I8?>,\,"6]]#VFQ2B0X
M$QY!$>MO%3.T9+],]AWN!^>AR5- %F3\$1^^1ZC.<R$C^33'3[7,'%;7&/!4
MZ\X?+(8DDW*)GQ\U!%\ 9;]]BT=Q58@OP".:?1XDPC\/D6F\J&;V' P?"\(]
M[M(KK5XPE606KWSR*WV(9KVP#4&2RBC[U?]8@ZC<+SB+WL=@XGY1S7XJ95!;
M[/\"!+R<$%)=^!$M7&3?[=N<86OF[T#+^%C*](X2_LK']VZL\JF8$K(V9?E8
MA'X50,58##%ZPV%8R,JB9<K?28A[]$8\+S-<^4S![P6-CVT4S@;(%QI#LW;4
M3612^&1CWN5#5W_,](P%SP<K6+]Z*6[=7;U&<#P]>1>'B0AI-SH%9Z@)O4NS
M1L?:OE<DOBGAH+Q?8'T!-#!B#$WBQ*H_?91\Q;V.R0ZODH_SU:C@>/P;3^]B
M;W*A!Q*DUCCC)P=X=H94B-;0'\F/F?1V<M$5.S%L1KAZ7-)?LKFY1Z#/GS=H
M?FV4NGZJJR<?M'644N+@"^DFCJ_D&.6#BK.2W3#IZF*![71]S#(MG5CGE+(^
M[8MZ+44_^I)SOP"&X[1<XS-#UGYJ=VOU_G0PK]=DJ@[0&"D9KNF'?P $J5T*
M'Y*X&T06M ZCYZ(.7X"(!R%:JJ=:VD]!Y'O[R2,RJ?W C^5443E%/R$1@AV5
MPA;:UI;L\P\8!8QW7^/W7&'JK/R45]_9Z+K\L"RNY(=E^VC4&U'_K2] QJ;:
MZ- ;05QJYW\0LV]S676CY]&T4@9^,#:W>5*7MAIE_R":%H^ZE7[4\OX_TF_1
MZ>MGM 6-4B/CRQ]T"_&V%$DKO7+9B/Q_DSW#>9P(8E#"/S$RH-XP?P%V->AN
M>!VV#M^#OP#8'3 7SFO?='D]=%Y^E,'SIR5F5C)*W<LLTF;7=2JE0L$WFM3H
M^# 'LMY:<)CO.5'S(PT[M$JCK(LE^5VFEXL?+T56?P$Z*;@YE6I@\W:.F9C"
M@\YZ:<F>>MCJ+MJL4A\-?$L@!"EGWYKRQ[\ _Y:33-<U BV^]1NU_*.06?[X
M!UD>TTWIY?"!E.5;6VO:O\:"ALU!J4^!>;^NT8P"3,<";<)Y+?WU[LRFI]P[
M+U*K<=YLNA5MP;V*6%1Y*M4CBF"#9_GOA>#$N2)&1%)6Q;_-_K#0/8D&VR5?
M&4U.2:Y!P5Z7)1/0S)&O7Y/3+(QN5^2X*J4$A>A'EJ^2,YZU<?<O[?K0H-.D
MC]_\4#T5Q.0@E"?8:(]-WOU!>)TQ3<<C%G'>$?UXEQH M/Z&=S- A.@LB$OS
MVB+#60FB352=,3IFGF=]42KR62;@/&W!-4Y89&"5072&&5\3%D0><(!E?M7%
M1L;RI!K@_N&6D;DR8A]"*L_\3=8@59AL^=Y0TA,C3%LYB$+07K:P$;T0A%!B
MZNS:[VUN[<H8.1WA<2XF-C#1<5+=_/@;97Z1LK5G2^<4QAH[*%'81GQ<8WI*
M'XM^,UZ^^0M (5?_J??"1?/B:49=_'#P\;,Q] 1;22 G4"1%SECD\)H$5BPW
M\ O@4AR <:P>$_&][8RT0I= A (\/9RL_AJFC+C.I59RPOD+ ',19GEIY@X5
M:C!A&$E-K,CUJ.)4HI:GED\A7$3A%'$T5ENB>A6Z$ 6><&B$I/X,* <SJ$1/
M"@JXG 6#K. E_46739&"H3HH,@X%^WT<1T+^+16['(<\59]467U^S#O\WVJQ
M3 LT@4^"A4^E0'I/"5)$L3"9V34CQ2H09JJY(ZY"013 SR,M#PGS39,E@9-^
M2A#891P+!Q0"41*^LW6$D0XFZ#A&>.LO3X2N8O(9'?+$#B3HJ \4\A]T!%CI
MDCX"QS3:(7EF%-V_9?;UCZWQRXPMD--9=\"G(>BI<*>C@"7!Y5F74?'/,@VM
M $4*\6.DLE*[9=1YLH$-] =]*<2V4*R5 ;7,E2$Q:.")05G"]>#!62!.ZB;E
MH8#RE3!P0&==I# HYD]IWU59(0PX=&7)!#?)FI8R%JVH<%"HHVB.F<6P(ZA4
M- 10YBV-*5JM=^)\#@$VQGEWJYR3J@E6C1Z\C)(8!%X.J1Y+JN[:28=WE%H
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M!I0']=B'%*HX>X=I5EMY<9;W$EG41;YM5(8<5[U@L7HI)<F\K#T*)O+UVVA
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M)R'.0S>NE?B>=6-'2#<8E%_PX"4DF^KH-B^2."2F8"QSZ"9%DA1NK_W;=$&
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M>-2[;#%@/2S-%V_IEUPS+P%+JW\<Y#TRO9]9::+.,^:F\HB=XA$&!!MB=G;
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M8RD\3]HE"^FIT #W44A=SJDO2FR!S.*HOGY[H"[E=[-41G*QD'2(F\UB$HA
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MVOP8 $V)MVRA#--+O3SJ)@#+.0LY,K3$$A3NE#6.+C338A:69$H 7N&,H!1
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MI>$- 55U]W?BZ\ AJ.:$Z(M-"Z. 7S8($-38KK7ZT:YYHL(:9_6>'#7N80T
M3L%_5IV55S"&G#GI7VZ'W(:@<#4Y:]EU[3"&I/6AX]ZJSPAJ%[+H5KE[6H2B
M0AJ2J&_4[N*9-U76$-%ID^8+-2[\ (0TZZWU[A+VSA#1.#Y BSNO;RK"&E-!
MKQK^G-WA#471V/'4+V5=>1*&AJ..5&3)$<$K1ZT"&I6N0"U]Z<BJ56$-%&8[
MA?KX0AI2UK:6]V3PAHY%BNO=0M:-:$6+.$],G_DJ7CQ^WGPZCKD^X'&V.>O(
M>V-K!>0_C'U")?&YR2$0;H6NI'LILA&>?04B_%R0B"KGJ"$HA8WR&+KQS6:4
M]:VM9I*AYO'PU.DP<4@/F11K*@$* 24(!*A=E/8\',&48^%+,:XIF0@E0%0@
M+8^< SI'(Z<D,V',C^8CV)&:@N)7KS"QXL+W57*G?J=\X*9)/@F 25U]VV#H
M_#QL"28FR$N$:GI@]CK6@CY7M.USX&+-**@G(:&LLU7/-EM>-N97)9Q6U.R&
MH'$?%P$ZFDNE0$NFAE\P@O3,V*S@?K$RO=4%KVQCF#[6N3MD^V[-@8N)AH)L
M/#Q)Y3-+)-+YLI(4 RD@D(Q"J%C)@[%LAGDWRH) (!FE** 0I,R&H#%<K1DV
M7VCEU1EJ<RZ/?R65/YO,A"RN)^N"/]'2.<2223E9T2:?9GK8G![O>))[I0GN
MM)IS=,[5A)AD2S8B2J0<, [PF2;<(FF 64@#SD8+,A,;LFQ[*BJ1*2448AHA
M<B8!900P9:@ RB+NE_#G"O9Q$%].H@2(57Z(,'&0HE\Q]&"<3J2F;+S: E *
MHB-<F2RNI]FMJ,I(E68X4T^Z#)-*#++)-N;WBPI(GE0@+,%) *1G^Q6RJTR#
M>3T9P4)L#.4>5;NMW%B4A0U)3.VDSK"<,Q\3.'50U'*7$+#3.;P,N+$HD\HG
M+"=VAJE+OVIHT \:=4PR662R"2&DK-TMMYQQA8>X))9))Y]Z3#G)\9-B 2RG
M>DW7PRA\7B*710@L.BMD&&3,2I,TLB&< $"4S @J)@1,B;TIO,4B;-D8N$AH
M^-F=10\N@9:S,HZ*BA*9I[+,F9HAIE "&BR?7!H=Y ID>-F@,IZ8VG?$B3$D
M2H^%NI,,0@GS';"F!0%R+*1J_8O9D)4(X1,12/-5%G05%Z YB)E[P\Q,-YZ_
MBZCA_-Y)!3(S,0M.S6/+4?*/0;3!DK+1#4\9/KDTR*C162PVSR;#,?9G:3-+
M*A682D+XL3 32SS2K+-A@C[U,H15J&*/L5LSE6"BDY#("A&(00=X."0G%Z37
M-DH^B)#,)],JEDL5Z,FPA&97#,D=Z6-3>=R4#("E).P47<D'+*:V<'P@VG'(
M DF"H_F *DA /VIBD[7\TTW8F;HO904)!-/-,^9!3[82R*:5E(!"+;M1VZ=R
MF%IE_ U5)YU$U)%2N#,)#1$J @64RA]/A4)(\<(-;N%MVTXOC"9,23Q8),QD
M !$H<R$X0$R92$DO8B)/1>R$ C=)-$,[$E@?/5R54L'<7SU$</E*PC4;#MS"
M;Q+4-24KC97%0L7*6H"/J,2BN^\4]!,=U/4]@EMOU799!#(JTM-#7GYO"3I9
M999=P3>-683#!FF.&3(9I1YLN[,!B2^<=\ E!AMNQL2]%[(A,P*;OFD;\H$[
MI>90LLP 24S5,X<Q9-36;DD'4-NI/*GDZ<N*CJ(T]4D4_P"Z2\=D4(/7*2DD
M#T&&JT:8()9'>9.0I(R?&7I0"=9=[=&\DIV>@WQNA,(B:8&4K1T8.# Z*V4[
MJS "8[I7?('HI,F^H"%64!#>MQ1EC:09E\='.WU02\S&4S";RV$B(J4LFDVI
M+1T]G3#58@R,^Q4[4E >=XTP0&D4D#O8=HZ6VW%,@)EGFEGDDG3#EE&)-B3X
M>'O88F)W9<.:8&8+B)100AV\#HO9,#>() (FF )GF,H ,R3D%3,4\U!*I<@1
MC6Z%)2ZUM22!_2C^<0[Z&BYD8,32+!F0F-%5A.Y,[G+2+^L%5L2AD\BC;+0P
M0SK?Z,VG&Q\*;? ,L\H$T@,A(EQL'#Q#(4'I"7%4D(LI#*2G/V_ V<3B4$^:
M5#3HLL\P! )"!9"Z&^2Q[ RQZ_C)=+GT0X\VB(F#\])9  [Q* +N!S&![()4
M@Z^1L11#9JK;.XS9QK]87)$! JJLO65%3]=OU.0&X %!^IV]SXL:T2JG=/%E
MN38%*F+5C.";>&VMHR2Y)UQSXZFV4R-C\$Q_IUBFE(*=N??O6$<^ZST^^>6-
M7\7KV?7"(]T(B8_/GOIXO7L^N$1(!P=643:@:D/P0>N$>!O:Y=L)6'9J7'M#
M0U,V1I^ZT)<RCZCJB,FLYK6:4PU(O0DW8DW='FU-U&'C)+7>/?8RT2$PA[O1
M/1,O2$DTQGGE$DVXDNZZ"4@'>F4@B8$G30F-G"PA./.!4\@E7$M05#E$:P4^
M2/Z*TNYG]AQ06QS\L4X7*\S0&/COUW3KGP1QA^R3_DX7MQ>'6(W/(I'*6^G]
M??K2Z*-^BE+HU+,FH")X1J'AD@V8TEF[$Z!0D Y- GPR <DDIA!\$L8INXD]
MZ^*1O_,]=DB)MAE1 Q5%6[NAF+ B];+?9N0?1$%PYUEOAAI&&'3Y3YV>>%)H
M$A,[J H3"KKM2_!SM1KC8B<-FXU\H1*WX1S=HE. "204#4!KDI-'<::QEZ4=
MN=7,W0-</M,PZG8U],T)W[N*;!*CDA4A.079'P:XQE$WC\4MELX7_3M=63A6
M//X_2YP21NRG=- MEJLA'=%41E.6=L/6,S"&R<CAL ]T5E,6L@J0K=-MM+[B
M 3C;)8_P5]*;-A38@Q-^4*5W=G"T^CMYR1AVQR-I\*=R82RX<H="N^0R"HPY
M;M<<WCV%L=<:,NO:JC+B1$"ZDSZK9*XF[<M</V8UB$+\?S-E]W&0V1@D!G!(
M9:5K ^7],]'[;L&TXFS#%3%PI@)AN883> F!!.)/*0A5IC7-8]-T7M/E>SRX
MV)++*9U:68HQ3)E4U)9#<QF0!I.0V7GT&VPZX\!K6^V=]V-^.+29);3NX/L[
M93 'BG(^.B8A^>E?F@\.JG**[LJN*ZFM<^-$B/Z9^?=U!\;8Y6E9PM3Q_366
M(J$.O7''NM'E]\?ET^VBK\-WU=M<] 8W)<NT^^(NW3MWE@(<Y5K\!)UF,Q-3
M$2X8E<=ZZZQS::[OBNL9(D8#6[=^Q(O'+5C>AO6H2_&CLCVA#3-D<KKK1S]=
M4$(:4%53B2NN=H0TIHI]E $NGNA#2N3AO8OK]4(:C(=0+Y.MT<V)[80U*\KH
M0Z< ?6]6A#4]Z=^OWPAJM42A.N1F&CU+-J4(0U*"]]4]V=*<S"&E+)77B<Z\
M3FY9#0<5<]=>7/A"&H"HI*]7L9_:'$(:GKY-[5;VKP0U 8ULA+VN4*697U9(
M0T;0/Q=B.%F**>U#4FESS3G4=G)H0T]G#*ET8YA>%4-#S2O4]$]=T1X0TYLE
M]+^_E2Z&E"Y[W];E!93"&G'EP'J_1PA#0L+L_4I>I>]3VPAJ&:P")0A!UHUV
M]4(:GU<R<J)WK>$-*:\U)S/+1?9"&B4:G"FG-,J=:&F7=[YT=E2W!#44-RU.
M?%5:I:KY(:DG5.I<E>W$/;5#112N?8]$8D+SR2$-._?OGFR&G5WH.^5,D-1?
M->U&*L@"'1USA#1> = !GD:L7L$JBT0T'-0RH[GG2]KHD(:GC;MK0%7MP<&$
M-!D[%.Q?JS]<(:?7W;*C^UT-0J"S<W5&16)4#)*&D(L6;_MT?^2I=_WY]^>_
MP.JSU/ >LZZY&](V<)=PI](O8)*"I8][Q+E"$')=E3ER3<HI"CIW=B,<96-&
M1:"E&+/K+V&L4Z92Z!G$MF$KF;@/X"907FD5")_K8I!0HR,YPA]E4QJ-GV\[
M)B2S!5EF)!+@%"%/F3YE%Y%HTIL/RI=]$(<$!P5 +$%G-ZQYE5[PF7"D<UB3
M1KN&JFGS&+",M1DIE\R@"24$Y &0&2FZDY'4_4^@O"XX>%*)YAZ*$$@*$% <
M!SFBD VOXOI?H&6>8D E:5+N3^RHAX7%7,6,XX;[ZPKYP]<47&.'\,?.X.+@
MYQ*55-D]/C?QST7!':Q/"W9,0$'=14(,\U5+?>'+%J(FD<:3P>VF\TR%PDLH
M4,Z>-JI1Z&J(HGG?#_Q .(&(ECB0S:'@HF+,9&0WK%*?1\=,AC($_ "X"HAW
M*$ZYF+T[L&(=XS2 [JA)L0D ER@PU0I1+,,M_#\'=I2LU$I(F8KBVI[4B>>V
M4XF7J!]!U,GG?G6*YE('I'X3].ZJ;E-L :R#ICHU"!N+NY3CS!KXJFE*I>,7
MV*VRY+)42*)ERWWFJDUF5U6GPMD.(6403Z$@Y-/I- Q 6*AH6KI5+I='$9!Q
M/S[U!SN%P=7'2W1\YE*23S2E97GFFE)(!1)&)  + DUA]BMJ&\Z L6D"LGTT
M?(I4G02\QLO?]ZY<049)I[$PXA/,X2&BJCD[0]&H2G[?(/VG5#G9%#6;#I78
M#O&4R%" =TX@&\=TOYA<B87O0DB-<]%;4R[RL0NX:&RXE%!'+,15I=:SB3E!
M?^8RZ:J93ZN8J24S 04M:G'II9.R)^/030]#AGO(FP39*3=)]'$R[TLJ[V^%
M\9+O3&089))E299<02N#4 .(?8O:P5$TP4/][HJH%Q&"A6=7! !BV7MDKXO8
M(P;Z3S6)@/.C%F%B:BE)E_I$E#-R/3_VRX7YSK8P^D>CL(RD3 D?XU:T>4FI
M5&.BB!Z)VJ]"Y^]D!;IXPC.K#128ZW'#Y=YZ0Y%&/4(!_;B4?.OI_(]V.1V4
M].3PDV+"E3>"!FFG6W]Z/"] B14]$[24&\A&8D/)/&<O6L5]S83B&=NW\.YI
M^?.(>)A/0\4(:KI2GHW;T.")]]J %V"=<G6@?"/H@[JX4A0^,"S8S3!A. <%
M5"GSF8D$BL; Z,VNN],J *)9-5E]-""M%*FQCO\ D0XC0[\AZOS8.8F4^ASY
MU44IQ+3-_3GH<DS[&P93<CV1NNJCPBZ')48,@\XXA\_%!,QE,F\V JB4F7>+
MHP*!(C[%[7>8L  =V1@Q8[SK5 0U5M!]8KB'>>?%_)I]$^G,S41=72G]6H!B
M<CT_[3)140C"#=-<_!Z8Z/D )\6!*TJ&=OF^8DA5F(E6I#/&SC=%[7,RS*4)
M*2(6!+G$'++*D97MEPNUI-*AE%178?\ FL!(Q+#!RN(FK4SCXQID@M2EIID#
M]8$/VI()R65++6N?TAX78&S23R8&Z)IMZ7?E)033*-\K@$&95)((0@&9J;VQ
M>"F/M1$V(24EWIO-E3=D!*??D"BE"5:6T>A00D#E@@$D#.X*80]Y"4PFR;^"
M4:$DHJ@-9[(@L:L5,>^BV:HRU 8!_2&^0(&6-E(^;EKGEBY(YG.;('J9(1G
M[%.AUM@ ,(Y\?$];WB:XVS96\SV77.XA*AK=WPE\1,UG#,'5EW*MJ2D[F2:Y
MM &A9M.I-7= 4NS:R?&G_3-,T2S:RJ;JLU9Z=[V.XSW>QA'9T FP\,Y&:4?1
M=1ND$(I=414!EEC=D 1,@S4"W:@<W0V!$?2QP)6KXGK:4O=%WQ%57&S!S5->
M2Z<VFI.;W5G-\)[0U),4C3T),Y1.KGU#1-&QM0MU'4L+.Y\VX]6W3%/.GY<.
MFWH3N:>T3X<QE$DLHW-X3;DNZI]$$HA24@;H+),@(>-+,6OE?U>V/0EH*/BN
MM#$MS[]D(X/&2V@'B?P>[5<:7? &ONB04*Q\0/T5:GTPO"DR2@9L]6X7. *P
M84JA..@'P.#KW/@ALLLTN+-:68R.%*"24H?.IYU@V:1LX'HDESO'A26P0<X\
MTIO8K@M-QK.3FD)S1$VM>[L4RZN=!S^\+4#+9YQ$3VC:[GE$2R>S@5 :AHB1
M5-4%%=\L,FENZ>[Z[TA:SUI(&[AS;54RH5+2S2E@?-)\T6J,R@4!3U1@2JQ(
M55!"MG7UZUOGBUEFNR_$[<&77#EDP@/5NIA"3.+N7.8*9SNF16-C3.JMGDG
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MK9%9@Z]>]?TE>1N4(+OE$Y^?Y_?U$+U-*5#FI_314O'$J@&0>:+L0>9"@$]
M0&>>D9RM'!5T75'(4 D:@"Z1Q)Y@XZ[*N#@(B+E!G?=#I%2;@MFM;%F(170/
M6J&.10E"53GE4*D@ $D'?P]^%1)0E"Z7ZU 0K]3&RVC4Q]N!\'#>.A[S 3_3
MGKI%^V,X:V(Y\=#3EV5 =,(=R&60I\4"D;*/ =-02 YA':&@??T^?\FJ>,T[
M?JA'+5V+]7KA$"4"ZB9 Z*E.;0CP.[7'L>*R[2ZX]H:YIB]E.6GA[9T?4M,1
MT!.*)FM4-3L3N<,S@)YO4M-,L,JSW2K:,M!LDIG77Z,Z7FV!1("=Z8$AG64
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M:)934LB#-&]3[@T?Q:\63Y/..)SB)B1A3%7DN)@=Y!GUA 1G;<H00<'7L9?
M_HF4H-EV8G/R>4K0TWZ:JEQIYS;<:<23><769!-,,[J5"F9C=5="=G:3XG>)
M-_Y 1/$)>V+"(?.[KW$.,X]J?E<;KME,ZWI?!#HI/UMLHK^UI2"NGC"$KV5#
M1XC;MHQ09C+B3RU833*>:A*I<Z9^JW9RW8NI67$')Y'5ERZ_JF4Q5.5%'>BZ
MHK2JI[+>^[E;+3IIJ43R=O1WG;9[SLETV6&O:0$+KY[X<]';+L6!/-@;)L^
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M?L@I"LY.$]H(F40$D$IN,CHI&HA0$5L%"#(@$D+H_.(=44J$*\L#W$XR452
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M4 $ J3F&"'47$<3@@( -TR3M@Y0;8 *$]TY!()1!4($%B*DY"H%F +L75#$
MF$VR00N#T:"@+R5=B%T@$M1R"Z#\9P%J%6B*T1)R0>6$()4@J1L#@8&X RBY
M")NG8A*U)%+*$J '3*!)!Y+OL JY!(/0\B>0.4.D06-EK0!5H7R-0383.AB)
M\/'*%DE2-\$=$RNY((*%$Z]J$5-VX76I((8Q&"R<8WP.84%4R J'N\@2B9*
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M^3+-/,N#B22MXK<EGEFF"(""0)3OR33QS,;H[&!F)EDFWE  .[N^>"J'$?>
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M."H..8V3.![1(.1NRIW)1-5BBNH+9>JI(J*C4P5 ,@'KR0!%Q@GPSRP.2)5
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MZSI.HJ4F417[^,@X2IY+.)%,XN6MR21LNGQ<SH!ZTR"R\9'<W(:951WA\?\
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MTB[!W*A#<.@+E$*"Z5%H#.V0A!VY$H@ 4% $)!\ F-(!U1PA!I0*C!U9B0=
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M$T3):D:;M52/$?2!9%2AJMN]ZGM I&55KGJ#HK,#:@B-VA*K0@(E9J"P*D*
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M+#@$/$V"D7"7!B.R#&X4C!159 [P'Q*+@]4*&0HX6UUE 4/]1N8@@P<-*NX
M.3MD;8P0@+1[JX0(#B"'10A<O44U8$M#N@ #_A!KV0,\\G<%0"H1<872(0
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M9;9LC42$6+-_VZ(ZRF7>_#<^/S+\V>NJSAUR [2>[QL813#-#YQKP'7PB6P
M%]PWWR"%7 "IS11U!UCC*P14RNJN$7(4NB\#$<+S (Z X0 [;X 3VL\TV*'!
M7%$4(PMH!0O>RP*],]Y&4ROQ)V/A@[#!P@246^\VMZFW"M QB&P. N-_!1LI
M[P"+MCNYP4*(L;&_)LRJ(V0!L4,0,X./N=B2$(*83"<P"B8"E42'1T%J%61N
M%V5+ DJ'=Z(J)GNHJY4DXP4)4A 1XH@;J43*U5<E3<,JH@09LIRP54@*?:**
M0A !!)&V%V.D2[HC&IOYS41 "I/#*"E 4PB,E $P0>NR!HG)3&Q)TB%+$41
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M^+>(N&?R-@:0NR:;NX :*,@)/ KI[7J/!5TLS&EEJ227O%!?EHBEVD0DBX\
M-^6X4H,3NP#R58Z?U2Y@V1NQ.@GBJN]H[0+<C6=],/J)MUE)+D]R^SQI*QO\
M+<U/=YYT_C)I95%TLF*GJKYOF.X,B$4]>']U_/+P+N ^]\HNX/N3IHT3IKN
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M1;>&(EQLX7^9ES;NO#_"/"_F7PH)\)>* \C^K,SO80!_%MY%%]#ASF ;$-S
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MPGQU,8I$/9N,TI+(=9KJ'4<"/&N;J5%9+1YRPJ6,C:*YVV]*G5%4QIS2<>E
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M[#JP)<>V,\;=0$V;G44\BY,*[:5'3<TH\X\*$"WS^ (UT5?+ UGW+K?$DLW
MDJD-VR,':^!$3>6C#IQX4ESP,OG0VC LW=Z46-YJ&EG9N?XE.FD:M;=>5UMO
M>#!-O.Q&3B?SZ_:.\;8J6W1E$'I>CAJW@6/9+)(K2<.,Q8FNO!026_C(A1!,
M.92N&B;!I94.0SC93W!/5*//:/G$^S7J-+A(46?(%NCW0U7LE-H<_0IT;,6=
MWOD/6==+/"Q]EF\'RAO'!.<=0V<EKTW@8V63I"HE)AA_?32]))C;"69)7,C\
MXEQS9PG9VFQ6V4+XGLUMX68.J8<UDI4FD?#6=I<E(="=S0<1#TS4K 'F(S9(
MF,KOD;!>&R)B[^ZTCI4='Z=T-^AA<;MO4RN]+4M*W"+#=%+HJNQI63R<M!]R
M8KSXL?JWP_#HN6+H"6W>H?N )WE+?0%,HOXO/U.7JM8*.(IE<U?HE+KW*'1
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MN\4P5ME!"7)#,0U^MULJON,9/';K>$_%DI>08>"A;7TH7=S\/A, 8R#>=TO
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M(]E;P##688F&J>I$5>6DD+PT4F?[]FOW_6-H9^-K^IKZRR<M]BV&)!,Z?OG
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MUXRU.MP%C)N]"V!!<Q9BB;H K'.W4H0%=1G(EL/<5!7+O/#Q-NS%J5>7E5&
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M7U.GO5*G3Z<U->@*EQG(Z9C"078P>5'67&P2 I20R1@K&4N$D]N^8?\ "(K
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MK2V^NIGK'EY[KTIWGZ[J7ZM6Z;K<JBTA6?BJ]X?)S [%#3$>0X1GN<). >Y
M&1S#!<(B?SQ-A<43$=9>;W\>L*<I_P 8\]^_77OU/GD]4W5-3V'4UWHYN!:6
MFUJ=73;@3,06DI/B*XJ@HYHX<E+2"%E (24JP=4</X:\@4\>>:1$TH$Z?-S
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MD4^<:)7'X'QE&HE87#=98JBJ5Z3#]/0TT3XL14Z.'5(;4'T>'A?2HFD*H)I
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M+2%*4[G)206E CLDG(UZ+@.&J,:<:X?)0'Q"PB]0BY@\QY6P#!AUQE%UX_\
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M/A^CR5EM[PW\L*264Y*A"_(<L&U]=Y$C[ZYDYX[^_#W)6U(PHH(6E8*NQ0>
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M]]/=T31GS5W]I_M^;MV'_+)UZ,P3_B;7\ 8S@Z6RBX18RC.3GW=CV\QYCO\
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MG)COO17W(4J.MF2TW(96AYI3S*UM\VEI<2%'@I)P1R4ZS^9HG603!$@&#TB
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MTI<2G*2,@^*JU'!P#I&N8G.;F2;:9]]O:8(R!E-R?(?O_%E!][I"O!3KZ_\
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M7<D7OH+Y=U,&APYM'HU.IDV9Z;.A0*=#G/N*\1;S\1(3(<;R2/#<=!;RIPN
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M$B-1!M'Z0+](F;=+%4@C,>]Q[\)5I(2>XY8[G!\P .X/S?/CRQ[.\SM$MOX
M=C>\P+S(@B%+Y>GC[\]U:%IR?8.^/FR,?3[?GS@^S0SF ;6&YS$]8.7<G56Y
MM%QM]QY?>Y5_GDD_23\_T#]N^IK<&#(TF3G%]<@-@()4/C[_ &$>X"1M^6Q(
MO"W95 9JJZ2B8IH/2&8[+CBFT.!91R6DJ];  SV'?V:YL-4^#5^*6%UN4 1:
M)&OKZPNIB\,_$L%-K@V)F02=-O?=;VA4URET6ETN5-74%0(K,4RG&T(<6([*
M6PI(;2$@K(RYR!RG [8.L*]2K4K?%82QH=S%IN3%[D>.IC,Q*E#"-HT74G07
M%I;S7 $Q! -Q]\]E%[>7;]5#N&UKRLT,1ZY5[QHT5VDK46:9.KA5,<I-1+:2
M$I<C$2$R<84ZVXT$8XJ.O4X'B J8*K1JTW.#>8!\B0T- <'=#-KDB#.D>1QW
M#*E#B3:[*K>4L8>0!T\Q>Z\VT$=#'@IV]XKKMLK9W"V\J<'URE^KT9MR9#0L
M.*YN*2DJ4%'!6,#'AE';/GJW<.;BG_Z6(8P$'E#I<0V   1!SG3<W@K?#BHP
M]%K78:HXL$$M+1,';+7TLM92]Q++N3>&EU>GU&&S'39JV'7:@TU!<1.%1DN8
M=5(2G[/X;J,$G(&!W&2-@[AN)X?P3%U2/S &(IR:6Q8+%SC:P.ZU=#BE+&\6
MHT"#0>ZD]P-6#\H,6#;F28F?&#>2B93;S0#,E$AE2BDNQ_#?#H"0X"DME06#
MD84#@#S'?7D:C*M"DW'?!>YKR'?"$!P#W<HEQ$6UO<Z!>MI8VC4KNP0< ]LC
MXI/RDL:'3$$WC[]4R&VS%7C[G[LKJ$MF0PF10TNI2VIMTIDQZBN ."AR!CMI
M>2X3GD5I*< *UN.*UV,P'"*E1CL.*]"LYC:EY+'4P^XF\Y]XC-=+A56CB\7Q
M2B*[ ["5J#'N,GG^(VHYI: )$!MYZ[7>B?+<B0IDIB'*G.L075HCM<4KDJ82
MIT-MJ6>*5.*0AH*5VY.)/DGOIL)4P]6JT#$TQS.@_JY6 P)RN #-KP#X;+$?
M#P[7.=58\ #],W,3%XO 3-=/LZ5)V_BH>ILB&F/4JV$./K04R!)J\Z8LM<,G
M][N25Q7,X)=86I.4J&MAQ5N&PHHO_-TJC:DNEG- (Y9!YHR !B,CE(A=7A^+
MH\0?5I!PHNH $\_S<W-.0:+1$7]$H]Z)3K&VETAJ*Y)4_$9:6&E!/H[?I3"E
M/N%> 4(*4I(2,DK!'S\?#/R^.J<C<52IM!,U'AQ:"(L8 SR&T1<K/B->GP]L
MN>VK<0&'ESUEUM$K[,FO5"V*'(>@OT]2Z7%S'D*2IQ!:89;P5([$+ "TG ]5
M0\]9XD4J5=]%M>G6<R/F8'0Z;<P!%LXSSDY*X>LW$TFU*<B1!:2) -\_'3=*
M8J2GMDD^X)5W[^_ 'L_HQGV< @ZCKI-C)\9OV@KGY73<?3SL1E[LJAQ#>5K/
M!"?64I8  (/)*0._=2DA(QY<L]L'7#7J4Z0IEYD/K,IMAT %P,'60(OD3*Q=
M+0#RDWR&=P3%YB,KZG5,%5JO3&=_K>C29S,>0Q8DJE.MN$GA,E3HDB*T5)&#
MXS;;J@?)(;/+';6U;0 PAK<P@/<0"#+FWN,[R(N3D")!7&^O\-P::;B>4#,:
M]_+T3^).75)SZZ 0I*1R3C (.?+UA[LGMW.M87!P+VM+K@$#,_2T&V7=9-)>
M3#"V(S/W0M1[ 9*B?:,# [=R <=O9\_;V9DFW^E4.EHN;7SL/2]C9<GPW?XF
M(G,><[?1>"H>D(@S%14(>E)CO+99*^'C.I05);"\)">9' $JQDC7+1DU #3<
M 9!)C("18"YTF]PL'N%%I>_Y6B))B!S&!.\R(R$GS9?8&16'+'6W5X,>,6KC
MNOT9R.^EPNEVZZRXL=CC,98\-XJ(  4H=L:[55ADCD+2)D$@@R<\[==Y"X6X
MG#N _P!1D$BXF8CML=IG.ZP[U;C6="M&YK>D56%*K<R"Y']#B*$E05XC:UEX
MH*FV\,I<)"NX(]^-;;@6 JNXEA*L!K&.+KR"98_*QG./*;+1<<XEAV\/Q5,'
MG<6L :VY/^JPC2,@3I>UBM/M#M_59[D?<&^PW*KSC(32Z>]W12X C-,PU)9/
MJ%P,A#A\, D*'M)SR<9XE0IUC@J%(L'/>HUX.9/-UN29-_HN'A6!J5: Q1-N
M20V((ZR+6!MVFXNEAO$^TS3+83(EL)=D7A0E!+CJ4*<2S-9(4V%8X-)QZP5W
M&,^>M8WG;+P1R!LN: 9(-RT3%SF8$6(7<:]M2I3IFFX.+X#B1 -X=&<#PZIU
MZK4&:32JA5'D/2&*?$D3W6XC*I#SS,2"J0XF*TV%+D.J2V4MLM@K<60A(R1K
M7U6BK%^6+21K, F-(Z]M%OL.#2TDP3:T@QO'L9V7/A7PC-@A91^Y3O'ZB'5+
M6+.J/ *:EJA\$J]%PM2@DN@H[<, #EKEHX1XAIK,$F)(LT$S).F<S:8ZPLJC
MN9Q(!&E\[;JBOA&-OU@@[5;QISZF?D;4QQSVS_Z+GMG/;R \SKM.X/5<V1C<
M.?!TQ:-=YGQ6-OK.OI;Z_LG8I'4HYN19L"Z;)A52U)#U>D41-K7I0WXM>KCS
M;K)8;A,NAI0CI\1QUV4K[&EM6<Y2=::O@:U%P#J[7#F!AH.0N8,D&<ALHK$[
MP[@/4VJ(2MB-<4F;3WZ<PB#13%@4<UI='J*67O%,9U3+;2UH3.\1U2\+1R40
MG7+RD"2;=<[G,],K#+Z/K[C[I>UO>UNA4FSIB+<GW8BX+<8K[DAMV+2Q&9>K
M= H")CB)"0H/&;<4/*.R?";=<P ,B!I('>,XOY_5)OEG.W[>HB$4G?V+5JU2
M:*W;4V,N;<*+1JLB16*>'J%6%*N)'H8B "1.9S;<P^GQ!Z-]D0,Y"M(CPZ1:
M8_CS4-\^AVUMGUTS6GNW=6ZX"KBG4:;08I@W,FU:)9512I-4KTU),!57"%+#
MYF2YA36HP0KT95,RLH(]<8AKIDR?U$6BTR!;,"=>G57WY]]O>BU-!WQN>Y+K
MIE,ALPS2[CG4NGT)?HSB5<Z.\]$OIZ6OR6&'$M2&E)QEIY(!)!.L^4@@;]=3
M_=Y.ED]^_P"DX5P7S=-)NJ[J:[-MZWZ'3[)3<-(K%09??\#%2:@/SZEQ5Z[H
M\3C%8;XKPV5$$$:D'0BQB.V8.QT\; E7+,&XF?>><]8SS2 A]2,:@L4^GWA2
M)TBL/KG2Z?-IOA.M56@2(M3^3%34E!):D7%6*>W;[+*_78J4^(XZ TZ-7E,6
M$P;C497CWDFM_'WNE-N-N;<=IW7&IL9V+#MZ+2;;EU1AN,U6IR:A5Z[-ILUJ
MH /HFT^/*I4:,S3I40/LNU,2 TAL#&L0+SF3K$&+P.L9=8O<*)1[<7A7[F50
MZC6Z];3\>XJ*S7F[:AL>-5:&\XVAR/%>D*'))B-N!A:'_LW-)Y>MG-#29L09
MC*"3&8\!-SMT5RZY&,_ Y3U3U @ <23W)[XRH'N2<#&2?=Y#5+2"!OEU]]5/
M?OWJK5.#EC!S\Q'?RQC/F.WN]YUDS/PCWY(-=O9SZQ96MDFJ6T<'O>=E=_G^
M4D#S&?F[ZUW$JD-;\IGUN=NGT4=D;:'QS_I3YUYN7?X^H"J3<?[[ZM_)NWOZ
MTN?62)2:(C1$:(C1%SNZJ.K69M545T';>13+@NFC2Z[+O.EBF5&IRZ33:';?
MQ['<=AQV,,Q5I6F)7*X'EPJ135PY,M3*GU %+7MU^VO:VFR]&S?4;?=\;MN6
M[5H]OO6O<J]SQ;D6F2'GJK0/W*K@BVT^]5T.(2%QKG6\9["G %L%IU$5+B$I
M)Q<3$Z@](CMM?I>XA!IGD<\[6D^[RGEW:6_-N6@18L.=*?10Y*'O"BOO)2LS
MFW,AQ*.*D=_5.<XXY .N_P .KBF^21<P<M.^O95(!-$K2D\A2IXSDX,9X'UC
MGN"D_-G'8:W_ .<HG-PZ_,/I?WW,V;9&>^V5HT\\[W6-5!K7+[ES0?8/1GB?
MI[(P<C/O[''LT_.4A8/$9"2)RC?Q5GO$1!,VZ6LJ&A5D8!I4[(['$9X9[_\
MP^1\\]_R8T_.4K?,WK<>$70$B]^\??OH9!,G.ZN%%K7X)G8!Q_Z,[[/F*<'V
M?-J'%4"9+A/0CUF?84 DW!,WMGWZJU5"K1];XJGXQV_>KOS_ .S_ #:#&4<@
M]MM)!(]1[SNL@Z)Y1;.^>FRO30ZT!]RI^0>V(KOL_P#EQG/]^GYNB;\[3!T(
MC.=#F-+^&<R03)$SG?MEEUB^VUV>W5M>^:A-L1NCV75:Q'I=[46NU"0AG@W"
MB4X2P^1DI=\97CMELA);(Y94D@:V>%QV'IX>J348"XN:6EPD@\I)@F^L97R!
MNM1C,.ZMBJ9#20&-RD_,'.\L[Z1?1.XY0*P^VM#](FNL.D+<1(B+7'"',80>
M;:D*(.4>?+U?8.).O/%6M?##^FP((:8'4.!^N^Z[[<!2=3^:/TWUT)R(G(:B
MYG91ANW:6WJ]O-2[7J5LNQFI5CRJC(I\..[%D//_ !I*;1, 82ES!0TE <">
M&4]^X./7X;C36_A3'U*CP[EX@P$/Y72WX##$$DR#-]#-M3X_%\,#OQ7PX406
M-. J?I) YA6?), 2((_A;F9T[791TJ>L6Z+PH#R4N+AP)0>G04<V^#8Y*2X2
MA/VI0G)3](!UHZOXBP=7A=)I;2@?#:"/A\Y(J:W$"Q^Q"VHX+BF<5JO#WB?B
MF9?!^6+&#K!/;P37VE3^H"D7]N+"H<&GW?7*8]0FKFY)4RX^XJ',-*4A+R6E
M#QFDRUCD$G 3\Y/L<>?P[BN#\#.-JFC_ ,OB74B QP/-49\2;$Q9L7@3X+R/
M!GXW#\7_ !"UK^;_ )K"AWS.;9K*@&9ZS;33)+]^[=_(45T5+:&6X]P=8+U*
M#LAMM]Y"BT7DI4"A##C2''./VR X$!13C7GZ6"_#!J TN)4VCF;9SZ0/*".;
M8\Q ,6SB0O2XG$UOA'G8XS,_,XB>6QO(!G*8UBZ;W:2^=RHMGQXU$VJK=?IP
MGU-<&? :D!@\Y\@S6R7>*U+143,22$\0D)&>04!L,?@?PY4I,_\ Q3#,IM:?
MD?5I/?S7YB"=#8W$Z6E:KAV*K,Q%3X=.J2X_.6\P! /RS%LYFYVB"MAN?=V[
MLNQ[A:KNU%4HE!>A>%4*A*3) C,*?9(=46^X"76VTJX@GU@ #C&IP? ?AIKO
MDXI0CFDMYZ0-IF" 0)ZCI$E<O&L77=R\[*@$"Y+[2.HO<B+#.V92EMN^MZVJ
M'27F]F:O,A_%T%J._&0^GG'1&;"7@DDJ5XR4H<25)&4D9P<)/0QF$X-^=JC#
MX^C4?_N!J-,-F!9LR1Y:Z6[N&XA5PF"H.ITW.+SRD07& T$'.P.AN+V!@K?#
M=+<1KM.V9O9I0[*X1%.-@_[/B+2"?H.>Q\LDZXA@,+,C%4(BT/ F8SS69X_B
M1'^A4DZ<E]>M\O'19/W8Y[2DIJ.U>X# 4%(4H4;QD!2D+"2M(</J(4I*RH#.
M4@#.<:ZN)X=A7_! Q%*V(I']8S!,$P##;YQEK"Y:/'*[R14I. #2X_+L8%YB
M<[3E?9,W+W<MM>Z=$N67;%>2XQ:$EEV%+HF:O(DN3(Z(\OT98SF*F.ZD/$^H
M'D@?;8'J'<&;3X8\NQ%$S4#@6U"6AA;(9^DPXF2 0,],CI<7^)_]?E#' @ '
MY66,D?YBV0[#S=G]VN3+.*?MK?T\_;)6Q2@%/)6.R@A+N>* !RSC&?;K0_D,
M/28YYQ%$-Y@WEYVS<=1:#8]<ENJ7'7C#BI\)Y)+6_H&W_EKIZ=;OW3K_ '1F
M!LO?KP[ >DT]3"2,^U2'%+!_^7YB1KC^%@O_ *AH,YA]-PS@ZZ: Y7VOB?Q'
MB!/_ "[LO\+Z1><KSV&5A'BJE_[S,4V;4'-G*Q3J=$CO2I4^H>.AF'&8277'
MW\C'!I"5+5WY''8%6 >[P_#\.J8RE3=BFCG+F@\S3+B"  !_DX\MI@G9=7%<
M8Q>,H/H"B6<_+)Y"(Y7A\R#D0VT SU38;2VWN+NM;TR%1K@8H=G4ZX*NF6Q;
M3WI-36]5*W6*HZE4IH.>"7G$A6/$"TM\VW #D:[/&*N!PM4 %K:CP7 RT AD
M Z0+D2(F]\X$P'#\77I6J.@1:7D@Y [G+7S3FWYL;1[!VRN^?2Z+(]*9IKTV
MHUNML.RYKJ0XTF1]F<2OPUK05H;PH)Y*2"0,ZZ7!>*TW\3PE$/!YJCA#7 Y4
MWFWS03:=X77XMP7$8?"8C$U'$LIL:3)=D7M;<EL"Y'?0Q$OI9-%N<VS1G:C%
M=FS/BZ$X9,.(\&EM/1T(:#84A/VK 2E0( *NZ<C!/EN.XME/BCN2P%0G,&#S
M7O)[FYV$9+W' &,=PP%SA/( TF/F$>O?+5>FN[=1KE7'^-[6DSDQ'4.1"^S(
M2ME:5!7B)X@#FE0!2>X&!G7/_P 3: QI>T!Q -VZB+B;'U$76#,*QM5U2!+3
M(D7SO>(W@62@%!K+*&PBF3D-L%Q+23&?"6D%HH04E*"LJ;/K^1\L#..\=BJ)
MR>TET<QEMX(.4Y"-Y7*;ZWZ]O?=>95L2% <*,X&FF4NH;,-O@EM:\ J^Q\E.
MA[#AQD>_N"-<;\4X!Q:^8DB#>0#U&TQ;S5OOG/C[GU6/Y.R%8!HZR1@83!];
MW#_L59*NWF#Y>1\CEA\:][?]1Y!%YYHMIFZ_U\E0XC*_AO'CHFZOJ#8%&=H;
ME]L4V+(0_(107J@"W(292FL26GF6V%(>\1Q#;CN/!:0M"75H"AF5L2TD$NFX
MY@#,.&8%[ WL3<G*4)GR T@#IGK[O 3LQW9R Y<-+G-VE'DTV;2V*_2TM,>/
M3JC4DNNT>$Z$$R&7)JF%S$14I#KLCNTT'%!PXC%T_P#,?+-Y%P<B;F=AZW6-
MO?KX'MTZI>L4>VZQ HU18IU+F4VITOP+?6TEA^#,IJO0/ 9ISW+PWHBUQ/26
MO")"*@Q#*PE0&+^;I_YMZW )&>]]HM8D"\)[_GP]S=)67M!:<R\;<O%$=QBH
MQ4Q*C2X<29"129T>5%J\V-4&X?H_I$Y:S7*FR'TS5OEY3B0,,.E 8RE<<PF(
MFP.42-)L"=T6ONN7M!"KLA^[4VNS7K<G\I50J$<,N4^J-Q/366Y,X*V]=5A4
M7=LV/B!**""I= L,I8 @2'<-,0R@--(Q0X-T"-("0W?- $,IW:%T28<,(2TM
M(2/]X?T^<;_O]XOG.X[OS[7WVM>ZSO-:<5YKS^S5CA]9M64^@8Y=P>>(O5C(
M36U_,\U"H62P<G]-Y#;GK?C$NKXXO=CC [KR;RS/DJBL'2V)!G..H/=T?D05
MU)/B"-&X^#Y?+$>Y)?%/V'(=PICG(GC>)0F!6SC,7_N[I$J6&7N(OW>EZGEG
M.&E<FIU7KPYJY'C$=?(ZR8[B;L0C2Z"9"N(S0BDS>5;'-CDX*T9=0)73;)U]
M;/H<'LJ57+2Q%9  4U.SDO^USR= F8@YF-4;A?K<6RY20*%K5.C4!=3KL6FG
MNBP_T[L3()GM(6?$8BO:C\' DVF[6,77TA_6GP/U2>=K*#JC$([#R.YJZDW7
M5!+F:T[AP5/,MKA.BBK:6;5IBWRG-I++D]L9JH1D1F'50.3LUA4L@'>^5GYO
M.@AZ7=*;!4(J>_4^)LN79 ;2)!I!/W6/,U[NP0U=[['./>$G)6RR*:]#2ZX&
MN,#*JM;V%G1K+NVYP98S5KVI%[Q@\S"ZS$%'X</HAD$EGE9JFOV\1JYH)!N7
M<UPT<GJ@ZG)=(",#-D=_WB&D]5(FZI6^- AHJ_$I//;!:B7+U-&+HUY'EGF;
M9VY2#$_CK*3O+"XDU=B+[ZTSN$>/EOK7_P;F;<ZF?EW%'?+R\M?8[TZ=DR3I
M3)5;5&K9\^,+,"7<Y1'QXVLW/-5-!^E$)!_O3Q3FU1W<E[8'%S3$D0YW@\ 1
M TXNM(][DXD# HB$RA_5=*:Z?3!5F@1AZA/SSKVB=E:A+_&U<U(N@)=SQU%$
M5C%^Q+L)\=>7P!M ?ZGG^?B/,8O$IO_*-,B\?/;<8QLJ\^5;RKWINJ9$S8^W
M;@"T'6]RS57C M$5B):E<,TZU7C#R"*]N[^["56C. O1EL1%+85^/Q#62=?Q
M9=94'M,Z=:=3L[KE'@6NZ.DL@G@GG5%JU-2R''X:9SY2=/,;.<7RBV.$")O#
M^Z':P+5 ).9Q@U+0=K"W0GS5(EOMDRT9"-:J8P,BV\X8OYA)/#*C_ZN+NKJ$
MKV=WT'#EK:I-?=<8,V%<<( [?T4 #BD&X"DS I3[60.Q#H+VSL+&RF(%4]=C
M!'3T(HY7HB\.BVYG2,<28$B.C>(:M>\-X/0\OX@,724IG#)V02@1<.&G1:O1
MR)"AD7.]!%$@;F1(W;K5N>CMR%QS=GR<"ZD>Q6KV$;V-F"?>7?[;4FDS_L'0
M;1==%)94*!L0!T":E^@A0J6,V^;7-H1]+R:M)6 O;2>=*DIN\>H&$+N]KKAE
M]!)-BO%X<MBL^3$CG86W:O;WN4W(>TKRN^(/?9D["H_!.<\B>C_4<GNR&R@Z
M W-^EESRQ!!:VI67#C^4G6.D(OH4R#/@F459V8![*_ XG!]-XBYK^I&IJX9Q
M10@1V60D^)O1D+F=OY@HKR)5Q6%T47Z]/&Q*P29IV\U)L(=F_;"I[S$1R5VH
MS.=@^(J43FB&2WK$:'KJP*MDLSZIG#$*KG2W,I/0>RW?:O"53ZGC@3'&*"6I
M6384!J-M>M DKG#79,*"K1DFKD K6 %\Q6GF6*VE]9:G*Q-!_C;H_IVQPVS.
M=[U.^_C!G0(T*D5$>>'(UR/<4-$/I>",]= DPR-<3O[3FHA (O-A)V.2R,^K
M#?O"=-KX6BVR9.]1(5"&\,T)2TH=\VXM< ;UC.]P['OC<2PX'H&"T2^&<([G
M=E6V.BH3-7.& W!;<IM\J$KNFBZM6V?1)]4'S?Q@<-V;NN,]IID!F4Q;)A7J
M,@KL\_)[U=^;1$ITL!^0 1YGQ,<]LP7(S)G3#KCE7*=Y89L^I;%DK0/0(KOZ
M*:F^*:A'K.B90563KP9M%H1BP$%.\XR]3;911:U"/+!:T=5W3TB3+[I_#\N6
M5A-.,1 J95!J*ZO,0E.R#@Y;Q)^D\R"-OA8NL\!;IN[FXKHF=T>=%2 >?-:_
MOGMGM7;2</P+[T:'IXAKF5JP5'0^%K6,>U,XVJ?9I:YPHYK;L_SWU-SQ@RY5
M#,OQZH06'3^-W[ZC5)@HV) M$<?)3 I#P&B/^K*]_"G)FMQ9HQ"+<?RMN^8>
MXZ2KW-L1G<655/95FZ8L%M '-US7/MHJ(K,*@=:/;1$&=1Y38_)5/ ,Z>X=D
M*13\"409DBOL;.W*X.4J-)Z'0/7C&"9I4(WD@(+#&ESA4\]4X:7L]O<VKE=[
MSU@?.>+PZYON"+<&KWU>)@1R%X6O^:2.COT\"@3@]$&_VP!4#^]*3*^N?@MY
M<.:C+#T2D.IQ&N-^5TU)8%AM[[QWM.);@0R D/& 4&#\^\61;L5]Y3N3YC-@
MFOT)Q:K$^.VKJ)&ZI[X)"9E!Q>>S>?U]Y] ;@%;FQ"'OMV"<ER_",VR%"!Z(
M$Z>_,N(1J4IKR]FM<?0?P#."& RW5>RE_Y*TWX'OIE)R7R@4./>\^; @KEU*
M@:?#"B'FW!-KB!LC[#$"QFZ!&E9MH&&D*F'%, 'R:TJ.:.T[7L-O@#HHL>\D
M P#GAGO,O!:@92\Q!=+ %9.'9ID'235]Y-]HD>-&5H%\QQJ_-\BW(PA$+'GR
M\'C8ZVBA.!0/B!8_.N4P*IJM?Q0]3_+J]^GPN@%@+\.JK%QS<HWS8ZBQ4VV*
M>.Y]_MQ$)V'X/L1>&#W.6".69DYW ]CMN Z)'=P\<Y=@TSCBBALKH"S$H>IS
M4.CG]-5>TD$9GQ (JDQ6@Q*I"IH*J>V*J[[1!Z\@L<B?: X"^1)K0^.JL%@]
M/KEG#H'810MF[R#$<\HK $?)<?K2J2UHG?'>48;$,IL)XE)"'OOHIY=?I /5
MY+\+64A%3YK\V.AK/3WM*S' ?$6#3Z\1&3W+J-ZG"(,$0BLVCP)(:3=X(;=$
M5YZ?N^Y[KK*+0#A/0P@2A#0SNN:)]!#**[%SO2P4R5Z9#CQC!6"$E"6?#P4R
MBT@;\5*<E3P@WPGDQ6*4L&(-&GHB\;J=VU-UOZ)$\[O;:M.'06\QP5883[(>
MT\8J<D9'E$3EX4K2;'$V/CV*-21^WLZ?YG=BPP9V0>97%7=ZD]1 FRD 7.I1
MO'!,>)])%]O46U[QFL[&+/54VW<W@*\(Z_6$I%6);T7$UL#)N<6E.6U;T@((
M(V\H2-7U3<M\^ @G23H!GOM=PTB*Q(<R2IJ:/?<T#&*>[?7J!3PE=-=K$!SZ
M[!P>-(CKI&[>M/$]B3UL>5:V,0.4VX2'-5^0:M@WM^*@"-DA1YCCJ[L\F_6Y
M71AXSZ>I6-8#E6K**Y_1J7E]) 1GIB.%\M3YVO%&PIXP%$H[5?+S(:KJ_)BY
M.ERL5,7.JK[OAY$F$:WJA-2$W4K?N#?<ID.*A@66D(<FLAHH);!W[-)W?0^5
M*X,Y.[ X4";+P([3BSW:J8P?C$"Q>G PDM0X4B"FDYNQ9Y2N#(<!O@A2Z4)K
M_W><K_$FTUKL+-9\$JCBH,)QE,+>]'&D'\\'W F_L<^ ,'HF#'I47[8)I#L
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M'.%Q87$(Q/VA3R[).3*V-R9F/KA/4,1@]JL9H!*+ML  E904G.[AT5VV:FV
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MI4:/-<WZ;(1Y[T[A"$9_](T.7:NDM0X?=Q;\^7R'VO)SN5D7O37>NBVA[8;
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M1 #<0(YC>9!^"P1WK&"^, ?LV7VY"$:.)^2K4:-:U:XUM(/4)$$M]F/P^>=
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M$\E(C^W&;^6=Y;G#RHN?Y_1$0]/S%=WU(YZ1/Y=N;CN;'M5*5:]JSD>_B[P
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MTDIQ%4S5FLQ# FC0:Z"QKE/49:'R\++4)/:TGSE2?+X%?RPGAG.,W7%3'_F
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MVT);.(UO&LM 0BXRZM_J@O!\:##]>&UB1],%X>&7O!4-3?OP(RJ+EQ]'A=?
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M3*LM5>E&D9:*"_QIR]#!S&A?L[.SDDS7*/)<>GS4%(Q-(OC" " H3'D]A0L
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MBU;S.(9]_UC$D.RZHK/,_-F#+?&O25&F*XA3MJ))#OZ('=6.S$ B&C6@/PP
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M?LC%J?VKM#-KIJ*\C@=]Z) R>2:XM7<$_%5$*J<R(/(:0%'!/[M.)ABS)#L
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M* M52*>Y=$4-LM)9^+'Q]--)4M"R2/DXC5(;F.!CFT[#P!BJJ3-.&$Y<AB@
MG6HNSV%C4\O;DY/DZ5,AA@M+)P2S0\G3H\M7Z6295,1L<PH1>7(8.@ @<\C,
M?G%F#(-,!8/$[E]_QS&& 4C,_S,Q3A4N-)&W$/#_8J[_OPXHCU!,48-D33.Y
MT-$A("#N(- 4Z,'ZWO#*6R5T[FB0$0-\?F ^Q^>'!03>K[4^!Q*:PF94R>\,
M=]!"AQS673W+2[H2XOQ\'NQ8.-^RWVS=<O%G]8IFN2I'F%/$:'<%XIU^[)%W
M9+I6HE:&1LJ#V(>^[] IFI-T6)PP9R7U[[3LRQRAN66BL:)W7RKO&M^RG$2L
M']<J ZB@ SN0(;^?-OC ;1$"[4B#GF$C<^ *_ >+: 9_D#E91_U_&&!PP0MP
M4-ZU;U_CWO1_>GN0,/@_5P<'.HP,,_!W4!$# <<< )9"'@ DAP10= 0&QN^B
M8T \0JQ0-@=_XW 2Q\<#0Q C,OMLL$PR:\\(@#D/H2*?,C;M3_""$.>)TK1K
M*AVKUPW;6@<$LX-M\G2[%I)P^,N\*K7RYWI^CL$H"/T>""[(\FZC _ 0QIH_
M"*WJES'TVQ@1OA*Q6=9H13%T-(Q4CY^$9[:5DJ]37R:-C#28L&A^ 2;.(N=E
M\2]*'EL&&R]4>X0EF;['KZ*#H+WLI7+L3CY&+4E9#]%HG!/6?X]+82-(E<N-
M.S1ZF,3OUZ_E\'ZVEN7[&K3H:=X\(<.M89RH,J:CZ4%(HGT+114&?KMTEP9>
MU"M4J5J6::OWS@LXVU?#-WI:SQ-@3^CF6!^JVGNMXDW<VL:<4I05EN>;RU7'
M7H17M6DEH.<K#V11X\L+ZT<8N,U),2.;9_"9/8QP>?==MU$-\WY63".X[$"V
M[*FI'W_RG]5&/>@I,QA9:&:Y6L;[$NSG-+:(EWZ'4=3L9V_=J$7 1E7,C3 A
M14Z5X7"GB9@G)5"CZK'E_:!IZ@#HTY]T;OH#$ 5I^^HUIYH/G\L#.])F3U#7
M-W (N.$X<LHH8+"&X^E;])VRGZ3HZAJ+E!OG1ENH>JI'%NP91FD%!\B=>6B4
MZ#FQ,=2O>.>S--FA].UOQQMV&\<QLB2Y!J'4(MP-HS/B@O:9?6F&QG$NB7.7
M-3=F1Z9.%!#@)R,JZ_'/(38BVU)5%FFN.TI9!N3W+TZFKNJ?.NZ"0#H>&PA/
M"!.X2#A?T-?6=<]:-XFB^ZBS)KGQW#/6SC^BRRAVYL!M$O20-<M*UMBI$#J-
MT!Y0[NH>>8N>]7F+W%,Q@K;ZBG=*B5Z(A^F+5!LP-^AKS%)"AU4UO;C4E_IV
M+6%<T5,VG8(8J"\'ER0QDZJIZ H2R(V),N !9 <#3%6!.]B0*"0CSGP:YPC4
M#D<*"V84K[S)SC\ WK';^1"[C&A4J2_<28TIMK6'W(?$OA3"5DD*V&H51JF&
MTQQK-G0\E&V--G7OLQK282#IG8?[O)^I%P(HW=D\<8>TQ'=8(.(_ );5/2J*
MCLC](BC@%&M<NF2: Y$ANM@@+1(._IT%)$TO/=>RY>Q&@6F%Y]S!JIM;.O ,
M/YD2R(NS4O\TXUPH")61+[7B3"<SUF#+J.=0;9JW#"DQIQQ75$KF&.A(5QLN
MR7G(;:E.A@0;KQ9@+IUC09@[C1W+I?#\V&G$"Q5/2M=AVG]G!D7K63IQ0GD2
M3WSWX/L*SVN4A)9 &^%R(I*74#FF)-U0LXRC;SMQ0VF>'Q;NI6Y85GPHG16B
M(:M8DA..%W4H@.J)TQ</]],])XH9T\MW'@^7B=+N50M;S<'ULFA1I\?7.ZO"
MX[KDN^7"^$\YR;->OLFDYKQ<R@GZ*F60F^Y%7:^FAG54$4UD-M ZHKIKTNQQ
M[0KIZVVPS>1DJXM73;*E<RT6=[<YN$':<Y_.);=TO4FOTW9._/HH*M E)U6D
MW( TRQPUNNR?V_\CRS^A8.8NISH3,HPB\9.TO"R-=_:Q:J].H)U6&Y)&U3;/
M4*-6K99VT/ &-;7EB0[$%IT+I_E(/&FO"FR-?I7<%;-PG."2:]CIE+ZY]8QN
M%4S"85$(#*]EY>F/3B&\J];(C:NH$4G=E-I*,DKM-FGY41$%T4U&U45.;Z<O
M+#"?,$&SYC-GQ1VKT"[JLY.S?%^EJE/S;H#W.1\LLCQ#LJK^H\\H\MJJ5 :G
M?M:S;3(P".(ZME36F',NS)IEJBR>1,S@W$QTK5PU!IM,1->@T )J4<^*BM)7
MHO6$VNFM,F?&$!=<T;11[)INJ:8CW5^J=>7TB8OV9-K:E$B,USH6Q$U02:;4
M!'1NNCV8B4/)0^;JD*[H0Q?SFYFJWK,_OG?=4G>DG#Z56,'+^>]R+R3;_.+=
M@6U=/7\ZXPWAD @9M>,9RTF3_D57FV'@ C)#\8RWOOJ,O8%>E],).]2M"CPV
MY:V$]43JZIDL;173$OH6C\>(7M+2-*VA]\D[7:SJ,,<OS^5S; P#^QM_V((]
MI84*IX<9:=(W[A8!".50Z5%T^JY(G-S.#XYS=56S_$\=KM;Z/AJN\3SDQ\DD
M\FZN.H?(7-_XCXJ5!=#81A"P>\^/>TS"*'Y<N25Q#<XXT;V+9FY8R'?NU;]3
MIINR&V#HS1 A2(_1&][WHFBR@Q5XL4OON%0[#JH1YL#Q10%C)X/RJ>[H+KD2
MVA:'*\KP51'R]?KF%2SS9Y/1Z0\:'. %++ "QG\$N"\L$0EEO[](18R#!7UN
ME6%95)*SE"+=4M*3 UZ1?DN;Z_))=9G@=C:2"CY)+NC55,IO>RU8WPV4J0?.
M:SFYPGF9?5XU,'.95=0@LF*RA.<_#?[ZH/O_9O_?!^UYE6D_KF.Y#_VAI;-8
M5_L);!UUK%GUMH69/#X3\@9(<E]=AE&2FN9!3(R./&<G\S3:1EZ#[A;Y+206
M36=N@FY3DMP9A'TG[8BQ?/TQ+\F[,!!R.(]8+\)H;9*\N,.,]KE]&TN?Z0M>
M[-1"6%#/@[N)UGFC%3DR44Y/DMUV,*W"MQ+-VA5>>)!/8U*=?9-ZGKE88X?)
MP69$CZO23"[_"HBD# OFMC=)=?^&I+UJY?HUWHBV6;;7Q3?Q4I7U6RNO!:8M
MD6WYT9 >;2F5P:@0-.JYQI'M661'EI5&Q7D'R1SGS)&%3N]J&S_.&]JX(\+\
MKAZ.9BNJ3?(\*.1=BU9QO*GM34@C/FV44R P+)@A3J>:_VN"9@(>UP[(K(^\
M%G$V1W(Z*?NB-5Z#Y?-OP12GL=B3W_$'KI_[$/WR9]YIENZ.N(RH<'Q,D;@F
MA^N-)"MC$\R[CR>_\53M;C^L(;Z]A54%8"MK:(G\(MH@'VP.,V0>Q)VF2Z*"
MV2]MT,+JS(U(4?#"'X]"16>[UK/2&U6F:CQFY$#JM@_VH879^*[:2ZJF?V8I
MI-4NK68ZK9%C\*BX+Z,(G*>9<MUA,AK$H; [!J\R\CK.>4_X<++:>8Z^.SM=
MZ'])*K)_"2;"7;Y+MYWFM#,AD!Y^Q9P62-6D27;4FNCT6-"I-2EC<JZQP60)
MK2O7D9%AU<@YTJ8'2L51)7_ZU- -6F]>=3_G> TOE5.X@37)G#DHB7BWNV54
M3TNIDUPMM2#B:9[B#_C(&::1;5RUPYN:!LK+""BZ],8MURFLF18N2VK(M!SE
MU2UW=J(>X]%7)%GI\=DV:?Z:2_G<-A>Z!J=UGNO@- UH ?LAV$71)@5SCIKZ
M<*,;%?SP8'0?XY125KYF(WR$719M5;KGB.,U$,0:ZW.9$[(8=M_FE#_%OUH?
M9Y8VHB>-(R:C]:YX0[SS'7SL8B%;UJQ>^9R>NPH1;76=Z(P_^;-'?9S6@LE;
M;\HI<V<X)6=1YQNUPYQ)C7*]&59^HN63^CQYH@27!X*7%W6]GC_+I'BD[VV*
MHE8&,(%;%=?H@!ORX+(:(9;]B4D5E8QV7D3"K">&4J-LZW,6Z=Q"CI'G<#XA
MJ:P594-&D#Y,#AY[YF_$#?A6T26#+,L3>1E2OU.^KJ*+8QH""\K$O8M\FTFW
M2]Z,VSF>T/W>L'#A2+T+PM_CP);:15-;=,<4J'Q!G>,MB+(KCZ).&:S&2";)
M&4+(Y'@:(HS*1/ZZK@<Q6QU.6"%['=>B(![_0\2XD5U,3SLTSC!GXUA?NPPW
MI]^I7=QRI1YJ4$<^)]S6AW1:!@N8874Z-6A68].QD_H=VR2TL+-OY8H4NZE1
M'2B/VRGS7/Y-V6FY%>O=O8HHDK4N$Z<]MK?5<2;X1:6]B!=4Y4UY*F&ZN FV
MGD ]6(J).Z^J,P-[@]I5(QFJ5^08X]C@\#A'5!:[>4NSE5B)R5SFPLNZ>S/=
MH,RQ9QP$UL$&DQ1#13B$[W*5]!MPP^\2%HQFE?+1Q> 2ZF(FC(J]F0&L%LJ5
MK;=/23MB]7Z)JKI%WSD5YB3*8W!1OVUK0@=DP1A(.'H6C!/[HRX?"EW1[,>S
MR7@9?3'7*0]O;BH?Z0D>RG+1))RV2*YK[RS5KU)L*2%D&S>V5W6+/4^JB948
M3(Q"%N63HQ/CCR#Q50*NAO$:\N2/K3VEQ-6EH-HU15G28L3=&=BTB_6NLZ'L
MC_3*+._C)JW=H[;]VIE=1+QTR\T]HRK2;:^1:N;NW^%(QJ;<QI@7%Z*<9O=C
M#.K8CCE@C-2YM(JAD../K.ZH:@YX9YQH[ACNSTMIS944(N5"N1+M\>70!D8?
M96B.@PRRF(+43:=ZCG1Z-*@?4?KKI)'7(SF[MQZ#YWMQE"4&YF3R6=>5DR+L
MMK7M(JYF2-B-:UJBY#"7E.''Y;@U+HRLM!&["RWWVWW6.3'U-:7'Y;5E?ZX0
MTPI@ PR&,G^[]-#O2JC].Y*/CSQANWZ]N_!IT0A,(S(0>E.8PB8BEV3AV6"X
MBCLM8G(JSX^B6(=:^RRJ<!S@08(75YJ_4J8_,2#+GFZW-<EW+BL')<QFY;_L
M&SJH>S*_17ZGEO@)^_+-Y.N(-Y2 I,$=IPUJKWJE+/M(BX"K?$:?-E4-%_0G
M7"DN?J(H>CF$Y12724U&<%V/#W*Q4:AL/7$J%AZQG/1EG5&DB:4N/]#^YT_5
M9SQOS>P/3[KV9HIT,_W6:;=?XN KKLQJ\?K$UG?7#!/!&\*M.^OV5T$?3T8"
MIKV/9Q?D5'"L@I[_\V-[<MU8P-<H7KC. ?>4;_YY-5F=8W;4]8C)F(76!\PN
M[K)FDQLD&PH"<WO?G6:-/R4VQ97I3&NDR60K6J'12:FB$$;F8C"<E^0"?Z<<
ML@C91_/DZ1NL7+-;K-L/66%X79_E9^W7U,<>@C3=7KGVI]89.@,F>36K:K]
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M8,4\UR DDNV4(N!FZQ^UN;X*SJHQ():0F9F!<=YBY[;38V- >K!(&FAUXL]
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M/"_3D60)C2PF%);!P?IZ<?@4[>2M8S-*%3LN).%$U6SKQ *U!L&&0P% T>3
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M LZY&<OP6J(R]"_1G/+2OI9<,=TREQ@PES#$2FE9;GR!,'[!E4V?]L@N0-9
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MX?Z>&B=*);!WMBG:!SO)27^ '0UWUN!!><R&A#?#)\5[>;@K<>T'=78&YC_
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M&IE/EG7U(.9:P#0)IL[.PCGG58?PMF3'I"Z-S49KKWA^<@UT;L!HBYG2YG-
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M(P ^43/3I57-1J].)%-+>'3X/L%*[CX]L*@)-="\L\4S#=,R*_,"==+1>.4
MLR1EGT4+=$[\XA9=,%O+=7RFPN$)K9[I S.GM<](%8 CM!O-NW15Z?&2S8]R
MCD@%D;-X%/CFE<(XKT\;#"4=H!&Z7\1+BJ7&UB5KZ*KPFB!8YM=#"EL&/_"'
M<XT-?05TW%FYXCGEQXB:5I2,NC;,DRO%OGPT G8I5P?4X^/G8.;&2]W>9-4.
M;\9"V9A<R"I32S8(1SS.^JOSL0NO'Y- L:"$>/4L*)J #.[\,C6V/U)X/KW9
MZ6^<YI'A[\:?0SR=-%^/+VQ\_72L-[/W[^QM=5%RA>5/03/4'0:V&*2$V#YG
MS)65S%Y38OM(!QM1#;_LG"P:\ R M.':$EB9$5+SG^/Q4;5WM-=]7W_IN7Q@
M/@3>RR%PM+ZK7I62TQT!*P9H3,E\=F$=6)ZDUDM-0D/D]P5L.]4RQH'0&/OG
M&5&F%M:Q?9%^M%[_32"-#K<ZIB/ELGZ:0D0B_\USZY!@ D-;JB%E$IG<CDS)
M_1II/?'-TY=4^ /?H)P>16F"+&E!60+]-NJX?[*W!7_J9LAF;G5-ZY95)CV/
MDD[5-=F2I15(5YV-;[4USF6XRXO@;/7)4K8QEKFP)6Q>*"Z<M"%"&KNE& :R
M:*IOBAIPMF0$8Q5+T=7AI2[@@5-">'%X%+X@:A?G+:*6:H]'QO"1[*'?7(?6
MC2[&$0=Z[2=7ZE@NWZPO_]GV_P"3;9\+L>7837'!G#C<VD63X5^EW)[[C!6=
MJR$D8!; DMF74ZUZN,. V@):"@V("JSW=;@U00OZ_+%>KH9 V*]Y<DC<X_MA
MA''S10=J;'NX4[$56=B6'+W#WB3H(,ZFSD300%?Y);,5^>EF<M9ZE4P,((/U
MA?M""AS(+0/!E?\81:,\UDL#YM2L/?H;/_N^B[[+HT.:3A^6-Z"VS9&*>X?V
M73 E.KVA+R/6:ST+]Y4X?4VV$=O89:)W[:X(?56' (K;OTCLM48(3-^[I"1&
M_)D#DE^!@1LCPNVI>@K2ON2Z/Q>]Q.\C1\D)=M_R_(RDB*_'[TEK3 OS+\98
M[S+(DM(K-N$+>B7?MF4CT<0B,,9-YD'&+\9H$2WY3S6EX04=$1*5" 14 PVQ
M',Z!/!((#Y=3XUSZ#&"1%#71MON.F\W:@+]:XRVR[K</C@\3K2,,E_'QED*B
M,A&6LCC61;/DW/OOFZ#S*H4+[-A5)),$N?M+U@M8;_V (9/MN0-WZH&$04K7
M2&.=W+4&<E?$6#&I%/OE,I9)^X"C#W&825\LR?B2DKH-#];J0W7;IYN4"%-8
MVCYI^HO2+,>Z!5^A1* 5DRF5AF'0T_*L-:?DW=5HTG@8/ K:K@JW$2-GMN0S
M[8YXAW(/XZXTN<F#$:7E>>.&AJ;N8%@^8\XP)F/%5Q,>7>BX4KWGQ^YUEPDI
M/F)(K,$EST(!V1QTT:- /_!846627MNM,[9#DF@J+#&^JU^%5T3$>FS.ZSV)
MT9T=N]/#/@3Z,[\Q8L1;A@LO#&1\'DV+W '&I0PKF5801)O"A"#E&>CGHW![
M A#B.N*F .2 C,G:P461*)6(GA"R31$9MTG]+?TX3/T/;"\L@AVM)/W!UIP.
M?4I#2"'YY.^B,P<GI CS:2PII6.T:' Q:2Q#,]$E((/90M7#F8D"J/\ G2.R
MUF-=E$]$11+6+(H],"/[0=N\K^^_IH>P7ZE<Z\DF73R3==&K!4XAZ-K\O:*E
MZF3RU*\1^9U]U@+.Y[!U8H>SRL,IH"-";I<W\,1;ROT;CJ_AYDY>1G+S!S1
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MS-:\'[]Y2I%3KJ.8_V4\BAM[_9'RVX8AUW$.)6A][=E)(FX4Y4<,I-F2YF3
M-F(@<UO .6?9A?BHR[PB@]P,DT)T1(?EL4LF5Z6VMSG7VJ>#%T(S3GB:PL+:
ME%Y-RMY(KP+S9?7]S#)1,985BRJHAK<US3@I>^7,N3@,"&,STL(T_!$J-QQK
M41BI+&ULK*(EVF>_KFENJH/Y!Z*[8]'#>J;L.!086"*RH&'PFCFDGS)KFA;&
MNWW*@T#,JSG.YV2MF''X=E.(F,F^B0VPEN ?WW$6P!+@P-&E!47.RGL :0L%
MO&YE;C27LO*SS_;)B1&?\N[&':+BNR&9-L]]LPNXJ]_H)X9ZIMI(X@\M3Q\%
MDZ^SLKU]T<2<'KH=$HQ;#(BB"S':3*QT&(]9(@K:W\2GKO((GQR;O.CL;<3?
MV:[JGV?N(H/8A^A!RM:EI!&TY0!.PO:)EZSN(S-3#R/XE6Z%44TW\6Y[;(WJ
MG$VZ/8<*B0:W]YD_B\"P:B76DF@D5E;6/(J"\X)>MTRAEM=&2/;/]QMM37-=
M+FQ&^OF1>!0A=(288C9,G@2\RE^L6],9.:=Y.5*[PF,L&FDN!0JV65I=:(D[
MYJ^6B._409MT2\W+I8X5O2(XSF&=SEB<PYE"&GA>FY5$5"$:5+U2'SQ?)*_8
ML.>2Y,(FYH'#N9;7PYB:W*03S)_UE0"<<M%BT04D9-2UVM/F3*1^.6S*MV=I
M906W(;)I$6:\C3[;-@*IEH'X9UE':V57'(<Y(^7#-H?7\86QR=]C91[QJ%Q@
M&:=/'UNJO4*N1PNA]LB,;'1TN,@IDNS\@]\P@N=7FE@(TAVX"<80V#HQO/-J
MB(R@16'10H8]#M^MLLA5/ZC/J>/.:]XQJ&0;SV#;:%QE>*FK9< 'K$+1/\AL
MX*CXJY[8ZQKB^*EF4*CWBX4PQW.G#"U>2'%E+=OH6CDT3=][1_R) ?W]!U"=
M[+#8ZHWSK&@)3I!/E=-U:/Y%X(N1OF#D9G/*Q?J]4$F8%6PM6CSE>8<GC3-'
M&V6FU==38+M.!OU<C3=(51>1"<,+NH.[4]#?:=3V]RSE6<<$EA(W";4/^D?J
MQ7ZE88 U""BGQG_,]N K(A7P4E**/DDN< PY3"+[P&[64+OF%:]%4^F8Q8]\
MB"O($OK]R8MSJ9YR9\Y+_XH&[[N%-1HJLX*[-29OH)J03!U\]$9F0#;P2:QT
M-@TSX]2S>;[-MLD-?;W/J&96GPF-+F'HQ\\Y?!Z>4-TQ2D$F5*POH@6LJ-SH
MA6C1<$$\+#^JH>:FIJL"1U)$!*)J565^B%!.4\\#Q7(TMD'V6=QZYD[3K$E>
MK-\%6/,Y;&RVE@^CQ2*NVX[#L*]^\:0@B_VP%;46A3!74:Y9^9R4;PKVI1#L
M'(ID6M3WOL2R9-7'.R&M&)+)7HB'0,@0G4C\3I<YLZDC#3U^!2(,21U_5O3E
M6N@(^9)XQ(UN.;X( .S(E!YS1<>$I/?3U=\#?MU33V-R2@[T?M,A63"$WB*/
MNN,!$/Z[(Z$T92JA'Y_[; 8+X9E9J3_>[QCDYDF]!-1$NJ0M7F0-]R J-C87
M*O'$=W7&N_QH5)E@%3"I3%$URF(ZS>C%?P-7E#-3:EXR0/KU8D1)G1^Z>:(<
M :"M[T=LT>1+>>3R>Y$]QDF/S-7OJ37+FIM_:)D4C2'#: >NMT(W+^2^/-9#
M!04@%J#<9J?P3R&7"5E/PP)#6"(45=-DWFZLS_7?<^=K5\R[B=Q&WZGK,O'&
MS;L-8HB>,L!&2_P:$R]B)8NW-F -&C/7I#6(*4J<E1Q#)[%@A]A2B<_BL;\$
M==\2?!JC?RZ6V1ZUZGR6(^ 9HEI 8L!*KAP;;4M,9%83%6U?C2EGJEU1F1QO
M3G/:*[0KM"9RR/3 (YP3(I2W[:^.5P.Y/?B-55@AZMSV%+$LQD^N.\F(&0^G
MDV[Z;^9/;LLY5<867C- -]_(RRJ0X!0@/0</CTQO.16]KCQM"X%MJO:)_94)
M&P?(-'XN_<$4$9?AA/Q!QG,@AIPN@;N\C7X&G5G(@,32^84N_^H3@R'#&47.
M5H.S45IC,6^4\R,8[9M===7L!OM*$6F$D!0?HT#FQWC(9P-<89ORAD>AU<I?
MX7+W+CW7E9C[WX25]=S.SO?_3&+E?9DEY-G]%F0A$(M*>P[8.+T.UNL&942<
MOPJC(Z#W@I(88CE-(J4_Z]@1+@126P>%W7$XW9Z+(A51<]!S)#:RE88Y]FK@
M*:-8*TV%9'KY%F>:6VLQ89,^\>_7Z&S[)K3#>K9VG=DD8554DE42H^\K)_#T
M]18@WL>?>9])KO EQ].>' G>N]VQG,V)*.N:^&+JR$#I[%=, JI&O*N,64$G
M0Y=OAYW?,/T3:>._JKO&<M;/X2L6CYAZ:*+XN*>@%6H*.\!'VW K6*UF &?E
MG<PX?HB%,$1$!K1>[TPB_//V=CY=YU1JMV!G\P3\'?GA0;/A/52XB.?E[EY5
M WNU^[59O2L"8U%DS6:3VW3GN9!+R@C4I/\$7,K-C P_OK<<:YV,6\X E"@A
MJZ)E5=!&7"I81FEOZ+A7(V%ZW5Z2N:?JM-'@)<\EU]OJ%WNM#6:@"=CX1#-#
MTWFD0O."XY%]Q;@"NJOH(,H2A=<A@/J769Y\RUBW"E[;0-<L0)C-EPE#,YT$
M!4,7B2'EPJ.7BHFOS;9,QQIV_"@%49:9J->5D.%UERMA8O )57$4K/NYEO2G
M,3U;Y:$I1SE/6" 3!L\CI-N0WN%1M8L,@JNZ3',SU2QC'S^<-;LDL"/1A5K8
MY'MZEW[ ?REK'@1%7:H"*CMK)MC,NS19N83[E8X7QO_AF. Z;P)($6)RY6\+
M0.V.!N\2TEATE"6&L7"CG(N2 UR<+SXG(<-RWC_2,4U;KG?WO';GT.\Y\^#5
M;"HW* K;7J\+.AVIX]\)>H-?=&&[L?&!4==Y/(0Z!AH0<MY1USZ:DN94[4K"
M"0\*2?"GI$6L;6\D!$5JF6)<Q,1^\GO@:>4E>;\/ .]N4Q!G;N5Z3NJ*B^F!
M0/_6DP[_%B-BJG$^(L3.*9$CU4X"-$J#:X=8P&J.-8%6RBCZ@=9-"O  \5+'
M/\0[8YEYZCAAPA\%\QFJC_@,\*O20JH?V;L#/;PW: 2>8@YR\[H:WWCR"Q!0
MHF%9O "X #<0=>,UL<N0.,,^_TP@0"?C/AVZEX5ID#<TJ@=>P;E@<DO[2Q+R
M#Q"O^D?BH\OM61WT<; EQ/5V*.9U?)/^'^#S3M\!01^.VOF&<]D&]M)+WR@^
MTP73S[2_I"%W%W<QVW\^O+JV76RHM5)6W7],I%=;5MMC&]W@>GO]7>C[]%'W
MY\)5DL/OG8,8H@\&HA'??G8]_8;Y_LV1W*%:MA]1W9!?\'1_8- .)&A7H.S+
MOMGZ<!VS$_4W<%*M]?U_Y;H3_H]3WG]S]*XR''Z?O(W-_9^[&6JM)E7WWV[H
MH),/<"&%>\]@ZK_UG3O_ $JUDCNFRP L2YJ=F='+JESEBA0<V$>T#WN"L\\#
M-T_?S1>NZAR#1M_&[E\]1^2$OK)^J\X;T'LV>9LMFV R0OW[+>VL]D.K2?5A
MCO2'M[&C)")<48)G!81_ )/_;<FOG;)]D>#&*XLWV[>QI&R:1Z:?\/?O:W\#
MJ"3_AZ'ZTVB+"NP?@$+^?\JJ_5>V[L^<Z%M?E5_ V?_?X>CW,9OT-WTM.^&#
M T,7D_\ )4MOENN%R<G_ (L)! ^ISXK_ !A]?C?_ -JJW2$?TBX>SQY'6T(\
MD^Z3'P)8H_[C\M[7.QB/&E+?^1_;WYT7TKW!-1C--A^?DE=J [<[".E9_S9&
MH5'O"6[] ^P1U&W??(S2^X_S[W^ &[K_"#.X"<)\T>C^(V3F"Z ,95<-_XCP
MIVL1R=@G[^>5DC1:+-.23Z#\M/PO"MN4]Z:N_K5'M9SS?V>5J0=<2*M,;QLN
M93.S>IIK1$ACH#N,^D\:'IQI(E;J)\P4I4XJ_0#AWJ2G@CKIK>V=^2XU^=B1
M95QD;BD+,'-<BE([SY^,S*R:<?9M3;>U[ ^BRU]D*ET\[V+^QAJ/* MLR:0B
M#_,P[3,*11X!L&9$'U8%5T[=]'/4O?7)A61TL^> UM$,G[@B/BO R'GS5M^S
MI"[^8FSU7KM?.W#8'_BQON?F\(KT;F6'L;B[_-.Z2&N'BQ?\O0^*!>$*\B++
M9U(#V7V:.00-0L+'-"##;<_^#552P9I<D?XH88 &63Y (N+=K:,FM!A%2?$*
M0<J:G<G=8N)Q.J37'MYYA-J'IE4N,;+"IO,\9 DK+,)5Z;)120;+J'2R@%%H
M"#\KG>5**!=$8((9C[G_RCDZ%QN=X8TZ$G=#L"Q)HSL2#OE= .__EA_>^G2Q
M6-'77IF'.A0>-'2T[92M/'D]W*]0< ^!B\L$?PV60H=-NIH T>\$AA&X74PM
M,]$EN/U#<Q41J1"1ZG]1>I1+WQWQ)[5G5BO!A:+8;/$=Q#DE:XFA@D.($.'Q
M6/=;A"$A7$#^Z@8"!:%XC)7BLP\2A==%+3H_H(N"C>V(L?W]D15M+"HS_/L4
MTC[229O9SIR]%_8X+2X^G_.O>,0RB%+O@-@(OI/))U5S! 1<7()@VLV 2&6?
M&R RR"0&(@,D_.+IO78E&32UPD"&&*I)42(,A&4"WH!H$:JL%!)(]_$ZVDQF
M5(6B\!&$<8'"'R C=0#FF&"7 'XM0AI^=\_T]2FFIDP.32R-^Q$2!5 3+?:;
M%$)$04<KPL9HOFM;8OKQLI!$: >>(R2ZOKLI_5L.78^JN.E%4GT^6(,XH7_X
MOZ$=-S>?AOQ3APRR+X'?RTU]8ANF3_4</@J&C II3-XSBW#+D\D*1=@KYV+M
MNPX3>K@+#)@Y@K6(HL43/!Z+B*@93:B#)P0 %:(<4155@F-!N8I-J%Z_Y;30
MG$?BHOE8M"#R80K7ECA@*^7\#VKP,LI0@%SGAAOUC0_"IA>>K"U%8>;;T/BD
M&D1@&DW4]P':3\KHSEVYAH G\ ^0+8D4[0?:$L2[WPRX>;J(G'E/+X<;#S3W
M!SFCL=^E3\?.1_3I]16^954J.D'Q:*--^KO[M0"NN^8LH3[<[^9V1BVQ.X8T
MT FP!R_SZ<GO/D1B?#(H3@JPP@,[L(U9H@DKS-!#XJ5RX 7MA'(N/0!LYTX7
MI!QI"O4O&.GLQR^6<6H6W277MJ/9N[I D#9/C5$,G!MT# &&!,<BKP:X !B8
M@:])25]_^T#L<2\P%*1PHG1YK.NY<<+FV*=4?=4R1'/,#WVLA!]Y@'G<^#&
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M>BK>75+]+&THZ[[AB:RT3/ZE=UL@E5#&!&;,'^6!3ND9F\S.=&VABMMM(7I
MRO8F+TF[B:%E,2W661<G*CW*-J4AMKK%HGI5SU#47X'L=L;X%4!PLM+#2EQ'
MU%7M<FP;5^""P2K%WMEA#D 3O[6AII?^ /3W(<)DM!,0LM>&>,-3:LM,,PVD
MHKI?#VU\/--#;>W0I5OPQ34L7,*4&ABC0R<9P.!0JPO#.5/3'+I.Y7?H+_X
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M;7Z='I$S"_96>;77IMIPI!&ELR.]K+NMM]UF$B86^WRJPFY3>-ZHHG:&:LL
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M5C&B;G1DDZ@)@=,YGD)]A*?T<Q3)IJDWT4)\+K;&U0.JVQ+"+LE6-[-37*Z
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MU^:#3,3GDV?\,"B<%C,K3'[AIT5V*M-U AI04@$D*E@_+W"<&]^B@Z**YPM
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MLR3VB#6YW4H>=[F@R*P':<YHZ':Y.?%ME*5E-6;6?$)NU*5H1NJV/UIF+GV
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M,3<N:G!G[+P'6%19LRZ\FYR#())S5'+.0?*0<Q*P:9HD= /=-"A*$DD***"
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M)S[]Q1$^.UJBCS\Y8F='OC\X9S:_GUVC9]+)/Q+FTFGW_WS?62SP?D3TS"\
M0_''^_<^QE]Q^M&F/;W"%/OE_8\AH.<H!L.OT/V=_L0[E0-=^@\$?M$?"P,
M\W(]+;#3M13'#NX%LT?\R[R$((5^NGE:S'\J).!?*@ZX^JLR?[AA^*OPSH:
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MQ&0D)&24)"0DE*<'$LH?*N3_&0,G-0 Y'MKY-$P0*X!!#L(D!YU,H@=*<-(
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MV1W.9]9I)(YZX+,;5_4TE/%*2.6-OWJZVN=@Z.8ZHQN@V\@X5;EQ'QQ[Q]3
MJYV+=:\RR3ZQI5R3*J.A58WS<HD/I H7(.!DU]3I<+O)'Y\^LGR53K)C)H+N
MJMQR86Y"G.(3899/1,D'PD36,X]N1 J_+6UX(_EV;;UPSD2>3=A$F> 3N&%D
M-]PMX962FO+0:E<6!UW]6Q&6.QPLUZ-C_ CHEUXBR"MT/S9?"/G$WS1<L@)K
M=!)__Z9M2))W+NJ*I-U8%":E$09SP[B@BT:X3G9)0CBGJSN.U4&6+?U3NCMC
M)'VU3.O)Q8'*L%20(7%UG^CD\9WC2 2O+T6:JH.=N*EJ6%[LT*+X9G3CD[>9
MWI!WLY<N,(E+%G>+WAD][NM*'92 ,MF.$"CH,1T\6-T_^!K?DX*Y*RYU[#09
MNGAX=Z& /1GWP)^I$7-<8<RLK+YA,,[/AT!^6O"XWR^=^ 2(<T0O1M4+KU4F
M_%SO5NST72J[+-5DN_Q 8H_]H/CH^3/,ALGXX^N9)\#*==SA%SM<2BQ'D0\Q
M-NUMCQ&=AKI\QR/;/'YK)X"S[>>D8I\-.D6#]X /X-=7GXL<N3.664B+Z1?1
M('GTB*MJ0@);*;RAR>\S5\,WDEUN1O2PIYG*4+W5.36B_J3;@M)[,,9-8H.1
M.X!I6TOR6F65?IF4Q#,)>=F#;<UO3C):U<'KR9C7)_Q F=%Z"M_HYC:/W>1#
M5MI\Z;B$F1)]3X"A9,_WGNJ2<=6HNR45?I6ZH[LGP$.G$V _<6Y/=!\_[;B+
M].TU6[TX,W9/ 5[I#-L*I3&K<O1*>@(L7);0GX:EEG3=W9B>SO4E3//KPL=E
M2F)+75P0$J%?N(W?(':D@)MTV6\=U]G\^Y:0X_0DKOIXAT)##:E_[AW+N:,+
MO0JHWA,@T/%PD C!,CMKL3#2W\HUF;9^^9B"RM^Z"B/+K;_^J FW(GM:+56E
MQ':RQ/^CQ0D@1 3]9"?LG57X,LO7T5?K!+C'D Q@9O>("NZ+?T]\ZS8_M[E:
M==CB>V74'6>"ZBHGG<U&(G>UN6 96"*K0-3,16 3P?A"?FW3V8=TMW<,2^ZS
MJ,*GYSOC4RS5"=]7CBC77MRT(%S.CM)SFY"C<)VAG+]OZ,5[7&*KOYZVSC<B
M,7NKNUJW&N@-QLV)_LUAVJS:\OCNRDC7X.-DG"Y6N^+#"=6/(J&K5F'1[Y6^
MA?0;2^J\*(Z?"[W/J'%0PO"\N@[5/7<,ROQ^ZWA;@6N^?XD_0*$H*'I?&'H"
MA,6'Z62JBTP/?9N-W^A!/?'''U?0^QX4/7P"?.Z>9\K41S$IXNZ@H$_5VF[[
MMW'UOY=JZ(/IB-@*H?T27 $U?(W/3ZVA]!BYM=DS,*T' -_V;B0ZCEA;JJRY
M1JG5R"ZAC5V'!R1;%\3*9B]\^)+2BEGF7U* "?&0@5+XP#]C4P-3<M)&XLLS
M!4<R)"56*(FKQ:41>*+6]/6$0M*R6!V8=]+%/$0,VM95+R\T)8^_^7HZH(H3
MP'4P:3DPT^=FM*6C3?4J\==72R'A!]GHY3*D^-@NGXHK\:L)KNLW9X?I<0D'
M4O<:@[+EY0-M)L7E J_/JZ]V!*X^D.I=8^'O7 .(HRM<<5%?2ANTNI!'=B04
MJ:$O#=:?K5]9/3)"V:27:Q!(A-TZ[L?-GI23ST/OW$Q%A0U^]A$3_@HKZE'\
ML,TPV_9[<Q'RIY/*\7-2T7?_ .YC^<TQ>([-A]MEQ,HC*1CJ(R,G %;X1_6R
M;,?WN0NJFZF57')K$[3[;!O=NT_<CHI1MDR?B9ER>K=$]L3W#E.O(B_8CHR$
M&XU2G0#)RK.8W)J-SW>?3_FF<$VBW3JF0,$-C@(RO9ALIVS?3-DP>$^G&:!1
M;!,+JP_8D-4PIJC/*^_:-T^ H_>?]==3UZ^0'CBL56]CT^,>9[LML,W,+0[K
MI4OCKKGZ!WN> /1>$X@!_TO-[S_'?2B^DY7#,#3KTMMF@(W5>#>;,L!P1X@(
MSV2,&\'DCE53ASS6^!:@SUAIS58XQO<X.WIMC5=WP",LM(BHCDPY+$\C8D^S
ML)XZ@R5;R3=#9*HQ]SNF(CW?RBX'*M>#N&'!)F5F.RQ\X1V&TB3*L%?WW=O@
MJ- ",79-DHJE5J' !VK$]102&(00F/J\5;*95!L'L5?4D,L58BM'1S>((W&X
M#*OD=3HRE?E 0;P'K"P/259C(>3,05U2CQ!/R[ CIF)&[?08/N\E%GVM<O[0
M\;;2\W&AH9 ^GE)$3MJNYFO0$_0-4_AH1H,E+Y3"/ A'D#Z4'$02GNE4X#RF
M%IDYIE#]W*(>W_-S+'4P#;5U($O&HW0K5I0(7)Q_PBIVJCWL2C>,U.GHS:@
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MQ@LX^% A+M;!]K1]4_#3,9AK,O5LZCQQVW=EP50#$>].USUETH!7*RWG]*2
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M9S(*XP;+JY+:2X,/E(J)6#N"5-AI(UI"XMK#)XPYMOD=HTGQ6Y49^1"=PB=
MU-:&:)8]AR>A](<H5-,7-<[@4HP\^B_7R2)=@E5D%O*F&4U:&"!:TI*$7D,Z
M'!= K%#QJH4WA7VBOI(=IFIT6AKU3\(:R0*HR'6O8Q!)2ET0"P["XIS5P*4O
MZ,R"ZW/7I6O;)1#8&.%KZ)-)!MD?C-DAXE1RI%KT]9M C-DCZNX,=_CR6&<H
M8&+5U4\'R8 ^=4QYG;9E3ZG.F7);G="=%?F'_J:\W'?\L6G33#Y][$/(UK<0
M,!-Y3*<A3[\U/+R</?3P!##E.0&0DW*UIAXLOQ7P?]?N0C#C7S-$T/7#T[QL
M-;,[KD4=&KO$T 1\U'BRI5XI^:'5!H%37^#U^<A[8*P/=Z71J\FS84A#E9A]
MIE[J1?:>X<>@A/I9!EG<ZTL*\>WY2RNTTYE+Z$?.$HS>FF(9I=JJO&LX=$/B
M ?CWHR2O;7O7F=%3[9P :S=KII&T@G@*7&NV#X,;#Z:C:UG:W!>%U#?]@YFM
M#V_M#.L>IH_<YZ/J(K.:*FY<]:/(88OX9$[ZVA.BEAMOH^JEF1B8\!FSJ:7Y
M.6_2]?0M;J.8:REC\TC+B1I^U$=.P<38NPDF+M<! 10&(*=LH_.*):);M]<.
M*T;T%06>Q*,;^#CK@U89Z1/N-0NRA\.+E!X8R5I+4$R_)*2^]-ZM: ,FAM)]
M1@;^@97O<MW(6M*5<%$BSD_N-/<CYE0V^%&XQ'U)BWRS+E%@4J5Q]^D&N;G5
MX>PIT,9 <1_?7&\#*\:!KRY+C=CXP=2K"QV#&)=#TBD^6?EI+$JDP>1G5IAL
M"L?Z]%8:6_9S<3"@(TSD2KI[SQ<E<BIJ;M^1]0+U8;/<)Z $;225KFU*BPCF
M/M-NE>I<8JS"7-X^DI9_2#H8WJ4*H+)>?FG8(NKVQ]J\3C@@+]KY/9-YI&-&
MDM9ZO] A042T8EB)@?3RZ':!DA F@IL[XSHPHB(Q(1U 4N+L[DRUS_\(4N0O
M W%V8+R@W(P?3/4A',?(XFJ=I/(%I=0:A-OR5NP<+KNF8UDB2;UG^11WSSO?
MN8$[IIX6J]G\D(>IIDHQSH*WYM5:>4<#^S1%,*!8CUGM.)DI47M#MT11*-8N
M.CHALB(J-19[G/ZK+)Z*6$&*O#X!9>]N)5Y*]'O'HT#7$$IB_L;[\@2/F0QT
M;Y-,*HE^<A'\Z17)K%'3UY4NA\CV(<ZBJ"E*VJXQXBM$;1@\ASR3909/NXRE
M[V%3@H:I[F<U\8(%J=4BB>P8'BI&<:,7(:71"[N^XD_N94!*B82 KNBO25\K
M&0XM8\Q")ES %L&?7(13:1*'A!D@]]M4HT;J^/JV+SZA:1<Q*5*].M08I"(2
M&FD@Q_$<UDT?X7#+YQVN6P\S30W9/NO@OH7@0S8Z\G5 /("?B%W%/'8C/IAI
M:%0RL_@MAHH^T?3E.\,73 ^]&U-)$YZJ8X/3'R6W24HGT<1>]QQ\;KGSP*Z<
M*O[FEU'=NHIKL4H\IF2%7\@O;M_U7O_MD^F50:4+G"_BAIB8^R&!G8DA$D%]
MY!1-U\,4^R,N]*HP2BH%DS6I$^!AZ6H/!_HZ-!DV^B $F+ZN#M&+X.5Z33C@
M$P7[A*L7KV%WT+V6,RD0+YQS6<(#:&;YXES4+@@%I5%VDMCQ="B284E7:Y%7
MM9+5,>)=)[]+I.+GWM"!%[%/9FE$0'$YJ?8VMD"L6<K5&T[T9KV;F4]?2$V)
M,]$9;S\1>V,0Z52_DS4BG*=GN-DSO#)0<L_B:;=98B1LA</>T="QI#CC=;B!
MHC8V,9^87R)Y<<D-C<@XM1XW-Z8\+!3T?LO:&#D^+V8A6) <OP47L.9DKG"8
M"']D:!OB&AD$_A)/0"]M-Q[Y=-#TY:=GK,(I)P"70HB<U$!*R'900O_#Z)?U
MG8G)#WQ];@W2<&DS:K%/V'1HEKDH)UX-)!9=)>:_HJ7#K'@]:JBNK<6"['/M
MVKW7[NL)H#%?+9_TL#J\T: + BX:3F#L&O9UHL\H3D7:(:.8D-%R-KO?A@BB
M9Q8O6CXONMRV0$=BFU+ZV]7J_/)PV6!>.1."-2+C.N+4EUNLRKD+T%X\OI1O
MC2(FE\@XWXTEJ?9A5YKVCJY3V/-^6")2GXSB3FZXAJ<[$%CM5$ 2'/D0:R1F
M.VEBX/9$VZX^4ENV"0#(0 Q5FO5II-$\95)^$(!:E@B065VG+@GE(S*)Q=0L
MY:]U I?8SR)O=EG@- C>6(A-F+R%J\=X=]]+O"1TOU#J>+GB(N!-U"E;7R&O
MBSV 8(Y-J"U88[BM8'VT7V&I?31RUQ\956R0JW%="2[ CDCJD4\_DG9S5G#@
M5[60$:2;0$#\.786R(%I6  &'<X46W6??+7I5$6)-<[8%8V\V2A)5&L8<6Y-
MIKYF%(VN%NZWL(=MNDXJFV !J_=/3H#"D-78MUD+*R#5+)P:NC4V^4/E]F:X
M@D[Y:K[\8=I5<'%O[8.&,44B3851RZZ;U?^+LZ^,BNM[MFR\(;B[-.Z-.VF@
M<7<)[N[N01MW"Y  (3@$=_>@(;@[P34$"V3XO?=FWIN9_YJ9-1_N7>NL=:MN
M59U]=NVZ'[HC&=HN%>"2$JP]BKJ]ZWX+7\GG^A:U7;T9,/)FI-.]CMFE9V2=
MJDIN>CB>C&6A)SZ2PF^69]*[2TZ5-6=I5(L6"<N!P -@R3]WO&6;_%ND9LP:
M6FBVX>&PHX#O,<TBSIR:9[FHFPY,V=!1[%H[H0@Z?HWY/X?L]T2P I0C.@<&
MP@8FR$Y)R'"C82BA&"?!GX:OL"B\@0$F%9%MC:L1**[>CBO9 ;*9/T7&1I8'
MT3_H&KFZZL?7,'K!JYV*G/&]8+Z)%LA:IL)]] U^\0\2#U%YFG:Z??=LJQ)
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MR8!S>$]/_P+R@KB5PX7, N^Y?EV\'J*O=GVA:,[D2J;43(C,]?STV,PZ% N
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MA <*9H]ME%9V:-HQ_?%FOS^D&J#NE,D&O,G6_B1&-7[5'HA(-)K&2#?U.IO
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MM9'CG2IC 'W8=A8/MWZBS+BLBUBB;M5X;SY,?;9$6,7IS]R[L3&EKCI9V*B
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MAM2=1IAF1I#_J2Y4 @<\B(I,+=5GIP9T$R))+G_L4"'_($(9T[>XV$#;>'C
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MM<>9[<F$'RANMOD3HVOCPZ*=B&!7;ISJ?)XNMKQM-H^"DZ'6,C%Z'O(E)7-
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M%Q6/"QI%\^TZ;K)%$!@3+_(^M.^N@<$<%1&J)'RH@6)]I7X_G7=5P5D1:@:
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M@+.]^J@_]0_39@/X(TD*_+Y"H,_!,Z2?8,"PA FWF$Q+("&"B%KL,\KHB'@
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M)(I7H.'YF@$;R#K-8VZ*OF)*SD+>@&.%[5$5MLA^AN!DIH5,W<I8XN]R!9N
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MBPV8-RQKQL#HL2^N$#B^E9S;8[0 +6U"\7KDTUO/S?O3^_A2O+XG=Z@H+\D
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M_R&#;QG_ P)OO3\[^C5S\6[BO5_Q_P!W';C]'^&*YZ<WD)[C?P#RL]N_@?\
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MV,_Y["D^6.LEB81Y:14#PWUO25V,0CV:5JMUG?4I4^MKQ+YFKBJ1VFR(Y@=
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M-NCJ0@)IX/>/!70A=&^F;\_N7!.PHC6CX*E>'UN>]<YZE*;.\0P^&69_*DU
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MV&?+M%S^PU57*TD&L=>G]8!:Z[#F_4_2"A$K="(&_B=^2#]H?\^062*!C(O
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M[_4!17K)&/L&Z-)DW,7,?0.T+!KYLJN9.O!%_E^Q1:<6^[/S%9D[H(4?7[9
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M+GYW6>%A7R[[DN.K@//ND'M-B=TJV=^ _ 8,[C6?KEBTK/6YGQ%V:Z:=UEX
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MVFU)V9/2FZ>Y'>@FM$B2WG4OWKP3N<M)9<I!>S"<J51.RNF74H9J>+J.._7
M$)7="Z=!;? 0PIW?R2(A$+^5["/4%6$N/;F<=M@"T]L.E"N)(<$QE%G V,)K
MI20,J-Y0P6=2.*9EJ\@\4RG@/LXR(HPU/F.\?73G@N Y#YPAFW5-LK1+T,IN
MGUB1IME1U E?9Y0>KS.="1KDA7^]JL%]4&[:/6/DP-RA($\L'MZ&B$?9OR(M
M8J,=3$Y^1EL 6E_.?O!4%37CP[,;&ZU3V13QY#Z*N7^RD<ED4*5!#&1'I/_*
M;W5;Z]HJ9[1,-:1S\J]R7WKL3@+_Y-^1/T+#ZL JJ/,1=P?A]PQ+$Y8FTL<+
M(#[0H&\+U7\=!-O\=]C>;#W)MI66;O^+'::I@)8:)5.S\C2_U5].!N-&'90(
MAG&N&.$%QP+K(.,  6:4ED/BM@$+'VR6].JBFN#]/[$YA0;NZ7(6T9_WO*6S
MV+[,YW3PT2@AY.F/HF&K?\P6R?JNWT8>3J+3ST/56!(N#S\*7C^<1;<G7I3:
ML'TZ8OZ;<_O8-3&;SV;V;\EV]?Y_)[ST)W;.-O>?1H=OCX_WL]C,TS7!$]$H
M_PRE:DLXV2T[S+(Y<8^SO7[5_3=6_?GHJ&27<XX__V^M4TN SO^9'^ U6_Q%
M;'?DK= R_?C/4O:4+]Z#>13C/[B%O:!@"T+%GU#SWCUZ/$U1!KO$MS_O^+$Z
MIX03,#N!_.XR=;<>,*'F#HZ4@LOYUU9_=4P'A:?5^0-5A[@<3B%[W>@AB//:
MHN0IQ;P?'QYY:R/5,K74)5!$3 D!S(FJF?N!V_+ER2M2L/(,K)#X./MAJK7V
MC CB\?/\?M0\SL9_+U'EE'&G=O>'I+8I3*3MR3DC<BB@0UK;=7.L2K1&K.SP
M%@S\^K%L@P!8 (8JJ3%@^R9S'S<X 3)"+0 FBHS#SV;"QJ^S'Z^SB (I52:P
MN!%T=XA.1#>LVQ(:Q#,, /T2!GV!9XCM#NWN%RN#SL);)7TEG0*N,M[D]:-I
MG#%9F?Z9*5[\+JFTQ5;#!01SW#$IETZ1PE\;^LH(OS3LI :O;B\'%X758_X=
MYO ;@/R5\F,;"7^KL>:\)S6FQ?P;,$?#MZSA.P)+A\80^F0UU/,B6O$-6,+L
MXO5['5E>ULMW&?E,^@8<Y'T#_'_\7NINBB3P'4SX\PW A/.PN@^)I24"^R+A
MN^T/R#OU_+C#."O[!KR*^3T@#8A-\,8BX[Z%AO1(J/O*Q[[W?.76>?#22L3M
MN*LF9=)]U?$]H>3Z[ESA?P,(B6NFULP>LVL^K^A?ATRI\&)P[36\5^C='/"!
M+H50ODA/.L\SOSYARGU+1]YB/T&LZ)O$]-\+33)33I>=?O\C));=$-^ /AFY
M;P!QR[*?5<XY#_FG6Q(<ZV -<L_J/1!QM_8HJVS^:-15?H,WICL3^KI'QNO8
MS+?LE,_,7.H73Q(=_>2M(:1ZADA'5OMIJNEGCE'/?^V/:OJ*V&_ "GG/X3^B
M%OJV+(VUEC@*>47-K(O\ O&WQ-+]>GA*;]MWP!#H^T!^BSLP8"<W7:-](?;(
M]T[6]-9BLH>UD7\J5G_\+G2#_Q']C_U6/\EXB%GX5CVL]P"]+?9OE>=PMTR<
M1M:^ 2WKT_'@;OAKFP"VA\\*P<<W )1=Q8"W9\[!_5OM-Z#$XAO -BOQ%XH7
M;=MQO<0@UU<)8L=M.Y5V JJC$H<\-"VV9\"FZ7BSWB[[$B?^"B;BTST)CSG;
MG-IE6*GS/X;FY]T\6] *^(S2YQ[IQ?28UW_]\(EVLQL;^P:0SD&]!+=%;]FH
MQFL@8^&8#:+)=BK?71 @U*FZXO/%),M])+)^Y'VLG7UV?36$?F+[OHSH//ZO
MT4&W37]>C<7#-J[UYC[[^/ -(,>?>\CRN[$3(7IK2P7SXJZYVU/Y6^OV-L+C
M>U>*F,,E=+C;4W-P6N6;9&&QQ F]MD] M;POQZ*#\N-&ZG^-#H%',;4DJ<KX
M_W1O?C2D8K@#0\?$1Z-*+'4A/@JYHY,S76=1E4"W>N#;:8M*BB3P%AW%!D5H
M=C%^>)Z<Y/O%NKN Z8-0')[L_T :5V:2N7UYW?7F.IEDZY#DO":WMK?D9RY9
MQ=72;*WI'5DS(\-9F-7WJ.<?ZE4G,-&1K=SD6%@9%Z6\A("JBC#3BV I$@6S
M'_QYT*TJR\MA$IJ<$1'5QM4H.3S(E2BA.:$<.?ZP?[?GZE'\"R6[#+,D0-?6
M"CN[\D+(P1..TW"'OPAEH]!EJEL'@KG[=0+*'E(-T\QJW))1SZ(9L7M]>ZE*
MAJQN0(E].%*UJ/+F#B+6IUFLL,#1 I?B>65\&&'?0.4O&>UFJXS8@75!R(YQ
M%"1J<7ZWDN5\*&>91'AK9O]K4W"*&JXF+W)D(:BD-- #@Q0UKD%Y"CXJ$:Q;
M@*@G0GDBNW1SW8AJ58G T/\5X.S5OE7 Z;B7NB/E%$_L<I7_I']).<"*8WLT
M'2$H1J:]H>D@(UFBQR)](03'+-T05U Z^\-]9)R!07(V>#7%WF(E:+/)\Y+B
MA(TJ0]"1DQS<B)%RU&W9W8#R2M'U?0B2:-AMK9BN6SV$[-H^/#!5D+13.7#!
M*$WCX*!BID**VSHB7(PIK6YXC$'_]#3NV'%66 4U7)R,.B@PLK8SJB,GPL[8
M_677D;6C*6LK"[?.M"!W/YM0,]M^:N)*5V"0VZL\L# =%C.MZ/!G6]2++,U5
M!LH>N?CX?4C09 [F;H!.M]/]IH@0'N^+Y&\K\1^4(G5VLJ%I6;Z$#&,?UE;-
MR0<C^Z@,-;J%RJ9_! .ZIVGF6+0Y3%N8J,E@;17;SR)X,<JL108WGL45W+==
M0^S+,"#[/25O'GI@RN)B"A55+ XK'0J'*)3)KB.F^9O,*[-^N7!@7TK:"GB@
M(TO/.-$4#?;W[MA3\TP?<Q]A'3@,C)"/7",EESQ!OU>5H<MA ]GF("3/?U(K
MSL4U26[J#K!;ZG"D5$1RM*9@KBPG5/]8+8",077<57[O.S3J%J+NYK4$"&$Z
MSA=C+144PPR$[S.'CFG[(T0;T05[F^2DF>@$V<]1*0RYBO9^1CA"^%D8$3L)
M47.L)@39?U&O35SZBR7/HK+MYD,A8KN"^'4>DU_!*F,0TP#C'>.@=17]Q960
M>_710-=!>OFE2_^-;X$S"K/Q[BC+9880&8J<_GZ>)BDVQ%T=50K+<8J0I%!,
M&TL2'B8B OXN#)_*U[*&?#)*1WA"88COQ#(A6%]SVQ(YJS4GR)>$#4$1+Z:
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M\PPD,[:D[)Q;Y9+@,0YW*CN;[L#&([-IW01ATFVYC8D9&<D,573)>S\IR>M
MX:@]M<+&:;QATD<7IY^'L,NI)[Z=,RZVVD<,+9AD#)]973-QW:IW/%P=W5SA
M$BO=A B>>LCU-,T;:;\R#(Y1R&TW1Y+[DJ!LJE1P%8_G* :UF&T!5N&BRGI
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M$?B40C"2!I22H$:.:9*@ .)\/O7'V_S*8C#('> GV R_*S*^$,#//X*'7\@
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M<_ST-QGM3A28%@Q8Y +=Y<TX_Z(;N"'!R?MR)__I 2KIA]U.<WK,<Q0K"C=
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M@F 2E-PBAS:+ 3UL5AJ+4&LIL1=(BG+PU"N\T5)]U-G9RFQK#P@.L\5R!B
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M&TX7[MRA=WWKD2:#CNTA[G("',9IFFQDLR#%I[@+[2].SBZ^OB#I^7[A,*,
M^\#WQ9"L,-EN?K7(D)4>[G:"Z.G\?$6]OLTJ5'Q\6HM4D6?;Z;<(MM;OQ\&-
M\9J.IQISG&_)GZBJ5-LF:PDY/R2I+P 3PYSFTYDY!WMG4Y_0UJ=%M^!&;KP,
M>7A8#I_IK9S(V+@8IS)]R8]SQ?6M38"LKVALU\5YVM=S)D)(.3EQ@QL,*FFT
M7-I>7W6!4:(9KN[;?.%*LLF($<ZG^W<85MH0AH_INQX'\3F9&UL0B"DR2N<0
M++1<$H@(L&#2=$PR"5&V&.A2-?=U:&@H4P@,Y!]C&V?!F@4:W[;Z>&5!P7 L
MP4Y $QK ET.!<1KW/5.6+YT'I3QGDJHHZE&LTL[;(G"FZYY$71"W: \L3E#'
M?'2UB^BO'P-%2M'7XW*IV57(T_Q1BO$DH29H4(#T75@(B#N:Z"^@+R"4Z+_
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M(C!<-6IV,)8((BE R!P$%SGP.>NQJ#[#EVZ +CB):83_1^<0+#JQ4]%V?C"
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MH(>S+C[M&HXN/O8 MC>%PH0CGM7B9$P&)"D51C8BXNX5TZXDY;&3/@%F.C1
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MM$3())C EHY<"'"_^+A-&EBAQ81&#E<72-BGF#6T5#AN^:5O9;FQHM]_'U?
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MJ5M9 R77WERA&V[D(.JGI!0A;4^8C3JBB7XTZ"$N];<6%H@ "1$!:1F_3PW
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MT[CKJC!2U836B]R1A^1I>05WAYM5<LPE[Q5_?]!E.+JB^AZN'>,!N00Y&IK
MD2M))9/RT#_[[ZX'L$@W"-:<P1$I_@?7=-' $Q\>XT&$#X47]UG$QA5NJ<
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MTCMAB,ZKE]DW*-<XBL5B;YRQBZ[\YD7F?8.@%!?*W7P _KW)]IFV5[WF! ^
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M/(X(.MCI^T["".S2_"!XNJU$32PS&:F0T?J*/UO!RJ/5XH,J$29)M"<T(A2
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M8Y8-F2";?<7PZ*@ZMDMMJUZ 7<?)<B,5Q9$(QO#D& C.?;&U8/N3X/QG9DP
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MXUDZJ@9[;RZ&"?9&QBU+&V?F^)]F"RH]66_(=I$CN'X$:.=(< RVXS^C[7]
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M9R[/R=3).P )5%5=%0 $H@']@?X P,GF)4%=!X07PM,!X<XHQ,L/$%=4U\+
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M9N<+MI6Q4 8_C@:S9MZVN%V\4VQ>?RFTXGIZY'W=:,,K;V*Q'A>_@$.H 4$
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M(17-V[Y_3KGO?0+0_(!Q#'<!SL)D#?IM6&T:LQ,UY^?R^"OCT3!168HPJ5
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M K!6M077(\A!=7S*K;R'=FPY_/B/GF7+HT(C5ZQI"4K#T]7A7AA[PJS_"T1
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M= ^E=6!W&\6\*5SD3"L!/\Q8:M@I@X(!#CQ^:Y#1@/\ :%>K-O@##(^'8C.
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M/8H%* &TIVH?"UL]<'QDN9*Q 3,<+EK4"%$726+D V?0M2E 8W9,P376"5.
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M$.[]=^2=>V_F1_#QK?R(^O5M.").86+_ %_[^C[-3>+N+P^$(3/))*$I*O\
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M4H$B0I14H*2HJEJF**EK42 OLU*(4HK[TLE2E*['_3J,Q4RE.T^492DI4P8
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MS,*^7R6O$$<?_C?[/BC)CF,GDA+49-&I_M-_^ -MSDH^($-I6.U-:0Y#$N6
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M/Y;'\M:]O?7\O._GOJKU8^KO>S^M&T:)^WAZMX>/2T0^O@@;\'P?\-:W]?\
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MPH_F"U#R?'DU4.C/KH[?UM&P3QE21=_*[CSW\H!^X-'?])O?@;V"#O?GW_\
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MY;@^Y\D^3Y5^\?/NK]3[G]>M/6K,I1<D%2B'V)\OL(WM(9*1L *= T0_Z/\
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M?Q 2I8HDI5F(+%;ND%BUQ8WM1Z=R5[:MTE5*G%M#\A#98A10.U<R<X%"O@)
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MI%CDBFPIB6ZF!5CN3IJOAK+;[R5*[06WY22X  5]L=(!V>T^JH$*4DGY3E%
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M.#DD.&8N'#:U:.73\/,PLU:5!N]8@ @,2 SJ:E[U !%*I](W^[[@Z!\^YU[
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MQ]_O".QJ4J"Y(Q68OMF5+17 ?4&]3ZAQ6HDIM);0?Z@T6JQU1)"EM GO[MB
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MSBPK$F97VT9".4,J@$$ANFPP*!P<*\#XV1E*>TI6,1="M'C/-7Q9PV#5-EX
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MT?/U^?T/R_O/\2=G4GP<4VTW&OD/ !@Z[N2_WIU(_6(#?L#HGYG7M\QYV=$
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M("\4H@(3W0XF?J>HG^HGH9]:7?9(D^,=+2ZO^8^YO@'8IN1J@U:$&\;]!4!
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M/&$Q;[($N6Y(&87?T7SE[ #-+[N2B:V7U8L-,H5!G[%=P4F&*!'11==7[*!
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M;-E;>7/[4P-V-H7EG'X./ACY&4XN>$XT-MI)-]K08"PV]9"2Y/(,#$0;6L[
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M]"[G] 9+X/<=UC\MJ?]]N@"Y +D N0"Y +D N0"Y +D N0"Y +D N0"Y +D
MN0"Y +D N0"Y +D N0"Y +D N0"Y +D N0"Y +D N0"Y +D N0"Y +D N0"Y
M +D N0"Y +D N0"Y +D N0#Y7P8A^/-O%J$P1UFP+_BJW(]9@!( ^#^D,R?_
M4Q_ \Q_. 6)C6&,"R7_]<$X/X#+@]\_B_/K33%P@-@X>/@86)@'AJ0*"# #
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M=\(>W8U\=HE=WXG^'C[C[ S;"/'X%>7[EE;I5N]GYR])O\H[&-TU6C>GT2Y
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MK_=9L'53C'='XWAXF8?&>/[2W1+%B2:&D+J->,)JJ1"U07G-K&?6BC8[\GT
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MVT2#D_4Q5DHV!P@XAZZLXS#%28Z$);/B9.,]:>Y]M++;&[=:#30**B'$&"
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M7""MJ[5SO$7H)Y0@4F6N!T*R<95Z7C*V8Y3'BKBI3!,TU385W%:*!5"IE//
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MY&VJ=+196_23:Q,GLUTK!^Q+'U]:^:],5S+.%654PB;)=9G3;G'E2!#$@O?
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MO89GM!1>V)G<"6Z\PPH86X727]]_2YSWWSSPN;O0W?7H,;6&)95$6#@/0.%
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M]G%3U6'S<4T'\TLKE@>JZQ%I/,88@3%/JH<VT22+Y3Z15\J>X3,!V<=XJSY
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M1! -0P8"G/37HU7&%Q*-LS@K)OG6PHA0W0 /L[/QN]K8J::^1.O[N6=)[^$
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MB6"4/W9C8Z8TXZV?Q$K@(_J#<U&CMA-BPJH3_]"WI1,+SOSA9N0B-0!Y'FC
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MT=(AMC#A7#YFGKLAX/]D19^Z4/9S:_)7.X&C[3A> 54H,D6=XFM,:'A75V?
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M[\)7?U]PE#8_%BMYKX]$>.<G>_)=5SKKL9-!,TP&Y:T]=V& J<AQ)1ID  Z
MDCM<85@A?R?IP?+I/%2PJ3<_L+[AV#NSI8WIM#[CP7LH5)PF@[5V(5Z',FY@
M2W *K!Y!D5I^OW,6E0LBT$]BFB^<+&+E<O#LV_RLQIP[-# F:CB"*,D8+"?Z
M2TXCMIJBV/MI4*35-B$EEVM,0'E_C(T_ C8W,6&AM51GB;EL9&J!<AEK39+:
M^K1]E8\F07%9WPKCJ5W/T.PT;4'YXR3;3]Q[=-9]3,8-?3*"WMT\6 [A9;"2
M*N8:!:F? 2+6RR%!5F^OH3O_Q<PBTT/XD/FZXX4_<Y4LA< Q]=$<0&B?[VRI
M?D/XX<@.-MDGK\""1/_9O.?>2R]N!_C3_^,G8P[JG5V"T8B]=E<@ $#\VU7(
MI?9X+\^SX/-P28_'(SFQA]Y7^NN4W,%+NMLML[&7(_)"HU5B"UM1D6M^-E21
MD^T S;>Z'Q+_0@]UV7_X1\W>T:9KG?;4$J:G!\5D@[TZ1?^L=QQUWNK^84:6
MWDJ F!5J>?PS2>7?AE3L \44EH4S[AD-?GZL)&5Y6?5=UGDO6;[-),,0ZFP*
MC%,W1F^,*4 ?=;2H?!QR;QXQ>%M2&BM(]B Q9,?K1P+\>EXN??H-G*9V 5@6
MKJ$F5$N@G;?C30O7,@G,D7T1<IPGIE_HG(6$8(U+L\.>7JE9L#<B8 ^4P;+B
MF?./4VST!?ND['ZD1G92)\X >YC-/V0AU(3H* 9C5%4<8+L'/XYO*\?=!M]9
M\&^1NGU7ME06F.,_)VL./%/XPA3D.,?^$I?\%U#1E"_N$5EU3C8N+71F_\^%
M)3I;.1GA\.P3+[ *_2C&3FBN)^_T3:I%<:+N1/\JO3Y6A 9!<IU6;@N89OZ<
MM[/(GMO/9MH'FZ#D+F"LK;\X(S&V 5E<3]+H:.?K:)O1B "DW2O;/6H.P:P)
M5P%PE(.G&:4D*T]-M[J[<G7=$=:X4IGK8RHS;*N;_4Z9@^3<'GS*4$VHZBJF
M>7!,*SA"8&%WX5FJ)')$X0\8E:)-4%3))&XS_F!6R#S,DUL#8 5XS=%4_31)
M9LMQJE+%84]FV1"3 #@<I""SVRV@&#LJ7CQCC9RRS'Z7@UX3OPSSR?^JH/A7
M,<D9I^N6E58/2=4LD<21)>FC['0*F5I9<QWQ5&TB3A0E[F33DBJ7OO>;6&I]
MPI54O_;@2,FH[C.F#9< Z](3YFXSU(5W.T,9\A/@9=_]8B5=F28PNQD&)@8/
MTSV+R>,UQ;@"?DCR$:_ 7TS';C];!?@,Y#D7(BGC^VW3NRU?EIZ+M,O%%^C+
M2N)66-;7)&GK$<;6_6B[JG69*C,DF)?^\W"A)P_W@4@#<=I,P4PRMX.(+![7
MDZLGO]B1; JEG>WP$=DZH8B,;(;?=-(R# TVF=+AJ!Q-:%WS-\L-6H;48NCK
M+W':-@EG5955-XQEWOZ[K"(*^(=/$QDK;U1 6#SA?80TA/E["Q7;)5YY'P"Q
M,AT3'<T"B]NA#EU7";1;+S^$A8QB'#V+A9.VCFC)MV'_\^8O&=N"Q894Q7S)
ME1H3)_/YOG] ;6>4N",FHR6<*-,A;U]0-&0B"P"B@H-YFWE3F;\@U6BIYCX.
M%G2BE2E9L$/),02\"IYP3.YO*J\=,?TZX<FI%(3<Q^?H(N?*EQ09L]&.F>JR
M>=P0]_D0LDZKK,L9'I\9%E_:+ZZB86:1NIG\M-+5AT18=S F]8G[T=A1EW!F
MPUK*T)4E)3[ @9(AJEN3Y <>S3TZLZ2H^DXPE3.2VLK<MDPNH6*(H_:]F+8O
M_2>K%/BTF:\P?P$O#G/DTO[(RJ7S0I#CXT7/^YFBDGBZ5(.9BZ4*G&,[:)A*
M1#>JOQ=I/MZOVAA[JL(POS0U2]_';X8T<]F^9VU* \P*N^DPK*7'!>TQO2MG
M-&;645E\MC[)WTF.!-5V*X-QI 8*(%#V@;^ 5-&UBWS>0NG21>X%G9+5%4'!
MJE_GC=RAD%)9\;+Y_D>B$ETG?)-?8@?3OQ/]\(ON30POE-%*BV?.NL%:FF=^
M3 _5/!$5LF7<,UI>9SGBT)(D;[L9NWL_(VPL:7SFJO;%%14VR]V&*&?*S*(4
M-S@*!W=79::)I$?!X4& @*+318X5)N(+-@R6(GDJ9KH"K1Z[0(*5!=)?@-4C
M__SQ?&6-8FEU';6JB$D$CQ.V-$4;NB)P^X*'>Y:L5 Z^.FBTEZRI3#3M,:*F
M5$A0!"]7KR3)21EG3@U%;G4%P;^+YD* #O(=1<7QL63?IX2L(8OD,-'QWM(V
M"+@/,AM#1 ,1HIQ];_7*L2^I#H^*2!H9@A\B0,=$.NUF^@G!CEL#//EO@T5T
M9/@MLF4H#)&NQ[ESA'_)[K'DL2T?R6:.XK[8&LPAVZ !.$.!=!R$DC *L#"8
M_# *0'K2STYU\\KZZG\!M^D?D<8QL4=!*:^]\%^2I7$BA2CP.0@^N.L"ULE&
MIC'6_7UP=N5IGHNW7TW[27<5-MDN2*T[4<VY?W+EM'\YZ5D=,]%68T1Y(:K"
MP(.SVZ_,4';8AU,>8//C2=7CL1".*]]91@GK+-"QH[1!(#.7Q^]@$]]&A>YT
MO_"ZH=M2+S'V5HUPGC=/*7'):60C;R4QGHO_E!'X^N$X^ .ZWS_^&9JR_8>H
MI,ILN4XHP/7GG4"!J,\7()D?V-0H^SDDB774U OOW[;V1H4@A *Q$.87"+?>
M#,\L7YVS!C'BWA4(=+/5$,%WLC<':G2(^%[&LM^SW,-S^(3=_>'?^M3/%NW"
MOT%4Q$[WD4H6;B0/F(LY; $!U_MK"Y7\.R*CFV=&S]&MG$)1<ZBY^D\3!.F_
MF]7175@FXX>DDE\SG0_QZ&-]V,%*&BFH'GM]NO-C&@(HKN2.2I_ENH+]6^G0
M\!)TW6Q&8^[N=V6N+1(\6%]1@&_++K3?]]P)C>QK"HQ] W=%U\:W6R)K3!BE
MVZ9VU@S"$+(:?V89GQ#;:R'Y1]LOI'"K ]UEJ*G)TH>F5+5T&RLU4S[$&OM^
MA8']D!MGKC [2;]!^K/S:4,)-8!A].39O/LWEY!B07G=DA'T<F;,:%_3B9:(
M/G:L]*PUIC@\I"R\++$)3Y+2.V58-YD)&H]TH%3#N(R!G 3=P[IU92$FG3:5
M'DL;]<86\76...G353SH]&A^-+_=>EVDB^;)LO2(Z%V4MY_RX\TN\T5'Z%*&
MD]U4G:7^2-E7N5]BRDPF)5GTDM5N0347]NQ"LE3;U]0T*,3?F<4>WWWY\<.C
MO9'WI0,Y3H<UQQWJ%XG*]<I.B_;;&-6B).CV_?1ZHLZ4Y2^E,)I0W3Z=RG-U
MH2M:G.A>.1B,\_UP8["^T4[8]B.>&]IP :-=\XAB)V5X=W:LBR^O(P_TW76.
MM]5']+<;.Y)3]&JNP>#*7&]3ROJ1SB<23A\&:YNKKI8>1C0/7"ZFHJQP&(Q,
M0AG=,8E$'/+%=Z$V(9#^C(-$MX,93V2%C&F2;E",X5Q;VGH(^NOGTK4<:$O-
M3&EUJI$7DFWE+'=KC#RTQ)[:[ 1:W6J=I"Q%E)-D'UC^^]PM</AA9T]P.WZT
M.]U+4^V5J)'V6[MG&^A\H]M1((R1:M8\BXSN5AQETM)<^#1/.!C@Z=U&=)BH
M79+?@X%>4]I&EVSG/O![X^(5O>A;W*./G=U9?;6I$P?/2>SYG)$IWPT.QRH%
MDF2,'3 ) $RNO/K3.6(".UX)QVR1R!$MQ4&+$HSX01+T%U"Z!$I:]O+GTZON
MI:7(@\6TZ&STW]ZV7GH2X5[P"C1I;JV0 =!H$FAIM=N3*W1_:=S\/G]*]J&!
M. $8'>PW^:D(EFL>+I^"PR+3J:LI"<6&\N8/O7;%[\V<K+ 6>9].;^_ (Q2W
M[G?AN7FT+JB?@8MR66S4VOKNYG'8)/&+;=IV^<%=##/\3\T5RU/2B9-ATD@S
M*$@F-4&8D.+S-^^N; [@Z!$F-@O:[=@;#$:<$E7E6(SE;"K0H8Z[/Y@3XJK4
MFG04 41S"IY*L6.W(%W&9O/MBXLV\)<[DMJ#K%[.]PKE>K01Z*AIS:(1.ZSZ
M8-V/N!-P>#VYFAZ.$02\7IT[<M''-SX^'M]G6/1\1D6U%;@2>/_CTQ=X;>%Z
M=_V<&(7XVWN$N^1W8I/G@L5TW_U3HUX>CIAF6F^0'O^+S?K-]"'IN^#5K]];
M NE')]]<CW84EE&=_Z.1=MKJ_?B$@3Y[3:Z[]N=W8/^Q*&'?,WX?.#=2#":3
M_ZC+[#[QC=_XW?'TX'^FH+H!PW55MQR/BU>Z>[*0/>G3MG1EEP;,ZE.I>920
MN4!+[?R#(ME<.CU:Q960+B6@1AZT+U<H^-?P/NG.>CLX;XUB>Y18GJ#Q,R^[
MUZ@Q.2768,[!*.M$LZ!>T[-ISTW4S%9J;]W/=C+WU^N!-+;U@2VV+^]:A+FC
M<:_ BC:P92H574A9<5A32CZU*2C#(532Q"UU@"3"<<.1MBS;K>\>/]$1^(,8
M&<;=KF0Z;JCY-N:Y3?G[5V7MEZ(;W2^",L-!%;R+<QP#EV'SXLF_FR+4I6F4
M,NEX,+MH03\9Q[63>^3%-65,:V&RP,#%_7,6SLD1%FY,\\$D!\M)RB-/L->L
M@";/NW00%3=W!Y8)@JM3TT>R[B,4:#2!0QRV[@D<%YX34>8V ")+I8$NR1@6
M':D5&[S;)YW5/W5Y%QU']O[5:<[WVW6[M>#Z]L22PH+QZQU#37D%0_7C:ZXX
M*3-Z,)I6>'B"X(1%! *\1#3(TKU8"31%W'&U0;9YY3HD!--]ZR=IZ3)NJ<^2
M*J7F6)H]^\G98AL6J,%.DZ\5G%5B*B&XJ'MK"<*!C'#T3A$QI3#LP5OS1RLI
M'6_^!?A\SQG9W]_DVV%#[(D#I[7JL:=T-V=_2ZCNKE.5R$F'8\+7=05(S5)D
M'=ZLE[-'?0I$%VN@Y7=VNG(:?KY7\_I:7E4E46]@B$MZP*HFN%U1":/*0%U"
MR_VI:(@,PJ#>'(U2Q5D$6[PI4Q05.L+H>#5=$)"IW<JK,H3'HG=E'X8EQW;^
M@3(>%J^2T84R[CD@\LYKWK HC%)'6N-_!^(XU%C?>1/L_P@ER-*C+%SAK=K7
M NTDRG7509K)=":VZ!"2?:7T0VHSIE3<&"\,0**\V@6,[WR(H,&$;//ED9NP
M?U/@<\)?P+H2LE'L[_0 B95'N9[UWD77R<W)<7D6USJ%.L<>D"'AR:+@\_7Z
M5#+:[>6D; 1],76W'4-,;W0ZY373![K+S__ 1"TI!2??9$9>QMDX,]77YIBY
ML_.',R SD-NQ&REN-B>V5EC7XKIBS=)5U4[>>BULS0BF"!"=.8% AP!$03U^
M8Y1@-S-7]XJ::F3[K7QB!GB--P?0;V^)0+[P?S8HJ<7]TOX.>T6:M^*'74E:
MF0V=VN"_KQ=!DY,5ON!=OZ&!P(;+"WO -\WD)\O;X07L6RY_C7(<6"FK//'T
M4E7$BXGX1;F]QX?/O8O7=),^$(F)'L"ZQ:38,HKSZ('MU%$_:R%MD6$]L;:_
M:41IAY*>^FU3S3Q5K"KS4=L#O45A!/()@.1VB.60:KQ:(ZL&V\;=!0O<SH"-
M]*4AJ+ >RO*Z%XVPM26MJ3F^'[6OXTVS'?:G<8RID*->(-9GLH>-.:E%+'>-
MG5FB;4^NYZ_]O6GG3I1',]$M7U5 [R,8D.\8++N"WWS'\/CX9X63H,_YH\T0
M=!JLH#8>9A+_B-:UYO<7X&#+W3V2:"/#_65!K4$KMI,8Q_;T94@.)OY.;.,O
MX$#QU]:MVG'0"\/2&]=,O.B67;ZFAC3W<2]%V0GWZ$>5)FAMOK_!8BO.;\IG
M"3L>&)4YU0LYDY4UCQK#Y"H^W0<'@SV_\<QY0Z)UNSR&3,HO4E)(DGD1H$0.
M=(ZHU)M(TZ5+P9%(V5I;5"*+,SO&LB7YLN0V>5PDXYRP^"*8')_0(?:[5.U%
MKU/&!NEJS&O/>66ZG%;-I*$N'IV/ ^IN@'FP0_B@BUQO>2,+B:JK\X4>492D
M<9X5OL21@F4L"?4].EV[6X0D!_2RZ84@TU?%A=4NB&D"OXV?,TW%(Z3/JZ')
MRZ+D@ND#3J@R5;%<F8"?8HX=#0ANC)B70V?6.['"J*[B?+5-A#=5'OHK1KYT
MAWEF23LAM:U%65_AP<+(<Q99G7E61XLJL4!:<T8J&:MW,3FA>,5^+1R3KX[;
M+Y]0_^#\8@IXL,6BA_EI68J3^-F+)&&O8:[G<ZIV:2G58;6-&S>&WB!^TQA@
MT23K46[FS._Q'U_*J<;5M,&6#\JQQ4>9A(W+E_&9>H18+AX>11GR1Y5J8>0N
MS+1^Z2K^40,)AO?H"N9#00L(AI7%7%.=-7VE0 $$&BBV6%[1^]>M5@F9/V][
M$!I# ES;GE1^+BVOU?2)H?-VR_M2J1TX= ;L;%CE'5NK>5IBOI"PD8.R.?F]
MT7F0H3R8)]0:5A+QZ*W;QE(),0>40[!!K)6)>]REI-4E5[!=U,Q@@%78'^/P
M=CN[N$V]E8/522DN?*R*&@)_5DMJ=3S@#2YAGO8$=(XXX?Z)-MO@5 ?X?;(
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MOH<F@9!BY7N^YM/J@*@,B27_ JH\U1GQ6>Q%36-'OTB(3HJ>">D>W3=A8*R
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M3GH=ET<>5".(D<3M'%)62\DZX('("*")?T3=M%S#M_)$+:/0E$LA 6E&  G
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MOX1JR1_.H8Z9*$\[ZX**"+U?6E?G"1%/HLK4\YS Z:#_S.A1FGT"D\2&DH"
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M-QG$00@<LUYOHL<:(>HFG)@>J4-XYJ),0MR2YG!ACWCTWEX:U2BEU,"8P9G
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MZ]X+8-M3>+' G)4)LW)"\@G%WY%MI3P%U&G_H?*6RJ:<18RS$)RT\&3DF,2
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MAU;VW=/=JY@.)0\E[]=./#D%_34P/+CC+V!M>?R/4EM %AXG1V:#']Z8 ,\
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MR8OW/VGZ_]\*7LRGIH U$1$5HWNTYLGM5L?=4L?D2X21?EZ,)@C>F FGMVW
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MJTZ:;50&$>IEC9CXO/_]@N]\R ;.U[Q%7'\^0IL^,;XNX9''0UQZB-T-V?\
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MQ>.XMI]\7^B3;R5^[B$HW"?'(%DZJXI))G[9,'Q"7+[RSS1+RJY,J$IBO"Y
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M.2IK&%).6$/<Z-<63)\?C&(E_38-IBO%V,I&3?Q'T>%_@MC'Q7\#4$L#!!0
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M$-\=!$!4%12/3C@GUW:LK'8H#QLYU S@)ZFZ(?_"4X#_54[!S<[ $(E6X8#
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M+P"VW/?]1QWSKSA]+],?7^&(_O+^.[4>Z?SL3RS 7^DWWHE<ZW\A\(O^&"X
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M*!+M?N2QT)\]MK.5L$>Y(:S1,C"$M0-4 .KB;B\E\ ?W/^W@48=I:?W7Z8U
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M5;-;-&(>#VG/<5[21]-Q7;8)3+BGJ*1L$)S''92$J6X=F/LV#B#&.?E^%05
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M#QE+;[$7:*[6Q"I'A:9B0^\H/;D?3Z..T^MF(1+>G_3UP\M5W7FP(0P#Q(
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MVDM+"885FT9<0K\5PH"$X)^H":KB!]E21M+=:W&++9X,:FE^H!NM>!)4-K3
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ML2VX1))'C$!*#D@3AZ"7^>*K>@OKAK,.F3?./]WLD_X4%!ZV(S->H7%;UX-
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M;G$ XDSP)V.J66D6.%O;2J]!F[7L&1P,6&M]H=<=E_29]YGX$J]7^[G^.;K
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M$C3HA'39\5\*84E?\Y?1X<N[>M\)+KGI_#;F7<=Z*O.<U ;?A9XHR!.<C&L
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M(A;G'4KI+?SNEY$X+)>ZAW.?R3EW6.=NZO/)F1OH+)1R $V3-X!2X&'BA19
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M>+O32D'WP[ 'AXJVIIR294&#9Y68ID?$KJCOVE?S1>6*FT,*@^UK^(+7J^L
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MS[M2LIY5-A6!C[XVCEN<MH!8HXADH 26)'*,GQ;4>NM;7(]Y<FH:M@?J,\3
MH:I7<O@XX G/7"$^3\=CX:/LHY"U*L8." 2<4X<91@)>3\M3:L3HF^^KQ$\0
MB(L>\V"MCV1J)[.TMX_")=\M (*TB<,!5$TIQ$O5@K2#=-V^$(@V>4:^,A^.
MSJ@WZ>S@,[MTF!5'P]5H>D8\>K$6:<E)2_UQ569$S/;<LT<2Z*BP>LC_]FL>
MA??8)%>[6P!/@H'J3F6"ZO7\ZT]::=^AL^6 SPI):+^)UJ2OLT]IH",<*K..
M&!:"W7L?'*;O0GOKN_I<CB,A)V%\!];?["9_G%8CT[<:FH5'=49-L50Q"E59
MVFD_;1O18A^LJ,WG.0$=QG-IE]$$QYW8,'NF?.8BQ7KI&]T:D*Q 05 ,>WK2
M/%&VDR,T(Q##S>K]=)&2NUEX-B1K$7&QF'&E;&U2-Q.WU,F31Q9YM'ADOZ?E
M;6J<@@\A'])I&SA)FG"E)H!"<F02Y^/ER*6]=K#KA2><CGFA?S'$Y8S&B@K*
MS(9#NDM%UV$W*YO_  [8,QO54\/N@C?N'U3R+1_H; F<Y>?;3H@%$0P@3EPZ
M\P(2O_M+0@\R Q97 S*RX)Q"$#IK?XKH/,X0K.,#C>.5=["1@35*</B8:./[
MU%76,(7'5$+ 9]W)E>_[[VR.I:)Z&]@]L!5R/Q]]JRF0I"P+#0OFYB@/+D&"
M@7+H<HR/.($!FL7:A7'YGE@42" [4CKD8#OD.TNK\_9,^[TGTEAJ!2<_5<8?
MWB\OC8K2*S.1#\VVO&$\OU/95<!R%]>YWH?X/TH'FC_KQZ=**5JM^&X5H_]!
M2:3,?S#+WS+PC;=M=$[G9!)4)T&TW.L%+.3*#VG)'6@5T-I#)K&SZ'!94/@@
MG#\Q!W=)XB=#0<4S\2#H03W)E2$D0R$E<O;P'92LJ+FD$DG+$/(/H,Q@C$C4
M>G^3"IL:MTM]J?LZ2N_!X?(5#&JCHE!& 6V \PSFR+_#DF)M"L:5B)I8O;Z>
MM#B2$[Z^$#S^&W-D.!A&FVB\;).BSS2, N^F4>M:F9M4 )K"$?1-"9"84W&Z
MAT.ABGI&SY _&T0R-4)(KZ_)145:@3O!<B>3Y?=#4JF3'B-3*JKJJ5(W,K6I
MVMH$VCIK_/2U!V5,,[[IHF#ST5P];^K$_11S0KX9<X?V'=!$>$(ST2.ENU^N
MR1<;'+\-Y(>I7 4RPL<C_5Q?+>$U,33:. >ITD_[CY4T71JP&MUV&OY,JPR,
M.JL=T7J:,'J]J\AE==&2YI,?J"G$5;HU<!Y:)Q%J$("'8WQ&LTELG6$VEPTK
M=):9-B%@$<B,8$6IIQ I<O'JDY*EE.-\7I44'JP2<V1H&F#0*G1NK@*(&D/E
M!='@\)(4N9VJ,K>:;][I.[_R#1UC)R9LM\GJEW-"+YX'0RC?:\#WJID&8_ 3
MS Y>5'CB'L*TA-*U2QA1JAA3">#P&TT26#><(L3Y8DT;HIOY!PD$M\ZEST!T
M00R5&0FN?K5DWK<Q/%7V.<Q[N^%;\][>*>EF]IU@)PJ*ZVQ[UT^:;<5W<T^V
M$]\53C@#>V'2$Z)J,2M6KQX?W2,('W]H<#:P3%42@($RPZ/9!S:AX9_DM(!X
M['GW)RZNOTA=6^ G\>VPDA*VE78GDU 2<J:&%.SO?T/&()?-K91N+W('UF;$
M!OX!IL^&7RY .KRTS)%89LO.:89O@%W]+50JZ@>E"($OC=D!Z$)WKFX5/DE.
M!;(F5O@\-E2OLM%NTL:26;&75-TBA(I"ET=4 ?3B<YX;[R0-)@0F7MM,P]/1
MS14[[;V8?NBAARH]N$]7G?*O.I^1-/;SNL4I+G ;T#;!QLI,'=9<<T;M":!A
MMA 5XX80SE\*:/LN/OX"*SLTUQF*O2)E;!5]%3R[O1]><..I=VR[9>Z*ZD_O
M"C%)]:,J=H261]^R!N?);8]D+'RX;6V=;+6UV2VF.XH23J%8WA:(%H#WX.0+
ML"/\AAH#YV'<;>P= ^?>;_@I:;^_UXP(A>RT:!MF@QE?D51K18YWD=TI(%HT
M%%=7EQ5#/=0@M=D1W(/6A7KG9.>Z$.-L%6B)V*)6UKXA:PK>L<^Q=(;WYSQZ
MRS7SZH=T/4:V8ZSPREXH;GQ9H+%AGJ35B?=97&Q;X%JEFI/(\O978B.4O=ON
MBQ[QV904:Y4;.T<[E4>*IQSO^T['II-FWR>%8,W]H;RNP_@)XE?>NM?;MXQ/
M>?W_ &4+E28GW"[$:B:)%X9&4DSB]>JRO?=30XF!H=);769FM??U3I^5GU-R
M9U7^ 7[E7F__WO^VLM)*_=?:?^NEGRM)^('GE3KQ4T6'+YV7#+O#@ZC#RH)W
MB^A+)@Y=@[2_T'@R.5O:A"WL^NUV"8NO3<MQ'MP#Z4FF-FS5"Z0Y#770K5?Q
M#/1].SM\^R TK#>BKZ_R)1-H^>=.D^J(6L<QPF>^F$29^MH9O3W$LS?2*ICW
M3/U]"&9UY&=U_.K1+7R"?4;@*V+75S4_3=<WLRZQJ//E2_?F%"[4*F!Q'!$
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MZ'N_?/(>7^Y(6V9M6=:F_,7(J9,)15<-*PUW1(I8YM]:+'_'HSVE?[U>3]?
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MQ><>$,9'-[0Z$7R+DU'+$DBA98,R-M6W("S&#R2"&+6,X%W*_<>W(3[)<_
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M5ZTQYV1!KHZF6J&8V_Y<@3W4NLH,LM)0Z %N$>OM; L,-ZTT% J/<MB! @Y
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M.I)R94-#;:DJ0@RFH?EN(22EQM*E J4=;WA7#-I>M!1>!476DF%H$I4A><2
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M"%=/!N;>_P")[9*4M6AR!0@9W "3O)YR.7EI53$L.X%Q)8[Y%H'4Y95D;4L
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M )!)"W!!DQ&9,'620#RF--;I>#<*,]TRA6$@N$M(2'[90)R:A1!TE"=2HZ@
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MVB8  ),$DZ"3&LF03J:Z25)(/!/*1R OJ02!Z<@\=/T]7!X[>A[ZLG7;H.A
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MNI0G<.S'@/AK*@O@)U8\&#XLD961W5K:-WH;0T(<H]?4BW;XLWXB056 >X;
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MKI'V*2=561@IJ;1WJ&=M*W9&U;V(]LN7",M/=RL6V3F!0-@&C/+_U,>QQIJ
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M]SW-8E+3U6B%4;*O=2&Q2FE)BXFLN]9 G8>3OHW5QIO)1 )1<E&B;3666_-
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MTQ(0$#"@-3O3^L(C33W9P+S6F]5PT]*,T$RQ/#N8MYQ.^O;B=ZE6XOI;<_D
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M+,(M+:H?,:" &P1A145  )N:K-"Y--V[@K/"9J)M(@1<-#7+W"\F3G</4Q[
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MA^8/'7YFQ>7U;V>IJR" S&#_9%[C(K7_B:\.!/_@/[0'WM?]Q;X-M(?::EN
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M[%#4J_*E/( @\K> O;[XA%Y<?@8@H-V_X#L"[@ 0SD?/-P 8$J90$]!C*64
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M;D^6,3KC17E,R^#\?F9%Z]#"@9:9HV]L5F7;\.(AOYRVN9-?7'95^\C25QP
M(N*%M\A7/MU 1>&]<H&:$Q?YP@,[&CP4KF<1^)<>O%?KW^:F,_EB[QTII4X
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MB@>'JE/5D*&.F\$38AVI['WQ"<K*[^^UB^H&3KV63J)6(/N-3D[+'EY+3N>
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M/8N(2BWI'V3@EE13+W^_343/RR<E:^*(=H>''RXM S0%V7O[O,B\,$Y^@8N
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M%&61V(\*3'#VD?>,G-TW# ""@TT+;.T$Z]HV@240M35,;H/QPV]TJWQO5!P
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MXB%M"X[3G-?3XD_-T^FUT7,K#O BE5%!#!"ERDY&V,3%H'"I;.L"R?NXH/6
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MZ,OL2[/-KIVQC[^%FL70H#>"%-A3:)[RO9FNZ&9T^),3B-EWJ-/J,R I!\9
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M$F5?6<$4B]5:,5A*TYPXYHM5<6C!Q8UR9&[]P8UYT)B![ON!RCO:I9*'M?D
MYHI<UP)T\3^\YWN/$[>'WYTG<7'CZDL9X.14Z%75^>00G<3>=P9@('K+A(15
M5HG590*39Z=5S3)]0PW43<=I#AF6!,%59ORA.-/7Y:;MI/;B'P]D=;7EL>O]
MDH,QV!E#L:D]V-)#L5)^]\7 "&-)0^)&F+["Q(G,4S+E@?;0OW%)E!_D5>,
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MU\?W9\<*%DH2HH!8_!2[!&8AQ)/\8J^;;.)12# B;R9Q@D%Z_=R+W-%7J#U
M,"(?-WD3Z<4IG[E9>E_I$'"/P3K!'SQX^1# G!L=Q&*3WTC<%ASS!#M$AP);
MV(DY5$%#XJ'!&A 6(]I%C4@JJE2'2 '_]>%BPKJ=9)QK/<8% 8M39U!Y6!"7
M+6C7F'U]5&8W*]B%2LR#")N#X-W&AJ^!' Y1<:75BRZ$ZEMH?R4K^+2-%9#\
MQ1YF%S'VI-/\U\IR,.:-PF37+#BDM36:.S[56]-Y-)251$8M7T8EI;0$;VLT
M]OH!Z!;?&6[ QCV!6!_&JBWKF1-BFHS<=U#"8P%+KT>T/J@]_L72$CIU2QT+
M _41Z2&6BAJ,FD*_0N\W,I.EL9%4>!AK3TQBAD%<'1LK4.)0[["H?;+*H5S0
MA(XY??-09TX:F'KO;JPM6Y:]^M&6P(RBHY&#GO' ]VJ5&QM&1PIBFP[34V8M
M;Y5?PH%!,?YC^.\@MQZWC6TS_\!/AR^5(\RT ^>/[JK=$3.96L6V8R6N<:Z:
M1@BY[$D 2WQR8JW5WIRQ/2O!7MVV!44:<3E$XN%F!TLV7;S^GFV3U.B<@*B%
M^8[&WKY3"DD:X\8Y").F;@I^PB)VI'V1H?11B:5?XA\2Z4VM]ZHS* ^9CVF)
M.52K6]EY"Y%H ,ZNP'<FI2UO<!WLH9(<X6S1$67KO=;GCWI!#T1D\!1%)4K+
MX\PL7.CPJ' V@#+!_K6/]GZ0,]S8M9.<F+%>I[\R/3C<]O.C4M[CXG=%H/ER
MJ#^A6XEUPA&2ZJ2^$Z5*/$M(;9?^1=?/+.7U?/I:!DWDMQ"-7=JE]M2+S8H0
M:JXIT)65=6B/S%G;IGHRPMM*=OV"4VDF7&YZ/372O3(,)[L\=<>3SL:SU'1;
M0_G(#G<])D\9OGN?L&_ZAZ&#6H,PDJC2UIO?LS*WD;1)Y\N=75U(0R%G"" D
M!)<:$/]^9JZ&(Y\SK(;]78,61R7L&!K^/"J B0GP&R2:('?7 8[>3CUS*4S<
M/?6-H_YY2KW<,DXSZ SFO;DTTZ:QIXU?7%L8MN?7F8^75EE6@I$5LU:U*_0J
MM=&244E YG]PVN0'TF_RHN-WL?+[8/V(0K%&T8F\^MEE[LHJ*#P;7+ JBZZ!
MNB;24G=L-(.SJ5ZCK#KP0,8>8]$ZY1S.4\E,E6!W"B:W^CG[^=9BL,(!Y)R]
MUFEFE94Z[H;W491?MT)FF;_YSR9$V"RWMLN1LP: J'/TE__\QIX^RDG3:KZ/
M!<>)5'6KEY3/7E^<[+O,(.]X?::8%!2A H:1\C9:5UY\F27,\8#(Z@?=AI^R
M$=FO,LHSVU@B]H:GI627:HYO_"7S4O$1%T#^'(O.05V=6F-G@:V)>"$K_@#[
MB%R-Q!.RG,'1'!9RWVL)YMIZXSJ2EDLP5MZ@N^JA':J;41IF"2F=74/I("YF
M*&8*=:E42""8Y#Q-LI^X,&#C"_62:HEPF03.;AJW"8%O'1MG;)@%E%WODH#*
MD ]-<V3.[G16XV?CI0W_QY*IVN? GC,SB5"-IA"2<+;A0P-WAC/0U*8?9QDU
M8FN'?6#A9VH@:>)F1\CAGHU (;\:"79D/!;/\_*)D^,9$B#G%A/D9*-G98=P
MUBD0X2X+[L45B[C@(5:/UI"</]@T<G!#2H#%\)R#9B&B!HUY+1A+]IUT!+1F
M#8>Z6ST\E\VWA(3_(1-R8AZIC8R>"ZD:8=BL285FA=142T0*7'^D4!(;9TSY
M6D[PU5,*?8M)O2KV5U@<?\>DK.V8:Z5;H<!>JP@S^D*KSMQVG:'E=Q,N6,<Q
M=\K[F#.+%G&2"YS==.:\7 O.V%GR^674>Y8:M(CYV([CH^89'[MF/-"<RA^V
MM<)11QIW34ZI9+;-58N=7]FL9@JM6]]I:/0X4T("N<30>NG.,[E_6!K;?NK_
M N=![F_?_(C64IW9+M67T8QGW/BA@U7E,.K;,.\+OB?77BEGBR ^[.T-[> !
M[==!VL3!^/3X2YO?!BCQ*HI)2;X_"Q8]R<9]$??^4SZ<77P2OZQ#+4:FS9%U
M):R736"RWWT0.[G5WG!%(.O/FGS?I<4/IR.AK!_,12HC8;\D2;Q]ZA;-QV6H
M9+W9>&%7C9"IM8GGJ:@]Z([+&](8^\H=BS-+DK71TQ(YZ?/U4$JO*'KK"^7K
MTDVCVMQU)6+8Y92]0-+(>[FTXNJ"S]6.M,TN\3/2)=&1\T8:(YG-V8X+H/,K
M$)C.$LBKTEOT_@<"5:4LNBL=.9$S=V,S\4WC8%4.PGQQ;!(X=3VQN"^V<6==
MJ'M^S,F3L/Q#/[O6-U6YNA59D.0[,MV8AF*JC[S@<P1EI4DQ4V<D)PDQ",^A
MCR,!0LC\DH_!'&)Z;[?[&!/E70M5GF#UG@WIS,U0R^',9G(JVYK*=BGRM4)N
M2'M(7HJ/S,\/A:7YOC*11[?6:([;$]75AM*WE@[UE1=<#]9NCY2;>V6H^Z-$
MMI4V6L P#&$U_P,ZQ,%NY@",DQU_H(Z/X^Y$Y<OP\>]KMP[:LY(_+EA7$U2I
MG[M4U"?RT*7EA+NEM^(1>.'CR6AYDP BB"HVX1_)OB%9Y6V37M$.YMU[+X(&
M)K"F_Z1*.08-4W?#,)YN,O"5*@& WS"81@V!=([P)?N' E!_Q>J<*G_DMUD\
MOCU5(45""JG*F<PD4&**7)#\!'<::28G,OTHS!@U@4@'%(+>.?9D"?='+ZH+
M>?MGGZ_G;IJ7,UKV0<EI[-XJ0X:L_'JG,_EU'=P7GG0TPI[H@5*0@J7P[<?'
MJP?=3")++T3?X:<?^9R>*+QU/_9RV9-_ 7E[7>!#<;HU$68#HVH +T@(&,72
M,T^.N[U'NSC_G.).3X! X$#%S\XFE;J03(2:^E';E\DY<3.-.P+F'.U9""'V
M;0EBUV0M:D\15>Q[#QVD)+[^F71E'[T#:)G,:/-^*^;!HJ33L.3I.0HFRP>3
M"O9,4B=42C5C#%]U5J_MEOFP"Y#N^OIZZQZVX9'Q[_1\+^;E[7VF^#0QR4+?
MR)FO*"!C4F2). S6:=F^*&D.D)J;.WDJJ1>;7+4X.USE(E$G%M#T]+,V0Q!5
M!&-V'[!0T-M\/8TI3"T8/,#[08;.G:S'\RFGY!0RAB'EE=.R='2#I>=[G9JR
M(Q>XX2<A&(8DY=E#9$N;([C35R7J15O:GY*3CXAUTGOIY^?R=$_[SWE.H0S,
M_J)!S@-*BGZ_\S#Z!;9 G(N^T .C/M"U5Y*!COHZ(HL]6?)&=;F?VMMJ,,)*
M_L$KK/5UZ@-J(Z+?O7R]R32EG7D)[02I^M@.WP?Z@G5FDG@]IY<Z"XZ.KE\!
M.,>_ETP"(I]>AB(>#KWV&$WC;AB%^NYWZ&.7[[Y\'0)[>JM$K*<C2^_P'[PA
M1B:DU\ZU,R:0"8R[$G+.7_8]81!-3:FIP1^9214%8$[+VLTX(Y-+.UDE^#[B
M+JH@PA_ZO=%GJYK]UM*;;V)KZV@[TH1/V*&<,:XJ&;>Z#(O> RKV=3N!FQX[
M*J$QL5LF4Q&(HI'WIY?QA)!YY/1,/\>&_<!G_A0]A*(HIG$C?2QUEK;+GME5
M0.C$.&YK<I=/*EUT)1-LK*NJL2Q7TQ=#+%;J](6'4EP-/21O)A</RBM#8L>/
MFX[,Z[,81QQ]JSUX35IY?L+>^(&_ +H9PY9:^"2[!S,UOGLXJ\ML?'(]U;UH
MQDP"B8_Z1/;7O;&[T;5B0OH!J7X9^8L-2RFYX/I1B8AS'0M>RW"=MR>!ZT,%
M.,&LGG2]4-2*FJY=WZLD*2X_'&F7;YCV&8\>0'=D>:\9[0BA[;9BC6&N8L@X
M*K"375PN6<CYA.Z* 2#FY4*$18L@OYDCWM3BD,31!9'*V:-'GJ*Q$/$T4V/Y
M@7Z07UW\G#D9TAX-#S6]T,B!Y1NYKD! MDI(C5/*Q4T3B4 )H*G#3\+G(2!H
MPG\?;V(8X(F)4.&*/P,T[#C*IW"(L4@T8J(V5+)=E^9=J^H4[.\=3UN<8LLX
M.)3-(Q$!(S&#Q88I&!5EHD'D U)*&_*5,DK;:(X<N:^ ZS.[QO-=%H>YLK)Y
M8P)R:Z\XC8[%>4/9Q)86WE+<"HV;[:2;?A4X&]V34H[AN#02:]&UB!HM&6[,
MI!*E*?"^CH%.MDQJ%;9:2RP'AJFR2HW/N&L3-1HR5Y,N1$S$F .0^DOB[T!?
MEYE/%PA /'_(4DHKZYD\;.PN/O:ROQMP;1*W-IX=K=$.;$\)7U67<VW8=ZT9
M\9Y-K82'+MDPHCA)R%_#-R6P+S6\]RYILO]<>#P1]K35RPTR QGP1+.>LM^<
M1+GS6A(S2H\L4+'$TU$30\E(6@(G!WL^R,V_?*3D#O6D0@NLK?1E<OR=EM-O
M8>:2;1]RBJ\RLZD]AN>JDVF[W1,,^RD:G2\U9NA]0]K4(HS*,./I/34Z\L7V
M@XU=#1-/QCN,L/7K?,Y>$1RCV-KF\]I*<D0MO<N90[?[-Z^9W>U/H]OGVE/7
M2X(]9BH5D34;+">[*M<:557M5J#A=<20(BHR9=@G\LJJ$^K[@+S-*L1,J*!)
MMO=NOO(OU*7G0MU?O@Z=C"[Z!ILIQW,!OY(?'R_U5'5;UB&5O68F2<*XRBH
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M(R8)7B->Y'4)"W_[GGQ%\-"@]F>S<+%MB=1V:"W6/6F(>1)];.:K2@UUH3)
M!$+&OF(JMM%14L0T'1T1L*82Q?3<VK#&\6;6N9A]\8193ZN."E(OF[#R[^ 5
M+S.IH'F='K_@)-^)KP2LD0Y#!YL3YH)?30N^<U$+T(2"Y!+'U7QU&345:SS_
MB\0IU]=O+( $2H$)V_Y.W7 (L?UZI$DF\H?>:@^"$A?1\E[67QB@?0P%4'L:
MM= FZ9TEOP(R?\:] I"$;CSW(3^]GU/0:3JI,<M!&4H">L%AVR60$K&1O;]E
MM$GK*,]40_O146_<[9C41IHNH+^GR6TOVXU>RNB2>"3\M[&(05#PB]-6/KV^
M[?-HP?*R*O;8EY.;?D%YU60M9G^>>#U-(4.&2C<RB3N+I85/A>/8,]XHF$4?
M^H('PR+J$LEIZ*5)    .@#@B @<1PPGHHS[]]G+7!7D[7@@]UX2!O ,PSPB
M$, -%RB027GDAH9;WBZMHGFMAG2(V!6/"Y%*WYTD8"^BET:"H7^#M?YVP1R_
MW6YA\IG_<W3H4!4$LG*RR[,1H6FDIY"H$P&#DH=%5!3A2X*D(!$M1<B* E1Q
M 3S_**W6\J\A0>'T2D!33*$4R^CQ:3N*_O(V44/'4-Z&0@1N%22P3B"I!)TR
M7/F0)P9%/HO"?[ 6)@^"@<<4(0G"^ I/!HMT142YN21?%[@DGU<\/8%D1X%,
MDJ2(+ UP!M/V3HCK7?^[8,1NRI)]+L7 [TV4K_1.R#I>8!3P@1)5R@_8Y$'R
M0!%$<8,$  D&@#^\[0IC[!0X]I\<!Q(SQ=HZ4X>+HM]%U5*X57A_IU[,8G?P
M)N%U'0+B/$GVH_][7@1\P.W8J(N#(1^K[2T+Q/"DB/GBE%-;,WUGOKU;UW_,
M@+')R]T(I:QNH2]EKL7$#HR%36(9_CTB?%Y:18]>F>?DZCFU[Y@/JAVVZ^XQ
MX/S^\,2+4TH_ +)1QZ:I:U12IP5E=DO<Y/A&?!"#0ZBXJC'=5^\V?_"^O85F
M]D&T>Q)?_]_9_#N\%8'^XSQ7>[V7O@&*NU?GD_C)'J\ _S85V]T-][4L+B=&
M6YM:X/BU5]7O+34W%.-Z1'=_>?18C:1IT# VZ P5VR"567?T6C*:G#TL2P9*
M.6(_Z,7IH=^V=%6WP+RSG54=OPZ-&S+/N%5.5[1>O.2(VU;;B3-U'5]H2# ,
M&[U?9N1F_4ZC]*'Y/5>?<[<R?F_#?VV15L>DXEAP?4M%$Y=\;*8YC0_;\1W]
M=4/CYG5B\8#_I9Z0M, BDZE:(QN>2S<S#] VS-"L1%\44[IA.L:>UK)]CJIP
M:>%IKY6;>79M([O H\WR<SD?O*:]VRW6UW);R_./+C:H[R8IU;@J+TDZ&21L
MUR,_.^TH#^;T,K6&_/3TGMZYDH "AWT2D]Y"0O.?L<O'_<'$=.--O=C#U8NG
MH_3XLPWG.V,J.AL4R*KCE2("5"5)B&]B1/LOVI9VJ+PO\#B7LUYS<H]WJT<B
M\/$+K?7-KNJILK+6Z!$PC8I&&_KU(4. BW+ AF&:LE'K89-I<"1EL2^50IJV
MVG##!+)Z&[?JFPSJ]H Z(#P7\M<W0EAK&1;5TA;Z])9&_S*29)1S7KP""+$<
MB+YYGRK9$?2E;7[*4&"<5-I$QK^?G)#>OO2\>@7D'-]:1J?]\W1DY1SVJ(V3
M85)(J52\(#9*_!O?KP,!\#E?)@G&!;=]BY:"G19MW+)Z7)IK?Z&'&S>/U]N[
M[_I_3NBK2\]:=][HB6[Q@JDI,0N:GC*L_2;9HX\I:%(1\S<=^[C(#<L6H[;8
M#EK3G,.YJ%?@6J>_E.MBUA3OOK%LIOJMOC%WJ)YWWGYUAH,G!3TSB\",QT+;
MX# BE+#CD.Y];M*;=8VVX/TOD:VHMCP.INMW)W-W9OJHQNT5*HF:(#= /5$;
MK8I6/KO>=F5<J#VF8BSB,#6J-YR0.VV84HV!AF5YA[V&]E(^<3M1I[!^BGYF
M])0.L7BR'=\QK^<2;.9B,N)!7SEU5T0^1OU855T='R/?.>1HL3XO"GJ49=7^
M,N TL":M+"BD&)>S8V=3([FSFY538S]OD<Y6I]LNYGH78#,_8D$#ZZX.;LH*
M]@I7-IW66%29B4Q/356NH!ZV]' &^MGGIOS ELC\7P]',@JUMV$TMCW'2?9[
M:'ZPH"D)-N\?<_9C\[,]')4^@8ZJEMLQ4O?5A%)!O?9/&?A#$$W:C]!IY+D+
MDQAZ8;MJ0;5]/VKT\). /)%;ZI-EI?1?:*RB87'5/.S80WF;#=W$T4N "4?5
M[1NJU;Q;Y3HS$EK_GCKJSW862Q./>K&F3X+1'XW;EH&/WPD84D$E0/W9CZGI
M.&!0W8:5TM2&2I>8E4NIWLT3NP3U OIXF\C":N94LA4KTGT#W["M(M2P>$%[
MHC:9B-=8_+J-V,NEA/?7APAQ+=:95X 3-J]/DRY8-4H;[^Q?JL^&*]G\=BW@
M$W%EQ4J%#K-%X'9IU,HN'\_#Y,8\%[:IU^3OI]2IO)%]>S5S V3Q$-A"0$WA
M99)$_&6'HL$P]GF4?IN/M;8!8[R>0GM)R*EBQE#Z.[.*#ZE-%1P.'Y^/OJI:
M&+ZC!C<4!XPILH]@Y",*NV*9/8- !@+J^E*R[SCLY.6X;VX:SQ=E68U$HZ8^
MQ./ST6V V$;E\YI^)_:H)+Q)YK\K1=;V>O'1V+Y[!1@J;R]5!XJ.L+#>FS?!
MWR@V5KHMILJ*[TPO%)>Y4NNJ,9M8)I0=40]'Z2DJV6*#*?<KC[\N+!:X;3F8
MV2^JBBYK6=GV-\<=WVY(I8SI6"[4F8?(/L2V:1S\CIK1IFR7QU)*06R1D9&N
M4T,' $^PI/ZY2[ \\%Y>]T_MW)>"B!-#01@-EE$SIKJ$#0OFHM^K*;LNEFQ#
M/PR(A'V<4GN72O7'MPC9_N6;""E:%4T^9@KXR$ZAE"H$FJ 04?J<=#Q9MY)=
M8""Q2,+,2?<]24W;PR%RUKW>@@%5DA]I)-N)T[<X5W- ,!;V9[IN)%9._BCX
M:A+O_E_$4MB!0@2R330SW'55T>^(AAG-U Q4)RP%4$::;&3,U< @,H2&*QD5
M-1AXEQ%I<E(LXW;T+H$41L>V=A3F63%Y=#$[;2_SJSEMW*R;A2GV;6^P<IT7
M_OA:-_MDMC?(QO&8T)K?8IMCY0<X09]R6*!EZ3N+5<T(J&/I\(/G+%5LKSB*
MMZ? @3F3:T#%T:G 1[%QH,;?;XIOC2*%CJNX2EEJ]8[_<WEP9AHP/*PG[9"C
MKQ_D!,OYWT:5 +,P29@_<9=;$#CA_A_WX?_NT9KC!3WAOBHI:LIR^E/>&Y)7
MB%<!D;Z4IGU CV@,;@Q@\!^R[WA0L5VQ9X7,]/RJTVO#6/HY!"T/)\88J^/'
MC==:5Q.,G)"3CH+@CTY1L8?W),'(O$10CLI_/R&0^LD7^M/3@%7*,7,L>71K
M/6W!-VY=V= ,N=*Z9[4IILC&ZTK4M!Z_?Q#.B TWI:2=3#I1\VFRU=6'IG&A
MZ6A[<F\DMYN.=EMCLFS):@EQ0[/!P L:VWX$JMQ,@824]E'GP!;&DV)IR]>>
MA#<OE2]8O *R>%%^A0D"VG760/*F][5$0X(.Q6?/--62UKJ3SS1^/4^%WHHR
M+8K3TH?DT<0&#UJ<A+%?%X"3J /-@(VELQ8X6R=IV*:VO0A-/V;&*;N":& 8
MA>-4MZYB>YT4O0@\7:+MN1;;MH.T3 NRJ6!-*/D/VK8S%$\4:B#WWUQA0<3D
M?!#+V(-MD\7<^RW,_B;$AG$_+MAA)B??('>TYF"J*N.15K$8[O<1^.@>5JY-
M>E8L>>DRN$E*/)/X8VV<#GWHDT_:ZJWJ4 V/Y@N0A7:W ]&R-ZW3KV*&LITJ
MJGC9<M_2@6])#?3SXWBXK<.BTX/4EE'/^__WM&=AAPZED^Z?.OU^8OE4(\7?
M=&5M9W+EAT>VLR5NR,EW-)_M%Z9=N:;<-N6B0UH[=C4*'%EB'Q @$IBZ"_<E
M>:@B-3W2Z-%T@84O(?[^RQFWXY!HID.M" _'<.ZOU>-A^?BO%2B5NT( QO%:
MBAW-3JJ ^^FD'>>%0S[H2^'X"4XKZ\K(:8YW7A_R97F!0D;9G07OGO>,9:RK
M&P5,G43#1 I)T6I?=B%^#LV)H$+#DR^>WL;6VLDDP=@KP.*]U YO\J4EJG[;
M"FE:Y?&\^S3(YT^6KPY[19=)+*5V0PS3'U(%0@?@^8!+!2X$9^B*^F:_'!6J
MG)-U*>&;X[BE2^(O5_4'IZ#6,RBA-9TLF!4)DDJ6GTY9JG^)?"Z:D+S-KJ[O
MX&,7/NCRPG*I2]J2-_'TSC?/+^63'*+?':/KIXZIF31E#ZH/XY<$=;C@S&7G
MD<L/^TXVGZ:>JIO9*"R*FL0U=:1 J9=J:>RW[_).7@%VK7X-I,=>22>D'P57
M7TS1=NQ.Y6W</P,;KL-CU+MT)W- @U@O40D0G!GD[217B1OEVEH/!?P_&XE<
M3?KPS[/&F6R?O3(:7 <&MPW\J&@6FU3">BA_N%ZCAYQ[D;R%9"?_3QJ@-MC#
M!V3L\Z>-CZ.EI5C$YV.GZ;%M]<4R3(/HA\8T58X4J?#$Y="Z4F?S:?94HAF:
M/O;1<= FRGA$;33S Z@IZ_,)'*//\1V!,Q;8HNW#R_VR'0XV_0"&1>N'&8RL
MHSHIB!Z"'M4]LSHEJG.?14H)# PC.99%V-F)@<!/8L-O)X(JU_?WNT[Q\@,G
MD JW)HOF=RXTX9IX<SI>3:M(0B(R=L)DGUPE+-PG:E\63PS--A:X2&N&@4N)
M,7K&D"Q!6X\ZC*RJWAZ=9Q!K(MD4SEIYJ\LD% RW_W I$4.P1NU@'I->'S?M
M;@AM7";D<ZI_:*@X(M.QWZSWX)VRM=@<,I[R<<19[5=U)J&7!=5MXDTIU6 G
M(!7KXERJV0*''*CE+UU85F*GQRX>6]0RJ)Y*TGE2)+NM=SY=BP%C,3Z%WL7T
M)UQAK24TIB5L12&=J:_",@4>M\T/VCQ]7#C]4[6BM7VU[0"THN49GDZ8,+9Q
M.BF");&NX2 ,9<4,R)^:V2#Q_ $!4X[^_-\SR?W/[+BO"_\#4$L#!!0    (
M +J+75,'+&;H"EL! +VR 0 1    9S$V-#8X,&<P,6TP,RYJ<&?LO058E-W7
M-SIT@[0BW2'=W0T"0TD($D,S0PQ((]U=(E+2TB"-HD@C("%(*-TA'0)R!HQ'
MG^?YO]]WOO<]YSKGNE@W,W/OM?9:O[776GO?]Q[P]N+CQ0S@AI*<HAP #@X>
MSAW.'0"XV"1V4K>"0"'.5A '2FXV#H" E*(J(B( 1L0ZK_2@?S4!Q*1P^@"$
MVW3ROS[A 0#8SW<5NJL^-SKO$R]":\ 'DZ\$$U^ONAM>R82N9(N7<M@+[JJ%
MX>!D#8:JN4 =7*"P)M(E3]T9JFD*@=A=]5 $0T$@L(O]S_/+3VD[I\LVSI6N
MIK7;90\I:^BESE\V04YW3>Q!6K+WM'Z!?5=0=X) +#1!4!<'-5,;,Q@;$Z .
M< ) 8(<%@!*@"0 !H  7@,.5"KK#K]X_S4C90<$_/,(T=;&V@UJ#KTS"VFA7
MO:55]92_1T/XLC\\ZQ\CQOMMQ&H.4&L(V/DRJE?C<H""?PX"-DA3IU\-H*6S
MZE\2)[#T7PTP]*^&BJF=\Z_&74NHZZ^&K+V=S*\&+(Y_F98RL[7\$8CO#@*
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MP[Q$@KNB'V%$ ,#!(R(AHZ"BH6/ _5T(!X!'^"F\ 8!#A$. 1X1'0D%&14+
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MG'4G==5'&@9/C,@,)K<\MTKSFN&TSD5]!0MWG@,"JN;Q^&W%4<B^L+-UHRC
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M7%_M?J-;;Z 9K6[!WC ;_:@[<C>,Z3%K'4X_]X.!A%NVKN(2SO&> S5GIQ>
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M/6NB0ZTO8%W6DZ(XS$XI/'<@@#*0QN3M>]_.L=/]0)[?#J4J*2)@? UB86#
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MTM.&KA[=>(M T:E>*7?SFAXT]84HZ;B3&%Q?OO?2];!-2??)PEO-&[:B&1>
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M[Y\E)CBQ:.:\+-\ X]Q,7=ER1*(NPI:NKIDB_3Q2.4=S)T8)F$A0F!@-G-E
MUSXX%R\WBDTII'TT0JFU+$]T?%!KX1>[MD]U_J+4+'1G+?:9O&\*I=?QO':(
M1W#./1R<$M-<%0SA+.TH%F-S25$J27/G(:D&-3)#URV4YRWC9%T?'DR!=D[2
MQ&^RPN_;=1B>C\ +N/9P1HZ:],D&Z7GRU/CV99ILKM1AR_FUEWH(4B.B 9!3
M_0&[AJ /-S">%'![+G>Y+^W$/(;7 @S+V62H#0C4]XC>EZ3U)]XA]S4VF;P
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M=VQ;NY-7[9"65SZ.KNH[*0F3(?84>E,4(+YV%A6YT\^( $5%/'3AY>@TBY^
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MJ]-Q$P=JG?5,RB$[&LY[CZ8UA;1S&2XM)'+(N*TR8.#5Q09@?WB&R>EQ4$5
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ML*>8ZRH1K)5):%#4\QY!"_8 2B5QQSPOM]!3")TD$!BH.^Z20389 TX!O".
M2AW$X@^L JH26&Z"P+AVHSEV(ID\>3AU5E51BE369AE:<UR:)6I:M\E3CS.+
M>_)![*DC%XZW&JWXN5?D26T<@))2$G5H#U4U<A-:'5K-1WH]>5($@J40X!46
M"B*!W?>!+YWO>\:\G-F_%.G%KBCAV-]&@.+8JX.*Q;_ DU:H-C+>EW<Y2GC[
M2FQB/K;EQTJX4%H2EGE@KX<O&OC:^G!\[1)*7;4%BQ:N9+5-R*O1OK&.#,-F
MO$U[;1ME.:9/58I;Q!4VU7E>U\#<1JL@W=?-C^Q6]J<>,JN]D$MV1#L)#D7X
M.A+JW VHA70!Q<N0/%J.]!XY1'JD$U=ZDT!+4U&]6Q9Z,T<3^VOC#BVEGD30
MR2/DEE5W,)N5BLS;>2VIYR;C=A'>R6FEY_MO"DY!,KX4Z NZJ[HNLSV&W4WB
M*HH<4;)F<LUCU+D7B72D4^J 2Q(8.0P-1F*LQJ,XNIO#B_B.S/;#!::'6Y6]
M8R*&1%S.KQ?+=M(%HQ<@I]VR;R7</4='85SA"%SX]!;E9?4@--7$3VA]X _
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M]H<-AIYE8Z<9&&!3WDT(7-W:^KZDF49B@2?V2[U=HW+9/9S%XW#@[/E"?BU
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M#Q)*3D]Q';?1K-GR]DXF;)G8].[M"0CN<(K9R-XB2AU[^T96Z33=W4S0
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M] /V2!1]!)T2EA"EK*GVSV.EK7L%9J"7TJ'XUP^^ZWA\,[6WQVF-L-'^C1?
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MH43!FU<"U6UG[GQ[J\G;45G UZO:3<3 UH\GG/3 &$XZVH$O':X\B7CUGY6
M_B"E(]P/6F<XXH7Q8K[JI?>F[N Z>E;G.>0P(68L>*(4^;)'0KJ&MYY@3% !
M$_K]N)V=G0>R YU&#OTCXU'U]I_/CLFKMT%+3@PSSWM$;8V#'*6_35,&H/1R
M82P+[6GJ;:1-71T\%=4D#'5M:MSECN'F)@*T%G"LWV_CEEJQ8]%8>O-"?W4.
MTK]I2B%R] /LC CM<#YE+HI8HQM7BG/[Z'3$DH]$K2",?/Q#'\():+W/P^OY
M>4V)_TAGU&-B'7]Y#!Q*2]MY(UN!/N<S,= Y_$M$2J=QMDF7H&A-PM+AJ\YH
M7:)"8VWV^S;^F9WZTB2)&KUP,X=K+^;B-^EB/9/R7,AUJ+)!<ZV:31]C"FN7
M=*4A7QJ\HN<+%%,ZR>'2%M*13&O:O8U,0=JO]OFPC8R9EI@W9AHL6Y"LF3NE
MCZT#7*RS-&PU==]O$9Q]ZB"+M<0HY&2KK4O2J_.5LQ?!E:N"&>X.R'[S$X6[
MB:;Q[8L5PG$V;="#+,1S,E,!9&FH8?I<,-J3?9>%3]>V=D@O@/LZN84PQ -L
MB^^WR\&JN6$;$M:_X6%FN .[B[]TQW)6BM4Q6@@&'#?U1[YDC4[2<,5+"YVZ
M$E:Z^*=MHMD_,KX &%()Z+F+PM#$BN"X5[4VC2^ ;VIJ3,QS$VA\7MS5@\XV
M;U<RAX(-9^I V#)>^3CC^AW1\T+5_E2W'S+,6U:WSG@:;P?X5[?<'63X!,-Y
M"#S#FN(\QUDQ1UX3W<&D#/^@U,,D;F5P&5-@,J]$][--'=WNE>I9!$Y=M5X
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M%0SK50;U:'Y!K)Z/[*!ETP5M5RJ8UT2IL9L:MD]]3KDBNKG#0=C[>>GX(W3
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MMG"W9E8,H]<&*G.+#6=AS,JO&+E_(_E?]*G(V?<#P,0+OPW[O5CKM8BZ+VQ
MVBN;NHUC!IB:' 6(-GQ*P,2W08TN@F:* =6)&7;0QF)O)9 T09,RD!J(',&,
M <#LDG6WS"'B5W@+R2*,J:%-AS:W7M0[,E:!?U9]F0G(-F_=:REAJZA#IA3)
M/,V./HK6QO R3B.^@JD0.P;;"!CB2#,-WLL<^Q\X2#>G]$(%1<HE/Z9YT7
MWH339W)+L^)O<L[Z3'!1BGI)DSD($_S$:IQ&4W9N%@2]54! 5T1@1HH7-X3O
M;-0N:(<.I^*S(S!+@Y_+99"+4 M]B^R_J>1&L6CO,)59S\*H]$LAVDK4$*6M
MKUZH-,8XGUHOGW^A7GXZ_=P9("%?XXH2SO?:LB2BFPGLK1_L?XZ/K8P@94XB
M]0$G?Z.(YG\=L'4GCWATL'X4I4H&+O\8OH';'4Z5)'UJEK-+U< +(#,T'\,
MF!#*;!KT>RHRF]5F6+NW4?GO_,!( >2Q<"@UB/LSHS.;\G^B)V$%0X*"Q/XZ
M/H*@Q&TH 0! V,L7TOJ9VQN5<=@X#V[H^5 '4Y9]*SB',?S.':V6 EO$XW75
MD&$,3KCAKR<"[9*^ZO@,)=;XO)XMDX++I$9Z"S4J&W-;BR@#W/!D?I_W6_XW
M[X."2;<Y/.*WX&OR'<*F:);-S[2ZB(80*#^'!>>(DH%"J=_$3%D4>%1MGT-
M!M5-WC*'Y>87<>=G<="F*V65D>NB19L8G<_5N%U-F9W,N%+D[RYL80,W+.;U
M"YRJ^A1V$ 8=0(S&^:]33HUUUV.GM9#N3H0J UX_U1.@?7 XNJ;N=$Y/D.M
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MHGH^?4REWY5QD>[/1UW> >"P^[!1!FA8]&="-:<RT]>)Y:.51]D.,@-:?:J
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MNSE]RW%*?KB;1,1/\LA5W),6/S3DI41XZ,BHG&U"2Y(;<W=%-ZD-%D^-NLU
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M[JPED*)9];<#**4E9X@7AVK/^2*B_C:=E2C-^]AW 46S_MM4=!==.KO)$#A
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M[]#]&L&.O#6UYR706_%M.K?*#[.ES\A/:T8YB<+^&I6;O"+) 7X(S[AE-^_
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MXF8N*,2T%M29'$>T$$NG,TB@FJ[,KAC>2;\2KBRVA86^5VV0;T)BZ'67MI=
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M/_051)N/ -OD1'>-N3M<X[J3B?"_(%=J\VD8V1<3!2?N=\RI1?ZB;2FTA3/
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MM32++(-Q95F].WY-JCH,K,I>_/IB\(WK.F&CJ-_3'N;3PHNOE^8B5\ HHN^
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M11.D9<>6*_]Q(6^C2)K*W:'3.&#V<' 5_XHC*TJ;3)-70:2I1%?MPX>DP)2
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MM0E,5.W+UG@9)AJ%*2=HCM6FH"#<YQF3)$/'$\BI[+UIG_R$:>4E,*4IFU?
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M35$IWWIOO"_>=)K=C>E4%*/R!B.O;F.O-IP;@+0"R%Z(K-8J(8H:8,*(5V-
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M^0=OX7[?YR$3S6D!<?H?+O>V15$ZOET$;<-H*:)5D8OR0&?8QZ^BK'A-7M]
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M4WF)3.)C-\+*&$%?HUSM.$E7JKAUUV_1&2PND00K'90H*$2\J#MP^WU8C__
M<&($PG(DN?CK-,\SCC,T0XTXV.N5-&&^OZAYOJ@?IC"A9VII*1%S:*DG4!J
MMIBR:H,.+S\BM72]^)J7OL=AQ8=N:).QE,3 ITJ#TG*;VA'V[BR,ALAC!]<M
MU*LO0A?C%62&4[)!=8@+HKU<7YS+G*L&?_6SO%WU=<<['JE_+A?E]-$C@:T\
M61MU*MPBY%$9N@-2/Y"QU)",*;V9]Y%_QWT]CYTGIWX3?W0=T_X74$":<$DE
M=Y7][U&.^%^FB6=JIW#Z:I&[C4O?+K*_.!TOB)S?JHQ!B?U[["A>U$<<UUY.
MMYVK1_J\-\#@D9/K1.!3$9S;&UM:$9)!>+FAF&R7FUKF_:%K P/C?'R'H%3)
M!-U#ZQZ+EQ%YM9E>])7EXVS;"WL80%PJKE)>?2=D'D/M*8Z6:I.6TC$9MXY@
M";'P1VSS'T-65YC\NI3DNZ]W*2DYA?6^[(?'H/CU*W(*3RGEJ@2^H?/Y]M32
MMO6<U@0J%>9"D'31>WS\5R<B3/'8F5#IP<K"(E[V"Z-(0L6&L1L8X2S.>P\C
MW3;[F=TSE\=\ ?6]T:]E1];MF8?'#E9BW!RB9X6%TU?Z+\2L#F=5L-S"?5P-
MP]/VS!?T$(OI>!DY/X,6*S/6"XHTJJAX*;RTNO.X/#&2Z!0NI=XG&V3\X[=J
MMIC)!I5^,9F(%]Y6YVY1PR$S*T9U7F2X'4I_X8;D:GBW:RW=]*/RVM21*=#B
M_<5\YFB])]>J(Z4?='AU8=^<]Y-WKF@W>1(MGZ>R/F-76WH<C-%W;HS30N:^
M;"@<WK;E:OD=;EH:.BT<C51X20*WI?32A!'%J=JHYD2ML^2!A><A/\I?+^V+
MJU&.DJ[&?U,,>^/MJDLT4[O^*P.WY$L80TNX;GZV]_SINRRJM@%P!EF>83E%
M(IE7&$/XK.2S4RT$NH&C&2&RBNU6JSR30%)6B0F1I_>O(EU0.PBJ&#].T;1,
M3S+[O]O11-T#5JU_=F_^6HO%GI\<7%ZU:*. ^5LM__1*NPKI-L8_=?CQKB_%
MP+(U+=DC;#5][7-+R_KY=HPOAXY0EJ0(<ST8:@3I$3GQ:Y%KCB$!I]5*KO<.
MT\-$*7?,TP)([[OJ.GU-'\$X=H4ZK?3FUV1/ 2MUM=&C% 8(WQ1])H3CCQ@;
M]U4/#36K21:-6:23<2@3\S?KT+)"P=W13Z=.1UX%3E\M9?<NN+_@G;DZM*Z*
M^ +:9XF[9;:'<I),L[3RK_4&O>T:"'$.!?)YAH/L7PSFY\.?<W=%;J\2RE$[
MKA=&*6'7ZKIW8NMJ"F);:-2Y'O.,@O_^!F6>$+5.UJD]<N$.ML-1;%(1-#75
M(PI.$'(/@R[8H)(3%J<RK5M\M6*-AME(JAVS@]%/H.XS2Z9I,6NDG>B=R9J4
M8C7H0G'</-8>>$WW[W$9/$*LI[(+=([ETQ5#YS]J-NS_V$E\&75CT QT"R-6
M\C1O><'AN=7#DTXG7#7=%T.YY=M/55:"%V'6>W.1)NZ.,L<N=K +&2A5#&]'
M7F7:Y'#;3T&# *J"P?Z6EQ2@CSC5XF^$\71?9G$[%5<_X1-"0E-QR70V@*P4
M_1E%R@9>8;C^6CP$V@N<AO52]^HG1M[#8R56NR=@EE*PI4KMABU/1ZL*",)0
M^<0.@5DD[_-45))/S)ZSSV?F_P#-)74%(A>.$RHX_E /Q+J8[3$G"5X5YN].
MB80"LCM=#L'22NR549BZSLU0PP9Q!1X/;%\'C@T/BJBWF5?%HR*C<>2L>+L,
MU<_#B1-JK2(ELY">U%)J80;82&_4D#D,$V@;\)8-<_LL@\>6U\[ WLMMQ[D?
M2(:9;$7D0C&<*=#)5PI3AH'"7X*8*K$$]\.JNR\3VW)4F4+FRXD1EH-2$L.T
M++HLE%MK\S!AU4^FEIH/BNDQQ3G1C2C06VO7GWQ\X8RR8_UF99>OMLIL5YU2
M3M_NR&]FRM$ERKN(X_6JXCQNY#I9-T J.;>LS#5QC=*H=@/W/0]:LG"X&I?Z
MP0+?J:*H B_0A%Y*FN>QXB)"$AT9@+S$C8O7??A73[_7<S^.G/_R8$:%7+&8
MJIN)CUGFG\;P&'O2%=T;VNP49^BS=<[7G4BFS/NHBF'L7&T7?*O9E6)XP_&Z
MG+D_>3]/<3@\[7N(59E"@&&NL6(30]?>I8"C_<+R7C2K?H?2'!H+PT_ Z[E7
ME9'Q.,,F%G\!//^X?''ZGZE*:1^KSPH.<PNNJE7W6D+%B/Q3?BVD_.&U^>61
M&+%;W_0YV^7S2*U8_#SN+ZU[U1L5U<>E\JMUR7?17\;_V(S_!9"W_!&6E[K2
M61.;%A3;TRX8M4$/8'EA>BIG^F6[\'A.^__+;$"3,/_T'SH9T?+8;M6%.=7B
M2(\?&))X\I$ZF )]_1+*$J-)<'Y&1"_K3C:.FVBU:("/JJ_N-=OL=HL@)_;C
M&8N6:VS.@%..^61!D!K5]UKGK7/6[P;1\1PW1P@R2\S6JL>KG:^FG-^E3<&R
M\82*S,>4;M6=^AW(B?(?7JZ]*.->[7 ]2K*11"MWMV_DA6_DFKR+IQI_-VJQ
M;BZOD=MRJ)C MK5G_V0':ZG%; LC% A+3]P58] :0!$]SXA4>8?'8I90E<:Y
M0[B3 2C0)/F((0B[<@#)^J6%"JHK1K"=O:+I1+IX'BG<H]1PYGRN)FNY6Z#M
M_@W"O3PUCR'/ :))[JG6))('O*T%E[#6]III=@WU-P79X?OI75?K2IQF B&Y
MH<NE6&D?Y0!3^ZAH03B4LX253<2Z^$=\O&2M;D4[5]H\Z68<J5(VF;"]AL\E
MPU)&X*:D<5H8W0BGH@*F03VW81D2OF8[-%'^80K?^7J<7./TM;B"J=HLY+8B
M 9>[D1M@2\5OOV.;,J?)J\^UW:\B4&GO6'964;VA=R^AKA"#C]:LKV/*L:^E
M-$8KHAVX+QP#XLJ*O#J6&D3*M9ZR7#9T3?.((68R\\0W9#H5J,Z."4HS)-"N
M<?,/"^-R_FY+1/M5-%Z94(J7-4W_O"GE056U7F&O[\?Y!N[G'KQGG%G]?>O=
M\?W\=VVS[]MR/!/5QS/,!97KI)-@G^:7H?F8T/1#Y"(Q]D2!O;;$A#?_B\\A
M3?T;"C;\XE@5.1.TDIQ)Z?@Z46JM<T>W>*_+N2\??+1^Z(0:;'@.W/-2W\\O
MT!70*6NT<1M7C=@98HE;O;G@@FZF'ND;5LX*A"\2&YB)6>(MIPPL\@=ZOIW_
M@@4J^8GSN6"&:[>KC$H$O?7N6Q(Y);$&M8A;STFV36A@/L'8@2*Z*J"2?B6_
MI+*%XCUO_'P"5#LUOR!('%<+D31:!2%"%*B5%A11=Y6BJ4%;VP\-8:VG@[2!
M6&PC^:HCHJ O\[][<AKS.;CW#?N2-<R[8YQ^E>ZFT(WJ54R8&;>3_ PO'AQ
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M<XW]A;\4,32^D4,KJ]2O^89=;T,74^5:D9F\-"D31M6EE.750N=!_-$P:IR
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MT6\-J=FH2LX"PKNTVZ6EQ98YVJ4%;:Y%\D<\^C(1= YSOO3=K[%#GAI$;5D
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M(_*ES/OMHG8KC4QMR3%:BX$XB!L6!E*S2F&7;C8;]9/?1M8XJ62L4<D2)*?
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M\Y!W-6ZM8OQL(^EIE9)V*5XCI;-*@TJA;Y0@WH@ID6Q=5_EDCC\%>C&]W1E
M[(+,F N1$N3QF:OQ3<P0R(-&U!LL:GGX&!NAQ%DGEXM-=%7MUH$$X^&+U$I"
M&D%Y1JF/G[UR13/>0%(FU?7P&U9-E4;YN8883/3O^U1II&K$DK<9PG\<%OJB
MQS=K/F,JM")162*IRI&=DY])W\;W_^XYP'\=F/:BTT>UK*"__+OZV>^<-"BC
M3H!VJ\*_W%3UZUZ8EK E+\E:$(-#8I#!VYD3!$$B6[')S<FDV?7*\.4*7&EJ
MT(;?RUF@B<0M!PIQ>N+ATE3> <?TBW8KRV@-C/:X8-!D;,CUZ)W5L8_KQ^02
MQ..DDI*Z'^^1#EN."B!%!<WX><O,>6PF^"4$P8AG$*'V)QCEM1DLPU7P]HT9
MQ_%J)C/RG4(ZC5E"<!")!C7 VGIOKE:5\Z5DT+36O/":OR]Q;8%SWKNI^9PW
M%XOJ]/>*!&GR_+3+:M!U<::;_)KG1\U#PH-FTF&QY?;5:3P2H>,/:OAA:*6P
MT=Z]24$*:[AS%%%UD>FO"J)5'9C_QQY/M,S2BXR8[,;0BY*[7XUL5K+$LQAB
M2.GT2^(?!;K6N62Z9-]\_A';?\J#7=X%#_C&VIM8<'H%:\YQ28N0^Q=CO_)>
MEYMLGYEJ<Z^VD^2/;GDN2_^#\Z%TC^GF0:>D2UJC;YYRD T.4-C4<8L^"B>*
M^#4 D"^#BM%0AX1:_;ZJ= ,:,81$("SKGZ73_R74U: 4CLP0C;X[)DT6/'[5
MC!RM*!+F HG>E%-/;_P0UZ/PQ=)DD6NS/YB6T+("Z805I,OJJUA"Y?[I2?U_
MSE-0$"SD(.@BY 9?W+D UYGOGTE+/>^.VF_P>\WC99A"AOF(#YL9$ITX9_U0
MF0?Z5M7:9I#]"2LMGPO"V[5K"7E0]Y(R0EB088OO:%!\=?"A=,^4J*P+N$+,
M>'J&O\G]?!W!+:3G4/_8ZUVS)W,L^FIO7_\I-TEZN:]AUC>*TX_=B;LBKV)@
MHP<-J8]SONXC5-'!&_7+2Z@^-D"BB.B\9E"P&57<I6U8>9NF>XH2*F)9JLL'
MK#,U+?.)A@)JBBIN]JM<71>62/17?@&[]28B,E-/Q>8>ETCWB0=Z61W9('P/
M0;#O5^,G[>6FX$48#!"DE0VI&T:,-Q&9KF#J:%WKO$VSFM9&I\V]W,GRBBG9
MZ44-+H*[A/K'E)H?%K,+-@5O-R7%K45#G^3._V;[S,9?2#KX+"[4^DO$3POT
MB$%$Q >"Y+VI689,Q[#]4MVTLN.5(L7IP)6BZBFN/!O15E'@>ER9&E=_D-@U
M0,]/PY'M- [U"B.AI#O-+P$JWJ O?YNFD0%V>T6GP)N<3@-GI7%VC_AL#10N
M\OFR+PHL3;A8!;=PZIZ87[*M6A_NS,^ML#ZN(1/NLMOR56U]D@FUHZ^9Z-H6
MO'TQM(Q/[=%6"$?2XGU(2V'W'?5\1$ZB)N$HRICG5%-*@O/PH-O(=WJVN]6
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MI2).0U;^0(+_M9W6=,7[!B?G0>UJ],HEBIYJ\FS%L@>S3+.QKN+>/'BAJO9
M,7(SJM_&A\BIG:D3(E;HBU>OH[ZF#+QY=9?X\J=,29ZVC[LRP[>U3S868O[(
M!LMT.6P\.6H>/04$3"6/ZL)8OVCFW+$."*);U6 -]O=6D@CNLMEH+LLC9+FJ
MB^2'9] /2A&7@+"(A:H#-,.XW8JRR-Y',Y!YG+&-]E, XS++&JEX:@:)!V5O
MPK4<\K*=9 J/@E:]0V:)??PG$GRN@4_D13SE;PFK8;QEW=XL(U?M*T^+0$:G
M\-:N^6 V31P<<6?VEG?8$//=M+PQSQ@#W3E3Y/2A9.($CK0J8UU*SG!B8L(0
M$H7WPF#V1H4*V$;L%[Q+GTX^5C_!KCN:[1RA$%>-)1,HG9UERW#RW>'*7I'6
M%98T>;#M;LQ#L%A?YAB(*EB/4^#0O551*Q\J)^C%]IBB:'9WXXW#V\L,BL:/
MRY55)D??%\\9LMV]WW]8BL9+2L_=\5)=[Q,1 68_1!])0RD':ETC1M,2IF69
MYJ?Z)(OQBSQ--DYG11[L8_*(F9[VPU*2647%RN3':N0<6!Y3@06I[6DEA(EN
MM,K.7)OSZR1CCF&*?)MZ#(JR]V@<:U>L'9V^R*9>&1(MV/6SU[POPCYIZ"NL
M)3G(%6%WU]?AV13A@XK/36C$A]%BELORM=[QH3&0 .[Q!-/1,A1^:]#]M]8C
MMJZ)7Q2^996I/[A?P$$]7C)CL%LW9>\J9K^"9\BSP_ !BI<R?(^E*\D;@TV?
MP!#2)YQ./V_1W1#+$WT*="EO](9.,7R.O*VEB('%%2J SYE8PQ;"IH0C6R0W
M2Z0+(B+^B(/!0>]QOY('*^=6^ZJ14<55B5<Y06B1A9\YRH;5S03BJB;<@ZP<
M'@NG7$Y.QD3C<<C &RB4C-(]<N1ZQ1/=SY+AFG^#4%>Z:. 6VL"C\FVC=-%C
M!NT1/STBAX@1#MUWSKG6!CM=[Y@$(B7#Y7KIL:6"E&CU*T6.F.*5A"E)M'PQ
MY82&T:8(X^K+):5;[P9QX,67<ESK+LG/]\7"_::@4B%.D:91RDE$O!M/UT_2
M'.2A@@')3B6A,>YG;)CF'V.+D>T4J+)^4V%(11<\8##X^KF7DXJ$TQN]Q^96
MRD838]ZU#<1Q&.[A@R0Y@N'1BI;]JN(<D^$&HYZS(';9=R)C&DDQA66#H&V#
M3Q^J#>-S3@%,Z]K#*>A\]3VXF^%L!5NS["PX;>W!;*=F'K'K1K7SE*8A!GS8
M6EV7T,T"98&TA@S_F$5[J+JY%?\S<VI[LQ@D.&)@UN\@(._$H3;@P GEOYB7
MBNUG$],-]?-<E'#O7%Z*J53;4=M^1KLR1B.^\N5%+'\#03=A2EUA_ZOC[Q7:
M([--];M7/NKQ7YM]RI)M].&111JB<GV:0OOSM 8S0[@3*V<DF._=GZ?)R9OK
M@M2-"V5P+4>D@")9O55AXUU7>$4RJ8V"N%N\4W%T9E,PN.0H/YEKWQC:<@@A
M,2A=YX9@,K'RU&9ZI![PI2U1UP.WOC9M#?6#3L)/ ?_K\2[YIL_9"OI.@<_N
M=&@>Y=L*#;L%EI!)US8MI^WP<B1*T[(;<:> 0]RA1O_QG,/!07#4T<.-X%<V
M)P[67R:_\1;>.'#[<@KLL^:? K.0DY0=&9%,J6]O%D\V).D.3&0RR4Z$_C>$
MV**@IT"M(N,I4-\2'7SDDMK^ZH3A%%C&Z[>;X\Y>V.Y]ON@05)%.4UTH=@K$
M-L3:68W=ESEY5J.770>:I:/'2$@EE,:-4&EMTP9\OBA47&N?34,.KF*+7'S;
M@ C+K:N$@\@DC5%0TCH75]:'<BB-X^7\^VWIU+)RA7,A4$YUJ.K]/FK-M_?6
MI$2;!2FRL94,A&A=#?QP>&P-8+N6#)";=$DQC>FE$(K,SZLQ',N\$YQ^.II1
M8 H2(@6=2(@=!WEH8FCA-ZI#AH)U\,S\S-H^WVP78V,LE4F\OQ&T&US#'QH8
MB0]"<V?Z,.]4N+YMJN2RE^W+ +=F&'H.6&"%*)F:;-.DX@W6?],NH@#?F_ L
M8[HE'7OK*6^MDLA2 UO/RMU#AVL-Y-FLZ+?L1N;3FPC#T#@5"'O9HO&+>?.M
MY6Q"S&AX.N0^#J\'\7Y(QN&12HXF5$T&U3@R?3UIG?-\/:':,S,GYM33(<0E
M5]6(':6]?_DJ>X-]# N?Z8%>NQ\5/N>EO5+8!!-&K4X-NGM:P8JF&;CF61VC
MA#L5RLV.F!R(" %5E)M,7KO<L(YTLIV<T.'':+E73MIQNJK-*O4V9+>*'I,'
M#^.Q'_;<W;S]=DINWT"2K8&KVT,2OQ!5?LG1[$HESUA,[7,64VJG^_VLI*_9
M)]ZND9BIR!C)^6_&9H=9"CS@ ,GV(-N+O%&4#N]0HU2*X.NB9=P;(>@W:G1H
M>>CM-^+[C7L.0-[DCM.N&0;SOJ",FS -$-3:-Y1D@[_,_F+Z\O!!9G]/>P#Q
MEYR/ B$=^/8H/3<&6+EW*HWP#!S@4RRO;C^IVO-+@  0FHH;4==12!W%-C<@
M$=BO][,+;M0)9MA$-,K- WQF4?6[1WH,I-.CKU/#"1Q;:'V(0N[5;FC<LZ29
ME=\H>9%N<)U,Y5V#H8ZA@+;JJPA"<=/4<BEO* 96P2-7S>9X>)BR]CO)'#N"
MFVQW#]C(BW>#']+);[K;C]N,;[AON"_&CC/N51)'VY2GP-VT8+#7A&]I[\P9
MAU!:I;",-]1G=O!+=+Z@_U*^FC.Q7(=KR'JI!<UC*L6C=#"]B)EK3P(9DI =
M=&NY3M +1Y?%DFE6/[.?0C@^4PE.Q#)FZ([$^+FR+?HZ6@V?24^1R54-51Q_
M'QI!I199E&9L I/X!9X%8(5D*UQC(K<V5K#07-$6J$D03.(Y,+^!K^1E_"TE
M8?#$V%!]=&KURO,.PQ@1K?6E%T/7[@359):A-3<.J8RB.];)-L1>C8FU(8P.
M>>GS_N$A>)=E>KA7*!N"D2QA=0LS^% KFA$K9*>C&K7:;3^"GX";>[8'-^]9
MY&=A?EN^CX,#HM""6CO#9'=*Q<G\NB2Q.C7WJH$PGD6A;JR:"5?--L:&3N1H
M#P.-()>[)52 -74^ D" 2E:ZSN[U;MOC_,N(E8$U?',@H&Y3>S06L\]=K>_8
M&/].R]SJ5YOFMY)LK6G%NT\I:WJO/2<E5%?69LZ>A!TPW^4H[_<?R=%@:H$)
M<23.-+KCZ[*_JH@Q9L.*$>'C4=RLWF==T^42RJ:'$LB8C>$("P3;]=[;Y5$E
M@OB^6)<2"]XWRTQ2F".D:)[5KCB:<CX9V()R*&>6<TP?*K9R61+-Y3U(\5-<
M,3=EZQWWRNRL\[YK5@^VUA#VX5HO8X6]C#(H$^=X2^ <-]83OD8V)NEF+DE#
M.4YUU4V?K*Z.=%\DC#.IA]J1U[[@=0B&+=,EG3 3!YRXAOJ'$+#97 > MAU+
M[\;2ZE(9C7]/?6C7^HC)>MQ*976"M;WY^&K[JRC[DP_HGR&G0._CDSOC,E<;
MCH./B,:"-Y*#U:[096O>.]GZA+@:T"0>5= -(Y9[RAO_'PHES?C5WTY^"-QJ
MGEOY@C&?A,(&T%WC[;GF*',BO.&&85<?)U]7#PA/T.3A.5^?81"8&U2:IU1%
MN<4QFN.S]<UW<C)O-F(CD<ADN3![.>TFT5V2(??\*20@A-S=3#@SR@#=&VQW
M5WFN" P\2J'+;0VSC;\W7",JYW7C)?^QGW_IP@<1FKHB*AV\5%<Y49/>Q<](
MVUP['4'5=1ZX'P:K!>L=!P[W'V5+*1D:$E]SKY@<F!5($#RH(GI2_DEL9=PQ
MA#PP54D@21R9KNMJ@'+MF*2QUM@&5T]Z3GII)#DH.MH<%'2#7'?$^&.]N8*;
MK1.UT@"1>#(O3;GC]HYQWK^RQ3@[6),&=YU\<L'%$[Y&]Y8'BK<YWRN MMR<
M=N7*5Q]^*OP'QLCUUUX\M>*(1>Z^=,WB;C#J8V^E0=>>HT5Q4P'_37G7F/ZI
MV@\4!,+=8;E,X2$  >Z29 42HTW30JS2W&-W14/3VG7P@':Y/8<2P:(:BR]+
M;3^%@WKL ,&*@%5R!:I.).AA2#18%W=_9WZH+XS'U;TP^['>=G5L80!ZX*?8
M>ABZ7%G7RXV<BJ1<8!:U4_&ZU/1(7H]C#WNW91J>TI;]ZQ$:'HRW?:C][Y^H
M!7GJ*W_%S)@='$ST0*6^%IEKQ^9']_8PB2*HJ\B-4U?(9IOE_0L2&GL:\G&?
M0XQ&[H) P:H:K91JVKA^6(/-$0^<AEUA^HJOML--;R&A>^KCL[K(EP=686Q@
M/Q=CTQ0,S2FBM$)A9OU6RP'.\;*W!60YSYDP)>3><D*R)QT&U_9:R92D9IV+
MM;-9#6YH3\%7YM9DKDNR"']&AZH7!ZOKU<\TAS)=0Q;'>-#=G+58:1"T/K2$
M/*;91Y@FZW XKS6^DN-W><#A2]4(F_($T:TRKKSAP; ;I<-ZJYRE$N6B[UWZ
MH]2%2W%%,<J=2U>U306NC3$(HKR19TDFUA)P*T-C,RLI?M9ZS2CD'5HF^SIS
MMKA2!D6#R@OA,%,_ N?#I&]SWH=5E@5JZ%[V#DD/5AF856,80/XVKPJ?!FAJ
M<A.Z-B77%N-(8-0Q7A>M=TD?O\[-6D>G[-Y1W@11Y[L99<U7.BZL)\_#(97.
M:R3.OJ9[,ZDL]]XC/5O_2^! DGO>W";3 PVSO,A+,X<;!HU.^MN]%H;-!8C[
M/+V*L9.FYQ4=!?EU-(-?6S/JN6UV/-37E7T'GNH+["$?C.ZA'.-0FWFE/+CJ
MGLH:X47^3%C6P;$KI!!%M4%I[;:<O\G.O2I['<UW(U#SMY5JE_726H(Q7(P=
MB0Z;):GUD_RXG%PX'G/X\K(FE[*/N!2W8*64EZD:00W+M+ML;BH2H#QY_V2J
MTMS_T2?[$"HJ&N/BJUP;C.NQ3SFMH.(:\M-^A=<FQ(59U-.5U+JZ%1[=NA7A
ML,-?AN6?\3SZO7IQ)%\FQ7Y5?,= 6C<)*7MBE?#4]-3#)T;^.K6ZQ */IW6U
M+K_SL^I2W$-58I<2-V^^6<BP4@BY-_CVF.\%7(F,+=X8W:&</#IC$KIHBZ48
M'W<0$^+6+ETTW6VI)BF:MJ9.J'NM])E:P(.Q5 ,8"8G*?;T)_83YRY.<S\03
M<^;X,5P"20MA7-DJJO5PG&Q(K'LG [C^7F5;RO&X12/WY0EK;6&W]\C,I>YW
M*Z$S0P5:Y0PY#:TX15>4!"O>O^"2)Y0F>;_CP9ZIIO!4K[0A,5/BUEW% 2F&
M-/?RVWV:3W6O0"2'66A6P42845<B>L%$&(GDT3'Q$,86Q2[&7C%(M!=!ZZ9W
M:^4-:3GAH1L>-@3MM!M@[462)$Y?GI1H[,*;_H,T@ODJ&*&QT5*JL85Z5;.&
M28&SC+F0D*KDD!+$\H"29 GCJ=6:YJ=,ZH/G@4WM&C7?AREY+^@CLX1!H.;"
M[)-3]&(&N4CHG<09$)LXKWIJ8.L4P**G&KH\F94/:LGEDC]L>?'FJCG=U;7'
MC.OX#N2N0O,LE4YI![QDSE&C\%Q:?UV])E[U*1)4J*?HDUX !'[H$XW:?EEJ
M<R1Q+[%A_'/TQ'[4M6-*"XI@P7WF_E:P4Q]Y,:SCO<W74J[JA]_H/O?L'SKU
MD'WKD:Y\$[<=7/2=^'1^_3ZQ]0'1^U=?VLD.]0:/\,=.@4M2;9G;2J> SS\1
MU7^*NV2.SOO-FF"=T@8E(]_V%+ 65K[%MZWHR'PUC:?HX5V%+L(0+V0"'/O/
M(<1%!'P9RCT 6\A+=_)A>\WQ7'IK7IQHD8Q&;6M'@<+;]E&SROBM@NHAK ];
M.3FT-2:D*)KIJP30699W2HO-.'7:XQY03U8X$69JU2:G\')DS!I[0@BURK9B
MOP[K0W-SJNR)+*KU(27B6*A]2Y(J:[?O%)KWN+EYD42 XQH;(Y2E.D$$3REB
MT6+!%&#!2!Y.HNI'^>N?3$,WR6>?[N=D4;2N]\!5(YE?A8^E?^">A4!V&WA1
MECE83&Y)F^6%+YCYU)G !X0U#>H'K)69%O.=;/D><RB^GE1QS&=.D119M22Q
MX@G+6S@%[.#V.#HG:3XD7;2B] K4_,GTM(0@ O0#7$Q'Z>?CK7<7\^H8"O%K
M"<61_,0%F6CBZH8_]J](8/4KO1TD6<D*Q]5KO%GAR$F&2S.A[8HA <.VOQ-/
MH\SGJ]85XQ+6QLA$4P9=L<ZY?B"^/:]P2&._B>)_>(WEB,X)-Q>-%,;;X\_@
MK/*$ 0+FL\L#[*0G-KXL\CW%(23*B4%- "@H4U@ZT_U;4_J7GDY6]+&5O8,U
M5'I16;1#&LH?U1#B%91C>=9[L$0(Q#QXR?2%BZK?B3=#%&6@HBY]:E*B6$3H
M?IZ9.(3\JHYI*&K'6-R")7W<"P<<98RJ*+='%H\Y0R8D+TD^11FZ_U4!+-(9
MDH-]&S1#WKAQ;V+#-M>^0.!9I?L)H<?*>\^K"Q%QRCM>!65HZ@-*Z;VU#]V:
M+KW7X)IFJS3/]Y>U9:-N;N[<I>U]/3S;,Y<;'4$O9/65@!S23*RUA4E*9OUF
MD"X0WHK'^]5;EIL-8]_S'0/.(A?*EH$]RX1$M9KI89VD\_#V)3]-I[0"+'F)
M? M6R\=7=0*D,U6?['S.BN*_IQ6-P68\1/XL1,2-NM/M>@[=PUV\9V/<</TY
M_J-5!NQU@E=U:/)@W!ED!9$,=.;%V)<8+^N:W#$92BPT!RI5.]TW:6:1'SB_
M-\LMO+?BH)=4Y^<\F5P]?U,-S/6@*>527&H+_VN9\*3D!5>:.K5P>D-=-O<1
M.!;F\M*ZC.*N%&2:AN-Y_4!L+P&FA.RM?#OD+GIOVMP^D<R>ZQHTD'[3C$KD
MV8<MUZ==Z@@[HH)"9BMLVC(+XYZM7JG1'*L3FM3 (MFDT1#@VJ8:[O/8?VND
M\&BMWC7[SH XS#[-K,89,ZD(@/M:H+^PWS562E0F-6HMV82TX.C&Z>(PR<P2
MD-L[%63$$$)7&B?@R!3T<G7'K/ZI8QTDOBES+<T;H:+5' FX60F<00+BV13A
M*8]]=::J2FS&D]W0C(:7'$H'@PKNQEJ./_Q()O&@!LTK.<F2Q$@S]D'NM831
M0^Z"F:?4_I0V]5=#G/?];Q,@$_ 2.YBIV",+JO;BD*E%;M/C^\<5.[.LT0YW
MKUA%SR8Q.2R0EX3CF(5P\N1MW,RZ,Q(4:<ZS/C>Z>WQ3COB$$EK1O*:&%=-\
MK5O88%].\:Y*KRH/";&^(B.M("?QM"!<3E2=@I&"82O_.OD8=[V;I!2C=N1V
MG?-"[&ML58;HV0P-)$A+=U8/6?/'9C+SQO%=-DS6V2:7+O<\81R0P.U.\9@G
M$YOT]=55GY](\S"_3^'*R+KO1J:?)[18,307,^SG93PE=!Q+F*)*Z7"+D=&5
M5#=>C#&L^%6J7")+.7<^\J'5\*&,[>SM-V9C]75N+BBZ2E!';FJ0BP/7\@%#
MB#@+VR8UN>L*1>I.?0ZOW#C74DU-Q%,W(DOZ3EFYZ*N%]VLQ;+"%^OT>3!O/
MW$C\NKQ+^T;S2_XIT-3F--6\?8-WMRA]GZ[@)/#J=<&EN).EZ^;M9$NG@+JI
MM>VAS+NH1Q/2;.T?6?_;DO'2+7E>;+!CT94VR;7]+*6BHGGC6&0<Q>@(156Q
M-+W7>0_YPA259HNMFD;97$,5%0&D)1HR[).<4P#U*__@W J!61+R8R[@1:V<
MSUC%P*/(=F>0$:TTCYCAG37[F2]@D<@L&?(NB.W0VM7H6]WN&2$6*H$SHNBI
M="OMA:L'7O[)SU6CMT#!!AN?YIB3^L'=AY6#?9U6D__J[P'73$\!'.3CT='E
M4X#0\?(Q#SH1^.%A5Q6Z\V[,->&E![DB#U_RD+XF:WB:=7SG72=9U?7$ET,#
M&Y5#45/,OJP4.&RK+Q4DEI16@G:>S8P3U@^WN/MVV RDOMNBGQT45S-E,DU6
M"$F+S13$Q*)7:H17V?H+$=\JJBV1*+=H'':<)-76ZNY=O6IF+JC,?E-?RFSX
M.7G]+I::'@_K/9&$9.=9I;<.9DCH[%\HM0>U-+5K/O2E5-:8.S_SAU!U.73I
M@.LE&A0D] JT=G.<\+-&\J<K!VX3XBX_OQMO#R71W>#X>M<1?]&P< 0GCU$3
M4TQK7JN@D"/V3='NK3'NWLPL-P/8YROJQ4:.5?%IRJ9ON]*56#/<H [IAMA$
MR3>ODA*,JA69]BFF[]'ID%341=5L]2B[Q$R*M8O4F+W@8I:;*&?5"**3^^)!
M7,:U,5"&6\BMEF'ZRMQA7^,AV>=N;0WNA3)_PYW9E9&(IXNIJ@\:U(W9YVKO
M./;W]TC<M#2P5$^>?TG\H:K-=6=H^-F&!0XW6,U07"4]85([>8BM+*O22E)D
MJHPLVS>=Y'-%1ZK!QOM"$U+=2 ?1O&53GCGRFI@B5GHFUV.LVDVU%Y;NI@9I
M;^R&V,MQFL*><;7<#'W@=O>V;9:@)H?2!TR)H%OE9<ICNMN[7,U!=GXJT?6<
MY -/$L2[GNO"IM0R.@)Y(L3XDLW[5_OL\6K#BQE=K99I<$GD:HJ7LXSYOB:4
M8[Q7J_LZQ;S,SDK<W_W$FM](RWG/YMY(.0.U#MK2M]KP+B)V],OE6?T4EIG?
M8MUKBME+TMP;C0_\=Z*&.3R-S!X4"&H.%V88>"?)81)EXLQIJ#W8)<A2FZ51
MTW?63Q"65>P*DY7H-K07=*N1XOL8EL]2S$:\,WZKXL/7=0E']:3A&"S=KV5J
M'-[51L5W\X31]0422#V*2(I'!!D@W_@8.I7+/K*!30VKDG,2F&IW.++B0X8"
MX&D6PNS*Y1IZHWO'BL>3OA8ORF@,4HBJY<;9!WEN,G)U>5*LA-[E:.Z-><27
ME@NCD7YR<IA>8HY8)AZ83'V3FXF2CQ\GO%^RD"6549+YJ'BGJJ34Q!%+D&2>
M!3YTDZ!RP5*YG9C!%9.R"*YSXYD9Y@=OAV%_#_+\1QC\,CS9>D_JQ?MS<%;K
MF;>>YDS>PGG;0F#\ZE-)\<NID0^?U?F2;F)ILC7DKZ:4C,8J<QNOB\4FQ?AR
MTQ\OE.O'8)<1M#V[[K67XZK^L6U#4<YH@G/L\=4[?DQ$W6M?]M>K7HCBD@XR
M]R@G.Q91"!LYBL,,X]=3J9^3Z6F]]+E/K*DZB0/,F!+NO3QBIG<-KRI9:-C2
MR JO:9K@%"B]3LY@9VD,]K.P'PSYF#4=_;PMP8-I4ZUW+\[%J5Q15:5JM&*(
MTB0]+P&%"!2_UBM5'54B9.Z4G:7C+\FY6F=@J:;QUN 6D3BSL$[?XWQVCIU[
M&073.!4EIIVT68#W6+9I@*&@RC!+UL##P.Z/R,XA#6I6! '/74Y>Q^R\ZZNX
MS?[<;+[&D+0KWR=5R,A\1%-J:.:+F?NSY3H?YS6GS\(65T7]F I5!W,#A#U$
M5>X9*1F"[VS"4IAM& EJ.DPKE.J2)Q_9.0;6^3703J@\\G[LH0 -QYK6>QCS
MC.T)L\K.%<3-=&^0,[M85J]1N9^^QDHUX)C%MY/"7[D2&M=C7A<TKH3JL(/;
M>-VI*]6OQJ;?HG-#\QET4W6NQ&W>Y7T V])Z%BC',VA1)=[6W&!.58:+"Z=;
M8I-*9953-FU0%*^0B6$E;TJ-F< #9R%VJ#VQU?/=-,=V<05*B]B47B6T'BE
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MTH@4&>%9#GF7?$P6A-JAIMB-B\O3)XS+">^E-+V/\:L@D?APQ&EDS[%K&!_
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M&3GDG>W=G<\["]O7J.6%9,C2'N!U]4Z9=-BCDT.\P00@I.A$,1C&M@V.8F*
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M"N.L]!-I\$-4\T12>*V!4[Q1!!99%&-I ZZ,&UDI<W)?6R^(+DZR^6-H" 8
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M'I!,I3G^UJ>9W&5%$@YDD E<:#28S(Q3&DR:+M9G$9E@8E'<GI' L!K5YH,
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MYBFS=4'@^67X3EO8YZ=^P0W*MBN,L!!\I."-7FW$70WUA;E&-)S5%&BQNFP
MN\:=8,-'CR"$6D,_WYJ E5H&(>5EO->+'*& B&3M[#43L%V3UO4FPZ/OVYPM
M],V5CI\5_\5T.7.Y"^HXQ<\:4_Z_ -<?0N7)8YEIPYE+:"5[[P7U1SE,?AB
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M;J?TS\(\<3C]6E!#=* F?B]"131D[5'69/Y)EZ01)H-,SA>SC!)%LF[@U=2
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MC4MINGW/TM>'P<>Z1!?I*DZ%R00S?#]_""3)H5*RE[-#2+ 3VC60L(J,97)
MW1YBMCBU"^@N,M SU(]"0&]N@O%)D@44JSQS@R=W(\,0S!F 6-,X47)8,Q$V
M11,$U^YSBTRZ)6\+Y))TB-_DS'W?LAN&S*_"KJJ.K3EX<9M)8Y-4[46D;.4Q
M^8ICE[+"/(<R)ZC*O];8GW"_-E^@,Q1RUW*;_>D@ASA&5IV]"M-/1R TIL<*
MDGZ#)0!2\C06CW0W@B9%,F;V"0N+34/4;>6+?XZPVA/G^*DN8L_(P54M68WV
M)N[]B"@UMT\4%=(Q$U,+LX2T+9,UFMVOYX"856N?BQ6*(_15*L1G[K8BD8&;
MC;%3=$1.V*10;O01L%"=M (HV P0='0^&-Z;D&YZS4\\?$BA_?DV9?:%8N4'
M)NWS%#>HO&98@JLU:NS$NPDWC@M&S4_P"DN+_:EK8%).%C,?];SKL'21KT@8
M:ZG_9N<<B KTM88 O1#<S_/#>#>>J[\WB!9[^VTO8$HOH#2\-S7=G)L@%_=<
M;_8H.ST[*S[SY6&IAHV)N6[CXDU%):H5^7>6\I:JT8<(.]F.!-ZV5,X*17O3
M7W4>:L/EP!CJ&"T>K'.8#B5^!'?4@.)7IQ<*]<$3*UF[0F"_="/2SV1&A#R#
M)/3]QL'U*V3FL&#ZW29 =*XEDC2##$-MAGQ!3^ "6T7[N[YT/WF9"DZ%[NH3
M?@]1GDWH8G3^_AE3H^9\F$J7AYY2Y"[!S&RM^?96(HZNFT)Q:SL4(V_^A=/Q
MSH6T13,7$%DNU?H8 '#<B2R4N"(M]("1&KQ%'%K]D&X_3<(8-ABFBBIG_TU6
MG&Z78EHD+%6UB"U%GJC78. PW)G\Z_O!18-KQ='%XU8YX6Z4%\38A?C?<.1(
MC LH&0O-,R=ATKC5;UUD>W"*N?O LB9G^EULD"Q]V<$\_W-IT#?:.SFZV<+F
MX'UZ0GS3?INM;[+(TOF),A*FQ![#QW19. NJ%1G5F01>54*-@NA*7[AR12*C
M7+@.OI>(8X$L4]YRS0H=2$MP^Q'A<L:JB^3WRBI'.JUW\!^&HY</#ODV](,Y
MI)7-Q>>^,5I?Q8[/O3+@HL2JEQCNF1XP,481+C1)6,P1Z:])K4#_W!"=4TDF
M63_A-]9(?:,D&BP<6]8F[;D?&CPR-I+?5OWK[(.S*:M=AFXM 'OEYR_!0AA.
M>I,O>NA6^!489*UR#TYZ J45H-H_1\TQNC24K8:M^<FMM"(AJ;=[MH;ZJ\F6
M21-OF6NA*L4E9P4PH#L.3QPYL8;SY,>WA'N?)X>0V#4$&>'>5H[V$Q$9'4#&
M)154=U3E6[^_AD4)=6\CT*8#N901*.NM_;FPC;\==YH#N+_AF[V*AL^6GC%:
M.4?Z2ZL_[$&LD:?,Y"8T+^O/>"KT.NM8(\L:7U9FU3LO@3&&A"DI9.$O&9G<
M:,6J_305M%718Z,9A_.4O@:0K,O%CE$*<"MN@9"@@_T$1N2\[>"VVHY7-NOZ
M!@-V5"[8'->AIBMR"D2Y:N )I^J5F4#ARIN)R3GR[$,:9Q=>5O]4[8I#B WV
MHKV!=A1)&B\IQ\E:3;'HH^QI^5=T7:).6WD'9JSB7^UC\G8VD*].%$!D[M4D
ME)F7U'OXR9*P2,;+#H0N%2F^EZO4(5T#EZ">25^,5A2+M0C921;RPX35 >T=
MEO6VIY$,#FN6-X>"R GNBN\^E5?X^W#M+L9H@C.(DF")P6&!JC22IQ"V9T5?
M>0CM"OOW80=;Q'[F05)L,+II@Z ,Y6<"QT'\P6NX^>U26! .OH1+5=9*FH??
M2!:5.2BA/(*Q29]\*R(3HE-+Y&%XB,S#9EUU6ZF4FE'F0<AMPL__ZF4>T92-
MDE:#>XD%>E7K\8P3?7FXL\K&*DWUE8"2; I*M(=?A.-QO11*MH LF>,@>"[:
M+*@/ TX9M*-@9HK5:>+<,]C.GY%\Q%C!'C6-OP-O&<W/C:\^\*#5OH$F)3\M
M^B^9XV8E3SQ.9JN\42Q+E]*2G]>16M.T@\Y>Y-LN:A9C5NEW%,<%B\5L,*(+
M:2[A;LR.-C&.]%&/Y,Z\/1Q)1V<$F.7LD@]$%9,UA+TQEVD"OB4GD(_,YN&U
MY@F7<A: /_+*6AK3J@FE1\'4>(-)-!G?F^=FEN\7;#8$:DID*Q92=Q@7Y#JB
M]*.0,]C=WY*N^.^TNST\+\Q#2AILN C0W>G/R4.Q>3-<W1$]9:#[V*5;C3[9
M6:2&W@XK$H"6=I_KOP V W$ 4 01[X-Y=U!@,"\R+BM49Y0+H@\$<&TX;<>]
MZ"%+4#^7@-6-?#N,?!+:[I11^7* =935F, /:9@C#S'(A 6H=_&_("GR8TPQ
MGY&5HJPHA]=HE6T1?[[$KV\7[W4$D[1B&3Z^6@_GZ%JYR&*=WO&IB[\^/40J
MCGH/:C13@A'<;0 D[M +-CET3#;/]ETFOP W'WY5>IC"Q>>L7K>_2YNB^[0)
M!8H6C]6Y/W!FRP=VI(,C/%>U.I_T%+Y1HMT/>77YA3R\'.X2<87@5_"4^S;V
M*/CY6-/U< 3>:"&K7Z2QUCG?7@MN=O;0=7ZC1+TX$)9W]8A%SYD[4&L/C:/^
M-$?7(^%RHQ4W&LSDV:YU849W _OV0PM9]<2];*-?_@CXY:+T7YC_NR4E8WD>
M&"_^88F/<HK$(<$KH=B_ %Y<LK^5!4S0OW>C?CXUC=SDT/Z9KO"T*_IKH8^P
MPZCB!U?"PZ#/SXK_##UIHWCQO,2;PR,O1J6V)"Y_KH#O?C9X,$$_C8]=^3NG
MOE5M9=<.$G(^+=:UQ::C"HN6$H.*?UR1=PME;_-Q.<>*1&5G=7#!P[9L4Y_&
M?+IZN# IT>?>PL@=Z!*7^%)DZ,WS]?%KY5<AEK<O7XGHY;(]!WXU>_OI0/G+
MP$U)Y.[TT?,2:>>S=O?3?U%G:868_H^MK;QAYU<]^P>'0WF#@0C[:9\BCC06
M..%:TWAS_8' )[1$D^<7.3+:V8:\6W>M7])BMSICUR__E55%T^U\VCG@4^K6
M>)[/I]!GNGL\^C^:[).&\J:?:,;SO GOX[;%$G]</IV8^S8]_ 5HB?POG3*"
MXNZ4Q._X=" B4$9_JGA[_]YGOS*>L#W".M^H$,%J4/P*]\WBI]2!T/W]%[X(
MH"T>WK[Z26<U_$X03<DD ]V'##'ZBM.TH8JCX1/3H]U7(==Z?Z2&_4,)P\5?
M@!3.0+RI5*:H5WD_]4R^/6C^NYF&_6=T'S/\)GO;OFPWU,T.P^G,?^34=SZ
M."3OO+X]&RX46LIX3TI],;N%A,0.F-%P?TKVN8JY^F3M)'Z42O-MA%=!["Z2
M.*!*Z0P(QO;<0CT2&2G,'?455)3$%<5* L3\VODE*?K#W*3]HHU>^7QY*"JZ
M:EQZ=G(/"5VF'0;LD'[[3@EU9,!448KZYX?>:[>K;YOCDY&N:]R4=FPES.[&
MR*[X-PGV,6V()4!9Q-W,U*-U6,3QX)U;!!&:UB>U#Y6#NO']5&J@7_[6ZBC
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MKVT):()CB10+'O'UC"_W[@CNW#!6-U/\X&#<]L!V#S0^5,9'&_<OV6-;HL@
M/U%3Y6*<P<$QR;CO%N&@RMV%XJ-W6SE_K;2AH#BH\\7B"Z;/%JE?H&FA],&
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M8SP4_I(K/CZU-RP%4_ BM0C!T3^:[-M*"4\VO6;M>5P%'.7;<X;%;5/OMT7
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MRTVUT<D</)H$W1#A_!&E"'S@7J,-F-07JPM4%^?EQ).(3[ADJFX#X8EHBJG
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M_3UNR;O9Z]WHKTJO/YE"@UX(=3\B._G3/&G[UW@R'>O=Z7-X.]A@:% _*E&
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M&)>08<B+FI3U!+SG^?V6@.5QUJ$*K)Q[:(US_4=,SBVCE3&:DJ3)IG/(^S?
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MIROZ0U-5B5ST2H-3J]VE3B1G6Z0I&:[."1H+?O6DQ&JK'&]A2B7(*+!S(I_
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MA%^N_KS^M63LCM(R_K;3_&_M0 =%O(AN"J\7YMW/ YQ;1T0R<8S@2XH.6PH
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M2*(5X9U+!3QG]68TOORUP7LAGGEVW22D,8,9NJK%J*%#,0U$L6PJYQM"4AX
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MSC%OL^@12H*;BYQ_+?\74$L#!!0    ( +J+75,+"^ZT^$$!  >? 0 1
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MX4G8_[6>!,122]L1*D.E80\%_$(2]I;D?\?7<+&'7O/5W.W%3 >#R+^S4=R
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MUV6T:Q<@?P0LZ_*BNKS]  "(7]ZCZ  ( 3 7DQ>; #1Q2[ YT$12&0![L07
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MH':2>^^RGY?I#+3':[ Y%BA%4?O4R(WU*1[+=B'U?BGG:S/CB,.>]I4T3ME
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MH$$&\7:3E_'=BDJ2C"*I\H8^/\%L6F-T3E;?*M>K2UDRH*B^OU]7\@04VRL
MMF5D.,QZ7XF%90CI0ZS9M>-=GJ[X%O/9AE/"5@;'SK!22?WU *Z_-59):*S>
M.AWS(:?QTY3IW$X.2P1L:Q$3ESL*IB137U0G]Y>R][$(3!UCZWGVZ_D&[4I
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M6;$]7W&*D?^^SG6^F1KS QS;AA_5:*/GU(3OEQC1AV@O*\^@J^L@X],W8M\
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M73R^CK4+P G2Y:ZNV./!>XG@XQ:3"P#YY9'I-V0!Z WP#? -\'\;N'1F^8Y
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M$V.0 &:H1-N(+]?JAE F$PGWV8QPT*:\,JG#"MCS**&:7Q]NOB9)C5 IYOF
MA_)=^AU>[7BYY0"N#)PDQW)Q_)6EL228P&$Z&G5E/'9A(F+E;/5U^V?^QLME
M2*;^9'%UUK9VGQ96UU +X@=?VV*A[4?0]']ISKR'OT^MF/IIL,,ZUB2BJK0X
MV>L3:;!Q/A>3O4[!_O%\4MIHH*'@CMOB!P7QS]4'<R=$^!8% S9,'/%8X2J/
M- @,P\,* _4=%ZS(!VG\V<67Y':I#1/A=^A8B03-/U+!4BWOY)<1/V]R" ?
M*\ND9>5\>3.W48TG3$PND<%,9(-VI/G>LG DXP&N"Z/!_6X4S_7U4BOZTH^R
M]_N< DZTY41K?;"V=$+(ACUE)XNUTF$UVR8S7'2^F,W"C14O^SSX%VE$:@PT
M1*']2+*;VH7I666X2#@ U:;MV<HX?CLYT##0M!YQ/F-Q;W#N"$34>>81D%#+
MM?,T<J&#Z>X=%CH 3D*&IP [&DI<2=8A><#,UJUU%6Z#]5X^4GEE=MG[2QY,
M8]J/G<1)7E.](+\ 5*Z'X+^$SA[,<CT]J ]G,%,QV9-ODNI:3HAJ-YQ5SL^E
M?^0*_?#("I#!&\:-2IVN\(RS-ACUK#+\EK>Q*::A:'3^^MA0+D30^8T+SZ O
M4QAGJ1*.9RV$)=4[(&/<&?UX=-J2A<XX=B8*ABDUE.Z9A3"C_2>0'U4V8PSS
M(@&K:/)E<_53'QDNU2E]S.S66RD3YK94;$2/ZIS&%'HGD^OAZQ-YOD-$2#]7
MHYSW86?FUEX;"=IVQMATR\#HNFN)L2&!?',B&K'*BS'G!FJ.7?^(*/GBLX:-
M)_NC'K2&R2J.O>>*ULTG%@M<<!]W5NY3%DZ+R'%'/4WEDEE7H,[)X<D:BSUH
MR4ESZX3I"AF,1D+M?K3)L$',$I^2C,V.S,)?CC*EE6>PNHSQQG6D$V3/I:'
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MFND_)!CWNPO_:=>/9_N>&P)<_2:: @)K\I^VDIU-_FRI7N7[P(.\S]=/VWM
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MC"1QCZE,V&N[SU+6\655YS1YM>'W5@3,7;R 8G68FAJ:H-@CRWW2Y_V%0@8
M72HH%OL +ZLL6>>@&V>CN0LTYANLT73?RW H-&S[TWRO]\8!+6-.1@WS7H_#
MED<'Z2U)]-& KL8[C4C>1&6G#MCXB+U_3]J,TNA^\[&UM;+O&0!:.]@)$$6
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MYS2'3BATQ<% <FW"=KWLM6KG*&?#:!PR220P6^1N.>O4 *ZP?I_F0OJ.+6*
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M*" BHXO8<5_2Q<D?:)'"%"=<5J'34NHZ1W[,WA1*066*JF$I>"(,_?TD$)7
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MEQB_)Y(0P:G.S89YQ7%%EF=R'6])!%IS:?R0*O&DS#F+-<VXA90*89QSM0C
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M#4@.?#6V=$\[8Q!M#U$>X][M&\2F. ,[F,%I8R%BK0[TIN_(Y3)BY6%/\AS
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MKLK$Q7](T1B;IH/KPDQTI<6[<U"^PU]--LV%?[]1NQX(BA:_*GW<R'U\JF;
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M'*0W=(!(5Y(/^#>B+XYF"/Q]WTWF!H?YNL5B\5A'K_J=FN86U8T<982?V]&
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M]V[M9]S=6?CRDM,3@UIU<>\CX90#WJ%"4%4,<C=PTX+5]YPMM)SKT^ 40C'
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M_@ $M!.?_OXU==B^X^L3.-(2MR]8$?<$@;);5<-K^"(JJ08@K!L!U\_REGX
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MO 7.Z:&7%[OLY517SG.D9%X(B< 2^,;6EF"9K]J-E)\S=;M_6E>^:QV'NY:
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M[O#T9!YK!'A94^?_  @6- *"8*IQ00@QC,6/=,W!)=W8N@\ ](.4?[H8ZI3
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M-3["%5G!/'U%IN1TB.+$:=F1W.W*U@DS2,W.4M3@1%(?#L(U2G#S/&P]M'Y
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M9(?.\E,L@88O*J9,KT_OZ8YTQG3LA0OHVFM 1>3(_QTD ]-3NB-;664K/LZ
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M:IWXP&AE_8OIO+-Q*4[#6+E$0MOB/1"1G#&)*16I_Y'OK_;2^1D%FX>U&%6
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M:V@M>JJI00NF+]@K0OOBEP0NBM<8NSEJ(>OCK&Q*+ CYVU:C0TZ;&LSD*]M
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M.1\M0H@S/2:&YQRRZEMR;LK.)34P=I<3R>TFDW\N9_J(,*-ZPOIK]K_GS6;
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M"_;LI78J8YTE!IL6<6!3>F'&DNA+$,B<)J1 L-FNS^J%=C'IZ3FOEY&<11Z
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MOR_&[G_Z5%-;V?GH$CN\;2YO5%D"GDK!LR@K!.7$>R96"3@G=%2GY]A?O1$
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M:.<D;!%?)Z$CMNX@I;W%"$'=BFBC\D$YQBWZ?'';OSN_?3&O1D[A:(8') H
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M+6[//OS!4 Q0<="R+\=U-^\=J@%=U"UK9"!ZEYQ?]QF@WG_01$KB2'=@[0S
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MUKICM]G*.3N74\)>H41TI>@;+^GSAEVJ]+T@;#E$GP- TC>EHQI$,) \PW5
MA3=&^VKT4ICSJ_-7]YX&"SQ<G]A?I=&VU7I=75Y K)Y3&TE)],43X]GH4V_N
MB*Z;6QVP6@.=!?$MS0R^%X/I4B2X=X4$<.9NF-P6@JHGY6&]8(?T14^YIZ8S
MQ;M4S?$[F]>-ID%68%4T+)#1CI?$I"R@F ,D7 (*\N.M\9EC<1(N\^'9)CVH
MG(\R.!5[_#!M%I+Q\HF;NGO>K2G7QUF8326/S;%+OVS5[CR6+6/O\:TVRAF/
M9<<*GGWD1/HPA+UE#T2TYHE/F=Y1X1$[O"26EM@R^2;D ST+$WJ/GE@;78[L
M_5)^E(B],?&PU4/M*-5N#,1 3\I^O^?^@PK2Z4<^GR7. )R#YS,[F,B_2[1R
M\05AT(*GK,+<JT%HJM@ULVP2'F(\GLA<'J3HT^M3_B,HS?T9Z&09XDQG@,/;
MWEWAFV< 37<*Z%O7$,UEAYF$"/*6=-,CR[N?31Q29NO[,%EDDY/DWKUXD(]Y
MO5 M<Z<R.Z@Q+BNOB-*XJK.OJF7\Z%2LKB/YL&2>3&0N37?!+>Q MP 3(A&Y
M&4QS]VD[Q+U2R/+UT#-S3G9;#OW"F(P)RFC>,2SN1S *4/=('WT1/"!Z7/*@
MO@MG#?=^DJWP(?[25U]_C9/7@TN\5$&C]>O>K5IV!Y%FVX0C,?CCT\>]BCTG
M-/YA_^:]C^<)<=B%4K2>PT?I4I*2W" T( 9=# %0O5LAS[7U>"T':"J4]YR"
M>.'$_8%H3HIY=?:;J2-<BI;,":C.J&%2WS?A!- -6W@0P:8!J&]-;(@.*F/I
M7U^R>CN7ORF$676H-$DU9'.J$%?!)1B/:+3P=2!!(0Y=0"!=5.:,)C[]5PDQ
M#/ECG!7L] S*7/\ $YP]@1$#JKSRE^&"?!4$UC'2&NU9V[<I*G)?QP91[8,_
MW!3;_>)KL-G&E/W93;8\M]]@L-,UV\T5#^W ?UAB/IMBNB%# BHRS2?/G1)C
MR^6P7(L/);$C6=E;M7V!>B>_Q;ZNJL76?=0OX/BQTDQG5O/U3S=M/JCJ]=S"
MN;<0[E?_2E.RI<?9TEX%(\V&+NOUFCLX_WK_X5-,%N<Q8@H'MA=S@^.B65:O
M1A9B*E,R];13GG]+(\:R_)H^PNIU6VDOKXK71U?R4"2BJ(?<RC"^"['X<;]#
M(EZ!7N]#V_ZOWKC<DU!,>[[:1C;RKN=CS[L23%@+S057WA.U'#C5,]OS^:4>
M%>XG?N.YKGL=\:LOCBST45RK_AVVG.+>.&D=D/\KE*SM).- JW=6Q*$[;"./
M=4QT!_(K".^P*O,T>JNUY:ZG=8 C>YKC#;+J*.OB=P98PI:PY0]+T['R&PDJ
M,%\H.VDY:(0RCVL_SRV.>_9LQ,O0WCQ?);7S2XON8,FNGK/HS,L7P'A"GG00
M356$[X*!V=1; ]JZP0;G)?;*''J*A0%&5B;RBB\]AV[DTMK6G2.:X<KQ3 S+
M8&4F ?[#C]55*70UYE9!GTCW>L8CDE[8;5L;C^EX0I*R)GI3JK69E3=''LZA
MHMU*1"@(6:__MB?&P.4"C-VH6^S^4(8NMT2JSV82N+;VT9<%J]:EEN;S&)FG
M7L06-P2;$!W"0_T-?[T U/WL*_K+G5=)A<+>O"NS@E4$<\N\*=F?3T?&S6.^
M5%B5!@5V#]F6+SH9-<=;R[^,1\E>5.;-F!DQY+"*Z[-S/9B&?:0M](IY)62.
M,ZD92SJ(8+Z;UI'<4?U*UBO4(5SA38L6,+_@Z>'[GL=6%FRJR'@(+0X>.]MA
M0LW/PFO;PVZK!*XFAQIH=U4$-]8ZQE@]S]S68QY886*IQZF$QSU73K[]-8X>
M!+H;X=M&E[O!*C >\+Q%5T#Q;IQ7T_'U)HLN2ZX2)IWJ6"-/+&W1*817[*)+
MK!T.,?$Q#PO"X[&M<?GZ^SQ-C1?DM)]-LM.E.#TL&=V;X'=O'MN#,E 4];0,
MN+ \O]V0HS,13_(YT+I&L#]B+8CM/?;+6T?$YN\Y\GB=15+4 J7:29J_F61W
MQ@/O4S"AF3'%KQZEQ^WYO;F>C$FMO RJE."OH^]\LY*OGEV@K,X)"U4RWT@S
M'MKI:%\@)119.JP\L4)RM\U=KWX:9H?M6%X6\2'M0XVVAL D=E?5=%G1Y_P#
M\O9!4L]E2V?F!$)N9HN'_*.A..GQ8$9,0#K#BN% 'RGSYN>4K]-,PSM#$,P1
M@Y>6=O9\::?R0W"=;SF83_MM!N)OM&=[?D"ON/&ANBH-I59@>:/-C,U';>8
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MDFUW7/SD BS&GIM<A0FF@,#9/%'-_L]OC1F;I'H^*]GURW7"?Q'6X;T43^5
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M^\(D0(T($MIO-VAW=2Q09L8VFG5"MB^@9#!8((\8"Z'#A=[6T0L2K8122['
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M%L\$PZ/W&#-1NH.AF56']XPC5<<-..KETYOQC8A$>$HJIWV2KIQ(_0Q/RCF
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M&J^.Q5D8 8+]W%W?\)M< 6DC<3EQ6TO:*?^?Y[J9Y3EX;_V!8IE#\OO$PGF
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M?U7RTNQ?(U 4P$46,)K%=KZ@O:M9<Y/'V%G/+BJ^V@WH+R\KQ7_?;7+Y^)C
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MA>WQVNN9?'(E[F#O3OCFQN<+2E;7HRMKNT5NT/8/"*;D5?G$1\"DH >89DJ
ME@C)K'Q1.O?0JG[FP/_S[]E52BRO_<\DOI#O80G!BCK/U4(F&51ARD[3VG'
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M#,LFELWUDF'3F35KY(9?/@7-RD>MJX*;0VY*IZ ^F0G&]@L17=VZ)9F]M6L
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MWU;]!''#:V1-+WT8)TK7#!3FI'DNN:LJQ)GA%Q!6.'05MVZHE:M>OVT#]"B
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MYI7OXUK(8K:$ZW5C8+J,4%P8*N/)5]+\9>O01']&^TK;@RA(:#DY5LK$H&W
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M;>]!Q!RD*B:FFMM"V_!GE0PZUHP^FGF3Z/VV99#($F<OZ*':-8#*P)JA9R#
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M_Z$HALRD,5 45Y%4$D]HCMZD9[>%##A49?_$D;\1ZS"D17':0@V5>:&Z&(Y
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M:%YH7@# \0HY4L<>CH2[VL.=Z01XK@-$Y=4T,3$!)X7\9KT1W>]- .%5-!,
M!C6SRE5T .#D\5V4^8Q'U-:QYY?35(^#Y>Q>4(CU5NN,)W[&FSGEGSS1SEIX
MS@@(#*GMAG1V0YXTL4YI.JY(/2LXW.E,0@V&!(-A;M ?]=-W!2?$:9OP3%</
MXGDJ(0]!GNK\;A.,T+*$@O65;NK_!/NNH(. PVWUP$@W9VTK!^L3\B6 #@ !
M@)_\V0+H 'H ,  )< ,XGZG@.O^4_F%&W@D)^\VC2U9N$"<D!'9F\J2-<R:M
MH&FL\3T:$J?RZ-R_])CD#SW6=D9"X##7$RK%6;^<D; ?G3CII!7B9P-HYZKY
M.P<!4_B] 4/^WKAAY>3ZLZ%EAW3_V5"".BG^;)S$\7?3\M:.=K\%XKN# *"*
MO,+)&\99W8:.S@;N9B4+_PSX4500L#_1Y)W^+">/L-$W@"&5&8%.2, ?BKR3
M#=U?T8&N3L@SNHZGDZS1JQ]D7'>P-1*.4+1$6O[,"AT['=<?67%:_^U=X2P(
M8%OD7YG7/TGIOZ+K63M]I^L@K&6-?Y*)K!%P9R-[\,G@GHP7!&;W(V($IPS@
MB4_R<"02#G6"P^Q^4[GT@W/JPA_H^#_H0(B=_1\9>#\8)[[]))]F#L;*=Q\P
M&HZ$3B87VH_WLZQB.>,1_-X#F<#?9A_^6?-T?GJ>M2E_MFG/K'X]:^/\T$,[
MTV(E^A[F'\/_'05CZZRN"N"UM3WA.)V\7OA-Z3LE/?')3PK_V:O)R>L/BM#9
M*_?OE#.;W\[J)S/I^"\+QOPI^[_/.XO%Q>\1/?,+@"[[_?D;C_9GG+ZWJ4YK
M&$(_O?_>!?J3Y_N?H?MS^0/M5.Y4_F\%?I;?%P8 S,WI-,%.U](+5G WF(WK
M/\Q+:R3?#S=/D_D/B03XAXP#R/_,S.]N '\FWED7+K@Z0:S!KH9.-TZG#MHO
M.%AGO),*R<D3^ZRAIO@'V]AV"+B;\R^D"W $Q [R<U54TCM5TCZCG;3Q+=V0
M<!4P#(RP1()MSKSW<OZQJ.-^%SZEG'+4H'9T_P?ZC^&&</IE:S@+_J\435>[
M7[>/"Y9.2'U+NU]H!-;@$SVP)U+-555?\\:/!>KB#_(OPCCV<(2WG!/$[D>D
M"+]W7O4'^32Z-F!;2[>S%0K''8Q _H6XX0_RK^)X5G8*<"<XX@_!)?ZN(*_R
MDW'JAA8<=OJ.@X0[GVQ#KN _!@[7Z220?Z)>LCI;ZOY$QT.<+FC_0#Z;06S?
M]4[36>8+X'<Z\5D5[?O*@TEZUCH=T MG[4MG2G*_!2SMY'FRJZ)]!@ :9$_H
MS( K +3C@>.5$Q$;N!780D$3@'Z\"B X:P%L D_UCH<!08!+%R]>Q+EX"0?G
M$C$>+AXQ&>&E2X1D5RY?)KM\^0KQI;/RV]M?%S1\/#Q\ GPB @(B4@(" M+3
M%P+2[RK$_XZ!XU< XHLGSJ=AH#$ T(G1,(C1CD=/.HI[_ Y-YL1+++2S\EL8
M,0!HZ)A8%[ OXN#BH?TC$PV CO&#201 PT3#0,=$Q\*^<!$+XY+ "9,8 Y.>
MA ]+3M?R,H/+;?X+I%'IQ?*,3&3 UU8"@H@[G0K8S-%Z7R;6K5V%R)^5W&51
MC-&W47J3@12FZ#*8!&^4!KWM=IOZJLP:FQE<%O>N9WHSJ_Q][\R6H:W[O?CG
M%8U]L]LB*D9V'B$)V:BF_KD=8@ Z^HFWF&<^85_ $CIS@9Z/!//$ Q>&RUC\
MMZ-(3SUX#>S\(L!D-8&X$ZV@1V;M*KC.?.'4 6P6H3==)TYD4-@H&0@CP9,_
M7?A[#UA_=^%X"' )XPR3&" #V!(IDPJW9,)&Q\&\6[A:53_[4L-;\S$9A8 ,
M_YKYLG='GHM[7Y+"M87'U'[*H#VEZEPW^/SF,6#B*?S@$*CNZNU<__*C[')-
MX19H3WG0VG3 %5;<\ Q>C?(/JS\&?$F243FBA+^D>EF1,%'_UE8U*ZWVNG>$
M?7$B-=Y\;LV276=NA<^AMO8!Q=SX8:'185/+,6# 1V8#A[T^&G!>SLMY.2_G
MY;R<E_-R7L[+>?G+<CPA76F/1#J+\_+"7'DL3P]S/-9P**^GI3,O'\]U7H"D
MC*>SI;4C&$EG!;:#P*08UFH:&.@@-E(,1D*:US6=%<#V$%5O!%C/6TO?VMO1
M6LR&048:5])3W!/J# 4C+>D\H4XP5W%/*88SX^(G]5,R+P/=F0C248KA[ A)
M=U-3ATX!C@#3"?$(<%M?Y^.C$Q;FX1,4$A;FXZ+CO\['SWO]Y"',S2<H+B0L
MSB]"]UMAD,8]>95$V-B* Q65?X,[:4DQ_-8O#P\/'@\!'CC"CI=/3$SLU P_
M/_>)!+>K%PQIZ<D-<V7\;N2''46PJS4"<G9_F.ZT;6D%=T-*,3#@TOVA_-8O
MJ/-/H+\,X$_+I\9/I,45$&!+)%CQY"G-?YV?CYOO.C>_L#Z?F/AU 7$A4<[K
M0N("UR5Y_T'RKVS $?IPN).T)L0: 7>%VR+?%- 9P1$VI[$2_H.!W\3^P8(F
MW 9BZ_477@CRB5\7^J,7?Y#\1QLGXVACB;3\MZS\4?9'K'G_(=C_VT%P_L-H
M_S(()XR301#X=1!.B.(Z"+B-FS48\7?1^T7FO^VNC?5/;YW=$$YGF6ECS0MV
M D/!,*3KB<=\OWIL8RUN"T= +9'2$*BE'9@7[.QJ*\G[._6_[>#)@&EJ_O.T
MAD)Y_TK3%:GDCOSGFJZGM\)X@6!7N!O"&JSD?M)EQK\V!03_S;#^M:D3<<9_
MG&V:FN)J,%>D)>ST/JKT"8$' K$1EY?CD[\N+ZH@+"P@K*3 QR?'IR L)R<D
M+ZS +W9=5$[I+&5_5?V3646XM=OI</UFUN;4K.B_9_8/JG\R^_W&K:73?V#^
M+TS\"485XGJR,'A)_Q+WLS31 [O\2OW!<(*<I8VS)<+U[(ZQ%,./P#/\2>%4
MYRP5Q"VMSQ+1U=(=;"/)^POM[Y4@?S%D_[+S?U+]>_L>]F#8GQ:L'ZO5'T3^
MWL+IBN%AB0#+V9T$6/K[!O;[A[<*>L)T;$80F W<PY7]A\5?5?[>M+6])<P.
M;"/-^T/Q!^%/H\+[?5C^KQPNL?^WA^L/^\OYB,&DK>&PTT\L_@>C=H)C>7(E
M!D:X2MLBX% Z2V=G)XBUY:D6KSO,YK?EUOEGB)!PNC_N/G\R\G^PLS9@!.1_
MDJ!_\/)GG.C^O];I_WQ._LM=[WQ._DK]=2_\L;_^>>_\<4GP/2V53Q/KWQMG
MR;.+G/_M OH/JG]EV>9_<QGQ)]6_L@S_3RY4_M;$GZ/]AZ#^]\\-/W+M;TX/
M/]A_/LC]9(F??;I[<D8"2PM*\OX5^9\Z_9UZ<FX].3+S_CPS_U5>__?+.<@Y
MR#G(.<@YR#G(.<@YR#G(.<@YR#G(.<@YR#G(.<@YR#G(.<@YR#G(.<@YR#G(
M.<@YR#G(.<@YR#G(.<@YR#G(.<@YR#G(.<@YR#G(.<@YR#G(.<@YR#G(.<A_
M&03W]_]"!\-LI!@\&&2DCX<!"@"T_["<&OE/;:"=_> 8&A-:"P8:\8\?''L'
MH#W]'37LWW]+[*2@8V">_I88&A;N"=^""("&@8&!CHYY$?<")LX%0@#:"1^
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MM\@*8G^HSV+I<%=3G<PS_:Q7-'"7<N4UK2+5E$SSK@\= N/Y?+O,)P_-?.7
M!RF%N?%-A\;7'[V/'^K@S<R_IQMOQ7.]PF-V]/6#Z#@L.2U?,@FKH=+ZIY[K
MBT<0\H*G JT?1LUN=*P]D>AVMWAJ4ZT9;FHWI=WBUB9>U.J_#ZT>'FL0[B90
MX3'^3'DYL\F/@OT&"VX2S.*APEH.>Z];R-3<E_R$.U,?[O'5Y;1L!L\SMSEE
M18 6[NI9<&'N<V%O<%GV5$2GD<HK))$4'.PBAKW';W-ZRW#.(A50->/C^P%F
MN/^-2)U5=T4FC@&7S2(:/@^^#3@&J&^YI$X?U$6*SG3?P:C#V.S+KM-XJ_P2
MU'.M4B!454'[TM%>/#IQPNM*.8W,56K$6+<1,O40:_OIJ$%(_UI[',\J83-T
M*GE%X5:Q?^Z6MNC\,4"R7])1*U^,P"UBUBM%R/HM-)(7,6EF94WY;#W>/ H+
MGKC!7(65S?J!V%01443>0M+73).>D&IV_1@PO@7JBFV?ZZVOWPQOV$3;Z9[X
M$/!\14T_7EX_MF0)]=&L*2.(*T$G?H29GH0T.Z8(3W? L%DIF;=V7L,FUF-M
MA2O V21P+W H,/R_$*>S*F%8 .MGQX: (_64@(9>\S53NUT97AL"<63]9ODF
M6;<C7X$FJ,\-B&8RGNI6X=T2<(6B*^>E>H5)00>/?+37<_'$"!)U#UO]@=Q1
M%>8L7S*.'0NHN!=U:)0_->08<&,WJ."I8-3R-?$0K]JVINMB\37\H%2/U&@T
M9)T,D93TQ3!?:+-(4&5P2/_D5Y>*9&:,E_Q?OS$6!G-_W5]LE&A'4)N%%/JG
M9H-%0C4?P)&CN3F@_M @SAL60;V^C;6&I,N)-RI,0>GO!8-8PYNWI28K-/I#
MC):\:EXNNB=CIIB$W<XDP=7[!K+6Q0&2J.I^T]BLBCM(KF"M2E=K>'0HNMOT
M6KIWX&@C[=IYX_^.AMCRY9Q*CAY5=1W^/(Z'/<_0@>@P#ET.70  A^EV<1JO
M,"UT^VU8=3;1'GJ7SIH@.RZ:7.-5;##='5)<'])(E91-++=_DN_?4,> 0STD
M[91C)7SO&/ YPHCR2+MU$".\CO?ZU"C6YG1L;I^"=Z&3R57+O)AVDKYT"WU*
M]HKV>SL4^IZIQ.H/98<4M+++;3@SQY 6,L*HJ@;QW%!'OT)Y5SR6&%O^M:'*
MKUTL5OT?PYRGKLQ"9W*5AR:?*=] -MZ&\;Q[I.X+#(R<?+AC<+)2SEY;RD^5
MC,C/I>&U-V\H#1TI?ZNQ[B=7;UU1>@%S:=GCFO_HTAV)'6%ZR>ZH$6C(3$DP
M.R"V\#44Y#Y4P=YK_,A@_O-\F&)JZ//459_DQT]%9'C>N)ET>S ==B;?7-T*
M8)*)\7DFD_$<;9]RO -8&,+\18BQIO<@HKFN\UIG-^#PT=I<KM';Z&]44:.+
M1RK38_,1\PN!_HT>7WOR)II]\55/3#!NP)$JF\A7,M82NXL&7Z;K+V1Z>#=$
M[8I4,^Z)W[I6G'RPQ?$-88$!E*BS^'"0-$I\2'.=<*#]R#O.5XSW=B[-6.&T
MO^;J_:/PQ]C+=@%2ZO57$U[UA*\9;<BP["@&J-S V!9H2,FR(-#X[*#BD;=[
M[=SA__\Z[$AA?'AQ,RX[F7O)'!X\[T\3#O9LO+HU]-:O F>YHWPD0_O.S43B
M<3-)6OMHG?SPX:Y3S=Y33>17]9H%VT2VZ"Q>]'=737K48[-IFJ"KHN7LBKGJ
M)CU9[(K1^L^TDQ64E?_)'GB-:END8A1M59H@7GC'R;KRXM$75:%V1WC(,8 W
M""9!1C:2!\.#^89+;4[V:-]/U;[OQ\4<+V3+$6D>1K8]P-9#/2@?G:B7OT#
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M7'OOAG,(;5O/Y;?Z&&79XC:EQQN?,".O]_ !_0 %7L:ZX1)S/RXYB'6(;A6
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M_/@FB4??G+X<KDC%I8LY)5.%9%W:XLR/0ES<\/402LQ]XB[$[D16_3Q_PS0
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M/7=9=<IU::WWQ-JF.N#^TVORK ; ]XM)!OQU9(O4EZJLBBT]JQ-\.TW)%UC
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ME]Z&@&.0V8>$K)1I98+P6L@<P3@S:VC&&QEW+FN9 ]/XP\%Q(?5N2.?$Y#&
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M%A.MK#OG",T=E5HB89F<VZ9?BIW7T_/O#;OYZ!GZ\GJ+NU2\?<Y#RX.YY6+
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M7K2I*_/P)FKJB,(66OSH;Q^_ OE?E:L3\2 >$7DG+-4%0J*-_*5Y=%C$.=V
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M[CCZ["C)Y96R;R1:/3W)]/% _I:RT#BM/FH81H)UL.&0D:5H&];-->3J*W/
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MW6FRU+ =M.U=T9)S (JN/^*:<,XT?*$:M^U]I5/\MH. >Y7EO)7V);5A5T6
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MI4+CR851''.QT#_H0[AFJH/Y[01E@]?,@W.SI!Z_>91<)B2IF=BX+A@7?9T
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M5AKL-2T" ZWX"GOMDFQG*5+$1WPOPYHLU)=LRN];G#ZK0G%-H?@'Q5YO1&6
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M!$QD*7<_HG'5[I8/T'FEMW;:]KWSNLWTPJSRE"?V]^5[+#W:W<VZ-ZY%B5#
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M_(_H$#A8FM&345;F= J@"$#Y;]*YD_^N#Y2+-\.B4*$DHJ$0_7PS[&O =0
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M*^9 QB%15#D9"T2[+_N!%O'<W2JZ"$/K)ZPS10VJ9:J1JP_C#U/5@=.A#,P
M6@7R!-)(.0RTK5+#@@<%P-09K5=^V7W,5RVF<UU:'M0<<H?'][Y6,N?8$5S!
MBL+SL1HMVA,4-NB)A^:G2BB+.#!UXUE !P8G<Y7\JM/R]G77'-B9./!TQA@U
MVKF/Q]2@IP!HK[G%ELB!W#[$:8LFYT7LG:TE+J&>8Y7!Y\??[KH]!#:Q1ZX
M A;KAF\?K9'.Z U/+DR__EKJ-DS"@(/^^*DAJ#ZF>_@)VP>:JB-U2MW]K<B3
MP^E6_^^^11,W/>,7%**DBBST.D>X ^,#Z\2N F!6S86\LT^E.PH)676X<!CW
M(W?$.2W>88+$ L0GW9X]_J#BJ%F#.#([=*C>R$/JK\',]Z##5*7A;H7>?%Q\
M%KIQVH]#(OLK\:!X0%PC,]^@\*WRD<_N*YN(\'@ME3?*Y=B8<.P81A5KN='O
MSQWQ-Z,_,7J[K;SS]YKL@ZYF6K].>.GF5LA_$^Y;/6MFEM\1G)+K.1O B58C
MFJPE.A+ P2(875>O:J[MTX,ARY:7>MU>/]=BU?"F:.8"JQI Z$7T4(=8G%.8
MR;$6HY/<TYJVU&7! D(2=\:<BA&G0O&^RBQ*$W']!]AR/!RF#'?&^NQ!? DB
MNG+=;#=I7[Y"C[6>.WC<M9.6)/?YSK9(E.G-8 R -TV&4J"VKT?G\62)*Z$*
M:%>9\C#H/=?"BR+81F@->8C W@QM?X(SGD^FL^%T]I10.$L!.7I3RF(]FPI<
M:9GIQ9%1#!6+!"FR2?S;&TRP4J61>OI]CP,3K:3WEJ/ELZ)T0XB0",3$P1+Q
M5(#W8+$'M]]1Y$#CAOA.9B[G$VP#!N5BO3S%$KYUBI6=S(P\L<%T:^M))NVC
MH0'2,G!AB"OS/)CPVS?51T<8-CO^GY'*ODHJ#R*(J!B%E.P?G)W(3/_59MD<
M%]-LC&S)4YG9Y=I*&APF7;7OWMNZTW0A;E<*)? ?-QVVU(2_3@!)9&G/4E6F
M0E\1\<"^?]N:X>9^S5Q'\[;NDP%V)=[C*SDV9;%N$7<S;6TX0*]$RM2_/6:P
M&$3?TECEP[Q6%Y)/C?Z:I,W+<6[6H%YTWV!FMLO+#.$ENH#L[X[*$W4;-&X8
M-;/I#Q]32X4U[C;90E49DQRWF>ML9:_$8D?7[Z<+I$NA;[/KO[&C":,ZXBX+
M*CTD.S 96_QRS?/Y4)-6]4%)* 1CJ^NS:%<%Q1LWT:)8M2R:*0C+.S$B&".+
M;6&=5AOQ3E-V^5*)Z:[Y[-F<2_#-9XB5"ESX[N;D S<JW-*BUW[114,/PAMN
M!-]_^R&>)"U2[/Y<.ZOL4F6>F8EJ"G)Z%B_#,5HTE5'N]E/1ZM7<YVJSW.^]
MWDM)":9OB+ QK*9O9O)(O@P6]2MKR!=O%IHPG[IE;=DML0['KU&T,(&E!!:H
MA;&/:LCR:3[>S+O"T1QB][QY2O>V@]6^X_M30/1\$%0H65,,D1*<VHL'QG[,
MAX_QR<K+L0ZE:"&,=?D5I4GJK#\)??['..1HK6MZPU2,6L/:=LX$K>HT29UV
M7ZJEI2YG=QEH1>^C0<:#%>]10W2)(ETZ176!M/!Q' : P[SSN(5-<K#CM0%S
MW+O*KJ.U_ 0"Y@S3 DX/O^"*>I?QQ#%\:,CJ"F)BI)^UM&6 Y+PW]@-^F:IO
M2FJAD [5;JT=<Q%EX+.VY,K"Z/)I!1H6Z42P* CVYL3!NZQV4'!U"@^7!%>D
M"H"$L_=?#A8\@.$+<[Y]-98G)][K6.>?F;* GR06:^Z45?\!=Y4S<3-TV!=2
M?M<CUHEU:&FM4\'&JRYRX[MIP=CF9 )J$I[]:A(&YO.]-2:$L?OPX^>;$D)X
M80=D '%+%Y$]U@!=G]C<(E#<3<+OK(9]-_/G:B&R:1MM/!W\J1&YDY]? 5,?
MTI.'WVYXFQ2$INE/>2S/[WL_3I!D@5ZL.PF*VO&:B-/9N.[F<DVCT<,&LIK.
MDEN@VM78!Q'RN-;2;;X6?-9#G\KT8W?DH5I&-:#P^^_RG1/3-=JKLROC[\+S
M:"1%TLUN '0A7N]>H8OWQ?1>O9(PED4A$W>3[?4 $2.A62_$5S7V ;6&Q*<5
M?;<-!_+Y20%8DZ(/>ZU?*FM.NW?CCEM=8Y*Y!@D\)3#[Q?T^$>DQU+5"[2))
MMJ_)\660&V2.&PM:!-G!/$^,4M>L+$%9,S930C=?*M/3VAFX%=72"*.;R<EX
MU.QF+MADSZ&*WG=+G@.(JU&,J<P?BBR7Y/;$%X%@[4XM;7Y;EJWU"%"9H=HT
MGB>BY*BU?I<Z9SU?+>9+J>;=Z*,WA;6% ^_JV+?"M#@8J4TW;I%4]8M>%;U^
MF"@"C3.<9>C_1CK?Y#_1[M__F9N94N#VQPC<R"R<P EQS"VE]W,H-/3)_1/E
M Y/PEW'R>5T%SYGU+0KT^V1 EE<8+7C]PVUZ8-]C& HFYQ9U -&+#L#Z1VM?
MW*<M]88R=L*JY7F8'PP2IE#S^D*C 5WNCZ\RW8*1]R=@X$?91(V5<SU1^126
MVE/^$(CEGE-B.EG;K^Q:Y67FFT 'V7.>\!Q)9L573]2J@+^;ZYM.V8 8LF8&
MR4P[)#;*%8%8^-8$TS1O6DC+F'F0RG:JCXU*(.-[=\5=U.L/Z%8JX&B>QSIN
M",O6[!GRON4[(Y^&9*_MWS$J4,BI4<O6A2(;_7(H]*%NM_+RZA(;"(N!LZ!$
MI/%-YKZW]][?,=:39\=E>)FISZ7&_ 7XH L4KLKB1TZL8ACW*)W(C"0%J"/.
MKI%\#1A/7$/WC8;6"!1"N +RWYCV&)"8JA!>?W!X2]Z,5K%0C$&K/E1O5AS%
MOD<=_?:C-+I.*L8J"84)<PM2D %%5TRB/]H2#]NS;TGM3W6SGAI/U2*UCQ:2
M&RMTC]B4DZA203-]K:$26E9"Y#D\6SE-;!O#I4E0$)6U8X52-%E?J!Z?T(-^
MS%30RZ0((NFK-_<F"3$XU$!4^LK*G&^4 2SRKQ.PO(NX3#S%S QB9?P?3OTG
MEXC:U?C$T=S '&(U@+_.&/H^%F6;=+4RT>;[7)['%!O==5.P:E'R58,;X[M)
MF\7!/L<\DP4@F2EKS90[MKE:41SN'!H11"-%!"K0IY7^D,)8M.>G@,<'V-YH
MT3MLP1UF4<A5I_Y-N?>2IA0P@53#'/(2,DEX%6(TV&-5R.R8X(-RL3[8!\^O
MP)!RA$*/)4F!1:CVKD$L9EC!5.@PVY.?$2MK,XEW^MFY5_%[)S^W?[8-)6UP
M8QAFD7OP??5>V6>!&:N:KK O* Q;H>[J7.#&J]&5D[$&Q"C,CJYR]"18_.VZ
M:ETQ7+VP2>*9PN9&0VFXH3G^<*(UGZ%X;E8M]>-RRE@T<!96PSQS05M'+>>P
M/4#ZA5!7()A.58?=XJZY1IH%UH/D-^ULMY:C#",3P)-Q3)JAG.^?R!)F%:ZE
MTJ[>,:SB<#$G4#'_I,_"PWW_!2R!G7@2 %1#HY)H4:0>P?&7BXMF=5\^^%C1
MG4=4/][/.-1N&JI<5V;2$ZKZ9*C(Y1;RADJ!@C67L@,#[BW,J^-L3S^4@O>W
MBC76-FOZF87O,S\&J!/=359IP(@=4(XJ:<0S^U@M*L9#KTK]T8N0(V.F+"<'
M3BN^YIU<;D[$0Y6FGN0;;W:'N:N)8X T$Q1G>J>6QD!='27)PA04+J,K1[4[
M]R7J%9'ATQW-4T#^H-/+>], IK<KWJ3"-27X8@7;?2H&1<]1,#G"PKKB$NMJ
MG5M&(J*KU^I&"'=+%!]*3_ETQ]@J/'GSD,X 7?^#89$A[P/(E>JGH9/*'(7S
M:FUS.1DOYCH6^:G[?3G%A+=XG5,I&C\\[FUX'9/);EJF$MH%D>Y(F>H[!>B>
MS(V*J05JPP(2E;X(+/97EDD,\>GI98'8:K35CJ2)5YY=UY(64]=P :T!\9F6
MY#@0_C3$@&\JXOC*/G"D@:^%/"%#9_M+KPXK?86X2<O&6?(5NY#G@-EI+( U
M]BCLC<0>80RKD(EKT>?,AP1Z%A&4G];K7WO2%S9@=%P#:6@5<W:98^"H.^5A
MH)/2%_@7SBTH=KE$:[9)3LRFYT&S^U !W%1XXT=05,([2]YVNNQDN=7A93)D
MIORY.6!D7_C0@E1N2'"W4V.(#P*0!UBXZXP#6*QMQ*U9>9]NK)^X^57;>OH*
MMSBGPU#1$30(<S_#K-\47$F@^ZD[OTD-GHI1;/-2$:X?0Q;_TJ5!PV6"W4#7
MOV<J=O&MV&=VAI'&A:1N#2-O+?78 PK[E20E$QT&& R2'XV10B6FA&HCMK,T
MX,NH$($IY:5W==C^F1GLP<!C'%B^*12%0&@("@0EO@O.PP;* 4$ -<#9=04/
M#T\L''R/_28K=DOPHWJ7AXZ0#0#*MC_*UI2AH261F^#GQ(DZZ0'PN!NW7W)#
M':S'4&&N8 PC&:E>6\XI7>&F7"!7(<_(.'FW0JF!L4/3K.^&1+!,+^O+EW%3
MRE?XU);Z)YSW5B"%N[0N\LUUJA[EE)\Y#!R+4^'FY-VURE,\5:9/"^/;Q4RJ
M[U'D\W75%FFJ80)3(@MTO[?7 \.WU1D_K.UOR0^7Y[,!."B9NE4;S1<R3/4H
M&7"9KP9-WT6\^U3\P>A@PAS+?%5EI[$X]5:3[Y!)$ )4*-J.V1\FXWXVC^#E
M@\77XO;3F',J&[V_>KLPTA?,#T\X)\RA)@I(;I_(5#:2#4GU5277&#RKKIX0
MDE2A6=G=G=J9C*,K08Q8UP<;<I!Y569&KSO$&W?M3>ZET1A,MKW< Z Q8_IN
M;6=0/QRPE' DCL]GD-3.8.F3QS$0\</ NHXGOF#N5&:EB"NOPW?7TM 8K0_+
M<64*XBZM,_5P,FMZE< 7/K,JW5<1Q#/]\+9:R\T2 YZ\(3)Z6;U2T$(+_S,O
M=)PKC^WC5\FG0EI(TZ+D)=(QDXCMM$%-;R""J,)5B/:\-Y8*J<2SV<H%!A;.
MC8V/,#E*<V@6YC>7VSMW9WGN$<#9,[X-W'(OA8]NF)ASP_B]X<I#.M6PO)&5
M8:$13EN@57&9(3(GE:C]=13'B:O!4!]?CQFK18@P40[X^4MRY<*- Y"D?*-P
M*/<:\=>'+J,I^<!"24)ND3JRC@55..YT8IY!D>Z3[_=M'+$UGG W#X)(<RO"
MF'5N?V"+HAF:A!#+X7Y?^JSSB ,MW&!>.ER@O$OZA:G:)CE2F8"WOW8=C^=+
M<MT[;K^>5I[\8NVI:).J#3N6(8<Q9O:7[JXAF$\_Y.<4E\D%5XL;0=5T7C:M
MUN(.=P^HTT2< I[-%E* C!T\Z8*:1)0Q3VJ9N^(4ZE?6=?R+])*(]:'.UXVD
MQM= #TEL)+O#-%%!0V5%#, .I*'XKR6-"^ZZN$V<0,:,2DRV)$<3%! HE8F0
M8-SF'GM7@:/7A8L6\^+MTXUU@5(O;?4!LH[PE[$)I=M<H"^Q6;JZ7H\*E\2Z
MI"L%L(]VE?U&XD7R<E'EKG6_H*0GNUZHQJ)$N-J!Y2JD'$3V -ZE23J<<^>N
M;MX+N**" Q62@RX[:O6PC29-7<W,-3IZ[ONT_</W26F$V=7U>;G98 A-X!N'
MW7"-X.T]V?NY 3%!!Y_2#]Z'9:SRNL*Y\R8E:P]K[/O&N QL/Q5%D"N"/BB&
MCY@MYNJQC2X_0^%*V9"8+C" 6 AC6C,W?^ $!XLD<,L1L[O7INO/)G /34DJ
MI[^9FOE4,'N %A]^+#!0RR64DI>D1>J0KCE]"B"UKB$3>AP[UYFO%F7H#-1/
MP&[/C:4(]#P^*#=*&*(8SJU<B/O634G;U8^]$;/(5.M7K?QVL\33]J0*WF06
MV7=P:]*O+A4AJU\,IR5\:[UB5BZR"N=+=36/W#[BB!]2U#=/I+KUNG$A&0M[
MJ+6'VLZI:<?\GIIO3'W2D.>T>>Q<R2T1=ZHB-7C[M,1([4R5Q$J4 %ZE(_<#
M-;&[W)QJMI(D@5?!6#@X*.B?LM8D;HE3%A6OH-3$+=*> C:.GC=RUJ>/M+38
MS4K+6PSPX+T<&>^.IV)IHA-N-PYS#N]?5$RF*E\U!\ZQK=>M&(0(K#MC.@!Z
MO+EPY,%)?B]3#FVEZ?>>/RU(4HY;U!QOLGQ,/L(Z'H1:YCPXWZ 8)B',N&2;
M:6!&VS O"%)@.S3<BV.6Y)<I* W#!3ZT>A1-2=*NR4WVE\LELNH$B D@4G7V
MVBE =J:4>%[D*NOWT$QTO9T[HL"ZFD&/_?)7_)DUG&/M$J/-N6*3\4NLM"X%
MU_(-KF:IYD]RJD.3IF79-;J7 J:]BV61@<MRS&A0 ==E7_RRC\\[>B<ZZ9:'
M["474E>K DCG6DM%U.!NE*R>2)^H4K,D[D-H?/V>QCT$MX\D<4]<>T_($;)/
M VG&):#P %IKTSA4"6P*S!&L0*LML5]PM#H(/;R-XI@D9EJ;VI^\Y P\SNCX
MRK;7UZ;77IG'"J,P[ 05JMD?8P+J%[B$RR/6A#8_W7[XPI1:I6I8FG4EA\OE
M<8VC49D']7;Q_<BV4+VJ],BWK^?A9/$&5H_(,S[$?C$3%\(>\ZD/+[4O?O=R
M:-[-!#M0/NP]\^-F)31?2^_]6NIYSZ&2!^-;%=KYQ'RS:]+EW_I+MT<;_,'8
M)'[8CT-2\]TM:Q* #ZN?,=;AC!:.$;Q"=0=%"* [M(C,P%P=^H>,/N/%3YML
M<"R1YDE-:H.$=XJ^J]_/6KQ?PNVK1#NGLBO/0XL6RL_G59%N/L==<V*Q4<@A
MO&MO_=0+V%1!Z"Y1OQSN92N!@O8Q]AWOV-DU1^6JV:OIB=U)P[K]*H1Q8>2T
MR%&"A&8CV.>8D?=5:,%@1CPJI#J(/PDW]03E@XI@186B/>AUDGPS7QAUY1@*
MYD$](W=T!E=WK0S)9!-1DT,&$Z'\UWN4P2]LZBSHV,<ZA9X_<$N>%Y"'SIT"
M<(*LLK?>K\&/_8^[7=XQF5<W4777Z)FY6GI;+)WU.5D[G(:'"Y/XZM -(5H<
MGA96(+4:/:W7EVN-.;4<?3=@$MPV:18\"R;8!,-)MZ+"I\<FOK)9.?75RK[Y
MHMEN.$G&%6X0@C)?H+[A(EQR;S#9GLV?A\U@VIUE%.--;2(MG>V46=D8KSIY
MB7'"D'9A:6>$K1[D7>XP8TI/0ZY?%@N+/9Q(5[]7+F/U!0KZXO?YTGP<S"<I
M5 <FF\_*'=,\'XBP,NL<R:<E?9+!/ 40%&WT'"DMK(8;V(M7\RUZEQ6%E:]6
M( [E FE&PR$5SM&T>M$(-F1]8TL^;']U4[C I[,0S[;[F<?H9V50E%H"R(*=
M0NPYV(*,:G(QZ//3N<ZZHB)(^[R49@&.N)&XT=17!Y/5QPHZ_GR![S11#P*7
MH>0 MV=]=Z1DVPQ=IM@W;LB<9;._<RYM;,318O6K[8 ;QZ#CHWKX\R>S3<YH
M<@TH6@^(]74CZ)P\T4J[@!;0UW/9L'JT"&[FVR[Z#@JQ=^8.#AUWA5:%UQTG
M(>7$F+>#G&V5U"*DY4.^;Y$H[W+)I$Z:?4P?Q ZDN:%D1Q](4&6*]$#WPSGI
M4SD%-)T";/:56J 4(O=P4)Y#)JD1\E/'4\W['YM<+&JHS+A+" -'?)H:")J(
M!1* +@GT3>1)*C">_DSN.DH-]=AQE[9N"0:MNKGMK)[J3=KNVK4ETJE!9ER+
MGG;&JKH-LSJEKD%P-[[1DO'P]V1/;N&#!B'2F^::W<!4-/H/6:-L ?N;HR/N
M>LI<VO)O@K.(W@ X!F8?7_N> D(!W(Z<:>L/+_?>:J+EGS)/-2JT,&]QWTC?
M<<9U// 3Z2P;L2G.'?8PI$L5:,'%ASH)[3S[)A3"?:-Q&]6@W$)^*-1O[WM.
MG-\-$,Q!9 "4,P$#Z<-:#,NU\WMSAV\6A[_2Y]1IVN\#WDG@U!\)]U]84E.3
M*0$1F[T$!>=>]2SVX[I1^]TN)28JV$.P3PT/4&OF#/AD9ACLHF\QF%/>QF**
M;O\P.BE=]LDD4B.E.PM!!ELU2R]GE!GK:5H;J'W6TSPQI&NO__$9]5 (*NRF
M?I\T;5&W5?1"H 9,B!A7K=^M9[]_>39*FL*\S-:/RL+HW1LB2CB!^/VY#EW]
MJYI>A?;MX(*E&T+!U8D&&3UR:%\EN(K68+ 1$5JEB*Q[3FNZHMU(I8T-=6[Y
M#*[I8%6V;K_\(O;[9L!<UF=?BF'( FL43JE<1@/WVD64UW&MTE=B6F/?>53<
M]:ASX_5"2A>G.QI"-\Q&BD->QRMY)+DI:7H;[0@QX>)]L6X0B!,G6=5;!3G7
MY@ +GDXL@.DY5RJFDF8T2/*5=@;'EBB3>WJ ]:5B/5YN>"[5\<S,[)EABIF9
MT^3)\L! O5. >COX!.%5')2DM3QX?V26.D*K9.8+;*IQ/Y.SPBT?)5-"N<*R
MY-V8:I++:U<I4ZTI,FCU"M'[3(Z$VH6E0WAC8,V-PEC!=]]T;MN]BHUN$02Q
M#]/&3QT:-A&&X89031>DV CA!HT 77.:>RQM%85Q</6W3SAJ6!6CI/P,&Q=Z
M7AC#I.-IUV9)OVH@J^/IK-"88PWB'Z%$+GE=PY#[1B=I7_RE1KSF1G /[-4C
M&@XQ=2<K;S2QGJII\+>M1:6;HS.<#$!FMC#C:(5M9UQM*3^LM0'RD'KJ=!N8
MNPB+V4D3AU$USHX>)O6>J=JC,.(T=7V724Y<+ETUKEM70<%LL3T@W  %FV<'
M9J-#6[5C\-W)8XFVYT6B%E/NMPV8Y%S:N>M7/0<U]Q^6/5G(JO_&'\,I[BKF
M72.2$"O/3'7DN4&EX)5/?,V(_"HP.OI))J<N .SU08?N5EN_7[6AZ]0=#M\@
M+L^*Y*0]/.]R7^ZO^X>U;65%]0/J^7J3MGC=I9U%;9".I>+F8ZV%;5;U95K=
M 4H:YU?^3[:2M'Q\?,PH6^/=#@GUI+TX0@9[_=I"JZOMIQ(W3-WGS9O&=+1>
MZ489U%-6YTZ/>!L9.#1_"M.XTA_EQ(/O[=7S;A>.]VVPTG+W0^'W8]_#"=F:
M6HA:KL%X\-<(_G$!/6(%?W9;=>C-H$B,JPDBH5X4Q&JX<KI=_4@=R$X8>9%]
MC6J-$ZY;XJ[649%A435RC_C]NE$Q'VW+O$'.4&9SK@H)Z9K6\ =R9OWY8:8Z
ME<(F0[B@^@VA&D:5EF.WC[F?6Q6D5=-Z8V+Z_"A I LV;4JA))Q 1F8>-12&
M@\'A>Y:OGWS%-2^7 $I&!P<*$+H;)C_:[EW[NC*F-.#.I3W-V=']/GZFS.6#
MY4[*$V%:E]S.4.E)W0;VM49K?18-X*)RL=;9:A6B$7U(.B2,0Y1F\I(09S:Q
MY9A"=E\45BRROP/;T+"K/?*XH;;2R"S9;$B]7:%S-\RX9DRIF%&3M!,%T5O:
M8'G$HZ3.IZ$I],8U?*A]&-#_P;%B^?%1)"?V5FM>TDWF[5W:^4@+0@$YP+&Z
MM#_=/6/X(6>#S1BP$-DTAEA+C2&?;?;8G1HJ4H1S>L:G&HY8?'K<T--H8J[S
MM/>#*) ]9$5+%\(EO]MZHX: E!\J/MDA>%*]."H2U;8A$F>1#X>\LA/7R=E8
M/TI\-%-5][F<\@"O-N@91T6-D:MB#4;9)X>*'GW!=V\XOQKRO=.G1T4:*/E)
M?O<V1:;ON4#:21XQ'ZSS9[Q78Y(^\MC)X='<8ZBKVO2;+Q\6!;9-1[RHG J%
M=4Z!QPWMB:P&AE^R41VNZHUTZ+N;DA@3U?1YVTK&Q-X?C)9_TYI[4.SM(;SI
M510T.&R^'5IM4"_I/Z-5'.\P<V?JZ9I.9[IE@!UG#F7=W%B> M"FJUCUD0*M
MN3I*_29?"&IM8H[VRY9F2],-GHZQ1;.Q$:/J=DN/M+55$$<\SHA'D9$['5C"
M[^9B:1,1KJ:$$X5=]7HRSWQM=&Q5S'CT5)5C6T;Z!ZO T+$6&>&M4=@S9UWS
M$.V5Q #MQM*>8&^,95&%QYM3YA0)9@32S3MD0#_K[1K8\&L8PS+K#*GMNQ"Q
M56\%F_M&:PG?N]Y\H??V.05@?3T(TQH\61^I&[OMD>GI.&P+ZQDY!NMN<I:A
MA#ZZOR*,$].5CB^EOKRB =MOPQ4# MC$1Y2./_WX?O&F<_72;.K+!TR4;5\V
M,G<.A:-Q6%T%,'8_R304T8\3,7::2'5."$W56#VKKV49L6_&DFB7AKV.KMZ/
MT(6P)P#C9YV]VS/>$)*A8B\^\M=N-I</?N><Q\UC51\HC]IQ^& W*.4H\PJ,
MPNGXB2*)P99 @E$2WPO'%;$ O<1>\=RI2!L62MCFXTV.5!+D1)W?BU=3"7XZ
MAGTWZQ=K^NZ78X.8RA\M<G,[]'K9![[BZ'DJK:H&N'T]00/\?5K24?84L&1(
MO<=)>U/< LQM3Z7=6C]YG<[(8R+;Z.',(4%Z<%GEOA\ [:X*&O'03I'H*V:Q
M8=\P@1760UY-1]4BC8PB+>M/)5.UC_ \\-^:'OF-:,=Y&-PL:*&BF&2_XUR@
MJ!&Z8#3II[ Z"$HHF(VXPSI:U*15'Z#U*(C@MN12#A5V';%=Q(N1.^NL3/-2
MM#0:YH$>-Q:*W]TQ*/[ZZGMQP/Q&5WWU.-H\-[V$@;EG/L%8'3I>1P-5QOI#
ME;;I<!A<$]A[. /\E.P\)3C'B/0"&7\>'N94[/9V9A31[\3N![Q=+EZGFNJO
M",,LIQ<*K^"A;]DD>@Z@QPQHN@U J2/*W.V5_1H34!+:OE[GWY<:-B5)0@OT
MS^VH3/6 V1I **3+9EUFH<[>$DLDO*%:YHX-@UGKW//W]#_%FVF_AY&0IJ!3
MZ4=2[K'!']Z-?U5A,&5FSD<@(PD$+@"RU^;!++=1#F&9(<46G6+"Y1!.391*
MSP-HY6/1-^ZE@%/ N$5%[QW/+V?W'%<B/YL+&1:^#=L_H8!:W]*-PFE;N*<[
M,X0Z*[ZG:"T[Y(:2/ECE.U$K.74//@WLDXEPM/0U1<CEMRK4<.YYDW9\F.9T
M(RD>\>K+UAHF0<FMAL9DOI$:7LQCD<>0=O&BVGS=6&+5"Y\C[99A$Y'2[KWF
MPHS] +#,M72'_PMKU_@4_B.^HOM3DO(UT$6/!Z&R'Y*&;3CTJH<<BX2$&IYN
M+(OU^5-%[B+51=VX2_8-R=?*!K:X7^9)';NR%_G$DY@IE[&&D*>-FZ&%YPHS
M+%/I2P792G@'AS36<"T;3I#1T5!9"A,>RS-CR7$3.-E2\Z"IT>.''ZQ?^<*:
MWU%H+A^?K)Q=O7(]<<S T5RWZ2/QW.W$^^)36<2?+:$H".&[*8Z#;W5+6;/:
MY<TSGY$_'S9WQTT-6!E8K09B?AJZGFK@66D!/>"ETI\KQ&\@F[W.CO)T<G)D
M]3X%5?5XW\*"Y;QC6_*8]R9]5[-VR9*U#"?,08S\'??+H>QJ_E1@"Y460>ZZ
M$4\MS7#IZ'O1(JM/@]-TY#7E](!%06!W?L\3<P,JI9<A:GD#*]%@4O8BW+LW
M6*^YJ(.>&N"^\\I$SGT;6WD:/P-,D+"5LY%;C#,37*S8;T6K+JXC"JNPS(TS
MRP/&)4P?4-_B>+CF1]YEE M(HRE3EFX59[#!-J%SQC5<7JDP^[;!_# :\68]
MU;2IKW9XQ96^M[DP)D_)W>4#WV[^NS4=(2^)D,#2)4XL93!^%YT#QQY@ \]U
M<R/_N<C.79@YYNJ4;&?^HEJJ9I1+>R;N5H"BK:<87.TVWSJS;HJY0&RY&C&M
MVKH:\[.N7N>M5L/P22'6T9F4]^N;G;JCAL=&A>.DQZWY@NK9'743!?K0D15C
MDGZ9_*4N ; XHQ6,I[ @2%U#CL8^KG-GI?.K%&["]2;M8?HLGL.Z<-U0TE(=
ML,N'F#;+!/^$-'":_QT;*L]9].KEN\VJA-_8'7TF=@?J/?.^U1S+F]2^%"4[
M5%;X^,1B?T1@2W62=+R#T3*OS^]CYOVAI]VOE#5@=<_!6> (XJ'T_I2]75J9
MK?R7!B))8)%M[H3K;AR&8V,F96/%"=XZ'9%VAB552;HIBU<G7NGFL&AGUP^D
MH&##I"N!D6'T#M+W.$:+MLA'#*S5@QB_YO@(YK3B6#5\4@S@K<TMLV_K E%Q
M,9C2: NI8S'B+DLV7=>R[2V""8L6I=*6/<EPN/K>_SA;)<%;-7N8C=,BQ5>4
M<X;35>,>:;RH>%>'XMTB4U-3=&)F(N8#RNT=*6.E3^8M-08^%KB:CH,/'N^.
M7[W]M*"@>K'M\8 Y)/\6LK!H@H !T+P0!HK_J'/G$XHXZIU8N=XH@[X]])/Q
M+<,FQZ%L>#O=:/UZ:C_&$=0HFM&0H;.>8SA\B2!_-;Z(N;U(WB/3Q4 ^@IZT
MCH4_7[A#TXA&.5 0:^C-IM0\,[5.>M50Q%<D1\OD*@%Q:".1J+FKZ&AW4SD5
M=ZJKR?XZM?5L@6FUV1V\#+]GH)(F\=KK?CU!;6\4$DWV9D"FYI6CDR P.R<;
MCFAKIJP.+^1&0@NUT=4MZDE_W)2]N!Y'=:)DERK**ZAJW_S P?Y\][C&?5=D
M(QN/)1-\6_UV=>\N/%MXT71 V%#KISB^/T/A6A+' YRAFZ]>,0:G^#GD/L@I
MMD_@N")4S;<ZSS6?HW9%F'IA&%4!Y(\+&4YNC>],5%PGC9V@VG_G]'[*W-Q=
M<QIHJ?<0?C5X2<5B].%0;@B9>GS^.R!3OF([O(ZLM;L3!H4^O1KOKXXZB 7B
M?:NSX7O@LSS)/3G55( HEHP?(11^HY:N<P0/,'---G[2O.Z)[I,K_BP=.IH6
M> K(/P0EN+C8*Y#%Q^(PTSR0YDGFSIOL3ZE]M@9Z.OIAU.' L$[3EG-U1+J]
MWD%W5<"/+UE@29]E../!3F5"4E)?#0NG'@X:FE)M^KA?MH;0EO88U[.63])-
MCX!.WM)'=ITSBX="AGR2BYH3TJM%L"7@LWM3[Q,>FI>\30 FVFCECQ518!!K
M8=8 DVF77&#PMM@J8ALO'^HYB0E<*G:_;W:/,ZLK"*?>>4C"#J0]9UK]IN(;
MN04=5XX,[<T,=I5#42/@[<4O2M0]-").S)Y(KPAU84._ ?6?36JLX,J2/LFY
M(J._M[AVT/PHH4728I&0Q;@=P,R6W%O[XMN5&R1OVCH()8^%C%D(*\J>C'-W
MOO]&7> &WW#2=S!R'*9*2 :VEAB$\Y<K%X' ^O!KZOD&-@*O\[/X>9BR.=BC
MIQ-NW.G6X]F654M@/71>ENV*^PJR?=DDHNBTX>#^Q.FF<XQ*'H]-# 9HSJ=*
MB!/90')KS^ZMW[>HJ)OZ[4\7PPD8Y*M=8!RH.K<4OQHZ51T\=.3DLWUQ=S_[
M/JM2#.5V<C?4*C3%'$$^C<Y!B#E<CJN.B]>&)5&LMG"E<7D7GB[A'5)5X#"_
MR5U$5:1?ZQ31U%R'K;]2-K8I7?&T>.3;:!G%L+R&\QK'$T,PB'EZ0-'M0S%3
M+&KL=L[CS:.5"D,_G]U455FI?%?]$]8MF(')%TKE%24<6TDU:'L_%,A=^\KE
M6S19;-[]@83KJ0W7]7.XV3S@Z5DSW/5-Z[CWE_B5'KH.0.2.;I[54Y))GG1P
M*]T3[52RT5D' _$;-0Q/0Z+,AW9)<6E ZB0X5:G&0Y'#+9 QHOH]L[Y%AQ>0
MHH24R'D+D@5#3JT.#ZZ= KT\@XS[J[8BWZ('W&N><.&B<:BCURT/(KX?#S?=
M_ I#D/1_S4)/0]7L>+$I1[FUJ2T$4B5:?:*R8BZ)U40=!FPN3^V?* 8QF9$X
M3<Y4Z?$7##D:=).!#>>:7SUDT84H%VXS?!2KK^8:=$[\'&W\G,KS^XW108+"
M*;Q6M_+1 ]P9OXV7);J:7GQ3(5H%>O9&->R#'*3C R:ZA&I6>5)V?29X\943
M"]+\L4%I.M<7XX^"BJ,YW_>5FQED=J;>B8W%M!7 =':)-8R2M233W3R9C,P\
MD/6.:Q15V31ZWI=DWP3OJUI)&K&-4/.IH@-S1*\]JM+.I*V];LM%PA3OLK":
M^='U*0Z'XT=D!-:=[U7-$4_+M1Y-F9O19I_5SX"J?P'%]0W'B,/7+PIH>$I;
M9+(9OB%0*]7Q7"R;\!W4EC_=P_V00OMJ@HNIT+S"==.,X!O16/E):@5/!ILP
M2N+'XRC<KT7ZQ=UE3_!PS0=2\HI02OT7Y#%,T1T.9CWU9>V[=F*^?WX3&<&;
MI0'/\]/E-:V[LUU/_49E.GQ82![&;4F**QWU;#?_!K"X@80UK6GHMI/&H%,(
MQAV;F.G\,DRIT(9H%/JULF6QFETB1^6^^!<KRX[4$[2I4\<%MKF-KT1HFXAG
MM=2'G3W,%B3IZU<[=)K"U,2E'G Q%]EIIQV/Z/Q\CA^IX0#\P/[593VJV?/Z
MJ$KB&XNW&;=TBMOY&P_J>RG4Z.I:S9$F/A':I*(Y'0D<C]\"8Q\\"^IGP3B8
M43>C!M-06+(K1&&^C)?\VC8FK_A1WYO1C%IJ [K"#'!;\EW:PRFFUO8, ^!7
ME.=XKZ1T:#:6=9%=BP]+<$":Q0\JV>OT0HL$T,)ZO/CRL&B \3)!Z$OT<P0J
M\R7D<5K!0_:L9A/VL!KQ]N7/L)$- J3LP0?P&GE EZ.$N4+SVUODCL2]6)M
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M)=#46"!TL;$9MST6EYGD$T*GIM8@H2A,4>*,)Q,?".H+UV![6T.0$4*A>O,
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MPY_3J0\P&@ @/B0 &1*-M-UP,)^'Y#,N%1#>L5!".OSNQ+YTRYE:UI<+7]4
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M(' AA/]=OO!*&BBDLZA605?*%979[C<JWDGGE@I^"VLM[T1QJ^Y"T%Y:$ZQ
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M^S^'LQS;B(KGJZKR3MM*PF#]J\4I!4P#/9:0! BS$;A/U72&4'XQ"#.GV*!
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M:@U3JU$M-G?^-FS/S0VF4^Q'V;O:'0V2E.OUO5^+3_& P0X]IHC&HQ2/ZH_
M1$H?.#G:BCZQHHH8'>JZ[Q)3C9"!Z"/36YA(9YB__:I;#7ZV!G3N^_H"C/:P
M@85?T3V$%'5,L8PY T8[VT0G':SXR[H?1RY!F:=1G7GJ6Y)03GC"GF16H*_W
M_LNG&6I(!S>7R\Q/JV]1[*U&VG9[/2MN=85-[A22$9!U]KGLFL/D9Z[;YAU#
MQACL)M=/L_7VI!36A]S,IPHQ' 8<M%]P_1@EB:3=?05^1ZFTPAR^*K3Q,=Y.
MPU/*<"Q,S;&4)9KM^K396;NG/+FRPBA_O.MO_4& Z4QZ8][PZ\MV!X$ T:2O
MHN3/2&0<A2G?Z77<Q.@29KD<1]R@H*WA0  #)I/@F:9&;)<^2].IHVM58U*E
M0>+(LDKVWGI0F/=:*@MX>>X>?[IN6ZM^32/ALYF+<*9?D]""==HT0KLG<5LT
MJC047HQIU_L#YO!9U)?:U],9Y$ D_/,[A+\]BZ!YB7TVN,W Q.+,GB^3-@GK
M*J^[O$8E_AE_ 7TKT;-/<_#XQI+A+3"*:\F^WOR/VA5^?#LU?!"\RA6HA\B<
M3W'I8&%O4?_/]&N5QI/Z/D7K&\*5BJPZD-)_#R:?I)J6+F38<+\7/5I65.;9
MFB=3_[I_UMAD8=1BTGR326=OX2JFV^;F"2]O05M7KIMV70?KL-H97-/5R06\
MOKZW0\"F)Q&3F::^;KF,46H0>WE\>B^X;Q_!"4"XS:>3]-(($9G70 "%PAA(
M%#[1S>YVIH1Z .XH?P$)DG9%';6DUAIV9LQ.QZ#)XDU[Z_CN.*LQ]17Z.FQD
MLE58IZYS/\UI6S1CA-)[&)EZ>6X$)QFK-(!_D=2S;F_4QI-.SX5<F@-;OOJ
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MG/D5K,6N4@=;QSZ-B*"L-P\C=FO<L2ICH\=DG\-C2&#X+#K@#EJQ6OO<Z3[
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M'@[YDDJ0LW1T.F7@"+B]MFEPQ>)ZH17&&[]FG6L]%\1$I-#4ZV!,P?]K+>E
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M>\A[4QT;7R1WCP2.W_Y)3N;TFMR%8$SR<3K?EV>C^R7>J>!'VD*(Y/&YR2M
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MI+$+(WJ/\B(.F_YNCPQ)@:009^ [=8%:AJ,J04C5_ D\DOICY,\-!,M:*<Y
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M*E?2W2A@DFO<*WH%G!*)(YG,"?2LKI[=O0*>E%\!6X51@T\N$4.ZI>%"4_)
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MWSOC$ 9U_'<W@E HPC_7/==1ZY.\="?.I%JM_E&YM#E39ZYUF96,U3*-^"N
MBM0BY_E;]M]63?+]KBY5GD4:BM+6+U9<5+O-FS.4 6'*4Z7#$;#R!>!3 Z96
M1)"Y%(5/OZU!]T--:FSE5Z)^/8AK +-1%""'>:BZ?GP"BA4L1!5:Q T^CX<;
M/?Y?A+QE4!Q,V"TXN!/<W6T(P=UM!A]\L! @P5V")4AP&]S=/01W]P2W,+@[
MP1WVO7=WJW;_?/=G5TMU/]5]3I^NIT_PG-JJTZS/AU]G P+VVG;N,7^SYUCV
M3OW$]N*.&]7B$=O5ZDZ]>?9U#Q-,\,VB3-,Y=-+>";#PAS'PWA6<3Y/*-4'7
ML^U.5\MERY;TFI9 )4/&7^PK>9LJ=AOE55R91.'\D4$'21B$\XSS-Y]'X\$A
M#/)A.V)TH\Z/-81,9QT-J,8<X#E8B"L8ZF(9[87 +IM4LS8*8NU!DS>F7.GL
M/J)^8MENH:ATLNHW6*G<K\FN[P!RM//9I6P)IIW&:0I(5*OQSNH@%Z>=FQ!)
M=)?"!;Z.PFZ4=0S#CR^UF&39'E\:M]=1A-6]ZJ)+4^,7^7_/WK+Z*#"6K&:E
M-@E5F;0<HI5SIYS#.8PCJ17E*2Z%@LMP4CJ[YHO'M-\+<= ,0F^JU^JYTX'%
M94F8%OA%:',I1603KYWP!(7[ 77%/6Q+WDF5PX1'=:<K/(U](E:ILN_>HARI
M_X^2LALO>M7[U#=>GG)<(SP[MA,MG)#PPPJ9'D!XN6DX^;VK\PWP(;"]FK+0
M$TJ7@#T>GLXR.VPPB^T =GK_F95PR_-:M#*\-+ELP%&@;M.:!],I>WF</MU^
M/.++\A\=J%'PM@)B0MC<\EQQ6W)'&DW; SN8X^P'&]>N9?;7LF@Q3@K'(J_?
MV7MU8>YIK /R@:>N3M8OA*^<]QFQA-<-GFMSU3(] K\'3[E\^P%(7NY">)2;
M>$8=V'CHX6 WVQ.=E.+A)C;WR$QSA;80FACU4DFX9:[AC['/M$P\1T1%HB1'
M<OE@$"O3\:QZ"DVV?HKYH225 R019R1 Z8=*:.B>(V]S*F&SY^M,S[=@RF;!
M]C+=<B5\ ^UE@U]W"_TM%!HNY88;L UX2JJ\(TP>F*%0KYRN;AO)/C=L?6A3
MUD?:IQB/P\4O%RH2=\@A*C?>]Y 4L-Q>9)?R@CH'Y*?N.B:-E.9??]F)8(RI
MM0OG3)8HC"T,)UO^NF(P&"KIHD1J_"E;ZQ2;6.WCA>:<G:NW"Y,+014F$;Y@
MTK'.D7W80=VZ+5?Y!P,?8[PG:RLUF20\9'?DA#!*D(,Z'1Y$&V[R_:*RJ^7!
MJ)%B+WW%<1,@/QDQV$-)0[D0T)'T8>F1Z&B3.F:@'2.&<NE6M%&_FU K]EW!
MT8_.JLIWS/#YC#NUWG1.T0I^0P<%1TMA@FD2>6]8IV+"1AR':-*V&_E.+%"2
M1I^)_:=P'')@56N#7,:2L\?>GP"W^*0O?OEN18])7EW:*T.]#E+XN%S^.<OQ
M3GA,U$O(!OM8X[J-F_H%-=2.J<J5<BC%C23%N.(+P?E8-L,KMCI?-&DVOA8/
M!(&)BOSR[H8X<53P0=' -%ZY9B\W9/G&83K13&54I5J4V(&-.L5.S)M_@P'1
M$O9 :%(=]CN+Y=MSWD(LM.C EDV@RUJ\54B3_1AQ/JX\!Q W2@72KLP?:6EM
M1B#%MFU:%X)?U'$,<F;&<&>-U.')(]*IGNTWMVEH@-@9^:)J!WU$1P0  MV0
MX0STJI^GE@T69U[49Y8I97.(:&?:;;8Y/U7,O./RUZ36.@]XC"$I;<."KI[C
MX9^:H":,N(^7S&2A-@SZW^5$$='I,)#%^)<=U_##S<AQ2NCCHG9,'; ;X'9:
M%I'\8V2>:&<SUKC,/:@\7Z--IMX_4;*P].SC4\8-:[EX8)LR4;3H;W(Z+58!
M^O5QB?\UY.^_ 8A[SR+5Q6I22?D3OK"B)LU]V1N)(:'RJN#&(,RU:1#@MHBA
MYQKR42I9QCIOZK=V #OOLLEJ+B<%9$V#HU1#<;:FJ)3M1_"6/L#PT.CX\3IN
M7,C&W@#,R17/8P8^WQEQ%R4+0S@0B\'5)4-MOVW*=6^H%OJ]<K901@W=F3=\
M@0 T&%A:DYY1?"P";8]Y !%5!O!R/Q.[FHL>*^$A>&G,O9K]N$J!NF%&=.\;
MY287AKI;.6C+Y5.4 HVA3E<7C$MNQ7X'HA='8(?\0J=N1)4S\D_!B )U&7L'
M6E_Q5<5GV,3I4*80'DFT>7&&H+&!JO4H1UD#P7-S1=O!5H[-"<=VSHR9"G39
M!G$GN16(FRZ=/5&X%$&2K^ K$W5';\G2LVI7NF(VA[P;B$J$R\^\Y,>1R!;[
M\ID?Q3;^&\=E'O*XH#/PNIGI[TEAT_-UUK8*3*B0X.D6R(![\7/G2,Z]@[)'
M%>M!B"L[S8;M ]+"MP&N((^U"2ZT+HLP[)O97L8*B='89/:7V3:\GY@ZN<W,
MK)&Z2]%MQZ\9P_MHE!H\:%2E(E.],Z(:>VO@=/S<-T#<%K#?L$GA4YB^4%L2
M;.]<7Z\AGZNEZ;BF<(?\.B7MTC252GP-O.([^WY$D\HL-C=I@#M6:&29R>>:
M+[5M7/K(U_US:&9,FS[%F*QFB("I!XH]<P-S1WZ((H9#%P?[J/]OKF31J@!:
M1TN?7@R1/9&!?S.XAN3/0R,Q3ZN+<!>.E<K6O5RP(4+%+HB;$;?A;G#0A9=$
M[F+<G!T+ 9=YD-GTWENI=B79:6BQ%9_:M3DUH\4+[CD50+W"F><*28)%9@T(
M+N?ZH24M^UNUA>$30XA*,UW"<N.!YIRQH9>_"*2[9#U>0X:R+"ID[XZ]9@(L
MSG07E@,PP"B??&!9>4!;#O TW87+X+#=%E7"9AQU"/L:V(7=V]_?[56$^5H0
M]C68Y/+FPYZNXLLYIA&FWNZJ'0Q=$\));)94=#%<4AI$+1?!FJ/W5P8LG(R8
M!\RSFGGMD""B7$1=#K8@)(DU]E 6N^H N0R3K1@UA/$DDQRY:2;G!>G@FD$3
M+O5 1KT&[NP-H4;7X.SLNYNC8%\YTLP>ID,>+B=_>]Z$&M;O0N$?LT<[XG.3
M@J%E(CVXV\S<@JX@D;-:M)^,K4;_$@_XQF=3,PHS']IWA?5V37$%JRZW#<L;
MNOI_:1[&I\Q5Y8XQL2L#-EE%F>\1]B6^,GT[S^RI&78YZ_UA19,-M=[*AZ6L
MX;;MU^B0_-KY66)J"@!K%HZ(2;R\ 3"^&3=>S:K8W606?A<*I*>O'FJ#DYWI
MZJ<UQY\?/E:+]AC1[<K-R<6Y:7%X@WJ0NVE;'H7.:AF_-:>;"G$?Z]MOGT:&
M*JW'1:M+F9U,RXG[H_W;/B&8[\H<J7M0&V[70:"EJU*C"J3C<G65Z\7"8&K:
MD&UA0X3DP]7OV3L4/[-"<#J:C<3Y0'KW3J2[F$(T1QPG<$<1O3320[K- A6-
M/&:0]:,3,SM[PA:EOQ6F!K6$Z\G%G;:?RV+(]J%]K"LW=H50E^]<&)%^ZZ+1
M(9WSOD[6<H:>.EB6&98' 8.8J&B7U9X;#R3X1!Z&4G^;49YW9,'T6X4TB*JQ
M]&P]T%SQ?A;DH/I*)R,,$'0PP8J9/Q*QE7UE N \?M-M<&HZCR9R!"[#0YJG
M9"L)5F3EPQ+I4#M9"WUL8PWE@ G)O\@\YI3BB(A]0D ,^_3]9=M_J;"98V[6
MZ)+B5FF.(0\$C1E_I#G)A+?RV7*%)_RB[RY*ZE.!HA>YNY:24U_*(K(=4M^_
M![_W%XJP87^9/COAQ& ]74X=(Y+F[$V0'4/@Q,EA=R^=A4PE$Q<%;D=U]#QA
MZ#KY"P4B !R)IV Y(!EB0YI*<[4&>-B\@WT8,=.0K6JTX)1.J2E46ATQ,C7V
M-7@RQ?BD\JG]G!T3S=6Q1V,OWJ ,^^N$QN ;0).V<%T!:3MB4OAR=C$TBP#U
MT8E-1"S9L^K=1D4]?U&N(\AE7[,H. C2-)<,@"CBRDA^>?]]4\MHNP-S2[=E
M4<29B7%!3='."A:=HV4DWY/RC5'8CU@X#R\WNW<0"/=ZL7O0]S-;'GH6OS_L
M-7M9$_I1VK5M8IP4?XG9\2]%;]TR98YYU]R"V2](7:.K]+O9V5IY%T9@<NT*
MK90#!/?)B2,0<R6SDE:C\8AZY SA#0"6B !PUIUH.)#,=Z\.?T5,^K>BDDP@
MY]"4CE$QR:QVR>F!Y0 ![,0JM)R'X&(')8Q"6IGWU]]-YG@:,ATP9E?O>I\S
M>_C>=("A+6<*"TDTXK)VV@2@5WQ-W*PO#QRC5S#U"!:/*V27W2&F['?,<EU/
M(PC;+7?FPL*8U1J,4E]U@M ?@] EMQ4LCY#MW.Y-% YN-VI-*35W]?;*QZMU
MB-T7/I(W8G"/P-)^SQ[FIRQ#8XVB5E54F9ZK6XZC;O1 XUV7.E[KES[E>N'B
MU+*7"00:=)I!1(DAT45-PB0K(&!*E,UX)'2J&#O!:[UMY'ONU0OM_NC_FU!J
MH)_XJ'%S3*=X]SKPV,<RZW86V9EIJV=W30FU6M>)H"H!TB!N_]J)P.4O;FCE
M+6I9BD$)RH&0S)BYT^&%C@K3_,D.*8P8XLT\FBV@V0N;\U,F8$(BC_](Y<:
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MH\DO[O"L)T;&,RE/OY<U_V?K,AMD\K$'L;-Y68RA=U14&U\9#U>^OF83K]$
MF: K_(M=6'7^V-\W#+\_'AN_ ?X]?HZJ2'_\'W\X&A@BS&'?:2H#O$^Z+..O
M^]0_Y&R339/^GM3-=-/JK,%9+&+)U(+8"CS"V1)IB$H!\A&XY>*8AO3RQ;]O
M+W*_W:M6[2EWR)LQBB@,B]=O)SS\2[_GOB,^_M7XH9RX:#;7?[")&/,;HMY6
MZJ@R5S0V&]* YQ#Z7.YVKM=C$3G+5=&0DGC-IX?<,<>:\][X]H;T/7^<"GA/
M5G*C1M:O3;"LC+KA$"I@N.[,=R/SKS8]FGHUC=*%]8A\3<AUZ^S$WNEN&&^F
M>W]UJ^C':VG/7 $9.GY(SFZ6%QHK4AW9HW49@7!O3M@'5%8MW\F,A\MCTI(_
M&P5._MOLE30GV;B%D'@.\;0&T:S0A:!-0#$HZCSKM6L@L #+*#4=*7RR2",Y
M**IB*7O35CAI;W6M*R/.47!7IY;65=Y)Y#&;.+'(._,)*2,W-_@-4.J_D=YQ
M+3J>$C()*IG)LI4?Y2M+9B$\#'&]GA3NOPI2[GU1FHBTQ#Y2A-!9 OF^FW C
M/FJM81+?T#I]%I!I^H_*HYR3CO$V9G9KQ[^.H.2/VFE.XJ^X#"?P3W+^FS="
MGZP%3:;XA7&R:=21>#[&:Z>;P>%]F+O"!Q9;AX24(SL'F&"5+W3/18G/B>L3
M626^W<L.MX:(;O%9@3TKB#[.X6E-E:53H@$A;:??'R4[5@J!>_V777VI_P[D
M[.@(?L&"B)++;D5&GIYJ<Q+7LX(/4I!CLR:TDPC-\?=Y]=4^];62Y_'KRE4*
M,#4$0$U$#30UU24_4@@S-EOLN#X>[G,,]FX_Y,C;30U6-=XW^)9 3+63P$W?
MS/"82R<_O %@-+Z^_K[QZY"ORZX4=\>W>H#+6%:N3LGF/U:'.IDAK6PRA?/Q
M*RANP7QH/3V2J<<O%.6DY':"=\=TGHAK);(5Q2&T]1SRQ=1]'\&,PK?/,(FX
M[H/I3U3*Z1%SUL)7(F9GF OD,6;Z$Q5JFI4Y?/\(Q9C\UR(F?&]%)ITDW:%1
ME%CJ>HGYF3)[ HL*1_B5N4E_6,I$B(CB-3*4Q@J4&:?)'CVI7YZLJUPGQ4LG
M8^N]3>_#RWX9ZY2Y?6HB(IY0!7$)17]\GJ #*/(Z.Z.Y%<!04^8N]BPDW$C%
M(SCI:8K)]XEF>2E=/@**&HJJ8C?\>IE@?' FA"R$@A_9(OOCTJ@=+ \3,C[9
MN3A!R[1)_>K"TF J%V!98A;"$5$(V_85!/08P ^-/^3;S2T84XQC/A^K)]'^
M4SJ6$7L<X$K+#<8KBMYO4IYL"D<7\;_>CS<MELO9 N.KE[$KD2%2[F11Y?22
M_\.8@[G2/5141^KJ&BH7S>F.<H(P@SF1V3'!@5MKW_ES:=X GA6)(JI7:!<5
M5:(HBIS6-OP^X6"B8D%)3)OKR$!,1J 7)B;[<+/%?B]@FSQ!Y+NX3_+9$W?Y
MLR'D#1"0^@9@58#H@RK*F1G2(:/#:80?EO[;\_'3Q$.'NNH(M)]UZ@/7-YBW
M?]+LYK8K).#^\T)(:7NP&P3R^Y31O:1KO@$"DZ_?  ^B"<)QFK$)Z,&GPQ6M
MMVH&MVJ\A;E.U^1FEUT9REL2LGL4,BU,=N1/Q#)*53N?TS6'NQ^Q<Q]$*^4\
ME4+6PBY3;(C-UT_:XIZQ:Q^@0$*Z &R8.^,Q AV$HU7JJ"UB-_I=8/*)Q!N
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M.B]@+@9ICBDS'O'+KSHZ'OUM5Y*-<S9ULQR*$BT89,@DR,5X3-:KU$E()1G
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M/*NMN!CXO(&G_G1>7:R4DX2S^^Z[JL2]:Z&SXTP5>=PR<9&Q>V5H#,$\K[$
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M3;J'>BU' L+P09=5 9P>QV+,.@:)CL%#&IMR^/L")!EE8ZBA+;/8'/BG1?Y
M7#)T;S*4;8MY*6A/XI2;C@#)U!A+9I44:(VXLLU<)73_IX'GYJ>80!J'W.9I
M;EWVOWJ;;SGA0SI+-V49PF'?\O!.[U([-X=4 X&<7BLY22SK8KYN \9MB7=_
M=C%#(V>U[5QWH",)\Z[Q!I7/0(&ME R'R2#8+(8,388Q.JA7Y%$X._DU(%^:
M8&&&"#D!:@@46R1@]'P@4#OEW+)WBK6U]Z]7PE<L1CTYS3J:NW7<(\AT*<2Y
M/)HN&;N!X_IKJU>)%JTQF=+/1LQF!ZHW5WK.TPP43ZVU.(":_D#J$#F08H>S
M-5PY1U7&C>+HF1>Q*JZ3<E24T1C)3CQI\)=8M>GSS^UD+"Q%5[;EMCZXJA*X
MF:677I3,O0$$+2JZJ8U05_,UJ(GKWGD00K*UM(KJ)H!,""U,>&C8B6).IV&Z
M1(_,[4T<E49$E:)KB>#PET-UET7.>4[;A&WSEOC#27HS'(@/GYJ"MV/"8@E)
M0\[CUO[VP<>#C^7F'&([=0U_/%NH]Q#E!8J6C3[A-)H5PXV\-JI,IP9.;<4X
M2?4IH]<J'@5HP\A$=8],\P.W_4>Y>-#3&E@JFF=0KU868RB*#<MFBSY(KQY9
MW?ZQ&1O(5=3%9-;E_8TN^ 1RB'3?V_SQLQ7W,9:XR?AC2"72GGD3T/:<>T";
MOWM! "EGWTF&+@Y+GC^ V^.HVW+R0M_\HR?E3S+J3-WV>U1SLS BY\&]=@.9
MRL=FVK1'A7W?G>PI9 R&T<U5[JSSI:8?&2SC<U^:N7=;S+N_UARU[K4RCSN4
M6+&H4B"O(<^:P;8W&]FPF6%$O)I\UY4;G--%SBV:9NKH[UED<!,^MJ&WQR%)
MKL/^O@&VL%S$S+Z<FM0'_*T1%B5>7M#\VV++[2"+7F)[UL31TO^Q)1=#)-'?
MZPYK+<,86)#N8"1(3.$Y:T)*=:]W^;GZR!^:#6VT\[Q*I"EC_[7%,5G3]/R
MVZ9CG"16B2!\"?FK&V5S/K7BP8I$.44EI,S]D_5KFM@:6R9WX993Z$6:_Z\_
M>9XEK[,/ZG8_;S*59]U<["O;R&9;K)M@0 <^@/06R%?0R+866/?K/;(R/LM:
M\^JZIYD'R78JH7RP0940 1.F+Z;SI:H@O?9A_CP]E?X'0AHD+.07K=!*#6SG
M4VNQXHF/J#-WK3M.!!A!&Y^1T\T2[X-M-BXRH=G4V=#6I7L_2=IW@=71+I7A
M^8HQ@G,UG*(J64<MI9^H005SAW-6@G\+#"7R_\;F \=V]1I;B*+ C2ZFZ*[
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M$+/[-&;=:<8X\F>+ZZ6(Q)]L]_#NARDU!ZY!UCE]NH*/GAM#3%K)THUQ//W
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M<H$;41+.0V*I(L9/(=A#FO NRDLI[WNAMZU(O;0$4<G_GEN=Z! =MEC$AU^
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M+ PA@ZP?_^5#P/\WJ'G]\S]02P,$%     @ NHM=4Y0!B);>E   %^0  !$
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M\\#CWY2N.Q3UIHQ^$U*LWP*6>9T/5[=? ("@JP-C#W 7 ',Y=KD!0!<S YL
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M7YT-2,.<8!8BPSYP'G(5AQV24_I4D\8, FV]_JRI04U+6T4$;LQ%J,O2T A
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MQK>>U0SY+>F&<F<ASF_)9WB4_&3W+9U;S7K0H$']TGK*++(0?D;AG PBJHP
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ME%,'2BR1I'^MROU%]DOE^SF.!/'N]2,W[/KGQD?\$U.F<$$FZY< 11=!+($
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M0A(656-L;!Z3$D->L[ZJ&-6!C?-SF\)Y!5]U/Y/:BO4GXUI*H8CQ331N]G9
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MRE8Y"*R\.8L_0U&$?1;(ZU(32+.<P]SEI1!8-(KS3_HVT=7:8%R&%J+$#@]
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MJK 8QJ'EAZL8>)^)C(PR,+2\<56"(1JL,!0D.;LG@6A7%9-0=ODET"Q[X3^
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MC;>^H\>#9L)*UPG#D7>[9-*N*\<LO'>[\Y1024/-\JV]RHUJ3 :S\L)>1:/
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M=E._T;&N283TZN)S&,>X Y$_/^3ENB906->S?CU:-?F7NVA5YD=4@924?82
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MUMB])^K^7M5=];_K G57W0T=8U7!01B'WC&QPE[Q()1N)6QNN^I%58)%_!O
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M>UH@DI._03D9(Z!+Q=?.8-U+?X <I3], 'W)/*Y+J&,+?6\,X#K:@8PAN$B
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M,!=(5H0=3Z""9<'S#<9.5F_6EG$]XV67B?X*$B[9#@J61VG\)JU!)7KX/;7
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M&XV/9Y0H98<)(;ZB%77E7$X6:>O7Z)31F 2R0= G/+"&RHE1V8XMT&>&-,D
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M8MQ&W5.>S"EO[H2/>0%/6\1N"&<82L\#Y>:!PC1Q3VCZ2)21+1P..970@*'
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M,*( 28 L0!&@"M $Z &, 1: ZP [@!, BKEG\ +X ^X @@$/ (\ <8#'@#1
M!B 74 0H!: !=8 &0#.@ _ >T \8!4QB[GN6 9\!NX!#(!"(#R0%4@'I@1>!
MG$ ^H"A0"J@ 5 5J PV!%L";0$<@#.@!] ?> SX 1@,? ].!N< 28#6P =@&
M_  <!DX!%X&;P ,L;"P2+&HL)JQ+6$)84EA*6%I8QE@V6(Y8[EB^6(%8$5B)
M6,^P"K JL1JP.K#ZL2:QEK%VL '8Q-BTV*S8 MA2V"K8>MB6V [8".Q;V&'8
M\=C/L(NP:[!;L'NQ)[%7L+_@X.%0X;#@".#(XJCCF.#8X;CCW,()QWF,DX-3
MB?,6IQ=G"N<SSC$N*2XC+A^N#*X&KCFN(ZX7;C!N/&X6;@5N$VX_[ASN+AX>
M'BT>%YXDGCJ>!9X+GA]>.%X*7C'>:[P/>#-X._CX^/3X?/CR^'KX('P4?C!^
M$GX!_BO\'OPY_'T"8H*+!*($UP@L"6 $=PGB"?((7A+T$"P0'!)2$'(2RA#J
M$=H3^A!&$F80UA!V$\X1'A*=(^(BDB<R)G(AND.42%1$U$0T1K1%3$S,1BQ-
M;$#L3'R;.)'X!7$K\13Q%Q)*$EX2%1)K$@^2"))LDM<DPR1;I*2DET@522U)
M4:01I+FDC:03I/MD5&2"9!ID]F2_D26359+UD*V1$Y)SDBN17R?W)8\G+R/O
M)E^A(*2X1*%" :*X19%,44TQ2+%SCNJ<R#F]<]!SX>?RSK6=^T2)3WF)4I72
MGC*0\CEE(^4,%385.Y4*E1W5/:H,JB:J.6H\:BYJ#6H7Z@?4A=1=U)]I*&G$
M:$QIO&F2:>II)FFQ:2_1:M!":"-I2VD': _.,YU7.@\^'WJ^Z'S/^3TZ!CI%
M.C!=&%TQ73_= 3T+O2J]*WT4/9I^_ +.!=X+!A>\+J1>:+JPPD#-(,M@QQ#&
M4,HPPHC%R,MHR.C'^)RQDW&'B9E)C<F-*8FID6F%F999D=F%.9;Y)?/B1:J+
M"A>=+\9>?'5QB86&18D%PI+(\I;E,RLCJSJK!VLZ:Q?K(1L7FPG;7;9BMG%V
M(G8I=@?V6/8W[)\Y+G+H</ASY'.,<!)R2G$Z<29PMG#N7>*Z9'8IY!+ZTB<N
M.BX-+E^N?*XQ;E+N*]SNW,^X^WCP>*1X7'E2_O6:< 9G< 9G< 9G< 9G< 9G
M< 9G< 9G< 9G\-^";U,*M;]_9PM#"H+LX;9@03LX5,@;Y"8D(B@L!)"[XNT&
MLG,%HUALP8[.,'FV]=I7;"S.]O)L9N(ZPCIN*F G9W5?!-C(5]?8SM?53MJ>
M[8H"D9RWC#?4#0I&@5B\H1 84L9;GNW4N P&/R$+L;&<BJ!<Y=F43A@LYCKZ
M+"IP!)A%7/"R@)VPB B+A(2@B)BXA(0(/XNHL(BHD##FDA 0$9,1EY 1E63Y
M'=@4B##O<@A[!QG#J]=^=X=IR;/]\EVTUV5!.,)12$1:6OK$C*BH $9" .D#
M0X&\!6!(]N]&?MBY"D;:(9Q/GTI@.6F#;.$>*'DV-B*67^#W<4'=?CKZQP#^
MM'QB'",MHX( @U#@JYB7@JBPJ(B B+" J(2QB+2,\&49<2D^87&9R\)R0G^1
M_"<;<(0Q' Y1T'&V0\"1< ?4FR(6,SC"_B16$K\8^%WL+Q9TX/;.#CY_[86H
ML(RPA(RPY*^]^$7RKS8P>;0'H4#_)2N_ROZ(M=!?@OT_38+;+]G^4Q(P#$P2
M+O\Y"1BBC#X";N]A!T;\J^C]2>;?W5U[NY^]=?- 0$XKT]Y." P!0\$P%!+3
M8Y$_]]C>3L8!CH""4 K.4) C6 CLAG20$_J#^N_N("9A.CK_<5E#H4+_I(E$
MJ7JB_F--Y,D/L$*&8"3< V$'5O7$#)G]GTT9@O]%6O_9%$:<_:^S34='1@.&
M1(%@)[_>*V (@L[.]C(J(L+"TI)2TA*2ER54541$E$14))24Q)4E5$2EA:64
M5$]+]L^J?S-[%6[G<9*NW\W:8\PJ7_NOF?U%]6]FOS\N (+\+\S_@XF_N5%W
M1F(6!A^%/\7]M$R,P.Y_IOY@0)Q/R\8-A$">/J<@S_8C\&Q_4SC1.2T%&9#=
M:2$B09Y@>SFA/]'^M9+SWU/VGP_^;ZK_VKZ7$QCV#PO6Y1\+UB]2_]K(R:+A
M!4* E1PQ,5;XOH?]\=2@BI$$"[>9,\P>[H7D^6'QSRK_VK2=$PCF"+97$/JA
M^(/PM\0(?<_,_XT94Q'^_S]CDF<9^R,[=G#8R:,R_XVL8?R ,(<Q, *IX("
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M;&*1ILD@]+6WY&&=*9QG+.]Q&*@$,:UP);3?XLIB1WNIM/<JF8K#.(V?AO+
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M2Y_]#W [^64Y2N_Y@NJ>QQN^*X;QH[_>B$V,P)R#$OCKHVF>7 S+UVY_L!#
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MIHY&4>U7A*.UUA<1(.BN/+'(NQS6=]U7*)I%5B)(=VCLFQJB^WPN1I;9T(I
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M^S Z%1<^IB:UM![+N!96'A:$'G9@)/9ZVV$*</S'SVO IPH4U 0*+8H>P?I
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MT>G&7@V1)4+O>)6,#$AH$>L'RY3Y+:=M!A1OU5O1/^Q?O6;2T R>-SZWICU
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MFIGX%2 VC-HW7\A["2AOF1?$L-&[W9K;7BR*4 Y$-C3*#4:^^XE2_+AG7E9
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M^P-4 *2T1F[TOP2.(U2&ON_J\B^IS%I6WJGN_"EW4>V+P3Y93"W?'=CL2Y'
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M8_V"$Z=E1<4Z)']X;'1KW=VRNX?/(3Z\]X4M?_5NSF*C_<N6@29LO==TY29
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M\_WS"O:I2*4Y:J>;-V%A/R9&DNIR_P9'Q[S*OWE#*("H+-\$*;V#X5HY_W.
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M9,SLF%8P.RM;U%V?Q4N3'P7;PGJ\&ZFH9QZH%G0\DVR&@WR2T!@)0FZ7YG(
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M+0R9E2<G5\D-U-0)MX M7S,H\UC.&IAP.9 $[&_J1^:>L;CP8/7D./GPXA9
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M/WF-\9X_7O:,]ZDL:&FN3WGQ81T=K&RUGA12#A;XP066O/[0S8ON:V!#J"H
MV+C>X"CCH>K:S40KI=J*(LMK.C=BQQ2#.9')U\M]2'OC!+V[@D.VH4\;!=0^
M#ZYTD!G!(]1FHV$=3.0&7: (_DP3U4#5N8^9@]5/(O:P5O>D-)0H[M6GQAKB
M7YT9K2"82'%N'\ 0RR,?A0S!8^EQ!T3=U[7EUN?7=75]D-UMR[64Y,A:T(!2
M\H7SQAVH.ZHV2[(%Z>N>Q;F4(=+> :=Y1"$2@M;4)QVQ%$Z6_'77V%HNH]^P
M$\H_(#7,XC\F9=)XR#&?!^)?^IE2YJ\\3#O1//@%5<IJC/Q.#(AQ9$3(7-WX
M^OA57GM6>?8P<;9O00 E^.8M68!K?.*![^%ZUFBTVNX_!5OY*-^@V"@6X9K+
MHC53)X75 )CH)#'7X3=[;HIG!5EF^WWML( 5; ;PH%??F5N)!:$$O06, FZP
MER?$I?>.?@S&,/TXO3@<_8MYY\#6,PD_(K\+O:W#Z[] E\=@*Y^Z!EE.NT<)
M#;@JP->VD;>9<IFA5]%W0#>#I;< _/PMX&:.?K/;:L"'H+3H/Y(=FWY56P0
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MHS !7?<=>J#;CR#MET%+>[:4G'/A*T/=MX"&&[XKCYM7_WGP,.OJE0!4S#,
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MO.H+ *J#1Z]Q[KL*SQ1D).9;;W@O8K<O;[A]K1^K>5'O327!3VUUY<'I\>X
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M[N:VV$,JWO#DM_:4\.ERT JHOFGC!N7>9AL:BK^ZV5-1>A=B[FA_N<U(,5^
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M+9!]_<61 [H+N-&!%LAG130*)6T;JW:W]$#W7WW!>(L,&QO5":.Z]4&!E=O
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M@= G,'L3+'W!DJX9G83>>FPP.8K&?_=#9&=T+J[2@G.;@T.+GG#_LT"_<)&
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MHC@O)"1NZ&1\):#U95D4/VU1S7X1^H\2/<$::7CR%-/FNZK81V:"S!^,BWB
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M[:/HFOER@(I"-7@>#U1GM9!!_F;=STU^K^]#*N9\AGY=LC,)CU$<JYMP+*?
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M7&]^M-4M_+2OZ2;:O$B2V[,9A8WUW9L4<]B=R?.DG='?"[H#\0#[YI">LY'
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MR$G1K?N]A\]/,G (/@,-Y-/QYDR4^]JP$'P<$B)72["_*#2,81N$W%KC?C+
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M?PYL#+5G!SHLVC8'Z;D@AP!JA.S ^UOVX6HC8Z-)E/$X>%&IY#5R^L7!KB(
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MGZ$.8A ,<=V^22_:,,OW,3=6BK<>Z/?W#@V2]TL6Q@?W 7[OCG,> ,(+M \
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MW-8EP@.!21P!DN5HC"=Z__"GTBSLI:J$\"YS=[^XG'LE G.U#O1<E_#"'-_
MM0I<?ZK<.F>=4)XDL>UV<*Z?;HO]Z&)EB7\DF2V9<A]V1:UD[#$R?N((NDX#
M@W-(*A\9-:](X!ZPKGD0T>#,QQ6[V2_>4X_$NHHL+,+UVVL.L]^(2[Q)DUA=
M]6;L^CJ^]BY&X8>?.(&K*A3S[LWEX@S?=!GO8#Y_A 7LNZ;SJ!^_M"RH-Y[E
MF1--4[ERFYI*78K<5ODIC_PPRB'(:]A]TRM"O_)-[ZVX"W<1]\6 %^M%D(0'
MSO/ B#QG*[X?.MRB429(YYK;=.R/[X+$\0I;Q$-M4Y_8X"M%OY$+<)<M %TE
MED]6!S9;LVN+PO>FU".\+HT%YMG,VZQ,_^TB-OB$%[G%2NC+&,+J02_K]:CS
MR#N#I7V\[4"=C>ZT.R!"HLX9.I>_Q)U9@FGQ6YGK0O9.X@NA4E.#D82HCZ;@
M+A1_-6>0QY;;H(M)C)%HU"RBO=K.W<((B"M$:O=1U52<\Y@HLR@&%6)<]'CI
M$K)TJ'W?_5&P1=@[+-U";]&QBPK:.V]SI95P@86\*YJ#;%\(I-Y]I0S4^_-!
MTV*:7(AX4G;/]R(5V>50R'S@_#FNX+QQ\GASE<3ZY\GZRB4C2OI_"R ^X@R-
MJ\A*GWR;P4_\6[?D [,8$TE,1^0O'">0CL8(\G$6,"[G$"GA:^'P  #/1):'
M#_&4_=J:S=*8<#^%9F'F5E.A]KP(R'CX2K-<5!6*O0Q*S,:YL0@VG3FA;?Q"
M4IHX&/--J;K:1$F+>1"AYB62>H"A5_=7'"\?R7.E6:.7==1*C =>KCWNB26*
M<:"C'2108FZ*&?3GS1$<)7@TKL^*;:$$A=/;Z,+:SA";83C7(XAE[\Q'IZ0-
M=\8.RI1A3:)JM V(.G75^HSR=_;%]>P]=K#7(W4G!E8>H/M#VLX\'"Y[VU^1
ME6^Z,(VV+! (*"2RY?SB8TB'XEELP/GA]GS--H==A8,S5SUJ+Y@M(+TI_>)9
M%[>S6*<06JFB&9X;*+2(9> )FQHG;+MZ,8;*1P3,@/H^L$CI7#_JO7T \)Q?
MT@Y>4CS*H?HK<X_DGF3OUK.G.ZW^%VP'!?7C -30%&J !5.*'Y'TOFS^]DTA
M->&8)7_!IUH!'40F/'^-'#NS0%6\4,DAW4+[S$Y'*M!6 X^]Q9XKY]&2;1V(
M3-X[(OY@6K71*-U27:^OOWR[]:*V(-VLP'V<OL\IC,OT==Q*=X:ZR?;MD%UA
MWB^:;VBU:Z73'+X_+8N_B2N.),M'@%>2K5+V:WYF5UO_XJ+EB3I'W$^-BCLP
MJ_(O4W^'"IUR!1N9U+V:41;U(5C*2_*(F5A#Y,30$PI^9D7K7.!]#ZU.WG.>
MK92W9PSA->8#YHC3?L4<'-!LFF640M*50FP=RWX>?5%Q;J0*C6R;*YKIOR ,
M'4KY;FPX_A85$;#JV8UW*TL/%TGU(O'00A&T#%H:7/EZ[[^T,H2X]!F0C<1\
M)(;D_IMYL9*26*9=%!VE)!D'W5EFZ$Z0GM.S[-#TGTCJ^<8@;J@?]?V7YT;L
M);6T*"$CB?]0?V)N[S,>FB,%_#42;,_]Y6@OH/<C4L%LDO*\!(2S$T=4T2*G
M T'@A*716 VDSSIBFAK^ /A'I!O* K /12GJCG'F==;VOA$E0,;OS'Q%JG=)
M)U)S/\'.E3XV?+/XZIQ?(ZNPP<-Y;",M\P"E))0*GR$5?<)<8T-6J#,[.R_?
MD]N=_:(4L*9?4YE?I4[4S,JCIZ0E&[1U\O*DMGSSMO5Q-LO.YT^.LY6Z%AD=
M]7H3B8:@GH]1#BD:;?'=[\E?&*6HTX<5,4W9Y? +O1S[B0FM8Y$UB'\,6Q.[
M+/<^95>9]JRKM&/?<;@@<JRBXDY>0.+G5_4[L^\H"LL5%Z?GOK((J?O9[_0B
M.67B0RUQV(><9Z,D^Y5@"('2-4VC+QH5CD"%D2+UE,==V%_#^C7HK?[>29V]
MM7H3\FDJ&2Y):M!?^/,/-NGSS*?^6?MH;/'T<Y=Q=QQ*$2/,P?+^,(H"ORR%
MOR=W[:R:C\)F[IFDJ/U>^M=-LC&$$\@H@5P)-"?SS2  A!SUF"?1T9PZZ ?;
MW?<>!A.O6[SS;D%^G#<5$2Q_]X*I1VNA%_Y=0Y/]2TBV/(-3OC*!.H?^VR6+
MC:3U6JMWD[?ALXN57S1,4$_))IB'^!J2@^N>409&"-RRCC9_VO*OZ^6I?A'!
MJJR(=P8.+9!Z[H7K1(P.O3?PS.I<+/SB^=TZ1G-XL;DFPBFQ5N5>U !C+4-C
M<>835S\=V5]N=DQXI7'@BXWGD= ;KSG7GKP32T*]/7?,]95@FD<M395;T\D?
M00*Q'WIZ;;^IOAB]NJ1E>OC1DI(^53QLW;G8(%/R>U*V!%J30<TNS/#;&6V:
MLHU7?BS:_G)W3*3QS;[*CG'1SGST1W*+IALH)6OP97B1F;HE_)^/"LY!4:+:
M#51E_)U?-8EH_EEL2<IWT4*?)#_^!Y$?1M4L;B;1:CH.C?F8R6E?M[1?N/;'
M00)7-\;AI7)2D'S?"<47C@P=2KC?XRJ#BC0!!%)28K#7QN&72$'3A!RK*K2[
MHW9)B<+C1',@:-,TJ_WZ 3##U3N2^PGB'5^;A!#6=17Z@CG@BI:84/'GFK/B
M&NG=4),MM5P'%22B(HSD0EV%T>(TO"GM)K!Z$NRMLIV8(F6#"&^,1Z/-GM,.
MI3L[]P'%H-.T+4?Y>KDE@6](_DP)T/J@/"QQW/X:Y+\^;^CX"Q7*84U#(:5V
M7>'CTTHC]P=5WHFZ&RV6A]0A+24ST"Z&L1WZA#Q0XHWRS16QXI/7_/1-NQ8;
MM#)1,&#\WT>!R@H_ZO]SP":/:KWZ$ 0/(LZ+U8KU_:U!%>!W2ROI"Y"QLG//
M?2:M 'S"R$BHSO(;X"6AON%[]G3_?XCH&3.RL VW5M-M,TAU<_A5T&D"LM@D
MT4$/D0HIVR.JM>J?@VM9DUCCE4:I%QZ%9UQ,MJIG\HUTV=07.3*L))PFZ=^'
M_Q9 8C>AW&%Z-MHI?54QVK,2J.<47O79[LI64'J9G0LQK-W]Z /HU/&*0&-@
MW6RHO&[HVC])$\;3('Q3@QG'7 R(F@"!VN<D 7:4YV)^8-=#I-L ^%FTGP(J
M]2OP&M^?O[B^=9D]O/[MQ7:!WL\A:.I8^9A0UI281;:-",-27ZL8DY(@"KZR
M(F(B]5P=V+9OB+.8Q"E@>D%7W !'+M+X,%7KY#=X!T<[RX0AGE>*O< /$N=E
MI[.=(&;X^D'Z7<?0TW@?0/1RQ6_? '6Z&\_1^!#*P*^50'_[M+X2TLS:Z*IT
M9(2@8/V!=IBH:</7$Z+8]QPJ9 ?$^]+FL1]T^A1UZ4*^MM#06I];" 8YT"S:
M^S2WAP6O.SI0SRUT-L]%'M?US]Y1C53UDKKKDA"K=#.0F6ORNN@SK?= RN*8
M\)4KL$3PG9QK-!PD))T/:KCYTD AJ6OTK/AL3K@@K1R1)Z3$09756EYWUUC3
M%I3(^IE"E\#]_0,%8D(39+D%\=MT-Z;-S&8S/%6?']\U%CZQA3SCK<AA&]%6
M7%9ZKR$A@M7ZG'>Z6<F^L]!W>E0_CJOWB,KM+#&H,-LG!_8;G'A!;\,0$JT
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M =#E?KQ^TUW[5:<?_-6S,PSA7]G_:$(5RD?Q5^G^3G^0G=F=V?]+@U_T^\(
M@'FYG VPL[44V];-"V;O^9=Y:8?@_YGFV6#^PT "_&7$ 11^C<P?:>C_&GCG
M3<#V=(':@3V-733/I@[:GW"PSG6H$U+4"^><45/Z0VP<![B;E_N?1-AN<*@#
M]->J"#(X<](YEZ%X(ALOA)L*& :&VR# ]N?9^[G_7-3Q?QB?2<XT:JX.]/\'
MVH_A!7?YTZ7AO/A_EFAY.OSY\H%MXX(PM''XD^R2'1CE!_9%J'FJ&FII_ER@
M<'^*_V2,Y^@&]Y=W@3K\K-3E'XU7_2D^JZX]&&+C=;Y"X7F#X8A_,#?^*?ZS
M.8&M@Z*;BQO\#\4E^>&@H/)+<9:&MAOL[!T/X>:.N@QY@O]8.'P75"'_)B6T
M/5_J_B8G@)\M:'\1G\\@MA]^9\-9=AOPNYSD_!3MQ\J#27[.G74H]CE_9@^@
MF/JM8-FHER_J]!T \/Y,W@2X D [?7VZ!2"4MW>S!5LK:@'03S\"+IUS /M[
M9WZGLX"' $)<7%P\7$(\/$(2 GP"$HK+A(27*:Z0D5&0D5TA(3RGW][^F="(
M" B(+A$17[I$3'[ITB7RL\,E\A\N)/^5 *?M !)<5/+9&&A  #H)&@8)VND;
M5$/Q3[O19%%98J&=TV]EQ "@H6-B8>/@XN$3H/U5B09 Q_BI) :@8:)AH&.B
M8^%@XV)A$ JBE"08F RD_%CR>C9D0(_[ MCD,3E/%1B9*/0[; 6%X(&CBCC,
ML0;;[S_;>0I3YE8]8%&*,[0'=>8A1*C&C!; .]4/N\:]%G>56>/S']4D=$\L
M[174]DPN[QM#O(,2"^N>3ZT<B*J8./@$)Q75][Y:/20!H*.CLL4\SPD'&TOX
M/ 4&?E),5 8>0#(L@?LQY&<9=.B/;@LRV;Z'!\8J&E#8>0I]9L8^2P"'1;AS
M#)5$'I4]R$@$ 5[XE<*_SH#U]Q1.9P"$&.>8) !9P)K9(^WAS)FU]EM5_)Q-
MH[$[L^D[:%4?M:+LTE=.W,;W[^ALWYJ_CCW 77E79\TU=T3;<C8\!.=K;W64
M@4_;J,..3&K+.'*-3J'L1E;2HPW+X:QPYXHJ9''U'&=!?1;L0+K2<^UX0+8S
M((9*,._8N)?H>1MIT[ B3T2$N\=-NXRX(_66H6.R-C^FNN#)DR YQDNYES$Q
M3P&[MW+OSDF<+'55(A(GVR9?M]\8Y79G'9L1$!$0=>F=/[*>,_Z\RU\%!>]+
M7=TD'4/P\^]9?=R,O=KVT[%MY5#I%-#@==Q_"D!:?[K<S+QN\JWK$QY[SBE
MM(GUN*ORH\:)&T+G6[#U7.71X^/WAP4M6<TR>_&[^X@;":[U1_?CL=]"D1&N
M<E><&?*F*GI;/GJVW3&[;G1D]F[D;HX.SLF3/(BPL<S1SK9KGTW+P=@!9;=T
M1'%CY'[I+:OJB7(:G-%VN]+G[2_LKFUU!SS>H+D['N"LH.8QS*M*>&NSI[^@
M]NT1K6LOLJ C#;)N\4'\E1'D%/!R\W"V:GX/.JLR^8I8Y"T3C.SQB]#7A,=I
MNUF;IP!CSHKG#1AKD3D\M0=#CQ)=]S$LZC)>B8[O>0<\.+Z^9D@7/D'O\JRX
M3O%!W]Y@'(WER+AKI=LSE!_S7CY!N=X[Q'#H!.U[16X GZQ7_%B[8GC:UAOE
M3X,J=^76(@8J:<9JWY9:G@+,:O6=8/-#52.*,X<!MH^24[SYI@Y7&],VGL9R
MSHT-G12U39T""-I.ZM=*$\4/',8S/C@(C?4:LT%O%LPNSKO>J&Q]WON4MZ H
MH/9['1Q;5O$@V"#@<'U*)/6&G7515=1HR[.[:A:G@+035SZWR=BQ]QN4V$>1
MOKE5+T?F/6"R1Z> V; -#_A]QS<35Y^?.$N+)'E^?'I2G?Y-^)CS%-!I=@IP
M+7X,*S1U8"SV3V.HF#5^N757U4E4\J[L4./\$>^XND/$2W^K0RM=NV1'=^A<
M/]/(JLN>C^"';Z*G +%""1RM4IE4.@-8Q4RYYX-IT\ N[<Y7!E;:IP#\O=L6
M/+VMWP)&DFXV!UY19'@J(YHQ<N@Z?Q*1P"@PX+8N-.>Q6=A44EOA]4PN*55$
MR.76*6"TA9G[UW RDJ@$K9F^D=GX\!SL/851>LN>LH&D=HB^_(G\N_Z\5[)+
MZ5GKIP#BV.NG+S])7/YR^5C4YA3P8;\43#XC7QOAYQ*4!+#SCHR8;ZYJ.M.*
MO#_3WA4M>I5LNMI0.UG7WOE6_FEK>(;L9YB_NNJ<IO&3J1EG9UK%]/:I>ZJ!
MKRA[5[9,K0)24Q(TS*>>1A2WHZX("SKXLP$5QC-6NOW-.-(CB4V7&YZ^_33D
MB=P[!1CZ'!<:2M01.+J:*O1*Y]%-'D5.? L_GM^+IWVURSHLNY<XLNSI# %-
MAB>;:="BE4=6^LUXV;1T;,ZLG@+R*K]6?E%R(G"!++3WUB2:#GLWMJG"OJ^<
MW*([B4"O#G&I9&582$]W&M*QFZ\1=+]6N+[J&N$]_W+VZZ:QA_G"++<[]WZ9
MB' %L:)W5<FAZ*[E@=&ZZXGY"/U=!O.33_N)^G+/OV#Q/?^"V5(.]0QQ-F>*
M:\=HU-E8K(=MF+Y\1SNF"J@YIOHH\Z9U@K/#G;#'=1O?)F(;U\LZRKG.Q/G&
M)^P4*;=30/$A)Q&>_C:E,\T[\BZ:=V3W"M&%&K >J-PS(+R&)D8WT:Z>Q'55
MBOP=9L.H_(@C0T$[U1T2H$['54OTCU&8H@H.%J9\-Z9?HC5HICC?.O'NW=)4
M=R>\)WIT=Y?GI/%[A,)&UHZVSO[=$*6U0D>?_9$EI^NHV1,+OUOZ7>%ES_>Y
MVZF[7T?23D=1?0VXH NZH NZH NZH NZH NZH NZH NZH/^?TNE[F6>."(2[
M!"\OS)/'YNP/[#QV;JZ\OC;NO/P\?+P *5E?=QL[9S""WA;L (5) S\]:P/2
M0^VE@2;"6GQ:[HI@1ZBJ/QQLX*]M:.?O;"=N#Y25P9?RE?!U=7<%(VSH?5U=
M8)X2OM+ \^ 2J/,S,2^0_MP$X2P-//^S/KVIEBZ]HAL<3"_,(\AMQ\?/3R\B
MPL,O)"PBPL]%+\#'+\#+A_H5X>87DA 6D1 0I?^-@#+XJ*,4W!XBH:^D_!L<
MBI,&_M8N'Q\?'A]!'C>X R^_N+CX61@! 6Z4!;>G'PQAX\L-\V3\$>1G'"6P
MIQT<>OZ9/?T9;V/KYH60!@+QZ?] O[7+U?T7T#\6\%?DL^ H:PE%.-@& 59"
MO60$^ 3XN?GYN 5$#/G%)?@$)83%./F$)03YI'C_8OE/,=S@AFYN+C):4#NX
MFZ<;!-%906_B!K<_JY7('P+\9O:7"%IN]E"(WU^S$."3X.>7$!#^8Q9_L/QK
M#%0_VML@;/Y+4?YH^[/6O'\I]O]N)[C_H;?_U DH!:H3!/_<"2BAA"[<S=[+
M#@S_5]7[D\U_.EU[NU_9NGO!7<Y'IKT=+]@%[ J&(3Q1&?/_.6-[.PF(&]S5
M!B$#=;5Q /."W3TA4KR_2__3":(Z3$OKWP]K5U?>?_+T1("\$?_>T_/LXTE>
M?;"GFQ?<#@SR1C69\9]#Z8/_1;?^<RB4.>-?9YN6EH0:S!-A SO[;%L&)>"!
M0NTEQ)3%!?@%Y15%Y 5%0(K\_/+\J%-Y804110%Q/C%YT/F0_;/KW\(JN=EY
MG777;V'MS\(J_=?"_L'U;V%_?)ANX_+?"/\/(?X&HPKU1"T,?C)_JOOY,#$
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M]P,<%P</I38G :!AH*-CXV!BX6 38&.CGS^+E8$?0QZ3%)74-A8J*50^V&1
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M@\ 3*1J"\+Q[CR/*6<S,6-(-R1K)8O?4S2P3/*FUI*7#$D RFZ9^Q8#L!Z^
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MHZ4X!=#=5>N),?G#GJ?O4L*GMCN4=R/JP?.#M/O=-%[UW9Q5'[]=WN8L_Y(
MZFT-O=QVS"D;\<WY^B#AO6X"KV?=I1*+F]6'5YME-6'>*]?T09LV3+FE97VY
M3&8%-5A:&B8?P9H"MAMJ<Y'6B8)]<[15FAV*899R*>V"I 7T?D^>C*J:]%->
MN^-?5U*&40V9O66ZK'SC1;'$3GB9H#5?]:%3^F"VB+*=V!M(9#$D15QQ5,OH
MZ3Y6P"[NA@U=D%?C8\(F.C9^CSX+9OILLE#08O7U@E. A">ZGLY8BF2B>[PR
M;/GCK!GJ[N16GP/90Q4-C/$&]O#/L27^]F-4R_I]99:8MP5CU%1#H(VW[)EP
M8Q73/ ^!(S54FM44A?[*X D6/=:/)%X'=LN(IN)'J<I*.H_,Y-17]&)(=J$V
M-Q44#*IQD8;V7$**;E>"=!.GUDDIL1F3:?S>UWSDV-DM."F*A-TKJ99E>/=A
M\,D08?Q0\VS.:E5)Z-?NM]S4FL&O! *CDLJ?3$AZNO<;<)OJI^N8>=US3]/_
MODIS./:B94="Q?MA])+]KNS&<2J3?BJ05#')+Y@M+,;$9<@V<X!CS), 2RQ-
M\Z;J3ATC>Z.FA2?5#+2:<#VV3J'7V(.MWL2^I8RLENF&YQ#4CU"0&IS4&/O1
M>E0X3J\_#.2S?;L$6\9')-C9!WX-'YOCYB"9/;N578B7R=AKX)LK7N7/#Q/E
MF=9N C"\I-/E1>G3:$@\ MFW__UV^0?+0=7N>ZR":3GW 36I_5P66N]M06OD
M6%X]$8[!/,*1,05^?N;I^NRSQ'!Z @7I8MX'CM3 (62Z%R_;_9!D+2?UR*PX
MD6-^-/PY"<I%A@^3Q+OKU9KU/G0,[&*L#+<+#NJ1.W=9/FC.#S?F41P[URP;
M81[H++]AIN:^']</WD5*%.FGVI)Z75VG'X@-)= C\5S+MT#JQ OLH*.I*]/>
M'DF2N531W,!5GFC%(.Z:[(5U74O)8+S)UEG?V.Q^XKC0H"UXU)U\R@:\19O>
M_KC0#N*N :?D[YL$6J;VY=$G-OAT7>HJ#@EGO.2WO1 N9&\\1OQU%T_=4.C-
M90,Y/>&'B6WI:NM]N3;F]^Z4\+0%A 72Z1LM8QKI;G\TC,4JD(SJX_I6P*F/
M!IQN)C%=-V43CP]TY4GN4GRNL4*L(Z<BW\/ HPCJ>'Z9)>Q1B.O- A>E)QN/
MFQ+0\2FSY:^TTKQY>&#+WU-IEWK06$C[2B@05U*>0)/7ZQ/-I\4W)M;F[?*!
M$/D'V((AEM,//GQ_G4@F;9!F[2%T5'K(2CB1JSKA[)2@.%%6V:\G0*I;WMU=
MEYUPCX8K,-H'AM>;Y5-'Q[Z'@_ 86R0<IBD]TC)7C099BFI[<O;:K;60OQ%Z
M=W/AIB0Q,3;-C2$[S,'W#X2)70%N%J":0G7]QL\)?7D<U!-&''N!>87.ZPIU
MB2!1++[<4@D1:;*KL*)[H8B"Q$G &J$R\S(V$!SS]$DD:7!2E 7T4KJB#SHT
M ^J?U?W1ZLLP/=_[T4IN4LS1]@=6L5I'%35!J=/<Q]F<J;;(X8P\J.5.XG(S
M'9CS7ISNQ%)L>FA$9&EQXQ .7V197L%P&Q6_^[@1YE"Q<;J!^XLP]];I:F_*
MSSM&JRD:H\=71EZPKY43\0^J8>QUL^A 6 Q&*]4^4 MEYMN2\;'[K!F..*4L
MVN@)]CW.)&HO%':H\-!&#A0,V$J+!="I5IW -K% JTPE"84<J9EB_<C->X]?
M@.JZ.:'\@]U*ZBSN7I3'WWMOLI"JBIK@V0:+&HXRX-/WNT\GK_8Q)EA@WQD:
MJ.:XS%=2 BN%U?<?5)604J;F% @AR%L-NSSP!(NC&/#]1?S(B#<\(,ROT#7*
M&.3Q1,5896J_)<I(TQ DV >I+Y<]$,J**(:7\CGXA>L:4J1'E(09I<0ANQL%
M$HZG^X!TBOPG.F@$@#F,</,NWBZO#E&S#JJ*Z<.\R>:82D?UMXQ\<YFRJBLK
MGI"FF\G1'?TWKZ>L7K-J1]TOAICZ&L$Z.]2;0QNFX;HQ$'4;0U5YYE?#;V_%
M^#M=M[TRUS)H652YYM+OE;S9-#BW6[JJ.SJF##1'KC7O9(%TG/#MV1H2VMNP
MZ\T@UL)N=Z#$4#6U>?H8V#XH94^8@7*B"5D&;?*W(1U)Z.S09HEV)W'KHI"(
MKJDFW7 BHA"JP2EO,B2*3.R@*GV0*LH?'/PXJ;M+N4.)\4[R:Q.+D$>A6M&+
M,+Y=#0N8R*Z\#:>K.IY^V\L.BE5,RV^#W-$BQH.T P\K2V;@^CT.@F$[Q6MV
M<;B^3"-O@[W0B;Y\=??"#S6G?-0PJ@'6NR166WI75SHK[Q3 EL$_FGJ-5>4F
M5.FF$S9_=\1MEO5V0D1( W6W;NB##S/62TG3;[/&[L;[MA"5Y[^7M7J=AY\<
MA:-OZ847BY8,M-^R>,;N=!7?F@@'L]/F/<-5&$6AA:H<..0FZ8"CNO('5]PJ
M.4HTEG9O_U:9I-#PD$T'C?UTZY %K_#,W<]B;_,G/E5,?C2_%OG\IB .7AY1
M@]8536?E8F=3 -'C;"$",RALO)'/=B.5T5&=5Y3Y*UU*O%"0@WQA:49G^R"T
M*2PF4S,UM7M\4JA0>BKFVJ#4%%W#5X4T:RLL$@K*W9O!&5T?!^(^U-<'=L$C
M(@J]EF7Q4@E=K].9.W11UW,/.=T5SLEYM[BF9M]II=VBVJC>#S7.,JPC3?%7
M.'J?=Y.XIK4X:#;4XXX;Q;M(*25RR=(1+')K%=S,(>;) KM4C^JRWHAA'\'(
M9\4Y^=%/W+VX%B@O&; EJ#%7#>T#=7@3U0N(=P[\"Y#JL $]#@S2]-DH&4,S
M_<K7%=;&ZM6M%H=0:ORRE>&KLJ*6(<1:2'W5,*TUC>+8*I_@&W,:\(F<%X\
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MN5MTAZ7-IB<#LCX?+;G6QH;*6QV.&=.XZJM7-%<&:@)&]DL565;T^X0Z4F[
M('L@B:9Q/A)&FA=?U))=6F,'H4F4,[0V^M,@1<K^*<8Y1S,Y1Z!:&#HON71<
M%>$A[VN(MHF@9F__#'ICEGYU/]#'<(P4;V\A!FE#A293Q&(@;B]EZ9+HBOWN
MDJ(F^/.E1B+RSN>[;B+Y,1Z!#Q24.XTUU=X"#L+?Y=SIH$S8:JD15JM^;CTZ
MG@H6FF@%U@XV6?,N;D@,Z1R_6/[>%&#[&&0@;4O,P<.>;,WJFNQMCJ<P?P=M
M,D?&&[><AGE+6FPX_5%)M7J%K2*I8U@]'[270UW\=3"R?TI/H5P#9 ;D=]1X
MLDU6#'EK;N;?$6SF\:26R8V4&Y(O,CDB0M/OC]JZLZ^3B#O41(BGD30:H $%
M%67S5FI<92602 B'Z T%^E6^2:E4_4>R$]A&6%2D02F\A1L=%%'V=!6"KQRI
M U2-A2E?2O)RX/ 5()9!,@/J 48B6CZ$W;<Y/6+&<$W>1G'S\T-K&QY)U94W
MB,9'FK)*=;X)(:K9X;%+]_JH.N#4J+%/@0<:VP\?=9T@]>K0CE#C+UW^4+BT
M5<CO,3+"_%GHL2U$M]\&SUY9CF6IP97L/>-=H2U0H6'AO%FUS@NXALQNF)9B
MN\MA3==TZ2%QCX3=R6:QJK\L[RZ-<+$I<LE>@^U^JJ#YRT:H -QVG,Z\P "9
M3L@ED?O:8+A>ZB!W_QN-:U'R+?D5"DDLF6*XN0=C.3R15P 27T @&@&KZF?K
M&5QC?F$_NJ69#*4H0U].P.S'+\I2[7R_5$O;>I7N>0)79'"D>UQ2N>]FLS>D
M*3/DW4PB>70"F]#.6"XIL:5K#0PKT$(/7PV[_T3?")Z0G_XY?5,$IT:XO5DH
M6$H$4_.5I-QP-C4N;C(+H>JP[V4*";OZ6*.F# K4%@E-=]2B1 1?51000539
M3@O.AUY;)(H*$FL<(KYQ589>L^^]MF"C)1^-)'L]P528#;'6GMS3)[O/\[1\
M%^5#",P#KH=F?]_*$:59=**LRZ)[W@4ZK)3]<-?R3D.6KZS#MRT]HJ/YG83#
M?E(9XW>G@,RLL@6OPIX6&$[SM=OT][@<BA_ZJ4L:G +B568?9I1M<9"\>K"C
MH..6&;='J]QL67,*<+Q,MGRH"ICKU>-<O:%"?/\4(':GX5;'-]EYIV2W*91C
M9<[G$9^7-<<.E_V>U'\;DK'!I1;S"I0*^_8J?QMP"AC6F0TY#':6;99%W9SD
MM8UB[>5;AE^ZBI2%747MSSN.<Y;4E;=OW6Y7L*71JVT?.P6PR\)84;/\%-!R
M6&RML74_!Z=I<4LL^G-:"DVZ5#_'[0*,R*S=(%:K++.VM]>*[Y-.K\B6R92^
MKQ@IF_]TV5 ^1(7SNE9KF?#T?MKQN_#5>(QVUK&G1T^FW*;<'/=!-*4;>@V&
M\>&!JD;#&??8:#:*;*9>9T#"&RX]"4_0#XC<?)T#2<CIUVH0?, --7_^K,1Y
ME1U/6E:KIUUCI=;>(WDPNNNS??,"H4HZ>39YY3*A\C.9ZKO-TH;C?K-)=VY3
M97^)W]+9C5C-/@5\,8\]NM_U(TND5G"-/V\;:0;RQ&-P]Q1@A)0]:G"NWA#]
MUC7)YO(_>'?+H+JZ9FMTXQ#<W5T3W-V=8"&XA\UF(\'=+;B[N[N[0[#@[L'=
M'2[/*U7GUOUSJ[XZW_^U9L\Y>G2OT;UZ(EUFD76^R'$5/@[9S[QJY'>._6OS
M6T?13B2]4:%2LZNMTNQ_LMY*I\67'?IQFVC9G)O)H=7]%[]-ADK-D?*LN[X#
MRK""*/\#6NGPQJ(G^B7=<E:6S+KKA[_FW"2>89O]KK&<B%YS]B5@%0#NJ+EE
MVVH-+%G/)JY_776GXY.*,S@N9YK06.'9/)>6!3>KHD^^N<P;61B!0B+LJ$Z2
MPQ_6/ FQP'*?K6/:+S_V#X2$6%!!OGUB#B-2E2G$PR+E$1+O >;A&+*C5W7C
MG;GKSG<\=5?'0&PBE"E*^J8G"&-$E+0X1.X7/97)>B8W_ALT396/\Q5_(*8V
MF6\OX#UGJ?9627#R-/YV<2O#CVJDD?&+JX#,?YH_,Y&/])[QX[W_($9V(A@(
MOUADJ;[B_O%>.D 7EYY/4DYNH%?>%*#B@_Q+]BNMWE90FU>;V_!5(/Q#/%CQ
M^K^6_[." G%P=2GL +_ZAGY,^P5E,D<%G>@91>_F-2[NZ7]=!F=TPM 5*C0K
M[NR<;R( D*6B4G7(\/M6%H%X_CW62PR>&DIQUZARLO*#=!J?HD*5YH1Y]ES>
M :6S1:^Z_R9?(4K?XK>-4,W9#9X]-^_2^*)7A?\XMH3EJ>L:YO[#!<(3O)G>
M1PVT[X!OR$Z>YN\ %[<R\;>JJ(N\[:\-W*@;A).,**1GJK$?'CX_&-#61FHC
MU+$:0JW,@^Y"$J_V'[S6B:M-J@+XURC-00/XI-F'G5]_3VN_ _:>KSN9](*\
M)Z0A-[;W:^G#5ZW4+J#\A(V+VL6>/[B1MD\\J7RK&?O\9>''O,U]<.DLYQ\J
M_(E T@]'==JMWOSCX\]U_]U2_@=>55G_;_IF> A7\NN\R&7EOU6]V;P#U#UD
M&PNNG=VDZ@8 ,,7Q,U@AVJO?8)@EH<^*8IE7BOM!;%WY^#W1/%Z->L^8-UES
M^]J[2PZ4QGHE(@;?IWDS)G !U]]D56&0F3R2"&2@' V/.RHFR8/JA-K<5@5_
M=-7HPIE/\T7E%I]\;?BR,RV8&;"H^\])TRP=H"+_!VD,4/J?O])3,QSB3<+
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MO/ [H/ANZR/E"ZT0 O'6M))IW_RR,F[*+XF\&X1@N :G\'^K5AQM6^9Y2<:
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MSI93H=  ,$3:AYI;2Q_7MF4TTTM=L76[_.<LG2X/&QN]I#?Q+SOAX!!I79=
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MC:<X=:_B"8N'R^56" H',H8(YM)D[@$+Y-'!F&"LGPP?XMWS85\0G6Q%I:5
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M?;,L$>SE6]X[8&ECT7OD7-8=>HVQ\.*)$%.)!^Q*8,*'OY@3V4,PA'2HA3*
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M#_R;&+C@A6/;YG0!>Y O GI%ZY-H.5'3C_N /B/[45&";@SE(Q]X-/CTX=%
M2&!B/)92(OWI*=GVHH)])SF::"@K*V)),BK<K2+7:4-WN[W$,IKH;O&6-\J*
M\5,73GGHNNNY=AWRM()J[G9C\6J*N$2T8I/KT><M&R4N:\S@?GFRD,> C3,=
M6 ),= /D;6J^^(@51(.9PH[&U]9-(L0&<V0;2]L$)_]R0 A[1J7[=4M*'%H^
M.+< T4=::%(I7; CN3IG^,&J@F\^#[FWGI+^YM?Y%?W?/%L;$JG>Y<L;_7>
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M6]G:BF+S=1#),CCI3:+PX(9@3)62FL..^W/CD 1C+PH/"@_U4D(U:-;^9W(
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MYR(E-2C4G#F72L>":N.N:P_). ]RI70"-D(]USM5N MR78>Y,1*9 AL;:[N
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MQ%=?>%]X/XLF;^>KC6X8='^U7;D2R9>*S/<M*#A9?XG6VY 9<2:#]]E%TXZ
MD[!@9F4IC;0'*LF9'S>4X9A6U>OW@O[)V.D5;2V5L6#N8M8(%&TU>'-%>*@&
M;%E![2_%#/F2<CTN.L'H#O_'UN'ZU7DG,!"WL4NA!3I?_*TYP#[0)P)L!]!R
ML>8]]##@77+][JC/3Z9LZ^\S$ LG&;@GXGNT=6YV]ZQQ:]#?SG@5)7"FYD+S
MY#;VN1[5+JWU0?>UA$EIYZUAN]JE:]" U?FSL;>CLQC[\?=GR\HDD89XA3XV
M_K!6T?P;S34(/5HN>9 ([);M: <% B>95LTE7[&?U2Z4+H."+$),^TQFR^/,
MDH;H;=XTZF 9B4E"WL>:M8^VDN:Q?W<W\S#6T)1TWC9UY:B,AK<Z6Y_I<UKS
M8V%_ 7DUSDCPE/PL\S_"?<$7'5W_Q7[S"]87,JYWNL+9EP_3#'.NNX$7^FD=
M53VX6T4JSS>C.=+ZR@"6-BQ.6<6=795&Y+[GMYAE)YF$>="2N,!:S[HE6=W"
M<N9K>N"2(X.\[[W8NV@ =T88HR07M&-;)+XE;MQ'RPPL%I/R$3,H9VS#PI!^
M&"Q\+G >O+H=BE0!*?W9/2%P=W;!4P[1["J6^$O<C =$T_<ND7!H$[6 Z]03
MW,KVFG8!N R#]X3]>SGWDYX^%=X_ZXRGN.[,-5=-_26?TF#KSJS$EE#_!YA5
MZ?O=W!'W#Y!B]J?]V\<GC_[-GXH757HA.R#^?P F_J?"(/GK^2>!F!>3WZ.!
MA\O[2ULNOS^]2;W^?)P>^5^A57?IRH"[?=F28^BFSR.RN!O2+O0![;KGV_ [
MVE4P@X;;7;GTW3^ XOQQ\-;X(P(U-_RN\P/K7-?O#W_&ZCL[;!\ZOW_YF^&W
M^F?A<1^W3L+\Y=,!D:+K_ST5^S\AV81\"NJ!O XU (=R/S?T>VSIY/A1?\Z7
M'V3H?Y[+_P%N^$Z/_!7P:@E^FIRU@?K(["A0[/N$_P$RU#X$%L1+<,10_9&(
M##FWOZ][3L5L3YDYMK1@V:J65C2,VZ5W83/RSIC?7T^^5CMW"]D2G?3AKM8M
MW="R3QQEETX/@CFC&Z[_">S[[980440%JN;J#'="O52N**FX&E6@1B4IH:<>
M*/OZ'PQ4S,RB0([KA(NS2UAJ0QI:W0]V_K_F\"5.]P?V\3:$$,C7$5QC._:6
M<[]JC#YL!/^\:W+:W4J^95FY$_\ 9+>[SM8%Y[4TK<WSN3]U@U4GE#C! 3]F
M8K:=M^AQ_7[__LWEEPJHS:L,%&K0'R==R<4GP>(<Y9O"1VO,&&[MQQX \Z!4
MS1XZCPDIMYWFX&_! 7=PJFU]QT+QK%M)K1:V;>YSI02S+%W9@RE)+>7XPB&;
MY"_L^9O\0"T+7QH:4DK"!?=^E\[KL00-7K)$+TI*?,($/"UH5MV:0/O=!>'S
M/BZBHT 3;.:3&4\CJ3>E]SG2V-1!Y&W"/6%[2HJ8P:;Z%G(02['G-G;C@E)]
ML#Y^P^-^(1J@6MK:9H#,\%T4Y0TKF86[T(<=<(18/6T=0O!AH)%0CSLVQDQF
M5&KZF)8F]^/K1C1-D5MF%B6EOVS7SK8J\>4"U_U3$AL6%LZL(RI]SM=2)850
MWPUKXW6!O)2D"CM#&P$$XW=C<3R%#XY@-WISH05XT,!C^:%3QD?>!I)9=&X5
M,)^_)9'.,+A?A7TB2MJ/=YE^J =T(M M2,Q@8A/AZ>* *O2'3G9@D%BD^YH]
M I,!)A2&#P, 4WGPC+Y$\%$Y]WWY:WI9*"Z^80NCBM8W@ W8]JY2H?C: 6P0
MX79-U\[<_/Q4<A?1H"H2O7V?*2^3EE>_Q0$=DYEK]-LBR6J!V*6E[,[!,3 S
M4;PM<00$4'(PU3D%D7&3(U)SMQQ5KQL_::*]&^, *B/G'\""FPG,TSD%9ODN
M-([:/1M$C@KOHE_\Z/[U0^)H9+:G[?4%#B()72T3NUI+L!%_=.ZWG<D-;\;G
M[<2O)+A#1<9:;K,$E=BW$B7<8)&"Q.#VBB<YA'\ 5HGM6-NS^UW1[_DJ2$DI
M(IB4U=VCU(?]!J<S=O:UI89*"M@RDU=D_N6EREZK;W>.8G^KZXRWZBJ]=EE>
MA3,#I#1)W%"S^I$9)I\UF.HL3N^Y11MC84+)95V5W4L%YG;=<.I'];[[MD$E
MPR'R!R#V;R?8YV+'2(?1/7O8I$IA<3B9][KF/T,K4_+2<T/L/HRGJK$9,H8G
M5[O_L,SK<61B3?(AX% \?5KIFP+G[6@]6*ORQ7Z-N..+56T_BLR.8T]OXCQY
M2K%M$^ K%#S\!H-?6H97 6JJ>6:0L(/3E,#Q+@@B*3W^&QQ)G8R+;<ZKMW/G
MJ3I6DZ*0-=?F56!ET\HWNR<&&E6N=RM6P36@F)83T8>M6!F(5*.BV]4N36DK
M.FI^66OT6A-6]#C)+:-<"$F^M1<!?9@'(7SF9E&'ZI_<G/*SY+R1H;K>E,F?
MU@*G*@4SK46-VO%QN<JF*CH$2#-%FK;JU=)0*9$33GU">.DP/=$R)A<'+D\Q
MB7#[P9$A;X%*UXVSG)08@<XC0"[OL,-FDBL_4 &?1QG4_E"X[K"!_%D0Z?>>
MW9F\N/#CG]SWUO()"JI*#$V26*IHXG5BCW[( S;(CM%'QVM4A1I/<8G:5M3&
M9RH7'J6+3F.:B![;+$(Z/_>_&)*_?M=?MS'#-\%E)Q\/)[Z\9IE::/_9<.A2
M3+0GZJ'A=_#=)P('DGH^KSSA8A]0W<%V0/BY#J7X[O#-2%U&:BGA]LB=IEF9
M;B9SJ@^$B&A9;3V\R;&R39"2]60+5^B[9!<EQ?K*50CENTD3&Z0W/ZQ)?6=_
MTB<Z]4. **3:-E,JE;[ SDN@K]G]+ _/W_N59=6UWD.4HU&%UYDZ[$#E9D?T
M'\#@!D8<BEKX@WNS<$!,>8D/1#W]I9]],4>OOAM.-Q1OU_+%@M^8-N;S;4N+
MN2+(E:XU]NGEQ6WTV9@#% H/@(?T7F%4\R@NV:SR0/@9LSMJYWC@:WUBQ5 .
MA%^/4,-(LCN[\C1)CVPPD$792Z6B'(#[,6P^^SE?.L=QS[JZ$4S,LSB">$VZ
M8=@LHDC&FL["YF[G>&-;VRE8'C,%%XG_J;(D%/\0.^]3[V/>A#[N9,/B*(\J
MQH(XSB/N^Z,4!1<Q<H+BTNQ:/(K^,9NT8-OH4]SUN:/':3S@0I [#]<_;/Y.
M#P2$P#:<R'^J6E,_3@ETQD1]Q?IB MU,*KT6CS^(L!2[57*NN7(6^3&$.;RA
M\Y_#6*,PEJ9F:LS?.+O0@(;D:&1I&UEJXB;AY/K?"B:Y3B(-(K )HNDHT:G.
M6J,I5MV<E5=]?R[JQ.0+'+;F!CR Y"Q'CPN9Z^FA>5(N9DW9/%U; PQ-H9*#
M1['[)@Q^7.E/\-]CPHBFZXX _,K1"33JJR1#FG*_NB;+V-0EN3V_2?7C@MI.
M,E=2^[N7(RLH>BLH%,#>>QK\IV?)*MTG1<+_I]N3)<_2,;6"@,!N\7T;.^]]
MN)P,ZOV^+'JR<WC!U6:P/^4N8DJU1C6Y/K*,;,>(]NVNNZ,K)ZLTI=K4[9!8
M\%]4J?+/M89D!6]\SQ@F#6Z$VTVV+4[=]UO2@ C(1.*\!*J/<1.-@ 32._]A
MB#N_6+.O%QRRLSI3M^HF%T;H%V3S:T5$LIK/JN0!7Z[&Y1*7[Z@11'H%;G8I
M7>UJDU&'G! \CM*"K BV-=R#R$KW=B!K&^O2]N+4@U2-B#;TCIJ%/":^LQ\+
MBOQ>G7'($&O;()<F'Z<R K]5SCLU%U,6!LE>KS\)Q/T/TVPOM_[:5LY#WMO8
M/T6GL9SGQ/[?^^@GAU*+!FG/S @FI#-RZ^BB15M@]X(9AW+(P0JP#);'E7$0
M[<AUBZ5/,0.%'T_#.</&)H#L]&QA0,<:4G\%2B:@#@&#P%?XLZ$3]%14@2?X
M0"24;RY,:D(.BG*]BBZNHF.77PX"N&1G@U/A,;:9KL%MF)8(E@$X.&!CRH<9
MRX=/T^N_0#%_WQ;^ 5Z*J'N#2WZDM-QAMQ$+Z+8QFPYVR-[,?U9;$@JRI6(Z
MUO84^@>X:%-]3=LMH=PW^ -]&QE'.'<6T[JI]L3YF_864QU#9=IU,_JQ<K2/
MFYQM/+1:\]:.BUH%49(ETU7BH_JXZ*V07V8X!XTNGH?;V-HMPOZSV0[LG!K*
M]W7"=^U%RLRU ='OI-I([J"3MW9$*-Q^S?N>!$L'WF.>O<BORLC%-QQ,*/&-
ML+-_,PX;6$PMJU+>PS0<*VJ^\= I&I@UB,)"BO#%;'F_DX!FK,FQR8NM*A=(
M8(Q3_9'<)12%(U46<>QYM3R5_(+[_E?5XLC/($O2;\,I=1=^2-01(?1#>+V^
MQ@'";L\' XY\N?V&YG$^.K-(D(6]2ZFVE>W^SDZU@()C36:4[?5U0U<*&]VS
MQ6_N!>KY+P!JE5.%+;2L4L:A-Q^CFU'MP_=5;C7N9HDE02\QA<Y^G^7+D=SI
M8F]TE%J>3C=LP'0(CZH?.L;*A=ROSNHMB6^[W'AHB*.6(<+7>_]ICUT<B/,(
M3S]>_@2Z%22W(Y,N+!5T[@>5*D)P4CO%;K6 Z5X4W6PR!>$?2N4+07]5.Z^%
M0DVBI<M'G(0C3DVF>RJVH]^-=2WD/C\Y><>U?2W%(J_KE>EGKF$V+-*)9['G
M+GE.%F&4T]^R2._D9X7L[K(BF_R ;UO6=+O1IV <^WYC9RD][7!YG6Y!JZSJ
MAZL'\PQI*J*\S1=Q6VPBB[LS_@?PJV-$AZ4B1-"/*JMYGBC\5#"H_R#3(H##
MK:Z%1%MJ\T%67Y $E7RX:;ZCZA9^H6J7A9G>)8FS48SK0LP$2XE4E[*CU2N?
M.DWD(+DY '349OI:96[&2](M@6,?K3S1=H/T3N-XDF.Y6VB%NV[-4]B0Q@UX
M7(K-.>BLT,*LF<1PISO58!_N?LNSW_ ]\;KQLF]27["<M=O;L&\HXV#,X<AW
M#D<1916)Y-"*:+%C+(;WR>/5K\D-.W)_M2#OJ&[EY/*0:$]79/-[ULA7_&*_
M7KX9KY5NJP&8QDX2VIHR/S*.T.;R)A;:&O#:Q4>E][8OWK#/W6)K^B909*,V
M<DC3N,9("[KA5C=+;9QA=N7QUE;6+,;UF9KS^%/P0[4V:_XDXQ()PI>]XJ6W
MNW+2G9,;]#;8,:Q00[UK;V=,OANK<=)06TD/M,.\S3T>>JE0LD2P_B.[:[%$
M/S&QUM+YZHZY4R>YS8TO>L>V==JH87VKJ7BF^:&WDB%SIM&>Q\%1.#R;.M>O
M<)&G2PCK@^@TVQ5E9#A*BH?FU7F]SB0R>5?QP@5Q;@EEL[55^O6Y[I&%&K0C
MB4O?*!9S\HJABBV/CK?H$L4T.JJ4A;PMM2JWW*K)71A/B^3_H.TM@^J(GK7?
MV;@$$MP)KL%AX[ )$B"X!(('MXV[!4D@N+N[N[N[N[N[N^3F?TZ=^][W?C]?
M5]54]:R:Z=_SK.[I2>E,X &J!H)3Q1A^L+O^T""7%]<6"UXU[KBSW;Z)G**3
MJBA)^E-1VPQ@9YV0]\A= 8"FAZS3.=R4CSN51V992H!QP&%_&-.<4YV^W3*'
M5EFQ9*W3>-Q&?NW-Z30N'O&7H%_+3-@+:0+ S-)KUTZR[<5IW\J;P+UT[<$G
M!MF<77=+DL*[Y-69RQU^T-.XT(BTKQELR:E0,O_, J453SB.DI**N ]?\(+[
M,GQ3(WC-^\Y<6#=PTSH;%RU?D4P=X+@!.; "7S"6*3T1^:5SZ97^5%#IQAN]
M/AA\AN1XVZTXGQQKHYP-4YEUS6WGOY_SZN#]YP[4Q*[GYQMTO#&-)K]:[O,M
MAY8!F)9LJG/Y?P'JPTL!3^VT?4*08D7?-+NQI5 Y$L'02-HDV = ]:J?R[.S
M^XWE363.R;V].-P?YJ=E=8\2B %3;2#L6T>$7A,)*]Q#2E)H%+,2X7!:>;%Y
MU,]_/KNG9IQ=YQRN4EQF"O/%\VWXX?BG!/\./H:(\@&SOCP6+ZH#,3?R,@*3
M?5UEQ&9+-.I6YTVV*?=RH]J*U_I+^]O@%Y(5F*=D=70 -/)\'(HFQ:]F4V#5
M26+HZG+1VGH_"*YH+5U!G/_I:?--ZI(,!'71#=QQ65I*HR01R4$GDZKER',W
MZZ"SH(!$F23>9A7*P5&MS</^[F>!M<V#"Q+)J#U4,/$R\+]=]N_OR$P(R; M
M*$]2**&+DIRO"?]97J]E3@%GSZ4=BJBB_*D(4\ZCUF7KVU:W]]>64_]S5J ^
M@^CUHYH5V'J(=U1/W7&P)1TMMM3*+BAH\NNYQ7(PLW]-!V#O^4:G'"=W4/LZ
MUNIWJT_1\JDY <E )!-$4=V25;9&J.D-NQB2:F<'SCW B;%PI!,AU$(3[WV(
MXMS^X7[1QMT-/VHZ()6P9G_\HN:$E *.%M'X"Y@NNTE),U"+J:=IIP14(QKA
M_D&T6KLJTS<S0@V#\T4<>N)_?5NQ&JJ0'T(^+LS8B]:*"^$$C+S6/[Z[PV'Q
M=%G'E$FL:OI&/A53U+6A?F_A?OSL26P[F?47X+$ :L8=E,>I6<QXH)3'^.?K
MR@O<.2A1.3K;"97U5,&ZVNC>S[9U_C_[U TL.L>MGO;JIPB]O)^\BK.<CB+W
MT+QN9[0*N(>7=-]D3(Z%=812[^R?/HH]T_9Z3)\B4>9Q+K[5?'S\/)!P'=R5
M_;][4(*+,K[R/'R::MIWW-(7FMPYF$U[9:X$7P@O*%1D8L][\FK%P1 _E(-]
MTV;$E=@CM"U'Q06/M.5_GB+2*79&PSM&6_@EEK==;A^-*F@O)?:;G1FE(IM-
MWWM6NJ1ZYGW+HN_6]*X.MP8TD:/)9B8/$OI: 2K\%<MCF7+4U!#O<=6WIS22
MKZB3RS8[:.[*?5-VWW>_[LI\940N";/GSF(D(*'5_#PA':RM4H22GR*98:@Z
ME"/M$ZRBEYN'!9_)>K9 LKR1]^AY/&1$L[XHDGH^8:F@@C!Y&=72[::URJ$N
M6V<\+H6&C(?&Z4KOGRRL/GI@RF>,H(CYFYE,EI+FM$N4-:>\1!H3'<EMJ\4]
M\*QH];>LT9KN1UJQ(7AE D/B3UUF< &9JG@@YF#-4M%>\6X:*GXT--*3=_KJ
MP4J:1BB^@>J*3'0;<2FG/_J%QC%K?S+?+0U\FBHGOWI+*:!=4V6WJS6.+\B?
MD363G5"];G2XL6RJ#A@^>G.F\,EE-&W\X)LHUM\U=9T87?)9BI8MIPQ7&W^;
MZGJ=R)V_KI#=S[(D=CRI"O=/!HVJ8H*<F=FKVA>9(@;,NERSD+Y<0WL>:7-G
M-:->605):B69CHAA8V57BTME:24CUA_LCRG8G<RN5)HLS-9@['UA759>Y_,S
M'[QAOH5/_/7^U],"F;:0''S+0:7/I9ZSO0H,?-Z8-;'TTF9F#"B&=<XQ<L(X
M+ZT_(QY,6,;=/JS^9P@0NF1BN0E""A7HF3E(_$]X?TFT8W9I#A4@#"K[MC&%
MF!]?_D_RP9!,]/@ABD]DU["HV<9'NX]C%+UWH??_"\3_!<88C_H6_@+C^J_U
M+F5["S:D*)#DY#!PO?<]CS\R3LVR6<B]ZRT]LX^F<^KJ6IU<G6^DA=8E>'X]
M_;A72X1SD90!;G^QVNFF&WI.1^2Z O^(OF[=SL@J69JW+/>Z'-/1.%S7S,\2
M]\P8A-'T"238(O<>K@?&=3]1LX(GV";$7VH.,PLG<XOG<+@=0<F0N(K_GDD=
M*1%.X]4L)L>O8/<VQ)11A*,*Y:![O'A4[A=.LA-J="@^62+.D/M+(^.W0+:F
M?TK3E_N#H/8+S_/39=9L/GU%G:O:;U,&I\18)8PVZ&+IZ^.=OJ9[OTI:Z7.O
M:N\Y\:Z] $A0J0R-T@'5IK;YT3/NM#<5.Z0 89-KT0V:P2BQ7I2\T7,24B3E
MC=W)O[>6MD:RD-,O<,ND@<S)UA[*;UX&K?F0_(1\][9.^D_>!7(2VT?'-INY
M869)91 C<N^1T4_V3]Z&B(+@!B@2I_6K1= QD5H/(^580_<!LJ6>H_?5[425
M?A^.!OXDK_&N=YIJ[$,,_2@FZ.?*R"M^/06@?R.9A^T/^,G41P"'5NU26CS#
MCC+F1!-&G8>:)>DKM9A0>%*1Q0TB_[R\1N;I?/=>LD<8+;-J REI8.PVJ)]B
M9AU1M,==*.F*<N<QL?12:;J48*R4FW;)%)6$R5H*O/7^A#1YF\D#]V,,20;L
MOEGC!KNF^?2/89MD\;#G>7[Z>^6NE>?WS-?#BZ$$P?[[$$LD6HZX#O#E1ED?
M3U(BAKFR!^QN+WB*6U(15L3=W"48'9>D"?4"?[=WRB9A:X*%W5&[80YN;+:L
MV!F=.1QK(\427OTGHW(!Y5?/@%O[?E$Y4B%D/4L\$02D#+)1/:=;60J-"6V*
M>A^K"B='FT&9F)A";NYMJ]/WSC_YMSFR_=^#9,H-QKZ*,@T@I[X9KTIKKY[R
MK*^O+P=:C_ .*H*GR=#$!R?0P81A,/?@1EI--$2OEEM#WG%''/_.6*E:NU)Z
M\.G&,_0L.$T@P.3XB5??H(Z?]SS+5SS@^_*])4EMS0*=KA(SY)3,;0Q%T[;'
MI3@9&NRDKN4FU*ZPN<$\^<$^$$C(&$ESBFKV!NQ'T(V+%)@AQ*.M+I-S7#@(
M5%T5#5N\60VLHS6X%=L']T\ ;)R$GQGOPUQS9_!9T &(1MY8)24<"MWX"Q!#
M$C'J$U?*$OX"E.=>0F7C]L&: =^IHE\30K7G-!YN 0#[:7[N?"7#O3H1ICMQ
M'M-+]Z2^I^ C]UWJ!C8J67(8[JVM$$] 4M\$;4W9U!2%^*EA=IG5D2/M[_)N
M'3[[<\K09G]/E<TJ)IUQ(GDG4M(E(NA1J_[.X"IO9SA+P6KJ_JRT['T0A$&@
M!*@][>H^Y!GY)H-BZZ/549AF2N]4$2$SS6Q7ITI&'/6^36K7W:W9D_O6(C2N
M\!/&M^U 2;SY:FW.<SC-^-FPNF/\("4:.H1NBKV \NH:5M2S\EQQYQC?L*<9
MD0J^-"&^]7!CNJ:$T<1 6F?K)-6?=,]7?2./7W0#M<D@L'J_FL?.?'D7W-K&
MY_@O#:77W7765BS78^R36(+M'?FN6@.L6EZ%7BZ-EOT' ),Y\,Q,\+?50VJZ
M@BB7] )-_/8]@9T:BG?.IXH\9T>2+QA>8\+JK3>[]J6EP; 782=%4MB\:9OV
M5)]!5&C-]?VA/#GU]2UG>*\)S984? WGV@GZ^)/]/1?/)9F.'<EWR^E9+X*D
M @@LK-P7VTI.(5DS'))JR595*HSN.NN+H81DH-&Y_PK\:\NFG+?65<7IQ_KC
M77=&*MS["S$2D4OBL;B)Y0!,'K>G&NFMM>WRR^M2W*=JWW?RHX+UZ]B1E11'
M33WT7W[?0S=^19;GO.83F?Z<DOFG>/B*U(PY$"<^<M];)9\@6EJ=:RL._;QO
MR?VY4R>8L7TX;B*<>2-?Y:$V0CJEG/<D^EK_BO8=B]36A?-_>UC)OK.D1SH]
MC4J:O/B^7^(F_? AJ:UR]4-2/PV)&#^VRI4V*G$@U36;0<9R:)$1IZD;]1X>
M;^YN6#MMJ+)B-?*O(KS76%_[<<%@Q)/BA&AQHV\F"M=+T^SF1?SL'%B<=L>&
MA-5L.[4[776EA2R-^ZI X:TX6SXY!5QB8HSHZ'1MJD*#N%RN*:JY+:ND%?E7
M*$<\_[$&.HJ Q''JBJ<%HV(A;_+W6(D3@\B:&/]B.>.34;G]%"OW8>+<HL+/
M!W4[#CAJ<H&&7>8GD:R5-$VIXJPS<80(>N3FIJ8SXF4,-!]+*N6UKG>MQ;F_
MX)HJQ+QIG[1^EJV[6M)AKI(E^*IL9?FJN/-* "L^9'+648] C\A  W:*&TL*
MB&W;C^KND:TF'YC)(T#KDVC8MOH@#<4+<XVM4WD;6)8? G>.M2PE0K$2E+5:
MBZJBF0Q9$6CBA\(I2O5W51%,1K*K1@^D9(7OI2@CIV5GJASJE9'R5D*-/8F:
M^?ZHE$*[F 3<>:[8B3XX33VW(-==*W%HX,$S%UPGFZ3^<9(8YO7\SK!$:2))
M?.(_)BE52BN03S*\+6^YFOY=X&;+@B.Y4WJWES<@0?65$D\BCS3[<U'BIS=-
MY5JLQK:73R#)-G>HUOX9P5Z $85]V.".W%>>$Q!/ E>2)KF2JZ/N_F_G"YT1
M'.QLBR%:KL/!EB+9R-B4*-&X* VAY*ANN8,BSY2FDL7":=5II@F'GMU]DQB!
M- -E"1I'1.G/,_:N8:<U?U);8PHWXH(&^.'ZM>0]D(8LZHF,)??8GP(8*6E4
MJ:8R?X?YC.2*BO#3Q9,G?"@(^E#AGT7]Y^O7 '^+8K-X'3L*JDQDT4IT>O"7
MK7\:Q/XOT,DC?-Z*CCY^(12YS)FDR6YB0AK/%S-"BMU(IB."H1V#JN"]"LW!
ML<8&3TFMK7%7R;7[.CX*Q@E<7IWQ/O 15K^A93S4_QK==5L_#G[9F+OC'QLX
M4H5;6;&M;4%L[%/WM:W,6WO&3)9K;#M=+<X=\P^L(:7)2_V/G$GM66Y[ZPPA
M_B\IDV7_@M#3+7M.=(6XG-_>&E+C3<M;9SRIY;_:JE!G%/Y1W/:S\Y?P]OS4
M,0;#1-[Y0MTT]VE+&[4_3VR3/B:VI*CU8M4/]1UYR_L'3Y<>,DTO<>,-FWLJ
M!W)7I>?#B_[X46XMSW6%W9C;W559N7Q$]))J%-"3]NQZPDB 4*T.W)N5>JE:
M"8/H;P,IO"(ZDRF:X(ZUT&W^4.I/W<_@&C;=J$4H<9:?<'_C*52"?N9ZO%7G
MH&!Y=DLK\-O?7"]UV]J+<G[3EQ/35#_^[%J-)O%HZKT0R=)Q?K'R49^<PX1F
M^]GE9T. @GUY/M9U;5KXDPNQ+NR^L.'#[SS$,:_!2^2>T&TK_"-MJ1Y*!_1E
MS?7V>G@GCQ7$U;U<:>>Q\_Q9W^92-H'^%'OZGG_JDM?^O))T!:<B^=*"$/,=
MNK.Z8<YGYQGXT^5-WX/]RG]Q'N!N".:OIR$E?!DB3<_8R/F^(M#UXR.=FY=?
M4/NNH [YYP1:E[.[Y^<+DIQWQNL)]E&TR2:03]CR)"S6Z!UHM>#&V@%8V2^<
M81ZJ5;G R)0K 2I:SNS<\@H>7_'!JV=^7(:9'71[?+LZ9(H;O;K^[+)Q -D6
M:3F,LM=3LLG[/TA'=;2'MC)S KHGNX53KRD\%[AH.6O1<,G?:#G8Y*Y5)R;A
M;(FOMPHDFZ+>PT"$HD-E01MJGUM81TL00;<6-ZGR0B,F*=IC.2EY_FC.0<[B
MYI-4O'U1=%0PB#_6> /Z<M!7%!UIA ?-EK?'9RTT5[9%R-9[$FF:A4KM?/0+
M/8IGX$ B3UU-,VM.="FR _48^Q]!Y\,D[QW[-F>,/;$W*P8C8PMUWF#+[;X;
M:D4XU!.1OEJZE^;QIE^CDQHYF4?:)HQ I9MV?P>@4SVX'WNX(B,DHB8M63+K
MRV,ZB?.A$_U*Z>G(/:VCXY[PU)?\NN6Y=_87^#]G#=JK,T?RH Z -\6TN1P[
M3]1JR/+RLK[MD3;V] !V?>V!D9HG JAW?+R>>3 H0)'MY0H;S6)1QB$M(ES(
M*!34\5";)UZ1/2VL]V\Y>]]>#V,TRY^'!F]%83+>W!C*%M.3C$%4/-:3L<'2
MGP;6-J,5TFBQT:SK]K[XVG0HN4K<2G)_=V]VV#?Z8;++W;R"*;[A;6YS4>LZ
M-Y^2_NNYA?OZG?YP9BD8EMG^FD[I)(+IZ;:]NKD9 V?3:*5#E!!M\S\G"N[0
MFW>&VU1II*#O"MO-?^[G V^=EI6[B:JTYD*\2>INCZ+5M1<HU%>\<02021ZI
M5+*R5,0#=Q<'W%G9.*L: W-CF'DP/W&IUIRUM[<UK,;J)7%B:0U&R^YW:)M.
M7WAS#R[J7&^F=>7>U[:>^Q366*G!T&&6?R)+/LR8UP9-Q[5XK5AU?165$+N;
M>: +BJZQ&<IZKK>*R4IM=MY@EFILO$/_6"XW"L^$.PNG;!;4ZT'?<5.9 U T
MTRNW5=Y#LNJ;GJ14SS[Q/-^[:/ZNG,S^X^F=F<$1SS4R= 7ZW8 V-SHFQ%'W
MN(^R].0;L14 4RH(O"\F--6=XOD);:.VR%7.3A'^L8:NK3^D>]^4*[R3)^07
MGB>8_A8X*=3YNM7V[2[ZR43VGY80=O@4',[>0OB_-I46.N8V4)V5,;PXDTQF
ML63 5$VC=PV5+G9KBW!KBAL@5SE[L3]5'I/;N9B</(#*>1!2:@7'LS8[3K"
M(T(P[/P$V%$M+(.&4<:%.5!SOYJRT X?ZM-&@P]/"@;N#V>+&/@P03,,?N+4
M:*C@ /_@4*.]S'<>_"-=WK_$5OE[Y]S;SNP4J^<3]]24P?K>8U)>\M.E)G5Z
MRKS96NV[;$5EA4%41B=4;U^(:WHE#6@<BDR4%\P\'NWV-3BBX0E74"MS>[LZ
MN[B:)NB_7\JR/UN8S2V[YF*B6I$S0D5;&>!I9WU9"@-^()O1_XC)3;^B_VH*
M*F5RZI"-@.9.0UG%+S]4C);V$P7\0.?/+A:5E%XA[IK!1"D?=TF^[L2FBQM>
M5OKV!Y^3B=:508:#7$J-9.,S,]IMP]S31N :,:LXS(_,B*TU,7YZUTD3DJ^2
MZ#R<DQ;(:PK7RCUIL!5Z?ZQP"6(;MA5.:K:'UAVA-;^8>BWVF:0D&=522E6D
M9NXV@E.)W ZYA[Z:O4WOR:/Q?#'JK7QHWUU_^=/]W_]B%8K42E+U'A*8"SG#
MP28R1>EK89DK>#X<_\ATB$ TT7RCC>CMQZU3!<PCF%/RY+JF1/\@\D9?M80O
MS;C?#6$;/[R\-]#WNA2R* C6R;*8XZ<79Y2U+B#UX-J%2MT]>3H7BX5.:^<Q
MS>J88<#LLP@$X+=I]^W\@D-%]W"_\.R'KQ:!R>*VW]<N[!.2^@N$>/D$_L>8
M6PV3"@76V @)&W-J;N[/[N5#B?8;-%[?WN[Z0F"0QPR*@HT#HZM:GDS,:=U:
M>\)(XF[L[^N-.35\F1)(;"@N9:[R>I4^?(-Z(K2]"2%B3B"7_SJI>YO]L5OE
MSGT.I YM3'%+Q-66KCF^MC[$2WP;<+V==CU".0UDJ^)([PZD\9'!:H&0"KVV
MN.@7&P=2*2T&_E<19C:'U(._=E[^6_YL2,IA1OW/U:U? X"847TYPW7K+UNA
MC^J=\0("7=Q[)%[P[!-KJLWA4VP3PQ>HV>\ &8"^VD4-^W\X2%@:4RCRO>+R
M%N-V&9ZL<Z_ENE9@"<82:(!5^M(NI)."6XJP+U!%? \OM'<;Q8EWIW[1:;J>
M0+/T/Q DCJWZ;_3YTF!<!>0?\!2_*<]N80?S!R0H:[I_U7EI-^;XCZ6%G,C5
MC*,QEYU""X1E:\&[I?Y)86;$#\4B00I0SI2FZXR*2"4+&R@(MN9:6.'L?,OU
M M!8L5\=L]]E0.^T)ME/<HK^!]:G2$?0$N0V!;MN^\^E&GAY:AL"_S8N%W]2
MV^S0K&E051\$C;;33U3**VY VD]SCE+)5D(TPY]8&.LJ8:8T54,@J/7>^.0I
M\1>0QUI>+*WB3!EL";:YN/'A"Z21K<*2-G8Z'6:<^P@;L>>5 FG8PHG&.VI^
M=%I[NM>?BV[VB*;Y"] /C&TF+>M5TMIXTW\]_8"P_*OYI?6C#HV>7%_%?0%T
M',^E]G,5\AJQX,U=.+'HJ($IUM*/?\R#83',#H,[<DEE\H+]\Q\WZ!7*09PV
MUM#VI<N]XN+N[)+(?B2I/P2/-K!-H"W;R3E=E?[+&AE,]E 'P&+5>9,VICYB
MK*?$PLJSDK@7=/J#+#%/:]>R",++Z'X>Y:JSYBWX>OX_IE:\O+#UX>Z:[SZ,
M#^/G%Y7H&6 #K+'38T]2JH<QJPE:MRHV<K0&4QT;KKVP%-X=%_9:->./_ :G
MOE SE-'VO/*L$ "GF/4P !$<':FS \8(JIO0J%<98>"U6.E][6G?Z.-GE AP
M^?_?U@Z!4M"R2^:8FE*4I!45J:[[F!^#)OY062HVG!U9.M9GWU[L\3]$!L-(
M$A6P%T9B)89E,!@6X+"-C5V+L$8QK/.OMH6=:(DAU3"OL+TS30PL>^18R_C_
MNEEF-  O[5IJBSVTST@'VC2H4'KJ_M.8TV2([T5Z,9WN^)+>)'6UR34,=O+I
M;4T4]YO4;;;=3C#JY?-[%K,9Y[ 0X2ASBW4:2D^YU4:115](<.*E9--?("G;
MXKW9";!BOVM%6F*)L."CQ\Y5=CUBW'Q1D3'(-=*YKJRHE2TP6]E?H]&HT>%$
M=/:<MG9B[4V+58"T+11[I*V>P0VJP2@163*Q%I1B/V# )00VN2MN+S=+_P+?
M."<.IWCL=0,S;#%H^\LBDM3_ K@M;]TMKW:+"8REKA+.55M1@E5Q_Q"8V_K_
M(E#Y+N1G6,WK0\;\27UDHZ&':^PFQO_:5QUVU7Z,A9;'&0PKA25+88&Y%JX&
M5X'#F(\AAE5<-EW,A$PBB;^P1MM1GBB(S X<P36?ZJ+@?<BB$P>]P#L$U)&-
MC4G?.T5W$0:CQAM'0D87X[151DWZYF>9L(021G<QW@D$YC3%)_3>VDZPO2/_
MA3N@^?7/UXM 124Y2O\SC*;40=+D5]>5=DN''+X?](5P%#^6?LE\2ON.GO"-
M],J??&H$"RW7_V/C\:(A%7BZ9W6&FI&O&#-XXO]JL=S'7=/]R1[^)C8R_A<@
M&4[Q8GIT_0N0+[X]3@K?>5(TWJ3OC0N7S.8$ JD0X2Z6OT 7XT<Z_>@WFO*_
M %-F^./ %>I\)8#?Q_V8I[3VY+/S29#[_NGYO00;6E_?\KFNB%0I7YY)^X]#
MN4S^0M@ 8:\UTA;]K]54LA(JDB&9//V#PI?A$VQU !P?A L/M5H<J+V.Q)AC
MW, RW?#P&M'>@!7!OF8T\48#NQ4N2UPB5KP2OSYN+>B+7([1#Y1*MQ$9R[V-
MMXQB-?\&G(_[)T.1_(CJQJW>4+\ %'R]6^#4%LK1;\$%"RO7]3\73WH8-\%2
M8)\5^=#")->\+O$!/'#]T0DQ4R!WYF)_.BI3*@PP]!=P'3D=4#=.D'8> );3
M6QLM?D6[70Y"HMEPQX==*[;*9*MGO1TWK;Z=/M7R](XE*;VZSALZCKEFT@ Y
MNOUN1ADH)R[J6P]D> 18%\F7J%KO4UZCM[#,(+2R@K2G_3)H?A7,.4<?L,KY
M->.=2PX#U?3@$K'D67.EI0<D!=_*?^;#FP!P'9DED-5Q*IX8N&!0=^"IX%_
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MK=CUR;'K&Z(J\08STJW8D!,+?Y\_()8GU6)K1J@PS0"0V736W..=L$0,I/[
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M?T'3]9_DZ7A_C.YOH)YIX'ZN^I#^G2O1%N(TF'75BR/L#(!6? +"_P/P=7T
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M"K_X/3QM_A6]E3YUCY%H--B^\_V [&5D"5%6+8"(=W-7'FE/86+ZV?$T[@@
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M[6LND#N+'%^V5S$]8$8C$99?5"GGH<PQ56D^^EU-Z9#V69M! JQ&FBI"P;F
MA([WGN<^4LN*GL@4#0L3YVC7Z?I5^9PFUR.QQA2!NB1(!#.1/<5*K-.- ="_
M"&>9"8#N_(V3W#3@0'FSZ;'E -7F/E>T]?K\ZG/#A=R&V(_4$+U85 03[>F>
M3PXR;4 CZ^@ NW?]82)G*.ZIJBV_[A-TY@MGX[DR%*-APKHEB8(G >ZA()R.
M-60_N^Z?#7,@]D1$3^P)^A^380Z!GWVJW<2+3L8"FKSL-C=+/]\.+=K111)
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M1C4BM2 5-,7G-K6%2?;BUN\46:KWMK\YS9HQ*5TRNQ>MJ-E\N))"$JJ2/;E
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M=O+7JQ$/:EI&5&N"HR8D0 39/#Y%P41B4K#<18"U)-R&FF6_N2M<FB8XJ#2
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MF*>M?9G2?:JM)\=69^POCV*V;5F8-9O3!+>>@&7"Y->YXWGH*T,$X<L>S'\
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MU,%DW1H8W+1FS<-T6,NGI58D;H&(*.?MI@ FOQE^F69@<(X/1B]HW9N:SL(
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M+&-34S]KT][27%Y08Y9L_'WI$)3&DWZX)S\6OI*^=!CER+>' >:* W[4NBU
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MQODTL6X1Z%IO>A]2>X\.D"/@P2>C3B@L4%GB-H#"1=Z5TP^FBX91(5%PXDO
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MAHM3[B58 "O)7V0:7>@Z0\]3B*#CT+M]M'JAJX37?E UNC\\./:NOYW X5^
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MP9P)5W#"6)=&R<9<X@(7LQ!MB\F9.6G3CC_;#*\9=PTJY_<@^&1)!=0)C3H
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M?><RZ=W 32DF&GKZWO97^:N2S^#.4SAR7F,!$S:R?S1G.9*&OBZK,7"0]FJ
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M=^M]YE$O7=OW*IYTGY@ 51R#;[9@1<>K&?3#Y$.(:H=X,.!@GO_'UY%*I]-
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M$OZ^A)VJ07AW4'&0*-"M3Z!1WZ71PX$:X1R-Q7[+,BX$EN^Z%AK_-Z)-(9W
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M+C?CH]L6<D^%V]^0M[BFG M/<>>770@$%[5VRZ %3G\WGC%*<[F\8WS39<&
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M)KYQOCKR*(YIL2X^\H:&AU#I0/2SL2 69D9VEY11'H0&UF*'2<?5OAU>X<G
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MR\PK_,@\REQFILA#H./3'X-E1:L$2?)4X^OIX0=C3]^UY:=B1EQ2XH_LNUW
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M;KOTLT3;<"' *I]]L!)KGBWYL*5_L7B;>*3=)W4WWE>#A6+(N_)J5$V6Z]C
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MU*/8[7>"NVLNQ#XQJ8N+_0.@L^*,*0:Q41NL0[Q7O'@MX7,A2ZT52,47MR.
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MKUGK3J:L:]]==RG4KVS/<G L"U<V[!;F^\:U9>AX<B$)FFIXS> ,;8/KL)V
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M&),T/\G 1SW9PN-%>#*MM<+%=^..^YQ<A1#)R9W,6-FE1!8U:C%1283L=:'
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M$.=CVM7T)$-B:GFFD]ZJB3%0#3M!!U8.^UG/]U6!?P*31R-?*T\_;&99ZCL
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M 19,'W7+GU)FS1IMF;%N,6N,GLI. $&TA&''!-BGV-G)N7MD*OV';0@ 3#D
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M6-O_)!?G8AED/OL;S06>JC]PI&@HP7I'$R(+U@<Q;KNH8D3PS73B"ZU85P6
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M?*"SO<L5_XZ'_4U],XJ6[VQT-Y"YBP-4SM3%]%=6W+&ZX_PS*R[O?UQEKX(
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M0TZ#(,=VMF-5^IO\R0M-6#'+Z6YGFS.OFKM+>(FV/JQ$;RY8K8#=W2X 3RX
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M&%]AE1F,*'IN/5<.6#*-E1B/EF#)2BM>I#^7KX*MX4_L?:7]SZ68<0[W/"\
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M4;=G7>O^J=(>83;Z@+&>9]@!*=4M6=-<AR7PA[52A\0/^I)T;SC$F48G7[&
M-.=E;XMNJMBFXN$M<"$))<K$9?F]*$*QN)E1<?0A6L*D'*/TO3U=I O*Z6!5
M8.SH&Y\]K>C)(,T /Q 6ORDZ%-,V]_%CQO.C&J-Z4PQ<DU)C!#H+;VB\R*EK
M3@4A9]&ZO)*$?WVHJ&7VY-)&9HUE6H8M4H:@W+-]A L $=%C&GRD9FN)^>,$
MM=OO!,"X2[Q@W&[.-Y5@31IUO&0WGL701&.GH+M: 3F<.@5 [?R*9."PCL5;
M5RP[@R!QC"#$R<S@1\-<+8\@[8*.+7<S",5R"JMV*]!7!<?*\ROTZ>A=.>@^
M![L%<RL[84L$9F?G:T=51JDH,K4@QJ"5) *W(Y/<VKFL[&X ;@L1A2FG5,^=
M$H9I3(IKYJ]3EXFY3'<^!VFF5#X4?)-"J^P:3XW"HKC-OBA@=-P[H-LMT;.-
M_G:*035)E""17Q+?JWS3/=A:->@9IW]*20UHBFF3/&V10"^N8$B(EEQ_6^AT
M_,L>KD02SQ"97-*0O+73A'H.S=<!HFXG9<G/=Q=W[H\0QN71&K@_Z:]>58[%
MQ QABJ4A)2J'8QM'F7Y?@$9D(=4#-7S>ET M%AO'D:L%)7.ZI6ESJ,<11]L/
M= ?X[Z5&=/I\^[*1X@;#+;>T(W_G(9F]'SD%DA:0T?=L./9:4C,O,BIM"5Z(
M8"FQ,\(J4 5&+*EH*C/$#L=V*A!C^BT+13]J%6DA@*<#K*YKR S[E 0<B=][
M]ZEU+DJ=:6A>\33K0%\@'HF1J0976:*=9!.W3R*B0\I\VF=VLRXEZE#N=&1^
M4]S)\NB5DU?Q,5'>_72%U@GQO4CLV39?R5=I_B==Z^W3?@]7G]$<+#\W*8-P
M?+"Q);@E6!ZBQ*K,.S7#*KX%M[0JEO8D3ZLM",6"F=AF2G(VKC5PF,PPGCU)
MY\.P&X(KSV0#?$QJ?8S;$E F]AP-$!Y,+DRS$4E._D:D47W:H/B8JNA^NF([
MJQ(<3?D$VM3# B1)M(\%Y/C;\ULR[9! L9./MDXUJ74Y$96&QWCIFQ;4W<GG
M#ECCWCR+DD3N"YL=IY&%^=5NI3624D(;'KSF#8(HB,I.@>0@6]FD '&NFOD4
M%=5PL0'.AL&>%%>4^/9\EP731WQX>'W(75\J$D5JHD/EK/!AQ\Z46S4/V:;E
M&6_* (K] "IN\/PT<.6K@)N !P!R;+[6N9@^(Z7ID[=Y'>!5P\CJ\F9FNZ,F
M$F,^C&9\FZG((_FUR'^,O6*FK=1HZVEJV?*.J6,7,[[-+OVY)BS29'F] ^4-
ME!> ^7=4V1_W/5*B-&;PBRM</6 AT36T/^'$HA2K0:[!!>3[/]N,\WO9$*K5
M6ZGR:A&@T=SE)$Q;YXD^))7 Y^266O<RS<Y9#:@24AK4$-N3/3<UHSP> ?1T
MIP>QV'O9*WU-HQ 1IQ5IU#K;M<I=C935/BL-JILJ"W)XZ!\EO/3QOK*X0\?T
MXQ07P0=-^&%5[A]#PTWNEML4*C.,MDX?2.=,GCL0N^'>[V)MGWR@= &(NYO_
MA5-Q<OQ>;/7I+"87*>(\6(K!MX=;VXLH>].>NQM6'1F6DTY"Z7C22\2%*ZM>
MI?+L Q]JJ13;!+_XSCH]TP]Y;!1(PK$M[]E76*2R;I=6V*3UP4PL=]^^(W!T
MP^VYH8$Y0XTL)U()NAZ]-1A5QGV"50GAOLCG&GAX88MYJAU5M44.O8?L_4\,
M7!/9K3Y44]N9/E0?V_=H 3RFO75?+Z1JL_,RX;\P2D]V2<<*GLZ21[F9GM,/
MJ'T[T?2E7ZNT*=39+S*ER@A?$'"C 0@=>KD 7*:ZG$0<W62:E$X4!;ZWXPUE
MN?0-]6D11^I-JJ:A$)+S^2=J0#>JR& A<JRDF[3BVSVH@+WMY73N["!L["Z]
M\*K-#IJ14==;.?GBVT:H6ZCBG7;Y4K[57T^^06ZRHJIS#=42N7.$>F4 "#^T
MD&_V4E;4G'O?B%(X.1C?=:=);V!FP\(.Z9A$5R0(&_Y<GM69:?OP>\KLNIO6
M61#,@W&^=L*2O-6F4 D1)D@JBSQJD@%D$!)AM/:F](.T)Q\;&/>KYG(*HK.#
MFY,Y\Z("[\1)#%:D+"6D*<%Q5?=/V6'5$3RJ8KQ%\X)*DIS%-!@L_$B\4238
M&W/EXQ?CNHHG.$U6=UK3#A@-=.MR"!NB7]22Q4?;$)IT$+R3;2]@W[L=1F*3
MBQ4 XFSL5RA+8BS==IPJ$ZK*B]N'I%O;>UWF-=>I25Y[Y!&UCFB3;5IR5L_X
M4"TC83FHSPB7MGSA_3?]]0=5@P3AHPO/GX>_P.VK9I2R>H(1> M[S!I.0FGI
M..O@+M\0U4B<Z!,]74]U:L7(#WIZ3#-%Z';ZI)AU^<;OD=]);O+C3M66-'G.
M:G["1=>HRO"7REZ>"<@7%?9-R.G=);=Z[F0JJM[*$VLD5I)[^':0-OZ#]@B_
M"3MEJJ*-CT^T6DDJSH<LK,K\ > TX>BW$*+>*F1I/P\%=U\0Q?HA@@ML%"M.
M"J76K5*&()(;'K"_V%3-3IP(ORN.YJBGYVQ".*YGYQ?\V7++I*-$UN/@A2@6
MG8[+IR6M(BK:*JPNE=II1VL(*78HCO5D(\F\V9OI!;W5I=/X)*<B+QV-(+GW
M+]1+[XI*=3<D=V;KEAJ-[JL.TG-)H#HME&H'-<E9Q?CU:,<D))2:!&$-2+N
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MQ6NX6U1FOOSL@R.22.Z(]^((_&%'S_')'9M1YP2B,ZVT<#>OS('/GECQX)*
MG @-,G&A[5YPH'_2FY7T6-ZX\KC P:.H+'VE)6L:_.U/#>LZ$-7^Y(#Q3MI8
M(UK]A,P)45/D$VI?W++RQ[B.3EZ9A>.EGM!/KN)<;[X-K)KPXNVB^;0SB="4
M/5/()7N_[D7!O;6]-.*%5OH>UV20(D6#$93 QUDY74!Z5JJ;[S3" RJV=!6-
M\V0I<8@1,Y-)UT!ZC),.JNB/9T\RGM9AXQM8L5;S<IU(($)Z]L&B?]E-S[&\
MJ^%1/[[<AB6)9>J,1A?=8I)$HD5-CG*:; 5!QQW7!Q6F$FNZB:FHSL$SHW9
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M5 Q['HD[RE H!Z2^4TW6K96?3*Q8%E6U\Y$4)7Q:=UCM3OCNK9>$^:<1=\I
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M@U5]Q68^$#Q4'NOKAKG=9)=+<XWU-S;/DQ#[B1-:H30FPVF<(.XV=,6K"N;
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M-[A3G9;7+VB#\;KC'U,&Z'H/I:.0O-JYA#RJRM+%Z8=FG66W7714T!%[A18
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MJMF.SCE/ Y%A=?DE7@8[;$>L9 -TNJG+=QU*D2^%13TJB,>6<:FI+"(PO*T
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MM_HX<5&$CRT7ELJI$-R:N)N,L>)MW8BUP5\*5)3P<+'4HD&KY;0[L::1SK:
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M!7]V9Z'>F'^6&4;.NAZU(=H)$0?3042F?/.*3<M@MTY;7\MYT5QI%_Z!%VJ
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M+@J5.=*#:V63UGR$'2>O\>THNB1U)JZ+;ID+ I:N.S^>4U#;YEJ9!S]_X4-
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M>!#MX%&PO&>C:S7/MSJ#/RW=>5 0.1KU5(?LVJGYJ+I6*)]RAG2Q+[65:!>
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M%5L[$D8;1ZI$&.QX=\#PP;&(D,-%7U+[-$=34T:%!KS,![DS[.CGEZ)NZ6_
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MAD?1",4N41NRC6;YF*;U2)P\<\P=HL_&5FBD:5>M3Y_RS2#7(L4YL1!;JMY
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M@T&?_?.]JU&4P&LQV&!\XE?X^>T#NVY3=<Y%U7I[JWB(A4?5=J;KB8XE"W7
MK*X+WVXLN_+M2"C%B\92C[R2<NETBL)^G]!:].<:K;8][6+'C%C[Y4=F!SL;
M03(V6_>RSP]44TE+>//'#/&3=VET"G$%<LN7:,P2*&!^5AEE 6BML^;B FU
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ML4KR0<[>4 %*J?HG078PW8.M]+E+>R/J\&CL2T4^JE88ZJ4?+7+*F0_%+DE
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MHB2YG2+RECZ$Z?]*H^21,-B!$*WQ"4TZ@NY#< P.F3V47DE'3;-YW$ I9KO
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M3 I3]%7I*J4&TUG\94/*N''"&?8*N\H_$_9 :47Y@/H@$,Y*[_FD'4"KD(A
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MBDM6E$LZ]D,Z'W>)BAAWT)89<TC!K3! %0Z=+I+83_NQ%@_$\V#>0DW9=IA
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M X.\C[*1RIMN29E_Q/ "?NJW72GFA5:H-PZZG,B\9\#41$"S\<L_P+<L_<Q
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M*1I=$^5;+L$@-:"G$PW"W(']WVN\@"+W>NX?LU&VRXL'AIB)F,'R6?;^OD9
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M80PPP;<<_;8",O@'H/EO-P+G4^%0Z>676/EHZ#NCEXA@'?B+X?*VP_N)Y3^
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M-6?H4=;!8'D^ W)JA!B4@XU]40J):5DU47%J&$M2=%%7VW)B\(N[Q3:H.DL
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M5L&N*WBNII!LAB:& OK=.HD":BMG_/ES4#O@ZUJ8( 5>#:I?!0SD5&"3O?+
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MK[CO-$%+%OH#0[;UCP95O1J^9?Z!<;[@)$S8SU2VW@#3E:SDA-Y- F?)1/[
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MQ(S*V-(P#>)J2FF:'BT-^HPZLQ(NEQ^9:$3(A!\UV%#>4(^1UUV4"(1@8AJ
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M!BR^<L'K&CGSN_(CC_Z,\EAU/#R5]7*/PO6J2@3->H&839^EKKM<,O[:C_X
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M:^WS#'4OYH9>-XMMI#HB5&Q15?7/8L%K($6(?B#>ZA%:>UVYN'66^KY\W5H
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MD4ZK<DYJ?:2:[8@DR?6Q^VPQG' 4:["8BW!:.DM[O2+X1EEW'.16O%2#.ZQ
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ME+5+0S9,?L6LKXZXJ4A$=]W!> 47!=3M[#$/@-VJS)9M2:LCBY(<(1M[7HL
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MY=<+Y&JHJDJ%XHMBI0OAB+> #\#\ZGE-V9JN+#&7!,>R[8+@]( JX:VPM:K
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ML@O]5MIP @=FDMZ4.W\L3H&B#PHN'M9=:[ 5UJOW(8TW+84L7%;P8,H)6"K
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MQ +91-+%5*XZ'H3<YIB=#F@CX)_#+DXR0 0&(3_N/.+M (;5B -'3RQ^0E0
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M>EEMT)O_9=^P=.M]V7XB"VS8[)M= 9^@.'$@N8T,GM0M/\-7EB9I6I38V%N
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M8+%O+C=U>T7)I?':.II67#ZU;PO=4"WB[Q$C'C]*,KU#N !N2PMQ%(MHSW8
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MC&J'7773EX\DN)W(I$&(.&7T93D[)XNXWY3C+0^AF3AT?S^/A');;N 969-
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MU^2/KC5 ]GC');X+V"_IY=14 >VT[.R358AKKPYS<&8UOG 9Z\=LFDKEK@\
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MFVM*BO<T^HT%!-M%/)!,L:)B)@29KUZHDRC#QHDZV);M:K&*A;[=%N>4^A6
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M,.WX0SXFLMXPCS2S8&EV1"!75,91&!FTS^3-X.OK, &TMJ=#_(T8TU>+]0'
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M2YMJ]'OHIAM_D9I#9?BQF^X?:>QJE^9J[O$#@"+.X:NMWYMJD-K# B-7[PN
MR25 B''^)]>=3"^96^78O8?IX/C\_25?F")+2$&/Q;NCC?8@5SGLT)# !OO
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MIA#\ -S,VY"-S#VQRM4O+M.?4:OK2,S.*\;5IVNJUV_G\$+UVZ3JJR_J 5"
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M#W9(B'4QVTGFA6M@,\=ENOT'?>Q6I '"Z,A-V;%YJ=*-NF./?"/6NO@)9;;
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M]X&CI>MMASZ=AAOA4<[^#S5OV%[?*^$)&EC_[A[!Y@8_O&<VY1.^3QK(@7T
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M>HW!ED[1M)^O$M7[%>C*J0/IO&JA?JW"YIV)#8JW4!LI2\=$QIK_8J : Z$
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M7#EM6;1BV09LFR#5JV12;-VS=(B2"#=%,J2*"21  B:221")D3* %*4H
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MK[Y+6I^=TMO7'D%M@B+G[W;HQ&2FU@>V=RM4$T>P97$E%'77(FEMTW 2NB@
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M%5L> &)-<KN\3Q_@2?@I[H?'>J/)PR1MD-(.3R+\RJXALXNUMAHXA0$=[WX
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MR?DIRH^5!YW\O'664/3S]ID\0/3QMX ]1;Y,D:=3 %!B@>27 )< %,0P8A7
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M1 O_5&<$ >P'M2$ G(J C8+Z800P400]B3YZS-M#YU,)/>J;X5B'F\R#(Q"
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M__#A,1_64G'$Z0U;, ( !VO!<0K\5[20DV>":[L86;]/ LZN:/FGUD7(RVA
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MF 3QH'4&[P+GQAW-2])K5H8U'3L"/.0'^B?);=@I-W/:\!L('L<4TLLM"G$
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M+E41*C8<%Z[O7NPWK,FJ-U+#JA(BU.\DD!&)17=61M"D%8T_NJRYB/'Q@:L
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M;&SH$#,J]ZBP=!?Q]1[0"']20UO*MG<G5_I0,PW*)MCXPGI#M"%O9(-!+)Q
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MN&3FX60N,N9Z(S$D-QLXPY&9$LK"RN*_)GJ6\BZAXB4NEQ=["Q"M-!KI>T>
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MFS$245JBA$:C0HKD<*FJ:Y%OO-@<BVPDE/,HBZ1MN<>BG Q-AP]DQT$I*L;
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MO!YQ!H* W.?B&SA^M.)XEQA+\=14FU[>0W_([]/,X5) +$"X<Z?E8\1K%0%
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M-"/4&?I)C*=+56JE(]3=AJ?YQ4$0)4=*DHD?2"P% H8ZOJX&6C,WG]:TY<]
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M,JDM20]4YK<5@@'P&UA2[=K#91U'0CWX4DG2WBUNO'3S4(#O<N2\'1^0XV\
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MNKS<2,K7FB CH.G*![PD7^%B;8NI7AJ$,1;G_P YI&3^!/G]:4(['*>:P'8
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MA.M/E_\ G! 3#\=]!"@VTZ@FGQ6U"6Y9Q.UU@EL-/NO W@68$*))"=TDL'(
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MPPKE8IT6K,Q6Z)E^4D*CRYJU&H5 $ A4)"P I![R.4VOKVR-I[1&\4!0WDW
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MJN&_#/+>6ICC[DYMAN34?%45*1-D(2M3/,+V#!"6U$:<P/2PQU.QX8P<()2
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M(S26FFH\>.A#:?82"M0!+BR5K*E**B4HBG3X;2DD#EOS\Q)%CS:B_P"OQPP
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MAY0,GF3)=F)?K4<5O.KTMQ2W92W7%&ZE*<YE$[$W)UN>W3W:Q*VC#0",-D@
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MD^]@G#<E0)WTE)#]X [$BSM>!37%["YN;"Y[GJ?CCZLPTA&&A D(0E(.H2D
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MNI4""%6!)%\H@W8(4(4&*=X#)BS96(9FU^$JJ<O<((<EM53Y$.O^I1GJ5%S
MIY%.#\J0PY(3,2BT@B$RU+.P2X[_ '=,70K;""E*U)9/NW%DB&*M8$G[MKT^
M!G$ L9#1%@0T9@?$]E3*/"+,$]$B5,8H]-D4QI3T655'ERH4@U&;!3-85?E\
M-;$1F04RP4GQ[A.H&(\1>WI!*58JR+)22QS U<DM<N >)($O.]'$R _#QRDU
M%7$;Z.E5^$*2\T['CY?RJTEQKE'-(9H\-IY/L<HYX\QQ3PWLM9)MIC4V;O64
M<0G>5B8A8DF%8B]U[$P4L>)(%JA=C))9(DC/=#B1%CD,Z8I9)]WG8_CC40E
M'O)!+%WD'AF <G MG2;YMSG.S!^.9KQAM20=>H/NVUU]WEV/G5PP,*,,!.H%
M@[\YD_413AO!RHD!N5^3:VOU H[%=D093$Z$\Y'F19+4V,^RI33C4M@\S+S:
MTD%"T$#E4-AI:VF(]HP<+:$J[Y"<3W3]X9M2[XR)>P9_)XOK5D<X1XG'')#^
M?::RW'XD9+A1OY^08S8!S'1P0TC-$9A !<EL._U6J)0/:#C<NR; 8YO8\3%V
M#'P]EQ%J^R8I4-F*BIL)8&]W!47]U8!.&Y$@I+DIJ9N\25?O@ J!:=5<6S;-
MCJ:JP@DG4G:^I/W?@<=;AJ2M, .TP/&9J/UZM2HRXDZ$ WTN1?7XC37I;[](
M7<M#@YYMT@CA\+*PC>#B#Z\QKYBE%GV@2=;&P^7;; 5$*#$B"8Y'TU.W1N.W
MI]+5LY-;WZ]OXX7WV_=\W^GRJLZ?P^9HT$BPN!?KH,.%@]\ZE8:#P%9^%ILG
MW6^S:V"EK2ZE(C%0 "@@D&PT(!MAJB0A)%R9/0&D81PMTI#+KKB0RA:@JVI!
MUL-Q\?UY5RHM"G#L!Q+?";A]7JXDDFYXSEUXM1.IMH:CLQ6K.RIUO$4/K,WZ
M$#;?78W'P#2M9+.9-C#S;D\7X$FK:$I()W!F9&F;YD#HYI$JU-#2&J'!2HO"
MPD\@U>4 /KVN5:GW[DXDWAF7NXC($=)AV89&U1H2HV(BV5^;Z2>ASH[ R](H
MY99C)3+K4D$DJ%V(@-[\^X%AK8W/GW%+!8M,')V87M)?X,+O?PDJ(^\0)86!
M)^#$R26+$B\>2W49>4KPT?25<D7#\@CQ&6"1;EC)U(UV\]3Y1*W288 #@/(2
M6_,"P,J H#WRY?+ZS\/.O8='6WX=5S.KF5(4GU*GZJ6ZM1!1XJ">875:X ^&
MHO K'P\,$*:'O=QRGH&=ZG1@8F(4A$.H3>]A#@\.A85++F4)*X\9VOMJIE%+
M"77A;U<,,+'M.-J("4-H;/,I*KE201N<96-V@<2, E-Q[IO(B9>V4',&*Z78
MNRE)(5M".\ +^^')'R(D=:K]G?/K>034*!P\SI)FY7EK0]F&0I)9880R+K@P
M';^RN6D\CG)OS7T&UO8]A.U +Q\,*4_NA7O$[Q<F "WRN#<[2D86"&0@(#,=
MV',R9(;GK::H/G[B!&S'F!^INQWT064%EF.7;K6A.W,3<V.I/[Q'7'9=E]GG
M90 @;EB0   ")$'/.6SXU!BH2Q.X! OITUTR+\JKMFO-YEO.*;(8:9OX2 ;!
ML"^W4Z;WO8DZ#3&SC8;-OSNLJ0#Q?)F%A=V'//4!O;H YBUY/TEM!K!59S(9
M)(\19MNKF()UN-1[6]P-1U.,[:=N0A)W"$P;#D'G6US).@IZG =V=[A^&98.
MURTOSI@5:H**.92RHVM>Y)MU%[[[[BYO[L<CM6V*6LE2R7)OGD#KHW0,(-5%
M8^*-[WC8MKG.3-$6YNU1U4*LL$@.*&UQS?+3]?9<TRI6KWX3S$^K5GJVC&GW
ME'H'T $/:Y^)LA/R'CH2DG_K;'W^[:V&7N/'CX^NE1E:U&5$]=3'CGQ&C4EK
M<6O5:BJW?$14HYG^E3,-!=^M87/<Z;>6&L-*5A,";\>='(Z4G< ^R#KKJ<*J
MYYGXTU)=(?U-*[24IOR@"UK6Z;[=L(Y<2;'R:KB,-#'W1?Z4>:',G74]_F,/
M23+DPDG72I=U.@HXRQ?4@Z_,_K]:[-WE:GQHW4Z"/77K2@S'Z6TO8 :GIK>_
MG[O(=3>.I\:4@Y1Q;GZZ5T)]!F*0WQ/YA?VLF 7%[#_*P]#IO\[],8W;!4?L
M\_WT6;^R_A/RXTU05!#Y\-/%K<(Z_II8\/KF:&"BM2SKWL+Z;^[?R'SP4GW0
M6%I]7KEQ_*&9JKD.)EK+U.$AF$ZV_4'WV5%*%/)=2R$. 7"_#2M3B0;VW ..
M?[7?>AVTDD',BP=Q]&A_0OT?;.C'VY6\'+ $G+W=3EF_.2XI3] 3-M;S-2\R
MT^H>*Y$@188$EY2K/OAX-MFYT*TLW!4GZP&M],1]D'WR7T<N1G\1;+5\ZC]O
M-A7@;2"1"EJ $:.T/D]VS-=,D I4$DWY4IN?.Q!ZGKCI*X >ZD</B?SK?@IU
M4T]-/TFCZ,/!2K9LI=/<S)Q*S95:7PZX+9+9Y3,SCQ1S:ZJ#E6F-LI473!CR
M2:I6Y"04QJ3$F.*MX8YBD+M&<#G^5S21Z$'HT/>CAPH3'SI4AFSC;Q+J3W$+
MCAGYY']>S5Q#K;?K%1"G%V=%+I(=<I5!A*LW%IL-IIM",% #/S>KP!*;)T^J
M !?H+=MKX*6LL%%%I#Z6F%O&Y0$JN-M+'4>=Q[C]N&K^ZK_"?@:4!R!J6KDY
MGV2N=4LS2T1G)#<J?43$?1,3&0IM$JQ9F-%P@K*DV2%(OH-;8X?V,2-JV#M+
M%S1M&. <XQ5N_'4MGPK:5ALD08 (/$ ,>+ F X=J2LI3%4NA!QR#&C*NLA45
MU"22J]_JV%SKS'J>VHQ%[*;*.T_:#%P2 0E94U_NF[1,0. %[U<3%W07@3Y"
MYEH^<:U7_BAG+PQ+)?40>;F)4"=.86O8:]-Q?J=<?3O8FS8B2A(2VZ D."(
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MXD#B;\"=1:["J2\K_+IQ^O*F3+4VIRRD@C4&]^M[7Z7'>YVP_#SRLUGCY6J
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M/,1;37PG*LOHP_W1\Q^>$WQH?+ZTVMB8*VSJ--SU^V^G3KAP4"]XUZTKZB;
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M>-]!B$EI"Y:5EPGE'UR/:6%#6Y%]R;G%C&/= E!*8>"PX:.2\WUDFK>)N 0
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M6YPQ>(4_O6SS$CU(TTBRD.Q/$AB<R_C<%[C5C70KT+6:2RWQ&2CUIXWRAS.
MV!M_.@"P5;8WV[]\8O:&/B'N@5J+=Y8.S[F@O%0XQ'N@9;W2U?HJ8\TKD*&"
MBA@HH'8X**HCZ<_"K)F?>"69I%2E-97S51G(U9R;FV&TANL4O--,?3)H[D=]
MHH??:7)0A+C/.0M"E)*3?3)[<[9P^P.S-JV[&(2G#PE$ Z@.")$@L3/PKI?9
M?9-I[8[0P-@P0O$&*L(6G((,/8@-,V(\:BS@#Z5?%+,M9X;9(SK1LONS:E$I
MU(KE8A.32_(J<:"&Y,TM/.\J%3'6E2'$A-D*6I(%K7\;]C?TN8'M'VVOLX$$
M.0![Q<A13#XA\&C( O7H?M?^C8^SG9YV]2BIP5W2 "H!6219P&N>3TG\7TL9
MI_E3O18RW-9\2/P]X"<8>(<1-BM"*I7*C0LMLO\ *;A+J&X[X2L:A*UB^I&/
M>A(!UKQ?-O'Y>/RKJ@!8 =@!\L%%>X**&"BM71'O/WC##]]/+ZTBK'D?A59O
M21E'^:$6*IF4ZAZJ%+C,=0;D -"[<UAPM/$(CJ/,4@ E.FV@XKVW)&Q832-]
M+C,>\)GP;SJ]L9]XP_\ 0OPM,YUSSJ)]8S#":4Y.FB/8ER*M27HX ^M)LU'#
MFVH W]V#MG"?%V,Q_880(D_N):3:+&S=*5/[W!1.NGSSCY&/>)*@E/,I+@(:
M600HW5J;*(OH;VN;;W[X]^]B<-MAPFB$N_(.8_*L/M&',S()EI8<B7RROG7/
MG.BBN5**B3J2+ZD:BWW_ *L,>K;.'9^(Z>\6K&Q+JY?*H)JVY/6Q'P&-S9P-
MWDS=1-4<0R.3^)IK/H20=.GWD_GB:Q;BW_*]3&"(R'F _K*]Z;<N*D"X%OG[
M^X_6UKXD2HB S/ZGZV;2DL?1'KJW4T0\)?;[#^6)KT5I+:3]9(/OQ+OI-P?
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MM/==;#H8?<2'2G?V%$@&_O)&V..VS]*79&SJW3BH#&7!\?O9',9<:V,'LK>
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MO=^$L,Z5A!<."3#]8?.-8M<4H47+KD-Q4&8^JF07%-I2X[XI<<6E23RD<H2
MK;:UC<Z:89WA.A^''-WD</&E,M;/CJSCH_!F%ZO-Z*KU-ITCB)&@J\=M!RIS
MJ2I1LY_E(% \O+O:^HOBOCXA)2Q, W:78O;CH*K;02R-T?BLPTU!&MOF*^[W
M'.UQ-#!10WP446,5C0EL**4D &Y&I)O:^JKGZWUAT."BN(U6X/>DSEOT[)?&
MZ@\,WI-$JF9XM&KM>4[2G:10^'7J9@-UJA#UI%9J]>E)>=C3:$MI,:&A0G(Y
ME)N563B )7( 8"W7G3<-(PC[@9W<P;S+W?U!J5N-.0?27B^DWF#.G">'GN/3
M<P4C(U.I,RFU/+C.0GW(-5"\P)SJQ.2[5'8S=,4_ZL8084M]320I9N,-0D8;
M[@9^M^;TJWQ(7(/$A^@8,XX_1.A9-]-MJM4^LQ:Q5:5'RU!H*H>587T$SE[,
M%3J'$"M,YC_G CU!,I;$'*+M/EI1$=9*>713CG."LDE_'\F^= #0+, V46J*
M,L<,/35J?'C*G$#,M-SC-E0*-D^A9NJ>9IN6*GEN.^SQ$JM2S9#R)!I[*Y<?
M+2LM.P%P9<KG4J4%A$DK24X/6L]/7$"PVLVX',3Y\#,5LEU+TV>%W#S*%3XE
M\1<W&%F$\(WN)$Y^IY5AYQH]:JAXKQL]93X:NNQFJ6S.;?B\-YZX$SUMTP/I
MQ<)Q]UU*6CUIZX_G2%\G:Q8.WYZ1J<HOCZ"6>L^\1/1PRGFOB/)S!5LP5.IY
ML6U4LPNTQVKS*.QF>H(R_*E/4ODI\EV51S$2Y)@E3'(E2B0-RG \-=>FGK45
M=&Y(!.X2"+ZD'FMOUL-,5U)"\8!4A$I&A*1(IPA);,L>352GTDG.7,U%2U-$
M>0JDOH0W(CO283@4\D?M4LL/ELD%0"@$J%]#;'#[5^V]LMD[P;XP(PG'W'P5
MONEQ)B]I,,*N8<I$@$AW/,M9C=[7/*J=1E.*KM32Y->;*([A3'1%<9C$K]E2
M@N1'8-CTUT%MB1?37^V[1PQB^^!B) &B07:)(CF;WI,;W$NF'(>=1H02,H.6
MEJAGB,M21)\1M2!ZL=4JN" +BP!.@U-NH\@,?2'LYAHPM@P>[2$^ZFSAR0<S
M+DZYWBN7V[WE3K#9"^;YCT7%4=S-[3SA-SRD@7TT.FOP.._P26 /X02)O&LU
MG"-T"Q*CEE:W*HHFI <4 + %1^(_6N+>&XMSZN1\A31+OD"1PM\HX94BO[V_
M6P_/$P6H D%BX&6;_05&JQ/7K9_"B3+(ER8T8:*>DML7L20'%!-[#M>]@;G;
M#2M69F3;2[ZWI;<@(^#7)+\O$U..>/1SS%07J+%HJY&89E4J%0IH@(I\N)40
M:5#B3G9P8EH;"Z:IE];;DT'P0\PZ HW QC8';Z%+(4@A( DON J44L%)!!5&
MN89W-.W$W(?J08SFX.<&Q=FF*'."_$!]<Z,SE:H-S(T]-)+$@!MU=14_&B(A
MQ8[X:4](6]-9Y5I4I!/+;3&U@]L[&4[RDI "2HJ=3;K$E3Y  &8 &9INX(9#
MD$@#-P+6$GF^39TWH_"W.TR"Y.:RW+;C,T\U>1(=!82S&":@(["D2O"(?ELT
MRHRDHW*6&2D*2K5OZZP78H!B+@D0Y#!RQ(?G)#BG:PS'GGG=G>UB!)>"Z:]P
M$S+!S!4Z+EUJ7F!%,JF9(,IYR(Y#99:RW/:HKKZIRSX(3(G3J<JXN.9](!L0
M"B.W\%>&A:D[JEI20ERX*D[^ZW[Q !FT&2'IR@ 2 Y8D.T06)?3*PE@9IKM\
M)>("H-1J)RO/9ATL5'U\N-+CO-N4U3XF>$PY:2MB*^V[%4YX5OV&IOBX.TME
M6P"AO**0D[T>\S/F5$%V"2[]:9N!C[MGAC)=C!#"PTL;5'_M*'LMZC0@#6YZ
M:@:Z[;GWXL#$WF(^ZSVNW1Y\J9NI+QX%R/#/QE[TX\NY9J^9JG%I%'AO2Y<@
MA+<=*%*=)4>4<_+H!V'7KKBCMFW['A;,O;CNX6'@A14ARG>*7)<$;T-.Z'EW
M:0[9\'%6KWG4EWW?X= YA^8(MPKJ;P<]%;)W#ZGQ<P<59D1-:=C1Y=/H\MM:
M6UK7[1CDE(/,JZ1J!8WOK:W@OM#^E;#[0Q]H[-[%Q%;'CX>^%XR7+E(EAB80
M01!>23+%Q/2[-L6 4I?"2\/<:W (8L;0[DD!JL*[Q2^BV"SE&@P\M08DT4Z<
MT\AIWF96-)2/#0'(Z>0%25+.W:^/%=J[>[4QE8@VC;5XH*EDON!W,Y7X<;VK
M=&R;&D#N\ !;@05.#KH <\B.34RY>>JY-:=4O-,Z8J!44"-]'MN20U2UKYEJ
M:<;0"M0'L645:Z7..>Q]JV3$63M"0LF^\I08\6,!Q>>+4#9-H<=TX2[C=#M\
MSQN>IK,YRS%#,Y<2MUEDRJG'GQW9C;K+=.BI"BM]\K04\ZA:R-MML18>+L 4
M.Z0D$& DK@GF3GX<*M'9\=()6Z@P?>$<8($.=>8I^4[B]F!$:LO+$6OT]R2U
M%@1@D+G/K*@MPEEQ!38M(0![-N5]1Z#&YLO:NV[/N_9]I5A,00V[#%P9>V4Z
M546G"2KWL,9:BX&C6YY'C1+//"+@SQVC5QIN+&RSFR*B&M2(Z&6G&WWDCQ&'
MR.5M14LV(0"1RZZBV/3>P?;GM39L3#3M^WXF(@;H924@<)"7MF[SI65M/9^S
M@J4G" >U^;@"&+YB]KURWXH<%<U>C]G:,:]1DU>E1)XD,%U+GJ=7BD B')<1
MH@#?12=.O0?0/8?M'@=J[-NIQ=TKPV"Q!2HAGE+ AXAG+-7.;1@8N&O]F+&V
MN=SE(M%(G$KCGQ/XOS4+SAF*?-@QS'ATZ@0G'(.7*/38K;34=B+ ;#44!MMA
MIM*BUS<B CFY;C%O8O9WL_LT[^Q;,C!7'OI<J)$NHDDDN7B Y(NU4$[1M>(?
M?Q%*&]H&8-:""# %@1/&HV983SA2D@*2HK%A[)4="2D62K0]1;ITQM;Z@G=Q
M%;S,-+ YVC\JG&#A+E: J7S$Q,9O/'/*C5EG3OITMVQ7*U.6,90*D 3 ;A"A
MY,I_)ZV",D;)0/\ M?QP!2A8D4N[A\/'\ZVH;4@CE*1J#]8&_P \&^K,^0^E
M!W,V+#7(=:5 =MOB!]NF$"C$DCF;>-,>6AGT%GY490A*@?9%]+:=3?Y_+$XW
M0 S\9?P-)G.1F (Y#.MZ(ZDVY4\M[7MRC^/XX"A%WRLQ\(A^-/= !:">=Q(\
M^E'HY*20#8:?<?RQ15!('URXTJ@ F(:W4TI)6I(N"02!>W73^)Q(E(($20,\
M_P"O2E(#2(#GCJ9K/D;4-;BV^EA?WW)M]O<;8<=D7<8CQ'NAO_$W4"J@VS +
M-@@&Q(?,YAKQ8'XUJ]4%]B1UU(^\ _('ROB)6RK2'&/8.7 /*RC?C4Z=HPBW
M[+Q</Y#P?R>CB8]C<)M;6UE:V^ OUZ;:W%L5L/M"P*3;14<;68'3.*AVG&P1
M_98;%\@3'(=3?3IXZVH VTU&Q^&EQ<ZWZV.FFFMM.UH4&*3Q+%I;@?!OR=LJ
ML/$!*TI,&X81RTU8\7#444R2M+=@I>I)( W/R^(T]PQ7VW&"<?"1AI#,"LAV
MN&=A< :EN-*G%!5 9+V<W L3=O'SJT/HBRZ53N/>49E:1#72H[-0<J/KR6U1
MTHB177D+Y7+HNDM@HTOS#0WQS?M>O:5=GJPMC*D*Q0Q[L$%B0EB6?/(R')M5
M[!Q,!)"MT.)<D@N[F( R#ZP!3.](7B##XF<7,X9HI4%B!2GI[T.$B.VVA+L6
M,?"]:/(@?M)!257N5<NM]3B7V7V?:=DV?"P,3$64A("@=1=GF[Q.8JOB*[Q1
M*I<J(S'\-LQ\WL:A)X+;2"-"!;S(Z"VN_P!ORQTVTJP<%0*  M9=^9(/QZ"H
MTI2'*0SN6:-"23#7RFVAK)EYQ:1=7* ;V(WL;VL1MIVTZZ80 &_N\98/\M-9
MS(9R&W@X?*+^F>CPGH6KD'U1OM8][[[]+_(8:0DAI=X:W#0OT$^-7DDW;1WR
MD<P+:^=(U6DH= 2 /9)L.GP['87Z?*S5I2&W;EF\'+O=P[ZV(JPF7<-D#J2;
MWY\" -:7*?D:F2X*)$Y2P]/;Y8W*\FZ'+"ZTI)L>VH.NU\4EXBDJ9)(9W8Y&
M1S+-?0F!-7</"0H.4.6&I&?',:RP+D,];J)E_P#FA1LQSY5BX'U,,.$6*VK&
MR4][?;IK<7PAQDKQT)4?=+0W!P)YBS3TI<5(2$D!CG&FZ'S$&&D3PH[Z+F3&
M\Z\;\NHEM"5%I?K]=G!U%VPFFM+DQ@NP_P#.%R(T8$G7D3;VCBC[1[7]CV-2
M<#]DK$!PSN@N0MD_O6N<A<M K0V0!>Z5 $03?4%[O8..(+S%5Z_E%,_.\3O2
M#S%2H\U(I/"ZE4O+BD>(DMJJ;Q,BJED:!2T2*G#8=O=1\%8-N2PM>PFP#8MA
MWT(*3C;RD@?A()$9.D/E)F8/587N$@0S F1!W1>UYY7KG]Q!9I\7,%0RSE62
MY4*:PJ"R"">275H=);9F*(NH\OK0==!"B/$*K"YU[38]H*E/M+=X=YP89)42
MD0\A) +,7\[FXE<D;QB2Y<AK'/YU7S-%4,M,:*IKP&XB/"3866XX+W4L6N%:
M6-^N.@P</#2'2 Y8].&HZ7I,4[HAP/'* 6 X\*ARM2 DFRK"QOKJ0 ;[[C?7
MKON,8_:6,I(4D%G?-[@VZ>!XU45B+ +*FXT.3NW1^0S J**JI"U%20-;DD$W
MMY=.O6P[#'*8J]X$9RT9OF<]'%4CBK5<F+6.?T\(M:F?/<3]4=CYFQOT_P =
MM.F,[%2@A15H>$LT!P\Y%M&:F&1,PVI;H7?2.5A3+FE06;'7H;7.MA[]NGRQ
MF!2K.9ZGZ^%-L!T'P%)X2[S!1(^S0'>VF%WC^(>!_P M+1QJ.#J1<G;36_N_
M+[]HUEGW8MZ%W_JSM*X:%+,O:T>=F?1XL[TM1(I5RWN=KWT._;N+_H[4E8JP
M6WB);A?*#_2Y$5<1@I+ I$&\N6F^I8\@P)>G-$B$6LG6X(TN0!\1^M!A^)ND
M$,.CZWF=3SEKM:W$M(;QDM$WTX3E#KK"%$ZC0$:6%_G\>]_+&?B%(+@,;B;
M9GUUBFE R&NOS/327T=[T6(F/'E32PEU*&@GD(*K+5IS $$ W(T^.F*J\;%(
M)WC'"U_4Z&]5]U1>8+P<GMK(_H:6H%-<ENLM-H47EV"DH3S;Z7.UAU-NA&^@
MQ57M*$)6%N5;J@#!8[IE^!GQ;.AG ! >S3,L7O=S,W>'J7&2&)U'@E"$3*2J
M+,:?2M#:E+BNH>2E;A3S)02@"YN$C4;7QSN.5XZ#O'>#.0;:">'G<N:FP<!
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M'(@5)3;R5 !*?8VU!&.&Q2WMGAPS;NK']@HOEJ>'%JN('N@,0V7\PDFX#@,
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M\.0W-2WX+\_*R&G'0FX6]R)4 M23(.S]C PY<X>Z4%R"?<5AN7)>%EPXL'(
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M-"9#@)7SC4&Q40-#?&)V![9=G=I8*L;?22DJG=7JH$C]FF8X929I3L"@7(^
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M9H^#O\'/B7ION3.="T%0LI(;-O9]FXTN+$:7VL=-R+XDP4#$V_&P\0;P0 4
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M(J(4SY*G7$>$_P"$TX5M.%MO]JJ^A*N2Z]#>RBI-NEAB=RQ$<C_0M5%@"8D
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M4J"Q.0;7.7&@U+P_&&<J91CN.I>F>R0$/-\BW$^&J_,1["T@A6UE$@7TZ7]
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M"8N=.A=_A5U/18D.T697J<\4OM3(O.E"EJ'MM)*E*"@H&^@L+@#>PMCA/;M
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MJ.<U)BI80M>7E)Y&TJ+A(KI4M5T**22=M!O88KH4 5=,QQU(]7RJGMH2.[D
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MJHTMH$EE:CZXLJEK()(]67>Y6!:]^MS;3&SLW_OKL3,?:=I8"Q!PU93>0!D
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M:78AIDQ>2\BV3Q$6U>!<:CS/.! )-2A2>&S[\.FLJJ<!4NI+2B,R%N/K4\;
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M,L0Q>3?EPDOSZ:9;;:0@#E2AL-CR2 FPWN=1;SMIOCZ2QRR4[,H?LP$!@\A
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MM&C2X^6 9*F9P9947&$J0@H4XXPHGPU*22@7"3:^.P]G/93%]H,486$DJ&\
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M[9V":[UM:DE*$)]!/B6DR"+-N;Q^NQ;R9[NI\SM6ZMA9&0BZ__E>V$S_0S1
MN:<#:C!W4A"X):6OA&MJ:+I0DD& VVAS@77(E!+:+&\C>T18%#BQ^D#Y>N7(
M.:S%AXK >,/X#R#"79I*S4$15DF0A+ WG.L8?5.<JJ^;&@8)R8?-40$UO;K3
MM)&?=*</CJC(]3<*#.;NI?$/A]8H 5+ 9Z2&?LZ>F.@&8W\5#5&9B82+AVS.
MD3*0'^GUT(.Z-1LSP].MC?. (0E?%O1\NIT^>7Q $8U$T18Z1 <F]:9[<6(?
MNE ^W3EX+NW[O9+#WHV25KV+@6<9N8N-LAKZO6'[C>.%HGFL$ /U"SAF9M.
M8WOKO[NDT-S-K;LB4CDSIH3*S6:Q^P58E-K 91UF9W9#]LQ^%? A=QR <>TN
M.FWV.\<?Y'C",7F@5R:0IAYG$O2?%L9/ <IYG)W8FIU>]2!XU-?5?R8<I'%\
MK4Z1XDLD>\X5?R4XWN;;*/7J]]6RP&;/<0HO7SQWQHV;GPT7LM2=3ZYX!ATQ
M<0I!W"AA\D<F"< ,[NL A\_2+YU0U_N4"0Y\J9;>G8G7V%:F3_MPGU8:W9*2
MZN?J5 C1#MZ];LB*0_/GCPYB]0YF1T?50L_&0_2R:<]B1U_WK,A=*S^4NS?J
MT*;MKN&:9G_2]]TF.I6S,^"=)3/GJQ7V27H+4M(, FWB"8 '_IHFC9#?S+OK
M3QN8]KQZ@VQP8YC9F7\6Y$Y].$69F-,RA0-?9F8H8V:([?V*EG1++"4,+%:R
M_0A&'9/;%\XE+N26:L***;5AQA/SL*$?V8!%\6T=/IGZO%,W>)'0Q*577Z^3
MV@$ /)Z5S*%V0[N>0LYPL^&IN^!(U-IV)#UE-BJZ)EN7<LI5 HBC790L;^ _
M ')?I%%:>;6\ R &%[:;YA_@I.;(",3[8//G[7\?7_E?9UBD$$^P\1-]M@],
MN5],R9-#J0(].C(Q;?\!E(.H;.A,)R^GE@O!M(./E>'IF<1TNM;5K9!5)/_!
M']_RDDDJ,Z/71(.K?Z$8^ZB&;C\Y;Y"CCEJ235W"?X](TG+_J;E7=HUGVK\K
M(,_6$ALQW:;\*Q<Y)'R)GW+YEW_B3B%E_LEAG&,3MYZF;&HJ%I\RJ50RDVN,
M@$5?[Q6Z1?-4@S7(<+Z3(ZPXE Y1I4];#NU<7'0+P&?=YF'3$I9<!I0&@VEH
M,Q/V1@@CB5=,\%20MVO8R(X)/*G51\F20]#4*Y*U&+EP>%;4[=Q["GT;,*W7
MFF-+B<0\HVG[Z+<074VR%P.2BP.ABK,2CA5-GZ* //GI YB]4[U>W'4 P*-F
MPZ  )*\C<6I<'-,'>7T9/XAKI/7R2*#<TA+NQNEQAJ826(Q)2>!$S!,56.'4
M'Y4,=4QDY[L"(RIPT<S#*D^)DAEBQ ,CW&:8T0Z1CX?Q*SB>).@K3W^'XVF=
MW3&[6?Z/1?Y>0)DGL7,!;)D6WVP"-@-K^M;_/)],0[*MDB'P(3O^!RLOUF$I
M^U_\R4S2@Q=!.(3H,N?"?OQU<&1RK10[M1N/&\ ;7C17(?^D8^N- :_5'K8)
MLONJP&RXFMISUKW.OD#+2.5)S -E-S^2UU!+ @J3I_@9A"[BBX1+C["?!;_$
MJ,9%CFM8W^*:_68>I\):/_RLW]37\',-&&:^2K1LO.XMKMB%YRYW,M H^V_<
M=.-V<M;<0'LWR3JE@K<)"59B+[;_9T6([)T:84]DLJ9*6D-QRMA+Z51,:!SL
M9V7DWFZBVF!BDGT(!_.7BR22<SX!S'(Q5S6N!D&@3^;7_12P75#01E:G=NC]
MH>1:B(!R#4&&K)##9,451(= 39G6.%S8EE]T_P,PBL;FHJ-*@7:<02EEX3Q!
MLN7B0!BV.[;^IQK[XB9A*_6G'>R.(<>_&I\D \6\E(#>GW^Y3F>U,>VKG/T^
MI$5Y7A<\,*AJO$2,U,LK@R*P 7[=PIZ>J@KP))?!=_#I6*+&V_ZZ$ZLXJ[G,
M)B^Y.?1QGX<C[]CWOZHZ.R-N_8M]RG&(FMMC_\XYM&!2,CQ'CZ!SPXRG=0Y.
M6>W=<YU<B6@-M(B$_S7Z+Z55^*K^4(.D486VX;IQP\MC,:[@\G6NAUY@"$(U
M%8)R +J06ISGXA92>E'><O_<<&W2QR8,]9K,7[DD2<5>;*JC3*SY*:VAC]"V
M]Q*Q(!=1I:3= &32,96SN&"6<G^7.0EK[T%/+\\V"O]K(I%HT#WWNNN&OO4/
MD*[NX1_\UP8?3CM6^$HP\OUM+TI5Y2?%/@++-DQ\*&? X"J00(WJ7ICF1 =K
MPQ@]M?#O$X4<=PO!>,R(>T8F+^O;?$CP@+(GWBG=%J3>0E[0LIU;J[0J-;=L
MW%'.UT,>HT!:(EXYYZ)D5)$]44ER[)&/2DRQ![5UE&+H2!-M<\-Q+J0XK^S9
M)!V!2@J" 05(89)Q(Q53@W"D7OX8UNT!5UWT;*&P)%*"MXY^97WH3#9^K&4:
M:")RC[^ZH_QL2)&(4G=@CI:W'G=%)$:+5*WB;V&X<+)FQB%2 ]518#QQ3ZH'
M;E]!W:$]";/"DJPS[*CI@^34!!K+P]N3&Z(R?VCA:W:$(6.+Z_>E(KC] FVW
MFDT72E\F0Z0JF7QR?D&++J_,KK[:R Y]AML1-80I#86Y.Z<]+^9'P!NY@41]
M.3.7[,MM+IN*['OW>8/V>!KS6-0Q#[YU,P"+NQ<M];PE(Y$0XS8YZ?[4*P;<
M M3/U*H!]+6PL?!IX(VXG+%^+>JMYJ*$% R!E"((T$1HW0G*F5F& 5.7*'OM
MW0I,1W_YZ*%M7"P/2X'Y9+:M=_,;);A]'R;<B52C:-OHKXD4%^/TA?7O[ATF
M\B ))1"]2JNSMQJ6-OGSD6#+:JS;O7WN>OQ*>C&ODHY/7H0CA2 C.UQ,4K:[
MGN'4VE9N&/Q8F$IM8J?<W?<;>)>;&\#1OO9)I?-'.)6LN\0NCI%K>QZT6G*5
MSY]B4DI4>V-X@;_C:VR.<]W%X%!H,$JSC-=.@FW,E+. X3QW*+  T5T>?G(0
MY4/05M<. TNX/JL^?@ \8'(W7"='&'2YZ1)DEG[^DVS "IY8\G9+!$:0+M_
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M5W=^I6B^)F.!H"*U7"7UUPCYH.AJ*-GN=U]_"!T<)<BI,,,]K2N[@FD6H95
M1;]'8M*0V*TZQ F&1[) Y; +FV-A2HGPN\FP,?N^CMOH'JTCD;TM0\[(.B Z
MJ6?ZLW1-V[^RU@DSS*-[(03$$ 1/3OAYBN+)UAB9S-B _#4=FS+8$@WWS^R0
MUO>S)OP)9"];ZQ3.9@,=543ZNWE$&::11HB#R898WDCUGM_0ETWS5+P4__VY
M!H^N[R-RXH&*V]?DSAG3KV[DQKN?S(44K++YGON"W[@C-4MG"97GF#CC+76Q
M4,=3,S$"'0O$FE=3/%>'8$/9TZ_[=58#UEP9'1CQF[E1I.!-\<*O5Q$LNQO@
M0A1^)?*&?SW/MB0W%J90<?XPEPYX43]/4@O;#RI2=$.F%VG6S/K.]0J]B&F2
M-\+;55!SQ08=,.'R19\M.<WZSUU#"RT$.CUA9EJ6+%B,+V!S4D$XKEI5YZ]7
M\Q\"]<!SHL4,)-*2I81,'8"U656U]R6+BQG!UHDGX3L$6>#F=+^M>E;^61+Z
M'Z"1>J>O_,4HU)?H8.'W>-G__GWP?Z'IFZ^FG=L[O^]+-$8=:#+U-9[?5.(;
M<@,)B7CF6A!NIM3O(3(//]CA-DA>RA830\(]I8LVD2@.)9B+YEN'Q!>S2\\Q
MLAU42<16$*D87M-?-W9$6'F8-+;3[S0NA,YEFJ3F\UAE"P;P&M^+U&R80GCS
MU.BFZ6-1;;#I&)AJTN/ 9GYFD^]\C1[=H^Y!#NU=Q=A>N"$(CNC!K0>ZO!8A
M"2L)PT^^,,T-3%CZ9.RTJ@9,4W2/4IQI-$4Z-CR"@UM^5#>ND&)D.\7 $?4W
MX9'K#@$L'+^' 2@W;G&H;).F2J79V!?RW1EDYU&0$'V'E2R(SOFJY)F\CQN[
MC0!9&],%'+1N1")FEQ[L@>8_EW=(F!P3X1 P(7<2.>W"Y/Z6&ZOU:P**N1/:
M#M,';?M3K+M+.37<_A)%!B H,/CP-8MP<BB6+WN#A8^CG[V$,X1V$P-J4QN,
ML.\^'!*08DCU$GTNZK)0]9T4XZQA="$:I<MFU!89YYA?/]ONRRM4B'IM@B37
MYK#KNH) KM?[G3TW87A_%(ZP$=FKR8]\EZ,_)*E(#)-8*GU*.UK=$F=Z;9@;
M5R(Y2/9HDD_ORB<AK.@44M;]F21&2 P6"=!RXY@F5^>%_IW6RX->>T7I/O*)
M4P%3#TQ\0^4;I5).86#=5]>"Z_8J.U?8KWD7X(.Z7KO41;08F?ZLR[Q$X[]F
M]Y70BZ(K>:<BC+0)?$B0H.4\3B',6;>F-Q-$QHPV=+NS.(^U@S_> R,DV_\
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M[^0I#KR6F4XK,*^60>*E+VLZ?^R,1I*B_#>K$V=W!?@BD.0YD?,2:) !0UJ
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MJ;-+*1-LUYZ:#9=0,BB$&N6V-Y"B?;KY9 ]KLE'[)=X4&L\;;+* 8AC\+UL
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M4DY(O>!RXH%R]HTM.ZO8\+1]7>>WMW%A/A+K1L17KU7 24>/>*-_  1^4Q>
M6N6SJN408RT'!O9*O<@(+T)_W%_52E6SLI>CD11<1#,Q^,2VQ02,\?<CD@&N
MQ@444[!J.Q,Q[ V&)GMFX#DC!NP<X^" 9V.6!Z26E&D#;!,6<2:/8ANB,V2?
M Q5(O>)XXE:B"+)772^T:P".-LKIFC(_38\QQ!F.]+F3 )G6/<#"SK,&[T:X
M!1VBJ7L:(8EW-7QW0X<35_&07_Q(K)-F3YB,LEN5.:W*;/0']T$N(X.-"C"]
MS%HV:F?DC+]/SQYK-*R9_$>@&J[^*14K^?T;[K&3>X]>87*R- %9#?K!46?W
MSP8 A!WOP1G M]-JNF"Q6FCT_;$_CV;,:V1C; ,Y.PZN]1] :A[I5Q<<!' C
M$>Z1V!.)9@'>&1+*V8*E8)Y6D%SGHF)3(]H1\C%1<51\R^=ES)Q14)#D!:BI
M<_.EZ O#ZS5*SBZV<\+X4=IY8%)G_-A36$0>2J=.C#%5\NW8.]6U]?%AQ'Q_
M?]<0?O</T)6R:,N ;WDKC64.%3A?-?L8'HY=A]+[I5;&Q4M$YE?+WVTITSF:
M_P]@Z>S3G16(@)8WC@PAA5DY.CD6Y_1(4J\=C1V\]+,=/<TSDH9$&*.U]86P
M5V:8[\J+ C+NTCZ<52]_[#-;06]XA'DU"%5G"3\&NWD)J)V=0'&60);/-\5K
M2>]Z#%3W"83# @<UPLAMCQY&'EK,USXFLG<1Y ^)M0O^[!;T\):2MS#J.-(B
MRRZ@1H](SGD@$%[6W[AM;>UH.[\$517Z7\*E3PNOBSO!4#6"P)X)Q=Z\G8X0
M_@&\997A[J[8.R]=BL@W0 LV$?B1)\/*GLC,Y)LJ&H(\1X>G&'O:A#%_V!!G
MBE1T>10H395AO=G&TVB;EML<3'7T,&RV=/0<H\%$%F45OK;J5[%:N@4V@AQA
M0W+!G+)ZXXVZEI_2N?<5)WE*Z,S?T53M5+$VU>&M;=-XY"N)N4A9V^F 0-F<
M3HIV@=*U7)>OYK68:X&"_F&W*KZI'4!7UBU-Z^P@L:!H;05&%U M61P@L9VU
M02332"7&R'0,V'N6.P@7JWB7-R6]6C<G8"4PE)0%=H4)C$;&JFT90:2YG*,+
M5TR*AJV&@PX,!J7'?OWN+8EIM),R'!>\*'"=A@+_*!&=JR"W?'?3*XC:I: 0
MQL"P^YF/GY[/./<T6@L2J32-3E;!]8C?>G?UNM]1:FN52@W.0BMKE!%S+A8X
MD%1UQT9TT:1.25 ;&,,9C):55H''0D8(OIK1VO_+T;'+_P]0N32?)]I*+5PE
M2_V<YJP0"4!7&%C3\<]^,]'"\9ET(@_Y4S%>+T4+2W\PA]_;SV?-RJM*:ZH(
M+ :##'%6N/+ N\F#:GC;"><E#N</+WSL\-G4EHKP[U>Y?]/DF.4@_&V*F=A]
M P=(.JYLY.(>&1]T+LF$NCFXG[G?<S E";+=9<9)SWK_NV3#4-GI#$:E9(G.
M4/9W==R'P!WGU+T2^=9C:AW_-B7S4IDZ$"&9QZ",04H4")!N[!1*V(VE!Q[Z
M"-'YJXUMJYG#9 ?R\U?YXZ8"H3.X\&RZNCZ%M+5_3P8E]4M6S6\IL3U6$>:!
MIQ^Q"[ 6[R4"4ZOYK.!I ->5G8(617UK)9&07^*!3%4Q8!;[LF); )D30S.V
M$C#%C@<K^J($=:<1SB%I-S"JO)5-B1^6=C[:+P"B>!;.D)MT)I>\!]X\Q=+&
M"N($]WNG!B(".>9&BXIVMN7R8A)D!O3R1DK^"TP1.80FQ!*#]417_K:%F$,4
M?);9B8,]PE\\> 00'%;$77;.;X.)=E,D!P946G[(8Q5M*0Y0)+3@0R<#J*57
M=N4OH/J,,7/RBM"=X8*"7&67V1OM%VPR3B%>)V'^HE:"Y!:BI#Y:VK7<A!$@
MGIO2B.J]F3^; YBKK!6-#.D^.9BCQWE9PC#.6NT0;\ZKMHM5\L$3,STL^4?#
M,H+K_E0N,U2TK?2SETC_"DPAA+ @X:?*"*LG"NK<<G2W>.G,/>^%$&\ZMXV4
M"\NOG/!V':NP<>4DDB?:/QNBM>VVR9@PX7"P"@V%,-EK<SIMT4?CBBS85 ,*
M,DU7EV/*%!,LM;/9?U(,RO2TUD-(CWIJ1ZPYJ$^JKRQ&6:J_[/1_</YT*M[#
M?)?W5[Z3>(/X_09R#:E@I&:\@!&#2#)*;6=+7?TS/#(D!P% G3GJ2'Q8?%L/
MJLS.($W^F%$GB&Q1(_ WSD=+.O!TH*&PY[,(.I9IO%M@5YS<Q71BP ;''X3T
M.O> ?JXFU6V12>]^1,G,;0:T:L<#U''\>A9;IBV3+</T^<*0M[Y8C$O1>1SL
M&(K:G2)L;5\;RHGVB1+((#+[W-(V@J0Z.LEZ??X!WIQG48:N:T +SP*R/?^C
M_?2_T<-'Y#0HH9(@7:WT)B-119H;);%6!B@:96&!%Z8!"PLC:5<U]DHL](JO
MT.L@_#.L_-Q@,D+1.#GL;"LPQ'A"$,.NU=J65M<NXV@/.S?&"^M.-5;]!5F.
M9>F=7Q$BDSP]:9>>(^P&#?IN#"77#):AI=K@W7IJW[#9OKZ""E[3WZ>7%,[B
MFO**3C4D0T4O5,R(PY=">,J6F[T7C<D=SH)$K0M446Q?''%[. <1[E[5+_;8
M$FN($(N@08\/1NZ]10]O.J:$8Y8>R4#.W"--280[J?-QCI*<!JL\R1SWM2W'
M*7[O^SF=?4"S-L$GEH$G$L/NX0\/N^VMQ":K%6,>Z;OX2ZTF/R&IF=1"&(+Q
M)GOKYFS\ Q!UM[&+1JJRPP 0QL<2 ^6#$<X^]5^P&89R$GZKVN?8]/5ZVP:$
M9Z8:4Y_6B^XT_"5-C*-:.36(M3R?'Y.=)-<3MW0HJ[/C0WOOR\Q%)^?>^P[C
M<F(69I[G9/*7JB%B+X#SZ_L'F(;Q&OXV?]A%F@SC<O7'.!":U1X;^G@:O3>:
M4/VLD8H5ZDG(_+QKF;W/%.P"Y5-_O_M;#7M@5&25=['*^':^KGX;;?G>+6 @
MYRIR.GRRKS*\./>\;O>IUXGP#SWC$KZC\[EOK+8;N&-8PV# AD;9HWWA\:4;
MU;0IH]8=@V\.#PL*R3?0N6Y,%973,11 .5%X;]YJP<O5YOC/E 8C%P;;*\35
M-8WCM3[[_XDM3@V3*]WBVSPV/]1S']_ XX3%NQK,#4?%69O7>54KD)A]TRZ=
M.C"W;5>L:O=B)4SYF;XW9<P;T"BGQ&76<WTEPTG[=AAZW3?T'-+T#V"SCA,M
M0N6G=X+;5)K!U",\?3Q?L_XAMQZ_(CVL@7   *,9W>8;# I,I%1X&ZA;H8])
ML[E624FLGHL.-W(MBB9032*L,Y2!3_+WL;IZ)'#EXLV56R-<=O\&T%S7JM42
M)XLZAF.$1A!S@5F<:FV7K:TQ-JS,!'8 OA?5WG+0IK[ELV\1'SFU96?=,>Z)
MK#7CA[RPR@GQ0R-42;"%E3@+'VW*NF)=8YY?UK\7ON*7PY7YZED &29%9PX_
M.4Q*UI&7U@LP?@I__X6B"-MXNT/R =)'YYZ@7S.6;BJE W]VE]+LK\&@R_9M
M>X,MZ1@-7M5U0#U[8Q+M^#_)-A/RC[9RY5XWV/VR2 Y+<D3DQP:X8=B6BIA6
MK&8D;JA.?S!5RMK7=U>_Q_6\G,?YXA,4D7.;D\I*A-6C<!U=JSW'-2/\( \G
M#T>\)=4;B/T=S)8M3ZY;FC(Y@PG@U;].@]AFQ!J/1GJKK_DRB9NA2$SJ+1>=
M>6'TG.2JI;<5>.*FR+O19-N:=!H)Y$"TGC=M$!=D<X+.W+:A YZK6CU$=V+1
MWFM,14<ZAJ7+)N>K%HN%B+0&+J5>*UE]"!EK#>&$H*"1[2"((!_A.!9Z@6NO
M%.;E5O("947PM34A)O,N<!ON;OF.95>,8_2GTSC)_]"JGC?(VF.V%WH?<\#:
M#8/+XD%-,$$OE/(X\RQB<K31/WO8[=E1(XP0AX$75B+GK?'/Y"%,EN.31Q)W
M6#@?C[1NDA2=.H\ZDTT8D!;U'T+2D-#:K:PQ9>*M(8G^FF*T1T?G-5%]&AMY
M88+J!1FA4=2^H]#6=<9,"/T\<CBY3@/\</J J:<''#E/+I"O.9_[S;M4@6 N
M\^(I5'*MS6\+0H'VQCC$;18G.P%YM*PCG72R. F48E7MM+CQEX%6)H:I: V9
MRY=]F9'/;6,RCO1:D= RQ!O\)ROT(="2=1F)0H+.QR'#N1^Z3@Q+SNF&J1G^
M);-+Y+"30J<=;4-2/<G0'_H+#:T^ LRM%)";/C]H0#J#ON7OP$ 9U(=[GHO/
M3=4LZT32=P'SDY_B,]OJTSRD\!Q>&]OF=$H/.T>1ECK)/('+I86$P:!1MDT9
M&>KU.4K>>HR0X+)V@A-8.\6_C^XYV& X _C"?XS+>2,)[R=??!_M+>"9X'Y_
MH4VPXZ^HS?'439(7NVI*1V20EA*(RHW()'/]SC[NW)TBB=O04236I\0B),2A
MH9%M5X\TQ>(K<81-E!%4YX3_GDAFQA(Q9SQR,K9(BN&+K"PBI%FN$_%32_;1
MS)/!_8O5VTZEZ[H6.3P^O#TR,$ <B&-D%&*5M^1SXI4]J^2=]H,*CV J+RTF
MTEX^J6< #L!&0#,N/;,>'5IO+6%?!IGRI)6Z;_L/\-Z:UOX/<'((8_6LT_1<
MK,@(GMN_I;]7<%<:H-5KN>\>OQZZV3%%+QK^TDN6M\O5YWI0,')U3U/*_F2D
M!'F&67G_*:?S\4WP O)5'GC&6__*$]_?OU;$^=C4)['T (?DLQI::>FW\3&S
M,HD+08&P$.Z+%0S -9:M7:'"N%0MY0W6IFCE+OQS)P+;A6%HYR>EW[$S<#4;
M8ZYX@RX'&/;2.5J3B^#\^51-=]VW."+XT#C]GW]4AC"@8"I%1RR>AE;X5$0I
M?$#,IMEB/ FU=RK? KU 2U?$F$<ADFIC=(NTEN0&$Z +(YWQ#F %:W'1S(P<
M&R5J49W>[KCGG<QXG*3O=",/;J6A537)@I"^>6_^#-[9&-[;)OWL2G"*?"U-
MJR.G(H9M]"(+31%T)<'I8.H8L.C)\%-"0/T'(*4SUCZ5!KK!JW<&"J*K<=E6
M&FQLRNW>C)00F:N1OXU3+XG4"6QMO/5,YL$,GTINR@H_RT!J&LBY$?K[-1'+
M8EW=3T0Y@7B!TLD8A:2SYITPBFUU061%O)=+!G&M'TUX=4S=70#?LJI0B(,#
M_S@1F0[RE,*.-;\!]Z'*#N>10*V!=[7-_SIKV"J8M(_Y%N/SL>LK[M0$ -A/
M6DE;+>L4#*512S-Q+>=#Y?T#U*$E;@3&UDFD)CFU1D&HV/G] ^#MPCIIF(:V
M)$NJ^#-A85>!1PK>%!5U=8_<S_6D*5J;CK:5;4ST/G>"'XSK=SG8YQPTOG]R
M;^\RQ5F6R7()BD7@V7CZ&W6CEX\R/$GFKR?!9!_10Z%5-<$3GU=L,3****K[
M(,$INS/"TE\1SK)!XFUX+DJZH>YDCDS91/ZJ_3!)'N PEND-SR 0-!Z)E4X-
M>NE'O _B6CV,E?9.+92WXC4?)OFRDZEA>:002O.-K!G%-J63D%52]7O9!"J$
M;ZM+R\I_#(G81!Y"0S?JW@%$]4?N B)*Y"MT=.RQ\B32L<(^=*H4XM7 [9XD
MVOC0XA@R.H?7/VJ9.A)+ ^42?SCK15%%"8&IV$5TT\ V)[$5D<259NS;T17O
M1&JU117\QK+=D[2VJY$)TTB1IE7^%85LM\0_3OO>()9:> 'O=J^;N(<MTY[^
M(?'[P%;'<N-9[ZB-6CM>TIN9<>89;'VGRW]@! J,ELDJ""4E&$:*7O_E&)O(
M&?XW$3;ED>TAO/A/5-1KKG.LV_UED@E:=OF)89-U9.X\"N:8,D67.NT:PI@U
M/G=L2W>OL6%M]6@N]2XY%H!#:0:@DY$@LP.JIEI%Q&Y@84PW9&[)W?Z'RJ6:
M#+U"#AJUT^,/10HC^EJL#=-4FM.X*%D]3J"=(9/1<6>CW5H(W@\\T0AW$1Q#
M<DJ%9J:&IW**01H-B>,1_ '\WZOF5F7 (C!%:V<4)M8I#=D@<O=CW)"V=%#Y
MABX9DF'PO%<46]5WGK7]->N?'(@ G&GESPNAQ$FK8V15D_(VT'TGD4-^Q]!F
M<*+?@# +<:9MP9$@YF)J2^!(9_\V)Q65']3&LJ8DF3)]4<<6D=?+QD#<7,?@
M!J=KZM<B/E:>I\T0NU7U*!P+I(-F,EY@Y]T9'1"A:"#(R&533R%^W#[$!83_
M+0@OS&"(-#V-]_D03!I&07PB!^U,3W5 QN6/>1"?1DYNYP<G ">08),4.QH\
MG]+:_.=ZG+'EX"<-U*8>7,M/D*S?HM%TLA<969:ACUP[-9F-@XW^WBW(Q"4:
MI^I7SYP8FI=YT_[9 ";-!OW8X@T;*._1DC+?=4.M15KVB#-],3A91!L3%E+_
ML#Y$[NU"9HR26UD&FO(E@<#5R7ROPS - O%H"PX_(G#JN:=&/^$'\E*LR^%/
M]M=%7-<"0\ZD+Z,::\8?=0VN\7GWG%&JXMU<(F@G\]J:QF0)&#5@3L2GQ@S6
M0SA@5*K50:_V'F>*NX29E;UYMGN>NX$@H0(J15]6!Z73L;R6%TR@#'&0F68@
M@\G]^=(UZ,>/8,G'F(HBKGZL8T)$XD134W$K!O=%KU$A$T%$+),J&5HZY!9;
M$8G9*=FN8*@K*7GC.ECE#*M.<_/,TP#LJH46=+A.L.M]Y]4]JTUIN_5JN\S:
MJG,4(JCRH!79?H;)KS\NSG:%#R!,EN1 3%5'!+TM"">3%$].4=?]_<I \C5T
M9]X>"_\(S@Y?KHEEW_)1Q;)L%PZ!+,5%?J42XB)5:S0Q&SOW7U2-F'GQY>^[
M"F];2BT3E#?"<%A]V4?C.JVV5SA4%LB%"^^S<\_&@L@*E" V">1N2@;<^"PG
M&B==U1/=IOUZVS"\UZ+2+Z T&"<G]@-W:7\+?S/_1U$LS'Q)S(@6R&X3@P8>
M0+N 'PSO$C ['8XD(]C$DJZO0T?WJY8&5I.3I,E/>"VEDW?7Q#^R)=QP"(Q7
MT.)QL1E_&CO=)OT\7<^X]J4D"QUO=HY_0_8?8/+;N%0S6<(F0&@>>CJ<JTD;
MH6QV\.,Y8_YL@'GZFHM@,%%FE#+@S997J$#D;V^"<L/_&*7RO]&'.L!?6=UY
MCB<I/M.,7!D.<5DQ@P@M.^-&Z"RL"EP$'I(>O..A>[N>\-G D<$\11KW_. 4
M#DRS[SZFJDA3C/#BUP9@!W$Z@;,F/HGMZ"1>+F?=T)S1^%F;C2K0^.N<_VHL
M+2P;Q_=% O\QA53K4)[Y51'YE1B_ GD+#OVW@^^C3D!2%S+H5^..%Y]N)[X@
M$U(>_4EFD'R7K:S=3+((]-0-KT,3-J'&TGIO[.C.VIW:72TB1]:L]&RYO@U"
M"WT3\I%SR.#ON[OJ]AQ#<M[C!3?(/ \8^QP"F:U+6V\#LX/\>]5\L^'.-N4Q
M6QL$E%N8$['A<WRX5E%U;O>^;&L8Q3XQ^Y=-AP!AN0R4U!2F^?T!P9:?C<3!
MNG"&WRB%V*_L!H8V%1?_  GC>D\@9!B?3Y4<[L,1A6R&,O)T)MXX7BM&QA'4
M@^3=A#6[I?[[ZRWC*3GG.+($4H<BCYS6">*$\S>;O^XBR>L.:C'V'+U!9P$Z
MFOO'&]Q:/5%1C3%)BO#T ^>C@7T))\-II+RZ1&IG/D@B#Y]^[[9.GMB(,E A
MFI[XN^]J?&\X!W,&"4=0F$ZM9%5O!<UW-_RW81[F_IPN'A81\Z*CL;C"IQS<
M'="'*B-6.1)6G3?^%LCEG<NOV?.C!@']CT,LRV]^-'0!O%UKU\]>WQ'I.&DL
M9M!HB+M_CF?Y/->8P]T=@D 9L@, ^+C.S@E:!&PB!GH4DZ:F7?2TO4 C%'H!
MD!?I[? >+045_AJ3N]0M%F16\'H>8+6M, _NF1,6\*7,5*$G^/$TYC\?66OW
MURY3!NZE778!SVU:\/&(C %"0*[9*"[VUN@@P^^ *_7&-,+/N=%./VX\BQ$Q
MW6PH^1%H4B5KM,P@-O@+&.1#N7'M,([I?C-^Y5=(<',.3Q%_+HWH "?W.7/T
M5%Z_<4V.MAU&31Y,G./D.4V#.UC%F3/&?XL4A%[&T3,H!W>LQ]DV#5R$JIN)
MX!&+5.G\'3Q)8/\?W=SB%W0ED?]H.JIXKT+1A*EHV@Q1-O^KKI;(QD?56O*&
MEB18J0-:6,;C0#-'I/S;M!;X"'&]3*R\7B3S*_;S22JQBJ&G;;QIGV+0?.DH
MY9Y[]SG :/@JEC6X4(L<O P#B[6J=7.HV7VYQ)9",Q93[$&0[<_#3P[V(;AE
MB&I^O0G\="S.)05Z#] T7D%MHYH6PZ%[;(^2H%NR.[ZKWL:!=)P\FW/N67NX
M+3T/0@'PN;_?1\<&>>]\"6$G;2W=<8 ;_)!DSM:J=T&<9K]#W*4?R?:)W!29
MU@DF_ ?F\F]!RRH57>S[0S82>]7C9 8O9CU&*>U6WB(D JFQ_)6K[^&V"H^?
M-",RZ3K)!%';7)")^*61 +FEH2F$"D^T;%>TI";H$6V."G#NKS'(KH^:>0ZN
MT(B8:7,=9?/&Y*)K$M@LM(-TD-%,<LFLG6*'Y;-#<S) &]U#GJVTT1RRQ/7U
MV%HENAC!0<;Y6I"B!XJZ9)$N\EP&I3.=$NWCX7<OVN@9@[VIN&5>Z^VN:JA2
M,Q^MX#Y0,@0#Q^);,-O16W Q=X"<.3$BY*?0WQ\U_P"A_C[_ (FF 0&/G D!
M!92O!E]XZ_\ /:/_ 'XQ3R7](I/(GA!"TQ+;?^,/G,.*YXM4%?==K]HE8AM]
MTRYB>%U[WXUVWP4:B7I[:OR.#W)T7BKJQ(\G=_HA_20X:#]M#GJ=6CF4Y[."
MY&O<B^4P5P>N,!3%Y1#0&?Q:N(93U@CR R>'AQGLCFXSH,9[Z@Y]L$N>0]G2
M_PR[$9%9QY9-Y? \3>11RD\B$%>],763'*Y^T\W1S/X#S(%N,U":E]-?#+4I
M"N10"+$J?7;OO8]L2.Q-?/*-KDF$4>MJU<O?/2YC.BR'AB&\$1S/I[D/K?EV
M["YP9\\KAS12_720&)I&#O7,LS&3DI+?_"R78&4G:3L;J<0V=O,A9GN=*J@3
M9[,@1L]NJ\&%R34+A/K>?>ZE?",*Z)O;BE^JX-7,?D_6^5:=)M%H29QS5+B8
M6A":LS&+P\9-LD#43\S\[>*+02DCKZ1,[US1L<53)NI@^F4Y-H87 DU@LZOR
M$@QD;L(LV,D8@94[4^"!/I90!@/;^QA EQ] OE?5D/<)\Y(LTL@>:2<>J31;
M->PJ7T&N8"5/.)?(#) A<=9V&=(^2]JHYB&@>3:I,G\/B7?!><X>$E@A6*DL
ME8;$_U&NF?&2OH'X\(/7J7& <B3P+:'GF?XXI%\J>9Q8W9E!ORF]LK7\]S;)
MVDKM9&;)LDE1,UPG&8<Z.3QYNY=($GJ-HATT;3JXEDJXZO>K7ACR'UF-[8?H
MQ%1L6G< C'2X*LUDL&D.O.(_ )S\'ARYUM$3MK^R%X<*1 32W92&HKHYNHM)
MZMO/O/81;%$)I5QY9C1UFCL>5;#60D[L*5/!5"35NBMZ@5:<B5_N]9<!W:K5
MY\0^QXS[&9!9AGI;:@#P-W1BI6(<LRH?,/7L&_(D(QM4UXZ^[-VZC\UR7H4"
MU#+ZDA28GB/0HHLU !+;W!.%'Y>(@1*'NPYL=$M/RL_),% D\,H9N[R35XCX
M'P#&6^ @1D>ASN>RW>X;1_1*Q$;O!&3>#W,)=$!SS9P_=2C0GK06S8%\ OFX
MG_<5U(T6<N96#!?463T%;ZK6<4TQ391NVG_9];9L*N6CGR,5WI'4N_8UR2*@
M*C6$40L@IO7\AM4FA4&7"#HATVO'O6!_.Z#L2[ECL#BOLR+]=(Z8>WL;F66M
M;FG;#HT(YDD'W*N[@*;+^[0=>N,1QB,:(O#T6YB->#4S['W[J=GGDR322-DN
MHJH/(6;BU-27UA2[; 5V-'-<P1$P.)=[!\'9]I1D8Z^1?PY$-,81!2)QV;>,
ML9J+I"XNA[4\"JEHEZX9*(P.;NHDI).3P".RN:.;CF,9\XL]6HYI6K7#"?B[
M7KBS\:3_S *S_"%Y>S"LD*P8F$;N.QO^&@%H /R^,IODG V1N;@>DU^KO/60
M8>HV9'.I\B",B3%+>F0P(#'/]C<I8SAKA6</S]B/J1@S(YR^2B7 6@[-X%>S
M/5A5/ )#WFPRO,Z4%5U$\0P#'(@0MY9BDR7],(&PUIB9A*0HD +;)2..K8CA
M,/#G<BR)^,Y8!X=!H[8O9_0N_I.VWTDX)&H@IT_G2 NKU%*!_@K$ P[0(#0N
M'(:L<?96K,?57*T=Q7(4=,F)T.\?QVS@=-I>-E[5E5XC4>@2Z@)TE&J2QCJY
MQ .O';CG2\WA?66A[-,RRA8IZG7T&["Z27-_1\1<,\#)FA6UK-619^"#:73"
M$-R/:3!"8PF"I[8TH-$Y&KA2=R.,A5#Q2-A<,X0#Q3Y&1%J:=3TMRF+4= ]E
MG;-^Y6"FOF<?=VC:5?!++H(G#&R\@ @$IZ-VB/6^0)!R&_?#+(OEB6!DEQ;(
MT.9DOVS4_ 3!]2BDA6%Z6SH(D%K:IZ]'=#1P5)*L\#_=W&/B2;--\3(9<946
M3LCXM'(F(DAHE;6P^AL!;1$5>>TO1.XL;;%,KIE^,$B>4ES>M4#(2.=MP_ ^
M$P6['Z4C8 /"OZ-P<]X(NB[;2F.>EW#P).$5[YF,G4D7-^0$Y1F8%""K$?@C
MYO:.H7=^K5CSP6/U=ZN =N^)&-X/L3&0MH/LA7?S=IEU:+F*(M-)WN[LU>XK
MNBE"0SGWA2]4^K+]')@=0.UZU,;[/+R)%<B,(*Z_($AX'<!@KF)1PT3FPZF<
MRHY@HU>N=J>:"(+V7."FS057W_/2-$Z.) [);]1/W?7MF(E+Z1!Z6S]?;OQJ
M\^E;R;JE/Q*I%V33T14*C'I3PG(779LNWRSD05/LL+V!;<SWC5O3XI$_S>W9
M,BSMW:I"I>TP5WF%<X?YQ?#CJL3.K%NHY)#%?#MBJ&G:4ML(I+?UJ2$1D%Q[
MYVTM#NQD  [LF99HN!;3A[]$(5A23(;$T C=D68SSN].R8:TXB]R/"L&M;4I
MZ#K!:+"@C\X BT=G"O<%,:VE%(YPQ(FC.V]Z.Q+?KG-'-'N!8BRLU\._'IH'
M,Q]ND=G*@!*"O-2J"]N2PD:LRT,KN*QN3DH]Z/ +>);4Z==N:%,<(/RI>_FS
M=7_=7%<F[PP40TUSZ =&LY@-MT?6)^O?C,#].;D:+B;F]JP*N8J15+E[#*A,
M^]Z]6A>23ONV/N,Z8$8RID)8V^@/XPQ2S;Y\(E*RH0:C*SG$$GBHZ1[(27_4
M@8WEI9GU]R2!-X7C#=<SNRG13+?WX$/OC75@/5 GMC@58HK)#%4R^SJ<?O_D
MCPV_ME8AT52MG0\0%59D>QD:^1,2 F+BCH&;D9X[0H3_K%%F"\S1G?SZ_3*:
M.P)EI]%12HN ]4\-9@4&@<[@!&( 6TGL#<]29Q2*$($A?5A+L6V*O<V%-.YU
M%:_^=E-F&R]?T_FE%NXQ#_H&2DH!7(W4V2'),>*!VD'"/P!VU^8_@")RWA53
MV#I35,;6PVZU0#$8#N2,L7Y ]],7W?DA89:^S/_'8FC7+X]=7(Q,O[A5;>I]
MQ!S: ^G&KV/0;,;IM:Q\MD(+UPD-@GR"7COQ\>..6A><#M^>(S_@2Y.-+E)"
MOP$$#A;VO$+2B-<H0W2B2KOL?5-<9KFU$1J3R^ WDW1B"2-V\XSV3 .HK8?@
MU\ES#"13E71"HODT9D-BUJ2O[C!K24?%?':=/::I8<#&(F2;(DLB:*"N27:G
MWX/2!*T9HI9/=*6>0KOA&+%;+;'!)>9ISJ1[X[/_@@C:F[K]6:&Q $ /]-1]
M-L4+8>F,#L03A*=J@:+0O(7B0R\2\393;,O3JM,\FSE4^N+B%!?7'+Q@B?=$
MO^WY8<+=QECV0@8AST"YE,REVD_VDV2<JJ*@_KAZKR]KR%I);;7"I!7Q\]>/
MVX<V+L=5S%WH^QC+ZY$@\.P4BO4M S*7Z4.6(I,)$Q\(GYQK^WZCRXV- U<*
M<IYI40,FOJQCU#GES#RMR3T7IJ+7R-*(Q$1.D,ISK'S6/K$46<UV!5EFY7D_
M0\LCYJ9<0L"ETLH]<<MTU.703GD05K2HMT!]Z07OTQ?$[NDN%M\H.GCH<2I>
M0J504K!()J5%0LQ]/ZYBP(7!#$H6CI,*(-&9OZYBT1+=M1,I!>9-1?"_(U>B
M+@@>"Q_?5W6CCGN[-D^8'@?_HXAHE741I!<L+LNL$,@4!+FMI+F\E34[K/%'
M<KZ"GX40]O.F\(F\884\6QQ_,/FWD:20%+B[@E9N=:(;%NCTNX(,_?XS,M8*
M;#=^56G:#%&3\Z&>$^.@GYR6>RQ6[QF%1![5W$+04AK$$F%8>Z@\0C",.J4M
MGLVE6GEH:?\J?Q&DN'';&-=UZM8?C6REZ]:GE=D!($JP80/"'1+H:RK7[E%#
MIQRW(W9DY1XCCDREX-13LFF0&CLNIIMR=-,9MS*+9&E\.B$[&);!/4 JL;'(
M4]=QN6E&Q@?4LH$CW#$8-CGS0=:Y)H81]F<\DP!?C+%%Y-9DBV/T&<DC^!0F
M%@*S)U)>C0RYX*G>NKOKU7&LE:#-"[QJ( 1?&WK!Z,G]EW4?J;LM\$(+(SG:
MS1)\)\I;*H.-B>M:)(WALGEO?6)2^&[V[_M&D@]&)YDR-(;9P":PJ$^.C\A-
M$2]V1_,38OEU4Q)YC\QC6QH)^F<"C#\E*WL$Q3/^73"P4/,]%,^AGX7T9.^9
MP&W\5S/2\L?>N4M]EF=! U_+(7%E-YNFF+S9J25NKR$Z/;TTC [$-_>B(@[8
M4 9OU<S"T5:OU3W:5H$7U6'C)FRMP&4:LIR0\#=I5E_#D&1[>QCZJ<IU@YZ_
MG^/7[L&OA&-E>\IM@OE8#00:19! Z^6Q0_^K45W^0[O$]-9ZJ->W:P42N)ZX
M"^']/M;RJP;%,:I4@,=Q.#ZY#(+.[NWI]+&2ZS<1FW9G0L:$OV: >U)V?^9R
M=TGDA7]K1F0#4_OC:/R]ANFK[ZVZ!\;X6#L46J%0 VB]?,UH0'1=RFL"%1%V
MBF84#C*\B2=[.O>9R.$TM)7RO_VU*K$'G>"#3>0AY1$Z_D3IJ)F_ "C1F2&#
M52/0^!8U.9[ BI8 /P.6-V.49J, [(1C%8<\F(+5*"$RH.!O&<N'ZL_"%EC)
MP) GI?^\!@#71F[!V8CQ\0@:T+'2#@UR"<7@3**?@2)[(CX-K;(L>+I7>KV*
M6T/*\.DO";H4!8FNC?>#@6VBSHC/DHA<>(61^_NZ2@,2&<@?I9AA*3._DR-T
M9!5F(VUYBW<R9(.1YHF'T(,-/% "X11>_<55Y]#Q;C5-ETY\*S=E:0'5(Q7Y
M(/##D=..W@;#LA^E^H/"EL)MN,K)N@D5)3FJP.(BWL\PFV%%>&2IH@J-!BC"
M 'ZYRZ4%W;Y^WK\MW02"O_J'Y4E0==/G=F6%>WXA0_!O[' $W3/8YW4JG8:_
M6''YJ_RM:@\O>5-:C6=MA7YS[5@=L5D=#P#I,I>RN/B8'CY..*^J^O9PW&P9
M!@4DY "'CEU<$"KRSF1$PQK<-N7TGS?[.D)+43VI\^7OS'7HDA!I#UC2>A@@
M:MH3L!Y+X0"XP % E>)#5\ LZ2K$B_=;B!WG,$[',L8!CYP7_T-?K)M]<Q02
MV+C\4W]D*8Y]>1X+.H_L.B]_F#5RUP?IML\M:'+0FA%9&3&*3 ?.P[SYKG)!
MKAV)GRAP:AU>8J:%DF+2SPSL]_&7ABC*U2+RUCD@Q0=I@H@ET)@:^V&/]?@4
M[&*#.;$EPU];;[;G@DO<RG6RR&FYS93\RW4+:E..&NG=8<E6"[C8Z/&[ U4R
M;A'NSVBU<"L%,7GPZ'!O+4[W&DIY,KWE_>7?"EJ*!'A?)K/KI+FBU>?6OQ=*
MF9?AT) PD-Q64P@94VX)L3;2JFD8M1)]3BFJT\'\OU*&/D^&$"Z^[=3QY7T'
M"49_,-.? XF ]N"ZHJF8[>B,I0@ #JJLYXJF.Q\)F0U4K%I=EIM<#N87<V&Y
M00#?QDKWFHX+TRT '_QG+#,AZY:7:L$27F@<8XK*@89.O)G*!?)0=2]OZH8Z
M;0C%ZGCMA.@Z44OI<@D#@ILX^N:Y,-4&]_R5_BH?Y<UT*Y8L'B(4,[06XPG6
M#ZQSCFT&F@U43%-HDA@6+,[$%P]>$$6SAGR!'*FGHWK5[PEW 9FPB!QE3Q>*
M=@QG+:^6?/7"=:[>> $ZH_%A54IQ&&BR_Q1Y@301=T? 0O!'E$YP#'0NR-;5
M?J4/E;;-TT%(U.\A)#@NS5<8E;,W^?S&N>630FQ>>L<%3[47_,L9PJAL]+F1
MC5Y(@R#3&]EQ7=&M4E=W#+(Y9"*"98DLF.R#U D3ZE;"L\;W5,$J9G\(A#]N
M6D@!*3%F^[1MRKN\OHK,=R?-*]40"IBVE.IR6S@JQEXWL.6%+B;&_E2&)Y!L
M7RO@\V\[CT5T;:0@W>O>,JLA#. U&I8FR96;%O\D&Q; _.EF5ZE)CA1$G)__
M=>,4%]L:;%<4VQ=LGN&(UC-G2@C^#X#XVDK=UO8I7%@HPT5Y:$#W\?*RNYW7
M0HXY'9EE8\'&]#!;U5W[Q\XAUWH)OT-U*O=,Q+9,5D8$#!+#D<G%Y'AWVXXE
MI*40O9A>Y-6Y$Y][9]7Q'A; '6YS89AAM2"#HBJH>P!M5$:ULO! )84%BP&.
M!7:64ZE;&&P/AZTPEH%SFO%[/PA,8H]WQN ]_(*MAF:#!<O"G>A%4J+8V--L
MG^,/]S8CPEEN;K^",Y#LO5EY-W+H_#(1AO:(C2@5*W!%(=]EHO"'RW0T=PXA
M&OS'\ZH=/YN'C9R"EN@*U' '_7PF_;P@Z=\#ASB.U)[/+GD+JV2*QLK3X4K^
M0RN_00L#)'143+!?)  P_[8Q1<;)<%95,]X-7Y*X3O6_UYZ3GS"JW>Z0L/Y,
M<UZ8&7G-'$[IF34:IM-F$&EP#&/6+XTD]E)&%00=2UFC#%(&-CH'\933X5R9
MJ)HY[5.'E*>34]=(13G/MH;).1"XLV?+/P)#8ZJWHU=1%(N$/^<J=NLU2&&7
MXRWJ(Y3BLBL/D)_$&SQ/<-J5IL?R4'<: 9H[F\]K&T<Y_P#(0\N@<+BY&\JY
MP]19F?!6(V@9L&%LP/":8(-/,*B"7PNJM6S$$AC&-24Q>*)0K[J\ED/X=1U^
M8$02B]V#%Q-DT=&.P28+(H[!F8_1&W;R;M6/BW8:L2!%%X:?WK-U_0=PGS_T
MI9P/3W1B\UOW'7M<K^%S"%@+(?8(#)C,\Q,Y7+B<_']D!?XW$FGO<@K ;:7@
M$9PUO4K3@DO1]VA(9#IZN\]MSC<QG[?S^"31@RQDU7;P*;9\.U0;,8$5)N1]
M?N):[WHSXW0N$BQ.>M4#NK01;!AF_K-*%(ZKX<M>NE8CT-LZQ-:%#\')C #.
M/IZ^62'+L9'UK"GP&+!$+X#8T=((?&?\*!D=J@59OH/OUC N<'J^78B).8-(
M/H+L'T!5U;9BV(Z..%173_S!SF=76&8LX;?G1[?V$IG'3Z-P>6=(<;#,ZNU2
M@*C9/X Y,3I$ZSP;)P>Z!:T1(77[L_4OCH1^^UXF^[SG\;ZK'#'#4AXLDYIS
M!Y8QNO2NZ;A%7;>D?.$.Q'5MZQZ-?<@,76E2$&=G4^_DTO[2Q&4Y+ST]$)C!
M@SB\L==;?O14><&=/-8N+:#4W5> G./KY$4+"7C,W5WZ8E""9\N/]TRH\KHK
MO^K8)]TC>.HO&-</]><:;4EW(!!DG(/#)[03#>R8R>C]UNV!XC)MFI&Y#%BX
M;!A6:2/$W!)#SA)41,$R@8GU[_5^#\UBJ((,#80[<UNV]H>'N1^-V)'>=^^+
M)PE[G\TN3J:B<V8Y\N>%=^@*EJ+!0Y7>>.:UB:"9B/V&]/1:U':#F6&Y(%HH
MGN-4V3U\^?;K76OF[3FM4,)S/%2F82"5&EBM-[+1=?#[!XB'P4U 4X)'Y0J!
M_2CWSAZ@X,3&73/PA1J@F(V:/E>J,W&ZQ4&*T8M1T=K9V,W^8FI\,=@N_P>P
MIT&D%ZU0;?1D-)&[GX[C0=4;L)W\/,W=:*,8@N.O(G&'I*?2L81=QGA_& T*
M"\5)HD=L.O6*Q]" 7@9J$DC%9<5\&DAEKV$;0DT ML@AC/QW0-/[H3A3J,S#
M 1%SH/M*9$J2 .]_@(, @ML,WH$NZ=; 9R\F/[L3K[A_ 'YV$VHI-\CYKAPA
M^M_>>I]B5;-C+Z"#3_TF X84GV1ZCF4D@4.1TZ@I3F=8Q3WZ.X!373\CY@H3
MFG!,?OF+E6" [-HN"P SI'/!H,'9W^<Z^F+(V$,K)E'2Z!&O1+N^!U$]IRHZ
M*Z2QV\+$\]XGRTD"#K^_P.CU8 !J2G^0USR#5*+%ZU##(Y5P02?M>C^/4O=%
MB"U"5??"5\%DAB\AGXR6WF^1^/)O:>EIJ4U1WT9 1,&F??NP1^T#M&Y>\=;M
M0Q4<'*.9+CVT MI;1JWH))F=](<_=X8;N::B(0IM<COWF?#";L/PT_WYSI\P
M=*GCOT'R4,+H)0/( C @;:9+N>\+_]UY]"4/I7U"JL^5[M65;X<9HX^3&?;Y
M@[^ADT&^NW-2 \XEEJY,E9N?;E]^:X'4R>8CC5&XX&SWGH<B<GRCFRR3;UJW
M4FN>%"2\FKI??09,9$O('COH< "TB;YP(J$PQ#USL6 8UA&]6\$XZO?)&Z$_
MW&[B$_N';W^P91V*7K:^_?[N&H0UAM7?^XR61*"-654;'YEAQXL=>N++@6MJ
MIX>CA8<,J%VQ$X(GL!<SLG\9(*BC.E_>U3:JI5UX$-Z_[!6W[Q4W/0O-?C"/
MRVGJO,+,'R_F'M?&. ; ]"NFZM'1^*+9X.T<MM-LW@VA[MVI&*4F"KJB03W0
M+I@G3;53#)%3S )D*/@N>X,Z=QO[E5*YR#4YBD\Y\\M'EICOQ9*6%/0IAPX,
MTJP<DY?+6TAL3D7MG'^4?1/XB_7A &\4Q3/FQD/<D KD7CT;H9OX>:,$+<J(
MNVZ#6U]GTMC/^=_QP!5:!  $?=PF7%GW0MH="3T"9A(&B1W(G+K0?BR76DO7
M6'^%>NO"<_Q "_YQVMP:C#!TB%\6=Z6TJ9!*,OZTJ9>_\.=: HL'S["G;3;E
MKNU&KT-OQ7K66Q%G\\;<^]36XBL>ID4FM_\NRT]DV<LYV>J:+9IC%FQTQ)R)
M7)]X<+8VXDLU$><1"X2<)\;!J+$>*@O/_WE=]NZ$3?=*Q<Q0-RP-!J95/T-9
MK9Y\.=QMO'#ZDJ9R,L,'C!R/_PH@2A,)ZF^D_P%1'T*6[\>>T]JT1X6;54&A
MRS8_;>W^JZ;QB1?^M&;$*G6RV5XTN=VK1_H")BTUWP#Z,'4-P4F@=^VU8ZWW
M>R89'),%3IH8LK#3W0C\J-%>=<T]P"X,TRB-6T76XC63A?&E@)D@J/8[Q3\^
MA=M.-4=GLL:[)+$9//4RR22-H5ILKI*F8X"\DI%;A1!O$K9QZU"IB4_SP+[(
M/E?\H]:%E*@6P],/_YD,:222WE<NS[/E<Z#4C59"- O^,Q[6N3.;KCURBA"@
M5UP'+HT-4ETBJ':/>R#(1Q#8/CUZGIN7=<P4HK2:(HK!O_97"3U+0*]C%"BD
M1T[_="-3?+F-T>PP+5^7Z;;91SJRRN+@)(R^E(6WK=0>&WGJZ_.Y/'X8H_P3
M]A)C:E>8>8YU0)BIE\L2]7Z/9.C)Z5JX/* #YT34"O*YX2+W"]'C6CO,&Q_B
MT?9%]'JXH &PID,%@;V>FO#JG#>/'O^GY6$.$ PW02 @GMGI[NM )P( =M=B
M>9#$:9LOUV@?8!#UHRGC":L] &0GY1#7E-#"1QB 0:@D6J_WB@P3&XZ1 <.
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M^<.[ TJT1DR1\Z5Y)K-W9/%]./,?*Q\FX6JU\"H/QY%U4MC^!J1B>#'@Q_X
MWXJZW]&[.+EO-LN 0YJ>0L+KK8,1&RT32\%MR1'/8[T/2?[G%@^1>;HWJC,O
M)O*4YHXMK5);%L!8'XJ:G=T<("'AM?P+NPPVN< Z>^C&VU1FF&-#[E&9:B'G
M&^ GAG5;F$5<V5?-MPGVC, 19V]]3TA\/-C,T@!O*&=^J.]]_%&>0T7 .7YK
MY>XV[*Q?X%2ZRI;O)G!J$!S[Q*?G;+O?13!:=/'Z(J=V+I$E7C!:UL>D'RF?
M3A8Z;1^!KZIN_YB0X)?E6$!UZ%DO4M2-(S(C6<9B25HM56M"62VZ:"145"/"
MFT=7FHU;H9;-=M88P<^&I\4=L0@5R'=6L0*RD^*08O8"J#0@C+G'_3QEWP/+
M5XDKL0=+(Q?L1QNT8"/ RQQ/"G'C.P_NF#]A2W;G*C"=66N9KX'M&>AM&TF(
M=Y8!HV"DI&O0/ ^"1*^R%3C.'QS H>3) .WN)=0?)IR9$ Y'(L'S]&@C9(U8
M%"[T9;T>"NM,)J'@V-A6H*E/"FLP\LW'52B)2;,II' MI*Z_TR,;0X%8AD6A
M/H\<L7W_#?K$5-7]J[/BZJERYYD8(AU4O,*!Y"PUBR4>+#*DOFF-5[91L"57
MH9R88!>3M"!5S6&!>RI?"*N;=IUI#:^0(;GTQ6>VN:0QQ'-6CW<7C9+#!(B:
M>"'LF[&OF,2H1:)WZFOSN<=G,.GZGA[;C0,G'UM4BX6"P[2;/^=1=-TI51:%
M9Q6CW)L:^O0.6OHW$EOR/:6TT5U$/\]NP:?WE/B%:*P@601:O.-45\JW:\1<
MR,/*Y&Q(DCU29Y+XUY??[43;>M5"0O,5Z=01Z[J$O)O$LX(XP<P&8IJ(.HX4
MM/)+:)&"O>.=C?U@C!WZ2+=?AM9;Y2F@',)ZON[[Q]OC\_!,:=!T[K!8$V=&
MZH;HT=1L:&G.0,B>!^T+_ENLXY?:% Q7Q:WV7*?7<\XS&00R)\B(SA,SR/#!
M-*24@/M3'W?J.B-^4#BK\PTNU8]HKYZ,']$/Y5N^/+[&!;73L[K:H>?)MH0<
MFET[:K=$GT'+JR=/,=#U5/\NN7M*(54=&;(L66OKZH#^:I28) SEKOK6ME8_
MSJX6;01&V6[A,OI?)7 G(Z /='&L8&=$+Z:CS>V]>P3W_HB0[+AP]K0*NK6_
M,Y9\G)G0BM#4LUCT<X!YOJ ?:"9&YH-+]TO$\7EG"6X[4Y"LG^A%H]8\$CN>
MKXZJIL@ #]$AH9W\Y6?M7=/#*E:;,G!%/!R)&+/5&BER57,<^*S+>VIN8.1\
M;XTP:)^U67D17="1T\.;"VP:_L05U?V@5IG)<2JA6<6$1^,#,Q%F7P"!PME9
M;T)$FC?OB9'Q$L4(I.>&+"%D]RC/3N!T[1(P+Y'VM_H,!JYC[%3K"W%03/K;
M)HC?P&D)H[-H,[KBU*9R=50OT"X7]5]!S<\?S3L8M^AH",+A_F$\: 0$4WKY
M2]>/5=:G2Z22N),FPN/ST,/Z*PX<?09UM>B60\B19A#M"U]TLQM+GPD4T-?X
M-&X6CF/B1AH9U_03_Q\IJ/]W<44%B?NI?>G)SBU.3*.JZI7<D)GIGJ3JK"P<
MGG:J1$W;A1WOQ /;$7M*9W'EN9H#6U4'*:1]0*4,+==.]$9][T#+9]75=1HD
MK(E(+MC./;HG0A(/^+H1==LH,55EA9@SQM1\\-;><(X9+EI"B=!=&MR@".ES
M@AV<)K@(W+-)FU7NB6V_MJ,72<]6OUK6L=$1!TD:$R3: D'NI\7S+S^+=EI_
M6F^:PYMTLR383JU+"'OD9L3/?&20'M'LO^.E[7\X]H5R-PPF<\B/$PVM=Z/P
MXTD6A];3-58^U=ZU>7_.M!6CZ8Y?SP&M.2/A6: ><@C,N1QP<;!;XI5XN&'2
M>.8+Y4M-6K'%_"Q"_QU&'[?WV[*(*!2']7.>^JE)G>D*VAS&. .1E<>W]Z<%
M26IV*R?7_3%67)M[SY#N,^H/B@O?S5XC_8U9%F:0WS>@!O0\M_>#[*O'IX<6
MB4A1\@J^.ZX#!GR& (.[Z(KQ:&5GY]\YUPH66-OALMV0S.S(62CKX\5RK"QR
M<Q72P60 \[#G640P&&5^2^-! LD%@CX18\/Q-M]CP]]P39&TT5"P\@;(Z])W
MOS=X4#B':IGGA(_/RQ+WEMHD[LDHS^Q$@M'9S8?3FT_@L^ES&(KFR;;_!W99
M5J[E@6&))#_QRH5X*"P M>IU[EBJCPA/<X]T(SJQ_?-O4)Q$'G)^F6.5Z,EC
MT8!8_Z:]W\U\F5/_-Z!9"&*7UC/U0XC\0B^I4 9ZIR"R(MT?[*/_]>^.EFW#
M:[9X;XUOQ'Q2DSB-:*=4K\4WP)]HDC?>0- -XW+)^EBHI2O'X&O@U7B*YR6O
M1K8]1V!V.8GH:9&WY\USXV;$CC[D0WSR;1'(YH7V/TFT'-73EL'HRDY $W9]
M[^G9#5'G+U<H=ED .(\E%3W,FN1E;2C\SI]S9^OL]#323ABLXP ^,[>]UWGZ
M!G7$U_!GB)F3R9;+DUXRTCRJ94MIO*B[ R6X+=3LC]Q-$E=J4FV78K?_E9[E
MKI*.-_$V<PLW%7,MZD^$C.KBP$G&6=Q>P52NJXQ()9&*<U_"2^IC0E54M5SS
M-Z^O+^KV(B;]#IOTN.9G1:!"LPOQ4_-F:^BDG65HR=^7WT7[+IQ+\<AI'G/5
M!%PK4A$,,MH4#7.S&7E^8"]:'QU]$>-G ^$CNZQ-:YV^ 1#S;.93%]Y?/;R:
M..%)__E>2BC3-Z!IX?+5XQM U.[ME@1F:2W@U5:ZG,*5 _/HC]6&6V,IXC>&
MA@.36%Q370,D>]JY)<ZEAT+OLO8\4ZD@ 1=9.  JN'T#JH41:#H[/L)8?JC\
M+5]>U<T-_N_94D6!%](LE /H;CD&-/UP@)8WBNUM89&AI%:6W3>]T*9PN2P;
M_NIYL075?5#+.!FOK9O8L%)GOMSV!NBJ6TM:=6P?^L8V_$A RE=VG"-&>4P*
M)%=I[:M+ X=05'J=5T&[M:=X!\*1),@J"WIP8[_8+MA)[0X89S*#0NP-'CH2
M;&:(&$O[K;U:+:@/)')##VQ<W"E_OI1>M[6+G&,E%PA;K=2BBD99V/K+NV>V
M35P1D091LXYE6]?L/11GJK_YN=.S_BE37_^[?/U',Q]QT -@9&NTY9>SM2YJ
MFO'Q*6CM\_)VID#S$%6[1#YOSM>:\M:-K;J?4HP!4=#!U=NUX]"Y\T,%9LMD
M!BG8B VQN3N!+.7^QO6/?$N9HOHCADVKEEHBH9C-HB=6B4#_?\2T4*B)9+-M
M H8SB;.M<PD]4A;)K(V,L.#34.$,[$BHVS6>57YS( 7E';I"_"B9(+BD%3'/
M3/<(WNHB'U(_O@G[YK9-AB)VSN"D.B)>C2HZ&*+#"1(F&+(O+8(N-I5-GEN
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MB?V3;.%#8W9(;RU<@<#5?D>;;%_6DPL/@&VC1N#A"9M$1B3=MJ_J.EPJ7_B
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M&0YF\W)@F5J?'T*BY2)9/UYI()K9\A>\+$MC:5!N,LME+?A*_^4D9C<!CCO
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MPHWCK>C"G)E\S)\^GJ9]J%6@YFYU53_GHHN0X+]8/M=E_0;#+WL8X7JIX/[
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MFB;4*%?0.-2BYRK@B.9D9>I)3 0HR.%MZ55(,(,YA)XD6.Q%Y^G,XS[X[CW
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M@M3+RYB!((8J$(*5RFY0[LQB0W$M4.0YE">)<G,(7:A#5*?J;Q.?B%";;.%
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MU:VOLJ?)^%P#C"Q]J6E4$_>9]+" \7'J*T4;9@D.48D3]U,L0!._'RR%8O\
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M$>:4Q)'#A)S8^9>V_2]M/TSA'DU*U<L[^#C#K#P.4%81:6DI5BU$H#O"ST_
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M; 8<K3QSEM7O=7],?W/<8MTX>O-%'A\R@*J1":N#/RK@^]CQN8*+N0>1 =0
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MQ2^2?[:!R:.CG9_=OV7E5]D?L1;Z4[#_ITGP_B7;?T@"9@"3!+$_)@'#E#%
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M+J^MKGYZ\X(K5.@;A?UV^+?JK>P&Q9'&_(/:\';F!7*%V2&7%]PYB]$$BX?
MPNM6BK7-1$V%A^1RS8L)_HSO='808@C(&=T;8&<Z&.00V,UD>:G=,1*L.^W
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M%!G\*$X<?A2+]D-@D5I4(>F&*OXA\'E3D:7=*$$GP%(U&W-_>H8G??!LYUF
M,SGF_E3*WM108:-L=/%ZS(Y_B](^YG9PDS(PFEUI*7=7GGQ38>US@B+^,D.;
M39I[GT%AF&9-":<T'6GJ$#U'G5R>(ZJPOFPE>V*$6INP17HMC:_(_2L[_DSN
M!@-^?]"="^!#(+DF"-@-SF4$%+AO!<GM[5TMW/*J+20M3^@*)5CK*<F]]1C6
MFK]A9?KTP88#-^GUND\L-]09S@A-?=CP>YL>>K]QFJ1Z]N+H-9^KR[1/(*U<
M:WFUB"YC-T.W#IW(HAY6\MNW-$L86104W7?87[8TAGUNM!3,%KCE?ZNKN7:E
M'QZ96+\ %*32".XQK#(%=&]T/3MGOCSIV##?F#E209/ID@D-4K+21J<*!["Z
MS'%K[;"1L5;[^HUKM*Q=NR+R\((N6<^[T)(+?7#Y3W,?%P0>H:T_,V.A%2\L
M?>AJ?5EP*7"JZ#S(S8(PX^NR[]FK%W+F8FQ"*-6FXEH%1%-%U G2UM*4P; .
MU2BC N+XD/Q.VOJWTY")@Y'M]H<MX8USNIB[8-1BIIR6G\4<TQO[\?&NLZ:A
MY4Z<X8'FT5$RKR8T?9:U#5?1_F_B8Y]7I+1*.FTT6E?*DA2-2II!ZXK8$&[B
M@GDTC#N:63M#GCN-;Z=/=W6>?U \M3[BE-*7PCG%A4/,6FTR(S.AFF,2FJ^B
MW^ \+1KE>T G.U(Y#R;L39X.>EF>_"Z_?W([QS\_^6E<\5>;EE!$567KYR^;
M"1:H]":2P6DBV"OU6T^(Z@SOWL7^Y)>>8+!3%JJARF,4TCK_;@K2-<P6S,+#
M%F/.PX8]>P@$AS[V+U!X\*J@-@4E-=:=_.T*CTE-7:"]DP $:K;A28"BEEX$
M.X4T4:J9VA1LO-+X]&(G68 8KI[U:$")J&H89D"\!NI/*T(W;QCN)#2FW/ML
MOC\QA>[7@[0GT608/4EC^JS63!5#!X5CV6@F^0MA7;A!7IQ\,4X_Q_ML'[^8
M2J=2!<[@^B69>K5@PYE4ZI</-CCV'FK44"KWY#Y%&IS=?82$CS"/V[H,,1X"
MT5S;%)]NIBKD^EYM__; ]JEQ[V#'BF38!@EF\RY:,,\>[;A H@G=#UCW:M$*
M(7NZ+JZXH]#F&[%3'JHAK?]U\W.A6BDKYU(O",Z)4YP;L/7.$/O#F_;>B8X;
MN]'KBE\;PJ_I^YEL93;ECC86CWYT(WOY->2ZF<(XF<LK*>_M2VU145)I%H=
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M"\[6Y;AI>IR62SRP&SN0K\TH?%+'DVAG)W4+1DM>[<M>K7972S&Q[Z[].Y.
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M/-.^CFKMRU>HM4&+5.X5)FAK24397;%N<,53I,9EJ"Z*%,RM H&:8H^@WG"
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M4.J-,:H)0YR\P!58=CN>^<K8$C!JI?M;0):@_^*=NZ:OCKOFQ (M??$L5BH
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MA)!=K%H(V'#P+ 6)4\ZBBA%5I40O79%,:%EJH;WFX%6S;V'>W'XFCB1T!#L
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MN'V]CN3,%_1? QD>HT9I>QD(Y?WF47=&0RTK9_ F&\3)B,[,1 G!C@B8#R5
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MMT26 IX,%M8C)[Z:)LO%9]T)][E=,)DEF%N\"AWAX>^I<[U7&;3_$XY,W>9
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M>\<*.;IJ)\!>='=+[>WZIJ)7;MIHT^1MQ]+V_77,!8EZ>:O]M*&YR-V^Y:
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MYWX(4"7I<0-##6E;&<1"WC^\A%;[5$1&V$01*T/-,>C"+,P.BD"7,7U.&7F
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M8:"]1:2&+A1]Y:544+A4O2 &FTRS*==.8N0SMR;GOCQ@^U2]LG82'\?"O/F
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M>J3RRA0Y"A2QOQN Y3;07*MQ3/5'X/PFRB[5F^MGZ 0;\1+EY,E($7WK!JH
M2OQ([1O7I<0-TV,SQL)D3$!$*:5\J.R %THT0W,,DJ??'\AW2/=9"B>-0Y<@
M;D/SV$Q'2ZTZ5R?%[$,:M38M,L"/'IQIC@42B;2:X"WT'IM>0B*B(I THX5U
MB41=BJ$4&[82.[U89_P.%M;GH"80.G(M8V"F^C*P66SP=UQ$1C42-?U'-W9
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M0"FB(JHV8U!8]3!GL#>KB-'+(^.U_$_0'0H -7ZAH:P*=@O&P*C4OM4"3OK
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M<MT%V*3K/K>TN#H\6@KD+_\@N<I7NCMT_@DR_<G'B.93);<SQUDH6"2]W6G
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MZ C5BSDHPF^3' P$[(-LSM._X_FWV"#5\+)/0*>G.V.*E-IFF3?T!3H#*D^
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MC'N/++S)"TJN95U8V!0<&9<9;"9]/+')K=Z*:DT#<'M\G4Z+7(BI>H>DL"S
MJ3&*5#7BTT==OIL&D^1)D4JM;W_<O5HI#STXWQ2Q+9&;+(A;NOM#D4&AX Z&
M18Y96",S1#!4,\.P%;E81 T5M('=I]9U $S-05,0?C?V)H9;D5.EISZ6M4MA
M4",&FB_Q5A^E/HZ1[:SW0H@4K8*QGJDOM!,R+F H]'\*0/]G.\A\?O_^OS<T
M##C*Q^']Q5*6CY&!QT#[&S5:Y \U03\9EB4ZN82O8_>71AP(\8J_YW3([DO(
MI,)I)&Q!5VU/6DNHY#MG-#T]QCK="YG3'S>QW3Y>)%L"165M^(3G>*X5]98,
MMP2/UDE,/[0G[V53<0M.S']TQUG3IOUBV0KW/'ZYB21-,AR=KU>V0>0#<WYA
M@>*+=3<:W8-\U]0M9"X.(7??#SZ:$>*RJ10H4B/R^0D1KCARI;#]B:I4Y6$E
MP*]^](+O'&8CUU>2WKU/@,B3385+;J'=+[(GE 2V%[=TC===5>T;_#>$#U'O
MQ2?UW?Y.U/]297>I&+]JYQ)&S%LQ-XSC^XG^N[1H+[Z9E[Y9/V2=DGC-EHDX
M95_)H)5>];Y;7AXI7M#!H!TM!W@+@K\L11!NO[(NI]*(4M8EO\I+LC'C'3;M
M%&5^!IEQ#*1D9!@($\6$^PG/;D>S#.#.[#HMOGG3W',QT"\"I;%$.6/"X(M^
MQHY+FOH*:J!Q8-+6V.SO1>^F;"-.,5)]EM/^,:'\YPH;"Q_Q7&P*N% O$)O4
MJYL&TWVMCB=X$E5J5'=E:8,-VY1(6\3*%PT^?+H,^WF'C22V2/F@DS:;5Z&%
MF<_0A UUQB?__;9Y]F]KH)>%84[\50RH$A]MX3CMMR2R&9N"B#W=:? KEO0C
M&SV&:^<>"M?3J?5;KXE"ZA<Q\$:9ROO^X"#V)M^_*L#-LG9MKE\0^DA24L/6
M6\@@.,P@,6#;)B?]_=?/N1J.SS?TT3M?;3$R/X<(^-VRE\/?6V!A?Z;G],=.
MHWB!;5^01AO6>AQ!L<PV7#V6SL<Z(M<S"/<CHA'3@J]7X'%'8;+7+T<] 5ZO
M]F<>6J%]%@1?Q6!.VBGD>,1$\K]YY&R/%?XY]:_:_VV5 EQ48GM/@(N80XMF
M2N1=7^#[;E,DO["G=)?T$V#T?N(?$1=N=RN8V<98CXC_S=^X^8!8>Y3'2%J?
MV8-"/\GL<;/U1+?&"E5$V.?M'0FQ39(2=BUX&N2QT8747G=!/RG@69P&(SHR
M**<V<&C\! 0+>\G$4=T\%"*Y@M%_7V:26KS$^O6_Y#6BJ+]/3.1/@._K?!B!
M#P'8ELT:N%/9N%HTDM6B_B&H7U6B!<:)\%(P GZ0)0YG,W^J5N$T,58P<;N7
ME>")MP,7$4- _N3X&^U1&/:_7G(.D>7"T[Y]KD#7VV%"QO\L]\:DNA;%1(&X
MW5;6@@'G';=6%DHI;(U8KWU34>;GX+P'+][*%7]"51GEF^';OLF@4/+VZT#;
M!5B2?L66SYC:(/C?=-[@7H)'O!DP#Z0T!$1P)4J9FLV$]0L0B$3CG.+<('5N
MC*IK86ZC'M+JY?[U0MPQ%_\*AJVC'^O1 KSU&7SM]3VV4Z!IMH.IHGNKJ)RP
M@OST\^]2GMAR>LP&(+*P0Y37]UGH>(A#S]!,8Z^>F#N\#^3NU'_7?O4H: 5.
MPJA<E^[DB1C "$-ISKR^(,W\<??'$BK^]VJ!Z2;L74Z#AW$RDT>S]G!;&RA
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M+/\ON[<Q ZO?1^7=]0KIDG;0Q#T;*PFB6YD4T(\7$Y<J RJO7;DF"5RC:8-
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MT<.2O6ZJ>YO&09F=^+3B8TRA-N^C?MHUZ61JASZRRLG9D2#6ODTS8(8B*SR
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MZVT6?M^K:PQ5D2C7S=]&YF7A[O!+@];U$H<D1QA]&&3J:,R 2!12&3Y\\@S
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M5U@.>[=Y9 H/;;)60[:DH?ZQ$1TL[0 P3XLIIWV,Q!/>(( M;H&<-IV[]3W
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M;3P%Y]@]U31>9D-7M9B#5L><=*'C8Q^/;Q32%NX\]W<&CBALZV D1:_N[O<
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M;\;-CV5>P\=W]Q-[M?I91B<1B;A$#$7H_ 6T+=K"'@ZRCJ&?Z[ZPENQ'::5
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M%[5L;W+?RNUYP87(7-?N;H^X32.RPXQ?R[I/3AAQ:G3#E>OGA%*8UF>DM19
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M56YB<N?J2B?Q<'NTAN6)%Q]6J23D(=WVQDF/\ &$$SG$6P=:HO<Y(@T)&T2
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MMG#Z1.ACVW%Q1:0]]]?/)4]4>MV(V[.@90*TOB8A!I1U45G6N;=]\0*<!8[
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MI0N6,)*6ZN9M+QX-3H;3H>1Y:,>7 ^X0 2^Y9/?W][<1D3DE%6Q](M=*]$"
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M=ZA=1OB0> 9I>5@YH^%B1T6_;(MLW![ZOMTF26HKOALB9\'%OU)@AGW1A>#
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M61I4+A-M/TDM_.M5=D3^'U!+ P04    " "ZBUU3S$II?;@W  "KB   $0
M &<Q-C0V.#!G,C)S,C(N:G!G[7P%7)1;N^\0$@H(2)?#T,W0C4AW-X@P,^0P
M \-0$@9(-XB4("&(A(2TTIW2(B&-"DBHA*)<P-CNO=WGGG.^[Y[?O??'PIGW
M7<^SGN?_U%KO6J_HX8O#60"QFI*J$@ # Q/#&\,; #A</S^F8X]$(]WLD2Y
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M0T"E09X@69G#28 \ .-?;,=*_E4=&(>- !(\ "^F)18&"0"3! .+!..P%<
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MI.4LKG==[APP@MJL,<5.L9KS,Y$QB<2383\4/]>]7W9YH6A(L@8C)O&>PZX
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MMM_:.$[![/'B!M;-:E<(YW(]X=D2D.L^MHD!O<EG@"E1J_W8>DNUEW23]&[
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M1"$MAU._#"9/$JL<)JW-3//$U/V%$'R4;5!-4G7*/4AZ2-?#%[2@\I&*LY_
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M&JE9C1Z$9[FK_OJ;]X<3_PM02P,$%     @ NHM=4Q,;I07U6@  2ZT  !$
M  !G,38T-C@P9S(S<S(S+FIP9^R\!5@57=<W/G1(EXA(=W=W@W1*<X!#<PX<
M#JF@M(* =$F7='<IH4@I( TB72(BB$I^@+?>WO$\[Q/O]UW__W6QQIDS>]5O
M[;77WC/G#,[IQ.D[ $]%05D!0$! 1/!&\ : TRVR6YIV4#C4S0[J0L7+P04(
MR2BK(2,#9T0FUF9+\GL3 )$C& %(U^D5R1$! /']&CFB)H .@_'P<@GR")$C
MH@!2:O96,*@;U 9.90"%65.Q4VE#[3U $#@5E3;8#>0$IM(QYZ;2L()#+<$P
M*AY^*AXN'FXJ02XN%V<J62<P"/(=G/X"#>^1$[D6EBF?H?^KD;Y=C3W\"YG(
MA6SY7'ZV(URTKKC ["%P#7>XBSO\K(ERSM-T@^M80J%.%QK*$#@8#'%W_G%^
M_BGK!#MOXU[8ZMA[G6O(V,//;7[W"8:I@YS!NO*W='^"?3?0A$&A-CI@N+N+
MAJ6#U1D;"] $8 #T;+,!J  =  S  7? Y<($T^6G]@\W,DYPR&\185FZVSO!
M[2$7+L_:&!?:LFJ&-[]G0_1<'Y']#STF^*7'&BYP>RC$[8Q[]:)?+G#(CTZ<
M==(2]K.A;>NF]KL$!I']O0&!_]Y0M71R^]E0MX5[_&S(.SO)_6R<Y?%WUS)6
MCK:_)>)[@("VHHSLV0?2Q;DU%94UU-U2"OH.^$&*,,A?>#).?]63@5GKZD'@
M"K3:3G#@%Y)QLJ;Z.[ZVFQ/\@J_IY23E:/&#C>D!/JLZF!P(#OI9%9JVFFX_
MJN+\_+=/V8LD@&W@?^=>]VR2_!U?Q\KI.U\39B5E^).-=S8=7 SLP&>#>S9>
M]A#;'QG#.1=HG\4D X7#H<Y.4(CM;R98/R3G(?S"Q_[!U[:WM?M5<.6'X"RV
MG^SSRD':^AX#4OL)/X ((/[XO*@JA@L9SN\]D+SWW0H9^Z)Y/N.]+MK7?K8I
M+KSN7K0Q?M@A7%@QXGU/\X_A_XZ"]/GB7 G@M+$YDSB='5%_,_K.R4I.^<GA
MN3@:G1U_</@OCNR_<RY\?KTX/YM)IW]+2&OGXO]]V44NT+]G]"(N %'J^_Z;
MC.)GGKZWR<[/D/A_1O^==LYL='ZF[J_T"^]";^>?*/RDWQ<& .+N=%Y@B.>P
MEE!WB+7;G^:E%9S[1YCGQ?Q+(0%_JCA YO?*O A#^V?A782&ZN9D;P5VTW=2
M/9\Z"'_ 0;F0G9T0G.UH%PUEN5]\H]G"H.XN?V"A0F'VMO8_5T5YG7,CC0O>
M61L;Y Z'*H(A8!@(#K:^B-[;Y<>BCOE=^9QS+E%VMJ7Z?]!_)'>8TQ\N#1?)
M_R-'S<WVCY</5) 37!=D^P<>CA7XS [L!5=V4])54_VQ0*'_8/]!&<,."O.1
M=K*W_9$IW.^=5_K!/L^N-=@&Y'ZQ0F%X@&'POU'7_\'^H_H52UM9J!,4]DMR
M\;\;R"C^%)R'H0Z%G']BP*$N9Y<A-_"OB<-T.DOD7[A8EA=+W5_X5V#G"]J?
MV!<SB.F[W=F.*/D1^)V/?W&*\'WE02:Z:)T/*/)%^UP?P&WY+6&99[OTV>D[
M / ^VW$S 5( X73B= O DK8^NPTQEU4#$$\_ #@7+<#ZWKG=Z300!&"AHZ-C
MH&-A8&#A7\&\@D^,BX6%2TQ*2$A,2$B*CW5!OWW\/2%@7[F"C8.-AX.#1X2#
M@T-T?L A^FZ"_Z\X.'T*X*.?!9^)A$ #(.(C(.$CG,Z>=13SM M!\BQ*%(0+
M^BV-2  "(C(**AHZ!N85A#\+$<Y6_Q]"/  !&0$)$1D1!0T5'04)B_=,B(^$
M3$W C2*M!2*D<?7G026*SJJ4H:4CUGYFR<L'"QB21:./T?DXOV/EQD^2717(
M(!>K:RW?D0,7N#JLMP#^5!W4.>*^N*O &)<;7!/?]69I+Z^V>W3YL[Z-1TA"
M?MWSL95]044#6\_0Q(+Z%^.K7_ !1,2S:)$O8D)#1>&_"(&:FP#Y+ )7&D(4
M'O]HHO,(GFD/?>2ELYR'!<3(ZA!;N?'MT*.>!X#&P-\Q?!9$SE5K>3T!.'CA
M9PC_. +&WT,XG0*PD"XP\0%)H&#<K^K8LJ#L,XO]AB'QJ+Y>25E= S!6V\4?
ML7_BD',*B+15WUTNT_BV> K0-,^< D_$D3A%&3E6EZ_ V'WK4*=>SPZ*IE6V
M1>]GWEUT_>SVY=,IL#5V"JP3Q>U([A9O"IX869\"CR4_L9H3LFZJ*XZ^3R\^
M-. =MSGD9L%U,M07MACP&,?5^W!,>TQY\V3!?.-NH/$I\'7&U^3XJ/W0O?U
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MYZ]Q/'^?X^^!(/QXF^.9V!#_O(F"A(J&@86*CH9P(060\5%0":BY":6UT(A
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MD"HR#KV@+,>Z_+/7-U0.8H?/X?UW!JKSRS2%\JMP\/2&B.6MXYCO9]LRJ^H
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M]8I)ZI1Y>H\F?[%YP;32$SN)8-E=C9I=23I0XX 8KK"6;?;<7VP!--#OW"_
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MOL%;WQ09)CK;T<-/&?'BQZ](Y@J4Y.=WR+Z(7'>/7T;]\,V#ROT4P#'V/:[
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MRQ*Z0/A !#[(%I&], 47X'Q!O.8S]9EQ=V),VP:<K&2]I9)C:ZCI2U(:S6^
M%)]UFPQ5B%1'5VYF:F"B):NW3)D@4>*UW.-B;"YP/ NYJW/.3H/Y!%5]O3*U
M(N::$AU+\HY.PFIC^F1L:ZS^*KL W^QZB\?#T<SN0G8'C=Z7*FT&-=5XRRDS
MG242J?S*3KDBY6TAZP]*PESEJ_3AQ=V+/26R48?=]E(O!1V+G.)?CJ)5#K\6
MF*01I=>7+^*<9)BOUD]+#@AG'F3)+[!6YM-EPJE1FVFO&GA9;VO*ZJ!',#)"
MZ'4%TI!(\*FC$R<HJT4)HXBWSZO#D3S'8'IFVU'M[;7IY=[CH?JT>LARK&5B
MJBU(D%$2S%=#,PSJJ$?$'#,R1*!)$@-S<EE=J9XYX?G&W4;QI.+YUR\LC7SQ
M,7&US12#CZHT4A@>MMN]9&OB,*J$-3#EV*SM2XPI+:L2"3W2I9"P68,%F*:2
M^([56N?9CM<DQ>N6C:)TTX5R"=6YYC)]?49U+PUX>QL<W/NB<8#  .S9&1]>
M[L6),FK79SC63#BB[Z-:K<[V<@ML=-=RL;]&>[I,)!&I2%H+HSN$ZWV@3I_@
M'>&0'0<X*AM)M_V$4DWC-GQY)/'#XE.XEEJF<K9-6IGF,H7[^.HF%\RKMO9Q
M0_V&S6"U=<2;FM>%V W/$TPTW9SRF/ >8SR3<A.*UT9AOK52-L?1$G#+<_#;
MVV!8J_L<Y'/1@#8]T@1YG,"=*O#'1-EPW"VN!62!ITHS)87E)S9.+^HZS<+G
M?$^!O%'\/?'"<LJ"\<6Y%XOC^,?7YBI/WD_=K6[<LR@54KQ[6-3ZZJEM;_#4
M#5072PI76:)=GA5.XYV[UXO,R_9.(CCGOMB,'*?-5>(VE<\<G@)$'*^V,O8[
M^P>2ZH%M']YRO[;##5'H&NKL]-SAY[LYHI^/)VLEP6X248%$YYXS";RUFHF(
M7Z4CI?'U4#HMZHG(?]4:2&B@(,$/]??74A(#>]K2*7I.T=GES@_JUHC+%3Z,
M?_!$A'J:([E;_SB>AER>]G%17#=NN3"V>8"GVB''Q[JM5 G;F3M]8L/[A3(C
M"XOJ^$&%U"QJZA8C<#_GV[GE[ ]ZK[((E"XWCCTL;;54?6FHUC=%P#K5UU1G
M?<UY*0M$DU=/D$L>&?1:=R1I_ADC_O7(S[T94<5'=HN4I9T''M_$BSM2KRRW
M-YEXX5?91L9LW*!Z?#2#;-"OW"59VINQG_.PK6Y]7BWXT]PL9Q-C*^&)M.8N
M@2ON)JS@^,DB9VF3EP[H3OV7FQ]"_W41Y9]%.!A>H0@(VY""-U2B.-K/K^-T
MMLT-GP**GV[+MDUUO2W&A2^$!.%-HF:.>VENHC8^K U+9?&ENQ%016OTK1Y]
M0SQ6>"?9_ND;$S3J3D9,N<#G_/FC1]YV"GV*5WR%IT'R4C72+Z_3I:%ZN)-G
M*CKTX;?;B&;QY*P&"6PX9V_5V_5/T4S77*F&+"9!N]C%PO",7%G <ID!4AU:
M<H_Y\K5Z"IOEU5!5<[SDT3$+F6GBM.VBY1&T3)[;,CV-&9AEZ^[\-.$_IIL<
M(Z.]BN^FODW=1:S7_8'^E@W89HJ$Q6GRBD=%&"R^8PN!FK !QT6SC6K&Z8.@
MN-R&+,;3SH</7-D5]&K,Q"!4M"^,U*2H<C53 NRLL.-+-'-)9O7I%[K413 !
M E1\*6:3 6PX40G(,.'E\,T,+K & CCU^LUXLU*[^#H*_;L"P\M. HS#,M&/
MH""O@X-Y9E0M3/I)2VT>%%YYG*Q[*X2.[C3' ]4%:37TY+*X(GUJ1#6]J?;7
MJ67JII4Z8E:*D/&U.IFZ7SJJC;T.Z.A1*5()<1C))&\Y )/IK= M4(XM:QQJ
M/3<WKAU,'041:(A?BX&!+6S\TAF]"S.'!<*J"MXX#KP1$:T*38J]?]<X7G)+
M\9JO\YN/^1W?H!\29TD/AR27B'&Y&?%.ZEGN3D7R'$P7! M<[;L+;UN[_9^+
MB"C0O]ZG)(8\H:WX6A7)O3%7/NY96Q"LCS<,*\",$%!WV:7@CG%*GM>\I0^?
M-<6Y.R@Q> I8I3THFT@,>E^,YFU%T:&\;^M),TFZB>+7\:B&K)\%<&NZ%QOC
M$-TM%W786XP/,8VD6^:6NV,>YZB@_;IVV33>TRY(F;Z6%3-V$8VDR*LS(#1%
M>%H\%#RI3:$LTUL<]#'?<-^'5NW@Y@UAQ8?]+7*/.9(Q6^$J,FQ92DAONX1.
M ;I\8"=)K?Z^XG-$1"I)'9C8B,K2_C,69TQZWG@6)2V#^:@5Y<(>  4]\YKB
MBGD3QI>AWM85%3-7)I7<BBQ6;6V,V 3D(3H'75V%8*, %IS0+])?ODU'!4OV
ME:M-<+F#<DXH5REX!_/%FMN:FN=GT>96(1)$IP!'*L9=JO'BH_G?)(L2SVL]
MKQ&\&:Y:V+ZBQEJ3^'\Z[^YX-ORN[2BM4COT9Y8:05 S:JM-4$'%IK1B4ZNV
M4K%B$WN7(%81FZ*U-[$:M&JU=HO:U-/[>>_[>=\_G\_[__4]YSK7=;[G<XXT
MJ%J,:D&5035F5'VXB@!!W[9@2>,&:-?F=M_BN"6SZIHU5Q7S#V(*H:A0NF7J
M#TI:V^#^7IM&<PN6"]4G@=$XLG[YBLMKKI:L.G7%FO,\PGAG-UA[8%ULN(L:
MA2 /G_+9Z*'4M+ ,53J$Q<@<.+D7.U @&0P?^?M5*6,,RH>@6A./E763.FV/
MU?,JHO/:-E&JFIHO<K>E5#&//LGLG-J>:5J][+B4E-M%IO+Y6/SQ;UI(,R-X
M4+;$8YX(J&F9E!=.,/!Q-2U;Z57+9JYWE/1]0"S D3UC#8(["H[GV'Z:(Y;7
M7X4P0I5DM_FA2OI6DR0H8I.O69%BUX>[TP]4X()[KGJF"JE/%6RJ&J#8?HT&
M_<6,'=H%K?(<*U4T/\.N^L-9,0=T_[,-XL.3^&_M)Y;Y&UAQ" @+6M:^3?!I
M.*-J*61Y8D!V,*/% T+"9J9$YW=S*@-<VRTKJ9XJ3SOA@YN_T_0.EYKPVYKF
M%2>V+*(862P%4)&9;P&]8 \N_*$T;:H?=&P( 4NPJ$\/BE-=&.5:$H<9>&K4
M#"X-2HJ!::[1E>5_]W: M'];>%#6#H=0205B OJ=9F'!SEV$S8?:$&&N!#:H
M2Q')!E:+&M3U!<ZZ8\3U8F3U7O"=VSKB9Z;C:H^@A#9K#[*'9*Z3]8W" &5^
ML^_%:59U=CAV7'\*$$>)FN>;7=NK'>$^GTR+LX@MEM1\23S^%LK)PW#_(?0Y
M2;<JB:J_BAW"G$ZRLJG'$X\1J./-QWTW-Z#13FS(]7;NK:;7A'H@J!K&I;41
M^PMS0&/_\Z$VG%\)4\,&>FDDFJ"M<)@-12L-:?%51)-0C/$G%92=R>>&#]RU
M@XBG"P7"0W#]HN2X_'29:: @R^OI3#A ,-J.FUQ_]WE6A%C,@)L-Y8 E''X#
M&!HS5S@$[9GM/7U(V;(OC3!@M.G;[>T)EQ.D<_K'FAZ&'O#+6Z^?2FZ/Z8@\
M^TQ%&,=^QZ0)RXM@=$;KTV36<4\HM#-5_NZJ_:*"S'S$2+_%7W8IE-8.J\I_
MS]J(]L'9>*_X?K&FXH9FV= ]PTY=)2TK>+Q5S12P)OSV$L,+H)L-Z&+(HNCS
M5JY'Z6XLU';<UMOTYR+%,(^!9O;"G4$B>K.<>S!H'F.JI3/:=IGG_GFRZWSU
MX@/X7,CHZ4I.YW5YZ=[C]5BH#[B[,'W1QT'+C,ELICY)S<FVD8KB_?V*)H5:
MJ>&6PZ8CWI(7AI5-+!2I3(Y&@4$'V"8=H%L%1\4$.1GHUALY7N$XW2K[<Q4<
M=YFKEI*-6:HK@>3H'*L%S[<K>4Z5%FH!'38@]%: L$4UFTW&W"=C9?8F7OM?
MS9F5%KM?$5(,X7'3XH;DBUG>15)/1_G=SJ*5T17KT 2..ZT"B;NB_I 3@:8)
M'%9'[7/^7&D)@IN5EY;JC[R1OF?Q@ -Q>/AS(R!-F:[H=R#O[.9."PB?$M"O
MULH%6K\4'L8]!H\()GA>NDUIWE6N(!^F9U"S*2S-'G@B*?C[PVK(OED3RF4K
M2^MX\*FBQ,64L.#14Y?<_G./Y0\1X<I(-B6.'\#\YRNV;Z@,.6O$I<,?C'$]
MCU%^C0.2/>;NR'O+\^E=&'M_2;$$JOB5E)L7'Y84_8Z#Y>QB=KD3[_MV,A.W
ML7]=)MBJ89F>%X P;:CCNW0$$^3J$N\APU61N3N9X[)I>^L+DVUPG0_5\@%5
M_@UZ4$ZW\?2T/!_WL=J5[JAL34VP6P,/E+-P/3DI7IV)=#%A@M6UR_CG,/46
M\&[B!IOO9 \IW(PW@;; B!2^>;CO)=IF@W],LSJX!]E!^?YG%I=^LAZ$;/?D
MCOK[!OOX=K/+BZ I]L:7^AY@T$0'%[?N$$W6#DZ\))1Z\].7CQJ/>D6#0&"%
M/YL'J>]F!#('?V3*T';001+\?C</:?&P?)RP30K*4&#KS/T2OX@\C[_T6"+.
M7$+=66O.VSD  $CAG59=T>X] J^^/0TY)2>9)#?=90W%@)]!L35&B3.)7N0S
M-9J[$6ETQ0YFA!2CY'P_Y*QJ"IW<LYD4.@!6>H#Y$O>(_;@JHT2VZ[7B05>[
MI38B$<6UJ>.T]EGVW8>%C,LMKHWQ/X&ZV0I\D1"/7;;)_9FN92WV1[Y'"RY3
M!ZJBE8G/]Z->8_Y<:)Y[=>5/_WW\,-XBD-1;ME'X%*\QDG=UDB,1I$_QKW"%
M0+&U&X"95H "[_@U59>:N^]OGTU8*-DGL9/EOX#?ONI]O[!AGAH,K6T%48Y'
MU)DD:T5>"-R'H-TZ^N%4(O#17$P&J0F=R[!H@0C:2%K)UTG22045BX8TYF3:
M/K5T;T'F\E? R,A-N0'H'2,VL4&$>I+9L!>DL$8YC9>,"_K2P;-H1%QSYTI1
M)9!Z<0V57=)D.9+JYQ[9+B^9A-Z7J?(E)#U*EVWWE'I9K.DI&'OGU<&8[A?>
M\83D7C/&F"3RNM#^E>!+GBP(2+_P]Z1'($3(!!8Y7 _F0!0"U8"1+1TP0V9S
MG^=*=ROF!-2$R=6H F _F7[H7+-JC_O8]!*B.%\X",0=YW/F(9(C$O.2[84M
MWG#.8KN!IK]943$?XOT,<NJD75K)>4S%,\,^CUIZU0]3UTZ/N-XUC(8.TWD\
MYR8O*0<PY&<Y#DC-];["**-A=XJ4GI\G>"]/#WBKR?^/56:7?P4',K><4&WZ
M.EG_+$G,D#W?DW0X>\<X.U#KJ])N< ,(Y@YJ79YPQ&GTT?37R(>WL?WO?$8A
M1UO"FM#)2^2R;ZB\Y4-$#BIDW9L;RV%AUK32&+/$QT$P+8[4(J:7D.'VF+(Y
M)ZZ?!2<";JPRWXK%V:8CEG);SP^@ON1Y+^B+]-_OPL0B1<*"V9H7/6@/$CH.
M3T*%[I0#KMBD :0_!,Y]-( R6AX,9V4W@+9W@EO\"4D>_5;F1O>%X5H:#%^-
M#%SJIB5GH_/?9<8PD@"T!V7O1M]UD65Y-?\Y-W%4)$&OBENH/ZDPIE[YB_*S
M%,2RB996(9'6LK*Z_KG=?EA:ME=:X&"#M@(,,P3XYM@=@5>V?%F(;*&\G\M
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MEH^L>X2EGI[",@J_"[?_:A0A,U;Z)?EE'>>(\)=/(UK=I01#J(L0]%&14 N
M#%J;DCUSFR;(Z5>7G4CL"&*,<.=K<ZFK=!E&^"U[MG=;U(/%AD.#.-?*!PRV
M"[-: M@1[0QZP^3T8;U[=<?SQ.#]:N2+%4&^>C4O+.VC.!3J@?SFK3<?'I$\
M> %REQ_FX%"0KVW5D>5RM#:V%QD1E_4K!:TOF9??/D&'&_%(H5XQT$9%0R2J
MG#TSQ+Y4VQWZ"''%G.XN%@@+.'!:4O-[IKITQ;O*I4D:&JJ4USP)AZH7D*B6
M?NPP7'E<?$7Y[<U'P"GIH7/7$?:5YK,>XM%+#N-BJ_+#DF'=<GN^XZ>(Z@[%
M*RS]?X]J:FZO(YF.0^,-NAM 0^.7?S+'@Y)O +/M5XP/.&'W6E^PHS_.L8C[
M-*\M&=!L'X12+6=4^H]O=,+ZKWI[-&2>46"[+**+)L"]SW)7E3CUOSV1X*%"
MQM7K@UUX^^:0H0Y$U8ZL!UNNH;E>;!_GG7JTI79-0B[4;C/.H\(H+U\M4=Q6
MY.3D%D4]%Z'_1%P;%CZ>T&G=E=!4^<,-W9*2/<@<4=A *F(G <7+N>"]>AUU
MI?Z\N\R<+&WEJL,7%OH?ESLT\)./N[[D"U^=@H*R$&+, RQOJQ&_G7%OLKD#
M/O1?!VSG()I;)H^D4H\O#4TN[BA:[A""W<;^.*1<*.0@.BI#V@)7J(YW.YL1
M-P )K6!V79R549>E_*^H@!-K\W\%Z4PL);P'+]?DGZE\"!2N)G2-T5EK3+O,
MI[G/ZP5Q, 0^N@%,$2:&:'FZ+A6*?"I"()WLE#)LWG(<E.+Q!]^<8Y?"/KHT
M*>V'4%>N#PK6L5G66# M5]1/C,Y]H)8PM;^K!O["/:_2; PF;].AWW7.BE4N
M5T%WM*VY,JF7)26!WM)/@EV:ZF!5D4?*?+H>%*M"1+U)&!N.&8&2.!G'HO'"
M><N9A 'H[QH;N>;TL\RJ+WQ9LN0K<@-"*'>:##F!>\+4?BR1P@)JTO8C"[;V
M\65X%\UF%FX#!AI^-&6T_OQ=P8QLQXB&5=!71VH)EN!>F^X]N9=O'4_;^,+R
M;AW>DMQ^7L(9JXTB,W!2?DI3\1+,GUGC76/>G\NS9LT_Z"';]\AF7$2":>$W
MP_ZH[^0!JK?S'V2"TU"5L[$8&#2#@:MMZPSO;1?"@#5UO0&G;*_Y23@-]&-\
MY/!HI#ZT/S?>&4D>EC2"]Y+I7^$BIPL%D+%$B$^(;_'60)S_K]9S1_\6V\3W
MO=UQ^^/S=]J;%Z[9A]476S^1LO/U%U]RKJ9X?@=+COG#K[U//['][PQ&,;]'
M+([/(TX?%-T 2+3\N@3>.$#N5;MY%+?,]F[Z+-/324C< +BVUMB#%.NLGO]1
M?!LWB [G=3%2" [Q!!W4CZ%E@K>> %A+3)! &E420!\1T6<5#S;_+SMP :5Z
M^C0JMVSZ<KX@R+;Z-5=<0>E4F^&!;>N\''0^;'-%I5,AG_VCLIQ?_?[*:MZC
M$"N?W($&2\-=*]AW_6<Z7BZW 92CLG\/&-B=%@D='<EANL6?DDG&JD6S&"ZN
M0F@H;7<K+]].K ?!U/Y^"1?=D@VF"H^N0*?H\D%DH^X>!Q*J+Y:15S,]FQ<#
M^>-!-?;'^]<M/9F:5RC#$T1(KRRA.C&AZZ[BJ39U\=:$O8*Q^,5IR)(T,G$0
MHXBPWU7YD+TL^B;V5Q[B\YN/.C(]-MLW -X#9XFQ,70-SO!.S/![*<?,Z?[H
ME]Q.!=T8<3.E*Z8\@;)NU"G._/KGV0?2.1NBOWK6[E!U%OVAGE]C?U"8F]/[
M_E/IF_NI9Z<^I5WW3&8LD!&DWPP**!*'LJ8'1KZIW:HS/PK[^OO!)QLBJO7:
MSRK/MVGV0FI/&A-E<SX5CY>"R35E[<6D(M^0WYE(ND>?G/H _#O]98CM&5>A
M#Q6MU8ES(/5!"+"?Z K?TU=[_"9U!Z([]IP=.1H$O,85T/Q!O_@9%&%Q16X8
MM3ZZM;KQ2V(3KTA:;0SXV!A"\]C09H$_U(V%I?RU2E]5ZF,(\@]0]+Q@4;J/
M'<,(4M=F7_=LC4@]DY4N8!=?U?@F8#36';B,7/;T.>6/_"-T%1P^O7,5, WT
M,DF7'NT32=7%H:N-"CY%B203.([XH=<["FYC(;3+;^763*L/W?]6>!EE[6GB
M?E7=$?R^*[;RP-D\;^Q9R-^,RXO2!T87EL05?$G)/>?TI3&*J;@:[A^_9/1,
M$S\*0.H6 ZXXSH_\5C.IHU?_RHN[()JM!GW_7IX\CN #ZI_^@& G5IRGB1]R
MZ0UB('J7XG(:FT^<&>IHOWZX(\NXZ$[7_7J'Y@;P^'=;8U).3OD5Z,4WXX-Q
MIZ?V*TZ^?6H%'#XI: G#ABH<J"! L8@8[AP4^>!TY?%24==?LLW6\.OW%3&M
M%7]S\2.977/GB296E AD-$1T!J%I?'0\65@&Z2!*S@^[<SU]UN'4EYBHJ>.W
M9:!^9EV=1/HW;C\74%@RYK^M E'<';V.]L59''>1G6/_@A+E<\\M)G:^7'K\
MO\WWH_I,;TQ'(;%J2EI2JVIF:&2DO3<$_3\(C9K#,OAK>.%V(V"=5G5=E55%
M0Y",9CA+A59$OZZ=2<>+\3O_:R+I.!O*7E7O])V*BIDUE#Y_!6KF69 2%E2F
MU.7M;J+,!#6W(W.L35%Q+7D(2*/3A#[1Y/[N("ZZ>1H//2Z GW4!?^O:-/H.
MM^Y4=D*V_?)Q5 =8!=SV\C^K(3&EA&7PCYJ:LV<'\@BV-8-@^]E.X=YKH"ZN
MTVC"TO(7=C5@5+:_Y&*B,L@ZY@*48Q]4F=_6OF+8>YSI&Z_UG^"2X^?&\CZ^
MG\IB=D1^,J?N*%0?A/!N9A?-.Y_-2RCFUY"6,LCIF4;YS128'KO''BBJSBRT
M;[ >SRZ3Y_-6#80Z_.Z2O8)5'O_L.KO%>P.(O0&4S(']%X"-GAT>E=%;<7A=
MPZS)GUO/_('%>&3Q!X4J!;^O,E>:%XJSD/39J>($ZH/*3I%_,0VY_/^EZIIW
M6!.P_3-"#SAG\Q7".Q=LOGJE-R6Q*+MA\6^:/1U.>E47S7UG!>\<F_Z/EO\N
MZOV_BYI=:#-P6HN2V&[T_MU#UY*/8](AD=/1MDM"Q2;$/=DACU*73T5HL2E1
MZ<.&FK3$&%<! !!=3!. \@0PEXW&,&/5-% QO%7=*3[<YVLWA/\"4$L#!!0
M   ( +J+75.IUAPB9W\! .;< 0 1    9S$V-#8X,&<R-',R-"YJ<&?LO 58
M5%W7-SYT(]TBW1U#@W2#=$C/## PPP S@ JH("$(2$B'2G<W@B(M)=TJ(""E
M(B6@\@'>>GO7\[WO^SS_[_I_U\?2$VNMO=9O[;77WN?,.7J.)X_? $BTU#35
M &AHZ&C7T:X# ,>;=/)7G!$H!-(9X<XD*B $D%32U,7$!)P0'4N+8_3O+,">
M <T2@$'/KLZ #@"@;[QC0+\"P/7T%!$5DA"19$#' ES6A8(\$4B$(XK)#.$)
M9N)G,D1 O>W=4$Q,AA"D/0S"9&0KS*0/0B$<()Y,(N),(D(BPDP20D+N<"9E
M&,3>[3LX^QD:232,P8#06LPB8'"D=UM_A_1,)WVF6SK5GVQH9QR!NR?4#:7O
MA7+W0IVP6*>R*TB4D0," 3MKH>F&@D#<O. _SD^/RC#/4_["F:T1]-II"R4H
MZM3F=Y\03SU[.,18U=SX)]AW@RN>"(2C$03EY:[OX (Z$1,"K@ \ 8B3/XX
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M/'F\"2!4!)_<AM@JZP+0C]\#B,\X /CVJ=WQ#" (0(B+BXN'2XB'1TA*@$]
M2GF!D/ ")0TY.24Y.0TIX1G]=OA[0B,B(" B)B(A)B:A("8FICC=$5-\-R']
MKS@X?@8@Q3T)_A$&&@L G10-@Q3M>.ZDH_C'[6@*)U%BH9W1;VG$ *"A8V)A
MX^#BX1.@_5F)=K+Z_U"2 - PT3#0,=&Q<+!QL3 (14^4I!B8S&3"6(H&]N0L
M'@$BV!0QCRN46-DH#5L=1,4\ X>4<=ACC3[.;X&0XE29E7<X5.*,P:K/LU!
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M7\?^-T;M!,?^Y';WY*Y,WM$3 6>R=W>'04'VIU:"WF[@WU9<]Y\I0B&8?KT
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MWT%U7B8[Q=YP,GH)UY5LJ2^D1%%XCNE:,/23&_:H:D%R"XO*[D-NW\8T$=[
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M^;M1I(Y<R6P799F>F8[ 8T&IB EZ&CU>,>N''1G<0@5L;0^#N[3Y/JO1RY;
MC7=9X&_C#)NW$['%<'16$M <H_&L3*IU;G*J2.SV0:X4H_K"&RLYR"D\:/:N
M,O3#[,C<QK%K)F0NQT]4[+4,Q&4&7Z64N[XD'OPZ'PGI+-$<61K%3IL.'MIT
M9W R<KM+C'1U@3X9BM5F%RC7+"ET?*"BUNS@HG8%\< Z,3?U@K_R4GY@J32?
M($E,Y6"(Q'4J=MM00RI1PG"?!8HA$5DMJ=5U'KKNPJ3Q!$4*I-K\Q0BMZ=S.
MR06_DQN,'&(0+RYH%;J62RP>JWJ1KPQ9P-@#G4>^1O/ -FN4P.BDGA+8@5S)
MW1J[3C(P<N-+W903;R\<-@2ND=&(XB@:,A,Y%.[)";)>J[6:YA^)%+$3;KXA
M7/1I[66@8O]<>BNM:;>N*<\[QZ[LC;<B(G1&3(6Y?OP%I;%RF7+IKR9T-T8#
M%J *U=3&8IWC3[$7ZN]E"LR^K-7XV.E0*3ZL7=60)-NA-V%YU/D>\EKO#<U,
M.STIL0!B2;]NOPBK3M%P.S"RN.P),LK[O=!JNE38U8JFG&S&A0FBCQ0RVV M
M%ZQ7JJ^TFFJ;9&Y$*D8P@9^,0RGI4BM1QCNEJ,D[%E<.^=1)@@>+VD#.42$N
MX\H::]2CA%K0(EJ5-SQVH1[ZLB5A0R^Z<^-#0'':\KW<:0YP57Z^5+'=^S)>
MA'G(Y;T0%:@#F./1S1"S#VQ1HDPQJ=U)OBIS3B79.S>/)NAK#%>R64J]5K2M
MPDNM$T,K9=@?7;9DK(0OO4SB';K#/(Q#/<QH8G>9XW#Q5A'PBY&]N=5<U>/G
M#N'.[@>%0DF0L&&BQ?;1T=)8H,9+ MLK-JRN42.I?,'/'J((%TI*[@/R2^+[
M$DHEB[)=)WO%:):2BWV3O -(L3?KS=$[S6^[F=F[X">O%3HT[EB#'DTY7DC;
MX=PLH%H_HH_RM3#1\C"3HC%3]?/H+8A,?)848J@Y:))=]*YXD56<L<V%,-!>
MYW!@I&^6;1Y%,?\Y&)/4=/B*NH:0X]BX2(3ZE4-O$:UN,*H_LJ2=/27[16?2
MRK0(SHK0'=R(<?SI, *H"]A+=E?_X<P<!7&^0%BEU&; )FG#ZZFD[CL$=[*F
MB/A;ESY\E1_NS+.J8'(UY1#(>388U5[Z<%1J(?=%R=Z>5K%Q)M5.=?Y,U8L^
M_DLRC3CD7)6 $:D7;[-O:QC"OX':H*#"_+P,GH0FPBX:Z-OB-F$\A]C86"GH
M^E4!6MF/G>RO)''9IA)2-(X!KW2F:+:*/7@:T@D]5=G8:Z[YUO7G%>5$*8I5
M K7\P[L78X[H 8FU&S&E7TVIHF\PZF\,:JA?>:-=_!CK2&#]H8>.^#L?K+I]
M=XLY&^\ WQ(:V[5[E\P.%I<>FG,_P!IJI_!M8NW"-0O+XF!%K;0?287VFT2U
MQ'^B2W+=*AF_I,F.*9 3$NJBH<WEDI.7W\X4C1-F&RHUD!D9A7R<WH>DHKA6
M8\3<%O0X-9G[X]?&@ADCIA2M5/$C+Z%*\P(P9-IRNK:BYH*[*R1"KO0JL/.F
M9*?'QP'1^_>[:#\O?B,\!C#<NC4H;6O\S\^>_QLLM<I:=4B;-+IUR<6@79\8
M"]Y/@[OR$(2#58^L3LB!Q,@EC\()OK:NT<ZM95;'3M3 U(3TMK*!+%%Z>?>[
M&2.\O#0"2W/"F!<@K]9]G>CV+\5NK>EE-R4Z&$(DY (Z:24JR(O8"/U\X6^]
MV7S]&-0I)[@?C\28;^[MC'7<XYOXT%.%]&2C"9KA&'N39YF@UK1:]T*G]S;+
ME3</I1>LB-*97^GNA/-!>_CA5CL[U7'&FNSBQ$=3S+ZE+SRN[/5(WG498HN\
MX-Y<6P4@0T2@/G:(C9&V=^H:-+WN'G+2;L"J@&>P1WH UD&0*5-7YX*:=A.>
MQM81TW6\":;+CQ0>HA?K96L$6#Y!%+5\\B?%#*1A.8Q%/.W)?0H\<EI,VQH=
MU3<SD#/1B4K)S(7R<,:/3\=",U;98L8!UA^0:3! 0S=:[ NNK$"N^;#',<KT
M+)&!>V"/:O%(ZH8J2P UVU*R =^K:@_N8O7I8X!#!<9R GJ)#@%Q!PR;; /G
M4D)(=;R[?NC56&T%>#CG&T:6%'CMM/E^YXQKQJCW/5J*C9R]_GS6@.IBT.HJ
M& F=;"5G(9/'T:[L?@:2.ZII$ O..R@-O;$:A*EQ8"UZ#Y+^>+BYX_UU$)BP
M*4W3?:J"4ZAAZ/!#!TN#X]$E.<V<5%?B\:]YG5WSIN-?L]L/ZI:K]A]62=7Z
M#\AO[Z5R'P-D6X\!Y!]O$@XX;4<L?F[-VB.W%<ZE6(@6VZ!59<+$5S2JV&1)
M!"?X H^035\9.[L:*[_,*#_=>^AXWP_R.NX##/'!_]NZJ]?3Z?VZ&?K^I[=<
M7<6/%"9:!(:G^">_W8A(11,(JJ)O.0;X!FW WC@2!515%SO;U(0DV-516*A4
M".MIQZQ06,S+:(8$:@PM3K8;9T9)'TQAV/N+ B9?=>FR[ZUF%4SM):UF,+PY
MO+8$$W!-FQ"J&<#<  9L'RD79(DD8V:GEX1JS<#Z/GO7"29GHT]9M3$Q24J2
MX":+1CC1=GI$+$H.B$8L+D8L*N1ZI#GMG$RFU_>E@Y^4OVO8%""^=8DW_ EV
MVA[/32[2,8^PRCHMMX(*FXY;EV@]U2?G!82:YI._U;WL5!BY>6OG)CSEL,LL
M[<K MHU+__7"?9^0\OY-;'^@]_[K[*_6Z:54/>Z^8HS]&[ZY1\#%J3JI#3=,
MWY+QNJFYHY17LV9<+B8Z6LZSG^@^-;];,'V4IVK"!B?4KC'W2N&())RG#5O@
M1RP9K&'>H0ZK3D.D<'_S]WF]W#'FI5?D=3W#P'(MSM0EY5-/L$&BGY/K5.6R
M%KO,LSVJA):.6B:^()*[6$*1&0,LLV[:REE"&V[[JJ7U2,*;\ZZE!)X26,I:
M<JJ[!5BFO5HFG05W3$O)N5(ZL5OUC/O 9;UA14\_]U7BP@3B>[;"UBO0W2N8
M4F7Z\BYGS_C7;BYOFCGG%>:6)%(7>>G20^"B>]/CG9STHM,<XA62HQ)S^8*1
MG>Z I"< ['M", %)QSP((3I/X(BHMJ;@7&K7A_K$:A7D7?%G*L@(<;#)H-5G
M?WVMSIKW"!O;%-][<N%/Y5FY,KO\4=K\WJ/OVG2Y8F>K_<+AHQ5RHQN::0PJ
M\I#.Z+:[NVO"7QR+1U,BU#+U74-2,CR\:TH#H^R-M EH.FO*.S#?:-,SD]:4
M"7B5KMC&\HD$7AQ?2^!P Z>8=V/&L*LX<F=[L"5?8E.W?Q]=GS#I3O45^<&Z
M/H^7'>IW#,C(*8Y.)WC1V* R%W2 W02&$4Q U5L[$TOOW7>IQI"@IOLJ64O%
M%=HNY+I3Q;NU 2*'1925I>14#A+I!"P(UQGHD[\)<8()9W=W9\>D6M9+)L)E
MQ..!],IJEM""9#RPI]+SN:PJADJ@!0TP#3:AT5D?!>(E".Y,',\@DA"WZ-KN
M+1S:1D7NE[,5$?*UAL?L;1!!$Z$1)'<MN1$%Q?JO@-H#--V9? $.J8ILTX3+
M,JI1A&I65[?3#=J=[BK*:6<P'+PAK>3OZT/J>'94,-AUL3(\-Y^@2@0L!3S_
MN*TQ?0E\U[!BV7P>$, 0/.#]20*=L0?-=V.O7A*'*I .UK062KNR0UZH,C2L
M;&2FE6?!S>7*M47C]8[2\J$9+!(OB1\TXVGY?KP!31+"33_(5VRE9],>^UQS
MJ]7DWL2$2$E-%5T!K\OJNE-^RH=\5/5+8Z/V\98]F!)/J(3W>$@  []C+XC(
MJOSEB%$+]>7^7NB;A RNY =*4MGA9K$S5D_=F+Q[&@2B&Y?:B_.TY/3D2E/7
M[O(AACA&4VL]PFY]BO+G+2J\T7U35,!CVZ$^QS/-_U+._1HR/J>OHLMQ\)-?
M0-^Z#IV. 7;T8B!>H_O.L85]5,>  [(> 9_]M&OFQ+9.H3O'@"S$7M:-.^E+
M,KF*/O3'@",=D$BM[HHGR.$K=(&CCG3C@<$;%[*W^.K\ODTBQ?-P<TFSB?8$
M2K<[#$GQ0;(LD?M"_75#]^DT:S\/W)2+DU&-J*0V"I^0INZ1+05'CV@?:B4V
M:LY>Y!-$ZI0ATS83T9#NV-K&\\98"_I.:/,50E0]O'*3EO0DS)78T9VWL5I[
MK\X6CQSRKCPMS]J6'3-=#N><!+N\O[G(HLI3V]9B8UKE>*OY:-XZ7.;:8(^4
MQ#97C01TCW61 W4,D)HX0E8(0N-FK&QK#-YODK+I!:K-.('L7S8,4<$VW'H<
M!P:T05/<S6F&[RTV%AV'S#?FRLC$7NU/7T";GYB>09N8[O?9'G-MGS*9U3"5
MW3,.2S5[()&XIJ'U]D.OH6MT4.?,LB0(;,@V3,L1LV#A7FT-C%OMB/2;@)LH
M<^=DP:+@8B/*LA4$V#U\1/'1S0=PR?:I94+,J:8)$@%-JQ"N.5X./FSSR<^3
MV[XUL532:A$;&'TP@1<K8*?8\$W&:O?U^*!42,AM/&]1&H;1D.<UY?D\:KI4
M3%I]&Q!1=]:7N3QK8T,7$B1W9B='T&*1;-&N3]-S))PK"J4]-/6M]D9J8CI9
M_(RW)7PHJOK)%70I@FJY75PNT6LR1\4? ;&@O<$O];E3M+R3M6<_[;6HD>V+
M .7&0=/ C,DL8N!^+7V-IT"5!$/10W,H$S*Q)H;!,,$MY+*!"-,V4[A6Z[R8
M,O#M@,V*OL@X[QT!6@T>J,0#?V#J=>':SS-Z?'HM^%/"N"X7*<%-7QL687 V
M$^&M 2 &)AP6T[V74',;L%B)%=SP6E.7CR@WENDS;1-_9,< X/ERBXBF]Q _
MTM+-RDW-!_-U9?,5;FM@<6?\K>*"VK&KKMAYV2B!8!Q@FRXM^F N<*"2V!RL
M2LJ<(A:=P$RJ+CFB"DSY$"5-M]8'S)5^@1\&=7DL,-=/4&OS<CFA(>_*LEQV
MS88[GZ^F:XHBLY.!/I:Q?F NAR[!9@U#)#&THEYN  JH>7ZRJPY$,P!^R[VQ
MU*RJ2V^C:198'[E(P).O-/J1+M0>08P)^Z#-Y'@?')/EOO4H<B#Y25 E,=H=
M"4]UFFL+FPK3&2]]K6KR* N\5#ZJZW)?!\?(9W#".RY4R47EP@SD/X1%W@5R
M-@S:N68LH 8NA-" [DPND';PYD)J4_9>;%4>2)2X/VC>K+*Q^F3S\N5ZR&V9
M0#GHF_;"=(:TRIR@M]MWKS,4L>!X! Q*72P>M"M\)_FI@X*I?>UZ*E36\MW-
M8O!D'^7^)3SAYZ^&0/#X*D*](K\^Q<DB,"H5\>7-NU2,PGMI#-;,P25W0ZU#
MA"NJJMRK)&T8S4%BT1O2B9/W,&"O(1=$<"]C6F0JV>!6W?GZ9GVR5$.^:4LU
M7T \0&I:EOD=Y8NO6N\:;S6+R+![Y]^S[/< <>N*7%^.5)(3 TA5 (/5<QO[
MD_=8K70C;.\ODNEK&AX>].U04E*B/"7L0S(R"V]!\V,Y*DI<=4:^Q6Q.\7%L
M3DW)\-01/H(9*4T[[YN0JF)NR.B1J1+ZYB<MK) ?2GX=KR>9CVE^QAOIM5L6
MM&/LA;\TF&2:SOZ(]TM(&F$Y"4?^%3"IJ=9MV@DR9H5HBB<D;>(,VUK%6QV,
MHLH/S4$'R*Q-*HG003,C]3#C-G%4TV$#QIV^[;"+7.D+:LU->]W[S7&WV4%I
M"UVU2UH1@A<*HVCRLL,U5F<J"#3XYZK 0IW#PR--_&BE]NRE "MZ+ %[%G^R
MA3JREUW*A4_8(B]GO6/Y;&RG7S'FO$A4;$#,8+^(H0KX?%_#OK-1/5*\L[[+
MI"71?Q-;O='__>>^%6H-R,R,B-1[MH:E;UO(,/8)MEC3Y<W4YO$V%5_ZYDF
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MX;UQ.P-+?60[/<12S/OXO:Y=:&6TKN4FG#J/2W0Q?:ZF:OM.MTWYE'/E5E<
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MO8@OEJTDK]SI0,^5<^,CD2>]D--%*52;\$RBBL -;VIU()%8<FQJYT^NM_/
M\:K*GMT^"M$(HO;'OYBJ<;*KVFVS8(QTV9@+_AZW1W-='),G))0::8Q*S2+"
M>I]@<J%T^31NOGV'S@XHA6*T.YM$;>O+J&7Z.Y X<?BC*:&7]J6<OUV3=[_T
M@JLRR+Z- 1 XO9@:;QC$D\XN_9+KDOAIA,%)F&7$D?F;HF'4 7H$.CP38;@6
MHJ3"7R^\<_39V<,RS^(0AE--B88P-FV\)?R:*H;X8P^)T95)-BR-6XSVR?;T
M< LEZ5'9HT7 X<91J3C?:O"//K]L@&/3U["0WQ?@MEV0:UJYM$X[P%;WME4C
M@!SDC.I!9:M$DDRG;'4>ZZ>E\\P=E(,^FB+.,%Z0!(>!:3B]?1?!\K?^ XJH
M8 )2%8CZ 16V>NS'B3@"N$_VA3L5-N131@K+!3J5<+T>QM>>M".F8 N2&.M?
MSB.S[*\P:W*:Z3Q-BVH@T<D8'N<GHV"/)%NG6FN$*(*2SC:-[>U))5_JMWN,
MK5JDVP,HUKX(_BFU]Z=MV+\+,M7/?0];";'.AV-UE^_4<_$/;IMSG,9#I)XP
MKM8ZR_]L]S=0O0JYM,SEYE6(ID4\MQI_3Y;/+ [<Q9^%7]&1+7S/+I=#IL>W
M(_ZW^EQ=JH>H<&W#*V*(@T@"VE9=:25RLISGZ)O&!>N/:U!S[F+6LSE?VP+^
MTB*HZ&3?MU-V*F5P\6IX74&SO\/7%LI(OV%V5%!]@P;[>9FWUBED"ETF?KXD
MO;)J$GW]:V@="I++/=L(7"9K(4>Y5?0\+%Y<9FH$*&309QE>IPK+ZT?I<$0I
M$9$OHBF3O>U:HR&CI^/U08ROV@MC<GF2BV'YYX/#YOKCTL7F+<L7M+!$S5@
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MHE:N]$>G\V6XNHTPW<[JH4L_/XFQ5I<ED]-/*I=NE'79L["*KE0&:?]=M)%
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M)^').UO=/( GN9.O+;I#XD-A@HPN>O69!#'?"S(7.\ZCLF=N:C7G$CA* 9
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M@<TX!G;>MA.I9I836-*VD7C6UX=S_R02E,QTW'9\FH\))NGS>C?TJMR>(_R
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M*3?Z-F""G(";WTNKIZ\Z=8[->5K]G('M"8N*O!8X=])I\X&O;*TYZD(J&\=
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M^CY6-9B.VZDJZQK*BZS""P-[7N)B#@*>_08NS<01VLRS^*3YY=,%AV]@#CU
M  7O#WCG^/8>>I6R\"^N,&.>/-CKD#.'>[,+<')F)\ZY9O@4*ZI/MT7:^>(K
MDX]8HMF)@$R5)U-R0^_G !35I=&R$OBZ^HK%2'L?"QUD;B*"OWCJ)LX)>2LX
M"^MC. F#/P:=76;X5JH.Q@(U]Y?9"3OQ+[M\TP^*B;>]\D35::4Y0I2@!\Y4
MX"SN1!DSR__F6A2P:"%96<WHJBK'P#93,9:J+$%(.X(AG!&U^:JP&&/HCUF$
M-Y!8O804/\;GFZ8!<1?F$N)[B4BKC;J9.5$:!?W&DTFN*'5[_;K8$19WI77$
M N^D<-?!Q[O1!-'1'B=\#.<JYQ4?%EGC)?'MP,+;FR97B:OSKLKF*L[\ G"J
M 5YAJX.2 D9)*[.P>64*?U _C(YY8.2 =C?'<,:O&2W1N<V%<ZP%EW=YCJ@/
M*.&,#*V4&CLXJW)7IN0.A]W%H-%8@E^W7(>;8XS-!"6CQ:=H0A[#\UJ,Q 54
M)6SLR]K]:BHN+"XZH=] V&V*[L.5!#<AY91-W&76;5&S1V&(Z& ?8Z48<M<2
M]O%\T$(K9$+>:G-/:!WIP48\OFVV[T=25@,M'8;Y\?RW% /"DN@Y*=E6EX[O
M&M?Q/ %H;!JN(I@6W]WS4Y3;':1:\<< ?FR,?SWI6'II5R:F>R5]#]?6(M:C
MXXAH^0MV.W5;OTR#PXJAZ_/]++GXNAO>N8!/S;VT$RX,ZYV')W9##'!S*HWD
M.>J='1I[V4MZ%<E4JWRV0PM*/5D^D_O5.(>Y+@SA(<_GYR+^23TV&?)XE+T>
M%Q5GYJ/X>;^6A:I9=4)$0Y!%4^$6X3:@7[%T3PX)VF[+A7-\[)>"1A'.W.:]
M2EUBT'7\GE+(*^P*+@!^%HR-,C2A )9U#$8BS#,#Q;*]NT91S1Q0X4RA!4X*
MX_/A3FFC"3E+98O>KW%H5"-YNN<.^<09'YOZE174:%ONR]L3;BE;O8A[Q.GR
M).:[4;]7P>N]ROP86:K/EL(L,.;*^_TSUAUL>_%?"SE5P(UI&<@W+0TA;>^N
M:L_-<\TOF J'4T^OU5?G@D:OC*?TY"=P)+8F/MY6 1JF3&'?#U#&9-5!%8D8
MG[/:YODXY75CYD)-^:9I0%CAG=O9KJZ"R]E%/M#2#)O\#OA?.<?U^S,;'"A8
M'2>'9A^9/B>KV:'!H>H:R*U>[NE'C"U7K1X;GB1OUS8N\SZZ_>+BQ9,HV04C
M]O*5E6JJJ=KQ])))5+J3(7S2S?+5OMO>*MZ8E=DINA]5,0]VKSOJ4"*4Y4@?
M*C)G(!Y#YN#9](9$%Y"F&0>BL+W':!?&,'&N^MR!62T%X$<,'H7?-R43;R,&
M3DZ4:UJ*YX8]RXL\2^5RIVV>M:PI-!F3K1#.<2EIO_0]9?QF)7.6@]#I$":Z
MF".TZ%0P[AAUKR[$I*W<;T^U>#T+$Y]\DR;N(VPP0V3E2T'<UYO,15HU246,
MWM?>5+$RH5_DP;* IM-C%,3R497+'.,X'?DIA!@@(2DI(+$_-05"%8:-<E&B
M,*U)..TI>^K/2)G-N3M@)9@[BSB^;QNZ]=PR(1AB2H1/X@;>5H2'PR(QZX%Z
MMH]91:UH^\\Y^L<W#;H&'RX 1 _QMRF-]N8'LTUS *J&.V&5,ZQ+=9V6-PUJ
MA*<Z?>?)<TFF:0V^PE1>_]#FJ1OWJHN0/[.A./23M7T"J7&/+I=3 \R.YV/]
M>AOWYUR$MH::D1TP!Y0O>"5)G?4_6=Z:[G0N<,J&C_+$)D$*D8MI!@)ERG1Y
M=.MRMG1NC (#<K8N&Z;5_3:J$V6VW%E=Q"1S4Q,\O^9?PW:/<!AF_"69?4)>
M7GI_-WS?5/ZQ>HR2I"Z2*T&EOU$B7A+)QHI4D%IB*C9(NYPJSV7X/IY-J#I$
M*WU1"*D*[-C]^7>H\*6AZ6^[,7/VR3\"77?L64.M 1\U:;A,]4<N>CF'R"OL
MV:)I?4!Q@K1$K?1,E1(](A+)/Z"XS1E*=.4%0\+F-G!LAQ.<WH^"A@+P2 AB
M/_?_ IQYS7<B*?A9<'*S'1Z-1EY1E-S!FJJ<=,\4P0V\,*C0$N)QFCAP.WUU
M(E9;#1WC+Z,MW2,W,]#<7QW)&0O?GUA\#TNJ*IHAC='V,/5N.RL=+R7.%2^1
MMCCTA.D)T-F](KY'/5#R7XK4+6E,:S&H5I#%Z@":EDYONS#3FI'QKVL-:@2/
M?O\RBE69LU$Z-<0BTE%O2!M\UFNF;\3L +KZ<C\35P=O7*-E+/,:_=8$XZ,M
MCT2QH\ 1S%TABM'7B"Z])O"9+S+\[RXU'P0\UJ/N['[GI[,.:'VS]+P93_ [
M1KW.UK+^LQWL2M 'SEOZ7BF8;[9JMT7]&9UZ( [36[[JF0T#P7F079+^\?]3
MV0;APO-['U"_FMXGO<F?*%_)A-L*T!ZRYX3W/#V>,ZXK7[ N-JHO7GNO48?\
M8K.?U0W(FVX>_]0@HRF\"$BO ._0"2KD_H1J_-#[;L#*>!H^9-ZDG@1A,H+@
M36HFY,]+2G(Q6W8VMBXP/9MXCBF/,2S!M1KH<VU/I0BG+BAUUOH(/&]V<X4W
M7^RN1CJ^Y7M2HDJBSWO-_CS+-Y*L\=N]"C6I<M"Z%!@DZ$%>D>C#3ZE8V2K6
M!FW:':?HZY2U7Q>/&;B(%!N9#U2:J6J$+"^42DZ</\#>Y,HT$-@"ZJJURV6.
M&7IYYHW?C2S1;'&_VJ\P"$2TTMW;+[51W:>H&YP4%J*X;AWZ%#8NN]9'5SKF
M?V,X -"X<I$I%9,K90TD+XXILZ5]EJ?E$W<%G?#M9LET3G>@\_$^/N_?=_%.
M+>3)?(\JHQT8H&'- !F3-L#+P1S24_N.^,6[#(Z7##)0T^*YKJE0Z75O4:8S
MW2/WAHT[G4L:>?\?-ZVX3_Z*#1OB&71Z-B$AV<S>CUW/_(!*V'V[^%*^+)BM
MB^0KSBV4A<'PC7EDVH.ISDM2:".\^=#I)$S-^N::A]AW(@YG2\?CU]W9TI_2
MO% V=+:RD72RW;5:%[!VI:W)BN>^[\L)-]VNO,0Y3EML[?N9+<[7#2K#T(C6
M9K\:1,C 9N4SO!5.J?H?/.YPNR'TT%J*L@:<)$!]*LAT)FE*H&[OTSAF<J=T
M]M^ Q2;$]$VP^CO1NLX%F/)H00X[:.VIBLCU=2<G8Z$U7U6I'C46VU>1LI+8
MB\T89B9E_[//<\ (+7AX]AQ)@0ME0H#WT/O1X9SO#4?:U!9I5?YSVIAN'!#Y
M$1HM5U4SKZ$SPP1S.D6_9HY45[3>0=A&O/;%X/2$4L/WF0NF=GX0P,3NGSZD
M'5.C!;? 9;VPP-Y=:;]:4[T\F3.%0,77O@G9/$QZ7[SZ<=4Y,5!K1=4X)=_Z
M"@*N755/+GIZG6 ;47:&.6?-PQ8O;1SJW((*HHMUJH-^66G Z2(0VGD6JHN%
MTL@.'5D I;@&=#6(C>1L@R0K =]X*YJH0G/L!,0P2Z G!#CWDX:[[BXT(\&^
M>"[YTSX S&O/#RCZV+CGT=7XUIRC4KKBXF8MZ0/=^&YRJXN)HM$:$U2/^A=$
MY('M3EU[H:&P=D=).C$[V0/9.WKULN=]K2IUVM\'U2LQU=,\<6M43-WF!2S)
M?'6L/^%ZBNB]AGUPY"FO%^,R"+@X!W5[V(_"P(K)YR+LB1 027'$L?+=V?RG
MH[(V'Q*$Q>>UPZ"BT"G-/NY:3BZV'("K^QU!ZTK>$.Z/[:CGE=' S%2%8"R&
MANDS7/18(<%?4_KTFU/\AW>00<BE,N6QL/Y4 <VL7-^4#N0U'>?FZRW3C8<B
M9QND+KT-?ZZ>N$S/-3..>&8YTD8@X*VH5[E@TXL0K$_![TXLE"GD8=+'X".,
M5NQ9.U9M!P5_(RBQD Q# +]%5/B'2;&?;RL3G@Q]0&AGQV;D-W<Z[?X*2PJ[
M=-'RJIZZ)O?_]6_$N0^H:E-NS,![QQ_R]2QD^V[K\R/$@\="N#M54V><F"YU
M$7WB!1E[42B]Y!@-W);?X1X3\)^>S+S0M(\/O3O4L!_=&-AHB@5LC8IU4L=9
M'Y@XJ,_E\LZ$@5WB30I8J @RVF46I*Q-_C)- $KR4XZOYJS8NP?Z%%>0J=@%
MU.)8/TZ75W)W2>B;B[/M4YJ7*O4/*/'?EQ&>_U-P@;?Z;+B -,2<%Z=5VY1=
MQE%'!WL=#4F5UDYOT*,>HVRTX:RA\[K5@<,CKYRP8HI15(S%KXVVG)70V-,Y
M8*BAWZ\4I*LPVD6RUSO&_H R7;P^Z:C=.ADP;^Y"Y;M1'0>:-'+8'? 5*GH[
M\=>U\O2:B&OHLHY*<$Q@YK.!=>@YN&=W[K\)B.SQW#Q"5W] R1]#?IC,OD=.
M5]![39DXG;@!A90&:^O03I\YK58NAQ?FZ!6@7Q>H$*AL1:DU%*8Q/Y'W0]Q0
M-R#\34-#;>VK0XI\=&NP=7,"#8?).@[;&ZV(:'7"J=^.P R'7S5/ >DO1YJ*
M*PT2,^7K'U!4C$N/I(BVW+HZM &(E3+0$K!U#J:VP<U?<:4^*VIL3- ;*CO\
MXW.T/-U#^RXBKTX^@_H[Y<7*7(NC"^6S17(^3179HX5^TVW#@^L;1&*1!/#3
MPIA,17OFW&]W0I8E2_6#I9ZS[FN%[,^$N;@C#,=DTX\D\9@EGQDV!8;W6*JR
MM*WRLOHX1'AM:7='<4F#7@48]Y*UG099^T11//]2SL4)M%EA_1@@;ME0W-\$
M4,P1V&?NXDYZ#UM_WQ$&,;8M,D_?D-[M*(/R$A@2I0%,7Y:TZRE^>FH6W47@
M;X22T0-8 C)RUW9M8K+@=MA,BDHKQ!N12^H0\SGG+%D'Z83T;+&Y+\=86NNP
MW]W3&-Z8]VQDF_*L.$<IP.(<-=!)964S"JF??]/5=9GH 2B9 &V,*LZX8:Q2
MX_[FCFIX4^-X9HO:-("-+#G1_\#2P_L'U']B*::K>+[2P9^S" 2HC:G<:>,;
M)BG0.L!>5#,UK&_\2FY,QP=WQ>O>([>*5F$!HL!-%2-+(.$.!J!F9J=(,]Y8
M3=*FIF9L\,5AO(^0C=<Y=QC'H'CB7-O N:V<%:!+HB9GQQZFBQ/'6;MR@/$?
ME:LZ[F=<@Z=+!D>1!U7IS<9K1S(BEF6KBK/4[U\AC2T-GRES+YJ3%2"-*_M[
M>-%9+JLV/N ^WJ%@;8O_<ACKCO(=K_":[0=47?:73EGA+\KGQY_?#F^GGHBS
M?(M>RWT'^!\J^#^@6-N#:C9W#]^3-(=!>21>=O8MA^4 L0>-YF4Z#;X2Q(P\
MHY\_U:J%["9IY'=PRA"!@0>1N/96\;8JQJ0];.==7G=_H";JQ1CXKT?O/[UY
M-C^%B'ME>S7]_(>PT+?]Z/O>;6GI(C4\%_@7X99IQG/-J+!,PI5-@P.]T<F\
M?.MFSHF<N=6?^G1M=&J4!&P:87)OKE-XA:@%QQ]00P)U=SMP/F RNZY>%@+?
MTP^H(&'P!Y2& 'E !_!]P7WJZCV^#?3F<6O_?B! [W)M/TP'Z?T_[ CIJ^1N
M7>=8<7RHJYMN.ZM%5#3G3'KY_"97\S6W[PQ>2$T>3^+WEWE2&RNEC?,&W%_A
MC875H;)&LRKT@@ZG+H48GF>V%^L$V0MYX#60D;5E&K\A]B>!\)9UW16Y!B.]
MS0PMZH ^6N=",@?GMJG?B%XY8:@5=/"(M.' )Q=P=&BYNJ-7F.<IJ@]#>LX@
M>)!W/?+JTT-$':Y+3;+@Z7I%3M&]N*74X0*!I+<Q4/UQIU$28&7CW2Q6?K8Q
M[(3+L)4;/C(UE*)/(E;[^2Z@9IA@4TQ>\9S75BO :Y.M1UR /"N (%:*)X&O
M:,+6T^OG1>C(VZ^#)G4-9IF&@()['QW%<P/;621, B-8*(QES *E@E+">?5F
M[%FD+<4@9"UV<#;2E7"L.[$<^IX-JJ>%G;3"1=*%306J9L8"BUJ%U]*_84'<
M<(J9 =O7X%B<M3>8*2>)K?..KFQ@_58E#_V(55:FA76S649MS,$=OXJQ?*9!
M7J3OE &=1 NTO C-RGSYL\JO]]D&Y'T-%BVA--MK3!EZ9%Q !.._%25BN1(#
M9%M5PLMGD#Z%"=K +D3T+IN&K\ZB=V7;EQHHS2)\&]!;@>//Y/7DP%#<8P+K
MS5^JKNN4ZQ9HJLY;(^ L0K O\W2B$0-,$'22+KU]_>7[PO![::M-A!E9):MJ
M!HK8"CPA5:V[,-KP_S,H_F]BP9=3\O:F;8 ETQ=_;<[#QJ <TK(RK^&K^$)1
M)MCQVQ?HE%&;&AN9GT!RQT2BFF<+2]A856YBRP\HQKO%#BM;S>I;;YY*2>V.
MJ".!L<O;NPQ07G7S ;+^73F5]H)OODQ5!&U2KXV@T14_?DQT[P0)9#9N9M^P
M9\$N1!LDB(.$'=RZ_Z<N/H\GC %R+90R_/14F7LOPC>E<5?K(P@X080 \-=B
M B^R[PA$GB60RZA==#U'RC_EE#1&X)TZ/RY'%OR<9R.4Y)A3%-.N:DX4G;J4
M-*CP]KOZ7-^GEO%"7E)?5P-4)IKW=,^7*Y?[BO,>)'"]6'V1B-5?'I>8DOA)
M_V2\6T6P1A4YCMI2;B.!&*3?NNOU2&/ ,I2<+U#WMSF^#5JH;F-^Z51\!1&5
M6!@W^E:9/4@&#I]KRZH.5++?KO#WJY84(9"-XP?E!Y0'%CHM"84]KU(KY))!
M_+^P=7AGVV(Y"SWVD+0"!7#W^YRZX0)0+,=\QCJ(! =U"(YP"TJJ%,QJA!,5
MCGDN#34Q^+P)%.(@7W3I:XN>JLA*SZWNLIWQ?/LW[+P4@I(7\.*1N>27L;$?
M[M+#:WHJ8'7F.24QB^)N9D/!##_16E)#V@2.Z IJFC#@";Q/^1?PMK@ZPPT:
MGR7Q,D)6!0N;-01K5R ^-$E"H/GF=:.?<V@R?8(D'#IST0M!*A0&PXE3VL9#
M-4L[9O$H,H*_R\6:'8FA-C9%TC<V,5 ]KGD?3:5")#>:I$^;ZN#>27ZW&#3H
M=XM* T^FZCBSLI=C#[T=Z"M(&#-G8!H\H2/"A&Q">AH.6#7ZDI>&"MC0@9\D
MD&G0 =BK9;[J<=7,L"WK[;??6K;LE-E^.8I\0YSTM);03UWPH=Q9URCRN_6@
M*?9Q'9Q;/E$QERM9)NYW ]E._5I>1G:>?"J,X]D]:6D8'V(L%P:^\#PS"+JI
MC(#4:58!PNA^><$I&!Y_>0Z=NC_M&@I@EVT]N&PF/IM4$ORRG3\61M./-%'^
M%;VP.-Z0? 6$#,T2 %FQ@>YA?=0] S<7*"&%*3+[3U*5*=&B4<_.0CZO/#$&
M<[_;KX:CO3JEF7E1"1?:MCCH)ZT$Q/,,U].7DQQT_L+ '6>O"INF:A0C$/!&
M&^C:0Y.9CV%JPFG%K"R(5!_!D6/ZA)*PHVQC)_SOS%EUF[U(^<RH.&QNL!R\
M'\69L8U-_I<TP[NR,2 P&0T/1V2W7 =?HCB!K>XLE>S9@.-%$FV*.2.QGI.S
M,G-.RLP9&JF_^W""HLS:N""4Q\1$[]C4>TYJL2;?"OP@R@4?:)U:.FZL:8.
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M>1Y%VKJ2,EN9RI34TS;FT^^VP?7$WYS= S 0W<6^/3^C$QSGFXMS*J.8 \4
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M+O9)\]A]^=;FQI:?!?&HU_^V1TI4XS,';VY&)3,7-O,^H,-?[UF! (^6&&G
M 5M%?[/(M[)D0L3QT$_-6 _S!@CJ$<FP*GR1Q?%W.9*M-K^B%:1)Y.>=I,^D
M)0IQW<.H=ACYR!=.]13Z/A/A-I'Q+)/'-^W[84UHG&>G]^ZYUO-4,>XTJX2R
MR!H76G&Q[W<K%LUQ^N/.BWWB@Q3C =W0CH !'ONHLMJ9^%S!Y'&.V/1NV6LU
MUABD]%'5:ZI#B[[B#$)3^ME"L]79%]_X&'NGOO;WRI[@VVY="H-:J:MB7Z4.
MP<KQ4O3*Z\?/N<4%MWBKG_A-@;Z(D]$7C1G)'O12K01EE68A\@8P+\X%;I?Z
M+W HO-C;\=5X8KYQ*B F9TCV0YG3?A'1J$-*AH8ESZEC>)5^@YN1O-Z+8)X)
M=;E)BNF!&"/9&#R5 &Z#,@)I$6IX?Q$&:$&[6D8>Z:"$:@KU3Q%9:Y\*RFP^
M.^< S3]CF=,,K#I.](<WD7$XE^4F%75[\V=IG(/7O!\,R'L>E?)?$YC/0@V7
MOPV;#9H3J_-23[MX'A@;WN7;?P@6C9FROT8U_VQC\9"_)%[=V$@@X Y!E&=V
MWM_"?#J)W4<=8NC;=5!@O NZ^C[1?[G' <(:9*SZ91>B#%Y(GHS8+3W&= 'W
M66NK@HP&<(N966(+^>Q_;2-J,B\,MA6?VY><('\B""JU*Q(+4HK:#;LS:K.@
M!N\Q.)B@5XZE%6V1(F8OO7\O1XK*SKGW.#H9EHFTA[3 4N0:$%;(G8"7WI,K
M[.R+@(>/9VJI-KQIY?O%,FAU3^'/"&2Z@U1MP%[JQ)W9C].(:/Q33%U&HDL'
MYNL\O:(;RCK7GX3:T$2,^2Q9LJ6!V'$ZAK2;-1!PKL.6KZVAK=4^H)B!Z-55
M5NMJ.SA)<4<#&#*&=+GUM]-T;&Q9VY*JH3F(YC9<P'' BJY%P0HTNV03?Q3:
MF\FWZO12D3%KBN[/[.AA8<FBB_L[=4V,N#0VL?(3_^!A'BY5) >:26;R"3+J
MQ'EG/S\2^G![,M#J'2(/HG"(Y5-?^-AA04(^OS2D6[MUQ#S6CG>U "_D9P.+
M/V<J?>B!DY8PQ.*=I")/1"1$C1-+SW0J^@_O+[ZA#:9O65Q$/E^3'#5=QV*$
MI2(*9V&;@'U\O4V[ESHD:0(3%TZ&44.N_%A9+U>24>>'3;SXS$]JXTK$ ^GK
MD9$V>VYD%AXRS=(K*7T/?\(Z;!NFO"VX365XO^\!D32E(<W;^8JCAB>.?)'6
M4 1[E#LV=WDI>+!DU(A')_C6BNBA2V!CD(R*TC_FT#!] Y1W/1(02S?.H&BF
MYC<S@!0_0&8I10 XJQ:\F?.,M2%&DZ+C *+8_L4PVUE?:42VQ'XLSD(IBIXD
M8G6A2Q48? \%KC'&L#%X=8[2"__NJEGI$O&MBAFW9[T\6?UC/;X!_.7\XK)+
M^.KI\*<J%S^ZWLAJQ%M3P-GBS^#LG&N&C^@%CN]7@NI%( K!$=P,+Q6/-&<R
MKB)->PC,FCD[IV#HLPM*O@/%S5P']E"#_"@%"$1:-D0:CLS+G\=<2@-1%9F.
M <B/#"P-:VC8IU4[MPMF6HU9+:,[L.#C"\&';- 4>JC:Y9Z#D4\^A/VZ'%F[
M! G,RCAC395MH;ZL4P5VOF:\P='.3P?\1[(<^F]D><W3*UTX*]8\YA27 @]O
M.7RHC2J>!PS3LXZ 5(C&98F1X<MN;../+$LT5W-*)6J6]!?*FOH;.T?W%>#T
M/]CKHEQ3Y6IG 6UZR[6?X(!T=)%__5MH2:3@>L9V:J9VBIOTY[URT?B5H8TV
MD3"AI/YMUCUUC?T*4GC=BB'.5:%A6"TEVR^-C?U?)"']RZYP^@K.(^\JUU(]
M($[AD[4=?J)B6+$<>>&@NV=1L0[HL]_G3BM#E^A]$BCQ@UM<+$>TU=9SM]CX
M->CPY3B0#24_4)\C[J#=:?X-;J^LGO@-+OS1_S#C_@TN[1^(B)70CO7N4N,%
M>1#ML0(V5OB_VCXG^.32H?U90=S)FNXO!-  /C)5_, W#5R^Z5K2;/^;%&>D
M-Y- ;7D1C^;^PYR=F2@):6$>:;#=(?$+_7$<0+8M4TO&$VVA"1_?Z:>([PZ>
M)Y[3(;%^E*=#KVMW$(94_Y$=(<M):)N42P.#F?$,>D$#9A%Q!H,\W8]"^KH=
M5%%X3JUT(<)&D2R 4$ =ALY%>PK\15PUFW-8J$=BFE7]Y77ST"\87P-YBHH4
M(EOM]>V6E8'.D;$<Q&[F//IGZ2_>)NF!4UT]R 0I^C&F]!Z8%T+ER(ST.VN?
MXG%_O-JP+89 F52_8*T";W,X"Y!B7L^-9 L1V&'NK3',UC%V.;7M[_^ZKE*P
MB/VM[:@V9RDT]&=2A)JVP>X>)B1?2GC!6OBL-*";(CR+=^..T+K^3JD/""0V
M1WV#R\J89JE][#J0/[I=N[Q<(3 T?9CN>KQU N@(:KM0K$H=_ETD;3JY\:GW
M4'10G^!MZN!JRC^P2<.J,<X!C(?7XKS@$"D5>"FW/3XP^C[J_^D"7$W\M'!$
ML[ZN%=,N9T7GXLL\,JV:%C] R3/0 J-Y&7G/.:C4@#%4\7*[4_$'#OI'9L1+
M?MMS+)IG(IGLV95-)T9JO?9 GMO^4^?V"4HY6!QE6>Y'DPX6V4UZ#P4(-"_Y
MQX%I)9)=95'DBN?I3YG=_ U M5RU/:5>JX:>]U OK/+$R-K<;O[H[B%A'@3R
M_'& ^![/F:,]EO,RTD-VZ+4!/@=O(:I-]DN<=:1LT$C[E(D-"[+:C-/ZT+<3
M$0LCC0HL0]L<7Y_=I%)]W"1!%R4T*W^L%FTA3_8E=#S6":U*&X-9BOYA'8OT
MIN7QH.!AYT@#\D[#HH1@3SEYR)"Z2MC<!'CB8+-MX-PVF^1"KOYE#0!2L\)B
M]C5+B#$K2J79Z_BZI(YY,I$QZ<>Y.$W,C.EX6=G]Y0HX'E/:?($R@ECK1K;/
M,_'3+FO #H99DY; H>U]!QR=U7 ?R95,0DU]_=F3FS0EJ_<M,\MG]HF:6H&W
M^,-GSX_$F ;;\F9:KK'FU8"H)M\*$E)I1*J!W0%%!H?K,.1M>&S[F-3:+^F#
MVSK;=FOW='^:Z[ '/KJ1D@40F#O.EW5N5PH6,)R9= S/96IS3(9>B'D>;%*_
M S3T)GCQGZ1MN_G8"R<Q4BA'CV0^TOL&-]/2Q7,@D9=N*_$WL)\F ]74. M=
M2)(LDOD/&]BILW?J!/HB1$=_DIHU3V-D#&!%-...T246"JR3_>8CB2*VP>5E
M<]@ RF8I0S('2&DP$OEU1=<2G5_-;9AM*MP*8HHY/TE">$\'UL-S2@E]!:(;
MAM6FK5;8.@RIH\/X/E7X3.#[UQC-3+WZ'L9SOVN]2"#^_>71+,/I,WX42H,.
M<RQ(G0*"T8R$1(",BU%?/TS-@5S?%U&CN2(SC:\I[*[:.[KM9]X\8=[B[A[M
M!P#F?K F9\3[U34[WP]QP+E-"Q=9JS=AB9@9.0H?.<B%_#HI TQZ?+4CLDC4
MU>L[(;#V Q <+Q=SA[5@5_A<>)6XU_IPJJ6-3U3<[MR51L=E$V>UV:9!P,+B
M_N\II6:3T_R;UX7G2N?4WSW]P'0JB>4D=M -MZVB+*H>@*USN_)A5Q6GAO%#
M,>W9AUC%"'BW[XC1+ EQFY0LY5KH7$A<1UY*UKYO-?9I*G6P<-=/C$60W7%W
M77*A)V$BQBQU.M*Z*WJY>>H](*RJK+6(4_SGO:1UH4^O6ESWHF+/$TK>&SQ/
MIF>;YYN[<VQETR;I/)I]0D)T]"\A]0\6E^Z[T+/7)L7K:JXG9M0',^[J9L%O
M+NAVKFWM\ZX#+MT+(U83OO^JG,#,&5>$EI*4'9YM/;@Y=B_.%2DL.UQSIG6(
MD&,WH)Y:7+NE-#<NN4[Z4M%4.$S#T"15]%LT-473I+#E"[]+:*LN0M*X(.LH
M76?05/];"+6OVZY%ZQN<J>\Z'UA9R/:D"X'I73.)WV+02HRV,;R,OH-="TTI
M6[P+*OL[ /L),U5BOW=,^%>M05VQPZR!:LZD FB?)DQL6[\?QTZ;'L.MS!B\
MSGPQQZ18:5WU*#ZWC]^]*^ND1V9'7]D])XVZ.4<4<770\Z/:. /B68)OO;BT
M:G)Y>0,YSG9(F<K83>\N?+AZOV-CMU/:_<D^> O2T<B?M/11)=1 'UU#]R/P
MVZ@OCBV&,A5YL^W'!*X9<OG?<B1E\3<X6>],H_MM0A@^R];\SVCT!O?Z>O9B
M//[X!D?Y#\SK>=1VVY^DNQDH-4P Z;_DW'8T?6>*) G0N@7?3D\+3 .>AUUL
M%-+LY29)5UCQJV/TE*MTR3B60DEDN>D3RB]$(UX"*?59OKE!V]/JN^+FLT36
MZ:5SE@E]PT\+.7,CYB$ %9B4?X+($MA]0R=%J(6[MF#5\=VKZ='2>09+PG<9
MW-SX"W?-??Q=UAP[""6L3]U1BQ=>_.=[MS9@!G8=N3V 4O6A)K"'ZII;5'FH
MCO^&-NMVTYV W*@NP$6'<NG*@.?0)Y>Z,&K&_@141,U,'.S8WV?N[B3/4U(A
MAYJF8?8;IL[6$]/)1>*Z4]'*\'CHE@'4=9X.\PY*@/_:Q"J#;UD*FB=IUV%J
M/N&M>$)$=&QBZ*4/]NNC=V^3UFK]>;.*#2I-FE)9"A<UB=*5311IJ-W :YO
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M3>YJ0_"'?\OQV56GS,W(\93<EPS<%]UO3&J$.+>Y'1$GK?TR9GD!C(>?QS?
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M$;C;"R$Z>?<(PK6Z%*E2FJB:EC#XHE?LFW6*(*V.KZV_B'(KR"?M2]'K^H%
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MO]WS!E=6$'C'L85WLT5 ['. [^A83)AZI?3.C(G>LI 8KJ!>AR]QP,6=W!&
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MA6=2(8E!" @^\%BR^,$Y_;AY/)ZW^[)UO&?_E.2 UGB%.Z)^J2]]&Y\;0-C
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M-FY.K'&?NODRQZ79+)OV-SK$#O+@D"T$=;:H+*#KX7S=JK^4BA0CE"="5>5
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M=2&M[=V^><U<A$JZ3$'I[^RD/ QM1_9KE#)(VJ'JM+3(0QB5J*<93*47,G,
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M-OB\+'U.?MC;F)J<J QS8)9RG/H;NR]*U %?&%SP=8;=-ZG8W[AS7CL/1GU
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M:LZ(B79*:&8%GM1W+#@J2D,_CAVI^L=5*>X#QF1 R_9@:V YT^<B'ZAU2=,
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M&9#69X\7]@L*X"\7>Z"A\RC_'O>TXNZ,@=IQ'BIU&BE3HEW\2 #!$(VHXOU
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M)_YW6=]#%J'_LTCM1"/%NH.WV8FG#4TJ".]B -^ZQ)WI,C.31VBV#DX-YD4
M2\ULR8*SCXM*"KB \IRV97[&2K_#Q"3W/>HVOXPL^![ER>NVGY[%%%J+@6+Y
M58>4/[:H^X>&?U,[5^/=4PI+:YMSADI'Y'XV<0M.AE$^1N4]9H@.4!(S5C&
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MSI>&AV2O$S5VU<JUM6.76%.KP:\ZLI))Y=X+#]#MD]2PYO(MC+U'#CYTZ*/
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M\T<F9?>X>N<C4Q=Q.5S[2J75LMO6FC^:W2UI.$O# ^(8ZL1XN5U1P"1M7'9
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MY\8I?K"7NRGWSR]Z3MF!K^F5>?6-AG5,&XIDV6%2IE7*1!B&4//]JL6B8+8
MS]\K5(L9TY'SB+\,]U96$A)"]G<@'R]YU7P#H^M?:Q;\7JY[3;ZO_87Y>$E*
MWBCL#N_LF*-3DE@Y3E+AT8KTB#H926!]!OHZ:<XT,.$8Z_Y1-[-4>6ULL$$4
M?%"?/_[/.:E$/B8TKO&M"\NXPIPX[58R/!Z",'R15-ZX.BODFU[37G7W.U_Y
M07$+LT9EQ6O6@;SLZ> 6S+I3HA(=2_0KQ5.'-$UH=4.[D>HQ1SQ>^<>'?K$1
MI%Y_G82@SGM(%(49?K1GF$]F1]=:]Q]U28+6>HQ,48B5R5^8W^*0YOR*V:[:
MH"SZG]IG5]CWFETQK1;Y(Y!UP;T783EP$:H3Q,MC2UKJ KX.'1<%MY06X7N"
MX0,PVVU ?QR3\MML0N>S:68@9%(XP7WBC04&QOO0;0[&O>AEI:Z'MA+\R.K[
M]O)\CONE G2O,KFW@>M=RT@@:-M9(V\@UDNZH<2FA*T,'Q5($C3$*J6!.UP^
M30,4:U8K>Q,K%/*U.<TZR KL=7\V9;GMZ,IXT:O1^1/*WT1J6&5LWU)3Z]5O
M",),M*\\^P6-[#D+ N*[Q'%!<9;P$2U8$CGLV[ RQ36)VTE5(\?"4F5N#S*[
MWM,).T6A^_X^81F7DI,Q9+$G0NTE 4=U UM0@W,E0KN@AYJ5F5;0,%N68?1B
MG<@MF[Y4%:C+V*OO8U#0IO'D'0C95,6G/;Z'K,*-$#2;F=G1VMKFFY89U*=,
M]0])\MZR$L[2NDCT4V=Y-J1\K+XW'7"(V)(_G?NR )3VP ST_02FW[5A:]#]
M]!8AP -4^\R4LZ)3SV^_!CY]JLNMRG"3O:@ ;0 -N-T^31;YOF)T,5U0V$B)
M)#2<F0=Y$3+%";RAG.%G7AP6XV_5F.W?R%69V)\N;/OR?D!W3C(7"I/NK" )
MV$!MFE4!.>@LK_((==OR@!S+[;ZEP??3%OF^L1>YO ( O8JP#XV]TP]-GSJ.
M&H1M0!'!K7[#3Z5^&6ZF["AG>)-;B/M/K6+M$6K]/(U^][['CTUZ_-F<26)S
M?G[H-6FFI_9CV-]:!4B_.%RUQU Y(RP>A[\6-1@+/G[J<DZ+R$74I?D+<T<A
M(K%DXY^(-"KZ)M<;?=^S+G5EVTMWNGF$&8Q# 1T[ZQ?;GG$$%DW735O&LB(:
MM4O4TH#U[=HT2PUC4G XR@K4O^CG,N)5QF%G>Y^MZ,U=_\QCY6=U&7/4W[1K
M@.6=M'&X[]TH%%<HBIAMCGP%GI7E5>5N'^Z<>/?M:\/Y7]![8HS YM[?5YXL
M$14 %J[1FFH-J(IQU"_@DZ0M6-#Q$[X)C?.>):%U//FP*+3/KHA) P*@HV__
M'[](^U\[T>QS;^UO[LB*^/3RHJ/Y%P:VX8)R/7BD^"_,"UWS;/5;:W#\+B7$
MZB^,YOV"%]QK1O"5QE\8.M9?%R^6@N_B7L%!043O.Z/B:&^<;W?7LT_<KSTW
MGH^3>N(1US8R8>O6+*[*X8\FT'N"^ _E1HO&9@BU1_MWMD8XZ&*INPXJ'*_9
M+0!+&7"X@P6L;3HSA;$D;7T4_"5XUR'!"8F"YO$,\-6S.N'K\U1#RWI!9QGB
MO'6UL"J@J[Q08Q5*GOT!F\E-I.1(T_.'O#-:\T]%.6[S&[9B FJ#\.SHJHL:
M:))]7:TV-_^&]W<%A*YU<RHZ *NY!EY;._WL\0D'O?2#^UGGD6*C4JH1Y^9Q
M%TLLS-<?7%WWJ8.1. $B5T5B9+]_(>%SW.8.M5*:^7\$G#_$24!<U0P1C0$=
M<X9\6/0)W:<)\%L_SB0L]MV  .Z2=?UQMZ<CUEQ580#DE4J"!FRCQSP%[589
M_VB-<CZ7RYNB.#' ZACB);GK3D0>)H+S<1UW91\F#_L&^[OD/NQL;;(EB8]L
M!.I0QYAFDH!Q4G8,1^QJ*8&&K8[&+V+NA)F4KM#'&-T\*7!M_)K3&')S9873
MCZW86.,,,2N:@X&Q9XEJ8VK"'/?=E%47C(:T))5ZB;KM&K24V"VCAABG8JYE
M?Q2@ +E*+ C9."]9C#8OL'V<0!\8B KO#L54^'8ZK^RMHN,S_!TG/@,'\R&5
MJ4!E[A)^TIM0D-3%BM+<BU)<WK:9\H42N0M_<Z/@4])QY;>%Y>%G/Z"XHJ<!
MD<8?'6.708B)00$BHJA;+^[#M D#IL"K9R)QHS6>"XD=]Y@RAG*&Y??Y2]I"
M^JX\G9;8)4\+;I)A$_5S+YI2EL5%- ^6< :NG^KN# RUL8%6\;"S/"F>L185
M.VYL;)LK^9<HD_S?%MH,Y\0G<QK6:Y.H.4V?!Z"48 'CT-^HF'</\=N!+3?C
MF$=H7VQN T^LU*@)9.IHK%RG/^J@X@[*[2O(*/W #G"_Q)G30NI91\$3FNR(
MQ:_5YMO8!_UH=:$:+D# \BFA.?_ONK3_//GYSU^8LS?Q]S_89K-=^$#4X67B
M->G>@7NW6>NZ;T-HA]03$XG?S'?5S\$.C!P"\'Q?.(4E!.GVK$,&.8 XZI I
MV7I2I"Z+YI7HWW'396K4NX%&\Y=WVU?X%9=9; $-'K*W1#7 ^(K26[HH,A?%
MAKI("@+=CZ?\H*,D10T^&*P8/SVK6R0.P4-)L4RR:)$?Q,>VE$/-WW9:?VX>
M+=2K6IV^"U+NBL]IYBW[F<4?\U6RJ%@<'>@74D5(H(XU846_+,&S"&E5V;.@
M PXFA(4#^T8^-5.)/7L_^F1X@;XL-[@@=XX9;VZB^H:.?D']('_L'?P X 7N
M= +Z*TV_I5V[L9=I"(IUK]J]/;0,R^TC2#:TG:*HUQ]JM6'0'(#)\7L7_\0]
MQS>FV7X=5C>E4$"]N5K)F;(+DH-D?24TNI<@\)KC$S820;1*1AC%A1CE733$
MOSA+';0H6XFT%VH_SXHW!^$OS=@Y;05R1CB[@DKM@*[. <'@95(I?\<%&Z+L
MK\0).D>3(ZVX>%ZU)N%%JB&Y)Y/LB:4[G U97&"Z5$^&E7YRX:M"F;Q"*F:/
MAYAIND:O*.;JG<5@ /,2";E&&/:0P.],>'M@]SG32*8#1AC&'E92B!<X:..W
M _I0&-5K1VO!V,8D*GL1QGD'99*7GR&VB\_VIN]S?*W@J<[7+LT7])A@"\WE
M!1.@EOD0(W,F2_&E ;1E*(+^:J^>F^3(SP76D2^7Z55[N>KPL\'#1\24<32T
M3Y[74AB==AE7^[/=@$#NV;C=>]ISP.=>=>LIZ(K:48VR0Q!]\] YJAR@!GN,
M\+"$1P6O)-RL.:/,T7;_9\PWJ +51L"A8-U(CL/.$W!.K[ZOY[8O5!5WN=&.
M@+)/V/>#EQL?W""=4;C%+8YMO]"19:/*>D85?!U)<):D#%3@IN/U5(Y_*KO7
M\SAS?_:X>SXCG!J4\)7UGKKE&B=H TL&/"TP*(7&=2S2="FP82;Y,RJX-99,
M-;IE':38)^:,7!W5;7+N:BHE,$0^V=E$15(5"!LV*X,?E#*U&Z9<<Z.7QK3+
MOZ'6]YY3=_KG=,GV\>66IK;E1T=RPW>\" FZ5=2T;V.F4,A>7?$#3"L\0QP:
M_E>H9/R ZZX:,74^2O*(1"2RBK S-FP:/'@:_L:YY[]5]]5!=;1+GR<$=PCN
M#L'=+;B[NP9W]P"!!'=W]X,?W-T)=O $#QS<G<U[[U?[R;U;6UM[=VOWCYFJ
MF:FI1[J?[OYUM;@.T23:@%9/HG<+_V@B8\A+D/'.%JXREP_6TZ?.L539UJFZ
M1Y1;:/NS#YV25*19ASWS#W43K%.,^H073SE%J8K<2?QG('9)),6C.XRG\8I*
MFWI-KW*/ \,-?ZPE9-M@T@5[.\.*.MWC3T5TY,<2?%#]RYZLO-'U8U_;R#9%
M6C9EO&@-C0\OC7KT RSWC2K5CI.9U3^80FYC$_R.%,A=V,?V(B=F-Y5>CC^]
MJI6P7C!\';N-L)Y#8Z.,*%:9M!&PB6#7R'I\-Z$,8^K__X&&WDI!6T>6(#W4
M?9Q51'7A-#8BVM:YG=]B)!5.SQ0!DPKJKAE7E$V53=5.78Q$U7;KR>Z\I!YJ
MW4BOEW4N:I.I.V[GS$V(:54MD9@TQB98N!@(41M+JE?_1F!I_GX&C"7CE5C>
M=1HE$^J3?Y#AR*X #2P9VY$1V#EQ[-A=SC"L_MH'!4-$Y+^5/UY-M =[VHM,
M9692MC!'YY#,P4X+SF 'BXO/,DH:L3X6?8H#\MB7L%LJ*"OIHR\RXGWO_Q+I
MQ):Y>#\/5P=@J8D)3$5F=*EGF98)MKD,L.%\N&C[%D+3P\S]$,$IPW:1_-U]
M/1*NA!6FMK[+(;%1W*+IE!"2\(GD'6LZAKFBRZVV=P1ZP5TJE$F: J3I#__]
M."MU 758X8^$*84.'&F&GQ?^UV[DZ,YB$]#06)Q4V!&79',)R.IIMS^V=<\Y
MU9Q*Y_?QKF+V'KW7, ZS'6@\P"*D\.4RFZM1LS7"E3RU1-3R&5X$:?4SC)J0
M4'Y'QK"(\<7W>)=]_.%:G%FHW?8-G\<UEUJ_8:'D3^BZKU)(?N$B-12<O2#A
M"YVHKA;4BBH7OJ@8S/LFR;)X&A U(N%S&-?\VRX54N*0XNV[LY-^9;:JRW"&
M59?A5V*'OY#["WQ.A T%M?L9.+/P<;"VL[YT!I4LWK=G-#K5^,JY\4L=[!3?
MOB*0$>8+K< %N6A@M6_@&V#Y"2[_-NBSDR?J^.W O;OGG0=O#0O%SPQU@#R/
MB+&TCE"*#^)8J/>\$+>6_5$4).R;(#KTT54@-F4]4MD^K_-$/WBFBMRY$037
M3K)&#-=.Q)1!F0%'D[L5OUI;^5KYPT=$Y&8EV60H6_T-@)Q5BWGH4,C=:'T3
M7Z?#6B+413#'9V.EYS@Y:MEVG$DO:S+7.2.KJ#?$J:08..^\RVOY6W@]0$M
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M!+9E*AS_F\N1/NBTEGQWPRMMX<O1<T_.]2^-.V5#D :N6(D6,(1QY<Q_W^/
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MK?38A0]PK!*S!TVM0U@QJ=E=O<(\CKLK93&]766.-,W;/'4@><F>R RHK/L
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M69&(5X*'B4\M8'E\#>88F%#-"UI!]=R9R=5[9[Y5TQJ+Y(;(_P9@V"&I_"$
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M"5:+X%3-G;"G=IIKX@"RY'8T/%0L^J<^]'YX*K98UH&!4LKP=[^B#"G"\8K
MAI2Q0G]7TL-_-/1X5,)_0J+OGJA?@ E!<2PZ07?)NZ_8CD6#_@L/6_]*L$NX
MZ;,)NO7H()@0/]($51#6):\PU.4SUHY5UP.?7Q!Z=1-[5/2&+4K$AA4]WXMM
MF418[."B)B1@$(?AD-E0E)<E9B*.ZQ4A[965<]1G'9G3;'L*9UI3V]>S^^R0
M%C.RS9"Y$<G+>]A^E#B+U)*G^M!/9>\Z2.FR,4[8%3.5DL@VZ1/+LPS:NJCO
MZX4B1F2[^4J(G3)\2ZL46_MA$/]2L)U[C*.J)"$L40#/'@ALXD.FQUJNJG3@
M#M/LUS[NQ1=O;46R1-1DUFD4&C0L#N#B5"P-@3_XS$7"2&[)&IZ8R^^F=/^[
M@#%[BHE+HJFI88%;<3WXVKDG@+-A@NQ'(-9*2>"C+.F'NCN5M':UASWW0JUN
MKQ,I?*)Z:<[)B,E5&P>)F&5SO&&2R3] 797C2X)2S^8!H3KCC-JGF(\)DH:M
M!M51ISAV)KRQ1<!]DN%I#(="O0-/:\#$"""\E&M%BZ*;QC/1^U:>CDX\ZF-^
MSAM@#:&BN+@L,3$S5<5V0F?T,'=4(1Z^S#L$KEM;CL9_I0,AX@ZV,+^)WX;"
MYM9/7/"*V\?*=!WJH%OEX'C<XCL^"4'O1GCC[,3"JOHO^$_F31LD&BU&<^U,
M>JXJ(0"-#ICF@+D1Q>CKW[B"Y +#APS]F9]J9%V^6G]5?T]7Q+=;XQK7C%TW
M2EM66A1>+HLB7JDW]I,2\K&"JJBTFC&S4$:?$T-1Y7YU- OUU6O\=T[]>U,1
M^+*$\(^6Y8DH:5++\D5V^D@'%I?B3:-9E$4)%X/@-,%1\Y@:3)0*A9PZX5:H
M^@60";^V),[TB"YLG8YY;D5JW%**RN[U[2=LYD6#7N1CR9WF5+46.?X1*$ZA
MZPD4V/<P1"2TMR&RY%ASILMNAT6-^5] 51[0T55#]#M^<,T;)S'+70I^%3F,
MRI'\+@PD.G>R2<[#[.(,MI5?:UL3#<NY=^WRBX*G7-9U2Z8*PIY<PH4:^-5&
M6/EJ/G^PN.%2I4M9Q. U4?M@=+6^7.P[R0NO:U 6OL>5!E^DJ?T47NVKB#WA
M:&J!$.IA&U:SK,MCF(-&(GG2\O%)E<,J%>A=:'\<WK,RB"$(DHL<&>#BOI_0
MT,?2<;!7-7.OC<6W]% 4=![S7E\A!Z?!F9J;19RQM<N9?TP4)5HNP&1W""42
M'3UJM^J.U>([CI9DV'7(1;*(%L$A,B<)]6+\PU!L/,SWY@_^ BCO_^@$X[_E
M$,&=7C4\IP>NF^3=D;YHNH+_5P/AO1LEB68GD.M'&-6&.M5&N-,3^<Q_&C:M
M\KG_W(F@_&D( @=POW"#'>KSYOFNAL _F42<Z;[5^XZ=='VTHMQ3;M0_NB4)
MU$1;5%(>?MAOD8)'5BKY\CA_ZO1HQ<=^$?-KM(/MM]2(_)KH)Z(1.3&CQ=41
M8^'.!D7%6"WN-K*UN&>J+*L)8;VP@ <6JBJVFZ T5Z,(#>%YK?DL55%+F>-W
M6M4UN-&M,(H?%FM4PG2!%-;#4:P32;V!=O*3ZYGWT5%S4O?I8S(-.B^.-X\8
M?9C,M!.4V/KSU1"IN2C])9A;[ACL#MMK7N>.P^B5HJ^5F1RFJ.U8?5_>XQ@T
M*I/PG$?55!^6YD[=*MA%VV5?H!ER3[<?QKA$!ZX]\?Q5Y_75<^7!+?HYR,"<
M8.?.7Y!>2KPS0+DR[[\W>HLJ<;, @EVK<. .52UWG"&'K'OY]&\ /O^1(TM?
M26]^;_:^MI]23HUZM$NL>66T/T*4DYR2HS2-QORJ@7&X,%TW'QVS^:NK?A*"
M<<D]C'Y0IWS3K+UZQ#5"5Y.OU20$K[7)?P;EZU)II&L8H'W?2I6F!U&EHE]U
MGBR^YMBR0^T&YTK\;+4*/)5Z-+2A:#8Y[;XA/?HA)'95"R1I:'Z6%:HPUJ_4
M?5\3_$/ ! 3?$=8TBT4G5;= S(PB]K&,C8V2WK^Y)DM/#KZ0O^$)YW<EYAU_
MC'*<0>!=.^A=6<2R$X?]VO ZK/8;8!>.J[Y6N\M.>;+"J-)V0[U6_N/ZSMH;
MP-F!\G&"\!XXZ9>NA>F[:OL ?G(\]B3__MLVG,4 [^I81K4X-8 T*^5@D!VR
M-=/J/XK_TPAW1JR>N:WK-H(@-6K/+I9[\EUY][?$YF?VUOVYM*5>GQH,Y=IG
M'GEP78;=9&(T'F5*2/H&S9(/IJEW$=O@:3-7W%J]3IL]3 [W2%73.^8>0=SI
M!QNGFGMOG0<2O,_VKBTDS['90_>$;MUI;<_&R6B*U5<.W\*^K8/!>M*VAC%1
M<R<PX[^/9825V=)[\29$KZ-<OH:5UP]W$L5A=KD@JSIT74(N6B15.!]]]GZQ
MQ/\JVY,+D6O"9MA)9-6*@C<=X:/*8A1'*ZT?(!DB9(-1O+X&&[ITSLO2N "%
M!:RVXA"! _\ 9/\O@.6_9SZQ/0;YD2('MLT<YGU["/(4,7CMQO YCSA_^=ES
M/3)P=_ &,+Z:.7RZ>GP#I G_^1FLO#WPTOLR\090_'-!0D(/?@8JB#BR*C_%
MO5:V^1_8!5FYL" JWUQ7EKS"&*^*-+T!8B3? ->R5GF:#[9O /Q^D?"QUQ)(
M\3'<W1^>WRQZE='OL!$4JS'3F#/#DX9NV\NRN274,?_J8[%I^!VLRQU*8 ?T
MG%R5IKEX%O:WZ?88%OPKG.: -CFV1AI(TKOQ:"U#Y^&8=OQ"/WC#:#W?A<^/
M&@^OU9XF1U&V_H#TT:E%?U)+[[&>2EZ7Z<E!#LIG2^\0*:6W;T)>'QAQ7Y7.
M9PN_Y_=@&^AC#5I. J8-!J#LON@@.L05I1AL=3*P+@ZV5H $K!IW%]SQ^6HE
M%1KI<D)RN9]$FGYJEO2'S+/8?$:P-W7 6^[RJ,S5.MU;KQ.@[=F-@.+X^-I\
M:X>GE+-JISI^SG:D?O188&UH2,<D.H@V14*H5"U.F5GG T7FY-91:0V]71K4
M%6QBY>B?!.SN3)X9972J?GFJJFN<,U A/?CBV]R8N?89(>OHO7JN']9*/E)V
M$6]O]M>4**BJ.>XYUB:AD-#OZ :UZ^S?:5G0*N;S(ILW_XX!^.X#GW?P7D0,
M#K9>2;>>>PR"1#8> ]\ \/E19WZUFM^@Y+ZS>;@6'B\ 63SUI9K5+06R^%MS
MT05(78*S9CV1Z(*X%/3UKGDSY^L4)>BH]L1!7GTX80&ISY\F* [U]K.[M4BV
M;OG+MO?*>&O4[3M!%<G/"?30C&I.1J*/H(;P\NJKEMKFT33MTXV5'Q*>83]/
M*D/-OFX3^UZ=0N2KO\#N[A+,N7:=_9G.3@:5T0I& +;O3>T\C="',DW?.R-I
MM3O:,MIG[8ZB#B:GM WUT-$NAW!6QV@#4D^8!,(A[#!IT3"4F@V8=XX*+L::
M!C_B4[M^:0W:9(##_3N9;J9?);4)K9$<9U$7IQ>;0* [Q;ZZ^@['=TAV_M.%
M)>)*SC7<;X 5IP#]DQZ_1CI(EQ!%LF8LV=&2EX+G!A>J-98D]-IW6:O&1/Y<
M!7L-0E2!M&4P_'7( <15\!W?WNQVZVWP30NQO??A0&ZQON9G[S< HHFLX.J=
MM^M(F6%%5U)]KF3]N7CPU\I(COQB(HLC%&99[=!&J-!<O-"GL6:*@-(H[T_A
MC%+-;3X>MT+C*+#M69O/WW?*]^Q;0[S7Y6[X7%FUXH3K.=CD&9"XCN5F(V0P
M_3[@T.+?SI/H8VY/FYJ3Z3LE[DZ?V^5X#+HX?'>GAVG8;?@SA[)_/-_Y(A8]
MS7,L%WL0M-?+[+S^F@7ON,R\_]V.H_^C1R;W5T:1=;3UGNOUGM=6.N& N]V!
MVQWH-T#K&^"H*FW:L^76"_.\^(](D:LT_B^> ./_X E0^G=/@(W[FK=%G.*K
MXFU4 %<2/X1V#+1Z8.@UG67.?W9YP+O&?Q(-:1G8RO;GR!,T#+@+F7L#U'8*
MB32MXRZ_8CNCY2YHJ EE=H!%7R/*%?GXPY]*U*D5*UK<L\\#Q?RKF>ET6%%G
M4S0S<?EI>#6G2>405&$H'G\+H@W^[!FTR+B@>JD--+B:M 7MS52.J!UB1R;)
M$S+XI.Q!5:3V[]CLFHVS<4Z*'VL,XPQ%^!#9B]&$M]N>//Q PT^%JS6<]'.3
M:21-^[,Z*]*>G:?ZIS> ,OA9I%1D+&YO"PO%X"&HP:W>'.\-(/D"ZWN0TW@Q
M XG>?,D?;KT///87-G@]^WGQ$O3MZ^-'R%_=SVOZ;V0/(KGJC$^Y;-F)EZN5
MBSK"PB0MI4YR,C!WQZ\M?O>&KD1]_M /U>O"LT%B7Q_)J#9%DVDO61PW>+>)
MU5Q,WP;?B=B\S.\1M"FB4[%H*Q3JPSR )\A,%T 7F%&WL%JSL8B+^7O/X:,6
MDFA 3G:U0Z:6F@Z7Q*[,!-F[;A/=ELD8)Q->R.2R/TLML$7Y3F 5G)9",K;&
MLWV=0AIYAV!I?) ]W514LCZE@BV2 ]TIANGV.%12)[>T@(;&NMG.%"'I8(=G
M!9=_-4  ,B1 F+V\?A8KF,)?)FP*#42EBF[$_\W>K3V;#3R#N7$L&AEMT6"H
MP'<YO+I/R)K_)0Y1G'6,F6M78[.]8A2O#:@C E$+)H(>*0AB; JU(U5*BQT'
MG92;JJ)H[&H@(S4XT#_%F_-YH'Y=3'YP<Z3=Y)GNL\>IG92I0TU6PR[4U7B_
MBAKN5FF%L6E1OD]@R!Q"X&0B@$3&O.X"HT0?A:<ZW"P@BDB"HY(7(3)'&G<#
MF?R8)\0.TB98YW_X&:[=\F%\<;[-^SMN%?))>-2MYY5SBS9LM9V0@XR++FJ=
M(YU4E6:=:4,O?37,>YIO8J+S&&^ \$-D-S.TPHDO+5Y&B)?=MAKA\+#S;''(
M*M(Y=TG\XB0)-AG4:P)C-![S!#L"8]TK/P,:X[(<&G- TVYY<5^-?OYS#/U_
M'J;_'X_&V6@B/,.I^T"84BH'W<I6Y_:;+W/?FBIN'].'+7V+$O\G?K@N6_IV
M&H$32-C0[>"O>)SI9R;Q'<U-<W YD7]L#G?G79-(]48A1,ZGCOO+20BS8049
M\D3&U:9_89^!$7<="Y!MW:N@M_Q3*IC(01]&)V2*[R'K>9SP8B?G8=_MD6%D
M<^66\]FKH/[FMLT Y!D,^1PD+5,SZ:%KP#S&,P9HY,QS_13KC6M#%=VLS<%9
MQY\NDS3Y DTK\QLQLF3U+.A[!^EX5.E%MX->K-4=5366@*EQ/19BLU9QD0JP
ML9FTD@YOB(=_RX*M$0P%KWUM"EZ%T>=:;.)BF9$%3XSTC+0I^ <*'!-?5<+]
M* ;B6R"!?VI)L$W9N@E/7<1WW7*@$3DV-=O=2"<>KWA]2481D#%5+3R\$U&3
MR<: KW8H7=,HHN#^X=FH7;&8TH:KQ<T@7]*\*VKO$EJ+I*X/HI+<WAV8P,)P
MX</8#44@L@[T*8U3_-Z<=)JVG33<I5/C^</ D)YH_V:$N=.H)J9=RL[+I1;]
M>L .A511?&]]K2IF.7=&K;#C8P=CZR?U!=>"Z'C30"#F[I)''LE[^;7C<NAX
M0-?95CPMNRN!C=]%<VIZP)=GL8".6U+AA>J;\)99W@-!\9.X\L+B$V(G3R&,
MRKT8G<MP:YS+4SABX:T&LH, 5 $D,7!-5W]_\2CUJ9B,+,.6Q?G1ZCG/V2/C
M%X>P8UD[(+,HM!&8!TZ($9YLGYG)#ZY7B%*>1?:V<\*_K5.?Z*EYP GVUC'*
MR^GCGX/$PV_5*;M=302<D:&:\*S.19KR:N$WQSN"F*X;EE!$IN+BG@I<[J2%
M>XTOG=7W37>%!^>'P)]10>WLY+3]9G(#11[40HN-E!RU@B>V/(ZG/N\^HPII
MX48@O[(EJU^N+/8]-9HW;VKW$=$,+]9X_K('*LZ[BA,MN1R0;W8;>E=D+ V/
MI(8*L02XP;4^KOCV8$J$?Q GXO)0(8=@7@]NN]4@5@R[MS,&6["MG7-V! :J
M_G@)^/FB<$1IV(S&(7GQ300?;"R"U8+:W%/FQ1@N9XT.$.W#@R:'ZI-4L-%!
M]Y;N@\4 <9.U7:!FFJE9K>&MVNP^E*39FPN<@/SIVP+_^<%]18/\K3S:/4?>
M99!@D.#.L\BOX:"X 7R*X)?H$%>^(]Y?X;IWX!;?']RKDB1S9]64?J3CWRD,
M#DDZK-![!=5F.#.&N2+A[U(5(,".DPK5!-Q]85OOOTJHO0'0SN]5A45J!V[>
M #2!I"/WKV=;?\:Z&AG\,XG[U^,WP+?K^R#2L^>@;Y>OO*]O@-[_YS/ZO>RG
M8ESWD:DC;7:@,:,2W]T\C&9],DEU* P1/"F;X<P< =7;7=E<G9R/3$4'MOX%
M/HQ[OC%I[ I>E8MD!L:TYWY;6#:J++B1(.82ZA)2O>0<*I#G$Y*E3[."+4:@
M@,*#-?=&<1'/(N&G+O.Y>O"KS4L#RY=SS.2)UPC;F8G\V=+:NV?ZOQ6$8;D7
MI%@0V58\1KE:W%0^X_'<]TUZ<IGI<KKA'+_=8I?+;QWSV.PH<0XAY^Y-':QR
M&$*HX/B-\'$R(==]Q3I3RC1T!HN?%-7S_OQ" Z#T>2"GUHG9X*GM=Q/A<8_]
MLV) A?E]5$5^.>C"G=3T,./7$A^*[@X2(1YR@FRK%JU?.^EXL'KKV@2;UHA&
M4[2EJX[\47\$YD<"5J89U0)H[WLOFZU?#8Z]@'C%FS:<6;3%R9_,W+C-0Q&(
M/S3_V/!ET^VX'>TK.&AF+LX@WV)?X+>%:ON +[>F_N4'GTR\'<*7;G'&4,D3
MZF(WJ@A6]72=Z5 M]-%=TUUN)T=&E..?+G1.VOO!A/Q$P3/Z>B/R[_VR&W9;
MA)-F";I!2AMF@50LI!["81,G#NN\%M;TS 4_I&ODN9G@;9+ DRZ"[$QF-8(\
M4JE3HA],9083L=NNLOSOT8P_+>7<Q[CU,#EMBU+M*WGV$&[NA@7:)G]MVM@,
ME,8R_7[QO1JDQWY=E<:TS G!B*5?QJHR[H:.AB$_+$6-WW:?SAC^:H<[1A+W
M(0@+@,*N^RU,_?&O$-T_-])_KI0'F+X S(BRK8-_95!_M4]5>&\2L85>M!^.
M/$63IZ7S"7K ,DXY]L=W<JJ3:#'!M=^25:N6QNM'> C'N,96#_@I1V?L:B7S
M!RV\$]!E""GMP!\YG5Q32M#LTO,.1PS%[H12A4!/63C]#_.(@(*P7#_'BXLG
MCUR#@X1Y9<\!RN'=)+]W^2 KCC0')%(77.VT7VCF77X6JYCF,C^UM&R/C[ Z
M;&YIW9JVB*DIM&MX&BOB5%?Z'X!+4E!-.4>4RLP8IC26DZX[N>V6 W'!#4C+
M%D[F!?CHJ &_<J4_Y=1ZT NHGXJJS%5Q3<1(S-4;'C2ON3D@:[C8<0AI>[0(
MM$&U5MC/23TTO#?S#.]C4$OB7*=?#%3RNOG>V!:6\]0^H_PM5X\PIZG^P=^=
MI M"@)AU']IKZ9SQ2,N7[2P&"O^%J5-#*8Z0Y^$ZIY3D[8/NAT,W!\W([>)2
M%W.)E69/4V>K_UB/3;M5MG-Q3]9\U=4X;^AC-4">%S,ZP[I_]#*)ON3]&V=:
M[2'\BP[\<W>+!06 S$[(/;\RBX]HTU'WO#;A\68Y3NXU):%_3D!?*F1M+)VZ
M7A@N+D^7D-[>?6*&)8$,C;W._H]5@DX3O-1OM?@PZYAJM"74 ?/U.WN#SRF%
M%V+M5)7HE8L^:[-)='3?\GL#C845.<RA$+M69Y&$-O.MF;BX-<E,]?BGPEH@
MC:5;@WK&U9IS\[/^/#FM.'AVTJ $DD5UDZ$/GF_,Q/QY:%!8'6GX?2)SA[+&
M(M30/T31",TX/)OOP*]J*RVBA\2 JSE8\,S^FRGD17\5:PG&Q(.D4:M=M0J[
M :<K19RKUA[XR,AA@S/+26]+W[!4'*P;Y#]IT+(XO-3'1D=04?X!QL(KSW!C
MDV\_UZA3H.-9\U^<GOT'YHF^LA'/E:G<M$\,Y-"#I*TAP8O+ZL2QN0@5>V.*
MOV]P;ZG#VIX'= >L$9L?DQ*XC6FH%D..1VCN4QV^W3B-<2-H:J\2V-OBVW1E
M(03(,Y"S)VC]T/ZF.:#,0+Z1VDX[?CE[\HLG5CXZ'#Q\.X\1CLQN+W2<K*BW
M;/A^X%W86F0K=4K)DS:J.1X"H<@%]^#F>'$@@M!JF?$<I+=4T][<IU/OH#V4
MOW@VQ5!55U8760KY6'%7T+_RF[C9=[K&A+*G4$4 ;Z"K?*R(<-GE2,BB\K'W
MK]14?GK^SW-"C7*ZJEP2BS#'D;GDA%^!R]2GA(HK%JZ"3]4NABRF+O!F'%M/
M'X0+"PV?Y/&0[2-YC^_&+[?J9CWUV'G<,G]X\;Z_MGL)2GLV\H:Z'CR/I#R]
M]HN3WO7RY1%I5?[4JHLS""6?7VT_'E.CG$H^PZ%Y_/$4,B-M1I> D;(2E@I8
MGVD)6T;%=!SZ-*B),W54ULS]>VYT?AV2>!4<8+O\P  @5L.J=-.7 W,V$\"I
MN!B2V*'QJ8>F[(]/?[C][0HT+&DE(G-][6*$&'6+1#*>M@S-LQX1MR0;,H*%
M8S1XP$&:"6=<4X7;]H1,XE:WV('Q268*.91:^^QLW(S,!D+458T;(!N:27/#
M.J0O7;[DTP]V07%KWX:/9I,F?1Z&5J<L5:56]4>.;QWJ>1%YW@E/J1NZ&(Q!
M,EYF,>V+'#B3A9H)%48$71*R3P1]92MPW,Z'13S9GEY%.DA['OX8!3<SD)<_
M:J+S7N+>/RCOP2UN)_HO6R(H:2=N(_L?JK7^N__B]:[O:+-O(4VCAHFD.(8C
MJ3K"8*D4V4KV6&W>(05&&3?>63JF8)0;)'/C;A$I \.F@^<(91WK:1M+$=+N
M!%PWBYNNWF[Z#2)1R5R<*[_[6&UGF!V+P=A\<(TD,W#VP#C1$J-[2^(_O+04
MU(8D<;#>SI7*L6@YH=ZL/Z)$"TD-Q%'JSA7?J]#<\4VK.!5Q/,YZ,F<>6*L\
MD_+YJ$:1@MA.W<^0[X5K4ND?/X1P96'N:P5U&LD[$&AN]I$*1;E%CQE4T8YT
M 1Y^]KN^)^.>Q.B_/>/NJDV?$'(E'A]6YJE&_7:4ZL#_53(LF4B?6*,!,25A
MY=.,+W'B=K!F4ZC6]&&Q\FAS?8$N>O-ROX1XM*8EC U! NQI^[F2> \+8:R(
M\I"JU//!U]+^\*J ^B.V!9-6]\> J9=R0J[E\.JHD,3X4&BK5FEM,"*Y(6Q3
M]!,5?V7PC$B.HC]+ZY"79[TPB:#WWOWJTBD@ OP=!W=Z:F'/S\)I^ W 7DS=
MF3>_1UY3TG<J]%U,\IT'FN5*UY>LV[[PPC0$M?419*[&=1U2[@<_&Q&8&$XN
M5UPV,V_XC)#=LC1"MYGYZ6?V'8NNF3\J/.Q&F/94*9/Q]4KMIE%?W'>>]'.-
M^YSMLU37A.-3P+-WRHM9O)\[AT[NADX-U? 2#%I5HW9.>TH!?VU=NJ%!!'?=
MRCGLQ,&YR ?[-KM<HTI"EX.?.<VDK*+3(\)(E8@91YBP$=DVQSM.HTLVX^LC
MAA.J+7H:7!3JN\0\"Q8]+E\-H08Y!:XE"2"W(*7@2I.I)WF"[UJ3XN9^:YW.
M@/5]/JN1L#88[C4AU&*#_=_([D="BAI=.#O$TPY)/=_AL>($1K@_ITCJ&@,D
M^U0:.>W)<2Q=,K"FSV.8AW SQ"(-.$]%N:9_'4Q:3;094<M?:]2[MHZRMBZ%
MT!%@]68H".9(A/-RD<W#K_F,TQM(7TU+=)Q079YT9IV UOS]Z3O0_K4(75/$
M+<!<_"0(H<F-!@]+GTIUOV\F#Z-LY!*IH6_TN3B""JRX^\..^#,YPQ\"*%X6
M)&3UD6X,<B:\\%CX28M\9FNWEQ,JF__06EOF],>.EJ3,ZK*&_F(1'3X#,PIE
MO4SDB11\Q-9)+VB,EIFR1J'"DSPG0$XL_FZ9ZHN,^:EY8F_.VKKH*DJSVS-;
M  O#8J",9O@]D%Q 6F'U0XV+4^N>LF;M-ZH,<<6O!7N9I%6E#3);IU));),+
MHR%IKI12R"N/:.,B=FNK]JI-U^QMR\+$3>/J5FS-FFB@U_I)<F!]723@PG,0
M+%00[E7GT972A_I!PJ+<Q,%#%35+&J_01J!</)CB5F",VQYIG<"IPT:?]VI:
M>^$O9VB7^@S\[+@LAP3OS@C5KK)@IB0RZU#IV@1CPQBH?HC(URYG-RF@OC33
M#K1FA3?L]H=T]334MTZU)T298SCKE& $RC4#2'<'A/IJE7%;D7M>A'EUK)1K
MNL,N>X?WCPB;OQ[#>OF+!#>O/3.O_Y&B?S<4@TC_ZZOGH+Y_(UE=U %/T?7-
MIZ(>+?#*(F "91 AEF92I>ZY+=*'!OQ;'O7)5NX;BB8^[),]WP0^4>=H&7K%
MUOI78XHZM2Z;7\/#@E27X\GQR)F(IZ%'/8=H3/YJGH(:4FA8F6)]K#6L @4I
M.05DL3>^:75]1>Y'4\BA#/KA.2OZS%+K'H:<1I4NQ'KN^] +YB:T>C25EL!N
M776SKHH4V#= DSR26JM"U(-/TDIS[/#@U.?D1L)^P2?E8LH!V*^ZW+E=+KR+
M4K'"-IHQ$@IH=F'UM8-F,GZ?DB.'7<GG ]P9SLQ$X\PH:3$'J X74])?=]]9
M?L^.PT@WX.NRV^)H0!E^'JX/9YC2&L0T(_!F)S\$VZ:KD\5B4H93R$@6<^U?
MV9#P!!A@\5]-I9<@JYB2SRR]^A[,"%YM]]AWN6R=&K+5->__QN-R:&29+&,1
MI_FZG-68L\,Z"N?:@!REV( A!+3,(+P\.;D\<^QM;7!([<9N@P#%-O%9%+H;
MSWW, E!]4AQYJRL:C5SR?V#1P$NW#7!F&)#::^@:82A*A-7' T<S,\$<C0P0
M(E4)!75ERB NKDBZWFA>TS[T0@1H<41.# @691QJY@@R^D@I6[6+-$GF86GF
M#@$$V#K,=CXL2+$;]%<"G_+6O]P%]_/I^:^RYL\]O_[MC0Z+TL%A>X]@VY4^
M!F.HM$\-J+J)26K+>E)E#8',#1U5]\NBQM>!ZAXU7H*JS]79D&M\)D%\>$PU
M>O%C-"#14[SOY<E/YNVET]I9>DXC]:DY8*W^F>W9K=Z0PJY&BM_X=%+$\A27
M4FO?5))W<OZ:8LGBY  T\_%$VHA>R25([Q)WIA.IB@6MNE-+IC!1SG16MM/E
MK)-P_73M#/7))J8E*J"IX4 1%&=_H-A8NF:3#;D \PW[IQ*_EIU&K;U$&\B_
M?,]X]=X4.:&-0GT#J-])&G0E[6C*,>F^)V#!;MKXE3&?Q)A1:2A SFUAIDZ7
M>II@/,JUZG4PQ?AK[92S_0W ;Y\EIF'?JY\:F9\<L6)'9.?]F-=C@"'__ 8
MG^I;%:HS>AI9.Y@-OE8'3QQM.@K1\HEN9=8K6*3Q.0]1VN^9)BG@N$[Q%UU=
M!YT/]6'<P,8XD;X!?CP53O341T4$U7\0F2$<>2F^,/UY%/B[PKBEJ:^-D4NG
M]:PJ@+2-BYQ6%#2>F>(*.;IXJ/G(.ZR9R-,8RD P&G7LA$;TF>MV4LKW!GUZ
MO[PF\(%7LV7"^W+AY96_S,#W]&H7 9>.1<^[_M-WA:94,3F9666RQK73QVG.
MQ*'JK#CA]A7/X88!T$JL@KE#?<S--!LH2&'O;U/P$/)/8WC":TU[PN!XON@,
M6E7&^6LK(V/]%+7F4S9^,[3%51%3UI5%6(!&/JO5$%<1 #QGP&H[4E<,#9(V
M]U:%C9WN4,3V!,TZ#XA1^K-:BQI*.Y;?.(X"O2 9[3D>:8;K3CC=]1>"$*";
M"@_^-%OV#@_2R C^M+ (\AM@C_9LY/1O6W%4*[(\--BS')%W$+/S.N===W8C
MXJZA#EJ:*'K"GK#1"%)ZC#G(Y?81K5IN]]T,G>,I8S3\84^%Y%7')A=<%.,2
M:U9"3REE9YG!^[!Q\]W_&,"*.C0$,D91?+CJR4NCVH:[ON)'4ZDUOF5S8;FE
ML'K8\?XCCG+E_\8A$J_#S-2O@PIO $$GTMNDH6]!%4^%!4JS!"(M:E> ET^'
MC9<+#E78*NT+VD8M3S"?%7VKE^R7"$D\D"-FQ>9BEZ6J3(4:\0!ZU(ZCH9X$
MNOQ"LI\GO"&3+Z\#$%](;4UM[7\>E%'@17GCGXY9%N^&UW_K[\O7B=.KS-/8
M%:01^5LHJVO"6%&GR UF YTPN?&PHDF2T;Y%X+5S7J"Q@9IB5E$U-F*'Q==1
MDLWQZBCP;B\03M^@L#7H'S=3^=ALV_A88N9J^.(-8".HX_68UT[_L;_*<K/C
MY"C)]_JJ_&H<&OJF=>D&]^5]L9.RY0NQ?@77M#^7!P..23)TRSCDR3 ABPA2
MZ)DA6IY9 <*+J(=HZ(\L[.WDVJ3Z_F1!%7KP?K?3?U?[C\P4-1Q@MNT][!89
MG/$7 Y"">.+ (FCSI*\-0:1_Y[:OOJ"(;TI'N'HCFM=W99?T%UP[IU% '+L1
M;>8&^2%N53K2AI1._H_<A]J9)8*>EE5R>%JG^\^O9^P6XXR'%-1.I.K@RD#2
MN+(\4H&+?R8#@CV$X6:.#)9>; LN?<ZTY3;XAQ]K%#+_',Q4B)UOB:Q53:VU
MV;PQ*?+)> @9;&\D:JX8;23=UD/+\&/U7^3"XCBZTSPV\Y1W@K>$H-SEN$([
MMC=2$4M-+UT_^,E"@T+;$W#9&LGP/FG6AU4QEJ/25@]3F9Q+NB>J1464=';!
M]H@8&VO6@$E$E.-'F>+^QXCD?__Q#P[J^6=?"X"/X ;J?90,9_[++&7%L!M,
MZO(<$[1&YG;+VP;L1V^0C64%<TSB^#ONSY4\;.LJ6_D4YL=99SE8F0JM/\7+
M!"QK VK7*QY)NNZ33;MXI7/+KSXF@@X'M&L8+Q88(%,5KA<R^G=I<^XX"SOR
M[[W$\8R"B^6:=!,Q\_LC#2;=M+]ML4-R'@_V\L\J<T0V?!Z?[8X-FI6\KXSZ
M9B$,)+:U*CDL%8NUQU6_(VU*@0?<G$O\:/L\ECA%&(SPH*:P(W-F[T=#>V6$
MG9MY=E[7]Y.QN*"^Y_^PO%>1?U^T.2G:P>/!SN,!WQL@[L[\:?GE?QXU^K;R
MWP!02P,$%     @ NHM=4U,8VRML30  2)H  !$   !G,38T-C@P9S(U<S(U
M+FIP9^R\!UA4R[,O.H 2)0DB.6<D"P@(2 8EYXR$(3,#PY %%! 0R5&2Y#3D
M+""@1,F2,X@DR9(EOP&W;MWA?\^]Y[S[O?=]E,Z:U=5=]:NNKJ[N7FOT?/3\
M$P#GH92L%  ! 1'!%<$5 #A?QU]1L@!#P0X68#M*;C8.P#TQ6?EKUP!PPN^I
M5Z7_LP@P(D70 2"1T$F3(@( B&M?2!&5 *@0"!<W!Q_7/5+$ZX '\I8F$+ #
MV Q*J0F&F%*R4JJ +9V,0%!*2A6@@Y$-D%+5D)-2T00*-@9"*+EX*+DXN#@I
M^3@X[&PIQ6V 1J#OX'27:#AA-J3*-_3O:C_K'>C<4=S%O:P3N*Q;N*B'?Q N
M2QAV$$L05-$1:N<(A1>O7_"4'*"JQF"PS64+61 4" 0YVOZXO_@6MX%<E+$O
M954M72Y:B%E"+V3^U F$*!C9 M4DM=1^@GT74(* P6:J0*BCG:*QE0F<?0.@
M!(  P/ _9@!*@"H "( "' %VER+H=C];_U C9@,%_6'1#6-'2QNH)>A2);R,
M=ME:7%[[T7=O"%ZT1V3]K<<W?^FQHAW4$@QR@'-O7_;+#@KZT0EX)XTA/PLJ
MY@[R?]9 0.)_%D#0/PMRQC8./PL*YE"GGP5)6QN)GP6X'_]4+69B;?Z'([X;
M"%"1%A.'?R%=WIM24IJ"'8T?@#\!?I T!/0WGIC-W]N)04S5U$%0*1H5&RC@
M%Q*S,:7\)[Z*@PWTDJ_D8O- \\$/-KH3$!YU$ DCJ-'/J% R5W+X$147]W]\
MBU\Z 6@&_2?U:O!)\D]\51.;[WPEB,D#[9]L'/ATL-.T ,('%SY>EB#S'Q[#
MNJA0@=LD!H9"P;8V8)#Y'R(W?M1<F/ +'_,'7\72W.+7"HP?%7#;?K(O(@=I
M_;L-2 UG/ !$ .*/[\NHHK^LP_JS!R)/OTM=P[PL7LQXE\LRT<\R^:76G<LR
MV@\YA$LI!ISO;OXQ_-]1D'8O[V\">"X;7L0P\G>AR]J#RWM2>!+Z1T+Z\H=%
MJ-_[<:D#@/C@^^>/.O*?UGTO$U_<(?'\1/I.@W#1S)\&_YU^X5VV&_P/#7[2
MG],1 '*TN1A6Q M88[ CR-3A+[/!!,KYP\R+$/IE^ !_&6> V)_Q<&F&RL_A
MOC0-V<'&T@3HH&$C=Q&P"+_A7+^L UQX' ! N2S(2ORB&\4< G:T^XV%#(98
MFEO^S$62JA="BI<\>!G3R!$*E@:"@! C*-#TTGI7NQ^I%/U[XPO.18VLK3GE
M_X7^(SE";'Y+R)?._YTC[V#^>])&-K*!JAF9_\;#,@'"Y8 N4%D'&35YN1]I
M ?4'^[?&:!9@B)NHC:7Y#T]A?^^\S _VA7=-@69&CI=Y <T)"('^0W.-'^S?
MFV,8FXN#;<"07YR+^UU 3/IGQ849"F#0Q3<:%&P'3_X.P%\=AVX#=^3?N#>,
M+Q/,W_@8D(LT\A?VY0QB_"X'_R"*? 7\R<>]O$7X/M^OX5^6+@;T>SZY<6G"
MR!\.2X%_E.&WGP" 6/@'O19 "$ X'SU?!]P0-84O_H;B\O#R!@#KL@0P?7HA
M=SX!\ 7<0$5%14.]@89V Q<#'0/W%O:-&]BW"/'P;N'A$>+>N*0_OOZ9$# Q
M,#"Q,'&PL'#PL;"P\"\N6/C?17#_*PK.WP%P4>'&IR A4 ,0<1&0<!'.I^ =
M13]O1A"!6WD=X9+^<",2  'QVG5D%%0T= R$OU8BP'/NCTH< ,(U!"3$:XC7
M49!1KR/=X(97XB)=H[K)>5U4V0B/VOX9%S)^>&J)& WM+97WQMQW(=Y]XBAT
M$:I?9[=,''@(TDI]Z"4BU4PE&].AO+?[U3\#M\M\FP8<YW:D&*(RGI='-P_.
M[V96M PM[&F8.?G%9%6V#B_N\TEKFCO[QV97M8TL'> "$!'AUEZ[M D%^3K/
MI0E4G#>OP2VPI\:[SO4L'/_"@O<J?5^Y:8UG(=X1XJJW3!SN;M$A7QB 0L_3
MV \W(OVVJ:0Z+Q3X^:<)_VX!PY\FG(\#;B!=8N("1 "[^2%QSSUY" N+@(2
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M_]Y\("H93Q ZM<H13;3H41-^$W\2XRUE4,()KSH07UW\RTI*DJ0"$)_CVVT
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M%DB8(<^%<ZV-O\<(,>HY(UJ0"2K"@VL2#Y!$'E ^1L)_\) 2\9+(WCT0__!
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MWYF@O&0PO,RC"U0K%8L4)LBE^_O;V$]G/4-.VTY^_U' X<FV^'_^$8U5,&G
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M *4       \@  #L  'N  \@SSC&?__94$L#!!0    ( +J+75-AEBL@(3X
M %V+   1    9S$V-#8X,&<R-G,R-BYJ<&?MO0=84UNS/QQ0$1!0!%20)KU#
M0J\JO87>JY"$&@BD4$6.#:1+[Z#T$I#>P2-*Z""]B2A5NC055/@ R]%S]+WO
MO??]_Y_O^QX6;O9>LV;F-VMFUNRU=S3N#>^] IQ15511!.#AX>-YXGD" 'O+
M%%U:=@@T F6'<&$4Y!, B,FJ@(\?!^PWBI(&+=F_N@ K6CP3P+&+K$JT^
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M$<@1R!'($<@1R!'($<A_&(3XKW_>#W.&2C.Y,UV6V1L#R 'P_I=M[T_ *4+
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M]:6L><GV>G+@22 6KE?([+(C(RV;-*.=J- #OT[[ 63\I'2"X6J/1S.SM/>
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MM*W R%,W)+LY/2\SF[MS6,#'*GHD4$U:9=IQHM3_*4ZY>E@6KZ,1TR)<L%L
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M:G!G['P%6)1K\_<N78*D(-W=W9W2W;W TBQ+@RB(A'1)HW0KW2**=$AW2(.
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M82#X*&SHO-2-AQ9*G#J9RL_,[:?-0P*]UQ#4_]R)'DX6[)Q-,U^EG8H\&/N
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M"4CI)>3,F>@H$;?NX%1.]&Z?F&%R>6K]3*K1Z526JX_CT_P+QZ##NJ<GZY<
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MYI:5&6TI>@EGXO#>I_#>D8FC*T"%\+3@U=<*4=JY\ 7X24(!9EH?0J&( "@
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M=V>@K4Y#LF!49%E9.KTS-))LW$;(0"[6F!_%Y4YN@@&EY<'(NB*/F56X^.$
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MYI'E*7*0%7CL=Y1Y9U*]M7#L?!Q7,K'%I\E]O#)DX)B3Q^.HG3_LPY94FY[
M)1?@#17),H+X!^#<*4(ER!ID0'V\=?\[%MU=Z22NU(.5K>E@+3 WZ=?6TEBG
MR@].$^8,)PPOJ++X]-C<<'^B]JL 4B<^70C!=LT]7#=B,CX_S:'IX7<AOG-O
M'61ISIHH^F/UI/E)9#D=.$Q7[;"!O4DIA@%$JE[-+@D*]DO$Y.<&N1I,.S->
MV+K@[=-1[Z2E@%HY1)O<]&!'N\N[Z*7:]D_8QI;:#]S,^,PV> $M<FP4#:$"
M*78F+2M $F9&?)%2!01EZEK\#;RRR\8>>=IVY:7@$C^K;^;NU0S2%*BNS)"
MB4O?C/GQL@&K#Q+;XR+90-^PBSVW R6\,CWX*[*2K2:TV9<#1NO\G/;66;],
MRBH3%S5(2H.BEH/7QK9UA88+G= #!ZA(P^'AK,R><CD\6%S#]$Q%P>S@E&8X
M_7PJC*O4CEP;K8F ,M&W4QM]>OI*\KJ[FXO+N7(?3XL>)A?T.@Q@K^33LN$G
MI$X)D!>@.P9\,*X0VW-T:-:+.H_@/&1L3E-<\D<]G+>]\9VP/6F\SIGZME9]
M>ZFDZ[JB,'V.='KVUJT),W][,T.2!L7CHO9T.LG8L"S WTY&'A6G"$=I:BI
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MI%FDETEK2=M)ATAG2)^3?B2C(^,FDR!3(S,F<R#S(@LDBR1+)RLBJR'K('M
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M,%4X_WXM:HT@M2"T+QI!@(*#T"@,7BU(DW]'N!JQOTV6X0?OL!!\-/FUMR?
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M1$("HJ2BH:6CH , R$C)*8 D(  E%2,?1)N)C</* 9HQLI>9A96=T]XO3-C
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M[!C?H7J=,BJ^=:$LPLV+ EO9\=GKW#F/3JA0SMUX*=@TK<@5/UPFF$%.?:2
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MJ\CJ*,KD'*E<C);9_<K^WO:]Y@G+56 [3Z%? Z3[]_;]'Z7:CS$N8>#7VQ-
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M05?-J?:S>GNJR?!=PH-)0"CK@LLL"P_%J[FM;L8P?*E_Q)AD4I_4^Q0:<SD
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ML:;Y9+E' W=+K<>-@$4;%WMOEKGWY<]Z!;H* B>DCGPX#YYD=S8>RW>NF53
MAE8(9P5JVM$,H[C>9/%T,M-#3#DI#V&CV='9?K6/T!LQOD6,_)\083(G:,@D
MV]@]YB@(_]3/8O):D/NK/9$+C?MZYIIVYQZ5\Z,!Y]V=F(G N+R+^K48:+%4
ML.A7(7%?EIPA?P&_1ODK :QV(\4FOWB!]:TK,=#&0]._L%W&"3P]I>D7Z<[F
M8(XNC_KN/ -D1H9RXO^P(^]P\1O^G6"CB8#*,X!\;/O,EX7^G^J:4/19Y-J*
M;1K[!94D=YZ?1+-\VD43H>3GEI.H9S)J?\D-T[VX_C54ZGT3[;2_-7WL(J8B
MIOPG@(;?H]^/-<U/^G7-[3,@\-[+^0^TW\"'\HWN7F>)LGJ#SW=OVQ__2^LR
M:74W[=<K@9#*KJYA1JI]+3^B.-[B6E'N??@7I'8HN]7HJ-DC=N)I3@9ZMJ59
M?7H,"L4NK'F\0]Q&Q+Y,(:I-MB*C@2TNA7+X:$>-- :\VZ-M-HS$#CL@Y4:#
M=#6W1 TN$M9&&&D:J:SW %/'U0[2841.<1=C$*8G9PD*#%\E-VYH#[Q2Z*\J
ME#)V9Y/=0+1#VDLKIFXFN[?RG)FU#G;PIEN1:W%D2&;O,H(3>\2&16C$1[[:
MRR3$_0SK#O-P8[QJ%JD;(9.^K]2'261"D4+@*#W\(;/-X*L?J+U<=XLC,2A)
M$YUBJZBD<&-F:B,9M'Y!G;R2EB2Y1W*=KYLE$3%90I<YP8R"0Z@:?:Y3?)AL
M^+W.O&TAB3IECDS.X3/\(FO3%MVG[_^G']O91/4M;LJ%KXAICA:$0K,B*0OB
MJ?0:"1\;#B4_^[OEKRR\PH,(5DIR09!F=#D.&!=5;U0;C%ZHL<K8J*E-#1[5
M:MYHH-__8H1;&3^KZ_PH%CIINW+V?EG2RU7]PLN6LRA8-=0MN9=8SUPA'C%D
MS/;;E+IS)1?6&V4F!Z%P=Z&TZ-#<U\L3O3.URI1JS;1>7(N?G8*&V*/E,@,Z
MSL(AY#_/CXN=2D?9>K"=D""CN 39M@>*D1O;4W/2PCA6=>?FW?78KUQ#+]%>
MYOU /Z%L.>HZJ%YU-8@N4['>K'7E::_4BY\3V?&Y>_=%8-S=8R3^0)O-W5LJ
MCVZ"/P_<7>>*6MFSZ9L1^EX(Z&#[[1D0K[6HOPW3288'1&5.UX'MU^V$.-OC
M9C.NQV]_>(](A5 3NNB^3#9?#<C#]UGG&WZ#ZN?29 RP'=8*D6\QO6[$D6V>
M8LD<$LYU6,%MPYN!6!DR2P3POK^$F$&PI=YH]D6O'7QZ],6.1A0QH'.##] A
MF+%F95_.BY.31#O0L.A3]F_3@RN=N*P>;;UU1+*P[5+19YC$;!D\ H55D&8K
M0(+X9Q4ASJT;:@FB\^FEBY$-B>PFCD]\@7'4N[8-9T*9A9TL'PY;]L5#= \<
MJ U7XO:&/MZ="7:'!!A,J2Q-8NEO+!QOUC/0=Q/G0!0]!\,W+8L*:+N%"ER$
M3&^*J+5/V@I>XQO.?.'*PL=)RD4:5F.GQ!R(@<F-0P.:Z;ZU#I+6]Y]9(]4T
MM0*<>KYM152;*JUW%'4E^?162<Z)F[O--HTDV3CBBQD%Q'[+!Y6RF:&*(E9J
M.:HELD'5_*J: "RQXN37B)(9IN2OY?]A0D>#;;"J]-?)3/$;.,3U/!3D'I2A
M-:\<I,;MNY'US%L7D\\0^;H6=N[J9BU]'BK;RAR=-0%:_[K(NH7X[+2+(4[8
M]S]Z,<-"K*69'-*HF(E%Y;N\J$Y-B.'#<?LMZ3FCZRD=*Q]9?34=D'NYSVJ_
M:&U [&OF*UGBJDA[B=4Y7O5[?-[V/FZSGS_[ACEIB8*LJ_/)2U F@%09->2B
M88[LEF#_'3,LGU *2Y1W4/!]U[7Y< Z!43CUN'\@!B#E:QPZH96-=;5V%TWW
MH$D/?,* T$[-.X-PLTSDC1(Y2@TD;5*D@X+6![6JVE*AQ/D@VQ@F#NZI)*H)
M9J^<")IRVAL+-1'WDG)RJ@K36>5EKII/=0J:Z$.OU#D9TON&&VEP=K70U!;,
M!QBH%,\NDC3WP;F>7U18!5VOE%:7^)E12$S3I3L<XPEG3AJ/#^Y7_6/E;M^(
M?S\G"D--_@RD_'Z5)86OBH8IEZ_C)2'*UW/LYLKY-0!UI W.K(4/7AX^UOCK
M/BT,>LVKAB)(0^$YB1]?+N?MA@9O3[X33>S"YG@Y.JND>E23H]443N7BHNY,
MD0QZ24X!A@!E\K2GHZ/_=55809KORF0A==K<SD<E"MA!VB7IG/.2U@6QNI -
MPUFIL9!%[10KW5]1I*QO7GGD-P,_-HEOR--C;ME-C7Y@^5Z&[D-I&1BQ"N/A
M%62X"O.I!?\S?7)%9HN^6>$/GC>;*6NTUI6=P1<-O?8XJE.Q^Q2J[;C2>O6Q
M% AGF%&\BZS'=%%J\$I8[CB">8IG..]]KUJU3.(G0)SF9>/TQ\7",->_&N5O
MW3.3A2B%3*E4/?B=,Y2]PW5@SHF<]+/6+XQ3EB!,]JR(RA]+(O!YB??G1L5'
M54?A54)=5MAX, ".-$1:$B9B]D2BZT)ELWM#L]-1BA"&=>P8MWBF8U%5W(7N
MUF8\,)!)LXMF;LV+=ZG$@[3CRAZ]'B4VUY2\9@27*"_#U5SZ.R+)$#9NC_R8
M%]:W_=<COA*8 /MK^U.#^/_C(_G_]8M%*[-+G#U"W='KNW-OH/Y'%*DP*86A
M. K9QL&GZ/>?,D4W.8&+QEJ4UV%RP1,;^3!)@V$(-OGX'W4.TX#:-&*^*)T3
MJ7I(PQ4V$4Y.3M7S/9G+RFI:27IH@SQ2W$L(NE:AM-PZM*OM9!C9 ZM[D<=^
MS$.V TK4-'18D7(ABCF*<IRZE)\G%:ME_5\J >YE#?VDSS#79*F$8K^;$:,
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MY^1AJ@>LNW.VX6-XHTG5LIK97E=BJ2#<.=I)H,CM:)E-)*&9?+*L-(<CTT-
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MA5KQG>=:)Q*<&_(,^,B]>8EY>A5Q=#IF];ZFD9?)TJ1^IS:8J!>HCLR.CAF
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M)[;QQ^IOGE@UCPH$7;32;^_0#'*M#9: A$"ZC@"_>X25+<BE(A>(U?O6V:Q
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M !$   !G,38T-C@P9S4V<S8V+FIP9^R\!5A46]LW/G2WTIW2,/002H.$"(*
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MB<U?+C%G[:R=M;-VUL[:63MK9^VLG;7_E]K1C%JQ'1KM#!(6AJ.$K$X>787
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M_1%)?#I)2*Q6^]Y]V_78KT_[0*]L)]-I0[O+S$/C\53,Q9THQ?=0FLXXF4>
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MYP7DGE%)@Y-+F%K)>!Z3Z3JRW-6>S4Q5P$!$DS@D5LK-!^XXZCJE:\\![D"
M.^&'#C54^.4E%V>IUHDRW3\*<^^$ARTGH]7C\G0&8?ZM>T'H(I7XI)$X/]ES
MFN44(Y'BT:[;E=I6V]Q<<73VI/R;&E#^E9SI;[2YP6\@8F9:""9NKZ+, $GK
M"8<+'?#0PD"M<_=+<H!%Z_*YDWNXB;,B0FV6MQY'#*0R!0QX@(/SV5T6L>]A
M!>I[FN<BRAKY-1<10=T8&]]<EY+WMAPSG04M>,8<-PP_F6]7\RSD[(IG?88
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MJ":,$?Q?5"IX/'?D-E71^V\.FYDN?W%\M&M5PSS/#K@\I(C]IBTLP-=>X*X
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M(QEOX+9VM2]-H6OF;?\+M;F:-#!#0'NEM^&-AZV@=]1T0M?/K=&]SZ<.\Z;
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MEC.DYLIA+G<S/XHATZGAT0[Y9&4O2-ZHN^^6Z!)<RIKDZJI\=S3JAJI_1EK
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M7#\S'Z"CR4_KB=%[.VG:T[W_5EE_98Y%W$&XYU!WK7O@LK/1ITP;+(C"._T
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M1F]HSE*\=6AA?FBJT1_L;79%A!X094UJT$HV*N?^X?TBC2X*EHSMWL1F#9(
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MN0=L%7SC[DQAA;%>PO!7@"E)4#%$2"QWVDR<'K4@P:%I.@M#7N^ L*O11+X
MXP"^(=0R;)GCT81'Z:RFRQ-B=#P^.S)#P,,*&<1P+;J_]._?<G'ALX%&7[E9
M.1*(A]AO32?]">\(E\EIF>"'_6\,JB0=BJ8B4\7KTT2B2.Q_JD19]SH8:K,J
MQ!EHD0B20*2RD$8P%H2CI<LQYT.0B(0P2A'O6JS8UB%+3=87+[N($XW]1RB
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M@;M]]N&IL9<3B5.\M=(X_$.[@Z<T0?.SQO=N)B/@+R3"H0F7B':J!AE1]A_
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MY5(EEJQFA_7ZA_XR;?CI/EQQE,_L05#[3+>3).[BN8H4OGB8#C;>H3W (V@
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MYR[3%9-=3W5,?U-8W[F%8&2W9E;%\P75%/FX!%AC^?;20G3W,K0Y6JB.?L-
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M?I:-Q!Y6TQ,O^/6Z$3SI%ZM""%)Q/20SR$%M. )_O),UP<:\AG@V?8T=O5*
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M7B-08O3<;WM2>PE/N;CG>FLM_(.:*-Q<5W:7^]',5KW=O_[WZY9(Y?V:"]D
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M#- .L7[KF;Z'*^ZK"Z^_7<G> MZB(YM9C4Q\#X%'(V3*QF]M.=L-SD 3ST]
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MJ\0G@FCYUV^ GY^V*ODE08X"H+OFH;G?8QU$DNF/Y_2@N*,W@#5BN6]08_R
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M;CC2Z6O)E1@H5C&V0*.Q4CN4;@.=,: %]8U(KWI;&$5R&[/W;J,:&K)+6LQ
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M@MI2NP;OOC2C%P$763/6D"^3,=0O :\L=#DV;TB6Y+"P._Q9]G(U4FIOXPV
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M.3^""JXKH4F^"@THD?I1)]$FI1]B7A#.Q[XOUB"=B4-T-"S5#BME[#> ;.G
MVJ+3ZAW4"[VS?6*UW\YB;3'#ZHS&76/J+J[U988!6&H@\B\Z$C:KVJ4@KVN]
M_^$Y;X"^Z;9AJ[W[>'V>WV)>1=K W5A(&E!!C5L!"[6 06D26O-$3>B6Q 4]
M,W<NR)F=N:5#EH^#'B)+I.[&GO#BQ!+M-DN:'XR0CPA'6J!:'$ZBJ>O:.:FR
M2P?A2M^VYLIN);+O\O(B]# 8?"FC\OJS_8_:7.9J1ZA(M,!V 2PXNR^>I,#
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M<301)#WX&WKW%PL?_]#@?IS_-U!+ P04    " "ZBUU3<"A:L+KZ  !=6P$
M$0   &<Q-C0V.#!G-3AS.3DN:G!G[+P%6%3;UP<\='=WAY)##(UT-]*A,#/
MR## S%""!4@W2"HBJ*AT-PK2J2 =TJAT2)@?X-6K]WK_;_V_]_G>[V'IS#E[
MU6_MM?=>YYP]/.?KZ-<9 +F.AK8&  ,#$\,/PP\ ^+I&#S=R<4>[HUS</=C%
MA44!TBK:^MC8@".B-VITY/ZS"1!BQK &8#'Q:/XX8@( 1_^9,7$ %&I0I)N#
MMP,:803S@,)A".@W1SPGEN1]H3-,0]M"?*9[\V?S9 $+)S+9$]GBL?SH@W'2
M(O) PA!H0R^TAQ?ZJ(ESS#-"H4T=W=WA)QK:"#04BO!R^WY^?%2%(X_;9">V
MIC#?8PT5&/K8YD^?4*2!@QOTO+KE^1]@WPR,D.[N3J90M)>'H>,E\!&;&& $
M0 +<C_XY =@!I@ H  WP GB<F!!Z_-#^[D8%CD;\$1&QHQ<,CH8A3EP>M0E.
MM%7UK72_94/N6!]3Z)<>4_[48T,/-,P=@3KBTIWTRP.-^-Z)HTXZ(G\T3)Q1
M^G]*D C5/QL(])\-/4<XZD?#P!GM_:.A[@97^]$XRN.?KE7 KLY_).);@  3
M3175HP/6R3F$G1WB[N6HY#X#^$Z:2,3?>"KPO^NI("'GS1!H#2X3.!KP$ZG
M(>R_XYN@X.@3OI$O7,GO!YO0&PI&NR/5'- ./V:%D;,1ZONL.#[_XZAZD@2H
M$_IW[L\?3?C?\4W!\&]\(R18R>H'FQR,=/>P<($>#>[1>,$0SM\S1GHL,#F*
M2<4=C79W@[LCG/\P(?XN.0[A)S[)=[X)S-GE9P'1=\%1;#_8QS,':^U;#%A/
MOT@>+3G,[\>36<5[(B/]LP?GKG^SPB8Y:1ZO7M:3-L.O;:R=DS;!=SN,$RL^
M\F]I_C[\ (P3W?<GYUH $2>G(PG\Z!OW#Z-OG'MIZ3\X8B??UD??WSF2)]]"
M?W).?!Z<G!^MI*^_):PWQ^)_O^PD%_C?,GH2%P!3Z=OG#QGKCSQ]:S,>GV%)
M_HC^A+"*CU(W_B-U?Z>?>,=ZQ_K_J/"#_BP, (07_'B"81[#.KI[(2"HOZQ+
M,!KX/<SCR?S31 +\9<8!5'[,S&]AF/R8>"==P$7!86 HRARN=[QT,'[!P3F1
M'9U0'GWP3AK::C_YQG-&NGMY_,+"=4?"G&$_JJ*ZZ;&1X0GOJ$WBX(5VUX0B
MH$@'-!1R$KV?Q_>B3OA-^9AS+-%V<V;_7^@_EA<2_LNEX23YOW+T4<Z_7CYP
M'>#H\P[.O_!(P= C.Z@O6ANE=5Y?[WN!PO_._D69P,4=>5D9#G/^GBFR;YW7
M^LX^SBX$ZN3@=5*A"+RA2/1OU,V_LW]5)W)T5G6'NR-_2B[%-P,5S1^"XS ,
MW!''1P*TN\?190@%_3EQA/"C1/Z-2^QX4NK^QB="'A>TO[!/5A#_-[OCZ7QN
M$_ GG^+D%.-;Y<&F/FD=#RCV2?M8'T#2\T?"LHX^\D>G,T<EX_H1OQA #\#X
M.OIU#4"L#'%WA%Y0U0=@?ET'D)ZT )#KQW9?)P#! &)\?'P"?&(" F(*(D(B
M"AHR8F(R&GHJ*AHJ*GH*XA/ZX_![PB A(B(A)2$G)26G)B4EI3[^(J7^9D+Q
MGW'P]1F  O\H^"PL#$X )@4&%@7&UZFCCA)^;<$X=Q0E#L8)_9%&+  &)C8.
M+AX^ 2$1QE^%&$?5_[N0'("!C8&%B8V)@X>+CX-%+'XDI,#"YJ $XB@;.U!Q
M>MX0PZ6.OU>BPL5-8]+D*"Z!#'RIBL>38+HYNP5&2=)FEP;QJB6>AZ@WYZ!!
M= -F<]#MLN#G@U[S.QI\2?=OEM]J>;6P^Z"B=6CQO;F3=TCRP\JVX:4]*4T+
M9Y_0E-RJ]I'E?0H )N91M-@G,>'AXDB>A, !I,0^BL"3DPI'[$8\]7$$328O
M-\6Y'6>1@0FJIC1@E,06#^YQ 'B\DLT#1T'DT$'4S4!HZ-R/$/XY KX_0_@Z
M#B#&.L&D )P#O#^?H,W#U?C!\YW72$/%^=')_51,@Y>/OYC<9!CU(_-"7[ K
M<DF1C"%E]_UHN'U+[Y/>B-V[N<81Q&)F<4$!.VYT]*[(5-VA]H>K("^+AC&F
M2/R]];HAP,>KD0J$H&N9"1D,RC6^A_1)$,)"?S;[/88K""'6SP4HN\:GYE5?
M :F/KK:^(W%]5_1D^HR704&!AVOFP-J]Y,L?;&JBW=]_!:18ET2^E'5B]4H;
M'9U-,\>3W$M1:*E8C$4IK*.L>U^-K'UJO38UH[BK%C:Q;1KKK+$B@I.3;\GX
MAONR/MZ;Y&I0FTRLJYUK@^$G$O4[YQXUCICW52\G![TS9[#RX)GPOR;U:7"T
M\LHTUH:9Z =S7)KA"^%*3[J5P!VH,':ZB1P60>>WPB4;8Y^6#]1\%V>_")KI
M,UTF,RI-%M^[\Z 7?#/QJ5O,>Y**FB]WAAJB=MV>LHZOE.W>O?>!#?J8#BOG
M/;'NBO^'Z)3AD9KATK8$.*E3U_AR;?OEJY&?OP)RK &G=$JG=$JG=$JG=$JG
M=$JG=$I_H:^S&N4N:+2'K(@( B7L</R8+@QV=Q/Q=? 0 0J+B@#DS_EZ.(!=
MH6AV1Z@S#*' N5'WE),=!E'@M)#4%]7W4(6ZP+0N(Z&FEPW.@R^[@F4@G.<4
M">5]97W=/-R@: =V7S<X B7KJ\!YXESVZ/R8+<+)?J*"=E7@/-D<8+?4-V)7
M=4="V26%Q87 HD @.P@D#)20!(& @NQBHD Q$=&C_R AH(2L)$A63(K]#^)4
M)#SZED="G&1-U#3^@#MJ*7#^T2\?'Q]A'W%A=Z2S"%!&1N;8C9B8T)&&$,H/
M@7;P%4*@N+XY^>Y'#8H"(V$G.__LQVT'1W<OM (G)R'[3_0-" +^@>/AA82?
MH$# (E XU V*0*..<@@4^>'\V#\$+.ODCG1S0"O"W!R<H2)0#Y23O,B?W%]5
MT3 T'*KX"^Y)A,IP]*_<[P(X[#@P6;@#PEF!TU?HC[TG3L6__1@D+_)-_2_.
M1?[N_22Z7P+YIO53EOZ[V3N: #_2]]OI]TOJCK1E]8_F#L0![:#F@(8JBHF*
M 86 HD)B4N>!,K*2HK*20 %125EQ47F1O^G^U8\[!.;D]Y_R\J?F7WRH(J%'
MW%]]2)X'@F1%CWR A$0ECDZ^^?A)\W<^W)'GW=WABM_6P9^__:F:@MCY+6 (
MB+L/ZLQ/COY0_W]A,/3U__5PN+F)_,X2A3:!.OUK2]3QUJ:("13E[H4$0X_4
MN7[O2-T;_5]QI.Y]M,JX_CI+]/5EM1$HM /B>%]<\8@A#(-!9$7%U<4TI( @
M<:"XE+HJ$"@M+B.CHJXAKBXJ(2$CJJ%ZDN%?3?_F5LT=['6\L/]P"SER*RXC
M(0H6/ZHH,C)'U4E"5,9)R$',24)(W$'<450&Z"0!@DI]=_V3^=]<?]N,=X#_
MI./E=>1?4DU,5%I&3$)&7$5#304(E %**$M+RHBJB0,E1:55I;_[_HW]WS!,
MH @(['@NJ,(=4"C%/ZK#=P]_D?Z]\U DS!L*T4"ZNYW,)0\').KD9P$%SN_C
MP?F7<G(R,V1AOQD,L?]H,/YF^CO/D/_N>/S-_'?>W?_;0_*/]K^#0?[#J/Q6
M^G-=_MNP_'W,M&"HHWKA]YM+B"G4\Q\O(?^YT?W1B:-%*^L /JD]*(>C4(Y#
M_XGWST:_F1CB$+ 34!HB(01V$A,7DI 2EQ%R%'6 "LDXB<F(B4I)28N*.7[W
M_T^3XQ<,'Q<HXI?Z+"$K!I25$/U>GW_2^F<G*'<GM(\#$JKL?#2,?Q1J;3C<
M"X5&'M=C=C%)80EV?GT', QQ7+S/?'?[J]T_^P>['%VPH1!%D>^&WQE_&Z'?
M7K;_OS%TZD!5%3$5:7%QT7]>T__-83NY-$O(R(I*?+\T_[>'[1^OK__W1@SL
MCCC^ ?*_,&I'. Y'M]]0)$K1Z;B,?[L'O>0!=69'N[,[>'C 86"'8Q\BW@C(
M'U=?C^\)^X[RDY/_Q<Y"OI6Y_TY7?^2)_?]:I__G:U+L=$W^WZJB_YD[H__)
MB/WR@',Z8O^.*OH?E)#C*O/SP_[_/ZKH_Z%._\_7Y'_XZ'BZ)G_E_OIT\?U1
MY2]/(_^VK0O8G[?BO]\]^$GA[_M*/PEE3=$.2+27AQ'2W0D&ARJ>_&6IO,B_
MT/@'/W]LU)AZ.?ZTM?/3$\.O/O^B_>].CP?D'W9GC@1'Z1#_-1U'3-FCWD&\
MP%#D]YFEIL$.ASDB'9!^[$"0\/%CTR]:__: O\_D?PC[N_CO8_E#)*L'=78
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M5<5:--V 7>:E08!Y>8?CT@+J\B=P$IF81K>R,(OO6$#?7&.:-7<_W-W-JXC
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M6%^FZ<;BF]GW%H?Z%<33CUD]%MTY4*+1SAZG[BBEL=PVIY0@IBD8GR+92^:
M\DM?VDB[3YPJJ S-Y/&S$@?9]#(%7?=X*22[JL3^YLV;H,(G@_DX?O]RV_*?
M&I'A]0=SKW(3[-@_L;A4N_6)F\0&(H9-UPH>F\>UW0JLZP-91EW):PCCB$SV
MU.3K*G<4H,X4CH&.-]I:6RY/7"YZ)\]UMRAX9OJL1PH#K_H^T# WIB.,CW:<
M+SI1IOR!KU?(<Z:['$(PBIJ"N+M!N><2[W_TDW<9"GG&5<Z3B;E$WQ^BBW&K
M@%/1!S!%*;/?)57!TMT7*TT:^69SL9PJBO$C>%7H7G7R\$WNV-MU\6X*9<6O
M >,EE/R\E3#VA<A=%;+S8P*5C#+4 _HFD.FYTAIIE)G',OU$M^==4IM^VP<Z
M(5*O<VX6P.D_>?'JJW0S*TV '6[-\:*T=DJYP&C I<C1CI6Y]7:3,]!T%%&F
M=L!@EY4\8B5+>Y&Y79]MA6H$:E:_.+>[A&N1L^P"*_ $X>2CK]<PD21(J<)\
M$3V9R@_$]*^1QP:-6KT=H[=HXE4S:I8=50[B454\PZ8F+N4V"1(.,Z/JG]5[
MK^NY%4U\9[S,OJL1;R!1)+%"XT[M^W6K3.L+L.<"/$_:&:+B-3K3F-LT@;UH
M1!*3%2-28]7VA2J70T$?K]NEK5Y!]P#CDH0#,G &ASN?P&UKVV<8>*D24=UA
MMAH+5NO2_3M#$^U7-SN&NQ=6BSRF]CH&/PSL$/#3;7T,OOQN/.GLUD799^=;
M8KV9RJ_AKHU0SDE%&J\.8:_=H/.=5&^QM$2A6S^9LX5GY]PHBE[(27BZ_D*O
ML]Y<:HTA0WYD(8]-WAZ(RF"_7;-.6;'JAGXT[J4=0 0JV4A?329(Q]>+=7 _
M\_EY .@9M_?=SBQK2P#S?4'EM@?CUJA,?Y;R91NWZ/5YN(?RPR*\#M^^C*86
MC^E) L8K?M2E%W<5$>K-Q%K;A.\C"L;JKYKRM:N)MM)8WM(>@D3%G.-I/F]G
MOB=%"?QD_7%[-K=SNY]6%C8V8Y'?J0JIHL8TKY;IA3C$=7P.;;-^+&I(JG.!
M\DR^[VA;LY 8V8V=BF"%;=JUDIK%8!?*M8:<$AR35E_52E:TZ%N7VWP:3'@-
M7!,8(2T3F[;L@NH(@GI+UI>C!K98G(0:9RC%' 4M$Z,Z@]H,I2['<SRS!#G*
M[ >W1D8G2N<ROX;5Z()*B[LCTC/>@@L^3KR.SI.O_N &+T@G(&('3W9F)?OJ
MZK*)3^Z7S?E[3L5FK#)NM5KU%G?:2&SY.I1U#?=S1=J. .QGF$<J8D?E"P"L
MU[\"XDE0C00:,E,="OXY4@]?W^K<A=/9$40A4V)JJ\QO3/0SZ#C&XDM#VT>O
MLX]VQ5YZ\QQK+ Q=1RD4JX#H\=?K:.S%J "Y.UI)$3BL0SVEQU] W:82VK"D
MXIZ") N+'/+)>L:2+_B$?%H/;2'Q9R%BWJ\'9C4PT 3VW'KD:IUN,1+!6[EF
MR1'3Y)IJ\$2CC:Z6%@\W@4QF4!/(+B+"6KZ^<!L95?[B8<D"[$W22,X*Y!UO
M:6]GVT%C=.2#DGK:HG;7&2"^+5P-R4--@\XHCBP 6G#B1$E<B1MH:7_(T^;E
M).;;E8I[/F:/EHG&MSE&_058W%NLK#:EI7TRO?7Q0G)O.(;(;3-69F.9&UMM
M.UQFDGG]/(-<V94'"ZV]MK*MYN87DVB3FX<UF:R8P4JBG54R3>/^UV&6TPF#
M<H1>N1_.>(W%"""NNWI^3*;DK7M+T'8+Q"X6O2.FJ#/N9"&%-=(2+(4KW!YJ
MK\Z%:"UX'1IP=L^L#/N5R9XIG\Y#W7&<T>H@!@$4\SFB$N''21':JO522N_R
M%WT%RWI&.CB":R83Q QN?J# \8,4A82_6H85>#5W)->E3Z'P#D+!!K%J4G?&
MF6#N<5.WBJ5O@?P*95U+P>W:JFFTW>- NLLVI2N8$4D986#>CNU"KV3^T,[.
M-OX$*Y68X2BK9@;I1H&:;L'$YH-9TSG9WKK5^G.2@,!H)I+.T L78_)CPUJ8
M M)4'3VC\)_=#L7]Q*7TOD:(+K7LPZ.YMP\<@HSJTC4J)B<B]0^N^[3X28U\
MG-8I?6TM$&?]%7!%-[>4_QQW9%.5#TEY7V64\T/I+9S7D'SK<T_FXK5#$C)*
M1X%OL:;,4&+*P5'YT$1S(M_]+PJZBAY#;5@[)0P!"O4*UAXVS9KN="UC<F51
MF9>F.3*91Y9++ 3,=I=NIGSBAT!4I!3F]5XLDN+LP8?+:-)X BS86*("R*NF
MWK5"UN)*$LSC=-I3_::9YY;>K&X\9@'%ZGER>M(LGM.0LPK)'=5D'_>/L!'U
M&[3!51PP:;?O[)).C0]K61(3S;=M3NW,6=4O)69Y@A#M)1X37Z7M;";(LQ:\
M2V%6<GT^U[QC,&+8, RX$7$6I8@W%0AZ-@%R51;(@ TM!1@D6U#D],U\QE3I
M#8P<0U'T8Q?&$)I*]J5E&Q(LWRY)4"C8?#[.S#C%QE$07Y9'12KNMBDO,.5F
M,I_<<7F):>"0=Q*# [,BW@PJLJL#SQ'T_X)':XGR>>C0\E%.PXT&/^*&/6<_
MSWD;6B[;PI$K%G(Q*>$E!C*U@FYWG<G!T"J>-ZW>4-U<GR"$Q[Z8 '!'9ITR
M7D#W.E:Z1JA#IX'3RU(F$PND,W?Q: ;!DI>;*$JM%_/-5!:>2+/2MJLVVR#$
MS'>]]]76^]LJ/6W9J#> Z9=%O)X;O&28L9W@-W/ELL9T[?);V'HNRVDXPA22
MY[7\@RV<$I[P)A-"9Y.Q7R&I,)QD5L_7\!::9[1'6&6EONNA6ME_V;$7#DZZ
M;C\P0D[ X56PF$R[+B69H"%%';V LMZ+G6JX^Z8:JVOI*R!;F57W<&D&C[2&
MC6U)[X(-X@VZIHKY\CG6C=Q/Z%O:X,6T=F=H97EM9WLGMN#[4LS[5ED<@V/.
M+O1Y&>WAQ:POX>0V$@6AI9[7*!V<9A]O.*X.RQ0"G3C2GFSJ4^7FLLH6BXNY
MC"YKDTG<J'C/[A[5KC6CA1?0*';SX04(B(&O=JXWQW@#',2#W@[ EGY;Q'&S
M?\+;<@;/(&)KI#3Z^<N\CCZ'TI0M_VL;!<!._2[7@!62\'9I%7^6'2KDON%K
MVIL]JI9QK9B/.BT>D2+6YN_3&#M$*D">)6*F5CL\J<.5BMZL![T[7%7DX@MJ
M;0U[JBOE\A(\ES\,DC.#;D[SD)&@8URMU_!"%%;]92[$$^4[%KPFR[W4Z^_-
M<HGADJB>ZOVQ *1$-6V<%B#A7*T63B[84$J*ND9??C963BHI4;U/?<T O'W.
MN']>_DI,$)_PJ+&=#VY2HI%)^_- IQKJ*/XVC>U%&_ZFO$JW5EZU2.,NQ<X@
MQ12Z%FG&V_K-OH^00]SMF\-4/ 8!+=NE#6?6)PN;N!R2+21#V \LN:[)I2]K
M6;;+B]\9!9VQ361+*/TP0% T'JAA!M9+%*-?D*]?N\AWU] 3Y56,.]6E33(^
MS=,L[4\PY5EUV3F[._.RS44FBC.18J-UYG0E-U:*U_3;M+.TZ[-V(SVZ<3$O
MPFK]0K4JE5CS>^?W:J1:)46@HLO5$2.4UJT]DW?9-I--[HN-%'^P_'A^L88K
M^\[MF")JZ?&-M"WI<#U'I]"2F.EG+_MR6/!714>>+^3I[#5DP^9NQ4O(Q' K
M]!5OOIB95IIK5KW]@BSUU57Q=YGJ*_H;;=7".:_D8\K%&.J'3:#W:RZT:]F6
M8K2_H0KGJD*&[Y4O7LIG !D-@VF,\J&6_)N(\.1^ZM75SW$NP:'W^B"B524R
MW5;,,533^7/7\Y)F5WN?[.V )K!L[.]\82-#!:LH<=VV"8B.$344M/$,Q;U/
M.UMB(,U>-2O6OB$PG4<=;Q96?9#PW,=Z:7$LMGE1V'.E?^SUT%3 ESKN;$$F
M%S%O36LX<)6Q^O+A)T;KSD3>L$>S@U6(Z^3*9>8=/#$ZA;/-71<3^'-C=/@?
M^LZ&2'4+6!^BF=OL[^]72T956?6CPDA<F<2);L]=!@"X$U]@5*AEI2X X,GR
M +D$:R6VRS/MFB-J;7FW/<%JG7XF>'':/9I)21D*697<?1?H1P+OAHT.O ),
M+>5>?G5I[B4_#46;G52G&I6D(X*U"#I&8\;3X!IUY=["V2U<:V;L4935:B _
M<O?)<.9"5/(M']WN> ??N/8S ?H>8Y'/B;%E134EHYJ?\\CV5T_8\T[O#Z5;
M,5$Q\R0FT>.["T_DDE]K*/67#EH;WPK'8ZE)Z=.>'I]-'EZ$B">-?[0/>DDI
M!,U/7S-NBL? LQ=&671Z= L.C^1T4W<X$<EJ-YH;!7B&JS$J=DL4NZL3D2_Y
M.M\\"Z[.8'L^[$$GW)D<^'X?_%K@8>4$!83C;;?G5GM_U\!E1>>V90E,?5/@
M>R0#@],]A=%U=2+76OIZ#RPN0;0(VP?:FA:O5575BK?Y.-*)]6C[V)F*9>-I
ML^<^N-7#-A)R!:_;Z1_U?DDN=0?=Z7R(*4G:-H@_/ZT^7DKJ&39QAXG+F4U]
MOFI&7*N;PXT65N],?O0$8"^X;U5]M0_T_IU8%4UZ"2_SM.0E96N]:,$T^?B:
M@99#^3,<Z#Y7*]'-UUPW6B3@PP719&[#EB$,Z?!78/@!IS;;T1*LQJ[&K9:0
M*2+&<Y/O=;%2B[79EGE*(4U46CE"0TS)DW-8S^DN>/V2XKGVG#KBS&B7-22]
MUL('<^K6K"R^!Z26M5HOX.E1%^NJ #1R"<):3N]U1>V:,SGG/EA^80^/ZMHL
MO^5JV['$EYDH5@2VO!AT!M:7X'*1#/>,<GQ3=*H:OC/GXRT;B1)DOWZ?5T D
M-,!H",PCV0Y<ON+;+L"Z38"2P#/?>;-:F(Y "&_;0(&3$^3NO+P/*EB;!VR$
MI',)^V$=62$]^%V[][*,1A/'9'.3^>5;O%T.SD=2)]'!T^ZP7>]>2M"VFF8&
M22D$9:]"^6;>M<?G)F7#/>5EY,1D5HN2(EQ!5H!@C8/E)YWLHU?O$'7O:B_*
MN5*O=6]01B;($KCV,,2B*:X3K=1$.21FI,J4DG^98I;Q][+M&K)&V%5Z+:O9
M"O;3[+,#+^/Y]6"XETQ@Z:3A,E5$D."*!K^:$[:41FQ3FHV[!7-Q)&8WB;D_
MNT59%Y#(MG>E397/^N:&2V5._SPT$1A>),RSN^VIRP$O'8\><D39$[EI3,-8
ML'&60/K,-YX]??CP[+8^+:64Z9WLBG F:.D(BJDR[,Z<-$4.4TPZZZ;,9#L)
M"\WZDB:;]W35$A\_!.XU?' MUV<]/K!)4H?9<SZY8JKI3@P6/A6%^$/]68%H
MELHTQ\U!G&ZQ,\R7I(BRGF@(!8W QR_V93+VS!=Z#./B3;6(\X1U353$>;M+
M^M-QL4D^%FQ-"AO)9"N?[,CD"D Q*+([3E@OH_3?E;5>7?DD8%ATJ=SX^?HM
MA]O(4B!3GEP+^/,D':E3PXV<(BD3W(?>K"4+I/E<K0HZA7>GHBXV5<-<=&S
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MQ/H8B%X&Z(HOH>V#]+DUI:ZELGLZ9S+H!/*?,)R)5YEZ\O.,TYT>KMBX)EF
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M=10J6=Q)1".?EORP"FD_.;+1$NJWL!Z1N>Y@S$S#(ZLUS8U[@0.=+KB@[/M
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M(.6LHX$+$E?!<#I]T)73=S#W9ZO4D.OJV0)+IZ"DKTM\>@,(+K$>GGZ$3MT
MI-:;&^G^SEXXC2R\0FRT#Z^#@P</>5_*;GFJA"IT2G!Q?:9OA(]N2.YWF0LJ
M#XORC[?FKM&^5W"B^(*Y+_VQQ=,'ZA_M'R81^\N0T]K^NQM98?:KIZO3,V;<
M4QH2ZX2C9$]%F@?*E5$)@_,;=$O^^CP.'!\HYV/.8XVS E.R5Z0W =][FO@A
M_U@3I<>Y/VMVXLMU9<CL;.F^LJ30>S[*,[@ZAK-EJ\%N##Q:9Z3#WVOT^(V#
MST=[,K05EY>X129S<L?29&39@E^NL;MP$;#W@@."=O,Y/# U!BSJ.U0$'>Y"
M5S4J.U)1)+F,H3^3)ZG>( FWSY"\4KBGK!MG_OJ^+DRD+I)R3)FA6!E7TW50
MDLM]DN\,:N44^?CMWFQ]1-HP0C3EZX5>JS"Q$41,,J0\R.!R3!<.F?TN77?Q
MLDR!@<YW;OT,#*I2(9?^4W_<5DV7BXIY=%]:FWI:\< 9(%.M]T$O<H]RT?&L
M[(WMGDX?2)?/_\Q]-7_]S<;'/,Y$5Y&L<@3$0YDLKR8--\L]-6ZW8JCKZZ;0
MTDH:V^0-*AE:"TIIGW>P7Q6HLTQ8&?O*DB  ZLMZJ.X;&2=6N&CTK\*\%]L*
MM%4;$0@6=6+IQ>\$L0[OA&('/\YEON[%:QHA,:P9N)I"=%IU^$P.+285\2D/
M:__:"R=<[!O\F+Q&:,HF-WXZYY13<.MQKJ:?43D:I%0G6QMG'#HHJ0,(R<WP
MV!(+<]SO?U%+/=OS_9)[*YO$RLXA<T?F.<T6[76XU!AY=),BT,$\X=167-8N
MU@.$8\K^O:8 .L:SL+:DO?#E%ZNOQ"9#/;?SUJ_*-B]D%.^1@/F9,6 /IHL,
M.W6QTHK(UCL?;0,*&BL9I+-G72,?]C8=)\QY6/!6)K%&?KA83RO;%Y &H#-.
M%E/N^0V61NZ^UW7.(.-3+9'39]WI+!Y#\#$F>EFF,NV6TCIT+["CAK7X=([R
M=1JYTB25<(56V@8,)0!NP71%'RAI0;Y;H$[WA'"#3=.%^R6VEWK=VF.G^/9U
M#XJI*<]"K3SG!J)O;:-][!4>/*(U^@]Q>;(S]MPUEJM>E)'E ,F @^3YF;OD
M&6M^P^M'3@JH<BM@N-CR5-97T0_%<MC5H#O>G;S8 DI"1T&7YZ,C5J'G<5R+
M(U\!85X!G;[?W4[=N38?6-TBO:V+&-B!O_QSK4<T(C?-HXP@89C*F_S"R@*6
MDQ[^S;8F+_T@;FIM]*;FV1./6?<L5XV96V.O4HA(<GHH,^670'2NO5XE+OZZ
MEFPEQW #N$'(;/ "O;8P,. =%>7B53F_;<]=UQ+UEX/&CL+'TC^AYZ6><P$M
M#B<'@8X1I7KCC'6]PU:C[@\V%OTQD-@O"XE-$/W\)>/]7I/5F\>@IJW@=V\(
M=/<;A2,0!&3/#Y98K5TL#K;<M6=TQBVXMRLW?J\%0:!2%1[-Y2X\,:+[7Y5P
M$R8E5+-JQ'9;EOL_4EYC5B*YCO9B3XW8OFW%=.!9[CL7DZA(BGX<.0V;^W6#
MYCR/+Z!KE8PU'.?_:]WZ Z5-=G#Y>XQ:X<7_F"T.2-*LFIS*#-\[TZ4\-HC-
M8='J4\K5?N22_AWJ7RUJ9O+L#VC^K\W)JL^I7/IO&>W^:\:?47P7#2G>U%?N
M:R./OFLE[JUSQWG"%X\IBQ=_T4YFY33]:XK_"_/%_WOF90W]US/BO-BWPO,Y
MB%S95UE4-+1_X"U_T: 4P"U,5$9>,(16;)"4*UG]I=295,3;7CI2UHT?5Y6T
MQ67#UF=ZH@!X<@L>NW6V^%F[18"8E;,M'OA]IL&$STY $U.,N+)1O^ O3UJ*
M3EHK% D 3-)E)!._21L*]&\M+/T# L>0EO0>L"0K,_NY")T3,I8\"XSS7(Z?
M*:&=LX:RZ4>04!]@&#4P]?78O&1M\<*6<*S%^=% ^3-JH#0]C;7T0W'R&]8B
M*JLP;RNHWHZ?$WANL!*\B*P9]:6=V&TJ$*L$ARWN_H*0Q\MB$&-+T%&P #7?
M,\>/TFRF4S&0UGQ *#)K]F\. A+BGHTDQ+VH GUU,\(Q>H;!4^5@<]CPKV[Z
M7?BN-.AD5.3U(G\LD,)"0>GHQBP9LR !\^2TB6@$>R>;8ZUG:+[>?:>P/,PJ
M%>Z\L6\9\4J[S-.;U#PQ]J/8B&I,82:0XD<BFQJKJD6^<1, -$AW.70-5Q50
M0(B=AO=;@3%BUFP"%_:H-V]DB! +^#2#L^L/E\.D+OH+9K,2NIQA,,S(9':;
MY=A""^_-*O_+2N'O\.:L!+*R_QB^)6X^";",<</UGXY&.;7Y<:1JVR,/:I(B
M="GYMSA1D".1ED2"YA7BA=8XYV+WH,EU@^B.[VW%7D?&Z'_%_%5F_ML; VY_
M5Z?3A?V)OVBFM^__HGT4,&#:YR*2GB5R$Z:9^L3JN!#<Z>>\TJNYD(ZT=(#R
M\N-7M@MZ)52C3*O-%E??KO/JNC$P5&9SJ]B ;[68/=_],!1!PBB(W<;?2<2H
MR 9S(&^N]_T)1D&.XCIF0+WWCHI:*ND97'57]%5IL0JF58.1T-;9>[8/]@NR
MV)!?&H@:5/6.#^9?M*_-SZBCQ#^\^^A&M44!"1TV=[(84Z[:Z4 >[BTXK7Y?
M GF%L'%%TQ/?AH@6P+2%\?7/2VSL>M5$??[X.?80IXM>LI%E_.2;O-'*3#+L
M>%V%-J@U*HC'O/"<SGV2K=@D?7)A7SPK%EP9KJD0@9;A&$5&-L33E9%@.J*[
M_/1#B3V*+7PM2)W\+]K"M'+@L-(H$<3X/Z-EFIGV#[1_""XX2O^B_?QA&W7X
M7[::RS)F6:;YG+,8_,GN<D@NK3\WLWC2MS: WE;JEC?1WZ-B--Y-^*OE?, K
M*R_^=>:52$4V73C!"RL2KW0[&[^S@/##I]^Y%1*6P4-B[L^6FC(FLLV'Q'R@
MG2Z[SYHGN1TXAZ2CL;7:)7^O&'>*BM![(]BF,ULGECO0N([(3BN<A-/MQ#"M
M# GF]65YG3@#O[$NY"WQIP)/LX&(O-?P;RADU\7S..D6F4#344=38>][]ATG
MW":\_BZLSKZ=^T;5#_7#RE3,V#PTN(X?&(0IF'9:C,A9?S0<:P^JDR>_DF@F
M[U_1YT#*OWJ<<_G,:^Q4E<MCS'B[+4Y$&M7R!4G&"SD;\<9YAM/L%-10^XMQ
M0]>G-/F-P9!%MO>2A"&GR8R\Z%DS/EYLG[NF*:T\]3"MKOH+O@;C<KQF%.1L
M:*Y#Y\2QQ>>N:E;.X+%!U*$_:T,T^L@XIQ1T'NDN+SR P]2NGE9P4,:D&@6W
M]/.^5E543A5R#TIEZKW7Y.*SOXF6(?$<SV3)$4G:H*<;7:V #6Z]KG?]"08E
M]2N$U\.$=?E[(6Z@VGZQ J'$!H4P:05PTC:/[GJ'P]-,6[;SE6&HMTQT+:41
MO=6%BF,F;@5G;GJ?OKU>#HU%+_%"[WPZA\$!$&15)E 45/ZP:7_6UE&]+++%
M'$ #K[_QER"P(EIFSDF:?S8-2IKB/CC^K $TY$I/$WLU(7YK><S?R]2ST+>Z
MDSA_AYYE!6M,]58,YYP>_!1.HI/$?RYM>(;IGC0N86NW)O@QM+<=S@2TLH'=
MT-! 9TROUE"&;-D;W*P=_0ME5&.892^DJ=IOES8_A1%2O4[X%L0Y;1J!S7_%
M4SMR&[7^>7#0GA# 8$= *+K$,9N !W33E#<YM*7IW&:J61TII8SVINK+7-\B
MYII3RON=-,S&,3#K>F;%'-'!E-:ZYKDGH@EQSB$PZ)ON48^N?/# ZF,QN'/S
M8^L]=C0'&#%SISB2XV2K?F,.LGARU6FU:<BQIPS@&W.YDHAQG;V!1W*NE*4-
MOP3X'G=Y EY&7F['SNH-O94[,@1\B^F3KO_\R2'0*T($VV?RI$=DSUAIY>SN
M>0E;HJ7-F,/*D%F75D3,KV'!7W5SG1[YG(; B)8("R1ERS35ML9\TLJ.!T_0
M$]KZ+9M'N%D)%8-+8Z88+4! 6(:@YS0X).!WX)AX,4^+M*:ENUS21-?]AWNW
M*F@X!4%=-L!*CY??>5MQ-?T0B!B$&)Z%(A0<:.N^D)F--H-2JN3S,BD 7UV!
M6-S1^"^-A[%T)]^?#7PIUU4&6FD%C+3-RWB^QV5H;(4>$"H/0<\=;]E2*X+[
ML04MVFHA"\RHX+]HB?0O=T'M?8[S^\M8;48[7N& [6>HZUBIJKWMA$H,:>&:
M\/QW^PB4[_U[[/)N_]P%IF$@WXFH'U8T88T)]9B'G0)0&KX)83(X":F9T(.!
MB1* 52Y+>"KY'@HQH;S(Y@9B>DXRVI9&.UY(LB/2]?:\47_IG#G">C]!9'AG
MG2VQ\3B3*]C24$!%<%$($F1L B"([=*TEB'327I3,QX($,O<&[AH'&2.X_:#
M2;QU:QM[70'&3.VO\^Z@<4&2W<N/SV\&\(\LC.Y"^G#QZ\T4:5Y7&&?&ZY09
M8,H;%-IVN860Y4:)J###VRJS[2S]4U;RV\R&UW\&C#6 8=H!:YN[7]?4F4ZN
M5BMC5(W?)S'_(%,6T@!.*+5@H:_QNR6R&&P_?$FMBIY)E1KTK(BJL]"I59:Q
M#HX1] F@Z=K+T?W8+HY3563)*_YV_;T5*/5F66\W!7'F'0L:!+. 66P);#DG
M11D6$77JUK,79-X,4;5^$I@>]0H?Q-5C:O4Y]*!]OD0-MCL.OJJGHUX+7Q4%
MZXIJ/GQNKSN7.WJEVD7//NPA*?.!>GJ=].O;)(T1C6@VC'X*TK.A#ZSRJ(*>
M'.$$<4\;%N[MS7'E7TTIJ2+>'\:,ZNU+Q>\EB;JO:K1/X1:Y@NP4XF64MZ!T
MME8B8/8YHL%+VNU,S130:E,?%R\V8NZD&/F8*U5M[CTNAI@113*.L6PJ\-/.
MIFT4VV?M,_J::K;4Z(*'8Z)>/2L"NCOK1'SZ=B'[J8?T@E]%2_7L1/7LB;6
M3?-MCQPH.IG185@;N!Y='!)1X4'N^E!BM984"./09P6V@&?O"7<K*(7/' R9
MLR6,A''(>BY5@?*B!TCWJC24G>\:,XPN11D(]:LE;]2 9QUOQU;$-H/?&GG1
M^\IOJ=LU)=O<;$F!I;Y'9?GYD:C-,X:U?1C!LQ2RFXEZY6$(N#W2N_9FNH[6
M4K5V]"GT'8VJWGB\DEX)S0EVL>;Q]=06K_*5P *;7)V*-Z/ .V#3LLH5K]_W
M7H=+/H^(JHV'OV@LO54Q4#*BE*]\Y(G]0730 2P)0ENQ?Z2(EUGH7(SQ(+^
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MRVQA'089>6^R\6+WID,]H^'672&><80$QG$SGX80MG&0O<.>S^&+RH& '42
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M6PM=M8D[M%N]K\<RRD+^BQQ)4J\VM!4A D\\GB/&9%1^J5<?BG7P,]M;5_-
M7/DST=NV[W@D%K+CF>Z<U@MD]+_L-Q_FH\YK$=8;?NGT5#O>#?9O)0<9 >UL
MVUB<-LL;^U"=-!<VG-:>YQHEL?E\2 DJ4)=:Q3[OHSV4"OURK2..AD@1Q,M(
M;MOW=F%IS&;6].=_)48_-02QVZG IT3A)XK\B>YD>TEE(RC_7%HU:6-8CO(?
M["XE;JV^ZAP?IV/($WT&<SE%H^AS.60I7-B7R6?H?/PZ09=O+LVX>+BXRCB.
MKH:_LX4Y@?]ER#CV #QPJ:T+2P3%F-SL.7GC\^&VI>!V]UW;/"E007'%-5E)
MO0\% R&B*$ SC9*EU@B7"20<VTOA&.SK/G KI%MI*1B"FE;7^XZPQ7:6 _O/
MAX ^#8?F8/.@T6().7&$P$EO)E'%=H7 S@5;3WQ:CB!A@L!.-6L H+];C<WA
MU]*=TW&*8B)"83/A@ *2TN#V@Z%X9TMCFCINS2)#ETI0QU/#,LU3(X)?F*8!
M]T:'@(7E4O:J:!!?]RYV#HR:R0E<Z(56?K 8RWO?XGPR/=1DO5"+ _QQ2L!8
MJ4D1CE <+4O[(W4SS=TDZ=N.M8WG_!U'E-/J;DVDI=/J)=Y<0TXRSS@%7$,.
MA@P) )%:!IEU/HF&)%QF+TU2 IFY9EJ.OI:;E7LSRG\"+-4>7!/Y;MP!Q8+"
MKQU*SSBBUS&$5A?!+^TRV38PI]V';6Z,4-VJH=I;UY^B/P$&K=_?X*Z.V_?L
MKR[,"K*3+A=I]K;TZ;:?[%X03*#7''GN.?NV(T-9S ?@F=2<51NU-L,;Y27A
M%S$0*.DY\C-FP8-"3$Q^(R10KZ7S)6X6GAZ1X0+:S0%9LGM>YX5XEU4!^T#)
M*/"8.6,F?;KKR902_G;>2.4?D\&:)J"=M'#3:)PMT!K=XMP/_5M)J, I"&=2
M=Z^CNP(DY;B' 8 =!0,T2(-U, ;?HLOP3W?4]"/3.X,A=X0<<0,_]SI._P,1
ML = ]FKSJQF0#=.?"C=!AA[ZQ98)?UN$7;5.-T&'TU7EU%X.6;^VTPJ863TP
MOOA'UCC&^0&F.) YS(35?]08S3*6:^-0J]-0D-.%W #?=PZ_V4K'QFS910>E
M9*^1<Y$90L<KA1NHN3#B17:'=Q5<S]V<0C4IB/_@_1^#NF)NITLRE0^\U.HM
MEJ-::44TLD/B4-?2K5:@.&^H\JJ;H'<8F#OJ.+$J/0/:.&T[:0X$Z-XU<U3
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MS! ^T9UE!87T'U7^RZN;I9NG\,]X"7_/2B8$53BL[M(R\116.6U/D!OA:9C
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M,15ZZA8=;K3%%!=YS]T1-QD^J@[GR[GQZ;<&W@PW&GTI?##^9G7-6"WP"&4
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M6&Z"/OK35N64V;H]V!U6^]*0I:$PZR/%O3+6T F_^:/.7O/,@MXKP$R]&3:
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M^?WF*V :=HU'&?-OZ^C@WI_)3_TWN@.8LXR2L'\NMK[YKX!,MZ(N':$JH;F
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MFS-^="1"+1%@P0#]M.!'AZ_PZ8P"_NSG^O%_H(#N'%P^^+3]2!]5].?[?70
M]0W)SBMK*#<('-O%AQ-_6,=%;@(F>%N2"^03Q)CU&3]#VY%E1$-I,[BY$?&-
M(G7/2-@^!PR8,<U5STPAT@_M#-9C?T?5[W [ZNP4O[LZZ&+;_\'_FTC8=4K
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M3K>,LLEDDXTEV'Q$[4(3)6SM8W_B2)88;_6;.R\^/7U\NC[V>[M(A_E6%:7
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M4)+.V[\AS7.W\D9@:N)&BS9PV=N7+%SR'R?>'/<R?U<9G)XJ7+L<KE3@FG-
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M8]#QD*RSZEFJU_"8U@V6?-3IH/1OVP]:YE;U^9&;\$["9W;I&I+U V&6%)B
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M$9%7LE?$&<3;[:%&/WM1)=PKX$4ARJ5=STDF0#'#CK23G"YXUSNQ7TEF1"U
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MB;$\ *XLB!L__1;T;Z0]K HFH.W(]\2PBPJB.'T [.WA;WJCJJ(\SK+9@WS
M';@M]6UTK0Z?+VLEE_>OS(-%3<8J.X7W+QX H4MNC;JL*S9+Z:2-G> TU@>
MYE4#Y^;0 V ?MA%V<J'T #@GO:ZE2WF__T= $/JTI7/FKDF6@=+G+GTV8+_:
M_$K:/V#_0MS'#ME>Y28M?D7Q -@6@Q4] +)[.H<G%S*W3O=/=;XU='9"V!\
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MD+:6$,4'@!DI'L 1-^]F^5?X_,YMZ&K]E&[)?\HO^O]8>)C];U!+ P04
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M.9S=Z+Z!?,>1![L!8?87%T'4YWDK^,'&78*6%I/ZI_2-" 3\P0.%'T\N6$!
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MM:/-NKJ6WA:YJ67MO8*G;LFRK&=7S!KZ@BLPU5Q@=)W!6..&S\9)T&QFX!E
M-9GBEF4):]=BS+T4G:+\97WJ<.%W2N_KBEX"3<4X$V9U:5\.($REAY*10UXI
M#.X?0SNQ@M I1:JIZ9#O'A6N1FP8<FO57#]T;JMD5ITRJO!0*&RHT(.89;;:
ML'>G6#_[S%<,,'AN2H%0W($)0'I\VGYXG/G6$;C5_$Z>N"GZOJW-T'JVJT^W
MX),2&X.5(QEC?;SU:^2PQTD\%4#.:$?MA:.@@=@NNIAQS]/Y:]S&GX5IMW*>
MB[FT*4V(^+ 7YC=D-M6NY!8TOBN9'!=\9.&UCP=Q#63WP'9>06(7FH;Y9R=<
MX=;'ZE&VJD%BJL8X&" 1X6N_<T ;':J*JEZO^")%34&X:!("<[%.B^<:U./:
MV5W+6:TS_(Q)SLH].WR_\;1>#&%X:%>M5G&,UK$)>5YV1'O%Z.YCO7NWOLZN
MZ5'M4]*Y]F_<YY^$=2?W$H:N06>[@9AHK4O2I]YSRSO%4J>:QM<#Q0]I-C_=
MVK+N/1)O*%QP&1<=3%;PJZ%M$BBC;WY?3=*2\UI0[['([E<+!EJ.7%9>-@IK
M]Q>6C&B8@O8YB$>Q#*Z)IFNL6X>L2EL2A 5$QC<5D2H\LNG?&I76L8!U*!VY
MT>J7S6&E'LPYA%$A"]FV&U ,$B1R^G;)QT?ZH>$4G@4YC["C<-ZBOJM4?/D@
MQT1!8)40,\^9\$ZW+DW_9]!;B4SQS<;Q4^A!7MU=O=#8F,_::XZ[OK$TZC=0
M;JI&(YLNR3F>"K8C .-3,$IC:Z"E[%S%'6:+):0;!<I.ADR:+Q.CLEY_O+TR
MU!AA1AVAS%3Q@5]WB5.@[=2KDN"]F5O%IX"%_2_K%N9G@/6O;FC#9>]@__X)
M2K5K-9;TL&F28>UI>W@YDLFJKLTS%>K1#ZI59CVXPA[5[YQ?IT?3O\7CS22
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M.XY8)^0974P[5>#*6_9&82G8]C%&2X.AE*VU]&'U2MPC>S<\62(3Z1O(+-R
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MZ]\G8JJ?G\S2&^39&)7U6OE,S\B_!X/3+@<H!^3K^\A4<(T,K$C>I)EY-.X
M#!I&!+:[LQ-6N(:O80P]4/F1NMH)E7$RM<?T3JC-E]]DF)#S&^VF"K[!-W]M
MP 2=K"+Y@D4.M,FJ*"A/"EFT#0AP.LZ-9'A9#I9_ 8^6_![(!(3*<#[1T_*8
MT81P>F#5+3"?D3)/@+-+"036390]-Q6O.B4C=M?V=>QN#7DI3FOCM'.8>Q(Z
MC]!D?I=C_63N9$M.=]5U]FNJK=(*:,OWKCJ")F.=#L6#'_\D25)X^$U$<+R[
MP+F53$\&YMGU^@F[DX%HXF0<YSIT-3,YM?V+&JV H,WXK_E+#OZ;'D_0*54+
M@O>"=$;++E67]5VL<U#):4!5YPH:4"+=D8YLD?[09:P"./'<'.XTI9JQ/D6<
M>MW69?$WT635P"W)MDDB5$^UG2[8'N\] [8FHW']KT1>O"\!I/^[C.8'8"(@
MG.))Y<Q<9KAEV_O^O,>>#%?[;PH[B(!1"+M3=:U(K^0F:MT1P%LS.\'*M,)O
M,_R9F%3J3&(0$=.7?K'B_.D\H,-7R>Z4$*F:>(/OSNV\$:2]Q-ZXMNI2D#\S
MV>J2D^LZCM/<CF[FV$$B^YFP(5W-D9G Z[MY,^Z$,2928? :W1,DQ)=P']9L
M*Y*!S1(D$AWZK=P"ATG^+98-,"^TNM.!.T-<S[A(JMT@R52B&G.<ZR6$BR)*
M%<><1RI+X\K/'M39:?(:3,!+&"(L[$.,Y-W.2\$/U[W08E2I)KGM?+2VL\G2
MJ[G"./" "6-.;URF)E<FS 3"PS/1O%,HML3C^-V23@V3H7:3&$HSV+=G,AYH
M8"TJVM]8[WU$\@G[-QMW(OA0#=D%B^<B6&O4.%1T-1=)ZEYXR=-QUH[=A8((
MA6(A-'YOWR3FZV&9V9\+N&J!BCGE>N'/J1-7ZEN1CFST&^T:,79]=:(JZO ;
M X2?>% U>W0/I)T0?Q"F$ULZU^BV-C9:W-?BO6_$'6*P@\BQ_W+B!=">3$W_
MMYQ#&O(R=<+D&^X1NE!R4\4=4,4!OK_LYZ+'TGB]'6NATMD]=_,\DK=#/+$G
M)XA0ZF^T0[!QLATJ%YQZ0+YIJ4RY#^R*PLQNZ0^D/$<K:FV##O4M#^DVO"5P
M3WS)YHPR8<=R2DUDLB[.=DJ/M?3R-ZS5I2^TW^"( /CMT[)#0TA]AZC]7^*
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M-4A9^(?,F[%OMG@(,S)NVCT),C?O^# .8CXILYP96427($+&OW=(F[7'&)%
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M"14%UH("9=TU0.ZO)&OWB8=#ZJEAP]ACEN1&(\X&40A;UTYH-7'\<V706?!
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M%N1H^T<BO@4(T%62E3OY0#L[!M/1@6%NUM*PMX#OI 2'_HTGZ_1W/5DX6-\
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M=VIS:ON/"C_HS](!@+HYG4Y!U%,X:Y@;%(SXR\H%(7F^AWPZW7^::H"_S$F
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MB.J(8KJIU+*[7^TC$,4Q7EN\F0GH?U0L:%J'/V)>6+N)UM1.>\TFOP3J<Z^
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MU]&:+!ET0Z2S=$/D!GJS4-8(8 ^2>B4DT,;I:#(R@QYXNU)\K*C/DNP_2);
ME;RS;$7P$OW6)-J@7T"3N9H@]!W&Y6)_]BH3/J9"MUB&8+:8EZK(>/GWO+;J
MS42LP=8AZJAT=/1--X(KG:9(S:JA_G@3N=AT_JQ78Z\QZ1ZB,.G2J\H/H )(
ML63C']P8 VP=N%*\K;"SQ1;C,UQP]U>2P90-M7Y':D <&ISS-&GA:JR_+/8
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MR*PE3?TR,J]G9-PCT++WE<#9ON9]0J1^CPA>2DV$AFTULS:\T4U;M#I^@')
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M3D%^T="M=NU*GU"@!6^EO82/ZML4LK@[##G#WKSMAHT0WEK857-ND>7-X1>
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M.F;=RR# 0K2I-)T_%EV$/]:J#/4KZF"=W<HWB.2=YU&@,,M6_Q&!+B:18GM
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M$1E!U+G9T78CAPETTV>BDFU ]1TQHQV6\%5=D7(*^.:*6%)\DEB\]=C3$)N
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M7U UU'WY-^:B_A7V\@C\!#3S? (^+$JNL:BBO?X<;THI39)"690.'"M]#0^
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MU?H30.<]?HK'ADATH#=S9.W%H-_D7MXT4]5<BCO"Y,"\R&T%"&L<5RH +F2
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M'^_S!T[((TXA0'R_L(*<)JB2,KTRGSR>VBE>5?4WJ>K<(YSW/#/&7RBFBA"
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MH:,O3;2<0^$VO(.^_HR/CW,T@+>KAP]PY(OVBQS?FGVKN7)C,XYV%;(K?<K
M]1G9IL9ZT7WP5,N++&F9\7&:XG@^\YG\1:IYWRQ@(: DU2WA05&X1P>JLXK&
MM!N3;IJFW%"[8$(@#Q)5N$-Z,$T 5?E&".@L@PMAT^DHUIB:5^T2):3)70]L
M?A4*7ST[8==PR^E/+TD=:3*=1ME<;>%+7T,%*$W1N"B&JU?$/77Y7H4.MJW>
M/\_<)'>9)12V''42+,5="ZI9H^2B]?9)'^WCV8QQ6+-T_IZG LKR!>8"7[3-
M27](!]^9$BR[]EEX3=^^WO'VN:N_^+XLOH(]S5!A3XD:?P\'LKHDFEUE[*7>
M/5R]V:/_W6K9<7%]]94U=5R,$(B;BHR-R3?L+ TTFG"U#O67]:?*]'27*3=F
M6JQ8U-D"JU8T>@2FF2_R C5NT1O[67IL5:KD0?&FM(YRJU*J)$M=M[Y4OKYZ
M]P=S5\N O"X_\'M_YUU@''-?3^GR_*]?0TR0#8[1W!RU:7:&0(6>!)*+PZ95
M_$_ &7;$OU$?QH_^=^^63\ JP2?@$\ V^Q15<N,87):N$/TA0%9'IQ1F7R1:
MG" V5L&6/EH_7:AB!W'_^J,1,_6$[.3^.1)#"()H_@CGR-BN(R!M*5PW&IF-
M A?7B7G#_90I,-_'[Q- @7[$/$*%/B$/+UMM F3C4JO!]ZXQM!'-K%[T?+7/
M#;&Q']QRREP1L*?#FQ4/.E J3L*ZU.*1$QY4ZAJ ZS(;%E).+Y/_0:WT$A 0
MM@NYQMG1R%)GM*;_^Y#;$EP+:(YS/!=Y32[%-<GD+HN.($U)&,,//'_:M_26
M(EL_C!>!'7XPX":">1+?_P1$]:&64''&?.ULP/8J'3&T-08:N3+B/VOQAEJ#
M<=F1'!R&K 7>.XF>P"D!)?&T\1<Q.!I@G1Z_K7C'6)[,OS?;;S&E=YIU"<ER
M*SE4JP4E,0X.5!6-' ]DK8<3X LNK+" H[C.=^87K3O_$]CI$)?V5B0)[0%3
MCT&NV=1DUSXR?DVP-'Y53WZC==-@;$M8K+;D'X86XFH<4Y^??2=L76A/>MR1
M589%+VGES_C1M$(TS68'J6MRPG\I/@'K&QL\N!%!^:(XFQ5MRW2K%3$W/16%
M48O2WZQ>PVEEG^'NSR5Q)I$NLX@I86[#_.\O^(V#D H!,VYHD\1WK;J'4EYQ
MON)7%O,WV5$(WIQT#8<G;18?%KEH$TP9@EJ9*\YK\H@NAA"7+0(HRB'_=2DD
MX@-PA6K)#JK*=+]4I#$UH(;A:1-A-(_)"_.);DLCUKE9Q5A"*C)<HX6I*QU9
ML)E0N:,6L.A_;4M%<19]5]^=KAOL_'%5 ZV8R1"XU'04[*@*(2*&?#,H_!CA
MNZ5/NN^TTC1TQNZV 2NO2VFJR^F4"&S3(PM(/J&/+&&U+G4*#PQW2B^%0$%!
MV67"P&.WO;=9Z7)\IN:Z%\&8_02D6</"#/N'*G\"@M8Q?J+(OH4'A4&-_F3I
MD>HU/T_)= N\5B]:H[I=R;XU]&P]>M"2JM&:"FG-8<U"6ZW)D58C <ZFV N4
MU3G8%A<U1)FD>QQR;Z1JLH%51!S1%1Q-[ V:F[I:XTP:+I>G+Q^!O2!;^ZF^
MU+^3<[A!(CO\/3U0,D33B]S=001;\.4-YR0%O=\9$GH,[SK&#>1SK'__>]";
MQ.BC9_43 $;R_P1DG/B(4X](MJ3&^F,],VLE)U$I7:(2_U&O0U'J"@%]1)(6
MC K=$;6<VT3[V.,#5P^Y?<$.#&2/0>H\!;$#K'_H1'=S>4A2PD9FAF=!S6\$
M2RC^F%^?^DD/'A"S6/WJII(K?K1/'*JCHO(V9=A4ASIR%N;V-7^KH%-W*PP0
M#+YDZ1$6 BQL;QX96W$<.6F$S\:_CC>;^O)\?4K[O7>].:\1.'G2'HO&0[@D
MR-N<SJ= GGB6[37^Q/=KX/&4L^$F#7*=.]Z[&CCZQ&-LX=@YJ)8X5?LAH+5L
M<W]H,TSERX:L9_DA)%O>+)<;YG!XE#*V 72<"/'3G!0*<S/.D+#R,IH2_^?>
MO2$R-H7G9%!GSK1)8S X,R[9ITYDLFI%%/F#"7$OM+&!=^YV74W.U^,AU5&8
M$]3R@Q=C-%]H6VO'$)8)DF/Y$.*PAZN,ZQ3>7;VR.0NA.#7H4"%Y,"V"0QM_
M]_Q00.K').1!)%W^[3:+JCP^XT]PW]%_[*+'[A!Y@B,T+OY-Z'(MO"36HS"7
M"G:0W2:5*XX*1":ZO'/E+$6VK4J[(8O!L%ID1_7'+B7B5#M(I*S?N+DVU"-7
M8#)6G2>6:/<;N(OTMK*N*MER4]3CL9SJ--ELP+:77S?E_DZX8BT=ZSE[A ^5
M6)B-+@=U4(%=6,!OJ8@Z_N5M&FVL_@B,Q#'"0K6:&E?A9$WVJE-" C(CM?@K
MPP.CE^S?$87T,1IM!EOAA #STRUVN0-T0?A*TKK,M'?@\;KB%EB&2KPZPHVZ
M9=M"B*KL\O^CH!5[4I#"H.59Z["%SCUFI&8^76=> O.@I9+;)[98WO!T_S%O
M!IGEN:*SXJI\8M"??&O*XT@C-7&4=JE5T];V@$APAL,WAS_JU/7OS01+W>7L
M[D-POD K1ZS#DA(O$9EW/">R4;WP@V"5ECZ\=\K"D6\FV-.&WKUFH4Y;RP0!
M??@6G="I[TA_."2A/7W5U"8!=.>XR(3W?_Z3B=$SH+8$CQK:ZHDJROS-2H/3
MO=4R9.#/JT-GB4)=(8]+!N1;!)U;=E<K<K[WHGG'NX"8F"OWS,Y4:DWOS#XA
M'ZSC<U>]B!6H;\M<ELS$,-YW.Q!NEY&C47<+201HZ51AKP85O*"28,*RLD)A
M"97:L.+=X=%U9O_K8LG5&$$YNY1D5"7^ "T[%, BIP((C#0.A\/Y[UB%@H(*
M@:RPA@+W/29X.7A?<EUU&PWN>[P(%(J+".$?*'<H8M)*]Z@P 51YOB'0$!HQ
M0C-E#5PDCMBDPP3&+)9<_?#7'BAM-0R)A12RXY\H"'N'.))'\4/3AE.56<L:
MZ-VZ.PLBMVZ,.S[S+K[@@(CCV'[]<N1NQHBIWV-MD)/&@%BM.&=GZ'S I$[(
ME>4-X(J_9+CEZ>+'QR?@^;;8+U!]JNTLAYIIQ-JFY@BU=TA]]KF-VO)!HQ/@
MWV[IV=P$_PX'^$W! E?3V(82M*L"R&BL*A7<S1YD#X[2#R/. \E;;;!;I#R]
M16S9-['&C\0,?U TUR@<!G$L+N8YD,D.6\NZ(WK1[E6NTYN=DGT"I$Q*8]^1
M8V,ZI\. $R7]DEZL E\.T MGK-J>,"$T95NTOZR@E=651_L&,517"0N58XC\
MR#\.^5E*(R?^S9B@A$6LH&IX)@LWOB>VGD, WLUJ7.@2*/=D4!?H_!6VG4P,
M#>MO3'O=;(479+N=>M"\Y,?%@'Q*UM-=M_V%0*K.)L?I_X<42P9BCQG@-;S$
M<M.??C_T^TB&0_%4W[;%5I+!-]NR/_/=7GUU@K7N/57%JE,,=/"6+31Z304J
MPWL)*DKT59A+V2;:->^=TZ,7B7B$1;/2@./CCDY&2T&Q@,.D1UCD;GN:4(E^
MPJ E.%.?!M8?H%!!2RB%3"S^MI)9<<)P\GC(\T;+!Q$'6 \!ZX'_@'*8'#%=
M[,_T;SKEF3[P;67AHKTR (50VCJ$W;WF[\[X2ZL6M(/G*.7A7M[CJ^QY2J0D
MX/FX"?--_E_C0"+8S1<LW25"[W4M+Y:U5WI\PM8"A TFJ47\9<EA#U=/;4@I
M&!#6N#S&)>-F=%QPBJIYR[R6KCM)3K6!;?*&:LVXX'G+NLHPS"=@^T<-M2ZL
MMJJ0$?)\CX1:(-LK1N G8.P3T+&Z9GUNXKKP4(0/7["64UXHC6N"X$_S410_
M=!!F&?4Q,DSL7J67T%O!-A6/>1F>3N""2]BQ+H6OAQ\!%!AZUD#T;[%JF6+=
MB[EU''5\F2.8P G+>RL;VN\RFK!O$>AFY*1LF3SYMGH7Z)R\2UNWNQVCE=L2
MSDA,_53;9!9=]]T^/]:VP"=&D1]KYQA@>6R9%9Q))YHV+VC&L$I%G!V4CW:A
M4Q77;Y&U;N&P8-9X^4X7<SI@^M*5M#LE@+6OC_Q@W]#?%!1U'03D8OCE;A(Z
MIA79_GJ] EBO%2JKA^$FZ3QE(/-;H&I./.S0C@VO^/%?^"T>[]/?MV=PETOK
M(!"8CI_,*R"1_M *IN%)00-@JD0:'ORU*U9(A_L68IXX]!W..T# &_THE N$
MD20V0L$;R34\-$+R>,<<?W2V-8O4<[:$"+\(7&[33^DXG4-T[6)>S-2^U[Z<
MX:0T(22 V%IA[<A_;>V:'.W^[U)@!7X0>?AT  49K&.[L:>M6)-P%\4N++2M
M#EO^U<Z[?)EL9("? /4B]Y[=FH61BF+CMQDKLP)9E=5X=[0$0SWU>6GM"$1Q
MSA<IJ)POPBN0ZWJSTXI]HA:BK<*/'3$1L^UB(%DZG"/^H16B(=B.:H@_C7(D
MD5S<[*XN8N0.)A!V'[Q1>(X8OM7:MLG1HZ]V!3]-[_EZG,IXF'Y.[.P;%^S;
M/:@[GE5]U?ZA;[M&75XX)I72)8FFJ/M%3H>Z*5]Z- *UL=B Q_R&;'1Q!9B_
M>!='0MUIBF\?KM(=XQDDJ01K=/LEH\D4=#U&#H243F^1U*PBCV[2LTI&H%30
M-R=:THIK8[S@/==&YXOZ]K $,M%[WWALJ#T:DS0Q<-P"WOWN/]37_8LT#-'I
MK\E _Q A ,4M!:FS5C(X +K;3\]6D5.CQA0A@?Z1["NC$B&LH!S^+@;8S/\B
M% Y;IZ29G[D^.NLG:FFK&IP50:^@E]<DO5^)D&C%KKC$P.VW@>!6MTG;Q+0"
M>.P6C_PHHWKKRP]/CO3<I04WAAW+$X/@?\.A<FJK#GG3EZ?+0(?.43_ V$K?
M?0*$IKI_SRA]@7L5 ]&\0PTPE1:1BJE?8WD?Z_E*YG6D 4>'+K=M0%I];NM?
M+[Z$W 2>=DPBIL(6B^>VA#;NNE9FG(L?%UFL^\@-RK$)"[ZCKD,;>]N5CL',
M6:)DUGJZ3E2;_31BO,^(G+M70B4KM1IM5*MTHL>D3@;O%V'S*K/4SO("V?T6
MFI(QY$W#G9[M52/?^=A+MWY9?R5Q)"[>;(TGZE\.&P(+Q$)A]=0X? ]07X/,
M: ,U:58?H&WI#&S5>&'U=3MU=M<D3,O-POE@X1!"AZ\3C!@E2FTN<0S@O [5
MP#B+CGS/7A=G/;Y[3.(I+0TRA*+UDG GWZVR]DH4G(UD>:!*&&P5#HPDYNT2
M0CG.W<]&.;S>L1VQ)T:MEZQ5=TFN@_@$[-%T_^%K!D T\>3RBVYA-.1YK=]6
M<\@QD7<0,:,'CX!T^$"Y"B-_#O/-10G1<YH6!*C+7GD/XQJ\<M(GH^!4EFR3
M12SWQJ;":S3^;G%9K'&/GV/M:CJ,JC),)R3--(@E)48U3$Q-FVFCCF'K#Y(4
MGC^&9RCF?J_:[?L%%9O)$O3-?1/[>'*+=]LU>[W%6J+M>Y\ .H>5.?,@A_9]
M(W-WJX0WVX0*,;N>0-'5T;)SR?*N;M<LH3[NA#FPH6GMOIH0AQ'N*)*$/'ZE
M0>"KS@+^,/.@W9MRF.78KD@A/JI.=YR'- Q"7JDH9=9A3"Y*V!UZ?*P2Z2#)
M0"'%(T89@"L_W"O@!;G,00O').$Z\6O,A1'9<&I[<T+O"[F;7DTL,E"?#Y:C
M%O <L VWV2KPL=O3VZ#[7P5KT:X"06&Q/S@RNF2J(V\N95'5J_L;W 6<NS0Q
M29)M=4O42&>=.<RRG933MR<Y*DNLEZ.$XM6R@1:**%=;PPL@L17Z[C"I2Z1N
MU);9E186HG&.?$.7))G+1\U9/,['U'J>?G]0^Z1!TEIB+6V7[N@,/@_\0VEL
M+A.F=#''8V,'/I*9-B:.E'T4?PRKE X"8JHG6<0+VDW53L4A<4;N3W7^1-S(
M4@Z]-.72C1SS/QY)Z=,-+V#)\SP3ETS,98ZSTB9I1LE6A^":%3W0P/(^EF5+
MPA\_FSZG\R/D?8(P-BS#3@07%1P\DM2YXK:X4, T"!7#G EWG]?_&V[N\*$G
MC $/]K)^; ^_%]N=WO$KV1]?%8I1)@T[Z9M]FEW@PM\;8 <3^F#,5)<=W^XO
M-YQR>/=R28',GYP22M%W2P:27U%4Y-G'G2N-44(P,>X>RRFH,13\+3%Z;\.]
M8\#4L.5Q^0!?OCJ(? CR> #Y<U[$-*3%-NPV=O\%GR,OX@I521<B/M_T"I7H
ML$U2G:>^K]J_= (T&)CZ=B]$S'9)?*I!S-FV NHPHXV"YDH2K]E;;1\(6FB7
M<*P]G8[LO.Y$U]$/$<\BS/XQ96?+^$V\<'WJ<.([(S:/ZIF%#IEO!!ZY=RNG
MBQ\^[^OHBB3FOZM<C%YHJ<O@O6#J$W KP!1><D%:]Z%$6JCI.SF\P8'IF4/4
M5=T()7NIJVOZ$&Z+,9)O,*!PT&/E9D[M]3:079Y6$"A"?<J6'ZV7L8JLQ@3[
M?0,Q9^\H=@?QJ:.^(R\X_+$\C-_*'G-DT] QZ9N5$W6_I,I8._BEHW$Q]I65
M-;B(8:EYJ:/W7I"\$EB<>9Q=6=AHJD8!]]V8.O,79/P^LR^"2K+P(,H+'!R<
MVS+*OUJ50*'NBUS /:&43#CK+G84\]1"3#CP01?;H/AN!]=K4*FI^4PQ-_B(
M-$Y%SH^]XGL/<H'>^8:'Z"F+L:-\ID!K'&BV<"]F#+-)W^>MB@K&E VMZY4F
MH^_QG;NJI(ZY)-A*H@?UV5<ZY)$<R0ZQ@"9,YMHK^IH/NV553.+6%ZPN+PW-
M+PVB!':,6(1F-3$#W:EUW68EQQKQGX"B&DW+/O2DPW0D5/H%([/PXL-D-DQB
M3A4Z?.NG/*OW" ,Z9Q([CP'%(<G(1&_'@"&/\1>CB]%>)-4FUR=OCYS]E'MY
M-J.)G)4+6;&AOW34OU9OOV0FS'QO9Q:;N<*B'OX$>%$X%$ ;6L/3&EC2.K]^
M(^'=^TCTC,,&(:BC4X\FZ["WXJ.7FYQCC7$IAN\P1,Z.%6K#V1M(\4WC_UP_
M NQFQSZN:D4#:W2OBD)&&3<#<'9.K]9VEIHP_*:4+N>:>O>/F1S([K=PQ8J@
M<LJ\KI\K9%34Y[4&@]U&R.8@WCOWEF1P+Z:D8Z5Z?]5)U?HJD!1 <%O!/P5K
M2J2_Z3+1;E7C97LG"IEJ(]K:"64DO]:P!!=!^RE[KT04H;*-N%SO2>I>CLRD
M[84YP/.LP_N<)9[<MI<B^[IWWQ]:20C=>!(^5-/C!<G%[M419A1N572:F?,>
M_&@87 4J_^)N3HG4Q9+"$ON;5<J$RHPZ;U/LM>W6Z(A&S9$4Y94Y7JS-Z199
MGL@0#](?U$Z-E:AN8?@AJ<O&57S7;IO(TF^3BHM?-LBNX*,BH4.NZ$VPA$M(
M-W_#L=<F,:!>-<HY8NS^<YG7F8B/ET=S6XM<F:-QX.I0:JBGI(CQ$NW^/^S-
M^?\RJ'Q$?+$;,TT=\P$&1\W<P;G+2.C6WHSQ*N(.$R;#W\9W:A9%JX&QL7X[
M\&KYLKAC":5_35T@DXQQBOY]7&U6DFM%O5-H-N;853B8 1_*1W3IT<3&-V6(
MM)MB;+[9[;YHA*P'B]]?.5VD$^^<Y<:<#I2S>1J7-Q^Z4!HQ)K_KPY1QT(H;
M$A+CBS?#&140,+ 03:T'J6GI:P3\_5F:<ZP^LB*@895A:HZ>V=.!54"]R:/V
MK7,ADIY..43"68(L*$7,>B$DGJR_..J,[!5AF8ZQU0LGO7+TS(W"]RVYYB3U
M/8"WGVO>J KE;8/WS\8 ,\R]56W&G!2_:.T^P="F<;6'KJL4]R-6%75F&>%0
MKZ*Z#]C*Q/Z@1LK7@BN5GJ)VV,!Y7&0R-)J]$FO1YG7-#/G?XZ'YBS/W'OZ1
M"N4MHQWQG4V:/K_&2ZF=T3V1HSMA@C:1+\A(0NPL;=6W]J$DWO.X)?JQN:LT
M<0A2]CQ4OCACJBN73PEH^10*3=S?BU\*4 J3XRV_(P:Y'_(1'GNW(HWRDL_Z
M-IG@263O0*5ICQ65#<3)59(#1RC^JH=Q#&X@D#EFX+P_NU'4_+LL*/6? 'VP
M_T.8T"=@_*Z7-*T]JB(WU,PD*+-.FA)>4F%@N%](RA]:2X9-*ZH8]!$FXOI-
MZ.6!I]#T6A8AV":3:^#ZL5$BE=OO2N9VK09SM=5J<OJ)82FS>4)0(=)C R-&
M")9EW^\>_6F%\\4;9E1/EA9>07*N\(R30T!,S!9C%J_( M+K77@P+R21Y+<P
M%((2! #E#M$/2T,V M0IVJ&ES4TI]'@?5C7U^J:9BPS:])EW#]%./4+=F]5R
M5VMW3#G>%)AZ*XBV IE";/FV@K56W;<,+SNSNBQ+9%'Z9FA?7!E'A#LET/3K
M@)'.J,P#H]1!H7;;^>0.$ZN49*EH<KJ8V#-.\AC2YZ91YG4K]%&EPY6* IWU
M^C4"LO1H(L9<DF3N147[A^WNP&67!X%.9Z+%GF+N+ZV:/KVBD,E%&8.30%.6
M1;(F;4.\*Z+^C42)*RUV=.9.?!2I)7%^-&F$:A][9SF2O?>'Z=4?@P%GRN:)
MBXVET4M <Z<,O#R#,:+:)EJ_ZADT"%3VJ@ ;KXO8P0P_,8X'01&Q1'MX'CVV
M&G/*>;#/<M8E4Y]X#4/.;_9]ZO;4I=YI/M<<#RZ\S9DUDY9266S5JO1=EAM1
MV?3KT=T^@GU6F1%JB;WO>[I!6)RZ>80) VF1X]?X[K#TG;[5_%>P/ ^5^J@K
M%QOE>(Z8P)[M.K3&X=-TM5^M6M6]+ 2:Z$J)4[<,NA/#4.*Q-0J67<)>3\-I
MY]'V]_=%3 XA&,%WR?-\KG1Q9MP?8B#5*.1A.CZFT#C;:M$U(ATD N^1L.Z'
MOD)FW[8]FU8;EZ.JVY\*.];<X'/\P0A6#UG$(3.#,@4"D'3,*%8,C)E5P_@U
M\=PYR*^KL >VZ7DE'U@E+;SSP81B=B,#/UB5"F]<=QQ[;\GOY"=#>PMO6"VV
M:GI.?\:8!^IDY]<YL:2<11+O-TNQ('B?^Q)_QF)^#+).$\N;'@P>/'=:Y8^L
MR08R/["E%&:&W-=,*-!.M0X?6,2P.ZRXR)UXBR4.K7#BDRU#YGP)FUUP'/F^
MN\3L1K=OD!R&RA^_$3JH62/+1]<IM6GTZU9XJ:NBEF60K&C&Q<9OF8MD7=KU
M[C_92J5G$IZAP373>Y\2:1Q2 RK]302.2%=30.=T<)./LO(4DJO=-0\D!9))
ME6NV3E&8Z5,G<1_:Z=%F2MSJ=*A'(S79F8O L\-O^JPK9 ZQV]Y(W98V<J\>
M]0QPQ) 'M*;;4&K$FY(,[EA.Q?<(J61 (<*6<H-4FZ;(HHQKU&$@*:+4R2-[
M/()+<C7W@-ET7,<342,[T/01JV]^U^^@3P!2:7#)-E>-56!OT<L:^:!RY^")
M\M<7C(5T#8EY2MQR$@XN8:[5LXOF7"))GDU[S8%=Z4] 5AA.8P:,_]9P_T)L
M]2? AR7)32*1/+%VW-Q][SH7>C6J87TL@\U7"WMH+%LH5HZ_=R+(_,FGC.;K
M!=-:M"'MZ,9"1081YC)8_D>.ZM29(_N+N!M1A7J0M802"C,]_M 0LYT(ZL/W
MA09T.82"<3,-S=]FV8RNV'KB6$KBB#UUVCU2)G7J.-M!E*$@#'D$$^'73 "^
MH.ES>^*N-'FN;^+(OC-7]?Y-F\V^$]8^ZTJ'D\64L47NFD\B-G=H -Y0$-X0
M3$,,$ \PPL=[]3\($RN6L0WN+&\@84BH3INI.J7B8OE]#:M(^>B#.%SCB&SY
MH-YM=1]<X0ERV+3K[Y#8@2CIS*SYB[H#5NW\"][=4)C>MU';MP.@**IH:_/'
M*3'Q"6I; 6+[5QF(]'T7W20)$H9O^9D[*6,DJ:IY91F=<Q5_[?33R]';2[G'
MD".0B=<Z1[5T^_W/[HS_.V)'#*@"!WVWJ'+[+KGUC,&H+,9E9ZN8C819&N1*
MW3UV9ZPZ(7/AL,+0MM0I;F=&C2*CQ<-G\&1<-MMB8*+O#44X]*V\WIYR9MY*
MTAS AR,3O&T=<DY3+'(7QA6;(#IT68(<PDQAWA-GZ?W-N Y_PH[,0P*)6/66
MJN5>V<P1]5BN,-8)@I:Z9G!O=@#<.6>L-OC430?5,;B0"LTDE:OSYB['-7F7
M]G8?QLBH57*I67=@?!G\C ]*)3A8&Q2I]DVI:E:664E9)0B4(_DY2YJ%1G%:
M1OLK,,]>IZ-%7)JVGS0VCT'":@UQ5*1F9&_]Q*H#5-+$\?OK\:3O_84$/Y?]
M>W(A/B+T=#--&>*4,DC1'3X/;6*0AUQ)>0*$[B-=/H*??>Y.4H!+]J'R1].S
M"5[$JD/^L<&)6V-8KNDM2['.AIV:#VQ3A]>:3%::Z)!8_I[J56$6[M:LEIMG
M:DQ*&=>P8*$M%)QIZDB<^)ZX17V:;YJJLA37@R11K+ZS#'S)(E<$TZ-+[!'<
M']H_4 :I=]+H7'@K1-A%S#GQ0V^RI;>%=1LGRASR?&_1VZ3@_X7/PCJ!D(/;
M#'7GA'$0NB$=0.@P.IF_%,;1*.2MGL =&;31BZ=/O=Z<,5%!FY)8TS2F->5C
M5J+!E(9A!GS<Y2<O@G>1PW\NNT=NDQ@G#<E$G0)>;"]HH8B/&T\HN"#.6'JI
M'&(TN%XI=*AO?L,+)GC3JW;%%K<@,&$>D0&BBA!>(FG"%[HTK)@%++ERJG?#
MPC%,2?*K'\K83)<(V(RWRA^:5FUU4@8]_DQ(W0V2WB];(BAHY.2A$_QR>'+-
M$](\[FG796YFK8B\D1 ;NO33% Q6F,+9D,#(F6S#48ZJ$OA>BZE)QH :,Y[9
MUKWAKD !E"68;; >F\]N2D.DU(%7E[$0 FW0/VE(#5^HI?R5??.;+Y.K\"]&
MQBJ>7'-<D6BI7[.\,D/9,(VOZ65CL$H-Q>9>WAEMJ?.556('27)I"UXTR99W
M_6U!=['?TWV45]O*B9E3]7'.8II1(_M/@./3PS(2H*,]Y;GRM0-SPW#&>$CW
M?+!4>ROBR#WO)3DQ?;!$>;S0>.49RJ]/@#.L2:IF?LSL!+G#P)^V$;K5(6;?
M"^]PH.1 ? ^FM7:/,6URE6:'M3N,J'8UJV8#VU02:2A6KS2![X2)M.!V,\D!
MU]#P,VS"C.<BEWC1V=.;"+"T;7-Y2L#O8=8J)-Z35.Y0F>3$$(+:K59J@FH*
M7Z$E)4UD]2N\1$7";*8]_"R6VK7!SALZQ\C3XIA!YM!>[7J-XPQWZYSC0Q6D
MWM^FU2?]&TJK7![<AIF2]7I=V.EW>L+5WA0!YNT>_!<)C^29G97U5"9<9RQ0
M/1_>ATCL,$\'W*04UDHL96=R_$SFUZG($UZ8Q?Y1TP& *,B?!C0/\$L_"WSS
M/WNQG_:_1RX3W""N9.M[<N[RV?\&_PSPMQ4@_@1<TPFE&/1=R^5=71Y([N_E
M?1B\WW\"#CX!=>^"W:\.?N63GX"=R=>V3X#6:Q]QF,M;@%!K;MPGX"DE;Y3J
M387JC>]9Z9G[Z.P3<&GP"1#,_I^/7'X"GH5 TO_+.<D&>==RBCM;HW$C2__,
MM$VU29Y&7WX0_+/R-"\>]F%NYE\I+6A-S^*5Q&P?;%Y,<3KLC.XBUS-7 \Q!
MT=GM%$T2FK1N)Q"I2G_#V6L;(WVZ+-4CV$384JWEOVY[')@EDJNXK'RIX]!P
MTKWP+$J*\1+:7[$!PE3KV!.-+YLF7MJ'XI;_84=-7]69/^+5<.63X R-[6WZ
M*X#F];WG5X>0X-W9'^Y-)^D\(C9BC71'2RU]&'88G3X8\P6^U"S^WN^Q>+M9
MD*2G6,4NO^K!)OQ#VL4O9&XW7U:7).:5X\B+V:/'E#5N;3RKBY3+N_5U9'WN
M]VC'0M9HZ<V8T./,77";>Z<W[A.Z><O_L*WOU<].&>.O0%+*TFXCH#XQVN#<
M7'T-_?5=W]CC_2N]E%D'990>FPDIY0VCZ+A1G<P1_NY"!HB[WC/V-L,JZ<"3
MN*K[3F??L[01T@WM,*)J]XRU%JW@.!&/J7E)-XTLX^9HR%)R3*RB]>A6):;_
MS?J U1'_O8#E_NX!T3@:"_?ZI^2Q:A0>+8X8H(3XYWW>GWX>U>M6H\ 1$;VM
M(O-[=Y-*8K]W(,GIPOUC'K;HI@9Y5HKCL/YQK'G('-==U5Q.6PWR)P HNTAO
MOPX;UN@"Z_3E!#3Z138\,3#@F<&/)20_\D\*4QJH6N7E58,^])(AN=!\2U%)
M#47S8P8R@0(@NB2TGQ$F23'\5,OM?FJ_"AX;G>5?-=F;/H3S7R?0YEJ.5X<<
M$>NZ1T F'R9:)<,ZUT%ZWWE^=D0\(;KYRGL! 3_ )*B]_ DPAX0<+V>(-0+X
M5MC:F9;\E!-]4'W7&#]63U^RABWW7HNYC_ 5EM$@_?(-VF]JI\5[>5_+)BJ
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M:.9N;UXSZ3\*[SEB4E$%:YFQ/EJN,-_RCK;B5D".24YPWJ>4-BK]A26?<%W
M%6V-4R\":AXZ"PXFA;+6Z/F4N69X8.*UR34D#!ZKMPG*8B^(DM&-QR3T;IBG
M(4JC5R8NXMWFWC24U &;CTVC2@J<_ASGQ1G?XB(I#<(_/5*V\31AMH.J]TB9
MK+!.I,.=BP*7UZ,B?)<+?3A-DDJUL2HZ.2'8+++0DMA*)YK+68^\;CDK._%V
M)\<?NEQCK,!T40H&)FI8%=KYHNOBQ* <++?*CA3IGEPD_JIZ3Y*FBOAKBGN^
MA,BT?MENM(MRFY;.T\SD8BY0U.:AI2),OT5,%C"'\N^-A7:[@]:JO[&39I%+
M;N&)W+Q3R]ZTGV3<EC.9G42>PTF^,^F(253F^"]NR)U4S[%6:^UL\5OY:]P;
M[[$M9/YIG0^"JAN.\T?Y7\4;A[O*I676%< VS=2IW>H;ZXQQDP,2\SB$6:(^
M2PJE<_*N5&8'Y\0H7#4M?B*NL2:>3:'A=4?ZQ![9A,46,FA' 9]?X:M/AYY(
M)M%.6#"B?,!>&@+22(W$71!Q5P^LE]"=V0G7C.5;1P]T]R;,I@:F\EAC+,BT
M?9%V;*<I+K#&]"K*5;S#5C??B46G<L1VK4(O@%,S;69!>9#8KEJCAH7)Q-3$
MYF=#DIR!J%1+6H3;JG0FXZP^IUK"@A7I\($J=-?B*"$LC;>:W%]16-?36]8!
ME"G\] =Y=')@D;>I$;*E WU"<0MXYOPPA]N=,/+)G4S&Q_:U_95%$>JN1E'=
MTE:$ H@Z E4;,Y[;7=#XAYIA;C>AX+K+U@$*<^O!;$^!-/8>H;.D=B&E<BV+
M]YE&P(H-F@OE6JI*X,<$C@D=HFVY(N>=-Z39+P<C;4'Y@H#?,%I%R>OU+N"B
MF%PJ!G=X&]WB!U><+>AP2L/,DM4D %6)6U=/% >5)6(J]@,O<%6'#.?AB55S
MM4-[J*6T2P2<^;70,W)"EN6\WZX8_+#=!!^GZE0?Q*F]?<AS[B*0?>K^S:Q5
M".D&HE]%-R\XY :L5\5>>)H58@(EUQ@3N\$DH6;KQA IX6I1!)%DP;Q!Q>DE
MM%H@38>MO6%ZC5&GG"8$POL$*$<5'UQ=>J8>?M$BG%V"Y;M-8VZ2$J4UA6,*
M'&QA)41/-V\I!^U?J+:.4WHTKR=5G8\7X>[,3XCC,#(P0/97I44$="X0ALI-
MGZEZ[:"+*L_>24LG_5_76V!%E?]TLD1>U/LV_K<#JR@YG9EV>V>]>KTJ[J?5
M5^W 6/']@TS?ZP"IOS!]A!2,3Y^ ^IG$(0BDY3T6'H+!.+6AA<3Q@E)I>"\M
M1 ^=%S<&S93Q.N5F/R?-)OJ?0WR]$K]VADW+=[?OLQYP]1D+\'F#\^AGN^Z^
MUT'9^CQ8^(7'PI$E6B&;LPSZN'J^'J@7N=UJGWX">%O.,=+;[(^57#N_8&N
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MP0/H3@_$0:'BYY*KUONR>RFDN6>O-:[6<\L-ZEELV[2GD[0@]2:$2! HF\=
MM*8/0#@ \"<<X/-'OB/\ U!\07KGC$R=FC_G9YB4/N*"QT^N@$_W.P$I_?RE
M77:C'W=_,^3*4O)[5C(@79FN;CFQ<Z\R7)0RB:>#'$BQU" 0W")>7,./J+$^
M//!\K<PUMS4X\+6H\C&GG&&7E&!'*F$2\[B>H WD,J&'_BY<(A\F4&& ,$K?
M%[O?9!19 I6R$5^W-"Z")NI:JUL_WB,V:6B*#9:@S7JQM5%UFO+C%''& ?W
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MTORK$D%ZP797_M:"_4T");/0ZF^5F(,A;RQ@&_&]S/U!)F':<*HK#S"UZ \
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M-$SP>P%/C9? 1 T>/J\XL[N<699,*V=1-/LDK.7 OKINSX%0 ] <-:-A\(M
M/:$Q+!EGN$]A%KP2WNK(U92S%OW2?/QFB"=VZ5!G[J.(O9A!V0/IZLGEGCIU
M%_9MBN@IQC<6"UI66.YEK":19 T0XMTS^6Y*?4Q$$<*'=S^17QPN=^8>CM(]
M;DBTR%U%:CM?-=. 2Y02S^>7NSV5A>]LZV74P'%*VR79[0AY0XB'K%#J,17H
MH)AGVDG]#^Y5L"69S6+58J8\6!SYH)O+Q-T8J9-@MVZ%6Y$7S!IH@9=<\!!6
M-[-6[-61MC,,N3S,BE97#8@)6F8EW.JVKO%'SJ7B=;WE_*!=M 57:;Z36I0K
M[A24@E"6]7#><>6-X8:J\DV=,E26<%2-]S&" [W>YR.6I8H)D(IR1GR6QWUU
MP'>V VV,,/CM^YS'!S6_+DPI<KXFS R)Q47B02UEJX'93@7-0C1K1U;6SAA2
M^\&<+\;V$\O/?P!4NV_S-_I5J>O]RA-S^?@J:N +86D5&=V,R?J#*$QR&Q5N
M;$+239Z :'Z-$7CP]KG%6"?F.,UW1YU3;;VVOFYMUBIE&F?RMNI:[")N.A"W
MK)F^NJ9D?D N-[ Q6 UVYHA3C11]]S:[FWCDA_"I"/[K0@:$ZYOHXBVK]MQG
MQ(0E!AV'_EH!<7?QZ[V#X%7WC,Y"6&LE@^5,Y?58&2O3W[EHKE-;X>!J:9J&
M,7:))C0RHQ5Z1V@T(VGC-, @,I,L@)Q)%!H:]@02DE ( JD,SA>V4%\?Y/>/
MI"U'=*@"3P3U4DVDG(4=BONN@/-9![!.+D;F:GCS1?!B4?&%ZVE*<O129TT9
ME91W4:-2$0I-<4U=MH_P-V6)Z%T-1G4<VD2AT)^P7-7C>U&[01HL=[^'EV-B
M6Y+J>:/1C=+$=^;-I:\3B69-6>[+IRS50GV:-1NY6L> 2!GL/7?D7;RQ9C:V
MS@<4'73BXF%?)NJ(4+* \#3W-652]E1G=?/($EP:%KL'?@=BU:(# 8;<DMLE
M>L1 L]5M"G)9#6'?SD\08E^(=)_-5,B"<AZ=X/TP2@C(E35M #J49*/LE =%
M9%;#0"@@O2R^W2J"J[O6*,![+U@JVB,]I"N9Q$[.G,N(;SU@N%U\AY3 J*7$
MVZ0AW6.& 1-'/_#FE;.M0$)[B$YSL-X*#WNRTL49YJC!N"_*19O9=+;=3*I#
M/48GGA6/0X@$@TQ1C)DLP8P:3CD) $E,EB!'NI]\F:*%?SA*!G;>B[\@G_+>
MVM$]Y$S0/425(DN03F**CHD!L[/%U^5'F^#B#C'EP31562* M $0>0   (&!
MG-QX+EZ86(OB\SBW745)G36OG106O2*3=$<2#HZ@4X.+K'&R6J+D:(D).J(A
M"I(NA63_.HHW--C*V83!TCMC:W#2_"5*Z$P2E^"F"[+SXON##O14#=XZ?F+X
MEI%I+'0]QQC>S'(GI/8R)U<O*L3<H^S_V&FF$Q6Q;Q;81V#X?HJ4F_'CIIM'
M:I:,4(?7I)%U]$"?6U_:@B71M+,9R=6K;:*CR93:5MWN()B+I.PUI<7\@EB7
M:N_ WSBP)<)OQ-.%-X4NQ'%^WY4P+3#:1M',.+[V!A?>$L$0?+MV8&H8T94I
M0[6.@ #)O42-9"-.T2LC+;&VZY8>E3[MDFA2;%+<M^$=X3R1M*)]PC+FIF>/
M?Z2K[Z/S39<T[V%AFA2;VCAVBMVKXTQ )5[GS.'J@6-RSW+Y40RI_*:+NETN
MSW9(-X^67-LOVUO8)@!'BT:'[//M=.0C=IQZ*G5P"X$_"IK784ZE711QC-&C
M.9,\0X,DZRM#$TY#C',C2?<C07Q"*K%1#J^?>66:;!&8+A(/R:;1OM/[VI.B
MJ>G"%6)A;>[+*F;#6DJT[85-J5A2S-]]_""#1KNX^Y>NA#\ ATIET'EWU.0Z
MI?'IK!3>&@4DSEM#24RW44#AF20Z!B+QD7":7_9I<6Q/0I;ZL'*35W_H /KI
MN+DR;&8GI^:C2ZQW4QY/ N2M3H=\",7@J=IQ[WPA6WEA$)%"W&GRI-U4!\+9
M:U"1?#<)U_WD:\8?0%1;:,N^[_=/J::>\$NUC3!&0** "+'/[W;W+STJAAM#
M#X'ZXKBNI($!HQC"@2$=E,96RI[F%CS1A2P<R['YQ'LX#K^K^NEYF1HT@"8?
MISQQ_> UYS5)6![0P9GH.,8WCH)R(I/=T<-VSFX&25,\VQ^QDR_-"EP:VB>I
M43O.EWBP/[G=&O-K/$ZON6?>-A1$).C;%4,7\U3L9)%@_?!"961CPG"? >2E
M&7)]@WSVB-%:R>DA6E1:.,7Q/FO H)%.XXK8? ?>UUE;1%C$+YZ;%*I&S+7U
MU2*QNJ%[\]+VV/DM<<,JXSO'TTP^MJ#=,1WDINN>J@M[X5]:/1(?";:W.CA'
M9)5G\%QG2AE;+(F[$_K5TTKWF=AO%,872 )^E<3UP!Y854G-!\F5#"F\'%^%
MI[)FP#M*_9,]'1G';[8TJSI N:^OR &\;9#"ZMU[/'0 [ S4P[NO1+>3GP;.
M=F$8K/WX'T#SDO'R=+CFY=.9#]_XT8BC9ACFT\8\%P!JC>[./[)=IAOO+A ,
MY+\D<KW6@]C]^(;@9U'OW\NE'!"0.,?C:%H6X/625,0LG ;WSE^J*G)\? )Q
M?R9"&PM][Y"NS^I">A=R@.K_KB 12]CAW^75/;!["54ZQ^^$9=\3<Q0&Y &\
M#G\_3J#TW=KQ>?6$ZK6:CG)F^BM^+'^*("*81=)D?^0PA+E#$O$VO_/*R^(3
M]+?8RIWIA3HB(EV*GB)RB> DL,D&%QK,8=+W(OE+Y@8-*/1[O?F.$^]REMY[
M$*30#+F>P8<5\!;I"#Q,$DJEW@D\"#V^]^9 S'931R<"?&/VE2FI0^"M[RE*
MKA -W'<4YOV<%H=GH(X +N&D1Y#V0B^N\LY@A-0K1-LK9&<P->6./]]0GH C
MWNS26W)P:+<P+Z'L1^PNM/_^1TP7B5!A=>]+B@P)[\<A,H]G%=RSQIY]]J=;
M9?4PH]EFW>K?QO5_.ZPI1G[2JF09E74 0YN=Y]XK5V:9M4RX,<.)TF7/\'*^
MI\@,7[)5;< T<FJ'U/L1\V KY-0A\OX&81>[6GY-RW""DAY;-I<,"VA]/3QL
M-ZCM,.R]%%C]XE>)UYZ@4;.X4S?H"!8Z"IO?G-(!T0=5C3W;%Q[9F1!:I%]I
M=\9B]6_&!F7#FIN5;=2A[4RQOBQPH25$9&/1KK1BOS@+'[[3&_(CF'.>AK)W
M2)<LLAY<+F61EPS-_/X,9>26.^[-IEC1Y<WX( -5U(OB[=<XKLO&Y2*R-VE
MV 2=D7^KUKP]H1]+/\K,?,CLT,A<6 +F9%HI"SM:^FELB% <58-]U@?MQ]#2
M)DG&\$A)7A,]N++K0XH$"[^K'G'_LF"1LN4<S^/-[FE/GL5!F9,C<M[=L6F
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MX9\\D;^;'G_$I9#&,CSN0PKL<'V6FRV#F2R66);VN\+_\X#VWV943A[8M=]
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MJ!M;1<%O##_C2NVAYF^&5QVKJ[]-5_4!8RB*H2F;^#P>PA8_?_2BT'Q$M[5
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M(^+2@H*4JY<0DYZK1;WL1SW,$ZG[EVW)Y06O &%)EU^UE)1 LD<;CR9^\[@
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M07JZ_:\,&QB)V'N)^%\('08'A'F\AZ+<E&![]?S;0Y*C"]2.%8UD!;FXP!W
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M1_T[HP*&V8-D6N]J#H(J]2VH9SU7AG'[[DJJ#Z]T,CC?5;RA?%>29!"OU:K
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M<,Q^CE[76-J"G@]HK9D\453]?(:%SK*^X/5]*?<+9248)R._WGW]W/&^%2K
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M*X@#Q O: 1(%28$40+M FB $R 1D";(''02Y@0@@/]!1T$E0-"@1E ZZ""H
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MR ;(OQF$Z:]_\8\E8#2@ = ]FFL/ 5T ]"\2U<B_:@.T=@-@9P 4P,XT('8
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M56+.WE<SX'7Y1?CH\]=*($RR@4'VOLWT0*_&O&1VOA\ARL8^GW_O4YM$F[8
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M=?2E:;O-QV<\0_#WQPL=U>;4+-/RFS5S7-1+I)C1;\WMO!=((ID*!$),>?"
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M&!7I,]Z$C;'$/.S"1SDHXP$0*9,R\>.X"'>($WH!"UID/&$V8\C&$T;<KI2
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M0:Z ,JH-<0_B528-"2J:($5Z4NM2X>Y\H ^ 4$QL20;D@4"5P_"C'#EK.IY
M7"R2*F2<*G<"Y(0JB13R""Q1@3D3!P3>3,Z(Y 1J)$-:7.JT+9E2F]-Z.9Q/
M'H,HY @[V9Y!1H3/C]ES@@@: <*45>R(Q,(X 9$"DRH= YQF*VKQ6"G(*$T&
MY<HP"$7#'%N(U$8M3HB%LI@RES<;JT3@$/(,&1 *FUP.+F+)*D,"ER2(8CI*
M265S_R#ZUX@<$KC8S*6U,LQ _V/TF9_E/U5@@4#4)8C:X+""@T=2[K YA.)Z
M&I( :H=$YC!E3.D$CX $0FG2D'/9) #K-S,</L"5YM,*VB[RLJM21IA0@I]P
MY/@YAR*8B<'Z+)?4I"3I#$7*4+F1DX8X1A!B,I15Q*Z*H)L$8-@IYNMIT&>$
M(F8V0<Z' -+K<:)RKUJF]U)ZJ4'JUI'..)6U9B%*&Q-S #??XXXF=0BHD^!0
M%!:X38Y$G '"X8A/@BF(."_"R"G:$P:\ROS.$N3S6/4HCMET.05F)QU5'A1C
ML$".]3!AUI#<*:LHQM6"GGPAQV)@_9.4A;I2%EB* 39OYK*.2P+0.4X>8W/3
M\KMK:+Z)2/.$ZI"7MLE@-M(' ]%D(,>H1-%HP.XS.T(A,Y34!VR8*!0.([P@
MG4ZCGJ ?DOM2P6J!^JA>KW $00C2J-GL4@5J*3-?)L-P3 L8DSEY)(3:,SF[
M+@AYX^D$DD4U_I F%)&9^0JM'J)(+,HW9XRH&TJA>6R39G.U'.LF]4C*&=/D
M#$H7' 4@?1QU&?Z^$[M]NZU#D(=PW58QN[;^?J+WX$PJ@^3,(@* LX#%D>%)
M^1$=@R@81U)/\RQ0!/(8,$*;AJVLI^?HPV["SN"TEBNW$B@:LH,>FP $' D@
MR<M%J@5FI #L-L3#H0@JC7OY*,\IQ#B"C +RP]PH@'J@$ Q'HE&E!4@%:"4?
M2(G#64?6"EJ1M,YMT$-6/&E-T%I=1H+(\D-VI:5);M3#B3(08[2;S28SC8$Z
MH2224\34M-N6<I!AI1RU,9 (Y:J0-.2SR3A>4FO3J>SAE =TIWA4%3Z7<?,"
MHZR#<M!5D53 E9OO_L2O D6&*@@?8"/@W9^XOBI/=UM,6O7;I_R06<D/%$KS
M":&/[P4QL\)#LQU2P"0'AK(<2APC^3@-)_@Q6JIRHB)2G^]A6(8 1)@1NM5A
MM55-\21R:4[*K@=>3)IC[!%8$ $H09#'YR5#6E1O 2,$A/@S!ABRQ2(YI9[-
M.)4AS&_G2"SY,)JR_RW?9"-85T' 8;%';$O$C3F>1I3FNG410F@6TCE%W)_D
M&_)@"4G99&!*I6/M6@(+332I-XH3)D0:"VM!#1)1N2@RKJR"/#XIP_&$$2,<
M<TAL_*PB'='&[5A4H4O[TZ"0Q]%'7/D0D-%I6(!$QZ,X/VP :%+&((EP%%*!
M*DU('7+RLD)AT.6-8^: "@$AISBFT.62XDC";46%[$R$)1Z.BXM5I:#A/"3^
M_?.__9@/]'<^>])\GDFOM[GT? N;\[J,$KM?F^+84[1&D,R**9J34K,3$M;[
MY)C-;".]$8Q-1/W&.#^<C;N(!(+EH8C2RS<PZK \JG;A9J65;^4'5 Q.F?[:
M&22J]@$S*2.?R(H%*C^6R)N-7^E6T)09LD5M'IV+%)O=6D/,I*!X)$Z)60:N
M(>+BH?:DVYC2\9 83P!Y.6HT$@F#438FDF*C(6-C[$P"\C#Y(7MC$9%/QPNX
MK$[8AJ;"H9A-SY%BA@CID^O"X@ABM(LUJ1P+#3U<N4HGC<9U24C*-7@)5QAD
MT*@C+D1 A3;K3E'Y$, &'5RD)& AA4NT53 Q)>$KLPD)S^D!LT%,%=;JTUXS
M*$Y[ &5*%1-[,E*EP!!#0%<6%""9A#@ITZ@T\7A *[H=EP6R &,5<=-L#'&R
M$,0C<7("4A57KLY  H##X\:X<C879H'L7]/=CBE_C_C/=! 7P-6V*)H$0RXP
M&D&$MOPF1LH5B1)R-M_**)U2?L#@H)5BL]6L-8-F:RYL=T#A$.8P)5Q&!1<W
MJ=0H9%8D!2PPCD6#')]$Y>9XV$P "CA<W/RW%5:74L43*712'^ZE<@&MVQ03
MPCBA\J 0Y S\A<]WZ\4 QQT@<FZS(\GD>YCD)ZV>E$*GMX4ID-0C>L2O)#EI
M7=5V;)S/=;+:U^HY+#K3NS 1BV6A=")!1JUZ-PZ%9%X[+Z(UV:5\6DPBPGR^
M;%:R093- M&8R,YAG5V.GX@P.;T"Q0AQQ&<R&!T&/QW&J8S=3E$):1B2:YT^
MF,T"O8$LC^>V2(,IGS$IC26%^CS&)F2PVV$B^'B$$3@C8-CEDB>$ %_.T:0"
M+!B-1KA$(&XAQ*0/)F !F)-Y$_)X2(0%X9!7@41,@C@G#L$FA,[&\YNZKJ \
M!K*1PZMQVP4J-IQ+7!F(EH%F;BH=\'.1*O?N$G"X"IE EJS"L\Z 1*H5!*HV
M5^^ERG_)];=(_Y**XDAX>7R82S$&@I?EN'+NA#AJ\<MS^BP4=H4C(5;IB@P4
M9@@.E"*2N:17+R2-9 @TZ&,X0:BI;#*2RV6D67%"IL9L/&$B'P*X#!IV4Y0Y
M8=4EPVX+S>=0::O)&!6H@T+ [D*SA#@AIG"90F]3P$:;D9$:>"S:>"""M1$Q
MBD-X$@F>.8:E/28@B9FDJ(ERF#4P+RYT1:A #*>,&<@92R*8 H(Q2$?X@; M
MF7:! AT$@AAMRL05>1UFH$P203U*?H:P>50Z'Q@2J:(N5\CM-0+"8$+NE @I
MTFVA8%\ M_'-K./#P90S*E/:]1956$8D]6:51 NZG&PG\\B!S?VSYJ %<EB9
M:JB>='!T[!+6!]CE)8FD<'8%9ST9C2$I,@K#H <EI';\/D3Y+PK_#N4]1%Z=
ME5V5+H56%.(I'3%23,"I+,')AU$Z$PN;?2F93!D.(-QLU;8PDZ*248]5[I:)
M%&9QV!()D%F=0"^4"5PN-K&4A-D08:@* BF=#.(:4SDMS ]B CB?/%J$81.4
M(B-0U$?'0GJ] ?*G>11&(C9:9=1#*D,6$-#NJ,%EYV8I Y<AA=%$BD()6FOT
MFZT^9TI'>4Q.@1SCAV/YY#$339$9B<P<%2.:I 'D>40NS(L@3AH7,#)7F).0
MNRF^BS8;XNX(GA.0 =SBD?!]!DH>B#E!@Q>SI[(<(&=C;'E\&$OY:$BH0@0F
MDPM%3%RU0,'@BHP:2L0T3#(#!T&88W;B(;U$(J6L9C"CU'E)B4$#>E..,&ZB
MLU(E9<(=>KT9R6^F.11J52 IC.IAJPQW06;(5;712*6!&*Y1N1T>DS"I8;T6
MRK7P8]&DSV=';2 8-F8U>EX8(3+:M(H%)AG('N8:\INZ+A))\HADR*N';3F#
MA*]&'(R:U2',H1(!O<(#>"68BTF8!21/D('4'#<W*Y'FQ!YV@E,N"2YB2%XB
M$L9C.@+-?^/#@_E>)HM+XQ8_&.&8Y%G4R:ZN6 !T(TX^D=&;=5D]Y,C$X7#5
MSJB5 @5</4=7O6OZI^>\M[E/Y?_D.?\UW'](6-5S?@_VKP@I2R+NB]-^P*OP
MZ/7NI%"LC-F$E#3!6+-A:=;&H31)HSECA0/YMPAD4<QAY^-A?5@?#9'*($3(
MC$*U3B\01!#0[8 1$0@$[(P73_JUR7C<J 6"$2!E<!H$@!D*L2[!K)4Q0"@.
M&/SYF&+529U9R)>Y'Q9VV_T:-LA[N70&"OS/,OJ[<GM4+!"EI3RW-DI)&9TX
M"[O\KJIW"OCAL#V&RR"=7A_''>:,*4+SO-&\#B,N/F6"'+!5*@J8E'RI% !\
M[H221IS9M"5M50L,5"C,A-/1",<,,SF7E#5$*,ZB +^#38AS/E5<[0?2C$Z2
M%.<S>AF2!-6AB#H<]3H 6!73ZQBCUTY)8SH-@P4E%"7GFCTYN]9HR9A)LP9W
M2UTF85C.B#2H1Y4RQ2QN#6F-XT;<1^4W)(.8120D(#@F8CBPD92 0J%7EY5P
M:';E9*1\GX*%^4$_/^(C8 CPA-UF%4\H!<04&=)R?(%H5)B4.'B,@N2EDWG#
M)G!.D@8M7H_,[0!PA0VC5!P))C6DI':*!:&L;Q<A7+,6,CNE:;''ZX%2B,T-
M<"+>2!RV),)\;U*>-CJD0=JAS6?T<1.DXJ,)I0GRT58KJK?J*).-1;_R#.23
MP4FNB%\%Z2@)E\68GH";3G'\[)357)/'V/>M_N<U^=3LP8R>M #,^N)ICY>-
M@ &"31[-@:A/1 (QF\AOTD1S&*ZWFZ1Q0T;MR&?T6ERIY\@4(DB5@G0I04B"
M0!E(YS=)A1R49JU!G ;816').F"%)DC#).K(YBQ4U,H3<IP9NT6A%P<LD2 )
MI4**?-1SY')9%CJQ8!#WZ#"WVPV&56@VFZ'5;@*RY4#($5=RM8Z8*^!#A$'4
MI1?5O V?-<9O@Z5$ !!2J7^V_5'C#<\'J:A6FC9:;3(_P:/$#-^J<KH!I08U
M<S&'@@3= J74'T7MZB# "8.N8(AKP?DF;]*(IT-XT"-.B1,&0<PB%>;21DM^
MI43\*;%#R@NK7+ZD5^RELIJ,5 B']92;X$,R$G:3 "JE?;PD$24U".;&:'W:
M'DS+= :[+!;P1=E5Z'%;8PX':^YY'<*@T1N **LIXF+1LP/** V<>,(9#_JU
M7)\)2<)(1,YB?I5 A$?\\J!94Y5:PC5N*>3WL?\'FQ7WVZ>X\U7F_V@'I":A
M^;3BW]A6N5=H/I.J85N%[\NF#5+,;)&QV"FA27'3<H'7Z(&, C9?,82T6<9'
M>NU&HU^I5XCU$85)HC'AQEC^M02/)!$ LY2%0"$[A@>B81\<LZK#_!B@L0A-
M2#HK<,7#'IY6% 8T1H-<0U%2E\)JC(;H)&Q("'[_E@&B\E^V$AZ;V9&*2SB<
M!!!+QIU*KTCCDX61I"034"I!#DBZ)0@+P' JI!)II52:;T^X$B"',NL5)I[3
MJDL;^5DJ8K?JP_FM*L(+@):0!*!0R.7B&JMP3=P%6_A$F, -40-F$2<C49LA
MS.91#MJ@!^VNB,\61,(VF0FR0V&179KBFZ6,#'%+\D%*9(_Y-1B,V2',Y8I$
M(+W6)Y>$)<X@&A98#''N@[95[GW,O^?PG]EAJ7[,YRG_08EY./>W&" = AO4
MD0Q.8$EVY3D,@:Q"Y(S%,,R10P"/CZ\RLJE)M4!49<C -KO")]=E=&ZK26\S
M>UB$[PQP7%8CP8DI)0DBXHC (<Q)@6[0;5>[#&DAF8F@H#UARU J#^CARB*]
M?G^-.?^.\I]>S>;FW\V^YTUN[I]?Y<Z_%U[CN]]E)$MMI>/^)(K1Y7*4CB,P
M4ZC"$PR;+&)T(<#KP?[=_;;['QCN$N1'2QF<(;!_^&)Y)DJ4$G LV*LH4^+'
M G"28(K*33C;D40\P!2Z60Q86%)HC^,I.,84%MJQ!$Q@A8[^0*$%9>((VT6^
MJ+#JC?A""8]'1@N5! ;'>OCC:.:?Z*>&SE<-R/_[29M_8U@TFQO@=%$YR!I/
MH1F.8J7W, 6E@IA(V@/.KT%7 J-C?Z:B:4 $ +?CA3&.PD2A$[^7BB\N8=52
M4JT/0%8J$)3R1=4,:H>S!O(_TO-*>;_1.ZK'70AA=-6QE]^Y^#WROO'N(Q%W
M$_%%/80]\GW4L. AA*.%3):\NUD%3!<J0S"=?\NH^M:M6S=G""LD:2Q 5+WH
M7XB&,#12B"<*T7B4)# &ZU%H9><U@15BL422Q@JC<"S)*J":+E$(LR5W*/V%
M)&L3)!U'L42B!ROY]V:JV@C$"2*>QF-!]BG&Y%G9=A,8:UQXK)!A25C;258=
M.BJM9OJ]XUJ,2&$,CL+W*R]1Q G__9I#XT2<_D?M*4U>P^_22OXWK^H6_N%Z
MJ7EM5*T:-'\6IH85X\"H^ZV8\COV_:!N_)&_NAM_;JRJ"[</?L D2; 34]5'
M+AE/,/D>5_/]Z6A(6?XH6:D)9K/*(.; <]C?//525GV.K#1=+@;X/7C55QGW
M3EE-E*%RB>Q>RE"-E,D8SI2S.15KJG<(JXON\>WW]+N&49FKZA+EP&_DMPO^
M3*F%$Q">P!$"<])P+,$.'XNAV7(0)A+8;]SW(7J0-$L*HTF:'<E]1?U.\6<Y
M52?G:CJSI("#_YDS2]5G^$JKG$*5AR[_;5%7J?T/-0]F!N$H3F1K9K]=]U<"
M4*S<A/GQ9/2/O.A?-5TURO*J6R%P-V=U\?TY4WGG[6!8Q0?+>3R@QVVC_'/E
M_854.=]X F>P.W-[;_%?C)D-C'FM0_VKKQY64-&S\*Y/IC_HX@[YWT-$A?]A
MBZAV\_^/F,6]#?__Q2@4?S *Q7_"*/*E?_0>O[FD>YW-'2=D)6"FNI&:/-&#
M8ILR"\?^RCC+3:Q#CC'P7])YL2I,\9=D"@)&(_\DF#YHD'<TX$C##!K2T/$D
M^0]U\,]/D)8&JYJIGE-5/C$HS#=?6-U^/CVZB^C!<JHMGG<W4XUKX'^@L/OH
MI.RNH]=WC@<[DDC-QXK+N ^@_N,TF$RE*HS&4Y@?I./1OP]1[%B@%(\E&#B&
M8CI5.2NI!X[[2WD 7R1!1>*2@ 3UEPA$0GX)(@@@)6*I5"CS2U% +*Q>^?>P
MUR3]#I"]+=W_#Z7?Q5Z3]#B-!_$83*C^W(H(8&6*Q7")6(3R2R2P4%B"B 6"
M$C$/$0@ &8RA/-&=5FH04U-K+)[QXU6X44G B43Y[<STCI![:N\QBC_.4 W3
M]^<1P#Q> (6%O!*I  NP_19*2V0B'EJ"RE >YH?%;*GH-]DU]?RV:-V?)_B?
MB-;5-,&W15O^7?W?5\R?FM+B"=;\L_^;#J;Z!P=*8;0Z?4G [%Q5S>U=9?=G
MJF$1_5T#O(?]_FVD0UCLGG/^?&$I7WKGG/]=5/<74K6!DF:1N;PJKM3P4P95
MN?K=.SLU<=U?.AJ"8T',7\Z]PWBGX'\;E?TG)PY#!$B 'Q"4 'ZQJ(2/"44E
M"%\D+1$)Q2),QI-(^7[@WYVXJDV8_T[<'R<.C<=8&,G\@\ECVV&#/,-BS_)
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MF(?5'O+,'&L5LGFH=^FGN6&!)I,;SOYXJ_;SG4V'36V[^\S<MWKO^B7D&#!
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M;^[<D!X[;:>T\.R4SYY:E4@_DGQ1-4B5&?_8]"4/2_4-VTS:M.6KK\:2_)'
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M^(>T54_0#*SKQR)E9YG'$?2_2CE9<_-[K&86NSBZ=,CZZ^**B-MS-,;+FWT
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MR &0D)"1/) \ (#3==)B=6LX NYL#7>@X>7@ @A)*:B@H@+.B#2ZR>+Q'T6
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M! )N#X7#(#]4L'[6G+OP&Q_[)U_3!F+]>P7FSXHSWWZQSS,'9?V[#RC-)_P
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MBSOHUG>]LQU9X@O@#S[^Q272]Y$'E?"B=-ZA:!?E<WD ]M:/@#TYVP7.+C\
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M!_0<)=ULY;_:*X_'6*0X_V4;E^+0<VG.9G-RQ#O#QP6>@7U\S3LIM5*<M[S
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M.4@"T/7;-O&4B>"5+S!*3CR),;JE>^"&8TO2U_4L!!4?RDC;B5+%]K=65M6
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M$M-LSF.5X#9@ENBOB!\-='?W[$29XE4<DR?,^\M6_'0I@!A?D\<JE)("DX/
M?"GZS?VKO,Q=TS29(490G&Z%=NWYXMKX=ZE@15WNI8YL^:@X>ETW5XR0,(.D
MT)<Z.J@5UTL!!*HM3QX_J< #D#$\!J#D,ZP!-OF?%?<<V7AF9([2(DER31^[
MXW)4?"/DT:>*I[5?&@Q:V'A=^<VY:-%4,V<$J2*_AOOK>R6@C_ORD?@WE;:)
M-Q%>0RH$;[]X*0U;U2/HQ?KU\PV0VO=>1$_2N[ ;'N\2+.^D=E\G?Z&W:TXC
MAWND11&)NS:B6C]7R=I\PMOX;AI#!%AD$]$?QT.X:M^VLJG->%^:%6AP,#F5
M'%Y.TW[$S,)2=PS.*>AX/#A/Y27W\)M:B^$=^;J:&(,Z@)6);,!M<I@Y9:SQ
M8Z+EP%H2+*0^@6M$^=.;'#E.5^6)R](?PBM ]<E6/4E"]-R)QR HI<$86[PH
MHBQF)W^_GF_-_^OLH"Z9=&Y.A!M0K%8[]N%"HN*1^S'DO:/I_C'4Y\7 W1K_
M 0;_D:OV'Y0?!+V_-1O!Y8D6P:^MD?'Y_B#I1B&*6#2WFYN;N$DW[_554+2:
M,F2.BR5?973W;2A#HHF?8HVI%=%RB\5SHLX4-O_R''=5WS!2^JM]!4*;2XM[
M6^OA^SMO6>M7R5%YS4PFQMM$NET<L>NPD-7R>#-W(TX!U!21&M)\;6S<2JPN
MBX_(>B4IN_* @S-K@"7=ICV5W0V+)TY2[ZZ[A.Q&QUFN'BW:1N02E'B#][Q0
M7\8KNW<T:4[1%S-1C<.'(\D&X4TQ[C=?EE?78+>&'Q"K&YNB1#142&*^6GU_
M%S>"E147=V40QC:.'EX<154[;7GW6(S$?$IU.)&(\QZZW:+FX,AZ4M9S-D[2
M[G!L;J=RA;+()LVG[7D=[1#FCIKXCZGM.DO"NKY'P\5-*>ZV;$7%&84F7)_Z
MB'(:H#ZRQ0LQ5&/!I6Z6H%GRG5?17OH[T])WUL2-Y$A. <\VYI/3GS:/CZ=Z
MW#I;.=K- <PB.7BQ\[#BU3+ZKGI/QUU+!?7R1FH&]452?SET_TALEF<M]\ZA
M)T+P58JN?H1@NP[??LURAEJ'9[TI-I/;$$!\EOU%D(],;R*EGUOKM,O9>FU+
MLZ,=#VZ_J+DQ>0IH<7_JN+1C7N,JW76R8>K<K?5MV=7-E"R8JE%5;G.#F 5H
MRJ^U+<*18>9]"E@C^;RNXJ)X"H#8T@0-U49,$X>? CJC*Y_D"69,Y3RL:NT5
M.SRIYLZ@/C'>FO 15<9AG V9;+M9W)]Q4B2@%MS[Y(LM_J<5+#%>Z-5]5;&]
M(7/S,U.1T/!@7NTUW_ID9]*^+I6@)' AK<<I(&&D=AS3,WEK_\#(:W#?\T54
MP/*@L@6PZHF9E.@A9K=7M+C_G77G32+8$:6#1$5C8/-2Z/S,*< E>^^H@ PV
M@\*QHY/BX:!15P'*:6!6J5(=4[YW.-81!QI(.3*A+>2<I"+7VE,E2IW'T#LR
M&(.>).[Q+-P77=$E$TVIQ^G7C@J( 3'.XZ\N,@V)Z,2FLC[/E7KH(7]2#+6T
MW%4LVUA97MU\-9W0__F]S3>\G9>KU<.!D=<Q-+0DAQ;87%Z5ID)8NT<,ZZR>
MD*OE416"-85:HE9TQ>;)^@2Q)<+=C;19JD5VDL1*[CT6[YJ<$IX!U]2N01@.
MLE9N3]*5.2\;/JH]KDIK>=:K+V>";KPXOV1L7WWRN%?<O2(6C*E)8:]2A-%%
M',C$K*F=ZDD89VX&S='7Y=V?IQK?3'7_V/&"K->K_1 F'\1SM=TG!457B.R3
M_((<KDE9ZL;J"K<!9HX79)RC@;#[P,[)U$:J_".E]E7-#6I-QIX"3%V59TJY
M4L6V%4M 8Q;:Q;R1',8[O=Y+Z 4.O?=+F$V,%"KJ+3!"%\(9!R("HE>N4W9A
MU[$5I&)'#+O9/7L_#EJIX6D7Z+K"3O:J;\>^)P6[J5,T;3-LNL2D>0)0\[J0
M%-BW\M(>,,]>?KREYTD+28%3Q2[D8R#R5:6Z@,UN5-K&C8ZQH+XW2 ;?JM*E
MBX^O3BKU">+8JJ&D6U0;QH,?I!U?_3RGP:?(';AN7LM$GZSR4+</\GJ D\7L
M)<5=WQ$L5B]#'@\%((8ZTK31X>JHP\'BQ)WL-S8^&4A6XECF6RL/Q)YY%4IY
M^S;/Z2AH/^2:5"G8)G28OTXZMYF*X]SYI7!3W#FPZC-%;$>!S>#D4YCV"XV)
M"46O>M'$_4R&<"HY\&-DX<>ZTY!GXS,E_(7+M-0VP)Z'@\*/2L?(.KC0%-Y@
M.1KPOO4ML?GMS10+ZGMM[$%//P/AO!H+Q#S1PR.3@+NESY7%6_<E<S%3+0]<
M*>(<,?P[EY7"3QBH"+?,M+853A)OXE6)GDA0;03?7]4&S@XRN)(8"<3=Y$"=
ME(R_4^O>\[(#8SFP,V0]'5N338"55*LX[\LWPODQ>^$N?>F'?0_RA%OBBG2W
MJ>_&V [+]:S:3:7XF)5>EQK-Z8@(2JN62J""ML,=&6.%6V1\;W!(Y=RG46<%
MW5)\5Y:A"U3\@.4-^/QY:]\BR\_T/=7Q9K/D._@JZJAAM+PM\5JZ)?HZ8*+<
MF%*8O1Q-VB>*UUPNXFV/[DZV"XN;>:%XT/&C1'J2AW0('\50$EK"\<B51*8^
M0N4 "8D$U0P_Y8T7[5=8O ^:-L2GW6)ZG\''&]9%@8VQGRF@:(+* R1YM/ :
M<CZ7:(?0Z;ZF^1T;_0=Q#"3V@K7K_ =B1?:4U611S5(?BAR9'4&"]^DC",0\
MOVV?F):8%11_/@7H/3)PLZW>2A7I9BZ@.21B*KX+V@G;1JH74LDU?1M6JF@C
M9,[P]?JD$>8DBA2YER2;KH1RN7]JDG*FG>GS$9K-SAG2SWW-\(S9K6<;RRLS
M+S/<>\<WEQL=;0IVB*VZ 3#:>ESZI@(OXE, .X["_(QB/S=?@TXNZ?#'@.WQ
MWJ<$!KE3:'&%6%70MOD'@EZ]!+G#'5$K.UXVS16YTW+>7I&^HHUQ\H&1ZZ)#
M2E>P:W:L;Y^8-KF^>^^2815.2W)E(<6DTKQ'%-8!'Q[% J$^$I W07'-H^I*
M!E8R!-R!L<.!WGM>,]3 OHXB>^G"W&FU 3X+ 2SV3.3!^XOZ L E;DYQD'J
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M1AA1-:MC(A7E@@4HA"J[?RPV7W[5H:T3&7B;L2-/FHJ35CE8C#P6J/^7?ZG
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M;!O(["^\3XAJG'P'6W.D<FS?#$(#A8;0/)]J.NT;7\FX=$Y1?A,0?UCM/R*
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M!+X7]X)]'YZT9;M7',7-K]+R@HTPA@/C8U;G!Y0=!%:NL;&2-48L#A"6YC]
M2MQD!V2@P[T_,@@CJ.<$?%/K\4:-6B1>6VZ_#8\C?M_W'R'W5@O4G0KFG[K
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M.22JBTU)WF1*A0.>7"UG1*O1<6ZYMD9V9;;C)>I21>=%M4TQVKP7=!:DP<\
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MX*7RZ!8F0C[T\^1"F]EPE0<JSJ5==@$=SX-"+.N;E >CX[,_&"24)%'^!$Q
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M8[GC5#*/3PP3VW]JY&?RAKXVW%72<]W=&*:[JKA5:D-\UV:?1U5PX7KB3!N
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MZ:1CH%$;HN^6W.%IUH]*S\HQDFX@RHZI K^^9V.S>68$<FJ_GHNG3%]"F'J
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M2@QNDY$BR"SK>4R6W=\;KG7I;*3Q$7Q/P$4C_K$HK<I]IB9< 6'YBR.\$K-
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MK\Y2K^3Y>3A.BY2HW9".BW3D'M_3RPPHD%5EN&W*N6@FBL.FDYNJ6"5'UK1
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MG/0%ODR2(JTW'OE$81,M1;:?;](NKZ<NH#1R!#)*&?'6;60PZ1^2YI%83)V
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M&3WNM[L(&IH>GPH:O]]T>9.2BZR4_=5C=>F7G'"KP-?^B8ATJ+I3='$JNQ7
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M/JGV<O6V+T"UV$^ZC9?KC:^W797S_8ZI&)*21*X]8[N47"B?B9B(5M]SW$T
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M/J26%[WM(R";(:PN$3.BX/&,20YG?<F2C2J&1*11TC*AM;%&ML2"#%E1Y%5
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MANY=:4FS!B3B6J2D]\]QV;I]C-\DS98J06O-K9ND');]]Y4;8<GA+!&(Y&E
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M#=:L.\U-/*5#S273Q#I!A-U$L*B?  /4IH.#!!=$VC$L4D/=6=H\.9F2KLS
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M/OE>KP4-G&?>W!FW N=YY):>0D]R(47EFR9I(<H0[FC(H7[JDO#73KNW*;:
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M<U$]'X),3++Z#]LJ=A7B%!]3V\X"P8&(AW:#WE9?U=_C^Z_A*VKD+I0_UQK
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M4R4V=M2@BM5]V)0 N5JCT1Y_W;NTX(G[/IZ^5ZN5)5Q/MS/%Y(HTGTEG.WU
M73XB^S>B%,H1!QT.ZRO?\%2!BDS<Y=HO(Q#<O\M_W1;5,1A$)!,:Q5(H,@Y;
M&S'01)QR(?5K)>5,%X2./#3$V#@8NMXWBXP=6498"/+NA]/LV<!H?C'LCEL(
MVV+T">O#3X)9U!8MB9'&813E137^NM1Q(B=>"Q7*& /M]SX$"%3*8JL8.C^\
MOL%NQ+RKJ[,<'80'$.S24WCZ3JS[=LOZ*"W?#3)#AJ[F-A40N=PUWZ75.+>_
MR8,9W9?AN.\9@W2]?^KYP%@LN8T^ N7%]?J72"[ D<;JGE.6*MO69=<D]973
MI0/4YN1BYTZM%91-ZME3C=N,U;QQRK)L,!\1G&GQ QV@[&S7J1F#Q\?V95_E
M++4<Y/Q@GU@( _TW+B[M*P0Z;83&-&^C?4[-AU_[>\7^?8#:KD"ZG[,9-^8,
M1X/AT//.P]MD73TV(,51!?Z:(=A::?4MM2PHXQJ?J?M$Y,]?X($:VUN@>Z.C
M]P;@VT<RTI/+\0Y9E9T23*T 6Z"XW!VHW*7GD=R?,S-HI/%B25"/9_PAZQPR
M @WM$)$&-"O0"1R+-1;(77S0<^M(W.*O$I8ALM!!]?^BUZ3_9YP,")S^OBI#
MH?R325AI3AW4@63UR9HM@"2TN=#GF[/ALUI,5WR&#S[EPH_AC^B#QH;V8;]I
M4L=.LOLZ((W#FWT1W!JRJ\K9^0^&/$>79;2%>I3G/V.WZ"BR#"@RB*&A,D^C
MGCN(3P9R;LRU)S7C?Y"*<^'+JX/U2-"#'@?,=44:LQKD]JMMC50T1B?[8L3T
M.,?E8SY10Y(]HYM1W_QS]P&LDW.>"+#WQ$ 6)L]/E=0%N0H%MQ>)NZ2:4\JL
MQZ-64^*AFUFZ#U[,"#A31U$?#+1YB YB$="OL?+NZ58+ET[[-A8^A"VE_YA"
MP& ?-[)AM/T2WV!P3$W&:$/O]J&A3;(2J^:]C$ZLBD(:E(UN C^:B^64W*_2
ML5IF:V-R[FM,*BEQ&A.#>!K+SQ!T1B,/F(*_.:'%4D#D\LYI,_\7,('3#SG*
M[\KZ0HZLE/5"+&AY@FF">YE;:&3$,S$._U\%A_^[Y* \3#I<DB6&BO5,M 5/
M6_)LN'4=\ZK8L5^N:L>#.0KKDD KA>= 4$?*3 <@%LP@XP=O&BG^]TAN&6KZ
M:"1T!MH+F9]*$34\2>:P,=U5P>X22+MQ@"/)J")BN; (=E4)J4E^LB9P^I)#
M0WRQ.4-T,R.F7 4(RA_^=H8=OO8(0V9#\*@4MJ>MP9I\R C7OT=!$B)6-AT0
ME<-;3RJ5:21EN+ACL!$;->0#PEAF1*M_8!:H2_T\,Y^1#S,;_<QR=XS[?N(-
M)O?\V?#WC.//7LD]AG'F4)M]+(SC<=<M>&N('[QL_?AM^?-F:/]3S4(2!J"$
M0*\9\&U2ZXJJ;_Q%0L)@B3I>F0#@A,C2JF,5&7B('$/=BS>BG)RR=2GYM%#[
M+F4]\"&>L1WJG,$Q-A'Z7C?M/,>PK:?;V<2OJ],9BAJ8%Z@.J]:O;HGI7&<Q
MH"609BW[1!I!)(-B(SR$G!)!1"MV]8$4S:=/;#Z^Y&=+-CW<FK+2P"PFEJ[I
MD/Z#Q1=],QWU&C:GG/5[M%1$NG)'5O<#$^<1-I$I _#)/*V%>3P@Q]P,PUZW
M:8HI0X6U8="8)C]W.1P12YG!AMGFRS<]2GO](_V23%U1/)YPI2]D=>^+%^:Q
MF.%5K7*V<+69:"_&-1MT+.3E?I,D=,,H4Z2L\K<^%6OLWLRW-L.3O;3V]B^_
MZ,VWR]*8'*Z:I^JNX920P6%>6P]=5;B;?DXI+3(Y7B4K)@MFB/08XGW2^4]?
M^FSFH".[,^) ,B54MP\ 2'@"^WWT4H[OUU5K)&'9&/?E\K%QO5QG'-OWJMPP
M6_'H[FX(#Y&_(?X(:4?2QU1;',7WT4!,TD@9*U[%D<,D2K? /'Z',=ZI,O@P
M@##9(%3IF_Y(X<=E#IL> >@8-X\?SX&M<2%SB#7+,,IT&Z\=C2.&JMY- 9WR
M7;GPW9,JZ(MK35:$>]ZA7YO<3-8E?RR*YR]V!;!+J+5,I2.I#ZT\ ?=@>F;@
MQ&\.B(U$15^J@$D/1E,:MV\'J3/&D&2=VU-.P!/< ?.F-52]6 8R?8,2!/61
M$FZG]IE.G*^9RCQF[.S(M56IS-./":13L0\D 6PM))E_2?*C3@@7I'#7_99@
MG$FL!FTT0&B\MD$ /,]I&'8J]OX/^M)'[>17RP];JH#-7A8TU^E]XSJTV(Y<
M X*E!]WDT5=UGKD:D";JWP3,F83_H,;=4@POC$S&/%>+ ,"_7L2JX.>D]W^5
M(JK[K:I]/B3)>=4,+M4$HYP*TK\LN>OQ^DZ<7B/E@U.$9=B]1F+HS!O;2.NS
M=0NM&D'XSN24)RK$690L,6R6^Z=OTZT9\_*Z;3?.1.</C1V& H)[6\_S5E?(
MAL8S<,%4MGRR#\8-E+ >0(Y*5-QZM]G0+H!WTO>GWXX5H!^G4.I<Y_+!]MO?
MGB>#1.<SG+.-@YWI+I<<(9!S1(^#9+-3PR)[1U)ZSJ: FCKZ"-<UX6&*T^]K
M![P2>=\#)([W9%&4NAN^/\?'T3X[,?P:O*=Z9 "]=+GOG6P9BM<;"/9]+"NM
M$84J4P0\[.0ST:TCP.[6KSW)ZX(RQ3 TEDO>$9UQL9#S*,FLC5>MNZ82D7?C
M)6T6,Q9D6\G<[&VL[3WZ_IJOWU)W!_\"V]UM%?\ZM7R/J_W */I.L;?N;M8!
MF.V\]BJ/:ZTO3U]*EXB]9SGA4?F(VLZ_Q7&5++MNV+["5</#1]=R0E5G-D#!
M2V#4KKIB2T]9U,^PTK:_-+SN<RD\QM>W=;]N9T5U-E7_R=-5W=78Y?67>:S.
M;_)?86,N.1NNV!]8*XW=Q?K@GU8X!YIUV3%;%1VZ-5(C"$A4843RH4S8J6CF
M?IPB_2G?R'[]";S>_AO\O/Q7E+I/RN^-:D=4/U%D:;:?6,P3LOQ;AY\\(SJ1
MU_?AP!%N!4?E?V71JS>>5,:/"55&7?=$F*O058D@ KTCN8\/8/3<SR;=F[<<
M[H?K]*'5U(D]2"4WE?S1++RL(KE06+Q#NF<4;_ITY9XW).BH-%W02JA!Y;:=
MH!$R#1B#9:C'5\\D(/>KC+9^&NJS+^<I/](XV,7] ;I^\ ^X8G5MY%MVOQ$G
M::+_8*0QOU$-WR363.HSN?-M*Z[?3FU74I<;W6!@ -6YD7\%D>$RQCB<2^S.
M\YD2CY]?C*W+.N&F2[R!GJA>\FP/E?Q;X/7M:W\\]JA#>RTD+,2?QOMXBDC'
M0B5!X*?;HK[0UW\(GR$L9O\[."TQ9C,X!Q/56FQ@$-O5:4;??9HAVF=0&9E"
M>O;.CA%&I@BP,?8A>[43W6P\P0"*L[#,L0Z*/S0K@=SY4[3>Q]/G?7 Z2EKS
MFO@IQX:+)U./2ZZ:1/FEB0&+5S06B-81B2YP?-XMA71'<-$W?#KH#JDDNAYW
M5@-DF=JN))LF>L0[BJQ8P]C&8VDOZ@\PYD)XQ)(YWA7^&:)1MT<!B@-A^PCQ
M-8/4IA0(GN[?D;2"M3PPI'K?R?A4G$'9<<4W08-,N;4%#6(W]#Y%WE(M(ANN
ML_<GEA8",26:V8VL>G<U9G+5U(I(DR1FZCDU8S[1-0Q$6QX<<81@CDCRX2@\
M\,$Q-:B<,?!7EO^J25*+?]8'+_,MM2C*AQM 8P>5DF@;,@ZX$JO2 >$'-JNR
M?20PP:E0A) N38$V"AYQ2<4K-OA34>N^N3\4>K:I1UC/!9GYOGLO1%=37WJ\
M5P]0"!9Y3DU_%_SD1P6 BPSBK&'%,;Z<,-.=F-Z SZ$R@^(B(W;3H7;TO6=Y
MF>FAP&=!G9^=N42P43]63J"!7N17\@ECE\=5:C#O[8@F.8:2,V'2#5)ZYL36
M=U:5+292V(*M7PAGMQG<X^I5SN-4<X/#&31;5*S_HZ_EHPKKT.^0&&'E8>HO
MPT<G)UW+]L)1F<DY3>Z3/NC!Y*D+;ZD=3L2+ J86G(O+^,]"IB,FX>!(+&>_
M&^;T]PV\%JR?D):K6+UESV66<066"9RST<)VESX2#/<WH0>^\[^S04F12>\Y
MHE*#[:Q'Q,XFE_?V+H5NK1X(9C:;936-.FP.&[U:P^=Q!KG]K):')8V>B=UR
M; C*7LH5&C/HF!=]*>H0^_(;#M_P5@+X=+T'ZR[VT]ALMGR4(W>)U2"VIWY%
MI9QHY3.,5B/0'OQS[7KG"A?@<VW'&$/FL##IG4%B)\\^$@)AU;5%114AU?"%
M9+J%PB63AF Y?H1/-)E'K9)RIDF@D6'Y:/C+UYQZO$T?\,E[\AL;8NB!)"Q@
M*#-)2M&$NO[T=R7Y:?9H!(MCB ZG89V88@08+H9]=\?@$RE(_ _!B(O#;[DE
M_TN#U^( !O@?PO2<"*Z_RA=)2:$5M4..%355TT&A>-8(S:??5$W-_!]UH/ Y
MW8-K6_7A]M._CIPJ!R+S&ZKC_=Q">PJ4[G9:'_.Q;[#>%L<>-M4C=ALU'Q[1
M) ;DBO!8;Z@!BPX4<]^+,$I\_R&<29_^0U@Q1D-<ER!T&OX<[B%A_Q'>)\'
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M.IH (! #& @,! ".5[BV#%T0*(2/"\(+)"XD I!1U='#P@*@B6NP/OGF[UV
M*Q/0&H#)R*7U\XH! &"\+&3", 3@(9&BDJ*B,J),&-B \WJN$"3"!^&$ ED@
MD%"0(,@8X>H']D2!0,8P'S <!C*Q%P490% (1Q@2)"8)$A,1$P5)BXAX>8#4
MX#"PYW<GN$Y1R2;6N)U"]Z;<F/R(G!"=HRFG8W*G8[,GX^@/\+1'Z(5T]409
M^**\?%'H+O8)S] '9>*(0,!/)70\43"8IZ_'C_;)50V./.F3GNJ:N :<2*BZ
MHDYT?K<)0^J#/6"F&I:F/\&^*Q@B$0@G$QC*U\O T0V"9A,!# %(  +]QPD
M I@ 8  4P!?@=:I"X/53^H<953C*\S>/B!Q]7>$H5\]3D^@^_JFTFIZ5[O=H
MR)_(8PC^8<84O\S8P OEBO#T07-I3^?EA?+\,0GT)!V1/SO&SCYZOX\@/=5^
M[WBB?N]<=(3[_.SH.Z/\?G8T/.#J/SOH./YN6A7B[OQ;(+X["##64E5#7S!/
MVU 0"(KP=3R/F #\("VDYU]XJO"_RJDBH:9FGBA-#F,X"O +J<*AH+_C&_O
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MZII*!.@)__CYQ-_5]7^?SD#.0,Y SD#.0,Y SD#.0,Y SD#.0,Y SD#.0,Y
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MJI%@M / 1KQD(*D2]?0RDC!@A60.GZ^MN+BFPX6$ 9^Z4B'_N2;:H$A=\H)
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M JETN5GE3N+#CAUS*JU*(#P_-65$0U75:XZ\U;AO]H!OD,'&2-E13=;5V&+
MMCQVP)X5P9T)'B*>[$J>KHK70F!Q8R."R^P^M)<56M?@A_X#CB?42L!%?:;Y
M59$ Y:9 N:\E#HL'5K2O&KH;JU)Z!?<-N^Z9"F_E0*ULI*Q3:UM9 8Z<!]B4
M!Z\ND23W+-BP7'E-*>%]Q[C^7F9^*&W\/"=4<^/8U.:TTT3C9),TYV+23/]/
MB(R:$=/]BEBUAW)W58<B:(XM$4TWL^"!<.E;O*EO,VTRZ@I)>X7L/W*U.RE-
MG0AN>,O%-2HRQZTB_%CZ*]-.*J):]@--ZQO(G^BZ'0":*ZB<H5P[C+\XWBD@
MJ7PL#)(CE9$E*OKI26-/5B6F+MD G<NQR-=PB#0TO1%*5J]3Z*VRZRJENS>M
MPQ\)TY,C3(J;P&9<H<"*=OK .?!9!4LRA!ZC!.K(9>!V+A+@L>-]NOW.'=QX
M@EMWY[Z_WZT?:8QC6Y/1*<\[>^8[4YML8_2ED".5C?4&>WN 8FU;<;.2H9^(
M_+GE?8_UZ?;.H"&>Q&P?H_SW^BTW)SC828G4*X<SRH $V(OH!!LUP*^NL+J?
MQ"UUJM8U\FFXU@6+$(8W1J%G+ZA\A5Y(<'%%>K";!@S5: $'67=1+JFP:GY(
M$O]Z!Q]>.Y$YTQ_09:N_OC,3:3AG2Q'M94LCP+O&M9C5D*HM%]CNS;R]J.2L
MBY'*V"5O_<FP<MND!]_.]%YTOC4WYQYWV5##=CB0X.4U*EQ1TVK6+AW_!NZY
MHE&*%N9[*QU>%;"1,$K!BUPT+P ;'K;QA)P<KLYB9D-+HD2K'H%'9A*^(F'@
M&@?KD$]!X0GV6A1SBV 5S'L5"MB6)DJW=6&[G.*L)N^) ^C@%1 A?CF^M<U
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M9#7'@_XDK$U7SDC;QP';GDV;*Z4EEJ4 <XFB4ZL])ZPBYE1%I<Q#19*=QLE
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M\K/?];,..3WYTR3^(9SO(HOJ^1C+Y[\_\ >?@MQ]7ORFD\XWW.NP%[>U23]
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M6HPO:X_0RT/=#E^OLJ*]!OQQ"A=0M;FO0%(OP.D@;BC&:CCT+P[W;WVF?C9
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M87N@[SND; LYV.5V']DB1&[2,DW"C;9T1@-(1('448O@Q>W1H\EHY):,]]M
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M?9C;4;IAC99NC$_9'5M^1#PC.//7+B]F<<=<&?N>Y>XOIYS\_-+,!3^1MXW
M?N736:DX;&M=G 3)[C\4/#5OWA'?:6@&4OHO^%D1$2-WKE#X'T$31\,OKY5%
MP=N$WO=/+2I4)?N/+Y5)R_"%LFG,JU\:9PL&2FA-GATK3F+/LR:9!C%6#<P!
M<&BTO 74]B\ C:7OFLQA'Z$MH-!"FEO.R&IT"(B><;LI%TFD&&W*P^QC*>66
M^Z#'_<AO, _G[SN/$/K-/_L1V4CDFQA;PPI+870):M4Q+9ZB(E8J00^5H3A1
M>AK7XDT"IE5']7'G*'-E2("BAA=)E:6?[[RVI,541(.&!42*]&I=$*PO#3S+
MTS"1JEV8G].?(X4\Q[6U<A!-959Z5&8@6S0W=\1[S]^&:<W8:TB;$ KM7I50
M[?\%0"(;6IJSRUNO6ZR!32GW5GLE5\<M"WFGVU8.2:+WC(O"HU5&XA+\"$X/
MOX5T!0*S%F_=N\?%:4VJ;BKQ]"?'.]J25>>JPU]D3:/<L7F:>H\Q6LYY%KQL
M6^37T_.;392-X?3O8<?@-_MIF!VJ_2= 6X6=D@BWY%T_GPOUFY45<<_;%S=4
MBNG&R^.H>JP8#@\9BQ JKWI176Y=>0EG>**1PA#SR5<=+SB%OAQ^5S\T^@8K
MKT#,ST];Z"4H8D*V/C]Y=XU?G4ZX%Q'K)H-+Q5':PX8/YCJ2<&56D:)?21.2
M3;3*V)'@R+H>._VL%$5%B_5-Q3Z4D0V,.6E_+__4_NBNDA^>\Y+KR[+IM>O*
M2UGJ>?JNJ.%G11=+DY^["]G>%U 1/FT$Y)C H94D8#U>$O*I>(Q7E^]46I"N
MQ><8['ZYNU8RFB>^BGS'.?H7X!&1[*A\+$)0&!^/4%,W<=SF !K.-_*PD]UY
ML-/^*%JL^5)9R@;TCB&E0:>^E*YVX_LG6*!M%O JHY@<KJ]LCTI3W^3FQIXT
M&D<5%V[J]^@P\]SH^\E#Z2/_6UG$>[:"!<W1HJ!=V;XYY[)$_%1<MJF%L#SA
M^E4+[/$RU5%Y]=//@-R=-0.-NC&F= XM#T/1(.?:G(BY.!2Y&><JD%7LW::?
M/K2SM2U%N]RX,^"%:@#XXGEG!.0+,#V)79BZ)77,8U61M*N;CX-9LYI^F'R#
MSU8[S+0YI4)(RU=70= 7?@N/?<>_11;.)!0-"2Q<#A(_]M<\J<9"KNB81OC4
M<NG['HF7<%/<F.!Y A-QC*S065WMM^J="7_Z64EG"@8EN@Q:Z0X,(.9H63V8
M?W+D?)1UO3!,+L,4/=B(WLC':X2;Q,]8Q+O_D<0\1[O1D,(P%VFTM$,]5<,M
M5-YH\;_;5 EF#F$XI/,X>V[L:<(;+4>IQ3E+QB1:G9A63&2\)60T<7,1S*0
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M.=MS-M#?7*U9F=:"5]R]]$G]M ZU"&'_L(7<#.(M-E1Q1V%<1YDR0@]I!XO
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M+Q\KDNO!+4CN>E%W-D3!4=?/R0PE\8\6F$.K:#N6=B YY$R2K[N@,+;#<O:
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M&-['2M<IMT 3)M..+9A5A(LV;0&_EV'-W)56)7PQF$*]FE^[\LLDPVL>9MO
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MF(A]T[6\_$4>$FIP$(@XA>LT3+[F.VP07S(K#6U>6+B=Y".<5US>_C)H]Z7
MA1K94D#2"2O)L_?BX#@I&3R[AKY2(!PL%40: #XT9C_5\'GR$@US+^^]$D@
M8,1Q9!OA+/[O?6G:U7O<YEU[$S+>5-T[Z'GNSDONJ_P]D7?<CB8S4VZ$MWF>
MPWXQS<EQ)&FX9]7'(&X(.'D)L=?M;?A/_WTG"Y9FN&0)5OZE7;K]81U(DQUY
M*1TTFYJMZVCK04ZQ/ \QP]Q:12L>W2$*A2IW=[5T!%QIYHY_2[@M[15O59'U
M0I=UX8.:AVE^HEZ%[;3^$G B6ZF-" ),AIX9$38Z]#&$4(7ROP(F]S+->51_
MI^#OT-Q\@7([6"68N>:LO4Z8Y-TV0'U7RU&@X:;0,K46#T,I&HCP-8Q%%8$X
M#]!]8"5N%2#+[3KE:?/LG3G-W>O=F\@JTO7&^_H-XH=),"X(L1&4FH=<\%]O
MSJ/:AN2ZVB. Y(&VRDG^DUF<_2$U6!'*(OA5[ CE+B;.C?\.&QOPQ/$/4,Z;
M^ZNV/KI#K[%1!^/!HT!OL5X?B?PF1\CQ-E$;FX1MN?_S$=>HC[?V:[%[;F$G
M\P?)'<COF\??B'<^="27N1B.;=^$$?C,QMP>&39\/PO&&^W6C#,&F>73S.SE
M.%LM7!L^L#<;&$*D@RN(TI1W@<8) 4HMF.7?-<S^S--;=-!D3(V/N#5LJY4,
MM^Z3>B]-II\^JZ]3"$UX,0UWJFX+AB2+DK^?C9RT4>6B#!6*7![T(KVY7+IJ
MVRWX,%#DNC8VX9K6^!'%*-O>Q%(A^8.I.DU6@2VV)RY_,2S/:$6W> VKF*(Z
MY'4(2,%:A3,^=XN:9*:9N_/DP?$FH1PQ0Y=J"GI(^_WN&NA9<_;*/YVEN;R$
MS"!+(Z(ADE1@7*ZRZ+ES49*,^CKQ1KL@X-%U8^\7BCU&[/_?'=S_^J+G_H^;
M]U3>:GRG9_6Q>LKH<($HR"5"2WW1)4<^X+6BBK@-&E:I4#+<L %F*5+K&27-
MCNMQR X;4GYZV/GA^P_@8-,0I)"U1!P@DL!ZR:R-3&GMP=H9]6^*Y<][D]?2
M'NR?)O=Y41K12 N#FB+741_2HX2)T4>74B REPL_\Q9W.]-T66(DCR,>5O\!
M=$I#7$N Z-$@0*+[E!PW.LB\(J^@$WN$0$,%\YJ'C\+CDB9Q3JS)WIMU3MZ<
M]I@]X3+6WUSY$$BY$\++K1S!3N-1:X7N*<HQD)9X824GI*@7E2Y:EF4H:AJP
M.E]!K'B?(C)^UIP=R7_F8%KD%'>SNGGP"1R4)GYYH7FY\)NI\[ BORYQMHC'
MYEF^X],IS4>MT'E7R&?U@5=[B<RE/!T&(^K$I)8G]K9B3"7+GM&G0,KN*9)9
MNA/$Z:)F<I_X \$V6T<Q:<(_ *1)@WLJKL7W';[_WAKSNFOMI9RH:+OY62(_
M=Q"=*YD,%1<ZFRVGK7=NQJ0J3]#/XBS,F/8%%]*C.145?ZL/RS]*Q'4$\2::
MXQ=&?^VB5%US$)'=><<J/R6=R>>CI767I5?4<19;G)11Q#ZVMGUQ29C8'MCS
M?!9A\/WL?#;A^H:Q7K9_(VK))(]\1X*>NA0E ;(XQQ]25M/LP.XU.K;8D%!;
M*(K8'&#SPZ3XZ!RY[]]>\IP)=SF0?U5R])FR1A^;]LN!Z=)]=>KED7EG7#W?
MB1@>R!@KN_XCNYR..NWJ*@>+#5%7:#M^RXAZ[<WK6DI?9A73X\':LCR@!=6\
MI&F(-0&3TGE@C?S*G\SQ% NX4(?Q&(XN%AS73#2S)-:6>;&6!8A5=6D^31MS
M_:BDJ9=G9,43*',K%*L6:^LO^V:;#<(IH3*B83Y&?6S%X1-^4D:]WI1L'WDQ
MH7%#NTLM_OSZ!:.3Y?*CW_>OT<W&M(WU)\5U#6*G38%E<!X>;XEVU<.A,)01
M5.F-GW+8%4CFW+TT1:V\GHX!_E,(,T')@-/JX=RL')T47E"3N J)@BGM&4XV
MGL8WB<J*%'B "QO#A-#$YKMZ7D_$8U7BS>EO?Q[S(+4'2=9(A2\02Z .JDE;
M@)V2\.]&I&QG4%?&;#^CUZ(M!QZ#RR[1%,AXB7UJ]?<_P'RKM!4=/M7W!=)9
M=78RX"T\ST129H0K"QF5370&W-T_!APU/*G?!NQ,2KB\&"5X4B-V';%:):+T
MOA,F3>4F!JU?*-0@AR'(N!3ESL@L"^&+Q9X%B.^F-1"'$?_A3:GQ_44=LP:9
M0Y9Y)M^%$#4RUW0 #\9'BS"YV2&Q4/]\)9%'NT.+@UY+]'K\-=N0WG+.[/W0
MSZ":,UPD/AYO:^NAB%3<'#NAKJ<6M2>&]#L'8>-(Y_1O;>B-6&:DGJWG+/NO
M6J9Q,=\%II06@;XJ=R6DRE2]WAJ,\@>TO1-)7<.0;QB*.<&]"  A]L!);+K\
M[DH>JR-<:;[K1;]KA$R7CNQ+_\N89L?XADR:P^V24:O' ,UU9N?R!;E.D+O.
MSX6Z$>P0=3/'#U1@%FS\R>O_:A5WWZ](F(AZZ==AF?NK@FC"].[4(]1L_(JJ
MA*D?5,QXX[2!YA<S%8M6VO,JVB>=\N]@%%W&9[YQ84JM/_=;:ZT8[;]'<FQ4
MG1 QCQK8_EK4PZXS<'\C^J+>_Y(F8SI ATV';<BU'\=Y##M/DR%UO)ZQ^_(.
MI_WY656Y[DUY H#=6NLS*ZD2(N@@\N+3]EV4@J<VKA=RI<6P#0S&^5%T]TX/
MPPXI/,VD:(2N+"]2O7S4-I)/VBL$8(6UW $MK"6R"5A5&[ICVI>M/LF*($>>
M,I8_5$:PR79D1!:_NJ7YLSF5._H@AJ".9S9^\-J2:JG*"?'!\_!@;6-P@[RC
MGP-H5[4^_V[ZRJ]N[]INO/^6$4IM\BH##J)]\&TAPQCI'*^CI]D[[&*+G')"
MR,*>G7CU/VNN_G[Y$]NGV=1A!IW]TMTNB#"@_G*?C?AIL$/3'WU8_7!:"&VR
MFG\6^P<XT'=PO&YZF7H\*V^Q.M_:^,9L>N_F0'_877%?9:'X:XF)D^^UIK^^
MOM6W)<O<KZV]]NQ6[3^+8'.2:\V.6CU;50V-EG!1IAA83=U,A9=YQ4C<ZVK2
MDJPQPWLDR?M9Q4BB6BVEUXZ=$;IDM2Y,574)_J.7,RHM4RS+F")3B!,OGD\N
M%>39)E,25HN,PQL0@ND)IE >0T#9%+51U1"DD@E(-2A\^R/2)C;NY*\<F<Y/
MI8M'@X ] YQLY\J#GF[)A1I@\WVLMX*6C4391*5%78*-!<N/PY%GZ**V&NP_
M+-.-8"%9L -EP6DVA_0/X/H[/IF.!* 4@48AG%HH_8_#=ODS8(DYT4=%%\FT
MN 8I()S'QX?+?$XA-(M?CB9,R$TBA+PV-^<B6O_OBFODNFO\!NX;B1'?&<>Z
M)78?U^HYO0\MF<(V8?7HL,%&OI!)+S4GR[QC\JZ(JYBLR8ZL3MR='/FLUBAX
MSJ+A7(_8&+GQ!;TU5#R7SP/06G*#7'D/,<-/AYFJ5A6F%ZFT3-IYB>PWE*2<
MH7K3;&500\WRAB5R5H('@F\^9A]# >J;/)TET<GV&6&#&50&S4A\P*[673R&
M2A(JL:IQ8KPND_0&7%]?7T,DP'CU!987?$.G_\LQ.91KD,^XAHJ6OSAKB&MU
MT9"@>PM'6H5)#+%),\.U0Z'T&O!"O/%R/\;J8,+0^D 9)U#V)6['RTSP?O2=
MD"59YV@\GV],OZ^(.G$[<99<]X!W:%VN_T'R((4D ^9E\VFPZASRH/VLK,4<
M+_(EV/O1'_^"7$ZDNQ:L8Q"D4SGQ[1LG$Y/7P5/5]<''NR/+\;2G_XNF4$*]
MW(1VBQOCB;G[%C5Y%6-7_0-XN^EF_$ET$3&O!1%@.,&T:)EU%&.K1SAND(ZX
M)?TNZU167]2B4R!O[O6T)TYZ3"A-1;:L;)LKTJL8/O"+>J"/7@C2/:_*22_]
M-.U:_P< *U] ]L/1/#H8-J@9(R]=IM399NH"18Q26NU]( 7-ZOU54E6RKV,K
M<LZ*;7KBZ[M,"A>D0%&3&MV:DXWOM"[3QYCQGB/O5JR/1DZ=OY#80%O7+U5E
M7@G_W@#-_P/8"40UC(_</G_L%Y@&9[P4"9DOL;^MJ#6]U=?_%0O;T?GHE#6=
M*.=3KI/0I\)WZ^<BL=7,;&G&)31,A"<S?*7\D.3^UT)DOQ?[F;%+Z. ?0.5Y
M\^/=."C@^:_!V<.??X!'V8J.K1>W-_\ )B-6=GE__J++EA%]ZI#\]!-CZV"K
M=[NG_#RJ?H0/'!C2 _TVH(-0-.+L'(E0K#LP&F?''J]Z:7FS8&]?]W2)!_\T
MN^$!S+6C\:_XFZ'RZ4[LUS^ DTAON-^]^YA6MN.%[P;=3@IEI\\L_<F^JKVM
MH/8Y,0LI:)&HS&3^S';8_U'?JUV1Z7J\B.]U5O^N3-S5.@?<YQ.E39)]]ZI)
M[@.:3@K0?-N]K"#HUNCKBYR.[KMHW-R'HZS^#;=WY"\B9N]6I;]OX6XS9.>?
M'WQ<49"DUG\57]N&M( KU]F 1L)QWW$RO:B6<.GH11C\/LO9_6JL1,53.&05
MTT7C0%I&^:*0\T L_?G%-;<LO<K"L1R"NM3FG+MT_,X)<'=RV:,(QH+_#]'+
MUMW]Q?NOKO[V7L^2S.0O[=UYY,],QWQYWNI^6DH\>[@I8C_]\^=_"H]B6NIQ
M;R;M^:_JE[\)_W>>3/]','D.A_%:A!V*-VG3_<87\M,426++P.-)\(X)"U#^
M20"B-T28[1B0]!===8S8WGZJ\:AY'S8E"RFL*KM;I9V8P=E#GY(@Q(&K>(U;
M^_P#5%WG<!$#+^1B9A?SIH92R.<75+C"Z47 ,<Z 7QWS?/*Y&C_.%6]NY]N%
M?0T>?#LK[:VH3P:=MI&3C7:<QS^.7M5>*O'4?)*C9V\(HTTFS6FAK?[ULPA?
MNF@'FP  ^MJD9Z0QF/:U?H' $.L@NQ$"21+'\4TUJ65H1F&F54J86;+,#J$S
M\FSFN4W\;"BGIZ U0-JBIVO<X;Q;+CC!4B\=-2B8ME$<GF5^I'R(;[CYGI.3
MJ:BHJ/QMKY+2S<SIGI7)98^ E?=_.9R1/;YYTDN[>:*(^$LOK&B@J&3P]$DL
METB/)]_E=,QM)+TY?3.U>^1"UN)NW/ME(>TR@FHAN*@X20N,>#JU]=:$JN=8
M$,DTQ#1G0[Q2?=?IV_1'6?"  (+6T.W0BY:$;_DSSGG_ ,_:K9\\&V0'HZ3Z
M77^!+C(YE]RN5R@:[-:?+M5TW$)M3?2R/E-CO_O>TL]LJ:1XJ:3A[48ZX"_1
M\3HT5G^,=/?=\II4F%!2PBH(0)/[^\0-K#U2[9^>?$4KD\=1S)#Y 3(M9*6<
M=.-9UC:)R5MM3DJ_]LFIC%AW9(:?NOI^B0KTP;YU945;RHZ OL)N,@%+=9Z)
M_4 R;TDLSX#('[G"7GQ)5HE,)1,X7&RM2-C> F.:J5^X(E&Z;!+[5"O[P\,A
MM$% E%<N<J.JB)/VDSG_P4]V?IF?XS&"YJ<%[4F2&RU@^ZW)K$"2"*\GO1$&
M$%,Y5W\#]1;"QT:L*&DG\(.QQ#,VLS/FZHC/?.YSVN3')&KAB@'[^,3NM&E,
M>$*0W%JOET3<X8@QS4J+A=;M5.,?!5OFCHIQ5G+X-)Y=>VO#H79?2]*UL>(W
M 4;4'H5(3F8Z^G=VG!3-2J^]+DEVZ^9 $8>%?05#%C0)OIAQ"AID=B3"(LD+
MJI0/]@3M"#S&P4 X;9N5\]\X<ZVU:]:/KUCB?X R%!>%=#6PH?FLPO;G33D3
M)C70@<\R36KDD@29;<W?_!I0=A^CMG9FV98,;8R3]%C::EKS)9X^+6MW_[6F
M5#T6 G@E?=85P(+SC\(#BXKJD'D)XA0XPX]<T0+FZF30*L[Z'!DU9IAQE*ZS
M3:\S<Y[%JM1Z>XJ/V)8[3/KM=0]7J.<1J?6C&^$KTG8DVVC><6F#4VTVGT/?
M>I%HZY1K,P!E5G$NI."/QQ902<?P<3+P16:G)15K7X73M]A>@B19ULH+7 A#
MV?;'.ZSNAF.E$H&4ANK*;.IZ?:8M1G+<19-F[3&0$^]V?7Y.;.(_NT#(67W
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M;<@E^0VU!6,TER*#%#=&>M(@EXF0)A&E>A 7%;W4?W.DU@8T&B09HOVU(O(
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MLU\PDY7FN9!BFM-ZE8V/5X1:&ZW-YZD!C)%6H6O;43"D-STSX10D\FK3V'^
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M<YG2-A2:'DJ5<VNPK>[S=+7]U:NK,\W;\VVYWUEL<EIO9T5_=[64-?PU)^3
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ME=-/T;N<#L(;[FFD^_ ^I.7*:&T2QVR1RU96:DRZ^2=+HE$U/':X?=#SIY0
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M^O*,;'1[,.(K9#U^35V#Z'[W'DE@4 *L8T1W?O<!)2;2$)6&-LV0:**Y=!Y
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M-)X8=.ZSK*PHJ<QL'"*-W2M+G I(0[D0F/_C4M&=52\FL-V(>$H.;*QV>E1
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M+V>75_'S5946#E'/OGUT<DD_'E_I\W$_:RD^7@'93^)'K"T[91]F8*"NI<E
M;?&^JI/KV#7"'-7+:490#WYG6%#![L<_C%_'6L(3PGCJ2WP1@MD5?/)G>O8[
M8A/;**B>/&G>S$&U\'N7;XB(JP'JI*PUK P;D">]Q)K\3<;MTN:H6V]O&))@
M@Z-F--$2R/?R$%Y7MKPP<_NKQ.']MW&G3V51%7X$_%)I2Z,E8Y75+E7TCR59
M&P:AV1BC0Y<N%1\PJ+9J?=)NM]&+V#]Y$38]_6&X5/' $!@2'^""!* I](;
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M#GL EW,GUHIZ60X;E],03-T&Q17;)@?NB"OM<!JRXK!!<=APV,AQG'#P\0:
MX#8#ZAF<$S0YR D:UKG9^I%Z=XZ0L'/-CZ:[;\-%3F3RJ2>R"XX8^<D#Z<D%
M4(W/&;.LL&NHC&]X$NB).2Z^N"*8<V>GX40#&+.L9&"P;-#WV_.) A#<SGDR
MWCVQ503'/L9H+'#&*IW8_.Y3R9!]B7I$7T'?_\1O*I 43P9O P^$!\$&X *
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MJZRT,]*VL^3XFTW;3PDF!*5?^"._\14Y8UP?_RJH^BE0VL7[R3[M'.F^TQ@
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M4C<9=U./<,^&>QM>H >0A][>I8\V?$%^IOZI 3-/0(&F0:E/9T) H8YAI1&
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M.0,Y SD#.0/Y#X,0_>NO^\,0EM=8W5BO2Q]/ .0!6/]+.G'RO_6!==P ("/
MNH=U 0>+#(!-AH5#AG7< F " +!P<+&P_O6/&F !\ FP<8"X>(1$&+D&*4:.
M@PW$P</!Q0/BXF#C8YT*R5B$ /CDLA0Z9@24K,A'$6G/-PBIA!O[J=GDH+.;
M["*BYC0<*)](>=TRL71:3DNGJ(QRC#=&+  6$.=7-,P8%P\;!Y^ $"/6)L.
MG6+AX>)@81 ),6!D0!8 +KF0K(X9'L5O2)3"<HW]L_AL4/--*I%('VIV5-G
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MY(I+#<3!6^*<]HL4K<-E7H&7Z7&?N8L@;KM]P7NQ#)0K*B?W8L6AWGXF]59
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M#PJ46(A.E4JDXE*GLNY1]H6J%Q0=IWT)J>^2D@.TR&RM2 "5$'P=TL@P%'4
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M];2%.IP"0DI62 .PTTTXK2T0M?=A<!1 .L D F#S^[M8R#MB92D%(),%202
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MU^*EARI&270Y39K4*.TF6@A;*YC825)ZT)9YA5FO?6^A!9(#:M.H2HI!!TD
M>*2JT;B]SAFH+8;%&5A1IW5E"D@_S-93I  F2 )%]I$2,:2APT4E34^!UQ*F
MI4>2N8PX0ZF2WXJUN-NDA82M^1*=42!XBY<A:AEY>6:W75$H6H%#>I*4J,PG
M8"-MDI\@!:#.+6BC8=IR"V0:AMMQY0&E2E%*5E2K3.LJ49XJ-XW;N!R7L2!6
MTUW]WNRI+3WO,2/+?5(BQ9'7X@=;97\/4AS"FL_\G "!KCB1?S[,GJ9-,JI2
M$!*4*TB%K2!$+6 "0>,P2=R;88L=G<L8JC5(IB7))2%$J0A4[H2;)(F) !&T
M\W4\!CK#GA-=><ASP&NK([A6.H>ASQ$]ZN(U(@#^I5_8CUG$SW:?Z#:+09'U
MTY6Q>RH$ZYQ_V@@Z=_+'"=XOBI/HHCCTZ6O//"Z ?PGV(\CU!X8O1U$NH/4<
M?$<](T'2K<;YS^'V!WBC>4$&=E$#AQ_?\YQ6GPFRIL(N#8BPOROP_,X7BJU'
MAISVP/ZCMKG3\>-&'WB_I'_'!\8YQX:?UY>N=-<<&"_] _X_7T+S@>(?_MZ=
MSDY&FQ^_G\^"3%C];<^5M\)'_P"G?B8-_H=<(N*QHWKV.3I]_J=/+SQP7Y^7
MO]>N @G\$>A)MM<\OKA!+JO\@QD9R5;>ISYYP-L_7A9/,^^"#_1/4@S;;CA>
M*3GX/+.IU)^1_/OMPE[WW\^.\WO/PP0?Z/@K]<#K.A*0//??(TUSG'?Y' T/
M&P3ID1:QGA/$3T/BX=-L8E))$@B#/IM Y V^5SB-EN>R=R2M.^F.8U!MF5!N
MN-4WZNW-15)7AB9)4MQ]2XYPVIMTK7UMGX5 XXL-1VKSNIH3ESU2ARE+26U(
M[M/W$@!("K&1 OUY[<\R_P#A;V-RO.T]HJ'+5L9LFH<JDU":AR"\Z27"42 4
MK),IV.V))ET[= P,'<GSSC7N<>ASN=.*V;$Q @^=QRX_'Y8Z( 8'AFW$$[\[
M_P">N%XJB22V,'ODY]2>V^F1^1SPA*B29N0 3&X'#<1]#"P?Z/@KWWP@ZK.K
M8Q@$'78;9UV['&A^7!)Y\(X[<M]NF"#?P;]%?K;8;8(=4-T#SW5Y:DY_/UX)
M//KZ\]_KG@$C\/P5Y<\+Q2#CHWWU/?TSKOG\M>"3N#!]_/B/KX$?V7/16WO@
M%XYT0D'))R2-1MMYG7\QG@$@1(W!VY<Y)GZWP1_9\%?KA>,K3X4Z>I\]/P)^
MN.PX"2003N(.]_C/QVM,82/[-MK*Z]>N$%J(.48R<8!).-QD'._GZ?0YI/,@
M F\B=O> 9^HP%)/X2/(&WE[3AL*\Y&L&KL7,ROW2WJO(7%N2$@%,:/*++S\:
MNM-@=#*\1ULSRD)\5):40IQ146CFFG<^T A+2U$/) ("3=27!:!9,*BYMN3B
MU4"'>T%$YE3B2[F5(V'LK?/^\XR'$-NT"E&5+$N!=.#.@E>R0,9UH07ZLX;V
MK;!75*HDJHT=W"T4.BK_ .E9BC!;1(F-XDRY2 ''4NMM$A*%)*M!3A%0X(6J
M>[%H;;.P2>:A!609,@&P QHSBH%(G_0:!9^RTB@*UU TJKZX?[KCI^\6F5?R
MF6E>%!0I8$D$.#XA!U1IZDCR^7J3^'EQOD\_K?\ 3%<C^V?,&UND<#[8P:G5
M&J53*E5'D$M4R!+GN)"L%3<-AR2M(.< E+9 WU.QTX4;%1-D@GC $3/*Q$^4
M^NMU8:;6XI,):;6XHP;);&I6YY#?8;\L-M85Y37K>K]1N:8ETT:<$/2D-])+
M;M/@S2VTVG4CQYBF8K>J@DM,@Y&>&U,\7FEO+(04K5!X%-C M,@&_6/+%:[/
MYPY6Y755U<I 33/OI*TB &TI2X!:\@*TIM)L!AP*'<$&OT]BIT[K5&=4M&'V
MU,O-N-JZ7$.MK'4AQ"OA4D['30@\.$N!:4J;/@(D6-]Y)GKM.T8GZ*J9KJ=N
MIIU%QEP:D$@@QU$R"#O\ML;CQ"<_ #DZX*OY=\_APLF][GT^OK;#N)_!\%?K
MA>,K)P@9SKG.PQD^FP';;7MP D2)M]?5HP09G1\"?F< O*UP@:[G)^WX:=M]
MNZ$SOQP0?Z/@K]?J, .JW#8[#<DX[YW!P=1GR^7"R;&;@0+?5M[?'!']@]E?
MKBKQ/^P>6Y_6>$O]#C[_  ^."#_1_P";]<67 ET*2IK"E#!6G'4, @$$@D8[
M9!QL=,YR2HI,[C>)(!/7RM[8UN-)<"@IL#4DI*@"%:3]X!6XD<B(WQDR)$B6
MOQ);KTE8"4X<4$M%L:AOP6$MLJ;0HE2$*;(0H9!R >,U.*TD21,BVT_B@SJO
M:;B>>^&S-!3,$%#"2JWB5XE&T@D\28G:9)-\6_%(  0 -N^P[#Z_3\.-<D[G
MZ^H]O*'L&XT"_0_.9PO&5_D!SD]R"HXT&?U^/"7B)M,_7USYX+_T?!7ZX/BD
MG'0G;;&H/XC3@OZ^7Y3^>%D_T#_C]?GA!TYQX8^W?^OGIC@O]#]\'B_H'_'%
MZ.\H/(RVD:JQVTZ%:_A^/H>#&*@2DC2!/&(XSO!\MNF,+J=UUUTQ@(^N=.$^
MC-STB_UYX<Z%?T^>PZ?M@!3F=3H=\!&3^' 9X;]=O6,'=F3*?/:;<[X(4[Z#
MUPG/X>7;@/.]N'/IL?A@"%7A/3]-C\^6!U.Y['MJ$ZC\_7@W X;?XP%M7%/3
MAP\\$J<['OH"$9P=SG&-3P">/O)WG8#ZG:(V-!/X?EQW]\ *=\\?1/\ (<!M
MS/SMZ_YZX.[4/PD?5_W]SA9<WSG.<CX<?T/\N%D[1 &QM)G?K[X3NC))3?C/
M#W/EA=3N2<XT.- ?+37.,X^G"7$03.Q,Q;TM\,+W2MM'RO'SPBIP'0C;&<)R
M?GG)X!U^>W2T?7$X V1LGATV\_;!"G#N1IMD).OTVX#(VGWON-@9GZ P:%<O
ME@=3OGKGR1M]LYX(,]/,S.WM'QO@[M7]-SY>G'!"W<ZDX] C/Y<!F+;]<&A7
M+Y814X>^V-PG?TT_/@O_ (Y=;_+!H-A$^V_UY806YD9U[?X1I]!G'R(\M^,@
M.@.^Z@)M[[\<!0J8*3/UQ\Q>\6@X14YDCJ)^B-]Q\QCOY]M.$(CWYSSXCWB.
MG(X-"N1ZS N/6\<\4E3IW/\ ^/;_ 'X.GU[[X-"H^[;CM&&(]I:XHMK\FKLJ
MU2I57JU-9-(1.8HK*'YS45RL00](#9=;*FP@%A89*G5>,E*4*"E<16<OIILL
MJ776W'$)[O6ED!2@DNH!(2;JWB!<S %[= _A?E3^:]MLHHZ:JI*.I6FL53NU
MRRW3K=315'=ME82M*5:CWB=<('=DE0*1C(JU\5-B7R_8I2)%&IU1@TNH2(,M
MMA+Z84AR/'8@S2%.(C)3&<2XM3:^II:0%G(4GAR:B](E"2E+P!*5)A004@A-
MK!0!$D;&9%L<C[5YA593VFHLJ0^P^7\P>165+8*FGP'N[<+2G$H5I4LDI7 U
M  I$1+XA2P!DDGN,?/.X^@QC)P<G/#U(!!DF1/E$Q!)L3(WBTW)OB<TFQ@GF
M(/Y7'T>@:CFG<3;4%NV(KG5.JW@O5 ) /N=%;>*G%OC!21578YIS3"R"_'5/
M=0E:(;@X:5KP:9* 86X-($DG3?4HR-H, C<F/N@E5-[9YLUE^6KI$*FKKT+;
M2D$@H8D)=<7!LE0!:2+25$B="H:-JKL-T"K4%MX&74KI@RI4,$)6:3%HL,JD
M+&X9$]J*AL@@N.-N(1U>$[TL4.Z*%:0H:E+TQ,*(L3 Y 1Z$@8HS%?3T_9&H
MI$NI%34URD%H*A?<Z$J*M(N$RE(U&+V!B</-RJ?0JVWVF5Y=9K-5+S9 *VRY
M(*TDI(Z@%I/4@XPM&%#3A_27IFXF +WL#Z;=+ST&V.A=CRVO(J7NE:R@K2Y%
MRA8/B3&XB>DB\8<TJ7V&#C308!SK@D '3&<9X< $6)M??<S''SGC^UIT'@DP
M.,6$]8 Z'K.!UO>?X)_IP1Y^YP:%<OE^N"5KSDG  W(3D;9/IID^6!J.%2!^
M([]3'D+V\SZX"@\4[>^_G\/?$-O:VYD\][#BV,]R,MYFZ9E5IW,U^N0Y!+45
MM-&LQ52H,OWYN%.#;S54'7$A^$/WHZ!$2Z@Y/!%S\+CD3R,_ &1'5O4%Y 3W
M2"LG7J!_M1(_"?Q;18CKB+5$]KWGE_X+<SJ+*HE>JGM)/56/1>65M1K)J24J
M56&(3<6I.J6PS3I$:F^),FNJ=ELI<4PAEPMA>0O';W//:=N'D-M[X;!][NW4
MZ5&HU0VC01,@09'A@7FXV,GB9X>S#?\ ?/,3DO:E9YF42IVYS'@)F6Y?%,JE
M,-*D)N&A2G(4B<F'XCK;;-7C)BU5H1WY$=L32PV\LLDG$R)$7'4W-P=[>E]A
MZNV.\<90I:%)7!2L$1XA()-X\42(M!B9G#^A3H!U^0PDYR==>#C^_P"6-W=J
M%M.W"UOC@]3F/XM?+"=?EIP7GIYF1Y\_J9P:%<OE]<#[8 4[Y]M,!&_;MMP>
M7QG;Z_3R-"A:(Z6PNIS?(SGR3]\XX(OQ]SOY;?5\'=JN=/GM[^GYX74Z-COJ
M=$C7[:_/@YS(X;G;GT^>#0K@G>_"_7YXR(REEY 5DYZNR=N@GMKN. VN3 'S
MVO\ 6^^V$*#%Q;S'/H?+&+Z'&<YR21G33.VWHKMG).G!&U^/7]?SWN<.="O[
M?<^GX?\ '7 !WT\QU9)P/GTC7Z'Y\+Z^_P"T870KC'N3^0P==>DY&I)QC7/?
M.FWD1_5(Z^0_7B;B0;'K@T'I\?T^N. "1H-01CRP2=-1U>9]1Y;<$;_O\Y/Y
M<\!0KAI/J1_^R<$G/<^6XQDYVPD_0X!.OEP$3Q/P_3":%?V^Y_\ 3@#([#(T
M)SD:XT((!TVTTT^G !'&3SO\I^/K@T+_ +?^1_\ 3@DG0C7&5:Z'&Q&G]/0;
M:E^?N/TC\L+H5L-)GF3,](2?+ZG"!)4<8.==R .W<9_7V(/._E]<8]+;WP:%
MQ^'>]SQ_Z;['Z.*B<Z 9'F#KH?D?(_/MKIPOU]?7G@T*_M]S^F!E1P0!G!&F
M2-O/;4^G;!.X"09WX=?U_?KA-"_[?<_^G%(SCI/<#&N?F,@;'UV'!!B)Y?O[
M\_SN30K^WW/_ *<$!6Z=M1N#IIJ 2""#G&=QZ[90+6'G<D>>]ICK;RQEW:HX
M&_"3;K:/C/G(C D2U(=]UC-F1*"0KH"O":8"AD+EO%"PRE0R4(0EUYQ(RAHI
MRH/*2@=JB2B$MZH6XJ0!T$GQ+ (\(M(N0(Q$YIFM+E384^HJ=4#W;#<=XLBT
MD*TZ$21*E$<8"C; $*6YE4NH/95G+,-"(\?!U"0HAV5U#4*<]Y:"L9#:-1Q8
M6<II&@"I)=5$$K40"8,^%)!$^O4XHU3VIS)Y1+!;I&YLE*4.+@[:EN)4%1_:
MA/QP%0I2,F+4I 4D#I;EMM28Z1G!ZNE,>6HX)*5&60"<J"QA)'<IHG!X4*:/
M]2%J-X%BE94(D&WA)'$&^"F[4YFTJ7BW4MDSI6V$+BTA"VDI"3:/$A8!,Z=P
M"Q-<2\F+,9]V?65AI8<#T:1@=1##_0V?$"1U*9?99=^%9;2ZTGQ3!5>6O4LJ
M5XVKPI ,[P H$G09$ $D&0 9D"Z97G-+F@*6SW50E.I5.X?&1Q4VH#2XF8B"
M%C\:4XOS(<6>P[$G1XTV,Z$>+&E-(D,.^&XEQ'6RZE;:RAQ"7$!2?A<2E2<%
M.D:M(4-*DI*2 2E29XR 0HJN+2(W$C@<3[#E13N(?8=6PZC[KK2UM.)*DE"H
M4CQC4@J"P"-0)29!.&JYHVU*J#,:O06#*338CL6HPFPHR/W>XM+QD1&TX+KD
M5U =6VD^*6$J]W0MWI06M6PMU"5H/B:D@;$Q>T "9B./OBB]L\BJLQ8:KZ,S
M5T.I92DD..(G6K08!UH4-0&ZC( )C'&4Z_KOAP1'9J5.J#7AH]RG5& ])E):
M4D>&7Y$:I1&YH">GPW/#:>6,.//2'"IQ3-&8N)04K1K5MJ*E)B"=TP23.]P#
MP Q3J7^(&:4].67Z9FI?2-*:A:U-JL" 76PE0<4#$P6I(DRJ^.76J0\_)F2Y
M3LV;-<\>9+?Z2Z^YT);2,(2E+;332&V6&D(2VVRA"=596MDZZMY96LR3:(@
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M729#A:O_>-DY%-3HPJ'-F\88PH/WKM>B5K11=:>%-%-=3?W/+D=->M?Q:K;
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M"&W"6=M9^*U9TLA\F/;HQ;^R\_< IKNKAQH:AEZU4U[/'\(T-TF->\[]P*W
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MBR\0IC/(XSA*F PJ",I-V6U$>Z/^3"3A^E?]>60*H^I&B^*O>O33I+]# M^
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MB'4&+?02,*QHK=["1-<\V&F,)99<+ R+T&;-,*8%PYBD$(>)'!9&7B<%3R\
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MIQZXH<<2RGJ5U$DA"4('4XXX=$-MISE:U$Z D@#XB0E)/&;;:W5I0VDJ4HP
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M\1@XTSYYP<Y';/\ +RX,)RMOSY&((VD[],;F@.)]P<8W<C3)B74[ZOR7)C1
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M+;2!'A0E*4I  Y) \A<SQNCY>8^6-L]_4=L'Y9QQG!X<9VDP-O/8R,(@$84
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M\^V,^OEH8U/?<5/3_P PQCD9'<:ZZY\QW.VN?,CZ<&-L7VXVY7VW^$\,'O\
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M1(5$E2&VFW%(Z9?@I>4A'B'BZY?4MLOH62%-NMZ"H$*"4JA0,C>%)23Q U0
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M3$6@(A1JQ$D1WE9 =E38BF9;?4<)):1$A80#DJ>!."L$T_M(E)J6% ^(M0H
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MN4Y3FR\\W&5(::?E/QT'^_B0D.*F3$=*R(K+RTH=4E*%9HKGJ))6A2M"8U(
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M4KA>IVG6E)#S*U(?0X?$VZRX(4EUMP)6E0D @;X;?V.N7_-FA<O*!>?.B_\
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MO^D52K<NH@ET^F5ZL6R]-8A-PX3]1H<MV!4/=Y8^"9'9EMN-I=:4L*"24 Y
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MA.($&>(&_&>?#IZ<ZOOMM^N_UX,+'"_#P\>)C;E>>$X';7ZZD[>N^>#"\"
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MRB!!Q,9;1,J;7F%>5)R^F4$J2F NJ?4"INE8DQK6!J<6;--A2U"(QMZ%0X=
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M&5""F2T:0Q,CL2X[B7H\AIMYEY!!2MMU(6A25ITU!V!UU'8\7M*DJ 4DA25
M*209!!N".8N,<Y6A3:U-N I6@E"TD&4J28((D>1VXVFYOY_TQD_TQ]=.%QCY
M2"!POY^5K#EQ. 1J-L8U\SC77SV]3C/!A)/.?\?& (,VW@1?'(7%;S=20J0R
MG$A)2KH0$]96E#B4NM=:2$NMA:U$IP<A*TGQ4H/$C19C44H<;;=4VAU!0H@
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M14N.G+Y'&/QVG 90Z/^< A#28875Z"<AG&SG>-!G^;%G]Z8(7S":=&[EDX/
M6O!Z %'6NND7M?1-P\!JKB\;WRWS^A-.ER"=="@F]9^.1 .2$HN6#-OZ1DC5
M;)U<^$,L*N[5.$**>++$*5UY0I5FS06NU--K+^*O!YI^ $I?*/W+E:E .S^_
MXT-SQ4%?@^@X66U/Y%E8Z?Z/\,/!!T._0GKE5EV8=[C/%-/W0I<1RPK_H73;
M4$:Z85>9)' E<+VKV'[H;RR7BEW]Z_J?9AY9KX7Z;%RU <^_L$#S],.!0OP=
M"=-+!,*:T01@@DSQC^7UXC,BI68R6QXYX/97:1];&]2XJIEX9K\D-]@VJ!$\
M B;] _S5(A#\K,%4W64J%S(LR*[@7:H849+QAVQ2R4KR23?!X\X.>W<_/SLJ
M%R#CR42U0\&,GX-I?V*6<'PWHCM+;S\PD>#:];!BAB/^39$'*<WJ S: DMQR
M3,C.F>2;4DB2"24#.P1V)JI'H,O>;\(+L8RC31?:!# =-],T?DS/%'[,'56;
M[H?G-#G-((>TC3,*2P\0OUSV53SSW>_NJ7K$ (?T99%R01B^&R<@6V:?Y=T6
M"//SJY-;JM!1G$RR-V!;*_5M78E)'NR:6U%(@I"R3<MQ0QG2$RK[#\" CA(X
M!MW P+*!2AQ6J( PJ,O>24<]FOUNM%B"JS+]78=8B?OT-,^!P7DDV[!<H"Q-
MVV@0N76?8K;*VK7UICA<0D3A98P(#$LCTWK.;2MF3HK6P#77"5H>::0"V3/P
M7>V@R">+4<V_^O>XOF=W[/UT@-\+;@5@26>7MS$?W!(?[-(P(5L*(9(@VD^]
MKB8'/U\/)3$G%[H"^6N*] W%X.T<--V,LUVT]>1JMI.->"YR$M?2]OQ4B*8G
M.61#O-I1O/$J_!2\DNHOM613 W\@@P20JX PQ G5P'H34BR[:7N5>L?3:<"N
M'@%(*_$G $>J" 8$ 7Q(C8SD9C)</X^ "PN[3LMZ\^V ,E-TH<N!;U+4)'>S
MS];Z2>4=4K=W_'AW]LQUEGB&W#G_QKX.71LH5HMS+).6YJKX$Y0.#(CZX.H.
MS.@=D%6)8J/(B8V\*>@PHQ,/V]QQ6(*"B_\!RDM&.^^;AK?.KV*&H"T828[D
M9?->BJ:(!--#>H=0=G;$UU)9KN>M1M'5<J]-I>A:9>+\*.  76.6_Z8VDMOM
MXE2>L#;*FPZ68]I;B^'/B1XJ%59;6*T$2+V3C]&'_MVB2D<G,AV^*0 P($Y&
MYGUY(UMMR,"K?BIQ= :_:3G[\F%V$'!%O*3W+OHW'!Q3L%$A:;?]>5'C8R.>
M.\6FW6MJ[XC;4]]->\&/_^O#O>)=_C1#DD_1[#"[]-,,"6%K,@5WN\H&YWJ4
M9KI<+@FA3D5Y3R$72P+LE0$["^Y%LFU#;4CIL%!X2PZ0CHJ0B7BATL:"A65;
M\+[)ROL/+JNM--;?Z3-MNCP^6P*,]:XP9D6VE<J"!!1!;]G(#.!X]^"U/XS&
M@K_?Y\T!%[PXJ@,=PPV/\:>DLY-ATY?PZ6S%48MNN["D2>LR.:_HVO!\4?1=
M_H]OBP:! Z]O9QNTZ=UA7^U;5T1\6$?)1^]8'6CHR)6%AT'LU-[>AC0F?V N
MMG"A1WVL3%5H S_*QYL^"B/UVF[:TJ10\R8[P!"O(.R%8SR 0I%6,ZN$DKE<
MH.HVIT9X,>!'YU:AE(-9EBJ?YF]A?'GXUUR%CJ<VZ+9&;2C""X8VAPAF$N^+
M(CX)ZR.\;.9\L<)0$5C:)OCXS_$<#LTOI$= /HWF!P(8D  *>CH^H)8:@U@*
M=X]#%  ;7Z611LXV02 _0:[HLE-*3I9^V_JR( ? QL)Y_KC]1,L^V%:FTFN%
MT9D85W?^DV;#P$9'P+@)AK'FNK:0"ZXBF?<UKE$:YJ?NDA7]@NWSQZP)-2V4
M,9:4'^8F2+U>CN1:=Y<,+R;N-:IZTP"'"+7/WWO,B1=U;E[*@];9(-1R6\X<
M#HD[<^H^_Y(!TWO#F_"=JT.DRM)_%-<RE'5=\ :?2!\HW= \$P@/7/9&J(3_
MBGEZ6OJWUCFJ\V%*=-PF'GZ%^UL*8J=7W:,_=8CYR_$QZD/(*K$7E7=8K)C#
MV1U^?C >)\RCV5/MJ*/4?G)?:><YYV/9U>@>.K&CO0@&&+*JD:%DSTA-#U"R
M^R9E"[ V<+::S8@#TIJ%[].%IC)3B)2:UDU8DP0\&PEW39 RW\MI_Z@ =B'B
ML?'$/VITB#6_K;GY%B 71P ,:"+<")62R/RH-NR<6?@AC-V'G6LF(*3[MC1]
MF>/TAT[DS8Y=;,VU8/*/+YS:USJKW2=D;[@<4724+^( P8PE , (>#?=1?!T
M)O$Q(R?G G?MQ(QOOL#"TT_Q*[8QL1H1*ZL4;>=4ZYZ[L'AH/S25C$#M_E&C
MG WMU;*5@CN7<X46D0N#>L?WSG5OG5L;/D$V+,2*A)(2 O8BU7J.U5A!DX.-
MODGRR9M#GON%JO!/D.H$,2SBH^+*]]O#NDP9 MY#RKM_G/HQ-,98_8BN UC,
ML_,]@0 #Q,KGQ*./1P*M<N1;N;@L1+P!WL=,+24W/"C=6 E[MATI3T_&,/%N
MESJ]K.-V 44@OSA2XL(KZ%P*6QR4W3XS2 UZDSQMWOJJ0G3#QFPVKY\C-[L,
MG;G?#UA#DNJ]B:N6W ! !+3;64[W20T.Y=[7>W(P5!'8M-8X>EFB@JX+%-1N
MAPX>#RANQEQ/%'GNG"]S7ZZ3]),E3EPPRF8_YIJLN;):W;^;I(UN-HXVBI;,
M&#Y?[G@;52HW3!O>S1-UD;/KN5SD\GY[MDW[?65%^>\?D@*\>C.B-IJ-HL-G
M8=Y$"MLV"&FD8E6O4?_<+*@NH7#?66\]0.#J[44N\K<-MF]VK,Y*\ @S:NXW
ML.$+E^U.>V!$8*G4(>C[K7751*Y[LV3<^)NRX9^>6!6B>RXYJP9>P>RS7.'N
M!OZ.TBX'TZ>[WJ?2TH%Q-(/ RY&#=HK)PH.>:GLJP3?_ /?.LV:(J:C]*>1Q
MY4YGDU-'CIU;8E-_C$=#.8_SMU*HV9G"1OG@GQ3X&50>[?KJQP=:[NE^6HO,
M,6[=BQO0K]OK4WK< &[[]IPR'.+!HZX[9,PVS2PYR2C/Z3C'@0>VY;<<N,2E
MYLJBV"EDC</L84SH\5)*/KUT)ZM?DIK9#N^6U)XI<W@'"C^(GYX)\LH1MGOF
M\OQ86)+';:L;DX"6.S&KE-ND=/K&6O\)M910S$5D1 '56AVHJ(@H/?X@;[-O
M4_4Y+[C+<KJPP5J%W]+L=0K+%D%H,8PI+8FI(MLI!5#;*=\/]C+2$S0(.>'^
M(Q>:2M0+@V0,EY'MA:]3>6<II5_OD8],YGT\5V*3*Z]6:0D]/^GG^$_AJ\2*
MQ13Y.Q*E0'KU#P>T3CF-E<3^.KP=XW$0OV.S?T),WGRW$?(X3?&@\U/MK*W;
M=JU1<HF)(N _D^1S<4U;3DJW6C.W.^WK'IO%%58I,OY(M&R[K)6YH1+Q1% 8
MJJ?*]/YU%]@U9"]H*Z=4IXA&[CR \I3R4YW=5U7',#++T@L&OK  %KQ-Y9-0
M39WL*\^B@N_F2Y "KC064H-55O>3JS 1$7<#41,DV1#!$_C#R#W2P'HV,:;A
MC-2"Y[Z$.+FLN;G!IF-2=0&PNL+KT+:AL[VHX_N'Q4"9%%V=OOAL%+F18A8O
M,C(:L-XR!0O2V:(+/V5DS7&YW7P$:-TG7+/_!XA0'J:3S70IP#=]QV<J_@,\
MMRM+/S:]I(SV)5+;@ZUH7<$3=X  Z?@*3H):[B?BII;:FJ#?K4ON)8S$9;+7
M07C> T*U-Z_B@+-U_=U$,81J':I)8]H'=_F8DR8S>M0WS2+3J1NC,2TO+[?J
M=0ZZ?!L(^T2UW"3]'XSJGR'Z)MN#<09!Z.A;SA&NL//!OR,UWB9:HS8!H'"8
ML_QQZ@Z/U6G/>/.=98$*2TJE@F [C46-S,C\^^:3S5+9A#>"_@_ ZNNS9[)E
MR=]T!Q;6L$ASX[/LAX5+<XQPC-.!2W[]@W^ X16N.TY"%6L0N&R!3=%W5V9#
M-B=,BJ33/UOIKI/*4Z*N7TI/L'YWRC:%!V9P'E7:3DU;6M)5DLB$L:-I_:UN
MW'<@A2GA*C\EWB1B'Y[OGG2?MIT03J5C;E0LAD97#44Z@U2?1.::&XY2,@EL
M::0^EH(<(S9['1R:WP3$/.WN;KLIE=NS^@%3+\CD#+QI/=E] =4IG-CA=)_L
M=3I??4XFH8P):MJ0D%3EW!0!$FH 9JZR_/XNX50)PR0;5R^^_@,8^,72]<PO
M8Z\"\,OPX/F]6"IJQ.JI9(>?<@<?55D4T#[\<(RTKNVQ85UG*25PW#YR6W(%
MF!XZQ;4#VFGO@%!WZJS? XV#LT].<#C&^CEUXK'/6,U*F!J]B@O=[:LZ=X-7
M&Y/1P:KEFWAIZ]PRU[KB8X'H9[=E48@%,U>PS0C1FJIQ6A]N<.Q^2K2JA,K"
M)N.T&#X ]#TLJSKIY*Q/!")BI(!"EM/]U" \G7[2JV>MD6!$$V&D0UJ'9J;6
MC,N%M** _IN=2U]Z'MI^[L P!#= 84CS:@ )O$]/Z<K'+V]+:B25[C2PM&S
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M:$:X#>P%"]=RF/#STWA24L89IU'"F I,CDE$G,$^CT+!Z&82)RUFNNII/78
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M15Z3,!]TJ,"?&D1))"E((:>0X4+4%)4"D'.0<CC=@0ZTX@+0XA2%&0H*!%I
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M#"\XYVCSY";;1Z;Q:RB.RT5^"RTUXJNMTMM(07%G_&LI">L_]Q)4.QX0 "8
M$F3 B3S/,X514K2DDD@ "3,#> 2=NG"!!OB]D]B3\AYZY!R/I@Y'?/"X2_.1
M!''8CSB!;K<6FV&)]H3DA!Y_V71+(JM=J%OT^G\P^7][2Y=(>DQ*F^Q9%SP;
MC73X$^'(C2:9+G^XB*S4V'%K@N.)D!E_H\-9]?7N<,JZD16M(94I2$I?9>*D
M$I60TM*]*5 @H*H/B!,&+&,0/I_[-.[Z5'_=E+]H^XXE&C\O19$"GQJ?6(:
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MY[W4K&$(F),US('V*@<70$!20?G4*0!RG+]1(\CW8PHPHT(S &!0,LI1H0,
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M4Z^%;)N_T35!D".Z&AQT3?\[&1_9( ZZUF!D<I'YLH%:'4?L'(JA@;1)$H9
MP.PA,*C5-Q&\8P[*A)_H9X_I&C96UC\S<(\92-N^DU&5@S%_9 -&[3XO !V
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M64;T?U>E ?Z'OOF[*N1R^M_W-&5E(06H$\(,BCI1BR$)'#8V%D(\7%PR CQ
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M./(<"A;C$>'\&_E?&GU$U9"6%<-!.GS\Y<3?ZOH_/TY 3D!.0$Y 3D!.0$Y
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MG>%H7RA[WE*$26#!-=1\I++= H^M=4$CWQ@CQF4)Q"O\BJ NOAU'20?=<6#
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M;+"MZ^YRFR@WC 7E[JL3F+.!F.N^ZF;K84AT4.*X=)&&S%W'I75YMU%%N_Q
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M>H.1S7N<ZKG]&^;BL&G.,F25\G8:+)YUYW,+1I6"^*7C.KF$*KD7V5_OK1T
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M-MI#&7Y^^@ASO$O Z,FRK1493CU9U:'=SI3,IC>^ \WOBT/Y*_$4>0$LV,]
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MR%.H.HEGP[9VVZWZU+;06L^S&L<WGQ<3VGTH=.N'(O*(GB_6I^EC9CV?!1\
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MW1!(=\??3(A_2(Y#^(5_[@??T-G1Z5?!V1^"H]A^LH]G#L[*]QAP&@_$ -@
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M04Y!3D%.04Y!3D%.04Y!_L,@1+^_H 'N#I-E\6&1ESL<!R@#L/Y-.G;R[_K
M^O[^OX?8UCA89#_>_]<"8 )@ ;!P<7Y_MQ\ 0("'3TB$A7L&!_OLD8(I*0"
M=_)V/1Q\_&,1 .O[R_^.O)$S@P@I*!6I#.RI63PNL H;7H^+%S&Z5]$TN,JF
M9 :I>C6U1D3#SJF<PB$J[AD<,B(!A:-]0I,KVX[\,F#]]EK!WU^ @77B%YN
M\$BL=A3C\6L%<?#.8.,!<''Q<(Y@ ;AD9YCQR$&*% ;V^)0L'M?CA.]5O%JE
M:F)5,AR86J-F$X$0H(-S+B@;&8?$BXJ9_/'%?.]FM(S^L)ER-ZCY/IVFNT47
M0YYOQW69UF>'&I]/KR?_RUD;D:BEF^U)\X/$EY6'%VD%+]9#WBB^.,C2]1H<
M8V-Y!;I ??9:4+&:1&>[-N-;E&<%)P.*9T3%MU3/G$ML=,WWR1*ZQ^ZK5W*G
ME+#84__V2 A;U8VG;CEBOA8;'^/T.@1FHR:MUQW]/EB)E)6_['I&Z$G&H<>T
MMK??L.3QA*$-)9UUT/B@6VSG_ 7V"9AOE4B3&5FK&=@8^VM2R2UCT<]^AG/.
MW2*2T^<F7)]WS#\8+"XN()T:;!L=XAT\)PONP^VB\BXS#GA\$"AB$+*XV9\<
M\'B\=KR?ZL/C-62X%P2R2*Q\^_P%3C)\W&X::G"8Q+LNE0>D:3@XV%J3RGSG
M+DP1:1LEZ)=A%5D^<KG;5>1\N?P<S7//Q>7&Q5%15CJWS7<(G*Q,B>5O)OIZ
M%Q#^<QFNM7OG4QF3Q8C.SUV^SAHY3L)UNY->L6]UU"HV<<ML4P\!JCQG\=RG
MG"O<G,R1Z&U4<.A< )O[ 45-<_^#E8WE6]QM:A+L9E(3-^?7%Z.\VFTREQ06
M8F07:P6YBZ+?SFC?1#M>OM$B;E7A55:FC3P3^7ZC1N5*9$7)$X)OYXHO=CN;
M:@TS?ACHY=9//C/%/$AX00449?IB7SZ[KQI':@*&K2"[*NPQNM&^:+! YM&;
M62I#)S'MR&/J:MPY'DC[R(K;H$S-F*[G\:VV$7>^I0!)8)<VS;PC++,R=YES
M\'8]M6GE\(W" (,8\:RP<-C-&OG T>6]CSP:3>T(QP<'$[,(<6E2@G[$%Z:P
MP OI*@W2M$JHY3OD'BY[J451.3>W>:0_QHQS>##2"U1:<,UU9(42O!IC5VLS
MI_/L.',A&!,5?P60QM*K0-LVTVBU<CWK^=;B[@QBVW3-NRT,W!178C\1FOC,
MOH$WFOW>M2&(!$7M].=#P.42P;,Z8Z]+5M#D@P]*EN'II;F&$SG0C.'14-R)
MAXE7>.Z\=D .?I6W;I370F=0U(Q_>>?N%@.Z3=#WC1S/)>'YI.!J&I$RCL$Z
M'G&CV3J'951QSQA%B6S!Z^4AKH:X!'[?&<8.*597BQ':VB^"Q94DB+ZI'!O&
M*NI>OR+OTK3B"-6H@[3^C>7UW:'U#!AI0%W0E;AXO/?>GU^:.HF)S:<;_O-6
ML3BMDU39Q_F"Z@FQ2-Q=T*,7[0E%6]EA7=T#KIXB!GIOTS3!*SRO$EVWK<QM
M'G<^4E3)89SE>OF YRYM6D:-[U1EJW%LG*R_/_'GQ9JO.R-\+C8<&9K2MTKS
M7?G<LLK'S^ZYZ_8+=-U3ZMX8(^(-#WU=?E5TVG7UB279:U9(3D#AL"/78&A0
M9:6I[C!E!G96,'?EC6NU-)U+PJ#;X!V&]@<6C3T-%I[! ]SR/LTDLDJW(8(R
M]R-H7[1-]XB.F(_-$Z'KA-2:-=33>QKJ^.?'6XK &?:LLHKGQ1W95=DI61F^
M/%^I^;:SXW^MWJL2/^)I^2B6>6S[RU4,+V>;06*=C#,LME:Z7/6YQ\5#P'E-
M4_8<IN%!/(Y*A?;TUK4S8<.;?B8B#AH"QB\4^@4_:S/N]-N'/'N>_5CWV_!Y
M_NF-="1UJ$D ,G9UZVJ(]ESDLKM[_./EL;L+'D_?M,K:&+?0B3.4R=U(,QA2
MP((%L]C092HE2_6DX5*!"U+R1=ZY6V_O'@("^_,\#=8<ZE29-<)3VE UR1_N
M:;EAXBIGM_6?0-J9X^9+>^]9SU@0,PK;$V+"RB5NJ4J+?+8V$5&@HG!_M=Y[
MP;JYZX97N]5M "T^D]7N#O2IE@VE[W[#0LH7;%M4M1C##7="]3"BV-?='_/6
M+=Q+7:EB:GREG'9XV$%<W4KE)<6U[GU2L^,B<0,$NU-&J6^,[:)F,9(',T^.
M0NM5[$X)?T<NE4.=HM]"U8.,_.ACN8T3SS^0DC0^RTDJ.<YSN0Q4SF.*C'F_
M6 M.-E)(,L-+#O?$@M@-R([#9^Z;FC0E.]+N^",/ 8Q9U6W?%G" &<C;XN-2
M./(/]%V,YZ_)"#\^/V$QL9:40\'09__5I9%(.S?C6:WT ZLT;8<[*_%W7)YT
M  :'P^,CPRQD@J=PLU1$$,8L*EAG\C/9+W(RI:1X1F#=!HU>FU26I#L$B*R7
MR,RTSG#VR\30.S8_DZMZ(? I_E5/0YM[6JBFY^PUM@<-DD/)MVA*-6&*WRBT
MC%];.-@P>$]WL2^W]5AVU;I/])EOT!P"&OP"GKVGUX^N897>W03L1-?%%BC7
M,J2^HSGK6C6D^(GHOFIITS/)O:(7\CW(]#=SL\(29",'=/'PYE*BU^\CX'.\
MGM5?3(O6NR5S"J-$MLD620<<P?#LD1O0?ND9MQI 1G;AA_/9.LLL&=0>9^(D
MLUM84\M?+SV(MO]([<I*Q,;'\,9T3GCIL66JGY6AZ=CRHA?U;72E<(4A27J+
MZ@-[]T2M4DH/+O4N*8>W>P=N6[LS-6M[!TC#C3]=0G]LQH)K)%VT%XA7G3/0
M-NRI/EAQKD)),\/P5*'K"0&O]LHF*_ **Z%.B/6Z^D=IFG7NXS/\B;$Z\+"J
M&"4.'C)#<.SGC&N6GQ<;D^R7TJ;#6_+QRV&A4A9$/CR6=QPE) <>Z?4M&X%&
M+K67N=2:\R4X><3#?'WO62T*, N4IY<ND/6:3=FV:HYF2V5D5HI#29:=WG7/
M-2X_[I>?O'\]+B1;N'ZK3^@\]WK?E;U6LR<E;:P"P@_6^/&5FS>+&8I3FO,^
M<TWM++NUM:),79JUVS>EWUZ_G\#C()=V5R2Y3'E\+I-?]T['FJEP7?#-KS<L
M#)+AF4I5BWM'M9C1BV:<+>X9R07)Y7GUN/$-?*C' T9!,YF ST"</<%HOAXG
M@S%T-1_/DQHEI0V1N-7/A -6^EH6FH:6-*+4&;)OXB,\=$MFUVZ;VL.91CG?
M&EI6/63I+;GV=;R(;G/Y)8;N2T[4%U:/(0SN3#_[8WR:#4 &[*!2,"+?)<>6
M6S)Z_D*S"^Q2IE3%W,6FN:@$<#?CN\^^=_CG)LSI1'>5<4WMYJ=&K]\S??F(
M\QSX"IW81_)RZ/M,=956Z8I>#<#GC//)^\:8_B)Y;9\WDQ!YRHE)ERQ1PS'\
M*,3H7D5,K39ZP&8X\?9=.Y[66^QVVH]2RM&5/C03V@=-./Q"R9($<45@-Q<=
MZ8\18KYF/3.Y5MV:;7HZ7]I(Q'<PRT$:O02 VWI*5PDGL(+\9QIUKO<18C](
MYEHS>0J/S.)A"SQ/1GJY;P,^E9-M=R>E,Y[5^]:=:4.2KFW:H3/6SV1DV(.?
MV,27T_6E>KG?-'4AT@+;@"6)ZZ+I^C>.LKYCE+CS.5CC.2ZTW*<_K4T8] [-
MT[ RK>K;OC._<L.YMC*2(]I[U*A5AZV45G-30#70O\.$EH[R3!WGQ:KVP<6.
MZ?3UZ#BM?D<Z,EL)%N%/=$UU6@P0R9C]ISZ3N72.*S7M##[]UFVO]U5]:1:B
M]I:C?*FG\+GA5(5C3*(>'+NBL8@Q$6#;C S4@CT"S_U#9/@WN"VI>BY>4ZFH
M.60:<M#2Z+FF3J N6]6-3G?VR\?B9#2G7;HJ7LS*ZULX5].+-@6WI5YAR@8-
M5USJ>=GE@4C=[8\R:(DI5):V[?CH>(\;3RPI(^D5/F:D-.WNV^+<#["1>!6&
M2,IW37N'@+HLZZH,9'33[H'E(6!D,VHA4@T&MXP/C6R3#-4:>9.][951Q?>(
MEQMJR4E!4M7)\U8GAK1MA:2<E?GM68,L+=]8K/5+;$[QHAJF5&IRL$_^WIT'
M/COSQ0&!TTUQ[^@N-KU>>W;Q]A7N\V$E-9T.8Q5[F-FDSUSZUN.6X\6;PZ![
MUT=8;YB$W?.H%A0:?AO0)2OMY">^EE-5^$ZV8N[=SN#&9C[>M\RJ\6X&GR7-
MK:UB8<XVZC%,[N &6#)/JP<7/BIFLN#1&\C\XG+>0F]4,1^,/! F7>I=56@Q
MT9,S'U_2J=Q1@5HO#ZP^KU4A!2&4[W^WLSN8?R6SGFQA<#$F]]KP:&\6QX2R
M^C#-:X^- .+H1_2NJ$KYF *'T!UIJ@J3S'=D*NUE3LD<;%&/V\8N-]M8)_68
M1Y.VL;U?7*X9H7SEI,-]/;-2O1M?<KVS;_\0P),1(.8QYMX[H:"[.B86 ;G[
M*;4-SZ4II>#>)SU'U]75V+>5ETAUS4QM[A'<'[0JHEK3G!WTS@#?CDZ['W>)
MC42F)8GN2UN@>[VC_(8Y[T#BWVY)$!$]8E^*L'L/[HA#B>959(UA> WW%VV"
MXQ3YPBTUXXI+;43TR:]-W%1]PPD:L 9B<RE?R$\"QF4P/G49HZ!'R6-?T@$1
MR##A)7G)!&[75 [/TAL*<<TL:--!<[I:)7S?2MXOB;W8GDMD0N:N,L$1+@X.
M?=T%B]?SS-CW']*:-L/U12J]W[N.Q$_MIFB'B9G7^5UK6]UT#?@X_3#%@8*W
MW6Q97*,>QI>K@NCK:(C"T//Z@"+!J%W9%J.!D$HUN4!/!5W/42:Y&09%_)KQ
M[9UAH[!5_%N?29@2!!@=&(8XA:5=/(3SKBD=C+#PO/CT;)Q#OD$D W>*];VK
M$!\-[ YTAX; H70LKN2Q"]LP54=X"\>->,U].=N'Q= P1KQ:MLXT0=KQ N%,
M6QJA>Y<A819LI!#JLH)2D]*7VL^*SU1?=C64^*I)RY? W@EW/N>H>,:R2QI*
MWT6V-Y2[@Q<H:!/RS:?HS..E:_L>41_5OC+L/>Z]5-*K'AR0Z=PFE7XP2CCN
M9B"\MBKYXHL(-]Y<<UKZT,Y]^ZG<K-T!\6Q/\T>$<_;0;&H5WFV1B[IB>(;Y
M%[ +)V#N,M^\Y9//F:*JK]%R\@C7^N.)T&L-@9X.)WURCZ7?2:@17>Z1T[J:
M0*O7+:PZ-1R>;)\(O.^&*SW(/J>G6J_?<@C@,!$N%EF.KLB804 ?=".3+&DF
MO)XCFT&;I<;>YT4O$8;QM$E<&W'G^A@N9="I >^@T=H(UHRXU*D$VQRW&A=1
MZ2J/>L_R?I8\]<:%A7<,_LC!P3+=@R? O57%_KG,)6G3_JDK@5TQ8[FQ'^(>
M9UBR)JWH\IF"]QZ9BI-8GETSX!A8%*W^&/P1DJ&A[,&-N%-AQB!MXA7-#4U+
M>I F;MC?-2W>)RNR7R,7^%0XH'__^FZ07)!Q43[*HZGK/)<446RH1V4,3^3^
MO?9M#8SN5@FK=(:'&V1;S%#6.G(^;INSO)2JVHILG&>V) G&V]'V1+^+^!#@
M'Y%R\;<%?E'DE2M7"B4(7MU_G\.G!E8:WHKG_]ABZ'S]\>424&Q<)/I>GVYX
M:BP%-EU1!.I;G6%I^W/?TL5#@&^MT2% @/\0L']E_=VU=SKUBUH!^!&-B,B;
M$KLSD8';MLJ-C=VOKR'Y;Y4O[.P&%.D%K9DU'@*<:HV.5GRZ)W;[C55Z"QL%
M&T^Y5QEY#@$#')2'@.[(0-OV0X">O]OFX,[ZCM'R[M6ZP/XR.9Q6VUV5%X$[
M'JC]=]^N?O,YB.8V#;9):$O?R2H#,=PNU#1Y\UQ<J6NJE+*$)R1YBA]8E,IO
M$B@OR,XNQYUJPA8%_:JKUN8RW)* QIB\N_K,7.Z:+^W.51>9O?Z-<GFK+T4C
M"D*4=SVX8\X I"(,F+7=GJTFYD##%=0]L,.C@ RXS>^TTO>=M8ZWAWMZUA7/
M1)Y+F;'-=1G24C! =P/*V@9U+8B(.IQK7^.>V2VS;#9/4CJW7$$9U!O.,E4'
MJ-""\J4&T5#2=N 423*!*\@#E%?/T-J4ORZE\!46 &.S#%ZPT=+"+B4I(=LB
MK'5RM?;FOJO.5:K(4AJ/ KGG0+OB>2_)1FKBFII[Y\ U^E#@K,E;W\QBOD3V
MX4]34LTQ3K]>TEQ$F8;=J2QSNG4CS156)P5I(Q*@JD]R*X@3>UI2X,+RR T/
M+TT5;N1]/\>%\L'"BD'(L\G&B82:X;==>XHHV^"IM>AUPR+-VXXM5M.' $B!
M<S5/_8P5NT&DQ1MG<UKA&@<3XGNL7;,/)FM-GG?$D3'U<W#J[!U -XN:@#-W
M\:4^X.OIQ/C[])=9TONT,85&?Z:]VL Y*Y=+89]2FM5N5C%8N.+PZI$Y;-33
M0LU?0"HQQ)R[8&"%"MTTXS4;-* 9$5:_=4.")Y65+J!QNORC+<4DTZ I%654
M_7L?;P3D7,Y%:5WQ:O)A&,*3NVGWXK=F(=YD-QN]1CZK8/VN).S.6H.2E[PA
M].E&^!T[/DO25WDGDJ9G@F6,@*V<3Z3)C-@F9)-S'O$JA$7YQB=%8GL(H[3.
M4G>6#LB!>X&F<DHO$K![P,*:@'K]]SP /06]#J;'_0-%NA<ED]^/RXP)4,K8
MXZN4PPA*6KO4T*&?*O0C*GHNZ9>>'66""5>'XCMIIID!U?GFDZP&=<:>(GR*
M*J6#\P7G#P']+].CO^TUM'>+*;W[VC?%J =:4X_X)%FRDM=XBY@*TFBUD,^%
M2:O-"#'*:6%<P[13CH47%'A(\&O;OE_J4]!AIR)XX>["K8^!RWSA?WNTCB<Y
M!( ,L20GW#U&"^+DK'6E/[J,JWX-0HV?/;OH%L#^#G1S<=^'9,PCE"LAS_["
M"%\%19* 81G(O_9 +2G@X4#X[%M:G6?>F3&=5H9YP#=*\%U$#-*PY. @RTL2
M^%$=I='QG+8/C=6N#UZ09'!YK[VFJAIYNV75%<609#8-VLNWO*+R(M)@->1L
MKR$GO=0-2]99E_UIT^UN^ES#)#_W$%V65J,&*8M%D&2D>*' UTHXK!!'.A[P
M2??* AU U[N/1,Y+?@U1:KPM4]C_XM5\1>G5X'-12QAI=CB/5TQIZ0O5.*_S
M=J5W&8U59M0%3'7-BQV,\ZZ=3;U@=6X^T\!D.S$_L=A_Z&9F#W$PY1B!4SUS
MQVTU^>P8'U[RB?=U:I=MA""[8H/!:;5\*DV<A80FPHY"J7D@XCQSP:.J<Q"'
MRA\/S+T2&.AQ"!B?VCX$8!7UWSU:FOE',8GL7!OZ>IXJ</$"D??G'<G'6TR'
M@&R2=_)K(_*""QO]"T9;^_(NQW5M,_RF7,B1PI?=6^-O&^?RY&J_!7H<U[3!
M@S54P5 @Q_;J44E;_<*X_RS=L/;(9?;B!<+]P$^3[[XU'Y6SD-W JL*]6PN-
M_0_F]!XL?C/)KAFH'?5+X"87\B,)3I3FT+TD]PE,8L%1SJ^[&BJBZ;*7^'&F
M*.V,!C8_=8P,>J7SB^H&.E4O_T A(%R^3#Z[!U)P"5++BR%:43'%&!OA\SS6
M^ #,>:]PQECU##4*8PC.:--A+:\(,\!.,\'%?9%WM3I/-,]OX!69R*M/+(XL
M,_F0S&"[3\+F"<XT7Q0B.FM5Z$5\XWN3<3/8XA>#P^_$P1*,Z^EO"G$;EX50
MS_#::=PL8##@NR?D>Y,]N,G@0<^->\OOB^ST6,A!GZXZ3Q'5S86)9(M"%>&*
MJ3E$3&E:C_SN:7/>LG- ]Y9<,+P_:3%740.LU"K BLU=0(#,=?<-6D&DG@DU
M25-TW:/Z5YRB\*E&!_J,XR'C4T(>Y /+:BWUV?**AP"FR>RF3=S=G:L\[Z:U
MJYY/PJLM[$$4#4SN-6:@]TUC%T=+O&["*5I[;.4*!6VD!J)X'A09H/4?N H"
M7X)7X_K&B"^%%F;<5S;8?_QMX<"Y=H.6=B=V00_\^')S%".6IY=;C'^T3_3E
M>GN .E>_-8_8A_$6=B5>;OD6KR^WO.O5A3U>GD>J4E,-)?BK#!KJ *@_OBV=
MJG/!E.=8&?M"&=0E;TK?.G?3?=[OILD<J>LCRBF3U+ &K4':*A\BI_A6!BZZ
M'3:[UA<?SFI8XDS?];*H3[@TQ(.:5$=F-=/LX\DI#Y2D!-BMGJ.?WEN;-&Y:
MR8"D$9BX]^NM8A=A[]8[(!5" Y>>2HC$%5O"QHWU;]OES)7URK+)9W0.3"IF
M]X.CZ&?H#@$D<M>4BU9,\C7Z,H#016VW>.&KD52C'\=XGA'.U,.3.9BE$8_4
M5'-]!%03[]3@9<(O4P^4A>HO\TQR-[:0ZZSF.P*,N,#D6&UCX_WYU][N%??-
M"8CZLD85:[^2>4,"B\Y[N^B[[4EI BFJ45L]/\^OXV+0+]>K4]Y%8%^\374;
MRE$/N&QO2UG:$28WZ\X<6U"P8(CC/0[QD:D_SQI1LV9^)V07U\0Q:FRWMT:J
M@'K@U5>QH2R%^% _?.6"D06.N^3!/G@'+_P?Z3&2[7NU)+21JL89C"6ZY/3J
MWDVK,[C^S-]_\R 0C&4PMW4(:"QX">5H]'&7D 2W5+5Z,MQ,ZRJ\3$LT9)(5
M;=#*83X,RI+:RR'GN_GUX]5@CBIV:\O!=J4>4)3[YC+6@)W3L*Q=K\3GEYO2
MGQ?&OQ1'G(T,/#]?EMYI!1$ZX/"A=DPD&K>TX@"QW1T="0M-28J*UJJ<]]
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M>>IO3N:P 'PWZ#[%JF4'5^O@O;H3\6C-M5CF')N%]0W(DE/&/5!XAUOE:UP
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MX(2S%2^SI&O*&DM=%Y\!YF+.5V:YW$&[L&QSYW'D<"08UJ;H$%N^U3J3>'U
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M;;=-7TE\%.(UYM_Q'(&Q[8/?L3M]:16))^-\9V( &<$>OEW W':J.+FFR@H
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M5MVX1\8KA+R#2XJ0R+:SXJNB;)N2Q0$^R="P3DRIE*Y-#2B)#HOV*RH'5;;
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MH"2K<# &M_LK<V%C%;Y\5K:$*2O5V5<[#J.8_A!\QO7ROQ#J:<3\3WNJF/\
MI\&L:D9%\4@B"*:8)SR,H"MX:GFE*DC(;!Z5A#X1_&#XFLB<6E4IF?\ 'F/,
M>8:O]KF:0O(%8O(R=IDNFUE255G*R[L"*/57-C;Q]<61>)(E2=2P'_-\@[ZI
MIW%$\^J+:7444,<DCQ9(Y7C<!N122<GF=0F"-BP/S[KQ7[$]+TW@NXUO0[V]
MU*^LK:&]"JZ30W5NSQ^\R1QID(J6[/<!D+96(]0<C9S$Y (*@F*"8%$XG$0
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MX;QT@Z<LB&.1 IAQ&H^X&Z=]-:7W614D6.9</ [J#);END@A<E%D& Z@-U)
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M@U>.IU'B<PY$@:A6(D'!6$/7(&UR<+#-D =+N' &&/8(*KBJJH(N55MA #
M<DU+D&H7B11K%"MQ-'&JY5516*+W)Z+D]=PW;%?>/"'O3\,\/RWUS)>7T^DV
M-Q=7,I4R2W$]M'+*Q*JJD<\A5< #E5>I!JI:K" KY7YL=MBAU#Y  #\MQWVW
MZ=?8-@U8#??? []MQMZ^>>V_G6VA0!U& #OG&>NXSVS^OIM)>K53S@3#R_N@
M =>7;??;W#KON/7\0W]M3GSZ>0[[]_W[=A5%Y N22!MU'Y  ;$_IOBKSL:'S
M(E,#?OT =@^7<0Z]-]MQ_MZZ]<N3WZ9/GDY.-_[_ 'K'/?QH3S'.-NY.<';[
M_P S7E35(!--0?)V, ;@.VX".VV_8/V=-MNFX]]05;MGIZ G89SCS\NO7O52
M&\CDZ$9(P?D=OU\C5@;56O**J'E[; ;<# '0.W3IL _[M1OZ]?S[_6L@CY^V
M.HR1W_MVJ,MLA@ JA1+MR@(E'8-]O?V[;_+_ ':';I@[?;S[XSOMYGH<YPD3
MY'8'Z;]>W_'>L_'_ $=;+EP1R!G'!SZ7<.Z3]FX>ZPD2Y='.E%31)%TQDEHU
M!0P@DF\:F0]4DB4A?-3*L<!,8!#?N";J1FN[5F)C54D16.>5LD' W !'7?RQ
M7RK_ /$;HUFEOHFMQ0JEX\\]G/*B@&6'PTDC$A W9&YN4D_A.!TK;"UT&OE.
MO-F)B+K\3)SLV^;1D/#,'<I*R+Q0$FK"/8(*.GCMPJ;H1%NW2454,/8I1V 1
MZ:]QQR32)%$C222.L<:*,L[N0JJH[DD@"H9E169B%5068GH% R2?0 9-8X)+
MQ=N!:.DUXS\J,@_%!4Z0OXVJ3;N,4$AA*)T7A6Y2J)FV$2' NQ@V$.^M[C]F
M7&<D:RC264,,A7FB5\$9_"6S6 ;BC14<H;P$@XRJ.1GYXQ6.#CC\9J"M=,F,
M8<*J<ZW6L+5>,GLHRS):&<,(UR047;2K1RP@](]<IBHD:66!,B""@'9B*VYD
M]_X-]DEU'>0ZAQ+X2Q0.LD>G1N)3,ZD%?'=<H(P<$H,DD$-MUU_6N+X3"]OI
MA9GD7#7!4J%5A@^&#@D]LYV[=ZUNIZ92B(R3FGZAU/3(JNEC',)E%UC;B4HG
M,(B91=8Y"<QAWYS\PCUWU] LRPQ? H5(DPBC8<HP%4 8V. H&, ;=MN>HK32
M 9)9V._4Y)!)).<8&2<G)R-]Z@_-S;^P23B3?K&467.;E*(B)$4^Z:*11'8B
M:11V  [["(B)C".L%([.S.V^3GT [@#RP/SK.(BQ*J@;@ #/4D;<Q/F<#/IY
M]*\7<?F/[QU&!Y=>OK7H#/3R(Q_I)QV[;Y]<4YA^?;_G^WK^.F.OK_U4[]!M
MG SM@8.=\;9.<8V!.>V*^B#A9JJFX;JG261.51-1,PE.0Y!W*8I@VV$!#N&W
M[M2"001L1T/<5&S*=AC!'IUV![GKZYR<U,_'MH-::^@Z6$OKV@@TD #<.=4A
M2\BX!L'1=,.;W % 4 .A0UFK>;Q8@3^-2%;[=<9VSC<@#H?/?"W$)BE(4D(V
M7!WZ9WZ=QD;=<8SCI5[\<VR+I%V@+3-5&#O<7#O07?U.R%7-#S#4Z9DE4%_2
MK(JIK%(H*K5<JFR+HJ2IB*%**8VVJV,NH6$UK!>36,LBYCNK<XDC=3S#J-U.
M,,-LKG&#\53:3I;S+(\,<R@?%'(,K@C (!_S+GF7_P!W4G.!F+QU0^#SB1J<
M+ T*KORWMW6[1]JZ:RC&$%?X-RY3,YA['51=R!&5G3B%B<S1-H<Q7*(&:JD,
M<!4#CU_><2Z)=7$E[<I';QW%M[G>//+<V$X3"S6]P44B#QEW?Q "K$$;[5>K
M;RQ>YRP-=:M%X-X+^T2&"&Z7G^*"6($YE,.,IRGE(')C<$SQK&#+1+XLB,29
M;S[;<Z4R DV24K4E'<?"-:;'1-:];7J=?JVFS+)W4K8R+9R,'&N#BKZ(4 67
MYQ#6DW5Y;#49-2LM'M]&FE3FAD02S+?L]P8YKFSN6)CLPQ) ED "ALD9%;%_
M5))+..UCNFO0H*7G.\:2Z4XMO%@AN+7_ -2ZD7&?!AYBP7E&3FO"F)&=X<X&
M.S;AJ";8VLAX$K63A$:W(P.,<ZU]N5<5I*2K/*)J';H50W_8KUTD@NZ\DS5Z
MF=%<ARI;2WU%KJUO)3?6MJTD\BBYCEO])* -X<5P2!>PRJ/\01E@N00000;2
MQXAN;:VM_>%:TN;Q%AL[[W.:.TU(L619IK4CFLGCD*A1( S@';!%64@N,+[<
MFDELZ8OJMJ:K C)PSN.C4(F:)*"(B\46E(ML*BYEVYTTSHN3J@0X<X'W$1#U
M:R6D=M!>6%QJO#\4Q\.W-WXE_;WD+9"&%$YDB(<$!?A8],' K WD%[)>W=GJ
M5OHW$TML/&N39A=/N[&Y0GQ1+(4C9PR8).753U;.:MNYL[3*J;6APB=[>R9A
MEXK&=<MUEAHNKU1Y,&.NYFGYF1S22\3 QZ3R2\IL@=R^38@T*!3' H7]YJNO
MZ?IEQJ=EI^C6FHW?(@EN&=;F]*.(49K>0(.9@?$,8P?J:M=%T3A'5>(++2==
MUCB*YT2Q:62XCL8HY(K%)(FN&2*6)B>3*>"+@KRJ#SG\(!D#,8<X<4,=A3&\
MUB7-UHF(1O\ E+RWD.24B;BVM0KF)'A3UCLS%K$'"E8-P@6T2B";$&OYY%01
M.*FCV' )G6XN>)K36&U.\F>X2YMH1+(Q(61I$D$I:$QR$", [ )N<;=;U?VU
M7=E<65KP+J&AV/#FDVJ6<6D7$A2T6(&2%8;R!HPMV+B$$W4CAB[N_P *C%2N
MMM:PJ_+1N"C)>%TLYP5D8U!V-ELJT(K*RXJL%'R4^,G%M8=15:LH*/UFRJA$
M7"S=LL8$E_.,52C'PN;_ $";4K[59+JWTZ>4BWU+QKAO&MI0(%DS_A\\AY%.
M/A^(<Q"YJ@_M#N-'XPCM=!T:#1K[6+:*)KK0/!L8Q;7]OS79MS\3K&B^)( Q
MYCR%T /*:PV<;/!9C&3XAG. L.G8TVK0SBLLR*J5EFHXD+.Z;MP<L"6I-)L+
M<"NI(L45DJW.GZEH*YEC% !UE[KAB;C7AU?Z@+71[+:X+Z=P_:+(8K97(D6[
M5E?D=&)D0#/PC;()JMPQ[4U]E'%4E]8'4N*M6"36"0ZUQMJCVXEO613'+I+I
M+")(YU BE9P0&++\+ UE\XNN$WAGP]PMTU*"Q?48QQC!F2$K;,JD8PEY5Q,Q
MR)Y%1V]] L_ML\*L.D\:MG*Y06-ZP2*))F "X/@6VMK747T^"RMIH9+=\%M+
MM]1GQ;!BABBFQ@OSDR8.6(7/2KKVF<0\0ZS;IKEYK^J6UT;Y#+X?$-]HMD!>
M,@=9IK1BBI%X2K!E0J*7898X.N$_J$,WNJZLFUDE&;UN#Q5LW8,X58BZPG23
M(W:E44;I-RB0O8X&.;FV !UJ/&FC\.:=QNDFOV&NWEOJVE>\+9Z;IT.CS+>1
M2B"(V]K"9>:W%M;2-,R*&:8E\8#5]+^R/B_CS6O8U)!P3K7!FDWW"W$ON4NK
M<0:_=\5VLNCW-O)?7"WVHW@M##?MJ6HVZ6JR2&..SC2)&YG13E*X7N/?)/#3
MBP<35&@0%RK,1+2LO5?M5-2+"1AT["]<3,Q$J#%-G::[-:>=R<FR5$04(>17
M;&*"2"0:P-UK.E6%_8:9H^FZEI.E3&WA2;B%I%:!Y;AEN;EF6)6>T@5T<\JL
MXY9!C'+FXD]G&N<46&N\6\5\3:'Q!Q-!'>75Q8\!0VTL=]%9:;'_ $ZRACDN
MFCCU.\:UE@7Q)%BDYH&)4^)BN,[>)+Q 7^(K\558JHT%JDA(*6ULQ1/;&EC5
M5.@BUC'2$\T22&#!J9SZMFHB8\@=;E.*::!/,N^,)H](LK6?3.(]#U626X,,
M]M8BXDD5#'(XE<3QHO@ H(WW+%Y% &,FL1['N$H.(M;U:UXGX'XST&W@L5N=
M.U+67LK. 3K<0Q^#&]C/+)[ZRRF:-MHTB@E/-SD"OUB[BJX<^(E>LX!XJN'K
M$U7:VQ!W!&RI5X:*J[%C83-C&@WZ@LFC-U7P?N2 U**;M6/:R3A@"PG:BN<F
MKV6MZ=JACL=1L;>$RJ4,H5%3Q-^7!&&3FQMN0&QO@@UT'B3V<\7\%)=\4<(<
M3:M?1V4B3C3I9IY[CW7FQ.'#N\5UX*E2PY.=HN=E', #@KXKL:SF!,GY<X>&
M]L>R])JUY*\:-TI$'4-*H*Q*,I5IY9!,ZK()@M:GVK5^\; F<ZXN43'.@4A=
M:IJ<,VGW-UIR2LUL)E<+S JP90\;8'^8*P4XQG!SM7>.#[ZTXLT/1.+I+"*'
M5;BPD@FF\+DFC=96ANX@Q <P//"SQHW,%!4C<[W!\(C+UQQ)QYX?A*[-+-JY
ME.<2H-NAA=&)%33*9!1NU57;\_DK/8YV9-W'*  JE63 I1Y5#E-?<+74L&K0
M1JQ$=P?"D0D\K9!Y21TRO4'?IC-:?[9]$LM3X'U:YGA5KG2X_?;28(#+$T1#
M. V,B.1.9)-\$;G>M]777:^"ZHG(N1Z3B:G35_R)86%6J->;"ZEIJ24,1LU2
MW I V(4ZBJJIQ!-%%(AU%3B!2%$1U=65E=ZC<Q6=E ]Q<SMRQ0QC+,?3.  .
MI)( JE//%;1/-/(L<2#+.QP /6L?"OC!<"R:KA+\I$XH#<#F\Y*FSIT5^3?H
MW/Y >:)]ON  !S;AVWUNX]EW&A"G^E <V-C<0AAD _$.;(QG>L&>*=$&?_-]
M,_\ Y;]MO*L./B%^+$ZXB(%[AW [6:JV,9 W)9[/(E/'6"X-2CN$:BS*8%HJ
M&4, "Z(L8'3L !(Y2)#N/6.!/9:=&N$U?73%/>P_%;6B8EA@?/\ ZKMNKR $
M<HZ+N>O34=?XJ]]B:SL Z0O_ .I,?A>1=_A4=0I[]STZ=<#%UL9*M7W+\H%%
MT?\ R9B3V]0H'*4VP]>1,H"<P_0 ]]=CN)?"C9AD$X49VR2#@G'TP /6M/MX
MO%D5=\;LP'^D;$>O-@@[CR\JA>]>.GZZKQVL==RLH*BJJ@\QS'$1W'J(@ =0
MY0#H4   Z;:P>2Q+$Y))SN3OV'EL-JS:A5&!@+C  QTQG/GC8_L,5TMQZAN/
M^_\ QO[_ .[48&<XWKUD9 '?'8XP>@&^QQ].NV=J;CWW^NIH"-OV.^!G;'3;
ML?EBO1B91]#OVT@P7,@Y;* <ABB.Q@#;F3.'8Z9P#E.0>@@/SZZE69&#KD,"
M.F>F>_IYUY=$965L8)R<[[G_ (.*F]6IQ&Q0<?+H@!0=H@*B8;B*2Y#&372$
M=A_06(8F^VQB@!@Z&#6>B<2QHZC=AN"01S#9AY['Y'OU%8&5#%(\9P.7H=\@
M;,N^_F,_/KL!5WL8V:H5BUM'U[J3>YU)P*#6<C0-Y,NA'ED63Q=U .5%T&R$
MJ";,R"(O-VQB+G*J)2CN.-UBRN[NU/N5T;2ZA69HF8L()&>)T"SA!S<B\W."
M#D%?+./(6.16A=Y8HY'BYI8 #<(B2*Y$?/A?BQRG.^^V2=\TM2P_PFY_@+N7
M#L9^392%RD3*]8RS#OT&V1<,H1<&I*/:]=:1)NTWWV;B98@H0JT0D^<N'3="
M2**:Z35NXXW=:EQ%I<EG_4I/?7ETPZ7=:1,LCZ?K+2SB%9K2]3FC,\T1YYB[
M(L>.3)!8C+VY6TN-166W<Z9)J;ZC::RL\(N=*MUMA.\%S:,5E6&"5&2W2-7>
M3#M@$(M2YFL0Y(R)!8V'/^6G?$&WQ[;Z7,4E@BO'*5"_GM+*S6.(LF48 6C%
M[43-(V68UM"7?*(MAC#)N1; IY:I]7CN--M;B]_INFKI#7EI>PW@?G66P>VE
M@@DATR?++>MS1/,T2#/BY3.-JOM0U/5IT@9;M;N*WU#2YK P/&XU*WO+6:X4
MZK$P5M.A9FCC65\#PV#'&U>+D:;O^ "3LS@M2P8WI2 1$WGS#,4B>2IL.+Q:
M/@U+EABUS*3F'70<KS,86RUA%4R,L"*DBR*DNW=E4MU&GF%+K5HH-79F>VT:
M[:18+V:1F)AM=2MHV61')C80S,%$7. Y(935>;4KV_CEL;6XN-!NK2+WW5TC
M@>YL? C0+,UC=%'CFC_Q4=XXPYD*$*/Q&K-ON)BJVN'9,\EX6:R]E( -W-\@
M)$8O(9DFCYW(Q*OI&WI*XNNV2,FV<F()2.&R:A4UN?80R:>\6=PUMI4NIQ7>
M$DDT"XM?%TZ)9?"AG=KMBSM N><,K$<S 8WK3Y1;7MHMUK5KI$MIF6%.([6\
M\+59W@\:YM8Q9((T$[*OA,C*I903S8&1]V&9<>HST6KB"KW)IFBVSJZ1,N7M
MPQG(JAQ9VAT)NS_ F1W<E+S\4U34^#LS.@24?"CYH)HHB XCBMN)+J/_ ,-:
M7>Z.YD!CN+2U!M_<HXQXID=IN16YPZ\B(&+,06R"2-J]G4? EG=/QAQ/8:\+
M>T_\W9RSHER=8NW)ACLXVA\1H0"KM+-(ZA40A!S  W,HO#MB2VVF%J#Z_P!:
M6M:,A(7F R<#*4A,_25O8BZDHZ?<62:!XR%V]?)<KIDJP/$^AW8HE*DF0=:W
M?<$:=9:(+B*PU>#4H9+=;C5H[@ 00.^_XI$$S.AE?,1+$$-\*9V& 1U)WO3O
M;-Q)J/$LD%QJ/#]SH%S%=QV_"UQISQ6YL?"D6UM D@7#*JKS2@\S/ERQ8U5/
M"[@/%-DG.(/(V1:^^?2\(NXE'MY7L9BR,-*(()-)"'9-V4<W;I-Y=2.,^E'K
M=NH#M950A$DDP !]GA>+@[4K/4=*OYK_ %76^5&-[;1D^[R)&"R%F(R3CK@[
M^M4M0]J6H^TSAV7AS6],M-'X9X4B:2.WTNYE13=QR2NHG!7XQ&I94*A@H&>I
MS6.1M6GF7.)!O1JM6YIPKENY,JZJD@TC))& J+94@2LT:50.+I%-M%%66)(R
M;9$WG*)IFYCE NK#VG\(6=S[KJM[>:A)J4CP6<4"6=O#;B('FF9WC=F^'!Y9
M"",X VK?_P#X>_:KJ>AZ??Z%I]CHUOHMA:W^KS7\NJ7=S>RWO+R6,,-NR"'+
MN55H$*GE!9L]I4<87"GBNGS;3ARPWDR7HL-%TU,;E3V!H^P2\HM/IB]&4F4)
M5%,Q5GS<Y'956!%"!S$.;RE * ;+P9;I<\//HZS>%;6Z268C1+0N898V!YC)
M\9<\Y/.R]QO@9'*/:!KNH0\:CC.]T[^H:AJ%S%JBWDKWB0)=VTXY4B\+E1(D
M= O@I* %&-LD&]\*@OP;X9QY 5?BLB8B$P;AB'<6''<;6W[ZRSKJP.4S-)UY
M48:)7<3<K)+K!Z<RKQ!V1 BBBA3H[K!K.E6V@Z7#=6#:+JNK2Z9+)'(]HZLW
MANY,*R1QJ5\7'0ACS#!QC%;AQ)J/&/&FHVFN'6M!X?3BMH9;5]1+Q0QS0P@7
M/@7-RP86J."6#( &)CYLUD6HO%U'9DQ#6LE</-?D<Q$<O#PEG9%;GKLS69=D
MU0.Z;SL#(BB_8.UE5#&*W,40(GRJ;F(JF8<;I$.F:I<7*W5]_2$B9@([F&7Q
M4D#D&"5"O-')&,<P<#/;RJMQ7:\0\*I91+IBZU-<PQS)<6-Q%):7-LZ*8[VU
MGC9HYX)SS<CQDJ,$-@[5X_#OAA7',UGCB%M<Y;Z39,U23N4F:QD&Q(.JM0O0
MR<VX9O8[U#T6C1@NXEQ.D58[44(M&/C?Y-JF;6,O-*L=*U&_DLM3:_AN!'(9
MV+)"C<I8A$DP%",Y4GIL!T K8HN+M5XIT#AK2]0X=M]+FT836T<-K$#?WJ,Z
MH&G>)2TCR1Q*P&&;G9G(!;%:_O"SPK9[XC^)6QX@RM6Y&-H>(\F.+9E'*H-_
M-C[FNA-#-QK6IV 0!&>/<U$T5_BS!5PBTBW+A[SBX%N13F-AH=Y>:S(UT&\&
MWN#--/U$S!RZ!'VYA(0#E20%.3N17USQ5[1^'M X%MI-$9#J6K:.FFV.FLWQ
M64;0>[W$EU!UA-H"R^'(%+S +@J":V-N(/-^$HC[*<.-UMT]#3'$]!VO'%+D
MJ@W>.W" R+ M8=/4)^.$R40^:N)E!-@\!05$'Q054\@B)E2[_=W5JABLI9'1
M[]9883&&)V3#$.N0A ;X2>]?+7#^AZW.E]Q)8V=O/;\*S66I7\=V\:K@3":)
M&MY2&G1S$?$C (,9P<YQ5S^'K"T=P]XCJN)8JR6"VLJP,P<D_9W1W<N]5FYR
M2GG(*G.JL*35LXDU6D<T*J=-E'H-6B9A31+JM9VJV=M%;*\DBQ @/*Q9VRQ8
MEF.YW.!Y# Z"L=Q%K<O$6LWNLS6UK9R7KQLUM9QB*WB$<,<*A$4 998PSM@%
MW+,=R:B?Q@^&9@7B\F4+G+B_Q]DI20B59V_59NW6E+/#Q4<E$I0\VU>G](Y!
M&.;,VS!^4I'+)-HFF03IF$ Z'POQ_KG"T;VMLZW5B8Y1'9W!;PH996Y_&B*_
M$IYRS,N>5BQ)WK1]5X?L=599)5,4X9"TT8'.Z)MR-G8@K\(.,@;=,U [Q _#
M6X6<(<(^4,FXSITO$W2HH5)>+DE["]>D*FO<*_&R1G#=4/+7%Q&.GB9^;8 .
MIY@  AK<>">/^)]5XHTJPU#4#-:74\B2Q>&J@@PRLH4C=0'"G;L,5A-<X>TN
MTTN[N(+<K-#&I0\Y./C4=#UV)S^5:PJ@CR*;=# 0PA[]0 =MOQ /V;[Z^F#G
MKUV[#&"1D=.^X.>]<S&!CS/YKD=<^@./3UQ4!YHZIIB5,J(BH:2>F/OU'G%R
MJ)M]_?<1WUK[_C?;!YF)\\Y.<^OG6?0 HF_^4#. ,@KT _<=>G6O+$?<1_:.
MO-5?X.^U-*C.Y!QL,_3?]/YBFE, ['?'Z_3&_P#/*JGJ)E$K+!'1$05^(M]A
M#]( $=C;?_#S?LWU4@)\9 !OS#'J,X/V[[YQOM5&;>.3?8*01UZ'OG?<=QOD
M;$U.?<!#?H'MUZ_L]N_?;IK/8(.-SWVV^O?ITSO6$&,9)&=P3MOOT[=JS1>%
M&]X:<EUW-'"=G^/B".\P/XB6J,P^].QD7+B/8H,CPL%.'(9:-E&RS<)!F1-0
M@.3.5TB%.<3@;B_M2BU[3[S2.)]'DFY-.CDAN%3F=(^9V<231 @/$ZMR.2"-
M@21VW/A5]/N8;S2[Q4Y[A@R$[%L*!RHV_*P(RH!!W(&XK:7Q!BNKX2QM4<5T
MPTH:KTJ(;PL,,U(K2LGZ)L @F#I^OLJX4 !VYC &P;     &OG/4M0N-5OKG
M4+KP_>+N5II?"01Q\[')Y4&RBND6UO':P1V\7-X<2A%YF+-@>;'<FKDZL:KU
MK.\9V_\ UK\WC_\ C]>Z?_L>L=?V!OT_MTI49@#M[AL)1_#Y_0>@ /?^C2E;
M-7!WM_U5.'?;_0YCW]_V8C=_Z=]*?S]JOS89N.K4!-V*75!"*@8F0F))<0W!
M%A&M%GCM00]P(@BH80^FO+L$5G/15+'Y*"3^0JK!#)<3101#FDGECBC7S>1@
MBCZL0*_FVWJZQ>4LS98R;#0XP,/D7)U]O47!G,!U8>.M]LEK$PC5%"!RF48M
MY%-N<2;$YTC<FQ-M<+O9EN+RZG5.1)IY)47;X5D<N ?,C.#T]-J_3/AW3YM+
MT31=,GE\>;3M+L+.6<9Y99+6U6)Y-]P',?-DY.",C-7CI;0@BEN7OL ".W3L
M&W7W#H'[M6VX4#&,^@R!M\/RVW^>U;"QVZ>F#@=N^V=ADY.Q[ =*F-1HM$_I
MRB'<"CMT]QZ?B !MT'M\]>U .>A&>^^PZ;$>60#GZ5A=0D*+@;=,;G.^#\CG
MS]/+K+JLU!!VW*4J1#'Y0$PF#?V[ (]OP[=OH&JZH20< #&V=QOYX.?7[[=J
MU&XNBC;]QU^7IWQW)_*J0N];0;$5 I0 Q1. @ ; .P#U'N'<! 1#]_OKPRD#
M!  !Y>W7KV/7R[=.M7EI<$\I7R!&.I&>I..@WV_8U#B]QZ905^X&X<W;?J !
M[_AT]_GMJBPP3C'G\NW3IOMG;]SM]M(60$'?'D?GZDGKY]:A]<6Y0.<=NFY@
M#;IMOOO[B ![#OT[:\MV/GV^N/L,;>0\\5>MNO7;'UR>N!Y#&V-NPWS5Q.!;
MBER)PB<2<=?L94(^4;#/P4U3$J 15X16?/*@BY3% &)3N%';(62JJ!$RB E.
MJ(AK,Z'J,^GWH>"$W#2(T7@C8N3@C&.I^';Y^=<T]I/"VG<5\/26>I:@NEP6
MUQ%>&_94(MQ'E2&YR%"R<ZJ23V'IC>"X*<_Y-XD\)1^2<L87F<&6MS,2T<I3
MYDZQE%6;%P*3:4:E=%*[(V=D#F*5P4I]P$0#EVUUC3KJ:\MEFGMGM9"Q'AOU
MP.C#N ?7>OAGB[0].X?UB33],U>'6K5(HW%W"  &=<M&W*2I93_I/IZF4DY"
M1-EAI:NST>VE8.=C7L1,1CPGFM)",D6ZC1\R<I[ASH.6RRB*I=P$2''80'8=
M9.*62"6.:%VCEB=9(Y%.&1T8,K*>Q5@"/45JKHKJR. RN"K*>A4C!!]"-C6)
M</!9X2SY8G;XNG8QI<LQ.DQQ2U=$95^#D5C)&6?,91,32AT0\L_IF"IA1;@L
M<I3& I1UTG_\5^*AID-@L\8N(GRVHD%KB6,9Y8W0_!MG=^K>0K63PEI+74EP
MT;&-QM;@XC1N[*1OO_IZ#Y5A"\63ABQ5PMYUH%3P_#O(*LV+$S"QR#1[(KR1
MCSIKA;8M=PFLOL=,IH^/CT_*#[H&3$_<XZ[)[+.(M4XCTK49]5N/>9[:_P#"
MC?E"XB-M"X7E48/QLQ)\CZ5IG%>FVFFW-M'9Q^$DD!=@22"QDD'4G;X0, ;9
MZUADR^94M*<@D(B4[]@1<0[BF"AC]?;E\TJ6P=M]M='O=H,C(',NV<CE/-D[
MC89 W\^^XK7K(9G&<;J_7;? _7/TWQO41.81'??6'(SUK,# (\@,D_3&X/0Y
M/0>8KC2IVSD;EC\CT[=QYD]=^^U-*; 8)SD;#?)V ^?R';Z;-*G&^_;\/GN-
M\X\\'KZXQ4B<%F4Y[ 0-_)$K,1#L'F@*X%[=AY.?8?EO\@UD=/R?%V[(0.N^
M=_0[&L;?XPF_G@Y/0C()V\USCS-2$,7<#;;;F*(;#ORC^.W78>P[==NW760)
MR"#W!W[[Y_N<^M60 4Y&W3([8!R>OIMZ5LZ8[K_"WQ(8^X;.)5C%HQ)N'B@L
M*MEE&B2KNOWV-G(2,9144DYAH1-):7;/W3=9^W>K' IBO!366.!U2Z^:KH\0
MZ%?Z]PZ\CM)K5^;G3!>1QS6$T4DS2N_BS$B(JI565?\ 2=NE;CJ=Q:3V=AJI
M11I=G9R0ZLUL\B:C&Y41Q+ L6"Q=R3S9 !().Q%3.AI2$J=4AKU-8[3813:9
M2_(1'6UF_;V7[2-8\QOCV1+.B(F(Q>LW"A2R,H!A;[@V+]X%-]?FBFNKJ:RA
MU$R3/$?ZY):O&]M[L\G_ *&G6S8S)$X&8HL<Y'-G!!K%P36UA96^I7&DB*".
MX3_PU%>1R)>&[2(DW6JWBC_TY(W/+-/^#'+@[D^%F"/K6,\66M$(B]GFLM5%
MY8YR?:S*]WIM9=JF66<LHEZ_2<I,&;A5<S87#3R56S=0I4_Y/I3MFN-5N-Q8
M7$&E2-:PZ>T:V%[J*<H51(L94NY !PQ(+;GK56[%IHMH2#J-I<:U$E[/JJ3G
M4=/TR0R<[&)Y58)$&;\<8!5,!3TS@Y0Y%&C--8PHHIJ)I*L$W"R>QR$Y2 *Q
M@$IS)!]PYP%/8Y0%QS[],K9\VFPW@DR;:.0R7'#<TG_G;%693#+8O\3/(A/,
M%0$D X [8:_*ZK-8,I"W<T7A6W%4"$:?J;HC">#4UPJQQL,HS/R[XYBQ.US\
M-MU7^6L=,R6,U5>.; X:ISZ#E('<*4L-*KI.3*O068@!TTCM@4,'IS Z4**9
MAVWHWC(ICU220\0VK21PQZ9J_BPW]E),_P +10KR/+C'XP#L >IVN;%2PETB
M.-.%[U(Y99=5T$PSZ=J$5O&3R7%PWB10 YYE#%=V(QM61;(UYB5^'V-KF1:3
M5Y8K.TH0[ZZ,G\<RG9=:/9 X8R$B6";).# ^,Y=E6#F*T5\D#E+N&VLKIUE(
MO$+W-A?74):U:>.SD@FD@B$CE9(HUG8@B/E4@X+ G>L+JFI02<+16FIZ=9S&
M.]6WEU!)(8[F8PH&CEE]V16/B"1PW1&Y0<9&U+R<4XH^5:E6&.7K'C)VM3HB
M9:S$X_CYMC3)69A!?-V9WZK-Q)'CU%5TVY6X*@N"#LP(F3; *874,J7VD7ET
M^CVVJ(+V:%X8(IX'NX890C2B-7$*R*%+99<<R?%E@#5E+ VG:S8V<6NW6CR'
M3[>=;BXFBN8M/GN+8RK&7:-IC'S,JA>;F"R$+A,UAZXBLU-J]E2Q51++JU:S
M+3KR]A+?9V5?DIB91G(EX*"Z\?*G5,B=9%TB( L1 WF%. )E)RE$NM\2\:<'
MZIIAX:T[B!=%N)I8K.1(;9Y9XAS)BVB50!'*TBK$S98$,RG/,<]H]G'LB]I&
MAZI;<?:WP >+M'M[.?6(?>[Y+6RN T$C"^NY69FGMT@>281_"055P5\,59:T
MMLCO+C&2-MR#D3(C68D6LE+R=I=6>/;>K6="FY.HU7=N4VN[3G$[UFV3%%-5
M4B1-P$H\LO/9_J.@\1\/3+<ZUJ6FWEV(]0N9DN;.*#FR%1Y;1BX61%8D*H&5
M"NP#YKZ;T+VV<+<7^S[CJR72>#N&N(=(TAYN']/LVTW4;F\6,('FA@U.)(F>
MWE=%#/(Y D:2-&:!LWV5J"L9:(N*C8H&LP$.C8#-V4M)3CDL8O&-)^/EES/T
M ,T8'B7:+M-T4#("DX*=4R9RD*.VZOI$4'%7"\W"ITV36M/N+JYO8I]6E65M
M-B2%)[>1KX.(A.D\D:XPRO(^%V)'*N&.,Y=0]FGM&M_:3_6H>#]=L[#2M'N[
M/ANTDM4XCGN+N2TOH8])$#7$ME<:?;SN&+1LD$8+$&,&\=?B%YI1PY8-@%XB
M1%F=)P_,]!8#+-G!3I++)D;D]*W7=BF  8JBRW*J(%3 -83VGZS8:GJ_#VF\
M6:9_34@$UW+>Z1?0:DXL9X[F(P(L/*G.]Y;V[.'/,L4>5 #BLY[ ^&M:X=X9
MXVU_V;:^VNSWK6FF6^E<2Z7>Z+$^KV<UE<^]NUUEQ%!I5[?QV[1KX<MS,4F)
M$0 FMPL\'$;Q'R%U-;;B>K1=-<$B#0D66-7L\G).XYE()R@HF$"H5MFE(-DR
M/2)F]?*$<L.<I&S@!TB?AW@V_P#!FX>O=3FA59H[M+V)(9!*/":%X\,S%"'E
M#9PI(4#?..B2^U+VL<,>+:\8Z)H$%W.;2YTZYTZ>6ZMVM^>[2[@F8*L8FYHH
M#&H)=49W8;I6/7B\PFPP5EBU8K:VZ-O2,"SB7BDXQ;@V4:+RQ7BGV?FVY1,@
MA/L6C=G(OTV9C-2-Y=@4NRP+$+SW6M.32[TV\5P)E5%?FV#1Y8_X;@; @8)
MSA2/6OIGV<<57'&/#L6K7>FOI[--) (W//%<K$$S<6Y8<Q@9VDB!89+QR;8P
M3%G""^.F_$IAZ2S6=L]QU^4BJGO+FP++NV PA9-HBZ<3*JIEEUXULU(3U:9_
M,#T2(H@4$R@4/&ERP-J=HUZ>:$S)XK2$LHSLI9CDX!"\P.V!Y=<KQM;ZDG!>
MO6_#B/%J T^X%E'9HL<G.P+.L 4 +*XY@I3!YR6!!WJK?$0SK@2K<?M3S5P=
MQ<&:/QPM2IV0<5MD>)K%CR- S#Y\[<PZ*!$B&;G8GB(]P[:((HJN$%4DTN9
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MB=/J!B@_F%FZ*A@Z!RJD,J!!#?H!O;70^"(0$O9L;EHT#>F"Q'W/\Z5\F?\
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MY1F@WD7A]^5>5F+).**$9MQ$YMW2:"14T2;%Z+&EIH^G@-R106\0\1L <[8
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M"RD6:296S*,<',W<(F!2.<* KR#T7AF^MK:$:7,C6MXCDLLNWC,?]).X(&
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M\4>T<:<!4*8G2V^.:/5I=>QN(A&;7EG\].BS48,7$DY*1LT.TBV[E\+)N1J
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MFI!YB ?EU\N^//\ 7H,'>A4#/\Z]L],=_3 )SM38.@;#U$H]>O[![[; 'O\
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M1*[5.9-8"'5OEURWT@V]]I]U#-I5\[&[X;B,BBTDD@*RL#(&3FYT5E=0 #R
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MOAH3;1R,HMP&/BB4ID/T93L"2#6PW'#=W8Z9-?79"E1$8X4/,1SL 3+D#EY
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M,PHMU(#]4!//BR3G:6]JJ3"5YCC-)0Y'R%&$E?6=K'>31U9WHLX2E<K:\6,
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M<;5Q^_!5Q8S[QSZ3O*YN\$QTBFG\()QE2V]^]IJ3(W,#;Z_;>K3#SJ#S(9.
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M>94E\G81W"OJ6K79\T 5(W;AV.WWG5TEQA<[QQ?:>V_]B$0.F5LE>9%GM9?
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M"F,Q[N3.._,9$<;<$I=W([U'U[''%NY1D;,7FW7Q3/@E<[ ^E8W$YS\#]KM
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M?')OI;1N)>Z@X1!P#,#%%\+J+XE[:@=1@5#"5)NGBE]#T2>?*=+<?:L@H&X
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MC*9ET-*P%1LJ-]8L/<3BJ&K?"*$91)A7Z,9*4QBEH$"<?V<#4BQ1INHJ X?
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M[(A[AN _2'#CW(V%%@<64,L94!T'6P!K</D)PR2@MMX9IUU*%-+:_F"-G0
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MR%+KFG7])US[_QJ.!U^4RNL\?GA.Z)]ER1R;GU(2D/?3=A:@.CI@3I0?@>5
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M:*@9^<<C&VJ@79X?7EPSJ9R1@ Z"#4D&J1E";#,OCAW;MV?$N48(.?+2#;"
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M1WLR1@_=.DCY^2A3!VWZ2]Q73ZR-6+8"6CE)"BZ)(992#1U-OFN#K6&T4KA
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MT?#9)US7:J,:UM4;[5:SD1%P'3G=FTL?'M8W-CM<K?R=QTY-AXI9]'225<*
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M58\0(+N1:;B_]2Z&Q24-XGZV!7&H/:TW<6Z;JP<,.M"-GJ;UQ]ERN7'35FJ
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M]:"!PZZ!57C^6CQ%&2WUX":0&C>2YUYZ>7GYAW8 "Q,W43)KRJLY)7*I0VD
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M7/,<4\9<F 5+5*.P]D^6(ZKH![V!::FK1A7"OUW'SP1PO"41#I3 *BJYUF3
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M\/ 5 !#\^)#/ * %8!R,':P"B.4=$':0BXK: ,R#-0#I<0O@<./([F 2< M
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M!Z_'JFK7]I3EO#Y#&Y9DERA#@4V35M$6PAS1D74DI?;$26'I2][7VRJ'JPX
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M2PFO+^.R(Q?V\%@GP\+:^=G',9_3RY,? %RN1!GY7".)-#'&UC%UWY]YTWH
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MNWUXCO/ LR?(55.N05M3#]GC33?TQD1*0I.L8,<N#V)D"$D3?Z^H7WF*_&;
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MN->$=.OP7.TRP1EQ/.WR62.=?MF;ZNGF!^T*U =^@_#&Z<P^!<L,F!CE<*&
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M@. [=4EHULI:-0[#B*2#BIN ';(:DVSV$C"HY*MXR8X^O:.9R6"SL40\%E!
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M/6SW(@C<<9<65J&MC%6CP"Z7'HQ')T87HQ-7U4D"4\-)'6&.F6I2GI9HY*9
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M240@SBE=,1>^AW^2595JJ&CK":B>IIS4=T2"FDJ(TBD #3D3QA(XRB5'$Q=
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M5=E0$$XFP^$UKV'Z3'$>0GER\NK(Y:IE>.-Y64H,P"3:..X%V[41<R" 0O6
M-[@:G2U352-MK"N2I]"'OJYV0ST3C",&$F@V?5C ^246$[<L<:7:,>0W&"A-
M-I(<>:SY>F)@*>L .M8WM8GS$\K^7E?LU2QD'49GZF2A2Q(7GU@.9%KCG;D;
M7TS4:AG<DC:L5O,AZF- 9/E*KS(:BUQK'"D)ER-Y1"G77R=(ULNVX>,>3KK#
MX>&.F*WOBMRN)Y#FOZI\X^3LTXDG(!WY-F!DW)^W,<^3?[0Y_+J(T[7C$^U7
M RG1!R/*H(FXRL6P0; 9.D%0:G/0JNJUD'@KVF -K(3*XCKWG-XR9!5SR3!"
MD(0**<(LY2V2XQO:]AC=@OZMQF;X\P>3<U %L@G$<:RWQD+SH"06<O93(W,N
M<L!B7[1<IR8DR>"CT@6 0,:H54<8$Z!J +!7U$, ;(3>7<9D)!&)K&.<+(3-
MO 9#KI/#O/+M')KM+MG:01!V*HL0191R([#V=HN;'R7U699223))<@JQ+M<@
MVNI-^8-A<'D;"XY:XWGZ)O8]*?B!!O8XZW&YC3^KAMB=*O&2Q11$Z?W-F+5?
M&0T:K=(=9,8TU9,(M8L1&$><=3+'JY8@VMSQYJ/)V<R /E/G.L^.P+W?#,J6
MN;<2P8@\_A656)_V0?(-9P!"A50 !*TRA:*JAG@6" +@PX%HY6V,DP@0#PQQ
MAPD[:ZYGC'TCCFVUQF3&V<8ZR%46   '(  "P\PMV?NU L[$EF9BW,DDDL1V
M$D]MOEO;7&"JM66BQB+JY7P H<$9B&"3KA18M2RAV!>8X8!XXH\$FAB'$9UU
MQB8H4<F3RIH(]]<!5'(*H [  .5R"?)Y2 ?G /DUDR2$DEW)-KDLQ)L"!<D^
M12P'F!('(G4=22<97 LHM,%5G#-+&0 ?GU.%ANFCM4&7!@!\!8<;%9\8!C\M
M# BHQ]F<)V#28IM"]9)(J8V)*X$BX/(7&5R0;BXRYL0>T&_,&^K'6HB #\5
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MRPL%E0HS D V-PKM&>PGL=&7YQYK$R%BS"4B[&'R[1#Z3!P;;1P$$[XE/,A
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MLUIK';BNX70S)N59!^X!1>X5MT3U9+5=*0Q[BX>3&2-JEK*:M)]U"FN%F;M
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M$)SFN5ZLNN+U_%"I.Z,%:O8#*SQAQ.@JS U*XJI!=G/:6\PET-+\79*C0/9
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MF>1SBS@0QO/2RB!&>.(B,) Z! I"JP!)!*BQ"O@_7A^KHV3DA2!;'0CD':^
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M.\;)LX=%HU6377$?Y H8EU6[6?_P E-NRPOSK.33VR69N"MI/&#,4"^LA<?
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ML=)^?M':[OAMTHAWTQNTD>YBX,O";2VW9.@V<4ZU$Y-\QJ2NQX33P9D^ ,6
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M+6;V_Y)4UD&P"<$PZ5GTWR=K2/LNP;"0G E!W\^_;]<F!,__1>SE_T]UT#L
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M>UF><]T.$KV=KJRUF8RIUL".45%1<#HYW$L'2) &0+E,"".1 :2I  "J!!]
MBQ7M$WKN"FU?VZIP=OF5/A#O$B$QTXN$++8=MQDRQ:2LX%0N:TF&6>,Q+Z]Q
MT5R\<H#OP#5VYT)JSH)S=#!_6)/NFMQR_(;+7[=.MYJ0[A7 _X)?Z;8_]89*
M'C+WF:(Q 6;-DAZ.P\,0=0Z@^U9VAAET[9?<QJZ[X=]\9HK[4WLK@[A-75Z[
M=+#UH_JI! U>W%G+.GS 5VSLP$#\@*6C\D)\D V+%2.QYC0GH?.C?^HGDODK
M.^5&M!0",^WVKBWZ8+EJ7$'2+3E3&BKG'X+RION3]9=SFN5@6N7$,4+0J,R
MYFD)8EE_<9]&@G>$TTE=8Q0.:T@?FVF"NF5&GW(0P:$'B9;U@3[IU(=TCFTA
MKK^+_ZDP>U:3,$%GOBTRC=PIRSAG)'RMEJKC#G1.9*9]LM.   2<-O,%*^\I
M-0>@)CEY-!BC=QW55'VFT8#8S-ZCJ<IMVNYF1%%U*&4(EA-9+5 L-63AZRBQ
MN91.)I1/ GR[<6FX3T?&C=4^<!FE6)=7:TBTSRS=+BPV.U?BD\N2!IJH_[)$
M&X:Q]8LQ1N3J:)DS+K\M^9!(H2\8WG0>$X3/9JR\SS!C$9UV$1G?AL4,\2_9
M2 OTVM)-+U\/9@08 1VIH@C,TL4G/Y-9(.. J28UH45 9*AVXS(W<3XK&U%)
M9;I:RR1LS!(ZVHV! ^&4#3J<I7SGP_J(R..C/_8W5E#0:J'2_$IB<?CE)D]Y
M_J"-=PY%<+CEL&/U!I!]A0=FD9>SA/8XV'XL&'X9BHI1;[!KCJ*.WIOE "=G
M%>F"\G$E<(BAF53PL6PU*GV^5@V!O_A4?*;#7D+J7J$_:F-KMG4WR7;"5.[.
M(W;8#;3OU?+_VZV(7/ -GREZRZ:,K;AV3MD6<0/6HVOZBM+4D7"5.BC&NXQ-
MR L_$_J&+%SKDR&D7\/!,EK3K9OTGY&%4'MJXB#Q[=+%*A-&WRYGAD>AU+)I
M;2;5DZK6L)[3M(ULYG^5@3Y@2HSI^+X<]TBHIS\B-N=F;Z[:'R08QKI&;-SZ
M<R#R3!6<I)(E1@E"N<!>1C820$3F#"V)S3<IZA52%@D.T.)EU13I6L<2+0I
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M*?5@[)N8$G1]\6]7#4B ^H,#=T$T^6NL1)WKQ#J#4=W<WJXO>\U3I[3LZ:Q
MFC"D, !J)0W2&"-.!A[$OP8@ ;V<A1%THU/)6AB=XO$712/+_#V!4+ ),C4
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M+OD/P/_SJ=?O<^4_0,V?XW\ I6IYN?T]Q]NM:AV[N?^ ;3]^O^WY\FGH?JM
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M"LWM28WO'$E[;12NH7S!OJA UZ9]WGF:*T_R-$:DUMO&7BP'IR:R;<X+(5^
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MXZL<QFK?"*F$HE:F'?TYK:XE4+M?FMXXGB21K\5U@)=H3D<CG').L%!=!S;
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M'I*ZZP%RS4/J9M>Q22764?%2XQ#HTS4\G][?^5-W^E@:<D=7!^(9J]M@#YK
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M7:2S #%-RE38:E1GJZ+D0OQ'$N@"I647QQOX<@Q3=_ YI#JT$/!<%]  +S&
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MWO1 >FLCN=O^VK-^[\26\#QH6.MT6%KK:1F(X)0,>%%M3?V/D[_F3271^Q>
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M$E)$9373+1T9;?.2H=ZE87_@DAZEK+LR_KM-EX$MP(YF)PQ'SS%2THWMHS_
M1M[,SKEH-E*EX-N74=9+6ZK:NRJ\U3N2OP!WK "OBU'!#4$YIW'AH9>OD+^
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MJ3Y"+<5T-:E3==SG8G"5< -4_OI:S3+FJI:U="V:Q#?R6XZWQD*<X>;2R,+
M$^F8;A:2R1D#@-9IN.HLI3H<WB:.^6>.-<DS=97R(PIC-RY_B3=UK3D.2^:N
MKF[?V^]4@DQPN9BDK_@:^BMO,BCP&B6X@2QV\CBN/A4X1'9#=/WN9M+F"4Q\
MTP<KIDE)$O7:-RPQ;!BE39$D*NG\487C*^GB>$&I \G.)3DCOUUE[UQE-YST
M]+2GT<?A4\=TO67((W0-JW,Q/;P1R*-_?;6ALNG$F*]_S%MY33=5K-1\9Y?T
M3<JHID DIK/HZ*E,E:U_<+J"X#;S0>9@DQJ=.XODQ_3 SC.\D!1].OI)/&VB
MROJW0E9'8H%$>EYTM,-N5KDX;%*9Z==]2NIUA,I ;^^6QP=Y(-/8<;8TH#3&
M&K_GBC9W!C60 Y-UQK>9ATLGKS-G.=#MVI-8Q+?/0[ TUKX3&8/BA^SI>RD3
MHG8;72Z_*=@0'+&^8(T^9L>67U*4-]%5A(J!O9"&JIDNX2/C!G/JHW!+,C\V
MLXK?'69-BD&\LZ9RBVP!K:%+##I?E=$6?A\SZD)T;(% 0Z-*2=D$_D%$0F/)
MSVYXU^>Y.QZC'K/5[G[.((Z95ERD%E[.<#IN5\^C\./:63>88Q>[1%RF@(.U
M,^T\S8HZG->=N,]<;V_%^X\HEC6-PH@BZ([%,YU8:R.W)2)VY-4&R>,YK(V=
M[)G@-4SDP;IM*1N\<+*#$R0.-L8#E2NJ56E6MH32KBH:! )O]!3KPJOICMP6
MV-4UQ\X606G7+23-H*YS:LVVQQV).X_& RF/A)6>0$XBVR4]75<.A'?)9-!6
M2F+PZ%&-+6]4\H1O%! WGD.BZ[>!G)6(R3AS!792-$2/G&@T^8@)("E3VN*P
MQ:,O%O"D8U<FO\U6LHE![[T+80R3/I".0<PBZK1@EF@<[!TW=EN7<6Q_%T,H
MV?SM@,-)-/F'>9R$M1QSRQ=*V[KX>GO"U1IEUV^M/8>_RGG:DU0],+E*DN<.
M0*],485''DU\U8+73-ZW?FPW0]A*@\,?<#W;V1^CC<[.*XJCF-*9/"I!4=GO
M)%P9$\<<$@T7QO2X"$RE + 53)OT/KJ3C0YI:O'J-M%BWI?LRW$M,H]R6@RK
MQ"\;IMR<E8[CO5*6R'.!@N@&RX!<X1^)F#K?<B4:#'P-X&VU_,J_W:S&2-C1
M9C%B#7)=%O,,Q@ J+GB)B44-6.O$8LW.86*1VJJDM%)H,EH,T4H[]%$\-4/2
MZ/3)1W@AH*$/V^4(]Y'P"][+4!S%K87Y.%G%R9IT?N/DI==Z8I\# XO1'*P,
M>P>&?,?#"TOKUAGC')ZE,!^8=8IO&.KRH("SF73-&$]).DCYIG(EV260."9&
M A(MU"F6YF+*,=$H7==8<AP6H8M!0ET[H)D6BC=+BK$9&+=ALO3HNO$ZP($2
MWG^4D1;65G('YXT5?JJF8TON:@0>?ZBZ,ASF5/QT5LUV..VH3/"=2 +L:DH<
M7]R 7Z5_15Y#7EI6Q398:L-$65J>"F-57 5V\[)1F8:ENW-[8. +-C/Y[)!A
MNC.$<M!K.5AH/5PPUAS(LU4=D^&FZ7 FB *JO%,I0E[[*1/>#Z3KW;!(!9DZ
MK"$'_0BTO6(+Y=KQF[WR'Z3./^^F_Y*V]=@O5Y4O-X%_(9B9:NBO4YNK]1,>
MO7&X.8<C-(1_8J:*FF]J)(F2KWK3..;F=I(PB<?Q"3;&+#AYP/OH0*=CRZM$
MM (R$E*PG[0Y,/^2SC5 923A-AP\5?3MCW[)AQ:RUMKIJA=OYO@7CRO+MA8]
MXM:_@$2VN2/)^_+1X*M#3O?T?KL2O4HY]MVQM<YS((?1+&/;.);T,#VQ:'(I
M,%L>A,PTF/2&63-5$UMBSE?86B\H1["J/0%-(*]&(W(X5!S&W1'" V#F"M%]
M9?)'0$*E2DEO>I/9'GV4RTAUT4_>&&^%Q9;!SJN&1>4O/"RU5-3I/*Y"Q& H
M\=@S,^C*YJVZ].2CQ*.\FL(U2PP.;#<-@4 YM8,2.^9Y$BRIM)VJ+"9G98*9
MJJ:0G8D3N-9)B)RS2A(C79#.FP-%YR'$&DR(D?F1 X$/Z'54@\K5?L2B8UKT
MC*=?-%U*O325Z.DJ")9,XO7/_FGD6;6ZAWK )JHT<$NO.U7#Q4GI;PMG<^61
M=!6]U@;X23%(:!;VOFMIA<V;M#A7QN\,E:5A*!WY")F3 HZ6K()V?[;C-9(P
M^>?WD<4ZYXAEZ1K&@.PL!&JI+")F:9 M;S<[?+NPL(P:UG$;)><PT07JM>N3
M$@G_ASXQ]0\"!A=MP6?E9<>M+!I?ILZ*X(>+"6$F%T777#7ER[I%)$;I<V<F
MU,WO88AEI+I-/@FV'IAS]:&&NCI*O4XAYYP9-NOTQ7E-J]J<NLIEO J"8K(U
MK,F*/\.4?&T=?9AX70GRPV]J?B(+$:V8]C[[XL*A3OV978WF8<NGK&.XC_QM
M0)FAI_<%(M-X&QLP Q]+0]WO%^QQ5I=;5:#[!&CS+OY.>I#6-$9OX"NI6V/-
M%&*RH?)-J4 AU=(9T5FI [\"DP]K:X9X[W*[3FF@(J(?FU^5@-2D9=3.ES$+
M*C/^^VM<N4YM3;0Y]T"/PLP#EUK9LLK[C2^)#^P9_N%)N%<V?4;X[([KV9TQ
M^R3:PT<*>!_;=J9.XC+&/D]*8XX\\38?L+VMV9=%;1?6-2-J,T9'-(W#;*$>
M/H"L4OL%Q35L$Q5R->L]O(QW2,7ZFJH<?!/$PJDWK >?*%EFBK*_VB:-%+.,
MN*CIX7^$<S10 $5PQ*R[]0Y1675NIMR)C[@VVNB8D\_2,.ZTU109K7>\!S?O
M*GO*AGP_3SQ)B>8R^93+2UWA=%*B@.[=5+<J8O/('.8Q-TVGG9SY9G58,,\O
MRKN/W*,6@HR2V= :ND+<%,_(LL!0 8G\R*,PXF-DY!7-T7;( AMG92+SY[7%
M\NB*+OGVZ8C]*4#N1>G%@B^;AUZH5NP:_\K;Q3-\N0,F!/9M-](G8SMZ0M T
MN.19+]^)&'$!E%/SC>L1K%>'A!7PB1"S.E560#='85P8#4*8NCD$WI>]<10&
MJUYJR2.[R3O5M92\-?++[O/8?%P35+A=FU]XT'21BK.?IG<1R+Z/&>;.;&V;
MJ#0!N9KNO3=#V*U3VELI?;;:^BK<&^JA?3M91'5+JJ^:!QZ3IAE3N96V%K.@
MC6=!((MADPU"G:T'RA.83*,$[A.7FGE+U-65)IVQ=-''F'C7TU%T^U#+W3(;
M3UI1JX&#,7IAC<D)#&17$MI;<PFPC2D[G^'=7P =MSV6.@E;KW9:8%C [WHZ
M+)-K?LQMP$D\U="V[D=QE!YQ >D*)%W=4._2P50!^7H]<0X@X2VMTRPM';]<
MNH]M*L<S79(X_<[PIC63W$#KS$%><I&"1NI"@X.?VL-#=!Q<@#(K4 4\<:Q7
M8!JG6+A1V>AD)FS&>2TT0N/D7)6.[+BK==[*ZT^SW@.Q,ZOF"J8/4_U:6M9I
MQ@G6_V)5IVH="E1QYDI)75G2VF2;U3#8$H!_CBV,Y-6C@VH _4DQN[+2=1FB
MG<DW>4F.IG1CR*'JLE$=BJ'I0$8>*T3GC9^#I KNLLH^TH.:!BR3E&)5V7(X
M3L&;LPH^19.3SRXTP[+=]@G@P- CS@9]WM/$4&W]KE]^^)PV1,[=(^][8@CX
MXS21AQR/L@,\LP3,3-E5=8?I2MT'J<<3Z6Y[>(@FB>D\+T! 3:=#-+&M@*ON
MZ%HJ"1\^N;0S.J%P2,IH'++)&KU.5U5*D$P;VW#:IZO SHNQW+XP)XZFU;J$
M%]K1+<D3\65X%>KET=XI/6AU NXS=E]1.L4?F<,K*WDLH Q3,1/44]JU^NSQ
MJ2PONTR*/D.D6_14(&*SN$(#J:80 4B52I]$/$Y;I49?7Q@7<B@NX8"?RWJH
MP9,'W=C9W=*"JOHZD!DTV. U-Q@NO]_O+N$-=*]Z*YG+E(3X"@L/C'D(5G9Z
M*[L^?;(2#@M%:N-Q2*ED_<RAC]F74I/\S4,$E$<<EX<-[G*Q#*L:X2CE,X3$
M)VST>9("A!CC;<SHKGJ DW7>YCX:UAC+-:7D7Z5PQXH4;\J).+2K$)!#1QB2
M_BS2=26AIB(,2]R2N*1O,:Y11/CJ!854#9I\V:8 U<2< UHK28>ZXVXM4]?
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MOG1.G7KU%(C9F\A37V>#98Q^LXJ3\+5/B8;/>JLF(8;A@,[K3BK9UJ'#@$)
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M%&WR2I%_;F9:II[F;J'9PO-5OL1[ CH/[:/BCFC4T50;-RB 0[:[@(!BE)S
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MQ'K>/\_6T@L+/&CA5L!2=M\1BK)T2H>)&UQW\!:ENO-:# I)HUJG)F%K1_3
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M5*C!"[IM;TPD5[/F2!1U%PED7QG(@?4*S5^^,$_N5O;W6LCHMFY^UK<EN3F
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M/] 'T1S<4GM&WXMKV"I4Z52E0%(I><>%$X0)4S>Q""U/<G)L:<I1 K)I$HY
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MS 8UZZJ^NLUM>EZL<;L"Z.?R#-@%%;WE\]WI:/,\CY6J.KG'V?0)*BNH7#J
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M#U.A#F"-D *5P6G1[<*CVGN)U#0G>/*.PA<)Y2J68:9C<>"!IK9Q4$D!:($
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ME\W?%3A@V-QU;9BXYF1'%X)<],/]8$WU0^.Y:>')U*E-:WS83;E;,>P N*0
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MKXV/:S?EKDI*7QV50E?NHT9?ICIO;7WSSLO'.H[?[;?U'P#X5?W^'\#]DS^
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M##WK#O'4K),-\VCY>9&Z%/A;02XR=;'DAVS@.NKK5BK"[W[3\?LV2]G5CY!
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M>" KE5GW0%JU-O@TO%?4WQSW2>XK2E?4?W$7)G;C/'+U4LB"Y6WK5$WWGXN
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M7:\OAV-5N@O#+))(#:/%&9+#&N%0E3)K7SH/PU3?&S!D'\1ERE0Y.TZ8.W4
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MM3WB6!B5G>%XKP&TD5HFJV *3V]!">BV7Y,NB:@V@9B6_0P7(4,MI"DM$Q>
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M7* 9)T)&>CD8X>[?*_C$^W2FJCY, G0BD-/(W;_W\?YL?OEKBV=H_6.[D;1
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M$*B_SR+17[]E54[3+>M(,C&$\OZ[^6M2"^\!]RP_-0&8^S:S]$3VD>S -'8
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M7+A3!.S\0#QV*Y$6.V$[#I(K-J=P!P"AOJ+LCF!HK9W9S>T(F58(3!%+2&-
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M9$QFXW[()@CO=3%3S\? V8$CEW$"3*C1@D=:BPDCM'X>W1!ZI<0%YB!$CTQ
M@R5P+2+^@;/WT"&'3I3I1%\I5\_PJLT=%U2SJ,N(UE""M8/LLAABB*1.!M*D
M'+(M\N;?"4LX["W],CB>C@65V 6!"""G4)9*^.4:&!-NT"Y"N&@Y6S+_'FHL
M4<5K6DL<DZ&N)A+V3'CEM(R&-OU9LJN4O3L_JY/>'?T:S6I=+")G [&AKRP]
MCC$66<,M4;$7; $XU$HR,G$BJAWD?$[FJV!3*XH[^HC-0$=SK+XIA:/R*52M
M(9:D5M@27]C]FTBXZRB  !9'J.JX$*6V?FH"3?K;.M= O))L<-  O9]21D8,
M ?\L-/4VUWN/M;W;6;-0M$-3Y_.))YF1/Q(R.Z4!8<_:MQ"D#'K5' 'XV?YB
M,.DH3G%_0Y^>H4D9HXK:#BU!'6OD#+^[MI4'FCQD3 .%L9H29S1AGV M>Y6'
M?XL EV0WDS:U-([6M;\ZL=Q5$K#Y99[ V+K2R &XV."R*@XX3O9<C++5/^E+
M&&=U8(P@L_88$J9WYSR-O8O$NP>UJL(9,I@ N*HY0LAM!M^.PSN<V;"KH[([
MJ'-PF;'M-WC6 X%F(JBD'[HJ[P-LDBM1B.ROJ"5['A11TAEV4[14YW"ST8/;
M/>PK3B1<6B3DDW/07V4.9!BA1@4?H%=S AF69OM(]NJ9M.Z>!N;\6]SKD6M>
M<5Z,THA&4FN!Y0*3, =BUG#ZXKE@\([V":@=<_JUI2FTZM02Q&;@E<GJDI>"
MPYFRY]$-.O5T]BD_PNZ*I@S5-0-&YZWF4_#262S"*RE-B"Q#96.G<0NGVT>"
M^7&N@YVPH=(.W0.!EG"2B2"RO<*H%%:Y4MV[8"'T-9P7&<&2%*%X*&ULIBQV
MM)[N6;)> !%D 9/6D8/I5B1UNP04JNNY>?IW] Z*_1+E!%MX4U69P\:BYI*L
M>K&*#FM/1?&DAX<@"%"S5#'6G#M1-,EZ;_65"DMY8R#26#UP?RCIO:LBX]Z\
MVCDUQ@DX3 ?Q6K H5#. NQQ-3(*/\6^7'G,LB05\\[!XB?$,Z S(F(-6Z@IF
M9U;/(;^'G[TO[**4V6$@>P;@*#A?OP@6D@IJ[KB ,F *O'!2D\9ZL/*B;/YH
M16[&<N;QZ856S_<5YF/S+IU37'G)=CFA+HT7M$ZU",VCP'>G.8_$[=H"!V)=
MCOB8R>^K5^F;W<D>K\ZR12.2,*>*.;I/0V]1K;A^[&<J<FB.KJ/=V$QWL2T:
M+SK^:\:]_47T;?IZ/*.7+H+.>-:5QYN$/4QLDB8URLN2(B;\:74VXT^]62?T
MQGS<DV[!Q@WI$L82,B=%K(R;>\J](=]>*/ERM+I;*90DL766!8H^Q+J.^519
MVK/,S09S5W#'TH!ID;98&E(&42WN.:YJ/K_/=J;@B_8VR?<I6E=Q[Y+Y+"<K
MMHSH(Z*IFX"F&4E25FZ7"9;7@LZP9LHDR'[_L+F]\_Y 4#V&W5UMMP77TJE\
MU\:[%Q_$_#6C\R/@0-%T S2?]W9'NR5;9W91UESP "ZV?4%C .&SV6B>^S/@
M[;?]RXX9W>]^0BPL1>8=!!^R")(*,Q$!LB";J==1'KG%NO+-,B*]UL8=]TPK
MOJ9?3M,^.A[:0$GU64*-,HUK\RH5*@CI^(R%42UD"C%H?!7V+-*HK#')72Y2
M? +NC!YZ(.MZ;F7Q*N(O+O/QD=A(BQQ$[J6ZZ=P8<Y^2*%Q:5QS1^5V5B?%W
MQI(LMFN^1Q;F*]+,?A5GI"!-+LY&-*O@K%LSU)TOI+!QDP7;1NTZ8TBX$ 0#
MO5)8N9?RLGO.CF?8SNH\P_>#!9,=5[!'-5^/T27K,=$%=L6][AK8^)'"J0'K
MAV3J[<D;!]6\'-VY<#^\>PSXGSO5JM^+;L3OF?][AO>/=Q]'TZ]:G@%>KX1M
MKP-F[^/^=;_4[.4SH&Y[PRJ7+WYTZL>OK7_]%_7IQYM/SEUJ69]V+N^N[)GB
MR&)X2OG&?\Z2]_C"Z%%3ZD)<U:V^1.%&HL#%4_)T#Z6H?)'$\-T1^JIZ,R+V
M#-"9 +V5I9OI'"50N%*D32B/#&QJXJJ'DZ!+7D)N+,P,KDRSHF(B'V.LA[O*
M>R,^]LEX_ %PLBQODR,-P-C".-/ODD&'JKS#HDW'R2PQ.$.2A C?'5BDYJ)D
M^"N7W<\7VV:T_J)##*<*$':O*]%R#WG+'I84G-&MK4D64_'*+HK@:GM:PA[7
M>P?U)7?UU,JW"B20!!F)\8C<Z<&NAN.%WAV>LH]C[=W-?$O'7Q=E54%?EY=V
MZ<(KW0ZI@KW9N]U,#3<5YR3D6EE*?[595;//+@;E=,>*U#/KI[]M)7.-__P4
M\J8;Q "TV:()UT WMXX+VKM(DO6@,)'L8@*VB2RYT>I)TLI36TI2<TV&*9BA
MB;)#U>APHWE>G9O&?=+&K>VL/O&+T]'F+XNW[3[[:$?X(;Z51<I^682E)L=Y
M2-3,9WE#Z3;!,N-0T*K3Q-4*(ZZ8@=TS S*8  =8(- ,'61LQ:8X*UC>B>;V
M8=I'5)+/2-ZM)XOK5)E!Q7"!IX\V -QVOYY3*\Y.-IO'P!990@>O96(3WS8,
M^RLLW/;0-EEQ)%6>X\N4P&P+VR#JZZL\JW+U>SKSK?(AM:;N&*BD8*A?(O5"
M#Z[!R>?B#*$4]\]#ALP'-/4-*"@J4?S4TBTQ,4W )[+LVQ'?G]%!^)WQ^#1"
MID-,,V;PN]7[O.VQ"0V5"(OU]?5C+L[V,.^.>9^"Q:Z6%)96 RZEL!,/IK1X
MNP8];5V09P6CO)[&4HA^8'54"X25O-#8?%$+L9&),\$B"9IKSB+=A=2!]A:-
M)(550$?:#:$^"<[<!*DA]N:3<&=&D30#RW2.2C1M4Y%';@J2F7"_=$(E.F6K
M3I/3N.".@OO*X-BBLQ9B#Q]+)4*NX*('WQ!)K5L ^8+=VY'I.,Z%5P+Q[1,H
M\*-."P,&@WISB_G'(,MF;'M>E]6<^+C4W]^L:(56<01&6&\>I+%:9:%4&QD"
M['M\/Q/D,SE8&S.OO*:S;.GYTPZ==K2\O5F87=E,=)DV&IW02YR@GYSVLI4,
M:_#A?7].+P2"OGJ6+28**1*DMG'8S>(KS83A=^'+;,W%Z,%GS<OJ/MA':I+;
M:O!J,(!F&E?3U,R1CXQUAC/9,XPB4>U9XFF2'(UF:@V+H7D"L#4:T!#&D$:K
M7:.^&K.VE@6&,DSBE26\1':]/FFP=GU$DA"1)^O9Y1LZ1T0"PC-&RR.H@)(%
M]4<#96!?$1'Z73_QN8+^5_Q\J9G!JB*PDU8'OH7&"(JH(D>>11 QW0JG[P#G
MP#8G<052HWWR^&?'KU:(;TT!(V;PU]R!*M6HNBE59I8.",S:PR[HYBD_8D0$
MML^82UP97U;05RG]H-74=8EYA0U?AKK]18NEL4RC&*/JIGFD#211 ^7JBL&8
MRE#GS<+-Y,UWHV>'5=!$T<4"F6E08-1P* A,1#I:"AB^D^#LM>RCS!_,!VFH
M8"9O.MNT$2F,6-BDBP\Q2S+I#3XA^8D(F_&"B,@VVNN<()6]U6!VY;DP,<M>
MJ(T3F_11<HSU!W#X.*-.N+) TCSF_#DSY ,]^[[SNVX*FV#->9Z!BLV41.I&
MI6,JVIHD'M=X('%CXN)4J5O<1(=]H(-CLFMYJCI>GD!@>*<IRXAKCC!YXEQ@
M#GTP)S$'EB@*O1.]]TDR%$%Y-/4[?W:/1P#I\CKX^+HZK2F]_MMIC4LF.G)3
MN@'-2!GQ5C4@W6R6Q]B<P*(><ZYZ?PTO?:*]")V453ARJ7&5[-J2'U9A BIT
M*L%K0\S3C7_'R,$+3111)Z7=&QHMKRW8)*?>WZL>ES#A0LC=;E&;]*:-9# F
M]S*?5Z19LO?HARB.5L2O=-38;0PQS?EJ>'C$G32R)>>XMEO5HMH,9>,K3=*K
M,SNB1ZT!H2C5/*-5T1OA'\CUJ=@)@+1Q)I.*]"F4UCD;KI45'5O(32[D4)[8
M:Z5P?EL2#<[2#ADT>-;$,:?&3YOJHZ0+)_/=O2TYA%GZU,A#?:GOG=^U/Z2?
MY7PN-VJ#TY YPA<A7$_R,C;S5OG:+9C(QNQF1&\+&B8WA;BZY1%U (^4KJ!]
M0D!7;)&5!:KK^7??<[J=0TU&Z!%P%B^;+V>3%\S8JX@MVVEIG-"N%HCB_>QV
M^^[2,XYRHCQT1TYA60O%-4WD,!"Z?;8&LXX[02,Q:6_(\)TML,[>1= ".=5T
MOT_+\OWIBGKK@0?QX1ZN2J,@!X/@TBX^HHZ4@D+_,1L,?7E\]WINOS9P[K4B
MHDJ#E%&NPG!^'&MW 0)HH;-#Q^$7D:@V@&^\Q5-1O2<UI+I-.2T!.G)@43M?
ML)"TTJ;<="7//-^1=Z&TO/S%W-H:Z7<B6A/1G98N1V7F+HG"RW/U\-K8Y.(O
M<D^]+-6*6423JJ=E=[J"CY=^$"<!R&L(UNDBS1)'+\SC2D1U?&C#B3Y$\G.O
M\(-SW&+PDX*5W3XR.8VV]TEHP"$%;V H$-/9 Y%GBGKQB1GQ<'?SWNKJ!.N+
MU5A#7W^BL#'%K)!5#]PFQ::A<&7:@0-8'Z6*UA.Q.E-I(,$ZZA$RZS^?-27M
MEEAS'D_"%K#?2Z33;8/@Z+*Q+.X%@4X#WK[KUM;FGB,P"T^:D]#EN>E7"N7D
M=L^ I Z!E,) *RM=5#^C@2ILEE?D9O8.\[G">^4>=!78.$V?!C4&)B&UKB P
M3OB](EWP4*$EFB65V< FVWVPFOEZI5DL#0M\(3PG-WPA=3B"!QZB?Q(2(Y\]
MT,^5"IU8;64T)EZ(--*+^8J'QX?YR:KOZT%NI>*)J;*6I%1U%1C#H[-3>UG-
MS%A4 ^$254^T5L[BT4<Q'!EGB"(XY^UN[!CU-G>#4U']L+D&,A-P2 X!'E7
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MYG[:S#$-2RB.A>=^[R(JDU22<!0]J6CL\!:6-]%$YFG'Z)8;G91XPT);KH$
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M*<89T;8YW56-8'THWHQ]9OSC#\VB=BHNW;CY)2;RZPG.G1RL'05#I*C"2(]
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M/[W7.@#OHZ[B!>\]GI?_#U!+ P04    " "ZBUU3X@B;BE1R 0 +T@$ $0
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MI[/L#N!W/O'9(<JWRH-.=M8Z'5"TL_:I/H#0\+>$99Z\-$X.7P, 82?'A.*
MBP"4KQ-?MP#X\K90:]!U12T ZM=M ,%9"V ;<&KW=1H0!,#'QL;&P<;'P<$G
MQL/%(R8GQ,<G)+](2DI.2GJ1&/^,?OOX:T*Y@(=W@> "$0$!$1D! 0'9Z1L!
MV3<3XG_&P=<G &+LD^ ST5"8 *C$*&C$*%]G3SJ*^[4#1?8D2@R4,_HMC6@
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MO@@#NS$88@OU0/RO'#$;*.3T+O!_8M1.<( GW[Q!<(2,W6D)__;UTQ$&LF=
M0AF ,)@SV 9XZH/7'6+[VZX+^YZP[R@_.?D?[*SMMS+WKW3U1YX8_K=U^K^^
M)O^)G?!\3?Z_-&+_S+>B_^*(_7YN<SYB_XXJ^A^4D-,J\_-Y_O\?5?1_4:?_
MZVOR/SQE/%^3OW)_/;OX?JKRA[.1?]LE"_#O7\7_^JK!3PI_OJ3TDU!"'PF$
M(]U@.G"H'=@9)'/VHU\IWG^@\3=^?KM H^]F_=-5G9_.&'[U^0?M?W=Z8+9_
M<U7F1'"2#L%?TW'"E#CIG:V;#0C^?68IJ3 X@ZWA0+@7 [\(S^EITR]:__:
MO\_DOPG[N_C/8_E#)*$)L@?:>*GI&"@J@>U!"*2,HJB@$)\@OZ""D(*BHKRH
M$K^ @(*HO*(BO[B@()^RLI 4[S\P_DN(LQ].:D%M03*_&/_._H=Y^<;54U*1
MP3U9']\OE?_5POSWTSG(.<@YR#G(.<@YR#G(.<@YR#G(.<@YR#G(.<@YR#G(
M.<@YR#G(.<@YR#G(.<@YR#G(.<@YR#G(.<@YR#G(.<@YR#G(.<@YR#G(.<@Y
MR#G(.<@YR#G(.<@YR#G(OQD$]_>'SX @MM),'DRR,E^G 8H E/\BG3KYK_I
M.7N6+PH-JB4:"O'W9_EV "Z=/J(8$PWEIV=ZHYP]I!<-'0,5[T3!C>A$C@I
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M'I>^1HBG)KJ1.G"ZVTXSF#_HGA>4+0D[[@ZC%R;4'%RG1S1$-(5Y3T%!3S(
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MJ%8X&_^;ZY+Q'7[[@$#VL)H2$3O4]X%H1<MT%Q\/"2F1P6$?KD:%Z&S<-WF
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M)%C4"O$[<;+SP$<B(%&5>  =Y!*$^N+E\51D_-=OC:3K]L_!E&A78<5),W2
MV_,6D<>!4I[K6;;;,^0LDP/UKK,1Y#8>M#G7%'''TWI!C-9]L.OWN$;PL[[]
MZCZ(;\V8=BJ[F_W'X[,&W5+1Q[F#1S=KCTF_HI<&^?O=$UE=[KO',#.?(1HB
MH]=VL6KULEOAVP!Z,4K"PM52#J&]IU (Y)BO=9/YR/G]#,C$$NAGUZQC=)'N
M!BMBOQ\_W"?W*[\>^1> &8T6)N;K9<S,#$Z)L JCN$YE'G'I4E]^.;&?.V3U
M$\LL''/'47@"IJIEZ\X--]Y(<(%WN45^&4<^973D-(7O9$I8T/P,^<$GMF/[
MF73B6'+40!!\/7#3("\W9,E"+,]< UTV(V 5<VTNU.=Y=K0$FI=,B1Y;R_'O
M?7P1F6P.\>B9WC$(OR%\NAO6@D#N G_B*VEIH6=/E2!&3QT<BBR:0":DVP=?
M='T@Q7OV'M!G]P'!12U/GB^O#+:P2\4CE]#G!_-"HN=/GA-BO-=S[8I)?=$4
MIU1K8]6JF$_)T?4E7J^MBC;!C0*O'PR5]M\@X_N3]:#'HPFPOB.0.MRVSA2%
MFY/WA,,],L>VS)E()(3:5L#8+WYS<:LO5GY59;M'3"6U@TAM@*0!$2LU6=9>
M!9^0XV?*7"U<H]P_*&"6\FJ%O$$EZJ1;9^GX0 <.,THK:;$%9@>K$P\FF=6)
M*#IA)GO/+35;)S5/9O[ <0A,6H]36S9)SO;RD4/"3JA30^!:ZVGYNL"S[*KN
M<F>A0K]R,X_W7ZUQ*W.2!AR+6G V71 O$^;\#PQ'GYL,@=A.N<!M_ES]"=G4
M 0L$9;47?<U(A2!0TI\OZK^7NW'.[4I494!RPP4MVXZ%CX$G*=K-!64.#TV<
M#.:"S,QF4QC;6)!:)V;$0F3H*7_JP,DWZ;#!\8]U$R]1+I3:W&2=\_^CG:T$
M[*$_^<G\1NW'GMBL#5?AU'&9.7-[QR+E;J$A NXA.A_JC<<A5^1BVI&U'>W(
M+<' WX1YQ^1+G*E36UGHT^P+$UT15H\;HS('W)50,"1T$C5NZ2 A4Y]6R@!3
M]NX^TK:AL#*Q$^Z8?":CC<N?WF_FM;L(UFZFQ$&W)]J = 5+DVSVX+&I)2H%
MRS^]-Y4<W$,1)$*W9PKFKSO"_):>RX^!=@;D[[E.LXV<B:CIU7L#.&;/*KEI
M[BO% :G&AIT58\@O'L]28G &ZQ4W9Z=JV-&^HKZ(&*?!&:6(+;KM$N*&@%J%
MS'%.&A2)R0(C26*GG_9#(Z_C'O@WN(/!K@HS_Y]O3MUN [-:UV8;VGT>ZY5\
M&[2D\FKD3K&83CEMUX.YR.#6=MI:Q$SOW[],Y46DE;D+ZO;Z0(<3J3R2F)1L
MQ[E (TDFMEF47:^-PG4*@!QUFDH?M+L<5-YD/@\M"9;4^2IA+!H58[!2]B:1
M79:!/'!7?U&,&FW5$8HZQ%5OW 1GGK<?PC/8,EK/7<;,[G*AO97QH[6+D9IQ
M RA:14%6IZ5=/Q >""ZXDNX5_%&1CI#$7)$M_U\X/IG#_(GCB: ]0,<&=L42
MI.9 G$KI,5(Q!BG+KO1^FFX6_;S#L+BT,LIK'!J0B/34]PSBYZXJP1XEET_,
M*$B"7 3$5FG76F#Q*&WS<,10E@BV:@PLD895(NQ1B0;(ZHP\](@.($-]QWG4
MN?EB6;W4]H6G;;C=OMZV?P^P$[ELQ1!'Q_Y)QC7BB1?3"<K4DM7:(:*[C:?O
MHW9\/!/RJL4T245Q8$CD(:HSU_3"T-R);85G(.!;JP%X9:??D]C9NB',XKT1
MPKWP#2#E5!'18/UYO:Q\2<-@'HHT!*#(\SH]%:!82S)"3QI+)O+!I#DYE]XB
MBH3.;0M]^+_X(HKJ)$<+5;5-=,RE$K,^PV8S.]G/>">N[U)L,P@4\&1&E<.2
MF#HI:U_YLYS&A8+5W[$,8J(R>C^#[PUGE>JV8?6E?U<6_-390J\][[ C7[?,
MW"KY@I>65*5XKW8T4M%H16/5]08/*%NUP,?ZY0;8UYB4SO^]VNZ6+?W)F;?F
MB,.#I\:"[>59PL34WP=4T[I7(^KKCG/G$?P'M=*<YKHQREW+PVKAFQ!2TF/3
M>(!?W*1H6.->I7TYI^MZRVT6@,I5F<C# 0#8@@/8<2& IK2[+%03JP9M,B[Q
M]DKRHFYN? 2.@H]::'$T])E:, 6^G/3(KEUS@728D40&,I6_/P*.,PE2&_R(
M/OHBDFT^"01SH/,D<!8'V_'*TB"K4[QZO]+!_W#Q\,PPSHHP!KQI3#%FYR=]
MM.Q%VP!,B>NQM.VZ)B:(=^.,+""0J:?OJ;!X[1-$P#M*C.P+V=X8\&$J 4*W
M[.^W]H*B9,84-QEC%30E< >@"([%Z80:_(XY0<82L=X)_Z"^LV+_/-(/^,0#
M;WBK_DTR_0?UGF[\&.3U&_=U:@FE;> !KZ6%^.Y%BVN&T,ZY2;.*_^P)F ME
MD)5K];3:!ON#SK;JSR]\"][BLAG!5@?^7-HF'KS*E%0M)")"0*A!+2M*:[JG
MPN!>OHC=!!C<H8NK%!';.K7%J"@<[G7:E6[-]ED1I_8FJ4$HCVE=2MXWV[EK
M;%%I6;QD)P-.BZ3PUFU$PR&UB'GK)?S$Y!,_O%>_S:Z&Y'MHZ&)FQ^:*G0M;
MUV+;<2)RS?",<1JT2F6.I8_ID:][K[>M1!F-4H9/G^=$MW7.Y,C'HN??.M(Z
M?^'>PL[_O>>XQX#//+!"37&J*?;3R9N'!T4A+*6CT@XH8ZZ)P\*)T-3,W<DU
MP7@@C2T7I:Z1RC6MSKZN-D&!I'9!RSY/#LR '9<2@P7%:8GD;6LA!;^B?%@9
MXN?X(95EK@3\$.K]4LI.$.+Q"?+RR"F!?0P3"C$.+&20D%]VF*QEVH04^OQ4
MP4W7S8@NU3%(/RMJ@<6?Q4E$7AI7L)YSQX"Z26Y"?5C]=>:P]7K*>5$WRK__
M]WJM6,=$6TO!\K3R5.MNM4V5K !.:LB]+PZ3G0Q#FH(W3:K\"8 1^0\J/3$H
MPOA#(!9DC+<, <(/EQ?W)W7!YLP_VKH8FZR=/_R#TF@7^2ORLZV:D:@(3RCD
MH@56,DMO>Q>0T'F[U&[$N1;"A4=BR.0Q^VH;(/:RG4L%>7[V.VL4[QSFNG!$
M*W@Q]$+SNZ?-)6XL79HZ^IZHXC--2K#S<TJI8RY)FR)))/ ]0":3_TGW7;CP
M+8G@7,DDJG# ;V?).*N?<Q+\AYC?QNWQW,DN*6A*F)_,=-AN$/U[=RQ)-,N*
M6:9(,0^Z+<FP;\V0;$R7(>O!4I1DW<,4=-& +*EP(-_/H:PUQEN0B+#DCWLA
M>/8Y8Q.[/P=+F:IC#;^Y;I]NEQ@L7^_/+I@#DJVN?E:[1!-:6G),>WE_#GE4
MALRQ-"V(K:<[>*&C6(AYK+[6'VV 5):LV@Z>-/#75(8DF0,8^/)O!WN(>]#H
M.DA\44S]WKGFFJIV/0C<UGU_UGU:=%W:5(]!Z(J,(C2ME=MABSD?K8JRYXH<
M ^[FS\=]G_2?8:HA]V,B)D1Q'7\YCR.;^D%L$Z+D>;WZE9NJEV'=7V!&TL(O
MH;C+I#G0&Z15C&&7AOT18W %;:LQ[W-CH\<5^BH&*4Y"?V*V!=2?-)_P\LN-
M/6F@HO19*H^?->+_+>"AG+),'3M=\B(_"7QL\'!__1Q:BB\6)4NO;BZQ6?6Z
MHXO>..LK(241\.]%9S\!@><%DI= N+ JADSR<R+&*EZDW^D627^61-<?3Z@6
M?T\RY-,H-M&9@+P&%[,::MZ^N)4DCT @H T(YBD9NK&):!*#8+35B\?:>(#=
MT5)S]UAS^\Z\\% S.IIN5?>2Y%B_\7"DU9=V6<-R&KL!)\2KZ1)MW<X&,>*3
M&QAWCY#R7!_Z9%7:@PH#[07!/:F%TVQR=VC20/RU+*XN<C/=+XJ QS/#8C98
MAU:<RIZ%^G.*J5VW.5M\ D0UQO/FX[WVZ?0XBP"E=S-)5+,&#I@8%.1T03^P
M<WF<H3VC,O< M[-#['+^J:B(77/SQ<B[DN]PVQ_6D;\CA[2E:N'=6P[W>4^-
MA/B(&E^]KK2<(@.:5V%>VTQ ^4)%#I+5_CYK&G^CQ2Q):?>^;4+:!'^*VE>:
M6T4[_(/"$QAK$T\F$BRK'ZW8W^C8]Z0A4C9P"""8?3,PY]I186!8G+NLZ9''
M9=+O C65&1G-!#6&'U&1,1H I>.E#N*\P^%VKM:&LUWV%)JWOR<UK:*1\]F7
M[G>0]OSZ\MW1*7>0SHZJL^/I8DOC@^'WIXY!E=3"M-ZS>*6>Q-5C<U-#_5"X
M@T*#.#1XLB\J/UVOS1E30CS@?$FDF=^JR6^UZ::].HFQFS"02-[MB]E&JF,7
MKLI>S^-NI8FN+HQ[?'O#6YB[ I)UQU[5K&V;G*:+ZK>J_9XWMU4YCA3!+M5*
M?.?Q.X:EG<M*B\PE^W]09/[65^Z@ 5W7A;%!TGOK7[RQ^]Q>1E_T35BR#8*S
M62(;EG0I[ S5RWKSI83LG(V9D30;!9Y46-CGP3IQ2>P%-:WEY/DFRL@$=]<M
MMY7 1>P QY[6[7RB4-^KL+7V>N?-GM6NS8MD+UXDP733;=^&9=2&1][-;%[E
MF89J4)&97I/#Y+S69VJZT=97/NH^RS3 &OS7WCEFI^ FO\< SR.%;47:3&N2
MT@(>]D-0N/ _J/),T_SS.1H$;6#T/KV?3#]E58X^/0N63DI-K&:'U&1;('VL
MIC'@Z,G<3'XVD@=BX\9M]FV33(B^$E5.PO*[/6=U60I23^_OK$K:TQ$SAG58
MS1H7ZB2+G;$=DZS7./,<!?-8)76LG"IH0)PIJ80&CA@<'!S__[RX/V"<%6OO
MTAOJA@EZ7;Y!$$H3WGH>O=%$1&8UZ':^N[T#E/PN*SGX(,UHBY+%13A5:-&,
MCR8F(MO:\@%D-]4@DLI=LJ5,$VH]YKI(7'7L4"3++L^O^SWL:)3D,.I$:D@X
M_L@_!OI";+)W^/;;VU[&_*^E'T,S%P[[=D,"Q!P,3/0;RVVPMV5C*(>5!E[#
MVO^?8I:7B; +Z8I/4P*--(Q/XAY]H62.%%(>?96QC=[H14Y,MS@;1WQ3F6V5
M!KU[AF8#IEOV>/Y>OG605-/PB5J$+_U<T\)W^GUOK;#)ZS9QRP1 ;VBXJSJ<
MIF(>IP>UOJ-*/S5C[520P>]ZT_10"1>R"0)$@J)I3>L"U<4QL[X48.$J2ZR[
MFD0QW5G'=L3W'*6(YD-5Y:)T_(Z>^'S.L&G1^!>#$XY]*Q->_'$"=84,S70;
M\C%]!0MJ(_0A7,:[6"4MR@DAL:#@H6*ZZ)AH=G0=]L=H$[0I0T1*_M>+%QO#
MK#@M3C](+@E9.RD=/MKGQ;W_Q4L=G>N9AB/W3M7&%VB%7!SW08Y)F2N*)R$B
M]V_&X]2+7F&T+=IE<'Z;^XYQK5D(S%%<:-SP944Q>E3846G:-0ZT/^0<,_GA
M-XAH-@"1&1UO63]-'U3/,2X+;GZ\M-=I+QRZ5*HP[=D@YYU>8,9T%2S5-WLA
MC1.*P2M5<A I%"81!4#GB^KM<5T]+37R?!5HX;DH2#VRRB$^UH/_2J,\QO\-
M5!.[/3.FR*;7T$#=3X-KP8QSFQ&/FV5_0H,ZFM)R*)'NE@O/(*^P6I&666JK
MAB*Q7 +LH(>G$:L4PY .2D$2K&3\SQ99:4MAZ_8%6DX?+PU8M9X)3R%/#6!0
M""4/<X:-REO,:%/SC6=9T<]9!!-(QJ=LM&E#A"KXEPNDUW,+IB0FV%NU,5-3
M6@:IX2@UDHC!R.I&:W[(#%Q[9AMIP.%8@#O&I7$$GUHUDB\%M E7J'DE3D-(
MZ$!9"O:P R)62TI#%!98<I!"Y8_RLJ;<XID8BCC#M/&99WX&@+?3\3/IQ5PR
M5IJ*^KL9ZY8A S-EM=&X,S](J\(1F0(!SZ"KSYT(]:IWS?=/BN<A NV1T*&Y
MMP"'LWK5<)#KMT(YOCVF,1Q,"(G(*P#%C"*@6S"Q3X \-"#PA"<E8Y>Z!].G
M[A1"PITLO7(=4D8LV V%58$U"-$_H5"@CB\<K:=L;7)%.Y_;A_7D0PZ!@]J#
MDY+,@0I!WXKQ1">56:B=QIXF'!/R[Q>[O0<9(]HN/=_="O_EKAY><2J4M/P'
M]?L4'83<'/.,\F#_<:2M4Q1BC1!,^!_&WA^YB/S/\9U-,-[3Z_UVE8PW\4WA
MJTE.RR CY5[>7HE/$]1S@]=@>JR>D[RC#Q%!M^UE)FR> @F\EG)CW1!X=+I=
M!0)D['8NU=*3PLPR/32NICVA#_CRB'WWKM.N_I2,KB%%TSL/SX\@3U Z9[T6
M 5,VMHGL"N4H80A5BURWHR?^=V8],$"V6^&3H'97RH%Q$*&ZI5X;KXM/,#.8
M9<XD "KO>EMI;)Y3_L&Q'#Z;RIUVX5TKS3U,=7'CW90_=YK;@7+C2.8?%*=<
MTH/L?CQ%)]<[&G.UOFY;2@=]I;P0:LPZ%E(K7!CR(JROH35SP*/??:9BNT&?
M\E00/=_F[3&IJ0ZK\EF2%/\#NSIKNF-JKV_&K]^E!_.![B/"WL2>/<])DBJ\
M@UJ]FV@Z<\9-A$%="+5"G7'NGH=^=K+)0_T#FIFZ/_8X X#V*D>>P_=VV A/
M<_4I(KN#F;IRA&YGS5:^P]GG#Z_LBT>L1/=S"Q>JQ$VHO?8J/D]^*^'!)/I?
M/X\NEWIO_\PQNI%8;_+;.MHEO.0_!W4L?K[YX9,<)Q$8ZJ7_O'ZK@^^%.//R
M+B6^[(@0:. *G#0;2\&""L]3?V99J @/[KM721$ON;WU"WI4,;NC,[X[*2,$
M\KT.1[)7-OE!7W9_C[;BA#E3X\2'O6PY:W;V,3W+WKBMX9D1,"$/1'<>HK91
MK5[[U"70)2JZ\5L[VO$OADT=-AHL4#Y/Y#NYI2MF]9(.&89V\M,_WF'J?2SD
MJE(9NBB&WMES;'LB"Q(I5O$CO28-?+KSZ#UD_N'CT0NYN#(]N[D\ME?]WGVP
M<[H^\?IG$_S.77-?K1T]5A]2I5HL/#2;\%KL-F\OR%H5Z%0"G10<_);O>J 4
M;[RY['I)E4JH7T)*"^J&4M$Y*WSG/EO_^'[Q:/[#8'@GM_8L6T?P;&-GJBEG
MJ7^)Z/6BIN>4.3#QYMDJ9:F[:?IEUU!:66XIYTX%9O4#MIJ<$_P CNWUN&4W
MCS$.#,_!@)+R0V2M$H;M0L!.'IR85Q"T::VY4",ISA(^!DV)SEJMNNWEFI\N
MF&D8016$%6=%8%L4+M57B_!<X)J;B$:SHQ4-IV<;2_X'@[].]AU.G9L:'A;/
MVA,3/\#WR<:!??>0@VG$9E$=\F/8><E?$T(['2?S11*[[K A;^Q29>8Y91HX
M4E6 $ 7SG/)I,3')'"0D=]*"'ZY(Y!CB<(:8.>2_Q0]1Y1'9Q.&PD'CA,#R%
MQ!%'2^#9>V.@8G#X<\3@ DKW8>YY66%B(RI/A4*4:%C9;Z#,?^D??\E':S=W
MY,^'"8 6 IA[M/(0;!&'DAO^@7G"%W)D=6<@4R4U)GY]"=P?&BJYG9#MOQC>
MFVK73UXK_A3E/?V/A(4[BX(77S2I^+R=R%-14+::M.UT$&%"ODW:>[M*T>?
MYL9)'<SM06/"Q";.I<2<3?_-K01\=KBER2LQ\<!Y?CF&C777:QD,94ASJ;P4
M2 Q:^R@VHV0MWZR@AFJ0Q1\_80K-90;4D'M#HY-SP!51;SR<T37]U*Z>+.H_
MI+/]\^Q<Z]KIO9DQ.'2R2]0SWBW,G7@$W"_1FR6O;-=SU,U6\Z93MN^>_3,<
MEIH;&>/#BW^&S&>N^JR&RPCU@>"MX;8VYH.LT?7&:8S-_1.CG\C4-;*;Z,]$
MZ_GJYB<!WESTGJ-]86UCE[E"*S=CTTOXSAV'<R-O8G(#Q 55OWV\TP*:XYQN
M;DM7.KG#:Q?MP.%Y^W1/(6GVLN1*L7!92%SST7K]0%'/A._/X>C:.#K^PV^2
M\-[S[3<JG2(\!,(OD@Z,B2Z:<P;'V,.I@&JB+LCO/*&"6:1)4+F,!,G'17+9
ME$A[SH$3OXFB^Y)(V?5P]'C<K OZVU+'=[GS(.Q:B/Y2NX\!Z/$2[ZI)G_MO
M<_XA!8.FE%#PD+/S-T*(GGS=5"72J:1#D;S3/RA&YY@,_TKU'PM:D^[;YW^8
MM1@)A?B\39_*-"$#KK)N1'0_K!?!NV[G+!3T^:)QM.^P,7Z?U]?>KPU7N$&R
M\K$*+EKB*S5] OFB5'#AVXT*F!Q3.KHPM[=8UX>F%KD3G4>9[4>S3P>Y!^J[
M0<5&&I_R6]63HXX]R*#G[61KYYBP7S]M[08CS0Y-HKXMU!TEH)8LJ;?JU?<]
M)#99:#IL=2Z#)4H(+_WTJI'X_/,!&ITI#VYEQU V)5<$)%QWJE][UC>W_N>\
MVR3CYEM&5!\HWIC.ZQY.;E\@>QSMH&&2/ =:+L&29Z2%+5$N$BT2\*UDMP1Z
M&8K?OQVBA":>&6X&Q)'7V/+DQ5'%91&TDFWF\#C299A1(+'YJ7V4SQE 9M7V
MM'NFN8;/B[<F^,%\O/J?*^GVP1Y+E\M.0.@46P"?]ZF=#M'(;EU+H*%K.U=8
M6%JKD(P= 24QG)@"4Y>5U?0CVD $-@:I,3DE0?WD,O%(JR7FWW:TO/1LOFMJ
MA\Q[/,B\EOR,O.@VZ=NG6B//12$IP482Q*99 S(O!G_Y6&7/,_QU_JM0'$LE
M34&'^>Y782@MPQ"J@V)ZKK7F!IXY%:'#8>ZNE&J\IO$27-(#O0W5FD IUW]0
M'<?KD9N"2RJ7=ADQ7KBQI9?;6D/*U&N?X'4SD_Q43PGLYU,.,>#;.">E#$F,
MM)QA#2<5^>]>3!,KVC<]%0HJD>WX)(O)>CRS];7_&Q6WODYI/VF8 #_/?PCC
M,'6YN>&M2.%@-4Q .^8LS(6DB)W7DI$^#GC:O2%66B]0;FC^W SHW1#&ODSS
MCB9]?$UT.? %.$O6ZCOOYM91CR>4N .Q*NHD9RCD 7;,S(+-L(:J:U&[]5;>
MMF:^ 1,##K;A*P3ZN#9F!S-RV*?4R071>)E5U%Y&#(K)C4^9P]_BQC=S2C1=
MT"\IO-NYZJ6YXF4X<"&YM"N_.E='?^EM3O?P.1]KQUG*W'E@_<C%.-UG:YB
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M*Q<K\#:DU#NW^&B$';X8T\4=K)+%$SR==1+8:L"X)0GXUC)Z"=;''8?\2*F
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MLN!+_@"+Q[T>?;2._&RFWP]97^@]J+XHU&6.IK:H+P#Y*$ZP&5;;2%9\N&D
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M1DI(:"8BS>D7\WR508$C=<PZXU$Z&+V8#7]K8R[G%9F?3]_52>='%:?U.BV
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M:$/&4:E;)&8RIXZ3SX";4I?,B*!'3C"%.BL6I6'03XN@4=2/40"F:%;2'\,
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MY[,4ESO*AB*.8NQ/J VOD7[I?UQ*KL<\- :#-*X"6P46AES:<A3@E-7VU9D
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M$S$V8A0A]?:\O812&0T*(K2*I*8V*3=6@LX2DCS/+\<UL!^41#+A(OAS\@-
M7U+TIV8QN6/CI> W%N9'1^7VF*AH9W&X7H[8IK^$MW,O,#PK)))BRXRB3N4\
M#GK7&I,;J#*Z6)U:A@B\_0/0SD4\K%,TK82MFL\T" DYUDE$)UE4(JFSF?+(
MUDSZ(>M^)0\II"XO\W=@"X7ORAHF46Q]CV06'OQV&*\E*37A7+.AJ\4H)&"H
M+DZ]-D^^['$$H=2G3!#JPH6":^YDAFRSI.4S:(XLIX>\&>2\!>Z__V6.L@<:
M%EBN>A>/*PLS#\DG1[*[)MQ'R@'=&UH<&;&M9C:\+Y/"/S'3&%(:Z$=IGZ1]
M"A5?[:+]C!C&H_\S7%81I=3:9^BHM..^ZF_R':E^O% U7.4(M@3HV^?1+E;/
MUZ? 6Z1Q_MCQE_.P]_F04>W4VNDL%\W^#L#?K>^;:7T&<XMQ#!V\;J;^6@D&
MO0;>GON3/\=NC67?)<,J%6SY!HNC5U=X]2X'?G $>3.NA<V=R60?+#VR%-PV
MGK\]U/2 (,J=JVJ12N?5ERQ_4-H5W"U/M3($@68E[&)#'"H[VR*VA4"U3X!4
M-1CZ>]3,_>U86HXHZI$ @>$*_W)"U=TL P4Y*#/CX>^9K;+'#?)%&F)^0]P3
M:C6!:I9"#'D.;/Z,<?K"* EL )S4,!L X(8Q08XI!DAR!QCD]3%HB79W*O)A
M[O[./GS*Q^JHC"F&I6=<J'J2:3T?2R''1PI2I]\W:23WT* OD<X;:?FNR?]J
MS8!>SN^5P&--.KB A86<!L[_8Q>+BT]B>?S&<[<'&WF 6*4PEZLAR)H?:J<T
MPMJAV6ZP K2[^E()(EQB6,4SV_>\T&IT<HIJ%>6*:V%)B6IJ.>N(@E%F/K)'
MJTF"776MB*$)4,/>H)F_(9/YUE0B/Y(/#(7%)A]F5,3;(?,+X=OIJ7!@+ML;
M<B1/L&<^/TAT;*YWWCUF7*R"6C<9VG/RK,<&VR[:-,KQI^4WZ91L32E/C0NK
M:GE1,3%1-H?/H1E4F=-WEBM6-95CL$]3Y1JF9<:MV[/-VS>M21#9@$LA,R$Q
M22'4<"$_34W@JWY3'RE!.8UP#=JHXVK>7WRNSM1I_V,+#"E!,#S3SW3":$S>
M<YE4U6$&#[L*%G.9>(0;^OD-Q\?K"H\F)D??[A,6JQ[<VB/?46K<B8DEX8"[
M#R6#S8,Z,K(<8D%TANO'=>CVFYB 3.E4"B3B20+).HJR')\A.)XYW+VEKJ24
M0AH%-3KRA 1YWKD@@Q5;5YRWS!OI 3\GA _ZDRO2_=^5.><=7&Z"3,.6!UM:
MMRQ%2\@'_1(46QP<Z8@VY;5#XEB)5:,TT(Y,,1'5$7;N?7SPA;37/X"\OX(#
MG09;$)'IEUJ40D2>/<1]W3'E,PD?-,?R=6VUK*JJ_^\Q$DR:*AXXAJ[[0.=K
M6R5.9#[#BB.,\8)/FU2=#B*3EY5P/JXP:DA,A:CFT'>=NR-2$O59Q4*^,MJI
MH8W@]2 7BO)^S1U#E5B=P'OU]9M:EN8.+6[V^ORZ_V 2G9I37^^?YB#:S^R"
MIK':T9<CE0<D& T.M?0^?&;TE8JGR*2M32-R5*119N26!KYKC7H' YV3<EO,
MLR&"193$ W,YTH(AXADIR6?)7L3D%FD'X))KK#[W6G!>4V.>IL^O^X@CX6V?
MV@I!M9:PTXT/@(MHC;>OC-+3,N3\0>?W[_[)I&Y.QU 'RY])/6H41RF&56IW
MK9<!X_.*<8;:#ACW8P<(U9#*G(GRW^>,+6N=9T1Y?8%#R '8G7RT8*W@G/(;
MB6D:.1947B<4(NG-:GV7V8'4G+6S9<GT50X-X64:Z:)"<%V:_[S"7*."M+A,
M(?ZYB=QO3HXD<(+2NZRCS+%!;)M7E';A8$=WQ7N^FHM^-5W5AI'Q)6^WX(C?
M%\RLN(E2 M[=K89I@85L$13=&_/O/TM&>E;4/7_<R!9_FZYW6[GC=&&Y<,,;
MON5T:8S"5;J$&H0'2,9CY&LCSY57/RU?\MC(K2PRFY 4)[W5J;AIFW%-+W38
MIC((UN%J"88A(M;&ZG5K5G:Q&_!@;8+V(\RE?MLA9D0I]RQ50>EH\'C;",_2
M:M.]H6M"MQ/*6I-;J;0+X$ BWW*OT]CRQDJB7H.+VE\M?)2=]H8+/969-97U
MK)]63EM;CL;66+-$:UOJM$<,KXFPO'4'MV1;ZW\;IECK_)B%UY;AVJT\;VUS
MN>Q-5A'PN7VK9NF.Z]R.,F)L&5[<SI$%UH6XZ8YKHX*C?-5"C2!WVP.A:@(J
M&+Y52 HX10X'JPY_/HYN0DQH']?QU_[@XF3#91,;TU^(3%??/D5IAKY7U-8-
MDX5=D;A7.29_&[IW';.7UL< O9H&+X%7O^.$6HCY'CIVU8W'"LBRP:""??J*
MS*D#KC4>M#&4S3)BYE /OLN;/?&<4G>%P\>S98RW$:P:^JSX?<SPYSN_V\D#
MKUIB@3[_^6M&*8=PR,L-R0_+104H;_M%J.$QGN /IS%\/7'G11.*M,/)$'_6
M5JY]F8J(>#&!*:QDU=!;=B)&H79L*?[R4EX)9X3:K3,W+&NFE82(N;&67C"
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MQ4S2*BDYA_SZ?F.8.F PY+(Z)1ZVF(3;?<AW7T)?&#$)216F. 0HZ%DB&YV
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M[.W7#6/M5/+@KVRC+$,MW;/4-5H;"%GK\/Y]Z+:AQ6ON:)='34IMI#,L4T'
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MJ5F#  !Q8;;X0O]\*2C>?TUJ>[J3VFJ,?AA%9+D<50R1X*HI4OE(X2N>R#,
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M:J[A,7=W&U[WUM\7ISGM[+ 7EDPII+2MJ=X!+7)3_(?+TFO[PDJM-S.@VL\
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M#"Q?2PI)89" TQRSWY>A6 T;Z-E^O)4*-ZZ/R1_*'X#-)F3RA/KDUT\E+>U
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M%;AJ@YFTU05<17PQ-M\/=!XTOLBF+\_Z1C<IGE!2$92[M9T[8\(HZ'&" 3@
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M17HA'H5H="]9;^:NBA7)TH@M@59-B5/%V2XV@KU-BV_><>5E\Y1ANC&XHW"
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M>>2UW<IX2!D_0+0U]&N#Z5UY7EP\M^K"$N7.C+(U<UL:7(HCN,S3'XNS4KY
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MK%OA/9OWCI(.VB-M;Y_VQ%/\CV> *?^#/\)YS-PYPD-XK<<S8&J]B8C_.E[
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M++Y8,.YE?=]5V/>T?/"<;5B$^:!.UM25C1$RF_V^47'(5?U#;<S0 8A;@H"
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M?0>08?5XGFU;]X57C/\[O]9AEBT+^0_CB:^"X24WRH0W5C\8*1P)W4*(@<?
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MY5)'J9%E@'3%77V>N)H2 QV"'.Z:Z,_?YB03'YCG\?)'L*!;MB.).M*V(X!
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M"GS_E[!?-W^5)1=V_F\R)/\3)S3LB\=O '51NTPT\U94V;?:HIGFB^B.C;K
MY&^KMXQZHR9E??-\7%^A8=0E/^&!R*/? -BC9!OFSR;RC20_7?^.=.Y99K#,
M+QC&YS>@UO<WX-;\I^ ?<5.(82Z0$ASE(#% E0PW-_2'X6<&@F/ [FE*])V\
M')P1." @[@YI"*M["4M!Z2"^U@<M'K>,&JP$C2=[=ZF 2#.[LDO)I];I3VAZ
M4"2@I+N8]!.!;G_+<U]+*Y:EM3LX<[@V"G^KO254_^OJEV2RVY]A U5_\^,_
M"-O\2?I?C/UX=E0H_]]AE7\@OE:@_"_N3P\\]7]5KTG^!E"*,3.%G3K)*X3\
M)\XZ_TA^>NZB\/] VO\EMK5HY@U))?AO2ODQ_TUUZT8)T;]>S53V[M?Q?[8E
MU/$WX'#]EA_WS_)2&?AC@"\^U\9_ U-\9?3IV+GEO^VK@"72.#7YG](7_9O%
M_U/,O[0,L___L;9\6/-_GFG\-T"U*;_O<.V6/X3DCREB<5CG,I4T*X4C]49D
M+AZ7/(\$ORT,6,?-*6?5>4QL>Y?[00S _EF)>\6YR38U:Z^BEO'E4RQ+&HX<
MXS$^!Q$.Q[D8U[13V4Q*>DN.]2<#?>AV3XDJP)!B9F4'R)+GA!BKX:<P=GUM
MFQ!.2? ,:"3E0&JL8_LJ'/)&!E:E7GS@DZNVP/[8S%-"\Y! ,^XH5YARG(=K
M9FOI5BRI.G.;-J-.R6"FK?F(V!-8O*GE4Z:(@\^[IGX='I")3BE55GM-C-?R
M4ZZ5.^4#;H0R9A:D:9A.51SYQIR R+>!O)(Z"[,XC8* E,S'%'D-1&Z=CT+^
MN@G[O?Q_ %!+ P04    " "ZBUU3X@H0*IJD  #9%0$ $0   &<Q-C0V.#!G
M.3ES.3DN:G!G[+P%7%1=US8^=(-(=Y=T=TB#@'2#P,R0PPP,0PB"@B!(=P@&
MJ;2@=$FWTAU2BH0H2AC(?\"X]4;O]WG>]WF_W_?]?VPGSEYK[W6M=:VU]^$<
M\!Q.'#X'G-%4U5 %H*"@HEQ&N0P '&Y2C.@ZPA P#T>8&Z,PGP! 0E%#&QT=
M@&P4U8TV\+^Z #9:%', &@V;&BTJ (!\T:)B (B5P7!76R];!%37R0T,<8*"
MOQI@.YYQ9B/A[2*5#;1U--23MQBMX<FQ3NI8MW*D1[Y1CGMX;G G*.*B)\+-
M$X'L8AS)=#T0!G8P&.1XA 84 09#/5V_'Q]]*T'@1WVBX[D&3CY'(Q2=$$=S
M_K()ANO8NH(-54P-?X!]G: +A\'L#< (3[>+=LY I!@?H N  V#(?_8 1H !
M  Q  #P!;L=3<-U^C/YN1A&"@'[S"-_.TPF"<((>FT3V<8Y'*VF;7?C*AO31
M>%3>7R(^^U/$%]T03C"HQQ'GQW&Y(:#?@T &:0?_T=%W\-#^2P.'*OW5@2+^
MZFC903Q^='0<$%X_.BJN$.4?'22/?YE6!+HX?"/BJX, ?35%)>07VO$QB)$1
M!/.T4X ]!WQO:G#H"9DBY.0X13C(T B*4&71AR  /S5%"(CQ=W)]#PCB6*[K
M U'P =U_\U6,ZP4&(F!P95N$[8^JT'70]?A>%4?'W[Z5CDD VR-^9]X06>B_
MDQL (5_ENG"@@MD/\1D@'.9FX@A&)A>9+R>HPW?&"(\4^DB?%&$(!,P5 H,Z
M?)N"_UUSY,)/<H+O<GTG!\>?%7C?%4C??HB/*@=M\ZL/:$U?1)%+#O7[]W%5
ML1_K"/^*0/[:MUG;7PE#+N_C]E6*3G L/5K+],=]JE_[:.^.^SC?K:$<S^(X
M\\T6RG?Q\=B=XV-U +^]/5(#07YB?IOT59*9=NN'1.CXTQSY^5TB>OS)^Y?D
MV.;^\;';=Z__WM!6C]3_>=TQ%]A?>3[V"X"J\/7]34?_@Z>O?>JC(S31']X?
M-]0V)'6W?U!WLOTD.QIW-/Z/ WZTO[8+ -03<E1VJ$>P=C!/*,CC;ZL5B!#\
M[N91B?]47H"_U2% \4>]?G5#_T<Y'H> Z0%Q H(]C"%:1PL*Y1<<C&,=\N L
M\HUUW-%0_LDVE@,<YNGVBP@3!G=R</JQ5ZH8'$VZ>"Q#]@EL/1$P-3 4#+=%
M@$''WE]V^[[5XWX=?"0YTFBX.C#^'X@?S1,.^>6$<4S^KQ)M#X=?3RJ8MA"$
MH:W#+S)"(!@Y#^R#T/!0-]36^KYM87\7_S(8QQ$&]ST/<7+XSA31U^#5OXN/
MV 6![6T]C_<M'"\P'/&;X<;?Q;\.Q[-S4()!8/"?R"7^.D%1[8?BR T=&/3H
M&P<!<T.>G#S /Q.'"T$2>4**;W>\ 9Z0X\&/MKF_B8]7$.?7>4?E+/]M=S^6
M$Q\?HGS=>=!)CWM'"44[[A^-!Q"P?2/L'O+-ASQ\#@ 8*R#E. !* ,KAQ.$F
M /\\"&8'OJ2D#4 ]? T@/.X!0->.YAU. X(!^-C8V#C8^#@X^,1XN'C$9$3X
M^$1DE"0D9"0DE,3XQ^W;U^\;"@$>'@$AP1E"PC.DA(2$I$<?A*1?IQ#_*P8.
MGP"(L9'.WT-#80:@$J.@$:,<SB(#Q3UL0Y%'>HF!<MR^T8@&0$%%Q\#$PL;!
MQ4/YNQ(%>4[XKCP#0$%'04-%1\7 PL3&0,,71BJ)T="9S@IBG->S)6%V#Q3"
M)(W++%-D8273;[83%H$'#2IAL<4;O%EX"_00)<\JO\ZNG& (4FG)1HA1#!DM
M@K<?!;<.>RZ]4^5(S EYG-0VLOP^MZ)]=&7'V-[K1G)>9<?8BUUQ-1,'[]"4
M^U6=XR_WB &HJ$AOT8]]PL+$$#UV@4GP+#K2 W=F$@RAP#C2(P^:]0??"+/:
M+<"#XI4,R( >(F_9,(\<P&(7;1E".I%- 5(Q$D. %W^X\&</./YRX7 *@(]V
MC$D,D =L^G::O;+^DC)J85!%OM7)_A(ZY5Q3YR]CL"[:F,L?\&S_HL&'NF1I
M#[F\J1>MK;TO'3_I.+%X#Q\",#[R3@<$->Q$U]='YV'PKXU@"A@/!M&L-HI-
MKU/43DV-?TG;.. XZ'CT!6^TVY7JZ35X0!D@('GMN?C'8=B!HD\D]IB-CV&<
MPY[&QSI_^7P$!/-C:GM29(?0P*?7W=+35>^EZ=*4FIH_'9 '.+RJ#(ASM-M9
M$^;_),>;.C:+_M&U9I@@ZA"P>_>=-Y_+;H"+F<7&FJQ7DW[E)"%T<;93L^A]
MT2-P_V[-QN=G!E^$A]-K[1TGZ2Z62(] %RKR5$N@O9@'H_*37XCI::^^Q-HO
M5^G=NSA%U_NE9''>/XVH%0BMF=XL+RH$G+;3=MI.VVD[;:?MM)VVTW;:_G_1
M#A=42QT1"#<I?GZH!Y_MT04P'Q#FRN]CZ\8OR"? #Y"1]W&S!;J $8QV8 <G
MJ"SS5ET3,Z,32);91%1;0-M-">SHI.X+!QOXZA@"?5V DB!F>3E<&1\I'U<W
M5S#"EM''%0+UD/*193XV+H4\/A+S,S,>#T&XR#(?7W8SFFKK,BK!X&!&43YA
M7J" H""CF!B?H(BHF)@@#Z.0@* 0OP#R)<8K*"(E*B8E),[XK3'+X2(_9> @
M>RE]9=5O<,B>+/.WN+R]O?F\A?E@< =^04E)R2,S0D*\R!&\'I>A"%L?7J@'
MRU<CW^TH@SV <*?C.^V,1WU;.Y@G0I:9&9?QI_85" 3\@>/F"8<<HX" _& (
MV!4,17@@.13D_V'\R#X(*&4/@[O:(N2<7&T=P/Q@-P][&?Z_I+\.13@A(&"Y
M7W"//3P/0?PJ_:Z .!TY)@6QA3K(,OOP?KNKPRQWXI<O,OQ?A__-./])Z\?>
M_>+(UU$_L?3?90]9 #_H^VWY_4(=<K24-K)V0+8(6V5;!%A.2$!(D%=0@%=(
MW%!04DI$1$I8A%M 5$I80(;_Q-B_VX&!G.PO_TM6_AKY-QM*<#!2^JL-44-D
M?8H(2(F*\@J(2 E\L_'3R-_9@,$-83"(W-=U\-?OV(2$^008.;5M@4[0(PG7
M3[:^S?A?R(>V]C]GQ-65_W<S/1#Z8/M_GNEQ=-^07Q_L ?.$ \'(X2R_-Z3B
MA?AW#*EX(1<:R]\+15M;2@/J@;"%'MUTED,*^)R<0%+BRBJB A(2JH+GA<55
ME 0%%27/JTB(BDHJG5<4$!%35CUF^->I)\PJPX">1VO[FUG0D5G%?\WL3U-/
MF/UZE]L6\M,83T^D;5%E(0$)22$126%%565%04%)09'S$J*2 LK"@DA,)8GO
MMG\S_P2&/A@*<CJJ R6(K8>'W+?-X;N%OVE/!@Z&.WF!0:IPF.MQ';G9PCV.
M[[?+,G_/!?/?=I/CJI!R^DTBE/XKQDY,_9UET'\G%R>F_LXR[+^=CC_._QT,
M_ \9^:WVYRWY1$I.YDO=R0.Y3US^S=G# .S^Q[/'OY;9'T$@%ZN4+?!XS_&P
M1;IRY/I/LC]/^DU1"(. ]H(2(!%>H+V0,*^(N+ DKYV +9A7TEY(4DA 7%Q"
M0,CNN_T_%<8O&-Z.8.C?MF8A0>3N_'UK_FG4GXUXP.P1WK9P\'D'9!J_[=$:
M$(BG!P)^M \S"HGRB?RZ2_]NWI_M QV1YVHP2([_^\3O@A,9^NT9^_^.U(F?
M_Z]7W7\S;5_/RL)2(D+?S\K_[;3]=6I5,A!CY#1Q@H)@WA[_3V8,"(,>_5;O
MW\@:$L<6^9,W&.XA9W^TA7_]\=/9#>S B( QVKJY09R MD<V^+V@H&]G7;?O
MA'U'^<G(_\%@05^WN?].J#]X8OQ_+>C_^9K\%\Z$IVOR_ZJ,_0L_%?V/,O;S
MM<UIQOX3N^A_L84<[3(_7^?__V,7_7\HZ/_YFOPO+QE/U^2OTE^O+KY?JOSM
M:N0_=LO"Z:\?Q7]_U^"G 2=O*?VDE#) V,(1GFZZ<)B]$P0L=_Q'G#+\_S#B
M#W:^W: Q\+3[Z:[.3U<,O]K\V^C_-#UNH#_<E4$JD'0(_TH'4BB%C [D"03#
MOU>6LBHCQ,D.;@N_S"@HQG=TV?3+J/^XP]\K^0]N?U>?S.4/E906V,$6>%E#
MUU!)V<D![(&04Q(7%A$0%A16%%%44CHOKBPH)*0H?EY)25!26%A 145$AO\?
M)O\6XO@/X;1A(+#<+Y/_$O\C+U^E^LJJ<KC(]?']5OGO%N9_OIV"G(*<@IR"
MG(*<@IR"G(*<@IR"G(*<@IR"G(*<@IR"G(*<@IR"G(*<@IR"G(*<@IR"G(*<
M@IR"G(*<@IR"G(*<@IR"G(*<@IR"G(*<@IR"G(*<@IR"G(*<@IR"_(=!</]Z
M^ P8"I)E]F:6ESN<!B@!4/Z'[<C(_]0&RM=GLY:@6J&A$']_-FL;@!YP].15
M -I/SVA&.7[J*AHZ+BI2[W8&@(*&AHJ"AD> BXF'CXD'P$3'P$)%PP:@X!!3
MFI*14U Q&9DDIXR.G24AI18\KQ>7-#0\,FY@;.L>&)^06?:&F8U=3+^9@U-4
M7"4T,>_^X#*NL(B$HJH:V#ZW=4%(">@9_):%U1#DX'VC_'%E.Q*1]N@9L*AH
M*#][A(F%AHZ!BHW4FA CV41'(<+&PD#'047'.M(>/2B6 I,8Z0"YGJ%17'SB
MX/ (DS[2A:3,(3+!\SFC"V_< Q/*FK&$[-I8A46"L]H7E]XRLRE[7,]F$551
M!7GF_OITU4_[ P2  0;RZL# #R:8BZ*62MG!<<O$G(K5]^_HM"@)1EHPC<8;
MC(1?@*JX1!N +C"%YP:JW&RFOT6#!QPS5(@V&2_4%'?2#G':@C4\_*1=(M?-
MQUU&J XLNFA8X@B=,J2)5(7 V'3M2(.&+Y-6L908Q#*I."[BF\CK/[W!1EB?
M 4ZBQL$E](XQ)Q%35]UZ:4Q1,M=%>0N8(;3$+.C!B<*6K17%?8OT'-2(:]'3
M].K8>Y.8U^=K]DC$.O*7TOKOJ8/?I#L\2*/COTD]*J=-03BQ[BL]N:J!AS%2
M=:T^/W;_VD/YBPL#:5HW8UJ[8R2&GE(87P-&VE>^[0;Q^#/4 PM$*2*9XUGQ
M^-0I9NEYYSPUDU_1WNKU7)_@"Z?W4E1XBA4#B>NSS6?6CL4>49^8I=76+\',
M[[9,O%GF7]2A@@;T7RAJLWN=6>2.N,!B_#FDY:K.*'4#21PV+8QJHL%1:FQC
M](&VDP1%78?W2W!12=N9S);("#<\Z[W@/GB+!@G9U*(JEPPFQ/SY+$=/-"#*
MK>_![KE\#+PTWJ1:OFX)VV1.W@K094X4^_7DUQ-8QM5B,<3A;P;:SV^/B9>5
MLP\JKD,AP:X1:7.Q5G4<&5P5KGXNMX-[XV>J;^VD[Z[JV<\:3=0Y;TK#H"MD
MT'.[-A>[N?=OBPU<5Q!!4Q#!N,LT57<%L-CBY\U_J9Y>V[D_7<0(OCE=164\
M")TM1+@V>,Z4-+S*"^><]BTH],^_[[HW[_H8JTW]$E[-JE)(L[7.@!@*=:VL
MVTLKVID0QM4U8TC:B^T$N^<<CW/,V*>^K/LW+$_P#9^-*.X*:2.1,%Y^GJF8
M.\*BYL3^'$'#)%0:EH&CO(+&D;C-VNS6H7XM7'D2<QBET[7'.#)I85VYLH@G
M\+D)%3M*K])(GPZ%<DOMQ+4^_$OC.1L!KR$=!;FL^0KW5,P^M#7/LSRLX KI
MELB/MHYPO^C!Z:9Z]AZ7%&IVV*V#5Y&U*I7 :).BNDCFN*KJ#4,+&I /LX\K
MMW.F@_IL=\NSHG-H[CZ28,++RSC+&1'<LW099M-V"]Y#F8O5(\%4:\QW4]))
M&)DC0TD-HG6?],<9*KZ*'[XBV[4-$P+J#TT=U-]X/6!15:;PE%(0-[Y-1F._
MX)RW?PJA.6'GP]BT/.6DT7FOXIUFH)BR1$-4N+2I XBV4@SC0J'INN[ %+?&
M#7/>QWF7M,<Q3,9+T,K,4>Y1?WVAK6!B+)3R]YE=C9,45KIR">]QFZ71MKG!
ME,9C$C;&GAH;KE"7Z=QPFJY"'R<,BYAX\C8:<S,K5WY<\NG<<:]/55R%?N(*
MK:;3HB_S:&P?(^@S$IBMFF=\7+%Z>/#[J[\0/KA.NU+B_>0M[@V]"F>[^Z*?
MQ#C"">@BHEXEFK.58Z(7E0R1J+?L5GY23)1[XH/K$_Q6%WB3.2NZ8:53%%^_
M0P>'QX$JJ(0M(>_%PP^T>#[FCUES]H5-J88Z%; Z+7AM'W>DQNNQ9NG'Y@KE
M672G5(H$#M2[]EHSA6;HW<S2.->[6B]L9W@[S=)VT73T+9["%[DHM:Y9QAH%
M1&X$?:*X>%(RJ26D]K."21*K8LZHW!D,HD"B,T1B8P_P.&MD&)TZ29GC=-.,
MA44B8XHHNB4I]U%B5;A?/@J5,.J1HN]P?-!<;37&&^T^<C[--6M2Q=;@$PL*
MRK9RE&*Q)W_^\^CG#)JW?J(Y6Z0:?H%JNBU"^!8&E1VCUQICT3DMV;CR!\K)
MKQA5HLFM5DRP4C:L&8G]*.S+?8.FA9QQ>6OK9B[ ?$-<"[+:TU,JZ[%*:>+L
MH=S][S3NL6PLJE&IU^L\RH \)5/#Q4]A9R.V:1L]RQG<TK%:I$>\%.C.&GQ6
M2D80WG;M&2TQ[US7+&]2=2V/A8_1@5QCPYU2,-"RO3KHK;S_]1?BZ?#ZO! 2
MJB\,Q(1TJ2WI]P0;B3DZ$\)K,G!PALE1K6("R<2ZSM]SU;2>9^32596X4K]$
M5Y2*G=3P./[!F:?8[X;#-4C;0_L?BVKH%0HNPVZ61&4)60H4])-D-T>&[[?&
MA2_WL'P&QFT]JA'%$6.&0W.O;5&?48.\+H(SX>&.>8=H13Z'R-,,7JL:7N7J
MLQ9,"Q=Z8C9&PQ%BA;Y4<R7SP6SP549*JPN9^W87SOBXQ92M>7EDRJ8,XRA7
MXPS5E=%%1'*36T,-[[P#,*C^Q?<WUE^4AFMY)N[N7W^\G"=0GG)&;JF)<"B>
MXXG8B_%S'2_OF5RNZ',V#<Z'ZT0I6H2F*& ;J=L0)'M9KICYV&PZ39'-U-]:
MB179HH)?N,FJW!0:(!>=Q15EM]OG_P33UDU1(B=?]WU)A_&T/]_%>7$OEXY)
MW;2,.[(*R97KSJ6]NA9:!G4>DGI^DG[<B^O="O?[J?#:R*&=D9\)I9*%XK!C
M+W!RT;/*EBW1B" . 7'[^X-I.P+=!CA^"0#-\5[55A3..,&9Z+1;V=(@/6[7
MFQ@]TG[.?%?J4PGCW16CMX.@; NF*00Y29M"V76/=QZQJ]*@U0W$FM77$?72
M&*F_X-D 1G:WXJE/4M3LE(+=]C]B7B88O"VO1ZP;G]=KX^'NI;WR17))AT-E
M/XZT*S4Y-4 F(\U!N630'1&N8-5&23JBD=:EH^9?%UU#:\ BT&,D4=^MU:LV
M&%RO6424SL:0.I$4;"P/(<Q3E*2XW6:IF61K&:1FW?RVYQ%^@[RX*CUK7/$[
M:E!7&R?T;&='A7CHV9I<4Y8X6'R!)ZNSGABM;)CR S&XM\%ECZ>? KNCF<X\
MO<BS:);NS$SY1<,#ZRD6).!)C4!4?FQ0)3GEQ&OR]E;Q-%[<.H*J6"M5 7X&
M[87HIV,C^G&XV[YG\NMJUPV9&C&*L=7>)54W4:B:*+-S;N)5O$&W\MIQUW^1
M14T6O4S:4Z*HKJRA,!M/UA6D:P$Q?3^UWZ#/"'I*06ZI.:Q4FQ[^Y.ESR?[V
M)UD2/2^%2+!BKY]7GR_D[[^8^OG*]B-Z,-YEQ2?<#U,UW2,%=,>F!,KQ:\T4
M0\ Z'VS>#+J7Q0-+5IZO/WME_F0O#<XO'77WH0$3:?7RH^!KXV1OI0AP,/BC
M4RT57ER.92LR"I";9$&@7P>JOK3G<I*J0%L*?:WP9J?3?N*M=C,B2YP!WU+S
M6B.JT%[8APA4>^Q&R!U6O2 E:P:TD(2-FZ%+@OF)L@+]^D.#//DW5%OHF1:8
MMF/#EL7S<PH9+-OF1]2\1\R=?>014P<5:X#.82CDK6.T.17J-#[K!0TE</UJ
M5/M++%,ZH<[)^J?4&=3*97UV&O31[G:7H)83UNAE!@UYU7-RH7P]W8Z6.?::
M8--6WZ3 G9WW]\?""NZW9RVY: PQ*V@6A]S6PR6?'8/.1+U5\O4KZ3X#70!+
M'0QR7#*/X/*VO-/2OZ$'\Q1SM=Y!Z&/X'9_X_[=?F(PQSRGMN<426<-V):G(
MY&_=(9;7S.-]4+4>MM+_R/-3I:4_0@_^L>Y5NHLGHGIF%KJ2-T*1,<//JF&_
M-BHZB\:_BGG-\<1K9'1".U2CJ @.O[;XN#MA2K?&=R4ROXCCHMTHV;QAL7[$
MN&.%?7\A8J8A8&=JM0HZ*VIB93BL\VESNFY),+16C>#I4J;WO70">-2$S_F^
M$,=FYK-:C$F$M"3%QM?$Q!.S'@55=-,86)HOYE*N-EMDUR:NGC6O+79=YUQ_
MG"1:E[(U"ATE,RG?BNRP?H5WNU-QZ[P8A=%^=LB0Z<*NG7[,V80VNV>:6#BY
MTB\4C(&!0Z2E&AVC@G+I,XPYX,Q7@F?;(L]1S]"1E)2_+Y:VZB4M:7)N=VD4
MIO++X?.FPVM GS"XH2"A=ZNLG 3K4FO\8):^9[-2, O'V]9W-!\2@-3EWDSL
M:O;E*HYT&M,=L25,EBV!*GN&D8ZC=9P:KJA^/9Q6;U-[9YD\JE>M5ME;MF@[
MO]"RDRL88H<!SRM>-BO;7.-KE'C/NF>O84^5*=JB9D-3'(/[0!#"4%E&!W/I
M=';7'$6>;/EK[Z3O5A5[=P#Y$2%?R<+UMH526>"IJ\DJM?L'V2EBQ7&9MI:X
MW:G(9LZ<&IQFI(H-DZH9B6W!/#=#LWH9S&H\M3AI/H(HU@9ZBGG]:@D@0(3+
M)0%IZQ$U"#U[)A@1X< %>$#Y18*'!@.:+U616"IXQ8;-#4*I4FN\LU9IN)M/
M$#6<97+5Y4[EK1U#OOT^\.O8FAD$WWL26Q4[T +N1>K8OM:M">,M8FS)+#!O
MXIFNP8K5ST8+_<Y>NQU92K@:OM=:%E<;S$6B'LR:Y.@^S[2[X+@YGV\45?*+
M+:]0Y<]\RQ+OLRQB!NW,^O2)ZQH[XAW=PXA%?)FJWVDZ[&V&$U"IDT<]A':T
ME=$,-SY]JB$.<3),:X<5L30Y[USX.867%U/];K"^4^KODKQ/FN<'3,J^=Z,Z
MIXA:)?-&%5WIR+Q2OR+1,]**L=K$ F<US<T-:"%H;Z^LPL^L9LWDBKW0GKKE
M:RD*7YR'O9\[!+&RVX"+!Z5W<^>I(AN&**2C0^:"()P["T_/3#,^Y++DQA_0
MS[]MAFM;,"@VI) ;B#JB73C/(PPM=*#I6\VP3(_E]JB\E:,Q5JJ<O/.1OZ ,
MNOASW9)% RFO#RX*O@T8?S;TLX+4BU:JY6SR%+TJDRDHZLYBE>I'.E,]L;K*
ML8:X02#-$#6%>(%N<JXKD7;A%!V)J[=?_^LP<O'"K*''5473OY3@HS[@&5^9
M#CG^J0\??U%(1MH1J85UMG^Z)/\+>?^N_*)@QOG5=U0^32XO7_U<9UB"D4@Y
MY7Z3R_/E+W>;9SZ;_TOP?S*'_4(P3):>A8%B\\K!SX5C\P>YK4R'.U9V'_A$
M[FC_;3FR!OI.UL"_:X<EM8/QO4_DE4L5[]XC]\&46L67[@-U ]K7_Y?EP>\H
MV^@:^BY'>AT"WO_9J2V_N]L'F[]C-O1#D\OL_M7W)ZS2QPC&1.PV!J3\O&:.
M*OKU.Y_(RP'T52=3\IU*OYE#0,J6T^_KY5]+_'=KK^%7Q3?][F)]N5MS(K1/
M&7,L]!>O%_\;-4XX]T)&]>1JN1RY2*26VGMBAMJ1UV]/>HV#]%HF(V,.> QO
M>??+;XH6>#(FVC]L.!Q'>;K\NZ0_/9+7GTBZQU%ZB$^FYPY0XOK@"Z$3&P[Q
M\3;Q'P@<Z]^4X_S[5#P]RBN0[S=Y_7>=PGDA? 3.__M-Y:13_W;>CN0PCW_<
MMOR^;'UN^(-J[N7G)K__I<IU->KUVK(H&9WBK'/>)+.H@:Z(C$-7:E_-W5HM
M":\\^KR]EU?@/.WK?-]_=]YU=]Y**?6Y_L0%QK+/=Z-8*U"6?".V(_,."$06
M;F4.+G3T1O/SIVZ0D$FDX/%4;?B:JV:_<Z! !=);1%5NY=%X?2'X-.XZZD9H
M;[E0<U=B)>+#A2!>8LY!A+\08W--,C]7$'FL.N-U W19\2=/$EKBE8<\=--S
MAS58)8C1O^A/7JYR9W,VZ]X0XZZJW;QE$%@?_PQ/XQR#:$AT$/U-(7:%> ^C
MI\YW;DZPQ'(F2J@$QN"SKSIJOA-QQ-%$*5LVJFD0%).6FBCV:&9Y-QOR=+S$
M*J_P$TIN=7YHAK* T"Z;;'@K5GR?.]GSY3W^(+4]<>7E2T3VRL-8G7WZ]'(R
M _E#!3S8B7U9ZD1J>X]4M#?V(BZ>U:L-IUXO>4-^8T9"(@JH*F(O)U%PDY*M
M,F.BU87P(J&;$Y=DQ1K\BPB/ _PR6YRWE!-Y;F(MC%*8,;=G_Q!@.$%[>VD7
M,38.:R"=F<'OYW@SV<?*_R&^1^?L02*8J,]'UYLFM2*J52 '&.OS$E6[.%XD
M.PS3EOC-@*D?[:AGKW>(F'HOM[]K?">O('/5%3,IE:A>P#;X!B?("Q@+&IE%
M6UBN"-?[T.84-."'< /1D$=TET-"J%ZD@AY:2/"$4ZKCM54YA=BMNV!-W\8_
M2*EA >>J#[$A;-7,T9][93FT3XI<O)%GHT# 031)P77W20WZB- F7#04B(H:
M+TPY.1L+L7^2PT=!&V1I5%X<5YEUR8+NOFACG?-T0LA'GLFY 4H.-H$7< ;*
M*[>&=#R4XX3K,\/LVB-L]]L%P&AN Y-32T'L]Q6ZJ#5"\K+%3+8QU.-3N5!3
MA^@K!?76@F\9BHY9]ZEBHA-1/ ._NC:2AKGR_/VSB@RCLAAGFA>MBM@@ 1&X
M3HT#(W=WNHGV@! I,7'GJYFP\(1G$([.GAO8Z*W7NJQ!"^.YNPIO1_%>!+L2
MH4K>?Y32F1LZ$'3A4?LXUZXS.SN5U-4>;);"'K,S]V2J[0<2[<CMS\VMXA.^
M !A^9DZ]S5C&C7(3=]'E"3"8*4-Y*HU9):EB99 E%9+ ,X&-:7H($,,K3R0H
M[C(.HORR(#@EDR=\#D,_GK_)N=5_HVJ:;6GM&I\T:FEUB^'<1@C$VE)R/4 3
MOZ6'+&/I P&&7+YS-]QK_2R8B[9M+*F;Q[W0A^:&[;,2%7M-K?:\"WK)TQ7G
MEU%UT/4V#C!32\7..,6D9@H'AK[OT1?5]<?^[>78?_'"MQ+4>MN&B9^GGG3)
MB @[]\I9JET[E):@EZ+!#B$\"TQ]VBQ,D!S6+>@R.&:CCU>[;Z,W*=_-_:)S
MNF62D1&C#8?,(:"#'!'40X?-IJP9E9AVGYR^(;)&NBR[X<%;"=_KXA:,Z4K3
MM\SH['(^JP[%AVB)8?'S^%0&TA0D=5/<U\14=.^-A#BCA.62/0)$$7_>]N&E
M5 :+P8I,IYP#0+G]--@%!(/9>OXLQ<YIU@FU4U[E\Q#XNG0%NC=U@:M%Q34Q
M8?_=:=>]^0#MRM=;C5]>3%^17L7:^70+Y1YMW17YT&W8:]@'!-K>_D$_"CA:
MW3:D+1[[VOI*J)!$\8=[-@<E0YYCT*C&)NR8.R+B^?6YO,$]);QGN6PN9ZU[
M[MS<G'2OLMM9=^'EU 81#5L&T;Z'7J(5DS,U=D;O8U:P;%4)2;P$=I"ION"H
MX;DC;F!Q/B T/7 Y<;(R2C^B>\^EKG9:H[(^W6]A9R>CKM2ZRFZT=UQ\WIG7
MHL:KR4#%FWN'_-5<[5[>;*U+#;PX?SI DW?0R!/6K2VR9?S)M9J\^'IF.Z,7
MJ-!D5OQL(Q-D;2J\$X>GX;6D9[K#1_XQILMYU_%TTBN-*CP)K>SNQ8=<*4YZ
M//2J<G47=5FQ3#I<)&)H%)[3&W_?]*[?&"E;0ZVG<7Z#?6&^T=3#?-'^S7&=
MG0D#^YX(T8^%WL46-=J&$*R*3Y^M7U^#;S;5--7,S+^!O7$\YO$ *:ST$B9[
MT/-@-^7%6M0#JGM/RV[!-@TJRBQ*JJAXFBRU*Z>W7&O?513V[_*/-TA;&]BJ
MU%F8-$3,W2,B'JPNLC\#9*6M-V/  9 QB0L$Z('-$S>R6J+P&,+HMC@4;INO
MD%N8G^&Q@+>P%AC-5MD5D' T^!;PCF"$<BVSJN#C15*HJXA/IVO/GBF[7B48
MF9Q.22M;75%X1;.'C.'ZP[C;R76ON^:>[_@_]G'O=F:_L8<E6FF0J5AP$"MH
M5_2ZW3"3Y>4G3=%B,-L57FJHLSUZ_-V88?G.5Y46C(^;VK4"GY[UR9HXH/,B
MNS/%=<9AAO=<&R[.GG/Y\QL5 -#UR,3@I0%=#<9KBRW-5)KO9,/:;8!,(K&O
M6*VNTIK;#*H#VA ]^OH.Y67DG<Q-QF)]*XKNR>-8.T9F3LKY5O=X$LVJ(@AA
M@UU+EFU/-AJ-G;%\<$T'9M37)/)9,QJ:LT3+/UO/=>5H<0TI^3I[V&( Q7SI
M_/BNPDQ;Y.:>O[ZS=DXAA_79%0WSV#+/-'\ZSM;IC3HN_1RM#V197KFJ#UA
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M8\M9:R%=3G,DUA+-_"T/RD-KF]\L>SVO#D?<:%A^2O])?BBB@(+IOH^VST*
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M[EX!HM)882%Z8T1<@YEB;A=MFZ:-2.92[OY"3NX#99[NGC&AW$<1,=K)J7?
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M)X;]"RRCW*P]91Q72I/W\O5E:T(#JB5(462O:.'0?Z9,>R$5*-2O"E*3T4X
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MF1>6P@BV$M]TF\/H2C<[ TB+)9)WK''ULRW[6AGL?QH:QZDPXEK$CI3.9/E
M@T(68*1JSDVT&K$+\<&L<<I/3Y-1+2;'IA%DO##,.2.?6,'Q.B@444YH8JW9
M*)UDA^9\D3MA#@>#-T&4(6C0X"Q9CAVF7XQGE]""O-D[ST#@C2K12>B^^V08
MB&8:2Z&\VN*6?Z].W</#PRX%1PU-0H)!G<?P06$%H[VK6;R#J8AW:SI&RW61
M*!=EJ0I' [!4YU@&V5'3%3$SCS8.8$^,S%X&NQ?2ZM72U+W<6DOKFO\!D4X4
M*/_AQ2[[0:VK\%?6VJ8&L&@I*?J:93BF<6<@' P>LK:\:95OCW*[!,8=-UK
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M<ATCPA3J\R\V+$KUZJ%4_O=?B4!189N5458!@B95>"=507=IDZJ+:8=M*V#
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M178_#.U$_(3]#4L-^^0+9==FEM\\ZE3B;[QR[I4'-ZY5YB%X1+K$"KS.&F_
M.>KZ>+SM[!&^YO_QG412[CB/BG3 IP_MAE,#,(144$9A>9UC5[25?,'VG_&;
MYQ0$44/E@41+'8DGK-)+*2X_(KNIA8QCSZ X]]LE-^I@<7)QY)<*-=D +MD^
M6^(\I)!P9/@O7A Z-AESX]BFE> B/Y1<JO$Q"/MNTM2][/BT1AM*I1L:I)30
M_YHQ!SKO-/0R^L"IKUIE%.I[7?!!GPS1)23)U] \A]-1S1%G(ZS")XAR5>0F
M&NAR%.ZZ TW:ZCY,2R2T9D-/2CXCT?J'X5+;97)C""^DX (<-/-AY394)PO]
M97Q3R"B]#"3J#]#&WWW6YKJ_YB.0#B,:RW%H!I9J.K1""<MU8:%B<D'G"M#H
MV@I;C+R]CBZKAY+2A&"*%=+=FX!/E(U!"]*&#M:#S<1>2DF%VJ0\?8G[C<J:
M;=FJ:M66Q_*[QDQ]:/LF(XH0F<8LBKM_$JW(\Q,G.KC8[,U=G\W5&YP3%B-T
MF[@/0=/BXZ +VZ8.S)?ZO!8!F>43N7-=\3H2M0$0.D$-H_!=9P+-MB3UO&.7
MWZ59*.CX<<6JC0:),?GY1:[R@U[S^HJ>TNX-8BUTHS3P3VJ]\M'$G].:YFHJ
M,U#3%U*)9I%XIRI@4*FLST9%Y^#U*O428YFH\36L%QF&1$(J;#D/004:@7<X
MRI?H8D74J2/=6EJ7X4WX7+IO<E&J::"4Q7B*5WHDGN3UFT0A(L=11\<D-HH&
M+WIEOQ+!QDD'OHCN0T6!M\'0B<L3_8#O3[(_X0KQL$'<M]&].HB??J2\$-D1
M!MQM<("/W/RBGK/8@2D@G=BP/!6.SO/YS1 KGJ0(!;FT<=<T-'RV.30!K!U3
M:?=.:F>N(M?E';G?J#8NBX*+W0"1[P6=MWI(?>0'K#""F N1)7'^X%LR$@Q/
M8]28-V2DU(BR"544Y'KP' ( B(%\2T4F 2A>M 5*[$+/75Z:DM=%(=!B5@'\
M](NPAY_%3BX#U@_/^Z.N2CSQ].F5:_G>LX.-H0A(8P;U-Q!1YR$+CPJX3&KL
MLH@_>XJ#:>JA&Z'CD1HX$K.-BM@7=E_..:VE!,"'$4Y\B]Z M8K0Y-8^.$K#
M.Y,P6X)GUK?SYC;KQN'A2KQ[E04OKIU:@"/\4-FM_A'.UQ\3!HQK:6\]+X^U
M2HFL+8EL%X.,UC\X'],]7.47(J%8OZ!\X%FP0;:0OZQOB!!#Y[_T)B8LE^.<
M@7.HDW3[S ZH.=^'6F0Z_W$<UJF"/O&(Y), 71I\=W995>?Z>2U-JK LI@XQ
M3@7Y!#L94DBTU.4WP@@<T8,N4D!>1Q?QD9_L<1].<@84>#J)PJ6QCT7(\0WN
M[E__D7N[+LJHEJ;;ZKK-CBF.[,W6.BB]36CX.RL),>S2CHT4KK)O$$_OHM:>
MGB3]3.D2.4U=4Q5@NFAY9,K&\[AX"5R98@0TNBQ4-&3TB1)CV'2*C_"W18\L
MBQ";+ZGQ/*S1UZHPZ-<H,S88=KN(GIUVQ<%Z<Z1AURTLI(4;5JWN/(I7XD37
M.3=/"TRIJJRRJ'6[*"FST?S"C7=TUIEW)'AC%O- -G/9$IJZ=Q[5^)'+7OO6
M )! P7,@>V[?-(@8UP"WF2-V'B<U5U3^3?RNX%4007*:L41D$UK+7PDF+FDL
M2R;>[7JO]A90S"L:EG<=B_$V5^SR1K=JDGE)L/U!;[L; E1.WJ_D'1\YIN.1
MW6!,#"&<D&$T*&AL(3U*1L1S^[UYI#.WSN#@B#TQMR?!T-E[QMY9BJ1*)1W=
MF"MEJ)6_KM*:L"&ZKQ9?CK70;9%Q=)-8DN?U^;/)-JV;S 9AHCGNA(S6[R/8
M7EP1G7>!:*0=YS)VMNT36BC.D ;Y(G8I\O>G9M7R,J9?U?]E2+NFO&6!>T)P
MINC5.Z1MBK(#Y0FOR_.HXX0/C%M_"K&O'UB.<X7>S!3]+[RRJWNFN3&-:2&;
M:G%[-B.N,<OYU22:51'SK(%S;L:(ZN&1T=;/!<]F7NP]FRF[Y[.()"U3E=>K
M$[(<Z8SSYYS+W<]SBAT^0>S*$X ?D*XO_[*,6^?(/JWOG9Q?]7\]T&]*VBCO
M-_YE*VZMQ<?Y9K\CK^M14C>)?\%!F3&BYI#>)^?E\03QW.?&:YNB>.HW\_EX
M3.[_R(!L\J>'/O/KHG+Y>@6NP8V$;%UJ01KP1BYG:,Q8-N^#VJZ44MA$Q.2D
MN[MJ75-MV<["UN7.<JO.SM<X@<<%X]A=*Q&Y:@9O7V_C'RFQ+>)<:LA]%^K6
M,-AJP9N!=-/^YB6X-)<<,JIE.I8'3Q#S!\K2ABDYW5WO0]5LB!4"0CZ?WE8:
M#=Z1&2Q,2@ZP:V"4O)T^4&PK0@RYU(B_:YNG>X)8?72)ONE=NN<9OYA%,EWR
MGIN!M]<8%W2G&TAOZ7_&K8_!(4C[X&)>P.#MC0/F3U#&WTDC@>,)(J_Z"<*Y
MJ<] J([Q8?WVYCU!PNR;"L/4D5 K_,1\.1C31Z[HJ_?'^)!^>#,.2OK\B?FR
MVW2)7NLA2+UUITG.8-#*F#KSL*D(!\J\A?+)+R#]MP9^54-?5_\A#OFNS>^Z
M]^**\VA7Y].EQ]PS6X^#?.:@XE?_Y_;M]Y4DUQ['ZX2@N]^U >@&,E%''T;;
M4 E_WA;GS;U>E,#'7N8,=/Q$8SGG*HTG"/O'N>A'ANO[=U>W-;\576HF\)'W
M$7!%/\JT-?*Z+S]![%V=_S[L3^S+]9K(-J'[Z6=^L/TS'7L&^IR<<9$2.';T
MWI;XVNLJRO[BD?X?VB)_TX8G[MYV%=7>?W3E9>+;'FG)0UWQ3,5Q15;]T$JX
M&8+D[.7E=11U?'O^^\Q313]G[D4EY'I\@B#XL^17=Z'MWXS\>%!+X\QME/MP
M\P[M>>FS*V%0W*4[!>W/+E[E_>K[>3WK'_M ^1OGR1,$W?/1NNXE\&_BQ8Q3
ME.+BJA2>("+)^+XD7?>N;DPTSG[3L5R]_ ==QW,",D8DZ.Z:C@"5(5C=#^-'
M=IZ$L\#?9/UCR,?MATIB<-/2$T2I%Z7]\F_[B?B' 5Z4UV*_->2EETQOLFF.
M]VJC?*[Y$67_Y_'G[;JW)7G\2ABT?G7S9P)^*??RNED3.O$Z)G0'WS?"_5+6
MN8-K8V_3#6R"%OX^CPL!OY&,^]KE8XGEJX.S<WPZ>C''HI9=M ?Y]'I<N@)T
M9X!#08VD!NQ4T *!V\)A4]/8W%KQ9A.GM9),HW?>NW5LV/F7<!S8D@L0@; *
MU,7&2$AXQB;X3FTT@=J(CHWYM![^3O*+(B9;1QQ'9'(MEAB /?3C/:^ K][<
MUZ/M)SJ%D80N+>\P^ H"5 RKO16#=LZ)[Z><ZE\RHX:6A0?BMBGNN\!RL5J^
MU30XPJ0;"VPTRJ$TH,2:G6&G%<'RD;)8Z<8#5JK+N8GA.SH;<*"RHA#8]R87
M/+XCUF1#(ND]1I2;FQ8IL9WT"8^<)&_@$S<1=/>A=:+#?.%B:O-1DJ>L: /A
M:W2%8@[=.XC.G4LCQU#_;N6(>7HW_*@7:1/].<,6VAG][>*^+U%[.Z2S)W!@
M05+PO5T*E;4MS&-K!"L1'W?AUD2R]*FU O)OLC_:K2]ZS_>L)!MITBQ&#N'@
M@_01E1#ZY:J0[8<HF+(5*_MDA#K$H)!#$%=*-(-\;>57-PY&<VB4 )[1+**R
M^E-?8NQ74:<40W=ZD*)/L?WPC*VSJ\+?QV"SI."7J2OS#4^#.-&#^)80M1M(
MB2<T\2;95(\V]W-'K-%KZ<Q?-NE"3;'/N-\+L+T7C15'SX[O-=C"ZH26P:6+
MV"S:J]Z%AQF2V!7Q'Z%^BT\/IX?AF3V.&RL&<=F-Z)2!BT<PM_BA.X>/ 3>'
MLZ(#F\>+!<HI7*%[6LSB3>?K46KA,TA(;L,4D@Z0VI5^5E&Q2*0JD?;16)1^
M+9VI].Z;H&5%=AUE5L<]2&VA0"7U5UI]\M:"_0>GX7ES[:+BX=9#Q)]"K8@L
M[2@<R3YG3?-:D*/LF4ON"@)3V#X#,G\81G<H#_FZ0REG3[L'8Q CXJ5QIG:A
MO@YXCRUA-"88;)[(KES*)*[#@[V&)D"<;X3[6;)=ILG&6$0R#S8=81AX":M2
M%YA<B@@#1[$T XK&J;/BQ0-1,QACZ<IIM2XRB>O/E!_VN25(QD?SAJ-(\B>Y
M;5?SFP"_XD9-ZUP0-%3=.>2!; Q55#1?+H!@#IG;74(PO25'!<6XU.-%%\6H
MBS&-R>8M?*ZM,M^XSWTG-XB/*#\,^ #E[S3-F>-D(3]W8YN_U#*2L= 27HJ@
M:[!RB,6*]@J=]KTULX.Y!-9"])<\<4S4]ZS,GT)&P4BI!)V2H2*+Y<+6(LX$
M>WC\<^8-;ABE9<.#?@J^B1J-4FXDJJ>GFY!;6AT&J!0B##8-L/F19U B3$9<
M'I3$'78?I!T_>TC<7227F)UDT/>0U&?HU\Q'0]% JRU::P;,Z+NV=NP-K0ST
M;"7Z];!V-$LCGO@(N],N0\>1@K[["Y 9G*+K,F$.?:8R3=CX%H71M7HH1*+6
M'39G#R7S4I4NR6G;")Y:@X"#5=/<6(,GB_F6 #L(MU\Q:Z"_*W0(ADDP9FYC
MI<EV+$'D1_]@C[QQ@8@L-<<%-=TA&I"'>\1\06,*D50[A<C6?N7.,55O3D,R
M]>L,H'7,]"7BVW8CB+R/=48=#OWBE8-<IR-G=])E[%32H^DLDW0U\E+6TVK
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M:7WQBQ*!DA"EF:,?;XYI$"#54A3KR5>-9]&S!7E<SB$D;8*2+%R=+K0.6^\
M@W4,=X!6D$TKR+TY[?FG35L#\.[PY#"+H#A3YNI"RP[0>F?3QK"89@.\3SO\
M>1_*PS9[+S_/+>^>B;P60L'GQV&>Z>#!H37C\,O2_C1U\4'QX'[P-S7C+"ME
M/N[L^_JB&Z_2HC;C=-N8\=XY\=EZU=1X*DSJ"L@Z#*//E)SEK?.8!'6)]7E(
MA'R: ;3N:Y" 3N%NZ%4$Y_3)9O8Z'2M'H"&FN,&Q$.VNK#3;/=G1C/C(1-4P
M9OF+-&<PH(';&62M<\.Q"8Y+\O*S"?)JS\(]!BX?W0&.W)L.ZYK:*, $#\.M
M^'=I9G#Z67,RU_[-"BDW#5W!D%(LK!S^=2VVZ@M54 X;\$4ZU!>\BAE"820U
MY44'Q[I7G()%_+=%!6&7=:5P7Y*L=8#/GGGJRC2X-YT]^^1^G_GH735D)%\!
MU]X_"+9B68Y&T"+-NF6DU/[J7"T6CU@."%=U%DR0H3XN%NS9RTF <Y8.7*+:
M+S@K<::M%OE.4]8-/_)-V&^GO&QI3')?)VD O;J92,RB+G$/7][]Q;3;ZV%&
M!]7037;J^I[:'I#'$X1R2$=-B5D9/Y':%1@ W 0_7P[;.'M<;8!L!EN]:P20
MA(W:57,_FI8PKAV[URO.'!IT= %GK&<V*C,\IR@_2<<8$_38V:@G?M.1LYE6
M,70[O&U24;#+8GBX @'JP#]O-/J3\RX-\-.\XV, T+MZDC"8CM\C'(U_KM&)
MA8#&\YJ_-B >;(/,X<I"@.E>7UXS5:==<?"#$#N[UJ!CL(1.M=]MKZO_@$K$
M41S+BV%IY&AI>6L)[.PI\RQR]0C0^C#J#KBZJGGE5@1J>,Y=F[WUT9U[K4V_
M+#C)<PN,^+CE;7<XV+K89'<(!!W7,3H#ZC9!@"O0T@;8HVX##-X KX _:!Y3
M= B-KG:,RAT.=RF^BFOZH,63MIQOBQL&!Q<C-*$*0C]44;.P^FAF:Z^AHYLS
M'0935]!XV>0TW.2MP_/7-\<B=3OS4\#C6?LE= U]1%(SRJ]Z:[H4F:J'3R7S
M(<.[J0P$M!H0Y6\)+9\2KC-V+RS2G>4 IEDJSR^'I2W-@ZO=PA.FW>T#36QR
MM?->(=-SUR]S.Y7122F8G<U;?WKL1\%C-C0TU% IWFM.J'Q;\D54?,[' F61
MMSO$@ABW$=ME@H1'C&8XHFR_>/HP0NV;WE1"B=WLNHW--LN[4^:K;M+R[5N)
MF:ELBX1>T]0IK,Y'<-YFY[='VS"I-EC24/RV]+Z[KEXP>F3KA,/SFDO14?9"
M\B<(1@&O'^&:.M<*>/*']UMBRQ3OKO,<+^/RX93+N?EFLEH)&/_"T/L[@R.5
M9GY+976+"<S[P2F]^W7,)$]T,71>+^Z8JY"H5FI\C[R]L5K)]>IA"[C5M2>(
M;>R:II,<KMS>-L+/@V"/JSE20B=04A*@<90+'&?CE^1*F71[\4Q9.;]<#;EW
M] 1!^!)\#\9,>D07^Z9Q<DHUX+*W:= +[#"VM6:E)C467EL<^9##1]MZ.;5\
MK"BY% UL7(HNT?7!S3=#5EU+H E3Q9P*(9<$+"VQ9^Q0'JC^E-K]^ ,R[0DB
MZ?!YYA'^Z(GCCF"]K>@KY-.M06 3%AJ'F/K:8NI>+Q9NR-C+Y+Q*V_;5=J6F
MJMM#RAC N.:LF,J@]J**BNQ5$A>M<JV,LW)ADU,MG#*0EW?FXU\LXA\!MYIX
M;*Q?A6P3FK^5KY4RK!XV@5M]@M!Y?@:U=?W+A!C0Y=!H<ZGG*1_XD%0UH%AM
M'O?9YZ3[%LB?PBI^"I/;BL_\D^C;'=GCB,RS.[;S6[60)_<O__ S&W0UU'I\
M1DGX68[K06^>]'+O5\L6$SAOK"<(KN[\Z2>(LYSWM"47I'7'*5]<N1[67'L7
M1(L?NW]UE045PW@-=C^W939W7A6V%?KKHGAZQ?J-'YJ^URYM-SWT#/=4D51.
M#]6LQY2$S7)<=^+/,4OL-74;>HY9DY37C\^:>L\)DN!O^SSTO'LDMG==/R*W
M;\4?FAMKZ!6;OTR:9K1-9#5X/7H1__*JZ?WS:C5&'_SG]7?]O<=H(^\FV)\G
M=/4J>$XE@ZS<$X1>4%)GS9_)\IQ/N4J(6J9,>\BS>$[6G>%SQ%&]D@K_$+=4
M*KH&BE4J1DN@(!F'E?*3[#T@FO=W*,+GI'*H.K85W0.J6ZRW#!05(624V=BX
M:RD!K_A5IX]5>">+GB#,'0GI"J\F@NQZQ[^E1#F_!>W7KB<5#W36P@\V:39\
M6JNB;VBB);-H,;%4+:W]$1J=(2*WU,N)?=A9&P#HI-,^ ';0\!OOU1I;N5RH
M*+:G3B?PU^Z?J2[J>J)>N7A[2GI</T&D>[51W,Y@6LY?7*5$9(?3F_X_M7UU
M5-/MW_\,1!J4[AC2)2$#011&EY1TCY(0D-$@TIVC0YJ!@#2C&T:#="DETB$E
M^4.]GUN]XWN^O_.<YYS]L\_UOE[UOCX[N[:S:W+>:3[U<]1446E"=,-]17V-
M.J\'.PC+<IH'6G2W<7&0"JF1JR;C^N5<OF]7W]GOQ-6VW=A37LERT:B8:-2!
M^6;_':+9S A#X[W^RCR'8P#J4NZ Y'Z9[D!QG29QR]C+"="QS.S"M:],7X:%
M6,>O.VT2^G%6I/!A_Z'0;3]<AJ\6Y:^ZMLQ-JN]VFOU=0['I^!P;IL%S 4N&
M[]44M<GU8[G]VPL73U=-ZM/TG'Y,"?L%GK<I51#\=^,O&,*&_JY;&VVQ_!]T
MEZUO_UWW_Q?P\W?_BSC^*>/S2\"'G;>_*ZO[>TSD9_1;NX"SF*^KE+'/O1Y"
M@T6)-?N34!^AN=:)//(^AG^IO;!=_9>PBV[N3OT5A8IC[1* _'-]K'O,SGX[
M%-;*+D59GCL5ZT&7F9G\PVNV=L;.<E'J:=3\$?<?\G'A8@6T(^B()7/:O*TY
M;L]HY=%3W25Q@E*]2T>T0JP_#V6GH]=L*QM^)"VAW6D/1_M$##Z#^?;0MI]L
MQ<DR[+$& :V%71CM['S8.B(U'62?X_)AYT.(&Q)X,6591<TTU<FAU1HU<@$<
MND[5'&7;"N-+9NM\-U>P5LG(@J6,=L][%Z2Y\"KFU"TBFC=Q03=\C(Z-;7A*
M&WH41N/Z-WUX*>=XZ]X) ^5Q\/$"GR(6EE&C[&N39#[Z9G"W*K-.+4+?5>!%
MB950CV03Q=X1$RQJ'T>PZ\"CR..NH:?(),V(P]L0,,[5!$P3,4X-IL[(F70Z
M![;]!:DJP\<XX54UJ K)(MR4^$WJXAR^HE%2B'OWD\54GS<CCIF\ZZ1;\J='
M;]YB!79@1E9'[D;@9J1XM6PRFAI:*"T@ZNUK&)IC5_Q6WO!H?/#OK5Q0@<UH
M$;*]BVQH4E0D=^;NBC:[YI8>RFWFI[ $K&7M#V^3DV:QH^<$E='31E/<-C(^
M2@["H"*\7OQDA&=/%IZ,.=1&B,F;6AKYF?$>YF-&6(-^I.*, 9TPX8,@OD6?
M.E$F5A$R4!6K_0%S9(,7$T+F_#7C*22JE0#K,"*0[X.X^"$<%Y\(FQ(2@L,'
MM*NSNXUT#[S/?;_/9")])%FHWKAZ$BCI6Z1>2"_(Q/?,DJD_S^GI["Z=65+K
M:U5]'FECL=>2JL3<KM?:#PX.]HC=J/SVOU+>P:Z1YJ0F5.36*" +8("&]CW9
M4HU<\^*B^81E;TQ;2V\]4.<W3]"SSXNT8LH^S1/'&&8KMS4?'HEH\BW0YW@5
M@H;<[9'K^V2;%^//P!_4T65 'J#!S;]1=I,,]4-8,L6K6[K6UJ\5@>7D71>]
M@7Z?-0ENO+<HK\7H52GWX<V%OR"0=+R9"T6CHY*:>C/$?U.8B[']X,Y$M)@?
M#]A:-XJVDJ09,RGR2,#?WA4[3/Z4'*L\@YEQDK657ET;KOVJ8V@LDPT=, $2
M1 FXE]S_4B"VZ::QMK5C]*1T<GOP#!D5\1RI9@G;%GM);;7 VC:#?3I^3,F=
MK "BC$:PK_E0M'J%W.%^_H;7*;!]$MZ#7>TF<9\5.AW!LKL,5-55,%I%>['0
MQJU:,F//&V)#K71H5CH!:GGCK.\CKB [8[V1XG4N">'@X5>1G'E4/\A#S>$'
M5>>Y^_@YE3\A_3OF'D F9IZTC#]^3H=PYWL#V_+DCN2UQ^&8]&)F:'ZZ9-LS
M#M[UTJM%P?F+<.NNB34@3GFTS2>B]<F#DU/9..J=Z6X)+]I8EOY5J2<+3(K7
M>;SI3'*;J@A,CP68#6B0^=ZSTY#8N&J$N9Q\*5"7L%I80?2%2'/:G>N'#IJC
MQIFF H#]]FKGI?@]W'9?VV6$+LA !D-7L%,4C>^!P]-[$M>537&YY9LL"JQ)
M  $%IB%WC+6QH=R4'#:/<>AK*30"$]!U4&]-W\;W'U\R7(HW%4#(,' )[R@+
MP)D[0*+][[*2/$1MZMY[,?5QQ_$OO0)>L]D2U+)WM?.G!1O,EV\2J*M5AK9(
M+([$OA6_>5"7?@.8N)/.YX8;\0P8*(+?C<(_W6;17LH+Q!)2UXNY+R_&ESIO
ML#9>D.]8^U36$O-=.C_-<' %JW\TB,7(6!-I!3%?<W]5V5]M"9FG,5$!V<@L
M1H9D#"3S9,/N=D5\KGT802^,DUC5C">3F:2.PGVZ63V,)+;G34?@3L:"0H@Z
M-MLB>];S!5?]+;TJL9*%QSHUK%& 7DU#?8HASG$RP!=<4-<6-FAFY(TSWMO!
M(5G7:%:H-*2[BWH_T^N_S<Z.>^EC' 9E3<R57MM4M; 6+G.[0%R;8OOU/*E/
M"QBMD[E"D6#)67H&X@&S^J=1242X:#E,LRMVIZ*$14^A,)P-W9;)6ZTJJF 5
ME=Q)RIX"B\J*=4$;>X&\Q"K7IZ&]B8[LCIS[P9PAY:%M%3@6"#6:IT\U[$[Z
M^S]K'@PED>$?C"]U6KS.C4_C1N]Y*B>J72BLHJ9#-RUH)P@&@YVV.CK&8+$U
MXT5U_CSG18/ATE&/@(6I:>O"N8P-1:U'T?V8'6:;8ZK.\+(VG.?E],-9X4@6
MT]Q+0&-K-@CL8$=5E_K"U:-9PKJTH$\NE=I5)YT2!O20TA)Z-)R<48/ F5/@
MY_IM\.:_#[+_Z\RS[8L5,^4X!$R,//5PNDUN^LQUD\;JE.^J\J3VM\KPY^4L
MPV^]D7<=IRACEHE&)SSVG)N#!!U@NA:6NS>F-M'W"ZCWQ&8/_?]4;Q@V"WF6
MF/10Y+#V23USU\/(!^[IJ_)/W77\MQF2B3.K-%0_Y0S@"A4-%DN7X@#9&LU<
ME&.>/:,Y1:[<8OP9S"^D!*-=_R5IYK^2@E0_Y?TDE?OPC53OF<$/TGY5YWSN
MWTCS+V8RZF$@G*/>5(X]R>^R_E)QQ7P _0]V=;3_&^8?=LDDPNK(_7>_,FFJ
MO)]NEF]')^48USG>O2O^N2;:JF.61UFN](A*;^H2H,)<X'XT-UYX,C9M5>%1
M[+XZ/FJC%FXQM(18G'1%>&;&!QG$..*.@"M7S5NE"XQ7^WQ]T_%8Z-34M/-A
M40VJRE%\%LX!E<2!%LQKYCW2A0(2:H193@$! ;O+,%?#4Z4*&RL/N:A-]_)C
M1=M=U0=I#J\U3]V$361L="V<PL:G)7R.J B4G8]D]&S\>[7&$Q-&H U3;@S5
MQ_E) S7?*@WGZD;Z,RL.W\\_[FQ7F7,?'I^>_T)X\"G'@:*X,@T=6Y@YY\M6
M;,,'G/BJ8E[NO&]$"M^)7E8<'KNUUSO#4R2>;^:VN(8'P>M.LXNK6C^QK??)
MK@GJ60GCD[NIRJW,LKDW4'%=Z3%5<IP_')H7ZMRY!- K>_07'?%<86"X?%$6
M^%.IW9F[SO25V%??V.#?)*!M_2X!+KAS9G:4=4310+64;R-\<0FH>"Y+^\U%
MUI6UAW^UEG782.K&R']Z>@G@57;SG/W@^#,*J];-S"OA'/6-FO#*I:O;^65%
M#MYWH?^B_OA'2@WN1X]0ZW]Z_<< %'Y<7":0._9<_]!ZC'#?_ EUA4]Y=^9_
M\*__QQZ@;3T*+U3Y4'S\ER8R\O\7362H.!S:1F[I,F=/7P*.'@R/I8[J]9C]
M&>Y_U5_YP,VJ>]-6.U;((M'_]D<@5X_C\<ZW21%3HISQ:_S]7RN?(Z5FMME;
M[>S)T>U(C)MFZ' "L):4HU\F3<RZ>I?MWULD8T0))9= WM6E6O-7%0I5V\):
M+P96W\I<O&6SDASTM=6>"NL^MFM^_"(MET\K=9;%DC(+!W>Y3AJ.T]ES-"^"
MV%SW-?B=>W@M<'C0P@/Z9QM9XO<#*?)9M>7D? :*BXO?43QKRWR8T8/YFFS^
M T,_B)S#WE\3,_5YS^2K>_(\-X138#%$UEA^S-K&MWC-J0A8'8.U9Y<+@F*9
M5&7*WI5"UO.F#G@F%6\YSB_24#Z.GV9>,M=LH''N5RM@V1.DB.QD5:(+N=@7
M(""0MY-\YR6J;YE)'?"N;,/+1ZKB35;VW?ZM(@RB](PL(BN61LT7H.</3825
M1+,3>I7:8[+O1[Z,8DK(BK1S4F#"-/8*>0 (M1/@"D^-ZHZ_>OT@*TD/[/5:
MM"=B;N[30JH-OHJW^F+<-:+^U!S)2')?H2L3G0N#.:F].K@[+X4:$]9KDDS/
MX=KM^EC:3@R=/7C!\"!(;Z7[5H!.+IA3IMD<LJ-^.*]E)-:RE4[\E 5FA86<
M%0=LZ.HIW =5,AFZ.> (#9@M6[::A@=HRV3@Q5B"T(EP,%$XD<.]$1-L5N<E
M=1J[TLLBN\%K@C=YIDEL8S<59TK (U);(RB!=VT98<O ZVCXM49GI&#2%EL:
M8?'P)6;NF^$^7V3*#X!&Y4C<SC4P,LGF!G]GA^W="L+4$92>![,I2\>%E9'X
M;%NQR;.O2I.K$R OM(7(D=F/=[PTWWJ%-@<O0C^6W(E<&A+8<TL*+#EP":1P
M'OD8ZG.>V*I=/:CY0>[F3I!P]735;7O&)U/;9LOE6.5D4782K._\+%Y2U/F!
MD)QWC7("-J<> @VM3-E!WD'3,J):>F1>$.?(V\&@]:3[ZF,:H3/ +RY#M&JZ
MO0LES?60) (O/[J--;=(8T[6#!+/\FBB%:86@C9]XUM%15:T?5;P-ZM0D[AL
ME;RJE^9F3UPR+)1XPQS'\":>:;ETA9X'TKEGAZOHU-PB0ET@XTH8"-CF3 73
M9K[?*0)A8))V\4;C+V9IF1HV,')@8$UUX$K.EPO&R+(2;U,&O,D?"6$-_=K]
M10LF;\VG3@*>:=I/Y*_K+2KD]&+FB9"ZPW#4:ZD/2Q05EQSC576DMM,.(Y!<
MXP42]7FAQ4<QXEH_,08,TZ)&VK03O:_5912[WESA>_BJ3IN[BC6QC6[580B?
M\+,<8WN4Z-E+\CZ$HO<-.G!R<7N77#UB,D.JJZEK33-FE"LYLA&-SH[%KU@@
MBOEY"&H(":M074VTU\@,?PK1$E0XL#L<G23F4:%'E%C D0$1#;J-O"B9E.]N
M3S>I+]I<$'F\]F Q85WD05&S;0$S0P\[4R=6"#%;913(J^SD_^(/\/[X;B=Q
M4BK2R:$UW%:BU(R$Q1!>]/HP*%:4R]@2YIKX=.M-OIND>KIHO/MH0-R8>-!R
M^<&L77G^9H5J?I5%/MNH*SM<.B1QU/5I;P^5"$+]EL&46TFQ7HUX%+T>7:U.
M#B6-9J&9=3^2I% G<4QUK"H0E/:X:]+?@BO ;YA>-[,VQ=\JGR4+6JBA15E3
MJ#O1%VIQL,[F,@/;-Z<B:2"S.L*;M>F8Q,,:6_,IL*D)(_&-FA%5QWI@]7HL
MK/8^2DVT"@'X=!]-U<CE 7G&P93&D81<]^$'KG3-_,XLS1''5@7L2T!6_<W.
M'9KCC%6;Q=S76!QB-PL5-R8FQ#1J=9<5-G=[-0,WXJ \L#>0&:]1GC@KU_Z-
MS];:8N.UH0=""E(ZYE$NHXGYF0[HHVJ"M&.9#>0<)S*#LI[7J8(?AFA#7ZCH
M4'S:C?>SI1#);D?./B%DW.,P$T^?7(:L$#G*().6V@ZMJVNJ&1L02*MN9B4$
MY+0;IE/KL>PP\J="\"5 R@4M_*/H+J0F.O09=NR1_75\XB\,&9X1T:ZWOVX"
M1;'O.?%+K//F'M*XPA+0?;/@50K0Y7!UE[K*\;<S")N1DZ"UW+_K"SI'Y[W@
M<N-61>,$P-M;?0$987RI**^+6W#=YVFJ7!_$,)5^;@*]V,N!.I))$^0WFMO;
M\71;S2EE;!)!BPZZ\Q4+58U*Z2\.*$YZ F">]PY;>Y4O >(4GHD"_,B4XS,Y
M8[-SSL>5_3+@U<F$6?WJV('-UK9][GI6T\J&U\^[[]#IN5? 9#)=5%TS5"JR
M&PXVB\=\Z:==$KE:7W#9*BK 8E.;VQI]7=Y7J*44=#D6"EBIJT7&PGS-?=54
M<S1434H+&.L"DUNSA^?;1!O$J1#0KSXVD5D&ZYB5W3R!Q@'#=%(Z>-EBF@<P
MY9B,MTA9*5MG"UH]M(UJWX#0IN;( V-S"KBS*9M#.GW5D]A<P:V*0ALZ^W1T
M4J+ZK$9('X1Q>#A=KB]Z<BJL(E%?#RN7+;V.=47']\F%ZL)>9>@$@5@_NGH5
MY8L[\$@1 /VGE':*(O6Z->Y:J\[\R*V'R\[,6D68M9-K%M/P]V/IO%-OI^=@
MWV R!N<([8M:\KGCC_?NM$RQDE#=0</D5I]E$?G8%.!] T/)HDB[O@8ZYE>U
M'_K9T@:Z/%T[)9TZ6K^E7=2HO)9?X#YF[N7&%RSJI-%?BTZ6JK"0.>%^_/43
M1</&]72Y=HMKLW1O4!:(1N>@U>?.<O,P!:*$(GC-J<OZZ/1H1OZF];@U_[C:
M.DO^X3I/4P,9^+LE/[H$H+9L?*OE+6URF)$*?)8DN=(N6-W(ZP!CDW-#H?8Y
M'@M9NY@!P_5 E80[@D!\@;OWJ*SNV;YI3T?4-2/@!^A]G!Q^0V8V&*!Q@ZW.
MSF,.LF")EK<13ZJDZ?",O1;$(!_?+'?D34;SS[HBP%]0CV#%X]OLU$IO0]T]
M^C)&CT8MM.$5UN=]59,F\42M9N4/?)/7WW6S@Z2"MC%'PVK;T%-0UR&V9-5M
MBY2 (M.W#K,6#$1JI-/X=3JBRBR9P?8N1[=JWEK[6HS<'F4JL3O1(A@LD\68
M+]<D:^EWF'C6629(U:9!=@M\#5T<E41)ZTE_TT-F8'?7L-_8],DP7T?.,'Z7
M(K"B\O1DZB5\4R,SSO.I^$R-1@[*SA0;UKRIP 8+^9G!Q4Z7'A#GY&GV+QUT
M/FX]GX]HI%)"/6=</M?\909=6LBC.1*,):]+@#3/+UI WV<T2%+M9QX=E?\R
MH/"(V+/N/@X2DS+&X^K=]KV3?P9;9YS^C8?\S!"KL>D^$?+&18SKR6\#_Z2X
M>:"#:AO3=T_D$I!-^DLUPQ5##W+DBL,/1QKDJ1;[<X'=7EG$.?)[\I7:<SB4
M]?WU8RM"OYVR%.C=@1;J#W$>;[IT!DZR/(?#/RPL_\9.\XT]&(Y),? E;<_\
MEZZ&>7"A.AES1%U%-OQST>C_.\LWO:*H6?\2R&_I?@LQ[M2;QBWBT:K$QI'[
MELXO6'C_P?L<">J2U_DEP$""X>/1RU\0);ZWY7N\OYI(]>"\!#@94T41"S&>
MGV_^PH)]9:_VCR!Y_@'HJK^_ _U(@UBPT?OKT%?/+UN_CMKO^)\VMMTGLH\^
MPVV>73X&_0;Y8(#8VV;G'QQ]2W]7\M&WWI_N>;"K_K)B?UE_,C_O?N\_\OR+
M9M!Q&\7?BWV^[/J?MO[(V''/;O47O;/NM;56C:W%93XK1/A#XRUG^J0$E"2&
M/"^ /9BT1GDB%<KYN"T^V A;K/275/R:W;UBGT(H9FM.8FZA1W,*J>H[B,*F
M$N.&Y*2LO?(LN0BU%LY"J5Y+B.ES?KP0E8IRWIL0N&ZA1=?1;/EB!'UP;0;[
MC@0W9J8\\S(/Z3M51' F(V[!$V#149ZAR42NZ_*1]^0T\F3\'!,%UW3,.":0
MC_5A')C8#UFT"$%V*STG('6'MD*B0"2&(*8;!>Y<=(";3C!2OTK] EKN-?@M
MT0#5O#H#6C@UI;(!.()KR3>B[ 7<K8+W%6E!')($%>TV +*B;O&Y6\EA5P_[
M@A'G(T.O2(%E 40&@;'#3_]L;@(ODR!*44!Q3:!WBM%ZL#L9*Z(+])YKWBY[
M TG);NRUH?C9TI44]V%K2"!%(0AWY[C+/F7B#H[X9F]LFA8QD$90M8RO4N/-
M[#ELX1U*^+;\NA+HP_7!M"\MVC<)7QCZ<H,^F=0;1$%8<.+-?.85TS.&J<T^
MD3B:!Q4BP[QQ;,]*#\RR#B:?,%:B^!+T ,=&6#"4M/E/B:)J[GB5*98WLS&T
ML5,KQW]IE0R)K91UC&A+Z[[5^Z'5+WEN5XMTC@FZ!CC>+;FW8(5=H T;=[C=
M+"WN:CX*$N2NI1'Y'+M#>N]+_%>^='VWWEF0Y!J%B 'Y)8#<$/Q2EYPU+'NA
M>O,4&YO,&CL"[%TE8BJ<(=%F)SI-,RA9[G*TX10Q&M0E2"\[G-JN;VG<G+QR
MAXEU:9@K,C12C5/),\+0]D(,YS4& 3>>X+4%;,($B<$R[N:[-\JX3Z3X9.+O
M/]YEZ0'7]&)LB0L9=-+?)ACQJT^E'BTY*^AF-!'")<)U@_C?T%'D*:!-0,<-
M+G$%#M[UM\$AJCZ[-GMV=EW,R-Z!&PJ*(2\N/[B._-IB]OY%DR%A''19A1'G
M:N,Z.,=JVYL<R]G;1-RAS6JM-$E=6J7Q(I#N73 37D=P9<<U<[GY%C!^S!,Z
MUI!P4D$:]7MB7%PJ*TQ@E/VHV^+H'<U LG4.WFLV2]BFQDVLH3ST&%&,1:)W
M8<MO^%CE-LSXYQWR40@[HIQQC1A<:FV#5H?7;$AXRQXYC)0<R(K/B\896(A7
M13"G]^@+,6#&]:B?=>ERQ932#T4]8'X<[#\LK,+HEZFVO)/D]AX'(H71I>P*
MN=:3V='L+V6!%78S/FB)IB4.KWR8ULL_-Y>688BHC=J(/^V17<B(Y<V4+5,I
MXV75MY Y.O_H)QM6T#*N5(6$U!O9P[5HS\J8N"%9(E8",:E-X902>7[66"I6
M;(,7#P\@[%>[^2(1YWG6H%[\:T; 7A/>=RCB8/)';>8^@V)>JQ/R9*50J#)9
MCVI=9+%Q@^Y0]>F-H&=#!1E;O6H2.L-YZN#:Q?OU27>N6YTU*IMR<K#DH+UV
MOHL2F;/9/QO(1=%MDD"3S?5J0J#..M5*RHM.(1+%_][0811+7@MKO5"H VY?
MET]14<X$.]1%>TKI0>D+0;:_;T8^70+.!VN5_,5EE2:%H&8'_AIIHRX'JN][
MU@/I<)37W,&UR76I&46Z>LI;F\B>V:4/5"6H;VM<56(EAR<%8\;>!C3DY C7
MK,7+.9R*O'S?02_9G:%F?;_>0<]"5!\L#*D9L3VMX1C6.ZFL.A_93IPS<>NH
M0.@^*]0)-ZTHMO*<WZ"PX-_NN02\I]VRLYI%>'Z<]KSH.SU-U)'_6OC)M%<F
MX1.AD%EJ97U%HW^Y0]YB#W*]JW[[''()\(R[!-1Z8+'GNB6'[AUR^RI?W?@D
M"Z?J_6,$\C8&9$'\FY6GV\Y$]E9'EP"WQFW/G:D_(+5@RRZC$X>NFH?C%Y2M
MS=4+FU5+<VMZ _7[I']4N+T5-*N :?0W**\2<IJJRII3*M?W4#09L%4MY:\P
ML/?>YCN-6QR?=WFC8N$N:"XD)_=)&G;N$,NUMY>6M6RNJ<$./A1IN6?F"/DR
MXOOH9<G7<>%@W<=S%)+*1S)4*?:?RV_ T=W78Q\)KPR9H2KAGP]WKFB?L '6
MGJ35J)^M)WG.FZ$^';D$R/]Q62!M=>)L/0W\Y@K@7/ '0-Z:9Z[1ER)WPE<.
M% JSK!X. QF#=T=\]:[(CH0&O,_7121^ _Z&D'0)F/_&]QUYYJSQI-A31" B
M]P3Z2."'D)^4/Y3\E=)C]0]*&H7]C>^4V%E,I]GA XA]S6LC#C^<AG_#W(K]
MANEQ"8C[@^'*JM4;,AZFZ0N=\'[$OA[AJ]0LIN7EN>6K9[N7@/K-XTL Y:NP
M+*:CHF_$$E]?7F74<,6WY?Z]=.L2@-WI.)]_M5B/]8IG!_&NZ-Y_#_8GW3]D
MF2;QAD+B3P=P]/\)[0KQ(B7T@FI^YH3CX,B#[=J53R1R;</#?2!SZ5N00@/S
M$V>/6A$[VY> TF,0S]5<U\;6DMD/<0C5?@7/2P#DV-/3Z?;/H(1#X$=\9UH>
M?5"<ARE_._N+.$?;9S$!&0GS$[=PTDXV"T*:O8\82BAW4N*3@J0LN1;<Z+"=
MQ(6[DE;<:+/9P,A_[BHCZDTW72!]@O]&-UNHB3V"FO.XCE57,+QSNOV)*(DB
M=@AVQ9#.;4V2:5:E%%)!REJ=Z2-W< W?W)KO@^("59>"(-4/#3F;TQ5>T,]8
M;OZ[)AA>J7.W%SZVR]IP8.;YGL=^-GP)*</UMG_=:7R-ABDT4#)*XF/>S#B3
M=CR0M&FG$$;96>076N\3;/S1DO*O'Y9>3OX_4$L#!!0    ( +J+75-SP \F
M]AX  'U? 0 1    <F]I=BTR,#(Q,#8S,"YX<V3M76USX[B1_GY5]Q]X_G"W
MJ8K']LSN)C.724I^V_C*,_)YY"175U<IFH0D)!2I)4B_Y.K^^W4#( F*! 52
M$.1$^K [M@ET/^C&6S<:C=_\[F41>4\D932)/Q^=O3L]\D@<)"&-9Y^/\FQZ
M_.NCW_WVG__I-_]R?/P3B4GJ9R3T'E^]R^N;K]Z?SN]OO9N897X<$.\R"?(%
MB3/OV)MGV?+3R<GS\_.[<$ICED1Y!@S8NR!9G,#W/PB&WOV'=Z?P*_STX?1X
M'&3)(TF/WY^^/_/^^_3]I^^___3A^__Q_G?TY?^.CQ$$"^9DX7N9G\Y(]M5?
M$+;T _+Y2+)+$_KDQQEG@D1.?_R S8D(HKI.TL4EF?IYE'T^^CGW(SJE)#SR
MH/TQ^X15U]#A!<LRV+3G#^^2= 9%3L]._O3E]AM'5U",:/S76NF7QS0JRG\X
MP<^//B-%\9=&>4G][./'CR?\:UD4"-$.TE0J1"T?9F4%M? /)^)CA:*#[I]N
M%1 Y.Y[Y_K(L/O79(R\J/W#!'9^>'7\X*ZH$21YGZ6L=""/!NUGR="(_\FIE
MA3Q-H3/J:LBOM2HAH>VEX4.M('D)YNTE\4NM:.S3@+67Y9]JA1D-VHO"AUI!
MD%/VNB2L58+\2XL(6;9,->3ARXHDEBD)<+AJ5?KQQ$^#-(D(\ ZR8_*RC/S8
MSY+T]1I^+WFF61,C_+$-7IKI&E5^:JD69NE*M1I2^'R"G['F*=:$1N)LX,=Q
MDODXK_#?EDL:3Q/\$0?+)VS7!&IY^,/#_4WKZ.:-OTA@_COR* A*_%C2" E,
M7I1S.(-!#C.5,L?QLK\Y62U8U,T9"<?Q;_G/H D&E3A6'$2REBS25J,B:%8^
M\*,@C_0,3FHR&22D."0QT(,?8#JG(?:L<S_"B>;;G)",%1)<6TXCWO<@TV\@
M(U+*5U+R5%*>I.4)8@?YEW*]\V$ZS.8DHP#&5!GU2AK-?!BB&>^[&NU?[+>F
M2O&Q\72\Q&T4;H<ZM*2IH-'0]V8:JHAZR=2KR!YT4XCZ(EE ,^=0ACZ1VX29
MJJA93Z.I'X9HJD;=0_('C162_S:':6:>1"&8%%<_YS1['<7A/0D)[,4?(_(U
M 6L&=I9)!(QG-W%&0":9H5:'T=9H_L<AFE<1_)LG,'A^''H5"J\.PRMP'+I(
M.3A]-K^.DF?CP5R6UZCR5X,&,5#U.-F]T<PE84%*E\A@/#W/&8T)8S"$;BET
MY!"ZLE#(^F(:/?P:=^24!5'"\I3@+Q4E%'E!BX^8DMK>B/];OECXZ2O,8W06
MTRELP^)L%'!+&R:*.^BG 25R4!B6U2CBXZHB)#D^A54$O8JB5Y#<&VW<Q$\P
M*_/I0(A<_4.[7,].5^6JU-D;P8T8(] 78?0R#DM,#0%.N*-92H@B4K.B&F&?
MK0J;4_-4<G(BX02]BN+>J *&-<V213))_9CY 3(JI5#.(_H2&L&_;YD].!%/
MH5*)>V^DK5KJ: (D<=73-=\T$OZP*N&:K>Y5!/9&MK=)/)L0/!)XS'"22/P8
MI #=KNK*W44TDOY^5=)(Q4,R'M(1$PA0\BI2>R/S#4PUFY;8V0^-^>9@99DI
M[]SG9M-B"0L@YZ5HI_E-(_X?6\5_S.M[*H&]D>T]B=!@O//3[%59\N14K_VJ
MD>^O5N4K"7B<@KJF[L]TC_)(T/#(@>2*_U7S32/=ILVI5-]'G^H-S(L+,O%?
M2&G75'_0"+%A+XHZ'J^T-Y*[)3#E2:')G]OE];YA!XKB>R.I:K/$+OA8FY&X
M\EUHOVJDV3#T% +>O_J+Y;][-3I[(^9KGZ9_\*.<?('N!:)1+.OV3QH!-PPZ
MK.WQZIY:?V\$>XF N,,Y2^DCCX6Z P.L<'^V?]0(MV'+R?J>2L!#"GLCWG$V
M)ZE80JY></M(OA)I.+1_THBV8;SQVMYWHOXO/$GAEQ[0V!OA0EOQQ/&.I#A-
M)C'?K0OAMG_2"+=A=4%M?I;IP9[)$P2$*; WHOV6/S+R<PZMN'JJIMK&7S4"
M;=I1945/U-PC09J<7@PY\5AS\O&^86R9GWQXWQ4_[4]PC)G0)^AQZ:4F64.C
MI(;-UD=)@O3^J*C='%95TEE"HX*&Q:<QF_=/WNV>?%7>G27:Y?VA83'J//[[
M)_!.O[XJ=Y."&O$W3,SUQP#[IXA!3OW:VK ! 8WBFF>1P\\&]E2CC8. ALIT
M)30Z:5B\N@.#_1.XXFM5I=S\LT:T#8M7=<3NGSB%6[6V!JA_T0BQ8=F*2OLG
MOE8GH2K-K@(:X3:L7(TO<?^DW>K:4J7=54 C[88YV^$!VS^)M_J[5(EW%=!(
MO&&;:MUB^R?OM8'!HS#D>/WH)IXFZ8)CN2293R/#T.(N"AJ--4U9DZACC"<L
M>7D*,^\[P6Y_U&KFTEFKV\W)M"OX^X;MW,-==-!R/RWCI?DPC\AX.IK-4C+S
M,S):8!EY#P/_0Z/KR8]PE>?V'<M2&F1@0<"W_AW"$D=-WVD8_KWZ3H$-2Y?H
M/ FON$3R2W&51,'X2VF0%C!%@4./6Z/_*Y;1!49&/3 RS:-;^D38)OVI@YZF
MM[1%/@_K+25O3S#W./?]ZP/*!8FU"XAA68WN&EX)A=QA&>AW>V.MJC:FHE%B
MP_]A?.?#.SYH>/VE$)--W*#*&GTV0[L[KY(<QNF:8ZAJ<>..@ N><R?C@Z2V
M5 ZNK=%CP^NC/;ZJ+X/"72$9B<&\AXO@.FW =B+-22B=.;T4V5Y5H\6&-\E0
MBY))X6TZ:+!S/-U2_Y%&@+Z?)KM):#3:\%8-&I<*N_U3;>>ILJI DX(:-35<
M5";'SP=%*/)=NW$97+M=93\T0_R!P7&WR@Z[%XTN+Q*PQ=*,\B" C+ [_Q5=
MY]7DAQ.5'[^"&1'G?@2?^9Z^0[^;4=3HW"1*1&'L<<Z>9+TRPTK^_\8\@< K
M(.Q?9U@?%G+1# M9;ZG8IJKI%$,C4(XOVD)0#E/$1KVB&M_%<!I/1>5O),C3
MQJ9KVTPT?:8]0F9XGU$GEF4QC\#/1!!B):P][4:- ":SV:-7-8VJ&QXK;3#4
M8>AWZZP:=F58RHBQ?,$/<INC>EA]C1;;4Q"T:U$=C$KPB\+KH%&ID?+ )DN"
MOXZY<$9!1I]@TC+0Y_K:&FT:9S18.>%!/IY@Y!6<#KI<T48YN,;3/\#JA*GZ
M2O7T4*H!&8UVFU=\C+2K#%7X3?"LJ_R@Z;J*J@-L+J8'P&XR#1M4UVBV>2_(
M2+/*0;O0)V=U4.>*/NY(RO<<<4!$AV<#YN*U1#2J;68D-%*MPDZ.4G:8F76Z
MN?"72Q**C<\27QN@_/L]G<U[#5P3.NUJ_K$9JF6D9L&QV$@I/#W!]*!J_3#<
M<)8VHZ11=S.ZJO>H/DS>9F.[BE\>/?MI.&#J7D-"H^)V]]?Z$:T&2G-VAWE;
M:]^T?I:'K7WL) ,Z&BV;7^FJ6TRZ4I+I_JFZ_2YVJ2+XO$R8'_V4)OF2W<1!
ME./37NVUQ"6/,FMY+8Y^ZVPT':7A[M+=&Z_ZR7CJ%7@\ <@K$6FKRWMO55;W
M0T^JJ[A,BG^=)HOVLCTZC#DU3;]H.-#6]XM:#GX/&>N3$.R;\G4Y)M?ZM8=4
MU*BTX473YZT\^+;;;@!7#FF\/W9.0"I$^7S^^A-)9JF_G-/@GLSH:C#TQG0T
M>FWXSVIWC.O^;7[Q37"L%WM\]2JNGF![4#9(K0JY&D_+SW([=$YB:$&V1LWF
M%#0*;KC1= I6PL- UU6I:OLF^?UBKU5K<''!J*Q&79W)5P\S:_?,>DFF)$U)
M"'\6T<6:Z,NAE=MU]JN6AT"T<VC!A8^L(@1:X;3?@TNYKC6=$G015&O;/6PW
M[@GL" ,05=>H&T1$H]J&3ZM#M24W=?)$AEZ=X_YI6*3<J/3RQ<]DB$KY?F(\
MXX4T W83 AK--EQ9,B](7:<5(^511K!4>>$]#Y46.BF,QKH:[I-<3&ZC..RC
MX<VI:=3=\&E5ZJXLT%7]WH\?BCD:P[,.ZN\8TW6]7"0LZQS!^N(:!3;?;FD;
MKZLJXH3W3SFMJ7R4>T+%8%)ZL"P9CK(J&",>W6,P80KR//<9K2ETNRPTG:#A
M6-+E&UJYLE2-877,%G@\/ZL%A,2>[Y6H/ [KT(7,K@+WKJ51M'%BJ8-%U*FP
MB[D?SV#[.YD3)<8*?KLD*=3'W>H?_33UM1?5K%/5*+SAA](K7'#W:.QE<[(2
MR85_J4!X$L5^K]1K9FI%@P]Q\LA(^H01Z#?Q,L^DDW>2R'";2<(OWZ?D(0Y)
MVG4]O,=2L54 FN[6\(J9+23USJ:B]3C<TBL^2<H(I2SQ)&:/@UYWZWWO^N<E
M FH^L6&0/JQW/4UO:$D:-FU_M>.PWI1J:TU@6!EP;5_Q6$\\WI/#SJK];-(^
MV7:E_[KAM>O*IE@W$SL*\I/+"LQ>GUNV)EPL58G[Z@ ,A$L:Y3!E0F$A4"C.
M"Y8Q2A@(IO80^V0U/:3A_--G?ZSU#PZ!6QL2!*\HG8)WN +P.DI@%(]U._2/
MX8J\\S%WP9QD%%!OJ;.T\=#TG(9S<<L]IP9M#X\05E_E,<AL9%Y!H^-FE-SJ
M"S__\)L%_-\C^F?)U'OA?\G@\^<C1A?+B!S)O\U3,OU\A#H[?G_Z'N,+3_\,
M37KWLHB*(DBYU.[S\_.[E\<T>I>DLY/WIZ<?A(Y7I2 9%R3\-&A0>?[ :9Q]
M_/CQA)<"(LD2+^P3=E* /_).+#0()-ZW074EO:WF1/YCW^9 %1*]O99 U^[;
MDI718+D])_YR26$N$#_'<2*Z-/X*C4G2S(O]!6%+/^@"2F.68<C\D<? /EWX
MMTG R714P=^.BWK'^*?CL_?''\[>O;!08NL!H&I5/P!%O9X 5$H_\-_"S)AU
M40%Y_F#";>JS1UXY9\<SWU^>8'<Z/CT#L.U,60&QM>8)B3)6_.6XHF7<<$:"
M=[/DZ80G&DU?.=$U0-JJ%+]P"/V9\P1103_N:IWRMV'\R4LP[\.[+,]_&L8S
M]FG ^C"M*H@?A[&%76 ?ID5Q_&$@PVR9]N)8E.<_&?-<'9@?Q80;\U3*H=EX
MCM*T5@L']4><2,Y^W B"X72BL,\V9BW7$IAO@NR8O"PC/_:S)'V]AM_-X:A4
MKBHB/='5]!L2VJ<[%,7Q!^/.H$Z5N)HS6[,L)]9SFBTILC0;C ;J*DA*2AM
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M]$3D6! 8](TWK\+K/.;W8%$I;TDN&H ;S-<G+)B3A?_;_P=02P,$%     @
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M-_;;J4DCISN0<YS2_S+M2D:3T8+I(=.GI@++6MNUY%=XOB!@1LO 5W"'DTX
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M*VK45$_); Y8PJOC+$GE.2@_2$ Z Y4LE\9SMK1V3YFVPB@AU[$M4 +^%J(
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MJKF8F4VP=6(BZ_I!!Z!3[>UIYXYMKDU1[D"/#E9CI+KAV-AJM&VP-,RU:/,
MM,/*BG?><?(T@8!BL]5ZU0SET73-VNHIPRT02YAU[$QCHJI6)L"F#?94(=K"
MEFB%8UNP"1IKXV&;1@] .^PLC>=-XT,=:$@[NV/G3SH@76H3M>78EFT"T\)D
MV:RY U 58_NFP&J]XR ^ELJ@?#=RD<N$_< OWW)UT^5: )5+\:;,_J]QW>HI
MA:"BPFYO *L+O75%JT!B+UT=QS-,4N9?;<*#J+#?/(@D]M+;\+> 0!;P:T*#
MH*S?+ @$]N62XMH$OHDPJ$_F[I-3W@&Z/P)BJ99%0+CRBCCS)O8?,F,HFDUH
M=N,F'0\G.YZW(F8:P_9RA3*%8Q"*;=O20:B!Y_'7-BATH=?V;1V.!O@<;VV!
M0Q=J;=W4P6B S_'5-C T8;3631V. G@<3VT(PSB8NEE[!Z$*?D91<QM@;B-<
M^2D\@+2X9E'X*[MM062*='1\XS+6+B/;"*NR?FDJ.O+.75]HP2Z'3I?W()WA
M:(A>@:EOKK:^T]%FQI;805>+S,MS5O42*UTB2&'I7C(FP.'E2<C\4BZ_;MIJ
MQXO&*>VB:=22Q.MH>R&1^12)2O:HGZ48C \ NUWOKYAG(N*9VU&"8Q@%*8@N
M@YB]#Q[/ $NLN^\!J+V4HY+)>/^2766$J'VJ:^6<JFNU-^O#OR:IEPOF59 P
MMVKV/[;2OP8Q6]T'^74T= CRY$8*-@SK>\!23;/J9!D"\7)5?:)K#(',FXF)
MKQ]"DO+^DR01W$N#7^[P83BIB0K[3X=(:B]M;X\$TSU%NGRD2R]+5,U&.(\A
M41]:U=4\X$=&C%IP+ZUC59M.[0("8[>:K7H>DZ21W,OD%=4)^ &CT'*Q*5?Q
MF!NYT-W>(M/9L;HPS!09*=EMJC%.,J(^9:LK>DR13G0O,T>L$X&:V1B%I3VF
M1"BOE[D92CL7HTE,4MYC+B02^Y)4P4/32,DYCFZ9QBD.?Y_AF/9/DMO 50-5
M6W7_,XWR?CYA*;=O!@U[?VO.T=_!YSK=0$E$_4E05-@78@PXT%F['%M*!F&(
M,[HLK6XF,K V2BKX0HGFA"X3W\_H>"HMR4!D-5X4=?K#D0Q!QU'J.SFJ%^X7
M!E8N3<6>$*:#X6<$.M\06@TM:8V^\"23O^-@<,V-HVR'"Z.5XX[!:*G<RZFI
M[#D3-E#\C+^6C'6S0Z.^KB_\64YU!B=*3PPM[,85([)D%7QG2":W>72QRT7(
MW/@BJ>0[/2K9)>^2!;:8-LM0,6B'*$E)QJUR]W0T9W1*'J2%Z52V$!E7]Y4)
M.Q023EQ[:>#Y'.8&U?R:738E Q2JC3O*6K[0967L42*24.?<-R,"8![P*Y%1
M2"6F'15SW[:5;R 'O/8R&<S9<5WY-JU)<[TDNQE4B18XMFQLHQZBU55RCYAP
M2M*4P)<L97B?L1BQ0B^Z>D O-:4K\!+=<6QNL7H3(7WWX(K3;C5?S[R41<?F
M%[9T8<3EU?I4;A7UC$'5\EP57,*%8R^6013!7*3' $9#=!4L8*I,"2ZMT1-F
MI/)+"&IJ=9&<0<;92Q(2R!^3/($0P%<VVF5G#FEQSWM;+;RDJQT;2IY8("$"
MT4U $)UPDT$89G/6O2"Z!A,8*B]--:GL.6<V4"0,.K:IE"3EU@8Z"R\(F &4
M%!GI6##? TA'D^?@7?TNS:ZEGG!KC4OB4-[4,M,1T?<08<(W4-KCP'91SZCJ
M<A.X#5;"G\"*LULOI_$LH'I6QDW/-95S[=4VS$TBK\?B>O"\\AB$J\1>CL*_
MUP+=8O($%AD)9T$"UM(IU%%3;__Q &)Y2OM7>S"5RDY'FQ%+6R$#!JB\C&"3
M",XG^J:*6:G\8;BLH#(.9-OM#%EV^63+,F;Y_,O):/EZG;\QR;U976:^:!W.
MM=>!0<""'O960=%ZH27EW<>#&\6B2:3W<LKBQA%Z),^SSZN.P]H:/6%'*K^7
M\;0/..46Z#L<E(_P]'R@'T4&=7O"F0$2+P-OUSZOEL2IJ_6$,S4(+V-S2]=K
M&DV%DO(](4@BO9\AN1M4]S )04RW:@!G=OL?<<V>L*7%T2JQW"E[Y@O=FO_E
M_P%02P,$%     @ NHM=4V%*/%[=<   !%0' !4   !R;VEV+3(P,C$P-C,P
M7V1E9BYX;6SMO>MNX\BR)OI_@/,./3V_N\ORW0O3,Y#MJEX>N$H^MJM[!@<#
M@193,G=+I!=)N<IK,.]^(DA=*"GOS%0DW07LM=ME,Y/Q120S(^/Z7__[]]GT
MIU>6%TF6_O9S[]>#GW]BZ2B+DW3RV\_S<OS+^<___;_]/__IO_[G7W[YG:4L
MCTH6__3T]M/UIYLO/_W/R_O;GV[2HHS2$?OI.AO-9RPM?_KEI^>R?/G'AP_?
MOGW[-1XG:9%-YR6\H/AUE,T^P-__J%_XT_W1KP?P3_CIZ."7P:C,GEC^R^'!
M8>^G_^_@\!_'Q_\X.O[?/_V?_N?_^\LO2,0T2?]ZB@KV$Q"=%K_]W'C-]Z=\
M^FN63SX<'AP<?5@^^'/]Y#^^%\G&T]^.EL_V/OS/S[</HV<VBWY)%DA6HW :
MWKC>Q<7%A^JO\&B1_*.HQM]FHZBLV*BDZR?A$_BO7Y:/_8*_^J5W^,M1[]?O
M1;RB"YZ)R]5KFA.<?*C_^#.R*\^F[)Z-?ZHH_4?Y]L)^^[E(9B]31%C][CEG
MX]]^SK/DM>+ZP>G1 ;[HOUQE:<S2@L7P P@OB5'LE]$4N?/PS%A9_/P3SO[U
M_F9%!LX2I64E8OS;!YU)/OBF\R[*84D^LS(915,G1&_-Z /!0PG_'S^E8C >
MO.!'AQ^/+?6BV7Q3_O ,G'K.IC%\[!__-4_*MWX:W[.8P;?R-&5?,MAGTA((
M@-=,;M*2Y:PH78"T?+%O?EQ%Q?.G:?;-B2 ;D[6D^V$^FT7Y&[ MF:3)&%9U
M6O9'HVR>EL">.WCY*&$Z-.M.U)9>3\N*9M7<LRF*%C:5\NTQC](B&NE^[.*A
M+6FZ :0S]AA]UQ+[QM.MOZ'9+"FK)0X+'Y<-*"-ZJT\\M"5-GZ(D_R.:SMEG
M%A7SO/X -0@2C&O]M3X5[%]SF.OCJR8ANT/VLF,XWSG<[B"74;6[SEY@FZU.
MQ$?\RK6HE0YW]^UI$\09XV/-:],C'=V2LB^LO,V*XH[E^,%G:24,;<JDH_?R
M5?3C.,'E$DUOTG&6SZJU<\W**-'13AV\8R\H\4(5SZ=L,/Y8E,D,CZFO!1O/
MI[?)*RL<P]5[6>OO$N:JCY=V(M2=J"6]_:)@P"O08XKJ'04H,[?)"'7*_B1G
MS &2]J]HOQ:3,IME#>5G]>+6WYG=S"T1-2^:>+AD*?)PO<!A\>=S%G_\CL>.
MP8=D.6]+-+=9.GED^>R:/96X-K(H76MI[01D/[7WV\?5[BVAY6)T_DHO^I,#
MD&9S>D&Q_B966@SL<_/92[7#M82C-[D?7*NCM,Q&?PVJ-_9A8WN%Y=06E<;4
M?C'=PX+/DU%E(@$2OJ9)V5I4.G/[105::K7F8>.NF5JX%ICZ#7X17D4O+RRN
MOX.7EYR-DNKO]\GDV9T M5ZR-TGZ7*J:K_$LT_7%JO\MRF/7:U8UO^?=D_OG
MA=[D;!_5>8DGNV.[4]QJ5G<6D_7YBK?\2P:O8HT_7[[]SK))'KT\)Z-[-C&[
MM;5_B7N<:U5^,%[]>;%.+EG*QDG9!J'!].ZPM;U=ZTWD8\U=LS'+<Q;#KZNK
M<7&;1$_)%(@PN*E9S^P#T<?QF.'VNE[?]_!YW[-1EH[@]=:BL7N##YMFXPI<
M,;8R8:QXNW@R[I>KP8.T#]3-\QSN6K!%)_J2]?Q^']QI]RV:3^D#P]5SE$Y@
M>3T^LS43Q_"O:Y8#P;CV_HQR.*M*F\_5_2O]KO(&/5_3[*E@^2O:$&[2EWFY
M.+P?L\5=X#&KC'LY^YK&+)>9Q%Q] WZI<^QY:VMA-)BMM5?UE>5:+M3J.>]Q
M$*!6Y.P9GH$/ 74H)_$0NY.VQ''-BE&>5(MM,+Z<%TG*BGI_AF47HQ6NU0)H
M-_V>O3C]"7Q,$^!V?X;/+.)/\']HD'R-IM421JOD\MJ)?_/FYVE'CF<;_:!\
M9OD5G-!HB:X.=6=F>O'4>\1D<TRVG-^G'\*-R\$1I==),:J"5^8L7H?J-4Q9
MBZ"O3WDVXS^KO_\X>Y5;Z< &#Z=0F52>C9(5=]$;Z@#KM8+K)TK?X/M.Y]$4
M_ER= +9B;/FZMMA!#6IN; OFII/J#U=980),?RXW5"^7RN:+[K/YZBJS^1>;
MC</=JUIK V,XH>/*TY8\5='L=["GM=4!S"?U$3^SXB_>*$? S>MD.H=3$QZN
M[^7P>/7@ROR*1F5MF![>&0X7-L+!*5C")<"O%;QQ3_L#5*R%DZ&^F+DR@NN\
MPUU,CUG@SGZB<UR%X'B-LVD93.-)8[+6?SS1HQV@*!_N1<NW5M\]T:/-*_EP
MW[=_%U?\/=WC]2.;C:;S>2MK>Q_S2YTV0[5FH<B',0MVMYW=BQ9BK5KXN@/8
M*_JM*:KL)K5NN/#+@JZH08]@G ]JM%>:=+0/?=]637=T?]:^_3IZG_ZFM?$X
M1;SLVHBQM+<,QO7@!_1]FID0O%/@U^8'?W[)BFCZ>Y[-7PKX/J9S3,[GCZH_
MGY5?Q)4QT 4-/O:6M5V(]U>T7-:I@',@UL)$ZN&=CNV%GZ-RL1BW;6,MC&UV
MLU?(HGRT!+?XL?G"5:&")"T_Q,GLP^*9#]%T^K.2&X*2"<N*!U@KX:1B4C5;
M&W+@9_0C9NDO,1M'\VGID#C.W(Y(S691DOJA=#%U*T*K.7Z9L=D3^IC=4;DY
M;QL2GX&:?#1_8K^LH#LDE#M[&W+3K.P[_6Z6$U9$Q:BQ5C:E6YAJXR7L>\G2
MF,7+UR UK:J 5*5=LM'&2Z983"7+=Z$42YZ,H^*I C,O?IE$T<L'W"D_L&E9
M+']3[9V_'/06Y5/^R^+7P]79!-#8#?Q8+%\SC9[8M'KY4/SP\+"W8-(^B5YX
M.IZ*,H]&I83@S0>'O:,=B?;S3;)A12WG6RPNR^]Y#*>?%O<6;\^4E,\+H"5[
MJ;TA/_^4Y:#%_?8S'?^5?!\>]2CYS6&AC-<5M7P>'Y+Q>!G@H+O4MYX?]HX[
M) $>\7R!'%$+1%<0PZ-S>@'P^*HAAXIV/O^/"?A?W3%TA;#[\/#HM$N2$ #@
MB^.$0!P8%(,Q(UN!9N55E.=O<#>J_)42"6F-'QX==DEH^ICX<CPED.-F7*#Z
MR^(^/SP*X)S1EY,8 U\N9P1R6;I+-ESM0JEPGAX>7M#+1./L%Y'.%\4YQ<FS
M&6F%R;*#\=>"51!EAY!LW/ P@/-(0SQJ$'Q!7="J".B,,]$2UL\/CPZZ(1@A
M\8*+X@&!1!H?]2J("4WETPQ37B2BD0\<'@:@5FO(2 .%0%@4U_J[/(./O7Q#
M=RRZZ%&'>4'BOTBW.=FPX6$ BH&&H)08!&*BL QL:B]:&YUHR/#PK!/BD=(O
M$ V%C:#A"X)%5$5I;GI;U78<W2F&/=(MT,B8:81)($X*DT.#;GU#G'C0L$>J
MD1M)02E('C:!Z"C,$XLJ;KL$RRQWHC'#$U)=7<%U@2E/"D8@*0H#Q"*H<IEM
MI"4FSH#AR4D7921"(A 0B27"Y!OBK+=34AN>E6 $* 1"H;=)+.E]T[",2P<.
M3T@50BMA:2 2"([,1F'T20E&#$])O:MVHI) $;A>C:P6NU%B^)OALF80AETD
M\2(.3>.;T1\\[,$K3PY"T>_4$K&!)I 0A:FBF4R@=0/F#Q@>AZ+866OD8EP"
M<5&8+#XG:98#H'6K$*&@MA\=GH2B/MB*B(M((!P*HX7@_-2SH*O&#H])#8 .
MQ*<'42!/LD")!G!]5PAWT/ X%)706H)R; +1D015K!OWU/4XFKU[A+*3C!H>
MAZ*2V I/!4X@/0I+1@.MW@UY>$QJPW5K$*S "*1!;+;@HFMA@Q^>=/U0TT(H
M$":%N</*E2+AS"%I)+@# 2JP"41'8?#HCT;SV;PJ6%F7-FM6)ZQSQC"O] LK
M!^/'Z+O<\&LRT_"4V$,FE9#0(FP,41 B31'NT2C%HXS_W'IT>$JZIUI)BXM!
M( Z2/(U5\:R[*(EOTJOH)2FCJ>P3XX\8GI(Z5^P^)0D4@8PH3"-&B@GGH#XE
M5?"M)"- (1"*D4E$8 #&"L/+\C/%/1NQI"JF+#+Y"AX?GI):"XUXK<0AX#:%
MP>(>TZ93%G^,\A0N=T7C$,1B(:-$'MJD&CP\)35@6'TBFJ@$0J0P7>S"7-5&
MN,ORBN=E7? %E^!C)NHA;;#WV;Q@>/+^-']K/@B6CY'M1+#CKNRD-RD@FE?V
M&TX+!]$.K#F\]DW1IO6V$*D=5('4*&PLJN)7-0>6Z4]UA7+I7FX^W?"$-%S?
MP0=MC5JP$&CL,XMPT$>!7L5_<+CR1KH57J.(2LO050Z]=:V(?Z"DV/?RX[3Z
M\V\_%VQ25]M;_GV:%2S^[6?XIIE05O8&F8*-?IUDKQ]BEM1B@A\JZ=2E0%@R
MO&63:/HQ+7$5?D]X)FG.4\.>'V5)4E!$(J$&TS>D(R)<D*UL;PI1<[FFX'JC
MXLP6BYN/#'N>[A""XC=KYHIXMLO9'7H%;+4W:?A@ZW"SB) W]FZ607+ WS7A
M C[3F"46G^#5-"J*13];P3:B'#,\]'-&N]U4]& (9$01N-&D3_BEB!\>]CP9
M]91;D1ZG!397/@Z!6"C,&>W%0KV5.9>/<HM;KL0/F[6V]EQ]:Z-]0.=*<9U1
MQ#PT7"!5<=&B/R^?LSSY]UHJ<N?/]JCA!>E]3L!7I?^'"R.<BET[E-X4Q=Q,
M1/6(X05IU'D[\30@A%/H:X?*P;PLRBA%@YZ)?!K#AA>D,;/MA+2-(YP*8,U8
M:YD%4_K\\+P[LA$#"*<LF*WEZ<R/G</4\B1F/H=>AY8G&A>1RSOEF9_;2YL[
MY=G.=5\/1CC5P-K>7<X\;6X.KI3(:.TKRYEPCZ-PL[272O@W2D/QJ&Z4]DX0
M7X;U,S_Q;6[W*Q'AKFM\N3< GWER EO9U<]V2@]RZ75>J,L'6ZFW#FO^JK8(
MDAI;F\TJ!WGU1<:58KWL:*EWZ1.-'IX3!P3:W?VD<!3%M_9N-%R!7#<#P7Z)
M73,8]@XH;M%U%/NB6_UFJ-(]>\$(IG2R^))7E?)T:OVWFG=X$=I74PF'_]FT
M1QJ.87*=TR!J%Z04N6SPL$=; ;^]J&1+0(T\'#/G)L7\=EG+M!8IH[370XMW
M /-($Q[VLVQ:,R@<T^RJ+3ABDZR0C>>&O:,.[?H<TL.QPFX0US+0VW@N8$9H
MM3!UY:@/+QPS[JH@QJ+5GXYR)AP#G K-H2B1G0)&.';<WUD*E$[[:=R/9\!5
MI+),7I?=&2624HR$C9_T6U-(@"\V+4SAF'MW,)I\6 "&]%"S$I  13@M(.Y9
MP8 1V-WEFKVR:585!U=_3=)Q )(T,\U*5!J('!B+!5E%*XJOLH+;#X7S%-!$
MFK9IQ&4A_0'U=%B1IZ5Q<YX&A::+9_XV@("LRFIS@.-D3#\O!+X2UQDP-\/Y
MX4% [2;4,"_9.,L7U4D>H^^L^/@=-CB@.4FC_*WBHX<%9OU6X'!H?6!;K;*6
MC BH?<8RVWWI_+F,BF2$BD8RG9<LUKAG:LXPO""NY&"R DPP!=0\0T&VO1"!
M5Z1JLXD\K"1: PRHF89Z#P(D6R!4KFSK.8$[I$I">_&WA!Y0[PX3?T+;)6(U
M.W",=*=WO5A:,"&@CB(*KE25[\R<_Y8S#B^(2P,YU .D& /J7/(GPQZBL/9?
M8?E.V)<Y\F@P;BY8S108PYFP@DK >X%4?OP58<6 @'JA".C?(;SBE/E"X,\#
MGQBI!V-ORT &WT6SE3TL@FWBM:X/=A/"QT&:F+7?9:'B0T"M7BP,(-L=-P#=
MYBQU2:7/K'S.8KT&ZWND8M@[(EV)WNU3[1@34%N;>_;*0!-? L?O\<^D?+Z:
M%R6@R3]^7YA_L<\M_%\L+V]M,1MP)+1L><E2L0884+,<VW33WH&?.%33?%.)
M>'@4.\PX;=$+QUNMLX/PZA+5;-\0D)!TYYUKW.</77C2M>W*G1WLE*WA$NR\
MIXP/OH:8EZ7'8%5B%DF[&!,[FR.;)1QN'7)#F2,+J'_,2OM<!.%<LA0XKG9
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MXHT#)ODQMOH^B<1@ BI>L46D<MOC/@^H/)G.S,\D,=?YXI( "JC@A#,Q!7=
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M?!*2.X8A+']5 4U+K3YFS7@=T5'0;M9AKW=T<4H;S&0H(,[N[XH'+@H":@3
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M-,ET[EN[=M"]DS.2T!09$Q]!,I=3>:%>O0D07FB'2<UQP6EB@BJ<;LZV%S_
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M/:5FD6&M\0@[N P^B2Q-0 ED26'U^%JPP?AC428S0"MS8FX^B$;73DF'1[U
M#!2&"EZ>@:F%47L.O/MUR;1H"DP@5PK;Q:<L9\DDO9KG.4M'&V6H8).H_CFM
M[FT&_G?K.9$]7?IHVP(5K ,CZX:HWSQ+61Y-@8Q^/ -&%I5KZI4M+&D:TK29
M!H\/TA;D)CX@.VP"#SI1S^$Z)U__TQ0-P0.G"X+3Q"$0$DW#G5=6E&9N&N$8
M7(.T#5Y,Q20'(I#3TI3AO<SYCG6RLL=T,%KO[) D_V#TS.+Y%#37-3?OHC>D
MK?\MRN.JUFMM\"U0/ZJ; !7%?%;_KN*V5M*"TQ<!N\*++3G;-0%Z11].9*"U
MB?W,4UJ;L8E=)CL>S4&D1]@+K%ITC_ :@=V=^QQ"#]#R7LN#*SH>^>%$W/'/
MKWX.EXY)'=5R^<;?+M:XTAA];U^B&1-:GWV^#GE*50A.)F03=Z83#H13).2]
MK"IJ_TA RTLW6::-M>$J>GEA<64"Z[^\Y&R4+.)@)\]E\7E#&]JV,&@,18V%
MUASH[]/GV"7T.>(@-E$DT&PVR])*L:P@J(3(?QS)I(U0VJ_@I%QP$'0H$-8=
MRZL6J^F(+6X!<FF)GD=DM %&>Q67@@T.X@O5\EHG[U3+YBNP7%]XXL&XY&@-
MZ5225/(DH(#"U;6^R:.KK"@_9?DN<QJ\ZT\KNC":;LSG-,X"+$8&6AA9]D@/
M2B6X^&0M6\S^F1126.2*#5^RRL;+8MZ7UQ^5R6M2OEFL08MYD4W!6<>UUI(]
M6.>!EVZMP<WEW313ME@8MI,CPX++]3:T^EHA=A$O*M!DMFA\XF]]J_"(P?B/
M:I4W2%<N "_O0<X$E]_$60L^P2LB7??49Z:K#K?3DVX5:C\))!NAXIN>JZ2B
M^9T7:C\)T"52\WU#1&+BNU"H_22H7(2*;;OLY=#<A2I=)V&F(N@R.<1"[>OS
M_IJ-69ZS&$[*?E&PJNC/;1(])=.DBMHV5YZ-9L1:6\&%X<H.D%8PPRGJL,;Q
M<3QFJ-JSE<9T#QRY9W <C@!+I*5!NY@6>11<9*[64K#&&D[AAS68&L,E&V?Y
M&@]L9Z#P)R-8XXN 9(LE834S<BJX#'2M5=$&KMR1L_=F#YV]01V1Y#LL6<@[
M%Q9LC0<I[ _S/$_2"3SP)4OSY3^K\ERK&+M'-GI.DW_-#8[BO;P?.[F%]UT>
M"2.M]LF4<.(>5ZCE8"MT7]/LJ6!YE75YD[[,RZT#S&3E.7P=\C2X2%J=A>:>
M!^&$9ZY/.=/OJL)MH3PX> ]R,3P%4[R2?( /*+C4OLM.*%VM):+CT>S0SNBS
MU+>MG=&3C[UEEQW-KM9BW[?][=R'+<R7\]G2SGBDTW!9[$.VO^GZX6V8=D9-
M)JOLC/NX/7YAY6U6%'<L7P0JHC>QJ[?'DW-:U>ICE*=PF",WE^[YRG!PG4SG
M)1H>S8UR)C,B X)S8%<R4=KC+&"&<V>S+P=W[N>>9%X.3B(D'LU!Y*KYJP9W
M[N?2T:X:7,5WM6)4$=\!)^')N2<ODF4QN'-N=T<.S1UHY0-T!JD8Z3*Y.ZU\
M^G&<U,3=I%6T.?[CFI51,M57GY1Q=+OOE6E(^H.'QR=&>X(H=2'/1HS%!1;Q
MO6=3%M5EJV"M?+MF+UF1E"(JU2.'O=[!28^F6;@I(S=7MC' <!0:E>RXSPT!
MQ-D!36Q .TDIX#C06RR^<)$NJ3<08/J);^*JE@X^%$U$#A5/G]J0G>)Y[*G.
MF9;>:20%I1IZ+*YD%I*F=.RKHJ"5$EHQ3:$>'8M+!89D]P0R0]1 -3FLTC])
MH[ROIE%1@%I:913+:ZT(QP!(PAAC^ZU&$U@XK5R:]"D+7^P^/#SVU=Q!NQ:*
M@M5\^8B0A-.>Q8%@J#<X#Q)2;7PD&='SIR*)$[B+/T15OI/.QB<: RPA;-/M
M8..3 PLI&7A-'V;K#\:-0KCJ$D#*P8#74S";_LXHEX5 @)K(0DKA]2_)8+92
M?R)5]K?82WU3+:-FPR^WJ#T??RW8>#Z]35Y986K=]-WH4&8*U1\\O#B@2.L1
M$L;CO U WCR E;2LLZXT^)^;!=1P+*M"XI<TCV7^8XW1 )BT<HHGV6X###&P
M5DB\,BQ <PJ [D=YE<8+M).H&;8@S+L>ON[+-XW*N!JC@4M^(D;,0A/,9&KV
MI6^##2<%5PP67JU4A#5& V!/X5O:=QIML1A*=1MD.'FU>Y%J*/>;_8@W1//Y
MIWD.')_G6$'P4_(=?Q+75%0/&E[T2!-3M#\TOB!5P,(QH-]BR,1S-HUO9B]Y
M]EIGMRH%)QD% $F3TUI*3HDL'!/[0S8NOT4Y:[1L5PI.. ; D2:OMA2; E<X
MUG8L)C<O6;["IQ298 1P@[1L<$N!25$%9&;7E],.DAYI&9>6\N&B41C-_5:O
M6S:U\AH3VGB-S.XI?!;XY*)8=3]-Y]$4OY%LCCRZPE*E.>J@6$?E4Y;?Y8MB
M.U4ZAXA"PVF&%S3UJQ7<W%R@]L#"L5+6Y)8)=G->$8K^C8K:XJ8HYBS^^H+%
MB9>XI >$\6S#BV.2JJQ&DFZ-SU]@::/IP.!;RN++:(IUT&N"!N-^_C0OY\*-
M0V_T\,)3IRWG7Z,)GG",B5_3G$73Y-\L_AW8@4F:@[0!6_+!*4;";D/B(K#Z
MN+2P.+ 1JL];:4#V]G, :8\U#\P_"3Z]#LWO)"7RG(9(7AP2FMIE0N)?,.4X
MPC'$M0V\N^A1=X=3L%J@) B0A&-I<R"84,S<#B6DLF63&-98GK#B<E/95)O6
MQ*. +:1-$$0?AV"K4P$)QYJVWL$U_+^[#P,</S8:/V>0"$! YK)-$J]@FYAD
M>?+ORD2C_(+4@P&O)PN%]NDD$H*.R,20 @I'W8,(0SG'?,A2.PYUGS(=E,\L
M7]./AK,H330\M/*!PXMCTM9/NE\77YXZV!3]6LQEZ"NW]>+0C_O.[4DFI%S
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M@FHBN'1WTF!D@S*@!&JEO:O8-GA]F2,C!^,FKC9F1*T7P$="6M' FSG1 'U
M.=NF%:P$M9Y\M8SW*U,)F(!2L)<FL<=L<0#QP]&D#0PTIX!-C;26KZT@S?"Y
M2,T6&827&2.#\3V\-$]&Y<+I+;3]"D<,>P<'I*7,[>R\*CS.$[9=1[T:IC[I
M3P([2Z?D:8O0>>*X:PE_38&BZ5N23I9'.&COM8YO+&C)7, -TD+;;N6M!.HQ
MB;VQJ2PB>:6)"(+'<0/JE)ZB <9%\KHO/67E:$]7W1OQOIS&_?$8+L]1*6^<
M9S$=+,3WH;]H8W615^]+_DMNL )V"EB]4?&\-*&8R%TR#5RG.N5/M<?H(K5?
M%!*Y"OK#'28M@0$P:+)<@O]D4W&0L'HHJ-R=LD2;X0HH=_^>O;)TSA8&3*1H
MY9FOC_+-!_XM_0C-)P-^=%*YM47JH@2 Z(.L=X=*X7IXP0(2L W 98H!2YY7
M49C";U)K-)P>G3+9&T-S41# ?56-FW1]@&^<[$61C:K?PAG_/S)@ZA_P.#;_
MLJ[#X>15L-8[>87QPP<790P<E_U IX5D/30?&UZ<=M(OLXO!8YT#W< _3M1;
M]]0</@B/50>^H(-U/$]C](]\?0$8:;EX-YRO+'D5YZ-I# 7R.[59F>%R42U
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ML& L<@FQE(LJG9+S*)QBG?J4Y3@$;*8HQE!5S[K$3I#8H1LVF"I,5O8)<@?
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MH=@K533AAQZV,3C0;5.3L8)U3Q&TZ(\5:P,"S1IOO!_9_IZ3'_;)1,':=6A
MW[[S[7I<^VDLM?@K3.[M7X#&L/,#ZLQG?P>^!T8)U@U9J1T;SEVS8I0G%08?
MUL+&]/BQA6UX)K(2[O)(L+!(*CA;YX)_?TGR.AT7E&4?:VOS#<BZL&-VB)87
METV"%4;F\+"YB:V!Z15[</$.9%_8+E('J\PAHP2I@$'&*HLX]V6.(EG$>1?]
MURB98MPV* ^_8\L$'UN;XI7(W/=HF=D3WP2+DBS2V>9[6RBK'[^S?)04"/)/
MANHIW(5>61Y-V#U#22;IY"I+RSP:E?-HBD6%E$[A_5*#9C/2(BFA;JBM62I8
MY22% 5HRH2X;M/EQ>US&O-?AUO%CG5KQ3+ 0G3E7=IA2W=,?LX:!'KXAH!<^
M&JGSQ&0B_,C>8[F95MP02'KI_-A_>:AUDMZJ:DJ_*.:S>LW^J!,E6!9FS=3_
MIM5C/'6R]%\]YE@8*>F:/0ZKQU HY[;IR<=^XC/(TI/%70-YR .J1^4ATKC-
MUFL7V'SLR6UMG9W<HG"H/0?"J2GU7E95J,G)!,M+E9Q,&KWC)N_C\"3LVXK]
MSJ"('Q"PPD&-+?])Z)Z:#(4F,QTV.*B_17U]XUU!L6PKYNM>)Z])#-?=>T^^
M4MUW([>[[UF0W'#VQ$ '%<FH;:\RQ-X<"<J7(G^[G\"A6* ^.>>@0%N(&^E]
M4OSU*6?L)BU9SHIRGQLI[]THY.Y'.^UI(Y4P,)QB=4X1;_GR_LBF,-L4&Y#M
M<=U*B4#^=S^>:D\+6(>3BK)]!,Z1^6P6Y6^+!B&UTMT?E:#,E&\_7"."!77:
MJ="EW2""VD/K@TNB=R'3NI]Y(VYG[8MAX?A!NN:9._&C>/GWS$D6F6/V./3,
M47AV;#USGKIHDGGF3G9:M,N0__"AN+5DGGJRE%E[YL3](3UR(!R7R7M95:%Z
MY@B6E\HS1YI?[,@S1]L>U./.8.Z9$[<#I?#TV'6/.O%SV0E0Q^  #\?O8=^Z
MZ,23V<NV>]2)T,G-)3T< W\;$81R!K:1A>KP,K)BA](5YY0TCH2[XCG1!.:8
M7'15,<I2,+$0C41)0%5:&^;URAJJ[I\(X.G9>[3YD7$RM.8L+3*%!O.R*.&[
M3-*)9D;;H>3H(* &1=)]SYC"H$W"4H^M8:QYMO\-5VM/"#LRD&)WU66;BW8V
MY :KQ:?V*<O'+,'ZP<7-HO#"%AL6WB5AZ4@J4E 88=L]/'L%_? SH)X^K3E0
M?<'DZUJ?"EP/W0_Y\KBDC5GIHE=1("$8G,_98Q &YVW(TNX7,/ 7AB%FF8O^
M2H&LPLTO\/<\*[P$3(G?ABSM?O5R?ZM0S#(7?:."7(4V%RPB2E#)^K%Z7;,S
MH&9;;4T?JX+$FX<*:[_(28A" ;U[G8&2L^^A[]BNU<][C/'.NU#*[]$BYIMA
M ;4A<PC1EZG #07(^G?O/M@;&P-JE.8P$8!H!6M2@(=7V-4D@LGHT&!C0"W5
MVNI#[Z$:[=F[-^&2L%3188TP^_$>-'CX',M%:YBO\,X?E2%%2^OB1_Z9.F+V
MPH]CTW_^V84P:-LU>_ZFE2'/WUEL^(7PI.$A#R=_T$?2P_XSA2X\*>'6^6?G
MPNAHCQSXD=7HFJ>AQ-X'L+Q"K S)4UCO'[XJ<]"DXX:]HX.P[_3V.P1_S>BP
M(YRD0[M<M',_AL8 ]0T.\/ 2"<T3H<X]62-L<]'.=])MI*2_AW3 \XM0SL,V
MLE =9$;>]E!RT2Y(?7[<%;\I$$M,[Z#HW1(BG+'S:FO?[AN^\I7[#(<TIP(E
MT/T&CQ)#SMY9Z2*Q,OC5O!GY1+*4-TE YG<_=(=B'7/Y&%K^I1?DJW F?P$\
MIC0@^[L?<4FQC/F,=)%A2;V.WT$4\47WG<P>UG0K=H:6UODCBG@MH*.#[J=Z
M*M8[)6=#2_ITP8L@EKK6WM/]6,X]+&U=3BHR/@G#A';[$_VHE2Y?5T<'G;)8
MA9''<-0+VPNG*W<_JJ&(8>%$!G4L5NWHP,_QY3U63;;('+.GX[72K3S'1P?O
MJU)Z+4@-SW$%/)R0(FNWY=$!==M@#E_UO)45Z>&$V[0109B>8S-9."W!'8CG
M^*A'VN22N^+;>HXK3.'$O%B&2!\=^/%:!7CP\)"'$S#S+H)9CWJ>#(^V(=*5
MD"WO1O8<"*<D^'M95:$<[ $LKWU4.7?74_WH,.RH"/N/G*,_*-CP'B)SPBFO
M=]3K?*""1\N=F&7O(;0FG/)Z1[W.U\'QN K%+.M28,Q[K@I]U.N\/[7-^O7#
MS]!B8]IPH'M5H8]ZG6^%XG-)&[,RM'"7OV<,X]$AJ0F5>E5[8:>+>N>>>E#M
M9'>0-:(RIP2Y^QZC*FC9^8[*HG>H=N11K_/9:?N)#])@HXN2ZIZV6S&0_6VT
M)C3@GM#Y&&]?6ZP%(]]13?1WT._OZ/#=FW9)6*HH?TX8[7T5O;RPN/HB^R\O
M.1LEU=_O$=Z/ZI"B-784I+GT?>7#'AV%[<#472>.%4!+1OX('+>-:SKR8_[Q
M'S@N67R.V=/QP'';"+[#]U5TK!:E5@3?H=#7TBU72TBQ5D>>_-G6$7R'PH!.
MCQP()QS^O:RJ4"/X");7/B+\I1<J>3"?QE" <1QVW(O]I\\Q2.ES))Q\ +LT
MM$,_A5("U"4XP,-)!K#/@3JB#L#G\%4N@ W2PXF<;R."4,ZZ-K+81YCYWM/0
MCDCMRMP5SSENS#&]A\CR[E8P/3KJ?L 9A8E0Q,KW$*'>Q0JF1T?=CW6@6,=<
M/G8IP/T=1TT>=S]*PL.2;L7.T*+;6[C2WU_EQ^/N1PDKUCLE9T,+A7?!BR"6
MNHX CCI?Q'<?2UN7DYVH_/BC5ZS!XCHAN>YW+(SBV,\FXC^,XD3<9-HQ>_Z>
MO6*/CM]9!;YCH;67ASR<,)CWX? ^\:2'6X=1' MKT'GDP(_@'-<\#<6U%,#R
M<MHK5ET(B:>+:E=%$@\&**=AW]GM/W^.;\N$)QWO!GMT_+ZZSTLT"@[P\")A
MS#WYQYYJH]@&4QP+&W)S27\/\2S'YZ&<>&UDL8]NL(J=51U*H3T![NZD^?W<
MU6Y^V.P@"JP/[-_*NGO2_1@*B8EFWYS\6P0$A1A"<=+]S&7%,MX?'_\6<4!A
M)KV>A!W='^HRYC/R1RA0$*% )]VO=.EA3;=BYX]0H(!#@4ZZ'R^Q!XW:EK.A
MA0+]S4+N3[I?E8-"01&Q,MQH(/CE#/Z)#]5.AQ]=8.7+ZI2D(F3'PH!._6P?
M_L. 3L5^5L?L^9N& 9WZ,>"0.>U.A1V*>,A_A &Y]8*?4G<%Y0EYKW$:IT)K
M](\P('N>AN(4#6!Y[2,,:*&$HN>PHD95087_.)![%K8-ROX3YWA?Y5P()[CG
M[WA]/@L[Y*RE)KQW5H83[+0'WP:)U=\A>2BS[@<;4"Q_8QZ'$X'FCRE_5!PA
MW>$W24#>=S_KG6)]<_D83DFJ?0$/<X,WI!&EUWT? ?U7H,OHP&(G_T:Q.J=A
MWRE#7>9\1OXM B<;74W#W.M-",3]I_MUJPAOLR9<_EN$9(885WS:_6 >BB7.
MY>-[B,<T1![F-F\>='C6_?!Z^L] E]&*Z$["H"#^GS]^QQ_9C\@@P<H[)PE.
M[%ADT+F?S ?_D4'G8M>K8_9T/#+H)H5MACV4L.,AO;?X*N2"/$Y(,@K9XL>?
M1A8U=+[3"$.?#^'$$ EH589M2,<A2D_9S]I1/6HA& EO U@XP3K^Q!=*^(P_
M.3J-BG$DS]]9"@KGM)_&_7@&# =U-<)V!@N]31A38S0>T9.:@W2^,;Y43?"%
M$SYSSPH&+'H&LJ_9*YMF+PA;5Z8:HQ$QJ2?'7J+ZZ,*)(.E/J]E9++UDR2*J
MM29 W-V/PA KW49<D,=)^+QHW[,I$GD7Y>7;(T OHE%E,>C'<5*3<Y-6-52J
M%4]SLQ;0J'-O5@T=]GI'%+Z=JZPH"]@5%LN@:-(I@2,;AE!(MTE-7O,_%PUD
MX=P@!4C[LVR.QK=QXW?F:Y,W"W* 5*EI)5MSH.%<(=>7:M%.>?FV\1=M4Y7!
M?,@5/U=.J5FJE=#; '5H8**XM^H!5MB;]"=!I@5E?K(0N,F^(69!.%?=)H%*
M>\7NPX#'4R=6?1N3,??50MP %](-MKVP0K$H^96:RJID=%\5Y%H]S&=)F<TR
M>8K5YE.(A=0S+%SEF^P5D^X@4E[*3[SUZ7!T_1P21EH%S)RG.\3+8[=]WJMK
MF]%C])T5ZX/Q-BN*2P;7:=;X\^7;[RR;Y-'+<S*Z9Q.+:[9 \*MW7"<%JDKS
MG,FNS,HQP][1!9V_#GGW"=;(%2B%23I/TLD E).HWMRV>?HY2;.\"HDH6<Z*
M$BZ6F[/4$1.?6?F<P5\P#K1RB_6?T.8Z*B7[/P$UR'B2A [=)2%S4E!P*AQ+
MP1YY$,::10D$8*RG6'7D7\&"]PZ,)_HGBLC>(7T>"=VC/<-N&]-!$):AHLC+
MQLX$_]K>E>!7PY4;:ZUU1%.!+4+Z/+* L%:.EG@V!*J#QIL%04\V];IITB:\
MCTJ?1S2>='>E_4"'S1S!**!XLQ80"(;:5N!#0DXM QN2*MCHUTGV^F&$WH+\
MK1;6XA^5K"HI+7XQO/S,$<GZCT@K2;J<SAK?Y/D.T:Z3Z<T8>_5/"6.O_HDT
MDKCS[1F[(MI?3Y8J#E]N=FD\@N20I/F8\U! NNLD8+,E^O5!LD2_/B"-)$Y4
M^R6Z(EJ1EKIG2Q8&LF1IE6@R7OUYX;F_9"F\N71DPY*]26G,TAH\/#MS<362
MO4MZ1U(.! +WF))@RCC.MJ")**PL@CW?G<[._&ST^E<G72D97*$J4-Y"-_:L
MJ)_Y*M77\@)5,=E$.S\35]O;F\W!I53"OCW9B,=?K+Y;_>GL/$#MM%K>0NVI
M(MF![<"-?G_FR>KIFH%\PL.^V)]=D)2TM%Z<2Y+#OM6?T3@>K;FZ)-EUT;8E
M5V.6U!R%'];<A'\,;]DDFGY,RT08V<=Y"J 0]HBVUP.%4'P9 ,1\KRD0JA/;
MCP"9GFP 2KU.R+1=WNY2[+PNE1?.4NMF+5BL4L)(:AQ=S?,</DV!C87G3-:(
M8+&?%/A$$F77SBCA"G= 98/D4*QE#^HRB8+J2D(V<J\Q!]3(\)J-&1 <N_WH
M6\P*O"6)Z''SU;<&'E"C/P46>_'#1T":7M9:2%:RKU$K6M_M/UK01*YB9"2W
M83>?K!240%S+Y;LG3YB3].A]Q6V?GU!4W%]\JND$HQ:OHCQ_ T95?6 DZUD\
M:'CNJ3-;ZQCHBKW\E:R"X\"=Y3M4\]Q3VVS+2$T.LS7H=^AKW)LGRYFO\?S4
MC__809AF+9Q=;XD<RWMQ9IV?4M41TV"RB0^K O)>0F<!#+49R[UX5-8M%\XP
M^+[[\_)YD;I0N8_^QSQ/BCBI4U#E?C*]T</S\P =$M7ZYQQ*)IAHO6LJU^\Y
M3>-"8[9ODTSK7?O]4L+5WR^!Q  =ZA*N+DGVY5USX[,\I^GN9LW5)<G[]YW9
M^2S/3ZACUTST22&"#GC4SD\\77FM?)45UQ2.M(IBYPXT+YRE5O):L%CIJZ0K
MMMQ4>;0J:F\/ 'Q^O U^MA<=, $YEW;)U*RFO#L$L%%%4N@P75=,33 !N7H<
M"XIZL_,C,>4^2-).'"_N_32^A7=,F]<]92UDQ4C0$DGK\<B_';[TM" I7#J^
M34?W6/!78EE=_1V4>#_&!W^6U"W:!9QVX![2Y[3P,]AZ BCVY,/4,H]N<4[
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MW*I"X+4&#\\N7/0HD+U+&F:M' @$^M'JQ?'6!HSCW,,T$051[<E;1,P!M5]
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M?AAR@HN^9 "UK*EYS!Z?DQS(S,NWNWD^>@:BA1N#]@3#'KSZM$=R,6CA&;7
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M;H]0ABR?B>PURH%(X3LJ^E#SFV.2T65$.,X,+L4&[F2M\8":ME&]?_';\"-
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M@2%@-,5U'[.4!N-&DQ'%"<-]'O?S;ATR,A@"Z5#$)C0(+.H,I6C]FZ9%0YE
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MFBJ2&]:><6F]-5%0N)NRZ6#N;].F(QETXU86F;^,@SS?'<2:9/LE,H6^&FA
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ME_NUNEE?S6E!7WJ=L+VZZ"7M2:21!,OKM>6VZ'N%P //9"]^Z6XBO?AHWF,
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M[F@>.(9TA#*JL6[W^_2<%#G;V_&0B,<L"$VG,[8,4(U4HY.E@5;4I"3?$,'
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MG&,"#^",AK::#640+-Z()%8.QC?*!G/%XP[;^LCS-3Q*#9O3<N7P0W_F 7/
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MB444.7*.Z4@NTTXKL/B_KG2]*X6R 6KNTME"PD6T#8YV.Q9MO:&VBR*;U9N
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MQAIM,\[KU2,H_E@B3?AK!V,-)2,)U$F^66[S<6+3'K&4TKH*@-T 6."G=1T
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MVN+ 6)\Y7$$$[E.EI:1% J_Y$9(6"#.6[I?I\4BS?13$'Z.8YD6:C*0M-Q!
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M:1-HTJ%!HR- = BH&L.I>&V*NJTM7$HUL:&:B"I-I$L-FM-EK57W34;9I9K
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M_?L=<[1L/"G^\&HY69J46U)>Q@;YHWO5:[Z@AP' !L'H,XC UL#)6X@G:14
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M6JRJ<-:UWS LF2 %=<6.*=VEH-*D>)VD(?TA(S/6)L-$RCQ!6^'M#2\BPE3
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M:Q%6 F&G1RVD\XLDRQ6NE7#*.CTN&8YTN.IB3**E/+D2(=3O\%! H%P(,*B
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MET?\G%S2&EFRBT)6Y7[S='S)HC *TG?1MB/8<)P'MSO7MZJE^]V$I:O&A<C
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M#0AQ^?,S,H@4,MR2:L5/Y!\OQ"GZ/_\/4$L#!!0    ( +J+75,>[MY:?H8
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ML+!QL9J"$N$ '-\(J!M38M$;'_EKPE)XDO_A#@:Z 8']R!C,?>,E"'R'+K4
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M56T K(<%?"R^S$T@SHH*T+HLY98M_UM1CS']](,EHS!59@VP[@MX;-6NH"+
M3M08J+MK--Q"G7E8#*>:0FR!<E:TP$,E6%JEE;5@JP-@S)>0W3IJ($1%6Y-
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M>Y:4JD/M/[-(D$1 ,PZ##\ DQXBD"4J$(MAW>SPF7Y*T#8(@/BO3\"O^:G2
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M+D)Q'9[!Z^(*QRUWFX"NHRFC]Q14Z V_EG8=!%0'*=&8=GD313D#;,^(C/L
MXDX\C"-2:(<M-(E.M,OQ>!,G+)Q&5SD,-QIMUFN)QOS'69&DVD)'JO:)Q+;K
M0*(N5(D.M<OA^ #F<Y2S&R"37_P# OX*LY>K/,U@%4[,%<>N(Z2P70[J2O@D
MD3_M\D5^9=]+Q^])',$_1T72&ML5R+8K7,';M1!51"A1E#UY)R7;5 66KW'V
MGRSKCV'(;&RX7:W8'7Y*[3BM<(!2H@?UG9)^!#SS**\.A#N?GI.$.X]>V#B?
M8;E*X6DH9]?H H%51PB7^'!(*PO)GK$*3M)P:LE,O 8B/>181E*-OZ5LDL_N
M8"NL5PAWG2-YQ,=%EDKB''M38=XT!;V(IFK2LEX4>>77&FA5=JKPDJX,D\L
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MWI<,:)6@=I_()W%8M86&N(+;UOT=CS-[B6<PW!1]P-D[SZD\9FR.,+_&$>Z
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M6R+8O62+9PGTY3Z))R'W1BGT8OT00"<V#!N7_S981SN+-Y8\QY2UY;/"28O
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M1&&&!4^B\4WX _\EKZJK;P3$$%]!K2EH';1.'"3&D^P[D'G-WM@L-ON@I6V
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MP%TRDZB=X9TQD^37"]Q$A=8YHVN.AOU5F;$9 T8W=.!"@$"QJ:AT6]W7[QU
M=V^5'1UVX![ WGSPIH2ZJOM;-6U]0Y/^3L8!LJG??B0HF6Z>F=(2ZJJ"L!\E
MKEMLW73S+)6*2E?%?_WP\->X"->!*GI'AQ_@E):$5%>5?GVK47(5O+ZR,9\/
M^J_PVE%8W ]#<GX6*]F^#7=X1C&OM>S.XQ'Q/LN)E"7SCV.:/O*=QT/J0PC'
MLA1KC CUSSN/OMQY/"+>2HBTP_69EI8 '^\\*LT2]84:@Z8 _-CW361U>0JV
ME>:<?-Q+D8?4IX%[68\$H#_VI<@CXK,R@4#4DML8^<]+D4@$L=-#*!G!+&R/
MZN>ER'U<BCRB/BW9R\SOC*H/?2FRG2FWCXZZ</OA2%VN>H]4_KQ<V<I")$='
M7;@80?$9")G\V'<SVUN(Y.BH"W<B*#X#&9D?_8YG6ZTBZB.(MGX'8BJ[=5>T
M1IA!^W)D'U$[/_?P)>R3RX]T:;3#(>/'7;A(T< "48M05Q=(JX:,^[9(=*8.
MR7$7+ECL81&IRJVK"Z9=^7"\^%",A$=]P-"2#\.4RP]2@>0!2$G"$1#RF,6C
MO[]%X<^0W)U@S>,3BBFL92&YQ\3;.R=2;CXD]UB^<VN53[MJ2.XQ]?&(8UF:
MA>0>2X\R?H;D[C\D]X1X$R'2CKV&Y)Y(+7UORI"(#!/CFB3RQ@#^U/<M9'69
M"@+";%CYN(&YQ]2GE7M9E02@/W9@[C'QX9Q ((:!N<?2LS#:P%S-=*,/RS7N
M *<\8I^'4"KV<_ .II\AN?L(R3VA/GC9RYSOC*J?(;GM"SXY\?T&FJGRT0>?
MG$@OKOT,R?4])/>D"QE+*#X#(9.N0G)]."+\8$&Y)UVXHD'Q(<C(=!R4^_33
M.-KCBDY]$M'6CT%,Y<_(W-;&CIQ0>S_W\"7LD\N?D;F=B,P]Z<+5C086B%J$
M=J>TR\^XW+)HNW"Y8P]+2%5NNU/XY4-95J?49PPM^2Q,N>QR5"[\<@X_XD-%
MM,<H"]]@)_8S')=M!FJ>'E',72T+QSTE=O4YD7+SX;BG<B=>JY;6JN&XI]1'
M(XYE:1:.>RK/MMXJJ7<C'/>4V/TDTHZ]AN.>2GU&Q!ER"XL$ Y7X^'59<<6/
M \ SWSTIU>4F"/=2\]"%(%O_@[M.J0]W]K*N.:.J"V' '^W\\M3W2=54^>C/
M+T_=15.W^<RFE<%=IUWP/%-\!D(F/W3HN9:R/_FT0:K_FT- F[(++F8*_1<R
MZ2C*_6=LX][#\<Y\O];IZW<@([-NM/O/?*,4INQ9%_( ^;$K.).G 6IIY=H]
MV)$D(5ZNQXC"ISX8:>MW5(WJVH'T'VGCX><W9CE&%'P7KJ/0;UU,J785H=_1
M;VQA!^>@BWY^8#8#1)%3'X&T]>NJP+.KB/^.?EKN C>)AX?B[L)E&=(-EBG+
MKJX*^!CL*?[SIQ_X3_8SXK/<,6C#^<'/B$]MF, Y<;(/)U)N/N+S7)K(HUV;
MS=L(YAKV"&+FN._P54B%.OY3T0JYH?:A.Y:S6)OT''0A-E2"4AODJ6R'_! [
MF/72LY+Z!B[2($Q'<G\ J0"C+_UH?,W>V"Q^1;@+RT(:P&G1&KDB=MR8R%*L
M!>;XNA"G^9E%8&+/ &Q_/ ^C$)=:+ )NJ@U&[9$O8E=#=7VP0?BA@R3W%KE[
M3GWPLA<;Q!E5I$E@75U>FO'>V5BY*U;=:C+J !GK@O/F7'H_Q8J'ID+]FO:L
MX#XSCK(PRO$Z/4MXG^G*LP)_?HW38/8YB?/7%%:&63X.HZFXU=;"0>AXV1T;
MFB@;6 P]+18]#7L'J_JT=2X*;?2NIGSQCVBZ4$8%*%==(TH/BM/8RV7S(W=,
M!ZD/I+X>*0UY!\JD[!\H/";RMCG6@GHJ9D)2%WPI%I1H-A3JN=O12Y!Y(BNZ
M4?5LC*DN^'UJD.Y&*;=[16Z)_$2^::&$&E<NIC@+9FU2N\+JOHM3E3.A7L?(
M,)%3REOEVV&'U*%5WP3\'(01HAE$CP'Z:R[S%';)0J5RU3421^1"\,KPT_!3
MURGEQ]41"SYN(_@(6)H5GYB;66VS3V26Z,*W;Q.:D)BZWJS6JIQ3&VZK4^26
MR'/BJ])M,M.%HD@V)&-(G]M-0ZE'X)2J)I=OVB:@Q5'Q(6I5$WU92[/T!N0A
M?.223>*$%0\^!3]L'>#V;T#.B6*A]J6*#FER=4F2>B.[BQ<P?II,V"CCYTJ[
M?[?51%U_2"A1?!6=WAF2THDK@@;?6/J5 1/J:<ZF&Z2OBX<5-;AP=A/.NPG+
M@(SK/ &&[U^"E WRK+A"N#6O][,L"9_S#,-8GN*O<82] .(9]R(5AG #B["C
MD:%M3IP4Q\5YKU]L=N*&V]ZHO.=:XL,G4HP$A4@<V]_*3V*#O4Z4KFF0.AIU
M1^$07TEHB6HOF&JLE QQX-]5D+[<S.+O"C/P \;WK4J^=OI0CKJ69S6Y-'8&
MIZC'N:\#D?J:)(YA=J!'XHZ1-N+H< HM4I)!&KO75(SH;72?Q",W4Y+F#4@C
M<99N"ITR8Z6IH+NFS9#%?7;8&F3O3TD 7\RHX'0\#@LPMQ'87?/"+*.Q.*1C
MU)L8NJ;#7N_0ZLZ \W0,LA%>OF_\Q3CU@D5_ /Z(>+-A*!_Q[J(.Z"XD33!#
MK<FA8-X),N=-2@5[B8MUR!I^%VX E*%I4RCL/HP?)?$5)&NQZ:6_@<W' E:/
M^3S,8ER^U96KMI]#!HBSZ4AY%IAFDN&39C!02F0>F\AC^13"(;X4;B^-K<%W
M(7> 9 :Y,\@,H&N*+%'7L=C70KD-N@LW^'ER+]CN+<[MTS)TA5JHFB$[Q&EF
M# 4HEKX!MBX4VY%PU)_'.>: G)1^9S\_B'I![HB]O;7TPAYJ4T'&33M*5@=/
M+%U/KNBQWCJ78C"S?F;Q- E>7\+1 YO2^4U68[I>)3,T<)DH6F&NC0L'=I/@
M%3('A_)Y&,^%%PG<5&P)C"H-'@]]$VF2E?0.?MK6.?C5<)5Y9*W_P4SB?E ^
MCSQ07OG6R&=3HB9(/'0:F$F43;=12?T%RN>1!Z(]J(E\!!+5(/'GDGW*1K]/
MX[<_1KCD)N^%4!<_<)ER:2Y^,?SV*!#=^H^(CL@>,6%]4TX[P_8GRZ&=4*[^
MJ1#*U3\1'=%A;G6AK(;MC[/ 3BB77Q1"N?R"Z(A.0ZL+935LTFVZQ"KDU\34
MKK32(PB$R EMS[]D\*1;9G/;7.43T[9!J)27SZQL.5,T7;@INQF&>57$/831
M=!U7L;.S_1)&<<+K8A31]/UHO-E+43;C"\M>8O@+%L@PK:I ,!J4)>4-70,]
M$SM=Z+CJPK7=/;+GA[ZC[+Q(<4ZAL>1?T()]9[>*/?![8FQE'#'NX%W]>7$R
M<,DB-@FI<L^Z]WB>K2IQUS&J5(PI/9_:AC! XK-]+7L"$\L0EC^.T.76<<S"
M0AOA'^LM(_PPO&/38/8))A)IQ)7@*8!)F8#+4 R; I3"\,?)J9=6,7:I+W/[
M$0!(Y!63LKTKE-T!^^.DI#I(.#NCS/A4Z?LR .2/GY/J..'LC-+WII:.S6$"
MQ]%6#ZGN+.'LW$L''>=<>I+ !^U/%)/;@X0S*H='98DL!^U/=)';4X0S*N=H
M98DL!TWJ W5SA'!&%3UB3;YXZ*3NN I;7>U!@E%CX(<RJU@EH\X676/NHKW&
MT>9)PJ]*"EU$(J^;@;.F>J? +&50D87TQ4[+NL@[D7).34)EO0&SCSB0L*YT
MJ^A,@=I9_CC23$"+D;J=;&KT"E*AK!=2>[:I#;T;.=;4+%17'?CTJ+.\U!5P
M);TI<'<B^9B]3L@YH8R0J3U5*&$Y2]"UG9UTCP>?/B7#<'_$>;Y*TNPX;JS:
MG8YSZB0S6JX$6SLUFNZ?8YZ?4)ZSJ-G7'U_RT7?Y^/+\A&CG*V5;<WS)!_SS
M^/+\E#+7N<UG98#CYZGE^2FEOUDM'9M32XZCK:>6NC.R<ZJ0' /.I6=DY_(
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M?U3LOP!C,MV:#%-*<!PN^VX $17I[JC3UO/X!69^'PCV^[]02P$"% ,4
M" "YBUU3=F>6A]4"  #*!@  $0              @ $     9#$V-#8X,&1E
M>#(S,2YH=&U02P$"% ,4    " "YBUU3].R9H0 "  ##!   $0
M    @ $$ P  9#$V-#8X,&1E>#(S,BYH=&U02P$"% ,4    " "ZBUU3Z X.
M;\L.  !$.P  $               @ $S!0  9#$V-#8X,&1E>#4Q+FAT;5!+
M 0(4 Q0    ( +J+75.NQ'%]R @  (H:   0              "  2P4  !D
M,38T-C@P9&5X-3(N:'1M4$L! A0#%     @ NHM=4^8[Y.AI!P  )AD  !
M             ( !(AT  &0Q-C0V.#!D97@X,2YH=&U02P$"% ,4    " "Z
MBUU38!I6G"H&   $$P  $               @ &Y)   9#$V-#8X,&1E>#@R
M+FAT;5!+ 0(4 Q0    ( +J+75.]: ^-?M\) &9L<0 .              "
M 1$K  !D,38T-C@P9',Q+FAT;5!+ 0(4 Q0    ( +J+75/\8 9"-X(  %?0
M   1              "  ;L*"@!G,38T-C@P9S P>3 Q+FIP9U!+ 0(4 Q0
M   ( +J+75,%=I#\S;P! .D) @ 1              "  2&-"@!G,38T-C@P
M9S P>3 R+FIP9U!+ 0(4 Q0    ( +J+75,%<^ CP5," "2P @ 1
M      "  1U*# !G,38T-C@P9S P>3 S+FIP9U!+ 0(4 Q0    ( +J+75,U
M$7G1(&T! 'RW 0 1              "  0V>#@!G,38T-C@P9S P>3 V+FIP
M9U!+ 0(4 Q0    ( +J+75-IZT05M,(! +\= @ 1              "  5P+
M$ !G,38T-C@P9S P>3 W+FIP9U!+ 0(4 Q0    ( +J+75.K3+@F)K<! !T+
M @ 1              "  3_.$0!G,38T-C@P9S P>3 X+FIP9U!+ 0(4 Q0
M   ( +J+75.I1JS$&, ! .05 @ 1              "  92%$P!G,38T-C@P
M9S P>3 Y+FIP9U!+ 0(4 Q0    ( +J+75-G=4Z;Y=<! "\C @ 1
M      "  =M%%0!G,38T-C@P9S P>3$P+FIP9U!+ 0(4 Q0    ( +J+75/:
M+=*B7X@! )/? 0 1              "  >\=%P!G,38T-C@P9S P>3$Q+FIP
M9U!+ 0(4 Q0    ( +J+75/"_ 7NA)$! "#8 0 1              "  7VF
M& !G,38T-C@P9S P>3$T+FIP9U!+ 0(4 Q0    ( +J+75,B\"':)?4  'Q)
M 0 1              "  3 X&@!G,38T-C@P9S P>3$U+FIP9U!+ 0(4 Q0
M   ( +J+75,'AW^OV$P! (&@ 0 1              "  80M&P!G,38T-C@P
M9S P>3$V+FIP9U!+ 0(4 Q0    ( +J+75,:+L?C]Y ! !?E 0 1
M      "  8MZ' !G,38T-C@P9S P>3$W+FIP9U!+ 0(4 Q0    ( +J+75.6
MP/;3IO\  -Q+ 0 1              "  ;$+'@!G,38T-C@P9S P>3$Y+FIP
M9U!+ 0(4 Q0    ( +J+75.)CE2N4",! .=R 0 1              "  88+
M'P!G,38T-C@P9S P>3(P+FIP9U!+ 0(4 Q0    ( +J+75-W)6):XOT  .A.
M 0 1              "  04O( !G,38T-C@P9S Q;3 Q+FIP9U!+ 0(4 Q0
M   ( +J+75.R &H6QKH  !T6 0 1              "  18M(0!G,38T-C@P
M9S Q;3 R+FIP9U!+ 0(4 Q0    ( +J+75,'+&;H"EL! +VR 0 1
M      "  0OH(0!G,38T-C@P9S Q;3 S+FIP9U!+ 0(4 Q0    ( +J+75,>
M('2\L.T  *-, 0 1              "  41#(P!G,38T-C@P9S Q;3 T+FIP
M9U!+ 0(4 Q0    ( +J+75,+"^ZT^$$!  >? 0 1              "  2,Q
M) !G,38T-C@P9S Q;3 W+FIP9U!+ 0(4 Q0    ( +J+75/\2?[/O[D  (T1
M 0 1              "  4IS)0!G,38T-C@P9S Q;3 X+FIP9U!+ 0(4 Q0
M   ( +J+75-T"JCTB8   "[9   1              "  3@M)@!G,38T-C@P
M9S Q;3 Y+FIP9U!+ 0(4 Q0    ( +J+75/%;*8^Z10! '%G 0 1
M      "  ?"M)@!G,38T-C@P9S Q;3$Q+FIP9U!+ 0(4 Q0    ( +J+75.4
M 8B6WI0  !?D   1              "  0C#)P!G,38T-C@P9S Q;3$R+FIP
M9U!+ 0(4 Q0    ( +J+75-YN%Z/V*P   $! 0 1              "  158
M* !G,38T-C@P9S Q;3$S+FIP9U!+ 0(4 Q0    ( +J+75,/21P/'+0    "
M 0 1              "  1P%*0!G,38T-C@P9S Q;3$T+FIP9U!+ 0(4 Q0
M   ( +J+75-VR4V;_2 " +.) @ 1              "  6>Y*0!G,38T-C@P
M9S Q;3$V+FIP9U!+ 0(4 Q0    ( +J+75.Z7ZD1?=(! )8O @ 1
M      "  9/:*P!G,38T-C@P9S Q;3$W+FIP9U!+ 0(4 Q0    ( +J+75,V
M;F2.%9D  "WP   1              "  3^M+0!G,38T-C@P9S Q;3$X+FIP
M9U!+ 0(4 Q0    ( +J+75.,)-^84$T" /6: @ 1              "  8-&
M+@!G,38T-C@P9S Q;3$Y+FIP9U!+ 0(4 Q0    ( +J+75,]B=;B!10! &ER
M 0 1              "  0*4, !G,38T-C@P9S Q;3(P+FIP9U!+ 0(4 Q0
M   ( +J+75/,2FE]N#<  *N(   1              "  3:H,0!G,38T-C@P
M9S(R<S(R+FIP9U!+ 0(4 Q0    ( +J+75,3&Z4%]5H  $NM   1
M      "  1W@,0!G,38T-C@P9S(S<S(S+FIP9U!+ 0(4 Q0    ( +J+75.I
MUAPB9W\! .;< 0 1              "  4$[,@!G,38T-C@P9S(T<S(T+FIP
M9U!+ 0(4 Q0    ( +J+75-3&-LK;$T  $B:   1              "  =>Z
M,P!G,38T-C@P9S(U<S(U+FIP9U!+ 0(4 Q0    ( +J+75-AEBL@(3X  %V+
M   1              "  7((- !G,38T-C@P9S(V<S(V+FIP9U!+ 0(4 Q0
M   ( +J+75,+62=@+'T  -K,   1              "  <)&- !G,38T-C@P
M9S,P83 Q+FIP9U!+ 0(4 Q0    ( +J+75-"-XR;R6X  %'/   1
M      "  1W$- !G,38T-C@P9S4T=#4U+FIP9U!+ 0(4 Q0    ( +J+75,!
M-F\FFND  %E' 0 1              "  14S-0!G,38T-C@P9S4V<S8V+FIP
M9U!+ 0(4 Q0    ( +J+75-P*%JPNOH  %U; 0 1              "  =X<
M-@!G,38T-C@P9S4X<SDY+FIP9U!+ 0(4 Q0    ( +J+75-=8NCZVY<  !'L
M   1              "  <<7-P!G,38T-C@P9S8P=#@U+FIP9U!+ 0(4 Q0
M   ( +J+75/; 7^$FN@  (%) 0 1              "  =&O-P!G,38T-C@P
M9S8T93 R+FIP9U!+ 0(4 Q0    ( +J+75-=D*!\23T  *64   1
M      "  9J8. !G,38T-C@P9S8X>CDV+FIP9U!+ 0(4 Q0    ( +J+75/O
MN\G^W3@  +B4   1              "  1+6. !G,38T-C@P9S@S938V+FIP
M9U!+ 0(4 Q0    ( +J+75,6D8CB7F4  +*:   1              "  1X/
M.0!G,38T-C@P9S@S;C4X+FIP9U!+ 0(4 Q0    ( +J+75--ZY@=BE\! #^S
M 0 1              "  :MT.0!G,38T-C@P9S@T834U+FIP9U!+ 0(4 Q0
M   ( +J+75,[>HR':% ! "FN 0 1              "  634.@!G,38T-C@P
M9S@T=S4U+FIP9U!+ 0(4 Q0    ( +J+75/2N9.-\Y ! %/H 0 1
M      "  ?LD/ !G,38T-C@P9S@X;#8W+FIP9U!+ 0(4 Q0    ( +J+75,6
MF/,>YS@  -"%   1              "  1VV/0!G,38T-C@P9SDQ=3@X+FIP
M9U!+ 0(4 Q0    ( +J+75.64&''CS,! '"' 0 1              "  3/O
M/0!G,38T-C@P9SDR:S8V+FIP9U!+ 0(4 Q0    ( +J+75/.SP.^K-D  '!&
M 0 1              "  ?$B/P!G,38T-C@P9SDV<SDV+FIP9U!+ 0(4 Q0
M   ( +J+75-'\R,&8X$" +L" P 1              "  <S\/P!G,38T-C@P
M9SDW<SDW+FIP9U!+ 0(4 Q0    ( +J+75/B")N*5'(!  O2 0 1
M      "  5Y^0@!G,38T-C@P9SDX<SDX+FIP9U!+ 0(4 Q0    ( +J+75/B
M"A JFJ0  -D5 0 1              "  >'P0P!G,38T-C@P9SDY<SDY+FIP
M9U!+ 0(4 Q0    ( +J+75-SP \F]AX  'U? 0 1              "  :J5
M1 !R;VEV+3(P,C$P-C,P+GAS9%!+ 0(4 Q0    ( +J+75,$*&YXE!<  .1N
M 0 5              "  <^T1 !R;VEV+3(P,C$P-C,P7V-A;"YX;6Q02P$"
M% ,4    " "ZBUU384H\7MUP   $5 < %0              @ &6S$0 <F]I
M=BTR,#(Q,#8S,%]D968N>&UL4$L! A0#%     @ NHM=4SGV2,E6L   T,X*
M !4              ( !ICU% ')O:78M,C R,3 V,S!?;&%B+GAM;%!+ 0(4
M Q0    ( +J+75,>[MY:?H8  $E,"0 5              "  2_N10!R;VEV
G+3(P,C$P-C,P7W!R92YX;6Q02P4&     $( 0@!'$   X'1&

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
